<SEC-DOCUMENT>0001121404-24-000009.txt : 20240223
<SEC-HEADER>0001121404-24-000009.hdr.sgml : 20240223
<ACCEPTANCE-DATETIME>20240223111526
ACCESSION NUMBER:		0001121404-24-000009
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		277
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240223
DATE AS OF CHANGE:		20240223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		24667948

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>sny-20231231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:sny="http://www.sanofi.com/20231231" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sny-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-38">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-39">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-40">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-41">0001121404</ix:nonNumeric><ix:nonNumeric contextRef="c-81" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" id="f-646">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1467" name="sny:PossibleIncreaseInMortalityTableInYears" format="ixt-sec:duryear" id="f-4225">1</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-1463" decimals="4" name="sny:CapitalLossesUsedAgainstCapitalGainsPercentage" scale="-2" id="f-4226">33.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sny-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">sny:AmericanDepositorySharesNASDAQGlobalSelectMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">sny:OrdinarySharesNASDAQGlobalSelectMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:ErnstYoungEtAutresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="emission"><xbrli:measure>sny:emission</xbrli:measure></xbrli:unit><xbrli:unit id="scenario"><xbrli:measure>sny:scenario</xbrli:measure></xbrli:unit><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:TR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vaccine_dose"><xbrli:measure>sny:vaccine_dose</xbrli:measure></xbrli:unit><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:StockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>sny:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2007-11-01</xbrli:startDate><xbrli:endDate>2007-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>sny:agreement</xbrli:measure></xbrli:unit><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:NewAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:PriorAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OutsideUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OutsideUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OutsideUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="bond"><xbrli:measure>sny:bond</xbrli:measure></xbrli:unit><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesSecondAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesFirstAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesFirstAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesSecondAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesThirdAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesThirdAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OutsideUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:PriorAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-01</xbrli:startDate><xbrli:endDate>2015-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:DevelopmentOfCemiplimabREGN2810Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:DevelopmentOfCemiplimabREGN2810Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:DevelopmentOfCemiplimabREGN2810Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sny:MajorCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sny:MajorCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sny:MajorCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:TwoThousandFourteenAmendedInvestmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:SaleOfStockAxis">sny:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-29</xbrli:startDate><xbrli:endDate>2020-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:MajorTerritoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherTerritoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:OtherIntangibleAssetsExcludingSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-09</xbrli:startDate><xbrli:endDate>2023-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-09</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-09</xbrli:startDate><xbrli:endDate>2023-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ProventionBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sny:ProventionBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ProventionBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ProventionBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:QRIBIntermediateHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:QRIBIntermediateHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-29</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:QRIBIntermediateHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-08</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-17</xbrli:startDate><xbrli:endDate>2022-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:EPICBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:EPICBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-17</xbrli:startDate><xbrli:endDate>2022-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-03</xbrli:startDate><xbrli:endDate>2022-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:EPICBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-17</xbrli:startDate><xbrli:endDate>2022-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:EPICBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RegulatoryComplianceCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:ManufactureAndSupplyCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:ManufactureAndSupplyCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:ManufactureAndSupplyCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KymabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KymabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-29</xbrli:startDate><xbrli:endDate>2021-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TidalTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TidalTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KadmonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KadmonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OrigimmBiotechnologyGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OrigimmBiotechnologyGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:PharmaceuticalsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:VaccinesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>sny:lease</xbrli:measure></xbrli:unit><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:OfficeSpaceCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:LaboratoryFacilitiesCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:IOLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:TevaPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ALTUVIIIOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ExpenseCategoriesAxis">sny:AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ExpenseCategoriesAxis">sny:AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:ExpenseCategoriesAxis">sny:AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherProductAndServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherProductAndServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherProductAndServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:NKCellAndProXTenTechnologyPlatformsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:EloctateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:SAR444245Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:MCMVaccineBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:BioAtriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:BioAtriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">sny:InnoventBiologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">sny:InnoventBiologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">sny:TranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CommitmentsRelatedToUnquotedDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CommitmentsRelatedToUnquotedDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:QuotedEuroDenominatedSeniorBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:QuotedEuroDenominatedSeniorBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:SeniorBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:SeniorBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:IncreaseOfTenPercentBasisPointInMarketInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:IncreaseOfTenPercentBasisPointInMarketInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:SPMSDContingentConsiderationAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">sny:FairValueOfSPMSDContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:SPMSDContingentConsiderationAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">sny:FairValueOfSPMSDContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:SPMSDContingentConsiderationAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">sny:FairValueOfSPMSDContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:FinancialAssetsHeldToFundDeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:FinancialAssetsHeldToFundDeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:FinancialAssetsHeldToFundDeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sny:WriteDownMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sny:WriteDownMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sny:WriteDownMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ConsolidationAdjustmentsIntragroupMarginInInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ConsolidationAdjustmentsIntragroupMarginInInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ConsolidationAdjustmentsIntragroupMarginInInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ProvisionForPensionsAndOtherEmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ProvisionForPensionsAndOtherEmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ProvisionForPensionsAndOtherEmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:StockOptionsAndShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:StockOptionsAndShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:StockOptionsAndShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:BioverativMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:PrincipiaBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AblynxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AmunixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:DeferredTaxRelatingToRestructuringProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:DeferredTaxRelatingToRestructuringProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:DeferredTaxRelatingToRestructuringProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:DeferredTaxRelatingToCapitalisationOfRDExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:DeferredTaxRelatingToCapitalisationOfRDExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-28</xbrli:startDate><xbrli:endDate>2021-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-27</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-27</xbrli:startDate><xbrli:endDate>2023-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:May252023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:May32022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:April302021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2023ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2023ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2022ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2022ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2022ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2022ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2021ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2021ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2021ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2021ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2020ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2020ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-840"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-847"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-851"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:CashFlowAndFairValueHedgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:CashFlowAndFairValueHedgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:CashFlowAndFairValueHedgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-03-05</xbrli:startDate><xbrli:endDate>2013-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-859"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-05</xbrli:startDate><xbrli:endDate>2014-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-24</xbrli:startDate><xbrli:endDate>2015-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-867"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-04</xbrli:startDate><xbrli:endDate>2016-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-869"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-10</xbrli:startDate><xbrli:endDate>2017-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-02</xbrli:startDate><xbrli:endDate>2018-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-874"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-876"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-30</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-877"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:StockSubscriptionOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-883"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-891"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-892"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-893"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-894"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-895"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-896"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AdjustmentToDebtMeasuredAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:OneBillionBondsMaturingJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:OneBillionBondsMaturingNovember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="extension"><xbrli:measure>sny:extension</xbrli:measure></xbrli:unit><xbrli:context id="c-920"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:SyndicatedCreditFacilityCanceledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="credit_facility"><xbrli:measure>sny:credit_facility</xbrli:measure></xbrli:unit><xbrli:context id="c-922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingDecember2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="performance_indicator"><xbrli:measure>sny:performance_indicator</xbrli:measure></xbrli:unit><xbrli:context id="c-925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-932"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-934"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-935"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-937"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-938"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-939"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-941"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-943"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-944"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-945"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-946"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-947"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-948"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:April2016EMTNISINFR0013143997Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-950"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2020EMTNISINFR0013505104Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-951"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:April2022EMTNISINFR0014009KS6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-952"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:September2015EMTNISINFR0012969038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-953"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2018EMTNISINFR0013324340Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:September2014EMTNISINFR0012146801Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-955"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:September2016EMTNISINFR0013201639Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-956"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:April2016EMTNISINFR0013144003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2019EMTNISINFR0013409844Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-958"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:April2022EMTNISINFR0014009KQ0Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-959"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2018EMTNISINFR0013324357Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2020EMTNISINFR0013505112Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-961"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2019EMTNISINFR0013409851Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-962"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2018EMTNISINFR0013324373Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-963"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:June2018SNFISINUS801060AD60Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:ShelfRegistrationStatementProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-964"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ParticipatingSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingDecember2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-966"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>sny:program</xbrli:measure></xbrli:unit><xbrli:context id="c-967"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-968"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-969"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-971"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-974"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-975"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-977"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-978"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-980"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-982"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-984"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-985"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-988"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-989"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-991"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-992"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-994"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-995"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-996"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-997"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-998"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-999"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1000"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="currency"><xbrli:measure>sny:currency</xbrli:measure></xbrli:unit><xbrli:context id="c-1032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1035"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1036"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1038"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1039"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1041"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1042"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1043"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1044"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1045"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1046"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1047"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1048"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1050"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1051"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1052"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1053"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1054"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1055"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1056"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1057"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1058"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1059"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1060"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1061"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1062"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1063"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1064"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1065"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1066"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1067"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1068"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1070"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1071"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1072"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1074"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1075"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1076"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:WeightedAverageInterestRateBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:WeightedAverageInterestRateAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1078"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:PlusHundredBasisPointsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ChangeInEuroAndUSDollarShortTermInterestRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1079"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:PlusTwentyFiveBasisPointsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ChangeInEuroAndUSDollarShortTermInterestRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1080"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:MinusTwentyFiveBasisPointsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ChangeInEuroAndUSDollarShortTermInterestRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1081"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:MinusHundredBasisPointsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ChangeInEuroAndUSDollarShortTermInterestRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1082"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1083"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1085"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1087"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1089"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1090"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1091"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1092"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">sny:OtherCurrenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1093"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">sny:OtherCurrenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1094"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1095"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1096"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1098"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">sny:OtherCurrenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1099"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">sny:OtherCurrenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TranslateBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireHumanGeneticTherapiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>sny:Country</xbrli:measure></xbrli:unit><xbrli:context id="c-1198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:LumpSumRetirementBenefitPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:DefinedBenefitPensionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:TopUpDefinedBenefitPensionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:SanofiaventisPlusPensionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:MultiemployerDefinedBenefitPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:MultiemployerDefinedBenefitPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:MultiemployerDefinedBenefitPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>sny:plan</xbrli:measure></xbrli:unit><xbrli:context id="c-1206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">sny:QualifiedDefinedBenefitPensionPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:DefinedBenefitPensionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:DefinedBenefitPensionPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">sny:NonQualifiedDefinedBenefitPensionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:HealthcareCoverAndLifeInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:HealthcareCoverAndLifeInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="age"><xbrli:measure>sny:age</xbrli:measure></xbrli:unit><xbrli:context id="c-1213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:DefinedBenefitPensionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">sny:MinimumPlan1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">sny:MaximumPlan1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">sny:MinimumPlan2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">sny:MaximumPlan2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfMedicalCostTrendRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfMedicalCostTrendRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfMedicalCostTrendRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfMedicalCostTrendRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfMedicalCostTrendRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">sny:ActuarialAssumptionOfMortalityTableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">sny:ActuarialAssumptionOfMortalityTableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">sny:ActuarialAssumptionOfMortalityTableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">sny:ActuarialAssumptionOfMortalityTableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:EffectOfAssetCeilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:EffectOfAssetCeilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:EffectOfAssetCeilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CashAndCashEquivalents1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CashAndCashEquivalents1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CashAndCashEquivalents1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:EquityInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:EquityInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:EquityInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:BondsAndSimilarInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:BondsAndSimilarInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:BondsAndSimilarInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:RealEstate1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:RealEstate1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:RealEstate1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CommoditiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CommoditiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CommoditiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:HedgeFunds1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:HedgeFunds1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:HedgeFunds1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:InsurancePoliciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:InsurancePoliciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:InsurancePoliciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:OtherEnvironmentRelatedProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">sny:UncertaintiesOverIncomeTaxTreatmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">sny:UncertaintiesOverIncomeTaxTreatmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">sny:UncertaintiesOverIncomeTaxTreatmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:USLegalRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:USLegalRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">sny:ActuarialAssumptionOfMortalityTableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesOperatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesOperatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesOperatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesFinancialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesFinancialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesFinancialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:EquityDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:EquityDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:EquityDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarUSBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarUSBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-1797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1840"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1847"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1851"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1859"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1867"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1869"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1874"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1876"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1877"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1883"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1891"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1892"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1893"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1894"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1895"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1896"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1920"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1932"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1934"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1935"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1937"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1938"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1939"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1941"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1943"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1944"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1945"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1946"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1947"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1948"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1950"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1951"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1952"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1953"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1955"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1956"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1958"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1959"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1961"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1962"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1963"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1964"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1966"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1967"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1968"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1969"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1971"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1974"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1975"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1977"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1978"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1980"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1982"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1984"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1985"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1988"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1989"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1991"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1992"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1994"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1995"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1996"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1997"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1998"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-1999"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2000"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:SuppliersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AblynxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2035"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AblynxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2036"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KymabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KymabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2038"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2039"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:ScribeTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-19</xbrli:startDate><xbrli:endDate>2023-06-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:ScribeTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2041"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-03</xbrli:startDate><xbrli:endDate>2023-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2042"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:TevaPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-04</xbrli:startDate><xbrli:endDate>2023-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2043"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:TevaPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2044"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:ProventionBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2045"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:ExscientiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="molecule"><xbrli:measure>sny:molecule</xbrli:measure></xbrli:unit><xbrli:context id="c-2046"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:BlackstoneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2047"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:IGMBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>sny:target</xbrli:measure></xbrli:unit><xbrli:context id="c-2048"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AtomwiseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:InsilicoMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2050"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2051"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2052"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2053"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2054"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:LonzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2055"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:LonzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-27</xbrli:startDate><xbrli:endDate>2017-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2056"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-27</xbrli:startDate><xbrli:endDate>2017-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2057"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:WorldHealthOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2058"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesGivenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2059"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesGivenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2060"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesGivenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2061"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2062"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2063"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2064"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:OtherGuaranteesGivenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2065"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:OtherGuaranteesGivenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2066"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:OtherGuaranteesGivenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2067"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesReceivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2068"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesReceivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesReceivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2070"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:SanofiPasteurHepatitisBVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>sny:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="c-2071"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:TaxotereProductLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>sny:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="c-2072"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:TaxotereProductLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="trial"><xbrli:measure>sny:trial</xbrli:measure></xbrli:unit><xbrli:context id="c-2073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:TaxotereProductLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>sny:case</xbrli:measure></xbrli:unit><xbrli:context id="c-2074"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:TaxotereMississippiAttorneyGeneralLitigationInTheUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2075"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:ZantacLitigationInTheUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cancer"><xbrli:measure>sny:cancer</xbrli:measure></xbrli:unit><xbrli:context id="c-2076"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:ZantacLitigationInTheUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="complaint"><xbrli:measure>sny:complaint</xbrli:measure></xbrli:unit><xbrli:context id="c-2077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:ZantacLitigationInCanadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="action"><xbrli:measure>sny:action</xbrli:measure></xbrli:unit><xbrli:context id="c-2078"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:GoldBondProductLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2079"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:GoldBondProductLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2080"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>sny:claim</xbrli:measure></xbrli:unit><xbrli:unit id="person"><xbrli:measure>sny:person</xbrli:measure></xbrli:unit><xbrli:context id="c-2081"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="ruling"><xbrli:measure>sny:ruling</xbrli:measure></xbrli:unit><xbrli:context id="c-2082"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2083"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2085"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="family"><xbrli:measure>sny:family</xbrli:measure></xbrli:unit><xbrli:unit id="claimant"><xbrli:measure>sny:claimant</xbrli:measure></xbrli:unit><xbrli:context id="c-2086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2087"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="expert"><xbrli:measure>sny:expert</xbrli:measure></xbrli:unit><xbrli:context id="c-2088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="proceeding"><xbrli:measure>sny:proceeding</xbrli:measure></xbrli:unit><xbrli:context id="c-2089"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInSwitzerlandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2090"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInSwitzerlandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2091"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInSpainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="children"><xbrli:measure>sny:children</xbrli:measure></xbrli:unit><xbrli:context id="c-2092"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInSpainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>sny:patient</xbrli:measure></xbrli:unit><xbrli:context id="c-2093"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInBelgiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2094"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInIrelandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2095"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInGreatBritainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2096"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInNorthernIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DengvaxiaProductLitigationInThePhilippinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2098"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:RamiprilCanadaPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeArePlaintiffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>sny:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="c-2099"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>sny:patent</xbrli:measure></xbrli:unit><xbrli:context id="c-2101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeArePlaintiffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:JevtanaRelatedPatentLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeArePlaintiffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:JevtanaRelatedPatentLitigationInTheUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixLitigationCommonwealthInAustraliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="aud"><xbrli:measure>iso4217:AUD</xbrli:measure></xbrli:unit><xbrli:context id="c-2104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixLitigationCommonwealthInAustraliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixAttorneyGeneralActionInHawaiiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixRelatedLitigationInFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-05-14</xbrli:startDate><xbrli:endDate>2013-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixRelatedLitigationInFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:A340BDrugPricingProgramInTheUnitedStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ContingenciesArisingFromCertainBusinessDivestituresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:AventisCropScienceRetainedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-03</xbrli:startDate><xbrli:endDate>2022-06-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ContingenciesArisingFromCertainBusinessDivestituresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:InfraservHoechstRetainedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>1997-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>sny:employee</xbrli:measure></xbrli:unit><xbrli:context id="c-2162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:DaiichiSankyoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:ImmunooncologyAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:ImmunooncologyAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:ImmunooncologyAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="executives"><xbrli:measure>sny:executives</xbrli:measure></xbrli:unit><xbrli:context id="c-2199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:LargestCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NKCellAndProXTenTechnologyPlatformsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SAR444245Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:PharmaceuticalsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:VaccinesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AuditorsNameAxis">sny:ErnstAndYoungMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AuditorsNameAxis">sny:ErnstAndYoungMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AuditorsNameAxis">sny:PricewaterhousecoopersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sny:AuditorsNameAxis">sny:PricewaterhousecoopersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:HoechstGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisDeutschlandGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:A.NattermannCie.GmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiBelgiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AblynxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeFlandersBVBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareSpainSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiOyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiWinthropIndustriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisRechercheEtDeveloppementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisGroupeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiChimieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisParticipationsSASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurFranceSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisPharmaSAFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiBiotechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiMatureIPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurNVLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SECIPESASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurMerieuxSASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareInternationalSASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareFranceSASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareGroupSASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymePolyclonalsSASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiaventisAEBEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisPrivateCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ChinoinPrivateCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareHungaryCommercialKFTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareHungaryKFTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:CarraigInsuranceDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeIrelandLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisHoldingsIrelandLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiSRLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareItalySRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeGlobalSarlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeLuxembourgSarlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisNorgeASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiForeignParticipationsB.V.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiaventisSpZooMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcarePolandSpZOOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurSpZooMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiProdutosFarmaceuticosLdaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisSROMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareCzechSroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisRomaniaSRLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareRomaniaSRLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisUkHoldingsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisPharmaLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiSynthelaboUKLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisPharmaHoldingsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareUKLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AOSanofiRussiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisSuisseSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeGlobalSarlBaarIntellectualPropertyBranchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiIlacSanayiVeTicaretASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurAsiTicaretASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareTuketiciSalAnonimSirketiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiSaglikUrunleriLimitedSirketiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeTherapeuticProductsLimitedPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiUSServicesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisUSLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ChattemIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisubLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:VaxServeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:BioverativIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:BioverativUSLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:BioverativTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:PrincipiaBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiResearchInvestLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiBioverativHoldingsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:RPRUSLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:KadmonCorporationLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AmunixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SynthorxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:QRIBIntermediateHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:QRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:TargeGenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ChattemGBHoldingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:TranslateBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisSouthAfricaPtyLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisAlgerieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiArabiaTradingCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisArgentinaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisHealthcarePtyLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisAustraliaPtyLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiMedleyFarmaceuticaLtdaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareBrazilLtdaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisCanadaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:MerieuxCanadaHoldingsULCCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiHangzhouPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiChinaInvestmentCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiBeijingPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurBiologiesCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ShenzhenSanofiPasteurBiologicalProductsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ShanghaiRonghengPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisDeColombiaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisKoreaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareKoreaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisGulfFZEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiEgyptSAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiHongKongLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiIndiaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiHealthcareIndiaPrivateLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisIsraelLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiKKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SspCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisMalaysiaSDNBHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisMarocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisDeMexicoSADeCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurS.A.deC.V.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AztecaVacunasSADeCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisDePanamaSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcarePanamaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisPuertoRicoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisPhilippinesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcarePhilippinesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisSingaporePteLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisPharmaManufacturingPTELTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiManufacturingPteLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiTaiwanCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisThailandLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurThailandLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisDeVenezuelaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisVietnamCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiVietnamShareholdingCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:HaleonUSLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:MapharMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:MCMVaccineBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:EuroapiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rightpershare"><xbrli:measure>sny:rightPerShare</xbrli:measure></xbrli:unit><xbrli:context id="c-2714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sny:NonINBRX101BusinessSpinCo.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:INBRX101BusinessRemainCo.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-2716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:INBRX101BusinessRemainCo.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-23</xbrli:startDate><xbrli:endDate>2024-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121404</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sny:NonINBRX101BusinessSpinCo.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-23</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-318" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-318" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-319" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-319" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-393" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-393" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-394" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-394" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-392" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-392" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-397" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-397" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-395" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-395" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-396" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-396" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-458" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-458" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-459" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-459" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-457" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-457" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-320" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-320" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-321" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-321" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-322" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-322" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-323" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-323" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-460" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-460" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-461" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-461" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-462" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-462" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-335 f-336 f-334" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-375 f-376 f-374" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-6" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-504 f-502 f-503" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-510 f-508 f-509" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-519 f-517 f-518" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-9" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-537 f-535 f-536" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-10" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-541 f-542 f-543" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-11" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-548 f-549 f-547" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-12" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-551 f-552 f-550" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-13" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-580 f-581 f-582" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-14" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-339 f-337 f-338 f-290 f-283 f-284 f-282 f-287 f-288 f-285 f-286 f-289 f-350 f-353 f-354 f-351 f-352 f-348 f-349 f-342 f-343 f-340 f-341 f-346 f-347 f-344 f-345" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-317 f-315 f-316 f-390 f-391 f-398 f-313 f-314 f-399 f-312 f-382 f-383 f-380 f-381 f-386 f-387 f-384 f-385 f-388 f-389 f-452 f-453 f-450 f-451 f-456 f-454 f-455 f-326 f-327 f-324 f-325 f-463 f-464 f-465 f-466 f-401 f-400" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-474 f-475 f-473" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i9fa7f69b4904450e9c43e8444c203165_1"></div><div style="min-height:0pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span><br/></span></div></div><div style="text-indent:-49.04pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_4"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_7"></div><hr style="page-break-after:always"/><div style="min-height:36.85pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:15.5pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:15.5pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:15.5pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">20-F</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.822%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="f-2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">REGISTRATION STATEMENT PURSUANT TO SECTION&#160;12(b) OR (g)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Or</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-3">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-5"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Or</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.978%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.822%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Or</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentShellCompanyReport" format="ixt:fixed-false" id="f-7">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">SHELL COMPANY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of event requiring this shell company report </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-8">001-31368</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:15.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-9">Sanofi</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">N/A </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-10">France</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Jurisdiction of incorporation or organization)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-11">46,&#160;avenue de la Grande Arm&#233;e</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">75017</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-13">Paris</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-14">France</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:ContactPersonnelName" id="f-15">Roy Papatheodorou</ix:nonNumeric> , Executive Vice President, General Counsel</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressAddressLine1" id="f-16">46,&#160;avenue de la Grande Arm&#233;e</ix:nonNumeric>, <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressPostalZipCode" id="f-17">75017</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCityOrTown" id="f-18">Paris</ix:nonNumeric>, <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-19">France</ix:nonNumeric>. Tel: +&#160;<ix:nonNumeric contextRef="c-2" name="dei:CityAreaCode" id="f-20">33</ix:nonNumeric> <ix:nonNumeric contextRef="c-2" name="dei:LocalPhoneNumber" id="f-21">1 53 77 40 00</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Securities registered or to be registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.681%"><tr><td style="width:1.0%"/><td style="width:42.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Title of each class:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Trading Symbol</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-22">American&#160;Depositary&#160;Shares,&#160;each&#160;representing one half of one ordinary share, par value &#8364;2&#160;per&#160;share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-23">SNY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-24">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-25">Ordinary shares, par value &#8364;2&#160;per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-26">NASDAQ Global Select Market</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">*</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Securities registered or to be registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Securities for which there is a reporting obligation pursuant to Section&#160;15(d) of the Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">The number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of December&#160;31, 2023 was:</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Ordinary shares: <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-27">1,264,799,969</ix:nonFraction></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-28">Yes</ix:nonNumeric> &#9746;&#160;No &#9744;.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or&#160;15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;&#160;Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-29">No</ix:nonNumeric> &#9746;.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or&#160;15(d) of the Securities Exchange Act of&#160;1934 during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-30">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during&#160;the&#160;preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to submit such&#160;files).&#160;  &#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-31">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See definition of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221; or &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.465%"><tr><td style="width:1.0%"/><td style="width:23.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.552%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-32">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-33">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> provided pursuant to&#160;Section&#160;13(a) of the Exchange Act.&#160;&#160; &#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)&#160;The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&#160;5, 2012.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15&#160;U.S.C.&#160;7262(b)) by the registered public accounting firm that prepared or issued its audit report&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-34">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section&#160;12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-35">&#9744;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive- based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this&#160;filing:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:57.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAccountingStandard" id="f-36">International Financial Reporting Standards</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">U.S.&#160;GAAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">as issued by the International Accounting Standards Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to&#160;follow. Item&#160;17.&#160;&#160; &#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item&#160;18.&#160;&#160; &#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If this is an annual report, indicate by check mark whether the registrant is a shell company (as&#160;defined in Rule&#160;12b-2 of the Exchange&#160;Act). Yes &#9744; No <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-37">&#9746;</ix:nonNumeric>. </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Not for trading but only in connection with the registration of American Depositary Shares representing such ordinary shares.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:36.85pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_13"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">Presentation of financial<br/>and&#160;other&#160;information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements contained in this annual report on Form&#160;20-F have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union, as of December&#160;31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unless otherwise indicated or the context requires otherwise, the terms &#8220;Sanofi,&#8221; the &#8220;Company,&#8221; the &#8220;Group,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221; refer to Sanofi and its consolidated subsidiaries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All references herein to &#8220;United&#160;States&#8221; or &#8220;US&#8221; are to the United&#160;States of America, references to &#8220;dollars&#8221; or &#8220;$&#8221; are to the currency of the United&#160;States, references to &#8220;France&#8221; are to the Republic of France, and references to &#8220;euro&#8221; and &#8220;&#8364;&#8221; are to the currency of the European Union member states (including France) participating in the European Monetary&#160;Union.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of the date of this report on Form 20-F, all commercial trademarks mentioned here are protected, and are trademarks of Sanofi and/or its subsidiaries, with the exception of:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">trademarks used or that may be or have been used under license by Sanofi and/or its affiliates, such as ALDURAZYME, a trademark of the Biomarin/Genzyme LLC Joint Venture; ALPROLIX, a trademark of Swedish Orphan Biovitrum AB in Europe; ALTUVIIIO, a trademark of Sobi in Europe and in Africa; ANKET, a trademark of Innate Pharma; ATOMNET, a trademark of Atomwise, Inc.; CIALIS, a trademark of Eli Lilly; ELOCTATE, a trademark of Swedish Orphan Biovitrum AB in Europe; STAMARIL, a trademark of the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Institut Pasteur; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">TAMIFLU, a trademark of Hoffmann-La Roche; VAXELIS, a trademark of MSP Vaccine Company (US) and MCM Vaccine B.V. (Netherlands); ZALTRAP, a trademark of Regeneron in the United States;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">trademarks sold by Sanofi and/or its affiliates to a third party, such as ALTACE, a trademark of King Pharmaceuticals in the United States; HYALGAN, a trademark of Fidia Farmaceutici S.p.A.; LIBTAYO, a trademark of Regeneron; PRALUENT, a trademark of Regeneron in the United States; SEPRAFILM, a trademark of Baxter International Inc.; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">other third party trademarks such as PLAN BEE, a trademark of Am&#233;lie Perennou in France; STOXX, a trademark of STOXX Ltd; UNISOM, a trademark of J&amp;J on certain geographic areas and Paladin Labs Inc. in Canada; and ZANTAC, a trademark of Glaxo Group Limited (except in the US and Canada).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Not all trademarks related to products under development have been authorized as of the date of this annual report by the relevant health authorities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The data relating to market shares and ranking information for pharmaceutical products, in particular as presented in&#160;&#8220;Item&#160;4.&#160;Information on the Company &#8212;&#160;B.&#160;Business Overview &#8212;&#160;B.5.&#160;Markets &#8212;&#160;B.5.1.&#160;Marketing and distribution,&#8221; are based primarily on sales data excluding vaccines and in constant euros (unless otherwise indicated) on a September&#160;2023 MAT (Moving Annual Total) basis. The data are primarily from a IQVIA local sales audit, supplemented by country-specific sources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Product indications described in this annual report are composite summaries of the major indications approved in the product&#8217;s principal markets. Not all indications are necessarily available in each of the markets in which the products are approved. The summaries presented herein for the purpose of financial reporting do not substitute for careful consideration of the full labeling approved in each&#160;market.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_16"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:120%">Cautionary statement regarding<br/>forward-looking statements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This annual report contains certain forward-looking statements within the meaning of applicable federal securities law, including the Private Securities Litigation Reform Act of 1995, as amended. We may also make written or oral forward-looking statements in our periodic reports to the Securities and Exchange Commission on Form&#160;6-K, in our annual report to shareholders, in our offering circulars and prospectuses, in press releases and other written materials and in oral statements made by our officers, directors or employees to third parties. Examples of such forward-looking statements include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">projections of operating revenues, net income, business net income, earnings per share, business earnings per share, capital expenditures, cost savings, restructuring costs, positive or negative synergies, dividends, capital structure or other financial items or ratios;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">statements of our profit forecasts, trends, plans, objectives or goals, including those relating to products, clinical trials, regulatory approvals and competition; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">statements about our future events and economic performance or that of France, the United States or any other countries in which we operate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;can,&#8221; &#8220;contemplate,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;is designed to,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;objective,&#8221; &#8220;target,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;ambition,&#8221; &#8220;guideline,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; "goal," or the negative of these and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forward-looking statements involve inherent, known and unknown risks and uncertainties associated with the regulatory, economic, financial and competitive environment, and other factors that could cause actual future results to differ materially from those expressed or implied in the forward-looking statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These risks and uncertainties include risk factors, which could affect future results and cause actual results to differ materially from those contained in any forward-looking statements, and which include those discussed under &#8220;Item&#160;3.&#160;Key Information &#8212;&#160;D.&#160;Risk Factors.&#8221; Additional risks, not currently known or that are currently considered immaterial by the Group, may have the same unfavorable effect and investors may lose all or part of their investment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a result of these factors, we cannot assure you that the forward-looking statements in this annual report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Moreover, forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information, future developments or otherwise, except as required by law. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this annual report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">You should read this annual report and the documents that we reference in this annual report and have filed as exhibits completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these statements.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_19"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Abbreviations</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Principal abbreviations used in the Annual Report on Form&#160;20-F</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:11.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ADR</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">American Depositary Receipt</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ADS</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">American Depositary Share</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AFEP</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Association fran&#231;aise des entreprises priv&#233;es </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(French Association of Large Companies)</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AMF</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Autorit&#233; des march&#233;s financiers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(the French market regulator)</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ANDA</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Abbreviated New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">BLA</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biologic License Application</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">BMS</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bristol-Myers Squibb</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CEO</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CER</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Constant exchange rates</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CGU</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash generating unit</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CHC</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consumer Healthcare</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CHMP</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Committee for Medicinal Products for Human Use</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">COVALIS</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi committee for internal occupational exposure limits </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(Comit&#233; des Valeurs Limites Internes Sanofi)</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CSR</span></div></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate Social Responsibility</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CVR</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent value right</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EFPIA</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">European Federation of Pharmaceutical Industries and Associations</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EMA</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EU</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">FCF</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Free cash flow</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">FDA</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US Food and Drug Administration</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAVI</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Global Alliance for Vaccines and Immunisation</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GBU</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Global Business Unit</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GERS</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Groupement pour l'&#201;laboration et la R&#233;alisation de Statistiques</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> (French pharmaceutical industry statistics partnership)</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GCP</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Good clinical practices</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GDP</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Good distribution practices</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GLP</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Good laboratory practices</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GLP-1</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Glucagon-like peptide-1</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GMP</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Good manufacturing practices</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GRI</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Global Reporting Initiative</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Hib</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Haemophilus influenzae type b</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">HSE</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Health, Safety and Environment</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">IASB</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ICH</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International Council for Harmonization</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">IFPMA</span></div></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International Federation of Pharmaceutical Manufacturers&#160;&amp; Associations</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">IFRIC</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International Financial Reporting Interpretations Committee</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">IFRS</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International Financial Reporting Standards</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">IPV</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inactivated polio vaccine</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ISIN</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International Securities Identification Number</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">J-MHLW</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japanese Ministry of Health, Labor and Welfare</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">LoE</span></div></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Loss of Exclusivity</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">LSD</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lysosomal storage disorder</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">MEDEF</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Mouvement des entreprises de France </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(French business confederation)</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">mRNA</span></div></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">messenger RNA</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">MS</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Multiple sclerosis</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NASDAQ</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">National Association of Securities Dealers Automated Quotations</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NDA</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NHI</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">National Health Insurance (Japan)</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NYSE</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">New York Stock Exchange</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">OECD</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Organisation for Economic Co-operation and Development</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">OPV</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oral polio vaccine</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Over the counter</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PhRMA</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceutical Research and Manufacturers of America</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PMDA</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals and Medical Devices Agency (Japan)</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRV</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PTE</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patent Term Extension</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">QIV</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quadrivalent influenza vaccine</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ROA</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Return on assets</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SA</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Soci&#233;t&#233; anonyme</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> (French public limited corporation)</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SEC</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SPC</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Supplementary Protection Certificate</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TRIBIO</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Committee for Biological Risk Prevention (Biosafety, Biosecurity, Biosurveillance)</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TSR</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total shareholder return</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UNICEF</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Nations Children&#8217;s Emergency Fund</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States of America</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-bottom:1pt solid #919191;border-top:1pt solid #919191;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">WHO</span></td><td colspan="3" style="border-bottom:1pt solid #919191;border-top:1pt solid #919191;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">World Health Organization</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_22"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.678%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.144%"><tr><td style="width:1.0%"/><td style="width:4.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:63.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.822%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_28">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:right"><span style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_28">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_31">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_31">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_34">OFFER STATISTICS AND EXPECTED TIMETABLE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_34">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_37">KEY INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_37">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_40">A. Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_40">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_43">B. Capitalization and Indebtedness</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_43">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_46">C. Reasons for Offer and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_46">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_49">D. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_49">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_52">INFORMATION ON THE COMPANY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_52">15</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_58">A. History and Development of&#160;the&#160;Company</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_58">15</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_61">B. Business Overview</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_61">16</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_121">C. Organizational Structure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_121">49</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_133">D. Property, Plant and Equipment</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_133">50</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_6815">E. R&amp;D Appendices</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_6815">53</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;4.A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_148">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_148">54</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_151">OPERATING AND&#160;FINANCIAL REVIEW AND PROSPECTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_151">54</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A. <a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_154">Operating results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_154">54</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_223">B. Liquidity and Capital Resources</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_223">74</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_7107">C. Research and development, patents and licenses, etc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_7107">78</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_7137">D. Trend information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_7137">78</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_7164">E. Critical accounting estimates</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_7164">78</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_241">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_241">79</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_244">A. Directors and Senior Management</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_244">79</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_310">B. Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_310">110</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_334">C. Board Practices</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_334">134</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_337">D. Employees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_337">141</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_340">E. Share Ownership</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_340">142</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_343">F. Disclosure of action to recover erroneously awarded compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_343">145</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_346">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_346">146</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_349">A. Major Shareholders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_349">146</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_355">B. Related Party Transactions</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_355">147</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_358">C. Interests of Experts and Counsel</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_358">147</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_361">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_361">148</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_364">A. Consolidated Financial Statements and Other Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_364">148</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_367">B. Significant Changes</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_367">150</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_370">THE OFFER AND LISTING</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_370">151</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_373">A. Offer and Listing Details</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_373">151</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_376">B. Plan of Distribution</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_376">151</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_379">C. Markets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_382">151</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_382">D. Selling Shareholders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_382">151</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_385">E. Dilution</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_385">151</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_388">F. Expenses of the Issue</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_388">151</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.154%"><tr><td style="width:1.0%"/><td style="width:4.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:66.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_391">ADDITIONAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_391">152</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_391">A. Share Capital</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_391">152</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B<a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_394">. Memorandum and Articles of Association</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_394">152</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_397">C. Material Contracts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_397">156</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_400">D. Exchange Controls</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_400">156</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_403">E. Taxation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_403">156</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_406">F. Dividends and Paying Agents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_406">160</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_409">G. Statement by Experts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_409">160</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_412">H. Documents on Display</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_412">160</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_415">I. Subsidiary Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_415">160</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_7079">J.&#160;Annual Report to Security Holders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_7079">160</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_418">QUANTITATIVE AND&#160;QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_418">161</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_421">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_421">165</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_436">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:right"><span style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_436">167</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_439">DEFAULTS,&#160;DIVIDEND&#160;ARREARAGES AND DELINQUENCIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_439">167</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_442">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_442">167</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_445">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_445">167</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;16A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_448">AUDIT COMMITTEE FINANCIAL EXPERT</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_448">168</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;16B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_451">CODE OF ETHICS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_451">168</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;16C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_454">PRINCIPAL ACCOUNTANTS&#8217; FEES AND&#160;SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_454">168</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;16D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_457">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_457">168</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;16E.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_460">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_460">169</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;16F.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_463">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_463">169</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;16G.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_466">CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_466">169</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;16H.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_469">MINE SAFETY DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_469">171</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;16I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_472">DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_472">171</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;16J.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_6992">INSIDER</a><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_6992"> TRADING POLI</a><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_6992">CIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_6992">171</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;16K.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_6992">CYBERSECURITY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_6992">171</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_475">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:right"><span style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#7802e6;font-family:'Georgia',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_475">173</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;17.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_478">FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_478">173</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item&#160;18.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_481">FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_481">173</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Item 19.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_484">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_484">173</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_493"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">[CETTE PAGE EST LAISS&#201;E EN BLANC VOLONTAIREMENT]</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_28"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;1. Identity of Directors, Senior Management and Advisers</span></td></tr></table></div></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Part&#160;I</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_31"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;1. Identity of Directors, Senior Management and Advisers</span></div><div style="margin-bottom:2pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_34"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;2. Offer Statistics and Expected Timetable</span></div><div style="margin-bottom:2pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_37"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;3. Key Information</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_40"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A. Selected financial data</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_43"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B. Capitalization and indebtedness</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_46"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C. Reasons for offer and use of proceeds</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_49"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D. Risk factors</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Important factors that could cause actual financial, business, research, or operating results to differ materially from expectations are disclosed in this annual report, including without limitation the following risk factors. Investors should carefully consider all the information set forth in the following risk factors and elsewhere in this document before deciding to invest in any of the Company&#8217;s securities. In addition to the risks listed below, we may be subject to other material risks that as of the date of this report are not currently known to us or that we deem immaterial at this&#160;time.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risks relating to legal and regulatory matters</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product liability claims could adversely affect our business, results of operations and financial condition</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Product liability is a significant risk for any pharmaceutical company, given that liability claims relating to our industry are unforeseeable by nature. The evolving regulatory environment worldwide (the ever-more stringent regulatory requirements applicable to the pharmaceutical industry, plus more stringent data, quality and supply obligations) clearly impacts our potential liability, and we may incur different liability claims to what we have handled in the past, with regard to their nature, scope and level. For a detailed analysis of the regulatory environment in which we operate, refer to &#8220;Item 4. Information on the Company - B. Business Overview - B.5.3 Regulatory framework.&#8221; Substantial damages have been awarded by some jurisdictions and/or settlements agreed &#8211;&#160;notably in the United States and other common law jurisdictions&#160;&#8211; against pharmaceutical companies based on claims for injuries allegedly caused by the use of their products. Such claims can also lead to product recalls, withdrawals, or declining sales, and/or be accompanied by consumer fraud claims by customers, third-party payers seeking reimbursement of the cost of the product and/or other claims, including potential civil or criminal governmental actions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are currently defending a number of product liability claims (see Note&#160;D.22.a. to the consolidated financial statements included at Item&#160;18. of this annual report) notably with respect to TAXOTERE, ZANTAC, DEPAKINE and GOLD BOND, and there can be no assurance that we will be successful in defending these claims, or that we will not face additional claims in the future.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Establishing the full side effect profile of a pharmaceutical drug goes beyond data derived from preapproval clinical studies which may only involve several hundred to several thousand patients. Routine review and analysis of the continually growing body of post-marketing safety data and clinical trials provide additional information &#8211;&#160;for example, potential evidence of rare, population-specific or long-term adverse events or of drug interactions that were not observed in preapproval clinical studies. This causes product labeling to evolve over time following interactions with regulatory authorities, which may include restrictions of therapeutic indications, new contraindications, warnings or precautions and occasionally even the suspension or withdrawal of a product marketing authorization. Following any of these events, pharmaceutical companies can face significant product liability claims (see Note&#160;D.22.a. to the consolidated financial statements included at Item&#160;18. of this annual report).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Furthermore, we commercialize several devices (some of which use new technologies) which, if they malfunction, could cause unexpected damage and lead to product liability claims (see &#8220;Breaches of data security, disruptions of information technology systems and cyber threats could result in financial, legal, business or reputational harm&#8221; below).</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Although we continue to insure a portion of our product liability with third-party carriers, product liability coverage is increasingly difficult and costly to obtain, particularly in the United States. In the future, it is possible that self-insurance may become the sole commercially reasonable means available for managing the financial risk associated with product liability in our pharmaceuticals and vaccines businesses (see &#8220;Item&#160;4.&#160;Information on the Company &#8212;&#160;B. Business Overview &#8212;&#160;B.8. Insurance and Risk Coverage&#8221;). In cases where we self-insure, the legal costs that we would bear for handling such claims, and potential damage awards to be paid to claimants, could have a negative impact on our financial condition. Due to insurance conditions, even when we have insurance coverage, recoveries from insurers may not be totally successful due to market-driven insurance limitations and exclusions. Moreover, insolvency of an insurer could affect our ability to recover claims on policies for which we have already paid a premium.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Product liability claims, regardless of their merits or the ultimate success of our defense, are costly, divert management&#8217;s attention, may harm our reputation, and can impact the demand for our products and generate speculative news flows and/or rumors relating to such claims. Substantial product liability claims could materially adversely affect our business, results of operations and financial condition, and/or may have an impact on market perception of our company and negatively affect our stock price.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Claims and investigations relating to ethics and business integrity, competition law, marketing practices, pricing, human rights of workers and other legal matters could adversely affect our business, results of operations and financial condition</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our industry is heavily regulated and legal requirements vary from country to country, and new requirements are imposed on our industry from time to time. Governments and regulatory authorities around the world have been strengthening implementation and enforcement activities in recent years, including in relation to anti-bribery, anti-corruption and ethical requirements with respect to medical and scientific research, interactions with healthcare professionals and payers, and respect for the human rights of workers.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have adopted a Code of Conduct that requires employees to comply with applicable laws and regulations, as well as the specific principles and rules of conduct set forth in the Code. We also have policies and procedures designed to help ensure that we, our officers, employees, agents, intermediaries and other third parties comply with applicable laws and regulations (including but not limited to the US Foreign Corrupt Practices Act (FCPA), the UK Bribery Act, the OECD Anti-Bribery Convention, the French Anti-Corruption measures law (Sapin&#160;II), the French duty of vigilance law and other anti-bribery laws and regulations).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Notwithstanding these efforts, failure to comply with laws and regulations (including as a result of a business partner&#8217;s breach) may occur and could result in liabilities for us and/or our management.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and certain of its subsidiaries could become the subject of investigations or proceedings by various government entities or could face audits and/or litigation, including allegations of corruption, claims related to employment matters, patent and intellectual property disputes, consumer law claims, competition law and tax audits. We are currently the target of a number of lawsuits relating to pricing and marketing practices (including, for example, &#8220;whistleblower&#8221; litigation in the United States), which we are vigorously defending. With respect to tax issues, the complexity of the fiscal environment is such that the ultimate resolution of any tax matter may result in payments that are greater or less than the amounts we have accrued. See &#8220;Item&#160;8.&#160;Financial Information &#8212;&#160;A.&#160;Consolidated Financial Statements and Other Financial Information &#8212;&#160;Information on Legal or Arbitration Proceedings&#8221; and Note&#160;D.22. to our consolidated financial statements included at Item&#160;18. of this annual report. In addition, responding to such investigations is costly and may divert management&#8217;s attention from our business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unfavorable outcomes in any of these matters, or in similar matters that may arise in the future, could preclude the commercialization of our products, harm our reputation, negatively affect the profitability of existing products and subject us to substantial fines, punitive damages, penalties and injunctive or administrative remedies, potentially leading to the imposition of additional regulatory controls, monitoring or self-reporting obligations, or exclusion from government reimbursement programs or markets, all of which could have a material adverse effect on our business, results of operations or financial condition.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The unpredictability of these proceedings could lead Sanofi, after consideration of all relevant factors, to enter into settlement agreements to settle certain claims. Such settlements may involve significant monetary payments and/or potential criminal penalties, may include admissions of wrongdoing and may require entering into a Corporate Integrity Agreement (CIA) or a Deferred Prosecution Agreement (in the United States), which is intended to regulate company behavior for a specified number of years. For example, on February&#160;28, 2020, Sanofi US entered into a civil settlement with the United States Department of Justice and agreed to pay approximately $11.85&#160;million to resolve allegations regarding certain charitable donations Sanofi US made to an independent patient assistance foundation that assisted patients being treated for multiple sclerosis. In connection with this settlement, Sanofi US also entered into a CIA with the Office of the Inspector General for the United States Department of Health and Human Services effective the same day, which will require us to meet and maintain certain compliance requirements in the United States.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our activities (including our products and manufacturing activities) are subject to significant government regulations and regulatory approvals, which are often costly and could result in adverse consequences to our business if we fail to anticipate the regulations, comply with them, maintain the required approvals, and/or adapt to changes in applicable regulations</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Obtaining a marketing authorization for a product is a long and highly regulated process requiring us to present extensive documentation and data to the relevant regulatory authorities either at the time of the filing of the application for a marketing authorization or later during its review. Each regulatory authority may impose its own requirements which can evolve over time. </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:right;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Each regulatory authority may also delay or refuse to grant approval even though a product has already been approved in another country. Regulatory authorities are increasingly strengthening their requirements on product safety and risk/benefit profiles. All of these requirements, including post-marketing requirements, have increased the costs associated with maintaining marketing authorizations (see &#8220;Item 4. Information on the Company &#8212;&#160;B.&#160;Business Overview &#8212; B.5.&#160;Markets &#8212; B.5.3.&#160;Regulatory framework&#8221;).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Moreover, to monitor our compliance with applicable regulations, the FDA, EMA, WHO and comparable national agencies in other jurisdictions routinely conduct regulatory inspections of our facilities, distribution centers, commercial activities and development centers (including hospitals), and may identify potential deficiencies which we must adequately address. For example, in November&#160;2020, the FDA issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for sutimlimab, a monoclonal antibody for the treatment of hemolysis in adults with cold agglutinin disease (which has been approved in the meantime), referring to certain deficiencies identified by the agency during a pre-license inspection of a third-party facility responsible for manufacturing. More generally, if we fail to adequately respond to regulatory inspection observations identified during an inspection or fail to comply with applicable regulatory requirements at all or within the targeted timeline, we could be subject to enforcement, remedial and/or punitive actions by the FDA (such as a Warning Letter, injunction, seizure or cease and desist order), the EMA or other regulatory authorities. In addition, we have an obligation to monitor and report adverse events and safety signals. In order to comply with these duties, we must regularly train our employees and certain third parties (such as external sales forces and distributor employees) on regulatory matters, including on pharmacovigilance. If we fail to train these people, or fail to train them appropriately, or if they do not comply with contractual requirements, we may be exposed to the risk that safety events are not reported or not reported in a timely manner in breach of our reporting obligations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Due to regulatory or geopolitical constraints, we may face delays in our clinical trials due, for example, to the new EU Clinical Trials Regulation review process for approvals of new trials or for the transition of ongoing trials under such new regulation, and/or restrictions imposed on clinical trial sites, and/or delays in the supply chain for investigational products and/or the initiation and enrollment of patients in our clinical trials, and/or disruptions related to regulatory approvals, for instance due to the inability of health authorities to perform inspections in other countries and/or delays in label expansions for existing products. We may not be able to fully mitigate these delays, which could negatively impact the timing of our pipeline development programs and may have a negative impact on our product development and launches and hence on future product sales, business and results of operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, all aspects of our business, including research and development, manufacturing, marketing, reimbursement, pricing and sales, are subject to extensive legislation and governmental regulation. Changes in applicable laws and the costs of compliance with such laws and regulations could have an adverse effect on our business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For example, in response to the European Union regulations for Medical Devices (EU MDR), which entered into force in May&#160;2021, Sanofi created the EU MDR task force. This task force was commissioned to address the risk of potential delays in approvals (for new drug-device combination products, for substantial changes to the design or intended purpose of the device component of already approved drug-device combination products, and for medical devices) and of product discontinuation (for some legacy medical devices), as well as compliance risks for existing products due to increased requirements for post-marketing surveillance, clinical evaluations, traceability and transparency. A similar task force was set up in the first quarter of 2021 to examine risks related to the new regulations for In-Vitro Diagnostic Devices (IVDR) implemented in May&#160;2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For information about risks related to changes:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in proprietary rights rules and regulations, see &#8220;&#8211;&#160;We rely on our patents and other proprietary rights to provide exclusive rights to market certain of our products. If such patents and other rights were limited, invalidated or circumvented, our financial results could be adversely affected&#8221; below; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in environmental rules and regulations, see &#8220;&#8211;&#160;Management of the historical contamination related to our past industrial activities could adversely impact our results of operations and reputation&#8221; below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, changes in tax laws or regulations or their interpretation or exposures to additional tax liabilities around the world could negatively impact our operating results. Changes to tax laws or regulations may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Furthermore, most of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains. However, the outcome of those mechanisms developed to resolve such conflicting claims can be uncertain and can be expected to be very lengthy. Accruals for tax contingencies are made based on experience, interpretations of tax law, and judgments about potential actions by tax authorities. However, due to the complexity of tax contingencies, the ultimate resolution of any tax matter may result in payments materially different from the amounts accrued.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely on our patents and other proprietary rights to provide exclusive rights to market certain of our products. If such patents and other rights were limited, invalidated or circumvented, our financial results could be adversely affected</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Through patent and other proprietary rights, such as data exclusivity or supplementary protection certificates in Europe, we hold exclusivity rights for a number of our research-based products. However, the protection that we are able to obtain varies in its duration and scope. Furthermore, patents and other proprietary rights do not always provide effective protection for our products. We cannot be certain that we will obtain adequate patent protection for new products and technologies in important markets or that such protections, once granted, will last as long as originally anticipated.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">3</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For example, governmental authorities are increasingly looking to facilitate generic and biosimilar competition for existing products through new regulatory proposals intended to achieve, or resulting in, changes to the scope of patent or data exclusivity rights and through the use of accelerated regulatory pathways for generic and biosimilar drug approvals. At the EU level, the proposed wide-ranging revision of the general pharmaceutical legislation may pose downside risks to innovation and competitiveness in Europe, primarily due to the reduction of intellectual property (IP) protections and a stricter incentives framework for orphan medicinal products (OMPs). Such regulatory proposals could make patent prosecution for new products more difficult and time consuming or could adversely affect the exclusivity period for our products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Moreover, manufacturers of generic products or biosimilars are increasingly seeking to challenge patent validity or coverage before the patents expire, and manufacturers of biosimilars or interchangeable versions of the products are seeking to have their version of the product approved before the exclusivity period ends. Furthermore, in an infringement suit against a third party, we may not prevail and the decision rendered may not conclude that our patent or other proprietary rights are valid, enforceable or infringed. Our competitors may also successfully avoid our patents. Even in cases where we ultimately prevail in an infringement claim, legal remedies available for harm caused to us by infringing products may be inadequate to make us whole. Moreover, a successful result against a competing product for a given patent or in a specific country is not necessarily predictive of our future success against another competing product or in another country because of local variations in the patents and patent laws.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, if we lose patent protection as a result of an adverse court decision or a settlement, we face the risk that government and private third-party payers and purchasers of pharmaceutical products may claim damages alleging they have over-reimbursed or overpaid for a drug. For example, in 2009, in Australia, our patent on clopidogrel was ultimately held invalid. Following this decision, the Australian Government sought damages for its alleged over-reimbursement of clopidogrel drugs due to the preliminary injunction we had secured against the sale of generic clopidogrel during the course of the litigation. The Australian Government&#8217;s claim was dismissed following two decisions, one of the Federal Court of Australia in April&#160;2020 and one of the Full Court of the Federal Court of Australia in June&#160;2023. On December&#160;18, 2023, the Australian Government was granted a special leave to appeal to the High Court of Australia.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also rely on unpatented proprietary technology, know-how, trade secrets and other confidential information, which we seek to protect through various measures, including confidentiality agreements with licensees, employees, third-party collaborators, and consultants who may have access to such information. If these agreements are breached or our other protective measures should fail, then our contractual or other remedies may not be adequate to cover our losses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In certain cases, to terminate or avoid patent litigation we or our collaboration partners may be required to obtain licenses from the holders of third-party intellectual property rights. Any payments under these licenses may reduce our profits from such products and we may not be able to obtain these licenses on favorable terms or at all.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Third parties may also request a preliminary or permanent injunction in a country from a court of law to prevent us from marketing a product if they consider that we infringe their patent rights in that country. If third parties obtain a preliminary or permanent injunction or if we fail to obtain a required license for a country where valid third-party intellectual property rights as confirmed by a court of law exist, or if we are unable to alter the design of our technology to fall outside the scope of third-party intellectual property rights, we may be unable to market some of our products in certain countries, which may limit our profitability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, the pursuit of valid business opportunities may require us to challenge intellectual property rights held by others that we believe were improperly granted, including through negotiation and litigation, and such challenges may not always be successful. Third parties may claim that our products infringe one or more patents owned or controlled by them. Claims of intellectual property infringement can be costly and time-consuming to resolve, may delay or prevent product launches, and may result in significant royalty payments or damages.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Furthermore, some countries may consider granting a compulsory license to a third party to use patents protecting an innovator&#8217;s product, which limits the value of the patent protection granted to such products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have increased the proportion of biological therapeutics in our pipeline relative to traditional small molecule pharmaceutical products. Typically, the development, manufacture, sale and distribution of biological therapeutics is complicated by third-party intellectual property rights (otherwise known as freedom to operate (FTO) issues), to a greater extent than for the small molecule therapeutics, because of the types of patents allowed by national patent offices. Further, our ability to successfully challenge third-party patent rights is dependent on the legal interpretation and case law of national courts. In addition, we expect to face increasing competition from biosimilars in the future. With the accelerated regulatory pathways provided in the United States and Europe for biosimilar drug approval, biosimilars can be a threat to the exclusivity of any biological therapeutics we sell or may market in the future and can pose the same issues as the small molecule generic threat described above. If a biosimilar version of one of our products were to be approved, it could reduce our sales and/or profitability of that product.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We currently hold trademark registrations and have trademark applications pending in many jurisdictions, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on our trademarks and trade dress to differentiate us from our competitors increases and, as a result, our business could be adversely affected if we are unable to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate our rights.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If our patents and/or proprietary rights to our products were limited or circumvented, our financial results could be adversely affected.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:right;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to comply with data ethics and privacy regulations could adversely affect our business and reputation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We operate in an environment that relies on the collection, processing, analysis and interpretation of large sets of patients&#8217; and other individuals&#8217; personal data, and the operation of our business requires data to flow freely across borders of numerous countries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The legal and regulatory environment of data privacy is diversified, with regional legislation such as the General Data Protection Regulation (GDPR) in Europe, the Personal Information Protection Law (PIPL) enacted in 2021 in China, and other significant privacy legislation, including the California Consumer Privacy Act (CCPA) in the United States. As the framework continues to evolve, some uncertainty remains with respect to absence of clear guidance or case law.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such uncertainty could result in an operational risk limiting or preventing the transfer of data across borders, which may have an impact on our activities (e.g., on clinical trials). Breach of the regulations described above could also carry financial sanctions and may harm our reputation and those of our activities that rely on personal data processing.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Furthermore, the increasing volume of data processed and advances in new technologies, such as artificial intelligence, have resulted in a greater focus on data governance and the ethical use of personal data. Failure in our data governance and ethical use of personal data could affect our business and reputation.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risks relating to our business</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The pricing and reimbursement of our products is negatively affected by increasing cost containment pressures and decisions of governmental authorities and other third parties</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The commercial success of our existing products and our product candidates depends in part on their pricing and reimbursement conditions. Our products are negatively affected by continued downward pricing pressure and scrutiny due, inter alia, to:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">stricter price and access controls imposed by governments and other payers around the world:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">requirements for greater transparency around drug pricing and drug development costs,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">widespread use of international reference pricing and therapeutic reference pricing, among other pricing methodologies and caps,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">mandatory price cuts, renegotiations, industry payback and rebates,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">delisting from reimbursement and restrictions on the label population,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">access restrictions for high-priced innovative medicines,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">prescribing guidelines and binding medicine utilization controls,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">Medicare drug price negotiations under the US Inflation Reduction Act (IRA),</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">greater use of tendering and centralized procurement (national/regional/class-wide level),</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">cross-country cooperation in price negotiations, contracting or procurement, which is already occurring to some extent, such as the Vaccine Alliance (GAVI), the COVID-19 Vaccines Global Access (COVAX) initiative, the BeNeLuxA alliance in Europe, and the Pan American Health Organization (PAHO),</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">shifting of the payment burden to US patients and access disruptions through co-pay accumulator and maximizer programs as well as alternative funding programs,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">more aggressive formulary utilization management controls (including stepped therapy, strict prior authorization criteria, formulary exclusions) by US insurers and pharmacy benefits managers (PBMs), and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">discriminatory and non-transparent pricing and procurement policies (e.g. government procurement restrictions, import bans) in favor of domestic pharmaceutical companies;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">widespread use of health technology assessment (HTA) to inform coverage and reimbursement decisions:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">more stringent evidence and value requirements (e.g. comparative effectiveness, patient preferences, real-word evidence, health economic modelling) by payers and HTA authorities, raising the bar for market entry,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">unreasonable thresholds for cost-effectiveness, and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">increasingly restrictive HTA decisions with significant variation across markets;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">increased generic and biosimilar competition, accelerating price erosion:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">next generation biosimilars coming to the market across major therapeutic areas,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">potential savings from increased biosimilar use, expected to be a cumulative $285&#160;billion globally through 2025 according to the IQVIA Institute, and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">evolving regulatory landscapes to support interchangeability (e.g., in the US and EU) and pharmacy substitution (e.g. in the EU Nordic countries, Germany and France).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the United States, which accounted for 43.0% of our net sales in 2023, the IRA was enacted in August&#160;2022. The law includes three core drug pricing provisions (Medicare negotiation, Part&#160;D redesign, and Medicare inflation penalties) with effective dates ranging from 2022 through 2026. The IRA legislation is likely to have a negative impact on industry revenue growth and future innovation. While significant uncertainties remain on the process and methods of Medicare negotiation, we anticipate exposure to the negotiation provision in the latter part of the decade, and in the case of DUPIXENT not before 2031.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Furthermore, we face increasing pricing pressure and gross-to-net (GTN) erosion from continuing vertical integration and consolidation of the US health insurance market. With the three largest pharmacy benefit manager group purchasing organizations (PBM GPOs) (i.e.&#160;Ascent, Zinc and Emisar) now covering over 85% of prescription drug claims, consolidation has led to increased utilization management and restrictive formularies, resulting in strong bargaining power to negotiate discounted prices, thereby adversely impacting our sales.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">There is also uncertainty about the potential impact of the continued growth of the federal 340B drug pricing program, among other risks.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In China, pricing pressure is likely to intensify as a growing number of our products are subject to national reimbursement drug list (NRDL) price negotiations and national volume-based procurement (VBP) tenders, with the lowest prices prevailing to compete with local champions. At market entry, new drugs listed on the NRDL had an average price cut of 60% over the past five years. Further expansion of the VBP policy to biologics and biosimilars also poses a growing threat to our key established products, with over 500&#160;drugs targeted for inclusion by 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Europe, budget pressure remains high in the wake of Covid-19, translating into an acceleration of cost-containment policies in major EU markets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The industry is also facing high uncertainty in the context of the new pharmaceutical strategy in Europe, including numerous policy changes to the EU pharmaceutical legislation, HTA and joint procurement, among others. If passed, these reforms will likely create new challenges and risks for access, innovation and competitiveness in Europe, primarily because of the reductions in regulatory data protection (from eight to six years for all new drugs) and market exclusivity for orphan medicines.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our research and development efforts may not succeed in adequately renewing our product portfolio</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Discovering and developing a new product is a costly, lengthy and uncertain process. To be successful in the highly competitive pharmaceutical industry, we must commit substantial resources each year to research and development in order to develop new products to compensate for decreasing sales of products facing patent expiration and termination of regulatory data exclusivity, introduction of lower-priced generics, or competition from new products of competitors that are perceived as being superior or equivalent to our products. We must pursue both early-stage research and early and late development stages in order to propose a sustainable and well-balanced portfolio of products. In 2023, we spent &#8364;6,728&#160;million on research and development, amounting to 15.6% of our net&#160;sales. As part of an update on our strategy, we announced in October&#160;2023 our intent to increase our research and development investments. Failure to invest in the right technology platforms, therapeutic areas, product classes, geographic markets and/or licensing opportunities could adversely impact the productivity of our pipeline.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are pursuing our strategic transformation through R&amp;D, including potential multi-indication assets such as amlitelimab, frexalimab and the oral TNFR1si, intended to address unmet patient needs in markets with low penetration of advanced therapies. We focus our R&amp;D strategy on oncology, immunology and inflammation, multiple sclerosis, neurology, rare diseases and rare blood disorders. In&#160;2021, Sanofi acquired Translate Bio to accelerate the deployment of mRNA technology for the development of new vaccines, including for seasonal influenza, and beyond vaccines, therapeutics where there is a strong unmet medical need. However, mRNA technology is still in its early days and the ability of this technology to produce strong results and safety still remains to be fully asserted. We may also fail to improve our development productivity sufficiently to sustain our pipeline (see also &#8220;&#8212;&#160;We may fail to successfully identify external business opportunities or realize the anticipated benefits from our strategic investments or divestments&#8221; below). Other new innovations under investigation, such as natural killer (NK) cells and conditionally activated biologics, raise similar uncertainties.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, the competitive landscape includes a high level of uncertainty as numerous companies are working on or may be evaluating similar targets and a product considered as promising at the beginning of its development may become less attractive if a competitor addressing the same unmet need reaches the market earlier. There can be no assurance that any of our product candidates will be proven safe or effective (see &#8220;Item&#160;4. Information on the Company &#8212;&#160;B.&#160;Business Overview &#8212;&#160;B.4. Global research &amp; development&#8221;). Over these research and development cycles, usually spanning several years, there is a substantial risk at each stage of development &#8211;&#160;including pre-clinical activities and clinical trials&#160;&#8211; that we will not achieve our goals of safety and/or efficacy and that we will have to abandon a product in which we have invested substantial amounts of money and human resources. For instance, in 2022 patient enrollment of Phase&#160;3 tolebrutinib trials paused globally after a decision of the FDA regarding potential side effects. As another example, the global clinical development program of amcenestrant (breast cancer) was discontinued in August&#160;2022 following the outcome of the prespecified interim analysis of a Phase&#160;3 trial. More and more trials are designed with clinical endpoints of superiority; failure to achieve those endpoints could damage the product&#8217;s outlook and our overall development program.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Decisions concerning the studies to be carried out can have a significant impact on the marketing strategy for a given product. Multiple in-depth studies can demonstrate that a product has additional benefits, facilitating the product&#8217;s marketing, but such studies are expensive and time consuming and may delay the product&#8217;s submission to regulatory authorities for approval.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, following (or in some cases contemporaneously with) the marketing authorization, the dossier is also submitted to governmental agencies and/or national or regional third-party payers (HTA bodies) for review. These HTA bodies evaluate evidence on the value of the new product, assess the medical need it serves, and provide recommendations on the corresponding reimbursement. Such analyses may require additional studies, including comparative studies, which may effectively delay marketing, change the population which the new product treats, and add costs to its development. Our continuous investments in research and development for future products and for the launches of newly registered molecules could therefore result in increased costs without a proportionate increase in revenues, which would negatively affect our operating results and profitability.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:right;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Lastly, there can be no assurance that all the products approved or launched will achieve commercial success.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, even after a product reaches the market, certain developments following regulatory approval may decrease demand for our products. Clinical trials and post-marketing surveillance of certain marketed drugs have the potential to raise concerns among some prescribers and patients relating to the safety or efficacy of pharmaceutical products in general, which could negatively affect the sales of such products or lead to increased volatility in market reaction.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Breaches of data security, disruptions of information technology systems and cyber threats could result in financial, legal, competitive, operational, business or reputational harm</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our business depends heavily on the use of interdependent information technology systems, including Internet-based systems and digital tools. Certain key areas such as research and development, production and sales are to a large extent dependent on our information systems (including cloud-based computing) or those of third-party providers (including for the storage and transfer of critical, confidential, sensitive or personal information regarding our patients, clinical trials, vendors, customers, employees, collaborators and others). We are therefore vulnerable to cybersecurity attacks and incidents and misuse or manipulation of any of these IT systems could result in exposure of confidential information or the modification of critical data.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We and our third-party service providers, suppliers, contract manufacturers, distributors or other contracting third parties use, to the best of our ability, secure information technology systems for the protection of data and threat detection. Like many companies, we may experience certain of the following events which pose a risk to the security and availability of these systems and networks, and the confidentiality, integrity, and availability of our sensitive data: breakdown, outages, service disruption or impairment, data loss or deterioration in the event of a system malfunction or increasing threat of data theft or corruption in the event of a cyber-attack, security breach, industrial espionage attacks, insider threat attacks, cybercrimes, including state-sponsored cybercrimes, malware, misplaced or lost data, programming or human errors or other similar events. Also, in the event of an attack, US and European legislation related to the financing of terrorism imposes increasing restrictions on payments of ransom. As a result, our ability to recover the data might be limited. Therefore, our business continuity could be at risk if we are unable to recover data through back-ups and restorations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are increasingly using generative artificial intelligence to enhance our business processes. Although we have set up a governance body to control the artificial intelligence initiatives taken on a company-wide scale and have made a generative artificial intelligence charter available to all our employees, this new technology, like other artificial intelligence technology, entails risks linked to transparency and explainability, privacy and confidentiality, eco-responsibility, and cybersecurity. Those risks could lead to, among other things, unethical practices, business and reputational harm, cyber-attacks and security breaches (see "&#8212;&#160;We may fail to develop or take advantage of digitalization and prioritizing data as an organizational asset" below).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Each of these events could negatively impact important processes, such as scientific research and clinical trials, the submission of outcomes to health authorities for marketing authorizations, the functioning of production processes and the supply chain, compliance with legal requirements, trade secrets, security strategies and other key activities, including Sanofi&#8217;s employees&#8217; ability to communicate between themselves as well as with third parties (see also &#8220;&#8212;&#160;Product liability claims could adversely affect our business, results of operations and financial condition&#8221; above). This could result in material financial, legal, competitive, operational, business or reputational harm.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Although we maintain relevant insurance coverage, this insurance may not be sufficiently available in the future to cover the financial, business or reputational losses that may result from an interruption or breach of our systems. For example, certain types of cyber-attacks could be considered as an Act of War subject to insurance exclusion.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The manufacture of our products is technically complex, and supply interruptions, product recalls or inventory losses caused by unforeseen events may reduce sales, adversely affect our operating results and financial condition, delay the launch of new products and negatively impact our image</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Many of our products are manufactured using technically complex processes with production constraints, including the need for specialized facilities, trained and certified employees, and highly specific raw materials. We must ensure that all manufacturing processes comply with (i)&#160;current Good Manufacturing Practices (cGMP), (ii)&#160;other applicable regulations issued by governmental health authorities around the world, as well as (iii)&#160;our own quality standards. Third parties supply us with a portion of our raw materials, active ingredients and medical devices, which exposes us to the risk of a supply shortage or interruption especially in the event that these suppliers are unable to manufacture our products in line with quality standards or if they experience financial difficulties.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Epidemics and other public health crises, such as the COVID-19 pandemic, expose us to risks of a slowdown or temporary suspension in the production of our APIs, raw materials, and some of our products. Any prolonged restrictive measures put in place in order to control an outbreak of contagious disease or other adverse public health development, in any of our principal production sites, may have a material and adverse effect on our manufacturing operations. Any of these factors could adversely affect our business, operating results or financial condition (see &#8220;Item&#160;4. Information on the Company &#8212;&#160;B.&#160;Business Overview &#8212;&#160;B.7.&#160;Production and raw materials&#8221; for a description of these outsourcing arrangements and &#8220;A failure in our crisis and business continuity management processes in case of unpredictable events could have negative consequences for our business, operations and reputation&#8221; below).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our business may require the transformation and adaptation of our plants in order to ensure the continuity of production of our products in sufficient quantities to satisfy demand. This may be necessary to meet the need for the production of new products, including biologics, or to ensure the scaling up production of products under development once approved. This need may also result from new regulatory requirements. Furthermore, our biological products, in particular, are subject to the risk of </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">7</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">manufacturing stoppages or the risk of loss of inventory because of the difficulties inherent in the processing of biological materials and the potential difficulties in accessing adequate amounts of raw materials meeting required standards. In addition, specific storage and distribution conditions are required for many biological products (for example, cold storage is required for certain vaccines, insulin-based products and some hemophilia products). These production difficulties may also be encountered during testing, which is a mandatory requirement prior to drug products being released. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The complexity of our production processes, as well as standards required for the manufacture of our products, subject us to risks because the investigation and remediation of any identified or suspected problems can cause production delays, substantial expense, product recalls or lost sales and inventories, and delay the launch of new products; this could adversely affect our operating results and financial condition, and cause reputational damage and the risk of product liability (see &#8220;&#8212;&#160;Product liability claims could adversely affect our business, results of operations and financial condition&#8221; above). In addition, some of our production sites, and some of our suppliers&#8217; and/or contractors&#8217; sites, are located in areas exposed to natural disasters such as floods, earthquakes and hurricanes. Such disasters could be exacerbated by climate change. In the event of a major disaster, we could experience severe destruction or interruption of our operations and production capacity at these sites.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When manufacturing disruptions occur, we may not have alternate manufacturing capacity, particularly for certain biologics. In the event of manufacturing disruptions, our ability to use backup facilities or set up new facilities is more limited because biologics are more complex to manufacture and generally require dedicated facilities. Even though we aim to have backup sources of supply whenever possible, including by manufacturing backup supplies of our principal active ingredients at additional facilities when practicable, we cannot be certain they will be sufficient if our principal sources become unavailable. Switching sources and manufacturing facilities requires significant time and prior approval by health authorities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Supply shortages generate even greater negative reactions when they occur with respect to life saving medicines with limited or no viable therapeutic alternatives. Shortages of specific products can have a negative impact on the confidence of patients, customers and professional healthcare providers and the image of Sanofi and may lead to lower product revenues.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A substantial share of the revenue and income of Sanofi depends on the performance of certain flagship products</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of the presentation of our strategy in December&#160;2019, we announced our intent to prioritize our activities on growth drivers including DUPIXENT and our Vaccines operations, which we have identified as key growth drivers. Nevertheless market expansion and new launches of medicines and vaccines may not deliver the expected benefits. We may also encounter failures or delays in our launch strategy (in terms of timing, pricing, market access, marketing efforts and dedicated sales forces), such that our products that may not deliver the expected benefits. The competitive environment for a given product may also have changed by the time of the actual launch, modifying our initial expectations. The need to prioritize the allocation of resources may also cause delays in or hamper the launch or expansion of some of our products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Also, we currently generate a substantial share of our net sales from certain key products (see &#8220;Item&#160;5.&#160;Operating and Financial&#160;Review and Prospects &#8212;&#160;A.2. Results of Operations &#8212;&#160;Year ended December&#160;31, 2023 compared with year ended December&#160;31,&#160;2022 &#8212;&#160;A.2.1.3/Net Sales &#8212;&#160;Biopharma segment&#8221;). For example, DUPIXENT generated net sales of &#8364;10,715&#160;million in&#160;2023 representing 24.9% of our net sales for the year and is Sanofi&#8217;s biggest product in terms of sales.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Among our flagship products, LANTUS, LOVENOX, PLAVIX and JEVTANA</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">already face generic competition on the market. LANTUS is particularly important; it was one of Sanofi&#8217;s leading products in 2023 with net sales of &#8364;1,420&#160;million. AUBAGIO, another leading product, has faced generic competition in the US since March&#160;2023, following a settlement agreement entered into in 2017 and in Europe since the fourth quarter of 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">More generally, an expiration of effective intellectual property protections for our products typically results in the market entry of one or more lower-priced generic competitors, often leading to a rapid and significant decline in revenues on those products (for information regarding ongoing patent litigation see Note&#160;D.22.b. to the consolidated financial statements included at Item&#160;18. of this annual report).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The introduction of a generic product results in adverse price and volume effects for our branded or genericized products. For example, although we do not believe it is possible to state with certainty what level of net sales would have been achieved in the absence of generic competition, a comparison of our consolidated net sales for 2023 and 2022 for the main products affected by generic and biosimilar competition shows a loss of &#8364;651&#160;million of net sales on a reported basis (see&#160;&#8220;Item&#160;5.&#160;Operating and Financial Review and Prospects &#8212;&#160;A.1.2.&#160;Impacts of Competition from generics and biosimilars&#8221;). However, other parameters may have contributed to the loss of sales, such as a fall in the average price of certain products (e.g., LANTUS).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Furthermore, in general, if one or more of our flagship products were to encounter problems (such as material product liability litigation, unexpected side effects, product recalls, non-approval by the health authorities of a new indication for a marketed product, pricing pressure and manufacturing or supply issues), the adverse impact on our business, results of operations and financial condition could be significant.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely on third parties for the discovery, manufacture, marketing and distribution of some of our products</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our industry is both highly collaborative and competitive, whether in the discovery and development of new products, in-licensing, the marketing and distribution of approved products, or manufacturing activities. We expect that we will continue to rely on third parties for key aspects of our business and we need to ensure our attractiveness as a potential partner.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:right;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We conduct a number of significant research and development programs and market some of our products in collaboration with other biotechnology and pharmaceutical companies. For example, we currently have a global strategic collaboration with Regeneron on monoclonal antibodies for the development and commercialization of DUPIXENT, KEVZARA (sarilumab) and SAR440340 (REGN3500- itepekimab) (see&#160;&#8220;Item&#160;5.&#160;Operating and Financial Review and Prospects &#8212;&#160;A.1.7. Financial Presentation of Alliances &#8212;&#160;A.1.7.1/&#160;Alliance Arrangements with Regeneron Pharmaceuticals Inc.&#8221;). We rely upon Regeneron to successfully carry out their responsibilities with regard to the manufacture and supply of these collaboration antibodies. (see&#160;&#8220;Item&#160;4.&#160;Information on the Company &#8212;&#160;B.&#160;Business Overview&#8221;). We may rely on partners to design and manufacture medical devices as well, notably for the administration of our products. Finally, we may also rely on partners for the development and commercialization of in-vitro diagnostic tests used in clinical trials and in-vitro diagnostic tests which are specified in the labeling of our products as necessary or useful for the management of patients taking our products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards products recently launched or under development for which we have a collaboration agreement with partners, the terms of the applicable alliance agreement may require us to share profits and losses arising from commercialization of such products with our partners. This differs from the treatment of revenue and costs generated by other products for which we have no alliance agreement, and such profit sharing may deliver a lower contribution to our financial results.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We could also be subject to the risk that we may not properly manage the decision-making process with our partners. Decisions may be controlled by, or subject to the approval of our collaboration partners, who may have views that differ from ours. We are also subject to the risk that our partners may not perform effectively, which could have a detrimental effect when our collaboration partners are responsible for the performance of certain key tasks or functions, for example related to manufacturing or distribution. This risk is further increased by the growing number of distribution centers divested by Sanofi as part of its global strategy and by the resulting growing externalization of distribution tasks and functions. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Any failures in the development process or differing priorities may adversely affect our business, including the activities conducted through our collaboration arrangements. We also cannot guarantee that third-party manufacturers will be able to meet our near-term or long-term manufacturing requirements, for internal reasons (e.g., in case of financial difficulties), reasons directly related to their contractual relationship with Sanofi, or external reasons (e.g., in the event of a health crisis). Thereby, following the completion of the spin-off of EUROAPI in&#160;May&#160;2022, EUROAPI became a third-party manufacturer and continues to manufacture a certain number of APIs for Sanofi. We are also subject to the risk that contract research organizations or other vendors (for instance regarding digital activities) retained by us or our collaboration partners may not perform effectively.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Any conflicts or difficulties with our partners during the course of these agreements or at the time of their renewal or renegotiation, or any disruption in the relationships with our partners, may affect the development, manufacturing, launch and/or marketing of certain of our products or product candidates and may cause a decline in our revenues or otherwise negatively affect our results of operations.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to the risk of non-payment by our customers</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We run the risk of delayed payments or even non-payment by our customers, which consist principally of wholesalers, distributors, pharmacies, hospitals, clinics and government agencies. This risk is accentuated by recent concentrations among distributors and retailers, as well as by uncertainties around global credit and economic conditions, in particular in emerging markets. As a result, we may be affected by fluctuations in the buying patterns of such customers. The United States poses particular customer credit risk issues because of the concentrated distribution system: our three main customers represented respectively 11%, 9% and 7% of our consolidated net sales in 2023. We are also exposed to large wholesalers in other markets, particularly in Europe. An inability of one or more of these wholesalers to honor their debts to us could adversely affect our financial condition (see Note&#160;D.34. to our consolidated financial statements included at Item&#160;18. of this annual report).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In some countries, some customers are public or subsidized health systems. The economic and credit conditions in these countries may lead to an increase in the average length of time needed to collect on accounts receivable.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global economic conditions and an unfavorable financial environment could have negative consequences for our business</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Over the past several years, growth of the global pharmaceutical market has become increasingly tied to global economic growth. In this context, a substantial and lasting slowdown of the global economy, major national economies or emerging markets could negatively affect growth in the global pharmaceutical market and, as a result, adversely affect our business. For example, unpredictable political conditions that currently exist in various parts of the world could have a material negative impact on our business, in particular armed conflicts between Russia and Ukraine since 2022, and in Gaza following the terrorist attacks that occurred in Israel in October&#160;2023. The consequences of those conflicts are difficult to predict and will depend on developments outside Sanofi&#8217;s control, including, but not limited to the duration and severity of the conflicts, and the consequences of the ongoing and additional financial and economic sanctions imposed by governments in response. Other related issues have arisen or are arising such as regional instability; geopolitical uncertainties; adverse effects on fuel and energy costs, supply chains, macroeconomic conditions, inflation, and currency exchange rates in various regions of the world; and exposure of third parties to gas shortages. Collectively, such unstable conditions could, among other things, disturb the international flow of goods and increase the costs and difficulties associated with international transactions.</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> The information in this section supplements the disclosures required under IFRS&#160;7 as presented in Notes&#160;B.8.7., D.10. and D.34. to our consolidated financial statements, provided at Item&#160;18. of this annual report.</span></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> The information in this section supplements the disclosures required under IFRS&#160;7 as presented in Note&#160;B.8.7. to our consolidated financial statements, provided at Item&#160;18. of this annual report.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unfavorable economic conditions have reduced the sources of funding for national social security systems, leading to austerity measures including heightened pressure on drug prices, increased substitution of generic drugs, and the exclusion of certain products from formularies among others (see&#160;&#8220;&#8212;&#160;The pricing and reimbursement of our products is negatively affected by increasing cost containment pressures and decisions of governments and other third parties&#8221; above).</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Further, our net sales may be negatively impacted by the continuing challenging global economic environment, as high unemployment, increases in cost-sharing, and lack of developed third-party payer systems in certain regions may lead some patients to switch to generic products, delay treatments, skip doses or use other treatments to reduce their costs. In the United States there has been a significant increase in the number of beneficiaries in the Medicaid program, under which sales of pharmaceuticals are subject to substantial rebates and, in many US states, to formulary restrictions limiting access to brand-name drugs, including ours. Also, employers may seek to transfer a greater portion of healthcare costs to their employees due to rising costs, which could lead to further downward price pressure and/or lower demand.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Consumer Healthcare (CHC) business could also be adversely impacted by difficult economic conditions, as the financial resources of our customers may be reduced as a result of the economic situation.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If economic conditions worsen, or in the event of default or failure of major players including wholesalers or public sector buyers financed by insolvent states, our financial situation, the profitability and results of our operations and the distribution channels of our products may be adversely affected. See also&#160;&#8220;&#8212;&#160;We are subject to the risk of non-payment by our customers&#8221; above.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A failure in our crisis and business continuity management processes in case of unpredictable events could have negative consequences for our business, operations and reputation</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Despite enhanced crisis preparedness and response, due in particular to recent crises such as the COVID-19 pandemic and the war in Ukraine since February&#160;2022, unpredictable and extraordinary internal or external events, or a combination of escalating events that may occur as a result of a large scale cyber-attack (see also &#8220;&#8212;&#160;Breaches of data security, disruptions of information technology systems and cyber threats could result in financial, legal, competitive, operational, business or reputational harm&#8221; above), a pandemic or natural disasters, which could result in the failure of critical processes within Sanofi or a third party on whom we rely. Such failure may adversely impact our business, operations and reputation.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The occurrence of these unforeseen events may also heighten other risks such as a disruption or temporary suspension in production of APIs, raw materials and some of other products and/or lead to manufacturing delays or disruptions and supply chain interruptions (including to the extent those measures apply to our third-party suppliers) and may have an adverse effect on our business (see&#160;&#8220;&#8212;&#160;The manufacture of our products is technically complex, and supply interruptions, product recalls or inventory losses caused by unforeseen events may reduce sales, adversely affect our operating results and financial condition, delay the launch of new products and negatively impact our image&#8221; above). Also, a sudden increase in demand for selected medicinal products in the event of a crisis can result in short-term unavailability or shortages of raw materials.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to our operations, including an adverse impact on global temperatures, weather patterns and the frequency and severity of extreme weather and natural disasters. Natural disasters and extreme weather conditions, such as a hurricane, tornado, earthquake, wildfire or flooding, may pose physical risks to our facilities and disrupt the operation of our supply chain. The impacts of the changing climate on water resources may result in water scarcity, limiting our ability to access sufficient high-quality water in certain locations, which may increase operational costs. For example, some of our facilities are located in certain areas in France where specific administrative prefectural orders have been issued to regulate the water consumption (e.g. prefectural order issued by the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Pr&#233;fet de la Gironde</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in April&#160;2023 regarding requirements imposed on Sanofi for the operation of a drug manufacturing facility located in the city of Ambar&#232;s-et-Lagrave (i.e. implementation of specific water saving measures in the event of a period of drought)).</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Concern over climate change may also result in new or additional legal or regulatory requirements, designed to reduce greenhouse gas emissions and/or mitigate the effects of climate change on the environment. If such laws or regulations are more stringent than current legal or regulatory obligations (e.g. increased carbon taxation risk), we may experience disruption in, or an increase in the costs associated with sourcing, manufacturing and distribution of our products, which may adversely affect our business, results of operations or financial condition.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The increasing use of social media platforms and new technologies present risks and challenges for our business and reputation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We increasingly rely on social media, new technologies and digital tools to communicate about our products and about diseases or to provide health services. The use of these media requires specific attention, monitoring programs and moderation of comments. Political and market pressures may be generated by social media because of rapid news cycles. This may result in commercial harm, overly restrictive regulatory actions and erratic share price performance. In addition, unauthorized communications, such as press releases or posts on social media, purported to be issued by Sanofi, may contain information that is false or otherwise damaging and could have an adverse impact on our image and reputation and on our stock price. Negative or inaccurate posts or comments about Sanofi, our business, directors or officers on any social networking website could seriously damage our reputation. In addition, our employees and partners may use social media and mobile technologies inappropriately, which may give rise to liability for Sanofi, or which could lead to breaches of data security, loss of trade secrets or other intellectual property or public disclosure of sensitive information. Such uses of social media and mobile technologies could have an adverse effect on our reputation, business, financial condition and results of operations.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:right;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risks relating to Sanofi&#8217;s structure and strategy</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may fail to successfully identify external business opportunities or realize<br/>the anticipated benefits from our strategic investments or divestments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We pursue a strategy of selective acquisitions, in-licensing and collaborations in order to reinforce our pipeline and portfolio. We are also proceeding to selective divestments to focus on key business areas. The implementation of this strategy depends on our ability to identify transaction opportunities, mobilize the appropriate resources in order to enter into agreements in a timely manner, and execute these transactions on acceptable economic terms. Moreover, entering into in-licensing or collaboration agreements generally requires the payment of significant &#8220;milestones&#8221; well before the relevant products reach the market, without any assurance that such investments will ultimately become profitable in the long term (see Note&#160;D.21.1. to the consolidated financial statements included at Item&#160;18. of this annual report and also &#8220;&#8212;&#160;We rely on third parties for the discovery, manufacture, marketing and distribution of some of our products&#8221; above). Once a strategic transaction is agreed upon with a third party, we may not be able to complete the transaction in a timely manner or at all.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For newly acquired activities or businesses, our growth objectives could be delayed or ultimately not realized, and expected synergies could be adversely impacted if, for example:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">we are unable to integrate those activities or businesses quickly or efficiently;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">key employees leave; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">we have higher than anticipated integration costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Translate Bio acquisition (see in &#8220;&#8212; Our research and development efforts may not succeed in adequately renewing our product portfolio&#8221; above) which was completed in 2021 may not generate the expected results in terms of developing new mRNA-based products to meet existing or future needs, and the potential of Translate Bio&#8217;s mRNA platform may not be realized to its full extent or because of the difficulty of integrating the activity quickly and efficiently into the Group.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We may also miscalculate the risks associated with business development transactions at the time they are made or may lack the resources or ability to access all the relevant information to evaluate such risks properly, including regarding the potential of research and development pipelines, manufacturing issues, tax or accounting issues, compliance issues, or the outcome of ongoing legal and other proceedings. It may also take a considerable amount of time and be difficult to implement a risk analysis and risk mitigation plan after the acquisition of an activity or business is completed due to lack of historical data. Acquired businesses may not always be in full compliance with legal, regulatory or Sanofi standards, including, for example, current Good Manufacturing Practices (cGMP), which can be costly and time consuming to remedy. As a result, risk management and coverage of such risks, particularly through insurance policies, may prove to be insufficient or ill-adapted.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">With respect to divestments, their financial benefit could be impacted if we face significant financial claims or significant post-closing price adjustments. Furthermore, the value of the assets to be divested may deteriorate while we are in the process of executing our divestment strategy, with the risk that we do not realize the anticipated benefits.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because of the active competition among pharmaceutical groups for business development opportunities, there can be no assurance of our success in completing these transactions when such opportunities are identified.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The globalization of our business exposes us to increased risks in specific areas</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of the presentation of our strategy in December&#160;2019, we identified our strong presence in China among our core drivers, with revenue amounting to 6.8% of our net sales in 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Nevertheless, the difficulties in operating in emerging markets, a significant decline in the anticipated growth rate or an unfavorable movement of the exchange rates of currencies against the euro could impair our ability to take advantage of growth opportunities and could adversely affect our business, results of operations or financial condition. For instance, if a long-lasting epidemic and prolonged or repeated restrictive measures to control the outbreak were to result in an economic slowdown in any of our targeted markets, it would reduce our sales due to lower healthcare spending on other diseases and fewer promotional activities, and could significantly impact our business operations. Furthermore, it is not possible to predict if or how the current health crisis will impact any particular affected jurisdiction, or to what extent (see also &#8220;&#8212;&#160;Global economic conditions and an unfavorable financial environment could have negative consequences for our business&#8221; above).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Emerging markets also expose us to more volatile economic conditions, political instability (including a backlash in certain areas against free trade), competition from multinational or locally based companies that are already well established in these markets, the inability to adequately respond to the unique characteristics of emerging markets (particularly with respect to their underdeveloped judicial systems and regulatory frameworks), difficulties in recruiting qualified personnel or maintaining the necessary internal control systems, potential exchange controls, weaker intellectual property protection, higher crime levels (particularly with respect to counterfeit products), and compliance issues including corruption and fraud (see particularly &#8220;&#8212;&#160;Claims and investigations relating to ethics and business integrity, competition law, marketing practices, pricing, human rights of workers, data protection and other legal matters could adversely affect our business, results of operations and financial condition&#8221; above).</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may fail to develop or take advantage of digitalization and prioritizing data as an organizational asset</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have undertaken several digital initiatives, such as the implementation of artificial intelligence across the business. For example, in research and development, we have built multiple artificial intelligence programs to reduce research times through improved predictive modelling and we seek to automate time-consuming activities, enabling research and development teams to scale and accelerate research processes and improve potential target identification in therapeutic areas such as immunology, oncology and neurology. In manufacturing and supply, we have developed an in-house artificial intelligence-enabled yield optimization solution, which enables consistently higher yield levels and optimizes usage of raw materials, contributing to our environmental objectives and supporting improved cost efficiency. Other examples include the opening in June&#160;2022 of the Artificial Intelligence Centre of Excellence in Toronto, joining our global network of existing digital hubs in Paris, Boston, New York and Barcelona, which focuses on using leading technologies to develop world-class data and artificial intelligence products that accelerate research and development; the opening in March&#160;2022 of our Accelerator, an internal unit that functions like a startup business within Sanofi to develop products and solutions that will support our mission to transform the practice of medicine with the use of digital, data and artificial intelligence; the Future4Care initiative of June&#160;2021, where we joined a startup incubator along with other CAC40 companies to help nurture emerging leaders in health tech; or our enabled manufacturing facility in the&#160;US.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our success in these efforts will depend on many factors including data availability; technology architecture; entering into successful partnerships and alliances with technology companies; a profound transformation of the organization, including a cultural change among our employees and the development of relevant skills; attracting and retaining employees with appropriate skills and mindsets in a tight labor market; and successfully innovating across a variety of technology fields. The COVID-19 pandemic has accelerated our digital transformation, including in the ways we engage and interact with our stakeholders. However, there is no guarantee that our efforts toward a digital transformation will succeed. More generally, we may fail to capture the benefits of digitalization and valuing data as an enterprise asset at an appropriate cost and/or in a timely manner, and/or enter into appropriate partnerships. Competitors, including new entrants such as tech companies, may outpace us in this fast-moving area. If we fail to adequately integrate digital capabilities into our organization and business model, we could lose patients and market share. This could have an adverse impact on our business, prospects and results of operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The success of digital initiatives will also depend on our ability to shift our culture to a data-driven culture. This calls for clear accountability for data and a collectively owned operating model with supporting tools and competencies to manage data as an asset, and for the definition of a robust life-cycle management process for data that is applied consistently across Sanofi. Good overall management of data supports our overall operations and the delivery of exponential capabilities, including artificial intelligence and machine learning to fulfil our innovation and efficiency ambitions. Failure to do so could result in business, operational and financial harm.</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may fail to accelerate our operational efficiency and perform our transformation program</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of the presentation of the next chapter of our Play to Win strategy in October&#160;2023, we announced our intent to improve our operating efficiencies to fund growth. We also announced savings of a total of up to &#8364;2 billion from 2024 to the end of 2025, most of which will be reallocated to fund innovation and growth drivers. We further announced our intent to separate the CHC business in the fourth quarter of 2024 at the earliest, most likely via the creation of a publicly listed entity headquartered in France. To deploy our strategy, we must also disrupt our normal course of business and transform our operations. Nevertheless, we may not succeed in federating employees behind the transformation program, which may hamper our ability to execute such organizational changes. Besides, there is no guarantee that we will be able to fully deliver these operating efficiencies or separate the CHC business within the targeted timeline, or at all, or generate the expected benefits.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unsuccessful management of sustainability (environmental, social and governance) matters could adversely affect our reputation and we may experience difficulties to meet the expectations of our stakeholders</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Companies are increasingly expected to behave in a responsible manner on a variety of sustainability matters, by governmental and regulatory authorities, counterparties such as vendors and suppliers, customers, investors, the public at large and others. This context, driven in part by a rapidly changing regulatory framework in the US and in Europe, is raising new challenges and influencing strategic decisions that companies must take if they wish to optimize their positive impact and mitigate their negative impact on sustainability matters.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have adopted a sustainability strategy that aims at ensuring global access and affordability, addressing unmet needs with transformative therapies, and minimizing the impact of our activities and products on the climate and the environment. The strategy includes leveraging our personnel&#8217;s experience and making societal impact a key driver of our employees&#8217; engagement. However, despite our strong commitment we could be unable to meet our sustainability or other strategic objectives in an efficient and timely manner, or at all.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We may also be unable to meet the ever more demanding criteria used by rating agencies in their sustainability assessments process, leading to a downgrading in our rating. Financial investments in companies which perform well in sustainability assessments are increasingly popular, and major institutional investors have made known their interest in investing in such companies. Depending on sustainability assessments and on the rapidly changing views on acceptable levels of action across a range of sustainability topics from investors, we may be unable to meet society&#8217;s or investors&#8217; expectations, our reputation may be harmed, we may face increased compliance or other costs and demand for securities issued by us and our ability to participate in the debt and equity markets may decrease.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:right;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our success depends in part on our senior management team and other key employees and our ability to attract, integrate and retain key personnel and qualified individuals in the face of intense competition</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our success depends on the expertise of our senior management team and other key employees. In 2023, there were&#160;2,264&#160;&#8220;Senior Leaders&#8221; within Sanofi. In addition, we rely heavily on recruiting and retaining talented people to help us meet our strategic objectives. We face intense competition for qualified individuals for senior management positions, or in specific geographic regions or in specialized fields such as clinical development, biosciences and devices, or digital and artificial intelligence. Our ability to hire qualified personnel also depends in part on our ability to reward performance, incentivize our employees and pay competitive compensation. The inability to attract, integrate and/or retain highly skilled personnel, in particular those in leadership positions, may weaken our succession plans, may materially adversely affect the implementation of our strategy and our ability to meet our strategic objectives, and could ultimately adversely impact our business or results of operations.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Environmental and safety risks of our industrial activities</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks from manufacturing activities and the handling of hazardous materials could adversely affect our results of operations and reputation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Manufacturing activities, such as the chemical manufacturing of the active ingredients in our products and the related storage and transportation of raw materials, products and waste, expose us to risks of industrial accidents that may lead to discharges or releases of toxic or pathogenic substances or other events that can cause personal injury, property damage and environmental contamination, and may result in additional operational constraints, including the shutdown of affected facilities and/or the imposition of civil, administrative, criminal penalties and/or civil damages, and affect Sanofi&#8217;s reputation.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The occurrence of an industrial accident may significantly reduce the productivity and profitability of a particular manufacturing facility and adversely affect our operating results and reputation. Although we maintain property damage, business interruption and casualty insurance that we believe is in accordance with customary industry practices, this insurance may not be adequate to fully cover all potential hazards incidental to our business.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management of the historical contamination related to our past industrial activities could adversely impact our results of operations and reputation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The environmental laws of various jurisdictions impose actual and potential obligations on our Company to manage and/or remediate contaminated sites. These obligations may relate to sites:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">that we currently own or operate;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">that we formerly owned or operated; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">where waste from our operations was disposed.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These environmental remediation obligations could reduce our operating results. Sanofi accrues provisions for remediation when our management believes the need is probable and that it is reasonably possible to estimate the cost. See&#160;&#8220;Item&#160;4.&#160;Information on the Company &#8212;&#160;B.&#160;Business Overview &#8212;&#160;B.9.&#160;Health, Safety and Environment&#8221; for additional information regarding our environmental policies. In particular, our provisions for these obligations may be insufficient if the assumptions underlying these provisions prove incorrect or if we are held responsible for additional, currently undiscovered contamination. These judgments and estimates may later prove inaccurate, and any shortfalls could have an adverse effect on our results of operations and financial condition. For more detailed information on environmental issues, see&#160;&#8220;Item&#160;4.&#160;Information on the Company &#8212;&#160;B.&#160;Business Overview &#8212;&#160;B.9.&#160;Health, Safety and Environment and Notes&#160;B.12. and D.19.3. to the consolidated financial statements&#8221;.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are or may become involved in claims, lawsuits and administrative proceedings relating to environmental matters. Some&#160;current and former Sanofi subsidiaries have been named as &#8220;potentially responsible parties&#8221; or the equivalent under the&#160;US&#160;Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended (CERCLA, also known as&#160;&#8220;Superfund&#8221;), and similar statutes or obligations in France, Germany, Italy, Brazil and elsewhere. As a matter of statutory or contractual obligations, we and/or our subsidiaries may retain responsibility for environmental liabilities at some of the sites of our predecessor companies, or of subsidiaries that we demerged, divested or may divest. We have disputes outstanding regarding certain sites no longer owned or operated by the Company. An adverse outcome in such disputes might have an adverse effect on our operating results. See Note&#160;D.22.d to the consolidated financial statements included at Item&#160;18. of this annual report and &#8220;Item&#160;8.&#160;Financial Information &#8212;&#160;A.&#160;Consolidated Financial Statements and Other Financial Information &#8212;&#160;Information on Legal or Arbitration Proceedings&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Environmental regulations are evolving</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For example, in Europe, new or evolving regulatory regimes include the Registration, Evaluation, Authorization and Restriction of Chemicals Regulation (which would include, if passed, the restriction proposal on per- and polyfluoroalkyl substances (PFAS) recently released by the European Chemicals Agency (ECHA)); the Classification and Labelling regulations applicable to hazardous chemicals; directives related to the control of major-accident hazards (the &#8220;Seveso&#8221; directives); the Industrial Emission regulations; the Waste Framework</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Directive; the Emission Trading Scheme Directive; the Water</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Framework Directive; the Directive on Taxation of Energy Products and</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Electricity; as well as other regulations aimed at preventing climate change. Stricter environmental, safety and health laws and enforcement policies could result in substantial costs and liabilities to our Company and could subject our handling, manufacture, use, reuse or disposal of substances or pollutants, site restoration and compliance to more rigorous scrutiny than is currently the case. Consequently, compliance with these laws could result in capital expenditures as well as other costs and liabilities, thereby adversely affecting our business, results of operations or financial condition.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;3. Key Information</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risks related to financial markets</span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fluctuations in currency exchange rates could adversely affect our results of operations and financial condition</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because we sell our products in numerous countries, our results of operations and financial condition could be adversely affected by fluctuations in currency exchange rates. We are particularly sensitive to movements in exchange rates between the euro and the US&#160;dollar, the Japanese yen, the Chinese yuan, and currencies in emerging markets. In 2023, 43.0% of our net sales were generated in the United&#160;States, </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">24.1% in Europe, and 32.9% </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the Rest of the World region (see the definition in &#8220;Item&#160;5.&#160;Operating and Financial Review and Prospects &#8212;&#160;A/&#160;Operating results&#8221;), including countries that are, or may in future become, subject to exchange controls (including 6.8% in China and 3.7% in Japan). While we incur expenses in those currencies, the impact of currency exchange rates on these expenses does not fully offset the impact of currency exchange rates on our revenues. As a result, currency exchange rate movements can have a considerable impact on our earnings. When deemed appropriate and when technically feasible, we enter into transactions to hedge our exposure to foreign exchange risks. These efforts, when undertaken, may fail to offset the effect of adverse currency exchange rate fluctuations on our&#160;results of operations or financial condition. For more information concerning our exchange rate exposure, see&#160;&#8220;Item&#160;11.&#160;Quantitative and Qualitative Disclosures about Market Risk.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risks relating to an investment in our shares or ADSs</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign exchange fluctuations may adversely affect the US&#160;dollar value of our ADSs and dividends (if&#160;any) regardless of our operating performance</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Holders of ADSs face exchange rate risks. Our ADSs trade in US&#160;dollars and our shares trade in euros. The value of the ADSs and our shares could fluctuate substantially as the exchange rates between these currencies fluctuate. If and when we pay dividends, they would be denominated in euros. Fluctuations in the exchange rate between the euro and the US&#160;dollar will affect the US&#160;dollar amounts received by owners of ADSs upon conversion by the depositary of cash dividends, if any. Moreover, these fluctuations may affect the US&#160;dollar price of the ADSs on the NASDAQ Global Select Market (NASDAQ) whether or not we pay dividends, in addition to any amounts that a holder would receive upon our liquidation or in the event of a sale of assets, merger, tender offer or similar transaction denominated in euros or any foreign currency other than US&#160;dollars.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Persons holding ADSs rather than shares may have difficulty exercising certain rights as a&#160;shareholder</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Holders of ADSs may have more difficulty exercising their rights as a shareholder than if they directly held shares. For example, if we issue new shares and existing shareholders have the right to subscribe for a pro rata portion of the new issuance, the depositary is allowed, at its own discretion, to sell this right to subscribe for new shares for the benefit of the ADS holders instead of making that right available to such holders. In that case, ADS holders could be substantially diluted. Holders of ADSs must also instruct the depositary how to vote their shares. Because of this additional procedural step involving the depositary, the process for exercising voting rights will take longer for holders of ADSs than for holders of shares. ADSs for which the depositary does not receive timely voting instructions will not be voted at any&#160;meeting. US investors may have difficulty in serving process or enforcing a judgment against us or our directors or executive officers.</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales of our shares may cause the market price of our shares or ADSs to decline</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of large numbers of our shares, or a perception that such sales may occur, could adversely affect the market price for our shares and ADSs. To our knowledge, L&#8217;Or&#233;al, our largest shareholder, is not subject to any contractual restrictions on the sale of the shares it holds in our Company. L&#8217;Or&#233;al does not consider its stake in our Company as strategic.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our largest shareholder owns a significant percentage of the share capital and voting rights of&#160;Sanofi</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, L&#8217;Or&#233;al held approximat</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ely 9.35% of our issued share capital, accounting for approximately 16.77% of</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> the voting rights (excluding treasury shares) of Sanofi. See&#160;&#8220;Item&#160;7.&#160;Major Shareholders and Related Party Transactions &#8212;&#160;A.&#160;Major Shareholders&#8221;. Affiliates of L&#8217;Or&#233;al currently serve on our Board of Directors. To the extent L&#8217;Or&#233;al continues to hold a large percentage of our share capital and voting rights, it will remain in a position to exert greater influence in the appointment of the directors and officers of Sanofi and in other corporate actions that require shareholders&#8217; approval.</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> The information in this section supplements the disclosures required under IFRS&#160;7 as presented in Note&#160;B.8.7. to our consolidated financial statements, provided at Item&#160;18. of this annual report.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_52"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;4. Information on the Company</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_55"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the remainder of this section, a product is referred to either by its international non-proprietary name (INN) or its brand name, which is generally exclusive to the company that markets it. In most cases, the brand names of our products, which may vary from country to country, are protected by specific registrations. In this document, products are identified by their brand names used in France and/or in the&#160;US.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported three operating segments: Pharmaceuticals, Vaccines and Consumer Healthcare. As a consequence of (i)&#160;progress on the &#8220;Play to Win&#8221; strategy leading to the creation of the standalone Consumer Healthcare Global Business Unit (GBU), and (ii)&#160;organizational changes to Sanofi&#8217;s Manufacturing &amp; Supply global function (previously known as Industrial Affairs), with effect from January&#160;1, 2023, our operations have been split into two operating segments: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Consumer Healthcare operating segment comprises commercial operations relating to our Consumer Healthcare products, and research, development and production activities and global support functions dedicated to the segment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to our Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#8217;s results include the costs of global support functions that are outside of the managerial responsibility of the Consumer Health Care GBU. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our internal reporting, our segment information, and the layout of this section have been adapted so as to reflect the new organizational structure of our operations in a coherent manner.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_58"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A. History and development of the Company</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The current Sanofi corporation was incorporated under the laws of France in 1994 as a </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233;&#160;anonyme</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a form of limited liability company, for a term of 99&#160;years. Since May&#160;2011, we have operated under the commercial name &#8220;Sanofi&#8221; (formerly known as Sanofi-Aventis). Our registered office is located at 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France, our main telephone number is +33&#160;1&#160;53&#160;77&#160;40&#160;00, and our website (which contains information about the company and information filed with and provided to the SEC) is www.sanofi.com. Our principal US&#160;subsidiary&#8217;s office is located at 55&#160;Corporate Drive, Bridgewater, NJ&#160;08807; telephone:&#160;+1&#160;(908)&#160;981&#160;5000.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The SEC maintains an Internet site at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Main events over the last three years</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April&#160;8, 2021, Sanofi acquired the entire share capital of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Kymab</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;14, 2021, Sanofi finalized the acquisition of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Translate Bio</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a clinical-stage mRNA therapeutics company.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November&#160;9, 2021, Sanofi completed the acquisition of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Kadmon Holdings,&#160;Inc</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease areas of significant unmet medical need.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;8, 2022, Sanofi acquired the entire share capital of the immuno-oncology company </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Amunix Pharmaceuticals, Inc. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(Amunix), thereby gaining access to Amunix&#8217;s innovative PRO-XTEN technology and a promising pipeline of immunotherapies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;3, 2022, Sanofi&#8217;s General Meeting of Shareholders approved the decision to distribute approximately 58% of the share&#160;capital of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">EUROAPI</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a European leader in the development, manufacture, marketing and distribution of Active Pharmaceutical Ingredients (APIs), in the form of an exceptional dividend in kind to Sanofi shareholders. On the dividend payment&#160;date of May&#160;10,&#160;2022 (further to the admission of EUROAPI shares to listing on the regulated market of Euronext Paris on&#160;May&#160;6,&#160;2022), Sanofi divested control over EUROAPI and its subsidiaries, resulting in their deconsolidation from the Sanofi consolidated financial statements as of that date. On June&#160;17, 2022 (the date of delivery of the EUROAPI shares to the French State via the French Tech Souverainet&#233; fund), EPIC Bpifrance acquired a 12% equity interest in EUROAPI. Following completion of those transactions, Sanofi retains an equity interest of 30.1% in EUROAPI, which has been accounted for using the equity method since the date of loss of control (see note&#160;D.6. to the consolidated financial statements).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March&#160;13, 2023, Sanofi and </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Provention Bio, Inc.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8220;Provention&#8221;), a US-based publicly-traded biopharmaceutical company developing therapies to prevent and intercept immune-mediated diseases including type&#160;1 diabetes, entered into an agreement under which Sanofi acquired the outstanding shares of Provention common stock for $25.00 per share in an all-cash transaction valued at approximately $2.8&#160;billion. On April&#160;27, 2023, Sanofi announced the completion of its acquisition of Provention. The acquisition adds </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TZIELD</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (teplizumab-mzwv), a therapy for type&#160;1 diabetes, to Sanofi&#8217;s core General Medicines asset portfolio.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;28, 2023, Sanofi announced that it had entered into a definitive agreement to acquire ownership of</span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> QUNOL</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a market-leading US-based health &amp; wellness brand. This transaction was intended to strengthen Sanofi CHC in the Vitamin, Mineral and Supplements (VMS) category, one of the largest and fastest-growing consumer health categories in the US, focused on the </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">dynamic healthy aging segment. Sanofi&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">acquisition of QRIB Intermediate Holdings, LLC was completed on September&#160;29, 2023, at a purchase price of $1,419&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">More detailed information about these changes is provided in Note&#160;D.1. to our consolidated financial statements, included at Item&#160;18. of this annual report.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_61"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B. Business overview</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s activities are organized around the following categories: DUPIXENT, Neurology &amp; Immunology, Rare Diseases, Oncology, Rare Blood Disorders, General Medicines Core Assets and Non-Core Assets, Vaccines, and CHC. Except for CHC, which is a standalone operating segment within the meaning of IFRS&#160;8, all of those activities fall within the Biopharma operating segment.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_64"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.1. Strategy</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The market context for Sanofi</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Several fundamental trends continue to point to a positive outlook for the pharmaceutical industry. The global population is growing, and aging, and unmet medical needs remain high. Health needs have further increased, strengthening the key roles of innovation in R&amp;D activities and cutting-edge manufacturing. The industry has taken steps to increase R&amp;D productivity, with the objective of launching a higher number of innovative medicines and vaccines. Patients around the world &#8211;&#160;including a rising middle class in emerging markets&#160;&#8211; are demanding better healthcare, empowered by access to more and more information. It is a particularly exciting time scientifically and technologically: the promise of genomics is being realized, immuno-oncology is transforming cancer treatments, and big data is generating new insights into how to diagnose and treat diseases. Digital technologies and advanced data analytics are having a transformative effect across sales and marketing activities, R&amp;D and manufacturing, and are acting as enablers for new businesses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the same time, increased geopolitical uncertainties, inflation, supply shortages, and issues around budget tightening will continue to put pressure on healthcare costs, and on the entire healthcare value chain. Although we believe that pharmaceuticals and vaccines will remain a fundamentally attractive business within that value chain, the bar for innovation will most likely continue to rise. Payers will continue to put scrutiny on prices and reimbursement criteria, and demand demonstration of real-life outcomes to confirm the efficacy of medicines and vaccines. This will be coupled with more innovative pricing and contracting practices, and more transparent policies. In view of growing concerns over increasing healthcare costs across global markets, the pharmaceutical industry will be increasingly judged by its contribution to improved access for patients and to the development of innovative, highly cost-effective medicines.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic framework</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Sanofi &#8220;Play to Win&#8221; strategy is organized around four key priorities: 1)&#160;focus on growth; 2)&#160;lead with innovation; 3)&#160;accelerate efficiency; and 4)&#160;reinvent how we work to drive innovation and growth.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">1) Focus on growth</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;padding-left:11.27pt">DUPIXENT (dupilumab)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:700;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> &#8211; By leveraging the product&#8217;s unique mechanism of action targeting the type&#160;2 inflammation pathway and its favorable safety profile, we have raised our DUPIXENT sales peak ambition.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;padding-left:11.27pt">Vaccines</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> &#8211; Our Vaccines business is expected to deliver mid-to-high single digit net sales growth</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> through differentiated products, market expansions and launches. Contributors to growth are expected to be pediatric combinations; boosters; influenza vaccines; meningitis; and BEYFORTUS, which addresses Respiratory Syncytial Virus (RSV)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Sanofi has progressed in the field of mRNA technology with our Center of Excellence. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">At least five First in class / best in class vaccine candidates expected in phase 3 by 2025 across diverse preventative and therapeutic areas.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;padding-left:11.27pt">Pipeline</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> &#8211; We are focusing our investments on priority projects, including six potentially transformative therapies in immunology, hematology, neurology, vaccines and oncology.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">2) Lead with innovation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">We have been able to shift from a priority asset list to a steady flow of assets in a refocused, consistent pipeline. Our pipeline is showing potential opportunities for market-leading products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To continue fueling our promising pipeline and enhance our position in our core therapeutic areas, we have:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">entered into a strategic collaboration with Teva to co-develop and co-commercialize asset TEV&#8217;574, currently in Phase&#160;2b clinical trials for the treatment of Ulcerative Colitis and Crohn&#8217;s Disease, two types of inflammatory bowel disease;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">established a strategic collaboration with Recludix Pharma to advance a novel oral STAT6 inhibitor in multiple immunological and inflammatory indications;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.57pt">expanded an existing collaboration with Scribe Therapeutics to access CRISPR X-Editing (XE) genome editing technologies to advance in vivo genetic medicines for sickle cell and other genomic diseases;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.96pt">acquired Provention Bio, adding to our portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes;</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In partnership with Regeneron.</span></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cumulative Annual Growth Rate (CAGR), 2018-2025.</span></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In partnership with AstraZeneca.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.83pt">established a strategic collaboration with BioMap to co-develop Artificial Intelligence (AI) modules to accelerate drug discovery for biotherapeutics;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">vi.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.96pt">entered into an exclusivity agreement with Adocia for M1Pram, an innovative combination of insulin and pramlintide developed by Adocia to become the reference rapid-acting insulin for people with diabetes and obesity;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">vii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:4.09pt">entered into an agreement with Janssen Pharmaceuticals to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, currently in Phase&#160;3;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">viii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:2.22pt">modified an existing collaboration agreement with AstraZeneca, giving Sanofi full commercial control of BEYFORTUS (nirsevimab) and enhanced agility in the US;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ix.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.32pt">out-licensed the Capeserod Phase&#160;2 program to FirstWave Biopharma so it can be repurposed in gastrointestinal disorders with significant unmet needs, enabled by AI-empowered analyses of the drug&#8217;s properties.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">3) Accelerate efficiency</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In October&#160;2023, we announced new Strategic Costs Initiatives. We are striving to accelerate our efforts to improve our cost structure, launching efficiency initiatives across our Biopharma business that we expect to free operational resources to support accelerated R&amp;D investment and unlock value-creation opportunities. This will include prioritizing our investments in R&amp;D and modernizing our approach to commercial delivery. Given our decision to support the full realization of our pipeline&#8217;s long-term potential, our ongoing investment around new launches as well as pricing headwinds in General Medicines, we are no longer targeting 32% business operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> margin for 2025, while maintaining our focus on long-term profitability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To embrace the transformative effect offered by digital technologies and advanced data analytics, we are investing to become the leading digital healthcare platform for employees, patients and providers. This is expected to help us discover, test and deliver medicines faster, run our business more efficiently, and create engaging digital experiences. The digital transformation required to meet our ambition is under way. We are using advanced algorithms to harvest real world data to support our R&amp;D efforts. We are also developing new go-to-market models by enhanced physician engagement through a variety of channels, building precision marketing, and providing better e-commerce capabilities. And in parallel, we are investigating the possibility of integrating drugs, devices, data and services, to bring innovative solutions to patients across many different disease areas such as diabetes and atopic dermatitis.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, we made further progress regarding the implementation of AI across the business: </span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">In partnership with Aily Labs, we rolled out plai, an application developed with AI, to more than 23,000&#160;internal users. The application delivers real-time, reactive data interactions and gives a 360&#176; view across our activities, using AI to provide users with timely insights and personalized &#8220;what if&#8221; scenarios to support informed decision making. </span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">In Research, we have built multiple AI programs to reduce research times through improved predictive modelling and automate time-sink activities. As a result, AI assists R&amp;D teams to scale and accelerate research processes from a matter of weeks to hours and improve potential target identification in therapeutic areas like immunology, oncology or neurology.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">In Manufacturing &amp; Supply, we have developed an in-house AI-enabled yield optimization solution which learns from past and current batch performance in an effort to enable consistently higher yield levels. This optimizes usage of raw materials, contributes to our environmental objectives and supports improved cost efficiency.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">4) Reinvent how we work</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transformation and simplification have started, with the aim of increasing empowerment and accountability. To drive implementation of our new culture built on stronger focus, diversity and teamwork, we have streamlined our executive leadership team from 15 to 12&#160;members. Four new members were appointed to the executive leadership team: Madeleine Roach as Head of Business Operations; Houman Ashrafian as Head of Research &amp; Development (succeeding Dr&#160;John Reed), Emmanuel Frenehard as Chief Digital Officer (succeeding Arnaud Robert), and Brian Foard as Head of Specialty Care (succeeding Bill Sibold). The complete Sanofi Executive Committee now includes the four managers who head up our global business units (Specialty Care, Vaccines, General Medicines, and CHC) as well as the heads of each of the following support functions: Research and Development, Manufacturing &amp; Supply (previously named Industrial Affairs), Finance, People&#160;&amp; Culture, Digital, Legal, Ethics, Business Integrity &amp; Global Security and Business Operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, we progressed further in building and simplifying our stand-alone CHC organization. We have further reduced our portfolio, mainly through divestments, to 117&#160;brands (47% fewer than in 2019). In September&#160;2023 we announced the acquisition of QUNOL, a leading US health and wellness brand that strengthens our CHC operations in a key market, and within the promising Vitamins, Minerals and Supplements (VMS) segment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">By the end of 2023, all the CHC legal entities required to establish a standalone organization had been established, except in India, and staffed with dedicated teams. Sanofi has announced its intention to separate the CHC Business as it increases its focus on innovative medicines and vaccines. The intended separation will seek to create two entities, each better equipped to pursue its own business strategy, resourcing and capital allocation and enabling each to focus on long-term growth in its respective markets. Sanofi believes that the separation will unlock further opportunities for CHC to leverage its portfolio of leading brands and continue to drive growth and shareholder value. Sanofi is reviewing potential separation scenarios, but believes that the most likely path would be through a capital markets transaction, by creating a listed entity headquartered in France. The timing is driven by the desire to maximize value creation and reward Sanofi shareholders. Subject to market conditions, the separation could be achieved at the earliest in the fourth quarter of 2024, following consultation with social partners.</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure: see definition in &#8220;Item 5 &#8212;&#160;A.1.5.&#160;Segment Information &#8212;&#160;3.&#160;Business Net Income&#8221; .</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In line with our high sustainable development ambitions, Sanofi CHC North America achieved B-corp accreditation in July&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s Corporate Social Responsibility (CSR) strategy aims to build a healthier, more resilient world by ensuring access to healthcare for the world&#8217;s poorest people and bringing focus to addressing broader unmet needs. Sanofi&#8217;s commitment to society also aims to accelerate our goal of reducing the environmental impact of our products and of our worldwide operations. Key to tackling the global challenges that face our company are our people, who each have a role to play in building a diverse and inclusive workplace.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s CSR Strategy focuses on four building blocks integrated into with our Play to Win core business strategy:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">affordable access &#8211; to ensure affordable global access to health, while helping healthcare systems to remain sustainable;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">R&amp;D for unmet needs &#8211; to be at the cutting edge of R&amp;D innovation, to help people live fully and drive growth;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Planet Care &#8211; to minimize the environmental impact of our business through environmental sustainability; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in &amp; beyond the workplace &#8211; to give all Sanofi colleagues the chance to become a leader of change, unlocking the potential of our diverse teams.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital allocation policy</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We will continue to pursue our focused and disciplined capital allocation policy. Our priorities in deploying the cash generated from our three core GBUs and the standalone CHC business are, in the following order: (i)&#160;organic investment; (ii)&#160;business development and merger &amp; acquisition activities, focusing on bolt-on, value-enhancing opportunities to drive scientific and commercial leadership in core therapeutic areas; (iii)&#160;growing the annual dividend; and (iv)&#160;anti-dilutive share buybacks. We also have the potential to raise capital through asset disposals, including streamlining &#8220;tail&#8221; brands in our Established Products and Consumer Healthcare business.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_67"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2. Main biopharma products</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The sections below provide additional information on our main products. Our intellectual property rights over our pharmaceutical products are material to our operations and are described at &#8220;B.6.&#160;Patents, Intellectual Property and Other Rights&#8221; below. As disclosed in&#160;&#8220;Item 8.&#160;Financial Information &#8212;&#160;A.&#160;Consolidated Financial Statements and Other Financial Information &#8212;&#160;Patents&#8221; of this annual report, we are involved in significant litigation concerning the patent protection of a number of these&#160;products. For more information on sales performance, see&#160;&#8220;Item&#160;5.&#160;Operating and Financial Review and Prospects &#8212;&#160;A. Operating Results.&#8221;</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_70"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Care</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">DUPIXENT</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">DUPIXENT (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. Dupilumab is jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60&#160;clinical trials involving more than&#160;10,000&#160;patients with various chronic diseases driven in part by type&#160;2 inflammation. The dupilumab development program has shown significant clinical benefit and a decrease in type&#160;2 inflammation in Phase&#160;3 trials, establishing that IL-4 and IL-13 are key and central drivers of the type&#160;2 inflammation that plays a major role in multiple inflammatory diseases, such as atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis. DUPIXENT comes in either a pre-filled syringe for use in a clinic or at home by self-administration as a subcutaneous injection or in a pre-filled pen for at-home administration, providing patients with a more convenient option. DUPIXENT is available in all major markets including the US (since April&#160;2017), most European Union countries (the first launch was in Germany in December&#160;2017), Japan (since April&#160;2018), and China (since June&#160;2020).</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Atopic Dermatitis</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Moderate-to-severe AD, a form of eczema and a chronic inflammatory disease, is characterized by rashes that sometimes cover much of the body and can include intense, persistent itching and skin dryness, cracking, redness, crusting and oozing. Eighty-five to ninety&#160;percent of patients first develop symptoms before five&#160;years of age, which can often continue through adulthood.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2014 the FDA granted DUPIXENT Breakthrough Therapy designation and after a Priority Review evaluation: in March&#160;2017 it granted DUPIXENT marketing authorization for the treatment of adults with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. In 2016, the FDA granted DUPIXENT Breakthrough Therapy designation for adolescent patients aged 12 to 17&#160;years and in March&#160;2019, the FDA extended the marketing authorization for this age group.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2016, the FDA granted Breakthrough Therapy designation for DUPIXENT for the treatment of severe AD in children aged six&#160;months to 11&#160;years. On May&#160;26, 2020, DUPIXENT was approved as the first biologic medicine for children aged six&#160;to 11&#160;years with moderate-to-severe AD. Having accepted DUPIXENT for Priority Review in February&#160;2022, the FDA approved DUPIXENT on June&#160;7, 2022 for children aged six&#160;months to five&#160;years with moderate-to-severe AD and whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, making DUPIXENT the first biologic medicine to significantly reduce signs and symptoms in children as young as six&#160;months.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The European Commission (EC) approved DUPIXENT in September&#160;2017 for use in adults with moderate-to-severe AD who are candidates for systemic therapy, and extended the marketing authorization in August&#160;2019 to include adolescents aged 12&#160;to 17&#160;years. On&#8239;November&#160;30, 2020, the EC extended the marketing authorization to children aged six&#160;to 11&#160;years with severe AD and on June&#160;28, 2021, the DUPIXENT Summary of Product Characteristics (SmPC) was updated with long-term data for up to three&#160;years, reinforcing the product&#8217;s well-established safety profile in adults with moderate-to-severe AD. On January&#160;27, 2023 the CHMP adopted a positive opinion for DUPIXENT, recommending expanded approval in the EU to treat severe AD in children aged six&#160;months to five&#160;years who are candidates for systemic therapy. In March&#160;2023, DUPIXENT was approved by the EC as the first and only targeted medicine for children as young as six months old with severe AD.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On June&#160;19, 2020, the National Medical Products Administration (NMPA) in China approved DUPIXENT for adults for the treatment of moderate-to-severe AD after identifying dupilumab as an overseas medicine regarded as urgently needed in clinical practice, leading to an expedited review and approval process. On December&#160;28, 2020, the National Healthcare Security Administration (NHSA) officially announced the results of the 2020 National Reimbursement Drug List (NRDL) negotiations, with DUPIXENT 300&#160;mg included in the updated NRDL effective March&#160;1, 2021. DUPIXENT was approved in China in September&#160;2021 for adolescents aged 12-17&#160;years with moderate-to-severe AD. The indication for children aged six&#160;years and over, along with the adolescent and adult AD indications, was included in the current NRDL reimbursement scope, which was reviewed during the DUPIXENT NRDL renewal in 2022 in accordance with the two-year cycle for the China access process. In May&#160;2023, DUPIXENT was approved in China to treat moderate to severe AD in infants and children aged six months and older.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January&#160;22, 2018, the Ministry of Health, Labor and Welfare (MHLW) in Japan granted marketing and manufacturing authorization for DUPIXENT for the treatment of AD in adults not adequately controlled with existing therapies. More recently, on September&#160;25, 2023 DUPIXENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">was approved in Japan to treat patients with moderate-to-severe AD aged six months and older.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April&#160;2023, new late-breaking abstract data from a long-term efficacy open-label study presented at the Revolutionizing Atopic Dermatitis (RAD) 2023 Spring Conference in Washington, DC showed that DUPIXENT demonstrated robust and sustained efficacy with progressive improvement of AD signs and symptoms in patients with moderate-to-severe AD who completed up to five years of treatment: the longest duration of data for any biologic medicine in this disease. Additionally, the long-term safety data from a 52-week open-label extension trial in children aged six months to five years reinforced the well-established safety profile of DUPIXENT observed across all other approved age groups. This data is built on the existing evidence supporting the selective way DUPIXENT inhibits IL4/IL-13 pathways, both key and central drivers of the type&#160;2 inflammation, thereby significantly improving itch and skin lesions and other important measures that impact a patient&#8217;s quality of life. In June&#160;2023, the inclusion of the results from the five-year OLE Trial for Adults into the DUPIXENT label was approved in Europe, and in October&#160;2023, by the FDA in the US.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March&#160;2023, positive results from the clinical trial assessing DUPIXENT in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis were presented in a late-breaking session, one of more than 20 DUPIXENT scientific presentations, at the American Academy of Dermatology (AAD) 2023 Annual Meeting. The trial evaluating a biologic for this difficult-to-treat population met its primary and key secondary endpoints. In August&#160;2023, the clinical section of the DUPIXENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">label in Europe was updated to include the hand and foot dermatitis populatio</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n. In January&#160;2024</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the DUPIXENT US label was updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These Phase&#160;3 data are from the first and only trial evaluating a biologic specifically for this difficult-to-treat population and have also been added to the DUPIXENT label in the European Union, with regulatory submissions underway in additional countries.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="background-color:#ffffff;color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Asthma</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">DUPIXENT was granted marketing authorization by the FDA in October&#160;2018 as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12&#160;years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. In May&#160;2019, the EC approved DUPIXENT for use as an add-on maintenance treatment in severe asthma patients aged 12&#160;years and older with type&#160;2 inflammation whose symptoms are inadequately reduced by other treatments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2020, new long-term data from a Phase&#160;3 open-label extension trial showed sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma. On May&#160;17, 2021, detailed results from a Phase&#160;3 trial showed DUPIXENT significantly</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">reduced severe asthma attacks, and within two weeks rapidly improved lung function in children aged six&#160;to 11&#160;years with uncontrolled moderate-to-severe asthma with evidence of type&#160;2 inflammation. Moreover, DUPIXENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">significantly improved overall asthma symptom control and reduced an airway biomarker of type&#160;2 inflammation, called fractional exhaled nitric oxide (FeNO), that plays a major role in asthma.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In October&#160;2021, the FDA approved DUPIXENT as an add-on maintenance treatment for patients aged six&#160;to 11&#160;years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma, thereby bringing a new treatment for children who may be suffering from life-threatening asthma attacks and poor lung function affecting their ability to breathe, which could potentially continue into adulthood. On April&#160;7, 2022, the EC approved DUPIXENT for use in children aged six&#160;to 11&#160;years as an add-on maintenance treatment for severe asthma with type&#160;2 inflammation characterized by raised blood eosinophils and/or raised FeNO, whose symptoms are inadequately reduced with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March&#160;2019, DUPIXENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">was approved in Japan for treating patients aged 12&#160;years and over with severe or refractory asthma and whose symptoms are inadequately controlled with existing therapies. In November&#160;2023, DUPIXENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">received approval in China for treatment of moderate to severe asthma patients aged 12&#160;years and over with T2 inflammation.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chronic rhinosinusitis with nasal polyposis (CRSwNP)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CRSwNP is a chronic disease of the upper airway that obstructs the sinuses and nasal passages. It can lead to breathing difficulties, nasal congestion and discharge, reduced or loss of sense of smell and taste, and facial pressure.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2019, the FDA approved DUPIXENT for use with other medicines to treat CRSwNP in adults whose disease is not controlled. In October&#160;2019, the EC approved DUPIXENT for use as an add-on therapy with intranasal corticosteroids in adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. In March&#160;2020, the Japanese Pharmaceuticals and Medical Devices Agency approved DUPIXENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as add-on maintenance treatment for adults with inadequately controlled CRSwNP.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eosinophilic esophagitis (EoE)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">EoE is a chronic and progressive inflammatory disease that damages the esophagus and prevents it from working properly; swallowing even small amounts of food can be a painful and worrisome choking experience. In severe cases, a feeding tube may be the only option to ensure proper calorific intake and adequate nutrition. As the disease progresses, patients may continue to experience symptoms despite multiple treatments. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;14, 2020, the FDA granted Breakthrough Therapy designation to DUPIXENT for the treatment of patients aged 12&#160;years and older with EoE, and subsequently accepted the file for Priority Review on April&#160;4, 2022. On May&#160;20, 2022, the FDA approved DUPIXENT to treat patients with EoE aged 12&#160;years and older. With this approval, DUPIXENT became the first and only medicine specifically indicated to treat EoE in the US.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;16, 2022, the EMA CHMP adopted a positive opinion, recommending the approval of dupilumab in the EU to treat adults and adolescents with EoE. On January&#160;30, 2023, the EC expanded the marketing authorization for DUPIXENT in the EU to include the treatment of EoE in adults and adolescents aged 12&#160;years and older.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">There are currently no approved treatments specifically indicated for children under 12&#160;years of age with EoE. On July&#160;14, 2022, a DUPIXENT Phase&#160;3 trial showed positive results in children aged 1&#160;to 11&#160;years with EoE, making this the fifth pediatric pivotal trial across three type&#160;2 inflammatory diseases to reinforce the well-established efficacy and safety profile of DUPIXENT. In January&#160;2024, DUPIXENT was approved for the treatment of adult and pediatric patients aged one year or older, weighting at least 15&#160;kg, with oesinophilic esophagitis (EoE). The EoE pediatric indication was submitted in the EU in the fourth quarter of 2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prurigo Nodularis (PN)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PN is a chronic, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">debilitating skin disease with underlying type&#160;2 inflammation and has one of the highest impacts on a patient&#8217;s quality of life among inflammatory skin diseases due to the extreme itch it causes.</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Those</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> with prurigo nodularis experience intense, persistent itch, with thick skin lesions (called nodules) that can cover most of the body. The disease is often painful &#8211; with burning, stinging and tingling of the skin &#8211; and can negatively affect mental health, daily living activities and social interactions. High-potency topical steroids are commonly prescribed but are associated with safety risks if used long-term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FDA evaluated the DUPIXENT application for prurigo nodularis under Priority Review on May&#160;31, 2022. On September&#160;29,&#160;2022, the FDA </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">approved DUPIXENT for the treatment of adult patients with prurigo nodularis. With this approval, DUPIXENT became the first and only medicine specifically indicated to treat prurigo nodularis in the US. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FDA approval was&#160;based on data from two Phase&#160;3 trials evaluating the efficacy and safety of DUPIXENT in adults with prurigo nodularis. Efficacy in&#160;these trials assessed the proportion of subjects with clinically meaningful reduction in itch, clearing of skin, or both.&#160;On&#160;December&#160;15, 2022, the EC expanded the marketing authorization for DUPIXENT in the EU to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy, after the previous positive recommendation on&#160;November&#160;11,&#160;2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The DUPIXENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">prurigo nodularis indication was approved in Japan on June&#160;26, 2023, and in China on September&#160;22, 2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chronic Spontaneous Urticaria (CSU)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CSU is a chronic inflammatory skin disease characterized by the sudden onset of hives on the skin and/or swelling deep under the skin. Despite standard-of-care treatment, people with CSU often experience symptoms including a persistent itch or burning sensation, which can be debilitating and significantly impact quality of life. Swelling often occurs on the face, hands and feet, but can also affect the throat and upper airways. On July&#160;29, 2021 a pivotal Phase&#160;3 trial evaluating DUPIXENT in patients with moderate-to-severe CSU met its primary endpoints and all key secondary endpoints at 24&#160;weeks. Adding DUPIXENT to standard-of-care antihistamines significantly reduced itch and hives for biologic-naive pa</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">tients, compared to those treated with antihistamines alone (placebo) in Study&#160;A (the first of two trials) of the LIBERTY CUPID clinical program.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Study&#160;B of the clinical trial evaluated DUPIXENT in adults and adolescents who remain symptomatic despite standard-of-care treatment and are intolerant or incomplete responders to an anti-IgE therapeutic (omalizumab). Although positive numerical trends in reducing itch and hives were observed, the study was stopped due to futility based on a pre-specified interim analysis. The safety data were generally consistent with the known safety profile of DUPIXENT in its approved indications. In December&#160;2022, CSU was submitted to the FDA. In October&#160;2023 the FDA issued a Complete Response Letter (CRL) stating that additional efficacy data are required to support approval; it did not identify any issues with safety or manufacturing. An ongoing clinical trial (Study C) continues to enroll patients; the results, due in late 2024, are expected to provide the additional efficacy data.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Japan's Ministry of Health, Labour and Welfare granted marketing and manufacturing authorization for </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">DUPIXENT</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the treatment of chronic spontaneous urticaria in February 2024.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Life cycle management</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">DUPIXENT is currently being evaluated in clinical development programs for diseases that are driven by type&#160;2 inflammation. These include chronic obstructive pulmonary disease (COPD), bullous pemphigoid (BP), chronic pruritis of unknown origin (CPUO), eosinophilic gastroenteritis (EoG) and ulcerative colitis (UC). See &#8220;&#8212; B.4. Global Research &amp; Development.&#8221;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">DUPIXENT is developed and commercialized in collaboration with Regeneron. For additional information on the collaboration, see&#160;&#8220;Item&#160;5. Operating and Financial Review and Prospects &#8212;&#160;A.1.7.&#160;Financial Presentation of Alliances &#8212; Alliance Arrangements with Regeneron.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Neurology &amp; Immunology</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Multiple Sclerosis (MS)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">MS is an autoimmune neurological disease in which a person&#8217;s immune system attacks the central nervous system, damaging myelin, the protective sheath that covers nerve fibers. This causes a break in communication between the brain and the rest of the body, ultimately destroying the nerves themselves, and causing irreversible damage. More than&#160;2.5&#160;million people suffer from&#160;MS&#160;worldwide.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our MS franchise consists of AUBAGIO (teriflunomide), a once-daily, oral immunomodulator, and LEMTRADA (alemtuzumab), a monoclonal antibody. Both products treat patients with relapsing forms of MS.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AUBAGIO</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">AUBAGIO (teriflunomide), a small molecule immunomodulatory agent with anti-inflammatory properties, is a once-daily oral therapy.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">AUBAGIO is approved in more than 80&#160;countries around the world including the US (since September&#160;2012) for the treatment of patients with relapsing forms of MS; the EU (since August&#160;2013) for the treatment of adult patients with relapsing remitting MS; and China (since&#160;July&#160;2018). In June&#160;2021, the EC approved AUBAGIO for the treatment of pediatric patients aged 10&#160;to 17&#160;years with relapsing-remitting multiple sclerosis (RRMS). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2017, Sanofi reached settlement with all 20&#160;generic AUBAGIO ANDA first filers, granting each a royalty-free license to enter the US market on March&#160;12, 2023. In the European Union, the first generic competitors to AUBAGIO became available in the third quarter of 2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">LEMTRADA</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">LEMTRADA (alemtuzumab) is a humanized monoclonal antibody targeting the CD52 antigen. LEMTRADA is administered by intravenous infusion as two short courses 12&#160;months apart; for the majority of patients no further treatment is necessary, making LEMTRADA the only disease-modifying therapy (DMT) that can provide long term durable efficacy in the absence of continuous dosing.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">LEMTRADA is approved in more than 70&#160;countries including the EU (since September&#160;2013) and the US (since November&#160;2014). Because of its safety profile, the FDA approved the use of LEMTRADA in patients with relapsing forms of MS who have had an inadequate response to two or more drugs indicated for the treatment of MS, and included a black-box warning on potential side effects. In the US, LEMTRADA is only available through a restricted distribution program called the LEMTRADA Risk Evaluation and Mitigation Strategy (REMS) Program. In January&#160;2020, the EMA updated the indication for LEMTRADA to include treatment of relapsing-remitting multiple sclerosis if the disease is highly active despite treatment with at least one disease-modifying therapy, or if the disease is worsening rapidly. The EMA also added new contra-indications for patients with certain heart, circulation or bleeding disorders, and those who have autoimmune disorders other than MS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bayer Healthcare received contingent payments based on alemtuzumab global sales revenue through September&#160;2023. For additional information, see&#160;Note&#160;D.18.&#160;to our consolidated financial statements, included at Item&#160;18. of this annual report.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rheumatoid Arthritis</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease causing inflammation, pain, and eventually joint damage and disability.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">KEVZARA</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">KEVZARA (sarilumab) is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R) and has been shown to inhibit IL-6R mediated signaling. IL-6 is a cytokine in the body that, in excess and over time, can contribute to the inflammation associated with rheumatoid arthritis. KEVZARA is available in 20&#160;countries, including the US.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May&#160;2017, the FDA approved KEVZARA for the treatment of adult patients with moderately to severely active RA who have had an inadequate response or intolerance to one or more disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate. In&#160;June&#160;2017, the European Commission granted marketing authorization for KEVZARA in combination with methotrexate for the treatment of moderately to severely active RA in adult patients who have responded inadequately to &#8211;&#160;or who are intolerant to&#160;&#8211; one or more&#160;DMARDs, such as methotrexate. In September&#160;2017, KEVZARA obtained manufacturing and marketing approval in Japan as a treatment for rheumatoid arthritis not responding well to conventional treatments. In February&#160;2023, the FDA approved KEVZARA for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate a corticosteroid taper. In October&#160;2023, the FDA accepted the filing for polyarticular Juvenile Idiopathic Arthritis.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">KEVZARA is developed and commercialized in collaboration with Regeneron. For additional information, see&#160;&#8220;Item&#160;5.&#160;Operating and Financial Review and Prospects &#8212;&#160;A.1.7. Financial Presentation of Alliances &#8212;&#160;Alliance Arrangements with Regeneron.&#8221;</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Rare diseases</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Rare Diseases business is focused on products for the treatment of rare genetic diseases and other rare chronic debilitating diseases of high unmet medical need, including lysosomal storage disorders (LSDs), a group of metabolic disorders caused by enzyme deficiencies.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CEREZYME</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CEREZYME (imiglucerase) is an enzyme replacement therapy used to treat Gaucher disease, a chronic, inherited, progressive and potentially life-threatening LSD. Gaucher disease is caused by deficiency of the enzyme glucocerebrosidase; this causes a fatty substance called glucosylceramide (also called GL-1) to build up in certain areas of the body including the spleen, liver, and bone. Gaucher disease exhibits diverse manifestations, a broad range of age of onset of symptoms, and a wide clinical spectrum of disease severity. It is estimated that Gaucher disease occurs in approximately one in 120,000&#160;newborns in the general population and one in 850&#160;in the Ashkenazi Jewish population worldwide, but incidence and patient severity vary among regions. CEREZYME has been marketed in the US since&#160;1994, in the EU since 1997, in Japan since 1998 and in China since 2008, and is approved to treat Type&#160;1 Gaucher disease in more than 85&#160;countries. It has also been approved to treat the systemic symptoms of Type&#160;3 Gaucher disease in most non-US markets, including the EU and Japan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CEREZYME is typically given by</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">intravenous infusions for 1-2&#160;hours every two weeks at an infusion center, a doctor&#8217;s office, or at home as medically appropriate.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CERDELGA</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CERDELGA (eliglustat) is the first and only first-line oral therapy for Gaucher disease Type&#160;1 adult patients. A potent, highly specific ceramide analog inhibitor of GL-1 synthesis with broad tissue distribution, CERDELGA has demonstrated efficacy in the treatment of naive Gaucher disease patients and in patients who switch from enzyme replacement therapy. CERDELGA has been approved to treat type&#160;1&#160;Gaucher disease in the US (2014), and in the EU and Japan (2015). It is also in development for the treatment of type&#160;1 Gaucher disease in pediatric patients. See &#8220;&#8212;&#160;B.4.&#160;Global Research &amp; Development.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MYOZYME and LUMIZYME</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">MYOZYME (alglucosidase alfa) is an enzyme replacement therapy used to treat both Infantile Onset and Late Onset Pompe disease (IOPD and LOPD). Pompe disease is an inherited, progressive and often fatal neuromuscular disease, caused by a genetic deficiency or dysfunction of the lysosomal enzyme acid alpha-glucosidase (GAA) that results in the build-up of glycogen in the muscles&#8217; cells. For infantile-onset Pompe disease, symptoms begin within a few months of birth and there is impact to the heart in addition to skeletal muscle weakness. Other symptoms include difficulties breathing, frequent chest infections, problems feeding that result in failure to gain weight as expected, and failure to meet certain developmental milestones. Patients with late-onset Pompe disease typically present symptoms any time after the first year of life to late adulthood and rarely manifest cardiac problems. The hallmark symptom of late-onset Pompe disease is skeletal muscle weakness, which often leads to walking disability and reduced respiratory function. Patients often require wheelchairs to assist with mobility and may require mechanical ventilation to help with breathing. Pompe disease occurs in approximately one in 40,000&#160;newborns worldwide, but incidence and patient severity vary among regions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">MYOZYME was first approved in 2006 in the EU and has since been approved in more than 70&#160;countries. In the US, alglucosidase alfa has been marketed as LUMIZYME since 2010.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NEXVIAZYME</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">NEXVIAZYME / NEXVIADYME (avalglucosidase alfa-ngpt) is a novel mannose-6-phosphate (M6P) enriched enzyme replacement therapy (ERT) treatment designed as a monotherapy for the entire spectrum of infantile-onset and late-onset Pompe disease (IOPD, LOPD), for both switch and naive patients. NEXVIAZYME/NEXVIADYME is scientifically designed to specifically target the M6P receptor, the key pathway for ERT, to effectively clear glycogen build-up in muscle cells. It helps replace the GAA enzyme for people whose bodies do not produce enough. Investment in the clinical development of NEXVIAZYME is continuing, with an ongoing Phase&#160;3 trial in treatment-naive IOPD patients aged less than 12&#160;months. NEXVIAZYME/NEXVIADYME is administered as a monotherapy enzyme replacement therapy every two weeks.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">NEXVIAZYME was first approved in the US by the FDA on August&#160;6, 2021 for LOPD patients aged&#160;1 and over. On June&#160;24, 2022, the EC granted marketing authorization for NEXVIADYME as a potential new standard of care for the long-term treatment of both LOPD and IOPD. NEXVIAZYME/NEXVIADYME has successfully launched in 25&#160;countries including the US, Japan and Australia. In all launched markets, the vast majority of eligible patients have switched or will be switching to NEXVIAZYME/NEXVIADYME.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FABRAZYME</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">FABRAZYME (agalsidase beta) is an enzyme replacement therapy used to treat Fabry disease. Fabry disease (FD) is a multisystemic, progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal &#945;-galactosidase&#160;A activity resulting in progressive globotriaosylceramide (GL-3) accumulation in the lysosomes of various tissues. Fabry disease affects both genders. With age, progressive organ damage develops, leading to potentially life-threatening renal, cardiac and/or cerebrovascular complications. Fabry disease is characterized by different symptom severities and rates of progression, ranging from classic disease with early symptom onset to late onset disease with cardiac and/or renal complications later in life. Fabry disease is seen in all racial and ethnic groups and is an under-diagnosed condition. Prevalence estimates vary across regions. Classic Fabry disease mutations are estimated to be approximately 1:40,000 in males with more wide-ranging estimates for atypical presentations of Fabry in both males and females. FABRAZYME has been marketed in the&#8239;EU since&#8239;2001 and in the US since 2003 and is approved in more than&#8239;70&#160;countries.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ALDURAZYME</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ALDURAZYME (laronidase) is the only approved enzyme replacement therapy for mucopolysaccharidosis type&#160;1 (MPS&#160;I), an inherited lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase, a lysosomal enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). MPS&#160;I is multi-systemic, and children with MPS&#160;I are described as having either a severe or attenuated form of the disorder based on age of onset, severity of symptoms, rate of disease progression and whether there is early and direct involvement of the brain. MPS&#160;I occurs in approximately one per 100,000&#160;live births worldwide, but incidence and patient severity vary among regions. ALDURAZYME has been marketed in the EU and the US since 2003 and is approved in more than 75&#160;countries.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XENPOZYME</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">XENPOZYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(olipudase alfa) is an enzyme replacement therapy (ERT) designed to replace deficient or defective acid sphingomyelinase (ASMD), an enzyme that allows for the breakdown of the lipid sphingomyelin. In individuals with ASMD, an insufficiency of the ASM enzyme means sphingomyelin is poorly metabolized, potentially leading to lifelong accumulation in and damage to multiple organs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The significance of the unmet need that XENPOZYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">addresses has been recognized by Japan&#8217;s PMDA with Sakigake designation, by the EU with PRIME designation, and by the FDA with Breakthrough designation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">XENPOZYME was approved first in Japan on March&#160;28, 2022, followed by Europe on June&#160;24, 2022, a few months before the&#160;FDA approval on August&#160;31, 2022</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">XENPOZYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">is the first and only ERT for the&#8239;treatment of non central nervous system manifestations of ASMD, with demonstrated improvements in&#8239;hepatosplenomegaly, pulmonary, liver and&#8239;hematologic function, dyslipidemia, and growth (children only) in clinical trials of adults and&#8239;children with ASMD. XENPOZYME is given as an intravenous infusion once every&#160;two&#160;weeks, and the dose is based on body weight.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">XENPOZYME has to date been launched in eight countries. In 2024, It is anticipated that XENPOZYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">will be launched in many additional markets worldwide. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SARCLISA</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">SARCLISA (isatuximab) is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumor activity via multiple mechanisms of action. It was approved in March&#160;2020 in the US in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, and by the EC in May&#160;2020 in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. SARCLISA is now approved for this indication in more than 50&#160;countries. In addition the first biologic license application (BLA) for SARCLISA, in combination with pomalidomide and dexamethasone, was accepted by the Chinese health authorities in late 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">SARCLISA was approved for a label extension in combination with carfilzomib and dexamethasone in March&#160;2021 in the US for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received one to three&#160;prior lines of therapy, and by the EC in April&#160;2021 for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. The Japanese Ministry of Health, Labor and Welfare (MHLW) granted approval for SARCLISA in combination with carfilzomib and dexamethasone, in combination with dexamethasone, and as monotherapy for RRMM patients in November&#160;2021. SARCLISA is under investigation in the Phase&#160;3 IMROZ trial as a first line treatment for patients with newly diagnosed multiple myeloma who are transplant ineligible. In December&#160;2023, the IMROZ Trial was reported to have met its primary endpoint; the results will form the basis of a future regulatory submission. In addition, the Phase&#160;3 IRAKLIA trial investigating the development of a new subcutaneous formulation with an on-body device system was initiated in the second half of 2022 and is enrolling in over 20&#160;countries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">SARCLISA is also being investigated with several innovative agents in multiple myeloma in an umbrella Phase&#160;1/2 trial.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JEVTANA</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">JEVTANA (cabazitaxel), a chemotherapy drug and cytotoxic agent, is a semi-synthetic second-generation taxane that prevents many cancer cells from dividing, which ultimately results in destroying many such cells. It is approved in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. JEVTANA was granted marketing authorization by the FDA in June&#160;2010, by the EC in March&#160;2011, and in Japan in July&#160;2014. The product is marketed in over 75&#160;countries. In Europe, generic competition started for JEVTANA from the end of March&#160;2021. In the US, the JEVTANA composition of matter patent expired in&#160;September&#160;2021. Sanofi has filed patent infringement suits under the US Hatch-Waxman Act against generic manufacturers for cabazitaxel in the US&#160;District Court for the District of Delaware asserting three Orange Book listed US patents for JEVTANA. Sanofi entered settlement agreements with most of the defendants and went to trial against the remaining defendant, Sandoz on one of the patents (the &#8216;777 patent) in January 2023; see Note D.22.b. to the consolidated financial statements, included at Item 18. of this annual report. The district court issued a final judgment in favor of Sanofi in connection with the JEVTANA patent litigation against Sandoz and on August 2, 2023, Sandoz appealed to the Court of Appeals for the Federal Circuit. On October 5, 2023, Sanofi and Sandoz filed a joint stipulation voluntarily dismissing Sandoz&#8217;s Appeal, bringing this matter to conclusion.  </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASTURTEC/ELITEK</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">FASTURTEC/ELITEK is used for the management of plasma uric levels in patients with leukemia, lymphoma, and solid tumor malignancies receiving anticancer therapies.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Rare blood disorders</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Rare Blood Disorders franchise was created in 2018 following Sanofi&#8217;s acquisition of Bioverativ and Ablynx.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ALTUVIIIO</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ALTUVIIIO (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein) is a first-in-class high-sustained factor&#160;VIII therapy that is designed to extend protection from bleeds with once-weekly prophylactic dosing for adults and children with hemophilia&#160;A. Hemophilia&#160;A is a rare, x-linked genetic bleeding disorder characterized by a deficiency of functional coagulation factor&#160;VIII, resulting in a prolonged patient plasma-clotting time. As a consequence, people with hemophilia&#160;A bleed for a longer time than normal.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ALTUVIIIO temporarily replaces the missing coagulation factor&#160;VIII by intravenous injection. In adults and adolescents, it is the first factor VIII therapy that has been shown to break through the von Willebrand factor ceiling, which imposes a half-life limitation on earlier generation factor VIII therapies. ALTUVIIIO builds on innovative Fc fusion technology by adding a region of von Willebrand factor and XTEN polypeptides to extend its time in circulation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ALTUVIIIO was first approved in February&#160;2023 by the FDA, which had previously granted Breakthrough Therapy designation in May&#160;2022 (the first factor&#160;VIII therapy to receive this designation), Fast Track designation in February&#160;2021, and Orphan Drug designation in 2017. ALTUVIIIO has since been approved the by regulatory authorities in Japan and Taiwan. The EC granted Orphan Drug designation in June 2019, and a marketing authorization application was filed at the European Medecines Agency in May 2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ELOCTATE</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ELOCTATE (antihemophilic factor (recombinant), Fc fusion protein) is an extended half-life factor VIII therapy clotting-factor therapy to control and prevent bleeding episodes in adults and children with hemophilia&#160;A. In the US, it is indicated for use in adults and children with hemophilia&#160;A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Hemophilia&#160;A is a rare, x-linked genetic bleeding disorder characterized by a deficiency of functional coagulation Factor&#160;VIII, resulting in a prolonged patient plasma-clotting time. As a consequence, people with hemophilia&#160;A bleed for a longer time than normal. ELOCTATE temporarily replaces the missing coagulation Factor&#160;VIII by intravenous injection.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We market ELOCTATE primarily in the US (since 2014), Japan, Canada, Australia, South Korea, Taiwan and Hong Kong.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ELOCTATE is developed and commercialized in collaboration with Swedish Orphan Biovitrum AB (Sobi), whose territories include Europe, Russia, the Middle East, and some countries in North Africa.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ALPROLIX</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ALPROLIX (coagulation Factor&#160;IX (recombinant), Fc fusion protein) is an extended half-life factor IX therapy clotting-factor therapy to control and prevent bleeding episodes in adults and children with hemophilia&#160;B. In the US, it is indicated for use in adults and children with hemophilia&#160;B for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Hemophilia&#160;B is a rare, x-linked genetic bleeding disorder characterized by a deficiency of functional coagulation Factor&#160;IX, resulting in a prolonged patient plasma-clotting time. As a consequence, people with hemophilia&#160;B bleed for a longer time than normal. ALPROLIX temporarily replaces the missing coagulation Factor&#160;IX by intravenous injection.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We market ALPROLIX primarily in the US (since&#160;2014), Japan, Canada, Australia, New Zealand, South Korea, Taiwan and Hong&#160;Kong.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ALPROLIX is developed and commercialized in collaboration with Swedish Orphan Biovitrum&#160;AB (Sobi), whose territories include Europe, Russia, the Middle East, and some countries in North Africa.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CABLIVI</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CABLIVI (caplacizumab) is a bivalent anti-von Willebrand Factor (vWF) NANOBODY</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> VHH for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP). CABLIVI is the first therapeutic specifically indicated for the treatment of aTTP.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquired thrombotic thrombocytopenic purpura is an ultra-rare (3.5-4.5&#160;episodes per million of population), life-threatening, autoimmune-based blood clotting disorder characterized by extensive clot formation in small blood vessels throughout the body, leading to severe thrombocytopenia (very low platelet count); microangiopathic hemolytic anemia (loss of red blood cells through destruction); ischemia (restricted blood supply to parts of the body); and widespread organ damage, especially in the brain and heart. CABLIVI has an immediate effect on platelet adhesion and the ensuing formation and accumulation of the micro-clots.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CABLIVI was granted marketing authorization by the EC in September&#160;2018; by the FDA in February&#160;2019; and by the Japanese PMDA in September&#160;2022. CABLIVI is currently available in 26&#160;countries including the US, the majority of European countries (17), Brazil, Colombia, Japan and five Greater Gulf region states. Additional commercial launches are ongoing.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CABLIVI was developed by Ablynx, a Sanofi company since mid-2018. See &#8220;&#8212;&#160;A. History and Development of the Company.&#8221;</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ENJAYMO</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ENJAYMO (sutimlimab; formerly known as BIVV009) is a monoclonal antibody targeting the classical complement pathway (CP) specific serine protease (C1s), thereby inhibiting CP activity which is associated with a variety of immune disorders involving the presence of autoantibodies. ENJAYMO is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease (CAD).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CAD is a rare, serious, and chronic autoimmune hemolytic anemia, where the body&#8217;s immune system mistakenly attacks healthy red blood cells and causes their rupture, known as hemolysis. The disease impacts the lives of an estimated 12,000&#160;people in the&#160;US, Europe, and Japan and is associated with profound fatigue and increased risk of thromboembolic events and mortality.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ENJAYMO has previously received Breakthrough Therapy Designation (BTD) and Orphan Drug Designations (ODD) from the FDA, and orphan medicine designation by the European Medicines Agency. After priority review, the product was approved in&#160;February&#160;2022 as the first treatment to decrease the need for red blood cell transfusion due to hemolysis in adults with CAD. ENJAYMO was approved by the Japanese Ministry of Health, Labor and Welfare in June&#160;2022 and granted marketing authorization by the EC in November&#160;2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ENJAYMO is currently available in the US, Japan, Germany, Austria and the Netherlands. Additional commercial launches are ongoing.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_73"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Medicines</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has prioritized core assets with differentiated and/or established profiles that have significant opportunity for growth in key markets. Some of these well-established medicines are the standard-of-care for patients living with diabetes or cardiovascular disease. These core assets include TZIELD, REZUROCK, TOUJEO, SOLIQUA, PRALUENT, MULTAQ, LOVENOX, and PLAVIX.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Core assets</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TZIELD</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">TZIELD (Teplizumab) is a CD3-directed antibody (CD3 is a cell surface antigen present on T lymphocytes). It was approved by the FDA in November&#160;2022 to delay the onset of Stage&#160;3 type&#160;1 diabetes (T1D) in adults and pediatric patients aged eight years and older with Stage&#160;2 T1D. The product is currently marketed in the US, with plans for pursuing regulatory approval in other regions. The product is currently being developed for another indication for patients already in Stage&#160;3 T1D.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">REZUROCK</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">REZUROCK (belumosudil) is a selective ROCK2 (rho-associated coiled-coil&#8211;containing protein kinase-2) inhibitor. It was approved in&#160;July&#160;2021 by the FDA for the treatment of adult and pediatric patients aged 12&#160;years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. REZUROCK&#8217;s favorable market adoption, especially in the US, is a reflection of its clinical profile. The product has been approved in Australia, Canada, Great Britain, Israel,  China, and United Arab Emirates with other countries granting accelerated regulatory review processes.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">THYMOGLOBULIN</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">THYMOGLOBULIN (anti-thymocyte Globulin) is a polyclonal anti-human thymocyte antibody preparation that acts as a broad immunosuppressive and immunomodulating agent. In the US, THYMOGLOBULIN is indicated for the prophylaxis and treatment of&#160;acute rejection in patients receiving a kidney transplant, used in conjunction with concomitant immunosuppression. Outside the&#160;US, depending on the country, THYMOGLOBULIN is indicated for the treatment and/or prevention of acute rejection in organ transplantation; immunosuppressive therapy in aplastic anemia; and the treatment and/or prevention of Graft-versus-Host Disease (GvHD) after allogeneic hematopoietic stem cell transplantation. THYMOGLOBULIN is currently marketed in over&#160;65&#160;countries.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MOZOBIL</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">MOZOBIL (plerixafor injection) is a hematopoietic stem cell mobilizer. It is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin&#8217;s lymphoma (NHL) and multiple myeloma (MM). MOZOBIL is marketed in over&#160;65&#160;countries.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TOUJEO</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">TOUJEO (insulin glargine 300&#160;units/mL) is a long-acting analog of human insulin, indicated for the treatment of diabetes mellitus in adults. TOUJEO has been granted marketing authorization by the FDA (February&#160;2015); the EC (April&#160;2015); and the Ministry of Health, Labor and Welfare (J-MHLW) in Japan, where its approved brand name is LANTUS XR (June&#160;2015). TOUJEO has now been launched in more than 60&#160;countries, including China since the end of 2020. In January&#160;2020, the EC approved an expansion of the indication to include the treatment of diabetes in adolescents and children (aged six&#160;years and above).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">TOUJEO is available in TOUJEO SOLOSTAR, a disposable prefilled pen which contains 450&#160;units of insulin glargine and requires one-third of the injection volume to deliver the same number of insulin units as LANTUS</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">SOLOSTAR. In the US (since 2018) and the&#160;EU (since&#160;2019), TOUJEO is also available in a disposable prefilled pen which contains 900&#160;units of insulin glargine. In India, TOUJEO is also available in a dedicated 450-unit cartridge in combination with a dedicated reusable pen (TOUSTAR).</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SOLIQUA &#8211; SULIQUA</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">SOLIQUA 100/33 or SULIQUA is a once-daily fixed-ratio combination of insulin glargine 100&#160;Units/mL, a long-acting analog of human insulin, and lixisenatide, a GLP-1 receptor agonist. The FDA approved SOLIQUA 100/33 in November 2016 for the treatment of adults with type&#160;2 diabetes inadequately controlled on basal insulin (less than 60&#160;units daily) or lixisenatide; and in February&#160;2019 for patients uncontrolled on oral antidiabetic medicines. In January&#160;2017, SULIQUA (the product&#8217;s brand name in Europe) was approved for use in combination with metformin with or without SGLT-2 inhibitors for the treatment of adults with type&#160;2 diabetes to improve glycemic control, when this has not been provided either by metformin alone or by metformin combined with another oral glucose-lowering medicinal product or with basal insulin. In Japan, SOLIQUA was approved in May&#160;2020 for type&#160;2 diabetes mellitus, where treatment with insulin is required. In China SOLIQUA was approved on January&#160;2023, for the treatment of adults with insufficiently controlled type&#160;2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral antidiabetic drugs. SOLIQUA received National Reimbursement Drug List (NRDL) status in China in December&#160;2023. SULIQUA is available in over 40&#160;countries. (SOLIQUA is approved in over 80&#160;countries).</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Integrated Digital Care Solutions</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi, in collaboration with Biocorp and Glooko, Glooko XT, Health2Sync and Emperra, is building a connected set of digital tools and features to support people living with diabetes and taking insulin. Sanofi intends to use aggregated de-identified data to generate insights to inform patients and providers, and to evaluate additional clinical or quality-of-life outcomes. Successful launches in several countries demonstrate the value of the integration of digital tools into a fully connected ecosystem.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRALUENT</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PRALUENT (alirocumab) is a human monoclonal antibody (mAb) for self-administered injection every two weeks or once-monthly. It blocks the interaction of proprotein convertase subtilisin/kexin type&#160;9 (PCSK9) with low-density lipoprotein (LDL) receptors, increasing the recycling of LDL receptors and reducing LDL cholesterol levels. PRALUENT is indicated as an adjunct to diet and maximally tolerated statin therapy in certain adult patients and in paediatric patients eight years of age and older with heterozygous familial hypercholesterolaemia (HeFH) with uncontrolled LDL cholesterol. PRALUENT has been approved in more than 60&#160;countries worldwide, including the US (in 2015), Canada and Switzerland, as well as in the European Union (in 2015). In 2018, the FDA approved a PRALUENT label update for some patients currently requiring LDL apheresis therapy. In March&#160;2019 in the EU and in April&#160;2019 in the US, PRALUENT was approved for use in patients with established cardiovascular disease to reduce the risk of cardiovascular events. In November&#160;2023, the EMA approved a PRALUENT label update for paediatric HeFh patients aged eight years and older. In December&#160;2019, PRALUENT was approved in China, where it started to be commercialized in May&#160;2020. Since April&#160;2020, Regeneron is responsible for commercialization of PRALUENT in the US, and Sanofi is responsible for all other markets outside the US. For additional information on the commercialization of this product, see &#8220;Item 5. Operating and Financial Review and Prospects &#8212;&#160;A.1.7 Financial Presentation of Alliances &#8212;&#160;Alliance Arrangements with Regeneron.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LOVENOX/CLEXANE</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">LOVENOX or CLEXANE (enoxaparin sodium) is a low molecular weight heparin (LMWH) indicated for use in the prophylaxis and treatment of venous thromboembolism and in the treatment of acute coronary syndrome. Enoxaparin generics are available in the US, and biosimilar enoxaparin products have gradually become available across various European countries and in a growing number of international markets. LOVENOX or CLEXANE is marketed in more than 100&#160;countries.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLAVIX/ISCOVER</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PLAVIX or ISCOVER (clopidogrel bisulfate) is a platelet adenosine diphosphate (ADP) receptor antagonist. It is indicated for the prevention of atherothrombotic events in patients with a history of recent myocardial infarction (MI), recent ischemic stroke or established peripheral arterial disease (PAD), and for patients with acute coronary syndrome (ACS). PLAVIX is also indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic and thromboembolic events in atrial fibrillation, including stroke.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">COPLAVIX/DUOPLAVIN, a fixed-dose combination of clopidogrel bisulfate and ASA, is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome who are already taking both clopidogrel and ASA.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A number of clopidogrel bisulfate generics have been launched in most markets. PLAVIX or ISCOVER are available in more than 80&#160;countries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is involved in two PLAVIX product lawsuits. See Note&#160;D.22.c) to our consolidated financial statements, included at Item&#160;18. of this annual report.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MULTAQ</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">MULTAQ (dronedarone) is an oral multichannel blocker with anti-arrhythmic properties for prevention of atrial fibrillation recurrences in certain patients with a history of paroxysmal or persistent atrial fibrillation. MULTAQ was approved in the US and in the EU in 2009. MULTAQ&#160;is available in about 35&#160;countries.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Non-Core Assets</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LANTUS</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">LANTUS (insulin glargine 100&#160;units/mL) is a long-acting analog of human insulin, indicated for once-daily administration for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above. LANTUS relies on more than 15&#160;years of clinical evidence in diabetes treatment and a well-established safety profile. Approved in the US and the EU in 2000 and in Japan in 2008, LANTUS is available in over 130&#160;countries worldwide. Two insulin glargine biosimilars are available in the US, two in European markets, and two in Japan.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APROVEL/AVAPRO/KARVEA</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">APROVEL, also known as AVAPRO or KARVEA (irbesartan), is an angiotensin II receptor antagonist indicated in the treatment of hypertension and for the treatment of renal disease in patients with hypertension and type 2 diabetes. Sanofi also markets COAPROVEL/AVALIDE/KARVEZIDE, a combination of irbesartan and the diuretic hydrochlorothiazide. A combination with amlodipine (APROVASC, Aprexevo, Aproxxamlo) has been launched in several countries.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A number of irbesartan generics have been launched in most markets. APROVEL and COAPROVEL are marketed in more than 80 countries. In Japan, the product is licensed to Shionogi Co. Ltd and BMS KK. BMS KK has sublicensed the agreement to Dainippon Pharma Co. Ltd.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DEPAKINE</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">DEPAKINE (sodium valproate) is a broad-spectrum anti-epileptic that has been prescribed for more than 50&#160;years and remains a reference treatment for epilepsy worldwide. DEPAKINE is also a mood stabilizer, registered in the treatment of manic episodes associated with bipolar disorder (in some countries this indication is branded differently, for example as DEPAKOTE in France).</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We hold no rights to DEPAKINE in the US, and sodium valproate generics are available in most markets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is involved in product litigation related to DEPAKINE. See Note&#160;D.22.a) to the consolidated financial statements included at Item&#160;18. of this annual report.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_76"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vaccine products</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Vaccines division of Sanofi is a world leader in the vaccine industry and a key supplier of life-saving vaccines all over the world and for publicly funded international stakeholders such as UNICEF, the Pan American Health Organization (PAHO) and the Global Alliance for Vaccines and Immunization (GAVI).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Vaccines portfolio includes the following products:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">RSV protection</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi launched BEYFORTUS (nirsevimab-alip), a long-acting monoclonal antibody designed to protect all infants from RSV. It is indicated for protection of all infants in their first RSV season, and for those infants born at high risk who remain particularly vulnerable in their second RSV season as well. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">BEYFORTUS is licensed in several countries, primarily in North America and Europe. In 2023, the US, France and Spain implemented broad protection programs with BEYFORTUS. In 2024, further licenses and introductions are expected worldwide, including in Japan and China. BEYFORTUS is part of an alliance with AstraZeneca, where Sanofi is the commercial lead and AstraZeneca is the development and manufacturing lead. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Influenza vaccines</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is a world leader in the production and marketing of influenza vaccines, offering several distinct influenza vaccines that are sold globally to meet growing demand.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">FLUZONE Quadrivalent is a quadrivalent inactivated influenza vaccine, produced in the US, containing two type&#160;A antigens and two type&#160;B antigens in order to provide increased protection against more circulating strains of influenza viruses. FLUZONE Quadrivalent/FLUQUADRI is</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> available in seven countries (including the US) for children aged over six months, adolescents and adults. FLUZONE 0.5&#160;ml QIV is the currently-licensed standard dose (15&#160;&#181;g/strain) quadrivalent influenza vaccine for ages six months and older.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">FLUZONE High-Dose Quadrivalent, designed specifically to provide greater protection against influenza for people aged 65&#160;years and older, was approved by the FDA in November&#160;2019. FLUZONE High-Dose Quadrivalent was approved in the EU in the second quarter of 2020, under the name EFLUELDA, indicated for adults aged 60&#160;years and above. Both FLUZONE High-Dose Quadrivalent and EFLUELDA have been available since the 2020/21 influenza season. To date, this product has been distributed to 25&#160;countries worldwide.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">FLUBLOK is a quadrivalent recombinant protein based influenza vaccine indicated for adults aged 18&#160;years of age and older. FLUBLOK is currently licensed in the US, Hong Kong and Australia. This same recombinant protein-based influenza vaccine is also licensed under the brand name SUPEMTEK in Canada, the United Kingdom, the European Union and Switzerland.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VAXIGRIP</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">is a trivalent influenza vaccine, containing two antigens against type&#160;A influenza viruses and one antigen against type&#160;B influenza viruses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VAXIGRIPTETRA is the quadrivalent (QIV) version of VAXIGRIP, including two antigens against A strains of influenza viruses and two antigens against B strains. Compared to the trivalent influenza vaccine, it contains an additional influenza&#160;B strain; it was licensed in 2016 and has been launched in more than 95&#160;countries since 2017. VAXIGRIPTETRA is not licensed in the US where FLUZONE Quadrivalent, which is produced in the US, is distributed.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Poliomyelitis, pertussis and Hib pediatric vaccines</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is one of the key players in pediatric vaccines in both developed and emerging markets, with a broad portfolio of standalone and combination vaccines protecting against up to six diseases in a single injection. Due to the diversity of immunization schedules throughout the world, vaccines vary in composition according to regional specificities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">TETRAXIM, a pediatric combination vaccine protecting against diphtheria, tetanus, pertussis and poliomyelitis (polio), was first marketed in 1998. To date, the vaccine has been launched in close to 90&#160;countries outside the US.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PENTAXIM, a pediatric combination vaccine protecting against diphtheria, tetanus, pertussis, polio and Hemophilus influenzae type b (Hib), was first marketed in 1997. To date, the vaccine has been launched in more than 100&#160;countries outside the US. In most European, Latin American, Asian and Middle Eastern markets, PENTAXIM is being gradually replaced by HEXAXIM.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">HEXAXIM/HEXYON/HEXACIMA is a fully liquid, ready-to-use 6-in-1 (hexavalent) pediatric combination vaccine that provides protection against diphtheria, tetanus, pertussis, polio, Hib and hepatitis&#160;B. HEXAXIM is the only combination vaccine including acellular pertussis (acP) and inactivated polio vaccines (IPV) currently prequalified by the WHO. First marketed in 2013, HEXAXIM is now available in more than 100&#160;countries outside the US.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PENTACEL, a pediatric combination vaccine protecting against diphtheria, tetanus, pertussis, polio and Hib, was launched in the US in 2008.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">QUADRACEL is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis, used in children aged four through six years as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ACT-HIB is a standalone vaccine protecting against Hib, and is mainly distributed in the US, Japan and China in conjunction with pertussis combination vaccines that do not contain the Hib valence.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is a leading provider of polio vaccines and has been a partner of the Global Polio Eradication Initiative (GPEI) for over 30&#160;years, with more than 15&#160;billion doses of oral polio vaccines (OPV) delivered during that time.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Between 2014 and 2023, Sanofi has provided more than 400&#160;million doses of inactivated polio vaccine to UNICEF, to support the WHO &#8220;Polio End Game&#8221; strategy for the world&#8217;s 73&#160;poorest countries.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">VAXELIS</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VAXELIS is a hexavalent combination vaccine protecting against diphtheria, tetanus, pertussis, polio, Hib and hepatitis&#160;B. This vaccine (developed and distributed in partnership with Merck) was approved in 2016 by the EMA and is distributed in various EU countries. VAXELIS was approved by the FDA in December&#160;2018, becoming the first hexavalent vaccine to be approved in the US, and launched in this country in June&#160;2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Sales of VAXELIS in the US are booked to the MSP JV and credited to Merck and Sanofi as equity income and therefore are not reported separately in each parent company&#8217;s net sales. Fifty percent of the JV profits are included in our share of profit/loss of associates and joint ventures line.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Booster vaccines</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ADACEL is the first trivalent booster vaccine offering protection against diphtheria, tetanus and pertussis. The vaccine can be used from four years of age following primary immunization and is the first Tdap vaccine indicated for use during pregnancy for protection against pertussis in newborns. It is available in 68&#160;countries including the US and other countries mostly in Europe, Asia and Latin America.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">REPEVAX/ADACEL-POLIO is a combination vaccine that provides protection against diphtheria, tetanus, pertussis and polio. It is the first Tdap-IPV vaccine indicated for use during pregnancy for protection against pertussis in newborns. It is currently marketed in 25&#160;countries outside the US, with a strong focus on European markets (such as France and Germany).</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Meningitis and Travel &amp; endemic vaccines</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">MENACTRA, the first quadrivalent conjugate vaccine against meningococcal meningitis (serogroups: A, C, Y, and W-135), one of the deadliest forms of meningitis, is indicated for people aged nine months through 55&#160;years. Since launch, it has become a strong leader in the meningitis quadrivalent market. It is commercialized in a large number of countries (excluding Europe). MENACTRA was the first fully liquid (no reconstitution needed) meningitis quadrivalent conjugated vaccine, and more than 100&#160;million doses of this vaccine have been distributed since launch.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">MENQUADFI is a novel fully-liquid meningococcal quadrivalent conjugated vaccine expected to have a broad age indication from infants (six weeks) to the elderly, with flexible dosing schedules. MENQUADFI is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers compared to a monovalent serogroup C vaccine (standard-of-care in multiple markets in Europe and internationally). MENQUADFI will progressively fully replace MENACTRA. It is already available in the US (for people over two years of age), and in Australia, Canada, Europe, Japan, Argentina, Brazil, and Chile for people aged 12&#160;months and above. Marketing authorization is also pending in numerous other countries. Extension of the age indication down to six weeks of age will follow submission of additional Phase&#160;3 data. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi provides a wide range of travel and endemic vaccines including hepatitis&#160;A, typhoid, cholera, yellow fever and rabies vaccines. These products are used in endemic settings in the developing world and are the foundation for important partnerships with governments and organizations such as UNICEF. They are also used by travelers and military personnel in industrialized countries and in endemic areas.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">COVID Vaccine</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">COVID-19 recombinant adjuvanted vaccine: </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VIDPREVTYN Beta is a recombinant spike protein vaccine developed in partnership with GSK and using GSK&#8217;s AS03 adjuvant. It is indicated as an adult booster to protect against SARS-CoV-2 infections. Phase&#160;3 results demonstrated significant vaccine efficacy against symptomatic infection with a Beta variant-containing vaccine in the face of an Omicron variant predominated pandemic period. Significant efficacy was demonstrated in naive individuals and individuals previously infected or vaccinated. These results, coupled with data from comprehensive studies to evaluate the vaccine as a heterologous booster for people initially vaccinated with Emergency Use Authorization (EUA) vaccines, supported VIDPREVTYN Beta&#8217;s full marketing authorization for the booster indication in both the EU and the UK. The first doses were supplied at the end of 2022 and Sanofi fulfilled all of its commitments in 2022 and 2023. </span></div><div id="i9fa7f69b4904450e9c43e8444c203165_79"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3. Consumer Healthcare</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, we progressed further in building and simplifying our stand-alone CHC organization. We have further reduced our portfolio, mainly through divestments, to 117&#160;brands (47% fewer than in 2019). In September&#160;2023 we announced the completion of the acquisition of QUNOL, a leading US health and wellness brand that strengthens our CHC portfolio in a key market, and within the promising VMS segment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">By the end of 2023, all the CHC legal entities required to establish a standalone organization had been established, except in India, and staffed with dedicated teams. Our CHC business now publishes its results as a separate dedicated segment, including all its support function costs, within the Sanofi environment. We also announced our intention to separate our CHC operations at the earliest in the fourth quarter of 2024, most likely through a capital markets transaction, via the creation of a listed entity headquartered in France.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In line with our high sustainable development ambitions, Sanofi CHC North America achieved B-corp accreditation in July&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our CHC sales are supported by a range of products, including the following brands:</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allergy, Cough &amp; Cold</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">ALLEGRA comprises a range of fexofenadine HCl-based products. Fexofenadine is an anti-histamine for relief from allergy symptoms including sneezing, runny nose, itchy nose or throat, and itchy, watery eyes. The ALLEGRA brand family is sold in more than&#160;80&#160;countries across the world.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">MUCOSOLVAN is a cough brand with many different formulations. It contains the mucoactive agent ambroxol; this stimulates synthesis and release of surfactant. It is sold in various countries in Europe, Latin America, Asia and Russia.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pain</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">DOLIPRANE offers a range of paracetamol/acetaminophen-based products for pain and fever with a wide range of dosage options and pharmaceutical forms, and is sold mainly in France and various African countries.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">The BUSCOPAN range (hyoscine butylbromide) has an antispasmodic action that specifically targets the source of abdominal pain and discomfort. It is sold across the globe.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">We also have local pain brands such as EVE in Japan; DORFLEX and NOVALGINA in Brazil; and ICY HOT and ASPERCREME in the&#160;US.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Digestive</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">DULCOLAX products offer a range of constipation solutions from predictable overnight relief to comfortable natural-feeling relief. The products are sold in over 80&#160;countries. DULCOLAX tablets contain the active ingredient bisacodyl or sodium picosulfate, which works directly on the colon to produce a bowel movement.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">ENTEROGERMINA is a probiotic indicated for the maintenance and restoration of intestinal flora in the treatment of acute or chronic intestinal disorders. ENTEROGERMINA is sold primarily in Europe, Latin America and parts of Asia.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">ESSENTIALE is a natural soybean remedy to improve liver health. It is composed of essential phospholipids extracted from highly purified soya and contains a high percentage of phosphatidylcholine, a major component of the cell membrane. ESSENTIALE is used in fatty liver disease and is sold mainly in Russia, Eastern Europe, various countries in Southeast Asia, and China.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nutritional</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Nutritionals include a range of products to maintain general health, provide immune system support, or supplement vitamin deficiencies. These products help manage energy, stress, sleep and anxiety, and include a number of brands across the globe&#160;including NATURE&#8217;S OWN in Australia to improve and maintain health; PHARMATON (mainly in Europe and Latin America); QUNOL in the US for healthy aging; MAGNE&#160;B6 in Europe; and a range of sleep brands, including NOVANUIT in Europe, UNISOM in the US, and DREWELL in Japan.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">GOLD BOND offers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">products for daily hydration, aging skin, cracked skin, overnight nourishment, and specialty skincare needs like eczema-prone skin</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. GOLD BOND is only sold in the US and Canada. Sanofi is involved in GOLD BOND product litigation in the US. See Note&#160;D.22.c) to our consolidated financial statements, included at Item&#160;18. of this annual report.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">29</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_82"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4. Global research &amp; development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the past three years, Sanofi has reshaped its discovery and development of therapeutics, built a robust pipeline, and sharpened its research focus, employing cutting-edge therapeutic platforms and creating a culture that responds to the urgent needs of patients. Discovering and developing new medicines is a costly, lengthy, and uncertain process and our continuous investments in R&amp;D for future products and for the launches of newly registered medicines could result in increased costs without a proportionate increase in revenues. See &#8220;Item&#160;3. Key Information &#8212;&#160;D. Risk Factors&#8221; for further information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s new Head of Research &amp; Development (R&amp;D), Houman Ashrafian, was appointed in September 2023 with responsibility for bolstering the company&#8217;s strategy to develop first or best-in-class medicines. Focusing on its portfolio of 12 new molecular entities, including multiple late-stage assets, Sanofi&#8217;s strategy is to prioritize development and leverage its leadership in immunology across all other therapeutic areas.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Details about Sanofi&#8217;s R&amp;D pipeline and three &#8220;pipeline-in-a-product&#8221; assets are presented in the sections &#8220;&#8212;&#160;B.4.1. Biopharma pipeline&#8221; below.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_85"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.4.1. Biopharma pipeline</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2023, the main changes related to the pharmaceuticals and vaccines pipeline were:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.031%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.476%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Project</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Potential Indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reason</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">TZIELD &#8211; Anti-CD3 mAb</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Type 1 diabetes</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Added</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquired from Provention Bio</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:115%">SAR447189 &#8211; Anti-TL1A mAb</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ulcerative colitis; Crohn&#8217;s disease</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Added</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Co-developed with Teva Pharmaceuticals</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR445399 &#8211; Anti-IL1R3 mAb</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inflammatory indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Added</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Entered confirmatory development</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">SAR445611 &#8211; Anti-CX3CR1 NANOBODY</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%"> VHH</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inflammatory indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Added</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Entered confirmatory development</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR446422 &#8211; Anti CD28/OX40 bispecific antibody</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inflammatory indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Added</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Entered confirmatory development</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR445514 &#8211; Trifunctional anti-BCMA NK-Cell engager</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Relapsed, refractory multiple myeloma</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Added</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Entered confirmatory development</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR445953 &#8211; Anti-CEACAM5-Topo1 ADC</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Colorectal cancer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Added</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Entered confirmatory development&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR444836 &#8211; PAH replacement AAV-based gene therapy</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Phenylketonuria</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Added</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Entered confirmatory development</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">ALTUVIIIO &#8211; Factor VIII replacement therapy</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Removed</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercialized</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR444419 &#8211; Anti-TNFa/IL6 NANOBODY</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> VHH</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Inflammatory indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Removed</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Development discontinued</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">atuzabrutinib (SAR444727) &#8211; BTK inhibitor (topical)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Removed</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Development discontinued</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">tusamitamab ravtansine (SAR408701) &#8211; Anti-CEACAM5 ADC</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NSCLC and other solid tumors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Removed</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Development discontinued</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR441000 &#8211; Cytokine mRNA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Solid tumors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Removed</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Development discontinued</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">&#160;(b)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR442257 &#8211; CD38/CD28/CD3 T-Cell engager</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Multiple myeloma/non-Hodgkin lymphoma</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Removed</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Development discontinued</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR443216 &#8211; CD3/CD28/HER2 T-Cell engager</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Solid tumors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Removed</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Development discontinued</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">alomfilimab (SAR445256) &#8211; Anti-ICOS mAb</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Solid tumors</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Removed</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Development discontinued</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">SAR445710 &#8211; Anti PD-L1/IL-15 fusion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Solid tumors</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Removed</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Development discontinued</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Shan6</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">DTwP-HepB-Polio-Hib</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pediatric hexavalent vaccine</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Removed</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Strategic decision</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">ExPEC vaccine (9-valent)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Prevention of invasive E.coli disease</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Added</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Partnered with Janssen</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">BEYFORTUS (nirsevimab), anti RSV mAb</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Passive prevention of RSV infections in all infants </span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Removed </span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercialized</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">mAb: monoclonal antibody. ADC: antibody-drug conjugate. NSCLC: Non-small cell lung cancer. RSV, respiratory syncitial virus.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) SAR445953: co-developed with Seagen.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) SAR441000: termination decided jointly with BioNTech.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The portfolio of products in clinical development (from Phase&#160;1 to Phase&#160;3) and in registration as </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">of December&#160;31, 2023 </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">is described in the section &#8220;Item 4.&#160;Information on the Company &#8212; E.&#160;R&amp;D Appendix.&#8221;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Phase&#160;1 studies are the first studies performed in humans, who are mainly healthy volunteers, except for studies in oncology, where Phase&#160;1 studies are performed in patients. Their main objective is to assess the tolerability, the pharmacokinetic profile (the way the product is distributed and metabolized in the body and the manner by which it is eliminated) and where possible the pharmacodynamic profiles of the new drug (i.e. how the product may react on some receptors).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Phase&#160;2 studies are early controlled studies in a limited number of patients under closely monitored conditions to show efficacy and short-term safety, and to determine the dose and regimen for Phase&#160;3 studies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Phase&#160;3 studies have the primary objective of demonstrating or confirming the therapeutic benefit and the safety of the new drug in the intended indication and population. They are designed to provide an adequate basis for registration.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">B.4.1.1. Products in development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Products in clinical development include three &#8216;pipeline-in-a-product&#8217; assets &#8211; amlitelimab, frexalimab and the oral TNFR1 signaling inhibitor SAR441566 &#8211; intended to address unmet patient needs in markets with low penetration of advanced therapies. In addition, our clinical pipeline features nine innovative medicines and vaccines: tolebrutinib, rilzabrutinib, itepekimab, lunsekimig, the IRAK4 degrader SAR444656, the anti-TL1A monoclonal antibody SAR447189, the ExPEC vaccine, and two mRNA vaccines respectively against respiratory syncytial virus and acne. The pipeline of potential market leading opportunities is summarized below:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><img src="sny-20231231_g1.jpg" alt="SlideR&amp;D Day_EN.jpg" style="height:193px;margin-bottom:5pt;vertical-align:text-bottom;width:653px"/></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Phase 1/2 study of acne mRNA vaccine to be initiated in the first half of 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Further details on these products, and on other products in clinical development, are given below.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a) Immunology&#160;&amp; Inflammation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">amlitelimab (SAR445229</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a human anti-OX40L monoclonal antibody, is currently being assessed in clinical programs for the treatment of atopic dermatitis (AD), asthma and hidradenitis suppurativa (HS).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Phase&#160;2b study (STREAM-AD) in adults with moderate-to-severe AD whose disease cannot be adequately controlled with topical medications or for whom topical medications are not a recommended treatment approach, met its primary endpoint of percentage change in Eczema Area and Severity Index (EASI) score from baseline at 16&#160;weeks. Four subcutaneous doses were studied, and continued improvement was seen through 24&#160;weeks. The Phase&#160;3 program started in 2023 with the first study (Coast&#160;1) initiated for treatment of participants diagnosed with moderate to severe AD, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.<br/>The Phase&#160;2b study (TIDE-asthma) is assessing add-on therapy with amlitelimab in adult participants with moderate-to-severe asthma; results are expected in 2024.<br/>In November&#160;2023, a Phase&#160;2 proof-of-concept study assessing amlitelimab in adult participants with moderate to severe HS was initiated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">frexalimab (SAR441344)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a second generation anti-CD40L monoclonal antibody that blocks the costimulatory CD40/CD40L pathway which is important for activation and function of adaptive (T and B cells) and innate (macrophages/microglia and dendritic cells) immunity. Sanofi is developing frexalimab under an exclusive license from ImmuNext Inc.<br/>Frexalimab is being evaluated in multiple sclerosis (see details in section &#8220;&#8212;&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">c) Neurology</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221;). The compound is also being evaluated in Phase&#160;2 trials for the treatment of Sjogren&#8217;s syndrome and systemic lupus erythematosus, respectively. In 2023, a Phase&#160;2b study assessing frexalimab in adults and adolescents with newly diagnosed type&#160;1 diabetes was initiated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR441566</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the first small molecule TNFR1 signaling inhibitor, is intended to provide patients with an oral alternative to anti-TNFa monoclonal antibodies in the range of inflammatory indications where these have been approved. SAR441566 is currently being evaluated in two Phase&#160;2b clinical studies that were initiated in 2023, respectively for the treatment of patients with psoriasis and with rheumatoid arthritis. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">itepekimab (SAR440340)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a human anti-IL33 monoclonal antibody co-developed with Regeneron that is currently being evaluated in a Phase&#160;3 clinical program (AERIFY-1 and AERIFY-2 studies) for the treatment of COPD in former smokers; itepekimab is also being assessed in a cohort of current smokers in AERIFY-2. In addition, an exploratory Phase&#160;2a study (AERIFY-3) is evaluating the mechanism of action of itepekimab and its impact on airway inflammation in former and current smokers with COPD. Itepekimab has FDA Fast Track Designation for the treatment of COPD.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">rilzabrutinib (SAR444671)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a covalent and reversible inhibitor of Bruton&#8217;s tyrosine kinase under development for the treatment of autoimmune/inflammatory diseases.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Phase&#160;2 study evaluating rilzabrutinib in adults with moderate-to-severe chronic spontaneous urticaria (CSU) met its primary endpoint consisting of improvement in weekly itch severity score (primary endpoint in the US) or in weekly urticaria activity score (itch and hives; primary endpoint outside the USA). Improvements in secondary endpoints were also observed. The Phase&#160;3 clinical program in CSU will be initiated in 2024. Further Phase&#160;2 studies have been pursued, assessing the product for the treatment of patients with moderate-to-severe asthma and IgG4-related disease, respectively.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, the development of rilzabrutinib for the treatment of atopic dermatitis was discontinued, based on the results of a Phase&#160;2 study in which the primary endpoint was not met.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, rilzabrutinib is being evaluated for the treatment of immune thrombocytopenia and </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">warm autoimmune hemolytic anemia </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see details in section &#8220;&#8212;&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">e) Rare Blood Disorders</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">lunsekimig (SAR443765)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a bispecific NANOBODY</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> VHH which blocks both TSLP and IL-13, key upstream and downstream mediators (respectively) of asthma. After Proof-of-Mechanism findings were obtained earlier this year, a Phase&#160;2b study (AIRCULES) enrolled the first participants in 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR444656</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a selective, orally administered small molecule targeting Interleukin-1 Receptor Associated Kinase&#160;4 (IRAK4), which is necessary for proinflammatory signaling and cytokine production. SAR444656 is developed in partnership with Kymera Therapeutics. Based on the encouraging results of a Phase&#160;1 clinical trial, Sanofi has initiated two Phase&#160;2 studies, respectively in atopic dermatitis and in HS.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR447189</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(also known as TEV-48574), an anti-TL1A monoclonal antibody, entered our Immunology &amp; Inflammation portfolio in 2023 and is co-developed with Teva Pharmaceuticals. SAR447189 is currently being evaluated in a Phase&#160;2 clinical program for the treatment of adults with ulcerative colitis and Crohn&#8217;s disease (inflammatory bowel disease).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">eclitasertib (SAR443122)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a small molecule targeting the receptor-interacting serine/threonine-protein kinase&#160;1 (RIPK1), which is being co-developed with Denali. In 2023, it was decided to discontinue eclitasertib in cutaneous lupus erythematosus, based on the efficacy results of the proof-of-concept Phase&#160;2 study. The compound was found to be generally well-tolerated and a Phase&#160;2 study evaluating eclitasertib in patients with ulcerative colitis is ongoing.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">riliprubart (SAR445088)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a complement C1s inhibitor under clinical development in various indications (see details in section </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8220;&#8212;&#160;e)&#160;Rare Blood Disorders&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and section </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8220;&#8212;&#160;c)&#160;Neurology&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). A Phase&#160;2 study is currently evaluating the compound for the treatment of patients at risk of antibody-mediated rejection (AMR) or diagnosed with AMR.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR442970</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a bispecific NANOBODY</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> VHH that combines the blockade of TNFa and the immune co-stimulatory regulator OX40L progressed to Phase&#160;2 in 2023 for the treatment of Hidradenitis Suppurativa.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR444336</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a non-beta IL-2 SYNTHORIN molecule designed to selectively engage CD4+ regulatory T cells (and not on effector T or NK cells), is currently being evaluated in Phase&#160;1 for the treatment of inflammatory indications.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR444559</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, an anti-CD38 monoclonal antibody with engineered format, is in clinical development for the treatment of inflammatory indications.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, new products originating from Sanofi&#8217;s research entered Phase 1 for the treatment of inflammatory indications:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt;text-decoration:underline">SAR445399</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, an anti-IL1R3 mAb monoclonal antibody;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt;text-decoration:underline">SAR445611</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, an anti-CX3CR1 NANOBODY</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> VHH; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt;text-decoration:underline">SAR446422</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a bispecific antibody targeting CD28 and OX40.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b) Oncology</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">pegenzileukin (SAR444245)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">is a non-alpha IL-2 SYNTHORIN molecule currently being evaluated in a Phase&#160;1/2 program initiated in 2023, to optimize the dose schedule for the treatment of solid tumors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR444881</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a monoclonal antibody targeting the Ig-like transcript&#160;2 (ILT2) receptor co-developed with Biond Biologics for the treatment of solid tumors, is currently being evaluated in Phase&#160;1.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR445419</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is an off-the-shelf NK cell therapy currently being evaluated in Phase&#160;1 for the treatment of relapsed/refractory acute myeloid leukemia.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR443579</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a trifunctional anti-CD123 NK cell engager developed in partnership with Innate Pharma. SAR443579 is being investigated in a Sanofi-sponsored Phase&#160;1/2 clinical trial in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia. SAR443579 has FDA Fast Track Designation for the treatment of acute myeloid leukemia.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR446309</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, an HER2-based T&#160;cell engager, is currently being evaluated as a single agent and in combination with pembrolizumab, in a Phase 1 clinical trial for the treatment of locally advanced or metastatic HER2-expressing cancers.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR444200</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a GPC3-based T&#160;cell engager designed with a NANOBODY</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> VHH format that is currently being evaluated in Phase&#160;1 in patients with advanced solid tumors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR445877</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is an anti PD1/IL-15 fusion protein under assessment in a Phase&#160;1 trial in patients with solid tumors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR445514</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a trifunctional anti-BCMA NK cell engager developed in partnership with Innate Pharma for the treatment of relapsed or refractory multiple myeloma; a Phase&#160;1/2 study was initiated in 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">SAR445953</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, an antibody drug conjugate (ADC) that binds to human CEACAM-5, is under Phase&#160;1 clinical evaluation for the treatment of patients with colorectal cancer or other solid tumors. SAR445953 is developed in collaboration with Seagen&#160;Inc.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c) Neurology</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">tolebrutinib (SAR442168)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is an oral investigational brain-penetrant and bioactive Bruton&#8217;s tyrosine kinase (BTK) inhibitor that achieves cerebrospinal fluid concentrations predicted to modulate B lymphocytes and microglial cells. Tolebrutinib is being evaluated in Phase&#160;3 clinical trials for the treatment of relapsing forms of multiple sclerosis (RMS), non-relapsing secondary progressive MS (nrSPMS), and primary progressive MS (PPMS).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">frexalimab (SAR441344)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a monoclonal antibody against CD40L (see section </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8220;&#8212;&#160;b) Immunology &amp; Inflammation&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), a key immune costimulatory component involved in MS. Through its unique upstream mechanism of action, frexalimab has the potential to address both acute and chronic neuroinflammation in MS. Data from the placebo-controlled part of the Phase&#160;2 study data in adults diagnosed with RMS demonstrated significant reductions in new gadolinium-enhancing lesions at week&#160;12 (primary objective), plus sustained reduction of disease activity over week&#160;24 in both high-dose and low-dose frexalimab groups. The treatment continuation open-label part of the study is ongoing. Two Phase&#160;3 studies were initiated late 2023 to evaluate the efficacy and safety of frexalimab for the treatment of adults with RMS and nrSPMS, respectively.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR443820</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is an oral brain-penetrant RIPK1 inhibitor that targets inflammatory cell signaling and activation of cell death pathways in MS pathophysiology. Its multitargeted mechanism of action and flexibility to be used as a monotherapy or in combination gives the compound the potential to address neurodegeneration and disability accumulation. SAR443820 is in-licensed from Denali and has been evaluated in Phase&#160;2 clinical trials for amyotrophic lateral sclerosis (ALS) and MS. Results of the Phase 2 trial in ALS (HIMALAYA) obtained in February 2024 indicated that the primary endpoint was not met; development of SAR443820 in this indication will not be pursued. Sanofi will continue the Phase 2 study (K2) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">of SAR443820 in participants with MS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">riliprubart (SAR445088)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a complement C1s inhibitor (see details in section </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8220;&#8212;&#160;e)&#160;Rare Blood Disorders&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), is being assessed in a Phase&#160;2 trial in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR446159</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a bispecific antibody targeting both alpha-synuclein and insulin-like growth factor&#160;1 receptor (IGF1R) developed in collaboration with ABL Bio for the treatment of Parkinson&#8217;s disease. A Phase&#160;1 study assessing the safety and tolerability of intravenous SAR446159 is ongoing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">d) Rare Diseases</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">venglustat (GZ402671)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is an orally administered brain penetrant glucosylceramide synthase (GCS) inhibitor that blocks the conversion of ceramide to glucosylceramide (GL-1). Venglustat is currently being evaluated in Phase&#160;3 trials for the treatment of three lysosomal storage diseases: late-onset GM2 gangliosidosis (Tay-Sachs disease and Sandhoff disease), Fabry disease, and Gaucher disease type&#160;3. The data of the Phase&#160;3 study in late-onset GM2 gangliosidosis and subsequent submission are expected in 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR442501</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is an antibody (Fab format) that directly targets fibroblast growth factor receptor&#160;3 (FGFR3), which has a gain-of-function genetic mutation leading to premature closure of bone growth plates and the achondroplasia condition, the most common cause of dwarfism in the world. In 2023, a Phase&#160;2 clinical trial was initiated to evaluate SAR442501 for the treatment of achondroplasia in children from birth up to 12&#160;years of age.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR443809</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a humanized monoclonal antibody that selectively inhibits the activated fragment of factor&#160;B (termed Bb) in the alternative pathway of the complement system, is being evaluated in a Phase&#160;1 trial for the treatment of rare renal diseases.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR439459</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a monoclonal antibody targeting transforming growth factor beta (TGF&#946;) currently evaluated in a Phase&#160;1 study in adult participants with Osteogenesis imperfecta, also called brittle bone disease, a rare disease in which bones fracture easily. Orphan Drug Designation was granted by the FDA for this indication.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SAR444836</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a phenylalanine hydroxylase replacement gene therapy based on adeno-associated virus vector technology that is developed in collaboration with MediciNova,&#160;Inc. In 2023, a Phase&#160;1 study was initiated to treat patients with phenylketonuria. Orphan Drug Designation has been granted by the FDA for this indication.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e) Rare Blood Disorders</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">rilzabrutinib (SAR444671)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is being investigated in a Phase&#160;3 trial for the treatment of adults and adolescents with persistent or chronic immune thrombocytopenia (ITP), for which the FDA has granted Fast Track Designation. Rilzabrutinib is also being evaluated in a Phase&#160;2b study for the treatment of adults with warm autoimmune hemolytic anemia (wAIHA).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">fitusiran (SAR439774)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a first-in-class, subcutaneously administered antithrombin siRNA therapy, is currently in Phase&#160;3 clinical development for the treatment of hemophilia&#160;A or&#160;B, with or without inhibitors, which includes lower doses and less frequent dosing while maintaining an antithrombin target range of 15-35% (antithrombin-based dosing regimen, AT-DR) in all ongoing studies. The Phase&#160;3 open-label extension study (ATLAS-OLE) demonstrated during an interim analysis a substantially improved safety profile versus AT-DR, and the risk of thrombosis was reduced with rates comparable to those reported in the general hemophilia population. Pre-specified efficacy analyses confirmed that fitusiran provides consistent protection with as few as six injections per year. Sanofi is currently in discussions with the US FDA regarding filing in 2024. Planned submissions in the European Union and Japan will require data from the ongoing Phase&#160;3 ATLAS-NEO study.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">riliprubart (SAR445088)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a humanized IgG4 monoclonal antibody that binds to and inhibits C1s, thereby inhibiting classical pathway (CP) of complement activity. Activation of the CP of complement is associated with a variety of immune disorders involving the presence of autoantibodies. Inhibition of autoantibody-mediated CP activation on the surface of erythrocytes via C1s binding prevents complement opsonin deposition on red blood cells and protects them from phagocytosis and extravascular hemolysis in autoimmune hemolytic anemia such as cold agglutinin disease (CAD). SAR445088 is currently being evaluated in a Phase 2 study for the treatment of patients with CAD.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">f) Vaccines</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Vaccines R&amp;D portfolio includes projects enhancing existing vaccines, and projects addressing novel targets. As shown below, several projects are in Phase&#160;2 and Phase&#160;3.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">mRNA Quadrivalent influenza vaccine (SP0273)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">is a quadrivalent influenza vaccine based on mRNA technology, which is currently in Phase&#160;1. Following results of Phase&#160;1, the mRNA influenza vaccine program is being adapted in order to enter Phase&#160;3 with an optimal next generation influenza vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">Rabies Vaccine (SP0087):</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> a next-generation purified human rabies vaccine (VRVg) is under development, aimed at replacing both of Sanofi&#8217;s currently commercialized rabies vaccines (IMOVAX Rabies and VERORAB). It will be cultured on Vero cells and will be free of animal or human material. VRVg is currently in Phase 3 trials in order to support pre and post exposure indications.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">Vero Yellow Fever (vYF) vaccine </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">candidate (SP0218)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a next generation freeze-dried live-attenuated yellow fever vaccine produced on a Vero cell line, for subcutaneous and intra-muscular administration in people aged nine months and older. This vaccine aims at replacing STAMARIL and YF-VAX with a single product. Following positive Phase&#160;2 results in 2023, Phase&#160;3 will be initiated in 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">ExPEC vaccine (SP0282): </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ExPEC is a vaccine for the prevention of invasive E.Coli disease, including sepsis, which is expected to complement our older adults vaccines portfolio . This 9-valent vaccine is partnered with Janssen Pharmaceuticals Inc., a Johnson and Johnson company; it is currently in Phase&#160;3, which was initiated in 2021 and continues to enroll patients.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">RSV toddler vaccine (SP0125)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">: All infants can be protected against RSV during their first season with BEYFORTUS (nirsevimab), now launched in the US and several other countries. The goal of RSV toddler vaccine is to expand RSV protection by providing protection to all toddlers against RSV, from the second season onwards. Positive data from a Phase&#160;1/2 study performed in the US evaluating the safety and effectiveness of two doses of an intranasal delivery device in infants were obtained at the beginning of 2023, which will enable a move to Phase&#160;3 in 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">RSV older adult vaccine (SP0256)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Sanofi has initiated Phase&#160;2 with an mRNA vaccine against RSV for the older adults population. This vaccine aims at providing protection against RSV, and is key for a respiratory combination providing additional benefits against other unmet medical needs (hMPV, PIV). Consistent with this, we started Phase&#160;1/2 in November&#160;2023 with an RSV/hMPV combination vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">Meningococcal Group B (Men B) and MenPenta (Men ACWYB) (SP0230):</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s MenB vaccine candidate is intended to provide active immunization against invasive meningococcal disease caused by </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Neisseria meningitidis</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> serogroup B (Men B) for all age groups. Following positive results of a Phase&#160;1/2 study initiated in March 2021, and positive pre-clinical data obtained on MenPenta, a MenPenta Phase&#160;1/2 was initiated in October&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">Pneumococcal Conjugate Vaccine (PCV) (SP0202)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">: Sanofi is collaborating with SK Biosciences (South Korea) to develop a 21-valent pneumococcal conjugate vaccine that will provide expanded protection against pneumococcal disease. Data from Phase&#160;2 studies assembled between mid-2022 and mid-2023 will allow us to move to Phase&#160;3 in the pediatric population in 2024.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">B.4.1.2. Line extensions</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For more information on DUPIXENT, KEVZARA, TZIELD, SARCLISA</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, REZUROCK</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">NEXVIAZYME, FLUZONE</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and MENQUADFI</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">s</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ee also </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">B.2.&#160;Main biopharma products</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">DUPIXENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, jointly developed with Regeneron. DUPIXENT has received regulatory approvals in several countries for use in patients with AD, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis (EoE) or prurigo nodularis (PN) in different age populations; details about clinical and regulatory activities pursued in 2023 are provided below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">DUPIXENT is under assessment for the treatment of dermatology, respiratory and gastrointestinal diseases:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt">in October&#160;2023, the FDA issued a Complete Response Letter (CRL) for the sBLA for DUPIXENT in CSU, an inflammatory skin condition, which causes sudden and debilitating hives and swelling on the skin. The CRL states that additional efficacy data are required to support an approval; it did not identify any issues with safety or manufacturing. An ongoing Phase&#160;3 clinical trial (Study&#160;C) continues to enroll patients, with results expected in late 2024 that are anticipated to provide the additional efficacy data. Sanofi and Regeneron remain committed to working with the FDA to advance the study of DUPIXENT for patients living with CSU who are inadequately controlled by antihistamines;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">the primary and all key secondary endpoints were met in the BOREAS Phase&#160;3 trial evaluating DUPIXENT compared to placebo in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled COPD and evidence of type&#160;2 inflammation. Clinically meaningful and highly significant reduction (30%) in moderate or severe acute exacerbations of COPD (rapid and acute worsening of respiratory symptoms) was obtained, while the trial also demonstrated significant improvements in lung function, quality of life and COPD respiratory symptoms. The second, replicate Phase&#160;3 trial (NOTUS) met its primary endpoint (significant reduction of exacerbations of COPD with DUPIXENT compared to placebo), confirming the results from the BOREAS pivotal trial. Supplemental BLA in the US was completed in December&#160;2023, following Marketing Authorization Application submission in Europe; the respective approvals are expected in 2024;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt">a Phase&#160;3 clinical study (LIBERTY-BP) is ongoing to evaluate DUPIXENT in adult patients with bullous pemphigoid; results are expected in 2024;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">the product is being assessed in a Phase&#160;3 study (LIBERTY-CPUO-CHIC) for the treatment of chronic pruritis of unknown origin in adults;</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.52pt">a Phase&#160;2/3 trial evaluating DUPIXENT in adult and adolescent patients with eosinophilic gastritis with or without eosinophilic duodenitis was initiated in 2023;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">f.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:9.17pt">a Phase&#160;2 clinical study was initiated in 2023 for the treatment of patients with ulcerative colitis.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Phase&#160;3 study (LIBERTY-CINDU) evaluating DUPIXENT in chronic inducible cold urticaria did not meet the required efficacy endpoints to continue this program. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Discontinuation of DUPIXENT programs in allergic fungal rhinosinusitis and chronic rhinosinusitis without nasal polyps was decided due to portfolio prioritization; the respective studies will be completed.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">KEVZARA</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a monoclonal antibody against the IL-6 receptor (developed with Regeneron) is already marketed for the treatment of moderate to severe rheumatoid arthritis. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The product is currently being developed for the treatment of polyarticular juvenile idiopathic arthritis. Based on the 52-week data of the pivotal Phase&#160;2 study assessing the pharmacokinetic profile, safety, and efficacy of sarilumab in children aged two to 17&#160;years old with polyarticular juvenile idiopathic arthritis, KEVZARA was submitted for approval to the FDA and to the European Medical Agency (EMA), respectively in August and November&#160;2023. The extension of indication is further supported by extrapolation of efficacy data in adults with rheumatoid arthritis to the pediatric population with polyarticular juvenile idiopathic arthritis.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A repeat dose-finding Phase&#160;2 study evaluating KEVZARA in children and adolescents with systemic juvenile idiopathic arthritis (SKYPS) is ongoing in Europe and in the rest of the world, as part of the pediatric investigation plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">TZIELD</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a CD3-directed monoclonal antibody acquired by Sanofi in 2023. TZIELD is the first and only disease modifying therapy in type&#160;1 diabetes (T1D), a chronic autoimmune condition where the body&#8217;s ability to regulate blood sugar levels is impacted due to the gradual destruction of insulin producing beta cells by one&#8217;s own immune system. The product was approved by the FDA in November&#160;2022 to delay the onset of Stage&#160;3 T1D in adults and children eight years and older diagnosed with Stage&#160;2 T1D.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The potential of TZIELD to slow the progression of Stage&#160;3 T1D in newly diagnosed children and adolescents is currently being evaluated in a Phase&#160;3 clinical program.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">SARCLISA</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a monoclonal antibody designed to selectively bind to CD38, a cell surface antigen expressed in multiple myeloma (MM) cancer cells and other hematological malignancies. SARCLISA is approved in several countries in combination settings for the treatment of adults with relapsed refractory multiple myeloma (RRMM).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">SARCLISA is under assessment in combination with current standard and novel treatments across the MM treatment continuum:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt">the Phase&#160;3 study (IMROZ) evaluating SARCLISA in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free survival compared with VRd alone in transplant-ineligible patients with newly diagnosed MM. These results will form the basis of a regulatory submission planned in 2024;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">a Phase&#160;3 study (IRAKLIA) investigating the development of a new subcutaneous formulation with an on-body device system in RRMM patients who have received at least one prior line of therapy is ongoing; this program is managed in collaboration with Blackstone Life Sciences;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt">a Phase&#160;3 study (GMMG HDF) is evaluating SARCLISA in combination with lenalidomide, bortezomib and dexamethasone for induction and with lenalidomide for maintenance in patients with newly diagnosed MM. This clinical trial is being conducted in collaboration with the German-speaking Myeloma Multicenter Group (GMMG);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">a Phase&#160;3 trial (ITHACA) is assessing SARCLISA in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering MM;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.52pt">SARCLISA is under evaluation in new combinations with emerging novel mechanisms of action in a Phase&#160;2 study for the treatment of patients with RRMM or newly diagnosed MM patients.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, the Phase&#160;2 study evaluating SARCLISA in combination with chemotherapy in pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS) was terminated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, the Phase&#160;2 study evaluating the safety, pharmacokinetics and efficacy of subcutaneous SARCLISA in adults with Warm Autoimmune Hemolytic Anemia (wAIHA), a rare blood disorder, was discontinued based on the preliminary results and portfolio prioritization. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">REZUROCK</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">is a selective ROCK2 (rho-associated coiled-coil&#8211;containing protein kinase-2) inhibitor that is approved by the FDA for the treatment of adult and pediatric patients aged 12&#160;years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Clinical development of the drug has been pursued in 2023 in two additional indications:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt">A Phase 3 study is evaluating REZUROCK in combination with corticosteroids for the treatment of newly diagnosed moderate or severe chronic GVHD;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">Another Phase 3 study is assessing REZUROCK on top of azithromycin and standard-of-care regimen of immunosuppression in adult participants who have evidence of progressive chronic lung allograft dysfunction (CLAD) despite azithromycin therapy.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">NEXVIAZYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:700;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">is a long-term enzyme replacement therapy targeting the mannose-6-phosphate receptor to effectively clear glycogen build-up in muscle cells. This enzyme replacement therapy is approved for the treatment of patients with Pompe disease, a rare disease caused by a deficiency of the enzyme acid alpha-glucosidase (GAA)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Europe, the treatment is marketed under the brand name NEXVIADYME. </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A Phase&#160;3 program is currently ongoing for the treatment of patients aged six months or younger who are affected by infantile onset Pompe disease.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">FLUZONE</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">: QIV HD is a higher dose quadrivalent influenza vaccine licensed in the US and in Europe for the elderly population, who do not respond as well to standard-dose influenza vaccines due to aging of the immune system (immuno-senescence). Safety and efficacy in the pediatric population will be assessed in a Phase&#160;3 trial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">MENQUADFI</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">: Sanofi&#8217;s Men ACYW-TT vaccine is our latest advance in meningococcal quadrivalent conjugate vaccination, designed to help protect an expanded patient group including infants and adolescents through older adults. MENQUADFI is already licensed in the US (for people aged two&#160;years and over), and in Europe and several other countries (for people aged 12&#160;months and over). MENQUADFI has also received WHO pre-qualification for people aged 12&#160;months and above. Phase&#160;3 trials are ongoing to evaluate immunogenicity and safety in infants aged 6 weeks and above, and allow for extension of the age indication down to six weeks of age.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_91"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.4.2. R&amp;D Expenditures for late stage development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Expenditures on research and development amounted to &#8364;6,728&#160;million in 2023 (&#8364;6,706&#160;million in 2022), comprising &#8364;6,509&#160;million in the Biopharma segment and &#8364;219&#160;million in the Consumer Healthcare segment. Research and development expenditures represented approximately 15.6% of our net sales in 2023, stable compared to 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Within the Biopharma segment, investments in Pharmaceuticals and Vaccines R&amp;D represented respectively &#8364;3,816&#160;million and &#8364;885&#160;million in 2023 (&#8364;3,978 million and &#8364;724 million in 2022), mainly reflecting additional spend in Immunology and reduced spend in investment in oncology (Pharmaceuticals), while Vaccines made further investments in the mRNA vaccines platform. Medical Affairs investment and R&amp;D Support functions came to &#8364;2,027&#160;million in 2023 (&#8364;2,004&#160;million in 2022), while cost control efforts continued overall.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_94"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5. Markets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A breakdown of revenues by business segment and by geographical region for 2023, 2022, and 2021 can be found at Note&#160;D.35. to our consolidated financial statements, included at Item&#160;18. of this annual&#160;report.</span></div><div style="margin-bottom:2pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following market shares and ranking information are based on consolidated national pharmaceutical sales data (excluding vaccines), in constant euros, on a September&#160;2023 MAT (Moving Annual Total) basis. The data are mainly from IQVIA MIDAS local sales audit supplemented by various other country-specific sources including Knobloch (Mexico), GERS (France) and HMR (Portugal).</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_97"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.5.1. Marketing and distribution</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have business operations in approximately 70&#160;countries and our products are available in more than</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">180&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ountries. A&#160;breakdown of our aggregate net sales by geographical region is presented in &#8220;Item&#160;5. Operating and Financial Review and Prospects &#8212;&#160;Results of Operations &#8212;&#160;Year Ended December 31, 2023 Compared with Year Ended December 31, 2022.&#8221; Sanofi is the seventh largest pharmaceutical company globally by sales. Our main markets in terms of net sales are respectively:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">United States: we rank ninth with a market share of 3.9%;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Europe: we are the fourth largest pharmaceutical company in France where our market share is 5.5%, and we rank third in Germany with a 4.2% market share; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">other countries: we are ranked sixteenth in Japan with a market share of 1.9%, and ninth in China with a market share of 1.4%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Although specific distribution patterns vary by country, we sell prescription drugs primarily to wholesale drug distributors, independent and chain retail drug outlets, hospitals, clinics, managed-care organizations and government institutions. Some products in Rare Diseases and Oncology may also be sold directly to physicians. With the exception of Consumer Healthcare products, our drugs are ordinarily dispensed to patients by pharmacies upon presentation of a doctor&#8217;s prescription. Our Consumer Healthcare products are also sold and distributed through e-commerce, which is a growing trend in consumer behavior. Our vaccines are sold and distributed through multiple channels including physicians, pharmacies, hospitals, private companies and distributors in the private sector, and governmental entities and non-governmental organizations in the public and international donor markets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We use a range of channels from in-person to digital to disseminate information about and promote our products among healthcare professionals, ensuring that the channels not only cover our latest therapeutic advances but also our established prescription products, which satisfy patient needs in some therapy areas. We regularly exhibit at major medical congresses. In some countries, products are also marketed directly to patients by way of television, radio, newspapers and magazines, and digital channels (such as the Internet). National education and prevention campaigns can be used to improve patients&#8217; knowledge of&#160;their conditions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our sales representatives, who work closely with healthcare professionals, use their expertise to promote and provide information on our drugs. They represent our values on a day-to-day basis and are required to adhere to a code of conduct and to internal policies on which they receive training.</span></div><div style="margin-bottom:2pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Although we market most of our products through our own sales forces, we have entered into and continue to form partnerships to co-promote/co-market certain products in specific geographical areas. Our major alliances are detailed at &#8220;Item&#160;5.&#160;Operating and Financial Review and Prospects &#8212;&#160;Financial Presentation of Alliances.&#8221; See also &#8220;Item&#160;3.&#160;Key Information &#8212;&#160;D.&#160;Risk Factors &#8212;&#160;We rely on third parties for the discovery, manufacture and marketing of some of our&#160;products.&#8221;</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_100"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.5.2. Competition</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The pharmaceutical industry continues to experience significant changes in its competitive environment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">There are four primary types of competition in the prescription pharmaceutical market:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">competition among pharmaceutical companies to research and develop new patented products or address unmet medical needs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">competition among different patented pharmaceutical products for the same therapeutic indication;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">competition among original and generic products or original biological products and biosimilars, at the end of regulatory exclusivity or patent protection; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">competition among generic or biosimilar products.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Generics manufacturers who have received all necessary regulatory approvals for a product may decide to launch a generic version before the patent expiry date, even in cases where the owner of the original product has already commenced patent infringement litigation against the generics manufacturer. Such launches are said to be &#8220;at risk&#8221; for the promoter of the generic product because it may be required to pay damages to the owner of the original product in the context of patent infringement litigation; however, such launches may also significantly impair the profitability of the pharmaceutical company whose product is&#160;challenged.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Drug manufacturers may also face intra-product competition through parallel trading, or parallel importation or reimportation, where permitted. This may take place when drugs sold in a foreign market under the same brand name as in a domestic market are permitted to be imported into that domestic market by parallel traders or importers, who may repackage or resize the original product or sell it through alternative channels such as mail order or the Internet. This situation is of particular relevance to the EU with its common market, where such practices have been encouraged by the current regulatory framework. Parallel traders or importers take advantage of the price differentials between markets arising from factors including sales costs, market conditions (such as intermediate trading stages), tax rates, or national regulation of&#160;prices.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, pharmaceutical companies face illegal competition from substandard and falsified drugs. The WHO estimates that falsified products account for 10% in low- and middle-income countries. All therapeutic areas are affected, including vaccines.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Worldwide, falsified products are an issue in part due to the exponential increase in Internet connectivity of those engaged in the manufacture, distribution and supply of substandard and falsified medical products.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Similar types of competition apply in CHC.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Vaccines, there are two primary types of competition:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">competition among vaccine companies to research and develop new patented products, including new vaccines originated from disruptive technologies (such as the emergence of mRNA vaccines to fight the COVID virus in 2020), or address unmet medical needs; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">competition among different patented (or non-patented) vaccine products marketed for the same therapeutic indication.</span></div><div style="margin-bottom:2pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Generics and biosimilars are not an issue in vaccines at present, since vaccines are still mostly produced from proprietary viral or bacterial strains. As with pharmaceutical drugs, vaccine manufacturers can face competition through parallel trading. However, the extent of such practices is limited by the need for cold chain distribution of vaccines, and by the fact that vaccines are sold and administered through pharmacies or dispensing physicians.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_103"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.5.3. Regulatory framework</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The pharmaceutical and health-related biotechnology sectors are highly regulated. National and supranational health authorities administer a vast array of legal and regulatory requirements that dictate pre-approval testing (including testing in human subjects) and quality standards to maximize the safety and efficacy of a new medical product. These authorities also regulate product labeling, manufacturing, importation/exportation, safety reporting and marketing, as well as mandatory post-approval requirements and commitments.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The submission of an application to a regulatory authority does not guarantee that a license or approval to market will be granted. Furthermore, each regulatory authority may impose its own requirements during product development or during the application review. It may refuse to grant approval or require additional data before granting approval, even in circumstances in which the same product has already been approved in other countries. Regulatory authorities also have the authority to request product recalls and product withdrawals, to impose penalties for violations of regulations, and ultimately the ability to revoke product licensure or approval.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Product review and approval can vary from six months or less to several years from the date of application submission depending upon the country and regulatory jurisdiction. Factors such as the quality of data and evidence, the review procedures, the nature of the product and the condition to be treated, play a major role in the length of time a product is under&#160;review, and whether or not the product is ultimately licensed or approved.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">In the EU</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, there are three main procedures for applying for marketing authorization:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the centralized procedure is mandatory for drugs derived from biotechnologies; new active substances designed for human use to treat&#160;HIV, viral diseases, cancer, neurodegenerative diseases, diabetes and auto-immune diseases; orphan drugs; and innovative products for veterinary use. When an application for human use is submitted to the EMA, the scientific evaluation of the application is carried out by the EMA&#8217;s CHMP and a scientific opinion is prepared. This opinion is sent to the EC, which adopts the final decision and grants an EU marketing authorization. Such a marketing authorization is valid throughout the EU, and the drug may be marketed within all EU Member States;</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if a company is seeking a national marketing authorization in more than one Member State, two procedures are available to facilitate the granting of harmonized national authorizations across Member States: the mutual recognition procedure or the decentralized procedure. Both procedures are based on the recognition by national competent authorities of a first assessment performed by the regulatory authority of one Member State; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">national authorizations are still possible, but are only for products intended for commercialization in a single EU Member State or for line extensions to existing national product licenses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">In the EU</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, vaccines are treated as pharmaceutical products, and therefore have to obtain marketing authorization under the centralized procedures described above.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Generic products are subject to the same marketing authorization procedures. A generic product must contain the same active medicinal substance as a reference product approved in the EU. Generic applications are abridged: generic manufacturers only need to submit quality data and demonstrate that the generic drug is &#8220;bioequivalent&#8221; to the originator product (i.e., performs in the same manner in the patient&#8217;s body), but do not need to submit safety or efficacy data since regulatory authorities can refer to the reference product&#8217;s dossier.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Another relevant aspect in the EU regulatory framework is the &#8220;sunset clause&#8221; under which any marketing authorization ceases to be valid if it is not followed by marketing within three years, or if marketing is interrupted for a period of three consecutive years.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">In the US</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the FDA has broad regulatory jurisdiction over all pharmaceutical and biological products that are intended for sale and marketing in the&#160;US. To commercialize a new drug or biologic in the US, an applicant must submit to the FDA a New Drug Application (NDA) under the Food, Drug and Cosmetic (FD&amp;C) Act or a Biologics License Application&#160;(BLA) under the Public Health Service (PHS) Act, respectively, for filing and pre-market review. Specifically, the FDA must decide whether the product is safe and effective for its proposed use; if the benefits of the product outweigh its risks; whether the product labeling is adequate; and if the manufacturing of the product and the controls used for maintaining quality are adequate to preserve the product&#8217;s identity, strength, quality and purity. Based upon this review, the FDA can stipulate post-approval commitments and requirements. Changes to an approved product, including but not limited to a new indication, require submission of a supplemental NDA (sNDA) for a drug or a supplemental BLA (sBLA) for a biological product.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FD&amp;C Act provides another option for NDA product approval via the 505(b)(2) pathway. This 505(b)(2) application contains full reports of investigations of safety and effectiveness but at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. For example, under the 505(b)(2) pathway an applicant may seek to rely on literature or earlier FDA findings of safety and effectiveness for approved drugs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sponsors wishing to market a generic drug or biosimilar product can file an Abbreviated NDA (ANDA) under 505(j) of the FD&amp;C Act or abbreviated BLA (aBLA) under 351(k) of the PHS Act, respectively.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">ANDA applications are&#160;&#8220;abbreviated&#8221; because they are generally not required to include data to establish safety and efficacy but need to demonstrate that their product is bioequivalent (i.e., performs in humans in the same manner as the originator&#8217;s product) to a reference product. Consequently, the length of time and cost required for development of generics can be considerably less than for the innovator&#8217;s drug. The ANDA pathway in the US can only be used for generics of drugs that can be referenced as having been approved under the FD&amp;C&#160;Act.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">aBLA applications contain evidence that the potential product is biosimilar to a reference product already approved by the FDA. A biosimilar is highly similar to and has no clinically meaningful differences in terms of safety, purity, and potency (i.e., safety and effectiveness) from an FDA-approved reference product. The abbreviated approval pathway for biosimilars was created to help reduce the time and cost of development of biologics without compromising safety and effectiveness. Consequently, the length of time and cost required for development of biosimilars may be less than for the innovator&#8217;s reference product.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">In Japan</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the entire process of approval review from review-related inspections and clinical trial consultation to review for the drugs approved by the Ministry of Health, Labour and Welfare (MHLW) is undertaken by the Pharmaceuticals and Medical Devices Agency&#160;(PMDA). The PMDA conducts first scientific review of the NDA submitted, assessing particularly the safety, efficacy and quality of the product or medical device proposed. Results of this primary evaluation are then submitted to the PMDA&#8217;s external experts. After a second evaluation based on the external experts&#8217; feedback, a report is provided; the Pharmaceutical Affairs and Foods Sanitation Council&#160;(PAFSC) &#8211;&#160;one of the councils organized under the MHLW as advisory commission&#160;&#8211; is consulted, and advises the MHLW on final approvability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For Japanese registrations, clinical data for Japanese patients are necessary. The regulatory authorities can require local clinical studies, though they also accept multi-regional studies including Japan. In some cases, bridging studies have been conducted to verify extrapolability of foreign clinical data to Japanese patients and to obtain data to determine the appropriateness of the dosages for Japanese patients.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The MHLW may require additional post-approval studies (Phase&#160;4) for some specific cases, to further evaluate safety and/or to gather information on the use of the product under specified conditions. In approval of new drugs, new indications, new dosages or new administrations, the re-examination period is determined by the MHLW. Post-marketing information on a drug for the predetermined period after approval is collected to reconfirm its efficacy, safety and quality at the end of the period. This collection process involves both post-marketing surveillance (PMS), which is a non-interventional study, and post-marketing clinical trials.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For generic products, the data necessary for filing are similar to EU and US&#160;requirements. Companies only need to submit quality data, and data demonstrating bioequivalence to the originator product, unless the drug is biopharmaceutical. Common Technical Document (CTD) submission for generics has been mandatory since March&#160;2017.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) was created in&#160;1990 and reformed in 2015.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The ICH currently includes 21&#160;Members and 37&#160;Observers. Harmonization is achieved through the development of ICH Guidelines via a process of scientific consensus with regulatory and industry experts working side-by-side.</span></div><div style="margin-bottom:2pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition to the joint efforts, Free Trade Agreements (FTAs) have proven to be one of the best ways to open up foreign markets to exporters and to allow for discussions on harmonization topics for regulatory authorities. Some agreements, such as the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS), are international in nature, while others are between specific countries. The requirements of many countries (including Japan and several EU Member States) to negotiate selling prices or reimbursement rates for pharmaceutical products with government regulators significantly extend the time to market entry beyond the initial marketing approval. While marketing authorizations for new pharmaceutical products in the EU have been largely centralized within the EC in collaboration with the EMA, pricing and reimbursement remain a matter of national competence.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of risks relating to the regulatory environment in which we operate, refer to &#8220;&#8212;&#160;Item 3.D.&#160;Risk Factors &#8212;&#160;Product liability claims could adversely affect our business, results of operations and financial condition.&#8221;</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_106"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.5.4. Pricing &amp; reimbursement</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are operating in a</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">highly volatile and competitive</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> market access and launch environment globally. The pharmaceuticals and health biotech industries are highly regulated (see &#8220;&#8212;&#160;Item&#160;3. Key information &#8212; D. Risk Factors &#8212;&#160;Our activities (including our products and manufacturing activities) are subject to significant government regulations and regulatory approvals, which are often costly and could result in adverse consequences to our business if we fail to anticipate the regulations, comply with them, maintain the required approvals, and/or adapt to changes in applicable regulations&#8221;).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Faced with mounting budget pressure, governments and payers are using several </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">drug price control policies</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> such as price referencing for imported drugs, increased patient co-payments, restrictive formularies, prescribing guidelines, tendering procedures, generic and biosimilar substitution, and medico-economic evaluations of healthcare products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, companies are required to demonstrate the value and cost-effectiveness of their products throughout their life cycle (e.g. comparative efficacy studies, real-world patient data, budget modelling) to meet</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> diverse and stringent payer evidence requirements</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, raising the bar for market entry in many countries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Despite numerous pricing and reimbursement challenges, payers and regulators remain committed to providing </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">access to new innovative therapies</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, with greater emphasis on real-world evidence (RWE).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These trends are likely to</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">continue in the coming year amid </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">macroeconomic and geopolitical headwinds</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Overview of the US health insurance system:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Commercial insurance is offered widely as part of employee benefit packages and is the main source of employee access to subsidized healthcare. Some individuals purchase private health plans directly or through marketplaces established under the Affordable Care Act, while publicly subsidized programs provide coverage for retirees, the indigent, the disabled, uninsured children, and serving or retired military personnel. Double coverage can occur.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Commercial insurance includes:</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Managed Care Organizations (MCOs), which combine the functions of health insurance, delivery of care, and administration. MCOs use specific provider networks and specific services and products. There are four primary types of managed care plans: Health Maintenance Organizations (HMOs), Preferred Provider Organizations (PPOs), Exclusive Provider Organizations (EPOs), and Point of Service (POS) plans; and</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Pharmacy Benefit Managers (PBMs), which serve as intermediaries between insurance companies, pharmacies and manufacturers to negotiate rebates and discounts on formulary placement for commercial health plans, self-insured employer plans, Medicare Part D plans, and federal and state government employee plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Government insurance includes:</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.27pt">Medicare</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which provides health insurance for people aged 65 and older and for people with permanent disabilities. The basic Medicare scheme (Part&#160;A) provides hospital insurance only, and the vast majority of beneficiaries purchase additional coverage through Part&#160;B, Part&#160;C and/or Part&#160;D. Part&#160;D enables Medicare beneficiaries to obtain outpatient drug coverage. Almost two-thirds of all Medicare beneficiaries have enrolled in Part&#160;D plans;</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.27pt">Medicaid</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which provides health insurance for low-income families, certain qualified pregnant women and children, individuals receiving supplemental security income, and other eligible persons determined on a state-by-state basis; and</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.27pt">TRICARE</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which provides health insurance for uniformed service members, retirees, and their families including comprehensive healthcare, prescription and dental coverage.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">In August&#160;2022, the Inflation Reduction Act (IRA) was signed into law by President Biden</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">This legislation contains three core provisions related to drug pricing which are to be phased between 2022 and 2026:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Medicare drug price negotiation, inflation penalties on list price increases, and Medicare Part&#160;D redesign. Importantly, all of the policy changes enacted under the IRA apply to the two Medicare programs that cover separately reimbursable prescription drugs: Part&#160;B (physician-administered outpatient medicines) and Part&#160;D (self-administered medicines).</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">39</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the IRA, for the first time ever, the federal government will negotiate the prices of selected drugs with high budget impact on Medicare Part&#160;B and Part&#160;D, starting with 10&#160;drugs with high Part&#160;D expenditures, whose negotiated pricing will take effect in 2026; up to 15 more high-Part&#160;D expenditure drugs, whose negotiated pricing will take effect in 2027; and up to 15 more drugs with high expenditures under Parts&#160;B and/or&#160;D drugs; whose negotiated pricing will take effect in 2028. Up to 20 more drugs with high Part&#160;B and/or Part&#160;D expenditures will be selected for negotiated pricing with effect in 2029 and each subsequent year. No Sanofi product is among the initial 10&#160;drugs that the government has identified for negotiations in 2023 and 2024 and for which negotiated pricing will take effect in 2026.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The IRA also imposes inflation penalties applied to Medicare Parts&#160;B and&#160;D if prices rise faster than inflation (based on the consumer price index, CPI), beginning in October&#160;2022 for Part&#160;D and January&#160;2023 for Part&#160;B.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other measures of the Act redesign the Medicare Part&#160;D benefit, including a monthly $35 insulin cap in 2023 and an annual $2,000 out-of-pocket (OOP) spending cap in 2025 for Medicare beneficiaries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Altogether, the IRA&#8217;s prescription drug-related provisions are expected to reduce the federal deficit by about $237&#160;billion through 2031 according to estimates from the Congressional Budget Office (CBO). The new legislation is also likely to have a negative impact on industry revenue growth and future innovation, though significant uncertainties remain over the process and methods of Medicare price negotiations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">In addition to the IRA, the industry is exposed to increased price pressure from the continuing vertical integration and consolidation within the US health insurance market</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. With the three largest PBM group purchasing organizations (GPOs) (i.e. Ascent, Zinc and Emisar) now covering over 85% of US prescription drug claims, consolidation has led to more aggressive formulary utilization management controls, resulting in the GPOs having strong bargaining power for negotiating discounted prices, thereby adversely impacting manufacturer&#8217;s revenues.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">China</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">China continues to pursue reforms</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">towards</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Healthy China 2030</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Healthcare is one of the growth priorities under the country&#8217;s fourteenth Five-Year Plan (2021-2025), with policies aimed at addressing a large and increasing burden of disease (especially cancer, diabetes and cardiovascular diseases), while balancing access to innovation and costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">China continues to improve regulatory timelines</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. For example, DUPIXENT received approval for the treatment of adults with moderate-to-severe atopic dermatitis in June&#160;2020, within six months of filing through an accelerated review process.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Pricing pressure is expected to continue and further intensify </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a growing number of products are subject to National Reimbursement Drug List (NRDL) price negotiations and volume-based procurement (VBP) tenders, with the lowest price prevailing to compete with local champions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Access to innovative therapies has been accelerating in the last five years, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">fueled by annual NRDL updates, albeit with steep price cuts across therapy areas. According to the National Healthcare Security Administration (NHSA), 126&#160;new drugs were added to the National Reimbursement Drug List (NRDL) in December&#160;2023, with an average price reduction of 61.7% in line with recent years. Over the past six years, 744&#160;drugs have been added to the NRDL, bringing the total number of covered medicines to 3,088 (1,698&#160;Western drugs and 1,390&#160;traditional Chinese medicines).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Further expansion of the VBP policy </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">will drive down the prices of a growing number of products, with more than 500&#160;drugs targeted for inclusion by 2025.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Europe</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">In Europe, health systems have been under</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">mounting budget pressures. These remain high in the wake of COVID-19</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, with rising inflation and slow economic growth translating into an acceleration of cost-containment policies in major EU markets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">The industry is also facing</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">high uncertainty</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">in the context of the new Pharmaceutical Strategy for Europe</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, including numerous policy changes to EU pharmaceutical legislation, health technology assessment (HTA) and joint procurement, among others. These reforms will have a far-reaching impact on the pricing and market access landscape in Europe and will likely pose additional challenges for industry.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">On April&#160;26, 2023, the EC adopted a proposal for a new Directive and a new Regulation, which represent the</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">largest pharmaceutical reform in over 20&#160;years.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> The most concerning proposals under review relate to the potential reduction of market exclusivity for orphan medicines; greater transparency of R&amp;D costs; faster availability of generics and biosimilars; and more stringent obligations for the supply of medicines. If passed in its current form, the legislation could have a detrimental impact on access, innovation and competitiveness in Europe.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">The Commission also adopted the new EU Health Technology Assessment (HTA) regulation in December&#160;2021, after years of joint work between Member States</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The regulation will introduce EU-level joint scientific consultations (JSCs) and joint clinical assessments (JCAs) that will serve as the basis for national value assessments and price negotiations. The joint HTA process will be implemented in a phased approach starting in January&#160;2025 with oncology medicines and advanced therapy medicinal products (ATMPs), before expanding to include orphan drugs in 2028 and all EMA centrally authorized medicinal products by 2030.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Additional uncertainty is caused by the evolving joint procurement approaches of vaccines and medicines at EU level,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> building on the lessons learned during the COVID-19 pandemic. The Commission may promote the use of EU joint procurement as a means to improve affordability and security of supply, which is already occurring to some extent with existing cross-country collaboration initiatives such as the BeNeLuxA alliance, the FINOSE collaboration and the Nordic Pharmaceutical Forum.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Pricing and reimbursement pressures are being felt in other regions and countries around the globe.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To overcome these challenges, we are developing tailored market access strategies early in the drug development process, engaging in dialogue with payers and multiple stakeholders throughout the lifecycle, based on a thorough understanding of evolving market dynamics.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_109"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6. Patents, intellectual property and other rights</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.6.1. Patents</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Patent protection</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We own a broad portfolio of patents, patent applications and patent licenses worldwide. These patents are of various types and may cover: active ingredients; pharmaceutical formulations; product manufacturing processes; intermediate chemical compounds; therapeutic indications/methods of use; technology platforms; delivery systems; digital applications; and enabling technologies, such as assays.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Patent protection for individual products typically extends for 20&#160;years from the patent filing date in countries where we seek patent protection. A substantial part of the 20-year life span of a patent on a new molecule (small molecule or biologic) has generally already passed by the time the related product obtains marketing authorization. As a result, the effective period of patent protection for an approved product&#8217;s active ingredient is significantly shorter than 20&#160;years. In some cases, the period of effective protection may be extended by procedures established to compensate regulatory delay in Europe (via Supplementary Protection Certificate or SPC), in the US (via Patent Term Extension or PTE), and in Japan (PTE).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The protection a patent provides to the related product depends upon the type of patent and its scope of coverage, and may also vary from country to country.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Europe, applications for new patents may be submitted to the European Patent Office (EPO). A European Patent (EP) may cover 39&#160;European Patent Convention Member States, including all Member States of the EU. The granted EP establishes corresponding national patents with uniform patent claims among the Member States. Since June&#160;1, 2023, it has been possible to obtain a Unitary Patent, currently covering 17&#160;states, which are all Member States of the EU and of the European Patent Convention.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We monitor our competitors and vigorously seek to challenge patent infringers when such infringement would negatively impact our business objectives. See &#8220;Item&#160;8. &#8212; A.&#160;Consolidated Financial Statements and Other Financial Information &#8212;&#160;Information on Legal or Arbitration Proceedings &#8212;&#160;Patents&#8221; of this annual report.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The expiration or loss of a patent covering a new molecule, typically referred to as a compound patent, may result in significant competition from generic or biosimilar products and can result in a dramatic reduction in sales of the original branded product (see &#8220;Item&#160;3. Key Information &#8212; D.&#160;Risk Factors&#8221;). In some cases, it is possible to continue to benefit from a commercial advantage through product manufacturing trade secrets or other types of patents. Certain categories of products, such as traditional vaccines and insulin, were historically relatively less reliant on patent protection and may in many cases have no patent coverage. It is nowadays increasingly frequent for novel vaccines also to be patent protected.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory exclusivity</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In some markets, including the EU and the US, many of our pharmaceutical products may also benefit from multi-year regulatory exclusivity periods, during which a generic or biosimilar competitor may not rely on our clinical trial and safety data in its drug application. This exclusivity operates independently of patent protection and may protect the product from generic or biosimilar competition even if there is no patent covering the product.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the US, the FDA may not grant final marketing authorization to a generic competitor for a New Chemical Entity (NCE) until the expiration of the regulatory exclusivity period (five years) that commences upon the first marketing authorization of the reference listed drug. Significant new uses of existing NCEs, including new indications, may qualify for an additional three years of regulatory exclusivity if certain conditions are met. In the US, a different regulatory exclusivity paradigm applies to biological drugs. The BPCIA (Biologics Price Competition and Innovation Act) provides that the FDA may not approve a biosimilar application until 12&#160;years after the date on which the reference product was first licensed.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the EU, regulatory exclusivity is available in two forms: data exclusivity and marketing exclusivity. Generic or biosimilar drug applications will not be accepted for review until eight years after the first marketing authorization (data exclusivity). This eight-year period is followed by a two-year period during which generics or biosimilars cannot be marketed (marketing exclusivity). The marketing exclusivity period can be extended to three years if, during the first eight-year period, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which are deemed to provide a significant clinical benefit over existing therapies. This is known as the &#8220;8+2+1&#8221; rule.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Japan, the regulatory exclusivity period varies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In general, the regulatory exclusivity period is of four to six years for drugs for a specific use, and for medicinal products with new indications or with new dosages; eight years for drugs containing a new chemical entity; ten years for orphan drugs, and for new drugs requiring pharmaco-epidemiological study; six to eight years for Innovative drugs (&#8220;SAKIGAKE</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> products), and for orphan drugs with a new ethical combination or new mode of administration; and six years for other medicinal products, such as new prescription combination drugs or drugs requiring a new mode of administration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">41</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric extension</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the US and the EU, under certain conditions, it is possible to extend a product&#8217;s regulatory exclusivity for an additional period of time by providing data on pediatric studies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the US, under certain conditions of the Hatch-Waxman Act, it may result in the FDA extending regulatory exclusivity and patent life by six months, to the extent these protections have not already expired (the so-called &#8220;pediatric exclusivity&#8221;).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Europe, a regulation on pediatric medicines provides for pediatric research obligations with potential associated rewards including extension of supplementary patent protection and six-month regulatory exclusivity for pediatric marketing authorization (for off-patent medicinal products).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Japan, there is no pediatric research extension of patent protection for patented medicinal products. However, regulatory exclusivity may be extended from eight to ten years.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug exclusivity</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under certain conditions, orphan drug exclusivity may be granted in the US to drugs intended to treat rare diseases or conditions. Orphan drug exclusivities also exist in the EU and Japan.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging markets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">One of the main limitations on our operations in emerging market countries is the lack of effective intellectual property protection or enforcement for our products, which frequently do not provide non-patent exclusivity for innovative products. While the situation has gradually improved, the lack of protection for intellectual property rights or the lack of robust enforcement poses difficulties in certain countries. Additionally, in recent years and especially during the pandemic, a number of countries have waived or threatened to waive intellectual property protection for specific products, for example through compulsory licensing of generics. See &#8220;Item&#160;3. Key Information &#8212; D.&#160;Risk Factors &#8212; Risks Relating to Sanofi&#8217;s Structure and Strategy &#8212; The globalization of our business exposes us to increased risks in specific areas&#8221;.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Product overview</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We summarize below the intellectual property coverage (in some cases through licenses) of our most significant marketed products in terms of sales, in our major markets. In the discussion of patents below, we focus on active ingredient patents (compound patents) and, in the case of NCEs, on any later filed patents listed as applicable in the FDA&#8217;s list of Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;) or in its foreign equivalents. For biologics, the Orange Book listing does not apply.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These patents or their foreign equivalents tend to be the most relevant in the event of an application by a competitor to produce a generic or a biosimilar version of one of our products (see &#8220;&#8212; Challenges to Patented Products&#8221; below). In some cases, products may also benefit from pending patent applications or from patents not eligible for Orange Book listing (in the case of NCEs for example, patents claiming industrial processes). In each case below, we specify whether the active ingredient is claimed by an unexpired patent. Where patent terms have been extended to compensate for US Patent and Trademark Office (USPTO) delays in patent prosecution (Patent Term Adjustment &#8211; PTA) or for other regulatory delays, the extended dates are indicated below. The US patent expirations presented below reflect USPTO dates, and also reflect six-month pediatric extensions when applicable. Where patent terms have expired we indicate such information and mention whether generics or biosimilars are on the market.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We do not provide later filed patent information relating to formulations already available as an unlicensed generic. References below to patent protection in Europe indicate the existence of relevant patents in most major markets in the EU. Specific situations may vary by country.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We additionally set out any regulatory exclusivity from which these products continue to benefit in the US, EU or Japan. Regulatory exclusivities presented below incorporate any pediatric extensions obtained. While EU regulatory exclusivity is intended to be applied throughout the EU, in some cases Member States have taken positions prejudicial to our exclusivity rights.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">42</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">European Union</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Japan</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AUBAGIO (teriflunomide)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patent: coverage ranging through April 2027 with SPC*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patent: coverage ranging through March 2024</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Generics on the market</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: August 2024</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Generics on the market</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:20pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALPROLIX (eftrenonacog alfa)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Use: March 2028 with PTA* and PTE*</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: May 2024 (May 2029 with SPC* in most EU countries)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: May 2024 (February 2026 with PTE*)</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through December 2037 (pending)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through December 2037 (pending)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through December 2037 (pending)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: March&#160;2026</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: May 2028</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:20pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO (efanesoctocog alfa)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: February 2037 with PTA* (PTE* pending)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: January 9, 2035 </span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: January 9, 2035 (PTE* pending)</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through March 2043 (pending)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through March 2043 (pending)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through March 2043 (pending)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: February 2035</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: September 2031</span></div></td></tr><tr style="height:27pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BEYFORTUS (nirsevimab-alip)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: January 2035 (PTE* pending)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: January 2035 (SPC* in process of being granted across EU countries)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: January 2035</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patent: coverage ranging through September 2042  (pending)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patent: coverage ranging through September 2042  (pending)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patent: coverage ranging through September 2042  (pending)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: July 2035</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: November 2032</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CEREZYME (imiglucerase)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patent: expired</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patent: expired</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patent: expired</span></div></td></tr><tr style="height:33pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">DUPIXENT (dupilumab)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: March 2031 with PTE*</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: September&#160;2032 with SPC* (March 2033 with pediatric extension of SPC* in process of being granted across EU countries)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: May 2034 with PTE*</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through December 2042 (pending)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through January 2042 (pending)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through October 2041 (pending)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: March 2029</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: September&#160;2028</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: January 2026</span></td></tr><tr style="height:27pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ELOCTATE (efmoroctocog alfa)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: June 2028 with PTA* and PTE*</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Use: May 2024 </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(November 2029 with SPC* in most EU countries)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: May 2024 (August 2026 with PTE*)</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through December 2037 (pending)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through December 2037 (pending)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through December 2037 (pending)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: June&#160;2026</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: November 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ENJAYMO (sutimlimab)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: November 2033 (PTE* pending)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: November 2033 (SPC* in process of being granted across EU countries)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: November 2033 (PTE* pending)</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: Coverage ranging through March 2042 (pending)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: Coverage ranging through March 2042 (pending)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: Coverage ranging through March 2042 (pending)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: February 2034</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: November 2032</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: June 2032</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FABRAZYME (agalsidase&#160;beta)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patent: expired</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patent: expired</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patent: expired</span></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: March 2028 pediatric indication (ages 2-8 with confirmed Fabry disease)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Generics/biosimilars on the market</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">JEVTANA (cabazitaxel)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Compound: Expired </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Later filed patents: coverage ranging through October&#160;2030</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Compound: expired</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Later filed patents: coverage ranging through October 2030</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Generics on the market</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Compound: expired</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:83%">Later filed patents: coverage ranging through November&#160;2030</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LANTUS (insulin glargine)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Generics/biosimilars on the market</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Generics/biosimilars on the market</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Generics/biosimilars on the market</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LOVENOX (enoxaparin&#160;sodium)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Generics on the market</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biosimilars on the market</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LUMIZYME/MYOZYME (alglucosidase alfa)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td></tr><tr style="height:27pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NEXVIAZYME / NEXVIADYME (avalglucosidase alfa)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: March 2030 with PTA* (PTE* pending)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: January 2028 (SPC* granted in BG, ES, FR, GR, HU, NL, SI and SE; pending in many other EU countries)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: December 2032 with PTE*</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through May 2032</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through May 2032</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through May 2032</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: pending</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: no (a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: September 2031</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PLAVIX (clopidogrel&#160;bisulfate)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Generics on the market</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Generics on the market</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Generics on the market</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">43</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">European Union</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Japan</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TOUJEO (insulin&#160;glargine)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compound: expired</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through May&#160;2031</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through May&#160;2031</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through July&#160;2033 with PTE*</span></div></td></tr><tr style="height:20pt"><td colspan="3" rowspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XENPOZYME (olipudase&#160;alfa)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Use:  March 2031 with PTA* (PTE* pending)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Use: August 2030 (SPC* in process of being granted across EU countries)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Use: August 2030 (PTE* pending)</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through 2043 (pending)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through 2043 (pending)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Later filed patents: coverage ranging through 2043 (pending)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: August 2034</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: June 2032</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Regulatory exclusivity: March 2030</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;PTE: Patent Term Extension. &#8211; SPC: Supplementary Protection Certificate. &#8211; PTA: Patent Term Adjustment.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to legal challenge before EU General Court.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Patents held or licensed by Sanofi do not in all cases provide effective protection against a competitor&#8217;s generic or biosimilarversion of our products. For example, notwithstanding the presence of unexpired patents, competitors launched generic versions of ALLEGRA in the US (prior to the product being switched to over-the-counter status) and MULTAQ in the EU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We caution the reader that there can be no assurance that we will prevail when we assert a patent in litigation and that there may be instances in which Sanofi determines that it does not have a sufficient basis to assert one or more of the patents mentioned in this report, for example in cases where a competitor proposes a formulation not appearing to fall within the claims of our formulation patent; a salt or crystalline form not claimed by our composition of matter patent; or an indication not covered by our method of use patent. See &#8220;Item&#160;3. Key Information &#8212;&#160;D.&#160;Risk Factors &#8212;&#160;Risks Relating to Legal and Regulatory Matters &#8212;&#160;We rely on our patents and other proprietary rights to provide exclusive rights to market certain of our products, and if such patents and other rights were limited, invalidated or circumvented, our financial results could be materially and adversely affected.&#8221;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As disclosed in Item&#160;8. of this annual report, we are involved in significant litigation concerning the patent protection of a number of our products.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Challenges to patented products</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;Abbreviated New Drug Applications (ANDAs)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the US, generic companies have filed Abbreviated New Drug Applications (ANDAs) containing challenges to patents related to a number of our small molecule products. An ANDA is an application by a drug manufacturer to receive authority to market a generic version of another company&#8217;s approved product, by demonstrating that the purportedly generic version has the same properties (safety and other technical data) as the original approved product. As a result of regulatory protection of our safety and other technical data, ANDA applications are generally four years after FDA approval, and include a challenge to a patent listed in the FDA&#8217;s Orange Book. If the patent holder or licensee brings suit in response to the patent challenge within&#160;the&#160;statutory window, the FDA is barred from granting final approval to an ANDA during the 30&#160;months following the&#160;expiry of the&#160;5-year regulatory exclusivity (this bar is referred to in our industry as a &#8220;30-month stay&#8221;) unless, before the end of the&#160;30&#160;months, the parties reach settlement or a court decision has determined either that the ANDA does not infringe the listed patent or that the listed patent is invalid and/or unenforceable.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">FDA approval of an ANDA after this 30-month period does not resolve outstanding patent disputes, but it does remove the regulatory impediments to a product launch by a generic manufacturer willing to take the risk of later being ordered to pay damages to the patent holder.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accelerated ANDA-type procedures are potentially applicable to many, but not all, of the products we manufacture. See &#8220;&#8212;&#160;B.5.3.&#160;Regulatory Framework&#8221; and &#8220;- Regulation&#8221; above. We seek to defend our patent rights vigorously in these cases. Success or failure in the assertion of a given patent against a competing product is not necessarily predictive of the future success or failure in the assertion of the same patent. See &#8220;Item&#160;3. Key Information &#8212; D.&#160;Risk Factors &#8212; Risks Relating to Legal and Regulatory Matters &#8212; We rely on our patents and other proprietary rights to provide exclusive rights to market certain of our products, and if such patents and other rights were limited, invalidated or circumvented, our financial results could be materially and adversely affected.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;Section&#160;505(b)(2) New Drug Applications in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our products and patents are also subject to challenge by competitors via another abbreviated approval pathway, under section&#160;505(b)(2) of the Federal Food, Drug, and Cosmetic Act. This pathway allows for approval for a wide range of products, especially for those products that represent only a limited change from an existing approved drug. The 505(b)(2) pathway is distinct from the ANDA pathway, which allows for approval of a generic product based on a showing that it is equivalent to a previously approved product.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Similarly, entities wishing to market a generic biologic can utilize an abbreviated approval pathway established in the PHS Act. This &#167;351(k) pathway enables an applicant to rely on a reference product sponsor&#8217;s data when seeking approval of a biological product shown to be biosimilar (highly similar with no clinically meaningful differences) or interchangeable with an FDA-licensed reference BLA product.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">44</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;Europe</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the EU, a generic drug manufacturer may only reference the data of the regulatory file for the original approved product after data exclusivity has expired. However, there is no patent listing system in Europe comparable to the Orange Book, which would allow the patent holder to prevent the competent authorities from granting marketing authorization by bringing patent infringement litigation prior to approval. As a result, generic products may be approved for marketing following the expiration of marketing exclusivity without regard to the patent holder&#8217;s rights. Nevertheless, in most of these jurisdictions once the competing product is launched, and in some jurisdictions even prior to launch (once launch is imminent), the patent holder may seek an injunction against such marketing if it believes its patents are infringed. See Item&#160;8. of this annual report.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.6.2. Trademarks &#8211; Domain names &#8211; Copyright</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our products are sold around the world under trademarks that we consider to be of material importance in the aggregate. Our trademarks help to identify our products and to protect the sustainability of our growth. We generate new assets (trademarks, domain names, service marks) when creating global brands for new, innovative products. We support the development of the product, from the branding of biotech platforms to the protection of service marks for patient support programs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Trademarks are particularly important to the commercial success of our products and services in a competitive marketplace, providing a strong visibility and assuring patients of the origin of the products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Domain names are essential to inform a range of communities about what we do. We also pay close attention to ensuring that no damage is done to our reputation online.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We aim to ensure that the product trademarks we submit to healthcare authorities to obtain marketing authorizations are available, and are protected. In certain cases, we may enter into a coexistence agreement with a third party that owns potentially conflicting rights in order to avoid any risk of confusion and to secure our rights.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Ongoing digitization emphasizes the importance of securing copyright protection for software and web layouts.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We monitor and defend our trademarks based on a specific policy designed to prevent counterfeiting, trademark infringement and/or unfair competition.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_112"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.7. Production and raw materials</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have opted to manufacture the majority of our products in-house. There are three principal stages in our production process: the manufacture of active ingredients, the transformation of those ingredients into drug products or vaccines, and the final packaging.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our general policy is to produce our key active ingredients and main drug products at our own plants in order to reduce our dependence on external suppliers. We also rely on third parties for the manufacture and supply of specific active ingredients, drug products and medical devices. Active ingredients are manufactured using raw materials sourced from suppliers who have been subject to rigorous selection and approval procedures, in accordance with international standards and our own internal directives. We have outsourced some of our production under supply contracts associated with acquisitions of products or businesses or with Sanofi plant divestitures, or to establish a local presence to capitalize on growth in emerging markets. Our pharmaceutical subcontractors follow our general quality and logistics policies, as well as meeting other criteria.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our manufacturing activities require significant amounts of energy, the costs of which increased in 2022 and 2023 as a result of inflationary pressures and supply constraints due to the war in Ukraine. The Group uses supply contracts and hedging to mitigate those risks and costs. See&#160;&#8220;Item&#160;3.&#160;Key Information &#8212;&#160;D.&#160;Risk Factors &#8212;&#160;Risks Relating to Our Business.&#8221;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also obtain active ingredients from third parties under collaboration agreements. This applies in particular to the monoclonal antibodies developed with Regeneron.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our production sites are divided into three categories:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">global sites, which serve all markets: located mainly in Europe, these facilities are dedicated to the manufacture of our active ingredients, injectable products, and a number of our main solid-form products;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">regional sites, which serve markets at regional level, giving us a strong industrial presence in emerging markets; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">local sites, which serve their domestic market only.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Vaccines produces vaccines at various sites, with the main locations situated in France, the United States, Canada, India, Mexico and China. The pharmaceutical site at Le&#160;Trait (France) also contributes to Vaccines&#8217; industrial operations by making its sterile filling facilities available for vaccine manufacturing.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All of our production facilities are good manufacturing practice (GMP) compliant, in line with international regulations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our main sites are approved by the FDA:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the Specialty Care facilities in the United States (Framingham MA and Northborough MA), France (Lyon Gerland, Vitry-sur-Seine, Le&#160;Trait), Germany (Frankfurt), Ireland (Waterford) and Belgium (Geel);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the General Medicines facilities in Germany (Frankfurt), France (Aramon, Sisteron, Ploermel, Ambar&#232;s and Tours), Italy (Anagni and Scoppito), Singapore (Jurong) and the United States (Ridgefield NJ);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the CHC facilities in France (Compi&#232;gne) and the United States (Chattanooga TN); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the Vaccines facilities in France (Marcy l&#8217;&#201;toile, Le Trait, Val-de-Reuil and Neuville-sur-Sa&#244;ne), the United States (Swiftwater PA) and Canada (Toronto).</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">45</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Wherever possible, we seek to have multiple plants approved for the production of key active ingredients and our strategic finished products (this is the case with LOVENOX and DUPIXENT, for example).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">More details about our manufacturing sites are given below at section&#160;&#8220;&#8212;&#160;D.&#160;Property, Plant and Equipment&#8221;.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_115"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8. Insurance and risk coverage</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are protected by five main insurance programs, relying not only on the traditional corporate insurance and reinsurance market but also on our direct insurance company, Carraig Insurance DAC (Carraig).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These five key programs cover Property &amp; Business Interruption; General &amp; Product Liability; Stock &amp; Transit; loss and liability arising from cyber and digital risks; and Directors &amp; Officers Liability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Carraig participates in our coverage for various lines of insurance including Property, Stock &amp; Transit, Cyber/Digital, and General &amp;&#160;Product Liability. Carraig is run under the supervision of the Irish and European regulatory authorities, is wholly owned by Sanofi, and has sufficient resources to meet those portions of our risks that it has agreed to cover.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Carraig sets premiums for our entities at market rates. Claims are assessed using the traditional models applied by insurance and reinsurance companies, and the company&#8217;s reserves are regularly verified and confirmed by independent actuaries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Property &amp; Business Interruption program covers all our entities worldwide, in all territories where it is possible to use a centralized program operated by Carraig. By sharing risk between our entities, this approach enables us to set deductibles and cover appropriate to the needs of local entities before the market attachment point. It also incorporates a prevention program, including a comprehensive site visit schedule covering our production, storage, research and distribution facilities and standardized repair and maintenance procedures across all sites.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Stock &amp; Transit program protects all goods owned by Sanofi while they are in transit nationally or internationally whatever the means of transport, and all our inventories wherever they are located. Sharing risk between our entities through Carraig means that we can set deductibles at appropriate levels, for instance differentiating between goods that require temperature controlled distribution and those that do not. We have developed a prevention program with assistance from experts, implementing best practices in this area at our distribution sites.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Cyber/Digital insurance program protects our operations against loss originating from various sources, and against liability in respect of data security. Centralized through Carraig, the program enables us to set deductibles and cover appropriate to the needs of local entities before the market attachment point.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our General &amp; Product Liability program was renewed in 2023 for all our subsidiaries worldwide in all territories where it was possible to do so. For several years, insurers have been reducing product liability cover because of the difficulty of transferring risk for some products that have been subject to numerous claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal risk exposure for our pharmaceutical products is covered with low deductibles at country level, with a greater proportion of risk being retained. The level of risk self-insured by Sanofi (including via Carraig) before the market attachment point enables us to retain control over the management and prevention of risk. Our negotiations with third-party insurers and reinsurers are tailored to our specific risks. In particular, they allow for differential treatment of products in the development phase; for discrepancies in risk exposure between European countries and the United States; and for specific issues arising in certain jurisdictions. Coverage is adjusted every year to take account of the relative weight of new product liability risks such as those arising out of biotechnologies and new technology platforms.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our cover for risks that are not specific to the pharma-biotech industry (general liability) is designed to address the potential impacts of our operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For all the insurance programs handled by Carraig, outstanding claims are covered by provisions for the estimated cost of settling all claims incurred but not paid at the balance sheet date, whether reported or not, together with all related claims handling expenses. Where there is sufficient data history from Sanofi or from the market for claims made and settled, management &#8211;&#160;with assistance from independent actuaries&#160;&#8211; prepares an actuarial estimate of our exposure to unreported claims for the risks covered. The actuaries perform an actuarial valuation of the company&#8217;s IBNR (Incurred But Not Reported) and ALAE (Allocated Loss Adjustment Expense) liabilities at year end. Two ultimate loss projections (based upon reported losses and paid losses, respectively) are computed each year using various actuarial methods including the Bornhuetter-Ferguson method; those projections form the basis for the provisions set.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Directors &amp; Officers Liability program protects all legal entities under our control, and their directors and officers. Carraig is not involved in this program.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also operate other insurance programs, but these are of much lesser importance than those described above.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All our insurance programs are backed by highly-rated insurers and reinsurers and are intented to be designed in such a way that we can integrate most newly acquired businesses without interruption of cover. Our insurance cover has been designed to reflect our risk profile and the capacity available in the insurance market. By centralizing our major programs, we are able to provide what we believe to be excellent, cost effective protection.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">46</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_118"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.9. Health, Safety and Environment</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our manufacturing and research operations are subject to increasingly stringent health, safety and environmental (HSE) laws and regulations. These laws and regulations are complex and rapidly changing, and Sanofi invests the necessary sums in order to comply with them. This investment, which aims to respect health, safety and the environment, varies from year to year.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Applicable environmental laws and regulations may require us to eliminate or reduce the effects of chemical substance discharge at our various sites. The sites in question may belong to Sanofi, and may be currently operational, or may have been owned or operational in the past. In this regard, Sanofi may be held liable for the costs of removal or remediation of hazardous substances on, under or in the sites concerned, or on sites where waste from activities has been stored, without regard to whether the owner or operator knew of or under certain circumstances caused the presence of the contaminants, or at the time site operations occurred the discharge of those substances was authorized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As is the case for a number of companies in the pharmaceutical, chemical and intense agrochemical industries, soil and groundwater contamination has occurred at some of our sites in the past, and may still occur or be discovered at others. In Sanofi&#8217;s case, such sites are mainly located in the United States, Germany, UK and France. As part of a program of environmental surveys conducted over the last few years, detailed assessments of the risk of soil and groundwater contamination have been carried out at current and former Sanofi sites. In cooperation with national and local authorities, Sanofi regularly assesses the rehabilitation work required and carries out such work when appropriate. Remediation works have just been completed at Dagenham in the United Kingdom and Neuville in France. Long-term rehabilitation work is in progress or planned in Mount Pleasant, Portland in the United States; Frankfurt in Germany; Valernes and Limay in France; and on a number of sites divested to third parties and covered by contractual environmental guarantees granted by Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We may also have potential liability for investigation and cleanup at several other sites. We have established provisions for the sites already identified and to cover contractual guarantees for environmental liabilities for sites that have been divested. In France specifically, we have provided the financial guarantees to the authorities as required under French regulations for environmental protection in connection with the operation of activities on French sites.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Potential environmental contingencies arising from certain business divestitures are described in Note&#160;D.22.d. to the consolidated financial statements. In 2023, Sanofi spent &#8364;33&#160;million on rehabilitating sites previously contaminated by soil or groundwater pollution.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Due to changes in environmental regulations governing site remediation, our provisions for remediation obligations may not be adequate due to the multiple factors involved, such as the complexity of operational or previously operational sites, the nature of claims received, the rehabilitation techniques involved, the planned timetable for rehabilitation, and the outcome of discussions with national regulatory authorities or other potentially responsible parties, as in the case of multiparty sites. Given the long industrial history of some of our sites and the legacy obligations arising from the past involvement of Aventis in the chemical and agrochemical industries, it is impossible to quantify the future impact of these laws and regulations with precision. See&#160;&#8220;Item&#160;3.D.&#160;Risk Factors &#8212;&#160;Environmental and safety risks of Our Industrial Activities.&#8221;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have established, in accordance with our current knowledge and projections, provisions for cases already identified and to cover contractual guarantees for environmental liabilities relating to sites that have been divested. In accordance with Sanofi&#160;standards, a comprehensive review is carried out once a year on the legacy of environmental pollution. In light of data&#160;collected&#160;during this review, we adjusted our provisions to &#8364;493&#160;million as of December 31, 2023 versus &#8364;526&#160;million as of&#160;December 31, 2022. The terms of certain business divestitures, and the environmental obligations and retained environmental liabilities relating thereto, are described in&#160;Note&#160;D.22. to our consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To our knowledge, Sanofi did not incur any liability in 2023 for non-compliance with current HSE laws and regulations that could be expected to significantly jeopardize its activities, financial situation or operating income. We also believe that we are in substantial compliance with current HSE laws and regulations and that all the environmental permits required to operate our facilities have been obtained.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Regular HSE audits are carried out by Sanofi in order to assess compliance with standards (which implies compliance with regulations) and to initiate corrective measures (36&#160;internal audits performed in 2023). Moreover, more than 100&#160;specific visits were performed jointly with experts representing our insurers.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has implemented a worldwide master policy on health, safety and environment to promote the health and well-being of the employees and contractors working on its sites and respect for the environment. We consider this master policy to be an integral part of our commitment to social responsibility. In order to implement this master policy, Sanofi key requirements have been drawn up in the key fields of HSE management, HSE leadership, safety in the workplace, process safety, occupational hygiene, health in the workplace and protection of the environment. However, despite these efforts, Sanofi may be unsuccessful in the implementation of its policy to reduce and mitigate the harmful effects of its activities on the health and safety of its employees, customers or the general public and on the environment more generally. See &#8220;Item&#160;3.B. Risk Factors&#8221; for further information.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">47</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">From the development of compounds to the commercial launch of new drugs, Sanofi research scientists continuously assess the effect of products on human health. This expertise is made available to employees through two committees responsible for chemical and biological risk assessment. Sanofi&#8217;s COVALIS </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Comit&#233; des Valeurs Limites Internes Sanofi)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Committee is responsible for the hazard determination and classification of all active pharmaceutical ingredients and synthesis intermediates handled at Sanofi facilities. This covers all active ingredients handled in production at company sites or in processes sub-contracted for manufacture. Any important issues involving raw materials or other substances that lack established occupational exposure limits may also be reviewed. The COVALIS Committee determines the occupational exposure limits required within Sanofi. Our TRIBIO Committee is responsible for classifying all biological agents according to their degree of pathogenicity, and applies rules for their containment and the preventive measures to be respected throughout Sanofi. See&#160;&#8220;Item&#160;3.&#160;Key Information &#8212;&#160;D. Risk Factors &#8212;&#160;Environmental and safety risks of Our Industrial Activities &#8212;&#160;Risks from manufacturing activities and the handling of hazardous materials could adversely affect our results of&#160;operations and reputation.&#8221;</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Appropriate occupational hygiene practices and programs are defined and implemented in each site. These practices consist essentially of containment measures for collective and individual protection against chemical and biological exposure in all workplaces where chemical substances or biological agents are handled. All personnel are monitored with an appropriate medical surveillance program, based on the results of professional risk evaluations linked to their&#160;duties.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, dedicated resources have been created to implement the European Regulation on Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) and the European Regulation on Classification, Labeling and Packaging of chemicals (CLP). To fully comply with REACH, Sanofi has registered the relevant hazardous chemical substances with the European Chemicals Agency&#160;(ECHA).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Safety</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has rigorous policies to identify and evaluate safety risks and to develop preventive safety measures, and methods for checking their efficacy. Additionally, Sanofi invests in training that is designed to instill in all employees a sense of concern for safety, regardless of their duties. These policies are implemented on a worldwide scale to ensure the safety of all employees and to protect their health. Each project, whether in research, development or manufacturing, is subject to evaluation procedures, incorporating the chemical substance and process data communicated by the COVALIS and TRIBIO Committees described above. The preventive measures are designed primarily to reduce the number and seriousness of work accidents and to minimize exposures involving permanent and temporary Sanofi employees as well as our sub-contractors.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The French chemical manufacturing sites in Aramon and Sisteron are listed Seveso&#160;III (from the name of the European directive that deals with potentially dangerous establishments where dangerous substances may be present in quantities exceeding certain thresholds to prevent major accidents and limit their consequences). In accordance with French law on technological risk prevention, the French sites are also subject to heightened security inspections due to the toxic or flammable materials stored on the sites and used in the operating processes.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Risk assessments of processes and installations are drawn up according to standards and internal guidelines incorporating the best state of the art benchmarks for the industry. These assessments are used to fulfill regulatory requirements and are regularly updated. Particular attention is paid to any risk-generating changes such as process or installation changes, as well as changes in production scale and transfers between industrial or research&#160;units.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are using specialized process safety-testing laboratories that are fully integrated into our chemical development activities, apply methods to obtain the physico-chemical parameters of manufactured chemical substances (intermediate chemical compounds and active ingredients) and apply models to measure the effect of potentially leachable substances in the event of a major accident. In these laboratories the parameters for qualifying hazardous reactions are also determined, in order to define scale-up process conditions while transferring from development stage to industrial scale. We use these data to enhance the relevance of our risk assessments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We believe that the safety management systems implemented at each site, the hazard studies carried out and the risk management methods implemented, as well as our third-party property insurance policies covering any third-party physical damage, are consistent with legal requirements and the best practices in the&#160;industry, although no guarantee can be given that they will prevent accidents of various kinds.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environment</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Beyond healthcare, we have developed an ambitious policy aimed at minimizing the environmental impacts of our products and activities while strengthening our resilience in the face of environmental changes. We have identified six major environmental challenges relating to our businesses: greenhouse gas emissions and climate disruption; eco-design; water; pharmaceuticals in the environment; waste; and biodiversity.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The initiatives already implemented since&#160;2010 are continuing, and we have been keen to give them fresh impetus through the Planet Care program. Reflecting our environment strategy out to 2030 and 2045, the program sets more ambitious targets for reducing environmental impacts across the entire value chain. Planet Care is a global project that involves all of the Company&#8217;s resources in defining objectives and engaging with external partners.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Compared with 2019 figures, we are undertaking to reduce our carbon emissions by 55% (scope&#160;1 and&#160;2) by the end of 2030, building the path to carbon-neutral status by&#160;2030 on our scope&#160;1, 2 &amp;&#160;3 (direct and indirect emissions for all activities), and net zero by 2045. We have also set ourselves the target of achieving sustainable water resource management, especially at sites which are under hydric stress. On this new scope, by the end of&#160;2023 we had reduced CO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:1.19pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">emissions by 38% (scope&#160;1 and&#160;2) and water withdrawals by 18%.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">48</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Overall waste valorization at sites is already above 88% and is expected to be more than 90% by the end of 2025. The landfill rate had dropped to 2.3% at the end of 2023 and we have committed to move towards no more than 1% by 2025. Biodiversity management at our sites is also a priority, with the aim of making all employees aware of this challenge and implementing risk assessment and management plans at priority sites by 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, we are pursuing the policy we began in 2010 of managing pharmaceutical products in the environment throughout their life cycles. At the end of 2023, all priority production sites had initiated specific risk-based programs to monitor, manage and reduce emissions of pharmaceuticals in waste water (where needed).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In line with this approach, we are engaged in the Industry Roadmap for Progress on Combating Antimicrobial Resistance. Together with the other AMR roadmap signatories we have co-developed reference guides and methodologies for producing antibiotics responsibly. The initiative includes a specific commitment with respect to antibiotic production sites that are operated by signatories or their suppliers, involving the deployment of a shared framework and safe-discharge targets for managing potential emissions of antibiotics. See &#8220;Cautionary statement regarding forward-looking statements&#8221; and &#8220;Item 3.D. Risk Factors.&#8221;</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_121"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C. Organizational Structure</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_124"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">C.1. Significant Subsidiaries</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is the holding company of a consolidated group consisting of almost 260&#160;companies. The table below sets forth our&#160;significant subsidiaries as of December 31, 2023. For a fuller list of the principal companies in our consolidated group, see Note&#160;F.&#160;to&#160;our consolidated financial statements, included in Item&#160;18 of this annual report.</span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:28.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant subsidiary</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date of<br/>incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Country of<br/>incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Principal&#160;activity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial and&#160;</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">voting interest </span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis&#160;Inc.</span></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 1, 1968</span></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">November 21, 1991</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Europe B.V.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 24, 1991</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hoechst GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 8, 1974</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Deutschland GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 1997</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Participations SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 25, 2002</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Singapore Pte Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 14, 1997</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Biotechnology</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 23, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Foreign Participations B.V.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 29, 1998</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Winthrop Industrie</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 11, 1972</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Inc.</span></td><td colspan="3" style="border-bottom:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 18, 1977</span></td><td colspan="3" style="border-bottom:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="3" style="border-bottom:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td colspan="2" style="border-bottom:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-bottom:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since 2009, we have transformed Sanofi through numerous acquisitions and divestments (see main recent events&#160;in &#8220;A.&#160;History and Development of the Company&#8221; above), in particular the acquisitions of Genzyme in April&#160;2011, Boehringer Ingelheim (BI) Consumer Healthcare in January&#160;2017, Bioverativ in March&#160;2018, Ablynx in June&#160;2018, Synthorx in&#160;January&#160;2020, Principia in&#160;September&#160;2020, Kymab in April&#160;2021, Translate Bio in September&#160;2021, and Amunix Pharmaceuticals, Inc in February&#160;2022; the deconsolidation of EUROAPI in May&#160;2022; and the acquisitions of Provention Bio, Inc. and QRIB Intermediate Holdings, LLC. in 2023 The financial effects of the Genzyme acquisition are presented in Note&#160;D.1.3. to&#160;our consolidated financial statements for the year ended December&#160;31, 2013, included in our annual report on Form&#160;20-F for that year. At the end of&#160;December&#160;2016, Sanofi Pasteur and&#160;MSD (known as Merck in the United States and Canada) ended their Sanofi Pasteur MSD joint venture. The financial effects of the resulting divestment/acquisition are presented in Note&#160;D.1.2. to our consolidated financial statements for the year ended&#160;December&#160;31,&#160;2016, included in our annual report on Form&#160;20-F for that year. On&#160;January&#160;1, 2017, Sanofi and Boehringer Ingelheim (BI) finalized the strategic transaction agreed in June&#160;2016, involving the exchange of Sanofi&#8217;s Animal Health business (Merial) for BI&#8217;s Consumer Healthcare business. The financial effects of this transaction are presented in Note&#160;D.1. to our consolidated financial statements for the year ended December&#160;31, 2017, included in our annual report on Form&#160;20-F for that year. The financial effects of the Bioverativ and Ablynx acquisitions are presented in&#160;Note&#160;D.1.1. to our consolidated financial statements for the year ended&#160;December&#160;31,&#160;2018, included in our annual report on&#160;Form&#160;20-F for that year. The financial effects of the Synthorx and Principia acquisitions are presented in Note&#160;D.1. to our consolidated financial statements for the year ended December&#160;31, 2020, included in our annual report on Form&#160;20-F for that year. The financial effects in&#160;2021 of the Kymab, Kiadis, Tidal, Translate Bio, Kadmon and Origimm acquisitions, and in 2022 of the acquisition of Amunix Pharmaceuticals, Inc. and the deconsolidation of EUROAPI, are presented in Note D.2. to our consolidated financial statements for the year ended December&#160;31, 2033, included in our annual report on Form&#160;20-F for that year. The financial effects of the acquisition of Provention Bio, Inc and QRIB Intermediate Holdings, LLC in 2023 are presented in Note&#160;D.1. to our consolidated financial statements for the year ended December&#160;31, 2023, included at Item 18. of this annual report on Form&#160;20-F.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In certain countries, we carry on some of our business operations through joint ventures with local partners. In addition, we have entered into worldwide collaboration agreements&#160;in particular those with Regeneron on DUPIXENT and KEVZARA</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and with AztraZeneca on BEYFORTUS. For further information, refer to Note&#160;C.&#160;&#8220;Principal Alliances&#8221; to&#160;our consolidated financial statements, included at Item 18. of this annual report on Form 20F.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">49</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_127"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">C.2. Internal organization of activities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and its subsidiaries collectively form a group organized around two activities: Biopharma (General Medicines, Specialty Care and Vaccines) and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Within Sanofi, responsibility for R&amp;D rests with Sanofi, Genzyme Corporation, Sanofi Pasteur and Sanofi Pasteur,&#160;Inc. (in vaccines) for the Biopharma segment. However, within our integrated R&amp;D organization, strategic priorities are set and R&amp;D efforts coordinated on a worldwide scale. In fulfilling their role in R&amp;D, the aforementioned companies subcontract R&amp;D to those of their subsidiaries that have the necessary resources. They also license patents, manufacturing know-how and trademarks to certain of their French and foreign subsidiaries. Those licensee subsidiaries manufacture, commercialize and distribute the majority of our products, either directly or via local distribution entities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our industrial property rights, patents and trademarks are mainly held by the following companies:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Biopharma: Sanofi, Sanofi Mature IP, Sanofi Biotechnology SAS (France), Sanofi-Aventis Deutschland GmbH (Germany), Ablynx (Belgium), Genzyme Corporation, Bioverativ Inc., Kadmon Corporation LLC, Amunix Pharmaceuticals, Inc., Kymab Ltd, Principia Biopharma Inc., Sanofi Pasteur (France), Sanofi Pasteur,&#160;Inc. (US), Sanofi Pasteur Vaxdesign Corp., Translate Bio (US), Synthorx, Inc., Aventis Pharma SA and Provention Bio, Inc.;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">consumer healthcare: A. Nattermann Cie &amp; GmbH (Germany), Chattem Inc. (US), Opella Healthcare and SSP Co. Ltd (Japan).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of our principal items of property, plant and equipment, see&#160;&#8220;&#8212;&#160;D.&#160;Property, Plant and Equipment&#8221; below. Our property, plant and equipment is held mainly by the following companies:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in France: Sanofi Pasteur&#160;SA, Sanofi Chimie, Sanofi Winthrop Industrie, Opella Healthcare International SAS and Sanofi-Aventis Recherche&#160;&amp; D&#233;veloppement;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in the United States: Sanofi Pasteur, Inc., Genzyme Therapeutics Products LP, Genzyme Corporation and Translate Bio;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in Germany: Sanofi-Aventis Deutschland GmbH;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in Canada: Sanofi Pasteur Limited;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in Belgium: Genzyme Flanders BVBA; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in Ireland: Genzyme Ireland Limited.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_130"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">C.3. Financing and financial relationships between group companies</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Sanofi parent company raises the bulk of the Company&#8217;s external financing and uses the funds raised to meet, directly or indirectly, the financing needs of its subsidiaries. The parent company operates a cash pooling arrangement under which any surplus cash held by subsidiaries is managed centrally. There is also a centralized foreign exchange risk management system in place, whereby the parent company contracts hedges to meet the needs of its principal subsidiaries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, at December 31, 2023, the Sanofi parent company held 91% of our external financing and 75% of our surplus cash.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi European Treasury Center&#160;SA (SETC), a 100%-owned Sanofi subsidiary incorporated in 2012 under the laws of Belgium, is dedicated to providing financing and various financial services to our subsidiaries.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_133"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D. Property, plant and equipment</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_136"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.1. Overview</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our headquarters are located in Paris, France. See&#160;&#8220;&#8212;&#160;D.4.&#160;Office Space&#8221; below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We operate our business through office premises and research, production and logistics facilities in approximately 70&#160;countries around the world. Our office premises house all of our support functions, plus operational representatives from our subsidiaries and the&#160;Company.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A breakdown of our sites by use and by ownership status (owned versus leasehold) is provided below. This breakdown is based on surface area. All surface area figures are&#160;unaudited.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:40.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.331%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.968%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.632%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Breakdown of sites by use</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Breakdown of sites by ownership status</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Leasehold</span></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Offices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #21004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #21004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Logistics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="border-bottom:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">50</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_139"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.2. Description of our sites</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sanofi industrial sites</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of the process of transforming Sanofi and creating Global Business Units, we are continuing to adapt the organization of the Manufacturing &amp; Supply department in support of our new business model.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Manufacturing &amp; Supply department focuses on customer needs and service quality; the sharing of &#8220;Sanofi Manufacturing System&#8221; good manufacturing practices; and the development of a common culture committed to quality.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The organizational structure of Manufacturing &amp; Supply is aligned on our corporate structure and our four Global Business Units: Specialty Care, General Medicines, Vaccines and CHC.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">EUROAPI is a standalone business created by Sanofi and dedicated to the production, development and marketing of active pharmaceutical ingredients (API) in Europe. EUROAPI houses the activities of six manufacturing sites (located in Italy, Germany, the UK, France and Hungary), and was first listed on Euronext Paris on May&#160;6, 2022. Following that initial listing, Sanofi no longer controls EUROAPI, and now accounts for its residual interest (29.8 % at December 31, 2023) using the equity method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Manufacturing &amp; Supply department is also responsible for Sanofi Global HSE and Global Supply Chain.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the end of 2023, we were carrying out industrial production at 54&#160;sites in 24&#160;countries:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">8&#160;sites for our Specialty Care operations;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">22&#160;sites for our General Medicines operations;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">10&#160;sites for the industrial operations of Vaccines; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">13&#160;sites for our CHC operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The quantity of units sold in 2023, including in-house and outsourced production, was 4.3&#160;billion. This comprised:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Biopharma: 2.3&#160;billion units; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">CHC: 2.0&#160;billion units.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We believe that our production facilities are in compliance with all material regulatory requirements, are properly maintained and are generally suitable for future needs. We regularly inspect and evaluate those facilities with regard to environmental, health, safety and security matters, quality compliance and capacity utilization. For more information about our property, plant and equipment, see Note&#160;D.3. to our consolidated financial statements, included at Item&#160;18. of this annual report, and section&#160;&#8220;B.7.&#160;Production and Raw Materials&#8221; above.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our main production sites by volume are:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Le Trait (France), Frankfurt (Germany), Waterford (Ireland), Geel (Belgium) and Framingham (United States) for Specialty Care;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Aramon, Sisteron and Ambar&#232;s (France), Frankfurt (Germany), Csanyikv&#246;lgy (Hungary), L&#252;leburgaz (Turkey), Campinas (Brazil), Jurong (Singapore) and Hangzhou (China) for General Medicines products;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Compi&#232;gne and Lisieux (France), Cologne (Germany), Origgio (Italy), Chattanooga (United States) and Ocoyoacac (Mexico) for Consumer Healthcare products;&#160;and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Marcy-l&#8217;&#201;toile and Val-de-Reuil (France), Toronto (Canada) and Swiftwater (United States) for vaccines.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research &amp; Development sites</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Pharmaceuticals, research and development activities are conducted at the following sites:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">four operational sites in France: Chilly-Mazarin/Longjumeau, Montpellier, Strasbourg and Vitry-sur-Seine/Alfortville;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">three sites in the rest of Europe (Germany, Belgium and the Netherlands), the largest of which is in Frankfurt (Germany);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">six sites in the United States: Bridgewater, Cambridge, Framingham/Waltham, Great Valley and San Francisco ; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">three sites in China (Beijing, Shanghai and Chengdu).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Vaccines research and development sites are:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Swiftwater, Cambridge and Orlando (United States);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Marcy-l&#8217;&#201;toile/Lyon (France); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Toronto (Canada).</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_142"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3. Acquisitions, capital expenditures and divestitures</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The carrying amount of our property, plant and equipment at December 31, 2023 was &#8364;10,160&#160;million. During 2023, we invested&#160;&#8364;1,693&#160;million (see&#160;Note&#160;D.3. to&#160;our consolidated financial statements, included at Item&#160;18. of this annual report), mainly in increasing capacity and improving productivity at our various production and R&amp;D&#160;sites.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our principal acquisitions, capital expenditures and divestitures in 2021, 2022 and 2023 are described in Notes&#160;D.1. &amp;&#160;D.2. (&#8220;Changes in the scope of consolidation&#8221;), D.3.&#160;(&#8220;Property, plant and equipment&#8221;) and D.4.&#160;(&#8220;Goodwill and other intangible assets&#8221;) to our consolidated financial statements, included at Item&#160;18. of this annual report. For associated commitments, and in particular future contingent milestone payments, refer to Notes D.18 and D.21. to our consolidated financial statements, which provide disclosures about liabilities related to business combinations and our principal research and development collaboration agreements, respectively.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">51</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, our firm commitments in respect of future capital expenditures amounted to &#8364;638&#160;million. The principal locations involved are: for the Biopharma segment, the industrial facilities at Frankfurt (Germany); Le&#160;Trait, Maisons-Alfort, Compi&#232;gne, and&#160;Ambares (France); Cambridge (United States); Geel (Belgium); Origgio, Anagni, Brindisi, and Scoppito (Italy); and for the Vaccines segment, the facilities at Swiftwater (United States), Toronto (Canada), Marcy-l&#8217;&#201;toile, Neuville-sur-Sa&#244;ne and Val-de-Reuil (France), and Singapore.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the medium term and assuming no changes in the scope of consolidation, we expect to invest on average approximately &#8364;1.5&#160;billion a year in property, plant and equipment. We believe that our own cash resources and the undrawn portion of our existing credit facilities will be sufficient to fund these expenditures.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our principal ongoing capital expenditures are described below.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Care</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Specialty Care industrial operations are organized around two end-to-end clusters. We have four dedicated biotechnology hubs: Paris/Lyon (France), Frankfurt (Germany), Geel (Belgium) and Boston Area (United States). Exploiting the innovative techniques on which biotech relies, including cell and microbiological culture and the development of viral vectors, our Specialty Care operations call for highly specific knowledge and expertise backed by dedicated production platforms to support global product launches.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Waterford and Le Trait sites manufacture pre-filled DUPIXENT syringes.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Medicines</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our General Medicines industrial operations are organized through end-to-end clusters, with chemistry, pharmaceutical and injectable sites organized through a network of 22&#160;regional and local industrial sites in 14&#160;countries, supporting growth in those markets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This new organization encompasses a dedicated Launch Sites cluster from API manufacturing to finished goods packaging (Sisteron, Aramon, Ambar&#232;s, Scoppito).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Frankfurt facility is our principal site for the manufacture of diabetes treatments.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vaccines</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The industrial operations of our Vaccines business are in a major investment phase, preparing for the upcoming growth of our influenza and Polio/Pertussis/Hib franchises, plus the mid-term growth linked to our mRNA roadmap and New Vaccines pipeline. </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Major investments were announced in 2020 and&#160;2021 with a new Evolutive Facility in France (Neuville-Sur-Saone) and a new facility in Singapore for our New Vaccines pipeline</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Other major investments are under way in France (including construction of a new influenza vaccine building at Val-de-Reuil), Canada (a new pertussis vaccine building), the US and Mexico.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Healthcare</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The pharmaceutical industrial operations of our Consumer Healthcare (CHC) business are spread across a dedicated network. Global markets are supplied from our facilities at Compi&#232;gne (France), Cologne (Germany) and Origgio (Italy). We have recently invested in new production capacities in Narita (Japan), Origgio (Italy) and Lisieux (France).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovation and culture of industrial excellence</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The ambition of our Manufacturing &amp; Supply department is to continue to raise safety, quality and operating standards in Sanofi&#8217;s production activities, and to remain a world leader and a benchmark in the global pharmaceutical industry. To achieve this goal, all our activities share a common culture of industrial excellence, enshrined in the Sanofi Manufacturing System. This sets out a series of priorities (such as customer service, constant improvement, site network optimization and transverse optimization) that constitute our industrial vision and will be crucial to our mutual success.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In terms of operational excellence, we continue to build on our Top Decile performance program, focused on core sites and fully leveraging digital opportunities and technology innovations. We are also reinforcing the Sanofi Manufacturing System to drive more improvement directly from the sites and reach our performance goals, while creating a culture of best practices shared across the industrial network.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_145"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.4. Office space</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We continue to evolve our roadmap to ensure our sites reflect the best-in-class experience and reinforce connections between people, no matter where they are based.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, we have enhanced our services to provide even more productivity, wellbeing, collaboration, innovation and ultimately foster greater employee engagement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A number of projects are currently under way to deliver the next generation of work experience and hybrid work.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We continue to actively revisit our real estate footprint to ensure we are taking the right steps in the carbon neutrality race.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">52</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_6815"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4. Information on the company</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E. R&amp;D Appendix</span></div><div style="margin-bottom:2pt;text-align:justify"><img src="sny-20231231_g2.jpg" alt="R&amp;D Pipeline Q4 2023_EN_FINAL_phase 3.jpg" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:623px"/></div><div style="text-align:justify"><img src="sny-20231231_g3.jpg" alt="R&amp;D Pipeline Q4 2023_EN_FINAL_Phase2.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:623px"/></div><div style="margin-bottom:5pt;text-align:justify"><img src="sny-20231231_g4.jpg" alt="R&amp;D Pipeline Q4 2023_EN_FINAL_Phase1.jpg" style="height:265px;margin-bottom:5pt;vertical-align:text-bottom;width:623px"/></div><div style="height:39.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">53</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_148"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 4A. Unresolved Staff Comments</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;4A. Unresolved Staff Comments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_151"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;5. Operating and Financial Review and Prospects</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">You should read the following discussion in conjunction with our consolidated financial statements and the notes thereto included in this annual report at Item&#160;18.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS)&#160;as issued by the International Accounting Standards Board (IASB) and with IFRS endorsed by the European Union as of&#160;December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements that involve inherent risks and uncertainties. Actual results may differ materially from those contained in such forward-looking statements. See &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; at the beginning of this document.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Unless otherwise stated, all financial variations in this item are given on a reported basis.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The discussion of our operating and financial review and prospects for the years ended December&#160;31, 2022 and December&#160;31, 2021, including a presentation of our consolidated income statements for the years ended December&#160;31, 2022 and December&#160;31, 2021, can be found in &#8220;Item&#160;5. Operating and Financial Review and Prospects &#8212;&#160;A. Operating results &#8212;&#160;A.2.&#160;Results of operations &#8212;&#160;Year ended December&#160;31, 2022 compared with year ended December&#160;31, 2021&#8221; of our annual report filed on&#160;February&#160;24,&#160;2023.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_154"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A. Operating results</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_157"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.1. Significant operating information</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_160"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.1.1. 2023 Overview</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During 2023, Sanofi continued to implement its &#8220;Play to Win&#8221; strategy, initiating the second phase which aims to launch major innovations, redeploy resources and develop leading innovative R&amp;D. For further information about our strategy, refer to &#8220;Item&#160;4. Information on the Company &#8212;&#160;B. Business Overview &#8212;&#160;B.1.&#160;Strategy.&#8221; Other significant events of the year are described below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January&#160;11, 2023, Sanofi Ventures announced an additional multi-year commitment from Sanofi, which will increase the capital of the </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">evergreen</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> venture fund to more than $750&#160;million. In addition to serving as a financial partner to top-tier early-to-mid-stage portfolio companies, the fund supports future efforts for business development and M&amp;A opportunities within Sanofi. The additional capital, confirmed by our Executive Committee, will also be allocated to advance the expansion and investment capacity of the Sanofi Ventures investment team on a global scale.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March&#160;13, 2023, Sanofi and </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Provention Bio, Inc.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (Provention), a US-based publicly-traded biopharmaceutical company developing therapies to prevent and intercept immune-mediated diseases including type&#160;1 diabetes, entered into an agreement under which Sanofi acquired the outstanding shares of Provention common stock for $25.00 per share in an all-cash transaction valued at approximately $2.8&#160;billion. On April&#160;27, 2023, Sanofi announced the completion of its acquisition of Provention. The acquisition added </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TZIELD</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (teplizumab-mzwv), a therapy for type&#160;1 diabetes, to Sanofi&#8217;s core General Medicines asset portfolio, and further drives our strategic shift toward products with a differentiated profile. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April&#160;9, 2023, Sanofi and AstraZeneca simplified their contractual agreements for the development and commercialization of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">BEYFORTUS</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (nirsevimab) in the US. Sanofi thereby obtained control of all commercial rights to BEYFORTUS (nirsevimab) in the US, and ended the sharing of commercial profits between the two partners in that territory. In line with the terms of the revised agreements and in accordance with IAS&#160;38, Sanofi recognized an intangible asset of &#8364;1.6&#160;billion for the fair value of the additional US rights. On the same date, AstraZeneca and Sobi ended their participation agreement, signed in 2018, which transferred the economic rights for the US territory to Sobi. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi simultaneously entered into an agreement with Sobi relating to direct royalties on US net sales of BEYFORTUS (nirsevimab). In line with the terms of that agreement, on April&#160;9, 2023 Sanofi recognized a financial liability of &#8364;1.6&#160;billion. That liability is classified as a financial liability at amortized cost under IFRS&#160;9. Other than royalty payments, subsequent movements in the liability comprise (i)&#160;the effects of the unwinding of discount and (ii)&#160;changes in estimates of future cash outflows for royalty payments. Those movements are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net financial income/(expenses)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with paragraph&#160;B5.4.6 of IFRS 9. As of December&#160;31, 2023 the liability was remeasured by an amount of &#8364;541&#160;million, reflecting the strong success of the US launch of BEYFORTUS (nirsevimab), which led to sales forecasts being revised upward from the initial estimate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For territories other than the US (except for China, which is now considered a &#8220;major market,&#8221; with profits/losses shared 50/50 with AstraZeneca), the existing agreement between AstraZeneca and Sanofi continues to govern the principal terms of the collaboration: Sanofi recognizes the sales and cost of sales, and shares the Alliance&#8217;s commercial profits with AstraZeneca.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">54</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On June&#160;20, 2023, Sanofi announced that in a dispute referred to the International Chamber of Commerce arbitration panel, the panel had dismissed an indemnification claim against Sanofi from Boehringer Ingelheim and confirmed that Sanofi will not be liable for any potential losses in relation to the ongoing </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ZANTAC</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> litigation in the US. This decision is final and non-appealable.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;28, 2023, Sanofi announced that it had entered into an agreement to acquire QRIB Intermediate Holdings, LLC (QRIB), the owner of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">QUNOL</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a market-leading US-based health &amp; wellness brand. The deal reflects Sanofi&#8217;s ongoing drive to pursue growth opportunities and value creation for its CHC business. Sanofi&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">acquisition of QRIB was completed on September&#160;29, 2023, at a purchase price of $1,419&#160;million</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On October&#160;3, 2023, Sanofi announced that it had entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson &amp; Johnson company, to develop and commercialize the vaccine candidate for extra-intestinal pathogenic </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">E.&#160;coli </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(9-valent) developed by Janssen, currently in Phase&#160;3. The deal was closed on November&#160;9, 2023. Under the terms of the agreement, both parties will co-fund current and future research and development costs. Sanofi paid $175&#160;million upfront to Janssen, and may pay to Janssen milestone payments contingent on the attainment of certain development and commercial objectives.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On October&#160;4, 2023, Sanofi entered into a collaboration with Teva Pharmaceuticals to co-develop and co-commercialize asset </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TEV&#8217;574</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, currently in Phase&#160;2b clinical trials for the treatment of Ulcerative Colitis and Crohn&#8217;s Disease, two types of inflammatory bowel disease. Under the terms of the new collaboration agreement, Teva received an upfront payment of &#8364;469&#160;million ($500&#160;million) and may receive up to &#8364;940&#160;million ($1&#160;billion) in milestone payments, depending on the achievement of development and commercialization goals.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On October&#160;23, 2023 Sanofi, along with WhiteLab Genomics (a specialist in applying AI to genomic medicine), the TaRGeT lab at the University of Nantes (INSERM UMR&#160;1089, one of France&#8217;s leading gene therapy labs) and Imagine Institute (AP-HP, INSERM, Paris Cit&#233; University, Europe&#8217;s leading center for research, education and care in the field of genetic diseases), collectively launched the </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">WIDGeT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (Viral Vector Intelligent Design for Gene Therapy) consortium to accelerate the development of adeno-associated virus (AAV) based gene therapies for the treatment of rare-to-frequent diseases (especially kidney and eye diseases) by using AI to develop next-generation AAVs. The consortium receives financial support from the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Sant&#233; de France</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (Healthy France) 2030 tranche of the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Innovation Sant&#233;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (Health Innovation) Plan, overseen by the French Healthcare Innovation Agency and operated by Bpifrance, the French public investment bank.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On October&#160;27, 2023, Sanofi provided a comprehensive </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">update regarding its Play to Win strategy</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. This strategy continues to focus on the critical goals of executing transformative medicine and vaccine launches, driving agile and efficient resource deployment and enhancing R&amp;D productivity. To that end, Sanofi announced plans to increase its R&amp;D investments in an effort to fully realize its pipeline potential, drive long-term growth and enhance shareholder value. Sanofi also announced its intention to separate its Consumer Healthcare (CHC) business, to enable greater management focus and resource allocation to the needs of the Biopharma business, where value-creating opportunities and longer-term operational levers have been identified to support the accelerated R&amp;D investments. The intended separation would be completed at the earliest in the fourth quarter of 2024, most likely through a capital markets transaction, via the creation of a listed entity headquartered in France.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;5, 2023, Sanofi announced the signature of a major research collaboration agreement with </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Aqemia</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to use artificial intelligence to accelerate the discovery of future medicines. This new collaboration dovetails with the discovery process, from identifying initial active ingredients through to selection of preclinical candidates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, various health authorities granted marketing approvals to several Sanofi products, paving the way for innovative new treatments. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Europe and China, </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">DUPIXENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (dupilumab) was approved for the treatment of severe atopic dermatitis in children aged six months to five years who are candidates for systemic therapy. DUPIXENT was also approved in the European Union for the treatment of eosinophilic esophagitis in adults and adolescents aged 12 and over.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the US and Taiwan, the FDA and the Taiwan Food and Drug Administration approved </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ALTUVIIIO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (efanesoctocog alfa), the first sustained-acting replacement factor&#160;VIII in its pharmacotherapeutic class, indicated for routine prophylaxis and on-demand treatment and control of bleeding episodes, as well as for perioperative management, in adults and children with hemophilia&#160;A.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Nirsevimab (marketed as </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">BEYFORTUS</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) was approved in Canada and the United States during 2023. It has also been accepted for priority review in China, and submitted in Japan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Europe, the EMA issued a positive opinion on </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Fexinidazole</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Winthrop as the first oral treatment of the acute form of sleeping sickness (rhodesiense) found in East and Southern Africa.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December 21, 2023, Sanofi announced that the program evaluating</span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> tusamitamab ravtansine</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> had ended after a Phase&#160;3 trial as a second-line treatment in non-small cell lung cancer (NSCLC) failed to meet a primary endpoint.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For further information about the biopharma products we sell, and about our research and development portfolio, refer to&#160;&#8220;Item&#160;4. Information on the Company &#8212;&#160;B.&#160;Business Overview.&#8221;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our net sales for 2023 amounted to &#8364;43,070&#160;million, an increase of 0.2% from 2022. At constant exchange rates (CER)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net sales rose by&#160;5.3%, mainly reflecting strong growth for DUPIXENT and increased sales for our Vaccines business, more than offsetting lower sales for our Non Core Assets franchise.</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure: see definition in &#8220;&#8212; Presentation of Net Sales&#8221; below.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">55</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;5,400&#160;million for 2023, compared with &#8364;8,371&#160;million in 2022, a&#160;&#8364;2,971&#160;million decrease. Earnings per share was &#8364;4.31 in 2023, compared with &#8364;6.69 in 2022. Business net income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was&#160;&#8364;10,155&#160;million, down 1.8% on 2022, while business earnings per share (business EPS</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) was 1.8% lower than in 2022 at &#8364;8.11.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the Annual General Meeting on April&#160;30, 2024, we will ask our shareholders to approve a dividend of &#8364;3.76 per share for the 2023 financial year, representing a payout of 46.3% of our Business net income (see &#8220;&#8212; Consolidated balance sheet and debt.&#8221;).</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_163"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.1.2. Impacts of competition from generics and biosimilars</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some of our flagship products continued to suffer sales erosion in 2023 under the impact of competition from generics and biosimilars. We do not believe it is possible to state with certainty what level of net sales would have been achieved in the absence of generic competition. A comparison of our consolidated net sales for the years ended&#160;December 31, 2023 and 2022 (see&#160;&#8220;&#8212;&#160;Results of Operations &#8212;&#160;Year Ended December 31, 2023 Compared with Year Ended December 31, 2022&#8221; below) for the main products affected by generic and biosimilar competition shows a loss of &#8364;651&#160;million of net sales on a reported basis. However, other parameters can also contribute to the loss of sales, such as a fall in the average selling price of certain products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the change by&#160;product.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:41.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change&#160;on&#160;a<br/>reported&#160;basis</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change&#160;on&#160;a<br/>reported&#160;basis&#160;(%)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">APROVEL Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.9&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LANTUS Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-16.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LOVENOX Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PLAVIX Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">JEVTANA Europe</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-63.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LANTUS United States</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(476)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-62.9&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LOVENOX United States</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-58.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">APROVEL Japan</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-27.3&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LANTUS Japan</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-30.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PLAVIX</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-37.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,511</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,162</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(651)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-30.1</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We expect the erosion caused by generic competition to continue in 2024, with a negative impact on our net income. The products likely to be impacted in 2024 include those that already faced generic competition in 2023, but whose sales can reasonably be expected to be subject to further sales erosion in 2024 (see products listed in the table above). In addition, we have experienced generic competition in the United States for AUBAGIO since March&#160;2023 and for MOZOBIL since July&#160;2023, following expiry of exclusivity in that country. In Europe, AUBAGIO generic competition began in in the fourth quarter of 2023 and will intensify in 2024, while generic competition for MOZOBIL is expected to begin between February and August&#160;2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, aggregate consolidated net sales of those products in Europe, the United States and Japan amounted to &#8364;1,511&#160;million; this comprised &#8364;288&#160;million in the United States (including &#8364;281&#160;million in net sales of LANTUS); &#8364;1,165&#160;million in Europe; and &#8364;58&#160;million in Japan. The negative impact on our 2024 net sales is likely to represent a substantial portion of those sales, but the actual impact will depend on a number of factors, such as the impact of generics and biosimilars on our molecules, but also the market entry of generics of molecules that are in competition with our products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In China, the authorities have implemented a range of healthcare cost containment measures, including the Volume Based Procurement&#160;(VBP) reverse auction that particularly impacts our insulin-based products, PLAVIX, APROVEL, and LOVENOX (see also &#8220;Item&#160;4. Information on the Company &#8212;&#160;B. Business Overview &#8212; B.5.4.&#160;Pricing &amp; Reimbursement&#8221;). A large number of molecules were selected to submit tenders under successive waves of the VBP program, with the successful bidders being awarded a high level of market share in return for offering lower prices. We participated in a number of VBP bids and were selected for only part of the volumes awarded for 2022, 2023 and 2024 in respect of insulins (TOUJEO and LANTUS), PLAVIX and APROVEL, in return for a considerable reduction in unit prices. Sanofi was not among the nine companies selected to supply enoxaparin sodium based products in the latest VBP allocation, which covers 50% of volumes for the 2024-25 period.</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure: see definition in &#8220;&#8212;&#160;Segment Information &#8212;&#160;Business Net Income&#8221; below.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">56</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_166"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.1.3. Purchase accounting effects</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our results of operations and financial condition for the years ended December&#160;31, 2023, and 2022 have been significantly affected by our past acquisitions (acquisition of Aventis in August&#160;2004, acquisition of Genzyme in April&#160;2011, exchange of our Animal Health business (Merial) for Boehringer Ingelheim&#8217;s CHC business in January&#160;2017, acquisition of Bioverativ in&#160;2018, and certain other transactions). See &#8220;&#8212;&#160;Critical accounting and reporting policies &#8212;&#160;Business combinations&#8221; below for an explanation of the impact of business combinations on our results of operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Genzyme business combination has generated significant amortization of intangible assets (&#8364;405&#160;million in 2023, and&#160;&#8364;513&#160;million in 2022). The exchange of Merial for Boehringer Ingelheim&#8217;s CHC business has generated amortization of intangible assets (&#8364;184&#160;million in 2023, and &#8364;188&#160;million in 2022). The Bioverativ business combination has generated significant amortization of intangible assets (&#8364;633&#160;million in 2023, and &#8364;375&#160;million in&#160;2022). The Kadmon acquisition has generated amortization of intangible assets (&#8364;156&#160;million in 2023, and &#8364;160&#160;million in 2022). The Provention acquisition has generated amortization of intangible assets (&#8364;144&#160;million in 2023).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to isolate the purchase accounting effects of all acquisitions and certain other items, we use a non-IFRS financial measure that we refer to as &#8220;business net income&#8221; (see definition and discussion of reconciliation to the IFRS financial measure </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in &#8220;&#8212;&#160;Segment Information and Business Net Income &#8212;Business Net Income&#8221; below).</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_169"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.1.4. Sources of revenues and expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Revenues. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenue arising from the sale of goods is presented in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Net sales comprise revenue from sales of biopharma products, consumer healthcare products, and active ingredients, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. Returns, discounts, incentives and rebates are recognized in the period in which the underlying sales are recognized, as a reduction of sales revenue. See&#160;Note&#160;B.13.1. to our consolidated financial statements included at Item&#160;18. of this annual report. We sell biopharma products directly, through alliances, and by licensing arrangements throughout the world. When we sell products directly, we record sales revenues as part of our consolidated net sales. When we sell products through alliances, the revenues reflected in our consolidated financial statements are based on the contractual arrangements governing those alliances. For more information about our alliances, see&#160;&#8220;&#8212;&#160;Financial Presentation of Alliances&#8221; below. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is used to recognize all revenue that falls within the scope of IFRS&#160;15 but does not relate to sales of Sanofi products. It mainly comprises (i)&#160;royalties received from licensing intellectual property rights to third parties; (ii)&#160;VaxServe sales of products sourced from third-party manufacturers; and (iii)&#160;revenue received under agreements for Sanofi to provide manufacturing services to third parties. Royalties received under licensing arrangements are recognized over the period during which the underlying sales are recognized. VaxServe is a Biopharma segment entity whose operations include the distribution within the United States of vaccines and other products manufactured by third parties.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Our cost of sales consists primarily of the cost of purchasing raw materials and active ingredients, labor and other costs relating to our manufacturing activities, packaging materials, payments made under licensing agreements and distribution costs. We have license agreements under which we manufacture, sell and distribute products that are patented by other companies. When we pay royalties, we record them in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Our operating income reflects our revenues, our cost of sales and the remainder of our operating expenses, the most significant of which are research and development expenses and selling and general expenses. For our operating segments, we also measure our results of operations through an indicator referred to as &#8220;Business Operating Income,&#8221; which we describe below under&#160;&#8220;&#8212;&#160;Segment Information and Business Net Income &#8212;&#160;Business Operating Income.&#8221;</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_172"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.1.5. Segment information and Business net income</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">1/ Operating segments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators. The operating segment disclosures required under IFRS&#160;8 are provided in Note&#160;D.35. to the consolidated financial statements included at Item&#160;18. of this annual report. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and CHC). The costs of the global support functions (Corporate Affairs, Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Sanofi Business Services, etc.), which are mainly managed centrally at group-wide level, were presented within the &#8220;Other&#8221; category. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in order to reflect (i)&#160;progress on the &#8220;Play to Win&#8221; strategy leading to the creation of the standalone CHC Global Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its own dedicated global support functions (including Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Global Business Services,&#160;etc.); and (ii)&#160;organizational changes to Sanofi&#8217;s Manufacturing &amp; Supply global function (previously known as Industrial Affairs).</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">57</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, with effect from January&#160;1, 2023, Sanofi reports two operating segments: Biopharma and CHC </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#8217;s results include the costs of global support functions that are not within the managerial responsibility of the CHC GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The CHC operating segment comprises commercial operations relating to CHC products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The CHC GBU segment&#8217;s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">2/ Business operating income (non-IFRS financial measure)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We report segment results on the basis of &#8220;Business operating income.&#8221; This non-IFRS indicator is used internally by Sanofi&#8217;s chief operating decision maker to measure the performance of each operating segment and to allocate resources. For a definition of &#8220;Business operating income,&#8221; and a reconciliation between that indicator and IFRS </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, refer to Note&#160;D.35. to our consolidated financial statements included at Item&#160;18. of this annual report.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At Group level, &#8220;Business operating income&#8221; is a non-IFRS financial measure which is reconciled with IFRS </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. IFRS </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for 2023 amounted to &#8364;7,875&#160;million versus &#8364;10,656&#160;million for 2022; refer to Note&#160;D.35. to our consolidated financial statements included at Item&#160;18. of this annual report. Our ratio of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net Sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was 18.3% in 2023 versus 24.8% in 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our &#8220;Business operating income&#8221; for 2023 amounted to &#8364;12,670&#160;million, versus &#8364;13,040&#160;million for 2022, while our &#8220;Business operating income margin&#8221; was 29.4%, versus 30.3% for 2022. &#8220;Business operating income margin&#8221; is a non-IFRS financial measure, which we define as the ratio of our &#8220;Business operating income&#8221; to IFRS </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our &#8220;Business operating income&#8221; and &#8220;Business operating income margin&#8221; are not standardized measures, they may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures. Although management uses those non-IFRS measures to set goals and measure performance, they have no standardized meaning prescribed by IFRS. These non-IFRS measures are presented solely to permit investors to more fully understand how Sanofi&#8217;s management assesses underlying performance. These non-IFRS measures are not, and should not be viewed as, a substitute for IFRS measures, and should be viewed in conjunction with our IFRS financials and performance measures. As a result, such measures have limits in their usefulness to investors.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">3/ Business net income (non-IFRS financial measure)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We believe that the understanding of our operational performance by our management and our investors is enhanced by reporting &#8220;Business net income.&#8221; This non-IFRS financial measure represents &#8220;Business operating income,&#8221; less (i)&#160;net financial expenses (except those related to financial liabilities accounted for at amortized cost and subject to periodic remeasurement in accordance with paragraph&#160;B5.4.6 of IFRS&#160;9) and (ii)&#160;income tax expense related to &#8220;Business operating income&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Business net income&#8221; is a non-IFRS financial measure; it is reconciled with IFRS </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which amounted to &#8364;5,400&#160;million for 2023 versus &#8364;8,371&#160;million for 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our &#8220;Business net income&#8221; for 2023 was &#8364;10,155&#160;million, 1.8% lower than in 2022 (&#8364;10,341&#160;million). </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">That represents 23.6% of our net sales, compared with </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">24.1 % in 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also report &#8220;Business earnings per share&#8221; (&#8220;Business EPS&#8221;), a non-IFRS financial measure we define as &#8220;Business net income&#8221; divided by the weighted average number of shares outstanding. &#8220;Business EPS&#8221; was &#8364;8.11&#160;for 2023, 1.8% lower than the 2022 figure of&#160;&#8364;8.26, based on an average number of shares outstanding of 1,251.7&#160;million for 2023 and 1,251.9&#160;million for&#160;2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below reconciles our &#8220;Business operating income&#8221; to our &#8220;Business net income&#8221;:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:68.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,670</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,040</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income and expenses (except those related to financial liabilities accounted for at amortized cost and subject to periodic remeasurement in accordance with paragraph&#160;B5.4.6 of IFRS&#160;9)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(234)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense on business operating income</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,334)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,465)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business net income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,155</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,341</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We define &#8220;Business net income&#8221; as </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> determined under IFRS, excluding the following items:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3), or to business divestments;</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure. </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">58</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">restructuring costs and similar items (presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">other gains and losses (including gains and losses on major divestments, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">other costs and provisions related to litigation (presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">upfront payments and regulatory milestone payments received and recognized with the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and arising from transactions outside the scope of Sanofi&#8217;s ordinary activities;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">(income)/expenses related to financial liabilities accounted for at amortized cost and subject to periodic remeasurement in accordance with paragraph&#160;B5.4.6 of IFRS&#160;9 (Financial Instruments);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the tax effects of the items listed above, the effects of major tax disputes, and the effects of the deferred tax liability arising on investments in consolidated entities following the announcement on October&#160;27, 2023 of Sanofi&#8217;s intention to proceed with the separation of its Consumer Health Care business;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the share of profits/losses from investments accounted for using the equity method, except for joint ventures and associates with which Sanofi has a strategic alliance; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the portion attributable to non-controlling interests of the items listed above.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below reconciles our &#8220;Business net income&#8221; to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:74.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi (IFRS)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,400</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,371</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,172&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,053&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(454)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income from out-licensing&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(952)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,490&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial (income)/expenses relating to financial liabilities accounted for at amortized cost and subject to periodic remeasurement&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax effects of the items listed above:</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,097)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(459)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">amortization and impairment of intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(267)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">fair value remeasurement of contingent consideration</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">expenses arising from the impact of acquisitions on inventories</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">restructuring costs and similar items</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(397)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(231)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;padding-left:8.95pt">other items</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other tax effects&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Business net income (non-IFRS)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,155</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,341</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.7&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.9&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Basic earnings per share (&#8364;)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reconciling items per share (&#8364;)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business earnings per share (&#8364;)</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.26&#160;</span></td><td style="border-bottom:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;For 2023, this amount mainly comprises an impairment loss of &#8364;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For 2022, this line includes a reversal of &#8364;2,154 million on ELOCTATE franchise products following FDA approval of ALTUVIIIO dated February&#160;22, 2023, partly offset by an impairment loss of &#8364;1,586&#160;million on intangible assets relating to SAR444245 (non-alpha interleukin-2) based on revised cash flow projections reflecting unfavorable developments in the launch schedule in key indications.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;For 2022, this line includes an upfront payment of $900&#160;million and a regulatory milestone payment of $100&#160;million in connection with the out-licensing of LIBTAYO following the restructuring of the Immuno-Oncology collaboration agreement with Regeneron (see Note&#160;C.1. to our consolidated financial statements, included at Item&#160;18. of this annual report).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;For 2023, this amount corresponds to the financial expense related to the financial liability recognized in the balance sheet to reflect estimated future royalties on sales of BEYFORTUS in the United States, which has been remeasured to reflect the strong success of the product launch.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;For 2023, this amount corresponds to the deferred tax liability recognized in respect of investments in consolidated entities in light of the proposed separation of the Consumer Healthcare business in the fourth quarter of 2024 at the earliest.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e) &#160;&#160;&#160;&#160;In 2023, an impairment loss of &#8364;231&#160;million was recognized on the equity-accounted investment in EUROAPI in view of the fall in the share price since March&#160;2023. The amount of the loss recognized was based on the share price as of December&#160;31, 2023 (&#8364;5.73), as used in determining the recoverable amount of the equity interest as of that date.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">59</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The most significant reconciling items between &#8220;Business net income&#8221; and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders of Sanofi </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">relate to&#160;(i)&#160;the purchase accounting effects of our acquisitions of groups of assets and business combinations, particularly the amortization and impairment of intangible assets (other than software and other rights of an industrial or operational nature); (ii)&#160;the impacts of restructurings or transactions regarded as non-recurring, where the amounts involved are particularly significant; and (iii)&#160;remeasurements recognized through profit or loss in respect of (a)&#160;amounts receivable in respect of business divestments and accounted for at fair value, (b)&#160;liabilities arising from business combinations (IFRS&#160;3) and accounted for at fair value, and (c)&#160;liabilities accounted for at amortized cost and subject to periodic remeasurement under IFRS&#160;9. We believe that excluding those impacts enhances an investor&#8217;s understanding of our underlying economic performance, because it gives a better representation of our recurring operating performance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We believe that eliminating charges related to the purchase accounting effects of our acquisitions and business combinations (particularly amortization and impairment of some intangible assets) enhances comparability of our ongoing operating performance relative to our peers. Those intangible assets (principally rights relating to research and development, technology platforms and commercialization of products) are accounted for in accordance with IAS&#160;38 (Intangible Assets) and IFRS&#160;3 (Business Combinations).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also believe that eliminating the other effects of business combinations (such as the incremental cost of sales arising from the workdown of acquired inventories remeasured at fair value in business combinations) gives a better understanding of our recurring operating performance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Eliminating restructuring costs and similar items enhances comparability with our peers because those costs are incurred in connection with reorganization and transformation processes intended to optimize our operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We believe that eliminating the effects of transactions that we regard as non-recurring and that involve particularly significant amounts (such as major gains and losses on disposals, and costs and provisions associated with major litigation and other major non-recurring items) improves comparability from one period to the next.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, remeasurements recognized in profit or loss during the period in respect of (i)&#160;assets or liabilities accounted for at fair value and recognized in the balance sheet in connection with business acquisitions or divestments or (ii)&#160;liabilities accounted for at amortized cost and subject to periodic remeasurement, generally determined on the basis of revised sales forecasts, are not reflective of our operating performance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We remind investors, however, that &#8220;Business net income&#8221; should not be considered in isolation from, or as a substitute for, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to equity holders</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reported in accordance with IFRS. In addition, we strongly encourage investors and potential investors not to rely on any single financial measure but to review our financial statements, including the notes thereto, carefully and in their entirety.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We compensate for the material limitations described above by using &#8220;Business net income&#8221; only to supplement our IFRS financial reporting and by ensuring that our disclosures provide sufficient information for a full understanding of all adjustments included in&#160;&#8220;Business net income.&#8221;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our &#8220;Business net income&#8221; and &#8220;Business EPS&#8221; are not standardized measures, they may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_175"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.1.6. Presentation of net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the discussion below, we present our consolidated net sales for 2023 and 2022. We analyze our net sales by various categories including segment, franchise, product, and geographical region. In addition to reported net sales, we analyze non-IFRS financial measures designed to isolate the impact on our net sales of currency exchange rates and changes in the structure of our&#160;group.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When we refer to changes in our net sales at constant exchange rates (CER), that means that we have excluded the effect of exchange rates by recalculating net sales for the relevant period using the exchange rates that were used for the previous period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A presentation of consolidated net sales for 2022 compared with 2021 is available in our annual report filed on February&#160;24, 2023, in &#8220;Item&#160;5. Operating and Financial Review and Prospects &#8212;&#160;A. Operating Results &#8212;&#160;A.2.1.&#160;Net Sales.&#8221;</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_178"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.1.7. Financial presentation of alliances</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have entered into a number of alliances for the development, co-promotion and/or co-marketing of our products. We believe that a presentation of our two principal alliances is useful to an understanding of our financial statements.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">1/ Alliance arrangements with Regeneron Pharmaceuticals Inc. (Regeneron)</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration agreements on human therapeutic antibodies</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In November&#160;2007, Sanofi and Regeneron signed two agreements (amended in November&#160;2009) relating to human therapeutic antibodies: (i)&#160;the Discovery and Preclinical Development Agreement, and (ii)&#160;the License and Collaboration Agreement, relating to clinical development and commercialization. Under the License and Collaboration Agreement, Sanofi had an option to develop and commercialize antibodies discovered by Regeneron under the Discovery and Preclinical Development Agreement.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">60</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discovery and development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because Sanofi decided not to exercise its option to extend the Discovery and Preclinical Development Agreement, that agreement expired on December&#160;31, 2017.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a result of Sanofi&#8217;s exercise of an option with respect to an antibody under the Discovery and Preclinical Development Agreement, such antibody became a &#8220;Licensed Product&#8221; under the License and Collaboration Agreement, pursuant to which Sanofi and Regeneron co-develop the antibody with Sanofi initially being wholly responsible for funding the development program. On receipt of the first positive Phase 3 trial results for any antibody being developed under the License and Collaboration Agreement, the subsequent development costs for that antibody are split 80% Sanofi, 20% Regeneron. Amounts received from Regeneron under the License and Collaboration Agreement are recognized by Sanofi as a reduction in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Co-development with Regeneron of the antibodies DUPIXENT, KEVZARA and REGN3500 (SAR440340 - itepekimab) is ongoing under the License and Collaboration Agreement as of December&#160;31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Once a product begins to be commercialized, and provided that the share of quarterly results under the agreement represents a profit, Sanofi is entitled to an additional portion of Regeneron&#8217;s profit-share (capped at 20% of Regeneron&#8217;s share of quarterly profits since April&#160;1, 2022, and at 10% until March&#160;31, 2022) until Regeneron has paid 50% of the cumulative development costs incurred by the parties in the collaboration (see Note&#160;D.21.1.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On the later of (i)&#160;24 months before the scheduled launch date or (ii)&#160;the first positive Phase&#160;3 trial results, Sanofi and Regeneron share the commercial expenses of the antibodies co-developed under the License and Collaboration Agreement.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is the lead party with respect to the commercialization of all co-developed antibodies, and Regeneron has certain option rights to co-promote the antibodies. Regeneron has exercised its co-promotion rights in the United States and in certain other countries. Sanofi recognizes all sales of the antibodies. Profits and losses arising from commercial operations in the United States are split 50/50. Outside the United States, Sanofi is entitled to between 55% and 65% of profits depending on sales of the antibodies, and bears 55% of any losses. The share of profits and losses due to or from Regeneron under the agreement is recognized within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which are components of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, Regeneron is entitled to receive payments contingent on the attainment of specified levels of aggregate sales on all antibodies outside the United States, on a rolling twelve-month basis. A liability for those payments is recognized on the balance sheet when it is probable that the specified level of aggregate sales will be met. The opposite entry for that liability is capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> on the balance sheet. Two payments of $50&#160;million each were made in 2022, following attainment first of $2.0&#160;billion and then of $2.5&#160;billion in sales of all antibodies outside the United States on a rolling twelve-month basis. The final milestone payment of $50&#160;million, payable to Regeneron in the event that $3.0&#160;billion in sales on a rolling twelve-month basis is attained, was made in 2023.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendments to the collaboration agreements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January&#160;2018, Sanofi and Regeneron signed a set of amendments to their collaboration agreements, including an amendment that allowed for the funding of additional programs on DUPIXENT and REGN3500 (SAR440340 &#8211; itepekimab) with an intended focus on extending the current range of indications, finding new indications, and improving co-morbidity between multiple pathologies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective April&#160;1, 2020, Sanofi and Regeneron signed a Cross License and Commercialization Agreement for PRALUENT, whereby Sanofi obtained sole ex-US rights to PRALUENT, and Regeneron obtained sole US rights to PRALUENT along with a right to 5% royalties on Sanofi&#8217;s sales of PRALUENT outside the United States. Each party is solely responsible for funding the development, manufacturing and commercialization of PRALUENT in their respective territories. Although each party has sole responsibility for supplying PRALUENT in its respective territory, Sanofi and Regeneron entered into agreements to support manufacturing needs for each other.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective September&#160;30, 2021, Sanofi and Regeneron signed an amendment to their collaboration agreement in order to specify allocations of responsibilities and associated resources between the two parties in connection with the co-promotion of&#160;DUPIXENT in certain countries. The terms of the collaboration relating to REGN3500 (SAR440340 &#8211; itepekimab) are unchanged.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective July&#160;1, 2022, Sanofi and Regeneron signed an amendment to their collaboration agreement in order to increase the additional portion of Regeneron&#8217;s quarterly profit-share attributable to Sanofi from 10% to 20% with retroactive impact as of April&#160;1, 2022.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-oncology (IO) collaboration agreements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;1, 2015, Sanofi and Regeneron signed two agreements &#8211;&#160;the IO Discovery and Development Agreement and the IO License and Collaboration Agreement (IO LCA)&#160;&#8211; relating to new antibody cancer treatments in the field of immuno-oncology.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Amended IO Discovery Agreement, effective from December&#160;31, 2018, was terminated through a Letter Amendment dated March&#160;16,&#160;2021 in which Sanofi formalized its opt-out from the BCMAxCD3 and MUC16xCD3 programs. </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">61</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">LIBTAYO (cemiplimab)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the 2015 IO LCA as amended in January&#160;2018, Sanofi and Regeneron committed funding of no more than $1,640 million, split on a&#160;50/50 basis ($820 million per company), for the development of REGN2810 (cemiplimab, trademark LIBTAYO), a PD-1 inhibitor antibody. The funding was raised to $1,840&#160;million by way of amendment effective on September&#160;30, 2021. Regeneron was responsible for the commercialization of LIBTAYO in the United States, and Sanofi in all other territories. Sanofi has exercised its option to co-promote LIBTAYO in the United States. In 2021, Regeneron exercised its option to co-promote LIBTAYO in certain other countries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The IO LCA also provided for a one-time milestone payment of $375 million by Sanofi to Regeneron in the event that sales of a PD-1 product were to exceed, in the aggregate, $2 billion in any consecutive 12-month period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the IO LCA Sanofi and Regeneron shared equally in profits and losses generated by the commercialization of collaboration products, except that Sanofi was entitled to an additional portion of Regeneron&#8217;s profit-share (capped at 10% of Regeneron&#8217;s share of quarterly profits) until Regeneron had paid 50% of the cumulative development costs incurred by the parties under the IO Discovery Agreement, as amended.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">LIBTAYO is approved in the United States and Europe for the treatment of two types of locally advanced or metastatic skin cancer (cutaneous squamous cell carcinoma and basal cell carcinoma) and non-small cell lung cancer (NSCLC). It is also approved in Brazil and Canada as a second line treatment for recurring or metastatic cervical cancer. In the fourth quarter of 2022, it was approved in the United States in association with chemotherapy for the treatment of NSCLC, and in Europe and Japan as a second line treatment for recurring or metastatic cervical cancer. LIBTAYO is currently approved in more than 30&#160;countries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2022, Sanofi and Regeneron restructured their IO LCA. Under the terms of the Amended and Restated IO LCA, Regeneron holds exclusive worldwide licensing rights to LIBTAYO with effect from July&#160;1, 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July&#160;2022, Sanofi received as consideration an upfront payment of $900&#160;million (&#8364;856&#160;million), which was recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> on the date of receipt. The same line item also includes a regulatory milestone payment of $100&#160;million (&#8364;96&#160;million) following the US FDA approval in November&#160;2022 of LIBTAYO in combination with chemotherapy as a first line treatment for NSCLC. In addition, Sanofi is entitled to royalties of 11% and to milestone payments (&#8364;116&#160;million in 2023, &#8364;111&#160;million in 2022) linked to global net sales of LIBTAYO; those royalties are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in line with the pattern of sales. All of the cash inflows relating to the above items (&#8364;196&#160;million in 2023, &#8364;952&#160;million in 2022) are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by/(used in) operating activities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amendment to the terms of the IO LCA resulted in Sanofi recognizing an accelerated amortization charge of &#8364;226&#160;million in&#160;2022; this was allocated to the LIBTAYO product rights included within the residual carrying amount of the intangible asset recognized in July&#160;2015 to reflect rights to an antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) under the Sanofi/Regeneron alliance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transaction also includes a time-limited transitional services agreement with Regeneron which includes manufacturing, distribution (for which Sanofi acts as agent), and promotion.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor agreement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2014 and 2020, Sanofi and Regeneron amended the investor agreement entered into by the two companies in 2007. Under the terms of the amendments, Sanofi accepted various restrictions, including &#8220;standstill&#8221; provisions that contractually prohibit Sanofi from seeking to directly or indirectly exert control of Regeneron or acquiring more than 30% of Regeneron&#8217;s capital stock (consisting of the outstanding shares of common stock and the shares of Class A stock). This prohibition remains in place until the earlier of (i)&#160;the later of the fifth anniversaries of the expiration or earlier termination of the ZALTRAP collaboration agreement with Regeneron (related to the development and commercialization of ZALTRAP) or the collaboration agreement with Regeneron on monoclonal antibodies (see &#8220;Collaboration agreements on human therapeutic antibodies&#8221; above), each as amended or (ii)&#160;other specified events.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Starting in 2018 Sanofi began to sell shares of Regeneron stock and announced on May&#160;29,&#160;2020 the closing of its sale of 13&#160;million shares of Regeneron common stock in a registered offering and a private sale to Regeneron (see Note&#160;D.2.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Pursuant to subsequent sales in 2022, Sanofi no longer holds any shares of Regeneron stock, as of December 31, 2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">2/ Agreements on the commercialization of BEYFORTUS (nirsevimab, previously MEDI8897) in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March 1, 2017, Sanofi and AstraZeneca entered into an agreement to develop and commercialize a monoclonal antibody (MEDI8897, nirsevimab) for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the agreement, Sanofi made an upfront payment of &#8364;120&#160;million in March 2017, a development milestone payment of &#8364;30&#160;million in the third quarter of 2019, a regulatory milestone payment of &#8364;25&#160;million associated with the approval of BEYFORTUS (nirsevimab) by the EMA in Europe in November 2022, and a regulatory milestone payment of &#8364;65&#160;million associated with the approval of BEYFORTUS (nirsevimab) by the US FDA in July 2023. In addition, Sanofi could pay up to &#8364;375&#160;million if sales objectives are met. Those amounts are recognized as a component of the value of the intangible asset when payment becomes probable. During 2023, an amount of &#8364;25&#160;million was recognized as an accrued expense further to a contractual threshold being passed.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">62</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The agreement also specifies that AstraZeneca is responsible for development and manufacturing, and Sanofi for commercialization. Sanofi recognizes the sales and cost of sales (purchases of finished products from AstraZeneca) and shares the Alliance&#8217;s commercial profits (i) 50/50 in major territories and (ii) based on 25% of net sales in other territories. The share of commercial profits and losses due to or from AstraZeneca is recognized as a component of operating income, within the line items</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. In addition, Sanofi and AstraZeneca share development costs 50/50, with Sanofi&#8217;s portion recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">s.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2023, Sanofi and AstraZeneca simplified their contractual agreements for the development and commercialization of BEYFORTUS (nirsevimab) in the US. Sanofi thereby obtained control of all commercial rights to BEYFORTUS (nirsevimab) in the US, and ended the sharing of commercial profits between the two partners in that territory. In line with the terms of the revised agreements and in accordance with IAS 38, Sanofi recognized an intangible asset of &#8364;1.6&#160;billion for the fair value of the additional US rights. On the same date, AstraZeneca and Sobi ended their participation agreement, signed in 2018, which transferred the economic rights for the US territory to Sobi. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi simultaneously entered into an agreement with Sobi relating to direct royalties on US net sales of BEYFORTUS (nirsevimab). In line with the terms of that agreement, on April 9, 2023 Sanofi recognized a financial liability amounting to  &#8364;1.6&#160;billion. That liability is classified as a financial liability at amortized cost under IFRS 9. Other than royalty payments, subsequent movements in the liability comprise (i) the unwinding of discount and (ii) changes in estimates of future cash outflows for royalty payments. Those movements will be recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net financial income/(expenses)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with paragraph B.5.4.6 of IFRS 9. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023 the liability was remeasured by an amount of &#8364;541&#160;million, reflecting the strong success of the US launch of BEYFORTUS (nirsevimab), which led to sales forecasts being revised upward from the initial estimate. The resulting adjustment was recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For territories other than the US (except for China, which is now considered a &#8220;major market,&#8221; with profits/losses shared 50/50 with AstraZeneca), the existing agreement between AstraZeneca and Sanofi continues to govern the principal terms of the collaboration: Sanofi recognizes the sales and cost of sales and shares the Alliance&#8217;s commercial profits with AstraZeneca.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May 2023, data from the HARMONIE Phase 3b study confirmed that nirsevimab prevents infant hospitalizations due to RSV with consistent and high efficacy.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">BEYFORTUS (nirsevimab) was approved in Europe in November 2022, and in the United States on July 17, 2023. </span></div><div id="i9fa7f69b4904450e9c43e8444c203165_181"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.1.8. Impact of exchange rates</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We report our consolidated financial statements in euros. Because we earn a significant portion of our revenues in countries where the euro is not the local currency, our results of operations can be significantly affected by exchange rate movements between the euro and other currencies, primarily the US dollar and, to a lesser extent, the Japanese yen, and currencies in emerging countries. We experience these effects even though certain of these countries do not account for a large portion of our net sales. In 2023, we earned 43.0% of our net sales in the United States. An increase in the value of the US dollar against the euro has a positive impact on both our revenues and our operating income. A decrease in the value of the US dollar against the euro has a negative impact on our revenues, which is not offset by an equal reduction in our costs and therefore negatively affects our operating income. A variation in the value of the US dollar has a particularly significant impact on our operating income, which is higher in the United States than elsewhere.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of arrangements entered into to manage operating foreign exchange risks as well as our hedging policy, see&#160;&#8220;Item&#160;11.&#160;Quantitative and Qualitative Disclosures about Market Risk,&#8221; and &#8220;Item&#160;3.&#160;Key Information &#8212;&#160;D.&#160;Risk Factors &#8212;&#160;Risks Related to Financial Markets &#8212;&#160;Fluctuations in currency exchange rates could adversely affect our results of operations and financial condition.&#8221;</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_184"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.1.9. Divestments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reserved.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_187"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.1.10. Acquisitions</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;28, 2023, Sanofi agreed to acquire QRIB Intermediate Holdings, LLC (QRIB), the owner of QUNOL, a market-leading US-based health &amp; wellness brand. The acquisition strengthened Sanofi&#8217;s CHC operations in the Vitamin, Mineral and Supplements (VMS) category. The acquisition of QRIB by Sanofi was completed on September&#160;29, 2023, at a purchase price of $1,419&#160;million. The impact of this acquisition is reflected in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for&#8239;using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows and represents a net cash outflow of $1,410&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March&#160;13, 2023, Sanofi entered into a merger agreement with Provention Bio,&#160;Inc. (Provention), a US-based publicly traded biopharmaceutical company developing therapies to prevent and intercept immune-mediated diseases including type&#160;1 diabetes. Under the terms of the agreement, Sanofi acquired the outstanding shares of Provention common stock for $25.00 per share in an all-cash transaction valued at approximately $2.8&#160;billion. The acquisition of Provention was completed on April&#160;27, 2023, with Sanofi holding all of the shares of Provention on expiration of the tender offer. The impact of this acquisition as reflected within the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of $2,722&#160;million.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">63</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;8, 2022, Sanofi acquired the entire share capital of the immuno-oncology company Amunix Pharmaceuticals,&#160;Inc. (Amunix), thereby gaining access to Amunix&#8217;s innovative PRO-XTEN technology and a promising pipeline of immunotherapies. The acquisition price of Amunix comprised a fixed payment of &#8364;970&#160;million, plus contingent consideration in the form of milestone payments based on attainment of certain future development objectives of up to $225&#160;million, the fair value of which as of the acquisition date was &#8364;156&#160;million. The impact of this acquisition was reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;852 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For further information about the acquisitions mentioned above, see Notes&#160;D.1. and&#160;D.2. to our consolidated financial statements included at Item&#160;18. of this annual report.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_190"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.1.11. Critical accounting and reporting policies</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our consolidated financial statements are affected by the accounting and reporting policies that we use. Certain of our accounting and reporting policies are critical to an understanding of our results of operations and financial condition, and in some cases the application of these critical policies can be significantly affected by the estimates, judgments and assumptions made by management during the preparation of our consolidated financial statements. The accounting and reporting policies that we have identified as fundamental to a full understanding of our results of operations and financial condition are the following:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">1/ Revenue recognition</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our policies with respect to revenue recognition are discussed in Note&#160;B.13. to our consolidated financial statements included at&#160;Item&#160;18. of this annual report. Revenue arising from the sale of goods is presented in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprise revenue from sales of pharmaceutical products, consumer healthcare products, active ingredients and vaccines, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. In accordance with IFRS&#160;15 (Revenue from Contracts with Customers), such revenue is recognized when Sanofi transfers control over the product to the customer. Control refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from, the products. For the vast majority of contracts, revenue is recognized when the product is physically transferred, in accordance with the delivery and acceptance terms agreed with the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For contracts entered into by Sanofi Pasteur, transfer of control is usually determined by reference to the terms of release (immediate or deferred) and acceptance of batches of vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards contracts with distributors, Sanofi does not recognize revenue when the product is physically transferred to the distributor in case of products sold on consignment, or if the distributor acts as an agent. In such cases, revenue is recognized when control is transferred to the end customer, and the distributor&#8217;s commission is presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We offer various types of price reductions on our products. In particular, products sold in the United States are covered by various programs (such as Medicare and Medicaid) under which products are sold at a discount. Rebates are granted to healthcare authorities, and under contractual arrangements with certain customers. Some wholesalers are entitled to chargeback incentives based on the selling price to the end customer, under specific contractual arrangements. Cash discounts may also be granted for prompt payment. The discounts, incentives and rebates described above are estimated on the basis of specific contractual arrangements with our customers or of specific terms of the relevant regulations and/or agreements applicable for transactions with healthcare authorities, and of assumptions about the attainment of sales targets. We also estimate the amount of sales returns, on the basis of contractual sales terms and reliable historical data. Discounts, incentives, rebates and sales returns are recognized in the period in which the underlying sales are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net Sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as a reduction of gross sales. For additional details regarding the financial impact of discounts, incentives, rebates and sales returns, see Note&#160;D.23. to our consolidated financial statements included at Item&#160;18. of this annual report.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenues from non-Sanofi products, mainly comprising royalty income from license arrangements and sales of non-Sanofi products by our US-based entity VaxServe, are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. This line item also includes revenues arising from the distribution of ELOCTATE and ALPROLIX under Sanofi&#8217;s agreements with Swedish Orphan Biovitrum AB (Sobi) and revenue received under agreements for Sanofi to provide manufacturing services to third parties.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">2/ Business combinations</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As discussed in Note&#160;B.3. &#8220;Business combinations and transactions with non-controlling interests&#8221; to our consolidated financial statements included at Item&#160;18. of this annual report, business combinations are accounted for by the acquisition method. The&#160;acquiree&#8217;s identifiable assets and liabilities that satisfy the recognition criteria of IFRS&#160;3 (Business Combinations) are measured initially at their fair values as at the acquisition date, except for (i)&#160;non-current assets classified as held for sale, which are&#160;measured at fair value less costs to sell and&#160;(ii)&#160;assets and liabilities that fall within the scope of IAS&#160;12 (Income Taxes) and&#160;IAS&#160;19&#160;(Employee Benefits). Business combinations completed on or after January&#160;1, 2010 are accounted for in accordance with the revised IFRS&#160;3 and IFRS&#160;10 (Consolidated Financial Statements). In particular, contingent consideration payable to former owners agreed in a business combination, e.g. in the form of payments upon the achievement of certain R&amp;D&#160;milestones, is recognized as a liability at fair value as of the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a liability, subsequent adjustments to the liability are recognized in profit or loss (see&#160;Note&#160;D.18.&#160;&#8220;Liabilities related to business combinations and non-controlling interests&#8221; to our consolidated financial statements included at&#160;Item&#160;18. of this annual report).</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">64</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">3/ Impairment of goodwill and intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As discussed in Note&#160;B.6. &#8220;Impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method&#8221; and in Note&#160;D.5. &#8220;Impairment of intangible assets and property, plant and equipment&#8221; to our consolidated financial statements included at Item&#160;18. of this annual report, we test our intangible assets for impairment periodically or when there is any internal or external indication of impairment. Such indicators could include primarily but not exclusively (i)&#160;increased market competition resulting from (for example) the introduction of a competitor&#8217;s product; (ii)&#160;earlier than expected loss of exclusivity; (iii)&#160;increased pricing pressure; (iv)&#160;restrictions imposed by regulatory authorities on the manufacture or sale of a product; (v)&#160;delay in the projected launch of a product;&#160;(vi)&#160;different from expected clinical trial results; (vii)&#160;higher than expected development costs or (viii)&#160;lower than expected economic performance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We test for impairment on the basis of the same objective criteria that were used for the initial valuation. Our initial valuation and ongoing tests are based on the relationship of the value of our projected future cash flows associated with the asset to either the purchase price of the asset (for its initial valuation) or the carrying amount of the asset (for ongoing tests for impairment).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Significant underlying assumptions requiring the exercise of considerable judgement are applied in the future cash flow projections used to determine the recoverability of intangible assets, including primarily but not exclusively (i)&#160;therapeutic class market growth drivers; (ii)&#160;expected impacts from competing products (including but not exclusively generics and biosimilars); (iii)&#160;projected pricing and operating margin levels; (iv)&#160;likely changes in the regulatory, legal or tax environment; and (v)&#160;management&#8217;s estimates of terminal growth or attrition rates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The recoverable amounts of intangible assets related to research and development projects are determined based on future net cash flows, which reflect the development stage of the project and the associated probability of success of marketization of the compound.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The projected cash flows are discounted to present value using a discount rate, which factors in the risks inherent in cash flow projections.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in facts and circumstances, assumptions and/or estimates may lead to future additional impairment losses or reversal of impairment previously recorded.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Key assumptions relating to goodwill impairment are the perpetual growth rate and the post-tax discount rate. A sensitivity analysis to the key assumptions is disclosed in Note&#160;D.5.&#160;&#8220;Impairment of intangible assets and property, plant and equipment&#8221; to our consolidated financial statements included at Item&#160;18. of this annual report.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">4/ Pensions and post-retirement benefits</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As described in Note&#160;B.23. &#8220;Employee benefit obligations&#8221; to our consolidated financial statements included at Item&#160;18. of this annual report, we recognize our pension and retirement benefit commitments as liabilities on the basis of an actuarial estimate of the rights vested in employees and retirees at the end of the reporting period, net of the fair value of plan assets held to meet those obligations. We prepare this estimate at least on an annual basis taking into account financial assumptions (such as discount rates) and demographic assumptions (such as life expectancy, retirement age, employee turnover, and the rate of salary increases).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We recognize all actuarial gains and losses (including the impact of a change in discount rate) immediately through equity.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Depending on the key assumptions used, the pension and post-retirement benefit expense could vary within a range of outcomes and have a material effect on reported earnings. A sensitivity analysis to these key assumptions is set forth in&#160;Note&#160;D.19.1. &#8220;Provisions for pensions and other benefits&#8221; to our consolidated financial statements included at Item&#160;18. of this annual report.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">5/ Taxes</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As discussed in Note&#160;B.22. &#8220;Income tax expense&#8221; to our consolidated financial statements included at Item&#160;18. of this annual report, we recognize deferred income taxes on tax loss carry-forwards and on temporary differences between the tax base and carrying amount of assets and liabilities. We calculate our deferred tax assets and liabilities using enacted tax rates applicable for the years during which we estimate that the temporary differences are expected to reverse. We do not recognize deferred tax assets when it is more likely than not that the deferred tax assets will not be realized. The recognition of deferred tax assets is determined on the basis of profit forecasts for each tax group, and of the tax consequences of the strategic opportunities available to Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The positions adopted by Sanofi in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, Sanofi assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of Sanofi&#8217;s best estimate and recognized as a liability; uncertain tax assets are not recognized.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">65</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">6/ Provisions for risks</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and its subsidiaries and affiliates may be involved in litigation, arbitration or other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights, compliance and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures. As discussed in Note&#160;B.12. &#8220;Provisions for risks&#8221; to our consolidated financial statements included at Item&#160;18. of this annual report, we record a provision where we have a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources. We also disclose a contingent liability in circumstances where we are unable to make a reasonable estimate of the expected financial effect that will result from the ultimate resolution of the proceeding, or a cash outflow is not probable.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For additional details regarding the financial impact of provisions for risks see Notes&#160;D.19.3. &#8220;Other provisions&#8221; and&#160;D.22. &#8220;Legal and Arbitral Proceedings&#8221; to our consolidated financial statements included at Item&#160;18. of this annual report.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">7/ Provisions for restructuring costs</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions for restructuring costs include collective redundancy or early retirement benefits, compensation for early termination of contracts, and rationalization costs relating to restructured sites. Refer to Note&#160;D.19.2. to our consolidated financial statements included at Item&#160;18. of this annual report.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions are estimated on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management&#8217;s knowledge at the date of preparation of the financial statements. The assessment of provisions can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Given the inherent uncertainties related to these estimates and assumptions, the actual outflows resulting from the realization of those risks could differ from our estimates.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_193"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2. Results of operations &#8211;&#160;Year ended December 31, 2023 compared with year ended December 31, 2022</span></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Consolidated income statements</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.676%"><tr><td style="width:1.0%"/><td style="width:48.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.439%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.440%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">as&#160;%&#160;of&#160;net</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">sales</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">as&#160;%&#160;of&#160;net</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">sales</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,374&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14,236)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-33.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13,695)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-31.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32,208</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">74.8</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31,694</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">73.7</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-15.6&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,706)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-15.6&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,692)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-24.8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,492)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-24.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,969&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,516)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,531)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,172)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,053)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(896)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,490)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(370)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,875</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18.3</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,656</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24.8</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,313)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(440)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,153</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16.6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,422</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24.2</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,602)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,006)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,436</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12.6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,484</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19.7</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,400</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12.5</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,371</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19.5</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.7&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.9&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares after dilution (million)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,256.4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,256.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share (&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.66&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">66</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_196"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.2.1. Net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consolidated net sales for the year ended December 31, 2023 amounted to &#8364;43,070&#160;million, 0.2% higher than in 2022 on a reported basis. Exchange rate fluctuations had a negative effect of</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> 5.1</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;percentage points overall, due mainly to adverse trends in the US&#160;dollar and Argentine peso against the euro. At CER</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net sales rose by&#160;5.3%, mainly reflecting strong growth for DUPIXENT and increased sales for our Vaccines business, more than offsetting lower sales for of Non-Core Assets within the General Medicines GBU.</span></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Reconciliation of Net sales (IFRS) to net sales at CER (non-IFRS)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales (IFRS)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+0.2</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales at constant exchange rates (non-IFRS)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45,259</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+5.3</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To facilitate analysis and comparisons with prior periods, some figures are given at CER.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We calculate net sales at CER by recalculating net sales for the relevant period using the exchange rates that were used for the previous period.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9fa7f69b4904450e9c43e8444c203165_199"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">1/ Net sales by operating segment</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our net sales comprise the net sales generated by our Biopharma and Consumer Healthcare segments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:49.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change on a reported basis</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change at constant exchange rates</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma segment</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,890</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,812</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+0.2</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+5.1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer Healthcare segment</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,180</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,185</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-0.1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+6.3</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+0.2</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+5.3</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure: see definition in &#8220;&#8212; Presentation of Net Sales.&#8221;</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">67</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_202"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">2/ Net sales by franchise, geographical region and product</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:27.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.894%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (reported)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rest of the world</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change (CER)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">DUPIXENT</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,715&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+34.0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+29.2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,145&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+32.6&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+30.9&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+46.1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AUBAGIO</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-52.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-53.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-67.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-14.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-33.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MYOZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-15.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-17.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-16.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-9.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FABRAZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+11.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+18.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CEREZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ELOCTATE</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-15.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALPROLIX</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+11.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+11.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NEXVIAZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+126.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+116.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+77.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+494.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+190.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">JEVTANA</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-14.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-14.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-63.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SARCLISA</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+37.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+29.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+33.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+27.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+53.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">KEVZARA</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+17.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CERDELGA</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+23.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALDURAZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+23.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CABLIVI</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+171.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FASTURTEC</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ENJAYMO</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+240.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+227.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+152.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+420.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XENPOZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+347.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+333.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+980.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+106.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+800.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ALTUVIIIO</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-46.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-50.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-32.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-80.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Specialty Care</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,040</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+14.2</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+9.6</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,917</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+13.2</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,206</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+6.7</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,917</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+26.6</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TOUJEO</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-23.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+26.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LOVENOX</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-14.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-58.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PLAVIX</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-11.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">THYMOGLOBULIN</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+14.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+11.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+19.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MULTAQ</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-25.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+15.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PRALUENT</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+15.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+12.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-101.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+30.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+46.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">REZUROCK</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+54.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+49.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+51.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+400.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MOZOBIL</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-14.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-15.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-22.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-20.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SOLIQUA/SULIQUA</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-18.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+24.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+40.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-25.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,270&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-7.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,797&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LANTUS</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-32.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-37.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-62.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-15.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-17.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">APROVEL/AVAPRO</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-12.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+28.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other Non-Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,687&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-15.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-24.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-14.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,424&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Total Non-Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-16.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-22.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-48.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-14.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,536&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Industrial Sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-58.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total General Medicines</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,376</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-7.1</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-12.4</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,084</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-24.9</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,932</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-4.6</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,360</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-1.3</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Influenza vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,669&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-12.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Polio/Pertussis/Hib vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Meningitis, travel and endemics vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+41.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-8.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Booster vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+16.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Respiratory Syncytial Virus </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+96.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+94.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+223.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+18.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,474</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+8.3</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+3.4</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,264</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+4.9</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,697</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+26.6</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,513</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+3.3</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Biopharma</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,890</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+5.1</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+0.2</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,265</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+5.2</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+4.3</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,790</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+5.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allergy</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+29.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+13.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cough, Cold and Flu</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+11.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+14.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pain Care</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-12.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Digestive Wellness</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+15.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+8.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Physical and Mental Wellness</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+139.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Personal Care</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-7.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-Core/Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-30.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-41.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-12.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Consumer Healthcare</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,180</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+6.3</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-0.1</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,247</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-0.9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,557</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+3.9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,376</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+11.7</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Sanofi</span></td><td colspan="2" style="background-color:#21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+5.3</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#21004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+0.2</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#21004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,512</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+4.8</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#21004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,392</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+4.3</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#21004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,166</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+6.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#21004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">68</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_205"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">3/ Net sales &#8211; Biopharma segment</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since 2023, our new Biopharma segment comprises our Specialty Care, General Medicines and Vaccines businesses (see &#8220;Item 5.A.1.5, Segment Information&#8221; for detailed disclosures about our operating segments and Note&#160;D.35. to our consolidated financial statements included at Item&#160;18. of this annual report).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, net sales for the Biopharma segment amounted to &#8364;37,890&#160;million, up 0.2% on a reported basis and 5.1% at CER. The year-on-year reported-basis increase of &#8364;78&#160;million reflects adverse exchange rate effects amounting to &#8364;1,858&#160;million, and the following principal effects at CER:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a solid performance from DUPIXENT (+&#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,822</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;million) and the launches of NEXVIAZYME (+ &#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">247</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;million) and ALTUVIIIO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"><br/></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(+&#8364;168 million), which more than offset a drop in sales of AUBAGIO (-&#8364;1,069 million);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a 16.5% decrease in sales of Non-Core Assets within the General Medicines franchise (-&#8364;1,176&#160;million);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the launch of BEYFORTUS (+&#8364;572&#160;million).</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Comments on the performances of our major Biopharma segment products are provided below.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Specialty Care</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">DUPIXENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (developed in collaboration with Regeneron) generated net sales of &#8364;10,715&#160;million in 2023, up 29.2% on a reported basis and&#160;34.0% at CER. In the United States, sales of DUPIXENT reached &#8364;8,145&#160;million in 2023, up&#160;32.6% CER, boosted by continuing strong demand in the product's approved indications: atopic dermatitis, asthma, nasal polyps, eosinophilic esophagitis, and prurigo nodularis. In Europe, the product posted 2023 net sales of&#160;&#8364;1,224&#160;million, up</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">30.9% CER, driven by continuing growth in atopic dermatitis, asthma and nasal polyps. In the Rest of the World</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">region, DUPIXENT posted net sales of &#8364;1,346&#160;million (+46.1% CER), driven mainly by Japan and China.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Net sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">AUBAGIO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> fell by 52.6% CER in 2023 to &#8364;955&#160;million, mainly due to the arrival of generics. In the United States, where generics came on the market on March&#160;12, 2023, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">AUBAGIO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> fell by -67.8% CER at &#8364;460&#160;million. In Europe, generic competition for </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">AUBAGIO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> began at the end of September&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales of the </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Pompe</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> disease franchise</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (MYOZYME/LUMIZYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and&#160;NEXVIAZYME/NEXVIADYME) were up 8.8% CER in 2023 at &#8364;1,208&#160;million. Sales of NEXVIAZYME/NEXVIADYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">reached &#8364;425&#160;million, including &#8364;272&#160;million in the United States, reflecting switches of eligible Pompe patients (advanced stage) from MYOZYME/LUMIZYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and increased uptake by new patients. Sales of MYOZYME/LUMIZYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">were down year-on-year (</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">-15.1%</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> CER at &#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">783&#160;million) as patients switched to </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">NEXVIAZYME. In 2023, sales of NEXVIAZYME/NEXVIADYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">represented 35.2% of total sales for the Pompe disease franchise.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales of the </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Fabry</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> disease</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> treatment </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">FABRAZYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in 2023 were &#8364;991&#160;million (+</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11.2%</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;CER), driven by the Rest of the World region (+</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">18.8%</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> CER at &#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">247</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;million) followed by the United States (+</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">9.8% CER at&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">503</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;million). The year-on-year increase reflects more patients adopting the product across all three regions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales for the </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Gaucher</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> disease </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">franchise (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">CEREZYME </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> CERDELGA</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) reached &#8364;985&#160;million in 2023, up 8.4% CER. CEREZYME sales were up 9.1% CER at &#8364;687&#160;million on a solid performance in the Rest of the World region (+25.9% CER at&#160;&#8364;269&#160;million), driven by new patients on therapy and favorable pricing. In parallel, sales of CERDELGA rose by&#160;6.9% CER to &#8364;298&#160;million, with growth reported in the United States (+5.6% CER at&#160;&#8364;164&#160;million), Europe (+6.3%&#160;CER at &#8364;118&#160;million), and the Rest of the World region (+</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">23.5% CER at &#8364;16&#160;million)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as new patients adopted the product or switched treatment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ELOCTATE</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> generated net sales of &#8364;471&#160;million in 2023, down 15.5% CER, due to the adoption of ALTUVIIIO and competitive pressures</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ALTUVIIIO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> , a first-in-class, once-weekly factor VIII replacement therapy that confers significant protection against bleeds for hemophilia A patients, was launched in the United States at the end of March 2023 and generated sales of &#8364;159 million in 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, net sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ALPROLIX</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">were &#8364;540&#160;million, up 11.3% CER, driven by the&#160;United&#160;States where sales of the product reached &#8364;440&#160;million, up 11.6% CER.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">SARCLISA</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in 2023 were &#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">381&#160;million, up 37.1% </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CER</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, with good performances in all three regions: &#8364;165&#160;million (+33.9% CER) in the United States, &#8364;111&#160;million (+27.3% CER) in Europe, and in Japan (&#8364;77&#160;million, u</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">p 28.8% CER).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">JEVTANA</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> posted net sales of &#8364;320&#160;million in 2023 (-14.8% CER), reflecting the launch of generics in Europe in March 2021 and competitive pressures in the United States.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">CABLIVI</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">posted net sales of &#8364;227&#160;million in 2023, up&#160;10.0% CER, reflecting increased awareness of acquired thrombotic thrombo-cytopenic purpura (aTTP), and treatment in line with guidelines from the International Society on Thrombosis and Haemostasis (ISTH) recommending first-line use of CABLIVI for all aTTP patients. Sales reached &#8364;112&#160;million in the United States (+4.5% CER), and in Europe net sales were up 4.3% CER at &#8364;98&#160;million, mainly due to greater market penetration as a result of increased product awareness.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">XENPOZYME</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">reported net sales of &#8364;91&#160;million, mainly in the United States (&#8364;52&#160;million) and Europe (&#8364;31&#160;million).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">ENJAYMO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;72&#160;million, with sales being generated primarily in the United States and Japan.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">69</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">General Medicines</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, General Medicines GBU net sales reached &#8364;12,376&#160;million, down 12.4% on a reported basis and 7.1 % at CER. Industrial sales were &#8364;582&#160;million, down 6.1% o reported basis and 5.5% at CER.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Core Assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Core Assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;6,270&#160;million, down 1.9% on a reported basis but up 3.3% at CER. The main drivers were a solid performance from REZUROCK and strong contributions from TOUJEO, THYMOGLOBULIN, PRALUENT and PLAVIX, partly offset by lower sales of LOVENOX (due to strong competition from biosimilars) and MOZOBIL (due to loss of US exclusivity). Core Assets accounted for 50.7% of total General Medicines sales in 2023, compared with 45.2% in 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">By geography, Core Assets sales reported growth in the Rest of the World region (+9.3% CER) and Europe (+4.2% CER), though the impact was partly offset by the effect of insulin price erosion in the United States, where sales were down 7.7% CER.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">REZUROCK</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;310&#160;million, a significant increase of 54.6% CER. Since its launch, approximately 4,000&#160;patients have been treated, with strong persistency rates. Sanofi recently reacquired rights to be the sole marketing authorization holder for REZUROCK in China, where in August&#160;2023 the China National Medical Products Administration (NMPA) approved belumosudil (REZUROCK) for the treatment of patients aged 12&#160;years and older with chronic Graft Versus Host Disease (cGVHD) who have an inadequate response to corticosteroids or other systemic treatments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the second quarter of 2023, Sanofi acquired Provention, adding </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TZIELD</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> , an innovative first-in-class treatment for people with type&#160;1 diabetes, to the Core Assets portfolio. In 2023, TZIELD sales were &#8364;25&#160;million, in line with the expected gradual ramp-up as a result of early patient identification programs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">TOUJEO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> net sales were &#8364;1,123&#160;million in 2023, up 6.2% CER. Growth was driven mainly by the Rest of the World region (+26.9% CER), due to the Value Based Procurement program in China and the associated acceleration in sales volumes. The impact was partly offset by lower sales in the United States (-23.0% CER) due to price erosion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">SOLIQUA</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;217&#160;million (+5.6% CER), driven by growth in the Rest of the World region (+40.3% CER) and Europe (+24.3% CER). SOLIQUA was launched in China in May&#160;2023, where it was added to the National Reimbursement Drug List (NRDL) in December 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">PRALUENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> posted net sales of &#8364;422&#160;million, up 15.2% CER. Growth was reported in Europe (+30.6% CER) and the Rest of the World region (+46.7% CER, due mainly due to China), though the effect was partly offset by lower sales in the United States following the release of a glyceryl trinitrate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">PLAVIX</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> net sales reached &#8364;948&#160;million in 2023, up </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.4% CER</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, in line with consistent volume growth in China.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">LOVENOX</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were &#8364;1,125&#160;million in 2023, down 8.7% CER, reflecting strong biosimilar competition across all geographies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">MOZOBIL</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> sales were &#8364;220&#160;million in 2023, down 14.6% CER, due to loss of exclusivity in the United States and China. In Europe, the European Patent Office Technical Board of Appeal invalidated the SPC (Supplementary Protection Certificate) which protected MOZOBIL until August&#160;2024.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Core Assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, net sales of Non-Core Assets were &#8364;5,524&#160;million, down 22.4% on a reported basis and 16.5% at CER, due mainly to divestments (negative impact 1.3% on total General Medicines net sales) as portfolio streamlining gathered pace. The General Medicines GBU has achieved its objective of reducing its Non-Core Assets portfolio from around 300&#160;products to 100, generating total divestment proceeds of approximately &#8364;2&#160;billion between 2020 and the end of 2023 (two years ahead of schedule). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The other main factor in the decrease in Non-Core Assets sales was a decline in sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">LANTUS</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to &#8364;1,420&#160;million in 2023 (-32.3% CER), mainly in the United States (-62.6% CER, due to lower net selling prices reflecting a higher proportion of sales through government channels) and China (due to the Value Based Procurement rollout).</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_208"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Vaccines</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, the Vaccines segment posted net sales of &#8364;7,474&#160;million, up 3.4% on a reported basis and 8.3% CER. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">he main driver was the launch of BEYFORTUS, which more than offset slow sales of influenza vaccines</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">BEYFORTUS</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> launch began in late September 2023, in the United States and Europe. Sales of the product reached &#8364;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">547&#160;million in 2023, reflecting strong demand through All Infant Protection Programs rolled out in United States, Spain and France.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">influenza</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> vaccines</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> decreased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">5.5%</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> CER in 2023 to &#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,669</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;million, due to a slight reduction in vaccine uptake and increased competition in the United States.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Polio/Pertussis/Hib (PPH) vaccines</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> posted net sales of &#8364;2,165&#160;million in 2023 (-0.1% CER), reflecting the ongoing expansion of VAXELIS in the United States at the expense of pentavalent vaccines in the first series of infant vaccinations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> In the US, VAXELIS became market leader at the end of 2023 in the three-dose primary series market. As a reminder, sales of VAXELIS in the United States are not consolidated, and the profits are shared equally between Sanofi and Merck &amp; Co.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">70</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Meningitis, Travel and Endemics vaccines</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for 2023 reached &#8364;1,170&#160;million, up 0.5%&#160;CER, with 41% growth in Europe more than offsetting lower sales in the Rest of the World region (-8.1 %) and the United States (-0.7% CER at &#8364;650&#160;million), reflecting a favorable pattern in the US while the divestment of the Japanese Encephalitis vaccine in 2022 impacted the Rest of the World region.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Booster vaccines</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> advanced by 5.1% CER to &#8364;598&#160;million, driven by strong growth in Europe.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net sales of other vaccines were &#8364;325&#160;million (+96.4% CER), and include sales of the monovalent recombinant-protein COVID-19 booster vaccine </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">VIDPREVTYN</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Beta.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_211"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">4/ Net sales &#8211; Consumer Healthcare segment/GBU</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, net sales for the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">C</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">HC segment fell by 0.1% to &#8364;5,180&#160;million on a reported basis but rose by 6.3% at CER, driven by double-digit growth in the Rest of the World region. Divestments of non-core products had a negative impact of 1.7&#160;percentage point. CHC therefore achieved organic growth of 9.6% in 2023 excluding divestments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi announced its intention to separate the CHC Business as it increases its focus on innovative medicines and vaccines. The intended separation will seek to create two entities, each better equipped to pursue its own business strategy, resourcing and capital allocation and enabling each to focus on long-term growth in its respective markets. Sanofi believes that the separation will unlock further opportunities for CHC to leverage its portfolio of leading brands and continue to drive growth and shareholder value. Sanofi is reviewing potential separation scenarios, but believes that the most likely path would be through a capital markets transaction, by creating a listed entity headquartered in France. The timing is driven by the desire to maximize value creation and reward Sanofi shareholders. Subject to market conditions, the intended separation could be achieved at the earliest in the fourth quarter of 2024, following consultation with social partners.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">United States</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, CHC net sales amounted to &#8364;1,247&#160;million in 2023, down 0.9% CER, mainly on lower sales in the Personal Care, Pain Care and Allergy categories.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Europe</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, CHC net sales were up 3.9% CER in 2023 at &#8364;1,557&#160;million, mainly reflecting growth in the Digestive Wellness and Cough &amp; Cold categories.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Rest of the World region</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, CHC net sales were up 11.7% CER at &#8364;2,376&#160;million in 2023, driven by growth in Digestive Wellness, Allergy, and Pain Care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;29, 2023, Sanofi completed the acquisition of QRIB Intermediate Holdings, LLC (QRIB), the owner of QUNOL, a leading US health and wellness brand. Sales of </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">QUNOL</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> are consolidated within the Physical Wellness category.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_214"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">5/ Net sales by geographical region</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth our net sales for 2023 and 2022 by geographical region:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:49.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change on a&#160;reported basis</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change at&#160;constant exchange rates</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,512&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,275&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1.3&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.8&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,392&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,999&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,166&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-3.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which China</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,912&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">-6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">+0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+0.2</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+5.3</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, net sales in the </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">United States</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reached &#8364;18,512&#160;million, up 1.3% on a reported basis and 4.8% at CER, reflecting a strong performance from DUPIXENT (+32.6% CER at &#8364;8,145&#160;million) and the </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">launches of BEYFORTUS (&#8364;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">407&#160;million) and ALTUVIIO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, (&#8364;155&#160;million) partly offsetting by the impact of generics of AUBAGIO and lower sales of LANTUS and influenza vaccines .</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Europe</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net sales advanced by 3.9% on a reported basis and 4.3% at CER in 2023 to &#8364;10,392&#160;million. The performance of DUPIXENT</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(+30.9% CER at &#8364;1,224&#160;million) and</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> the launch of BEYFORTUS (&#8364;140&#160;million) more than offset lower sales for the Non-Core Assets franchise (-14.4% CER).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Rest of the World region</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net sales for 2023 decreased by 3.8% on a reported basis but rose by 6.5% at CER to&#160;&#8364;14,166&#160;million, due to exceptional performances from DUPIXENT (+46.1% CER at &#8364;1,346&#160;million) and CHC (+11.7% CER at &#8364;2,376&#160;million).</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_217"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.2.2. Other income statement items</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">1/ Other revenues</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other revenues increased by 41.1% to &#8364;3,374&#160;million in 2023 (versus &#8364;2,392&#160;million in 2022). This line item mainly comprises VaxServe sales of non-Sanofi vaccines (&#8364;2,167&#160;million in 2023 versus &#8364;1,567&#160;million in 2022, recorded within the Biopharma segment). The year-on-year increase also reflects higher revenues from manufacturing services contracts and revenues from the COVID-19 vaccine (in particular, &#8364;411&#160;million received from the US government in connection with the supply contract for the recombinant COVID-19 vaccine candidate).</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">71</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">2/ Gross profit</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gross profit for 2023 amounted to &#8364;32,208&#160;million compared with &#8364;31,694&#160;million in 2022, an increase of 1.6%. Gross margin (the ratio of gross profit to net sales) also rose, reaching 74.8% in 2023, versus 73.7% in 2022. The year-on-year increase in gross margin reflects in particular stronger gross margin for the Biopharma segment, which reached 76.4% in 2023 versus 75.0% in 2022, driven largely by a favorable product mix in Specialty Care and revenues related to the COVID-19 vaccine, which more than offset the effects of generic competition for AUBAGIO and unfavorable pricing effects for LANTUS in the United States.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">3/ Research and development expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses amounted to &#8364;6,728&#160;million in 2023, versus &#8364;6,706&#160;million in 2022, an increase of&#160;0.3%, as investment stabilized. R&amp;D expenses represented 15.6% of net sales in 2023, the same as in 2022.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">4/ Selling and general expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Selling and general expenses amounted to &#8364;10,692&#160;million in 2023 (24.8% of net sales), versus &#8364;10,492&#160;million in 2022 (24.4% of net sales); the 1.9% increase was a result of increased marketing spend in the Biopharma segment and commercial spend in CHC.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">5/ Other operating income and expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other operating income amounted to &#8364;1,292&#160;million in 2023 (versus &#8364;1,969&#160;million in 2022), and other operating expenses to&#160;&#8364;3,516&#160;million (versus &#8364;2,531&#160;million in 2022).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Overall, this represented a net expense of &#8364;2,224&#160;million in 2023, compared with a net expense of &#8364;562&#160;million in 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:61.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.153%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,969&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,516)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,531)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(985)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other operating income/(expenses), net</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,224)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(562)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,662)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The increase of &#8364;1,662&#160;million mainly reflects&#160;an increase in the share of profits generated by the monoclonal antibody alliance with Regeneron under the collaboration agreement (see Note&#160;C.1. to our consolidated financial statements, included at Item&#160;18 of this annual report), the principal factors being (i)&#160;increased sales of DUPIXENT and (ii)&#160;the impact in 2022 of the recognition of the proceeds arising from the restructuring of the immuno-oncology (IO) collaboration agreement between Sanofi and Regeneron (see Note C.1. to our consolidated financial statements, included at Item 18. of this annual report).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The net contribution of items related to Regeneron to this line item is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:489.75pt"><tr><td style="width:1.0pt"/><td style="width:367.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &amp; expense related to (profit)/loss sharing under the Monoclonal Antibody Alliance</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,321)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,325)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total: Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,196)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,367)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immuno-Oncology Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other (mainly ZALTRAP and LIBTAYO)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">217</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,120</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other operating income/(expenses), net related to Regeneron</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,979)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,231)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of December 31, 2023, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to &#8364;2.1 billion, compared with &#8364;2.7 billion as of December 31, 2022 (see note D.21.to our consolidated financial statements included at Item 18. of this annual report).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Following the restructuring of the Immuno-Oncology collaboration agreement between Sanofi and Regeneron effective July&#160;1, 2022 (see Note&#160;C.1. to our consolidated financial statements, included at Item&#160;18. of this annual report).</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">6/ Amortization of intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization charged against intangible assets amounted to &#8364;2,172&#160;million in 2023, compared with &#8364;2,053&#160;million in 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This &#8364;119&#160;million increase was mainly due to (i)&#160;increased amortization expense in 2023 against ELOCTATE franchise assets further to FDA approval for ALTUVIIIO (&#8364;206 million) and (ii)&#160;the acquisition of Provention Bio, Inc., which led to &#8364;144&#160;million of amortization being charged from the acquisition date against the intangible asset related to TZIELD product; those effects were partly offset by the non-recurrence of the &#8364;226&#160;million accelerated amortization charge taken in 2022 against LIBTAYO rights following the restructuring of the IO LCA with Regeneron (see Note&#160;C.1. to our consolidated financial statements, included at Item&#160;18 of this annual report).</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">7/ Impairment of intangible assets, net of reversals</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2023, this line shows a net loss of &#8364;896&#160;million, mainly comprising an impairment loss of &#8364;833&#160;million reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">72</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2022, this line item shows a net gain of &#8364;454&#160;million, mainly comprising:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a reversal of &#8364;2,154&#160;million relating to ELOCTATE</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">franchise assets, following FDA approval of ALTUVIIIO (the commercial name of efanesoctocog alpha, corresponding to the BIVV001 project); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an impairment loss of &#8364;1,586&#160;million relating to the development project for SAR444245 (non-alpha interleukin-2), based on revised cash flow projections reflecting unfavorable developments in the launch schedule.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">8/ Fair value remeasurement of contingent consideration</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Fair value remeasurements of contingent consideration assets and liabilities recognized in business combinations represented a net expense of &#8364;93&#160;million in 2023, versus a net gain of &#8364;27&#160;million in 2022. For 2023, this line item mainly comprises a change in the amount of contingent consideration payable to Shire as a result of a transaction carried out by Translate Bio,&#160;Inc. prior to the acquisition of that entity by Sanofi (expense of &#8364;74&#160;million in 2023, versus &#8364;2&#160;million in 2022).</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">9/ Restructuring costs and similar items</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring costs and similar items represented a total charge of &#8364;1,490&#160;million in 2023, versus a charge of &#8364;1,336&#160;million in 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring costs and similar items increased by &#8364;154&#160;million year-on-year. For 2023 they include the impact of French pension reforms on future annuities under the rules of each severance plan, while for 2022 they mainly comprised severance costs recognized further to the announcements made during that period. Also included in restructuring costs are the impacts of ongoing transformational projects, primarily those associated with the creation of the standalone CHC entity and the implementation of Sanofi&#8217;s new digital strategy.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">10/ Other gains and losses, and litigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2023, this line item showed an expense of &#8364;38&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">million, comprising costs arising on the settlement of litigation with Bioverativ former shareholders.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2022, this line item showed an expense of &#8364;370&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">comprising (i)&#160;the pre-tax loss arising on the deconsolidation of EUROAPI (see Note&#160;D.2. to our consolidated financial statements, included at Item&#160;18 of this annual report) and (ii)&#160;costs associated with major litigation.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">11/ Operating income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Operating income amounted to &#8364;7,875&#160;million in 2023, versus &#8364;10,656&#160;million in 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The year-on-year decrease was largely due to the movements in impairment allowances against intangible assets.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">12/ Financial income and expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net financial expenses were &#8364;722&#160;million in 2023, versus &#8364;234&#160;million in 2022, a increase of &#8364;488&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cost of our net debt (see the definition in &#8220;&#8212;&#160;Liquidity and Capital Resources&#8221; below and Note D.29. to our consolidated financial statements, included at Item&#160;18. of this annual report) was &#8364;22&#160;million in 2023, compared with&#160;&#8364;124&#160;million in 2022; the reduction of &#8364;102&#160;million was largely due to an increased return on cash, cash equivalents and associated derivatives (&#8364;533&#160;million in 2023 versus &#8364;241&#160;million in 2022, an increase of &#8364;292&#160;million).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, a financial expense of &#8364;541 million was recognized in 2023 in respect of the liability recognized in the balance sheet for estimated future royalties on US sales of BEYFORTUS, which was remeasured as of December 31, 2023 to reflect the very successful US launch of the product (see Notes&#160;C.2. and D.29. to our consolidated financial statements, included at Item&#160;18. of this annual report).</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">13/ Income before tax and investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Income before tax and investments accounted for using the equity method reached &#8364;7,153&#160;million in 2023, versus &#8364;10,422&#160;million in 2022.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">14/ Income tax expense</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Income tax expense represented &#8364;1,602&#160;million in 2023, versus &#8364;2,006&#160;million in 2022, giving an effective tax rate based on consolidated net income of 22.4% in 2023, compared with 19.2% in 2022. The reduction in income tax expense was mainly due to a year-on-year increase in net amortization and impairment losses charged against intangible assets (impact of &#8364;563&#160;million in 2023 and &#8364;268&#160;million in 2022). In addition, a deferred tax asset of &#8364;133 million was recognized on the remeasurement of the financial liability recognized in the balance sheet to reflect estimated future royalties on US sales of BEYFORTUS. Those effects were partly offset by the deferred tax expense arising on investments in consolidated subsidiaries, which Sanofi expects will reverse as a result of the proposed separation of the CHC business as announced in October&#160;2023 (&#8364;365&#160;million impact in 2023). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, income tax expense included taxation of income from the out-licensing of LIBTAYO (&#8364;246&#160;million impact in 2022) and the effect of the reversal of impairment losses relating to ALTUVIIIO (&#8364;503&#160;million impact in 2022) following FDA approval.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The effective tax rate based on business net income is a non-IFRS financial measure (see definition under &#8220;&#8212;&#160;Segment information &#8212;&#160;Business Net Income&#8221; above). It is calculated on the basis of business operating income, minus net financial expenses and before (i)&#160;the share of profit/loss from investments accounted for using the equity method and (ii)&#160;net income attributable to non-controlling interests. We believe the presentation of this measure, used by our management, is also useful for investors as it provides a means to analyze the effective tax cost of our current business activities. It should not be seen as a substitute for the effective tax rate based on consolidated net income.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">73</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When calculated on business net income, our effective tax rate was 18.8% in 2023, compared with 19.3% in 2022.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below reconciles our effective tax rate based on consolidated net income to our effective tax rate based on business net income:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:74.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(as a percentage)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate based on consolidated net income (IFRS)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22.4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19.2</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax effects:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate based on business net income (non-IFRS)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18.8</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19.3</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">15/ Share of profit/(loss) from investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was a net loss of &#8364;115&#160;million in 2023 (including an impairment loss of &#8364;231&#160;million on the equity-accounted investment in EUROAPI &#8211; see Note D.6.), compared with net income of &#8364;68&#160;million for 2022 </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">16/ Net income</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net income amounted to &#8364;5,436&#160;million in 2023, compared with &#8364;8,484&#160;million in 2022.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">17/ Net income attributable to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net income attributable to non-controlling interests was &#8364;36&#160;million in 2023, versus &#8364;113&#160;million in 2022.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">18/ Net income attributable to equity holders of Sanofi</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net income attributable to equity holders of Sanofi amounted to &#8364;5,400&#160;million in 2023, compared with &#8364;8,371&#160;million in 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per share for 2023 was &#8364;4.31 versus &#8364;6.69 for 2022, based on an average number of shares outstanding of&#160;1,251.7&#160;million in 2023 and 1,251.9&#160;million in 2022. Diluted earnings per share for 2023 was &#8364;4.30 versus &#8364;6.66 for 2022, based on an average number of shares after dilution of 1,256.4&#160;million in 2023 and 1,256.9&#160;million in 2022.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_220"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.2.3. Segment results</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our business operating income, as defined in Note&#160;D.35. (&#8220;Segment information&#8221;) to our consolidated financial statements included at Item&#160;18. of this annual report, amounted to&#160;&#8364;12,670&#160;million in 2023, compared with &#8364;13,040&#160;million in 2022, a decrease of 2.8%. That represents 29.4% of our net sales, compared with 30.3% in 2022.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth our business operating income for the years ended December 31, 2023 and 2022:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:55.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,247&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,490&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-2.1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As percentage of sales</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consumer Healthcare</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As percentage of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-153.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Business operating income (non-IFRS)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,670</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,040</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-2.8</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div id="i9fa7f69b4904450e9c43e8444c203165_223"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B. Liquidity and capital resources</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our operations generate significant positive cash flows. We fund our day-to-day investments (with the exception of significant acquisitions) primarily with operating cash flow, and pay regular dividends on our shares.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Net debt&#8221; is a non-IFRS financial indicator which is reviewed by our management, and which we believe provides useful information to measure our overall liquidity and capital resources. We define &#8220;net debt&#8221; as (i)&#160;the sum total of long-term debt, short-term debt and current portion of long-term debt, and interest rate and currency derivatives used to manage debt, minus (ii)&#160;the sum total of cash and cash equivalents and interest rate and currency derivatives used to manage cash and cash equivalents. Lease liabilities are not included in net debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023 our net debt was &#8364;7,793&#160;million, compared with &#8364;6,437&#160;million as of December 31, 2022. For an explanation of the increase in our net debt, refer to section&#160;&#8220;B.2.&#160;Consolidated Balance Sheet and Debt&#8221; below.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to assess our financing risk, we also use the &#8220;gearing ratio", a non-IFRS financial measure (see table in section &#8220;&#8212;&#160;B.2.&#160;Consolidated Balance Sheet and Debt&#8221; below). We define the gearing ratio as the ratio of net debt to total equity. As of&#160;December 31, 2023, our gearing ratio was 10.5%, compared with 8.6% as of December 31, 2022.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because our net debt and gearing ratio are not standardized measures, they may not be directly comparable with the non-IFRS financial measures of other companies using the same or similar non-IFRS financial measures. Despite the use of non-IFRS measures by management in setting goals and measuring performance, these are non-IFRS measures that have no standardized meaning prescribed by IFRS.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">74</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_226"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.1. Consolidated statement of cash flows</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Generally, factors that affect our earnings &#8211;&#160;for example, pricing, volume, costs and exchange rates&#160;&#8211; flow through to cash from operations. The most significant source of cash from operations is sales of our branded pharmaceutical products and vaccines. Receipts of royalty payments also contribute to cash from operations.</span></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Summarized consolidated statements of cash flows</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:70.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by/(used in) operating activities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,258&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,526&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,200)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,052)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,821)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,026)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,638</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="i9fa7f69b4904450e9c43e8444c203165_229"></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by/used in operating activities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> represented a net cash inflow of</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8364;10,258&#160;million in 2023, compared with&#160;&#8364;10,526&#160;million in 2022. The year-on-year decrease was due mainly to a lower level of operating cash flow before changes in working capital (&#8364;9,494&#160;million in 2023, versus &#8364;11,233&#160;million in 2022) and a net increase of &#8364;764&#160;million in the working capital requirement in 2023 (versus a net decrease of &#8364;707&#160;million in 2022).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by/used in investing activities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">represented a net cash outflow of &#8364;6,200&#160;million in 2023, compared with a net outflow of &#8364;2,075&#160;million in 2022. The net outflow in&#160;2023 was mainly a result of the acquisitions of Provention Bio, Inc. ($2,722&#160;million) and QRIB Intermediate Holdings, LLC (</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">$1,410&#160;million</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">). For 2022, the net cash outflow was mainly due to the acquisition of Amunix Pharmaceuticals, Inc (&#8364;852&#160;million), partly offset by the proceeds of &#8364;150&#160;million from the sale of a 12% equity interest in EUROAPI to EPIC Bpifrance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of property, plant and equipment and intangible assets amounted to &#8364;3,024&#160;million, versus &#8364;2,201&#160;million in 2022. There were&#160;&#8364;1,719&#160;million of acquisitions of property, plant and equipment (versus &#8364;1,606&#160;million in 2022), most of which (&#8364;1,619&#160;million) related to the Biopharma segment, primarily in industrial facilities. Acquisitions of intangible assets (&#8364;1,305&#160;million, versus &#8364;595&#160;million in 2022) mainly comprised contractual payments for intangible rights under license and collaboration agreements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After-tax proceeds from disposals (&#8364;1,015&#160;million in 2023, &#8364;1,488&#160;million in 2022) exclude proceeds from divestments of investments in consolidated undertakings and investments accounted for using the equity method, and mainly comprised divestments of assets and activities related to the streamlining of the portfolio, and disposals of equity and debt instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by/used in financing activities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">represented a net cash outflow of &#8364;8,052&#160;million in 2023, compared with a net cash outflow of &#8364;5,821&#160;million in 2022. The 2023 figure includes the redemption of bond issues totaling &#8364;3,664&#160;million. Other movements included (i)&#160;the dividend payout to our shareholders of&#160;&#8364;4,454&#160;million (versus &#8364;4,168&#160;million in 2022; and (ii)&#160;the effect of changes in our share capital (repurchases of our own shares, net of capital increases), representing a net cash outflow of&#160;&#8364;398&#160;million in 2023 versus a net cash outflow of &#8364;309&#160;million in 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">net change in cash and cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in 2023 was a decrease of &#8364;4,026&#160;million, versus an increase of &#8364;2,638&#160;million in&#160;2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8220;Free cash flow,&#8221; a non-IFRS measure,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2023 was &#8364;8,478&#160;million, virtually unchanged from the 2022 figure of &#8364;8,483&#160;million. This reflects our operational performance (including the effect of cost containment measures), and proceeds from asset divestments during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For details of the arrangements in place to manage our liquidity needs for current operations as of December&#160;31, 2023, refer to Note&#160;17.1.(b) to our consolidated financial statements, included at Item&#160;18. of this annual report.</span></div><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Free cash flow&#8221; is a non-IFRS financial indicator which is reviewed by our management, and which we believe provides useful information to measure the net cash generated from our operations that is available for strategic investments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (net of divestments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">), for debt repayment, and for payments to shareholders. &#8220;Free cash flow&#8221; is determined from our &#8220;Business net income&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> after adding back (in the case of expenses and losses) or deducting (in the case of income and gains) the following items: depreciation, amortization and impairment, share of undistributed earnings from investments accounted for using the equity method, gains &amp; losses on disposals, net change in provisions including pensions and other post-employment benefits, deferred taxes, share-based payment expense and other non-cash items. It also includes net changes in working capital, capital expenditures and other asset acquisitions</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> net of disposal proceeds</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, and payments related to restructuring and similar items. &#8220;Free cash flow&#8221; is not defined by IFRS, and is not a substitute for </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as reported under IFRS. Management recognizes that the term &#8220;Free cash flow&#8221; may be interpreted differently by other companies and under different circumstances.</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Above a cap of &#8364;500&#160;million per transaction.</span></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure, as defined in &#8220;&#8212;&#160;Segment Information &#8212;&#160;Business Net income&#8221; above.</span></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Not exceeding a cap of &#8364;500&#160;million per transaction.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">75</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth a reconciliation between</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Net cash provided by operating activities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and &#8220;Free cash flow&#8221;:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:72.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.611%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by operating activities (IFRS)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,258</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,526</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and software</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,771)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,656)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of intangible assets, equity interests and other non-current financial assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,113)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(824)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from disposals of property, plant and equipment, intangible assets and other </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">non-current assets, net of tax</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayments of lease liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(291)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(803)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Free cash flow (non-IFRS)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,478</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,483</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Free cash flow includes investments and divestments not exceeding a cap of &#8364;500&#160;million per transaction.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Cash outflows relating to repayments of the principal portion of lease liabilities (IFRS&#160;16) are included in free cash flow.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In 2022, includes an upfront payment of $900 million and a regulatory milestone payment of $100&#160;million related to the granting of the LIBTAYO license.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_232"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2. Consolidated balance sheet and debt</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total assets were &#8364;126,464&#160;million as of December 31, 2023, compared with &#8364;126,722&#160;million as of December 31, 2022, a decrease of&#160;&#8364;258&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">equity </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">was &#8364;74,353&#160;million as of December 31, 2023, versus &#8364;75,152&#160;million as of December 31, 2022. The year-on-year net change reflects the following principal factors:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">increases: our net income for 2023 (&#8364;5,436&#160;million); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">decreases: the dividend paid to our shareholders in respect of the 2022 financial year (&#8364;4,454&#160;million), repurchases of our own shares (&#8364;593&#160;million), and negative currency translation differences (&#8364;1,540&#160;million).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net debt</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was &#8364;7,793&#160;million as of December 31, 2023, compared with &#8364;6,437&#160;million as of December 31, 2022. The increase in 2023 mainly reflects cash outflows of </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8364;3,915&#160;million on the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">acquisitions of the newly-consolidated entities Provention Bio,&#160;Inc. and QRIB Intermediate Holdings, LLC and of &#8364;4,454&#160;million for the dividend payout to our shareholders, less the &#8364;8,478&#160;million of free cash flow generated in the year.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Net debt&#8221; is a non-IFRS financial measure which is reviewed by our management, and which we believe provides useful information to measure our overall liquidity and capital resources. We define &#8220;net debt&#8221; as (i)&#160;the sum total of long-term debt, short-term debt and current portion of long-term debt and interest rate and currency derivatives used to manage debt, minus (ii)&#160;the sum total of cash and cash equivalents and interest rate and currency derivatives used to manage cash and cash equivalents.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:70.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,347&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,857&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,531</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,218</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a) </span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(non- IFRS)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,793</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,437</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74,353&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gearing ratio (non-IFRS)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8.6</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.64pt">Net debt does not include lease liabilities, which amounted to &#8364;2,030&#160;million as of December&#160;31, 2023 and &#8364;2,181&#160;million as of December&#160;31, 2022.</span></div><div style="margin-top:1pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Net debt&#8221; is a non-IFRS financial measure used by management and investors to measure Sanofi&#8217;s overall net indebtedness.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To assess our financing risk, we use the &#8220;gearing ratio&#8221;, a non-IFRS financial measure. This ratio (which we define as the ratio of net debt to total equity) increased from 8.6% as of December&#160;31, 2022 to 10.5% as of December&#160;31, 2023. Analyses of debt as of&#160;December 31, 2023 and December 31, 2022, by type, maturity, interest rate and currency, are provided in Note&#160;D.17.1. to our consolidated financial statements, included at Item&#160;18. of this annual report.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We expect that the future cash flows generated by our operating activities will be sufficient to repay our debt. The financing arrangements in place as of December&#160;31, 2023 at the Sanofi parent company level are not subject to covenants regarding financial ratios and do not contain any clauses linking fees to Sanofi&#8217;s credit rating.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, we held 13.5&#160;million of our own shares, recorded as a deduction from equity and representing 1.06% of our share&#160;capital.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">76</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other intangible assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(&#8364;73,723&#160;million in total) rose by &#8364;2,191&#160;million. The year-on-year increase takes account of (i)&#160;the purchase price allocations relating to the acquisitions during the year of Provention Bio,&#160;Inc. and </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">QRIB Intermediate Holdings, LLC on </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">April&#160;27, 2023 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">September&#160;29, 2023, respectively (see Note&#160;D.1. to our consolidated financial statements, included at Item&#160;18. of this annual report on Form 20-F) and (ii)&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">the recognition of an asset corresponding to the additional US rights to BEYFORTUS (nirsevimab) acquired under the terms of the agreement reached between Sanofi and AstraZeneca in April 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see Note&#160;C.2. to our consolidated financial statements, included at Item&#160;18. of this annual report on Form 20-F). Those upward movements were partly offset by amortization and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">impairment charged during the period, and by movements in currency translation differences.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(&#8364;424&#160;million) decreased by &#8364;253&#160;million, mainly reflecting an impairment loss taken against the equity-accounted investment in EUROAPI to reflect the drop in the quoted market price of EUROAPI shares since March&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amounted to &#8364;3,218&#160;million, a year-on-year increase of &#8364;123&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net deferred tax assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> amounted to &#8364;4,570&#160;million as of December 31, 2023, versus &#8364;3,540&#160;million as of December 31, 2022, a year-on-year increase of &#8364;1,030&#160;million. This mainly reflects deferred taxes arising on the spread tax deduction of R&amp;D expenses, partly offset by deferred taxes arising from temporary differences related to investments in consolidated entities dedicated to our CHC business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (&#8364;7,602&#160;million) showed an increase of &#8364;1,261&#160;million, mainly due to the recognition of the financial liability in respect of royalties payable to Sobi on net sales of BEYFORTUS (nirsevimab) in the United-States (see Note C.2. to our consolidated financial statements).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were &#8364;70&#160;million lower year-on-year, at &#8364;709&#160;million.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_235"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3. Liquidity</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We expect that our existing cash resources and cash from operations will be sufficient to finance our foreseeable working capital requirements, in both the short term (i.e. the 12&#160;months following the year ended December&#160;31, 2023) and the long term (i.e.&#160;beyond such additional 12-month period). At year-end 2023, we held cash and cash equivalents amounting to &#8364;8,710&#160;million, substantially all of which were held in&#160;euros (see Note&#160;D.13. to our consolidated financial statements, included at Item&#160;18. of this annual report). As at December 31, 2023, &#8364;476 million of our cash and cash equivalents were held by captive insurance and reinsurance companies in accordance with insurance regulations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We run the risk of delayed payments or even non-payment by our customers, who consist principally of wholesalers, distributors, pharmacies, hospitals, clinics and government agencies (see &#8220;Item&#160;3. Key information &#8212; D.&#160;Risk Factors &#8212;&#160;2.&#160;Risks Relating to Our Business &#8212;&#160;We are subject to the risk of non-payment by our customers&#8221;). Deteriorating credit and economic conditions and other factors in some countries have resulted in, and may continue to result in an increase in the average length of time taken to collect our accounts receivable in these countries. Should these factors continue, it may require us to re-evaluate the collectability of these receivables in future periods. We carefully monitor sovereign debt issues and economic conditions and evaluate accounts receivable in these countries for potential collection risks. We have been conducting an active recovery policy, adapted to each country and including intense communication with customers, negotiations of payment plans, charging of interest for late payments, and legal action. Over our business as a whole, the amount of trade receivables overdue by more than 12&#160;months (which primarily consists of amounts due from public sector bodies) increased from &#8364;51&#160;million as of December&#160;31, 2022 to&#160;&#8364;81&#160;million as of December 31, 2023 (see Note&#160;D.10. to our consolidated financial statements included at Item&#160;18. of this annual report).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At year-end 2023, we had no commitments for capital expenditures that we consider to be material to our consolidated financial position. Undrawn confirmed credit facilities amounted to a total of &#8364;8,000&#160;million at December 31, 2023. For a discussion of our treasury policies, see &#8220;Item&#160;11. Quantitative and Qualitative Disclosures about Market Risk.&#8221;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We expect that cash from our operations will be sufficient to repay our debt. For a discussion of our liquidity risks, see&#160;&#8220;Item&#160;11.&#160;Quantitative and Qualitative Disclosures about Market Risk.&#8221;</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_238"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4. Off balance sheet arrangements/Contractual obligations and&#160;other commercial commitments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have various contractual obligations and other commercial commitments arising from our operations. Our contractual obligations and our other commercial commitments as of December 31, 2023 are shown in Notes&#160;D.3., D.17., D.18., and D.21. to our consolidated financial statements, included at Item&#160;18. of this annual report. Note&#160;D.21. to our consolidated financial statements included at Item&#160;18. of this annual report discloses details of commitments under our principal research and development collaboration agreements. For a description of the principal contingencies arising from certain business divestitures, refer to Note&#160;D.22.d.) to our 2023 consolidated financial statements included at Item&#160;18. of this annual report.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s contractual obligations and other commercial commitments are set forth in the table below.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">77</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;5. Operating and financial review and prospects</span></div></td></tr></table></div></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:47.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.162%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less than<br/>1 year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1 to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3 to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5 years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Future&#160;contractual cash flows&#160;relating&#160;to&#160;debt&#160;and&#160;debt hedging instruments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,853</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,200</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,154</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,044</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,455</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal payments related to lease liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,088</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">291</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">360</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">989</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other lease obligations (with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">221</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">25</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">146</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Irrevocable purchase commitments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">given</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,141</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,446</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,090</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">778</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">827</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">received</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(550)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(443)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(96)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research&#160;&amp; development license agreements</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Commitments related to R&amp;D and other commitments</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">381</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">256</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">101</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Potential milestone payments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,886</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">280</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,757</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">818</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,031</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Obligations relating to business combinations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">133</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">64</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Estimated benefit payments on unfunded pensions and post employment benefits</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,238</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">86</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">117</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">144</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">891</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total contractual obligations and other commitments</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32,391</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,209</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,661</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,173</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,348</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Undrawn general-purpose credit facilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;See Note&#160;D.17.1. to our consolidated financial statements, included at Item&#160;18. of this annual report.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;See Note&#160;D.17.2. to our consolidated financial statements, included at Item&#160;18. of this annual report.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;See Note&#160;D.21.1. to our consolidated financial statements, included at Item&#160;18. of this annual report.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;These comprise irrevocable commitments to suppliers of (i)&#160;property, plant and equipment, net of down payments (see Note&#160;D.3. to our consolidated financial statements, included at Item&#160;18. of this annual report) and (ii)&#160;goods and services.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;This line includes all milestone payments on projects regarded as reasonably possible, i.e. on projects in the development phase.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;See Note&#160;D.18. to our consolidated financial statements, included at Item&#160;18. of this annual report.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;See Note&#160;D.19.1. to our consolidated financial statements, included at Item&#160;18. of this annual report. The table above does not include ongoing annual employer&#8217;s contributions to plan assets, estimated at &#8364;86&#160;million for 2023.</span></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We may have payments due to our current or former research and development partners under collaboration agreements. These agreements typically cover multiple products, and give us the option to participate in development on a product-by-product basis. When we exercise our option with respect to a product, we pay our collaboration partner a fee and receive intellectual property rights to the product in exchange. We are also generally required to fund some or all of the development costs for the products that we select, and to make payments to our partners when those products reach development milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have entered into collaboration agreements under which we have rights to acquire products or technology from third parties through the acquisition of shares, loans, license agreements, joint development, co-marketing and other contractual arrangements. In addition to upfront payments on signature of the agreement, our contracts frequently require us to make payments contingent upon the completion of development milestones by our alliance partner or upon the granting of approvals or licenses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because of the uncertain nature of development work, it is impossible to predict (i)&#160;whether Sanofi will exercise further options for products, or (ii)&#160;whether the expected milestones will be achieved, or (iii)&#160;the number of compounds that will reach the relevant milestones. It is therefore impossible to estimate the maximum aggregate amount that Sanofi will actually pay in the future under existing collaboration agreements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Given the nature of its business, it is highly unlikely that Sanofi will exercise all options for all products or that all milestones will be achieved.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main collaboration agreements relating to development projects are described in Note&#160;D.21.1. to our consolidated financial statements, included at Item&#160;18. of this annual report. Milestone payments relating to development projects under these agreements included in the table above exclude projects still in the research phase (&#8364;16.8&#160;billion in 2023, and &#8364;18.0&#160;billion in 2022) and payments contingent upon the attainment of sales targets once a product is on the market (&#8364;17.9&#160;billion in 2023, and&#160;&#8364;18.5&#160;billion in 2022).</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_7107"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C. Research and development, patents and licenses, etc.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our research and development teams utilize our deep expertise to contribute to the growth of our business. As of December 31, 2023, we had 11,660 employees engaged in research and development activities. In the years ended December 31, 2021, 2022 and 2023 we spent &#8364;5,692, &#8364;2022 and &#8364;6,728 respectively, on research and development. For a discussion of our research and development activities, see &#8220;Item&#160;4.&#160;Information on the Company &#8212; B.&#160;Business Overview&#8221; and section &#8220;&#8212;&#160;Operating Results&#8221; above.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_7137"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D. Trend information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a discussion of trends, see &#8220;Item 4. Information on the Company &#8212;&#160;Business Overview&#8221; and sections &#8220;&#8212;&#160;Operating Results&#8221; and &#8220;&#8212;&#160;Liquidity and Capital Resources&#8221; above.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_7164"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E. Critical accounting estimates</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a discussion of our critical accounting estimates, see Note&#160;A.3 of our consolidated financial statements included in Item&#160;18 of this annual report.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">78</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_241"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;6. Directors, Senior Management and Employees</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_244"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.&#160;Directors and Senior Management</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since January&#160;1, 2007, Sanofi has separated the offices of Chairman and Chief Executive Officer. Annual evaluations conducted since that date have indicated that this governance structure is appropriate to Sanofi&#8217;s current configuration. When the term of office of Serge Weinberg as Chairman ended, our Board of Directors decided to continue separating the offices of Chairman and Chief Executive Officer. The Board believes this governance structure is still appropriate to the current context in which Sanofi operates and its share ownership structure, as well as protecting the rights of all of its stakeholders.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Chairman</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> organizes and directs the work of the Board, and is responsible for ensuring the proper functioning of the corporate decision-making bodies in compliance with good governance principles. The Chairman coordinates the work of the Board of Directors with that of its Committees. He ensures that the Company&#8217;s management bodies function properly, and in particular that the directors are able to fulfil their duties. The Chairman is accountable to the Shareholders&#8217; General Meeting, which he chairs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition to these roles conferred by law, the Chairman:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in coordination with the Chief Executive Officer, liaises between the Board of Directors and the shareholders of the Company;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is kept regularly informed by the Chief Executive Officer of significant events and situations affecting the affairs of the Company, and may request from the Chief Executive Officer any information useful to the Board of Directors;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">may, in close collaboration with the Chief Executive Officer, represent the Company in high-level dealings with governmental bodies and with key partners of the Company and/or of its subsidiaries, both nationally and internationally;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">seeks to prevent any conflict of interest and manages any situation that might give rise to a conflict of interest. He also gives rulings, in the name of the Board, on requests to take up external directorships of which he may become aware or that may be submitted to him by a director;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">may interview the statutory auditors in preparation for the work of the Board of Directors and the Audit Committee; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">strives to promote in all circumstances the values and image of the Company.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chairman is also required to develop and maintain a proper relationship of trust between the Board and the Chief Executive Officer, so as to ensure that the latter consistently and continuously implements the orientations determined by the Board.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In fulfilling his remit, the Chairman may meet with any individual, including senior executives of the Company, while avoiding any involvement in directing the Company or managing its operations, which are exclusively the responsibility of the Chief Executive Officer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, the Chairman reports to the Board on the fulfilment of his remit.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chairman carries out his duties during the entire period of his term of office, subject to the caveat that a director who is a natural person may not be appointed or reappointed once that director has reached the age of&#160;70.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Chief Executive Officer</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> manages the Company, and represents it in dealings with third parties within the limit of the corporate purpose. The Chief Executive Officer has the broadest powers to act in all circumstances in the name of the Company, subject to the powers that are attributed by law to the Board of Directors and to the Shareholders&#8217; General Meeting and within the limits set by the Board of Directors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chief Executive Officer must be less than 65&#160;years old.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">79</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Limitations on the powers of the Chief Executive Officer set by&#160;the&#160;Board</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The limitations on the powers of the Chief Executive Officer are specified in the Board Charter. Without prejudice to legal provisions regarding authorizations that must be granted by the Board (regulated agreements, guarantees, divestments of equity holdings or real estate,&#160;etc.), prior approval from the Board of Directors is required for transactions or decisions resulting in an investment or divestment, or an expenditure or guarantee commitment, made by the Company and its subsidiaries, in excess of:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a cap of &#8364;500&#160;million (per transaction) for transactions, decisions or commitments pertaining to a previously approved strategy; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a cap of &#8364;150&#160;million (per transaction) for transactions, decisions or commitments not pertaining to a previously approved strategy.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When such transactions, decisions or commitments give rise to installment payments to the contracting third party (or parties) that are contingent upon future results or objectives, such as the registration of one or more products, attainment of the caps is calculated by aggregating the various payments due from the signing of the contract until (and including) the filing of the first application for marketing authorization in the United States or in Europe.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Attainment of the above caps is also assessed after taking into account all commitments to make payments upon exercising a firm or conditional option with immediate or deferred effect, and all guarantees or collateral to be provided to third parties over the duration of such commitments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The prior approval procedure does not apply to transactions and decisions that result in the signature of agreements that solely involve subsidiaries and the Company itself.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Remit of the Board of Directors</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors establishes the orientation of the Company&#8217;s activities and ensures that they are implemented, paying due consideration to social and environmental issues. Subject to those powers expressly attributed to Shareholders&#8217; General Meetings and within the limits set by the corporate purpose, the Board addresses any issue of relevance to the proper conduct of the Company&#8217;s affairs and, through its deliberations, settles matters concerning the Company.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">French law, Articles of Association and Board Charter</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The rules and operating procedures of our Board of Directors are defined by French law, by our Articles of Association, and by our Board&#160;Charter (English language versions of which are reproduced in full as Exhibit&#160;1.1 and Exhibit&#160;1.2 to this annual report).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Board Charter describes the rights and obligations of Board members; the composition, role and operating procedures of the Board of Directors and Board Committees; and the roles and powers of the Chairman and the Chief Executive Officer. It is prepared in accordance with the French Commercial Code and our Articles of Association.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">80</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Composition of the Board of Directors</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 our Board of Directors had 16&#160;directors, including 11&#160;independent directors and two directors representing employees. 43% of the directors (excluding directors representing employees, in accordance with regulations) are women, and 50% of the directors (including directors representing employees) are non-French nationals.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.313%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.187%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gender</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nationality</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">directorships</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">in listed</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">companies</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Independent</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">First<br/>appointed</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Term<br/>expires</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years<br/>of Board<br/>service</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">AGC</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CC</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SC</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SciC</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fr&#233;d&#233;ric Oud&#233;a, Chairman of the Board</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">French</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yes</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2023</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2027 AGM</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">C</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Paul Hudson, Chief Executive Officer</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">British</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">70,805 </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2026&#160;AGM</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Christophe Babule</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">French</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">No </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2026&#160;AGM</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Rachel Duan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Chinese</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2024 AGM</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Carole Ferrand</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">French</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2025 AGM</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lise Kingo</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Danish</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2024 AGM</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Patrick Kron</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">French</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2026&#160;AGM</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">C</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Wolfgang Laux</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">German</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2025 AGM</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Barbara Lavernos</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">French</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2025 AGM</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fabienne Lecorvaisier</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">French</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2025 AGM</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">C</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gilles Schnepp</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">French</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2026&#160;AGM</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">C</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Diane Souza</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">American</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,244</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2024 AGM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Thomas S&#252;dhof</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">American/<br/>German</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2024 AGM</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">C</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yann Tran</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">French</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2025 AGM</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Emile Voest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Dutch</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2025 AGM</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Antoine Yver</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">French/American/Swiss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2025 AGM</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Independent directors</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.22pt;font-weight:700;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(f)</span></div></td><td colspan="12" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Female directors</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.22pt;font-weight:700;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(e)</span></div></td><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-French&#160;directors</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#21004c;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">79%</span></td><td colspan="12" style="background-color:#21004c;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">43%</span></td><td colspan="15" style="background-color:#21004c;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">50%</span></td><td colspan="3" style="background-color:#21004c;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">AC:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Audit Committee.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">AGC:&#160;&#160;&#160;&#160;Appointments, Governance and Corporate Social Responsability (CSR) Committee.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">CC:&#160;&#160;&#160;&#160;Compensation Committee.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">SC:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Strategy Committee.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">SciC:&#160;&#160;&#160;&#160;Scientific Committee.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">C:&#160;&#160;&#160;&#160;Chairman/Chairwoman.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">M:&#160;&#160;&#160;&#160;Member.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes all non-executive and executive (and equivalent) directorships held in listed companies. The office held within Sanofi is included.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Fr&#233;d&#233;ric Oud&#233;a was initially appointed as a non-voting director by the Board on September&#160;2, 2022, and then appointed as a director by the Annual General Meeting on May&#160;25, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;Amount including shares definitively granted to Paul Hudson in May 2023 pursuant to the long-term incentive plan dated April 28, 2020</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) This table only refers to independence as defined under the AFEP-MEDEF Code. However, Christophe Babule is independent for the purposes of the NASDAQ Listing Rules and Rule 10A-3 under the Exchange Act. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)  Director representing employees.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Directors representing employees are not taken into consideration for the calculation of these percentages, in accordance with regulation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In line with current legislation and given that less than 3% of our share capital is owned by our employees, Sanofi does not have a director representing its employee shareholders.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">81</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Term of Office</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The term of office of directors is four years. Directors are required to seek reappointment by rotation, such that members of the Board are required to seek reappointment on a regular basis in the most equal proportions possible. Exceptionally, the Shareholders&#8217; Ordinary General Meeting may appoint a director to serve for a term of one, two or three years, in order to ensure an adequate rotation of Board members. Each director standing down is eligible for reappointment. Should one or more directorships fall vacant as a result of death or resignation, the Board of Directors may make provisional appointments in the period between two Shareholders&#8217; General Meetings, in accordance with applicable laws.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Directors may be removed from office at any time by a Shareholders&#8217; General Meeting.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A natural person cannot be appointed or reappointed as a director once he or she reaches the age of&#160;70. As soon as the number of directors over the age of&#160;70 represents more than one-third of the directors in office, the oldest director shall be deemed to have resigned; his or her term of office shall end at the date of the next Shareholders&#8217; Ordinary General Meeting.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Changes in the composition of the Board of Directors during 2022 and 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows changes in the composition of the Board of Directors during 2022 and 2023:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual&#160;General&#160;Meeting <br/>of May&#160;3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual General Meeting <br/>of May&#160;25, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">End of term of office</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Melanie Lee</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carole Piwnica</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Serge Weinberg</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Renewal of term of office</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Paul Hudson <br/>Christophe Babule<br/>Patrick Kron<br/>Gilles Schnepp</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proposed new appointments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carole Ferrand</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emile Voest</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Antoine Yver</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fr&#233;d&#233;ric Oud&#233;a</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Co-opted</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">None</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Melanie Lee and Carole Piwnica </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">left the Board of Directors before the General Meeting of May&#160;3, 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The term of office of Serge Weinberg expired at the Annual General Meeting held to approve the financial statements for the year ended December&#160;31,&#160;2022, and could not be renewed (see below). Acting on a recommendation from the Appointments, Governance and CSR Committee, the Board of Directors appointed Fr&#233;d&#233;ric Oud&#233;a as a non-voting member of the Board on September&#160;2, 2022. The Board meeting of February&#160;22, 2023 decided to ask the Annual General Meeting of May&#160;25, 2023 to approve the appointment of Fr&#233;d&#233;ric Oud&#233;a as an independent director, to replace Serge Weinberg.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The term of office of Serge Weinberg expired at the Annual General Meeting of May&#160;25, 2023, which approved the appointment of Fr&#233;d&#233;ric Oud&#233;a as his successor. The Board then appointed Fr&#233;d&#233;ric Oud&#233;a as Chairman.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">That appointment brought to the Board Fr&#233;d&#233;ric Oud&#233;a&#8217;s:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">experience from senior executive roles in international groups;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">experience from Board membership in international groups; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">competencies in finance and accounting.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Following his appointment, the proportion of independent directors increased from 71% to 79%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For further information about the career of Fr&#233;d&#233;ric Oud&#233;a, refer to his biographical details later in this section</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Changes in Board membership to be submitted for shareholder approval at the Annual General Meeting on April 30, 2024</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:69.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expiry of term of office</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diane Souza</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thomas S&#252;dhof</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reappointments</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rachel Duan<br/>Lise Kingo</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proposed appointments</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Clotilde Delbos</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Anne-Fran&#231;oise Nesmes</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">John Sundy</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Co-opted</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">None</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">None</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Diane Souza's term of office cannot be renewed because she will be over the age limit set in our Articles of Association.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">82</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The terms of office of Rachel Duan, Lise Kingo, Diane Souza and Thomas Sudh&#246;f will expire at the Annual General Meeting to be held on April&#160;30, 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Annual General Meeting will be asked to:</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">renew the terms of office of:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">Rachel Duan &#8211; refer to &#8220;&#8212;&#160;Detailed Information about Members of the Board of Directors&#8221; for her biographical details, and to &#8220;&#8212;&#160;Competencies of Board Members&#8221; below for details of what she brings to the Board,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">Lise Kingo &#8211; refer to &#8220;&#8212;&#160;Detailed Information about Members of the Board of Directors&#8221; for her biographical details, and to &#8220;&#8212;&#160;Competencies of Board Members&#8221; below for details of what she brings to the Board;</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">appoint three independent directors, who would bring the following competencies to the Board:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">Clotilde Delbos: Senior executive role in international groups, Board membership in international groups, International experience, Mergers &amp; acquisitions, Finance &amp; accounting;</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">Anne-Fran&#231;oise Nesmes: Healthcare/pharmaceutical industry experience, Senior executive role in international groups, Board membership in international groups, International experience, Mergers &amp; acquisitions, Finance &amp; accounting; and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">John Sundy: Scientific training, Board membership in international groups.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to optimize preparations for the expiry in 2025 of the term of office of Fabienne Lecorvaisier, Chair of the Audit Committee, our Board of Directors would temporarily have 17&#160;members with effect from the Annual General Meeting of April&#160;30,&#160;2024.</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Rules relating to the composition of the Board and its Committees</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Each year, the Board of Directors conducts a review to ensure that there is an appropriate balance in its composition and in the composition of its Committees. In particular, the Board seeks gender balance and a broad diversity of competencies, experiences, nationalities and ages, reflecting our status as a diversified global business. The Board investigates and evaluates not only potential candidates, but also whether existing directors should seek reappointment. Above all, the Board seeks directors who show independence of mind and are competent, dedicated and committed, with compatible and complementary personalities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acting on proposals from the Chief Executive Officer and in liaison with the Appointments, Governance and CSR Committee, the Board sets objectives for gender balance on Sanofi&#8217;s executive bodies, and more generally ensures that an inclusion (non-discrimination) and diversity policy is applied within the Company. That policy is fully embedded in our Play to Win strategy. As of December&#160;31, 2023, 25% of the 12 Executive Committee members were women, and 67% were non-French nationals.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors is also kept informed, in particular on the occasion of its annual discussion on its equal opportunity and equal pay policy, on how Sanofi&#8217;s inclusion and diversity policy is cascaded down to &#8220;Senior Leaders&#8221; and &#8220;Executives&#8221; (the positions in Sanofi with the highest level of responsibility).</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">83</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Competencies of Board members</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors, in liaison with the Appointments, Governance and CSR Committee, must ensure that the composition of the Board is balanced, diverse and fit for purpose.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In assessing its composition, the Board takes account of the new challenges facing Sanofi and our corporate strategy, and determines whether the qualities and skills of serving directors are sufficient for the Board to deliver on its remit.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In recent years, the Board has adapted its composition in line with its roadmap by bringing additional scientific expertise onto the Board and maintaining the level of other key competencies, especially in finance and accounting.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board has completed an overview of the Board&#8217;s current competencies. The matrix below</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> shows a comprehensive, balanced spread of the types of competencies required, both in general terms and by reference to our strategic ambitions (the matrix shows the number of directors possessing each of those competencies)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:16.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.926%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Scientific training</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Healthcare/pharmaceutical industry experience</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Senior executive role in international group</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Board membership in international group</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International experience</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Mergers &amp; Acquisitions</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Finance/Accounting</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g5.gif" alt="Formation-scientif_blanc.gif" style="height:18px;margin-bottom:5pt;vertical-align:text-bottom;width:18px"/></div></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g6.gif" alt="Exp-sante-pharma_blanc.gif" style="height:18px;margin-bottom:5pt;vertical-align:text-bottom;width:18px"/></div></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g7.gif" alt="Dir-groupes-inter_blanc.gif" style="height:18px;margin-bottom:5pt;vertical-align:text-bottom;width:18px"/></div></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g8.gif" alt="Membres-conseil-admin_blanc.gif" style="height:18px;margin-bottom:5pt;vertical-align:text-bottom;width:18px"/></div></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g9.gif" alt="Exp-intern_blanc.gif" style="height:18px;margin-bottom:5pt;vertical-align:text-bottom;width:18px"/></div></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g10.gif" alt="Fusion-acquis_blanc.gif" style="height:18px;margin-bottom:5pt;vertical-align:text-bottom;width:18px"/></div></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g11.gif" alt="Finance-compta_blanc.gif" style="height:18px;margin-bottom:5pt;vertical-align:text-bottom;width:18px"/></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fr&#233;d&#233;ric Oud&#233;a</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Paul Hudson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Christophe Babule</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rachel Duan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carole Ferrand</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lise Kingo</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patrick Kron</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Barbara Lavernos</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabienne Lecorvaisier</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gilles Schnepp</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diane Souza</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thomas S&#252;dhof</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emile V&#339;st</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Antoine Yver</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% coverage for each competency</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21%</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">36%</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">79%</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">50%</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">71%</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43%</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43%</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Based on the composition of the Board as of February 22, 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The information shown excludes directors representing employees.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It was not considered appropriate to include CSR as a specific component of the competencies matrix. CSR is a broad field that encompasses a wide variety of knowledge, competencies and experience, some of which is highly technical; thus it was not practicable to attribute overall competence in CSR to one or more of our directors. All members of our Board are in practice engaged with CSR issues, and have complementary skills and experience in the field, for example (non-exhaustive list):</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Christophe Babule, as CFO of L&#8217;Or&#233;al, is in charge of financing the L&#8217;Or&#233;al group&#8217;s sustainable transition. He is also a director of the L&#8217;Or&#233;al for Women endowment fund;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Lise Kingo holds a Master's degree in Responsibility &amp; Business Practice from the University of Bath in the United Kingdom. She was Professor of Sustainability and Innovation at the Vrije Universiteit Amsterdam (The Netherlands) from&#160;2006 to&#160;2015, and in parallel held various CSR-related positions including Director of Environmental Affairs at Novozymes and Executive Vice President, Corporate Relations at Novo Nordisk, before becoming CEO &amp; Executive Director of the United Nations Global Compact from 2015 to 2020 &#8211; a key role at the Paris COP21 climate change conference in 2015;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Barbara Lavernos was appointed Vice-Chair of the L'Or&#233;al Climate Emergency Fund, to support vulnerable communities to develop greater resilience in the face of climate disasters created in September 2023;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Fabienne Lecorvaisier has experience as Executive Vice President of Air Liquide with responsibility for sustainable development, public and international affairs, along with experience acquired through her involvement in societal programs such as the Air Liquide Foundation and Inclusive Business; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Gilles Schnepp led Legrand&#8217;s CSR policy as Chairman and CEO from&#160;2006 to&#160;2018, and since March&#160;2021 has been Chairman of the Board of Directors of Danone, a </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233; &#224; mission</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (social purpose company). He also chaired the Ecological and Economic Transition Commission of MEDEF (the French employer&#8217;s federation) from 2018 to 2021.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">84</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since 2018, when the remit of our Appointments and Governance Committee was extended to include CSR, our in-house CSR team has been updating Committee members on specific CSR issues on an as-needed basis. In addition, a progress report on our CSR strategy (established in 2021) is included as a Board agenda item on an annual basis. The report is presented by our Head of CSR, who is available to answer questions &#8211;&#160;including on technical issues&#160;&#8211; and inform the Board about each of the key CSR issues specific to Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The number of meetings of the Appointments, Governance and CSR Committee has increased from 2023 onwards (five meetings in the year, versus three in 2022), so that the Committee can look in greater depth at each pillar of our CSR strategy; a CSR update is included on the agenda for every meeting. There are also regular updates on extra-financial ratings and regulatory changes.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Director Training</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No training was provided to Board members during 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board meeting of October&#160;26, 2023 considered the training needs of directors and agreed on a training plan for 2024 that will include modules on CSR, cybersecurity, and AI. </span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Independence of Board Members</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the AFEP-MEDEF Code, a director is independent when he or she has no relationship of any kind whatsoever with the Company, its group or its senior management that may color his or her judgment. More specifically, a director can only be regarded as independent if he or she:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is not (and has not been during the past five years):</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">an employee or executive officer of the Company,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">an employee, executive officer or director of an entity consolidated by the Company, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">an employee, executive officer or director of the Company&#8217;s parent, or of an entity consolidated by that parent (criterion&#160;1);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is not an executive officer of an entity in which (i)&#160;the Company directly or indirectly holds a directorship or (ii)&#160;an employee of the Company is designated as a director or (iii)&#160;an executive officer of the Company (currently, or who has held office within the past five&#160;years) holds a directorship (criterion&#160;2);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is not a customer, supplier, investment banker or corporate banker that is material to the Company or its group, or for whom the Company or its group represents a significant proportion of its business (criterion&#160;3);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">has no close family ties with a corporate officer of the Company (criterion&#160;4);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">has not acted as an auditor for the Company over the course of the past five years (criterion&#160;5);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">has not been a director of the Company for more than 12&#160;years (criterion&#160;6);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">does not receive variable compensation in cash or in the form of shares or any compensation linked to the performance of the Company or its group (criterion&#160;7); or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">does not represent a shareholder that has a significant or controlling interest in the Company (criterion&#160;8).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The influence of other factors such as the ability to understand challenges and risks, and the courage to express ideas and form a judgment, is also evaluated before it is decided whether a director can be regarded as independent.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with our Board Charter and pursuant to the AFEP-MEDEF Code, the Board of Directors&#8217; meeting of February&#160;22,&#160;2024 discussed the independence of the current directors. Of the 16&#160;directors in office on that date, 11&#160;were deemed to be independent directors by reference to the independence criteria used by the Board of Directors pursuant to the AFEP-MEDEF Code: Fr&#233;d&#233;ric Oud&#233;a, Rachel Duan, Carole Ferrand, Lise&#160;Kingo, Patrick Kron, Fabienne Lecorvaisier, Gilles Schnepp, Diane Souza, Thomas S&#252;dhof, Emile Voest and Antoine Yver.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with the rules described above, Paul Hudson (who is an executive director of Sanofi), and Barbara Lavernos and Christophe&#160;Babule </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(who were appointed on the recommendation of L&#8217;Or&#233;al, a major shareholder of Sanofi), are not deemed independent.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, the proportion of independent directors is 79%. This complies with the AFEP-MEDEF recommendation of at least&#160;50% in companies with dispersed ownership and no controlling shareholder (which is the case for Sanofi). In accordance with the recommendations of the AFEP-MEDEF Code, directors representing employees and elected by trade unions are excluded when calculating the proportion of independent directors.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">85</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:23.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.272%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fr&#233;d&#233;ric Oud&#233;a</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Paul Hudson</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Christophe Babule</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rachel Duan</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carole Ferrand</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lise Kingo</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patrick Kron</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Barbara Lavernos</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabienne Lecorvaisier</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gilles Schnepp</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diane Souza</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thomas S&#252;dhof</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emile Voest</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Antoine Yver</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Criterion&#160;1:&#160;</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">not&#160;an employee/executive officer&#160;in&#160;past&#160;5&#160;years</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NO</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Criterion&#160;2:&#160;</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">n</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o&#160;cross-directorships</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Criterion 3: </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">no significant business relationship </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Criterion 4: </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">no close family ties</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Criterion&#160;5: </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">not an auditor</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Criterion&#160;6: </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">not held office for &gt;&#160;12&#160;years</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Criterion&#160;7: </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">no variable or performance-linked compensation</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Criterion&#160;8: </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">not a significant&#160;</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">shareholder</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NO</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deemed independent</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NO</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NO</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NO</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">YES</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This table only refers to independence as defined under the AFEP-MEDEF Code. However, Christophe Babule is independent for the purposes of the NASDAQ Listing Rules and Rule 10A-3 under the Exchange Act.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Failure to fulfil one of the criteria does not automatically disqualify a director from being independent.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In assessing the criterion related to significant business relationships (criterion&#160;3), the Board of Directors took into account the various relationships between directors and Sanofi and concluded that no relationships were of a kind that might undermine their independence. The Board of Directors noted that the Company and its subsidiaries had, in the normal course of business, over the past three years, sold products and provided services to, and/or purchased products and received services from, companies in which certain of the Company&#8217;s directors who are classified as independent (or their close family members) were senior executives or employees during&#160;2023. In each case, the amounts paid to or received from such companies over the past three years were determined on an arm&#8217;s length basis and not at amounts that the Board regarded as undermining the independence of the directors in question.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">86</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Selection Process for Board members</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Appointments, Governance and CSR Committee has a remit to organize a procedure for selecting future independent directors. Once the desired profile and skillset for a new director has been defined, a search for potential candidates is conducted by external consultants.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Once a shortlist has been established, the Committee interviews two or three candidates. The candidates also meet with the Chairs of the other Board committees, and in some cases the other Committee members as well. In all cases, they meet with the Chairman of the Board of Directors and the Chief Executive Officer. After completing the interviews, the Committee makes a recommendation to the Board on the candidate with the best fit for the profile, supporting that recommendation with an explanation of how the interviews were conducted and giving reasons why a candidate was selected. Before recommending a candidate to the Board, the Committee obtains assurance as to their availability, in particular as regards any other executive posts or offices the candidate may hold.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of selection process for Board members</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.898%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#b38ef4;padding:0 1pt"/><td colspan="3" style="background-color:#b38ef4;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Definition of profile and skillset</span></td><td colspan="3" style="background-color:#b38ef4;padding:0 1pt"/><td colspan="3" style="background-color:#8c56ee;padding:0 1pt"/><td colspan="3" style="background-color:#8c56ee;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-selection</span></div></td><td colspan="3" style="background-color:#8c56ee;padding:0 1pt"/><td colspan="3" style="background-color:#4c16ae;padding:0 1pt"/><td colspan="3" style="background-color:#4c16ae;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selection</span></td><td colspan="3" style="background-color:#4c16ae;padding:0 1pt"/><td colspan="3" style="background-color:#330e74;padding:0 1pt"/><td colspan="3" style="background-color:#330e74;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Appointment</span></td><td colspan="3" style="background-color:#330e74;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Independent directors</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-left:1pt solid #b38ef4;border-top:1pt solid #b38ef4;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Appointments, Governance &amp; CSR Committee defines the profile and skillset</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #b38ef4;padding:0 1pt"><span style="font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><br/></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-left:1pt solid #8c56ee;border-top:1pt solid #8c56ee;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Appointments, Governance &amp; CSR Committee pre-selects three potential candidates from a long-list suggested by external consultants</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #8c56ee;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-left:1pt solid #4c16ae;border-top:1pt solid #4c16ae;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Some or all Committee members interviews two or three short-listed candidates</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #4c16ae;padding:0 1pt"><span style="font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><br/></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-left:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Appointments, Governance &amp; CSR Committee recommends a candidate, and explains the reasons for its recommendation</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #23004c;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #b38ef4;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #b38ef4;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #8c56ee;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #8c56ee;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #4c16ae;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #4c16ae;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #23004c;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #23004c;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #b38ef4;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #8c56ee;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #4c16ae;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Directors representing employees</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" rowspan="4" style="border-left:1pt solid #23004c;border-top:1pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:14.17pt;text-indent:-14.18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6.8pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.8pt;font-weight:400;line-height:120%;padding-left:11.86pt">One Director representing employees is designated by the trade union body which is the most representative, in the Company and those of its direct or indirect subsidiaries that have their registered office in French territory, </span></div><div style="padding-left:14.17pt;text-indent:-14.18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6.8pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.8pt;font-weight:400;line-height:120%;padding-left:11.86pt">One Director representing employees is  designated by the European Works Council</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #23004c;padding:0 1pt"/></tr><tr style="height:39pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="21" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #23004c;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #23004c;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #23004c;padding:0 1pt"/></tr><tr style="height:48pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-right:1pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #23004c;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Succession&#160;planning</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General principles</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The remit of the Appointments, Governance and CSR Committee includes preparing for the future of the Company&#8217;s executive bodies, in particular through the establishment of a succession plan for executive officers.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The succession plan, which is reviewed at meetings of the Appointments, Governance and CSR Committee, addresses various scenarios:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">unplanned vacancy due to prohibition, resignation or death;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">forced vacancy due to poor performance, mismanagement or misconduct; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">planned vacancy due to retirement or expiration of term of office.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Through its work and discussions, the Committee seeks to devise a succession plan that is adaptable to situations arising in the short, medium or long term, but which also builds in diversity &#8211;&#160;in all its facets&#160;&#8211; as a key factor.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To fulfill its remit, the Appointments, Governance and CSR Committee:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">provides the Board with progress reports, in particular at executive sessions;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">co-ordinates with the Compensation Committee. In that regard, having a director that sits on both Committees is a great advantage;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">works closely with the Chief Executive Officer to (i)&#160;ensure the succession plan is consistent with the Company&#8217;s own practices and market practices, (ii)&#160;ensure high-potential internal prospects receive appropriate support and training, and (iii)&#160;check there is adequate monitoring of key posts likely to fall vacant;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">meets with key executives as needed; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">involves the Chairman and the Chief Executive Officer insofar as each has a key role in planning for his own successor, though without them directing the process.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">87</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In fulfilling their remit, Committee members are acutely conscious of confidentiality issues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Although aware that separating the offices of Chairman and Chief Executive Officer provides continuity of power, the Committee nonetheless assesses the situation of the Chairman as well as that of the executive team.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Succession planning for the Chief Executive Officer is also reviewed regularly by the Appointments, Governance and CSR Committee.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of the Board and its Committees</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the Board Charter, and in accordance with the AFEP-MEDEF code, a discussion of the operating procedures of the Board and its committees must be included on the agenda of one Board meeting every year. The Charter also requires a formal evaluation to be performed at least every three years under the direction of the Appointments, Governance and CSR Committee, with assistance from an independent consultant.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In practice, even in years when the three-yearly formal evaluation procedure (assisted by an independent consultant) is not conducted, an annual internal evaluation is conducted using a detailed questionnaire sent to directors by the Secretary to the Board, and covering the composition and the operation of the Board and its committees.  Each director is allowed a few weeks to complete the questionnaire using a secure digital platform. At the end of that period, the responses (which are confidential) are analyzed by the Secretary to the Board. The results are then presented and discussed at a meeting of the Appointments, Governance and CSR Committee; the detailed report prepared for that meeting is then submitted to a Board meeting at the start of the following year.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, as reported in our annual report for 2022, from 2023 onwards the evaluation procedure also includes one-on-one interviews with each director (including the Chief Executive Officer), intended to measure the contribution of each director to the work of the Board and its committees and to record any suggestions they may have. The interviews are conducted by the Chairman of the Board, and a summary of the key points is provided to each director.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The most recent &#8220;formal&#8221; evaluation conducted with the assistance of an independent consultant took place in 2021 under the direction of the Appointments, Governance and CSR Committee.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, the evaluation was conducted internally via questionnaire (as described above).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The results of the 2023 evaluation were presented and discussed at a meeting of the Appointments, Governance and CSR Committee. The detailed report prepared for that meeting was then submitted to the Board meeting of February&#160;22, 2024.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Detailed information about Board members</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following pages provide key information about each director individually:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">directorships and appointments held during 2023 (directorships in listed companies are indicated by an asterisk, and each director&#8217;s principal position is indicated in bold);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">other directorships held during the last five years;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">training and professional experience; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">competencies.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">88</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_247"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fr&#233;d&#233;ric Oud&#233;a </span></div></td></tr><tr style="height:17pt"><td colspan="3" rowspan="6" style="padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g12.jpg" alt="DOT_ADMIN_23.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Date of birth: July&#160;3, 1963 (aged&#160;60)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Nationality: French</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">First appointed: May&#160;2023</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Term expires: 2027</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 1,000</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.514%"><tr><td style="width:1.0%"/><td style="width:48.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.593%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chairman of the Board of Directors</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairman of the Strategy Committee</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Appointments, Governance and CSR Committee</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Scientific Committee</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Lead independent Director of Capgemini*</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Supervisory Board of Sonic Topco, non-listed simplified joint stock company </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:130%">(soci&#233;t&#233; par actions simplifi&#233;e)</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%"> registered in France - since February 1, 2024</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chairman of Foundation S</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:130%">In Foreign companies</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Sienna Investment managers, non-listed company incorporated under Luxembourg law,  since December 11, 2023</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Board member of ALD Automotive*</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Graduate of ENA (</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:130%">&#201;cole Nationale d'Administration</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Degree from </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:130%">&#201;cole Polytechnique</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since November 2023</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Senior Executive Advisor of Bruxelles Lambert Group*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since May 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chairman of the Board of Directors of Sanofi*</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since February 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Board member of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">&#201;cole Polytechnique</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since January 2022</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chairman of the </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">&#201;cole Polytechnique</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> Foundation</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2015-2023</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chief Executive Officer of Soci&#233;t&#233; G&#233;n&#233;rale*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2009-2015</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chief Executive Officer and Chairman of the Board of Soci&#233;t&#233; G&#233;n&#233;rale*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2008-2009</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chief Executive Officer of Soci&#233;t&#233; G&#233;n&#233;rale*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2003-2008</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Group Chief Financial Officer of Soci&#233;t&#233; G&#233;n&#233;rale*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2002-2003</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Deputy Group Chief Financial Officer of Soci&#233;t&#233; G&#233;n&#233;rale*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1998-2002</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Head of global supervision and development of the Equity Department of Soci&#233;t&#233; G&#233;n&#233;rale*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1995-1998</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Assistant Manager, then Manager of the Corporate Banking department in London at Soci&#233;t&#233; G&#233;n&#233;rale*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1987-1995</span></div></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various positions within the Administration (General Inspectorate of Finance Service, Ministry of the Economy and Finance, Ministry of the Budget and Office of the Minister of Budget and Communication)</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.514%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Senior executive role in international groups, Board membership in international groups, Finance/Accounting</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">89</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_250"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Paul Hudson</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="7" style="padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g13.jpg" alt="DOT_ADMIN11.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Date of birth: October&#160;14, 1967 (aged&#160;56)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Nationality: British</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">First appointed: September&#160;2019</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Last reappointment: May&#160;2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Term expires: 2026</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 70,805 </span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.365%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chief Executive Officer </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></div></td></tr><tr style="height:11pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairman of the Executive Committee </span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director </span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Strategy Committee </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Degree in economics from Manchester Metropolitan University, UK</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Diploma in marketing from the Chartered Institute of Marketing, UK</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Honorary Doctorate in Business Administration, Manchester Metropolitan University, UK</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">From September&#160;1, 2019</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chief Executive Officer of Sanofi*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2016-2019</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CEO of Novartis Pharmaceuticals*, member of Executive Committee</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2006-2016</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various operational and managerial positions at AstraZeneca* (including President, AstraZeneca US; Executive Vice President, North America; Representative Director &amp; President, AstraZeneca KK, Japan; President of AstraZeneca Spain; and Vice-President and head of Primary Care United Kingdom)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Before 2006</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various operational and managerial positions at Schering-Plough, including Head of Global Marketing for biologicals.</span></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various sales and marketing positions at GlaxoSmithKline* UK and Sanofi-Synth&#233;labo UK</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Healthcare/pharmaceutical industry experience, Senior executive role in international group, International experience, Mergers &amp; acquisitions</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">90</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_253"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Christophe Babule</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="7" style="padding:0 1pt"><div><img src="sny-20231231_g14.jpg" alt="DOT_ADMIN3.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Date of birth: September&#160;20, 1965 (aged&#160;58)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Nationality: French</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">First appointed: February&#160;2019</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Last reappointment: May 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Term expires: 2026</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 1,000</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.365%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Director </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Audit Committee</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of the &#8220;L'Or&#233;al Fund for Women&#8221; charitable endowment fund</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:130%">L'Or&#233;al* Group:</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of L'Or&#233;al US Inc. (United States) </span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">MBA, HEC School of Management</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since February&#160;2019</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chief Financial Officer at L'Or&#233;al*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 1988</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various positions within the L&#8217;Or&#233;al* Group, including as Director of Administration &amp; Finance for China, then Mexico; Director of Internal Audit; and Administration &amp; Financial Director for the Asia Pacific Zone</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Senior executive role in international groups, International experience, Mergers &amp; acquisitions, Finance/Accounting, CSR</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">91</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_256"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Rachel Duan</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="6" style="padding:0 1pt"><div><img src="sny-20231231_g15.jpg" alt="DOT_ADMIN12.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Date of birth: July&#160;25, 1970 (aged&#160;53)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Nationality: Chinese</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">First appointed: April&#160;2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Term expires: 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 1,000</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.365%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Compensation Committee </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of AXA*</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of HSBC*</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Adecco Group*</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">MBA, University of Wisconsin-Madison (United States)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Bachelor&#8217;s degree in Economics and International Trade, Shanghai International Studies University (China)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since September 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent Director, HSBC*</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since April 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent Director, Adecco Group*</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since April 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent Director, AXA*</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1996-2020</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior Vice President of General Electric* (United States) and President &amp; CEO of GE Global Markets (China)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:107%">Healthcare/pharmaceutical industry experience, Senior executive role in international groups</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%">, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:107%">Board membership in international groups, International experience</span></div></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">92</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_259"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carole Ferrand</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="6" style="padding:0 1pt"><div><img src="sny-20231231_g16.jpg" alt="DOT_ADMIN17.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Date of birth: April&#160;2, 1970 (aged&#160;53)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Nationality: French</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">First appointed: May&#160;2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Term expires: 2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 1,000</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.824%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Audit Committee </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Honorary President and Director of Terra Nova (non-profit association)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">President of Capgemini Ventures SAS, non-listed company</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Capgemini Solutions Canada Inc, non-listed company</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Capgemini UK plc, non-listed company incorporated </span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of CGS Holdings Ltd (United Kingdom), non-listed company </span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director and Chair of the Audit Committee of Fnac Darty*</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Executive Committee of June&#160;21 SAS</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Capgemini*</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Sebdo, Le Point</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Archer Obligations (previously Artemis 21)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Editions Tallandier</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Audit Committee of Capgemini*</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Collection Pinault-Paris</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of June&#160;21 SAS</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Substitute of Alain de Marcellus, Capgemini Brasil SA (Brazil)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Pallazzo Grassi (Italy)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Capgemini Espana SL (Spain)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Altran Innovacion S.L.U (Spain)</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">HEC School of Management, Master's degree</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2018 - 2023</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chief Financial Officer of Capgemini</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2013-2018</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financing Operations Director of Groupe Art&#233;mis</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2011-2012</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chief Financial Officer of EuropaCorp</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2000-2011</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chief Financial Officer and General Counsel of Sony France</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1992-2000</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Audit and Transaction Services at PricewaterhouseCoopers (PwC)</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:107%">Senior executive role in international groups</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%">, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:107%">Board membership in international groups, Finance/Accounting</span></div></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">93</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_262"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lise Kingo</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="6" style="padding:0 1pt"><div><img src="sny-20231231_g17.jpg" alt="DOT_ADMIN7.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Date of birth: August&#160;3, 1961 (aged&#160;62)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Nationality: Danish</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">First appointed: April&#160;2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Term expires: 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 1,000</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.824%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Appointments, Governance &amp; CSR Committee </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Danone*</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Supervisory Board of Covestro AG* (Germany)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:23.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.017%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Master&#8217;s degree in Responsibility &amp; Business, University of Bath (United Kingdom)</span></div></td></tr><tr><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Bachelor&#8217;s degree in Marketing and Economics, Copenhagen Business School (Denmark)</span></div></td></tr><tr><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Bachelor&#8217;s degree in Religions and Ancient Greek Art, University of Aarhus (Denmark)</span></div></td></tr><tr><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director Certification, INSEAD (France)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director of Danone*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2021</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director of Covestro AG* (Germany)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2021</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent Director, Aker Horizons ASA* (Norway)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2020</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Member of the Advisory Panel for Humanitarian and Development Aid Coordination, Novo Nordisk Foundation (Denmark)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2015-2020</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CEO &amp; Executive Director of United Nations Global Compact (US)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2002-2014</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Executive Vice President Corporate Relations &amp; Chief of Staff at Novo Nordisk A/S (Denmark)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1999-2002</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior Vice President, Stakeholder Relations at Novo Holding (Denmark)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1988-1999</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Director, Environmental Affairs of Novozymes (Denmark)</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Healthcare/pharmaceutical industry experience, Senior executive role in international groups, Board membership in international groups, International  experience</span></div></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">94</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_265"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patrick Kron</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="7" style="padding:0 1pt"><div><img src="sny-20231231_g18.jpg" alt="DOT_ADMIN10.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Date of birth: September&#160;26, 1953 (aged&#160;70)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Nationality: French</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">First appointed: May&#160;2014</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Last reappointment: May 2022</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Term expires: 2026</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 1,000</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.824%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairman of the Compensation Committee</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Appointments, Governance and CSR Committee </span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Strategy Committee</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairman of Imerys*</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairman of Truffle Capital SAS (non-listed company)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairman of PKC&amp;I SAS (non-listed company):</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:4.02pt">Permanent representative of PKC&amp;I on the Supervisory Board of Segula Technologies</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Viohalco* (Belgium)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Interim Chief Executive Officer of Imerys*</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">ElvalHalcor* (Greece)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt 0 9.5pt;text-indent:-8.5pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Holcim* (Switzerland)</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Degree from </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#201;cole Polytechnique</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#201;cole Nationale Sup&#233;rieure des Mines de Paris</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2019</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chairman of Imerys* (and Interim Chief Executive Officer from October&#160;2019 to February&#160;2020)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2016</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chairman of Truffle Capital SAS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2016</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chairman of PKC&amp;I SAS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2003-2016</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chief Executive Officer, then Chairman and Chief Executive Officer of Alstom*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1998-2002</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chairman of the Managing Board of Imerys</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1995-1997</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Manager of the Food and Health Care Packaging Sector at Pechiney, and Chief Operating Officer of American National Can Company in Chicago (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1993-1997</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chairman and Chief Executive Officer of Carbone Lorraine</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1993</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Executive Committee of the Pechiney Group</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1988-1993</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various senior operational and financial positions within the Pechiney Group</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1984-1988</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Operational responsibilities in one of the Pechiney Group&#8217;s biggest factories in Greece, then manager of the Greek subsidiary of Pechiney</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1979-1984</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various positions at the French Ministry of Industry, including as project officer at the Direction r&#233;gionale de l&#8217;Industrie, de la Recherche et de l&#8217;Environnement (DRIRE) and in the Ministry&#8217;s general directorate</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Senior executive role in international groups, Board membership in international group, International experience, Mergers &amp; acquisitions</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">95</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_268"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Wolfgang Laux</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="6" style="padding:0 1pt"><div><img src="sny-20231231_g19.jpg" alt="DOT_ADMIN15.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Date of birth: January&#160;24, 1968 (aged&#160;56)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Nationality: German</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">First appointed: April&#160;2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Term expires: 2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: </span><span style="background-color:#ffffff;color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2,277 FCPE shares and 1,558 Performance </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">shares</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.824%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Director representing employees</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Compensation Committee</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Post-doctoral research fellow at the State University of New York at Stony Brook (1998-2000) and at the University of Montpellier (1996-1997)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Ph.D. in organic chemistry from the University of Frankfurt am Main</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Corporate Director&#8217;s Certificate from SciencesPo/IFA </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:130%">(Certificat Administrateur de Soci&#233;t&#233;s)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">European Board Diploma by ecoDa</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2006</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Industrialization Coordinator at Sanofi Chimie and Sanofi Winthrop Industries, Croix-de-Berny and Gentilly (France)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2014</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Staff representative on the CFE-CGC ticket</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2016-2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Union delegate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2014-2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Works Council, Sanofi Chimie headquarters</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2016-2019</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Committee on health, safety and working conditions (CHSCT)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2000-2006</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior scientist in Process Development at the Frankfurt site of H&#246;chst AG</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Scientific training, Healthcare/pharmaceutical industry experience, International experience. </span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">96</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_271"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Barbara Lavernos</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="6" style="padding:0 1pt"><div><img src="sny-20231231_g20.jpg" alt="DOT_ADMIN8.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Date of birth: April&#160;22, 1968 (aged&#160;55)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Nationality: French</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">First appointed: April&#160;2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Term expires: 2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 1,000</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.824%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Director </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Appointments, Governance and CSR Committee</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Aucun</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Strategy Committee</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:130%">L'Or&#233;al Group*</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Board member of Lactobio A/S (Denmark)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Board member of Bak Skincare ApS (Denmark)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Bpifrance Investment and Bpifrance Participations</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Graduate of the HEI chemical engineering school at Lille (HEI France)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since September 2023</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Vice-Chair of the L'Or&#233;al Climate Emergency Fund</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since May&#160;2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Deputy CEO of L'Or&#233;al* in charge of Research, Innovation and Technology</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">February&#160;2021-May&#160;2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">President Research, Innovation and Technologies at L&#8217;Or&#233;al*&#8211; Member of the Executive Committee at L&#8217;Or&#233;al*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2018-2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chief Technology and Operations Officer at L&#8217;Or&#233;al* &#8211; Member of the Executive Committee at L&#8217;Or&#233;al*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2014-2018</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Executive Vice-President Operations at L&#8217;Or&#233;al* &#8211; Member of the Executive Committee at L&#8217;Or&#233;al*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2011-2014</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Managing Director of Travel Retail at L'Or&#233;al*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2004-2011</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Global Chief Procurement Officer at L'Or&#233;al*</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Senior executive role in international groups, International experience, Scientific training</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">97</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_274"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fabienne Lecorvaisier</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="7" style="padding:0 1pt"><div><img src="sny-20231231_g21.jpg" alt="DOT_ADMIN_21.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Date of birth: August&#160;27, 1962 (aged&#160;61)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Nationality: French</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">First appointed: May&#160;2013</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Last reappointment: April&#160;2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Term expires: 2025</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 1,000</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.824%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairwoman of the Audit Committee </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Safran * </span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">&#160;&#160;&#160;&#160;&#160;(Member of the Audit and Risk Committee)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Supervisory Board of Wendel</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">&#160;&#160;&#160;&#160;&#160;(Member of the Audit Committee)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Air Liquide Group*: </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Air Liquide International</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of The Hydrogen Company</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Air Liquide Finance</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of ANSA (</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:130%">Association Nationale des Soci&#233;t&#233;s par Actions</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Rexecode (economic research institute)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Air Liquide Group*:</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairwoman of Air Liquide US LLC</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Executive Vice President of Air Liquide International Corporation</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of American Air Liquide Holdings, Inc.</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.215%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Civil engineer, graduate of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:130%">&#201;cole Nationale des Ponts et Chauss&#233;es</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021- May 2023</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Executive Vice President in charge of Sustainable Development, Public and International Affairs, Social Programs and General Secretariat of Air Liquide*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">July&#160;2017-July&#160;2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Executive Vice President of Air Liquide*</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2008-2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Executive Committee member of Air Liquide*</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2008-2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chief Financial Officer of Air Liquide*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1993-2008</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various positions within Essilor* including Group Chief Financial Officer (2001-2007) and Chief Strategy and Acquisitions Officer (2007-2008)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1990-1993</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Assistant General Manager of Banque du Louvre, Taittinger Group</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1989-1990</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior Banking Executive in charge of the LBO Department (Paris)/Corporate Finance Department (Paris and London) at Barclays</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1985-1989</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Corporate Finance Department, then Mergers and Acquisitions Department of Soci&#233;t&#233; G&#233;n&#233;rale*</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Senior executive role in international groups, Board membership in international groups, International experience, Mergers &amp; acquisitions, Finance/Accounting.</span></div></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">98</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_277"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gilles Schnepp</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="7" style="padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g22.jpg" alt="DOT_ADMIN6.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of birth: October&#160;16, 1958 (aged&#160;65)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Nationality: French</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">First appointed: May&#160;2020</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Last reappointment: May&#160;2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Term expires: 2026</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 1,000</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.824%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairman of the Appointments, Governance and CSR Committee </span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Strategy Committee </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairman of the Board of Directors of Danone*</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Saint Gobain*</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Socotec, non-listed company</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Vice-Chairman of the Supervisory Board of PSA* </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Legrand*</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Graduate of HEC business school</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Chairman of Danone*</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2006-2018</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chairman &amp; CEO of Legrand</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2004-2006</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CEO of Legrand</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2001-2004</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Deputy CEO of Legrand</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1989-2001</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various positions within the Legrand Group </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1983</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Merrill Lynch</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Senior executive role in international groups, Board membership in international groups, International experience, Mergers &amp; acquisitions, Finance/Accounting</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">99</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_280"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Diane Souza</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="7" style="padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g23.jpg" alt="DOT_ADMIN4.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of birth: July&#160;3, 1952 (aged&#160;71)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Nationality: American</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">First appointed: May&#160;2016</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Last reappointment: April&#160;2020</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Term expires: 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 2,489</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;American Depositary Receipts, equivalent to </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,244</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;shares</span></div></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:49.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.599%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Compensation Committee </span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Audit Committee </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amica Insurance Companies (United States)</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, non-listed company:</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">&#160;&#160;&#160;&#160;&#160;(Member of the Compensation </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">and Investment Committees)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">UnitedHealth Group:</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Unimerica Insurance Company, Unimerica Life Insurance Company of New York, National Pacific Dental, Inc., Nevada Pacific Dental, DBP Services of New York, IPA, Dental Benefits Providers of California, Inc., Dental Benefit Providers of Illinois, Inc., Dental Benefit Providers, Inc., Spectera, Inc. and Spectera of New York, IPA, Inc. United&#160;States</span></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Farm Credit East (United States)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director</span></div></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Degree in Accounting from University of Massachusetts</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Honorary doctorate in Business Administration from University of Massachusetts Dartmouth</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Certified Public Accountant</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Diploma in Dental Hygiene from Northeastern University, Forsyth School for Dental Hygienists</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2008-2014</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chief Operating Officer of OptumHealth Specialty Benefits (2008), then Chief Executive Officer of UnitedHealthcare Specialty Benefits (2009-2014) (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2007-2008</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Principal consultant at Strategic Business Solutions, LLC (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1994-2006</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various positions at Aetna Inc. including Deputy Vice President Federal and State Taxes; Vice President and Chief Financial Officer, Large Case Pensions; Vice President and Head of Global Internal Audit Services; Vice President, National Customer Operations; and finally Vice President, Strategic Systems&#160;&amp; Processes (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1988-1994</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various positions at Price Waterhouse from Senior Tax Manager to Head of the Northeast Insurance Tax Region (United&#160;States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1980-1988</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Various positions at Deloitte Haskins&#160;&amp; Sells, from Audit Staff Accountant to Senior Tax Manager-in-Charge (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1979</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Audit Staff Accountant at Price Waterhouse (United States)</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Healthcare/pharmaceutical industry experience, International experience, Mergers &amp; acquisitions, Finance/Accounting</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">100</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_283"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Thomas S&#252;dhof</span></div></td></tr><tr style="height:17pt"><td colspan="3" rowspan="7" style="padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g24.jpg" alt="DOT_ADMIN_22.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of birth: December&#160;22, 1955 (aged&#160;68)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Nationality: German and American</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">First appointed: May&#160;2016</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Last reappointment: April&#160;2020</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Term expires: 2024</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 2,485</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;American Depositary Receipts, equivalent to </span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">1,242&#160;</span><span style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">shares</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.824%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairman of the Scientific Committee </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of CytoDel Inc. (United States), non-listed company </span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Scientific Advisory Committee of NeuroCentria (United States)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Director of Abide Therapeutics (United States)</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Degree in medicine from the Faculty of Medicine of the University of G&#246;ttingen (Germany)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Elected member of the National Academy of Sciences of the US (2002)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Elected member of the National Academy of Medicine (2007)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Bernard Katz Prize of the Biophysical Society, jointly with Reinhard Jahn (2008)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Elected member of the American Academy of Arts and Sciences (2010)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Nobel Prize for Physiology or Medicine, jointly with James Rothman and Randy Schekman (2013)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Albert Lasker Prize for Basic Medical Research, jointly with Richard Scheller (2013)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Elected foreign member of the German Academy Leopoldina (2015)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Elected foreign member of the Royal Society of London for Improving Natural Knowledge (2017)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Elected member of the Norwegian Society of Sciences </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2020</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of Danaher Corporation (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2020</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Co-founder and member of the Scientific Advisory Board of Boost, Inc. and Recognify, Inc. (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2020</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of NeuroCure, Charite, Berlin (Germany)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2019 </span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of the Neuroscience Department at the Institut Pasteur (France) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2019</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of the Chinese Institute for Brain Research, Beijing (China)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2019</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Advisor to Camden Venture Partners (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2018</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of Jupiter, Inc. (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2018</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chairman of the Scientific Advisory Board of Capital Medical University, Beijing (China)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2018</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of Alector, Inc. (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2017</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of Cytodel, Inc. (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2017</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of the Chinese Academy of Sciences Institute of Guangzhou (China)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2016</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of the Picower Institute, MIT Boston (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2016</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of Simcere, Inc. (China)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2014</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of Elysium, Inc. (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2013</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of the Shemyakin-Ovchinnikov Institute of Bio-Organic Chemistry (Russia)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2008</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Avram Goldstein Professor in the Molecular &amp; Cellular Physiology, Neurosurgery, Psychiatry, and Neurology Department in the School of Medicine at Stanford University (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2002</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Co-founder and member of the Scientific Advisory Board of REATA Pharmaceuticals (United States)</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 1986</span></td><td colspan="6" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Investigator at the Howard Hughes Medical Institute (United States)</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">101</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2017-2019</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of C-Bridge Everest Medical (China)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2017-2018</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of Abide (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2014-2018</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Committee of the Institute of Cellular and Molecular Biology of A*Star (China)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2014-2018</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of the Chinese Academy Institute of Biophysics (China)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2014-2018</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Scientific Advisory Board of the Singapore National Research Foundation (Singapore)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2014-2017</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Co-founder and member of the Scientific Advisory Board of Bluenobel, Inc. (China)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2013-2016</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Review Board of Genentech Neuroscience (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2011-2019</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Co-founder and member of the Scientific Advisory Board of Circuit Therapeutics, Inc. (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1986-2008</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Professor and subsequently Chair of the Neuroscience Department at the University of Texas Southwestern Medical School (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1983-1986</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Postdoctoral Fellow, Dept. of Molecular Genetics, UT Southwestern Medical School (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1981-1982</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Intern at the University Hospital of G&#246;ttingen (Germany)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1979</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Student on exchange clerkship program at Harvard Medical School (United States)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1978-1981</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Research assistant at the Max Planck Institute for Biophysical Chemistry (Germany)</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Scientific training</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">102</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_286"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Yann Tran</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="6" style="padding:0 1pt"><div><img src="sny-20231231_g25.jpg" alt="DOT_ADMIN2.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Date of birth: December&#160;5, 1965 (aged&#160;58)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Nationality: French</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">First appointed: May&#160;2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 9.5pt;text-align:left;text-indent:-8.5pt;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Term expires: 2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: 1,385 FCPE shares</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.824%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Director representing employees </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:0 1pt"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Coordinator for Industrial Europe on the Sanofi European Works Council</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the French Strategy Committee for the Healthcare Industries and Technologies Sector</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">IFA Company Director Certificate from Sciences Po (2022)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">DEA in Biochemistry: Integrative Protein Biology from the University of Paris VII (France)</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Master's degree in Biochemical and Biological Engineering Sciences and Techniques from the University of Paris XII (France)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Head of Labor Relations, France at Sanofi</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Coordinator for Industrial Europe on the Sanofi European Works Council</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2014-2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Federation delegate for the Pharmaceuticals industry, in charge of negotiating and monitoring of industry agreements and national collective agreements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2014-2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FCE-CFDT federation delegate for social welfare</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2010-2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Trade union leader in labor relations in the Sanofi Group</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2010-2014</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Member of the Supervisory Board of Sanofi employee savings plans (PEG and PERCO) and member of the Sanofi Group Committee</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2006-2010</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Bioinformatics researcher at Sanofi R&amp;D</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1995-2006</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Researcher in molecular biology at Sanofi and Aventis</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Scientific training, Healthcare/pharmaceutical industry experience</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">103</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_289"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Emile Voest</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="6" style="padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g26.jpg" alt="DOT_ADMIN18.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of birth: August&#160;20, 1959 (aged&#160;64)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Nationality: Dutch</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">First appointed: May&#160;2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Term expires: 2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held:</span><span style="background-color:#ffffff;color:#5064a9;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> 1,000</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.824%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Scientific Committee</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chairman of the Board of Cancer Core Europe</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Board Member of the Center for Personalized Cancer Treatment</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Supervisory Board of Hartwig Medical Foundation</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Ph.D. in Medicine, cum laude, University of Utrecht</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Founder of Mosaic Therapeutics and Strategic Advisor</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2019</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Senior Group Leader of the Oncode Institute</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Director of Cancer Core Europe</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Since 2015</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Founder and Member of Supervisory Board of the Hartwig Medical Foundation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2015-2020</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">ESMO (European Society for Medical Oncology)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Chair of the Publications Committee (2016-2020)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Executive Board (2015-2020)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2014</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The Netherlands Cancer Institute</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Medical Oncologist (since 2014)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Executive Medical Director (2014-2020) and senior group leader</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2013-2016</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Co-founder and Non-Executive Medical Director of Hubrecht Organoid Technology</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 2010</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Co-founder and Member of the Executive Board of the Center for Personalized Cancer Treatment (CPCT)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Since 1999</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Professor of Medical Oncology at UMC Utrecht</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Scientific training</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">104</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_292"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.208%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Antoine Yver</span></td></tr><tr style="height:17pt"><td colspan="3" rowspan="6" style="padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g27.jpg" alt="DOT_ADMIN16.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of birth: January&#160;31, 1958 (aged 66)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Nationality: French, American, Swiss</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">First appointed: May&#160;2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Term expires: 2025</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Business address: Sanofi &#8211; 46, avenue de la Grande Arm&#233;e &#8211; 75017&#160;Paris &#8211; France</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of shares held: </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,000&#160;American Depositary Receipts, equivalent to 1,000&#160;shares</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.824%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Current directorships and appointments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Independent director </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Member of the Scientific Committee </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%">Director of Spotlight Therapeutics *</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Past directorships expiring within the last five years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WITHIN THE SANOFI GROUP</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OUTSIDE THE SANOFI GROUP</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In French companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">In foreign companies</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">None</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.708%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Education and professional experience</span></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Doctor of Medicine and Pediatrics, University of Paris-Sud 11</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2021-2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Chairman of Development of Centessa Pharmaceuticals</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2016-2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">EVP Global Head Oncology R&amp;D at Daiichi Sankyo, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2009-2016</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AstraZeneca*</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">SVP Head Oncology Global Medicines Development &amp; Lead China GMD (2013-2016)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">VP Head Oncology Global Medicines Development &amp; Lead China GMD (2012-2013)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">VP Clinical Oncology &amp; New Opportunities (2011-2012)</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">VP Clinical Oncology &amp; Infection (2009-2011)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2006-2009</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Executive Director in Oncology at the Schering-Plough Research Institute</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2005-2006</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior Director Oncology at Johnson &amp; Johnson*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1990-2005</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior Director Clinical Research at Aventis</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1981-1990</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Medical doctor at the </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Assistance Publique des H&#244;pitaux de Paris</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.268%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Competencies</span></td></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Scientific training, Healthcare/pharmaceutical industry experience, Senior executive role in international groups, International experience</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">105</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_298"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Attendance Rate of Board members</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.514%"><tr><td style="width:1.0%"/><td style="width:60.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attendance&#160;rate&#160;<br/>at&#160;Board meetings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attendance&#160;rate&#160;<br/>at&#160;Committee meetings</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Serge Weinberg*</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fr&#233;d&#233;ric Oud&#233;a**</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Paul Hudson</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Christophe Babule</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rachel Duan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carole Ferrand</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lise Kingo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patrick Kron</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wolfgang Laux</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Barbara Lavernos</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabienne Lecorvaisier</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gilles Schnepp</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diane Souza</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thomas S&#252;dhof</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yann Tran</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emile Voest</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Antoine Yver</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:60.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.123%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.099%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average attendance rate <br/>at Board meetings</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average attendance rate <br/>at Committee meetings</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#23004c;padding:0 1pt"/><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">97</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#23004c;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* Chairman of the Board of Directors from January&#160;1, 2023 to May&#160;25, 2023.</span></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">** Chairman of the Board of Directors from May&#160;25, 2023 onwards.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Directors who were absent from some meetings provided clear and substantiated explanations for their absence, which related mainly to personal matters or to unscheduled meetings called at short notice (especially where sudden developments on an ongoing project necessitated a Board meeting).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Declarations by Board members (including convictions and conflicts of interest)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, no corporate officer has been the subject of any conviction or court order, or been associated with any bankruptcy or winding-up order. As of this day, there is no potential conflict of interest between any corporate officer and Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the members of our Board of Directors collectively held (directly, or via the employee share ownership fund associated with the Group savings scheme) 24,270 of our shares, representing 0.0019% of our share capital.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Service agreements entered into with Board members</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">There are no existing service agreements between the Company and its subsidiaries on the one hand, and any Board member of corporate officer on the other, that stipulate any benefit whatsoever.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_301"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Executive Committee</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Executive Committee is chaired by the Chief Executive Officer. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Four new members joine</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">d the Executive Committee in 2023 and early 2024: Houman Ashrafian (Executive Vice President, Head of Research and Development); Emmanuel Frenehard (Executive Vice President, Chief Digital Officer); Madeleine Roach (Executive Vice President</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, Business Operations); and Brian Foard (Executive Vice President, Specialty Care).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of February&#160;22, 2024, the </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Executive Committee had 12&#160;members, three of whom are women. In accordance with our Board Charter, the Board of Directors &#8211;&#160;in liaison with the Compensation Committee and the Appointments, Governance and CSR Committee, and on a proposal from the Chief Executive Officer&#160;&#8211; has established a policy on gender balance within Sanofi's executive bodies. A key objective of this policy is to support the creation of a talent pool of both women and men who can potentially join the Executive Committee in future.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">106</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paul Hudson</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: October&#160;14, 1967.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul Hudson joined Sanofi as Chief Executive Officer on September&#160;1, 2019.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Previously CEO of Novartis Pharmaceuticals (2016-2019), where he was a member of the Executive Committee, Paul has had an extensive international career in healthcare that spans the US, Japan and Europe.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Prior to Novartis, he worked for AstraZeneca, where he held several increasingly senior positions and most recently carried out the roles of President, AstraZeneca United States and Executive Vice President, North America.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synth&#233;labo UK.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul holds a degree in economics from Manchester Metropolitan University in the UK and last year his alma mater awarded him an honorary Doctor of Business Administration for his achievements in industry. He also holds a diploma in marketing from the Chartered Institute of Marketing, also in the UK.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul Hudson is a citizen of the United Kingdom.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Houman Ashrafian</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Head of Research and Development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: February&#160;4, 1975.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Houman Ashrafian joined Sanofi on September&#160;11, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Houman joined Sanofi from SV Health Investors where he was Managing Partner of the global private equity and venture capital investment platform which has a special focus on biotechnology, healthcare growth equity, and medtech. He has a robust track record in building high value, successful companies in the healthcare space, that brought transformational medicines from discovery to market: he co-founded and chaired the biotechs Alchemab Therapeutics, Dualitas, Enara Bio, Mestag Therapeutics, Sitryx and Trex Bio. Previously, he was Vice President and head of the Clinical Science Group at UCB with a main focus on precision medicine strategies and early clinical activities across the R&amp;D portfolio. He also co-founded Cardiac Report, a cardiac services company, Heart Metabolics, Catamaran Bio, as well as Weatherden, a boutique clinical consultancy.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Houman is an Honorary Consultant Cardiologist at the John Radcliffe Hospital in Oxford, and a Visiting Professor at the University of Oxford in the UK. He has received numerous prestigious awards and recognitions over the course of his career, including the Michael Davies Early Career Award from the British Cardiovascular Society and the Schuldham Prize. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Houman has a bachelor&#8217;s and master&#8217;s degree from the University of Cambridge (UK) and a BM BCh and DPhil from the University of Oxford (UK).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Houman Ashrafian is a citizen of the United Kingdom.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Natalie Bickford</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Chief People Officer</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: July&#160;16, 1970.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Natalie Bickford joined Sanofi on August&#160;1, 2020. She has worked in HR and HR leadership for more than 20&#160;years and brings a wealth of experience in consumer-facing industries to Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Prior to joining Sanofi, Natalie was Group HR Director at Merlin Entertainments, the world&#8217;s second largest location-based entertainment business, where she was responsible for 30,000&#160;employees across Europe, North America, and Asia Pacific. She also held senior HR&#160;positions at Sodexo, AstraZeneca and Kingfisher Plc.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Natalie has a solid track record of transforming organizations, with a strong focus on inclusion and diversity. She was awarded &#8220;HR&#160;Diversity Champion of the Year&#8221; at the European Diversity Awards in November&#160;2019. Natalie is also Board member of the Kronos Workforce Institute, a reflection of her deep interest in understanding and shaping the future of work.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Natalie holds a degree in French and International Politics from the University of Warwick in the UK.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Natalie Bickford is a citizen of the United Kingdom.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">107</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olivier Charmeil</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, General Medicines</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: February&#160;19, 1963.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">From&#160;1989 to&#160;1994, Olivier Charmeil worked in the Mergers &amp; Acquisitions department of Banque de l&#8217;Union Europ&#233;enne. He joined Sanofi Pharma in 1994 as head of Business Development. Subsequently, he held various positions within Sanofi, including Chief Financial Officer (Asia) of Sanofi-Synth&#233;labo in 1999 and Attach&#233; to the Chairman, Jean-Fran&#231;ois Dehecq, in 2000, before being appointed as Vice President, Development within the Sanofi-Synth&#233;labo International Operations Directorate, where he was responsible for China and support functions. In 2003, Olivier Charmeil was appointed Chairman and Chief Executive Officer of Sanofi-Synth&#233;labo France, before taking the position of Senior&#160;Vice President, Business Management and Support within the Pharmaceutical Operations Directorate. In this role, he piloted the operational integration of Sanofi-Synth&#233;labo and Aventis. He was appointed Senior Vice President Asia/Pacific, Pharmaceutical Operations in February&#160;2006; Operations Japan reported to him from January&#160;1, 2008, as did Asia/Pacific and Japan Vaccines from February&#160;2009. On January&#160;1, 2011, Olivier Charmeil was appointed Executive Vice President Vaccines, and joined our Executive Committee.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May&#160;2015, Olivier Charmeil and Andr&#233; Syrota were appointed as Co-Leaders of &#8220;Medicine of the Future&#8221;, an initiative developed by the French Minister for Economy, Industry and Digital Affairs, the French Minister for Social Affairs, Health and Women&#8217;s Rights and the French Minister for National and Higher Education and Research. They have been tasked with assembling a group of industrialists and academics, with the objective of imagining how French industry can accelerate the launch and export of innovative industrial products, with an emphasis on new biotechnologies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">From June&#160;2016 to December&#160;2018, Olivier Charmeil served as Executive Vice President of our General Medicines and Emerging Markets Global Business Unit.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">He took up the position of Executive Vice President China &amp; Emerging Markets in January&#160;2019. In February&#160;2020 he was appointed to lead the General Medicines GBU, created out of the former Primary Care and China &amp; Emerging Markets GBUs. He also serves as sponsor for China. Also in 2020, Olivier became a Board Member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Olivier is a graduate of HEC (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">&#201;cole des Hautes &#201;tudes Commerciales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) and of the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Institut d&#8217;&#201;tudes Politiques</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in Paris. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Olivier Charmeil is a citizen of France.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jean-Baptiste Chasseloup de Chatillon</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Chief Financial Officer</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: March&#160;19, 1965.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Jean-Baptiste Chasseloup de Chatillon</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> joined Sanofi on </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">October&#160;1, 2018</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Until July&#160;2018, Jean-Baptiste Chasseloup de Chatillon served as Chief Financial Officer and Executive Vice President of the PSA Group. In that capacity, he was also a member of the Managing Board and Executive Committee. He held various manage</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ment positions within the PSA Group in finance (Treasurer in Spain, Chief Financial Officer in the United Kingdom) and in sales and marketing (Business units: Bank/Insurance, Spare parts, Used vehicles, Proprietary dealership network).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">He was also Chairman of the Board of Banque PSA Finance (BPF) from 2012 to June&#160;2</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">016. He joined the Peugeot&#160;S.A. Managing Board in 2012.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">He was appointed as Director and member of the Audit Committee of Sodexo (a French listed company) on December&#160;14, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Jean-Baptiste holds a Masters from Paris Dauphine University and studied Finance in the United Kingdom at Lancaster University.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Jean-Baptiste Chasseloup de Chatillon is a citizen of France.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brian Foard</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Specialty Care</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: December&#160;20, 1973.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As head of our Specialty Care GBU, Brian oversees an extensive portfolio of medicines in immunology, neuro-inflammation, rare diseases, and oncology. Brian and his colleagues are responsible for launching treatments in those fields, and for implementing the strategy to bring Sanofi&#8217;s scientific breakthroughs to patients.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Brian joined Sanofi in March&#160;2017 as the Global Head of Dermatology and Respiratory, and held roles of increasing responsibility, including as Head of Global Immunology for Sanofi and then as US Country Lead and Head of Specialty Care for North America. He has over 20&#160;years&#8217; experience in the specialist biopharma industry, and began his career with Galderma where he spent more than 10&#160;years in the US before relocating to Paris to lead global marketing and launch readiness. During his time at Galderma, Brian also served in roles including General Manager for Australia &amp; New Zealand and Vice President &amp; General Manager of the global prescription business unit.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Brian received a degree in business from East Carolina University and has completed an executive education course at Wharton.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Brian Foard is a citizen of the United States.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">108</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emmanuel Frenehard</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Chief Digital Officer</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: October&#160;18, 1972.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Emmanuel joined Sanofi in 2020 as Global Head of Digital, and was appointed to the Executive Committee on August&#160;31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Prior to being appointed Chief Digital Officer, he held the positions of Global Head, Digital GBU teams and Digital Products. He also led the Sanofi Digital Accelerator and a number of digital commerce initiatives.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Before joining Sanofi, Emmanuel spent 20&#160;years leading large global organizations as well as three years in startups. He has built and launched multiple global digital products in support of existing and new business models. In particular, he managed iflix&#8217;s rollout across Southeast Asia and led the launch of DisneyLife, Disney&#8217;s direct-to-consumer digital subscription service, in the UK.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Emmanuel is a graduate of the European Business School (EBS) and holds a Master II in Business, Finance and Audit from the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Institut Sup&#233;rieur de Gestion </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(ISG).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Emmanuel Frenehard is a citizen of France.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brendan O&#8217;Callaghan</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Global Manufacturing &amp; Supply</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">July&#160;16, 1961.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Brendan O&#8217;Callaghan joined Sanofi on January&#160;1, 2015. He joined the Executive Committee on October&#160;1, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Brendan joined Sanofi in 2015 and was previously Global Head of Biologics and Industrial Affairs Head of the Specialty Care portfolio. He has played a key role in supporting our transformation to a fully integrated BioPharmaceutical company and advancing the digital transformation of our manufacturing network.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Prior to Sanofi, Brendan worked at Schering-Plough before moving to Merck/MSD as Head of Biologics and later Vice President of its Europe, Middle East and Africa Operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Brendan graduated in chemical engineering from the University College of Dublin, where he currently serves as an honorary adjunct Professor of Chemical and Biochemical Engineering.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Brendan O&#8217;Callaghan is a citizen of Ireland.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Julie Van Ongevalle</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Consumer Healthcare</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: November&#160;22, 1974.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Julie Van Ongevalle joined Sanofi on September&#160;1, 2020.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">With over 20&#160;years of international experience, Julie Van Ongevalle has a deep knowledge of consumers and digital, as well as a proven track record in brand building, from identifying growth opportunities to building and implementing delivery strategies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Prior to joining Sanofi, Julie worked at the Est&#233;e Lauder Companies, where she held roles of increasing responsibility across the company, starting in 2004. As Global Brand President of the Origins brand from 2016, she led a global organization of&#160;4,000&#160;people, growing the company&#8217;s market share across geographies. Prior to Origins, she spent eight years in the M.A.C.&#160;Cosmetics division, first as General Manager Benelux, then of the EMEA Region and finally North America.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Julie started her career as a marketing manager at GSK Consumer Healthcare and Clinique.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Julie graduated from the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Institut Catholique des Hautes &#201;tudes Commerciales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (Belgium) with a Master of Science in Commercial and Financial Sciences.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Julie Van Ongevalle is a citizen of Belgium.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_304"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Roy Papatheodorou</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vic</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">e President, General Counsel</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: May&#160;15, 1978.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Roy Papatheodorou joined Sanofi on February&#160;1, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Prior to joining Sanofi, Roy was General Counsel of Novartis Pharmaceuticals. He has a wealth of experience in leading global and diverse teams, having also headed the Legal Transactions team at Novartis and having previously been the General Counsel of the Actavis Group, one of the largest generics companies at the time.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">He started his career at international law firm Linklaters, where he specialized in international M&amp;A, corporate and private equity based in London, with time also spent in Russia and Brazil.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Roy holds a LLB in Law from King&#8217;s College London and a Legal Practice Course from BPP School of Law in London.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Roy Papatheodorou is a citizen of Cyprus and Italy.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">109</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Madeleine Roach</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Business Operations</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: May&#160;23, 1984.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Madeleine Roach joined Sanofi in 2022 as Head of Internal Audit and Risk Management, before being appointed to the Executive Committee on October&#160;1, 2023. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Prior to joining Sanofi, Madeleine served at AstraZeneca as Head of Group Finance Services, Asia-Pacific and Head of Global Business Services Site Lead in Malaysia, delivering a wide range of business services to stakeholders and further expanding the site with the addition of value-add services and digitalization capabilities, whilst attracting top talent through strong employer branding.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Madeleine also held positions of growing responsibilities in Finance and Global Business Services at AstraZeneca, after starting her career at PricewaterhouseCoopers and KPMG in Assurance and Advisory services, in Germany and the UK.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Madeleine holds a BA (Hons) in Economics and Politics from the School of Oriental and African Studies, University of London.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Madeleine Roach is a citizen of Germany.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_307"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Thomas Triomphe</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Vaccines</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date of birth: August&#160;6, 1974.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Thomas Triophe joined Vaccines in 2004 and has since advanced within the company in several roles of increasing responsibility in sales and marketing at country, regional and global levels. From 2015 to 2018, he was Head of the Asia-Pacific Region, based in Singapore. Before that, he served as Head of Vaccines Japan from 2012 to 2015. In 2010, he became Associate Vice President, Head of the&#160;Influenza-Pneumo Franchise after three years as Director for the same franchise, based in the United States. Earlier in his career, Thomas worked in banking and strategic consulting.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Thomas served as Vice President and Head of Franchise &amp; Product Strategy for Vaccines from January&#160;2018, in which position he implemented the strategy for our vaccine franchises, in close collaboration with Manufacturing &amp; Supply and R&amp;D.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">He was appointed to his current position on June&#160;15, 2020.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Thomas earned his MSc in industrial engineering from &#201;cole des Ponts ParisTech and the IFP School, and he also holds an&#160;MBA from INSEAD.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Thomas Triomphe is a citizen of France.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_310"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.&#160;Compensation</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Compensation and other arrangements for corporate officers</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Process for determining the compensation policy for corporate officers</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The compensation policy for corporate officers is established by the Board of Directors, acting on the recommendation of the Compensation Committee. The Board of Directors applies the AFEP-MEDEF Code when determining the compensation and benefits awarded to our executive and non-executive corporate officers.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All members of the Compensation Committee are independent, and were chosen for their technical competencies and their good understanding of current standards, emerging trends and Sanofi&#8217;s practices.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To fulfill their remit, the Committee regularly invites Sanofi&#8217;s Chief People Officer and Head of Reward and Performance to attend their meetings, although the latter absent themselves when the Committee deliberates. Committee members also work with the Chairman and the Secretary of the Board, who have contacts with our principal institutional shareholders ahead of the Annual General Meeting.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, the Chairman of the Committee:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">discusses the financial, accounting and tax impacts of the proposed compensation policy with the Chairman of the Audit Committee;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">plays an active role at meetings of the Appointments, Governance and CSR Committee and the Strategy Committee (to both of which he belongs), thereby gaining assurance that the proposed performance criteria are consistent and appropriate in light of Sanofi&#8217;s strategic ambitions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The compensation policy is not subject to annual review, although some arrangements for implementing the policy &#8211;&#160;such as the performance criteria applicable to the Chief Executive Officer&#8217;s annual variable compensation, for example&#160;&#8211; are defined by the Board of Directors on an annual basis.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">110</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After consulting the Compensation Committee and as the case may be the other Board Committees, the Board of Directors may, under the second paragraph of item&#160;III of Article&#160;L.&#160;22-10-8 of the French Commercial Code, temporarily derogate from the approved compensation policy for the Chief Executive Officer in exceptional circumstances and to the extent that the changes are aligned with the corporate interest and necessary to safeguard the continuity or viability of Sanofi. Derogations from the approved policy are possible in respect of the performance conditions applied to the Chief Executive Officer&#8217;s compensation, and may result in either an increase or a decrease in compensation. The circumstances in which it is possible to apply such a derogation are a change in the structure of the Sanofi group or &#160;major events affecting the markets. Such derogation may only be temporary and must be properly substantiated, and will remain subject to a binding vote at the next General Meeting of Sanofi shareholders.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation policy for corporate officers</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This section describes the compensation policy for corporate officers of Sanofi, as established pursuant to Article&#160;L.&#160;22-10-8 of the French Commercial Code. That policy describes all the components of compensation awarded to corporate officers of Sanofi as consideration for holding office, and explains the process by which it is determined, divided, reviewed and implemented.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our compensation policy for corporate officers has three distinct elements: (i)&#160;the compensation policy for directors; (ii)&#160;the compensation policy for the Chairman of the Board; and (iii)&#160;the compensation policy for the Chief Executive Officer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Each of those policies is submitted for approval by our shareholders at the Annual General Meeting, in accordance with Article&#160;L.&#160;22-10-8&#160;II of the French Commercial Code. The compensation policy approved in any given year applies to any person holding corporate office in that year. When a corporate officer is appointed between two Annual General Meetings, their compensation is defined by applying the terms of the compensation policy approved by the most recent Annual General Meeting of shareholders.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">General principles and objectives</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our compensation policy is based on the following general principles:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the policy must be simple;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the policy must prioritize long-term performance;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the level of compensation must be competitive, so that we can attract and retain talent; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">there must be a fair balance between the corporate interest, the challenges of delivering on our strategy, and the expectations of our stakeholders.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Compensation Committee must ensure that trends in the compensation of corporate officers over the medium term are not uncorrelated with trends in the compensation of all our employees. In terms of annual variable compensation and equity-based compensation, the Compensation Committee aims to achieve convergence between the performance criteria applied to our Senior Leaders and those applied to the Chief Executive Officer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our equity-based compensation policy, which aims to align employee and shareholder interests and reinforce loyalty to Sanofi, is a critical tool for our worldwide attractiveness as an employer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Grantees of equity-based compensation plans (including our Chief Executive Officer) can only be awarded performance shares. Awarding performance shares reduces the dilutive effect of equity-based compensation plans while maintaining the same level of motivation for grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acting on the recommendation of the Compensation Committee, the Board of Directors determines the performance conditions attached to equity-based compensation for all beneficiaries at Sanofi and its subsidiaries worldwide, thereby furthering the attainment of our objectives.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors makes any grant of performance shares contingent on multiple, exacting multi-year performance criteria in order to ensure that our equity-based compensation plans incentivize overall performance. Failure to achieve those criteria over the entire performance measurement period results in a reduction or loss of the initial grant.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to align equity-based compensation with our long-term performance, performance is measured over three financial years (the &#8220;vesting period&#8221;). Awards of performance shares are also contingent on continued employment in the Sanofi group during the vesting period, followed by stringent lock-up obligations in the case of the Chief Executive Officer (see below).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The terms of prior awards cannot be reset subsequently, for instance with less exacting performance conditions.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation policy for directors</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Directors hold office for a four-year term, as specified in our Articles of Association. They may be removed from office by a shareholders&#8217; meeting, at any time and without restriction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The maximum annual amount of overall compensation allocated to the directors is capped at &#8364;2,500,000 (the cap was raised to that level in 2023 to reflect the increasing number of Board and committee meetings in recent years and the growing proportion of Board members resident outside Europe). The arrangements for allocating the overall annual amount set by the Annual General Meeting between the directors are determined by the Board of Directors, acting on a recommendation from the Compensation Committee. Directors&#8217; compensation comprises an annual fixed amount of &#8364;30,000, apportioned on a time basis for directors who assumed or left office during the year, and&#160;a variable amount, allocated by the Board according to actual attendance at Board and Committee meetings. As required by the AFEP-MEDEF Code, directors&#8217; compensation is allocated predominantly on a variable basis.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">111</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows how the variable amount payable to directors for attendance at Board and committee meetings is determined</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board meeting of February&#160;22, 2024, acting on a recommendation from the Compensation Committee, amended the allocation rules for that variable amount as follows, with effect from 2024 onwards:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amounts payable to (i)&#160;members of the Audit Committee resident outside France, (ii) members of the Appointments, Governance and CSR Committee resident outside Europe and (iii) the Chairman/Chairwoman of the Audit Committee, the  Appointments, Governance and CSR Committee and the Compensation Committee were increased; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">when a director residing outside France attends a Board meeting and one or more Committee meetings and/or strategic seminars during the same trip, he will receive a lower amount than the scale for attendance at certain Committee meetings and/or strategic seminars, except for Committee Chairmen/Chairwomen, whose usual compensation is unchanged.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:14.17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.064%"><tr><td style="width:1.0%"/><td style="width:33.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Compensation per meeting</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Directors<br/>resident in France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Directors&#160;resident outside France but within Europe</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Directors&#160;resident outside Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chairman/Chairwoman</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board of Directors</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;5,500</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;8,250</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;11,000</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Audit Committee</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;8,250</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;11,000</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;13,750</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;13,750</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compensation Committee</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;5,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;8,250</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;11,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;11,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Appointments, Governance and&#160;CSR Committee </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;5,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;8,250</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;11,000</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;11,000</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Strategy Committee</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;5,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;8,250</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;11,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Scientific Committee</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;5,500</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;8,250</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;11,000</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;11,000</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The introduction of a separate compensation scale depending on whether or not the director is a European resident is intended to take into account the significantly longer travel time required to  attend Board meetings in person.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Directors who take part via videoconference receive compensation equivalent to that paid to a director resident in France attending in person. Committee Chairs continue to receive the usual compensation in respect of the Committee they chair.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As an exception, in certain cases two meetings held on the same day give entitlement only to a single payment:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if on the day of a Shareholders&#8217; General Meeting, the Board of Directors meets both before and after the Meeting, only one payment is made for the two Board meetings; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if on the same day a director participates in a meeting of the Compensation Committee and a meeting of the Appointments, Governance and CSR Committee, only the higher of the two payments is made to cover both meetings.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Directors do not receive any exceptional compensation or equity-based compensation and have no entitlement to a top-up pension plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Neither the Chairman of the Board nor the Chief Executive Officer receives any compensation for serving as a director.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation policy for the Chairman of the Board of Directors</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The term of office of the Chairman of the Board is the same as that of the other directors (four years), and the Chairman&#8217;s term is aligned with his term of office as a director. He may be removed from office at any time by the Board of Directors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The compensation policy for the Chairman of the Board of Directors is discussed by the Compensation Committee, which then makes a recommendation to the Board of Directors. The Chairman of the Board is not a member of the Committee, and does not attend meetings where his compensation is discussed.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The compensation of the Chairman of the Board of Directors (where the office of Chairman is separate from that of Chief Executive Officer, as is currently the case) consists solely of fixed compensation and benefits in kind and excludes any variable or exceptional compensation, any awards of stock options or performance shares, and any compensation for serving as a director.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The annual fixed compensation awarded to the Chairman of the Board of Directors is&#160;&#8364;880,000&#160;gross; that amount was set at the Board meeting of February&#160;22, 2023, and became applicable with effect from May&#160;25, 2023, date on which the current Chairman took office.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This amount takes account of the specific remit of the Chairman of the Board of Directors as described in the Sanofi Board Charter, and of his membership of three Board Committees (the Strategy Committee, which he chairs, the Appointments, Governance and CSR Committee; and the Scientific Committee).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The compensation of the Chairman of the Board of Directors is not subject to annual review.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Where the office of Chairman is separate from that of Chief Executive Officer, the Chairman of the Board is not entitled to the Sanofi top-up defined-contribution pension plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Nor is he entitled to a termination benefit or a non-compete indemnity.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">112</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation policy for the Chief Executive Officer</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">General principles</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Chief Executive Officer is not appointed for a fixed term of office. He may be removed from office on legitimate grounds at any time by the Board of Directors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The compensation policy for the Chief Executive Officer is established by the Board of Directors, acting on the recommendation of the Compensation Committee. The compensation structure is not subject to annual review and is applicable for as long as it remains unchanged. The arrangements for implementing the policy may vary from year to year; a table showing the changes made to those arrangements in 2024 and 2023 is provided at the end of the present section.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The compensation of the Chief Executive Officer is determined with reference to compensation awarded to the chief executive officers of the following 12&#160;leading global pharmaceutical companies</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">: Amgen, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb&#160;Inc., Eli Lilly and Company Inc., GlaxoSmithKline plc, Johnson &amp; Johnson Inc., Merck Inc., Novartis AG, Novo Nordisk, Pfizer&#160;Inc., and Roche Holding Ltd. This panel comprises companies that are comparable to Sanofi, with no limitation as to geographical region given that Sanofi operates in a particularly competitive international environment. Consistency with market practice is fundamental in order to attract and retain the talents necessary to our success. In 2023, on the basis of information published as of the date of this annual report, the median fixed compe</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">nsation of the chief executive officers of the aforementioned 12&#160;leading global pharmaceutical companies was in the region of &#8364;1,619,000; the median of the annual variable compensation awarded was in the region of &#8364;2,523,000; and the median of the long-term compensation awarded (whether equity-based or in cash) represented around 861% of fixed compensat</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ion. Within this peer group, Paul Hudson&#8217;s overall compensation (fixed, variable and equity-based compensation) lies in the low range of the second quartile </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">of the compensation paid by the panel companies.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> The practices of the main CAC&#160;40 companies are also tak</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">en into account.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">On taking up office</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the Chief Executive Officer is an outside appointment, the Board of Directors may decide, acting on a recommendation from the Compensation Committee, to compensate the appointee for some or all of the benefits he may have forfeited on leaving his previous employer. In such a case, the terms on which the Chief Executive Officer is hired aim to replicate the diversity of what was forfeited, with a comparable level of risk (variable portion, medium-term equity-based or cash compensation).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">During the term of office</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Compensation structure</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our policy aims at achieving and maintaining a balance in the compensation structure between fixed compensation, benefits in kind, short-term variable cash compensation, and medium-term variable equity-based compensation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The compensation policy for the Chief Executive Officer is designed to motivate and reward performance by ensuring that a significant portion of compensation is contingent on the attainment of financial, operational and extra-financial criteria that reflect Sanofi&#8217;s objectives, and are aligned with the corporate interest and with the creation of shareholder value. Variable cash compensation and equity-based compensation are the two principal levers for action, and are intended to align the interests of the Chief Executive Officer with those of our shareholders and stakeholders.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the meeting that follows the Board meeting held to close off the financial statements for the previous year, the Compensation Committee examines the levels of attainment of variable compensation for that year. In advance of that meeting, the Chief Executive Officer presents the Committee with a report containing narrative and quantitative information necessary to measure attainment of the objectives. The members of the Compensation Committee then discuss the information provided and report to the Board on those discussions, giving an evaluation of the Chief Executive Officer&#8217;s performance against each of the criteria (determining the level of attainment for quantitative objectives, and evaluating the level of attainment for qualitative objectives compared to the objectives set at the beginning of the year).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Annual fixed compensation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The annual fixed compensation of the Chief Executive Officer has been set at &#8364;1,400,000 gross since 2022. It had previously remained unchanged since 2019.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of fixed compensation is not subject to annual review. It may however be changed, provided that such changes are not material:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">on the appointment of a new Chief Executive Officer, to reflect the new appointee&#8217;s competencies and/or then current market practice; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in exceptional circumstances, to take account of changes in (i)&#160;the role or responsibilities of the Chief Executive Officer, for example in terms of market conditions or the size of the Sanofi group or (ii)&#160;the performance level of Sanofi over a given period.</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Survey conducted on the basis of data supplied by Pay Governance and Baracay.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">113</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Annual variable compensation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Annual variable compensation is in a range between 0% and 250% of fixed compensation, with a target of 150%. It is subject to a&#160;range of varied and exacting performance criteria, both quantitative and qualitative. The criteria are reviewed annually in light of&#160;the strategic objectives determined by Sanofi. The Board of Directors sets the criteria for each year at the start of that year on&#160;the recommendation of the Compensation Committee.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2024, the criteria are:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">60% based on financial indicators published by Sanofi: sales growth, free cash flow (FCF) and business earnings per share (business EPS), each accounting for 20%; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">40% based on specific individual objectives: transformation (15%), R&amp;D pipeline (15%), and corporate social responsibility (10%). The individual objectives set for variable remuneration for 2024 are described in &#8220;&#8212;&#160;Compensation and benefits of all kinds awardable to corporate officers in respect of&#160;2024&#8221; below.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors has decided, acting on a proposal from the Compensation Committee, to streamline the annual variable compensation structure by refocusing it on three key financial indicators. The &#8220;business net income&#8221;, "business operating income margin" and "new asset growth" criteria have been replaced by the business EPS) criterion, chosen so as to align more closely with key industry-standard indicators in the pharmaceutical sector and with guidance communicated to the markets. The Board also decided to increase the weighting of financial criteria from 50% to 60%. This change takes into account actual market practices, and comments from investors who wished to see the weighting of financial objectives increased. Although for each of these financial objectives, the Board of Directors &#8211; acting on a proposal from the Compensation Committee &#8211; has set specific objectives, they cannot be disclosed for confidentiality reasons.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The percentage of variable compensation linked to the attainment of quantitative criteria may be scaled down regardless of actual performance, in order to give greater weight to the attainment of qualitative criteria. This flexibility can only operate to reduce the amount of variable compensation, and cannot compensate for underperformance on quantitative criteria.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payment of annual variable compensation in a given year in respect of the previous year is contingent on a favorable shareholder vote at the Annual General Meeting.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Equity-based compensation</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chief Executive Officer&#8217;s equity-based compensation, which can only be in the form of performance shares, may not exceed&#160;250% of his target short-term compensation (fixed plus variable).</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chief Executive Officer&#8217;s equity-based compensation is contingent upon attainment of exacting performance conditions, all of them quantitative, measured over a three-year-period. Such awards ar</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">e contingent upon both: </span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">internal criteria based upon:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">business earnings per share (business EPS), free cash flow (FCF), and development of the R&amp;D pipeline;</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">Affordable Access and Planet Care &#8211; extra-financial criteria; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an external criterion based upon the change in total shareholder return (TSR) relative to a benchmark panel of 12&#160;leading global pharmaceutical companies: Amgen, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Inc., Eli Lilly and Company Inc., GlaxoSmithKline plc, Johnson &amp; Johnson Inc., Merck Inc., Novartis AG, Novo Nordisk, Pfizer Inc., and Roche Holding Ltd.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors, acting on a proposal from the Compensation Committee, has decided (i) to replace the "business net income" criterion by "business earnings per share (business EPS)", which is a central element of Sanofi's financial communication reflecting a significant part of the Company's performance, and (ii) to add an R&amp;D-linked criterion, to demonstrate Sanofi&#8217;s commitment to building a robust pipeline of products in line with the Company's strategy.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acting on a proposal from the Compensation Committee, the Board of Directors sought to maintain common criteria for annual variable compensation and equity-based compensation, in order to ensure that short-term performance does not come at the expense of long-term performance.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Measurable, material extra-financial criteria aligned with Sanofi&#8217;s CSR strategy were introduced into equity-based compensation plans in 2023 following discussions with investors, who were supportive of the criteria selected.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The valuation of performance shares is calculated at the date of grant, weighted between (i)&#160;fair value determined using the Monte Carlo model and (ii)&#160;the market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Each award to our Chief Executive Officer takes into account previous awards and his overall compensation. In any event, the maximum number of shares to be delivered may not be more than the number of performance shares initially awarded.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For details of the proposed award to the Chief Executive Officer in respect of 2024, refer to &#8220;&#8212;&#160;Compensation and benefits of all kinds awardable to corporate officers in respect of&#160;2024&#8221; below.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Share ownership and lock-up obligation of the Chief Executive Officer</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chief Executive Officer is bound by the same obligations regarding share ownership specified in our Articles of Association and Board Charter as our other corporate officers.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, until he ceases to hold office the Chief Executive Officer is required to retain a quantity of Sanofi shares equivalent to&#160;50% of any gain (net of taxes and social contributions) arising on the vesting of performance shares, calculated as of the date on which those shares vest. Those shares must be retained in registered form until he ceases to hold office.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In compliance with the AFEP-MEDEF Code and our Board Charter, the Chief Executive Officer must undertake to refrain from entering into speculative or hedging transactions.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">114</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Multi-year variable compensation</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chief Executive Officer does not receive multi-year variable compensation.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Compensation for serving as a director</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Executive officers of Sanofi do not receive any compensation for serving as directors. Consequently, the Chief Executive Officer does not receive compensation in his capacity as a director or as a member of the Strategy Committee.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Exceptional compensation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No exceptional compensation can be awarded to the Chief Executive Officer.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">On leaving office</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chief Executive Officer is entitled to a top-up defined-contribution pension plan, a termination</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> benefit, and a non-compete indemnity.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such arrangements are part of the overall compensation package generally awarded to executive officers; in line with the recommendations of the AFEP-MEDEF code, there are very strict rules about how they are implemented. The termination benefit and non-compete indemnity are intended to compensate for the fact that the Chief Executive Officer may be dismissed at any time.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Each of those benefits is taken into account by the Board of Directors when fixing the overall compensation of the Chief Executive Officer.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Pension arrangements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chief Executive Officer is entitled to benefits under the top-up defined-contribution pension plan introduced within Sanofi on January&#160;1, 2020. This is a collective plan falling within the scope of Article&#160;82 of the French General Tax Code. It is also offered to members of our Executive Committee and to all senior executives whose position is classified within the Sanofi grade scale as&#160;&#8220;Executive&#160;Level&#160;1 or&#160;2&#8221;. The Chief Executive Officer&#8217;s entitlement under this plan may be withdrawn by a decision of the Board of Directors, but not retroactively.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the plan, the Chief Executive Officer receives an annual contribution the amount of which (subject to attainment of a performance condition) may be up to 25% of his reference compensation (annual fixed and variable cash-based compensation only; all other compensation is excluded). The rights accruing under the plan are those that are generated by the capitalization contract taken out with the insurer, and vest even if the Chief Executive Officer does not remain with Sanofi until retirement. The Chief Executive Officer may elect for the rights to be transferable as a survivor&#8217;s pension.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The performance condition is as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the level of attainment for variable compensation is equal to or greater than the target (i.e. 150% of fixed compensation), 100% of the contribution is paid;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the level of attainment for variable compensation is less than 100% of fixed compensation, no contribution is paid; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">between those two limits, the contribution is calculated on a pro rata basis.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because this performance condition is linked to the attainment of the performance criteria for annual variable compensation (which itself is determined with reference to the strategic objectives of Sanofi), it ensures that no pension contributions could be made in the event that the Chief Executive Officer fails to deliver.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The plan is wholly funded by Sanofi, which pays the full amount of the gross contributions. Because it is treated as equivalent to compensation, the contribution is subject to payroll taxes and employer&#8217;s social security charges, and to income tax in the hands of the Chief Executive Officer; all of the above are charged on the basis of the bands, rates and other conditions applicable to compensation, and paid and declared on his pay slips for the contribution period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subject to (i)&#160;formal confirmation by the Board of Directors that the performance condition for the previous year has been met and (ii)&#160;approval of the Chief Executive Officer&#8217;s compensation package for that year by the Annual General Meeting of our shareholders, the annual gross contribution is paid as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">50% as a gross insurance premium to the fund manager; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">50% to the Chief Executive Officer, to indemnify him for the social security and tax charges for which he will become immediately liable.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with Article&#160;39,5&#160;bis of the French General Tax Code, deferred compensation as defined in section&#160;4 of Article&#160;L.&#160;22-10-9,4 of the French Commercial Code can be offset against corporate profits as a taxable expense up to a limit set at three times the annual social security ceiling per beneficiary.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The pension entitlement is not cumulative with (i)&#160;any termination benefit paid in the event of forced departure or (ii)&#160;any non-compete indemnity.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">115</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Termination arrangements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The termination benefit only becomes payable if the departure of the Chief Executive Officer is forced, i.e. in the event of removal from office or resignation linked to a change in strategy or control of the Company. Compensation for non-renewal of the term of office is irrelevant in the case of the Chief Executive Officer, because this office is held for an indefinite term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, no termination benefit is payable and the arrangement is deemed to have been rescinded in the following circumstances:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">removal from office for gross or serious misconduct </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(faute grave ou lourde)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the Chief Executive Officer elects to leave Sanofi to take up another position;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the Chief Executive Officer is assigned to another position within Sanofi; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the Chief Executive Officer takes his pension.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payment of the termination benefit is contingent upon fulfillment of a performance condition, which is deemed to have been met if the attainment rate for the individual variable compensation objectives exceeded 90% of the target; that condition is assessed over the three financial years preceding the Chief Executive Officer leaving office.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of the termination benefit is capped at 24&#160;months of the Chief Executive Officer&#8217;s most recent total compensation on the basis of (i)&#160;the fixed compensation effective on the date of leaving office and (ii)&#160;the last variable compensation received prior to that date subject to fulfilment of the performance condition.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of the termination benefit is reduced by any amount received as consideration for the non-compete undertaking, such that the aggregate amount of those two benefits may never exceed two years of total fixed and variable compensation.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Non-compete undertaking</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the event of his departure from Sanofi, the Chief Executive Officer undertakes, during the 12-month period following his departure, not to join a competitor of Sanofi as an employee or corporate officer, or to provide services to or cooperate with such a competitor.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In return for this undertaking, he receives an indemnity corresponding to one year&#8217;s total compensation, based on his fixed compensation effective on the day he leaves office and on the last individual variable compensation he received prior to that date. This indemnity is payable in 12&#160;monthly instalments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">However, the Board of Directors reserves the right to release the Chief Executive Officer from that undertaking for some or all of that 12-month period. In such cases, the non-compete indemnity would not be due for the period of time waived by the Company.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Consequences of the Chief Executive Officer&#8217;s departure for equity-based compensation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If the Chief Executive Officer leaves Sanofi for reasons other than resignation or removal from office for gross or serious misconduct (in which case any award of equity-based compensation is forfeited in full), the overall allocation percentage is prorated to reflect the amount of time the Chief Executive Officer remained with Sanofi during the vesting period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If at any time prior to the expiration of the vesting period of his performance shares the Chief Executive Officer joins a competitor of Sanofi as an employee or corporate officer, or provides services to or cooperates with such a competitor, he irrevocably loses those performance shares regardless of any full or partial discharge by the Board of Directors of the non-compete undertaking relating to his office as Chief Executive Officer.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since 2021, if the Chief Executive Officer retires at the statutory retirement age prior to the expiration of the vesting period of his performance shares, the overall allocation rate will be apportioned on a </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">pro rata</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> basis to reflect the amount of time for which the Chief Executive Officer remained in the employment of Sanofi during the vesting period.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">116</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Summary of benefits awarded to the Chief Executive Officer on leaving office</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below presents a summary of the benefits (as described above) that could be claimed by the Chief Executive Officer on leaving office, depending on the terms of his departure. The information provided in this summary is without prejudice to any decisions that may be made by the Board of Directors.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:15.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Voluntary departure/Removal from office for gross or serious misconduct</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forced departure</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retirement </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Termination benefit</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">/</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 months of fixed compensation as of the date of leaving office</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 months of most recent individual variable compensation received</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amounts received as non-compete indemnity</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">/</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-compete indemnity</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 months of fixed compensation as of the date of leaving office<br/>+<br/>12 months of most recent individual variable compensation received prior to leaving office </span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 months of fixed compensation as of date of leaving office</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+</span></div><div style="margin-bottom:1pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;months&#160;of&#160;most&#160;recent individual variable compensation&#160;received prior to leaving office</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">/</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Top-up pension</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">/</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">/</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Annual contribution of up to 25% of reference compensation </span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Performance share plans not yet vested</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forfeited in full</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rights retained </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pro rata</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> to period of employment within Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rights retained </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pro rata</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> to period of employment within Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">i(f)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The amount of the termination benefit is reduced by any indemnity received as consideration for the non-compete undertaking, such that the aggregate amount of those two benefits may never exceed two years of total fixed and variable compensation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Board of Directors may decide to release the Chief Executive Officer from the non-compete undertaking for some or all of the 12-month period. In that case, the non-compete indemnity would not be due, or would be scaled down proportionately.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Defined-contribution pension plan, within the scope of Article&#160;82 of the French General Tax Code. Subject to fulfillment of the performance condition, assessed annually.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Subject to fulfillment of the performance condition assessed over the three financial years preceding departure from office, as described above.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Subject to the Board of Directors enforcing the non-compete undertaking, the amount of the termination benefit is reduced by any indemnity received as consideration for the non-compete undertaking, such that the aggregate amount of those two benefits may never exceed two years of total fixed and variable compensation.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;In this case, the Chief Executive Officer remains subject to the terms of the plans, including the performance conditions and the non-compete clause.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Policy to recover erroneously-awarded compensation (&#8220;clawback&#8221;)</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, the NASDAQ listing rules were amended to include Rule&#160;5608, in application of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Section&#160;10D-1 of the Securities Exchange Act of 1934 which requires listed companies to implement a c</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">lawback policy.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On October&#160;26, 2023, our Board of Directors adopted a clawback policy under which Sanofi must, within a reasonable time-frame, recover the portion of the Chief Executive Officer&#8217;s variable compensation (cash-based or equity-based) that is wholly or partly contingent on the attainment of financial performance criteria and was paid to him (according to the definition contained in the NASDAQ listing rules) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">based on financial information that has been determined to be erroneous and has required accounting restatement to correct an error in previously-published financial statements. The policy applies to compensation paid on or after October&#160;2, 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The clawback policy also applies to members of our Executive Committee and to our Head of Consolidation (equivalent to the Chief Accounting Officer within the meaning of the NASDAQ listing rules). </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Summary of changes made to the compensation policy for the Chief Executive Officer</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below summarizes adjustments made to how the compensation policy for the Chief Executive Officer is implemented. Some of them been thoroughly discussed with our shareholders.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:6.66pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Annual variable compensation:</span></div><div style="padding-left:22.68pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.93pt">To reflect shareholder expectations, the weighting of financial objectives has been increased from 50% to 60% (removal of criteria related to business net income, business operating income margin and new asset growth, addition of a criterion based on business earnings per share (business EPS)).</span></div><div style="text-align:right;text-indent:6.66pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:14.17pt;text-indent:-14.18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:11.79pt">Equity-based compensation:</span></div><div style="margin-bottom:2pt;padding-left:22.68pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.93pt">The criterion related to business net income has been replaced by business earnings per share (business EPS).</span></div><div style="margin-bottom:2pt;padding-left:22.68pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.93pt">To demonstrate Sanofi's commitment to delivering on the strategic roadmap, a criterion linked to the R&amp;D pipeline has been included in the Chief Executive Officer's equity-based compensation plan.</span></div><div style="margin-bottom:3pt;padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Clawback Policy:</span></div><div style="padding-left:22.68pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.93pt">Pursuant to the new NASDAQ listing rules as amended in 2023,  on October&#160;26, 2023, our Board of Directors adopted a clause allowing the clawback, in full or in part, of compensation paid to the Chief Executive Officer wholly or partly contingent on the attainment of financial criteria based on erroneous financial information.</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Annual variable compensation:</span></div><div style="padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.93pt">To reflect shareholder expectations, Sanofi is from now on disclosing the content of the qualitative criteria.</span></div><div style="text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:14.17pt;text-align:justify;text-indent:-14.18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:11.79pt">Variable equity-based compensation:</span></div><div style="padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.93pt">To link equity-based compensation (long-term compensation) to delivery of Sanofi's CSR strategy, measurable and material CSR criteria were introduced into performance share plans awarded during or after 2023.</span></div><div style="text-align:justify;text-indent:6.66pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Clawback Policy:</span></div><div style="padding-left:22.68pt;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:6.93pt">Pursuant to Section&#160;10D-1 of the Exchange Act, SEC regulations and NASDAQ listing rules, the Board of Directors were to adopt a clause allowing for the recovery of some or all of the components of the Chief Executive Officer's compensation that are wholly or partially contingent on the attainment of financial performance criteria based on erroneous financial information.</span></div></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">117</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Arrangements in favor of executive officers in office as of December&#160;31, 2023 (table No.&#160;11 of the AFEP-MEDEF Code)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:17.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.634%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Executive officer </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contract&#160;of employment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Top-up<br/>pension plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indemnities or benefits<br/>payable or<br/>potentially payable<br/>on&#160;cessation of office</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Indemnities<br/>payable under<br/>non-compete clause</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yes</span></td></tr></table></div><div id="i9fa7f69b4904450e9c43e8444c203165_328"></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation and benefits of all kinds awardable to corporate officers in respect of 2024</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The section below describes the components of the compensation and benefits of all kinds awardable to corporate officers in respect of the 2024 financial year, pursuant to the compensation policies described in &#8220;&#8212; Compensation policy for corporate officers.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits of all kinds awardable to directors in respect of 2024</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amounts to be awarded to directors in respect of 2024 will be determined in accordance with the principles described above in&#160;&#8220;&#8212; Compensation policy for corporate officers &#8212; Compensation policy for directors.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits of all kinds awardable in respect of 2024 to the Chairman&#160;of the Board of Directors</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The components of compensation awardable to the Chairman of the Board of Directors are described above in &#8220;&#8212; Compensation policy for corporate officers &#8212; Compensation policy for the Chairman of the Board of Directors.&#8221;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acting on a recommendation from the Compensation Committee, the Board of Directors meeting of February&#160;24, 2024 decided to maintain the amount of compensation payable to the Chairman of the Board of Directors at &#8364;880,000 gross with effect from&#160;May&#160;25, 2023, the date on which Fr&#233;d&#233;ric Oud&#233;a took office.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chairman of the Board of Directors does not receive any variable compensation, stock options or performance shares, in accordance with AMF&#160;recommendations. Nor does he receive any compensation (i)&#160;for serving as a director or (ii)&#160;from any company included in Sanofi&#8217;s scope of consolidation within the meaning of Article&#160;L.&#160;233-16 of the French Commercial Code.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Benefits in kind for 2024 comprise a company car with a driver.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits of all kinds awardable in respect of 2024 to Paul Hudson, Chief&#160;Executive Officer</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed and variable compensation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acting on a recommendation from the Compensation Committee, the Board of Directors meeting of February&#160;22, 2024 determined the components of Paul Hudson&#8217;s compensation for the 2024 financial year.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul Hudson&#8217;s annual compensation comprises (i)&#160;annual fixed gross compensation of &#8364;1,400,000 (see the explanations provided under &#8220;&#8212; Compensation policy for corporate officers &#8212; Compensation policy for the Chief Executive Officer&#8221; above) and (ii)&#160;annual</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> variable compensation in a range from 0% to 250% of his annual fixed compensation, with a target of 150%, and subject to both quantitative and qualitative criteria.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acting on a recommendation from the Compensation Committee, and to take account of actual market practices and comments from investors who wished to see the weighting of financial objectives increased, the Board of Directors has decided to amend the structure of annual variable remuneration. Consequently, with effect from the 2024 financial year, the objectives are based 60% (versus 50% previously) on financial indicators (sales growth, free cash flow (FCF) and business earnings per share (business EPS)), each accounting for 20%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Floors have been set for each financial criterion, below which no variable compensation is payable for that criterion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.750%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Objectives based on financial indicators</span></div></td></tr><tr><td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales growth</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales growth</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Free Cash Flow (FCF)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business net income</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business earnings per share (business EPS) </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business operating income margin</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Free Cash Flow (FCF)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Growth in new assets</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TOTAL</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">60</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">50</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">118</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors has also streamlined the individual objectives for 2024. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Individual objectives for 2024 and 2023 are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:42.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024 individual objectives</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023 individual objectives *</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business transformation </span></div><div style="text-align:justify"><span style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Reallocation of pipeline resources, Centralization, hub strategy, Smart spending), Asset Portfolio, Digital Transformation)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.0%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business transformation <br/>(CHC, Vaccines, General Medicines, Manufacturing &amp; Supply, Digital &amp; Information Systems, Specialty Care)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Development pipeline </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">M1 (Lead selection), M2 (Candidate selection), First in Human, Pivotal Studies, Submissions, Approvals</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.0%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">People and Culture<br/>(Diversity, Culture, Succession Pipeline, Simplification)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7.5%</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CSR</span></div><div style="text-align:justify"><span style="background-color:#e7e7e8;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">People &amp; Culture, Environment, Governance (reinforcement of the strategic dialogue with the Board of Directors and functioning of the new Executive Committee)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.0%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Development pipeline <br/>M1 (Lead selection), M2 (Candidate selection), First in Human, Pivotal Studies, Submissions, Approvals</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12.5%</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CSR</span></div><div style="padding-left:7.08pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:2.68pt">Enhancement and progress on CSR program: CO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:0.98pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> emissions, Affordable Access,  Development of Sanofi Global Health Unit (GHU)</span></div><div style="padding-left:7.08pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:2.68pt">Image &amp; Reputation: ongoing rollout of new corporate branding)</span></div><div style="padding-left:7.08pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:2.68pt">Compliance/ Ethics &amp; Business Integrity: launch of new Code of Conduct</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.0%</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;For details of individual objectives for 2023 refer to "&#8212; Compensation and benefits of all kinds paid during 2023 or awarded in respect of&#160;2023 to Paul Hudson, Chief Executive Officer" below.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="background-color:#ffffff;color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-based compensation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acting on a recommendation from the Compensation Committee and within the limits set out in the Chief Executive Officer's compensation policy, the Board of Directors meeting of February&#160;22, 2024 proposes awarding&#160;82,500&#160;performance shares to Paul Hudson in respect of 2024. In accordance with the AFEP-MEDEF Code, the entire award will be subject to criteria that are both internal and external: </span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">internal criteria based on business earnings per share (business EPS) 35%, free cash flow 25%, R&amp;D pipeline 10%, and CSR criteria 10%;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">external criterion (accounting for 20%) based on the change in TSR as compared with that of a panel of 12&#160;leading global pharmaceutical companies: Amgen, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Inc., Eli&#160;Lilly and Company Inc., GlaxoSmithKline plc, Johnson &amp; Johnson Inc., Merck Inc., Novartis AG, Novo Nordisk, Pfizer Inc., and Roche Holding Ltd. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the plan applicable to Executive Committee members, the TSR criterion is measured in relative terms (variation from</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> the previous ranking). That&#160;variation (the &#8220;Sanofi TSR Rank Improvement&#8221;) is determined by comparing the Endpoint Sanofi TSR Rank (established over a three-year measurement period) to the Baseline Sanofi TSR Rank (established over a one-year measurement period). TSR-linked awards would be 50% if the ranking improved by one; 100% if it improved by two; and 150% if it improved by three. For the Chief Executive Officer, any TSR-linked payment will remain contingent on Sanofi achieving an Endpoint Rank greater than or equal to the median of the TSR panel.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The CSR criteria, both of which are quantitative and which count for 10% of the award, are:</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:9.53pt">Affordable Access: providing essential medicines to non-communicable disease patients through Sanofi Global Health; and</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.46pt">Planet Care: Carbon Footprint Reduction, scopes&#160;1 &amp;&#160;2 (reduction in CO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:1.19pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> emissions vs 2019).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Details of the performance objectives applicable to the Chief Executive Officer's equity-based compensation plan for 2024, including the mechanisms used to determine the attainment level for each criterion, will be published on our corporate website, in the "Compensation" section of the "Governance" pages, in advance of the Annual General Meeting.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:26.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.162%"/><td style="width:0.1%"/></tr><tr><td colspan="18" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Summary of performance objectives applicable to equity-based compensation plans</span></div></td></tr><tr><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business earnings per share (business EPS)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Internal financial criterion</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Business net income (BNI)</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Free Cash Flow (FCF)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Internal financial criterion</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Free Cash Flow (FCF)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">R&amp;D pipeline</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Internal financial criterion</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CSR criteria</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Internal extra-financial criteria</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CSR criteria</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TSR</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">External extra-financial criterion</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TSR</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with the AFEP-MEDEF Code, Paul Hudson is bound by rules on insider trading that impose blackout periods, as contained in our Board Charter.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with the AFEP-MEDEF Code and our Board Charter, Paul Hudson has undertaken not to engage in speculative or hedging transactions, and as far as the company is aware, no hedging instruments have been contracted.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">119</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_313"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation and benefits of all kinds paid during 2023 or awarded in&#160;respect of 2023 to&#160;corporate officers</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The section below constitutes the report on compensation of corporate officers required by Article&#160;L.&#160;225-37 of the French Commercial Code. The arrangements described therein will be submitted for approval by our shareholders at the Annual General Meeting called to approve the financial statements for the year ended December&#160;31, 2023 pursuant to Article&#160;L.&#160;22-10-34 of the French Commercial Code.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_316"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation elements and benefits of all kinds paid during 2023 or awarded in respect of 2023 to&#160;directors</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The compensation policy for directors (as described above in the section entitled &#8220;&#8212;&#160;Compensation policy for directors&#8221;) defines the fixed amount of compensation, and the principles for allocating the variable portion between directors, up to the limit of the overall amount approved by the Annual General Meeting.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Directors&#8217; compensation includes an annual fixed payment, apportioned on a time basis for directors who assumed or left office during the year; and a variable amount, allocated by the Board according to actual attendance at Board and Committee meetings. As required by the AFEP-MEDEF Code, directors&#8217; compensation is allocated predominantly on a variable basis.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2023, directors&#8217; compensation was determined in accordance with the compensation policy for directors as described above in the section entitled &#8220;&#8212;&#160;Compensation policy for directors.&#8221;</span></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Compensation allocated to directors for serving as directors (table No.&#160;3 of the AFEP-MEDEF Code)</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows amounts paid in respect of 2023 and 2022 to each member of our Board of Directors, including those whose term of office ended during those years.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Directors&#8217; compensation for 2022, the amount of which was approved at the Board meeting of February&#160;22, 2023, was partially paid in July&#160;2022, with an additional payment made in 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Directors&#8217; compensation for 2023, the amount of which was approved at the Board meeting of February&#160;22, 2024, was partially paid in July&#160;2023, with an additional payment to be made in 2024.</span></div><div style="margin-bottom:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.612%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.991%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.991%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.991%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.896%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Compensation in respect of 2023</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Compensation in respect of 2022</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fixed<br/>portion</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Variable<br/>portion</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total amount (variable + fixed portion)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fixed<br/>portion</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Variable<br/>portion</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total gross<br/>compensation</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total gross compensation apportioned on a pro rata basis</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(*)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Christophe Babule</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104,500&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134,500&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129,250&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159,250&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134,912&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rachel Duan</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Carole Ferrand</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86,835&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lise Kingo</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118,250&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148,250&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144,231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patrick Kron</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145,750&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175,750&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139,571&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wolfgang Laux</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99,966&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Barbara Lavernos</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabienne Lecorvaisier</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Melanie Lee</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carole Piwnica</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gilles Schnepp</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145,750&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175,750&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155,879&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diane Souza</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">217,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200,144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thomas S&#252;dhof</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">192,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197,814&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yann Tran</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)fi)(g)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90,647&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emile Voest</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)(h)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103,143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Antoine Yver</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)(h)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">217,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133,429&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fr&#233;d&#233;ric Oud&#233;a</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,016&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45,016&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,769&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">432,016</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,856,250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,288,266</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">420,000</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,922,250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,342,250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,999,948</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;Due to the high number of Board and committee meetings, the theoretical amount of compensation payable to directors exceeded the maximum amount set by the Annual General Meeting of our shareholders. Consequently, the amount payable to each director was scaled down on a pro rata basis, as explained above.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The amounts reported are gross amounts before taxes.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Director resident outside Europe.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Director resident outside France but within Europe.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Director appointed by the European Works Council.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Director representing employees.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Director who resigned from office on May&#160;2, 2022. </span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Compensation due to Yann Tran is paid directly to F&#233;d&#233;ration Chimie &#201;nergie CFDT.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Director appointed by the CFDT, the leading trade union organization with Sanofi in France.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Director appointed by the General Meeting of May&#160;3, 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Non-voting Board member appointed by the Board of Directors on September&#160;2, 2022 until his appointment as Chairman of the Board on May 25, 2023. In accordance with the Articles of Association, the compensation of the non-voting Board member is deducted from the annual amount allocated by the General Meeting. </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">120</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Each of the two directors representing employees has a contract of employment with a Sanofi subsidiary, under which they receive compensation unrelated to their office as director. Consequently, that remuneration is not disclosed.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Variable compensation allocated to directors in respect of 2023 represented 81% of their total compensation.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_319"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits of all kinds paid during 2023 or awarded in respect of&#160;2023 to Serge&#160;Weinberg, Chairman of the Board of Directors from January 1, 2023 to May 25, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Serge Weinberg held the office of Chairman of the Board of Directors from May&#160;17, 2010 to May&#160;25, 2023. He never had a contract of employment with Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Serge Weinberg was a member of the Appointments, Governance and CSR Committee, the Scientific Committee and the Strategy Committee.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The remit of the Chairman of the Board is specified in the Board Charter, which is reproduced in its entirety in Exhibit&#160;1.2. to this annual report.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During 2023, the activities of Serge Weinberg as Chairman of the Board of Directors included:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">chairing meetings held from January&#160;1, 2023 through May&#160;25, 2023 (six meetings of the Board of Directors, three meetings of the Strategy Committee); attending meetings of Committees of which he was a member (two meetings of the Appointments, Governance and CSR Committee, one meeting of the Scientific Committee); and participating in Committee meetings to which he was invited (Audit Committee and Compensation Committee);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">close monitoring of the proper implementation of the decisions taken by the Board;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">discussions with Fr&#233;d&#233;ric Oud&#233;a, appointed Chairman of the Board of Directors at the close of the Annual General Meeting held on May 25, 2023, to (i)&#160;explain to him how the Board operates and answer his questions, (ii)&#160;in connection with the evaluation of the Board&#8217;s operating procedures, and (iii)&#160;on matters relating to the projects presented to the Board;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">meetings with directors in connection with (i)&#160;the evaluation of the Board&#8217;s operating procedures and (ii)&#160;matters relating to the projects presented to the Board;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">regular meetings with the members of the Executive Committee;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">meetings with Sanofi employees and visits to subsidiaries of Sanofi;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">meetings with biotechs and medtechs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">organizing the strategy seminar held in April&#160;2023; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">representing Sanofi at events or official meetings (in France and abroad) with representatives of the public authorities and other stakeholders, in line with his remit as defined by the Board Charter.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chairman also has a role in explaining positions taken by the Board within its sphere of competence, especially in terms of strategy, governance and executive compensation. In furtherance of this role, Serge Weinberg drew on his experience of corporate communication&#160;in:</span></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"> answering letters from investors and shareholders; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">holding meetings with certain shareholders and proxy advisors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those tasks were carried out in coordination with the Chief Executive Officer.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Compensation paid in respect of the 2023 financial year (from January&#160;1, 2023 to May&#160;25, 2023)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;22, 2022, acting on a recommendation from the Compensation Committee, the Board of Directors determined the components of Serge Weinberg&#8217;s compensation for the 2023 financial year. For that financial year, Serge Weinberg&#8217;s annual fixed compensation was &#8364;800,000 gross, unchanged from the 2022 financial year. Over the period from January 1 to May 25, 2023, Serge Weinberg's compensation amounted to &#8364;324,964 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">gross.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In line with our compensation policy for the Chairman of the Board, as approved by our shareholders at the Annual General Meeting of May&#160;25, 2023, he did not receive any variable compensation, and was not awarded any stock options or performance shares. He received no compensation for serving as a director, and no compensation from any company included in Sanofi&#8217;s scope of consolidation within the meaning of Article&#160;L.&#160;233-16 of the French Commercial Code.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount reported in 2023 for benefits in k</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ind (&#8364;3,225</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) relates to a company car with a driver.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Serge Weinberg was not covered by the Sanofi defined-contribution pension plan.</span></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Compensation, options and shares awarded to Serge Weinberg (table No.&#160;1 of the AFEP-MEDEF Code)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:70.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compensation awarded for the year (details provided in the following table)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">324,964</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">807,740</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Valuation of stock options awarded during the year</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Valuation of performance shares awarded during the year</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Valuation of other long-term compensation plans</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">324,964</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">807,740</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">121</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Compensation awarded to Serge Weinberg (table No.&#160;2 of the AFEP-MEDEF Code)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:41.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts <br/>due </span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts <br/>paid</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts <br/>due</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts <br/>paid</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed compensation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321,739 (b)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321,739 (b)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">800,000</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">800,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Annual variable compensation</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exceptional compensation</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compensation for serving as a director</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Benefits in kind</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,225</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,225</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,740</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,740</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">324,964 (b)</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">324,964 (b)</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">807,740</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">807,740</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The amounts reported are gross amounts before taxes.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Fixed compensation due in respect of a given year is paid during that year.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Compensation apportioned on a pro rata time basis for the period from January&#160;1, 2023 through May&#160;25, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits of all kinds paid during 2023 or awarded in respect of&#160;2023 to Fr&#233;d&#233;ric&#160;Oud&#233;a, Chairman of the Board of Directors from May&#160;25, 2023 onwards</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Fr&#233;d&#233;ric Oud&#233;a was appointed Chairman of the Board of Directors on May&#160;25, 2023. He does not have a contract of employment with Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As Chairman of the Board, Fr&#233;d&#233;ric Oud&#233;a is a member of the Appointments, Governance and CSR Committee and the Scientific Committee, and Chair of the Strategy Committee.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The remit of the Chairman of the Board is specified in the Board Charter, which is reproduced in its entirety in Exhibit&#160;1.2. to this annual report.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During 2023, the activities of Fr&#233;d&#233;ric Oud&#233;a as Chairman of the Board of Directors included:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">chairing meetings of the Board of Directors held from May&#160;25, 2023 through December&#160;31, 2023 (five meetings); attending  meetings of Committees of which he is a member (three meetings of the Appointments, Governance and CSR Committee, five meetings of the Strategy Committee, and five meetings of the Scientific Committee); and participating in Committee meetings to which he was invited (Audit Committee and Compensation Committee);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">close monitoring of the proper implementation of the decisions taken by the Board;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">meetings with directors, including (i)&#160;in connection with the evaluation of the Board&#8217;s operating procedures, (ii) on matters relating to the projects presented to the Board, and (iii) on corporate governance matters;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">regular meetings with the members of the Executive Committee;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">meetings with Sanofi employees and visits to subsidiaries of Sanofi;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">meetings with biotechs and medtechs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">organizing the strategy seminar held in October&#160;2023; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">representing Sanofi at events or official meetings (in France and abroad) with representatives of the public authorities and other stakeholders, in line with his remit as defined by the Board Charter.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chairman also has a role in explaining positions taken by the Board within its sphere of competence, especially in terms of strategy, governance and executive compensation. In furtherance of this role, Fr&#233;d&#233;ric Oud&#233;a drew on his experience of corporate communications&#160;in:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">answering letters from investors and shareholders;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">holding meetings with certain shareholders.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those tasks were carried out in coordination with the Chief Executive Officer.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Compensation paid in respect of the 2023 financial year (from May&#160;25, 2023 onwards)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;22, 2023, acting on a recommendation from the Compensation Committee, the Board of Directors set the annual compensation of the new Chairman of the Board of Directors at &#8364;880,000 gross. Over the period from May 25, 2023 to December 31, 2023, Fr&#233;d&#233;ric Oud&#233;a's compensation amounted to &#8364;5</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">28,505 gross.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In line with our compensation policy for the Chairman of the Board, Fr&#233;d&#233;ric Oud&#233;a did not receive any variable compensation, and was not awarded any stock options or performance shares. He received no compensation for serving as a director, and no compensation from any company included in Sanofi&#8217;s scope of consolidation within the meaning of Article&#160;L.&#160;233-16 of the French Commercial Code.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Benefits in k</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ind for the period from May&#160;25, 2023 to December&#160;31, 2023 were &#8364;2,418</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, and relate to a company car with a driver.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Fr&#233;d&#233;ric Oud&#233;a is not covered by the Sanofi defined-contribution pension plan.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">122</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Compensation, options and shares awarded to Fr&#233;d&#233;ric Oud&#233;a (table No.&#160;1 of the AFEP-MEDEF Code)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:70.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compensation awarded for the year (details provided in the following table)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">528,505&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A (b)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Valuation of stock options awarded during the year</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Valuation of performance shares awarded during the year</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Valuation of other long-term compensation plans</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">528,505</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">N/A (b)</span></td></tr></table></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Compensation awarded to Fr&#233;d&#233;ric Oud&#233;a (table No.&#160;2 of the AFEP-MEDEF Code)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:41.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts <br/>due </span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts <br/>paid</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts <br/>due</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts <br/>paid</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed compensation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">526,087&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">526,087&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Annual variable compensation</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exceptional compensation</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compensation for serving as a director</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Benefits in kind</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,418&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,418&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">528,505</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">528,505</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The amounts reported are gross amounts before taxes.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Fixed compensation due in respect of a given year is paid during that year.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Compensation awarded to Fr&#233;d&#233;ric Oud&#233;a for service as a non-voting Board member, an office he held from September&#160;2, 2022 to May&#160;25, 2023 (the date on which he was appointed Chairman of the Board of Directors), is disclosed in the section entitled "Compensation elements and benefits of all kinds paid during 2023 or awarded in respect of 2023 to directors" above.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i9fa7f69b4904450e9c43e8444c203165_322"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and benefits of all kinds paid during 2023 or awarded in respect of&#160;2023 to Paul Hudson, Chief Executive Officer</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul Hudson has served as Chief Executive Officer of Sanofi since September&#160;1, 2019, and holds office for an indeterminate period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul Hudson does not have a contract of employment with Sanofi, and receives no compensation from any company included in Sanofi&#8217;s scope of consolidation within the meaning of Article&#160;L.&#160;233-16 of the French Commercial Code.</span></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Compensation awarded to Paul Hudson (table No.&#160;1 of the AFEP-MEDEF Code)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:66.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compensation awarded for the year (details provided in the following table)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,792,797</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,750,797</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Valuation of performance shares awarded during the year</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,779,025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,967,950</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,571,822</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,718,747</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Weighting between (i)&#160;fair value determined using the Monte Carlo model and (ii)&#160;market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The parameters used to calculate the valuations are market parameters available in the financial press.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">123</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Fixed and variable compensation awarded to Paul Hudson (table No.&#160;2 of the AFEP-MEDEF Code)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:32.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.100%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.106%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts <br/>due</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">paid </span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts <br/>due</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts <br/>paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed compensation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,400,000</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,400,000</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,400,000</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,400,000</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Annual variable compensation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,379,300</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,337,300</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,337,300</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,308,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash bonus (sign-on bonus)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"><div style="margin-bottom:2pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"><div style="margin-bottom:2pt;text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,013,534</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exceptional compensation</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compensation for serving as a director</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Benefits in kind</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,497</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,497</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,497</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,497</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,792,797</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,750,797</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,750,797</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,735,831</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The amounts reported are gross amounts before taxes.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Fixed compensation due in respect of a given year is paid during that year.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Variable compensation in respect of a given year is determined at the start of the following year and paid after the Annual General Meeting in that year, subject to shareholder approval.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Cash bonus in respect of the 2021 financial year (Second Tranche of the Phantom Stock Units plan), vesting of which was subject to performance conditions (see separate section below). The Board meeting of February&#160;22, 2022 formally noted the attainment level of the performance conditions, and the overall allocation rate. Paul Hudson was awarded 21,775&#160;Phantom Stock Units in respect of 2021. The amount disclosed in this table represents the final valuation of the 21,775&#160;Phantom Stock Units in respect of 2021 determined as of March&#160;31, 2022 (the vesting date of the Second Tranche).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fixed and variable compensation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;22, 2024, acting on a recommendation from the Compensation Committee, the Board of Directors determined the components of Paul Hudson&#8217;s compensation for the 2023 financial year.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chief Executive Officer&#8217;s annual compensation for 2023 comp</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">rises (i)&#160;annual fixed gross compensation of &#8364;1,400,000; and&#160;(ii)&#160;in line with our compensation policy for the Chief Executive Officer as approved by our shareholders at the Annual General Meeting of May&#160;25, 2023, annual variable compensation in a range from 0% to 250% of his annual fixed compensation, with a target of 150%, and subject to both quantitative and qualitative criteria.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The objectives applicable to annual variable compensation in respect of 2023 were:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">50% based on financial indicators (sales growth, BNI, FCF, BOI margin and growth of new assets, each accounting for one-fifth); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">50% based on specific individual objectives. For 2023, the individual objectives set by the Board were:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">business transformation (15%) &#8211;&#160;quantitative and qualitative objective,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">development pipeline (12.5%) &#8211;&#160;quantitative objective,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">people and culture (7.5%) &#8211;&#160;quantitative and qualitative objective, and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">CSR (15%) &#8211;&#160;quantitative and qualitative objective.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the start of 2023, the Board of Directors established a precise matrix for determining each of the individual objectives. To reflect shareholder expectations, Sanofi discloses the content of the qualitative criteria, accompanied by narrative for each sub-criterion explaining the level of attainment reached. Those criteria are always assessed by reference to the performances of the leading global pharmaceutical companies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">124</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_7234"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acting on a recommendation from the Compensation Committee, the Board of Directors meeting of February&#160;22, 2024 reviewed the attainment level of each criterion and sub-criterion. The Board&#8217;s conclusions are summarized in the table below. </span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:3.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.715%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Criterion</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weight</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Target/Maximum<br/>(as % of fixed compensation)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attainment level</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comments</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payout<br/>(as % of fixed compensation)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">2022 reference</span></div></td></tr><tr><td colspan="24" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial objectives</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Sales growth</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Quantitative</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">10%</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">15%/25%</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">112.90%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Confidential target,</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Performance above budget</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">16.93&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">17.14&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Business net</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Quantitative</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">10%</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">15%/25%</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">112.43%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Confidential target,</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Performance above budget</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">16.86&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">19.87&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Free cash flow</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Quantitative</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">10%</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">15%/25%</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">105.61%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Confidential target,</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Performance above budget</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">15.84&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">17.77&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Business operating income margin</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Quantitative</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">10%</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">15%/25%</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">104.00%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Confidential target,</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Performance above budget</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">15.60&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">15.30&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Growth in new key assets</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Quantitative</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">10%</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">15%/25%</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">157.79%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">DUPIXENT and vaccines performance significantly over budget</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">23.66&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">16.35&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">%</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">125</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:3.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.715%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Criterion</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weight</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Target/Maximum<br/>(as % of fixed compensation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attainment level</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payout<br/>(as % of fixed compensation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">2022 reference</span></div></td></tr><tr><td colspan="24" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Individual objectives</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr style="height:96pt"><td colspan="6" rowspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Business Transformation</span></td><td colspan="3" rowspan="6" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Quantitative / Qualitative</span></td><td colspan="3" rowspan="6" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">15%</span></td><td colspan="3" rowspan="6" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">22.5% / 37.5%</span></td><td colspan="3" rowspan="6" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">101.83%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Vaccines:</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">mRNA: On track for First Visit of First Subject for a new lipid </span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">R&amp;D: 2 successful POCC achieved, 2 First-in-Human objectives achieved out of a target of 3</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Nirsevimab: US license for BEYFORTUS  granted on time and file submission in Japan completed on time. Obtained unanimous Positive ACIP recommendation &amp; VFC inclusion in August 2023</span></div></td><td colspan="2" rowspan="6" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">22.91&#160;</span></td><td rowspan="6" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td><td colspan="2" rowspan="6" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">22.61&#160;</span></td><td rowspan="6" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td></tr><tr style="height:71pt"><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">General Medicines:</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Accelerated core assets growth almost at budget impacted by price challenges</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Continued portfolio simplification, exceeding the 2023 divestment and product family reduction targets</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">SOLIQUA launch and acceleration of TOUJEO in China</span></div></td></tr><tr style="height:63pt"><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Speciality Care:</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">DUPIXENT sales: performance above target </span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Launch of ALTUVIIIO in the US : sales above consensus</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Amlitelimab data presented at the European Academy of Dermatology and Venerology (EADV) 2023 congress  </span></div></td></tr><tr style="height:47pt"><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">CHC: </span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Acceleration on digital and e-commerce sales </span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Carve-out scope finalized</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Progress made on CIALIS and TAMIFLU switches</span></div></td></tr><tr style="height:71pt"><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Manufacturing and Supply:</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Significant acceleration in 2023 for M&amp;S Transformation, with key performance outcomes improved across Safety, Quality, Supply and Cost, and improved industrial performance delivered vs. 2022</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Excellent performance of service level for Specialty Care</span></div></td></tr><tr style="height:105pt"><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Digital:</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Contribution to BOI above target due to value creation</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Acceleration of commercial transformation with a Digital-first, AI-first approach to Health Care Providers and Sales Reps: on target, adjustments made to include priority products in the US launch</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Digital and data-driven mindset development program for senior executives: exceeded target, with 93% of this population having completed the program by Feb 2024</span></div></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">People &amp; Culture</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Quantitative/</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Qualitative</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">7.5%</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">11.25%/18.75%</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">105.00%</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Reduction of voluntary turnover of women in senior roles </span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">The succession pipeline for Key Value Driving Roles has been strengthened</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Progress on Sanofi culture shift (engagement score increased) </span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Individual Development Plans in place for senior high potentials: exceeds target </span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:8.95pt">Delivery of simplification projects above the original goal </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">11.81&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">11.03&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">126</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:3.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.715%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Criterion</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weight</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Target/Maximum<br/>(as % of fixed compensation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attainment level</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payout<br/>(as % of fixed compensation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">2022 reference</span></div></td></tr><tr style="height:99pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">CSR</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Further reinforce and expand on the CSR agenda</span></div></td><td colspan="3" rowspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Quantitative/</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Qualitative</span></div></td><td colspan="3" rowspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">15%</span></div></td><td colspan="3" rowspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">22.5%/37.5%</span></div></td><td colspan="3" rowspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">105.00%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">Year on year Scope 1 and 2 CO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:112%;position:relative;top:0.98pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%"> emissions reduced by 12% </span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">Global Access Plans developed for products in Vaccines, Specialty Care and General Medicines</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">5 countries enrolled in the A Million Conversations program (quantitative)</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">260K patients with non-communicable diseases (NCDs) reached by the Global Health Unit (GHU) Impact fund, ahead of target </span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">Several investments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%"> made under the GHU  </span></div></td><td colspan="2" rowspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">23.63&#160;</span></td><td rowspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td><td colspan="2" rowspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">24.75&#160;</span></td><td rowspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td></tr><tr style="height:51pt"><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Image and Reputation</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">Built and grew strong corporate brand equity, establishing solid brand governance, built strong connections of Sanofians with the brand, purpose, and ambition within 18 months post-launch</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">Partnership with Paris 2024 Olympic Games   </span></div></td></tr><tr style="height:60pt"><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Compliance / Ethics &amp; Business Integrity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">Fully digital and modernized digital Code of Conduct with supporting training rolled out to all employees</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">Deployed a unified Sanofi thoughtful decision-making framework for all employees with practical experimentation and progress measured</span></div></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Development </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">pipeline</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Quantitative</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">12.5%</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">18.75%/31.25%</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">120.82%</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">R&amp;D has achieved above execution focused KPI : 15 entries into M1, 15 development candidates i</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">nto M2, 9 assets have entered the clinical phase (FIH), 12 submissions (including 3 accelerated), 4 Phase 3 studies initiated </span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">Total of 11 approvals (including 2 accelerated approvals of DUPIXENT in asthma and PN in China) vs 14 in 2022 and one NME (ALTUVIIIO in hemophilia)</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">Reinforcement of the pipeline through Business Development or Acquisitions: 16 pharma and 4 vaccines partnerships signed. Acquisition and full integration of Provention Bio (Pharma)</span></div><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%;padding-left:8.95pt">R&amp;D and PLai.gra have made significant progress in delivering AI powered decision intelligence</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">22.65&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">22.13&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;border-top:0.25pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100%</span></td><td colspan="3" style="background-color:#7802e6;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">150%/250%</span></td><td colspan="3" style="background-color:#7802e6;border-top:0.25pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">113.30%</span></td><td colspan="3" style="background-color:#7802e6;border-top:0.25pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">169.89</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">166.95</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.25pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;For a definition, see &#8220;Item&#160;5. Operating and Financial Review and Prospects &#8211; A. Operating results &#8212; 1.5. Business net income&#8221; in this annual report.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div id="i9fa7f69b4904450e9c43e8444c203165_7274"></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acting on a recommendation from the Compensation Committee, the Board of Directors meeting of February&#160;22, 2024 set Paul&#160;Hudson&#8217;s variable compensation for 2023 at &#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,379,300 gross, equivalent to 169,9% of</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> h</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">is fixed</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> compensation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payment of Paul Hudson&#8217;s variable compensation in respect of the 2023 financial year is contingent on approval of his compensation package by the shareholders in an Ordinary General Meeting, on the terms stipulated in Article&#160;L.&#160;22-10-34&#160;II of the French Commercial&#160;Code.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">127</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Equity-based compensation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Using the authorizations granted by our shareholders via the twenty-fourth resolution at the Annual General Meeting of&#160;April&#160;30,&#160;2021, and acting on the recommendations of the Compensation Committee, the Board of Directors meeting of&#160;May&#160;25,&#160;2023 decided to&#160;award Paul Hudson 82,500&#160;performance shares in respect of 2023. The valuation of that award as of&#160;May&#160;25, 2023, determined in accordance with&#160;IFRS and incorporating a market-related condition, was &#8364;6,779,025, equivalent to&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4.84</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;times his fixed compensation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The entire amount of the award is contingent upon the achievement of performance objectives based on (i) internal criteria based upon BNI, FCF and CSR, and (ii) an external criterion based on improvement in TSR relative to that of a benchmark panel of 12&#160;leading global pharmaceutical companies (plus Sanofi): Amgen, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Inc., Eli Lilly and Company Inc., GlaxoSmithKline plc, Johnson &amp; Johnson&#160;Inc., Merck Inc., Novartis AG, Novo Nordisk, Pfizer Inc., and Roche Holding Ltd.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To align equity-based compensation on our medium-term performance, a three-year period (2023-2025) is used to measure performance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The above criteria were selected because they align medium-term equity-based compensation on the strategy adopted by Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The arrangements relating to these awards are as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the performance criterion based on BNI accounts for 45% of the award. That criterion corresponds to the ratio, at constant exchange rates, of actual BNI to budgeted BNI. It represents the average actual-to-budget ratio attained over the entire period. Budgeted BNI is derived from the budget as approved by the Board of Directors at the beginning of each financial year. The BNI objective may not be lower than the bottom end of the full-year guidance range publicly announced by Sanofi at the beginning of each year. If the attainment level is less than 95%, the corresponding performance shares are forfeited.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:14.17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.064%"><tr><td style="width:1.0%"/><td style="width:69.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.238%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">BNI actual-to-budget attainment level (B)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">BNI allocation rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B &lt;&#160;95%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B =&#160;95%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B is &gt;&#160;95% but &lt;&#160;98%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50 + [(B - 95) x 16])%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B is &#8805;&#160;98% but &#8804;&#160;105%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B is &gt;&#160;105% but &lt;&#160;110%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(105 + [(B - 105) x 3])%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B is &#8805;&#160;110%</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120%</span></td></tr></table></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the FCF criterion accounts for 25% of the award. This criterion was selected because it is aligned with Sanofi&#8217;s current strategic objectives, and is transparent both within and outside the company.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The FCF criterion represents the average actual-to-budget FCF ratio attained over the entire period. The award is based on a target FCF, below which some or all of the performance shares are forfeited.</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:14.17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.064%"><tr><td style="width:1.0%"/><td style="width:69.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.238%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">FCF actual-to-budget attainment level (F)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">FCF allocation rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F is &#8804;&#160;70%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F is &gt;&#160;70% but &lt;&#160;80% </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">[(F - 70) x 5]%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F =&#160;80%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F is &gt;&#160;80% but &lt;&#160;100%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50 + [(F &#8211; 80) x 2.5])%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F =&#160;100%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F is &gt;&#160;100% but &lt;&#160;120%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">F%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F is &#8805;&#160;120% </span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120%</span></td></tr></table></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the criterion based on TSR Rank Improvement accounts for 20% of the award. It corresponds to the change in rank of Sanofi&#8217;s TSR when compared to the TSR of peer companies included in a panel. The TSR corresponds to the trading price of Sanofi shares increased by the dividends per share during the measurement periods, without reinvestment. Sanofi TSR Rank Improvement is determined by comparing the Endpoint Sanofi TSR rank to the Baseline Sanofi TSR rank.</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">The Baseline Sanofi TSR is equal to the following formula: (average prices of 2022 &#8211;&#160;average prices of 2021 +&#160;dividends per share 2022)/average prices of 2021.</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">The Endpoint Sanofi TSR is equal to the following formula: (average prices of 2025 &#8211;&#160;average prices of 2022 +&#160;dividends per share 2023 to 2024)/average prices of 2022.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">128</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our TSR is compared with the benchmark panel of 12&#160;companies listed above, so as to determine the ranking of Sanofi within the panel. The number of performance shares vesting depends upon the improvement in our TSR ranking, as follows:</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:14.17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.064%"><tr><td style="width:1.0%"/><td style="width:48.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sanofi's improvement in the rankings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TSR allocation rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+3 or more</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No improvement</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Even if there is an improvement in Sanofi&#8217;s TSR ranking based on the principles set out above, no TSR allocation can be made if Sanofi&#8217;s ranking is below median TSR, defined as the performance of the company ranked seventh in the panel;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the CSR-based criterion accounts for 10% of the award. This performance condition has been added to our equity-based compensation plans with effect from 2023, and equates to the attainment over a three-year period of annual objectives plus a "stretch" objective, linked to the following pillars of Sanofi&#8217;s CSR strategy:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.7pt">Affordable Access: providing essential medicines to non-communicable disease patients through Sanofi Global Health,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:4.63pt">Planet Care: Carbon Footprint Reduction, scopes&#160;1 &amp;&#160;2 (% reduction in CO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:1.19pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> emissions vs 2019).</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Attainment of each annual CSR objective will earn one performance point; a maximum of three points, plus one extra point linked to the "stretch" objective, can be earned for each CSR pillar. For each criterion, attainment of the objectives for 2025 will earn three points even if the annual objectives were not attained.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the end of the period, the Board of Directors will determine the CSR Allocation Rate, corresponding to the number of points earned, as shown, below:</span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:14.17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.064%"><tr><td style="width:1.0%"/><td style="width:47.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CSR points earned</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CSR Allocation Rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Less than 3 points</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 points</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 points</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 points</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 points</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 points</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 points</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120%</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Other terms and conditions</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul Hudson is under an obligation to retain, until he ceases to hold office, a quantity of Sanofi shares equivalent to 50% of any gain (net of taxes and social contributions) arising on the vesting of his performance shares, calculated as of the date on which those shares vest.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In compliance with the AFEP-MEDEF Code and our Board Charter, Paul Hudson has undertaken to refrain from entering into speculative or hedging transactions, and so far as Sanofi is aware no hedging instruments have been contracted.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:9pt;font-weight:400;line-height:120%">Historical allocation rates</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the interests of transparency, we disclose below attainment levels and allocation rates for the most recent performance-linked equity-based compensation plans awarded to our Chief Executive Officer (bearing in mind that only the April&#160;28, 2020 and the April 30, 2021 Plans apply to Paul Hudson):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Attainment level</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allocation rate</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">BNI</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">FCF</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TSR</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April&#160;30, 2019 plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019-2021: 101.99%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019-2021: 127.67% </span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019-2021: 50% </span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019-2021: 97.00%<br/></span><span style="font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">i.e. 213,400 stock options and 48,500&#160;performance shares</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April&#160;28, 2020 plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020-2022: 103.27%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020-2022: 117.67%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020-2022: 0%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020-2022: 86.94%<br/></span><span style="font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">i.e. 65,205 performance shares</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April&#160;30, 2021 plans</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021-20</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23: 103.58%</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021-2023: 110.31%</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021-20</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23: 51.77%</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021-2</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">023: 95.23%</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">i.e. 71,423 </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">performance shares</span></div></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">129</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Performance shares awarded to Paul Hudson in 2023 (table No.&#160;6 of the AFEP-MEDEF Code)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:7.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Plan date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation of <br/>performance shares (&#8364;)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of performance<br/>shares awarded<br/>during the period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vesting<br/>date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Availability</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">date</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance conditions</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/25/2023</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,779,025&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">82,500</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">05/25/2026</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">05/25/2026</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yes</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Under the terms of our Board Charter, Paul Hudson is required to retain a quantity of shares corresponding to 50% of the capital gain arising on the vesting of the shares, net of the associated taxes and social contributions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Each performance share awarded on May&#160;25</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, 2023, was valued at &#8364;82.17, valuing the total benefit at &#8364;6,779,025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The General Meeting of April&#160;30, 2021 restricted the number of performance shares that can be awarded to executive&#160;officers to&#160;5% of the overall limit (set at 1.5% of the share capital). The number of shares awarded to Paul Hudson in 2023 r</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">epresents&#160;0.44% of the total limit approved by that Meeting and 0.006% of our share capital at the date of grant.</span></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Performance shares awarded to Paul Hudson which became available in 2023 (table No.&#160;7 of the AFEP-MEDEF Code)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul Hudson was awarded 75,000 performance shares on April 28, 2020. The Board of Directors meeting of February 22, 2023 noted the level of achievement of the performance conditions applicable to this plan (86.94%), and Paul Hudson was definitively allotted 65,205 shares on May 2, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.897%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="background-color:#ffffff;color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="background-color:#ffffff;color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Plan date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="background-color:#ffffff;color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of performance</span></div><div style="text-align:right"><span style="background-color:#ffffff;color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">shares awarded (after vesting)</span></div><div style="text-align:right"><span style="background-color:#ffffff;color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">during the period</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 28, 2020</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65,205</span></td></tr></table><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with the Compensation policy for the Chief Executive Officer, until he ceases to hold office Paul Hudson must retain a quantity of Sanofi shares equivalent to&#160;50% of any gain arising on the vesting of performance shares calculated on the date of delivery of the shares, net of taxes and social security/health insurance contributions that would apply in the event of a sale on such date (i.e. on May 2, 2023, the delivery date), at the highest applicable marginal rate. Pursuant to that rule, Paul Hudson must retain 10,589 shares under the plan dated April 28, 2020.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because awards of stock options to our Chief Executive Officer are not permitted under our compensation policy, tables No.&#160;4 and No.&#160;5 of the AFEP-MEDEF Code are not applicable.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pension rights</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul Hudson is entitled to benefits under the top-up defined-contribution pension plan introduced within Sanofi on&#160;January&#160;1,&#160;2020. Under the terms of the plan, the Chief Executive Officer receives (subject to attainment of a performance condition) an annual contribution of up to 25% of his reference compensation (annual fixed and variable compensation).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The performance condition for the vesting of pension rights is linked to the attainment of the performance criteria for 2023 variable compensation. The Board of Directors, at its meeting of February&#160;22, 2024, ascertained whether that performance condition had been met, noting that the attainment level for the variable portion of Paul Hudson&#8217;s compensation for the 2023 financial year was 2,379,300%, i.e. 169.9% of his fixed compensation. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The annual gross contribution is paid as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">50% as a gross insurance premium to the fund manager &#8211;&#160;the amount due to the fund manager with respect to 2023 is &#8364;472,412.50; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">50% to Paul Hudson, to indemnify him for the social security and tax charges for which he will become immediately liable. The amount due to Paul Hudson with respect to 2023 was set by the Board of Directors at its meeting of February&#160;22, 2024 at&#160;&#8364;472,412.50.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payment of those amounts is contingent on approval of the Chief Executive Officer&#8217;s compensation package by the shareholders in an Ordinary General Meeting, on the terms stipulated in Article&#160;L.&#160;22-10-34&#160;II of the French Commercial Code.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Social welfare and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">health insurance</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Paul Hudson is subject to, benefits from and contributes to the same health cover, and death and disability plans as are applicable to other employees of Sanofi based in France. He also benefits from an unemployment insurance scheme.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Benefits in kind</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The benefits in kind received by Paul Hu</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">dson in 2023 were valued at &#8364;13,497, and correspond to a company car with a driver.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">130</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_331"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Compensation and benefits for other Executive Committee members</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The compensation of Executive Committee members other than the Chief Executive Officer is reviewed by the Compensation Committee, taking into consideration the practices of leading global pharmaceutical companies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition to fixed compensation, they receive variable compensation. Their target variable compensation depends on their position, and can represent up to 100% of their fixed compensation. The target amount of individual variable compensation is determined in line with market practice. It rewards the joint contribution of all Executive Committee members to Sanofi&#8217;s performance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Fo</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">r 2023, the variable component consisted of two elements:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">attainment of quantitative objectives (accounting for 50%) which are measured at consolidated level: sales growth 30%, ratio of BOI to net sales (&#8220;BOI margin&#8221;) 35%, research and development outcomes 20%, and FCF&#160;15%; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">attainment of quantitative and qualitative objectives both individually (30%) and collectively (20%) within the Executive Committee (together accounting for 50%).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The indicators used are intended to</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> measure Sanofi&#8217;s annual performance objectives; individual objectives; and the attainment of people objectives, individual career development plans, transformation of the corporate culture to align with the &#8220;Play to Win&#8221; strategy, and reducing Sanofi's carbon footprint.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, Executive Committee members may be awarded performance shares.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2023, the total gross compensation paid and accrued in respect of members of the Executive Committee (excluding the Chief Executive Officer) was &#8364;21&#160;million, including &#8364;8&#160;million in fixed compensation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A total of </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">190,648</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;performance shares were awarded in 2023 to members of the Executive Committee (excluding the award to the Chief Executive Officer). No stock options were awarded to members of the Executive Committee or the Chief Executive Officer  in 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In compliance with the AFEP-MEDEF Code, these entire awards are contingent upon three internal criteria, based on business net income (BNI)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, free cash flow (FCF)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, and Corporate Social Responsibility (CSR) indicators; and on an external criterion, based on TSR. Those criteria were selected because they align equity-based compensation with the strategy adopted by Sanofi. The Board believes that the performance conditions applied are good indicators of shareholder value creation in terms of the quality of investment decisions and the commitment to deliver exacting financial results in a difficult economic environment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The arrangements relating to these awards are as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the BNI performance criterion accounts for 45% of the award. This criterion corresponds to the ratio, at constant exchange rates, of actual BNI to budgeted BNI. It represents the average actual-to-budget ratio attained over the entire period. Budgeted BNI is derived from the budget as approved by the Board of Directors at the beginning of each financial year. The BNI objective may not be lower than the bottom end of the full-year guidance range publicly announced by Sanofi at the beginning of each year. If the ratio is less than 95%, the corresponding performance shares are forfeited.</span></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.676%"><tr><td style="width:1.0%"/><td style="width:75.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">BNI actual-to-budget attainment level (B)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">BNI allocation rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B is &lt;&#160;95%</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B =&#160;95%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B is &gt;&#160;95% but &lt;&#160;98%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50 + [(B &#8211;95) x 16])%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B is &#8805;&#160;98% but &#8804;&#160;105%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">B%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B is &gt;&#160;105% but &lt;&#160;110%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(105 + [(B &#8211;105) x 3])%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If B is &#8805;&#160;110%</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120%</span></td></tr></table></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the FCF criterion accounts for 25% of the award. It represents the average actual-to-budget ratio of FCF attained over the entire period. The award is based on a target FCF, below which some or all performance shares are forfeited.</span></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.523%"><tr><td style="width:1.0%"/><td style="width:75.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">FCF actual-to-budget attainment level (F)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">FCF allocation rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F is &#8804;&#160;70%</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F is &gt;&#160;70% but &lt;&#160;80%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">[(F &#8211; 70) x 5]%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F =&#160;80%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F is &gt;&#160;80% but &lt;&#160;100%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50 + [(F &#8211; 80) x 2.5])%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F =&#160;100%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F is &gt;&#160;100% but &lt;&#160;120%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">F%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">If F is &gt;&#160;120% </span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120%</span></td></tr></table></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure. For a definition, refer to Item 5.A.1.5.3 Business net income (non-IFRS financial measure), in this Annual Report</span></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non-IFRS financial measure. For a definition, refer to Item 5.B.1 B.1. Consolidated statement of cash flows, in this Annual Report</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">131</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the criterion based on Total Shareholder Return (&#8220;TSR&#8221;) Rank Improvement accounts for 20% of the award.<br/>The TSR Rank Improvement corresponds to the change in Sanofi&#8217;s TSR rank relative to the TSR of a panel of Sanofi plus&#160;12&#160;peer companies (Amgen, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Inc., Eli Lilly and Company Inc., GlaxoSmithKline&#160;plc, Johnson &amp; Johnson Inc., Merck Inc., Novartis AG, Novo Nordisk, Pfizer Inc., and Roche Holding Ltd).</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">TSR corresponds to the market performance of Sanofi shares uplifted by dividends per share during the measurement periods, without reinvestment.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the plan applicable to Executive Committee members, the TSR Rank Improvement is determined by comparing the Endpoint Sanofi TSR rank (measured over a three-year period) with the Baseline Sanofi TSR rank (measured over a one-year period). The TSR payment would amount to 50% for an improvement of one place in the rankings, 100% for two places in the rankings, and 150% for three places in the rankings;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the criterion based on CSR accounts for 10% of the award. This performance criterion is linked to attainment of (i)&#160;annual objectives over a three-year period and (ii)&#160;a "stretch" objective, linked to the following pillars:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.7pt">Affordable Access: providing essential medicines to non-communicable disease patients through Sanofi Global Health,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:4.63pt">Planet Care - Carbon Footprint Reduction, scopes&#160;1 &amp;&#160;2 (% CO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:1.19pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> emissions reduction vs 2019).</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Attainment of each annual CSR objective will generate one performance point; a maximum of three points (plus one bonus point for the "stretch" objective) may be obtained for each pillar. For each criterion, attainment of the 2025 objectives will generate three points, even if the annual objectives are not attained;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the number of performance shares vesting depends on the overall allocation rate, which for each period is the weighted average of the BNI allocation rate (45%), the FCF allocation rate (25%), the TSR allocation rate for the period (20%), and the CSR allocation rate;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a multiplier is applied that will uplift the number of performance shares vesting by 10% if (i)&#160;the maximum TSR allocation rate is attained and (ii)&#160;Sanofi ranks greater than or equal to the median for the TSR benchmark panel at the endpoint;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in order to align equity-based compensation with medium-term performance, performance is measured over three financial years;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">vesting is subject to a non-compete clause;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the entire award is forfeited in the event of resignation, or dismissal for gross or serious misconduct;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in the event of (i)&#160;individual dismissal other than for gross or serious misconduct, (ii)&#160;retirement before the age of 60, (iii)&#160;the beneficiary&#8217;s employer ceasing to be part of the Sanofi group or (iv)&#160;termination of employment contract under the terms of a collective separation plan initiated by the employer in accordance with locally applicable legislation or other measures approved by local authorities, the overall allocation percentage is apportioned on a pro rata time basis to reflect the amount of time the person remained with the Sanofi group during the vesting period;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if any of the following events occur, full rights to the award are retained: (i)&#160;retirement on or after reaching the statutory retirement age, or early retirement under a statutory or contractual early retirement plan implemented by the relevant Sanofi entity and duly approved by the Chief Executive Officer of Sanofi; (ii)&#160;disability classified in the second or third categories stipulated in Article&#160;L.&#160;314-4 of the French Social Security Code; or (iii)&#160;death of the beneficiary.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pension arrangements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total amount accrued as of December&#160;31, 2023 in respect of corporate pension plans for persons who have held an executive position during the year 2023 was &#8364;10&#160;million. That amount includes an expense of &#8364;1&#160;million recognized in profit or loss during&#160;2023.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_325"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Pay ratio between compensation of executive officers and average/median compensation of Sanofi employees &#8211; changes in compensation of executive officers and employees relative to the performance of Sanofi</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This information is disclosed in accordance with Article&#160;L.&#160;22-10-9&#160;6&#176; of the French Commercial Code, further to the enactment of the&#160;&#8220;Pacte&#8221; law.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has referred to the guidance on compensation multiples issued by AFEP (version issued February&#160;2021) in establishing the calculation methods used for the ratios presented.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Explanations of calculation methods and of year-on-year changes in the executive pay ratio:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the scope includes Sanofi SA (the parent company) and all of its direct and indirect subsidiaries located in France, and hence covers more than 80% of total payroll of permanent employees in France. No separate ratios are published for Sanofi SA (the parent company), as the low headcount at Sanofi SA means that such ratios would not be representative of our total headcount in France;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the employee compensation used in the calculation is the full time equivalent (FTE) compensation of permanent employees with at least two financial years of uninterrupted employment;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">compensation includes fixed compensation awarded during the reference year, and variable compensation related to the previous year and paid during the reference year. All compensation amounts are gross amounts;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in order to maintain consistency, we have excluded from the numerator (i)&#160;compensation items not included in the denominator and (ii)&#160;non-recurring compensation items. This applies in particular to accommodation expenses related to the relocation to France of the Chief Executive Officer (Paul Hudson) in 2020, and to expenses related to unemployment insurance;</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">132</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">long term variable compensation: performance shares and stock options awarded during each reference year are valued at the date of grant in accordance with international financial reporting standards. The valuation of performance shares that include the Total Shareholder Return (TSR) performance condition incorporates market conditions where applicable. Awards are subject to a continuing employment condition (three years minimum) and to performance conditions. Consequently, the valuation at the date of grant is not necessarily indicative of the value of stock options and performance shares at the end of the vesting period, especially if the performance conditions are not met;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">since Olivier Brandicourt (our previous Chief Executive Officer) received the same number of stock options and performance shares each year from 2016 to 2019, fluctuations in the Sanofi share price had a significant impact on the pay ratio during this period;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">2018 and 2019 figures have been restated for comparative purposes, to (i)&#160;exclude Sanofi&#8217;s equity-accounted share of Regeneron&#8217;s net profits (see note&#160;D.2. to our consolidated financial statements, included at Item&#160;18. of this annual report) and (ii)&#160;include the effects of IFRS&#160;16;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">regular benchmarking reviews are conducted to ensure that the level of compensation awarded to our employees and CEO is competitive and consistent with pharmaceutical industry levels.</span></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Comparison of compensation of Sanofi executive officers with employee compensation* (parent company and all direct and indirect subsidiaries located in France), and year-on-year change in compensation of corporate officers and employees with reference to the company&#8217;s performance</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:43.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.080%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chief Executive Officer</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2018</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2019</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2021</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2022</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in compensation </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.5&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ratio versus average employee compensation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124.55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124.49&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year-on-year change in ratio </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ratio to median employee compensation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159.97&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year-on-year change in ratio </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chairman of the Board</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2018</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2019</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2021</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2022</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in compensation </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ratio versus average employee compensation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.09&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year-on-year change in ratio </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-7.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ratio versus median employee compensation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12.97&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year-on-year change in ratio </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-7.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employees</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2018</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2019</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2021</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023 </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">vs 2022</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in compensation </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.7&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.4&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Company Performance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial criterion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BNI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BNI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BNI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BNI</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BNI</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year-on-year change </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-1.8&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Table based on the model table recommended in the AFEP guidance on compensation multiples (February&#160;2021).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)  2019: Olivier Brandicourt left office on August&#160;31. Paul Hudson was appointed as CEO on September&#160;1, 2019.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2020: The 2020 CEO compensation includes Paul Hudson&#8217;s 2020 fixed compensation (&#8364;1.3&#160;million), his 2019 variable compensation as paid in 2020 and annualized (&#8364;1.95&#160;million), and 75,000&#160;performance shares awarded in 2020.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)  Fr&#233;d&#233;ric Oud&#233;a with effect from May&#160;25, 2023, the date on which Serge Weinberg&#8217;s term of office expired.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Based on full-time equivalent permanent employees of all Sanofi legal entities worldwide with at least two years of uninterrupted employment, the ratios for 2023 were as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">CEO:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">ratio versus average compensation: 125.6, and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">ratio versus median compensation: 182.9;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Chairman of the Board of Directors:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">ratio versus average compensation: 10.2, and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">ratio versus median compensation: 14.8.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These ratios were calculated on the basis of annualized basic compensation, variable compensation in respect of the previous year, and performance shares awarded during 2023, applying 2023 average exchange rates.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">133</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_334"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C. Board Practices</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Application of the AFEP-MEDEF Code</span></div><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The corporate governance code applied by Sanofi is the December&#160;2022 version of the AFEP-MEDEF Code (the &#8220;AFEP-MEDEF Code,&#8221; which is available at https://hcge.fr/le-code-afep-medef/.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Board Charter requires at least one-half of our directors to be independent; contains a section on the ethical rules applicable to our directors; sets out the remit and operating procedures of the Board; defines the roles and powers of our Chairman and our Chief Executive Officer; and describes the composition, remit and operating procedures of the Board committees, in accordance with the recommendations of the AFEP-MEDEF Code. Collectively, our Articles of Association and our Board Charter establish the framework within which Sanofi implements its principles of corporate governance </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Board practices comply with the AFEP-MEDEF Code recommendations, with certain exceptions, and with the report of the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Autorit&#233; de march&#233;s financiers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> on Audit Committees, issued on July&#160;22, 2010.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Board diversity matrix</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides certain information regarding the diversity of our board of directors as of the date of this annual report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.361%"><tr><td style="width:1.0%"/><td style="width:38.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.451%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="background-color:#7802e6;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Board Diversity Matrix</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Country of Principal Executive Offices:</span></td><td colspan="24" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign Private Issuer</span></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disclosure Prohibited under Home Country Law</span></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of February 23, 2024</span></div></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of July 21, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Number of Directors</span></td><td colspan="12" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gender Identity</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Female</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Male</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Binary</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Did Not Disclose Gender</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Female</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Male</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Binary</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Did Not Disclose Gender</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Directors</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Demographic Background</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Underrepresented Individual in Home Country Jurisdiction</span></td><td colspan="12" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="12" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">LGBTQ+</span></td><td colspan="12" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="12" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Did Not Disclose Demographic Background</span></td><td colspan="12" style="background-color:#dbdbdb;border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under Nasdaq Rule 5606, Nasdaq-listed companies are required to annually disclose, to the extent permitted by applicable law, information on each director&#8217;s voluntary self-identified characteristics. This information must be provided in either the issuer&#8217;s annual report or on the Company&#8217;s website and all companies must disclose the current year and immediately prior year diversity statistics. Sanofi has collected and disclosed (on an anonymous basis) the gender identity of its directors but does not collect or disclose the demographic (race or ethnicity and LGBTQ+ status) background of its directors, because Sanofi does not believe the collection and disclosure is permitted by French law</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Activities of the Board of Directors in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During 2023, the Board of Directors met 11&#160;times (including strategy seminars), with an overall attendance rate among Board members of&#160;97%. Individual attendance rates of serving directors varied between 64</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">% and 100%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following persons attended meetings of the Board of Directors:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the directors;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the Secretary to the Board;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">frequently: members of the Executive Committee; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">occasionally: the statutory auditors, managers of our global support functions, and other company employees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The agenda for each meeting of the Board is prepared by the Secretary after consultation with the Chairman, taking account of the agendas for the meetings of the specialist Committees and the suggestions of the directors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Approximately one week prior to each meeting of the Board of Directors, the directors each receive a file containing the agenda, the minutes of the previous meeting, and documentation relating to the agenda.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The minutes of each meeting are expressly approved at the next meeting of the Board of Directors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In compliance with our Board Charter, certain issues are examined in advance by the various Committees according to their areas of competence, to enable them to make a recommendation; those issues are then submitted for a decision by the Board of Directors.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">134</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since 2016, acting on a recommendation from the Appointments, Governance and CSR Committee, each year the Board has held at least two executive sessions, i.e. meetings held without the Chief Executive Officer present. If the Chairman of the Board so decides, such sessions may also be held without the directors representing employees (or any other Sanofi employee) being present. The primary purpose of such sessions is to evaluate the way the Board and its Committees operate, discuss the performance of the Chief Executive Officer, and to debate succession planning. Two executive sessions lasting an hour and a half were held in 2023, in February and July.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, the main activities of the Board of Directors related to the following issues:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:1.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.838%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">FINANCIAL STATEMENTS AND FINANCIAL MANAGEMENT</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of the individual company and consolidated financial statements for the 2022 financial year and for the first half of 2023, review of the consolidated financial statements for the first three quarters of 2023, and review of draft press releases and presentations to analysts relating to the publication of those financial statements.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of forward-looking management documents.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Projected 2023 accounting close, presentation of 2024 budget and 2024-2026 financial forecasts.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proposed dividend for the 2022 financial year.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Renewal of share repurchase program.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Formally recording the share capital, and amending the Articles of Association accordingly.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Delegation to the Chief Executive Officer of the power to issue bonds.</span></div></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">OPERATIONS, STRATEGY AND RISK MANAGEMENT</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Play to Win strategy: delivery on the strategy, proposed separation of Consumer Healthcare business.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of minutes of Strategy Committee and Scientific Committee meetings.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on risks, and review of risk management activity report and 2023 risk profile analysis.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of acquisition projects.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on ZANTAC.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on France.</span></div></td></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">APPOINTMENTS AND GOVERNANCE</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Composition of the Board and its committees:</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">appointment of Fr&#233;d&#233;ric Oud&#233;a as Chairman of the Board of Directors;</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">composition of Board committees.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of director independence.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of management report, corporate governance report, and statutory auditors' reports.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Adoption of draft resolutions, the Board report on the resolutions, and special reports on awards of stock options and performance shares.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Annual evaluation of the work of the Board and its Committees.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of previously-approved related-party agreements.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on the Action 2023 employee share ownership plan.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2024 training plan for Board members.</span></div></td></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">COMPENSATION</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Determination of the compensation of corporate officers:</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">review of fixed compensation and determination of variable compensation objectives for the Chief Executive Officer for 2023;</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">determination of the compensation of the Chairman of the Board of Directors for 2023.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Allocation of directors' compensation for 2022, and principles for the 2023 allocation.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of fixed and variable Executive Committee compensation for 2022 and&#160;2023.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Adoption of performance share plans for 2023, sign-off on attainment  of performance conditions for prior equity-based compensation plans.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Adoption of a clawback policy.</span></div></td></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CORPORATE SOCIAL RESPONSIBILITY</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Monitoring of progress on the CSR strategy.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Monitoring of objectives for gender balance in executive bodies, and more generally of Sanofi's diversity policy.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Monitoring of Sanofi's equal pay and equal opportunity policy.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Implementation of the European Corporate Sustainability Reporting Directive (CSRD).</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.529%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:100%">l</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Annual items</span></div></td><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#171;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Non-recurring items</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">135</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addit</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ion, two strategy seminars were held, in April&#160;and October&#160;2023, in which all members of the Executive Committee took part. The seminar gave directors an opportunity to address issues including:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">monitoring delivery of the Play to Win strategy;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">pipeline review, especially in oncology;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">strategy and progress to date of the Sanofi Ventures investment fund;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">modernization of Manufacturing &amp; Supply;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">changes in the regulatory environment;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">acquisition opportunities;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">R&amp;D strategy;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">strategy for the General Medicines segment;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">proposed separation of Consumer Healthcare business;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">financial roadmap, including the new cost savings program.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Remit and Operation of Board Committees</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Board of Directors is assisted in its deliberations and decisions by five specialist Committees (for a description of the remit of each Committee, refer to our Board Charter, provided as Exhibit&#160;1.2 to this annual report). Chairs and members of these Committees are chosen by the Board from among its members, based on their experience.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Committees are responsible for the preparation of certain items on the agenda of the Board of Directors. Decisions of the Committees are adopted by a simple majority with the Chair of the Committee having a casting vote. Minutes are prepared, and approved by the Committee members.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chair of each Committee reports to the Board on the work of that Committee, so that the Board is fully informed whenever it takes a decision.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Composition of the Committee in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.686%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Audit Committee</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Composition as of January 1, 2023</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Composition as of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chair</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabienne Lecorvaisier (independent director)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fabienne Lecorvaisier (independent director)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Members</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diane Souza (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Christophe Babule</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carole Ferrand (independent director)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diane Souza (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Christophe Babule</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carole Ferrand (independent director)</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proportion of independent directors: 75% (3/4)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proportion of independent directors: 75% (3/4)</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This table only refers to independence as defined under the AFEP-MEDEF Code. However, Christophe Babule is independent for the purposes of the NASDAQ Listing Rules and Rule 10A-3 under the Exchange Act.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All members of the Audit Committee have financial or accounting expertise as a consequence of their training and professional experience, and all are deemed to be financial experts as defined by the Sarbanes-Oxley Act and by Article&#160;L.&#160;823-19 of the French Commercial Code. See &#8220;Item&#160;16A. Audit Committee Financial Expert&#8221;.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Remit of the Committee</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The remit of the Committee is described in our Board Charter, provided as Exhibit&#160;1.2 to this annual report.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Pursuant to Order no.&#160;2023-1142 of December&#160;6, 2023 transposing the European Corporate Sustainability Reporting Directive (CSRD) into French law, our Audit Committee has been given a remit to review the process for the preparation and certification of sustainability disclosures. Our Board Charter was amended by the Board of Directors on December&#160;13, 2023 to reflect this change. In fulfilling this role, the Audit Committee works in conjunction with the Appointments, Governance and CSR Committee.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Operation of the Committee</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition to the statutory auditors, the principal financial officers, the Senior Vice President Group Internal Audit and other members of the senior management team attend meetings of the Audit Committee.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Committee members had an exemplary attendance record, with an overall attendance rate of 100%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The statutory auditors attend all meetings of the Audit Committee; they presented their opinions on the annual and half-year financial statements at the Committee meetings of February&#160;20 and July&#160;26, 2023, respectively. The Committee meets regularly with the statutory auditors without management present.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chair of the Committee also meets regularly with certain members of management, in particular the heads of Internal Audit, Risk Management and Ethics/Compliance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For information about Audit Committee oversight of internal control and risks relating to the processing of accounting and financial information, refer to &#8220;Item&#160;15. Controls and Procedures.&#8221;</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">136</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Work of the Committee in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Audit Committee met six times in 2023, including meetings held in advance of the Board meeting tasked with finalizing the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The work of the Committee i</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n 2023 is summarized below</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.181%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">FINANCIAL POSITION</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Preliminary review of the individual company and consolidated financial statements for the 2022 financial year, review of the individual company and consolidated financial statements for the first half of 2023, review of the consolidated financial statements for the first three quarters of 2023, and review of draft press releases.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Financial position of Sanofi, indebtedness and liquidity, off balance sheet commitments.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Use of non-IFRS financial measures.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">INTERNAL AUDIT, INTERNAL CONTROL AND RISK MANAGEMENT</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of the work of the Internal Control function and evaluation of that work for 2022 as certified by the statutory auditors pursuant to Section 404 of the Sarbanes-Oxley Act, and examination of the 2022 annual report.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Principal risks (risk management and risk profiles) including CSR risks; Risk Committee report for 2023; tracking of whistleblowing and material compliance investigations; review of emerging risks, including geopolitical and macroeconomic risks; review of tax risks and deferred tax assets; review of material litigation.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Conclusions of Sanofi senior management on internal control procedures and review of the 2022 Management Report, in particular the description of risk factors in the Universal Registration Document.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Internal audit report and audit program for 2023.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Reporting on guarantees and endorsements.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">IT obsolescence.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Protection of information and prevention of internal threats.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Ethics and data protection.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-bottom:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Talent Management Review.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">STRATEGY AND COMPENSATION</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Presentation of 2024 budget.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of attainment of performance conditions for 2020 equity-based compensation plans.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-bottom:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proposed separation of Consumer Healthcare business - Tax aspects of legal reorganization of entities.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">COMPLIANCE, BUSINESS ETHICS AND CSR</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of European Green Taxonomy indicators included in the Universal Registration Document.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Implementation of the European Corporate Sustainability Reporting Directive (CSRD) and relating update of the work organisation with the Appointments, Governance and CSR Committee.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">RELATIONS WITH STATUTORY AUDITORS</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Audit engagements and fees.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review and budget for non-audit services (audit-related services, tax, and other).</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on audit mandates:</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">recommendation to reappoint PwC at the 2023 AGM;</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">update on transitional arrangements relating to the end of the EY mandate in 2024, and appointment of a new statutory auditor.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.529%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:100%">l</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Annual items</span></div></td><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#171;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Non-recurring items</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Committee did not use external consultants in 2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Attendance rates in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Committee members had an exemplary attendance rate of 100%.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">137</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Appointments, Governance and CSR Committee</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Composition of the Committee in 2023</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.686%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Appointments, Governance and CSR Committee</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Composition as of January 1, 2023</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Composition as of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chair</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gilles Schnepp (independent director)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gilles Schnepp (independent director)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Members</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Serge Weinberg</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patrick Kron (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lise Kingo (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Barbara Lavernos</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fr&#233;d&#233;ric Oud&#233;a (independent director)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patrick Kron (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Lise Kingo (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Barbara Lavernos</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proportion of independent directors:&#160;60%&#160;(3/5)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proportion of independent directors: 80%&#160;(4/5)</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Fr&#233;d&#233;ric Oud&#233;a, an independent director, was appointed as a member of the Appointments, Governance and CSR Committee by a Board decision of May&#160;25, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chief Executive Officer is involved in the work of the Committee.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Remit of the Committee</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The remit of the Committee is described in our Board Charter, provided as Exhibit&#160;1.2 to this annual report.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The remit to review the process for the preparation and certification of sustainability disclosures has been given to our Audit Committee (see above). The Appointments, Governance and CSR Committee plays a role in this work through joint meetings.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Work of the Committee in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The work of the Appointments, Governance and CSR Committee during 2023 covered the following issues:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:1.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.838%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">APPOINTMENTS</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Succession planning for the Chairman, Chief Executive Officer and Executive Committee.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Changes to the composition of the Board and its committees.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of expiring terms of office, and appointment of new Board members.</span></div></td></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GOVERNANCE</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on annual evaluation of the Board and its committees.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of director independence.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of management report and corporate governance report in the 2022 Universal Registration Document.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Governance roadshows with key Sanofi investors, and analysis of the policies of proxy advisors.</span></div></td></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CSR</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Updates on the four pillars of the CSR strategy:</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Affordable Access to Healthcare;</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Innovating for Unmet Medical Needs;</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Planet Care;</span></div><div style="padding-left:8.5pt;text-indent:-8.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:130%;padding-left:6.11pt">Inclusive, Diverse Workplace and Communities.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New regulatory requirements and roadmap to implementation.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of the CSR chapter in the 2022 Universal Registration Document.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on Foundation S.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on the Corporate Sustainability Reporting Directive (CSRD).</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.529%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:100%">l</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Annual items </span></div></td><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#171;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Non-recurring items</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Committee did not use external consultants in 2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Attendance rates in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Committee met five times in 2023, with an attendance rate of 100%.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">138</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Composition of the Committee in 2023</span></div><div style="margin-bottom:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.686%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Compensation Committee</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Composition as of January 1, 2023</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Composition as of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chair</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patrick Kron (independent director)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patrick Kron (independent director)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Members</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wolfgang Laux</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diane Souza (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rachel Duan&#160;(independent director)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Wolfgang Laux</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diane Souza (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rachel Duan&#160;(independent director)</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proportion of independent directors: 75% (3/4)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proportion of independent directors: 75% (3/4)</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Work of the Committee in 2023</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The work of the Compensation Committee during 2023 covered the following issues:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:1.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.838%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">COMPENSATION OF CORPORATE OFFICERS</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Components of the compensation of corporate officers (Chief Executive Officer and Chairman of the Board).</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of performance conditions applicable to the compensation of the Chief Executive Officer, in particular CSR criteria.</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Allocation of directors&#8217; compensation for 2022, and review of the compensation policy applicable to directors.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of the disclosures about compensation contained in the corporate governance section of the 2022 Universal Registration Document and the annual report, and of equal pay ratios.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of the draft "say on pay" resolutions to be submitted to the Annual General Meeting of May&#160;25, 2023.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Governance roadshows with key Sanofi investors, and analysis of the policies of proxy advisors.</span></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of the structure of the Chief Executive Officer's compensation, and objectives for 2024.</span></div></td></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EQUITY-BASED COMPENSATION</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Implementation of equity-based compensation plans awarded in prior years (sign-off on attainment of performance&#160;conditions for 2020 plans).</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Introduction of CSR criteria into the new equity-based compensation plan for the Chief Executive Officer.</span></div></td></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EMPLOYEE SHARE OWNERSHIP</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Status report and analysis of 2023 employee share ownership plan.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Consideration of next employee share ownership plan, and implementation of Action 2024 plan.</span></div></td></tr><tr><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EXECUTIVE COMMITTEE COMPENSATION</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Monitoring of fixed and variable compensation of Executive Committee members in 2022 and 2023.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Adoption of clawback policy.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-bottom:1pt solid #795c8c;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-bottom:1pt solid #795c8c;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Terms for incoming and outgoing Executive Committee members.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.529%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:100%">l</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Annual items </span></div></td><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#171;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Non-recurring items</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the Committee discusses the compensation policy for members of senior management who are not corporate officers, i.e.&#160;the members of the Executive Committee, the Committee invites the Chief Executive Officer to attend.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Committee did not use external consultants in 2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Attendance rates in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Committee met three times in 2023, with an attendance rate of 100%.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">139</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy Committee</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Composition of the Committee in 2023</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.373%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Strategy Committee</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Composition as of January 1, 2023</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Composition as of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chair</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Serge Weinberg</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fr&#233;d&#233;ric Oud&#233;a (independent director) </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Members</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Paul Hudson</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patrick Kron (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gilles Schnepp (independent director)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Paul Hudson</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Patrick Kron (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Barbara Lavernos </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gilles Schnepp (independent director)</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proportion of independent directors: 50% (2/4)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proportion of independent directors: 60% (3/5)</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Fr&#233;d&#233;ric Oud&#233;a was appointed as Chair of the Strategy Committee by a Board decision of May&#160;25, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Barbara Lavernos was appointed as a member of the Strategy Committee by a Board decision of February&#160;22, 2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Work of the Committee in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During 2023, the Committee's work included the following key issues:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:1.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.838%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Divestment and acquisition projects, and business development priorities.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Play to Win strategy and financial roadmap for 2024-2026.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Opportunities for alliances.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proposed separation of Consumer Healthcare business.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on strategy in France.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on regulatory environment and competition.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.529%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:100%">l</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Annual items </span></div></td><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#171;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Non-recurring items</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Committee did not use external consultants in 2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Attendance rates in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Committee met eight times in 2023, with an attendance rate of 100%.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Scientific Committee</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Composition of the Committee in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:9.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.372%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Scientific Committee</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Composition as of January 1, 2023</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Composition as of December 31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chair</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thomas S&#252;dhof (independent director)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thomas S&#252;dhof (independent director)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Members</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emile Voest (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Serge Weinberg</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Antoine Yver (independent director)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fr&#233;d&#233;ric Oud&#233;a (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emile Voest (independent director)</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Antoine Yver (independent director)</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proportion of independent directors: 75% (3/4)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proportion of independent directors: 100% (4/4)</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Work of the Committee in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During 2023, the Committee&#8217;s work included the following key issues:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:1.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.838%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="6" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of product portfolio.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Review of acquisition and alliance projects.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on Immunology &amp; Inflammation.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on Oncology.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on Chemistry, Manufacture &amp; Controls (CMC).</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">l</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on Neurology.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Update on Rare Diseases.</span></div></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#171;</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Use of artificial intelligence in R&amp;D.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.529%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:100%">l</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Annual items </span></div></td><td colspan="3" style="border-bottom:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#171;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Non-recurring items</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Committee did not use external consultants in 2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Attendance rates in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Committee met seven times in 2023, with an attendance rate of 100%.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">140</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_337"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.&#160;Employees</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Number of Employees</span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(a)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi e</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">mployed 86,088&#160;people</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> worldwide, 3,736&#160;fewer than in 2022. The tables below give a breakdown of employees by geographical area and function as of December&#160;31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Employees by Geographical Area</span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(a)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:25.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42,115&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42,151&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45,351&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,418&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,555&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">86,088</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89,824</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">93,548</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Employees by Function</span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(a)</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.207%"><tr><td style="width:1.0%"/><td style="width:55.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.254%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales Force</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,835&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,210&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,477&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and Development</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,660&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Production</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34,313&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Marketing and Support Functions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23,280&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">86,088</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89,824</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">93,548</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Employees on garden leave and ExCom management level excluded from the data.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Industrial Relations</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In all countries where we operate, we seek to strike a balance between our economic interests and those of our employees, which we regard as inseparable.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our belief in a balanced workplace for our employees is based on the basic principles of our Social Charter, which outlines the rights and duties of all Sanofi employees. The Social Charter addresses our key ambitions vis-&#224;-vis our workforce: equal opportunity for all people without discrimination, the right to health and safety, respect for privacy, the right to information and professional training, social protection for employees and their families, freedom of association and the right to collective bargaining, and respect for the principles contained in the Global Compact on labor relations and ILO conventions governing the physical and emotional well-being and safety of children.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our labor relations are based on respect and dialogue. In this spirit, management and employee representatives meet regularly to exchange views, negotiate, sign agreements and ensure that agreements are being implemented.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Employee dialogue takes place in different ways from country to country, as dictated by specific local circumstances. Depending on the circumstances, employee dialogue relating to information, consultation and negotiation processes may take place at national, regional or company level. It may be organized on an interprofessional or sectorial basis, or both. Employee dialogue may be informal or implemented through a specific formal body, or a combination of both methods. Whatever the situation, Sanofi encourages employees to voice their opinions, help create a stimulating work environment and take part in decisions aiming to improve the way we work. These efforts reflect one of the principles of the Social Charter, whereby improving working conditions and the necessary adaptation to our business environment go hand-in-hand.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Schemes, Employee Savings Schemes and Employee Share Ownership</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Profit-sharing schemes</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All employees of our French companies belong to voluntary and statutory profit-sharing schemes.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Voluntary schemes</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Voluntary schemes </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(int&#233;ressement des salari&#233;s)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> are collective schemes that are optional for the employer and contingent upon pe</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">rformance. The aim is to give employees an interest in the growth of the business and improvements in its performance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount distributed by our French companies during 2023 in respect of the voluntary scheme for the year ended December&#160;31, 2023 represented 1.05% of total payroll.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">141</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April&#160;2020, we entered into a new fixed-term statutory profit-sharing agreement for the 2020, 2021 and 2022 financial years, which applies to all employees of our French companies. Under the agreement, Sanofi pays collective variable compensation determined on the basis of the more favorable of (i)&#160;growth in consolidated net sales (at constant exchange rates and on a constant structure basis) or (ii)&#160;BOI margin. For each of those criteria, a matrix determines what percentage of total payroll is to be allocated to the scheme. An additional sum may be distributed, based on a CSR-related performance condition reflecting progress in environmental matters (reduction in greenhouse gas emissions) and capped at 0.5% of total payroll.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This overall allocation is reduced by the amount required by law to be transferred to a special profit-sharing reserve. The balance is then distributed between the employees unless the transfer to the reserve equals or exceeds the maximum amount determined under the specified criteria, in which case no profit share is paid to the employees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June 2023, we entered into a new fixed-term statutory profit-sharing agreement for the 2023, 2024 and 2025 financial years, which applies to all employees of our French companies.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statutory scheme</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The statutory scheme </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(participation des salari&#233;s aux r&#233;sultats de l&#8217;entreprise)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is a French legal obligation for companies with more than 50&#160;employees that made a profit in the previous financial year.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amo</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">unt distributed by our French companies during 2023 in respect of the statutory scheme for the year ended December&#160;31, 2022 represented 9.95% of total payroll.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution formula</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to favor lower-paid employees, the voluntary and statutory profit-sharing agreements entered into since 2005 split the benefit between those entitled as&#160;follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">60% prorated on the basis of time spent in the Company&#8217;s employment in the year; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">40% prorated on the basis of gross annual salary received during the year, subject to a lower limit equal to the social security ceiling and an upper limit of three times the social security ceiling.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee savings schemes and collective retirement savings plan</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The employee savings arrangements operated by Sanofi are based on a collective savings scheme </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Plan d&#8217;&#201;pargne Groupe)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and a collective retirement savings scheme </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Plan d&#8217;&#201;pargne pour la Retraite Collectif)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Those schemes reinvest the sums derived from the statutory and voluntary profit-sharing schemes, plus voluntary contributions from employees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, 90% o</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">f the employees who benefited from the profit-sharing schemes opted to invest in the collective savings scheme, and nea</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">rly 80% </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">opted to invest in the collective retirement savings scheme.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi supplements the amount invested by employees in these schemes by making a top-up contribution.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 202</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3, &#8364;143.5&#160;mill</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ion</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and &#8364;157.6&#160;m</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">illion were invested in the collective savings scheme and the collective retirement savings scheme respectively through the voluntary and statutory schemes for 2022, and through top-up contributions.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee share ownership</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, shares held under the collective savings scheme or in registered form by employees of Sanofi, employees of related companies and former employees amoun</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">te</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">d to 2.58% of our share capital.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For more information about our most recent employee share ownership plan, refer to &#8220;Item&#160;10.&#160;Additional Information &#8212;&#160;Changes in Share Capital &#8212;&#160;Increases in Share Capital&#8221;.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_340"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E. Share Ownership</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Senior Management</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Members of the Executive Committee hold shares of our Company amounting in the aggregate to less than 1% of our share capital.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Existing Option Plans as of December&#160;31, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2019, the Board of Directors reviewed Sanofi&#8217;s compensation policy and decided that stock options would no longer be awarded from 2020 onwards. That decision was taken to standardize the terms of equity-based compensation awards within Sanofi, and in response to feedback from some shareholders and proxy advisors who had concerns about stock options given their dilutive effect and potential unintended consequences.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Share Purchase Option Plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 there were no stock purchase option plans outstanding.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">142</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Share Subscription Option Plans</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:8.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Date of <br/>shareholder <br/>authorization</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Date of <br/>grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total number of options granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">to corporate officers</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">to the 10 employees awarded the most options</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Start date of exercise period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Expiry <br/>date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Exercise price<br/>(&#8364;)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Number of shares subscribed as of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">12/31/2023</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Number of options canceled </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">as of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">12/31/2023</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Number of options <br/>outstanding</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 6,<br/>2011</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 5,<br/>2013</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">548,725&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">261,000&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 6,<br/>2017</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 5,<br/>2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">72.19&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">439,660&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">109,065&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 6,<br/>2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 5,<br/>2013</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">240,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">240,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 6,<br/>2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 5,<br/>2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">72.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">175,920&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">64,080&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 3,<br/>2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 5,<br/>2014</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">769,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">364,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 6,<br/>2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 5,<br/>2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">73.48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">575,270&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">102,625&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">91,355&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 3,<br/>2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 5,<br/>2014</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">240,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">240,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 6,<br/>2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">March 5,<br/>2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">73.48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">193,440&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">46,560&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 3,<br/>2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">June 24,<br/>2015</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">June 25,<br/>2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">June 24,<br/>2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">89.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 3,<br/>2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">June 24,<br/>2015</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">202,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">202,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">June 25,<br/>2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">June 24,<br/>2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">89.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">157,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 3,<br/>2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">June 24,<br/>2015</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">June 25,<br/>2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">June 24,<br/>2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">89.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">41,536&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">178,464&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 4,<br/>2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 4,<br/>2016</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">17,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">17,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 5,<br/>2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 4,<br/>2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 4,<br/>2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 4,<br/>2016</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">165,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">165,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 5,<br/>2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 4,<br/>2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">82,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">82,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 4,<br/>2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 4,<br/>2016</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 5,<br/>2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 4,<br/>2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">41,250&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">178,750&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 10,<br/>2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 10,<br/>2017</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">158,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">157,140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 11,<br/>2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 10,<br/>2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">34,184&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">44,276&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">79,580&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 10,<br/>2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 10,<br/>2017</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 11,<br/>2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 10,<br/>2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">42,570&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">177,430&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 2,<br/>2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 2,<br/>2018</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 3,<br/>2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 3,<br/>2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">51,216&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30,<br/>2019</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30,<br/>2019</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 1,<br/>2023</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30,<br/>2029</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">76.71&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6,600&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">213,400&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Comprises the Chief Executive Officer, and any Deputy Chief Executive Officers or members of the Management Board in office at the date of grant.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In office at the date of grant.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes 293,812&#160;options cancelled due to partial non-fulfilment of performance conditions.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, 10,813&#160;stock options were exercised by individuals who were Executive Committee members as of December&#160;31, 2023. All of the plans involved post-date the creation of the Executive Committee (Sanofi plan of March&#160;5, 2013, exercise price &#8364;72.19; and Sanofi plan of March&#160;5, 2014, exercise price &#8364;73.48).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, a total of 1,333,013&#160;stock subscription options remained outstanding. As of the same date, 1,333,013&#160;options were immediately exercisable.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Existing Performance Share Plans as of December&#160;31, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors awards shares to certain employees in order to give them a direct stake in our future and performances via trends in the share price, as a partial substitute for the granting of stock options.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Shares are awarded to employees by the Board of Directors on the basis of a list submitted to the Compensation Committee. The Board of Directors sets terms of the awards, including continuing employment conditions and performance conditions (measured over three financial years).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The employee plans have a three-year vesting period, with no lock-up period.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">At its meeting of May&#160;25, 2023, the Board of Directors awarded a share performance plan, cascaded down into three sub-plans:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">a plan under which 466&#160;beneficiaries classified as &#8220;Senior Executives&#8221; were awarded a total of 1,209,790&#160;shares;</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">a plan under which 7,874&#160;beneficiaries not classified as &#8220;Senior Executives&#8221; were awarded a total of 2,425,047&#160;shares;</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">a plan under which 82,500&#160;performance shares were awarded to the Chief Executive Officer.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the 8,341&#160;beneficiaries, 49% were women.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">At its meeting of December&#160;13, 2023, the Board of Directors awarded a share performance plan, cascaded down into two sub-plans:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">a plan under which seven&#160;beneficiaries classified as &#8220;Senior Executives&#8221; were awarded a total of 58,347&#160;performance shares;</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">a plan under which one&#160;beneficiary not classified as a &#8220;Senior Executive&#8221; was awarded a total of 944&#160;performance shares.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of those eight&#160;beneficiaries, 25% were women.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">143</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The entirety of those awards is contingent upon criteria based on business net income (BNI), free cash flow (FCF) and Corporate Social Responsibility (CSR); in the case of employees classified as &#8220;Senior Executives&#8221;, an additional criterion based on total shareholder return (TSR) is added, accounting for 20% of the total. Vesting is subject to a non-compete clause.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The number of shares awarded to the Chief Executive Officer in 2023 represents 0.4% of the total limit approved by our shareholders at the Annual General Meeting of April&#160;30, 2021 (1.5% of our share capital) and 2.18% of the total amount awarded to all beneficiaries in 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The 2023 awards represent a dilution of approximately 0.19% of our undiluted share capital as of December&#160;31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Not all of our employees were awarded performance shares, but a new voluntary profit-sharing agreement was signed in&#160;April&#160;2020 which gives all of our employees an interest in Sanofi&#8217;s performance (for more details refer to &#8220;&#8212;&#160;Profit-Sharing Schemes, Employee Savings Schemes and Employee Share Ownership&#8221;, above).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Performance Share Plans</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.554%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Date of <br/>shareholder <br/>authorization</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Date of award</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total number of shares awarded</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">to </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">corporate officers</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(a) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">to the 10</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">employees awarded the most shares</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Start date of vesting </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">period</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Vesting date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">End of lock-up period</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Number of shares</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">vested as of 12/31/2023</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Number of rights canceled </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">as of 12/31/2023</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Number of shares not yet vested</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2019</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 28, 2020</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 28, 2020</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 02, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">65,205&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,795&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 28, 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">328,113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">120,951&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 28, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 02, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">245,789&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">82,324&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 28, 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">400,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">151,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 28, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 02, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">212,753&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">187,742&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 28, 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">753,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">19,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 28, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 02, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">717,595&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">36,125&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 28, 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,783,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">26,542&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 28, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 02, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1357661</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">425512</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">October 28, 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">73,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">73,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">October 28, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">October 29, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">October 30, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">57,745&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">15,282&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,614,023&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">19,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2024</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">314,691&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,296,843&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">701,824&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">163,877&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2024</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">202,582&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">499,242&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">595,878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10,918&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2024</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">36,618&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">558,791&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">497,695&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">150,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2024</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">43,973&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">453,722&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 01, 2024</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">October 27, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13,521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13,521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">October 27, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">October 28, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">October 28, 2024</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3,706&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,815&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 03, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,000,627&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">25,882&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 03, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 03, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 04, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">183,551&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,815,931&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 03, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,146,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">192,542&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 03, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 03, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 04, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">170,559&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">975,872&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 03, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">82,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">82,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 03, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 03, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 04, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">82,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 14, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">90,580&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">77,111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 14, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 14, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 15, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">90,580&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 14, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10,335&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10,335&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 14, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 14, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 15, 2025</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10,335&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,425,047&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">25,417&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2026</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">71,695&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,352,732&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,209,790&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">192,417&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2026</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">50,735&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,159,055&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">82,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">82,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">May 25, 2026</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">82,500&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">58,347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">58,347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 14, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 14, 2026</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">58,347&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 14, 2026</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">December 14, 2026</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Comprises the Chief Executive Officer, and any Deputy Chief Executive Officers or members of the Management Board in office at the date of grant.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In office at the date of grant.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Subject to the conditions set.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;87,416&#160;rights were cancelled due to partial non-fulfilment of performance conditions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, 9,522,209&#160;shares had not yet vested pending fulfilment of performance conditions.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">144</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;6. Directors, senior management and employees</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="background-color:#ffffff;color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Shares Owned by Members of the Board of Directors</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, members of our Board of Directors held in the aggregate 24,270&#160;shares, or under 1% of the share capital and of the voting rights, excluding the beneficial ownership of 118,227,307&#160;shares held by L&#8217;Or&#233;al as of such date which may be attributed to Barbara Lavernos or Christophe Babule (who disclaim beneficial ownership of such shares).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="background-color:#ffffff;color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Transactions in Shares by Members of the Board of Directors and Equivalent Persons in 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As far as Sanofi is aware, transactions in our securities carried out during 2023 by (i)&#160;Board members, (ii)&#160;executives with the power to make management decisions affecting our future development and corporate strategy and (iii)&#160;persons with close personal ties to such individuals (as per Article&#160;L.&#160;621-18-2 of the French Monetary and Financial Code), were as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">March&#160;13, 2023: Barbara Lavernos, director, acquired 500 shares at a price of &#8364;88.50 per share;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">May 2, 2023: Fr&#233;d&#233;ric Oud&#233;a, non-voting member (at the date of the transaction), acquired 500 shares at a price of &#8364;97.67&#160;per share;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">June 9, 2023: Wolfgang Laux subscribed 9.74&#160;units in the FCPE at a price of &#8364;95.12 per unit;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">July 20, 2023: Wolfgang Laux subscribed 250&#160;units in the FCPE at a price of &#8364;79.58 per unit.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span><br/></span></div><div id="i9fa7f69b4904450e9c43e8444c203165_343"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">F. Disclosure of action to recover erroneously awarded compensation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">145</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_346"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;7. Major shareholders and related party transactions</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;7. Major Shareholders and Related Party Transactions</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_349"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.&#160;Major Shareholders</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the ownership of our shares as of January&#160;31, 2024, indicating the beneficial owners of our shares. To the best of our knowledge and on the basis of the notifications received as disclosed below, except for L&#8217;Or&#233;al and BlackRock, Inc., no other shareholder currently holds more than 5% of our share capital or voting&#160;rights.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total number of</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">issued shares</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of actual</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">voting rights</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(excluding&#160;treasury&#160;shares)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Theoretical number</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of voting rights</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(including&#160;treasury&#160;shares)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">L&#8217;Or&#233;al</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118,227,307&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.35&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236,454,614&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.81&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236,454,614&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.61&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BlackRock</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86,592,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86,592,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86,592,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employees</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32,435,981&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63,771,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63,771,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Public</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,011,302,360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,020,079,451&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72.51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,020,079,451&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Treasury shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,245,648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,245,648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,264,803,301</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,406,897,400</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,423,143,048</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Based on BlackRock&#8217;s declaration dated December 15, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Shares held by the employees according to article L.225-102 of the French Commercial Code.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Number of shares repurchased as of January&#160;31, 2024 under the share repurchase program in force.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Based on the total number of voting rights as of January&#160;31, 2024.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Based on the total number of voting rights as of January&#160;31, 2024 as published in accordance with Article&#160;223-11 and seq. of the General Regulations of the Autorit&#233; des march&#233;s financiers (i.e. including treasury shares, the voting rights of which are suspended).</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Articles of Association provide for double voting rights for shares held in registered form for at least two years. All of our shareholders may benefit from double voting rights if these conditions are met, and no shareholder benefits from specific voting rights. For more information relating to our shares, see &#8220;Item&#160;10.&#160;Additional Information &#8212;&#160;B.&#160;Memorandum and Articles of Association.&#8221;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Neither L&#8217;Or&#233;al nor BlackRock holds different voting rights from those of our other shareholders.</span></div><div style="margin-bottom:2pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the best of our knowledge, no other shareholder currently holds, directly or indirectly and acting alone or in concert, more than 5% of our share capital or voting rights. Furthermore, we believe that we are not directly or indirectly owned or controlled by another corporation or government, or by any other natural or legal persons. To our knowledge, there are no arrangements that may result in a change of control.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023 we received one share ownership declaration informing us that a legal threshold had been&#160;passed, as required under Article&#160;L.&#160;233-7 of the French Commercial Code. Dodge &amp; Cox, acting on behalf of its clients and funds under its management, declared that on June&#160;23, 2023 it had passed below the&#160;5% threshold in terms of share capital, and holds, on behalf of its clients and funds, 4.99% of the share capital and&#160;4.43% of the voting rights.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition to the statutory requirement to inform the Company and the </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Autorit&#233; des march&#233;s financiers</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (AMF, the French Financial Markets Regulator)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> that they hold a number of shares (or of securities equivalent to shares or of voting rights pursuant&#160;to Article&#160;L.&#160;233-9 of the French Commercial Code) representing more than one-twentieth (5%), one-tenth (10%), three-twentieths (15%), one-fifth (20%), one-quarter (25%), three-tenths (30%), one-third (1/3), one-half (50%), two-thirds (2/3), nine-tenths (90%) or nineteen-twentieths (95%) of the share capital or theoretical voting rights within four trading days after crossing any such ownership threshold (Article&#160;L.&#160;233-7 of the French Commercial Code), any natural or legal person who directly or indirectly comes to hold a percentage of the share capital, voting rights or securities giving future access to the Company&#8217;s capital that is equal to or greater than 1% or any multiple of that percentage, is obliged to inform the Company thereof by registered mail, return receipt requested, indicating the number of securities held, within five trading days following the date on which each of the thresholds was crossed.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If such declaration is not made, the shares in excess of the fraction that should have been declared will be stripped of voting rights at shareholders&#8217; meetings, if on the occasion of such meeting, the failure to declare has been formally noted and one or more shareholders collectively holding at least 5% of the Company&#8217;s share capital or voting rights so request at that meeting.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Any natural or legal person is also required to inform the Company, in the forms and within the time limits stipulated above for passing above a specified threshold, if their direct or indirect holding passes below any of the aforementioned thresholds.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since January&#160;1, 2024 Sanofi has only received share ownership declarations of statutory threshold.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">146</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_352"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;7. Major shareholders and related party transactions</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, individual shareholders (including employees of Sanofi and its subsidiaries, as well as retired employees holding shares via the Sanofi Group Employee Savings Plan) held approximately 7.9% of our share capital. Institutional shareholders (excluding L&#8217;Or&#233;al) held approximately 77.7% of our share capital. Such shareholders are primarily from the United-States&#160;(34.7%), French (10.8%) and British (13.1%). German institutions held 4.2% of our share capital, Scandinavian institutions held 3.5%, Swiss institutions held&#160;2.2%, Benelux institutions held 1.8%, and institutions from other European countries held 1.9%. Other international institutional investors (excluding those from Europe, North America and Asia) held approximately 1% of our share capital. In France, our home country, we have 10,492 identified shareholders of record. In the United States, our host country, we have 55 identified shareholders of record and 18,346 identified ADS holders of record.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(Source: analysis performed by NASDAQ as of December&#160;31, 2023, and internal information.)</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_355"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Shareholders&#8217; Agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are unaware of any shareholders&#8217; agreement currently in force.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.&#160;Related Party Transactions</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">See Note&#160;D.33. to our consolidated financial statements included at Item&#160;18. of this annual&#160;report.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_358"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.&#160;Interests of Experts and Counsel</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">147</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_361"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;8. Financial information</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;8. Financial&#160;Information</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_364"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.&#160;Consolidated Financial Statements and Other Financial Information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our consolidated financial statements as of and for the years ended December 31, 2023, 2022 and 2021 are included in this annual report at &#8220;Item&#160;18. Financial Statements.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Dividends on Ordinary Shares</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We paid annual dividends for the years ended December&#160;31, 2019, 2020, 2021 and 2022 and our shareholders will be asked to approve the payment of an annual dividend of &#8364;3.76 per share for the 2023 fiscal year at our next annual shareholders&#8217; meeting. If approved, this dividend will be paid on May&#160;15, 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We expect that we will continue to pay regular dividends based on our financial condition and results of operations. The proposed 2023 dividend equates to a distribution of 46.3% of our business net income. For information on the non-IFRS financial measure &#8220;business earnings per share&#8221; see &#8220;Item&#160;5. Operating and Financial Review and Prospects &#8212;&#160;Business Net Income.&#8221;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following table sets forth information with respect to the dividends paid by our Company in respect of the 2019, 2020, 2021 and 2022 fiscal years and the dividend that will be proposed for approval by our shareholders in respect of the 2023 fiscal year at our April&#160;30, 2024 shareholders&#8217; meeting.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.361%"><tr><td style="width:1.0%"/><td style="width:37.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.148%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend per Share </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.56&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Proposal, subject to shareholder approval.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) And a dividend in kind of EUROAPI shares, at a ratio of one EUROAPI share per 23&#160;Sanofi shares.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The declaration, amount and payment of any future dividends will be determined by majority vote of the holders of our shares at an ordinary general meeting, following the recommendation of our Board of Directors. Any declaration will depend on our results of operations, financial condition, cash requirements, future prospects and other factors deemed relevant by our shareholders. Accordingly, we cannot assure you that we will pay dividends in the future on a continuous and regular basis. Under French law, we are required to pay dividends approved by an ordinary general meeting of shareholders within nine months following the meeting at which they are approved.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Disclosure pursuant to Section&#160;13(r) of the United&#160;States Exchange Act of 1934</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi engages in limited business activities with Iran related to human health products &#8211; namely, sales of bulk and branded pharmaceuticals and vaccines. These activities, which are disclosed pursuant to Section&#160;13(r) of the United States Exchange Act of 1934, as amended, are not financially material to Sanofi and contributed well under 1% of Sanofi&#8217;s consolidated net sales in&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s US affiliates and non-US affiliates owned or controlled by Sanofi&#8217;s US affiliates either do not engage in Iran-related activities or act under licenses issued by the US Department of the Treasury&#8217;s Office of Foreign Assets Control (OFAC).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and certain non-US Sanofi affiliates engage in limited business activities that neither are expressly authorized by OFAC nor require such authorization.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2016, Sanofi and the Iran Food and Drug Administration (IFDA), an entity affiliated with the Iranian Ministry of Health and Medical Education, signed a Memorandum of Cooperation (MOC) regarding: (i)&#160;potential future projects to reinforce current partnerships with reputable Iranian manufacturers (in particular, to enhance industrial quality standards); (ii)&#160;collaborating with the Ministry of Health and Medical Education on programs for the prevention and control of certain chronic and non-communicable diseases (in particular, diabetes); and (iii)&#160;potential future collaboration on epidemiological studies. In 2023, activities conducted under the MOC did not generate any revenue or net profits.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Certain non-US Sanofi affiliates engage in limited business with Iranian counterparties associated with the Iranian Ministry of Health, such as public hospitals or distributors. In 2023, those business activities generated approximately &#8364;27.1&#160;million in gross revenue and contributed no more than &#8364;3.9&#160;million in net profits.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, a representative office in Tehran incurs incidental expenses from state-owned utilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi believes that it and its affiliates&#8217; activities are compliant with applicable law, and in light of the nature of the activities concerned, Sanofi and its affiliates intend to continue their ongoing activities in Iran.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">148</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;8. Financial information</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Information on Legal or Arbitration Proceedings</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This Item&#160;8. incorporates by reference the disclosures found in Note&#160;D.22. to&#160;the consolidated financial statements at Item&#160;18.&#160;of&#160;this annual report; material updates thereto as of the date of this annual report are found below under the heading&#160;&#8220;&#8212;&#160;B.&#160;Significant Changes &#8212;&#160;Updates to Note&#160;D.22.&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and its subsidiaries are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures. As a result, we may become subject to substantial liabilities that may not be covered by insurance and could affect our business and reputation. While we do not currently believe that any of these legal proceedings will have a material adverse effect on our financial position, litigation is inherently unpredictable. As a consequence, we may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on results of operations, cash flows and/or our&#160;reputation.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Investigations and Related Litigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">From time to time, subsidiaries of Sanofi are subject to governmental investigations and information requests from regulatory authorities inquiring as to the practices of Sanofi with respect to the sales, marketing, and promotion of its products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">From 2017 through 2023, several government agencies issued Civil Investigative Demands (CIDs) or other discovery requests calling for the production of documents and information relating to Sanofi&#8217;s trade and pricing practices for its insulin products and/or LANTUS-related litigation. Sanofi US is cooperating with each of the previously reported investigations (including those conducted by the State Attorney General&#8217;s offices in Washington, California, Colorado and Vermont), and reached a resolution with the New York State Attorney General in April&#160;2023. In addition, Sanofi US is cooperating with investigations initiated by the&#160;US Federal Trade Commission in June&#160;2022; by the Texas State Attorney General&#8217;s office in August&#160;2022; and by the Ohio Attorney General&#8217;s office in October&#160;2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2019, Sanofi US received a CID from the US Department of Justice concerning DUPIXENT, KEVZARA, PRALUENT and ZALTRAP. In June&#160;2021, the government declined to intervene in the underlying complaint which was filed in November&#160;2018. The government investigation into this matter is now closed. Relators, however, filed their First Amended Complaint in&#160;October&#160;2021, which the Court dismissed with prejudice in August&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February&#160;2020, Genzyme Corporation received a CID from the US Department of Justice. The CID requests documents and information relating to Genzyme Corporation&#8217;s payments made to vendors or developers of electronic health record technology. Genzyme Corporation is cooperating with this investigation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In October&#160;2022, Sanofi US received a CID from the Ohio State Attorney General&#8217;s office, seeking documents and information about the pricing, sale, and distribution of pharmaceuticals and pharmacy benefit manager services in the State of Ohio. Sanofi&#160;US is cooperating with this investigation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In November&#160;2023, Sanofi US received a CID from the US Department of Justice regarding an investigation into Sanofi&#8217;s pricing submissions for ADMELOG. Sanofi US is cooperating with this investigation.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Insulin-Related Litigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In December&#160;2016 and January&#160;2017, two putative class actions were filed against Sanofi US and Sanofi GmbH in the US Federal Court in Massachusetts on behalf of direct purchasers of LANTUS alleging certain antitrust violations. Sanofi GmbH was later dismissed from the actions. In January&#160;2018, the Court dismissed Plaintiffs&#8217; consolidated amended complaint against Sanofi US. Plaintiffs appealed that order to the Court of Appeals for the First Circuit, which issued its decision on February&#160;13, 2020 reversing and remanding to the district court. In January&#160;2021, Sanofi-Aventis Puerto Rico, Inc. (Sanofi PR) was added as a defendant. In&#160;October&#160;2022, plaintiffs informed Sanofi US and Sanofi PR that they would proceed via joinder rather than move for class certification. Consistent with the Court's joinder deadline, new plaintiffs moved to intervene on January&#160;3, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">There are a number of insulin-related litigation matters pending in the US federal and state courts. These include cases brought&#160;on behalf of putative classes of consumers, wholesale purchasers of insulin, and state and local governments. The cases, which&#160;have been filed against Sanofi&#160;US along with other insulin manufacturers and, in some cases, pharmacy benefit managers,&#160;challenge those entities&#8217; insulin pricing practices (including Sanofi&#8217;s pricing practices for LANTUS, APIDRA, TOUJEO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and/or SOLIQUA). The suits allege some combination of: violations of the Racketeer Influenced and Corrupt Organizations Act (&#8220;RICO&#160;Act&#8221;); violations of various state unfair/deceptive trade practices statutes; unjust enrichment; common-law fraud; and civil conspiracy. The status of these matters varies from initial motions to dismiss the complaints to active discovery. In&#160;August&#160;2023, the vast majority of the insulin-related litigation was consolidated in an MDL (Multi-District Litigation - MDL) in federal court in New Jersey. On January&#160;24, 2024, the District Court for the District of New Jersey issued a decision denying plaintiffs&#8217; motion for class certification. Plaintiffs have appealed that decision.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Mylan vs Sanofi antitrust complaint</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May&#160;2023, Mylan Pharmaceuticals Inc., Mylan Specialty LP and Mylan Inc. (Mylan) filed suit against Sanofi-Aventis US LLC, Sanofi SA, Aventis Pharma SA and Sanofi-Aventis Puerto Rico (Sanofi) in the Western District of Pennsylvania for alleged antitrust violations related to Mylan&#8217;s insulin product SEMGLEE. Sanofi has moved to dismiss the complaint.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">149</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_367"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;8. Financial information</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.&#160;Significant Changes</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Updates to Note&#160;D.22.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">TAXOTERE  - Mississippi Attorney General Litigation in the United States </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February 2024, Sanofi reached a settlement to resolve this case, which now fully concludes the matter.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Other Changes</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January&#160;23, 2024 Sanofi announced the entry into a merger agreement with Inhibrx, Inc. (Inhibrx), a publicly traded, clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases (the Merger Agreement), pursuant to which Sanofi has agreed to acquire Inhibrx following the spin-off of Inhibrx's non-INBRX-101 assets and liabilities into a new publicly traded company ("New Inhibrx"). Under the terms of the Merger Agreement, Sanofi has agreed to: (i)&#160;provide Inhibrx's stockholders with consideration of $30 per share of Inhibrx common stock at the closing of the merger (approximately $1.7&#160;billion), and to additionally issue one non-transferable contingent value right per share of Inhibrx common stock, which will entitle its holder to receive a deferred cash payment of $5, conditioned upon the achievement of a regulatory milestone (approximately $0.3&#160;billion, if the regulatory milestone is achieved); (ii)&#160;pay off Inhibrx&#8217;s outstanding third-party debt (approximately $0.2&#160;billion); and (iii)&#160;provide a capital contribution to New Inhibrx (up to $0.2&#160;billion). At the closing of the merger, Sanofi will acquire 100% of the equity interests in Inhibrx, which will become a 100% wholly owned subsidiary of Sanofi. In addition, Inhibrx will retain a minority stake (approximately 8% equity interest) in New Inhibrx. INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. INBRX-101 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. INBRX-101 acquisition is expected to </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">support Sanofi&#8217;s portfolio growth strategy and complements the Company&#8217;s 30-year heritage in rare diseases and track record in immunology and inflammation. The transaction is subject to various closing conditions, including the receipt of regulatory approvals and completion of the spin-off of New Inhibrx. Assuming satisfaction of those closing conditions, Sanofi currently anticipates that the transaction will close in the second quarter of 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;1, 2024, Sanofi announced that </span><span style="color:#7802e6;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Fran&#231;ois-Xavier Roger</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> will be appointed Chief Financial Officer and a member of Sanofi&#8217;s Executive Committee effective April&#160;1, 2024. He will be based in Paris and will succeed Jean-Baptiste Chasseloup de Chatillon who will step down from his role to become Head of Apprentis d&#8217;Auteuil.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">150</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_370"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;9. The offer and listing</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;9. The Offer and Listing</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_373"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A. Offer and Listing Details</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have one class of shares. Each American Depositary Share, or ADS, represents one-half of one share. The ADSs are evidenced by American Depositary Receipts, or ADRs, which are issued by JPMorgan Chase Bank,&#160;NA.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our shares trade on Compartment&#160;A of the regulated market of Euronext Paris under the symbol "SAN," and our ADSs trade on the Nasdaq Global Select Market, or&#160;Nasdaq,under the symbol "SNY."</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_376"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.&#160;Plan of Distribution</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_379"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.&#160;Markets</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Shares and ADSs</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our shares are listed on Euronext Paris under the symbol &#8220;SAN&#8221; and our ADSs are listed on the Nasdaq under the symbol&#160;&#8220;SNY.&#8221;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of the date of this annual report, our shares are included in a large number of indexes, including the &#8220;CAC&#160;40&#160;Index,&#8221; the principal French index published by Euronext Paris. This index contains 40&#160;stocks selected among the top&#160;100&#160;companies based on free-float capitalization and the most active stocks listed on the Euronext Paris market. The CAC&#160;40&#160;Index indicates trends in the French stock market as a whole and is one of the most widely followed stock price indices in France.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our shares are included in European indexes, such as the EURO STOXX&#160;50, STOXX Europe&#160;600 index, FTSE Eurofirst&#160;300, MSCI&#160;Europe, MSCI Pan Euro, Euronext&#160;100, and STOXX Europe&#160;600 Health Care. They are also included in American and international indexes, such as the NASDAQ Composite, NASDAQ Health Care, S&amp;P Global&#160;100, MSCI World, and MSCI World Pharmaceuticals, Biotechnology and Life Sciences.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our shares are also part of the main extra-financial rating indices, taking into account environmental, social, and governance criteria (FTSE4Good, STOXX Global ESG Leaders, and EURO STOXX&#160;50 Low Carbon).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Trading by Sanofi in our own Shares</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under French law, a company may not issue shares to itself, but it may purchase its own shares in the limited cases described at&#160;&#8220;Item&#160;10.&#160;Additional Information &#8212;&#160;B.&#160;Memorandum and Articles of Association &#8212;&#160;Trading in Our Own&#160;Shares.&#8221;</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_382"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D. Selling Shareholders</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_385"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E. Dilution</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_388"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">F. Expenses of the Issue</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">151</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_391"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;10. Additional information</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;10. Additional Information</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A. Share Capital</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_394"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B. Memorandum and Articles of Association</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Company is a </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233; anonyme</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, a form of limited liability company, organized under the laws of France. The LEI number of the Company is 549300E9PC51EN656011.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In this section, we summarize material information concerning our share capital, together with material provisions of applicable French law and our Articles of Association </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(statuts)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, an English translation of which has been filed as an exhibit to this annual report. For a description of certain provisions of our Articles of Association relating to our Board of Directors and statutory auditors, see &#8220;Item&#160;6. Directors, Senior Management and Employees." You may obtain copies of our Articles of Association in French from the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">greffe</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (Clerk) of the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Registre du Commerce et des Soci&#233;t&#233;s de Paris</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (Registry of Commerce and Companies of Paris, France, registration number: 395&#160;030&#160;844). Please refer to that full document for additional details.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Articles of Association specify that our corporate affairs are governed by:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">applicable laws and regulations (in particular, Title&#160;II of the French Commercial Code); and</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.1pt">the Articles of Association themselves.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Article&#160;3 of our Articles of Association specifies that the Company&#8217;s corporate purpose, in France and abroad,&#160;is:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">acquiring interests and holdings, in any form whatsoever, in any company or enterprise, in existence or to be created, connected directly or indirectly with the health and fine chemistry sectors, human and animal therapeutics, nutrition and bio-industry:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">in the following areas:</span></div><div style="margin-bottom:5pt;padding-left:34.02pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">purchase and sale of all raw materials and products necessary for these activities,</span></div><div style="margin-bottom:5pt;padding-left:34.02pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">research, study and development of new products, techniques and processes,</span></div><div style="margin-bottom:5pt;padding-left:34.02pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">manufacture and sale of all chemical, biological, dietary and hygienic products,</span></div><div style="margin-bottom:5pt;padding-left:34.02pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">obtaining or acquiring all intellectual property rights related to results obtained and, in particular, filing all patents, trademarks and models, processes or inventions,</span></div><div style="margin-bottom:5pt;padding-left:34.02pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">operating directly or indirectly, purchasing, and transferring &#8211;&#160;for free or for consideration&#160;&#8211; pledging or securing all intellectual property rights, particularly all patents, trademarks and models, processes or inventions,</span></div><div style="margin-bottom:5pt;padding-left:34.02pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">obtaining, operating, holding and granting all licenses,</span></div><div style="margin-bottom:5pt;padding-left:34.02pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">within the framework of a group-wide policy and subject to compliance with the relevant legislation, participating in treasury management transactions, whether as lead company or otherwise, in the form of centralized currency risk management or intra-group netting, or any other form permitted under the relevant laws and regulations,</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">and, more generally:</span></div><div style="margin-bottom:5pt;padding-left:34.02pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">all commercial, industrial, real or personal property, financial or other transactions, connected directly or indirectly, totally or partially, with the activities described above and with all similar or related activities and even with any other purposes likely to encourage or develop the Company&#8217;s activities.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Directors</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Transactions in which directors are materially interested</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under French law, any agreement entered into (directly or through an intermediary) between our Company and any one of the members of the Board of Directors that is not entered into (i)&#160;in the ordinary course of our business and (ii)&#160;under normal conditions, is subject to the prior authorization of the disinterested members of the Board of Directors. The same provision applies to agreements between our Company and another company if one of the members of the Board of Directors is the owner, general partner, manager, director, general manager or member of the executive or supervisory board of the other company, as well as to agreements in which one of the members of the Board of Directors has an indirect interest.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors must also approve any undertaking taken by our Company for the benefit of our Chairman, Chief Executive Officer </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(directeur g&#233;n&#233;ral)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or his delegates </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(directeurs g&#233;n&#233;raux d&#233;l&#233;gu&#233;s)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> pursuant to which such persons will or may be granted compensation, benefits or any other advantages as a result of the termination of or a change in their offices or following such termination or change, in accordance with Article&#160;L.&#160;22-10-8&#160;III of the French Commercial Code. Each such undertaking must be included in our compensation policy for corporate officers, which is submitted for approval by our shareholders at the Annual General Meeting in accordance with Article&#160;L.&#160;22-10-8&#160;II of the French Commercial Code. No such compensation or undertaking may be determined, awarded or paid unless in accordance with such compensation policy. </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">152</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;10. Additional information</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">See&#160;&#8220;Item&#160;6. Directors, Senior Management and Employees &#8212;&#160;B.&#160;Compensation&#8221; for a description of the process for establishing and authorizing such compensation policy.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Directors&#8217; compensation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The aggregate amount of compensation of the Board of Directors is determined at the Shareholders&#8217; Ordinary General Meeting. The Board of Directors then divides this aggregate amount among its members by a simple majority vote. In addition, the Board of Directors may grant exceptional compensation </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(r&#233;mun&#233;rations exceptionnelles)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to individual directors on a case-by-case basis for special assignments following the procedures described above at &#8220;&#8212;&#160;Transactions in which directors are materially interested&#8221;. The Board of Directors may also authorize the reimbursement of travel and accommodation expenses, as well as other expenses incurred by Directors in the corporate interest. See also &#8220;Item&#160;6. Directors, Senior Management and&#160;Employees.&#8221; Furthermore, under our Articles of Association, the Board of Directors may compensate any observers </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(censeurs)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> to the Board of Directors, which would reduce by the same amount the total annual compensation available for allocation to the Board of Directors.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Board of Directors&#8217; authority to take out loans or borrow money on behalf of the Company</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All loans or borrowings on behalf of the Company may be decided by the Board of Directors within the limits, if any, imposed by the Shareholders&#8217; Extraordinary General Meeting. There are currently no limits imposed on the amounts of loans or borrowings that the Board of Directors may&#160;approve.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Directors&#8217; age limits</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the provisions of our Articles of Association relating to age limits applicable to our Directors, see &#8220;Item&#160;6.&#160;Directors, Senior Management and&#160;Employees &#8211; A.&#160;Directors and Senior Management."</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Directors&#8217; share ownership requirements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Pursuant to our Articles of Association, each director appointed by a Shareholders&#8217; Ordinary General Meeting must own at least&#160;500&#160;shares throughout their term of office. In addition, pursuant to the Board Charter, our Directors must within no more than two years from their appointment hold at least 1,000&#160;Sanofi shares in their own name, which must be retained until they cease to hold office.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholders&#8217; meetings</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with the provisions of the French Commercial Code, there are three types of shareholders&#8217; meetings: ordinary, extraordinary and&#160;special.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Ordinary general meetings of shareholders are required for matters such as:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">electing, replacing and removing Directors;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">appointing independent auditors;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">approving the annual financial statements;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">declaring dividends or authorizing dividends to be paid in shares, provided the Articles of Association contain a provision to that effect; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">approving share repurchase programs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Extraordinary general meetings of shareholders are required for approval of matters such as amendments to our Articles of Association, including any amendment required in connection with extraordinary corporate actions. Extraordinary corporate actions include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">changing our Company&#8217;s name or corporate purpose;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">increasing or decreasing our share capital;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">creating a new class of equity securities;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">authorizing the issuance of:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">shares giving access to our share capital or giving the right to receive debt instruments, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">other securities giving access to our share capital;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">establishing any other rights to equity securities;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">selling or transferring substantially all of our assets; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the voluntary liquidation of our Company.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Special meetings of shareholders of a certain category of shares or shares with certain specific rights (such as shares with double voting rights) are required for any modification of the rights derived from that category of shares. The resolutions of the shareholders&#8217; general meeting affecting these rights are effective only after approval by the relevant special meeting.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">153</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;10. Additional information</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Annual ordinary meetings</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The French Commercial Code requires the Board of Directors to convene an annual ordinary general shareholders&#8217; meeting to approve the annual financial statements. This meeting must be held within six months of the end of each fiscal year.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors may also convene an ordinary or extraordinary general shareholders&#8217; meeting upon proper notice at any time during the year. If the Board of Directors fails to convene a shareholders&#8217; meeting, our independent auditors may call the meeting. In case of bankruptcy, the liquidator or court-appointed agent may also call a shareholders&#8217; meeting in some instances. In addition, any of the following may request the court to appoint an agent for the purpose of calling a shareholders&#8217; meeting:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">one or several shareholders holding at least 5% of our share capital;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">duly qualified associations of shareholders who have held their shares in registered form for at least two years and who together hold at least 1% of our voting rights;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the works council in cases of urgency; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">any interested party in cases of urgency.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under our Articles of Association, the Board of Directors may take decisions by written consultation under the conditions permitted by law and as specified in the Board Charter (an English language version of which is reproduced in full as Exhibit&#160;1.2 to this annual report), including the possibility to convene an ordinary or extraordinary general meeting.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Notice of shareholders&#8217; meetings</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All prior notice periods provided for below are minimum periods required by French law and cannot be shortened, except in case of a public tender offer for our&#160;shares.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We must announce general meetings at least thirty-five days in advance by means of a preliminary notice </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(avis de r&#233;union)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which is published in the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Bulletin des Annonces L&#233;gales Obligatoires</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, or BALO. The preliminary notice must first be sent to the French Financial markets authority (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Autorit&#233; des march&#233;s financiers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the &#8220;AMF&#8221;), with an indication of the date on which it will be published in the BALO. It must be published on our website at least twenty-one days prior to the general meeting. The preliminary notice must contain, among other things, the agenda, a draft of the resolutions to be submitted to the shareholders for consideration at the general meeting and a detailed description of the voting procedures (proxy voting, electronic voting or voting by mail), the procedures permitting shareholders to submit additional resolutions or items to the agenda and to ask written questions to the Board of Directors. The AMF also recommends that, prior to or simultaneously with the publication of the preliminary notice, we publish a summary of the notice indicating the date, time and place of the meeting in a newspaper of national circulation in France and on our&#160;website.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At least fifteen days prior to the date set for a first convening, and at least ten days prior to any second convening, we must send a final notice </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(avis de convocation)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> containing the final agenda, the date, time and place of the meeting and other information related to the meeting. Such final notice must be sent by mail to all registered shareholders who have held shares in registered form for more than one month prior to the date of the final notice and by registered mail, if shareholders have asked for it and paid the corresponding charges. The final notice must also be published in a newspaper authorized to publish legal announcements in the local administrative department </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(d&#233;partement)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in which our Company is registered as well as in the BALO, with prior notice having been given to the AMF for informational purposes. Even if there are no proposals for new resolutions or items to be submitted to the shareholders at the meeting, we must publish a final notice in a newspaper authorized to publish legal announcements in the local administrative department </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(d&#233;partement)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in which our Company is registered as well as in the&#160;BALO.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Other issues</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In general, shareholders can only take action at shareholders&#8217; meetings on matters listed on the agenda. As an exception to this rule, shareholders may take action with respect to the appointment and dismissal of directors even if this action has not been included on the&#160;agenda.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Additional resolutions to be submitted for approval by the shareholders at the shareholders&#8217; meeting may be proposed to the Board of Directors, for recommendation to the shareholders at any time from the publication of the preliminary notice in the&#160;BALO until twenty-five days prior to the general meeting and in any case no later than twenty days following the publication of the preliminary notice in the&#160;BALO&#160;by:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">one or several shareholders together holding a specified percentage of shares;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a duly qualified association of shareholders who have held their shares in registered form for at least two years and who together hold at least 1% of our voting rights; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the works council.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Within the same period, the shareholders may also propose additional items (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">points</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) to be submitted and discussed during the shareholders&#8217; meeting, without a shareholders&#8217; vote. The shareholders must substantiate the reasons for their proposals of additional items.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The resolutions and the list of items added to the agenda of the shareholders&#8217; meeting must be promptly published on our&#160;website.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors must submit the resolutions to a vote of the shareholders after having made a recommendation thereon. The Board of Directors may also comment on the items that are submitted to the shareholders&#8217; meeting.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">154</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;10. Additional information</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Following the date on which documents must be made available to the shareholders (including documents to be submitted to the shareholders&#8217; meeting and resolutions proposed by the Board of Directors, which must be published on our website at least twenty-one days prior to the general meeting), shareholders may submit written questions to the Board of Directors relating to the agenda for the meeting until the fourth business day prior to the general meeting. The Board of Directors must respond to these questions during the meeting or may refer to a Q&amp;A section located on our website in which the question submitted by a shareholder has already been&#160;answered.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attendance at shareholders&#8217; meetings; proxies and votes by mail</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In general, all shareholders may participate in general meetings either in person or by proxy. Shareholders may vote in person, by proxy or by&#160;mail.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The right of shareholders to participate in general meetings is subject to the recording </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(inscription en compte)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of their shares on the second business day, 12:00&#160;a.m. (Paris time), preceding the general meeting:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">for holders of registered shares: in the registered shareholder account held by the Company or on its behalf by an agent appointed by&#160;it; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">for holders of bearer shares: in the bearer shareholder account held by the accredited financial intermediary with whom such holders have deposited their shares; such financial intermediaries shall deliver to holders of bearer shares a shareholding certificate </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(attestation de participation)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> enabling them to participate in the general meeting.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Attendance in person</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Any shareholder may attend ordinary general meetings and extraordinary general meetings and exercise its voting rights subject to the conditions specified in the French Commercial Code, the French Civil Code and our Articles of&#160;Association.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An attendance sheet and written minutes are established for each shareholders&#8217; meeting; failure to do so could lead to cancellation of the decisions at the shareholders&#8217; meeting.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Proxies and votes by mail</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Proxies are sent to any shareholder upon a request received between the publication of the final notice of meeting and six days before the general meeting and must be made available on our website at least twenty-one days before the general meeting. In order to be counted, such proxies must be received at our registered office, or at any other address indicated on the notice of the meeting or by any electronic mail indicated on the notice of the meeting, prior to the date of the meeting (in&#160;practice, we request that shareholders return proxies at least three business days prior to the meeting; electronic proxies must be returned before&#160;3&#160;p.m. Paris time, on the day prior to the general meeting). A shareholder may grant proxies to any natural person or legal entity. The agent may be required to disclose certain information to the shareholder or to the&#160;public.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A proxy is only valid for one meeting (or by way of exception for two meetings, one being ordinary and the other extraordinary, held on the same day or within a single 15-day period); it remains valid in the event such meeting is convened multiple times for the same agenda, and may be revoked by written statement of the shareholder granting the proxy.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Alternatively, the shareholder may send us a blank proxy without nominating any representative. In this case, the chairman of the meeting will vote the blank proxies in favor of all resolutions proposed or approved by the Board of Directors and against all&#160;others.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">With respect to votes by mail, we must send shareholders a voting form upon request or must make available a voting form on our website at least twenty-one days before the general meeting. The completed form must be returned to us at least three days prior to the date of the shareholders&#8217; meeting. For holders of registered shares, in addition to traditional voting by mail, instructions may also be given via the&#160;Internet.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quorum</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The French Commercial Code requires that shareholders holding in the aggregate at least 20% of the shares entitled to vote must be present in person, or vote by mail or by proxy, in order to fulfill the quorum requirement&#160;for:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an ordinary general meeting; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an extraordinary general meeting where the only resolutions pertain to either (a)&#160;a proposed increase in our share capital through incorporation of reserves, profits or share premium, or (b)&#160;the potential issuance of free share warrants in the event of a public tender offer for our shares (Article&#160;L.&#160;233-32 of the French Commercial Code).</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For any other extraordinary general meeting the quorum requirement is at least 25% of the shares entitled to vote, held by shareholders present in person, voting by mail or by&#160;proxy.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a special meeting of holders of a certain category of shares, the quorum requirement is one third of the shares entitled to vote in that category, held by shareholders present in person, voting by mail or by&#160;proxy.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If a quorum is not present at a meeting, the meeting is adjourned. However, only questions that were on the agenda of the adjourned meeting may be discussed and voted upon once the meeting resumes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When an adjourned meeting is resumed, there is no quorum requirement for meetings cited in the first paragraph of this &#8220;Quorum&#8221; section. In the case of any other reconvened extraordinary general meeting or special meeting, the quorum requirement is 20% of the shares entitled to vote (or&#160;voting shares belonging to the relevant category for special meetings of holders of shares of such specific category), held by shareholders present in person or voting by mail or by proxy. If a quorum is not met, the reconvened meeting may be adjourned for a maximum of two months with the same quorum requirement. No deliberation or action by the shareholders may take place without a&#160;quorum.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">155</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_397"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;10. Additional information</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.&#160;Material Contracts</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the ordinary course of our business, we enter into agreements for licensing or collaboration in the development and commercialization of products. Certain of the agreements which have led to successful commercialization to date are summarized in &#8220;Item&#160;5. Operating and financial review and prospects &#8212; A.1.7&#160;Financial presentation of alliances.&#8221;</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_400"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.&#160;Exchange Controls</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">French exchange control regulations currently do not limit the amount of payments that we may remit to non-residents of France. Laws and regulations concerning foreign exchange controls do require, however, that all payments or transfers of funds made by a French resident to a non-resident be handled by an accredited intermediary.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_403"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">E.&#160;Taxation</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following generally summarizes the material French and US&#160;federal income tax consequences to US&#160;holders (as&#160;defined below) of purchasing, owning and disposing of our ADSs and ordinary shares (collectively the &#8220;Securities&#8221;). This discussion is intended only as a descriptive summary and does not purport to be a complete analysis or listing of all potential tax effects of the purchase, ownership or disposition of our Securities. All of the following is subject to change. Such changes could apply retroactively and could affect the consequences described below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">This summary does not constitute a legal opinion or tax advice. Holders are urged to consult their own tax advisers regarding the tax consequences of the purchase, ownership and disposition of Securities in light of their particular circumstances, including the effect of any US&#160;federal, state, local or other national tax&#160;laws.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A set of tax rules is applicable to French assets that are held by or in foreign trusts. These rules provide inter&#160;alia for the inclusion of trust assets in the settlor&#8217;s net assets for purpose of applying the French real estate wealth tax, for the application of French gift and death duties to French assets held in trust, for a specific tax on capital on the French assets of foreign trusts not already subject to the French real estate wealth tax and for a number of French tax reporting and disclosure obligations. The following discussion does not address the French tax consequences applicable to Securities held in trusts. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">If Securities are held in trust, the grantor, trustee and beneficiary are urged to consult their own tax adviser regarding the specific tax consequences of acquiring, owning and disposing of&#160;Securities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The description of the French and US&#160;federal income tax consequences set forth below is based on the laws (including, for US&#160;federal income tax purposes, the Internal Revenue Code of 1986, as amended (the&#160;&#8220;Code&#8221;), final, temporary and proposed US&#160;Treasury Regulations promulgated thereunder and administrative and judicial interpretations thereof) in force as of the date of this annual report, the Convention Between the Government of the United&#160;States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital of August&#160;31, 1994 (the&#160;&#8220;Treaty&#8221;), which entered into force on December&#160;30, 1995 (as&#160;amended by any subsequent protocols, including the protocol of January&#160;13, 2009), and the tax regulations issued by the French tax authorities within the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Bulletin Officiel des Finances Publiques-Imp&#244;ts</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (the&#160;&#8220;Regulations&#8221;) in force as of the date of this report. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">US&#160;holders are advised to consult their own tax advisers regarding their eligibility for Treaty benefits, especially with regard to the &#8220;Limitations on Benefits&#8221; provision, in light of their own particular circumstances.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No advance ruling has been obtained with respect to the tax consequences of the acquisition, ownership or disposition of the Securities from either the French or US tax authorities. Thus, there can no assurances that either or both of such authorities will not take a position concerning said tax consequences different from that set out herein or that such a position would not be sustained by a court.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the purposes of this discussion, a US&#160;holder is a beneficial owner of Securities that is (i)&#160;an individual who is a US&#160;citizen or resident for US&#160;federal income tax purposes, (ii)&#160;a US&#160;domestic corporation created or organized in or under the laws of the United&#160;States or any state thereof, including the District of Columbia, or (iii)&#160;certain estates or trusts that are subject to US tax jurisdiction. A non-US&#160;holder is a person other than a US&#160;holder.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If a partnership holds Securities, the tax treatment of a partner generally will depend upon the status of the partner and the activities of the partnership. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">If a US&#160;holder is an estate or trust or</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">partner in a partnership that holds Securities, the holder is urged to consult its own tax adviser regarding the specific tax consequences of acquiring, owning and disposing of&#160;Securities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This discussion is intended only as a general summary and does not purport to be a complete analysis or listing of all potential tax effects of the acquisition, ownership or disposition of the Securities to any particular investor, and does not discuss tax considerations that arise from rules of general application or that are generally assumed to be known by investors. The discussion applies only to investors that hold our Securities as capital assets that have the US&#160;dollar as their functional currency, that are entitled to Treaty benefits under the &#8220;Limitation on Benefits&#8221; provision contained in the Treaty, and whose ownership of the Securities is not effectively connected to a permanent establishment or a fixed base in France. Certain holders (including, but not limited to, US&#160;expatriates, partnerships or other entities classified as partnerships for US&#160;federal income tax purposes, banks, insurance companies, regulated investment companies, tax-exempt organizations, financial institutions, persons subject to the alternative minimum tax, persons who acquired the Securities pursuant to the exercise of employee stock options or otherwise as compensation, persons that own (directly, indirectly or by attribution) 5% or more of our voting stock or 5% or more of our outstanding share capital, dealers in securities or currencies, persons that elect to mark their securities to market for US&#160;federal income tax purposes, persons that acquire ADSs in &#8220;pre-release&#8221; transactions (i.e. prior to deposit of the relevant ordinary shares, </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">156</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;10. Additional information</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">although our depositary has indicated that such transactions have been halted) and persons holding Securities as a position in a synthetic security, straddle or conversion transaction) may be subject to special rules not discussed below. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Holders of Securities are advised to consult their own tax advisers with regard to the application of French tax law and US&#160;federal tax law to their particular situations, as well as any tax consequences arising under the laws of any state, local or other foreign jurisdiction.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">French taxes</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Estate and gift taxes and transfer taxes</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In general, a transfer of Securities by gift or by reason of death of a US&#160;holder that would otherwise be subject to French gift or inheritance tax, respectively, will not be subject to such French tax by reason of the Convention between the Government of the United&#160;States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates, Inheritances and Gifts, dated November&#160;24, 1978, unless the donor or the transferor is domiciled in France at the time of making the gift or at the time of his or her death, or the Securities were used in, or held for use in, the conduct of a business through a permanent establishment or a fixed base in&#160;France.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Pursuant to Article&#160;235&#160;ter&#160;ZD of the French General Tax Code, purchases of Securities are subject to a 0.3% French tax on financial transactions (the&#160;&#8220;FTFF&#8221;) provided that Sanofi&#8217;s market capitalization exceeds &#8364;1&#160;billion as of December&#160;1 of the year preceding the taxation year. A list of companies whose market capitalization exceeds &#8364;1&#160;billion as of December&#160;1 of the year preceding the taxation year used to be published annually by the French Ministry of Economy. It is now published by the French&#160;tax authorities, and could be amended at any time. Pursuant to Regulations BOI-ANNX-000467-20/12/2023 issued on&#160;Decemb</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">er&#160;20, 2023, purch</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ases of Sanofi&#8217;s Securities in&#160;2024 should be subject to the FTFF as the market capitalization of Sanofi exceeded &#8364;1&#160;billion as of December&#160;1, 2023. In accordance with Article&#160;726-II-d of the French General Tax Code, purchases which are subject to the FTFF should however not be subject to transfer taxes </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(droits d&#8217;enregistrement)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in&#160;France.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wealth tax</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The French wealth tax </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(imp&#244;t de solidarit&#233; sur la fortune)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> has been replaced with a French real estate wealth tax </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(imp&#244;t sur la fortune immobili&#232;re)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> with effect from January&#160;1, 2018. French real estate wealth tax applies only to individuals and does not generally apply to the Securities if the holder is a US&#160;resident, as defined pursuant to the provisions of the Treaty, provided that the individual does not own directly or indirectly a shareholding exceeding 10% of the financial rights and voting rights.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">US&#160;taxes</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Ownership of the securities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deposits and withdrawals by a US&#160;holder of ordinary shares in exchange for ADSs, will not be taxable events for US&#160;federal income tax purposes. For US&#160;tax purposes, holders of ADSs will be treated as owners of the ordinary shares represented by such ADSs. Accordingly, the discussion that follows regarding the US&#160;federal income tax consequences of acquiring, owning and disposing of ordinary shares is equally applicable to&#160;ADSs.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Information reporting and backup withholding tax</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Distributions made to holders and proceeds paid from the sale, exchange, redemption or disposal of Securities may be subject to information reporting to the Internal Revenue Service. Such payments may be subject to backup withholding taxes unless the holder (i)&#160;is a corporation or other exempt recipient or (ii)&#160;provides a taxpayer identification number and certifies that no loss of exemption from backup withholding has occurred. Holders that are not US&#160;persons generally are not subject to information reporting or backup withholding. However, such a holder may be required to provide a certification of its non-US&#160;status in connection with payments received within the United&#160;States or through a US-related financial intermediary to establish that it is an exempt recipient. Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a holder&#8217;s US&#160;federal income tax liability. A holder may obtain a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the Internal Revenue Service and furnishing any required information.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign asset reporting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, a US&#160;holder that is an individual or certain entities may be subject to reporting obligations with respect to ordinary shares and ADSs if the aggregate value of these and certain&#160;other &#8220;specified foreign financial assets&#8221; exceeds $50,000 on the&#160;last day of the tax year or more than $75,000 at any time during the tax year. If required, this disclosure is made by filing&#160;Form&#160;8938 with the&#160;US&#160;Internal Revenue Service. Significant penalties can apply if holders are required to make this disclosure and fail to do so. In addition, a US&#160;holder should consider the possible obligation to file&#160;online a FinCEN Form&#160;114 &#8211; Foreign Bank and Financial Accounts Report as a result of holding ordinary shares or ADSs. Holders are encouraged to consult their US&#160;tax advisors with respect to these and other reporting requirements that may apply to their acquisition of ordinary shares and&#160;ADSs.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">State and local taxes</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition to US&#160;federal income tax, US&#160;holders of Securities may be subject to US&#160;state and local taxes with respect to such Securities. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Holders of Securities are advised to consult their own tax advisers with regard to the application of US&#160;state and local income tax law to their particular situation.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">157</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;10. Additional information</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">ADSs-Ordinary Shares</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">French taxes</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Taxation of dividends</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under French law, dividends paid by a French corporation, such as Sanofi, to non-residents of France are generally subject to French withholding tax at a rate of (i)&#160;25% for payments benefiting legal persons who are not French tax residents (and 15% for distributions made to not-for-profit organizations with a head office in a Member State of the European Economic Area which would be subject to the tax regime set forth under Article&#160;206 paragraph&#160;2 of the French General Tax Code if its head office were located in France and which meet the criteria set forth in the Regulations BOI-RPPM-RCM-30-30-10-70-24/12/2019, No.&#160;130), and (ii)&#160;12.8% for payments benefiting individuals who are not French tax residents. Dividends paid by a French corporation, such as Sanofi, towards non-cooperative States or territories, as defined in Article&#160;238-0&#160;A of the French General Tax Code, will generally be subject to French withholding tax at a rate of 75%, irrespective of the tax residence of the beneficiary of the dividends if the dividends are received in such States or territories; however, eligible US&#160;holders entitled to Treaty benefits under the &#8220;Limitation on Benefits&#8221; provision contained in the Treaty who are US&#160;residents, as defined pursuant to the provisions of the Treaty and who receive dividends in non-cooperative States or territories, will not be subject to this 75% withholding tax&#160;rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the Treaty, the rate of French withholding tax on dividends paid to an eligible US&#160;holder who is a US&#160;resident as defined pursuant to the provisions of the Treaty and whose ownership of the ordinary shares or ADSs is not effectively connected with a permanent establishment or fixed base that such US&#160;holder has in France, is reduced to 15%, or to 5% if such US&#160;holder is a corporation and owns directly or indirectly at least 10% of the share capital of the issuing company; such US&#160;holder may claim a refund from the French tax authorities of the amount withheld in excess of the Treaty rates of 15% or 5%, if any. For US&#160;holders that are not individuals but are US&#160;residents, as defined pursuant to the provisions of the Treaty, the requirements for eligibility for Treaty benefits, including the reduced 5% or 15% withholding tax rates contained in the &#8220;Limitation on Benefits&#8221; provision of&#160;the Treaty, are complicated, and certain technical changes were made to these requirements by the protocol of January&#160;13,&#160;2009. US&#160;holders are advised to consult their own tax advisers regarding their eligibility for Treaty benefits in light of their own particular circumstances.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Dividends paid to an eligible US&#160;holder may immediately be subject to the reduced rates of 5% or 15% provided that such holder establishes before the date of payment that it is a US&#160;resident under the Treaty by completing and providing the depositary with a treaty form (Form&#160;5000). Dividends paid to a US&#160;holder that has not filed the Form&#160;5000 before the dividend payment date will be subject to French withholding tax at the rate of 25% and then reduced at a later date to 5% or 15%, provided that such holder duly completes and provides the French tax authorities with the treaty forms Form&#160;5000 and Form&#160;5001 before December&#160;31 of the second calendar year following the year during which the dividend is paid. Pension funds and certain other tax-exempt entities are subject to the same general filing requirements as other US&#160;holders except that they may have to supply additional documentation evidencing their entitlement to these benefits.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The depositary agrees to use reasonable efforts to follow the procedures established, or that may be established, by the French tax authorities (i)&#160;to enable eligible US&#160;holders to qualify for the reduced withholding tax rate provided by the Treaty, if available at the time the dividends are paid, or (ii)&#160;to recover any excess French withholding taxes initially withheld or deducted with respect to dividends and other distributions to which such US&#160;holders may be eligible from the French tax authorities and (iii)&#160;to recover any other available tax credits. In particular, associated forms (including Form&#160;5000 and Form&#160;5001, together with their instructions), will be made available by the depositary to all US&#160;holders registered with the depositary, and are also generally available from the US&#160;Internal Revenue Service.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The withholding tax refund, if any, ordinarily is paid within 12&#160;months of filing the applicable French Treasury Form, but not before January&#160;15 of the year following the calendar year in which the related dividend is&#160;paid.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Tax on sale or other disposition</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In general, under the Treaty, a US&#160;holder who is a US&#160;resident for purposes of the Treaty will not be subject to French tax on any capital gain from the redemption (other than redemption proceeds characterized as dividends under French domestic law), sale or exchange of ordinary shares or ADSs unless the ordinary shares or the ADSs form part of the business property of a permanent establishment or fixed base that the US&#160;holder has in France. Special rules apply to holders who are residents of more than one&#160;country.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">US&#160;Taxes</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Taxation of dividends</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For US&#160;federal income tax purposes, the gross amount of any distribution paid to US&#160;holders (that is, the net distribution received plus any tax withheld therefrom) will be treated as ordinary dividend income to the extent paid or deemed paid out of the current or accumulated earnings and profits of Sanofi (as&#160;determined under US&#160;federal income tax principles). Dividends paid by Sanofi will not be eligible for the dividends-received deduction generally allowed to corporate US&#160;holders.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subject to certain exceptions for short-term and hedged positions, the US&#160;dollar amount of dividends received by an individual US&#160;holder with respect to the ADSs or our ordinary shares is currently subject to taxation at a maximum rate of 20% if the dividends are &#8220;qualified dividends&#8221;. Dividends paid on the ordinary shares or ADSs will be treated as qualified dividends if (i)&#160;the issuer is eligible for the benefits of a comprehensive income tax treaty with the United&#160;States that the Internal Revenue Service has approved for the purposes of the qualified dividend rules and (ii)&#160;the issuer was not, in the year prior to the year in which the dividend was paid, and is not, in the year in which the dividend is paid, a passive foreign investment company (PFIC). The Treaty </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">158</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;10. Additional information</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">has been approved for the purposes of the qualified dividend rules. Based on our financial statements and relevant market and shareholder data, we believe Sanofi was not a PFIC for US&#160;federal income tax purposes with respect to its 2023 taxable year. In addition, based on its current expectations regarding the value and nature of its assets, the sources and nature of its income, and relevant market and shareholder data, we do not anticipate that Sanofi will become a PFIC for its 2024 taxable year. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Holders of ordinary shares and ADSs should consult their own tax advisers regarding the availability of the reduced dividend tax rate in light of their own particular circumstances.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If you are a US&#160;holder, dividend income received by you with respect to ADSs or ordinary shares generally will be treated as foreign source income for foreign tax credit purposes. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. Distributions out of earnings and profits with respect to the ADSs or ordinary shares generally will be treated as &#8220;passive category&#8221; income (or, in the case of certain US&#160;holders, &#8220;general category&#8221; income). Subject to certain limitations, French income tax withheld in connection with any distribution with respect to the ADSs or ordinary shares may be claimed as a credit against the US&#160;federal income tax liability of a US&#160;holder if such US&#160;holder elects for that year to credit&#160;all foreign income taxes. Alternatively, such French withholding tax may be taken as a deduction against taxable income. Foreign tax credits will not be allowed for withholding taxes imposed in respect of certain short-term or hedged positions in Securities and may not be allowed in respect of certain arrangements in which a US&#160;holder&#8217;s expected economic profit is insubstantial. Further, recently issued Treasury regulations that apply to taxes paid or accrued in taxable years beginning on or after December&#160;28, 2021 impose additional requirements for foreign taxes to be eligible for a foreign tax credit, and there can be no assurance that those requirements will be satisfied. The IRS has indicated that taxpayers may defer the application of many of the additional requirements until further notice. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">The&#160;US&#160;federal income tax rules governing the availability and</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">computation of foreign tax credits are complex. US&#160;holders should consult their own tax advisers concerning the implications of these rules in light of their particular circumstances.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the extent that an amount received by a US&#160;holder exceeds the allocable share of our current and accumulated earnings and profits, such excess will be applied first to reduce such US&#160;holder&#8217;s tax basis in its ordinary shares or ADSs and then, to the extent it exceeds the US&#160;holder&#8217;s tax basis, it will constitute capital gain from a deemed sale or exchange of such ordinary shares or ADSs (see &#8220;&#8212;&#160;Tax on Sale or Other Disposition&#8221;, below).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of any distribution paid in euros will be equal to the US&#160;dollar value of the euro amount distributed, calculated by reference to the exchange rate in effect on the date the dividend is received by a US&#160;holder of ordinary shares (or&#160;by the depositary, in the case of ADSs) regardless of whether the payment is in fact converted into US&#160;dollars on such date. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">US&#160;holders should consult their own tax advisers regarding the treatment of foreign currency gain or loss, if any, on any euros received by a US&#160;holder that are converted into US&#160;dollars on a date subsequent to&#160;receipt.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Distributions to holders of additional ordinary shares (or&#160;ADSs) with respect to their ordinary shares (or&#160;ADSs) that are made as part of a pro&#160;rata distribution to all ordinary shareholders generally will not be subject to US&#160;federal income tax. However, if a US&#160;holder has the option to receive a distribution in shares (or&#160;ADSs) or to receive cash in lieu of such shares (or&#160;ADSs), the distribution of shares (or&#160;ADSs) will be taxable as if the holder had received an amount equal to the fair market value of the distributed shares (or&#160;ADSs), and such holder&#8217;s tax basis in the distributed shares (or&#160;ADSs) will be equal to such&#160;amount.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Tax on sale or other disposition</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In general, for US&#160;federal income tax purposes, a US&#160;holder that sells, exchanges or otherwise disposes of its ordinary shares or&#160;ADSs will recognize capital gain or loss in an amount equal to the US&#160;dollar value of the difference between the amount realized for the ordinary shares or ADSs and the US&#160;holder&#8217;s adjusted tax basis (determined in US&#160;dollars and under US&#160;federal income tax rules) in the ordinary shares or ADSs. Such gain or loss generally will be US-source gain or loss, and will be treated as long-term capital gain or loss if the US&#160;holder&#8217;s holding period in the ordinary shares or ADSs exceeds one year at the time of disposition. If the US&#160;holder is an individual, any capital gain generally will be subject to US&#160;federal income tax at preferential rates (currently a maximum of 20%) if specified minimum holding periods are met. The deductibility of capital losses is subject to significant limitations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Medicare tax</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Certain US&#160;holders who are individuals, estates or trusts are required to pay a Medicare tax of 3.8% (in&#160;addition to taxes they would otherwise be subject to) on their &#8220;net investment income&#8221; which would include, among other things, dividends and capital gains from the ordinary shares and&#160;ADSs.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">159</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_406"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;10. Additional information</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">F.&#160;Dividends and Paying Agents</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_409"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">G.&#160;Statement by Experts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_412"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">H.&#160;Documents on Display</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are subject to the information requirements of the US&#160;Securities Exchange Act of 1934, as amended, or Exchange Act, and, in&#160;accordance therewith, we are required to file reports, including this annual report, and other information with the&#160;US&#160;Securities and Exchange Commission, or Commission, by electronic means.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">You may review a copy of our filings with the Commission, as well as other information furnished to the Commission, including exhibits and schedules filed with it, at the Commission&#8217;s public reference room at 100&#160;F Street, N.E., Washington,&#160;D.C. 20549. Please call the SEC at 1-800-SEC-0330&#160;for further information. In addition, the Commission maintains an Internet site at http://www.sec.gov that contains reports and other information regarding issuers that file electronically with the Commission (these documents are not incorporated by reference in this annual&#160;report).</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_415"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.&#160;Subsidiary Information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_7079"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">J.&#160;Annual Report to Security Holders</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the extent we furnish an annual report to security holders, we will promptly submit an English version of this annual report to US security holders under the cover of Form 6-K.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">160</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_418"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;11. Quantitative and qualitative disclosures about market risk</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;11. Quantitative and Qualitative Disclosures about Market&#160;Risk</span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10.4pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-5.6pt;vertical-align:baseline">(1)</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General policy</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Liquidity risk, foreign exchange risk and interest rate risk, as well as related counterparty risks, are managed centrally by our dedicated treasury team within the Group Finance Department. Where it is not possible to manage those risks centrally &#8211;&#160;in particular due to regulatory restrictions (such as foreign exchange controls) or local tax restrictions&#160;&#8211; credit facilities and/or currency lines, guaranteed whenever necessary by the parent company, are contracted by our subsidiaries locally with banks, under the supervision of the central treasury&#160;team.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our financing and investment strategies, and our interest rate and currency hedging strategies, are reviewed monthly by the Group Finance Department.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our policy prohibits the use of derivatives for speculative purposes.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Counterparty risk</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our financing and investing transactions, and our currency and interest rate hedges, are contracted with leading counterparties. We set limits for investment and derivative transactions with individual financial institutions, depending on the rating of each institution. Compliance with these limits, which are based on the notional amounts of the investments and the fair value of the hedging instruments, is monitored on a daily&#160;basis.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows our total exposure as of December 31, 2023 by rating and in terms of our percentage exposure to the dominant counterparty.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:23.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash&#160;and&#160;cash</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">equivalents</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(excluding&#160;mutual</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">funds)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">amounts of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">hedges </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of currency hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">amounts of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">interest&#160;rate</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">hedges </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of interest rate hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">General<br/>corporate<br/>purpose<br/>credit&#160;facilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AA</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AA-</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">A+</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,403&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1pt;margin-top:2pt;text-align:right"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">A</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">A-</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BBB+</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unallocated</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,299</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27,689</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">75</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,405</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(165)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,000</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%/rating of dominant counterparty</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26.2%/AA-</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.9%/A+</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.3%/AA-</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6%/A</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Cash equivalents include mutual fund investments of &#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">5,321</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;million.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) The notional amounts are translated into euros at the relevant closing exchange rate as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, we held investments in euro and US dollar denominated money-market mutual funds. Those instruments have low volatility, low sensitivity to interest rate risk, and a very low probability of loss of principal. The depositary banks of the mutual funds, and of Sanofi itself, have a long-term rating of at least&#160;A. Realization of counterparty risk could impact our liquidity in certain circumstances.</span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:8.5pt;text-align:justify;text-indent:-8.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">  The disclosures in this section supplement those provided in Note&#160;B.8.7. to the consolidated financial statements as regards the disclosure requirements of&#160;IFRS&#160;7, and are covered by the independent registered public accounting firms' opinion on the consolidated financial statements.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">161</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;11. Quantitative and qualitative disclosures about market risk</span></div></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.&#160;Operating foreign exchange risk</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A substantial portion of our net sales is generated in countries where the euro, which is our reporting currency, is not the functional currency. In 2023, for example, 43.0% of our net sales were generated in the United&#160;States; 24.1% in Europe; and 32.9% in the Rest of the World region (see the definition in &#8220;Item&#160;5. Operating and Financial Review and Prospects &#8212;&#160;A/&#160;Operating results), including countries that are, or may in the future become, subject to exchange controls, of which 6.8% was generated in China and 3.7% in Japan. Although we also incur expenses in those countries, the impact of those expenses is not enough wholly to offset the impact of exchange rates on our net sales. Consequently, our operating income may be materially affected by fluctuations in exchange rates between the euro and other currencies. Sanofi operates a foreign exchange risk hedging policy to reduce the exposure of operating income to exchange rate movements. That policy involves regular assessments of Sanofi&#8217;s worldwide foreign currency exposure, based on foreign currency transactions carried out by the parent company and its subsidiaries. Those transactions mainly comprise sales, purchases, research costs, co-marketing and co-promotion expenses, and royalties. To reduce the exposure of those transactions to exchange rate movements, Sanofi contracts hedges using liquid derivative instruments, mainly forward currency purchases and sales, and also foreign exchange swaps.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2023, with the notional amount translated into euros at the relevant closing exchange rate (see Note&#160;D.20. to the consolidated financial statements for the accounting classification of those instruments as of December 31, 2023).</span></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Operating foreign exchange derivatives as of December 31, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:73.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.612%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,112</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,981</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">788</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">419</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">339</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">192</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,246</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,022</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">876</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">364</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,358</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The above positions mainly hedge future material foreign-currency cash flows arising after the end of the reporting period in relation to transactions carried out during the year ended December 31, 2023 and recognized in the balance sheet at that date. Gains and losses on hedging instruments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange profit or loss on these items (hedging instruments and hedged transactions) was immaterial in </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B. Financial foreign exchange risk</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cash pooling arrangements for foreign subsidiaries outside the euro zone, and some of Sanofi&#8217;s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e. the risk of changes in the value of borrowings and loans denominated in a currency other than the functional currency of the borrower or lender). That foreign exchange exposure is hedged using derivative instruments (foreign exchange swaps, forward contracts or currency swaps) that alter the currency split of Sanofi&#8217;s net debt once those instruments are taken into account.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place as of December 31, 2023, with the notional amounts translated into euros at the relevant closing exchange rate (see also Note&#160;D.20. to&#160;the consolidated financial statements for the accounting classification of these instruments as of December 31, 2023).</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">162</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;11. Quantitative and qualitative disclosures about market risk</span></div></td></tr></table></div></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Financial foreign exchange derivatives as of December 31, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:53.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.331%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.153%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,279</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">111</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6,628&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,055</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,073&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(b) (c)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,334</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">53</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of December 31, 2023, the fair value of these forward contracts represented an asset of &#8364;54 million; the opposite entry was recognized in &#8220;Other comprehensive income," with the impact on financial income and expense being immaterial.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2023, the fair value of the contracts represented a liability of &#8364;31 million, the opposite entry for &#8364;2.7&#160;million of which was credited to "Other comprehensive income" under the cost of hedging accounting treatment.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,044 million expiring in 2024, designated as a fair value hedge of the exposure of $1,044 million of commercial paper. As of December 31, 2023, the fair value of these forward contracts swaps represented a liability of &#8364;3 million, the opposite entry for &#8364;0.7&#160;million of which was credited to "Other comprehensive income" under the cost of hedging accounting treatment.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These hedging instruments generate a net financial gain or loss arising from the interest rate differential between the hedged currency and the euro, given that the foreign exchange gain or loss on the foreign-currency borrowing and loans is offset by the change in the intrinsic value of the hedging instruments. The interest rate differential is recognized within cost of net debt (see&#160;Note&#160;D.29. to our consolidated financial statements). We may also hedge some future foreign-currency investment or divestment cash&#160;flows.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">C. Other foreign exchange risks</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A significant proportion of our net assets is denominated in US&#160;dollars (see&#160;Note&#160;D.35. to&#160;the consolidated financial statements). As a result, any fluctuation in the exchange rate of the US&#160;dollar against the euro automatically impacts the amount of our equity as expressed in euros.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, we use the euro as our reporting currency. Consequently, if one or more European Union Member States were to abandon the euro as a currency, the resulting economic upheavals &#8211;&#160;in particular, fluctuations in exchange rates&#160;&#8211; could have a significant impact on the terms under which we can obtain financing and on our financial results, the extent and consequences of which are not currently foreseeable.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity risk</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We operate a centralized treasury platform whereby all surplus cash and financing needs of our subsidiaries are invested with or funded by the parent company (where permitted by local legislation). The central treasury department manages our current and projected financing, and ensures that Sanofi is able to meet its financial commitments by maintaining sufficient cash and confirmed credit facilities for the size of our operations and the maturity of our debt (see&#160;Notes&#160;D.17.1.c. and&#160;D.17.1.g. to the consolidated financial statements).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We diversify our short-term investments with leading counterparties using money-market products with instant access or with a maturity of less than three months.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, cash and cash equivalents amounted to &#8364;8,710 million, and short-term investments predominantly comprised:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">collective investments in euro and US dollar denominated money-market mutual funds. All such funds can be traded on a daily basis and the amount invested in each fund may not exceed 10% of the aggregate amount invested in such funds; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amounts invested directly with banks and non-financial institutions in the form of instant access deposits, term deposits, and Negotiable European Commercial Paper with a maturity of no more than three months.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023 we also had &#8364;8&#160;billion of undrawn general corporate purpose confirmed credit facilities, half of which expires in December&#160;2027 and half in March&#160;2029. Those credit facilities are not subject to financial covenant ratios.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our policy is to diversify our sources of funding through public or private issuances of debt securities, in the United&#160;States (shelf registration statement) and Europe (Euro Medium Term Note program). In addition, our A-1+/P-1&#160;short-term rating gives us access to commercial paper programs in the United&#160;States, and to Negotiable European Commercial Paper programs in France. The average maturity of our total debt was 4.45&#160;years as of December 31, 2023, compared with 4.71&#160;years as of December 31, 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Average drawdowns under the Negotiable European&#160;commercial paper program during 2023 were &#8364;0.2&#160;billion (with a maximum of &#8364;0.8&#160;billion); the average maturity of those drawdowns was three months. As of December 31, 2023, drawdowns under the program amounted to &#8364;40&#160;million.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">163</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;11. Quantitative and qualitative disclosures about market risk</span></div></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Average drawdowns under the US&#160;Commercial Paper program during 2023 were &#8364;3.4&#160;billion (with a maximum of &#8364;6.8&#160;billion); the&#160;average maturity of those drawdowns was four months. As of December 31, 2023, drawdowns under the program amounted to&#160;&#8364;0.9&#160;billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the event of a liquidity crisis, we could be exposed to difficulties in calling up our available cash, a scarcity of sources of funding including the above-mentioned programs, and/or a deterioration in their terms. This situation could damage our capacity to refinance our debt or to issue new debt on reasonable terms.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest rate risk</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi issues debt in two currencies, the euro and the US dollar, and also invests its cash and cash equivalents in those currencies. Sanofi also operates cash pooling arrangements to manage the surplus cash and short-term liquidity needs of foreign subsidiaries located outside the euro zone.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To optimize the cost of debt or reduce the volatility of debt and manage its exposure to financial foreign exchange risk, Sanofi uses derivative instruments (interest rate swaps, currency swaps, foreign exchange swaps and forward contracts) that alter the fixed/floating rate split and the currency split of its net debt.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The projected full-year sensitivity to interest rate fluctuations of our debt, net of cash and cash equivalents for 2024 is as&#160;follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:70.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in short-term interest rates</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact&#160;on&#160;pre-tax<br/>net income<br/>(&#8364;&#160;million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact&#160;on&#160;pre-tax<br/>income/(expense)<br/>recognized&#160;directly<br/>in&#160;equity<br/>(&#8364; million)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+100&#160;bp</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25&#160;bp</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-25&#160;bp</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-100&#160;bp</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock market risk</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is our policy not to trade on the stock market for speculative purposes.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">164</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_421"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;12. Description of Securities other than Equity Securities</span></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;12. Description of Securities other than Equity Securities</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_424"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.A.&#160;Debt securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_427"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.B. Warrants and rights</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_430"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.C.&#160;Other securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_433"></div><div style="-sec-extract:summary;margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.D.&#160;American depositary shares</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">JPMorgan Chase Bank, NA (&#8220;JPMorgan&#8221;), as depositary, issues Sanofi ADSs in certificated form (evidenced by an ADR) or book-entry form. Each ADR is a certificate evidencing a specific number of Sanofi ADSs. Each Sanofi ADS represents one-half of one Sanofi ordinary share (or&#160;the right to receive one-half of one Sanofi ordinary share) deposited with the Paris, France office of BNP Paribas, as custodian. Each Sanofi ADS also represents an interest in any other securities, cash or other property that may be&#160;held&#160;by the depositary under the Second Amended and Restated Deposit Agreement between Sanofi and JPMorgan dated&#160;February&#160;13, 2015, as amended by Amendment No.&#160;1 dated July&#160;23, 2020 (&#8220;Amendment No.&#160;1&#8221;), Amendment No.&#160;2 dated&#160;December 18, 2023 ("Amendment No.&#160;2"), and as may be further amended from time to time (together, the &#8220;deposit agreement&#8221;). The depositary&#8217;s principal executive office is located at 383&#160;Madison Avenue, 11th&#160;Floor, New&#160;York, New&#160;York&#160;10179.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For additional information on our ADSs, please refer to Exhibit&#160;2.2 &#8220;Description of Securities&#8221; of this Annual Report.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Fees and expenses</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fees payable by ADS holders</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Pursuant to the deposit agreement, holders of our ADSs may have to pay to JPMorgan, either directly or indirectly, fees, charges and expenses up to the amounts set forth in the table&#160;below.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Associated Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depositary Action</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$5.00 or less per 100&#160;ADSs (or&#160;portion thereof)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The deposit of shares and/or the execution and delivery of ADRs (pursuant to distribution in shares or distribution of rights to subscribe for additional shares, or distribution of any rights of any other nature), and/or the reduction of ADSs and surrender of ADRs for the purposes of withdrawal, including the termination of the deposit agreement.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$0.05 or less per ADS (or&#160;portion thereof)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Any distribution made pursuant to the deposit agreement, including, among other things:</span></div><div style="padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:8.61pt">any cash distribution made, or for any elective cash/stock dividend offered; and</span></div><div style="padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:8.61pt">the direct or indirect distribution of securities (other than ADSs or rights to purchase additional ADSs) or the net cash proceeds from the public or private sale of any such securities.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$0.05 or less per ADS per calendar year (or portion thereof)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Services performed in administering the ADRs (which fee may be charged on a periodic basis during each calendar year).</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">An amount for the reimbursement of such fees, charges and expenses as are incurred by JPMorgan and/or any of its agents (including, without limitation BNP Paribas, as custodian and expenses incurred on behalf of owners in connection with compliance with foreign exchange control regulations or any law or regulation relating to foreign investment)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compliance with foreign exchange control regulations or any law or regulation relating to foreign investment, servicing of shares or other deposited securities, sale of securities, delivery of deposited securities or otherwise.</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expenses incurred by JPMorgan</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify;text-indent:28.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency conversion into dollars.</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Depositary may sell (by public or private sale) sufficient securities and property received in respect of Share distributions, rights and other distributions prior to a deposit to pay any charge owing.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">165</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="-sec-extract:summary;padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;12. Description of Securities other than Equity Securities</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition to the fees outlined above, each holder will be responsible for any taxes or other governmental charges payable on his or her Sanofi ADSs or on the deposited securities underlying his or her Sanofi ADSs. The depositary may refuse to transfer a holder&#8217;s Sanofi ADSs or allow a holder to withdraw the deposited securities underlying his or her Sanofi ADSs until such taxes or other charges are paid. It may apply payments owed to a holder or sell deposited securities underlying a holder&#8217;s Sanofi ADSs to pay any taxes owed, and the holder will remain liable for any deficiency. If it sells deposited securities, it will, if appropriate, reduce the number of Sanofi ADSs to reflect the sale and pay to the holder any proceeds, or send to the holder any property, remaining after it has paid the taxes. For additional information regarding taxation, see &#8220;Item&#160;10. Additional Information &#8212;&#160;E.&#160;Taxation.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fees paid to Sanofi by the depositary</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">JPMorgan, as depositary, has agreed to reimburse Sanofi for certain expenses that Sanofi incurs relating to the establishment and maintenance of the ADR program, as agreed from time to time. Pursuant to a letter agreement dated October&#160;4, 2022 (the &#8220;letter agreement&#8221;), JPMorgan as our ADS depositary has agreed to make (i)&#160;an initial contribution to Sanofi, within 30&#160;days of the commencement date of the letter agreement and (ii)&#160;with respect to each 12-month period beginning on the anniversary of the effective date of the agreement (each such 12-month period, a &#8220;Contract Year&#8221;), a contribution, paid at the end of such Contract Year quarter, equal to the aggregate of the program share (equal to 100% of routine program revenues and 50% of non-routine program revenues) of any program revenues, less the aggregate of any program costs for the applicable Contract Year and any invoiced supplementary costs not paid within 60&#160;days of the date of the applicable invoice.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the extent in any given Contract Year the depositary does not collect/recoup the entirety of the program costs and unpaid supplementary costs, no contribution shall be payable to Sanofi and such excess will, at the discretion of the depositary, either be deducted from future contributions or be payable to the depositary by Sanofi promptly upon invoicing as supplementary costs under the letter agreement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">JPMorgan has further agreed to waive the $0.05 per ADS issuance fees that would normally be owed by Sanofi in connection with our deposits of shares as part of our employee stock purchase plans. Sanofi is responsible for reimbursing JPMorgan for all taxes and governmental charges in connection with payments to JPMorgan under the letter agreement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">From January&#160;1, 2023 to December&#160;31, 2023, we received a total amount of $24,020,797.28 from JPMorgan pursuant to the letter agreement.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">166</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_436"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 13. Defaults, dividend arrearages and delinquencies</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Part II</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_439"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;13. Defaults, Dividend Arrearages and Delinquencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_442"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;14. Material Modifications to the Rights of Security Holders</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_445"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;15. Controls and Procedures</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt">Our Chief Executive Officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule&#160;13a-15(e)) as of the end of the period covered by this Form&#160;20-F, have concluded that, as of such date, our disclosure controls and procedures were effective to ensure that material information relating to Sanofi was timely made known to them by others within Sanofi.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">Report of Management on Internal Control Over Financial Reporting.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule&#160;13a-15(f). Management assessed the effectiveness of internal control&#160;over financial reporting as of December 31, 2023 based on the framework in &#8220;Internal Control &#8212;&#160;Integrated Framework&#8221; (2013&#160;framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Qunol (QRIB Intermediate Holdings, LLC and its affiliates) that was acquired in 2023 has been excluded from the scope of management&#8217;s assessment and conclusion on internal control over financial reporting as of December 31, 2023. Qunol (QRIB Intermediate Holdings, LLC and its affiliates) is included in the 2023 consolidated financial statements of the Company and represents less than 1% of total assets as of December 31, 2023 and less than 1% of net sales for the year then ended.</span></div><div style="padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Based on that assessment, management has concluded that the Company&#8217;s internal control over financial reporting was effective as of December 31, 2023 to provide reasonable assurance regarding the reliability of its financial reporting and the preparation of its financial statements for external purposes, in accordance with generally accepted accounting principles.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Due to its inherent limitations, internal control over financial reporting may not prevent or detect misstatements, and can only provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting has been audited by PricewaterhouseCoopers Audit (PCAOB&#160;ID&#160;<ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-42">1347</ix:nonNumeric>) and Ernst&#160;&amp; Young et Autres (PCAOB&#160;ID&#160;<ix:nonNumeric contextRef="c-6" name="dei:AuditorFirmId" id="f-43">1704</ix:nonNumeric>) independent registered public accounting firms, as stated in their report on the Company&#8217;s internal control over financial reporting as of December 31, 2023, which is included herein. See paragraph&#160;(c) of the present Item&#160;15.,&#160;below.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt">See report of PricewaterhouseCoopers Audit and Ernst&#160;&amp; Young et Autres, independent registered public accounting firms, included under &#8220;Item&#160;18. Financial Statements&#8221; on page&#160;F-3.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">There were no changes to our internal control over financial reporting that occurred during the period covered by this Form&#160;20-F that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:5pt;padding-left:11.25pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">167</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_448"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;16A. Audit Committee Financial Expert</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;16A. Audit Committee Financial Expert</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Audit Committee is composed of Fabienne Lecorvaisier, Christophe Babule, Carole Ferrand and Diane Souza.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our Board of Directors has determined that all directors are independent financial experts within the meaning of Section&#160;407 of the Sarbanes-Oxley Act of&#160;2002.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors deemed Fabienne Lecorvaisier to be a financial expert based on her education and experience in corporate finance in various international banks and as Chief Financial Officer of Essilor and Air Liquide. She is now Executive Vice President, in charge of Sustainable Development, Public and International Affairs as well as the supervision of the Social Programs and the General Secretariat of Air Liquide Group.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors deemed Christophe Babule to be a financial expert based on his education and experience in audit and corporate finance in major corporations and as Executive Vice President and Chief Financial Officer of L&#8217;Or&#233;al. He has also served as a director of L&#8217;Or&#233;al US&#160;Inc.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors deemed Carole Ferrand to be a financial expert based on her education and experience in audit at PricewaterhouseCoopers and as Chief Financial Officer of Sony France, EuropaCorp and Groupe Art&#233;mis. She was Chief Financial Officer of Capgemini until end of 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors deemed Diane Souza to be a financial expert based on her education (she is a certified public accountant) and experience in audit and tax in major international corporations, as Chief Financial Officer of Aetna&#8217;s Guaranteed Products b</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">usiness, and as Chief Executive Officer of the UnitedHealthcare Specialty Benefits.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors has determined that all four directors meet the independence criteria of US&#160;Securities and Exchange Commission Rule&#160;10A-3, although only Fabienne Lecorvaisier, Carole Ferrand and Diane Souza meet the French AFEP-MEDEF Code criteria of independence applied by the Board of Directors for general corporate governance purposes (see&#160;Item&#160;16G.,&#160;below).</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_451"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;16B. Code of Ethics</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have adopted a code of ethics (hereafter the "Code of conduct"), as defined in Item&#160;16B. of Form&#160;20-F under the Exchange Act, containing specific rules relating to financial ethics. Our Code of conduct applies to our Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer and other officers performing similar functions, as designated from time to time. Our Code of conduct is available on our website at www.sanofi.com (information on our website is not incorporated by reference in this annual report). A copy of our Code of conduct may also be obtained free of charge by addressing a written request to the attention of Individual Shareholder Relations at our headquarters in Paris. We will disclose any amendment to the provisions of such financial code of conduct on our&#160;website.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_454"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;16C. Principal Accountants&#8217; Fees and Services</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">See Note&#160;E. to&#160;our consolidated financial statements included at Item&#160;18 of this annual&#160;report.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_457"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;16D. Exemptions from the Listing Standards for Audit Committees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">168</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_460"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 16E. Purchases of Equity Securities by the Issuer and&#160;Affiliated Purchasers</span></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item 16E. Purchases of Equity Securities by the Issuer and&#160;Affiliated Purchasers</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi made the following purchases of its ordinary shares.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:33.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.289%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(A) Total Number of&#160;Shares Purchased</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(B)&#160;Average Price&#160;Paid per&#160;Share</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(C)&#160;Total&#160;Number of Shares Purchased as Part&#160;of&#160;Publicly Announced Plans or Programs</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(D)&#160;Approximate Value&#160;of&#160;Shares that&#160;May&#160;Yet&#160;Be Purchased&#160;Under the Plans or Programs</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 2023</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,000,204&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90.60&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,000,204&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,454&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 2023</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,584,540&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,584,540&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,584,744</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company was authorized to repurchase up to &#8364;18,953,410,350 of shares for a period of eighteen months (i.e. through November&#160;3, 2023) by the Annual Shareholders&#8217; Meeting held on May&#160;3, 2022. Then, the Company was authorized to repurchase up to &#8364;18,912,535,950&#160;of shares for a period of eighteen months (i.e. through November&#160;25, 2024) by the Annual Shareholders&#8217; Meeting held on May&#160;25, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Million of euros.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For more information see &#8220;Exhibit 2.2. "Description of Securities" of this annual report&#8221;.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_463"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="background-color:#ffffff;color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;16F. Change in Registrant&#8217;s Certifying Accountant</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The term of office of Ernst &amp; Young et Autres, joint statutory auditor of the Company since 1986, will expire at the end of the Annual Shareholders&#8217; Meeting called in 2024. Ernst &amp; Young et Autres&#8217; term of office cannot be extended because it reached the maximum legal duration. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The selection procedure of the auditors to be appointed by the Annual Shareholders&#8217; Meeting in 2024 was overseen by the Audit Committee, following which a recommendation to the Board of Directors was issued.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Board of Directors, at its meeting of October&#160;27, 2022 approved the Audit Committee&#8217;s recommendation and decided to propose the appointment of Mazars as statutory auditor. Consequently, the Board of Directors will propose to the Annual Shareholders&#8217; Meeting to be held in 2024 to appoint Mazars as new joint statutory auditor for a 6-year term, i.e. until the Annual Shareholders&#8217; Meeting to be held in 2030, which will approve the financial statements for the year 2029.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The report of Ernst &amp; Young et Autres on the consolidated financial statements for each of the years ended December&#160;31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles. During each of the years ended December&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">there were no &#8220;disagreements&#8221; (as that term is described in Item&#160;16F.(a)(1)(iv) of the Instructions to Form&#160;20-F and the instructions to Item&#160;16F.) between Sanofi and Ernst &amp;&#160;Young et Autres on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreement(s), if not resolved to Ernst &amp; Young et Autres&#8217; satisfaction, would have caused Ernst &amp; Young et Autres to make reference to the subject matter of the disagreement(s) in connection with its report; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">there were no &#8220;reportable events&#8221; (as that term is defined in Item&#160;16F.(a)(1)(v) of the Instructions to Form&#160;20-F).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A copy of Ernst &amp; Young et Autres&#8217; letter, dated February&#160;23, 2024, is filed as Exhibit&#160;15.3 to this annual report.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_466"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;16G. Corporate Governance</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is incorporated under the laws of France, with securities listed on regulated public markets in the United&#160;States (Nasdaq Global Select Market &#8211; NASDAQ) and France (Euronext Paris). Consequently, as described further in this annual report, our corporate governance framework reflects the mandatory provisions of French corporate law, the securities laws and regulations of France and the United&#160;States and the rules of the aforementioned public markets.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a &#8220;foreign private issuer,&#8221; as defined in the rules promulgated under the US&#160;Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;), Sanofi is permitted, pursuant to NASDAQ Listing Rule&#160;5615(a)(3), to follow its home country practice in lieu of certain NASDAQ corporate governance requirements applicable to US&#160;corporations listed on the NASDAQ. Sanofi has informed NASDAQ that it intends to follow corporate governance standards under French law to the extent permitted by the NASDAQ listing rules and US&#160;securities laws, as further discussed below.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We generally follow the &#8220;AFEP-MEDEF&#8221; corporate governance recommendations for French listed issuers (hereafter referred to as the &#8220;AFEP-MEDEF Code&#8221;). As a result, our corporate governance framework is similar in many respects to, and provides investor protections that are comparable to &#8211;&#160;or in some cases, more stringent than&#160;&#8211; the corresponding rules of the NASDAQ. Nevertheless, there are certain important differences.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">169</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Item 16G. Corporate Governance</span></div></td></tr></table></div></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In line with NASDAQ listing rules applicable to domestic issuers, a majority of Sanofi&#8217;s Board of Directors is comprised of independent directors. Sanofi evaluates the independence of members of our Board of Directors using the standards of the French AFEP-MEDEF Code as the principal reference. We believe that AFEP-MEDEF&#8217;s overarching criteria for independence &#8211;&#160;that Board members have no relationship of any kind whatsoever with the Company, its group or the management of either such as to color a Board member&#8217;s judgment&#160;&#8211; is on the whole consistent with the goals of the NASDAQ's listing rules; however, the specific tests proposed under the two standards may vary on some points. Our Audit Committee complies with the&#160;independence and other requirements of Rule&#160;10A-3 under the Exchange Act, adopted pursuant to the Sarbanes-Oxley Act&#160;of&#160;2002. Our Audit Committee includes one member, Christophe Babule, who is considered non-independent under the AFEP-MEDEF Code, and which is permitted under the AFEP-MEDEF Code. Three out of the four members of our Compensation Committee meet the independence standards of the AFEP-MEDEF Code (the Director representing employees is not considered as independent) and the independence requirements of NASDAQ&#8217;s listing rules.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi follows the recommendation of the AFEP-MEDEF Code that at least one meeting of the Board of Directors not attended by the company&#8217;s executive officers be organized each year. Accordingly, Sanofi&#8217;s Board Charter provides that the Board of Directors shall organize at least two meetings a year without its executive officers, thereby providing the Chairman with the option of whether to include directors representing employees or any other Group employee, as the case may require, depending on the agenda of the meeting. Sanofi&#8217;s practice in that respect departs from NASDAQ Listing Rule&#160;5605(b)(2), which provides that independent directors must have regularly scheduled meetings at which only independent directors are present.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under French law, the committees of our Board of Directors are advisory only, and where the NASDAQ Listing Rule&#160;5600 series would vest certain decision-making powers with specific committees by delegation (e.g.&#160;the appointment of Sanofi&#8217;s auditors by the Audit Committee), under French law, our Board of Directors remains the only competent body to take such decisions, albeit taking into account the recommendation of the relevant committees. Additionally, under French corporate law, it is the shareholders of Sanofi voting at the Shareholders&#8217; General Meeting that have the authority to appoint our auditors upon consideration of the proposal of our Board of Directors, although our Board Charter provides that the Board of Directors will make its proposal on the basis of the recommendation of our Audit Committee. We believe that this requirement of French law, together with the additional legal requirement that two sets of statutory auditors be appointed, is in line with the NASDAQ's underlying goal of ensuring that the audit of our accounts be conducted by auditors independent from company management.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">NASDAQ Listing Rule&#160;5635 requires a NASDAQ listed company to obtain shareholder approval prior to certain issuances of securities, including: (a)&#160;issuances in connection with the acquisition of the stock or assets of another company if upon issuance the issued shares will equal 20% or more of the number of shares or voting power outstanding prior to the issuance, or if certain specified persons have a 5% or greater interest in the assets or company to be acquired (NASDAQ Listing Rule&#160;5635(a)); (b)&#160;issuances or potential issuances that will result in a change of control of us (NASDAQ Listing Rule&#160;5635(b)); (c)&#160;issuances in connection with equity compensation arrangements (NASDAQ Listing Rule&#160;5635(c)); and (d)&#160;20% or greater issuances in transactions other than public offerings, as defined in the NASDAQ listing rules (NASDAQ Listing Rule&#160;5635(d)). Under French law, our shareholders may approve issuances of equity, as a general matter, through the adoption of delegation of authority resolutions at the Company&#8217;s shareholders&#8217; meeting pursuant to which shareholders may delegate their authority to the Board of Directors to increase the Company&#8217;s share capital within specified parameters set by the shareholders, which may include a time limitation to carry out the share capital increase, the cancellation of their preferential subscription rights to the benefit of named persons or a category of persons, specified price limitations and/or specific or aggregate limitations on the size of the share capital increase. Due to differences between French law and corporate governance practices and NASDAQ Listing Rule&#160;5635, the Company follows French home country practice, rather than complying with this NASDAQ Listing Rule.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition to the oversight role of our Compensation Committee for questions of management compensation including by way of equity, under French law any option or restricted share plans or other share capital increases, whether for the benefit of senior management or employees, may only be adopted by the Board of Directors pursuant to and within the limits of a shareholder resolution approving the related capital increase and delegating to the Board the authority to implement such operations. While NASDAQ rules require shareholder approval when a plan or other equity compensation arrangement is established or materially amended, under French law our shareholders must decide any issuance of equity, as a general matter. We intend to follow our French home country practice and ask our shareholders to delegate their authority to issue incentive equity and define the final terms of any equity compensation plan or arrangements to our Board of Directors. We may, from time to time, ask for our shareholders&#8217; subsequent approval on an equity compensation arrangement in order to obtain advantageous tax treatment or otherwise. In addition, under French law, our Board of Directors must obtain the prior approval of our shareholders before establishing or amending a plan or arrangement that would exceed the limits of the granted delegation.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As described above, a number of issues, which could be resolved directly by a board or its committees in the United&#160;States, require the additional protection of direct shareholder consultation in France.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because we are a &#8220;foreign private issuer&#8221; as described above, our Chief Executive Officer and our Chief Financial Officer issue the certifications required by Section&#160;302 and Section&#160;906 of the Sarbanes-Oxley Act of 2002 on an annual basis (with the filing of our&#160;annual report) rather than on a quarterly basis as would be the case of a US&#160;corporation filing quarterly reports on Form&#160;10-&#160;Q.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">French corporate law provides that the Board of Directors must vote to approve a broadly defined range of transactions that could potentially create conflicts of interest between Sanofi on the one hand and its directors and Chief Executive Officer on the other hand, which are then presented to shareholders for approval at the next annual meeting. This legal safeguard operates in place of certain provisions of the NASDAQ listing rules.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">170</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM&#160;16G. Corporate Governance</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is governed by the French Commercial Code, which provides that an ordinary general meeting of the shareholders may validly deliberate when first convened if the shareholders present or represented hold at least one-fifth of the voting shares. If&#160;it&#160;is reconvened, no quorum is required. The French Commercial Code further provides that the shareholders at an extraordinary general meeting may validly deliberate when first convened only if the shareholders present or represented hold at least one-quarter of the voting shares and, if reconvened, one-fifth of the voting shares. Therefore, Sanofi will not follow NASDAQ&#160;Listing&#160;Rule&#160;5620(c), which provides that the minimum quorum requirement for a meeting of shareholders is 33</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8260;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:1.19pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">% of the outstanding common voting shares of the company. In accordance with the provisions of the French Commercial Code, the required majority for the adoption of a decision is a simple majority (for an ordinary general meeting of the shareholders) or a two-thirds majority (for an extraordinary general meeting) of the votes cast by the shareholders present or represented.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Company has, pursuant to Rule&#160;10D-1 under the Exchange Act, introduced a recovery policy for compensation erroneously paid to &#8220;executive officers&#8221; (as defined in Rule&#160;10D-1(d) under the Exchange Act) based in whole or in part on any financial reporting measures pursuant to the applicable NASDAQ listing rules, Rule&#160;10D-1 under the Exchange Act and applicable interpretive guidance. For more information concerning our recovery policy for compensation erroneously paid to &#8220;executive officers&#8221;, see also &#8220;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;6. Directors, Senior Management and Employees &#8211; B.&#160;Compensations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8221;. Our recovery policy for compensation erroneously paid to &#8220;executive officers&#8221; is reproduced in full as Exhibit&#160;97 to this annual report.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_469"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;16H. Mine Safety Disclosure</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_472"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;16I. Disclosure regarding foreign jurisdictions that prevent inspections</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">N/A</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_6992"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;16J. Insider Trading Policies</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Pursuant to applicable SEC transition guidance, the disclosure required by Item&#160;16J will be applicable to Sanofi starting the fiscal year ending December&#160;31, 2024.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_7067"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;16K. Cybersecurity</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risk Management and Strategy</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has implemented a cybersecurity strategy involving various dedicated personnel and resources aimed at preventing, detecting and responding to cyberattacks, as well as being able to recover promptly in the event of material impact following a cyberattack. Additionally, Sanofi has set up various cybersecurity processes applicable to subsidiaries within Sanofi group. Sanofi regularly updates its cybersecurity processes to address cybersecurity trends and threats. Cybersecurity processes have been established to address material cybersecurity risks, including in connection with the following areas:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">information technology and solution usage;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">access control;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">patch management;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">security on specific environments (i.e. cloud, virtualization, SAP, automated systems, IoT,&#160;etc.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">log management;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">network security;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">systems security standards;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">remote access;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">secure development of applications;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">cryptography;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">mobile devices;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">third-party management (including cybersecurity requirements in contracts); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">incident management.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi utilizes security standards and frameworks (i.e. the NIST framework) and has established cross-functional risk control capabilities to facilitate operational implementation aligned with its cybersecurity processes.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">171</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Item 16K. Cybersecurity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi regularly analyses its Internet-based services and performs regular penetration tests and attack simulations to assess the protections and the detections capabilities. The cybersecurity compliance status of computing assets connected to Sanofi&#8217;s network is routinely consolidated for Sanofi's business units, including within manufacturing, and research and development sites. Monthly dashboards are published and shared within Sanofi&#8217;s different business units and global functions. Sanofi implements corrective measures and improvement actions in response to these processes. Data classification and protection tools are in place, such as the implementation of a specific process and technology aimed at detecting and responding to abnormal data flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has set up a cybersecurity operation center in charge of detecting and responding to cybersecurity threats and attacks, as well as orchestrating Sanofi-wide incident responses. Incident response trainings and simulations are run within Sanofi to be better prepared in case of a cybersecurity incident. In addition, Sanofi&#8217;s employees, who are the main users of Sanofi&#8217;s digital assets, are regularly trained to face cybersecurity threats and attacks. In the event of a cyberattack, Sanofi has established a plan that includes criteria triggering the notification process for material cybersecurity incidents including from the cybersecurity operation center and the Chief Information Security Officer who can use the internal escalation channels to inform the management and the Board of Directors and, as appropriate, the relevant regulatory bodies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When dealing with third parties, our main commercial contracts include cybersecurity clauses aimed at ensuring such third parties comply with Sanofi&#8217;s cybersecurity rules and requirements, especially when providing services to and processing data from Sanofi. Additionally, Sanofi set up a vendor&#8217;s risk assessment program to evaluate the digital maturity of a vendor, which covers their business continuity as well as their related internal regulations, such as data privacy. As part of their contractual commitments major vendors and partners must report to Sanofi any cybersecurity incident which may have a significant impact for Sanofi. A dedicated process has been implemented for third parties&#8217; networks interconnected with Sanofi&#8217;s network, aimed at limiting any propagation of a cyberattack to Sanofi&#8217;s digital assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s cybersecurity risk management processes are integrated into its overall risk management system through its enterprise risk management process, which seeks to identify and address material risks to the organization. Each year, specific risk committees identify the risks that affect Sanofi&#8217;s local businesses in each country it operates and Sanofi&#8217;s global functions, such as Research and Development or Manufacturing and Supply.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Although Sanofi has put in place the cybersecurity processes described above, Sanofi remains exposed to cybersecurity attacks and incidents and misuse or manipulation of any of its IT systems, which could have a material adverse affect on its business strategy, results of operations or financial condition  (see &#8220;Item&#160;3. Key Information &#8212; D.&#160;Risk Factors &#8212; Risks relating to our business &#8212; Breaches of data security, disruptions of information technology systems and cyber threats could result in financial, legal, business or reputational harm&#8221;).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governance</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has appointed a Chief Information Security Officer who oversees Sanofi's information, cybersecurity, and technology security. Our current Chief Information Security Officer has been working for Sanofi in this capacity since 2014 and has seventeen years of experience in the cybersecurity industry, including eight years as the global head of cybersecurity at one of France&#8217;s largest telecommunications companies. The Chief Information Security Officer is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents through the cybersecurity operation center. He develops appropriate plans to mitigate such risks. Such plans are validated by the Chief Digital Officer and shared with the Executive Committee.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Chief Information Security Officer belongs to the digital division and directly reports to the Chief Digital Officer, a member of the Executive Committee. In addition, the Chief Information Security Officer is a permanent member of the group Risk Committee and reports on the cybersecurity risk to such group Risk Committee, to the Audit Committee and to the Executive Committee regularly. The reporting covers various matters, such as the outcomes of audits on Sanofi&#8217;s information systems, the main incidents encountered over the preceding period, Sanofi&#8217;s digital transformation or the cybersecurity strategy and framework for the coming years.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The group Risk Committee, comprised of the managers of Sanofi&#8217;s global business units, consolidates the risks identified by the specific committees and targets the high priority risks Sanofi is facing. The group Risk Committee then allocates each risk to the relevant Executive Committee member (i.e. the cybersecurity risk is allocated to the Chief Digital Officer as the relevant member of the Executive Committee, who manages the mitigation of such risk with the Chief Information Security Officer) and reports regularly to the Audit Committee. Following this identification and allocation process, the group Risk Committee reports on a quarterly basis to the Executive Committee on the progress of the mitigation plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Audit Committee controls that the cybersecurity risks are well managed and reports on such management to the Board of Directors. The Board of Directors is also informed of such risks, as well as other cybersecurity matters, through periodic reports from the Chief Digital Officer, the Head of the group Risk Committee, or the Chief Information Security Officer.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">172</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_475"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">PART III</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">ITEM 17. Financial statements</span></div></td></tr></table></div></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Part III</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_478"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item 17. Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">See Item&#160;18.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_481"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item 18. Financial Statements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">See pages&#160;F-1 through</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.511%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fa7f69b4904450e9c43e8444c203165_730">F-</a><a style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fa7f69b4904450e9c43e8444c203165_730">101</a></span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">incorporated herein by reference.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_484"></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Item 19. Exhibits</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1.1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit11.htm">Articles of association (statuts) of Sanofi (English translation).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1.2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit12.htm">Board Charter (R&#232;glement Int&#233;rieur) of Sanofi (English translation).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2.1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The total amount of long-term debt securities authorized under any instrument does not exceed 10% of the total assets of the Company and its subsidiaries on a consolidated basis. We hereby agree to furnish to the SEC, upon its request, a copy of any instrument defining the rights of holders of long-term debt of the Company or of its subsidiaries for which consolidated or unconsolidated financial statements are required to be filed. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2.2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit22.htm">Description of securities registered under section 12 of the Exchange Act</a></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8.1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">List of significant subsidiaries, see &#8220;Item 4. Information on the Company &#8212;&#160;C.&#160;Organizational Structure&#8221; of this annual report. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12.1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit121.htm">Certification by Paul Hudson, Chief Executive Officer, required by Section&#160;302 of the Sarbanes-Oxley Act of 2002. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12.2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit122.htm">Certification by Jean-Baptiste Chasseloup de Chatillon, Principal Financial Officer, required by Section&#160;302 of the Sarbanes-Oxley Act of 2002. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13.1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit131.htm">Certification by Paul Hudson, Chief Executive Officer, required by Section&#160;906 of the Sarbanes-Oxley Act of 2002. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13.2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit132.htm">Certification by Jean-Baptiste Chasseloup de Chatillon, Principal Financial Officer, required by Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">15.1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit151.htm">Consent of Ernst&#160;&amp; Young et Autres dated February&#160;2</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit151.htm">3</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit151.htm">, 202</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit151.htm">4</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit151.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">15.2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit152.htm">Consent of PricewaterhouseCoopers Audit dated February&#160;2</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit152.htm">3</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit152.htm">, 202</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit152.htm">4</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit152.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">15.3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit153.htm">Letter from Ernst &amp; Young et Autres pursuant t</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit153.htm">o Ite</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit153.htm">m 16F</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">97.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023-exhibit97.htm">Clawback policy</a></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:100%">104.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">173</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_487"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Signatures</span></div></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Signatures</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The registrant hereby certifies that it meets all of the requirements for filing on Form&#160;20-F and&#160;that it has duly caused and authorized the undersigned to sign this annual report on its&#160;behalf.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.642%"><tr><td style="width:1.0%"/><td style="width:16.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.621%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">/s/ PAUL HUDSON&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Paul Hudson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Date: February&#160;23, 2024.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">174</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_490"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firms</span></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firms</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Sanofi,</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Sanofi and its subsidiaries (together the &#8220;Company&#8221;) as of&#160;December&#160;31, 2023, 2022, and 2021, the related consolidated income statements, statements of comprehensive income, statements of changes in equity and statements of cash flows for each of the three years in the period ended December&#160;31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023, 2022, and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board and in conformity with International Financial Reporting Standards as endorsed by the European Union.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2023, based on criteria established in Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;23, 2024 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management.  Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits.  We are public accounting firms registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.  Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1)&#160;relate to accounts or disclosures that are material to the consolidated financial statements and (2)&#160;involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">175</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firms</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Recoverable amount of other intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:14.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Description</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of the Matter</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Other intangible assets amounted to &#8364;24,319 million at December 31, 2023. Management recognized a net loss of &#8364;932 million relating to impairment charges and reversals for the year ended December 31, 2023. As described in Notes B.6.1., D.4. and D.5. to the consolidated financial statements, other intangible assets not yet available for use are tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Other intangible assets that generate separate cash flows and assets included in cash-generating units (CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. Management estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. Value in use is determined by management using estimated future cash flows generated by the asset or CGU which are discounted and prepared using the same methods as those used in the initial measurement of the assets and on the basis of medium-term strategic plans. Management cash flow projections include significant assumptions related to mid and long-term sales forecasts; perpetual growth or attrition rate, where applicable; discount rate; and probability of success of current research and development projects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The principal considerations for our determination that auditing the recoverable amount of other intangible assets is especially challenging, subjective, and required complex auditor judgment related to the significant judgments made by management when developing the significant assumptions utilized in the future cash flow projections as described above.</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed<br/>the Matter in Our Audit</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These audit procedures included obtaining an understanding of the process and assessing the design and testing the operating effectiveness of controls relating to management&#8217;s other intangible assets impairment assessment, including controls over the significant assumptions used in the impairment testing of the other intangible assets. These audit procedures also included, among others, evaluating the appropriateness of the discounted cash flow model; testing the completeness, accuracy, and relevance of underlying data used in the model; and evaluating the significant assumptions used by management as described above. Evaluating management&#8217;s assumptions involved evaluating whether the assumptions used by management were reasonable by considering the current and past performance of other intangible assets in comparison to management&#8217;s previous forecasts and current trends, the consistency of certain assumptions with external market and industry data, and whether these assumptions were consistent with evidence obtained in other areas of the audit such as internal company communications and presentations and external communications. We involved our professionals with specialized skills and knowledge to assist us notably in the assessment of the discount rate used by management.</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Valuation of the provisions for rebates relating to Sanofi&#8217;s business in the United States &#8211; Medicaid, Medicare and Managed Care</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:14.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">Description </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">of the Matter</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">As described in Notes B.13.1. and D.23. to the consolidated financial statements, products sold in the United States are covered by various Government and State programs (of which Medicaid and Medicare are the most significant) and are subject to commercial agreements with healthcare authorities and certain customers and distributors. Estimates of discounts and rebates incentives (hereinafter the &#8220;Rebates&#8221;) to be provided to customers under those arrangements are recognized as a reduction of gross sales in the period in which the underlying sales are recognized. Provisions for the Medicaid, Medicare and Managed Care Rebates amounted to &#8364;1,421 million, &#8364;1,099 million and &#8364;1,028 million, respectively, at December 31, 2023. The Rebates estimated by management are based on the nature and patient profile of the underlying product; the applicable regulations or the specific terms and conditions of contracts with governmental authorities, wholesalers and other customers; historical data relating to similar contracts; past experience and sales growth trends for the same or similar products; actual inventory levels in distribution channels, monitored by Sanofi using internal sales data and externally provided data; market trends including competition, pricing and demand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">The principal considerations for our determination that auditing the provisions for Rebates relating to the Company&#8217;s business in the United States is especially challenging and required complex auditor judgment related to the significant judgment by management due to significant measurement uncertainty involved in developing these provisions. These provisions are estimated based on multiple factors as described above.</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">the Matter in Our Audit</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These audit procedures included obtaining an understanding of the process and assessing the design and testing the operating effectiveness of controls relating to management&#8217;s estimates of the provisions for Rebates relating to the Company&#8217;s business in the United States, including controls over the assumptions used to estimate these Rebates. These procedures also included, among others, developing an independent estimate of the provisions for Rebates by utilizing third party data on inventory levels in distribution channels, volume, changes to price, the terms of the specific rebate programs, and the historical trend of actual rebate claims paid. The independent estimate was compared to the provisions recorded by the Company. Additionally, these procedures included testing actual rebate claims paid and evaluating the contractual terms of the Company&#8217;s rebate agreements.</span></div></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">176</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firms</span></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Provisions for product liability risks, litigation and other and contingent liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.649%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Provisions for product liability risks, litigation and other were recorded in an amount of &#8364;1,283 million at December 31, 2023. As described in Notes B.12., D.19.3. and D.22. to the consolidated financial statements, the Company records such provisions when an outflow of resources is probable and the amount of the outflow can be reliably estimated. The Company also discloses the contingent liabilities in circumstances where management is unable to make a reasonable estimate of the expected financial effect that will result from ultimate resolution of the proceeding, or a cash outflow is not probable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The pharmaceutical industry is highly regulated, which increases the inherent risk of litigation and arbitration. The Company is involved in litigation, arbitration and other legal proceedings. These proceedings are typically related to litigation concerning product liability claims, intellectual property rights, competition law and trade practices, as well as claims under warranties or indemnification arrangements relating to business divestments. The issues raised by these claims are highly complex and subject to substantial uncertainties; therefore, the probability of loss and an estimation of damages are difficult to ascertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The principal considerations for our determination that auditing the provision for product liability risks, litigation and other, and auditing the contingent liabilities is especially challenging, subjective and required complex auditor judgment resulted from the determination that the measurement of the provisions can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions by management. There is inherent uncertainty related to these cases and in estimating the likelihood and outcome of the cases.</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These audit procedures included obtaining an understanding of the process and assessing the design and testing the operating effectiveness of controls relating to management&#8217;s evaluation of the provisions for product liability risks, litigation and other, including controls over determining whether a loss is probable and whether the amount of loss can be reasonably estimated, as well as the need for and the level of financial statement disclosures. These procedures also included, among others, obtaining and evaluating the letters of audit inquiry with internal and external legal counsels, evaluating management&#8217;s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable through the evaluation of the legal letters and summaries of the proceedings and lawsuit correspondence. We also evaluated the Company&#8217;s disclosures for contingent liabilities.</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Uncertain tax positions</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.649%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">As described in Notes B.22. and D.19.4. to the consolidated financial statements, the Company has recorded liabilities pertaining to uncertain tax positions of &#8364;1,595 million at December 31, 2023. The Company operates in multiple tax jurisdictions, carrying out potentially complex transactions that require management to make judgments and estimates as to the tax impact of those transactions. The positions adopted by the Company in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, the Company assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of the Company&#8217;s best estimate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:115%">The principal considerations for our determination that auditing uncertain tax positions is especially challenging, subjective and required complex auditor judgment related to the significant judgment by management when determining the liability for uncertain tax positions, including a high degree of estimation uncertainty of certain assumptions and interpretations of the tax laws and regulations underlying the positions. </span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These audit procedures included obtaining an understanding of the process and assessing the design and testing the operating effectiveness of controls relating to the identification and recognition of the liability for uncertain tax positions, management&#8217;s assessment and interpretation of tax laws and its evaluation of which tax positions may not be sustained upon audit and controls over measurement of the liability. These procedures also included, among others, testing the completeness and accuracy of the underlying data used in the calculation of the liability for uncertain tax positions and evaluating the assumptions used by management when determining its tax positions, the status of tax audits and investigations, and the potential impact of past claims. Our tax professionals assisted in evaluating management&#8217;s assessments by comparing the positions taken by management with tax regulations and past decisions from tax authorities and where applicable, evaluating opinions from the Company&#8217;s external tax advisors. We also evaluated the disclosures provided in the notes to the consolidated financial statements concerning uncertain tax positions.</span></div></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">/s/ PricewaterhouseCoopers Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">/s/ Ernst&#160;&amp; Young et Autres</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-44">PricewaterhouseCoopers Audit</ix:nonNumeric> <ix:nonNumeric contextRef="c-6" name="dei:AuditorName" id="f-45">Ernst &amp; Young et Autres</ix:nonNumeric> have served as the Company&#8217;s auditors since 1999 and 1986, respectively.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-46">Neuilly-sur-Seine</ix:nonNumeric> and <ix:nonNumeric contextRef="c-6" name="dei:AuditorLocation" id="f-47">Paris-La D&#233;fense</ix:nonNumeric>, France, February&#160;23, 2024</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:92.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">177</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firms</span></td></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firms</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Sanofi,</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We have audited Sanofi and its subsidiaries&#8217; (together the &#8220;Company&#8221;) internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the &#8220;COSO criteria&#8221;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As indicated in Report of Management on Internal Control Over Financial Reporting appearing under Item 15, management&#8217;s assessment  and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of QRIB Intermediate Holdings, LLC and its affiliates, which are included in the 2023 consolidated financial statements of the Company and represented less than 1% of total assets as of December 31, 2023 and less than 1% of net sales for the year then ended.  Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of QRIB Intermediate Holdings, LLC and its affiliates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated balance sheets of the Company as of  December 31, 2023, 2022, and 2021, the related consolidated income statements, statements of comprehensive income, statements of changes in equity and statements of cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;) and our report dated February 23, 2024 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Report of Management on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We are public accounting firms registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">/s/ PricewaterhouseCoopers Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">/s/ ERNST &amp; YOUNG ET AUTRES</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Neuilly-sur-Seine and Paris-La D&#233;fense, France, February&#160;23, 2024</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">178</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_496"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:120%">2023 Consolidated financial statements</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements are presented in accordance with International Financial Reporting Standards (IFRS).</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:80.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.277%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_499">CONSOLIDATED BALANCE SHEETS &#8211; ASSETS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_499">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_499">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_502">CONSOLIDATED BALANCE SHEETS &#8211; EQUITY AND LIABILITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_502">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_502">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_505">CONSOLIDATED INCOME STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_505">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_505">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_508">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_508">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_508">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_511">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_511">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_511">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_514">CONSOLIDATED STATEMENTS OF CASH FLOWS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_514">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_514">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_517">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_517">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_517">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;padding-left:13.5pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_520">INTRODUCTION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_520">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_520">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_523">A/ Basis of preparation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_523">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_523">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_526">B/ Summary of significant accounting policies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_526">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_526">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_610">C/ Principal alliances</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_610">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_610">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_613">D/ Presentation of the financial statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_613">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_613">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_724">E/ Principal accountants&#8217; fees and services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_724">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_724">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_727">F/ List of principal companies included in the consolidation during 20</a>23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_727">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_727">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;padding-left:27pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_730">G/ Events subsequent to December&#160;31, 20</a>23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:10pt;text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_730">F-</a><a style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9fa7f69b4904450e9c43e8444c203165_730">101</a></span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-1</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_499"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Consolidated balance sheets - assets</span></td></tr></table></div></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Consolidated balance sheets - assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.523%"><tr><td style="width:1.0%"/><td style="width:43.327%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.499%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.502%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.3.1.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-48">10,160</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-49">9,869</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-50">10,028</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.3.2.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-51">1,654</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-52">1,815</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-53">1,948</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.4.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-54">49,404</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-55">49,892</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-56">48,056</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.4.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-57">24,319</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-58">21,640</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-59">21,407</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.6.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-60">424</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-61">677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-62">250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-63">3,218</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-64">3,095</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-65">3,127</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current income tax assets </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentTaxAssetsNoncurrent" scale="6" id="f-66">188</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentTaxAssetsNoncurrent" scale="6" id="f-67">242</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentTaxAssetsNoncurrent" scale="6" id="f-68">175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.14.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-69">6,427</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-70">5,381</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-71">4,598</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-72">95,794</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-73">92,611</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-74">89,589</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.9.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-75">9,666</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-76">8,960</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-77">8,715</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.10.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-78">8,433</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-79">8,424</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-80">7,568</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.11.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-81">3,455</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-82">3,532</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-83">3,571</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current income tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentTaxAssetsCurrent" scale="6" id="f-84">391</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentTaxAssetsCurrent" scale="6" id="f-85">374</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentTaxAssetsCurrent" scale="6" id="f-86">612</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.&#160;-&#160;D.17.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-87">8,710</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-88">12,736</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-89">10,098</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" format="ixt:num-dot-decimal" scale="6" id="f-90">30,655</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" format="ixt:num-dot-decimal" scale="6" id="f-91">34,026</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" format="ixt:num-dot-decimal" scale="6" id="f-92">30,564</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Assets held for sale or exchange</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.8.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-93">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-94">85</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-95">89</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-96">126,464</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-97">126,722</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-98">120,242</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_502"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Consolidated balance sheets - equity&#160;and&#160;liabilities</span></td></tr></table></div></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Consolidated balance sheets &#8211; equity&#160;and&#160;liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.523%"><tr><td style="width:1.0%"/><td style="width:44.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.499%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.502%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-99">74,040</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-100">74,784</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-101">68,681</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to non-controlling interests</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.16.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-102">313</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-103">368</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-104">350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-105">74,353</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-106">75,152</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-107">69,031</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-108">14,347</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-109">14,857</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-110">17,123</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-111">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-112">1,904</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-113">1,839</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current liabilities related to business combinations <br/>and to non-controlling interests</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-114">501</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-115">674</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-116">577</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current provisions and other non-current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.19.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-117">7,602</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-118">6,341</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-119">6,721</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current income tax liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.19.4.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-120">1,842</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-121">1,979</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-122">2,039</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.14.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-123">1,857</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-124">1,841</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-125">1,617</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-126">27,904</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-127">27,596</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-128">29,916</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="6" id="f-129">7,328</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="6" id="f-130">6,813</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="6" id="f-131">6,180</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current liabilities related to business combinations <br/>and to non-controlling interests</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-132">208</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-133">105</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" scale="6" id="f-134">137</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current provisions and other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.19.5.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-135">13,741</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-136">12,021</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-137">11,217</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current income tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="f-138">597</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="f-139">574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="f-140">309</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-141">275</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-142">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-143">269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-144">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-145">4,174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-146">3,183</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-147">24,194</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-148">23,964</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-149">21,295</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to assets held for sale or exchange</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.8.&#160;</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-150">13</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-151">10</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-152">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity and liabilities</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-153">126,464</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-154">126,722</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-155">120,242</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-3</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_505"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Consolidated income statements</span></td></tr></table></div></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Consolidated income statements</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:45.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.35.1.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-156">43,070</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-157">42,997</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-158">37,761</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-159">3,374</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-160">2,392</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-161">1,414</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-162">14,236</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-163">13,695</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-164">12,255</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-165">32,208</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-166">31,694</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-167">26,920</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-168">6,728</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-169">6,706</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-170">5,692</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-171">10,692</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-172">10,492</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-173">9,555</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.25.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-174">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-175">1,969</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-176">859</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.26.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-177">3,516</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-178">2,531</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-179">1,805</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.4.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-180">2,172</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-181">2,053</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-182">1,580</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.5.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-183">896</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-184">454</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="6" id="f-185">192</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.12. - D.18.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-186">93</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-187">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-188">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.27.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-189">1,490</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-190">1,336</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-191">820</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.28.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-192">38</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-193">370</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-194">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-195">7,875</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-196">10,656</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-197">8,126</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.29.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-198">1,313</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-199">440</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-200">368</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.29.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-201">591</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-202">206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-203">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using <br/>the equity method</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.35.1.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-204">7,153</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-205">10,422</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-206">7,798</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.30.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-207">1,602</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-208">2,006</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-209">1,558</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using <br/>the equity method</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.31.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-210">115</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-211">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="6" id="f-212">39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-213">5,436</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-214">8,484</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-215">6,279</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.32.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-216">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-217">113</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-218">56</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-219">5,400</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-220">8,371</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-221">6,223</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.9.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-222">1,251.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-223">1,251.9</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-224">1,252.5</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares after dilution </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.9.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-225">1,256.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-226">1,256.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-227">1,257.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Basic earnings per share </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="sny:BasicEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-228">4.31</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-9" decimals="2" name="sny:BasicEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-229">6.69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-10" decimals="2" name="sny:BasicEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-230">4.97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Diluted earnings per share </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-231">4.30</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-9" decimals="2" name="sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-232">6.66</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-10" decimals="2" name="sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent" scale="0" id="f-233">4.95</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_508"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Consolidated statements of comprehensive income</span></td></tr></table></div></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Consolidated statements of comprehensive income</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:49.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-234">5,436</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-235">8,484</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-236">6,279</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-237">5,400</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-238">8,371</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-239">6,223</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-240">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-241">113</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-242">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Actuarial gains/(losses)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-243">171</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-244">654</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-245">686</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value of equity instruments included in&#160;financial assets and financial liabilities</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" scale="6" id="f-246">97</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" scale="6" id="f-247">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" scale="6" id="f-248">165</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" scale="6" id="f-249">3</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" scale="6" id="f-250">216</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" scale="6" id="f-251">54</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sub-total: items not subsequently reclassifiable to profit or loss (A)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-252">77</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-253">451</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-254">797</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value of debt instruments included in financial assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.7.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" scale="6" id="f-255">21</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" scale="6" id="f-256">77</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" scale="6" id="f-257">21</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value of cash flow hedges</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-258">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-259">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" scale="6" id="f-260">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in currency translation differences</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-261">1,540</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-262">2,278</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-263">2,459</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" scale="6" id="f-264">6</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" scale="6" id="f-265">105</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" scale="6" id="f-266">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sub-total: items subsequently reclassifiable to profit or loss (B)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-267">1,526</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-268">2,313</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-269">2,510</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other comprehensive income for the period, net of taxes (A+B)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-270">1,603</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-271">2,764</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-272">3,307</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-273">3,833</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-274">11,248</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-275">9,586</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-276">3,810</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-277">11,130</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-278">9,519</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="6" id="f-279">23</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="6" id="f-280">118</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" scale="6" id="f-281">67</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-5</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_511"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Consolidated statements of changes in&#160;equity</span></td></tr></table></div></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Consolidated statements of changes in&#160;equity</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:25.699%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.490%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Share<br/>capital</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Treasury<br/>shares</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Reserves and retained earnings</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Stock<br/>options&#160;and<br/>other&#160;share-<br/>based<br/>payments</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Other<br/>comprehensive<br/>income</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">to&#160;equity</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">holders of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Sanofi</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable<br/>to&#160;non-<br/>controlling<br/>interests</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total equity</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-11" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-282">2,518</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-283">362</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-284">705</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-285">60,149</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-286">4,138</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-287">3,356</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-288">63,106</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-289">146</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-290">63,252</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">for the period</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-291">797</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-292">2,499</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-293">3,296</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-294">11</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-295">3,307</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-296">6,223</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-297">6,223</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-298">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-299">6,279</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income </span></div><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">for the period</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-300">7,020</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-301">2,499</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-302">9,519</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-6" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-303">67</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-304">9,586</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out of 2020 earnings (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-10" decimals="INF" name="ifrs-full:DividendsPaidOrdinarySharesPerShare" scale="0" id="f-305">3.20</ix:nonFraction> per share)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-306">4,008</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-307">4,008</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-308">4,008</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to <br/>non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-310">49</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-311">49</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-24" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-312">382</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-313">382</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-314">382</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Exercise of stock options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-25" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-315">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-316">11</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-317">11</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Issuance of restricted shares and vesting of existing restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)/(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-26" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-318">4</ix:nonFraction></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-25" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-319">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-24" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-320">148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-321">148</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Employee share ownership plan</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-26" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-324">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-25" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-325">163</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-326">168</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-327">168</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Value of services obtained from employees</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-27" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-328">244</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-329">244</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-330">244</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects on share-based payments</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-27" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-331">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-332">23</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-333">23</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other changes in non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" format="ixt:fixed-zero" scale="6" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" scale="6" id="f-335">186</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" scale="6" id="f-336">186</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-28" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-337">2,527</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-29" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-338">532</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-339">939</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-340">63,013</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-341">4,405</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-342">857</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-343">68,681</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-344">350</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-345">69,031</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:25.699%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.490%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Share<br/>capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Treasury<br/>shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Reserves and retained earnings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Stock<br/>options&#160;and<br/>other&#160;share-<br/>based<br/>payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Other<br/>comprehensive<br/>income</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">to&#160;equity</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">holders of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Sanofi&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable<br/>to&#160;non-<br/>controlling<br/>interests</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total equity</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-28" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-346">2,527</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-29" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-347">532</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-348">939</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-349">63,013</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-350">4,405</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-351">857</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-352">68,681</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-353">350</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-354">69,031</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income for&#160;the&#160;period</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-355">451</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-356">2,308</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-357">2,759</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-358">5</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-359">2,764</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-360">8,371</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-361">8,371</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-362">113</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-363">8,484</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income for&#160;the&#160;period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-364">8,822</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-365">2,308</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-366">11,130</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-6" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-367">118</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-368">11,248</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out of 2021 earnings (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-9" decimals="INF" name="ifrs-full:DividendsPaidOrdinarySharesPerShare" scale="0" id="f-369">3.33</ix:nonFraction> per share)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-370">4,168</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-371">4,168</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-372">4,168</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of the distribution of an&#160;exceptional supplementary dividend of <ix:nonFraction unitRef="number" contextRef="c-40" decimals="2" name="sny:ExceptionalSupplementaryDividendPercentageOfShareCapital" scale="-2" id="f-373">58</ix:nonFraction>% of the shares of EUROAPI to the&#160;equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" name="sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" scale="6" id="f-374">793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" scale="6" id="f-375">793</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" scale="6" id="f-376">793</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-378">100</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-379">100</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-380">497</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-381">497</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-382">497</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reduction in share capital</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-383">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-384">587</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-6" sign="-" name="ifrs-full:ReductionOfIssuedCapital" scale="6" id="f-385">600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:fixed-zero" scale="6" id="f-386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ReductionOfIssuedCapital" format="ixt:fixed-zero" scale="6" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Exercise of stock options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-388">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-389">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-390">35</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-391">35</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Issuance of restricted shares and vesting of existing restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)/(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-392">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-393">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-394">130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-395">130</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Employee share ownership plan</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-398">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-399">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-400">153</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-401">153</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Value of services obtained from&#160;employees</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-402">245</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-403">245</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-404">245</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects on share-based payments</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-405">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-406">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-407">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" scale="6" id="f-408">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" scale="6" id="f-409">10</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" scale="6" id="f-410">10</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-411">2,522</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-412">125</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-413">706</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-414">66,734</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-415">4,658</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-416">1,451</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-417">74,784</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-418">368</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-419">75,152</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Consolidated statements of changes in&#160;equity</span></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:25.699%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.490%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Share<br/>capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Treasury<br/>shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Reserves and retained earnings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">options&#160;and</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">other&#160;share-</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">based</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">payments</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Other<br/>comprehensive<br/>income</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable<br/>to equity<br/>holders of<br/>Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable<br/>to non-<br/>controlling<br/>interests</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total equity</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2023</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-420">2,522</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-421">125</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-422">706</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-423">66,734</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-424">4,658</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-425">1,451</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-51" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-426">74,784</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-52" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-427">368</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-428">75,152</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income for&#160;the&#160;period</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-429">77</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-430">1,513</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-431">1,590</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-432">13</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-433">1,603</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income for the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-434">5,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-435">5,400</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:ProfitLoss" scale="6" id="f-436">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-437">5,436</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income for&#160;the&#160;period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-438">5,323</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-6" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-439">1,513</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-440">3,810</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-441">23</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-442">3,833</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of 2022 earnings (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="INF" name="ifrs-full:DividendsPaidOrdinarySharesPerShare" scale="0" id="f-443">3.56</ix:nonFraction> per </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">share)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-444">4,454</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-445">4,454</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-446">4,454</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-448">59</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests" scale="6" id="f-449">59</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share repurchase program</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-450">593</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-451">593</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="f-452">593</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Exercise of stock options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-58" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-453">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-59" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-454">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-455">37</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="6" id="f-456">37</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Issuance of restricted shares and vesting of existing restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)/(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-58" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-457">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-59" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-458">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-459">115</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" scale="6" id="f-460">115</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" format="ixt:fixed-zero" scale="6" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Employee share ownership plan</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-58" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-463">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-59" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-464">155</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-465">159</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" scale="6" id="f-466">159</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Value of services obtained from&#160;employees</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-60" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-467">283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-468">283</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" scale="6" id="f-469">283</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects on share-based payments</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-60" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-470">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-471">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" scale="6" id="f-472">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other changes arising from issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-473">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-474">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" scale="6" id="f-475">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other changes in non-controlling interests </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" scale="6" id="f-476">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-55" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" scale="6" id="f-477">9</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" scale="6" id="f-478">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" scale="6" id="f-479">10</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-480">2,530</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-62" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-481">313</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-63" decimals="-6" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-482">1,184</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-64" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-483">67,499</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-65" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-484">4,944</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-66" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-485">62</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-67" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-486">74,040</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-68" decimals="-6" name="ifrs-full:Equity" scale="6" id="f-487">313</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-488">74,353</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;<ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes the impacts of the IFRIC final agenda decisions of March&#160;2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April&#160;2021 on the attribution of benefits to periods of service, as described in Note&#160;A.2.1. to the consolidated financial statements for the year ended December&#160;31, 2021.</ix:footnote></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;<ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Notes&#160;D.15.1., D.15.3., D.15.4. and D.15.5.</ix:footnote></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;<ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote">This line comprises the impact of the issuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control of EUROAPI.</ix:footnote></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;<ix:footnote id="fn-4" footnoteRole="http://www.xbrl.org/2003/role/footnote">This line includes the use of existing shares to fulfill vested rights under restricted share plans.</ix:footnote></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;<ix:footnote id="fn-5" footnoteRole="http://www.xbrl.org/2003/role/footnote">This line mainly comprises changes in non-controlling interests arising from divestments and acquisitions.</ix:footnote></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;<ix:footnote id="fn-6" footnoteRole="http://www.xbrl.org/2003/role/footnote">This amount includes the valuation of the shares distributed as a dividend in kind, at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-40" decimals="2" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="f-489">14.58</ix:nonFraction> per share, as of May&#160;10, 2022 (see note&#160;D.2.1.).</ix:footnote></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-7</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_514"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Consolidated statements of cash flows</span></td></tr></table></div></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Consolidated statements of cash flows</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.523%"><tr><td style="width:1.0%"/><td style="width:52.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-490">5,400</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-491">8,371</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="6" id="f-492">6,223</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-controlling interests</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.32.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-493">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-494">113</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-495">56</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of undistributed earnings from investments accounted for using the&#160;equity method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="f-496">295</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="f-497">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="f-498">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" format="ixt:num-dot-decimal" scale="6" id="f-499">4,792</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" format="ixt:num-dot-decimal" scale="6" id="f-500">3,420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" format="ixt:num-dot-decimal" scale="6" id="f-501">3,351</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains and losses on disposals of non-current assets, net of tax</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="6" id="f-502">509</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="6" id="f-503">711</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="6" id="f-504">300</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in deferred taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="6" id="f-505">970</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="6" id="f-506">578</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="6" id="f-507">356</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in non-current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" scale="6" id="f-508">136</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" scale="6" id="f-509">280</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" scale="6" id="f-510">37</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of employee benefits (stock options and other share-based payments)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.2.</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;-&#160;D.15.3.</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-&#160;D.15.8.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-511">283</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-512">245</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-513">244</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of the workdown of acquired inventories remeasured at fair value</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.35.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" scale="6" id="f-514">20</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" scale="6" id="f-515">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" scale="6" id="f-516">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other profit or loss items with no cash effect on cash flows generated by&#160;operating activities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-517">283</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-518">138</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="6" id="f-519">57</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating cash flow before changes in working capital</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-520">9,494</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-521">11,233</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-522">9,113</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Increase)/decrease in inventories</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-523">840</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-524">927</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-525">357</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Increase)/decrease in accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-526">397</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-527">777</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="6" id="f-528">185</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase/(decrease) in accounts payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="6" id="f-529">402</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="6" id="f-530">452</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="6" id="f-531">451</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in other current assets and other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-532">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" scale="6" id="f-533">545</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-534">1,130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) operating activities</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-535">10,258</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-536">10,526</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-537">10,522</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and intangible assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.3.&#160;-&#160;D.4.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-538">3,024</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-539">2,201</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-540">2,043</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of consolidated undertakings and investments accounted for&#160;using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.1.</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-&#160;D.18.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-541">3,870</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-542">992</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-543">5,594</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other equity investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7. </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="6" id="f-544">134</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="6" id="f-545">488</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" scale="6" id="f-546">311</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-547">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-548">1,488</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="6" id="f-549">676</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-550">42</ix:nonFraction></span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-551">134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-552">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in other non-current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NetChangeInOtherNonCurrentAssets" scale="6" id="f-553">229</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="sny:NetChangeInOtherNonCurrentAssets" scale="6" id="f-554">16</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="sny:NetChangeInOtherNonCurrentAssets" scale="6" id="f-555">68</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-556">6,200</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-557">2,075</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-558">7,298</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Sanofi shares</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.1.</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-559">195</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-560">188</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-561">186</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends paid:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">to shareholders of Sanofi</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-562">4,454</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-563">4,168</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-564">4,008</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">to non-controlling interests</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" scale="6" id="f-565">61</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" scale="6" id="f-566">99</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" scale="6" id="f-567">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments received/(made) on changes of ownership interest in a subsidiary without loss of control</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries" scale="6" id="f-568">3</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-570">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional long-term debt contracted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromNoncurrentBorrowings" scale="6" id="f-571">48</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProceedsFromNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-572">1,549</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProceedsFromNoncurrentBorrowings" format="ixt:fixed-zero" scale="6" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-574">3,684</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-575">2,718</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-576">2,241</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayments of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-577">265</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-578">291</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-579">149</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in short-term debt and other financial instruments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" scale="6" id="f-580">765</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" scale="6" id="f-581">215</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" scale="6" id="f-582">414</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of treasury shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.15.4.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" scale="6" id="f-583">593</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" scale="6" id="f-584">497</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" scale="6" id="f-585">382</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by/(used in) financing activities </span></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-586">8,052</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-587">5,821</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-588">7,056</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact of exchange rates on cash and cash equivalents</span></td><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-589">32</ix:nonFraction>)</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-590">8</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-591">15</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-592">4,026</ix:nonFraction>)</span></td><td style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-593">2,638</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-594">3,817</ix:nonFraction>)</span></td><td style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-595">12,736</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-596">10,098</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-597">13,915</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#23004c;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td colspan="3" style="background-color:#23004c;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.13.</span></td><td colspan="2" style="background-color:#23004c;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-598">8,710</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-599">12,736</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-600">10,098</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;border-bottom:0.5pt solid #23004c;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160; <ix:footnote id="fn-7" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes non-current financial assets.</ix:footnote></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;<ix:footnote id="fn-8" footnoteRole="http://www.xbrl.org/2003/role/footnote">This line item includes contributions paid to pension funds (see Note&#160;D.19.1.).</ix:footnote></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;<ix:footnote id="fn-9" footnoteRole="http://www.xbrl.org/2003/role/footnote">This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.</ix:footnote></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2023 CONSOLIDATED FINANCIAL STATEMENTS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Consolidated statements of cash flows</span></td></tr></table></div></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) <ix:footnote id="fn-10" continuedAt="fn-10-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">Including:</ix:footnote></span></div><ix:continuation id="fn-10-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:56.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Income tax paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-601">2,623</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-602">2,452</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-603">1,280</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-604">559</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-605">380</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-606">334</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest received</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-607">547</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-608">173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-609">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Dividends received from non-consolidated entities</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities" scale="6" id="f-610">17</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities" scale="6" id="f-611">1</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities" scale="6" id="f-612">2</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;<ix:footnote id="fn-11" footnoteRole="http://www.xbrl.org/2003/role/footnote">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2023, it includes the net cash outflow on the acquisitions of Provention Bio and QRIB (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note&#160;D.2.1.). For 2021, it includes the net cash outflows on the acquisitions of Kymab, Kiadis, Tidal, Translate Bio, Kadmon and Origimm (see Note&#160;D.2.2.).</ix:footnote></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">)&#160;&#160;&#160;&#160;</span><ix:footnote id="fn-12" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For 2023, 2022 and 2021, this line item mainly comprises disposals of assets and activities related to portfolio streamlining and disposals of equity and debt instruments.</span></ix:footnote></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;<ix:footnote id="fn-13" footnoteRole="http://www.xbrl.org/2003/role/footnote">For 2022, this line item includes the net cash inflows (before taxes) of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-69" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-613">101</ix:nonFraction>&#160;million on the divestment of EUROAPI (see Note&#160;D.2.1.).</ix:footnote></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;<ix:footnote id="fn-14" footnoteRole="http://www.xbrl.org/2003/role/footnote">For 2023, this line item includes &#8364;<ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-614">946</ix:nonFraction>&#160;million related to the US commercial paper program. For 2023, 2022 and 2021, it also includes realized foreign exchange differences on (i)&#160;cash and cash equivalents in non-functional currencies (primarily the US dollar) and (ii)&#160;derivative instruments used to manage such cash and cash equivalents.</ix:footnote></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-9</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_517"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_520"></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="f-615" escape="true"><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Introduction</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi, together with its subsidiaries (collectively &#8220;Sanofi&#8221;, &#8220;the Group&#8221; or &#8220;the Company&#8221;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements for the year ended December 31, 2023, and the notes thereto, were signed off by the Sanofi Board of Directors on</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> January&#160;31,&#160;2024.</span></div></ix:nonNumeric><div id="i9fa7f69b4904450e9c43e8444c203165_523"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">A/ <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-616" continuedAt="f-616-1" escape="true">Basis of preparation</ix:nonNumeric></span></div><ix:continuation id="f-616-1" continuedAt="f-616-2"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.1. <ix:nonNumeric contextRef="c-1" name="ifrs-full:StatementOfIFRSCompliance" id="f-617" continuedAt="f-617-1" escape="true">International financial reporting standards (IFRS)</ix:nonNumeric></span></div><ix:continuation id="f-617-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements cover the twelve-month periods ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with Regulation No.&#160;1606/2002 of the European Parliament and Council of July&#160;19, 2002 on the application of&#160;international accounting standards, Sanofi has presented its consolidated financial statements in accordance with IFRS since&#160;January&#160;1, 2005. The term &#8220;IFRS&#8221; refers collectively to international accounting and financial reporting standards (IASs&#160;and&#160;IFRSs) and to interpretations of the interpretations committees (SIC and IFRIC) with mandatory application as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements of Sanofi as of December 31, 2023 have been prepared in compliance with IFRS as&#160;issued&#160;by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS as endorsed by the European Union as of December 31, 2023 are available under the heading &#8220;IFRS Financial Statements&#8221; via the following web&#160;link:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality, and aggregation.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.2. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations" id="f-618" continuedAt="f-618-1" escape="true">New standards, amendments and interpretations</ix:nonNumeric></span></div><ix:continuation id="f-618-1"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.1. New standards applicable from January 1, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following amendments are applicable from January&#160;1, 2023, and have had no material impact: &#8220;Disclosure of Accounting Policies&#8221; (amendment to IAS&#160;1); &#8220;Definition of Accounting Estimates&#8221; (amendment to IAS&#160;8); and &#8220;Deferred Tax Assets and Liabilities Arising from a Single Transaction&#8221; (amendment to IAS&#160;12).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;23, 2023, the IASB issued &#8220;International Tax Reform&#8212;Pillar Two Model Rules&#8221;, an immediately applicable amendment to&#160;IAS&#160;12 that was endorsed on November&#160;9, 2023. The amendment relates to the effects of the global minimum corporate income tax rate of 15% that will come into force in 2024, in accordance with the model framework of OECD Pillar Two.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The French Finance Bill for 2024 imposes a global minimum corporate income tax rate of 15% and introduces (i)&#160;a supplementary multinational tax and (ii)&#160;a supplementary national tax for annual accounting periods commencing on or after December&#160;31, 2023. Given that the legislation had not come into force as of December&#160;31, 2023, Sanofi is not liable for any current taxes in that&#160;respect. In addition, Sanofi has not recognized any deferred taxes associated with the minimum tax, in accordance with the&#160;temporary exemption available under the May&#160;2023 amendment to IAS&#160;12. At this stage, a material impact is expected in respect&#160;of Sanofi's operations in France and Singapore, because Sanofi&#8217;s average effective tax rate in those countries was less than <ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-619">15</ix:nonFraction>% at the end of 2023. Other things being equal, applying the Pillar 2 rules in 2023 would have led to an increase of approximately <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="sny:IncreaseDecreaseInEffectiveTaxRate" scale="-2" id="f-620">1.5</ix:nonFraction>&#160;percentage points in the effective tax rate based on the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS&#160;17 (Insurance Contracts), issued on May&#160;18, 2017 and applicable on or after January&#160;1, 2023, does not apply to the Sanofi consolidated financial statements because the insurance activities carried on by Sanofi&#8217;s captive insurance companies are internal within the Sanofi group (the sole policyholders being subsidiaries of Sanofi), and hence are eliminated on consolidation.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.2. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="f-621" continuedAt="f-621-1" escape="true">New pronouncements issued by the IASB and applicable from 2024 or later</ix:nonNumeric></span></div><ix:continuation id="f-621-1" continuedAt="f-621-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This note describes standards, amendments and interpretations issued by the IASB that will have mandatory application in 2024 or subsequent years, and Sanofi&#8217;s position regarding future application.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;22, 2022, the IASB issued an amendment to IFRS&#160;16 (Leases), relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable at the earliest from January&#160;1, 2024;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> it will not have a material impact on the Sanofi financial statements, and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has not early adopted it.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-616-2" continuedAt="f-616-3"><ix:continuation id="f-621-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January&#160;23, 2020, the IASB issued &#8220;Classification of Liabilities as Current or Non-current&#8221;, an amendment to IAS&#160;1, and then on&#160;October&#160;31, 2022 issued &#8220;Non-current Liabilities with Covenants&#8221;, a further amendment to IAS&#160;1. The amendments are applicable at the earliest from January&#160;1, 2024; they will not have a material impact on the Sanofi financial statements, and Sanofi has not early adopted them.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS&#160;7 and IFRS&#160;7, which is applicable at the earliest from January&#160;1, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union) and which relates to disclosures of information about such arrangements. The amendment does not </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August&#160;15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS&#160;21 (The Effect of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable at the earliest from January&#160;1, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union); it</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.3. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="f-622" continuedAt="f-622-1" escape="true">Use of estimates and judgments</ix:nonNumeric></span></div><ix:continuation id="f-622-1" continuedAt="f-622-2"><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date of the finalization of the financial statements. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions (see&#160;Notes&#160;B.13. and&#160;D.23.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment of property, plant and equipment and intangible assets (see Notes&#160;B.6. and D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the valuation of goodwill and the valuation and estimated useful life of acquired intangible assets (see Notes&#160;B.3.2., B.4., D.4. and&#160;D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of contingent consideration receivable in connection with asset divestments (see Notes&#160;B.8.5. and&#160;D.12.) and of contingent consideration payable (see Notes&#160;B.3. and&#160;D.18.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of financial assets and liabilities at amortized cost (see Note&#160;B.8.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of post-employment benefit obligations (see Notes&#160;B.23. and&#160;D.19.1.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks (see Notes&#160;B.12., B.19., B.20., D.19. and&#160;D.22.); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences (see Notes&#160;B.22. and&#160;D.14.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, Sanofi has also taken account of risks related to the effects of climate change and energy transition.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its Planet Care program, Sanofi has committed to move towards carbon neutrality by 2030 and net <ix:nonFraction unitRef="emission" contextRef="c-1" decimals="INF" name="sny:PlanetCareProgramObjectivesNetEmissionsBy2045" format="ixt:fixed-zero" scale="0" id="f-623">zero</ix:nonFraction> emissions by&#160;2045 for its Scope&#160;1, 2 and&#160;3 emissions. That involves:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">aiming for a <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="sny:PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030" scale="-2" id="f-624">55</ix:nonFraction>% reduction in greenhouse gas (GHG) emissions from Sanofi&#8217;s own activities (Scopes&#160;1 &amp;&#160;2) and a <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="sny:PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030" scale="-2" id="f-625">30</ix:nonFraction>% reduction in Scope&#160;3 GHG emissions by 2030 (versus a 2019 baseline), and a <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="sny:PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030" scale="-2" id="f-626">90</ix:nonFraction>% reduction in GHG emissions (all scopes) by&#160;2045. These objectives have been validated by the Science Based Target initiative (STBi);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">supplying all our sites with <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="sny:PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030" scale="-2" id="f-627">100</ix:nonFraction>% renewably-sourced electricity by 2030;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">promoting an eco-friendly vehicle fleet by 2030; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">engaging the Sanofi supply chain in reducing Scope&#160;3 emissions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The analysis of climate-related physical and transition risks facing Sanofi was updated in 2023 on the basis of <ix:nonFraction unitRef="scenario" contextRef="c-1" decimals="INF" name="sny:PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios" format="ixt-sec:numwordsen" scale="0" id="f-628">three</ix:nonFraction> global warming scenarios out to 2030 and 2050. A number of assumptions &#8211; on issues such as carbon costs, natural disasters, water stress, raw material scarcity and logistics disruption &#8211; were built into this analysis, which also takes account of certain capital expenditures on mitigations derived from the Planet Care roadmap.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, that analysis was taken into account as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the value of intangible assets and property, plant and equipment was subject to impairment testing conducted at CGU level, as described in Note&#160;D.5. Certain climate-related assumptions, such as the evolution of energy costs, transitioning to sustainable agriculture, and waste management, are already built into the forecast used for impairment testing purposes. For those assumptions not yet built into budgets, sensitivity analyses can be performed as needed;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the periodic reviews conducted on the useful lives of property, plant and equipment take account of environmental regulatory constraints, including not only GHG emissions but also physical risks;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">environmental risks are covered by provisions on the basis described in Note&#160;D.19.3.; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the credit facilities available to Sanofi as of December&#160;31, 2023 incorporate performance objectives, including objectives related to cutting Sanofi&#8217;s carbon footprint, which could reduce the cost of debt if they are attained (see Note&#160;D.17.).</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-616-3" continuedAt="f-616-4"><ix:continuation id="f-622-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is important to bear in mind that estimating climate change related risks involves an element of unpredictability. Uncertainties may arise from factors such as changes in government policy, rapid technological change, and varied responses from stakeholders. That high level of uncertainty adds complexity to assessment of the potential impacts on our operations, and to how those impacts are reflected in our budgets. Actual impacts on Sanofi&#8217;s profits and financial position could therefore differ from initial estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, in line with its environmental protection objectives, Sanofi has initiated projects to build eco-design into its products so as to limit their environmental impacts over their entire life cycle. Those projects will require Sanofi to redefine all of its production methods, and as such have also been built into definitions of the useful lives of Sanofi production facilities.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.4. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory" id="f-629" continuedAt="f-629-1" escape="true">Hyperinflation</ix:nonNumeric></span></div><ix:continuation id="f-629-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi continued to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of <ix:nonFraction unitRef="number" contextRef="c-72" decimals="2" name="sny:CumulativeConsumerPriceInflationOverTheLastThreeYears" scale="-2" id="f-630">100</ix:nonFraction>%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July&#160;1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of <ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="sny:CumulativeConsumerPriceInflationOverTheLastThreeYears" scale="-2" id="f-631">100</ix:nonFraction>% based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January&#160;1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.5. <ix:nonNumeric contextRef="c-1" name="sny:AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock" id="f-632" continuedAt="f-632-1" escape="true">Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK</ix:nonNumeric></span></div><ix:continuation id="f-632-1" continuedAt="f-632-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;18, 2020, Sanofi and the US Department of Health and Human Services extended their research and development partnership to leverage Sanofi&#8217;s previous development work on a SARS vaccine to attempt to unlock a fast path forward for developing a COVID-19 vaccine. Under the terms of the collaboration, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services, is helping to fund the research and development undertaken by Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April&#160;14, 2020, Sanofi and GlaxoSmithKline (GSK) entered into a collaboration agreement to develop a recombinant COVID-19 vaccine candidate, with Sanofi contributing its S&#8209;protein COVID-19 antigen (based on recombinant DNA technology) and GSK contributing its pandemic adjuvant technology. Sanofi is leading clinical development and the registration process for the vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;31, 2020, the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK was selected by the US&#160;government&#8217;s Operation Warp Speed (OWS) program. Under the OWS, the US government is providing funds to support further development of the vaccine, including clinical trials and scaling-up of manufacturing capacity. Initially, the agreement also provided for the supply of <ix:nonFraction unitRef="vaccine_dose" contextRef="c-74" decimals="-6" name="sny:NumberOfVaccineDosesToBeSupplied" format="ixt:num-dot-decimal" scale="6" id="f-633">100</ix:nonFraction>&#160;million doses of the vaccine. In light of the evolving context of the pandemic (including variants of the virus) and the availability of vaccines on the market, the parties decided to review the initial supply contract. At the end of 2023, the agreement was amended in respect of the supply clause, confirming that Sanofi had fulfilled its contractual obligations and setting the amount of compensation paid to Sanofi. On the basis of that signed amendment, Sanofi recognized an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-75" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-634">411</ix:nonFraction>&#160;million within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; that amount was paid to Sanofi in December&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has recognized the funding received from the US government as a deduction from the development expenses incurred, in accordance with IAS&#160;20 (Accounting for Government Grants and Disclosure of Government Assistance).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of government aid received from the US federal government and BARDA and recognized </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a deduction from development expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and other operating expenses was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-75" decimals="-6" name="sny:GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" format="ixt:num-dot-decimal" scale="6" id="f-635">59</ix:nonFraction>&#160;million in 2023, compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-76" decimals="-6" name="sny:GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" format="ixt:num-dot-decimal" scale="6" id="f-636">265</ix:nonFraction>&#160;million in 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-6" name="sny:GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" format="ixt:num-dot-decimal" scale="6" id="f-637">147</ix:nonFraction>&#160;million in 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2020, Sanofi and GSK signed pre-order contracts with the Canadian and UK governments and with the European Union for doses of the vaccine candidate. During 2021, Sanofi and GSK contractualized with the Canadian and UK governments and with the European Union on the number of doses ordered.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;15, 2021, Sanofi and GSK announced positive preliminary data on their COVID-19 booster vaccine candidate and indicated that their Phase&#160;3 trial was to continue, based on recommendations from an independent monitoring board.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November&#160;10, 2022, in line with the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, the European Commission approved VIDPREVTYN Beta vaccine as booster for the prevention of COVID-19 in adults aged 18&#160;years and older. Designed to provide broad protection against multiple variants, this protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK&#8217;s pandemic adjuvant. VIDPREVTYN</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Beta is indicated as a booster for active immunization against SARS-CoV-2 in adults who have previously received an mRNA or adenoviral COVID-19 vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;21, 2022, following the European Commission approval, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved VIDPREVTYN Beta vaccine for the prevention of COVID-19 in adults aged&#160;18 and over within the UK.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-632-2"><ix:continuation id="f-616-4"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;15 (see Note&#160;B.13.1.), Sanofi recognizes revenue when control over the product is transferred to the customer (for vaccines, transfer of control is determined by reference to the terms of release and acceptance of batches of vaccine). Payments received subsequent to signature of vaccine pre-order contracts relating to doses not yet delivered are customer contract liabilities (i.e. an obligation for the entity to supply goods to a customer, for which consideration has been received from the customer). They are presented within &#8220;Customer contract liabilities&#8221; in the balance sheet (see Note&#160;D.19.5.), and within &#8220;Net change in other current assets and other current liabilities&#8221; in the statement of cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The pre-order contracts for Canada, the United Kingdom and the European Union expired in 2023. The customer contract liabilities, which amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-6" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-638">269</ix:nonFraction>&#160;million as of December&#160;31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-79" decimals="-6" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-639">319</ix:nonFraction>&#160;million as of&#160;December&#160;31,&#160;2021 (see Note&#160;D.19.5., &#8220;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Current provisions and other current liabilities&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) were released to profit or loss in 2023, including an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-6" name="sny:OtherRevenuePerformanceObligationNoLongerRequired" format="ixt:num-dot-decimal" scale="6" id="f-640">94</ix:nonFraction>&#160;million classified in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other revenue</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in respect of doses which there was no longer an obligation to deliver as of December&#160;31, 2023.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_526"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">B/ <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="f-641" continuedAt="f-641-1" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><div id="i9fa7f69b4904450e9c43e8444c203165_529"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.1. <ix:nonNumeric contextRef="c-1" name="sny:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" id="f-642" continuedAt="f-642-1" escape="true"><ix:continuation id="f-641-1" continuedAt="f-641-2">Basis of consolidation</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-642-1"><ix:continuation id="f-641-2" continuedAt="f-641-3"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;10 (Consolidated Financial Statements), the consolidated financial statements of Sanofi include the financial statements of entities that Sanofi controls directly or indirectly, regardless of the level of the equity interest in those entities. An entity is controlled when Sanofi has power over the entity, exposure or rights to variable returns from its involvement with the entity, and the ability to affect those returns through its power over the entity. In determining whether control exists, potential voting rights must be taken into account if those rights are substantive, in other words they can be exercised on a timely basis when decisions about the relevant activities of the entity are to be taken.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Entities consolidated by Sanofi are referred to as &#8220;subsidiaries&#8221;. Entities that Sanofi controls by means other than voting rights are referred to as &#8220;consolidated structured entities&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;11 (Joint Arrangements), Sanofi classifies its joint arrangements (i.e. arrangements in which Sanofi exercises joint control with one or more other parties) either as a joint operation (in which case, Sanofi recognizes the assets and liabilities of the operation in proportion to its rights and obligations relating to those assets and liabilities) or as a joint venture.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi exercises joint control over a joint arrangement when decisions relating to the relevant activities of the arrangement require the unanimous consent of Sanofi and the other parties with whom control is shared.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi exercises significant influence over an entity when it has the power to participate in the financial and operating policy decisions of that entity, but does not have the power to exercise control or joint control over those policies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), the equity method is used to account for joint ventures (i.e.&#160;entities over which Sanofi exercises joint control) and for associates (i.e. entities over which Sanofi exercises significant influence).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the equity method, the investment is initially recognized at cost, and subsequently adjusted to reflect changes in the net assets of the associate or joint venture. IAS&#160;28 does not specify the treatment to be adopted on first-time application of the equity method to an investee following a step acquisition. Consequently, by reference to paragraph&#160;10 of IAS&#160;28, Sanofi has opted to apply the cost method, whereby the carrying amount of the investment represents the sum of the historical cost amounts for each step in the acquisition. As of the date on which the equity method is first applied, goodwill (which is included in the carrying amount of the investment) is determined for each acquisition step. The same applies to subsequent increases in the percentage interest in the equity-accounted investment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the criteria of IFRS&#160;5 are met, Sanofi recognizes the equity interest within the balance sheet line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The equity method is not applied to equity interests that are classified as held-for-sale assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transactions between consolidated companies are eliminated, as are intragroup profits.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A list of the principal companies included in the consolidation in 2023 is presented in Note&#160;F.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_532"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.2. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="f-643" continuedAt="f-643-1" escape="true"><ix:continuation id="f-641-3" continuedAt="f-641-4">Foreign currency translation</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-643-1" continuedAt="f-643-2"><ix:continuation id="f-641-4" continuedAt="f-641-5"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.1. Accounting for foreign currency transactions in the financial statements of consolidated entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets (other than receivables) and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate prevailing at the acquisition date.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the end of the reporting period. The gains and losses resulting from foreign currency translation are recorded in the income statement. However, foreign exchange gains and losses arising from the translation of advances between consolidated subsidiaries for which settlement is neither planned nor likely to occur in the foreseeable future are recognized in equity, in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Change in currency translation differences.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-643-2"><ix:continuation id="f-641-5" continuedAt="f-641-6"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.2. Foreign currency translation of the financial statements of foreign entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi presents its consolidated financial statements in euros (&#8364;). In accordance with IAS&#160;21 (The Effects of Changes in Foreign Exchange Rates), each subsidiary accounts for its transactions in the currency that is most representative of its economic environment (the functional currency).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All assets and liabilities are translated into euros using the exchange rate of the subsidiary&#8217;s functional currency prevailing at the end of the reporting period. Income statements are translated using a weighted average exchange rate for the period, except in the case of foreign subsidiaries in a hyperinflationary economy. The resulting currency translation difference is recognized as a separate component of equity in the consolidated statement of comprehensive income, and is recognized in the income statement only when the subsidiary is sold or is wholly or partially liquidated.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_535"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.3. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" id="f-644" continuedAt="f-644-1" escape="true"><ix:continuation id="f-641-6" continuedAt="f-641-7">Business combinations and transactions with non-controlling interests</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-644-1"><ix:continuation id="f-641-7" continuedAt="f-641-8"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.1. Accounting for business combinations, transactions with non-controlling interests and loss of control</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for in accordance with IFRS&#160;3 (Business Combinations) and IFRS&#160;10 (Consolidated Financial Statements).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method. Under this method, the acquiree&#8217;s identifiable assets and liabilities that satisfy the recognition criteria of IFRS&#160;3 (Business Combinations) are measured initially at their fair values at the date of acquisition, except for (i)&#160;non-current assets classified as held for sale (which are measured at fair value less costs to sell) and (ii)&#160;assets and liabilities that fall within the scope of IAS&#160;12 (Income Taxes) and IAS&#160;19 (Employee Benefits). Restructuring liabilities are recognized as a liability of the acquiree only if the acquiree has an obligation as of the acquisition date to carry out the restructuring.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal accounting rules applicable to business combinations and transactions with non-controlling interests include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">acquisition-related costs are recognized as an expense, as a component of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration is recognized in equity if the contingent payment is settled by delivery of a fixed number of&#160;the&#160;acquirer&#8217;s equity instruments; otherwise, it is recognized in liabilities related to business combinations. Contingent&#160;consideration is recognized at fair value at the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a financial liability, subsequent adjustments to the liability are recognized in profit&#160;or loss in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, unless the adjustment is made within&#160;the 12&#160;months following the acquisition date and relates to facts and circumstances existing as of that date;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">goodwill may be calculated on the basis of either (i)&#160;the entire fair value of the acquiree, or (ii)&#160;a share of the fair value of the acquiree proportionate to the interest acquired. This option is elected for each acquisition individually.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Purchase price allocations are performed under the responsibility of management, with assistance from an independent valuer in the case of major acquisitions. IFRS&#160;3 does not specify an accounting treatment for contingent consideration arising from a business combination made by an entity prior to the acquisition of control in that entity and carried as a liability in the acquired entity&#8217;s balance sheet. The accounting treatment applied by Sanofi to such a liability is to measure it at fair value as of the acquisition date and to report it in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, with subsequent remeasurements recognized in profit or loss. This treatment is consistent with the accounting applied to contingent consideration in the books of the&#160;acquirer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, management may where it deems fit elect to apply the optional test to identify concentration of fair value permitted under IFRS&#160;3 in order to determine whether a transaction is a business combination within the meaning of IFRS&#160;3, or merely the acquisition of an asset or of a group of similar assets.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.2. Goodwill</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The excess of the cost of an acquisition over Sanofi&#8217;s interest in the fair value of the identifiable assets and liabilities of the acquiree is recognized as goodwill at the date of the business combination. Goodwill arising on the acquisition of subsidiaries is shown in a separate balance sheet line item, whereas goodwill arising on the acquisition of investments accounted for using the equity method is recorded in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Investments accounted for using the equity method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill arising on foreign operations is expressed in the functional currency of the country concerned and translated into euros using the exchange rate prevailing at the end of the reporting period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;36 (Impairment of Assets), goodwill is carried at cost less accumulated impairment (see Note&#160;B.6.).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill is tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Such events or circumstances include significant changes more likely than not to have an other-than-temporary impact on the substance of the original investment.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_538"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.4. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" id="f-645" continuedAt="f-645-1" escape="true"><ix:continuation id="f-641-8" continuedAt="f-641-9">Other intangible assets</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-645-1" continuedAt="f-645-2"><ix:continuation id="f-641-9" continuedAt="f-641-10"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets are initially measured at acquisition cost or production cost, including any directly attributable costs of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. Intangible assets are amortized on a straight line basis over their useful&#160;lives.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The useful lives of other intangible assets are reviewed at the end of each reporting period. The effect of any adjustment to useful lives is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of other intangible assets is recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> except for amortization charged against (i)&#160;acquired or internally-developed software and (ii)&#160;other rights of an industrial or operational nature, which is recognized in the relevant classification of expense by function.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi does not own any intangible assets with an indefinite useful life, other than goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Intangible assets (other than goodwill) are carried at cost less accumulated amortization and accumulated impairment, if any, in accordance with IAS&#160;36 (see Note&#160;B.6.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.1. Research and development not acquired in a business combination</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internally generated research and development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS&#160;38, research expenses are recognized in profit or loss when incurred.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated development expenses are recognized as an intangible asset if, and only if, all the following six criteria can be demonstrated: (a)&#160;the technical feasibility of completing the development project; (b)&#160;Sanofi&#8217;s intention to complete the project; (c)&#160;Sanofi&#8217;s ability to use the project; (d)&#160;the probability that the project will generate future economic benefits; (e)&#160;the availability of adequate technical, financial and other resources to complete the project; and (f)&#160;the ability to measure the development expenditure reliably.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Due to the risks and uncertainties relating to regulatory approval and to the research and development process, the six criteria for capitalization are usually considered not to have been met until the product has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some industrial development expenses (such as those incurred in developing a second-generation synthesis process) are incurred after marketing approval has been obtained, in order to improve the industrial process for an active ingredient. To the extent that the six IAS&#160;38 criteria are considered as having been met, such expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as incurred. Similarly, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS&#160;38, in which case the related expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separately acquired research and development</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments for separately acquired research and development are capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that they meet the definition of an intangible asset: a resource that is (i)&#160;controlled by Sanofi, (ii)&#160;expected to provide future economic benefits for Sanofi, and (iii)&#160;identifiable (i.e.&#160;it is either separable or arises from contractual or legal rights). Under paragraph&#160;25 of&#160;IAS&#160;38, the first condition for capitalization (the probability that the expected future economic benefits from the asset will flow to the entity) is considered to be satisfied for separately acquired research and development. Consequently, upfront and milestone payments to third parties related to pharmaceutical products for which marketing approval has not yet been obtained are recognized as intangible assets, and amortized on a straight line basis over their useful lives beginning when marketing approval is&#160;obtained.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments under research and development arrangements relating to access to technology or to databases, and payments made to purchase generics dossiers, are also capitalized, and amortized over the useful life of the intangible asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subcontracting arrangements, payments for research and development services, and continuous payments under research and development collaborations which are unrelated to the outcome of that collaboration, are expensed over the service term.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.2. Other intangible assets not acquired in a business combination</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Licenses other than those related to pharmaceutical products and research projects, in particular software licenses, are capitalized at acquisition cost, including any directly attributable cost of preparing the software for its intended use. Software licenses are amortized on a straight line basis over their useful lives for Sanofi (<span style="-sec-ix-hidden:f-646">three</span> to <ix:nonNumeric contextRef="c-82" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:durwordsen" id="f-647">five years</ix:nonNumeric>).</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated costs incurred to develop or upgrade software are capitalized if the IAS&#160;38 recognition criteria are satisfied, and amortized on a straight line basis over the useful life of the software from the date on which the software is ready for use.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-645-2"><ix:continuation id="f-641-10" continuedAt="f-641-11"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.3. Other intangible assets acquired in a business combination</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets acquired in a business combination (in-process research and development, technology platforms, and currently marketed products) that are reliably measurable are identified separately from goodwill, measured at fair value, and capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IFRS&#160;3 (Business Combinations) and IAS&#160;38 (Intangible Assets). The related deferred tax liability is also recognized if a deductible or taxable temporary difference exists.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In-process research and development acquired in a business combination is amortized on a straight line basis over its useful life from the date of receipt of marketing approval.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Rights to technology platforms and to products currently marketed by Sanofi are amortized on a straight line basis over their useful lives, determined (in particular for marketed products) on the basis of cash flow forecasts which take into account the patent protection period of the marketed product.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_541"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.5. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="f-648" continuedAt="f-648-1" escape="true"><ix:continuation id="f-641-11" continuedAt="f-641-12">Property, plant and equipment owned and leased</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-648-1"><ix:continuation id="f-641-12" continuedAt="f-641-13"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.1. Property, plant and equipment owned</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in&#160;the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent costs are not recognized as assets unless (i)&#160;it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii)&#160;the costs can be measured reliably.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the&#160;item.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they&#160;relate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" id="f-649" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The customary useful lives of property, plant and equipment are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:49.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.671%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-83" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-650">15</ix:nonNumeric>&#160;to&#160;<ix:nonNumeric contextRef="c-84" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-651">40</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-85" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-652">10</ix:nonNumeric> to <ix:nonNumeric contextRef="c-86" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-653">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-87" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-654">5</ix:nonNumeric> to <ix:nonNumeric contextRef="c-88" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-655">15</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-89" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-656">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-90" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-657">15</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.2. Property, plant and equipment leased</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective from January&#160;1, 2019 leases contracted by Sanofi have been accounted for in accordance with IFRS&#160;16 (Leases). Sanofi recognizes a right-of-use asset and a lease liability for all of its lease contracts, except for (i)&#160;leases relating to low-value assets and&#160;(ii)&#160;short-term leases (12&#160;months or less). Payments made in respect of leases not recognized on the balance sheet are recognized as an operating expense on a straight line basis over the lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On commencement of a lease, the liability for future lease payments is discounted at the incremental borrowing rate, which is a risk-free rate adjusted to reflect the specific risk profile of each Sanofi entity. Because lease payments are spread over the lease term, Sanofi applies a discount rate based on the duration of those payments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The payments used to determine the liability for future lease payments exclude non-lease components, but include fixed payments that Sanofi expects to make to the lessor over the estimated lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After commencement of the lease, the liability for future lease payments is reduced by the amount of the lease payments made, and increased to reflect interest on the liability. In the event of a reassessment or modification of future lease payments, the lease liability is remeasured. The right-of-use asset &#8211;&#160;which is initially measured at cost including direct costs of the lessee, prepayments made at or prior to the commencement date, less lease incentives received and restoration costs&#160;&#8211; is depreciated on a straight line basis over the lease term, and tested for impairment as required.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi recognizes deferred taxes in respect of right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leasehold improvements are depreciated over their economic life, which is capped at the lease term as determined under&#160;IFRS&#160;16.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_544"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.6. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" id="f-658" continuedAt="f-658-1" escape="true"><ix:continuation id="f-641-13" continuedAt="f-641-14">Impairment of property, plant and equipment, intangible assets, and&#160;investments accounted for using the equity method</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-658-1"><ix:continuation id="f-641-14" continuedAt="f-641-15"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.1. Impairment of property, plant and equipment and intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;36 (Impairment of Assets), assets that generate separate cash flows and assets included in cash-generating units&#160;(CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. A&#160;CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS&#160;36, each CGU or group of CGUs to which goodwill is allocated must (i)&#160;represent the lowest level within the entity at which the goodwill is monitored for internal management purposes, and (ii)&#160;not be larger than an operating segment determined in accordance with IFRS&#160;8 (Operating Segments), before application of the IFRS&#160;8 aggregation criteria (see Note&#160;B.26.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Quantitative and qualitative indications of impairment (primarily relating to the status of the research and development portfolio, pharmacovigilance, patent litigation, and the launch of competing products) are reviewed at the end of each reporting period. If there is any internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset or CGU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets not yet available for use (such as capitalized in-process research and development), and CGUs or groups of CGUs that include goodwill, are tested for impairment annually whether or not there is any indication of impairment, and more frequently if any event or circumstance indicates that they might be impaired. Such assets are not amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When there is an internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. To determine value in use, Sanofi uses estimates of future cash flows generated by the asset or CGU, prepared using the same methods as those used in the initial measurement of the asset or CGU on the basis of medium-term strategic plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of goodwill, estimates of future cash flows are based on a six-year strategic plan and a terminal value. In the case of other intrangible assets, the period used is based on the economic life of the asset.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Estimated cash flows are discounted at long-term market interest rates that reflect the best estimate by Sanofi of the time value of money, the risks specific to the asset or CGU, and economic conditions in the geographical regions in which the business activity associated with the asset or CGU is located.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Certain assets and liabilities that are not directly attributable to a specific CGU are allocated between CGUs on a basis that is reasonable, and consistent with the allocation of the corresponding goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on property, plant and equipment, software and certain rights, are recognized within the appropriate income statement line item according to the origin of the impairment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on other intangible assets (products, trademarks, technology platforms, acquired R&amp;D) are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.2. Impairment of investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), Sanofi determines whether investments accounted for using the equity method may be impaired based on indicators such as default in contractual payments, significant financial difficulties, probability of bankruptcy, or a prolonged or significant decline in quoted market price. If an investment is impaired, the amount of the impairment loss is determined by applying IAS&#160;36 (see Note&#160;B.6.1.) and recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.3. Reversals of impairment losses charged against property, plant and equipment, intangible assets, and investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the end of each reporting period, Sanofi assesses whether events or changes in circumstances indicate that an impairment loss recognized in a prior period in respect of an asset (other than goodwill) or an investment accounted for using the equity method can be reversed. If this is the case, and the recoverable amount as determined based on the revised estimates exceeds the carrying amount of the asset, Sanofi reverses the impairment loss only to the extent of the carrying amount that would have been determined had no impairment loss been recognized for the asset.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reversals of impairment losses in respect of other intangible assets are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, while reversals of impairment losses in respect of investments accounted for using the equity method are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Impairment losses taken against goodwill are never reversed, unless the goodwill is part of the carrying amount of an investment accounted for using the equity method.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-17</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_547"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.7. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" id="f-659" continuedAt="f-659-1" escape="true"><ix:continuation id="f-641-15" continuedAt="f-641-16">Assets held for sale or exchange and liabilities related to assets held for sale or exchange</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-659-1"><ix:continuation id="f-641-16" continuedAt="f-641-17"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;5 (Non-Current Assets Held for Sale and Discontinued Operations), non-current assets and groups of assets are classified as held for sale in the balance sheet if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Within the meaning of IFRS&#160;5, the term &#8220;sale&#8221; also includes exchanges for other assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets or asset groups held for sale must be available for immediate sale in their present condition, subject only to terms that are usual and customary for sales of such assets, and a sale must be highly probable. Criteria used to determine whether a sale is highly probable include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the appropriate level of management must be committed to a plan to sell;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an active program to locate a buyer and complete the plan must have been initiated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">completion of the sale should be foreseeable within the 12&#160;months following the date of reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Before initial reclassification of the non-current asset (or asset group) to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent to reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held-for-sale assets or liabilities within the balance sheet line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Liabilities related to assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, provided that the disposal satisfies the IFRS&#160;5 classification criteria.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The profit or loss generated by a held-for-sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">represents a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is a subsidiary acquired exclusively with a view to resale.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;10, transactions between companies that are held for sale or treated as discontinued operations and other consolidated companies are eliminated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Events or circumstances beyond Sanofi&#8217;s control may extend the period to complete the sale or exchange beyond one year without precluding classification of the asset (or disposal group) in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that there is sufficient evidence that Sanofi remains committed to the planned sale or exchange. Finally, in the event of changes to a plan of sale that requires an asset no longer to be classified as held for sale, IFRS&#160;5 specifies the following treatment:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each asset is measured at the lower of (a)&#160;its carrying amount before the asset was reclassified as held for sale, adjusted for any depreciation, amortization or revaluation that would have been recognized if the asset had not been reclassified as held for sale, or&#160;(b)&#160;its recoverable amount at the date of reclassification;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the backlog of depreciation, amortization and impairment not recognized while non-current assets were classified as held for sale must be reported in the same income statement line item that was used to report impairment losses arising on initial reclassification of assets as held for sale and gains or losses arising on the sale of such assets. In the consolidated income statement, those impacts are reported within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the net income of a business previously classified as discontinued or as held for sale or exchange and reported on a separate line in the income statement must be reclassified and included in net income from continuing operations, for all periods presented;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in addition, segment information relating to the income statement and the statement of cash flows (acquisitions of non-current assets) must be disclosed in the notes to the financial statements in accordance with IFRS&#160;8 (Operating Segments), and must also be restated for all prior periods presented.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_550"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.8. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="f-660" continuedAt="f-660-1" escape="true"><ix:continuation id="f-641-17" continuedAt="f-641-18">Financial instruments</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-660-1" continuedAt="f-660-2"><ix:continuation id="f-641-18" continuedAt="f-641-19"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.1. Non-derivative financial assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;9 (Financial Instruments) and IAS&#160;32 (Financial Instruments: Presentation), Sanofi has adopted the classification of non-derivative financial assets described below. The classification used depends on (i)&#160;the characteristics of the contractual cash flows (i.e.&#160;whether they represent interest or principal) and (ii)&#160;the business model for managing the asset applied at the time of initial recognition.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through other comprehensive income</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments that Sanofi does not hold for trading purposes and that management has designated at &#8220;fair value through other comprehensive income&#8221; on initial recognition. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such instruments are derecognized, the previously-recognized changes in fair value remain within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as does the gain or loss on divestment. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through profit or loss</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration already carried in the books of an acquired entity or granted in connection with a business combination;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments whose contractual cash flows represent payments of interest and repayments of principal, which are managed with a view to selling the asset;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments that management has designated at &#8220;fair value through profit or loss&#8221; on initial recognition; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments: equity instruments that are not held for trading and which management did not designate at &#8220;fair value through other comprehensive income&#8221; on initial recognition, and instruments that do not meet the IFRS definition of &#8220;equity instruments&#8221;.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gains and losses arising from changes in fair value are recognized in profit or loss within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of equity investments in unquoted entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On initial recognition of an equity investment in an entity not quoted in an active market, the fair value of the investment is the acquisition cost. Cost ceases to be a representative measure of the fair value of an unquoted equity investment when Sanofi identifies significant changes in the investee, or in the environment in which it operates. In such cases, an internal valuation is carried out, based mainly on growth forecasts or by reference to similar transactions contracted with third parties.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets at amortized cost comprise instruments whose contractual cash flows represent payments of interest and repayments of principal and which are managed with a view to collecting cash flows. The main assets in this category are loans and receivables. They are presented within the line items</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Accounts receivable </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Cash and cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Loans with a maturity of more than 12&#160;months are presented in &#8220;Long-term loans and advances&#8221; within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. These financial assets are measured at amortized cost using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main assets involved are accounts receivable. Accounts receivable are initially recognized at the amount invoiced to the customer. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-660-2" continuedAt="f-660-3"><ix:continuation id="f-641-19" continuedAt="f-641-20"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.2. Derivative instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that do not qualify for hedge accounting are initially and subsequently measured at fair value, with changes in fair value recognized in the income statement in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, depending on the nature of the underlying economic item which is hedged.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that qualify for hedge accounting are measured using the policies described in Note&#160;B.8.3. below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS&#160;13 (Fair Value Measurement) requires counterparty credit risk to be taken into account when measuring the fair value of financial instruments. That risk is estimated on the basis of observable, publicly-available statistical data.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy on offsetting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order for a financial asset and a financial liability to be presented as a net amount in the balance sheet under IAS&#160;32, there must be:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(a) a legally enforceable right to offset; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(b) the intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.3. Hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its overall market risk management policy, Sanofi enters into various hedging transactions involving derivative or non-derivative instruments; these may include forward contracts, currency swaps or options, interest rate swaps or options, cross-currency swaps, and debt placings or issues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such financial instruments are designated as hedging instruments and recognized using the hedge accounting principles of&#160;IFRS&#160;9 when (a)&#160;there is formal designation and documentation of the hedging relationship, of how the effectiveness of the hedging relationship will be assessed, and of the underlying market risk management objective and strategy; (b)&#160;the hedged item and the hedging instrument are eligible for hedge accounting; and (c)&#160;there is an economic relationship between the hedged item and the hedging instrument, defined on the basis of a hedge ratio that is consistent with the underlying market risk management strategy, and the residual credit risk does not dominate the value changes that result from that economic relationship.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A fair value hedge is a hedge of the exposure to changes in fair value of an asset, liability or firm commitment that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument and changes in fair value of the hedged item attributable to the hedged risk components are generally recognized in the income statement, within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, or within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flow hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A cash flow hedge is a hedge of the exposure to variability in cash flows from an asset, liability or highly probable forecast transaction that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for hedges related to operating activities, and within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cumulative changes in fair value of the hedging instrument previously recognized in equity are reclassified to the income statement when the hedged transaction affects profit or loss. Those reclassified gains and losses are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When a forecast transaction results in the recognition of a non-financial asset or liability, cumulative changes in the fair value of the hedging instrument previously recognized in equity are incorporated in the initial carrying amount of that asset or liability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss previously recognized in equity remains separately recognized in equity and is not reclassified to the income statement, or recognized as an adjustment to the initial cost of the related non-financial asset or liability, until the forecast transaction occurs. However, if Sanofi no longer expects the forecast transaction to occur, the cumulative gain or loss previously recognized in equity is recognized immediately in profit or loss.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedge of a net investment in a foreign operation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a hedge of a net investment in a foreign operation, changes in the fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. When the investment in the foreign operation is sold, the changes in the fair value of the hedging instrument previously recognized in equity are reclassified to the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-660-3" continuedAt="f-660-4"><ix:continuation id="f-641-20" continuedAt="f-641-21"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its market risk management policy, Sanofi may designate currency options or interest rate options as hedging instruments, the effectiveness of which is measured on the basis of changes in intrinsic value. In such cases, the time value of the option is treated as a hedging cost and accounted for as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the option includes a component that is not aligned on the critical features of the hedged item, the corresponding change in the time value is taken to profit or loss;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">otherwise, the change in the time value is taken to equity within the statement of comprehensive income, and then:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a financial asset or liability, the change in the time value is reclassified to profit or loss symmetrically with the hedged item, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a non-financial asset or liability, the change in the time value is incorporated in the initial carrying amount of that asset or liability, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a period of time, the change in time value is reclassified to profit or loss on a straight line basis over the life of the hedging relationship.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of forward contracts and foreign exchange swaps, and of cross-currency swaps that qualify for hedge accounting on the basis of changes in spot rates, Sanofi may elect for each transaction to use the option whereby the premium/discount or foreign currency basis spread are treated in the same way as the time value of an option.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinuation of hedge accounting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Hedge accounting is discontinued when the eligibility criteria are no longer met (in particular, when the hedging instrument expires or is sold, terminated or exercised), or if there is a change in the market risk management objective of the hedging relationship.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.4. Non-derivative financial liabilities</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings and debt</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement over the term of the debt using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These line items record the fair value of (i)&#160;contingent consideration payable in connection with business combinations and (ii)&#160;commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adjustments to the fair value of commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests, are recognized in equity.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other non-derivative financial liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-derivative financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.5. Fair value of financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS&#160;13 (Fair Value Measurement) and IFRS&#160;7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt">level&#160;1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">level&#160;2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt">level&#160;3: valuation techniques in which not all important inputs are derived from observable market data.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="f-661" escape="true"><ix:continuation id="f-660-4" continuedAt="f-660-5"><ix:continuation id="f-641-21" continuedAt="f-641-22"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS&#160;7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:5.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.313%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.362%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type&#160;of financial&#160;instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in<br/>fair&#160;value<br/>hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>technique</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>model</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest<br/>rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market&#160;price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost/Approach based on comparables</span></div></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the&#160;end of the reporting period using the method described in&#160;Note&#160;D.7.3.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value held&#160;to meet obligations under <br/>post-employment benefit plans</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than three&#160;months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the&#160;consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1., D.19.</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The liability for future lease payments is discounted using the&#160;incremental borrowing rate.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160; year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&gt;&#160;1&#160;year:&#160;</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160;year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid&#160;Money&#160;Market  and LIFFE interest rate futures</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&gt;&#160;1&#160;year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid&#160;Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present&#160;value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160; year:<br/>Mid&#160;Money Market and LIFFE interest rate futures<br/>&gt;&#160;1&#160;year: <br/>Mid Zero Coupon</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (CVRs)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (other than CVRs)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Under IAS&#160;32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note&#160;B.8.4.</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div></ix:continuation></ix:continuation></ix:nonNumeric><div style="margin-bottom:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-660-5"><ix:continuation id="f-641-22" continuedAt="f-641-23"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.6. Derecognition of financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets are derecognized when the contractual rights to cash flows from the asset have ended or have been transferred and when Sanofi has transferred substantially all the risks and rewards of ownership of the asset. If Sanofi has neither transferred nor retained substantially all the risks and rewards of ownership of a financial asset, it is derecognized if Sanofi does not retain control of the asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A financial liability is derecognized when Sanofi&#8217;s contractual obligations in respect of the liability are discharged, cancelled or extinguished.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.7. Risks relating to financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Market risks in respect of non-current financial assets, cash equivalents, derivative instruments and debt are described in the discussions of risk factors presented in Item&#160;3.D. and Item&#160;11. of Sanofi&#8217;s annual report on Form&#160;20-F for 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Credit risk is the risk that customers may fail to pay their debts. For a description of credit risk, refer to &#8220;We are subject to the risk of non-payment by our customers&#8221; within Item&#160;3.D. and Item&#160;11. of Sanofi&#8217;s annual report on Form&#160;20-F for 2023.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_553"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.9. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" id="f-662" continuedAt="f-662-1" escape="true"><ix:continuation id="f-641-23" continuedAt="f-641-24">Inventories</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-662-1"><ix:continuation id="f-641-24" continuedAt="f-641-25"><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories are measured at the lower of cost or net realizable value. Cost is calculated using the weighted average cost method or the first-in, first-out method, depending on the nature of the inventory.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cost of finished goods inventories includes costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the launch phase of a new product, any inventories of that product are written down to zero pending regulatory approval, other than in specific circumstances which make it possible to estimate that there is a high probability at the end of the reporting period that the carrying amount of the inventories will be recoverable. The write-down is reversed once it becomes highly probable that marketing approval will be obtained.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_556"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.10. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" id="f-663" continuedAt="f-663-1" escape="true"><ix:continuation id="f-641-25" continuedAt="f-641-26">Cash and cash equivalents</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-663-1"><ix:continuation id="f-641-26" continuedAt="f-641-27"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash and cash equivalents as shown in the consolidated balance sheet and statement of cash flows comprise cash, plus liquid short-term investments that are&#160;readily convertible into cash and are&#160;subject to an insignificant risk of changes in value in the event of movements in interest rates.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_559"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.11. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory" id="f-664" continuedAt="f-664-1" escape="true"><ix:continuation id="f-641-27" continuedAt="f-641-28">Treasury shares</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-664-1"><ix:continuation id="f-641-28" continuedAt="f-641-29"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;32, Sanofi treasury shares are deducted from equity, irrespective of the purpose for which they are held. <ix:nonFraction unitRef="eur" contextRef="c-1" decimals="INF" name="sny:GainLossOnImpairmentOfTreasuryShares" format="ixt:fixed-zero" scale="0" id="f-665"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="INF" name="sny:GainLossOnPurchaseOfTreasuryShares" format="ixt:fixed-zero" scale="0" id="f-666"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="INF" name="sny:GainLossOnCancellationOfTreasuryShares" format="ixt:fixed-zero" scale="0" id="f-667"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="INF" name="sny:GainLossOnSaleOfTreasuryShares" format="ixt:fixed-zero" scale="0" id="f-668">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> gain or loss is recognized in the income statement on the purchase, sale, impairment or cancellation of treasury shares.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_562"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.12. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="f-669" continuedAt="f-669-1" escape="true"><ix:continuation id="f-641-29" continuedAt="f-641-30">Provisions for risks</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-669-1" continuedAt="f-669-2"><ix:continuation id="f-641-30" continuedAt="f-641-31"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;37 (Provisions, Contingent Liabilities and Contingent Assets), Sanofi records a provision when it has a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If the obligation is expected to be settled more than 12&#160;months after the end of the reporting period, or has no definite settlement date, the provision is recorded within Non-current provisions and other non-current liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions relating to the insurance programs in which Sanofi&#8217;s captive insurance company participates are based on risk exposure estimates calculated by management, with assistance from independent actuaries, using IBNR (Incurred But Not Reported) techniques. Those techniques use past claims experience, within Sanofi and in the market, to estimate future trends in the cost of&#160;claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow of economic resources is&#160;remote.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi estimates provisions on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management&#8217;s knowledge at the date of preparation of the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reimbursements offsetting the probable outflow of resources are recognized as assets only if it is virtually certain that they will be received. Contingent assets are not recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring provisions are recognized if Sanofi has a detailed, formal restructuring plan at the end of the reporting period and has announced its intention to implement this plan to those affected by it.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-669-2"><ix:continuation id="f-641-31" continuedAt="f-641-32"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="INF" name="sny:ProvisionsRecordedForFutureOperatingLosses" format="ixt:fixed-zero" scale="0" id="f-670">No</ix:nonFraction> provisions are recorded for future operating losses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi records non-current provisions for certain obligations, such as legal or constructive obligations, where an outflow of resources is probable and the amount of the outflow can be reliably estimated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of environmental risks, including at sites where operations are ongoing, Sanofi recognizes a provision where there is a violation of integrity in respect of human health or the environment resulting from past contamination at a site that requires remediation. The amount of the provision is a best estimate of the future expenditures to be incurred on the remediation plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Where the effect of the time value of money is material, those provisions are measured at the present value of the expenditures expected to be required to settle the obligation, calculated using a discount rate that reflects an estimate of the time value of money and the risks specific to the obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Increases in provisions to reflect the effects of the passage of time are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_565"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.13. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="f-671" continuedAt="f-671-1" escape="true"><ix:continuation id="f-641-32" continuedAt="f-641-33">Revenue recognition</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-671-1" continuedAt="f-671-2"><ix:continuation id="f-641-33" continuedAt="f-641-34"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.1. Net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenue arising from the sale of goods is presented in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Net sales comprise revenue from sales of pharmaceutical products, consumer healthcare products, active ingredients and vaccines, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. Analyses of net sales are provided in Note&#160;D.35.1. &#8220;Segment Information&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;15 (Revenue from Contracts with Customers), such revenue is recognized when Sanofi transfers control over the product to the customer; control of an asset refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from that asset. For the vast majority of contracts, revenue is recognized when the product is physically transferred, in accordance with the delivery and acceptance terms agreed with the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For contracts entered into by Sanofi Pasteur, transfer of control is usually determined by reference to the terms of release (immediate or deferred) and acceptance of batches of vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of contracts with distributors, Sanofi does not recognize revenue when the product is physically transferred to the distributor if the products are sold on consignment, or if the distributor acts as agent. In such cases, revenue is recognized when control is transferred to the end customer, and the distributor&#8217;s commission is presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects the various types of price reductions or rights of return offered by Sanofi to its customers on certain products. Such price reductions and rights of return qualify as variable consideration under IFRS&#160;15.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In particular, products sold in the United States are covered by various Government and State programs (such as Medicare and Medicaid) under which products are sold at a discount. Rebates are granted to healthcare authorities, and under contractual arrangements with certain customers. Some wholesalers are entitled to chargeback incentives based on the selling price to the end customer, under specific contractual arrangements. Cash discounts may also be granted for prompt payment. Returns, discounts, incentives and rebates, as described above, are recognized in the period in which the underlying sales are recognized as a reduction of gross sales.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These amounts are calculated as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of chargeback incentives is estimated on the basis of the relevant subsidiary&#8217;s standard sales terms and conditions, and in certain cases on the basis of specific contractual arrangements with the customer;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of rebates based on attainment of sales targets is estimated and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of price reductions under Government and State programs, largely in the United States, is estimated on the basis of the specific terms of the relevant regulations or agreements, and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of sales returns is calculated on the basis of management&#8217;s best estimate of the amount of product that will ultimately be returned by customers. In countries where product returns are possible, Sanofi operates a returns policy that allows the customer to return products within a certain period either side of the expiry date (usually 12&#160;months after the expiry date). The amount recognized for returns is estimated on the basis of past experience of sales returns. Sanofi also takes into account factors such as levels of inventory in its various distribution channels, product expiry dates, information about potential discontinuation of products, the entry of competing generics into the market, and the launch of over-the-counter medicines. Most product return clauses relate solely to date-expired products, which cannot be resold and are destroyed. Sanofi does not recognize a right of return asset in the balance sheet for contracts that allow for the return of time-expired products, since those products have no value.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-671-2"><ix:continuation id="f-641-34" continuedAt="f-641-35"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The estimated amounts described above are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a reduction of gross sales, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the balance sheet. They are subject to regular review and adjustment as appropriate based on the most recent data available to management. Sanofi believes that it has the ability to measure each of the above amounts reliably, using the following factors in developing its estimates:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the nature and patient profile of the underlying product;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the applicable regulations or the specific terms and conditions of contracts with governmental authorities, wholesalers and other customers;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">historical data relating to similar contracts, in the case of qualitative and quantitative rebates and chargeback incentives;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">past experience and sales growth trends for the same or similar products;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actual inventory levels in distribution channels, monitored by Sanofi using internal sales data and externally provided data;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the shelf life of Sanofi products; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market trends including competition, pricing and demand.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of provisions for discounts, rebates and sales returns is provided in Note&#160;D.23.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.2. Other revenues</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is used to recognize all revenue that falls within the scope of IFRS&#160;15 but does not relate to sales of Sanofi products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It mainly comprises (i)&#160;royalties received from licensing intellectual property rights to third parties; (ii)&#160;VaxServe sales of products sourced from third-party manufacturers; and (iii)&#160;revenue received under agreements for Sanofi to provide manufacturing services to third parties.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Royalties received under licensing arrangements are recognized over the period during which the underlying sales are recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VaxServe is a Vaccines segment entity whose operations include the distribution within the United States of vaccines and other&#160;products manufactured by third parties. VaxServe sales of products sourced from third-party manufacturers are presented within&#160;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_568"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.14. <ix:nonNumeric contextRef="c-1" name="sny:DescriptionOfAccountingPolicyForCostOfSalesExplanatory" id="f-672" continuedAt="f-672-1" escape="true"><ix:continuation id="f-641-35" continuedAt="f-641-36">Cost of sales</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-672-1"><ix:continuation id="f-641-36" continuedAt="f-641-37"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> consists primarily of the industrial cost of goods sold, payments made under licensing agreements, and distribution costs. The industrial cost of goods sold includes the cost of materials, depreciation of property, plant and equipment, amortization of software, personnel costs, and other expenses attributable to production.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_571"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.15. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="f-673" continuedAt="f-673-1" escape="true"><ix:continuation id="f-641-37" continuedAt="f-641-38">Research and development</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-673-1"><ix:continuation id="f-641-38" continuedAt="f-641-39"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note&#160;B.4.1. &#8220;Research and development not acquired in a business combination&#8221; and Note&#160;B.4.3. &#8220;Other intangible assets acquired in a business combination&#8221; describe the principles applied to the recognition of research and development costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contributions or reimbursements received from alliance partners are recorded as a reduction of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_574"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.16. <ix:nonNumeric contextRef="c-1" name="sny:DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock" id="f-674" continuedAt="f-674-1" escape="true"><ix:continuation id="f-641-39" continuedAt="f-641-40">Other operating income and expenses</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-674-1"><ix:continuation id="f-641-40" continuedAt="f-641-41"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16.1. Other operating income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the share of profits that Sanofi is entitled to receive from alliance partners in respect of product marketing agreements. It also includes revenues generated under certain agreements, which may include partnership, co-promotion arrangements and licenses not included in Other revenues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item also includes realized and unrealized foreign exchange gains and losses on operating activities (see Note&#160;B.8.3.), and operating gains on disposals not regarded as major disposals (see Note&#160;B.20.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16.2. Other operating expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise the share of profits that alliance partners are entitled to receive from Sanofi under product marketing agreements.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_577"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.17. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" id="f-675" continuedAt="f-675-1" escape="true"><ix:continuation id="f-641-41" continuedAt="f-641-42">Amortization and impairment of intangible assets</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-675-1" continuedAt="f-675-2"><ix:continuation id="f-641-42" continuedAt="f-641-43"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.1. Amortization of intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The expenses recorded in this line item comprise amortization charged against intangible assets (products, trademarks and technology platforms, see Note&#160;D.4.) whose contribution to Sanofi&#8217;s commercial, industrial and development functions cannot be separately identified.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-675-2"><ix:continuation id="f-641-43" continuedAt="f-641-44"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of software, and of other rights of an industrial or operational nature, is recognized as an expense in the income statement, in the relevant line items of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.2. Impairment of intangible assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item records impairment losses taken against intangible assets (products, trademarks, technology platforms and acquired research), and any reversals of such impairment losses.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_580"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.18. <ix:nonNumeric contextRef="c-1" name="sny:DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock" id="f-676" continuedAt="f-676-1" escape="true"><ix:continuation id="f-641-44" continuedAt="f-641-45">Fair value remeasurement of contingent consideration</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-676-1"><ix:continuation id="f-641-45" continuedAt="f-641-46"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in the fair value of contingent consideration that was (i)&#160;already carried in the books of an acquired entity, or (ii)&#160;granted in connection with a business combination and initially recognized as a liability in accordance with IFRS&#160;3, are reported in profit or loss. Such adjustments are reported separately in the income statement, in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item also includes changes in the fair value of contingent consideration receivable in connection with a divestment and classified as a financial asset at fair value through profit or loss.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, it includes the effect of the unwinding of discount, and of exchange rate movements where the asset or liability is expressed in a currency other than the functional currency of the reporting entity.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_583"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.19. <ix:nonNumeric contextRef="c-1" name="sny:DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock" id="f-677" continuedAt="f-677-1" escape="true"><ix:continuation id="f-641-46" continuedAt="f-641-47">Restructuring costs and similar items</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-677-1"><ix:continuation id="f-641-47" continuedAt="f-641-48"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring costs are expenses incurred in connection with the transformation or reorganization of Sanofi&#8217;s operations or support functions. Such costs include collective redundancy plans, compensation to third parties for early termination of contracts, and commitments made in connection with transformation or reorganization decisions. They also include accelerated depreciation charges arising from site closures (including closures of leased sites), and losses on asset disposals resulting from such decisions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, this line item includes expenses incurred in connection with programs implemented as part of the transformation strategy announced in December&#160;2019 (and previously in November&#160;2015), and intended primarily (i)&#160;to deliver a global information systems solution, further supported by the implementation from 2021 of Sanofi&#8217;s new digital strategy; and (ii)&#160;to create a standalone CHC entity and proceed to the proposed separation of the CHC business as announced when the new chapter in the Play to Win strategy was presented in October&#160;2023.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_586"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.20. <ix:nonNumeric contextRef="c-1" name="sny:DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock" id="f-678" continuedAt="f-678-1" escape="true"><ix:continuation id="f-641-48" continuedAt="f-641-49">Other gains and losses, and litigation</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-678-1"><ix:continuation id="f-641-49" continuedAt="f-641-50"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the impact of material transactions of an unusual nature or amount which Sanofi believes it necessary to report separately in the income statement in order to improve the relevance of the financial statements, such as:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gains and losses on major disposals of property, plant and equipment, of intangible assets, of assets (or groups of assets and liabilities) held for sale, or of a business within the meaning of IFRS&#160;3, other than those considered to be restructuring costs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment losses and reversals of impairment losses on assets (or groups of assets and liabilities) held for sale, other than those considered to be restructuring costs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gains on bargain purchases;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">costs relating to major litigation; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">pre-tax separation costs associated with the process of disinvesting from operations in the event of a major divestment.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_589"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.21. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" id="f-679" continuedAt="f-679-1" escape="true"><ix:continuation id="f-641-50" continuedAt="f-641-51">Financial expenses and income</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-679-1"><ix:continuation id="f-641-51" continuedAt="f-641-52"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.1. Financial expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise interest charges on debt financing; negative changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange losses on financing and investing activities; impairment losses on financial instruments; and any reversals of impairment losses on financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> also include expenses arising from the unwinding of discount on long-term provisions, and the net interest cost related to employee benefits. This line item does not include commercial cash discounts, which are deducted from net sales.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.2. Financial income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes interest and dividend income; positive changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange gains on financing and investing activities; and gains on disposals of financial assets at fair value through profit or loss.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_592"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.22. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="f-680" continuedAt="f-680-1" escape="true"><ix:continuation id="f-641-52" continuedAt="f-641-53">Income tax expense</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-680-1"><ix:continuation id="f-641-53" continuedAt="f-641-54"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">includes all current and deferred taxes of consolidated companies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi accounts for deferred taxes in accordance with IAS&#160;12 (Income Taxes), using the methods described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are recognized on taxable and deductible temporary differences, and on tax loss carry-forwards. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">French business taxes include a value added based component: &#8220;CVAE&#8221; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cotisation sur la Valeur Ajout&#233;e des Entreprises)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Given that CVAE is (i)&#160;calculated as the amount by which certain revenues exceed certain expenses and (ii)&#160;borne primarily by companies that own intellectual property rights on income derived from those rights (royalties, and margin on sales to third parties and to Sanofi entities), it is regarded as meeting the definition of income taxes specified in IAS&#160;12, paragraph&#160;2 (&#8220;taxes which are based on taxable profits&#8221;);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are calculated using the tax rate expected to apply in the period when the corresponding temporary differences are expected to reverse, based on tax rates enacted or substantively enacted at the end of the reporting period;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets are recognized in respect of deductible temporary differences, tax losses available for carry-forward and unused tax credits to the extent that future recovery is regarded as probable. The recoverability of deferred tax assets is assessed on a case-by-case basis, taking into account the profit forecasts contained in Sanofi&#8217;s medium-term business plan;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a deferred tax liability is recognized for temporary differences relating to interests in subsidiaries, associates and joint ventures, except in cases where Sanofi is able to control the timing of the reversal of the temporary differences. This applies in particular when Sanofi is able to control dividend policy and it is probable that the temporary differences will not reverse in the foreseeable future;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">no deferred tax is recognized on eliminations of intragroup transfers of interests in subsidiaries, associates or joint ventures;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each tax entity calculates its own net deferred tax position. All net deferred tax asset and liability positions are then aggregated and shown in separate line items on the relevant side of the consolidated balance sheet. Deferred tax assets and liabilities are offset only if (i)&#160;Sanofi has a legally enforceable right to offset current tax assets and current tax liabilities, and (ii)&#160;the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred taxes are not discounted, except implicitly in the case of deferred taxes on assets and liabilities which are already impacted by discounting. In addition, Sanofi has elected not to discount current taxes payable or receivable where the amounts in question are payable or receivable in the long term;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">withholding taxes on intragroup royalties and dividends, and on royalties and dividends collected from third parties, are accounted for as current income taxes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accounting for business combinations, Sanofi complies with IFRS&#160;3 as regards the recognition of deferred tax assets after the initial accounting period. Consequently, any deferred tax assets recognized by the acquiree after the end of that period in respect of temporary differences or tax loss carry-forwards existing at the acquisition date are recognized in profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The positions adopted by Sanofi in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, Sanofi assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of Sanofi&#8217;s best estimate and recognized as a liability; uncertain tax assets are not recognized. The amount of the liability includes any penalties and late payment interest. The line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Income tax expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the effects of tax reassessments and tax disputes, and any penalties and late payment interest arising from such disputes that have the characteristics of income taxes within the meaning of paragraph&#160;2 of IAS&#160;12 (&#8220;taxes which are based on taxable profits&#8221;). Tax exposures relating to corporate income taxes are presented separately within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current income tax liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (see Note&#160;D.19.4.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-91" decimals="INF" name="ifrs-full:DeferredTaxExpenseIncome" format="ixt:fixed-zero" scale="0" id="f-681">No</ix:nonFraction> deferred taxation is recognized on temporary differences that are liable to be subject to US global intangible low taxed&#160;income (GILTI) provisions. The related tax expense is recognized in the year in which it is declared in the tax return to the extent that it arises from the existence of non-US profits that exceed the theoretical return on investment specified in the GILTI&#160;provisions and are taxed at a rate lower than the applicable US tax rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;1 (Presentation of Financial Statements), current income tax assets and liabilities are presented as separate line items in the consolidated balance sheet.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_595"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.23. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="f-682" continuedAt="f-682-1" escape="true"><ix:continuation id="f-641-54" continuedAt="f-641-55">Employee benefit obligations</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-682-1" continuedAt="f-682-2"><ix:continuation id="f-641-55" continuedAt="f-641-56"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi offers retirement benefits to employees and retirees. Such benefits are accounted for in accordance with IAS&#160;19 (Employee Benefits).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Benefits are provided in the form of either defined contribution plans or defined benefit plans. In the case of defined contribution plans, the cost is recognized immediately in the period in which it is incurred, and equates to the amount of the contributions paid by Sanofi. For defined benefit plans, Sanofi generally recognizes its obligations to pay pensions and similar benefits to employees as a liability, based on an actuarial estimate of the rights vested or currently vesting in employees and retirees, using the projected unit credit method. Estimates are performed at least once a year, and rely on financial assumptions (such as discount </span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-682-2"><ix:continuation id="f-641-56" continuedAt="f-641-57"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">rates) and demographic assumptions (such as life expectancy, retirement age, employee turnover, and the rate of salary increases).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Obligations relating to other post-employment benefits (healthcare and life insurance) offered by Sanofi companies to employees are also recognized as a liability based on an actuarial estimate of the rights vested or currently vesting in employees and retirees at the end of the reporting period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such liabilities are recognized net of the fair value of plan assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of multi-employer defined benefit plans where plan assets cannot be allocated to each participating employer with sufficient reliability, the plan is accounted for as a defined contribution plan, in accordance with paragraph&#160;34 of IAS&#160;19.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The benefit cost for the period consists primarily of current service cost, past service cost, net interest cost, gains or losses arising from plan settlements not specified in the terms of the plan, and actuarial gains or losses arising from plan curtailments. Net interest cost for the period is determined by applying the discount rate specified in IAS&#160;19 to the net liability (i.e. the amount of the obligation, net of plan assets) recognized in respect of defined benefit plans. Past service cost is recognized immediately in profit or loss in the period in which it is incurred, regardless of whether or not the rights have vested at the time of adoption (in&#160;the case of a new plan) or of amendment (in&#160;the case of an existing&#160;plan).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses on defined benefit plans (pensions and other post-employment benefits), also referred to as&#160;&#8220;Remeasurements of the net defined benefit liability (asset)&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> arise as a result of changes in financial and demographic assumptions, experience adjustments, and the difference between the actual return and interest cost on plan assets. The impacts of those remeasurements are recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net of deferred taxes; they are not subsequently reclassifiable to profit or&#160;loss.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_598"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.24. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="f-683" continuedAt="f-683-1" escape="true"><ix:continuation id="f-641-57" continuedAt="f-641-58">Share-based payment</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-683-1"><ix:continuation id="f-641-58" continuedAt="f-641-59"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Share-based payment expense is recognized as a component of operating income, in the relevant classification of expense by function. In measuring the expense, the level of attainment of any performance conditions is taken into account.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.1. Stock option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has granted a number of equity-settled share-based payment plans (stock option plans) to some of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;2 (Share-Based Payment), services received from employees as consideration for stock options are recognized as an expense in the income statement, with the opposite entry recognized in equity. The expense corresponds to the fair value of the stock option plans, and is charged to income on a straight-line basis over the <ix:nonNumeric contextRef="c-92" name="sny:OptionVestingPeriod" format="ixt-sec:durwordsen" id="f-684">four-year</ix:nonNumeric> vesting period of the plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of stock option plans is measured at the date of grant using the Black-Scholes valuation model, taking into account the expected life of the options. The resulting expense also takes into account the expected cancellation rate of the options. The expense is adjusted over the vesting period to reflect actual cancellation rates resulting from option-holders ceasing to be employed by Sanofi.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.2. Employee share ownership plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may offer its employees the opportunity to subscribe to reserved share issues at a discount to the reference market price. Shares awarded to employees under such plans fall within the scope of IFRS&#160;2. Consequently, an expense is recognized at the subscription date, based on the value of the discount offered to employees.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.3. Restricted share plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may award restricted share plans to certain of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;2, an expense equivalent to the fair value of such plans is recognized in profit or loss on a straight line basis over the vesting period of the plan, with the opposite entry recognized in equity. The vesting period is <ix:nonNumeric contextRef="c-93" name="sny:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" format="ixt-sec:durwordsen" id="f-685">three years</ix:nonNumeric>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of restricted share plans is based on the quoted market price of Sanofi shares at the date of grant, adjusted for expected dividends during the vesting period; it also takes account of any vesting conditions contingent on stock market performance, measured using the Monte-Carlo valuation model. Other vesting conditions are taken into account in the estimate of the number of shares awarded during the vesting period; that number is then definitively adjusted based on the actual number of shares awarded on the vesting date.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_601"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.25. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="f-686" continuedAt="f-686-1" escape="true"><ix:continuation id="f-641-59" continuedAt="f-641-60">Earnings per share</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-686-1"><ix:continuation id="f-641-60" continuedAt="f-641-61"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares outstanding during the reporting period, adjusted on a time-weighted basis from the acquisition date to reflect the number of own shares held by Sanofi. Diluted earnings per share is calculated on the basis of the weighted average number of ordinary shares, computed using the treasury stock method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This method assumes that (i)&#160;all outstanding dilutive options and warrants are exercised, and (ii)&#160;Sanofi acquires its own shares at the quoted market price for an amount equivalent to the cash received as consideration for the exercise of the options or warrants, plus the expense arising on unamortized stock options.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_604"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.26. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" id="f-687" continuedAt="f-687-1" escape="true"><ix:continuation id="f-641-61" continuedAt="f-641-62">Segment information</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-687-1"><ix:continuation id="f-641-62" continuedAt="f-641-63"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported <ix:nonFraction unitRef="segment" contextRef="c-9" decimals="INF" name="sny:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-688">three</ix:nonFraction> operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Sanofi Business Services,&#160;etc.), which are mainly managed centrally at group-wide level, were presented within the &#8220;Other&#8221; category. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in&#160;order to reflect (i)&#160;progress on the &#8220;Play to Win&#8221; strategy leading to the creation of the standalone Consumer Healthcare Global&#160;Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its&#160;own&#160;dedicated global support functions (including Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Global Business Services,&#160;etc.); and (ii)&#160;organizational changes to Sanofi&#8217;s Manufacturing &amp; Supply global function (previously known as Industrial Affairs). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, with effect from January&#160;1, 2023, Sanofi reports <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="sny:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-689">two</ix:nonFraction> operating segments: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#8217;s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment&#8217;s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Information about operating segments for the years ended December 31, 2023, 2022 and 2021 is presented in Note&#160;D.35</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">., </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Segment information&#8221;.</span></div></ix:continuation></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_607"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.27. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" id="f-690" continuedAt="f-690-1" escape="true"><ix:continuation id="f-641-63" continuedAt="f-641-64">Management of capital</ix:continuation></ix:nonNumeric></span></div><ix:continuation id="f-690-1"><ix:continuation id="f-641-64"><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to maintain or adjust the capital structure, Sanofi can adjust the amount of dividends paid to shareholders, repurchase its own shares, issue new shares, or issue securities giving access to its capital.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following objectives are defined under the terms of Sanofi&#8217;s share repurchase programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the implementation of any stock option plan giving entitlement to purchase shares in the Sanofi parent company;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the allotment or sale of shares to employees under statutory profit sharing schemes and employee savings plans;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the consideration-free allotment of shares (i.e. restricted share plans);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the cancellation of some or all of the repurchased shares;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market-making in the secondary market by an investment services provider under a liquidity contract in compliance with the ethical code recognized by the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Autorit&#233; des march&#233;s financiers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (AMF);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares on the exercise of rights attached to securities giving access to the capital by redemption, conversion, exchange, presentation of a warrant or any other means;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares (in exchange, as payment, or otherwise) in connection with mergers and acquisitions;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the execution by an investment services provider of purchases, sales or transfers by any means, in particular via off-market trading; or</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.1pt">any other purpose that is or may in the future be authorized under the applicable laws and regulations.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is not subject to any constraints on equity capital imposed by third parties.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total equity includes </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Equity attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Equity attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as shown in the consolidated balance sheet.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi defines &#8220;Net debt&#8221; as (i)&#160;the sum of short-term debt, long-term debt and interest rate derivatives and currency derivatives used to hedge debt, minus (ii)&#160;the sum of cash and cash equivalents and interest rate derivatives and currency derivatives used to hedge cash and cash equivalents.</span></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-29</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_610"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">C/ <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfPrincipalAlliancesTextBlock" id="f-691" continuedAt="f-691-1" escape="true">Principal alliances</ix:nonNumeric></span></div><ix:continuation id="f-691-1" continuedAt="f-691-2"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.1. Alliance arrangements with Regeneron Pharmaceuticals,&#160;Inc. (Regeneron)</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Collaboration agreements on human therapeutic antibodies</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In November&#160;2007, Sanofi and Regeneron signed <ix:nonFraction unitRef="agreement" contextRef="c-94" decimals="INF" name="sny:NumberOfAgreementsSigned" format="ixt-sec:numwordsen" scale="0" id="f-692">two</ix:nonFraction> agreements (amended in November&#160;2009) relating to human therapeutic antibodies: (i)&#160;the Discovery and Preclinical Development Agreement, and (ii)&#160;the License and Collaboration Agreement, relating to clinical development and commercialization. Under the License and Collaboration Agreement, Sanofi had an option to develop and commercialize antibodies discovered by Regeneron under the Discovery and Preclinical Development Agreement.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discovery and development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because Sanofi decided not to exercise its option to extend the Discovery and Preclinical Development Agreement, that agreement expired on December&#160;31, 2017.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a result of Sanofi&#8217;s exercise of an option with respect to an antibody under the Discovery and Preclinical Development Agreement, such antibody became a &#8220;Licensed Product&#8221; under the License and Collaboration Agreement, pursuant to which Sanofi and Regeneron co-develop the antibody with Sanofi initially being wholly responsible for funding the development program. On receipt of the first positive Phase 3 trial results for any antibody being developed under the License and Collaboration Agreement, the subsequent development costs for that antibody are split <ix:nonFraction unitRef="number" contextRef="c-95" decimals="2" name="sny:PercentageOfSecondPartOfDevelopmentCostsFunded" scale="-2" id="f-693">80</ix:nonFraction>% Sanofi, <ix:nonFraction unitRef="number" contextRef="c-95" decimals="2" name="sny:PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty" scale="-2" id="f-694">20</ix:nonFraction>% Regeneron. Amounts received from Regeneron under the License and Collaboration Agreement are recognized by Sanofi as a reduction in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Co-development with Regeneron of the antibodies DUPIXENT, KEVZARA and REGN3500 (SAR440340 - itepekimab) is ongoing under the License and Collaboration Agreement as of December&#160;31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Once a product begins to be commercialized, and provided that the share of quarterly results under the agreement represents a profit, Sanofi is entitled to an additional portion of Regeneron&#8217;s profit-share (capped at <ix:nonFraction unitRef="rate" contextRef="c-96" decimals="INF" name="sny:PercentageOfProfitShareOnCounterpartiesProfit" scale="-2" id="f-695">20</ix:nonFraction>% of Regeneron&#8217;s share of quarterly profits since April&#160;1, 2022, and at <ix:nonFraction unitRef="rate" contextRef="c-97" decimals="INF" name="sny:PercentageOfProfitShareOnCounterpartiesProfit" scale="-2" id="f-696">10</ix:nonFraction>% until March&#160;31, 2022) until Regeneron has paid <ix:nonFraction unitRef="number" contextRef="c-95" decimals="2" name="sny:PercentageOfCumulativeDevelopmentCostsReimbursed" scale="-2" id="f-697">50</ix:nonFraction>% of the cumulative development costs incurred by the parties in the collaboration (see Note&#160;D.21.1.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On the later of (i)&#160;<ix:nonNumeric contextRef="c-95" name="sny:PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared" format="ixt-sec:durmonth" id="f-698">24</ix:nonNumeric> months before the scheduled launch date or (ii)&#160;the first positive Phase&#160;3 trial results, Sanofi and Regeneron share the commercial expenses of the antibodies co-developed under the License and Collaboration Agreement.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is the lead party with respect to the commercialization of all co-developed antibodies, and Regeneron has certain option rights to co-promote the antibodies. Regeneron has exercised its co-promotion rights in the United States and in certain other countries. Sanofi recognizes all sales of the antibodies. Profits and losses arising from commercial operations in the United States are split <ix:nonFraction unitRef="number" contextRef="c-98" decimals="2" name="sny:PercentageOfProfitsAndLossesArisingFromCommercialOperations" scale="-2" id="f-699">50</ix:nonFraction>/50. Outside the United States, Sanofi is entitled to between <ix:nonFraction unitRef="number" contextRef="c-99" decimals="2" name="sny:PercentageOfProfitsArisingFromCommercialOperations" scale="-2" id="f-700">55</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-100" decimals="2" name="sny:PercentageOfProfitsArisingFromCommercialOperations" scale="-2" id="f-701">65</ix:nonFraction>% of profits depending on sales of the antibodies, and bears <ix:nonFraction unitRef="number" contextRef="c-101" decimals="2" name="sny:PercentageOfLossesArisingFromCommercialOperations" scale="-2" id="f-702">55</ix:nonFraction>% of any losses. The share of profits and losses due to or from Regeneron under the agreement is recognized within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which are components of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, Regeneron is entitled to receive payments contingent on the attainment of specified levels of aggregate sales on all antibodies outside the United States, on a rolling twelve-month basis. A liability for those payments is recognized on the balance sheet when it is probable that the specified level of aggregate sales will be met. The opposite entry for that liability is capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> on the balance sheet. <ix:nonFraction unitRef="bond" contextRef="c-102" decimals="INF" name="sny:NumberOfPayments" format="ixt-sec:numwordsen" scale="0" id="f-703">Two</ix:nonFraction> payments of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="sny:PaymentRelatedToAttainmentOfGoal" format="ixt:num-dot-decimal" scale="6" id="f-704"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="sny:PaymentRelatedToAttainmentOfGoal" format="ixt:num-dot-decimal" scale="6" id="f-705">50</ix:nonFraction></ix:nonFraction>&#160;million each were made in 2022, following attainment first of $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-8" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="9" id="f-706">2.0</ix:nonFraction>&#160;billion and then of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-8" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="9" id="f-707">2.5</ix:nonFraction>&#160;billion in sales of all antibodies outside the United States on a rolling twelve-month basis. The final milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="sny:PaymentRelatedToAttainmentOfGoal" format="ixt:num-dot-decimal" scale="6" id="f-708">50</ix:nonFraction>&#160;million, payable to Regeneron in the event that $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-8" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="9" id="f-709">3.0</ix:nonFraction>&#160;billion in sales on a rolling twelve-month basis is attained, was made in 2023.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendments to the collaboration agreements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January&#160;2018, Sanofi and Regeneron signed a set of amendments to their collaboration agreements, including an amendment that allowed for the funding of additional programs on DUPIXENT and REGN3500 (SAR440340 &#8211; itepekimab) with an intended focus on extending the current range of indications, finding new indications, and improving co-morbidity between multiple pathologies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective April&#160;1, 2020, Sanofi and Regeneron signed a Cross License and Commercialization Agreement for PRALUENT, whereby Sanofi obtained sole ex-US rights to PRALUENT, and Regeneron obtained sole US rights to PRALUENT along with a right to <ix:nonFraction unitRef="number" contextRef="c-109" decimals="2" name="sny:RoyaltyExpensePercentage" scale="-2" id="f-710">5</ix:nonFraction>% royalties on Sanofi&#8217;s sales of PRALUENT outside the United States. Each party is solely responsible for funding the development, manufacturing and commercialization of PRALUENT in their respective territories. Although each party has sole responsibility for supplying PRALUENT in its respective territory, Sanofi and Regeneron entered into agreements to support manufacturing needs for each other.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective September&#160;30, 2021, Sanofi and Regeneron signed an amendment to their collaboration agreement in order to specify allocations of responsibilities and associated resources between the two parties in connection with the co-promotion of&#160;DUPIXENT in certain countries. The terms of the collaboration relating to REGN3500 (SAR440340 &#8211; itepekimab) are unchanged.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-691-2" continuedAt="f-691-3"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective July&#160;1, 2022, Sanofi and Regeneron signed an amendment to their collaboration agreement in order to increase the additional portion of Regeneron&#8217;s quarterly profit-share attributable to Sanofi from <ix:nonFraction unitRef="rate" contextRef="c-110" decimals="INF" name="sny:PercentageOfProfitShareOnCounterpartiesProfit" scale="-2" id="f-711">10</ix:nonFraction>% to <ix:nonFraction unitRef="rate" contextRef="c-96" decimals="INF" name="sny:PercentageOfProfitShareOnCounterpartiesProfit" scale="-2" id="f-712">20</ix:nonFraction>% with retroactive impact as of April&#160;1, 2022.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Immuno-oncology (IO) collaboration agreements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;1, 2015, Sanofi and Regeneron signed <ix:nonFraction unitRef="agreement" contextRef="c-111" decimals="INF" name="sny:NumberOfAgreementsSigned" format="ixt-sec:numwordsen" scale="0" id="f-713">two</ix:nonFraction> agreements &#8211;&#160;the IO Discovery and Development Agreement and the IO License and Collaboration Agreement (IO LCA)&#160;&#8211; relating to new antibody cancer treatments in the field of immuno-oncology.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Amended IO Discovery Agreement, effective from December&#160;31, 2018, was terminated through a Letter Amendment dated March&#160;16,&#160;2021 in which Sanofi formalized its opt-out from the BCMAxCD3 and MUC16xCD3 programs. </span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIBTAYO</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(cemiplimab)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the 2015 IO LCA as amended in January&#160;2018, Sanofi and Regeneron committed funding of no more than $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="sny:PriorDevelopmentBudget" format="ixt:num-dot-decimal" scale="6" id="f-714">1,640</ix:nonFraction> million, split on a&#160;<ix:nonFraction unitRef="number" contextRef="c-112" decimals="INF" name="sny:ContractualAgreementForAntiProgrammedCellDeathProtein1" scale="0" id="f-715">50</ix:nonFraction>/50 basis ($<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="sny:MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany" format="ixt:num-dot-decimal" scale="6" id="f-716">820</ix:nonFraction> million per company), for the development of REGN2810 (cemiplimab, trademark LIBTAYO), a PD-1 inhibitor antibody. The funding was raised to $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="sny:MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany" format="ixt:num-dot-decimal" scale="6" id="f-717">1,840</ix:nonFraction>&#160;million by way of amendment effective on September&#160;30, 2021. Regeneron was responsible for the commercialization of LIBTAYO in the United States, and Sanofi in all other territories. Sanofi has exercised its option to co-promote LIBTAYO in the United States. In 2021, Regeneron exercised its option to co-promote LIBTAYO in certain other countries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The IO LCA also provided for a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="sny:AntiProgrammedCellDeathProtein1SalesMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-718">375</ix:nonFraction> million by Sanofi to Regeneron in the event that sales of a PD-1 product were to exceed, in the aggregate, $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-9" name="sny:MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment" format="ixt:num-dot-decimal" scale="9" id="f-719">2</ix:nonFraction> billion in any consecutive 12-month period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the IO LCA Sanofi and Regeneron shared equally in profits and losses generated by the commercialization of collaboration products, except that Sanofi was entitled to an additional portion of Regeneron&#8217;s profit-share (capped at <ix:nonFraction unitRef="number" contextRef="c-115" decimals="2" name="sny:PercentageOfProfitShareOnCounterpartiesProfit" scale="-2" id="f-720">10</ix:nonFraction>% of Regeneron&#8217;s share of quarterly profits) until Regeneron had paid <ix:nonFraction unitRef="number" contextRef="c-115" decimals="2" name="sny:PercentageOfCumulativeDevelopmentCostsReimbursed" scale="-2" id="f-721">50</ix:nonFraction>% of the cumulative development costs incurred by the parties under the IO Discovery Agreement, as amended.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">LIBTAYO is approved in the United States and Europe for the treatment of two types of locally advanced or metastatic skin cancer (cutaneous squamous cell carcinoma and basal cell carcinoma) and non-small cell lung cancer (NSCLC). It is also approved in Brazil and Canada as a second line treatment for recurring or metastatic cervical cancer. In the fourth quarter of 2022, it was approved in the United States in association with chemotherapy for the treatment of NSCLC, and in Europe and Japan as a second line treatment for recurring or metastatic cervical cancer. LIBTAYO is currently approved in more than 30&#160;countries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2022, Sanofi and Regeneron restructured their IO LCA. Under the terms of the Amended and Restated IO LCA, Regeneron holds exclusive worldwide licensing rights to LIBTAYO with effect from July&#160;1, 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July&#160;2022, Sanofi received as consideration an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="sny:UpfrontPaymentsForProjectsUnderCollaborationAgreements" format="ixt:num-dot-decimal" scale="6" id="f-722">900</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-116" decimals="-6" name="sny:UpfrontPaymentsForProjectsUnderCollaborationAgreements" format="ixt:num-dot-decimal" scale="6" id="f-723">856</ix:nonFraction>&#160;million), which was recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> on the date of receipt. The same line item also includes a regulatory milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="sny:RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" format="ixt:num-dot-decimal" scale="6" id="f-724">100</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-117" decimals="-6" name="sny:RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" format="ixt:num-dot-decimal" scale="6" id="f-725">96</ix:nonFraction>&#160;million) following the US FDA approval in November&#160;2022 of LIBTAYO in combination with chemotherapy as a first line treatment for NSCLC. In addition, Sanofi is entitled to royalties of <ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="sny:RoyaltyIncomePercentage" scale="-2" id="f-726">11</ix:nonFraction>% and to milestone payments (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-118" decimals="-6" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-727">116</ix:nonFraction>&#160;million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-119" decimals="-6" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-728">111</ix:nonFraction>&#160;million in 2022) linked to global net sales of LIBTAYO; those royalties are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in line with the pattern of sales. All of the cash inflows relating to the above items (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-118" decimals="-6" name="sny:ProceedsFromCollaborationAgreements" format="ixt:num-dot-decimal" scale="6" id="f-729">196</ix:nonFraction>&#160;million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-119" decimals="-6" name="sny:ProceedsFromCollaborationAgreements" format="ixt:num-dot-decimal" scale="6" id="f-730">952</ix:nonFraction>&#160;million in 2022) are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by/(used in) operating activities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amendment to the terms of the IO LCA resulted in Sanofi recognizing an accelerated amortization charge of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-120" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-731">226</ix:nonFraction>&#160;million in&#160;2022; this was allocated to the LIBTAYO product rights included within the residual carrying amount of the intangible asset recognized in July&#160;2015 to reflect rights to an antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) under the Sanofi/Regeneron alliance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transaction also includes a time-limited transitional services agreement with Regeneron which includes manufacturing, distribution (for which Sanofi acts as agent), and promotion.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investor agreement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2014 and 2020, Sanofi and Regeneron amended the investor agreement entered into by the two companies in 2007. Under the terms of the amendments, Sanofi accepted various restrictions, including &#8220;standstill&#8221; provisions that contractually prohibit Sanofi from seeking to directly or indirectly exert control of Regeneron or acquiring more than <ix:nonFraction unitRef="number" contextRef="c-121" decimals="INF" name="sny:MaximumOwnershipPercentageAllowedToAcquire" scale="-2" id="f-732">30</ix:nonFraction>% of Regeneron&#8217;s capital stock (consisting of the outstanding shares of common stock and the shares of Class A stock). This prohibition remains in place until the earlier of (i)&#160;the later of the fifth anniversaries of the expiration or earlier termination of the ZALTRAP collaboration agreement with Regeneron (related to the development and commercialization of ZALTRAP) or the collaboration agreement with Regeneron on monoclonal antibodies (see &#8220;Collaboration agreements on human therapeutic antibodies&#8221; above), each as amended or (ii)&#160;other specified events.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Starting in 2018 Sanofi began to sell shares of Regeneron stock and announced on May&#160;29,&#160;2020 the closing of its sale of <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="sny:SaleOfStockNumberOfSharesIssuedInTransactionTotal" format="ixt:num-dot-decimal" scale="6" id="f-733">13</ix:nonFraction>&#160;million shares of Regeneron common stock in a registered offering and a private sale to Regeneron (see Note&#160;D.2.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Pursuant to subsequent sales in 2022, Sanofi no longer holds any shares of Regeneron stock, as of December 31, 2023.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-691-3" continuedAt="f-691-4"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.2. Agreements on the commercialization of BEYFORTUS (nirsevimab, previously MEDI8897) in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March 1, 2017, Sanofi and AstraZeneca entered into an agreement to develop and commercialize a monoclonal antibody (MEDI8897, nirsevimab) for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the agreement, Sanofi made an upfront payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-123" decimals="-6" name="sny:CollaborationAgreementsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-734">120</ix:nonFraction>&#160;million in March 2017, a development milestone payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-124" decimals="-6" name="sny:CollaborationAgreementsDevelopmentMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-735">30</ix:nonFraction>&#160;million in the third quarter of 2019, a regulatory milestone payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-125" decimals="-6" name="sny:CollaborationAgreementsRegulatoryMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-736">25</ix:nonFraction>&#160;million associated with the approval of BEYFORTUS (nirsevimab) by the EMA in Europe in November 2022, and a regulatory milestone payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-126" decimals="-6" name="sny:CollaborationAgreementsRegulatoryMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-737">65</ix:nonFraction>&#160;million associated with the approval of BEYFORTUS (nirsevimab) by the US FDA in July 2023. In addition, Sanofi could pay up to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-127" decimals="-6" name="sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-738">375</ix:nonFraction>&#160;million if sales objectives are met. Those amounts are recognized as a component of the value of the intangible asset when payment becomes probable. During 2023, an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-127" decimals="-6" name="ifrs-full:Accruals" format="ixt:num-dot-decimal" scale="6" id="f-739">25</ix:nonFraction>&#160;million was recognized as an accrued expense further to a contractual threshold being passed.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The agreement also specifies that AstraZeneca is responsible for development and manufacturing, and Sanofi for commercialization. Sanofi recognizes the sales and cost of sales (purchases of finished products from AstraZeneca) and shares the Alliance&#8217;s commercial profits (i) <ix:nonFraction unitRef="number" contextRef="c-128" decimals="2" name="sny:PercentageOfProfitsArisingFromCommercialOperations" scale="-2" id="f-740">50</ix:nonFraction>/50 in major territories and (ii) based on <ix:nonFraction unitRef="number" contextRef="c-129" decimals="2" name="sny:PercentageOfNetSalesArisingFromCommercialOperations" scale="-2" id="f-741">25</ix:nonFraction>% of net sales in other territories. The share of commercial profits and losses due to or from AstraZeneca is recognized as a component of operating income, within the line items</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. In addition, Sanofi and AstraZeneca share development costs <ix:nonFraction unitRef="number" contextRef="c-130" decimals="2" name="sny:PercentageOfDevelopmentCostsArisingFromCommercialOperations" scale="-2" id="f-742">50</ix:nonFraction>/50, with Sanofi&#8217;s portion recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">s.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2023, Sanofi and AstraZeneca simplified their contractual agreements for the development and commercialization of BEYFORTUS (nirsevimab) in the US. Sanofi thereby obtained control of all commercial rights to BEYFORTUS (nirsevimab) in the US, and ended the sharing of commercial profits between the two partners in that territory. In line with the terms of the revised agreements and in accordance with IAS 38, Sanofi recognized an intangible asset of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-8" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-743">1.6</ix:nonFraction>&#160;billion for the fair value of the additional US rights. On the same date, AstraZeneca and Sobi ended their participation agreement, signed in 2018, which transferred the economic rights for the US territory to Sobi. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi simultaneously entered into an agreement with Sobi relating to direct royalties on US net sales of BEYFORTUS (nirsevimab). In line with the terms of that agreement, on April 9, 2023 Sanofi recognized a financial liability amounting to  &#8364;<ix:nonFraction unitRef="eur" contextRef="c-132" decimals="-8" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="9" id="f-744">1.6</ix:nonFraction>&#160;billion. That liability is classified as a financial liability at amortized cost under IFRS 9. Other than royalty payments, subsequent movements in the liability comprise (i) the unwinding of discount and (ii) changes in estimates of future cash outflows for royalty payments. Those movements will be recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net financial income/(expenses)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with paragraph B.5.4.6 of IFRS 9. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023 the liability was remeasured by an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-133" decimals="-6" name="sny:IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-745">541</ix:nonFraction>&#160;million, reflecting the strong success of the US launch of BEYFORTUS (nirsevimab), which led to sales forecasts being revised upward from the initial estimate. The resulting adjustment was recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For territories other than the US (except for China, which is now considered a &#8220;major market,&#8221; with profits/losses shared <ix:nonFraction unitRef="number" contextRef="c-134" decimals="2" name="sny:PercentageOfProfitsArisingFromCommercialOperations" scale="-2" id="f-746">50</ix:nonFraction>/50 with AstraZeneca), the existing agreement between AstraZeneca and Sanofi continues to govern the principal terms of the collaboration: Sanofi recognizes the sales and cost of sales and shares the Alliance&#8217;s commercial profits with AstraZeneca.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May 2023, data from the HARMONIE Phase 3b study confirmed that nirsevimab prevents infant hospitalizations due to RSV with consistent and high efficacy.</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-691-4">BEYFORTUS (nirsevimab) was approved in Europe in November 2022, and in the United States on July 17, 2023.</ix:continuation> </span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div id="i9fa7f69b4904450e9c43e8444c203165_613"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">D/ <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" id="f-747" continuedAt="f-747-1" escape="true">Presentation of the financial statements</ix:nonNumeric></span></div><div id="i9fa7f69b4904450e9c43e8444c203165_616"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.1. <ix:continuation id="f-747-1" continuedAt="f-747-2">Principal changes in the scope of consolidation in 2023</ix:continuation></span></div><ix:continuation id="f-747-2" continuedAt="f-747-3"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Provention Bio, Inc.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March&#160;13, 2023, Sanofi entered into a merger agreement with Provention Bio, Inc. (Provention), a US-based publicly traded biopharmaceutical company developing therapies to prevent and intercept immune-mediated diseases including type&#160;1 diabetes. Under the terms of the agreement, Sanofi acquired the outstanding shares of Provention common stock for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="sny:BusinessCombinationPurchasePricePerShare" scale="0" id="f-748">25.00</ix:nonFraction> per share in an all-cash transaction valued at approximately $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-8" name="ifrs-full:CashTransferred" format="ixt:num-dot-decimal" scale="9" id="f-749">2.8</ix:nonFraction>&#160;billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of Provention was completed on April&#160;27, 2023, with Sanofi holding all of the shares of Provention on expiration of the tender offer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph B7A of IFRS&#160;3. The transaction was accounted for as an acquisition of a group of assets, given that the principal asset (teplizumab-mzwv, commercialized in the United States under the name TZIELD) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of a share purchase agreement entered into by Sanofi and Provention in February&#160;2023, Sanofi already held an equity interest in Provention, representing approximately <ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" scale="-2" id="f-750">3</ix:nonFraction>% of Provention&#8217;s share capital. On the date Sanofi obtained control of Provention, that equity interest was remeasured at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="2" name="sny:BusinessCombinationPurchasePricePerShare" scale="0" id="f-751">25.00</ix:nonFraction> per share, representing a total amount of $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-752">68</ix:nonFraction>&#160;million. The impact of the remeasurement was recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-747-3" continuedAt="f-747-4"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition price for the shares not already held was $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-753">2,806</ix:nonFraction>&#160;million. Out of the total price (including the fair value of the shares already held), $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-754">2,810</ix:nonFraction>&#160;million was allocated to TZIELD and recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction, after taking account of the previously-held shares and acquisition-related costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-755">2,722</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of QRIB Intermediate Holdings, LLC</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;28, 2023, Sanofi announced that it had acquired QRIB Intermediate Holdings, LLC (QRIB), the owner of QUNOL, a market-leading US-based health &amp; wellness brand. The acquisition strengthened Sanofi's Consumer Healthcare (CHC) operations in the Vitamin, Mineral and Supplements (VMS) category.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of QRIB by Sanofi was completed on September&#160;29, 2023, at a purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="sny:BusinessCombinationPurchasePrice" format="ixt:num-dot-decimal" scale="6" id="f-756">1,419</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" id="f-757" continuedAt="f-757-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation led to the recognition of goodwill of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-758">475</ix:nonFraction>&#160;million, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:66.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.907%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" scale="6" id="f-759">774</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="sny:OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate" scale="6" id="f-760">90</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" scale="6" id="f-761">8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" scale="6" id="f-762">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of QRIB Intermediate Holdings, LLC</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" scale="6" id="f-763">867</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" scale="6" id="f-764">475</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-765">1,342</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The other acquired intangible assets identified consist of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">QUNOL brand.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill mainly represents the expected future profits attributable to the development of the VMS platform in the United States as a result of the integration of QRIB into the Sanofi group.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The entire amount of goodwill is deductible for tax purposes over a period of <ix:nonNumeric contextRef="c-1" name="sny:GoodwillTaxDeductiblePeriod" format="ixt-sec:duryear" id="f-766">15</ix:nonNumeric> years.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since the acquisition date, QRIB has generated net sales of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="ifrs-full:RevenueOfAcquiree" format="ixt:num-dot-decimal" scale="6" id="f-767">71</ix:nonFraction>&#160;million, and has made an <ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-6" name="ifrs-full:ProfitLossOfAcquiree" format="ixt:fixed-zero" scale="0" id="f-768">immaterial</ix:nonFraction> impact on consolidated net income.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition-related costs were recognized in profit or loss during 2023 within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; the amount involved was <ix:nonFraction unitRef="eur" contextRef="c-141" decimals="0" name="ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" format="ixt:fixed-zero" scale="0" id="f-769">immaterial</ix:nonFraction></span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition is reflected in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for&#160;using the equity method</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows, and represents a net cash outflow of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-770">1,410</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-33</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_619"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-747-4" continuedAt="f-747-5"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.2. Principal changes in the scope of consolidation in 2022 and 2021</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.2.1. Principal changes in the scope of consolidation in 2022</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Amunix Pharmaceuticals, Inc.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;8, 2022, Sanofi acquired the entire share capital of the immuno-oncology company Amunix Pharmaceuticals, Inc. (Amunix), thereby gaining access to Amunix&#8217;s innovative PRO-XTEN technology and a promising pipeline of immunotherapies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition price of Amunix comprises a fixed cash payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:CashTransferred" format="ixt:num-dot-decimal" scale="6" id="f-771">970</ix:nonFraction>&#160;million, plus contingent consideration in the form of milestone payments based on attainment of certain future development objectives of up to $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="sny:CommitmentsRelatedToMilestonePaymentsBusinessCombinations" format="ixt:num-dot-decimal" scale="6" id="f-772">225</ix:nonFraction>&#160;million, the fair value of which as of the acquisition date was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-773">156</ix:nonFraction>&#160;million. In accordance with IFRS&#160;3, this contingent purchase consideration was recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and non-controlling interests </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see Note&#160;D.18.).</span></div><ix:continuation id="f-757-1" continuedAt="f-757-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation led to the recognition of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-774">609</ix:nonFraction>&#160;million of goodwill, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:72.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.394%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" scale="6" id="f-775">493</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" sign="-" name="sny:OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate" scale="6" id="f-776">13</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" scale="6" id="f-777">118</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" scale="6" id="f-778">81</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Amunix</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" scale="6" id="f-779">517</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" scale="6" id="f-780">609</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-6" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-781">1,126</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Other intangible assets&#8221; comprise PRO-XTEN, an innovative universal protease-releasable masking technology platform for the discovery and development of transformative cytokine therapies and T-cell engager (TCE) immunotherapies for patients with cancer. In 2023, an impairment loss was taken against the PRO-XTEN platform, in line with a strategic decision to de-prioritize  certain R&amp;D programs (see Note&#160;D.5., "Impairment of intangible assets and property, plant and equipment&#8217;).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill mainly represents the value of Amunix&#8217;s upstream research and development pipeline of immuno-oncology therapies based on next-generation conditionally activated biologics, especially when combined with Sanofi&#8217;s existing oncology portfolio.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The goodwill generated on this acquisition does not give rise to any deduction for income tax purposes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amunix has no commercial operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a cash outflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-143" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-782">852</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">EUROAPI - Loss of control and accounting implications</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March&#160;17, 2022, the Sanofi Board of Directors approved a decision to put to a shareholder vote the proposed distribution in&#160;kind of approximately <ix:nonFraction unitRef="number" contextRef="c-144" decimals="2" name="sny:ExceptionalSupplementaryDividendProposedPercentageOfShareCapital" scale="4" id="f-783">58</ix:nonFraction>% of the share capital of EUROAPI, thereby confirming Sanofi&#8217;s commitment (announced in February&#160;2020) to discontinue its active pharmaceutical ingredient operations. As part of the same corporate action and on the same date, Sanofi entered into an investment agreement with EPIC Bpifrance, which undertook to acquire from Sanofi &#8211; via the French Tech Souverainet&#233; fund &#8211; a <ix:nonFraction unitRef="number" contextRef="c-145" decimals="2" name="sny:PercentageOfVotingEquityInterestsDivested" scale="4" id="f-784">12</ix:nonFraction>% equity interest in EUROAPI at a price not exceeding &#8364;<ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-6" name="sny:ConsiderationTransferredMaximumAmount" scale="6" id="f-785">150</ix:nonFraction>&#160;million and to be determined on the basis of the volume weighted average price (VWAP) of EUROAPI shares on the Euronext Paris regulated market over the&#160;<ix:nonNumeric contextRef="c-146" name="sny:ConsiderationTransferredValuationPeriod" format="ixt-sec:durwordsen" id="f-786">thirty-day</ix:nonNumeric> period starting from the date of initial listing, i.e. May&#160;6, 2022. On completion of those transactions, Sanofi holds an equity interest of <ix:nonFraction unitRef="number" contextRef="c-147" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-787">30.1</ix:nonFraction>% in EUROAPI, which it has undertaken to retain for at least <ix:nonNumeric contextRef="c-148" name="sny:OwnershipInterestInSubsidiaryMinimumHoldingPeriod" format="ixt-sec:durwordsen" id="f-788">two years</ix:nonNumeric> from the date of the distribution, subject to the customary exceptions. With effect from that date, Sanofi exercises significant influence over EUROAPI as a result of (i)&#160;its equity interest, and (ii)&#160;having one representative on the EUROAPI Board of Directors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;3, 2022, the General Meeting of Sanofi shareholders approved the decision of the Board of Directors to distribute approximately <ix:nonFraction unitRef="number" contextRef="c-149" decimals="2" name="sny:ExceptionalSupplementaryDividendPercentageOfShareCapital" scale="-2" id="f-789">58</ix:nonFraction>% of the share capital of EUROAPI in the form of an exceptional dividend in kind.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;10, 2022, the payment date of the dividend in kind in the days following the admission to listing of EUROAPI shares, those Sanofi shareholders who had retained their Sanofi shares received <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="sny:SpecialDistributionSharesReceivedPerConversionOfParentShares" scale="0" id="f-790">1</ix:nonFraction>&#160;EUROAPI share per <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="sny:SpecialDistributionNumberOfSharesConverted" scale="0" id="f-791">23</ix:nonFraction>&#160;Sanofi shares, representing in total&#160;<ix:nonFraction unitRef="number" contextRef="c-150" decimals="4" name="sny:SpecialDistributionPercentageOfShareCapitalDistributed" scale="-2" id="f-792">57.88</ix:nonFraction>% of the share capital of EUROAPI. As of that date, Sanofi lost control over the EUROAPI entities, based on an assessment of the criteria specified in IFRS&#160;10 (Consolidated financial statements). The assets and liabilities of EUROAPI, which since March&#160;17, 2022 had been presented as assets and liabilities held for sale within the Sanofi statement of financial position in accordance with IFRS&#160;5 (Non-Current Assets Held for Sale), were deconsolidated. In addition, because EUROAPI operations do not constitute a discontinued operation under IFRS&#160;5, the contribution from EUROAPI has not been presented within separate line items in the income statement and statement of cash flows or in information for prior comparative periods. The contribution of EUROAPI operations to the consolidated net sales of Sanofi in the year ended December&#160;31, 2021 was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-793">486</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-747-5" continuedAt="f-747-6"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal consequences of the deconsolidation of EUROAPI are described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the derecognition of the carrying amount of all the assets and liabilities of EUROAPI, representing a net amount of&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-6" name="sny:DecreaseThroughLossOfControlOfSubsidiaryNetAssets" format="ixt:num-dot-decimal" scale="6" id="f-794">1,227</ix:nonFraction>&#160;million as of May&#160;10, 2022. This includes goodwill of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-6" name="ifrs-full:DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill" scale="6" id="f-795">164</ix:nonFraction>&#160;million, determined in accordance with IAS&#160;36 (&#8220;Impairment of Assets&#8221;), which was historically allocated to the Pharmaceuticals cash generating unit (CGU), and which for the purposes of the deconsolidation was allocated using an alternative method based on the relative values of goodwill as of the date of consolidation (the &#8220;notional goodwill method&#8221;). That method was considered more appropriate to the capital-intensive nature of EUROAPI operations than the method based on the relative values of EUROAPI operations and the retained portion of the&#160;CGU;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a reduction in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Equity attributable to equity holders </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reflecting the distribution in kind, measured at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-6" name="sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" scale="6" id="f-796">793</ix:nonFraction>&#160;million based on the weighted average price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-40" decimals="2" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="f-797">14.58</ix:nonFraction> per share as of the date of delivery of the EUROAPI shares to Sanofi shareholders and corresponding to the fair value of the distribution in accordance with IFRIC&#160;17 (Distribution of Non-Cash Assets to Owners);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a cash inflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-6" name="sny:ConsiderationTransferredMaximumAmount" scale="6" id="f-798">150</ix:nonFraction>&#160;million from the divestment of <ix:nonFraction unitRef="number" contextRef="c-153" decimals="2" name="sny:PercentageOfVotingEquityInterestsDivested" scale="4" id="f-799">12</ix:nonFraction>% of the share capital of EUROAPI to EPIC Bpifrance as of the settlement date of the shares, i.e. June&#160;17, 2022;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the recognition in the statement of financial position, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, of the retained <ix:nonFraction unitRef="number" contextRef="c-147" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-800">30.1</ix:nonFraction>% equity interest in EUROAPI at an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-154" decimals="-6" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="f-801">413</ix:nonFraction>&#160;million, determined on the basis of the weighted average price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-40" decimals="2" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="f-802">14.58</ix:nonFraction> per share and representing the fair value of the equity interest in accordance with IFRS&#160;10;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the reclassification within the net gain/loss on deconsolidation of unrealized foreign exchange losses amounting to&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-6" name="ifrs-full:NetForeignExchangeLoss" scale="6" id="f-803">35</ix:nonFraction>&#160;million arising on EUROAPI subsidiaries, in accordance with IAS&#160;21 (The Effects of Changes in Foreign Exchange Rates);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the recognition of transaction-related costs and of the effects of undertakings made under agreements entered into with&#160;EUROAPI setting out the principles and terms of the legal reorganization carried out ahead of the date of deconsolidation. The principal undertakings made to EUROAPI relate to compensation for:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">environmental remediation obligations on non-operational chemical sites in France transferred to EUROAPI, amounting to&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-6" name="ifrs-full:OtherProvisions" scale="6" id="f-804">14</ix:nonFraction> million, and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">regulatory compliance costs relating to certain state-of-the-art active pharmaceutical ingredients of EUROAPI, capped at&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-156" decimals="-6" name="ifrs-full:OtherProvisions" scale="6" id="f-805">15</ix:nonFraction> million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These elements collectively resulted in a pre-tax loss on deconsolidation of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-6" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-806">3</ix:nonFraction>&#160;million, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement. The tax effect of the deconsolidation was a net gain of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-6" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-807">111</ix:nonFraction>&#160;million, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cash impact of the deconsolidation of EUROAPI, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Disposals of consolidated undertakings and investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the statement of cash flows, was a net cash inflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-6" name="ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-808">101</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has entered into an agreement with EUROAPI for the manufacture and supply of active pharmaceutical ingredients, intermediates and other substances, which took effect on October&#160;1, 2021 and expires <ix:nonNumeric contextRef="c-157" name="sny:CollaborationAgreementPeriodAfterLossOfControl" format="ixt-sec:durwordsen" id="f-809">five years</ix:nonNumeric> after the loss of control. Under the terms of the agreement, Sanofi committed to target annual net sales of approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-6" name="sny:CollaborationAgreementAnnualNetSalesTarget" scale="6" id="f-810">300</ix:nonFraction>&#160;million for a list of specified active ingredients until the agreement expires in 2026. As of December&#160;31, 2022, that commitment amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-159" decimals="-8" name="sny:CollaborationAgreementCommitmentAmount" scale="9" id="f-811">1.1</ix:nonFraction>&#160;billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of the date of deconsolidation, the <ix:nonFraction unitRef="number" contextRef="c-147" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-812">30.1</ix:nonFraction>% equity interest in EUROAPI is accounted for using the equity method in accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), and the share of EUROAPI profits or losses arising from application of the equity method is excluded from &#8220;Business operating income&#8221;, the non-IFRS financial indicator used internally by&#160;Sanofi to measure the performance of its operating segments.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.2.2. Principal changes in the scope of consolidation in 2021</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Kymab</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April&#160;8, 2021, Sanofi acquired the entire share capital of Kymab for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-8" name="ifrs-full:CashTransferred" format="ixt:num-dot-decimal" scale="9" id="f-813">1.1</ix:nonFraction> billion (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-160" decimals="-6" name="ifrs-full:CashTransferred" format="ixt:num-dot-decimal" scale="6" id="f-814">973</ix:nonFraction> million) and up to&#160;$<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-815">350</ix:nonFraction> million contingent upon reaching certain development milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the KY1005 project, currently in Phase&#160;2 clinical development, and relating to the human monoclonal antibody OX40L, an essential regulator of the immune system) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-160" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-816">965</ix:nonFraction> million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-161" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-817">932</ix:nonFraction> million.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-747-6" continuedAt="f-747-7"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Kiadis</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November&#160;2, 2020, Sanofi and Kiadis, a biopharmaceutical company developing novel "off-the-shelf" natural killer (NK) cell therapies for patients with life-threatening diseases, entered into a definitive agreement whereby Sanofi was to make a public offer to acquire the entire share capital of Kiadis, i.e. <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="-6" name="sny:BusinessCombinationNumberOfSharesIncludedInPublicOffering" format="ixt:num-dot-decimal" scale="6" id="f-818">61</ix:nonFraction>&#160;million shares, at a cash price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-162" decimals="2" name="sny:BusinessCombinationPurchasePricePerShare" scale="0" id="f-819">5.45</ix:nonFraction> per share.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition was approved unanimously by the Boards of Directors of Sanofi and Kiadis, and <ix:nonFraction unitRef="number" contextRef="c-163" decimals="4" name="sny:BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering" scale="-2" id="f-820">95.03</ix:nonFraction>% of the share capital of Kiadis had been tendered into the offer as of April&#160;16, 2021. As of the end of the post-closing acceptance period on April&#160;29, 2021, Sanofi held&#160;<ix:nonFraction unitRef="number" contextRef="c-164" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-821">97.39</ix:nonFraction>% of the share capital of Kiadis, and proceeded to buy out the remaining non-controlling shareholders. As of&#160;December&#160;31, 2022, Sanofi held <ix:nonFraction unitRef="number" contextRef="c-165" decimals="4" name="sny:BusinessAcquisitionsPercentageOfVotingInterestsAcquired" scale="-2" id="f-822">100.00</ix:nonFraction>% of the share capital of Kiadis.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the K-NK technology platform) concentrates substantially all of the fair value of the acquired set of activities and assets. In 2023, an impairment loss was recognized against the K-NK technology platform to reflect the impact of the strategic decision to de-prioritize certain R&amp;D programs (see Note&#160;D.5., "Impairment of intangible assets and property, plant and equipment").</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-166" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-823">339</ix:nonFraction> million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-167" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-824">326</ix:nonFraction> million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Tidal</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April&#160;9, 2021, Sanofi acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a unique mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofi&#8217;s research capabilities in immuno-oncology and inflammatory diseases, and may have applicability to other disease areas as well.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Tidal Therapeutics was acquired for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="ifrs-full:CashTransferred" format="ixt:num-dot-decimal" scale="6" id="f-825">160</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-168" decimals="-6" name="ifrs-full:CashTransferred" format="ixt:num-dot-decimal" scale="6" id="f-826">136</ix:nonFraction>&#160;million), and up to $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-827">310</ix:nonFraction>&#160;million contingent upon reaching certain development milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the unique mRNA-based in vivo reprogramming technology) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-168" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-828">130</ix:nonFraction>&#160;million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-169" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-829">135</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Translate Bio</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August&#160;3, 2021, Sanofi entered into a definitive agreement with Translate Bio, a clinical-stage mRNA therapeutics company, under which Sanofi was to acquire all outstanding shares of Translate Bio for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-170" decimals="2" name="sny:BusinessCombinationPurchasePricePerShare" scale="-2" id="f-830">38</ix:nonFraction> per share. The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of Translate Bio by Sanofi was completed on September&#160;14, 2021, with Sanofi holding the entire share capital of Translate&#160;Bio upon expiration of the squeeze-out procedure.</span></div><ix:continuation id="f-757-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation, as presented in the table below, led to the recognition of goodwill of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-831">2,118</ix:nonFraction>&#160;million:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:72.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.394%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" scale="6" id="f-832">396</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" scale="6" id="f-833">93</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="sny:OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate" scale="6" id="f-834">235</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" scale="6" id="f-835">247</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shire contingent consideration liability (see Note&#160;D.18.)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate" scale="6" id="f-836">323</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Translate Bio</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" scale="6" id="f-837">462</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-838">2,118</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-839">2,580</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The other intangible assets mainly comprise a messenger RNA technological platform applied to the development of vaccines and therapeutic agents.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill mainly represents the effects of expected future synergies and other benefits to be derived from the integration of Translate Bio into the Sanofi group, in particular by accelerating the delivery of development programs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The goodwill generated on this acquisition did not give rise to any deduction for income tax purposes.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-747-7"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Translate Bio has no commercial operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-172" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-840">2,333</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the collaboration agreement between Sanofi and Translate Bio as announced on June&#160;23, 2020, Sanofi held an equity interest of approximately <ix:nonFraction unitRef="number" contextRef="c-173" decimals="2" name="sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" scale="-2" id="f-841">5</ix:nonFraction>% in Translate Bio. As of the date when Sanofi obtained control of Translate Bio, that interest was remeasured at the purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-171" decimals="2" name="sny:BusinessCombinationPurchasePricePerShare" scale="-2" id="f-842">38</ix:nonFraction> per share. The change in fair value was recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, in accordance</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">with paragraph&#160;42 of IFRS&#160;3 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see Note&#160;D.7.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Kadmon</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;8, 2021, Sanofi entered into a definitive merger agreement with Kadmon, a biopharmaceutical company that discovers, develops and markets transformative therapies for disease areas with significant unmet medical needs. Shareholders of Kadmon common stock received $<ix:nonFraction unitRef="usdPerShare" contextRef="c-174" decimals="INF" name="sny:BusinessCombinationPurchasePricePerShare" scale="0" id="f-843">9.50</ix:nonFraction> per share in cash, representing a transaction valued at $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-8" name="sny:BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis" format="ixt:num-dot-decimal" scale="9" id="f-844">1.9</ix:nonFraction>&#160;billion on a fully-diluted basis. The Sanofi and Kadmon Boards of Directors unanimously approved the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of Kadmon by Sanofi was completed on November&#160;9, 2021, with Sanofi holding the entire share capital of Kadmon upon expiration of the squeeze-out procedure.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was therefore accounted for as an asset acquisition given that the principal asset (belumosudil, commercialized in the United States under the brand name REZUROCK) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-174" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-845">1,739</ix:nonFraction>&#160;million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the consolidated statement of cash flows is a net cash outflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-175" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-846">1,575</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Origimm</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;3, 2021, Sanofi acquired the entire share capital of Origimm Biotechnology GmbH, a privately owned Austrian biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria that cause skin diseases such as acne, for an upfront payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-176" decimals="-6" name="ifrs-full:CashTransferred" format="ixt:num-dot-decimal" scale="6" id="f-847">55</ix:nonFraction>&#160;million and up to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-176" decimals="-6" name="sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-848">95</ix:nonFraction>&#160;million contingent upon reaching certain development and regulatory milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was therefore accounted for as an asset acquisition given that the principal asset (the group of Propionibacterium acnes antigens) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Nearly &#8364;<ix:nonFraction unitRef="eur" contextRef="c-176" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-849">55</ix:nonFraction>&#160;million of the acquisition price paid was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the consolidated statement of cash flows for the year ended December&#160;31, 2021 is a net cash outflow of&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-177" decimals="-6" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-850">50</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:9pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-37</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_622"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.3. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-851" continuedAt="f-851-1" escape="true">Property, plant and equipment</ix:nonNumeric></span></div><ix:continuation id="f-851-1" continuedAt="f-851-2"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.1. Property, plant and equipment owned</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock" id="f-852" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment owned by Sanofi is comprised of the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Buildings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Machinery<br/>and<br/>equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fixtures,<br/>fittings&#160;and<br/>other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property,&#160;plant<br/>and&#160;equipment<br/>in process</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-178" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-853">236</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-179" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-854">6,828</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-180" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-855">11,127</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-181" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-856">2,524</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-182" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-857">2,454</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-183" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-858">23,169</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-184" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-859">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-860">11</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-186" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-861">15</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-862">2</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-863">2</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-864">30</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-184" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-865">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-866">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-186" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-867">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-868">39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-869">1,404</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-870">1,504</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-184" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-871">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-872">75</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-186" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-873">153</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-874">80</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-875">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-876">314</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-184" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-877">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-878">169</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-186" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-879">155</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-880">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-881">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-882">443</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-184" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-883">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-884">227</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-186" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-885">453</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-886">136</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-887">839</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-888">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-190" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-889">240</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-191" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-890">7,170</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-192" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-891">11,648</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-193" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-892">2,655</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-194" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-893">3,097</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-894">24,810</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-196" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-895">17</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-197" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-896">294</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-198" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-897">1,480</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-199" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-898">163</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-200" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-899">150</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-900">2,104</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-196" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-901">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-197" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-902">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-198" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-903">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-199" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-904">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-200" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-905">1,642</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-906">1,748</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-196" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-907">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-197" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-908">161</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-198" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-909">240</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-199" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-910">155</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-200" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-911">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-912">559</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-196" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-913">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-197" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-914">122</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-198" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-915">144</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-199" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-916">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-200" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-917">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-918">347</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-196" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-919">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-197" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-920">480</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-198" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-921">722</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-199" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-922">108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-200" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-923">1,626</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-924">318</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-202" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-925">237</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-203" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-926">7,328</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-927">10,848</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-928">2,515</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-929">2,996</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-930">23,924</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-932">11</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-933">29</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-934">7</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-935">4</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-936">51</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-938">27</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-939">47</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-940">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-941">1,583</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-942">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-943">2</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-944">50</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-945">340</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-946">100</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-947">10</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-948">502</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-949">5</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-950">94</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-951">71</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-952">30</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-953">45</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-954">245</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-955">2</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-956">481</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-957">457</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-958">86</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-959">1,071</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-960">49</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-961">228</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-962">7,681</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-963">10,912</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-964">2,500</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-965">3,449</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-966">24,770</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-967">10</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-968">3,898</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-969">7,792</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-970">1,981</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-971">123</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-972">13,804</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:DepreciationExpense" format="ixt:fixed-zero" scale="6" id="f-973">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:DepreciationExpense" scale="6" id="f-974">306</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" name="ifrs-full:DepreciationExpense" scale="6" id="f-975">592</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-6" name="ifrs-full:DepreciationExpense" scale="6" id="f-976">167</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" name="ifrs-full:DepreciationExpense" format="ixt:fixed-zero" scale="6" id="f-977">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="ifrs-full:DepreciationExpense" format="ixt:num-dot-decimal" scale="6" id="f-978">1,065</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-979">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-980">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-981">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-982">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-983">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-984">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-985">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-986">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-987">149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-988">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-989">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-990">299</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-991">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-992">80</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-993">99</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-994">29</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-995">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-996">208</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-997">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-998">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-999">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1000">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1001">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1002">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-232" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1003">9</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-233" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1004">4,190</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1005">8,340</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1006">2,115</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-236" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1007">128</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1008">14,782</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1009">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1010">201</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1011">1,202</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1012">130</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1013">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1014">1,533</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-6" name="ifrs-full:DepreciationExpense" format="ixt:fixed-zero" scale="6" id="f-1015">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-6" name="ifrs-full:DepreciationExpense" scale="6" id="f-1016">356</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-6" name="ifrs-full:DepreciationExpense" scale="6" id="f-1017">622</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-6" name="ifrs-full:DepreciationExpense" scale="6" id="f-1018">164</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-6" name="ifrs-full:DepreciationExpense" format="ixt:fixed-zero" scale="6" id="f-1019">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="ifrs-full:DepreciationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1020">1,142</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-1021">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-1022">50</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-1023">58</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-1024">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-1025">75</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-1026">186</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1027">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-1028">133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-1029">201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-1030">153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-1031">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-1032">518</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1033">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1034">52</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1035">69</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1036">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1037">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1038">138</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1039">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1040">89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1041">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1042">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1043">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1044">142</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-244" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1045">10</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-245" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1046">4,225</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1047">7,637</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-247" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1048">2,015</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-248" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1049">168</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-249" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1050">14,055</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1051">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1052">5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1053">16</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1054">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1055">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1056">24</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-6" name="ifrs-full:DepreciationExpense" format="ixt:fixed-zero" scale="6" id="f-1057">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-6" name="ifrs-full:DepreciationExpense" scale="6" id="f-1058">321</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-6" name="ifrs-full:DepreciationExpense" scale="6" id="f-1059">620</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-6" name="ifrs-full:DepreciationExpense" scale="6" id="f-1060">139</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-6" name="ifrs-full:DepreciationExpense" format="ixt:fixed-zero" scale="6" id="f-1061">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="ifrs-full:DepreciationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1062">1,080</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1063">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-1064">30</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-1065">46</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-1066">4</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-1067">50</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment" scale="6" id="f-1068">130</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-6" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-1070">48</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-1071">334</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-1072">98</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-1073">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" scale="6" id="f-1074">488</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1075">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1076">45</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1077">44</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1078">21</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1080">112</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1081">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1082">22</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1083">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1084">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1085">18</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" scale="6" id="f-1086">31</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-256" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1087">8</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-257" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1088">4,500</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-258" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1089">7,873</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-259" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1090">2,037</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1091">192</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-6" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1092">14,610</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-262" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1093">231</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-263" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1094">2,980</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-264" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1095">3,308</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-265" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1096">540</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-266" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1097">2,969</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1098">10,028</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-267" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1099">227</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-268" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1100">3,103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-269" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1101">3,211</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-270" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1102">500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-271" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1103">2,828</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1104">9,869</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-272" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1105">220</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-273" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1106">3,181</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-274" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1107">3,039</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-275" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1108">463</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-276" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1109">3,257</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1110">10,160</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line includes in particular property, plant and equipment in process brought into service during the period, but also the effect of the reclassification of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-851-2" continuedAt="f-851-3"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" id="f-1111" escape="true"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:57.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1112">1,693</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1113">1,748</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1114">1,504</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biopharma</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1115">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1116">1,678</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-279" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1117">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-280" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1118">1,129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1119">1,010</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vaccines</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1120">421</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consumer Healthcare</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1121">101</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1122">70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1123">73</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-286" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1124">90</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-287" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1125">63</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestCostsCapitalised" scale="6" id="f-1126">26</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:InterestCostsCapitalised" scale="6" id="f-1127">17</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:InterestCostsCapitalised" scale="6" id="f-1128">14</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take into account of the two new operating segments, Biopharma and Consumer Healthcare, effective January&#160;1,&#160;2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock" id="f-1129" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments relating to property, plant and equipment as of December 31, 2023, 2022 and 2021 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Firm orders of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:FirmOrdersOfPropertyPlantAndEquipment" scale="6" id="f-1130">638</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:FirmOrdersOfPropertyPlantAndEquipment" scale="6" id="f-1131">861</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:FirmOrdersOfPropertyPlantAndEquipment" scale="6" id="f-1132">769</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment pledged as security for liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity" scale="6" id="f-1133">16</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity" format="ixt:fixed-zero" scale="6" id="f-1134">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity" scale="6" id="f-1135">9</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock" id="f-1136" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the net impairment losses recognized in each of the last three financial periods:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net impairment losses on property, plant and equipment</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="6" id="f-1137">130</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="6" id="f-1138">186</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="6" id="f-1139">39</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts mainly comprise impairment losses recognized as a result of decisions taken during the periods presented, relating primarily to shutdowns or changes in use of industrial sites.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-39</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-851-3"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.2. Property, plant and equipment leased &#8211; right-of-use assets</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="f-1140" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Right-of-use assets relating to property, plant and equipment leased by Sanofi are analyzed in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:82.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Right-of-use assets</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-183" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1141">1,711</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="sny:AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1142">93</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="sny:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets" scale="6" id="f-1143">963</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1144">91</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" scale="6" id="f-1145">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1146">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1147">2,745</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" sign="-" name="sny:AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1148">26</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="sny:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets" scale="6" id="f-1149">292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1150">232</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" scale="6" id="f-1151">101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1152">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1153">2,872</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="sny:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets" scale="6" id="f-1154">247</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1155">314</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" scale="6" id="f-1156">58</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1157">75</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1158">2,672</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" sign="-" name="ifrs-full:RightofuseAssets" scale="6" id="f-1159">513</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-1160">315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" sign="-" name="sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1161">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" scale="6" id="f-1162">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1163">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-6" sign="-" name="ifrs-full:RightofuseAssets" scale="6" id="f-1164">797</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="sny:AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1165">14</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-1166">341</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" sign="-" name="sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1167">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" scale="6" id="f-1168">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1169">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-249" decimals="-6" sign="-" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1170">1,057</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-1171">292</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" sign="-" name="sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1172">276</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" scale="6" id="f-1173">21</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" scale="6" id="f-1174">34</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-6" sign="-" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1175">1,018</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1176">1,948</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1177">1,815</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1178">1,654</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line also includes the effect of the reclassification of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In December&#160;2018, Sanofi signed <ix:nonFraction unitRef="lease" contextRef="c-288" decimals="INF" name="sny:NumberOfLeaseAgreementsSigned" format="ixt-sec:numwordsen" scale="0" id="f-1179">two</ix:nonFraction> leases on real estate assets in the United States (at Cambridge, Massachusetts) for an initial lease term of <ix:nonNumeric contextRef="c-288" name="sny:InitialLeaseTerm" format="ixt-sec:duryear" id="f-1180">15</ix:nonNumeric> years. The first lease, relating to office space, began in April&#160;2021; Sanofi recognized a right-of-use asset of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1181"><ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1182">320</ix:nonFraction></ix:nonFraction> million, as well as the lease liability. The second lease, relating to laboratory facilities, began on July&#160;1, 2021; Sanofi recognized a right-of-use asset of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-290" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1183"><ix:nonFraction unitRef="eur" contextRef="c-290" decimals="-6" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-1184">424</ix:nonFraction></ix:nonFraction> million, as well as the lease liability.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leased assets comprised offices and industrial premises (<ix:nonFraction unitRef="number" contextRef="c-291" decimals="2" name="sny:LeasedAssetsPercentage" scale="-2" id="f-1185">90</ix:nonFraction>%) and the vehicle fleet (<ix:nonFraction unitRef="number" contextRef="c-292" decimals="2" name="sny:LeasedAssetsPercentage" scale="-2" id="f-1186">10</ix:nonFraction>%) as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Annual lease costs on short term leases and low value asset leases amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" format="ixt:num-dot-decimal" scale="6" id="f-1187">19</ix:nonFraction> million in the year ended December 31, 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" format="ixt:num-dot-decimal" scale="6" id="f-1188">26</ix:nonFraction> million in the year ended December 31, 2022, and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" format="ixt:num-dot-decimal" scale="6" id="f-1189">25</ix:nonFraction> million in the year ended December 31, 2021. Variable lease payments, sub-leasing activities, and sale-and-leaseback transactions were immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total cash outflows on leases (excluding annual lease costs on short term leases and low value asset leases) were &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="6" id="f-1190">315</ix:nonFraction> million in&#160;the year ended December 31, 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="6" id="f-1191">389</ix:nonFraction> million in the year ended December 31, 2022, and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="6" id="f-1192">302</ix:nonFraction> million in the year ended&#160;December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A maturity analysis of the lease liability is disclosed in Note&#160;D.17.2.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Commitments related to short-term leases and low value asset leases, including future payments for lease contracts committed but not yet commenced, are disclosed in Note&#160;D.21.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_625"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.4. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory" id="f-1193" continuedAt="f-1193-1" escape="true">Goodwill and other intangible assets</ix:nonNumeric></span></div><ix:continuation id="f-1193-1" continuedAt="f-1193-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory" id="f-1194" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in goodwill comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:82.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-293" decimals="-6" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1195">44,364</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-294" decimals="-6" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1196">2,179</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-294" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill" scale="6" id="f-1197">89</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-294" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1198">1,602</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-295" decimals="-6" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1199">48,056</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-6" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" scale="6" id="f-1200">609</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill" scale="6" id="f-1201">258</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1202">1,485</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-6" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1203">49,892</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-298" decimals="-6" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" scale="6" id="f-1204">475</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-298" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill" scale="6" id="f-1205">90</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-298" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="6" id="f-1206">873</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-299" decimals="-6" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1207">49,404</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph&#160;86 of IAS&#160;36, and in 2022 the loss of control of EUROAPI (see note&#160;D.2.1.).</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><br/>In accordance with IAS&#160;36, goodwill is allocated to groups of Cash Generating Units (CGUs) at a level corresponding to the Biopharma and Consumer Healthcare segments. When testing goodwill annually for impairment, the recoverable amount is determined for each of the <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="sny:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-1208">two</ix:nonFraction> segments (Biopharma and Consumer Healthcare) on the basis of value in use, as derived from discounted estimates of the future cash flows in accordance with the policies described in Note&#160;B.6.1.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock" id="f-1209" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The allocation of goodwill by segment as of December 31, 2023 is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.361%"><tr><td style="width:1.0%"/><td style="width:55.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.078%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer Healthcare</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></div></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-300" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1210">42,324</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-301" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1211">7,080</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1212">49,404</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of QRIB Intermediate Holdings, LLC (2023)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation for QRIB Intermediate Holdings, LLC resulted in the recognition of intangible assets (other than goodwill) o</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">f &#8364;<ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" scale="6" id="f-1213">774</ix:nonFraction> million as of the acquisition d</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ate (September&#160;29, 2023), a</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">nd of goodwill provisionally measured at&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-6" name="ifrs-full:Goodwill" scale="6" id="f-1214">475</ix:nonFraction> million as of the acquisition date (see Note&#160;D.1.).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Amunix Pharmaceuticals,&#160;Inc. (2022)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation for Amunix Pharmaceuticals, Inc. resulted in the recognition of intangible assets (other than goodwill) o</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">f&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-302" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" scale="6" id="f-1215">493</ix:nonFraction>&#160;million as of the acquisition date (February&#160;8, 2022), and of goodwill measured at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-302" decimals="-6" name="ifrs-full:Goodwill" scale="6" id="f-1216">609</ix:nonFraction>&#160;million as of the acquisition date (see Note&#160;D.2.1.).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Translate Bio (2021)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation for Translate&#160;Bio resulted in the recognition of intangible a</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ssets (other than goodwill) of&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" scale="6" id="f-1217">396</ix:nonFraction>&#160;million as of the acquisition date (September&#160;14, 2021), and of goodwill measured at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1218">2,118</ix:nonFraction>&#160;million as of the</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> acquisition date (see Note&#160;D.2.2.).</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-41</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" id="f-1219" escape="true"><ix:continuation id="f-1193-2" continuedAt="f-1193-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets comprise:</span></div><div style="margin-bottom:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:53.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Products,<br/>trademarks and<br/>other rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other<br/>intangible assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-303" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1220">9,600</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-304" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1221">61,074</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-305" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1222">1,633</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-183" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1223">72,307</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1224">1,805</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-307" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1225">1,821</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-1226">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1227">3,626</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1228">339</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-307" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1229">159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1230">118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1231">616</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1232">313</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-307" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1233">173</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1234">16</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1235">502</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1236">560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-307" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1237">2,234</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1238">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1239">2,818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1240">784</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-307" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1241">791</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1242">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1243">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-309" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1244">11,207</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1245">65,906</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-311" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1246">1,752</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1247">78,865</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-1248">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" scale="6" id="f-1249">499</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-314" decimals="-6" sign="-" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" scale="6" id="f-1250">35</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" scale="6" id="f-1251">464</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1252">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1253">195</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-314" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1254">99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1255">571</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1256">72</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1257">423</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-314" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1258">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1259">543</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1260">518</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1261">1,994</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-314" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1262">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1263">2,533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1264">1,576</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1265">1,408</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-314" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1266">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1267">174</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-315" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1268">10,354</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-316" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1269">69,579</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1270">1,783</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1271">81,716</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" scale="6" id="f-1272">113</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1273">3,287</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" scale="6" id="f-1274">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1275">3,401</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1276">1,062</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1277">1,970</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1278">80</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1279">3,112</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1280">262</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1281">380</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1282">41</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1283">683</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1284">242</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1285">1,584</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1286">11</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1287">1,837</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1288">1,253</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1289">861</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1290">4</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1291">396</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-321" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1292">9,772</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-322" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1293">73,733</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-323" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1294">1,808</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1295">85,313</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at January 1, 2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-324" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1296">3,508</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-325" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1297">49,345</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-326" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1298">1,113</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1299">53,966</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-327" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1300">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-328" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1301">1,621</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1302">119</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1303">1,740</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-327" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1304">150</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-328" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1305">42</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1306">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1307">192</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-327" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1308">313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-328" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1309">133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1310">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1311">462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-327" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1312">132</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-328" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1313">1,869</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1314">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1315">2,022</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at December 31, 2021</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-330" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1316">3,477</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-331" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1317">52,744</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1318">1,237</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1319">57,458</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-1320">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-1321">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" scale="6" id="f-1322">11</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" scale="6" id="f-1323">11</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1324">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1325">2,099</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1326">97</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1327">2,196</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1328">1,107</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1329">1,561</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1330">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" sign="-" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1331">454</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1332">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1333">411</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1334">39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1335">525</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1336">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1337">1,567</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1338">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1339">1,591</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1340">388</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1341">214</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1342">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1343">179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at December 31, 2022</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-336" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1344">4,128</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-337" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1345">54,652</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-338" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1346">1,296</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-249" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1347">60,076</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-1348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" scale="6" id="f-1349">33</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-1350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" scale="6" id="f-1351">33</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1353">2,225</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1354">120</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1355">2,345</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1356">90</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1357">842</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1359">932</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1360">262</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1361">326</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1362">41</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" sign="-" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1363">629</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1364">94</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1365">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1366">9</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1367">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1368">128</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1369">268</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1370">14</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1371">410</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-342" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1372">3,734</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-343" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1373">55,908</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-344" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1374">1,352</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-6" sign="-" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1375">60,994</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-345" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1376">7,730</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-346" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1377">13,162</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-347" decimals="-6" name="ifrs-full:OtherIntangibleAssets" scale="6" id="f-1378">515</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1379">21,407</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-348" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1380">6,226</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-349" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1381">14,927</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-350" decimals="-6" name="ifrs-full:OtherIntangibleAssets" scale="6" id="f-1382">487</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1383">21,640</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-351" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1384">6,038</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-352" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1385">17,825</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-353" decimals="-6" name="ifrs-full:OtherIntangibleAssets" scale="6" id="f-1386">456</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1387">24,319</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes the impact of the IFRIC agenda decision of March&#160;2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement (see Note&#160;A.2.1. to our 2021 consolidated financial statements, included in our annual report on Form&#160;20-F for that year).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The &#8220;Transfers&#8221; line mainly comprises (i)&#160;acquired R&amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets as </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The &#8220;Changes in scope of consolidation&#8221; line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Notes&#160;D.1. and&#160;D.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;See Note&#160;D.5.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-354" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1388">226</ix:nonFraction>&#160;million in&#160;2022 (see&#160;Note C.1.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)  This line mainly comprises:</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April&#160;2023 in respect of the agreements on BEYFORTUS (nirsevimab) (see Note&#160;C.2.);</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1389">500</ix:nonFraction>&#160;million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co-commercialization of TEV&#8217;574; and</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1390">175</ix:nonFraction>&#160;million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli.</span></div></ix:continuation></ix:nonNumeric><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-42</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1193-3"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Products, trademarks and other rights&#8221; mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">&#8220;marketed products&#8221;, with a carrying amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-357" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-1391">16.6</ix:nonFraction> billion as of December 31, 2023 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-358" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-1392">12.7</ix:nonFraction> billion as of            December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-1393">11.7</ix:nonFraction> billion as of December 31, 2021) and a weighted average amortization period of approximately <ix:nonNumeric contextRef="c-360" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1394">11</ix:nonNumeric>&#160;years; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">&#8220;technology platforms&#8221;, with a carrying amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-1395">1.2</ix:nonFraction> billion as of December 31, 2023 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-362" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-1396">2.2</ix:nonFraction>&#160;billion as of           December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-363" decimals="-8" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="9" id="f-1397">1.2</ix:nonFraction>&#160;billion as of December 31, 2021) and a weighted average amortization period of approximately <ix:nonNumeric contextRef="c-364" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1398">18</ix:nonNumeric>&#160;years.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfPrincipalMarketedProductsTableTextBlock" id="f-1399" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides information about the principal &#8220;marketed products&#8221;, which were recognized in connection with major acquisitions made by Sanofi and represented <ix:nonFraction unitRef="number" contextRef="c-360" decimals="2" name="sny:ConcentrationRiskThresholdPercentage" scale="-2" id="f-1400">96</ix:nonFraction>% of the carrying amount of that item as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:20.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>amortization&#160;&amp;<br/>impairment</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortization</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">period</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(years)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Residual</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">amortization</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">period</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(years)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-365" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1401">10,279</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-366" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1402">10,071</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-367" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1403">208</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-368" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1404">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-368" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear" id="f-1405">2</ix:nonNumeric></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-369" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1406">621</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-370" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1407">1,032</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Boehringer Ingelheim </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consumer Healthcare</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-371" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1408">3,504</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-372" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1409">1,698</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-373" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1410">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-374" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1411">17</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-374" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear" id="f-1412">11</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-375" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1413">2,037</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-376" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1414">2,213</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-377" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1415">33,043</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-378" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1416">33,000</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-379" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1417">43</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-380" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1418">9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-380" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear" id="f-1419">11</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-381" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1420">58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-382" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1421">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-383" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1422">1,319</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-384" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1423">818</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-385" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1424">501</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-386" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1425">23</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-386" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear" id="f-1426">10</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-387" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1427">574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-388" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1428">593</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Protein Sciences</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-389" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1429">831</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-390" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1430">411</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-391" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1431">420</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-392" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1432">13</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-392" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear" id="f-1433">7</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-393" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1434">498</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-394" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1435">532</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ablynx</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-395" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1436">1,966</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-396" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1437">746</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-397" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1438">1,220</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-398" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1439">14</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-398" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear" id="f-1440">9</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-399" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1441">1,357</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-400" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1442">1,494</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-401" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1443">8,798</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-402" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1444">3,646</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-403" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1445">5,152</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-404" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1446">14</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-404" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear" id="f-1447">9</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-405" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1448">4,836</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-406" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1449">3,065</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">REZUROCK</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-407" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1450">1,907</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-408" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1451">327</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-409" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1452">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-410" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1453">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-410" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear" id="f-1454">10</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-411" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1455">1,702</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-412" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1456">1,750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TZIELD</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-413" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1457">2,546</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-414" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1458">141</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-415" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1459">2,405</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-416" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1460">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-416" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear" id="f-1461">12</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-417" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1462">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-418" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1463">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BEYFORTUS</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-419" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1464">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-420" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1465">76</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1466">1,870</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-422" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1467">18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-422" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear" id="f-1468">17</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1469">180</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1470">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QUNOL</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-425" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1471">741</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-426" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1472">19</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-427" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-1473">722</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-428" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1474">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-428" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear" id="f-1475">9</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-429" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1476">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-430" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1477">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total: principal marketed products</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-431" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1478">66,880</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-432" decimals="-6" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1479">50,953</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-433" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1480">15,927</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-434" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1481">11,863</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-435" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1482">10,752</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Weighted averages. The amortization periods for these products vary between <ix:nonNumeric contextRef="c-436" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1483">1</ix:nonNumeric>&#160;and <ix:nonNumeric contextRef="c-437" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1484">25</ix:nonNumeric>&#160;years.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Weighted averages.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Commercialized products derived from the acquisition of these companies.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal intangible assets brought into service during 2023 were:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ALTUVIIIO (efanesoctocog alfa), which extends protection from bleeds and treats acute hemorrhages in people with hemophilia&#160;A. The asset came into service on the date of marketing approval (February 23, 2023), and has a gross value of&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-6" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1485">1,110</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During 2022, some of the acquired research and development came into commercial use, and started being amortized from the date of marketing approval; the main item involved was ENJAYMO (sutimlimab-jome), a treatment for cold agglutinin disease.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main asset brought into service during 2021 was the Translate Bio mRNA technology platform.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of other intangible assets is recognized in the income statement within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, except for amortization of software and other rights of an industrial or operational nature which is recognized in the relevant classification of expense by function. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock" id="f-1486" continuedAt="f-1486-1" escape="true">An analysis of amortization of software is shown in the table below:</ix:nonNumeric></span></div><ix:continuation id="f-1486-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-1487">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-1488">10</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-1489">18</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-1490">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-1491">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-1492">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1493">100</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1494">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1495">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-1496">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-1497">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:fixed-zero" scale="6" id="f-1498">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1499">120</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1500">97</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-6" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1501">119</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-43</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_628"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.5. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" id="f-1502" continuedAt="f-1502-1" escape="true">Impairment of intangible assets and property, plant and equipment</ix:nonNumeric></span></div><ix:continuation id="f-1502-1" continuedAt="f-1502-2"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When testing goodwill annually for impairment, the recoverable amount is determined for each of the two segments (Biopharma and Consumer Healthcare) on the basis of value in use, as derived from discounted estimates of the future cash flows in accordance with the policies described in Note&#160;B.6.1.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The value in use of each segment was determined by applying an after-tax discount rate to estimated future after-tax cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A separate discount rate is used for each segment to reflect the specific economic conditions of that segment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The rates used for impairment testing in 2023 were <ix:nonFraction unitRef="number" contextRef="c-442" decimals="4" name="sny:ImpairmentTestingPercentage" scale="-2" id="f-1503">7.00</ix:nonFraction>% for the Consumer Healthcare segment and <ix:nonFraction unitRef="number" contextRef="c-443" decimals="4" name="sny:ImpairmentTestingPercentage" scale="-2" id="f-1504">7.25</ix:nonFraction>% for the Biopharma segment; an identical value in use for Sanofi as a whole would be obtained by applying a uniform <ix:nonFraction unitRef="number" contextRef="c-444" decimals="3" name="sny:UniformImpairmentTestingPercentage" scale="-2" id="f-1505">7.2</ix:nonFraction>% rate to <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="sny:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-1506">two</ix:nonFraction> segments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The pre-tax discount rates applied to estimated pre-tax cash flows are calculated by iteration from the previously-determined value in use. Those pre-tax discount rates were <ix:nonFraction unitRef="number" contextRef="c-442" decimals="3" name="sny:PretaxDiscountRateAppliedForGoodwill" scale="-2" id="f-1507">9.3</ix:nonFraction>% for the Consumer Healthcare segment and <ix:nonFraction unitRef="number" contextRef="c-443" decimals="3" name="sny:PretaxDiscountRateAppliedForGoodwill" scale="-2" id="f-1508">10.0</ix:nonFraction>% for the Biopharma segment, and equate to a uniform rate of <ix:nonFraction unitRef="number" contextRef="c-444" decimals="3" name="sny:UniformPreTaxDiscountRates" scale="-2" id="f-1509">9.9</ix:nonFraction>% for Sanofi as a whole.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The assumptions used in testing goodwill for impairment are reviewed annually. Apart from the discount rate, the principal assumptions used in 2023 were as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the perpetual growth rates applied to future cash flows were <ix:nonFraction unitRef="number" contextRef="c-445" decimals="INF" name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" format="ixt:fixed-zero" scale="-2" id="f-1510">zero</ix:nonFraction> for the Biopharma segment, and <ix:nonFraction unitRef="number" contextRef="c-446" decimals="2" name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" scale="-2" id="f-1511">1</ix:nonFraction>% for the Consumer Healthcare segment;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Sanofi also applies assumptions on the probability of success of current research and development projects, and more generally on its ability to renew the product portfolio in the longer term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Value in use (determined as described above) is compared with the carrying amount, and this comparison is then subjected to sensitivity analyses by reference to the principal parameters, including:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">changes in the discount rate;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">changes in the perpetual growth rate; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">fluctuations in operating margin.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No impairment of goodwill would need to be recognized in the event of a reasonably possible change in the assumptions used in&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A value in use calculation for each of the segments would not result in an impairment loss using:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a discount rate up to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="sny:PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss" scale="0" id="f-1512">2.8</ix:nonFraction>&#160;percentage points above the rates actually used; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a perpetual growth rate up to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="sny:PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss" scale="0" id="f-1513">4.9</ix:nonFraction>&#160;percentage points below the rates actually used; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an operating margin up to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="sny:PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss" scale="0" id="f-1514">7.2</ix:nonFraction>&#160;percentage points below the rates actually used.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="INF" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" format="ixt:fixed-zero" scale="0" id="f-1515"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="INF" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" format="ixt:fixed-zero" scale="0" id="f-1516"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="INF" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" format="ixt:fixed-zero" scale="0" id="f-1517">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses were recognized against goodwill in the years ended December 31, 2023, 2022 or 2021.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When there is evidence that an asset may have become impaired, the asset&#8217;s value in use is calculated by applying an after-tax discount rate to the estimated future after-tax cash flows from that asset. For the purposes of impairment testing, the tax cash flows relating to the asset are determined using a notional tax rate incorporating the notional tax benefit that would result from amortizing the asset if its value in use were regarded as its depreciable amount for tax purposes. Applying after-tax discount rates&#160;to after-tax cash flows gives the same values in use as would be obtained by applying pre-tax discount rates to pre-tax cash&#160;flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The after-tax discount rates used in 2023 for impairment testing of other intangible assets in the Biopharma and Consumer Healthcare segments were obtained by adjusting Sanofi&#8217;s weighted average cost of capital to reflect specific country and business risks, giving after-tax discount rates in a range from <ix:nonFraction unitRef="number" contextRef="c-436" decimals="INF" name="sny:AfterTaxDiscountRates" scale="-2" id="f-1518">7.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-437" decimals="INF" name="sny:AfterTaxDiscountRates" scale="-2" id="f-1519">8.25</ix:nonFraction>%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In most instances, there are no market data that would enable fair value less costs to sell to be determined other than by means of developing a similar estimate based on future cash flows. Consequently, recoverable amount is in substance equal to value in use. The estimates used to determine value in use are sensitive to assumptions specific to the nature of the asset and to Sanofi's activities. Apart from the discount rate, the principal assumptions used in 2023 were as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">mid-term and long-term forecasts;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">perpetual growth or attrition rates, when applicable; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">probability of success of current research and development projects.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The assumptions used in testing intangible assets for impairment are reviewed at least annually.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-44</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1502-2"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock" id="f-1520" escape="true"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, 2022 and 2021, impairment testing of other intangible assets (excluding software) resulted in the recognition of net impairment losses as shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impairment of other intangible assets, net of reversals (excluding software)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-447" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1521">932</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-448" decimals="-6" sign="-" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1522">454</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-449" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1523">192</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-450" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-451" decimals="-6" sign="-" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1525">1,561</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-452" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1526">42</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Biopharma</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-453" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-454" decimals="-6" sign="-" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1528">1,526</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-455" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1529">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Consumer Healthcare</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-456" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-457" decimals="-6" sign="-" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1531">35</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1532">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development projects and technology platforms</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)(b)(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1533">896</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1534">1,107</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1535">150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Others</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-462" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1536">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-463" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1537">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-464" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-1538">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;For 2023, this amount mainly comprises an impairment loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-465" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1539">833</ix:nonFraction>&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN  technology platforms.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;For 2022, this amount mainly comprises a reversal of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-466" decimals="-6" name="sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1540">2,154</ix:nonFraction>&#160;million of impairment losses taken against ELOCTATE and BIVV001 (assets belonging to the ELOCTATE franchise), consisting of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-467" decimals="-6" name="sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1541">1,554</ix:nonFraction>&#160;million for marketed products and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-468" decimals="-6" name="sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1542">600</ix:nonFraction>&#160;million for research and development projects respectively. In 2019, the launch of competing products for ELOCTATE led Sanofi to update its sales forecasts for products belonging to the franchise, as a result of which impairment losses of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-8" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-1543">2.8</ix:nonFraction>&#160;billion were recognized against the assets in question. The reversal reflects the approval by the FDA on February&#160;22, 2023 of  ALTUVIIIO (the commercial name of efanesoctocog alpha, corresponding to the BIVV001 project), which was submitted in 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;For 2022, this amount mainly comprises:</span></div><div style="margin-top:1pt;padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.93pt">an impairment loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-470" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1544">1,586</ix:nonFraction>&#160;million taken against the development project for SAR444245 (non-alpha interleukin-2), recognized following revised cash flow projections reflecting unfavorable developments in the launch schedule;</span></div><div style="margin-top:1pt;padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.93pt">the &#8364;<ix:nonFraction unitRef="eur" contextRef="c-468" decimals="-6" name="sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1545">600</ix:nonFraction>&#160;million reversal relating to the BIVV001 project (see above).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For 2021, this line relates to the discontinuation of the development of sutimlimab in the treatment of Immune Thrombocytopenic Purpura (ITP), and to the termination of various research projects in Vaccines.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, plant and equipment</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses taken against property, plant and equipment are disclosed in Note&#160;D.3.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and opportunities related to climate change</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has identified specific plausible scenarios to assess climate risks and opportunities liable to impact its activities in the medium and longer term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an Aggressive Mitigation scenario, based on global collaboration to start reducing emissions immediately to meet Paris Agreement goals (limit temperature increase to 1.5&#176;C above pre-industrial levels), generating risks related to transitioning to a lower carbon economy and entailing extensive policy, legal, technology, and market changes to address mitigation and adaptation requirements;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a No Climate Action scenario (leading to global warming of 4&#176;C above pre-industrial levels by 2100), with event-driven physical risks resulting from climate change or longer term shifts in climate patterns leading to potential financial implications such as direct damage to assets and indirect impacts from supply chain disruption; changes in water availability, and in the sourcing or quality of resources; food security; and extreme temperature changes affecting premises, operations, supply chain, transport needs, and employee safety; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a Most Likely scenario, encompassing fragmented regional efforts to start reducing emissions but not at a sufficient level to meet Paris Agreement goals (emissions continue to increase but at a slowed rate, leading to a 2.8&#176;C temperature increase).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The importance and likelihood of such risks have been assessed and have not led Sanofi to identify any material impact that could generate a risk of impairment of the assets of Sanofi&#8217;s CGUs.</span></div></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_631"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.6. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" id="f-1546" continuedAt="f-1546-1" escape="true">Investments accounted for using the equity method</ix:nonNumeric></span></div><ix:continuation id="f-1546-1" continuedAt="f-1546-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method comprise associates and joint ventures (see Note&#160;B.1.), and are set forth below.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" id="f-1547" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:49.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%&#160;interest</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-471" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="f-1548">29.8</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-472" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" scale="6" id="f-1549">162</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-154" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" scale="6" id="f-1550">392</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-473" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" format="ixt:fixed-zero" scale="6" id="f-1551">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH&#160;&amp; Co. H&#246;chst KG</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-474" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-1552">31.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-475" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" scale="6" id="f-1553">90</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-476" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" scale="6" id="f-1554">97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-477" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" scale="6" id="f-1555">80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-478" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-1556">50.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-479" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" scale="6" id="f-1557">96</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-480" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" scale="6" id="f-1558">104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-481" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" scale="6" id="f-1559">88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-482" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" format="ixt:fixed-zero" scale="-2" id="f-1560">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-483" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" scale="6" id="f-1561">76</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-484" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" scale="6" id="f-1562">84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-485" decimals="-6" name="ifrs-full:InvestmentsInJointVentures" scale="6" id="f-1563">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" scale="6" id="f-1564">424</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" scale="6" id="f-1565">677</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" scale="6" id="f-1566">250</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Following the distribution in kind and the acquisition of an equity interest by EPIC Bpifrance, Sanofi holds an equity interest in EUROAPI accounted for using the equity method in accordance with IAS&#160;28 (see Note&#160;D.2.). As of December&#160;31, 2023, an impairment loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-471" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-1567">231</ix:nonFraction>&#160;million was recognized on the equity-accounted investment in EUROAPI in view of the fall in the share price since March&#160;2023. The amount of the loss was determined on the basis of the share price as of December&#160;31, 2023 (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-486" decimals="2" name="sny:StockPrice" scale="0" id="f-1568">5.73</ix:nonFraction>).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Joint venture.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Joint venture. MSP Vaccine Company owns <ix:nonFraction unitRef="number" contextRef="c-487" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInJointVenture" scale="-2" id="f-1569">100</ix:nonFraction>% of MCM Vaccine BV.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-45</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1546-2"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock" id="f-1570" escape="true"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi&#8217;s overall share of (i)&#160;profit or loss and (ii)&#160;other comprehensive income from investments accounted for using the equity method, showing the split between associates and joint ventures in accordance with IFRS&#160;12 (the amounts for each individual associate or joint venture are not material):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:28.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.425%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint&#160;ventures</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint&#160;ventures</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint&#160;ventures</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-488" decimals="-6" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1571">101</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-489" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1572">216</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-490" decimals="-6" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1573">74</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-491" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1574">6</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-492" decimals="-6" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1575">26</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-493" decimals="-6" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-1576">13</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of other comprehensive income from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-488" decimals="-6" sign="-" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax" scale="6" id="f-1577">7</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-489" decimals="-6" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax" scale="6" id="f-1578">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-490" decimals="-6" sign="-" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax" scale="6" id="f-1579">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-491" decimals="-6" sign="-" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax" scale="6" id="f-1580">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-492" decimals="-6" sign="-" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax" scale="6" id="f-1581">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-493" decimals="-6" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1582">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-488" decimals="-6" name="sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" scale="6" id="f-1583">94</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-489" decimals="-6" sign="-" name="sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" scale="6" id="f-1584">208</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-490" decimals="-6" name="sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" scale="6" id="f-1585">72</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-491" decimals="-6" sign="-" name="sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" scale="6" id="f-1586">9</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-492" decimals="-6" name="sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" scale="6" id="f-1587">20</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-493" decimals="-6" name="sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" scale="6" id="f-1588">13</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;An impairment loss of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-471" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-1589">231</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> was recognized on the equity-accounted interest in EUROAPI as of December&#160;31, 2023, to reflect the fall in the share price since March&#160;2023. The amount of the loss was determined on the basis of the quoted market price as of December&#160;31, 2023 (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-486" decimals="2" name="sny:StockPrice" scale="0" id="f-1590">5.73</ix:nonFraction>).</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include arm&#8217;s length transactions between Sanofi and some equity-accounted investments that are classified as related parties. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-1591" continuedAt="f-1591-1" escape="true">The principal transactions and balances with related parties are summarized below:</ix:nonNumeric></span></div><ix:continuation id="f-1591-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:58.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.999%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-494" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions" scale="6" id="f-1592">157</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-495" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions" scale="6" id="f-1593">131</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions" scale="6" id="f-1594">70</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-494" decimals="-6" name="sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions" scale="6" id="f-1595">63</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-495" decimals="-6" name="sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions" scale="6" id="f-1596">81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions" scale="6" id="f-1597">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-497" decimals="-6" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="6" id="f-1598">249</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-498" decimals="-6" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="6" id="f-1599">330</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-499" decimals="-6" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="6" id="f-1600">269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases and other expenses (including research expenses)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-494" decimals="-6" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="6" id="f-1601">642</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-495" decimals="-6" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="6" id="f-1602">477</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-6" name="ifrs-full:PurchasesOfGoodsRelatedPartyTransactions" scale="6" id="f-1603">178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and other payables</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-497" decimals="-6" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="6" id="f-1604">71</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-498" decimals="-6" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="6" id="f-1605">132</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-499" decimals="-6" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="6" id="f-1606">28</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In 2022, these items include Sanofi's transactions with EUROAPI from May&#160;10, 2022 (see Note&#160;D.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Includes loans to joint ventures and associates.</span></div></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="eur" contextRef="c-499" decimals="INF" name="sny:CommitmentsMadeToJointVenturesAndAssociates" format="ixt:fixed-zero" scale="6" id="f-1607"><ix:nonFraction unitRef="eur" contextRef="c-498" decimals="INF" name="sny:CommitmentsMadeToJointVenturesAndAssociates" format="ixt:fixed-zero" scale="6" id="f-1608"><ix:nonFraction unitRef="eur" contextRef="c-497" decimals="INF" name="sny:CommitmentsMadeToJointVenturesAndAssociates" format="ixt:fixed-zero" scale="6" id="f-1609">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> funding commitments to associates and joint ventures as of December 31, 2023, December 31, 2022 or     December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For off balance sheet commitments of an operational nature involving joint ventures, see Note&#160;D.21.1.</span></div></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_634"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.7. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory" id="f-1610" continuedAt="f-1610-1" escape="true">Other non-current assets</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" id="f-1611" escape="true"><ix:continuation id="f-1610-1" continuedAt="f-1610-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:49.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income (D.7.1.)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-500" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-1612">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-501" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="6" id="f-1613">936</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-502" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="6" id="f-1614">823</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income (D.7.2.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-503" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="6" id="f-1615">346</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-504" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="6" id="f-1616">329</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-505" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="6" id="f-1617">447</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss (D.7.3.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" scale="6" id="f-1618">808</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" scale="6" id="f-1619">823</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" scale="6" id="f-1620">902</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations (Note&#160;D.19.1.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-1621">271</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-1622">269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-1623">408</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:LongTermPrepaidExpenses" scale="6" id="f-1624">114</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:LongTermPrepaidExpenses" scale="6" id="f-1625">286</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:LongTermPrepaidExpenses" scale="6" id="f-1626">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentLoansAndReceivables" scale="6" id="f-1627">591</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentLoansAndReceivables" scale="6" id="f-1628">452</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncurrentLoansAndReceivables" scale="6" id="f-1629">485</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivative financial instruments (Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1631">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" scale="6" id="f-1632">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1633">3,218</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1634">3,095</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1635">3,127</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;As of December 31, 2023, this line includes:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- the renewal of a loan of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-506" decimals="-6" name="ifrs-full:NoncurrentLoansAndReceivables" scale="6" id="f-1636">157</ix:nonFraction>&#160;million to the BioAtrium joint venture which matures on December&#160;1, 2031, of which &#8364;<ix:nonFraction unitRef="eur" contextRef="c-507" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1637">156</ix:nonFraction>&#160;million was recognized in "Other current assets" as of December&#160;31, 2022; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- a receivable under a sub-lease amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentFinanceLeaseReceivables" scale="6" id="f-1638">132</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:NonCurrentFinanceLeaseReceivablesGross" scale="6" id="f-1639">170</ix:nonFraction>&#160;million before discounting), versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentFinanceLeaseReceivables" scale="6" id="f-1640">164</ix:nonFraction>&#160;million (or &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:NonCurrentFinanceLeaseReceivablesGross" scale="6" id="f-1641">201</ix:nonFraction>&#160;million before discounting) as of December 31, 2022.</span></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-46</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1610-2" continuedAt="f-1610-3"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.7.1. Equity instruments at fair value through other comprehensive income</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quoted equity investments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line &#8220;Equity instruments at fair value through other comprehensive income&#8221; includes equity investments quoted in an active market with a carrying amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-1642">470</ix:nonFraction> million as of December 31, 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-1643">387</ix:nonFraction> million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-6" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-1644">396</ix:nonFraction> million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">There were no material movements in quoted equity investments during the year ended December 31, 2023.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main changes during previous years in quoted equity investments included in the &#8220;Equity instruments at fair value through other comprehensive income&#8221; category are described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in 2022:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">the sale in June&#160;2022 of the residual equity interest in Regeneron (see Note&#160;C.1.) for $<ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-6" name="ifrs-full:ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="6" id="f-1645">174</ix:nonFraction> million, the entire loss on which was recorded within Other comprehensive income, and </span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">the acquisition of an equity interest in Innovent Biologics, in connection with a strategic collaboration agreement to intensify&#160;development in oncology medicines signed in August&#160;2022, which had a fair value of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-512" decimals="-6" name="sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount" format="ixt:num-dot-decimal" scale="6" id="f-1646">250</ix:nonFraction> million as of that date and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-513" decimals="-6" name="sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount" format="ixt:num-dot-decimal" scale="6" id="f-1647">228</ix:nonFraction> million as of December&#160;31, 2022;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in 2021:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">following completion of the acquisition of Translate Bio on September&#160;14, 2021 (see Note&#160;D.2.2), the equity interest of approximately <ix:nonFraction unitRef="number" contextRef="c-514" decimals="2" name="sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" scale="-2" id="f-1648">5</ix:nonFraction>% in Translate Bio previously held by Sanofi ceased to be accounted for in the &#8220;Equity instruments at fair value through other comprehensive income&#8221; category.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A 10% decline in stock prices of the quoted equity investments included within &#8220;Equity instruments at fair value through&#160;other&#160;comprehensive income&#8221; would have had a pre-tax impact of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount" format="ixt:num-dot-decimal" scale="6" id="f-1649">47</ix:nonFraction> million on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as of&#160;December 31, 2023.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unquoted equity investments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item &#8220;Equity instruments at fair value through other comprehensive income&#8221; also includes equity investments not quoted in an active market with a carrying amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-515" decimals="-6" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-1650">618</ix:nonFraction> million as of December 31, 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-516" decimals="-6" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-1651">549</ix:nonFraction> million as of December 31, 2022 and&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-517" decimals="-6" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-1652">427</ix:nonFraction> million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The change in unquoted equity investments included in the &#8220;Equity instruments at fair value through other comprehensive income&#8221; category during the year ended December 31, 2023 was mainly due to various equity stakes acquired through the Sanofi Ventures fund.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, commitments relating to equity investments classified in this asset category amount to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-518" decimals="-6" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-1653">65</ix:nonFraction> million as of December 31, 2023 (compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-519" decimals="-6" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-1654">60</ix:nonFraction> million as of December 31, 2022).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.7.2. Debt instruments at fair value through other comprehensive income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Debt instruments at fair value through other comprehensive income&#8221; category includes quoted euro-denominated senior bonds amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-520" decimals="-6" name="ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-1655">346</ix:nonFraction> million as of December 31, 2023, including &#8364;<ix:nonFraction unitRef="eur" contextRef="c-521" decimals="-6" name="ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" format="ixt:num-dot-decimal" scale="6" id="f-1656">107</ix:nonFraction> million of securities obtained in exchange for financial assets held to meet obligations to employees under post-employment benefit plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi held &#8364;<ix:nonFraction unitRef="eur" contextRef="c-522" decimals="-6" name="ifrs-full:HeldtomaturityInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1657">329</ix:nonFraction> million of quoted senior bonds as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-523" decimals="-6" name="ifrs-full:HeldtomaturityInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1658">447</ix:nonFraction> million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards debt instruments held to meet obligations to employees under post-employment benefit plans, an increase of 10&#160;basis points in market interest rates as of December 31, 2023 would have had a pre-tax impact of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-524" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1659">1</ix:nonFraction> million on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards other quoted debt instruments, an increase of 10&#160;basis points in market interest rates as of December 31, 2023 would have had a pre-tax impact of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-525" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1660">1</ix:nonFraction> million on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other comprehensive income recognized in respect of &#8220;Equity instruments at fair value through other comprehensive income&#8221; and &#8220;Debt instruments at fair value through other comprehensive income&#8221; represented unrealized after-tax gains of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-526" decimals="-6" name="sny:UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity" format="ixt:num-dot-decimal" scale="6" id="f-1661">349</ix:nonFraction> million for the year ended December 31, 2023, versus unrealized after-tax gains of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-527" decimals="-6" name="sny:UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity" format="ixt:num-dot-decimal" scale="6" id="f-1662">256</ix:nonFraction> million for the year ended December 31, 2022 and of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-528" decimals="-6" name="sny:UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity" format="ixt:num-dot-decimal" scale="6" id="f-1663">322</ix:nonFraction> million for the year ended December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of the change in gains and losses recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, and of items reclassified to profit or loss, is presented in Note&#160;D.15.7.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.7.3. Other financial assets at fair value through profit or loss</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other financial assets at fair value through profit or loss&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">category includes:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration receivable by Sanofi following the dissolution of the Sanofi Pasteur MSD (SPMSD) joint venture, based on a percentage of MSD&#8217;s future sales during the 2017-2024 period of specified products previously distributed by&#160;SPMSD (see Note&#160;D.12.).</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of the MSD contingent consideration was determined by applying the royalty percentage stipulated in the contract to discounted sales projections. A reduction of one percentage point in the discount rate would increase the fair value of the&#160;MSD&#160;contingent consideration by approximately <ix:nonFraction unitRef="number" contextRef="c-529" decimals="2" name="sny:PercentageIncreaseInFairValueLiabilities" scale="-2" id="f-1664">1</ix:nonFraction>%.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-47</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1610-3"><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in the fair value of this contingent consideration are recognized in the income statement within the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Fair value remeasurement of contingent consideration </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see Note&#160;B.18.). As of December 31, 2023, the contingent consideration asset amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-530" decimals="-6" name="sny:FairValueOfTheContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-1665">214</ix:nonFraction> million (including a non-current portion of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-531" decimals="-6" name="sny:FairValueOfTheContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-1666">104</ix:nonFraction> million), versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-532" decimals="-6" name="sny:FairValueOfTheContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-1667">303</ix:nonFraction> million (non-current portion: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-533" decimals="-6" name="sny:FairValueOfTheContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-1668">196</ix:nonFraction> million) as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-534" decimals="-6" name="sny:FairValueOfTheContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-1669">378</ix:nonFraction> million (non current portion: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-535" decimals="-6" name="sny:FairValueOfTheContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-1670">275</ix:nonFraction> million) as of December 31, 2021;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a portfolio of financial investments (amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-536" decimals="-6" name="sny:FinancialInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1671">572</ix:nonFraction> million as of December 31, 2023) held to fund a deferred compensation plan provided to certain employees (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-537" decimals="-6" name="sny:FinancialInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1672">512</ix:nonFraction> million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-538" decimals="-6" name="sny:FinancialInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1673">549</ix:nonFraction> million as of&#160;December 31, 2021);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">unquoted securities not meeting the definition of equity instruments amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-539" decimals="-6" name="ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-1674">132</ix:nonFraction> million as of December 31, 2023 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-540" decimals="-6" name="ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-1675">115</ix:nonFraction> million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-541" decimals="-6" name="ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-1676">78</ix:nonFraction> million as of December 31, 2021). In addition, commitments relating to unquoted securities classified in this asset category amount to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-518" decimals="-6" name="ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-1677">159</ix:nonFraction> million as of December 31, 2023 (compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-519" decimals="-6" name="ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-1678">192</ix:nonFraction> million as of December 31, 2022).</span></div></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_637"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.8. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" id="f-1679" continuedAt="f-1679-1" escape="true">Assets held for sale or exchange and liabilities related to&#160;assets held for sale or&#160;exchange</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock" id="f-1680" escape="true"><ix:continuation id="f-1679-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets held for sale or exchange, and liabilities related to assets held for sale or exchange, comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:52.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.216%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets held for sale or exchange</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-1681">15</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-1682">85</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-1683">89</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities related to assets held for sale or exchange</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-1684">13</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" scale="6" id="f-1685">10</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1686">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i9fa7f69b4904450e9c43e8444c203165_640"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.9. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="f-1687" continuedAt="f-1687-1" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="f-1687-1"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDetailedInformationAboutInventoriesTableTextBlock" id="f-1688" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.829%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:RawMaterials" format="ixt:num-dot-decimal" scale="6" id="f-1689">1,676</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-542" decimals="-6" name="ifrs-full:RawMaterials" scale="6" id="f-1690">126</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:RawMaterials" format="ixt:num-dot-decimal" scale="6" id="f-1691">1,550</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="ifrs-full:RawMaterials" format="ixt:num-dot-decimal" scale="6" id="f-1692">1,613</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-543" decimals="-6" name="ifrs-full:RawMaterials" scale="6" id="f-1693">139</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:RawMaterials" format="ixt:num-dot-decimal" scale="6" id="f-1694">1,474</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-6" name="ifrs-full:RawMaterials" format="ixt:num-dot-decimal" scale="6" id="f-1695">1,344</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-544" decimals="-6" name="ifrs-full:RawMaterials" scale="6" id="f-1696">66</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:RawMaterials" format="ixt:num-dot-decimal" scale="6" id="f-1697">1,278</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="6" id="f-1698">5,869</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-542" decimals="-6" name="ifrs-full:WorkInProgress" scale="6" id="f-1699">553</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="6" id="f-1700">5,316</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="6" id="f-1701">5,663</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-543" decimals="-6" name="ifrs-full:WorkInProgress" scale="6" id="f-1702">678</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="6" id="f-1703">4,985</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-6" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="6" id="f-1704">5,579</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-544" decimals="-6" name="ifrs-full:WorkInProgress" scale="6" id="f-1705">554</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="6" id="f-1706">5,025</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:FinishedGoods" format="ixt:num-dot-decimal" scale="6" id="f-1707">3,045</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-542" decimals="-6" name="ifrs-full:FinishedGoods" scale="6" id="f-1708">245</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:FinishedGoods" format="ixt:num-dot-decimal" scale="6" id="f-1709">2,800</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="ifrs-full:FinishedGoods" format="ixt:num-dot-decimal" scale="6" id="f-1710">2,748</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-543" decimals="-6" name="ifrs-full:FinishedGoods" scale="6" id="f-1711">247</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:FinishedGoods" format="ixt:num-dot-decimal" scale="6" id="f-1712">2,501</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-6" name="ifrs-full:FinishedGoods" format="ixt:num-dot-decimal" scale="6" id="f-1713">2,696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-544" decimals="-6" name="ifrs-full:FinishedGoods" scale="6" id="f-1714">284</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:FinishedGoods" format="ixt:num-dot-decimal" scale="6" id="f-1715">2,412</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-1716">10,590</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-542" decimals="-6" name="ifrs-full:Inventories" scale="6" id="f-1717">924</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-1718">9,666</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-1719">10,024</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-543" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-1720">1,064</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-1721">8,960</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-1722">9,619</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-544" decimals="-6" name="ifrs-full:Inventories" scale="6" id="f-1723">904</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-1724">8,715</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Allowances include write-downs of products on hand pending marketing approval, except in specific circumstances where it is possible to estimate that recovery of the value of inventories as of the end of the reporting period is highly probable.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:InventoriesPledgedAsSecurityForLiabilities" format="ixt:fixed-zero" scale="0" id="f-1725">No</ix:nonFraction> inventories were pledged as security for liabilities as of December 31, 2023 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:InventoriesPledgedAsSecurityForLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1726">3</ix:nonFraction> million as of December 31, 2022 and&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:InventoriesPledgedAsSecurityForLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1727">20</ix:nonFraction> million as of December 31, 2021).</span></div></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_643"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.10. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfTradeReceivablesTextBlock" id="f-1728" continuedAt="f-1728-1" escape="true">Accounts receivable</ix:nonNumeric></span></div><ix:continuation id="f-1728-1"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfCurrentTradeReceivablesTableTextBlock" id="f-1729" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:52.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.216%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1730">8,528</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1731">8,537</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1732">7,705</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-545" decimals="-6" name="ifrs-full:CurrentTradeReceivables" scale="6" id="f-1733">95</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-546" decimals="-6" name="ifrs-full:CurrentTradeReceivables" scale="6" id="f-1734">113</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-547" decimals="-6" name="ifrs-full:CurrentTradeReceivables" scale="6" id="f-1735">137</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1736">8,433</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1737">8,424</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1738">7,568</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of allowances against accounts receivable in 2023 was a net expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1739">8</ix:nonFraction> million (versus a net amount of less than&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1740">1</ix:nonFraction> million in 2022 and a net expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1741">12</ix:nonFraction> million in 2021).</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The gross value of overdue receivables was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:OverdueReceivablesGrossValue" format="ixt:num-dot-decimal" scale="6" id="f-1742">689</ix:nonFraction> million as of December 31, 2023, versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:OverdueReceivablesGrossValue" format="ixt:num-dot-decimal" scale="6" id="f-1743">452</ix:nonFraction> million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:OverdueReceivablesGrossValue" format="ixt:num-dot-decimal" scale="6" id="f-1744">455</ix:nonFraction> million as of December 31, 2021.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock" id="f-1745" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:17.123%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;accounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">gross value</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&lt;1 month</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to&#160;3&#160;months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to&#160;6&#160;months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6&#160;to&#160;12&#160;months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&gt;&#160;12&#160;months</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1746">689</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-548" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1747">269</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-549" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1748">154</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-550" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1749">123</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-551" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1750">62</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-552" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1751">81</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1752">452</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-553" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1753">118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-554" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1754">161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-555" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1755">87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-556" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1756">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-557" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1757">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1758">455</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-558" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1759">169</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-559" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1760">151</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-560" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1761">67</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-561" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1762">12</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-6" name="sny:OverdueReceivablesGrossValue" scale="6" id="f-1763">56</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amounts overdue by more than one month relate mainly to public-sector customers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables&#160;derecognized was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:DerecognizedReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1764">761</ix:nonFraction> million as of December 31, 2023 (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:DerecognizedReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1765">131</ix:nonFraction> million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:DerecognizedReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1766">3</ix:nonFraction> million as of&#160;December 31, 2021). The residual guarantees relating to such transfers were immaterial as of December 31, 2023.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-48</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_646"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.11. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory" id="f-1767" continuedAt="f-1767-1" escape="true">Other current assets</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock" id="f-1768" escape="true"><ix:continuation id="f-1767-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax receivables, other than corporate income taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" scale="6" id="f-1769">768</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" scale="6" id="f-1770">658</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" scale="6" id="f-1771">802</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentPrepaidExpenses" scale="6" id="f-1772">768</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentPrepaidExpenses" scale="6" id="f-1773">714</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentPrepaidExpenses" scale="6" id="f-1774">615</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherCurrentReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1775">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:OtherCurrentReceivables" format="ixt:num-dot-decimal" scale="6" id="f-1776">1,290</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:OtherCurrentReceivables" scale="6" id="f-1777">805</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate derivatives measured at fair value (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:InterestRateDerivativesMeasuredAtFairValue" format="ixt:fixed-zero" scale="6" id="f-1778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:InterestRateDerivativesMeasuredAtFairValue" format="ixt:fixed-zero" scale="6" id="f-1779">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:InterestRateDerivativesMeasuredAtFairValue" scale="6" id="f-1780">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency derivatives measured at fair value (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CurrencyDerivativesMeasuredAtFairValue" scale="6" id="f-1781">201</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CurrencyDerivativesMeasuredAtFairValue" scale="6" id="f-1782">206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CurrencyDerivativesMeasuredAtFairValue" scale="6" id="f-1783">284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current financial assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherCurrentFinancialAssets" scale="6" id="f-1784">270</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:OtherCurrentFinancialAssets" scale="6" id="f-1785">664</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:OtherCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1786">1,054</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1787">3,455</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1788">3,532</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1789">3,571</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line mainly comprises advance payments to suppliers, and receivables relating to Sanofi's activities as agent under a transitional services agreement.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This item mainly comprises bank loans and receivables maturing in less than one year with high-grade counterparties. For 2021, this item also includes debt instruments derived from the acquisitions of Translate Bio and Kadmon (carried out in 2021) with maturities of more than three months at inception and less than 12&#160;months at December&#160;31, 2021.</span></div></ix:continuation></ix:nonNumeric><div id="i9fa7f69b4904450e9c43e8444c203165_649"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.12. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock" id="f-1790" continuedAt="f-1790-1" escape="true">Financial assets and liabilities measured at fair value</ix:nonNumeric></span></div><ix:continuation id="f-1790-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS&#160;7 (Financial Instruments: Disclosures), fair value measurements must be classified using a fair value hierarchy with the following levels:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">level&#160;1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">level&#160;2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">level&#160;3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The valuation techniques used are described in Note&#160;B.8.5.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock" id="f-1791" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the balance sheet amounts of assets and liabilities measured at fair value.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:32.131%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in the fair value</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">hierarchy</span></div></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in the fair value<br/>hierarchy</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in the fair value<br/>hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial assets measured at fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted equity investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-563" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1792">470</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-564" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1795">387</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1796">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-568" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1797">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-569" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1798">396</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-570" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1799">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-571" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1800">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unquoted equity investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-572" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1801">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-573" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1802">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-574" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1803">618</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-575" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1804">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-576" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1805">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-577" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1806">549</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-578" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1807">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-579" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1808">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-580" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1809">427</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted debt securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.2.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-581" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1810">346</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-582" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-583" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-584" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1813">329</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-585" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1814">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1815">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-587" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1816">447</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-588" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1817">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-589" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1818">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unquoted debt securities not meeting the definition of equity instruments</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.3.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1821">132</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1822">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-594" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1823">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-595" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1824">115</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-596" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1825">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-597" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1826">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-598" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1827">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration relating to divestments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.3.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-599" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-600" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-601" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1830">214</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-602" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1831">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-603" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1832">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-604" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1833">303</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-605" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1834">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-606" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1835">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-607" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1836">378</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.3. &amp; D.11.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-608" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1837">572</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-609" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-610" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-611" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1840">512</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-612" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1841">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-613" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1842">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-614" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1843">549</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-615" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1844">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-616" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1845">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-617" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1846">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-618" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-619" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-620" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1849">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-621" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1850">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-622" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1851">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-623" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1852">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-624" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1853">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-625" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1854">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.11.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-626" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-627" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1856">201</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-628" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1857">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-629" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1858">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-630" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1859">206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-631" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1860">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-632" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1861">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-633" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1862">295</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-634" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1863">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mutual fund investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.13.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-635" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1864">5,349</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-636" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-637" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-638" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1867">9,537</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-639" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1868">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-640" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1869">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-641" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1870">5,057</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-642" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1871">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-643" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1872">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total financial assets measured at fair value</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-644" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1873">6,737</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-645" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1874">201</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1875">964</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-647" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1876">10,765</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-648" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1877">206</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-649" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1878">967</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-650" decimals="-6" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1879">6,449</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-651" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1880">298</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-652" decimals="-6" name="ifrs-full:FinancialAssets" scale="6" id="f-1881">883</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial liabilities measured at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bayer contingent purchase consideration arising from the acquisition of Genzyme</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-653" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1882">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-654" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1883">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-655" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-656" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1885">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-657" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1886">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-658" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1887">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-659" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1888">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-660" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1889">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-661" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1890">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSD contingent consideration (European vaccines business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-662" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-663" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-664" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1893">127</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-665" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1894">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-666" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1895">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-667" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1896">204</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-668" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1897">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-669" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1898">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-670" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1899">269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shire contingent consideration arising from the acquisition of Translate Bio</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-671" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1900">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-672" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-673" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1902">441</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-674" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1903">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-675" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1904">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-676" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1905">380</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-677" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1906">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-678" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1907">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-679" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1908">354</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration arising from acquisition of Amunix</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-680" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-681" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1910">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-682" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1911">137</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-683" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1912">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-684" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1913">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-685" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1914">165</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-686" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1915">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-687" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1916">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-688" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1917">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other contingent consideration arising from business combinations and acquisitions</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-689" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-690" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1919">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-691" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1920">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-692" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1921">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-693" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1922">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-694" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1923">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-695" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1924">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-696" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1925">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-697" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1926">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.20.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-698" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1927">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-699" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1928">164</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-700" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-701" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1930">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-702" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1931">232</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-703" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1932">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-704" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1933">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-705" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1934">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-706" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1935">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.19.5</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-707" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1937">127</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-709" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-710" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1939">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-711" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1940">94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-712" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1941">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-713" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1942">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-714" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1943">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-715" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1944">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total financial liabilities measured at fair value</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-644" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1945">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-645" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1946">291</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1947">709</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-647" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1948">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-648" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1949">326</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-649" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1950">779</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-650" decimals="-6" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1951">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-651" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1952">85</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-652" decimals="-6" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1953">714</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No transfers between the different levels of the fair value hierarchy occurred during 2023.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-49</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_652"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.13. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="f-1954" continuedAt="f-1954-1" escape="true">Cash and cash equivalents</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock" id="f-1955" escape="true"><ix:continuation id="f-1954-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="6" id="f-1956">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="6" id="f-1957">1,385</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="6" id="f-1958">1,358</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1959">7,249</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1960">11,351</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1961">8,740</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1962">8,710</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1963">12,736</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1964">10,098</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;As of December 31, 2023, cash equivalents mainly comprised the following: (i)&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CashEquivalentsMoneyMarketMutualFunds" format="ixt:num-dot-decimal" scale="6" id="f-1965">5,349</ix:nonFraction> million invested in euro and US dollar denominated money-market mutual funds (December 31, 2022: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CashEquivalentsMoneyMarketMutualFunds" format="ixt:num-dot-decimal" scale="6" id="f-1966">9,537</ix:nonFraction> million; December 31, 2021: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CashEquivalentsMoneyMarketMutualFunds" format="ixt:num-dot-decimal" scale="6" id="f-1967">5,057</ix:nonFraction> million); (ii)&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1968">1,191</ix:nonFraction> million of term deposits (December 31, 2022: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1969">1,167</ix:nonFraction> million; December 31, 2021: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1970">2,768</ix:nonFraction> million) and (iii)&#160;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="0" name="sny:CashEquivalentsCommercialPaper" format="ixt:fixed-zero" scale="6" id="f-1971">zero</ix:nonFraction> commercial paper (December 31, 2022: <ix:nonFraction unitRef="eur" contextRef="c-7" decimals="0" name="sny:CashEquivalentsCommercialPaper" format="ixt:fixed-zero" scale="6" id="f-1972">zero</ix:nonFraction>; December 31, 2021: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CashEquivalentsCommercialPaper" format="ixt:num-dot-decimal" scale="6" id="f-1973">179</ix:nonFraction> million). Cash equivalents also include &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies" format="ixt:num-dot-decimal" scale="6" id="f-1974">476</ix:nonFraction> million held by captive insurance and reinsurance companies in accordance with insurance regulations (December 31, 2022: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies" format="ixt:num-dot-decimal" scale="6" id="f-1975">439</ix:nonFraction> million; December 31, 2021: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies" format="ixt:num-dot-decimal" scale="6" id="f-1976">427</ix:nonFraction> million).</span></div></ix:continuation></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div id="i9fa7f69b4904450e9c43e8444c203165_655"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.14. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDeferredTaxesExplanatory" id="f-1977" continuedAt="f-1977-1" escape="true">Net deferred tax position</ix:nonNumeric></span></div><ix:continuation id="f-1977-1" continuedAt="f-1977-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="f-1978" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of the net deferred tax position is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.854%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred taxes on:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consolidation adjustments (intragroup margin in inventory)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-716" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1979">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-717" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1980">1,388</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-718" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1981">1,292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision for pensions and other employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-719" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1982">853</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-720" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1983">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-721" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1984">1,117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of other acquired intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-722" decimals="-6" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1985">2,904</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-723" decimals="-6" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1986">3,269</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-724" decimals="-6" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1987">3,079</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Recognition of acquired property, plant and equipment at fair value</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-725" decimals="-6" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1988">21</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-726" decimals="-6" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1989">24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-727" decimals="-6" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1990">26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity interests in subsidiaries and investments in other entities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-728" decimals="-6" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1991">1,023</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-729" decimals="-6" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1992">617</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-730" decimals="-6" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1993">590</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax losses available for carry-forward</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-731" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1994">1,526</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-732" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1995">1,506</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-733" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1996">1,516</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock options and other share-based payments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-734" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1997">84</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-735" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1998">92</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-736" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1999">88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accrued expenses and provisions deductible at the time of payment</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-737" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-2000">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-738" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-2001">1,859</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-739" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-2002">1,585</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-740" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-2003">2,536</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-741" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-2004">1,755</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-742" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-2005">1,078</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net deferred tax asset/(liability)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-2006">4,570</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-2007">3,540</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-2008">2,981</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;As of December 31, 2023, includes remeasurements of the acquired intangible assets of Bioverativ (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-743" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2009">1,241</ix:nonFraction> million), Principia (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-744" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2010">610</ix:nonFraction> million), Ablynx      (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-745" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2011">204</ix:nonFraction> million), Genzyme (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-746" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2012">50</ix:nonFraction> million) and Amunix (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-747" decimals="-6" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2013">109</ix:nonFraction> million).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-8" name="sny:ReservesLikelyToBeDistributedInTheForeseeableFuture" format="ixt:num-dot-decimal" scale="9" id="f-2014">60.4</ix:nonFraction> billion) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2023, Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the&#160;European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December&#160;31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October&#160;2023 (see Note&#160;D.30.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes deferred tax assets related to restructuring provisions, amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-748" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-2015">286</ix:nonFraction> million as of December 31, 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-749" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-2016">256</ix:nonFraction> million as of                 December 31, 2022, and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-750" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-2017">226</ix:nonFraction> million as of December 31, 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes deferred taxes arising on the spread tax deduction of R&amp;D expenses, amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-751" decimals="-6" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-2018">1,331</ix:nonFraction> million as of December 31, 2023 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-752" decimals="-6" name="ifrs-full:DeferredTaxAssets" scale="6" id="f-2019">742</ix:nonFraction> million as of December 31, 2022.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The reserves of Sanofi subsidiaries that would be taxable if distributed but for which no distribution is planned, and for which no deferred tax liability has therefore been recognized, totaled &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-8" name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" format="ixt:num-dot-decimal" scale="9" id="f-2020">10.0</ix:nonFraction> billion as of December 31, 2023, compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-8" name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" format="ixt:num-dot-decimal" scale="9" id="f-2021">10.6</ix:nonFraction> billion as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-8" name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" format="ixt:num-dot-decimal" scale="9" id="f-2022">10.0</ix:nonFraction> billion as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Most of Sanofi&#8217;s tax loss carry-forwards are available indefinitely. For a description of policies on the recognition of deferred tax assets, refer to Note&#160;B.22. For each tax consolidation, the recognition of deferred tax assets is determined on the basis of profit forecasts that are consistent with Sanofi&#8217;s medium-term strategic plan, and taking into consideration the tax consequences of the strategic opportunities available to Sanofi within the period of availability of tax loss carry-forwards and the specific circumstances of each tax consolidation. Deferred tax assets relating to tax loss carry-forwards as of December 31, 2023 amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:TotalDeferredTaxAssetsForTaxLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-2023">2,729</ix:nonFraction> million, of which &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="f-2024">1,203</ix:nonFraction> million were not recognized (including &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="f-2025">473</ix:nonFraction>&#160;million in respect of capital losses). This compares with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:TotalDeferredTaxAssetsForTaxLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-2026">2,650</ix:nonFraction> million as of December 31, 2022 (of which&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="f-2027">1,144</ix:nonFraction> million were not recognized) and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:TotalDeferredTaxAssetsForTaxLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-2028">2,391</ix:nonFraction> million as of&#160;December 31, 2021 (of which &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="f-2029">875</ix:nonFraction> million were not recognized).</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-50</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-1977-2"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock" id="f-2030" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows when tax losses available for carry-forward are due to expire:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:70.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Tax&#160;losses&#160;available for carry-forward</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-753" decimals="-6" name="sny:TaxLossesCarryforwards" scale="6" id="f-2031">6</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-754" decimals="-6" name="sny:TaxLossesCarryforwards" scale="6" id="f-2032">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-755" decimals="-6" name="sny:TaxLossesCarryforwards" scale="6" id="f-2033">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-756" decimals="-6" name="sny:TaxLossesCarryforwards" scale="6" id="f-2034">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-757" decimals="-6" name="sny:TaxLossesCarryforwards" scale="6" id="f-2035">126</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2029 and later</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-758" decimals="-6" name="sny:TaxLossesCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-2036">8,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:TaxLossesCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-2037">8,933</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:TaxLossesCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-2038">8,503</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:TaxLossesCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-2039">7,644</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Excluding tax loss carry-forwards on asset disposals. Such carry-forwards amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:TaxLossCarryforwardsOnAssetDisposals" format="ixt:num-dot-decimal" scale="6" id="f-2040">5</ix:nonFraction> million as of December 31, 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:TaxLossCarryforwardsOnAssetDisposals" format="ixt:num-dot-decimal" scale="6" id="f-2041">5</ix:nonFraction> million as of       December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:TaxLossCarryforwardsOnAssetDisposals" format="ixt:num-dot-decimal" scale="6" id="f-2042">5</ix:nonFraction> million as of December 31, 2021.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Use of tax loss carry-forwards is limited to the entity in which they arose. In jurisdictions where tax consolidations are in place, tax losses can be netted against taxable income generated by entities in the same tax consolidation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deferred tax assets not recognized (primarily because their future recovery was not regarded as probable given the expected results of the entities in question) amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable" format="ixt:num-dot-decimal" scale="6" id="f-2043">1,062</ix:nonFraction> million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable" format="ixt:num-dot-decimal" scale="6" id="f-2044">995</ix:nonFraction> million in 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable" format="ixt:num-dot-decimal" scale="6" id="f-2045">615</ix:nonFraction> million in 2021.</span></div></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_658"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.15. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-2046" continuedAt="f-2046-1" escape="true">Consolidated shareholders&#8217; equity</ix:nonNumeric></span></div><ix:continuation id="f-2046-1" continuedAt="f-2046-2"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.1. Share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, the share capital w</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="0" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="0" id="f-2047">2,529,599,938</ix:nonFraction>, consisting of <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2048">1,264,799,969</ix:nonFraction>&#160;shar</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">es with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-5" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-2049">2</ix:nonFraction>. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-2050" continuedAt="f-2050-1" escape="true">Treasury shares held by Sanofi are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-2050-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:49.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of&#160;shares </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%&#160;of&#160;share&#160;capital <br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-2051">13.45</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-2052">1.063</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-2053">8.20</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-2054">0.650</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-2055">11.02</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-2056">0.872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-4" name="sny:NumberOfSharesHeld" scale="6" id="f-2057">8.28</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-19" decimals="5" name="sny:PercentageOfShareCapitalForThePeriod" scale="-2" id="f-2058">0.658</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares are deducted from shareholders&#8217; equity. Gains and losses on disposals of treasury shares are recorded directly in equity and are not recognized in net income for the period.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock" id="f-2059" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in the share capital of the Sanofi parent company over the last three years are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:33.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-759" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2060">1,258,971,738</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-760" decimals="INF" name="sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" format="ixt:num-dot-decimal" scale="0" id="f-2061">190,076</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-760" decimals="INF" name="sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-2062">1,836,179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 28, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-761" decimals="INF" name="sny:NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees" format="ixt:num-dot-decimal" scale="0" id="f-2063">2,562,702</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-762" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2064">1,263,560,695</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by exercise of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-763" decimals="INF" name="sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" format="ixt:num-dot-decimal" scale="0" id="f-2065">490,373</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-763" decimals="INF" name="sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-2066">1,499,987</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 27, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-764" decimals="INF" name="sny:NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees" format="ixt:num-dot-decimal" scale="0" id="f-2067">2,027,057</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of December 14, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reduction in share capital by cancellation of </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">treasury shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-765" decimals="INF" name="sny:ReductionOfSharesByCancellationOfTreasuryShares" format="ixt:num-dot-decimal" scale="0" id="f-2068">6,742,380</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-766" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2069">1,260,835,732</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by exercise of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-767" decimals="INF" name="sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" format="ixt:num-dot-decimal" scale="0" id="f-2070">504,956</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-767" decimals="INF" name="sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" format="ixt:num-dot-decimal" scale="0" id="f-2071">1,330,558</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 27, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-768" decimals="INF" name="sny:NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees" format="ixt:num-dot-decimal" scale="0" id="f-2072">2,128,723</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-769" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2073">1,264,799,969</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Shares issued on exercise of Sanofi stock subscription options.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Shares vesting under restricted share plans and issued in the period.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the disclosures about the management of capital required under IFRS&#160;7, refer to Note&#160;B.27.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-51</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2046-2" continuedAt="f-2046-3"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.2. Restricted share plans</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" id="f-2074" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note&#160;B.24.3. The principal characteristics of those plans are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:38.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.007%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.007%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.007%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.007%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.007%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 25, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 3, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 14, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 27, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Service period</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-770" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-2075">3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-771" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-2076">3</ix:nonNumeric> years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-772" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-2077">3</ix:nonNumeric> years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-773" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-2078">3</ix:nonNumeric> years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-774" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-2079">3</ix:nonNumeric> years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-775" name="sny:NumberOfYearsServicePeriod" format="ixt-sec:duryear" id="f-2080">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares awarded </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-770" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2081">3,838,434</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-771" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2082">65,129</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-772" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2083">3,344,432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-773" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2084">109,981</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-774" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2085">3,484,420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-775" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2086">13,521</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-776" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2087">2,425,047</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-777" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="f-2088">944</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-778" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2089">2,000,627</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-779" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2090">10,335</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-780" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2091">2,209,901</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-781" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-2092">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-776" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-2093">87.69</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-777" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-2094">77.42</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-778" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-2095">91.19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-779" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-2096">79.17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-780" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-2097">77.27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-781" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" format="ixt:fixed-zero" scale="0" id="f-2098">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-782" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2099">1,413,387</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-783" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2100">64,185</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-784" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2101">1,343,805</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-785" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2102">99,646</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-786" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2103">1,274,519</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-787" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2104">13,521</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-782" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-2105">83.74</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-783" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-2106">74.50</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-784" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-2107">86.65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-785" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-2108">69.60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-786" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-2109">71.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-787" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriod" scale="0" id="f-2110">68.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer - additional shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-782" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" scale="0" id="f-2111">43.60</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-783" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" scale="0" id="f-2112">34.90</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-784" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" scale="0" id="f-2113">49.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-785" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" scale="0" id="f-2114">54.70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-786" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" format="ixt:fixed-zero" scale="0" id="f-2115">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-787" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" format="ixt:fixed-zero" scale="0" id="f-2116">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-782" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" scale="0" id="f-2117">82.17</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-783" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" format="ixt:fixed-zero" scale="0" id="f-2118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-784" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" scale="0" id="f-2119">84.46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-785" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" format="ixt:fixed-zero" scale="0" id="f-2120">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-786" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" scale="0" id="f-2121">71.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-787" decimals="2" name="sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" format="ixt:fixed-zero" scale="0" id="f-2122">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan at the date of grant </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-770" decimals="-6" name="sny:FairValueOfPlanAtDateOfGrant" scale="6" id="f-2123">326</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-771" decimals="-6" name="sny:FairValueOfPlanAtDateOfGrant" scale="6" id="f-2124">5</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-772" decimals="-6" name="sny:FairValueOfPlanAtDateOfGrant" scale="6" id="f-2125">294</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-773" decimals="-6" name="sny:FairValueOfPlanAtDateOfGrant" scale="6" id="f-2126">8</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-774" decimals="-6" name="sny:FairValueOfPlanAtDateOfGrant" scale="6" id="f-2127">262</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-775" decimals="-6" name="sny:FairValueOfPlanAtDateOfGrant" scale="6" id="f-2128">1</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Weighting between (i)&#160;fair value determined using the Monte Carlo model and (ii)&#160;market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Additional tranche subject to a higher level of market conditions: <ix:nonFraction unitRef="shares" contextRef="c-788" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2129">121,097</ix:nonFraction>&#160;additional shares were awarded in May&#160;2023, and <ix:nonFraction unitRef="shares" contextRef="c-789" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2130">5,838</ix:nonFraction>&#160;additional shares were awarded in December&#160;2023 (versus <ix:nonFraction unitRef="shares" contextRef="c-790" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2131">114,874</ix:nonFraction>&#160;additional shares awarded in May&#160;2022, and <ix:nonFraction unitRef="shares" contextRef="c-791" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2132">9,066</ix:nonFraction>&#160;additional shares awarded in December&#160;2022).</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" id="f-2133" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:58.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.224%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023 (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022 (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-792" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-2134">231</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-793" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-2135">206</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-794" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-2136">193</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested as of December 31</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-795" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2137">9,773,084</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-796" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2138">9,245,513</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-797" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2139">9,507,849</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-798" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2140">3,780,513</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-799" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-2141">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-800" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-2142">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-801" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2143">3,099,158</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-802" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2144">3,330,801</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-803" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-2145">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2021 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-804" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2146">2,893,413</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-805" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2147">3,097,531</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-806" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2148">3,364,895</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2020 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-807" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-2149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-808" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2150">2,817,181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-809" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2151">3,014,496</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2019 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-810" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-2152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-811" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:fixed-zero" scale="0" id="f-2153">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-812" decimals="INF" name="sny:NumberOfRestrictedSharesNotYetFullyVested" format="ixt:num-dot-decimal" scale="0" id="f-2154">3,128,458</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Additional tranche subject to a higher level of market conditions: <ix:nonFraction unitRef="shares" contextRef="c-813" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2155">126,935</ix:nonFraction>&#160;additional shares were awarded in 2023, versus <ix:nonFraction unitRef="shares" contextRef="c-814" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2156">123,940</ix:nonFraction>&#160;additional shares awarded in &#160;2022.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.3. Capital increases</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" id="f-2157" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The characteristics of the employee share ownership plans awarded in the form of a capital increase reserved for employees in&#160;2023, 2022 and 2021 are summarized in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:58.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.224%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 2, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 3, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Subscription price </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-815" decimals="2" name="sny:SubscriptionPricePerShare" scale="0" id="f-2158">79.58</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-816" decimals="2" name="sny:SubscriptionPricePerShare" scale="0" id="f-2159">80.21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-817" decimals="2" name="sny:SubscriptionPricePerShare" scale="0" id="f-2160">69.38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Subscription period</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 5-23, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 9-29, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 7-25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares subscribed</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-815" decimals="INF" name="sny:NumberOfShareSubscribed" format="ixt:num-dot-decimal" scale="0" id="f-2161">2,009,306</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-816" decimals="INF" name="sny:NumberOfShareSubscribed" format="ixt:num-dot-decimal" scale="0" id="f-2162">1,909,008</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-817" decimals="INF" name="sny:NumberOfShareSubscribed" format="ixt:num-dot-decimal" scale="0" id="f-2163">2,438,590</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares issued immediately as employer&#8217;s contribution</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-815" decimals="INF" name="sny:IssuanceOfFurtherSharesAsAnEmployersContribution" format="ixt:num-dot-decimal" scale="0" id="f-2164">119,417</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-816" decimals="INF" name="sny:IssuanceOfFurtherSharesAsAnEmployersContribution" format="ixt:num-dot-decimal" scale="0" id="f-2165">118,049</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-817" decimals="INF" name="sny:IssuanceOfFurtherSharesAsAnEmployersContribution" format="ixt:num-dot-decimal" scale="0" id="f-2166">124,112</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subscription price representing <ix:nonFraction unitRef="number" contextRef="c-10" decimals="2" name="sny:PercentageOfAverageOfQuotedMarketPricesOfShares" scale="-2" id="f-2167"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="sny:PercentageOfAverageOfQuotedMarketPricesOfShares" scale="-2" id="f-2168"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="2" name="sny:PercentageOfAverageOfQuotedMarketPricesOfShares" scale="-2" id="f-2169">80</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the average of the opening quoted market prices of Sanofi shares during the <ix:nonNumeric contextRef="c-1" name="sny:NumberOfTradingDaysPrecedingPlanApproval" format="ixt-sec:durday" id="f-2170"><ix:nonNumeric contextRef="c-9" name="sny:NumberOfTradingDaysPrecedingPlanApproval" format="ixt-sec:durday" id="f-2171"><ix:nonNumeric contextRef="c-10" name="sny:NumberOfTradingDaysPrecedingPlanApproval" format="ixt-sec:durday" id="f-2172">20</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>&#160;trading days preceding May&#160;31,&#160;2023, June&#160;6,&#160;2022 and June&#160;3, 2021, respectively.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:AdditionalInformationAboutSharebasedPaymentArrangements" id="f-2173" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the expense recognized for each plan:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:58.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.224%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense recognized</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-818" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-2174">52</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-819" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-2175">39</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-820" decimals="-6" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-2176">51</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which employer&#8217;s contribution</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-818" decimals="-6" name="sny:ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution" scale="6" id="f-2177">12</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-819" decimals="-6" name="sny:ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution" scale="6" id="f-2178">11</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-820" decimals="-6" name="sny:ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution" scale="6" id="f-2179">11</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-52</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2046-3" continuedAt="f-2046-4"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.4. Repurchase of Sanofi shares</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Annual General Meetings of Sanofi shareholders held on May 25, 2023, May&#160;3, 2022 and April&#160;30, 2021 each authorized a share repurchase program for a period of <ix:nonNumeric contextRef="c-821" name="sny:PeriodOfShareRepurchaseProgram" format="ixt-sec:durmonth" id="f-2180"><ix:nonNumeric contextRef="c-822" name="sny:PeriodOfShareRepurchaseProgram" format="ixt-sec:durmonth" id="f-2181"><ix:nonNumeric contextRef="c-823" name="sny:PeriodOfShareRepurchaseProgram" format="ixt-sec:durmonth" id="f-2182">18</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> months. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock" id="f-2183" continuedAt="f-2183-1" escape="true">The following repurchases have been made under those programs:</ix:nonNumeric></span></div><ix:continuation id="f-2183-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.185%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:29.25pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in number of shares and &#8364; million)</span></div><div style="padding-right:29.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year of authorization</span></div></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023 program</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-824" decimals="INF" name="sny:NumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-2184">2,584,540</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-825" decimals="-6" name="sny:AmountOfSharesRepurchased" scale="6" id="f-2185">230</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022 program</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-826" decimals="INF" name="sny:NumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-2186">4,000,204</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-827" decimals="-6" name="sny:AmountOfSharesRepurchased" scale="6" id="f-2187">363</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-828" decimals="INF" name="sny:NumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-2188">1,510,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-829" decimals="-6" name="sny:AmountOfSharesRepurchased" scale="6" id="f-2189">137</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021 program</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-830" decimals="INF" name="sny:NumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-2190">3,976,992</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-831" decimals="-6" name="sny:AmountOfSharesRepurchased" scale="6" id="f-2191">360</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-832" decimals="INF" name="sny:NumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-2192">2,765,388</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-833" decimals="-6" name="sny:AmountOfSharesRepurchased" scale="6" id="f-2193">242</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020 program</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-834" decimals="INF" name="sny:NumberOfSharesRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-2194">1,758,569</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-835" decimals="-6" name="sny:AmountOfSharesRepurchased" scale="6" id="f-2195">140</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.5. Reductions in share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reductions in share capital for the accounting periods presented are described in the table included at Note&#160;D.15.1. above.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those reductions have no impact on shareholders&#8217; equity.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.6. Currency translation differences</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock" id="f-2196" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Currency translation differences comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-836" decimals="-6" sign="-" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="6" id="f-2197">31</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-837" decimals="-6" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-2198">1,499</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-838" decimals="-6" sign="-" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="6" id="f-2199">865</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-836" decimals="-6" sign="-" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-2200">37</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-837" decimals="-6" sign="-" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-2201">37</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-838" decimals="-6" sign="-" name="ifrs-full:NoncontrollingInterests" scale="6" id="f-2202">42</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-836" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-2203">68</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-837" decimals="-6" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-2204">1,462</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-838" decimals="-6" sign="-" name="ifrs-full:Equity" scale="6" id="f-2205">907</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The balance as of December 31, 2023 includes an after-tax amount of &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:HedgesOfNetInvestmentsInForeignOperationsAfterTax" scale="6" id="f-2206">574</ix:nonFraction>) million relating to hedges of net investments in&#160;foreign operations (refer to Note&#160;B.8.3. for a description of the relevant accounting policy), compared with &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:HedgesOfNetInvestmentsInForeignOperationsAfterTax" scale="6" id="f-2207">580</ix:nonFraction>) million as of&#160;December 31, 2022 and&#160;&#8364;(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:HedgesOfNetInvestmentsInForeignOperationsAfterTax" scale="6" id="f-2208">317</ix:nonFraction>) million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The movement in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Currency translation differences</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is mainly attributable to the US dollar.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-53</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2046-4" continuedAt="f-2046-5"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.7. Other comprehensive income</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" id="f-2209" escape="true"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Actuarial gains/(losses) excluding investments accounted for using the equity method (see&#160;Note&#160;D.19.1.)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-839" decimals="-6" sign="-" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" scale="6" id="f-2210">171</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-840" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" scale="6" id="f-2211">650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-841" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" scale="6" id="f-2212">685</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-839" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-2213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-840" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-2214">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-841" decimals="-6" name="sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-2215">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-839" decimals="-6" sign="-" name="sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-2216">18</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-840" decimals="-6" name="sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-2217">212</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-841" decimals="-6" name="sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-2218">36</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;padding-right:29.25pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-842" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" scale="6" id="f-2219">97</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-843" decimals="-6" sign="-" name="sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" scale="6" id="f-2220">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-844" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" scale="6" id="f-2221">154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-842" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-843" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2223">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-844" decimals="-6" name="sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2224">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-842" decimals="-6" name="sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" format="ixt:fixed-zero" scale="6" id="f-2225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-843" decimals="-6" name="sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" scale="6" id="f-2226">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-844" decimals="-6" name="sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" scale="6" id="f-2227">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-842" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" scale="6" id="f-2228">21</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-843" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" scale="6" id="f-2229">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-844" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" scale="6" id="f-2230">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-842" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-2231">77</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-843" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-2232">451</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-844" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-2233">797</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-845" decimals="-6" name="sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-2234">21</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-846" decimals="-6" sign="-" name="sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-2235">77</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-847" decimals="-6" sign="-" name="sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-2236">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-845" decimals="-6" name="sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-2237">4</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-846" decimals="-6" sign="-" name="sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-2238">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-847" decimals="-6" sign="-" name="sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures" scale="6" id="f-2239">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow and fair value hedges:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-848" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" scale="6" id="f-2240">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-849" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" scale="6" id="f-2241">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-850" decimals="-6" sign="-" name="sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" scale="6" id="f-2242">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-848" decimals="-6" sign="-" name="sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-2243">2</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-849" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-2244">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-850" decimals="-6" name="sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-2245">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-848" decimals="-6" name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-2246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-849" decimals="-6" name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" scale="6" id="f-2247">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-850" decimals="-6" sign="-" name="ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" scale="6" id="f-2248">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-848" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-2249">1,551</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-849" decimals="-6" name="sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-2250">2,643</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-850" decimals="-6" name="sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-2251">2,719</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Currency translation differences (investments accounted for using the&#160;equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-848" decimals="-6" name="sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-2252">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-849" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-2253">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-850" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" scale="6" id="f-2254">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Hedges of net investments in foreign operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-848" decimals="-6" name="sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" scale="6" id="f-2255">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-849" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" scale="6" id="f-2256">354</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-850" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" scale="6" id="f-2257">254</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-848" decimals="-6" name="sny:ChangeInCurrencyTranslationOnTaxEffects" scale="6" id="f-2258">2</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-849" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationOnTaxEffects" scale="6" id="f-2259">91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-850" decimals="-6" sign="-" name="sny:ChangeInCurrencyTranslationOnTaxEffects" scale="6" id="f-2260">71</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-848" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2261">1,526</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-849" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2262">2,313</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-850" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2263">2,510</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: <ix:nonFraction unitRef="eur" contextRef="c-845" decimals="0" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:fixed-zero" scale="0" id="f-2264">immaterial</ix:nonFraction> amount in 2023, <ix:nonFraction unitRef="eur" contextRef="c-846" decimals="0" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:fixed-zero" scale="0" id="f-2265">immaterial</ix:nonFraction> amount in 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-847" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2266">4</ix:nonFraction> million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-851" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2267">1</ix:nonFraction> million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-852" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2268">2</ix:nonFraction> million in 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-853" decimals="-6" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2269">12</ix:nonFraction> million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-854" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-2270">56</ix:nonFraction>) million in 2023, and &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-855" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-2271">40</ix:nonFraction>) million in 2022 (including &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-856" decimals="-6" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-2272">35</ix:nonFraction>)&#160;million relating to the deconsolidation of EUROAPI). The amounts reclassified to profit and loss were <ix:nonFraction unitRef="eur" contextRef="c-857" decimals="0" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:fixed-zero" scale="0" id="f-2273">immaterial</ix:nonFraction> in 2021. Currency translation differences arise from the translation into euros of the financial statements of foreign subsidiaries, and are mainly due to the appreciation of the dollar against the euro.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-54</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2046-5" continuedAt="f-2046-6"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.8. Stock options</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock option plans awarded and measurement of stock option plans</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No stock options were awarded during 2023, 2022 or 2021.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock subscription option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Details of the terms of exercise of stock subscription options granted under the various plans are presented below in Sanofi share equivalents. These plans were awarded to certain corporate officers and employees of Sanofi companies.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock" id="f-2274" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table shows all Sanofi stock subscription option plans still outstanding or under which options were exercised in the year ended&#160;December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:18.961%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.224%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date of grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>options<br/>granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Start&#160;date&#160;of<br/>exercise<br/>period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options outstanding as of 12/31/2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2013</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-858" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2275">788,725</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/06/2017</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-859" decimals="2" name="sny:StockBasedCompensationStockOptionsExercisedPricePerShare" scale="0" id="f-2276">72.19</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-860" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:fixed-zero" scale="0" id="f-2277">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2014</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-861" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2278">1,009,250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/06/2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-862" decimals="2" name="sny:StockBasedCompensationStockOptionsExercisedPricePerShare" scale="0" id="f-2279">73.48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-863" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2280">91,355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/24/2015</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-864" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2281">435,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/25/2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/24/2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-865" decimals="2" name="sny:StockBasedCompensationStockOptionsExercisedPricePerShare" scale="0" id="f-2282">89.38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-866" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2283">337,714</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/04/2016</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-867" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2284">402,750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/05/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/04/2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-868" decimals="2" name="sny:StockBasedCompensationStockOptionsExercisedPricePerShare" scale="0" id="f-2285">75.90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-869" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2286">264,750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/10/2017</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-870" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2287">378,040</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/11/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/10/2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-871" decimals="2" name="sny:StockBasedCompensationStockOptionsExercisedPricePerShare" scale="0" id="f-2288">88.97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-872" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2289">257,010</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2018</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-873" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2290">220,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/03/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-874" decimals="2" name="sny:StockBasedCompensationStockOptionsExercisedPricePerShare" scale="0" id="f-2291">65.84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-875" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2292">168,784</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">04/30/2019</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-876" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2293">220,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">04/30/2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-877" decimals="2" name="sny:StockBasedCompensationStockOptionsExercisedPricePerShare" scale="0" id="f-2294">76.71</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-878" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2295">213,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-879" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2296">1,333,013</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The exercise of all outstanding stock subscription options would increase shareholders&#8217; equity by approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="c-880" decimals="-6" name="sny:ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions" format="ixt:num-dot-decimal" scale="6" id="f-2297">107</ix:nonFraction> million. The&#160;exercise of each option results in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-880" decimals="INF" name="sny:NumberOfSharesIssuedByExerciceOfEachOption" format="ixt-sec:numwordsen" scale="0" id="f-2298">one</ix:nonFraction> share.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of stock option plans</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock" id="f-2299" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A summary of stock options outstanding at each balance sheet date, and of movements during the relevant periods, is presented below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:58.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.224%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise&#160;price</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">per share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-881" decimals="INF" name="sny:NumberOfShareOutstandingInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2300">2,579,270</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-881" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-2301">75.61</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-881" decimals="-6" name="sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" scale="6" id="f-2302">195</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-881" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2303">1,845,050</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-881" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-2304">74.51</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-882" decimals="-6" name="sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" scale="6" id="f-2305">137</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-883" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2306">190,076</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-883" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="f-2307">59.53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-883" decimals="-6" name="sny:ValueOfShareOptionsExercisedInShareBasedPaymentArrangement" scale="6" id="f-2308">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options cancelled</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)&#160;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-883" decimals="INF" name="sny:NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2309">51,216</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-883" decimals="2" name="sny:WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement" scale="0" id="f-2310">65.84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-883" decimals="-6" name="sny:ValueOfShareOptionsCancelledInShareBasedPaymentArrangement" scale="6" id="f-2311">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-883" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" id="f-2312">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-883" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="f-2313">50.48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-883" decimals="-6" name="sny:ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="6" id="f-2314">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-884" decimals="INF" name="sny:NumberOfShareOutstandingInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2315">2,337,968</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-884" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-2316">77.13</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-884" decimals="-6" name="sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" scale="6" id="f-2317">180</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-884" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2318">1,949,184</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-884" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-2319">78.15</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-883" decimals="-6" name="sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" scale="6" id="f-2320">152</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-885" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2321">490,373</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-885" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="f-2322">71.39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-885" decimals="-6" name="sny:ValueOfShareOptionsExercisedInShareBasedPaymentArrangement" scale="6" id="f-2323">35</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options cancelled</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)&#160;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-885" decimals="INF" name="sny:NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2324">9,626</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-885" decimals="2" name="sny:WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement" scale="0" id="f-2325">80.56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-885" decimals="-6" name="sny:ValueOfShareOptionsCancelledInShareBasedPaymentArrangement" scale="6" id="f-2326">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-886" decimals="INF" name="sny:NumberOfShareOutstandingInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2327">1,837,969</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-886" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-2328">78.64</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-886" decimals="-6" name="sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" scale="6" id="f-2329">145</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-886" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2330">1,624,569</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-886" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-2331">78.89</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-885" decimals="-6" name="sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" scale="6" id="f-2332">128</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-887" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2333">504,956</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-887" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="f-2334">73.65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-887" decimals="-6" name="sny:ValueOfShareOptionsExercisedInShareBasedPaymentArrangement" scale="6" id="f-2335">37</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-888" decimals="INF" name="sny:NumberOfShareOutstandingInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2336">1,333,013</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-888" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-2337">80.53</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-888" decimals="-6" name="sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" scale="6" id="f-2338">107</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-888" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2339">1,333,013</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-888" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-2340">80.53</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-887" decimals="-6" name="sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" scale="6" id="f-2341">107</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Mainly due to the grantees leaving Sanofi.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" id="f-2342" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">residual&#160;life</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price per</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price per</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-889" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-2343">60.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-890" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-2344">70.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-891" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2345">168,784</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-892" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-2346">4.34</ix:nonNumeric></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-891" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-2347">65.84</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-891" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2348">168,784</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-891" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-2349">65.84</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-893" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-2350">70.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-894" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-2351">80.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-895" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2352">569,505</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-896" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-2353">3.12</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-895" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-2354">75.82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-895" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2355">569,505</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-895" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-2356">75.82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-897" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-2357">80.00</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-898" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-2358">90.00</ix:nonFraction> per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-899" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2359">594,724</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-900" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-2360">2.29</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-899" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-2361">89.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-899" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2362">594,724</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-899" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-2363">89.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-901" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2364">1,333,013</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-901" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2365">1,333,013</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-55</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2046-6"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.9. Number of shares used to compute diluted earnings per share</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" id="f-2366" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.991%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-2367">1,251.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-2368">1,251.9</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-5" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-2369">1,252.5</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-2370">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-2371">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-2372">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" scale="6" id="f-2373">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-5" name="sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" scale="6" id="f-2374">4.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-5" name="sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" scale="6" id="f-2375">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-2376">1,256.4</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-2377">1,256.9</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="6" id="f-2378">1,257.9</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023 and 2022, all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. In 2021, <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-5" name="sny:StockOptionsWithNoDilutiveEffect" format="ixt:num-dot-decimal" scale="6" id="f-2379">0.6</ix:nonFraction> million&#160;stock options were not taken into account in computing diluted earnings per share because they had no dilutive effect.</span></div></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_661"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.16. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory" id="f-2380" continuedAt="f-2380-1" escape="true">Non-controlling interests</ix:nonNumeric></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-2380-1">Non-controlling interests did not represent a material component of Sanofi&#8217;s consolidated financial statements in the years ended December 31, 2023, 2022 and 2021</ix:continuation>.</span></div><div id="i9fa7f69b4904450e9c43e8444c203165_664"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.17. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" id="f-2381" continuedAt="f-2381-1" escape="true">Debt, cash and cash equivalents and lease liabilities</ix:nonNumeric></span></div><ix:continuation id="f-2381-1" continuedAt="f-2381-2"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.17.1. Debt, cash and cash equivalents</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfChangesInFinancialPositionTableTextBlock" id="f-2382" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in Sanofi's financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.991%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2383">14,347</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2384">14,857</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2385">17,123</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2386">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2387">4,174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2388">3,183</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2389">139</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2390">187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2391">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2392">16,531</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2393">19,218</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2394">20,250</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2395">8,710</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2396">12,736</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2397">10,098</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2398">28</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2399">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2400">169</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2401">7,793</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2402">6,437</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2403">9,983</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities, which amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2404">2,030</ix:nonFraction> million as of December 31, 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2405">2,181</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> million as of December 31, 2022, and&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2406">2,108</ix:nonFraction>&#160;million as of December 31, 2021 </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(see the maturity analysis at Note&#160;D.17.2.).</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Net debt&#8221; is a non-IFRS financial measure used by management and investors to measure Sanofi&#8217;s overall net indebtedness.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" id="f-2407" escape="true"><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Reconciliation of carrying amount to value on redemption</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:25.167%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.193%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustment<br/>to debt<br/>measured&#160;at<br/>fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2408">14,347</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-902" decimals="-6" name="ifrs-full:LongtermBorrowings" scale="6" id="f-2409">42</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-903" decimals="-6" name="ifrs-full:LongtermBorrowings" scale="6" id="f-2410">157</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2411">14,546</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2412">15,143</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2413">17,176</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion<br/>of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2414">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-902" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:fixed-zero" scale="6" id="f-2415">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-903" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:fixed-zero" scale="6" id="f-2416">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2417">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2418">4,178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2419">3,183</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2420">139</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-902" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2421">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-903" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2422">157</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2423">18</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2424">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2425">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2426">16,531</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-902" decimals="-6" name="ifrs-full:Borrowings" scale="6" id="f-2427">42</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-903" decimals="-6" name="ifrs-full:Borrowings" format="ixt:fixed-zero" scale="6" id="f-2428">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2429">16,573</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2430">19,273</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2431">20,314</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2432">8,710</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-902" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2433">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-903" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2434">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2435">8,710</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2436">12,736</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2437">10,098</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2438">28</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-902" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2439">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-903" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2440">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2441">28</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2442">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2443">169</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2444">7,793</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-902" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-2445">42</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-903" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2446">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2447">7,835</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2448">6,492</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2449">10,047</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-56</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2381-2" continuedAt="f-2381-3"><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a) Principal financing transactions during the year</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" id="f-2450" continuedAt="f-2450-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the movement in total debt during the period:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:14.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.391%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash&#160;flows&#160;from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">cash</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">flows </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-907" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2451">14,857</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-908" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-2452">12</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-908" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-2453">48</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-908" decimals="-6" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2454">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-908" decimals="-6" sign="-" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2455">30</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-909" decimals="-6" sign="-" name="sny:ReclassificationFromNonCurrentToCurrent" scale="6" id="f-2456">604</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-908" decimals="-6" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2457">88</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-909" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2458">14,347</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-910" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2459">4,174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-911" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2460">3,672</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-911" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2461">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-911" decimals="-6" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="6" id="f-2462">903</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-911" decimals="-6" sign="-" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2463">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-912" decimals="-6" name="sny:ReclassificationFromNonCurrentToCurrent" scale="6" id="f-2464">604</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-911" decimals="-6" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2465">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-912" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2466">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-913" decimals="-6" name="ifrs-full:Borrowings" scale="6" id="f-2467">187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-914" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2468">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-914" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2469">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-914" decimals="-6" sign="-" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="6" id="f-2470">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-914" decimals="-6" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2471">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-915" decimals="-6" name="sny:ReclassificationFromNonCurrentToCurrent" format="ixt:fixed-zero" scale="6" id="f-2472">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-914" decimals="-6" sign="-" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2473">69</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-915" decimals="-6" name="ifrs-full:Borrowings" scale="6" id="f-2474">139</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2475">19,218</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2476">3,684</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-2477">48</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="6" id="f-2478">895</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2479">22</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:ReclassificationFromNonCurrentToCurrent" format="ixt:fixed-zero" scale="6" id="f-2480">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2481">76</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2482">16,531</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts mainly comprise &#8364;<ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-6" name="sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-2483">946</ix:nonFraction>&#160;million related to the US commercial paper program.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;These amounts mainly comprise changes in accrued interest balances, and fair value adjustments.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi did not carry out any bond issues in 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="bond" contextRef="c-1" decimals="INF" name="sny:NumberOfBondIssuesRedeemed" format="ixt-sec:numwordsen" scale="0" id="f-2484">Three</ix:nonFraction> bond issues were redeemed in 2023:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-916" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2485">1,750</ix:nonFraction>&#160;million issued in March&#160;2018, redeemed at maturity on March&#160;21, 2023;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">$<ix:nonFraction unitRef="usd" contextRef="c-917" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2486">1,000</ix:nonFraction>&#160;million issued in June&#160;2018, redeemed at maturity on June&#160;20, 2023; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.57pt">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-918" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2487">1,000</ix:nonFraction>&#160;million issued in November&#160;2013, redeemed at maturity on November&#160;14, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi entered into the following transactions relating to its syndicated credit facilities during 2023:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a new &#8364;<ix:nonFraction unitRef="eur" contextRef="c-919" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-2488">4</ix:nonFraction>&#160;billion revolving credit facility, linked to sustainable development indicators, was put in place on March&#160;8, 2023. This syndicated facility was initially due to mature in March&#160;2028, and included <ix:nonFraction unitRef="extension" contextRef="c-919" decimals="INF" name="sny:CreditFacilitiesExtensionOptionNumber" format="ixt-sec:numwordsen" scale="0" id="f-2489">two</ix:nonFraction> extension options of <ix:nonNumeric contextRef="c-920" name="sny:CreditFacilitiesExtensionOptionPeriod" format="ixt-sec:durwordsen" id="f-2490">one year</ix:nonNumeric> each; it replaced an existing &#8364;<ix:nonFraction unitRef="eur" contextRef="c-921" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-2491">4</ix:nonFraction>&#160;billion facility that was canceled on the same day; and</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the maturity of this credit facility was extended to March&#160;7, 2029, following the exercise of an extension option in December&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, as of December&#160;31, 2023, Sanofi had <ix:nonFraction unitRef="credit_facility" contextRef="c-5" decimals="INF" name="sny:NumberOfCreditFacilities" format="ixt-sec:numwordsen" scale="0" id="f-2492">two</ix:nonFraction>&#160;syndicated credit facilities to provide liquidity for the purposes of current operations, each of them linked to environmental and social indicators:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-922" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-2493">4</ix:nonFraction>&#160;billion facility maturing December&#160;6, 2027, with no further extension option available; and</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-923" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-2494">4</ix:nonFraction>&#160;billion facility maturing March&#160;7, 2029, with a <ix:nonNumeric contextRef="c-924" name="sny:CreditFacilitiesExtensionOptionPeriod" format="ixt-sec:durwordsen" id="f-2495">one-year</ix:nonNumeric> extension option.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In line with Sanofi&#8217;s commitment to embed sustainable development in the &#8220;Play to Win&#8221; strategy, those <ix:nonFraction unitRef="credit_facility" contextRef="c-5" decimals="INF" name="sny:NumberOfCreditFacilities" format="ixt-sec:numwordsen" scale="0" id="f-2496">two</ix:nonFraction>&#160;revolving credit facilities build in an adjustment mechanism that links the credit spread to the attainment of <ix:nonFraction unitRef="performance_indicator" contextRef="c-5" decimals="INF" name="sny:NumberOfSustainableDevelopmentPerformanceIndicators" format="ixt-sec:numwordsen" scale="0" id="f-2497">two</ix:nonFraction>&#160;sustainable development performance indicators:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">for the facility maturing in December&#160;2027: (i)&#160;Sanofi&#8217;s contribution to polio eradication, and (ii) the reduction in Sanofi&#8217;s carbon footprint; and</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">for the facility maturing in March&#160;2029: (i)&#160;Sanofi&#8217;s contribution to improving access to essential medicines in low-income and intermediate-income countries via its Sanofi Global Health non-profit unit, and (ii)&#160;the reduction in Sanofi&#8217;s carbon footprint.</span></div><ix:continuation id="f-2450-1" continuedAt="f-2450-2"><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the movement in total debt during prior periods:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.391%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash&#160;flows&#160;from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>cash<br/>flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-925" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2498">17,123</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-926" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-2499">11</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-926" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2500">1,549</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-926" decimals="-6" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2501">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-926" decimals="-6" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2502">56</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-907" decimals="-6" sign="-" name="sny:ReclassificationFromNonCurrentToCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2503">3,632</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-926" decimals="-6" sign="-" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2504">228</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-907" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2505">14,857</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-927" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2506">3,183</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-928" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2507">2,707</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-928" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2508">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-928" decimals="-6" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="6" id="f-2509">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-928" decimals="-6" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2510">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-910" decimals="-6" name="sny:ReclassificationFromNonCurrentToCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2511">3,632</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-928" decimals="-6" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2512">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-910" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2513">4,174</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-929" decimals="-6" sign="-" name="ifrs-full:Borrowings" scale="6" id="f-2514">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-930" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2515">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-930" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2516">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-930" decimals="-6" sign="-" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="6" id="f-2517">373</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-930" decimals="-6" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2518">366</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-913" decimals="-6" name="sny:ReclassificationFromNonCurrentToCurrent" scale="6" id="f-2519">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-930" decimals="-6" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2520">243</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-913" decimals="-6" name="ifrs-full:Borrowings" scale="6" id="f-2521">187</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2522">20,250</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2523">2,718</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2524">1,549</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="6" id="f-2525">330</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2526">442</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:ReclassificationFromNonCurrentToCurrent" scale="6" id="f-2527">7</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2528">18</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2529">19,218</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the&#160;Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These amounts include movements in accrued interest and fair value remeasurements.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-57</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2381-3" continuedAt="f-2381-4"><ix:continuation id="f-2450-2"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.391%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash&#160;flows&#160;from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>cash<br/>flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-931" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2530">19,745</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-932" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-2531">38</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-932" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2532">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-932" decimals="-6" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2533">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-932" decimals="-6" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2534">124</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-925" decimals="-6" sign="-" name="sny:ReclassificationFromNonCurrentToCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2535">2,704</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-932" decimals="-6" sign="-" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2536">4</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-925" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2537">17,123</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-933" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2538">2,767</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-934" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2539">2,203</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-934" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2540">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-934" decimals="-6" sign="-" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="6" id="f-2541">615</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-934" decimals="-6" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2542">248</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-927" decimals="-6" name="sny:ReclassificationFromNonCurrentToCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2543">2,704</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-934" decimals="-6" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2544">282</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-927" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2545">3,183</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-935" decimals="-6" name="ifrs-full:Borrowings" scale="6" id="f-2546">119</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-936" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2547">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-936" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2548">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-936" decimals="-6" sign="-" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="6" id="f-2549">197</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-936" decimals="-6" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2550">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-929" decimals="-6" name="sny:ReclassificationFromNonCurrentToCurrent" format="ixt:fixed-zero" scale="6" id="f-2551">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-936" decimals="-6" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2552">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-929" decimals="-6" sign="-" name="ifrs-full:Borrowings" scale="6" id="f-2553">56</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2554">22,631</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2555">2,241</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-2556">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" scale="6" id="f-2557">812</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:ForeignCurrencyTranslationDifferences" scale="6" id="f-2558">381</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:ReclassificationFromNonCurrentToCurrent" format="ixt:fixed-zero" scale="6" id="f-2559">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-2560">291</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2561">20,250</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These amounts include (i) effects of changes in the scope of consolidation, amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2562">299</ix:nonFraction>&#160;million; (ii) movements in accrued interest; and (iii) fair value remeasurements.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b) Net debt by type, at value on redemption</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" id="f-2563" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:14.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current </span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current </span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-937" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2564">14,416</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-938" decimals="-6" name="ifrs-full:BondsIssued" scale="6" id="f-2565">718</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2566">15,134</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-939" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2567">15,044</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-940" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2568">3,817</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2569">18,861</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-941" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2570">17,118</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-942" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2571">2,828</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2572">19,946</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-937" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2573">130</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-938" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2574">1,118</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2575">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-939" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2576">99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-940" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2577">187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2578">286</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-941" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2579">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-942" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2580">163</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2581">184</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-937" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-938" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2583">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2584">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-939" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2585">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-940" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2586">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2587">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-941" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2588">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-942" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2589">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2590">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-937" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-938" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2592">203</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2593">203</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-939" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2594">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-940" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2595">168</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2596">168</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-941" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2597">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-942" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2598">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2599">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-937" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-938" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2601">18</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2602">18</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-939" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2603">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-940" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2604">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2605">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-941" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2606">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-942" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2607">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2608">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-937" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2609">14,546</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-938" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2610">2,027</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2611">16,573</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-939" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2612">15,143</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-940" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2613">4,130</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2614">19,273</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-941" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2615">17,176</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-942" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2616">3,138</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2617">20,314</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-943" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-944" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2619">8,710</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2620">8,710</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-945" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2621">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-946" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2622">12,736</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2623">12,736</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-947" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2624">&#8211;</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-948" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2625">10,098</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2626">10,098</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-943" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-944" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2628">28</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2629">28</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-945" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2630">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-946" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2631">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2632">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-947" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2633">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-948" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2634">169</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2635">169</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-943" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2636">14,546</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-944" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2637">6,711</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2638">7,835</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-945" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2639">15,143</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-946" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2640">8,651</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2641">6,492</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-947" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2642">17,176</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-948" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2643">7,129</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2644">10,047</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities (see the maturity schedule in Note&#160;D.17.2.).</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock" id="f-2645" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bond issues carried out by Sanofi under the Euro Medium Term Note (EMTN) program are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.889%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issuer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ISIN code</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issue date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual&#160;interest&#160;rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013143997</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2016</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-949" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2646">0.625</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-949" decimals="-6" name="ifrs-full:NotionalAmount" scale="6" id="f-2647">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013505104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-950" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2648">1.000</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-950" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2649">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0014009KS6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-951" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2650">0.875</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-951" decimals="-6" name="ifrs-full:NotionalAmount" scale="6" id="f-2651">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0012969038</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-952" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2652">1.500</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-952" decimals="-6" name="ifrs-full:NotionalAmount" scale="6" id="f-2653">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013324340</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-953" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2654">1.000</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-953" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2655">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0012146801</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-954" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2656">1.750</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-954" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2657">1,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013201639</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-955" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2658">0.500</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-955" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2659">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013144003</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-956" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2660">1.125</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-956" decimals="-6" name="ifrs-full:NotionalAmount" scale="6" id="f-2661">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013409844</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-957" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2662">0.875</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-957" decimals="-6" name="ifrs-full:NotionalAmount" scale="6" id="f-2663">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0014009KQ0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-958" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2664">1.250</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-958" decimals="-6" name="ifrs-full:NotionalAmount" scale="6" id="f-2665">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013324357</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2030</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-959" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2666">1.375</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-959" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2667">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013505112</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2030</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-960" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2668">1.500</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-960" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2669">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013409851</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-961" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2670">1.250</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-961" decimals="-6" name="ifrs-full:NotionalAmount" scale="6" id="f-2671">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013324373</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2018</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2038</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-962" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2672">1.875</ix:nonFraction>%&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-962" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2673">1,250</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bond issues carried out by Sanofi under the public bond issue program (shelf registration statement) registered with the&#160;US&#160;Securities and Exchange Commission (SEC) comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:14.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.889%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issuer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ISIN code</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issue&#160;date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual&#160;<br/>interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($&#160;million)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US801060AD60</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 2018</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-963" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2674">3.625</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-963" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-2675">1,000</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-58</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2381-4" continuedAt="f-2381-5"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other borrowings&#8221; line mainly comprises participating shares issued between 1983 and 1987, of which <ix:nonFraction unitRef="shares" contextRef="c-964" decimals="INF" name="sny:ParticipatingSharesNumberOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2676">58,115</ix:nonFraction>&#160;remain outstanding, with a nominal amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-964" decimals="-6" name="sny:ParticipatingSharesCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-2677">9</ix:nonFraction> million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to manage its liquidity needs for current operations, as of December&#160;31, 2023 Sanofi had:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a syndicated credit facility of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-965" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-2678">4</ix:nonFraction>&#160;billion, drawable in euros and in US dollars, maturing December&#160;6,&#160;2027; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a syndicated credit facility of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-966" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-2679">4</ix:nonFraction>&#160;billion, drawable in euros and in US dollars, maturing March&#160;7, 2029.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi also has <ix:nonFraction unitRef="program" contextRef="c-5" decimals="INF" name="sny:NumberOfCommercialPaperPrograms" format="ixt-sec:numwordsen" scale="0" id="f-2680">two</ix:nonFraction> commercial paper programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a &#8364;<ix:nonFraction unitRef="eur" contextRef="c-967" decimals="-9" name="ifrs-full:CommercialPapersIssued" format="ixt:num-dot-decimal" scale="9" id="f-2681">6</ix:nonFraction>&#160;billion Negotiable European Commercial Paper program in France, with an average drawdown of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-968" decimals="-8" name="sny:BorrowingAverageDrawdown" format="ixt:num-dot-decimal" scale="9" id="f-2682">0.2</ix:nonFraction>&#160;billion and a maximum drawdown of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-968" decimals="-8" name="sny:BorrowingMaximumDrawdown" format="ixt:num-dot-decimal" scale="9" id="f-2683">0.8</ix:nonFraction>&#160;billion during 2023, and an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-967" decimals="-6" name="sny:BorrowingDrawdown" format="ixt:num-dot-decimal" scale="6" id="f-2684">40</ix:nonFraction>&#160;million drawn down as of December&#160;31, 2023; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a $<ix:nonFraction unitRef="usd" contextRef="c-969" decimals="-9" name="ifrs-full:CommercialPapersIssued" format="ixt:num-dot-decimal" scale="9" id="f-2685">10</ix:nonFraction>&#160;billion Commercial Paper program in the United States, with an average drawdown of $<ix:nonFraction unitRef="usd" contextRef="c-970" decimals="-7" name="sny:BorrowingAverageDrawdown" format="ixt:num-dot-decimal" scale="9" id="f-2686">3.7</ix:nonFraction>&#160;billion and a maximum drawdown of $<ix:nonFraction unitRef="usd" contextRef="c-970" decimals="-8" name="sny:BorrowingMaximumDrawdown" format="ixt:num-dot-decimal" scale="9" id="f-2687">7.3</ix:nonFraction>&#160;billion during 2023, and an amount of $<ix:nonFraction unitRef="usd" contextRef="c-969" decimals="-8" name="sny:BorrowingDrawdown" format="ixt:num-dot-decimal" scale="9" id="f-2688">1.0</ix:nonFraction>&#160;billion drawn down as of December&#160;31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financing in place as of December 31, 2023 at the level of the holding company (which manages most of Sanofi&#8217;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking spreads or fees to the credit rating.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c) Debt by maturity, at value on redemption</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock" id="f-2689" continuedAt="f-2689-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:34.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2690">15,134</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-971" decimals="-6" name="ifrs-full:BondsIssued" scale="6" id="f-2691">718</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-972" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2692">2,600</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-973" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2693">3,010</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-974" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2694">1,150</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-975" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2695">1,606</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-976" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2696">6,050</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2697">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-971" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2698">1,118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-972" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2699">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-973" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2700">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-974" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2701">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-975" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2702">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-976" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2703">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2704">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-971" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2705">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-972" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2706">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-973" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2707">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-974" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2708">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-975" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2709">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-976" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2710">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2711">203</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-971" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2712">203</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-972" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2713">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-973" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2714">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-974" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2715">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-975" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2716">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-976" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2717">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used <br/>to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2718">18</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-971" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2719">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-972" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2720">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-973" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2721">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-974" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2722">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-975" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2723">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-976" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2724">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2725">16,573</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-971" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2726">2,027</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-972" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2727">2,698</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-973" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2728">3,011</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-974" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2729">1,151</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-975" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2730">1,607</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-976" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2731">6,079</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2732">8,710</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-971" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2733">8,710</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-972" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2734">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-973" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2735">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-974" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2736">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-975" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2737">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-976" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2738">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used <br/>to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2739">28</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-971" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2740">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-972" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2741">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-973" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2742">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-974" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2743">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-975" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2744">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-976" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2745">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-904" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2746">7,835</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-971" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2747">6,711</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-972" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2748">2,698</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-973" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2749">3,011</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-974" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2750">1,151</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-975" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2751">1,607</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-976" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2752">6,079</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities, which amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2753">2,030</ix:nonFraction>&#160;million as of December&#160;31, 2023; &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2754">2,181</ix:nonFraction>&#160;million as of&#160;December&#160;31, 2022; and&#160;&#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2755">2,108</ix:nonFraction>&#160;million as of December&#160;31, 2021</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> (see the maturity analysis at Note&#160;D.17.2.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, the main undrawn confirmed general-purpose credit facilities at holding company level amounted to&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-977" decimals="-9" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-2756">8</ix:nonFraction> billion, half of which expired in 2027 and the other half of which expires in 2029.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, no single counterparty represented more than 6% of Sanofi&#8217;s undrawn confirmed credit facilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:34.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2757">18,861</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-978" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2758">3,817</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-979" decimals="-6" name="ifrs-full:BondsIssued" scale="6" id="f-2759">600</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-980" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2760">2,600</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-981" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2761">4,160</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-982" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:fixed-zero" scale="6" id="f-2762">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-983" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2763">7,684</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2764">286</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-978" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2765">187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-979" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2766">61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-980" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:fixed-zero" scale="6" id="f-2767">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-981" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:fixed-zero" scale="6" id="f-2768">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-982" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:fixed-zero" scale="6" id="f-2769">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-983" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2770">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2771">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-978" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2772">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-979" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2773">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-980" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2774">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-981" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2775">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-982" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2776">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-983" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2777">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2778">168</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-978" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2779">168</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-979" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2780">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-980" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2781">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-981" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2782">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-982" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2783">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-983" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2784">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2785">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-978" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2786">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-979" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2787">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-980" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2788">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-981" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2789">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-982" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2790">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-983" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2791">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2792">19,273</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-978" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2793">4,130</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-979" decimals="-6" name="ifrs-full:Borrowings" scale="6" id="f-2794">661</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-980" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2795">2,600</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-981" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2796">4,160</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-982" decimals="-6" name="ifrs-full:Borrowings" format="ixt:fixed-zero" scale="6" id="f-2797">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-983" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2798">7,722</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2799">12,736</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-978" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2800">12,736</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-979" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2801">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-980" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2802">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-981" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2803">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-982" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2804">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-983" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2805">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2806">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-978" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2807">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-979" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2808">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-980" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2809">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-981" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2810">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-982" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2811">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-983" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2812">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-905" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2813">6,492</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-978" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2814">8,651</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-979" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-2815">661</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-980" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2816">2,600</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-981" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2817">4,160</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-982" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2818">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-983" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2819">7,722</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-59</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2381-5" continuedAt="f-2381-6"><ix:continuation id="f-2689-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:34.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2820">19,946</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-984" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2821">2,828</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-985" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2822">3,629</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-986" decimals="-6" name="ifrs-full:BondsIssued" scale="6" id="f-2823">600</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-987" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2824">1,750</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-988" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2825">4,160</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-989" decimals="-6" name="ifrs-full:BondsIssued" format="ixt:num-dot-decimal" scale="6" id="f-2826">6,979</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2827">184</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-984" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2828">163</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-985" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2829">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-986" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2830">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-987" decimals="-6" name="sny:OtherBankBorrowings" scale="6" id="f-2831">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-988" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:fixed-zero" scale="6" id="f-2832">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-989" decimals="-6" name="sny:OtherBankBorrowings" format="ixt:fixed-zero" scale="6" id="f-2833">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2834">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-984" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2835">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-985" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2836">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-986" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2837">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-987" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2838">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-988" decimals="-6" name="ifrs-full:OtherBorrowings" format="ixt:fixed-zero" scale="6" id="f-2839">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-989" decimals="-6" name="ifrs-full:OtherBorrowings" scale="6" id="f-2840">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2841">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-984" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="f-2842">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-985" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2843">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-986" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2844">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-987" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2845">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-988" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2846">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-989" decimals="-6" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2847">&#8211;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2848">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-984" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" scale="6" id="f-2849">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-985" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2850">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-986" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2851">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-987" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2852">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-988" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2853">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-989" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageDebt" format="ixt:fixed-zero" scale="6" id="f-2854">&#8211;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2855">20,314</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-984" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2856">3,138</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-985" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2857">3,647</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-986" decimals="-6" name="ifrs-full:Borrowings" scale="6" id="f-2858">602</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-987" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2859">1,751</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-988" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2860">4,160</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-989" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2861">7,016</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2862">10,098</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-984" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2863">10,098</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-985" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2864">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-986" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2865">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-987" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2866">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-988" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2867">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-989" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2868">&#8211;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2869">169</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-984" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" scale="6" id="f-2870">169</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-985" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2871">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-986" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2872">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-987" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2873">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-988" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2874">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-989" decimals="-6" name="sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" format="ixt:fixed-zero" scale="6" id="f-2875">&#8211;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-906" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2876">10,047</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-984" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2877">7,129</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-985" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2878">3,647</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-986" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-2879">602</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-987" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2880">1,751</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-988" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2881">4,160</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-989" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2882">7,016</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d) Debt by interest rate, at value on redemption</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock" id="f-2883" continuedAt="f-2883-1" escape="true"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below splits net debt between fixed and floating rate, and by maturity, as of December 31, 2023. The figures shown are values on redemption, before the effects of derivative instruments:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:34.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-990" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2884">16,080</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-991" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2885">1,664</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-992" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2886">2,600</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-993" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2887">3,010</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-994" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2888">1,150</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-995" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2889">1,606</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-996" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2890">6,050</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-997" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2891">14,228</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-998" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2892">1,852</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% fixed-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-999" decimals="2" name="sny:DebtPercent" scale="-2" id="f-2893">97</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Floating-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1000" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2894">511</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1001" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2895">381</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1002" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2896">98</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1003" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2897">1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1004" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2898">1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1005" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2899">1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1006" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2900">29</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1007" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:fixed-zero" scale="6" id="f-2901">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1008" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2902">24</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1009" decimals="2" name="sny:DebtPercent" scale="-2" id="f-2903">3</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1010" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2904">16,591</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1011" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2905">2,045</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1012" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2906">2,698</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1013" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2907">3,011</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1014" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2908">1,151</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1015" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2909">1,607</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1016" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2910">6,079</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1009" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2911">8,710</ix:nonFraction>)</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1017" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2912">8,710</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1018" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2913">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1019" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2914">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1020" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2915">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1021" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2916">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1022" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-2917">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1023" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2918">4,115</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1024" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2919">4,251</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1025" decimals="INF" name="sny:DebtPercent" scale="-2" id="f-2920">100</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1025" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2921">7,881</ix:nonFraction></span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1026" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2922">6,665</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1027" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2923">2,698</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1028" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2924">3,011</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1029" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2925">1,151</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1030" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2926">1,607</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1031" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2927">6,079</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi issues debt in <ix:nonFraction unitRef="currency" contextRef="c-5" decimals="INF" name="sny:NumberOfCurrenciesDebtIsIssuedIn" format="ixt-sec:numwordsen" scale="0" id="f-2928">two</ix:nonFraction> currencies, the euro and the US dollar, and also invests its cash and cash equivalents in those currencies. Sanofi also operates cash pooling arrangements to manage the surplus cash and short-term liquidity needs of foreign subsidiaries located outside the euro zone.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-60</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2381-6" continuedAt="f-2381-7"><ix:continuation id="f-2883-1"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To optimize the cost of debt or reduce the volatility of debt and manage its exposure to financial foreign exchange risk, Sanofi uses derivative instruments (interest rate swaps, currency swaps, foreign exchange swaps and forward contracts) that alter the fixed/floating rate split and the currency split of its net debt:</span></div><div style="margin-bottom:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:34.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1032" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2929">11,382</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1033" decimals="-6" sign="-" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2930">3,034</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1034" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2931">2,600</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1035" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2932">3,010</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1036" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2933">1,150</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1037" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2934">1,606</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1038" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2935">6,050</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1039" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2936">11,382</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1040" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:fixed-zero" scale="6" id="f-2937">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% fixed-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1041" decimals="2" name="sny:DebtPercent" scale="-2" id="f-2938">69</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Floating-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1042" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2939">5,191</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1043" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2940">5,061</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1044" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2941">98</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1045" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2942">1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1046" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2943">1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1047" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2944">1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1048" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2945">29</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1049" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" scale="6" id="f-2946">113</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1050" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2947">3,300</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1051" decimals="2" name="sny:DebtPercent" scale="-2" id="f-2948">31</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1052" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2949">16,573</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1053" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2950">2,027</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1054" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2951">2,698</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1055" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2952">3,011</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1056" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2953">1,151</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1057" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2954">1,607</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1058" decimals="-6" name="sny:IncreaseDecreaseOfBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-2955">6,079</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2956">8,738</ix:nonFraction>)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1060" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2957">4,642</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1061" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2958">2,132</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1062" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2959">1,143</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1063" decimals="INF" name="sny:DebtPercent" scale="-2" id="f-2960">100</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2961">7,835</ix:nonFraction></span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1064" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2962">6,711</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1065" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2963">2,698</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1066" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2964">3,011</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1067" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2965">1,151</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1068" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2966">1,607</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1069" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2967">6,079</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock" id="f-2968" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the fixed/floating rate split of net debt at value on redemption after taking account of derivative instruments as of&#160;December 31, 2022 and December&#160;31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:49.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed-rate debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1070" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2969">16,386</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1070" decimals="2" name="sny:DebtPercent" scale="-2" id="f-2970">85</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1071" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2971">17,612</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1071" decimals="2" name="sny:DebtPercent" scale="-2" id="f-2972">87</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Floating-rate debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1072" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2973">2,886</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1072" decimals="2" name="sny:DebtPercent" scale="-2" id="f-2974">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1073" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2975">2,702</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1073" decimals="2" name="sny:DebtPercent" scale="-2" id="f-2976">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1074" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2977">19,273</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1074" decimals="2" name="sny:DebtPercent" scale="-2" id="f-2978">100</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1075" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-2979">20,314</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1075" decimals="2" name="sny:DebtPercent" scale="-2" id="f-2980">100</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1074" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2981">12,781</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1075" decimals="-6" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2982">10,267</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1074" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2983">6,492</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1075" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2984">10,047</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The weighted average interest rate on debt as of December 31, 2023 was <ix:nonFraction unitRef="number" contextRef="c-1076" decimals="3" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2985">1.6</ix:nonFraction>% before derivative instruments and <ix:nonFraction unitRef="number" contextRef="c-1077" decimals="3" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-2986">2.1</ix:nonFraction>% after derivative instruments. Cash and cash equivalents were invested as of December 31, 2023 at an average rate of <ix:nonFraction unitRef="number" contextRef="c-1076" decimals="3" name="sny:CashAndCashEquivalentsInvestedRate" scale="-2" id="f-2987">3.9</ix:nonFraction>% before derivative instruments and <ix:nonFraction unitRef="number" contextRef="c-1077" decimals="3" name="sny:CashAndCashEquivalentsInvestedRate" scale="-2" id="f-2988">3.7</ix:nonFraction>% after derivative instruments.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock" id="f-2989" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The projected full-year sensitivity of net debt to interest rate fluctuations for 2024 is as&#160;follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:53.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.412%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in short-term interest rates</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact&#160;on&#160;pre-tax&#160;net</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">income&#160;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact&#160;on&#160;pre-tax</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">income/(expense)&#160;recognized</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">directly in equity</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+100&#160;bp</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1078" decimals="-6" name="sny:ImpactOfChangeInInterestRateOnPreTaxIncome" scale="6" id="f-2990">48</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1078" decimals="-6" name="sny:ImpactOfPreTaxIncomeRecognisedInEquity" format="ixt:fixed-zero" scale="6" id="f-2991">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25&#160;bp</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1079" decimals="-6" name="sny:ImpactOfChangeInInterestRateOnPreTaxIncome" scale="6" id="f-2992">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1079" decimals="-6" name="sny:ImpactOfPreTaxIncomeRecognisedInEquity" format="ixt:fixed-zero" scale="6" id="f-2993">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-25&#160;bp</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1080" decimals="-6" sign="-" name="sny:ImpactOfChangeInInterestRateOnPreTaxIncome" scale="6" id="f-2994">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1080" decimals="-6" name="sny:ImpactOfPreTaxIncomeRecognisedInEquity" format="ixt:fixed-zero" scale="6" id="f-2995">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-100&#160;bp</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1081" decimals="-6" sign="-" name="sny:ImpactOfChangeInInterestRateOnPreTaxIncome" scale="6" id="f-2996">48</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1081" decimals="-6" name="sny:ImpactOfPreTaxIncomeRecognisedInEquity" format="ixt:fixed-zero" scale="6" id="f-2997">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e) Debt by currency, at value on redemption</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock" id="f-2998" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows net debt by currency at December 31, 2023, before and after derivative instruments contracted to convert the foreign-currency net debt of exposed entities into their functional currency:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:53.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.412%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Before&#160;derivative&#160;instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">After&#160;derivative&#160;instruments</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1082" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-2999">10,113</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1083" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3000">6,852</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1084" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3001">2,376</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1085" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3002">1,169</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1086" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-3003">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1087" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3004">1,143</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pound sterling</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1088" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-3005">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1089" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-3006">509</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1090" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-3007">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1091" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-3008">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other currencies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1092" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-3009">166</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1093" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-3010">259</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1025" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3011">7,881</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1059" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3012">7,835</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-61</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2381-7" continuedAt="f-2381-8"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock" id="f-3013" escape="true"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows net debt by currency at December 31, 2022 and 2021, after derivative instruments contracted to convert the foreign currency net debt of exposed entities into their functional currency:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:74.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1094" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3014">10,489</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1095" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3015">13,129</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1096" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3016">2,404</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1097" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" scale="6" id="f-3017">669</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other currencies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1098" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3018">1,593</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1099" decimals="-6" sign="-" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3019">2,413</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1074" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3020">6,492</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1075" decimals="-6" name="sny:DebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3021">10,047</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">f) Market value of net debt</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfMarketValueOfNetDebtTableTextBlock" id="f-3022" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1100" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-3023">7,086</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1101" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-3024">5,227</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1102" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-3025">11,024</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1103" decimals="-6" name="sny:RedemptionOfDebtInstrumentIssued" format="ixt:num-dot-decimal" scale="6" id="f-3026">7,835</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1104" decimals="-6" name="sny:RedemptionOfDebtInstrumentIssued" format="ixt:num-dot-decimal" scale="6" id="f-3027">6,492</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1105" decimals="-6" name="sny:RedemptionOfDebtInstrumentIssued" format="ixt:num-dot-decimal" scale="6" id="f-3028">10,047</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of debt is determined by reference to quoted market prices at the balance sheet date in the case of quoted instruments (level&#160;1 in the IFRS&#160;7 hierarchy, see Note&#160;D.12.), and by reference to the fair value of interest rate and currency derivatives used to manage net debt (level&#160;2 in the IFRS&#160;7 hierarchy, see Note&#160;D.12.).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">g) Future contractual cash flows relating to debt and related derivatives</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock" id="f-3029" continuedAt="f-3029-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:42.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3030">17,710</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3031">2,153</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1107" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3032">2,912</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1108" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3033">3,187</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1109" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3034">1,285</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3035">1,719</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3036">6,454</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3037">16,468</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3038">1,917</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1107" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3039">2,703</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1108" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3040">3,011</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1109" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3041">1,151</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3042">1,607</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3043">6,079</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:InterestUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3044">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3045">236</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1107" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3046">209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1108" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3047">176</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1109" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3048">134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3049">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3050">375</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash flows related to derivative instruments</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3051">143</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3052">47</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1107" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3053">32</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1108" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3054">23</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1109" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3055">24</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3056">16</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3057">1</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3058">17,853</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3059">2,200</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1107" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3060">2,944</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1108" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3061">3,210</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1109" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3062">1,309</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3063">1,735</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3064">6,455</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2023.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Future contractual cash flows are shown on the basis of the carrying amount in the balance sheet at the reporting date, without reference to any subsequent management decision that might materially alter the structure of Sanofi&#8217;s debt or its hedging policy.</span></div><ix:continuation id="f-3029-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt as of December 31, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:42.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3065">20,408</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3066">4,206</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3067">868</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3068">2,803</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3069">3,184</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3070">1,283</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3071">8,064</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3072">18,932</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3073">3,928</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" scale="6" id="f-3074">661</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3075">2,601</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3076">3,011</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3077">1,151</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3078">7,580</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:InterestUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3079">1,476</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3080">278</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3081">207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3082">202</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3083">173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3084">132</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3085">484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash flows related to derivative instruments</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3086">209</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3087">24</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3088">60</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3089">38</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3090">31</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3091">31</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3092">25</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3093">20,617</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3094">4,230</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1113" decimals="-6" name="sny:TotalUndiscountedCashFlow" scale="6" id="f-3095">928</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1114" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3096">2,841</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1115" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3097">3,215</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1116" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3098">1,314</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3099">8,089</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:42.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3100">21,728</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1118" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3101">3,330</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1119" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3102">3,826</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1120" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3103">791</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1121" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3104">1,937</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1122" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3105">3,176</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1123" decimals="-6" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="6" id="f-3106">8,668</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3107">20,086</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1118" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3108">3,055</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1119" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3109">3,588</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1120" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" scale="6" id="f-3110">601</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1121" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3111">1,751</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1122" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3112">3,011</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1123" decimals="-6" name="sny:PrincipalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3113">8,080</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:InterestUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3114">1,642</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1118" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3115">275</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1119" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3116">238</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1120" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3117">190</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1121" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3118">186</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1122" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3119">165</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1123" decimals="-6" name="sny:InterestUndiscountedCashFlow" scale="6" id="f-3120">588</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash flows related to derivative instruments</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3121">51</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1118" decimals="-6" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3122">59</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1119" decimals="-6" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3123">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1120" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3124">2</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1121" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3125">2</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1122" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3126">2</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1123" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="6" id="f-3127">3</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3128">21,677</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1118" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3129">3,271</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1119" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3130">3,825</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1120" decimals="-6" name="sny:TotalUndiscountedCashFlow" scale="6" id="f-3131">793</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1121" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3132">1,939</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1122" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3133">3,178</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1123" decimals="-6" name="sny:TotalUndiscountedCashFlow" format="ixt:num-dot-decimal" scale="6" id="f-3134">8,671</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2021.</span></div></ix:continuation></ix:continuation><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-62</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-2381-8"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.17.2. Lease liabilities</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock" id="f-3135" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A maturity analysis of lease liabilities as of December 31, 2023, 2022 and 2021 is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:41.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.398%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Undiscounted future minimum lease payments</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less than 1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From 1 to 3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From 3 to 5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More than 5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Discounting effect</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total lease liabilities as of December 31, 2023</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3136">2,030</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="ifrs-full:LeaseLiabilities" scale="6" id="f-3137">291</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1124" decimals="-6" name="ifrs-full:LeaseLiabilities" scale="6" id="f-3138">448</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1125" decimals="-6" name="ifrs-full:LeaseLiabilities" scale="6" id="f-3139">360</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="ifrs-full:LeaseLiabilities" scale="6" id="f-3140">989</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:LeaseLiabilitiesEffectOfDiscounting" scale="6" id="f-3141">58</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total lease liabilities as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3142">2,181</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-6" name="ifrs-full:LeaseLiabilities" scale="6" id="f-3143">320</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1126" decimals="-6" name="ifrs-full:LeaseLiabilities" scale="6" id="f-3144">515</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-6" name="ifrs-full:LeaseLiabilities" scale="6" id="f-3145">436</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3146">1,129</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:LeaseLiabilitiesEffectOfDiscounting" scale="6" id="f-3147">219</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total lease liabilities as of December 31, 2021</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3148">2,108</ix:nonFraction></span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1118" decimals="-6" name="ifrs-full:LeaseLiabilities" scale="6" id="f-3149">314</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-6" name="ifrs-full:LeaseLiabilities" scale="6" id="f-3150">476</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-6" name="ifrs-full:LeaseLiabilities" scale="6" id="f-3151">362</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1123" decimals="-6" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3152">1,184</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:LeaseLiabilitiesEffectOfDiscounting" scale="6" id="f-3153">228</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Lease liabilities include leases relating to real estate assets located at Cambridge, MA (United States), as described in Note&#160;D.3., which have a lease term of <ix:nonNumeric contextRef="c-1130" name="sny:InitialLeaseTerm" format="ixt-sec:duryear" id="f-3154">15</ix:nonNumeric> years.</span></div></ix:nonNumeric></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_667"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.18. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock" id="f-3155" continuedAt="f-3155-1" escape="true">Liabilities related to business combinations and to non-controlling interests</ix:nonNumeric></span></div><ix:continuation id="f-3155-1" continuedAt="f-3155-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the nature of the liabilities reported in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, refer to Note&#160;B.8.5. The principal acquisitions are described in Notes&#160;D.1. and&#160;D.2.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS&#160;7 fair value hierarchy (see Note&#160;D.12.).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock" id="f-3156" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:34.734%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bayer</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">contingent</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">consideration</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">arising&#160;from&#160;the</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">acquisition of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Genzyme </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">MSD<br/>contingent<br/>consideration<br/>(European<br/>Vaccines<br/>business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shire</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">contingent</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">consideration</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">arising&#160;from&#160;the</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">acquisition of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Translate Bio</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contingent consideration arising from acquisition of Amunix</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at January 1, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1131" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3157">104</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1132" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3158">312</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1133" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3159">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1134" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3160">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1135" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3161">189</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3162">605</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">New transactions</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1136" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3163">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1137" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3164">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1138" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3165">323</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1139" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3166">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1140" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3167">37</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3168">360</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1136" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3169">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1137" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3170">75</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1138" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3171">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1139" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3172">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1140" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3173">152</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3174">258</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1136" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3175">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1137" decimals="-6" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3176">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1138" decimals="-6" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3177">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1139" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" format="ixt:fixed-zero" scale="6" id="f-3178">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1140" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3179">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3180">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1136" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3181">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1137" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3182">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1138" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3183">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1139" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3184">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1140" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3185">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3186">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1136" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3187">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1137" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3188">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1138" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3189">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1139" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3190">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1140" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3191">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3192">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1141" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3193">59</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1142" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3194">269</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1143" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3195">354</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1144" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3196">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1145" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3197">32</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3198">714</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">New transactions</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1146" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3199">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1147" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3200">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1148" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3201">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1149" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3202">156</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1150" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3203">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3204">156</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1146" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3205">29</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1147" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3206">79</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1148" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3207">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1149" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3208">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1150" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3209">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3210">136</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1146" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3211">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1147" decimals="-6" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3212">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1148" decimals="-6" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3213">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1149" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3214">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1150" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" format="ixt:fixed-zero" scale="6" id="f-3215">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3216">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1146" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3217">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1147" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3218">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1148" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3219">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1149" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3220">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1150" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3221">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3222">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1146" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3223">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1147" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3224">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1148" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3225">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1149" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3226">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1150" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3227">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3228">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1151" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3229">26</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1152" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3230">204</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1153" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3231">380</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1154" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3232">165</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1155" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3233">4</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3234">779</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">New transactions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1156" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1157" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1158" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1159" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1160" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1156" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3241">21</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1157" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3242">77</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1158" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1159" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3244">69</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1160" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3246">167</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1156" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3247">5</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1157" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" format="ixt:fixed-zero" scale="6" id="f-3248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1158" decimals="-6" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3249">74</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1159" decimals="-6" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3250">45</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1160" decimals="-6" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" format="ixt:fixed-zero" scale="6" id="f-3251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" scale="6" id="f-3252">114</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1156" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1157" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1158" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1159" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1160" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1156" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1157" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1158" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3261">13</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1159" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3262">4</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1160" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" format="ixt:fixed-zero" scale="6" id="f-3263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" scale="6" id="f-3264">17</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1161" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-3265">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-529" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3266">127</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1162" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3267">441</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1163" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3268">137</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1164" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3269">4</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3270">709</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Portion due after more than one year: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" format="ixt:num-dot-decimal" scale="6" id="f-3271">501</ix:nonFraction> million as of December 31, 2023 (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" format="ixt:num-dot-decimal" scale="6" id="f-3272">674</ix:nonFraction> million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" format="ixt:num-dot-decimal" scale="6" id="f-3273">577</ix:nonFraction> million as of December 31, 2021); portion due within less than one year: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" format="ixt:num-dot-decimal" scale="6" id="f-3274">208</ix:nonFraction> million as of December 31, 2023 (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" format="ixt:num-dot-decimal" scale="6" id="f-3275">105</ix:nonFraction> million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" format="ixt:num-dot-decimal" scale="6" id="f-3276">137</ix:nonFraction>&#160;million as of&#160;December 31, 2021).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Amounts reported within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, and mainly comprising unrealized gains and losses.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Mainly corresponds to the recognition of the Shire Human Genetic Therapies&#160;Inc. (Shire) contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="c-1165" decimals="-6" name="sny:ContingentConsiderationLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3277">382</ix:nonFraction> million resulting from the acquisition of Translate Bio in September&#160;2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column mainly relates to the contingent consideration liability due to True North Therapeutics as a result of Sanofi's acquisition of Bioverativ which was settled in the first half of 2021.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-63</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-3155-2" continuedAt="f-3155-3"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprised:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture, which amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-529" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-3278">127</ix:nonFraction> million as of December 31, 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1152" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-3279">204</ix:nonFraction> million as of&#160;December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1142" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-3280">269</ix:nonFraction> million as of December 31, 2021 (see Note&#160;D.12.). The fair value of this contingent consideration is determined by applying the royalty percentage stipulated in the contract to discounted sales projections. If the discount rate were to fall by one percentage point, the fair value of the MSD contingent consideration liability would increase by approximately <ix:nonFraction unitRef="number" contextRef="c-529" decimals="2" name="sny:PercentageIncreaseInFairValueLiabilities" scale="-2" id="f-3281">1</ix:nonFraction>%;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi&#8217;s acquisition of Translate&#160;Bio in September&#160;2021. In a business combination carried out in December 2016 and predating the acquisition of control by Sanofi, Translate Bio (then called Rana Therapeutics, Inc.) acquired from Shire the intellectual property rights relating to the latter&#8217;s Messenger RNA Therapeutics (MRT) program. As of December 31, 2023, Shire was entitled to receive the following potential payments:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">milestone payments contingent on the launch of products based on MRT technology, and on the attainment of a specified level of sales of those products, and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">a percentage of sales of those products.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of the Shire liability was measured at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1162" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-3282">441</ix:nonFraction> million as of December 31, 2023, compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1153" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-3283">380</ix:nonFraction> million as of&#160;December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1143" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-3284">354</ix:nonFraction> million as of December 31, 2021; it was determined by applying the contractual terms to development and sales projections which were weighted to reflect the probability of success, and discounted. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately <ix:nonFraction unitRef="number" contextRef="c-1166" decimals="2" name="sny:PercentageIncreaseInFairValueLiabilities" scale="-2" id="f-3285">12</ix:nonFraction>%;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the contingent consideration liability arising from the 2022 acquisition of Amunix. The fair value of the liability is determined on&#160;the basis of the nominal value of payments due subject to the attainment of specified</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> development milestones. The liability was measured at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1163" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-3286">137</ix:nonFraction>&#160;million as of December 31, 2023 </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1154" decimals="-6" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-3287">165</ix:nonFraction> million as of&#160;December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. If the discount rate were to fall by one percentage point, the fair value of the liability would increase by approximately&#160;<ix:nonFraction unitRef="number" contextRef="c-1163" decimals="2" name="sny:PercentageIncreaseInFairValueLiabilities" scale="-2" id="f-3288">1</ix:nonFraction>%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Bayer contingent consideration liability arising from Sanofi&#8217;s acquisition of Genzyme in 2011 was extinguished during 2023 in accordance with the contractual terms.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock" id="f-3289" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the maximum amount of contingent consideration payable in respect of already-marketed products:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From&#160;1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From&#160;3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commitments relating to contingent consideration&#160;in connection with business combinations</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" scale="6" id="f-3290">133</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" scale="6" id="f-3291">69</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1124" decimals="-6" name="sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" scale="6" id="f-3292">64</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1125" decimals="-6" name="sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" format="ixt:fixed-zero" scale="6" id="f-3293">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" format="ixt:fixed-zero" scale="6" id="f-3294">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-3155-3">The nominal amount of contingent consideration was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" format="ixt:num-dot-decimal" scale="6" id="f-3295">604</ix:nonFraction> million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" format="ixt:num-dot-decimal" scale="6" id="f-3296">689</ix:nonFraction> million as of            December 31, 2021.</ix:continuation> </span></div><div id="i9fa7f69b4904450e9c43e8444c203165_670"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.19. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfProvisionsAndOtherLiabilitiesTextBlock" id="f-3297" continuedAt="f-3297-1" escape="true">Provisions, income tax liabilities and other liabilities</ix:nonNumeric></span></div><ix:continuation id="f-3297-1" continuedAt="f-3297-2"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" id="f-3298" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3299">5,262</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3300">5,822</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3301">6,430</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3302">2,340</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" scale="6" id="f-3303">519</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" scale="6" id="f-3304">291</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3305">7,602</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3306">6,341</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3307">6,721</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes derivative financial instruments: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" scale="6" id="f-3308">164</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">as of December 31, 2023</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3309">232</ix:nonFraction> million as of December 31, 2022, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3310">6</ix:nonFraction> million as of December 31, 2021.<br/>The figure as of December 31, 2023 includes &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1167" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3311">1,960</ix:nonFraction>&#160;million for the liability in respect of royalties payable to Sobi on net sales of BEYFORTUS (nirsevimab) in the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1168" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3312">1,112</ix:nonFraction>&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1169" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-3313">2,860</ix:nonFraction> million.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current income tax liabilities are described in Note&#160;D.19.4., and other current liabilities in Note&#160;D.19.5.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-64</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-3297-2" continuedAt="f-3297-3"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNonCurrentProvisionsTableTextBlock" id="f-3314" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth movements in non-current provisions for the reporting periods presented:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:33.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.998%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.000%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions&#160;for<br/>pensions and<br/>other&#160;post-employment<br/>benefits<br/>(D.19.1.)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions<br/>for other<br/>long-term<br/>benefits</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Restructuring<br/>provisions<br/>(D.19.2.)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>provisions<br/>(D.19.3.)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1170" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3315">3,276</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1171" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-3316">879</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1172" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-3317">868</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1173" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3318">1,975</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3319">6,998</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" scale="6" id="f-3320">2</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-3321">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1176" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-3322">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1177" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" scale="6" id="f-3323">37</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" scale="6" id="f-3324">35</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3325">247</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3326">156</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1176" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3327">67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1177" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3328">261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3329">731</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3330">222</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3331">122</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1176" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3332">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1177" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3333">107</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3334">459</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3335">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3336">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1176" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3337">35</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1177" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3338">145</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3339">200</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3340">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3341">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1176" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3342">370</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1177" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3343">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3344">425</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3345">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3346">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1176" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" format="ixt:fixed-zero" scale="6" id="f-3347">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1177" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3348">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3349">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3350">80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3351">30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1176" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3352">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1177" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3353">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3354">145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1174" decimals="-6" sign="-" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" scale="6" id="f-3355">448</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1175" decimals="-6" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" format="ixt:fixed-zero" scale="6" id="f-3356">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1176" decimals="-6" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" format="ixt:fixed-zero" scale="6" id="f-3357">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1177" decimals="-6" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" format="ixt:fixed-zero" scale="6" id="f-3358">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" scale="6" id="f-3359">448</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1178" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3360">2,947</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1179" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-3361">935</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1180" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-3362">524</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1181" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3363">2,024</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3364">6,430</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1182" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" scale="6" id="f-3365">96</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1183" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" scale="6" id="f-3366">28</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1184" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-3367">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1185" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" scale="6" id="f-3368">76</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" scale="6" id="f-3369">200</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1182" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3370">193</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1183" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3371">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1184" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3372">521</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1185" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3373">531</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3374">1,285</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1182" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3375">275</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1183" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3376">119</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1184" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3377">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1185" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3378">122</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3379">528</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1182" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3380">66</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1183" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3381">20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1184" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3382">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1185" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3383">191</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3384">288</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1182" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3385">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1183" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3386">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1184" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3387">265</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1185" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3388">23</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3389">274</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1182" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3390">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1183" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3391">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1184" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3392">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1185" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3393">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3394">64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1182" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3395">63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1183" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3396">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1184" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3397">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1185" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3398">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3399">113</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1182" decimals="-6" sign="-" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" scale="6" id="f-3400">780</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1183" decimals="-6" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" format="ixt:fixed-zero" scale="6" id="f-3401">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1184" decimals="-6" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" format="ixt:fixed-zero" scale="6" id="f-3402">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1185" decimals="-6" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" format="ixt:fixed-zero" scale="6" id="f-3403">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" scale="6" id="f-3404">780</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1186" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3405">2,039</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1187" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-3406">844</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1188" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-3407">761</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1189" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3408">2,178</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3409">5,822</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1190" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-3410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-3411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-3412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-3413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-3414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1190" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3415">141</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3416">185</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3417">315</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3418">311</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ChangesInOtherProvisions" scale="6" id="f-3419">952</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1190" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3420">162</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3421">107</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3422">25</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3423">114</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-3424">408</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1190" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3425">21</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3426">190</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3427">159</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3428">388</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" scale="6" id="f-3429">758</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1190" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3430">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-3431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3432">361</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3433">210</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-3434">572</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1190" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3435">70</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3436">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3437">23</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3438">24</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" scale="6" id="f-3439">120</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1190" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3440">23</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3441">17</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-3442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3443">25</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-3444">65</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1190" decimals="-6" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" scale="6" id="f-3445">171</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1191" decimals="-6" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" format="ixt:fixed-zero" scale="6" id="f-3446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1192" decimals="-6" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" format="ixt:fixed-zero" scale="6" id="f-3447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1193" decimals="-6" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" format="ixt:fixed-zero" scale="6" id="f-3448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ActuarialGainsAndLossesOnDefinedBenefitPlans" scale="6" id="f-3449">171</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1194" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3450">2,214</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1195" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-3451">718</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1196" decimals="-6" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-3452">554</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1197" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3453">1,776</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3454">5,262</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Includes the impact of the April&#160;2021 IFRIC agenda decision on the allocation of benefits to service periods, as described in Note&#160;A.2.1. to the consolidated financial statements for the year ended December&#160;31, 2021.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.19.1. Provisions for pensions and other post-employment benefits</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi offers its employees pension plans and other post-employment benefit plans. The specific features of the plans (benefit formulas, fund investment policy and fund assets held) vary depending on the applicable laws and regulations in each country where the employees work. These employee benefits are accounted for in accordance with IAS&#160;19 (see Note&#160;B.23.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s pension obligations in <ix:nonFraction unitRef="country" contextRef="c-1" decimals="INF" name="sny:NumberOfCountriesIncludedInPensionPlans" format="ixt-sec:numwordsen" scale="0" id="f-3455">four</ix:nonFraction>&#160;major countries represented approximately <ix:nonFraction unitRef="number" contextRef="c-5" decimals="2" name="sny:PensionObligationPercentageToDefinedBenefitLiability" scale="-2" id="f-3456">89</ix:nonFraction>% of the total value of the defined-benefit obligation and approximately <ix:nonFraction unitRef="number" contextRef="c-5" decimals="2" name="sny:PensionObligationPercentageToPlanAssets" scale="-2" id="f-3457">88</ix:nonFraction>% of the total value of plan assets as of December 31, 2023. The features of the principal defined-benefit plans in each of those four countries are described below.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">France</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Lump-sum retirement benefit plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All employees working for Sanofi in France are entitled on retirement to a lump-sum payment, the amount of which depends both on their length of service and on the rights guaranteed by collective and internal agreements. The employee&#8217;s final salary is used in calculating the amount of these lump-sum retirement benefits. These plans represent approximately <ix:nonFraction unitRef="number" contextRef="c-1198" decimals="2" name="sny:PensionObligationPercentageToDefinedBenefitLiability" scale="-2" id="f-3458">39</ix:nonFraction>% of Sanofi&#8217;s total obligation in France.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-65</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-3297-3" continuedAt="f-3297-4"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Defined-benefit pension plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These plans provide benefits from the date of retirement. Employees must fulfil a number of criteria to be eligible for these benefits. All of these plans are now closed. These plans represent approximately&#160;<ix:nonFraction unitRef="number" contextRef="c-1199" decimals="2" name="sny:PensionObligationPercentageToDefinedBenefitLiability" scale="-2" id="f-3459">61</ix:nonFraction>% of Sanofi&#8217;s total obligation in France.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Germany</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Top-up defined-benefit pension plan</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The benefits offered under this pension plan are wholly funded by the employer (there are no employee contributions) via a Contractual Trust Agreement (CTA), under which benefits are estimated on the basis of a career average salary. Employees are entitled to receive an annuity under this plan if their salary exceeds the social security ceiling. The amount of the pension is calculated by reference to a range of vesting rates corresponding to salary bands. The plan also includes disability and death benefits. This plan represents approximately <ix:nonFraction unitRef="number" contextRef="c-1200" decimals="2" name="sny:PensionObligationPercentageToDefinedBenefitLiability" scale="-2" id="f-3460">60</ix:nonFraction>% of Sanofi&#8217;s total obligation in Germany.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi-Aventis plus (SAV plus)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A top-up pension plan (SAV plus) replaced a previous top-up defined-benefit plan. New entrants joining the plan after April&#160;1,&#160;2015 contribute to a defined-contribution plan that is partially funded via the company&#8217;s CTA.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All employees whose salary exceeds the social security ceiling are automatically covered by the plan. The employer&#8217;s contribution is <ix:nonFraction unitRef="number" contextRef="c-1201" decimals="INF" name="sny:EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling" scale="-2" id="f-3461">14</ix:nonFraction>% of the amount by which the employee&#8217;s salary exceeds the social security ceiling.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Multi-employer plan </span><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Pensionskasse)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This is a defined-benefit plan treated as a defined-contribution plan, in accordance with the accounting policies described in&#160;Note&#160;B.23. Currently, contributions cover the level of annuities. Only the portion relating to the future revaluation of&#160;the&#160;annuities is included in the defined-benefit pension obligation. The obligation relating to this revaluation amounted to&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1202" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3462">744</ix:nonFraction> million as of December 31, 2023, versus&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1203" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3463">652</ix:nonFraction> million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1204" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3464">877</ix:nonFraction> million as of December 31, 2021. This plan represents approximately <ix:nonFraction unitRef="number" contextRef="c-1202" decimals="2" name="sny:PensionObligationPercentageToDefinedBenefitLiability" scale="-2" id="f-3465">26</ix:nonFraction>% of Sanofi&#8217;s total defined-benefit obligation in Germany.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Defined-benefit pension plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the United States, there are <ix:nonFraction unitRef="plan" contextRef="c-1205" decimals="INF" name="sny:NumberOfDefinedBenefitPlans" format="ixt-sec:numwordsen" scale="0" id="f-3466">two</ix:nonFraction> types of defined-benefit plan:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">&#8220;qualified&#8221; plans within the meaning of the Employee Retirement Income Security Act of 1974 (ERISA), which provide guaranteed benefits to eligible employees during retirement, and in the event of death or disability. Employees can elect to receive a reduced annuity, in exchange for an annuity to be paid in the event of their death to a person designated by them. An annuity is also granted under the plan if the employee dies before retirement age. Eligible employees do not pay any contributions. These plans are closed to new entrants, and the vesting of rights for future service periods is partially frozen. These plans represent approximately <ix:nonFraction unitRef="number" contextRef="c-1206" decimals="2" name="sny:PensionObligationPercentageToDefinedBenefitLiability" scale="-2" id="f-3467">59</ix:nonFraction>% of Sanofi&#8217;s total obligation in the United States;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">&#8220;non-qualified&#8221; plans within the meaning of ERISA provide top-up retirement benefits to some eligible employees depending on the employee&#8217;s level of responsibility and subject to a salary cap. These plans represent approximately <ix:nonFraction unitRef="number" contextRef="c-1207" decimals="2" name="sny:PensionObligationPercentageToDefinedBenefitLiability" scale="-2" id="f-3468">14</ix:nonFraction>% of Sanofi&#8217;s total obligation in the United States.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare cover and life insurance</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi companies provide some eligible employees with healthcare cover and life insurance during the retirement period (the company&#8217;s contributions are capped at a specified level). These plans represent approximately <ix:nonFraction unitRef="number" contextRef="c-1208" decimals="2" name="sny:PensionObligationPercentageToDefinedBenefitLiability" scale="-2" id="f-3469">27</ix:nonFraction>% (or &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1208" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3470">412</ix:nonFraction> million) of Sanofi&#8217;s total obligation and&#160;<ix:nonFraction unitRef="number" contextRef="c-1209" decimals="2" name="sny:PensionObligationPercentageToPlanAssets" scale="-2" id="f-3471">3</ix:nonFraction>% (or &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1209" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3472">23</ix:nonFraction> million) of total plan assets in the United States.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United Kingdom</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Defined-benefit pension plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi operates a number of pension plans in the United Kingdom that reflect past acquisitions. The most significant arrangements are defined-benefit plans that have been closed since October&#160;1, 2015. With effect from that date, employees can no longer pay into these plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under these defined-benefit plans, an annuity is paid from the retirement date. This annuity is calculated on the basis of the employee&#8217;s length of service as of September&#160;30, 2015, and of the employee&#8217;s final salary (or salary on the date he or she leaves Sanofi).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The rates used for the vesting of rights vary from member to member. For most members, rights vest at the rate of <ix:nonFraction unitRef="number" contextRef="c-1210" decimals="INF" name="sny:DefinedBenefitPlansVestingRightsPercentage" scale="-2" id="f-3473">1.25</ix:nonFraction>% or <ix:nonFraction unitRef="number" contextRef="c-1211" decimals="INF" name="sny:DefinedBenefitPlansVestingRightsPercentage" scale="-2" id="f-3474">1.50</ix:nonFraction>% of final salary for each qualifying year of service giving entitlement. The notional retirement age varies according to the category to which the member belongs, but in most cases retirement is at age <ix:nonFraction unitRef="age" contextRef="c-1212" decimals="INF" name="sny:RetirementAge" scale="0" id="f-3475">65</ix:nonFraction>. Members may choose to retire before or after the notional retirement age (<ix:nonFraction unitRef="age" contextRef="c-1212" decimals="INF" name="sny:NotionalRetirementAge" scale="0" id="f-3476">60</ix:nonFraction>&#160;years), in which case the amount of the annual pension is adjusted to reflect the revised estimate of the length of the retirement phase. Pensions are usually indexed to the Retail Price Index (RPI). Members paid a fixed-percentage contribution into their pension plan (the percentage varied according to the employee category), and the employer topped up the contribution to the required amount. These plans represent approximately <ix:nonFraction unitRef="number" contextRef="c-1213" decimals="INF" name="sny:PensionObligationPercentageToDefinedBenefitLiability" scale="-2" id="f-3477">100</ix:nonFraction>% of Sanofi&#8217;s total obligation in the United Kingdom.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For service periods subsequent to October&#160;1, 2015, employees belong to a new defined-contribution plan.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-66</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-3297-4" continuedAt="f-3297-5"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Actuarial assumptions used to measure Sanofi&#8217;s obligations</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial valuations of Sanofi&#8217;s benefit obligations were computed by management with assistance from external actuaries as of&#160;December 31, 2023, 2022 and 2021.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfActuarialAssumptionsTableTextBlock" id="f-3478" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those calculations were based on the following financial and demographic assumptions:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1214" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3479">2.95</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-1215" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3480">3.15</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1216" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3481">2.95</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-1217" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3482">3.15</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1218" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3483">4.75</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1219" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3484">4.50</ix:nonFraction>%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1220" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3485">3.55</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-1221" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3486">3.75</ix:nonFraction>%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1222" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3487">3.55</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-1223" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3488">3.75</ix:nonFraction>%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1224" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3489">4.90</ix:nonFraction>%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1225" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3490">4.75</ix:nonFraction>%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1226" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3491">0.10</ix:nonFraction>%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1227" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3492">1.10</ix:nonFraction>%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1228" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3493">0.10</ix:nonFraction>%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1229" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3494">1.10</ix:nonFraction>%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1230" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3495">2.70</ix:nonFraction>%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1231" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-3496">1.90</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">General inflation rate</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1232" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" scale="-2" id="f-3497">2.20</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1233" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" scale="-2" id="f-3498">2.20</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1219" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" scale="-2" id="f-3499">3.05</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1234" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" scale="-2" id="f-3500">2.50</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1235" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" scale="-2" id="f-3501">2.50</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1225" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" scale="-2" id="f-3502">3.25</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1236" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" scale="-2" id="f-3503">1.95</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1237" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" scale="-2" id="f-3504">1.95</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1231" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation" scale="-2" id="f-3505">3.30</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pension benefit <br/>indexation</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1232" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" scale="-2" id="f-3506">2.20</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1233" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" scale="-2" id="f-3507">2.20</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1219" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" scale="-2" id="f-3508">2.90</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1234" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" scale="-2" id="f-3509">2.50</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1235" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" scale="-2" id="f-3510">2.50</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1225" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" scale="-2" id="f-3511">3.00</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1226" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" scale="-2" id="f-3512">1.95</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1237" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" scale="-2" id="f-3513">1.95</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1231" decimals="4" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" scale="-2" id="f-3514">3.15</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Healthcare cost </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">inflation rate</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1238" decimals="4" name="ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates" scale="-2" id="f-3515">4.00</ix:nonFraction>%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1239" decimals="4" name="ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates" scale="-2" id="f-3516">9.75</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1240" decimals="4" name="ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates" scale="-2" id="f-3517">3.29</ix:nonFraction>%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1241" decimals="4" name="ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates" scale="-2" id="f-3518">6.56</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1242" decimals="4" name="ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates" scale="-2" id="f-3519">3.50</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-1243" decimals="4" name="ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates" scale="-2" id="f-3520">4.50</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retirement age</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1244" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3521">62</ix:nonNumeric></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to <ix:nonNumeric contextRef="c-1245" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3522">67</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1246" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3523">63</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1247" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3524">55</ix:nonNumeric></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to <ix:nonNumeric contextRef="c-1248" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3525">70</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1210" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3526">60</ix:nonNumeric></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to <ix:nonNumeric contextRef="c-1211" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3527">65</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1249" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3528">62</ix:nonNumeric></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to <ix:nonNumeric contextRef="c-1250" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3529">67</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1251" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3530">63</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1252" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3531">55</ix:nonNumeric></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to <ix:nonNumeric contextRef="c-1253" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3532">70</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1254" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3533">60</ix:nonNumeric></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to <ix:nonNumeric contextRef="c-1255" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3534">65</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1256" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3535">62</ix:nonNumeric></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to <ix:nonNumeric contextRef="c-1257" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3536">67</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1258" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3537">62</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1259" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3538">55</ix:nonNumeric></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to <ix:nonNumeric contextRef="c-1260" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3539">70</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1261" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3540">60</ix:nonNumeric></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to <ix:nonNumeric contextRef="c-1262" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="f-3541">65</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mortality table</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TGH/<br/>TGF<br/>05</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Heubeck<br/>RT<br/>2018 G</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RP2012 Proj.<br/>MP2021 White Collar</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAPS<br/>S3</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TGH/<br/>TGF<br/>05</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Heubeck<br/>RT<br/>2018 G</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RP2012 Proj.<br/>MP2021 White Collar</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAPS<br/>S3</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TGH/<br/>TGF<br/>05</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Heubeck<br/>RT<br/>2018 G</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RP2012 Proj.<br/>G.&#160;Scale<br/>MP2020 White Collar</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAPS<br/>S3</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The discount rates used were based on market rates for high quality corporate bonds with a duration close to that of the expected benefit payments under the plans. The benchmarks used to determine discount rates were the same for all periods presented.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The rate depends on the duration of the plan (<ix:nonNumeric contextRef="c-1263" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3542">0</ix:nonNumeric>&#160;to <ix:nonNumeric contextRef="c-1264" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3543">7</ix:nonNumeric>&#160;years, <ix:nonNumeric contextRef="c-1265" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3544">7</ix:nonNumeric>&#160;to <ix:nonNumeric contextRef="c-1266" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3545">10</ix:nonNumeric>&#160;years, or more than <ix:nonNumeric contextRef="c-1" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3546">10</ix:nonNumeric>&#160;years).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Inflation for the euro zone is determined using a multi-criterion method.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;No post-employment healthcare benefits are provided in France since 2020, Germany and UK.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average duration of obligation for pensions and other long-term benefits in principal countries</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock" id="f-3547" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the duration of Sanofi&#8217;s obligations in the principal countries:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:25.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted average duration</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1267" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3548">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1246" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3549">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1205" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3550">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1212" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3551">13</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1268" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3552">10</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1251" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3553">12</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1269" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3554">11</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1270" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3555">13</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1271" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3556">12</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1258" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3557">16</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1272" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3558">15</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1273" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="f-3559">17</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sensitivity analysis</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" id="f-3560" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the sensitivity of Sanofi&#8217;s obligations for pensions and other post-employment benefits to changes in key actuarial assumptions:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions and other post-employment benefits, <br/>by principal country</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement of defined-benefit obligation</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in<br/>assumption</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-1274" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" scale="-2" id="f-3561">0.50</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1275" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3562">56</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1276" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3563">170</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1277" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3564">78</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1278" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3565">42</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">General inflation rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-1279" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-3566">0.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1280" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3567">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1281" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3568">220</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1282" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" format="ixt:fixed-zero" scale="6" id="f-3569">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1283" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3570">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pension benefit indexation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-1284" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-3571">0.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1285" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3572">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1286" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3573">216</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1287" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" format="ixt:fixed-zero" scale="6" id="f-3574">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1288" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3575">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Healthcare cost inflation rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-1289" decimals="INF" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" scale="-2" id="f-3576">0.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1290" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3577">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1291" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" format="ixt:fixed-zero" scale="6" id="f-3578">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1292" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3579">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1293" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3580">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortality table</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+1 year</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1294" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3581">38</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1295" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3582">53</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1296" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3583">25</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="eur" contextRef="c-1297" decimals="-6" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="6" id="f-3584">19</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-67</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock" id="f-3585" escape="true"><ix:continuation id="f-3297-5" continuedAt="f-3297-6"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below reconciles the net obligation in respect of Sanofi&#8217;s pension and other post-employment benefit plans with the amounts recognized in the consolidated financial statements:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:63.065%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement of the obligation:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Beginning of period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1298" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3586">8,651</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1299" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3587">12,175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1300" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3588">12,456</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1301" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3589">140</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1302" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3590">193</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1303" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3591">227</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1301" decimals="-6" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="6" id="f-3592">346</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1302" decimals="-6" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="6" id="f-3593">206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1303" decimals="-6" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="6" id="f-3594">148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial losses/(gains) due to changes in demographic assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1301" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3595">34</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1302" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3596">219</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1303" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3597">162</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial losses/(gains) due to changes in financial assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1301" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3598">157</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1302" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-3599">3,006</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1303" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3600">210</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial losses/(gains) due to experience adjustments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1301" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3601">256</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1302" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3602">177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1303" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3603">120</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan amendments, curtailments or settlements not specified in the terms of the plan</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1301" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" scale="6" id="f-3604">36</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1302" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" scale="6" id="f-3605">229</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1303" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" scale="6" id="f-3606">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan settlements specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1301" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" scale="6" id="f-3607">40</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1302" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" scale="6" id="f-3608">84</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1303" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" scale="6" id="f-3609">66</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1301" decimals="-6" name="ifrs-full:BenefitsPaidOrPayable" scale="6" id="f-3610">483</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1302" decimals="-6" name="ifrs-full:BenefitsPaidOrPayable" scale="6" id="f-3611">463</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1303" decimals="-6" name="ifrs-full:BenefitsPaidOrPayable" scale="6" id="f-3612">503</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation and transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1301" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3613">14</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1302" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3614">114</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1303" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3615">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1301" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" scale="6" id="f-3616">13</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1302" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" scale="6" id="f-3617">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1303" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" scale="6" id="f-3618">417</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Obligation at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1304" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3619">8,930</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1298" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3620">8,651</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1299" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3621">12,175</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Beginning of period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1305" decimals="-6" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3622">6,899</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1306" decimals="-6" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3623">9,651</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1307" decimals="-6" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3624">9,358</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1308" decimals="-6" sign="-" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="6" id="f-3625">276</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1309" decimals="-6" sign="-" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="6" id="f-3626">163</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1310" decimals="-6" sign="-" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="6" id="f-3627">106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between actual return and interest income on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1308" decimals="-6" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3628">197</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1309" decimals="-6" sign="-" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-3629">2,398</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1310" decimals="-6" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3630">207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Administration costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1308" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" scale="6" id="f-3631">7</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1309" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" scale="6" id="f-3632">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1310" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" scale="6" id="f-3633">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan settlements specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1308" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" scale="6" id="f-3634">40</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1309" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" scale="6" id="f-3635">84</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1310" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" scale="6" id="f-3636">66</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan settlements not specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1308" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" scale="6" id="f-3637">17</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1309" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" scale="6" id="f-3638">161</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1310" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" scale="6" id="f-3639">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1308" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3640">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1309" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3641">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1310" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3642">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employer&#8217;s contributions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1308" decimals="-6" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" scale="6" id="f-3643">122</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1309" decimals="-6" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" scale="6" id="f-3644">238</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1310" decimals="-6" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" scale="6" id="f-3645">176</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1308" decimals="-6" sign="-" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" scale="6" id="f-3646">446</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1309" decimals="-6" sign="-" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" scale="6" id="f-3647">426</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1310" decimals="-6" sign="-" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" scale="6" id="f-3648">458</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation and transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1308" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3649">8</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1309" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3650">32</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1310" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3651">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1308" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" scale="6" id="f-3652">11</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1309" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" scale="6" id="f-3653">52</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1310" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" scale="6" id="f-3654">344</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan assets at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1311" decimals="-6" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3655">6,993</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1305" decimals="-6" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3656">6,899</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1306" decimals="-6" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3657">9,651</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net obligation</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1312" decimals="-6" name="ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan" format="ixt:num-dot-decimal" scale="6" id="f-3658">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1313" decimals="-6" name="ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan" format="ixt:num-dot-decimal" scale="6" id="f-3659">1,752</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1314" decimals="-6" name="ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan" format="ixt:num-dot-decimal" scale="6" id="f-3660">2,524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1315" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3661">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1316" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3662">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1317" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3663">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1312" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3664">1,943</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1313" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3665">1,770</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1314" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3666">2,539</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts recognized in the balance sheet:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded obligations (see Note D.7.)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1312" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-3667">271</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1313" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-3668">269</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1314" decimals="-6" name="sny:PreFundedPensionObligations" scale="6" id="f-3669">408</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Obligations provided for</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1318" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3670">2,214</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1319" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3671">2,039</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1320" decimals="-6" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="6" id="f-3672">2,947</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount recognized at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1312" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3673">1,943</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1313" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3674">1,770</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1314" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3675">2,539</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit cost for the period:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3676">140</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3677">193</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3678">227</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in&#160;the&#160;terms&#160;of the plan</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" scale="6" id="f-3679">22</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" scale="6" id="f-3680">68</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" scale="6" id="f-3681">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest (income)/cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="6" id="f-3682">71</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="6" id="f-3683">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="6" id="f-3684">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3685">6</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3686">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3687">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Administration costs and taxes paid during the period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" scale="6" id="f-3688">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" scale="6" id="f-3689">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" scale="6" id="f-3690">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense recognized directly in profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3691">190</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3692">168</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3693">276</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3694">171</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3695">650</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3696">685</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="sny:EmployeeBenefitsExpenseGain" scale="6" id="f-3697">361</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" sign="-" name="sny:EmployeeBenefitsExpenseGain" scale="6" id="f-3698">482</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" sign="-" name="sny:EmployeeBenefitsExpenseGain" scale="6" id="f-3699">409</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts include the impact of applying the April&#160;2021 IFRIC agenda decision on the attribution of benefits to periods of service.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;For 2023, this line includes &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1324" decimals="-6" name="sny:PreFundedPensionObligations" format="ixt:num-dot-decimal" scale="6" id="f-3700">66</ix:nonFraction>&#160;million of assets in the United Kingdom (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1325" decimals="-6" name="sny:PreFundedPensionObligations" format="ixt:num-dot-decimal" scale="6" id="f-3701">99</ix:nonFraction>&#160;million for 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1326" decimals="-6" name="sny:PreFundedPensionObligations" format="ixt:num-dot-decimal" scale="6" id="f-3702">220</ix:nonFraction>&#160;million for 2021); those amounts are not subject to any asset ceiling, in accordance with IFRIC&#160;14.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Amounts recognized in Other comprehensive income (see Note&#160;D.15.7.).</span></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-68</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-3297-6" continuedAt="f-3297-7"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock" id="f-3703" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show Sanofi&#8217;s net liability in respect of pension plans and other post-employment benefits by geographical region:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:25.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Measurement of obligation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1327" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3704">1,322</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1328" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3705">2,911</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1329" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3706">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1324" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3707">2,174</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1330" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-3708">995</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1312" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3709">8,930</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1327" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" scale="6" id="f-3710">675</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1328" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-3711">2,401</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1329" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" scale="6" id="f-3712">825</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1324" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-3713">2,235</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1330" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" scale="6" id="f-3714">857</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1312" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-3715">6,993</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1327" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1328" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1329" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1324" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1330" decimals="-6" sign="-" name="sny:PlanAssetsEffectOfAssetCeiling" scale="6" id="f-3720">6</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1312" decimals="-6" sign="-" name="sny:PlanAssetsEffectOfAssetCeiling" scale="6" id="f-3721">6</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1327" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3722">647</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1328" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3723">510</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1329" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3724">703</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1324" decimals="-6" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3725">61</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1330" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3726">144</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1312" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3727">1,943</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:25.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Measurement of obligation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1331" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3728">1,324</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1332" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3729">2,730</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1333" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3730">1,546</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1325" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3731">2,080</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1334" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-3732">971</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1313" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3733">8,651</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1331" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" scale="6" id="f-3734">697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1332" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-3735">2,317</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1333" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" scale="6" id="f-3736">860</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1325" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-3737">2,175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1334" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" scale="6" id="f-3738">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1313" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-3739">6,899</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1331" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3740">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1332" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3741">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1333" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3742">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1325" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3743">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1334" decimals="-6" sign="-" name="sny:PlanAssetsEffectOfAssetCeiling" scale="6" id="f-3744">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1313" decimals="-6" sign="-" name="sny:PlanAssetsEffectOfAssetCeiling" scale="6" id="f-3745">18</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1331" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3746">627</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1332" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3747">413</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1333" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3748">686</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1325" decimals="-6" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3749">95</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1334" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3750">139</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1313" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3751">1,770</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:25.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Measurement of obligation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1335" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3752">1,657</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1336" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3753">3,576</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1337" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3754">2,099</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1326" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3755">3,414</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1338" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3756">1,429</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1314" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-3757">12,175</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1335" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" scale="6" id="f-3758">838</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1336" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-3759">2,808</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1337" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-3760">1,127</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1326" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-3761">3,629</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1338" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-3762">1,249</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1314" decimals="-6" name="ifrs-full:PlanAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-3763">9,651</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1335" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3764">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1336" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3765">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1337" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3766">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1326" decimals="-6" name="sny:PlanAssetsEffectOfAssetCeiling" format="ixt:fixed-zero" scale="6" id="f-3767">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1338" decimals="-6" sign="-" name="sny:PlanAssetsEffectOfAssetCeiling" scale="6" id="f-3768">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1314" decimals="-6" sign="-" name="sny:PlanAssetsEffectOfAssetCeiling" scale="6" id="f-3769">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1335" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3770">819</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1336" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3771">768</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1337" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3772">972</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1326" decimals="-6" sign="-" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3773">215</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1338" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="6" id="f-3774">195</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1314" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3775">2,539</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The adoption in April&#160;2023 of pension reforms in France (including the raising of the retirement age from 62&#160;to 64&#160;years) qualifies as a plan amendment within the meaning of IAS&#160;19, and resulted in the recognition of an immaterial amount in the income statement and the balance sheet for the year ended December&#160;31, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory" id="f-3776" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the fair value of plan assets relating to Sanofi&#8217;s pension and other post-employment plans, split by asset category:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Securities quoted in an active market</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3777">84.9</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3778">84.4</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3779">86.9</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1339" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3780">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1340" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3781">0.7</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1341" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3782">0.7</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1342" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3783">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1343" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3784">21.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1344" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3785">25.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bonds and similar instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1345" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3786">54.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1346" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3787">52.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1347" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3788">53.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1348" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3789">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1349" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3790">4.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1350" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3791">4.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1351" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" format="ixt:fixed-zero" scale="-2" id="f-3792">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1352" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3793">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1353" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" format="ixt:fixed-zero" scale="-2" id="f-3794">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commodities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1354" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3795">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1355" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3796">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1356" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3797">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1357" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3798">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1358" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3799">4.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1359" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" scale="-2" id="f-3800">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities" scale="-2" id="f-3801">15.1</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities" scale="-2" id="f-3802">15.6</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities" scale="-2" id="f-3803">13.1</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1360" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities" format="ixt:fixed-zero" scale="-2" id="f-3804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1361" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities" format="ixt:fixed-zero" scale="-2" id="f-3805">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1362" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities" format="ixt:fixed-zero" scale="-2" id="f-3806">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance policies</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1363" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities" scale="-2" id="f-3807">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1364" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities" scale="-2" id="f-3808">15.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1365" decimals="3" name="sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities" scale="-2" id="f-3809">13.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="INF" name="sny:PercentageContributedToFairValueOfPlanAssets" scale="-2" id="f-3810">100.0</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="INF" name="sny:PercentageContributedToFairValueOfPlanAssets" scale="-2" id="f-3811">100.0</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="INF" name="sny:PercentageContributedToFairValueOfPlanAssets" scale="-2" id="f-3812">100.0</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has a long-term objective of maintaining or increasing the extent to which its pension obligations are covered by assets. To this end, Sanofi uses an asset-liability management strategy, matching plan assets to its pension obligations. This policy aims to ensure the best fit between the assets held on the one hand, and the associated liabilities and expected future payments to plan members on the other. To meet this aim, Sanofi operates a risk monitoring and management strategy (mainly focused on interest rate risk and inflation risk), while investing a growing proportion of assets in high-quality bonds with comparable maturities to those of the underlying obligations and in contracts entered into with leading insurance companies to fund certain post-employment benefit obligations.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-69</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-3297-7" continuedAt="f-3297-8"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock" id="f-3813" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the service cost for Sanofi&#8217;s pension and other post-employment benefit plans, by geographical region:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Service cost for 2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1366" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3814">50</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1367" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3815">30</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1368" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3816">20</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1369" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3817">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1370" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3818">40</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3819">140</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1366" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3820">20</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1367" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" format="ixt:fixed-zero" scale="6" id="f-3821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1368" decimals="-6" sign="-" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3822">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1369" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" format="ixt:fixed-zero" scale="6" id="f-3823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1370" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3824">3</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3825">22</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost/(income) including administration costs and taxes paid during the period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1366" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3826">22</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1367" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3827">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1368" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3828">35</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1369" decimals="-6" sign="-" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3829">5</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1370" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3830">11</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3831">78</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1366" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3832">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1367" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3833">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1368" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1369" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1370" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3836">6</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3837">6</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) recognized directly in profit or loss</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1366" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3838">52</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1367" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3839">45</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1368" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3840">56</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1369" decimals="-6" sign="-" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3841">5</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1370" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3842">42</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3843">190</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1366" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3844">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1367" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3845">98</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1368" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3846">26</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1369" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3847">44</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1370" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3849">171</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1366" decimals="-6" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3850">55</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1367" decimals="-6" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3851">143</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1368" decimals="-6" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3852">82</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1369" decimals="-6" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3853">39</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1370" decimals="-6" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3854">42</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3855">361</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Service cost for 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1371" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3856">61</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1372" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3857">44</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1373" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3858">50</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1374" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3859">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1375" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3860">38</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3861">193</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1371" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3862">60</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1372" decimals="-6" sign="-" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3863">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1373" decimals="-6" sign="-" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3864">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1374" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3865">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1375" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3866">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3867">68</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost/(income) including administration costs and taxes paid during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1371" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3868">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1372" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3869">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1373" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3870">30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1374" decimals="-6" sign="-" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3871">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1375" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3872">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3873">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1371" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3874">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1372" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3875">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1373" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3876">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1374" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3877">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1375" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3878">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3879">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) recognized directly in profit or loss</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1371" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3880">11</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1372" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3881">53</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1373" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3882">81</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1374" decimals="-6" sign="-" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3883">13</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1375" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3884">36</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3885">168</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1371" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3886">156</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1372" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3887">204</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1373" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3888">382</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1374" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3889">130</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1375" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3890">38</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3891">650</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1371" decimals="-6" sign="-" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3892">145</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1372" decimals="-6" sign="-" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3893">151</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1373" decimals="-6" sign="-" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3894">301</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1374" decimals="-6" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3895">117</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1375" decimals="-6" sign="-" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3896">2</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" sign="-" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3897">482</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Service cost for 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1376" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3898">72</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1377" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3899">47</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1378" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3900">57</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1379" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3901">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1380" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3902">51</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="6" id="f-3903">227</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1376" decimals="-6" sign="-" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3904">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1377" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" format="ixt:fixed-zero" scale="6" id="f-3905">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1378" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" format="ixt:fixed-zero" scale="6" id="f-3906">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1379" decimals="-6" sign="-" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3907">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1380" decimals="-6" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" format="ixt:fixed-zero" scale="6" id="f-3908">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" sign="-" name="sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" scale="6" id="f-3909">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost/(income) including administration costs and taxes paid during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1376" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3910">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1377" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3911">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1378" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3912">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1379" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3913">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1380" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3914">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" scale="6" id="f-3915">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1376" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3916">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1377" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3917">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1378" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3918">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1379" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3919">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1380" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3920">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3921">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) recognized directly in profit or loss</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1376" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3922">80</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1377" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3923">52</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1378" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3924">84</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1379" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3925">6</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1380" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3926">54</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-3927">276</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1376" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3928">106</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1377" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3929">113</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1378" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3930">157</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1379" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3931">236</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1380" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3932">73</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3933">685</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1376" decimals="-6" sign="-" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3934">26</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1377" decimals="-6" sign="-" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3935">61</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1378" decimals="-6" sign="-" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3936">73</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1379" decimals="-6" sign="-" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3937">230</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1380" decimals="-6" sign="-" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3938">19</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" sign="-" name="sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" scale="6" id="f-3939">409</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock" id="f-3940" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of the &#8220;Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)&#8221; line in the preceding tables is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:19.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.429%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) arising during the period</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1267" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3941">3</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1246" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3942">98</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1205" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3943">25</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1212" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3944">44</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1268" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3945">156</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1251" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3946">205</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1269" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3947">382</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1270" decimals="-6" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3948">131</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1271" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3949">106</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1258" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3950">113</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1272" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3951">156</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1273" decimals="-6" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="6" id="f-3952">237</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprising:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">on experience adjustments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1267" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" scale="6" id="f-3953">16</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1246" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" scale="6" id="f-3954">54</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1205" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" scale="6" id="f-3955">7</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1212" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" scale="6" id="f-3956">12</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1268" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" scale="6" id="f-3957">120</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1251" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" scale="6" id="f-3958">620</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1269" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" scale="6" id="f-3959">287</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1270" decimals="-6" sign="-" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" format="ixt:num-dot-decimal" scale="6" id="f-3960">1,328</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1271" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" scale="6" id="f-3961">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1258" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" scale="6" id="f-3962">182</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1272" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" scale="6" id="f-3963">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1273" decimals="-6" name="sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" scale="6" id="f-3964">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) <br/>on demographic assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1267" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1246" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1205" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3967">18</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1212" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3968">11</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1268" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3969">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1251" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3970">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1269" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3971">129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1270" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3972">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1271" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3973">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1258" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-3974">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1272" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3975">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1273" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3976">125</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) <br/>on financial assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1267" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3977">19</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1246" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3978">44</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1205" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3979">36</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1212" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3980">43</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1268" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3981">276</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1251" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3982">825</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1269" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3983">540</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1270" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-3984">1,143</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1271" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3985">46</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1258" decimals="-6" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3986">69</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1272" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3987">82</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1273" decimals="-6" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="6" id="f-3988">77</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Experience adjustments are mainly due to the effect on plan assets of trends in the financial markets.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock" id="f-3989" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The net pre-tax actuarial loss (excluding investments accounted for using the equity method) recognized directly in equity is presented below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net pre-tax actuarial loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity" format="ixt:num-dot-decimal" scale="6" id="f-3990">2,259</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="sny:NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity" format="ixt:num-dot-decimal" scale="6" id="f-3991">2,090</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="sny:NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity" format="ixt:num-dot-decimal" scale="6" id="f-3992">2,738</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-70</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-3297-8" continuedAt="f-3297-9"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock" id="f-3993" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The present value of Sanofi&#8217;s obligations in respect of pension and other post-employment benefit plans at the end of each reporting period is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of wholly or partially funded obligations in respect of pension and other post-employment benefit plans</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1381" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3994">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1382" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3995">7,463</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1383" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3996">10,416</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of unfunded obligations</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1384" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3997">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1385" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3998">1,188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1386" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-3999">1,759</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1304" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-4000">8,930</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1298" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-4001">8,651</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1299" decimals="-6" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-4002">12,175</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock" id="f-4003" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense for pensions and other post-employment benefits (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-4004">190</ix:nonFraction> million in 2023) is allocated between income statement line items as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-4005">34</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-4006">55</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-4007">77</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-4008">28</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-4009">52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-4010">65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-4011">61</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-4012">81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-4013">87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating (income)/expenses, net</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="6" id="f-4014">5</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="ifrs-full:OtherOperatingIncomeExpense" scale="6" id="f-4015">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="ifrs-full:OtherOperatingIncomeExpense" scale="6" id="f-4016">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" sign="-" name="sny:RestructuringCostsReversedAndSimilarItems" scale="6" id="f-4017">9</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" sign="-" name="sny:RestructuringCostsReversedAndSimilarItems" scale="6" id="f-4018">61</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="sny:RestructuringCostsReversedAndSimilarItems" scale="6" id="f-4019">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-4020">71</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-4021">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-4022">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1321" decimals="-6" name="sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-4023">190</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1322" decimals="-6" name="sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-4024">168</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1323" decimals="-6" name="sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" scale="6" id="f-4025">276</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock" id="f-4026" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The estimated amounts of employer&#8217;s contributions to plan assets in 2024 are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employer&#8217;s contributions in 2024 (estimate):</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1387" decimals="-6" name="ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan" format="ixt:fixed-zero" scale="6" id="f-4027">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1388" decimals="-6" name="ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan" format="ixt:fixed-zero" scale="6" id="f-4028">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1389" decimals="-6" name="ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan" format="ixt:fixed-zero" scale="6" id="f-4029">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1390" decimals="-6" name="ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan" scale="6" id="f-4030">46</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1391" decimals="-6" name="ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan" scale="6" id="f-4031">40</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-753" decimals="-6" name="ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan" scale="6" id="f-4032">86</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock" id="f-4033" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the expected timing of benefit payments under pension and other post-employment benefit plans for future years:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated future benefit payments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1392" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4034">103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1393" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4035">198</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1394" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4036">102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1395" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4037">116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1396" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4038">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4039">579</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1397" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4040">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1398" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4041">212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1399" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4042">91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1400" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4043">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1401" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4044">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1107" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4045">545</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1402" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4046">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1403" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4047">218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1404" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4048">95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1405" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4049">123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1406" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4050">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1108" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4051">556</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1407" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4052">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1408" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4053">221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1409" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4054">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1410" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4055">127</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1411" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4056">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1109" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4057">584</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1412" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4058">93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1413" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4059">229</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1414" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4060">101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1415" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4061">131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1416" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4062">62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1110" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4063">616</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2029 to 2033</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1417" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4064">438</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1418" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-4065">1,190</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1419" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4066">526</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1420" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4067">716</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1421" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" scale="6" id="f-4068">343</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1422" decimals="-6" name="sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-4069">3,213</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock" id="f-4070" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows estimates as of December 31, 2023 for the timing of future payments in respect of unfunded pension and other post-employment benefit plans:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than 1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to <br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to <br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated payments</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" format="ixt:num-dot-decimal" scale="6" id="f-4071">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-753" decimals="-6" name="sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" scale="6" id="f-4072">86</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1423" decimals="-6" name="sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" scale="6" id="f-4073">117</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1424" decimals="-6" name="sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" scale="6" id="f-4074">144</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-758" decimals="-6" name="sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" scale="6" id="f-4075">891</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-71</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-3297-9" continuedAt="f-3297-10"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.19.2. Restructuring provisions</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringProvisionsTableTextBlock" id="f-4076" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in restructuring provisions classified in non-current and current liabilities:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1425" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4077">1,233</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1426" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4078">1,118</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1427" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4079">1,499</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in non-current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1425" decimals="-6" name="ifrs-full:LongtermRestructuringProvision" scale="6" id="f-4080">761</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1426" decimals="-6" name="ifrs-full:LongtermRestructuringProvision" scale="6" id="f-4081">524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1427" decimals="-6" name="ifrs-full:LongtermRestructuringProvision" scale="6" id="f-4082">868</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1425" decimals="-6" name="ifrs-full:ShorttermRestructuringProvision" scale="6" id="f-4083">472</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1426" decimals="-6" name="ifrs-full:ShorttermRestructuringProvision" scale="6" id="f-4084">594</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1427" decimals="-6" name="ifrs-full:ShorttermRestructuringProvision" scale="6" id="f-4085">631</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in provisions recognized in profit or loss for the period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1428" decimals="-6" name="sny:ChangeInProvisionsRecognizedInProfitOrLossForThePeriod" scale="6" id="f-4086">435</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1429" decimals="-6" name="sny:ChangeInProvisionsRecognizedInProfitOrLossForThePeriod" scale="6" id="f-4087">636</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1430" decimals="-6" name="sny:ChangeInProvisionsRecognizedInProfitOrLossForThePeriod" scale="6" id="f-4088">183</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1428" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-4089">561</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1429" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-4090">522</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1430" decimals="-6" name="ifrs-full:ProvisionUsedOtherProvisions" scale="6" id="f-4091">571</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1428" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-4092">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1429" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" format="ixt:fixed-zero" scale="6" id="f-4093">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1430" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" scale="6" id="f-4094">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discount</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1428" decimals="-6" name="sny:UnwindingOfDiscount" scale="6" id="f-4095">31</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1429" decimals="-6" name="sny:UnwindingOfDiscount" scale="6" id="f-4096">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1430" decimals="-6" name="sny:UnwindingOfDiscount" format="ixt:fixed-zero" scale="6" id="f-4097">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1428" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-4098">9</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1429" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-4099">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1430" decimals="-6" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" scale="6" id="f-4100">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1431" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4101">1,132</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1425" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4102">1,233</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1426" decimals="-6" name="sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4103">1,118</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in non-current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1431" decimals="-6" name="ifrs-full:LongtermRestructuringProvision" scale="6" id="f-4104">554</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1425" decimals="-6" name="ifrs-full:LongtermRestructuringProvision" scale="6" id="f-4105">761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1426" decimals="-6" name="ifrs-full:LongtermRestructuringProvision" scale="6" id="f-4106">524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1431" decimals="-6" name="ifrs-full:ShorttermRestructuringProvision" scale="6" id="f-4107">578</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1425" decimals="-6" name="ifrs-full:ShorttermRestructuringProvision" scale="6" id="f-4108">472</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1426" decimals="-6" name="ifrs-full:ShorttermRestructuringProvision" scale="6" id="f-4109">594</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Provisions utilized mainly correspond to payments related to employees affected by separation programs.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions for employee termination benefits as of December 31, 2023 amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-4110">968</ix:nonFraction> million (compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-4111">1,039</ix:nonFraction>&#160;million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-4112">943</ix:nonFraction> million as of December 31, 2021).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisions apply mainly to France, and relate to various voluntary redundancy programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">agreement under the Job Management and Career Paths (GEPP) scheme affecting several French legal entities, signed on&#160;February&#160;28, 2022 and announced in April&#160;2022 as part of the &#8220;Play to Win&#8221; strategy. The agreement provides internal transfer and outplacement opportunities for employees whose jobs are undergoing transformation, and also includes an end-of-career paid leave program and an external retraining program. Most of the provisions charged in 2022 relate to this plan, which began to be implemented in 2022. The provisions charged in 2023 reflect adjustments to the job profiles deemed to be "sensitive"; the reversals recognized during 2023 are due mainly to the Borne Law, which raises the retirement age to 64 and hence disqualifies some participants eligible under previous legislation (in light of the maximum period for portage workers);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">collectively-agreed separation programs involving a number of legal entities announced at the end of June&#160;2020 as part of the rollout of the &#8220;Play to Win&#8221; strategy; these include an end-of-career paid leave plan and an external retraining program, and were still ongoing during 2023. In addition, Sanofi-Aventis Recherche &amp;&#160;D&#233;veloppement (i)&#160;announced a voluntary redundancy program in&#160;2020 in connection with the reorganization of R&amp;D operations in France, which was implemented in&#160;2021, and (ii)&#160;signed a collectively-agreed termination program in&#160;2021 as part of the rollout of the &#8220;Play to Win&#8221; strategy; these programs, which cover support functions, include an end-of-career paid leave plan and an end-of-career transition plan;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">programs announced in 2019 relating to (i)&#160;R&amp;D (Sanofi-Aventis Recherche &amp;&#160;D&#233;veloppement) and (ii)&#160;sales forces (the&#160;&#8220;SAF&#160;2019&#8221; plan implemented by Sanofi-Aventis France);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">collectively-agreed separation programs announced in 2018 relating to the reorganization of support functions (&#8220;Horizon&#160;2020&#8221; plan).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The remainder of the provision for France comprises termination benefits associated with previously-announced programs (early retirement plans and end-of-career transition plans).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provision includes the present values of:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gross annuities for self-funded plans;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">employer&#8217;s social security charges on early retirement annuities for all plans (outsourced and self-funded); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the levy charged on those annuities under the &#8220;Fillon&#8221;&#160;law (only for plans with termination of employment contracts).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The average residual portage periods under these plans were <ix:nonNumeric contextRef="c-1" name="sny:AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans" format="ixt-sec:duryear" id="f-4113">2.22</ix:nonNumeric>&#160;years, <ix:nonNumeric contextRef="c-9" name="sny:AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans" format="ixt-sec:duryear" id="f-4114">2.60</ix:nonNumeric>&#160;years and <ix:nonNumeric contextRef="c-10" name="sny:AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans" format="ixt-sec:duryear" id="f-4115">1.94</ix:nonNumeric>&#160;years as of December 31, 2023, 2022 and&#160;2021, respectively.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main other countries covered by restructuring provisions are Germany, Japan and the United States.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-72</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-3297-10" continuedAt="f-3297-11"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock" id="f-4116" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The timing of future termination benefit payments is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit payments by period</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employee termination benefits</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">France</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1232" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4117">611</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1392" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4118">215</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1432" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4119">315</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1433" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4120">79</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1434" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4121">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other countries</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1435" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4122">357</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1396" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4123">302</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1436" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4124">47</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1437" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4125">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1438" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4126">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4127">968</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4128">517</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1124" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4129">362</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1125" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4130">86</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4131">3</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit payments by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employee termination benefits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">France</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1234" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4132">804</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1439" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4133">185</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1440" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4134">412</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1441" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4135">207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1442" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:fixed-zero" scale="6" id="f-4136">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other countries</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1443" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4137">235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1444" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4138">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1445" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4139">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1446" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4140">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1447" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4141">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="6" id="f-4142">1,039</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1112" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4143">374</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1126" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4144">448</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1127" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4145">215</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1117" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4146">2</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit payments by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employee termination benefits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">France</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1236" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4147">614</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1448" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4148">269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1449" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4149">288</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1450" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4150">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1451" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4151">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other countries</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1452" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4152">329</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1453" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4153">207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1454" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4154">106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1455" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4155">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1456" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4156">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4157">943</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1118" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4158">476</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1128" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4159">394</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1129" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4160">67</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1123" decimals="-6" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="6" id="f-4161">6</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.19.3. Other provisions</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOtherLongTermProvisionsTableTextBlock" id="f-4162" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other provisions</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> include provisions for risks and litigation relating to environmental, tax, commercial and product liability matters.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Environmental risks</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:NonCurrentProvisionForEnvironmentRisks" scale="6" id="f-4163">493</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:NonCurrentProvisionForEnvironmentRisks" scale="6" id="f-4164">526</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:NonCurrentProvisionForEnvironmentRisks" scale="6" id="f-4165">650</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Product liability risks, litigation and other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" format="ixt:num-dot-decimal" scale="6" id="f-4166">1,283</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" format="ixt:num-dot-decimal" scale="6" id="f-4167">1,652</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" format="ixt:num-dot-decimal" scale="6" id="f-4168">1,374</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherLongtermProvisions" format="ixt:num-dot-decimal" scale="6" id="f-4169">1,776</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:OtherLongtermProvisions" format="ixt:num-dot-decimal" scale="6" id="f-4170">2,178</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:OtherLongtermProvisions" format="ixt:num-dot-decimal" scale="6" id="f-4171">2,024</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions for environmental risks relate primarily to contingencies arising from business divestitures, and include remediation costs relating to such environmental risks.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Identified environmental risks are covered by provisions estimated on the basis of the costs Sanofi believes it will be obliged to meet over a period not exceeding (other than in exceptional cases) <ix:nonNumeric contextRef="c-1457" name="sny:IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod" format="ixt-sec:duryear" id="f-4172">30</ix:nonNumeric>&#160;years. Sanofi expects that &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1457" decimals="-6" name="sny:IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-4173">86</ix:nonFraction> million of those provisions will be utilized in&#160;2024, and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1457" decimals="-6" name="sny:IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive" format="ixt:num-dot-decimal" scale="6" id="f-4174">194</ix:nonFraction> million over the period from 2025 through 2028.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards greenhouse gas emission quotas, which relate to Sanofi production facilities in France and Ireland, in the absence of specific IFRS pronouncements  Sanofi has adopted the "net liability approach". That involves recognizing a liability at the balance sheet date if actual emissions exceed the quotas held, in accordance with IAS&#160;37 and French GAAP (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Plan Comptable G&#233;n&#233;ral,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Article&#160;615-1s). Quotas are managed as a production cost, and as such are recognized in inventory at a zero value (if received free of charge) and at acquisition cost (if bought on the market). As of December&#160;31, 2023, no liability was recognized, and quotas valued at &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:InventoryTotalQuotasHeld" scale="6" id="f-4175">3</ix:nonFraction>&#160;million were held in inventory.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Product liability risks, litigation and other&#8221; mainly comprises provisions for risks relating to product liability (including IBNR provisions as described in Note&#160;B.12.), government investigations, regulatory or antitrust law claims, contingencies arising from business divestitures (other than environmental risks), and remediation costs related to leases.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main pending legal and arbitral proceedings and government investigations are described in Note&#160;D.22.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A full risk and litigation assessment is performed with the assistance of Sanofi&#8217;s legal advisers, and provisions are recorded as required by circumstances in accordance with the principles described in Note&#160;B.12.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-73</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-3297-11"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.19.4. Non-current income tax liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current income tax liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-4176">1,842</ix:nonFraction> million as of December 31, 2023 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-4177">1,979</ix:nonFraction> million as of          December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-4178">2,039</ix:nonFraction> million as of December 31, 2021).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item includes the residual liability due after more than one year arising from </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">the estimated tax charge on deemed repatriation attributable to the accumulated earnings of non-US operations (</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-552" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4179">247</ix:nonFraction> million as of December 31, 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-557" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" scale="6" id="f-4180">459</ix:nonFraction>&#160;million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-6" name="ifrs-full:OtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4181">576</ix:nonFraction> million as of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The expense was initially recognized in 2018 at an amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="c-1458" decimals="-6" name="sny:LiabilityRecognizedRepresentingEstimatedCost" format="ixt:num-dot-decimal" scale="6" id="f-4182">1,092</ix:nonFraction>&#160;million, and payment is being made over <ix:nonNumeric contextRef="c-1" name="sny:TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod" format="ixt-sec:durwordsen" id="f-4183">eight years</ix:nonNumeric> through 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current income tax liabilities include uncertainties over income tax treatments totaling &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1459" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-4184">1,595</ix:nonFraction> million as of                   December 31, 2023, versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1460" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-4185">1,520</ix:nonFraction> million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1461" decimals="-6" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-4186">1,463</ix:nonFraction> million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A US legal restructuring resulted in a capital loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1462" decimals="-9" name="sny:UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="9" id="f-4187">3</ix:nonFraction>&#160;billion&#160;recognized in the 2020 final tax filing. One-third of the capital loss has been used against 2020 capital gains and the remaining balance will be eligible to carry back for <ix:nonNumeric contextRef="c-1463" name="sny:CapitalLossesCarryBackPeriod" format="ixt-sec:durwordsen" id="f-4188">three years</ix:nonNumeric>. Due to management&#8217;s judgement about potential alternative interpretations of the prevailing tax law, no tax benefit has been recognized on this transaction in accordance with IFRIC&#160;23.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.19.5. Current provisions and other current liabilities</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock" id="f-4189" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Current provisions and other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Taxes payable, other than corporate income taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" scale="6" id="f-4190">395</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" scale="6" id="f-4191">420</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" scale="6" id="f-4192">428</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" format="ixt:num-dot-decimal" scale="6" id="f-4193">2,106</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" format="ixt:num-dot-decimal" scale="6" id="f-4194">2,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" format="ixt:num-dot-decimal" scale="6" id="f-4195">2,126</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring provisions (see Note&#160;D.19.2.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:ShorttermRestructuringProvision" scale="6" id="f-4196">578</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:ShorttermRestructuringProvision" scale="6" id="f-4197">472</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:ShorttermRestructuringProvision" scale="6" id="f-4198">594</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate derivatives (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CurrentInterestRateDerivativesPayable" scale="6" id="f-4199">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CurrentInterestRateDerivativesPayable" format="ixt:fixed-zero" scale="6" id="f-4200">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CurrentInterestRateDerivativesPayable" scale="6" id="f-4201">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency derivatives (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CurrentCurrencyDerivativesPayable" scale="6" id="f-4202">126</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CurrentCurrencyDerivativesPayable" scale="6" id="f-4203">94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CurrentCurrencyDerivativesPayable" scale="6" id="f-4204">62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity derivatives (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CurrentEquityDerivativesPayable" format="ixt:fixed-zero" scale="6" id="f-4205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CurrentEquityDerivativesPayable" format="ixt:fixed-zero" scale="6" id="f-4206">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CurrentEquityDerivativesPayable" scale="6" id="f-4207">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amounts payable for acquisitions of non-current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:AmountsPayableForAcquisitionOfNonCurrentAssets" scale="6" id="f-4208">945</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:AmountsPayableForAcquisitionOfNonCurrentAssets" scale="6" id="f-4209">714</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:AmountsPayableForAcquisitionOfNonCurrentAssets" scale="6" id="f-4210">559</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Customer contract liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentContractLiabilities" format="ixt:fixed-zero" scale="6" id="f-4211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:CurrentContractLiabilities" scale="6" id="f-4212">269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:CurrentContractLiabilities" scale="6" id="f-4213">321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4214">9,590</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4215">7,894</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4216">7,110</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4217">13,741</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4218">12,021</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:CurrentProvisionsAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4219">11,217</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;See Note&#160;A.5.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, &#8220;Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. The year-on-year change in this item between 2022 and 2023 includes revenue of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-4220">269</ix:nonFraction>&#160;million  recognized in profit or loss during 2023 previously included in </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Customer contract liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> as of December&#160;31, 2022, compared with revenue of  &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1464" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-4221">85</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">recognized in profit or loss during 2022 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">previously included in  </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Customer contract liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> as of December&#160;31, 2021</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> . <ix:nonFraction unitRef="eur" contextRef="c-1465" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:fixed-zero" scale="0" id="f-4222">No</ix:nonFraction> such revenue was recognized in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#8220;Other current liabilities&#8221; mainly comprises provisions and liabilities for customer rebates and returns; provisions for discounts and rebates granted to healthcare authorities and governmental programs (see Note&#160;D.23.); and the liability payable at each reporting date under the Monoclonal Antibody Alliance with Regeneron.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;As of December 31, 2023 includes &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1466" decimals="-6" name="sny:RoyaltiesPayable" scale="6" id="f-4223">131</ix:nonFraction>&#160;million (nominal value: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1466" decimals="-6" name="ifrs-full:OtherCurrentLiabilities" scale="6" id="f-4224">137</ix:nonFraction> million) for the current liability relating to royalties payable to Sobi on net sales of BEYFORTUS (nirsevimab) in the United States (see Note&#160;C.2.)</span></div></ix:nonNumeric></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_676"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.20. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory" id="f-4227" continuedAt="f-4227-1" escape="true">Derivative financial instruments and market risks</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock" id="f-4228" escape="true"><ix:continuation id="f-4227-1" continuedAt="f-4227-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the fair value of derivative instruments as of December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.153%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">assets</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current<br/>assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current<br/>liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current<br/>liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>liabilities</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2023 (net)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2022 (net)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2021 (net)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency derivatives</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1468" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-4229">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1468" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialAssets" scale="6" id="f-4230">201</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1468" decimals="-6" name="ifrs-full:DerivativeFinancialAssets" scale="6" id="f-4231">201</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1468" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-4232">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1468" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="6" id="f-4233">126</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1468" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-4234">126</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1468" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4235">75</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1469" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4236">112</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1470" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4237">222</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">operating</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1471" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-4238">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1471" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialAssets" scale="6" id="f-4239">67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1471" decimals="-6" name="ifrs-full:DerivativeFinancialAssets" scale="6" id="f-4240">67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1471" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-4241">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1471" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="6" id="f-4242">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1471" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-4243">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1471" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4244">22</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1472" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4245">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1473" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4246">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">financial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1474" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-4247">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1474" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialAssets" scale="6" id="f-4248">134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1474" decimals="-6" name="ifrs-full:DerivativeFinancialAssets" scale="6" id="f-4249">134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1474" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-4250">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1474" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="6" id="f-4251">81</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1474" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-4252">81</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1474" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4253">53</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1475" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4254">90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1476" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4255">212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate derivatives</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1477" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-4256">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1477" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-4257">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1477" decimals="-6" name="ifrs-full:DerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-4258">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1477" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" scale="6" id="f-4259">164</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1477" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="6" id="f-4260">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1477" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-4261">165</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1477" decimals="-6" sign="-" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4262">165</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1478" decimals="-6" sign="-" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4263">232</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1479" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4264">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity derivatives</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1480" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-4265">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1480" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-4266">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1480" decimals="-6" name="ifrs-full:DerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-4267">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1480" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-4268">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1480" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-4269">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1480" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-4270">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1480" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" format="ixt:fixed-zero" scale="6" id="f-4271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1481" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" format="ixt:fixed-zero" scale="6" id="f-4272">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1482" decimals="-6" sign="-" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4273">16</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="6" id="f-4274">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialAssets" scale="6" id="f-4275">201</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:DerivativeFinancialAssets" scale="6" id="f-4276">201</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" scale="6" id="f-4277">164</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="6" id="f-4278">127</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-4279">291</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" sign="-" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4280">90</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" sign="-" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4281"> 120</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" scale="6" id="f-4282">213</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-74</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-4227-2" continuedAt="f-4227-3"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Objectives of the use of derivative financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi uses derivative instruments to manage operating exposure to movements in exchange rates, and financial exposure to movements in interest rates and exchange rates (where the debt or receivable is not contracted in the functional currency of the borrower or lender entity). On occasion, Sanofi uses equity derivatives in connection with the management of its portfolio of equity investments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi performs periodic reviews of its transactions and contractual agreements in order to identify any embedded derivatives, which are accounted for separately from the host contract in accordance with IFRS&#160;9. Sanofi had no material embedded derivatives as of December 31, 2023, 2022 or 2021.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Counterparty risk</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of counterparty risk, refer to &#8220;Item&#160;11. &#8212; Quantitative and Qualitative Disclosures about Market Risk&#8221;.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">a) Currency derivatives used to manage operating risk exposures</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of Sanofi&#8217;s objectives, policies and procedures for the management of operating foreign exchange risk, refer to &#8220;Item&#160;11. &#8212; Quantitative and Qualitative Disclosures about Market Risk&#8221;.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" id="f-4283" continuedAt="f-4283-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2023, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.982%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as<br/>cash flow hedges</span></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which&#160;derivatives&#160;not<br/>eligible&#160;for&#160;hedge&#160;accounting</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which<br/>recognized&#160;in&#160;equity</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1483" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4284">6,112</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1484" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4285">30</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1485" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4286">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1486" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4287">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1487" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4288">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1488" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4289">6,112</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1489" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4290">30</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1490" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4291">2,981</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1491" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4292">35</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1492" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1493" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1494" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1495" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4296">2,981</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1496" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4297">35</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1497" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4298">788</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1498" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4299">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1499" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1500" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1501" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1502" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4303">788</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1503" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4304">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1504" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4305">419</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1505" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4306">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1506" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1507" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1508" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1509" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4310">419</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1510" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4311">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1511" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4312">339</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1512" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4313">6</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1513" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1514" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1515" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1516" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4317">339</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1517" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4318">6</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1518" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4319">192</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1519" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4320">4</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1520" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1521" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1522" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1523" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4324">192</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1524" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4325">4</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1525" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4326">4,246</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1526" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4327">8</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1527" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4328">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1528" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4329">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1529" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4330">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1530" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4331">4,246</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1531" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4332">8</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1532" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4333">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1533" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4334">12</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1534" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1535" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1536" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1537" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4338">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1538" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4339">12</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1539" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4340">876</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1540" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1541" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1542" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1543" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1544" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4345">876</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1545" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1546" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4347">364</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1547" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4348">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1548" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1549" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1550" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1551" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4352">364</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1552" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4353">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1553" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4354">137</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1554" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4355">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1555" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1556" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1557" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1558" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4359">137</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1559" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4360">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1560" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4361">123</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1561" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4362">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1562" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1563" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1564" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1565" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4366">123</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1566" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4367">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1567" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4368">10,358</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1568" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4369">22</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1569" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4370">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1570" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4371">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1571" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4372">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1572" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4373">10,358</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1573" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4374">22</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2022, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.067%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.354%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as<br/>cash flow hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which&#160;derivatives&#160;not<br/>eligible&#160;for&#160;hedge&#160;accounting</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which<br/>recognized&#160;in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1574" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4375">5,403</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1575" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4376">49</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1576" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4377">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1577" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4378">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1578" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4379">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1579" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4380">5,403</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1580" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4381">49</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1581" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4382">2,732</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1582" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4383">56</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1583" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4384">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1584" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4385">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1585" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4386">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1586" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4387">2,732</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1587" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4388">56</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1588" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4389">576</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1589" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4390">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1590" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4391">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1591" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4392">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1592" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4393">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1593" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4394">576</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1594" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4395">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1595" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4396">240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1596" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4397">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1597" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4398">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1598" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4399">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1599" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4400">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1600" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4401">240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1601" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4402">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1602" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4403">180</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1603" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4404">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1604" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4405">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1605" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4406">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1606" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4407">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1607" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4408">180</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1608" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4409">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1609" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4410">179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1610" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4411">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1611" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4412">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1612" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4413">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1613" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4414">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1614" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4415">179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1615" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4416">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1616" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4417">3,459</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1617" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4418">27</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1618" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4419">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1619" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4420">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1620" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4421">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1621" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4422">3,459</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1622" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4423">27</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1623" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4424">2,047</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1624" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4425">21</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1625" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4426">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1626" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4427">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1627" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4428">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1628" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4429">2,047</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1629" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4430">21</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1630" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4431">375</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1631" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4432">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1632" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4433">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1633" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4434">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1634" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4435">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1635" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4436">375</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1636" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4437">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1637" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4438">142</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1638" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4439">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1639" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4440">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1640" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4441">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1641" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4442">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1642" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4443">142</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1643" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4444">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1644" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4445">130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1645" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4446">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1646" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4447">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1647" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4448">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1648" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4449">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1649" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4450">130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1650" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4451">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Taiwan dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1651" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4452">84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1652" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4453">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1653" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4454">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1654" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4455">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1655" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4456">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1656" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4457">84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1657" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4458">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1658" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4459">8,862</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1659" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4460">22</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1660" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4461">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1661" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4462">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1662" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4463">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1663" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4464">8,862</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1664" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4465">22</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-75</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-4227-3" continuedAt="f-4227-4"><ix:continuation id="f-4283-1"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2021, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:20.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives<br/>designated&#160;as&#160;cash&#160;flow&#160;hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which&#160;derivatives&#160;not</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">eligible&#160;for&#160;hedge&#160;accounting </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which<br/>recognized<br/>in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1665" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4466">3,912</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1666" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4467">4</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1667" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4468">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1668" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4469">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1669" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4470">&#8211;</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1670" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4471">3,912</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1671" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4472">4</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1672" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4473">1,392</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1673" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4474">5</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1674" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4475">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1675" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4476">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1676" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4477">&#8211;</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1677" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4478">1,392</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1678" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4479">5</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1679" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4480">665</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1680" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4481">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1681" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4482">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1682" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4483">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1683" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4484">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1684" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4485">665</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1685" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4486">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1686" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4487">355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1687" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4488">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1688" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4489">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1689" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4490">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1690" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4491">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1691" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4492">355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1692" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4493">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1693" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4494">199</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1694" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4495">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1695" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4496">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1696" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4497">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1697" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4498">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1698" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4499">199</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1699" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4500">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Taiwan dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1700" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4501">122</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1701" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4502">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1702" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4503">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1703" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4504">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1704" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4505">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1705" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4506">122</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1706" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4507">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1707" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4508">2,374</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1708" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4509">6</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1709" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4510">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1710" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4511">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1711" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4512">&#8211;</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1712" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4513">2,374</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1713" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4514">6</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1714" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4515">833</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1715" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4516">2</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1716" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4517">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1717" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4518">&#8211;</ix:nonFraction></span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1718" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4519">&#8211;</ix:nonFraction></span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1719" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4520">833</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1720" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4521">2</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1721" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4522">696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1722" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4523">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1723" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4524">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1724" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4525">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1725" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4526">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1726" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4527">696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1727" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4528">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1728" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4529">255</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1729" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4530">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1730" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4531">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1731" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4532">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1732" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4533">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1733" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4534">255</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1734" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4535">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1735" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4536">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1736" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4537">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1737" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4538">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1738" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4539">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1739" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4540">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1740" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4541">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1741" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4542">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Russian rouble</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1742" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4543">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1743" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4544">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1744" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4545">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1745" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4546">&#8211;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1746" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4547">&#8211;</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1747" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4548">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1748" decimals="-6" sign="-" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4549">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1749" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4550">6,286</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1750" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4551">10</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1751" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4552">&#8211;</ix:nonFraction></span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1752" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4553">&#8211;</ix:nonFraction></span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1753" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:fixed-zero" scale="6" id="f-4554">&#8211;</ix:nonFraction></span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1754" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4555">6,286</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1755" decimals="-6" name="sny:DerivativeFinancialInstruments" scale="6" id="f-4556">10</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">b) Currency and interest rate derivatives used to manage financial exposure</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of Sanofi&#8217;s objectives, policies and procedures for the management of financial foreign exchange risk and interest rate risk, refer to &#8220;Item&#160;11. &#8212; Quantitative and Qualitative Disclosures about Market Risk&#8221;.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" id="f-4557" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:22.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.187%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1483" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4558">10,279</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1484" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4559">111</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1574" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4560">7,559</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1575" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4561">66</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1665" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4562">7,655</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1666" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4563">15</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1756" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4564">6,628</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1757" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4565">101</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1758" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4566">6,114</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1759" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4567">59</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1760" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4568">5,384</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1761" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4569">23</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1762" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4570">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1763" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4571">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1764" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:fixed-zero" scale="6" id="f-4572">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1765" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:fixed-zero" scale="6" id="f-4573">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1766" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:fixed-zero" scale="6" id="f-4574">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1767" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:fixed-zero" scale="6" id="f-4575">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1768" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4576">513</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1769" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4577">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1770" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4578">203</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1771" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4579">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1772" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4580">70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1773" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4581">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1525" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4582">7,055</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1526" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4583">58</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1616" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4584">4,997</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1617" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4585">24</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1707" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4586">9,293</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1708" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4587">197</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1774" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4588">3,073</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(b) (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1775" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4589">52</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1776" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4590">2,011</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1777" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4591">4</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1778" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4592">4,816</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1779" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4593">128</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1780" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4594">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1781" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4595">10</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1782" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4596">2,154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1783" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4597">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1784" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4598">2,910</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1785" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4599">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1786" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4600">341</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1787" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4601">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1788" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4602">205</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1789" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4603">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1790" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4604">235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1791" decimals="-6" sign="-" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4605">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1567" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4606">17,334</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1568" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4607">53</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1658" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4608">12,556</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1659" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4609">90</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1749" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" format="ixt:num-dot-decimal" scale="6" id="f-4610">16,948</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1750" decimals="-6" name="sny:DerivativeFinancialInstrumentsToManageFinancialExposure" scale="6" id="f-4611">212</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#7802e6;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes forward sales with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-1792" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-4612">3,615</ix:nonFraction> million expiring in 2024, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of December 31, 2023, the fair value of these forward contracts represented an asset of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1792" decimals="-6" name="ifrs-full:DerivativeFinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-4613">54</ix:nonFraction> million; the opposite entry was recognized in "Other comprehensive income", with the impact on financial income and expense being immaterial.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-1793" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-4614">1,000</ix:nonFraction> million expiring in 2024, designated as a fair value hedge of the exposure of $<ix:nonFraction unitRef="usd" contextRef="c-1793" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-4615">1,000</ix:nonFraction> million of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2023, the fair value of the contracts was a liability of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1793" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4616">31</ix:nonFraction> million, the opposite entry for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1794" decimals="-5" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-4617">2.7</ix:nonFraction>&#160;million of which was credited to &#8220;Other comprehensive income&#8221; under the cost of hedging accounting treatment.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-1795" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-4618">1,044</ix:nonFraction> million expiring in 2024, designated as a fair value hedge of the exposure of an equivalent amount of commercial paper. As of December 31, 2023, the fair value of the swaps was a liability of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1795" decimals="-6" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4619">3</ix:nonFraction> million, the opposite entry for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1796" decimals="-5" name="ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-4620">0.7</ix:nonFraction>&#160;million of which was credited to &#8220;Other comprehensive income&#8221; under the cost of hedging accounting treatment.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-76</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" id="f-4621" escape="true"><ix:continuation id="f-4227-4" continuedAt="f-4227-5"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:17.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2023</span></td><td colspan="3" style="background-color:#e3e3e3;padding:0 1pt"/><td colspan="6" style="background-color:#e3e3e3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></div></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive <ix:nonFraction unitRef="number" contextRef="c-1797" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4622">1.03</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1798" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1799" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1800" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1801" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1802" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4627">453</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1803" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1804" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4629">453</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1805" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4630">49</ix:nonFraction>)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1806" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4631">453</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1807" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4632">49</ix:nonFraction>)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1808" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1809" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1810" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive <ix:nonFraction unitRef="number" contextRef="c-1811" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4636">1.32</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1812" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1813" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1814" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1815" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1816" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4641">453</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1817" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4642">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1818" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4643">453</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1819" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4644">43</ix:nonFraction>)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1820" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4645">453</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1821" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4646">43</ix:nonFraction>)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1822" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1823" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1824" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive <ix:nonFraction unitRef="number" contextRef="c-1825" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4650">0.69</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1826" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1827" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4652">850</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1828" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1829" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1830" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1831" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1832" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4657">850</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1833" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4658">28</ix:nonFraction>)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1834" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4659">850</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1835" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4660">28</ix:nonFraction>)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1836" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4661">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1837" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4662">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1838" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4663">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive <ix:nonFraction unitRef="number" contextRef="c-1839" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4664">0.92</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1840" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1841" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1842" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1843" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1844" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1845" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4670">650</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1846" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4671">650</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1847" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4672">44</ix:nonFraction>)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1848" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4673">650</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1849" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4674">44</ix:nonFraction>)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1850" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4675">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1851" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4676">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1852" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4677">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive <ix:nonFraction unitRef="number" contextRef="c-1853" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4678">3.43</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1854" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4679">999</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1855" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1856" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1857" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1858" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1859" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1860" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4685">999</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1861" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4686">1</ix:nonFraction>)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1862" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4687">999</ix:nonFraction>&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1863" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4688">1</ix:nonFraction>)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1864" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4689">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1865" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4690">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1866" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4691">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1867" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4692">999</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1868" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4693">850</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1869" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4694">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1870" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4695">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1871" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4696">906</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1872" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4697">650</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1567" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-4698">3,405</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1568" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4699">165</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1873" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-4700">3,405</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1874" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4701">165</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1569" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4702">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1570" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4703">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1571" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4704">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2022:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:17.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028 and later</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive <ix:nonFraction unitRef="number" contextRef="c-1875" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4705">1.03</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1876" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4706">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1877" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4707">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1878" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4708">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1879" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4709">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1880" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4710">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1881" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4711">467</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1882" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4712">467</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1883" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4713">62</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1884" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4714">467</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1885" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4715">62</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1886" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4716">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1887" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4717">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1888" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4718">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive <ix:nonFraction unitRef="number" contextRef="c-1889" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4719">1.32</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1890" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4720">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1891" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4721">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1892" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4722">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1893" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4723">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1894" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4724">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1895" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4725">467</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1896" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4726">467</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1897" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4727">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1898" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4728">467</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1899" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4729">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1900" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4730">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1901" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4731">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1902" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4732">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive <ix:nonFraction unitRef="number" contextRef="c-1903" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4733">0.69</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1904" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4734">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1905" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4735">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1906" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4736">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1907" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4737">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1908" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4738">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1909" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4739">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1910" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4740">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1911" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4741">43</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1912" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4742">850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1913" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4743">43</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1914" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4744">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1915" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4745">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1916" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4746">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive <ix:nonFraction unitRef="number" contextRef="c-1917" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4747">0.92</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1918" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4748">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1919" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4749">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1920" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4750">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1921" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4751">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1922" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4752">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1923" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4753">650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1924" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4754">650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1925" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4755">71</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1926" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4756">650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1927" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4757">71</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1928" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4758">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1929" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4759">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1930" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4760">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1931" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4761">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1932" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4762">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1933" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4763">850</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1934" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4764">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1935" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4765">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1936" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-4766">1,584</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1658" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-4767">2,434</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1659" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4768">232</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1937" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-4769">2,434</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1938" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4770">232</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1660" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4771">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1661" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4772">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1662" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4773">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:17.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027 and later</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized EONIA/receive <ix:nonFraction unitRef="number" contextRef="c-1939" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4774">0.06</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1940" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-4775">2,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1941" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4776">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1942" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4777">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1943" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4778">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1944" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4779">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1945" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4780">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1946" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-4781">2,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1947" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4782">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1948" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-4783">2,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1949" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4784">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1950" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4785">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1951" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4786">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1952" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4787">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay -<ix:nonFraction unitRef="number" contextRef="c-1953" decimals="4" sign="-" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4788">0.57</ix:nonFraction>%/receive capitalized EONIA</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1954" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4789">600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1955" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4790">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1956" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4791">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1957" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4792">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1958" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4793">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1959" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4794">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1960" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4795">600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1961" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4796">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1962" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4797">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1963" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4798">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1964" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4799">600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1965" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4800">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1966" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4801">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized USD SOFR/receive <ix:nonFraction unitRef="number" contextRef="c-1967" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4802">1.03</ix:nonFraction>%  </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1968" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4803">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1969" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4804">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1970" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4805">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1971" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4806">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1972" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4807">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1973" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4808">440</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1974" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4809">440</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1975" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4810">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1976" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4811">440</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1977" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4812">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1978" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4813">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1979" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4814">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1980" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4815">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized USD SOFR/receive <ix:nonFraction unitRef="number" contextRef="c-1981" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4816">1.32</ix:nonFraction>%  </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1982" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4817">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1983" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4818">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1984" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4819">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1985" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4820">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1986" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4821">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1987" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4822">440</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1988" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4823">440</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1989" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4824">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1990" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4825">440</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1991" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4826">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1992" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4827">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1993" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4828">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1994" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4829">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">receive capitalized Eonia/pay <ix:nonFraction unitRef="number" contextRef="c-1995" decimals="4" name="sny:InterestRateSwapsInterestRate" scale="-2" id="f-4830">1.48</ix:nonFraction>%</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1996" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4831">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1997" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4832">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1998" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4833">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1999" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4834">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2000" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4835">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2001" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4836">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2002" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4837">99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2003" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4838">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2004" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4839">99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2005" decimals="-6" sign="-" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4840">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2006" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4841">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2007" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4842">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2008" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4843">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2009" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-4844">2,642</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2010" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4845">57</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2011" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4846">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2012" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4847">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2013" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4848">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2014" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4849">880</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1749" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-4850">3,579</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1750" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4851">7</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2015" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-4852">2,979</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2016" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4853">6</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1751" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4854">600</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1752" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" scale="6" id="f-4855">1</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1753" decimals="-6" name="sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-4856">&#8212;</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These interest rate swaps hedge fixed-rate bonds with a nominal of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2002" decimals="-6" name="sny:DerivativeFinancialInstruments" format="ixt:num-dot-decimal" scale="6" id="f-4857">99</ix:nonFraction> million held in a Professional Specialized Investment Fund dedicated to Sanofi and recognized within &#8220;Long-term loans and advances and other non-current receivables&#8221; (see Note D.7.).</span></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-77</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-4227-5"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">c) Actual or potential effects of netting arrangements</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock" id="f-4858" escape="true"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below is prepared in accordance with the accounting policies described in Note&#160;B.8.3.:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:31.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.081%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross carrying amounts before offset (a)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2017" decimals="-6" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" scale="6" id="f-4859">201</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2018" decimals="-6" sign="-" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" scale="6" id="f-4860">291</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2019" decimals="-6" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" scale="6" id="f-4861">206</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2020" decimals="-6" sign="-" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" scale="6" id="f-4862">326</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2021" decimals="-6" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" scale="6" id="f-4863">298</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2022" decimals="-6" sign="-" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" scale="6" id="f-4864">85</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross amounts offset (in accordance with IAS&#160;32)&#160;(b)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2017" decimals="-6" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" format="ixt:fixed-zero" scale="6" id="f-4865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2018" decimals="-6" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" format="ixt:fixed-zero" scale="6" id="f-4866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2019" decimals="-6" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" format="ixt:fixed-zero" scale="6" id="f-4867">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2020" decimals="-6" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" format="ixt:fixed-zero" scale="6" id="f-4868">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2021" decimals="-6" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" format="ixt:fixed-zero" scale="6" id="f-4869">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2022" decimals="-6" name="sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" format="ixt:fixed-zero" scale="6" id="f-4870">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amounts as reported in the balance sheet (a) -&#160;(b) =&#160;(c)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2017" decimals="-6" name="sny:NetAmountsAsReportedInTheBalanceSheet" scale="6" id="f-4871">201</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2018" decimals="-6" sign="-" name="sny:NetAmountsAsReportedInTheBalanceSheet" scale="6" id="f-4872">291</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2019" decimals="-6" name="sny:NetAmountsAsReportedInTheBalanceSheet" scale="6" id="f-4873">206</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2020" decimals="-6" sign="-" name="sny:NetAmountsAsReportedInTheBalanceSheet" scale="6" id="f-4874">326</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2021" decimals="-6" name="sny:NetAmountsAsReportedInTheBalanceSheet" scale="6" id="f-4875">298</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2022" decimals="-6" sign="-" name="sny:NetAmountsAsReportedInTheBalanceSheet" scale="6" id="f-4876">85</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effects of other netting arrangements (not fulfilling the IAS&#160;32 criteria for offsetting) (d)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2023" decimals="-6" name="sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral" format="ixt:fixed-zero" scale="6" id="f-4877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2024" decimals="-6" name="sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral" format="ixt:fixed-zero" scale="6" id="f-4878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2023" decimals="-6" sign="-" name="sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" scale="6" id="f-4879">171</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2024" decimals="-6" name="sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" scale="6" id="f-4880">171</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2025" decimals="-6" sign="-" name="sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" scale="6" id="f-4881">160</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2026" decimals="-6" name="sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" scale="6" id="f-4882">160</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2027" decimals="-6" sign="-" name="sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" scale="6" id="f-4883">67</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2028" decimals="-6" name="sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" scale="6" id="f-4884">67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of financial collateral</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net exposure (c) + (d)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2017" decimals="-6" name="sny:NetExposure" scale="6" id="f-4885">30</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2018" decimals="-6" sign="-" name="sny:NetExposure" scale="6" id="f-4886">120</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2019" decimals="-6" name="sny:NetExposure" scale="6" id="f-4887">46</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2020" decimals="-6" sign="-" name="sny:NetExposure" scale="6" id="f-4888">166</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2021" decimals="-6" name="sny:NetExposure" scale="6" id="f-4889">231</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2022" decimals="-6" sign="-" name="sny:NetExposure" scale="6" id="f-4890">18</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_679"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.21. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" id="f-4891" continuedAt="f-4891-1" escape="true">Off balance sheet commitments</ix:nonNumeric></span></div><ix:continuation id="f-4891-1" continuedAt="f-4891-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The off balance sheet commitments presented below are shown at their nominal value.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.21.1. Off balance sheet commitments relating to operating activities</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock" id="f-4892" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments relating to Sanofi&#8217;s operating activities comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.007%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.007%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.007%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.007%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.008%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" scale="6" id="f-4893">221</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" scale="6" id="f-4894">24</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1124" decimals="-6" name="sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" scale="6" id="f-4895">26</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1125" decimals="-6" name="sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" scale="6" id="f-4896">25</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" scale="6" id="f-4897">146</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Irrevocable purchase commitments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">given</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsGiven" format="ixt:num-dot-decimal" scale="6" id="f-4898">6,141</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsGiven" format="ixt:num-dot-decimal" scale="6" id="f-4899">2,446</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1124" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsGiven" format="ixt:num-dot-decimal" scale="6" id="f-4900">2,090</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1125" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsGiven" scale="6" id="f-4901">778</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsGiven" scale="6" id="f-4902">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">received</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsReceived" scale="6" id="f-4903">550</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsReceived" scale="6" id="f-4904">443</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1124" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsReceived" scale="6" id="f-4905">96</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1125" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsReceived" scale="6" id="f-4906">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsReceived" format="ixt:fixed-zero" scale="6" id="f-4907">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development license agreements - commitments given</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">commitments related to R&amp;D and other commitments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" scale="6" id="f-4908">381</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" scale="6" id="f-4909">256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1124" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" scale="6" id="f-4910">101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1125" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" scale="6" id="f-4911">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" scale="6" id="f-4912">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">contingent milestone payments in connection with development programs in progress</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" format="ixt:num-dot-decimal" scale="6" id="f-4913">4,886</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" scale="6" id="f-4914">280</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1124" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" format="ixt:num-dot-decimal" scale="6" id="f-4915">1,757</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1125" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" scale="6" id="f-4916">818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" format="ixt:num-dot-decimal" scale="6" id="f-4917">2,031</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total - net commitments given</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:TotalOffBalanceSheetCommitments" format="ixt:num-dot-decimal" scale="6" id="f-4918">11,079</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="sny:TotalOffBalanceSheetCommitments" format="ixt:num-dot-decimal" scale="6" id="f-4919">2,563</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1124" decimals="-6" name="sny:TotalOffBalanceSheetCommitments" format="ixt:num-dot-decimal" scale="6" id="f-4920">3,878</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1125" decimals="-6" name="sny:TotalOffBalanceSheetCommitments" format="ixt:num-dot-decimal" scale="6" id="f-4921">1,625</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="sny:TotalOffBalanceSheetCommitments" format="ixt:num-dot-decimal" scale="6" id="f-4922">3,013</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes the variable portion of future lease payments not recognized as lease liabilities as of December 31, 2023; the equivalent amount of these commitments as of December&#160;31, 2022 was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" scale="6" id="f-4923">38</ix:nonFraction>&#160;million.<br/>During 2023, Sanofi signed a <ix:nonNumeric contextRef="c-1" name="sny:LeaseTerm" format="ixt-sec:durwordsen" id="f-4924">15-year</ix:nonNumeric> lease which will take effect in 2025 and for which Sanofi is committed for a minimum period of <ix:nonNumeric contextRef="c-2029" name="sny:LeaseTerm" format="ixt-sec:duryear" id="f-4925">12</ix:nonNumeric> years, corresponding to a minimum commitment of $<ix:nonFraction unitRef="usd" contextRef="c-2030" decimals="-8" name="sny:LeaseCosts" format="ixt:num-dot-decimal" scale="9" id="f-4926">0.2</ix:nonFraction>&#160;billion. The lease includes <ix:nonFraction unitRef="extension" contextRef="c-2030" decimals="INF" name="sny:LeaseExtensionOptionsNumber" format="ixt-sec:numwordsen" scale="0" id="f-4927">two</ix:nonFraction> extension options of <ix:nonNumeric contextRef="c-2030" name="sny:LeaseExtensionOptionsTerm" format="ixt-sec:durwordsen" id="f-4928">five years</ix:nonNumeric> each.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These comprise irrevocable commitments to suppliers of (i)&#160;property, plant and equipment, net of down-payments (see Note&#160;D.3.) and (ii)&#160;goods and services. As of December 31, 2022, irrevocable commitments amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2031" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsGiven" format="ixt:num-dot-decimal" scale="6" id="f-4929">6,194</ix:nonFraction> million given and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2031" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsReceived" format="ixt:num-dot-decimal" scale="6" id="f-4930">574</ix:nonFraction> million received.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Irrevocable purchase commitments given as of December 31, 2023 include &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2032" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsGiven" format="ixt:num-dot-decimal" scale="6" id="f-4931">926</ix:nonFraction> million of commitments to joint ventures, and the commitment to EUROAPI as described in Note D.2. and amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2033" decimals="-6" name="sny:IrrevocablePurchaseCommitmentsGiven" format="ixt:num-dot-decimal" scale="6" id="f-4932">804</ix:nonFraction>&#160;million as of December 31, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Commitments related to R&amp;D, and other commitments, amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" format="ixt:num-dot-decimal" scale="6" id="f-4933">259</ix:nonFraction> million as of December 31, 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;This line includes only contingent milestone payments on development projects in progress. The equivalent amount as of December 31, 2022 was     &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" format="ixt:num-dot-decimal" scale="6" id="f-4934">2,919</ix:nonFraction> million.</span></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In pursuance of its strategy, Sanofi may acquire technologies and rights to products. Such acquisitions may be made in various contractual forms: acquisitions of shares, loans, license agreements, joint development, and co-marketing. These arrangements generally involve upfront payments on signature of the agreement, development milestone payments, and royalties. Some of these complex agreements include undertakings to fund research programs in future years and payments contingent upon achieving specified development milestones, the granting of approvals or licenses, or the attainment of sales targets once a product is commercialized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Research and development license agreements&#8221; line comprises future service commitments to fund research and development or technology, and contingent milestone payments regarded as reasonably achievable (i.e. all potential milestone payments relating to projects in the development phase, for which the future financial consequences are known or probable and for which there is a sufficiently reliable estimate). This line excludes:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">commitments given relating to (i)&#160;projects in the research phase, amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-8" name="sny:CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase" format="ixt:num-dot-decimal" scale="9" id="f-4935">16.8</ix:nonFraction> billion as of December&#160;31, 2023 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-8" name="sny:CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase" format="ixt:num-dot-decimal" scale="9" id="f-4936">18.0</ix:nonFraction> billion as of December&#160;31, 2022 and (ii)&#160;payments contingent upon the attainment of sales targets once a product is commercialized, amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-8" name="sny:CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets" format="ixt:num-dot-decimal" scale="9" id="f-4937">17.9</ix:nonFraction> billion as of December&#160;31, 2023 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-8" name="sny:CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets" format="ixt:num-dot-decimal" scale="9" id="f-4938">18.5</ix:nonFraction> billion as of December&#160;31, 2022);</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-78</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-4891-2" continuedAt="f-4891-3"><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">commitments received amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-8" name="sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" format="ixt:num-dot-decimal" scale="9" id="f-4939">10.0</ix:nonFraction> billion as of December&#160;31, 2023 (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-8" name="sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" format="ixt:num-dot-decimal" scale="9" id="f-4940">8.8</ix:nonFraction> billion as of December&#160;31, 2022), mainly&#160;comprising research, development and commercialization agreements with partners further to the acquisitions of&#160;(i)&#160;Ablynx&#160;(&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2034" decimals="-8" name="sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" format="ixt:num-dot-decimal" scale="9" id="f-4941">0.9</ix:nonFraction> billion as of December 31, 2023, versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2035" decimals="-8" name="sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" format="ixt:num-dot-decimal" scale="9" id="f-4942">1.0</ix:nonFraction> billion as of December&#160;31, 2022); (ii)&#160;Kymab (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2036" decimals="-8" name="sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" format="ixt:num-dot-decimal" scale="9" id="f-4943">0.2</ix:nonFraction> billion&#160;as of&#160;December 31, 2023, versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2037" decimals="-8" name="sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" format="ixt:num-dot-decimal" scale="9" id="f-4944">0.2</ix:nonFraction> billion as of December&#160;31, 2022) and (iii)&#160;Provention Bio (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2038" decimals="-8" name="sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" format="ixt:num-dot-decimal" scale="9" id="f-4945">0.3</ix:nonFraction> billion as of&#160;December&#160;31,&#160;2023), plus contingent consideration receivable based on attainment of regulatory and&#160;sales milestones for commercialized products under the terms of licenses or rights assignment agreements amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-8" name="sny:CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts" format="ixt:num-dot-decimal" scale="9" id="f-4946">8.5</ix:nonFraction> billion&#160;as of&#160;December&#160;31, 2023 (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-8" name="sny:CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts" format="ixt:num-dot-decimal" scale="9" id="f-4947">7.6</ix:nonFraction> billion&#160;as of December&#160;31, 2022).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The major agreements entered into by Sanofi in 2023 are described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">on June&#160;19, 2023, Sanofi expanded its collaboration with Scribe Therapeutics signed in September&#160;2022 and entered into an exclusive license agreement on CasX-Editor(XE) genome editing technology associated with guide RNAs for multiple targets including sickle cell disease and other genomic diseases. Under the terms of the agreement, Scribe Therapeutics received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-2039" decimals="-6" name="sny:UpfrontPayments" format="ixt:num-dot-decimal" scale="6" id="f-4948">40</ix:nonFraction>&#160;million and may receive more than $<ix:nonFraction unitRef="usd" contextRef="c-2040" decimals="-8" name="sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="9" id="f-4949">1.2</ix:nonFraction>&#160;billion based on the achievement of certain milestones;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">on October&#160;3, 2023, Sanofi entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), to develop and commercialize the vaccine candidate against extra intestinal pathogenic strains of E. coli developed by Janssen, currently in&#160;Phase&#160;3. Under the terms of the agreement, both parties will co-fund current and future research and development costs. Sanofi paid $<ix:nonFraction unitRef="usd" contextRef="c-2041" decimals="-6" name="sny:UpfrontPayments" format="ixt:num-dot-decimal" scale="6" id="f-4950">175</ix:nonFraction>&#160;million upfront to Janssen and may pay to Janssen milestone payments contingent on the attainment of certain development and commercial objectives;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">on October&#160;4, 2023, Sanofi entered into a collaboration with Teva Pharmaceuticals to co-develop and co-commercialize asset TEV&#8217;574, currently in Phase&#160;2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease. Under the terms of the new collaboration agreement, Teva received an upfront payment of&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2042" decimals="-6" name="sny:UpfrontPayments" format="ixt:num-dot-decimal" scale="6" id="f-4951">469</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="c-2042" decimals="-6" name="sny:UpfrontPayments" format="ixt:num-dot-decimal" scale="6" id="f-4952">500</ix:nonFraction>&#160;million) and may receive up to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2043" decimals="-6" name="sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-4953">940</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="c-2043" decimals="-9" name="sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="9" id="f-4954">1</ix:nonFraction>&#160;billion) in milestone payments, depending on the achievement of development and commercialization goals.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, by acquiring all of the outstanding shares of Provention Bio, Inc. on April&#160;27, 2023 (see Note&#160;D.1.), Sanofi assumed  commitments amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2044" decimals="-6" name="sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" scale="6" id="f-4955">946</ix:nonFraction>&#160;million made by that company to various partners under collaboration agreements previously entered into.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of commitments as of December&#160;31, 2023 also includes commitments under agreements entered into by Sanofi in prior years, the principal ones of which are described below. For a full description of each agreement, refer to the Annual Report on Form&#160;20-F for the year in which the agreement was entered into.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The major agreements entered into by Sanofi in 2022 are described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">with Exscentia: an innovative license agreement and research collaboration to develop up to <ix:nonFraction unitRef="molecule" contextRef="c-2045" decimals="INF" name="sny:NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement" scale="0" id="f-4956">15</ix:nonFraction>&#160;novel small molecule candidates across oncology and immunology, leveraging Exscientia&#8217;s end-to-end AI-driven platform utilizing actual patient samples;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">with ABL Bio: a licensing and collaboration agreement for the development of ABL301, a bispecific antibody intended as a treatment for alpha-synucleinopathies;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a collaboration and exclusive license agreement with Adagene Inc., a company specializing in the discovery and development of antibody-based therapies;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a strategic risk-sharing collaboration with Blackstone under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2046" decimals="-6" name="sny:CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement" scale="6" id="f-4957">300</ix:nonFraction>&#160;million to accelerate the global pivotal studies and clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody SARCLISA, to treat patients with multiple myeloma. That amount will be paid to Sanofi on the basis of development expenses incurred. In addition, Sanofi may pay royalties on future sales of this solution;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an exclusive collaboration agreement with IGM Biosciences, Inc. to create, develop, manufacture and commercialize IgM antibody agonists against <ix:nonFraction unitRef="target" contextRef="c-2047" decimals="INF" name="sny:NumberOfOncologyTargetsUnderCollaborationAgreement" format="ixt-sec:numwordsen" scale="0" id="f-4958">three</ix:nonFraction> oncology targets and <ix:nonFraction unitRef="target" contextRef="c-2047" decimals="0" name="sny:NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement" format="ixt-sec:numwordsen" scale="0" id="f-4959">three</ix:nonFraction> immunology/inflammation targets;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a collaboration agreement with Skyhawk Therapeutics, Inc. to discover and develop novel small molecules that modulate RNA splicing to address challenging oncology and immunology targets;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a collaboration agreement with Atomwise that will leverage its ATOMNET platform to identify and synthesize up to <ix:nonFraction unitRef="target" contextRef="c-2048" decimals="INF" name="sny:NumberOfDrugTargetsUnderCollaborationAgreement" format="ixt-sec:numwordsen" scale="0" id="f-4960">five</ix:nonFraction> drug targets;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a research collaboration with Scribe Therapeutics to leverage its CRISPR by&#160;Design platform and to obtain a non-exclusive license to genome editing CasX-Editor(XE) technology for multiple oncology targets;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a strategic research collaboration with Insilico Medicine to leverage Insilico Medicine&#8217;s AI platform, Pharma.AI, to advance drug development candidates for up to <ix:nonFraction unitRef="target" contextRef="c-2049" decimals="INF" name="sny:NumberOfTherapeuticTargetsUnderCollaborationAgreement" format="ixt-sec:numwordsen" scale="0" id="f-4961">six</ix:nonFraction> new therapeutic targets;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7-H3 from Innate&#8217;s ANKET (Antibody-based NK Cell Engager Therapeutics) platform.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal agreements entered into by Sanofi in previous years are listed below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Biond Biologics (2021): license agreement for the development and commercialization of BND-22 (a humanized IgG4 antagonist antibody targeting the Ig-like transcript&#160;2 (ILT2) receptor, in development for the treatment of solid tumors);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Kymera (2020): agreement to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Nurix Therapeutics (2020): collaboration to develop novel targeted protein degradation therapies;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Denali Therapeutics&#160;Inc. (2018): collaboration agreement on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases. The two lead molecules are DNL747 in multiple sclerosis and amyotrophic lateral sclerosis, and DNL758 in systemic inflammatory diseases such as rheumatoid arthritis and psoriasis;</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-79</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-4891-3"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and one of its alliance partners have decided to terminate the following agreement (the related commitments are no longer included in Sanofi&#8217;s off balance sheet disclosures as of December 31, 2023):</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">on January&#160;6, 2023, Sanofi and Regulus Therapeutics Inc. terminated their collaboration and license agreement on the discovery, development and commercialization of new micro-RNA derived molecules in fibrosis. The termination took effect on February&#160;5 ,2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, under the collaboration agreement with Regeneron on monoclonal antibodies (see Note&#160;C.1.), Sanofi is entitled to receive an additional share of quarterly profits (capped at <ix:nonFraction unitRef="number" contextRef="c-2050" decimals="2" name="sny:PercentageOfProfitShareOnCounterpartiesProfit" scale="-2" id="f-4962">10</ix:nonFraction>% of Regeneron&#8217;s share of quarterly profits until March&#160;31, 2022, and thereafter at <ix:nonFraction unitRef="number" contextRef="c-2051" decimals="2" name="sny:PercentageOfProfitShareOnCounterpartiesProfit" scale="-2" id="f-4963">20</ix:nonFraction>%), until Regeneron has paid <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="sny:PercentageOfCumulativeDevelopmentCostsReimbursed" scale="-2" id="f-4964">50</ix:nonFraction>% of the cumulative development costs incurred by the parties to the alliance. As&#160;of December&#160;31, 2023 this represented total commitments received of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2052" decimals="-8" name="sny:CommitmentsReceivedForDevelopmentCosts" format="ixt:num-dot-decimal" scale="9" id="f-4965">2.1</ix:nonFraction> billion (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2053" decimals="-8" name="sny:CommitmentsReceivedForDevelopmentCosts" format="ixt:num-dot-decimal" scale="9" id="f-4966">2.7</ix:nonFraction> billion as of December&#160;31, 2022), against cumulative development costs of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-8" name="sny:CumulativeDevelopmentCostsIncurred" format="ixt:num-dot-decimal" scale="9" id="f-4967">8.6</ix:nonFraction> billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi entered into an agreement with Royalty Pharma in December&#160;2014 relating to development programs, under which Royalty Pharma bore a portion of the remaining development costs of the project on a quarterly basis in return for royalties on future sales. The products in development under that agreement have been launched in territories including the United States and Europe, marking the end of the joint development programs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;27, 2017, Sanofi and Lonza announced a strategic partnership in the form of a joint venture (BioAtrium AG) to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. An initial investment of approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2054" decimals="-8" name="ifrs-full:InvestmentsInJointVentures" format="ixt:num-dot-decimal" scale="9" id="f-4968">0.3</ix:nonFraction> billion to finance construction of the facility, split <ix:nonFraction unitRef="number" contextRef="c-2055" decimals="INF" name="sny:PercentageOfFutureDevelopmentExpenseFundedByCompany" scale="-2" id="f-4969">50</ix:nonFraction>/<ix:nonFraction unitRef="number" contextRef="c-2056" decimals="INF" name="sny:PercentageOfFutureDevelopmentExpenseFundedByOtherParty" scale="0" id="f-4970">50</ix:nonFraction> between the two partners, has now been made in full. In addition, Sanofi could pay BioAtrium AG in the region of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2054" decimals="-8" name="sny:AmountsPayablePartnersInCollaborationAgreements" format="ixt:num-dot-decimal" scale="9" id="f-4971">0.6</ix:nonFraction> billion over the 2023-2031 period  as its share of operating expenses and the cost of producing future batches.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February&#160;2014, pursuant to the &#8220;Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits&#8221; (still effective as of December 31, 2023), Sanofi Pasteur and the World Health Organization (WHO) signed a bilateral &#8220;Standard Material Transfer Agreement&#8221; (SMTA&#160;2). This agreement stipulates that Sanofi Pasteur will, during declared pandemic periods, (i)&#160;donate <ix:nonFraction unitRef="number" contextRef="c-2057" decimals="3" name="sny:TransferPercentageOfPandemicVaccines" scale="-2" id="f-4972">7.5</ix:nonFraction>% of its real-time production of pandemic vaccines against any strain with potential to cause a pandemic, and (ii)&#160;reserve a further <ix:nonFraction unitRef="number" contextRef="c-2057" decimals="3" name="sny:ReservePercentageOfPandemicVaccines" scale="-2" id="f-4973">7.5</ix:nonFraction>% of such production on affordable terms. The agreement cancels and replaces all preceding commitments to donate pandemic vaccines to the WHO.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.21.2. Off balance sheet commitments relating to financing activities</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit facilities</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock" id="f-4974" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Undrawn credit facilities are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:37.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">General-purpose credit facilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:num-dot-decimal" scale="6" id="f-4975">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1106" decimals="-6" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:fixed-zero" scale="6" id="f-4976">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1124" decimals="-6" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:fixed-zero" scale="6" id="f-4977">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1125" decimals="-6" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:num-dot-decimal" scale="6" id="f-4978">4,000</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1111" decimals="-6" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:num-dot-decimal" scale="6" id="f-4979">4,000</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, total credit facilities amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:num-dot-decimal" scale="6" id="f-4980">8,000</ix:nonFraction> million (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:num-dot-decimal" scale="6" id="f-4981">8,000</ix:nonFraction> million as of December 31, 2022 and&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:num-dot-decimal" scale="6" id="f-4982">8,000</ix:nonFraction> million as of December 31, 2021).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock" id="f-4983" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the amount of guarantees given and received:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Guarantees given:</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2058" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4984">3,936</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2059" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4985">3,815</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2060" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4986">3,794</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Guarantees provided to banks in connection with credit facilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2061" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4987">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2062" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4988">1,007</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2063" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4989">1,042</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other guarantees given</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2064" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4990">2,869</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2065" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4991">2,808</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2066" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4992">2,752</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Guarantees received</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2067" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4993">1,272</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2068" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4994">1,229</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2069" decimals="-6" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-4995">1,149</ix:nonFraction>)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.21.3. Off balance sheet commitments relating to asset acquisitions and divestments, and to changes in the scope of consolidation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, Sanofi had received commitments amounting in aggregate to &#8364;<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-8" name="sny:OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments" scale="9" id="f-4996">0.3</ix:nonFraction>&#160;billion in respect of (i)&#160;divestments of assets relating to transactions not yet finalized as of that date and (ii)&#160;contingent consideration arising under past agreements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments of a financing nature with associates and joint ventures are disclosed in N</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ote&#160;D.6.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off-balance sheet commitments relating to securities classified in the categories Equity instruments at fair value through other comprehensive income and Unquoted debt securities not meeting the definition of equity instruments are respectively disclosed in Notes D .7.1. and D.7.3..</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The maximum amount of contingent consideration relating to business combinations is disclosed in Note&#160;D.18.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-80</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_682"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.22. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfLegalAndArbitralProceedingsTextBlock" id="f-4997" continuedAt="f-4997-1" escape="true">Legal and arbitral proceedings</ix:nonNumeric></span></div><ix:continuation id="f-4997-1" continuedAt="f-4997-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi&#160;products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures. Provisions related to legal and arbitral proceedings are recorded in accordance with the principles described in Note&#160;B.12.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Most of the issues raised by these claims are highly complex and subject to substantial uncertainties; therefore, the probability of loss and an estimation of damages are difficult to ascertain. Contingent liabilities are cases for which either we are unable to make a reasonable estimate of the expected financial effect that will result from ultimate resolution of the proceeding, or a cash outflow is not probable. In either case, a brief description of the nature of the contingent liability is disclosed and, where practicable, an estimate of its financial effect, an indication of the uncertainties relating to the amount and timing of any outflow, and the possibility of any reimbursement are provided in application of paragraph&#160;86 of IAS&#160;37.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed, we have indicated our losses or the amount of provision accrued that is the estimate of the probable loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a limited number of ongoing cases, while we are able to make a reasonable estimate of the expected loss or range of the possible loss and have accrued a provision for such loss, we believe that publication of this information on a case-by-case basis or by class would seriously prejudice the Company&#8217;s position in the ongoing legal proceedings or in any related settlement discussions. Accordingly, in those cases, we have disclosed information with respect to the nature of the contingency but have not disclosed our estimate of the range of potential loss, in accordance with paragraph&#160;92 of IAS&#160;37.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These assessments can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Our assessments are based on estimates and assumptions that have been deemed reasonable by management. We believe that the aggregate provisions recorded for the above matters are adequate based upon currently available information. However, given the inherent uncertainties related to these cases and involved in estimating contingent liabilities, we could in the future incur judgments that could have a material adverse effect on our net income in any particular period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Long term provisions are disclosed in Note&#160;D.19. They include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">provisions for product liability risks, litigation and other amount to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" format="ixt:num-dot-decimal" scale="6" id="f-4998">1,283</ix:nonFraction> million in 2023. These provisions are mainly related to product liabilities, government investigations, competition law, regulatory claims, warranties in connection with certain contingent liabilities arising from business divestitures other than environmental matters and other claims;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">provisions for environmental risks and remediation amount to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:NonCurrentProvisionForEnvironmentRisks" format="ixt:num-dot-decimal" scale="6" id="f-4999">493</ix:nonFraction> million in 2023, the majority of which are related to contingencies that have arisen from business divestitures.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">a) Products</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi Pasteur Hepatitis&#160;B Vaccine Product Litigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since 1996, more than <ix:nonFraction unitRef="lawsuit" contextRef="c-2070" decimals="INF" name="sny:NumberOfCivilIndividualActions" scale="0" id="f-5000">180</ix:nonFraction>&#160;lawsuits have been filed in various French civil courts against Sanofi Pasteur and/or Sanofi Pasteur&#160;MSD&#160;S.N.C., the former French subsidiary of Sanofi, and the latter a joint venture company with Merck&#160;&amp; Co.,&#160;Inc. now terminated, for which past ongoing litigation is now managed by the originating party. In such lawsuits, the plaintiffs allege that they suffer from a variety of neurological disorders and autoimmune diseases, including multiple sclerosis and Guillain-Barr&#233; syndrome as a result of receiving the hepatitis&#160;B vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January&#160;2018, the Appeal Court of Bordeaux found a causal link between hepatitis&#160;B vaccine and multiple sclerosis. In&#160;July&#160;2019, the French Supreme Court </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cour de cassation)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> cancelled the&#160;judgment&#160;of the Appeal Court of Bordeaux and referred the&#160;case back to the Appeal Court of Toulouse. On March&#160;30, 2022, the Appeal Court of Toulouse dismissed all the plaintiff&#8217;s claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there were <ix:nonFraction unitRef="lawsuit" contextRef="c-2070" decimals="INF" name="sny:NumberOfOngoingLawsuits" format="ixt-sec:numwordsen" scale="0" id="f-5001">six</ix:nonFraction>&#160;ongoing lawsuits related to Sanofi Pasteur hepatitis&#160;B vaccine.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TAXOTERE Product Litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, there were approximately <ix:nonFraction unitRef="plaintiff" contextRef="c-2071" decimals="0" name="sny:NumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="f-5002">6,770</ix:nonFraction>&#160;ingesting plaintiffs cases remaining in courts across the country.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Lawsuits have been filed against affiliates of Sanofi under US state law for personal injuries allegedly sustained in connection with&#160;the use of TAXOTERE. The actions are held in several jurisdictions around the country. In 2021, there were <ix:nonFraction unitRef="trial" contextRef="c-2072" decimals="0" name="sny:NumberOfBellweatherTrialsHeld" format="ixt-sec:numwordsen" scale="0" id="f-5003">two</ix:nonFraction>&#160;bellwether trials as part of a federal multi-district litigation in the Eastern District of Louisiana both resulting in jury verdicts in Sanofi's favor. In 2023, Sanofi settled approximately <ix:nonFraction unitRef="case" contextRef="c-2073" decimals="0" name="sny:NumberOfIndividualCasesSettled" scale="0" id="f-5004">100</ix:nonFraction>&#160;individual cases.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TAXOTERE &#8211; Mississippi Attorney General Litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In October&#160;2018, the Attorney General for the State of Mississippi filed a civil action in Hinds County, Mississippi, Chancery Court against various Sanofi Defendants related to TAXOTERE. The State asserts one cause of action based on the Mississippi Consumer Protection Act (MCPA) and seeks a permanent injunction prohibiting Defendants&#8217; conduct and civil penalties of up to&#160;$<ix:nonFraction unitRef="usd" contextRef="c-2074" decimals="INF" name="sny:MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation" format="ixt:num-dot-decimal" scale="0" id="f-5005">10,000</ix:nonFraction> for each violation. Sanofi filed a motion to dismiss the entire action in Hinds County, Mississippi, Chancery Court, which is currently pending.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-81</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-4997-2" continuedAt="f-4997-3"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZANTAC Litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2019, the US Food and Drug Administration (FDA) announced it was investigating the claims of an online pharmacy&#8217;s Citizen Petition that the medication ZANTAC (the brand name for ranitidine) used for stomach heartburn contains or can generate the chemical N-Nitrosodimethylamine (NDM), an alleged human carcinogen. As a precautionary measure, Sanofi initiated a voluntary recall of branded over-the-counter ZANTAC in October&#160;2019. Concurrent with FDA&#8217;s investigation, multiple personal injury lawsuits and class actions alleging that ZANTAC causes various cancers and seeking damages for either alleged personal injuries or alleged economic injuries were filed. Federal court cases were coordinated into a Multi-District Litigation (MDL) in the Southern District of Florida in February&#160;2020.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;6, 2022, the MDL Court granted Sanofi and other defendants&#8217; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Daubert</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and summary judgment motions. As a result, the Court entered final judgment in all cases involving plaintiffs&#8217; <ix:nonFraction unitRef="cancer" contextRef="c-2075" decimals="0" name="sny:NumberOfCancersAssociatedWithDismissedCases" format="ixt-sec:numwordsen" scale="0" id="f-5006">five</ix:nonFraction> designated cancers and dismissed the class action cases. Based on the preliminary estimates, more than <ix:nonFraction unitRef="plaintiff" contextRef="c-2075" decimals="0" name="sny:NumberOfPlaintiffsWhoFiledNoticesToAppeal" format="ixt:num-dot-decimal" scale="0" id="f-5007">12,000</ix:nonFraction>&#160;plaintiffs have filed notices to appeal the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Daubert</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> ruling in the Eleventh Circuit. The MDL Court subsequently dismissed all pending cases alleging a non-designated cancer for failure to serve expert reports.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other cases are pending in various state courts. The majority of the state court plaintiffs have cases pending in Delaware, where a hearing on defendants&#8217; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Daubert</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> motions to exclude plaintiffs&#8217; experts was scheduled for January&#160;2024. Trials are scheduled in&#160;2024 in single-plaintiff cases in several states. No ZANTAC case has gone to trial to date.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Overall, there are currently around <ix:nonFraction unitRef="complaint" contextRef="c-2076" decimals="INF" name="sny:NumberOfComplaintsFiled" format="ixt:num-dot-decimal" scale="0" id="f-5008">3,280</ix:nonFraction>&#160;product liability &#8220;complaints&#8221; filed. These complaints encompass&#160;<ix:nonFraction unitRef="plaintiff" contextRef="c-2076" decimals="INF" name="sny:NumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="f-5009">26,984</ix:nonFraction>&#160;individual product liability &#8220;plaintiffs&#8221; who have all filed against Sanofi. The vast majority of these plaintiffs participated in the MDL Court&#8217;s census registry program, allege cancers that the plaintiffs&#8217; leadership decided not to designate and pursue in the MDL, and have since filed their complaints in state courts. Additional cases may be filed.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, in November&#160;2019, Sanofi received a Civil Investigative Demand (CID) related to this issue from the Arizona Attorney General. Sanofi provided responses in December&#160;2019 and July&#160;2020 and has not received any follow-up requests.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2020, the New Mexico Attorney General filed a complaint against Sanofi, the previous marketing authorization holders for branded ZANTAC, a dozen generic manufacturers, and several retailers. The complaint brings claims for alleged violations of the New Mexico Unfair Practices Act, violations of the New Mexico False Advertising Act, violations of the New Mexico Public Nuisance Statute, common law public nuisance, and negligence. Trial in the case is scheduled for September&#160;2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2020, Sanofi received a notice from the US Department of Justice Civil Division and US Attorney&#8217;s Office for the Eastern District of Pennsylvania of an investigation into allegations that pharmaceutical manufacturers violated the False Claims Act,&#160;31&#160;U.S.C. &#167;&#160;3729, in relation to the drug ZANTAC and ranitidine hydrochloride through alleged failure to disclose to the federal government information about the potential presence of NDMA. In response to the notice, Sanofi provided information and documents including applications and communications with&#160;FDA, in August&#160;2020. Sanofi has not received any subsequent requests from the federal government.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In November&#160;2020, the Mayor and City Council of Baltimore filed a complaint against Sanofi, the previous marketing authorization holders for branded ZANTAC, generic manufacturers, and several retailers. The complaint alleges violations of the Maryland Consumer Protection statute, public nuisance, and negligence. Trial in the case is scheduled for June&#160;2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January&#160;2021, Sanofi was served with the Center for Environmental Health&#8217;s Second Amended Complaint alleging Proposition&#160;65&#160;violations. The case is pending in California Superior Court&#160;in Alameda County, and no trial date has been set.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZANTAC Litigation in Canada</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Between 2019 and 2022, <ix:nonFraction unitRef="action" contextRef="c-2077" decimals="INF" name="sny:NumberOfClassActionLawsuits" format="ixt-sec:numwordsen" scale="0" id="f-5010">seven</ix:nonFraction>&#160;proposed class actions naming some or all of Sanofi Consumer Health&#160;Inc., Sanofi-Aventis Canada Inc., Chattem (Canada)&#160;Inc., Sanofi and Sanofi Pasteur Limited as Defendants, relating to ranitidine were filed in courts in various Canadian provinces. The cases allege that proposed class members suffered personal injury from the ingestion of ranitidine, and seek damages in unspecified amounts, disgorgement of profits, restitution in the amount of the purchase price of ZANTAC and subrogated damages on behalf of provincial health insurers for health care costs related to ranitidine use.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May&#160;2023, in the proceedings pending before the Supreme Court of British Columbia, the Court dismissed the action, ruling that there is no scientific support for plaintiff&#8217;s claims. After this ruling, the Superior Court of Quebec stayed the corresponding proposed ZANTAC class proceedings in Quebec until the result of the US Multi-District Litigation (MDL) appeal is announced or&#160;October&#160;15, 2024&#8239;(whichever comes first).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of the remaining lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GOLD BOND Product Litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Over the last few years, Sanofi affiliates have been named in product liability actions in the United States regarding the alleged presence of asbestos in talc products originating from past acquisitions. A certain number of these claims were also dismissed during that time. As of December&#160;31, 2023,  there were approximately <ix:nonFraction unitRef="action" contextRef="c-2078" decimals="INF" name="sny:NumberOfClassActionLawsuits" scale="0" id="f-5011">500</ix:nonFraction>&#160;product liability ongoing actions. To date, <ix:nonFraction unitRef="action" contextRef="c-2079" decimals="INF" name="sny:NumberOfOngoingTrials" format="ixt:fixed-zero" scale="0" id="f-5012">no</ix:nonFraction> cases have proceeded to trial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-82</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-4997-3" continuedAt="f-4997-4"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DEPAKINE Product Litigation in France</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Civil proceedings</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, <ix:nonFraction unitRef="claim" contextRef="c-2080" decimals="INF" name="sny:NumberOfCivilIndividualActions" scale="0" id="f-5013">79</ix:nonFraction>&#160;families brought a civil claim involving <ix:nonFraction unitRef="person" contextRef="c-2080" decimals="INF" name="sny:NumberOfPeopleExposed" scale="0" id="f-5014">133</ix:nonFraction>&#160;people exposed in utero to sodium valproate against a French affiliate of Sanofi seeking indemnification under French law for personal injuries allegedly suffered by children in connection with the use of sodium valproate by their mothers during pregnancy to treat their epilepsy (DEPAKINE). These actions are held in several jurisdictions in&#160;France.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="lawsuit" contextRef="c-2080" decimals="INF" name="sny:NumberOfLawsuitsRuledOnMerit" format="ixt-sec:numwordsen" scale="0" id="f-5015">Thirty</ix:nonFraction> lawsuits are in progress on the merits, the most advanced was tried at the French Supreme Court level which issued in&#160;November&#160;2019 a ruling sending the case before the Paris Appeal Court to rule on Sanofi&#8217;s argument on the compliance of the&#160;product with mandatory regulations, as well as on the question of defectiveness of the product and the assessment of damages. In January&#160;2023, the Paris Appeal Court ordered a stay in the proceedings until the submission of the second expert opinion report as part of the criminal investigation (see below).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="ruling" contextRef="c-2081" decimals="INF" name="sny:NumberOfFirstInstanceRulings" format="ixt-sec:numwordsen" scale="0" id="f-5016">Seven</ix:nonFraction> first instance rulings on the merits were handed down in 2022 by the Judicial Tribunal of Nanterre. In <ix:nonFraction unitRef="case" contextRef="c-2082" decimals="INF" name="sny:NumberOfFirstInstanceRulings" format="ixt-sec:numwordsen" scale="0" id="f-5017">three</ix:nonFraction> cases, the Court declared the judicial expert report null and void and the Court dismissed one claim in another case.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Concerning <ix:nonFraction unitRef="case" contextRef="c-2082" decimals="INF" name="sny:NumberOfFirstInstanceRulings" format="ixt-sec:numwordsen" scale="0" id="f-5018">three</ix:nonFraction> other cases relating to births that occurred between 2005 and 2009, the Court held, on the basis of a non-fault liability, that Sanofi was liable in light of the wording of the patient information leaflet. Provisional compensation amounts were set in the range of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2083" decimals="-5" name="sny:LitigationAmountPayable" format="ixt:num-dot-decimal" scale="6" id="f-5019">0.1</ix:nonFraction>&#160;million to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2084" decimals="-5" name="sny:LitigationAmountPayable" format="ixt:num-dot-decimal" scale="6" id="f-5020">0.5</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All the judgments have been appealed and are still pending.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the class action lawsuit filed in May&#160;2017 by the APESAC </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Association des Parents d&#8217;Enfants souffrant du Syndrome de l&#8217;Anti-Convulsivant)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> against the French affiliate, the Judicial Tribunal of Paris ruled on January&#160;5, 2022 that a class is admissible, retaining Sanofi&#8217;s liability between 1984 and January&#160;2006 for malformations and between 2001 and January&#160;2006 for neuro-developmental disorders (NDD). This decision is based on the conclusions of a criminal expert report within the frame of ongoing criminal proceeding, for which the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre de l&#8217;Instruction</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of the Appeal Court of Paris had ordered a counter-expertise (see&#160;below). The APESAC, Sanofi and its insurers appealed the Judicial Tribunal of Paris&#8217; ruling related to the class action.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;21, 2021, the Judicial Tribunal of Cr&#233;teil (France) dismissed a claim for damages brought against Sanofi regarding a child born in&#160;1995. The Judicial Tribunal considered that the risk of occurrence of NDD in children born to mother exposed to sodium valproate during pregnancy was not demonstrated by the state of scientific knowledge at the time of her pregnancy. This decision was appealed and the proceeding is now pending before the Appeal Court of Paris, which had ordered a stay in the proceeding until the end of the criminal investigation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July&#160;2020 and December&#160;2022, a collective redress against the French affiliate was filed by</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="family" contextRef="c-2085" decimals="INF" name="sny:NumberOfFamiliesWhoFiledACivilClaim" scale="0" id="f-5021">64</ix:nonFraction>&#160;f</span><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amilies which represents <ix:nonFraction unitRef="claimant" contextRef="c-2085" decimals="INF" name="sny:NumberOfClaimant" scale="0" id="f-5022">273</ix:nonFraction>&#160;claimants including <ix:nonFraction unitRef="claimant" contextRef="c-2085" decimals="INF" name="sny:NumberOfClaimantExposed" scale="0" id="f-5023">100</ix:nonFraction>&#160;people exposed in utero, seeking indemnification for a</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> prejudice of anxiety</span><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. In September&#160;2023, <ix:nonFraction unitRef="claimant" contextRef="c-2086" decimals="INF" name="sny:NumberOfClaimantExposedWhoWithdrawedTheClaim" scale="0" id="f-5024">27</ix:nonFraction>&#160;people exposed to sodium valproate in utero and <ix:nonFraction unitRef="claimant" contextRef="c-2086" decimals="INF" name="sny:NumberOfIndirectVictimWhoWithdrawedTheClaim" scale="0" id="f-5025">56</ix:nonFraction>&#160;indirect victims requested the withdrawal of their claims. The trial hearing is set for June&#160;6, 2024.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Criminal investigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A criminal investigation was initiated in May&#160;2015 before the Paris Civil Court. In January&#160;2020, the French affiliate of Sanofi was indicted for aggravated deception and involuntary injuries and in July&#160;2020 for involuntary manslaughter. In July&#160;2020, a judicial supervision of the affiliate was ordered, together with the implementation of financial guarantees. In November&#160;2020, the Health Authority (</span><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ANSM) was similarly indicted for involuntary injuries and involuntary manslaughters.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March&#160;9, 2022, the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre de l&#8217;Instruction</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of the Appeal Court of Paris </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cour d&#8217;appel)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> ruled that certain complaints for involuntary manslaughter and several others for aggravated deception and involuntary injuries were time-barred. The Public Prosecutor, as well as the civil parties, have brought the matter before the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre Criminelle </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">of the Supreme Court </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cour de cassation)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2022, the investigating judges appointed <ix:nonFraction unitRef="expert" contextRef="c-2087" decimals="INF" name="sny:NumberOfCounterExpertiseExperts" format="ixt-sec:numwordsen" scale="0" id="f-5026">two</ix:nonFraction>&#160;experts for a counter-expertise following the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre de l&#8217;Instruction&#8217;s</span><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> ruling handed down end of 2021. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since 2022, several individual medical assessments have been ordered by the investigating judge.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June 2023, the </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre Criminelle</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of the French Supreme Court </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cour de cassation</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> confirmed the Paris Court of Appeal&#8217;s decision </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre de l&#8217;Instruction</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> dated March&#160;2022 which had ruled that certain complaints for involuntary manslaughter and several others for aggravated deception and involuntary injuries were time-barred. In August&#160;2023, Sanofi received the counter expertise report and sent its comments in November&#160;2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Public compensation scheme</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2017, the French government set up a public compensation scheme to indemnify patients for damages suffered in connection with the prescription of sodium valproate and its derivatives. The scheme was further amended through the 2020 Finance Law, with notably the introduction of presumptions of default for lack of information of the mother since 1982 for malformations and since 1984 for NDD. The scheme was amended again through the&#160;2021 Finance Law in order to increase the maximum premium applicable in case of refusal to make an offer (or insufficient offer) which would be deemed unjustified by a court ruling.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The committee of the compensation scheme has issued several final opinions holding the French affiliate liable for damages either in full or in part along with the French State, and, in some cases, healthcare practitioners. The French affiliate disagreed with the committee&#8217;s conclusions and has accordingly not offered indemnification to the claimants who have received compensation from the ONIAM </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Office National d&#8217;Indemnisation des Accidents M&#233;dicaux)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The ONIAM is now seeking reimbursement from Sanofi who has filed legal actions to oppose ONIAM&#8217;s payment orders.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-83</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-4997-4" continuedAt="f-4997-5"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Administrative Actions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July&#160;2020, March and June&#160;2021, the Montreuil Administrative Court had held the French State liable in <ix:nonFraction unitRef="proceeding" contextRef="c-2088" decimals="INF" name="sny:NumberOfAdministrativeProceedings" format="ixt-sec:numwordsen" scale="0" id="f-5027">five</ix:nonFraction>&#160;administrative proceedings initiated by families against the State. In March&#160;2021, the Administrative Court did not retain any lack of information of the mother regarding the risk of neurodevelopmental disorders for births in 1999 and in 2002, based on the state of scientific knowledge at the time. However, regarding the risk of malformations, liabilities were retained against the State, the healthcare professionals and Sanofi, notably for discrepancy between the SmPC (Summary of the Product Characteristics) and the patient leaflet. In other cases involving births in 2005-2008, the liability of the State was retained for both malformations and neurodevelopmental disorders, and partially exonerated, taking into account the roles of healthcare practitioners and Sanofi. Given that the French affiliate was not a party to these administrative proceedings, its arguments (i.e. notably several requests from the French affiliate to the Health Authorities to reinforce warnings to healthcare professionals and patients in relation to DEPAKINE) were not considered. All rulings were appealed by the claimants. Sanofi has filed requests for voluntary intervention in these proceedings to present its arguments before the Administrative Court of Appeal. In one proceeding, the claimants decided to withdraw their claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to make a reliable assessment of the outcome of these cases.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DEPAKINE Product Litigation in other EU countries and in the UK</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Switzerland, <ix:nonFraction unitRef="family" contextRef="c-2089" decimals="INF" name="sny:NumberOfFamiliesWhoFiledACivilClaim" format="ixt-sec:numwordsen" scale="0" id="f-5028">eleven</ix:nonFraction>&#160;families have filed a civil claim for damages concerning <ix:nonFraction unitRef="person" contextRef="c-2089" decimals="INF" name="sny:NumberOfPeopleExposed" format="ixt-sec:numwordsen" scale="0" id="f-5029">seventeen</ix:nonFraction>&#160;people exposed in utero. Some of them also involve the claimants&#8217; physicians. In November&#160;2022, <ix:nonFraction unitRef="person" contextRef="c-2090" decimals="INF" name="sny:NumberOfActionDeclaredTimeBarred" format="ixt-sec:numwordsen" scale="0" id="f-5030">one</ix:nonFraction> action was declared time-barred by the judge. The claimant appealed this court decision on the merit. The appeal is on-going.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Spain, there are <ix:nonFraction unitRef="trial" contextRef="c-2091" decimals="INF" name="sny:NumberOfOngoingTrials" format="ixt-sec:numwordsen" scale="0" id="f-5031">six</ix:nonFraction> ongoing actions relating to <ix:nonFraction unitRef="children" contextRef="c-2091" decimals="INF" name="sny:NumberOfPeopleExposed" format="ixt-sec:numwordsen" scale="0" id="f-5032">thirteen</ix:nonFraction>&#160;children. In March&#160;2022, in one trial, the Court condemned Sanofi to indemnify <ix:nonFraction unitRef="patient" contextRef="c-2092" decimals="INF" name="sny:NumberOfPatientsToIndemnify" format="ixt-sec:numwordsen" scale="0" id="f-5033">four</ix:nonFraction>&#160;patients. Sanofi appealed this decision. In January&#160;2023, in another trial filed by one patient, the Appeal Court confirmed the first instance's decision and dismissed the claim. The other actions are still at a preliminary stage.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Belgium, there are <ix:nonFraction unitRef="complaint" contextRef="c-2093" decimals="INF" name="sny:NumberOfCivilIndividualActions" format="ixt-sec:numwordsen" scale="0" id="f-5034">two</ix:nonFraction>&#160;civil proceedings (currently on hold) and a criminal complaint against&#160;X and against Sanofi.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Ireland, there are <ix:nonFraction unitRef="case" contextRef="c-2094" decimals="INF" name="sny:NumberOfPreActionProtocolCases" format="ixt-sec:numwordsen" scale="0" id="f-5035">two</ix:nonFraction>&#160;cases in Pre-Action stage and <ix:nonFraction unitRef="claim" contextRef="c-2094" decimals="INF" name="sny:NumberOfCivilClaimsOnGoing" format="ixt-sec:numwordsen" scale="0" id="f-5036">two</ix:nonFraction>&#160;civil claims on-going.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the United Kingdom, there are <ix:nonFraction unitRef="case" contextRef="c-2095" decimals="INF" name="sny:NumberOfPreActionProtocolCases" format="ixt-sec:numwordsen" scale="0" id="f-5037">three</ix:nonFraction>&#160;cases in the Pre-Action stage in Great Britain and <ix:nonFraction unitRef="claim" contextRef="c-2096" decimals="INF" name="sny:NumberOfCivilClaimsOnGoing" format="ixt-sec:numwordsen" scale="0" id="f-5038">one</ix:nonFraction>&#160;civil claim ongoing in Northern Ireland.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess reliably the outcome of these cases.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DENGVAXIA (Philippines)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since early 2018 up to present date, several claims were filed in the Philippines by parents of deceased children whose deaths were allegedly due to vaccination with DENGVAXIA. Early March&#160;2019, 2020 and 2022, the Philippine Department of Justice (DOJ) prosecution panel announced it had found probable cause to indict several Sanofi employees/former employees and former Government officials for &#8220;reckless imprudence&#8221; resulting in homicides. Since then, several criminal actions have been filed in court as a result of this finding and are pending at various stages of the legal procedure. Petitions for Review to the DOJ Secretary have been filed and the said petitions remain pending. Meanwhile, the majority of the respondents have challenged the jurisdiction of the lower court where the first&#160;<ix:nonFraction unitRef="case" contextRef="c-2097" decimals="INF" name="sny:NumberOfCases" format="ixt-sec:numwordsen" scale="0" id="f-5039">eight</ix:nonFraction>&#160;cases had been assigned and this issue is now filed with the Supreme Court. There are several claims that have not yet been filed in any court despite resolutions by the DOJ that there is probable cause.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">b) Patents</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ramipril Canada Patent Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi was involved in a number of legal proceedings involving companies which market generic ALTACE (ramipril) in Canada.&#160;In&#160;2004, Sanofi unsuccessfully brought Notice of Compliance proceedings (NOC proceedings) at the end of which <ix:nonFraction unitRef="manufacturer" contextRef="c-2098" decimals="INF" name="sny:NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug" format="ixt-sec:numwordsen" scale="0" id="f-5040">eight</ix:nonFraction>&#160;manufacturers obtained marketing authorizations from the Canadian Minister of Health for generic versions of ramipril in Canada. Sanofi filed unsuccessful patent infringement actions against all those companies and ultimately Sanofi was liable for damages under Section&#160;8. Sanofi made payment in complete satisfaction of those awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2011, Apotex commenced an action in the Ontario Superior Court of Justice asserting damages under the Ontario Statute of Monopolies, the UK Statute of Monopolies, and the Trade-marks Act (the &#8220;Ontario Action&#8221;).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the request of the parties, in June&#160;2021, the Court ordered that the action be stayed in view of the lower court&#8217;s decision in March in the Apotex vs. Lilly case. In the Lilly case, the Court dismissed Apotex&#8217;s Statute of Monopolies claim by way of summary judgment. </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April&#160;2023, the Canadian Supreme Court denied Apotex&#8217;s application for leave to appeal in the Lilly case and based on the Supreme Court decision, Apotex&#8217;s claim no longer has any basis. Sanofi is seeking the court&#8217;s assistance to conclude the case and recover appropriate costs.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRALUENT (alirocumab)-related Amgen Patent Litigation in the US</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2014, Amgen filed <ix:nonFraction unitRef="complaint" contextRef="c-2099" decimals="INF" name="sny:NumberOfPatentActionsInitiallyFiled" format="ixt-sec:numwordsen" scale="0" id="f-5041">four</ix:nonFraction> separate complaints against Sanofi and Regeneron in the US District Court for the District of Delaware (&#8220;District Court&#8221;) asserting patent infringement relating to Sanofi and Regeneron&#8217;s PRALUENT product. Together these complaints alleged that PRALUENT infringed <ix:nonFraction unitRef="patent" contextRef="c-2100" decimals="INF" name="sny:NumberOfPatentsAllegedlyInfringed" format="ixt-sec:numwordsen" scale="0" id="f-5042">seven</ix:nonFraction> patents for antibodies targeting PCSK9 and sought injunctive relief and unspecified damages.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February&#160;2021, the Federal Circuit affirmed the District Court&#8217;s ruling invalidating the Amgen asserted patent claims. In&#160;November&#160;2021, Amgen filed a petition with the US&#160;Supreme Court, asking it to overturn the Federal Circuit decision.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November&#160;4, 2022, the US Supreme Court granted Amgen&#8217;s petition for review. </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May&#160;2023, the Supreme Court issued a unanimous decision in favor of Sanofi and Regeneron regarding the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">patent infringement actions filed in 2014 by Amgen relating to Sanofi and Regeneron&#8217;s PRALUENT product. Sanofi is in the process of seeking certain legal costs from Amgen.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-84</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-4997-5" continuedAt="f-4997-6"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRALUENT (alirocumab)-related Amgen Patent Litigation in Europe</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2023, Amgen filed an action for infringement of EP&#160;3&#160;666&#160;797 against Sanofi and Regeneron concerning PRALUENT in the Munich Local Division of the Unified Patent Court. Amgen seeks a permanent injunction and unspecified damages and compensation from March&#160;1, 2023. In June&#160;2023, Sanofi filed a revocation action attacking the validity of EP&#160;3&#160;666&#160;797 in the Munich Central Division of the Unified Patent Court. These cases are underway: a hearing in the revocation action is scheduled in&#160;June&#160;2024 and a hearing in the infringement action is scheduled for October&#160;2024.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JEVTANA (cabazitaxel)-related patent litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">JEVTANA is currently covered by <ix:nonFraction unitRef="patent" contextRef="c-2101" decimals="INF" name="sny:NumberOfPatentsCoveringProduct" format="ixt-sec:numwordsen" scale="0" id="f-5043">four</ix:nonFraction> Orange Book listed patents US&#160;7,241,907, US&#160;8,927,592, US&#160;10,583,110 and US&#160;10,716,777. In&#160;May&#160;to July&#160;2020, Sanofi filed patent infringement suits under Hatch-Waxman against <ix:nonFraction unitRef="claim" contextRef="c-2102" decimals="INF" name="sny:NumberOfPatentsAllegedlyInfringed" scale="0" id="f-5044">12</ix:nonFraction>&#160;generic filers asserting the &#8216;110&#160;patent and the&#160;&#8216;777&#160;patent in the US District Court for the District of Delaware, adding the '592&#160;patent after its amended claims issued in&#160;August&#160;2021. Sanofi reached settlement agreements with most of the defendants and went to trial against the remaining defendant Sandoz on the &#8216;777&#160;patent in January&#160;2023. In June&#160;2023, the US District Court for the District of Delaware issued a decision in favor of Sanofi in connection with the JEVTANA patent litigation against Sandoz and on August&#160;2, 2023, Sandoz appealed to the Court of Appeals for the Federal Circuit. On October&#160;5, 2023, Sanofi and Sandoz filed a joint stipulation voluntarily dismissing Sandoz&#8217;s Appeal, bringing this matter to final conclusion.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLAVIX Litigation (Commonwealth) in Australia</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In August&#160;2007, GenRX (a subsidiary of Apotex) obtained registration of a generic clopidogrel bisulfate product on the Australian Register of Therapeutic Goods. At the same time, GenRX filed a patent invalidation action with the Federal Court of Australia, seeking revocation of Sanofi&#8217;s Australian enantiomer patent claiming clopidogrel salts (a &#8220;nullity action&#8221;). In September&#160;2007, Sanofi obtained a preliminary injunction from the Federal Court preventing commercial launch of this generic clopidogrel bisulfate product until judgment on the substantive issues of patent validity and infringement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In August&#160;2008, the Australian Federal Court confirmed that the claim in Sanofi&#8217;s Australian enantiomer patent directed to clopidogrel bisulfate (the salt form in PLAVIX) was valid and the patent infringed. On appeal, the Full Federal Court of Australia held in&#160;September&#160;2009 that all claims in the patent are invalid. Sanofi&#8217;s appeal to the Australia High Court was denied in&#160;March&#160;2010. On conclusion of the proceedings in 2010, the Sanofi patent was invalidated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April&#160;2013, the Australian Department of Health and Ageing (&#8220;Commonwealth&#8221;) filed an application before the Federal Court&#160;of&#160;Australia seeking payment of damages from Sanofi related to the Apotex preliminary injunction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and BMS settled the patent litigation with Apotex in November&#160;2014. In April&#160;2020, the Commonwealth&#8217;s claim was dismissed. In&#160;May&#160;2020, the Commonwealth filed a Notice of Appeal to the Full Court of the Federal Court. On appeal, the Commonwealth reduced its claim to a range of AUD<ix:nonFraction unitRef="aud" contextRef="c-2103" decimals="-5" name="sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs" format="ixt:num-dot-decimal" scale="6" id="f-5045">223.3</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2103" decimals="-5" name="sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs" format="ixt:num-dot-decimal" scale="6" id="f-5046">137.8</ix:nonFraction>&#160;million) to AUD<ix:nonFraction unitRef="aud" contextRef="c-2104" decimals="-5" name="sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs" format="ixt:num-dot-decimal" scale="6" id="f-5047">280.2</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2104" decimals="-5" name="sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs" format="ixt:num-dot-decimal" scale="6" id="f-5048">172.9</ix:nonFraction>&#160;million) which, inclusive of interest to&#160;December&#160;31,&#160;2023, ranges from AUD<ix:nonFraction unitRef="aud" contextRef="c-2103" decimals="-5" name="sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" format="ixt:num-dot-decimal" scale="6" id="f-5049">360.5</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2103" decimals="-5" name="sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" format="ixt:num-dot-decimal" scale="6" id="f-5050">218.0</ix:nonFraction>&#160;million) to AUD<ix:nonFraction unitRef="aud" contextRef="c-2104" decimals="-5" name="sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" format="ixt:num-dot-decimal" scale="6" id="f-5051">487.5</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2104" decimals="-5" name="sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" format="ixt:num-dot-decimal" scale="6" id="f-5052">294.3</ix:nonFraction>&#160;million). </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In&#160;June&#160;2023, the Full Court of the Federal Court of Australia unanimously dismissed the Commonwealth&#8217;s appeal following</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> its application seeking payment of damages from Sanofi/BMS related to the preliminary injunction. O</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n July&#160;24, 2023, the&#160;Commonwealth filed an application for special leave to appeal to the High Court of Australia, which was granted on&#160;December&#160;18,&#160;2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">c) Other litigation</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLAVIX (clopidogrel) &#8211; Attorney General Action in Hawaii</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March&#160;2014, the Hawaii Attorney General (AG) filed a complaint that sets forth allegations related to the sale and marketing of and variability of response to PLAVIX. The Hawaii AG specifically alleged that PLAVIX had a diminished effect in patients of certain genetic backgrounds and that Sanofi and BMS had failed to make an earlier disclosure of this information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February&#160;2021, the Court issued its decision, imposing penalties in the total amount of $<ix:nonFraction unitRef="usd" contextRef="c-2105" decimals="-3" name="sny:GlobalPenaltyFeeIncurredByDefendants" format="ixt:num-dot-decimal" scale="0" id="f-5053">834,012,000</ix:nonFraction> against both Sanofi and Bristol Myers Squibb (BMS), with $<ix:nonFraction unitRef="usd" contextRef="c-2105" decimals="-3" name="sny:PenaltyFeeIncurred" format="ixt:num-dot-decimal" scale="0" id="f-5054">417,006,000</ix:nonFraction> being apportioned to each company. In June&#160;2021, Sanofi and BMS appealed this&#160;judgment. The appeal was transferred directly to the Hawaii Supreme Court. In March&#160;2023, the Hawaii Supreme Court vacated the judgment and ordered a new trial. A second trial was concluded in October&#160;2023 and Sanofi is expecting a decision in Q1&#160;2024. To the extent there is a new judgment entered by the court, this would be split evenly with BMS.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLAVIX (clopidogrel)-related litigation in France</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In France, in the claim concerning allegations that Sanofi&#8217;s communication and promotional practices inhibited the entry on the&#160;market of generics of clopidogrel (the active ingredient of PLAVIX), the French Antitrust Authority issued its decision on&#160;May&#160;14,&#160;2013, imposing on Sanofi a fine of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2106" decimals="-5" name="sny:PenaltyFeeIncurred" format="ixt:num-dot-decimal" scale="6" id="f-5055">40.6</ix:nonFraction>&#160;million. This decision was confirmed by the Supreme Court </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cour de cassation)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in 2016. As a consequence of the May&#160;2013 ruling, claims were filed by Sandoz and by Teva in 2014 before the Commercial Court of Paris for compensation of their alleged damages: loss of margin and other ancillary damages. In June&#160;and November&#160;2016 respectively, settlement agreements were entered into with Sandoz and Teva. Consequently, they subsequently withdrew their civil claims, jointly and severally. In September&#160;2017, Sanofi and its French affiliate received a summons before the&#160;Paris Commercial Court from the French</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> Caisse Nationale d&#8217;Assurance Maladie &#8211; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CNAM</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(French Social Security) claiming&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2107" decimals="-5" name="sny:PaymentOfDamagesClaimedByCounterparty" format="ixt:num-dot-decimal" scale="6" id="f-5056">115.8</ix:nonFraction>&#160;million for their alleged damages. On October&#160;1, 2019, the Paris Commercial Court dismissed the CNAM&#8217;s action as time barred. On February&#160;9, 2022, the Paris Court of Appeals overturned the Paris Commercial Court's ruling, finding the&#160;CNAM&#8217;s action as not time-barred and designated an expert to determine the amount of damages. The expert report is expected to be issued in March&#160;2024.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-85</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-4997-6" continuedAt="f-4997-7"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">340B Drug Pricing Program in the United States</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is currently involved in several matters relating to the 340B&#160;program in the US (a federal program that requires drug manufacturers to supply certain products to certain &#8220;covered entities&#8221; at reduced prices). In 2021, Sanofi filed a lawsuit against the Department of Health and Human Services (HHS), the Health Resources and Services Administration (HRSA), and certain of their administrators in the&#160;US&#160;District Court for the District of New Jersey challenging (i)&#160;HHS&#8217;s December&#160;2020 Advisory Opinion&#160;(AO) stating that drug manufacturers are legally obligated to deliver discounts under the 340B&#160;program to an unlimited number of contract pharmacies; (ii)&#160;HHS&#8217;s December&#160;2020 Administrative Dispute Resolution (ADR) Rule; and (iii)&#160;HRSA&#8217;s May&#160;2021 letter to Sanofi concluding that Sanofi&#8217;s 340B integrity initiative (under which Sanofi collects limited, de-identified, claims data on 340B-priced drugs dispensed by contract pharmacies) violates section&#160;340B and that Sanofi has therefore &#8220;overcharged&#8221; certain covered entities. The court issued its opinion in November&#160;2021, upholding HRSA&#8217;s conclusion in the&#160;May&#160;2021 letter, but did not impose any fines, penalties or refund obligations against Sanofi for any &#8220;overcharges&#8221;. The court also rejected Sanofi&#8217;s challenge to the ADR Rule and dismissed its challenge to the AO as moot. Sanofi appealed the court&#8217;s decision to the Third Circuit Court of Appeals (Third Circuit) and the government filed a cross-appeal.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January&#160;2023, the Third Circuit held that Sanofi&#8217;s restrictions on delivery to contract pharmacies do not violate Section&#160;340B. It also enjoined HHS from enforcing against Sanofi its reading of Section&#160;340B in the AO and the May&#160;2021 violation letter. As to Sanofi&#8217;s challenge to the 340B ADR rule, the Third Circuit held in favor of the Department of Health and Human Services (HHS) and HHS is in the process of revising the ADR rule (HRSA has sent the final rule to the Office of Information and Regulatory Affairs for review). The Third Circuit remanded the case back to the US District Court for the District of New Jersey (District Court) and on May&#160;24, 2023, the District Court issued an injunction and declaratory judgment consistent with the Third Circuit&#8217;s opinion. This ruling concluded the case as to Sanofi; however similar cases brought by other manufacturers remain pending.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">ADR Proceedings</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January&#160;2021, the National Association of Community Health Centers (NACHC) filed an ADR proceeding before HRSA on behalf of a number of covered entities, seeking to require Sanofi and AstraZeneca to supply contract pharmacies with 340B discounts without conditions. On August&#160;10, 2022, the ADR panel granted the motions to dismiss filed both by Sanofi and AstraZeneca, holding that the Delaware district court&#8217;s decision granting AstraZeneca&#8217;s motion for summary judgment precluded NACHC&#8217;s ADR claims against both AstraZeneca and Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2023, the University of Washington Medical Center and Harborview Medical Center filed a petition for monetary and equitable relief against Sanofi before the ADR Panel. The petition alleges that Sanofi has violated Section&#160;340B of the Public Health Service Act, 42&#160;U.S.C. &#167;&#160;256b, by imposing data reporting requirements on &#8220;Covered Entities&#8221; that are authorized under that statute to receive discounts on certain prescription drugs and that in June&#160;2023, Sanofi further restricted access to 340B discounted drugs. The parties are waiting for a panel to be assigned to the case.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2021, HRSA referred Sanofi (as well as other manufacturers) to the HHS Office of the Inspector General (OIG) in accordance with the 340B Program Ceiling Price and Civil Monetary Penalties Final Rule. The Third Circuit&#8217;s decision and the District Court&#8217;s injunction and declaratory judgment (described above) would preclude action against Sanofi based on the particular program at issue in the Third Circuit case.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February&#160;2021, the Vermont Attorney General issued a Civil Investigative Subpoena seeking certain information about Sanofi&#8217;s participation in the 340B Drug Pricing Program. Sanofi cooperated with this investigation, including producing documents to the Vermont Attorney General&#8217;s office.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Mosaic Health</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July&#160;2021, Mosaic Health Inc. and Central Virginia Health Services (covered entities) filed a nationwide antitrust class action complaint against Sanofi and <ix:nonFraction unitRef="manufacturer" contextRef="c-2108" decimals="INF" name="sny:NumberOfOtherManufacturersInvolvedInProceedings" format="ixt-sec:numwordsen" scale="0" id="f-5057">three</ix:nonFraction> other manufacturers in the United States District Court for the Western District of New York. Plaintiffs allege that Sanofi and the other defendants conspired to eliminate favorable 340B pricing, particularly with&#160;respect to diabetes therapies. On September&#160;2, 2022, the court granted Defendants&#8217; motion to dismiss the complaint. On&#160;October&#160;3, 2022, plaintiff filed a motion for leave to file a second amended complaint. On February&#160;1, 2024, the Court denied plaintiffs&#8217; motion for leave to file an amended complaint and dismissed the case.  An appeal by plaintiffs is expected.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Adventist Health System/West</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2023, Adventist Health System/West sued several drug manufacturing companies, including Sanofi-Aventis US LLC, Sanofi US Services Inc. and Genzyme Corporation, alleging that the companies violated state and federal False Claims Acts through overcharging for 340B Program drugs in violation of federal &#8220;penny pricing&#8221; policy. The manufacturers jointly moved to dismiss.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preliminary investigation by the Parquet National Financier (PNF) in France</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In November&#160;2023, Sanofi learnt through the press of an ongoing preliminary investigation by the French financial prosecutor (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Parquet National Financier &#8211; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PNF) started in March&#160;2023 relating to allegations regarding Sanofi&#8217;s financial communication on the launch of DUPIXENT at the end of 2017. Sanofi considers these allegations as groundless and is cooperating with the PNF to respond to the potential questions relating to the ongoing investigation.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-86</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-4997-7"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">d) Contingencies arising from certain mergers &amp; acquisitions transactions</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a result of divestitures, the Company is subject to a number of ongoing contractual and legal obligations regarding the state of the sold businesses, their assets, and their liabilities, some of which may be subject to dispute.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aventis CropScience Retained Liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The sale by Aventis Agriculture SA and Hoechst GmbH (both legacy companies of Sanofi) of their aggregate <ix:nonFraction unitRef="number" contextRef="c-2109" decimals="2" name="sny:EquityInvestmentSoldPercentage" scale="-2" id="f-5058">76</ix:nonFraction>% participation in Aventis CropScience Holding (ACS) to Bayer and Bayer CropScience AG (BCS), the wholly owned subsidiary of Bayer which holds the ACS shares, was effective on June&#160;3, 2002. The Stock Purchase Agreement (SPA) dated October&#160;2, 2001, contained customary representations and warranties with respect to the sold business, as well as a number of indemnifications subject to limitation periods and caps, in particular with respect to environmental liabilities for which some outstanding claims from Bayer remain unresolved.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Infraserv Hoechst Retained Liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">By the Asset Contribution Agreement dated December&#160;19/20, 1996, as amended in 1997, Hoechst contributed all lands, buildings, and related assets of the Hoechst site at Frankfurt Hoechst to Infraserv GmbH &amp; Co. Hoechst KG. Infraserv Hoechst undertook to indemnify Hoechst against environmental liabilities at the Hoechst site and with respect to certain landfills. As consideration for the indemnification undertaking, Hoechst transferred to Infraserv Hoechst approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2110" decimals="-6" name="sny:ConsiderationTransferredToFundReserveForIndemnificationUndertaking" format="ixt:num-dot-decimal" scale="6" id="f-5059">57</ix:nonFraction>&#160;million to fund reserves. In 1997, Hoechst also agreed it would reimburse current and future Infraserv Hoechst environmental expenses up to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2110" decimals="-6" name="sny:MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense" format="ixt:num-dot-decimal" scale="6" id="f-5060">143</ix:nonFraction>&#160;million. As a former operator of the land and as a former user of the landfills, Hoechst may ultimately be liable for costs of remedial action in excess of this amount.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Boehringer Ingelheim (BI) Consumer Healthcare Liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and Boehringer Ingelheim (BI) have agreed upon respective indemnification obligations for liabilities as part of the swap of Sanofi&#8217;s Animal Health (AH) business for BI&#8217;s Consumer Health Care (CHC) business in January&#160;2017 and under a Global Settlement Agreement concluded in September&#160;2019 regarding notably the offset of respective AH and CHC claims notified under the SPAs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February&#160;2020, BI initiated an arbitration against Sanofi seeking indemnification for losses it could incur as a result of the ZANTAC litigation in the US (see above). In an award rendered on June&#160;19, 2023, the arbitral tribunal irrevocably dismissed BI&#8217;s indemnification claim against Sanofi and confirmed that Sanofi shall not be liable to indemnify BI for any potential losses in relation to the ongoing ZANTAC litigation in the U.S. The case is closed.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-87</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_685"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.23. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock" id="f-5061" continuedAt="f-5061-1" escape="true">Provisions for discounts, rebates and sales returns</ix:nonNumeric></span></div><ix:continuation id="f-5061-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adjustments between gross sales and net sales, as described in Note&#160;B.13., are recognized either as provisions or as reductions in accounts receivable, depending on their nature.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock" id="f-5062" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in these items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:25.699%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Government</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">and State</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">programs</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Managed&#160;care</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">and&#160;GPO</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">programs</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chargeback<br/>incentives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rebates<br/>and<br/>discounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sales<br/>returns</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>deductions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2111" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5063">2,507</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2112" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5064">908</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2113" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5065">333</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2114" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5066">1,557</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2115" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5067">688</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2116" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5068">46</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5069">6,039</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2117" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" scale="6" id="f-5070">3</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2118" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" format="ixt:fixed-zero" scale="6" id="f-5071">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2119" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" format="ixt:fixed-zero" scale="6" id="f-5072">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2120" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" scale="6" id="f-5073">2</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2121" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" scale="6" id="f-5074">1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2122" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" format="ixt:fixed-zero" scale="6" id="f-5075">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" scale="6" id="f-5076">2</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2117" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5077">5,855</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2118" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5078">3,037</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2119" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5079">3,813</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2120" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5080">6,330</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2121" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" scale="6" id="f-5081">582</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2122" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" scale="6" id="f-5082">97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5083">19,714</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in provision related to prior period sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2117" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5084">136</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2118" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5085">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2119" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5086">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2120" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5087">152</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2121" decimals="-6" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5088">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2122" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5089">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5090">242</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2117" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5091">5,561</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2118" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5092">2,979</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2119" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5093">3,828</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2120" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5094">6,291</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2121" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5095">697</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2122" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5096">105</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5097">19,461</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2117" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5098">72</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2118" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5099">32</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2119" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5100">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2120" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5101">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2121" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5102">20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2122" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5103">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5104">153</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2123" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5105">2,596</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2124" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5106">931</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2125" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5107">303</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2126" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5108">1,425</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2127" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5109">610</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2128" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5110">34</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5111">5,899</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2129" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5112">6,744</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2130" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5113">3,246</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2131" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5114">4,147</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2132" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5115">7,244</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2133" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" scale="6" id="f-5116">578</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2134" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" scale="6" id="f-5117">182</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5118">22,141</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in provision related to prior period sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2129" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5119">120</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2130" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5120">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2131" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5121">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2132" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5122">138</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2133" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5123">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2134" decimals="-6" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5124">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5125">315</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2129" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5126">6,824</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2130" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5127">3,208</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2131" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5128">4,093</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2132" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5129">6,809</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2133" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5130">599</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2134" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5131">166</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5132">21,699</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2129" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5133">207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2130" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5134">99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2131" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5135">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2132" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5136">83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2133" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5137">48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2134" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5138">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5139">464</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2135" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5140">2,603</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2136" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5141">1,021</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2137" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5142">362</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2138" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5143">1,805</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2139" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5144">629</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2140" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5145">70</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5146">6,490</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2141" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" scale="6" id="f-5147">2</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2142" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" format="ixt:fixed-zero" scale="6" id="f-5148">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2143" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" scale="6" id="f-5149">1</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2144" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" scale="6" id="f-5150">6</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2145" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" scale="6" id="f-5151">2</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2146" decimals="-6" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" scale="6" id="f-5152">4</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" scale="6" id="f-5153">3</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2141" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5154">7,758</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2142" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5155">3,590</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2143" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5156">3,861</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2144" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5157">8,177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2145" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" scale="6" id="f-5158">654</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2146" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" scale="6" id="f-5159">256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" format="ixt:num-dot-decimal" scale="6" id="f-5160">24,296</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in provision related to prior period sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2141" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5161">74</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2142" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5162">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2143" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5163">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2144" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5164">58</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2145" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5165">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2146" decimals="-6" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5166">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" scale="6" id="f-5167">155</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2141" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5168">7,251</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2142" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5169">3,446</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2143" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5170">3,564</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2144" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5171">7,603</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2145" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5172">511</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2146" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5173">278</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5174">22,653</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2141" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5175">76</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2142" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5176">34</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2143" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5177">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2144" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5178">46</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2145" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5179">30</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2146" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5180">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5181">213</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2023</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2147" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5182">2,962</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2148" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5183">1,119</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2149" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5184">637</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2150" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5185">2,269</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2151" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5186">715</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2152" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" scale="6" id="f-5187">60</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5188">7,762</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Primarily US government programs: Medicaid (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2153" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5189">1,421</ix:nonFraction> million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2154" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5190">1,307</ix:nonFraction> million in 2022, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2155" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5191">1,244</ix:nonFraction> million in 2021) and Medicare (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2156" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5192">1,099</ix:nonFraction> million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2157" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5193">775</ix:nonFraction> million in 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2158" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5194">941</ix:nonFraction> million in 2021).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Mainly rebates and other price reductions granted to healthcare authorities in the United States (including Managed Care: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2159" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5195">1,028</ix:nonFraction> million in 2023,     &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2160" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5196">934</ix:nonFraction> million in 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2161" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5197">896</ix:nonFraction> million in 2021).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Provisions related to US net sales amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1218" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5198">5,124</ix:nonFraction> million as of December 31, 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1224" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5199">4,270</ix:nonFraction> million as of December 31, 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1230" decimals="-6" name="sny:ProvisionsForDiscountsRebatesAndSalesReturns" format="ixt:num-dot-decimal" scale="6" id="f-5200">4,057</ix:nonFraction> million as of&#160;December 31, 2021.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div id="i9fa7f69b4904450e9c43e8444c203165_688"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.24. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory" id="f-5201" continuedAt="f-5201-1" escape="true">Personnel costs</ix:nonNumeric></span></div><ix:continuation id="f-5201-1"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfPersonnelCostsDetailsTableTextBlock" id="f-5202" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total personnel costs (other than termination benefits, presented in Note&#160;D.27.) include the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Salaries</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="6" id="f-5203">7,183</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="6" id="f-5204">7,145</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="6" id="f-5205">6,625</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Social security charges (including defined-contribution pension plans)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:SocialSecurityContributions" format="ixt:num-dot-decimal" scale="6" id="f-5206">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:SocialSecurityContributions" format="ixt:num-dot-decimal" scale="6" id="f-5207">2,098</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:SocialSecurityContributions" format="ixt:num-dot-decimal" scale="6" id="f-5208">1,929</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other employee benefits</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:3.9pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.1pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:OtherEmployeeExpense" scale="6" id="f-5209">531</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:OtherEmployeeExpense" scale="6" id="f-5210">748</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:OtherEmployeeExpense" scale="6" id="f-5211">786</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="6" id="f-5212">9,814</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="6" id="f-5213">9,991</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="6" id="f-5214">9,340</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes expenses related to share-based payments and defined-benefit plans.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total number of registered employees was <ix:nonFraction unitRef="employee" contextRef="c-5" decimals="INF" name="ifrs-full:NumberOfEmployees" format="ixt:num-dot-decimal" scale="0" id="f-5215">87,994</ix:nonFraction> as of December 31, 2023, compared with <ix:nonFraction unitRef="employee" contextRef="c-7" decimals="INF" name="ifrs-full:NumberOfEmployees" format="ixt:num-dot-decimal" scale="0" id="f-5216">91,573</ix:nonFraction> as of December 31, 2022 and&#160;<ix:nonFraction unitRef="employee" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfEmployees" format="ixt:num-dot-decimal" scale="0" id="f-5217">95,442</ix:nonFraction> as of December 31, 2021.</span></div></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_691"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.25.&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory" id="f-5218" continuedAt="f-5218-1" escape="true">Other operating income</ix:nonNumeric></span></div><ix:continuation id="f-5218-1" continuedAt="f-5218-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">totaled &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5219">1,292</ix:nonFraction> million in 2023, versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5220">1,969</ix:nonFraction> million in 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5221">859</ix:nonFraction> million in 2021.</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-5218-2">Other operating income includes (i)&#160;gains from asset divestments, amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2162" decimals="-6" name="sny:GainsOnDivestmentOfProducts" scale="6" id="f-5222">688</ix:nonFraction>&#160;million in 2023 (versus &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2163" decimals="-6" name="sny:GainsOnDivestmentOfProducts" format="ixt:num-dot-decimal" scale="6" id="f-5223">655</ix:nonFraction> million in 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2164" decimals="-6" name="sny:GainsOnDivestmentOfProducts" format="ixt:num-dot-decimal" scale="6" id="f-5224">418</ix:nonFraction> million in 2021); and (ii)&#160;income from Sanofi&#8217;s pharmaceutical partners, amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2165" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5225">290</ix:nonFraction> million in 2023 (including&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2166" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5226">227</ix:nonFraction> million from Regeneron, see Note&#160;D.26. below and Note&#160;C.1.), compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2167" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5227">1,178</ix:nonFraction> million in 2022 (including&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2168" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5228">1,147</ix:nonFraction> million from Regeneron), and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2169" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5229">245</ix:nonFraction> million in 2021. For 2021, it includes a payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2170" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-5230">119</ix:nonFraction>&#160;million from Daiichi Sankyo relating to the termination of a vaccines collaboration agreement in Japan</ix:continuation>.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-88</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_694"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.26.&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory" id="f-5231" continuedAt="f-5231-1" escape="true">Other operating expenses</ix:nonNumeric></span></div><ix:continuation id="f-5231-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> totaled &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5232">3,516</ix:nonFraction> million in 2023, compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5233">2,531</ix:nonFraction> million in 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5234">1,805</ix:nonFraction> million in 2021.</span></div><ix:nonNumeric contextRef="c-1" name="sny:OtherOperatingExpensesTableTextBlock" id="f-5235" continuedAt="f-5235-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2023, this line item includes &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2171" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5236">3,206</ix:nonFraction> million of expenses related to Regeneron (see Note&#160;C.1.), compared with&#160;&#8364;<ix:nonFraction unitRef="eur" contextRef="c-2172" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5237">2,378</ix:nonFraction> million for 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2173" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5238">1,568</ix:nonFraction> million for 2021 (as shown in the table below):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &amp; expense related to sharing of (profits)/losses under the Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2174" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5239">3,321</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2175" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5240">2,325</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2176" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5241">1,253</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2177" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-5242">668</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2178" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-5243">434</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2179" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-5244">127</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2180" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-5245">543</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2181" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-5246">476</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2182" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-5247">303</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total - Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2183" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5248">3,196</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2184" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5249">2,367</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2185" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-5250">1,429</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immuno-Oncology Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2186" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:fixed-zero" scale="6" id="f-5251">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2187" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-5252">16</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2188" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-5253">68</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other (mainly ZALTRAP and LIBTAYO)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2189" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-5254">217</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2190" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-5255">1,120</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2191" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-5256">12</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other operating income/(expenses), net related to Regeneron</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5257">2,979</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5258">1,231</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5259">1,373</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which amount presented in</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> (Note&#160;D.25.)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2166" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-5260">227</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2168" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5261">1,147</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2192" decimals="-6" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-5262">195</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Following the restructuring of the Immuno-Oncology agreement between Sanofi and Regeneron, applicable from July&#160;1, 2022 (see Note&#160;C.1.).</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="f-5235-1">(b)&#160;&#160;&#160;&#160;As of December 31, 2023, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2052" decimals="-8" name="sny:CommitmentsReceivedForDevelopmentCosts" format="ixt:num-dot-decimal" scale="9" id="f-5263">2.1</ix:nonFraction> billion, compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2053" decimals="-8" name="sny:CommitmentsReceivedForDevelopmentCosts" format="ixt:num-dot-decimal" scale="9" id="f-5264">2.7</ix:nonFraction> billion as of December 31, 2022 (see note D.21.</ix:continuation>).</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Charges to provisions for litigation and environmental risks are also recorded within this line item.</span></div></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_697"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.27. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" id="f-5265" continuedAt="f-5265-1" escape="true">Restructuring costs and similar items</ix:nonNumeric></span></div><ix:continuation id="f-5265-1"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfRestructuringCostsDetailsTableTextBlock" id="f-5266" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring costs and similar items amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-5267">1,490</ix:nonFraction>&#160;million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-5268">1,336</ix:nonFraction>&#160;million in 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-5269">820</ix:nonFraction>&#160;million in 2021, and were comprised of the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" scale="6" id="f-5270">489</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" scale="6" id="f-5271">507</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" scale="6" id="f-5272">193</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" scale="6" id="f-5273">293</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" scale="6" id="f-5274">261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" scale="6" id="f-5275">110</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs related to transformation programs</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts" scale="6" id="f-5276">676</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts" scale="6" id="f-5277">547</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts" scale="6" id="f-5278">463</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:OtherRestructuringCost" scale="6" id="f-5279">32</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:OtherRestructuringCost" scale="6" id="f-5280">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:OtherRestructuringCost" scale="6" id="f-5281">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-5282">1,490</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-5283">1,336</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-5284">820</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncreaseDecreaseInExpenseOfRestructuringActivities" scale="6" id="f-5285">154</ix:nonFraction>&#160;million higher in 2023 than 2022. For 2023 they include the impact of French pension reform on future annuities under the rules of each severance plan, while for 2022 they mainly comprised severance costs recognized further to the announcements made during that period. Also included in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> are the impacts of ongoing transformational projects, primarily those associated with the creation of the standalone Consumer Healthcare entity and the implementation of Sanofi&#8217;s new digital strategy.</span></div></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_700"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.28. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" id="f-5286" continuedAt="f-5286-1" escape="true">Other gains and losses, and litigation</ix:nonNumeric></span></div><ix:continuation id="f-5286-1" continuedAt="f-5286-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2023 represent a charge of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-5287">38</ix:nonFraction>&#160;million, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">including costs relating to the settlement of  litigation with Bioverativ former shareholders.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2022, this line item represented a charge of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-5288">370</ix:nonFraction>&#160;million, comprising the pre-tax loss arising on the deconsolidation of EUROAPI (see Note&#160;D.2.) and costs related to major litigation.</span></div></ix:continuation><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-5286-2">For 2021, this line item represented a charge of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" format="ixt:num-dot-decimal" scale="6" id="f-5289">5</ix:nonFraction> million</ix:continuation>.</span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-89</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_703"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.29. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="f-5290" continuedAt="f-5290-1" escape="true">Financial expenses and income</ix:nonNumeric></span></div><ix:continuation id="f-5290-1"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" id="f-5291" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-5292">555</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-5293">365</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:InterestExpenseOnBorrowings" scale="6" id="f-5294">313</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:InterestIncome" scale="6" id="f-5295">533</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:InterestIncome" scale="6" id="f-5296">241</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:InterestIncome" scale="6" id="f-5297">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:CostOfDebtNet" scale="6" id="f-5298">22</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:CostOfDebtNet" scale="6" id="f-5299">124</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:CostOfDebtNet" scale="6" id="f-5300">259</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="sny:NonOperatingForeignExchangeGainsLosses" scale="6" id="f-5301">2</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="sny:NonOperatingForeignExchangeGainsLosses" scale="6" id="f-5302">4</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:NonOperatingForeignExchangeGainsLosses" scale="6" id="f-5303">2</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" scale="6" id="f-5304">59</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" scale="6" id="f-5305">20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" scale="6" id="f-5306">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:NetInterestCostRelatedToEmployeeBenefits" scale="6" id="f-5307">73</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:NetInterestCostRelatedToEmployeeBenefits" scale="6" id="f-5308">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:NetInterestCostRelatedToEmployeeBenefits" scale="6" id="f-5309">44</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) on disposals of financial assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets" scale="6" id="f-5310">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets" scale="6" id="f-5311">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets" scale="6" id="f-5312">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-5313">39</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-5314">40</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-5315">35</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:OtherFinanceIncomeCost" scale="6" id="f-5316">526</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:OtherFinanceIncomeCost" format="ixt:fixed-zero" scale="6" id="f-5317">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:OtherFinanceIncomeCost" scale="6" id="f-5318">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-5319">722</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-5320">234</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:FinanceIncomeCost" scale="6" id="f-5321">328</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-5322">1,313</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-5323">440</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-5324">368</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-5325">591</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-5326">206</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-5327">40</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes net gains/(losses) on interest rate and currency derivatives used to manage debt: &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-2193" decimals="-6" sign="-" name="sny:GainsLossesOnDerivativesUsedToManageDebt" scale="6" id="f-5328">67</ix:nonFraction>) million in 2023, &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-2194" decimals="-6" sign="-" name="sny:GainsLossesOnDerivativesUsedToManageDebt" scale="6" id="f-5329">11</ix:nonFraction>) million in 2022, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2195" decimals="-6" name="sny:GainsLossesOnDerivativesUsedToManageDebt" format="ixt:num-dot-decimal" scale="6" id="f-5330">14</ix:nonFraction> million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Includes net gains on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-2193" decimals="-6" sign="-" name="sny:GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents" scale="6" id="f-5331">13</ix:nonFraction>) million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2194" decimals="-6" name="sny:GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-5332">68</ix:nonFraction> million in 2022,          &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2195" decimals="-6" name="sny:GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-5333">51</ix:nonFraction> million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note&#160;D.19.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes a financial expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:LiabilityRecognisedForEstimatedFutureRoyalties" scale="6" id="f-5334">541</ix:nonFraction> million (<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:LiabilityRecognisedForEstimatedFutureRoyalties" format="ixt:fixed-zero" scale="0" id="f-5335"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:LiabilityRecognisedForEstimatedFutureRoyalties" format="ixt:fixed-zero" scale="0" id="f-5336">zero</ix:nonFraction></ix:nonFraction> in 2022 and 2021) in respect of the liability recognized in the balance sheet for estimated future royalties on US sales of BEYFORTUS, which was remeasured as of December 31, 2023 to reflect the very successful US launch of the product (see Note C.2.).</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, 2022 and 2021, the impact of the ineffective portion of hedging relationships was not material.</span></div></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_706"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.30. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-5337" continuedAt="f-5337-1" escape="true">Income tax expense</ix:nonNumeric></span></div><ix:continuation id="f-5337-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" id="f-5338" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-5339">2,560</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-5340">2,774</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-5341">1,908</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-5342">958</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-5343">768</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-5344">350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-5345">1,602</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-5346">2,006</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-5347">1,558</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-5348">7,153</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-5349">10,422</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-5350">7,798</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" id="f-5351" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-5352">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-5353">25.8</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-5354">28.4</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-5355">13.6</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-5356">6.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" sign="-" name="ifrs-full:TaxRateEffectOfForeignTaxRates" scale="-2" id="f-5357">9.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="sny:TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes" scale="-2" id="f-5358">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" sign="-" name="sny:TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes" scale="-2" id="f-5359">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="sny:TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes" scale="-2" id="f-5360">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Probable reversal of temporary differences on investments in Consumer Healthcare subsidiaries</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" scale="-2" id="f-5361">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" name="sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" format="ixt:fixed-zero" scale="-2" id="f-5362">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" format="ixt:fixed-zero" scale="-2" id="f-5363">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" scale="-2" id="f-5364">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" sign="-" name="sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" scale="-2" id="f-5365">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" format="ixt:fixed-zero" scale="-2" id="f-5366">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-5367">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-5368">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="-2" id="f-5369">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-5370">22.4</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-5371">19.2</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-5372">20.0</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In accordance with IAS&#160;12, a deferred tax liability was recognized in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October&#160;2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In determining the amount of the deferred tax liability for 2023, 2022 and 2021, Sanofi took into account changes in the ownership structure of certain subsidiaries.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the periods presented, the amount of deferred tax assets recognized in profit or loss that were initially subject to impairment losses at the time of a business combination is immaterial.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-90</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_709"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.31. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock" id="f-5373" continuedAt="f-5373-1" escape="true">Share of profit/loss from investments accounted for using the equity method</ix:nonNumeric></span></div><ix:continuation id="f-5373-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was a net loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5374">115</ix:nonFraction>&#160;million in 2023 (including an impairment loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-471" decimals="-6" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="6" id="f-5375">231</ix:nonFraction>&#160;million on the equity-accounted investment in EUROAPI &#8211; see Note D.6.), compared with net income of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5376">68</ix:nonFraction>&#160;million for 2022 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5377">39</ix:nonFraction>&#160;million for 2021.</span></div></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_712"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.32. <ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock" id="f-5378" continuedAt="f-5378-1" escape="true">Net income attributable to non-controlling interests</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock" id="f-5379" escape="true"><ix:continuation id="f-5378-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the reporting periods presented:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of net income attributable to non-controlling interests</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2196" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5380">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2197" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5381">113</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2198" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5382">56</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5383">36</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5384">113</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5385">56</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i9fa7f69b4904450e9c43e8444c203165_715"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.33.&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="f-5386" continuedAt="f-5386-1" escape="true">Related party transactions</ix:nonNumeric></span></div><ix:continuation id="f-5386-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal related parties are companies over which Sanofi has control or significant influence, joint ventures, key management personnel, and principal shareholders.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has not entered into any material transactions with any key management personnel. Financial relations with Sanofi&#8217;s principal shareholders fall within the ordinary course of business and were immaterial in the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note&#160;F.1. lists the principal companies controlled by Sanofi; those companies are fully consolidated, as described in Note&#160;B.1. Transactions between those companies, and between the parent company and its subsidiaries, are eliminated when preparing the consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transactions with companies over which Sanofi has significant influence, and with joint ventures, are presented in Note&#160;D.6.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Key management personnel include corporate officers and the members of the Executive Committee (an a</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">verage of <ix:nonFraction unitRef="executives" contextRef="c-1" decimals="0" name="sny:NumberOfExecutiveCommitteeMembers" scale="0" id="f-5387">10</ix:nonFraction>&#160;members</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in 2023, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="executives" contextRef="c-10" decimals="0" name="sny:NumberOfExecutiveCommitteeMembers" scale="0" id="f-5388"><ix:nonFraction unitRef="executives" contextRef="c-9" decimals="0" name="sny:NumberOfExecutiveCommitteeMembers" scale="0" id="f-5389">11</ix:nonFraction></ix:nonFraction>&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in 2022 and in 2021).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock" id="f-5390" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows, by type, the compensation paid to key management personnel:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term benefits</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="6" id="f-5391">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="6" id="f-5392">31</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="6" id="f-5393">33</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Post-employment benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="6" id="f-5394">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="6" id="f-5395">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="6" id="f-5396">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="6" id="f-5397">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="6" id="f-5398">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="6" id="f-5399">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total recognized in profit or loss</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-5400">46</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-5401">52</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-5402">55</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Compensation, employer&#8217;s social security contributions, directors&#8217; compensation, and any termination benefits (net of reversals of termination benefit obligations).</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" id="f-5403" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the aggregate obligation as of December&#160;31 for each period presented for individuals who hold or have held executive positions within Sanofi during that period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:62.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee" scale="6" id="f-5404">10</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee" scale="6" id="f-5405">10</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee" scale="6" id="f-5406">28</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits" scale="6" id="f-5407">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits" scale="6" id="f-5408">5</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits" scale="6" id="f-5409">7</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_718"></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.34. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCreditRiskExplanatory" id="f-5410" continuedAt="f-5410-1" escape="true">Disclosures about major customers and credit risk</ix:nonNumeric></span></div><ix:continuation id="f-5410-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Credit risk is the risk that customers (wholesalers, distributors, pharmacies, hospitals, clinics or government agencies) may fail to pay their debts; for Sanofi, that risk is mainly concentrated on amounts receivable from wholesalers in the United States. Sanofi manages credit risk by vetting customers in order to set credit limits and risk levels, and asking for guarantees or insurance where necessary; performing controls; and monitoring qualitative and quantitative indicators of accounts receivable balances, such as the period of credit taken and overdue payments.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-2199" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-5411">27</ix:nonFraction>% of net sales in </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The three largest customers respectively accounted for approximately <ix:nonFraction unitRef="number" contextRef="c-2200" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-5412">11</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-2201" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-5413">9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-2202" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-5414">7</ix:nonFraction>% of Sanofi's net sales in&#160;2023 (<ix:nonFraction unitRef="number" contextRef="c-2203" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-5415">12</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-2204" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-5416">8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-2205" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-5417">7</ix:nonFraction>% in 2022; <ix:nonFraction unitRef="number" contextRef="c-2206" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-5418">10</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-2207" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-5419">7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-10" decimals="2" name="ifrs-full:PercentageOfEntitysRevenue" scale="-2" id="f-5420">6</ix:nonFraction>% in 2021).</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-91</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_721"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.35. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="f-5421" continuedAt="f-5421-1" escape="true">Segment information</ix:nonNumeric></span></div><ix:continuation id="f-5421-1" continuedAt="f-5421-2"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As indicated in Note&#160;B.26., Sanofi has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="sny:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-5422">two</ix:nonFraction> operating segments with effect from January&#160;1, 2023: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported <ix:nonFraction unitRef="segment" contextRef="c-9" decimals="INF" name="sny:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-5423">three</ix:nonFraction> operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Sanofi Business Services,&#160;etc.), which are mainly managed centrally at group-wide level, were presented within the &#8220;Other&#8221; category. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in order to reflect (i)&#160;progress on the &#8220;Play to Win&#8221; strategy leading to the creation of the standalone Consumer Healthcare Global Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its own dedicated global support functions (including Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Global Business Services,&#160;etc.); and (ii)&#160;organizational changes to Sanofi&#8217;s Manufacturing &amp; Supply global function (previously known as Industrial Affairs). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, with effect from January&#160;1, 2023, Sanofi reports <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="sny:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-5424">two</ix:nonFraction> operating segments: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#8217;s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment&#8217;s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.</span></div></ix:continuation><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-92</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-5421-2" continuedAt="f-5421-3"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.35.1. Segment results</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.35.1.1. Analysis of net sales</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" id="f-5425" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth Sanofi&#8217;s net sales for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.491%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.5pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="border-right:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" rowspan="2" style="border-left:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:9pt"><td colspan="42" style="display:none"/></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2208" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5426">8,835</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2209" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5427">17,265</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2210" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5428">11,790</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5429">37,890</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2211" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5430">8,498</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2212" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5431">16,985</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2213" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5432">12,329</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5433">37,812</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2214" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5434">8,426</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2215" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5435">13,246</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2216" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5436">11,621</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2217" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5437">33,293</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Specialty Care</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2218" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5438">3,206</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2219" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5439">11,917</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2220" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5440">2,917</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2221" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5441">18,040</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2222" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5442">3,016</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2223" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5443">10,848</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2224" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5444">2,593</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2225" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5445">16,457</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2226" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5446">2,764</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2227" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5447">7,847</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2228" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5448">2,141</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2229" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5449">12,752</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">DUPIXENT</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2230" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5450">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2231" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5451">8,145</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2232" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5452">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2233" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5453">10,715</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2234" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5454">940</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2235" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5455">6,346</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2236" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5456">1,007</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2237" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5457">8,293</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2238" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5458">649</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2239" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5459">3,971</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2240" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5460">629</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2241" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5461">5,249</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">AUBAGIO</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2242" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5462">437</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2243" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5463">460</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2244" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5464">58</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2245" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5465">955</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2246" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5466">511</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2247" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5467">1,420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2248" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5468">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2249" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5469">2,031</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2250" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5470">512</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2251" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5471">1,312</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2252" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5472">131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2253" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5473">1,955</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">CEREZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2254" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5474">229</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2255" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5475">189</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2256" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5476">269</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2257" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5477">687</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2258" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5478">239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2259" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5479">194</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2260" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5480">274</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2261" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5481">707</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2262" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5482">244</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2263" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5483">173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2264" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5484">266</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2265" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5485">683</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">FABRAZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2266" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5486">241</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2267" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5487">503</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2268" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5488">247</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2269" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5489">991</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2270" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5490">228</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2271" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5491">471</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2272" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5492">239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2273" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5493">938</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2274" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5494">223</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2275" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5495">395</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2276" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5496">226</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2277" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5497">844</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">MYOZYME/<br/>LUMIZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2278" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5498">341</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2279" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5499">254</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2280" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5500">188</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2281" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5501">783</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2282" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5502">408</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2283" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5503">318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2284" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5504">232</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2285" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5505">958</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2286" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5506">410</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2287" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5507">373</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2288" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5508">220</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2289" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5509">1,003</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">JEVTANA</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2290" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5510">12</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2291" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5511">230</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2292" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5512">78</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2293" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5513">320</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2294" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5514">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2295" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5515">275</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2296" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5516">83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2297" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5517">391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2298" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5518">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2299" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5519">253</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2300" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5520">90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2301" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5521">455</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ALPROLIX</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2302" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-5522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2303" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5523">440</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2304" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5524">100</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2305" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5525">540</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2306" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-5526">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2307" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5527">406</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2308" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5528">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2309" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5529">504</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2310" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-5530">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2311" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5531">332</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2312" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5532">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2313" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5533">414</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ELOCTATE</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2314" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-5534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2315" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5535">341</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2316" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5536">130</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2317" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5537">471</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2318" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-5538">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2319" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5539">450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2320" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5540">130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2321" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5541">580</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2322" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-5542">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2323" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5543">429</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2324" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5544">134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2325" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5545">563</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">General Medicines</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2326" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5546">3,932</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2327" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5547">2,084</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2328" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5548">6,360</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2329" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5549">12,376</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2330" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5550">4,141</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2331" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5551">2,846</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2332" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5552">7,140</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2333" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5553">14,127</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2334" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5554">4,437</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2335" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5555">2,637</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2336" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5556">7,144</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2337" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5557">14,218</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2338" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5558">1,988</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2339" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5559">1,485</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2340" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5560">2,797</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2341" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5561">6,270</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2342" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5562">1,917</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2343" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5563">1,653</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2344" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5564">2,819</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2345" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5565">6,389</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2346" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5566">1,868</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2347" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5567">1,315</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2348" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5568">2,585</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2349" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5569">5,768</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">LOVENOX</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2350" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5570">622</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2351" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5571">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2352" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5572">496</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2353" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5573">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2354" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5574">658</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2355" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5575">17</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2356" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5576">635</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2357" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5577">1,310</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2358" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5578">703</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2359" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5579">29</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2360" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5580">754</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2361" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5581">1,486</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">TOUJEO</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2362" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5582">441</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2363" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5583">213</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2364" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5584">469</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2365" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5585">1,123</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2366" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5586">421</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2367" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5587">283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2368" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5588">413</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2369" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5589">1,117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2370" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5590">394</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2371" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5591">259</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2372" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5592">316</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2373" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5593">969</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">PLAVIX</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2374" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5594">96</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2375" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5595">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2376" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5596">844</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2377" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5597">948</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2378" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5598">101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2379" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5599">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2380" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5600">873</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2381" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5601">983</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2382" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5602">115</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2383" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5603">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2384" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5604">805</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2385" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5605">929</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Non-Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2386" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5606">1,396</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2387" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5607">592</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2388" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5608">3,536</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2389" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5609">5,524</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2390" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5610">1,637</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2391" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5611">1,176</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2392" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5612">4,305</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2393" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5613">7,118</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2394" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5614">1,846</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2395" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5615">1,281</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2396" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5616">4,515</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2397" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5617">7,642</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">LANTUS</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2398" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5618">357</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2399" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5619">281</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2400" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5620">782</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2401" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5621">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2402" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5622">426</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2403" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5623">757</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2404" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5624">1,076</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2405" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5625">2,259</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2406" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5626">474</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2407" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5627">861</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2408" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5628">1,159</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2409" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5629">2,494</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other non-core assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2410" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5630">961</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2411" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5631">302</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2412" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5632">2,424</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2413" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5633">3,687</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2414" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5634">1,129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2415" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5635">412</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2416" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5636">2,840</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2417" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5637">4,381</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2418" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5638">1,285</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2419" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5639">410</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2420" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5640">3,034</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2421" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5641">4,729</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Industrial sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2422" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5642">548</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2423" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5643">7</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2424" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5644">27</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2425" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5645">582</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2426" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5646">587</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2427" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5647">17</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2428" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5648">16</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2429" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5649">620</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2430" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5650">723</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2431" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5651">41</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2432" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5652">44</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2433" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5653">808</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2434" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5654">1,697</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2435" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5655">3,264</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2436" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5656">2,513</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2437" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5657">7,474</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2438" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5658">1,341</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2439" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5659">3,291</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2440" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5660">2,596</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2441" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5661">7,228</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2442" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5662">1,225</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2443" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5663">2,762</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2444" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5664">2,336</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2445" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5665">6,323</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Polio/Pertussis/<br/>Hib Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2446" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5666">297</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2447" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5667">398</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2448" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5668">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2449" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5669">2,165</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2450" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5670">325</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2451" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5671">456</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2452" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5672">1,504</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2453" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5673">2,285</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2454" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5674">306</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2455" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5675">470</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2456" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5676">1,383</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2457" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5677">2,159</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Influenza Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2458" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5678">694</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2459" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5679">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2460" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5680">569</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2461" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5681">2,669</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2462" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5682">681</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2463" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5683">1,737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2464" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5684">559</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2465" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5685">2,977</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2466" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5686">729</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2467" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5687">1,366</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2468" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5688">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2469" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5689">2,628</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer Healthcare</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2470" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5690">1,557</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2471" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5691">1,247</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2472" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5692">2,376</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5693">5,180</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2473" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5694">1,501</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2474" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5695">1,290</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2475" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5696">2,394</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5697">5,185</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2476" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5698">1,333</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2477" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5699">1,139</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2478" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5700">1,996</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5701">4,468</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Allergy</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2479" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5702">70</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2480" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5703">412</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2481" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5704">287</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2482" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5705">769</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2483" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5706">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2484" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5707">439</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2485" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5708">276</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2486" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5709">770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2487" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5710">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2488" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5711">371</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2489" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5712">192</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2490" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5713">612</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pain Care</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2491" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5714">502</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2492" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5715">180</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2493" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5716">424</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2494" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5717">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2495" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5718">555</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2496" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5719">212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2497" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5720">424</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2498" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5721">1,140</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2499" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5722">515</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2500" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5723">196</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2501" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5724">382</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2502" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5725">1,093</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Digestive Wellness</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2503" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5726">520</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2504" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5727">138</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2505" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5728">844</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2506" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5729">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2507" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5730">432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2508" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5731">144</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2509" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5732">822</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2510" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5733">1,449</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2511" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5734">389</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2512" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5735">124</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2513" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" scale="6" id="f-5736">618</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2514" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5737">1,131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2515" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5738">10,392</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1205" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5739">18,512</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2516" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5740">14,166</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5741">43,070</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2517" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5742">9,999</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1269" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5743">18,275</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2518" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5744">14,723</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5745">42,997</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2519" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5746">9,759</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1272" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5747">14,385</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2520" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5748">13,617</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5749">37,761</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="sny:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-5750">two</ix:nonFraction> new operating segments, Biopharma and Consumer Healthcare, effective January&#160;1, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div></ix:nonNumeric><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.35.1.2. Business operating income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi reports segment results on the basis of &#8220;Business operating income&#8221;. This indicator is used internally by Sanofi&#8217;s chief operating decision maker to measure the performance of each operating segment and to allocate resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Business operating income&#8221; is derived from </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, adjusted as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature), are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3) or business divestments, and presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amounts reported within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">other gains and losses including gains and losses on major divestments, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">other costs and provisions related to litigation, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">upfront payments and regulatory milestone payments recognized within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and related to transactions outside the ordinary activities of Sanofi are eliminated;</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-93</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-5421-3" continuedAt="f-5421-4"><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates to&#160;joint ventures and associates with which Sanofi has a strategic alliance; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">net income attributable to non-controlling interests is deducted.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="f-5751" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi&#8217;s segment results for the years ended December 31, 2023, December 31, 2022 and December 31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:38.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5752">37,890</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5753">5,180</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2521" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-5754">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2522" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5755">43,070</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-5756">3,322</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-5757">52</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2521" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:fixed-zero" scale="6" id="f-5758">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2522" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-5759">3,374</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-5760">12,282</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-5761">1,933</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2521" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-5762">1</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2522" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-5763">14,216</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-5764">6,509</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-5765">219</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2521" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="6" id="f-5766">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2522" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-5767">6,728</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5768">8,868</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5769">1,828</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2521" decimals="-6" sign="-" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-5770">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2522" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5771">10,692</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-5772">2,387</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-5773">181</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2521" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-5774">18</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2522" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-5775">2,224</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5776">101</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5777">21</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2521" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" format="ixt:fixed-zero" scale="6" id="f-5778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2522" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5779">122</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5780">20</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5781">16</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2521" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-5782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2522" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5783">36</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5784">11,247</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5785">1,438</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2521" decimals="-6" sign="-" name="sny:BusinessOperatingIncome" scale="6" id="f-5786">15</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2522" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5787">12,670</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:38.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5788">37,812</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5789">5,185</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2523" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-5790">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2524" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5791">42,997</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-5792">2,330</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-5793">62</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2523" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:fixed-zero" scale="6" id="f-5794">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2524" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-5795">2,392</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-5796">11,793</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-5797">1,903</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2523" decimals="-6" sign="-" name="ifrs-full:CostOfSales" scale="6" id="f-5798">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2524" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-5799">13,692</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-5800">6,503</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-5801">205</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2523" decimals="-6" sign="-" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-5802">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2524" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-5803">6,706</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5804">8,736</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5805">1,761</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2523" decimals="-6" sign="-" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-5806">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2524" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5807">10,492</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-5808">1,679</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-5809">148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2523" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-5810">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2524" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-5811">1,514</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5812">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5813">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2523" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" format="ixt:fixed-zero" scale="6" id="f-5814">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2524" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5815">88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5816">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5817">16</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2523" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="6" id="f-5818">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2524" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5819">33</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5820">11,490</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5821">1,522</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2523" decimals="-6" name="sny:BusinessOperatingIncome" scale="6" id="f-5822">28</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2524" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5823">13,040</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="sny:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-5824">two</ix:nonFraction> new operating segments, Biopharma and Consumer Healthcare, effective from January&#160;1, 2023.</span></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:39.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5825">26,970</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5826">6,323</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5827">4,468</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2525" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:fixed-zero" scale="6" id="f-5828">&#8212;</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2526" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5829">37,761</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-5830">264</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-5831">1,095</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="ifrs-full:OtherRevenue" scale="6" id="f-5832">55</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2525" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:fixed-zero" scale="6" id="f-5833">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2526" decimals="-6" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="6" id="f-5834">1,414</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-5835">6,965</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-5836">3,430</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-5837">1,606</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2525" decimals="-6" name="ifrs-full:CostOfSales" scale="6" id="f-5838">250</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2526" decimals="-6" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-5839">12,251</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-5840">4,330</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-5841">712</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-5842">153</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2525" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-5843">497</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2526" decimals="-6" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-5844">5,692</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5845">5,326</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="f-5846">805</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5847">1,388</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2525" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5848">2,036</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2526" decimals="-6" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-5849">9,555</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" format="ixt:num-dot-decimal" scale="6" id="f-5850">1,172</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-5851">128</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-5852">111</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2525" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-5853">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2526" decimals="-6" sign="-" name="sny:MiscellaneousOtherOperatingIncomeExpenses" scale="6" id="f-5854">946</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5855">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5856">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5857">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2525" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" format="ixt:fixed-zero" scale="6" id="f-5858">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2526" decimals="-6" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5859">39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5860">49</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5861">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5862">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2525" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5863">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2526" decimals="-6" sign="-" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5864">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5865">9,409</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5866">2,609</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5867">1,493</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2525" decimals="-6" sign="-" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5868">2,797</ix:nonFraction>)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2526" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5869">10,714</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This caption reconciles segment financial information to total consolidated financial information.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-94</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-5421-4" continuedAt="f-5421-5"><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" id="f-5870" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS&#160;8, shows a reconciliation between aggregated &#8220;Business operating income&#8221; for the segments and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:57.552%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.684%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2527" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5871">12,670</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2528" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5872">13,040</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2529" decimals="-6" name="sny:BusinessOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="f-5873">10,714</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2530" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5874">122</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2531" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5875">88</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2532" decimals="-6" sign="-" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" scale="6" id="f-5876">39</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2530" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5877">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2531" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5878">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2532" decimals="-6" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" scale="6" id="f-5879">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2530" decimals="-6" name="sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5880">3,068</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2531" decimals="-6" name="sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5881">1,599</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2532" decimals="-6" name="sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5882">1,772</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2530" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-5883">93</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2531" decimals="-6" sign="-" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-5884">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2532" decimals="-6" name="ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability" scale="6" id="f-5885">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2530" decimals="-6" name="sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" scale="6" id="f-5886">20</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2531" decimals="-6" name="sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" scale="6" id="f-5887">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2532" decimals="-6" name="sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" scale="6" id="f-5888">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2530" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-5889">1,490</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2531" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" format="ixt:num-dot-decimal" scale="6" id="f-5890">1,336</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2532" decimals="-6" name="ifrs-full:ExpenseOfRestructuringActivities" scale="6" id="f-5891">820</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2530" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-5892">38</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2531" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-5893">370</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-2532" decimals="-6" sign="-" name="sny:OtherGainsLossesAndLitigation" scale="6" id="f-5894">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income from out-licensing</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2530" decimals="-6" name="sny:IncomeResultingFromOutLicensing" format="ixt:fixed-zero" scale="6" id="f-5895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2531" decimals="-6" name="sny:IncomeResultingFromOutLicensing" scale="6" id="f-5896">952</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2532" decimals="-6" name="sny:IncomeResultingFromOutLicensing" format="ixt:fixed-zero" scale="6" id="f-5897">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-5898">7,875</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-5899">10,656</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-5900">8,126</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-5901">1,313</ix:nonFraction>)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-5902">440</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:FinanceCosts" scale="6" id="f-5903">368</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-5904">591</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-5905">206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="ifrs-full:FinanceIncome" scale="6" id="f-5906">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-5907">7,153</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-5908">10,422</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-6" name="sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-5909">7,798</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;For 2023, this amount mainly comprises an impairment loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2533" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5910">833</ix:nonFraction>&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN  technology platforms. For 2022, this line includes a reversal of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-466" decimals="-6" name="sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" format="ixt:num-dot-decimal" scale="6" id="f-5911">2,154</ix:nonFraction>&#160;million on ELOCTATE franchise products following FDA approval of ALTUVIIIO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">dated February&#160;22, 2023, partially offset by an impairment loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2534" decimals="-6" name="sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5912">1,586</ix:nonFraction>&#160;million on intangible assets relating to SAR444245 (non-alpha interleukin-2).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For 2022, this line includes an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-2535" decimals="-6" name="sny:UpfrontPaymentsForProjectsUnderCollaborationAgreements" scale="6" id="f-5913">900</ix:nonFraction>&#160;million and a regulatory milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-2535" decimals="-6" name="sny:RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" scale="6" id="f-5914">100</ix:nonFraction>&#160;million related to the out-licensing of LIBTAYO following the restructuring of the Immuno-Oncology Collaboration and License Agreement with Regeneron (see Note&#160;C.1.).</span></div></ix:nonNumeric><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.35.2. Other segment information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the split by operating segment of (i)&#160;the carrying amount of investments accounted for using the equity method with which Sanofi has entered into a strategic alliance, (ii)&#160;acquisitions of property, plant and equipment, and (iii)&#160;acquisitions of intangible assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal investments accounted for using the equity method in the Biopharma segment are the interests in MSP Vaccine Company, and Infraserv GmbH &amp; Co. H&#246;chst&#160;KG (see Note&#160;D.6.).</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" id="f-5915" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:48.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.797%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.797%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.798%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-300" decimals="-6" name="sny:InvestmentsInAssociatesAndJointVentures" scale="6" id="f-5916">234</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-301" decimals="-6" name="sny:InvestmentsInAssociatesAndJointVentures" scale="6" id="f-5917">28</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2536" decimals="-6" name="sny:InvestmentsInAssociatesAndJointVentures" scale="6" id="f-5918">262</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-5919">1,619</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-5920">100</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2522" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-5921">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-5922">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-5923">18</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2522" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-5924">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"/><td style="width:48.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.797%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.797%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.798%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2537" decimals="-6" name="sny:InvestmentsInAssociatesAndJointVentures" scale="6" id="f-5925">248</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2538" decimals="-6" name="sny:InvestmentsInAssociatesAndJointVentures" scale="6" id="f-5926">37</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2539" decimals="-6" name="sny:InvestmentsInAssociatesAndJointVentures" scale="6" id="f-5927">285</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-5928">1,529</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-5929">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2524" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-5930">1,606</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-5931">574</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-5932">21</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2524" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-5933">595</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="sny:NumberOfOperatingSegments1" format="ixt-sec:numwordsen" scale="0" id="f-5934">two</ix:nonFraction> new operating segments, Biopharma and Consumer Healthcare, effective from January&#160;1, 2023.</span></div><div style="margin-top:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:48.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.613%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2540" decimals="-6" name="sny:InvestmentsInAssociatesAndJointVentures" scale="6" id="f-5935">159</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2541" decimals="-6" name="sny:InvestmentsInAssociatesAndJointVentures" scale="6" id="f-5936">91</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2542" decimals="-6" name="sny:InvestmentsInAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-5937">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2543" decimals="-6" name="sny:InvestmentsInAssociatesAndJointVentures" scale="6" id="f-5938">250</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-5939">1,024</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-5940">382</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-5941">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2526" decimals="-6" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-5942">1,479</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-5943">451</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-5944">108</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-5945">6</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2526" decimals="-6" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="6" id="f-5946">565</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-95</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-5421-5"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.35.3. Information by geographical region</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeographicalAreasExplanatory" id="f-5947" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with&#160;IFRS&#160;8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS&#160;16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>United&#160;States</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2544" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5948">43,070</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2515" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5949">10,392</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1267" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5950">2,379</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2545" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5951">19,216</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1205" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5952">18,512</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2546" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5953">13,462</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2547" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5954">10,160</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2548" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5955">5,659</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1232" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5956">3,085</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2549" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5957">3,316</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1218" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5958">2,322</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1435" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5959">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2547" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-5960">49,404</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2548" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-5961">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1232" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-5962">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2549" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-5963">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1218" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-5964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1435" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-5965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2547" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5966">24,319</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2548" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5967">5,566</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1232" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-5968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2549" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5969">17,852</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1218" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-5970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1435" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="f-5971">901</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.696%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>United&#160;States</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2550" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5972">42,997</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2517" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5973">9,999</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1268" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5974">2,296</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2551" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5975">18,984</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1269" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5976">18,275</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2552" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5977">14,014</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2553" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5978">9,869</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2554" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5979">5,365</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1234" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5980">2,875</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2555" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5981">3,284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1224" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5982">2,457</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1443" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-5983">1,220</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2553" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-5984">49,892</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2554" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-5985">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1234" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-5986">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2555" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-5987">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1224" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-5988">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1443" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-5989">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2553" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5990">21,640</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2554" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5991">6,257</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1234" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-5992">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2555" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5993">14,178</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1224" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-5994">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1443" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-5995">1,205</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:28.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.696%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>United&#160;States</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2556" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5996">37,761</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2519" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5997">9,759</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1271" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5998">2,256</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2557" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-5999">15,075</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1272" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-6000">14,385</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2558" decimals="-6" name="ifrs-full:RevenueFromSaleOfGoods" format="ixt:num-dot-decimal" scale="6" id="f-6001">12,927</ix:nonFraction></span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2559" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-6002">10,028</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2560" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-6003">5,959</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1236" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-6004">3,253</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2561" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-6005">2,998</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1230" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-6006">2,234</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1452" decimals="-6" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-6007">1,071</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2559" decimals="-6" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-6008">48,056</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2560" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-6009">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1236" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-6010">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2561" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-6011">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1230" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-6012">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1452" decimals="-6" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-6013">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2559" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-6014">21,407</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2560" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-6015">7,059</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1236" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-6016">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2561" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-6017">13,187</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1230" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="6" id="f-6018">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-1452" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-6019">1,161</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As stated in Note&#160;D.5., goodwill is not allocated by geographical region.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-96</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_724"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">E/ <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAuditorsRemunerationExplanatory" id="f-6020" continuedAt="f-6020-1" escape="true">Principal accountants&#8217; fees and services</ix:nonNumeric></span></div><ix:continuation id="f-6020-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PricewaterhouseCoopers Audit and Ernst&#160;&amp; Young et Autres served as independent auditors of Sanofi for the year ended December 31, 2023 and for all other reporting periods presented. <ix:nonNumeric contextRef="c-1" name="sny:AuditorsRemunerationTableTextBlock" id="f-6021" continuedAt="f-6021-1" escape="true">The table below shows fees charged by those firms and member firms of their networks to Sanofi and consolidated subsidiaries in the years ended December 31, 2023 and 2022.</ix:nonNumeric></span></div><ix:continuation id="f-6021-1"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:29.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ernst&#160;&amp;&#160;Young</span></td><td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PricewaterhouseCoopers</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Audit:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> Statutory audit of separate and consolidated financial statements</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2562" decimals="-5" name="ifrs-full:AuditorsRemunerationForAuditServices" scale="6" id="f-6022">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2562" decimals="2" name="sny:PercentageOfAuditorRemunerationForStatutoryAudit" scale="-2" id="f-6023">74</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2563" decimals="-5" name="ifrs-full:AuditorsRemunerationForAuditServices" scale="6" id="f-6024">14.2</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2563" decimals="2" name="sny:PercentageOfAuditorRemunerationForStatutoryAudit" scale="-2" id="f-6025">89</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2564" decimals="-5" name="ifrs-full:AuditorsRemunerationForAuditServices" scale="6" id="f-6026">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2564" decimals="2" name="sny:PercentageOfAuditorRemunerationForStatutoryAudit" scale="-2" id="f-6027">72</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2565" decimals="-5" name="ifrs-full:AuditorsRemunerationForAuditServices" scale="6" id="f-6028">14.1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2565" decimals="2" name="sny:PercentageOfAuditorRemunerationForStatutoryAudit" scale="-2" id="f-6029">97</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Services other than statutory audit</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2562" decimals="-5" name="sny:ServicesOtherThanStatutoryAudit" scale="6" id="f-6030">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2562" decimals="2" name="sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" scale="-2" id="f-6031">26</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2563" decimals="-5" name="sny:ServicesOtherThanStatutoryAudit" scale="6" id="f-6032">1.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2563" decimals="2" name="sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" scale="-2" id="f-6033">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2564" decimals="-5" name="sny:ServicesOtherThanStatutoryAudit" scale="6" id="f-6034">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2564" decimals="2" name="sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" scale="-2" id="f-6035">28</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2565" decimals="-5" name="sny:ServicesOtherThanStatutoryAudit" scale="6" id="f-6036">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2565" decimals="2" name="sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" scale="-2" id="f-6037">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Audit-related services</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2562" decimals="-5" name="sny:AuditorsRemunerationForAuditRelatedServices" scale="6" id="f-6038">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2563" decimals="-5" name="sny:AuditorsRemunerationForAuditRelatedServices" scale="6" id="f-6039">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2564" decimals="-5" name="sny:AuditorsRemunerationForAuditRelatedServices" scale="6" id="f-6040">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2565" decimals="-5" name="sny:AuditorsRemunerationForAuditRelatedServices" scale="6" id="f-6041">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2562" decimals="-5" name="ifrs-full:AuditorsRemunerationForTaxServices" scale="6" id="f-6042">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2563" decimals="-5" name="ifrs-full:AuditorsRemunerationForTaxServices" format="ixt:fixed-zero" scale="6" id="f-6043">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2564" decimals="-5" name="ifrs-full:AuditorsRemunerationForTaxServices" scale="6" id="f-6044">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2565" decimals="-5" name="ifrs-full:AuditorsRemunerationForTaxServices" format="ixt:fixed-zero" scale="6" id="f-6045">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2562" decimals="-5" name="ifrs-full:AuditorsRemunerationForOtherServices" scale="6" id="f-6046">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2563" decimals="-5" name="ifrs-full:AuditorsRemunerationForOtherServices" scale="6" id="f-6047">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2564" decimals="-5" name="ifrs-full:AuditorsRemunerationForOtherServices" format="ixt:fixed-zero" scale="6" id="f-6048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2565" decimals="-5" name="ifrs-full:AuditorsRemunerationForOtherServices" format="ixt:fixed-zero" scale="6" id="f-6049">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2562" decimals="-5" name="ifrs-full:AuditorsRemuneration" scale="6" id="f-6050">20.5</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2562" decimals="INF" name="sny:PercentageOfAuditorsRemuneration" scale="-2" id="f-6051">100</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2563" decimals="-5" name="ifrs-full:AuditorsRemuneration" scale="6" id="f-6052">16.0</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2563" decimals="INF" name="sny:PercentageOfAuditorsRemuneration" scale="-2" id="f-6053">100</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2564" decimals="-5" name="ifrs-full:AuditorsRemuneration" scale="6" id="f-6054">20.5</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2564" decimals="INF" name="sny:PercentageOfAuditorsRemuneration" scale="-2" id="f-6055">100</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-2565" decimals="-5" name="ifrs-full:AuditorsRemuneration" scale="6" id="f-6056">14.6</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2565" decimals="INF" name="sny:PercentageOfAuditorsRemuneration" scale="-2" id="f-6057">100</ix:nonFraction></span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst&#160;&amp; Young &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2562" decimals="-5" name="sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-6058">7.9</ix:nonFraction> million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2563" decimals="-5" name="sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-6059">7.3</ix:nonFraction> million in&#160;2022; PricewaterhouseCoopers Audit &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2564" decimals="-5" name="sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-6060">8.3</ix:nonFraction> million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2565" decimals="-5" name="sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-6061">7.7</ix:nonFraction> million in 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Services other than statutory audit provided by Ernst&#160;&amp; Young during 2023 comprised:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- contractual audits, including on the combined financial statements of the Consumer Healthcare business;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- additional procedures to enable reports previously signed by the firm to be incorporated by reference;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- issuance of the Independent Third Party&#8217;s report on the consolidated statement of extra-financial performance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Services other than statutory audit provided by PricewaterhouseCoopers during 2023 comprised:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- contractual audits, including on the combined financial statements of the Consumer Healthcare business;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- additional procedures to enable reports previously signed by the firm to be incorporated by reference; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst&#160;&amp; Young: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2562" decimals="-5" name="sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-6062">5.2</ix:nonFraction> million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2563" decimals="-5" name="sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-6063">1.4</ix:nonFraction> million in&#160;2022; PricewaterhouseCoopers Audit &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2564" decimals="-5" name="sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-6064">5.3</ix:nonFraction> million in 2023, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2565" decimals="-5" name="sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-6065">0.3</ix:nonFraction> million in 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="sny:AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices" format="ixt:num-dot-decimal" scale="6" id="f-6066">0.5</ix:nonFraction>&#160;million for services that can only be provided by the statutory auditors, such as comfort letters, attestation services required by regulation (which qualify as audit fees under SEC rules).</span></div></ix:continuation></ix:continuation><div style="margin-bottom:3pt;margin-top:9pt"><span><br/></span></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-97</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_727"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">F/ <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" id="f-6067" continuedAt="f-6067-1" escape="true">List of principal companies included in the scope of&#160;consolidation during&#160;2023</ix:nonNumeric></span></div><ix:continuation id="f-6067-1" continuedAt="f-6067-2"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">F.1. Principal fully consolidated companies</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory" id="f-6068" continuedAt="f-6068-1" escape="true"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi&#8217;s principal subsidiaries and their country of incorporation:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:60.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.668%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hoechst GmbH</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2566" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6069">100.0</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Deutschland GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2567" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6070">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">A. Nattermann &amp; Cie. GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2568" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6071">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Austria</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2569" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6072">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Belgium</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2570" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6073">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ablynx NV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2571" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6074">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Flanders BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2572" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6075">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi A/S</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Denmark</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2573" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6076">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2574" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6077">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Spain, SL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2575" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6078">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Oy</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Finland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2576" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6079">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2577" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6080">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis France</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2578" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6081">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Winthrop Industrie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2579" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6082">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Recherche &amp; D&#233;veloppement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2580" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6083">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Groupe</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2581" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6084">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Chimie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2582" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6085">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Participations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2583" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6086">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2584" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6087">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma S.A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2585" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6088">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Biotechnology</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2586" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6089">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Mature IP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2587" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6090">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur NVL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2588" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6091">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2589" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6092">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SECIPE SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2590" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6093">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Merieux SAS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2591" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6094">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare International SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2592" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6095">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare France SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2593" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6096">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Group SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2594" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6097">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Polyclonals SAS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2595" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6098">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis A.E.B.E.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Greece</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2596" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6099">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Private Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2597" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6100">99.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chinoin Private Co. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2598" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6101">99.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Hungary Commercial K.F.T</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2599" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6102">99.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Hungary K.F.T</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2600" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6103">99.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carraig Insurance DAC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2601" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6104">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Ireland Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2602" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6105">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Holdings (Ireland) Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2603" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6106">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2604" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6107">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Italy SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2605" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6108">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Global Sarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2606" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6109">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Luxembourg Sarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2607" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6110">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Norge AS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Norway</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2608" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6111">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2609" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6112">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Foreign Participations BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2610" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6113">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Sp. z.o.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2611" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6114">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Poland sp.z.o.o.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2612" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6115">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Sp. z.o.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2613" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6116">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Produtos Farmaceuticos Lda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Portugal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2614" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6117">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis, s.r.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2615" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6118">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Czech s.r.o</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2616" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6119">100.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-98</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-6068-1" continuedAt="f-6068-2"><ix:continuation id="f-6067-2" continuedAt="f-6067-3"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:60.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.668%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Romania SRL</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Romania</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2617" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6120">100.0</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Romania SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Romania</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2618" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6121">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis UK Holdings Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2619" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6122">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2620" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6123">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Synthelabo UK Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2621" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6124">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma Holdings Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2622" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6125">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare UK Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2623" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6126">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AO Sanofi Russia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2624" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6127">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2625" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6128">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi AB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sweden</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2626" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6129">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Suisse) SA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2627" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6130">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Global Sarl Baar Intellectual Property Branch</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2628" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6131">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Ilac Sanayi ve Ticaret AS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2629" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6132">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Asi Ticaret AS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2630" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6133">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare T&#252;ketici Sa&#287;l&#305;&#287;&#305; Anonim &#350;irketi</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2631" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6134">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Saglik Urunleri Limited Sirketi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2632" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6135">100.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:60.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Therapeutic Products Limited Partnership</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2633" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6136">100.0</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2634" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6137">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi US Services Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2635" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6138">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis U.S. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2636" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6139">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2637" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6140">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventisub LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2638" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6141">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2639" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6142">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2640" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6143">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VaxServe, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2641" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6144">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2642" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6145">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ U.S. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2643" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6146">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ Therapeutics Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2644" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6147">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principia Biopharma Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2645" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6148">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Research Invest LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2646" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6149">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Bioverativ Holdings LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2647" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6150">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RPR US Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2648" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6151">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Kadmon Corporation, LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2649" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6152">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amunix</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2650" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6153">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Synthorx, Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2651" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6154">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provention Bio</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2652" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6155">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QRIB Intermediate Holding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2653" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6156">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QRI</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2654" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6157">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TargeGen Inc.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2655" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6158">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem (GB) Holding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2656" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6159">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Translate Bio, Inc.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2657" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6160">100.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-99</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-6068-2"><ix:continuation id="f-6067-3" continuedAt="f-6067-4"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:57.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other Countries</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis South Africa (Pty) Ltd</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Africa</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2658" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6161">100.0</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Alg&#233;rie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Algeria</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2659" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6162">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Arabia Trading Company Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Saudi Arabia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2660" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6163">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Argentina SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Argentina</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2661" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6164">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Healthcare Pty Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2662" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6165">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Australia Pty Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2663" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6166">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Medley Farmaceutica Ltda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2664" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6167">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Brazil Ltda.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2665" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6168">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Canada Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2666" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6169">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2667" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6170">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Merieux Canada Holdings ULC (Canada)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2668" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6171">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (Hangzhou) Pharmaceuticals Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2669" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6172">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (China) Investment Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2670" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6173">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (Beijing) Pharmaceuticals Co.Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2671" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6174">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Biologies Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2672" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6175">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shenzhen Sanofi pasteur Biological Products Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2673" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6176">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shanghai Rongheng Pharmaceutical Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2674" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6177">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Colombia SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Colombia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2675" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6178">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Korea Co. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2676" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6179">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2677" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6180">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella healthcare Korea Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2678" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6181">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Gulf FZE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Arab Emirates</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2679" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6182">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Egypt</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2680" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6183">99.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Hong-Kong Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hong Kong</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2681" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6184">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi India Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">India</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2682" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6185">60.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Healthcare India Private Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">India</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2683" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6186">99.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Isra&#235;l Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2684" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6187">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi K.K.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2685" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6188">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SSP Co.,Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2686" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6189">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Malaysia) SDN. BHD.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Malaysia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2687" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6190">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Maroc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Morocco</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2688" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6191">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Mexico SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2689" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6192">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2690" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6193">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Azteca Vacunas, SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2691" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6194">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Panama SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Panama</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2692" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6195">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Panama SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Panama</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2693" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6196">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Puerto Rico Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2694" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6197">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Philippines Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Philippines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2695" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6198">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Philippines Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Philippines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2696" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6199">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Singapore Pte. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2697" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6200">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma (Manufacturing) Pte. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2698" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6201">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Manufacturing Pte Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2699" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6202">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Taiwan Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Taiwan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2700" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6203">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Thailand) Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thailand</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2701" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6204">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thailand</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2702" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6205">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Venezuela SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Venezuela</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2703" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6206">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Vietnam Company Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vietnam</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2704" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6207">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Vietnam Shareholding Company Limited</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vietnam</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2705" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-6208">85.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-100</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center;text-indent:-8.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.225%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div></div><ix:continuation id="f-6067-4"><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">F.2. Principal investments accounted for using the equity method</span></div><ix:nonNumeric contextRef="c-1" name="sny:DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock" id="f-6209" escape="true"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"/><td style="width:62.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.214%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Haleon US, LP</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2706" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointOperation" scale="-2" id="f-6210">11.7</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH&#160;&amp; Co. H&#246;chst KG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2707" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointOperation" scale="-2" id="f-6211">31.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Maphar</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Morocco</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2708" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointOperation" scale="-2" id="f-6212">48.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MCM Vaccine BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2709" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointOperation" scale="-2" id="f-6213">50.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company (formerly MCM company)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2710" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointOperation" scale="-2" id="f-6214">50.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-2711" decimals="3" name="ifrs-full:ProportionOfOwnershipInterestInJointOperation" scale="-2" id="f-6215">29.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9fa7f69b4904450e9c43e8444c203165_730"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">G/ <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="f-6216" continuedAt="f-6216-1" escape="true">Event subsequent to December 31, 2023</ix:nonNumeric></span></div><ix:continuation id="f-6216-1"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January&#160;23, 2024 Sanofi announced the entry into a merger agreement with Inhibrx, Inc. (Inhibrx), a publicly traded, clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases (the Merger Agreement), pursuant to which Sanofi has agreed to acquire Inhibrx following the spin-off of Inhibrx's non-INBRX-101 assets and liabilities into a new publicly traded company ("New Inhibrx"). Under the terms of the Merger Agreement, Sanofi has agreed to: (i)&#160;provide Inhibrx's stockholders with consideration of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-2712" decimals="0" name="sny:BusinessCombinationPurchasePricePerShare" scale="0" id="f-6217">30</ix:nonFraction> per share of Inhibrx common stock at the closing of the merger (approximately $<ix:nonFraction unitRef="usd" contextRef="c-2712" decimals="-8" name="ifrs-full:CashTransferred" format="ixt:num-dot-decimal" scale="9" id="f-6218">1.7</ix:nonFraction>&#160;billion), and to additionally issue <ix:nonFraction unitRef="rightpershare" contextRef="c-2713" decimals="0" name="sny:BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare" format="ixt-sec:numwordsen" scale="0" id="f-6219">one</ix:nonFraction> non-transferable contingent value right per share of Inhibrx common stock, which will entitle its holder to receive a deferred cash payment of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-2713" decimals="0" name="sny:BusinessCombinationCashPaymentPerNonTransferableContingentValueRight" scale="0" id="f-6220">5</ix:nonFraction>, conditioned upon the achievement of a regulatory milestone (approximately $<ix:nonFraction unitRef="usd" contextRef="c-2713" decimals="-8" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="9" id="f-6221">0.3</ix:nonFraction>&#160;billion, if the regulatory milestone is achieved); (ii)&#160;pay off Inhibrx&#8217;s outstanding third-party debt (approximately $<ix:nonFraction unitRef="usd" contextRef="c-2712" decimals="-8" name="sny:BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="9" id="f-6222">0.2</ix:nonFraction>&#160;billion); and (iii)&#160;provide a capital contribution to New Inhibrx (up to $<ix:nonFraction unitRef="usd" contextRef="c-2714" decimals="-8" name="sny:BusinessCombinationCapitalContribution" format="ixt:num-dot-decimal" scale="9" id="f-6223">0.2</ix:nonFraction>&#160;billion). At the closing of the merger, Sanofi will acquire <ix:nonFraction unitRef="number" contextRef="c-2715" decimals="INF" name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" scale="-2" id="f-6224">100</ix:nonFraction>% of the equity interests in Inhibrx, which will become a <ix:nonFraction unitRef="number" contextRef="c-2716" decimals="INF" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" scale="-2" id="f-6225">100</ix:nonFraction>% wholly owned subsidiary of Sanofi. In addition, Inhibrx will retain a minority stake (approximately <ix:nonFraction unitRef="number" contextRef="c-2717" decimals="INF" name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" scale="-2" id="f-6226">8</ix:nonFraction>% equity interest) in New Inhibrx. INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. INBRX-101 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. INBRX-101 acquisition is expected to </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">support Sanofi&#8217;s portfolio growth strategy and complements the Company&#8217;s 30-year heritage in rare diseases and track record in immunology and inflammation. The transaction is subject to various closing conditions, including the receipt of regulatory approvals and completion of the spin-off of New Inhibrx. Assuming satisfaction of those closing conditions, Sanofi currently anticipates that the transaction will close in the second quarter of 2024.</span></div></ix:continuation><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-101</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_733"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Notes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-102</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_7019"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Notes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:92.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-103</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_29686813957008"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Notes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.................................................................................................................................................................................................................................................................</span></td></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.879%"><tr><td style="width:1.0%"/><td style="width:4.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">F-104</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">SANOFI   </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:120%">FORM 20-F</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> </span><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:7pt;font-weight:400;line-height:120%">2023</span></div></td></tr></table></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_736"></div><hr style="page-break-after:always"/><div style="min-height:107.72pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.686%"><tr><td style="width:1.0%"/><td style="width:2.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.580%"/><td style="width:0.1%"/></tr><tr style="height:551pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.25pt;padding-right:4.25pt;text-align:center"><img src="sny-20231231_g28.jpg" alt="INFO_TRI_PAPIER_Brochure_EN_Noir.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:89px"/></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">English translation and language consultancy: Stephen Reynolds &amp; Jane Lambert.</span></div><div style="padding-right:8.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Photo credits: Front cover: Nils Libert, Associate Scientist, Ghent, Belgium &#169; Simon Buxton &#8211; Key Figures : &#169; Simon Buxton -  p.&#160;89&#160;: &#169;&#160;Yann Audic - p. 90 : &#169; Jean Chiscano - p. 91 : &#169; Alain BUU - p. 92 : &#169; GE China - p. 93 : &#169; Christel Sasso/Capa Pictures - p.&#160;94&#160;: &#169;&#160;Lisbeth Holten, Denmark - p. 95 : Christel Sasso/Capa Pictures - p. 96 : &#169; Julien LUTT/Capa Pictures - p.&#160;97 : &#169; Pierre-Olivier / Capa Pictures - p. 98 : &#169; Marie Etchegoyen/Capa Pictures - p. 99 : &#169; Legrand - p. 100 : &#169; Franck Parisot - p.&#160;101 : &#169;&#160;&#160;Augustin Detienne/Capa Pictures - p. 103 : &#169; Julien LUTT/Capa Pictures - p.104 : &#169;Oscar Timmers/Capa Pictures &#8211; p.&#160;105 : &#169;Jennifer Altman/Capa Pictures</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="sny-20231231_g29.jpg" alt="SIGN2022_LABRADOR_3couv_QUADRI_EN.jpg" style="height:31px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:48.19pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div></div><div id="i9fa7f69b4904450e9c43e8444c203165_739"></div><hr style="page-break-after:always"/><div style="min-height:0pt;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>a2023-exhibit11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0e05c1cae46d40fb8e19776620bd7228_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 1.1</font></div><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SANOFI</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Limited liability company</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Soci&#233;t&#233; Anonyme &#224; conseil d&#8217;administration)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registered capital &#58; &#8364;2,529,599,938</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registered office &#58; 46 avenue de la Grande Arm&#233;e &#8211; 75017 Paris</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registration number &#58; PARIS 395 030 844</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ARTICLES OF ASSOCIATION</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">This text is a free translation from the French language and is supplied solely for information purposes. Only the original version in the</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">French language has legal force.</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div id="i0e05c1cae46d40fb8e19776620bd7228_4"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">GENERAL PROVISIONS</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 1 &#8211; FORM OF COMPANY</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The company, in the form of a limited liability company (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233; anonyme</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">), is governed by applicable laws and regulations as well as by these articles of association (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">statuts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 2 &#8211; CORPORATE NAME</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The corporate name shall be&#58; Sanofi.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 3 &#8211; CORPORATE PURPOSE</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The company&#8217;s corporate purpose, in France and abroad, is&#58;</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Acquiring interests and holdings, in any form whatsoever, in any company or enterprise, in existence or to be created, connected directly or indirectly with the health and fine chemistry sectors, human and animal therapeutics, nutrition and bio-industry&#59;</font></div><div style="padding-left:27pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">in the following areas&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Purchase and sale of all raw materials and products necessary for these activities</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Research, study, and development of new products, techniques and processes&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Manufacture and sale of all chemical, biological, dietary and hygienic products&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Obtaining or acquiring all intellectual property rights related to results obtained and, in particular, filing all patents, trademarks and models, processes or inventions&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Operating directly or indirectly, purchasing, and transferring &#8211; for free or for consideration &#8211; pledging or securing all intellectual property rights, particularly all patents, trademarks and models, processes or inventions&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Obtaining, operating, holding and granting all licenses&#59;</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Within the framework of a group-wide policy and subject to compliance with the relevant legislation, participating in treasury management transactions, whether as lead company or otherwise, in the form of centralized currency risk management or intragroup netting, or any other form permitted under the relevant laws and regulations&#59;</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">And, more generally&#58;</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;All commercial, industrial, real or personal, property financial or other transactions, connected directly or indirectly, totally or partially, with the activities described above and with all similar or related activities and even with any other purposes likely to encourage or develop the company's activities.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 4 &#8211; REGISTERED OFFICE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The registered office is located at&#58; 46, avenue de la Grande Arm&#233;e, PARIS 75017.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Should a transfer of the registered office be decided upon by the Board of Directors </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(conseil d&#8217;administration)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, the Board is authorised to modify the statutes accordingly.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 5 &#8211; TERM OF COMPANY</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The term of the company will expire on May 18, 2093 unless dissolved prior to that date or extended by a decision of the Shareholders&#8217; Extraordinary General Meeting. </font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="i0e05c1cae46d40fb8e19776620bd7228_7"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II SHARE</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CAPITAL</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 6 &#8211; REGISTERED CAPITAL</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The share capital is two billion five hundred twenty-one million four hundred ninety-four thousand five hundred seventy-two euros (&#8364;2,529,599,938).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It is divided into 1,264,799,969 shares each having a par value of &#8364;2, of the same class, fully paid.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 7 &#8211; FORM OF SHARES</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The shares are registered or bearer shares, according to the shareholder&#8217;s choice, under the conditions established by applicable legal provisions.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The company may apply legislative and regulatory provisions concerning the identification of holders of securities giving them the immediate or future right to vote.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any individual or entity, acting individually or jointly, who acquires a number of shares representing a proportion of the capital or of voting rights equal to or exceeding 1% of the share capital, or any multiple of this percentage, even beyond the minimum declaration limits laid down by the legal and regulatory provisions, must inform the company of the total number of shares and voting rights held by the individual or entity and also of any securities giving future access to the  capital or voting rights which may potentially be attached. Notification is to be made by registered mail, return receipt requested, within five stock exchange days of the date on which the threshold was reached.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The obligation to notify the company also applies when the shareholder's holding of the capital or voting rights falls to a level below each of those thresholds described in the third paragraph of this article.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The legal penalties applicable to failure to declare the crossing of a statutory threshold apply equally to a failure to declare the crossing of any threshold stipulated in the articles of association and recorded in the minutes of the shareholders&#8217; meeting at the request of one or more shareholders holding at least 5% of the company&#8217;s share capital or voting rights.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 8 &#8211; CONVEYANCE AND TRANSFER OF SHARES</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The shares are freely negotiable.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The transfer of shares occurs by transfer from one account to another in accordance with the conditions laid down by law and regulations.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 9 &#8211; RIGHTS AND OBLIGATIONS ATTACHED TO EACH SHARE</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1)&#160;&#160;&#160;&#160;With regard to ownership of the corporate assets, sharing of profits and the liquidation surplus, each share entitles its owner to an amount in proportion to the number of existing shares.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2)&#160;&#160;&#160;&#160;Whenever it is necessary to possess a certain number of shares to exercise a right, the owners who do not possess that number of shares are responsible for taking any steps to combine the number required.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3)&#160;&#160;&#160;&#160;Each shareholder has as many votes as the number of shares he owns or represents subject to the provisions below.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">       A double voting right is assigned to each registered share that is paid for in full and that has been registered in the name of the same shareholder for at least two years.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">       The double vote ceases automatically for any share converted into a bearer share or transferred from one owner to another, subject to exceptions laid down by law. Bonus shares arising from an increase of share capital by incorporation of reserves, profits or share premiums receive the benefit of the double vote as from the time of their issue in so far as they have been assigned on the basis of shares already benefiting from this right.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 10 &#8211; PAYING-UP (LIB&#201;RATION) OF SHARES</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sums that are due on shares to be paid for in cash are requested by the Board of Directors which determines the dates and extent of the calls for funds.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shareholders who do not make the payments due on the shares they hold automatically owe the company default interest calculated on a daily basis starting from the due date, at the legal rate in business matters increased by three points, without prejudice to the compulsory enforcement measures provided by law.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="i0e05c1cae46d40fb8e19776620bd7228_10"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART III MANAGEMENT OF THE</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMPANY</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 11 &#8211; BOARD OF DIRECTORS</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1)&#160;&#160;&#160;&#160;The Company shall be administered by a Board of Directors of which the minimum and maximum number of members is set by current legislation. </font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A natural person cannot be appointed or reappointed as a director once he or she reaches the age of 70. As soon as the number of directors aged over 70 represents more than one-third of the directors in office, the oldest director shall be deemed to have resigned&#59; his or her term of office shall end at the date of the next shareholders&#8217; Ordinary General Meeting.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each director appointed by a Shareholders&#8217; Ordinary General Meeting must own at least five hundred shares throughout his term of office.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The term of office of directors shall be four years. Directors shall be required to seek reappointment by rotation, such that members of the Board are required to seek reappointment on a regular basis in the most equal proportions possible. Exceptionally, the Shareholders&#8217; Ordinary General Meeting may appoint a director to serve for a term of one, two or three years, in order to ensure adequate rotation of Board members.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each director standing down shall be eligible for reappointment. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2)       Directors representing employees</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In accordance with the law, one employee representative director shall be designated by the trade union body which is the most representative, within the meaning of the applicable legislation, in the Company and those of its direct or indirect subsidiaries that have their registered office in French territory, and one director shall be designated by the European Works Council.</font></div><div style="padding-left:27pt"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">An employee representative director shall hold office for a term of four years. His term of office shall end at the close of the Shareholders&#8217; General Meeting held during the calendar year in which his term of office expires to approve the financial statements for the previous financial year.</font></div><div style="padding-left:27pt"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the Company is no longer subject to an obligation to appoint one or more employee representatives to the Board of Directors, the term of office of the employee representative(s) shall end automatically with no other formalities at the close of the meeting of the Board of Directors which formally notes that the Company no longer falls within the scope of such obligation.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 12 &#8211; CHAIRMAN AND VICE-CHAIRMAN OF THE BOARD OF DIRECTORS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall appoint from among its members a Chairman, who must be a natural person. Except in the circumstances specified in article 16 when he or she also assumes the function of Chief Executive Officer, the Chairman may hold office for the duration of his or her term of office as director, under the conditions laid down in article 11.1 paragraph 2 above.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board may appoint from among its members a Vice-Chairman, who must be a natural person less than 70 years of age.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">They may be appointed for their entire term of office as directors.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the event of the temporary incapacity, resignation, death or non-reappointment of the Chairman, the Board of Directors may delegate another director to act as chairman. In the event of temporary incapacity, such delegation shall be given for a limited period and shall be renewable. In other cases, it shall be valid until a new Chairman is appointed.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chairman shall organise and direct the work of the Board, and be accountable for this to the Shareholders&#8217; General Meeting.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">He shall ensure that the company's organs of management operate properly and in particular that the directors are capable of fulfilling their duties.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 13 &#8211; DELIBERATIONS OF THE BOARD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall meet as often as required by the interests of the company, either at the registered office or at any other place indicated in the notice of the meeting. The Chairman may notify the directors of meetings of the Board of Directors by any means, even orally.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Meetings of the Board of Directors shall be chaired by the Chairman of the Board of Directors or in his absence by the Vice-Chairman. If the Chairman and Vice-Chairman are both absent, the Board of Directors shall appoint, for each meeting, a member who will chair the meeting.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decisions shall be taken on the quorum and majority conditions stipulated by law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The secretary of the Board of Directors shall be authorised to certify copies of and extracts from minutes of Board meetings as a true record.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors may take decisions by written consultation with the directors on the terms set forth in law. The arrangements for such written consultations shall be specified in the Board Charter.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 14 &#8211; BOARD POWERS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall determine the strategic orientations of the company&#8217;s business and ensure they are implemented, in accordance with the corporate interest and taking account of the social and environmental issues relating to its operations.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subject to powers expressly granted to shareholders' meetings and within the limits of the corporate objects, the Board shall address any issue of relevance to the proper functioning of the company, and shall by its deliberations settle all matters that concern it.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board shall perform controls and tests as it sees fit. Each director shall receive all the information necessary for the fulfilment of his duties, and may have disclosed to him all documents that he judges to be useful.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 15 &#8211; COMMITTEES</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board shall appoint a Committee, accountable to the Board, to oversee issues relating to the preparation and audit of financial and accounting information, in accordance with the law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board may appoint one or more other Committees to examine issues referred to them by the Board or the Chairman.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 16 &#8211; MANAGEMENT</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In accordance with the law, the executive management of the company shall be conducted under the responsibility of the Chairman of the Board of Directors, either by himself or by another natural person appointed by the Board of Directors and bearing the title of Chief Executive Officer.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall decide which of these two methods of executive management to adopt on a majority of directors present or represented.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall appoint from among its members, or from outside the Board, the Chief Executive Officer, who shall be a physical person aged less than 65. The Chief Executive Officer shall have the broadest powers to act in all circumstances in the name of the company, within the limits of the corporate objects and subject to powers expressly reserved by law for shareholders&#8217; meetings and the Board of Directors. He shall represent the company in its dealings with third parties.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the executive management of the company is conducted by the Chairman, the provisions contained in the law and regulations and in the articles of association relating to the Chief Executive Officer shall apply to him except those relating to the age limit. He shall take the title of Chairman and Chief Executive Officer and shall hold office until the Ordinary General Meeting called to approve the financial statements of the immediately preceding financial year and held in the calendar year in which he reaches the age of 68.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On a proposal by the Chief Executive Officer, whether this function be assumed by the Chairman of the Board or by another person, the Board of Directors may appoint from one to five persons in charge of assisting the Chief Executive Officer, with the title of Deputy Chief Executive Officer.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In agreement with the Chief Executive Officer, the Board of Directors shall determine the scope and duration of the powers granted to the Deputy Chief Executive Officers.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In dealings with third parties, the Deputy Chief Executive Officers shall have the same powers as the Chief Executive Officer.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 17 &#8211; OBSERVERS (CENSEURS)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On the Chairman's proposal, the Board may appoint up to two observers (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">censeurs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). Observers are chosen from amongst the shareholders and are appointed for a period of five years. The observers may be re-appointed. They may be dismissed at any time by decision of the Board of Directors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">They are responsible for ensuring that the articles of association are strictly observed. They are invited to attend Board meetings in a consultative capacity&#59; however, their absence from such meetings is not detrimental to the validity of the proceedings.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">They examine the annual accounts and address comments to the members of the Shareholders&#8217; Ordinary General Meeting as they deem necessary.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board may remunerate the observers by allocating sums from the amount of annual compensation allotted by the general shareholders&#8217; meeting to Board members.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="i0e05c1cae46d40fb8e19776620bd7228_13"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART IV STATUTORY</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AUDITORS</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 18 &#8211; STATUTORY AUDITORS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">One or several principal auditors are appointed and carry out their audit assignment in compliance with the law.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="i0e05c1cae46d40fb8e19776620bd7228_16"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART V </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">GENERAL SHAREHOLDERS&#8217; MEETINGS</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 19 &#8211; RIGHT OF ACCESS &#8211; REPRESENTATION</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1)    All shareholders shall be entitled to attend personally or by proxy, in the form and at the places indicated in the notice of the meeting, on presentation of proof of identity and of ownership of the shares held in an account before the legal limit of accounting registration.  </font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2)    Any shareholder may be represented or vote by mail on the conditions stipulated by law.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3)    Any shareholder may also, if the Board of Directors so decides on convening the meeting, participate and vote at meetings by video-</font></div><div style="padding-left:20.16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">conference or by any other means of telecommunication including the Internet that enables him or her to be identified on the conditions and accordance to the methods laid down by applicable legislation. Such decision will be notified in accordance with the law.</font></div><div style="padding-left:20.16pt"><font><br></font></div><div style="padding-left:20.16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Those shareholders who use for this purpose, and within the time limits, the electronic form provided on the website of the General Meeting centralizer shall be deemed to be among the shareholders present or represented.  The electronic form may be completed and signed directly on this site through a user code and a password</font></div><div style="padding-left:20.16pt"><font><br></font></div><div style="padding-left:20.16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The proxy or the vote provided by electronic means prior to the General Meeting, as well as the evidence of receipt which is provided, shall be deemed irrevocable and may be asserted against all persons, it being specified that in the event of a transfer of share ownership occurring before the legal limit of accounting registration of the shares, the Company will invalidate or revise, depending on the situation, the proxy or the vote provided before this date and this hour.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 20 &#8211; NOTICE OF GENERAL SHAREHOLDERS&#8217; MEETINGS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The meetings are convened by the Board of Directors under the conditions and within the time limits prescribed by law. They are held at the registered office or at in any other place indicated in the convening letter or notice.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 21 &#8211; MEETING COMMITTEE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shareholders&#8217; General Meetings  are presided over by the Chairman of the Board of Directors or, in his absence, by a director appointed by the Board.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The duties of examiner (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">scrutateur</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) are fulfilled by the two shareholders, present and willing, who hold the greatest number of votes both in their own name and in their capacity as authorised agents.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The committee appoints a secretary who need not be a member of the general meeting.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 22 &#8211; GENERAL SHAREHOLDERS&#8217; MEETINGS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ordinary and Extraordinary General Shareholders&#8217; Meetings, acting under the conditions of quorum and majority laid down by law, exercise the powers assigned to them in compliance with the law.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="i0e05c1cae46d40fb8e19776620bd7228_19"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART VI </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ALLOCATION OF PROFITS</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 23 &#8211; FINANCIAL YEAR</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each financial year starts on January 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and ends on December 31</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 24 &#8211; ALLOCATION OF PROFITS</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1)    The profit or loss of the financial year is the difference between the income and expenses of the financial year, after deduction of depreciation, amortization and provisions, as shown in the income statement.</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2)    From the profit of the financial year, less any prior losses, a deduction of at least five per cent is made, this deduction being allocated for the creation of a reserve fund known as the &#34;legal reserve&#34;. This deduction is no longer compulsory when the amount of the legal reserve reaches one-tenth of the registered capital. The deduction begins again if, for any reason whatsoever, the legal reserve falls to a level below the said fraction.</font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The remaining balance, plus any profit carried forward, constitutes the distributable profit.On the Board&#8217;s proposal, the Shareholders&#8217; General Meeting may decide that the distributable profit may, totally or partially, be carried forward or assigned to one or several general or special reserve funds.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 25 &#8211; DIVIDENDS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Shareholders&#8217; General Meeting that votes on the financial statements for the financial year may allow each shareholder the option, for all or some of the dividend or interim dividend distributed, to receive payment of the dividend or interim dividend either in cash or in shares.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the Shareholders&#8217; General Meeting may decide, for all or some of the dividend, interim dividend, reserves or additional paid-in capital that are distributed, that the distribution of such dividends, interim dividends, reserves, additional paid-in capital will be made in kind by the delivery of assets of the Company, including financial securities, with or without cash option.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Shareholders&#8217; General Meeting may decide that fractional rights will be neither negotiable nor transferable notwithstanding the provisions of Article 9-2&#176;) of the Articles of Association. The Shareholders&#8217; General Meeting may in particular decide that, when the proportion of the distribution to which a shareholder is entitled does not correspond to a whole number of the unit of measurement used for the distribution, that shareholder will receive the next lowest whole number of shares plus a cash payment for the balance.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="i0e05c1cae46d40fb8e19776620bd7228_22"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART VII </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DISSOLUTION &#8211; LIQUIDATION</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE 26</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On the expiry of the term of the company or in case of dissolution prior to that date, the Shareholders&#8217; General Meeting rules on the mode of liquidation and appoints one or several liquidators whose powers it determines and who carry out their duties, in compliance with the law.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The liquidation proceeds are first used to pay liabilities. Subsequent to this payment and after payment of liquidation costs, the surplus is used to reimburse the nominal value of the shares&#59; the balance is distributed amongst the shareholders in the same proportions as their participation in the share capital.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font><br></font></div><div id="i0e05c1cae46d40fb8e19776620bd7228_25"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART VIII </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DISPUTES</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE  27</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any disputes that may arise during the life of the company or its liquidation, either between the shareholders and the company or between the shareholders themselves, concerning the interpretation or enforcement of these statutes or generally regarding corporate business, are subject to the jurisdiction of the competent courts.</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>3
<FILENAME>a2023-exhibit12.htm
<DESCRIPTION>EX-1.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ifc27f45e4c4947ea9340511bc7cd391f_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 1.2</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">This text is a free translation from the French language and is supplied solely for information purposes. Only the original version in the French language has legal force.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SANOFI BOARD CHARTER</font></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approved by the Board of Directors on December 13, 2023</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">This text is a free translation from the French language and is supplied solely for information purposes. Only the original version in the French language has legal force.</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_4"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">LIST OF CONTENTS</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.733%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">I &#8211; Composition of the Board of Directors and term of office</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_7" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;I</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ndependent Directors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_10" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Directors representing employees</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_13" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8194;&#8201;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Outside speakers</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_16" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8194;&#8201;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Term of office and reappointment by rotation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_19" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">II &#8211; Ethical duties of Sanofi Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_22" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Information provided to new Directors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_25" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Training of Directors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_28" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8194;&#8201;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Holding of shares in the Company</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_31" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8194;&#8201;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Corporate interests</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_34" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Preparation for meetings &#8211; Attendance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_37" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#8202;Confidentiality</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_40" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">G</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.&#8194;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#8201;Holding of multiple offices</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_43" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8194;&#8201;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Prevention of conflicts of interest</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_46" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#8201;Privileged information</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_49" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">III &#8211; Remit and powers of the Board of Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_52" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IV &#8211; Operating procedures of the Board of Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_55" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Secretary to the Board</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_58" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Meetings</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_61" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8194;&#8201;&#8201;Written Consultations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_64" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8194;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#8201;Evaluation of the Board and its Committees</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_67" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;Provision of information to Directors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_70" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Attendance fees</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_1032" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">V &#8211; Roles and powers of the Chairman and the Chief Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_73" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Chairman of the Board of Directors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_76" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Chief Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_79" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">VI &#8211; Committees</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_82" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions common to all Committees</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_85" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Specific provisions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_88" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:58.5pt;padding-right:2.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%;text-decoration:underline">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%">&#8195;&#8201;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%;text-decoration:underline">Audit Committee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_91" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:58.5pt;padding-right:2.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%;text-decoration:underline">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%">&#8195;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%;text-decoration:underline">Compensation Committee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_94" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:58.5pt;padding-right:2.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%;text-decoration:underline">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%;text-decoration:underline">Appointments, Governance and CSR Committee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_97" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:58.5pt;padding-right:2.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%;text-decoration:underline">iv.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%">&#8194;&#8201;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%;text-decoration:underline">Strategy Committee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_100" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:58.5pt;padding-right:2.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%;text-decoration:underline">v.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%">&#8195;&#8201;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%;text-decoration:underline">Scientific Committee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_103" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:159%;text-decoration:underline">VII &#8211; Amendment of the Board Charter</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a href="#ifc27f45e4c4947ea9340511bc7cd391f_106" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none">16</a></font></div></td></tr></table></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_7"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board Charter (the &#8220;Charter&#8221;) describes the rights and obligations of Board members&#59; the composition, role and operating procedures of the Board of Directors and Board Committees&#59; and the roles and powers of the Chairman and the Chief Executive Officer. It is prepared in accordance with the French Commercial Code and the Company&#8217;s Articles of Association.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Charter shall be binding on all members of the Board of Directors. All members of the Board shall on assuming office be deemed to adhere to the Charter and shall comply with it in full.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors refers to the corporate governance principles contained in the Code de gouvernement d&#8217;entreprise des soci&#233;t&#233;s cot&#233;es (Corporate Governance Code of Listed Companies) applicable as of the date of the presents (the &#8220;AFEP-MEDEF Code&#8221;).</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">I &#8211; Composition of the Board of Directors and term of office</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall seek to establish an appropriate balance among its members and among members of its Committees, in particular in terms of diversity (representation of men and women, nationalities, ages and competencies), while taking the necessary measures to provide shareholders the market and stakeholders with assurance that it is fulfilling its remit with the requisite independence and objectivity. The Board shall disclose publicly in the Annual Report a description of its policy in this area, covering the objectives, procedures and outcomes of that policy.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_10"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Independent Directors</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At least half of the members of the Board of Directors shall be independent Directors.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A Director shall be independent when they have no relationship of any kind with the Company, its subsidiaries or its senior management that may color their judgment. Accordingly, an independent Director shall be understood to be any non-executive Director of the Company or of a subsidiary who has no particular bonds of interest (significant shareholder, employee, other) with either the Company or its subsidiaries.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It shall be the responsibility of the Board of Directors, acting on proposals from the Appointments, Governance and CSR Committee, to assess the independence of each of its members with reference to the recommendations and guidelines of the AFEP-MEDEF code.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The independence of Directors shall be discussed by the Appointments, Governance and CSR Committee and determined by the Board whenever a Director is appointed, and annually for all Directors. The shareholders shall be informed of such assessments.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_13"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Directors representing employees</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall include two Directors representing employees, designated in accordance with the arrangements specified in the Articles of Association.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subject to any legal provisions specific to them, the Directors representing employees shall have the same rights and be subject to the same obligations as the other members of the Board, in particular as regards confidentiality, and shall bear the same responsibility.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors representing employees shall not count towards the proportion of independent or female members of the Board of Directors.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_16"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Outside speakers</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the agenda so dictates, the Chairman of the Board of Directors may, especially if a Director so requests, invite any person (whether or not an employee of the Company) that he or she sees fit to make a presentation or provide clarification as part of preparatory discussions for Board deliberations.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_19"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Term of office and reappointment by rotation</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The term of office of Directors shall be four years.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors shall be required to seek reappointment by rotation, such that members of the Board are required to seek reappointment on a regular basis in the most equal proportions possible. Exceptionally, a Shareholders&#8217; Ordinary General Meeting may appoint a Director to serve for a term of one, two or three years in order to ensure adequate rotation of Board members.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_22"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">II &#8211; Ethical duties of Sanofi Directors</font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_25"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Information provided to new Directors</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When Directors assume office, the Secretary to the Board shall provide them with an information pack, to include the Articles of Association and the Charter. Directors shall ensure that they are aware of and comply with the obligations placed upon them by the relevant laws and regulations, the Articles of Association, the Charter, and such other internal rules and procedures of the Company as apply to them.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_28"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Training of Directors</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors may, at the time of their appointment and throughout their term of office, request such training as they regard as necessary to discharge their duties as Directors, and in particular training about the specific characteristics of the Company&#59; its business lines&#59; the sector in which it operates&#59; and its social and environmental responsibilities. Such training shall be organized and offered by the Company at its expense.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_31"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Holding of shares in the Company</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to their obligations under the Articles of Association, each Director must be a shareholder in their own right and must within no more than two years from their appointment hold at least 1,000 Sanofi shares in their own name, which must be retained until they cease to hold office. Any Director who does not hold such shares on assuming office shall use their attendance fees to finance the acquisition thereof.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors shall be required to convert into registered form any financial instruments of the Company they hold when they assume office and any that they acquire during their term of office.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In accordance with legislation, that obligation of holding shares shall not apply to Directors representing employees.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_34"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate interests</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors is a collegiate body acting in Sanofi&#8217;s corporate interests and representing the shareholders collectively. Directors shall discharge collectively, jointly and severally the responsibilities and obligations incumbent by law on the Board of Directors.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_37"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">E.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Preparation for meetings &#8211; Attendance</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In preparing for meetings of the Board and Committees on which they sit, Directors shall devote the time and attention necessary to examining the supporting documentation sent to them.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors representing employees shall be allowed sufficient time to properly discharge their duties as Directors.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless they inform the Chairman in advance of their absence, Directors shall participate in all meetings of the Board and of the Committees on which they sit, as well as in Shareholders&#8217; General Meetings.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_40"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">F.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Confidentiality</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Files for Board meetings, and information received prior to or during Board meetings, shall be treated as confidential by Directors, who shall be bound by this strict duty of confidentiality vis-&#224;-vis not only persons external to the Company but also persons within the Company who do not need to know such information by reason of their duties.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If a third party who is not a Director is invited to a Board meeting or to a preparatory session of such a meeting, the Chairman shall remind them of their duty of confidentiality in relation to information provided before or during such meeting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As regards information not in the public domain obtained in the course of their duties, Directors shall regard themselves as bound by an obligation of professional secrecy that goes beyond the mere duty of discretion contained in the relevant laws and regulations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Only the Chairman and the Chief Executive Officer of the Company shall be entitled to provide third parties and the public with information on the Company&#8217;s policy, strategies, activities and performance.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the event of a proven breach of the duty of confidentiality by a Director or any person attending a Board meeting, the Chairman of the Board, after consulting the Legal Department, shall inform the Board of Directors of the action he or she intends to take in respect of such breach, including any legal proceedings.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_43"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">G.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Holding of multiple offices</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">An executive Officer shall not hold more than two other directorships in listed companies outside the Company and its subsidiaries, including foreign companies. He or she must also seek the opinion of the Board of Directors before accepting a new office in a listed company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A Director shall not hold directorships in more than four listed companies outside the Company and its subsidiaries, including foreign companies. This recommendation shall apply on their initial appointment as Director or on their next reappointment.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors shall keep the Board informed of offices held in other French or foreign companies, including membership of those companies&#8217; board committees.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_46"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Prevention of conflicts of interest</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A Director may not use their title or office as Director to obtain for themselves or for a third party any pecuniary or non-pecuniary benefit.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors undertake to inform the Board of Directors of any actual or potential conflict of interest between their duties to the Company and their private interests and&#47;or other duties. They shall also abstain from voting and participating in debate on any such matter.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A Director who is involved in a transaction in which Sanofi has a direct interest or of which they became aware in their capacity as Director shall inform the Board thereof prior to entering into such transaction.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No Director, and no permanent representative of a Director that is a corporate entity, may be involved in a personal capacity in any business or activity in competition with those of Sanofi without having previously informed the Board of Directors and obtained its consent.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During their entire term of office, Directors (or permanent representatives of a Director that is a corporate entity) undertake not to seek and&#47;or accept a directorship in any business or activity in competition with those of Sanofi and&#47;or in businesses in which Sanofi holds a significant equity interest or more generally in businesses with which Sanofi is in significant collaboration without previously seeking the opinion of the Chairman of the Board of Directors. If the Chairman regards the holding of such a directorship as contrary to the corporate interests of the Company or as liable to create a conflict of interest, he or she may require the Director to resign from or refuse to accept said directorship.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At the end of their term of office, Directors (or permanent representatives of a Director that is corporate entity) shall allow a reasonable period of time to elapse before seeking and&#47;or accepting a directorship in businesses carrying on activities in competition with those of Sanofi and&#47;or in businesses in which Sanofi holds an equity interest.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In any event, Directors shall fulfill their commitment to confidentiality and loyalty vis-&#224;-vis the Company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors undertake to tender their resignation to the Board of Directors in the event that their other activities and directorships change significantly.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors who believe they are no longer capable of fulfilling their duties within the Board or a Committee of which they are a member shall resign.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors who abstain from voting on a Board motion due to a conflict of interest shall not count towards quorum.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_49"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Privileged information</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with their duties, Directors receive much confidential information, some of which may be privileged information on the Company within the meaning of securities law.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors who are in possession of privileged information must, for as long as that information is not in the public domain, refrain from directly or indirectly entering into (or recommending others to enter into or refrain from) any transaction involving the financial instruments of the Company (shares, ADRs, CVRs, bonds, futures, etc.) and from disclosing such information to third parties.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors shall also refrain from trading in financial instruments of the Company during closed periods determined and communicated to them by the Company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors shall refrain from entering into speculative or hedging transactions, in particular derivatives transactions and short selling. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors and persons closely associated with Directors shall, on the terms specified in the relevant regulations, notify transactions in financial instruments of the Company to the Company itself and to the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Autorit&#233; des march&#233;s financiers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which discloses such transactions to the public.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors shall send written notification informing persons closely associated with them of their obligations to declare transactions, and shall retain a copy of that notification.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_52"></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">III &#8211; Remit and powers of the Board of Directors</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board shall deliberate on issues that are within its competence by law or under the Articles of Association.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall lay down the orientations of the Company&#8217;s activities and ensure that they are implemented, paying due consideration to social and environmental issues. Subject to those powers expressly attributed to Shareholders&#8217; General Meetings and within the limits set by the corporate purpose, the Board of Directors shall address any issue of relevance to the proper conduct of the Company&#8217;s affairs and shall, through its deliberations, settle matters concerning the Company. It shall in all circumstances act in the corporate interests of the Company, seeking to promote long-term value creation in all aspects of the Company&#8217;s operations.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall carry out such inspections and verifications as it deems fit. It shall conduct an annual review of the key points in the Management Report and other reports submitted to the shareholders, and of the resolutions submitted to the Shareholders&#8217; General Meeting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of its remit, the Board shall have inter alia the following powers&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to be kept informed of any important event affecting the affairs of the Company, and more generally of trends in the markets, in the competitive environment, and in the main challenges faced by the Company, including its social and environmental responsibilities&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to determine the strategic orientations of the Company and the Group, based on advice from the Strategy Committee&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to appoint corporate officers responsible for managing the business and decide on the governance rules for corporate officers (separation or combination of the offices of Chairman and Chief Executive Officer)&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to establish an Audit Committee on the terms specified by law, and assess the appropriateness of establishing other specialist Committees on a permanent or temporary basis&#59; to determine the composition of such Committees with regard to the issues they will examine, and ensure they function properly&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to examine on a regular basis, consistently with the strategy determined by the Board and in liaison with the Audit Committee, the opportunities and risks (in particular of a financial, legal, operational, social or environmental nature) to which the Company and its subsidiaries are exposed, and the measures taken in response&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to ensure that the necessary systems are in place to prevent and detect corruption and influence trafficking, and obtain all necessary information to that effect&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to set the compensation payable to the Company Officers, acting on proposals from the Compensation Committee. The Board shall give reasons for decisions taken on such matters&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to determine, upon the Chief Executive Officer's proposal and, in conjunction with the Compensation Committee and the Appointments, Governance and CSR Committee, targets in terms of gender balance within the executive bodies and ensure that the Chief Executive Officer implements global non-discrimination and diversity policy within the Company&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to exercise control over management and oversee the quality of information provided to shareholders and to the markets, in particular via the financial statements or on the occasion of major corporate actions&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to establish the Company&#8217;s financial communication policy&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to be kept regularly informed by the Audit Committee of the financial position, cash position and commitments of the Company&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to call and prepare the agenda for Shareholders&#8217; General Meetings.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, without prejudice to those transactions for which Board approval is legally required (regulated agreements, divestments of equity interests or real estate, etc.), the following shall specifically require the prior consent of the Board&#58;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;any significant transaction outside the scope of the Company&#8217;s declared strategy (see also the limitations on the powers of the Chief Executive Officer mentioned below)&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;commitments in respect of investments, acquisitions and divestments that exceed the limitations on the powers of the Chief Executive Officer&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;authorizations given to the Chief Executive Officer to grant guarantees in the name of the Company, including to the tax and customs authorities.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_55"></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">IV &#8211; Operating procedures of the Board of Directors</font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_58"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;Secretary to the Board </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board, acting on a proposal from the Chairman, shall appoint a Secretary. All members of the Board may consult the Secretary and make use of his&#47;her services. The Secretary shall ensure that the Board&#8217;s operating procedures are complied with and shall establish minutes of its meetings, which shall include a summary of the discussions and the motions submitted for its approval. The minutes shall mention questions put and reservations expressed by those attending. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Secretary&#8217;s responsibilities shall include sending working papers to the Directors and dealing with any request from them for information about their rights and responsibilities, the operating procedures of the Board or the Company&#8217;s affairs. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_61"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;Meetings </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall meet at least four times a year, and whenever the interests of the Company require. Meetings may be called by any means, including orally, by the Chairman or by the Secretary to the Board at the Chairman&#8217;s request.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Meetings shall take place at the registered office or at any other place indicated in the notice of the meeting. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chairman shall chair Board meetings and organize the work done at meetings. If the Chairman is unable to chair a meeting, he or she shall be replaced by the Chief Executive Officer (provided the two offices are separated and that the Chief Executive Officer is also a Director), or otherwise by another Director chosen by the Board at the start of the meeting. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall organize at least two meetings a year without the executive Officers being present. Such meetings may also be held without Directors representing employees or any other Group employee being present. These meetings shall inter alia evaluate the performance and determine the compensation of the Chief Executive Officer. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The agenda for meetings shall be established by the Chairman. Directors may request the Chairman to add to the agenda an item that they wish to be discussed at the meeting, provided such request is made in reasonable time. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chairman shall ensure that the Company provides all relevant information and documents to the Directors on a timely basis in advance of each meeting. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors may choose to be represented by another Director at meetings of the Board of Directors. Each Director may represent no more than one other Director at any Board meeting. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors who participate in a Board meeting by video-conference and&#47;or tele-conference links that enable them to be identified and effectively participate in the meeting and that comply with the technical specifications stipulated in the regulations applicable as of the date of the meeting shall be deemed present for the purposes of determining quorum and majority at such meetings. By law, when the Board deliberates on the individual and consolidated financial statements of the Company and on the management report, a Director shall not be considered as present to calculate quorum and majority if he or she participates by video-conference and&#47;or tele-conference. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the Chairman of the Board becomes aware of a malfunction in the video-conference or tele- conference system, the Board of Directors may validly deliberate and&#47;or continue with only those Directors attending in person, provided that the quorum requirements are met. The occurrence of any technical problem affecting the course of the meeting shall be recorded in the minutes, including the interruption and restoration of the remote attendance links.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors may at the Company&#8217;s expense have recourse to external experts and commission external technical research on issues within its sphere of competence, on condition that a report is provided to the Board itself thereon. The Board must obtain assurance as to the objectivity of any external experts retained.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_64"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">C.&#160;&#160;&#160;&#160;Written Consultations</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to Article 13 of the Articles of Association, the Board of Directors may make certain decisions by means of written consultation of the Directors.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In such cases, the Chairman of the Board of Directors shall convene the directors by e-mail, indicating the appropriate deadline for responding, which shall depend on the purpose of the consultation. The statutory auditors are convened and receive the documents in the same way as for physical meetings.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Secretary sends the documents relating to the consultation and enabling the Directors to form an opinion on the subject presented, in particular the grounds for the proposed decision and the draft resolution(s). </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors respond to the e-mail sent to them, indicating the meaning of their vote. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors who have not replied by the end of the specified period shall be deemed not to be part of the quorum for taking the decisions contained in the consultation, unless the said period is extended by the Chairman. Decisions are taken by a simple majority of the Directors constituting the quorum.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Secretary consolidates the votes of the Directors on each draft resolution and informs the Board of the result of the vote. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors may ask any question necessary for their consideration or address any comment to the Chairman. The decisions thus taken and the exchanges are recorded in minutes drawn up by the Secretary. These minutes are kept under the same conditions as the other decisions of the Board of Directors.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_67"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Evaluation of the Board and its Committees </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">The Board of Directors shall evaluate its ability to meet the expectations of the Shareholders who have mandated the Board to administer the Company, by performing periodic reviews of the Board&#8217;s composition, organization and operating procedures, to include by extension a review of the Board Committees. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">The Board shall consider what is an appropriate balance for its composition, and periodically reassess whether the way in which the Board is organized and operates is appropriate to fulfill its remit. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">The evaluation shall have three principal objectives&#58; </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#8226; assess the way in which the Board operates&#59;</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#8226; check that the important issues are properly prepared and discussed&#59;</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#8226; assess the contribution of each director in the Board&#8217;s activities.</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">The arrangements for the Board evaluation are as follows&#58; </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#8226; the Board discusses its own operating procedures once a year&#59; </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#8226; at least once every three years there is a formal evaluation, which may be conducted with assistance from an external consultant under the direction of the Appointments, Governance and CSR Committee&#59;</font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#8226; shareholders are informed each year in the annual report about the evaluation, and any follow-up action. </font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_70"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">E.&#160;&#160;&#160;&#160;Provision of information to Directors </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other than in exceptional circumstances, Directors shall within a reasonable period in advance of each Board meeting receive the agenda for that meeting and necessary information for their consideration. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">They shall also be provided with information at any time between Board meetings if necessary. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors shall in addition keep themselves informed at all times of developments affecting the Company and the market. To that end, a Director must request on a timely basis such information as they regard as essential for making a useful contribution on the issues included on the agenda from the Chairman or the Secretary to the Board. </font></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors must be able to meet the Company&#8217;s principal executives, and may do so without the executive Officers being present provided that the executive officers are given prior notice. </font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_1032"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">F.&#160;&#160;&#160;&#160;Attendance fees</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acting on a proposal from the Compensation Committee, the Board shall allocate the annual attendance fee budget authorized by the Shareholders&#8217; General Meeting.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Members of the Board shall be entitled to a fixed fee to compensate their role as Director and any role as member or Chairman of one or more Committees, and to a preponderant variable fee reflecting effective attendance at meetings of the Board and of any Committees to which they belong.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board may also allocate additional attendance fees to Directors living outside France to reflect the necessity of their traveling to attend meetings.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors who simultaneously hold office as Chairman of the Board, Chief Executive Officer or Deputy Chief Executive Officer shall not receive attendance fees.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A Director participating in a meeting of the Board or of a Committee by tele-conference or video-conference shall receive the equivalent of the attendance fee paid to a Director residing in France who attends in person. Committee Chairs retain their usual compensation for committees they chair.</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As an exception, in certain cases two meetings held on the same day shall give entitlement to a single attendance fee&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;if on the day of the Shareholders&#8217; General Meeting, the Board of Directors meets both before and after that meeting, only one attendance fee shall be paid for the two meetings&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;if on the same day a Director participates in one meeting of the Compensation Committee and one meeting of the Appointments, Governance and CSR Committee, only the higher of the two fees shall be paid to cover both meetings.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors representing employees shall receive attendance fees in accordance with the rules described above.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Directors shall also be entitled to be reimbursed for travel expenses they incur in the exercise of their duties on presentation of supporting documentation.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_73"></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">V &#8211; Roles and powers of the Chairman and the Chief Executive Officer</font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_76"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Chairman of the Board of Directors</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chairman shall organize and direct the work of the Board of Directors, on which he or she shall report to the Shareholders&#8217; General Meeting. The Chairman shall also be responsible for ensuring the proper functioning of the corporate decision-making bodies in compliance with good governance principles. The Chairman shall coordinate the work of the Board of Directors with that of its Committees.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">He or she shall ensure that Directors have access on a timely basis to information required for the performance of their duties, in a clear and appropriate form.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chairman shall, in coordination with the Chief Executive Officer, liaise between the Board of Directors and the Shareholders. The Chairman of the Board of Directors shall have sole authority to speak in the name of the Board. The role of the Chairman of the Board of Directors shall include&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;explaining previously-disclosed positions taken by the Board within its areas of competence&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;ensuring that shareholders receive the information they expect about the Company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chairman shall report to the Board on the fulfilment of his or her remit in the event that the offices of Chairman and Chief Executive Officer are separated, and shall develop and maintain a proper relationship of trust between the Board and the Chief Executive Officer, so as to ensure that the latter consistently and continuously implements the orientations determined by the Board.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chairman shall be kept regularly informed by the Chief Executive Officer of significant events and situations affecting the affairs of the Company, especially in the areas of strategy, organization, financial reporting, major investment and divestment proposals, and major corporate actions. The Chairman may request from the Chief Executive Officer any information useful to the Board of Directors.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In close collaboration with the Chief Executive Officer, the Chairman may represent the Company in high-level dealings with governmental bodies and with key partners of the Company and&#47;or of its subsidiaries, both nationally and internationally.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As required by law and by the Charter, the Chairman shall seek to prevent any conflict of interest and manage any situation that might give rise to a conflict of interest. He or she shall also give rulings, in the name of the Board, on requests to take up external directorships of which he or she may become aware or that may be submitted to him or her by a Director.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chairman shall strive to promote in all circumstances the values and the image of the Company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">He or she may interview the statutory auditors in preparation for the work of the Board of Directors and the Audit Committee.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In fulfilling his remit, the Chairman may meet with any individual, including senior executives of the Company, while avoiding any involvement in directing the Company or managing its operations, which are exclusively the responsibility of the Chief Executive Officer.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_79"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Chief Executive Officer</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chief Executive Officer shall assume responsibility for the general management of the Company. He or she shall chair the Executive Committee. He or she shall have sole responsibility for directing the Company and managing its operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">He or she shall have the broadest powers to act in the name of the Company in all circumstances, subject to powers attributed by law to the Board of Directors or to the Shareholders&#8217; General Meeting and subject to the limitations on powers described below.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior approval from the Board of Directors shall be required for transactions or decisions resulting in an investment or divestment, or an expenditure or guarantee commitment, made by the Company and its subsidiaries, in excess of&#58;</font></div><div style="margin-bottom:9pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;a cap of &#8364;500 million (per transaction) for transactions, decisions or commitments pertaining to a previously approved strategy&#59; and</font></div><div style="margin-bottom:9pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;a cap of &#8364;150 million (per transaction) for transactions, decisions or commitments not pertaining to a previously approved strategy.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When such transactions, decisions or commitments give rise to installment payments to the contracting third party (or parties) that are contingent upon future results or objectives, such as the registration of one or more products, attainment of the caps shall be calculated by aggregating the various payments due from signature of the contract until (and including) filing of the first application for marketing authorization in the United States or in Europe.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attainment of the above caps shall also be assessed after taking into account all commitments to make payments on exercise of a firm or conditional option with immediate or deferred effect, and all guarantees or collateral to be provided to third parties over the duration of such commitments.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The prior approval procedure shall not apply to transactions and decisions that result in the signature of agreements that solely involve subsidiaries and the Company itself.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At each Board meeting, the Chief Executive Officer shall present a report on significant events affecting the Company&#8217;s affairs</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_82"></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">VI &#8211; Committees</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To fulfill its remit in a spirit of good governance and in accordance with legal requirements, the Board of Directors has established five permanent Committees, the members of which shall be chosen by the Board from among its own members&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the Audit Committee&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the Compensation Committee&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the Appointments, Governance and CSR Committee&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the Strategy Committee&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the Scientific Committee.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In accordance with the law, the existence of those five Committees shall not preclude any other Committees that the Board may decide to establish on a temporary or ad hoc basis.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_85"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Provisions common to all Committees</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">General remit of the Committees</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The remit of the Committees shall be to conduct analysis and in-depth thinking ahead of Board discussions, and to help prepare decisions to be taken by the Board. The Committees shall have no decision-making powers and the opinions, proposals and recommendations submitted by the Committees to the Board shall in no way be binding on the Board.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The operating procedures of each Committee shall be set by the Charter, in line with the principle of collegiality that governs the Board of Directors. The specialist Committees shall therefore carry on their activities under the responsibility of the Board of Directors and within the limits of the Board&#8217;s powers. They shall report regularly to the Board on their remit. The annual report shall include a description of the work of the Committees during the past financial year.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Committee members shall be subject to the same civil and criminal liability as the other Directors.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any member of a Committee may inform the Chairman of the Board at any time of any aspect of that Committee&#8217;s remit of which he or she feels the Board should be made aware.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Resources provided to the Committees</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company shall provide members of the Committees with all relevant information and documents.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Committees may at the Company&#8217;s expense have recourse to external experts and commission external technical research on issues within their sphere of competence, on condition that (i) the Committee has previously informed the Chairman of the Board or the Board of Directors and (ii) a report is provided to the Board thereon. The Committees must obtain assurance as to the objectivity of any external experts retained.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any person invited to attend Committee meetings shall be bound by an obligation of non-disclosure with respect to any information not in the public domain, and by a general obligation of discretion in respect of all matters relating to the Committee and the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Appointment of Committee members</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board of Directors shall appoint the members and Chairman of the Appointments, Governance and CSR Committee. It shall then, acting upon proposals from that Committee, appoint the members and Chairman of each Committee established by the Board.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board shall have discretion to allow a period of time to elapse between the date on which a Director is first appointed to serve on the Board and the appointment of that Director to a Committee, in particular to give the new Director time to assimilate, to understand how the Company operates and the issues facing its business, or to complete any training programs.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Members of each Committee shall serve on that Committee for a period concurrent with their term of office as Director, and may be reappointed at the time of their reappointment as a Director.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Board may summarily remove any member of a Committee without having to give reasons.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Committees shall avoid having any member who holds cross-directorships within the meaning of the AFEP-MEDEF code.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Quorum and majority</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Committee meetings may take place with members physically present or participating via video-conference and&#47;or tele-conference links that enable a list of participants to be established and enable the members to discuss and arrive at recommendations, conclusions and observations.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Committees may only deliberate validly if at least half of their members participate in the meeting. Members may participate in Committee meetings via video-conference or tele- conference links that enable them to be identified and effectively participate in the meeting. No member of a Committee may be represented thereon by another person. </font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proposals made by Committees shall be decided on a simple majority. In the event of a tied vote, the Chairman of the Committee shall have a casting vote.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Committee meetings</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Committee meetings shall be called by the Chairman of the Committee whenever he or she sees fit. Other than the Audit Committee, which shall meet at least four times a year, Committees shall meet at least twice a year.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chairman of each Committee shall designate a secretary, who may or may not be chosen from among its members. Committee deliberations shall be recorded in minutes validated by its Chairman and the secretary or another Committee member, and shall be sent to Committee members by any means of communication.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_88"></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Specific provisions</font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_91"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">i.&#160;&#160;&#160;&#160;Audit Committee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Composition of the Audit Committee</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Committee shall have at least three members, appointed by the Board from among the Directors.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At least two-thirds of its members shall be independent Directors and no executive Officer may sit on the Committee.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The members of the Committee must be competent in financial or accounting matters. At least one member must qualify as a financial expert within the meaning of U.S. securities legislation and of French legislation.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On appointment to the Audit Committee, members shall be provided with specific information about the accounting, financial and operational characteristics of the Company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When the Governance and CSR Committee proposes the appointment or reappointment of the Chairman of the Audit Committee, such proposal must be specifically examined by the Board.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Remit of the Audit Committee</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The principal remit of the Audit Committee shall be to monitor matters relating to the preparation and audit of accounting, financial and extra-financial information. Without prejudice to the powers of the Board of Directors, the Committee shall inter alia be responsible for monitoring&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the process of preparing the annual and half-year financial statements, and financial information more generally. The Committee shall formulate any recommendations to ensure the integrity thereof, and assesses the validity of elective treatments used for significant transactions&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the process of preparing the sustainability information, including in the electronic reporting format as required by law, and the &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;implementation process to determine which information to be disclosed herein. The Committee shall formulate any recommendations to ensure the integrity thereof&#59; </font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the implementation and effectiveness of internal control and risk management systems, and if appropriate of internal audit as regards procedures for preparing and processing accounting, financial and sustainability information, including in electronic reporting format, but without undermining the independence of internal audit&#59; </font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the statutory auditing and certification of the sustainability information.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The role of the Committee shall be not so much to examine the financial statements and the extra-financial information in detail but to monitor the process of preparing them.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Audit Committee must obtain assurance that the Chief Executive Officer has sufficient resources to identify and manage the risks, and in particular risks of an economic, financial and legal nature, to which the Company and its subsidiaries are exposed in the course of routine and exceptional transactions.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the Committee shall&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;direct the selection process for the statutory auditors, submit the results of this process to the Board of Directors, and issue a recommendation concerning the statutory auditors proposed for appointment by the Shareholders&#8217; General Meeting. It shall supervise any call for tenders, and approve the terms of reference and the panel of firms invited to tender&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;be informed every year of the fees paid to the statutory auditors of the Company, and be provided with their attestation of independence&#59;</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;monitor the independence of the providers performing the statutory audit and certification of the sustainability information, and examine with them any risks to such independence and protective measures to mitigate those risks. The Committee shall obtain assurance that such providers comply with the legal and regulatory requirements relating to independence. In particular, the Committee shall monitor compliance with rotation requirements&#59;</font></div><div style="padding-left:27pt;text-indent:-18pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;approve in advance any request to the statutory auditors to provide services that are ancillary or directly complementary to the audit of the financial statements and rule on requests to&#47;from the statutory auditors to supply services other than audit of the financial statements, in compliance with the relevant laws&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;examine risk exposures and significant off balance sheet commitments, assess the materiality of deficiencies or weaknesses reported to it and, where appropriate, inform the Board thereof&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;examine the scope of consolidation and, if applicable, the reasons for an entity&#8217;s inclusion or exclusion from that scope&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;obtain assurance that the Company&#8217;s internal audit function has sufficient resources to fulfill its remit&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;obtain assurance that the Company&#8217;s accounting policies are relevant, consistent and reliable, and examine any changes in those policies&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;ensure that internal whistle-blowing procedures relating to accounting, internal accounting controls and audit are in place and applied&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;oversee compliance with ethical standards within the Company and in its dealings with third parties&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;ensure that independent Directors receive no compensation other than attendance fees. The Committee shall be kept informed of projects and&#47;or significant financial decisions.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Committee shall be kept informed of projects and&#47;or significant financial decisions. </font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Committee shall report regularly to the Board of Directors. Such reports shall cover fulfillment of the Committee&#8217;s remit, outcomes of the statutory audit engagement, how that engagement contributed to the integrity of financial information, and the role played by the Committee in that process. The Committee shall inform the Board immediately of any difficulties encountered.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Organization of the work of the Audit Committee</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On appointment to the Audit Committee, members must be provided with information about the accounting, financial and operational characteristics of the Company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In furtherance of its remit, the Committee shall have access to all documents and interview the statutory auditors and the officers responsible for finance, accounting, and treasury management. It shall be possible for such interviews to take place without the Chief Executive Officer being present if the Committee sees fit. The Committee may also visit or interview managers of operational entities in furtherance of its remit, having given prior notice to the Chairman of the Board and to the Chief Executive Officer.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Committee shall interview the person responsible for internal audit and give its opinion on the organization of the internal audit function. The Committee shall be notified of the internal audit program and shall be sent internal audit reports or a periodic summary of such reports.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sufficient time shall be allowed for the financial statements to be examined. The examination of the financial statements by the Audit Committee shall be accompanied by a presentation by the statutory auditors highlighting key issues raised by the statutory audit (including audit adjustments and significant internal control weaknesses identified during the audit) and the elective accounting treatments adopted. It shall also be accompanied by a presentation by the Chief Financial Officer describing the Company&#8217;s exposure to risks and significant off balance sheet commitments.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For assignments relating to the sustainability information, the Audit Committee organizes its activities in conjunction with the Appointments, Governance and CSR Committee.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_94"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">ii.&#160;&#160;&#160;&#160;Compensation Committee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Composition of the Compensation Committee</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Committee shall have at least three members, appointed by the Board from among the Directors.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A majority of its members shall be independent Directors, and no executive Officer may sit on the Committee. The Committee shall be chaired by an independent Director. The Board may also decide to appoint a Director representing employees to sit on this Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Remit of the Compensation Committee</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The remit of the Committee shall be to&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;make recommendations and proposals to the Board allowing the latter to define the Company Officers' compensation policy, which includes compensation, pension and welfare plans, top-up pension plans, benefits in kind, miscellaneous pecuniary benefits, and </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">awards of restricted or performance shares or stock options to the executive officers of Sanofi (it being stipulated that when the Committee&#8217;s report on those topics is presented, the Board shall deliberate without the executive officers present)&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;define the methods used to set the variable portion of the compensation of the Chairman and the Chief Executive Officer, and check that those methods are applied&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;formulate general policy on the granting of restricted and performance shares and stock options, and determine the frequency of grants for each category of grantee&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;issue recommendations on the Directors' compensation policy (total amount of attendance fees and how those fees are to be allocated between Directors)&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;consider ethical issues that the Board, the Chairman or the Audit Committee may decide to refer to it&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;examine human resources policy, especially as regards industrial relations, recruitment, diversity, talent management, pay equality and building staff loyalty&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;advise the Chief Executive Officer on the compensation of key senior executives.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Compensation Committee shall also assist in the preparation of the sections of the annual report dealing with the Company Officers' compensation policy and compensation report. The Committee shall also check that the amount of fixed, variable and exceptional compensation paid or awarded to the Company Officers in respect of the previous financial year is consistent with the policy approved by the shareholders.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Committee shall also be kept informed of the compensation policy in place for the principal executive managers who are not Company Officers. On such occasions, the Committee shall meet with the executive Officers present.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_97"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">iii.&#160;&#160;&#160;&#160;Appointments, Governance and CSR Committee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Composition of the Appointments, Governance and CSR Committee</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Committee shall not include any executive Officer and shall include a majority of independent Directors. The Chief Executive Officer shall take part in the work of the Appointments, Governance and CSR Committee. In the event that the offices of Chairman of the Board and Chief Executive Officer are separated, the non-executive Chairman may be a member of the Committee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Remit of the Appointments, Governance and CSR Committee</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The remit of the Committee shall be to&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;assess and recommend suitable candidates to the Board of Directors for appointment as Directors taking into account the target balance of the composition of the Board and its Committees in light of the composition of and changes in the Company&#8217;s shareholder base, the skills and expertise needed for the Board to fulfill its remit, and the gender balance of the Board&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;assess and make recommendations to the Board of Directors as necessary regarding the reappointment of individuals whose terms of office are due to expire, in particular those of the Chairman and Chief Executive Officer&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;propose methods for evaluating the operating procedures of the Board of Directors and its Committees, and monitor the application of those methods&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;determine whether each Director qualifies as being independent, both on initial appointment and annually prior to publication of the annual report, and report its conclusions to the Board of Directors. The Board may at its discretion set independence criteria with reference to those set forth in the AFEP-MEDEF Code&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;establish corporate governance rules for the Company and monitor application of those rules&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;consider ethical issues that the Board, the Chairman or the Audit Committee may decide to refer to it&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;ensure that there is adequate succession planning for the Company&#8217;s executive bodies, in particular through the establishment of a succession plan for the Company Officers so that replacement solutions may be proposed to the Board in the event of unplanned vacancies&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;establish a procedure for the selection of future independent Directors and carry out research on potential candidates prior to any contact with them&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;debate the skills and&#47;or financial expertise of Directors nominated to the Audit Committee and report its conclusions to the Board of Directors&#59;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;examine and monitor the Company&#8217;s commitments and policy orientations in terms of social, environmental and societal responsibility (collectively referred to as Corporate Social Responsibility or &#8220;CSR&#8221;) and the extent to which they meet stakeholder expectations, and more generally ensure that CSR issues are taken into account in developing and implementing corporate strategy&#59;</font></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">ensures that on climate-related issues the Group&#8217;s strategy is accompanied by precise objectives defined for different time frames, and reviews annually the results achieved. The Committee may review the presentation to the shareholders&#8217; meeting of the climate strategy&#59;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;examine draft reports by the Company on governance (including the sections dealing with the diversity policy applied to members of the Board) and CSR matters (especially the sustainability information), and more generally ensure that all information required by applicable legislation on such matters is prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;ensure that regular exchanges take place with shareholders on corporate governance and CSR issues and determine how such exchanges take place, while making sure that the principles of equal treatment of all shareholders and the collegiate nature of the Board are not undermined&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;identify and discuss emerging trends in governance and CSR, and ensure that the Company is preparing as well as possible to deal with those trends in light of issues specific to its operations and objectives&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">where applicable, participates in the determination, in conjunction with the Compensation Committee, of the extra-financial criteria included in the Company&#8217;s remuneration policies.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_100"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">iv.&#160;&#160;&#160;&#160;Strategy Committee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Composition of the Strategy Committee</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Committee shall consist of at least three Directors, including the Chairman of the Board of Directors and the Chief Executive Officer. It shall be chaired by the Chairman of the Board of Directors unless that office is combined with that of Chief Executive Officer.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It shall be chaired by the Chairman of the Board of Directors unless that office is combined with that of Chief Executive Officer.</font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chairman of the Committee may invite some or all Directors who are not members of the Committee to attend meetings at which strategic development priorities and initiatives are discussed with the Chief Executive Officer and senior executives.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Remit of the Strategy Committee</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Committee&#8217;s remit shall be to identify, investigate, propose, support, assess and monitor strategic development priorities and initiatives relating to the Company and its operations. It may address any significant question relating to such matters.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It shall brief the Board of Directors on issues of major strategic interest, such as&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;external growth opportunities&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;divestment opportunities&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;development priorities&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;financial and stock market strategies, and compliance with key financial ratios&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;determining the appropriate level of diversification&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;strategic alliances and major corporate actions outside the Company&#8217;s declared strategy&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;and more generally, any course of action judged essential to the Company&#8217;s future.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_103"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">v.&#160;&#160;&#160;&#160;Scientific Committee</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Composition of the Scientific Committee</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Committee shall have at least three members, appointed by the Board from among the Directors. At least two of those members must be judged by the Appointments, Governance and CSR Committee to have scientific expertise and in-depth knowledge of issued related to R&#38;D. The Committee shall be chaired by an independent Director.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Chairman of the Committee may invite Directors who are not members of the Committee &#8211; and more generally any person he or she sees fit, whether or not employed by the Company &#8211; to attend Committee meetings in order to present a dossier or provide explanations to inform the Committee&#8217;s deliberations.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Remit of the Scientific Committee</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The principal remit of the Committee shall be to assist the Board in setting strategic orientations in the field of Research and Development. It may address any significant question relating to such matters.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">More specifically, the Committee shall be responsible for&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;assisting the Board in scrutinizing strategic orientations, in particular the quality and competitiveness of R&#38;D programs, and investments proposed by the Chief Executive Officer in that area&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;identifying and discussing emerging trends in science and technology, and ensuring that Sanofi is preparing for them as effectively as possible&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;obtaining assurance that processes are in place to enable optimal decision-making on investments in R&#38;D, consistent with the strategy determined by the Board&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;reviewing and evaluating the quality of Sanofi&#8217;s scientific expertise, and advising the Board accordingly.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div id="ifc27f45e4c4947ea9340511bc7cd391f_106"></div><div style="margin-bottom:9pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">VII &#8211; Amendment of the Board Charter</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Charter may be amended by a Board decision approved by a majority of the Directors present or represented at that Board meeting, except that provisions of the Charter that replicate certain provisions of the Articles of Association may only be amended insofar as the corresponding provisions of the Articles of Association have been previously amended by an Extraordinary General Meeting of the Company&#8217;s Shareholders.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">******</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.2
<SEQUENCE>4
<FILENAME>a2023-exhibit22.htm
<DESCRIPTION>EX-2.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="icda261be686147c1bcf1ee4a98b768ea_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 2.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Introduction</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2023, Sanofi (&#8220;Sanofi,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Title of Each Class</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Trading Symbol</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Name of each exchange on which registered</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">American Depositary Shares, each representing one half of one ordinary share, par value &#8364;2 per share</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">SNY</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">NASDAQ Global Select Market</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ordinary shares, par value &#8364;2 per share*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">NASDAQ Global Select Market*</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">____________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not for trading, but only in connection with the registration of American Depositary Shares representing such ordinary shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have one class of shares, which trade on Compartment A of the regulated market of Euronext Paris under the symbol SAN. American Depositary Shares (&#8220;ADSs&#8221;), each representing one-half of one ordinary share, par value &#8364;2 per share of Sanofi, have been available in the United States through an American Depositary Receipt (&#8220;ADR&#8221;) program established pursuant to the Second Amended and Restated Deposit Agreement between Sanofi and JPMorgan Chase Bank, N.A. (&#8220;JPMorgan&#8221;), as amended by Amendment No. 1 dated July 23, 2020 (&#8220;Amendment No. 1&#8221;), Amendment No.2 dated December 18, 2023 (&#34;Amendment No.2&#34;), and as may be further amended from time to time (together, the &#8220;deposit agreement&#8221;). Our ADSs trade on the NASDAQ Global Select Market, or NASDAQ, under the symbol SNY and are evidenced by ADRs, which are issued by JPMorgan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This exhibit contains a description of the rights of (i) the holders of ordinary shares and (ii) ADS holders. Shares underlying the ADSs are held by JPMorgan, the depositary, and holders of ADSs will not be treated as holders of the shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summaries are not intended to be exhaustive and, in the case of our ordinary shares, such summary is subject to, and qualified in its entirety by, Sanofi&#8217;s Articles of Association (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">statuts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), an English translation of which has been filed as an exhibit to Sanofi&#8217;s annual report on Form 20-F for which this exhibit is provided and by French law and in the case of our ADSs, such summary is subject to, and qualified in its entirety by the terms of the deposit agreement. Such summaries do not address all of the provisions of the Articles of Association or French law or of the deposit agreement, and do not purport to be complete. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized terms not otherwise defined in this exhibit have the meanings given to them in Sanofi&#8217;s annual report on Form 20-F for which this exhibit is provided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ORDINARY SHARES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The description below reflects certain terms of our Articles of Association, and summarizes the material rights of holders of our ordinary shares under French law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Share capital </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023, our share capital amounted to &#8364;2,529,599,938, divided into 1,264,799,969&#160;outstanding shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">with a par value of &#8364;2&#160;per share. All of our outstanding shares are of the same class and are fully paid. Of these shares, we or entities controlled by us held&#160;13,450,388 shares (or&#160;1.06% of our outstanding share capital), as treasury shares as of such date. As of December&#160;31, 2023, the carrying amount of such shares was &#8364;1,169&#160;million.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At a combined general meeting held on May&#160;25, 2023, our shareholders authorized our Board of Directors to increase our share capital, through the issuance of shares or other securities giving access to the share capital with or without preemptive rights, by an aggregate maximum nominal amount of &#8364;997&#160;million. See &#8220;&#8212;&#160;Ordinary Shares&#8212;&#160;Change in Capital in 2023 &#8212;&#160;Increases in Share Capital&#8221; below.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The maximum total number of authorized but unissued shares as of December&#160;31, 2023 was 131,106,097, reflecting the unused part of the May&#160;25, 2023 shareholder authorizations to issue shares without preemptive rights, outstanding options to subscribe for shares, and awards of&#160;shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock options </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Types of stock options</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have two types of stock options outstanding&#58; options to subscribe for shares </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(options de souscription d&#8217;actions)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and options to purchase shares </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(options d&#8217;achat d&#8217;actions)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Upon exercise of an option to subscribe for shares, we issue new shares, whereas upon exercise of an option to purchase shares, the option holder receives existing shares. We purchase our shares on the market prior to the vesting of the options to purchase in order to provide the option holder with shares upon&#160;exercise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Because the exercise of options to purchase shares will be satisfied with existing shares repurchased on the market or held in treasury, the exercise of options to purchase shares has no impact on the amount of our share&#160;capital.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Stock option plans </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On April&#160;30, 2019, our combined general meeting had authorized our Board of Directors for a period of 38&#160;months to grant, on one or more occasions, options to subscribe for shares and options to purchase shares in favor of persons to be chosen by the Board of Directors from among the salaried employees and corporate officers of our Company or of companies or groupings of economic interest of the Group in accordance with Article&#160;L.&#160;225-180 of the French Commercial&#160;Code. This authorization has ended on July 30, 2022. The Board of Directors has subsequently decided not to grant any further stock options from 2020 onwards. On December 31, 2023, no stock option plan was in force.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards of shares</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our combined general meeting held on April&#160;30, 2021 authorized our Board of Directors for a period of 38&#160;months to allot, on one or more occasions, existing or new restricted shares in favor of persons to be chosen by the Board of Directors from among the salaried employees and corporate officers of our Company or of companies or economic interest groupings of the Group in accordance with Articles&#160;L.&#160;225-197-1 et seq. of the French Commercial&#160;Code.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The existing or new shares allotted under this authorization may not represent more than 1.5% of our share capital as of the date of the decision by the Board of Directors to allot such&#160;shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The authorization provides that allotment of shares to the allottees will become irrevocable at the end of a minimum vesting period of three years.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the case of newly issued shares, the authorization entails the express waiver by the shareholders, in favor of the allottees of restricted shares, of their preemptive rights in respect of shares that are to be issued as and when restricted shares&#160;vest.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Board of Directors sets the terms on which restricted shares are granted and the arrangements with respect to the dividend entitlement of the&#160;shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See &#8220;Item&#160;6. Directors, Senior Management and Employees &#8212;&#160;E.&#160;Share Ownership&#8221; for a description of our restricted shares plans currently in force.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rights, preferences and restrictions attaching to ordinary shares </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Dividends</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may only distribute dividends out of our &#8220;distributable profits,&#8221; plus any amounts held in our reserves that the shareholders decide to make available for distribution, other than those reserves that are specifically required bylaw or our Articles of Association. &#8220;Distributable profits&#8221; consist of our unconsolidated net profit in each fiscal year, as increased or reduced by any profit or loss carried forward from prior years, less any contributions to the reserve accounts pursuant to law or our Articles of Association.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Legal reserve</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The French Commercial Code requires us to allocate 5% of our unconsolidated net profit for each year to our legal reserve fund before dividends may be paid with respect to that year. Funds must be allocated until the amount in the legal reserve is equal to 10% of the aggregate par value of the issued and outstanding share capital. This restriction on the payment of dividends also applies to each of our French subsidiaries on an unconsolidated basis. At December&#160;31, 2023, our legal reserve amounted to &#8364;282,280,863.45, representing&#160;11.16% of the aggregate par value of our issued and outstanding share capital as of that date. The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">legal reserve of any company subject to this requirement may serve to allocate losses that may not be allocated to other reserves, or may be distributed to shareholders upon liquidation of the&#160;company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Approval of dividends</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">According to the French Commercial Code, our Board of Directors may propose a dividend for approval by shareholders at the annual general shareholders&#8217; meeting. If we have earned distributable profits since the end of the preceding fiscal year, as reflected in an interim income statement certified by our independent auditors, our Board of Directors may distribute interim dividends to the extent of the distributable profits for the period covered by the interim income statement. Our Board of Directors exercises this authority subject to French law and regulations and may do so without obtaining shareholder approval.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Distribution of dividends</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends are distributed to shareholders pro rata according to their respective holdings of shares. In the case of interim dividends, distributions are made to shareholders on the date set by our Board of Directors during the meeting in which the distribution of interim dividends is approved. The actual dividend payment date is decided by the shareholders at an ordinary general shareholders&#8217; meeting or by our Board of Directors in the absence of such a decision by the shareholders. Shareholders that own shares on the actual payment date are entitled to the dividend.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends may be paid in cash or, if the shareholders&#8217; meeting so decides, in kind, provided that all shareholders receive a whole number of assets of the same nature paid in lieu of cash. Our Articles of Association provide that a decision of the shareholders&#8217; meeting taken by ordinary resolution may give each shareholder the option to receive payment of their dividend in cash, in shares, or in kind by delivery of assets including financial securities with or without an option to receive cash. In the case of a dividend payment resulting in the payment of a right that is a fraction of a given unit of measurement, the shareholders&#8217; meeting may decide that the shareholder will not receive any such fraction of a unit and will instead receive the next lowest whole number of such unit plus a cash payment for the balance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Timing of payment</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">According to the French Commercial Code, we must pay any existing dividends within nine months of the end of our fiscal year, unless otherwise authorized by court order. Dividends on shares that are not claimed within five years of the date of declared payment revert to the French State.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Voting rights </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In general, each shareholder is entitled to one vote per share at any shareholders&#8217; general meeting. Our Articles of Association do not provide for cumulative voting rights. However, our Articles of Association provide that any fully paid-up shares that have been held in registered form under the name of the same shareholder for at least two years acquire double voting rights. The double voting rights cease automatically for any share converted into bearer form or transferred from one owner to another, subject to certain exceptions permitted by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2023, there were 158,802,716 shares that were entitled to double voting rights, representing 12,55% of our total share capital, and approximate</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ly 11,26&#160;% of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the voting rights which can be cast at our shareholders&#8217; general meeting as of that date. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Double voting rights are not taken into account in determining whether a quorum exists.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the French Commercial Code, treasury shares or shares held by entities controlled by us are not entitled to voting rights and do not count for quorum purposes.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Articles of Association allow us to obtain from Euroclear France the name, nationality, address and number of shares held by holders of our securities that have, or may in the future have, voting rights. If we have reason to believe that a person on any list provided by Euroclear France holds securities on behalf of another person, our Articles of Association allow us to request information regarding beneficial ownership directly from such person. See &#8220;&#8212; Ordinary Shares &#8212; Form, Holding and Transfer of Shares&#8221;, below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Articles of Association provide that Board members are elected on a rolling basis for a maximum tenure of four years.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Shareholders&#8217; agreement </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are not aware of any shareholder&#8217;s agreement currently in force concerning our&#160;shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liquidation rights</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we are liquidated, any assets remaining after payment of our debts, liquidation expenses and all of our remaining obligations will first be distributed to repay in full the par value of our shares. Any surplus will be distributed pro rata among shareholders in proportion to the par value of their shareholdings.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Sinking fund provisions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Articles of Association do not provide for any sinking fund provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Redemption of shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under French law, our Board of Directors is entitled to redeem a set number of shares as authorized by the extraordinary shareholders&#8217; meeting. In the case of such an authorization, the shares redeemed must be cancelled within one month after the end of the offer to purchase such shares from shareholders. However, shares redeemed on the open market do not need to be cancelled if the company redeeming the shares grants options on or awards those shares to its employees within one year following the acquisition. See also &#8220;&#8212; Trading in Our Own Shares&#8221; below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liability for further capital calls</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders are liable for corporate liabilities only up to the par value of the shares they hold&#59; they are not liable for further capital calls.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Requirements for holdings exceeding certain percentages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The French Commercial Code and the regulations of the French Financial markets authority (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Autorit&#233; des march&#233;s financiers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the &#34;AMF&#34;) provide that any individual or entity, acting alone or in concert with others, that becomes the owner, directly or indirectly, of more than 5%, 10%, 15%, 20%, 25%, 30%, 33 1&#47;3%, 50%, 66 2&#47;3%, 90% or 95% of the outstanding shares or voting rights of a listed company in France, such as our Company, or that increases or decreases its shareholding or voting rights above or below any of those percentages, must notify the company, before the end of the fourth trading day following the date it crosses the threshold, of the number of shares it holds and their voting rights. The individual or entity must also notify the AMF before the end of the fourth trading day following the date it crosses any such threshold. The AMF makes the notice public.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the French Commercial Code and the AMF General Regulation, the participation thresholds shall be calculated on the basis of the shares and voting rights owned, and shall take into account the shares and voting rights which are deemed to be shares and voting rights owned, even if the individual or entity does not itself hold shares or voting rights. In accordance with this deemed ownership principle, the individual or entity must take into account specific situations where shares and voting rights are deemed to be shares and voting rights owned when calculating the number of shares owned to be disclosed in the notifications to the Company and to the AMF. It includes among others situations where an individual or entity is entitled to acquire issued shares at its own initiative, immediately or at the end of a maturity period, under an agreement or a financial instrument, without set-off against the number of shares that this individual or entity is entitled to sell under another agreement or financial instrument. The individual or entity required to make such notification shall also take into account issued shares covered by an agreement or cash-settled financial instrument and having an economic effect for said individual or entity that is equivalent to owning such shares. In the cases of deemed ownership described above, the notification shall mention the type of deemed ownership and include a description of the main characteristics of the financial instrument or agreement with specific details required by the AMF General Regulation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The AMF General Regulation provides that shares and voting rights subject to multiple cases of deemed ownership shall only be counted&#160;once.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">When an individual or entity modifies the allocation between the shares it owns and its financial instruments or agreements deemed to be owned shares, it must disclose that change in a new notification. However, the change must only be disclosed if the acquisition of owned shares due to the settlement of the financial instruments or agreements causes the investor to cross a&#160;threshold.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to certain limited exceptions, French law and AMF regulations impose additional reporting requirements on persons who acquire more than 10%, 15%, 20%, or 25% of the outstanding shares or voting rights of a company listed in France. These persons must file&#160;a report with the company and the AMF before the end of the fifth trading day following the date they cross any such&#160;threshold.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the report, the acquirer will have to specify its intentions for the following six months including&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">whether it acts alone or in concert with others&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the means of financing of the acquisition (the notifying party shall indicate in particular whether the acquisition is being financed with equity or debt, the main features of that debt, and, where applicable, the main guarantees given or received by the notifying party. The notifying party shall also indicate what portion of its holding, if any, it obtained through securities loans)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">whether or not it intends to continue its purchases&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">whether or not it intends to acquire control of the company in question&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the strategy it contemplates vis-&#224;-vis the issuer&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the way it intends to implement its strategy, including&#58; (i)&#160;any plans for a merger, reorganization, liquidation, or partial transfer of a substantial part of the assets of the issuer or of any other entity it controls within the meaning of Article&#160;L.&#160;233-3 of the French Commercial Code, (ii)&#160;any plans to modify the business of the issuer, (iii)&#160;any plans to modify articles of association of the issuer, (iv)&#160;any plans to delist a category of the issuer&#8217;s financial instruments, and (v)&#160;any plans to issue the issuer&#8217;s financial instruments&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any agreement for the temporary transfer of shares or voting rights of the issuer&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the way it intends to settle its agreements or instruments on the shares or voting rights of the issuer mentioned in Article&#160;L.&#160;233-9,&#160;para. 4&#160;and para. 4&#160;bis of the French Commercial Code&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">whether it seeks representation on the Board of Directors.</font></div><div style="padding-left:11.35pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The AMF makes the report public. Upon any change of intention within the six-month period following the filing of the report, it will have to file&#160;a new report for the following six-month period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In order to enable shareholders to give the required notice, we must each month publish on our website and send the AMF a written notice setting forth the total number of our shares and voting rights (including treasury shares) whenever they vary from the figures previously published.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If any shareholder fails to comply with an applicable legal notification requirement, the shares in excess of the relevant threshold will be deprived of voting rights for all shareholders&#8217; meetings until the end of a two-year period following the date on which the owner complies with the notification requirements. In addition, any shareholder who fails to comply with these requirements may have all or part of its voting rights suspended for up to five years by the Commercial Court at the request of our Chairman, any shareholder or the AMF, and may be subject to criminal&#160;fines.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under AMF regulations, and subject to limited exemptions granted by the AMF, any person or entity, acting alone or in concert, that crosses the threshold of 30% of the share capital or voting rights of a French listed company must initiate a public tender offer for the balance of the shares and securities giving access to the share capital or voting rights of such company. Cash-settled derivative instruments or agreements mentioned in Article&#160;L.&#160;233-9, 4&#176;&#160;bis of the French Commercial Code are not included in the calculation of the number of shares related to the mandatory public tender&#160;offer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, our Articles of Association provide that any person or entity, acting alone or in concert with others, who becomes the owner of 1%, or any multiple of 1% of our share capital or our voting rights, even beyond the minimum declaration limits permitted by the legal and regulatory provisions, must notify us by certified mail, return receipt requested, within five trading days, of the total number of shares and securities giving access to our share capital and voting rights that such person then owns. The same provisions of our Articles of Association apply whenever such owner increases or decreases its ownership of our share capital or our voting rights to such extent that it goes above or below one of the thresholds described in the preceding sentence. Any person or entity that fails to comply with such notification requirement will, upon the request of one or more shareholders holding at least 5% of our share capital or of our voting rights made at the general shareholders&#8217; meeting, be deprived of voting rights with respect to the shares in excess of the relevant threshold for all shareholders&#8217; meetings until the end of a two-year period following the date on which such person or entity complies with the notification requirements.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; meetings</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">General</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with the provisions of the French Commercial Code, there are three types of shareholders&#8217; meetings&#58; ordinary, extraordinary and&#160;special.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary general meetings of shareholders are required for matters such as&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">electing, replacing and removing Directors&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">appointing independent auditors&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">approving the annual financial statements&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">declaring dividends or authorizing dividends to be paid in shares, provided the Articles of Association contain a provision to that effect&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">approving share repurchase programs.</font></div><div style="padding-left:11.35pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extraordinary general meetings of shareholders are required for approval of matters such as amendments to our Articles of Association, including any amendment required in connection with extraordinary corporate actions. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extraordinary corporate actions include&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">changing our Company&#8217;s name or corporate purpose&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">increasing or decreasing our share capital&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">creating a new class of equity securities&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">authorizing the issuance of&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:12pt">shares giving access to our share capital or giving the right to receive debt instruments, or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:12pt">other securities giving access to our share capital&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">establishing any other rights to equity securities&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">selling or transferring substantially all of our assets&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the voluntary liquidation of our Company.</font></div><div style="padding-left:11.35pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Special meetings of shareholders of a certain category of shares or shares with certain specific rights (such as shares with double voting rights) are required for any modification of the rights derived from that category of shares. The resolutions of the shareholders&#8217; general meeting affecting these rights are effective only after approval by the relevant special meeting.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Annual ordinary meetings</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The French Commercial Code requires the Board of Directors to convene an annual ordinary general shareholders&#8217; meeting to approve the annual financial statements. This meeting must be held within six months of the end of each fiscal year. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Board of Directors may also convene an ordinary or extraordinary general shareholders&#8217; meeting upon proper notice at any time during the year. If the Board of Directors fails to convene a shareholders&#8217; meeting, our independent auditors may call the meeting. In case of bankruptcy, the liquidator or court-appointed agent may also call a shareholders&#8217; meeting in some instances. In addition, any of the following may request the court to appoint an agent for the purpose of calling a shareholders&#8217; meeting&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">one or several shareholders holding at least 5% of our share capital&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">duly qualified associations of shareholders who have held their shares in registered form for at least two years and who together hold at least 1% of our voting rights&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the works council in cases of urgency&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any interested party in cases of urgency.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under our Articles of Association, the Board of Directors may take decisions by written consultation under the conditions permitted by law and as specified in the Board Charter (an English language version of which is reproduced in full as Exhibit&#160;1.2 to the annual report on Form&#160;20-F for which this exhibit is provided), including the possibility to convene an ordinary or extraordinary general meeting,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notice of shareholders&#8217; meetings</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All prior notice periods provided for below are minimum periods required by French law and cannot be shortened, except in case of a public tender offer for our&#160;shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We must announce general meetings at least thirty-five days in advance by means of a preliminary notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(avis de r&#233;union)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, which is published in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bulletin des Annonces L&#233;gales Obligatoires</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BALO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The preliminary notice must first be sent to the AMF, with an indication of the date on which it will be published in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BALO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. It must be published on our website at least twenty-one days prior to the general meeting. The preliminary notice must contain, among other things, the agenda, a draft of the resolutions to be submitted to the shareholders for consideration at the general meeting and a detailed description of the voting procedures (proxy voting, electronic voting or voting by mail), the procedures permitting shareholders to submit additional resolutions or items to the agenda and to ask written questions to the Board of Directors. The AMF also recommends that, prior to or simultaneously with the publication of the preliminary notice, we publish a summary of the notice indicating the date, time and place of the meeting in a newspaper of national circulation in France and on our&#160;website.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At least fifteen days prior to the date set for a first convening, and at least ten days prior to any second convening, we must send a final notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(avis de convocation)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> containing the final agenda, the date, time and place of the meeting and other information related to the meeting. Such final notice must be sent by mail to all registered shareholders who have held shares in registered form for more than one month prior to the date of the final notice and by registered mail, if shareholders have asked for it and paid the corresponding charges. The final notice must also be published in a newspaper authorized to publish legal announcements in the local administrative department </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(d&#233;partement)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in which our Company is registered as well as in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BALO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, with prior notice having been given to the AMF for informational purposes. Even if there are no proposals for new resolutions or items to be submitted to the shareholders at the meeting, we must publish a final notice in a newspaper authorized to publish legal announcements in the local administrative department </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(d&#233;partement)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in which our Company is registered as well as in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BALO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other issues</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In general, shareholders can only take action at shareholders&#8217; meetings on matters listed on the agenda. As an exception to this rule, shareholders may take action with respect to the appointment and dismissal of directors even if this action has not been included on the&#160;agenda.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional resolutions to be submitted for approval by the shareholders at the shareholders&#8217; meeting may be proposed to the Board of Directors, for recommendation to the shareholders at any time from the publication of the preliminary notice in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BALO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> until twenty-five days prior to the general meeting and in any case no later than twenty days following the publication of the preliminary notice in the&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BALO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;by&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">one or several shareholders together holding a specified percentage of shares&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a duly qualified association of shareholders who have held their shares in registered form for at least two years and who together hold at least 1% of our voting rights&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the works council.</font></div><div style="padding-left:11.35pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within the same period, the shareholders may also propose additional items (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">points</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) to be submitted and discussed during the shareholders&#8217; meeting, without a shareholders&#8217; vote. The shareholders must substantiate the reasons for their proposals of additional items.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The resolutions and the list of items added to the agenda of the shareholders&#8217; meeting must be promptly published on our&#160;website.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Board of Directors must submit the resolutions to a vote of the shareholders after having made a recommendation thereon. The Board of Directors may also comment on the items that are submitted to the shareholders&#8217; meeting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Following the date on which documents must be made available to the shareholders (including documents to be submitted to the shareholders&#8217; meeting and resolutions proposed by the Board of Directors, which must be published on our website at least twenty-one days prior to the general meeting), shareholders may submit written questions to the Board of Directors relating to the agenda for the meeting until the fourth business day prior to the general meeting. The Board of Directors must respond to these questions during the meeting or may refer to a Q&#38;A section located on our website in which the question submitted by a shareholder has already been&#160;answered.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Attendance at shareholders&#8217; meetings&#59; proxies and votes by mail</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In general, all shareholders may participate in general meetings either in person or by proxy. Shareholders may vote in person, by proxy or by&#160;mail.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The right of shareholders to participate in general meetings is subject to the recording </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(inscription en compte)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of their shares on the second business day, 12&#58;00&#160;a.m. (Paris time), preceding the general meeting&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">for holders of registered shares&#58; in the registered shareholder account held by the Company or on its behalf by an agent appointed by&#160;it&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">for holders of bearer shares&#58; in the bearer shareholder account held by the accredited financial intermediary with whom such holders have deposited their shares&#59; such financial intermediaries shall deliver to holders of bearer shares a shareholding certificate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(attestation de participation)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> enabling them to participate in the general meeting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Attendance in person</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any shareholder may attend ordinary general meetings and extraordinary general meetings and exercise its voting rights subject to the conditions specified in the French Commercial Code, the French Civil Code and our Articles of&#160;Association.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">An attendance sheet and written minutes are established for each shareholders' meeting&#59; failure to do so could lead to cancellation of the decisions at the shareholders' meeting.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Proxies and votes by mail</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proxies are sent to any shareholder upon a request received between the publication of the final notice of meeting and six days before the general meeting and must be made available on our website at least twenty-one days before the general meeting. In order to be counted, such proxies must be received at our registered office, or at any other address indicated on the notice of the meeting or by any electronic mail indicated on the notice of the meeting, prior to the date of the meeting (in&#160;practice, we request that shareholders return proxies at least three business days prior to the meeting&#59; electronic proxies must be returned before 3&#160;p.m. Paris time, on the day prior to the general meeting). A shareholder may grant proxies to any natural person or legal entity. The agent may be required to disclose certain information to the shareholder or to the&#160;public.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A proxy is only valid for one meeting (or by way of exception for two meetings, one being ordinary and the other extraordinary, held on the same day or within a single 15-day period)&#59; it remains valid in the event such meeting is convened multiple times for the same agenda, and may be revoked by written statement of the shareholder granting the proxy.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alternatively, the shareholder may send us a blank proxy without nominating any representative. In this case, the chairman of the meeting will vote the blank proxies in favor of all resolutions proposed or approved by the Board of Directors and against all&#160;others.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With respect to votes by mail, we must send shareholders a voting form upon request or must make available a voting form on our website at least twenty-one days before the general meeting. The completed form must be returned to us at least three days prior to the date of the shareholders&#8217; meeting. For holders of registered shares, in addition to traditional voting by mail, instructions may also be given via the&#160;internet.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quorum</font></div><div><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The French Commercial Code requires that shareholders holding in the aggregate at least 20% of the shares entitled to vote must be present in person, or vote by mail or by proxy, in order to fulfill the quorum requirement&#160;for&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">an ordinary general meeting&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">an extraordinary general meeting where the only resolutions pertain to either (a)&#160;a proposed increase in our share capital through incorporation of reserves, profits or share premium, or (b)&#160;the potential issuance of free share warrants in the event of a public tender offer for our shares (Article&#160;L.&#160;233-32 of the French Commercial Code).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For any other extraordinary general meeting the quorum requirement is at least 25% of the shares entitled to vote, held by shareholders present in person, voting by mail or by&#160;proxy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For a special meeting of holders of a certain category of shares, the quorum requirement is one third of the shares entitled to vote in that category, held by shareholders present in person, voting by mail or by&#160;proxy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If a quorum is not present at a meeting, the meeting is adjourned. However, only questions that were on the agenda of the adjourned meeting may be discussed and voted upon once the meeting resumes.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">When an adjourned meeting is resumed, there is no quorum requirement for meetings cited in the first paragraph of this &#8220;Quorum&#8221; section. In the case of any other reconvened extraordinary general meeting or special meeting, the quorum requirement is 20% of the shares entitled to vote (or&#160;voting shares belonging to the relevant category for special meetings of holders of shares of such specific category), held by shareholders present in person or voting by mail or by proxy. If a quorum is not met, the reconvened meeting may be adjourned for a maximum of two months with the same quorum requirement. No deliberation or action by the shareholders may take place without a&#160;quorum.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Votes required for shareholder action</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The affirmative vote of a simple majority of the votes cast may pass a resolution at either an ordinary general meeting or an extraordinary general meeting where the only resolution(s) pertain(s) to either (a)&#160;a proposed increase in our share capital through incorporation of reserves, profits or share premium, or (b)&#160;the potential issuance of free share warrants in the event of a public tender offer for our shares (Article&#160;L.&#160;233-32 of the French Commercial Code). At any other extraordinary general shareholders&#8217; meeting and at any special meeting of holders of a specific category of shares, the affirmative vote of two-thirds of the votes cast by those present or those represented by proxy or voting by mail is&#160;required.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abstention from voting, blank votes and null votes by those present or those represented by proxy or voting by mail are not counted as votes cast, i.e. they are not counted as votes against the resolution submitted to a shareholder vote at any of the three types of meetings.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes to shareholders&#8217; rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under French law, the affirmative vote of two-thirds of the votes cast at an extraordinary shareholders&#8217; meeting is required to change our Articles of Association, which set out the rights attached to our shares, except for capital increases through incorporation of reserves, profits or share premium, or through the issuance of free share warrants in the event of a public tender offer for our shares (Article L. 233-32 of the French Commercial Code).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The rights of a class of shareholders can be amended only after a special meeting of the class of shareholders affected has taken place. The voting requirements applicable to this type of special meeting are the same as those applicable to an extraordinary general shareholders&#8217; meeting. The quorum requirements for a special meeting are one-third of the voting shares, or 20% upon resumption of an adjourned meeting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A unanimous shareholders&#8217; vote is required to increase the liabilities of shareholders.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial statements and other communications with shareholders</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In connection with any shareholders&#8217; meeting, we must provide a set of documents which includes our annual&#160;report on Form 20-F for which this exhibit is provided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We must also provide on our website at least twenty-one days before a shareholders&#8217; meeting certain information and a set of documents that includes the preliminary notice, the proxies and voting forms, the resolutions proposed by the Board of Directors, and the documents to be submitted to the shareholders&#8217; meeting pursuant to Articles&#160;L.&#160;225-115 and R.&#160;225-83 of the French Commercial Code, etc. The resolutions and the list of items added to the agenda of the shareholders&#8217; meeting must be promptly published on our&#160;website.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading in our own shares</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under French law, Sanofi may not issue shares to itself. However, we may, either directly or through a financial intermediary acting on our behalf, acquire up to 10% of our issued share capital within a maximum period of 18&#160;months, provided our shares are listed on a regulated market. Prior to acquiring our shares, we must publish a description of the share repurchase program </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(descriptif du programme de rachat d&#8217;actions)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may not cancel more than 10% of our issued share capital over any 24-month period. Our repurchase of shares must not result in our Company holding, directly or through a person acting on our behalf, more than 10% of our issued share capital. We must hold any shares that we repurchase in registered form. These shares must be fully paid up. Shares repurchased by us continue to be deemed &#8220;issued&#8221; under French law but are not entitled to dividends or voting rights so long as we hold them directly or indirectly, and we may not exercise the preemptive rights attached to&#160;them.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The shareholders, at an extraordinary general shareholders meeting, may decide not to take these shares into account in determining the preemptive rights attached to the other shares. However, if the shareholders decide to take them into account, we must either sell the rights attached to the shares we hold on the market before the end of the subscription period or distribute them to the other shareholders on a pro&#160;rata&#160;basis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On May 25, 2023, our shareholders approved a resolution authorizing us to repurchase up to 10% of our shares over an 18-month period. Under this authorization, the purchase price for each Sanofi ordinary share may not be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">greater than &#8364;150.00 and the maximum amount that Sanofi may pay for the repurchases is &#8364;18,971,999,535. This authorization cancelled and replaced the authorization granted to the Board of Directors by the combined general meeting held on May 3, 2022. A description of this share repurchase program as adopted by the ordinary general meeting held on May 25, 2023 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(descriptif du programme de rachat d&#8217;actions)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> was published on February 23, 2024. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purposes of share repurchase programs</font></div><div><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Regulation&#160;596&#47;2014 of the European Parliament and of the Counsel, dated April&#160;16, 2014 on market abuse and its Delegated Regulation 2016&#47;1052 on repurchase programs and stabilization measures, dated March&#160;8, 2016 (which we refer to in this section as the &#8220;Regulation&#8221;), an issuer will benefit from a safe harbor for share transactions that comply with certain conditions relating in particular to the pricing, volume and timing of transactions (see&#160;below) and that are made in connection with a share repurchase program authorized by the shareholders the purpose of which&#160;is&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">to reduce the share capital through the cancellation of treasury shares&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">to meet obligations arising from debt financial instruments that are exchangeable into equity instruments&#59; and&#47;or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">to meet obligations arising from share option programs or other allocations of shares to employees or to members of the administrative, management or supervisory bodies of the issuer or of an associate company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safe harbor transactions will by definition not be considered market abuses under the Regulation. Transactions that are carried out for other purposes than those mentioned above do not qualify for the safe harbor.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">However, as permitted by the Regulation, which provides for a presumption of legitimacy for existing market practices that do not constitute market manipulation and that conform with certain criteria, the AMF has established as a French accepted market practice, which therefore benefits from a presumption of legitimacy, the use of liquidity agreements for share purchases that are entered into with a financial services intermediary and that comply with the criteria set out by the AMF.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The AMF confirmed that all transactions directed at maintaining the liquidity of an issuer&#8217;s shares must be conducted pursuant to a liquidity agreement with a financial services intermediary acting independently.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of July&#160;3, 2016, the purchase of shares that are subsequently used as acquisition currency in a business combination transaction, which the AMF previously permitted as an accepted market practice, is no longer considered as such, although such practice, while not benefiting from the presumption of legitimacy, is not prohibited under the Regulation.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pricing, volume and other restrictions</font></div><div><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In order to qualify for the safe harbor described above, the issuer must generally comply with the following pricing and volume restrictions&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">a share purchase must not be made at a price higher than the higher of the price of the last independent trade and the highest current independent bid on the trading venues where the purchase is carried out&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">subject to certain exceptions for illiquid securities, the issuer must not purchase on any trading day more than 25% of the average daily volume of the shares on the regulated market on which the purchase is carried out. The average daily volume figure must be based on the average daily volume traded in the month preceding the month of public disclosure of the share repurchase program and fixed on that basis for the authorized period of that program. If the program does not make reference to this volume, the average daily volume figure must be based on the average daily volume traded in the 20&#160;trading days preceding the date of purchase.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, unless the issuer has in place a time-scheduled repurchase program or the repurchase program is lead-managed by an investment firm or a credit institution which makes its trading decisions concerning the timing of the purchase of the issuer&#8217;s shares independently of the issuer, the issuer must not, for the duration of the repurchase program, engage in the following activities&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">selling its own shares&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">effecting any transaction during a closed period imposed by the applicable law of the Member State in which the transaction occurs (i.e.&#160;under French law, during the period between the date on which the company has knowledge of insider information and the date on which such information is made public, during the 30&#160;calendar day period before the announcement of an interim financial report or a year-end report which the issuer is obliged to make public, and during the 15&#160;calendar day period before the publication of the quarterly results)&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">effecting any transaction in securities with respect to which the issuer has decided to delay the public disclosure of inside information, in accordance with applicable rules.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Use of share repurchase programs</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the AMF rules, issuers must immediately allocate the repurchased shares to one of the purposes provided for in the Regulation and must not subsequently use the shares for a different purpose. As an exception to the foregoing, shares repurchased with a view to covering stock option plans may, if no longer needed for this purpose, be re-allocated for cancellation or sold in compliance with AMF requirements relating in particular to blackout periods. Shares repurchased in connection with one of the market practices authorized by the AMF (see&#160;above) may also be re-allocated to one of the purposes contemplated by the Regulation or sold in compliance with AMF requirements. Shares repurchased with a view to their cancellation must be cancelled within 24&#160;months following their acquisition.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During the year ended December&#160;31, 2023, we used the authority delegated by our shareholders to repurchase our shares on the stock&#160;market.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to our share repurchase programs authorized by our shareholders on May 3, 2022 and on May 25, 2023, we repurchased 6,584,744&#160;of our shares for a weighted average price of &#8364;89.86, i.e. a total cost of &#8364;592&#160;million. Brokerage fees, financial transaction taxes and the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMF contribution (net of income taxes) amounted to &#8364;1.40&#160;million. Our Company did not resort to derivatives to repurchase our own shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During 2023, we did not cancel any shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During 2023, we did not use a liquidity contract.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During 2023, we did not allocate any shares to stock purchase option plans. </font></div><div style="padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In 2023, in addition to the 8,195,266 shares allocated to performance share plans outstanding at December&#160;31, 2023, Sanofi&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">purchased 4,000,204 of its shares at an average weighted price of &#8364;90.60 for a total amount of &#8364;362,438,477&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">transferred 1,329,622&#160; of its shares to beneficiaries of performance shares at an average weighted price of &#8364;86.49 for a total amount of &#8364;114,996,866&#160;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023, the 10,865,848&#160;treasury shares held under our share repurchase program were allocated to covering performance share plans.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023, all the shares created under the Action 2023 employee share ownership plan were allocated to employees.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In 2023, Sanofi purchased </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584,540</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;shares at an average weighted price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;88.69 </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">for a total amount of &#8364;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,235,418</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, which were allocated to a cancellation objective.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, no shares were held to cover stock option plans or for liquidity purposes.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2023, we directly owned 13,450,388 Sanofi shares with a par value of &#8364;2&#160;representing around 1.06 % of our share capital and with an estimated value of &#8364;1,169&#160;million, based on the share price at the time of&#160;purchase. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reporting obligations</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the Regulation, the AMF Regulation and the French Commercial Code, issuers trading in their own shares are subject to the following reporting obligations&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">issuers must report all transactions in their own shares to the competent authority of each trading venue on which the shares are admitted to trading or are traded within seven trading days of the transaction in a prescribed format, unless such transactions are carried out pursuant to a liquidity agreement that complies with the ethical code approved by the AMF&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">issuers must declare to the AMF on a monthly basis all transactions completed under the share repurchase program unless they provide the same information on a weekly basis&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">post on its website the transactions disclosed and keep that information available to the public for at least a 5-year period from the date of public disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ownership of shares by non-French persons</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The French Commercial Code and our Articles of Association currently do not limit the right of non-residents of France or non-French persons to own or, where applicable, to vote our securities. However, pursuant to Articles L.151-1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. and R. 151-1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  of the French Monetary and Financial Code (CMF), as amended by the decree (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">d&#233;cret</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) No. 2023-1293 dated December 28, 2023 and the order (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">arr&#234;t&#233;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) dated December 28, 2023 pursuant to the French foreign investment regime, any investment by any non-French citizen, any French citizen not residing in France, any non-French entity or any French entity controlled by such persons or entities that will result in the relevant investor (a) acquiring control of an entity incorporated under French law or an establishment registered in France, (b) acquiring all or part of a business line of an entity registered in France, or (c) for non-EU or non-EEA investors crossing, directly or indirectly, alone or in concert, a 25% threshold of voting rights in an entity registered in France,or for non-EU or non-EEA investors crossing, directly or indirectly, alone or in concert, the threshold of 10% of the voting rights of a company incorporated under French law whose shares are admitted to trading on a regulated market,  in each case, where all or part of the target&#8217;s business and activity relate to a strategic sector, is subject to the prior authorization of the French Minister of the Economy. Under existing administrative rulings, ownership of 33 1&#47;3% or more of our share capital or voting rights is regarded as a controlling interest, but a lower percentage might be held to be a controlling interest in certain circumstances depending upon factors such as&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the acquiring party&#8217;s intentions&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the acquiring party&#8217;s ability to elect directors&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">financial reliance by the company on the acquiring party.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Such strategic sectors include (a)&#160;activities likely to prejudice national defense interests, participating in the exercise of official authority or likely to prejudice public order and public security (including activities related to weapons, dual-use goods and technologies, IT systems, cryptology, data capturing devices, gambling, toxic agents or data storage), (b)&#160;activities relating to essential infrastructure, goods or services (including energy, water, transportation, space, public health, telecommunications, farm products or media), (c)&#160;research and development activities related to critical technologies (including biotechnology, cybersecurity, artificial intelligence, robotics, additive manufacturing, semiconductors, quantum technologies, energy storage, technologies involved in low-carbon energy production or photonics and technologies related to generation of renewable energy) or dual-use goods and technologies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This request for prior authorization must be filed with the French Minister of the Economy, which has 30&#160;business days from receipt of the complete file to provide a first decision which may (i)&#160;indicate that the investment is not covered by the activities subject to the prior authorization of the French Minister of the Economy, (ii) unconditionally authorize the investment or (iii)&#160;indicate that further examination is required. In the latter case, the French Minister of the Economy must make a second decision within 45&#160;business days from its first decision. In the event of a lack of response from the French Minister of the Economy within the above mentioned timeframe, the authorization will be deemed refused. If the authorization is granted, it may be subject to the signature of a letter of undertakings aimed at protecting French national interests. If an investment requiring the prior authorization of the French Minister of the Economy is completed without such authorization having been granted, the French Minister of the Economy might direct the relevant investor to (i)&#160;submit a request for authorization, (ii)&#160;have the previous situation restored at its own expense, or (iii)&#160;amend the investment. The relevant investor might also be found criminally liable and might be sanctioned with a fine </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">which cannot exceed the greater of&#58; (i)&#160;twice the amount of the relevant investment, (ii)&#160;10% of the annual turnover before tax of the target company and (iii)&#160;&#8364;5&#160;million (for a company) or &#8364;1&#160;million (for an individual).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A &#8220;fast track&#8221; procedure is available for investors whose holdings exceed the 10% threshold but are less than the 25% threshold mentioned above. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The CMF provides for statistical reporting requirements. Transactions by which non-French residents acquire at least 10% of the share capital or voting rights, or cross the 10% threshold, of a French resident company, are considered as foreign direct investments in France and are subject to statistical reporting requirements (Articles&#160;R.&#160;152-1&#59; R.&#160;152-3 and&#160;R.&#160;152-11 of the CMF). When the investment exceeds&#160;&#8364;125,500,000, companies must declare foreign transactions directly to the Banque de France within 20&#160;business days following the date of certain direct foreign investments in us, including any purchase of ADSs. Failure to comply with such statistical reporting requirement may be sanctioned by five years&#8217; imprisonment and a fine of a maximum amount equal to twice the amount which should have been reported, in accordance with Article&#160;L.&#160;165-1 of the CMF. This amount may be increased fivefold if the violation is made by a legal entity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in control &#47; Anti-takeover</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There are no provisions in our Articles of Association that would have the effect of delaying, deferring or preventing a change in control of our Company or that would operate only with respect to a merger, acquisition or corporate restructuring involving our Company or any of our subsidiaries. Further, there are no provisions in our Articles of Association that allow the issuance of preferred stock upon the occurrence of a takeover attempt or the addition of other &#8220;anti-takeover&#8221; measures without a shareholder vote.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Articles of Association do not include any provisions discriminating against any existing or prospective holder of our securities as a result of such shareholder owning a substantial number of shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See above additional information in relation to foreign direct investments under &#8220;&#8212; Ownership of Shares by Non-French Persons&#8221;. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in capital in 2023</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See Note&#160;D.15.1. to&#160;our consolidated financial statements, included at Item&#160;18. of the annual&#160;report on Form 20-F for which this exhibit is provided.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Increases in share capital</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As provided for by the French Commercial Code, our share capital may be increased only with shareholders&#8217; approval at an extraordinary general shareholders&#8217; meeting following the recommendation of our Board of Directors. The shareholders may delegate to our Board of Directors either the authority (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">d&#233;l&#233;gation de comp&#233;tence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) or the power (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">d&#233;l&#233;gation de pouvoir</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) to carry out any increase in share capital. Our Board of Directors may further delegate this power to our Chief Executive Officer or, subject to our Chief Executive Officer&#8217;s approval, to his delegates (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">directeurs g&#233;n&#233;raux d&#233;l&#233;gu&#233;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in our share capital may be effected by&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">issuing additional shares&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">increasing the par value of existing shares&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">creating a new class of equity securities&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">exercising the rights attached to securities giving access to the share capital.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in share capital by issuing additional securities may be effected through one or a combination of the following&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in consideration for cash&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in consideration for assets contributed in kind&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">through an exchange offer&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">by conversion of previously issued debt instruments&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">by capitalization of profits, reserves or share premium&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">subject to various conditions, in satisfaction of debt incurred by our Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decisions to increase the share capital through the capitalization of reserves, profits and&#47;or share premium or through the issuance of free share warrants in the event of a public tender offer for our shares (Article L. 233-32 of the French Commercial Code) require shareholders&#8217; approval at an extraordinary general shareholders&#8217; meeting, acting under the quorum and majority requirements applicable to ordinary shareholders&#8217; meetings. Increases effected by an increase in the par value of shares require unanimous approval of the shareholders, unless effected by capitalization of reserves, profits or share premium. All other capital increases require shareholders&#8217; approval at an extraordinary general shareholders&#8217; meeting acting under the regular quorum and majority requirements for such meetings. See &#8220;&#8212; Quorum&#8221; and &#8220;&#8212; Votes Required for Shareholder Action&#8221; above.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On May 25, 2023, our shareholders approved various resolutions delegating to the Board of Directors the authority to increase our share capital through the issuance of shares or securities giving access to the share capital, subject to an overall cap set at &#8364;997 million. This cap applies to all the resolutions whereby the extraordinary shareholders&#8217; meeting delegated to the Board of Directors the authority to increase the share capital, it being also specified that&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the maximum aggregate par value of capital increases that may be carried out with preemptive rights maintained was set at &#8364;997 million&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the maximum aggregate par value of capital increases that may be carried out by public offering (other than of the type specified in Article L. 411-2, 1&#176; of the French Monetary and Financial Code) without preemptive rights was set at &#8364;240 million&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the maximum aggregate par value of capital increases that may be carried out in connection with an offering of the type specified in Article L. 411-2, 1&#176; of the French Monetary and Financial Code (i.e. an offer addressed exclusively to a limited number of investors) without preemptive rights was set at &#8364;240 million&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">capital increases resulting in the issuance of securities to members of employee savings plans are limited to 1% of the share capital as computed on the date of the Board of Directors&#8217; decision to issue such securities, and such issuances may be made at a discount of 30% (or 40%) if certain French law restrictions on resales were to apply, i.e. a lock up period of five years (or 10 years).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2023, the shares held by the current employees from the affiliated companies in the Group savings programs represented 1,09% of the share capital.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At its February 2023 meeting, our Board of Directors decided to delegate to the Chief Executive Officer the powers necessary to carry out a capital increase reserved for members of the Group savings program. Every employee subscribing for at least five shares received one additional new share as an employer&#8217;s top-up contribution. Beyond the first twenty shares there was no entitlement to any further shares by way of employer&#8217;s top-up contribution (every employee subscribing for twenty shares received four additional shares as an employer&#8217;s top-up contribution). The subscription period was open during June 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During the subscription period, 33,132 employees from nearly 56 countries subscribed for a total of 2,009,306 shares. Of these,1,174,533 shares were subscribed via FCPE Actions Sanofi, the dedicated employee share ownership fund for employees of our French subsidiaries&#59; 390,165 shares via FCPE Sanofi Shares, the dedicated employee share ownership fund for employees of our foreign subsidiaries&#59; and 444,608 shares directly by employees who were eligible for the employee share ownership plan but were in countries where local regulations did not allow the use of a dedicated employee share ownership fund.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A total of 119,417 shares were issued by way of employer&#8217;s top-up contribution. Of these, 60,263 were issued to FCPE Actions Sanofi&#59; 27,814 to FCPE Sanofi Shares&#59; and  31340 directly to employees who were eligible for the employee share ownership plan but were in countries where local regulations did not allow the use of a dedicated employee share ownership fund.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Voting rights attached to shares held by FCPE Actions Sanofi are exercised individually by the employees who hold units in the fund&#59; fractional rights are exercised by the fund&#8217;s supervisory board.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Voting rights attached to shares held by FCPE Sanofi Shares are also exercised individually by the employees who hold units in the fund&#59; any rights not exercised by them are exercised by the fund&#8217;s supervisory board.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In each case, the supervisory board includes an equal number of representatives of employees and of Sanofi management.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On April 30, 2021, our shareholders also approved resolutions delegating to the Board of Directors the authority to increase the share capital by granting existing or new restricted shares to our employees and&#47;or corporate officers, subject to the overall cap mentioned above and under the following terms and conditions&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the authorization is valid for a period of 38 months, and is subject to a limit of 1.5% of the share capital as computed on the date of the decision of the Board of Directors to allot such shares&#59; see &#8220;&#8212; Awards of Shares&#8221; above.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:0.36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On May 25 and December 13, 2023, the Board of Directors used the above-mentioned authorization to grant 3,903,563 shares to 8,349 beneficiaries (including the Chief Executive Officer). At the grant date, this represents approximately 0.3% of the share capital on a non-fully diluted basis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Since June 30, 2022 i.e., the expiration of the prior delegation of power that had been authorized by the shareholders, the Board of Directors no longer has the authority to increase the Company&#8217;s share capital by granting options to our employees or corporate officers.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See also &#8220;Item 6. Directors, Senior Management and Employees &#8212; E. Share Ownership&#34;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Decreases in share capital</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with the provisions of the French Commercial Code, any decrease in our share capital requires approval by the shareholders entitled to vote at an extraordinary general meeting. The share capital may be reduced either by decreasing the par value of the outstanding shares or by reducing the number of outstanding shares. The number of outstanding shares may be reduced either by an exchange of shares or by the repurchase and cancellation of shares. Holders of each class of shares must be treated equally unless each affected shareholder agrees otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, specific rules exist to permit the cancellation of treasury shares, by which the shareholders&#8217; meeting may authorize the cancellation of up to a maximum of 10% of a company&#8217;s share capital within any 24-month period. On April 30, 2021, our shareholders delegated to our Board of Directors for 26 months (i.e. until June 30, 2023) the right to reduce our share capital by cancelling our own shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During 2023, we did not cancel any shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preemptive rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">According to the French Commercial Code, if we issue additional securities to be paid in cash, current shareholders will have preemptive rights to these securities on a pro&#160;rata basis. These preemptive rights require us to give priority treatment to current shareholders. The rights entitle the individual or entity that holds them to subscribe to the issuance of any securities that may increase the share capital of our Company by means of a cash payment or a set-off of cash debts. Preemptive rights are transferable during the subscription period relating to a particular offering. These rights may also be listed on Euronext Paris.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preemptive rights with respect to any particular offering may be waived by the affirmative vote of shareholders holding two-thirds of the shares entitled to vote at an extraordinary general meeting. Our Board of Directors and our independent auditors are required by French law to present reports that specifically address any proposal to waive preemptive rights. In the event of a waiver, the issuance of securities must be completed within the period prescribed by law. Shareholders may also notify us that they wish to waive their own preemptive rights with respect to any particular offering if they so&#160;choose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The shareholders may decide at extraordinary general meetings to give the existing shareholders a non-transferable priority right to subscribe to the new securities, for a limited period of time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event of a capital increase without preemptive rights to existing shareholders, French law requires that (i)&#160;the capital increase be made at a price determined by an extraordinary general meeting after submission of a report by the Board of Directors and (ii)&#160;the amount of a capital increase carried out each year in connection with an offering of the type specified in Article&#160;L.&#160;411-2-1 of the French Monetary and Financial Code must be limited to 20% of a company&#8217;s share capital.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form, holding and transfer of shares</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Form of shares</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Articles of Association provide that the shares may be held in either bearer form or registered form at the option of the&#160;holder.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Holding of shares</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with French law relating to the dematerialization of securities, shareholders&#8217; ownership rights are represented by book entries instead of share certificates. We maintain a share account with Euroclear France (a&#160;French clearing system, which holds securities for its participants) for all shares in registered form, which is administered by Uptevia. In addition, we maintain separate accounts in the name of each shareholder either directly or, at a shareholder&#8217;s request, through the shareholder&#8217;s accredited intermediary. Each shareholder account shows the name of the holder and the number of shares held. Uptevia issues confirmations </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(attestations d&#8217;inscription en compte)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> to each registered shareholder as to shares registered in the shareholder&#8217;s account, but these confirmations are not documents of&#160;title.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of a listed company may also be issued in bearer form. Shares held in bearer form are held and registered on the shareholder&#8217;s behalf in an account maintained by an accredited financial intermediary and are credited to an account at Euroclear France maintained by such intermediary. Each accredited financial intermediary maintains a record of shares held through it and provides the account holder with a securities account statement. Transfers of shares held in bearer form may only be made through accredited financial intermediaries and Euroclear France.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares held by persons who are not domiciled in France may be registered in the name of intermediaries who act on behalf of one or more investors. When shares are so held, we are entitled to request from such intermediaries the names of the investors. Also, we may request any legal entity </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(personne morale)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> which holds more than 2.5% of our shares or voting rights to disclose the name of any person who owns, directly or indirectly, more than one-third of its share capital or of its voting rights. A person not providing the complete requested </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">information in time, or who provides incomplete or false information, will be deprived of its voting rights at shareholders&#8217; meetings and will have its payment of dividends withheld until it has provided the requested information in strict compliance with French law. If such person acted willfully, the person may be deprived by a French court of either its voting rights or its dividends or both for a period of up to five&#160;years.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Transfer of shares</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Articles of Association do not contain any restrictions relating to the transfer of&#160;shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered shares must be converted into bearer form before being transferred on the Euronext Paris on the shareholders&#8217; behalf and, accordingly, must be registered in an account maintained by an accredited financial intermediary on the shareholders&#8217; behalf. A shareholder may initiate a transfer by giving instructions to the relevant accredited financial intermediary.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A fee or commission is payable to the broker involved in the transaction, regardless of whether the transaction occurs within or outside France. Registration duty is currently payable in France if a written deed of sale and purchase (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">acte</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) is executed in France or outside France with respect to the shares of the&#160;Company.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Enforceability of civil liabilities</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are a limited liability company (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">soci&#233;t&#233; anonyme</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) organized under the laws of France, and most of our officers and directors reside outside the United&#160;States. In addition, a substantial portion of our assets is located outside of the United States.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a result, it may be difficult for investors&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">to obtain jurisdiction over us or our non-US resident officers and directors in US&#160;courts, or obtain evidence in France or from French citizen or any individual being resident in France or any officer, representative, agent or employee of a legal person having its registered office or an establishment in a territory of France, in connection with those actions in actions predicated on the civil liability provisions of the US&#160;federal securities laws&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">to enforce in US courts judgments obtained in such actions against us or our non-US resident officers and directors&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">to bring an original action in a French court to enforce liabilities based upon the US federal securities laws against us or our non-US resident officers or directors&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">to enforce in US courts against us or our directors in non-US courts, including French courts, judgments of US&#160;courts predicated upon the civil liability provisions of the US&#160;federal securities laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevertheless, a final judgment for the payment of money rendered by any federal or state court in the United&#160;States based on civil liability, whether or not predicated solely upon the US&#160;federal securities laws, would be recognized and enforced in France provided that a French judge considers that this judgment meets the French legal requirement concerning the recognition and the enforcement of foreign judgments and is capable of being immediately enforced in the United States. A French court is therefore likely to grant the enforcement of a foreign judgment without a review of the merits of the underlying claim, only if (1)&#160;that judgment was rendered by a court having jurisdiction over the matter as the dispute is clearly connected to the jurisdiction of such court, the choice of the US court was not fraudulent and the French courts did not have exclusive jurisdiction over the matter, (2)&#160;the judgment does not contravene international public policy rules, both pertaining to the merits and to the procedure of the case, including the defense rights, (3)&#160;the judgment is not tainted with fraud and (4)&#160;the judgment does not conflict with a French or foreign judgment (or an arbitral award) which has become effective in France.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, French law guarantees full compensation for the harm suffered but is limited to the actual damages, so the victim does not suffer or benefit from the situation, it being specified that under French law, the principle of awarding punitive damages is not, per se, contrary to public order, provided the amount awarded is not disproportionate to the harm suffered and the defendant&#8217;s breach.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a result, the enforcement, by US investors, of any judgments obtained in US courts in civil and commercial matters, including judgments under the US federal securities law against us or members of our Board of Directors, officers or certain experts named herein who are residents of France or countries other than the United States would be subject to the above conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, there may be doubt as to whether a French court would impose civil liability on us, the members of our Board of Directors, our officers or certain experts named herein in an original action predicated solely upon the US federal securities laws brought in a court of competent jurisdiction in France against us or such members, officers or experts, respectively.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The description below reflects certain terms of the deposit agreement, and summarizes the material rights of the holders of our ADSs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JPMorgan, as depositary, issues Sanofi ADSs in certificated form (evidenced by an ADR) or book-entry form. Each ADR is a certificate evidencing a specific number of Sanofi ADSs. Each Sanofi ADS represents one-half of one Sanofi ordinary share (or&#160;the right to receive one-half of one Sanofi ordinary share) deposited with the Paris, France office of BNP Paribas, as custodian. Each Sanofi ADS also represents an interest in any other securities, cash or other property that may be held by the depositary under Second Amended and Restated Deposit Agreement between Sanofi and JPMorgan dated February 13, 2015, as most recently amended by Amendment No. 2 dated December 18, 2023 (&#8220;Amendment No. 2&#8221;), and as may be further amended from time to time (together, the &#8220;deposit agreement&#8221;). The depositary&#8217;s principal executive office is located at 383&#160;Madison Avenue, 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Floor, New&#160;York, New&#160;York&#160;10179. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A holder may hold Sanofi ADSs either directly or indirectly through his or her broker or other financial institution. The following description assumes holders hold their Sanofi ADSs directly, in certificated form evidenced by ADRs. Holders who hold the Sanofi ADSs indirectly must rely on the procedures of their broker or other financial institution to assert the rights of ADR holders described in this section. Holders should consult with their broker or financial institution to find out what those procedures are.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders of Sanofi ADSs do not have the same rights as holders of Sanofi shares. French law governs shareholder rights. The rights of holders of Sanofi ADSs are set forth in the deposit agreement and in the ADR. New York law governs the deposit agreement and the ADRs. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following is a summary of certain terms of the deposit agreement, as in effect at the date of filing of this document. Our form of second amended and restated deposit agreement was filed with the SEC as an exhibit to our Post-Effective Amendment No. 1 to Form F-6 filed on February 13, 2015. The form of Amendment No. 2 was filed as an exhibit to our Post-Effective Amendment No. 3 to Form F-6 filed with the SEC on December 18, 2023. To the extent any portion of any amendments and restatement would prejudice any substantial existing right of holders of ADSs under previous versions of the first amended and restated deposit agreement, such portion shall not become effective as to such holders until 30 days after holders have received notice thereof. For more complete information, holders should read the entire second amended and restated deposit agreement, Amendment No. 2 and the ADR itself. Holders may also inspect a copy of the second amended and restated current deposit agreement, Amendment No. 2 and the ADR itself at the depositary&#8217;s office. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deposit, withdrawal and cancellation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Delivery of ADRs </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary will deliver ADRs if the holder or his or her broker deposit shares or evidence of rights to receive shares with the custodian. Upon payment of its fees, charges and expenses and any taxes or governmental charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of Sanofi ADSs in the names the holder requests and will deliver the ADRs to the persons the holder requests at its office.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Obtaining Sanofi ordinary shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A holder may turn in his or her ADRs at the depositary&#8217;s office. Upon payment of its fees, charges and expenses and any taxes or governmental charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver (1) the underlying shares to an account designated by the holder and (2) any other deposited securities underlying the ADR at the office of a custodian or, at the holder&#8217;s request, risk and expense, the depositary will deliver the deposited securities at its office.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Voting rights </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A holder may instruct the depositary to vote the Sanofi ordinary shares underlying his or her Sanofi ADSs at any meeting of Sanofi shareholders, but only if we request that the depositary ask for holder instructions. Otherwise, holders will not be able to exercise their right to vote unless they withdraw the underlying ordinary shares from the ADR program and vote as an ordinary shareholder. However, holders may not know about the meeting sufficiently in advance to timely withdraw the underlying ordinary shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we ask for holder instructions in connection with a meeting of Sanofi shareholders, the depositary will provide materials to holders of Sanofi ADSs in the manner described under the heading &#8220;&#8212; Notices and reports&#59; rights of holders to inspect books&#8221; below. For any instructions to be valid, the depositary must receive them on or before the date specified in the materials distributed by the depositary. The depositary will endeavor, in so far as practical, subject to French law and the provisions of our </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">statuts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to vote or to have its agents vote the shares or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">other deposited securities as holders may validly instruct. The depositary will only vote or attempt to vote shares as holders validly instruct.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We cannot guarantee holders that they will receive the voting materials with sufficient time to enable them to return any voting instructions to the depositary in a timely manner to vote their shares. As long as they act in good faith, neither the depositary nor its agents will be responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">This means that holders may not be able to exercise their right to vote and there may be nothing holders can do if the shares represented by their ADSs are not voted as they requested.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Similar to our shares, Sanofi ADSs evidenced by ADRs that are registered in the name of the same owner for at least two (2) years are eligible for double voting rights so long as certain procedures are followed, as set out in the deposit agreement. For additional information regarding double voting rights, see &#8220;&#8212;&#160;Ordinary Shares &#8212;&#160;Rights, preferences and restrictions attaching to ordinary shares &#8212; Voting Rights&#8221; above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The deposit agreement allows the depositary and Sanofi to change the voting procedures or require additional voting procedures in addition to the ones described above, if necessary or appropriate. For example, holders might be required to arrange to have their Sanofi ADSs deposited in a blocked account for a specified period of time prior to a shareholders&#8217; meeting in order to be allowed to give voting instructions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share dividends and other distributions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Receipt of dividends and other distributions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary has agreed to pay to holders of Sanofi ADSs the cash dividends or other distributions that it or the custodian receives on the deposited Sanofi ordinary shares and other deposited securities after deducting its fees, charges and expenses and taxes withheld. Holders of Sanofi ADSs will receive these distributions in proportion to the number of Sanofi ADSs that they&#160;hold. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Distribution of cash</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary will convert any cash dividend or other cash distribution paid on the shares into US&#160;dollars if, in its judgment, it can do so on a reasonable basis and can transfer the US&#160;dollars to the United&#160;States. If the depositary determines that such a conversion and transfer is not possible, or if any approval from the French government is needed and cannot be obtained within a reasonable period, then the depositary may (1)&#160;distribute the foreign currency received by it to the holders of Sanofi ADSs or (2)&#160;hold the foreign currency distribution (uninvested and without liability for any interest) for the account of holders of Sanofi&#160;ADSs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, if any conversion of foreign currency, in whole or in part, cannot be effected to some holders of Sanofi ADSs, the deposit agreement allows the depositary to distribute the dividends only to those ADR holders to whom it is possible to do so. It will hold the foreign currency it cannot convert into US&#160;dollars for the account of the ADR holders who have not been paid. It will not invest the funds it holds and it will not be liable for any&#160;interest.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Before making a distribution, any withholding taxes that must be paid under French law will be deducted. The depositary will distribute only whole US&#160;dollars and cents and will round fractional cents down to the nearest whole cent. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Exchange rate fluctuations during a period when the depositary cannot convert euros into US&#160;dollars may result in holders losing some or all of the value of a&#160;distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Distribution of shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary may, and at our request will, distribute new ADRs representing any shares we distribute as a dividend or free distribution, if we furnish it promptly with satisfactory evidence that it is legal to do so. At its option, the depositary may distribute fractional Sanofi ADSs. If the depositary does not distribute additional Sanofi ADSs, the outstanding ADRs will also represent the new shares. The depositary may withhold any tax or other governmental charges, or require the payment of any required fees, charges and expenses, prior to making any distribution of additional Sanofi&#160;ADSs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rights to receive additional shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we offer holders of Sanofi ordinary shares any rights to subscribe for additional shares or any other rights, the depositary, after consultation with us, will, in its discretion, either (1)&#160;make these rights available to holders or (2)&#160;dispose of such rights on behalf of ADR holders and make the net proceeds available to holders. The depositary may make rights available to certain holders but not others if it determines it is lawful and feasible to do so. However, if, under the terms of the offering or for any other reason, the depositary may not make such rights available or dispose of such rights and make the net proceeds available, it will allow the rights to lapse. In that case, holders of Sanofi ADSs will receive no value for&#160;them.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In circumstances where rights would not otherwise be distributed by the depositary to holders of Sanofi ADSs, a holder of Sanofi ADSs may nonetheless request, and will receive from the depositary, any instruments or other documents necessary to exercise the rights allocable to that holder if the depositary first receives written notice from Sanofi that (1)&#160;Sanofi has elected, in its sole discretion, to permit the rights to be exercised and (2)&#160;such holder has executed the documents Sanofi has determined, in its sole discretion, are reasonably required under applicable&#160;law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the depositary makes rights available to holders of Sanofi ADSs, upon instruction from such holders, it will exercise the rights and purchase the shares on such holder&#8217;s behalf. The depositary will then deposit the shares and deliver ADRs to such holders. It will only exercise rights if holders of Sanofi ADSs pay it the exercise price and any other charges the rights require such holders to&#160;pay.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US&#160;securities laws may restrict the sale, deposit, cancellation or transfer of ADRs issued upon exercise of rights. For example, holders of Sanofi ADSs may not be able to trade such Sanofi ADSs freely in the United&#160;States. In this case, the depositary may deliver Sanofi ADSs under a separate restricted deposit agreement that will contain the same provisions as the deposit agreement, except for changes needed to implement the required restrictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other distributions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The depositary will distribute to holders of Sanofi ADSs anything else we may distribute (including, without limitation, through the distribution of sponsored or unsponsored ADSs representing such securities&#59; subject in each case to the fees, charges and expenses set forth in the deposit agreement and in the terms of such ADSs)  on deposited securities (after deduction or upon payment of fees, charges and expenses or any taxes or other governmental charges) by any means it deems is equitable and practical. If, for any reason, in the opinion of the depositary, the distribution cannot be made proportionately among the owners entitled thereto or if for any other reason the depositary deems such distribution not feasible, the depositary may sell what we distributed and distribute the net proceeds of the sale in the same way it distributes cash dividends, or it may choose any other method to distribute the property it deems equitable and practicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of Sanofi ADSs. We have no obligation to register Sanofi ADSs, shares, rights or other securities under the US&#160;Securities Act of 1933, as amended. We also have no obligation to take any other action to permit the distribution of ADRs, shares, rights or anything else to holders of Sanofi ADSs. This means that holders may not receive the distribution we make on our shares or any value for them if it is illegal or impractical for the depositary to make them available to such&#160;holders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Elective distributions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available to holders of Sanofi ADSs. In that case, we will assist the depositary in determining whether that distribution is lawful and reasonably practicable. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary will make the election available to holders of Sanofi ADSs only if it is reasonably practicable and if we have provided all the documentation contemplated in the deposit agreement. In that case, the depositary will establish procedures to enable holders of Sanofi ADSs to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the election is not made available to holders of Sanofi ADSs, such holders will receive either cash or additional Sanofi ADSs, depending on what a shareholder in France would receive for failing to make an election, as more fully described in the deposit agreement.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notices and reports, rights of holders to inspect books</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On or before the first date on which we give notice, by publication or otherwise, of any meeting of holders of shares or other deposited securities, or of any adjourned meeting of such holders, or of the taking of any action in respect of any cash or other distributions or the offering of any rights, we will transmit to the depositary a copy of the&#160;notice.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon notice of any meeting of holders of shares or other deposited securities, if requested in writing by Sanofi, the depositary will, as soon as practicable, mail to the holders of Sanofi ADSs a notice, the form of which is in the discretion of the depositary, containing (1)&#160;a summary in English of the information contained in the notice of meeting provided by Sanofi to the depositary, (2)&#160;a statement that the holders as of the close of business on a specified record date will be entitled, subject to any applicable provision of French law and of our </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">statuts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, to instruct the depositary as to the exercise of the voting rights, if any, pertaining to the amount of shares or other deposited securities represented by their respective ADSs and (3)&#160;a statement as to the manner in which such instructions may be given. Notwithstanding the above, the depositary may, to the extent not prohibited by law or regulations, or by the requirements of NASDAQ, in lieu of distribution of the materials provided to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">depositary as described above, distribute to the holders a notice that provides holders with, or otherwise publicizes to holders, instructions on how to retrieve such materials or receive such materials upon request (i.e.,&#160;by reference to a website containing the materials for retrieval or a contact for requesting copies of the&#160;materials). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary will make available for inspection by ADS holders at the depositary&#8217;s office any reports and communications, including any proxy soliciting material, received from us that are both (1) received by the depositary as the holder of the deposited securities and (2) made generally available to the holders of such deposited securities by us. The depositary will also, upon written request, send to ADS holders copies of such reports when furnished by us pursuant to the deposit agreement. Any such reports and communications, including any such proxy soliciting material, furnished to the depositary by us will be furnished in English to the extent such materials are required to be translated into English pursuant to any regulations of the SEC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary will keep books for the registration of ADRs and transfers of ADRs that at all reasonable times will be open for inspection by the holders provided that such inspection is not for the purpose of communicating with holders in the interest of a business or object other than our business or a matter related to the deposit agreement or the ADRs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sale or exercising of rights and right to receive the shares underlying the Sanofi ADSs </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Requirements for depositary actions</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Before the depositary will deliver or register the transfer of Sanofi ADSs, make a distribution on Sanofi ADSs or process a withdrawal of shares, the depositary may&#160;require&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">production of satisfactory proof of the identity and genuineness of any signature or other information it deems necessary&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary may refuse to deliver Sanofi ADSs, register transfers of Sanofi ADSs or permit withdrawals of shares when the transfer books of the depositary or our transfer books are closed, or at any time if the depositary or we think it advisable to do&#160;so.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Right to receive the shares underlying the Sanofi ADSs</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders have the right to cancel their Sanofi ADSs and withdraw the underlying Sanofi ordinary shares at any time&#160;except&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">when temporary delays arise when we or the depositary have closed our transfer books or the deposit of shares in connection with voting at a shareholders&#8217; meeting, or the payment of dividends&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">when the holder or other holders of Sanofi ADSs seeking to withdraw shares owe money to pay fees, taxes and similar charges&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to Sanofi ADSs or to the withdrawal of shares or other deposited securities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This right of withdrawal may not be limited by any other provision of the deposit agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pre-release of Sanofi ADSs</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of our form of second amended and restated deposit agreement, as amended, do not permit the pre-release of the Sanofi ADSs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deposit or sale of securities resulting from dividends, splits or plans of reorganization </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Changes affecting deposited securities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If we&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">change the nominal or par value of our Sanofi ordinary shares&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">recapitalize, reorganize, merge or consolidate, liquidate, sell assets, or take any similar action&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">reclassify, split up or consolidate any of the deposited securities&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">distribute securities on the deposited securities that are not distributed to holders&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">then either&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the cash, shares or other securities received by the depositary will become deposited securities and each Sanofi ADS will automatically represent its equal share of the new deposited securities&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the depositary may, and will if we ask it to, distribute some or all of the cash, shares or other securities it receives. It may also deliver new ADRs or ask holders to surrender their outstanding ADRs in exchange for new ADRs identifying the new deposited securities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disclosure of interests</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The obligation of a holder or other person with an interest in our shares to disclose information under French law and under our </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">statuts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> also applies to holders and any other persons, other than the depositary, who have an interest in the Sanofi ADSs. The consequences for failing to comply with these provisions are the same for holders and any other persons with an interest as a holder of our ordinary shares. For additional information regarding these obligations, see &#8220;&#8212;&#160;Ordinary Shares &#8212;&#160;Rights, preferences and restrictions attaching to ordinary shares &#8212;&#160;Requirements for holdings exceeding certain percentages&#8221; above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment and termination</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may agree with the depositary to amend the deposit agreement and the ADRs without the consent of the ADS holders for any reason. If the amendment adds or increases fees, charges or expenses (except for stock transfer or taxes and other governmental charges, transfer or registration fees, the transaction fee per cancellation request (including any cancellation request made through SWIFT, facsimile transmission, or any other method of communication) as described in the depositary agreement, applicable delivery expenses or other such fees, charges or expenses), or prejudices a substantial right of holders of Sanofi ADSs, it will only become effective 30&#160;days after the depositary notifies such holders of the amendment. However, we may not be able to provide holders of Sanofi ADSs with prior notice of the effectiveness of any modifications or supplements that are required to accommodate compliance with applicable provisions of law, whether or not those modifications or supplements could be considered to be materially prejudicial to the substantial rights of holders of Sanofi ADSs. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">At the time an amendment becomes effective, such holders will be considered, by continuing to hold their ADR, to have agreed to the amendment and to be bound by the ADR and the deposit agreement as&#160;amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary will terminate the agreement if we ask it to do so. The depositary may also terminate the agreement if the depositary has told us that it would like to resign and we have not appointed a new depositary bank within 90&#160;days. In both cases, the depositary must notify holders of Sanofi ADSs at least 30&#160;days before termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After termination, the depositary and its agents will be required to do only the following under the deposit agreement&#58; (1)&#160;collect distributions on the deposited securities, (2)&#160;sell rights and other property as provided in the deposit agreement and (3)&#160;deliver shares and other deposited securities upon cancellation of ADRs. Six months or more after termination, the depositary may sell any remaining deposited securities by public or private sale. After that, the depositary will hold the money it receives on the sale, as well as any other cash it is holding under the deposit agreement, for the pro&#160;rata benefit of the holders of Sanofi ADSs that have not surrendered their Sanofi ADSs. It will have no liability for interest. Upon termination of the deposit agreement, the depositary&#8217;s only obligations will be to account for the proceeds of the sale and other cash and with respect to indemnification. After termination, our only obligation will be with respect to indemnification and to pay certain amounts to the&#160;depositary.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Limitations on obligations and liability to holders of Sanofi ADSs</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The deposit agreement expressly limits our obligations and the obligations of the depositary, and it limits our liability and the liability of the depositary. In particular, please note the following&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we and the depositary are obligated only to take the actions specifically set forth in the deposit agreement without gross negligence or bad faith&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we and the depositary are not liable if either is prevented or delayed by law or circumstances beyond its control from performing its obligations under the deposit agreement&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we and the depositary are not liable if either exercises, or fails to exercise, any discretion permitted under the deposit agreement&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we and the depositary have no obligation to become involved in a lawsuit or other proceeding related to the Sanofi ADSs or the deposit agreement on holders&#8217; behalf or on behalf of any other party, unless indemnity satisfactory to it against all expense and liability is furnished as often as may be required&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we and the depositary are not liable for the acts or omissions made by, or the insolvency of, any securities depository, clearing agency or settlement system or the custodian, subject to certain exceptions and to the extent the custodian is not a branch or affiliate of JPMorgan&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the depositary is not liable for the price received in connection with any sale of securities, the timing thereof or any delays, acts, omissions to act, errors, defaults or negligence on the part of the party so retained in connection with any such sale or proposed sale&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we and the depositary may rely without any liability upon any written notice, request, direction, instruction or other document believed by either of us to be genuine and to have been signed or presented by the proper parties&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we and the depositary are not liable for any action or nonaction taken in reliance upon the advice of or information from legal counsel, accountants, any person presenting ordinary shares for deposit, any ADS holder, or any other person believed in good faith to be competent to give such advice or information. </font></div><div style="padding-left:11.35pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the depositary will not be liable for any acts or omissions made by a successor depositary. Moreover, neither we nor the depositary nor any of our respective agents will be liable to any holder of Sanofi ADSs for any indirect, special, punitive or consequential damages.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the terms of the deposit agreement, we and the depositary have agreed to indemnify each other under certain circumstances.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.690%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>a2023-exhibit121.htm
<DESCRIPTION>EX-12.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iaaa0d76f87e04125b6faf5e2c570eb84_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 12.1</font></div></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Paul Hudson, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Sanofi&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the Audit Committee of the company&#8217;s Board of Directors&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58; February 23, 2024</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.967%"><tr><td style="width:1.0%"></td><td style="width:13.306%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Paul Hudson</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paul Hudson</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:232%">Title&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:232%">Chief Executive Officer (1)</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Principal executive officer.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>6
<FILENAME>a2023-exhibit122.htm
<DESCRIPTION>EX-12.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0b9ca62af5234348bba2d09438d1413a_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 12.2</font></div><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Jean-Baptiste Chasseloup de Chatillon, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Sanofi&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the Audit Committee of the company&#8217;s Board of Directors&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58; February 23, 2024</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.967%"><tr><td style="width:1.0%"></td><td style="width:13.306%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Jean-Baptiste Chasseloup de Chatillon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jean-Baptiste Chasseloup de Chatillon</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:232%">Title&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:232%">Executive Vice President Chief Financial Officer (1)</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Principal financial officer.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>7
<FILENAME>a2023-exhibit131.htm
<DESCRIPTION>EX-13.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i16a27df2d8b64dee84aa85514169d02d_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 13.1</font></div><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Sanofi, a French soci&#233;t&#233; anonyme (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-bottom:9pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The annual report on Form 20-F for the year ended December 31, 2023 (the &#8220;Form 20-F&#8221;) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58; February 23, 2024</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.967%"><tr><td style="width:1.0%"></td><td style="width:13.306%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:121%">&#47;s&#47; Paul Hudson</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:121%">Paul Hudson</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:103%">Chief Executive Officer (1)</font></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to Sanofi and will be retained by Sanofi and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="margin-bottom:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Principal executive officer.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>8
<FILENAME>a2023-exhibit132.htm
<DESCRIPTION>EX-13.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1466c72871b04af5bbcaf130cafb6946_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 13.2</font></div><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Sanofi, a French soci&#233;t&#233; anonyme (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-bottom:9pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The annual report on Form 20-F for the year ended December 31, 2023 (the &#8220;Form 20-F&#8221;) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58; February 23, 2024</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.967%"><tr><td style="width:1.0%"></td><td style="width:13.306%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:121%">&#47;s&#47; Jean-Baptiste Chasseloup de Chatillon</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:121%">Jean-Baptiste Chasseloup de Chatillon</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:103%">Executive Vice President Chief Financial Officer (1)</font></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to Sanofi and will be retained by Sanofi and furnished to the Securities and Exchange Commission or its staff upon request</font></div><div style="margin-bottom:9pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Principal financial officer.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>9
<FILENAME>a2023-exhibit151.htm
<DESCRIPTION>EX-15.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3af485d477dc46e1a436c4ea9e0d306e_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 15.1</font></div><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Stateme</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">nts on Form S-8 Nos. 333,270976, 333-265050, 333-256208, 333-238686 and 333-225522 and on Form F-3 No. 333-258327 of Sanofi of our reports dated February 23, 2024, with respect to the consolidated financial statements of Sanofi and its subsidiaries, and the effectiveness of internal cont</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">rol over financial reporting of Sanofi and its subsidiaries, included in this Annual Report (Form 20-F) for the year ended December 31, 2023.</font></div><div style="margin-bottom:9pt;text-indent:27pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young et Autres</font></div><div style="margin-bottom:9pt;padding-left:45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Paris-La D&#233;fense, France</font></div><div style="margin-bottom:9pt;padding-left:45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 23, 2024</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>10
<FILENAME>a2023-exhibit152.htm
<DESCRIPTION>EX-15.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i829fa16861df458582bf572481c80fbf_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 15.2</font></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">on Form S-8 (Nos. 333-270976, 333-265050, 333-256208, 333-238686 and 333-225522) and on Form F-3 (No. 333-258327) of Sanofi of our reports dated February 23, 20</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24 relating to the financial statements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and the effectiveness of internal control over financial reporting, which appear in this Form 20-F.</font></div><div style="text-indent:10.55pt"><font><br></font></div><div style="text-indent:10.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#47;s&#47; PricewaterhouseCoopers Audit</font></div><div style="text-indent:10.55pt"><font><br></font></div><div style="text-indent:10.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Neuilly-sur-Seine, France</font></div><div style="text-indent:10.55pt"><font><br></font></div><div style="text-indent:10.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> February 23, 2024</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.3
<SEQUENCE>11
<FILENAME>a2023-exhibit153.htm
<DESCRIPTION>EX-15.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i74e861c27b314e58bc4c09d172adf9ee_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 15.3</font></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EY CHANGE IN AUDITORS 16F ITEM LETTER</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities and Exchange Commission</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100 F Street, N.E.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Washington, DC 20549</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ladies and Gentlemen</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have read Item 16F. Change in Registrant&#8217;s Certifying Accountant on page 168 of Form 20-F dated February 23, 2024 of Sanofi and are in agreement with the statements contained in paragraphs one and four. We have no basis to agree or disagree with other statements of the registrant contained therein.</font></div><div style="margin-bottom:9pt;text-indent:27pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young et Autres</font></div><div style="margin-bottom:9pt;padding-left:45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Paris-La D&#233;fense, France</font></div><div style="margin-bottom:9pt;padding-left:45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 23, 2024</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>12
<FILENAME>a2023-exhibit97.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0a6f74214f99426ebee77ce95bfa470f_34"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:400;line-height:100%">Clawback Policy</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This policy (the &#8220;Clawback Policy&#8221;) is adopted by Sanofi (the &#8220;Company&#8221;) as per the Nasdaq Listing Rules (the &#8220;Nasdaq Listing Rules&#8221;) as amended to include Nasdaq Listing Rule 5608 (&#8220;Listing Rule 5608&#34;) directed under Rule 10D 1 (&#8220;Rule 10D-1&#8221;) of the U.S. Securities Exchange Act of 1934 which provides that issuers must reasonably promptly recover erroneously-awarded incentive compensation (as described below) from executive officers if the Company is required to prepare an accounting restatement due to the company&#8217;s material noncompliance with any financial reporting requirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Individuals Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; this Clawback Policy applies to executive officers as defined in Rule 10D-1, which the Company has deemed to include the members of the Executive Committee (incl. the CEO) and the Head of Consolidation and Statutory Reporting,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> who served in such roles as such at any time during the performance period for the relevant incentive-based compensation. Any individual covered by this Clawback Policy shall be required to repay to the Company any excess awarded incentive based compensation, according to methods of recovery of the amount as shall be determined by the Company in its discretion.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Triggering Event&#58; the clawback requirement under this Clawback Policy shall apply in the event that the Company is required to prepare an accounting restatement&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">correcting an error that is material to the previously issued financial statements (&#8220;Big R&#8221; restatements)&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">correcting an error that is not material to the previously issued financial statements but would result in a material misstatement if the error was (a) corrected in the current period or (b) left uncorrected in the current period (&#8220;Small R&#8221; restatements).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Covered incentive-based compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; this Clawback Policy is applicable to any compensation (in cash or in kind) based wholly or in part upon the attainment of a financial reporting measure and that is received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> while the Company has a class of securities listed on a U.S. national securities exchange and during any of the three completed fiscal years</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> immediately preceding the earlier date on which (i) the Company concludes, or reasonably should have concluded, that an accounting restatement is required and (ii) a court, regulator, or other legally authorized body renders a decision that directs the Company to prepare an accounting restatement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">5</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The amount of incentive-based compensation to be recovered under this Clawback Policy is the amount (in cash and&#47;or equity) received that exceeds the amount of incentive-based </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Unless one of the exemptions described in paragraph (b)(1)(iv) of Nasdaq Listing Rule 5608 applies, in accordance with the Applicable Rules.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Sanofi has deemed this role to be the &#8220;principal accounting officer&#8221; as per Nasdaq Listing Rule 5608.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Incentive based compensation will be deemed received for purposes of the Clawback Policy in the fiscal period during which the financial reporting measure specified in the incentive-based compensation award is attained, even if the payment or grant occurs after the end of that period.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Including any transition period resulting from a change in the Company&#8217;s fiscal year within or immediately following those three completed fiscal years (provided, however, that if a transition period between the last day of the Company&#8217;s previous fiscal year end and the first day of its new fiscal year comprises a period of nine to 12 months, such period would be deemed to be a completed fiscal year).</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> It is specified that this Clawback Policy only applies to incentive compensation received after October 2, 2023. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Adopted by the Board of Directors on October 26, 2023</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compensation that otherwise would have been received had it been determined based on the restated accounts and must be computed without regard to any taxes paid. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For incentive-based compensation based on stock price or TSR metrics, where the amount of awarded compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, the excess amount must be based on the Company&#8217;s reasonable estimate of the effect of the accounting restatement on the stock price or TSR upon which the incentive-based compensation was received.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Implementation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  notwithstanding anything contained herein, this Clawback Policy will be administered, applied and interpreted by Sanofi in accordance with the Nasdaq Listing Rules, any applicable U.S. Securities and Exchange Commission or Nasdaq Stock Market LLC guidance or interpretations issued from time to time regarding such incentive compensation recovery requirements, and French law and the laws of any other jurisdiction which apply to the Company, including further to employment agreements governing employment of the individuals covered by the Policy.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Adopted by the Board of Directors on October 26, 2023</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>sny-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:d2fc6364-8fcd-4586-a9d3-e16cd96a566e,g:f65f6c85-de12-4c7c-b6b2-ea3943f1a47f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sny="http://www.sanofi.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sanofi.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sny-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://www.sanofi.com/role/Coverpage">
        <link:definition>0000001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.sanofi.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedbalancesheets" roleURI="http://www.sanofi.com/role/Consolidatedbalancesheets">
        <link:definition>0000003 - Statement - Consolidated balance sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedincomestatements" roleURI="http://www.sanofi.com/role/Consolidatedincomestatements">
        <link:definition>0000004 - Statement - Consolidated income statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedincomestatements_1" roleURI="http://www.sanofi.com/role/Consolidatedincomestatements_1">
        <link:definition>0000004 - Statement - Consolidated income statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedstatementsofcomprehensiveincome" roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome">
        <link:definition>0000005 - Statement - Consolidated statements of comprehensive income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedstatementsofcomprehensiveincome_1" roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1">
        <link:definition>0000005 - Statement - Consolidated statements of comprehensive income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedstatementsofchangesinequity" roleURI="http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity">
        <link:definition>0000006 - Statement - Consolidated statements of changes in equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedstatementsofchangesinequityParenthetical" roleURI="http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical">
        <link:definition>0000007 - Statement - Consolidated statements of changes in equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedstatementsofcashflows" roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcashflows">
        <link:definition>0000008 - Statement - Consolidated statements of cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedstatementsofcashflowsParenthetical" roleURI="http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical">
        <link:definition>0000009 - Statement - Consolidated statements of cash flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Introduction" roleURI="http://www.sanofi.com/role/Introduction">
        <link:definition>0000010 - Disclosure - Introduction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpreparation" roleURI="http://www.sanofi.com/role/Basisofpreparation">
        <link:definition>0000011 - Disclosure - Basis of preparation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://www.sanofi.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>0000012 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Principalalliances" roleURI="http://www.sanofi.com/role/Principalalliances">
        <link:definition>0000013 - Disclosure - Principal alliances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Principalchangesinthescopeofconsolidationin2023" roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023">
        <link:definition>0000014 - Disclosure - Principal changes in the scope of consolidation in 2023</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Principalchangesinthescopeofconsolidationin2022and2021" roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021">
        <link:definition>0000015 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipment" roleURI="http://www.sanofi.com/role/Propertyplantandequipment">
        <link:definition>0000016 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwillandotherintangibleassets" roleURI="http://www.sanofi.com/role/Goodwillandotherintangibleassets">
        <link:definition>0000017 - Disclosure - Goodwill and other intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Impairmentofintangibleassetsandpropertyplantandequipment" roleURI="http://www.sanofi.com/role/Impairmentofintangibleassetsandpropertyplantandequipment">
        <link:definition>0000018 - Disclosure - Impairment of intangible assets and property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investmentsaccountedforusingtheequitymethod" roleURI="http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod">
        <link:definition>0000019 - Disclosure - Investments accounted for using the equity method</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Othernoncurrentassets" roleURI="http://www.sanofi.com/role/Othernoncurrentassets">
        <link:definition>0000020 - Disclosure - Other non-current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Assetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchange" roleURI="http://www.sanofi.com/role/Assetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchange">
        <link:definition>0000021 - Disclosure - Assets held for sale or exchange and liabilities related to assets held for sale or exchange</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.sanofi.com/role/Inventories">
        <link:definition>0000022 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accountsreceivable" roleURI="http://www.sanofi.com/role/Accountsreceivable">
        <link:definition>0000023 - Disclosure - Accounts receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Othercurrentassets" roleURI="http://www.sanofi.com/role/Othercurrentassets">
        <link:definition>0000024 - Disclosure - Other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialassetsandliabilitiesmeasuredatfairvalue" roleURI="http://www.sanofi.com/role/Financialassetsandliabilitiesmeasuredatfairvalue">
        <link:definition>0000025 - Disclosure - Financial assets and liabilities measured at fair value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cashandcashequivalents" roleURI="http://www.sanofi.com/role/Cashandcashequivalents">
        <link:definition>0000026 - Disclosure - Cash and cash equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netdeferredtaxposition" roleURI="http://www.sanofi.com/role/Netdeferredtaxposition">
        <link:definition>0000027 - Disclosure - Net deferred tax position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidatedshareholdersequity" roleURI="http://www.sanofi.com/role/Consolidatedshareholdersequity">
        <link:definition>0000028 - Disclosure - Consolidated shareholders&#8217; equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Noncontrollinginterests" roleURI="http://www.sanofi.com/role/Noncontrollinginterests">
        <link:definition>0000029 - Disclosure - Non-controlling interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debtcashandcashequivalentsandleaseliabilities" roleURI="http://www.sanofi.com/role/Debtcashandcashequivalentsandleaseliabilities">
        <link:definition>0000030 - Disclosure - Debt, cash and cash equivalents and lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests" roleURI="http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests">
        <link:definition>0000031 - Disclosure - Liabilities related to business combinations and to non-controlling interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Provisionsincometaxliabilitiesandotherliabilities" roleURI="http://www.sanofi.com/role/Provisionsincometaxliabilitiesandotherliabilities">
        <link:definition>0000032 - Disclosure - Provisions, income tax liabilities and other liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Derivativefinancialinstrumentsandmarketrisks" roleURI="http://www.sanofi.com/role/Derivativefinancialinstrumentsandmarketrisks">
        <link:definition>0000033 - Disclosure - Derivative financial instruments and market risks</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Offbalancesheetcommitments" roleURI="http://www.sanofi.com/role/Offbalancesheetcommitments">
        <link:definition>0000034 - Disclosure - Off balance sheet commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Legalandarbitralproceedings" roleURI="http://www.sanofi.com/role/Legalandarbitralproceedings">
        <link:definition>0000035 - Disclosure - Legal and arbitral proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Provisionsfordiscountsrebatesandsalesreturns" roleURI="http://www.sanofi.com/role/Provisionsfordiscountsrebatesandsalesreturns">
        <link:definition>0000036 - Disclosure - Provisions for discounts, rebates and sales returns</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Personnelcosts" roleURI="http://www.sanofi.com/role/Personnelcosts">
        <link:definition>0000037 - Disclosure - Personnel costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Otheroperatingincome" roleURI="http://www.sanofi.com/role/Otheroperatingincome">
        <link:definition>0000038 - Disclosure - Other operating income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Otheroperatingexpenses" roleURI="http://www.sanofi.com/role/Otheroperatingexpenses">
        <link:definition>0000039 - Disclosure - Other operating expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuringcostsandsimilaritems" roleURI="http://www.sanofi.com/role/Restructuringcostsandsimilaritems">
        <link:definition>0000040 - Disclosure - Restructuring costs and similar items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Othergainsandlossesandlitigation" roleURI="http://www.sanofi.com/role/Othergainsandlossesandlitigation">
        <link:definition>0000041 - Disclosure - Other gains and losses, and litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialexpensesandincome" roleURI="http://www.sanofi.com/role/Financialexpensesandincome">
        <link:definition>0000042 - Disclosure - Financial expenses and income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxexpense" roleURI="http://www.sanofi.com/role/Incometaxexpense">
        <link:definition>0000043 - Disclosure - Income tax expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Shareofprofitlossfrominvestmentsaccountedforusingtheequitymethod" roleURI="http://www.sanofi.com/role/Shareofprofitlossfrominvestmentsaccountedforusingtheequitymethod">
        <link:definition>0000044 - Disclosure - Share of profit/loss from investments accounted for using the equity method</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netincomeattributabletononcontrollinginterests" roleURI="http://www.sanofi.com/role/Netincomeattributabletononcontrollinginterests">
        <link:definition>0000045 - Disclosure - Net income attributable to non-controlling interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedpartytransactions" roleURI="http://www.sanofi.com/role/Relatedpartytransactions">
        <link:definition>0000046 - Disclosure - Related party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Disclosuresaboutmajorcustomersandcreditrisk" roleURI="http://www.sanofi.com/role/Disclosuresaboutmajorcustomersandcreditrisk">
        <link:definition>0000047 - Disclosure - Disclosures about major customers and credit risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segmentinformation" roleURI="http://www.sanofi.com/role/Segmentinformation">
        <link:definition>0000048 - Disclosure - Segment information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Principalaccountantsfeesandservices" roleURI="http://www.sanofi.com/role/Principalaccountantsfeesandservices">
        <link:definition>0000049 - Disclosure - Principal accountants' fees and services</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023" roleURI="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023">
        <link:definition>0000050 - Disclosure - List of principal companies included in the scope of consolidation during&#160;2023</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EventssubsequenttoDecember312023" roleURI="http://www.sanofi.com/role/EventssubsequenttoDecember312023">
        <link:definition>0000051 - Disclosure - Events subsequent to December 31, 2023</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesTables" roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Principalchangesinthescopeofconsolidationin2023Tables" roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023Tables">
        <link:definition>9954473 - Disclosure - Principal changes in the scope of consolidation in 2023 (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Principalchangesinthescopeofconsolidationin2022and2021Tables" roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021Tables">
        <link:definition>9954474 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021 (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentTables" roleURI="http://www.sanofi.com/role/PropertyplantandequipmentTables">
        <link:definition>9954475 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsTables" roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables">
        <link:definition>9954476 - Disclosure - Goodwill and other intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentofintangibleassetsandpropertyplantandequipmentTables" roleURI="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentTables">
        <link:definition>9954477 - Disclosure - Impairment of intangible assets and property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsaccountedforusingtheequitymethodTables" roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables">
        <link:definition>9954478 - Disclosure - Investments accounted for using the equity method (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthernoncurrentassetsTables" roleURI="http://www.sanofi.com/role/OthernoncurrentassetsTables">
        <link:definition>9954479 - Disclosure - Other non-current assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeTables" roleURI="http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeTables">
        <link:definition>9954480 - Disclosure - Assets held for sale or exchange and liabilities related to assets held for sale or exchange (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.sanofi.com/role/InventoriesTables">
        <link:definition>9954481 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsreceivableTables" roleURI="http://www.sanofi.com/role/AccountsreceivableTables">
        <link:definition>9954482 - Disclosure - Accounts receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsTables" roleURI="http://www.sanofi.com/role/OthercurrentassetsTables">
        <link:definition>9954483 - Disclosure - Other current assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesmeasuredatfairvalueTables" roleURI="http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueTables">
        <link:definition>9954484 - Disclosure - Financial assets and liabilities measured at fair value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsTables" roleURI="http://www.sanofi.com/role/CashandcashequivalentsTables">
        <link:definition>9954485 - Disclosure - Cash and cash equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetdeferredtaxpositionTables" roleURI="http://www.sanofi.com/role/NetdeferredtaxpositionTables">
        <link:definition>9954486 - Disclosure - Net deferred tax position (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequityTables" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityTables">
        <link:definition>9954487 - Disclosure - Consolidated shareholders&#8217; equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesTables" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables">
        <link:definition>9954488 - Disclosure - Debt, cash and cash equivalents and lease liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables" roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables">
        <link:definition>9954489 - Disclosure - Liabilities related to business combinations and to non-controlling interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesTables" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables">
        <link:definition>9954490 - Disclosure - Provisions, income tax liabilities and other liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativefinancialinstrumentsandmarketrisksTables" roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksTables">
        <link:definition>9954491 - Disclosure - Derivative financial instruments and market risks (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffbalancesheetcommitmentsTables" roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsTables">
        <link:definition>9954492 - Disclosure - Off balance sheet commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsfordiscountsrebatesandsalesreturnsTables" roleURI="http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsTables">
        <link:definition>9954493 - Disclosure - Provisions for discounts, rebates and sales returns (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelcostsTables" roleURI="http://www.sanofi.com/role/PersonnelcostsTables">
        <link:definition>9954494 - Disclosure - Personnel costs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtheroperatingexpensesTables" roleURI="http://www.sanofi.com/role/OtheroperatingexpensesTables">
        <link:definition>9954495 - Disclosure - Other operating expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringcostsandsimilaritemsTables" roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables">
        <link:definition>9954496 - Disclosure - Restructuring costs and similar items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialexpensesandincomeTables" roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeTables">
        <link:definition>9954497 - Disclosure - Financial expenses and income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxexpenseTables" roleURI="http://www.sanofi.com/role/IncometaxexpenseTables">
        <link:definition>9954498 - Disclosure - Income tax expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetincomeattributabletononcontrollinginterestsTables" roleURI="http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsTables">
        <link:definition>9954499 - Disclosure - Net income attributable to non-controlling interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsTables" roleURI="http://www.sanofi.com/role/RelatedpartytransactionsTables">
        <link:definition>9954500 - Disclosure - Related party transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationTables" roleURI="http://www.sanofi.com/role/SegmentinformationTables">
        <link:definition>9954501 - Disclosure - Segment information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalaccountantsfeesandservicesTables" roleURI="http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesTables">
        <link:definition>9954502 - Disclosure - Principal accountants' fees and services (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023Tables" roleURI="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023Tables">
        <link:definition>9954503 - Disclosure - List of principal companies included in the scope of consolidation during&#160;2023 (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpreparationDetails" roleURI="http://www.sanofi.com/role/BasisofpreparationDetails">
        <link:definition>9954504 - Disclosure - Basis of preparation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails" roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails">
        <link:definition>9954505 - Disclosure - Summary of significant accounting policies - Other Intangible Assets not Acquired in Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails" roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails">
        <link:definition>9954506 - Disclosure - Summary of significant accounting policies - Summary of Useful Lives of Property Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesTreasurySharesDetails" roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTreasurySharesDetails">
        <link:definition>9954507 - Disclosure - Summary of significant accounting policies - Treasury Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesProvisionforRisksDetails" roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesProvisionforRisksDetails">
        <link:definition>9954508 - Disclosure - Summary of significant accounting policies - Provision for Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails" roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails">
        <link:definition>9954509 - Disclosure - Summary of significant accounting policies - Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails" roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails">
        <link:definition>9954510 - Disclosure - Summary of significant accounting policies - Share-Based Payment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesSegmentInformationDetails" roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSegmentInformationDetails">
        <link:definition>9954511 - Disclosure - Summary of significant accounting policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails" roleURI="http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails">
        <link:definition>9954512 - Disclosure - Principal alliances - Collaboration agreements on human therapeutic antibodies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails" roleURI="http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails">
        <link:definition>9954513 - Disclosure - Principal alliances - Immuno-Oncology Agreement with Regeneron Pharmaceuticals, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails" roleURI="http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails">
        <link:definition>9954514 - Disclosure - Principal alliances - Investor Agreement with Regeneron Pharmaceuticals, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails" roleURI="http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails">
        <link:definition>9954515 - Disclosure - Principal alliances - Agreements on the commercialization of Beyfortus&#8482; (nirsevimab, previously MEDI8897) in the US (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails" roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails">
        <link:definition>9954516 - Disclosure - Principal changes in the scope of consolidation in 2023 - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails" roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails">
        <link:definition>9954517 - Disclosure - Principal changes in the scope of consolidation in 2023 - Summary of Provisional Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails" roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails">
        <link:definition>9954518 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021 - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails" roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails">
        <link:definition>9954519 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021 - Summary of Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>9954520 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails">
        <link:definition>9954521 - Disclosure - Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentSummaryofOffBalanceSheetCommitmentsRelatingtoPropertyPlantandEquipmentDetails" roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofOffBalanceSheetCommitmentsRelatingtoPropertyPlantandEquipmentDetails">
        <link:definition>9954522 - Disclosure - Property, plant and equipment - Summary of Off Balance Sheet Commitments Relating to Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentSummaryofImpairmentLossesRecognisedinPropertyPlantandEquipmentDetails" roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofImpairmentLossesRecognisedinPropertyPlantandEquipmentDetails">
        <link:definition>9954523 - Disclosure - Property, plant and equipment - Summary of Impairment Losses Recognised in Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails" roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails">
        <link:definition>9954524 - Disclosure - Property, plant and equipment - Summary of Property, Plant and Equipment Leased (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails">
        <link:definition>9954525 - Disclosure - Property, plant and equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails" roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails">
        <link:definition>9954526 - Disclosure - Goodwill and other intangible assets - Schedule of Movements in Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails" roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails">
        <link:definition>9954527 - Disclosure - Goodwill and other intangible assets - Schedule of Allocation of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails">
        <link:definition>9954528 - Disclosure - Goodwill and other intangible assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails" roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails">
        <link:definition>9954529 - Disclosure - Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails" roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails">
        <link:definition>9954530 - Disclosure - Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails" roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails">
        <link:definition>9954531 - Disclosure - Goodwill and other intangible assets - Amortization of Softwares Recognized in Income Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails">
        <link:definition>9954532 - Disclosure - Impairment of intangible assets and property, plant and equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails" roleURI="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails">
        <link:definition>9954533 - Disclosure - Impairment of intangible assets and property, plant and equipment - Summary of Net Impairment Losses of Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails">
        <link:definition>9954534 - Disclosure - Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails" roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails">
        <link:definition>9954535 - Disclosure - Investments accounted for using the equity method - Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails">
        <link:definition>9954536 - Disclosure - Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails">
        <link:definition>9954537 - Disclosure - Investments accounted for using the equity method - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails" roleURI="http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails">
        <link:definition>9954538 - Disclosure - Other non-current assets - Summary of Other Non-current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthernoncurrentassetsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails">
        <link:definition>9954539 - Disclosure - Other non-current assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeSummaryofAssetsHeldforSaleorExchangeandLiabilitiesRelatedtoAssetsHeldforSaleorExchangeDetails" roleURI="http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeSummaryofAssetsHeldforSaleorExchangeandLiabilitiesRelatedtoAssetsHeldforSaleorExchangeDetails">
        <link:definition>9954540 - Disclosure - Assets held for sale or exchange and liabilities related to assets held for sale or exchange - Summary of Assets Held for Sale or Exchange, and Liabilities Related to Assets Held for Sale or Exchange (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>9954541 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/InventoriesAdditionalInformationDetails">
        <link:definition>9954542 - Disclosure - Inventories - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsreceivableSummaryofAccountsReceivableDetails" roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails">
        <link:definition>9954543 - Disclosure - Accounts receivable - Summary of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsreceivableAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails">
        <link:definition>9954544 - Disclosure - Accounts receivable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails" roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails">
        <link:definition>9954545 - Disclosure - Accounts receivable - Summary of Gross Value of Overdue Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthercurrentassetsDetails" roleURI="http://www.sanofi.com/role/OthercurrentassetsDetails">
        <link:definition>9954546 - Disclosure - Other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>9954547 - Disclosure - Financial assets and liabilities measured at fair value - Summary of Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsDetails" roleURI="http://www.sanofi.com/role/CashandcashequivalentsDetails">
        <link:definition>9954548 - Disclosure - Cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails" roleURI="http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails">
        <link:definition>9954549 - Disclosure - Net deferred tax position - Summary of Net Deferred Tax Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetdeferredtaxpositionAdditionalinformationDetails" roleURI="http://www.sanofi.com/role/NetdeferredtaxpositionAdditionalinformationDetails">
        <link:definition>9954550 - Disclosure - Net deferred tax position - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails" roleURI="http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails">
        <link:definition>9954551 - Disclosure - Net deferred tax position - Summary of Tax Losses Available for Carry-forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequityAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails">
        <link:definition>9954552 - Disclosure - Consolidated shareholders&#8217; equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails">
        <link:definition>9954553 - Disclosure - Consolidated shareholders&#8217; equity - Summary of Treasury Shares Held (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails">
        <link:definition>9954554 - Disclosure - Consolidated shareholders&#8217; equity - Summary of Movements Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails">
        <link:definition>9954555 - Disclosure - Consolidated shareholders&#8217; equity - Principal Characteristics of Restricted Share Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails">
        <link:definition>9954556 - Disclosure - Consolidated shareholders&#8217; equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails">
        <link:definition>9954557 - Disclosure - Consolidated shareholders&#8217; equity - Summary of Characteristics of Employee Share Ownership Plans Awarded (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofExpensesDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails">
        <link:definition>9954558 - Disclosure - Consolidated shareholders&#8217; equity - Summary of Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails">
        <link:definition>9954559 - Disclosure - Consolidated shareholders&#8217; equity - Summary of Repurchases Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails">
        <link:definition>9954560 - Disclosure - Consolidated shareholders&#8217; equity - Summary of Currency Translation Differences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails">
        <link:definition>9954561 - Disclosure - Consolidated shareholders&#8217; equity - Summary of Movements within Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails">
        <link:definition>9954562 - Disclosure - Consolidated shareholders&#8217; equity - Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails">
        <link:definition>9954563 - Disclosure - Consolidated shareholders&#8217; equity - Summary of Stock Options Outstanding at Each Balance Sheet Date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails">
        <link:definition>9954564 - Disclosure - Consolidated shareholders&#8217; equity - Summary of Options Outstanding and Exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails">
        <link:definition>9954565 - Disclosure - Consolidated shareholders&#8217; equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails">
        <link:definition>9954566 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Changes in Financial Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails">
        <link:definition>9954567 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails">
        <link:definition>9954568 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Disclosure of Movement In Total Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails">
        <link:definition>9954569 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails">
        <link:definition>9954570 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Net Debt by Type Valuation of Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails">
        <link:definition>9954571 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Bond Issues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails">
        <link:definition>9954572 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Maturity at Value on Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails">
        <link:definition>9954573 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Interest Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails">
        <link:definition>9954574 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate of Net Debt at Value on Redemption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails">
        <link:definition>9954575 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails">
        <link:definition>9954576 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Currency (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails">
        <link:definition>9954577 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Market Value of Net Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails">
        <link:definition>9954578 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails" roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails">
        <link:definition>9954579 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails">
        <link:definition>9954580 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails">
        <link:definition>9954581 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails" roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails">
        <link:definition>9954582 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails">
        <link:definition>9954583 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Non Current Provisions and Other Non-current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails">
        <link:definition>9954584 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Movements in Non-current Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails">
        <link:definition>9954585 - Disclosure - Provisions, income tax liabilities and other liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails">
        <link:definition>9954586 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Financial and Demographic Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails">
        <link:definition>9954587 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Weighted Average Duration of Obligation for Pensions and Other Long-term Benefits in Principal Countries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails">
        <link:definition>9954588 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Sensitivity for Pensions and Other Post-Employment Benefits to Changes in Key Actuarial Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails">
        <link:definition>9954589 - Disclosure - Provisions, income tax liabilities and other liabilities - Reconciliation of Net Amount Recognized in Respect of Pension and Other Post-employment Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails">
        <link:definition>9954590 - Disclosure - Provisions, income tax liabilities and other liabilities - Net Liability in Respect of Pension Plans and Other Post-employment Benefits by Geographical Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails">
        <link:definition>9954591 - Disclosure - Provisions, income tax liabilities and other liabilities - Fair Value of Plans Assets relating to Pension Plans and Other Post-employment Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails">
        <link:definition>9954592 - Disclosure - Provisions, income tax liabilities and other liabilities - Service Cost for Pension and Other post-employment Benefit Plans, by Geographical Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails">
        <link:definition>9954593 - Disclosure - Provisions, income tax liabilities and other liabilities - Remeasurement of Net Defined-benefit (Asset)/Liability (Actuarial Gains and Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNetPretaxActuarialLossDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNetPretaxActuarialLossDetails">
        <link:definition>9954594 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Net Pre-tax Actuarial Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails">
        <link:definition>9954595 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Present Value of Pension and Other Post Employment Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails">
        <link:definition>9954596 - Disclosure - Provisions, income tax liabilities and other liabilities - Total Expense for Pensions and Other Post-employment Benefits Allocated between Income Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails">
        <link:definition>9954597 - Disclosure - Provisions, income tax liabilities and other liabilities - Estimated Amounts of Employer's Contributions to Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails">
        <link:definition>9954598 - Disclosure - Provisions, income tax liabilities and other liabilities - Expected Timing of Benefit Payments under Pension and Other Post-employment Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails">
        <link:definition>9954599 - Disclosure - Provisions, income tax liabilities and other liabilities - Timing of Future Payments in Respect of Unfunded Pension and Other Post-employment Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails">
        <link:definition>9954600 - Disclosure - Provisions, income tax liabilities and other liabilities - Movements in Restructuring Provisions Classified in Non-current and Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails">
        <link:definition>9954601 - Disclosure - Provisions, income tax liabilities and other liabilities - Timing of Future Termination Benefit Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails">
        <link:definition>9954602 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Other Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails" roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails">
        <link:definition>9954603 - Disclosure - Provisions, income tax liabilities and other liabilities - Current Provisions and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails" roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails">
        <link:definition>9954604 - Disclosure - Derivative financial instruments and market risks - Summary of Fair Value of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails" roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails">
        <link:definition>9954605 - Disclosure - Derivative financial instruments and market risks - Summary of Operating Currency Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails">
        <link:definition>9954606 - Disclosure - Derivative financial instruments and market risks - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails" roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails">
        <link:definition>9954607 - Disclosure - Derivative financial instruments and market risks - Disclosure of Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails" roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails">
        <link:definition>9954608 - Disclosure - Derivative financial instruments and market risks - Disclosure of Actual or Potential Effects of Netting Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails" roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails">
        <link:definition>9954609 - Disclosure - Off balance sheet commitments - Summary of Off Balance Sheet Commitments Relating to Operating Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffbalancesheetcommitmentsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails">
        <link:definition>9954610 - Disclosure - Off balance sheet commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails" roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails">
        <link:definition>9954611 - Disclosure - Off balance sheet commitments - Summary of Undrawn Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails" roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails">
        <link:definition>9954612 - Disclosure - Off balance sheet commitments - Summary of Amount of Guarantees Given and Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalandarbitralproceedingsDetails" roleURI="http://www.sanofi.com/role/LegalandarbitralproceedingsDetails">
        <link:definition>9954613 - Disclosure - Legal and arbitral proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails" roleURI="http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails">
        <link:definition>9954614 - Disclosure - Provisions for discounts, rebates and sales returns - Summary of Movement in Provisions for Discounts, Rebates and Sales Returns (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelcostsSummaryofPersonalCostsDetails" roleURI="http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails">
        <link:definition>9954615 - Disclosure - Personnel costs - Summary of Personal Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PersonnelcostsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/PersonnelcostsAdditionalInformationDetails">
        <link:definition>9954616 - Disclosure - Personnel costs - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtheroperatingincomeDetails" roleURI="http://www.sanofi.com/role/OtheroperatingincomeDetails">
        <link:definition>9954617 - Disclosure - Other operating income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtheroperatingexpensesAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/OtheroperatingexpensesAdditionalInformationDetails">
        <link:definition>9954618 - Disclosure - Other operating expenses - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtheroperatingexpensesOtherIncomeandExpenseDetails" roleURI="http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails">
        <link:definition>9954619 - Disclosure - Other operating expenses - Other Income and Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails">
        <link:definition>9954620 - Disclosure - Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringcostsandsimilaritemsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsAdditionalInformationDetails">
        <link:definition>9954621 - Disclosure - Restructuring costs and similar items - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OthergainsandlossesandlitigationDetails" roleURI="http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails">
        <link:definition>9954622 - Disclosure - Other gains and losses, and litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialexpensesandincomeDetails" roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails">
        <link:definition>9954623 - Disclosure - Financial expenses and income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialexpensesandincomeDetails_1" roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1">
        <link:definition>9954623 - Disclosure - Financial expenses and income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails">
        <link:definition>9954624 - Disclosure - Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails">
        <link:definition>9954625 - Disclosure - Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails" roleURI="http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails">
        <link:definition>9954626 - Disclosure - Share of profit/loss from investments accounted for using the equity method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetincomeattributabletononcontrollinginterestsDetails" roleURI="http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails">
        <link:definition>9954627 - Disclosure - Net income attributable to non-controlling interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/RelatedpartytransactionsAdditionalInformationDetails">
        <link:definition>9954628 - Disclosure - Related party transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails" roleURI="http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails">
        <link:definition>9954629 - Disclosure - Related party transactions - Schedule of Compensation Paid to Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsSummaryofaggregateamountsPayabletoKeyManagementPersonnelDetails" roleURI="http://www.sanofi.com/role/RelatedpartytransactionsSummaryofaggregateamountsPayabletoKeyManagementPersonnelDetails">
        <link:definition>9954630 - Disclosure - Related party transactions - Summary of aggregate amounts Payable to Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DisclosuresaboutmajorcustomersandcreditriskDetails" roleURI="http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails">
        <link:definition>9954631 - Disclosure - Disclosures about major customers and credit risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationAdditionalInformationDetails" roleURI="http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails">
        <link:definition>9954632 - Disclosure - Segment information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" roleURI="http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails">
        <link:definition>9954633 - Disclosure - Segment information - Summary of Net Sales by Segment and Geographical Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationScheduleofSegmentResultsDetails" roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails">
        <link:definition>9954634 - Disclosure - Segment information - Schedule of Segment Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails">
        <link:definition>9954635 - Disclosure - Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails">
        <link:definition>9954636 - Disclosure - Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" roleURI="http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails">
        <link:definition>9954637 - Disclosure - Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrincipalaccountantsfeesandservicesDetails" roleURI="http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails">
        <link:definition>9954638 - Disclosure - Principal accountants' fees and services (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails" roleURI="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails">
        <link:definition>9954639 - Disclosure - List of principal companies included in the scope of consolidation during&#160;2023 - Summary of Principal Companies and their Country of Incorporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails" roleURI="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails">
        <link:definition>9954640 - Disclosure - List of principal companies included in the scope of consolidation during&#160;2023 - Summary of Principal Investments Accounted for Using the Equity Method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EventssubsequenttoDecember312023Details" roleURI="http://www.sanofi.com/role/EventssubsequenttoDecember312023Details">
        <link:definition>9954641 - Disclosure - Events subsequent to December 31, 2023 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sny_DisclosureOfInformationOnIncomeStatementLineItems" abstract="true" name="DisclosureOfInformationOnIncomeStatementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_SanofiPasteurBiologiesCo.LtdMember" abstract="true" name="SanofiPasteurBiologiesCo.LtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SuppliersMember" abstract="true" name="SuppliersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EquityInstrumentsIncludedInFinancialAssetMember" abstract="true" name="EquityInstrumentsIncludedInFinancialAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DefendantDomain" abstract="true" name="DefendantDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfBellweatherTrialsHeld" abstract="false" name="NumberOfBellweatherTrialsHeld" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_SanofiForeignParticipationsB.V.Member" abstract="true" name="SanofiForeignParticipationsB.V.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" abstract="false" name="BasicEarningsLossPerShareAttributableToOwnersOfParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_SanofiWinthropIndustriesMember" abstract="true" name="SanofiWinthropIndustriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiIndiaLimitedMember" abstract="true" name="SanofiIndiaLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CurrentEquityDerivativesPayable" abstract="false" name="CurrentEquityDerivativesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LegalAndArbitralProceedingsAxis" abstract="true" name="LegalAndArbitralProceedingsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SpecialDistributionPercentageOfShareCapitalDistributed" abstract="false" name="SpecialDistributionPercentageOfShareCapitalDistributed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_PretaxDiscountRateAppliedForGoodwill" abstract="false" name="PretaxDiscountRateAppliedForGoodwill" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_NonCurrentFinanceLeaseReceivablesGross" abstract="false" name="NonCurrentFinanceLeaseReceivablesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsGenzymeMember" abstract="true" name="PrincipalMarketedProductsGenzymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfSharesIssuedByExerciceOfEachOption" abstract="false" name="NumberOfSharesIssuedByExerciceOfEachOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsTable" abstract="true" name="DisclosureOfOffBalanceSheetCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock" abstract="false" name="DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_GenzymePolyclonalsSASMember" abstract="true" name="GenzymePolyclonalsSASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight" abstract="false" name="BusinessCombinationCashPaymentPerNonTransferableContingentValueRight" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" abstract="false" name="NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" abstract="false" name="IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MaximumPlan1Member" abstract="true" name="MaximumPlan1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DevelopmentOfCemiplimabREGN2810Member" abstract="true" name="DevelopmentOfCemiplimabREGN2810Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OptionVestingPeriod" abstract="false" name="OptionVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_MinimumPlan2Member" abstract="true" name="MinimumPlan2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OutsideUnitedStatesMember" abstract="true" name="OutsideUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_UniformImpairmentTestingPercentage" abstract="false" name="UniformImpairmentTestingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_InterestsInOtherEntitiesAbstract" abstract="true" name="InterestsInOtherEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_SpecialtyCareMember" abstract="true" name="SpecialtyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_USGovernmentMember" abstract="true" name="USGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MachineryAndEquipment1Member" abstract="true" name="MachineryAndEquipment1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiABMember" abstract="true" name="SanofiABMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RebatesAndDiscountsMember" abstract="true" name="RebatesAndDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GenzymeMember" abstract="true" name="GenzymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOtherNonCurrentAssetsLineItems" abstract="true" name="DisclosureOfOtherNonCurrentAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs" abstract="false" name="ReducedAmountOfCompensationClaimedByFilledPlaintiffs" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GuaranteesGivenMember" abstract="true" name="GuaranteesGivenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherCountriesInSegmentResultsMember" abstract="true" name="OtherCountriesInSegmentResultsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfAuditorRemunerationForStatutoryAudit" abstract="false" name="PercentageOfAuditorRemunerationForStatutoryAudit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" abstract="true" name="DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_SanofiSaglikUrunleriLimitedSirketiMember" abstract="true" name="SanofiSaglikUrunleriLimitedSirketiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PlanAssetsEffectOfAssetCeiling" abstract="false" name="PlanAssetsEffectOfAssetCeiling" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfDefinedBenefitPlans" abstract="false" name="NumberOfDefinedBenefitPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_March2019EMTNISINFR0013409844Member" abstract="true" name="March2019EMTNISINFR0013409844Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock" abstract="false" name="DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_NetAmountsAsReportedInTheBalanceSheet" abstract="false" name="NetAmountsAsReportedInTheBalanceSheet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OperatingSegmentsAbstract" abstract="true" name="OperatingSegmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_StockOptionPlansMember" abstract="true" name="StockOptionPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MerieuxCanadaHoldingsULCCanadaMember" abstract="true" name="MerieuxCanadaHoldingsULCCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsAblynxMember" abstract="true" name="PrincipalMarketedProductsAblynxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" abstract="false" name="DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember" abstract="true" name="AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" abstract="false" name="NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RestructuringCostsReversedAndSimilarItems" abstract="false" name="RestructuringCostsReversedAndSimilarItems" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_KadmonCorporationLLCMember" abstract="true" name="KadmonCorporationLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaHealthcareKoreaIncMember" abstract="true" name="OpellaHealthcareKoreaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfCreditFacilities" abstract="false" name="NumberOfCreditFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_TaxotereProductLitigationInTheUSMember" abstract="true" name="TaxotereProductLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" abstract="false" name="IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInJapaneseYenMember" abstract="true" name="ForwardCurrencySalesInJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" abstract="false" name="ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EquityDerivativesMember" abstract="true" name="EquityDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OrigimmBiotechnologyGmbHMember" abstract="true" name="OrigimmBiotechnologyGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiPasteurLtdMember" abstract="true" name="SanofiPasteurLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory" abstract="false" name="DescriptionOfAccountingPolicyForCostOfSalesExplanatory" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_FairValueOfTheContingentConsideration" abstract="false" name="FairValueOfTheContingentConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_QuotedEuroDenominatedSeniorBondsMember" abstract="true" name="QuotedEuroDenominatedSeniorBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GoodwillTaxDeductiblePeriod" abstract="false" name="GoodwillTaxDeductiblePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_NumberOfLawsuitsRuledOnMerit" abstract="false" name="NumberOfLawsuitsRuledOnMerit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_StockSubscriptionOptionPlanSevenMember" abstract="true" name="StockSubscriptionOptionPlanSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_StockSubscriptionOptionPlanTenMember" abstract="true" name="StockSubscriptionOptionPlanTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets" abstract="false" name="DecreaseThroughLossOfControlOfSubsidiaryNetAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PercentageContributedToFairValueOfPlanAssets" abstract="false" name="PercentageContributedToFairValueOfPlanAssets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ProvisionsForDiscountsRebatesAndSalesReturns" abstract="false" name="ProvisionsForDiscountsRebatesAndSalesReturns" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_QualifiedDefinedBenefitPensionPlansMember" abstract="true" name="QualifiedDefinedBenefitPensionPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_PercentageOfSecondPartOfDevelopmentCostsFunded" abstract="false" name="PercentageOfSecondPartOfDevelopmentCostsFunded" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_GlobalPenaltyFeeIncurredByDefendants" abstract="false" name="GlobalPenaltyFeeIncurredByDefendants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member" abstract="true" name="InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SynthorxIncMember" abstract="true" name="SynthorxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PlavixLitigationCommonwealthInAustraliaMember" abstract="true" name="PlavixLitigationCommonwealthInAustraliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement" abstract="false" name="NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock" abstract="false" name="DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_PeriodOfShareRepurchaseProgram" abstract="false" name="PeriodOfShareRepurchaseProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_PlavixMember" abstract="true" name="PlavixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" abstract="false" name="AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ValueOnRedemptionAfterDerivativeInstrumentsMember" abstract="true" name="ValueOnRedemptionAfterDerivativeInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ManagedCareAndGPOProgramsMember" abstract="true" name="ManagedCareAndGPOProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TypesOfAgreementAxis" abstract="true" name="TypesOfAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember" abstract="true" name="ChangeInEuroAndUSDollarShortTermInterestRatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiProdutosFarmaceuticosLdaMember" abstract="true" name="SanofiProdutosFarmaceuticosLdaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TargeGenIncMember" abstract="true" name="TargeGenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiEgyptSAEMember" abstract="true" name="SanofiEgyptSAEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisMalaysiaSDNBHDMember" abstract="true" name="SanofiAventisMalaysiaSDNBHDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_A340BDrugPricingProgramInTheUnitedStatesMember" abstract="true" name="A340BDrugPricingProgramInTheUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_May32022Member" abstract="true" name="May32022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" abstract="false" name="IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DeferredTaxRelatingToRestructuringProvisionsMember" abstract="true" name="DeferredTaxRelatingToRestructuringProvisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AlprolixMember" abstract="true" name="AlprolixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfActionDeclaredTimeBarred" abstract="false" name="NumberOfActionDeclaredTimeBarred" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiASMember" abstract="true" name="SanofiASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ProvisionsForOtherLongTermBenefitsMember" abstract="true" name="ProvisionsForOtherLongTermBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GovernmentAndStateProgramsMember" abstract="true" name="GovernmentAndStateProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty" abstract="false" name="PercentageOfFutureDevelopmentExpenseFundedByOtherParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" abstract="false" name="IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OverdueReceivablesGrossValue" abstract="false" name="OverdueReceivablesGrossValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ShireHumanGeneticTherapiesIncMember" abstract="true" name="ShireHumanGeneticTherapiesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BusinessOperatingIncome" abstract="false" name="BusinessOperatingIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AventisPharmaSAFranceMember" abstract="true" name="AventisPharmaSAFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems" abstract="true" name="DisclosureOfTaxLossesAvailableForCarryforwardLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_AmunixMember" abstract="true" name="AmunixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" abstract="false" name="DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfSharesHeld" abstract="false" name="NumberOfSharesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" abstract="false" name="DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock" abstract="false" name="DisclosureOfProvisionsAndOtherLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_LeasedAssetsPercentage" abstract="false" name="LeasedAssetsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_SanofiAventisSouthAfricaPtyLtdMember" abstract="true" name="SanofiAventisSouthAfricaPtyLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive092Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ImmunoOncologyCollaborationAgreementMember" abstract="true" name="ImmunoOncologyCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RoyaltiesPayable" abstract="false" name="RoyaltiesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiAventisGulfFZEMember" abstract="true" name="SanofiAventisGulfFZEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_KadmonMember" abstract="true" name="KadmonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_StockBasedCompensationStockOptionsExercisedPricePerShare" abstract="false" name="StockBasedCompensationStockOptionsExercisedPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_NumberOfClaimantExposed" abstract="false" name="NumberOfClaimantExposed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_LongTermPrepaidExpenses" abstract="false" name="LongTermPrepaidExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AventisubLLCMember" abstract="true" name="AventisubLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" abstract="false" name="UpfrontPaymentsForProjectsUnderCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrencyDerivativesOperatingMember" abstract="true" name="CurrencyDerivativesOperatingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiOyMember" abstract="true" name="SanofiOyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock" abstract="false" name="DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ALTUVIIIOMember" abstract="true" name="ALTUVIIIOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" abstract="false" name="DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement" abstract="false" name="CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IndustrialSalesMember" abstract="true" name="IndustrialSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfBondIssuesRedeemed" abstract="false" name="NumberOfBondIssuesRedeemed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_SalesOfAntibodiesFirstAchievementMember" abstract="true" name="SalesOfAntibodiesFirstAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LaboratoryFacilitiesCambridgeMassachusettsMember" abstract="true" name="LaboratoryFacilitiesCambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DepakineProductLitigationInNorthernIrelandMember" abstract="true" name="DepakineProductLitigationInNorthernIrelandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherCurrenciesMember" abstract="true" name="OtherCurrenciesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems" abstract="true" name="DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" abstract="false" name="NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ManufacturingAndSupplyMember" abstract="true" name="ManufacturingAndSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LonzaMember" abstract="true" name="LonzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DengvaxiaProductLitigationInThePhilippinesMember" abstract="true" name="DengvaxiaProductLitigationInThePhilippinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_March2018EMTNISINFR0013324340Member" abstract="true" name="March2018EMTNISINFR0013324340Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsBioverativMember" abstract="true" name="PrincipalMarketedProductsBioverativMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" abstract="false" name="CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GeneralMedecinesMember" abstract="true" name="GeneralMedecinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock" abstract="false" name="DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsRezurockMember" abstract="true" name="PrincipalMarketedProductsRezurockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AssociatesAndJointVenturesMember" abstract="true" name="AssociatesAndJointVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfPeopleExposed" abstract="false" name="NumberOfPeopleExposed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030" abstract="false" name="PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sny_InterestIncome" abstract="false" name="InterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_September2015EMTNISINFR0012969038Member" abstract="true" name="September2015EMTNISINFR0012969038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement" abstract="false" name="ValueOfShareOptionsExercisedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax" abstract="false" name="HedgesOfNetInvestmentsInForeignOperationsAfterTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IGMBiosciencesIncMember" abstract="true" name="IGMBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" abstract="false" name="DilutedEarningsLossPerShareAttributableToOwnersOfParent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" abstract="false" name="ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ContractualAgreementForAntiProgrammedCellDeathProtein1" abstract="false" name="ContractualAgreementForAntiProgrammedCellDeathProtein1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_CollaborationAgreementsRegulatoryMilestonePayment" abstract="false" name="CollaborationAgreementsRegulatoryMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember" abstract="true" name="ForwardCurrencyPurchasedInChineseYuanRenminbiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiPasteurNVLMember" abstract="true" name="SanofiPasteurNVLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments" abstract="false" name="OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_FairValueOfPlanAtDateOfGrant" abstract="false" name="FairValueOfPlanAtDateOfGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiSRLMember" abstract="true" name="SanofiSRLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_UnquotedDebtSecuritiesMember" abstract="true" name="UnquotedDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock" abstract="false" name="DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock" abstract="false" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_PaymentRelatedToAttainmentOfGoal" abstract="false" name="PaymentRelatedToAttainmentOfGoal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherRestructuringCost" abstract="false" name="OtherRestructuringCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiAventisRechercheEtDeveloppementMember" abstract="true" name="SanofiAventisRechercheEtDeveloppementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" abstract="true" name="DisclosureOfOffBalanceSheetCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_CommercialPaperProgramInUSAMember" abstract="true" name="CommercialPaperProgramInUSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateDerivativesMeasuredAtFairValue" abstract="false" name="InterestRateDerivativesMeasuredAtFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BusinessCombinationPurchasePrice" abstract="false" name="BusinessCombinationPurchasePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_StockOptionsWithNoDilutiveEffect" abstract="false" name="StockOptionsWithNoDilutiveEffect" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_JevtanaMember" abstract="true" name="JevtanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_QuotedEquityInvestmentsMember" abstract="true" name="QuotedEquityInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember" abstract="true" name="ConsolidationAdjustmentsIntragroupMarginInInventoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ParticipatingSharesCarryingAmount" abstract="false" name="ParticipatingSharesCarryingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PercentageOfProfitShareOnCounterpartiesProfit" abstract="false" name="PercentageOfProfitShareOnCounterpartiesProfit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" abstract="false" name="ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherGainsLossesAndLitigation" abstract="false" name="OtherGainsLossesAndLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OpellaHealthcareFranceSASMember" abstract="true" name="OpellaHealthcareFranceSASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" abstract="false" name="GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_QuotedEquitySecuritiesMember" abstract="true" name="QuotedEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_April2022EMTNISINFR0014009KS6Member" abstract="true" name="April2022EMTNISINFR0014009KS6Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RegeneronPharmaceuticalsIncMember" abstract="true" name="RegeneronPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MinimumPlan1Member" abstract="true" name="MinimumPlan1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IrrevocablePurchaseCommitmentsGiven" abstract="false" name="IrrevocablePurchaseCommitmentsGiven" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_StockSubscriptionOptionPlanSixMember" abstract="true" name="StockSubscriptionOptionPlanSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaHealthcarePolandSpZOOMember" abstract="true" name="OpellaHealthcarePolandSpZOOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutInventoriesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_AventisCropScienceRetainedLiabilitiesMember" abstract="true" name="AventisCropScienceRetainedLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TwoThousandFourteenAmendedInvestmentAgreementMember" abstract="true" name="TwoThousandFourteenAmendedInvestmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharesMember" abstract="true" name="RestrictedSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_VaccinesMember" abstract="true" name="VaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherNonCoreAssetsMember" abstract="true" name="OtherNonCoreAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SspCoLtdMember" abstract="true" name="SspCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" abstract="false" name="PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ContingenciesArisingFromCertainBusinessDivestituresMember" abstract="true" name="ContingenciesArisingFromCertainBusinessDivestituresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" abstract="false" name="ExpenseOfRestructuringActivitiesTransformationProgramsCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DepakineProductLitigationInSpainMember" abstract="true" name="DepakineProductLitigationInSpainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfPatientsToIndemnify" abstract="false" name="NumberOfPatientsToIndemnify" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_SpecialDistributionNumberOfSharesConverted" abstract="false" name="SpecialDistributionNumberOfSharesConverted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" abstract="false" name="ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" abstract="false" name="AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiBioverativHoldingsLLCMember" abstract="true" name="SanofiBioverativHoldingsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal" abstract="false" name="NumberOfPlaintiffsWhoFiledNoticesToAppeal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" abstract="false" name="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees" abstract="false" name="NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_IncomeResultingFromOutLicensing" abstract="false" name="IncomeResultingFromOutLicensing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ProventionBioMember" abstract="true" name="ProventionBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CumulativeDevelopmentCostsIncurred" abstract="false" name="CumulativeDevelopmentCostsIncurred" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OpellaHealthcareHungaryCommercialKFTMember" abstract="true" name="OpellaHealthcareHungaryCommercialKFTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OneBillionBondsMaturingNovember2023Member" abstract="true" name="OneBillionBondsMaturingNovember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral" abstract="false" name="EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LeaseCosts" abstract="false" name="LeaseCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ConcentrationRiskThresholdPercentage" abstract="false" name="ConcentrationRiskThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_PercentageOfCumulativeDevelopmentCostsReimbursed" abstract="false" name="PercentageOfCumulativeDevelopmentCostsReimbursed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_WithoutMarketConditionMember" abstract="true" name="WithoutMarketConditionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember" abstract="true" name="PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod" abstract="false" name="OwnershipInterestInSubsidiaryMinimumHoldingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_PropertyPlantAndEquipmentInProcessMember" abstract="true" name="PropertyPlantAndEquipmentInProcessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BioAtriumMember" abstract="true" name="BioAtriumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DebtInstrumentsMember" abstract="true" name="DebtInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember" abstract="true" name="FinancialAssetsHeldToFundDeferredCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember" abstract="true" name="GenzymeGlobalSarlBaarIntellectualPropertyBranchMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfOngoingLawsuits" abstract="false" name="NumberOfOngoingLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock" abstract="false" name="DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" abstract="false" name="DisclosureOfCurrentTradeReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock" abstract="false" name="DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ChattemGBHoldingMember" abstract="true" name="ChattemGBHoldingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ActuarialAssumptionOfMortalityTableMember" abstract="true" name="ActuarialAssumptionOfMortalityTableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisMarocMember" abstract="true" name="SanofiAventisMarocMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiBelgiumMember" abstract="true" name="SanofiBelgiumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity" abstract="false" name="NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" abstract="false" name="DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_NewAgreementMember" abstract="true" name="NewAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfGuaranteesTable" abstract="true" name="DisclosureOfGuaranteesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_UncertaintiesOverIncomeTaxTreatmentsMember" abstract="true" name="UncertaintiesOverIncomeTaxTreatmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsLineItems" abstract="true" name="DisclosureOfLegalAndArbitralProceedingsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfOtherNonCurrentAssetsTable" abstract="true" name="DisclosureOfOtherNonCurrentAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_NumberOfCurrenciesDebtIsIssuedIn" abstract="false" name="NumberOfCurrenciesDebtIsIssuedIn" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable" abstract="true" name="DisclosureOfDetailedInformationAboutIncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_TotalStockOptionPlansMember" abstract="true" name="TotalStockOptionPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_StockPrice" abstract="false" name="StockPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_DepakineProductLitigationInSwitzerlandMember" abstract="true" name="DepakineProductLitigationInSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfVaccineDosesToBeSupplied" abstract="false" name="NumberOfVaccineDosesToBeSupplied" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" abstract="false" name="IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AmountsPayableForAcquisitionOfNonCurrentAssets" abstract="false" name="AmountsPayableForAcquisitionOfNonCurrentAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember" abstract="true" name="ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CashEquivalentsMoneyMarketMutualFunds" abstract="false" name="CashEquivalentsMoneyMarketMutualFunds" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems" abstract="true" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember" abstract="true" name="FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisPhilippinesIncMember" abstract="true" name="SanofiAventisPhilippinesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" abstract="false" name="GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MarketConditionAxis" abstract="true" name="MarketConditionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_TransferPercentageOfPandemicVaccines" abstract="false" name="TransferPercentageOfPandemicVaccines" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare" abstract="false" name="BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_OtherBankBorrowings" abstract="false" name="OtherBankBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiManufacturingPteLtdMember" abstract="true" name="SanofiManufacturingPteLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasedInJapaneseYenMember" abstract="true" name="ForwardCurrencyPurchasedInJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" abstract="false" name="TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sny_GenzymeGlobalSarlMember" abstract="true" name="GenzymeGlobalSarlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ReductionOfSharesByCancellationOfTreasuryShares" abstract="false" name="ReductionOfSharesByCancellationOfTreasuryShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_PercentageOfProfitsArisingFromCommercialOperations" abstract="false" name="PercentageOfProfitsArisingFromCommercialOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasedInUSDollarUSBondMember" abstract="true" name="ForwardCurrencyPurchasedInUSDollarUSBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock" abstract="false" name="DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OtherTerritoriesMember" abstract="true" name="OtherTerritoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable" abstract="true" name="DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" abstract="false" name="IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MSPVaccineCompanyMember" abstract="true" name="MSPVaccineCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee" abstract="false" name="AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive343Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_HoechstGmbHMember" abstract="true" name="HoechstGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" abstract="false" name="AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" abstract="false" name="CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" abstract="false" name="TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement" abstract="false" name="ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ActuarialGainsAndLossesOnDefinedBenefitPlans" abstract="false" name="ActuarialGainsAndLossesOnDefinedBenefitPlans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PerformanceSharePlanOneMember" abstract="true" name="PerformanceSharePlanOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AntibodiesMember" abstract="true" name="AntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfPatentActionsInitiallyFiled" abstract="false" name="NumberOfPatentActionsInitiallyFiled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" abstract="false" name="DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_A.NattermannCie.GmbHMember" abstract="true" name="A.NattermannCie.GmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfInventoriesTable" abstract="true" name="DisclosureOfInventoriesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" abstract="false" name="DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AtMarketValueMember" abstract="true" name="AtMarketValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MinusTwentyFiveBasisPointsMember" abstract="true" name="MinusTwentyFiveBasisPointsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DerivativeFinancialAssetsMember" abstract="true" name="DerivativeFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable" abstract="true" name="ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_AllergyMember" abstract="true" name="AllergyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiBeijingPharmaceuticalsCoLtdMember" abstract="true" name="SanofiBeijingPharmaceuticalsCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired" abstract="false" name="BusinessAcquisitionsPercentageOfVotingInterestsAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sny_DisclosureOfOtherOperatingIncomeTable" abstract="true" name="DisclosureOfOtherOperatingIncomeTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_April302021Member" abstract="true" name="April302021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CollaborationAgreementCommitmentAmount" abstract="false" name="CollaborationAgreementCommitmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GainLossOnImpairmentOfTreasuryShares" abstract="false" name="GainLossOnImpairmentOfTreasuryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfCivilClaimsOnGoing" abstract="false" name="NumberOfCivilClaimsOnGoing" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_PercentageIncreaseInFairValueLiabilities" abstract="false" name="PercentageIncreaseInFairValueLiabilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncomeStatementLocation1Axis" abstract="true" name="IncomeStatementLocation1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_WorldHealthOrganizationMember" abstract="true" name="WorldHealthOrganizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" abstract="true" name="ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AventisPharmaLimitedMember" abstract="true" name="AventisPharmaLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" abstract="false" name="ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock" abstract="false" name="DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OthersCounterpartyMember" abstract="true" name="OthersCounterpartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AztecaVacunasSADeCVMember" abstract="true" name="AztecaVacunasSADeCVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsTableTextBlock" abstract="false" name="DisclosureOfNonCurrentProvisionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" abstract="false" name="DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ImpactOfChangeInInterestRateOnPreTaxIncome" abstract="false" name="ImpactOfChangeInInterestRateOnPreTaxIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RestrictedSharePlansMember" abstract="true" name="RestrictedSharePlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" abstract="true" name="DisclosureOfOtherOperatingIncomeExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_NumberOfFamiliesWhoFiledACivilClaim" abstract="false" name="NumberOfFamiliesWhoFiledACivilClaim" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_AtNotionalAmountMember" abstract="true" name="AtNotionalAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfFutureDevelopmentExpenseFundedByCompany" abstract="false" name="PercentageOfFutureDevelopmentExpenseFundedByCompany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ImmunooncologyAllianceMember" abstract="true" name="ImmunooncologyAllianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DefendantAxis" abstract="true" name="DefendantAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_ShareBasedPaymentPlansAbstract" abstract="true" name="ShareBasedPaymentPlansAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember" abstract="true" name="InterestRateSwapsPay057ReceiveCapitalizedEoniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment" abstract="false" name="MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfAccountsReceivableTable" abstract="true" name="DisclosureOfAccountsReceivableTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock" abstract="false" name="DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InnoventBiologicsMember" abstract="true" name="InnoventBiologicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PreFundedPensionObligations" abstract="false" name="PreFundedPensionObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PrincipalAlliancesAxis" abstract="true" name="PrincipalAlliancesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_CurrencyDerivativesMeasuredAtFairValue" abstract="false" name="CurrencyDerivativesMeasuredAtFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock" abstract="false" name="DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_CurrentAssetsMember" abstract="true" name="CurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock" abstract="false" name="DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_CostOfDebtNet" abstract="false" name="CostOfDebtNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SalesOfAntibodiesThirdAchievementMember" abstract="true" name="SalesOfAntibodiesThirdAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExpenseCategoriesAxis" abstract="true" name="ExpenseCategoriesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_StockSubscriptionOptionPlanEightMember" abstract="true" name="StockSubscriptionOptionPlanEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaHealthcareGroupSASMember" abstract="true" name="OpellaHealthcareGroupSASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BorrowingMaximumDrawdown" abstract="false" name="BorrowingMaximumDrawdown" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ConsiderationTransferredMaximumAmount" abstract="false" name="ConsiderationTransferredMaximumAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InsurancePoliciesMember" abstract="true" name="InsurancePoliciesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisAustraliaPtyLtdMember" abstract="true" name="SanofiAventisAustraliaPtyLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisDeColombiaSAMember" abstract="true" name="SanofiAventisDeColombiaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised" abstract="false" name="UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentDerivativesMember" abstract="true" name="NonCurrentDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommoditiesMember" abstract="true" name="CommoditiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CapitalLossesCarryBackPeriod" abstract="false" name="CapitalLossesCarryBackPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" abstract="false" name="ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CashEquivalentsCommercialPaper" abstract="false" name="CashEquivalentsCommercialPaper" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" abstract="false" name="DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_MajorTerritoriesMember" abstract="true" name="MajorTerritoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisAlgerieMember" abstract="true" name="SanofiAventisAlgerieMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfPersonnelCostsDetailsTableTextBlock" abstract="false" name="DisclosureOfPersonnelCostsDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_NonCurrentRestructuringProvisionMember" abstract="true" name="NonCurrentRestructuringProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ImpairmentOfAssetsAbstract" abstract="true" name="ImpairmentOfAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_NumberOfIndividualCasesSettled" abstract="false" name="NumberOfIndividualCasesSettled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities" abstract="false" name="DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfLineOfCreditFacilityLineItems" abstract="true" name="DisclosureOfLineOfCreditFacilityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_CommercialPaperProgramInFranceMember" abstract="true" name="CommercialPaperProgramInFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AventisPharmaHoldingsLtdMember" abstract="true" name="AventisPharmaHoldingsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AuditorsNameAxis" abstract="true" name="AuditorsNameAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" abstract="false" name="EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentLiabilitiesMember" abstract="true" name="NonCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2021Member" abstract="true" name="RestrictedSharePlan2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DerivativeFinancialLiabilitiesMember" abstract="true" name="DerivativeFinancialLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ChargebackIncentivesMember" abstract="true" name="ChargebackIncentivesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RamiprilCanadaPatentLitigationMember" abstract="true" name="RamiprilCanadaPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GoldBondProductLitigationInTheUSMember" abstract="true" name="GoldBondProductLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiMatureIPMember" abstract="true" name="SanofiMatureIPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NonINBRX101BusinessSpinCo.Member" abstract="true" name="NonINBRX101BusinessSpinCo.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CerezymeMember" abstract="true" name="CerezymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" abstract="false" name="IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaHealthcareItalySRLMember" abstract="true" name="OpellaHealthcareItalySRLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfSharesRepurchased" abstract="false" name="NumberOfSharesRepurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_SeniorBondMember" abstract="true" name="SeniorBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsBeyfortusMember" abstract="true" name="PrincipalMarketedProductsBeyfortusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PensionObligationPercentageToDefinedBenefitLiability" abstract="false" name="PensionObligationPercentageToDefinedBenefitLiability" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_SanofiaventisAEBEMember" abstract="true" name="SanofiaventisAEBEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TopUpDefinedBenefitPensionPlanMember" abstract="true" name="TopUpDefinedBenefitPensionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AntibodiesAllianceMember" abstract="true" name="AntibodiesAllianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfClaimantExposedWhoWithdrawedTheClaim" abstract="false" name="NumberOfClaimantExposedWhoWithdrawedTheClaim" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" abstract="false" name="CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ZantacLitigationInCanadaMember" abstract="true" name="ZantacLitigationInCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfTradingDaysPrecedingPlanApproval" abstract="false" name="NumberOfTradingDaysPrecedingPlanApproval" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss" abstract="false" name="PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="sny_RoyaltyExpensePercentage" abstract="false" name="RoyaltyExpensePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsChattemMember" abstract="true" name="PrincipalMarketedProductsChattemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaHealthcareUKLimitedMember" abstract="true" name="OpellaHealthcareUKLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiKKMember" abstract="true" name="SanofiKKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CurrentDerivativesMember" abstract="true" name="CurrentDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiPasteurHepatitisBVaccineMember" abstract="true" name="SanofiPasteurHepatitisBVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LeaseLiabilitiesEffectOfDiscounting" abstract="false" name="LeaseLiabilitiesEffectOfDiscounting" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity" abstract="false" name="UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCoreAssetsMember" abstract="true" name="NonCoreAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices" abstract="false" name="AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfOtherManufacturersInvolvedInProceedings" abstract="false" name="NumberOfOtherManufacturersInvolvedInProceedings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DepakineProductLitigationInGreatBritainMember" abstract="true" name="DepakineProductLitigationInGreatBritainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" abstract="false" name="DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_NumberOfCountriesIncludedInPensionPlans" abstract="false" name="NumberOfCountriesIncludedInPensionPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="sny_NumberOfLeaseAgreementsSigned" abstract="false" name="NumberOfLeaseAgreementsSigned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_UniformPreTaxDiscountRates" abstract="false" name="UniformPreTaxDiscountRates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ShelfRegistrationStatementProgramMember" abstract="true" name="ShelfRegistrationStatementProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GuaranteesReceivedMember" abstract="true" name="GuaranteesReceivedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiChimieMember" abstract="true" name="SanofiChimieMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030" abstract="false" name="PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember" abstract="true" name="ForwardCurrencyPurchasedInUSDollarCommercialPaperMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CollaborationAgreementAnnualNetSalesTarget" abstract="false" name="CollaborationAgreementAnnualNetSalesTarget" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsTable" abstract="true" name="DisclosureOfNonCurrentProvisionsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_SalesOfAntibodiesSecondAchievementMember" abstract="true" name="SalesOfAntibodiesSecondAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable" abstract="true" name="DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_MilestoneTypesDomain" abstract="true" name="MilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared" abstract="false" name="PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_MyozymeOrLumizymeMember" abstract="true" name="MyozymeOrLumizymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TaxLossCarryforwardsOnAssetDisposals" abstract="false" name="TaxLossCarryforwardsOnAssetDisposals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiAventisKoreaCoLtdMember" abstract="true" name="SanofiAventisKoreaCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FairValueOfSPMSDContingentConsiderationMember" abstract="true" name="FairValueOfSPMSDContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiPasteurEuropeMember" abstract="true" name="SanofiPasteurEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ChinoinPrivateCoLtdMember" abstract="true" name="ChinoinPrivateCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember" abstract="true" name="RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock" abstract="false" name="DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember" abstract="true" name="ValueOnRedemptionBeforeDerivativeInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ConsumerHealthcareSegmentMember" abstract="true" name="ConsumerHealthcareSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock" abstract="false" name="DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_PossibleIncreaseInMortalityTableInYears" abstract="false" name="PossibleIncreaseInMortalityTableInYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_LitigationAmountPayable" abstract="false" name="LitigationAmountPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfAuditFeesAndOtherServicesTable" abstract="true" name="DisclosureOfAuditFeesAndOtherServicesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" abstract="false" name="IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasedInHungarianForintMember" abstract="true" name="ForwardCurrencyPurchasedInHungarianForintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IrrevocablePurchaseCommitmentsReceived" abstract="false" name="IrrevocablePurchaseCommitmentsReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfOperatingSegments1" abstract="false" name="NumberOfOperatingSegments1" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_MinusHundredBasisPointsMember" abstract="true" name="MinusHundredBasisPointsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock" abstract="false" name="DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_RestrictedSharePlan2023Member" abstract="true" name="RestrictedSharePlan2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems" abstract="true" name="DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SwedishOrphanBiovitrumABMember" abstract="true" name="SwedishOrphanBiovitrumABMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_May252023Member" abstract="true" name="May252023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherGuaranteesGivenMember" abstract="true" name="OtherGuaranteesGivenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_March2020EMTNISINFR0013505112Member" abstract="true" name="March2020EMTNISINFR0013505112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PricewaterhousecoopersMember" abstract="true" name="PricewaterhousecoopersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense" abstract="false" name="MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems" abstract="true" name="DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_FabrazymeMember" abstract="true" name="FabrazymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes" abstract="false" name="TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_SanofiAventisParticipationsSASMember" abstract="true" name="SanofiAventisParticipationsSASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InfraservHoechstRetainedLiabilitiesMember" abstract="true" name="InfraservHoechstRetainedLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OneBillionBondsMaturingJune2023Member" abstract="true" name="OneBillionBondsMaturingJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DupixentMember" abstract="true" name="DupixentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OfficeSpaceCambridgeMassachusettsMember" abstract="true" name="OfficeSpaceCambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PainCareMember" abstract="true" name="PainCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock" abstract="false" name="DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_INBRX101BusinessRemainCo.Member" abstract="true" name="INBRX101BusinessRemainCo.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasedInKoreanWonMember" abstract="true" name="ForwardCurrencyPurchasedInKoreanWonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutIncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_RestrictedSharePlan2020Member" abstract="true" name="RestrictedSharePlan2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommitmentsMadeToJointVenturesAndAssociates" abstract="false" name="CommitmentsMadeToJointVenturesAndAssociates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiAventisDeVenezuelaSAMember" abstract="true" name="SanofiAventisDeVenezuelaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SubscriptionPricePerShare" abstract="false" name="SubscriptionPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_DisclosureOfPrincipalAlliancesTextBlock" abstract="false" name="DisclosureOfPrincipalAlliancesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember" abstract="true" name="IncreaseOfTenPercentBasisPointInMarketInterestRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TotalOffBalanceSheetCommitments" abstract="false" name="TotalOffBalanceSheetCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_FinancialInvestments" abstract="false" name="FinancialInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiPasteurThailandLtdMember" abstract="true" name="SanofiPasteurThailandLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InhibrxIncMember" abstract="true" name="InhibrxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CreditFacilitiesExtensionOptionPeriod" abstract="false" name="CreditFacilitiesExtensionOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios" abstract="false" name="PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_AuditorsRemunerationTableTextBlock" abstract="false" name="AuditorsRemunerationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MajorCollaborationAgreementMember" abstract="true" name="MajorCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" abstract="false" name="IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ShanghaiRonghengPharmaceuticalCoLtdMember" abstract="true" name="ShanghaiRonghengPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ProceedsFromCollaborationAgreements" abstract="false" name="ProceedsFromCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CarraigInsuranceDACMember" abstract="true" name="CarraigInsuranceDACMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherProductAndServicesMember" abstract="true" name="OtherProductAndServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" abstract="false" name="ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" abstract="false" name="DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiAventisDePanamaSAMember" abstract="true" name="SanofiAventisDePanamaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" abstract="true" name="InterestRateSwapsPayCapitalizedEsterReceive069Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CollaborationAgreementsDevelopmentMilestonePayment" abstract="false" name="CollaborationAgreementsDevelopmentMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NetChangeInOtherNonCurrentAssets" abstract="false" name="NetChangeInOtherNonCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrencyDerivativesFinancialMember" abstract="true" name="CurrencyDerivativesFinancialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RelatedPartyAbstract" abstract="true" name="RelatedPartyAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" abstract="false" name="ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember" abstract="true" name="MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfPayments" abstract="false" name="NumberOfPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_AuditorsRemunerationForAuditRelatedServices" abstract="false" name="AuditorsRemunerationForAuditRelatedServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PlavixRelatedLitigationInFranceMember" abstract="true" name="PlavixRelatedLitigationInFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiPasteurLimitedMember" abstract="true" name="SanofiPasteurLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherOperatingExpensesTableTextBlock" abstract="false" name="OtherOperatingExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_FairValuePerShareAwardedForThreeYearServicePeriod" abstract="false" name="FairValuePerShareAwardedForThreeYearServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_CambridgeMassachusettsMember" abstract="true" name="CambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" abstract="false" name="ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RedemptionOfDebtInstrumentIssued" abstract="false" name="RedemptionOfDebtInstrumentIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ContingentConsiderationRelatingToDivestmentsMember" abstract="true" name="ContingentConsiderationRelatingToDivestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_WriteDownMember" abstract="true" name="WriteDownMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisSuisseSAMember" abstract="true" name="SanofiAventisSuisseSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiAventisIsraelLtdMember" abstract="true" name="SanofiAventisIsraelLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfExecutiveCommitteeMembers" abstract="false" name="NumberOfExecutiveCommitteeMembers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfShareSubscribed" abstract="false" name="NumberOfShareSubscribed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ChattemIncMember" abstract="true" name="ChattemIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" abstract="false" name="DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_PrincipalUndiscountedCashFlow" abstract="false" name="PrincipalUndiscountedCashFlow" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfComplaintsFiled" abstract="false" name="NumberOfComplaintsFiled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_ParticipatingSharesNumberOutstanding" abstract="false" name="ParticipatingSharesNumberOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling" abstract="false" name="EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_EquityInvestmentSoldPercentage" abstract="false" name="EquityInvestmentSoldPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_SanofiAventisRomaniaSRLMember" abstract="true" name="SanofiAventisRomaniaSRLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_StockSubscriptionOptionPlanFiveMember" abstract="true" name="StockSubscriptionOptionPlanFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems" abstract="true" name="DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_MiscellaneousOtherOperatingIncomeExpenses" abstract="false" name="MiscellaneousOtherOperatingIncomeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ImpactOfPreTaxIncomeRecognisedInEquity" abstract="false" name="ImpactOfPreTaxIncomeRecognisedInEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock" abstract="false" name="DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ShareRepurchase2020ProgramMember" abstract="true" name="ShareRepurchase2020ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiIlacSanayiVeTicaretASMember" abstract="true" name="SanofiIlacSanayiVeTicaretASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" abstract="false" name="DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_StockOptionsAndShareBasedPaymentsMember" abstract="true" name="StockOptionsAndShareBasedPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NetExposure" abstract="false" name="NetExposure" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AwardsDateDomain" abstract="true" name="AwardsDateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SynthorxMember" abstract="true" name="SynthorxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_StockSubscriptionOptionPlanFourMember" abstract="true" name="StockSubscriptionOptionPlanFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NewBusinessModelRolloutInVariousGeographiesMember" abstract="true" name="NewBusinessModelRolloutInVariousGeographiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfPatentsAllegedlyInfringed" abstract="false" name="NumberOfPatentsAllegedlyInfringed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock" abstract="false" name="DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_EuroapiMember" abstract="true" name="EuroapiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount" abstract="false" name="InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_UnwindingOfDiscount" abstract="false" name="UnwindingOfDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations" abstract="false" name="PercentageOfProfitsAndLossesArisingFromCommercialOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember" abstract="true" name="InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BiopharmaSegmentMember" abstract="true" name="BiopharmaSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" abstract="false" name="CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GenzymeIrelandLimitedMember" abstract="true" name="GenzymeIrelandLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock" abstract="false" name="DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember" abstract="true" name="RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfClassActionLawsuits" abstract="false" name="NumberOfClassActionLawsuits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_BusinessCombinationCapitalContribution" abstract="false" name="BusinessCombinationCapitalContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentProvisionForEnvironmentRisks" abstract="false" name="NonCurrentProvisionForEnvironmentRisks" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EmployeeBenefitsAbstract" abstract="true" name="EmployeeBenefitsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DebtNetOfCashAndCashEquivalents" abstract="false" name="DebtNetOfCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InitialLeaseTerm" abstract="false" name="InitialLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_CollaborationAgreementWithGSKMember" abstract="true" name="CollaborationAgreementWithGSKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommitmentsReceivedForDevelopmentCosts" abstract="false" name="CommitmentsReceivedForDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ZantacLitigationInTheUSMember" abstract="true" name="ZantacLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ActionForWhichWeArePlaintiffMember" abstract="true" name="ActionForWhichWeArePlaintiffMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NotEligibleForHedgeAccountingMember" abstract="true" name="NotEligibleForHedgeAccountingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AuditorsNameMember" abstract="true" name="AuditorsNameMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember" abstract="true" name="PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember" abstract="true" name="ShenzhenSanofiPasteurBiologicalProductsCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsTZIELDMember" abstract="true" name="PrincipalMarketedProductsTZIELDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock" abstract="false" name="DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" abstract="false" name="RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AtomwiseMember" abstract="true" name="AtomwiseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInChineseYuanRenminbiMember" abstract="true" name="ForwardCurrencySalesInChineseYuanRenminbiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" abstract="false" name="EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_September2016EMTNISINFR0013201639Member" abstract="true" name="September2016EMTNISINFR0013201639Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DepakineProductLitigationInFranceMember" abstract="true" name="DepakineProductLitigationInFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_QuotedDebtInstrumentsMember" abstract="true" name="QuotedDebtInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiaventisSpZooMember" abstract="true" name="SanofiaventisSpZooMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MaximumOwnershipPercentageAllowedToAcquire" abstract="false" name="MaximumOwnershipPercentageAllowedToAcquire" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" abstract="false" name="IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PlusHundredBasisPointsMember" abstract="true" name="PlusHundredBasisPointsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiPasteurSpZooMember" abstract="true" name="SanofiPasteurSpZooMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030" abstract="false" name="PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sny_MapharMember" abstract="true" name="MapharMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal" abstract="false" name="SaleOfStockNumberOfSharesIssuedInTransactionTotal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_GainsOnDivestmentOfProducts" abstract="false" name="GainsOnDivestmentOfProducts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" abstract="false" name="CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiPasteurFranceSAMember" abstract="true" name="SanofiPasteurFranceSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareRepurchase2022ProgramMember" abstract="true" name="ShareRepurchase2022ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaHealthcarePanamaSAMember" abstract="true" name="OpellaHealthcarePanamaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets" abstract="false" name="AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_UnquotedEquityInvestmentsMember" abstract="true" name="UnquotedEquityInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisFranceMember" abstract="true" name="SanofiAventisFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PensionObligationPercentageToPlanAssets" abstract="false" name="PensionObligationPercentageToPlanAssets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ExpenseCategoriesDomain" abstract="true" name="ExpenseCategoriesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfFirstInstanceRulings" abstract="false" name="NumberOfFirstInstanceRulings" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_ManufactureAndSupplyCollaborationAgreementMember" abstract="true" name="ManufactureAndSupplyCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOtherOperatingIncomeLineItems" abstract="true" name="DisclosureOfOtherOperatingIncomeLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_PercentageOfNetSalesArisingFromCommercialOperations" abstract="false" name="PercentageOfNetSalesArisingFromCommercialOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_SanofiAventisThailandLtdMember" abstract="true" name="SanofiAventisThailandLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AcquiredRDMember" abstract="true" name="AcquiredRDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TotalUndiscountedCashFlow" abstract="false" name="TotalUndiscountedCashFlow" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod" abstract="false" name="TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_SanofiAventisUSLLCMember" abstract="true" name="SanofiAventisUSLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringProvisionsLineItems" abstract="true" name="DisclosureOfRestructuringProvisionsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" abstract="false" name="ExceptionalSupplementaryDividendPercentageOfShareCapital" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ActionForWhichWeAreDefendantMember" abstract="true" name="ActionForWhichWeAreDefendantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CurrentLiabilitiesMember" abstract="true" name="CurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_StockSubscriptionOptionPlanNineMember" abstract="true" name="StockSubscriptionOptionPlanNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiPasteurS.A.deC.V.Member" abstract="true" name="SanofiPasteurS.A.deC.V.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfInventoriesLineItems" abstract="true" name="DisclosureOfInventoriesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" abstract="false" name="PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_TypesOfAgreementDomain" abstract="true" name="TypesOfAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfOncologyTargetsUnderCollaborationAgreement" abstract="false" name="NumberOfOncologyTargetsUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_KiadisMember" abstract="true" name="KiadisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiAventisGroupeMember" abstract="true" name="SanofiAventisGroupeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ReservesLikelyToBeDistributedInTheForeseeableFuture" abstract="false" name="ReservesLikelyToBeDistributedInTheForeseeableFuture" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" abstract="true" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits" abstract="false" name="KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInTaiwanDollarMember" abstract="true" name="ForwardCurrencySalesInTaiwanDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisSingaporePteLtdMember" abstract="true" name="SanofiAventisSingaporePteLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures" abstract="false" name="IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" abstract="false" name="ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_FourBillionFacilityMaturingMarch2029Member" abstract="true" name="FourBillionFacilityMaturingMarch2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsTable" abstract="true" name="DisclosureOfLegalAndArbitralProceedingsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DerecognizedReceivables" abstract="false" name="DerecognizedReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod" abstract="false" name="IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" abstract="false" name="DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_GainLossOnCancellationOfTreasuryShares" abstract="false" name="GainLossOnCancellationOfTreasuryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DerivativeInstrumentAxis" abstract="true" name="DerivativeInstrumentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_ExscientiaMember" abstract="true" name="ExscientiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember" abstract="true" name="TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RoyaltyIncomePercentage" abstract="false" name="RoyaltyIncomePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_MarketedProductsTrademarksAndOtherRightsMember" abstract="true" name="MarketedProductsTrademarksAndOtherRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AventisPharmaManufacturingPTELTDMember" abstract="true" name="AventisPharmaManufacturingPTELTDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" abstract="false" name="PercentageOfDevelopmentCostsArisingFromCommercialOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInChineseYuanMember" abstract="true" name="ForwardCurrencySalesInChineseYuanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GeneralInformationAboutFinancialStatementsAbstract" abstract="true" name="GeneralInformationAboutFinancialStatementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" abstract="true" name="ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ErnstAndYoungMember" abstract="true" name="ErnstAndYoungMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BusinessCombinationPurchasePricePerShare" abstract="false" name="BusinessCombinationPurchasePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember" abstract="true" name="ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MilestoneTypesAxis" abstract="true" name="MilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_InsilicoMedicineMember" abstract="true" name="InsilicoMedicineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" abstract="false" name="DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_March2019EMTNISINFR0013409851Member" abstract="true" name="March2019EMTNISINFR0013409851Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PlavixAttorneyGeneralActionInHawaiiMember" abstract="true" name="PlavixAttorneyGeneralActionInHawaiiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiBVMember" abstract="true" name="SanofiBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" abstract="false" name="TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_JevtanaRelatedPatentLitigationInTheUSMember" abstract="true" name="JevtanaRelatedPatentLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock" abstract="false" name="DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems" abstract="true" name="DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_IncreaseDecreaseInExpenseOfRestructuringActivities" abstract="false" name="IncreaseDecreaseInExpenseOfRestructuringActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PriorDevelopmentBudget" abstract="false" name="PriorDevelopmentBudget" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DerivativeFinancialInstrumentsToManageFinancialExposure" abstract="false" name="DerivativeFinancialInstrumentsToManageFinancialExposure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ConsiderationTransferredValuationPeriod" abstract="false" name="ConsiderationTransferredValuationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_NonCurrentAssetsMember" abstract="true" name="NonCurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SaleOfStockAxis" abstract="true" name="SaleOfStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" abstract="false" name="NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ProventionBioIncMember" abstract="true" name="ProventionBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase" abstract="false" name="CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" abstract="false" name="NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AwardsDateAxis" abstract="true" name="AwardsDateAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_NumberOfYearsServicePeriod" abstract="false" name="NumberOfYearsServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_ProductLiabilitiesMember" abstract="true" name="ProductLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CapitalLossesUsedAgainstCapitalGainsPercentage" abstract="false" name="CapitalLossesUsedAgainstCapitalGainsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock" abstract="false" name="DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" abstract="true" name="DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_AmunixPharmaceuticalsIncMember" abstract="true" name="AmunixPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents" abstract="false" name="GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PaymentOfDamagesClaimedByCounterparty" abstract="false" name="PaymentOfDamagesClaimedByCounterparty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInUSDollarMember" abstract="true" name="ForwardCurrencySalesInUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasesMember" abstract="true" name="ForwardCurrencyPurchasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment" abstract="false" name="AntiProgrammedCellDeathProtein1SalesMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseOfBorrowings" abstract="false" name="IncreaseDecreaseOfBorrowings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" abstract="true" name="OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfGuaranteesLineItems" abstract="true" name="DisclosureOfGuaranteesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" abstract="false" name="DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_USLegalRestructuringMember" abstract="true" name="USLegalRestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiUSServicesIncMember" abstract="true" name="SanofiUSServicesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug" abstract="false" name="NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember" abstract="true" name="WeightedAverageInterestRateAfterDerivativeInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" abstract="false" name="TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable" abstract="false" name="DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SyndicatedCreditFacilityCanceledMember" abstract="true" name="SyndicatedCreditFacilityCanceledMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaHealthcarePhilippinesIncMember" abstract="true" name="OpellaHealthcarePhilippinesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LeaseTerm" abstract="false" name="LeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock" abstract="false" name="DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_FairValueMeasurementAbstract" abstract="true" name="FairValueMeasurementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_BusinessCombinationAbstract" abstract="true" name="BusinessCombinationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringProvisionsTable" abstract="true" name="DisclosureOfRestructuringProvisionsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_OrdinarySharesNASDAQGlobalSelectMarketMember" abstract="true" name="OrdinarySharesNASDAQGlobalSelectMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfVotingEquityInterestsDivested" abstract="false" name="PercentageOfVotingEquityInterestsDivested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_June2018SNFISINUS801060AC87Member" abstract="true" name="June2018SNFISINUS801060AC87Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_VaccinesSegmentMember" abstract="true" name="VaccinesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" abstract="false" name="GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations" abstract="false" name="CommitmentsRelatedToMilestonePaymentsBusinessCombinations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PlusTwentyFiveBasisPointsMember" abstract="true" name="PlusTwentyFiveBasisPointsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaHealthcareSpainSLMember" abstract="true" name="OpellaHealthcareSpainSLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesMember" abstract="true" name="ForwardCurrencySalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CashAndCashEquivalents1Member" abstract="true" name="CashAndCashEquivalents1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_QRIMember" abstract="true" name="QRIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiChinaInvestmentCoLtdMember" abstract="true" name="SanofiChinaInvestmentCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock" abstract="false" name="DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_NumberOfCancersAssociatedWithDismissedCases" abstract="false" name="NumberOfCancersAssociatedWithDismissedCases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_QRIBIntermediateHoldingsLLCMember" abstract="true" name="QRIBIntermediateHoldingsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock" abstract="false" name="DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities" abstract="false" name="PercentageContributedToFairValueOfPlanAssetsOtherSecurities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_EvotecMember" abstract="true" name="EvotecMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_March2018EMTNISINFR0013324357Member" abstract="true" name="March2018EMTNISINFR0013324357Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" abstract="true" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" abstract="false" name="CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember" abstract="true" name="IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_UpfrontPayments" abstract="false" name="UpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiMedleyFarmaceuticaLtdaMember" abstract="true" name="SanofiMedleyFarmaceuticaLtdaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseInEffectiveTaxRate" abstract="false" name="IncreaseDecreaseInEffectiveTaxRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_CoreAssetsMember" abstract="true" name="CoreAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies" abstract="false" name="CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering" abstract="false" name="BusinessCombinationNumberOfSharesIncludedInPublicOffering" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfShareOutstandingInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOutstandingInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="sny_OpellaHealthcareBrazilLtdaMember" abstract="true" name="OpellaHealthcareBrazilLtdaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement" abstract="false" name="NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_GainLossOnPurchaseOfTreasuryShares" abstract="false" name="GainLossOnPurchaseOfTreasuryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfCases" abstract="false" name="NumberOfCases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_SanofiAventisCanadaIncMember" abstract="true" name="SanofiAventisCanadaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock" abstract="false" name="AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ShareRepurchase2023ProgramMember" abstract="true" name="ShareRepurchase2023ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" abstract="true" name="DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock" abstract="false" name="DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" abstract="true" name="ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInSingaporeDollarMember" abstract="true" name="ForwardCurrencySalesInSingaporeDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ParticipatingSharesMember" abstract="true" name="ParticipatingSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_June2018SNFISINUS801060AD60Member" abstract="true" name="June2018SNFISINUS801060AD60Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiHealthcareIndiaPrivateLimitedMember" abstract="true" name="SanofiHealthcareIndiaPrivateLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" abstract="false" name="ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PercentageOfAuditorsRemuneration" abstract="false" name="PercentageOfAuditorsRemuneration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_NumberOfPlaintiffs" abstract="false" name="NumberOfPlaintiffs" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_ForeignCurrencyTranslationDifferences" abstract="false" name="ForeignCurrencyTranslationDifferences" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NotionalRetirementAge" abstract="false" name="NotionalRetirementAge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate" abstract="false" name="OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonOperatingForeignExchangeGainsLosses" abstract="false" name="NonOperatingForeignExchangeGainsLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EmployeeBenefitsExpenseGain" abstract="false" name="EmployeeBenefitsExpenseGain" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GainLossOnSaleOfTreasuryShares" abstract="false" name="GainLossOnSaleOfTreasuryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" abstract="true" name="ItemsSubsequentlyReclassifiableToProfitOrLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings" abstract="false" name="IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DefendantsMember" abstract="true" name="DefendantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital" abstract="false" name="ExceptionalSupplementaryDividendProposedPercentageOfShareCapital" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_TranslateBioMember" abstract="true" name="TranslateBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_StockSubscriptionOptionPlanMember" abstract="true" name="StockSubscriptionOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PharmaceuticalsSegmentMember" abstract="true" name="PharmaceuticalsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EloctateMember" abstract="true" name="EloctateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable" abstract="true" name="DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_RealEstate1Member" abstract="true" name="RealEstate1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncomeTaxesAbstract" abstract="true" name="IncomeTaxesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" abstract="false" name="CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiSynthelaboUKLtdMember" abstract="true" name="SanofiSynthelaboUKLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfCounterExpertiseExperts" abstract="false" name="NumberOfCounterExpertiseExperts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" abstract="false" name="DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" abstract="false" name="RoyaltiesAndOtherIncomeRelatedPartyTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PerformanceSharePlanTwoMember" abstract="true" name="PerformanceSharePlanTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOtherOperatingIncomeExpensesTable" abstract="true" name="DisclosureOfOtherOperatingIncomeExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_FinancialInstrumentsAbstract" abstract="true" name="FinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DerivativeFinancialInstruments" abstract="false" name="DerivativeFinancialInstruments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiVietnamShareholdingCompanyLimitedMember" abstract="true" name="SanofiVietnamShareholdingCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock" abstract="false" name="DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_BlackstoneLifeSciencesMember" abstract="true" name="BlackstoneLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IssuanceOfFurtherSharesAsAnEmployersContribution" abstract="false" name="IssuanceOfFurtherSharesAsAnEmployersContribution" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_AmountsPayablePartnersInCollaborationAgreements" abstract="false" name="AmountsPayablePartnersInCollaborationAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiAventisSROMember" abstract="true" name="SanofiAventisSROMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CashFlowAndFairValueHedgeMember" abstract="true" name="CashFlowAndFairValueHedgeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDebtTable" abstract="true" name="DisclosureOfDebtTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock" abstract="false" name="DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OtherRevenuePerformanceObligationNoLongerRequired" abstract="false" name="OtherRevenuePerformanceObligationNoLongerRequired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" abstract="false" name="DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiAventisSAMember" abstract="true" name="SanofiAventisSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SPMSDContingentConsiderationAssetMember" abstract="true" name="SPMSDContingentConsiderationAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisVietnamCompanyLimitedMember" abstract="true" name="SanofiAventisVietnamCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive" abstract="false" name="IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember" abstract="true" name="TaxotereMississippiAttorneyGeneralLitigationInTheUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_RestrictedSharePlan2022Member" abstract="true" name="RestrictedSharePlan2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" abstract="false" name="AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiPasteurAsiTicaretASMember" abstract="true" name="SanofiPasteurAsiTicaretASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CollaborationAgreementPeriodAfterLossOfControl" abstract="false" name="CollaborationAgreementPeriodAfterLossOfControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" abstract="false" name="ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfLineOfCreditFacilityTable" abstract="true" name="DisclosureOfLineOfCreditFacilityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock" abstract="false" name="DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock" abstract="false" name="DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" abstract="false" name="IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LumpSumRetirementBenefitPlansMember" abstract="true" name="LumpSumRetirementBenefitPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiHangzhouPharmaceuticalsCoLtdMember" abstract="true" name="SanofiHangzhouPharmaceuticalsCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TotalDeferredTaxAssetsForTaxLossCarryforwards" abstract="false" name="TotalDeferredTaxAssetsForTaxLossCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ReclassificationFromNonCurrentToCurrent" abstract="false" name="ReclassificationFromNonCurrentToCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OtherLiabilities1Member" abstract="true" name="OtherLiabilities1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ContingentConsiderationTranslateBioMember" abstract="true" name="ContingentConsiderationTranslateBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TevaPharmaceuticalsMember" abstract="true" name="TevaPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember" abstract="true" name="AmericanDepositorySharesNASDAQGlobalSelectMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiaventisPlusPensionPlanMember" abstract="true" name="SanofiaventisPlusPensionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember" abstract="true" name="ProvisionForPensionsAndOtherEmployeeBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsMember" abstract="true" name="PrincipalMarketedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" abstract="false" name="EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_GenzymeFlandersBVBAMember" abstract="true" name="GenzymeFlandersBVBAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" abstract="false" name="DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_OpellaHealthcareHungaryKFTMember" abstract="true" name="OpellaHealthcareHungaryKFTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member" abstract="true" name="InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AubagioMember" abstract="true" name="AubagioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement" abstract="false" name="NumberOfTherapeuticTargetsUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_CommercializationRelatedExpensesMember" abstract="true" name="CommercializationRelatedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LantusMember" abstract="true" name="LantusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DebtInstrumentDomain" abstract="true" name="DebtInstrumentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" abstract="false" name="FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" abstract="false" name="NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_RegeneronMember" abstract="true" name="RegeneronMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030" abstract="false" name="PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" abstract="false" name="InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_BioverativTherapeuticsIncMember" abstract="true" name="BioverativTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_USFDAApprovalMember" abstract="true" name="USFDAApprovalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BioverativIncMember" abstract="true" name="BioverativIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_March2020EMTNISINFR0013505104Member" abstract="true" name="March2020EMTNISINFR0013505104Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_AmountOfSharesRepurchased" abstract="false" name="AmountOfSharesRepurchased" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfIndirectVictimWhoWithdrawedTheClaim" abstract="false" name="NumberOfIndirectVictimWhoWithdrawedTheClaim" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DisclosureOfActuarialAssumptionsTableTextBlock" abstract="false" name="DisclosureOfActuarialAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ForwardCurrencySalesInKoreanWonMember" abstract="true" name="ForwardCurrencySalesInKoreanWonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiBiotechnologyMember" abstract="true" name="SanofiBiotechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="ShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_GenzymeCorporationMember" abstract="true" name="GenzymeCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfTradeReceivablesTextBlock" abstract="false" name="DisclosureOfTradeReceivablesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" abstract="false" name="DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_LargestCustomersMember" abstract="true" name="LargestCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock" abstract="false" name="DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiResearchInvestLLCMember" abstract="true" name="SanofiResearchInvestLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember" abstract="true" name="OtherContingentConsiderationArisingFromBusinessCombinationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SaleOfStockDomain" abstract="true" name="SaleOfStockDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" abstract="false" name="TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfAccountsReceivableLineItems" abstract="true" name="DisclosureOfAccountsReceivableLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_HealthcareCoverAndLifeInsuranceMember" abstract="true" name="HealthcareCoverAndLifeInsuranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RPRUSLtdMember" abstract="true" name="RPRUSLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DebtPercent" abstract="false" name="DebtPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DefinedBenefitPensionPlansMember" abstract="true" name="DefinedBenefitPensionPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BorrowingAverageDrawdown" abstract="false" name="BorrowingAverageDrawdown" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrentProvisionsAndOtherCurrentLiabilities" abstract="false" name="CurrentProvisionsAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfClaimant" abstract="false" name="NumberOfClaimant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember" abstract="true" name="EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" abstract="false" name="FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sny_TechnologicalPlatformsMember" abstract="true" name="TechnologicalPlatformsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfAverageOfQuotedMarketPricesOfShares" abstract="false" name="PercentageOfAverageOfQuotedMarketPricesOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" abstract="false" name="ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" abstract="false" name="DisclosureOfRestructuringCostsDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_VaxServeIncMember" abstract="true" name="VaxServeIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EmployeesShareOwnershipPlanMember" abstract="true" name="EmployeesShareOwnershipPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TaxLossesCarryforwards" abstract="false" name="TaxLossesCarryforwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock" abstract="false" name="DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_GenzymeLuxembourgSarlMember" abstract="true" name="GenzymeLuxembourgSarlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember" abstract="true" name="ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" abstract="true" name="DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" abstract="false" name="NonCurrentProvisionsAndOtherNonCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PlanetCareProgramObjectivesNetEmissionsBy2045" abstract="false" name="PlanetCareProgramObjectivesNetEmissionsBy2045" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_Patents1Member" abstract="true" name="Patents1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ToujeoMember" abstract="true" name="ToujeoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_MarketedProductsMember" abstract="true" name="MarketedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_JanssenPharmaceuticalsIncMember" abstract="true" name="JanssenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiPasteurIncMember" abstract="true" name="SanofiPasteurIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LegalAndArbitralProceedingsDomain" abstract="true" name="LegalAndArbitralProceedingsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherOperatingIncomeExpense1Member" abstract="true" name="OtherOperatingIncomeExpense1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems" abstract="true" name="ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" abstract="false" name="IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MarketConditionDomain" abstract="true" name="MarketConditionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" abstract="false" name="ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfOngoingTrials" abstract="false" name="NumberOfOngoingTrials" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DividendsPaidAbstract" abstract="true" name="DividendsPaidAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_StockSubscriptionOptionPlanThreeMember" abstract="true" name="StockSubscriptionOptionPlanThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans" abstract="false" name="AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_SanofiAventisUkHoldingsLimitedMember" abstract="true" name="SanofiAventisUkHoldingsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PensionsAndOtherPostEmploymentBenefitsMember" abstract="true" name="PensionsAndOtherPostEmploymentBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember" abstract="true" name="DeferredTaxRelatingToCapitalisationOfRDExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member" abstract="true" name="InterestRateSwapsPayCapitalizedEoniaReceive006Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FirmOrdersOfPropertyPlantAndEquipment" abstract="false" name="FirmOrdersOfPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_April2016EMTNISINFR0013144003Member" abstract="true" name="April2016EMTNISINFR0013144003Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable" abstract="true" name="DisclosureOfNetIncomeAttributableToNonControllingInterestsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths" abstract="false" name="IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiAventisArgentinaSAMember" abstract="true" name="SanofiAventisArgentinaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock" abstract="false" name="DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiTaiwanCoLtdMember" abstract="true" name="SanofiTaiwanCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BondsAndSimilarInstrumentsMember" abstract="true" name="BondsAndSimilarInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InfluenzaVaccinesMember" abstract="true" name="InfluenzaVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" abstract="false" name="ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" abstract="false" name="IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InvestmentsInAssociatesAndJointVentures" abstract="false" name="InvestmentsInAssociatesAndJointVentures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable" abstract="true" name="DisclosureOfDetailedInformationAboutShareBasedPaymentTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation" abstract="false" name="MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestUndiscountedCashFlow" abstract="false" name="InterestUndiscountedCashFlow" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DebtInstrument1Axis" abstract="true" name="DebtInstrument1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DigestiveWellnessMember" abstract="true" name="DigestiveWellnessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PolioPertussisHibVaccinesMember" abstract="true" name="PolioPertussisHibVaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaHealthcareTuketiciSalAnonimSirketiMember" abstract="true" name="OpellaHealthcareTuketiciSalAnonimSirketiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IOLicenseAndCollaborationAgreementMember" abstract="true" name="IOLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfSustainableDevelopmentPerformanceIndicators" abstract="false" name="NumberOfSustainableDevelopmentPerformanceIndicators" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_NumberOfPatentsCoveringProduct" abstract="false" name="NumberOfPatentsCoveringProduct" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember" abstract="true" name="AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDebtLineItems" abstract="true" name="DisclosureOfDebtLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_NumberOfAdministrativeProceedings" abstract="false" name="NumberOfAdministrativeProceedings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" abstract="false" name="CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CurrencyDerivativesMember" abstract="true" name="CurrencyDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" abstract="false" name="DisclosureOfMarketValueOfNetDebtTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" abstract="false" name="IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LeaseExtensionOptionsNumber" abstract="false" name="LeaseExtensionOptionsNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_OpellaHealthcareLLCMember" abstract="true" name="OpellaHealthcareLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock" abstract="false" name="DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiAventisHealthcarePtyLtdMember" abstract="true" name="SanofiAventisHealthcarePtyLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NKCellAndProXTenTechnologyPlatformsMember" abstract="true" name="NKCellAndProXTenTechnologyPlatformsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfChangesInFinancialPositionTableTextBlock" abstract="false" name="DisclosureOfChangesInFinancialPositionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember" abstract="true" name="BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock" abstract="false" name="DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" abstract="false" name="InterestRateAndCurrencyDerivativesUsedToManageDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfPrincipalMarketedProductsTableTextBlock" abstract="false" name="DisclosureOfPrincipalMarketedProductsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember" abstract="true" name="GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InfraservGmbhAndCoHochstKGMember" abstract="true" name="InfraservGmbhAndCoHochstKGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount" abstract="false" name="EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SpecialDistributionSharesReceivedPerConversionOfParentShares" abstract="false" name="SpecialDistributionSharesReceivedPerConversionOfParentShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_CollaborationAgreementsUpfrontPayment" abstract="false" name="CollaborationAgreementsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LiabilityRecognisedForEstimatedFutureRoyalties" abstract="false" name="LiabilityRecognisedForEstimatedFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PrincipalAlliancesDomain" abstract="true" name="PrincipalAlliancesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_GenzymeTherapeuticProductsLimitedPartnershipMember" abstract="true" name="GenzymeTherapeuticProductsLimitedPartnershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShareRepurchase2021ProgramMember" abstract="true" name="ShareRepurchase2021ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_FourBillionFacilityMaturingDecember2027Member" abstract="true" name="FourBillionFacilityMaturingDecember2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BioverativMember" abstract="true" name="BioverativMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfNonCurrentProvisionsLineItems" abstract="true" name="DisclosureOfNonCurrentProvisionsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering" abstract="false" name="BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" abstract="false" name="DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiAventisPrivateCoLtdMember" abstract="true" name="SanofiAventisPrivateCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable" abstract="true" name="DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" abstract="false" name="IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CashAndCashEquivalentsInvestedRate" abstract="false" name="CashAndCashEquivalentsInvestedRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_SAR444245Member" abstract="true" name="SAR444245Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember" abstract="true" name="WeightedAverageInterestRateBeforeDerivativeInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisDeutschlandGmbHMember" abstract="true" name="SanofiAventisDeutschlandGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_April2016EMTNISINFR0013143997Member" abstract="true" name="April2016EMTNISINFR0013143997Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiPasteurMerieuxSASMember" abstract="true" name="SanofiPasteurMerieuxSASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution" abstract="false" name="ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_EPICBPIFranceMember" abstract="true" name="EPICBPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AntibodiesCollaborationAgreementMember" abstract="true" name="AntibodiesCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_LeaseExtensionOptionsTerm" abstract="false" name="LeaseExtensionOptionsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sny_RegulatoryComplianceCostsMember" abstract="true" name="RegulatoryComplianceCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_HaleonUSLPMember" abstract="true" name="HaleonUSLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RetirementAge" abstract="false" name="RetirementAge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember" abstract="true" name="RemeasurementOfOtherAcquiredIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiHongKongLimitedMember" abstract="true" name="SanofiHongKongLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsQunolMember" abstract="true" name="PrincipalMarketedProductsQunolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DerivativeInstrumentDomain" abstract="true" name="DerivativeInstrumentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TranslateBioIncMember" abstract="true" name="TranslateBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfDrugTargetsUnderCollaborationAgreement" abstract="false" name="NumberOfDrugTargetsUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_PriorAgreementMember" abstract="true" name="PriorAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AblynxMember" abstract="true" name="AblynxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis" abstract="false" name="BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesMember" abstract="true" name="InterestRateAndCurrencyDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock" abstract="false" name="DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" abstract="false" name="ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LiabilityRecognizedRepresentingEstimatedCost" abstract="false" name="LiabilityRecognizedRepresentingEstimatedCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_BioverativUSLLCMember" abstract="true" name="BioverativUSLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_QuotedDebtSecuritiesMember" abstract="true" name="QuotedDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOtherLongTermProvisionsTableTextBlock" abstract="false" name="DisclosureOfOtherLongTermProvisionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_RestrictedSharePlan2019Member" abstract="true" name="RestrictedSharePlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets" abstract="false" name="AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InventoryTotalQuotasHeld" abstract="false" name="InventoryTotalQuotasHeld" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfAuditFeesAndOtherServicesLineItems" abstract="true" name="DisclosureOfAuditFeesAndOtherServicesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_InterestRateSwapsInterestRate" abstract="false" name="InterestRateSwapsInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_SanofiAventisNorgeASMember" abstract="true" name="SanofiAventisNorgeASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasedInTaiwanDollarMember" abstract="true" name="ForwardCurrencyPurchasedInTaiwanDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DaiichiSankyoMember" abstract="true" name="DaiichiSankyoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" abstract="false" name="DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems" abstract="true" name="DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfDebtByCurrencyLineItems" abstract="true" name="DisclosureOfDebtByCurrencyLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfTaxLossesAvailableForCarryforwardTable" abstract="true" name="DisclosureOfTaxLossesAvailableForCarryforwardTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod" abstract="false" name="ChangeInProvisionsRecognizedInProfitOrLossForThePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock" abstract="false" name="DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OpellaHealthcareRomaniaSRLMember" abstract="true" name="OpellaHealthcareRomaniaSRLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CurrentCurrencyDerivativesPayable" abstract="false" name="CurrentCurrencyDerivativesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" abstract="true" name="ShareOfProfitOrLossFromCommercializationOfZaltrapMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasedInUSDollarMember" abstract="true" name="ForwardCurrencyPurchasedInUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty" abstract="false" name="PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ServicesOtherThanStatutoryAudit" abstract="false" name="ServicesOtherThanStatutoryAudit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ValueOnRedemptionMember" abstract="true" name="ValueOnRedemptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DepakineProductLitigationInBelgiumMember" abstract="true" name="DepakineProductLitigationInBelgiumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember" abstract="true" name="CommitmentsRelatedToUnquotedDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" abstract="false" name="InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NonQualifiedDefinedBenefitPensionPlansMember" abstract="true" name="NonQualifiedDefinedBenefitPensionPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_InterestRateDerivativesMember" abstract="true" name="InterestRateDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_WithMarketConditionMember" abstract="true" name="WithMarketConditionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred" abstract="false" name="BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_CumulativeConsumerPriceInflationOverTheLastThreeYears" abstract="false" name="CumulativeConsumerPriceInflationOverTheLastThreeYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ChangeInCurrencyTranslationOnTaxEffects" abstract="false" name="ChangeInCurrencyTranslationOnTaxEffects" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SanofiAventisDeMexicoSADeCVMember" abstract="true" name="SanofiAventisDeMexicoSADeCVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CreditFacilitiesExtensionOptionNumber" abstract="false" name="CreditFacilitiesExtensionOptionNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions" abstract="false" name="ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_IncomeStatementLocation1Domain" abstract="true" name="IncomeStatementLocation1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss" abstract="false" name="PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" abstract="false" name="DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ContingentConsiderationLiabilities" abstract="false" name="ContingentConsiderationLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_LovenoxMember" abstract="true" name="LovenoxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_TidalTherapeuticsMember" abstract="true" name="TidalTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaHealthcareInternationalSASMember" abstract="true" name="OpellaHealthcareInternationalSASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ValueOfHedgeRecognizedInEquityMember" abstract="true" name="ValueOfHedgeRecognizedInEquityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_BorrowingDrawdown" abstract="false" name="BorrowingDrawdown" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SalesReturnMember" abstract="true" name="SalesReturnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisHoldingsIrelandLtdMember" abstract="true" name="SanofiAventisHoldingsIrelandLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsAventisMember" abstract="true" name="PrincipalMarketedProductsAventisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" abstract="false" name="DisclosureOfOverdueReceivablesGrossValueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_ScribeTherapeuticsMember" abstract="true" name="ScribeTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable" abstract="true" name="DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" abstract="false" name="DisclosureOfLegalAndArbitralProceedingsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_OtherIntangibleAssetsExcludingSoftwareMember" abstract="true" name="OtherIntangibleAssetsExcludingSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfPrincipalAlliancesLineItems" abstract="true" name="DisclosureOfPrincipalAlliancesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany" abstract="false" name="MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasedInSingaporeDollarMember" abstract="true" name="ForwardCurrencyPurchasedInSingaporeDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AventisIncMember" abstract="true" name="AventisIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement" abstract="false" name="ValueOfShareOptionsCancelledInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PrincipiaBiopharmaIncMember" abstract="true" name="PrincipiaBiopharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ImpairmentTestingPercentage" abstract="false" name="ImpairmentTestingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_MaximumPlan2Member" abstract="true" name="MaximumPlan2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" abstract="false" name="ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_AOSanofiRussiaMember" abstract="true" name="AOSanofiRussiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" abstract="false" name="DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_PrincipalMarketedProductsProteinSciencesMember" abstract="true" name="PrincipalMarketedProductsProteinSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember" abstract="true" name="ShortTermDebtAndCurrentPortionOfLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfPreActionProtocolCases" abstract="false" name="NumberOfPreActionProtocolCases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" abstract="false" name="ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfAgreementsSigned" abstract="false" name="NumberOfAgreementsSigned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_DepakineProductLitigationInIrelandMember" abstract="true" name="DepakineProductLitigationInIrelandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisGmbHMember" abstract="true" name="SanofiAventisGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ForwardCurrencyPurchasedInRussianRoubleMember" abstract="true" name="ForwardCurrencyPurchasedInRussianRoubleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfDebtByCurrencyTable" abstract="true" name="DisclosureOfDebtByCurrencyTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_HedgeFunds1Member" abstract="true" name="HedgeFunds1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherDeductionsMember" abstract="true" name="OtherDeductionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_PercentageOfLossesArisingFromCommercialOperations" abstract="false" name="PercentageOfLossesArisingFromCommercialOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_AdjustmentToDebtMeasuredAtFairValueMember" abstract="true" name="AdjustmentToDebtMeasuredAtFairValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" abstract="false" name="DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiEuroMediumTermNotesMember" abstract="true" name="SanofiEuroMediumTermNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ErnstYoungEtAutresMember" abstract="true" name="ErnstYoungEtAutresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_SanofiAventisPuertoRicoIncMember" abstract="true" name="SanofiAventisPuertoRicoIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_KymabMember" abstract="true" name="KymabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ManagedCareMember" abstract="true" name="ManagedCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock" abstract="false" name="DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" abstract="false" name="DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_PercentageOfShareCapitalForThePeriod" abstract="false" name="PercentageOfShareCapitalForThePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ForeignCurrencyTranslationMember" abstract="true" name="ForeignCurrencyTranslationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfRestrictedSharesNotYetFullyVested" abstract="false" name="NumberOfRestrictedSharesNotYetFullyVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_MCMVaccineBVMember" abstract="true" name="MCMVaccineBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AfterTaxDiscountRates" abstract="false" name="AfterTaxDiscountRates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" abstract="false" name="ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_SECIPESASMember" abstract="true" name="SECIPESASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_StockOptionPlanMember" abstract="true" name="StockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock" abstract="false" name="DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_MutualFundInvestmentsMember" abstract="true" name="MutualFundInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NumberOfCivilIndividualActions" abstract="false" name="NumberOfCivilIndividualActions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sny_AmortizedCostMember" abstract="true" name="AmortizedCostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_EquityInstrumentsMember" abstract="true" name="EquityInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking" abstract="false" name="ConsiderationTransferredToFundReserveForIndemnificationUndertaking" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" abstract="false" name="ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_ReportableGeographicalZonesMember" abstract="true" name="ReportableGeographicalZonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ProvisionsRecordedForFutureOperatingLosses" abstract="false" name="ProvisionsRecordedForFutureOperatingLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_September2014EMTNISINFR0012146801Member" abstract="true" name="September2014EMTNISINFR0012146801Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" abstract="true" name="OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss" abstract="false" name="PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable" abstract="true" name="DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sny_GainsLossesOnDerivativesUsedToManageDebt" abstract="false" name="GainsLossesOnDerivativesUsedToManageDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfRestructuringProvisionsTableTextBlock" abstract="false" name="DisclosureOfRestructuringProvisionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_SanofiArabiaTradingCompanyLimitedMember" abstract="true" name="SanofiArabiaTradingCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts" abstract="false" name="CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" abstract="false" name="InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_NumberOfCommercialPaperPrograms" abstract="false" name="NumberOfCommercialPaperPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="sny_CurrentInterestRateDerivativesPayable" abstract="false" name="CurrentInterestRateDerivativesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_PenaltyFeeIncurred" abstract="false" name="PenaltyFeeIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" abstract="true" name="MSDContingentConsiderationEuropeanVaccinesBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_OpellaHealthcareCzechSroMember" abstract="true" name="OpellaHealthcareCzechSroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" abstract="false" name="AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" abstract="false" name="DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" abstract="false" name="IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_April2022EMTNISINFR0014009KQ0Member" abstract="true" name="April2022EMTNISINFR0014009KQ0Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock" abstract="false" name="DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember" abstract="true" name="EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_NetInterestCostRelatedToEmployeeBenefits" abstract="false" name="NetInterestCostRelatedToEmployeeBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" abstract="false" name="DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sny_DefinedBenefitPlansVestingRightsPercentage" abstract="false" name="DefinedBenefitPlansVestingRightsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets" abstract="false" name="CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sny_March2018EMTNISINFR0013324373Member" abstract="true" name="March2018EMTNISINFR0013324373Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sny_ReservePercentageOfPandemicVaccines" abstract="false" name="ReservePercentageOfPandemicVaccines" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>sny-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:d2fc6364-8fcd-4586-a9d3-e16cd96a566e,g:f65f6c85-de12-4c7c-b6b2-ea3943f1a47f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedbalancesheets" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedbalancesheets"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedbalancesheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_4d4508b6-aa43-4937-bafb-2191b0e611c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_096dab39-2c81-4f16-8000-fe930680d38c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_4d4508b6-aa43-4937-bafb-2191b0e611c6" xlink:to="loc_ifrs-full_DeferredTaxAssets_096dab39-2c81-4f16-8000-fe930680d38c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_7647b609-187c-4f84-ab0e-ead8238a8e43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_4d4508b6-aa43-4937-bafb-2191b0e611c6" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_7647b609-187c-4f84-ab0e-ead8238a8e43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent_d339db24-4e2f-4802-bb79-c8cdf480c77f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_4d4508b6-aa43-4937-bafb-2191b0e611c6" xlink:to="loc_ifrs-full_CurrentTaxAssetsNoncurrent_d339db24-4e2f-4802-bb79-c8cdf480c77f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_854b35e5-6afb-423e-9f1b-1fa0de198763" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_4d4508b6-aa43-4937-bafb-2191b0e611c6" xlink:to="loc_ifrs-full_Goodwill_854b35e5-6afb-423e-9f1b-1fa0de198763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ebd4f6d5-d9e9-4a7c-b6a7-c7329111cf36" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_4d4508b6-aa43-4937-bafb-2191b0e611c6" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ebd4f6d5-d9e9-4a7c-b6a7-c7329111cf36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_796bb8dc-fabe-4916-b411-ac98dc25dadc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_4d4508b6-aa43-4937-bafb-2191b0e611c6" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_796bb8dc-fabe-4916-b411-ac98dc25dadc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_b6a17314-cf47-45af-b126-8cb43ebb4e47" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_4d4508b6-aa43-4937-bafb-2191b0e611c6" xlink:to="loc_ifrs-full_RightofuseAssets_b6a17314-cf47-45af-b126-8cb43ebb4e47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_77306436-0439-4f39-9515-01c8bc5ab6ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_4d4508b6-aa43-4937-bafb-2191b0e611c6" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_77306436-0439-4f39-9515-01c8bc5ab6ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_a27255d4-da1e-4ffa-b283-1253919434c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_d79ce564-7e60-4b38-aaf3-67fa0caa1cda" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_a27255d4-da1e-4ffa-b283-1253919434c5" xlink:to="loc_ifrs-full_NoncurrentAssets_d79ce564-7e60-4b38-aaf3-67fa0caa1cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_fe6874a6-4e17-4fcf-8d67-ecf2fef8fcf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_a27255d4-da1e-4ffa-b283-1253919434c5" xlink:to="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_fe6874a6-4e17-4fcf-8d67-ecf2fef8fcf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_f511c97a-f419-41fa-95e6-517cdd47758e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_a27255d4-da1e-4ffa-b283-1253919434c5" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_f511c97a-f419-41fa-95e6-517cdd47758e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_1d75be6f-34ea-4fe8-84f0-03096e3a40fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_36370a4a-6f03-4cfd-8bb1-18ecad33dc6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_1d75be6f-34ea-4fe8-84f0-03096e3a40fa" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_36370a4a-6f03-4cfd-8bb1-18ecad33dc6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests_53be3dbb-4867-4c79-8ccb-23680cef6b20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_1d75be6f-34ea-4fe8-84f0-03096e3a40fa" xlink:to="loc_ifrs-full_NoncontrollingInterests_53be3dbb-4867-4c79-8ccb-23680cef6b20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_256f097e-8e59-49d9-990f-ff7862620d9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_453344e3-fcad-4654-a99f-6a672ae24406" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_256f097e-8e59-49d9-990f-ff7862620d9f" xlink:to="loc_ifrs-full_Equity_453344e3-fcad-4654-a99f-6a672ae24406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_84326385-a2fa-4e5b-bfd5-362a93c78641" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_256f097e-8e59-49d9-990f-ff7862620d9f" xlink:to="loc_ifrs-full_NoncurrentLiabilities_84326385-a2fa-4e5b-bfd5-362a93c78641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_07de7481-4714-4f01-9de4-6a246a4de507" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_256f097e-8e59-49d9-990f-ff7862620d9f" xlink:to="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_07de7481-4714-4f01-9de4-6a246a4de507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_7d7c953d-de27-42d2-8bb7-304f3f81beda" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_256f097e-8e59-49d9-990f-ff7862620d9f" xlink:to="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_7d7c953d-de27-42d2-8bb7-304f3f81beda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_dc3c65f4-e311-4a6b-8ac6-d310bcc63046" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_48f9bce8-a055-4a4c-bd77-dd44c9d63801" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_dc3c65f4-e311-4a6b-8ac6-d310bcc63046" xlink:to="loc_ifrs-full_OtherCurrentAssets_48f9bce8-a055-4a4c-bd77-dd44c9d63801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_80469e38-b450-465c-a582-8d0acfe0f562" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_dc3c65f4-e311-4a6b-8ac6-d310bcc63046" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_80469e38-b450-465c-a582-8d0acfe0f562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_5700caea-7457-4bf7-9e3b-dcb9f63a1945" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_dc3c65f4-e311-4a6b-8ac6-d310bcc63046" xlink:to="loc_ifrs-full_Inventories_5700caea-7457-4bf7-9e3b-dcb9f63a1945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_6fb206cc-6355-432a-9ac5-2767ab3fc0ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_dc3c65f4-e311-4a6b-8ac6-d310bcc63046" xlink:to="loc_ifrs-full_CurrentTradeReceivables_6fb206cc-6355-432a-9ac5-2767ab3fc0ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_02c94f95-e230-4232-b396-71a80fe80788" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_dc3c65f4-e311-4a6b-8ac6-d310bcc63046" xlink:to="loc_ifrs-full_CashAndCashEquivalents_02c94f95-e230-4232-b396-71a80fe80788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_1705c83c-345e-4ccc-bed7-5606b67df6ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_06c06d97-6e0d-43e3-957a-b477b790aad7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_1705c83c-345e-4ccc-bed7-5606b67df6ea" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_06c06d97-6e0d-43e3-957a-b477b790aad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_2c0c3581-cebf-493d-80bf-5954a1c22d0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_1705c83c-345e-4ccc-bed7-5606b67df6ea" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_2c0c3581-cebf-493d-80bf-5954a1c22d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_9ee665d8-70ca-4500-8643-81d430a6ec23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_1705c83c-345e-4ccc-bed7-5606b67df6ea" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_9ee665d8-70ca-4500-8643-81d430a6ec23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_9165d5c6-56a9-427c-b9a8-b204d12b276f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_1705c83c-345e-4ccc-bed7-5606b67df6ea" xlink:to="loc_ifrs-full_LongtermBorrowings_9165d5c6-56a9-427c-b9a8-b204d12b276f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_f2a22e5d-ef98-4148-9a82-61d22d750254" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_1705c83c-345e-4ccc-bed7-5606b67df6ea" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_f2a22e5d-ef98-4148-9a82-61d22d750254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_39471e85-b421-46a5-ac99-a07b7500a9f0" xlink:href="sny-20231231.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_1705c83c-345e-4ccc-bed7-5606b67df6ea" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_39471e85-b421-46a5-ac99-a07b7500a9f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_e17f98c8-09c2-47ca-a8ca-9e2d09127b17" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_7b441cac-3a73-48a9-a5a8-b202831035e6" xlink:href="sny-20231231.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_e17f98c8-09c2-47ca-a8ca-9e2d09127b17" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_7b441cac-3a73-48a9-a5a8-b202831035e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_2f99c738-5a18-405a-b422-a17a8cfc2849" xlink:href="sny-20231231.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_e17f98c8-09c2-47ca-a8ca-9e2d09127b17" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_2f99c738-5a18-405a-b422-a17a8cfc2849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_26be725d-ec1d-4f34-a5e0-1d1a3739b1b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_e17f98c8-09c2-47ca-a8ca-9e2d09127b17" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_26be725d-ec1d-4f34-a5e0-1d1a3739b1b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_ff0a7e99-41f6-4732-83b6-1a00a099ed4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_e17f98c8-09c2-47ca-a8ca-9e2d09127b17" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_ff0a7e99-41f6-4732-83b6-1a00a099ed4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_822c57ab-46db-4265-baf1-bdceb4ab9646" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_e17f98c8-09c2-47ca-a8ca-9e2d09127b17" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_822c57ab-46db-4265-baf1-bdceb4ab9646" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_7032df35-29c1-435e-abb1-b59577bf3ae9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_e17f98c8-09c2-47ca-a8ca-9e2d09127b17" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_7032df35-29c1-435e-abb1-b59577bf3ae9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedincomestatements" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedincomestatements"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedincomestatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_0c5da0ba-a688-431a-b4c0-9b23712b46ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_d184a984-af3c-4f9a-8eba-f03fb1042b9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0c5da0ba-a688-431a-b4c0-9b23712b46ab" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_d184a984-af3c-4f9a-8eba-f03fb1042b9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_6b21bf3c-22d1-43db-ba05-239a174a7fdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_0c5da0ba-a688-431a-b4c0-9b23712b46ab" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_6b21bf3c-22d1-43db-ba05-239a174a7fdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_5fa9dfb3-4222-4f7c-bea2-4fdab4d2b303" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_47ee0b96-a0ca-42a3-b69f-30089c4bbb12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_5fa9dfb3-4222-4f7c-bea2-4fdab4d2b303" xlink:to="loc_ifrs-full_GrossProfit_47ee0b96-a0ca-42a3-b69f-30089c4bbb12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_07c2d214-59ae-4360-8df5-16af10c9e90d" xlink:href="sny-20231231.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_5fa9dfb3-4222-4f7c-bea2-4fdab4d2b303" xlink:to="loc_sny_OtherGainsLossesAndLitigation_07c2d214-59ae-4360-8df5-16af10c9e90d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_3ea08ec5-97fa-4227-bd43-16017a2cc7f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_5fa9dfb3-4222-4f7c-bea2-4fdab4d2b303" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_3ea08ec5-97fa-4227-bd43-16017a2cc7f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_6d864b4a-d4b7-4fd5-962e-21165df90ea7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_5fa9dfb3-4222-4f7c-bea2-4fdab4d2b303" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_6d864b4a-d4b7-4fd5-962e-21165df90ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_8eb4456f-1cfc-4b6a-87fe-de6ff9653886" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_5fa9dfb3-4222-4f7c-bea2-4fdab4d2b303" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_8eb4456f-1cfc-4b6a-87fe-de6ff9653886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_d637baf6-ee98-4fe4-b03b-7748b81005c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_5fa9dfb3-4222-4f7c-bea2-4fdab4d2b303" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_d637baf6-ee98-4fe4-b03b-7748b81005c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_fdd9c4ef-9349-4600-885b-c0875465718c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_5fa9dfb3-4222-4f7c-bea2-4fdab4d2b303" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_fdd9c4ef-9349-4600-885b-c0875465718c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_43f92a95-0b79-4844-8e04-51621def50a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_5fa9dfb3-4222-4f7c-bea2-4fdab4d2b303" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_43f92a95-0b79-4844-8e04-51621def50a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_6fc15a00-fcff-4743-8a2a-3b3f3645a9d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_5fa9dfb3-4222-4f7c-bea2-4fdab4d2b303" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_6fc15a00-fcff-4743-8a2a-3b3f3645a9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_5ea9a2b8-5a5b-4b03-b275-a4cf90777d5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_5fa9dfb3-4222-4f7c-bea2-4fdab4d2b303" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_5ea9a2b8-5a5b-4b03-b275-a4cf90777d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_9e1b75d3-9441-4c08-9b6c-8d4c9507c398" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_9cdfd706-1eee-4388-87a2-069170fdba9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_9e1b75d3-9441-4c08-9b6c-8d4c9507c398" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_9cdfd706-1eee-4388-87a2-069170fdba9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_f1e0a1b6-73a2-4165-ae84-03d5978ee820" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_9e1b75d3-9441-4c08-9b6c-8d4c9507c398" xlink:to="loc_ifrs-full_OtherRevenue_f1e0a1b6-73a2-4165-ae84-03d5978ee820" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_17aaab31-be79-400a-aecd-ee7d485b09ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GrossProfit_9e1b75d3-9441-4c08-9b6c-8d4c9507c398" xlink:to="loc_ifrs-full_CostOfSales_17aaab31-be79-400a-aecd-ee7d485b09ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_c7b25573-19a8-4b19-8d0f-751d174b24cb" xlink:href="sny-20231231.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_9ff34531-7394-4156-b0f9-1624970b79cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_c7b25573-19a8-4b19-8d0f-751d174b24cb" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_9ff34531-7394-4156-b0f9-1624970b79cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_a6fbc999-2e03-41bc-99a9-c3360eba5ad5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_c7b25573-19a8-4b19-8d0f-751d174b24cb" xlink:to="loc_ifrs-full_FinanceCosts_a6fbc999-2e03-41bc-99a9-c3360eba5ad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_c884849a-4afa-40a3-be1f-5ea9bd5c304a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_c7b25573-19a8-4b19-8d0f-751d174b24cb" xlink:to="loc_ifrs-full_FinanceIncome_c884849a-4afa-40a3-be1f-5ea9bd5c304a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedincomestatements_1" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedincomestatements_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedincomestatements_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_452c3dfd-4550-4d49-9c8b-a30bdff97d3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_ecc809fa-8b27-4ff1-8c53-60b4a5ed6487" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_452c3dfd-4550-4d49-9c8b-a30bdff97d3c" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_ecc809fa-8b27-4ff1-8c53-60b4a5ed6487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_6996c3e5-3a55-4d72-adc6-7026b6e37f22" xlink:href="sny-20231231.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_452c3dfd-4550-4d49-9c8b-a30bdff97d3c" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_6996c3e5-3a55-4d72-adc6-7026b6e37f22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_f13fd61c-f295-4007-9d75-0b993f38fe20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_452c3dfd-4550-4d49-9c8b-a30bdff97d3c" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_f13fd61c-f295-4007-9d75-0b993f38fe20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedstatementsofcomprehensiveincome"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_57ebf817-b60f-483b-a105-4bce6dc146f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_a406d1ae-3c4a-4f50-b44f-7a027347a647" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_57ebf817-b60f-483b-a105-4bce6dc146f2" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_a406d1ae-3c4a-4f50-b44f-7a027347a647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_578475af-0083-4d22-b4f4-e1a768a73ab7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_57ebf817-b60f-483b-a105-4bce6dc146f2" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_578475af-0083-4d22-b4f4-e1a768a73ab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_6f994b56-ff8f-4ec8-b968-568c096c73cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_96e7e71c-8935-49b5-a9e0-47200e5fbdde" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_6f994b56-ff8f-4ec8-b968-568c096c73cb" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_96e7e71c-8935-49b5-a9e0-47200e5fbdde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_6deb6c2f-0f42-4f57-b524-d5a603cc79bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_6f994b56-ff8f-4ec8-b968-568c096c73cb" xlink:to="loc_ifrs-full_ProfitLoss_6deb6c2f-0f42-4f57-b524-d5a603cc79bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_e52733c0-3a7c-4938-8567-e3041ee23fb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_10a67ac5-4e45-4664-901e-479ce51ffa25" xlink:href="sny-20231231.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_e52733c0-3a7c-4938-8567-e3041ee23fb5" xlink:to="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_10a67ac5-4e45-4664-901e-479ce51ffa25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_0a79f7a8-0c61-4292-8249-68ba04a5ef73" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_e52733c0-3a7c-4938-8567-e3041ee23fb5" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_0a79f7a8-0c61-4292-8249-68ba04a5ef73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_55af3083-fea9-42e6-93a8-d55d5d0cc2cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_e52733c0-3a7c-4938-8567-e3041ee23fb5" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_55af3083-fea9-42e6-93a8-d55d5d0cc2cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_b55e8d9f-bf30-4da0-9640-81734ccdb69c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_e52733c0-3a7c-4938-8567-e3041ee23fb5" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_b55e8d9f-bf30-4da0-9640-81734ccdb69c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_ced9057d-d9d2-4a25-b277-d6189ba182b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_86bf37c2-152b-416b-8f6d-1f8c0a6111f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_ced9057d-d9d2-4a25-b277-d6189ba182b3" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_86bf37c2-152b-416b-8f6d-1f8c0a6111f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_7a999c26-4ff1-471c-badb-5963d4786f11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_ced9057d-d9d2-4a25-b277-d6189ba182b3" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_7a999c26-4ff1-471c-badb-5963d4786f11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_d220fa61-8e7c-4014-b136-66b8c60ddf4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_ced9057d-d9d2-4a25-b277-d6189ba182b3" xlink:to="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_d220fa61-8e7c-4014-b136-66b8c60ddf4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedstatementsofcomprehensiveincome_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_ce3eaf04-88b5-4556-9f2b-4dd1e3a44813" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_4103cc9f-a80f-427a-8024-a19f63f76a1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_ce3eaf04-88b5-4556-9f2b-4dd1e3a44813" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_4103cc9f-a80f-427a-8024-a19f63f76a1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_4f9c71f4-e4f1-496f-abf1-bc02d9c9f6f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_ce3eaf04-88b5-4556-9f2b-4dd1e3a44813" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_4f9c71f4-e4f1-496f-abf1-bc02d9c9f6f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcashflows" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedstatementsofcashflows"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcashflows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_588fc88f-dadc-4c1a-8be9-eb0b4c348627" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2a78ebe9-4896-4bc4-894f-32d09a5dfad8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_588fc88f-dadc-4c1a-8be9-eb0b4c348627" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2a78ebe9-4896-4bc4-894f-32d09a5dfad8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_41aa3ce4-e4fd-4102-b101-ce606d3cf09a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_588fc88f-dadc-4c1a-8be9-eb0b4c348627" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_41aa3ce4-e4fd-4102-b101-ce606d3cf09a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_f3a97a37-f327-486b-8e7a-d67b8324b797" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_588fc88f-dadc-4c1a-8be9-eb0b4c348627" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_f3a97a37-f327-486b-8e7a-d67b8324b797" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1d9dae85-2d70-40e3-9b6e-d8368d5290ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_588fc88f-dadc-4c1a-8be9-eb0b4c348627" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1d9dae85-2d70-40e3-9b6e-d8368d5290ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7f44843f-5b2e-4f20-b0b4-2b068b65f8ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_ba988d50-bfe8-4854-a2c9-576ebc67c431" xlink:href="sny-20231231.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7f44843f-5b2e-4f20-b0b4-2b068b65f8ab" xlink:to="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_ba988d50-bfe8-4854-a2c9-576ebc67c431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_56133ab6-3b32-42ce-9490-e8419e96b729" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7f44843f-5b2e-4f20-b0b4-2b068b65f8ab" xlink:to="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_56133ab6-3b32-42ce-9490-e8419e96b729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_73fd0069-7cb5-456b-b968-9d2affd9916a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7f44843f-5b2e-4f20-b0b4-2b068b65f8ab" xlink:to="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_73fd0069-7cb5-456b-b968-9d2affd9916a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_ce4b5c11-0f13-46be-86fd-6d11cb459ddb" xlink:href="sny-20231231.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7f44843f-5b2e-4f20-b0b4-2b068b65f8ab" xlink:to="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_ce4b5c11-0f13-46be-86fd-6d11cb459ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_7ec7753c-02bd-49cb-a064-fc0b7652c2ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7f44843f-5b2e-4f20-b0b4-2b068b65f8ab" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_7ec7753c-02bd-49cb-a064-fc0b7652c2ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_14f658c9-0f83-4504-97fb-22431e879b33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7f44843f-5b2e-4f20-b0b4-2b068b65f8ab" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_14f658c9-0f83-4504-97fb-22431e879b33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_de77cf61-e46c-486b-9861-b0c289510498" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7f44843f-5b2e-4f20-b0b4-2b068b65f8ab" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_de77cf61-e46c-486b-9861-b0c289510498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_1d99a468-16bb-4bfe-915f-58563fe6811b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7f44843f-5b2e-4f20-b0b4-2b068b65f8ab" xlink:to="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_1d99a468-16bb-4bfe-915f-58563fe6811b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_9a06507e-5184-4dab-9707-551001a1ce9b" xlink:href="sny-20231231.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7f44843f-5b2e-4f20-b0b4-2b068b65f8ab" xlink:to="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_9a06507e-5184-4dab-9707-551001a1ce9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_46d07efb-c5bc-41d0-ab58-c95584c153c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_7f44843f-5b2e-4f20-b0b4-2b068b65f8ab" xlink:to="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_46d07efb-c5bc-41d0-ab58-c95584c153c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_9d3887ab-35d9-48d2-8f9b-9ce7a12bae75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_bd160384-9a6f-497d-8a8d-ac149084638b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_9d3887ab-35d9-48d2-8f9b-9ce7a12bae75" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_bd160384-9a6f-497d-8a8d-ac149084638b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_7dbb4933-7617-4f85-8853-6d7c8e7007bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_9d3887ab-35d9-48d2-8f9b-9ce7a12bae75" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_7dbb4933-7617-4f85-8853-6d7c8e7007bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_1f8b99ee-5733-4f68-b908-8243974cbf4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_9d3887ab-35d9-48d2-8f9b-9ce7a12bae75" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_1f8b99ee-5733-4f68-b908-8243974cbf4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_3b44cf59-296d-4a12-be0f-030e7239dca2" xlink:href="sny-20231231.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_9d3887ab-35d9-48d2-8f9b-9ce7a12bae75" xlink:to="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_3b44cf59-296d-4a12-be0f-030e7239dca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_e2de5c76-6e82-4d8b-a514-5817f64a0fd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_9d3887ab-35d9-48d2-8f9b-9ce7a12bae75" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_e2de5c76-6e82-4d8b-a514-5817f64a0fd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e9b65b26-4fc0-4a4c-ae2c-5df79d309466" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_f96ff0e0-839a-42f3-9443-afc24183914b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e9b65b26-4fc0-4a4c-ae2c-5df79d309466" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_f96ff0e0-839a-42f3-9443-afc24183914b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_5671fed9-d4e8-4681-a755-c0e36cd6af39" xlink:href="sny-20231231.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e9b65b26-4fc0-4a4c-ae2c-5df79d309466" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_5671fed9-d4e8-4681-a755-c0e36cd6af39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_636db99d-2ac1-48e1-a27d-9d1dfed03057" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e9b65b26-4fc0-4a4c-ae2c-5df79d309466" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_636db99d-2ac1-48e1-a27d-9d1dfed03057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_b03ea42f-9265-42df-a67d-8ce74210cb6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e9b65b26-4fc0-4a4c-ae2c-5df79d309466" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_b03ea42f-9265-42df-a67d-8ce74210cb6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_6f4ac657-5ce3-4411-852a-8f0a2bb3d744" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e9b65b26-4fc0-4a4c-ae2c-5df79d309466" xlink:to="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_6f4ac657-5ce3-4411-852a-8f0a2bb3d744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_50adf64d-da50-49f7-a47d-f88e77c8d5a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e9b65b26-4fc0-4a4c-ae2c-5df79d309466" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_50adf64d-da50-49f7-a47d-f88e77c8d5a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_4df4086d-4210-45ba-870b-f81fa0fe3af4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e9b65b26-4fc0-4a4c-ae2c-5df79d309466" xlink:to="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_4df4086d-4210-45ba-870b-f81fa0fe3af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_10eb5fae-c6a3-4af7-8493-2ce9f4d8b1cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e9b65b26-4fc0-4a4c-ae2c-5df79d309466" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_10eb5fae-c6a3-4af7-8493-2ce9f4d8b1cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_efe82ae5-824d-49b3-ac06-7a191f2fa026" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e9b65b26-4fc0-4a4c-ae2c-5df79d309466" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_efe82ae5-824d-49b3-ac06-7a191f2fa026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c47adc99-1c29-43a6-a875-d1a249b219c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_5a80cb65-510b-4f5e-aed5-de32d25e266f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c47adc99-1c29-43a6-a875-d1a249b219c8" xlink:to="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_5a80cb65-510b-4f5e-aed5-de32d25e266f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_4d7cafc4-04f1-474b-860b-514739583c5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c47adc99-1c29-43a6-a875-d1a249b219c8" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_4d7cafc4-04f1-474b-860b-514739583c5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_bff9cb9c-d74a-47dd-b8c8-0dd57dad0c19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c47adc99-1c29-43a6-a875-d1a249b219c8" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_bff9cb9c-d74a-47dd-b8c8-0dd57dad0c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_0cc38345-7b1f-49dc-8e60-10f86b0f1f22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c47adc99-1c29-43a6-a875-d1a249b219c8" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_0cc38345-7b1f-49dc-8e60-10f86b0f1f22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets_03572af1-2468-46f1-a045-87bee5c23208" xlink:href="sny-20231231.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c47adc99-1c29-43a6-a875-d1a249b219c8" xlink:to="loc_sny_NetChangeInOtherNonCurrentAssets_03572af1-2468-46f1-a045-87bee5c23208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_99da3323-d834-4324-a851-2232825073cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c47adc99-1c29-43a6-a875-d1a249b219c8" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_99da3323-d834-4324-a851-2232825073cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_b2b66e5f-58bc-4a05-861d-93c6d1dc3de3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_a9f4dbbc-7a61-4db0-8fb7-1adf64c07ba6" xlink:href="sny-20231231.xsd#sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_b2b66e5f-58bc-4a05-861d-93c6d1dc3de3" xlink:to="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_a9f4dbbc-7a61-4db0-8fb7-1adf64c07ba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_dfe9c097-5a15-427e-a9de-ce184707015b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_b2b66e5f-58bc-4a05-861d-93c6d1dc3de3" xlink:to="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_dfe9c097-5a15-427e-a9de-ce184707015b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_db053c53-98cc-4896-995f-183c7d72f8d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_b2b66e5f-58bc-4a05-861d-93c6d1dc3de3" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_db053c53-98cc-4896-995f-183c7d72f8d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_24cc50be-4986-45ad-9f39-317fdfe6a85c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_b2b66e5f-58bc-4a05-861d-93c6d1dc3de3" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_24cc50be-4986-45ad-9f39-317fdfe6a85c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_4149fe9f-78a1-46d4-b5d0-d2f148aa7ef2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_b2b66e5f-58bc-4a05-861d-93c6d1dc3de3" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_4149fe9f-78a1-46d4-b5d0-d2f148aa7ef2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures_80b496ab-ec2b-49c3-98c8-84be26615ba5" xlink:href="sny-20231231.xsd#sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_df722d0d-df2e-49b4-a8c1-dbe234e80fc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures_80b496ab-ec2b-49c3-98c8-84be26615ba5" xlink:to="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_df722d0d-df2e-49b4-a8c1-dbe234e80fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax_ddbb9f87-41ce-4060-a38a-8822b0e46eb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures_80b496ab-ec2b-49c3-98c8-84be26615ba5" xlink:to="loc_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax_ddbb9f87-41ce-4060-a38a-8822b0e46eb1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_d73a9846-4f0e-4bd8-b0c4-24d3ec253020" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials_65365c27-c66e-4c11-9c1e-7f6539132186" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_d73a9846-4f0e-4bd8-b0c4-24d3ec253020" xlink:to="loc_ifrs-full_RawMaterials_65365c27-c66e-4c11-9c1e-7f6539132186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_43e88e17-1daa-4584-9c57-e40497a9a380" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_d73a9846-4f0e-4bd8-b0c4-24d3ec253020" xlink:to="loc_ifrs-full_WorkInProgress_43e88e17-1daa-4584-9c57-e40497a9a380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_4b83c1e9-bd63-4ad4-be1f-d6da3c3f528c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_d73a9846-4f0e-4bd8-b0c4-24d3ec253020" xlink:to="loc_ifrs-full_FinishedGoods_4b83c1e9-bd63-4ad4-be1f-d6da3c3f528c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthercurrentassetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OthercurrentassetsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/OthercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_aa916df6-7efc-4253-b685-f6bfffe6cafd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesMeasuredAtFairValue_1d2008ee-ee58-4018-9bd2-8d28525bbd1a" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesMeasuredAtFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_aa916df6-7efc-4253-b685-f6bfffe6cafd" xlink:to="loc_sny_CurrencyDerivativesMeasuredAtFairValue_1d2008ee-ee58-4018-9bd2-8d28525bbd1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_5b00e84a-eb44-4422-839b-7c6f558f6282" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_aa916df6-7efc-4253-b685-f6bfffe6cafd" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_5b00e84a-eb44-4422-839b-7c6f558f6282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_64bf11ec-56c8-4c62-a961-7891d0e86550" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_aa916df6-7efc-4253-b685-f6bfffe6cafd" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_64bf11ec-56c8-4c62-a961-7891d0e86550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_f65b8b78-5a56-46fd-b370-7c467338029c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_aa916df6-7efc-4253-b685-f6bfffe6cafd" xlink:to="loc_ifrs-full_OtherCurrentReceivables_f65b8b78-5a56-46fd-b370-7c467338029c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_05e9ad2a-75c3-4b57-87e2-af5353ef20f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_aa916df6-7efc-4253-b685-f6bfffe6cafd" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_05e9ad2a-75c3-4b57-87e2-af5353ef20f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateDerivativesMeasuredAtFairValue_bdbab8cb-af3a-4a82-ba86-3dcf2e70fc8a" xlink:href="sny-20231231.xsd#sny_InterestRateDerivativesMeasuredAtFairValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_aa916df6-7efc-4253-b685-f6bfffe6cafd" xlink:to="loc_sny_InterestRateDerivativesMeasuredAtFairValue_bdbab8cb-af3a-4a82-ba86-3dcf2e70fc8a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/CashandcashequivalentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#CashandcashequivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/CashandcashequivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_411c22f9-bc86-4b40-83c4-0d93812fef6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_79ee02ed-ce70-49af-a998-072dab6556c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_411c22f9-bc86-4b40-83c4-0d93812fef6e" xlink:to="loc_ifrs-full_Cash_79ee02ed-ce70-49af-a998-072dab6556c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_7c78f9cb-b844-4cbd-a606-6e2b2486d5fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_411c22f9-bc86-4b40-83c4-0d93812fef6e" xlink:to="loc_ifrs-full_CashEquivalents_7c78f9cb-b844-4cbd-a606-6e2b2486d5fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_c6fe34df-8f13-43a1-a694-118ea5abb889" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_9026f9bd-7759-46b4-8844-0d7030b2bd96" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_c6fe34df-8f13-43a1-a694-118ea5abb889" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_9026f9bd-7759-46b4-8844-0d7030b2bd96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_fb471f85-4be6-4113-9214-5ea82f26a4ed" xlink:href="sny-20231231.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_c6fe34df-8f13-43a1-a694-118ea5abb889" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_fb471f85-4be6-4113-9214-5ea82f26a4ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_2f2390fa-db75-4c70-a678-9307fc96b1e2" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_c6fe34df-8f13-43a1-a694-118ea5abb889" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_2f2390fa-db75-4c70-a678-9307fc96b1e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_c0dc637d-ec56-4949-8015-2b7a84c80d12" xlink:href="sny-20231231.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_c6fe34df-8f13-43a1-a694-118ea5abb889" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_c0dc637d-ec56-4949-8015-2b7a84c80d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_a7cf7bdd-701f-4381-b3c6-9bc0947c0dfd" xlink:href="sny-20231231.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_c6fe34df-8f13-43a1-a694-118ea5abb889" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_a7cf7bdd-701f-4381-b3c6-9bc0947c0dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_d7a20639-2df6-4ec4-87d8-187d15b1ad30" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_c6fe34df-8f13-43a1-a694-118ea5abb889" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_d7a20639-2df6-4ec4-87d8-187d15b1ad30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_ba80e2e3-bff2-4c25-acee-6667a36a6e4f" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_c6fe34df-8f13-43a1-a694-118ea5abb889" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_ba80e2e3-bff2-4c25-acee-6667a36a6e4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d560ba77-fbf0-44f2-8e15-17f7ec2f1e9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_7c2437eb-8685-4807-a355-205361a13624" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d560ba77-fbf0-44f2-8e15-17f7ec2f1e9d" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_7c2437eb-8685-4807-a355-205361a13624" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures_4c4cde56-9c18-4daa-b784-905499031377" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d560ba77-fbf0-44f2-8e15-17f7ec2f1e9d" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures_4c4cde56-9c18-4daa-b784-905499031377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_25f9e19c-84ac-433a-a755-96a8b4a62004" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d560ba77-fbf0-44f2-8e15-17f7ec2f1e9d" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_25f9e19c-84ac-433a-a755-96a8b4a62004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_754590b3-e221-4aac-b8f8-071616320ff6" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d560ba77-fbf0-44f2-8e15-17f7ec2f1e9d" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_754590b3-e221-4aac-b8f8-071616320ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_19716cbb-b4c1-4ea2-8cd5-a7261b729a48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d560ba77-fbf0-44f2-8e15-17f7ec2f1e9d" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_19716cbb-b4c1-4ea2-8cd5-a7261b729a48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_0d8245b1-a33d-4914-82ed-852382cb1d9c" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d560ba77-fbf0-44f2-8e15-17f7ec2f1e9d" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_0d8245b1-a33d-4914-82ed-852382cb1d9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_1ed7b064-5673-43d4-9270-1a6a11f75317" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d560ba77-fbf0-44f2-8e15-17f7ec2f1e9d" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_1ed7b064-5673-43d4-9270-1a6a11f75317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_f9b9770a-db29-4be0-849b-281029a98742" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d560ba77-fbf0-44f2-8e15-17f7ec2f1e9d" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_f9b9770a-db29-4be0-849b-281029a98742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_07a220e9-8cc8-473e-a47f-9f0970c920f4" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d560ba77-fbf0-44f2-8e15-17f7ec2f1e9d" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_07a220e9-8cc8-473e-a47f-9f0970c920f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_527c6fd3-e963-4f20-9731-3f13a3e53049" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_a712d230-e545-4385-b64c-0a47057b7826" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_527c6fd3-e963-4f20-9731-3f13a3e53049" xlink:to="loc_ifrs-full_WeightedAverageShares_a712d230-e545-4385-b64c-0a47057b7826" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_34ba2c59-b8bd-4ca2-9d87-30836182384a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_527c6fd3-e963-4f20-9731-3f13a3e53049" xlink:to="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_34ba2c59-b8bd-4ca2-9d87-30836182384a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_2b8e3663-9b5c-46c5-b204-0ab1d4ec9a77" xlink:href="sny-20231231.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares_527c6fd3-e963-4f20-9731-3f13a3e53049" xlink:to="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_2b8e3663-9b5c-46c5-b204-0ab1d4ec9a77" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_a74bec05-14e4-4f80-b8c1-1aed4418d49e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_82057c00-ae60-41d2-9388-db9ef7debcc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_a74bec05-14e4-4f80-b8c1-1aed4418d49e" xlink:to="loc_ifrs-full_LongtermBorrowings_82057c00-ae60-41d2-9388-db9ef7debcc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_235523c4-d10a-4631-b2ab-a9af9be328ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_a74bec05-14e4-4f80-b8c1-1aed4418d49e" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_235523c4-d10a-4631-b2ab-a9af9be328ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_93783e2e-30f8-4719-a319-575661c48b75" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_a74bec05-14e4-4f80-b8c1-1aed4418d49e" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_93783e2e-30f8-4719-a319-575661c48b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_178198f0-ccb6-48c9-8d93-d243d3dc6c83" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_ec35213b-8395-4562-95a5-3fe5521e53d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_178198f0-ccb6-48c9-8d93-d243d3dc6c83" xlink:to="loc_ifrs-full_Borrowings_ec35213b-8395-4562-95a5-3fe5521e53d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_30548a85-e356-4802-8a59-25b13eea2c43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_178198f0-ccb6-48c9-8d93-d243d3dc6c83" xlink:to="loc_ifrs-full_CashAndCashEquivalents_30548a85-e356-4802-8a59-25b13eea2c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_bb580086-0c5c-4f50-b7e6-3f9d6baf455e" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents_178198f0-ccb6-48c9-8d93-d243d3dc6c83" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_bb580086-0c5c-4f50-b7e6-3f9d6baf455e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_09e4d3df-7e7e-4e3e-8d3c-51d84b9b0de5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_6136d0ac-0182-42df-aa04-9f2f857da015" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_09e4d3df-7e7e-4e3e-8d3c-51d84b9b0de5" xlink:to="loc_ifrs-full_OtherBorrowings_6136d0ac-0182-42df-aa04-9f2f857da015" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_ec0ce0cb-7932-41d0-a432-7a2626610826" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_09e4d3df-7e7e-4e3e-8d3c-51d84b9b0de5" xlink:to="loc_ifrs-full_BondsIssued_ec0ce0cb-7932-41d0-a432-7a2626610826" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_7ebcc59d-0898-4c50-8aa0-1ea4dfe8e94e" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_09e4d3df-7e7e-4e3e-8d3c-51d84b9b0de5" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_7ebcc59d-0898-4c50-8aa0-1ea4dfe8e94e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_2b132aa6-2b02-4c7f-8508-8fc5aa52e5c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_09e4d3df-7e7e-4e3e-8d3c-51d84b9b0de5" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_2b132aa6-2b02-4c7f-8508-8fc5aa52e5c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_d68d4dbc-7f3f-48f5-a25f-f6fed6a19dc0" xlink:href="sny-20231231.xsd#sny_OtherBankBorrowings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_09e4d3df-7e7e-4e3e-8d3c-51d84b9b0de5" xlink:to="loc_sny_OtherBankBorrowings_d68d4dbc-7f3f-48f5-a25f-f6fed6a19dc0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalUndiscountedCashFlow_ef511ac8-5475-4fd4-89c7-bbac64175dfc" xlink:href="sny-20231231.xsd#sny_TotalUndiscountedCashFlow"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_91ea4acf-6479-4992-9468-394e1f45db02" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalUndiscountedCashFlow_ef511ac8-5475-4fd4-89c7-bbac64175dfc" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_91ea4acf-6479-4992-9468-394e1f45db02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_86dbd38f-5809-4b0f-a44e-165929b5f557" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalUndiscountedCashFlow_ef511ac8-5475-4fd4-89c7-bbac64175dfc" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_86dbd38f-5809-4b0f-a44e-165929b5f557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_90bc87c7-5564-4490-bd7e-a4b490bfa06c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalUndiscountedCashFlow_bfa134e5-79e2-4b31-93b6-0473f4c27d9c" xlink:href="sny-20231231.xsd#sny_PrincipalUndiscountedCashFlow"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_90bc87c7-5564-4490-bd7e-a4b490bfa06c" xlink:to="loc_sny_PrincipalUndiscountedCashFlow_bfa134e5-79e2-4b31-93b6-0473f4c27d9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestUndiscountedCashFlow_5bd166e5-43e1-42ee-a9bb-452f55eef6d2" xlink:href="sny-20231231.xsd#sny_InterestUndiscountedCashFlow"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_90bc87c7-5564-4490-bd7e-a4b490bfa06c" xlink:to="loc_sny_InterestUndiscountedCashFlow_5bd166e5-43e1-42ee-a9bb-452f55eef6d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_0ca1ac5a-a836-4399-a86c-b4750bccb00a" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_e1e8b5b6-1d4e-4dd4-8897-c431da04c433" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_0ca1ac5a-a836-4399-a86c-b4750bccb00a" xlink:to="loc_ifrs-full_NoncurrentProvisions_e1e8b5b6-1d4e-4dd4-8897-c431da04c433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_538d4abf-769b-4377-8667-d4c53ede7fa7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_0ca1ac5a-a836-4399-a86c-b4750bccb00a" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_538d4abf-769b-4377-8667-d4c53ede7fa7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_c7376632-4e90-4274-a0e4-2502303628e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanAssetsEffectOfAssetCeiling_d6caee18-077e-44c3-9de7-ce73fc5c0c12" xlink:href="sny-20231231.xsd#sny_PlanAssetsEffectOfAssetCeiling"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_c7376632-4e90-4274-a0e4-2502303628e7" xlink:to="loc_sny_PlanAssetsEffectOfAssetCeiling_d6caee18-077e-44c3-9de7-ce73fc5c0c12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_c8ba1a43-636b-49e3-b230-b6beaeb9aa31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_c7376632-4e90-4274-a0e4-2502303628e7" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_c8ba1a43-636b-49e3-b230-b6beaeb9aa31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_f6b8b9d2-e675-40e4-af01-332c1bf8c770" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_c7376632-4e90-4274-a0e4-2502303628e7" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_f6b8b9d2-e675-40e4-af01-332c1bf8c770" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssets_dc3d1913-b90d-4c62-8934-f39e86715687" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket_80c4ef98-aae6-4bb2-97c2-7e2c6fe739f2" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_PercentageContributedToFairValueOfPlanAssets_dc3d1913-b90d-4c62-8934-f39e86715687" xlink:to="loc_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket_80c4ef98-aae6-4bb2-97c2-7e2c6fe739f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities_13e0f714-8f6d-4c72-b3be-884e9b6d1201" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_PercentageContributedToFairValueOfPlanAssets_dc3d1913-b90d-4c62-8934-f39e86715687" xlink:to="loc_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities_13e0f714-8f6d-4c72-b3be-884e9b6d1201" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset_e1bb791b-61c5-4ebd-ab0a-4b6304084f3a" xlink:href="sny-20231231.xsd#sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_ad7e07df-ab37-4684-8133-3066a308e0ea" xlink:href="sny-20231231.xsd#sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset_e1bb791b-61c5-4ebd-ab0a-4b6304084f3a" xlink:to="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_ad7e07df-ab37-4684-8133-3066a308e0ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_e1fdfb20-a33e-447d-8a3b-3b036f0f2be1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset_e1bb791b-61c5-4ebd-ab0a-4b6304084f3a" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_e1fdfb20-a33e-447d-8a3b-3b036f0f2be1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_c6b5e434-fa38-4cb3-9b5e-e68c2cf8c79c" xlink:href="sny-20231231.xsd#sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_38a25b6c-865a-493f-8de8-5bb34755ef05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_c6b5e434-fa38-4cb3-9b5e-e68c2cf8c79c" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_38a25b6c-865a-493f-8de8-5bb34755ef05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_c223916a-f323-4cd1-9558-00c4f23001f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_c6b5e434-fa38-4cb3-9b5e-e68c2cf8c79c" xlink:to="loc_ifrs-full_FinanceCosts_c223916a-f323-4cd1-9558-00c4f23001f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_63e8a5a5-dccc-4d9a-81f7-f49c94191513" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_c6b5e434-fa38-4cb3-9b5e-e68c2cf8c79c" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_63e8a5a5-dccc-4d9a-81f7-f49c94191513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_b98df116-20b0-463e-a896-9ff00671b67e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_c6b5e434-fa38-4cb3-9b5e-e68c2cf8c79c" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_b98df116-20b0-463e-a896-9ff00671b67e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_985bbe1a-60e4-4f45-adcd-b8e3bba2be67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_c6b5e434-fa38-4cb3-9b5e-e68c2cf8c79c" xlink:to="loc_ifrs-full_CostOfSales_985bbe1a-60e4-4f45-adcd-b8e3bba2be67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestructuringCostsReversedAndSimilarItems_169d3988-4970-4e06-a437-a12c990d2c1e" xlink:href="sny-20231231.xsd#sny_RestructuringCostsReversedAndSimilarItems"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_c6b5e434-fa38-4cb3-9b5e-e68c2cf8c79c" xlink:to="loc_sny_RestructuringCostsReversedAndSimilarItems_169d3988-4970-4e06-a437-a12c990d2c1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLongtermProvisions_87450378-877b-4556-be3d-ca9aa8d44018" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLongtermProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionForEnvironmentRisks_790c66f2-9eb9-4093-9fd1-817a6cdf8469" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionForEnvironmentRisks"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherLongtermProvisions_87450378-877b-4556-be3d-ca9aa8d44018" xlink:to="loc_sny_NonCurrentProvisionForEnvironmentRisks_790c66f2-9eb9-4093-9fd1-817a6cdf8469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_86ad535e-4030-47ba-a9f8-d22f04d6bece" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherLongtermProvisions_87450378-877b-4556-be3d-ca9aa8d44018" xlink:to="loc_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_86ad535e-4030-47ba-a9f8-d22f04d6bece" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_785901db-f583-4c4c-a327-d42a2f12b1ef" xlink:href="sny-20231231.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_837667bb-ca5b-461f-8308-56edbb5533a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_785901db-f583-4c4c-a327-d42a2f12b1ef" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_837667bb-ca5b-461f-8308-56edbb5533a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentInterestRateDerivativesPayable_4a29455c-4799-4d59-bfaf-a2b858daa719" xlink:href="sny-20231231.xsd#sny_CurrentInterestRateDerivativesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_785901db-f583-4c4c-a327-d42a2f12b1ef" xlink:to="loc_sny_CurrentInterestRateDerivativesPayable_4a29455c-4799-4d59-bfaf-a2b858daa719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_aec6ad5a-461a-4cf7-96fe-77e1eaf5b297" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_785901db-f583-4c4c-a327-d42a2f12b1ef" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_aec6ad5a-461a-4cf7-96fe-77e1eaf5b297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentCurrencyDerivativesPayable_7bbcf7e1-1670-4953-a8ab-c244ae9dfcb8" xlink:href="sny-20231231.xsd#sny_CurrentCurrencyDerivativesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_785901db-f583-4c4c-a327-d42a2f12b1ef" xlink:to="loc_sny_CurrentCurrencyDerivativesPayable_7bbcf7e1-1670-4953-a8ab-c244ae9dfcb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermRestructuringProvision_51b57602-6da4-4e73-ac03-e31acc8f9272" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermRestructuringProvision"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_785901db-f583-4c4c-a327-d42a2f12b1ef" xlink:to="loc_ifrs-full_ShorttermRestructuringProvision_51b57602-6da4-4e73-ac03-e31acc8f9272" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_9ec4568c-24c2-4df5-88f6-0a357e7891ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_785901db-f583-4c4c-a327-d42a2f12b1ef" xlink:to="loc_ifrs-full_CurrentContractLiabilities_9ec4568c-24c2-4df5-88f6-0a357e7891ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_361c22d8-8936-4a21-bf7e-b05c36edd570" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_785901db-f583-4c4c-a327-d42a2f12b1ef" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_361c22d8-8936-4a21-bf7e-b05c36edd570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountsPayableForAcquisitionOfNonCurrentAssets_25f17a5b-29dd-4e2d-ac43-136501108c65" xlink:href="sny-20231231.xsd#sny_AmountsPayableForAcquisitionOfNonCurrentAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_785901db-f583-4c4c-a327-d42a2f12b1ef" xlink:to="loc_sny_AmountsPayableForAcquisitionOfNonCurrentAssets_25f17a5b-29dd-4e2d-ac43-136501108c65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentEquityDerivativesPayable_c6ca8665-51f7-45e8-b873-e9d39218e3fc" xlink:href="sny-20231231.xsd#sny_CurrentEquityDerivativesPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_785901db-f583-4c4c-a327-d42a2f12b1ef" xlink:to="loc_sny_CurrentEquityDerivativesPayable_c6ca8665-51f7-45e8-b873-e9d39218e3fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_86ebc8ea-ec5b-4593-835c-1670f6c5f6b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_bf262cb5-ca85-49f9-93a8-79ef8a7d4884" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilities_86ebc8ea-ec5b-4593-835c-1670f6c5f6b9" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_bf262cb5-ca85-49f9-93a8-79ef8a7d4884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_72e5f839-7378-4404-bdf0-983ebbfd36a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilities_86ebc8ea-ec5b-4593-835c-1670f6c5f6b9" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_72e5f839-7378-4404-bdf0-983ebbfd36a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_ddd6f270-e769-4662-b400-29361c38de0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_ae1ef891-9ac8-4327-814e-bd87344f885c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DerivativeFinancialAssets_ddd6f270-e769-4662-b400-29361c38de0f" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_ae1ef891-9ac8-4327-814e-bd87344f885c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets_61507665-3734-4474-af7d-cd5b0d0797a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DerivativeFinancialAssets_ddd6f270-e769-4662-b400-29361c38de0f" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialAssets_61507665-3734-4474-af7d-cd5b0d0797a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_c073973f-6c8a-4914-a110-e2d4be315a9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_d177e4eb-b269-453c-88f1-0947178988f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_c073973f-6c8a-4914-a110-e2d4be315a9f" xlink:to="loc_ifrs-full_DerivativeFinancialAssets_d177e4eb-b269-453c-88f1-0947178988f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_c62675cc-c0ea-4aed-ab40-202552fd3c4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_c073973f-6c8a-4914-a110-e2d4be315a9f" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_c62675cc-c0ea-4aed-ab40-202552fd3c4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetExposure_f681c086-cdde-46e1-bf1e-2cad1c1429d7" xlink:href="sny-20231231.xsd#sny_NetExposure"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments_11cc48c3-d18c-49a1-b714-643d77fb1e34" xlink:href="sny-20231231.xsd#sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_NetExposure_f681c086-cdde-46e1-bf1e-2cad1c1429d7" xlink:to="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments_11cc48c3-d18c-49a1-b714-643d77fb1e34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral_9db6062d-dd56-449e-ba94-9652d2a7c5b0" xlink:href="sny-20231231.xsd#sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_NetExposure_f681c086-cdde-46e1-bf1e-2cad1c1429d7" xlink:to="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral_9db6062d-dd56-449e-ba94-9652d2a7c5b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetAmountsAsReportedInTheBalanceSheet_a08913bd-2559-4c4e-b869-a069e54f4a2a" xlink:href="sny-20231231.xsd#sny_NetAmountsAsReportedInTheBalanceSheet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_NetExposure_f681c086-cdde-46e1-bf1e-2cad1c1429d7" xlink:to="loc_sny_NetAmountsAsReportedInTheBalanceSheet_a08913bd-2559-4c4e-b869-a069e54f4a2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetAmountsAsReportedInTheBalanceSheet_9bc6975c-06d7-4076-aa11-12521aa9221d" xlink:href="sny-20231231.xsd#sny_NetAmountsAsReportedInTheBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset_d4c3ae89-b9e6-45d3-95dd-519554f976c3" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_NetAmountsAsReportedInTheBalanceSheet_9bc6975c-06d7-4076-aa11-12521aa9221d" xlink:to="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset_d4c3ae89-b9e6-45d3-95dd-519554f976c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32_264ca157-560f-41d1-9810-4131d6c4d4b6" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_NetAmountsAsReportedInTheBalanceSheet_9bc6975c-06d7-4076-aa11-12521aa9221d" xlink:to="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32_264ca157-560f-41d1-9810-4131d6c4d4b6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalOffBalanceSheetCommitments_45fcb56a-681e-4c0c-9277-94d27b9d1e6c" xlink:href="sny-20231231.xsd#sny_TotalOffBalanceSheetCommitments"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments_26e654a1-f98c-4c05-b369-eadfb99e9ada" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalOffBalanceSheetCommitments_45fcb56a-681e-4c0c-9277-94d27b9d1e6c" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments_26e654a1-f98c-4c05-b369-eadfb99e9ada" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet_b60baa61-b3d0-4bb9-9b57-9046b929091e" xlink:href="sny-20231231.xsd#sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalOffBalanceSheetCommitments_45fcb56a-681e-4c0c-9277-94d27b9d1e6c" xlink:to="loc_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet_b60baa61-b3d0-4bb9-9b57-9046b929091e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsGiven_51621c94-6311-45bf-9491-e81dc9df18b9" xlink:href="sny-20231231.xsd#sny_IrrevocablePurchaseCommitmentsGiven"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalOffBalanceSheetCommitments_45fcb56a-681e-4c0c-9277-94d27b9d1e6c" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsGiven_51621c94-6311-45bf-9491-e81dc9df18b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress_f74067d2-7bac-4ffa-bc84-7e001fcdc330" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalOffBalanceSheetCommitments_45fcb56a-681e-4c0c-9277-94d27b9d1e6c" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress_f74067d2-7bac-4ffa-bc84-7e001fcdc330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsReceived_4d02ab3d-efa9-44bf-8a1e-1c012c0f89ae" xlink:href="sny-20231231.xsd#sny_IrrevocablePurchaseCommitmentsReceived"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_TotalOffBalanceSheetCommitments_45fcb56a-681e-4c0c-9277-94d27b9d1e6c" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsReceived_4d02ab3d-efa9-44bf-8a1e-1c012c0f89ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PersonnelcostsSummaryofPersonalCostsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_916841b7-d184-4b85-a6d8-cac2d36093da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_215ea02b-112d-4351-a5f6-17fe13fc8caa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_916841b7-d184-4b85-a6d8-cac2d36093da" xlink:to="loc_ifrs-full_WagesAndSalaries_215ea02b-112d-4351-a5f6-17fe13fc8caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions_b324e2a0-020d-44aa-b2ca-d723eb03c4da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_916841b7-d184-4b85-a6d8-cac2d36093da" xlink:to="loc_ifrs-full_SocialSecurityContributions_b324e2a0-020d-44aa-b2ca-d723eb03c4da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_e067b8a4-9ac5-4ad5-860e-65808866ef3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_916841b7-d184-4b85-a6d8-cac2d36093da" xlink:to="loc_ifrs-full_OtherEmployeeExpense_e067b8a4-9ac5-4ad5-860e-65808866ef3e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_6a7d5ade-26b5-4426-ae00-4b601ec26827" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_8a99c93f-ee21-46d4-8d21-0d37e2ec7bf0" xlink:href="sny-20231231.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_6a7d5ade-26b5-4426-ae00-4b601ec26827" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_8a99c93f-ee21-46d4-8d21-0d37e2ec7bf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_6a4e9de8-a452-45d6-a9d9-153976a6cecd" xlink:href="sny-20231231.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_6a7d5ade-26b5-4426-ae00-4b601ec26827" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_6a4e9de8-a452-45d6-a9d9-153976a6cecd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_b706b589-7ade-4117-a8d8-aa6fc2f6246e" xlink:href="sny-20231231.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_6a7d5ade-26b5-4426-ae00-4b601ec26827" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_b706b589-7ade-4117-a8d8-aa6fc2f6246e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCost_bfa37f03-a77d-4f7c-a54c-714583411c95" xlink:href="sny-20231231.xsd#sny_OtherRestructuringCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities_6a7d5ade-26b5-4426-ae00-4b601ec26827" xlink:to="loc_sny_OtherRestructuringCost_bfa37f03-a77d-4f7c-a54c-714583411c95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#FinancialexpensesandincomeDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_0ef515cd-ce8d-44e0-9173-11ec823c820d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_77cd95f7-6385-45df-8711-5275de8a5a38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_0ef515cd-ce8d-44e0-9173-11ec823c820d" xlink:to="loc_ifrs-full_FinanceCosts_77cd95f7-6385-45df-8711-5275de8a5a38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_aa4cd049-c91c-411e-b4d6-58830f83b3ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_0ef515cd-ce8d-44e0-9173-11ec823c820d" xlink:to="loc_ifrs-full_FinanceIncome_aa4cd049-c91c-411e-b4d6-58830f83b3ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_e879452d-23de-4c81-89ba-91839e389098" xlink:href="sny-20231231.xsd#sny_CostOfDebtNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_493cfc10-b87a-4981-8859-36619a0f18b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CostOfDebtNet_e879452d-23de-4c81-89ba-91839e389098" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_493cfc10-b87a-4981-8859-36619a0f18b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_63208151-ffa2-4935-bf2c-848a0e2a3bb1" xlink:href="sny-20231231.xsd#sny_InterestIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_CostOfDebtNet_e879452d-23de-4c81-89ba-91839e389098" xlink:to="loc_sny_InterestIncome_63208151-ffa2-4935-bf2c-848a0e2a3bb1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1" xlink:type="simple" xlink:href="sny-20231231.xsd#FinancialexpensesandincomeDetails_1"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_5c9fba85-e589-4f3f-8328-aa1596949177" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_fe428584-68e5-4bd7-8712-95176bb933f1" xlink:href="sny-20231231.xsd#sny_CostOfDebtNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_5c9fba85-e589-4f3f-8328-aa1596949177" xlink:to="loc_sny_CostOfDebtNet_fe428584-68e5-4bd7-8712-95176bb933f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_0bf469bd-2384-4d8b-a11c-a71eccd6f9fa" xlink:href="sny-20231231.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_5c9fba85-e589-4f3f-8328-aa1596949177" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_0bf469bd-2384-4d8b-a11c-a71eccd6f9fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_f98e2f36-715c-4f6a-8503-b171983e6f4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_5c9fba85-e589-4f3f-8328-aa1596949177" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_f98e2f36-715c-4f6a-8503-b171983e6f4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_f01a3530-3474-41b2-9508-28afb1db060b" xlink:href="sny-20231231.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_5c9fba85-e589-4f3f-8328-aa1596949177" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_f01a3530-3474-41b2-9508-28afb1db060b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_c1ae370b-6971-4dc9-a640-7ceaf69d4179" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_5c9fba85-e589-4f3f-8328-aa1596949177" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_c1ae370b-6971-4dc9-a640-7ceaf69d4179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_dad67635-61d5-4bc9-ac79-207cd234385d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_5c9fba85-e589-4f3f-8328-aa1596949177" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_dad67635-61d5-4bc9-ac79-207cd234385d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_572f1100-448b-44f1-a192-83f5883a233c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_5c9fba85-e589-4f3f-8328-aa1596949177" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_572f1100-448b-44f1-a192-83f5883a233c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_aea566d3-53c1-487a-b8f0-ab5f1fd20991" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_dd04c0f1-4b7e-4095-a1ce-7fe5db202985" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_aea566d3-53c1-487a-b8f0-ab5f1fd20991" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_dd04c0f1-4b7e-4095-a1ce-7fe5db202985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_872594ed-7219-4d03-88d7-8c6aab6da6a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_aea566d3-53c1-487a-b8f0-ab5f1fd20991" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_872594ed-7219-4d03-88d7-8c6aab6da6a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_d28914a7-2104-4ed8-acb4-1adcd750a0c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_e8fd6002-fb19-46a3-b578-01e42d686d00" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_d28914a7-2104-4ed8-acb4-1adcd750a0c9" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_e8fd6002-fb19-46a3-b578-01e42d686d00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_095f896c-6d40-45e6-bbf0-fd80d3ed99c1" xlink:href="sny-20231231.xsd#sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_d28914a7-2104-4ed8-acb4-1adcd750a0c9" xlink:to="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_095f896c-6d40-45e6-bbf0-fd80d3ed99c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes_5ef0ab4a-1a5a-4c8e-899c-f423133ad674" xlink:href="sny-20231231.xsd#sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_d28914a7-2104-4ed8-acb4-1adcd750a0c9" xlink:to="loc_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes_5ef0ab4a-1a5a-4c8e-899c-f423133ad674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_fe14ccf5-7e20-4080-a646-8f39f358f728" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_d28914a7-2104-4ed8-acb4-1adcd750a0c9" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_fe14ccf5-7e20-4080-a646-8f39f358f728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_03fb2437-e64c-4fb7-9161-fcd41772a513" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_d28914a7-2104-4ed8-acb4-1adcd750a0c9" xlink:to="loc_ifrs-full_ApplicableTaxRate_03fb2437-e64c-4fb7-9161-fcd41772a513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_62f3ef10-460f-493d-a476-96a2229b0436" xlink:href="sny-20231231.xsd#sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate_d28914a7-2104-4ed8-acb4-1adcd750a0c9" xlink:to="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_62f3ef10-460f-493d-a476-96a2229b0436" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_f5ec5897-5b83-48c9-b7b1-b9f8b7ef0e4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_447b52c3-67cd-4e68-be8c-63592a70f593" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_f5ec5897-5b83-48c9-b7b1-b9f8b7ef0e4b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_447b52c3-67cd-4e68-be8c-63592a70f593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_2df96e0c-2c63-4f2b-a6f2-438f0ac974c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_f5ec5897-5b83-48c9-b7b1-b9f8b7ef0e4b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_2df96e0c-2c63-4f2b-a6f2-438f0ac974c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_5bf49d69-6d86-4108-84a7-2396e4f955a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_f5ec5897-5b83-48c9-b7b1-b9f8b7ef0e4b" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_5bf49d69-6d86-4108-84a7-2396e4f955a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationScheduleofSegmentResultsDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_f3865180-c508-42f2-9a7d-67411911c5de" xlink:href="sny-20231231.xsd#sny_BusinessOperatingIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_821e987a-3e7e-48c8-bcf5-65a8be001e04" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_f3865180-c508-42f2-9a7d-67411911c5de" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_821e987a-3e7e-48c8-bcf5-65a8be001e04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_9528cdcf-b096-4b77-9a63-3939cd450676" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_f3865180-c508-42f2-9a7d-67411911c5de" xlink:to="loc_ifrs-full_OtherRevenue_9528cdcf-b096-4b77-9a63-3939cd450676" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_e17405c9-46c8-4ca0-82b4-e0713222682d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_f3865180-c508-42f2-9a7d-67411911c5de" xlink:to="loc_ifrs-full_CostOfSales_e17405c9-46c8-4ca0-82b4-e0713222682d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_9940ba0d-71de-4111-8d57-2b525166c8e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_f3865180-c508-42f2-9a7d-67411911c5de" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_9940ba0d-71de-4111-8d57-2b525166c8e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_cc90bb27-9a43-446f-b539-ecde21f62d9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_f3865180-c508-42f2-9a7d-67411911c5de" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_cc90bb27-9a43-446f-b539-ecde21f62d9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_9de60690-d669-4505-b6f3-264238146d73" xlink:href="sny-20231231.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_f3865180-c508-42f2-9a7d-67411911c5de" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_9de60690-d669-4505-b6f3-264238146d73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_84a8ab5d-c5df-4c51-9c43-473a6c5fd790" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_f3865180-c508-42f2-9a7d-67411911c5de" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_84a8ab5d-c5df-4c51-9c43-473a6c5fd790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_972b8a2d-06bd-47d3-9cd8-a1e639902f63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_BusinessOperatingIncome_f3865180-c508-42f2-9a7d-67411911c5de" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_972b8a2d-06bd-47d3-9cd8-a1e639902f63" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_8410a955-9e98-4057-93e7-21c138fb483a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_d35308bb-1b1e-44de-944e-a618aeece27d" xlink:href="sny-20231231.xsd#sny_BusinessOperatingIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_8410a955-9e98-4057-93e7-21c138fb483a" xlink:to="loc_sny_BusinessOperatingIncome_d35308bb-1b1e-44de-944e-a618aeece27d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_dde8d786-403a-4120-8a3b-f7c8d4cc9f24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_8410a955-9e98-4057-93e7-21c138fb483a" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_dde8d786-403a-4120-8a3b-f7c8d4cc9f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_45d37a4b-d1ad-4cc0-b3db-75578b65fd9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_8410a955-9e98-4057-93e7-21c138fb483a" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_45d37a4b-d1ad-4cc0-b3db-75578b65fd9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_412e85ca-7809-4b4f-a215-6a176abcfd7b" xlink:href="sny-20231231.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_8410a955-9e98-4057-93e7-21c138fb483a" xlink:to="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_412e85ca-7809-4b4f-a215-6a176abcfd7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_10257170-db26-4eaa-a778-62e4b7da5778" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_8410a955-9e98-4057-93e7-21c138fb483a" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_10257170-db26-4eaa-a778-62e4b7da5778" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_770e664e-aabc-437b-9c2f-0c224297e2e4" xlink:href="sny-20231231.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_8410a955-9e98-4057-93e7-21c138fb483a" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_770e664e-aabc-437b-9c2f-0c224297e2e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_1167d8f0-5fe8-4ec7-bdbf-7c97f854ded4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_8410a955-9e98-4057-93e7-21c138fb483a" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_1167d8f0-5fe8-4ec7-bdbf-7c97f854ded4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_4b8600fb-9d25-4546-a166-755c1ba93e19" xlink:href="sny-20231231.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_8410a955-9e98-4057-93e7-21c138fb483a" xlink:to="loc_sny_OtherGainsLossesAndLitigation_4b8600fb-9d25-4546-a166-755c1ba93e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing_879b5a25-1af1-4b39-9d77-312e6127bfa0" xlink:href="sny-20231231.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_8410a955-9e98-4057-93e7-21c138fb483a" xlink:to="loc_sny_IncomeResultingFromOutLicensing_879b5a25-1af1-4b39-9d77-312e6127bfa0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalaccountantsfeesandservicesDetails"/>
  <link:calculationLink xlink:role="http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemuneration_15da379c-d919-4927-873c-3d405c0d6837" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemuneration"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices_8063a076-9fe5-4dfc-bdbb-7fa1b8b3480b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AuditorsRemuneration_15da379c-d919-4927-873c-3d405c0d6837" xlink:to="loc_ifrs-full_AuditorsRemunerationForAuditServices_8063a076-9fe5-4dfc-bdbb-7fa1b8b3480b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ServicesOtherThanStatutoryAudit_7b9efbc7-7c0e-4cf8-8ddb-a1bc460a2fa2" xlink:href="sny-20231231.xsd#sny_ServicesOtherThanStatutoryAudit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AuditorsRemuneration_15da379c-d919-4927-873c-3d405c0d6837" xlink:to="loc_sny_ServicesOtherThanStatutoryAudit_7b9efbc7-7c0e-4cf8-8ddb-a1bc460a2fa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ServicesOtherThanStatutoryAudit_2d5eae3b-a73c-43ba-ba26-2d43de6a8404" xlink:href="sny-20231231.xsd#sny_ServicesOtherThanStatutoryAudit"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsRemunerationForAuditRelatedServices_e28749ef-425e-4979-8840-a871faa18cb5" xlink:href="sny-20231231.xsd#sny_AuditorsRemunerationForAuditRelatedServices"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_ServicesOtherThanStatutoryAudit_2d5eae3b-a73c-43ba-ba26-2d43de6a8404" xlink:to="loc_sny_AuditorsRemunerationForAuditRelatedServices_e28749ef-425e-4979-8840-a871faa18cb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForTaxServices_d2ef9b1c-f460-43b9-bdb5-c1ae198858de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForTaxServices"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_ServicesOtherThanStatutoryAudit_2d5eae3b-a73c-43ba-ba26-2d43de6a8404" xlink:to="loc_ifrs-full_AuditorsRemunerationForTaxServices_d2ef9b1c-f460-43b9-bdb5-c1ae198858de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForOtherServices_e54b3312-a52e-4812-a75a-58f48d89e5e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForOtherServices"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_ServicesOtherThanStatutoryAudit_2d5eae3b-a73c-43ba-ba26-2d43de6a8404" xlink:to="loc_ifrs-full_AuditorsRemunerationForOtherServices_e54b3312-a52e-4812-a75a-58f48d89e5e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorsRemuneration_7b37827f-01aa-4653-b4d7-6b3376ea5bec" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorsRemuneration"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorRemunerationForStatutoryAudit_7db9b20a-a0cc-45b9-8ba3-d5da1b1fa46d" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorRemunerationForStatutoryAudit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_PercentageOfAuditorsRemuneration_7b37827f-01aa-4653-b4d7-6b3376ea5bec" xlink:to="loc_sny_PercentageOfAuditorRemunerationForStatutoryAudit_7db9b20a-a0cc-45b9-8ba3-d5da1b1fa46d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements_9e0ff976-55cd-4f33-9617-7319e98599bb" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sny_PercentageOfAuditorsRemuneration_7b37827f-01aa-4653-b4d7-6b3376ea5bec" xlink:to="loc_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements_9e0ff976-55cd-4f33-9617-7319e98599bb" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>sny-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:d2fc6364-8fcd-4586-a9d3-e16cd96a566e,g:f65f6c85-de12-4c7c-b6b2-ea3943f1a47f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sanofi.com/role/Coverpage" xlink:type="simple" xlink:href="sny-20231231.xsd#Coverpage"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_63282cf8-9552-4776-a356-846159c5b2ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntitiesTable_63282cf8-9552-4776-a356-846159c5b2ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_db442af4-7157-4aed-9a0a-f08f1d301e5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_63282cf8-9552-4776-a356-846159c5b2ba" xlink:to="loc_dei_EntityListingsExchangeAxis_db442af4-7157-4aed-9a0a-f08f1d301e5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_db442af4-7157-4aed-9a0a-f08f1d301e5f_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_db442af4-7157-4aed-9a0a-f08f1d301e5f" xlink:to="loc_dei_ExchangeDomain_db442af4-7157-4aed-9a0a-f08f1d301e5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_ca8d302a-cd4a-4f17-8809-278b32abaeb1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_db442af4-7157-4aed-9a0a-f08f1d301e5f" xlink:to="loc_dei_ExchangeDomain_ca8d302a-cd4a-4f17-8809-278b32abaeb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember_8c8839f1-3daa-44f6-83e3-249c2cf9388f" xlink:href="sny-20231231.xsd#sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_ca8d302a-cd4a-4f17-8809-278b32abaeb1" xlink:to="loc_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember_8c8839f1-3daa-44f6-83e3-249c2cf9388f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OrdinarySharesNASDAQGlobalSelectMarketMember_a909b0fe-09ea-431f-842c-528aa2d4efb1" xlink:href="sny-20231231.xsd#sny_OrdinarySharesNASDAQGlobalSelectMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_ca8d302a-cd4a-4f17-8809-278b32abaeb1" xlink:to="loc_sny_OrdinarySharesNASDAQGlobalSelectMarketMember_a909b0fe-09ea-431f-842c-528aa2d4efb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_6817344a-2e66-4742-b0dc-b42a85859912" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_63282cf8-9552-4776-a356-846159c5b2ba" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_6817344a-2e66-4742-b0dc-b42a85859912" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_6817344a-2e66-4742-b0dc-b42a85859912_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_6817344a-2e66-4742-b0dc-b42a85859912" xlink:to="loc_dei_AddressTypeDomain_6817344a-2e66-4742-b0dc-b42a85859912_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_b05ccb02-f289-4330-8085-f0552f062b31" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_6817344a-2e66-4742-b0dc-b42a85859912" xlink:to="loc_dei_AddressTypeDomain_b05ccb02-f289-4330-8085-f0552f062b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_3d39dac7-c774-4d57-8be7-c412c22069f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_b05ccb02-f289-4330-8085-f0552f062b31" xlink:to="loc_dei_BusinessContactMember_3d39dac7-c774-4d57-8be7-c412c22069f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_bcf70f67-8fde-4815-a4a7-c006d4084aa3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentType_bcf70f67-8fde-4815-a4a7-c006d4084aa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_50ff36dd-dfe8-4b8e-bdec-28fb5550e681" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentRegistrationStatement_50ff36dd-dfe8-4b8e-bdec-28fb5550e681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b7e98fa3-fd42-4d6e-a734-b1a6ff53832e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentAnnualReport_b7e98fa3-fd42-4d6e-a734-b1a6ff53832e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_778cd86c-68f5-4a3b-839c-e7d1ef5e63c6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_CurrentFiscalYearEndDate_778cd86c-68f5-4a3b-839c-e7d1ef5e63c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_929cff95-85f8-42c7-b405-ce4ee0392e15" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentPeriodEndDate_929cff95-85f8-42c7-b405-ce4ee0392e15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_17015b9f-7752-42e6-bc79-4cc4e38e859e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentTransitionReport_17015b9f-7752-42e6-bc79-4cc4e38e859e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_74bbf6cd-d0ac-4bac-a384-66841733dc4f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentShellCompanyReport_74bbf6cd-d0ac-4bac-a384-66841733dc4f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b6aaa2b9-3f7a-4dad-9203-d4997cb71279" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityFileNumber_b6aaa2b9-3f7a-4dad-9203-d4997cb71279" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_276619cd-a029-4416-8c3f-c697a65ebe0c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityRegistrantName_276619cd-a029-4416-8c3f-c697a65ebe0c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_900a6a1a-e920-46e4-9c35-d5d28fd76427" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityIncorporationStateCountryCode_900a6a1a-e920-46e4-9c35-d5d28fd76427" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_6df97151-5e91-4d4b-b526-123d43107d4c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_ContactPersonnelName_6df97151-5e91-4d4b-b526-123d43107d4c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ac31a46f-2c48-4c1a-bfdb-677fc1c3d30f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityAddressAddressLine1_ac31a46f-2c48-4c1a-bfdb-677fc1c3d30f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b7a202c5-8294-45ae-a943-2613dbba639f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityAddressPostalZipCode_b7a202c5-8294-45ae-a943-2613dbba639f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_168ce81c-5773-4332-9e9b-5f8d61b9877e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityAddressCityOrTown_168ce81c-5773-4332-9e9b-5f8d61b9877e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_3a4afa11-d1d3-42d6-ab78-edb2b10c3b84" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityAddressCountry_3a4afa11-d1d3-42d6-ab78-edb2b10c3b84" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_408c0e72-426e-4834-9a94-c67264ccbfb7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_CityAreaCode_408c0e72-426e-4834-9a94-c67264ccbfb7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c10d332d-5418-481c-80f8-af9c881cb35e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_LocalPhoneNumber_c10d332d-5418-481c-80f8-af9c881cb35e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5a4e42c4-1be5-4c38-9c45-b7f64402899a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_Security12bTitle_5a4e42c4-1be5-4c38-9c45-b7f64402899a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a8fedcc0-c7c7-44bf-ac4a-14e1468536fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_TradingSymbol_a8fedcc0-c7c7-44bf-ac4a-14e1468536fb" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d0b5d326-4e52-4568-a52f-4d6552672805" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_SecurityExchangeName_d0b5d326-4e52-4568-a52f-4d6552672805" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7530f6f9-ad8a-4093-849a-689e1c4cb663" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7530f6f9-ad8a-4093-849a-689e1c4cb663" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6021dbbd-eb17-4578-a686-be576628eb46" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_6021dbbd-eb17-4578-a686-be576628eb46" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f392f1a7-0e73-4c9c-8163-4f03551b628a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityVoluntaryFilers_f392f1a7-0e73-4c9c-8163-4f03551b628a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4ba1fab0-6b5b-4325-a46c-ac7f4fd7330a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityCurrentReportingStatus_4ba1fab0-6b5b-4325-a46c-ac7f4fd7330a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_014ee22a-a531-476b-ab8f-46210dcafe1a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityInteractiveDataCurrent_014ee22a-a531-476b-ab8f-46210dcafe1a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_996350c1-9113-4f9e-a5f3-5ad95fba93bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityFilerCategory_996350c1-9113-4f9e-a5f3-5ad95fba93bf" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_70cbef6e-41ec-492d-a274-7b38763f8ff7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityEmergingGrowthCompany_70cbef6e-41ec-492d-a274-7b38763f8ff7" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_b2012084-1882-4076-b53e-badbf71e517d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_IcfrAuditorAttestationFlag_b2012084-1882-4076-b53e-badbf71e517d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_847b56a5-db49-420c-bce3-23933d839064" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_847b56a5-db49-420c-bce3-23933d839064" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_e3cc20a3-8647-4902-9a5a-e69cb4a75421" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentAccountingStandard_e3cc20a3-8647-4902-9a5a-e69cb4a75421" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_38145670-8248-4e35-8d58-04c7c1c91a68" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityShellCompany_38145670-8248-4e35-8d58-04c7c1c91a68" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_79cebc9c-2e18-434e-b345-28ed356c640d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_AmendmentFlag_79cebc9c-2e18-434e-b345-28ed356c640d" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2762cbd2-2097-410b-baf6-109114fd889b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentFiscalYearFocus_2762cbd2-2097-410b-baf6-109114fd889b" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3e9f4975-17ac-41a8-9256-ec1187646e89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3e9f4975-17ac-41a8-9256-ec1187646e89" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0ca123be-1a5f-44cd-8fe3-712a6290f849" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityCentralIndexKey_0ca123be-1a5f-44cd-8fe3-712a6290f849" xlink:type="arc" order="34"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AuditInformation" xlink:type="simple" xlink:href="sny-20231231.xsd#AuditInformation"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLineItems_1413efae-ec16-458a-8c72-db461ea68b08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorTable_04790677-8977-4b1d-a49f-20e895528b85" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_AuditorLineItems_1413efae-ec16-458a-8c72-db461ea68b08" xlink:to="loc_dei_AuditorTable_04790677-8977-4b1d-a49f-20e895528b85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bebc0b1b-8dc1-414b-b7f0-c486f2c2ea4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_AuditorTable_04790677-8977-4b1d-a49f-20e895528b85" xlink:to="loc_srt_CounterpartyNameAxis_bebc0b1b-8dc1-414b-b7f0-c486f2c2ea4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bebc0b1b-8dc1-414b-b7f0-c486f2c2ea4c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bebc0b1b-8dc1-414b-b7f0-c486f2c2ea4c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bebc0b1b-8dc1-414b-b7f0-c486f2c2ea4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad83ff37-0b3d-4797-ba6f-8d6141551970" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bebc0b1b-8dc1-414b-b7f0-c486f2c2ea4c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad83ff37-0b3d-4797-ba6f-8d6141551970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ErnstYoungEtAutresMember_ee4cfc20-6864-44ef-b8f0-93c6e5496d68" xlink:href="sny-20231231.xsd#sny_ErnstYoungEtAutresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad83ff37-0b3d-4797-ba6f-8d6141551970" xlink:to="loc_sny_ErnstYoungEtAutresMember_ee4cfc20-6864-44ef-b8f0-93c6e5496d68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_780d9c14-081b-4173-9296-1afce09482fe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AuditorLineItems_1413efae-ec16-458a-8c72-db461ea68b08" xlink:to="loc_dei_AuditorName_780d9c14-081b-4173-9296-1afce09482fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_afbe459e-48d1-4029-87d1-2e00283c0b3a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AuditorLineItems_1413efae-ec16-458a-8c72-db461ea68b08" xlink:to="loc_dei_AuditorLocation_afbe459e-48d1-4029-87d1-2e00283c0b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_5714d34a-0c40-4ecb-aa1c-5e33c6a1511a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AuditorLineItems_1413efae-ec16-458a-8c72-db461ea68b08" xlink:to="loc_dei_AuditorFirmId_5714d34a-0c40-4ecb-aa1c-5e33c6a1511a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedstatementsofchangesinequity"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_7bafa3bd-2ddc-48b2-8091-89946f95392a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_7bafa3bd-2ddc-48b2-8091-89946f95392a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_11b2185c-0346-47d4-92d5-6811c22e4173" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_7bafa3bd-2ddc-48b2-8091-89946f95392a" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_11b2185c-0346-47d4-92d5-6811c22e4173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_11b2185c-0346-47d4-92d5-6811c22e4173_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_11b2185c-0346-47d4-92d5-6811c22e4173" xlink:to="loc_ifrs-full_EquityMember_11b2185c-0346-47d4-92d5-6811c22e4173_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_5f8e19d0-cb17-4e83-bd96-04659777cf2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_11b2185c-0346-47d4-92d5-6811c22e4173" xlink:to="loc_ifrs-full_EquityMember_5f8e19d0-cb17-4e83-bd96-04659777cf2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_5f8e19d0-cb17-4e83-bd96-04659777cf2f" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_1e3eeae3-de63-4035-811f-77213abd5422" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_IssuedCapitalMember_1e3eeae3-de63-4035-811f-77213abd5422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_8940f240-d9b2-4762-ba59-f2a9cc165053" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_8940f240-d9b2-4762-ba59-f2a9cc165053" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_fcc689eb-34d0-413a-aa56-f79c6aa9ea72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_TreasurySharesMember_fcc689eb-34d0-413a-aa56-f79c6aa9ea72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_e9e91e29-4da3-42a5-9f93-03d2b76c244e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_RetainedEarningsMember_e9e91e29-4da3-42a5-9f93-03d2b76c244e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_58b628fd-b2b2-4401-b288-88c1503b4896" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_58b628fd-b2b2-4401-b288-88c1503b4896" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_09baad76-f830-42c9-aec9-458f7f42a012" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_09baad76-f830-42c9-aec9-458f7f42a012" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_5ae5a375-43b9-4a64-908a-4a4717c59228" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_5f8e19d0-cb17-4e83-bd96-04659777cf2f" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_5ae5a375-43b9-4a64-908a-4a4717c59228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_130a2394-006c-472c-9cd9-92bd664b23c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_Equity_130a2394-006c-472c-9cd9-92bd664b23c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_e7b2d60f-8d3a-4f11-9f7a-a016395bf1f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_e7b2d60f-8d3a-4f11-9f7a-a016395bf1f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_bf9ff57f-49fc-4a13-98c9-9c96b6516a55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_ProfitLoss_bf9ff57f-49fc-4a13-98c9-9c96b6516a55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_7296f359-fc62-4705-b63e-31761b5e23dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_ComprehensiveIncome_7296f359-fc62-4705-b63e-31761b5e23dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_6b839d57-e80b-4777-bae9-66411a500ac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_6b839d57-e80b-4777-bae9-66411a500ac9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_a3169403-a2b1-481e-a6ec-a4ba4e380dc2" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_a3169403-a2b1-481e-a6ec-a4ba4e380dc2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_5a39a013-35c8-48e2-ac8e-375a9ce05217" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_5a39a013-35c8-48e2-ac8e-375a9ce05217" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares_e6f058d7-3ef5-4dae-ab8d-b502e720b515" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_PurchaseOfTreasuryShares_e6f058d7-3ef5-4dae-ab8d-b502e720b515" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_6c4e00ae-5a7a-43f9-b4e3-b9d18babd4ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_6c4e00ae-5a7a-43f9-b4e3-b9d18babd4ce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:href="sny-20231231.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_a0b71e30-09b6-4072-97c4-c9bb44c19d71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_a0b71e30-09b6-4072-97c4-c9bb44c19d71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_4203f77a-947e-4f1f-9584-47b8ca03be16" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_4203f77a-947e-4f1f-9584-47b8ca03be16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_0cd078bf-0f32-401b-8fe9-c469a83ec3bc" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_0cd078bf-0f32-401b-8fe9-c469a83ec3bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_9dbe527c-249c-4b2d-a000-806c35a30a15" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_9dbe527c-249c-4b2d-a000-806c35a30a15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_33585a5d-af10-4002-b6d3-6c30a85ed615" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_33585a5d-af10-4002-b6d3-6c30a85ed615" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_23fcaf92-4e6f-4221-a6a6-b56d54192a95" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_23fcaf92-4e6f-4221-a6a6-b56d54192a95" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment_a34d8c17-d36a-4d5f-ad0d-23156cc3ef1d" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment_a34d8c17-d36a-4d5f-ad0d-23156cc3ef1d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_048d47f1-6e6f-4853-9767-6eae9fd9a523" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_048d47f1-6e6f-4853-9767-6eae9fd9a523" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_7924d037-ec1b-4ebc-906e-9b6092f2a558" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedstatementsofchangesinequityParenthetical"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_2b41d346-a0c1-4953-af84-789e8c54f6ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_0d93a37c-358d-4357-871f-2d0a6326dde9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_2b41d346-a0c1-4953-af84-789e8c54f6ec" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_0d93a37c-358d-4357-871f-2d0a6326dde9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2a82c9e0-92b4-48d1-bb2d-05dda0fbed45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0d93a37c-358d-4357-871f-2d0a6326dde9" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2a82c9e0-92b4-48d1-bb2d-05dda0fbed45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2a82c9e0-92b4-48d1-bb2d-05dda0fbed45_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2a82c9e0-92b4-48d1-bb2d-05dda0fbed45" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_2a82c9e0-92b4-48d1-bb2d-05dda0fbed45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c0ca3a7b-3682-4320-9ba5-64d05622eb1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2a82c9e0-92b4-48d1-bb2d-05dda0fbed45" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c0ca3a7b-3682-4320-9ba5-64d05622eb1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_8dec5ea3-e739-488c-b3c2-6549cd025382" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c0ca3a7b-3682-4320-9ba5-64d05622eb1b" xlink:to="loc_sny_EuroapiMember_8dec5ea3-e739-488c-b3c2-6549cd025382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_b1260eed-88e9-4b5d-9995-1c6a36e9d573" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_2b41d346-a0c1-4953-af84-789e8c54f6ec" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_b1260eed-88e9-4b5d-9995-1c6a36e9d573" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_a324da66-0544-4bc9-8ce7-597d24f80c63" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendPercentageOfShareCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_2b41d346-a0c1-4953-af84-789e8c54f6ec" xlink:to="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_a324da66-0544-4bc9-8ce7-597d24f80c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019_6b3e75fe-bf2a-4ef5-861a-94088e788706" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_2b41d346-a0c1-4953-af84-789e8c54f6ec" xlink:to="loc_ifrs-full_WeightedAverageSharePrice2019_6b3e75fe-bf2a-4ef5-861a-94088e788706" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedstatementsofcashflowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable_95ff321c-0dfe-4c04-a1e9-77fc65c33330" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_srt_CondensedCashFlowStatementTable_95ff321c-0dfe-4c04-a1e9-77fc65c33330" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e688a65f-aeca-4464-b93e-bd9d86ef7d03" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedCashFlowStatementTable_95ff321c-0dfe-4c04-a1e9-77fc65c33330" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e688a65f-aeca-4464-b93e-bd9d86ef7d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_e688a65f-aeca-4464-b93e-bd9d86ef7d03_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e688a65f-aeca-4464-b93e-bd9d86ef7d03" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_e688a65f-aeca-4464-b93e-bd9d86ef7d03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_90fcd780-b5e0-4629-82d3-1cbbafa67d1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e688a65f-aeca-4464-b93e-bd9d86ef7d03" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_90fcd780-b5e0-4629-82d3-1cbbafa67d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_10f39549-541f-48d4-803e-ccd35e131e70" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_90fcd780-b5e0-4629-82d3-1cbbafa67d1c" xlink:to="loc_sny_EuroapiMember_10f39549-541f-48d4-803e-ccd35e131e70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1b07b115-59de-4474-a700-00dcce8f86ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedCashFlowStatementTable_95ff321c-0dfe-4c04-a1e9-77fc65c33330" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_1b07b115-59de-4474-a700-00dcce8f86ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1b07b115-59de-4474-a700-00dcce8f86ae_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1b07b115-59de-4474-a700-00dcce8f86ae" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1b07b115-59de-4474-a700-00dcce8f86ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_c00e8978-c97c-4a43-be39-dd0a675f0739" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1b07b115-59de-4474-a700-00dcce8f86ae" xlink:to="loc_ifrs-full_BorrowingsByNameMember_c00e8978-c97c-4a43-be39-dd0a675f0739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_98c09ff4-f71c-4df6-bc90-273c65d80538" xlink:href="sny-20231231.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_c00e8978-c97c-4a43-be39-dd0a675f0739" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_98c09ff4-f71c-4df6-bc90-273c65d80538" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_6842a529-23c3-4130-ac3d-3c188ccd20c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_6842a529-23c3-4130-ac3d-3c188ccd20c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_98cca87f-9548-479c-b0f4-bf84d7531c3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_98cca87f-9548-479c-b0f4-bf84d7531c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_d3be3566-d527-477b-82f7-d69de9919f84" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_d3be3566-d527-477b-82f7-d69de9919f84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities_91ca24cb-0e05-4ccd-b09d-c55320876f63" xlink:href="sny-20231231.xsd#sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities_91ca24cb-0e05-4ccd-b09d-c55320876f63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_ec299bce-1815-45ca-a9d5-0e715252e5b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_ec299bce-1815-45ca-a9d5-0e715252e5b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_d45b18d8-365e-49ee-9025-99fe8edfd600" xlink:href="sny-20231231.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_d45b18d8-365e-49ee-9025-99fe8edfd600" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofpreparationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#BasisofpreparationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/BasisofpreparationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_b2d57a9c-7689-4e68-91cb-ba83546329e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:to="loc_ifrs-full_GeographicalAreasAxis_b2d57a9c-7689-4e68-91cb-ba83546329e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_b2d57a9c-7689-4e68-91cb-ba83546329e3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_b2d57a9c-7689-4e68-91cb-ba83546329e3" xlink:to="loc_ifrs-full_GeographicalAreasMember_b2d57a9c-7689-4e68-91cb-ba83546329e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_65e4d995-417b-4106-8c3f-25ab6532843a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_b2d57a9c-7689-4e68-91cb-ba83546329e3" xlink:to="loc_ifrs-full_GeographicalAreasMember_65e4d995-417b-4106-8c3f-25ab6532843a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR_0809aa91-8809-4ef9-a759-44e94f526b7c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_65e4d995-417b-4106-8c3f-25ab6532843a" xlink:to="loc_country_AR_0809aa91-8809-4ef9-a759-44e94f526b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_869051ad-066c-4d72-928a-2bf35d3ee736" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_TR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_65e4d995-417b-4106-8c3f-25ab6532843a" xlink:to="loc_country_TR_869051ad-066c-4d72-928a-2bf35d3ee736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_6ff60dd5-090d-426c-828e-6187922a73ce" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:to="loc_sny_TypesOfAgreementAxis_6ff60dd5-090d-426c-828e-6187922a73ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_6ff60dd5-090d-426c-828e-6187922a73ce_default" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_TypesOfAgreementAxis_6ff60dd5-090d-426c-828e-6187922a73ce" xlink:to="loc_sny_TypesOfAgreementDomain_6ff60dd5-090d-426c-828e-6187922a73ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_62ea85b1-2ca6-4b7e-9bdc-7fff753688f7" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_TypesOfAgreementAxis_6ff60dd5-090d-426c-828e-6187922a73ce" xlink:to="loc_sny_TypesOfAgreementDomain_62ea85b1-2ca6-4b7e-9bdc-7fff753688f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementWithGSKMember_097a41e0-1711-4c5e-af46-f29bc5894bd0" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementWithGSKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_62ea85b1-2ca6-4b7e-9bdc-7fff753688f7" xlink:to="loc_sny_CollaborationAgreementWithGSKMember_097a41e0-1711-4c5e-af46-f29bc5894bd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_0054be0f-0825-46c8-aa76-3dde71c30736" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:to="loc_ifrs-full_CounterpartiesAxis_0054be0f-0825-46c8-aa76-3dde71c30736" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_0054be0f-0825-46c8-aa76-3dde71c30736_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_0054be0f-0825-46c8-aa76-3dde71c30736" xlink:to="loc_ifrs-full_CounterpartiesMember_0054be0f-0825-46c8-aa76-3dde71c30736_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_0a9406cd-760a-43e3-9689-43cb934a041f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_0054be0f-0825-46c8-aa76-3dde71c30736" xlink:to="loc_ifrs-full_CounterpartiesMember_0a9406cd-760a-43e3-9689-43cb934a041f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USGovernmentMember_bce85fda-3363-41f0-bb21-c5b1b486661c" xlink:href="sny-20231231.xsd#sny_USGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_0a9406cd-760a-43e3-9689-43cb934a041f" xlink:to="loc_sny_USGovernmentMember_bce85fda-3363-41f0-bb21-c5b1b486661c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_02cb42ab-d019-4639-92d2-a2477d8128af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:to="loc_srt_RangeAxis_02cb42ab-d019-4639-92d2-a2477d8128af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_02cb42ab-d019-4639-92d2-a2477d8128af_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_02cb42ab-d019-4639-92d2-a2477d8128af" xlink:to="loc_srt_RangeMember_02cb42ab-d019-4639-92d2-a2477d8128af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2958246b-9ed1-4d09-a093-4e2fa3eb8a20" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_02cb42ab-d019-4639-92d2-a2477d8128af" xlink:to="loc_srt_RangeMember_2958246b-9ed1-4d09-a093-4e2fa3eb8a20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60611265-945e-4809-800a-5b08452b54f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2958246b-9ed1-4d09-a093-4e2fa3eb8a20" xlink:to="loc_srt_MaximumMember_60611265-945e-4809-800a-5b08452b54f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_cfd5cb0b-ad27-49d0-a748-3a2a7a16b895" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_cfd5cb0b-ad27-49d0-a748-3a2a7a16b895" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInEffectiveTaxRate_c2461929-6731-47ff-9869-873bad5ff0f0" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseInEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_IncreaseDecreaseInEffectiveTaxRate_c2461929-6731-47ff-9869-873bad5ff0f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesNetEmissionsBy2045_335b0e93-9336-440b-8f7c-5e1dd3045a68" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesNetEmissionsBy2045"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesNetEmissionsBy2045_335b0e93-9336-440b-8f7c-5e1dd3045a68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030_cb165d26-41af-428c-9fd9-4608d1afa073" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030_cb165d26-41af-428c-9fd9-4608d1afa073" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030_8cff0d0e-e514-4e30-af3c-adc562bfdc39" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030_8cff0d0e-e514-4e30-af3c-adc562bfdc39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030_a53b7f01-3816-48e7-83d9-f2acba7948ad" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030_a53b7f01-3816-48e7-83d9-f2acba7948ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030_c7b561e9-1709-4dd4-9fe3-1548d75bd94c" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030_c7b561e9-1709-4dd4-9fe3-1548d75bd94c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios_6ea20f27-5369-4489-9c76-0c81a0b1b2e8" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios_6ea20f27-5369-4489-9c76-0c81a0b1b2e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears_eb9560ba-6451-4a87-b92b-c81432828958" xlink:href="sny-20231231.xsd#sny_CumulativeConsumerPriceInflationOverTheLastThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears_eb9560ba-6451-4a87-b92b-c81432828958" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfVaccineDosesToBeSupplied_df99360d-cc58-4791-9e3c-56346d9e17e8" xlink:href="sny-20231231.xsd#sny_NumberOfVaccineDosesToBeSupplied"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_NumberOfVaccineDosesToBeSupplied_df99360d-cc58-4791-9e3c-56346d9e17e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_1847b5e6-bd44-47cb-b51f-3aacfcc3cfa9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_ifrs-full_OtherRevenue_1847b5e6-bd44-47cb-b51f-3aacfcc3cfa9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_99f6b4e0-c3a2-452d-a4e2-4817a2b26aad" xlink:href="sny-20231231.xsd#sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_99f6b4e0-c3a2-452d-a4e2-4817a2b26aad" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_a8818da8-d65c-44fb-b908-33f186b80d38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_ifrs-full_CurrentContractLiabilities_a8818da8-d65c-44fb-b908-33f186b80d38" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRevenuePerformanceObligationNoLongerRequired_8cc1a26b-4d31-4768-b5fd-d8a4a0ead029" xlink:href="sny-20231231.xsd#sny_OtherRevenuePerformanceObligationNoLongerRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_OtherRevenuePerformanceObligationNoLongerRequired_8cc1a26b-4d31-4768-b5fd-d8a4a0ead029" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8dc11af7-a8ea-4ef6-9dd7-6bb4065f0bab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_fa9b8f26-1356-40a4-9b0f-0cae4e83cada" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8dc11af7-a8ea-4ef6-9dd7-6bb4065f0bab" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_fa9b8f26-1356-40a4-9b0f-0cae4e83cada" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_c138da3f-3e4f-48f2-a55f-1a50f532d4fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_fa9b8f26-1356-40a4-9b0f-0cae4e83cada" xlink:to="loc_ifrs-full_RangeAxis_c138da3f-3e4f-48f2-a55f-1a50f532d4fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_c138da3f-3e4f-48f2-a55f-1a50f532d4fc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_c138da3f-3e4f-48f2-a55f-1a50f532d4fc" xlink:to="loc_ifrs-full_RangesMember_c138da3f-3e4f-48f2-a55f-1a50f532d4fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_da418f5d-ae2b-480c-8344-0bf4e1b99e93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_c138da3f-3e4f-48f2-a55f-1a50f532d4fc" xlink:to="loc_ifrs-full_RangesMember_da418f5d-ae2b-480c-8344-0bf4e1b99e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_c24d304b-0092-4aed-b3e5-c531863f658c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_da418f5d-ae2b-480c-8344-0bf4e1b99e93" xlink:to="loc_ifrs-full_BottomOfRangeMember_c24d304b-0092-4aed-b3e5-c531863f658c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_fba6d0e8-99fa-4df1-88fe-28fb44c336d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_da418f5d-ae2b-480c-8344-0bf4e1b99e93" xlink:to="loc_ifrs-full_TopOfRangeMember_fba6d0e8-99fa-4df1-88fe-28fb44c336d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_99ad1362-7de4-4971-b843-26c624b4b132" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_fa9b8f26-1356-40a4-9b0f-0cae4e83cada" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_99ad1362-7de4-4971-b843-26c624b4b132" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_99ad1362-7de4-4971-b843-26c624b4b132_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_99ad1362-7de4-4971-b843-26c624b4b132" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_99ad1362-7de4-4971-b843-26c624b4b132_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_434fd109-11d8-40fc-a461-f8a366c692f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_99ad1362-7de4-4971-b843-26c624b4b132" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_434fd109-11d8-40fc-a461-f8a366c692f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_8d64745d-b3d4-4449-ac40-4054d2253305" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_434fd109-11d8-40fc-a461-f8a366c692f9" xlink:to="loc_ifrs-full_ComputerSoftwareMember_8d64745d-b3d4-4449-ac40-4054d2253305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_acbb0f9b-f4cb-4b4f-8b11-a12bc164f142" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8dc11af7-a8ea-4ef6-9dd7-6bb4065f0bab" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_acbb0f9b-f4cb-4b4f-8b11-a12bc164f142" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_555ea92e-c56d-4975-97eb-fcb94bba886a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d2716510-9e23-4b36-9bff-efeac730c8b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_555ea92e-c56d-4975-97eb-fcb94bba886a" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d2716510-9e23-4b36-9bff-efeac730c8b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_c4e50ccd-7ca3-4219-a7ae-e844fb0dcc98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d2716510-9e23-4b36-9bff-efeac730c8b9" xlink:to="loc_ifrs-full_RangeAxis_c4e50ccd-7ca3-4219-a7ae-e844fb0dcc98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_c4e50ccd-7ca3-4219-a7ae-e844fb0dcc98_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_c4e50ccd-7ca3-4219-a7ae-e844fb0dcc98" xlink:to="loc_ifrs-full_RangesMember_c4e50ccd-7ca3-4219-a7ae-e844fb0dcc98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_0741a82e-e3f3-4786-8a68-78a7c740cb68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_c4e50ccd-7ca3-4219-a7ae-e844fb0dcc98" xlink:to="loc_ifrs-full_RangesMember_0741a82e-e3f3-4786-8a68-78a7c740cb68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_05fdd040-8cec-41a1-a395-91847daef187" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_0741a82e-e3f3-4786-8a68-78a7c740cb68" xlink:to="loc_ifrs-full_BottomOfRangeMember_05fdd040-8cec-41a1-a395-91847daef187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_848ab844-97c3-4347-9c65-a1e1b5d89b46" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_0741a82e-e3f3-4786-8a68-78a7c740cb68" xlink:to="loc_ifrs-full_TopOfRangeMember_848ab844-97c3-4347-9c65-a1e1b5d89b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_280a8866-82f6-4130-84a7-e9ac46aa33fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d2716510-9e23-4b36-9bff-efeac730c8b9" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_280a8866-82f6-4130-84a7-e9ac46aa33fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_280a8866-82f6-4130-84a7-e9ac46aa33fd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_280a8866-82f6-4130-84a7-e9ac46aa33fd" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_280a8866-82f6-4130-84a7-e9ac46aa33fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_280a8866-82f6-4130-84a7-e9ac46aa33fd" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_8e14c9db-3644-410d-9120-c08fb69896f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:to="loc_ifrs-full_BuildingsMember_8e14c9db-3644-410d-9120-c08fb69896f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_c2ee911c-b6c9-4618-8958-3dee3d1171bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_c2ee911c-b6c9-4618-8958-3dee3d1171bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MachineryAndEquipment1Member_50a4abcf-6384-48ef-98eb-68dc95bae8a9" xlink:href="sny-20231231.xsd#sny_MachineryAndEquipment1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:to="loc_sny_MachineryAndEquipment1Member_50a4abcf-6384-48ef-98eb-68dc95bae8a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_4d036735-c421-453a-a243-1d7d633c439d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:to="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_4d036735-c421-453a-a243-1d7d633c439d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_da250b30-61b3-4d92-b191-c2878ceebac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_555ea92e-c56d-4975-97eb-fcb94bba886a" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_da250b30-61b3-4d92-b191-c2878ceebac2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems_af3a43fe-0842-45d9-b49d-224d45de55b6" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_b7fd2e62-5c4b-4c45-b2c7-34eb0c0c45f3" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems_af3a43fe-0842-45d9-b49d-224d45de55b6" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_b7fd2e62-5c4b-4c45-b2c7-34eb0c0c45f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis_f3934823-d849-49dc-964e-8ae096715907" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_b7fd2e62-5c4b-4c45-b2c7-34eb0c0c45f3" xlink:to="loc_ifrs-full_SegmentConsolidationItemsAxis_f3934823-d849-49dc-964e-8ae096715907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_f3934823-d849-49dc-964e-8ae096715907_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_f3934823-d849-49dc-964e-8ae096715907" xlink:to="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_f3934823-d849-49dc-964e-8ae096715907_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_6786a346-eda5-4433-8210-17246ae259c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_f3934823-d849-49dc-964e-8ae096715907" xlink:to="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_6786a346-eda5-4433-8210-17246ae259c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EliminationOfIntersegmentAmountsMember_b247e5a0-dbce-42d2-be43-ad23e245a650" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EliminationOfIntersegmentAmountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_6786a346-eda5-4433-8210-17246ae259c5" xlink:to="loc_ifrs-full_EliminationOfIntersegmentAmountsMember_b247e5a0-dbce-42d2-be43-ad23e245a650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5d0b4dd8-88f2-45f7-a539-6ee5237f0a29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_b7fd2e62-5c4b-4c45-b2c7-34eb0c0c45f3" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5d0b4dd8-88f2-45f7-a539-6ee5237f0a29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5d0b4dd8-88f2-45f7-a539-6ee5237f0a29_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5d0b4dd8-88f2-45f7-a539-6ee5237f0a29" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5d0b4dd8-88f2-45f7-a539-6ee5237f0a29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_45828091-dc36-44ba-8cf5-33b5f9b83d7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5d0b4dd8-88f2-45f7-a539-6ee5237f0a29" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_45828091-dc36-44ba-8cf5-33b5f9b83d7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember_7ce648b3-2efa-497a-96d2-31809d24ab39" xlink:href="sny-20231231.xsd#sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_45828091-dc36-44ba-8cf5-33b5f9b83d7f" xlink:to="loc_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember_7ce648b3-2efa-497a-96d2-31809d24ab39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_c54e8b53-4be7-431b-a335-a805e19446ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems_af3a43fe-0842-45d9-b49d-224d45de55b6" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_c54e8b53-4be7-431b-a335-a805e19446ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems_df69b263-6ed8-402e-b07c-e0de2174c390" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable_d333c313-1646-4903-810a-b7a5802e4f1b" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems_df69b263-6ed8-402e-b07c-e0de2174c390" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable_d333c313-1646-4903-810a-b7a5802e4f1b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6cb6327f-6080-4fa7-a59e-d84b0a7aeb20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable_d333c313-1646-4903-810a-b7a5802e4f1b" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6cb6327f-6080-4fa7-a59e-d84b0a7aeb20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_6cb6327f-6080-4fa7-a59e-d84b0a7aeb20_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6cb6327f-6080-4fa7-a59e-d84b0a7aeb20" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_6cb6327f-6080-4fa7-a59e-d84b0a7aeb20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_fb563770-5566-40c7-a755-8e42a82a05d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6cb6327f-6080-4fa7-a59e-d84b0a7aeb20" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_fb563770-5566-40c7-a755-8e42a82a05d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlansMember_e296ef81-9f59-4b4f-b280-521595612787" xlink:href="sny-20231231.xsd#sny_StockOptionPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fb563770-5566-40c7-a755-8e42a82a05d9" xlink:to="loc_sny_StockOptionPlansMember_e296ef81-9f59-4b4f-b280-521595612787" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlansMember_997dbf4d-84e1-44f3-ae71-669e9fa82324" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fb563770-5566-40c7-a755-8e42a82a05d9" xlink:to="loc_sny_RestrictedSharePlansMember_997dbf4d-84e1-44f3-ae71-669e9fa82324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OptionVestingPeriod_bc1b3836-da33-4611-9892-d9083997a197" xlink:href="sny-20231231.xsd#sny_OptionVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems_df69b263-6ed8-402e-b07c-e0de2174c390" xlink:to="loc_sny_OptionVestingPeriod_bc1b3836-da33-4611-9892-d9083997a197" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_45b17ee3-8574-4d7d-854f-0d258683e5b7" xlink:href="sny-20231231.xsd#sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems_df69b263-6ed8-402e-b07c-e0de2174c390" xlink:to="loc_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_45b17ee3-8574-4d7d-854f-0d258683e5b7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_696075d5-3d66-4580-a75c-91a46d2de6ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_ifrs-full_CounterpartiesAxis_696075d5-3d66-4580-a75c-91a46d2de6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_696075d5-3d66-4580-a75c-91a46d2de6ee_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_696075d5-3d66-4580-a75c-91a46d2de6ee" xlink:to="loc_ifrs-full_CounterpartiesMember_696075d5-3d66-4580-a75c-91a46d2de6ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_1342f330-3e1c-421f-8004-cf473b4712c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_696075d5-3d66-4580-a75c-91a46d2de6ee" xlink:to="loc_ifrs-full_CounterpartiesMember_1342f330-3e1c-421f-8004-cf473b4712c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_f02d6807-0dcc-45d8-93dc-c51a47670181" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_1342f330-3e1c-421f-8004-cf473b4712c8" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_f02d6807-0dcc-45d8-93dc-c51a47670181" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_f93b6bec-85c5-498f-8e4b-567a574e5b3b" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_sny_PrincipalAlliancesAxis_f93b6bec-85c5-498f-8e4b-567a574e5b3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_f93b6bec-85c5-498f-8e4b-567a574e5b3b_default" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_f93b6bec-85c5-498f-8e4b-567a574e5b3b" xlink:to="loc_sny_PrincipalAlliancesDomain_f93b6bec-85c5-498f-8e4b-567a574e5b3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_d7c44375-f81c-47fb-9531-fd8cf2b2f351" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_f93b6bec-85c5-498f-8e4b-567a574e5b3b" xlink:to="loc_sny_PrincipalAlliancesDomain_d7c44375-f81c-47fb-9531-fd8cf2b2f351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_7829df47-9427-4701-b064-db7ad64b7c3a" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_d7c44375-f81c-47fb-9531-fd8cf2b2f351" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_7829df47-9427-4701-b064-db7ad64b7c3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember_759afa28-b4f4-41de-ad50-9d7ab5f03cad" xlink:href="sny-20231231.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_d7c44375-f81c-47fb-9531-fd8cf2b2f351" xlink:to="loc_sny_ImmunoOncologyCollaborationAgreementMember_759afa28-b4f4-41de-ad50-9d7ab5f03cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesMember_2931f056-21e4-48c0-a323-fe90fd96b29f" xlink:href="sny-20231231.xsd#sny_AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_d7c44375-f81c-47fb-9531-fd8cf2b2f351" xlink:to="loc_sny_AntibodiesMember_2931f056-21e4-48c0-a323-fe90fd96b29f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_d5dafbd4-1bd0-4042-b2a2-82822106a97d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_ifrs-full_GeographicalAreasAxis_d5dafbd4-1bd0-4042-b2a2-82822106a97d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_d5dafbd4-1bd0-4042-b2a2-82822106a97d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_d5dafbd4-1bd0-4042-b2a2-82822106a97d" xlink:to="loc_ifrs-full_GeographicalAreasMember_d5dafbd4-1bd0-4042-b2a2-82822106a97d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_2f27affe-858f-4627-aa73-9c1859314594" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_d5dafbd4-1bd0-4042-b2a2-82822106a97d" xlink:to="loc_ifrs-full_GeographicalAreasMember_2f27affe-858f-4627-aa73-9c1859314594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_58e1dc1a-b952-4614-99b9-b16d0d2ee570" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2f27affe-858f-4627-aa73-9c1859314594" xlink:to="loc_country_US_58e1dc1a-b952-4614-99b9-b16d0d2ee570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OutsideUnitedStatesMember_d8c3109b-cbc6-45d5-9d77-0d2112d7ea45" xlink:href="sny-20231231.xsd#sny_OutsideUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_2f27affe-858f-4627-aa73-9c1859314594" xlink:to="loc_sny_OutsideUnitedStatesMember_d8c3109b-cbc6-45d5-9d77-0d2112d7ea45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_76dfdfc1-df98-469b-a2ee-0ec5d1df6582" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_ifrs-full_RangeAxis_76dfdfc1-df98-469b-a2ee-0ec5d1df6582" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_76dfdfc1-df98-469b-a2ee-0ec5d1df6582_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_76dfdfc1-df98-469b-a2ee-0ec5d1df6582" xlink:to="loc_ifrs-full_RangesMember_76dfdfc1-df98-469b-a2ee-0ec5d1df6582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_3325fd89-ba60-4b62-b731-bc75edd44edc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_76dfdfc1-df98-469b-a2ee-0ec5d1df6582" xlink:to="loc_ifrs-full_RangesMember_3325fd89-ba60-4b62-b731-bc75edd44edc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_eafb538e-85bd-4f73-b371-9a27bec5ac37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_3325fd89-ba60-4b62-b731-bc75edd44edc" xlink:to="loc_ifrs-full_BottomOfRangeMember_eafb538e-85bd-4f73-b371-9a27bec5ac37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_3d802566-cb19-4e6d-8011-137351fa0d66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_3325fd89-ba60-4b62-b731-bc75edd44edc" xlink:to="loc_ifrs-full_TopOfRangeMember_3d802566-cb19-4e6d-8011-137351fa0d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_fbbd4189-d468-46ac-82ea-48169850ac28" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_sny_TypesOfAgreementAxis_fbbd4189-d468-46ac-82ea-48169850ac28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_fbbd4189-d468-46ac-82ea-48169850ac28_default" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_TypesOfAgreementAxis_fbbd4189-d468-46ac-82ea-48169850ac28" xlink:to="loc_sny_TypesOfAgreementDomain_fbbd4189-d468-46ac-82ea-48169850ac28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_TypesOfAgreementAxis_fbbd4189-d468-46ac-82ea-48169850ac28" xlink:to="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesOfAntibodiesFirstAchievementMember_b8f6821f-6a1d-452f-9b44-90ec44670671" xlink:href="sny-20231231.xsd#sny_SalesOfAntibodiesFirstAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:to="loc_sny_SalesOfAntibodiesFirstAchievementMember_b8f6821f-6a1d-452f-9b44-90ec44670671" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesOfAntibodiesSecondAchievementMember_39130c34-5ee7-4fb2-b120-4a8cb8ff1674" xlink:href="sny-20231231.xsd#sny_SalesOfAntibodiesSecondAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:to="loc_sny_SalesOfAntibodiesSecondAchievementMember_39130c34-5ee7-4fb2-b120-4a8cb8ff1674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PriorAgreementMember_91ed8642-5871-45f6-abd1-f179b0acf7ca" xlink:href="sny-20231231.xsd#sny_PriorAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:to="loc_sny_PriorAgreementMember_91ed8642-5871-45f6-abd1-f179b0acf7ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NewAgreementMember_44209a6c-2315-4a78-b7e2-21d8f552e4fb" xlink:href="sny-20231231.xsd#sny_NewAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:to="loc_sny_NewAgreementMember_44209a6c-2315-4a78-b7e2-21d8f552e4fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesOfAntibodiesThirdAchievementMember_1d41e2f6-f001-46a0-984f-35deacce57bb" xlink:href="sny-20231231.xsd#sny_SalesOfAntibodiesThirdAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:to="loc_sny_SalesOfAntibodiesThirdAchievementMember_1d41e2f6-f001-46a0-984f-35deacce57bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_109c382d-b91f-4c3b-9f1c-fd08422f6619" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_srt_ProductOrServiceAxis_109c382d-b91f-4c3b-9f1c-fd08422f6619" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_109c382d-b91f-4c3b-9f1c-fd08422f6619_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_109c382d-b91f-4c3b-9f1c-fd08422f6619" xlink:to="loc_srt_ProductsAndServicesDomain_109c382d-b91f-4c3b-9f1c-fd08422f6619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7500fc9d-0fe9-44b3-8ccb-64d13a4f8f61" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_109c382d-b91f-4c3b-9f1c-fd08422f6619" xlink:to="loc_srt_ProductsAndServicesDomain_7500fc9d-0fe9-44b3-8ccb-64d13a4f8f61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesAllianceMember_315b31aa-ce22-4985-bf5a-37b4da78ac7e" xlink:href="sny-20231231.xsd#sny_AntibodiesAllianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7500fc9d-0fe9-44b3-8ccb-64d13a4f8f61" xlink:to="loc_sny_AntibodiesAllianceMember_315b31aa-ce22-4985-bf5a-37b4da78ac7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesMember_b6bc3095-0ef8-4aeb-ab52-2ecf425dcfa7" xlink:href="sny-20231231.xsd#sny_AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7500fc9d-0fe9-44b3-8ccb-64d13a4f8f61" xlink:to="loc_sny_AntibodiesMember_b6bc3095-0ef8-4aeb-ab52-2ecf425dcfa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_b13d1bc3-8cdc-47e2-9615-47ba4593e439" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_b13d1bc3-8cdc-47e2-9615-47ba4593e439" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_b13d1bc3-8cdc-47e2-9615-47ba4593e439_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_b13d1bc3-8cdc-47e2-9615-47ba4593e439" xlink:to="loc_ifrs-full_NonadjustingEventsMember_b13d1bc3-8cdc-47e2-9615-47ba4593e439_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_4e93cfb1-0315-4a5e-b6a3-6792f9131eda" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_b13d1bc3-8cdc-47e2-9615-47ba4593e439" xlink:to="loc_ifrs-full_NonadjustingEventsMember_4e93cfb1-0315-4a5e-b6a3-6792f9131eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorCollaborationAgreementMember_bb8eee78-33c5-4fd6-9947-4b08b732df3b" xlink:href="sny-20231231.xsd#sny_MajorCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_4e93cfb1-0315-4a5e-b6a3-6792f9131eda" xlink:to="loc_sny_MajorCollaborationAgreementMember_bb8eee78-33c5-4fd6-9947-4b08b732df3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfAgreementsSigned_f5510613-a75a-40cf-8618-6e96d0916a1a" xlink:href="sny-20231231.xsd#sny_NumberOfAgreementsSigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_NumberOfAgreementsSigned_f5510613-a75a-40cf-8618-6e96d0916a1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFunded_56c81334-96de-4b03-af0c-55ed6d5f6f40" xlink:href="sny-20231231.xsd#sny_PercentageOfSecondPartOfDevelopmentCostsFunded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFunded_56c81334-96de-4b03-af0c-55ed6d5f6f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty_6d9ac9a0-bb72-4195-adeb-ce12aadd504b" xlink:href="sny-20231231.xsd#sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty_6d9ac9a0-bb72-4195-adeb-ce12aadd504b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_80204b3f-8533-4540-98d2-d0246c8f2b21" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitShareOnCounterpartiesProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_80204b3f-8533-4540-98d2-d0246c8f2b21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_556d0660-4891-4f2e-adc6-9465e60e9f7d" xlink:href="sny-20231231.xsd#sny_PercentageOfCumulativeDevelopmentCostsReimbursed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_556d0660-4891-4f2e-adc6-9465e60e9f7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared_dd494764-5588-4c6b-b433-036a960de9a5" xlink:href="sny-20231231.xsd#sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared_dd494764-5588-4c6b-b433-036a960de9a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations_6ecedcac-8b21-4e14-96ef-5df2791a9459" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations_6ecedcac-8b21-4e14-96ef-5df2791a9459" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_d533f53d-77bf-458d-80fb-6e77902e6615" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitsArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_d533f53d-77bf-458d-80fb-6e77902e6615" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfLossesArisingFromCommercialOperations_ddbb55a0-39dd-4262-a872-815fa5f9210e" xlink:href="sny-20231231.xsd#sny_PercentageOfLossesArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfLossesArisingFromCommercialOperations_ddbb55a0-39dd-4262-a872-815fa5f9210e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPayments_2d55cb2b-6a71-478a-bce4-8ce103c8f579" xlink:href="sny-20231231.xsd#sny_NumberOfPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_NumberOfPayments_2d55cb2b-6a71-478a-bce4-8ce103c8f579" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentRelatedToAttainmentOfGoal_ca1f1c28-a38b-401d-87ef-d05e6ab1956e" xlink:href="sny-20231231.xsd#sny_PaymentRelatedToAttainmentOfGoal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PaymentRelatedToAttainmentOfGoal_ca1f1c28-a38b-401d-87ef-d05e6ab1956e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_f4e9725d-dc77-491c-8bb3-27564aec507d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_f4e9725d-dc77-491c-8bb3-27564aec507d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltyExpensePercentage_377fe15c-a6a8-42f3-ab1f-da1dfa0fda6d" xlink:href="sny-20231231.xsd#sny_RoyaltyExpensePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_RoyaltyExpensePercentage_377fe15c-a6a8-42f3-ab1f-da1dfa0fda6d" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:href="sny-20231231.xsd#sny_DisclosureOfPrincipalAlliancesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_44b37ca2-52ad-4228-89c2-e9bc68415014" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_ifrs-full_CounterpartiesAxis_44b37ca2-52ad-4228-89c2-e9bc68415014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_44b37ca2-52ad-4228-89c2-e9bc68415014_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_44b37ca2-52ad-4228-89c2-e9bc68415014" xlink:to="loc_ifrs-full_CounterpartiesMember_44b37ca2-52ad-4228-89c2-e9bc68415014_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_18f1c6d5-0681-4707-8f74-d62cbedb83e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_44b37ca2-52ad-4228-89c2-e9bc68415014" xlink:to="loc_ifrs-full_CounterpartiesMember_18f1c6d5-0681-4707-8f74-d62cbedb83e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_43b140df-2689-41d9-84ec-ba5e5d43261b" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_18f1c6d5-0681-4707-8f74-d62cbedb83e7" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_43b140df-2689-41d9-84ec-ba5e5d43261b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_11d2774e-e65e-48e8-ab08-d0079e8c3657" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_sny_PrincipalAlliancesAxis_11d2774e-e65e-48e8-ab08-d0079e8c3657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_11d2774e-e65e-48e8-ab08-d0079e8c3657_default" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_11d2774e-e65e-48e8-ab08-d0079e8c3657" xlink:to="loc_sny_PrincipalAlliancesDomain_11d2774e-e65e-48e8-ab08-d0079e8c3657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_822c8a73-9fcf-4ff1-abad-1355724429b7" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_11d2774e-e65e-48e8-ab08-d0079e8c3657" xlink:to="loc_sny_PrincipalAlliancesDomain_822c8a73-9fcf-4ff1-abad-1355724429b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember_216519d5-d788-4648-97e9-8be331166469" xlink:href="sny-20231231.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_822c8a73-9fcf-4ff1-abad-1355724429b7" xlink:to="loc_sny_ImmunoOncologyCollaborationAgreementMember_216519d5-d788-4648-97e9-8be331166469" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_f74c8020-05ba-4415-bfeb-04d4b5cc5d54" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_sny_TypesOfAgreementAxis_f74c8020-05ba-4415-bfeb-04d4b5cc5d54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_f74c8020-05ba-4415-bfeb-04d4b5cc5d54_default" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_TypesOfAgreementAxis_f74c8020-05ba-4415-bfeb-04d4b5cc5d54" xlink:to="loc_sny_TypesOfAgreementDomain_f74c8020-05ba-4415-bfeb-04d4b5cc5d54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_db4827e2-b86a-4ac4-a9fc-1634aa34bcd5" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_TypesOfAgreementAxis_f74c8020-05ba-4415-bfeb-04d4b5cc5d54" xlink:to="loc_sny_TypesOfAgreementDomain_db4827e2-b86a-4ac4-a9fc-1634aa34bcd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DevelopmentOfCemiplimabREGN2810Member_e59c7d3e-c900-4d73-977d-1ebafe141ae5" xlink:href="sny-20231231.xsd#sny_DevelopmentOfCemiplimabREGN2810Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_db4827e2-b86a-4ac4-a9fc-1634aa34bcd5" xlink:to="loc_sny_DevelopmentOfCemiplimabREGN2810Member_e59c7d3e-c900-4d73-977d-1ebafe141ae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MilestoneTypesAxis_618917b6-cdfc-41a3-8b17-dd5e0bbf930c" xlink:href="sny-20231231.xsd#sny_MilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_sny_MilestoneTypesAxis_618917b6-cdfc-41a3-8b17-dd5e0bbf930c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MilestoneTypesDomain_618917b6-cdfc-41a3-8b17-dd5e0bbf930c_default" xlink:href="sny-20231231.xsd#sny_MilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_MilestoneTypesAxis_618917b6-cdfc-41a3-8b17-dd5e0bbf930c" xlink:to="loc_sny_MilestoneTypesDomain_618917b6-cdfc-41a3-8b17-dd5e0bbf930c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MilestoneTypesDomain_cba2d50b-0f7f-4dd6-a722-7cb471cff12a" xlink:href="sny-20231231.xsd#sny_MilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_MilestoneTypesAxis_618917b6-cdfc-41a3-8b17-dd5e0bbf930c" xlink:to="loc_sny_MilestoneTypesDomain_cba2d50b-0f7f-4dd6-a722-7cb471cff12a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USFDAApprovalMember_0b045ae2-c9d6-4a2d-80a5-8847eed8acb8" xlink:href="sny-20231231.xsd#sny_USFDAApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_MilestoneTypesDomain_cba2d50b-0f7f-4dd6-a722-7cb471cff12a" xlink:to="loc_sny_USFDAApprovalMember_0b045ae2-c9d6-4a2d-80a5-8847eed8acb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_9557f18d-afb9-46f1-aeac-9e5c377a7adf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_9557f18d-afb9-46f1-aeac-9e5c377a7adf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_9557f18d-afb9-46f1-aeac-9e5c377a7adf_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_9557f18d-afb9-46f1-aeac-9e5c377a7adf" xlink:to="loc_ifrs-full_NonadjustingEventsMember_9557f18d-afb9-46f1-aeac-9e5c377a7adf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_e0df511b-8988-4465-afa6-a9e887e1c123" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_9557f18d-afb9-46f1-aeac-9e5c377a7adf" xlink:to="loc_ifrs-full_NonadjustingEventsMember_e0df511b-8988-4465-afa6-a9e887e1c123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorCollaborationAgreementMember_d040200e-1fef-4c25-83ae-f949ee91d5f1" xlink:href="sny-20231231.xsd#sny_MajorCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_e0df511b-8988-4465-afa6-a9e887e1c123" xlink:to="loc_sny_MajorCollaborationAgreementMember_d040200e-1fef-4c25-83ae-f949ee91d5f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_27e8dcef-5dd2-4c6a-baf7-911571d69fed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_27e8dcef-5dd2-4c6a-baf7-911571d69fed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_27e8dcef-5dd2-4c6a-baf7-911571d69fed_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_27e8dcef-5dd2-4c6a-baf7-911571d69fed" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_27e8dcef-5dd2-4c6a-baf7-911571d69fed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_3ac43989-e8c4-4ac9-a9f3-d81698593b85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_27e8dcef-5dd2-4c6a-baf7-911571d69fed" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_3ac43989-e8c4-4ac9-a9f3-d81698593b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_831a7289-39ec-489c-8723-0a969c4dae2d" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_3ac43989-e8c4-4ac9-a9f3-d81698593b85" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_831a7289-39ec-489c-8723-0a969c4dae2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfAgreementsSigned_932839ba-d867-48a2-b418-4c0f1c760178" xlink:href="sny-20231231.xsd#sny_NumberOfAgreementsSigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_NumberOfAgreementsSigned_932839ba-d867-48a2-b418-4c0f1c760178" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PriorDevelopmentBudget_fe021dba-0c82-4e9f-8e51-06645cd14044" xlink:href="sny-20231231.xsd#sny_PriorDevelopmentBudget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_PriorDevelopmentBudget_fe021dba-0c82-4e9f-8e51-06645cd14044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1_cbbf31cb-e90d-4cfe-bf9b-8d8e8be1277f" xlink:href="sny-20231231.xsd#sny_ContractualAgreementForAntiProgrammedCellDeathProtein1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1_cbbf31cb-e90d-4cfe-bf9b-8d8e8be1277f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany_f862c8b3-2a31-43f4-b873-fab178f692e5" xlink:href="sny-20231231.xsd#sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany_f862c8b3-2a31-43f4-b873-fab178f692e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment_ed2090ac-0fb6-42bc-8605-4a0a8e5b2b0d" xlink:href="sny-20231231.xsd#sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment_ed2090ac-0fb6-42bc-8605-4a0a8e5b2b0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment_51631d2a-15e6-439d-b812-a5bdf3b30503" xlink:href="sny-20231231.xsd#sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment_51631d2a-15e6-439d-b812-a5bdf3b30503" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_2c13ead3-98a9-4244-ace5-03a4577603bf" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitShareOnCounterpartiesProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_2c13ead3-98a9-4244-ace5-03a4577603bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_3c664237-94cb-405d-b463-311fdfd2aa04" xlink:href="sny-20231231.xsd#sny_PercentageOfCumulativeDevelopmentCostsReimbursed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_3c664237-94cb-405d-b463-311fdfd2aa04" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_40f63207-9447-42a8-83cc-cfcd0d28f7df" xlink:href="sny-20231231.xsd#sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_40f63207-9447-42a8-83cc-cfcd0d28f7df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_3f2b4b58-abab-4836-851f-e52ab5abc8c2" xlink:href="sny-20231231.xsd#sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_3f2b4b58-abab-4836-851f-e52ab5abc8c2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltyIncomePercentage_54a2cadd-39cb-4e4e-86bb-a51ce1ee1e0e" xlink:href="sny-20231231.xsd#sny_RoyaltyIncomePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_RoyaltyIncomePercentage_54a2cadd-39cb-4e4e-86bb-a51ce1ee1e0e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_cad9c292-7671-4fe5-980c-5909868d2ebc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_cad9c292-7671-4fe5-980c-5909868d2ebc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProceedsFromCollaborationAgreements_254d688b-9087-419b-b798-fb1f8ddd2a69" xlink:href="sny-20231231.xsd#sny_ProceedsFromCollaborationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_ProceedsFromCollaborationAgreements_254d688b-9087-419b-b798-fb1f8ddd2a69" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_9b700ec7-12c0-4f64-a3f1-2cfde43a80be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_9b700ec7-12c0-4f64-a3f1-2cfde43a80be" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_7a39d22e-16fd-4360-906c-f787416f4af7" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_7a39d22e-16fd-4360-906c-f787416f4af7" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_93cad380-90a3-4bf6-abac-57f55ab0960e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:to="loc_ifrs-full_CounterpartiesAxis_93cad380-90a3-4bf6-abac-57f55ab0960e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_93cad380-90a3-4bf6-abac-57f55ab0960e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_93cad380-90a3-4bf6-abac-57f55ab0960e" xlink:to="loc_ifrs-full_CounterpartiesMember_93cad380-90a3-4bf6-abac-57f55ab0960e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_424233e2-9071-4498-a3a6-384f690a8a81" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_93cad380-90a3-4bf6-abac-57f55ab0960e" xlink:to="loc_ifrs-full_CounterpartiesMember_424233e2-9071-4498-a3a6-384f690a8a81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_dc61d26d-b6d4-42fe-a163-4c81676a2dcd" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_424233e2-9071-4498-a3a6-384f690a8a81" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_dc61d26d-b6d4-42fe-a163-4c81676a2dcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_5ab4954f-7363-496c-9f03-68a0c521e597" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:to="loc_sny_PrincipalAlliancesAxis_5ab4954f-7363-496c-9f03-68a0c521e597" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_5ab4954f-7363-496c-9f03-68a0c521e597_default" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_5ab4954f-7363-496c-9f03-68a0c521e597" xlink:to="loc_sny_PrincipalAlliancesDomain_5ab4954f-7363-496c-9f03-68a0c521e597_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_6c84ae2b-1033-4e62-9043-0db1465a887f" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_5ab4954f-7363-496c-9f03-68a0c521e597" xlink:to="loc_sny_PrincipalAlliancesDomain_6c84ae2b-1033-4e62-9043-0db1465a887f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TwoThousandFourteenAmendedInvestmentAgreementMember_390b43e3-9d4e-46b7-9288-66db201ea468" xlink:href="sny-20231231.xsd#sny_TwoThousandFourteenAmendedInvestmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_6c84ae2b-1033-4e62-9043-0db1465a887f" xlink:to="loc_sny_TwoThousandFourteenAmendedInvestmentAgreementMember_390b43e3-9d4e-46b7-9288-66db201ea468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SaleOfStockAxis_4532f7e5-11e1-427e-9467-a7d4e54c09df" xlink:href="sny-20231231.xsd#sny_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:to="loc_sny_SaleOfStockAxis_4532f7e5-11e1-427e-9467-a7d4e54c09df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SaleOfStockDomain_4532f7e5-11e1-427e-9467-a7d4e54c09df_default" xlink:href="sny-20231231.xsd#sny_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_SaleOfStockAxis_4532f7e5-11e1-427e-9467-a7d4e54c09df" xlink:to="loc_sny_SaleOfStockDomain_4532f7e5-11e1-427e-9467-a7d4e54c09df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SaleOfStockDomain_67b64ba5-d5a9-49db-9f74-9a5beca7237b" xlink:href="sny-20231231.xsd#sny_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_SaleOfStockAxis_4532f7e5-11e1-427e-9467-a7d4e54c09df" xlink:to="loc_sny_SaleOfStockDomain_67b64ba5-d5a9-49db-9f74-9a5beca7237b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PublicOfferingMember_a2698598-b5c5-417e-b92b-f56dbbc81f45" xlink:href="sny-20231231.xsd#sny_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SaleOfStockDomain_67b64ba5-d5a9-49db-9f74-9a5beca7237b" xlink:to="loc_sny_PublicOfferingMember_a2698598-b5c5-417e-b92b-f56dbbc81f45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6916c5d4-62aa-410c-b788-6bc134b2d989" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6916c5d4-62aa-410c-b788-6bc134b2d989" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_6916c5d4-62aa-410c-b788-6bc134b2d989_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6916c5d4-62aa-410c-b788-6bc134b2d989" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_6916c5d4-62aa-410c-b788-6bc134b2d989_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_e0fc6501-3cf1-41d8-a51e-da071f26d26c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6916c5d4-62aa-410c-b788-6bc134b2d989" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_e0fc6501-3cf1-41d8-a51e-da071f26d26c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_158c81aa-8d31-433b-b628-6f2ad0dda7f2" xlink:href="sny-20231231.xsd#sny_RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_e0fc6501-3cf1-41d8-a51e-da071f26d26c" xlink:to="loc_sny_RegeneronMember_158c81aa-8d31-433b-b628-6f2ad0dda7f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumOwnershipPercentageAllowedToAcquire_f6c4e2cc-465b-40fc-b5cc-feadd64e18ae" xlink:href="sny-20231231.xsd#sny_MaximumOwnershipPercentageAllowedToAcquire"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_7a39d22e-16fd-4360-906c-f787416f4af7" xlink:to="loc_sny_MaximumOwnershipPercentageAllowedToAcquire_f6c4e2cc-465b-40fc-b5cc-feadd64e18ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal_8f13135c-3af8-4bb4-b034-38bd20009855" xlink:href="sny-20231231.xsd#sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_7a39d22e-16fd-4360-906c-f787416f4af7" xlink:to="loc_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal_8f13135c-3af8-4bb4-b034-38bd20009855" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:href="sny-20231231.xsd#sny_DisclosureOfPrincipalAlliancesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_0d449ccf-f9e8-46a9-8586-f53e630b730a" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:to="loc_sny_PrincipalAlliancesAxis_0d449ccf-f9e8-46a9-8586-f53e630b730a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_0d449ccf-f9e8-46a9-8586-f53e630b730a_default" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_0d449ccf-f9e8-46a9-8586-f53e630b730a" xlink:to="loc_sny_PrincipalAlliancesDomain_0d449ccf-f9e8-46a9-8586-f53e630b730a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_e0fb3bf2-e9c3-4f3c-adc2-df8d1d805d18" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_0d449ccf-f9e8-46a9-8586-f53e630b730a" xlink:to="loc_sny_PrincipalAlliancesDomain_e0fb3bf2-e9c3-4f3c-adc2-df8d1d805d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_919b6782-1aa2-48e9-9704-cbacdf99d362" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_e0fb3bf2-e9c3-4f3c-adc2-df8d1d805d18" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_919b6782-1aa2-48e9-9704-cbacdf99d362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_4e6f27f4-9507-4de2-8c2d-23361fc8f161" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:to="loc_ifrs-full_CounterpartiesAxis_4e6f27f4-9507-4de2-8c2d-23361fc8f161" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_4e6f27f4-9507-4de2-8c2d-23361fc8f161_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_4e6f27f4-9507-4de2-8c2d-23361fc8f161" xlink:to="loc_ifrs-full_CounterpartiesMember_4e6f27f4-9507-4de2-8c2d-23361fc8f161_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_589a882c-a62b-44de-8871-a48b4f15decc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_4e6f27f4-9507-4de2-8c2d-23361fc8f161" xlink:to="loc_ifrs-full_CounterpartiesMember_589a882c-a62b-44de-8871-a48b4f15decc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AstraZenecaMember_ef909429-618a-46cf-a272-2b743b458614" xlink:href="sny-20231231.xsd#sny_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_589a882c-a62b-44de-8871-a48b4f15decc" xlink:to="loc_sny_AstraZenecaMember_ef909429-618a-46cf-a272-2b743b458614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_e89171be-0937-44ad-9ef5-8aee2a1bfaad" xlink:href="sny-20231231.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_589a882c-a62b-44de-8871-a48b4f15decc" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_e89171be-0937-44ad-9ef5-8aee2a1bfaad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_98c1b14c-aa53-4f6f-a3f0-968a4018d2b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:to="loc_ifrs-full_GeographicalAreasAxis_98c1b14c-aa53-4f6f-a3f0-968a4018d2b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_98c1b14c-aa53-4f6f-a3f0-968a4018d2b7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_98c1b14c-aa53-4f6f-a3f0-968a4018d2b7" xlink:to="loc_ifrs-full_GeographicalAreasMember_98c1b14c-aa53-4f6f-a3f0-968a4018d2b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_e10ac9e2-3976-4f29-ae65-f5989dcd64ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_98c1b14c-aa53-4f6f-a3f0-968a4018d2b7" xlink:to="loc_ifrs-full_GeographicalAreasMember_e10ac9e2-3976-4f29-ae65-f5989dcd64ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorTerritoriesMember_68ab5fdd-948b-42b9-b22b-92ff1d0c1ba5" xlink:href="sny-20231231.xsd#sny_MajorTerritoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_e10ac9e2-3976-4f29-ae65-f5989dcd64ab" xlink:to="loc_sny_MajorTerritoriesMember_68ab5fdd-948b-42b9-b22b-92ff1d0c1ba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherTerritoriesMember_2bd32319-c271-42f4-ad01-da64ff9e42eb" xlink:href="sny-20231231.xsd#sny_OtherTerritoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_e10ac9e2-3976-4f29-ae65-f5989dcd64ab" xlink:to="loc_sny_OtherTerritoriesMember_2bd32319-c271-42f4-ad01-da64ff9e42eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_89bc0ea3-ce1c-49a4-9a73-02d6be9e017c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_e10ac9e2-3976-4f29-ae65-f5989dcd64ab" xlink:to="loc_country_CN_89bc0ea3-ce1c-49a4-9a73-02d6be9e017c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a2982fb3-1aee-476b-ad2d-d4a5807b8174" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a2982fb3-1aee-476b-ad2d-d4a5807b8174" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_a2982fb3-1aee-476b-ad2d-d4a5807b8174_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a2982fb3-1aee-476b-ad2d-d4a5807b8174" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_a2982fb3-1aee-476b-ad2d-d4a5807b8174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_81c519e9-a7e8-46ca-8a7f-83fc66c7ff3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a2982fb3-1aee-476b-ad2d-d4a5807b8174" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_81c519e9-a7e8-46ca-8a7f-83fc66c7ff3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_715b30c8-1d50-4b99-9a09-501b3dc00743" xlink:href="sny-20231231.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_81c519e9-a7e8-46ca-8a7f-83fc66c7ff3e" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_715b30c8-1d50-4b99-9a09-501b3dc00743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsUpfrontPayment_0d9f542c-1172-41fc-8e17-39f529c0f592" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_CollaborationAgreementsUpfrontPayment_0d9f542c-1172-41fc-8e17-39f529c0f592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_2d687618-4a8d-4282-a766-27e2dfc2541b" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementsDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_2d687618-4a8d-4282-a766-27e2dfc2541b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_6fe6f570-9130-4e26-acf6-bca19e79c22e" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementsRegulatoryMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_6fe6f570-9130-4e26-acf6-bca19e79c22e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_2740fb50-e97b-478b-a4d7-e65f5f6eea7c" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_2740fb50-e97b-478b-a4d7-e65f5f6eea7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Accruals_1a4597b4-380f-4412-8ca9-20511b89bf45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Accruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_ifrs-full_Accruals_1a4597b4-380f-4412-8ca9-20511b89bf45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_5eb6fed4-a7af-4363-bbbf-05e32952a8e7" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitsArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_5eb6fed4-a7af-4363-bbbf-05e32952a8e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_ac32ac4c-4eed-417b-a5ed-19bb5434c277" xlink:href="sny-20231231.xsd#sny_PercentageOfNetSalesArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_ac32ac4c-4eed-417b-a5ed-19bb5434c277" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_cb2b5f34-7072-4c43-90ea-b891f00fff04" xlink:href="sny-20231231.xsd#sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_cb2b5f34-7072-4c43-90ea-b891f00fff04" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_466587bb-94ac-429c-8aa4-20674a70a6c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_466587bb-94ac-429c-8aa4-20674a70a6c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_11a9e0f4-232e-4d69-801b-364e15f0461f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_11a9e0f4-232e-4d69-801b-364e15f0461f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_10d86b92-72cf-4a32-8080-46eeac2ab2f0" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_10d86b92-72cf-4a32-8080-46eeac2ab2f0" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ea1f9287-f0af-49ba-8a7b-f658a7359a8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ea1f9287-f0af-49ba-8a7b-f658a7359a8a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_d1e7e741-314d-441c-8de4-e9ffbbdde3ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ea1f9287-f0af-49ba-8a7b-f658a7359a8a" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_d1e7e741-314d-441c-8de4-e9ffbbdde3ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_d1e7e741-314d-441c-8de4-e9ffbbdde3ba_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_d1e7e741-314d-441c-8de4-e9ffbbdde3ba" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_d1e7e741-314d-441c-8de4-e9ffbbdde3ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_859ed6b4-1fac-424f-a963-78730e2c77e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_d1e7e741-314d-441c-8de4-e9ffbbdde3ba" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_859ed6b4-1fac-424f-a963-78730e2c77e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_0110d12f-3729-4649-a175-15041646b7f5" xlink:href="sny-20231231.xsd#sny_ProventionBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_859ed6b4-1fac-424f-a963-78730e2c77e1" xlink:to="loc_sny_ProventionBioIncMember_0110d12f-3729-4649-a175-15041646b7f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_73719dd7-cac6-4218-abbc-894d2a7a716b" xlink:href="sny-20231231.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_859ed6b4-1fac-424f-a963-78730e2c77e1" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_73719dd7-cac6-4218-abbc-894d2a7a716b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bec34f19-454e-4e62-bd52-1bb5eb13378d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ea1f9287-f0af-49ba-8a7b-f658a7359a8a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bec34f19-454e-4e62-bd52-1bb5eb13378d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bec34f19-454e-4e62-bd52-1bb5eb13378d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bec34f19-454e-4e62-bd52-1bb5eb13378d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bec34f19-454e-4e62-bd52-1bb5eb13378d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_47b8a371-5586-4f9a-8a93-570b63c05556" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bec34f19-454e-4e62-bd52-1bb5eb13378d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_47b8a371-5586-4f9a-8a93-570b63c05556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_75b8ecf7-d2a9-426b-9366-9d6ddb0265c3" xlink:href="sny-20231231.xsd#sny_ProventionBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_47b8a371-5586-4f9a-8a93-570b63c05556" xlink:to="loc_sny_ProventionBioIncMember_75b8ecf7-d2a9-426b-9366-9d6ddb0265c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare_85ad2ff3-0903-480a-8acd-b0781a219b61" xlink:href="sny-20231231.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_sny_BusinessCombinationPurchasePricePerShare_85ad2ff3-0903-480a-8acd-b0781a219b61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_8bee8e9b-4449-428d-851f-14b91b4193b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_CashTransferred_8bee8e9b-4449-428d-851f-14b91b4193b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_f5ecbd37-78d8-4a90-81be-ec6de1a7173b" xlink:href="sny-20231231.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_f5ecbd37-78d8-4a90-81be-ec6de1a7173b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_9ef3c090-aaeb-4781-90ae-522ca3d3eb58" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_9ef3c090-aaeb-4781-90ae-522ca3d3eb58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_e9a8d13b-3772-42f5-a32d-7bd59859afa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_e9a8d13b-3772-42f5-a32d-7bd59859afa1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_2df39ddc-3a89-4a62-9411-6d5d89854886" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_2df39ddc-3a89-4a62-9411-6d5d89854886" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_9e6d0946-520b-45fb-a609-24cd4ce9bdea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_9e6d0946-520b-45fb-a609-24cd4ce9bdea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePrice_08339f93-1cc3-4625-86d1-04ba8facfe7d" xlink:href="sny-20231231.xsd#sny_BusinessCombinationPurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_sny_BusinessCombinationPurchasePrice_08339f93-1cc3-4625-86d1-04ba8facfe7d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoodwillTaxDeductiblePeriod_be1fdbf3-f64f-457c-9008-d47cb4455330" xlink:href="sny-20231231.xsd#sny_GoodwillTaxDeductiblePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_sny_GoodwillTaxDeductiblePeriod_be1fdbf3-f64f-457c-9008-d47cb4455330" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueOfAcquiree_ee2f00e1-bd71-4702-b432-202cb9e3ee38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueOfAcquiree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_RevenueOfAcquiree_ee2f00e1-bd71-4702-b432-202cb9e3ee38" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossOfAcquiree_e25411b5-16b4-4012-86bd-e7d2feac74db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossOfAcquiree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_ProfitLossOfAcquiree_e25411b5-16b4-4012-86bd-e7d2feac74db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_d65e1e3e-92c6-4adc-9bc3-b687a2af0b7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_d65e1e3e-92c6-4adc-9bc3-b687a2af0b7d" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_b2a43033-e033-4f9d-941e-c15876ae83ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_b2a43033-e033-4f9d-941e-c15876ae83ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_47e1ad2f-5031-4a25-a155-3f9e22b8ac98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_b2a43033-e033-4f9d-941e-c15876ae83ce" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_47e1ad2f-5031-4a25-a155-3f9e22b8ac98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_47e1ad2f-5031-4a25-a155-3f9e22b8ac98_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_47e1ad2f-5031-4a25-a155-3f9e22b8ac98" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_47e1ad2f-5031-4a25-a155-3f9e22b8ac98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_6ac883b8-b7f9-4118-85e2-b3b4886c1cf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_47e1ad2f-5031-4a25-a155-3f9e22b8ac98" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_6ac883b8-b7f9-4118-85e2-b3b4886c1cf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_6d772f3e-c397-42f2-b5f0-5eb0ab1e3d5e" xlink:href="sny-20231231.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_6ac883b8-b7f9-4118-85e2-b3b4886c1cf3" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_6d772f3e-c397-42f2-b5f0-5eb0ab1e3d5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_2cf8b55e-e4d8-478e-b3fe-010d9b70432b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_2cf8b55e-e4d8-478e-b3fe-010d9b70432b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_5bb7f127-2be5-4802-9b95-c62638054e48" xlink:href="sny-20231231.xsd#sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_5bb7f127-2be5-4802-9b95-c62638054e48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_31d8137d-5eb9-456b-bbce-aa67b796bb25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_31d8137d-5eb9-456b-bbce-aa67b796bb25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_5ff6ef82-4883-4635-9a6b-d9828dd82257" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_5ff6ef82-4883-4635-9a6b-d9828dd82257" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f2b9dbfc-e9be-4022-b638-ae95e8c98df4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f2b9dbfc-e9be-4022-b638-ae95e8c98df4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_c62aa12b-39c2-430a-95a6-37f7d82bec45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_c62aa12b-39c2-430a-95a6-37f7d82bec45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_76ef74ce-2691-4515-9bb0-236350a74ec5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_76ef74ce-2691-4515-9bb0-236350a74ec5" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_d99532a4-300b-4e5e-a44a-93395b20339b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_d99532a4-300b-4e5e-a44a-93395b20339b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_d99532a4-300b-4e5e-a44a-93395b20339b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_d99532a4-300b-4e5e-a44a-93395b20339b" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_d99532a4-300b-4e5e-a44a-93395b20339b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_d99532a4-300b-4e5e-a44a-93395b20339b" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixPharmaceuticalsIncMember_8d2ab354-2c4a-4134-a213-843c06f4cbac" xlink:href="sny-20231231.xsd#sny_AmunixPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_AmunixPharmaceuticalsIncMember_8d2ab354-2c4a-4134-a213-843c06f4cbac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KymabMember_2d3636ab-391f-4993-a8a3-e1ab488a1a9e" xlink:href="sny-20231231.xsd#sny_KymabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_KymabMember_2d3636ab-391f-4993-a8a3-e1ab488a1a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KiadisMember_55da7907-48f5-4bee-a215-1e3469d812e8" xlink:href="sny-20231231.xsd#sny_KiadisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_KiadisMember_55da7907-48f5-4bee-a215-1e3469d812e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TidalTherapeuticsMember_99598765-5eb9-4f6b-9482-53b99e310a72" xlink:href="sny-20231231.xsd#sny_TidalTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_TidalTherapeuticsMember_99598765-5eb9-4f6b-9482-53b99e310a72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioMember_8f9448e1-439c-40ae-9288-4d36fc8cb7cf" xlink:href="sny-20231231.xsd#sny_TranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_TranslateBioMember_8f9448e1-439c-40ae-9288-4d36fc8cb7cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KadmonMember_f704348f-9799-4c6a-aaba-2c2d5d549627" xlink:href="sny-20231231.xsd#sny_KadmonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_KadmonMember_f704348f-9799-4c6a-aaba-2c2d5d549627" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OrigimmBiotechnologyGmbHMember_87193874-c65b-4133-a27a-b0bf1a004693" xlink:href="sny-20231231.xsd#sny_OrigimmBiotechnologyGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_OrigimmBiotechnologyGmbHMember_87193874-c65b-4133-a27a-b0bf1a004693" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_98f74a98-0c83-4518-be68-4c79bc19e745" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_98f74a98-0c83-4518-be68-4c79bc19e745" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_98f74a98-0c83-4518-be68-4c79bc19e745_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_98f74a98-0c83-4518-be68-4c79bc19e745" xlink:to="loc_ifrs-full_EquityMember_98f74a98-0c83-4518-be68-4c79bc19e745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_367f8f0d-ae97-439c-866d-3141ecad3e27" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_98f74a98-0c83-4518-be68-4c79bc19e745" xlink:to="loc_ifrs-full_EquityMember_367f8f0d-ae97-439c-866d-3141ecad3e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_ec0c205a-a125-44f9-93d2-99ad02231014" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_367f8f0d-ae97-439c-866d-3141ecad3e27" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_ec0c205a-a125-44f9-93d2-99ad02231014" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cf9523d2-20dc-40ea-9bb2-500aae6c4c12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cf9523d2-20dc-40ea-9bb2-500aae6c4c12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_cf9523d2-20dc-40ea-9bb2-500aae6c4c12_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cf9523d2-20dc-40ea-9bb2-500aae6c4c12" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_cf9523d2-20dc-40ea-9bb2-500aae6c4c12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_8328c06c-2a93-491c-a7a9-b4816e2d46c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cf9523d2-20dc-40ea-9bb2-500aae6c4c12" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_8328c06c-2a93-491c-a7a9-b4816e2d46c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_f331afad-aabd-415d-86e6-b21fe80a6219" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_8328c06c-2a93-491c-a7a9-b4816e2d46c4" xlink:to="loc_sny_EuroapiMember_f331afad-aabd-415d-86e6-b21fe80a6219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_ca411a85-ca30-4770-83a3-b145a45f6f38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_ca411a85-ca30-4770-83a3-b145a45f6f38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_ca411a85-ca30-4770-83a3-b145a45f6f38_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_ca411a85-ca30-4770-83a3-b145a45f6f38" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_ca411a85-ca30-4770-83a3-b145a45f6f38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_d43b3c28-dc93-4e1e-800e-25497a84bee6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_ca411a85-ca30-4770-83a3-b145a45f6f38" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_d43b3c28-dc93-4e1e-800e-25497a84bee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_a3d910ea-fe4e-47bc-a5cb-69cdead9d4ea" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_d43b3c28-dc93-4e1e-800e-25497a84bee6" xlink:to="loc_sny_EuroapiMember_a3d910ea-fe4e-47bc-a5cb-69cdead9d4ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_df644065-3248-48e3-a864-8c848acf1890" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_CounterpartiesAxis_df644065-3248-48e3-a864-8c848acf1890" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_df644065-3248-48e3-a864-8c848acf1890_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_df644065-3248-48e3-a864-8c848acf1890" xlink:to="loc_ifrs-full_CounterpartiesMember_df644065-3248-48e3-a864-8c848acf1890_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_5ed714d7-406a-4039-a4cf-8354e04b5a9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_df644065-3248-48e3-a864-8c848acf1890" xlink:to="loc_ifrs-full_CounterpartiesMember_5ed714d7-406a-4039-a4cf-8354e04b5a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EPICBPIFranceMember_8f52d986-30c8-4ae6-b0fe-d7a0bfc0cccb" xlink:href="sny-20231231.xsd#sny_EPICBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_5ed714d7-406a-4039-a4cf-8354e04b5a9d" xlink:to="loc_sny_EPICBPIFranceMember_8f52d986-30c8-4ae6-b0fe-d7a0bfc0cccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_3a2c32f3-ab9d-40a2-8079-d303184af503" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_3a2c32f3-ab9d-40a2-8079-d303184af503" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_3a2c32f3-ab9d-40a2-8079-d303184af503_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_3a2c32f3-ab9d-40a2-8079-d303184af503" xlink:to="loc_ifrs-full_OtherProvisionsMember_3a2c32f3-ab9d-40a2-8079-d303184af503_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_01433e72-499b-46cd-b93f-dde017895174" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_3a2c32f3-ab9d-40a2-8079-d303184af503" xlink:to="loc_ifrs-full_OtherProvisionsMember_01433e72-499b-46cd-b93f-dde017895174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember_f6e0ab82-9df5-452a-b343-59dc8e0e3c08" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_01433e72-499b-46cd-b93f-dde017895174" xlink:to="loc_ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember_f6e0ab82-9df5-452a-b343-59dc8e0e3c08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegulatoryComplianceCostsMember_4369ec9c-15c7-4fb2-86b4-265489e51462" xlink:href="sny-20231231.xsd#sny_RegulatoryComplianceCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_01433e72-499b-46cd-b93f-dde017895174" xlink:to="loc_sny_RegulatoryComplianceCostsMember_4369ec9c-15c7-4fb2-86b4-265489e51462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_73cade63-f06c-455d-93e0-410e3f27c3b4" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_sny_TypesOfAgreementAxis_73cade63-f06c-455d-93e0-410e3f27c3b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_73cade63-f06c-455d-93e0-410e3f27c3b4_default" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_TypesOfAgreementAxis_73cade63-f06c-455d-93e0-410e3f27c3b4" xlink:to="loc_sny_TypesOfAgreementDomain_73cade63-f06c-455d-93e0-410e3f27c3b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_d571c544-e49c-4255-bc1a-10204f2cfb7d" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_TypesOfAgreementAxis_73cade63-f06c-455d-93e0-410e3f27c3b4" xlink:to="loc_sny_TypesOfAgreementDomain_d571c544-e49c-4255-bc1a-10204f2cfb7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufactureAndSupplyCollaborationAgreementMember_cd00e9e2-fb11-4922-898d-235918186d3d" xlink:href="sny-20231231.xsd#sny_ManufactureAndSupplyCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_d571c544-e49c-4255-bc1a-10204f2cfb7d" xlink:to="loc_sny_ManufactureAndSupplyCollaborationAgreementMember_cd00e9e2-fb11-4922-898d-235918186d3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_9ed15688-ce5c-470d-acaa-bce756390f0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_CashTransferred_9ed15688-ce5c-470d-acaa-bce756390f0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations_d3f9d799-afb6-40e5-ac87-25c084f6f929" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations_d3f9d799-afb6-40e5-ac87-25c084f6f929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_86264647-300f-4885-a130-f5bd222559f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_86264647-300f-4885-a130-f5bd222559f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_538238de-d757-4bf0-b2e3-aace48ab6cbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_538238de-d757-4bf0-b2e3-aace48ab6cbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital_1bf769e0-82a6-4f96-8317-19f4e90bd4ad" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital_1bf769e0-82a6-4f96-8317-19f4e90bd4ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfVotingEquityInterestsDivested_095b7dd2-5240-4e77-b9c5-33ce7768a952" xlink:href="sny-20231231.xsd#sny_PercentageOfVotingEquityInterestsDivested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_PercentageOfVotingEquityInterestsDivested_095b7dd2-5240-4e77-b9c5-33ce7768a952" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsiderationTransferredMaximumAmount_c7c40e99-fbff-44d0-acdc-391535dbb6a8" xlink:href="sny-20231231.xsd#sny_ConsiderationTransferredMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_ConsiderationTransferredMaximumAmount_c7c40e99-fbff-44d0-acdc-391535dbb6a8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsiderationTransferredValuationPeriod_c6be73c7-fece-4785-9e6e-5f09194665e2" xlink:href="sny-20231231.xsd#sny_ConsiderationTransferredValuationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_ConsiderationTransferredValuationPeriod_c6be73c7-fece-4785-9e6e-5f09194665e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_c0a5b879-3f23-46ee-ba54-5be325bb8e4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_c0a5b879-3f23-46ee-ba54-5be325bb8e4f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod_8d5b4a2b-fad8-4b08-8ef4-97c3ff819cf2" xlink:href="sny-20231231.xsd#sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod_8d5b4a2b-fad8-4b08-8ef4-97c3ff819cf2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_55d740db-2861-438f-b9ec-e425a9feb3cc" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendPercentageOfShareCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_55d740db-2861-438f-b9ec-e425a9feb3cc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares_1cd091c0-0f81-400d-8a54-d3c2da4638af" xlink:href="sny-20231231.xsd#sny_SpecialDistributionSharesReceivedPerConversionOfParentShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares_1cd091c0-0f81-400d-8a54-d3c2da4638af" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialDistributionNumberOfSharesConverted_1e02fa74-8055-4b34-9857-a57edb26123f" xlink:href="sny-20231231.xsd#sny_SpecialDistributionNumberOfSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_SpecialDistributionNumberOfSharesConverted_1e02fa74-8055-4b34-9857-a57edb26123f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialDistributionPercentageOfShareCapitalDistributed_29826f5b-b1e9-4fbe-9bd6-18c30ffc1d3c" xlink:href="sny-20231231.xsd#sny_SpecialDistributionPercentageOfShareCapitalDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_SpecialDistributionPercentageOfShareCapitalDistributed_29826f5b-b1e9-4fbe-9bd6-18c30ffc1d3c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_baf58271-068e-4758-92aa-5fc9137a070c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_baf58271-068e-4758-92aa-5fc9137a070c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets_57ddebc4-dfa2-49a5-aa8c-083f97d437bd" xlink:href="sny-20231231.xsd#sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets_57ddebc4-dfa2-49a5-aa8c-083f97d437bd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill_69d7519e-8574-4f91-8afc-63075d8e4d68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill_69d7519e-8574-4f91-8afc-63075d8e4d68" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_2d615c96-e1cd-4a8f-9d83-74cbfb51ac9f" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_2d615c96-e1cd-4a8f-9d83-74cbfb51ac9f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019_fb58b1e5-c74f-447f-a681-d93f531d5ae2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_WeightedAverageSharePrice2019_fb58b1e5-c74f-447f-a681-d93f531d5ae2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_f4b9153c-42b0-4aa7-b90b-c73c5dca0e0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_f4b9153c-42b0-4aa7-b90b-c73c5dca0e0b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_b2743057-0b8d-4706-a072-1274d89cbf62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_b2743057-0b8d-4706-a072-1274d89cbf62" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_28025e97-a8da-4e17-92cb-bedb509b50d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_OtherProvisions_28025e97-a8da-4e17-92cb-bedb509b50d0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_141eed15-264c-44d9-bcd8-ebbb4c9c5850" xlink:href="sny-20231231.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_OtherGainsLossesAndLitigation_141eed15-264c-44d9-bcd8-ebbb4c9c5850" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b119abde-6e1c-4a33-9d74-bb2c65c2f77f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b119abde-6e1c-4a33-9d74-bb2c65c2f77f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_25cf48d0-3d46-4a99-8697-aa2d2c3dbfee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_25cf48d0-3d46-4a99-8697-aa2d2c3dbfee" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementPeriodAfterLossOfControl_97b86516-70ed-4b48-8c81-49eb5c6e7fcd" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementPeriodAfterLossOfControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_CollaborationAgreementPeriodAfterLossOfControl_97b86516-70ed-4b48-8c81-49eb5c6e7fcd" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementAnnualNetSalesTarget_3cac596d-34bc-433d-8f7f-d61617dfe466" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementAnnualNetSalesTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_CollaborationAgreementAnnualNetSalesTarget_3cac596d-34bc-433d-8f7f-d61617dfe466" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementCommitmentAmount_b7443b2f-cfe8-493c-bfe3-8c4c0b144757" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_CollaborationAgreementCommitmentAmount_b7443b2f-cfe8-493c-bfe3-8c4c0b144757" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_ab420b2c-7f7d-4bb5-8cda-bcf605391d98" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_ab420b2c-7f7d-4bb5-8cda-bcf605391d98" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_54444ebf-5600-4d3b-b3b0-6d70d1759f67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_54444ebf-5600-4d3b-b3b0-6d70d1759f67" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering_ada3b022-9752-4f9a-abfe-416eda575ede" xlink:href="sny-20231231.xsd#sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering_ada3b022-9752-4f9a-abfe-416eda575ede" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare_8f46a10e-9a11-44e1-846d-776bfb100a02" xlink:href="sny-20231231.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_BusinessCombinationPurchasePricePerShare_8f46a10e-9a11-44e1-846d-776bfb100a02" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering_ce9abc24-bd22-4937-b1cf-5304f5a63fb2" xlink:href="sny-20231231.xsd#sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering_ce9abc24-bd22-4937-b1cf-5304f5a63fb2" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_8bb9e03b-c91c-4f11-83f5-c3e48f1fc686" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_8bb9e03b-c91c-4f11-83f5-c3e48f1fc686" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired_65388710-80f1-4a60-846e-8fe265967c2b" xlink:href="sny-20231231.xsd#sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired_65388710-80f1-4a60-846e-8fe265967c2b" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_04bb830c-3299-4475-83eb-4e5dbc16c749" xlink:href="sny-20231231.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_04bb830c-3299-4475-83eb-4e5dbc16c749" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis_a09ca5fb-38c1-4fb9-b881-1f2f1db5229a" xlink:href="sny-20231231.xsd#sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis_a09ca5fb-38c1-4fb9-b881-1f2f1db5229a" xlink:type="arc" order="36"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_15854671-2da0-45ae-8e42-693dbda8b635" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_15854671-2da0-45ae-8e42-693dbda8b635" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_cb530c32-c78f-4cc1-8436-16c51b8dbc4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_15854671-2da0-45ae-8e42-693dbda8b635" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_cb530c32-c78f-4cc1-8436-16c51b8dbc4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_cb530c32-c78f-4cc1-8436-16c51b8dbc4b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_cb530c32-c78f-4cc1-8436-16c51b8dbc4b" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_cb530c32-c78f-4cc1-8436-16c51b8dbc4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_df393c82-9308-4de0-8115-3df81770a6b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_cb530c32-c78f-4cc1-8436-16c51b8dbc4b" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_df393c82-9308-4de0-8115-3df81770a6b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixPharmaceuticalsIncMember_81639444-5eb1-4b88-a0bd-1b916c56a245" xlink:href="sny-20231231.xsd#sny_AmunixPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_df393c82-9308-4de0-8115-3df81770a6b0" xlink:to="loc_sny_AmunixPharmaceuticalsIncMember_81639444-5eb1-4b88-a0bd-1b916c56a245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioMember_8a96dfa1-94ea-4e2f-ac7a-7fc7117725f7" xlink:href="sny-20231231.xsd#sny_TranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_df393c82-9308-4de0-8115-3df81770a6b0" xlink:to="loc_sny_TranslateBioMember_8a96dfa1-94ea-4e2f-ac7a-7fc7117725f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_777efb89-cbe7-4798-b65a-3da4c759a4aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_777efb89-cbe7-4798-b65a-3da4c759a4aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_828adc2c-d6c4-4a32-b509-b785c7055bc4" xlink:href="sny-20231231.xsd#sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_828adc2c-d6c4-4a32-b509-b785c7055bc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_89911798-59af-462d-bd1a-06b10a3fb94e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_89911798-59af-462d-bd1a-06b10a3fb94e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_fd785d6c-b5c5-44b9-a413-29b21bc74332" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_fd785d6c-b5c5-44b9-a413-29b21bc74332" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_53a022ba-afd0-4329-9adb-aebd0a7bc030" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_53a022ba-afd0-4329-9adb-aebd0a7bc030" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_96dda491-278f-4a94-8e30-7baa5d53db4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_96dda491-278f-4a94-8e30-7baa5d53db4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_26b94672-d7f4-4192-9192-b69d04abd5ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_26b94672-d7f4-4192-9192-b69d04abd5ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_7aee0651-6b2d-4940-8298-57301dfa1af6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_7aee0651-6b2d-4940-8298-57301dfa1af6" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3fe0523e-79cb-462d-91d9-bcdf49ab14fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3fe0523e-79cb-462d-91d9-bcdf49ab14fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_85f95052-036a-4a70-95ae-c01489ccf708" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3fe0523e-79cb-462d-91d9-bcdf49ab14fb" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_85f95052-036a-4a70-95ae-c01489ccf708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_85f95052-036a-4a70-95ae-c01489ccf708_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_85f95052-036a-4a70-95ae-c01489ccf708" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_85f95052-036a-4a70-95ae-c01489ccf708_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_85f95052-036a-4a70-95ae-c01489ccf708" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandMember_aff10b88-4b71-48a4-8278-7c420f85988d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:to="loc_ifrs-full_LandMember_aff10b88-4b71-48a4-8278-7c420f85988d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_65c9976a-6e88-41f7-88c7-db727a58dee4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:to="loc_ifrs-full_BuildingsMember_65c9976a-6e88-41f7-88c7-db727a58dee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MachineryAndEquipment1Member_cafd2a5c-6d4a-4667-9f6d-17987ea54f62" xlink:href="sny-20231231.xsd#sny_MachineryAndEquipment1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:to="loc_sny_MachineryAndEquipment1Member_cafd2a5c-6d4a-4667-9f6d-17987ea54f62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_e10d9345-cc88-4be8-bb8f-cabd7b664cc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_e10d9345-cc88-4be8-bb8f-cabd7b664cc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PropertyPlantAndEquipmentInProcessMember_26275620-913f-4b9e-8860-4a63a2cc50f6" xlink:href="sny-20231231.xsd#sny_PropertyPlantAndEquipmentInProcessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:to="loc_sny_PropertyPlantAndEquipmentInProcessMember_26275620-913f-4b9e-8860-4a63a2cc50f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506a5061-46e6-46d9-85c4-8c017a79cd4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3fe0523e-79cb-462d-91d9-bcdf49ab14fb" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506a5061-46e6-46d9-85c4-8c017a79cd4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_506a5061-46e6-46d9-85c4-8c017a79cd4b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506a5061-46e6-46d9-85c4-8c017a79cd4b" xlink:to="loc_ifrs-full_CarryingAmountMember_506a5061-46e6-46d9-85c4-8c017a79cd4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_5ea19592-8862-4d4c-9755-4bd82e0e879d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506a5061-46e6-46d9-85c4-8c017a79cd4b" xlink:to="loc_ifrs-full_CarryingAmountMember_5ea19592-8862-4d4c-9755-4bd82e0e879d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_e2e94b78-4d39-49cb-9f8c-987e5dd7c476" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_5ea19592-8862-4d4c-9755-4bd82e0e879d" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_e2e94b78-4d39-49cb-9f8c-987e5dd7c476" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_f6487b8f-39fa-4309-a425-ebe92a7ec23c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_5ea19592-8862-4d4c-9755-4bd82e0e879d" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_f6487b8f-39fa-4309-a425-ebe92a7ec23c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_3324623a-2ca4-48b2-8782-34f06f347340" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_3324623a-2ca4-48b2-8782-34f06f347340" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment_25b4d770-4f75-4e9a-b4cb-be17d2a9f25d" xlink:href="sny-20231231.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment_25b4d770-4f75-4e9a-b4cb-be17d2a9f25d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationExpense_9da319b8-fa00-458d-ae56-927291f882fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_DepreciationExpense_9da319b8-fa00-458d-ae56-927291f882fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment_4a68ef09-8380-4f34-9590-fe6079e8cc94" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment_4a68ef09-8380-4f34-9590-fe6079e8cc94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_83bec32a-e732-4287-8214-9e4ee52881a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_83bec32a-e732-4287-8214-9e4ee52881a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment_c64a6f04-f93d-4b84-aaff-f7b35ec286f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment_c64a6f04-f93d-4b84-aaff-f7b35ec286f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_ba324dad-eedc-43e6-9663-243f1725b910" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_ba324dad-eedc-43e6-9663-243f1725b910" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_4d73fc7b-bf9d-4376-9f84-0a251df9c5a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_4d73fc7b-bf9d-4376-9f84-0a251df9c5a9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_855639d0-5a5b-4d85-9c06-031564993db8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems_47b751e7-80cd-49c3-b7f6-feb75c171653" xlink:href="sny-20231231.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_040fe269-3e9d-44c9-b46e-52ed4fe88931" xlink:href="sny-20231231.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems_47b751e7-80cd-49c3-b7f6-feb75c171653" xlink:to="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_040fe269-3e9d-44c9-b46e-52ed4fe88931" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_b778d34d-12f6-48f9-a7d1-ffd824a3748e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_040fe269-3e9d-44c9-b46e-52ed4fe88931" xlink:to="loc_ifrs-full_SegmentsAxis_b778d34d-12f6-48f9-a7d1-ffd824a3748e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_b778d34d-12f6-48f9-a7d1-ffd824a3748e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_b778d34d-12f6-48f9-a7d1-ffd824a3748e" xlink:to="loc_ifrs-full_SegmentsMember_b778d34d-12f6-48f9-a7d1-ffd824a3748e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_b778d34d-12f6-48f9-a7d1-ffd824a3748e" xlink:to="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_40e536bc-0d5f-446c-9d03-b4c8247063d4" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:to="loc_sny_BiopharmaSegmentMember_40e536bc-0d5f-446c-9d03-b4c8247063d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaceuticalsSegmentMember_23d14567-2acc-44dd-a420-38fd2055c3b5" xlink:href="sny-20231231.xsd#sny_PharmaceuticalsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:to="loc_sny_PharmaceuticalsSegmentMember_23d14567-2acc-44dd-a420-38fd2055c3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesSegmentMember_49a28eac-5780-4b43-831d-afcc12b4ab83" xlink:href="sny-20231231.xsd#sny_VaccinesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:to="loc_sny_VaccinesSegmentMember_49a28eac-5780-4b43-831d-afcc12b4ab83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_77ba1d40-deeb-4504-b5e9-20a466fa5ca8" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_77ba1d40-deeb-4504-b5e9-20a466fa5ca8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_6b098cd4-1142-43a0-9eef-934c65bf4fc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_040fe269-3e9d-44c9-b46e-52ed4fe88931" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_6b098cd4-1142-43a0-9eef-934c65bf4fc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_6b098cd4-1142-43a0-9eef-934c65bf4fc4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_6b098cd4-1142-43a0-9eef-934c65bf4fc4" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_6b098cd4-1142-43a0-9eef-934c65bf4fc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_e25c1d04-96d0-4a12-b6b7-a0c8f8e27121" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_6b098cd4-1142-43a0-9eef-934c65bf4fc4" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_e25c1d04-96d0-4a12-b6b7-a0c8f8e27121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember_3a13cd1e-25b8-4c05-884d-d960d7a09100" xlink:href="sny-20231231.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_e25c1d04-96d0-4a12-b6b7-a0c8f8e27121" xlink:to="loc_sny_ManufacturingAndSupplyMember_3a13cd1e-25b8-4c05-884d-d960d7a09100" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_04b2b9ac-6f33-4a62-be9d-8595c53cc67a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems_47b751e7-80cd-49c3-b7f6-feb75c171653" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_04b2b9ac-6f33-4a62-be9d-8595c53cc67a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised_17d7d7d0-0e84-45c3-b02a-7da9018858dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems_47b751e7-80cd-49c3-b7f6-feb75c171653" xlink:to="loc_ifrs-full_InterestCostsCapitalised_17d7d7d0-0e84-45c3-b02a-7da9018858dc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_aae9ecca-8c7b-47e9-9f4d-0d10e7acd2cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_aae9ecca-8c7b-47e9-9f4d-0d10e7acd2cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bb4c6037-7ad0-48b3-bfc3-1a5dc8f6f84d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_aae9ecca-8c7b-47e9-9f4d-0d10e7acd2cc" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bb4c6037-7ad0-48b3-bfc3-1a5dc8f6f84d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_bb4c6037-7ad0-48b3-bfc3-1a5dc8f6f84d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bb4c6037-7ad0-48b3-bfc3-1a5dc8f6f84d" xlink:to="loc_ifrs-full_CarryingAmountMember_bb4c6037-7ad0-48b3-bfc3-1a5dc8f6f84d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_5dcfd018-243f-4161-b178-dcbfe19fbee0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bb4c6037-7ad0-48b3-bfc3-1a5dc8f6f84d" xlink:to="loc_ifrs-full_CarryingAmountMember_5dcfd018-243f-4161-b178-dcbfe19fbee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_2b5ca67e-2687-484f-a7f6-a377115ce5a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_5dcfd018-243f-4161-b178-dcbfe19fbee0" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_2b5ca67e-2687-484f-a7f6-a377115ce5a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_50a58187-01c3-454e-8f94-83eb3aff3289" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_5dcfd018-243f-4161-b178-dcbfe19fbee0" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_50a58187-01c3-454e-8f94-83eb3aff3289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_38dabd5c-78b2-4c89-9124-f42d9e9457cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_aae9ecca-8c7b-47e9-9f4d-0d10e7acd2cc" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_38dabd5c-78b2-4c89-9124-f42d9e9457cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_38dabd5c-78b2-4c89-9124-f42d9e9457cc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_38dabd5c-78b2-4c89-9124-f42d9e9457cc" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_38dabd5c-78b2-4c89-9124-f42d9e9457cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_8333746a-9b0d-4b78-8c96-33550ae27cd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_38dabd5c-78b2-4c89-9124-f42d9e9457cc" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_8333746a-9b0d-4b78-8c96-33550ae27cd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CambridgeMassachusettsMember_752bbc63-3d74-46d6-9ca1-6ba22e1c52b3" xlink:href="sny-20231231.xsd#sny_CambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8333746a-9b0d-4b78-8c96-33550ae27cd1" xlink:to="loc_sny_CambridgeMassachusettsMember_752bbc63-3d74-46d6-9ca1-6ba22e1c52b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OfficeSpaceCambridgeMassachusettsMember_5b35d7f6-a000-4aaa-ba3e-8b2fe27e83d7" xlink:href="sny-20231231.xsd#sny_OfficeSpaceCambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8333746a-9b0d-4b78-8c96-33550ae27cd1" xlink:to="loc_sny_OfficeSpaceCambridgeMassachusettsMember_5b35d7f6-a000-4aaa-ba3e-8b2fe27e83d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LaboratoryFacilitiesCambridgeMassachusettsMember_b2c8c116-06e4-4784-8066-1a91d6fab4e7" xlink:href="sny-20231231.xsd#sny_LaboratoryFacilitiesCambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8333746a-9b0d-4b78-8c96-33550ae27cd1" xlink:to="loc_sny_LaboratoryFacilitiesCambridgeMassachusettsMember_b2c8c116-06e4-4784-8066-1a91d6fab4e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_b1eb4e24-56e9-497a-8e30-ed11756240b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_ifrs-full_RightofuseAssets_b1eb4e24-56e9-497a-8e30-ed11756240b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets_ebba1693-f67f-4848-a052-071e32f58bd6" xlink:href="sny-20231231.xsd#sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets_ebba1693-f67f-4848-a052-071e32f58bd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets_4182fa98-7796-4ebe-a376-722a01210891" xlink:href="sny-20231231.xsd#sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets_4182fa98-7796-4ebe-a376-722a01210891" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_a19ac231-5138-4b9d-b63c-cd42cf0e22d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_a19ac231-5138-4b9d-b63c-cd42cf0e22d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets_2a45dd27-d6d9-48f7-9dab-110b71553358" xlink:href="sny-20231231.xsd#sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets_2a45dd27-d6d9-48f7-9dab-110b71553358" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets_4ec5d06e-12a5-468e-99eb-cca31eeab995" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets_4ec5d06e-12a5-468e-99eb-cca31eeab995" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets_b379c745-1197-481d-a5a4-ffa0332f0361" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets_b379c745-1197-481d-a5a4-ffa0332f0361" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_4af009c9-b17c-47a2-ad2c-026b2a138f1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLeaseAgreementsSigned_3a582881-2989-43cc-b3fa-c68834ff057d" xlink:href="sny-20231231.xsd#sny_NumberOfLeaseAgreementsSigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_NumberOfLeaseAgreementsSigned_3a582881-2989-43cc-b3fa-c68834ff057d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InitialLeaseTerm_38c9a9e1-3400-4122-a46a-fa8c0597f834" xlink:href="sny-20231231.xsd#sny_InitialLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_InitialLeaseTerm_38c9a9e1-3400-4122-a46a-fa8c0597f834" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_b37e9107-a70b-41a4-84b7-52c22c5d1e21" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_3ac25a65-f81d-4865-944d-864a07858efc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_ifrs-full_LeaseLiabilities_3ac25a65-f81d-4865-944d-864a07858efc" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PropertyplantandequipmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_006236c4-a6d1-410d-a059-80776e974490" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_753b0771-bda2-477f-a27a-62345133ac27" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_006236c4-a6d1-410d-a059-80776e974490" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_753b0771-bda2-477f-a27a-62345133ac27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_17d9d851-1ecf-4304-a7a7-6c6d1457f6b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_753b0771-bda2-477f-a27a-62345133ac27" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_17d9d851-1ecf-4304-a7a7-6c6d1457f6b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_17d9d851-1ecf-4304-a7a7-6c6d1457f6b0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_17d9d851-1ecf-4304-a7a7-6c6d1457f6b0" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_17d9d851-1ecf-4304-a7a7-6c6d1457f6b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_d4382ef9-7f69-4a55-9226-f474aa1d886a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_17d9d851-1ecf-4304-a7a7-6c6d1457f6b0" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_d4382ef9-7f69-4a55-9226-f474aa1d886a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandAndBuildingsMember_1185bc8c-e33a-422f-a395-733a6eb90bab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandAndBuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_d4382ef9-7f69-4a55-9226-f474aa1d886a" xlink:to="loc_ifrs-full_LandAndBuildingsMember_1185bc8c-e33a-422f-a395-733a6eb90bab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_a01d8717-a80f-4ea8-b821-9a29b1a77f86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_d4382ef9-7f69-4a55-9226-f474aa1d886a" xlink:to="loc_ifrs-full_VehiclesMember_a01d8717-a80f-4ea8-b821-9a29b1a77f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeasedAssetsPercentage_0337feae-2d16-4254-96a7-13fa5d3a43f2" xlink:href="sny-20231231.xsd#sny_LeasedAssetsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_006236c4-a6d1-410d-a059-80776e974490" xlink:to="loc_sny_LeasedAssetsPercentage_0337feae-2d16-4254-96a7-13fa5d3a43f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_1803d451-d0e7-4739-b57c-a635305d1258" xlink:href="sny-20231231.xsd#sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_006236c4-a6d1-410d-a059-80776e974490" xlink:to="loc_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_1803d451-d0e7-4739-b57c-a635305d1258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_a10c423c-f53c-43fb-916e-fbfaf1ab9806" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_006236c4-a6d1-410d-a059-80776e974490" xlink:to="loc_ifrs-full_CashOutflowForLeases_a10c423c-f53c-43fb-916e-fbfaf1ab9806" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_624e03e0-b1db-45d0-98f4-9b64b65afa4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_624e03e0-b1db-45d0-98f4-9b64b65afa4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_def3365f-77c0-4cfb-b599-2c88c3904f26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_624e03e0-b1db-45d0-98f4-9b64b65afa4d" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_def3365f-77c0-4cfb-b599-2c88c3904f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_def3365f-77c0-4cfb-b599-2c88c3904f26_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_def3365f-77c0-4cfb-b599-2c88c3904f26" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_def3365f-77c0-4cfb-b599-2c88c3904f26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_9a33f9ed-3921-4960-ab29-0ee3592dd311" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_def3365f-77c0-4cfb-b599-2c88c3904f26" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_9a33f9ed-3921-4960-ab29-0ee3592dd311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_6b08ad31-a92b-4c34-816e-403f357faa85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_9a33f9ed-3921-4960-ab29-0ee3592dd311" xlink:to="loc_ifrs-full_GoodwillMember_6b08ad31-a92b-4c34-816e-403f357faa85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_0138070d-e1e1-4bb0-839a-9b80f73ec16b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_0138070d-e1e1-4bb0-839a-9b80f73ec16b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_6d34386c-8171-4e80-a776-64caff298963" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_6d34386c-8171-4e80-a776-64caff298963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill_2a328050-a633-4e50-8669-756b4a29d787" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill_2a328050-a633-4e50-8669-756b4a29d787" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_566e6469-c3bc-4442-9e32-f7674325f109" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_566e6469-c3bc-4442-9e32-f7674325f109" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_11dc76e6-e924-4176-8309-0bf96e5f05fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_f6b8fd4d-b37a-49bd-a122-a4a917c0fa16" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_871db5ea-b90c-475f-ac59-246647763613" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_f6b8fd4d-b37a-49bd-a122-a4a917c0fa16" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_871db5ea-b90c-475f-ac59-246647763613" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_1ea1b05f-8843-4f27-a16c-d81450d9b829" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_871db5ea-b90c-475f-ac59-246647763613" xlink:to="loc_ifrs-full_SegmentsAxis_1ea1b05f-8843-4f27-a16c-d81450d9b829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_1ea1b05f-8843-4f27-a16c-d81450d9b829_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_1ea1b05f-8843-4f27-a16c-d81450d9b829" xlink:to="loc_ifrs-full_SegmentsMember_1ea1b05f-8843-4f27-a16c-d81450d9b829_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_0db619af-396a-4d21-9655-9ea8882e3292" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_1ea1b05f-8843-4f27-a16c-d81450d9b829" xlink:to="loc_ifrs-full_SegmentsMember_0db619af-396a-4d21-9655-9ea8882e3292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_3f70ecdd-8b66-42ba-87d6-5369382b1a73" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_0db619af-396a-4d21-9655-9ea8882e3292" xlink:to="loc_sny_BiopharmaSegmentMember_3f70ecdd-8b66-42ba-87d6-5369382b1a73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_37c6b9a0-c642-4dc1-8a49-1bb2f4b12562" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_0db619af-396a-4d21-9655-9ea8882e3292" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_37c6b9a0-c642-4dc1-8a49-1bb2f4b12562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_7a3cdf53-d29e-4b9c-b1a0-940a807d126d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_f6b8fd4d-b37a-49bd-a122-a4a917c0fa16" xlink:to="loc_ifrs-full_Goodwill_7a3cdf53-d29e-4b9c-b1a0-940a807d126d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_d558190f-3863-4651-b076-62bac3ba8fee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_d558190f-3863-4651-b076-62bac3ba8fee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_941875be-c441-4517-af34-625420a61ee1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_d558190f-3863-4651-b076-62bac3ba8fee" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_941875be-c441-4517-af34-625420a61ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_941875be-c441-4517-af34-625420a61ee1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_941875be-c441-4517-af34-625420a61ee1" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_941875be-c441-4517-af34-625420a61ee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_e8b9c24d-ca44-4ccc-85ed-0740ac71dc62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_941875be-c441-4517-af34-625420a61ee1" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_e8b9c24d-ca44-4ccc-85ed-0740ac71dc62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_0ca86b38-bbae-40ec-a268-f997edafcc57" xlink:href="sny-20231231.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_e8b9c24d-ca44-4ccc-85ed-0740ac71dc62" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_0ca86b38-bbae-40ec-a268-f997edafcc57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixMember_58034244-397a-4128-bd1a-06712277cb72" xlink:href="sny-20231231.xsd#sny_AmunixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_e8b9c24d-ca44-4ccc-85ed-0740ac71dc62" xlink:to="loc_sny_AmunixMember_58034244-397a-4128-bd1a-06712277cb72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioMember_127a30d5-3aaa-4cd4-9ed5-579c4379957a" xlink:href="sny-20231231.xsd#sny_TranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_e8b9c24d-ca44-4ccc-85ed-0740ac71dc62" xlink:to="loc_sny_TranslateBioMember_127a30d5-3aaa-4cd4-9ed5-579c4379957a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_319dd287-e6bd-4ab3-92e2-709c96021448" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_d558190f-3863-4651-b076-62bac3ba8fee" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_319dd287-e6bd-4ab3-92e2-709c96021448" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_319dd287-e6bd-4ab3-92e2-709c96021448_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_319dd287-e6bd-4ab3-92e2-709c96021448" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_319dd287-e6bd-4ab3-92e2-709c96021448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_319dd287-e6bd-4ab3-92e2-709c96021448" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_c123f3a6-e89b-43ca-aae8-821542629e42" xlink:href="sny-20231231.xsd#sny_MarketedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:to="loc_sny_MarketedProductsMember_c123f3a6-e89b-43ca-aae8-821542629e42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember_5611e0d2-f576-44d8-a210-57160ae0c900" xlink:href="sny-20231231.xsd#sny_TechnologicalPlatformsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:to="loc_sny_TechnologicalPlatformsMember_5611e0d2-f576-44d8-a210-57160ae0c900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_20186ac5-1c14-4936-97e9-ac807bedf0e8" xlink:href="sny-20231231.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_20186ac5-1c14-4936-97e9-ac807bedf0e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ALTUVIIIOMember_c47f0f62-5b85-476b-a726-45903efafacb" xlink:href="sny-20231231.xsd#sny_ALTUVIIIOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:to="loc_sny_ALTUVIIIOMember_c47f0f62-5b85-476b-a726-45903efafacb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_30c6cb96-174b-4a49-ab0b-24624fda83d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_d558190f-3863-4651-b076-62bac3ba8fee" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_30c6cb96-174b-4a49-ab0b-24624fda83d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_30c6cb96-174b-4a49-ab0b-24624fda83d9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_30c6cb96-174b-4a49-ab0b-24624fda83d9" xlink:to="loc_ifrs-full_CarryingAmountMember_30c6cb96-174b-4a49-ab0b-24624fda83d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_a30ff506-0a3b-4f63-b1c5-4a961685ba5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_30c6cb96-174b-4a49-ab0b-24624fda83d9" xlink:to="loc_ifrs-full_CarryingAmountMember_a30ff506-0a3b-4f63-b1c5-4a961685ba5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_c4a12644-1538-43ab-bf5a-475e0ad97f15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_a30ff506-0a3b-4f63-b1c5-4a961685ba5d" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_c4a12644-1538-43ab-bf5a-475e0ad97f15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments1_045cdfd4-32a0-49da-ae20-01ca50707180" xlink:href="sny-20231231.xsd#sny_NumberOfOperatingSegments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_sny_NumberOfOperatingSegments1_045cdfd4-32a0-49da-ae20-01ca50707180" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_bfbb8b3c-4db7-4306-87da-86c170fbf3b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_bfbb8b3c-4db7-4306-87da-86c170fbf3b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_67c65aeb-aec3-449a-9cc4-201c1769410e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_ifrs-full_Goodwill_67c65aeb-aec3-449a-9cc4-201c1769410e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_9981bf35-08f5-40d8-ae4c-53e19b886552" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_9981bf35-08f5-40d8-ae4c-53e19b886552" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_c6f9d58d-6d3c-4241-ad3c-c911925ca211" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_c6f9d58d-6d3c-4241-ad3c-c911925ca211" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_34498938-3622-4ad5-a4df-6d5a7b0fadca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_34498938-3622-4ad5-a4df-6d5a7b0fadca" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a5c314b3-a75f-4223-a2dd-e96cb96372f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a5c314b3-a75f-4223-a2dd-e96cb96372f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_a5c314b3-a75f-4223-a2dd-e96cb96372f7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a5c314b3-a75f-4223-a2dd-e96cb96372f7" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_a5c314b3-a75f-4223-a2dd-e96cb96372f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_d32ebdbd-ea2a-4b1b-95fb-729e2a3d01a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a5c314b3-a75f-4223-a2dd-e96cb96372f7" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_d32ebdbd-ea2a-4b1b-95fb-729e2a3d01a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredRDMember_c2774a21-701a-4f6f-aeb0-8946e53f309d" xlink:href="sny-20231231.xsd#sny_AcquiredRDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_d32ebdbd-ea2a-4b1b-95fb-729e2a3d01a0" xlink:to="loc_sny_AcquiredRDMember_c2774a21-701a-4f6f-aeb0-8946e53f309d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_5cb9ccaf-cd62-4ef1-b600-a00a267df830" xlink:href="sny-20231231.xsd#sny_MarketedProductsTrademarksAndOtherRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_d32ebdbd-ea2a-4b1b-95fb-729e2a3d01a0" xlink:to="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_5cb9ccaf-cd62-4ef1-b600-a00a267df830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_862eb23a-da84-4a1e-b2ab-a541faa792bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_d32ebdbd-ea2a-4b1b-95fb-729e2a3d01a0" xlink:to="loc_ifrs-full_ComputerSoftwareMember_862eb23a-da84-4a1e-b2ab-a541faa792bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_4c52ec54-ed25-4cef-b94a-741fcc388a24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_4c52ec54-ed25-4cef-b94a-741fcc388a24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_4c52ec54-ed25-4cef-b94a-741fcc388a24_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_4c52ec54-ed25-4cef-b94a-741fcc388a24" xlink:to="loc_ifrs-full_CarryingAmountMember_4c52ec54-ed25-4cef-b94a-741fcc388a24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_e1fae8a8-ec15-4fd6-bf44-5b06ed9bbee5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_4c52ec54-ed25-4cef-b94a-741fcc388a24" xlink:to="loc_ifrs-full_CarryingAmountMember_e1fae8a8-ec15-4fd6-bf44-5b06ed9bbee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1f990801-e908-4c05-83ca-26d387ceb240" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_e1fae8a8-ec15-4fd6-bf44-5b06ed9bbee5" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_1f990801-e908-4c05-83ca-26d387ceb240" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_7d3427a7-b36f-4b4b-9ed7-9b06a57e6d62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_e1fae8a8-ec15-4fd6-bf44-5b06ed9bbee5" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_7d3427a7-b36f-4b4b-9ed7-9b06a57e6d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_aeaac530-89de-47d1-b4e8-f49e0765cbb3" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:to="loc_sny_PrincipalAlliancesAxis_aeaac530-89de-47d1-b4e8-f49e0765cbb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_aeaac530-89de-47d1-b4e8-f49e0765cbb3_default" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_aeaac530-89de-47d1-b4e8-f49e0765cbb3" xlink:to="loc_sny_PrincipalAlliancesDomain_aeaac530-89de-47d1-b4e8-f49e0765cbb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_7b6e14e4-66d8-40cb-ae78-d0c92d85037c" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_aeaac530-89de-47d1-b4e8-f49e0765cbb3" xlink:to="loc_sny_PrincipalAlliancesDomain_7b6e14e4-66d8-40cb-ae78-d0c92d85037c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IOLicenseAndCollaborationAgreementMember_fd7f0baf-36ae-470c-bf6d-21e3b7ed4b95" xlink:href="sny-20231231.xsd#sny_IOLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_7b6e14e4-66d8-40cb-ae78-d0c92d85037c" xlink:to="loc_sny_IOLicenseAndCollaborationAgreementMember_fd7f0baf-36ae-470c-bf6d-21e3b7ed4b95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_81b2da00-9ec3-4060-ab69-a13d46e6d12a" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_7b6e14e4-66d8-40cb-ae78-d0c92d85037c" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_81b2da00-9ec3-4060-ab69-a13d46e6d12a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_a8e05ed5-137a-4ec2-9b4e-a7195b0605e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:to="loc_ifrs-full_CounterpartiesAxis_a8e05ed5-137a-4ec2-9b4e-a7195b0605e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_a8e05ed5-137a-4ec2-9b4e-a7195b0605e3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_a8e05ed5-137a-4ec2-9b4e-a7195b0605e3" xlink:to="loc_ifrs-full_CounterpartiesMember_a8e05ed5-137a-4ec2-9b4e-a7195b0605e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_eb1b2e74-d092-4319-a1d9-386723f76c88" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_a8e05ed5-137a-4ec2-9b4e-a7195b0605e3" xlink:to="loc_ifrs-full_CounterpartiesMember_eb1b2e74-d092-4319-a1d9-386723f76c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TevaPharmaceuticalsMember_6a792eeb-e336-4fbe-aae4-7baa170c3c71" xlink:href="sny-20231231.xsd#sny_TevaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_eb1b2e74-d092-4319-a1d9-386723f76c88" xlink:to="loc_sny_TevaPharmaceuticalsMember_6a792eeb-e336-4fbe-aae4-7baa170c3c71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JanssenPharmaceuticalsIncMember_248fe2f6-f2d3-48f3-b4a5-8f243db7e297" xlink:href="sny-20231231.xsd#sny_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_eb1b2e74-d092-4319-a1d9-386723f76c88" xlink:to="loc_sny_JanssenPharmaceuticalsIncMember_248fe2f6-f2d3-48f3-b4a5-8f243db7e297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_91b4389a-0bfe-4bb1-992b-32ce2f22694b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_OtherIntangibleAssets_91b4389a-0bfe-4bb1-992b-32ce2f22694b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_f627c0b1-2faf-4e55-a318-6b7596ca6149" xlink:href="sny-20231231.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_f627c0b1-2faf-4e55-a318-6b7596ca6149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_89531309-6c9d-48b3-b65e-b4d65741e8fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_89531309-6c9d-48b3-b65e-b4d65741e8fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_304e7deb-748b-4e5b-ae9d-ba266ad0aaa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_304e7deb-748b-4e5b-ae9d-ba266ad0aaa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_2c2b6843-18fb-4538-98ab-cd1696c4a4c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_2c2b6843-18fb-4538-98ab-cd1696c4a4c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_42afec47-7f4c-41a7-99e2-2ca2e92857df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_42afec47-7f4c-41a7-99e2-2ca2e92857df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_c100cdf1-00c0-4e5a-a8d3-5c3f4e07d8b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_c100cdf1-00c0-4e5a-a8d3-5c3f4e07d8b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_54b117be-2747-48cf-8c83-8bd13c8b3afe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_54b117be-2747-48cf-8c83-8bd13c8b3afe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_9ec574f0-5a73-4e23-a108-7910ecbc6502" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssets"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_19432bb7-c387-4409-865f-5a7f29c70ee8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_19432bb7-c387-4409-865f-5a7f29c70ee8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_ad11e782-76a4-44a7-8eca-6b718cbe794a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_19432bb7-c387-4409-865f-5a7f29c70ee8" xlink:to="loc_ifrs-full_RangeAxis_ad11e782-76a4-44a7-8eca-6b718cbe794a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_ad11e782-76a4-44a7-8eca-6b718cbe794a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_ad11e782-76a4-44a7-8eca-6b718cbe794a" xlink:to="loc_ifrs-full_RangesMember_ad11e782-76a4-44a7-8eca-6b718cbe794a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_e9577280-3bc7-4ba2-94bf-25d2b42f0f15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_ad11e782-76a4-44a7-8eca-6b718cbe794a" xlink:to="loc_ifrs-full_RangesMember_e9577280-3bc7-4ba2-94bf-25d2b42f0f15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_d19e08bc-523c-4f35-b33e-9f861b5fa28d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_e9577280-3bc7-4ba2-94bf-25d2b42f0f15" xlink:to="loc_ifrs-full_BottomOfRangeMember_d19e08bc-523c-4f35-b33e-9f861b5fa28d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_637e64d1-d7f3-420f-a8d3-b7f20de509b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_e9577280-3bc7-4ba2-94bf-25d2b42f0f15" xlink:to="loc_ifrs-full_TopOfRangeMember_637e64d1-d7f3-420f-a8d3-b7f20de509b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_061d8595-9018-4e12-ba84-207d050e6957" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_19432bb7-c387-4409-865f-5a7f29c70ee8" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_061d8595-9018-4e12-ba84-207d050e6957" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_061d8595-9018-4e12-ba84-207d050e6957_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_061d8595-9018-4e12-ba84-207d050e6957" xlink:to="loc_ifrs-full_CarryingAmountMember_061d8595-9018-4e12-ba84-207d050e6957_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_1f3ac7a0-6e5b-403b-ac66-017d3805f6af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_061d8595-9018-4e12-ba84-207d050e6957" xlink:to="loc_ifrs-full_CarryingAmountMember_1f3ac7a0-6e5b-403b-ac66-017d3805f6af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_f15897ee-4e12-4647-aac5-416624f47591" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1f3ac7a0-6e5b-403b-ac66-017d3805f6af" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_f15897ee-4e12-4647-aac5-416624f47591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_3cf10627-9143-4c28-9cc3-ed3dcb62a700" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_1f3ac7a0-6e5b-403b-ac66-017d3805f6af" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_3cf10627-9143-4c28-9cc3-ed3dcb62a700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5c925911-3821-40af-b572-dd627e3521af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_19432bb7-c387-4409-865f-5a7f29c70ee8" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5c925911-3821-40af-b572-dd627e3521af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_5c925911-3821-40af-b572-dd627e3521af_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5c925911-3821-40af-b572-dd627e3521af" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_5c925911-3821-40af-b572-dd627e3521af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3d43bd7f-a5cc-44c0-beab-4c2c3c294a01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5c925911-3821-40af-b572-dd627e3521af" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3d43bd7f-a5cc-44c0-beab-4c2c3c294a01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_842cb665-edb2-4b61-a00b-0bc60487e92d" xlink:href="sny-20231231.xsd#sny_MarketedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3d43bd7f-a5cc-44c0-beab-4c2c3c294a01" xlink:to="loc_sny_MarketedProductsMember_842cb665-edb2-4b61-a00b-0bc60487e92d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3d43bd7f-a5cc-44c0-beab-4c2c3c294a01" xlink:to="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsGenzymeMember_b4c534c7-e174-4ac9-baaa-70f00dd574dc" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsGenzymeMember_b4c534c7-e174-4ac9-baaa-70f00dd574dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember_fd83bafe-e58c-4d2a-8c5d-ad546d07cae4" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember_fd83bafe-e58c-4d2a-8c5d-ad546d07cae4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsAventisMember_cdca3d90-d11c-46b7-a0a5-21771b228210" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsAventisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsAventisMember_cdca3d90-d11c-46b7-a0a5-21771b228210" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsChattemMember_32c7e5fc-cada-4074-98d6-78703310de19" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsChattemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsChattemMember_32c7e5fc-cada-4074-98d6-78703310de19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsProteinSciencesMember_2178d6c0-ce7e-4849-82f8-b2d62b10502b" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsProteinSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsProteinSciencesMember_2178d6c0-ce7e-4849-82f8-b2d62b10502b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsAblynxMember_d7ed7a84-2cad-460f-9914-ad139abaf631" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsAblynxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsAblynxMember_d7ed7a84-2cad-460f-9914-ad139abaf631" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsBioverativMember_77f209eb-c8fd-4087-afdc-3ca1a5a0c2d2" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsBioverativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsBioverativMember_77f209eb-c8fd-4087-afdc-3ca1a5a0c2d2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsRezurockMember_b1ecf614-9ee6-4028-a141-dfb79fd52214" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsRezurockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsRezurockMember_b1ecf614-9ee6-4028-a141-dfb79fd52214" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsTZIELDMember_c09ce4a3-692d-49c6-962b-15b613ba101a" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsTZIELDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsTZIELDMember_c09ce4a3-692d-49c6-962b-15b613ba101a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsBeyfortusMember_3c17a9a1-6410-4724-bee1-0e24f35a23d9" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsBeyfortusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsBeyfortusMember_3c17a9a1-6410-4724-bee1-0e24f35a23d9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsQunolMember_3ef9412e-bf52-4687-9a35-694cf10bb7ab" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsQunolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsQunolMember_3ef9412e-bf52-4687-9a35-694cf10bb7ab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConcentrationRiskThresholdPercentage_3beafa2f-6a42-402e-b8c3-689284d203fd" xlink:href="sny-20231231.xsd#sny_ConcentrationRiskThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:to="loc_sny_ConcentrationRiskThresholdPercentage_3beafa2f-6a42-402e-b8c3-689284d203fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_9090772e-c449-46a8-9ef1-ff835543f92b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_9090772e-c449-46a8-9ef1-ff835543f92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_36c58013-f8b9-4672-b126-8347454e7ca2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_36c58013-f8b9-4672-b126-8347454e7ca2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_1a7f318e-8238-4f60-aa07-61ff5ea18299" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:to="loc_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_1a7f318e-8238-4f60-aa07-61ff5ea18299" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c957cc70-4dae-4eed-8961-515725107a7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c957cc70-4dae-4eed-8961-515725107a7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseCategoriesAxis_2bf4f1bc-e616-4917-88a5-75fcd4a57ea7" xlink:href="sny-20231231.xsd#sny_ExpenseCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c957cc70-4dae-4eed-8961-515725107a7c" xlink:to="loc_sny_ExpenseCategoriesAxis_2bf4f1bc-e616-4917-88a5-75fcd4a57ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseCategoriesDomain_2bf4f1bc-e616-4917-88a5-75fcd4a57ea7_default" xlink:href="sny-20231231.xsd#sny_ExpenseCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_ExpenseCategoriesAxis_2bf4f1bc-e616-4917-88a5-75fcd4a57ea7" xlink:to="loc_sny_ExpenseCategoriesDomain_2bf4f1bc-e616-4917-88a5-75fcd4a57ea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseCategoriesDomain_7dcc8a80-16c8-448f-b3b1-73881fbc2284" xlink:href="sny-20231231.xsd#sny_ExpenseCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_ExpenseCategoriesAxis_2bf4f1bc-e616-4917-88a5-75fcd4a57ea7" xlink:to="loc_sny_ExpenseCategoriesDomain_7dcc8a80-16c8-448f-b3b1-73881fbc2284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember_0d351fbd-1366-434c-b4c0-23351bb933ee" xlink:href="sny-20231231.xsd#sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ExpenseCategoriesDomain_7dcc8a80-16c8-448f-b3b1-73881fbc2284" xlink:to="loc_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember_0d351fbd-1366-434c-b4c0-23351bb933ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_51baa244-38e8-4e28-8b56-2f697a71fbe5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:to="loc_ifrs-full_CostOfSales_51baa244-38e8-4e28-8b56-2f697a71fbe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_92b78982-51fd-4b35-a682-99555c5c481e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_92b78982-51fd-4b35-a682-99555c5c481e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_ce4898b8-c3db-4d93-80ab-8f86e1a58239" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_ce4898b8-c3db-4d93-80ab-8f86e1a58239" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_8e2dbd8e-f3e6-48b3-920e-e3a16da72845" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_8e2dbd8e-f3e6-48b3-920e-e3a16da72845" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_483fee4b-e04c-403a-a6a8-ba3b8dbeb055" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_483fee4b-e04c-403a-a6a8-ba3b8dbeb055" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_faf364db-7a35-4717-a862-5aa4ce1fc98c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:to="loc_ifrs-full_SegmentsAxis_faf364db-7a35-4717-a862-5aa4ce1fc98c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_faf364db-7a35-4717-a862-5aa4ce1fc98c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_faf364db-7a35-4717-a862-5aa4ce1fc98c" xlink:to="loc_ifrs-full_SegmentsMember_faf364db-7a35-4717-a862-5aa4ce1fc98c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_1415d5e2-cc33-4e28-9d08-3d8c21620673" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_faf364db-7a35-4717-a862-5aa4ce1fc98c" xlink:to="loc_ifrs-full_SegmentsMember_1415d5e2-cc33-4e28-9d08-3d8c21620673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_9dcd270a-07fd-4d92-946d-c7bfad854fdd" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_1415d5e2-cc33-4e28-9d08-3d8c21620673" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_9dcd270a-07fd-4d92-946d-c7bfad854fdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_2b0dad7f-e34b-4398-b215-eff716a13adc" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_1415d5e2-cc33-4e28-9d08-3d8c21620673" xlink:to="loc_sny_BiopharmaSegmentMember_2b0dad7f-e34b-4398-b215-eff716a13adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_3855bef9-f83c-4cd8-b05b-1f39793e7cc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_3855bef9-f83c-4cd8-b05b-1f39793e7cc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForCashgeneratingUnitsMember_3855bef9-f83c-4cd8-b05b-1f39793e7cc4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForCashgeneratingUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_3855bef9-f83c-4cd8-b05b-1f39793e7cc4" xlink:to="loc_ifrs-full_EntitysTotalForCashgeneratingUnitsMember_3855bef9-f83c-4cd8-b05b-1f39793e7cc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForCashgeneratingUnitsMember_60418347-0c0e-4474-8a99-175457599205" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForCashgeneratingUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_3855bef9-f83c-4cd8-b05b-1f39793e7cc4" xlink:to="loc_ifrs-full_EntitysTotalForCashgeneratingUnitsMember_60418347-0c0e-4474-8a99-175457599205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember_80c24125-30e9-4172-860d-ca673c5eac03" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForCashgeneratingUnitsMember_60418347-0c0e-4474-8a99-175457599205" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember_80c24125-30e9-4172-860d-ca673c5eac03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cfebbe86-844b-4bf9-bf18-fe4f4752cdf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cfebbe86-844b-4bf9-bf18-fe4f4752cdf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_cfebbe86-844b-4bf9-bf18-fe4f4752cdf0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cfebbe86-844b-4bf9-bf18-fe4f4752cdf0" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_cfebbe86-844b-4bf9-bf18-fe4f4752cdf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_837c1b1c-0e78-4cfe-8912-804b412869b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cfebbe86-844b-4bf9-bf18-fe4f4752cdf0" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_837c1b1c-0e78-4cfe-8912-804b412869b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_1f60ea44-5d54-474b-ab74-6d81c5b67f4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_837c1b1c-0e78-4cfe-8912-804b412869b5" xlink:to="loc_ifrs-full_GoodwillMember_1f60ea44-5d54-474b-ab74-6d81c5b67f4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f4d442fb-27ea-44fb-90e8-ceaa12219261" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:to="loc_ifrs-full_RangeAxis_f4d442fb-27ea-44fb-90e8-ceaa12219261" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_f4d442fb-27ea-44fb-90e8-ceaa12219261_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_f4d442fb-27ea-44fb-90e8-ceaa12219261" xlink:to="loc_ifrs-full_RangesMember_f4d442fb-27ea-44fb-90e8-ceaa12219261_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_fb30afde-d49f-4817-baf5-0a9bfc687b86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_f4d442fb-27ea-44fb-90e8-ceaa12219261" xlink:to="loc_ifrs-full_RangesMember_fb30afde-d49f-4817-baf5-0a9bfc687b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_17f6e995-d4e5-4db1-9250-b08de6cce14c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_fb30afde-d49f-4817-baf5-0a9bfc687b86" xlink:to="loc_ifrs-full_BottomOfRangeMember_17f6e995-d4e5-4db1-9250-b08de6cce14c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_d2de7290-61ae-4c4d-b6fc-8b3b365a6304" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_fb30afde-d49f-4817-baf5-0a9bfc687b86" xlink:to="loc_ifrs-full_TopOfRangeMember_d2de7290-61ae-4c4d-b6fc-8b3b365a6304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentTestingPercentage_4c7d9cdf-00d5-4232-b665-11a7a6dac9cb" xlink:href="sny-20231231.xsd#sny_ImpairmentTestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_ImpairmentTestingPercentage_4c7d9cdf-00d5-4232-b665-11a7a6dac9cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UniformImpairmentTestingPercentage_60e1559d-e0c6-4a02-bf9a-9b8be11d12e1" xlink:href="sny-20231231.xsd#sny_UniformImpairmentTestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_UniformImpairmentTestingPercentage_60e1559d-e0c6-4a02-bf9a-9b8be11d12e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments1_2891579d-f5a9-4208-87d8-b61ac616a99d" xlink:href="sny-20231231.xsd#sny_NumberOfOperatingSegments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_NumberOfOperatingSegments1_2891579d-f5a9-4208-87d8-b61ac616a99d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PretaxDiscountRateAppliedForGoodwill_82a9bc20-53f4-4550-84a8-30a5bded3292" xlink:href="sny-20231231.xsd#sny_PretaxDiscountRateAppliedForGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_PretaxDiscountRateAppliedForGoodwill_82a9bc20-53f4-4550-84a8-30a5bded3292" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UniformPreTaxDiscountRates_a03ff356-b989-4e8a-88c2-1add63edf7dd" xlink:href="sny-20231231.xsd#sny_UniformPreTaxDiscountRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_UniformPreTaxDiscountRates_a03ff356-b989-4e8a-88c2-1add63edf7dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_ca0efe1f-f459-49ac-95c5-a296c8430f78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_ca0efe1f-f459-49ac-95c5-a296c8430f78" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss_39ed78b5-9004-4495-a802-268fe623baba" xlink:href="sny-20231231.xsd#sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss_39ed78b5-9004-4495-a802-268fe623baba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss_0b173e21-54c5-4a13-b3cf-41605beaa9db" xlink:href="sny-20231231.xsd#sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss_0b173e21-54c5-4a13-b3cf-41605beaa9db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss_b22a50b3-80b2-49b2-bbfb-637da01763e2" xlink:href="sny-20231231.xsd#sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss_b22a50b3-80b2-49b2-bbfb-637da01763e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_4518d4ab-df09-494a-a3bd-701a515f2309" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_4518d4ab-df09-494a-a3bd-701a515f2309" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AfterTaxDiscountRates_23d85066-bc26-48f9-88f8-3a658cadaeb7" xlink:href="sny-20231231.xsd#sny_AfterTaxDiscountRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_AfterTaxDiscountRates_23d85066-bc26-48f9-88f8-3a658cadaeb7" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_acdec203-a6e5-47f9-ae93-fe8cb9807498" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_acdec203-a6e5-47f9-ae93-fe8cb9807498" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_448d7249-0206-40c5-9c29-dfeba05e94ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:to="loc_ifrs-full_SegmentsAxis_448d7249-0206-40c5-9c29-dfeba05e94ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_448d7249-0206-40c5-9c29-dfeba05e94ad_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_448d7249-0206-40c5-9c29-dfeba05e94ad" xlink:to="loc_ifrs-full_SegmentsMember_448d7249-0206-40c5-9c29-dfeba05e94ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_65f28e17-de39-4751-95d2-b1ee15b6ba27" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_448d7249-0206-40c5-9c29-dfeba05e94ad" xlink:to="loc_ifrs-full_SegmentsMember_65f28e17-de39-4751-95d2-b1ee15b6ba27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_997fd8c2-9281-48e5-9036-da1e977fd70c" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_65f28e17-de39-4751-95d2-b1ee15b6ba27" xlink:to="loc_sny_BiopharmaSegmentMember_997fd8c2-9281-48e5-9036-da1e977fd70c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_ee11ff11-74b6-4d01-8b1f-037702321759" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_65f28e17-de39-4751-95d2-b1ee15b6ba27" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_ee11ff11-74b6-4d01-8b1f-037702321759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0ad9bb67-37f9-4783-a730-da237d61f6d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0ad9bb67-37f9-4783-a730-da237d61f6d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0ad9bb67-37f9-4783-a730-da237d61f6d8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0ad9bb67-37f9-4783-a730-da237d61f6d8" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_0ad9bb67-37f9-4783-a730-da237d61f6d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83b96020-596f-4c42-9e80-8df608bac85a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0ad9bb67-37f9-4783-a730-da237d61f6d8" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83b96020-596f-4c42-9e80-8df608bac85a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_93a6c0b2-48eb-42e9-a592-78b082f337a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83b96020-596f-4c42-9e80-8df608bac85a" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_93a6c0b2-48eb-42e9-a592-78b082f337a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_0cd0469f-66cd-4c0d-9881-e08740078df0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_0cd0469f-66cd-4c0d-9881-e08740078df0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_0cd0469f-66cd-4c0d-9881-e08740078df0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_0cd0469f-66cd-4c0d-9881-e08740078df0" xlink:to="loc_ifrs-full_ProductsAndServicesMember_0cd0469f-66cd-4c0d-9881-e08740078df0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_a4768eb3-37cd-4ba1-be65-27c677730c38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_0cd0469f-66cd-4c0d-9881-e08740078df0" xlink:to="loc_ifrs-full_ProductsAndServicesMember_a4768eb3-37cd-4ba1-be65-27c677730c38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_1e5e79a1-0b41-45e7-b53d-492cee9bb6ad" xlink:href="sny-20231231.xsd#sny_MarketedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_a4768eb3-37cd-4ba1-be65-27c677730c38" xlink:to="loc_sny_MarketedProductsMember_1e5e79a1-0b41-45e7-b53d-492cee9bb6ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_c711fced-a34c-41f8-8547-66530ed12df8" xlink:href="sny-20231231.xsd#sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_a4768eb3-37cd-4ba1-be65-27c677730c38" xlink:to="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_c711fced-a34c-41f8-8547-66530ed12df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductAndServicesMember_b9fd0d6d-931d-47a6-b5ed-9e177491d983" xlink:href="sny-20231231.xsd#sny_OtherProductAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_a4768eb3-37cd-4ba1-be65-27c677730c38" xlink:to="loc_sny_OtherProductAndServicesMember_b9fd0d6d-931d-47a6-b5ed-9e177491d983" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8058959-63eb-4048-b349-480dae7d32bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:to="loc_srt_ProductOrServiceAxis_b8058959-63eb-4048-b349-480dae7d32bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b8058959-63eb-4048-b349-480dae7d32bb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b8058959-63eb-4048-b349-480dae7d32bb" xlink:to="loc_srt_ProductsAndServicesDomain_b8058959-63eb-4048-b349-480dae7d32bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_791117ba-4402-48bf-a3a0-3dec71d299b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b8058959-63eb-4048-b349-480dae7d32bb" xlink:to="loc_srt_ProductsAndServicesDomain_791117ba-4402-48bf-a3a0-3dec71d299b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_c6133345-8f93-4740-abe1-dbaac05b6129" xlink:href="sny-20231231.xsd#sny_EloctateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_791117ba-4402-48bf-a3a0-3dec71d299b2" xlink:to="loc_sny_EloctateMember_c6133345-8f93-4740-abe1-dbaac05b6129" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SAR444245Member_b15923cf-b92b-4b91-a907-0c9f316aa954" xlink:href="sny-20231231.xsd#sny_SAR444245Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_791117ba-4402-48bf-a3a0-3dec71d299b2" xlink:to="loc_sny_SAR444245Member_b15923cf-b92b-4b91-a907-0c9f316aa954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NKCellAndProXTenTechnologyPlatformsMember_fc54d6f8-c518-48a1-a6d1-842eed176d41" xlink:href="sny-20231231.xsd#sny_NKCellAndProXTenTechnologyPlatformsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_791117ba-4402-48bf-a3a0-3dec71d299b2" xlink:to="loc_sny_NKCellAndProXTenTechnologyPlatformsMember_fc54d6f8-c518-48a1-a6d1-842eed176d41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_e1228134-029b-458f-8435-caca2f09e860" xlink:href="sny-20231231.xsd#sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_acdec203-a6e5-47f9-ae93-fe8cb9807498" xlink:to="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_e1228134-029b-458f-8435-caca2f09e860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount_f3c48f27-96fb-45cc-8fa8-ddbf0aeefd22" xlink:href="sny-20231231.xsd#sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_acdec203-a6e5-47f9-ae93-fe8cb9807498" xlink:to="loc_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount_f3c48f27-96fb-45cc-8fa8-ddbf0aeefd22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_71d80d26-da91-4f36-a4e6-a665053a6d1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_acdec203-a6e5-47f9-ae93-fe8cb9807498" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_71d80d26-da91-4f36-a4e6-a665053a6d1b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7a9b7d1b-84bf-4efb-9c9a-1813a07c9420" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7a9b7d1b-84bf-4efb-9c9a-1813a07c9420" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cc931b8d-4105-49f6-b9c1-40c447ecb163" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7a9b7d1b-84bf-4efb-9c9a-1813a07c9420" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cc931b8d-4105-49f6-b9c1-40c447ecb163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_cc931b8d-4105-49f6-b9c1-40c447ecb163_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cc931b8d-4105-49f6-b9c1-40c447ecb163" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_cc931b8d-4105-49f6-b9c1-40c447ecb163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_93dff1d9-6d82-4500-afc1-470a19dce855" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cc931b8d-4105-49f6-b9c1-40c447ecb163" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_93dff1d9-6d82-4500-afc1-470a19dce855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_995bcb99-2a33-4701-b574-1ec22c625212" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_93dff1d9-6d82-4500-afc1-470a19dce855" xlink:to="loc_sny_EuroapiMember_995bcb99-2a33-4701-b574-1ec22c625212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember_b75735e4-1d3f-44ce-9e62-4842ca7bab15" xlink:href="sny-20231231.xsd#sny_MCMVaccineBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_93dff1d9-6d82-4500-afc1-470a19dce855" xlink:to="loc_sny_MCMVaccineBVMember_b75735e4-1d3f-44ce-9e62-4842ca7bab15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_b1d2ce54-a7a6-4426-a647-0408ed24cff3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7a9b7d1b-84bf-4efb-9c9a-1813a07c9420" xlink:to="loc_ifrs-full_JointVenturesAxis_b1d2ce54-a7a6-4426-a647-0408ed24cff3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_b1d2ce54-a7a6-4426-a647-0408ed24cff3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_b1d2ce54-a7a6-4426-a647-0408ed24cff3" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_b1d2ce54-a7a6-4426-a647-0408ed24cff3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_d6195049-8894-45a0-b189-4e2e431cc117" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_b1d2ce54-a7a6-4426-a647-0408ed24cff3" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_d6195049-8894-45a0-b189-4e2e431cc117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember_8fd3f67f-b16c-4fed-b7c3-4ed0c4f7f53f" xlink:href="sny-20231231.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_d6195049-8894-45a0-b189-4e2e431cc117" xlink:to="loc_sny_InfraservGmbhAndCoHochstKGMember_8fd3f67f-b16c-4fed-b7c3-4ed0c4f7f53f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_286336f8-a401-44e4-bde1-c6ffa899120b" xlink:href="sny-20231231.xsd#sny_MSPVaccineCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_d6195049-8894-45a0-b189-4e2e431cc117" xlink:to="loc_sny_MSPVaccineCompanyMember_286336f8-a401-44e4-bde1-c6ffa899120b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_30933fd1-6016-44df-afc3-a67d3d7597d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_d6195049-8894-45a0-b189-4e2e431cc117" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_30933fd1-6016-44df-afc3-a67d3d7597d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_43303ade-1ce8-498a-ab66-cd4b0bf78936" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7a9b7d1b-84bf-4efb-9c9a-1813a07c9420" xlink:to="loc_dei_LegalEntityAxis_43303ade-1ce8-498a-ab66-cd4b0bf78936" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_43303ade-1ce8-498a-ab66-cd4b0bf78936_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_43303ade-1ce8-498a-ab66-cd4b0bf78936" xlink:to="loc_dei_EntityDomain_43303ade-1ce8-498a-ab66-cd4b0bf78936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0820da73-d813-43ff-a6ba-cc6486f142d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_43303ade-1ce8-498a-ab66-cd4b0bf78936" xlink:to="loc_dei_EntityDomain_0820da73-d813-43ff-a6ba-cc6486f142d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_173c6de6-2b99-4bd3-aebc-a84696e788fc" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0820da73-d813-43ff-a6ba-cc6486f142d1" xlink:to="loc_sny_EuroapiMember_173c6de6-2b99-4bd3-aebc-a84696e788fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_b198cc31-6d10-4ece-b62f-85f9d03a5642" xlink:href="sny-20231231.xsd#sny_MSPVaccineCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0820da73-d813-43ff-a6ba-cc6486f142d1" xlink:to="loc_sny_MSPVaccineCompanyMember_b198cc31-6d10-4ece-b62f-85f9d03a5642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_06b9349f-38e9-49d5-abd9-c8321fa646b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_06b9349f-38e9-49d5-abd9-c8321fa646b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_9df024e1-795e-4d4e-a669-532c1a76d12f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_9df024e1-795e-4d4e-a669-532c1a76d12f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVentures_ff82c817-26e8-447b-bfc3-5ba36169ccdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_ifrs-full_InvestmentsInJointVentures_ff82c817-26e8-447b-bfc3-5ba36169ccdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_2d19ce7b-7daf-418d-85a6-2445c401cc37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_2d19ce7b-7daf-418d-85a6-2445c401cc37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_8503c1f7-93da-42ad-82e8-058a96794e3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_8503c1f7-93da-42ad-82e8-058a96794e3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice_0524ed72-5925-4c42-8385-53acf4831a6e" xlink:href="sny-20231231.xsd#sny_StockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_sny_StockPrice_0524ed72-5925-4c42-8385-53acf4831a6e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_19d62085-3b49-4696-9254-34ae4bd38063" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_19d62085-3b49-4696-9254-34ae4bd38063" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f16668c0-e964-472c-84a5-f8a2a4593ba8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_19d62085-3b49-4696-9254-34ae4bd38063" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f16668c0-e964-472c-84a5-f8a2a4593ba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_f16668c0-e964-472c-84a5-f8a2a4593ba8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f16668c0-e964-472c-84a5-f8a2a4593ba8" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_f16668c0-e964-472c-84a5-f8a2a4593ba8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_363e8675-f422-4061-b5b6-2c19e2d57863" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f16668c0-e964-472c-84a5-f8a2a4593ba8" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_363e8675-f422-4061-b5b6-2c19e2d57863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssociatesMember_16927bf9-dbd7-4100-95e5-5546e465ac7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_363e8675-f422-4061-b5b6-2c19e2d57863" xlink:to="loc_ifrs-full_AssociatesMember_16927bf9-dbd7-4100-95e5-5546e465ac7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_f6a2016e-d3b9-4790-9ade-bd0c21d85da0" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_363e8675-f422-4061-b5b6-2c19e2d57863" xlink:to="loc_sny_EuroapiMember_f6a2016e-d3b9-4790-9ade-bd0c21d85da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_8217e0e2-f997-4b0d-9dd0-562dc8dccba2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_19d62085-3b49-4696-9254-34ae4bd38063" xlink:to="loc_ifrs-full_JointVenturesAxis_8217e0e2-f997-4b0d-9dd0-562dc8dccba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_8217e0e2-f997-4b0d-9dd0-562dc8dccba2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_8217e0e2-f997-4b0d-9dd0-562dc8dccba2" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_8217e0e2-f997-4b0d-9dd0-562dc8dccba2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_1ddb818e-3a82-41b2-876a-17881bedc9e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_8217e0e2-f997-4b0d-9dd0-562dc8dccba2" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_1ddb818e-3a82-41b2-876a-17881bedc9e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesMember_5e23acdb-fec9-47b1-8b04-4a44fec05c92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_1ddb818e-3a82-41b2-876a-17881bedc9e1" xlink:to="loc_ifrs-full_JointVenturesMember_5e23acdb-fec9-47b1-8b04-4a44fec05c92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6b5002a5-e33c-47a3-9fdf-8fe62c70f8f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_19d62085-3b49-4696-9254-34ae4bd38063" xlink:to="loc_dei_LegalEntityAxis_6b5002a5-e33c-47a3-9fdf-8fe62c70f8f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6b5002a5-e33c-47a3-9fdf-8fe62c70f8f2_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6b5002a5-e33c-47a3-9fdf-8fe62c70f8f2" xlink:to="loc_dei_EntityDomain_6b5002a5-e33c-47a3-9fdf-8fe62c70f8f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6308faf1-554c-4161-9d8d-955fc6457800" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6b5002a5-e33c-47a3-9fdf-8fe62c70f8f2" xlink:to="loc_dei_EntityDomain_6308faf1-554c-4161-9d8d-955fc6457800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_563e23ef-eed9-4fe9-ad61-1763812007a7" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6308faf1-554c-4161-9d8d-955fc6457800" xlink:to="loc_sny_EuroapiMember_563e23ef-eed9-4fe9-ad61-1763812007a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_0786e000-36a8-4f6f-a300-1a78c915b974" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:to="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_0786e000-36a8-4f6f-a300-1a78c915b974" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax_8dab8ca4-8983-43a1-8aa4-a744123dba53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:to="loc_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax_8dab8ca4-8983-43a1-8aa4-a744123dba53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures_ec3322db-eaa6-42c6-ba52-fd2ab3c5d379" xlink:href="sny-20231231.xsd#sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:to="loc_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures_ec3322db-eaa6-42c6-ba52-fd2ab3c5d379" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_d0002a07-8ef9-4ff7-8d14-3dd661fe8aed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_d0002a07-8ef9-4ff7-8d14-3dd661fe8aed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice_5982785f-bd1a-4fe9-9372-b30b8c8b02cd" xlink:href="sny-20231231.xsd#sny_StockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:to="loc_sny_StockPrice_5982785f-bd1a-4fe9-9372-b30b8c8b02cd" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_f9eb3031-07bf-4a9d-a5a7-1d2bc9e79b40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_f9eb3031-07bf-4a9d-a5a7-1d2bc9e79b40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_5f6dbfe5-140c-49db-a049-e0a496317b2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_f9eb3031-07bf-4a9d-a5a7-1d2bc9e79b40" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_5f6dbfe5-140c-49db-a049-e0a496317b2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_5f6dbfe5-140c-49db-a049-e0a496317b2a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_5f6dbfe5-140c-49db-a049-e0a496317b2a" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_5f6dbfe5-140c-49db-a049-e0a496317b2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_ca64e938-ba12-4bdf-8ee1-2d222dbe9de5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_5f6dbfe5-140c-49db-a049-e0a496317b2a" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_ca64e938-ba12-4bdf-8ee1-2d222dbe9de5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_4995f126-a2d7-420c-be53-c8d263e8ae10" xlink:href="sny-20231231.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_ca64e938-ba12-4bdf-8ee1-2d222dbe9de5" xlink:to="loc_sny_AssociatesAndJointVenturesMember_4995f126-a2d7-420c-be53-c8d263e8ae10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_03d0ee03-5af0-4064-a310-351db496819b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_03d0ee03-5af0-4064-a310-351db496819b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_4c2ec866-fcf4-441e-8d5a-3763f1ae79bd" xlink:href="sny-20231231.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:to="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_4c2ec866-fcf4-441e-8d5a-3763f1ae79bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_55e7daee-dcf1-45ad-b4e0-3f9999d32cc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_55e7daee-dcf1-45ad-b4e0-3f9999d32cc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_3ca7a9f2-d040-4e68-8564-e4529f07aabe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:to="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_3ca7a9f2-d040-4e68-8564-e4529f07aabe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_50703511-863d-4eb1-b2e2-61d709476521" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_50703511-863d-4eb1-b2e2-61d709476521" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_dc046185-58f4-4338-9ccd-f607507181a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_04c0da55-9dc2-44f1-bf97-58f203ff8883" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_dc046185-58f4-4338-9ccd-f607507181a6" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_04c0da55-9dc2-44f1-bf97-58f203ff8883" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ecf8f2c3-4d15-4659-8088-c27f179776f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_04c0da55-9dc2-44f1-bf97-58f203ff8883" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ecf8f2c3-4d15-4659-8088-c27f179776f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_ecf8f2c3-4d15-4659-8088-c27f179776f5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ecf8f2c3-4d15-4659-8088-c27f179776f5" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_ecf8f2c3-4d15-4659-8088-c27f179776f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9e99ab55-bd23-47b7-8a7f-24f749b6f3de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ecf8f2c3-4d15-4659-8088-c27f179776f5" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9e99ab55-bd23-47b7-8a7f-24f749b6f3de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_8f6dacba-7629-47a2-8b8b-23f57512f462" xlink:href="sny-20231231.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9e99ab55-bd23-47b7-8a7f-24f749b6f3de" xlink:to="loc_sny_AssociatesAndJointVenturesMember_8f6dacba-7629-47a2-8b8b-23f57512f462" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_d5b16b8c-420e-408e-b817-4ae7571ff1fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_04c0da55-9dc2-44f1-bf97-58f203ff8883" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_d5b16b8c-420e-408e-b817-4ae7571ff1fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_d5b16b8c-420e-408e-b817-4ae7571ff1fd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_d5b16b8c-420e-408e-b817-4ae7571ff1fd" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_d5b16b8c-420e-408e-b817-4ae7571ff1fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_21f2d9d4-a1fc-4d8f-ae5d-3d22845697b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_d5b16b8c-420e-408e-b817-4ae7571ff1fd" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_21f2d9d4-a1fc-4d8f-ae5d-3d22845697b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_6dad6b58-85cb-4aba-b0d5-f8a41e0f81a2" xlink:href="sny-20231231.xsd#sny_RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_21f2d9d4-a1fc-4d8f-ae5d-3d22845697b4" xlink:to="loc_sny_RegeneronMember_6dad6b58-85cb-4aba-b0d5-f8a41e0f81a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsMadeToJointVenturesAndAssociates_f9739bc3-6645-44f8-be13-af74f12a6ff3" xlink:href="sny-20231231.xsd#sny_CommitmentsMadeToJointVenturesAndAssociates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_dc046185-58f4-4338-9ccd-f607507181a6" xlink:to="loc_sny_CommitmentsMadeToJointVenturesAndAssociates_f9739bc3-6645-44f8-be13-af74f12a6ff3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_ff8aaad4-f5f5-4321-9c6d-e963e37b3e00" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_ff8aaad4-f5f5-4321-9c6d-e963e37b3e00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_5ac0ae24-20c9-47de-9682-cf84ec541337" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_ff8aaad4-f5f5-4321-9c6d-e963e37b3e00" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_5ac0ae24-20c9-47de-9682-cf84ec541337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_5ac0ae24-20c9-47de-9682-cf84ec541337_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_5ac0ae24-20c9-47de-9682-cf84ec541337" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_5ac0ae24-20c9-47de-9682-cf84ec541337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_c3f2a129-2567-4789-b4d4-16fbf04774eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_5ac0ae24-20c9-47de-9682-cf84ec541337" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_c3f2a129-2567-4789-b4d4-16fbf04774eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember_470f2ef8-7c6e-4494-858f-a1305f575f1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_c3f2a129-2567-4789-b4d4-16fbf04774eb" xlink:to="loc_ifrs-full_TradingEquitySecuritiesMember_470f2ef8-7c6e-4494-858f-a1305f575f1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember_f4b91bbe-38b9-461d-9526-095f76b9c049" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_c3f2a129-2567-4789-b4d4-16fbf04774eb" xlink:to="loc_ifrs-full_DebtSecuritiesMember_f4b91bbe-38b9-461d-9526-095f76b9c049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_98d9304b-ca7a-4ea9-ba77-7d631e7a558c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_ff8aaad4-f5f5-4321-9c6d-e963e37b3e00" xlink:to="loc_ifrs-full_CounterpartiesAxis_98d9304b-ca7a-4ea9-ba77-7d631e7a558c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_98d9304b-ca7a-4ea9-ba77-7d631e7a558c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_98d9304b-ca7a-4ea9-ba77-7d631e7a558c" xlink:to="loc_ifrs-full_CounterpartiesMember_98d9304b-ca7a-4ea9-ba77-7d631e7a558c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_a6e3adac-a44c-4e9b-8e66-8a0b4132fa1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_98d9304b-ca7a-4ea9-ba77-7d631e7a558c" xlink:to="loc_ifrs-full_CounterpartiesMember_a6e3adac-a44c-4e9b-8e66-8a0b4132fa1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioAtriumMember_b9a08d8e-19bb-4fe1-ac2a-e8b869ab8bfc" xlink:href="sny-20231231.xsd#sny_BioAtriumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_a6e3adac-a44c-4e9b-8e66-8a0b4132fa1b" xlink:to="loc_sny_BioAtriumMember_b9a08d8e-19bb-4fe1-ac2a-e8b869ab8bfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_fb855bd9-4e2e-4901-b7a5-f7b68e35c430" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_fb855bd9-4e2e-4901-b7a5-f7b68e35c430" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss_1cf7eec1-2866-4ba8-90d7-d0574707103d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss_1cf7eec1-2866-4ba8-90d7-d0574707103d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_7624c329-fa8c-4396-bf20-707916cd64da" xlink:href="sny-20231231.xsd#sny_PreFundedPensionObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_sny_PreFundedPensionObligations_7624c329-fa8c-4396-bf20-707916cd64da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses_7a7e0553-b44d-4308-b73f-57482a818442" xlink:href="sny-20231231.xsd#sny_LongTermPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_sny_LongTermPrepaidExpenses_7a7e0553-b44d-4308-b73f-57482a818442" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLoansAndReceivables_f64ec9e7-7734-4e85-8e78-ea340546ff79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLoansAndReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_NoncurrentLoansAndReceivables_f64ec9e7-7734-4e85-8e78-ea340546ff79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_47cd4ba0-44a2-44ea-b94b-e3ec2290dbb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_47cd4ba0-44a2-44ea-b94b-e3ec2290dbb7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_26c23b2d-f7b1-48d6-9581-4509ff7b516b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_26c23b2d-f7b1-48d6-9581-4509ff7b516b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinanceLeaseReceivables_1127e0b7-1333-45b4-8919-b28f8f98ae48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_NoncurrentFinanceLeaseReceivables_1127e0b7-1333-45b4-8919-b28f8f98ae48" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_ba505385-48f9-4245-9fa2-e9810e90dc6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_OtherCurrentAssets_ba505385-48f9-4245-9fa2-e9810e90dc6b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentFinanceLeaseReceivablesGross_77f0aecf-df3a-4367-be64-45d16dd5cd94" xlink:href="sny-20231231.xsd#sny_NonCurrentFinanceLeaseReceivablesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_sny_NonCurrentFinanceLeaseReceivablesGross_77f0aecf-df3a-4367-be64-45d16dd5cd94" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OthernoncurrentassetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_6dbba4a1-0539-464e-b888-41c997a95f75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_6dbba4a1-0539-464e-b888-41c997a95f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_6dbba4a1-0539-464e-b888-41c997a95f75_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_6dbba4a1-0539-464e-b888-41c997a95f75" xlink:to="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_6dbba4a1-0539-464e-b888-41c997a95f75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_b5dbd526-22d5-410b-b2fb-754cdb65089b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_6dbba4a1-0539-464e-b888-41c997a95f75" xlink:to="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_b5dbd526-22d5-410b-b2fb-754cdb65089b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_325c8abf-8f1c-47a8-a239-12ebe1259ac7" xlink:href="sny-20231231.xsd#sny_RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_b5dbd526-22d5-410b-b2fb-754cdb65089b" xlink:to="loc_sny_RegeneronMember_325c8abf-8f1c-47a8-a239-12ebe1259ac7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InnoventBiologicsMember_0da0db3e-d83b-4621-8503-9326c7c6c6ec" xlink:href="sny-20231231.xsd#sny_InnoventBiologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_b5dbd526-22d5-410b-b2fb-754cdb65089b" xlink:to="loc_sny_InnoventBiologicsMember_0da0db3e-d83b-4621-8503-9326c7c6c6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioMember_2d99b0bd-2f0c-465a-8980-a0c200dfc914" xlink:href="sny-20231231.xsd#sny_TranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_b5dbd526-22d5-410b-b2fb-754cdb65089b" xlink:to="loc_sny_TranslateBioMember_2d99b0bd-2f0c-465a-8980-a0c200dfc914" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_25b1b6bd-b14b-44f3-b70e-b6fafe0af073" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_MeasurementAxis_25b1b6bd-b14b-44f3-b70e-b6fafe0af073" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_25b1b6bd-b14b-44f3-b70e-b6fafe0af073_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_25b1b6bd-b14b-44f3-b70e-b6fafe0af073" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_25b1b6bd-b14b-44f3-b70e-b6fafe0af073_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_fe37f44d-bb97-4515-8ad1-a05bfd31f56b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_25b1b6bd-b14b-44f3-b70e-b6fafe0af073" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_fe37f44d-bb97-4515-8ad1-a05bfd31f56b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember_8b12a57b-dc30-4f0f-8ad7-c6540ba592d6" xlink:href="sny-20231231.xsd#sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_fe37f44d-bb97-4515-8ad1-a05bfd31f56b" xlink:to="loc_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember_8b12a57b-dc30-4f0f-8ad7-c6540ba592d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_ad1fe893-10d8-4e70-910d-60e15b0d9636" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_ad1fe893-10d8-4e70-910d-60e15b0d9636" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_ad1fe893-10d8-4e70-910d-60e15b0d9636_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_ad1fe893-10d8-4e70-910d-60e15b0d9636" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_ad1fe893-10d8-4e70-910d-60e15b0d9636_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_ad1fe893-10d8-4e70-910d-60e15b0d9636" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember_036bcf02-f072-43b7-b6ca-8e149d0c1a79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_ifrs-full_TradingEquitySecuritiesMember_036bcf02-f072-43b7-b6ca-8e149d0c1a79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnquotedEquityInvestmentsMember_695f13d5-9667-48f6-a3a5-1155eb8295b4" xlink:href="sny-20231231.xsd#sny_UnquotedEquityInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_UnquotedEquityInvestmentsMember_695f13d5-9667-48f6-a3a5-1155eb8295b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember_074067d2-ffe3-497f-8668-10f5358f1860" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember_074067d2-ffe3-497f-8668-10f5358f1860" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_fec1d229-ee49-4dfe-99fd-b8a0194af040" xlink:href="sny-20231231.xsd#sny_DebtInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_DebtInstrumentsMember_fec1d229-ee49-4dfe-99fd-b8a0194af040" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedDebtInstrumentsMember_2377ce6a-ffa9-464d-a526-7a9e5d4527e2" xlink:href="sny-20231231.xsd#sny_QuotedDebtInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_QuotedDebtInstrumentsMember_2377ce6a-ffa9-464d-a526-7a9e5d4527e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedEquitySecuritiesMember_3b5f6b6d-b2c2-499c-aea9-604b844ea57b" xlink:href="sny-20231231.xsd#sny_QuotedEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_QuotedEquitySecuritiesMember_3b5f6b6d-b2c2-499c-aea9-604b844ea57b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SPMSDContingentConsiderationAssetMember_aafc9d73-c514-4c9e-8806-1c2a8ef872fc" xlink:href="sny-20231231.xsd#sny_SPMSDContingentConsiderationAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_SPMSDContingentConsiderationAssetMember_aafc9d73-c514-4c9e-8806-1c2a8ef872fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember_bb9b4eaf-34c0-4fc3-80d6-a23def2f0d8e" xlink:href="sny-20231231.xsd#sny_NonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_NonCurrentAssetsMember_bb9b4eaf-34c0-4fc3-80d6-a23def2f0d8e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnquotedDebtSecuritiesMember_f48814ca-7fe6-4f55-9263-5296eba7fb16" xlink:href="sny-20231231.xsd#sny_UnquotedDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_UnquotedDebtSecuritiesMember_f48814ca-7fe6-4f55-9263-5296eba7fb16" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_e79c4d78-cf37-4413-b0ce-626ab886b2f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_e79c4d78-cf37-4413-b0ce-626ab886b2f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_e79c4d78-cf37-4413-b0ce-626ab886b2f8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_e79c4d78-cf37-4413-b0ce-626ab886b2f8" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_e79c4d78-cf37-4413-b0ce-626ab886b2f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_40c3ef4e-3560-4a3c-ad68-095f55f23292" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_e79c4d78-cf37-4413-b0ce-626ab886b2f8" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_40c3ef4e-3560-4a3c-ad68-095f55f23292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedEuroDenominatedSeniorBondsMember_d78a5578-4011-4bb3-bebd-9c36ec4910a4" xlink:href="sny-20231231.xsd#sny_QuotedEuroDenominatedSeniorBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_40c3ef4e-3560-4a3c-ad68-095f55f23292" xlink:to="loc_sny_QuotedEuroDenominatedSeniorBondsMember_d78a5578-4011-4bb3-bebd-9c36ec4910a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeniorBondMember_884e70b1-a02f-4eb2-ab8c-edb70822a218" xlink:href="sny-20231231.xsd#sny_SeniorBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_40c3ef4e-3560-4a3c-ad68-095f55f23292" xlink:to="loc_sny_SeniorBondMember_884e70b1-a02f-4eb2-ab8c-edb70822a218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember_23269efe-cad1-45f0-84ee-8c3caf30ceec" xlink:href="sny-20231231.xsd#sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_40c3ef4e-3560-4a3c-ad68-095f55f23292" xlink:to="loc_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember_23269efe-cad1-45f0-84ee-8c3caf30ceec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2f474c3a-17b5-4e66-9648-2271a8a42fb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2f474c3a-17b5-4e66-9648-2271a8a42fb4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2f474c3a-17b5-4e66-9648-2271a8a42fb4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2f474c3a-17b5-4e66-9648-2271a8a42fb4" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2f474c3a-17b5-4e66-9648-2271a8a42fb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4412f3e1-bee1-4170-bade-91a69809c0d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2f474c3a-17b5-4e66-9648-2271a8a42fb4" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4412f3e1-bee1-4170-bade-91a69809c0d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_eb3b2fd6-b0f3-41ed-8f6e-7d4fa6bb8d3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4412f3e1-bee1-4170-bade-91a69809c0d7" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_eb3b2fd6-b0f3-41ed-8f6e-7d4fa6bb8d3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis_c7e14908-bc3e-4bcd-bb4b-6f20f7bab699" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis_c7e14908-bc3e-4bcd-bb4b-6f20f7bab699" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_c7e14908-bc3e-4bcd-bb4b-6f20f7bab699_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis_c7e14908-bc3e-4bcd-bb4b-6f20f7bab699" xlink:to="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_c7e14908-bc3e-4bcd-bb4b-6f20f7bab699_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_f9e26735-0e4a-46dd-98d7-80faf3fde482" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis_c7e14908-bc3e-4bcd-bb4b-6f20f7bab699" xlink:to="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_f9e26735-0e4a-46dd-98d7-80faf3fde482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfSPMSDContingentConsiderationMember_5361b075-2e37-4c5c-b7ab-9fd8557aecfe" xlink:href="sny-20231231.xsd#sny_FairValueOfSPMSDContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_f9e26735-0e4a-46dd-98d7-80faf3fde482" xlink:to="loc_sny_FairValueOfSPMSDContingentConsiderationMember_5361b075-2e37-4c5c-b7ab-9fd8557aecfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_ef03167c-b25d-4a23-9590-5f724d8dc7e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_ef03167c-b25d-4a23-9590-5f724d8dc7e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_b0bc2470-0574-489b-ba6b-4a43f9f5bfbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_b0bc2470-0574-489b-ba6b-4a43f9f5bfbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount_12465bba-6730-438e-af90-3c3cec7eb966" xlink:href="sny-20231231.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount_12465bba-6730-438e-af90-3c3cec7eb966" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_701c9442-30ef-4c9a-bb40-031a474cde82" xlink:href="sny-20231231.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_701c9442-30ef-4c9a-bb40-031a474cde82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount_24de5733-4cca-4d64-9ae6-a48a6a2a6c56" xlink:href="sny-20231231.xsd#sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount_24de5733-4cca-4d64-9ae6-a48a6a2a6c56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_7b05ebad-84bb-4472-9329-c81b57179a7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_7b05ebad-84bb-4472-9329-c81b57179a7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_1ac85c76-b113-4943-914f-12148114c03a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_1ac85c76-b113-4943-914f-12148114c03a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_5f2b2b96-a36f-4381-a0ab-9e3e86f3c356" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_5f2b2b96-a36f-4381-a0ab-9e3e86f3c356" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HeldtomaturityInvestments_3b70e232-20c5-4d68-9115-0c1a88efcabb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HeldtomaturityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_HeldtomaturityInvestments_3b70e232-20c5-4d68-9115-0c1a88efcabb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTax_5d73b03c-9541-4f7d-af70-08a6622d9892" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTax_5d73b03c-9541-4f7d-af70-08a6622d9892" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity_4ac4fc01-d91a-4c49-8581-4836c885fe84" xlink:href="sny-20231231.xsd#sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity_4ac4fc01-d91a-4c49-8581-4836c885fe84" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfTheContingentConsideration_a83b523f-181c-44bb-85bc-191bac165325" xlink:href="sny-20231231.xsd#sny_FairValueOfTheContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_FairValueOfTheContingentConsideration_a83b523f-181c-44bb-85bc-191bac165325" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInvestments_f546b7d3-dce1-467b-98f3-23d666381c79" xlink:href="sny-20231231.xsd#sny_FinancialInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_FinancialInvestments_f546b7d3-dce1-467b-98f3-23d666381c79" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss_f9bb1f98-c33a-498b-96d2-8e865eeaab06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss_f9bb1f98-c33a-498b-96d2-8e865eeaab06" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:href="sny-20231231.xsd#sny_DisclosureOfInventoriesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInventoriesTable_4e5cd48c-93d2-45df-beb1-157ec9fb6278" xlink:href="sny-20231231.xsd#sny_DisclosureOfInventoriesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:to="loc_sny_DisclosureOfInventoriesTable_4e5cd48c-93d2-45df-beb1-157ec9fb6278" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7355c367-a0b5-4049-8a84-e862ed0642a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfInventoriesTable_4e5cd48c-93d2-45df-beb1-157ec9fb6278" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7355c367-a0b5-4049-8a84-e862ed0642a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_7355c367-a0b5-4049-8a84-e862ed0642a5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7355c367-a0b5-4049-8a84-e862ed0642a5" xlink:to="loc_ifrs-full_CarryingAmountMember_7355c367-a0b5-4049-8a84-e862ed0642a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_68851cc6-9d55-4e42-967b-1c3586c7c1c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7355c367-a0b5-4049-8a84-e862ed0642a5" xlink:to="loc_ifrs-full_CarryingAmountMember_68851cc6-9d55-4e42-967b-1c3586c7c1c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_a9b41f26-beba-4df1-94a0-7ec74fd18edb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_68851cc6-9d55-4e42-967b-1c3586c7c1c9" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_a9b41f26-beba-4df1-94a0-7ec74fd18edb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WriteDownMember_23be1407-224f-46fc-b9ca-1588b31f4591" xlink:href="sny-20231231.xsd#sny_WriteDownMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_68851cc6-9d55-4e42-967b-1c3586c7c1c9" xlink:to="loc_sny_WriteDownMember_23be1407-224f-46fc-b9ca-1588b31f4591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials_1060dfb4-561f-41fe-a408-52f9959dc94b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:to="loc_ifrs-full_RawMaterials_1060dfb4-561f-41fe-a408-52f9959dc94b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_ff752975-3685-46f0-b6f1-2c97a68765eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:to="loc_ifrs-full_WorkInProgress_ff752975-3685-46f0-b6f1-2c97a68765eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_d00c5b1a-051c-4489-a955-fce16aa5b08a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:to="loc_ifrs-full_FinishedGoods_d00c5b1a-051c-4489-a955-fce16aa5b08a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_a29858ad-a221-46a5-9ae9-9a08809a887c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:to="loc_ifrs-full_Inventories_a29858ad-a221-46a5-9ae9-9a08809a887c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#AccountsreceivableSummaryofAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems_fa378aee-c363-4a0d-8fa9-8119a323dbf5" xlink:href="sny-20231231.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable_bb80ef27-e9bc-418a-bfb6-b8fe265d8f2b" xlink:href="sny-20231231.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_fa378aee-c363-4a0d-8fa9-8119a323dbf5" xlink:to="loc_sny_DisclosureOfAccountsReceivableTable_bb80ef27-e9bc-418a-bfb6-b8fe265d8f2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_a018ec9f-515b-4012-b45a-c9f170c86df6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_bb80ef27-e9bc-418a-bfb6-b8fe265d8f2b" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_a018ec9f-515b-4012-b45a-c9f170c86df6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_a018ec9f-515b-4012-b45a-c9f170c86df6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_a018ec9f-515b-4012-b45a-c9f170c86df6" xlink:to="loc_ifrs-full_CarryingAmountMember_a018ec9f-515b-4012-b45a-c9f170c86df6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_6cdc590e-2e97-4692-af88-6857afeac13d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_a018ec9f-515b-4012-b45a-c9f170c86df6" xlink:to="loc_ifrs-full_CarryingAmountMember_6cdc590e-2e97-4692-af88-6857afeac13d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_8cbfd1ed-978d-47ce-89df-ca0ef0f2cf66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_6cdc590e-2e97-4692-af88-6857afeac13d" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_8cbfd1ed-978d-47ce-89df-ca0ef0f2cf66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember_0da97186-6d8a-4c8c-bca0-aa9f4d720c15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_6cdc590e-2e97-4692-af88-6857afeac13d" xlink:to="loc_ifrs-full_AllowanceForCreditLossesMember_0da97186-6d8a-4c8c-bca0-aa9f4d720c15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_4bda234c-0e21-4a35-92fd-fec7de9ba5a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_fa378aee-c363-4a0d-8fa9-8119a323dbf5" xlink:to="loc_ifrs-full_CurrentTradeReceivables_4bda234c-0e21-4a35-92fd-fec7de9ba5a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_219f2008-c769-40c3-b2a6-4e8a31368701" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_3fc60a23-cebf-40e4-8060-7933d0f4743e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_219f2008-c769-40c3-b2a6-4e8a31368701" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_3fc60a23-cebf-40e4-8060-7933d0f4743e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_a5b58cf8-81d0-400d-af64-b87a7ff57191" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_3fc60a23-cebf-40e4-8060-7933d0f4743e" xlink:to="loc_ifrs-full_MaturityAxis_a5b58cf8-81d0-400d-af64-b87a7ff57191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_a5b58cf8-81d0-400d-af64-b87a7ff57191_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_a5b58cf8-81d0-400d-af64-b87a7ff57191" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_a5b58cf8-81d0-400d-af64-b87a7ff57191_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_a5b58cf8-81d0-400d-af64-b87a7ff57191" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember_69f69448-fbd5-4444-afce-4bd6861e2c75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:to="loc_ifrs-full_NotLaterThanOneMonthMember_69f69448-fbd5-4444-afce-4bd6861e2c75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_0ab57546-4132-4936-a9bc-d2cbebdd0657" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:to="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_0ab57546-4132-4936-a9bc-d2cbebdd0657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_34575e3c-650a-490b-bb80-42bc7f7eecc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:to="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_34575e3c-650a-490b-bb80-42bc7f7eecc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_3b1d5f6f-2672-4e96-85ea-0609849d986b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:to="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_3b1d5f6f-2672-4e96-85ea-0609849d986b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_870b9e49-cd06-461e-b397-032a6531a1e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:to="loc_ifrs-full_LaterThanOneYearMember_870b9e49-cd06-461e-b397-032a6531a1e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue_c3c6dc44-d540-488f-90e2-cac49e64c7d9" xlink:href="sny-20231231.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_219f2008-c769-40c3-b2a6-4e8a31368701" xlink:to="loc_sny_OverdueReceivablesGrossValue_c3c6dc44-d540-488f-90e2-cac49e64c7d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationOnIncomeStatementLineItems_cbd12861-19ca-4d27-805c-9d860438114c" xlink:href="sny-20231231.xsd#sny_DisclosureOfInformationOnIncomeStatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_bf63c905-badc-4405-947f-53534720a715" xlink:href="sny-20231231.xsd#sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfInformationOnIncomeStatementLineItems_cbd12861-19ca-4d27-805c-9d860438114c" xlink:to="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_bf63c905-badc-4405-947f-53534720a715" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4b62978d-6b6b-4005-a6be-83384c3c2514" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_bf63c905-badc-4405-947f-53534720a715" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4b62978d-6b6b-4005-a6be-83384c3c2514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4b62978d-6b6b-4005-a6be-83384c3c2514_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4b62978d-6b6b-4005-a6be-83384c3c2514" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4b62978d-6b6b-4005-a6be-83384c3c2514_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26e25b8a-ed69-4c6c-971b-9ce222e502fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4b62978d-6b6b-4005-a6be-83384c3c2514" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26e25b8a-ed69-4c6c-971b-9ce222e502fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_df3765e6-2e15-45f5-ada0-1463134aae08" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26e25b8a-ed69-4c6c-971b-9ce222e502fc" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_df3765e6-2e15-45f5-ada0-1463134aae08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_b974e2f6-a077-4181-8cf9-ddef0eb0025c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26e25b8a-ed69-4c6c-971b-9ce222e502fc" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_b974e2f6-a077-4181-8cf9-ddef0eb0025c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_c7324e19-e5d5-450e-b097-5c3dd867e7ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26e25b8a-ed69-4c6c-971b-9ce222e502fc" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_c7324e19-e5d5-450e-b097-5c3dd867e7ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_579a3420-6535-4a7d-bffb-d5c3df5a9b91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_bf63c905-badc-4405-947f-53534720a715" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_579a3420-6535-4a7d-bffb-d5c3df5a9b91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_579a3420-6535-4a7d-bffb-d5c3df5a9b91_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_579a3420-6535-4a7d-bffb-d5c3df5a9b91" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_579a3420-6535-4a7d-bffb-d5c3df5a9b91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_579a3420-6535-4a7d-bffb-d5c3df5a9b91" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedEquityInvestmentsMember_dbd48ea8-828e-4c08-86fb-7398dd06a3c7" xlink:href="sny-20231231.xsd#sny_QuotedEquityInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_QuotedEquityInvestmentsMember_dbd48ea8-828e-4c08-86fb-7398dd06a3c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnquotedEquityInvestmentsMember_29b3d727-94b8-4e46-81d3-7a152349220b" xlink:href="sny-20231231.xsd#sny_UnquotedEquityInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_UnquotedEquityInvestmentsMember_29b3d727-94b8-4e46-81d3-7a152349220b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedDebtSecuritiesMember_417f0c6d-ef52-4ea0-8f0f-7fb2e7a78ca5" xlink:href="sny-20231231.xsd#sny_QuotedDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_QuotedDebtSecuritiesMember_417f0c6d-ef52-4ea0-8f0f-7fb2e7a78ca5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnquotedDebtSecuritiesMember_0224dc01-9a81-4674-b88e-80115a93436c" xlink:href="sny-20231231.xsd#sny_UnquotedDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_UnquotedDebtSecuritiesMember_0224dc01-9a81-4674-b88e-80115a93436c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationRelatingToDivestmentsMember_892cabc9-cf74-4f3e-8bd7-1b6733ba5dbc" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationRelatingToDivestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_ContingentConsiderationRelatingToDivestmentsMember_892cabc9-cf74-4f3e-8bd7-1b6733ba5dbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember_f5e61bcb-ef25-495d-8f4b-1f0c65bebf70" xlink:href="sny-20231231.xsd#sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember_f5e61bcb-ef25-495d-8f4b-1f0c65bebf70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentDerivativesMember_1bbe8cd9-ec19-4e1c-8ed0-ed1abc89bdc3" xlink:href="sny-20231231.xsd#sny_NonCurrentDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_NonCurrentDerivativesMember_1bbe8cd9-ec19-4e1c-8ed0-ed1abc89bdc3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentDerivativesMember_b8edfb68-6dbd-4a0a-8328-d8268708c71e" xlink:href="sny-20231231.xsd#sny_CurrentDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_CurrentDerivativesMember_b8edfb68-6dbd-4a0a-8328-d8268708c71e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MutualFundInvestmentsMember_6a379760-78e9-4e76-87d1-3bfa9cf1e10c" xlink:href="sny-20231231.xsd#sny_MutualFundInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_MutualFundInvestmentsMember_6a379760-78e9-4e76-87d1-3bfa9cf1e10c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_c35a65c4-5e4f-4d0c-ba89-525ea6e6f4ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_bf63c905-badc-4405-947f-53534720a715" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_c35a65c4-5e4f-4d0c-ba89-525ea6e6f4ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_c35a65c4-5e4f-4d0c-ba89-525ea6e6f4ff_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_c35a65c4-5e4f-4d0c-ba89-525ea6e6f4ff" xlink:to="loc_ifrs-full_LiabilitiesMember_c35a65c4-5e4f-4d0c-ba89-525ea6e6f4ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_c35a65c4-5e4f-4d0c-ba89-525ea6e6f4ff" xlink:to="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember_18a61988-15b3-4325-84ba-75884ce22da9" xlink:href="sny-20231231.xsd#sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember_18a61988-15b3-4325-84ba-75884ce22da9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_90250daf-1943-476f-be3d-a6ab0f6f3674" xlink:href="sny-20231231.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_90250daf-1943-476f-be3d-a6ab0f6f3674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationTranslateBioMember_e06adb61-9568-4a6b-afc6-6a82c80613b1" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationTranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_ContingentConsiderationTranslateBioMember_e06adb61-9568-4a6b-afc6-6a82c80613b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember_992c26f6-dbd9-40bb-8767-adfb51c91e2f" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember_992c26f6-dbd9-40bb-8767-adfb51c91e2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember_52cbcaa4-2d9f-4aa0-9d23-a5940883d4b2" xlink:href="sny-20231231.xsd#sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember_52cbcaa4-2d9f-4aa0-9d23-a5940883d4b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentDerivativesMember_88f6079b-1aff-4446-9973-b7e873c767d5" xlink:href="sny-20231231.xsd#sny_NonCurrentDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_NonCurrentDerivativesMember_88f6079b-1aff-4446-9973-b7e873c767d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentDerivativesMember_6b1b771c-8162-4c56-a634-de9cfcb06b3b" xlink:href="sny-20231231.xsd#sny_CurrentDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_CurrentDerivativesMember_6b1b771c-8162-4c56-a634-de9cfcb06b3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_16154276-1bd0-4c5e-9803-dc2eb71381f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInformationOnIncomeStatementLineItems_cbd12861-19ca-4d27-805c-9d860438114c" xlink:to="loc_ifrs-full_FinancialAssets_16154276-1bd0-4c5e-9803-dc2eb71381f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_92d4e5b0-0339-4c96-9275-0b03a47eeb13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInformationOnIncomeStatementLineItems_cbd12861-19ca-4d27-805c-9d860438114c" xlink:to="loc_ifrs-full_FinancialLiabilities_92d4e5b0-0339-4c96-9275-0b03a47eeb13" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dfba40ba-8bb9-4669-bb80-b60b1207dab2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dfba40ba-8bb9-4669-bb80-b60b1207dab2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_61b4a269-15d4-4e43-8e60-3cb653b83662" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dfba40ba-8bb9-4669-bb80-b60b1207dab2" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_61b4a269-15d4-4e43-8e60-3cb653b83662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_61b4a269-15d4-4e43-8e60-3cb653b83662_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_61b4a269-15d4-4e43-8e60-3cb653b83662" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_61b4a269-15d4-4e43-8e60-3cb653b83662_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_61b4a269-15d4-4e43-8e60-3cb653b83662" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember_7a802477-2ded-41da-b4bd-c28b8bc537ae" xlink:href="sny-20231231.xsd#sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember_7a802477-2ded-41da-b4bd-c28b8bc537ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember_1075bfbe-a11b-4586-99b0-5f9ac5af7843" xlink:href="sny-20231231.xsd#sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember_1075bfbe-a11b-4586-99b0-5f9ac5af7843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember_16a07ae1-4a66-406f-b22e-d48ce84acb28" xlink:href="sny-20231231.xsd#sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember_16a07ae1-4a66-406f-b22e-d48ce84acb28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember_577a75c6-7b9d-479e-ab95-94520b000eb6" xlink:href="sny-20231231.xsd#sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember_577a75c6-7b9d-479e-ab95-94520b000eb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember_934c40fb-8e6e-4baf-9256-a143e311b801" xlink:href="sny-20231231.xsd#sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember_934c40fb-8e6e-4baf-9256-a143e311b801" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_973ca4e2-6954-4575-82d2-c4bd7e3c77e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_973ca4e2-6954-4575-82d2-c4bd7e3c77e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionsAndShareBasedPaymentsMember_354ef9d4-1cdc-4527-973c-e2ad7c6c76e1" xlink:href="sny-20231231.xsd#sny_StockOptionsAndShareBasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_StockOptionsAndShareBasedPaymentsMember_354ef9d4-1cdc-4527-973c-e2ad7c6c76e1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember_2add3933-f9c8-4429-ab73-57c584351573" xlink:href="sny-20231231.xsd#sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember_2add3933-f9c8-4429-ab73-57c584351573" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_8c4dace0-e41a-42da-9e37-fa8f3658753c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_8c4dace0-e41a-42da-9e37-fa8f3658753c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DeferredTaxRelatingToRestructuringProvisionsMember_6a947cc5-8e21-47a0-82f0-66632db766d2" xlink:href="sny-20231231.xsd#sny_DeferredTaxRelatingToRestructuringProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_DeferredTaxRelatingToRestructuringProvisionsMember_6a947cc5-8e21-47a0-82f0-66632db766d2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember_4cf94f91-761d-4132-bdd0-645c3beee0bd" xlink:href="sny-20231231.xsd#sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember_4cf94f91-761d-4132-bdd0-645c3beee0bd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1eaafa21-fa70-423a-a87e-56c5488272d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dfba40ba-8bb9-4669-bb80-b60b1207dab2" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1eaafa21-fa70-423a-a87e-56c5488272d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1eaafa21-fa70-423a-a87e-56c5488272d8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1eaafa21-fa70-423a-a87e-56c5488272d8" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1eaafa21-fa70-423a-a87e-56c5488272d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1eaafa21-fa70-423a-a87e-56c5488272d8" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativMember_ed246bef-7978-4302-94a6-a20418bb352b" xlink:href="sny-20231231.xsd#sny_BioverativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_BioverativMember_ed246bef-7978-4302-94a6-a20418bb352b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipiaBiopharmaIncMember_ad3113cc-0ea9-4fd8-83c7-9a92e71e0217" xlink:href="sny-20231231.xsd#sny_PrincipiaBiopharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_PrincipiaBiopharmaIncMember_ad3113cc-0ea9-4fd8-83c7-9a92e71e0217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SynthorxMember_0067a1a8-d766-49a7-96ee-38ec8fc81a9c" xlink:href="sny-20231231.xsd#sny_SynthorxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_SynthorxMember_0067a1a8-d766-49a7-96ee-38ec8fc81a9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeMember_86683552-c1b7-4fc1-b548-62caa8f00bc8" xlink:href="sny-20231231.xsd#sny_GenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_GenzymeMember_86683552-c1b7-4fc1-b548-62caa8f00bc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AblynxMember_0f2489a8-97ec-4850-bc68-27fe54f76764" xlink:href="sny-20231231.xsd#sny_AblynxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_AblynxMember_0f2489a8-97ec-4850-bc68-27fe54f76764" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixMember_c8c4e128-9ab2-4ef6-9097-ab25f5dc7b7f" xlink:href="sny-20231231.xsd#sny_AmunixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_AmunixMember_c8c4e128-9ab2-4ef6-9097-ab25f5dc7b7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_47354b6b-313f-45fb-ac94-a56b47ed6970" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_47354b6b-313f-45fb-ac94-a56b47ed6970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_b0ced0cd-9f42-4b13-86d0-1f329b91ecc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_b0ced0cd-9f42-4b13-86d0-1f329b91ecc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture_315d8092-e05d-4db1-ac84-ef8d48790027" xlink:href="sny-20231231.xsd#sny_ReservesLikelyToBeDistributedInTheForeseeableFuture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:to="loc_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture_315d8092-e05d-4db1-ac84-ef8d48790027" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_50d45d18-8e94-45f9-b14a-dc1e9ac406d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:to="loc_ifrs-full_DeferredTaxAssets_50d45d18-8e94-45f9-b14a-dc1e9ac406d9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems_facd0f4c-2c88-4a29-a2e1-3891f79bbfd8" xlink:href="sny-20231231.xsd#sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable_55f0afcd-080b-412b-ab95-16e56061b596" xlink:href="sny-20231231.xsd#sny_DisclosureOfTaxLossesAvailableForCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems_facd0f4c-2c88-4a29-a2e1-3891f79bbfd8" xlink:to="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable_55f0afcd-080b-412b-ab95-16e56061b596" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_52f60016-ff2a-487b-ba34-79b4a107b735" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable_55f0afcd-080b-412b-ab95-16e56061b596" xlink:to="loc_ifrs-full_MaturityAxis_52f60016-ff2a-487b-ba34-79b4a107b735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_52f60016-ff2a-487b-ba34-79b4a107b735_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_52f60016-ff2a-487b-ba34-79b4a107b735" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_52f60016-ff2a-487b-ba34-79b4a107b735_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_52f60016-ff2a-487b-ba34-79b4a107b735" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_fc987503-38b8-4237-bf89-3889fa67d57a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_fc987503-38b8-4237-bf89-3889fa67d57a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_707362c4-e4d2-48de-a77f-695332d1e192" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_707362c4-e4d2-48de-a77f-695332d1e192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_a7ad3167-fa0a-4943-94c9-32bea844e722" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_a7ad3167-fa0a-4943-94c9-32bea844e722" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_4b6857fb-2a16-4311-a62c-d0428919c3cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_4b6857fb-2a16-4311-a62c-d0428919c3cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_3838cc71-28d8-4094-9400-47d34555422e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_3838cc71-28d8-4094-9400-47d34555422e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_9fe9111c-1de3-4477-948f-9b7a62417afb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_9fe9111c-1de3-4477-948f-9b7a62417afb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxLossesCarryforwards_dd210181-0a0f-4467-afbd-795a5193ed27" xlink:href="sny-20231231.xsd#sny_TaxLossesCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems_facd0f4c-2c88-4a29-a2e1-3891f79bbfd8" xlink:to="loc_sny_TaxLossesCarryforwards_dd210181-0a0f-4467-afbd-795a5193ed27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxLossCarryforwardsOnAssetDisposals_b1930aff-0ccb-4bc6-81e7-39f6f64e14a4" xlink:href="sny-20231231.xsd#sny_TaxLossCarryforwardsOnAssetDisposals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems_facd0f4c-2c88-4a29-a2e1-3891f79bbfd8" xlink:to="loc_sny_TaxLossCarryforwardsOnAssetDisposals_b1930aff-0ccb-4bc6-81e7-39f6f64e14a4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_cc9363fc-29fe-47f2-b7b4-760f9c121410" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_cc9363fc-29fe-47f2-b7b4-760f9c121410" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7f0b4d79-c768-4867-a831-a34d18bcf412" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_cc9363fc-29fe-47f2-b7b4-760f9c121410" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7f0b4d79-c768-4867-a831-a34d18bcf412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_7f0b4d79-c768-4867-a831-a34d18bcf412_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7f0b4d79-c768-4867-a831-a34d18bcf412" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_7f0b4d79-c768-4867-a831-a34d18bcf412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_72a2a314-815b-480f-a3c2-311c7c76ec06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7f0b4d79-c768-4867-a831-a34d18bcf412" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_72a2a314-815b-480f-a3c2-311c7c76ec06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanMember_0f4989aa-53dc-4f22-bc81-a04b0b2f6c0f" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_72a2a314-815b-480f-a3c2-311c7c76ec06" xlink:to="loc_sny_StockSubscriptionOptionPlanMember_0f4989aa-53dc-4f22-bc81-a04b0b2f6c0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateAxis_0f9f944e-85c5-4bea-9797-ea70cf12007a" xlink:href="sny-20231231.xsd#sny_AwardsDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_cc9363fc-29fe-47f2-b7b4-760f9c121410" xlink:to="loc_sny_AwardsDateAxis_0f9f944e-85c5-4bea-9797-ea70cf12007a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateDomain_0f9f944e-85c5-4bea-9797-ea70cf12007a_default" xlink:href="sny-20231231.xsd#sny_AwardsDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_AwardsDateAxis_0f9f944e-85c5-4bea-9797-ea70cf12007a" xlink:to="loc_sny_AwardsDateDomain_0f9f944e-85c5-4bea-9797-ea70cf12007a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateDomain_4be7f9fc-f5ad-4262-9c7c-eeec39a36f57" xlink:href="sny-20231231.xsd#sny_AwardsDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_AwardsDateAxis_0f9f944e-85c5-4bea-9797-ea70cf12007a" xlink:to="loc_sny_AwardsDateDomain_4be7f9fc-f5ad-4262-9c7c-eeec39a36f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_May252023Member_6ca07888-e915-4b1e-a15e-21e6938f98fd" xlink:href="sny-20231231.xsd#sny_May252023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AwardsDateDomain_4be7f9fc-f5ad-4262-9c7c-eeec39a36f57" xlink:to="loc_sny_May252023Member_6ca07888-e915-4b1e-a15e-21e6938f98fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_May32022Member_8688761d-d9dc-4558-8f71-7210c1af6ff9" xlink:href="sny-20231231.xsd#sny_May32022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AwardsDateDomain_4be7f9fc-f5ad-4262-9c7c-eeec39a36f57" xlink:to="loc_sny_May32022Member_8688761d-d9dc-4558-8f71-7210c1af6ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April302021Member_e2490167-3e4a-4806-b506-84fdb46eb8e2" xlink:href="sny-20231231.xsd#sny_April302021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AwardsDateDomain_4be7f9fc-f5ad-4262-9c7c-eeec39a36f57" xlink:to="loc_sny_April302021Member_e2490167-3e4a-4806-b506-84fdb46eb8e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_1a993f64-3f36-4d9e-a610-acda5d34f2d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_ifrs-full_IssuedCapital_1a993f64-3f36-4d9e-a610-acda5d34f2d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_63b8168c-1157-4d7f-9991-f047695f12c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_ifrs-full_NumberOfSharesIssued_63b8168c-1157-4d7f-9991-f047695f12c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_48df5865-ecad-40ba-b274-2a7a01307242" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_ifrs-full_ParValuePerShare_48df5865-ecad-40ba-b274-2a7a01307242" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodOfShareRepurchaseProgram_b07f9976-9ec1-4ba0-adae-900ccead725b" xlink:href="sny-20231231.xsd#sny_PeriodOfShareRepurchaseProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_sny_PeriodOfShareRepurchaseProgram_b07f9976-9ec1-4ba0-adae-900ccead725b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax_a9b94ba3-6b2e-4dd6-adb5-81f1a2003c39" xlink:href="sny-20231231.xsd#sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax_a9b94ba3-6b2e-4dd6-adb5-81f1a2003c39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions_45cc510b-78eb-4be0-8645-1e7e9bf57ae0" xlink:href="sny-20231231.xsd#sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions_45cc510b-78eb-4be0-8645-1e7e9bf57ae0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedByExerciceOfEachOption_ebf685dd-84d7-4258-ba7c-1151a6a199bf" xlink:href="sny-20231231.xsd#sny_NumberOfSharesIssuedByExerciceOfEachOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_sny_NumberOfSharesIssuedByExerciceOfEachOption_ebf685dd-84d7-4258-ba7c-1151a6a199bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionsWithNoDilutiveEffect_71c0aaea-9ca1-4e75-9136-d2aefb83f6ce" xlink:href="sny-20231231.xsd#sny_StockOptionsWithNoDilutiveEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_sny_StockOptionsWithNoDilutiveEffect_71c0aaea-9ca1-4e75-9136-d2aefb83f6ce" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_641c664b-4909-4d82-9f4b-d813f2c33a44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_641c664b-4909-4d82-9f4b-d813f2c33a44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_6402e1b9-ea79-46d0-aab4-3a3a97d10f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_641c664b-4909-4d82-9f4b-d813f2c33a44" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_6402e1b9-ea79-46d0-aab4-3a3a97d10f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_6402e1b9-ea79-46d0-aab4-3a3a97d10f1d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6402e1b9-ea79-46d0-aab4-3a3a97d10f1d" xlink:to="loc_ifrs-full_EquityMember_6402e1b9-ea79-46d0-aab4-3a3a97d10f1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_df6f4920-2710-41ee-8411-36d3804f1006" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6402e1b9-ea79-46d0-aab4-3a3a97d10f1d" xlink:to="loc_ifrs-full_EquityMember_df6f4920-2710-41ee-8411-36d3804f1006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_7951b6bd-e959-4af6-b6a4-2a876e7f42fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_df6f4920-2710-41ee-8411-36d3804f1006" xlink:to="loc_ifrs-full_IssuedCapitalMember_7951b6bd-e959-4af6-b6a4-2a876e7f42fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_724e0829-465a-4907-a656-5e5915a30e15" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_641c664b-4909-4d82-9f4b-d813f2c33a44" xlink:to="loc_dei_LegalEntityAxis_724e0829-465a-4907-a656-5e5915a30e15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_724e0829-465a-4907-a656-5e5915a30e15_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_724e0829-465a-4907-a656-5e5915a30e15" xlink:to="loc_dei_EntityDomain_724e0829-465a-4907-a656-5e5915a30e15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f81dc610-cc74-416b-acd0-7067de02ed3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_724e0829-465a-4907-a656-5e5915a30e15" xlink:to="loc_dei_EntityDomain_f81dc610-cc74-416b-acd0-7067de02ed3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember_6b3b508e-8c30-42dd-a648-814bc4c9bda9" xlink:href="sny-20231231.xsd#sny_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f81dc610-cc74-416b-acd0-7067de02ed3e" xlink:to="loc_sny_SanofiMember_6b3b508e-8c30-42dd-a648-814bc4c9bda9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_24d0a887-63d3-48d4-9d1f-a651fdb2ea37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_ifrs-full_NumberOfSharesIssued_24d0a887-63d3-48d4-9d1f-a651fdb2ea37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_668644c5-e094-4b7b-999f-c4c1932e5dea" xlink:href="sny-20231231.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_668644c5-e094-4b7b-999f-c4c1932e5dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_bf0dd41d-2b22-4d6f-b95a-287921998a44" xlink:href="sny-20231231.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_bf0dd41d-2b22-4d6f-b95a-287921998a44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees_ce0371da-16c0-4903-9364-80cdbe3b3b82" xlink:href="sny-20231231.xsd#sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees_ce0371da-16c0-4903-9364-80cdbe3b3b82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReductionOfSharesByCancellationOfTreasuryShares_1ff2220f-c757-42bb-97a4-2996c43e7273" xlink:href="sny-20231231.xsd#sny_ReductionOfSharesByCancellationOfTreasuryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_sny_ReductionOfSharesByCancellationOfTreasuryShares_1ff2220f-c757-42bb-97a4-2996c43e7273" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_b0b2f256-11a7-4d3f-a84e-a85d3243920b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_9a9aa3e6-b42f-44a8-8348-484315163d86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_9a9aa3e6-b42f-44a8-8348-484315163d86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1452ce22-d22b-41d2-b420-41a481aceb1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_9a9aa3e6-b42f-44a8-8348-484315163d86" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1452ce22-d22b-41d2-b420-41a481aceb1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_1452ce22-d22b-41d2-b420-41a481aceb1d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1452ce22-d22b-41d2-b420-41a481aceb1d" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_1452ce22-d22b-41d2-b420-41a481aceb1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2bec8307-6947-424d-8306-e1d2a9a7c3f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1452ce22-d22b-41d2-b420-41a481aceb1d" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2bec8307-6947-424d-8306-e1d2a9a7c3f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_b6874e0e-90c1-4d81-888e-7192c810383f" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2bec8307-6947-424d-8306-e1d2a9a7c3f6" xlink:to="loc_sny_RestrictedSharePlan2023Member_b6874e0e-90c1-4d81-888e-7192c810383f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member_812c2fe3-ba3c-45df-b781-6415dbec3d2c" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2bec8307-6947-424d-8306-e1d2a9a7c3f6" xlink:to="loc_sny_RestrictedSharePlan2022Member_812c2fe3-ba3c-45df-b781-6415dbec3d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2021Member_cf82e37f-a33e-4680-8c5e-e2648525549c" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2bec8307-6947-424d-8306-e1d2a9a7c3f6" xlink:to="loc_sny_RestrictedSharePlan2021Member_cf82e37f-a33e-4680-8c5e-e2648525549c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1240c0e7-6576-47a6-b11c-e3761eefd123" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_9a9aa3e6-b42f-44a8-8348-484315163d86" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1240c0e7-6576-47a6-b11c-e3761eefd123" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_1240c0e7-6576-47a6-b11c-e3761eefd123_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1240c0e7-6576-47a6-b11c-e3761eefd123" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_1240c0e7-6576-47a6-b11c-e3761eefd123_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_3354ea93-5c7f-4de3-8520-cee21731e325" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1240c0e7-6576-47a6-b11c-e3761eefd123" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_3354ea93-5c7f-4de3-8520-cee21731e325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerformanceSharePlanOneMember_6c913eec-7b07-4de1-b230-fb405234c4a4" xlink:href="sny-20231231.xsd#sny_PerformanceSharePlanOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_3354ea93-5c7f-4de3-8520-cee21731e325" xlink:to="loc_sny_PerformanceSharePlanOneMember_6c913eec-7b07-4de1-b230-fb405234c4a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerformanceSharePlanTwoMember_05f1aa27-6235-4283-9a44-56669169c15d" xlink:href="sny-20231231.xsd#sny_PerformanceSharePlanTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_3354ea93-5c7f-4de3-8520-cee21731e325" xlink:to="loc_sny_PerformanceSharePlanTwoMember_05f1aa27-6235-4283-9a44-56669169c15d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis_675f2250-be72-42b2-b146-1fb1ea8b0ad2" xlink:href="sny-20231231.xsd#sny_MarketConditionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_9a9aa3e6-b42f-44a8-8348-484315163d86" xlink:to="loc_sny_MarketConditionAxis_675f2250-be72-42b2-b146-1fb1ea8b0ad2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_675f2250-be72-42b2-b146-1fb1ea8b0ad2_default" xlink:href="sny-20231231.xsd#sny_MarketConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_MarketConditionAxis_675f2250-be72-42b2-b146-1fb1ea8b0ad2" xlink:to="loc_sny_MarketConditionDomain_675f2250-be72-42b2-b146-1fb1ea8b0ad2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_0b2cb4ed-2a94-4a68-ade1-4414642ec943" xlink:href="sny-20231231.xsd#sny_MarketConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_MarketConditionAxis_675f2250-be72-42b2-b146-1fb1ea8b0ad2" xlink:to="loc_sny_MarketConditionDomain_0b2cb4ed-2a94-4a68-ade1-4414642ec943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember_9f199d26-e314-4a7e-90d7-be374c0c0b76" xlink:href="sny-20231231.xsd#sny_WithoutMarketConditionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_MarketConditionDomain_0b2cb4ed-2a94-4a68-ade1-4414642ec943" xlink:to="loc_sny_WithoutMarketConditionMember_9f199d26-e314-4a7e-90d7-be374c0c0b76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember_2e43b9cd-710e-4ea4-a557-51c6adfcedc0" xlink:href="sny-20231231.xsd#sny_WithMarketConditionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_MarketConditionDomain_0b2cb4ed-2a94-4a68-ade1-4414642ec943" xlink:to="loc_sny_WithMarketConditionMember_2e43b9cd-710e-4ea4-a557-51c6adfcedc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod_a410a6dc-5ae0-4f7a-b4cb-da088438bec8" xlink:href="sny-20231231.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_sny_NumberOfYearsServicePeriod_a410a6dc-5ae0-4f7a-b4cb-da088438bec8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_e3e76f5f-d839-4ba5-9a07-4d735c05a1d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_e3e76f5f-d839-4ba5-9a07-4d735c05a1d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_a5ab7b06-d41f-4fae-8437-c231194c070b" xlink:href="sny-20231231.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_a5ab7b06-d41f-4fae-8437-c231194c070b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares_511d2b4e-bc5b-4f6c-8a1f-52a7d94b1674" xlink:href="sny-20231231.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares_511d2b4e-bc5b-4f6c-8a1f-52a7d94b1674" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer_95fdf6a1-5d1a-4484-80c6-f3faee5ea7dd" xlink:href="sny-20231231.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer_95fdf6a1-5d1a-4484-80c6-f3faee5ea7dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant_6805df77-bb8b-4304-92d9-e7925f29d207" xlink:href="sny-20231231.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_sny_FairValueOfPlanAtDateOfGrant_6805df77-bb8b-4304-92d9-e7925f29d207" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4afaffaa-71cd-46a0-acce-b73bb14bd1dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d39a7185-7edb-4efc-b428-214ffeed37e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4afaffaa-71cd-46a0-acce-b73bb14bd1dd" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d39a7185-7edb-4efc-b428-214ffeed37e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_98ba5370-316d-4c7e-9fc0-b265bb7d9d1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d39a7185-7edb-4efc-b428-214ffeed37e4" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_98ba5370-316d-4c7e-9fc0-b265bb7d9d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_98ba5370-316d-4c7e-9fc0-b265bb7d9d1c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_98ba5370-316d-4c7e-9fc0-b265bb7d9d1c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_98ba5370-316d-4c7e-9fc0-b265bb7d9d1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_4976aae0-34df-4a4c-9f78-ed30b950a8d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_98ba5370-316d-4c7e-9fc0-b265bb7d9d1c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_4976aae0-34df-4a4c-9f78-ed30b950a8d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:href="sny-20231231.xsd#sny_RestrictedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_4976aae0-34df-4a4c-9f78-ed30b950a8d4" xlink:to="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_489a9c05-2413-4f83-aec4-3f7304d1abaf" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:to="loc_sny_RestrictedSharePlan2023Member_489a9c05-2413-4f83-aec4-3f7304d1abaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member_8a0efc88-d4bb-4c98-9abf-2659b8e5eb45" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:to="loc_sny_RestrictedSharePlan2022Member_8a0efc88-d4bb-4c98-9abf-2659b8e5eb45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2021Member_18b71d19-158f-439c-8ca2-c91954d02ff2" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:to="loc_sny_RestrictedSharePlan2021Member_18b71d19-158f-439c-8ca2-c91954d02ff2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2020Member_e9596392-5552-4223-83de-787b11c03fbd" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:to="loc_sny_RestrictedSharePlan2020Member_e9596392-5552-4223-83de-787b11c03fbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2019Member_8593c38e-9501-4a0f-875c-c70f7e350356" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:to="loc_sny_RestrictedSharePlan2019Member_8593c38e-9501-4a0f-875c-c70f7e350356" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis_2b98c3b9-e4e4-476a-8295-0346f9d95161" xlink:href="sny-20231231.xsd#sny_MarketConditionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d39a7185-7edb-4efc-b428-214ffeed37e4" xlink:to="loc_sny_MarketConditionAxis_2b98c3b9-e4e4-476a-8295-0346f9d95161" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_2b98c3b9-e4e4-476a-8295-0346f9d95161_default" xlink:href="sny-20231231.xsd#sny_MarketConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_MarketConditionAxis_2b98c3b9-e4e4-476a-8295-0346f9d95161" xlink:to="loc_sny_MarketConditionDomain_2b98c3b9-e4e4-476a-8295-0346f9d95161_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_5c23f4ae-5982-485d-8148-c7d6d698c082" xlink:href="sny-20231231.xsd#sny_MarketConditionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_MarketConditionAxis_2b98c3b9-e4e4-476a-8295-0346f9d95161" xlink:to="loc_sny_MarketConditionDomain_5c23f4ae-5982-485d-8148-c7d6d698c082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember_67ebfbde-8651-4613-84df-42e562b237b9" xlink:href="sny-20231231.xsd#sny_WithMarketConditionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_MarketConditionDomain_5c23f4ae-5982-485d-8148-c7d6d698c082" xlink:to="loc_sny_WithMarketConditionMember_67ebfbde-8651-4613-84df-42e562b237b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_b238d7e8-dfef-4abe-ad2d-6cac57d35c7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d39a7185-7edb-4efc-b428-214ffeed37e4" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_b238d7e8-dfef-4abe-ad2d-6cac57d35c7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_b238d7e8-dfef-4abe-ad2d-6cac57d35c7a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_b238d7e8-dfef-4abe-ad2d-6cac57d35c7a" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_b238d7e8-dfef-4abe-ad2d-6cac57d35c7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_aec75cf0-da53-4c36-b071-c348fa3a5992" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_b238d7e8-dfef-4abe-ad2d-6cac57d35c7a" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_aec75cf0-da53-4c36-b071-c348fa3a5992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerformanceSharePlanOneMember_a1c525fb-7041-4f43-a6a3-d0edfd9b4ba5" xlink:href="sny-20231231.xsd#sny_PerformanceSharePlanOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_aec75cf0-da53-4c36-b071-c348fa3a5992" xlink:to="loc_sny_PerformanceSharePlanOneMember_a1c525fb-7041-4f43-a6a3-d0edfd9b4ba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_429b0d9a-8286-4323-800e-6f6b09536439" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4afaffaa-71cd-46a0-acce-b73bb14bd1dd" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_429b0d9a-8286-4323-800e-6f6b09536439" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_f76f2bd5-261f-47e3-aedf-29f910ce55c2" xlink:href="sny-20231231.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4afaffaa-71cd-46a0-acce-b73bb14bd1dd" xlink:to="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_f76f2bd5-261f-47e3-aedf-29f910ce55c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_4502dcf5-978b-4007-8d73-a454fd84c078" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4afaffaa-71cd-46a0-acce-b73bb14bd1dd" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_4502dcf5-978b-4007-8d73-a454fd84c078" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e9d96aaf-acb3-4a94-bdde-23feccdab8f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e9d96aaf-acb3-4a94-bdde-23feccdab8f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a4de4a6d-47dc-44fe-952e-f5df575aaa2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e9d96aaf-acb3-4a94-bdde-23feccdab8f8" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a4de4a6d-47dc-44fe-952e-f5df575aaa2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_a4de4a6d-47dc-44fe-952e-f5df575aaa2b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a4de4a6d-47dc-44fe-952e-f5df575aaa2b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_a4de4a6d-47dc-44fe-952e-f5df575aaa2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_9ded9403-6b87-42b1-81b4-de96ee9eadd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a4de4a6d-47dc-44fe-952e-f5df575aaa2b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_9ded9403-6b87-42b1-81b4-de96ee9eadd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeesShareOwnershipPlanMember_fa4245e8-6f03-4a29-852e-e76b9074d080" xlink:href="sny-20231231.xsd#sny_EmployeesShareOwnershipPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_9ded9403-6b87-42b1-81b4-de96ee9eadd8" xlink:to="loc_sny_EmployeesShareOwnershipPlanMember_fa4245e8-6f03-4a29-852e-e76b9074d080" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare_15fdfb76-61e0-434e-ad39-b310ec71edbf" xlink:href="sny-20231231.xsd#sny_SubscriptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:to="loc_sny_SubscriptionPricePerShare_15fdfb76-61e0-434e-ad39-b310ec71edbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareSubscribed_646c65a4-08b4-4ba6-9756-6bf6681c4c3e" xlink:href="sny-20231231.xsd#sny_NumberOfShareSubscribed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:to="loc_sny_NumberOfShareSubscribed_646c65a4-08b4-4ba6-9756-6bf6681c4c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_9544c801-3f0e-4d0c-9642-09abb46c0de8" xlink:href="sny-20231231.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:to="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_9544c801-3f0e-4d0c-9642-09abb46c0de8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAverageOfQuotedMarketPricesOfShares_35c347eb-db9b-4ffb-b6ad-e1a95a0a3354" xlink:href="sny-20231231.xsd#sny_PercentageOfAverageOfQuotedMarketPricesOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:to="loc_sny_PercentageOfAverageOfQuotedMarketPricesOfShares_35c347eb-db9b-4ffb-b6ad-e1a95a0a3354" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTradingDaysPrecedingPlanApproval_70368d63-c969-4e1e-93b3-19fd935a6760" xlink:href="sny-20231231.xsd#sny_NumberOfTradingDaysPrecedingPlanApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:to="loc_sny_NumberOfTradingDaysPrecedingPlanApproval_70368d63-c969-4e1e-93b3-19fd935a6760" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_272572df-a2c5-46d9-a75d-fc797db32ba5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_74a59dde-eaae-4a12-bd50-e9d49a5b9fc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_272572df-a2c5-46d9-a75d-fc797db32ba5" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_74a59dde-eaae-4a12-bd50-e9d49a5b9fc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_864ac8b3-f194-4c76-a75e-4be6cf65c2ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_74a59dde-eaae-4a12-bd50-e9d49a5b9fc6" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_864ac8b3-f194-4c76-a75e-4be6cf65c2ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_864ac8b3-f194-4c76-a75e-4be6cf65c2ba_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_864ac8b3-f194-4c76-a75e-4be6cf65c2ba" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_864ac8b3-f194-4c76-a75e-4be6cf65c2ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_d87d6f3e-c03a-48b3-a51e-f74e141bcb40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_864ac8b3-f194-4c76-a75e-4be6cf65c2ba" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_d87d6f3e-c03a-48b3-a51e-f74e141bcb40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeesShareOwnershipPlanMember_50fedabc-569d-4554-99d7-579fbd571681" xlink:href="sny-20231231.xsd#sny_EmployeesShareOwnershipPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d87d6f3e-c03a-48b3-a51e-f74e141bcb40" xlink:to="loc_sny_EmployeesShareOwnershipPlanMember_50fedabc-569d-4554-99d7-579fbd571681" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a8b7ee46-9a13-4997-92fb-81f165d645de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_272572df-a2c5-46d9-a75d-fc797db32ba5" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a8b7ee46-9a13-4997-92fb-81f165d645de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution_a14a6a0b-7629-49db-8d5f-e4917338a3fd" xlink:href="sny-20231231.xsd#sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_272572df-a2c5-46d9-a75d-fc797db32ba5" xlink:to="loc_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution_a14a6a0b-7629-49db-8d5f-e4917338a3fd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8d6ef13c-b141-444b-bd4a-5c1d326482ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6433f5b1-f082-4e73-ba6c-9294fd2de1e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8d6ef13c-b141-444b-bd4a-5c1d326482ea" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6433f5b1-f082-4e73-ba6c-9294fd2de1e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateAxis_0a031048-3998-469d-bdcb-9c1fdeac0c3f" xlink:href="sny-20231231.xsd#sny_AwardsDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6433f5b1-f082-4e73-ba6c-9294fd2de1e7" xlink:to="loc_sny_AwardsDateAxis_0a031048-3998-469d-bdcb-9c1fdeac0c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateDomain_0a031048-3998-469d-bdcb-9c1fdeac0c3f_default" xlink:href="sny-20231231.xsd#sny_AwardsDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_AwardsDateAxis_0a031048-3998-469d-bdcb-9c1fdeac0c3f" xlink:to="loc_sny_AwardsDateDomain_0a031048-3998-469d-bdcb-9c1fdeac0c3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:href="sny-20231231.xsd#sny_AwardsDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_AwardsDateAxis_0a031048-3998-469d-bdcb-9c1fdeac0c3f" xlink:to="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2023ProgramMember_dff6fe6f-738e-4d08-a83c-65a002b10a22" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2023ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:to="loc_sny_ShareRepurchase2023ProgramMember_dff6fe6f-738e-4d08-a83c-65a002b10a22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2022ProgramMember_e2e54ece-52f1-4720-96de-a20b0d853d1e" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2022ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:to="loc_sny_ShareRepurchase2022ProgramMember_e2e54ece-52f1-4720-96de-a20b0d853d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2021ProgramMember_7f6ac938-9d37-47a1-8a1e-efcc9e3bec89" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2021ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:to="loc_sny_ShareRepurchase2021ProgramMember_7f6ac938-9d37-47a1-8a1e-efcc9e3bec89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2020ProgramMember_3349357d-a67e-4cc8-8668-d52152ab1d16" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2020ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:to="loc_sny_ShareRepurchase2020ProgramMember_3349357d-a67e-4cc8-8668-d52152ab1d16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased_0db7c709-9562-4a60-8a44-b63d6d9e6ed7" xlink:href="sny-20231231.xsd#sny_NumberOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8d6ef13c-b141-444b-bd4a-5c1d326482ea" xlink:to="loc_sny_NumberOfSharesRepurchased_0db7c709-9562-4a60-8a44-b63d6d9e6ed7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountOfSharesRepurchased_8ad58f8c-a877-47eb-9308-7410ae8aa7de" xlink:href="sny-20231231.xsd#sny_AmountOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8d6ef13c-b141-444b-bd4a-5c1d326482ea" xlink:to="loc_sny_AmountOfSharesRepurchased_8ad58f8c-a877-47eb-9308-7410ae8aa7de" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9888ff19-b6be-437f-9c8f-d04a2985ed63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e317b4f1-e188-413d-a85c-2f9c755a2917" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9888ff19-b6be-437f-9c8f-d04a2985ed63" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e317b4f1-e188-413d-a85c-2f9c755a2917" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_cbf44912-e49a-40cd-978c-efc63c48c1ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e317b4f1-e188-413d-a85c-2f9c755a2917" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_cbf44912-e49a-40cd-978c-efc63c48c1ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_cbf44912-e49a-40cd-978c-efc63c48c1ef_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_cbf44912-e49a-40cd-978c-efc63c48c1ef" xlink:to="loc_ifrs-full_EquityMember_cbf44912-e49a-40cd-978c-efc63c48c1ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_043e4184-596b-4d11-907c-fbfa0644908d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_cbf44912-e49a-40cd-978c-efc63c48c1ef" xlink:to="loc_ifrs-full_EquityMember_043e4184-596b-4d11-907c-fbfa0644908d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_fa2f3a76-eee9-45d0-8b07-b2611079bb8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_043e4184-596b-4d11-907c-fbfa0644908d" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_fa2f3a76-eee9-45d0-8b07-b2611079bb8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_af980524-6c82-426f-8996-d2473e7144fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9888ff19-b6be-437f-9c8f-d04a2985ed63" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_af980524-6c82-426f-8996-d2473e7144fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests_73058556-d4a0-4775-b5a0-e1ecac3ea7c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9888ff19-b6be-437f-9c8f-d04a2985ed63" xlink:to="loc_ifrs-full_NoncontrollingInterests_73058556-d4a0-4775-b5a0-e1ecac3ea7c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_7d9bcac8-3310-45b7-8e50-9d088fa5e3a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9888ff19-b6be-437f-9c8f-d04a2985ed63" xlink:to="loc_ifrs-full_Equity_7d9bcac8-3310-45b7-8e50-9d088fa5e3a7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1ce21823-5a83-4fb2-9ed2-a0c919f2cf61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1ce21823-5a83-4fb2-9ed2-a0c919f2cf61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_1ce21823-5a83-4fb2-9ed2-a0c919f2cf61_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1ce21823-5a83-4fb2-9ed2-a0c919f2cf61" xlink:to="loc_ifrs-full_EquityMember_1ce21823-5a83-4fb2-9ed2-a0c919f2cf61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_ebbffbdf-111a-4fdd-897f-d4d1e4fda1f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1ce21823-5a83-4fb2-9ed2-a0c919f2cf61" xlink:to="loc_ifrs-full_EquityMember_ebbffbdf-111a-4fdd-897f-d4d1e4fda1f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_841805d8-0e54-48fb-bde8-6bf81c5789be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_ebbffbdf-111a-4fdd-897f-d4d1e4fda1f7" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_841805d8-0e54-48fb-bde8-6bf81c5789be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_4339477d-748c-4b18-ad72-56ea14155a98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_4339477d-748c-4b18-ad72-56ea14155a98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsMember_4339477d-748c-4b18-ad72-56ea14155a98_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_4339477d-748c-4b18-ad72-56ea14155a98" xlink:to="loc_ifrs-full_ReclassifiedItemsMember_4339477d-748c-4b18-ad72-56ea14155a98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsMember_158498b3-be8f-468f-8091-dad3d3aabd8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_4339477d-748c-4b18-ad72-56ea14155a98" xlink:to="loc_ifrs-full_ReclassifiedItemsMember_158498b3-be8f-468f-8091-dad3d3aabd8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_bd909701-6dd8-4321-b5a7-2289ae46731c" xlink:href="sny-20231231.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReclassifiedItemsMember_158498b3-be8f-468f-8091-dad3d3aabd8c" xlink:to="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_bd909701-6dd8-4321-b5a7-2289ae46731c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_0dd02f80-684a-4404-a3bc-f3f9f8d5e81d" xlink:href="sny-20231231.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReclassifiedItemsMember_158498b3-be8f-468f-8091-dad3d3aabd8c" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_0dd02f80-684a-4404-a3bc-f3f9f8d5e81d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f6fed796-5caa-4bf7-8a17-ab9cc76787b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f6fed796-5caa-4bf7-8a17-ab9cc76787b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_f6fed796-5caa-4bf7-8a17-ab9cc76787b2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f6fed796-5caa-4bf7-8a17-ab9cc76787b2" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_f6fed796-5caa-4bf7-8a17-ab9cc76787b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_9f5e809f-bbc3-4793-8047-0f52d483f8e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f6fed796-5caa-4bf7-8a17-ab9cc76787b2" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_9f5e809f-bbc3-4793-8047-0f52d483f8e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_b22e31b4-197e-40be-b664-d7a271acf195" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_9f5e809f-bbc3-4793-8047-0f52d483f8e8" xlink:to="loc_sny_EuroapiMember_b22e31b4-197e-40be-b664-d7a271acf195" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_3013393e-3f22-44a5-a5d9-33b0df168a61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_3013393e-3f22-44a5-a5d9-33b0df168a61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_3013393e-3f22-44a5-a5d9-33b0df168a61_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_3013393e-3f22-44a5-a5d9-33b0df168a61" xlink:to="loc_ifrs-full_FinancialAssetsMember_3013393e-3f22-44a5-a5d9-33b0df168a61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_3013393e-3f22-44a5-a5d9-33b0df168a61" xlink:to="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetMember_f5c47a12-a978-49f9-a438-5ec398dd03c2" xlink:href="sny-20231231.xsd#sny_EquityInstrumentsIncludedInFinancialAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:to="loc_sny_EquityInstrumentsIncludedInFinancialAssetMember_f5c47a12-a978-49f9-a438-5ec398dd03c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_460256f9-3e2f-4d42-a717-1dca75bc9931" xlink:href="sny-20231231.xsd#sny_DebtInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:to="loc_sny_DebtInstrumentsMember_460256f9-3e2f-4d42-a717-1dca75bc9931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_798428a4-be0d-4c26-91c6-61edee1238a5" xlink:href="sny-20231231.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_798428a4-be0d-4c26-91c6-61edee1238a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_d81d396e-a3c0-4a37-b7a2-9a759e053f2f" xlink:href="sny-20231231.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:to="loc_sny_ForeignCurrencyTranslationMember_d81d396e-a3c0-4a37-b7a2-9a759e053f2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_f1edd936-40c4-4d47-abd7-68c25c6c3984" xlink:href="sny-20231231.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_f1edd936-40c4-4d47-abd7-68c25c6c3984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_040f7195-b82d-4ccf-9cea-bc102b3770b5" xlink:href="sny-20231231.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_040f7195-b82d-4ccf-9cea-bc102b3770b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_f527a22d-f0a3-4c62-a76c-11dc3223d747" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_f527a22d-f0a3-4c62-a76c-11dc3223d747" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_49d2ff29-48cf-46e9-b7d3-25a0fbb8a616" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_49d2ff29-48cf-46e9-b7d3-25a0fbb8a616" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_c0b10786-c15b-46e2-8f05-db6dab3f0eb8" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_c0b10786-c15b-46e2-8f05-db6dab3f0eb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_2991c693-7cb2-4646-b124-dd61bd111812" xlink:href="sny-20231231.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_2991c693-7cb2-4646-b124-dd61bd111812" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_c7fb70ab-c2d5-49a0-849d-9cf19a284c14" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_c7fb70ab-c2d5-49a0-849d-9cf19a284c14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_4c507ecc-25af-4cb4-b902-540828796fbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_4c507ecc-25af-4cb4-b902-540828796fbb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_dffb19bb-11f1-4d1b-b03b-887c3be92263" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_dffb19bb-11f1-4d1b-b03b-887c3be92263" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures_8ad8154f-0520-4a37-a770-fbbb580382ff" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures_8ad8154f-0520-4a37-a770-fbbb580382ff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_ba57c234-8b8d-4d56-acc7-6e67d8e57742" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_ba57c234-8b8d-4d56-acc7-6e67d8e57742" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_9f2dd6e8-aebb-4d7c-8e60-9a381d247c14" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_9f2dd6e8-aebb-4d7c-8e60-9a381d247c14" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_63cf897f-a100-4fb7-a350-fcfbb9c3cc06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_63cf897f-a100-4fb7-a350-fcfbb9c3cc06" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_1a0ce096-7699-4b1d-ad14-8075ef845999" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_1a0ce096-7699-4b1d-ad14-8075ef845999" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_e52d747f-5ab1-4827-8e44-d802a6e7624c" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_e52d747f-5ab1-4827-8e44-d802a6e7624c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_1a4e86a0-239f-4ae4-b0d6-d20cd2654b39" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_1a4e86a0-239f-4ae4-b0d6-d20cd2654b39" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_c317c135-7120-43f3-887f-b89cd8b7176a" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_c317c135-7120-43f3-887f-b89cd8b7176a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_491ca491-d73e-4027-a9f1-65bc8b4205e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_491ca491-d73e-4027-a9f1-65bc8b4205e9" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_88757ed2-e10c-4cdd-b18b-3f82b757c868" xlink:href="sny-20231231.xsd#sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable_a2e2a8da-17fe-491f-9bea-ff0a217f2921" xlink:href="sny-20231231.xsd#sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_88757ed2-e10c-4cdd-b18b-3f82b757c868" xlink:to="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable_a2e2a8da-17fe-491f-9bea-ff0a217f2921" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_255e94f5-1d36-46ea-917a-a304baae47e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable_a2e2a8da-17fe-491f-9bea-ff0a217f2921" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_255e94f5-1d36-46ea-917a-a304baae47e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_255e94f5-1d36-46ea-917a-a304baae47e9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_255e94f5-1d36-46ea-917a-a304baae47e9" xlink:to="loc_ifrs-full_EquityMember_255e94f5-1d36-46ea-917a-a304baae47e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_dc8edc12-fb85-47f3-b87c-3508459c09e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_255e94f5-1d36-46ea-917a-a304baae47e9" xlink:to="loc_ifrs-full_EquityMember_dc8edc12-fb85-47f3-b87c-3508459c09e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_dc8edc12-fb85-47f3-b87c-3508459c09e6" xlink:to="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanThreeMember_c0951423-3dc7-43be-8cd2-ca7c7d84fb7e" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanThreeMember_c0951423-3dc7-43be-8cd2-ca7c7d84fb7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanFourMember_dd435c63-8853-41e4-b547-8668eff2d3bf" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanFourMember_dd435c63-8853-41e4-b547-8668eff2d3bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanFiveMember_d7308cf9-15a8-4388-b0d0-f3300c2c4c4c" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanFiveMember_d7308cf9-15a8-4388-b0d0-f3300c2c4c4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanSixMember_5f9800c3-1363-4ba3-b4a2-877df23cf39b" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanSixMember_5f9800c3-1363-4ba3-b4a2-877df23cf39b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanSevenMember_c2f48e55-fe2e-42f9-b60e-382248762661" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanSevenMember_c2f48e55-fe2e-42f9-b60e-382248762661" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanEightMember_220d8ce1-e891-47d6-b814-bf682f684a85" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanEightMember_220d8ce1-e891-47d6-b814-bf682f684a85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanNineMember_2d80a875-21f6-457c-979d-ea234a329779" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanNineMember_2d80a875-21f6-457c-979d-ea234a329779" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanTenMember_d9db98e1-0fcb-4943-9f85-157b15f9fd21" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanTenMember_d9db98e1-0fcb-4943-9f85-157b15f9fd21" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_35f43ef9-c459-43b9-be2c-c66b51c7551d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_88757ed2-e10c-4cdd-b18b-3f82b757c868" xlink:to="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_35f43ef9-c459-43b9-be2c-c66b51c7551d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockBasedCompensationStockOptionsExercisedPricePerShare_c24789da-9ec0-428b-9f23-8979e4462be7" xlink:href="sny-20231231.xsd#sny_StockBasedCompensationStockOptionsExercisedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_88757ed2-e10c-4cdd-b18b-3f82b757c868" xlink:to="loc_sny_StockBasedCompensationStockOptionsExercisedPricePerShare_c24789da-9ec0-428b-9f23-8979e4462be7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_bab09ac5-c773-4458-ae22-45f4f2d79233" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_88757ed2-e10c-4cdd-b18b-3f82b757c868" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_bab09ac5-c773-4458-ae22-45f4f2d79233" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_27cd8772-406e-48ee-a5ec-7940532da9ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_27cd8772-406e-48ee-a5ec-7940532da9ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_69f75679-9017-456a-9da0-25cb5a2f2b3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_27cd8772-406e-48ee-a5ec-7940532da9ed" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_69f75679-9017-456a-9da0-25cb5a2f2b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_69f75679-9017-456a-9da0-25cb5a2f2b3a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_69f75679-9017-456a-9da0-25cb5a2f2b3a" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_69f75679-9017-456a-9da0-25cb5a2f2b3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a39a107-4cb7-41d0-9b50-48c42ece855a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_69f75679-9017-456a-9da0-25cb5a2f2b3a" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a39a107-4cb7-41d0-9b50-48c42ece855a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalStockOptionPlansMember_f244b9a1-a2c4-4f50-9fd6-2e5d52f8d150" xlink:href="sny-20231231.xsd#sny_TotalStockOptionPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a39a107-4cb7-41d0-9b50-48c42ece855a" xlink:to="loc_sny_TotalStockOptionPlansMember_f244b9a1-a2c4-4f50-9fd6-2e5d52f8d150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement_7876134f-ac2b-47f3-b2e0-39268ea11956" xlink:href="sny-20231231.xsd#sny_NumberOfShareOutstandingInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement_7876134f-ac2b-47f3-b2e0-39268ea11956" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_8b469ccf-695d-485f-b5ed-7f216eda68e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_8b469ccf-695d-485f-b5ed-7f216eda68e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_24006c06-fb58-460a-b2f9-bce6e2bcea9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_24006c06-fb58-460a-b2f9-bce6e2bcea9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_f3c13a92-ec26-4ec0-85de-fea1ae467e1b" xlink:href="sny-20231231.xsd#sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_f3c13a92-ec26-4ec0-85de-fea1ae467e1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_bc183da5-035d-4dca-b690-f3473dc8d2ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_bc183da5-035d-4dca-b690-f3473dc8d2ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement_9b72abcc-f217-4757-9c5f-6f3fd836cf93" xlink:href="sny-20231231.xsd#sny_NumberOfShareOutstandingInShareBasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_5104cc93-ba2c-4b48-ba6e-0fbd68c9397b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_5104cc93-ba2c-4b48-ba6e-0fbd68c9397b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_6798239f-0214-45af-a75b-8dbb3529909e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_6798239f-0214-45af-a75b-8dbb3529909e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_e444008d-1e76-429d-8709-c33ce1710988" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_e444008d-1e76-429d-8709-c33ce1710988" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement_ce5f965b-f10d-4ddd-b260-e8b94ba8b83b" xlink:href="sny-20231231.xsd#sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement_ce5f965b-f10d-4ddd-b260-e8b94ba8b83b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_b647a1ef-2b50-4db0-bdd2-c93d5bf4418b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_b647a1ef-2b50-4db0-bdd2-c93d5bf4418b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3f4cccf7-e4ef-40ce-aa99-a85e9ba0e813" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement_5f68d36c-2214-48cb-9fd9-093a620b89af" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement_5f68d36c-2214-48cb-9fd9-093a620b89af" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement_7ba8fab7-8f51-470b-9ab6-0791abd293d5" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement_7ba8fab7-8f51-470b-9ab6-0791abd293d5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement_5afc2828-f7f1-45fa-8d62-32c42ec1485a" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement_5afc2828-f7f1-45fa-8d62-32c42ec1485a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement_0caba838-f523-4838-b7a8-43a71d93abf4" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement_0caba838-f523-4838-b7a8-43a71d93abf4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement_3adabe4b-8d3c-46ac-881e-ddaa028beec2" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement_3adabe4b-8d3c-46ac-881e-ddaa028beec2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement_59ba15db-96ef-4c28-bf85-0ed246cd75d3" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2ac0df50-124e-4c9b-b6cf-556a314324a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2ac0df50-124e-4c9b-b6cf-556a314324a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_4ae283a5-3672-45d7-82a5-d6f005be5d7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2ac0df50-124e-4c9b-b6cf-556a314324a6" xlink:to="loc_ifrs-full_RangeAxis_4ae283a5-3672-45d7-82a5-d6f005be5d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_4ae283a5-3672-45d7-82a5-d6f005be5d7b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_4ae283a5-3672-45d7-82a5-d6f005be5d7b" xlink:to="loc_ifrs-full_RangesMember_4ae283a5-3672-45d7-82a5-d6f005be5d7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_1b8479b4-4df1-40fb-8459-ead25f9b201a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_4ae283a5-3672-45d7-82a5-d6f005be5d7b" xlink:to="loc_ifrs-full_RangesMember_1b8479b4-4df1-40fb-8459-ead25f9b201a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_4402b974-19d2-4448-977a-9c6a1b61bea8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_1b8479b4-4df1-40fb-8459-ead25f9b201a" xlink:to="loc_ifrs-full_BottomOfRangeMember_4402b974-19d2-4448-977a-9c6a1b61bea8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_e687f060-7d61-4495-8caf-e75df82bb0a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_1b8479b4-4df1-40fb-8459-ead25f9b201a" xlink:to="loc_ifrs-full_TopOfRangeMember_e687f060-7d61-4495-8caf-e75df82bb0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_843c1218-d1f7-4db7-850a-cb63f28a586e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2ac0df50-124e-4c9b-b6cf-556a314324a6" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_843c1218-d1f7-4db7-850a-cb63f28a586e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_843c1218-d1f7-4db7-850a-cb63f28a586e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_843c1218-d1f7-4db7-850a-cb63f28a586e" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_843c1218-d1f7-4db7-850a-cb63f28a586e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_c948729f-a7ec-4f57-9dc6-c0f4e952caac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_843c1218-d1f7-4db7-850a-cb63f28a586e" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_c948729f-a7ec-4f57-9dc6-c0f4e952caac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember_82480155-ef57-4935-a9dc-06a752e6c137" xlink:href="sny-20231231.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_c948729f-a7ec-4f57-9dc6-c0f4e952caac" xlink:to="loc_sny_ExercisePriceRangeTwoMember_82480155-ef57-4935-a9dc-06a752e6c137" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember_f4282a34-af49-4930-bc3b-68e8f5580c22" xlink:href="sny-20231231.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_c948729f-a7ec-4f57-9dc6-c0f4e952caac" xlink:to="loc_sny_ExercisePriceRangeThreeMember_f4282a34-af49-4930-bc3b-68e8f5580c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember_12594b07-5048-438e-9623-843c7b6fecf9" xlink:href="sny-20231231.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_c948729f-a7ec-4f57-9dc6-c0f4e952caac" xlink:to="loc_sny_ExercisePriceRangeFourMember_12594b07-5048-438e-9623-843c7b6fecf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_fa53a27e-3276-48db-8517-83527644351e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2ac0df50-124e-4c9b-b6cf-556a314324a6" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_fa53a27e-3276-48db-8517-83527644351e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_fa53a27e-3276-48db-8517-83527644351e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_fa53a27e-3276-48db-8517-83527644351e" xlink:to="loc_ifrs-full_EquityMember_fa53a27e-3276-48db-8517-83527644351e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_146d8065-1c1c-4730-8835-ddb622dd5529" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_fa53a27e-3276-48db-8517-83527644351e" xlink:to="loc_ifrs-full_EquityMember_146d8065-1c1c-4730-8835-ddb622dd5529" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember_93c64f26-a579-4a7f-8a26-1dac07d459dc" xlink:href="sny-20231231.xsd#sny_StockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_146d8065-1c1c-4730-8835-ddb622dd5529" xlink:to="loc_sny_StockOptionPlanMember_93c64f26-a579-4a7f-8a26-1dac07d459dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_097f22fc-a12c-4287-85d0-e66ac3a9f255" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_097f22fc-a12c-4287-85d0-e66ac3a9f255" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_8ea61661-ba13-442c-a467-34156d05419f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_8ea61661-ba13-442c-a467-34156d05419f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dd398e28-9c2b-4f7c-aedc-47843d4c16b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dd398e28-9c2b-4f7c-aedc-47843d4c16b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_33f6e885-da5e-4b89-99c8-cf22247ffa53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_33f6e885-da5e-4b89-99c8-cf22247ffa53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_0343475d-7d6c-4802-b00a-6a11014e20fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_0343475d-7d6c-4802-b00a-6a11014e20fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_1f8e3d0f-9245-4977-b974-4b4cf7cb283a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_1f8e3d0f-9245-4977-b974-4b4cf7cb283a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_f2771df6-2a4f-4ec3-88d7-7e0b5a1f22c1" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_f2771df6-2a4f-4ec3-88d7-7e0b5a1f22c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_7232f18d-f7b8-4983-b83f-f7fe7e551a11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_f2771df6-2a4f-4ec3-88d7-7e0b5a1f22c1" xlink:to="loc_ifrs-full_MeasurementAxis_7232f18d-f7b8-4983-b83f-f7fe7e551a11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_7232f18d-f7b8-4983-b83f-f7fe7e551a11_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_7232f18d-f7b8-4983-b83f-f7fe7e551a11" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_7232f18d-f7b8-4983-b83f-f7fe7e551a11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_7d529ffb-8aeb-4347-9ee6-469e33f1d653" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_7232f18d-f7b8-4983-b83f-f7fe7e551a11" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_7d529ffb-8aeb-4347-9ee6-469e33f1d653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostMember_eb8efca9-50fe-425f-873f-836aae4eb81a" xlink:href="sny-20231231.xsd#sny_AmortizedCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d529ffb-8aeb-4347-9ee6-469e33f1d653" xlink:to="loc_sny_AmortizedCostMember_eb8efca9-50fe-425f-873f-836aae4eb81a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_f34fbb78-160d-4d26-8aea-eda2f2ecc7b3" xlink:href="sny-20231231.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d529ffb-8aeb-4347-9ee6-469e33f1d653" xlink:to="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_f34fbb78-160d-4d26-8aea-eda2f2ecc7b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_aaa0d9ea-32c6-4a71-9c8e-3b2bcf3f805e" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d529ffb-8aeb-4347-9ee6-469e33f1d653" xlink:to="loc_sny_ValueOnRedemptionMember_aaa0d9ea-32c6-4a71-9c8e-3b2bcf3f805e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_bdc8eb2a-bcc9-4943-9ead-5e84739df49e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_ifrs-full_LongtermBorrowings_bdc8eb2a-bcc9-4943-9ead-5e84739df49e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_bdc75cdf-b31e-4c6f-8492-beda7dda0aea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_bdc75cdf-b31e-4c6f-8492-beda7dda0aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_676d29a8-e8e4-40e0-9393-e5a5ae56068a" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_676d29a8-e8e4-40e0-9393-e5a5ae56068a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_a4e8d9c2-b7f7-4956-b911-a60ec4d12e9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_ifrs-full_Borrowings_a4e8d9c2-b7f7-4956-b911-a60ec4d12e9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_ab4e44e3-3b0a-4d7e-a71e-90333306d146" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_ifrs-full_CashAndCashEquivalents_ab4e44e3-3b0a-4d7e-a71e-90333306d146" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_57a25296-d180-4792-bde5-823dc143f546" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_57a25296-d180-4792-bde5-823dc143f546" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_744f44d5-afc5-4270-a66f-82600865796b" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_744f44d5-afc5-4270-a66f-82600865796b" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtTable_1691831f-df6f-4789-9968-5f4db472aa37" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_sny_DisclosureOfDebtTable_1691831f-df6f-4789-9968-5f4db472aa37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_628fb555-244c-43cb-98c9-7c473b9f50da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfDebtTable_1691831f-df6f-4789-9968-5f4db472aa37" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_628fb555-244c-43cb-98c9-7c473b9f50da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_628fb555-244c-43cb-98c9-7c473b9f50da_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_628fb555-244c-43cb-98c9-7c473b9f50da" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_628fb555-244c-43cb-98c9-7c473b9f50da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_c4592645-1b94-43e4-9227-736b626b4d85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_628fb555-244c-43cb-98c9-7c473b9f50da" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_c4592645-1b94-43e4-9227-736b626b4d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_f6b943da-a60d-4dc1-bc0c-016d4731819c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_c4592645-1b94-43e4-9227-736b626b4d85" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_f6b943da-a60d-4dc1-bc0c-016d4731819c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember_05027eca-e89f-4143-bf58-56e07a9dd265" xlink:href="sny-20231231.xsd#sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_c4592645-1b94-43e4-9227-736b626b4d85" xlink:to="loc_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember_05027eca-e89f-4143-bf58-56e07a9dd265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember_6273b138-569a-4128-9fbf-5483528600f3" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_c4592645-1b94-43e4-9227-736b626b4d85" xlink:to="loc_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember_6273b138-569a-4128-9fbf-5483528600f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_669f022d-a351-4884-a694-e534582d1e5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfDebtTable_1691831f-df6f-4789-9968-5f4db472aa37" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_669f022d-a351-4884-a694-e534582d1e5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_669f022d-a351-4884-a694-e534582d1e5a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_669f022d-a351-4884-a694-e534582d1e5a" xlink:to="loc_ifrs-full_BorrowingsByNameMember_669f022d-a351-4884-a694-e534582d1e5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_10e353b7-420a-42db-a434-01e46fa10d91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_669f022d-a351-4884-a694-e534582d1e5a" xlink:to="loc_ifrs-full_BorrowingsByNameMember_10e353b7-420a-42db-a434-01e46fa10d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_2227807a-505c-412a-9294-4e06695bbbe7" xlink:href="sny-20231231.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_10e353b7-420a-42db-a434-01e46fa10d91" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_2227807a-505c-412a-9294-4e06695bbbe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_226e98f9-d1b6-4c44-9a6a-b03c326976e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_ifrs-full_Borrowings_226e98f9-d1b6-4c44-9a6a-b03c326976e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_72ba9d60-7c04-41aa-8a1b-e3da65be50d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_72ba9d60-7c04-41aa-8a1b-e3da65be50d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_9d43ab31-68bd-4c91-8008-b7e65eadd369" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_9d43ab31-68bd-4c91-8008-b7e65eadd369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_5b7bb648-57be-4de8-a9b6-562284f09d32" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_5b7bb648-57be-4de8-a9b6-562284f09d32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationDifferences_f7698de1-b324-4a07-abeb-acef8a32bac6" xlink:href="sny-20231231.xsd#sny_ForeignCurrencyTranslationDifferences"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_sny_ForeignCurrencyTranslationDifferences_f7698de1-b324-4a07-abeb-acef8a32bac6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReclassificationFromNonCurrentToCurrent_eccad586-e779-4d84-8e65-30ee1e382f78" xlink:href="sny-20231231.xsd#sny_ReclassificationFromNonCurrentToCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_sny_ReclassificationFromNonCurrentToCurrent_eccad586-e779-4d84-8e65-30ee1e382f78" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_4155fca8-8366-4cba-8331-9109d28a9ca6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_4155fca8-8366-4cba-8331-9109d28a9ca6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_2ac5bd8b-ebf4-4851-a771-05489cc39331" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_b7786614-963c-40b5-91ea-cab897048457" xlink:href="sny-20231231.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_b7786614-963c-40b5-91ea-cab897048457" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings_4d9d3edb-9c68-4f3f-860a-b0ae15c285fe" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings_4d9d3edb-9c68-4f3f-860a-b0ae15c285fe" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5e43faa0-6063-47a3-8531-da8fcfcb56f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5e43faa0-6063-47a3-8531-da8fcfcb56f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_dec7ed3a-3996-467d-9185-1a7312567b19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5e43faa0-6063-47a3-8531-da8fcfcb56f5" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_dec7ed3a-3996-467d-9185-1a7312567b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_dec7ed3a-3996-467d-9185-1a7312567b19_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_dec7ed3a-3996-467d-9185-1a7312567b19" xlink:to="loc_ifrs-full_BorrowingsByNameMember_dec7ed3a-3996-467d-9185-1a7312567b19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_dec7ed3a-3996-467d-9185-1a7312567b19" xlink:to="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_f783167d-4b00-4430-800e-3fa3d2b1eca1" xlink:href="sny-20231231.xsd#sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_f783167d-4b00-4430-800e-3fa3d2b1eca1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingJune2023Member_d44e77af-6a55-4680-abfb-9329715d1947" xlink:href="sny-20231231.xsd#sny_OneBillionBondsMaturingJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_OneBillionBondsMaturingJune2023Member_d44e77af-6a55-4680-abfb-9329715d1947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingNovember2023Member_101c13d4-26cf-4d74-ae2b-438517154109" xlink:href="sny-20231231.xsd#sny_OneBillionBondsMaturingNovember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_OneBillionBondsMaturingNovember2023Member_101c13d4-26cf-4d74-ae2b-438517154109" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingMarch2029Member_b9f81b4c-50a3-4130-a4fd-0998dab8912c" xlink:href="sny-20231231.xsd#sny_FourBillionFacilityMaturingMarch2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_FourBillionFacilityMaturingMarch2029Member_b9f81b4c-50a3-4130-a4fd-0998dab8912c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityCanceledMember_6cb91c53-2021-40eb-a1b1-3344d9597497" xlink:href="sny-20231231.xsd#sny_SyndicatedCreditFacilityCanceledMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_SyndicatedCreditFacilityCanceledMember_6cb91c53-2021-40eb-a1b1-3344d9597497" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingDecember2027Member_bc11d497-5c0f-470b-bea8-d2cc73de27fd" xlink:href="sny-20231231.xsd#sny_FourBillionFacilityMaturingDecember2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_FourBillionFacilityMaturingDecember2027Member_bc11d497-5c0f-470b-bea8-d2cc73de27fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ParticipatingSharesMember_2a423ea3-7ab0-4226-b971-a6bcb1f157c7" xlink:href="sny-20231231.xsd#sny_ParticipatingSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_ParticipatingSharesMember_2a423ea3-7ab0-4226-b971-a6bcb1f157c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_7b94230e-b50b-44da-bcde-aabb71622637" xlink:href="sny-20231231.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_7b94230e-b50b-44da-bcde-aabb71622637" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_74e4edc8-3cbd-4a91-9803-965e5c11a2e4" xlink:href="sny-20231231.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_74e4edc8-3cbd-4a91-9803-965e5c11a2e4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrument1Axis_c5e6dffa-9f0b-4e9e-965b-fe34ea7f9993" xlink:href="sny-20231231.xsd#sny_DebtInstrument1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5e43faa0-6063-47a3-8531-da8fcfcb56f5" xlink:to="loc_sny_DebtInstrument1Axis_c5e6dffa-9f0b-4e9e-965b-fe34ea7f9993" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_c5e6dffa-9f0b-4e9e-965b-fe34ea7f9993_default" xlink:href="sny-20231231.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DebtInstrument1Axis_c5e6dffa-9f0b-4e9e-965b-fe34ea7f9993" xlink:to="loc_sny_DebtInstrumentDomain_c5e6dffa-9f0b-4e9e-965b-fe34ea7f9993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_c421a864-39f9-485e-b527-cfc768b8a168" xlink:href="sny-20231231.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DebtInstrument1Axis_c5e6dffa-9f0b-4e9e-965b-fe34ea7f9993" xlink:to="loc_sny_DebtInstrumentDomain_c421a864-39f9-485e-b527-cfc768b8a168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_90b2377f-8153-4831-ab2e-0c3d9bab333f" xlink:href="sny-20231231.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DebtInstrumentDomain_c421a864-39f9-485e-b527-cfc768b8a168" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_90b2377f-8153-4831-ab2e-0c3d9bab333f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_8bf3d59c-ef06-437e-8486-072399b9010a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5e43faa0-6063-47a3-8531-da8fcfcb56f5" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_8bf3d59c-ef06-437e-8486-072399b9010a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_8bf3d59c-ef06-437e-8486-072399b9010a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_8bf3d59c-ef06-437e-8486-072399b9010a" xlink:to="loc_ifrs-full_InterestRateTypesMember_8bf3d59c-ef06-437e-8486-072399b9010a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_5c251800-06ce-4d12-a17a-4733115877d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_8bf3d59c-ef06-437e-8486-072399b9010a" xlink:to="loc_ifrs-full_InterestRateTypesMember_5c251800-06ce-4d12-a17a-4733115877d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember_69231f5c-48c9-43f4-a2f3-cbab528f16a2" xlink:href="sny-20231231.xsd#sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_5c251800-06ce-4d12-a17a-4733115877d7" xlink:to="loc_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember_69231f5c-48c9-43f4-a2f3-cbab528f16a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember_a266d4b9-5396-4656-a047-0bbd264c8b12" xlink:href="sny-20231231.xsd#sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_5c251800-06ce-4d12-a17a-4733115877d7" xlink:to="loc_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember_a266d4b9-5396-4656-a047-0bbd264c8b12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondIssuesRedeemed_db9feb5b-4d11-4eac-9d02-1b381e66fc0f" xlink:href="sny-20231231.xsd#sny_NumberOfBondIssuesRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_NumberOfBondIssuesRedeemed_db9feb5b-4d11-4eac-9d02-1b381e66fc0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_fd2473fd-e1d4-4d4b-ab3c-4743f41105de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_ifrs-full_NotionalAmount_fd2473fd-e1d4-4d4b-ab3c-4743f41105de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionNumber_5e392628-8410-44e5-b5ba-819f7236802f" xlink:href="sny-20231231.xsd#sny_CreditFacilitiesExtensionOptionNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_CreditFacilitiesExtensionOptionNumber_5e392628-8410-44e5-b5ba-819f7236802f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionPeriod_81730799-36a9-4b0a-954f-e3ac898b80ea" xlink:href="sny-20231231.xsd#sny_CreditFacilitiesExtensionOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_CreditFacilitiesExtensionOptionPeriod_81730799-36a9-4b0a-954f-e3ac898b80ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCreditFacilities_1029bdf3-a6f8-4a1a-a4a5-83744bb61736" xlink:href="sny-20231231.xsd#sny_NumberOfCreditFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_NumberOfCreditFacilities_1029bdf3-a6f8-4a1a-a4a5-83744bb61736" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSustainableDevelopmentPerformanceIndicators_80ec4134-3290-4e32-8ff4-adb079e49a1a" xlink:href="sny-20231231.xsd#sny_NumberOfSustainableDevelopmentPerformanceIndicators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_NumberOfSustainableDevelopmentPerformanceIndicators_80ec4134-3290-4e32-8ff4-adb079e49a1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ParticipatingSharesNumberOutstanding_9825633e-5423-478d-849f-c20352d00a1d" xlink:href="sny-20231231.xsd#sny_ParticipatingSharesNumberOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_ParticipatingSharesNumberOutstanding_9825633e-5423-478d-849f-c20352d00a1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ParticipatingSharesCarryingAmount_662c9b98-ae70-485e-a574-6211a0cb4fcd" xlink:href="sny-20231231.xsd#sny_ParticipatingSharesCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_ParticipatingSharesCarryingAmount_662c9b98-ae70-485e-a574-6211a0cb4fcd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCommercialPaperPrograms_2fc5a436-e9ba-41ed-a5e8-9287832ebcb3" xlink:href="sny-20231231.xsd#sny_NumberOfCommercialPaperPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_NumberOfCommercialPaperPrograms_2fc5a436-e9ba-41ed-a5e8-9287832ebcb3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued_526a14d1-0562-4a87-812a-4af1919036b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_ifrs-full_CommercialPapersIssued_526a14d1-0562-4a87-812a-4af1919036b8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown_1147fe83-43b7-46b8-96ca-aeec7265b8d4" xlink:href="sny-20231231.xsd#sny_BorrowingAverageDrawdown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_BorrowingAverageDrawdown_1147fe83-43b7-46b8-96ca-aeec7265b8d4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingMaximumDrawdown_3539b0d4-a7b7-4426-9b1a-9d5b2d5b9140" xlink:href="sny-20231231.xsd#sny_BorrowingMaximumDrawdown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_BorrowingMaximumDrawdown_3539b0d4-a7b7-4426-9b1a-9d5b2d5b9140" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingDrawdown_f9be7cf7-77c8-4f01-846b-f9358e3eca80" xlink:href="sny-20231231.xsd#sny_BorrowingDrawdown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_BorrowingDrawdown_f9be7cf7-77c8-4f01-846b-f9358e3eca80" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCurrenciesDebtIsIssuedIn_953deb8f-4adb-41e8-8968-5de9983dfbf3" xlink:href="sny-20231231.xsd#sny_NumberOfCurrenciesDebtIsIssuedIn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_NumberOfCurrenciesDebtIsIssuedIn_953deb8f-4adb-41e8-8968-5de9983dfbf3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_8acace23-dd51-415e-b51c-fc574ad1f8af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_ifrs-full_BorrowingsInterestRate_8acace23-dd51-415e-b51c-fc574ad1f8af" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalentsInvestedRate_b66eae4f-77cf-49fd-9cb5-898126e63207" xlink:href="sny-20231231.xsd#sny_CashAndCashEquivalentsInvestedRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_CashAndCashEquivalentsInvestedRate_b66eae4f-77cf-49fd-9cb5-898126e63207" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_5d24f9c7-e4ad-49c3-87ab-2e5a7be28b4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:to="loc_ifrs-full_MeasurementAxis_5d24f9c7-e4ad-49c3-87ab-2e5a7be28b4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_5d24f9c7-e4ad-49c3-87ab-2e5a7be28b4b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_5d24f9c7-e4ad-49c3-87ab-2e5a7be28b4b" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_5d24f9c7-e4ad-49c3-87ab-2e5a7be28b4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_a76a70c0-e1e0-47f0-a10a-ee371b732673" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_5d24f9c7-e4ad-49c3-87ab-2e5a7be28b4b" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_a76a70c0-e1e0-47f0-a10a-ee371b732673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_3951a1d6-9b72-4346-8818-3b7cfdc1f3a7" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_a76a70c0-e1e0-47f0-a10a-ee371b732673" xlink:to="loc_sny_ValueOnRedemptionMember_3951a1d6-9b72-4346-8818-3b7cfdc1f3a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_c7cc84c6-c390-487b-b72e-0043f112e7a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_c7cc84c6-c390-487b-b72e-0043f112e7a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_c7cc84c6-c390-487b-b72e-0043f112e7a4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_c7cc84c6-c390-487b-b72e-0043f112e7a4" xlink:to="loc_ifrs-full_LiabilitiesMember_c7cc84c6-c390-487b-b72e-0043f112e7a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_9232a6ec-66e1-4ee4-8641-d4b10de7c54a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_c7cc84c6-c390-487b-b72e-0043f112e7a4" xlink:to="loc_ifrs-full_LiabilitiesMember_9232a6ec-66e1-4ee4-8641-d4b10de7c54a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember_aff558af-5f9d-49f1-99f6-fac3a30365b2" xlink:href="sny-20231231.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_9232a6ec-66e1-4ee4-8641-d4b10de7c54a" xlink:to="loc_sny_NonCurrentLiabilitiesMember_aff558af-5f9d-49f1-99f6-fac3a30365b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember_7ddeaba4-ab2b-4e91-89ea-7456011cdd31" xlink:href="sny-20231231.xsd#sny_CurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_9232a6ec-66e1-4ee4-8641-d4b10de7c54a" xlink:to="loc_sny_CurrentLiabilitiesMember_7ddeaba4-ab2b-4e91-89ea-7456011cdd31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_9ab3767b-c83c-47f5-9780-e1cd582b19b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_9ab3767b-c83c-47f5-9780-e1cd582b19b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_9ab3767b-c83c-47f5-9780-e1cd582b19b6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_9ab3767b-c83c-47f5-9780-e1cd582b19b6" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_9ab3767b-c83c-47f5-9780-e1cd582b19b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_36013d2b-afef-415c-b1b3-c05a886acf62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_9ab3767b-c83c-47f5-9780-e1cd582b19b6" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_36013d2b-afef-415c-b1b3-c05a886acf62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember_a5b2becc-9647-4734-84ed-44987b8039d7" xlink:href="sny-20231231.xsd#sny_NonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_36013d2b-afef-415c-b1b3-c05a886acf62" xlink:to="loc_sny_NonCurrentAssetsMember_a5b2becc-9647-4734-84ed-44987b8039d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember_3a90c6ab-0c51-4923-9f53-0d8a12d1b384" xlink:href="sny-20231231.xsd#sny_CurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_36013d2b-afef-415c-b1b3-c05a886acf62" xlink:to="loc_sny_CurrentAssetsMember_3a90c6ab-0c51-4923-9f53-0d8a12d1b384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_ea204372-a047-47f9-99b4-1ef0d36dcf23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:to="loc_ifrs-full_MaturityAxis_ea204372-a047-47f9-99b4-1ef0d36dcf23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ea204372-a047-47f9-99b4-1ef0d36dcf23_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_ea204372-a047-47f9-99b4-1ef0d36dcf23" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ea204372-a047-47f9-99b4-1ef0d36dcf23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_ea204372-a047-47f9-99b4-1ef0d36dcf23" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_208739dd-56a4-44fa-8aa5-0de72c99bfa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_208739dd-56a4-44fa-8aa5-0de72c99bfa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_ad13be56-d4ee-493b-b1fc-3c6f26a29db2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_ad13be56-d4ee-493b-b1fc-3c6f26a29db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_48c90606-99c8-4f4a-8bdd-8a676dffef3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_48c90606-99c8-4f4a-8bdd-8a676dffef3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_ff22db70-1c4a-4c8c-a77e-98c02a0e47ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_ff22db70-1c4a-4c8c-a77e-98c02a0e47ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_ffb7b537-54f8-4184-8c77-8bb754e59f74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_ffb7b537-54f8-4184-8c77-8bb754e59f74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_41d75c07-a650-4666-9cde-fb5d6adfec6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_41d75c07-a650-4666-9cde-fb5d6adfec6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_683a9a6b-ead1-4ad9-a805-4c39796eddfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_ifrs-full_BondsIssued_683a9a6b-ead1-4ad9-a805-4c39796eddfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_fa8d9f79-dbb5-4436-bd1f-0e9fad54111e" xlink:href="sny-20231231.xsd#sny_OtherBankBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_sny_OtherBankBorrowings_fa8d9f79-dbb5-4436-bd1f-0e9fad54111e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_6e25dd1a-30b3-4b15-8a09-6dbc7a578c48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_ifrs-full_OtherBorrowings_6e25dd1a-30b3-4b15-8a09-6dbc7a578c48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_bb6aecaa-37ec-4ba5-b394-21d9d3c313d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_bb6aecaa-37ec-4ba5-b394-21d9d3c313d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_bd277c03-05a0-44d7-9f2b-69c58ba11cde" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_bd277c03-05a0-44d7-9f2b-69c58ba11cde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_f3f8230d-6b3a-45e1-bee0-d5bcefdc4db7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_ifrs-full_Borrowings_f3f8230d-6b3a-45e1-bee0-d5bcefdc4db7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_637f5591-4b2c-4571-801f-46ce2e199012" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_ifrs-full_CashAndCashEquivalents_637f5591-4b2c-4571-801f-46ce2e199012" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_5293061f-43e7-4d55-ac15-3f7b2eeecba5" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_5293061f-43e7-4d55-ac15-3f7b2eeecba5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_c3d01ff8-2fa6-4c80-bb23-d1d8f711d183" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_c3d01ff8-2fa6-4c80-bb23-d1d8f711d183" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f29540b5-2d5f-46be-ab7d-8279a811e70a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1d4907e9-f2a4-4e55-985f-6af70701eb92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f29540b5-2d5f-46be-ab7d-8279a811e70a" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1d4907e9-f2a4-4e55-985f-6af70701eb92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrument1Axis_fb1fb3c5-a1f7-4b8d-8cb0-5a45fb8f3461" xlink:href="sny-20231231.xsd#sny_DebtInstrument1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1d4907e9-f2a4-4e55-985f-6af70701eb92" xlink:to="loc_sny_DebtInstrument1Axis_fb1fb3c5-a1f7-4b8d-8cb0-5a45fb8f3461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_fb1fb3c5-a1f7-4b8d-8cb0-5a45fb8f3461_default" xlink:href="sny-20231231.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DebtInstrument1Axis_fb1fb3c5-a1f7-4b8d-8cb0-5a45fb8f3461" xlink:to="loc_sny_DebtInstrumentDomain_fb1fb3c5-a1f7-4b8d-8cb0-5a45fb8f3461_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_4cddc669-4f99-42aa-a557-ded70f5d8427" xlink:href="sny-20231231.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DebtInstrument1Axis_fb1fb3c5-a1f7-4b8d-8cb0-5a45fb8f3461" xlink:to="loc_sny_DebtInstrumentDomain_4cddc669-4f99-42aa-a557-ded70f5d8427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_841c9caf-cddc-4a16-9d18-065920a5f6d5" xlink:href="sny-20231231.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DebtInstrumentDomain_4cddc669-4f99-42aa-a557-ded70f5d8427" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_841c9caf-cddc-4a16-9d18-065920a5f6d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShelfRegistrationStatementProgramMember_fda569c2-9a04-41b6-bb7e-0f1869a70f55" xlink:href="sny-20231231.xsd#sny_ShelfRegistrationStatementProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DebtInstrumentDomain_4cddc669-4f99-42aa-a557-ded70f5d8427" xlink:to="loc_sny_ShelfRegistrationStatementProgramMember_fda569c2-9a04-41b6-bb7e-0f1869a70f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_4b3cb4ba-951a-4f03-b580-45e5d130d232" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1d4907e9-f2a4-4e55-985f-6af70701eb92" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_4b3cb4ba-951a-4f03-b580-45e5d130d232" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_4b3cb4ba-951a-4f03-b580-45e5d130d232_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4b3cb4ba-951a-4f03-b580-45e5d130d232" xlink:to="loc_ifrs-full_BorrowingsByNameMember_4b3cb4ba-951a-4f03-b580-45e5d130d232_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4b3cb4ba-951a-4f03-b580-45e5d130d232" xlink:to="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2016EMTNISINFR0013143997Member_5887b558-c00b-4a91-91f8-c68098a04a0b" xlink:href="sny-20231231.xsd#sny_April2016EMTNISINFR0013143997Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_April2016EMTNISINFR0013143997Member_5887b558-c00b-4a91-91f8-c68098a04a0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2020EMTNISINFR0013505104Member_e9714714-8481-48b6-9539-233a1eaa43a4" xlink:href="sny-20231231.xsd#sny_March2020EMTNISINFR0013505104Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2020EMTNISINFR0013505104Member_e9714714-8481-48b6-9539-233a1eaa43a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2022EMTNISINFR0014009KS6Member_32900e81-2e5c-4c46-9078-1d23d61a8a30" xlink:href="sny-20231231.xsd#sny_April2022EMTNISINFR0014009KS6Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_April2022EMTNISINFR0014009KS6Member_32900e81-2e5c-4c46-9078-1d23d61a8a30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_September2015EMTNISINFR0012969038Member_46b08f51-6da3-45eb-a3e0-3455b59910f0" xlink:href="sny-20231231.xsd#sny_September2015EMTNISINFR0012969038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_September2015EMTNISINFR0012969038Member_46b08f51-6da3-45eb-a3e0-3455b59910f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2018EMTNISINFR0013324340Member_70ef88bd-834d-4d84-8f36-6e828979ca59" xlink:href="sny-20231231.xsd#sny_March2018EMTNISINFR0013324340Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2018EMTNISINFR0013324340Member_70ef88bd-834d-4d84-8f36-6e828979ca59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_September2014EMTNISINFR0012146801Member_73bbe9b9-b09c-4b33-83a7-53e170003423" xlink:href="sny-20231231.xsd#sny_September2014EMTNISINFR0012146801Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_September2014EMTNISINFR0012146801Member_73bbe9b9-b09c-4b33-83a7-53e170003423" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_September2016EMTNISINFR0013201639Member_2fd4a93e-ef14-454c-b1de-c10043905d53" xlink:href="sny-20231231.xsd#sny_September2016EMTNISINFR0013201639Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_September2016EMTNISINFR0013201639Member_2fd4a93e-ef14-454c-b1de-c10043905d53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2016EMTNISINFR0013144003Member_23479da7-1b08-4643-a4d1-f8fcfa01202f" xlink:href="sny-20231231.xsd#sny_April2016EMTNISINFR0013144003Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_April2016EMTNISINFR0013144003Member_23479da7-1b08-4643-a4d1-f8fcfa01202f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2019EMTNISINFR0013409844Member_e955e9e3-9d8b-4642-82e6-e63c146b1422" xlink:href="sny-20231231.xsd#sny_March2019EMTNISINFR0013409844Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2019EMTNISINFR0013409844Member_e955e9e3-9d8b-4642-82e6-e63c146b1422" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2022EMTNISINFR0014009KQ0Member_4a8a9ffb-0a59-49ba-8ba2-160612556df3" xlink:href="sny-20231231.xsd#sny_April2022EMTNISINFR0014009KQ0Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_April2022EMTNISINFR0014009KQ0Member_4a8a9ffb-0a59-49ba-8ba2-160612556df3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2018EMTNISINFR0013324357Member_bef93696-a4b6-406b-ac1c-3de9d9abf96c" xlink:href="sny-20231231.xsd#sny_March2018EMTNISINFR0013324357Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2018EMTNISINFR0013324357Member_bef93696-a4b6-406b-ac1c-3de9d9abf96c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2020EMTNISINFR0013505112Member_3225ceef-2956-4e6b-bfa7-2b9a9ca0bbb2" xlink:href="sny-20231231.xsd#sny_March2020EMTNISINFR0013505112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2020EMTNISINFR0013505112Member_3225ceef-2956-4e6b-bfa7-2b9a9ca0bbb2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2019EMTNISINFR0013409851Member_b9c1a8af-284a-4f37-a83c-3b2fd17e5344" xlink:href="sny-20231231.xsd#sny_March2019EMTNISINFR0013409851Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2019EMTNISINFR0013409851Member_b9c1a8af-284a-4f37-a83c-3b2fd17e5344" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2018EMTNISINFR0013324373Member_a08afe7d-c56f-4198-810e-5818f9258b46" xlink:href="sny-20231231.xsd#sny_March2018EMTNISINFR0013324373Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2018EMTNISINFR0013324373Member_a08afe7d-c56f-4198-810e-5818f9258b46" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_June2018SNFISINUS801060AC87Member_a48c419f-9198-416e-b9c5-1f98278ba9a6" xlink:href="sny-20231231.xsd#sny_June2018SNFISINUS801060AC87Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_June2018SNFISINUS801060AC87Member_a48c419f-9198-416e-b9c5-1f98278ba9a6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_June2018SNFISINUS801060AD60Member_86087cbe-a698-4d1d-89f9-49a697631d0f" xlink:href="sny-20231231.xsd#sny_June2018SNFISINUS801060AD60Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_June2018SNFISINUS801060AD60Member_86087cbe-a698-4d1d-89f9-49a697631d0f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_cd535c81-ba16-40b6-b0ed-96cc863e3bcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f29540b5-2d5f-46be-ab7d-8279a811e70a" xlink:to="loc_ifrs-full_BorrowingsInterestRate_cd535c81-ba16-40b6-b0ed-96cc863e3bcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_a271c157-55ad-4ee1-b5b4-3e4faedb27de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f29540b5-2d5f-46be-ab7d-8279a811e70a" xlink:to="loc_ifrs-full_NotionalAmount_a271c157-55ad-4ee1-b5b4-3e4faedb27de" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_b37153a5-5e68-4c13-887e-b5d67217fbfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:to="loc_ifrs-full_MeasurementAxis_b37153a5-5e68-4c13-887e-b5d67217fbfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_b37153a5-5e68-4c13-887e-b5d67217fbfb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_b37153a5-5e68-4c13-887e-b5d67217fbfb" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_b37153a5-5e68-4c13-887e-b5d67217fbfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_7c3cba0c-4005-43a3-b7e8-6bec76f8ac32" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_b37153a5-5e68-4c13-887e-b5d67217fbfb" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_7c3cba0c-4005-43a3-b7e8-6bec76f8ac32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_b46d708c-644a-4754-959c-bb2c9d449772" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7c3cba0c-4005-43a3-b7e8-6bec76f8ac32" xlink:to="loc_sny_ValueOnRedemptionMember_b46d708c-644a-4754-959c-bb2c9d449772" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_26f2a489-484d-4c16-a212-b48d2e884870" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:to="loc_ifrs-full_MaturityAxis_26f2a489-484d-4c16-a212-b48d2e884870" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_26f2a489-484d-4c16-a212-b48d2e884870_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_26f2a489-484d-4c16-a212-b48d2e884870" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_26f2a489-484d-4c16-a212-b48d2e884870_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_26f2a489-484d-4c16-a212-b48d2e884870" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_02cbc534-f9fc-4437-856f-4d6c5969b19e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_02cbc534-f9fc-4437-856f-4d6c5969b19e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_198a0388-a0e3-4208-b72b-fff34ab0da8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_198a0388-a0e3-4208-b72b-fff34ab0da8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_dddee576-cc42-4079-8076-e153b31c9a5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_dddee576-cc42-4079-8076-e153b31c9a5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_db1fd94c-ecb5-47b8-9768-a6377ad4cd96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_db1fd94c-ecb5-47b8-9768-a6377ad4cd96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_30018ed2-8e85-49f8-9cf5-03b6e90674ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_30018ed2-8e85-49f8-9cf5-03b6e90674ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_066c4d73-0a50-4c27-b857-d3dcb2df4155" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_066c4d73-0a50-4c27-b857-d3dcb2df4155" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrument1Axis_0db4d093-61fa-4b96-b8dd-37f2311892f9" xlink:href="sny-20231231.xsd#sny_DebtInstrument1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:to="loc_sny_DebtInstrument1Axis_0db4d093-61fa-4b96-b8dd-37f2311892f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_0db4d093-61fa-4b96-b8dd-37f2311892f9_default" xlink:href="sny-20231231.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DebtInstrument1Axis_0db4d093-61fa-4b96-b8dd-37f2311892f9" xlink:to="loc_sny_DebtInstrumentDomain_0db4d093-61fa-4b96-b8dd-37f2311892f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_92267f69-74f6-4023-8c03-e5733f2e594a" xlink:href="sny-20231231.xsd#sny_DebtInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DebtInstrument1Axis_0db4d093-61fa-4b96-b8dd-37f2311892f9" xlink:to="loc_sny_DebtInstrumentDomain_92267f69-74f6-4023-8c03-e5733f2e594a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_d266fc95-e887-4241-a051-06b696be9e9a" xlink:href="sny-20231231.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DebtInstrumentDomain_92267f69-74f6-4023-8c03-e5733f2e594a" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_d266fc95-e887-4241-a051-06b696be9e9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2bdd36fa-3220-4938-8f35-764bf1fef579" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2bdd36fa-3220-4938-8f35-764bf1fef579" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2bdd36fa-3220-4938-8f35-764bf1fef579_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2bdd36fa-3220-4938-8f35-764bf1fef579" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2bdd36fa-3220-4938-8f35-764bf1fef579_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_f0e31b63-6f55-4aac-a1d4-9d1bfb784b6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2bdd36fa-3220-4938-8f35-764bf1fef579" xlink:to="loc_ifrs-full_BorrowingsByNameMember_f0e31b63-6f55-4aac-a1d4-9d1bfb784b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember_5897ef47-07a1-46a1-8fd5-5a67e7d58125" xlink:href="sny-20231231.xsd#sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_f0e31b63-6f55-4aac-a1d4-9d1bfb784b6b" xlink:to="loc_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember_5897ef47-07a1-46a1-8fd5-5a67e7d58125" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_f15f7d36-fd51-45b9-b41a-33f40453c986" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_BondsIssued_f15f7d36-fd51-45b9-b41a-33f40453c986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_d4f31992-f945-4c0a-818e-baa61aa5fde8" xlink:href="sny-20231231.xsd#sny_OtherBankBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_sny_OtherBankBorrowings_d4f31992-f945-4c0a-818e-baa61aa5fde8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_96ed2687-a69d-4abd-b14b-0b343d058d76" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_OtherBorrowings_96ed2687-a69d-4abd-b14b-0b343d058d76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_8dd68bf6-2547-43eb-baf8-4f584efa93d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_8dd68bf6-2547-43eb-baf8-4f584efa93d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_f82b4857-50c7-4a69-bc61-232dea11427f" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_f82b4857-50c7-4a69-bc61-232dea11427f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_c187f170-d4a9-4c9c-a7d2-555be9d5dafe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_Borrowings_c187f170-d4a9-4c9c-a7d2-555be9d5dafe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_10c00f2e-f797-40aa-a0f8-9d9ebb9cd601" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_CashAndCashEquivalents_10c00f2e-f797-40aa-a0f8-9d9ebb9cd601" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_2ededf18-35fb-4983-8a02-18cbc0ee992f" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_2ededf18-35fb-4983-8a02-18cbc0ee992f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_f81fa868-e09d-4b1a-90a8-0ee070a33c19" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_f81fa868-e09d-4b1a-90a8-0ee070a33c19" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_f2e8d68d-0d7e-4672-a9a2-a8a70cc03592" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_LeaseLiabilities_f2e8d68d-0d7e-4672-a9a2-a8a70cc03592" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_3aa1b059-ace3-44fa-86f6-ac56f2aa93fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_NotionalAmount_3aa1b059-ace3-44fa-86f6-ac56f2aa93fc" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_e36a9254-0a62-4a67-b4c1-0dc3b9e2457b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:to="loc_srt_CurrencyAxis_e36a9254-0a62-4a67-b4c1-0dc3b9e2457b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_e36a9254-0a62-4a67-b4c1-0dc3b9e2457b_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_e36a9254-0a62-4a67-b4c1-0dc3b9e2457b" xlink:to="loc_currency_AllCurrenciesDomain_e36a9254-0a62-4a67-b4c1-0dc3b9e2457b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_ba8fa326-2b29-4c23-96ef-61ceca0e3c53" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_e36a9254-0a62-4a67-b4c1-0dc3b9e2457b" xlink:to="loc_currency_AllCurrenciesDomain_ba8fa326-2b29-4c23-96ef-61ceca0e3c53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_f0cf0446-da97-479d-b231-51f52a1d2fd9" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_ba8fa326-2b29-4c23-96ef-61ceca0e3c53" xlink:to="loc_currency_EUR_f0cf0446-da97-479d-b231-51f52a1d2fd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_56ab2e47-cb27-4dfc-a33e-f12c8f4b2f26" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_ba8fa326-2b29-4c23-96ef-61ceca0e3c53" xlink:to="loc_currency_USD_56ab2e47-cb27-4dfc-a33e-f12c8f4b2f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_SGD_b2b683dc-ff7f-4d54-a015-bfb345f3c3ff" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_SGD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_ba8fa326-2b29-4c23-96ef-61ceca0e3c53" xlink:to="loc_currency_SGD_b2b683dc-ff7f-4d54-a015-bfb345f3c3ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_4d6b461c-8427-4cc9-9001-1e31ce0adb1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:to="loc_ifrs-full_MaturityAxis_4d6b461c-8427-4cc9-9001-1e31ce0adb1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_4d6b461c-8427-4cc9-9001-1e31ce0adb1c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_4d6b461c-8427-4cc9-9001-1e31ce0adb1c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_4d6b461c-8427-4cc9-9001-1e31ce0adb1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_4d6b461c-8427-4cc9-9001-1e31ce0adb1c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_e059508b-4c23-4527-886b-8471b7869f05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_e059508b-4c23-4527-886b-8471b7869f05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_e059c6ad-b377-424c-bcbf-511555edc286" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_e059c6ad-b377-424c-bcbf-511555edc286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2fad621f-a4a3-4290-b901-8851c6b98eae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2fad621f-a4a3-4290-b901-8851c6b98eae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_6b9dc782-74f5-4098-9d27-ab15e6b6d530" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_6b9dc782-74f5-4098-9d27-ab15e6b6d530" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_64a3ea77-6da9-4601-9f56-f8edac26eb60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_64a3ea77-6da9-4601-9f56-f8edac26eb60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_d9c0c68c-108a-4c8d-845d-f0410ef13a2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_d9c0c68c-108a-4c8d-845d-f0410ef13a2a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_50f094aa-d253-4eb7-a85c-358bdb25cdc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:to="loc_ifrs-full_MeasurementAxis_50f094aa-d253-4eb7-a85c-358bdb25cdc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_50f094aa-d253-4eb7-a85c-358bdb25cdc9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_50f094aa-d253-4eb7-a85c-358bdb25cdc9" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_50f094aa-d253-4eb7-a85c-358bdb25cdc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_01f8c3a0-88ec-436a-93b6-beb79722daf6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_50f094aa-d253-4eb7-a85c-358bdb25cdc9" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_01f8c3a0-88ec-436a-93b6-beb79722daf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember_061b132b-df5a-4833-a5d7-50324b17d9b7" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_01f8c3a0-88ec-436a-93b6-beb79722daf6" xlink:to="loc_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember_061b132b-df5a-4833-a5d7-50324b17d9b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_a3902da2-745e-48ce-aeb0-c98ca302bd40" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionAfterDerivativeInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_01f8c3a0-88ec-436a-93b6-beb79722daf6" xlink:to="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_a3902da2-745e-48ce-aeb0-c98ca302bd40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_85f8bf13-8e4b-4053-bd4f-385fdca44b5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_85f8bf13-8e4b-4053-bd4f-385fdca44b5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_85f8bf13-8e4b-4053-bd4f-385fdca44b5d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_85f8bf13-8e4b-4053-bd4f-385fdca44b5d" xlink:to="loc_ifrs-full_InterestRateTypesMember_85f8bf13-8e4b-4053-bd4f-385fdca44b5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_77d3213b-aa24-474b-85de-0870ca7aabb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_85f8bf13-8e4b-4053-bd4f-385fdca44b5d" xlink:to="loc_ifrs-full_InterestRateTypesMember_77d3213b-aa24-474b-85de-0870ca7aabb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_daa6d0f2-248d-46d1-b5bc-b9cea28b4c2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_77d3213b-aa24-474b-85de-0870ca7aabb4" xlink:to="loc_ifrs-full_FixedInterestRateMember_daa6d0f2-248d-46d1-b5bc-b9cea28b4c2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember_35cbeb7d-e6bd-401d-8787-f74b5de2d457" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_77d3213b-aa24-474b-85de-0870ca7aabb4" xlink:to="loc_ifrs-full_FloatingInterestRateMember_35cbeb7d-e6bd-401d-8787-f74b5de2d457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfBorrowings_aeabfd52-d138-4bb8-9832-aea0a66f9a66" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseOfBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:to="loc_sny_IncreaseDecreaseOfBorrowings_aeabfd52-d138-4bb8-9832-aea0a66f9a66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtPercent_93272b45-15d6-4665-8415-79bc02cdccf1" xlink:href="sny-20231231.xsd#sny_DebtPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:to="loc_sny_DebtPercent_93272b45-15d6-4665-8415-79bc02cdccf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_8c5597e1-a713-40a2-8150-8bf3f36b5ff2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:to="loc_ifrs-full_CashAndCashEquivalents_8c5597e1-a713-40a2-8150-8bf3f36b5ff2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_c24f558c-74b7-4974-95fe-c287e8bc7b83" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_c24f558c-74b7-4974-95fe-c287e8bc7b83" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_6142f25d-295e-465e-afe1-a41cde27380c" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:to="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_6142f25d-295e-465e-afe1-a41cde27380c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_0255add0-4dfe-4c24-9d55-bda7bba96ebf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_6142f25d-295e-465e-afe1-a41cde27380c" xlink:to="loc_ifrs-full_MeasurementAxis_0255add0-4dfe-4c24-9d55-bda7bba96ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_0255add0-4dfe-4c24-9d55-bda7bba96ebf_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_0255add0-4dfe-4c24-9d55-bda7bba96ebf" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_0255add0-4dfe-4c24-9d55-bda7bba96ebf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_6760bac1-5038-4790-ae6d-96a18547857f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_0255add0-4dfe-4c24-9d55-bda7bba96ebf" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_6760bac1-5038-4790-ae6d-96a18547857f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_8a7e9400-71c9-4fd0-a316-6077cba444df" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionAfterDerivativeInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_6760bac1-5038-4790-ae6d-96a18547857f" xlink:to="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_8a7e9400-71c9-4fd0-a316-6077cba444df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_dee69d64-46ef-4c97-a738-fa7716a97199" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_6142f25d-295e-465e-afe1-a41cde27380c" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_dee69d64-46ef-4c97-a738-fa7716a97199" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_dee69d64-46ef-4c97-a738-fa7716a97199_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_dee69d64-46ef-4c97-a738-fa7716a97199" xlink:to="loc_ifrs-full_InterestRateTypesMember_dee69d64-46ef-4c97-a738-fa7716a97199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_37bfa880-aa45-4bfb-a16b-151026b2053d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_dee69d64-46ef-4c97-a738-fa7716a97199" xlink:to="loc_ifrs-full_InterestRateTypesMember_37bfa880-aa45-4bfb-a16b-151026b2053d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_7dce270b-cc97-4a51-853c-6e38bcde837c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_37bfa880-aa45-4bfb-a16b-151026b2053d" xlink:to="loc_ifrs-full_FixedInterestRateMember_7dce270b-cc97-4a51-853c-6e38bcde837c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember_3901abbc-4c73-4c0d-b0c1-e66de99f5068" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_37bfa880-aa45-4bfb-a16b-151026b2053d" xlink:to="loc_ifrs-full_FloatingInterestRateMember_3901abbc-4c73-4c0d-b0c1-e66de99f5068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_b458d926-b134-4f6e-80ec-469e6964b4be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:to="loc_ifrs-full_Borrowings_b458d926-b134-4f6e-80ec-469e6964b4be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_d0d7b4ad-a39f-448e-82e1-b58b30df7e8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:to="loc_ifrs-full_CashAndCashEquivalents_d0d7b4ad-a39f-448e-82e1-b58b30df7e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_7b299735-8757-4c79-bf5c-248a70329843" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_7b299735-8757-4c79-bf5c-248a70329843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtPercent_9b2a26cf-4349-4395-b2b5-ab80e8866a29" xlink:href="sny-20231231.xsd#sny_DebtPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:to="loc_sny_DebtPercent_9b2a26cf-4349-4395-b2b5-ab80e8866a29" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_ac86df26-b18b-4659-84ac-835f149c97a5" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_821bc404-7976-4969-aac9-64c177b90f5f" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_ac86df26-b18b-4659-84ac-835f149c97a5" xlink:to="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_821bc404-7976-4969-aac9-64c177b90f5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_bf183e94-f91f-4529-ad6e-c61e6e6c79e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_821bc404-7976-4969-aac9-64c177b90f5f" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_bf183e94-f91f-4529-ad6e-c61e6e6c79e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_bf183e94-f91f-4529-ad6e-c61e6e6c79e2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_bf183e94-f91f-4529-ad6e-c61e6e6c79e2" xlink:to="loc_ifrs-full_InterestRateTypesMember_bf183e94-f91f-4529-ad6e-c61e6e6c79e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_bf183e94-f91f-4529-ad6e-c61e6e6c79e2" xlink:to="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlusHundredBasisPointsMember_33ad52eb-744c-4dd9-a10b-0f5d29fb2e4d" xlink:href="sny-20231231.xsd#sny_PlusHundredBasisPointsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:to="loc_sny_PlusHundredBasisPointsMember_33ad52eb-744c-4dd9-a10b-0f5d29fb2e4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlusTwentyFiveBasisPointsMember_ecd7f625-dde2-4139-b66d-c801b33d8edb" xlink:href="sny-20231231.xsd#sny_PlusTwentyFiveBasisPointsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:to="loc_sny_PlusTwentyFiveBasisPointsMember_ecd7f625-dde2-4139-b66d-c801b33d8edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinusTwentyFiveBasisPointsMember_34815508-1954-4ae0-948f-1510125847b6" xlink:href="sny-20231231.xsd#sny_MinusTwentyFiveBasisPointsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:to="loc_sny_MinusTwentyFiveBasisPointsMember_34815508-1954-4ae0-948f-1510125847b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinusHundredBasisPointsMember_bd934b32-d762-4f1d-ba45-6c2ed00eff6c" xlink:href="sny-20231231.xsd#sny_MinusHundredBasisPointsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:to="loc_sny_MinusHundredBasisPointsMember_bd934b32-d762-4f1d-ba45-6c2ed00eff6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_10f7fe21-f0e4-49fc-84c5-fc31c5346813" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_821bc404-7976-4969-aac9-64c177b90f5f" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_10f7fe21-f0e4-49fc-84c5-fc31c5346813" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_10f7fe21-f0e4-49fc-84c5-fc31c5346813_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_10f7fe21-f0e4-49fc-84c5-fc31c5346813" xlink:to="loc_ifrs-full_BorrowingsByNameMember_10f7fe21-f0e4-49fc-84c5-fc31c5346813_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_60c4a018-019f-4e96-a1d9-1a5e1d5dcc77" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_10f7fe21-f0e4-49fc-84c5-fc31c5346813" xlink:to="loc_ifrs-full_BorrowingsByNameMember_60c4a018-019f-4e96-a1d9-1a5e1d5dcc77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember_ef00adce-ca0e-4877-837d-d5cb7bbcd11c" xlink:href="sny-20231231.xsd#sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_60c4a018-019f-4e96-a1d9-1a5e1d5dcc77" xlink:to="loc_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember_ef00adce-ca0e-4877-837d-d5cb7bbcd11c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfChangeInInterestRateOnPreTaxIncome_43e271bf-4087-4703-bb55-0338a9c8f887" xlink:href="sny-20231231.xsd#sny_ImpactOfChangeInInterestRateOnPreTaxIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_ac86df26-b18b-4659-84ac-835f149c97a5" xlink:to="loc_sny_ImpactOfChangeInInterestRateOnPreTaxIncome_43e271bf-4087-4703-bb55-0338a9c8f887" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfPreTaxIncomeRecognisedInEquity_3605ace8-f895-44ad-822d-c9e03f69d726" xlink:href="sny-20231231.xsd#sny_ImpactOfPreTaxIncomeRecognisedInEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_ac86df26-b18b-4659-84ac-835f149c97a5" xlink:to="loc_sny_ImpactOfPreTaxIncomeRecognisedInEquity_3605ace8-f895-44ad-822d-c9e03f69d726" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByCurrencyLineItems_941b0f6f-b003-4df6-9af8-060169a02e75" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByCurrencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByCurrencyTable_48f95cb9-27cd-4822-8065-7db5ba98c44e" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByCurrencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfDebtByCurrencyLineItems_941b0f6f-b003-4df6-9af8-060169a02e75" xlink:to="loc_sny_DisclosureOfDebtByCurrencyTable_48f95cb9-27cd-4822-8065-7db5ba98c44e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_09e4bacf-4e57-490c-a860-c74eea459bd9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfDebtByCurrencyTable_48f95cb9-27cd-4822-8065-7db5ba98c44e" xlink:to="loc_srt_CurrencyAxis_09e4bacf-4e57-490c-a860-c74eea459bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_09e4bacf-4e57-490c-a860-c74eea459bd9_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_09e4bacf-4e57-490c-a860-c74eea459bd9" xlink:to="loc_currency_AllCurrenciesDomain_09e4bacf-4e57-490c-a860-c74eea459bd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_09e4bacf-4e57-490c-a860-c74eea459bd9" xlink:to="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_0accc8c1-ebdd-4a16-b49a-703ca856e2a3" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_currency_EUR_0accc8c1-ebdd-4a16-b49a-703ca856e2a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_0187c3a9-44c4-4575-981e-bf8c78c6c54f" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_currency_USD_0187c3a9-44c4-4575-981e-bf8c78c6c54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_SGD_6e31a908-e5d8-465e-9574-8d70e39d50ed" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_SGD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_currency_SGD_6e31a908-e5d8-465e-9574-8d70e39d50ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_ff129047-45c9-43d4-9b21-2408888fa056" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_currency_GBP_ff129047-45c9-43d4-9b21-2408888fa056" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CNY_fd3f0506-e98a-46c0-8f4c-fcd753b21c16" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CNY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_currency_CNY_fd3f0506-e98a-46c0-8f4c-fcd753b21c16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrenciesMember_c113f21c-d66c-4b6b-8598-a4cb11a23a38" xlink:href="sny-20231231.xsd#sny_OtherCurrenciesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_sny_OtherCurrenciesMember_c113f21c-d66c-4b6b-8598-a4cb11a23a38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_93680ce2-6619-422a-adbe-1ef6e889c004" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfDebtByCurrencyTable_48f95cb9-27cd-4822-8065-7db5ba98c44e" xlink:to="loc_ifrs-full_MeasurementAxis_93680ce2-6619-422a-adbe-1ef6e889c004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_93680ce2-6619-422a-adbe-1ef6e889c004_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_93680ce2-6619-422a-adbe-1ef6e889c004" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_93680ce2-6619-422a-adbe-1ef6e889c004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_cf9ef94f-0c83-4ca2-a728-4945535757a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_93680ce2-6619-422a-adbe-1ef6e889c004" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_cf9ef94f-0c83-4ca2-a728-4945535757a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember_15037e71-9bd7-44d3-b5b6-800821623600" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_cf9ef94f-0c83-4ca2-a728-4945535757a5" xlink:to="loc_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember_15037e71-9bd7-44d3-b5b6-800821623600" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_7f1cd380-7f0b-4df4-949f-02b6dce28690" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionAfterDerivativeInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_cf9ef94f-0c83-4ca2-a728-4945535757a5" xlink:to="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_7f1cd380-7f0b-4df4-949f-02b6dce28690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_9532a818-6519-4ce3-8be8-067c8833c834" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDebtByCurrencyLineItems_941b0f6f-b003-4df6-9af8-060169a02e75" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_9532a818-6519-4ce3-8be8-067c8833c834" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9c493e0d-73e6-40f5-af71-121591784e1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_ce7648f2-b424-4ccf-80f3-53f59a99e1ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9c493e0d-73e6-40f5-af71-121591784e1b" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_ce7648f2-b424-4ccf-80f3-53f59a99e1ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_527760a2-b7dc-45c2-b9c9-9e45bde4df4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_ce7648f2-b424-4ccf-80f3-53f59a99e1ab" xlink:to="loc_ifrs-full_MeasurementAxis_527760a2-b7dc-45c2-b9c9-9e45bde4df4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_527760a2-b7dc-45c2-b9c9-9e45bde4df4f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_527760a2-b7dc-45c2-b9c9-9e45bde4df4f" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_527760a2-b7dc-45c2-b9c9-9e45bde4df4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_3dc0f04c-1bf6-4e1d-92ea-e933f8b3459b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_527760a2-b7dc-45c2-b9c9-9e45bde4df4f" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_3dc0f04c-1bf6-4e1d-92ea-e933f8b3459b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember_b7fc6cd6-85aa-4705-bb0d-4f8cd1afd669" xlink:href="sny-20231231.xsd#sny_AtMarketValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_3dc0f04c-1bf6-4e1d-92ea-e933f8b3459b" xlink:to="loc_sny_AtMarketValueMember_b7fc6cd6-85aa-4705-bb0d-4f8cd1afd669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_dcc20016-09d2-4523-abfc-cdd54a6657fc" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_3dc0f04c-1bf6-4e1d-92ea-e933f8b3459b" xlink:to="loc_sny_ValueOnRedemptionMember_dcc20016-09d2-4523-abfc-cdd54a6657fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_ce62a135-bfd4-4579-ad3e-a23c5dc8a332" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9c493e0d-73e6-40f5-af71-121591784e1b" xlink:to="loc_ifrs-full_Borrowings_ce62a135-bfd4-4579-ad3e-a23c5dc8a332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued_01e05d13-6da6-48b6-b253-255dec9ec72d" xlink:href="sny-20231231.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9c493e0d-73e6-40f5-af71-121591784e1b" xlink:to="loc_sny_RedemptionOfDebtInstrumentIssued_01e05d13-6da6-48b6-b253-255dec9ec72d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_746113ff-a30d-4e1a-8cb0-b403d2a21ff0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_746113ff-a30d-4e1a-8cb0-b403d2a21ff0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_e26f509a-62e1-4297-9e02-1e78704cb8b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_746113ff-a30d-4e1a-8cb0-b403d2a21ff0" xlink:to="loc_ifrs-full_MaturityAxis_e26f509a-62e1-4297-9e02-1e78704cb8b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_e26f509a-62e1-4297-9e02-1e78704cb8b1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_e26f509a-62e1-4297-9e02-1e78704cb8b1" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_e26f509a-62e1-4297-9e02-1e78704cb8b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_e26f509a-62e1-4297-9e02-1e78704cb8b1" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_77882879-b7b6-41a8-b40a-0687b0a1a462" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_77882879-b7b6-41a8-b40a-0687b0a1a462" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_4a30e93a-9a7b-4edc-929d-3283ff818f59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_4a30e93a-9a7b-4edc-929d-3283ff818f59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_452c7ed0-afeb-4622-9949-d12e1c8a8aaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_452c7ed0-afeb-4622-9949-d12e1c8a8aaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1cbb1aa9-ee02-475a-a801-f5a540c444bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1cbb1aa9-ee02-475a-a801-f5a540c444bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_fef2b5a8-a8d9-44f6-8d6c-de164c622c7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_fef2b5a8-a8d9-44f6-8d6c-de164c622c7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_2c28f70e-6952-49c7-b0b4-54786c4c9a1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_2c28f70e-6952-49c7-b0b4-54786c4c9a1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_9ad30cb1-e046-4e91-9af4-5f8aadf515a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_9ad30cb1-e046-4e91-9af4-5f8aadf515a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalUndiscountedCashFlow_1404b372-a2d8-4558-9269-c6a6da629fc8" xlink:href="sny-20231231.xsd#sny_PrincipalUndiscountedCashFlow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:to="loc_sny_PrincipalUndiscountedCashFlow_1404b372-a2d8-4558-9269-c6a6da629fc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestUndiscountedCashFlow_211b0353-2d87-43fa-b008-687a4dcd9877" xlink:href="sny-20231231.xsd#sny_InterestUndiscountedCashFlow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:to="loc_sny_InterestUndiscountedCashFlow_211b0353-2d87-43fa-b008-687a4dcd9877" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_866ed996-b4a5-48d2-9798-c47a31444c57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_866ed996-b4a5-48d2-9798-c47a31444c57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalUndiscountedCashFlow_6bb07c1e-bfac-4fc6-b035-06ce87928ebd" xlink:href="sny-20231231.xsd#sny_TotalUndiscountedCashFlow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:to="loc_sny_TotalUndiscountedCashFlow_6bb07c1e-bfac-4fc6-b035-06ce87928ebd" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_31387131-997d-4f8a-a5df-1eab206efc59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable_55bf40ac-b25d-471d-ae58-440386cb7af5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_31387131-997d-4f8a-a5df-1eab206efc59" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable_55bf40ac-b25d-471d-ae58-440386cb7af5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_3f083024-ace6-4f85-bda2-848a6e5b459f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable_55bf40ac-b25d-471d-ae58-440386cb7af5" xlink:to="loc_ifrs-full_MaturityAxis_3f083024-ace6-4f85-bda2-848a6e5b459f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_3f083024-ace6-4f85-bda2-848a6e5b459f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_3f083024-ace6-4f85-bda2-848a6e5b459f" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_3f083024-ace6-4f85-bda2-848a6e5b459f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_3f083024-ace6-4f85-bda2-848a6e5b459f" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_4b5e5c89-8eb7-4003-830c-d10664ad22c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_4b5e5c89-8eb7-4003-830c-d10664ad22c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_af15c2d9-a08f-475f-bd8d-db05468f10a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_af15c2d9-a08f-475f-bd8d-db05468f10a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_d4e49998-64ca-4ea3-97da-4cd8fb0ba889" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_d4e49998-64ca-4ea3-97da-4cd8fb0ba889" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_11a2b6cc-f166-4939-92a1-1444b8d347b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_11a2b6cc-f166-4939-92a1-1444b8d347b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_526dd989-0f22-4079-af58-dbb9b24ec148" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable_55bf40ac-b25d-471d-ae58-440386cb7af5" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_526dd989-0f22-4079-af58-dbb9b24ec148" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_526dd989-0f22-4079-af58-dbb9b24ec148_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_526dd989-0f22-4079-af58-dbb9b24ec148" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_526dd989-0f22-4079-af58-dbb9b24ec148_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_0bcd534a-cc92-4dc2-8c0f-045aa3255d86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_526dd989-0f22-4079-af58-dbb9b24ec148" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_0bcd534a-cc92-4dc2-8c0f-045aa3255d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CambridgeMassachusettsMember_81ad36b8-1a9a-40ec-9103-1c5797094512" xlink:href="sny-20231231.xsd#sny_CambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_0bcd534a-cc92-4dc2-8c0f-045aa3255d86" xlink:to="loc_sny_CambridgeMassachusettsMember_81ad36b8-1a9a-40ec-9103-1c5797094512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_66b4899d-511d-44a9-bbc7-27ea29f9c709" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_31387131-997d-4f8a-a5df-1eab206efc59" xlink:to="loc_ifrs-full_LeaseLiabilities_66b4899d-511d-44a9-bbc7-27ea29f9c709" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseLiabilitiesEffectOfDiscounting_50109ba2-ea4a-45b5-97af-543a5a5d2e9a" xlink:href="sny-20231231.xsd#sny_LeaseLiabilitiesEffectOfDiscounting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_31387131-997d-4f8a-a5df-1eab206efc59" xlink:to="loc_sny_LeaseLiabilitiesEffectOfDiscounting_50109ba2-ea4a-45b5-97af-543a5a5d2e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InitialLeaseTerm_900dcd2b-083a-4793-a70b-ee3f42a11646" xlink:href="sny-20231231.xsd#sny_InitialLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_31387131-997d-4f8a-a5df-1eab206efc59" xlink:to="loc_sny_InitialLeaseTerm_900dcd2b-083a-4793-a70b-ee3f42a11646" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_17b88e43-a463-4507-ba76-b5ed44f9a9cc" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_17b88e43-a463-4507-ba76-b5ed44f9a9cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_7fa66585-6f26-4c48-af51-ac8dd0b40c32" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_17b88e43-a463-4507-ba76-b5ed44f9a9cc" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_7fa66585-6f26-4c48-af51-ac8dd0b40c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_7fa66585-6f26-4c48-af51-ac8dd0b40c32_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_7fa66585-6f26-4c48-af51-ac8dd0b40c32" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_7fa66585-6f26-4c48-af51-ac8dd0b40c32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_7fa66585-6f26-4c48-af51-ac8dd0b40c32" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember_bd0b3783-3f10-4fe0-af38-8f7a9e9bd467" xlink:href="sny-20231231.xsd#sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember_bd0b3783-3f10-4fe0-af38-8f7a9e9bd467" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_c9edaf2d-835b-4f13-88d9-a2fd18f00b4f" xlink:href="sny-20231231.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_c9edaf2d-835b-4f13-88d9-a2fd18f00b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember_316dd29b-db99-485c-83c7-27ef1f585e31" xlink:href="sny-20231231.xsd#sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember_316dd29b-db99-485c-83c7-27ef1f585e31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixMember_37a821f7-4ffc-4fdd-b3af-d2d124db3a1e" xlink:href="sny-20231231.xsd#sny_AmunixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_AmunixMember_37a821f7-4ffc-4fdd-b3af-d2d124db3a1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member_30a74be9-dfd6-4e76-9409-05a66526b810" xlink:href="sny-20231231.xsd#sny_OtherLiabilities1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_OtherLiabilities1Member_30a74be9-dfd6-4e76-9409-05a66526b810" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioMember_88debb28-b0c7-4ef1-a1fa-ca5cfd7e94e1" xlink:href="sny-20231231.xsd#sny_TranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_TranslateBioMember_88debb28-b0c7-4ef1-a1fa-ca5cfd7e94e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_a04cf3cd-95d2-4c54-9c83-3de9f1851933" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_a04cf3cd-95d2-4c54-9c83-3de9f1851933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_6681f40c-213c-4d2d-b4e0-293d3b83b57e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_6681f40c-213c-4d2d-b4e0-293d3b83b57e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_33710821-4b87-4847-afda-bac0c7496236" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_33710821-4b87-4847-afda-bac0c7496236" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_040d0c73-d4fa-40d2-a28b-574d0fc4ed20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_040d0c73-d4fa-40d2-a28b-574d0fc4ed20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests_07409d24-ba58-47cf-8868-3eb10d18bfb1" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests_07409d24-ba58-47cf-8868-3eb10d18bfb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests_f1b8eef2-11d7-424d-bcec-942cd74a7159" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests_f1b8eef2-11d7-424d-bcec-942cd74a7159" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_ca3240d6-db47-4c8d-b407-7711da80e2f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_be80114c-3856-48b6-82a4-5a00d5894c79" xlink:href="sny-20231231.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_be80114c-3856-48b6-82a4-5a00d5894c79" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_d9d2d9a1-bf75-4122-80dc-58941aba733b" xlink:href="sny-20231231.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_d9d2d9a1-bf75-4122-80dc-58941aba733b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationLiabilities_3f7c8d1d-0eb5-4bf9-87ab-bdd6bd9ecc21" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_sny_ContingentConsiderationLiabilities_3f7c8d1d-0eb5-4bf9-87ab-bdd6bd9ecc21" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_b95d847f-fce3-4e51-be9d-bb1eb3cd39ba" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_83d22b0f-b070-497f-ac2a-d312211b49d1" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_b95d847f-fce3-4e51-be9d-bb1eb3cd39ba" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_83d22b0f-b070-497f-ac2a-d312211b49d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_6e764e06-c6f5-4f69-9163-cff3bc505175" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_83d22b0f-b070-497f-ac2a-d312211b49d1" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_6e764e06-c6f5-4f69-9163-cff3bc505175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_6e764e06-c6f5-4f69-9163-cff3bc505175_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_6e764e06-c6f5-4f69-9163-cff3bc505175" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_6e764e06-c6f5-4f69-9163-cff3bc505175_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_6e764e06-c6f5-4f69-9163-cff3bc505175" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_fd1fb0ce-f3e1-4299-96f3-703e27e4af04" xlink:href="sny-20231231.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_fd1fb0ce-f3e1-4299-96f3-703e27e4af04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember_97478fe9-36b0-4ab4-9905-fe4f36d4d006" xlink:href="sny-20231231.xsd#sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:to="loc_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember_97478fe9-36b0-4ab4-9905-fe4f36d4d006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireHumanGeneticTherapiesIncMember_09288179-aa26-4d1c-8a5c-278b7804d87e" xlink:href="sny-20231231.xsd#sny_ShireHumanGeneticTherapiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:to="loc_sny_ShireHumanGeneticTherapiesIncMember_09288179-aa26-4d1c-8a5c-278b7804d87e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixMember_cf853866-f497-4a2c-b00b-f14503feac63" xlink:href="sny-20231231.xsd#sny_AmunixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:to="loc_sny_AmunixMember_cf853866-f497-4a2c-b00b-f14503feac63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities_b5c1a388-f0ad-42ce-b9fa-799d914ba107" xlink:href="sny-20231231.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_b95d847f-fce3-4e51-be9d-bb1eb3cd39ba" xlink:to="loc_sny_PercentageIncreaseInFairValueLiabilities_b5c1a388-f0ad-42ce-b9fa-799d914ba107" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_6c8b29e0-7ebc-4eb0-bd09-52d8ca6d76c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_b95d847f-fce3-4e51-be9d-bb1eb3cd39ba" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_6c8b29e0-7ebc-4eb0-bd09-52d8ca6d76c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations_1561a4ff-a786-4920-951e-ef6b4c2a9eb0" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_b95d847f-fce3-4e51-be9d-bb1eb3cd39ba" xlink:to="loc_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations_1561a4ff-a786-4920-951e-ef6b4c2a9eb0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems_e6b18dc2-6782-4009-8baa-e1afe4a71f48" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable_50734351-eb27-4437-a079-02882afd7df4" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems_e6b18dc2-6782-4009-8baa-e1afe4a71f48" xlink:to="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable_50734351-eb27-4437-a079-02882afd7df4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_bce07a67-59f8-40e9-a265-e383c9198443" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable_50734351-eb27-4437-a079-02882afd7df4" xlink:to="loc_ifrs-full_MaturityAxis_bce07a67-59f8-40e9-a265-e383c9198443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_bce07a67-59f8-40e9-a265-e383c9198443_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_bce07a67-59f8-40e9-a265-e383c9198443" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_bce07a67-59f8-40e9-a265-e383c9198443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_bce07a67-59f8-40e9-a265-e383c9198443" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_0aaeff43-09e8-4da4-9caa-483edcbc2a97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_0aaeff43-09e8-4da4-9caa-483edcbc2a97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_9f955834-9c4f-4ab1-84ce-84b6fc8c7868" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_9f955834-9c4f-4ab1-84ce-84b6fc8c7868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_ca9e7f90-3e09-41c9-9f23-51bba04ace9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_ca9e7f90-3e09-41c9-9f23-51bba04ace9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_038d9476-5180-49e3-9e6f-fe56bd67418c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_038d9476-5180-49e3-9e6f-fe56bd67418c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations_019ab0ae-b304-4505-9f29-b05895ecfc85" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems_e6b18dc2-6782-4009-8baa-e1afe4a71f48" xlink:to="loc_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations_019ab0ae-b304-4505-9f29-b05895ecfc85" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_6e06637e-17b7-4e93-996a-0bcfbf76c40d" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_6e06637e-17b7-4e93-996a-0bcfbf76c40d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_687f41bf-86c3-4504-afb2-c83c0872f726" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_6e06637e-17b7-4e93-996a-0bcfbf76c40d" xlink:to="loc_sny_PrincipalAlliancesAxis_687f41bf-86c3-4504-afb2-c83c0872f726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_687f41bf-86c3-4504-afb2-c83c0872f726_default" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_687f41bf-86c3-4504-afb2-c83c0872f726" xlink:to="loc_sny_PrincipalAlliancesDomain_687f41bf-86c3-4504-afb2-c83c0872f726_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_e2d4c7f9-65f2-40c2-b4ff-22c9d59de0b4" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_687f41bf-86c3-4504-afb2-c83c0872f726" xlink:to="loc_sny_PrincipalAlliancesDomain_e2d4c7f9-65f2-40c2-b4ff-22c9d59de0b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_2c8e52e0-9b64-47df-a211-76b0ffc48e44" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_e2d4c7f9-65f2-40c2-b4ff-22c9d59de0b4" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_2c8e52e0-9b64-47df-a211-76b0ffc48e44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_c814c1f4-3f80-4d52-9644-d857f9548152" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_6e06637e-17b7-4e93-996a-0bcfbf76c40d" xlink:to="loc_ifrs-full_CounterpartiesAxis_c814c1f4-3f80-4d52-9644-d857f9548152" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_c814c1f4-3f80-4d52-9644-d857f9548152_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_c814c1f4-3f80-4d52-9644-d857f9548152" xlink:to="loc_ifrs-full_CounterpartiesMember_c814c1f4-3f80-4d52-9644-d857f9548152_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_13fec41d-10a0-4935-a69c-8dbcaead0021" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_c814c1f4-3f80-4d52-9644-d857f9548152" xlink:to="loc_ifrs-full_CounterpartiesMember_13fec41d-10a0-4935-a69c-8dbcaead0021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_f67c8507-4edf-4654-905b-5feccbc7b862" xlink:href="sny-20231231.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_13fec41d-10a0-4935-a69c-8dbcaead0021" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_f67c8507-4edf-4654-905b-5feccbc7b862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_fdb03f76-343a-4688-aaea-fe0cdab901d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_6e06637e-17b7-4e93-996a-0bcfbf76c40d" xlink:to="loc_ifrs-full_MaturityAxis_fdb03f76-343a-4688-aaea-fe0cdab901d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_fdb03f76-343a-4688-aaea-fe0cdab901d4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_fdb03f76-343a-4688-aaea-fe0cdab901d4" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_fdb03f76-343a-4688-aaea-fe0cdab901d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ebbced3d-48b1-4d5f-9e86-1a938aa3b54b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_fdb03f76-343a-4688-aaea-fe0cdab901d4" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ebbced3d-48b1-4d5f-9e86-1a938aa3b54b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_a964a21d-e1e6-4ca5-a954-2b30edbf04ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ebbced3d-48b1-4d5f-9e86-1a938aa3b54b" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_a964a21d-e1e6-4ca5-a954-2b30edbf04ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_215d61b1-a7f8-4a91-b657-d231e9034ee2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ebbced3d-48b1-4d5f-9e86-1a938aa3b54b" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_215d61b1-a7f8-4a91-b657-d231e9034ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_ac1ed249-6b27-4fa9-9e71-69bc8cdb991e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:to="loc_ifrs-full_NoncurrentProvisions_ac1ed249-6b27-4fa9-9e71-69bc8cdb991e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_1456afc6-0d99-47ef-b242-9ff26862831a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_1456afc6-0d99-47ef-b242-9ff26862831a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_31fb20d8-4197-4ade-a124-2bda9d060c47" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_31fb20d8-4197-4ade-a124-2bda9d060c47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_d7463160-b0b0-431c-8f71-ffe169f96950" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_d7463160-b0b0-431c-8f71-ffe169f96950" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_55faa2b8-9383-4595-91dd-a124b3a817fe" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_34cbc0c4-5509-4ace-a56a-c33d468825dc" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_55faa2b8-9383-4595-91dd-a124b3a817fe" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_34cbc0c4-5509-4ace-a56a-c33d468825dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_79afe6a4-9c55-4903-8ec2-9834a12f8566" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_34cbc0c4-5509-4ace-a56a-c33d468825dc" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_79afe6a4-9c55-4903-8ec2-9834a12f8566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_79afe6a4-9c55-4903-8ec2-9834a12f8566_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_79afe6a4-9c55-4903-8ec2-9834a12f8566" xlink:to="loc_ifrs-full_OtherProvisionsMember_79afe6a4-9c55-4903-8ec2-9834a12f8566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_79afe6a4-9c55-4903-8ec2-9834a12f8566" xlink:to="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember_0cdaa7e9-2fed-4c28-ba38-311fcef2d37e" xlink:href="sny-20231231.xsd#sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:to="loc_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember_0cdaa7e9-2fed-4c28-ba38-311fcef2d37e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember_103f5c68-01c7-4136-bd9d-e8148dc321fb" xlink:href="sny-20231231.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:to="loc_sny_ProvisionsForOtherLongTermBenefitsMember_103f5c68-01c7-4136-bd9d-e8148dc321fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember_936d0f11-9199-4962-ad95-66a1c3fab217" xlink:href="sny-20231231.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:to="loc_sny_NonCurrentRestructuringProvisionMember_936d0f11-9199-4962-ad95-66a1c3fab217" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember_341d60c5-e225-4ca2-ae0a-95ff9c50f210" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:to="loc_ifrs-full_MiscellaneousOtherProvisionsMember_341d60c5-e225-4ca2-ae0a-95ff9c50f210" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_55faa2b8-9383-4595-91dd-a124b3a817fe" xlink:to="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_2f7e804c-cf66-4297-8f70-a9ca4a2003a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_ifrs-full_NoncurrentProvisions_2f7e804c-cf66-4297-8f70-a9ca4a2003a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_c0fd20b0-4e86-41db-ba74-f998098fd31e" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_c0fd20b0-4e86-41db-ba74-f998098fd31e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInOtherProvisions_846c4ab1-a68f-4232-b827-6885e8bb51ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_ifrs-full_ChangesInOtherProvisions_846c4ab1-a68f-4232-b827-6885e8bb51ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_c40dcca6-bbf7-41f7-93bb-a30bfa5affaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_c40dcca6-bbf7-41f7-93bb-a30bfa5affaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_c776faa5-98ff-4168-91d7-e6f9e785ef2d" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_c776faa5-98ff-4168-91d7-e6f9e785ef2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_09cd4461-7d09-45e7-866b-adc4721b1c92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_09cd4461-7d09-45e7-866b-adc4721b1c92" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount_b4a62014-2893-4e0a-b38c-01559fc0b2b7" xlink:href="sny-20231231.xsd#sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount_b4a62014-2893-4e0a-b38c-01559fc0b2b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_1815135a-b305-4dd8-837e-8ac7e7393fd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_1815135a-b305-4dd8-837e-8ac7e7393fd4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans_d3b21ac5-4722-4650-a8ef-034b27152f9f" xlink:href="sny-20231231.xsd#sny_ActuarialGainsAndLossesOnDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans_d3b21ac5-4722-4650-a8ef-034b27152f9f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_e05277f4-9450-45ea-9179-06d847d1fc19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_d64f8516-3e43-4bcc-bb47-afcc2836ef7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_d64f8516-3e43-4bcc-bb47-afcc2836ef7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_d64f8516-3e43-4bcc-bb47-afcc2836ef7c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_d64f8516-3e43-4bcc-bb47-afcc2836ef7c" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_d64f8516-3e43-4bcc-bb47-afcc2836ef7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_d64f8516-3e43-4bcc-bb47-afcc2836ef7c" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LumpSumRetirementBenefitPlansMember_4bf8a67d-55ee-45cb-8d27-26b662b4f8a5" xlink:href="sny-20231231.xsd#sny_LumpSumRetirementBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_sny_LumpSumRetirementBenefitPlansMember_4bf8a67d-55ee-45cb-8d27-26b662b4f8a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefinedBenefitPensionPlansMember_0516e6bd-a3ba-4e37-a93f-2b8344b6cb73" xlink:href="sny-20231231.xsd#sny_DefinedBenefitPensionPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_sny_DefinedBenefitPensionPlansMember_0516e6bd-a3ba-4e37-a93f-2b8344b6cb73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TopUpDefinedBenefitPensionPlanMember_01707777-f279-4fae-b2dc-e7495c40754a" xlink:href="sny-20231231.xsd#sny_TopUpDefinedBenefitPensionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_sny_TopUpDefinedBenefitPensionPlanMember_01707777-f279-4fae-b2dc-e7495c40754a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiaventisPlusPensionPlanMember_eb668ad2-cf58-4451-b94c-d4e60dfe7a8d" xlink:href="sny-20231231.xsd#sny_SanofiaventisPlusPensionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_sny_SanofiaventisPlusPensionPlanMember_eb668ad2-cf58-4451-b94c-d4e60dfe7a8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MultiemployerDefinedBenefitPlansMember_f46582f1-0852-4884-9039-97cf2e9c801f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MultiemployerDefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_ifrs-full_MultiemployerDefinedBenefitPlansMember_f46582f1-0852-4884-9039-97cf2e9c801f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HealthcareCoverAndLifeInsuranceMember_2693b21a-0e3d-4566-80f1-74ac28884550" xlink:href="sny-20231231.xsd#sny_HealthcareCoverAndLifeInsuranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_sny_HealthcareCoverAndLifeInsuranceMember_2693b21a-0e3d-4566-80f1-74ac28884550" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_688c132d-161a-4901-976d-5d5f96fa7906" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_GeographicalAreasAxis_688c132d-161a-4901-976d-5d5f96fa7906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_688c132d-161a-4901-976d-5d5f96fa7906_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_688c132d-161a-4901-976d-5d5f96fa7906" xlink:to="loc_ifrs-full_GeographicalAreasMember_688c132d-161a-4901-976d-5d5f96fa7906_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_688c132d-161a-4901-976d-5d5f96fa7906" xlink:to="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_5122bc24-95ca-4bf8-aa87-dc5717273e9b" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:to="loc_country_FR_5122bc24-95ca-4bf8-aa87-dc5717273e9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_6bcce49e-4f2b-428c-9af7-58c4ee2703e5" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:to="loc_country_DE_6bcce49e-4f2b-428c-9af7-58c4ee2703e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7ce71bd4-1a00-4d2f-bc63-e4c909ddc530" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:to="loc_country_US_7ce71bd4-1a00-4d2f-bc63-e4c909ddc530" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_2d077a58-9832-48c8-bba9-2e02ff194df5" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:to="loc_country_GB_2d077a58-9832-48c8-bba9-2e02ff194df5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_fff40302-6197-4677-8c3b-93c9ea87ad41" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_RangeAxis_fff40302-6197-4677-8c3b-93c9ea87ad41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_fff40302-6197-4677-8c3b-93c9ea87ad41_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_fff40302-6197-4677-8c3b-93c9ea87ad41" xlink:to="loc_ifrs-full_RangesMember_fff40302-6197-4677-8c3b-93c9ea87ad41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_56cdf88f-97a9-4edc-bb25-4249ed2c5b72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_fff40302-6197-4677-8c3b-93c9ea87ad41" xlink:to="loc_ifrs-full_RangesMember_56cdf88f-97a9-4edc-bb25-4249ed2c5b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_51b19af3-a4ae-4e87-916c-5c4739807ba7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_56cdf88f-97a9-4edc-bb25-4249ed2c5b72" xlink:to="loc_ifrs-full_BottomOfRangeMember_51b19af3-a4ae-4e87-916c-5c4739807ba7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_4f0bf0d3-80ba-402b-aa62-5b97897a97c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_56cdf88f-97a9-4edc-bb25-4249ed2c5b72" xlink:to="loc_ifrs-full_TopOfRangeMember_4f0bf0d3-80ba-402b-aa62-5b97897a97c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_21d45091-c6b4-4e36-b7a7-febe8e00ad48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_21d45091-c6b4-4e36-b7a7-febe8e00ad48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_21d45091-c6b4-4e36-b7a7-febe8e00ad48_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_21d45091-c6b4-4e36-b7a7-febe8e00ad48" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_21d45091-c6b4-4e36-b7a7-febe8e00ad48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_21d45091-c6b4-4e36-b7a7-febe8e00ad48" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QualifiedDefinedBenefitPensionPlansMember_c0787548-0b71-4234-8b4a-8d8e299cefd1" xlink:href="sny-20231231.xsd#sny_QualifiedDefinedBenefitPensionPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:to="loc_sny_QualifiedDefinedBenefitPensionPlansMember_c0787548-0b71-4234-8b4a-8d8e299cefd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonQualifiedDefinedBenefitPensionPlansMember_7ef170a7-860d-4f69-b4b5-015fea937448" xlink:href="sny-20231231.xsd#sny_NonQualifiedDefinedBenefitPensionPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:to="loc_sny_NonQualifiedDefinedBenefitPensionPlansMember_7ef170a7-860d-4f69-b4b5-015fea937448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_36c92980-2e36-4c62-a20a-2a088b0dcca7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:to="loc_ifrs-full_PlanAssetsMember_36c92980-2e36-4c62-a20a-2a088b0dcca7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UncertaintiesOverIncomeTaxTreatmentsMember_05654d7f-8b47-42e8-a614-2fc63766c275" xlink:href="sny-20231231.xsd#sny_UncertaintiesOverIncomeTaxTreatmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:to="loc_sny_UncertaintiesOverIncomeTaxTreatmentsMember_05654d7f-8b47-42e8-a614-2fc63766c275" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_176d8ec2-6e02-417b-a428-29fbdb0c94ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_176d8ec2-6e02-417b-a428-29fbdb0c94ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_176d8ec2-6e02-417b-a428-29fbdb0c94ec_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_176d8ec2-6e02-417b-a428-29fbdb0c94ec" xlink:to="loc_ifrs-full_OtherProvisionsMember_176d8ec2-6e02-417b-a428-29fbdb0c94ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_31dc99bc-64e5-4453-845a-f5af4834d92b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_176d8ec2-6e02-417b-a428-29fbdb0c94ec" xlink:to="loc_ifrs-full_OtherProvisionsMember_31dc99bc-64e5-4453-845a-f5af4834d92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NewBusinessModelRolloutInVariousGeographiesMember_759bd1de-cf49-4ba2-86d6-db14a446abdd" xlink:href="sny-20231231.xsd#sny_NewBusinessModelRolloutInVariousGeographiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_31dc99bc-64e5-4453-845a-f5af4834d92b" xlink:to="loc_sny_NewBusinessModelRolloutInVariousGeographiesMember_759bd1de-cf49-4ba2-86d6-db14a446abdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEnvironmentRelatedProvisionMember_e68d82ea-9a1b-4655-a902-e8817b44b334" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEnvironmentRelatedProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_31dc99bc-64e5-4453-845a-f5af4834d92b" xlink:to="loc_ifrs-full_OtherEnvironmentRelatedProvisionMember_e68d82ea-9a1b-4655-a902-e8817b44b334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_8b1d91c1-37b7-4404-9700-5b8f162b990a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_8b1d91c1-37b7-4404-9700-5b8f162b990a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_8b1d91c1-37b7-4404-9700-5b8f162b990a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_8b1d91c1-37b7-4404-9700-5b8f162b990a" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_8b1d91c1-37b7-4404-9700-5b8f162b990a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_5eef6f53-dc2c-4c0b-ac04-f618a9e342ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_8b1d91c1-37b7-4404-9700-5b8f162b990a" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_5eef6f53-dc2c-4c0b-ac04-f618a9e342ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EvotecMember_da0ec3e1-5e87-4360-9fe6-1cda0e5e8281" xlink:href="sny-20231231.xsd#sny_EvotecMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_5eef6f53-dc2c-4c0b-ac04-f618a9e342ca" xlink:to="loc_sny_EvotecMember_da0ec3e1-5e87-4360-9fe6-1cda0e5e8281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_5a22572a-98c0-4e93-861d-a781ab632171" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_MaturityAxis_5a22572a-98c0-4e93-861d-a781ab632171" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_5a22572a-98c0-4e93-861d-a781ab632171_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_5a22572a-98c0-4e93-861d-a781ab632171" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_5a22572a-98c0-4e93-861d-a781ab632171_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_d42b3962-7ee0-446e-9c23-ceb51882f3ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_5a22572a-98c0-4e93-861d-a781ab632171" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_d42b3962-7ee0-446e-9c23-ceb51882f3ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_17c2ab30-638b-4607-8e7f-6023b914a49a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d42b3962-7ee0-446e-9c23-ceb51882f3ee" xlink:to="loc_ifrs-full_LaterThanOneYearMember_17c2ab30-638b-4607-8e7f-6023b914a49a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_6409055b-662c-40f9-a3c6-0d12bde1483a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_6409055b-662c-40f9-a3c6-0d12bde1483a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6409055b-662c-40f9-a3c6-0d12bde1483a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_6409055b-662c-40f9-a3c6-0d12bde1483a" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_6409055b-662c-40f9-a3c6-0d12bde1483a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_c5167015-ea7c-4451-b65f-5f3a758415fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_6409055b-662c-40f9-a3c6-0d12bde1483a" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_c5167015-ea7c-4451-b65f-5f3a758415fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USLegalRestructuringMember_28ec9c6e-898f-4af1-8856-2dc893e5aaf7" xlink:href="sny-20231231.xsd#sny_USLegalRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_c5167015-ea7c-4451-b65f-5f3a758415fd" xlink:to="loc_sny_USLegalRestructuringMember_28ec9c6e-898f-4af1-8856-2dc893e5aaf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCountriesIncludedInPensionPlans_e230d453-ef4c-4090-a3fd-ea6131b24990" xlink:href="sny-20231231.xsd#sny_NumberOfCountriesIncludedInPensionPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_NumberOfCountriesIncludedInPensionPlans_e230d453-ef4c-4090-a3fd-ea6131b24990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionObligationPercentageToDefinedBenefitLiability_0f3e51a4-8041-4806-abe7-cc2102b0eef9" xlink:href="sny-20231231.xsd#sny_PensionObligationPercentageToDefinedBenefitLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_PensionObligationPercentageToDefinedBenefitLiability_0f3e51a4-8041-4806-abe7-cc2102b0eef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionObligationPercentageToPlanAssets_d5042d9b-c5da-469d-872a-f07489f869a1" xlink:href="sny-20231231.xsd#sny_PensionObligationPercentageToPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_PensionObligationPercentageToPlanAssets_d5042d9b-c5da-469d-872a-f07489f869a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling_2413016d-4534-46cc-bca8-6f4dd47d7436" xlink:href="sny-20231231.xsd#sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling_2413016d-4534-46cc-bca8-6f4dd47d7436" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_657f0451-1bae-4284-a16a-56dd22f46106" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_657f0451-1bae-4284-a16a-56dd22f46106" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDefinedBenefitPlans_6ac7d8fd-6829-4e27-ad7f-f04472d8d429" xlink:href="sny-20231231.xsd#sny_NumberOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_NumberOfDefinedBenefitPlans_6ac7d8fd-6829-4e27-ad7f-f04472d8d429" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_4f098c4e-f608-494d-99cb-e22d26cec4ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_4f098c4e-f608-494d-99cb-e22d26cec4ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefinedBenefitPlansVestingRightsPercentage_384929dc-561a-4b64-be43-52b0a8d1a5f2" xlink:href="sny-20231231.xsd#sny_DefinedBenefitPlansVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_DefinedBenefitPlansVestingRightsPercentage_384929dc-561a-4b64-be43-52b0a8d1a5f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RetirementAge_5326649b-1a0c-45de-be17-8a8527d92bc2" xlink:href="sny-20231231.xsd#sny_RetirementAge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_RetirementAge_5326649b-1a0c-45de-be17-8a8527d92bc2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotionalRetirementAge_b4857dbd-7faa-45a2-81c6-a2ea948920c4" xlink:href="sny-20231231.xsd#sny_NotionalRetirementAge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_NotionalRetirementAge_b4857dbd-7faa-45a2-81c6-a2ea948920c4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans_d152a109-26e4-47a3-ae9a-53a79779fce1" xlink:href="sny-20231231.xsd#sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans_d152a109-26e4-47a3-ae9a-53a79779fce1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod_05440518-e5b9-48b7-84e0-7a95802e3c0f" xlink:href="sny-20231231.xsd#sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod_05440518-e5b9-48b7-84e0-7a95802e3c0f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths_5bec066d-78ce-42a9-83fa-6360b1e3bec4" xlink:href="sny-20231231.xsd#sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths_5bec066d-78ce-42a9-83fa-6360b1e3bec4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive_e56a1efa-9795-4ccc-9a03-d471056a3e3a" xlink:href="sny-20231231.xsd#sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive_e56a1efa-9795-4ccc-9a03-d471056a3e3a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InventoryTotalQuotasHeld_470521f1-bdc1-4c5d-b529-cc4ae5c55c2f" xlink:href="sny-20231231.xsd#sny_InventoryTotalQuotasHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_InventoryTotalQuotasHeld_470521f1-bdc1-4c5d-b529-cc4ae5c55c2f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_89bff345-fe5a-4275-a370-e41b3fabb86f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_89bff345-fe5a-4275-a370-e41b3fabb86f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_661d91eb-5267-45b0-b552-021e6379222a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_661d91eb-5267-45b0-b552-021e6379222a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognizedRepresentingEstimatedCost_a4d1de4f-d4f5-4c47-8355-5b6ea4b2dc10" xlink:href="sny-20231231.xsd#sny_LiabilityRecognizedRepresentingEstimatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_LiabilityRecognizedRepresentingEstimatedCost_a4d1de4f-d4f5-4c47-8355-5b6ea4b2dc10" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod_8efeb2f9-518f-4d18-8a05-95d6ec53c2ec" xlink:href="sny-20231231.xsd#sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod_8efeb2f9-518f-4d18-8a05-95d6ec53c2ec" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised_c7f69d58-bb1b-41d5-93fb-0daa0b040524" xlink:href="sny-20231231.xsd#sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised_c7f69d58-bb1b-41d5-93fb-0daa0b040524" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CapitalLossesCarryBackPeriod_4d481628-dfd9-47f9-b6d7-5fc4aa1cc0f5" xlink:href="sny-20231231.xsd#sny_CapitalLossesCarryBackPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_CapitalLossesCarryBackPeriod_4d481628-dfd9-47f9-b6d7-5fc4aa1cc0f5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CapitalLossesUsedAgainstCapitalGainsPercentage_fb99f819-da19-4b1a-8979-484ea67a41e1" xlink:href="sny-20231231.xsd#sny_CapitalLossesUsedAgainstCapitalGainsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_CapitalLossesUsedAgainstCapitalGainsPercentage_fb99f819-da19-4b1a-8979-484ea67a41e1" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f7085afe-e8ea-4f04-aff6-84cfaa4210b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f7085afe-e8ea-4f04-aff6-84cfaa4210b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_621f57be-6301-4238-b66b-1a74a1fe358d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f7085afe-e8ea-4f04-aff6-84cfaa4210b4" xlink:to="loc_ifrs-full_GeographicalAreasAxis_621f57be-6301-4238-b66b-1a74a1fe358d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_621f57be-6301-4238-b66b-1a74a1fe358d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_621f57be-6301-4238-b66b-1a74a1fe358d" xlink:to="loc_ifrs-full_GeographicalAreasMember_621f57be-6301-4238-b66b-1a74a1fe358d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_621f57be-6301-4238-b66b-1a74a1fe358d" xlink:to="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_e0d8fd76-bdd2-4897-ba4c-a86070da676e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:to="loc_country_FR_e0d8fd76-bdd2-4897-ba4c-a86070da676e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_9445173e-99f0-45a4-83fe-047cd2699e49" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:to="loc_country_DE_9445173e-99f0-45a4-83fe-047cd2699e49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b8d2851a-98e7-41c9-bdc4-7106cde4d4a8" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:to="loc_country_US_b8d2851a-98e7-41c9-bdc4-7106cde4d4a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_0bd8d214-c628-40a8-a8d4-9c0a58e34311" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:to="loc_country_GB_0bd8d214-c628-40a8-a8d4-9c0a58e34311" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_b2d024d3-8a9b-4a7e-a255-dd26920e966f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f7085afe-e8ea-4f04-aff6-84cfaa4210b4" xlink:to="loc_ifrs-full_RangeAxis_b2d024d3-8a9b-4a7e-a255-dd26920e966f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_b2d024d3-8a9b-4a7e-a255-dd26920e966f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_b2d024d3-8a9b-4a7e-a255-dd26920e966f" xlink:to="loc_ifrs-full_RangesMember_b2d024d3-8a9b-4a7e-a255-dd26920e966f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_b2d024d3-8a9b-4a7e-a255-dd26920e966f" xlink:to="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_be38d468-5d68-488a-a3ad-1057463e2d55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_ifrs-full_BottomOfRangeMember_be38d468-5d68-488a-a3ad-1057463e2d55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_61294a04-d280-4dcf-a0c6-12dbb1978b76" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_ifrs-full_TopOfRangeMember_61294a04-d280-4dcf-a0c6-12dbb1978b76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinimumPlan1Member_73cd3d92-b6f6-438a-8cd8-aa695224d2cf" xlink:href="sny-20231231.xsd#sny_MinimumPlan1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_sny_MinimumPlan1Member_73cd3d92-b6f6-438a-8cd8-aa695224d2cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumPlan1Member_39a9dc8b-fa4d-477a-b009-6668dfb87f5c" xlink:href="sny-20231231.xsd#sny_MaximumPlan1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_sny_MaximumPlan1Member_39a9dc8b-fa4d-477a-b009-6668dfb87f5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinimumPlan2Member_952fd100-31e1-4184-a5b4-e65b55a80db2" xlink:href="sny-20231231.xsd#sny_MinimumPlan2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_sny_MinimumPlan2Member_952fd100-31e1-4184-a5b4-e65b55a80db2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumPlan2Member_5a9d613f-bd95-4828-b39f-03018a992017" xlink:href="sny-20231231.xsd#sny_MaximumPlan2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_sny_MaximumPlan2Member_5a9d613f-bd95-4828-b39f-03018a992017" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_3e56b96f-dd4d-4f76-bd23-d416dd23cf30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_3e56b96f-dd4d-4f76-bd23-d416dd23cf30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_f97e2efa-d7a9-4f7e-91aa-197c8bf927a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_f97e2efa-d7a9-4f7e-91aa-197c8bf927a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_4c71d33d-1a69-44f4-8d86-1ea7dd9cd566" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_4c71d33d-1a69-44f4-8d86-1ea7dd9cd566" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates_e4e2af12-49ac-4160-9e6e-f50d51e42386" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates_e4e2af12-49ac-4160-9e6e-f50d51e42386" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_cd6673f8-ac60-4717-9da0-99e965761b08" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_cd6673f8-ac60-4717-9da0-99e965761b08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_5c03fbad-e4b8-487d-a845-936cbfa0aa35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_5c03fbad-e4b8-487d-a845-936cbfa0aa35" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_7479fce0-d6c2-48b4-8427-9589e3196f59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7b1ebae3-8aca-473b-9322-6b1be914ec57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_7479fce0-d6c2-48b4-8427-9589e3196f59" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7b1ebae3-8aca-473b-9322-6b1be914ec57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_157b8218-3727-46e4-998d-6ab864410546" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7b1ebae3-8aca-473b-9322-6b1be914ec57" xlink:to="loc_ifrs-full_GeographicalAreasAxis_157b8218-3727-46e4-998d-6ab864410546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_157b8218-3727-46e4-998d-6ab864410546_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_157b8218-3727-46e4-998d-6ab864410546" xlink:to="loc_ifrs-full_GeographicalAreasMember_157b8218-3727-46e4-998d-6ab864410546_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_157b8218-3727-46e4-998d-6ab864410546" xlink:to="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_b2c8c07b-d95b-484d-ac09-9d2137ea7be6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:to="loc_country_FR_b2c8c07b-d95b-484d-ac09-9d2137ea7be6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_38df537e-2830-4472-80a9-4b8ad7cb831e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:to="loc_country_DE_38df537e-2830-4472-80a9-4b8ad7cb831e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_da97e99f-95ca-4c71-8ae9-d48b514502d3" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:to="loc_country_US_da97e99f-95ca-4c71-8ae9-d48b514502d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_59fe8ce5-f1b1-4db5-b4ac-40f415c6ebee" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:to="loc_country_GB_59fe8ce5-f1b1-4db5-b4ac-40f415c6ebee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_c3e93656-f02d-458b-bd86-e026c58e19e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_7479fce0-d6c2-48b4-8427-9589e3196f59" xlink:to="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_c3e93656-f02d-458b-bd86-e026c58e19e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1ec06ed0-eca2-4274-b2ba-c53bd1846eee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1ec06ed0-eca2-4274-b2ba-c53bd1846eee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_aca9fea1-080b-46a0-ad02-cd7c90eca1bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1ec06ed0-eca2-4274-b2ba-c53bd1846eee" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_aca9fea1-080b-46a0-ad02-cd7c90eca1bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_aca9fea1-080b-46a0-ad02-cd7c90eca1bc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_aca9fea1-080b-46a0-ad02-cd7c90eca1bc" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_aca9fea1-080b-46a0-ad02-cd7c90eca1bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_aca9fea1-080b-46a0-ad02-cd7c90eca1bc" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_60de853a-71bd-440c-a6f5-a111bd86b5ca" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:to="loc_country_FR_60de853a-71bd-440c-a6f5-a111bd86b5ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_771667c7-aee2-4a52-985e-41e58d05920c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:to="loc_country_DE_771667c7-aee2-4a52-985e-41e58d05920c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5a2b402a-fab8-4a99-a92c-7325047a9a8d" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:to="loc_country_US_5a2b402a-fab8-4a99-a92c-7325047a9a8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_5f1b08aa-084d-44c1-a793-a8317acc23c5" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:to="loc_country_GB_5f1b08aa-084d-44c1-a793-a8317acc23c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_3a5ddea5-7224-4030-9f05-892eec001c20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1ec06ed0-eca2-4274-b2ba-c53bd1846eee" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_3a5ddea5-7224-4030-9f05-892eec001c20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_3a5ddea5-7224-4030-9f05-892eec001c20_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_3a5ddea5-7224-4030-9f05-892eec001c20" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_3a5ddea5-7224-4030-9f05-892eec001c20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_3a5ddea5-7224-4030-9f05-892eec001c20" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_f8751d1f-d852-4eac-b556-7b047bd8e68a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_f8751d1f-d852-4eac-b556-7b047bd8e68a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_e248aee7-8ff0-4166-ae8b-0d9a5cd263a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_e248aee7-8ff0-4166-ae8b-0d9a5cd263a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_14e2045f-e429-499c-9241-a5b07bfb4e1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_14e2045f-e429-499c-9241-a5b07bfb4e1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember_b714a08b-81db-4154-bb63-81a2abe23bca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:to="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember_b714a08b-81db-4154-bb63-81a2abe23bca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialAssumptionOfMortalityTableMember_a90850b7-21e5-45b8-8753-86920d47e2cd" xlink:href="sny-20231231.xsd#sny_ActuarialAssumptionOfMortalityTableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:to="loc_sny_ActuarialAssumptionOfMortalityTableMember_a90850b7-21e5-45b8-8753-86920d47e2cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_cc4ad276-89e7-4191-8cbb-4e2985e7a108" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_cc4ad276-89e7-4191-8cbb-4e2985e7a108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_940b36b6-b69c-41e1-85db-e9fd34c216b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_940b36b6-b69c-41e1-85db-e9fd34c216b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_9ff55d9e-85c1-410d-9c27-d5e8e6a926e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:to="loc_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_9ff55d9e-85c1-410d-9c27-d5e8e6a926e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PossibleIncreaseInMortalityTableInYears_91cc31e7-234f-4be2-9430-9f041800c827" xlink:href="sny-20231231.xsd#sny_PossibleIncreaseInMortalityTableInYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:to="loc_sny_PossibleIncreaseInMortalityTableInYears_91cc31e7-234f-4be2-9430-9f041800c827" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_ab142e2e-c06d-4678-8a1a-0412da178461" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_ab142e2e-c06d-4678-8a1a-0412da178461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_ab142e2e-c06d-4678-8a1a-0412da178461_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_ab142e2e-c06d-4678-8a1a-0412da178461" xlink:to="loc_ifrs-full_OtherProvisionsMember_ab142e2e-c06d-4678-8a1a-0412da178461_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_bec9cdc2-91c4-4af7-af6c-8769b047510d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_ab142e2e-c06d-4678-8a1a-0412da178461" xlink:to="loc_ifrs-full_OtherProvisionsMember_bec9cdc2-91c4-4af7-af6c-8769b047510d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember_7bf95bb0-7d83-4117-9789-196dcc4c8e2f" xlink:href="sny-20231231.xsd#sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_bec9cdc2-91c4-4af7-af6c-8769b047510d" xlink:to="loc_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember_7bf95bb0-7d83-4117-9789-196dcc4c8e2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_647abf2b-a0b2-4642-951e-054c07931830" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_647abf2b-a0b2-4642-951e-054c07931830" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_647abf2b-a0b2-4642-951e-054c07931830_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_647abf2b-a0b2-4642-951e-054c07931830" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_647abf2b-a0b2-4642-951e-054c07931830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_06c70d65-0e87-4c56-bbb0-cd31d656c582" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_647abf2b-a0b2-4642-951e-054c07931830" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_06c70d65-0e87-4c56-bbb0-cd31d656c582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_1fb16b85-4c6d-41b0-8ad4-f75c2d10591f" xlink:href="sny-20231231.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_06c70d65-0e87-4c56-bbb0-cd31d656c582" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_1fb16b85-4c6d-41b0-8ad4-f75c2d10591f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6a1746ac-459b-4576-8e47-b2fb77a4ec98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6a1746ac-459b-4576-8e47-b2fb77a4ec98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_6a1746ac-459b-4576-8e47-b2fb77a4ec98_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6a1746ac-459b-4576-8e47-b2fb77a4ec98" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_6a1746ac-459b-4576-8e47-b2fb77a4ec98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fb554368-fd93-411e-9a4a-d314b5a14982" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6a1746ac-459b-4576-8e47-b2fb77a4ec98" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fb554368-fd93-411e-9a4a-d314b5a14982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_3f5d41e7-7953-4a14-bf73-2e3839485fa5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fb554368-fd93-411e-9a4a-d314b5a14982" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_3f5d41e7-7953-4a14-bf73-2e3839485fa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_641d5a6d-3102-43ab-8de9-ad9fb8985429" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fb554368-fd93-411e-9a4a-d314b5a14982" xlink:to="loc_ifrs-full_PlanAssetsMember_641d5a6d-3102-43ab-8de9-ad9fb8985429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfAssetCeilingMember_78166727-42a5-4fb7-9111-cd5fad6a2ab9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfAssetCeilingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fb554368-fd93-411e-9a4a-d314b5a14982" xlink:to="loc_ifrs-full_EffectOfAssetCeilingMember_78166727-42a5-4fb7-9111-cd5fad6a2ab9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_511b8fe7-1fae-487c-8628-a1bea6747f64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:to="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_511b8fe7-1fae-487c-8628-a1bea6747f64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_511b8fe7-1fae-487c-8628-a1bea6747f64_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_511b8fe7-1fae-487c-8628-a1bea6747f64" xlink:to="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_511b8fe7-1fae-487c-8628-a1bea6747f64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_f98c0e62-d2f4-4bc5-9f4f-0aceaf564dc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_511b8fe7-1fae-487c-8628-a1bea6747f64" xlink:to="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_f98c0e62-d2f4-4bc5-9f4f-0aceaf564dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_1881f0e3-57f5-4a29-bd91-55017485c81e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_f98c0e62-d2f4-4bc5-9f4f-0aceaf564dc7" xlink:to="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_1881f0e3-57f5-4a29-bd91-55017485c81e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_ef4d04f7-3ba6-423d-b12c-a715dbdac7e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:to="loc_ifrs-full_GeographicalAreasAxis_ef4d04f7-3ba6-423d-b12c-a715dbdac7e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_ef4d04f7-3ba6-423d-b12c-a715dbdac7e9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ef4d04f7-3ba6-423d-b12c-a715dbdac7e9" xlink:to="loc_ifrs-full_GeographicalAreasMember_ef4d04f7-3ba6-423d-b12c-a715dbdac7e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_aa1b4336-26ef-4c84-a95b-910363cf4d31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ef4d04f7-3ba6-423d-b12c-a715dbdac7e9" xlink:to="loc_ifrs-full_GeographicalAreasMember_aa1b4336-26ef-4c84-a95b-910363cf4d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_4b89fe51-6b2f-4939-a2a0-482bb716bf64" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_aa1b4336-26ef-4c84-a95b-910363cf4d31" xlink:to="loc_country_GB_4b89fe51-6b2f-4939-a2a0-482bb716bf64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_b5bbe19a-b66b-46f9-b966-d412de5fa09a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_b5bbe19a-b66b-46f9-b966-d412de5fa09a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_9a08015d-36bb-406c-bea5-965ab9ab9578" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_9a08015d-36bb-406c-bea5-965ab9ab9578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_e0ebfee1-fe5e-4ada-9484-3d0d8e2e9686" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_e0ebfee1-fe5e-4ada-9484-3d0d8e2e9686" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_5e47fdcf-3579-40de-bc6f-e87cbca80ab8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_5e47fdcf-3579-40de-bc6f-e87cbca80ab8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_a7698bf9-4a41-41b2-b378-4ba98347e920" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_a7698bf9-4a41-41b2-b378-4ba98347e920" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_eadeea87-461b-4a88-a32b-eb1d7e797ad6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_eadeea87-461b-4a88-a32b-eb1d7e797ad6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan_e2c3d85c-4209-43fb-a88a-e6469b7aaf91" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan_e2c3d85c-4209-43fb-a88a-e6469b7aaf91" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset_d51e21d8-a6a2-4c38-84dd-2536fa28ec97" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset_d51e21d8-a6a2-4c38-84dd-2536fa28ec97" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BenefitsPaidOrPayable_d0c57f31-9e7f-4e93-b74b-732c863def5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BenefitsPaidOrPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_BenefitsPaidOrPayable_d0c57f31-9e7f-4e93-b74b-732c863def5a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset_18ca26f4-784e-4f9c-bc1a-8d9ec2304f71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset_18ca26f4-784e-4f9c-bc1a-8d9ec2304f71" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_91a4a3ae-349e-4622-8af4-2996b147b9d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_91a4a3ae-349e-4622-8af4-2996b147b9d0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_e4a0b049-d5c9-451b-a3f9-1fa2c4ccf936" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_e4a0b049-d5c9-451b-a3f9-1fa2c4ccf936" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod_4eb38a50-27ec-468f-9f96-278256ffb99d" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod_4eb38a50-27ec-468f-9f96-278256ffb99d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_6b0c65ee-5a4a-44bd-bc3d-d98bc76b80c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_6b0c65ee-5a4a-44bd-bc3d-d98bc76b80c8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_754bc410-7978-4b36-831c-9f5915351c6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_754bc410-7978-4b36-831c-9f5915351c6f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_957d97dd-05cb-4d72-8852-05b2f81c6c3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_957d97dd-05cb-4d72-8852-05b2f81c6c3b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_f1b47880-5955-4dcb-9fba-24ab20af7bcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_f1b47880-5955-4dcb-9fba-24ab20af7bcb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_4671a96d-3919-4cda-9be3-3836d2e7a4f4" xlink:href="sny-20231231.xsd#sny_PreFundedPensionObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_PreFundedPensionObligations_4671a96d-3919-4cda-9be3-3836d2e7a4f4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_c9d42b2c-c1d8-4528-8809-b7f46acf2d2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_NoncurrentProvisions_c9d42b2c-c1d8-4528-8809-b7f46acf2d2e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_548ceda2-f360-4651-a40a-7d6b307629eb" xlink:href="sny-20231231.xsd#sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_548ceda2-f360-4651-a40a-7d6b307629eb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_d89a5762-4769-446b-bb4e-e02d9bda0574" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_79bc2192-15bf-48fd-8153-4ed0fbc2c361" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_79bc2192-15bf-48fd-8153-4ed0fbc2c361" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeBenefitsExpenseGain_e93aab95-c0e6-4f61-8570-e47239f9cd51" xlink:href="sny-20231231.xsd#sny_EmployeeBenefitsExpenseGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_EmployeeBenefitsExpenseGain_e93aab95-c0e6-4f61-8570-e47239f9cd51" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f00e0961-74d5-4193-b488-5b1c6000d516" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f00e0961-74d5-4193-b488-5b1c6000d516" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_dec1ae08-4f38-4922-b083-83f2a3ad9f6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f00e0961-74d5-4193-b488-5b1c6000d516" xlink:to="loc_ifrs-full_GeographicalAreasAxis_dec1ae08-4f38-4922-b083-83f2a3ad9f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_dec1ae08-4f38-4922-b083-83f2a3ad9f6d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_dec1ae08-4f38-4922-b083-83f2a3ad9f6d" xlink:to="loc_ifrs-full_GeographicalAreasMember_dec1ae08-4f38-4922-b083-83f2a3ad9f6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_dec1ae08-4f38-4922-b083-83f2a3ad9f6d" xlink:to="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_0f9f6d55-bfde-4719-890f-57e751da9573" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:to="loc_country_FR_0f9f6d55-bfde-4719-890f-57e751da9573" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_b849f979-d7e5-4cbf-8593-9acce0082d76" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:to="loc_country_DE_b849f979-d7e5-4cbf-8593-9acce0082d76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c1bfe499-4f6c-426d-98b1-8680e711b68f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:to="loc_country_US_c1bfe499-4f6c-426d-98b1-8680e711b68f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_3fe0a4df-fffa-4676-ad72-70f380123f54" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:to="loc_country_GB_3fe0a4df-fffa-4676-ad72-70f380123f54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_0ebb4da2-6472-4591-b46e-604bcb50e393" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:to="loc_sny_OtherCountriesMember_0ebb4da2-6472-4591-b46e-604bcb50e393" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_8301d0b8-5f9a-459a-9b4d-21336ca82052" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f00e0961-74d5-4193-b488-5b1c6000d516" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_8301d0b8-5f9a-459a-9b4d-21336ca82052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_8301d0b8-5f9a-459a-9b4d-21336ca82052_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_8301d0b8-5f9a-459a-9b4d-21336ca82052" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_8301d0b8-5f9a-459a-9b4d-21336ca82052_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_9df7e86f-8c06-4edd-97cf-8c0bf7110e79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_8301d0b8-5f9a-459a-9b4d-21336ca82052" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_9df7e86f-8c06-4edd-97cf-8c0bf7110e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_25d1049c-0b0c-4fb9-ad30-8b9ab01a03b4" xlink:href="sny-20231231.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_9df7e86f-8c06-4edd-97cf-8c0bf7110e79" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_25d1049c-0b0c-4fb9-ad30-8b9ab01a03b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_d61457d9-97c8-450d-9646-437baa305b51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_d61457d9-97c8-450d-9646-437baa305b51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_96effc1b-6a57-472e-b423-d3f9ddbb5ef4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_96effc1b-6a57-472e-b423-d3f9ddbb5ef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanAssetsEffectOfAssetCeiling_aade5de5-d75d-4998-b673-c0703907400c" xlink:href="sny-20231231.xsd#sny_PlanAssetsEffectOfAssetCeiling"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:to="loc_sny_PlanAssetsEffectOfAssetCeiling_aade5de5-d75d-4998-b673-c0703907400c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_7f28e1a5-e68a-4a42-9ce1-12161ed48ec6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_7f28e1a5-e68a-4a42-9ce1-12161ed48ec6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_686f2627-2961-476a-9a18-c5a83d3ffe39" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_c28a6f8f-919d-4858-8b2f-b689e690aa8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_686f2627-2961-476a-9a18-c5a83d3ffe39" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_c28a6f8f-919d-4858-8b2f-b689e690aa8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_3acbf6f3-0210-48a5-b9c1-b64f9cac5cf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_c28a6f8f-919d-4858-8b2f-b689e690aa8c" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_3acbf6f3-0210-48a5-b9c1-b64f9cac5cf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_3acbf6f3-0210-48a5-b9c1-b64f9cac5cf8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_3acbf6f3-0210-48a5-b9c1-b64f9cac5cf8" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_3acbf6f3-0210-48a5-b9c1-b64f9cac5cf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_3acbf6f3-0210-48a5-b9c1-b64f9cac5cf8" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalents1Member_97e5be46-1b01-4477-8549-a3db5a6f1c2f" xlink:href="sny-20231231.xsd#sny_CashAndCashEquivalents1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_CashAndCashEquivalents1Member_97e5be46-1b01-4477-8549-a3db5a6f1c2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsMember_fa9d13ca-aa02-411a-8232-d8e6f364d2be" xlink:href="sny-20231231.xsd#sny_EquityInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_EquityInstrumentsMember_fa9d13ca-aa02-411a-8232-d8e6f364d2be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BondsAndSimilarInstrumentsMember_75777d5a-3583-427f-89e8-2ab2765fc620" xlink:href="sny-20231231.xsd#sny_BondsAndSimilarInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_BondsAndSimilarInstrumentsMember_75777d5a-3583-427f-89e8-2ab2765fc620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RealEstate1Member_102b86a7-1049-469b-89fb-9512af94bb9b" xlink:href="sny-20231231.xsd#sny_RealEstate1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_RealEstate1Member_102b86a7-1049-469b-89fb-9512af94bb9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_6b75a3c1-a421-43b4-9f6f-1a3195b528a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_ifrs-full_DerivativesMember_6b75a3c1-a421-43b4-9f6f-1a3195b528a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommoditiesMember_52e463ca-daee-4687-b7c0-238536eb9849" xlink:href="sny-20231231.xsd#sny_CommoditiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_CommoditiesMember_52e463ca-daee-4687-b7c0-238536eb9849" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssetsMember_a33f8c6d-7bc6-485b-9a57-014f3dfe61be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_ifrs-full_OtherAssetsMember_a33f8c6d-7bc6-485b-9a57-014f3dfe61be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HedgeFunds1Member_607fa5e7-3dc5-4e61-87bc-dbaddf0d4303" xlink:href="sny-20231231.xsd#sny_HedgeFunds1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_HedgeFunds1Member_607fa5e7-3dc5-4e61-87bc-dbaddf0d4303" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InsurancePoliciesMember_e38ea1a8-baaa-4821-a0a2-44144ebcf9c5" xlink:href="sny-20231231.xsd#sny_InsurancePoliciesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_InsurancePoliciesMember_e38ea1a8-baaa-4821-a0a2-44144ebcf9c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket_b2d52de9-cf8b-403c-b6e5-4db3f18034aa" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_686f2627-2961-476a-9a18-c5a83d3ffe39" xlink:to="loc_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket_b2d52de9-cf8b-403c-b6e5-4db3f18034aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities_63c2de71-0330-42dc-a220-9cc98a551fa2" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_686f2627-2961-476a-9a18-c5a83d3ffe39" xlink:to="loc_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities_63c2de71-0330-42dc-a220-9cc98a551fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssets_4c618caa-e036-402d-9e49-216340ab92ec" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_686f2627-2961-476a-9a18-c5a83d3ffe39" xlink:to="loc_sny_PercentageContributedToFairValueOfPlanAssets_4c618caa-e036-402d-9e49-216340ab92ec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_68901fe2-cf84-4bff-93dd-e4e3c8eae105" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_68901fe2-cf84-4bff-93dd-e4e3c8eae105" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_f4ea43df-6be7-483a-864f-5f4e077d28b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_68901fe2-cf84-4bff-93dd-e4e3c8eae105" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_f4ea43df-6be7-483a-864f-5f4e077d28b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_f4ea43df-6be7-483a-864f-5f4e077d28b7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_f4ea43df-6be7-483a-864f-5f4e077d28b7" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_f4ea43df-6be7-483a-864f-5f4e077d28b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_bbcc6825-6a8f-4f56-b678-939e93b3ccc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_f4ea43df-6be7-483a-864f-5f4e077d28b7" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_bbcc6825-6a8f-4f56-b678-939e93b3ccc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_28ab539d-f230-439f-b744-e389cea93bda" xlink:href="sny-20231231.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_bbcc6825-6a8f-4f56-b678-939e93b3ccc2" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_28ab539d-f230-439f-b744-e389cea93bda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_ab6d0bd7-945a-44e2-b254-a5e48178938d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_68901fe2-cf84-4bff-93dd-e4e3c8eae105" xlink:to="loc_ifrs-full_GeographicalAreasAxis_ab6d0bd7-945a-44e2-b254-a5e48178938d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_ab6d0bd7-945a-44e2-b254-a5e48178938d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ab6d0bd7-945a-44e2-b254-a5e48178938d" xlink:to="loc_ifrs-full_GeographicalAreasMember_ab6d0bd7-945a-44e2-b254-a5e48178938d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ab6d0bd7-945a-44e2-b254-a5e48178938d" xlink:to="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_fa440ab7-2fe1-4d60-808e-996b53bdc592" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:to="loc_country_FR_fa440ab7-2fe1-4d60-808e-996b53bdc592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_2525c0cc-ff4e-49b2-ab6d-ee5f7ad58ca5" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:to="loc_country_DE_2525c0cc-ff4e-49b2-ab6d-ee5f7ad58ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_543a5dbd-6a33-4a30-b9d5-3eff8e03474e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:to="loc_country_US_543a5dbd-6a33-4a30-b9d5-3eff8e03474e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_8bfbcf3a-b14c-4d40-8dc4-38cdea6c53a0" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:to="loc_country_GB_8bfbcf3a-b14c-4d40-8dc4-38cdea6c53a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_0e34c660-ab80-44cd-a83c-ff6ff3a85dcc" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:to="loc_sny_OtherCountriesMember_0e34c660-ab80-44cd-a83c-ff6ff3a85dcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_c95583e5-7988-43d3-933b-2875f2480d29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_c95583e5-7988-43d3-933b-2875f2480d29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement_6fb08c47-c9b4-4fbd-bb49-237f6adfd01f" xlink:href="sny-20231231.xsd#sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement_6fb08c47-c9b4-4fbd-bb49-237f6adfd01f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset_a8182946-fa77-47c8-8448-f702b377f6d5" xlink:href="sny-20231231.xsd#sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset_a8182946-fa77-47c8-8448-f702b377f6d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_0098441a-5359-4d5f-bc31-b734c3650ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_0098441a-5359-4d5f-bc31-b734c3650ecd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_99b5972e-d604-4cf9-80c1-9d9304208cde" xlink:href="sny-20231231.xsd#sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_99b5972e-d604-4cf9-80c1-9d9304208cde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a1ecb945-b04d-45b0-bd52-d2f74df60910" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a1ecb945-b04d-45b0-bd52-d2f74df60910" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset_c37f42fc-de7c-4295-b483-3de555a9d00f" xlink:href="sny-20231231.xsd#sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset_c37f42fc-de7c-4295-b483-3de555a9d00f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_e277e021-2c71-45cb-9de3-50743e470ae0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_e277e021-2c71-45cb-9de3-50743e470ae0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_ef121a30-04e6-49d6-974b-7288eaa75b3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_e277e021-2c71-45cb-9de3-50743e470ae0" xlink:to="loc_ifrs-full_GeographicalAreasAxis_ef121a30-04e6-49d6-974b-7288eaa75b3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_ef121a30-04e6-49d6-974b-7288eaa75b3c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ef121a30-04e6-49d6-974b-7288eaa75b3c" xlink:to="loc_ifrs-full_GeographicalAreasMember_ef121a30-04e6-49d6-974b-7288eaa75b3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ef121a30-04e6-49d6-974b-7288eaa75b3c" xlink:to="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_2222104b-22c4-4b7a-a1b6-42bbfc9183ad" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:to="loc_country_FR_2222104b-22c4-4b7a-a1b6-42bbfc9183ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_863692b6-7b89-42b7-9c1c-4a6896718dc4" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:to="loc_country_DE_863692b6-7b89-42b7-9c1c-4a6896718dc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0f3ed8a8-141c-40d1-a771-36c782e92c2f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:to="loc_country_US_0f3ed8a8-141c-40d1-a771-36c782e92c2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_18776ad1-4102-4509-9836-13fd1e07d883" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:to="loc_country_GB_18776ad1-4102-4509-9836-13fd1e07d883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_529bf6fc-53de-46cb-9967-c28e08a09bea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_529bf6fc-53de-46cb-9967-c28e08a09bea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments_8eb37f78-eddf-4d97-b46a-a12f577f0c99" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:to="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments_8eb37f78-eddf-4d97-b46a-a12f577f0c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_9a36d477-ae94-4c8f-bfe2-faddd4f36f79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_9a36d477-ae94-4c8f-bfe2-faddd4f36f79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_fa11a2ef-a525-4614-a536-9c3f46945a9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_fa11a2ef-a525-4614-a536-9c3f46945a9f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_b700d284-62a9-458c-a9fd-edb1d990bd7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_a55dd250-100a-4fd8-bdc7-07bcef355ba2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_b700d284-62a9-458c-a9fd-edb1d990bd7e" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_a55dd250-100a-4fd8-bdc7-07bcef355ba2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_e8fd4961-2a51-4164-9a88-d49cc9628472" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_a55dd250-100a-4fd8-bdc7-07bcef355ba2" xlink:to="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_e8fd4961-2a51-4164-9a88-d49cc9628472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_e8fd4961-2a51-4164-9a88-d49cc9628472_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_e8fd4961-2a51-4164-9a88-d49cc9628472" xlink:to="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_e8fd4961-2a51-4164-9a88-d49cc9628472_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_fefe1705-f7c4-4f1e-a226-43f02bca3334" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_e8fd4961-2a51-4164-9a88-d49cc9628472" xlink:to="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_fefe1705-f7c4-4f1e-a226-43f02bca3334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_7ba1f1a9-ae3c-4cc3-98f3-a52c319e8f7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_fefe1705-f7c4-4f1e-a226-43f02bca3334" xlink:to="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_7ba1f1a9-ae3c-4cc3-98f3-a52c319e8f7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_32f9b1e7-5167-4a88-ad69-3312111a25b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WhollyUnfundedDefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_fefe1705-f7c4-4f1e-a226-43f02bca3334" xlink:to="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_32f9b1e7-5167-4a88-ad69-3312111a25b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_0ed6e8bb-c0f6-4f1e-9b2c-d8f7242f0a49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_a55dd250-100a-4fd8-bdc7-07bcef355ba2" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_0ed6e8bb-c0f6-4f1e-9b2c-d8f7242f0a49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_0ed6e8bb-c0f6-4f1e-9b2c-d8f7242f0a49_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_0ed6e8bb-c0f6-4f1e-9b2c-d8f7242f0a49" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_0ed6e8bb-c0f6-4f1e-9b2c-d8f7242f0a49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_eb5055ed-916c-45d2-a2fc-d7d277b8ce04" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_0ed6e8bb-c0f6-4f1e-9b2c-d8f7242f0a49" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_eb5055ed-916c-45d2-a2fc-d7d277b8ce04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_1240a0ac-c54e-416f-808b-8b42656573fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_eb5055ed-916c-45d2-a2fc-d7d277b8ce04" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_1240a0ac-c54e-416f-808b-8b42656573fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_345afaa1-3f77-4373-9df0-e3c83278a164" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_a55dd250-100a-4fd8-bdc7-07bcef355ba2" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_345afaa1-3f77-4373-9df0-e3c83278a164" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_345afaa1-3f77-4373-9df0-e3c83278a164_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_345afaa1-3f77-4373-9df0-e3c83278a164" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_345afaa1-3f77-4373-9df0-e3c83278a164_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_7348657a-66d8-4a22-b122-92362bfb9f58" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_345afaa1-3f77-4373-9df0-e3c83278a164" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_7348657a-66d8-4a22-b122-92362bfb9f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_8c898c67-ac4c-4c78-85a0-07705da357ec" xlink:href="sny-20231231.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_7348657a-66d8-4a22-b122-92362bfb9f58" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_8c898c67-ac4c-4c78-85a0-07705da357ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_ec9efc65-7b37-49f2-aa93-087b6811e5c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_b700d284-62a9-458c-a9fd-edb1d990bd7e" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_ec9efc65-7b37-49f2-aa93-087b6811e5c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_27d5a4f6-b684-4167-ba79-607854c5c9e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_27d5a4f6-b684-4167-ba79-607854c5c9e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_8d2d85a1-c742-40eb-80e6-f796b55533f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_27d5a4f6-b684-4167-ba79-607854c5c9e8" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_8d2d85a1-c742-40eb-80e6-f796b55533f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_8d2d85a1-c742-40eb-80e6-f796b55533f6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_8d2d85a1-c742-40eb-80e6-f796b55533f6" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_8d2d85a1-c742-40eb-80e6-f796b55533f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_2f34ab52-24d8-479f-9661-bf3b0bf10add" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_8d2d85a1-c742-40eb-80e6-f796b55533f6" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_2f34ab52-24d8-479f-9661-bf3b0bf10add" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_694af423-d339-4e27-8cae-bd843e05b942" xlink:href="sny-20231231.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_2f34ab52-24d8-479f-9661-bf3b0bf10add" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_694af423-d339-4e27-8cae-bd843e05b942" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_33199781-9c46-46b3-b28f-0aa41695030e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_ifrs-full_CostOfSales_33199781-9c46-46b3-b28f-0aa41695030e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1a3d877f-9a66-4202-ae0a-2975b81f2d0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_1a3d877f-9a66-4202-ae0a-2975b81f2d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1e1d6b1a-98d7-4848-a5aa-789ac7fbe370" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1e1d6b1a-98d7-4848-a5aa-789ac7fbe370" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_0f69d178-a888-4a91-ab4f-54030b0b402a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_0f69d178-a888-4a91-ab4f-54030b0b402a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestructuringCostsReversedAndSimilarItems_0edcf299-30ff-41a3-abaf-c0fbde7dfb6a" xlink:href="sny-20231231.xsd#sny_RestructuringCostsReversedAndSimilarItems"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_sny_RestructuringCostsReversedAndSimilarItems_0edcf299-30ff-41a3-abaf-c0fbde7dfb6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_a51e9c31-e7f5-4ac9-ad0c-da44f2b7b726" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_ifrs-full_FinanceCosts_a51e9c31-e7f5-4ac9-ad0c-da44f2b7b726" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_ab73ab74-f06c-4814-91d8-fc1412611bfb" xlink:href="sny-20231231.xsd#sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_ab73ab74-f06c-4814-91d8-fc1412611bfb" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_bdefc291-6226-477b-9131-317970c76873" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_70d64836-a078-4553-9de1-f22e4402dfe1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_bdefc291-6226-477b-9131-317970c76873" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_70d64836-a078-4553-9de1-f22e4402dfe1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_49646f25-108f-4c97-aa5b-f1ce9f1f0fa4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_70d64836-a078-4553-9de1-f22e4402dfe1" xlink:to="loc_ifrs-full_MaturityAxis_49646f25-108f-4c97-aa5b-f1ce9f1f0fa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_49646f25-108f-4c97-aa5b-f1ce9f1f0fa4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_49646f25-108f-4c97-aa5b-f1ce9f1f0fa4" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_49646f25-108f-4c97-aa5b-f1ce9f1f0fa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_d7f44e3b-1cf1-4fd0-b634-1274138b5c4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_49646f25-108f-4c97-aa5b-f1ce9f1f0fa4" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_d7f44e3b-1cf1-4fd0-b634-1274138b5c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_ee1799f8-0c92-455e-8eae-a63f08b7bf51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d7f44e3b-1cf1-4fd0-b634-1274138b5c4b" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_ee1799f8-0c92-455e-8eae-a63f08b7bf51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_7eb1afa8-7a3d-47ed-84ee-bb791b59f4dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_70d64836-a078-4553-9de1-f22e4402dfe1" xlink:to="loc_ifrs-full_GeographicalAreasAxis_7eb1afa8-7a3d-47ed-84ee-bb791b59f4dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_7eb1afa8-7a3d-47ed-84ee-bb791b59f4dd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_7eb1afa8-7a3d-47ed-84ee-bb791b59f4dd" xlink:to="loc_ifrs-full_GeographicalAreasMember_7eb1afa8-7a3d-47ed-84ee-bb791b59f4dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_7eb1afa8-7a3d-47ed-84ee-bb791b59f4dd" xlink:to="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_e3e9b7a9-7ae6-4ce3-9795-9f5cea558907" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:to="loc_country_FR_e3e9b7a9-7ae6-4ce3-9795-9f5cea558907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_6583925b-af80-4df1-b99a-3bf551dd1f9f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:to="loc_country_DE_6583925b-af80-4df1-b99a-3bf551dd1f9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c9ace286-6439-4ced-9859-e4403de9857d" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:to="loc_country_US_c9ace286-6439-4ced-9859-e4403de9857d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_9b3478f1-ae4a-485e-8371-aa28bcf70c94" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:to="loc_country_GB_9b3478f1-ae4a-485e-8371-aa28bcf70c94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_cdd7b302-df1a-44ed-a469-26f806f5fbe6" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:to="loc_sny_OtherCountriesMember_cdd7b302-df1a-44ed-a469-26f806f5fbe6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_6295c5fc-681b-4118-a37d-ac18677dd1f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_bdefc291-6226-477b-9131-317970c76873" xlink:to="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_6295c5fc-681b-4118-a37d-ac18677dd1f9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_cb44161b-7a4a-4fc3-9f3a-f9bebe185a44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_77d3c64f-354d-475d-ad6e-3f51e5a734fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_cb44161b-7a4a-4fc3-9f3a-f9bebe185a44" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_77d3c64f-354d-475d-ad6e-3f51e5a734fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_17272ed2-3211-4c8d-a5eb-bf91b148b648" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_77d3c64f-354d-475d-ad6e-3f51e5a734fc" xlink:to="loc_ifrs-full_GeographicalAreasAxis_17272ed2-3211-4c8d-a5eb-bf91b148b648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_17272ed2-3211-4c8d-a5eb-bf91b148b648_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_17272ed2-3211-4c8d-a5eb-bf91b148b648" xlink:to="loc_ifrs-full_GeographicalAreasMember_17272ed2-3211-4c8d-a5eb-bf91b148b648_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_17272ed2-3211-4c8d-a5eb-bf91b148b648" xlink:to="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_c7ad791e-357c-46bb-8b0b-e1ba662843e6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:to="loc_country_FR_c7ad791e-357c-46bb-8b0b-e1ba662843e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_ff056a15-d2d7-4415-b402-7c542de76a29" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:to="loc_country_DE_ff056a15-d2d7-4415-b402-7c542de76a29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_dff3e63a-5050-40a6-a491-d9fc23681e12" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:to="loc_country_US_dff3e63a-5050-40a6-a491-d9fc23681e12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_0d4aba01-a896-494f-a651-fbf6f4e192d7" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:to="loc_country_GB_0d4aba01-a896-494f-a651-fbf6f4e192d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_2c4ae2ca-fef1-4832-aee2-7f4c9b56cd9f" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:to="loc_sny_OtherCountriesMember_2c4ae2ca-fef1-4832-aee2-7f4c9b56cd9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_1b708b50-4881-4e79-ba2b-3f55d4921906" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_77d3c64f-354d-475d-ad6e-3f51e5a734fc" xlink:to="loc_ifrs-full_MaturityAxis_1b708b50-4881-4e79-ba2b-3f55d4921906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_1b708b50-4881-4e79-ba2b-3f55d4921906_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_1b708b50-4881-4e79-ba2b-3f55d4921906" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_1b708b50-4881-4e79-ba2b-3f55d4921906_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_1b708b50-4881-4e79-ba2b-3f55d4921906" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_d0bb4c6d-4df6-48c6-a708-9b3b6c660eb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_d0bb4c6d-4df6-48c6-a708-9b3b6c660eb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c68bb4e7-e6fd-4649-9c08-d68df92d28b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c68bb4e7-e6fd-4649-9c08-d68df92d28b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_aec65f16-9c42-4451-8bb5-b825258c5424" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_aec65f16-9c42-4451-8bb5-b825258c5424" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_b77b7126-e996-4cb5-ad78-464d2063ae05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_b77b7126-e996-4cb5-ad78-464d2063ae05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_c35a0516-138c-4adb-bbeb-5715b54d0b25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_c35a0516-138c-4adb-bbeb-5715b54d0b25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_b6b0e810-4e28-4974-abb8-02c5e547b683" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_b6b0e810-4e28-4974-abb8-02c5e547b683" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans_c518fd41-7ef4-4552-be0b-11d7178ba853" xlink:href="sny-20231231.xsd#sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_cb44161b-7a4a-4fc3-9f3a-f9bebe185a44" xlink:to="loc_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans_c518fd41-7ef4-4552-be0b-11d7178ba853" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fa15f4a4-c9fc-4fab-91cc-bd33662a5195" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7e7d9a37-92a0-4e7a-9f97-7d37f0acc598" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fa15f4a4-c9fc-4fab-91cc-bd33662a5195" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7e7d9a37-92a0-4e7a-9f97-7d37f0acc598" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_ee0f7ce8-6ded-43c9-8428-6a59a21d72ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7e7d9a37-92a0-4e7a-9f97-7d37f0acc598" xlink:to="loc_ifrs-full_MaturityAxis_ee0f7ce8-6ded-43c9-8428-6a59a21d72ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ee0f7ce8-6ded-43c9-8428-6a59a21d72ae_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_ee0f7ce8-6ded-43c9-8428-6a59a21d72ae" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ee0f7ce8-6ded-43c9-8428-6a59a21d72ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_ee0f7ce8-6ded-43c9-8428-6a59a21d72ae" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_13496d8e-c9cf-438d-bc0b-ae19f5467614" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_13496d8e-c9cf-438d-bc0b-ae19f5467614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_dc1384a8-97a4-4026-b5ca-55af506553dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_dc1384a8-97a4-4026-b5ca-55af506553dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_f5a5caa1-38d0-4bb1-a804-6abd773a7739" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_f5a5caa1-38d0-4bb1-a804-6abd773a7739" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_2a67b0ba-cbe1-4add-a353-8b709e62c55f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_2a67b0ba-cbe1-4add-a353-8b709e62c55f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans_b720941e-b944-4b07-a3d0-ef292c0a2f71" xlink:href="sny-20231231.xsd#sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fa15f4a4-c9fc-4fab-91cc-bd33662a5195" xlink:to="loc_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans_b720941e-b944-4b07-a3d0-ef292c0a2f71" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringProvisionsTable_0d513a08-df0b-40b2-8045-a6a774902ab5" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_sny_DisclosureOfRestructuringProvisionsTable_0d513a08-df0b-40b2-8045-a6a774902ab5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_a423ec1c-297c-4783-9cfb-d3e783f966cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsTable_0d513a08-df0b-40b2-8045-a6a774902ab5" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_a423ec1c-297c-4783-9cfb-d3e783f966cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_a423ec1c-297c-4783-9cfb-d3e783f966cc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_a423ec1c-297c-4783-9cfb-d3e783f966cc" xlink:to="loc_ifrs-full_OtherProvisionsMember_a423ec1c-297c-4783-9cfb-d3e783f966cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_6f7b191a-311e-4c2e-99cd-52bc04f18cf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_a423ec1c-297c-4783-9cfb-d3e783f966cc" xlink:to="loc_ifrs-full_OtherProvisionsMember_6f7b191a-311e-4c2e-99cd-52bc04f18cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestructuringProvisionMember_f603c2f9-5941-44e6-8fcd-09397876d4cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestructuringProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_6f7b191a-311e-4c2e-99cd-52bc04f18cf0" xlink:to="loc_ifrs-full_RestructuringProvisionMember_f603c2f9-5941-44e6-8fcd-09397876d4cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_0450f2bd-9d1d-4703-b8b2-23b6fcf7c3b5" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_0450f2bd-9d1d-4703-b8b2-23b6fcf7c3b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestructuringProvisionAbstract_87006ed1-4f14-4e9d-b300-3e84cbced079" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestructuringProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_ifrs-full_RestructuringProvisionAbstract_87006ed1-4f14-4e9d-b300-3e84cbced079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermRestructuringProvision_b8d19ce5-f40e-4f1d-8af6-9cf4b5d6a1d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermRestructuringProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RestructuringProvisionAbstract_87006ed1-4f14-4e9d-b300-3e84cbced079" xlink:to="loc_ifrs-full_LongtermRestructuringProvision_b8d19ce5-f40e-4f1d-8af6-9cf4b5d6a1d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermRestructuringProvision_a3e30ba2-03b6-4887-9d7b-646220a1ba51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermRestructuringProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RestructuringProvisionAbstract_87006ed1-4f14-4e9d-b300-3e84cbced079" xlink:to="loc_ifrs-full_ShorttermRestructuringProvision_a3e30ba2-03b6-4887-9d7b-646220a1ba51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod_e3edab22-c25b-4474-a7cf-b61654cc3471" xlink:href="sny-20231231.xsd#sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod_e3edab22-c25b-4474-a7cf-b61654cc3471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_0c7f4cf1-3655-40eb-9e55-5840a6cb9b34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_0c7f4cf1-3655-40eb-9e55-5840a6cb9b34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_251a9552-a221-4300-b35c-6622f6e6ca7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_251a9552-a221-4300-b35c-6622f6e6ca7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnwindingOfDiscount_5d423037-918b-4e9b-a88c-6c0a09e03586" xlink:href="sny-20231231.xsd#sny_UnwindingOfDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_sny_UnwindingOfDiscount_5d423037-918b-4e9b-a88c-6c0a09e03586" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_a63dbc03-54d5-411d-94bf-6f57a915ac7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_a63dbc03-54d5-411d-94bf-6f57a915ac7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_70601ed4-33f0-4715-ad21-4feacd10e41f" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_9b8cd62b-448e-4acf-9c75-c67656ac427c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f3068181-ba65-44b7-b8c7-a2932144b201" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_9b8cd62b-448e-4acf-9c75-c67656ac427c" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f3068181-ba65-44b7-b8c7-a2932144b201" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_60fcdcaf-ef50-483f-84af-d24368954fb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f3068181-ba65-44b7-b8c7-a2932144b201" xlink:to="loc_ifrs-full_GeographicalAreasAxis_60fcdcaf-ef50-483f-84af-d24368954fb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_60fcdcaf-ef50-483f-84af-d24368954fb7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_60fcdcaf-ef50-483f-84af-d24368954fb7" xlink:to="loc_ifrs-full_GeographicalAreasMember_60fcdcaf-ef50-483f-84af-d24368954fb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_6ce8710b-4676-41d5-a8ba-812fb4465522" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_60fcdcaf-ef50-483f-84af-d24368954fb7" xlink:to="loc_ifrs-full_GeographicalAreasMember_6ce8710b-4676-41d5-a8ba-812fb4465522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_45a6e0f4-5149-4fc1-91ec-5c6d7cabeba6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_6ce8710b-4676-41d5-a8ba-812fb4465522" xlink:to="loc_country_FR_45a6e0f4-5149-4fc1-91ec-5c6d7cabeba6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_cc8512b9-f83d-4018-a01e-67addf1fbaed" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_6ce8710b-4676-41d5-a8ba-812fb4465522" xlink:to="loc_sny_OtherCountriesMember_cc8512b9-f83d-4018-a01e-67addf1fbaed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_f7c75156-4160-4731-81f4-e71532aa9849" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f3068181-ba65-44b7-b8c7-a2932144b201" xlink:to="loc_ifrs-full_MaturityAxis_f7c75156-4160-4731-81f4-e71532aa9849" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_f7c75156-4160-4731-81f4-e71532aa9849_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_f7c75156-4160-4731-81f4-e71532aa9849" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_f7c75156-4160-4731-81f4-e71532aa9849_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_f7c75156-4160-4731-81f4-e71532aa9849" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_55381cfd-d419-462c-b84f-fb353df22207" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_55381cfd-d419-462c-b84f-fb353df22207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_afe999e1-8845-46fd-a23d-3bf04b67b4ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_afe999e1-8845-46fd-a23d-3bf04b67b4ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_b519b09b-b324-4fbd-9a5f-2e4785899e6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_b519b09b-b324-4fbd-9a5f-2e4785899e6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_77e22068-ea98-4ee2-a23b-8224d1d446eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_77e22068-ea98-4ee2-a23b-8224d1d446eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_6a4c5e19-2e96-4eb0-b5af-6a0b07b975d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_9b8cd62b-448e-4acf-9c75-c67656ac427c" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_6a4c5e19-2e96-4eb0-b5af-6a0b07b975d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_86185204-bab6-4fce-9768-773e25c3e345" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_86185204-bab6-4fce-9768-773e25c3e345" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_595d2c41-7cf3-4d49-8bde-4653e415c349" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_86185204-bab6-4fce-9768-773e25c3e345" xlink:to="loc_sny_TypesOfAgreementAxis_595d2c41-7cf3-4d49-8bde-4653e415c349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_595d2c41-7cf3-4d49-8bde-4653e415c349_default" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_TypesOfAgreementAxis_595d2c41-7cf3-4d49-8bde-4653e415c349" xlink:to="loc_sny_TypesOfAgreementDomain_595d2c41-7cf3-4d49-8bde-4653e415c349_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_7fa4cde1-e12c-4f3e-b114-3c7dfdcb4426" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_TypesOfAgreementAxis_595d2c41-7cf3-4d49-8bde-4653e415c349" xlink:to="loc_sny_TypesOfAgreementDomain_7fa4cde1-e12c-4f3e-b114-3c7dfdcb4426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementWithGSKMember_e4042e6b-4204-4cee-9027-42beb46dca7d" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementWithGSKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_7fa4cde1-e12c-4f3e-b114-3c7dfdcb4426" xlink:to="loc_sny_CollaborationAgreementWithGSKMember_e4042e6b-4204-4cee-9027-42beb46dca7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember_07126f38-8e02-46d0-9eb8-1d009f6a35f6" xlink:href="sny-20231231.xsd#sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_TypesOfAgreementDomain_7fa4cde1-e12c-4f3e-b114-3c7dfdcb4426" xlink:to="loc_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember_07126f38-8e02-46d0-9eb8-1d009f6a35f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_6e5a86b9-e31c-467c-8aca-a9c4de5e308e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_6e5a86b9-e31c-467c-8aca-a9c4de5e308e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_a3d79bfb-0020-413e-b316-242f5f24613b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_a3d79bfb-0020-413e-b316-242f5f24613b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermRestructuringProvision_28cf096f-d51f-45db-b806-c8c11e339e88" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermRestructuringProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_ShorttermRestructuringProvision_28cf096f-d51f-45db-b806-c8c11e339e88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentInterestRateDerivativesPayable_ed2f4f1f-9473-4446-aeac-46e8671762fb" xlink:href="sny-20231231.xsd#sny_CurrentInterestRateDerivativesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_CurrentInterestRateDerivativesPayable_ed2f4f1f-9473-4446-aeac-46e8671762fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentCurrencyDerivativesPayable_c1dfa0ae-db5c-41f8-aa1b-96bf13c6ed2a" xlink:href="sny-20231231.xsd#sny_CurrentCurrencyDerivativesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_CurrentCurrencyDerivativesPayable_c1dfa0ae-db5c-41f8-aa1b-96bf13c6ed2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentEquityDerivativesPayable_5496f789-b7be-4dff-bca6-76a9ce5f6748" xlink:href="sny-20231231.xsd#sny_CurrentEquityDerivativesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_CurrentEquityDerivativesPayable_5496f789-b7be-4dff-bca6-76a9ce5f6748" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountsPayableForAcquisitionOfNonCurrentAssets_d3b60522-7664-43ea-a905-2bbfd7c12793" xlink:href="sny-20231231.xsd#sny_AmountsPayableForAcquisitionOfNonCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_AmountsPayableForAcquisitionOfNonCurrentAssets_d3b60522-7664-43ea-a905-2bbfd7c12793" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_4c0f2e22-f606-46c9-b1ea-ef4690807a38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_CurrentContractLiabilities_4c0f2e22-f606-46c9-b1ea-ef4690807a38" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_75cd0432-8525-4587-932d-fdc620762318" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_75cd0432-8525-4587-932d-fdc620762318" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_6292ccfd-cbdb-4bcd-aed2-1828c8bb5b4c" xlink:href="sny-20231231.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_6292ccfd-cbdb-4bcd-aed2-1828c8bb5b4c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_6ec8a74d-1595-4f70-a6e3-94a052a56a85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_OtherRevenue_6ec8a74d-1595-4f70-a6e3-94a052a56a85" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesPayable_3138a1ba-3e4e-4756-bc49-7b2bdcc6a9a6" xlink:href="sny-20231231.xsd#sny_RoyaltiesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_RoyaltiesPayable_3138a1ba-3e4e-4756-bc49-7b2bdcc6a9a6" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_dbabc657-d238-407d-a26b-0bac989d25ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_dbabc657-d238-407d-a26b-0bac989d25ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_d52854b9-7187-4bc2-a838-32d6fe5ba396" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_dbabc657-d238-407d-a26b-0bac989d25ca" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_d52854b9-7187-4bc2-a838-32d6fe5ba396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_d52854b9-7187-4bc2-a838-32d6fe5ba396_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_d52854b9-7187-4bc2-a838-32d6fe5ba396" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_d52854b9-7187-4bc2-a838-32d6fe5ba396_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_d52854b9-7187-4bc2-a838-32d6fe5ba396" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesMember_b94883c3-de6d-4bfe-bcc9-20f743efe92c" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:to="loc_sny_CurrencyDerivativesMember_b94883c3-de6d-4bfe-bcc9-20f743efe92c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesOperatingMember_9cee2896-5613-4520-b743-696caab0d65a" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesOperatingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:to="loc_sny_CurrencyDerivativesOperatingMember_9cee2896-5613-4520-b743-696caab0d65a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesFinancialMember_9c6b7ebb-b2ca-4f28-a753-3d3a0781d507" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesFinancialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:to="loc_sny_CurrencyDerivativesFinancialMember_9c6b7ebb-b2ca-4f28-a753-3d3a0781d507" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateDerivativesMember_518747a0-5b7c-4607-8485-7b7e84ee6702" xlink:href="sny-20231231.xsd#sny_InterestRateDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:to="loc_sny_InterestRateDerivativesMember_518747a0-5b7c-4607-8485-7b7e84ee6702" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityDerivativesMember_86c25e97-a735-4014-ad6a-974d85f83c60" xlink:href="sny-20231231.xsd#sny_EquityDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:to="loc_sny_EquityDerivativesMember_86c25e97-a735-4014-ad6a-974d85f83c60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_0ca71ff6-f2e0-4401-bd3a-38e7cf5e58da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_0ca71ff6-f2e0-4401-bd3a-38e7cf5e58da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets_a159d67c-d093-468b-860e-b5686bb8fc49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialAssets_a159d67c-d093-468b-860e-b5686bb8fc49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_27d23520-c6c9-4d1b-9bd3-bffd56bff1be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_DerivativeFinancialAssets_27d23520-c6c9-4d1b-9bd3-bffd56bff1be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_f558fe0f-6504-43a3-812a-124dfb4d3be2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_f558fe0f-6504-43a3-812a-124dfb4d3be2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_e6d4a8b9-5c55-4238-b384-190a499955a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_e6d4a8b9-5c55-4238-b384-190a499955a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_7421bd2e-73fc-416f-8c7c-88551dd2cf7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_7421bd2e-73fc-416f-8c7c-88551dd2cf7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_132736d9-a061-41a0-b20f-0a8bb86ecba0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_132736d9-a061-41a0-b20f-0a8bb86ecba0" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_26011cb1-284c-46c8-b63d-fedb8296af24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_fa20864a-bdea-4e55-82dc-e44d6d5a62fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_26011cb1-284c-46c8-b63d-fedb8296af24" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_fa20864a-bdea-4e55-82dc-e44d6d5a62fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_0e3fe47c-c756-4e3e-a6be-8d7c0c562381" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_fa20864a-bdea-4e55-82dc-e44d6d5a62fe" xlink:to="loc_ifrs-full_MeasurementAxis_0e3fe47c-c756-4e3e-a6be-8d7c0c562381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_0e3fe47c-c756-4e3e-a6be-8d7c0c562381_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_0e3fe47c-c756-4e3e-a6be-8d7c0c562381" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_0e3fe47c-c756-4e3e-a6be-8d7c0c562381_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_0fed53bf-0376-4002-9064-6020bd161e9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_0e3fe47c-c756-4e3e-a6be-8d7c0c562381" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_0fed53bf-0376-4002-9064-6020bd161e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_37e446bf-6970-4272-ad08-6148642d80e8" xlink:href="sny-20231231.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_0fed53bf-0376-4002-9064-6020bd161e9e" xlink:to="loc_sny_AtNotionalAmountMember_37e446bf-6970-4272-ad08-6148642d80e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_9e699dd3-555a-4706-9103-4c44ef3992ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_0fed53bf-0376-4002-9064-6020bd161e9e" xlink:to="loc_ifrs-full_AtFairValueMember_9e699dd3-555a-4706-9103-4c44ef3992ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_1b10de0d-8882-4bd0-a5c6-c530f8f5fa1c" xlink:href="sny-20231231.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_0fed53bf-0376-4002-9064-6020bd161e9e" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_1b10de0d-8882-4bd0-a5c6-c530f8f5fa1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_0e402936-caf2-41e3-8027-1dbe43f0036c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_fa20864a-bdea-4e55-82dc-e44d6d5a62fe" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_0e402936-caf2-41e3-8027-1dbe43f0036c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_0e402936-caf2-41e3-8027-1dbe43f0036c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_0e402936-caf2-41e3-8027-1dbe43f0036c" xlink:to="loc_ifrs-full_TypesOfHedgesMember_0e402936-caf2-41e3-8027-1dbe43f0036c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_fc2ea1ec-b9b9-420a-9c1f-da61dadb70f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_0e402936-caf2-41e3-8027-1dbe43f0036c" xlink:to="loc_ifrs-full_TypesOfHedgesMember_fc2ea1ec-b9b9-420a-9c1f-da61dadb70f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_3c9b2d2a-4397-4da4-a4de-fd9918e42146" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_fc2ea1ec-b9b9-420a-9c1f-da61dadb70f9" xlink:to="loc_ifrs-full_CashFlowHedgesMember_3c9b2d2a-4397-4da4-a4de-fd9918e42146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember_79953801-7864-4cfa-9b0c-82fa404d1fb2" xlink:href="sny-20231231.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_fc2ea1ec-b9b9-420a-9c1f-da61dadb70f9" xlink:to="loc_sny_NotEligibleForHedgeAccountingMember_79953801-7864-4cfa-9b0c-82fa404d1fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2ad05c5a-fa87-471b-8804-550ac0a3674e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_fa20864a-bdea-4e55-82dc-e44d6d5a62fe" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2ad05c5a-fa87-471b-8804-550ac0a3674e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_2ad05c5a-fa87-471b-8804-550ac0a3674e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2ad05c5a-fa87-471b-8804-550ac0a3674e" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_2ad05c5a-fa87-471b-8804-550ac0a3674e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_6589164a-c9ec-43be-99f2-941f3975f25d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2ad05c5a-fa87-471b-8804-550ac0a3674e" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_6589164a-c9ec-43be-99f2-941f3975f25d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_6589164a-c9ec-43be-99f2-941f3975f25d" xlink:to="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_f26aaf50-02ce-4798-9c27-e16b4d9c5a9f" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_f26aaf50-02ce-4798-9c27-e16b4d9c5a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_10e6d022-4d89-420b-9421-c265184f128f" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_10e6d022-4d89-420b-9421-c265184f128f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_2b0b558a-173c-4db8-940d-55953993515a" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_2b0b558a-173c-4db8-940d-55953993515a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInJapaneseYenMember_305a673f-956e-4abe-be0b-46168237fd2d" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInJapaneseYenMember_305a673f-956e-4abe-be0b-46168237fd2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInKoreanWonMember_677229a3-6f5c-4aad-b34b-66692e222ba6" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInKoreanWonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInKoreanWonMember_677229a3-6f5c-4aad-b34b-66692e222ba6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInTaiwanDollarMember_4a0ad8c0-c43f-4378-a233-094c6e227021" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInTaiwanDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInTaiwanDollarMember_4a0ad8c0-c43f-4378-a233-094c6e227021" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_6589164a-c9ec-43be-99f2-941f3975f25d" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInUSDollarMember_b2d43e04-08c1-4ff7-90fb-f8af7715c932" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInUSDollarMember_b2d43e04-08c1-4ff7-90fb-f8af7715c932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInSingaporeDollarMember_4946f79a-cd25-40c1-9a2f-e12d75d97504" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInSingaporeDollarMember_4946f79a-cd25-40c1-9a2f-e12d75d97504" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember_9fcefc7f-80e3-4bf2-900b-cdd8dfd62dab" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember_9fcefc7f-80e3-4bf2-900b-cdd8dfd62dab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInKoreanWonMember_77de5474-72ea-49c4-ae70-b7d283de4860" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInKoreanWonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInKoreanWonMember_77de5474-72ea-49c4-ae70-b7d283de4860" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInJapaneseYenMember_aea853dc-5139-4895-83bb-6a7bb4e4f240" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInJapaneseYenMember_aea853dc-5139-4895-83bb-6a7bb4e4f240" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInTaiwanDollarMember_d046da23-0f65-46a0-9c4b-e6a79db93da9" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInTaiwanDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInTaiwanDollarMember_d046da23-0f65-46a0-9c4b-e6a79db93da9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInHungarianForintMember_ac4aa2e1-4a18-421e-b6ee-809e4ace6049" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInHungarianForintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInHungarianForintMember_ac4aa2e1-4a18-421e-b6ee-809e4ace6049" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInRussianRoubleMember_4c417d44-ae2a-4a0e-80fc-1cf8ee808a5a" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInRussianRoubleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInRussianRoubleMember_4c417d44-ae2a-4a0e-80fc-1cf8ee808a5a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments_82841e54-3aee-43a9-b1b9-e460b612ad44" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_26011cb1-284c-46c8-b63d-fedb8296af24" xlink:to="loc_sny_DerivativeFinancialInstruments_82841e54-3aee-43a9-b1b9-e460b612ad44" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_30cf6538-0ff5-4909-921d-85c7a5928b44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_30cf6538-0ff5-4909-921d-85c7a5928b44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_41f32f09-ad9b-4045-a364-f83ebe568f3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_30cf6538-0ff5-4909-921d-85c7a5928b44" xlink:to="loc_ifrs-full_MeasurementAxis_41f32f09-ad9b-4045-a364-f83ebe568f3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_41f32f09-ad9b-4045-a364-f83ebe568f3d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_41f32f09-ad9b-4045-a364-f83ebe568f3d" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_41f32f09-ad9b-4045-a364-f83ebe568f3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_2ab78ff9-db80-4745-a6d4-aada94fca341" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_41f32f09-ad9b-4045-a364-f83ebe568f3d" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_2ab78ff9-db80-4745-a6d4-aada94fca341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_ecc4b003-149b-468e-a1da-5d0a14a0e2f9" xlink:href="sny-20231231.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_2ab78ff9-db80-4745-a6d4-aada94fca341" xlink:to="loc_sny_AtNotionalAmountMember_ecc4b003-149b-468e-a1da-5d0a14a0e2f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_41ba778d-491d-496c-bcd2-2d92596f6417" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_2ab78ff9-db80-4745-a6d4-aada94fca341" xlink:to="loc_ifrs-full_AtFairValueMember_41ba778d-491d-496c-bcd2-2d92596f6417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_5ba76cf8-7a56-42b1-9e42-fb110d9f10e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_30cf6538-0ff5-4909-921d-85c7a5928b44" xlink:to="loc_ifrs-full_MaturityAxis_5ba76cf8-7a56-42b1-9e42-fb110d9f10e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_5ba76cf8-7a56-42b1-9e42-fb110d9f10e5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_5ba76cf8-7a56-42b1-9e42-fb110d9f10e5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_5ba76cf8-7a56-42b1-9e42-fb110d9f10e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ff4b1096-02dd-47ce-941e-d4768b9c3bc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_5ba76cf8-7a56-42b1-9e42-fb110d9f10e5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ff4b1096-02dd-47ce-941e-d4768b9c3bc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_6dca7a9d-6d8b-40d4-afe5-de27bc597569" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ff4b1096-02dd-47ce-941e-d4768b9c3bc1" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_6dca7a9d-6d8b-40d4-afe5-de27bc597569" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_1f074568-fb34-42fd-8e44-45b67aaa336a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_30cf6538-0ff5-4909-921d-85c7a5928b44" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_1f074568-fb34-42fd-8e44-45b67aaa336a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_1f074568-fb34-42fd-8e44-45b67aaa336a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_1f074568-fb34-42fd-8e44-45b67aaa336a" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_1f074568-fb34-42fd-8e44-45b67aaa336a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_1f074568-fb34-42fd-8e44-45b67aaa336a" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_a65b4f89-f99b-4e5a-b6f1-7fd09dd3ab69" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:to="loc_sny_ForwardCurrencySalesMember_a65b4f89-f99b-4e5a-b6f1-7fd09dd3ab69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_183b2a4b-b363-4106-9b52-37d9677371e1" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_a65b4f89-f99b-4e5a-b6f1-7fd09dd3ab69" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_183b2a4b-b363-4106-9b52-37d9677371e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_da56eab4-1d49-4449-b1d1-32a957348d8e" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_a65b4f89-f99b-4e5a-b6f1-7fd09dd3ab69" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_da56eab4-1d49-4449-b1d1-32a957348d8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanMember_4a8e5984-915b-41c2-a24e-6f79fe0c8064" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInChineseYuanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencySalesMember_a65b4f89-f99b-4e5a-b6f1-7fd09dd3ab69" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanMember_4a8e5984-915b-41c2-a24e-6f79fe0c8064" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_ebba4cd4-e401-4eba-9a38-111977ab26ec" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_ebba4cd4-e401-4eba-9a38-111977ab26ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInUSDollarMember_0de51e8d-bf93-41b5-aef6-304edbdbeab1" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_ebba4cd4-e401-4eba-9a38-111977ab26ec" xlink:to="loc_sny_ForwardCurrencyPurchasedInUSDollarMember_0de51e8d-bf93-41b5-aef6-304edbdbeab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInSingaporeDollarMember_b1b7bf60-89a0-49b8-90f5-1cbb91251c89" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInSingaporeDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_ebba4cd4-e401-4eba-9a38-111977ab26ec" xlink:to="loc_sny_ForwardCurrencyPurchasedInSingaporeDollarMember_b1b7bf60-89a0-49b8-90f5-1cbb91251c89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInJapaneseYenMember_5837e857-cf98-47d1-b29e-a943bd77c661" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_ebba4cd4-e401-4eba-9a38-111977ab26ec" xlink:to="loc_sny_ForwardCurrencyPurchasedInJapaneseYenMember_5837e857-cf98-47d1-b29e-a943bd77c661" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember_5fc7b2ae-2223-41aa-ae44-bda05f703884" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInUSDollarUSBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:to="loc_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember_5fc7b2ae-2223-41aa-ae44-bda05f703884" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember_8e5c83ad-3ba9-4d54-8414-d607d6d772ac" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:to="loc_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember_8e5c83ad-3ba9-4d54-8414-d607d6d772ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_00c58fc2-47c0-4bbb-8d60-53fb36948704" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:to="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_00c58fc2-47c0-4bbb-8d60-53fb36948704" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_3ade63d6-f761-4ca0-b1e1-ad579dd9a256" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:to="loc_ifrs-full_NotionalAmount_3ade63d6-f761-4ca0-b1e1-ad579dd9a256" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_796b2a38-14c6-4671-a929-592de172d23a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:to="loc_ifrs-full_DerivativeFinancialAssets_796b2a38-14c6-4671-a929-592de172d23a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_a8ea35bb-abba-490f-b188-c9cbb05b71b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_a8ea35bb-abba-490f-b188-c9cbb05b71b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_99fd2a86-8186-42ac-82d9-7d7a111b5362" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_99fd2a86-8186-42ac-82d9-7d7a111b5362" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65e4c39c-8b8d-4792-9c5d-8d37584e0367" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65e4c39c-8b8d-4792-9c5d-8d37584e0367" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_bfbc2f1e-3cc6-4568-b755-f0e2f6b7d847" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_bfbc2f1e-3cc6-4568-b755-f0e2f6b7d847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_bfbc2f1e-3cc6-4568-b755-f0e2f6b7d847_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_bfbc2f1e-3cc6-4568-b755-f0e2f6b7d847" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_bfbc2f1e-3cc6-4568-b755-f0e2f6b7d847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_bfbc2f1e-3cc6-4568-b755-f0e2f6b7d847" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member_39717edc-a99c-4372-b01e-6fbaa8b906ca" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member_39717edc-a99c-4372-b01e-6fbaa8b906ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member_1dae4335-d80b-4c31-89e3-96024e2b6869" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member_1dae4335-d80b-4c31-89e3-96024e2b6869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_5dcf598a-d3d1-4843-bc18-ebe0d6c2ce7c" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive069Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_5dcf598a-d3d1-4843-bc18-ebe0d6c2ce7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_0256c234-9f4d-4e9c-8031-b2e2b387258b" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_0256c234-9f4d-4e9c-8031-b2e2b387258b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_f76bafe7-5a91-407e-b7fd-45c8f0be9b04" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive343Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_f76bafe7-5a91-407e-b7fd-45c8f0be9b04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member_ccd6b926-916a-47b7-8508-57f8b60c16d9" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member_ccd6b926-916a-47b7-8508-57f8b60c16d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember_07d59206-999e-4005-b6ae-84146f986ec3" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember_07d59206-999e-4005-b6ae-84146f986ec3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember_bebce6c7-7724-4686-a368-5fda4218c8de" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember_bebce6c7-7724-4686-a368-5fda4218c8de" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_fc46b097-9238-49a9-be90-8a9fc0407a90" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:to="loc_ifrs-full_MeasurementAxis_fc46b097-9238-49a9-be90-8a9fc0407a90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_fc46b097-9238-49a9-be90-8a9fc0407a90_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_fc46b097-9238-49a9-be90-8a9fc0407a90" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_fc46b097-9238-49a9-be90-8a9fc0407a90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_1d1dfb56-0db7-45e1-bb95-f32bc10d92fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_fc46b097-9238-49a9-be90-8a9fc0407a90" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_1d1dfb56-0db7-45e1-bb95-f32bc10d92fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_4cef8acd-0f9a-4c50-b882-fa95630decee" xlink:href="sny-20231231.xsd#sny_AtNotionalAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1d1dfb56-0db7-45e1-bb95-f32bc10d92fe" xlink:to="loc_sny_AtNotionalAmountMember_4cef8acd-0f9a-4c50-b882-fa95630decee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_0ba02217-f412-418a-84f9-75cab087b047" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1d1dfb56-0db7-45e1-bb95-f32bc10d92fe" xlink:to="loc_ifrs-full_AtFairValueMember_0ba02217-f412-418a-84f9-75cab087b047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_777eaceb-0dfe-4f96-abe7-feeffeb9344a" xlink:href="sny-20231231.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1d1dfb56-0db7-45e1-bb95-f32bc10d92fe" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_777eaceb-0dfe-4f96-abe7-feeffeb9344a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_0af56552-ea70-4ba3-94b3-0e2cb81f56d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:to="loc_ifrs-full_MaturityAxis_0af56552-ea70-4ba3-94b3-0e2cb81f56d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_0af56552-ea70-4ba3-94b3-0e2cb81f56d6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_0af56552-ea70-4ba3-94b3-0e2cb81f56d6" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_0af56552-ea70-4ba3-94b3-0e2cb81f56d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_0af56552-ea70-4ba3-94b3-0e2cb81f56d6" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_715ebc43-e8f5-4800-ab89-9cfcd2a6a850" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_715ebc43-e8f5-4800-ab89-9cfcd2a6a850" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c6b69124-83aa-4a79-b386-123a1b3655a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c6b69124-83aa-4a79-b386-123a1b3655a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_04404ae7-4d46-4a14-9253-797ac941e55a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_04404ae7-4d46-4a14-9253-797ac941e55a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_305df9c3-804c-4023-95c8-ebf538abb973" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_305df9c3-804c-4023-95c8-ebf538abb973" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_7c181904-4893-4db6-99c8-5ad3cdf70f50" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_7c181904-4893-4db6-99c8-5ad3cdf70f50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_d07e3959-99ee-4768-8a26-c4f4b400b945" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_d07e3959-99ee-4768-8a26-c4f4b400b945" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_d8678702-3a40-4413-ba18-f0e8618f3c47" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_d8678702-3a40-4413-ba18-f0e8618f3c47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_d8678702-3a40-4413-ba18-f0e8618f3c47_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_d8678702-3a40-4413-ba18-f0e8618f3c47" xlink:to="loc_ifrs-full_TypesOfHedgesMember_d8678702-3a40-4413-ba18-f0e8618f3c47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_3dec50fd-bb33-42f0-8157-c9c521c6de8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_d8678702-3a40-4413-ba18-f0e8618f3c47" xlink:to="loc_ifrs-full_TypesOfHedgesMember_3dec50fd-bb33-42f0-8157-c9c521c6de8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember_fd48a549-fb4d-4694-a8ed-3d8b5b1f108f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_3dec50fd-bb33-42f0-8157-c9c521c6de8c" xlink:to="loc_ifrs-full_FairValueHedgesMember_fd48a549-fb4d-4694-a8ed-3d8b5b1f108f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_d92710c1-aab7-47c8-8a51-94fb991f59de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfHedgesMember_3dec50fd-bb33-42f0-8157-c9c521c6de8c" xlink:to="loc_ifrs-full_CashFlowHedgesMember_d92710c1-aab7-47c8-8a51-94fb991f59de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsInterestRate_03dca2f6-ec33-45a6-aee1-6830f3e23207" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65e4c39c-8b8d-4792-9c5d-8d37584e0367" xlink:to="loc_sny_InterestRateSwapsInterestRate_03dca2f6-ec33-45a6-aee1-6830f3e23207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_3e0c7363-12ee-4b51-bea0-f6a96e777246" xlink:href="sny-20231231.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65e4c39c-8b8d-4792-9c5d-8d37584e0367" xlink:to="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_3e0c7363-12ee-4b51-bea0-f6a96e777246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments_9cfad909-ec73-472b-bace-14ac8dd63d44" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65e4c39c-8b8d-4792-9c5d-8d37584e0367" xlink:to="loc_sny_DerivativeFinancialInstruments_9cfad909-ec73-472b-bace-14ac8dd63d44" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_82101ac0-ed9c-4257-a5f8-aed234a72550" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_82101ac0-ed9c-4257-a5f8-aed234a72550" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_bd4ad79c-277a-457a-a75a-46271148e926" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_82101ac0-ed9c-4257-a5f8-aed234a72550" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_bd4ad79c-277a-457a-a75a-46271148e926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_bd4ad79c-277a-457a-a75a-46271148e926_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_bd4ad79c-277a-457a-a75a-46271148e926" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_bd4ad79c-277a-457a-a75a-46271148e926_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_3bb0aaf9-0a24-4d85-a59a-2495f83f0f40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_bd4ad79c-277a-457a-a75a-46271148e926" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_3bb0aaf9-0a24-4d85-a59a-2495f83f0f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialAssetsMember_6a8bbc2f-6f46-4e7a-aa6a-eba4162e3e24" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_3bb0aaf9-0a24-4d85-a59a-2495f83f0f40" xlink:to="loc_sny_DerivativeFinancialAssetsMember_6a8bbc2f-6f46-4e7a-aa6a-eba4162e3e24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialLiabilitiesMember_da6082d5-5187-43a1-8628-481aa4add155" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_3bb0aaf9-0a24-4d85-a59a-2495f83f0f40" xlink:to="loc_sny_DerivativeFinancialLiabilitiesMember_da6082d5-5187-43a1-8628-481aa4add155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeInstrumentAxis_563daaaf-a739-4143-ad45-c8baa72846ba" xlink:href="sny-20231231.xsd#sny_DerivativeInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_82101ac0-ed9c-4257-a5f8-aed234a72550" xlink:to="loc_sny_DerivativeInstrumentAxis_563daaaf-a739-4143-ad45-c8baa72846ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeInstrumentDomain_563daaaf-a739-4143-ad45-c8baa72846ba_default" xlink:href="sny-20231231.xsd#sny_DerivativeInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DerivativeInstrumentAxis_563daaaf-a739-4143-ad45-c8baa72846ba" xlink:to="loc_sny_DerivativeInstrumentDomain_563daaaf-a739-4143-ad45-c8baa72846ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeInstrumentDomain_1b0bfc2d-d026-4c2b-a852-b5c3effed5a0" xlink:href="sny-20231231.xsd#sny_DerivativeInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DerivativeInstrumentAxis_563daaaf-a739-4143-ad45-c8baa72846ba" xlink:to="loc_sny_DerivativeInstrumentDomain_1b0bfc2d-d026-4c2b-a852-b5c3effed5a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember_441cb859-4f21-4f5c-93f4-c690cc4351f0" xlink:href="sny-20231231.xsd#sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DerivativeInstrumentDomain_1b0bfc2d-d026-4c2b-a852-b5c3effed5a0" xlink:to="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember_441cb859-4f21-4f5c-93f4-c690cc4351f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset_2f22a933-48ab-4d4c-b855-aaadbee986f9" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset_2f22a933-48ab-4d4c-b855-aaadbee986f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32_da29c275-d317-4eb4-b214-1b29879e0336" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32_da29c275-d317-4eb4-b214-1b29879e0336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetAmountsAsReportedInTheBalanceSheet_68f24b60-aeb9-4ec9-b8e4-16214cd7c788" xlink:href="sny-20231231.xsd#sny_NetAmountsAsReportedInTheBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_NetAmountsAsReportedInTheBalanceSheet_68f24b60-aeb9-4ec9-b8e4-16214cd7c788" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral_901de762-5663-4852-aa17-812f71dfbf2d" xlink:href="sny-20231231.xsd#sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral_901de762-5663-4852-aa17-812f71dfbf2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments_4aafe789-cce1-4a90-9f2b-62e05e5af328" xlink:href="sny-20231231.xsd#sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments_4aafe789-cce1-4a90-9f2b-62e05e5af328" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetExposure_e50077b9-cf55-429e-ae4a-74235612cba6" xlink:href="sny-20231231.xsd#sny_NetExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_NetExposure_e50077b9-cf55-429e-ae4a-74235612cba6" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_9ab3624b-b545-4d7f-8b20-32e05224d2a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:to="loc_ifrs-full_JointVenturesAxis_9ab3624b-b545-4d7f-8b20-32e05224d2a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_9ab3624b-b545-4d7f-8b20-32e05224d2a8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_9ab3624b-b545-4d7f-8b20-32e05224d2a8" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_9ab3624b-b545-4d7f-8b20-32e05224d2a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_a766ee55-5f11-433e-aa41-3aabc5c2f613" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_9ab3624b-b545-4d7f-8b20-32e05224d2a8" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_a766ee55-5f11-433e-aa41-3aabc5c2f613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesMember_2ff421f6-b7e4-4349-a576-8114a3f0590a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_a766ee55-5f11-433e-aa41-3aabc5c2f613" xlink:to="loc_ifrs-full_JointVenturesMember_2ff421f6-b7e4-4349-a576-8114a3f0590a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_851f1d64-0d2f-4379-96f4-30f9ff89b437" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_851f1d64-0d2f-4379-96f4-30f9ff89b437" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_851f1d64-0d2f-4379-96f4-30f9ff89b437_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_851f1d64-0d2f-4379-96f4-30f9ff89b437" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_851f1d64-0d2f-4379-96f4-30f9ff89b437_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8c9472b6-9293-42a4-94bb-e5b97da88cf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_851f1d64-0d2f-4379-96f4-30f9ff89b437" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8c9472b6-9293-42a4-94bb-e5b97da88cf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SuppliersMember_d9fa09f3-b04b-43ce-91bd-3e709e0e8374" xlink:href="sny-20231231.xsd#sny_SuppliersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8c9472b6-9293-42a4-94bb-e5b97da88cf4" xlink:to="loc_sny_SuppliersMember_d9fa09f3-b04b-43ce-91bd-3e709e0e8374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_c7ebaad9-10d0-4489-b5ed-69c48d3731b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:to="loc_ifrs-full_MaturityAxis_c7ebaad9-10d0-4489-b5ed-69c48d3731b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_c7ebaad9-10d0-4489-b5ed-69c48d3731b3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_c7ebaad9-10d0-4489-b5ed-69c48d3731b3" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_c7ebaad9-10d0-4489-b5ed-69c48d3731b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_c7ebaad9-10d0-4489-b5ed-69c48d3731b3" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_fb669f6f-d993-42d7-9591-c2d10ecab478" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_fb669f6f-d993-42d7-9591-c2d10ecab478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_5431f87d-87e6-4621-9a88-fa9ebd478178" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_5431f87d-87e6-4621-9a88-fa9ebd478178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_32328268-c754-4fb9-9ec2-23b4c9889855" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_32328268-c754-4fb9-9ec2-23b4c9889855" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_1df3a840-a905-461c-8e45-099aa510e1be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_1df3a840-a905-461c-8e45-099aa510e1be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b7175773-c553-4579-ace5-702ce52dfc0f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:to="loc_srt_RangeAxis_b7175773-c553-4579-ace5-702ce52dfc0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7175773-c553-4579-ace5-702ce52dfc0f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b7175773-c553-4579-ace5-702ce52dfc0f" xlink:to="loc_srt_RangeMember_b7175773-c553-4579-ace5-702ce52dfc0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b2659b6-74fe-4b2c-a0cf-74f3fa9bc410" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b7175773-c553-4579-ace5-702ce52dfc0f" xlink:to="loc_srt_RangeMember_3b2659b6-74fe-4b2c-a0cf-74f3fa9bc410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2e2d07a4-e89f-42a9-82c8-305292b12219" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b2659b6-74fe-4b2c-a0cf-74f3fa9bc410" xlink:to="loc_srt_MinimumMember_2e2d07a4-e89f-42a9-82c8-305292b12219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b09b8525-f0ef-4834-9be8-65b4914f192d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b09b8525-f0ef-4834-9be8-65b4914f192d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b09b8525-f0ef-4834-9be8-65b4914f192d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b09b8525-f0ef-4834-9be8-65b4914f192d" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b09b8525-f0ef-4834-9be8-65b4914f192d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_a6d70682-d2b4-4061-aaa7-2131ef2acac5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b09b8525-f0ef-4834-9be8-65b4914f192d" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_a6d70682-d2b4-4061-aaa7-2131ef2acac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_83c71954-11ee-4c59-ab0f-94a44c22d98a" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_a6d70682-d2b4-4061-aaa7-2131ef2acac5" xlink:to="loc_sny_EuroapiMember_83c71954-11ee-4c59-ab0f-94a44c22d98a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet_c9e85566-42a3-48e9-85b8-da9d9b15b753" xlink:href="sny-20231231.xsd#sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet_c9e85566-42a3-48e9-85b8-da9d9b15b753" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsGiven_955aba27-87f2-4193-a5b8-fc447ccc7dbd" xlink:href="sny-20231231.xsd#sny_IrrevocablePurchaseCommitmentsGiven"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsGiven_955aba27-87f2-4193-a5b8-fc447ccc7dbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsReceived_2409ee34-6b4d-4864-b2cb-e8eda839442e" xlink:href="sny-20231231.xsd#sny_IrrevocablePurchaseCommitmentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsReceived_2409ee34-6b4d-4864-b2cb-e8eda839442e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments_146577ac-2c74-4f68-ac6c-1a7487b594b9" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments_146577ac-2c74-4f68-ac6c-1a7487b594b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress_5b415bf1-5be6-4e36-8b2c-3ad84dd6061a" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress_5b415bf1-5be6-4e36-8b2c-3ad84dd6061a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalOffBalanceSheetCommitments_0dfcc23c-3eb5-4ccb-ba4d-acb48a6396a7" xlink:href="sny-20231231.xsd#sny_TotalOffBalanceSheetCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_TotalOffBalanceSheetCommitments_0dfcc23c-3eb5-4ccb-ba4d-acb48a6396a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseTerm_f7ab12bd-9c0c-4d3d-b570-de957b946ca7" xlink:href="sny-20231231.xsd#sny_LeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_LeaseTerm_f7ab12bd-9c0c-4d3d-b570-de957b946ca7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseCosts_8113278e-d6e6-41b4-a7db-6e1ab7e7f53b" xlink:href="sny-20231231.xsd#sny_LeaseCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_LeaseCosts_8113278e-d6e6-41b4-a7db-6e1ab7e7f53b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsNumber_18a90061-4596-4928-9d3c-3110e1f3c65e" xlink:href="sny-20231231.xsd#sny_LeaseExtensionOptionsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_LeaseExtensionOptionsNumber_18a90061-4596-4928-9d3c-3110e1f3c65e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsTerm_db05dd9a-f65a-4ba2-b3ce-d77f77b6bd40" xlink:href="sny-20231231.xsd#sny_LeaseExtensionOptionsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_LeaseExtensionOptionsTerm_db05dd9a-f65a-4ba2-b3ce-d77f77b6bd40" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OffbalancesheetcommitmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_930c9d7d-d0a7-4e67-bc19-db995fa7fc22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_930c9d7d-d0a7-4e67-bc19-db995fa7fc22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_930c9d7d-d0a7-4e67-bc19-db995fa7fc22_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_930c9d7d-d0a7-4e67-bc19-db995fa7fc22" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_930c9d7d-d0a7-4e67-bc19-db995fa7fc22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fbf04ef3-e505-4182-a53c-e82aed9e48cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_930c9d7d-d0a7-4e67-bc19-db995fa7fc22" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fbf04ef3-e505-4182-a53c-e82aed9e48cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AblynxMember_46af2528-68cf-4b10-830c-76da7c1094f9" xlink:href="sny-20231231.xsd#sny_AblynxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fbf04ef3-e505-4182-a53c-e82aed9e48cd" xlink:to="loc_sny_AblynxMember_46af2528-68cf-4b10-830c-76da7c1094f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KymabMember_61dc3263-4fe0-4c06-9a04-25e03ae4c2f8" xlink:href="sny-20231231.xsd#sny_KymabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fbf04ef3-e505-4182-a53c-e82aed9e48cd" xlink:to="loc_sny_KymabMember_61dc3263-4fe0-4c06-9a04-25e03ae4c2f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioMember_5e03733c-54fe-4a32-9e1c-4cf7f111586c" xlink:href="sny-20231231.xsd#sny_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fbf04ef3-e505-4182-a53c-e82aed9e48cd" xlink:to="loc_sny_ProventionBioMember_5e03733c-54fe-4a32-9e1c-4cf7f111586c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_1a66c16e-e4d4-4704-87fc-b273a7be21f3" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_sny_PrincipalAlliancesAxis_1a66c16e-e4d4-4704-87fc-b273a7be21f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_1a66c16e-e4d4-4704-87fc-b273a7be21f3_default" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_1a66c16e-e4d4-4704-87fc-b273a7be21f3" xlink:to="loc_sny_PrincipalAlliancesDomain_1a66c16e-e4d4-4704-87fc-b273a7be21f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_2c0051a1-69e7-4646-9442-12c1e636f5da" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_1a66c16e-e4d4-4704-87fc-b273a7be21f3" xlink:to="loc_sny_PrincipalAlliancesDomain_2c0051a1-69e7-4646-9442-12c1e636f5da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_a758f39a-bc95-485b-a47b-d0e02577d5de" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_2c0051a1-69e7-4646-9442-12c1e636f5da" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_a758f39a-bc95-485b-a47b-d0e02577d5de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_a9d75441-eeee-4b05-a71d-e7ad7e0d8b47" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_ifrs-full_CounterpartiesAxis_a9d75441-eeee-4b05-a71d-e7ad7e0d8b47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_a9d75441-eeee-4b05-a71d-e7ad7e0d8b47_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_a9d75441-eeee-4b05-a71d-e7ad7e0d8b47" xlink:to="loc_ifrs-full_CounterpartiesMember_a9d75441-eeee-4b05-a71d-e7ad7e0d8b47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_a9d75441-eeee-4b05-a71d-e7ad7e0d8b47" xlink:to="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ScribeTherapeuticsMember_36465f48-f0cb-483d-8700-143529578b8f" xlink:href="sny-20231231.xsd#sny_ScribeTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_ScribeTherapeuticsMember_36465f48-f0cb-483d-8700-143529578b8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JanssenPharmaceuticalsIncMember_45e38aeb-b40b-40c9-83e0-219b4b90a574" xlink:href="sny-20231231.xsd#sny_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_JanssenPharmaceuticalsIncMember_45e38aeb-b40b-40c9-83e0-219b4b90a574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TevaPharmaceuticalsMember_828a08e2-cb9d-4e8f-928f-bc1057e81dd5" xlink:href="sny-20231231.xsd#sny_TevaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_TevaPharmaceuticalsMember_828a08e2-cb9d-4e8f-928f-bc1057e81dd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_b4362c4f-88eb-4067-a9d2-0088057f60d4" xlink:href="sny-20231231.xsd#sny_ProventionBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_ProventionBioIncMember_b4362c4f-88eb-4067-a9d2-0088057f60d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExscientiaMember_b2bce415-906b-4c42-9c37-af5da0672829" xlink:href="sny-20231231.xsd#sny_ExscientiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_ExscientiaMember_b2bce415-906b-4c42-9c37-af5da0672829" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BlackstoneLifeSciencesMember_865cbf3f-4a7c-4d49-b1cb-69b4880a9257" xlink:href="sny-20231231.xsd#sny_BlackstoneLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_BlackstoneLifeSciencesMember_865cbf3f-4a7c-4d49-b1cb-69b4880a9257" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IGMBiosciencesIncMember_e5e28358-4a3b-40f7-a027-a63e07ed9c3e" xlink:href="sny-20231231.xsd#sny_IGMBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_IGMBiosciencesIncMember_e5e28358-4a3b-40f7-a027-a63e07ed9c3e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtomwiseMember_c531f47a-fa54-445c-8f90-da311d32ee30" xlink:href="sny-20231231.xsd#sny_AtomwiseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_AtomwiseMember_c531f47a-fa54-445c-8f90-da311d32ee30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InsilicoMedicineMember_7e0b45cf-c655-4c69-a5d2-e1b684d07c14" xlink:href="sny-20231231.xsd#sny_InsilicoMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_InsilicoMedicineMember_7e0b45cf-c655-4c69-a5d2-e1b684d07c14" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_02092633-cb79-42dd-aa5a-ad53a2b0f807" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_02092633-cb79-42dd-aa5a-ad53a2b0f807" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LonzaMember_58dd11a4-61b3-451e-977f-5a68fea06c20" xlink:href="sny-20231231.xsd#sny_LonzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_LonzaMember_58dd11a4-61b3-451e-977f-5a68fea06c20" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_987130e9-f661-4c40-88bb-1f4ebb2990a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_ifrs-full_JointVenturesAxis_987130e9-f661-4c40-88bb-1f4ebb2990a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_987130e9-f661-4c40-88bb-1f4ebb2990a7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_987130e9-f661-4c40-88bb-1f4ebb2990a7" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_987130e9-f661-4c40-88bb-1f4ebb2990a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_764448b4-6714-4bb6-817b-5d89ed2b4802" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_987130e9-f661-4c40-88bb-1f4ebb2990a7" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_764448b4-6714-4bb6-817b-5d89ed2b4802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesMember_83b0ff20-6433-4ffe-85fe-2f39d7b9a660" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_764448b4-6714-4bb6-817b-5d89ed2b4802" xlink:to="loc_ifrs-full_JointVenturesMember_83b0ff20-6433-4ffe-85fe-2f39d7b9a660" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e7677915-5a49-4613-a22a-7714c5a70aa4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e7677915-5a49-4613-a22a-7714c5a70aa4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_e7677915-5a49-4613-a22a-7714c5a70aa4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e7677915-5a49-4613-a22a-7714c5a70aa4" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_e7677915-5a49-4613-a22a-7714c5a70aa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9588ba0b-deee-4781-98e1-a1af1c7eaf3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e7677915-5a49-4613-a22a-7714c5a70aa4" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9588ba0b-deee-4781-98e1-a1af1c7eaf3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WorldHealthOrganizationMember_13049d7c-b0b2-42a6-9534-e11daf7ad8cf" xlink:href="sny-20231231.xsd#sny_WorldHealthOrganizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9588ba0b-deee-4781-98e1-a1af1c7eaf3a" xlink:to="loc_sny_WorldHealthOrganizationMember_13049d7c-b0b2-42a6-9534-e11daf7ad8cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6fb65b6b-d716-4bf3-ab6e-8eeaabf29352" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_srt_RangeAxis_6fb65b6b-d716-4bf3-ab6e-8eeaabf29352" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6fb65b6b-d716-4bf3-ab6e-8eeaabf29352_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6fb65b6b-d716-4bf3-ab6e-8eeaabf29352" xlink:to="loc_srt_RangeMember_6fb65b6b-d716-4bf3-ab6e-8eeaabf29352_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63fad515-9fad-41c7-82db-56e79b28f258" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6fb65b6b-d716-4bf3-ab6e-8eeaabf29352" xlink:to="loc_srt_RangeMember_63fad515-9fad-41c7-82db-56e79b28f258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_46be5e43-ce2d-4a5e-b604-1c86eb0aea6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_63fad515-9fad-41c7-82db-56e79b28f258" xlink:to="loc_srt_MaximumMember_46be5e43-ce2d-4a5e-b604-1c86eb0aea6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase_8a053d00-23c3-457a-aa1c-20cf8bf279c2" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase_8a053d00-23c3-457a-aa1c-20cf8bf279c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets_b234bd91-0e71-464b-9544-95523e7ec83f" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets_b234bd91-0e71-464b-9544-95523e7ec83f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements_8ad95944-de4c-4f12-9763-00bf5c9d2dc5" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements_8ad95944-de4c-4f12-9763-00bf5c9d2dc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts_4bd6becb-961a-44b9-a5a3-476fbae47830" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts_4bd6becb-961a-44b9-a5a3-476fbae47830" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_db69ce53-badd-4bfb-a748-33358eee77bf" xlink:href="sny-20231231.xsd#sny_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_UpfrontPayments_db69ce53-badd-4bfb-a748-33358eee77bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_f46673fc-4a6f-4f9f-af45-61baec45bd4d" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_f46673fc-4a6f-4f9f-af45-61baec45bd4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement_f8087afd-98c4-4e45-894e-7adb8ff49ee0" xlink:href="sny-20231231.xsd#sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement_f8087afd-98c4-4e45-894e-7adb8ff49ee0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement_887dbe37-e8ed-4c8c-bc05-ea8bbcfa1169" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement_887dbe37-e8ed-4c8c-bc05-ea8bbcfa1169" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOncologyTargetsUnderCollaborationAgreement_538a8efd-f345-4fe2-8136-8bee54abaa43" xlink:href="sny-20231231.xsd#sny_NumberOfOncologyTargetsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_NumberOfOncologyTargetsUnderCollaborationAgreement_538a8efd-f345-4fe2-8136-8bee54abaa43" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement_4c7c9ac4-7519-407d-8ffc-42df454888b7" xlink:href="sny-20231231.xsd#sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement_4c7c9ac4-7519-407d-8ffc-42df454888b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDrugTargetsUnderCollaborationAgreement_817bc53e-1ba2-4950-92b9-8a360a6ac30f" xlink:href="sny-20231231.xsd#sny_NumberOfDrugTargetsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_NumberOfDrugTargetsUnderCollaborationAgreement_817bc53e-1ba2-4950-92b9-8a360a6ac30f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement_a4351099-06e8-49b0-9cb3-37c7ff5d5b94" xlink:href="sny-20231231.xsd#sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement_a4351099-06e8-49b0-9cb3-37c7ff5d5b94" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_b5c5726d-ad18-4e8b-9237-08d959dcd8ad" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitShareOnCounterpartiesProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_b5c5726d-ad18-4e8b-9237-08d959dcd8ad" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_379841eb-c388-45c3-b588-2d4eb256e38d" xlink:href="sny-20231231.xsd#sny_PercentageOfCumulativeDevelopmentCostsReimbursed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_379841eb-c388-45c3-b588-2d4eb256e38d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsReceivedForDevelopmentCosts_74396709-72c9-4f51-8385-a7a44184ddc9" xlink:href="sny-20231231.xsd#sny_CommitmentsReceivedForDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsReceivedForDevelopmentCosts_74396709-72c9-4f51-8385-a7a44184ddc9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeDevelopmentCostsIncurred_7d702a53-1be6-41d2-89a9-1592a8840ae1" xlink:href="sny-20231231.xsd#sny_CumulativeDevelopmentCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CumulativeDevelopmentCostsIncurred_7d702a53-1be6-41d2-89a9-1592a8840ae1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVentures_f2f96706-e70c-4622-a0d3-7e11567b3b85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_ifrs-full_InvestmentsInJointVentures_f2f96706-e70c-4622-a0d3-7e11567b3b85" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany_f03844e5-bc0b-4ce5-81ea-2cfb61b839c4" xlink:href="sny-20231231.xsd#sny_PercentageOfFutureDevelopmentExpenseFundedByCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany_f03844e5-bc0b-4ce5-81ea-2cfb61b839c4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty_4de6ee02-4b38-4205-8d22-c5bbdfcc649d" xlink:href="sny-20231231.xsd#sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty_4de6ee02-4b38-4205-8d22-c5bbdfcc649d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountsPayablePartnersInCollaborationAgreements_d0decb42-bd00-46ca-8a24-2a97d693c72c" xlink:href="sny-20231231.xsd#sny_AmountsPayablePartnersInCollaborationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_AmountsPayablePartnersInCollaborationAgreements_d0decb42-bd00-46ca-8a24-2a97d693c72c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TransferPercentageOfPandemicVaccines_b13b9aff-96e6-405c-b35d-e4748346567b" xlink:href="sny-20231231.xsd#sny_TransferPercentageOfPandemicVaccines"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_TransferPercentageOfPandemicVaccines_b13b9aff-96e6-405c-b35d-e4748346567b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReservePercentageOfPandemicVaccines_734dde7a-03fc-4a0e-8702-553eb196d758" xlink:href="sny-20231231.xsd#sny_ReservePercentageOfPandemicVaccines"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_ReservePercentageOfPandemicVaccines_734dde7a-03fc-4a0e-8702-553eb196d758" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_dcfd2264-49fd-4e19-93c0-309f91014c9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UndrawnBorrowingFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_dcfd2264-49fd-4e19-93c0-309f91014c9e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments_1366f4ea-5f8a-4cf4-beda-67a34ea9ab86" xlink:href="sny-20231231.xsd#sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments_1366f4ea-5f8a-4cf4-beda-67a34ea9ab86" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLineOfCreditFacilityLineItems_629859f2-381e-4ef4-9246-2a848f3f1764" xlink:href="sny-20231231.xsd#sny_DisclosureOfLineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLineOfCreditFacilityTable_9b4a1e2c-5c48-411d-a77d-f49e375d479e" xlink:href="sny-20231231.xsd#sny_DisclosureOfLineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLineOfCreditFacilityLineItems_629859f2-381e-4ef4-9246-2a848f3f1764" xlink:to="loc_sny_DisclosureOfLineOfCreditFacilityTable_9b4a1e2c-5c48-411d-a77d-f49e375d479e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_d965546c-fb67-429e-8bc2-ee13636315e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLineOfCreditFacilityTable_9b4a1e2c-5c48-411d-a77d-f49e375d479e" xlink:to="loc_ifrs-full_MaturityAxis_d965546c-fb67-429e-8bc2-ee13636315e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_d965546c-fb67-429e-8bc2-ee13636315e6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_d965546c-fb67-429e-8bc2-ee13636315e6" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_d965546c-fb67-429e-8bc2-ee13636315e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_d965546c-fb67-429e-8bc2-ee13636315e6" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_b75ff6cf-e263-4951-ad69-d3fb6d1ce7f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_b75ff6cf-e263-4951-ad69-d3fb6d1ce7f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_26295da7-3971-46ea-b43c-d33c5c96558d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_26295da7-3971-46ea-b43c-d33c5c96558d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_c4d80b6a-da52-4cb0-bc63-61a028aaaa06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_c4d80b6a-da52-4cb0-bc63-61a028aaaa06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_781e6033-d77e-4b76-b37a-0e8f764d599a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_781e6033-d77e-4b76-b37a-0e8f764d599a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_d98c89f9-84a5-4eb8-b1d4-617a50657852" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UndrawnBorrowingFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLineOfCreditFacilityLineItems_629859f2-381e-4ef4-9246-2a848f3f1764" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_d98c89f9-84a5-4eb8-b1d4-617a50657852" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfGuaranteesLineItems_18ff4301-4756-47dd-934e-d46d77b34e1d" xlink:href="sny-20231231.xsd#sny_DisclosureOfGuaranteesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfGuaranteesTable_e60ab289-6098-40bc-98b9-4db91013a560" xlink:href="sny-20231231.xsd#sny_DisclosureOfGuaranteesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfGuaranteesLineItems_18ff4301-4756-47dd-934e-d46d77b34e1d" xlink:to="loc_sny_DisclosureOfGuaranteesTable_e60ab289-6098-40bc-98b9-4db91013a560" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_43c6e663-a5d7-42c5-b9a7-4b5b6527c342" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfGuaranteesTable_e60ab289-6098-40bc-98b9-4db91013a560" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_43c6e663-a5d7-42c5-b9a7-4b5b6527c342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_43c6e663-a5d7-42c5-b9a7-4b5b6527c342_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_43c6e663-a5d7-42c5-b9a7-4b5b6527c342" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_43c6e663-a5d7-42c5-b9a7-4b5b6527c342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_7372a2b3-c1e2-43c1-9863-6f750f7677dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_43c6e663-a5d7-42c5-b9a7-4b5b6527c342" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_7372a2b3-c1e2-43c1-9863-6f750f7677dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GuaranteesReceivedMember_72619669-2348-49b0-ab78-8bd28bc68988" xlink:href="sny-20231231.xsd#sny_GuaranteesReceivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_7372a2b3-c1e2-43c1-9863-6f750f7677dc" xlink:to="loc_sny_GuaranteesReceivedMember_72619669-2348-49b0-ab78-8bd28bc68988" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GuaranteesGivenMember_d85868bb-353c-4fa4-a631-5c0c10169fd2" xlink:href="sny-20231231.xsd#sny_GuaranteesGivenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GuaranteesReceivedMember_72619669-2348-49b0-ab78-8bd28bc68988" xlink:to="loc_sny_GuaranteesGivenMember_d85868bb-353c-4fa4-a631-5c0c10169fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember_26ff1431-3cc9-4543-a301-7b52fb84d3a1" xlink:href="sny-20231231.xsd#sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GuaranteesGivenMember_d85868bb-353c-4fa4-a631-5c0c10169fd2" xlink:to="loc_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember_26ff1431-3cc9-4543-a301-7b52fb84d3a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGuaranteesGivenMember_57a6b8e8-1726-4ca0-82f5-1cd7a8850bf0" xlink:href="sny-20231231.xsd#sny_OtherGuaranteesGivenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GuaranteesGivenMember_d85868bb-353c-4fa4-a631-5c0c10169fd2" xlink:to="loc_sny_OtherGuaranteesGivenMember_57a6b8e8-1726-4ca0-82f5-1cd7a8850bf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_3a96713a-089c-410a-ab98-7f5fffc43139" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfGuaranteesLineItems_18ff4301-4756-47dd-934e-d46d77b34e1d" xlink:to="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_3a96713a-089c-410a-ab98-7f5fffc43139" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LegalandarbitralproceedingsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#LegalandarbitralproceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/LegalandarbitralproceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:href="sny-20231231.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:href="sny-20231231.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis_34dc58f5-c4ed-434d-b097-b6c143d6ae44" xlink:href="sny-20231231.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_sny_LegalAndArbitralProceedingsAxis_34dc58f5-c4ed-434d-b097-b6c143d6ae44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_34dc58f5-c4ed-434d-b097-b6c143d6ae44_default" xlink:href="sny-20231231.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_34dc58f5-c4ed-434d-b097-b6c143d6ae44" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_34dc58f5-c4ed-434d-b097-b6c143d6ae44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:href="sny-20231231.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_34dc58f5-c4ed-434d-b097-b6c143d6ae44" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurHepatitisBVaccineMember_091e213d-3f23-47d3-b928-d113faebb14f" xlink:href="sny-20231231.xsd#sny_SanofiPasteurHepatitisBVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_SanofiPasteurHepatitisBVaccineMember_091e213d-3f23-47d3-b928-d113faebb14f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereProductLitigationInTheUSMember_af05690b-d3a2-4341-9d31-2ae936d54743" xlink:href="sny-20231231.xsd#sny_TaxotereProductLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_TaxotereProductLitigationInTheUSMember_af05690b-d3a2-4341-9d31-2ae936d54743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember_95a1c260-5e4e-495d-8f35-c33adc266f21" xlink:href="sny-20231231.xsd#sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember_95a1c260-5e4e-495d-8f35-c33adc266f21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacLitigationInTheUSMember_75b481ca-7145-42d4-80fa-dbfcf1af3fcc" xlink:href="sny-20231231.xsd#sny_ZantacLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_ZantacLitigationInTheUSMember_75b481ca-7145-42d4-80fa-dbfcf1af3fcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacLitigationInCanadaMember_a2430e47-cb14-4a90-9877-4c43c3137218" xlink:href="sny-20231231.xsd#sny_ZantacLitigationInCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_ZantacLitigationInCanadaMember_a2430e47-cb14-4a90-9877-4c43c3137218" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoldBondProductLitigationInTheUSMember_ee515140-2697-44c4-9b54-05234e9c8ac7" xlink:href="sny-20231231.xsd#sny_GoldBondProductLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_GoldBondProductLitigationInTheUSMember_ee515140-2697-44c4-9b54-05234e9c8ac7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInFranceMember_34931760-980b-4a98-b3bd-ad38bf1ac157" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInFranceMember_34931760-980b-4a98-b3bd-ad38bf1ac157" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInSwitzerlandMember_55f3e6ae-0601-42f9-9bf9-490430931518" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInSwitzerlandMember_55f3e6ae-0601-42f9-9bf9-490430931518" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInSpainMember_e0a4229a-823d-4eb0-85bc-a71b1c3acde6" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInSpainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInSpainMember_e0a4229a-823d-4eb0-85bc-a71b1c3acde6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInBelgiumMember_cd9de0a9-93eb-4af9-be42-aa35e36899a5" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInBelgiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInBelgiumMember_cd9de0a9-93eb-4af9-be42-aa35e36899a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInIrelandMember_e16dff60-6196-44f1-85ab-3316f0299194" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInIrelandMember_e16dff60-6196-44f1-85ab-3316f0299194" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInGreatBritainMember_3d8c9417-94c0-42f3-8109-8dc091bde888" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInGreatBritainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInGreatBritainMember_3d8c9417-94c0-42f3-8109-8dc091bde888" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInNorthernIrelandMember_f46ac8db-4e3d-435a-93c7-77521037c983" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInNorthernIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInNorthernIrelandMember_f46ac8db-4e3d-435a-93c7-77521037c983" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DengvaxiaProductLitigationInThePhilippinesMember_a7239cf2-31e7-45e8-a93b-e4354360c66a" xlink:href="sny-20231231.xsd#sny_DengvaxiaProductLitigationInThePhilippinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DengvaxiaProductLitigationInThePhilippinesMember_a7239cf2-31e7-45e8-a93b-e4354360c66a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RamiprilCanadaPatentLitigationMember_ef201123-4a49-4b16-ac61-6c6eddfdb7c3" xlink:href="sny-20231231.xsd#sny_RamiprilCanadaPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_RamiprilCanadaPatentLitigationMember_ef201123-4a49-4b16-ac61-6c6eddfdb7c3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember_13fe4cf9-7c79-4eac-a3ee-a044bcea3730" xlink:href="sny-20231231.xsd#sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember_13fe4cf9-7c79-4eac-a3ee-a044bcea3730" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaRelatedPatentLitigationInTheUSMember_c1785738-678a-432e-91ce-dc904d105125" xlink:href="sny-20231231.xsd#sny_JevtanaRelatedPatentLitigationInTheUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_JevtanaRelatedPatentLitigationInTheUSMember_c1785738-678a-432e-91ce-dc904d105125" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixLitigationCommonwealthInAustraliaMember_87947178-d970-487f-83e5-088e160bcfc7" xlink:href="sny-20231231.xsd#sny_PlavixLitigationCommonwealthInAustraliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_PlavixLitigationCommonwealthInAustraliaMember_87947178-d970-487f-83e5-088e160bcfc7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_6dffee9d-0e5c-4c74-a9aa-8e50e945a0d8" xlink:href="sny-20231231.xsd#sny_PlavixAttorneyGeneralActionInHawaiiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_6dffee9d-0e5c-4c74-a9aa-8e50e945a0d8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixRelatedLitigationInFranceMember_b99fd71f-647e-4a86-afc3-2ccae884214e" xlink:href="sny-20231231.xsd#sny_PlavixRelatedLitigationInFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_PlavixRelatedLitigationInFranceMember_b99fd71f-647e-4a86-afc3-2ccae884214e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_A340BDrugPricingProgramInTheUnitedStatesMember_3ef09bca-53b5-43cd-90f6-7ed14b5c932c" xlink:href="sny-20231231.xsd#sny_A340BDrugPricingProgramInTheUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_A340BDrugPricingProgramInTheUnitedStatesMember_3ef09bca-53b5-43cd-90f6-7ed14b5c932c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisCropScienceRetainedLiabilitiesMember_734d09a4-312c-46a3-b9bf-faf041376d4f" xlink:href="sny-20231231.xsd#sny_AventisCropScienceRetainedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_AventisCropScienceRetainedLiabilitiesMember_734d09a4-312c-46a3-b9bf-faf041376d4f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservHoechstRetainedLiabilitiesMember_98e088a6-4ce3-4b51-80f4-baef5cfb714e" xlink:href="sny-20231231.xsd#sny_InfraservHoechstRetainedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_InfraservHoechstRetainedLiabilitiesMember_98e088a6-4ce3-4b51-80f4-baef5cfb714e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantAxis_e965c3c1-3d3f-4386-9bc5-a3b547b1c888" xlink:href="sny-20231231.xsd#sny_DefendantAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_sny_DefendantAxis_e965c3c1-3d3f-4386-9bc5-a3b547b1c888" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantsMember_e965c3c1-3d3f-4386-9bc5-a3b547b1c888_default" xlink:href="sny-20231231.xsd#sny_DefendantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_DefendantAxis_e965c3c1-3d3f-4386-9bc5-a3b547b1c888" xlink:to="loc_sny_DefendantsMember_e965c3c1-3d3f-4386-9bc5-a3b547b1c888_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantsMember_1cad0676-99d6-4247-8132-56df8516c763" xlink:href="sny-20231231.xsd#sny_DefendantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DefendantAxis_e965c3c1-3d3f-4386-9bc5-a3b547b1c888" xlink:to="loc_sny_DefendantsMember_1cad0676-99d6-4247-8132-56df8516c763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeAreDefendantMember_a5452264-27a0-4ad8-85be-77f2307ee314" xlink:href="sny-20231231.xsd#sny_ActionForWhichWeAreDefendantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DefendantsMember_1cad0676-99d6-4247-8132-56df8516c763" xlink:to="loc_sny_ActionForWhichWeAreDefendantMember_a5452264-27a0-4ad8-85be-77f2307ee314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeArePlaintiffMember_144bda1b-46a9-4bc2-8c6c-e0bc6f5f08d4" xlink:href="sny-20231231.xsd#sny_ActionForWhichWeArePlaintiffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DefendantsMember_1cad0676-99d6-4247-8132-56df8516c763" xlink:to="loc_sny_ActionForWhichWeArePlaintiffMember_144bda1b-46a9-4bc2-8c6c-e0bc6f5f08d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantDomain_189d9dcc-cfdb-4bc4-a246-e2c913d592d3" xlink:href="sny-20231231.xsd#sny_DefendantDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_DefendantAxis_e965c3c1-3d3f-4386-9bc5-a3b547b1c888" xlink:to="loc_sny_DefendantDomain_189d9dcc-cfdb-4bc4-a246-e2c913d592d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_2258cf65-63c3-4383-9ff9-6025636af4d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_2258cf65-63c3-4383-9ff9-6025636af4d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2258cf65-63c3-4383-9ff9-6025636af4d3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2258cf65-63c3-4383-9ff9-6025636af4d3" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2258cf65-63c3-4383-9ff9-6025636af4d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_0f555464-dcb6-4212-abad-eaa47c18b33f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2258cf65-63c3-4383-9ff9-6025636af4d3" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_0f555464-dcb6-4212-abad-eaa47c18b33f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingenciesArisingFromCertainBusinessDivestituresMember_6dca5915-27b2-465a-b5ee-7f8589419187" xlink:href="sny-20231231.xsd#sny_ContingenciesArisingFromCertainBusinessDivestituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_0f555464-dcb6-4212-abad-eaa47c18b33f" xlink:to="loc_sny_ContingenciesArisingFromCertainBusinessDivestituresMember_6dca5915-27b2-465a-b5ee-7f8589419187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1e288657-2ca5-492d-8cdb-7c52302515be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1e288657-2ca5-492d-8cdb-7c52302515be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_1e288657-2ca5-492d-8cdb-7c52302515be_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1e288657-2ca5-492d-8cdb-7c52302515be" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_1e288657-2ca5-492d-8cdb-7c52302515be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_ab36291c-cc45-4ce2-abef-3e3b830e899f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1e288657-2ca5-492d-8cdb-7c52302515be" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_ab36291c-cc45-4ce2-abef-3e3b830e899f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductLiabilitiesMember_249b0d59-d0b2-4194-a0c3-cf2d175535da" xlink:href="sny-20231231.xsd#sny_ProductLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_ab36291c-cc45-4ce2-abef-3e3b830e899f" xlink:to="loc_sny_ProductLiabilitiesMember_249b0d59-d0b2-4194-a0c3-cf2d175535da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_823d4030-ebbb-4ce9-90cf-135ecdeac8ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_ifrs-full_RangeAxis_823d4030-ebbb-4ce9-90cf-135ecdeac8ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_823d4030-ebbb-4ce9-90cf-135ecdeac8ee_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_823d4030-ebbb-4ce9-90cf-135ecdeac8ee" xlink:to="loc_ifrs-full_RangesMember_823d4030-ebbb-4ce9-90cf-135ecdeac8ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_f3ec29dd-e176-4122-a87c-9254ee2b310b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_823d4030-ebbb-4ce9-90cf-135ecdeac8ee" xlink:to="loc_ifrs-full_RangesMember_f3ec29dd-e176-4122-a87c-9254ee2b310b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_23f6a475-a26f-48d4-b159-613e572ae584" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_f3ec29dd-e176-4122-a87c-9254ee2b310b" xlink:to="loc_srt_MinimumMember_23f6a475-a26f-48d4-b159-613e572ae584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70d28cbf-24c2-4677-9bd8-d6d4b5b334b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_f3ec29dd-e176-4122-a87c-9254ee2b310b" xlink:to="loc_srt_MaximumMember_70d28cbf-24c2-4677-9bd8-d6d4b5b334b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_8f01e581-d3f5-46ab-9c4f-8fb31037e0a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_8f01e581-d3f5-46ab-9c4f-8fb31037e0a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_8f01e581-d3f5-46ab-9c4f-8fb31037e0a6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_8f01e581-d3f5-46ab-9c4f-8fb31037e0a6" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_8f01e581-d3f5-46ab-9c4f-8fb31037e0a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_036435f6-87d7-4637-ae93-f27f7d267843" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_8f01e581-d3f5-46ab-9c4f-8fb31037e0a6" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_036435f6-87d7-4637-ae93-f27f7d267843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_Patents1Member_b272bb6c-35d9-4137-a4a9-f5b3b1045ded" xlink:href="sny-20231231.xsd#sny_Patents1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_036435f6-87d7-4637-ae93-f27f7d267843" xlink:to="loc_sny_Patents1Member_b272bb6c-35d9-4137-a4a9-f5b3b1045ded" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_21375f95-5483-411b-b312-b706c62ed099" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_21375f95-5483-411b-b312-b706c62ed099" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionForEnvironmentRisks_67d74fb6-afa4-47e4-ae97-1c4708892577" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionForEnvironmentRisks"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NonCurrentProvisionForEnvironmentRisks_67d74fb6-afa4-47e4-ae97-1c4708892577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCivilIndividualActions_1f2a9d5e-1d10-439d-9f0a-1471ec9bb96c" xlink:href="sny-20231231.xsd#sny_NumberOfCivilIndividualActions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfCivilIndividualActions_1f2a9d5e-1d10-439d-9f0a-1471ec9bb96c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOngoingLawsuits_cc69607b-3b44-4f48-a439-cf2e3957c72f" xlink:href="sny-20231231.xsd#sny_NumberOfOngoingLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfOngoingLawsuits_cc69607b-3b44-4f48-a439-cf2e3957c72f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffs_0a22794c-9c58-418e-87a3-e598cd7beaec" xlink:href="sny-20231231.xsd#sny_NumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPlaintiffs_0a22794c-9c58-418e-87a3-e598cd7beaec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBellweatherTrialsHeld_d9df637c-0c26-4065-aabf-b08f864659e0" xlink:href="sny-20231231.xsd#sny_NumberOfBellweatherTrialsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfBellweatherTrialsHeld_d9df637c-0c26-4065-aabf-b08f864659e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfIndividualCasesSettled_cc61a13d-edd0-4c3b-8f7d-a0acbe3e460f" xlink:href="sny-20231231.xsd#sny_NumberOfIndividualCasesSettled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfIndividualCasesSettled_cc61a13d-edd0-4c3b-8f7d-a0acbe3e460f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation_4416b53a-2fa9-4bc1-a42d-b531da0b3493" xlink:href="sny-20231231.xsd#sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation_4416b53a-2fa9-4bc1-a42d-b531da0b3493" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCancersAssociatedWithDismissedCases_834874fe-41e3-450e-94c0-037dab7ddeb2" xlink:href="sny-20231231.xsd#sny_NumberOfCancersAssociatedWithDismissedCases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfCancersAssociatedWithDismissedCases_834874fe-41e3-450e-94c0-037dab7ddeb2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal_9108d191-4d88-4149-98fc-10041d408671" xlink:href="sny-20231231.xsd#sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal_9108d191-4d88-4149-98fc-10041d408671" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfComplaintsFiled_6260ab1e-1e66-43c2-8c10-c71ec003a5f4" xlink:href="sny-20231231.xsd#sny_NumberOfComplaintsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfComplaintsFiled_6260ab1e-1e66-43c2-8c10-c71ec003a5f4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits_bd6f6482-b14d-4f53-8462-35f9faa53492" xlink:href="sny-20231231.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfClassActionLawsuits_bd6f6482-b14d-4f53-8462-35f9faa53492" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOngoingTrials_2eb9562a-1fe3-451d-8ebc-975770b7b3f5" xlink:href="sny-20231231.xsd#sny_NumberOfOngoingTrials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfOngoingTrials_2eb9562a-1fe3-451d-8ebc-975770b7b3f5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPeopleExposed_c8da6d10-a126-4624-ab22-3a4825ec53e4" xlink:href="sny-20231231.xsd#sny_NumberOfPeopleExposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPeopleExposed_c8da6d10-a126-4624-ab22-3a4825ec53e4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLawsuitsRuledOnMerit_eb769a23-7146-4248-970e-4459e25bc31f" xlink:href="sny-20231231.xsd#sny_NumberOfLawsuitsRuledOnMerit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfLawsuitsRuledOnMerit_eb769a23-7146-4248-970e-4459e25bc31f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfFirstInstanceRulings_3fa177aa-e77a-40a5-b5d9-8f13ed1b1edb" xlink:href="sny-20231231.xsd#sny_NumberOfFirstInstanceRulings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfFirstInstanceRulings_3fa177aa-e77a-40a5-b5d9-8f13ed1b1edb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LitigationAmountPayable_71790136-15bf-4cd2-b92a-e0f7ad880228" xlink:href="sny-20231231.xsd#sny_LitigationAmountPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_LitigationAmountPayable_71790136-15bf-4cd2-b92a-e0f7ad880228" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfFamiliesWhoFiledACivilClaim_6e3910c1-898f-4f86-ac7d-5d7193839727" xlink:href="sny-20231231.xsd#sny_NumberOfFamiliesWhoFiledACivilClaim"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfFamiliesWhoFiledACivilClaim_6e3910c1-898f-4f86-ac7d-5d7193839727" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClaimant_5e71db26-38c3-48f2-88fc-c7064096a373" xlink:href="sny-20231231.xsd#sny_NumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfClaimant_5e71db26-38c3-48f2-88fc-c7064096a373" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClaimantExposed_807cb4a7-981c-4665-953c-c9fbeb85144d" xlink:href="sny-20231231.xsd#sny_NumberOfClaimantExposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfClaimantExposed_807cb4a7-981c-4665-953c-c9fbeb85144d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim_f0e2e2b0-4375-4709-b0ab-a73b312ba498" xlink:href="sny-20231231.xsd#sny_NumberOfClaimantExposedWhoWithdrawedTheClaim"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim_f0e2e2b0-4375-4709-b0ab-a73b312ba498" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim_5f027ccf-d918-49bf-9a7b-014a92236e8d" xlink:href="sny-20231231.xsd#sny_NumberOfIndirectVictimWhoWithdrawedTheClaim"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim_5f027ccf-d918-49bf-9a7b-014a92236e8d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCounterExpertiseExperts_bd6e6389-4ccd-4b51-83e1-8e512bb4a3cb" xlink:href="sny-20231231.xsd#sny_NumberOfCounterExpertiseExperts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfCounterExpertiseExperts_bd6e6389-4ccd-4b51-83e1-8e512bb4a3cb" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfAdministrativeProceedings_a77a1846-ab85-42bb-ad3e-f63260cf6fe3" xlink:href="sny-20231231.xsd#sny_NumberOfAdministrativeProceedings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfAdministrativeProceedings_a77a1846-ab85-42bb-ad3e-f63260cf6fe3" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfActionDeclaredTimeBarred_659ef074-553b-418f-8fc4-aabd05218238" xlink:href="sny-20231231.xsd#sny_NumberOfActionDeclaredTimeBarred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfActionDeclaredTimeBarred_659ef074-553b-418f-8fc4-aabd05218238" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatientsToIndemnify_37de7cbf-f868-4458-9431-d3c8d24c0e35" xlink:href="sny-20231231.xsd#sny_NumberOfPatientsToIndemnify"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPatientsToIndemnify_37de7cbf-f868-4458-9431-d3c8d24c0e35" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPreActionProtocolCases_147510b7-6b82-42a7-a06e-d3ffcbd3d677" xlink:href="sny-20231231.xsd#sny_NumberOfPreActionProtocolCases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPreActionProtocolCases_147510b7-6b82-42a7-a06e-d3ffcbd3d677" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCivilClaimsOnGoing_2b6d5cad-1b9c-430a-b320-ac00b241bd74" xlink:href="sny-20231231.xsd#sny_NumberOfCivilClaimsOnGoing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfCivilClaimsOnGoing_2b6d5cad-1b9c-430a-b320-ac00b241bd74" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCases_e4afee00-fb95-46d4-8c21-999eaf561a33" xlink:href="sny-20231231.xsd#sny_NumberOfCases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfCases_e4afee00-fb95-46d4-8c21-999eaf561a33" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug_7f4800f2-3fb7-451b-8150-da8ce712e549" xlink:href="sny-20231231.xsd#sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug_7f4800f2-3fb7-451b-8150-da8ce712e549" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatentActionsInitiallyFiled_99aec6d8-4da9-490f-9869-f246041bc4a4" xlink:href="sny-20231231.xsd#sny_NumberOfPatentActionsInitiallyFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPatentActionsInitiallyFiled_99aec6d8-4da9-490f-9869-f246041bc4a4" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatentsAllegedlyInfringed_d9023c69-ec29-4551-8172-e28dcd4a1303" xlink:href="sny-20231231.xsd#sny_NumberOfPatentsAllegedlyInfringed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPatentsAllegedlyInfringed_d9023c69-ec29-4551-8172-e28dcd4a1303" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatentsCoveringProduct_0b932012-0bf3-4278-8816-1090fdc1e5c4" xlink:href="sny-20231231.xsd#sny_NumberOfPatentsCoveringProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPatentsCoveringProduct_0b932012-0bf3-4278-8816-1090fdc1e5c4" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs_31fef068-dd1f-46b4-992a-b9a9974ea8d0" xlink:href="sny-20231231.xsd#sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs_31fef068-dd1f-46b4-992a-b9a9974ea8d0" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded_5255d6f5-c155-4f32-ba39-bd044d35d7c9" xlink:href="sny-20231231.xsd#sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded_5255d6f5-c155-4f32-ba39-bd044d35d7c9" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GlobalPenaltyFeeIncurredByDefendants_047b3815-a860-49d1-8ebd-974e6a74a1a7" xlink:href="sny-20231231.xsd#sny_GlobalPenaltyFeeIncurredByDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_GlobalPenaltyFeeIncurredByDefendants_047b3815-a860-49d1-8ebd-974e6a74a1a7" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurred_5d533cc0-224b-45a9-a18d-7c4ee1da38d5" xlink:href="sny-20231231.xsd#sny_PenaltyFeeIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_PenaltyFeeIncurred_5d533cc0-224b-45a9-a18d-7c4ee1da38d5" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentOfDamagesClaimedByCounterparty_da9d362f-b7f9-4c72-83b4-fd16e92a031a" xlink:href="sny-20231231.xsd#sny_PaymentOfDamagesClaimedByCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_PaymentOfDamagesClaimedByCounterparty_da9d362f-b7f9-4c72-83b4-fd16e92a031a" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOtherManufacturersInvolvedInProceedings_20e25ac3-dd1b-4d13-9eaa-8c4a10862b09" xlink:href="sny-20231231.xsd#sny_NumberOfOtherManufacturersInvolvedInProceedings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfOtherManufacturersInvolvedInProceedings_20e25ac3-dd1b-4d13-9eaa-8c4a10862b09" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInvestmentSoldPercentage_372417fe-3150-4b0d-8fba-deb402341abe" xlink:href="sny-20231231.xsd#sny_EquityInvestmentSoldPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_EquityInvestmentSoldPercentage_372417fe-3150-4b0d-8fba-deb402341abe" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking_b13023a6-ffa1-4dc5-9e68-d3f3b621263b" xlink:href="sny-20231231.xsd#sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking_b13023a6-ffa1-4dc5-9e68-d3f3b621263b" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense_84c0a55d-8954-4c1d-837c-fd329990ea9f" xlink:href="sny-20231231.xsd#sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense_84c0a55d-8954-4c1d-837c-fd329990ea9f" xlink:type="arc" order="41"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a65050e-468c-4cb8-ad8f-d65d70226a15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a65050e-468c-4cb8-ad8f-d65d70226a15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d5c2aeb4-9654-481e-86c0-edf51382e316" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a65050e-468c-4cb8-ad8f-d65d70226a15" xlink:to="loc_srt_CounterpartyNameAxis_d5c2aeb4-9654-481e-86c0-edf51382e316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5c2aeb4-9654-481e-86c0-edf51382e316_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d5c2aeb4-9654-481e-86c0-edf51382e316" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5c2aeb4-9654-481e-86c0-edf51382e316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02cad831-b4b5-4ac9-ad0f-b5ae55d09a8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d5c2aeb4-9654-481e-86c0-edf51382e316" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02cad831-b4b5-4ac9-ad0f-b5ae55d09a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MedicaidMember_e1e2352e-1c14-4c58-8e4a-5b0d00889e91" xlink:href="sny-20231231.xsd#sny_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02cad831-b4b5-4ac9-ad0f-b5ae55d09a8e" xlink:to="loc_sny_MedicaidMember_e1e2352e-1c14-4c58-8e4a-5b0d00889e91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MedicareMember_ad066566-e978-405e-b2b0-da788c255313" xlink:href="sny-20231231.xsd#sny_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02cad831-b4b5-4ac9-ad0f-b5ae55d09a8e" xlink:to="loc_sny_MedicareMember_ad066566-e978-405e-b2b0-da788c255313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_8b418b8f-7889-4932-99a7-5ab1ff1454e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a65050e-468c-4cb8-ad8f-d65d70226a15" xlink:to="loc_ifrs-full_GeographicalAreasAxis_8b418b8f-7889-4932-99a7-5ab1ff1454e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_8b418b8f-7889-4932-99a7-5ab1ff1454e9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_8b418b8f-7889-4932-99a7-5ab1ff1454e9" xlink:to="loc_ifrs-full_GeographicalAreasMember_8b418b8f-7889-4932-99a7-5ab1ff1454e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_67bdaf8e-c3da-4c52-b196-c54b68fa7fae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_8b418b8f-7889-4932-99a7-5ab1ff1454e9" xlink:to="loc_ifrs-full_GeographicalAreasMember_67bdaf8e-c3da-4c52-b196-c54b68fa7fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_39e1ef87-bb3a-47f4-88c0-fe1f9ab0cc79" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_67bdaf8e-c3da-4c52-b196-c54b68fa7fae" xlink:to="loc_country_US_39e1ef87-bb3a-47f4-88c0-fe1f9ab0cc79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_60326fbb-c69c-4e31-8e14-5b1f16ac013c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a65050e-468c-4cb8-ad8f-d65d70226a15" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_60326fbb-c69c-4e31-8e14-5b1f16ac013c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_60326fbb-c69c-4e31-8e14-5b1f16ac013c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_60326fbb-c69c-4e31-8e14-5b1f16ac013c" xlink:to="loc_ifrs-full_OtherProvisionsMember_60326fbb-c69c-4e31-8e14-5b1f16ac013c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_60326fbb-c69c-4e31-8e14-5b1f16ac013c" xlink:to="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentAndStateProgramsMember_2d525f42-9a25-4fa4-9295-df9dfc858a7b" xlink:href="sny-20231231.xsd#sny_GovernmentAndStateProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_GovernmentAndStateProgramsMember_2d525f42-9a25-4fa4-9295-df9dfc858a7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManagedCareAndGPOProgramsMember_3578c231-20c1-4d96-941b-74ff625c0614" xlink:href="sny-20231231.xsd#sny_ManagedCareAndGPOProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_ManagedCareAndGPOProgramsMember_3578c231-20c1-4d96-941b-74ff625c0614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChargebackIncentivesMember_c87c20b0-4c87-4c95-90de-2e04c6137fc2" xlink:href="sny-20231231.xsd#sny_ChargebackIncentivesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_ChargebackIncentivesMember_c87c20b0-4c87-4c95-90de-2e04c6137fc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RebatesAndDiscountsMember_8a909ea1-44a2-40df-a7db-9cd83558790b" xlink:href="sny-20231231.xsd#sny_RebatesAndDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_RebatesAndDiscountsMember_8a909ea1-44a2-40df-a7db-9cd83558790b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesReturnMember_f1e039c7-8c20-45df-b0bb-c773acb872de" xlink:href="sny-20231231.xsd#sny_SalesReturnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_SalesReturnMember_f1e039c7-8c20-45df-b0bb-c773acb872de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherDeductionsMember_23ccf82a-7dae-4c5f-99e7-b6bebd67f092" xlink:href="sny-20231231.xsd#sny_OtherDeductionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_OtherDeductionsMember_23ccf82a-7dae-4c5f-99e7-b6bebd67f092" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManagedCareMember_bae21d1b-8e94-4256-9f94-daea043ea2f8" xlink:href="sny-20231231.xsd#sny_ManagedCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_ManagedCareMember_bae21d1b-8e94-4256-9f94-daea043ea2f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForDiscountsRebatesAndSalesReturns_ee1cbe35-64dd-439d-acbe-a50584df8a91" xlink:href="sny-20231231.xsd#sny_ProvisionsForDiscountsRebatesAndSalesReturns"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_ProvisionsForDiscountsRebatesAndSalesReturns_ee1cbe35-64dd-439d-acbe-a50584df8a91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns_a8d13c5f-63d3-49c8-8b27-46045b2e13a8" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns_a8d13c5f-63d3-49c8-8b27-46045b2e13a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales_88b6d6f2-6f42-4e6a-b59a-0a69f196e8f8" xlink:href="sny-20231231.xsd#sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales_88b6d6f2-6f42-4e6a-b59a-0a69f196e8f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales_967203c6-e6e8-4100-afff-e71c95a57c39" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales_967203c6-e6e8-4100-afff-e71c95a57c39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns_cc47839c-e827-4e0b-a408-a55d2d0cd0cf" xlink:href="sny-20231231.xsd#sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns_cc47839c-e827-4e0b-a408-a55d2d0cd0cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns_63e40ef6-0882-4421-b45c-1a589e1c5222" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns_63e40ef6-0882-4421-b45c-1a589e1c5222" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForDiscountsRebatesAndSalesReturns_986d8169-66f7-423a-9ab2-be289609c83b" xlink:href="sny-20231231.xsd#sny_ProvisionsForDiscountsRebatesAndSalesReturns"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtheroperatingincomeDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OtheroperatingincomeDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OtheroperatingincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeLineItems_0249197d-8776-415c-9096-e4681f838929" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeTable_6325dafb-b0eb-4ed2-aa12-ed87638b51a0" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeLineItems_0249197d-8776-415c-9096-e4681f838929" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeTable_6325dafb-b0eb-4ed2-aa12-ed87638b51a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2cffbbca-b52d-4e45-b5fc-8391f975c331" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeTable_6325dafb-b0eb-4ed2-aa12-ed87638b51a0" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2cffbbca-b52d-4e45-b5fc-8391f975c331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2cffbbca-b52d-4e45-b5fc-8391f975c331_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2cffbbca-b52d-4e45-b5fc-8391f975c331" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2cffbbca-b52d-4e45-b5fc-8391f975c331_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_d56677a8-de37-4f44-b0f2-93c4ebaf9098" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2cffbbca-b52d-4e45-b5fc-8391f975c331" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_d56677a8-de37-4f44-b0f2-93c4ebaf9098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_80b0753c-283e-4530-92d1-aac7f8f6e282" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_d56677a8-de37-4f44-b0f2-93c4ebaf9098" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_80b0753c-283e-4530-92d1-aac7f8f6e282" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DaiichiSankyoMember_13fe255a-111c-414e-a61b-fd0922aaf4fa" xlink:href="sny-20231231.xsd#sny_DaiichiSankyoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_d56677a8-de37-4f44-b0f2-93c4ebaf9098" xlink:to="loc_sny_DaiichiSankyoMember_13fe255a-111c-414e-a61b-fd0922aaf4fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6f75f28b-20b8-4f44-8319-48f4220c987b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeTable_6325dafb-b0eb-4ed2-aa12-ed87638b51a0" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6f75f28b-20b8-4f44-8319-48f4220c987b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_6f75f28b-20b8-4f44-8319-48f4220c987b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6f75f28b-20b8-4f44-8319-48f4220c987b" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_6f75f28b-20b8-4f44-8319-48f4220c987b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_2a442ac7-16f1-4e79-b201-a27b4cd4d3a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6f75f28b-20b8-4f44-8319-48f4220c987b" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_2a442ac7-16f1-4e79-b201-a27b4cd4d3a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_18b5fe57-5b8f-4d5e-876e-dc44da064f03" xlink:href="sny-20231231.xsd#sny_RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_2a442ac7-16f1-4e79-b201-a27b4cd4d3a5" xlink:to="loc_sny_RegeneronMember_18b5fe57-5b8f-4d5e-876e-dc44da064f03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Axis_05bf4f04-20e1-4a9e-89bc-5a8df6a5b6da" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeTable_6325dafb-b0eb-4ed2-aa12-ed87638b51a0" xlink:to="loc_sny_IncomeStatementLocation1Axis_05bf4f04-20e1-4a9e-89bc-5a8df6a5b6da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Domain_05bf4f04-20e1-4a9e-89bc-5a8df6a5b6da_default" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_IncomeStatementLocation1Axis_05bf4f04-20e1-4a9e-89bc-5a8df6a5b6da" xlink:to="loc_sny_IncomeStatementLocation1Domain_05bf4f04-20e1-4a9e-89bc-5a8df6a5b6da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Domain_55cc5d5e-c5fe-4a5a-b3cd-616af4e66999" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_IncomeStatementLocation1Axis_05bf4f04-20e1-4a9e-89bc-5a8df6a5b6da" xlink:to="loc_sny_IncomeStatementLocation1Domain_55cc5d5e-c5fe-4a5a-b3cd-616af4e66999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpense1Member_107d13c1-bcf4-4dde-8966-d8fc157356e5" xlink:href="sny-20231231.xsd#sny_OtherOperatingIncomeExpense1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_IncomeStatementLocation1Domain_55cc5d5e-c5fe-4a5a-b3cd-616af4e66999" xlink:to="loc_sny_OtherOperatingIncomeExpense1Member_107d13c1-bcf4-4dde-8966-d8fc157356e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_48f8f32b-9f3c-419e-bb22-6d5803d3a18a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeLineItems_0249197d-8776-415c-9096-e4681f838929" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_48f8f32b-9f3c-419e-bb22-6d5803d3a18a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsOnDivestmentOfProducts_caa073af-b6a0-432b-9032-0061250366e7" xlink:href="sny-20231231.xsd#sny_GainsOnDivestmentOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeLineItems_0249197d-8776-415c-9096-e4681f838929" xlink:to="loc_sny_GainsOnDivestmentOfProducts_caa073af-b6a0-432b-9032-0061250366e7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OtheroperatingexpensesOtherIncomeandExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_27585492-052d-4f1e-aab9-a7b42482b668" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:to="loc_srt_CounterpartyNameAxis_27585492-052d-4f1e-aab9-a7b42482b668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27585492-052d-4f1e-aab9-a7b42482b668_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_27585492-052d-4f1e-aab9-a7b42482b668" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27585492-052d-4f1e-aab9-a7b42482b668_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91ce62d7-3f0c-4b7d-a783-1fe5c1d4e67a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_27585492-052d-4f1e-aab9-a7b42482b668" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91ce62d7-3f0c-4b7d-a783-1fe5c1d4e67a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesAllianceMember_d28c1b7b-07bc-4f51-a737-7f8562b28104" xlink:href="sny-20231231.xsd#sny_AntibodiesAllianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91ce62d7-3f0c-4b7d-a783-1fe5c1d4e67a" xlink:to="loc_sny_AntibodiesAllianceMember_d28c1b7b-07bc-4f51-a737-7f8562b28104" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunooncologyAllianceMember_381023e2-6bc4-4be5-a20b-16574d842310" xlink:href="sny-20231231.xsd#sny_ImmunooncologyAllianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91ce62d7-3f0c-4b7d-a783-1fe5c1d4e67a" xlink:to="loc_sny_ImmunooncologyAllianceMember_381023e2-6bc4-4be5-a20b-16574d842310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersCounterpartyMember_b1fdab9d-1191-4f2f-996f-a1fdcecc14fc" xlink:href="sny-20231231.xsd#sny_OthersCounterpartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91ce62d7-3f0c-4b7d-a783-1fe5c1d4e67a" xlink:to="loc_sny_OthersCounterpartyMember_b1fdab9d-1191-4f2f-996f-a1fdcecc14fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Axis_1e72930d-a5b0-45d7-ba45-d15877d77fa7" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:to="loc_sny_IncomeStatementLocation1Axis_1e72930d-a5b0-45d7-ba45-d15877d77fa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Domain_1e72930d-a5b0-45d7-ba45-d15877d77fa7_default" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_IncomeStatementLocation1Axis_1e72930d-a5b0-45d7-ba45-d15877d77fa7" xlink:to="loc_sny_IncomeStatementLocation1Domain_1e72930d-a5b0-45d7-ba45-d15877d77fa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_IncomeStatementLocation1Axis_1e72930d-a5b0-45d7-ba45-d15877d77fa7" xlink:to="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_8b0992d7-6d9f-4ee2-b9a1-2d4f2762224d" xlink:href="sny-20231231.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_8b0992d7-6d9f-4ee2-b9a1-2d4f2762224d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_0e23bc1e-f637-4c7d-b534-681edb1228ad" xlink:href="sny-20231231.xsd#sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_0e23bc1e-f637-4c7d-b534-681edb1228ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember_1e5eabc9-2631-4e1e-a098-8abe6381b817" xlink:href="sny-20231231.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:to="loc_sny_CommercializationRelatedExpensesMember_1e5eabc9-2631-4e1e-a098-8abe6381b817" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpense1Member_746374e0-15b4-4f8d-8795-96f8edc66e40" xlink:href="sny-20231231.xsd#sny_OtherOperatingIncomeExpense1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:to="loc_sny_OtherOperatingIncomeExpense1Member_746374e0-15b4-4f8d-8795-96f8edc66e40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_0ece645b-7065-4baf-bda8-df92f4b30252" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_0ece645b-7065-4baf-bda8-df92f4b30252" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_0ece645b-7065-4baf-bda8-df92f4b30252_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_0ece645b-7065-4baf-bda8-df92f4b30252" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_0ece645b-7065-4baf-bda8-df92f4b30252_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_b0322897-6e4c-44f4-bdaf-558b18cb6b5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_0ece645b-7065-4baf-bda8-df92f4b30252" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_b0322897-6e4c-44f4-bdaf-558b18cb6b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_00278c35-b3f6-4c26-b8ab-6bdb611cecbd" xlink:href="sny-20231231.xsd#sny_RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_b0322897-6e4c-44f4-bdaf-558b18cb6b5c" xlink:to="loc_sny_RegeneronMember_00278c35-b3f6-4c26-b8ab-6bdb611cecbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_4047a23d-f238-4384-98de-7031eb8ad78f" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:to="loc_sny_PrincipalAlliancesAxis_4047a23d-f238-4384-98de-7031eb8ad78f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_4047a23d-f238-4384-98de-7031eb8ad78f_default" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_4047a23d-f238-4384-98de-7031eb8ad78f" xlink:to="loc_sny_PrincipalAlliancesDomain_4047a23d-f238-4384-98de-7031eb8ad78f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_6bf9f6f6-6560-45e1-bf04-afda85123dec" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_4047a23d-f238-4384-98de-7031eb8ad78f" xlink:to="loc_sny_PrincipalAlliancesDomain_6bf9f6f6-6560-45e1-bf04-afda85123dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_66c99143-555b-4691-bc50-71c9537bd950" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_6bf9f6f6-6560-45e1-bf04-afda85123dec" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_66c99143-555b-4691-bc50-71c9537bd950" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_8e98ebdd-d930-483e-8208-34a3451e2e7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:to="loc_ifrs-full_CounterpartiesAxis_8e98ebdd-d930-483e-8208-34a3451e2e7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_8e98ebdd-d930-483e-8208-34a3451e2e7a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_8e98ebdd-d930-483e-8208-34a3451e2e7a" xlink:to="loc_ifrs-full_CounterpartiesMember_8e98ebdd-d930-483e-8208-34a3451e2e7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_465acba7-f2ad-4f76-b717-089e07c823d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_8e98ebdd-d930-483e-8208-34a3451e2e7a" xlink:to="loc_ifrs-full_CounterpartiesMember_465acba7-f2ad-4f76-b717-089e07c823d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_07103fd8-23be-42ee-a719-0d1b85af8ef8" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_465acba7-f2ad-4f76-b717-089e07c823d3" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_07103fd8-23be-42ee-a719-0d1b85af8ef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_f0dd2a7b-21a2-4677-a762-b82e8142af73" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_f0dd2a7b-21a2-4677-a762-b82e8142af73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_bb455d1e-21a6-49bd-9648-6068cc4531cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_bb455d1e-21a6-49bd-9648-6068cc4531cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_a2ddc426-2912-4537-ada8-f34c57c9e5d9" xlink:href="sny-20231231.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_a2ddc426-2912-4537-ada8-f34c57c9e5d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_ab0c72f8-48a0-45be-931d-ed6090381355" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_ab0c72f8-48a0-45be-931d-ed6090381355" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsReceivedForDevelopmentCosts_48e95fb0-4335-45b2-9abd-3822eee3f1a1" xlink:href="sny-20231231.xsd#sny_CommitmentsReceivedForDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:to="loc_sny_CommitmentsReceivedForDevelopmentCosts_48e95fb0-4335-45b2-9abd-3822eee3f1a1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#FinancialexpensesandincomeDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e05c8efb-a80d-49f7-96a5-8cc4b1f5f064" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e05c8efb-a80d-49f7-96a5-8cc4b1f5f064" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_f618d9f1-236a-4cba-9774-4f5c371983cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e05c8efb-a80d-49f7-96a5-8cc4b1f5f064" xlink:to="loc_ifrs-full_HedgedItemsAxis_f618d9f1-236a-4cba-9774-4f5c371983cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsMember_f618d9f1-236a-4cba-9774-4f5c371983cd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgedItemsAxis_f618d9f1-236a-4cba-9774-4f5c371983cd" xlink:to="loc_ifrs-full_HedgedItemsMember_f618d9f1-236a-4cba-9774-4f5c371983cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsMember_3e7ba616-38e8-4ae2-89be-c4b9d34b12c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgedItemsAxis_f618d9f1-236a-4cba-9774-4f5c371983cd" xlink:to="loc_ifrs-full_HedgedItemsMember_3e7ba616-38e8-4ae2-89be-c4b9d34b12c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember_1fae7689-b299-4cf9-82ff-e25f9a2aacd4" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgedItemsMember_3e7ba616-38e8-4ae2-89be-c4b9d34b12c1" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesMember_1fae7689-b299-4cf9-82ff-e25f9a2aacd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_57cec60a-503f-4c23-bc12-34d4505f7cbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_57cec60a-503f-4c23-bc12-34d4505f7cbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_6ec19886-bff1-4244-8a53-2d5b87864c3c" xlink:href="sny-20231231.xsd#sny_InterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_InterestIncome_6ec19886-bff1-4244-8a53-2d5b87864c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_a936ce8e-e93a-47f6-a1ce-642e61b31b71" xlink:href="sny-20231231.xsd#sny_CostOfDebtNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_CostOfDebtNet_a936ce8e-e93a-47f6-a1ce-642e61b31b71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_31d62177-a158-4dc6-9e0d-a2230762b08c" xlink:href="sny-20231231.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_31d62177-a158-4dc6-9e0d-a2230762b08c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_613a3a3f-66c7-4716-a20b-6397fc7177be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_613a3a3f-66c7-4716-a20b-6397fc7177be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_85caa58b-1365-4117-ac70-8d72bb8a9b64" xlink:href="sny-20231231.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_85caa58b-1365-4117-ac70-8d72bb8a9b64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_7640f2f2-041c-4f97-ae43-57265b892d6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_7640f2f2-041c-4f97-ae43-57265b892d6c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_86355e2d-a23f-4b60-876c-77712eb073d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_86355e2d-a23f-4b60-876c-77712eb073d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_c759c974-2334-4e4e-b14e-5ccf85e698a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_c759c974-2334-4e4e-b14e-5ccf85e698a8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_b4da615e-6ec9-4910-b74b-b38a9637a4a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_FinanceIncomeCost_b4da615e-6ec9-4910-b74b-b38a9637a4a9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_a01bb568-e1c0-4652-b314-43d4db788d7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinanceIncomeCost_b4da615e-6ec9-4910-b74b-b38a9637a4a9" xlink:to="loc_ifrs-full_FinanceCosts_a01bb568-e1c0-4652-b314-43d4db788d7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_6a3a366c-8890-49ac-8c3b-5f9fe1285e68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinanceIncomeCost_b4da615e-6ec9-4910-b74b-b38a9637a4a9" xlink:to="loc_ifrs-full_FinanceIncome_6a3a366c-8890-49ac-8c3b-5f9fe1285e68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnDerivativesUsedToManageDebt_eaa0836a-17f9-4c9c-91aa-db5548121e3d" xlink:href="sny-20231231.xsd#sny_GainsLossesOnDerivativesUsedToManageDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_GainsLossesOnDerivativesUsedToManageDebt_eaa0836a-17f9-4c9c-91aa-db5548121e3d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents_bbd674ff-d35b-4f4b-8100-9124283814f5" xlink:href="sny-20231231.xsd#sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents_bbd674ff-d35b-4f4b-8100-9124283814f5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_6b1cf5bb-c5fe-448d-abe7-5f69b11201f4" xlink:href="sny-20231231.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_6b1cf5bb-c5fe-448d-abe7-5f69b11201f4" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_40e06983-79f1-4e19-acf0-9e7a4abc1e87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_93020f3d-9f75-4f7a-a701-33bedaf01ebb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_40e06983-79f1-4e19-acf0-9e7a4abc1e87" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_93020f3d-9f75-4f7a-a701-33bedaf01ebb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1b4d4318-8b01-4fc7-97f1-82ddd45da1bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_93020f3d-9f75-4f7a-a701-33bedaf01ebb" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1b4d4318-8b01-4fc7-97f1-82ddd45da1bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_1b4d4318-8b01-4fc7-97f1-82ddd45da1bb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1b4d4318-8b01-4fc7-97f1-82ddd45da1bb" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_1b4d4318-8b01-4fc7-97f1-82ddd45da1bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_6bbfcbca-39d3-43e0-b341-de99d918d8f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1b4d4318-8b01-4fc7-97f1-82ddd45da1bb" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_6bbfcbca-39d3-43e0-b341-de99d918d8f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_bd8f0ae4-7437-495a-b5a2-e6f3a05bba62" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_6bbfcbca-39d3-43e0-b341-de99d918d8f3" xlink:to="loc_sny_EuroapiMember_bd8f0ae4-7437-495a-b5a2-e6f3a05bba62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_da055633-89d0-46cc-8d76-7cdc148c19e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_40e06983-79f1-4e19-acf0-9e7a4abc1e87" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_da055633-89d0-46cc-8d76-7cdc148c19e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_cd087c98-16d0-43d0-8f6c-442855629f9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_40e06983-79f1-4e19-acf0-9e7a4abc1e87" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_cd087c98-16d0-43d0-8f6c-442855629f9a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#NetincomeattributabletononcontrollinginterestsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems_22c9d146-403a-4c45-9f93-bdeb565459de" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable_1b3ee640-5e98-4b5c-a2e3-92d1b62819e7" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems_22c9d146-403a-4c45-9f93-bdeb565459de" xlink:to="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable_1b3ee640-5e98-4b5c-a2e3-92d1b62819e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_82cddb8e-bbe5-4b06-804d-b2cff916da0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable_1b3ee640-5e98-4b5c-a2e3-92d1b62819e7" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_82cddb8e-bbe5-4b06-804d-b2cff916da0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_82cddb8e-bbe5-4b06-804d-b2cff916da0a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_82cddb8e-bbe5-4b06-804d-b2cff916da0a" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_82cddb8e-bbe5-4b06-804d-b2cff916da0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_2ef02dcb-a748-4ab0-b899-67d517d71452" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_82cddb8e-bbe5-4b06-804d-b2cff916da0a" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_2ef02dcb-a748-4ab0-b899-67d517d71452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_4fbedaec-6904-4895-b832-085b2829b134" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_2ef02dcb-a748-4ab0-b899-67d517d71452" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_4fbedaec-6904-4895-b832-085b2829b134" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_db524729-7e87-4b3d-b678-41f9f0e0d99b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems_22c9d146-403a-4c45-9f93-bdeb565459de" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_db524729-7e87-4b3d-b678-41f9f0e0d99b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DisclosuresaboutmajorcustomersandcreditriskDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_0676e1da-fd80-4c3c-b6f0-9b7c62e199cd" xlink:href="sny-20231231.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_86c223c7-98ae-4089-adaa-b74cf50fd648" xlink:href="sny-20231231.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_0676e1da-fd80-4c3c-b6f0-9b7c62e199cd" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_86c223c7-98ae-4089-adaa-b74cf50fd648" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_b7a4867b-f01a-42ce-b6b9-af859fa1dd4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_86c223c7-98ae-4089-adaa-b74cf50fd648" xlink:to="loc_ifrs-full_MajorCustomersAxis_b7a4867b-f01a-42ce-b6b9-af859fa1dd4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_b7a4867b-f01a-42ce-b6b9-af859fa1dd4b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MajorCustomersAxis_b7a4867b-f01a-42ce-b6b9-af859fa1dd4b" xlink:to="loc_ifrs-full_MajorCustomersMember_b7a4867b-f01a-42ce-b6b9-af859fa1dd4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MajorCustomersAxis_b7a4867b-f01a-42ce-b6b9-af859fa1dd4b" xlink:to="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LargestCustomersMember_d14ccc02-89eb-40a6-8064-76cbde282d47" xlink:href="sny-20231231.xsd#sny_LargestCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:to="loc_sny_LargestCustomersMember_d14ccc02-89eb-40a6-8064-76cbde282d47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember_79a402eb-0855-4934-a354-a3a5140ffc3e" xlink:href="sny-20231231.xsd#sny_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:to="loc_sny_CustomerOneMember_79a402eb-0855-4934-a354-a3a5140ffc3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember_76c9e912-81e3-483c-91e8-d1e1a98ebd40" xlink:href="sny-20231231.xsd#sny_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:to="loc_sny_CustomerTwoMember_76c9e912-81e3-483c-91e8-d1e1a98ebd40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember_df6b7529-1bc6-4c3d-9bed-5408a492cae8" xlink:href="sny-20231231.xsd#sny_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:to="loc_sny_CustomerThreeMember_df6b7529-1bc6-4c3d-9bed-5408a492cae8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue_01d3654f-b610-471d-8023-53e3c1140e7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_0676e1da-fd80-4c3c-b6f0-9b7c62e199cd" xlink:to="loc_ifrs-full_PercentageOfEntitysRevenue_01d3654f-b610-471d-8023-53e3c1140e7d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_19e17268-a445-440f-8007-42d157af6f6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_b1a48f04-7adc-4180-927f-2aa375100a1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_19e17268-a445-440f-8007-42d157af6f6f" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_b1a48f04-7adc-4180-927f-2aa375100a1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_d86dbb47-3068-46c0-8b96-cfe4316701fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_b1a48f04-7adc-4180-927f-2aa375100a1d" xlink:to="loc_ifrs-full_GeographicalAreasAxis_d86dbb47-3068-46c0-8b96-cfe4316701fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_d86dbb47-3068-46c0-8b96-cfe4316701fb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_d86dbb47-3068-46c0-8b96-cfe4316701fb" xlink:to="loc_ifrs-full_GeographicalAreasMember_d86dbb47-3068-46c0-8b96-cfe4316701fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_ccaf0a56-50e4-4feb-bcb1-dd023ec49aba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_d86dbb47-3068-46c0-8b96-cfe4316701fb" xlink:to="loc_ifrs-full_GeographicalAreasMember_ccaf0a56-50e4-4feb-bcb1-dd023ec49aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_3f4e3f19-58c5-47a5-8cfe-abcbed9c37b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_ccaf0a56-50e4-4feb-bcb1-dd023ec49aba" xlink:to="loc_srt_EuropeMember_3f4e3f19-58c5-47a5-8cfe-abcbed9c37b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b5b12ddf-f821-48fa-866f-96e5531cec69" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_ccaf0a56-50e4-4feb-bcb1-dd023ec49aba" xlink:to="loc_country_US_b5b12ddf-f821-48fa-866f-96e5531cec69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesInSegmentResultsMember_4ad8a628-aef2-43f2-a367-673dbd3a98b1" xlink:href="sny-20231231.xsd#sny_OtherCountriesInSegmentResultsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_ccaf0a56-50e4-4feb-bcb1-dd023ec49aba" xlink:to="loc_sny_OtherCountriesInSegmentResultsMember_4ad8a628-aef2-43f2-a367-673dbd3a98b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_dc4a22d6-2996-47f1-bb8f-1fd378158b29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_b1a48f04-7adc-4180-927f-2aa375100a1d" xlink:to="loc_ifrs-full_SegmentsAxis_dc4a22d6-2996-47f1-bb8f-1fd378158b29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_dc4a22d6-2996-47f1-bb8f-1fd378158b29_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_dc4a22d6-2996-47f1-bb8f-1fd378158b29" xlink:to="loc_ifrs-full_SegmentsMember_dc4a22d6-2996-47f1-bb8f-1fd378158b29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_28cb5e5e-c8a0-4f18-a022-c18f36d845c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_dc4a22d6-2996-47f1-bb8f-1fd378158b29" xlink:to="loc_ifrs-full_SegmentsMember_28cb5e5e-c8a0-4f18-a022-c18f36d845c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_0d0b9a11-9d15-4d1b-9e76-d0c7228863a6" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_28cb5e5e-c8a0-4f18-a022-c18f36d845c2" xlink:to="loc_sny_BiopharmaSegmentMember_0d0b9a11-9d15-4d1b-9e76-d0c7228863a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_b1e33332-9d5b-48bb-a1ad-56dd2df3366c" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_28cb5e5e-c8a0-4f18-a022-c18f36d845c2" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_b1e33332-9d5b-48bb-a1ad-56dd2df3366c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_61a800c4-37c1-404e-98e5-ea33a352e2a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_b1a48f04-7adc-4180-927f-2aa375100a1d" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_61a800c4-37c1-404e-98e5-ea33a352e2a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_61a800c4-37c1-404e-98e5-ea33a352e2a1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_61a800c4-37c1-404e-98e5-ea33a352e2a1" xlink:to="loc_ifrs-full_ProductsAndServicesMember_61a800c4-37c1-404e-98e5-ea33a352e2a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_61a800c4-37c1-404e-98e5-ea33a352e2a1" xlink:to="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:href="sny-20231231.xsd#sny_SpecialtyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember_2cd2d67c-b082-4853-a3c7-5b87a6763b0c" xlink:href="sny-20231231.xsd#sny_DupixentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_DupixentMember_2cd2d67c-b082-4853-a3c7-5b87a6763b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AubagioMember_96123dd7-e536-4c21-9971-89e1b8bfdec7" xlink:href="sny-20231231.xsd#sny_AubagioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_AubagioMember_96123dd7-e536-4c21-9971-89e1b8bfdec7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember_5e4da4c8-1e4c-4d0e-9691-74667cb9c18b" xlink:href="sny-20231231.xsd#sny_CerezymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_CerezymeMember_5e4da4c8-1e4c-4d0e-9691-74667cb9c18b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember_982582d9-d130-4d08-854f-8bc5d8976161" xlink:href="sny-20231231.xsd#sny_FabrazymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_FabrazymeMember_982582d9-d130-4d08-854f-8bc5d8976161" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MyozymeOrLumizymeMember_a81c515c-151d-4cf2-9461-d087fa74c1cd" xlink:href="sny-20231231.xsd#sny_MyozymeOrLumizymeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_MyozymeOrLumizymeMember_a81c515c-151d-4cf2-9461-d087fa74c1cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaMember_a639e5a7-faf2-4823-ae22-abd20dc8a871" xlink:href="sny-20231231.xsd#sny_JevtanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_JevtanaMember_a639e5a7-faf2-4823-ae22-abd20dc8a871" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AlprolixMember_183dca33-cb22-4e2d-9f22-3882405a6941" xlink:href="sny-20231231.xsd#sny_AlprolixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_AlprolixMember_183dca33-cb22-4e2d-9f22-3882405a6941" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_b9233d97-31fe-404c-b0c8-08b14f265a92" xlink:href="sny-20231231.xsd#sny_EloctateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_EloctateMember_b9233d97-31fe-404c-b0c8-08b14f265a92" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralMedecinesMember_3d47fc26-c3ec-4e66-8a1b-7a8cec90a873" xlink:href="sny-20231231.xsd#sny_GeneralMedecinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_GeneralMedecinesMember_3d47fc26-c3ec-4e66-8a1b-7a8cec90a873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CoreAssetsMember_cbd2df30-f098-4d29-84aa-7504dcbcbac7" xlink:href="sny-20231231.xsd#sny_CoreAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GeneralMedecinesMember_3d47fc26-c3ec-4e66-8a1b-7a8cec90a873" xlink:to="loc_sny_CoreAssetsMember_cbd2df30-f098-4d29-84aa-7504dcbcbac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember_8174b587-1376-441f-8b77-a6f2dcb5b572" xlink:href="sny-20231231.xsd#sny_LovenoxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_CoreAssetsMember_cbd2df30-f098-4d29-84aa-7504dcbcbac7" xlink:to="loc_sny_LovenoxMember_8174b587-1376-441f-8b77-a6f2dcb5b572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember_20c34687-97d5-47bd-9ab8-073645729600" xlink:href="sny-20231231.xsd#sny_ToujeoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_CoreAssetsMember_cbd2df30-f098-4d29-84aa-7504dcbcbac7" xlink:to="loc_sny_ToujeoMember_20c34687-97d5-47bd-9ab8-073645729600" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember_d4f7d1e2-25e8-40c6-9d33-89b944a39e26" xlink:href="sny-20231231.xsd#sny_PlavixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_CoreAssetsMember_cbd2df30-f098-4d29-84aa-7504dcbcbac7" xlink:to="loc_sny_PlavixMember_d4f7d1e2-25e8-40c6-9d33-89b944a39e26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCoreAssetsMember_82ea56d9-d570-4723-b472-32460b17cfc3" xlink:href="sny-20231231.xsd#sny_NonCoreAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GeneralMedecinesMember_3d47fc26-c3ec-4e66-8a1b-7a8cec90a873" xlink:to="loc_sny_NonCoreAssetsMember_82ea56d9-d570-4723-b472-32460b17cfc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember_8eff31d4-0ee3-4b71-8a63-935cf74d6ebf" xlink:href="sny-20231231.xsd#sny_LantusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_NonCoreAssetsMember_82ea56d9-d570-4723-b472-32460b17cfc3" xlink:to="loc_sny_LantusMember_8eff31d4-0ee3-4b71-8a63-935cf74d6ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherNonCoreAssetsMember_8bb735d6-b49c-4b29-9b9c-47e4439adead" xlink:href="sny-20231231.xsd#sny_OtherNonCoreAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_NonCoreAssetsMember_82ea56d9-d570-4723-b472-32460b17cfc3" xlink:to="loc_sny_OtherNonCoreAssetsMember_8bb735d6-b49c-4b29-9b9c-47e4439adead" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember_49cad975-bf2e-483f-9571-612cc00060a5" xlink:href="sny-20231231.xsd#sny_IndustrialSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_GeneralMedecinesMember_3d47fc26-c3ec-4e66-8a1b-7a8cec90a873" xlink:to="loc_sny_IndustrialSalesMember_49cad975-bf2e-483f-9571-612cc00060a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesMember_e5dbfda1-4d8c-4881-95d8-d72a38dbfd55" xlink:href="sny-20231231.xsd#sny_VaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_VaccinesMember_e5dbfda1-4d8c-4881-95d8-d72a38dbfd55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibVaccinesMember_3d809853-0e55-45fd-a98c-d00101b716af" xlink:href="sny-20231231.xsd#sny_PolioPertussisHibVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_VaccinesMember_e5dbfda1-4d8c-4881-95d8-d72a38dbfd55" xlink:to="loc_sny_PolioPertussisHibVaccinesMember_3d809853-0e55-45fd-a98c-d00101b716af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfluenzaVaccinesMember_c5dc3c00-c04e-480f-8258-67ed06720ffe" xlink:href="sny-20231231.xsd#sny_InfluenzaVaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_VaccinesMember_e5dbfda1-4d8c-4881-95d8-d72a38dbfd55" xlink:to="loc_sny_InfluenzaVaccinesMember_c5dc3c00-c04e-480f-8258-67ed06720ffe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AllergyMember_7b46cafe-7b93-4186-86c8-594c1cf8a0bb" xlink:href="sny-20231231.xsd#sny_AllergyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_AllergyMember_7b46cafe-7b93-4186-86c8-594c1cf8a0bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PainCareMember_0bbb3a65-52d6-4c8a-9988-7977c702a629" xlink:href="sny-20231231.xsd#sny_PainCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_PainCareMember_0bbb3a65-52d6-4c8a-9988-7977c702a629" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DigestiveWellnessMember_7499c8e9-2ade-4ae4-ba44-80c8ef955d29" xlink:href="sny-20231231.xsd#sny_DigestiveWellnessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_DigestiveWellnessMember_7499c8e9-2ade-4ae4-ba44-80c8ef955d29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_ef22becf-d561-4c86-adf8-bc3af23f1324" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_19e17268-a445-440f-8007-42d157af6f6f" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_ef22becf-d561-4c86-adf8-bc3af23f1324" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments1_966874d5-6d43-4625-85b9-751b6a603ad0" xlink:href="sny-20231231.xsd#sny_NumberOfOperatingSegments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_19e17268-a445-440f-8007-42d157af6f6f" xlink:to="loc_sny_NumberOfOperatingSegments1_966874d5-6d43-4625-85b9-751b6a603ad0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationScheduleofSegmentResultsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_3c6db461-58ff-4d8b-addf-9f6df526d93d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_3c6db461-58ff-4d8b-addf-9f6df526d93d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_1907db83-654b-42cc-8fce-0de680510f02" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_3c6db461-58ff-4d8b-addf-9f6df526d93d" xlink:to="loc_ifrs-full_SegmentsAxis_1907db83-654b-42cc-8fce-0de680510f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_1907db83-654b-42cc-8fce-0de680510f02_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_1907db83-654b-42cc-8fce-0de680510f02" xlink:to="loc_ifrs-full_SegmentsMember_1907db83-654b-42cc-8fce-0de680510f02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_08f23aed-5490-4f74-b467-b6e24a39d2f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_1907db83-654b-42cc-8fce-0de680510f02" xlink:to="loc_ifrs-full_SegmentsMember_08f23aed-5490-4f74-b467-b6e24a39d2f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_08f23aed-5490-4f74-b467-b6e24a39d2f3" xlink:to="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_0b582692-b29e-46f1-8091-db769e7a7630" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:to="loc_sny_BiopharmaSegmentMember_0b582692-b29e-46f1-8091-db769e7a7630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaceuticalsSegmentMember_0818e87f-5035-4bb1-88b2-176c45fd2e11" xlink:href="sny-20231231.xsd#sny_PharmaceuticalsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:to="loc_sny_PharmaceuticalsSegmentMember_0818e87f-5035-4bb1-88b2-176c45fd2e11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesSegmentMember_832d0b7e-0ceb-46fd-bd07-8d638189557f" xlink:href="sny-20231231.xsd#sny_VaccinesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:to="loc_sny_VaccinesSegmentMember_832d0b7e-0ceb-46fd-bd07-8d638189557f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_5530a193-0ec3-4bc4-97c0-dff6e9586580" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_5530a193-0ec3-4bc4-97c0-dff6e9586580" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_5e20d67f-e443-4f11-83a5-dc97d562db30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_5e20d67f-e443-4f11-83a5-dc97d562db30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_6db49d0d-9e37-46af-8cf4-c316909600d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_6db49d0d-9e37-46af-8cf4-c316909600d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_b48c914f-2df7-4e68-be54-391c029b971e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_OtherRevenue_b48c914f-2df7-4e68-be54-391c029b971e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_2c36d6a0-2455-450e-bce6-574c73569def" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_CostOfSales_2c36d6a0-2455-450e-bce6-574c73569def" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_2627000c-a19b-4b91-9e7a-1b8ccb99fcb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_2627000c-a19b-4b91-9e7a-1b8ccb99fcb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_6cdb273c-45ba-4d19-8f57-2e0fab1e6d64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_6cdb273c-45ba-4d19-8f57-2e0fab1e6d64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_b4933d81-26d6-4c1d-8faa-c1ee626a0349" xlink:href="sny-20231231.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_b4933d81-26d6-4c1d-8faa-c1ee626a0349" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_6d209c4d-d316-4209-8954-af11fce2a818" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_6d209c4d-d316-4209-8954-af11fce2a818" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1de00692-52ba-497f-b9f6-195d1e3dc664" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1de00692-52ba-497f-b9f6-195d1e3dc664" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_debaf6dd-bccb-466e-a9d4-13f27ed00382" xlink:href="sny-20231231.xsd#sny_BusinessOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_sny_BusinessOperatingIncome_debaf6dd-bccb-466e-a9d4-13f27ed00382" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments1_023b5ab3-bcc1-477a-a0b3-c905952799b1" xlink:href="sny-20231231.xsd#sny_NumberOfOperatingSegments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_sny_NumberOfOperatingSegments1_023b5ab3-bcc1-477a-a0b3-c905952799b1" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis_a6987667-cdba-48ad-92cf-49567e1c3914" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_ifrs-full_SegmentConsolidationItemsAxis_a6987667-cdba-48ad-92cf-49567e1c3914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_a6987667-cdba-48ad-92cf-49567e1c3914_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_a6987667-cdba-48ad-92cf-49567e1c3914" xlink:to="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_a6987667-cdba-48ad-92cf-49567e1c3914_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_3939c222-b453-420f-9131-f29f9dfa2ae3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_a6987667-cdba-48ad-92cf-49567e1c3914" xlink:to="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_3939c222-b453-420f-9131-f29f9dfa2ae3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember_bbf58987-67ac-4123-95dc-94098c75c724" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_3939c222-b453-420f-9131-f29f9dfa2ae3" xlink:to="loc_ifrs-full_OperatingSegmentsMember_bbf58987-67ac-4123-95dc-94098c75c724" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember_23ae8782-b0c9-41e9-b07e-0996b707561c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_3939c222-b453-420f-9131-f29f9dfa2ae3" xlink:to="loc_ifrs-full_MaterialReconcilingItemsMember_23ae8782-b0c9-41e9-b07e-0996b707561c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bf5cadce-464d-41c5-9e0c-1cf59b76bd99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_srt_ProductOrServiceAxis_bf5cadce-464d-41c5-9e0c-1cf59b76bd99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bf5cadce-464d-41c5-9e0c-1cf59b76bd99_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bf5cadce-464d-41c5-9e0c-1cf59b76bd99" xlink:to="loc_srt_ProductsAndServicesDomain_bf5cadce-464d-41c5-9e0c-1cf59b76bd99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3f639f5a-fa9b-4ea6-beca-0689107e9e95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bf5cadce-464d-41c5-9e0c-1cf59b76bd99" xlink:to="loc_srt_ProductsAndServicesDomain_3f639f5a-fa9b-4ea6-beca-0689107e9e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_1dcf491e-e7d1-4b96-b559-7ca164e7e102" xlink:href="sny-20231231.xsd#sny_EloctateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3f639f5a-fa9b-4ea6-beca-0689107e9e95" xlink:to="loc_sny_EloctateMember_1dcf491e-e7d1-4b96-b559-7ca164e7e102" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_689b1e05-5459-49b9-b1df-4004ac1e4389" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_689b1e05-5459-49b9-b1df-4004ac1e4389" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_689b1e05-5459-49b9-b1df-4004ac1e4389_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_689b1e05-5459-49b9-b1df-4004ac1e4389" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_689b1e05-5459-49b9-b1df-4004ac1e4389_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_b3cf3b3e-eddd-4a63-9667-e1f8678700f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_689b1e05-5459-49b9-b1df-4004ac1e4389" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_b3cf3b3e-eddd-4a63-9667-e1f8678700f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_46e5843b-a255-46d2-a825-42eed5ee5e41" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_b3cf3b3e-eddd-4a63-9667-e1f8678700f0" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_46e5843b-a255-46d2-a825-42eed5ee5e41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_838630b3-1b12-41af-893b-2b6d4574e41b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_838630b3-1b12-41af-893b-2b6d4574e41b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_838630b3-1b12-41af-893b-2b6d4574e41b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_838630b3-1b12-41af-893b-2b6d4574e41b" xlink:to="loc_ifrs-full_ProductsAndServicesMember_838630b3-1b12-41af-893b-2b6d4574e41b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_af1be0e2-7381-461d-ba0d-02a4b232dc25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_838630b3-1b12-41af-893b-2b6d4574e41b" xlink:to="loc_ifrs-full_ProductsAndServicesMember_af1be0e2-7381-461d-ba0d-02a4b232dc25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NKCellAndProXTenTechnologyPlatformsMember_c4a49298-e512-4c5f-b9c5-7b0bec62f727" xlink:href="sny-20231231.xsd#sny_NKCellAndProXTenTechnologyPlatformsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_af1be0e2-7381-461d-ba0d-02a4b232dc25" xlink:to="loc_sny_NKCellAndProXTenTechnologyPlatformsMember_c4a49298-e512-4c5f-b9c5-7b0bec62f727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SAR444245Member_460121fa-7c1e-4fd8-a7a6-64a22dee4b3b" xlink:href="sny-20231231.xsd#sny_SAR444245Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_af1be0e2-7381-461d-ba0d-02a4b232dc25" xlink:to="loc_sny_SAR444245Member_460121fa-7c1e-4fd8-a7a6-64a22dee4b3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_5a3413a3-3e48-4dba-a724-0b851222e1e1" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_sny_PrincipalAlliancesAxis_5a3413a3-3e48-4dba-a724-0b851222e1e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_5a3413a3-3e48-4dba-a724-0b851222e1e1_default" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_PrincipalAlliancesAxis_5a3413a3-3e48-4dba-a724-0b851222e1e1" xlink:to="loc_sny_PrincipalAlliancesDomain_5a3413a3-3e48-4dba-a724-0b851222e1e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_51ca70ec-1100-429f-9b0f-c3a100a5d32b" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_PrincipalAlliancesAxis_5a3413a3-3e48-4dba-a724-0b851222e1e1" xlink:to="loc_sny_PrincipalAlliancesDomain_51ca70ec-1100-429f-9b0f-c3a100a5d32b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember_fbb8bba6-3674-47f0-8592-2923cb4f86b7" xlink:href="sny-20231231.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_PrincipalAlliancesDomain_51ca70ec-1100-429f-9b0f-c3a100a5d32b" xlink:to="loc_sny_ImmunoOncologyCollaborationAgreementMember_fbb8bba6-3674-47f0-8592-2923cb4f86b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_85549ccf-2111-4366-a97d-8358ee9a655a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_ifrs-full_CounterpartiesAxis_85549ccf-2111-4366-a97d-8358ee9a655a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_85549ccf-2111-4366-a97d-8358ee9a655a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_85549ccf-2111-4366-a97d-8358ee9a655a" xlink:to="loc_ifrs-full_CounterpartiesMember_85549ccf-2111-4366-a97d-8358ee9a655a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_1a78bacc-ef64-472c-bb28-419ff375b01e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_85549ccf-2111-4366-a97d-8358ee9a655a" xlink:to="loc_ifrs-full_CounterpartiesMember_1a78bacc-ef64-472c-bb28-419ff375b01e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_4b1019dd-b7ef-4376-ac6f-8fb444585c6a" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_1a78bacc-ef64-472c-bb28-419ff375b01e" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_4b1019dd-b7ef-4376-ac6f-8fb444585c6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_cf13cf69-d7e2-4f3a-8cc0-3c2dafe32d0f" xlink:href="sny-20231231.xsd#sny_BusinessOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_BusinessOperatingIncome_cf13cf69-d7e2-4f3a-8cc0-3c2dafe32d0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_fceda395-5bdc-492b-99e0-955eb775d5fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_fceda395-5bdc-492b-99e0-955eb775d5fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_84d20ff2-a061-4790-a104-9f130a5975bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_84d20ff2-a061-4790-a104-9f130a5975bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_a2220647-3e22-4943-8aa8-e20d706727ce" xlink:href="sny-20231231.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_a2220647-3e22-4943-8aa8-e20d706727ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_ffdc9624-55b1-4a24-b7ea-6f44c60a68af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_ffdc9624-55b1-4a24-b7ea-6f44c60a68af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_0c823fff-1555-43f0-bb23-af1379352b8a" xlink:href="sny-20231231.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_0c823fff-1555-43f0-bb23-af1379352b8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_0024353f-a3bf-4a1c-908d-865a42d5f27e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_0024353f-a3bf-4a1c-908d-865a42d5f27e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_6e018816-4047-4eec-833e-9a6204a1f386" xlink:href="sny-20231231.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_OtherGainsLossesAndLitigation_6e018816-4047-4eec-833e-9a6204a1f386" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing_924ef0fb-355c-47d0-9970-2eee89d684d1" xlink:href="sny-20231231.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_IncomeResultingFromOutLicensing_924ef0fb-355c-47d0-9970-2eee89d684d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_099f63ae-35a4-4fc8-aae8-21d96979e802" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_099f63ae-35a4-4fc8-aae8-21d96979e802" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_451dae27-bfdf-428b-9bda-3d56f61a8abc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_FinanceCosts_451dae27-bfdf-428b-9bda-3d56f61a8abc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_65f50bf1-0d32-42fa-b149-b7f11b948623" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_FinanceIncome_65f50bf1-0d32-42fa-b149-b7f11b948623" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_c8f437b2-9fe3-4eed-a4b8-b46daba37c0b" xlink:href="sny-20231231.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_c8f437b2-9fe3-4eed-a4b8-b46daba37c0b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount_eab52c4d-6662-4c1f-be42-d0554f2df4b8" xlink:href="sny-20231231.xsd#sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount_eab52c4d-6662-4c1f-be42-d0554f2df4b8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_f378a02f-b01c-4e51-8adb-21d27d9992ab" xlink:href="sny-20231231.xsd#sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_f378a02f-b01c-4e51-8adb-21d27d9992ab" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_201ac633-6cdd-49e8-9614-0eda78002c70" xlink:href="sny-20231231.xsd#sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_201ac633-6cdd-49e8-9614-0eda78002c70" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_dc75bc35-f1ba-424a-96ae-2fd0c2211c68" xlink:href="sny-20231231.xsd#sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_dc75bc35-f1ba-424a-96ae-2fd0c2211c68" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_230c010c-81eb-45fb-89be-4106a6b5601f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_88a7d95c-6cac-45ce-af23-e8b653ea3e9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_230c010c-81eb-45fb-89be-4106a6b5601f" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_88a7d95c-6cac-45ce-af23-e8b653ea3e9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_a377f6b8-cead-4922-90b0-0cdd1176102c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_88a7d95c-6cac-45ce-af23-e8b653ea3e9b" xlink:to="loc_ifrs-full_SegmentsAxis_a377f6b8-cead-4922-90b0-0cdd1176102c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_a377f6b8-cead-4922-90b0-0cdd1176102c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SegmentsAxis_a377f6b8-cead-4922-90b0-0cdd1176102c" xlink:to="loc_ifrs-full_SegmentsMember_a377f6b8-cead-4922-90b0-0cdd1176102c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_dbc0e98c-0234-43f7-9e64-84f43958ff3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SegmentsAxis_a377f6b8-cead-4922-90b0-0cdd1176102c" xlink:to="loc_ifrs-full_SegmentsMember_dbc0e98c-0234-43f7-9e64-84f43958ff3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SegmentsMember_dbc0e98c-0234-43f7-9e64-84f43958ff3b" xlink:to="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaceuticalsSegmentMember_bc953226-cf50-4ba4-9ba6-d8dd7762103a" xlink:href="sny-20231231.xsd#sny_PharmaceuticalsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:to="loc_sny_PharmaceuticalsSegmentMember_bc953226-cf50-4ba4-9ba6-d8dd7762103a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesSegmentMember_249e899c-fb63-42d0-8ab2-53507354fb05" xlink:href="sny-20231231.xsd#sny_VaccinesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:to="loc_sny_VaccinesSegmentMember_249e899c-fb63-42d0-8ab2-53507354fb05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_e98f5d27-c9db-47d5-8f19-9474558827e0" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:to="loc_sny_BiopharmaSegmentMember_e98f5d27-c9db-47d5-8f19-9474558827e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_10834494-674f-4da9-8668-a9d043d0f36e" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_10834494-674f-4da9-8668-a9d043d0f36e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInAssociatesAndJointVentures_b4325504-86dd-4f28-872c-3074d0905c40" xlink:href="sny-20231231.xsd#sny_InvestmentsInAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_230c010c-81eb-45fb-89be-4106a6b5601f" xlink:to="loc_sny_InvestmentsInAssociatesAndJointVentures_b4325504-86dd-4f28-872c-3074d0905c40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4c3475f0-c063-4db5-9b19-01c2526d483f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_230c010c-81eb-45fb-89be-4106a6b5601f" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4c3475f0-c063-4db5-9b19-01c2526d483f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_fb2c2067-8ab7-4156-ac45-f88ef1093a8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_230c010c-81eb-45fb-89be-4106a6b5601f" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_fb2c2067-8ab7-4156-ac45-f88ef1093a8e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_d9c7ca8c-ca4a-4941-b5a0-beeb600d207b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_d9c7ca8c-ca4a-4941-b5a0-beeb600d207b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_e8c7e833-42a7-42c7-8347-30637437a24f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_d9c7ca8c-ca4a-4941-b5a0-beeb600d207b" xlink:to="loc_ifrs-full_GeographicalAreasAxis_e8c7e833-42a7-42c7-8347-30637437a24f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_e8c7e833-42a7-42c7-8347-30637437a24f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_e8c7e833-42a7-42c7-8347-30637437a24f" xlink:to="loc_ifrs-full_GeographicalAreasMember_e8c7e833-42a7-42c7-8347-30637437a24f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_0577e3b7-0056-4077-8c24-ec4992823301" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_e8c7e833-42a7-42c7-8347-30637437a24f" xlink:to="loc_ifrs-full_GeographicalAreasMember_0577e3b7-0056-4077-8c24-ec4992823301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReportableGeographicalZonesMember_4ce1d438-12a2-47cd-b1d2-8db44b1bce0d" xlink:href="sny-20231231.xsd#sny_ReportableGeographicalZonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_0577e3b7-0056-4077-8c24-ec4992823301" xlink:to="loc_sny_ReportableGeographicalZonesMember_4ce1d438-12a2-47cd-b1d2-8db44b1bce0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_8fe0e9c1-b535-4921-9cb1-00caeb6cc400" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ReportableGeographicalZonesMember_4ce1d438-12a2-47cd-b1d2-8db44b1bce0d" xlink:to="loc_srt_EuropeMember_8fe0e9c1-b535-4921-9cb1-00caeb6cc400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_1cab799a-5725-41b1-a8ea-f43a665589d9" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EuropeMember_8fe0e9c1-b535-4921-9cb1-00caeb6cc400" xlink:to="loc_country_FR_1cab799a-5725-41b1-a8ea-f43a665589d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_00241120-0704-4264-a2d3-3d1fce599c39" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ReportableGeographicalZonesMember_4ce1d438-12a2-47cd-b1d2-8db44b1bce0d" xlink:to="loc_srt_NorthAmericaMember_00241120-0704-4264-a2d3-3d1fce599c39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_84b9501c-a68f-40fb-a4a2-92668282f7dc" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NorthAmericaMember_00241120-0704-4264-a2d3-3d1fce599c39" xlink:to="loc_country_US_84b9501c-a68f-40fb-a4a2-92668282f7dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_f25ac134-2630-4053-bca2-977770dfd95f" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ReportableGeographicalZonesMember_4ce1d438-12a2-47cd-b1d2-8db44b1bce0d" xlink:to="loc_sny_OtherCountriesMember_f25ac134-2630-4053-bca2-977770dfd95f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_f5609dae-9cfb-4f83-b06f-da7100efd6f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_f5609dae-9cfb-4f83-b06f-da7100efd6f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_aa533da6-9edc-439b-9e62-f18cb458f3e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_aa533da6-9edc-439b-9e62-f18cb458f3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_7134fedf-a681-496e-98c2-aca4f4cc22e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:to="loc_ifrs-full_Goodwill_7134fedf-a681-496e-98c2-aca4f4cc22e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_29a35da1-fde4-451e-8a7a-216ba34a5bf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_29a35da1-fde4-451e-8a7a-216ba34a5bf5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalaccountantsfeesandservicesDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:href="sny-20231231.xsd#sny_DisclosureOfAuditFeesAndOtherServicesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAuditFeesAndOtherServicesTable_2ac9596b-068e-4c44-ac60-2f5211c1d9d6" xlink:href="sny-20231231.xsd#sny_DisclosureOfAuditFeesAndOtherServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_DisclosureOfAuditFeesAndOtherServicesTable_2ac9596b-068e-4c44-ac60-2f5211c1d9d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsNameAxis_4106d539-3c62-41db-a72d-966fbb851ef2" xlink:href="sny-20231231.xsd#sny_AuditorsNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesTable_2ac9596b-068e-4c44-ac60-2f5211c1d9d6" xlink:to="loc_sny_AuditorsNameAxis_4106d539-3c62-41db-a72d-966fbb851ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsNameMember_4106d539-3c62-41db-a72d-966fbb851ef2_default" xlink:href="sny-20231231.xsd#sny_AuditorsNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sny_AuditorsNameAxis_4106d539-3c62-41db-a72d-966fbb851ef2" xlink:to="loc_sny_AuditorsNameMember_4106d539-3c62-41db-a72d-966fbb851ef2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsNameMember_a8fe76f6-777e-4d84-a95d-6f0a9fc41df8" xlink:href="sny-20231231.xsd#sny_AuditorsNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sny_AuditorsNameAxis_4106d539-3c62-41db-a72d-966fbb851ef2" xlink:to="loc_sny_AuditorsNameMember_a8fe76f6-777e-4d84-a95d-6f0a9fc41df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ErnstAndYoungMember_ba861fa2-a647-4473-a098-20d65b571b32" xlink:href="sny-20231231.xsd#sny_ErnstAndYoungMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AuditorsNameMember_a8fe76f6-777e-4d84-a95d-6f0a9fc41df8" xlink:to="loc_sny_ErnstAndYoungMember_ba861fa2-a647-4473-a098-20d65b571b32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PricewaterhousecoopersMember_5bffff80-212b-4ed3-a20e-c7fb1d5f19f0" xlink:href="sny-20231231.xsd#sny_PricewaterhousecoopersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_AuditorsNameMember_a8fe76f6-777e-4d84-a95d-6f0a9fc41df8" xlink:to="loc_sny_PricewaterhousecoopersMember_5bffff80-212b-4ed3-a20e-c7fb1d5f19f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices_3d730012-b70b-46a8-bb79-daf3d9c8484c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_ifrs-full_AuditorsRemunerationForAuditServices_3d730012-b70b-46a8-bb79-daf3d9c8484c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ServicesOtherThanStatutoryAudit_94e325f5-a47d-41ba-8a38-4cd32b8b67e2" xlink:href="sny-20231231.xsd#sny_ServicesOtherThanStatutoryAudit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_ServicesOtherThanStatutoryAudit_94e325f5-a47d-41ba-8a38-4cd32b8b67e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsRemunerationForAuditRelatedServices_9287d1f6-a8a0-4c50-beba-600a1e75e380" xlink:href="sny-20231231.xsd#sny_AuditorsRemunerationForAuditRelatedServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ServicesOtherThanStatutoryAudit_94e325f5-a47d-41ba-8a38-4cd32b8b67e2" xlink:to="loc_sny_AuditorsRemunerationForAuditRelatedServices_9287d1f6-a8a0-4c50-beba-600a1e75e380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForTaxServices_6f3dc2ec-e9f0-4e39-a5bd-6956bb1bc63b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForTaxServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ServicesOtherThanStatutoryAudit_94e325f5-a47d-41ba-8a38-4cd32b8b67e2" xlink:to="loc_ifrs-full_AuditorsRemunerationForTaxServices_6f3dc2ec-e9f0-4e39-a5bd-6956bb1bc63b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForOtherServices_1ff47991-1896-4c98-9920-a2de818227a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForOtherServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_ServicesOtherThanStatutoryAudit_94e325f5-a47d-41ba-8a38-4cd32b8b67e2" xlink:to="loc_ifrs-full_AuditorsRemunerationForOtherServices_1ff47991-1896-4c98-9920-a2de818227a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemuneration_47741e76-cb02-4aa2-8477-919c121e749c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemuneration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_ifrs-full_AuditorsRemuneration_47741e76-cb02-4aa2-8477-919c121e749c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorRemunerationForStatutoryAudit_008813b5-7adc-4825-8fd9-37561a1dd996" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorRemunerationForStatutoryAudit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_PercentageOfAuditorRemunerationForStatutoryAudit_008813b5-7adc-4825-8fd9-37561a1dd996" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements_7c713e8b-bd19-4b06-bacd-e541359cccf7" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements_7c713e8b-bd19-4b06-bacd-e541359cccf7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorsRemuneration_92d39bbe-8b37-4538-a519-d958b44521f3" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorsRemuneration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_PercentageOfAuditorsRemuneration_92d39bbe-8b37-4538-a519-d958b44521f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries_2792b25f-bc0f-4708-b8a0-c0b3646b47bc" xlink:href="sny-20231231.xsd#sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries_2792b25f-bc0f-4708-b8a0-c0b3646b47bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries_446e4ce1-02c4-4cbb-95ac-92eecafd9d0c" xlink:href="sny-20231231.xsd#sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries_446e4ce1-02c4-4cbb-95ac-92eecafd9d0c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices_aa449094-58ba-4891-b4df-3dc34492cd09" xlink:href="sny-20231231.xsd#sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices_aa449094-58ba-4891-b4df-3dc34492cd09" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_88bad13d-193e-4880-9ef3-6c7f93593ce3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ce2fe308-fdf1-4b32-a631-65886079da0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_88bad13d-193e-4880-9ef3-6c7f93593ce3" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ce2fe308-fdf1-4b32-a631-65886079da0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_58c6c269-a06a-4722-a7d3-188369fe94e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ce2fe308-fdf1-4b32-a631-65886079da0c" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_58c6c269-a06a-4722-a7d3-188369fe94e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_58c6c269-a06a-4722-a7d3-188369fe94e7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_58c6c269-a06a-4722-a7d3-188369fe94e7" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_58c6c269-a06a-4722-a7d3-188369fe94e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_58c6c269-a06a-4722-a7d3-188369fe94e7" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HoechstGmbHMember_1a7ab509-302a-4f64-9e7a-352c32d239c9" xlink:href="sny-20231231.xsd#sny_HoechstGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_HoechstGmbHMember_1a7ab509-302a-4f64-9e7a-352c32d239c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeutschlandGmbHMember_f73ffdf6-d21a-4cda-a908-2d4dd1524acf" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeutschlandGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisDeutschlandGmbHMember_f73ffdf6-d21a-4cda-a908-2d4dd1524acf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_A.NattermannCie.GmbHMember_30a76c3c-0609-4be2-8c0b-c675def98168" xlink:href="sny-20231231.xsd#sny_A.NattermannCie.GmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_A.NattermannCie.GmbHMember_30a76c3c-0609-4be2-8c0b-c675def98168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisGmbHMember_782e24f2-a6ff-491b-b1ba-782346d15a89" xlink:href="sny-20231231.xsd#sny_SanofiAventisGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisGmbHMember_782e24f2-a6ff-491b-b1ba-782346d15a89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBelgiumMember_6ef3c612-29a9-491f-a63f-1336c291b91f" xlink:href="sny-20231231.xsd#sny_SanofiBelgiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiBelgiumMember_6ef3c612-29a9-491f-a63f-1336c291b91f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AblynxMember_591b7ad9-4fb2-4170-857d-d41fb4846a9c" xlink:href="sny-20231231.xsd#sny_AblynxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AblynxMember_591b7ad9-4fb2-4170-857d-d41fb4846a9c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeFlandersBVBAMember_6924f87c-559b-4c01-9d87-00ee7ddbd933" xlink:href="sny-20231231.xsd#sny_GenzymeFlandersBVBAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeFlandersBVBAMember_6924f87c-559b-4c01-9d87-00ee7ddbd933" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiASMember_7644619c-2399-4430-981f-4ec98dcd6873" xlink:href="sny-20231231.xsd#sny_SanofiASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiASMember_7644619c-2399-4430-981f-4ec98dcd6873" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSAMember_e191d5e7-63c5-45a8-949d-958943ed1595" xlink:href="sny-20231231.xsd#sny_SanofiAventisSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisSAMember_e191d5e7-63c5-45a8-949d-958943ed1595" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareSpainSLMember_9a41d12c-b6ec-4c80-a0d9-1f7c234de040" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareSpainSLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareSpainSLMember_9a41d12c-b6ec-4c80-a0d9-1f7c234de040" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiOyMember_ecd23f59-e038-4a0f-8bf8-984f03c54530" xlink:href="sny-20231231.xsd#sny_SanofiOyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiOyMember_ecd23f59-e038-4a0f-8bf8-984f03c54530" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember_ddebf05d-1614-4e63-b9af-0b1d182c3777" xlink:href="sny-20231231.xsd#sny_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiMember_ddebf05d-1614-4e63-b9af-0b1d182c3777" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisFranceMember_3ece6a02-7ef1-4d9c-ba57-1d239fac4cf5" xlink:href="sny-20231231.xsd#sny_SanofiAventisFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisFranceMember_3ece6a02-7ef1-4d9c-ba57-1d239fac4cf5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiWinthropIndustriesMember_3167fd5e-fa35-4784-a044-c874cd6cee40" xlink:href="sny-20231231.xsd#sny_SanofiWinthropIndustriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiWinthropIndustriesMember_3167fd5e-fa35-4784-a044-c874cd6cee40" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisRechercheEtDeveloppementMember_310e1ddc-b4f3-461e-9cea-0249eee8c05a" xlink:href="sny-20231231.xsd#sny_SanofiAventisRechercheEtDeveloppementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisRechercheEtDeveloppementMember_310e1ddc-b4f3-461e-9cea-0249eee8c05a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisGroupeMember_87e7bd90-7272-4aae-ba47-5ba75992185d" xlink:href="sny-20231231.xsd#sny_SanofiAventisGroupeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisGroupeMember_87e7bd90-7272-4aae-ba47-5ba75992185d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiChimieMember_ae01a701-276f-4901-a770-02cc0b175509" xlink:href="sny-20231231.xsd#sny_SanofiChimieMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiChimieMember_ae01a701-276f-4901-a770-02cc0b175509" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisParticipationsSASMember_72b16f2a-d397-4dcd-abe4-0ae3849bf1b8" xlink:href="sny-20231231.xsd#sny_SanofiAventisParticipationsSASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisParticipationsSASMember_72b16f2a-d397-4dcd-abe4-0ae3849bf1b8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurFranceSAMember_a471ace3-1a87-4aa9-addd-43d5900e6ef0" xlink:href="sny-20231231.xsd#sny_SanofiPasteurFranceSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurFranceSAMember_a471ace3-1a87-4aa9-addd-43d5900e6ef0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaSAFranceMember_3728e222-c3a3-4251-9e38-4f39855e1591" xlink:href="sny-20231231.xsd#sny_AventisPharmaSAFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisPharmaSAFranceMember_3728e222-c3a3-4251-9e38-4f39855e1591" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBiotechnologyMember_e056218a-669d-4fe7-b86d-1e950d01a5c9" xlink:href="sny-20231231.xsd#sny_SanofiBiotechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiBiotechnologyMember_e056218a-669d-4fe7-b86d-1e950d01a5c9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMatureIPMember_63516574-dad0-41e4-b63d-f4847a5db1dd" xlink:href="sny-20231231.xsd#sny_SanofiMatureIPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiMatureIPMember_63516574-dad0-41e4-b63d-f4847a5db1dd" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurNVLMember_f5b3a002-8f85-4a07-8c60-d6e921a78c12" xlink:href="sny-20231231.xsd#sny_SanofiPasteurNVLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurNVLMember_f5b3a002-8f85-4a07-8c60-d6e921a78c12" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurEuropeMember_065becab-787f-42f7-a2bf-ae18b6ec5371" xlink:href="sny-20231231.xsd#sny_SanofiPasteurEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurEuropeMember_065becab-787f-42f7-a2bf-ae18b6ec5371" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SECIPESASMember_bb052e90-be13-42bc-9e56-42d0d50117bf" xlink:href="sny-20231231.xsd#sny_SECIPESASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SECIPESASMember_bb052e90-be13-42bc-9e56-42d0d50117bf" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurMerieuxSASMember_6df85f08-d4d9-41e9-8cdc-ce2cbae4b9a9" xlink:href="sny-20231231.xsd#sny_SanofiPasteurMerieuxSASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurMerieuxSASMember_6df85f08-d4d9-41e9-8cdc-ce2cbae4b9a9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareInternationalSASMember_58542b3c-5ed0-426b-8505-d293dd75e4bd" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareInternationalSASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareInternationalSASMember_58542b3c-5ed0-426b-8505-d293dd75e4bd" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareFranceSASMember_bd72f6e9-c623-402d-90e1-447c32a6d172" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareFranceSASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareFranceSASMember_bd72f6e9-c623-402d-90e1-447c32a6d172" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareGroupSASMember_d9d3ce4b-cfeb-45ff-bc88-e974b546e5b7" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareGroupSASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareGroupSASMember_d9d3ce4b-cfeb-45ff-bc88-e974b546e5b7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymePolyclonalsSASMember_4608f89d-c80c-49ec-b6b9-d6dd9453cde4" xlink:href="sny-20231231.xsd#sny_GenzymePolyclonalsSASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymePolyclonalsSASMember_4608f89d-c80c-49ec-b6b9-d6dd9453cde4" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiaventisAEBEMember_d05ed9e5-4d1b-4ace-a562-c328e970ba08" xlink:href="sny-20231231.xsd#sny_SanofiaventisAEBEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiaventisAEBEMember_d05ed9e5-4d1b-4ace-a562-c328e970ba08" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisPrivateCoLtdMember_20f0faf4-c1dd-4d6b-b256-c2af95ad4e8f" xlink:href="sny-20231231.xsd#sny_SanofiAventisPrivateCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisPrivateCoLtdMember_20f0faf4-c1dd-4d6b-b256-c2af95ad4e8f" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChinoinPrivateCoLtdMember_4eb66500-eee7-4a3d-9d23-4e57c5e8557f" xlink:href="sny-20231231.xsd#sny_ChinoinPrivateCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ChinoinPrivateCoLtdMember_4eb66500-eee7-4a3d-9d23-4e57c5e8557f" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareHungaryCommercialKFTMember_a7565f67-fbfb-4342-82f1-a90f9da60979" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareHungaryCommercialKFTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareHungaryCommercialKFTMember_a7565f67-fbfb-4342-82f1-a90f9da60979" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareHungaryKFTMember_a94e2646-1e92-480b-907c-5a6661039fc3" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareHungaryKFTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareHungaryKFTMember_a94e2646-1e92-480b-907c-5a6661039fc3" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CarraigInsuranceDACMember_8a55b8b3-ea14-4cfa-a674-f93edb64e06f" xlink:href="sny-20231231.xsd#sny_CarraigInsuranceDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_CarraigInsuranceDACMember_8a55b8b3-ea14-4cfa-a674-f93edb64e06f" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeIrelandLimitedMember_46a9ef43-e02a-4b5d-a3e8-cc4393dec80c" xlink:href="sny-20231231.xsd#sny_GenzymeIrelandLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeIrelandLimitedMember_46a9ef43-e02a-4b5d-a3e8-cc4393dec80c" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisHoldingsIrelandLtdMember_a6a9959e-8fb7-4287-a564-aa8396735b20" xlink:href="sny-20231231.xsd#sny_SanofiAventisHoldingsIrelandLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisHoldingsIrelandLtdMember_a6a9959e-8fb7-4287-a564-aa8396735b20" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiSRLMember_6a31cb5a-9e13-4644-aac1-5d5e1283d161" xlink:href="sny-20231231.xsd#sny_SanofiSRLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiSRLMember_6a31cb5a-9e13-4644-aac1-5d5e1283d161" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareItalySRLMember_347e8504-9911-4a8e-9316-8566f8b4cf13" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareItalySRLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareItalySRLMember_347e8504-9911-4a8e-9316-8566f8b4cf13" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeGlobalSarlMember_bc7bbd97-3667-4754-b32e-eb1998496d5a" xlink:href="sny-20231231.xsd#sny_GenzymeGlobalSarlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeGlobalSarlMember_bc7bbd97-3667-4754-b32e-eb1998496d5a" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeLuxembourgSarlMember_9c6c1aa9-7b62-4d31-af3f-ad581b9e7346" xlink:href="sny-20231231.xsd#sny_GenzymeLuxembourgSarlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeLuxembourgSarlMember_9c6c1aa9-7b62-4d31-af3f-ad581b9e7346" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisNorgeASMember_b2289aa3-ef7f-42cf-a020-e13cc97c03ed" xlink:href="sny-20231231.xsd#sny_SanofiAventisNorgeASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisNorgeASMember_b2289aa3-ef7f-42cf-a020-e13cc97c03ed" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBVMember_43909773-87b4-460f-b5d3-0b3e69272515" xlink:href="sny-20231231.xsd#sny_SanofiBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiBVMember_43909773-87b4-460f-b5d3-0b3e69272515" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiForeignParticipationsB.V.Member_ea6bc878-325c-4c58-9417-5c910dbf798a" xlink:href="sny-20231231.xsd#sny_SanofiForeignParticipationsB.V.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiForeignParticipationsB.V.Member_ea6bc878-325c-4c58-9417-5c910dbf798a" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiaventisSpZooMember_cc86b906-529a-4940-8cfc-8a6f59b3e157" xlink:href="sny-20231231.xsd#sny_SanofiaventisSpZooMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiaventisSpZooMember_cc86b906-529a-4940-8cfc-8a6f59b3e157" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcarePolandSpZOOMember_d50b587a-8760-424d-977a-53e3519278a6" xlink:href="sny-20231231.xsd#sny_OpellaHealthcarePolandSpZOOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcarePolandSpZOOMember_d50b587a-8760-424d-977a-53e3519278a6" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurSpZooMember_a662b206-2564-4ac9-bba9-e91498819685" xlink:href="sny-20231231.xsd#sny_SanofiPasteurSpZooMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurSpZooMember_a662b206-2564-4ac9-bba9-e91498819685" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiProdutosFarmaceuticosLdaMember_03fe1e0b-a5aa-4075-9405-7b104b341426" xlink:href="sny-20231231.xsd#sny_SanofiProdutosFarmaceuticosLdaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiProdutosFarmaceuticosLdaMember_03fe1e0b-a5aa-4075-9405-7b104b341426" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSROMember_5ac3d254-a68b-4a4a-a148-6666ec0396b4" xlink:href="sny-20231231.xsd#sny_SanofiAventisSROMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisSROMember_5ac3d254-a68b-4a4a-a148-6666ec0396b4" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareCzechSroMember_425521c4-7f36-4a4a-8a47-024a6a3070f6" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareCzechSroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareCzechSroMember_425521c4-7f36-4a4a-8a47-024a6a3070f6" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisRomaniaSRLMember_12899cd2-0c43-4079-98a8-e24230753c68" xlink:href="sny-20231231.xsd#sny_SanofiAventisRomaniaSRLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisRomaniaSRLMember_12899cd2-0c43-4079-98a8-e24230753c68" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareRomaniaSRLMember_6c74bb9b-5425-4b98-99f4-37d09f0cb32d" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareRomaniaSRLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareRomaniaSRLMember_6c74bb9b-5425-4b98-99f4-37d09f0cb32d" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisUkHoldingsLimitedMember_af4a1f3b-dc45-4132-8ccd-2b22563e0e84" xlink:href="sny-20231231.xsd#sny_SanofiAventisUkHoldingsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisUkHoldingsLimitedMember_af4a1f3b-dc45-4132-8ccd-2b22563e0e84" xlink:type="arc" order="53"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaLimitedMember_81cdffb6-87e0-45fd-98d0-0b00945018d7" xlink:href="sny-20231231.xsd#sny_AventisPharmaLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisPharmaLimitedMember_81cdffb6-87e0-45fd-98d0-0b00945018d7" xlink:type="arc" order="54"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiSynthelaboUKLtdMember_1a1be2e6-f964-40d9-86d3-ed69242583ab" xlink:href="sny-20231231.xsd#sny_SanofiSynthelaboUKLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiSynthelaboUKLtdMember_1a1be2e6-f964-40d9-86d3-ed69242583ab" xlink:type="arc" order="55"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaHoldingsLtdMember_90284b01-43f4-48e2-a704-8f846f965594" xlink:href="sny-20231231.xsd#sny_AventisPharmaHoldingsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisPharmaHoldingsLtdMember_90284b01-43f4-48e2-a704-8f846f965594" xlink:type="arc" order="56"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareUKLimitedMember_1a98719d-f4df-4f5d-8717-3534504825de" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareUKLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareUKLimitedMember_1a98719d-f4df-4f5d-8717-3534504825de" xlink:type="arc" order="57"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AOSanofiRussiaMember_5f046975-eccd-4f69-a7cc-e444b0c4cd95" xlink:href="sny-20231231.xsd#sny_AOSanofiRussiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AOSanofiRussiaMember_5f046975-eccd-4f69-a7cc-e444b0c4cd95" xlink:type="arc" order="58"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareLLCMember_fbd85746-644f-4163-bb66-5f8a0b864f92" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareLLCMember_fbd85746-644f-4163-bb66-5f8a0b864f92" xlink:type="arc" order="59"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiABMember_eae0138e-3c2a-4548-a0d1-c401ae289954" xlink:href="sny-20231231.xsd#sny_SanofiABMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiABMember_eae0138e-3c2a-4548-a0d1-c401ae289954" xlink:type="arc" order="60"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSuisseSAMember_b24e4142-e7ad-423d-83bb-b3f80d1d848f" xlink:href="sny-20231231.xsd#sny_SanofiAventisSuisseSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisSuisseSAMember_b24e4142-e7ad-423d-83bb-b3f80d1d848f" xlink:type="arc" order="61"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember_403f913b-afef-4a59-bfbc-a4fe792bff51" xlink:href="sny-20231231.xsd#sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember_403f913b-afef-4a59-bfbc-a4fe792bff51" xlink:type="arc" order="62"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiIlacSanayiVeTicaretASMember_29de1eba-0658-49e8-8c98-bcca04dded94" xlink:href="sny-20231231.xsd#sny_SanofiIlacSanayiVeTicaretASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiIlacSanayiVeTicaretASMember_29de1eba-0658-49e8-8c98-bcca04dded94" xlink:type="arc" order="63"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurAsiTicaretASMember_1d621f45-08b7-4857-a56f-42977a0c0b6f" xlink:href="sny-20231231.xsd#sny_SanofiPasteurAsiTicaretASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurAsiTicaretASMember_1d621f45-08b7-4857-a56f-42977a0c0b6f" xlink:type="arc" order="64"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember_e2ed0f2d-88f8-49fe-ab63-e0810527126f" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareTuketiciSalAnonimSirketiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember_e2ed0f2d-88f8-49fe-ab63-e0810527126f" xlink:type="arc" order="65"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiSaglikUrunleriLimitedSirketiMember_7fef6842-b9b0-4f64-b95f-a65bdb24d6ae" xlink:href="sny-20231231.xsd#sny_SanofiSaglikUrunleriLimitedSirketiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiSaglikUrunleriLimitedSirketiMember_7fef6842-b9b0-4f64-b95f-a65bdb24d6ae" xlink:type="arc" order="66"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeTherapeuticProductsLimitedPartnershipMember_fddbfd6a-0889-4923-901d-177d87356c12" xlink:href="sny-20231231.xsd#sny_GenzymeTherapeuticProductsLimitedPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeTherapeuticProductsLimitedPartnershipMember_fddbfd6a-0889-4923-901d-177d87356c12" xlink:type="arc" order="67"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisIncMember_1f226b18-0134-45ca-bd33-bed3f709c508" xlink:href="sny-20231231.xsd#sny_AventisIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisIncMember_1f226b18-0134-45ca-bd33-bed3f709c508" xlink:type="arc" order="68"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiUSServicesIncMember_3fc2c1bb-07cc-4acb-8857-0b61010e6f5e" xlink:href="sny-20231231.xsd#sny_SanofiUSServicesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiUSServicesIncMember_3fc2c1bb-07cc-4acb-8857-0b61010e6f5e" xlink:type="arc" order="69"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisUSLLCMember_34a2763c-a719-4b71-9f7e-1b89a632bd9f" xlink:href="sny-20231231.xsd#sny_SanofiAventisUSLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisUSLLCMember_34a2763c-a719-4b71-9f7e-1b89a632bd9f" xlink:type="arc" order="70"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChattemIncMember_2aebdce1-a245-4450-9ac6-c394d41d4daf" xlink:href="sny-20231231.xsd#sny_ChattemIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ChattemIncMember_2aebdce1-a245-4450-9ac6-c394d41d4daf" xlink:type="arc" order="71"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisubLLCMember_9ba625cf-c0ce-4101-b8c6-cacf162dca0c" xlink:href="sny-20231231.xsd#sny_AventisubLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisubLLCMember_9ba625cf-c0ce-4101-b8c6-cacf162dca0c" xlink:type="arc" order="72"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeCorporationMember_1b99e702-36a0-499b-b361-d195a81993fb" xlink:href="sny-20231231.xsd#sny_GenzymeCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeCorporationMember_1b99e702-36a0-499b-b361-d195a81993fb" xlink:type="arc" order="73"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurIncMember_968c4cd3-2b94-4133-add3-daba4a2b662f" xlink:href="sny-20231231.xsd#sny_SanofiPasteurIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurIncMember_968c4cd3-2b94-4133-add3-daba4a2b662f" xlink:type="arc" order="74"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaxServeIncMember_1b73a921-b3d7-4963-9855-419473853049" xlink:href="sny-20231231.xsd#sny_VaxServeIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_VaxServeIncMember_1b73a921-b3d7-4963-9855-419473853049" xlink:type="arc" order="75"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativIncMember_0940bdca-1bdf-4e2d-af6b-12c7fbf40c27" xlink:href="sny-20231231.xsd#sny_BioverativIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_BioverativIncMember_0940bdca-1bdf-4e2d-af6b-12c7fbf40c27" xlink:type="arc" order="76"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativUSLLCMember_3e04c317-494b-4824-8e61-a731645c0672" xlink:href="sny-20231231.xsd#sny_BioverativUSLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_BioverativUSLLCMember_3e04c317-494b-4824-8e61-a731645c0672" xlink:type="arc" order="77"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativTherapeuticsIncMember_e61f8954-576f-416f-931c-13fc156257ed" xlink:href="sny-20231231.xsd#sny_BioverativTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_BioverativTherapeuticsIncMember_e61f8954-576f-416f-931c-13fc156257ed" xlink:type="arc" order="78"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipiaBiopharmaIncMember_c0205645-4491-42b7-8fbf-ace84f071e20" xlink:href="sny-20231231.xsd#sny_PrincipiaBiopharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_PrincipiaBiopharmaIncMember_c0205645-4491-42b7-8fbf-ace84f071e20" xlink:type="arc" order="79"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiResearchInvestLLCMember_04f094f1-f000-4290-9e39-80329fa476c4" xlink:href="sny-20231231.xsd#sny_SanofiResearchInvestLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiResearchInvestLLCMember_04f094f1-f000-4290-9e39-80329fa476c4" xlink:type="arc" order="80"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBioverativHoldingsLLCMember_6b125643-fcf2-4385-991f-af098def9462" xlink:href="sny-20231231.xsd#sny_SanofiBioverativHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiBioverativHoldingsLLCMember_6b125643-fcf2-4385-991f-af098def9462" xlink:type="arc" order="81"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RPRUSLtdMember_f2fe1d98-e99a-42d8-87f8-bf0d2b939620" xlink:href="sny-20231231.xsd#sny_RPRUSLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_RPRUSLtdMember_f2fe1d98-e99a-42d8-87f8-bf0d2b939620" xlink:type="arc" order="82"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KadmonCorporationLLCMember_487d3fd4-ec93-4cbe-a104-7b4899330a47" xlink:href="sny-20231231.xsd#sny_KadmonCorporationLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_KadmonCorporationLLCMember_487d3fd4-ec93-4cbe-a104-7b4899330a47" xlink:type="arc" order="83"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixMember_751bf9a3-e2fd-4401-8f06-ef2832db4417" xlink:href="sny-20231231.xsd#sny_AmunixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AmunixMember_751bf9a3-e2fd-4401-8f06-ef2832db4417" xlink:type="arc" order="84"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SynthorxIncMember_31dd0a1e-e0f3-4fbd-a6b3-e688c753b62c" xlink:href="sny-20231231.xsd#sny_SynthorxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SynthorxIncMember_31dd0a1e-e0f3-4fbd-a6b3-e688c753b62c" xlink:type="arc" order="85"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioMember_38c76a5f-c82f-4f3f-b11b-50eb8721acc7" xlink:href="sny-20231231.xsd#sny_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ProventionBioMember_38c76a5f-c82f-4f3f-b11b-50eb8721acc7" xlink:type="arc" order="86"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_610f4a71-a61b-4021-946c-c60f2f9aaedc" xlink:href="sny-20231231.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_610f4a71-a61b-4021-946c-c60f2f9aaedc" xlink:type="arc" order="87"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIMember_535e0f0c-cbb3-45c2-852e-a20f14d87937" xlink:href="sny-20231231.xsd#sny_QRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_QRIMember_535e0f0c-cbb3-45c2-852e-a20f14d87937" xlink:type="arc" order="88"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TargeGenIncMember_df26de3c-4e93-44a6-8c10-10104760f661" xlink:href="sny-20231231.xsd#sny_TargeGenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_TargeGenIncMember_df26de3c-4e93-44a6-8c10-10104760f661" xlink:type="arc" order="89"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChattemGBHoldingMember_55a95701-a8b1-4acd-b1ba-eb43167485aa" xlink:href="sny-20231231.xsd#sny_ChattemGBHoldingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ChattemGBHoldingMember_55a95701-a8b1-4acd-b1ba-eb43167485aa" xlink:type="arc" order="90"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioIncMember_35a44280-99de-4d01-8075-ac2739a05501" xlink:href="sny-20231231.xsd#sny_TranslateBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_TranslateBioIncMember_35a44280-99de-4d01-8075-ac2739a05501" xlink:type="arc" order="91"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSouthAfricaPtyLtdMember_fc322da9-cf56-4741-8241-4f4553e28c71" xlink:href="sny-20231231.xsd#sny_SanofiAventisSouthAfricaPtyLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisSouthAfricaPtyLtdMember_fc322da9-cf56-4741-8241-4f4553e28c71" xlink:type="arc" order="92"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisAlgerieMember_c8f1427f-5b44-4e82-a765-801d2a34e12c" xlink:href="sny-20231231.xsd#sny_SanofiAventisAlgerieMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisAlgerieMember_c8f1427f-5b44-4e82-a765-801d2a34e12c" xlink:type="arc" order="93"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiArabiaTradingCompanyLimitedMember_5163f9d9-8f27-442d-9563-e007ea771b24" xlink:href="sny-20231231.xsd#sny_SanofiArabiaTradingCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiArabiaTradingCompanyLimitedMember_5163f9d9-8f27-442d-9563-e007ea771b24" xlink:type="arc" order="94"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisArgentinaSAMember_78135f9b-4386-4674-9ce4-54af1faaba26" xlink:href="sny-20231231.xsd#sny_SanofiAventisArgentinaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisArgentinaSAMember_78135f9b-4386-4674-9ce4-54af1faaba26" xlink:type="arc" order="95"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisHealthcarePtyLtdMember_1714bd95-0790-43ea-9de3-43ad658fee2d" xlink:href="sny-20231231.xsd#sny_SanofiAventisHealthcarePtyLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisHealthcarePtyLtdMember_1714bd95-0790-43ea-9de3-43ad658fee2d" xlink:type="arc" order="96"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisAustraliaPtyLtdMember_44d0d8a1-31fd-49dc-98e4-3539a9f7de3e" xlink:href="sny-20231231.xsd#sny_SanofiAventisAustraliaPtyLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisAustraliaPtyLtdMember_44d0d8a1-31fd-49dc-98e4-3539a9f7de3e" xlink:type="arc" order="97"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMedleyFarmaceuticaLtdaMember_6329fae8-1b3f-4232-9076-cee761903c2a" xlink:href="sny-20231231.xsd#sny_SanofiMedleyFarmaceuticaLtdaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiMedleyFarmaceuticaLtdaMember_6329fae8-1b3f-4232-9076-cee761903c2a" xlink:type="arc" order="98"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareBrazilLtdaMember_22e69630-0a4c-451e-8b81-2b31d9604750" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareBrazilLtdaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareBrazilLtdaMember_22e69630-0a4c-451e-8b81-2b31d9604750" xlink:type="arc" order="99"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisCanadaIncMember_42199202-1b52-43b1-b889-1395512df30c" xlink:href="sny-20231231.xsd#sny_SanofiAventisCanadaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisCanadaIncMember_42199202-1b52-43b1-b889-1395512df30c" xlink:type="arc" order="100"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurLimitedMember_a5a31789-53ea-44f6-a4f8-25996dcf8b7d" xlink:href="sny-20231231.xsd#sny_SanofiPasteurLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurLimitedMember_a5a31789-53ea-44f6-a4f8-25996dcf8b7d" xlink:type="arc" order="101"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MerieuxCanadaHoldingsULCCanadaMember_e3a4cd49-84d4-4813-8f32-76e59e61b21d" xlink:href="sny-20231231.xsd#sny_MerieuxCanadaHoldingsULCCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_MerieuxCanadaHoldingsULCCanadaMember_e3a4cd49-84d4-4813-8f32-76e59e61b21d" xlink:type="arc" order="102"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiHangzhouPharmaceuticalsCoLtdMember_cea21204-a1d7-497d-a025-1099c09a8f49" xlink:href="sny-20231231.xsd#sny_SanofiHangzhouPharmaceuticalsCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiHangzhouPharmaceuticalsCoLtdMember_cea21204-a1d7-497d-a025-1099c09a8f49" xlink:type="arc" order="103"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiChinaInvestmentCoLtdMember_3c70b2c2-e4dd-49eb-bbd5-6faa111f7951" xlink:href="sny-20231231.xsd#sny_SanofiChinaInvestmentCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiChinaInvestmentCoLtdMember_3c70b2c2-e4dd-49eb-bbd5-6faa111f7951" xlink:type="arc" order="104"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBeijingPharmaceuticalsCoLtdMember_b194e847-f2a1-4d3d-884a-bfc36c04fc04" xlink:href="sny-20231231.xsd#sny_SanofiBeijingPharmaceuticalsCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiBeijingPharmaceuticalsCoLtdMember_b194e847-f2a1-4d3d-884a-bfc36c04fc04" xlink:type="arc" order="105"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurBiologiesCo.LtdMember_30e61a07-6436-4459-a0f8-ee0002e8c91d" xlink:href="sny-20231231.xsd#sny_SanofiPasteurBiologiesCo.LtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurBiologiesCo.LtdMember_30e61a07-6436-4459-a0f8-ee0002e8c91d" xlink:type="arc" order="106"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember_3c25ecf3-7aac-43b5-8f5d-25e86b82d071" xlink:href="sny-20231231.xsd#sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember_3c25ecf3-7aac-43b5-8f5d-25e86b82d071" xlink:type="arc" order="107"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShanghaiRonghengPharmaceuticalCoLtdMember_a14fe677-19ae-4979-8f9e-2c1167dc0aca" xlink:href="sny-20231231.xsd#sny_ShanghaiRonghengPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ShanghaiRonghengPharmaceuticalCoLtdMember_a14fe677-19ae-4979-8f9e-2c1167dc0aca" xlink:type="arc" order="108"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeColombiaSAMember_a82dcbe7-173e-4e2d-a14c-12e5ff37683a" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeColombiaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisDeColombiaSAMember_a82dcbe7-173e-4e2d-a14c-12e5ff37683a" xlink:type="arc" order="109"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisKoreaCoLtdMember_fa58aa7b-bd13-44cf-8a11-fd7d2990813f" xlink:href="sny-20231231.xsd#sny_SanofiAventisKoreaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisKoreaCoLtdMember_fa58aa7b-bd13-44cf-8a11-fd7d2990813f" xlink:type="arc" order="110"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurLtdMember_19c03800-4e12-4479-a7b9-8311665e4c2e" xlink:href="sny-20231231.xsd#sny_SanofiPasteurLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurLtdMember_19c03800-4e12-4479-a7b9-8311665e4c2e" xlink:type="arc" order="111"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareKoreaIncMember_7982b156-6c6a-4aa7-842a-394d81c91ce4" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareKoreaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareKoreaIncMember_7982b156-6c6a-4aa7-842a-394d81c91ce4" xlink:type="arc" order="112"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisGulfFZEMember_4daa9270-5a59-4c1d-a799-1e9d3bfa3939" xlink:href="sny-20231231.xsd#sny_SanofiAventisGulfFZEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisGulfFZEMember_4daa9270-5a59-4c1d-a799-1e9d3bfa3939" xlink:type="arc" order="113"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEgyptSAEMember_c5457b01-b27e-43f5-8369-1ccc21ddc6d2" xlink:href="sny-20231231.xsd#sny_SanofiEgyptSAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiEgyptSAEMember_c5457b01-b27e-43f5-8369-1ccc21ddc6d2" xlink:type="arc" order="114"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiHongKongLimitedMember_2dbbcb4f-db9f-4540-a544-00244735e9cc" xlink:href="sny-20231231.xsd#sny_SanofiHongKongLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiHongKongLimitedMember_2dbbcb4f-db9f-4540-a544-00244735e9cc" xlink:type="arc" order="115"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiIndiaLimitedMember_5ca6513a-7b35-47bc-bb06-02c79b627658" xlink:href="sny-20231231.xsd#sny_SanofiIndiaLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiIndiaLimitedMember_5ca6513a-7b35-47bc-bb06-02c79b627658" xlink:type="arc" order="116"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiHealthcareIndiaPrivateLimitedMember_41749335-0b6d-4d51-ae5f-0a7bf02787f4" xlink:href="sny-20231231.xsd#sny_SanofiHealthcareIndiaPrivateLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiHealthcareIndiaPrivateLimitedMember_41749335-0b6d-4d51-ae5f-0a7bf02787f4" xlink:type="arc" order="117"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisIsraelLtdMember_299bcf75-b5cc-4440-9105-aaaa4357f24c" xlink:href="sny-20231231.xsd#sny_SanofiAventisIsraelLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisIsraelLtdMember_299bcf75-b5cc-4440-9105-aaaa4357f24c" xlink:type="arc" order="118"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiKKMember_b92243f9-38ca-4b92-8554-f635a5a74d91" xlink:href="sny-20231231.xsd#sny_SanofiKKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiKKMember_b92243f9-38ca-4b92-8554-f635a5a74d91" xlink:type="arc" order="119"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SspCoLtdMember_e72114fa-b9da-4d80-baeb-2aac77e119b0" xlink:href="sny-20231231.xsd#sny_SspCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SspCoLtdMember_e72114fa-b9da-4d80-baeb-2aac77e119b0" xlink:type="arc" order="120"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisMalaysiaSDNBHDMember_dacaa564-34d6-4947-8b1a-304398984dcd" xlink:href="sny-20231231.xsd#sny_SanofiAventisMalaysiaSDNBHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisMalaysiaSDNBHDMember_dacaa564-34d6-4947-8b1a-304398984dcd" xlink:type="arc" order="121"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisMarocMember_6bce2515-5d90-4103-aa7a-623dd69ca2ed" xlink:href="sny-20231231.xsd#sny_SanofiAventisMarocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisMarocMember_6bce2515-5d90-4103-aa7a-623dd69ca2ed" xlink:type="arc" order="122"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeMexicoSADeCVMember_7b0639a2-1eff-45f1-9580-0dbb42ffe360" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeMexicoSADeCVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisDeMexicoSADeCVMember_7b0639a2-1eff-45f1-9580-0dbb42ffe360" xlink:type="arc" order="123"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurS.A.deC.V.Member_27c58445-5600-4480-a68f-3b6a62bf6c63" xlink:href="sny-20231231.xsd#sny_SanofiPasteurS.A.deC.V.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurS.A.deC.V.Member_27c58445-5600-4480-a68f-3b6a62bf6c63" xlink:type="arc" order="124"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AztecaVacunasSADeCVMember_defe1fc0-789f-43dd-9c94-c4065c345bd7" xlink:href="sny-20231231.xsd#sny_AztecaVacunasSADeCVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AztecaVacunasSADeCVMember_defe1fc0-789f-43dd-9c94-c4065c345bd7" xlink:type="arc" order="125"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDePanamaSAMember_736fa05e-fd91-4d3f-a302-476d7371e219" xlink:href="sny-20231231.xsd#sny_SanofiAventisDePanamaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisDePanamaSAMember_736fa05e-fd91-4d3f-a302-476d7371e219" xlink:type="arc" order="126"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcarePanamaSAMember_24a10b33-bddb-467f-ad2f-f72ccc93fd21" xlink:href="sny-20231231.xsd#sny_OpellaHealthcarePanamaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcarePanamaSAMember_24a10b33-bddb-467f-ad2f-f72ccc93fd21" xlink:type="arc" order="127"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisPuertoRicoIncMember_464cf959-38d5-4ea7-b6e4-aaa1b868b83e" xlink:href="sny-20231231.xsd#sny_SanofiAventisPuertoRicoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisPuertoRicoIncMember_464cf959-38d5-4ea7-b6e4-aaa1b868b83e" xlink:type="arc" order="128"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisPhilippinesIncMember_d6c02812-e78c-487e-b402-385906865b81" xlink:href="sny-20231231.xsd#sny_SanofiAventisPhilippinesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisPhilippinesIncMember_d6c02812-e78c-487e-b402-385906865b81" xlink:type="arc" order="129"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcarePhilippinesIncMember_8c23df6c-3c2e-4f83-bbb2-d5e6b64e0a62" xlink:href="sny-20231231.xsd#sny_OpellaHealthcarePhilippinesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcarePhilippinesIncMember_8c23df6c-3c2e-4f83-bbb2-d5e6b64e0a62" xlink:type="arc" order="130"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSingaporePteLtdMember_5de0e20a-f697-4a48-b990-c002a370040a" xlink:href="sny-20231231.xsd#sny_SanofiAventisSingaporePteLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisSingaporePteLtdMember_5de0e20a-f697-4a48-b990-c002a370040a" xlink:type="arc" order="131"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaManufacturingPTELTDMember_fe8ec031-08c8-48ac-b1cc-d05d9f506924" xlink:href="sny-20231231.xsd#sny_AventisPharmaManufacturingPTELTDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisPharmaManufacturingPTELTDMember_fe8ec031-08c8-48ac-b1cc-d05d9f506924" xlink:type="arc" order="132"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiManufacturingPteLtdMember_23b1a676-613e-4205-869f-8c87809c632f" xlink:href="sny-20231231.xsd#sny_SanofiManufacturingPteLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiManufacturingPteLtdMember_23b1a676-613e-4205-869f-8c87809c632f" xlink:type="arc" order="133"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiTaiwanCoLtdMember_17da57a8-2183-4f26-a52b-8b02aa6644fd" xlink:href="sny-20231231.xsd#sny_SanofiTaiwanCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiTaiwanCoLtdMember_17da57a8-2183-4f26-a52b-8b02aa6644fd" xlink:type="arc" order="134"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisThailandLtdMember_e2513c77-2c45-41f8-81d9-0046e46c3e88" xlink:href="sny-20231231.xsd#sny_SanofiAventisThailandLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisThailandLtdMember_e2513c77-2c45-41f8-81d9-0046e46c3e88" xlink:type="arc" order="135"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurThailandLtdMember_15895ea5-8964-46a7-8208-dd4dca2cf39d" xlink:href="sny-20231231.xsd#sny_SanofiPasteurThailandLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurThailandLtdMember_15895ea5-8964-46a7-8208-dd4dca2cf39d" xlink:type="arc" order="136"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeVenezuelaSAMember_1c1cd16f-97ce-4de3-8b36-dde110659068" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeVenezuelaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisDeVenezuelaSAMember_1c1cd16f-97ce-4de3-8b36-dde110659068" xlink:type="arc" order="137"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisVietnamCompanyLimitedMember_cfb16c34-37d8-4744-ac84-102e94790d15" xlink:href="sny-20231231.xsd#sny_SanofiAventisVietnamCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisVietnamCompanyLimitedMember_cfb16c34-37d8-4744-ac84-102e94790d15" xlink:type="arc" order="138"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiVietnamShareholdingCompanyLimitedMember_1ce88a9d-0ee2-4306-8efb-7cb059f83a24" xlink:href="sny-20231231.xsd#sny_SanofiVietnamShareholdingCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiVietnamShareholdingCompanyLimitedMember_1ce88a9d-0ee2-4306-8efb-7cb059f83a24" xlink:type="arc" order="139"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_a3565864-ac05-457f-954f-0da2643f82fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ce2fe308-fdf1-4b32-a631-65886079da0c" xlink:to="loc_ifrs-full_GeographicalAreasAxis_a3565864-ac05-457f-954f-0da2643f82fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_a3565864-ac05-457f-954f-0da2643f82fd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_a3565864-ac05-457f-954f-0da2643f82fd" xlink:to="loc_ifrs-full_GeographicalAreasMember_a3565864-ac05-457f-954f-0da2643f82fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_29671df4-2c42-462d-b9af-5d7eaba4b620" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_a3565864-ac05-457f-954f-0da2643f82fd" xlink:to="loc_ifrs-full_GeographicalAreasMember_29671df4-2c42-462d-b9af-5d7eaba4b620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5c41e616-92f1-4262-8b47-3260c6af0c1c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_29671df4-2c42-462d-b9af-5d7eaba4b620" xlink:to="loc_srt_EuropeMember_5c41e616-92f1-4262-8b47-3260c6af0c1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_59613e2a-2d79-492c-a1ce-67d40236fb3e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_29671df4-2c42-462d-b9af-5d7eaba4b620" xlink:to="loc_country_US_59613e2a-2d79-492c-a1ce-67d40236fb3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_ffb8c486-4fcf-4421-aeeb-c56ad91eb76c" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasMember_29671df4-2c42-462d-b9af-5d7eaba4b620" xlink:to="loc_sny_OtherCountriesMember_ffb8c486-4fcf-4421-aeeb-c56ad91eb76c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_843e28e1-d03d-4db8-bc6c-aa99501a7be4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_88bad13d-193e-4880-9ef3-6c7f93593ce3" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_843e28e1-d03d-4db8-bc6c-aa99501a7be4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointOperationsLineItems_691ded62-0509-44bc-83e9-213a4b847e76" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointOperationsTable_64c5809c-407d-4391-a59f-b3bc1be4a2a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfJointOperationsLineItems_691ded62-0509-44bc-83e9-213a4b847e76" xlink:to="loc_ifrs-full_DisclosureOfJointOperationsTable_64c5809c-407d-4391-a59f-b3bc1be4a2a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointOperationsAxis_1a18e36c-e356-417a-b42d-74eb7a1405f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfJointOperationsTable_64c5809c-407d-4391-a59f-b3bc1be4a2a8" xlink:to="loc_ifrs-full_JointOperationsAxis_1a18e36c-e356-417a-b42d-74eb7a1405f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointOperationsMember_1a18e36c-e356-417a-b42d-74eb7a1405f6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointOperationsAxis_1a18e36c-e356-417a-b42d-74eb7a1405f6" xlink:to="loc_ifrs-full_EntitysTotalForJointOperationsMember_1a18e36c-e356-417a-b42d-74eb7a1405f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointOperationsAxis_1a18e36c-e356-417a-b42d-74eb7a1405f6" xlink:to="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HaleonUSLPMember_069ba7af-88a5-4c6e-b5be-a5881652d8da" xlink:href="sny-20231231.xsd#sny_HaleonUSLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_HaleonUSLPMember_069ba7af-88a5-4c6e-b5be-a5881652d8da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember_6f6cdbbd-fb13-4ea1-b576-10043f53b767" xlink:href="sny-20231231.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_InfraservGmbhAndCoHochstKGMember_6f6cdbbd-fb13-4ea1-b576-10043f53b767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MapharMember_c5e72f8d-671e-4e3b-8909-ce293bdbdc2f" xlink:href="sny-20231231.xsd#sny_MapharMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_MapharMember_c5e72f8d-671e-4e3b-8909-ce293bdbdc2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember_6279b298-5701-4eb7-b7af-8efeb9ce097b" xlink:href="sny-20231231.xsd#sny_MCMVaccineBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_MCMVaccineBVMember_6279b298-5701-4eb7-b7af-8efeb9ce097b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_c237124b-dd90-4b1c-9f9c-e7ce22733607" xlink:href="sny-20231231.xsd#sny_MSPVaccineCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_MSPVaccineCompanyMember_c237124b-dd90-4b1c-9f9c-e7ce22733607" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_c2f47064-c59b-44ad-aee3-b17da039beb9" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_EuroapiMember_c2f47064-c59b-44ad-aee3-b17da039beb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointOperation_a7d43cf8-442e-4b94-9d0c-e8454f516a40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointOperationsLineItems_691ded62-0509-44bc-83e9-213a4b847e76" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointOperation_a7d43cf8-442e-4b94-9d0c-e8454f516a40" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/EventssubsequenttoDecember312023Details" xlink:type="simple" xlink:href="sny-20231231.xsd#EventssubsequenttoDecember312023Details"/>
  <link:definitionLink xlink:role="http://www.sanofi.com/role/EventssubsequenttoDecember312023Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_4313d9d2-2271-4a3e-9c4c-5eae7d0c7020" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_4313d9d2-2271-4a3e-9c4c-5eae7d0c7020" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4313d9d2-2271-4a3e-9c4c-5eae7d0c7020_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_4313d9d2-2271-4a3e-9c4c-5eae7d0c7020" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4313d9d2-2271-4a3e-9c4c-5eae7d0c7020_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_41cda943-f580-414b-8c24-975ae7b6f472" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_4313d9d2-2271-4a3e-9c4c-5eae7d0c7020" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_41cda943-f580-414b-8c24-975ae7b6f472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InhibrxIncMember_7f9b2228-0f3a-481f-9b32-f10ec5d5598c" xlink:href="sny-20231231.xsd#sny_InhibrxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_41cda943-f580-414b-8c24-975ae7b6f472" xlink:to="loc_sny_InhibrxIncMember_7f9b2228-0f3a-481f-9b32-f10ec5d5598c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a35b6634-dcf8-4613-ae07-03de66f18d69" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a35b6634-dcf8-4613-ae07-03de66f18d69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_a35b6634-dcf8-4613-ae07-03de66f18d69_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a35b6634-dcf8-4613-ae07-03de66f18d69" xlink:to="loc_ifrs-full_NonadjustingEventsMember_a35b6634-dcf8-4613-ae07-03de66f18d69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_0328ddfe-517b-4b2d-8ba8-9faad425fe8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a35b6634-dcf8-4613-ae07-03de66f18d69" xlink:to="loc_ifrs-full_NonadjustingEventsMember_0328ddfe-517b-4b2d-8ba8-9faad425fe8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorBusinessCombinationMember_021c9dae-f1b0-4335-a7c5-ed69a0a2e7e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorBusinessCombinationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_0328ddfe-517b-4b2d-8ba8-9faad425fe8a" xlink:to="loc_ifrs-full_MajorBusinessCombinationMember_021c9dae-f1b0-4335-a7c5-ed69a0a2e7e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_ad32a8bd-f2d1-4eda-b97f-ab023b45b28b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:to="loc_ifrs-full_RangeAxis_ad32a8bd-f2d1-4eda-b97f-ab023b45b28b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_ad32a8bd-f2d1-4eda-b97f-ab023b45b28b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_ad32a8bd-f2d1-4eda-b97f-ab023b45b28b" xlink:to="loc_ifrs-full_RangesMember_ad32a8bd-f2d1-4eda-b97f-ab023b45b28b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_06abd1f7-5726-4a39-afb1-0a388b0de3cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_ad32a8bd-f2d1-4eda-b97f-ab023b45b28b" xlink:to="loc_ifrs-full_RangesMember_06abd1f7-5726-4a39-afb1-0a388b0de3cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_0e5ea3b3-8937-4a15-a4d0-5e82dea704ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_06abd1f7-5726-4a39-afb1-0a388b0de3cd" xlink:to="loc_ifrs-full_TopOfRangeMember_0e5ea3b3-8937-4a15-a4d0-5e82dea704ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63ad0d8d-cb08-4b0f-833d-65edb1181980" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63ad0d8d-cb08-4b0f-833d-65edb1181980" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_63ad0d8d-cb08-4b0f-833d-65edb1181980_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63ad0d8d-cb08-4b0f-833d-65edb1181980" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_63ad0d8d-cb08-4b0f-833d-65edb1181980_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b6a1b29b-2d41-43b9-a8fb-314b38f3b12e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63ad0d8d-cb08-4b0f-833d-65edb1181980" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b6a1b29b-2d41-43b9-a8fb-314b38f3b12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonINBRX101BusinessSpinCo.Member_16a1eb93-7d0f-4604-9b46-f894aa6771be" xlink:href="sny-20231231.xsd#sny_NonINBRX101BusinessSpinCo.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b6a1b29b-2d41-43b9-a8fb-314b38f3b12e" xlink:to="loc_sny_NonINBRX101BusinessSpinCo.Member_16a1eb93-7d0f-4604-9b46-f894aa6771be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_c39ee905-4758-4137-8ae3-f26fb6e93253" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_c39ee905-4758-4137-8ae3-f26fb6e93253" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c39ee905-4758-4137-8ae3-f26fb6e93253_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_c39ee905-4758-4137-8ae3-f26fb6e93253" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c39ee905-4758-4137-8ae3-f26fb6e93253_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_6939739d-0d83-40cd-b9bb-26f24af23b78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_c39ee905-4758-4137-8ae3-f26fb6e93253" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_6939739d-0d83-40cd-b9bb-26f24af23b78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_INBRX101BusinessRemainCo.Member_981a9155-e762-44e2-b677-4ed7b67b9d61" xlink:href="sny-20231231.xsd#sny_INBRX101BusinessRemainCo.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_6939739d-0d83-40cd-b9bb-26f24af23b78" xlink:to="loc_sny_INBRX101BusinessRemainCo.Member_981a9155-e762-44e2-b677-4ed7b67b9d61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare_3f2ffa8d-6c3f-42b3-aef8-80d5c68e6400" xlink:href="sny-20231231.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_sny_BusinessCombinationPurchasePricePerShare_3f2ffa8d-6c3f-42b3-aef8-80d5c68e6400" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_b1391cdd-fa94-411a-8910-c7a32ee3150e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_ifrs-full_CashTransferred_b1391cdd-fa94-411a-8910-c7a32ee3150e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare_96a646a9-c9c9-460b-a0b3-658cf15107df" xlink:href="sny-20231231.xsd#sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare_96a646a9-c9c9-460b-a0b3-658cf15107df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight_37416546-d43d-4437-80bd-159d67fcfadd" xlink:href="sny-20231231.xsd#sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight_37416546-d43d-4437-80bd-159d67fcfadd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_72ea4672-f1a8-4a99-8100-6a9fa80327d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_72ea4672-f1a8-4a99-8100-6a9fa80327d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred_22218186-5819-49d3-95d6-d14647d3e16e" xlink:href="sny-20231231.xsd#sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred_22218186-5819-49d3-95d6-d14647d3e16e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationCapitalContribution_2e479cc2-17cb-4ba5-824d-a6ecf1918033" xlink:href="sny-20231231.xsd#sny_BusinessCombinationCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_sny_BusinessCombinationCapitalContribution_2e479cc2-17cb-4ba5-824d-a6ecf1918033" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_52d68095-50c1-4663-99eb-325b4a6b1224" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_52d68095-50c1-4663-99eb-325b4a6b1224" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_a44f4a85-77a6-4856-8841-69b61ce8f8cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_a44f4a85-77a6-4856-8841-69b61ce8f8cc" xlink:type="arc" order="8"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>sny-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:d2fc6364-8fcd-4586-a9d3-e16cd96a566e,g:f65f6c85-de12-4c7c-b6b2-ea3943f1a47f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_1778e699-46f8-4d9e-a39b-341cfc65b0d4_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment for stock options with dilutive effect (in shares)</link:label>
    <link:label id="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of share options on weighted average number of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfEmployees_66aa70d4-4a37-4388-b215-c2bff88453b8_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_ifrs-full_NumberOfEmployees_label_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfEmployees" xlink:to="lab_ifrs-full_NumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_8022dca1-a746-4ff9-8c19-c73880538122_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross value</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_509c1ef1-de56-4a9a-8b03-d1c83ed4ab3a_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes arising from issuance of restricted shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Issuance Of Restricted Shares, Equity</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through issuance of restricted shares, equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:to="lab_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIntangibleAssets_f92ffe17-6743-41ae-b7ec-2b6c044b0ef6_periodStartLabel_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, beginning balance</link:label>
    <link:label id="lab_ifrs-full_OtherIntangibleAssets_876f2e8f-29e3-4597-99b4-4f5ce5d36e78_periodEndLabel_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, ending balance</link:label>
    <link:label id="lab_ifrs-full_OtherIntangibleAssets_label_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIntangibleAssets" xlink:to="lab_ifrs-full_OtherIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IOLicenseAndCollaborationAgreementMember_aa1ba2eb-c4bf-45ee-b16e-b037ca75df17_terseLabel_en-US" xlink:label="lab_sny_IOLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IO License and Collaboration agreement</link:label>
    <link:label id="lab_sny_IOLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_IOLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IO License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_IOLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_IOLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IO License And Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IOLicenseAndCollaborationAgreementMember" xlink:href="sny-20231231.xsd#sny_IOLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IOLicenseAndCollaborationAgreementMember" xlink:to="lab_sny_IOLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AventisPharmaManufacturingPTELTDMember_4f5218c4-0dbe-4988-855f-0e182b07b884_terseLabel_en-US" xlink:label="lab_sny_AventisPharmaManufacturingPTELTDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma (Manufacturing) Pte. Ltd</link:label>
    <link:label id="lab_sny_AventisPharmaManufacturingPTELTDMember_label_en-US" xlink:label="lab_sny_AventisPharmaManufacturingPTELTDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma Manufacturing PTE LTD [Member]</link:label>
    <link:label id="lab_sny_AventisPharmaManufacturingPTELTDMember_documentation_en-US" xlink:label="lab_sny_AventisPharmaManufacturingPTELTDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma (Manufacturing) PTE LTD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaManufacturingPTELTDMember" xlink:href="sny-20231231.xsd#sny_AventisPharmaManufacturingPTELTDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AventisPharmaManufacturingPTELTDMember" xlink:to="lab_sny_AventisPharmaManufacturingPTELTDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BondsIssued_29c2558a-0891-4c3d-aa00-73c5dcba12a2_terseLabel_en-US" xlink:label="lab_ifrs-full_BondsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bond issues</link:label>
    <link:label id="lab_ifrs-full_BondsIssued_label_en-US" xlink:label="lab_ifrs-full_BondsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonds issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BondsIssued" xlink:to="lab_ifrs-full_BondsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_c9e3e9a2-65f8-4d3c-bd72-996f89247202_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_c0848686-53c4-414c-b61b-65c6d1bd7005_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, category [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_86a64bf3-52c1-43fb-ab0d-204c5146a8d0_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement of defined-benefit obligation</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lab_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_073f1d6a-5962-49a3-a8ab-137714b4b424_negatedLabel_en-US" xlink:label="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made</link:label>
    <link:label id="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled liabilities, contingent liabilities recognised in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss_9e7d9606-af86-42af-b457-5076aba60dad_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financial assets at fair value through profit or loss</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial assets at fair value through profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_447729f9-2438-4175-a841-e617867b8421_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Non-Controlling Interests [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PeriodOfShareRepurchaseProgram_6853027e-7296-4c2d-9cd5-d30582c23d7d_terseLabel_en-US" xlink:label="lab_sny_PeriodOfShareRepurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of share repurchase program</link:label>
    <link:label id="lab_sny_PeriodOfShareRepurchaseProgram_label_en-US" xlink:label="lab_sny_PeriodOfShareRepurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Share Repurchase Program</link:label>
    <link:label id="lab_sny_PeriodOfShareRepurchaseProgram_documentation_en-US" xlink:label="lab_sny_PeriodOfShareRepurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of share repurchase program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodOfShareRepurchaseProgram" xlink:href="sny-20231231.xsd#sny_PeriodOfShareRepurchaseProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PeriodOfShareRepurchaseProgram" xlink:to="lab_sny_PeriodOfShareRepurchaseProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradingEquitySecuritiesMember_f31717bf-7bbb-4ecb-8471-e396bec7af3b_terseLabel_en-US" xlink:label="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading equity securities</link:label>
    <link:label id="lab_ifrs-full_TradingEquitySecuritiesMember_label_en-US" xlink:label="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading equity securities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradingEquitySecuritiesMember" xlink:to="lab_ifrs-full_TradingEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_3e09ffa2-5a8f-4c13-a6cf-5de76f3455f3_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains and losses on disposals of non-current assets, net of tax</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for losses (gains) on disposal of non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="lab_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock_77aa31eb-e613-4112-9c45-0929fcda993c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Changes In Liabilities Related To Business Combinations And To Non-Controlling Interests [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of changes in liabilities related to business combinations and to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock" xlink:to="lab_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsMember_3a3ba31b-c857-4ef4-8342-daf662745a9c_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total: principal marketed products</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products [member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal marketed products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsMember" xlink:to="lab_sny_PrincipalMarketedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_1d7c47cf-6745-4478-94b2-c8b6751e0857_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from losing control of subsidiaries or other businesses, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_62c7b739-bfbb-44bd-93d8-cc8a183a134e_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_2fe3dcd5-4482-44d2-ab5f-4fef5da4b742_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_79f24c24-378c-48f6-9590-47c8d9a488d6_terseLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration payable</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities recognised in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LiabilityRecognizedRepresentingEstimatedCost_77210e52-ae3f-4737-854b-11ce186cb8bd_terseLabel_en-US" xlink:label="lab_sny_LiabilityRecognizedRepresentingEstimatedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recognized representing the estimated cost</link:label>
    <link:label id="lab_sny_LiabilityRecognizedRepresentingEstimatedCost_label_en-US" xlink:label="lab_sny_LiabilityRecognizedRepresentingEstimatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Recognized Representing Estimated Cost</link:label>
    <link:label id="lab_sny_LiabilityRecognizedRepresentingEstimatedCost_documentation_en-US" xlink:label="lab_sny_LiabilityRecognizedRepresentingEstimatedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recognized representing estimated cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognizedRepresentingEstimatedCost" xlink:href="sny-20231231.xsd#sny_LiabilityRecognizedRepresentingEstimatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LiabilityRecognizedRepresentingEstimatedCost" xlink:to="lab_sny_LiabilityRecognizedRepresentingEstimatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_bc122de9-9e0e-4149-aec0-8739745e8524_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses, net of reversals</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognised in other comprehensive income, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalUndiscountedCashFlow_8972dc04-31f3-48c6-91c6-698811ef446c_terseLabel_en-US" xlink:label="lab_sny_PrincipalUndiscountedCashFlow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_sny_PrincipalUndiscountedCashFlow_label_en-US" xlink:label="lab_sny_PrincipalUndiscountedCashFlow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Undiscounted Cash Flow</link:label>
    <link:label id="lab_sny_PrincipalUndiscountedCashFlow_documentation_en-US" xlink:label="lab_sny_PrincipalUndiscountedCashFlow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal undiscounted cash flow.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalUndiscountedCashFlow" xlink:href="sny-20231231.xsd#sny_PrincipalUndiscountedCashFlow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalUndiscountedCashFlow" xlink:to="lab_sny_PrincipalUndiscountedCashFlow" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ReductionOfSharesByCancellationOfTreasuryShares_649a9793-11e1-453f-ab9c-9d92d271c931_negatedTerseLabel_en-US" xlink:label="lab_sny_ReductionOfSharesByCancellationOfTreasuryShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share capital by cancellation of treasury shares (in shares)</link:label>
    <link:label id="lab_sny_ReductionOfSharesByCancellationOfTreasuryShares_label_en-US" xlink:label="lab_sny_ReductionOfSharesByCancellationOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction Of Shares By Cancellation Of Treasury Shares</link:label>
    <link:label id="lab_sny_ReductionOfSharesByCancellationOfTreasuryShares_documentation_en-US" xlink:label="lab_sny_ReductionOfSharesByCancellationOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction Of Shares By Cancellation Of Treasury Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReductionOfSharesByCancellationOfTreasuryShares" xlink:href="sny-20231231.xsd#sny_ReductionOfSharesByCancellationOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ReductionOfSharesByCancellationOfTreasuryShares" xlink:to="lab_sny_ReductionOfSharesByCancellationOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfVotingEquityInterestsDivested_d81b2c9f-f4c6-4f25-9a89-ddbea19e91f9_terseLabel_en-US" xlink:label="lab_sny_PercentageOfVotingEquityInterestsDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting equity interests divested</link:label>
    <link:label id="lab_sny_PercentageOfVotingEquityInterestsDivested_label_en-US" xlink:label="lab_sny_PercentageOfVotingEquityInterestsDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Voting Equity Interests Divested</link:label>
    <link:label id="lab_sny_PercentageOfVotingEquityInterestsDivested_documentation_en-US" xlink:label="lab_sny_PercentageOfVotingEquityInterestsDivested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Voting Equity Interests Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfVotingEquityInterestsDivested" xlink:href="sny-20231231.xsd#sny_PercentageOfVotingEquityInterestsDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfVotingEquityInterestsDivested" xlink:to="lab_sny_PercentageOfVotingEquityInterestsDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PenaltyFeeIncurred_6b060ed7-1902-492d-ad2e-597828cf9882_terseLabel_en-US" xlink:label="lab_sny_PenaltyFeeIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalty fee incurred by Sanofi</link:label>
    <link:label id="lab_sny_PenaltyFeeIncurred_label_en-US" xlink:label="lab_sny_PenaltyFeeIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalty Fee Incurred</link:label>
    <link:label id="lab_sny_PenaltyFeeIncurred_documentation_en-US" xlink:label="lab_sny_PenaltyFeeIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalty Fee Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurred" xlink:href="sny-20231231.xsd#sny_PenaltyFeeIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PenaltyFeeIncurred" xlink:to="lab_sny_PenaltyFeeIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OperatingSegmentsAbstract_93ca45cd-246d-4407-997c-10eb98e77f52_terseLabel_en-US" xlink:label="lab_sny_OperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Abstract]</link:label>
    <link:label id="lab_sny_OperatingSegmentsAbstract_label_en-US" xlink:label="lab_sny_OperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Abstract]</link:label>
    <link:label id="lab_sny_OperatingSegmentsAbstract_documentation_en-US" xlink:label="lab_sny_OperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingSegmentsAbstract" xlink:href="sny-20231231.xsd#sny_OperatingSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OperatingSegmentsAbstract" xlink:to="lab_sny_OperatingSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TotalOffBalanceSheetCommitments_1be432bf-a47a-4677-b29d-f07fbac37d76_totalLabel_en-US" xlink:label="lab_sny_TotalOffBalanceSheetCommitments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total - net commitments given</link:label>
    <link:label id="lab_sny_TotalOffBalanceSheetCommitments_label_en-US" xlink:label="lab_sny_TotalOffBalanceSheetCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Off-Balance Sheet Commitments</link:label>
    <link:label id="lab_sny_TotalOffBalanceSheetCommitments_documentation_en-US" xlink:label="lab_sny_TotalOffBalanceSheetCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalOffBalanceSheetCommitments" xlink:href="sny-20231231.xsd#sny_TotalOffBalanceSheetCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TotalOffBalanceSheetCommitments" xlink:to="lab_sny_TotalOffBalanceSheetCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_227c3aaf-e17c-4783-a1dc-3e253fb5c2aa_terseLabel_en-US" xlink:label="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable reversal of temporary differences on investments in Consumer Healthcare subsidiaries</link:label>
    <link:label id="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_label_en-US" xlink:label="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate Effect Of Reversal Of Temporary Difference On Investments</link:label>
    <link:label id="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_documentation_en-US" xlink:label="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate Effect Of Reversal Of Temporary Difference On Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:href="sny-20231231.xsd#sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:to="lab_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtTable_86513d25-c2cf-4e58-b292-57fb7e47c953_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtTable_label_en-US" xlink:label="lab_sny_DisclosureOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtTable" xlink:to="lab_sny_DisclosureOfDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears_93af17cb-44bc-4f73-9c34-ac9931c3ac93_terseLabel_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative inflation rate over three years</link:label>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears_label_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Consumer Price Inflation Over The Last Three Years</link:label>
    <link:label id="lab_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears_documentation_en-US" xlink:label="lab_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative consumer price inflation rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears" xlink:href="sny-20231231.xsd#sny_CumulativeConsumerPriceInflationOverTheLastThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears" xlink:to="lab_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipiaBiopharmaIncMember_9fa2f3e7-ef23-4ab5-a2ac-8782beb3bee8_terseLabel_en-US" xlink:label="lab_sny_PrincipiaBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principia</link:label>
    <link:label id="lab_sny_PrincipiaBiopharmaIncMember_3ceeb9dd-8796-42aa-a059-1a2fe933ba23_verboseLabel_en-US" xlink:label="lab_sny_PrincipiaBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principia Biopharma Inc.</link:label>
    <link:label id="lab_sny_PrincipiaBiopharmaIncMember_label_en-US" xlink:label="lab_sny_PrincipiaBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principia Biopharma Inc. [Member]</link:label>
    <link:label id="lab_sny_PrincipiaBiopharmaIncMember_documentation_en-US" xlink:label="lab_sny_PrincipiaBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principia Biopharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipiaBiopharmaIncMember" xlink:href="sny-20231231.xsd#sny_PrincipiaBiopharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipiaBiopharmaIncMember" xlink:to="lab_sny_PrincipiaBiopharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainsOnDivestmentOfProducts_c7bb4c77-a3bc-49b7-8e93-5240e6ea9081_terseLabel_en-US" xlink:label="lab_sny_GainsOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on divestment of some mature products</link:label>
    <link:label id="lab_sny_GainsOnDivestmentOfProducts_label_en-US" xlink:label="lab_sny_GainsOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains On Divestment Of Products</link:label>
    <link:label id="lab_sny_GainsOnDivestmentOfProducts_documentation_en-US" xlink:label="lab_sny_GainsOnDivestmentOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on divestment of products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsOnDivestmentOfProducts" xlink:href="sny-20231231.xsd#sny_GainsOnDivestmentOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainsOnDivestmentOfProducts" xlink:to="lab_sny_GainsOnDivestmentOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_953b75a3-d434-4c3d-bab2-ae4039445685_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InsilicoMedicineMember_6134ad7f-1742-4210-9029-6cecb65f9097_terseLabel_en-US" xlink:label="lab_sny_InsilicoMedicineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insilico Medicine</link:label>
    <link:label id="lab_sny_InsilicoMedicineMember_label_en-US" xlink:label="lab_sny_InsilicoMedicineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insilico Medicine [Member]</link:label>
    <link:label id="lab_sny_InsilicoMedicineMember_documentation_en-US" xlink:label="lab_sny_InsilicoMedicineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insilico Medicine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InsilicoMedicineMember" xlink:href="sny-20231231.xsd#sny_InsilicoMedicineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InsilicoMedicineMember" xlink:to="lab_sny_InsilicoMedicineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AcquiredRDMember_b9e265ef-359f-41ae-bcef-bab1864b884b_terseLabel_en-US" xlink:label="lab_sny_AcquiredRDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired R&amp;D</link:label>
    <link:label id="lab_sny_AcquiredRDMember_label_en-US" xlink:label="lab_sny_AcquiredRDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired R&amp;D [Member]</link:label>
    <link:label id="lab_sny_AcquiredRDMember_documentation_en-US" xlink:label="lab_sny_AcquiredRDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired R&amp;D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredRDMember" xlink:href="sny-20231231.xsd#sny_AcquiredRDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AcquiredRDMember" xlink:to="lab_sny_AcquiredRDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_March2020EMTNISINFR0013505104Member_c9ef754c-113a-412d-b8d8-623af6c4a946_terseLabel_en-US" xlink:label="lab_sny_March2020EMTNISINFR0013505104Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2020 EMTN ISIN FR0013505104</link:label>
    <link:label id="lab_sny_March2020EMTNISINFR0013505104Member_label_en-US" xlink:label="lab_sny_March2020EMTNISINFR0013505104Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2020 EMTNISINFR0013505104 [Member]</link:label>
    <link:label id="lab_sny_March2020EMTNISINFR0013505104Member_documentation_en-US" xlink:label="lab_sny_March2020EMTNISINFR0013505104Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2020 EMTNISINFR0013505104</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2020EMTNISINFR0013505104Member" xlink:href="sny-20231231.xsd#sny_March2020EMTNISINFR0013505104Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_March2020EMTNISINFR0013505104Member" xlink:to="lab_sny_March2020EMTNISINFR0013505104Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock_b40cbcfb-d76d-4708-bbba-bbb1ea735d20_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions, income tax liabilities and other liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Provisions And Other Liabilities [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure of provisions and other liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock" xlink:to="lab_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock_d7da1579-0402-4823-a5b8-4404cd75f308_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Amount of Guarantees Given and Received</link:label>
    <link:label id="lab_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Guarantees Given And Received Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of guarantees given and received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_66408ab2-3c55-483d-80cc-0c6c0547c98d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FairValueHedgesMember_7e04cef0-858a-425e-9578-221397766ae1_terseLabel_en-US" xlink:label="lab_ifrs-full_FairValueHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as fair value hedges</link:label>
    <link:label id="lab_ifrs-full_FairValueHedgesMember_label_en-US" xlink:label="lab_ifrs-full_FairValueHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FairValueHedgesMember" xlink:to="lab_ifrs-full_FairValueHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_a6ad1ed6-35fe-4d0d-861a-e1c1f4d45351_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of stock subscription option plan outstanding and option exercised [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Stock Subscription Option Plan Outstanding And Option Exercised [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of stock subscription option plan outstanding and option exercised [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems" xlink:to="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesMember_0264b4e2-6e47-45eb-a720-daa76819ebdf_terseLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities [member]</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember" xlink:to="lab_ifrs-full_ContingentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_d697e232-48be-412a-9d36-b8a4b7050008_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock_243cb3db-3e0d-4c93-aca1-1af94ea09bf4_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Future Payments in Respect of Unfunded Pension and Other Post-employment Benefit Plans</link:label>
    <link:label id="lab_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Expected Timing Of Payments In Respect Of Unfunded Pension And Other Post Employment Benefit Plans Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of expected timing of payments in respect of unfunded pension and other post employment benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_8e33ec15-86e1-4db5-8d6f-3bd2532686b2_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flow before changes in working capital</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainLossOnCancellationOfTreasuryShares_ad87dab7-eba5-45ce-abd8-001e069f628e_terseLabel_en-US" xlink:label="lab_sny_GainLossOnCancellationOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized on cancellation of treasury shares</link:label>
    <link:label id="lab_sny_GainLossOnCancellationOfTreasuryShares_label_en-US" xlink:label="lab_sny_GainLossOnCancellationOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Cancellation Of Treasury Shares</link:label>
    <link:label id="lab_sny_GainLossOnCancellationOfTreasuryShares_documentation_en-US" xlink:label="lab_sny_GainLossOnCancellationOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on cancellation of treasury shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnCancellationOfTreasuryShares" xlink:href="sny-20231231.xsd#sny_GainLossOnCancellationOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainLossOnCancellationOfTreasuryShares" xlink:to="lab_sny_GainLossOnCancellationOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_QualifiedDefinedBenefitPensionPlansMember_e5086fea-13e9-427f-af2b-c1adefcecdf2_terseLabel_en-US" xlink:label="lab_sny_QualifiedDefinedBenefitPensionPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified defined benefit pension plans</link:label>
    <link:label id="lab_sny_QualifiedDefinedBenefitPensionPlansMember_label_en-US" xlink:label="lab_sny_QualifiedDefinedBenefitPensionPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Defined Benefit Pension Plans [member]</link:label>
    <link:label id="lab_sny_QualifiedDefinedBenefitPensionPlansMember_documentation_en-US" xlink:label="lab_sny_QualifiedDefinedBenefitPensionPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified defined benefit pension plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QualifiedDefinedBenefitPensionPlansMember" xlink:href="sny-20231231.xsd#sny_QualifiedDefinedBenefitPensionPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_QualifiedDefinedBenefitPensionPlansMember" xlink:to="lab_sny_QualifiedDefinedBenefitPensionPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember_dcaaf0e8-cb2f-4051-8cc9-b2144336d5a2_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases in Chinese Yuan Renminbi</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Chinese Yuan Renminbi [member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases in Chinese Yuan Renminbi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember" xlink:to="lab_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_2018bd86-3431-43c7-b37e-275b6c8215b5_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_ffab8301-4e48-41cb-b517-ba74f7278ae9_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other payables</link:label>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts payable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_f721bc37-4b71-4d5c-b643-4a3d0c99e459_terseLabel_en-US" xlink:label="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration recognised as of acquisition date</link:label>
    <link:label id="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_7f1de175-58ee-438b-8d06-34293e6d969e_verboseLabel_en-US" xlink:label="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAuditFeesAndOtherServicesTable_1f066f35-0f64-4616-a00c-6619c84447de_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAuditFeesAndOtherServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of audit fees and other services [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfAuditFeesAndOtherServicesTable_label_en-US" xlink:label="lab_sny_DisclosureOfAuditFeesAndOtherServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Audit Fees And Other Services [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfAuditFeesAndOtherServicesTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfAuditFeesAndOtherServicesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of audit fees and other services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAuditFeesAndOtherServicesTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfAuditFeesAndOtherServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesTable" xlink:to="lab_sny_DisclosureOfAuditFeesAndOtherServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_8848b8d2-f233-4e57-810c-a55e74cac4b5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember_e7c24517-3954-4476-9d46-947615039ebb_terseLabel_en-US" xlink:label="lab_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Main undrawn confirmed general purpose credit facilities</link:label>
    <link:label id="lab_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember_label_en-US" xlink:label="lab_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Main Undrawn Confirmed General Purpose Credit Facilities [member]</link:label>
    <link:label id="lab_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember_documentation_en-US" xlink:label="lab_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Main undrawn confirmed general purpose credit facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember" xlink:href="sny-20231231.xsd#sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember" xlink:to="lab_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfPrincipalAlliancesLineItems_06915c9c-0a36-4449-8c17-23538363ed6c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAlliancesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Principal Alliances [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAlliancesLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAlliancesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Principal Alliances [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAlliancesLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAlliancesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Principal Alliances [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAlliancesLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfPrincipalAlliancesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems" xlink:to="lab_sny_DisclosureOfPrincipalAlliancesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsProteinSciencesMember_263fe6fa-e5dc-4421-aeb1-75a16e6e6974_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsProteinSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protein Sciences</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsProteinSciencesMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsProteinSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Protein Sciences [member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsProteinSciencesMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsProteinSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal marketed products Protein Sciences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsProteinSciencesMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsProteinSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsProteinSciencesMember" xlink:to="lab_sny_PrincipalMarketedProductsProteinSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_9b206c53-781f-41a8-bbaf-d219be6d6a5e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Other Operating Income Expenses [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_label_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other operating income expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:to="lab_sny_DisclosureOfOtherOperatingIncomeExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_feb777c4-1711-4299-afc8-b00e4ca1afc6_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock_d24364de-97c1-47f8-a94c-3faa4c4f2654_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Liability in Respect of Pension Plans and Other Post-employment Benefits by Geographical Region</link:label>
    <link:label id="lab_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Net Liability In Respect Of Pension Plans And Other Post-employment Benefits By Geographical Region [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net liability in respect of pension plans and other post-employment benefits by geographical region.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock" xlink:to="lab_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_ba056e7f-23bd-4c1d-8a7f-c5c20c55fbb1_terseLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate and currency derivatives used to hedge debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate And Currency Derivatives [Member]</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesMember_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate and currency derivatives used to hedge debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesMember" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlusHundredBasisPointsMember_fcbaa7f1-0516-4e8c-9492-03169ac22634_terseLabel_en-US" xlink:label="lab_sny_PlusHundredBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">+100&#160;bp</link:label>
    <link:label id="lab_sny_PlusHundredBasisPointsMember_label_en-US" xlink:label="lab_sny_PlusHundredBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus Hundred Basis Points [Member]</link:label>
    <link:label id="lab_sny_PlusHundredBasisPointsMember_documentation_en-US" xlink:label="lab_sny_PlusHundredBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus hundred basis points.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlusHundredBasisPointsMember" xlink:href="sny-20231231.xsd#sny_PlusHundredBasisPointsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlusHundredBasisPointsMember" xlink:to="lab_sny_PlusHundredBasisPointsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock_7543a1ff-7da4-4113-b599-91037a917123_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Principal Investments Accounted for Using the Equity Method</link:label>
    <link:label id="lab_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Investments In Subsidiaries Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Investments In Subsidiaries Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CumulativeDevelopmentCostsIncurred_59e9a3ee-b757-452b-95a1-e235b2f04e43_terseLabel_en-US" xlink:label="lab_sny_CumulativeDevelopmentCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative development costs incurred</link:label>
    <link:label id="lab_sny_CumulativeDevelopmentCostsIncurred_label_en-US" xlink:label="lab_sny_CumulativeDevelopmentCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Development Costs Incurred</link:label>
    <link:label id="lab_sny_CumulativeDevelopmentCostsIncurred_documentation_en-US" xlink:label="lab_sny_CumulativeDevelopmentCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Development Costs Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeDevelopmentCostsIncurred" xlink:href="sny-20231231.xsd#sny_CumulativeDevelopmentCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CumulativeDevelopmentCostsIncurred" xlink:to="lab_sny_CumulativeDevelopmentCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_d5c9271c-6ee2-4b39-9400-1263904b6365_totalLabel_en-US" xlink:label="lab_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_label_en-US" xlink:label="lab_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments designated as hedging instruments, at fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" xlink:to="lab_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_fd2b79f6-d8b8-462a-9ecb-2c998e0e81ca_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pound sterling</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_1311f84d-3d51-420b-878a-51e59af88210_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International financial reporting standards (IFRS)</link:label>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_label_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of IFRS compliance [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfIFRSCompliance" xlink:to="lab_ifrs-full_StatementOfIFRSCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset_66ccd55e-5d61-4ddc-9629-617f636ff342_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amounts before offset</link:label>
    <link:label id="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset_label_en-US" xlink:label="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Assets And Liabilities, Gross Carrying Amounts Before Offset</link:label>
    <link:label id="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial assets and liabilities gross carrying amounts before offset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" xlink:to="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ad5c5479-46c9-429f-ae26-695139d2856c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInRussianRoubleMember_ce552fe5-8dbb-4b41-a180-7374cd1b8bae_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases In Russian Rouble</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInRussianRoubleMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Russian Rouble [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInRussianRoubleMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInRussianRoubleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Russian Rouble [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInRussianRoubleMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInRussianRoubleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasedInRussianRoubleMember" xlink:to="lab_sny_ForwardCurrencyPurchasedInRussianRoubleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_89e42985-22da-4e9e-9800-fd9a2edb1806_negatedLabel_en-US" xlink:label="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of intangible assets</link:label>
    <link:label id="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Impairment Of Intangible Assets Other Than Goodwill</link:label>
    <link:label id="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_documentation_en-US" xlink:label="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of intangible assets other than goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:href="sny-20231231.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:to="lab_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NKCellAndProXTenTechnologyPlatformsMember_52d0fecc-bdac-4db4-aab5-8f96e144c16f_terseLabel_en-US" xlink:label="lab_sny_NKCellAndProXTenTechnologyPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NK Cell and ProXTen technology platforms</link:label>
    <link:label id="lab_sny_NKCellAndProXTenTechnologyPlatformsMember_label_en-US" xlink:label="lab_sny_NKCellAndProXTenTechnologyPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NK Cell And ProXTen Technology Platforms [Member]</link:label>
    <link:label id="lab_sny_NKCellAndProXTenTechnologyPlatformsMember_documentation_en-US" xlink:label="lab_sny_NKCellAndProXTenTechnologyPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NK Cell And ProXTen Technology Platforms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NKCellAndProXTenTechnologyPlatformsMember" xlink:href="sny-20231231.xsd#sny_NKCellAndProXTenTechnologyPlatformsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NKCellAndProXTenTechnologyPlatformsMember" xlink:to="lab_sny_NKCellAndProXTenTechnologyPlatformsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncontrollingInterestsMember_015175cb-16d7-4904-97c6-1047c7122768_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attributable to&#160;non- controlling interests</link:label>
    <link:label id="lab_ifrs-full_NoncontrollingInterestsMember_label_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterestsMember" xlink:to="lab_ifrs-full_NoncontrollingInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GeneralMedecinesMember_fe9f6f9e-8008-4b98-ad05-f97778b96a45_terseLabel_en-US" xlink:label="lab_sny_GeneralMedecinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Medicines</link:label>
    <link:label id="lab_sny_GeneralMedecinesMember_label_en-US" xlink:label="lab_sny_GeneralMedecinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Medecines [Member]</link:label>
    <link:label id="lab_sny_GeneralMedecinesMember_documentation_en-US" xlink:label="lab_sny_GeneralMedecinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Medecines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralMedecinesMember" xlink:href="sny-20231231.xsd#sny_GeneralMedecinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GeneralMedecinesMember" xlink:to="lab_sny_GeneralMedecinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_d4b34a7f-6c63-49eb-89af-585a566da184_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_add4a8c8-8ad5-48e1-b1b3-a114a54b038e_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_174f9e76-c4ab-4f9f-b943-93b20acbe904_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and arbitral proceedings</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems_e7d123d6-a564-45df-a706-0774eea8ae73_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DebtSecuritiesMember_413bb75e-f7ca-49fc-9d5d-18d0d0aaea1c_terseLabel_en-US" xlink:label="lab_ifrs-full_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_ifrs-full_DebtSecuritiesMember_label_en-US" xlink:label="lab_ifrs-full_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DebtSecuritiesMember" xlink:to="lab_ifrs-full_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_783df234-19bd-4482-af19-9739fa5bcab9_terseLabel_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exceptional supplementary dividend, percentage of share capital</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_label_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exceptional Supplementary Dividend, Percentage Of Share Capital</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_documentation_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exceptional Supplementary Dividend, Percentage Of Share Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendPercentageOfShareCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:to="lab_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PensionObligationPercentageToDefinedBenefitLiability_8e82ca88-d65b-442a-9991-d30339185bb9_terseLabel_en-US" xlink:label="lab_sny_PensionObligationPercentageToDefinedBenefitLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension obligation, percentage to defined benefit liability</link:label>
    <link:label id="lab_sny_PensionObligationPercentageToDefinedBenefitLiability_label_en-US" xlink:label="lab_sny_PensionObligationPercentageToDefinedBenefitLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Obligation, Percentage To Defined Benefit Liability</link:label>
    <link:label id="lab_sny_PensionObligationPercentageToDefinedBenefitLiability_documentation_en-US" xlink:label="lab_sny_PensionObligationPercentageToDefinedBenefitLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension obligation percentage to defined benefit liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionObligationPercentageToDefinedBenefitLiability" xlink:href="sny-20231231.xsd#sny_PensionObligationPercentageToDefinedBenefitLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PensionObligationPercentageToDefinedBenefitLiability" xlink:to="lab_sny_PensionObligationPercentageToDefinedBenefitLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_7d59116a-4feb-4c2f-bbfe-90a071f6c60f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiForeignParticipationsB.V.Member_8b2100d1-d974-48ab-9bab-db3d9678f507_terseLabel_en-US" xlink:label="lab_sny_SanofiForeignParticipationsB.V.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Foreign Participations BV</link:label>
    <link:label id="lab_sny_SanofiForeignParticipationsB.V.Member_label_en-US" xlink:label="lab_sny_SanofiForeignParticipationsB.V.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Foreign Participations B.V. [Member]</link:label>
    <link:label id="lab_sny_SanofiForeignParticipationsB.V.Member_documentation_en-US" xlink:label="lab_sny_SanofiForeignParticipationsB.V.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Foreign Participations B.V. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiForeignParticipationsB.V.Member" xlink:href="sny-20231231.xsd#sny_SanofiForeignParticipationsB.V.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiForeignParticipationsB.V.Member" xlink:to="lab_sny_SanofiForeignParticipationsB.V.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_232f57ac-e96e-49eb-b404-16038f52934f_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_edf29bc8-421a-4ee7-b551-768d03731ba4_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, class</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsMember" xlink:to="lab_ifrs-full_FinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MapharMember_9826487d-f018-4677-ade6-b9117c5330f4_terseLabel_en-US" xlink:label="lab_sny_MapharMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maphar</link:label>
    <link:label id="lab_sny_MapharMember_label_en-US" xlink:label="lab_sny_MapharMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maphar [Member]</link:label>
    <link:label id="lab_sny_MapharMember_documentation_en-US" xlink:label="lab_sny_MapharMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maphar.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MapharMember" xlink:href="sny-20231231.xsd#sny_MapharMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MapharMember" xlink:to="lab_sny_MapharMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember_ed894f23-627a-4b37-8926-61f2fd7ba0dd_terseLabel_en-US" xlink:label="lab_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase of ten percent basis point in market interest rate</link:label>
    <link:label id="lab_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember_label_en-US" xlink:label="lab_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Of Ten Percent Basis Point In Market Interest Rate [Member]</link:label>
    <link:label id="lab_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember_documentation_en-US" xlink:label="lab_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of ten percent basis point in market interest rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember" xlink:href="sny-20231231.xsd#sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember" xlink:to="lab_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired_eeba593a-58b9-4778-9f5f-fe7f358bdc94_terseLabel_en-US" xlink:label="lab_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of share capital owned (in percent)</link:label>
    <link:label id="lab_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions, Percentage Of Voting Interests Acquired</link:label>
    <link:label id="lab_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired_documentation_en-US" xlink:label="lab_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions, Percentage Of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired" xlink:href="sny-20231231.xsd#sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired" xlink:to="lab_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiIlacSanayiVeTicaretASMember_a59c97dd-827f-4730-ba1d-1503584d4aa1_terseLabel_en-US" xlink:label="lab_sny_SanofiIlacSanayiVeTicaretASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Ilac Sanayi ve Ticaret AS</link:label>
    <link:label id="lab_sny_SanofiIlacSanayiVeTicaretASMember_label_en-US" xlink:label="lab_sny_SanofiIlacSanayiVeTicaretASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Ilac Sanayi ve Ticaret A.S. [member]</link:label>
    <link:label id="lab_sny_SanofiIlacSanayiVeTicaretASMember_documentation_en-US" xlink:label="lab_sny_SanofiIlacSanayiVeTicaretASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Ilac Sanayi ve Ticaret A.S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiIlacSanayiVeTicaretASMember" xlink:href="sny-20231231.xsd#sny_SanofiIlacSanayiVeTicaretASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiIlacSanayiVeTicaretASMember" xlink:to="lab_sny_SanofiIlacSanayiVeTicaretASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_ea48882d-533c-4c39-a5fb-d8a586f5dd4c_terseLabel_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains/(losses) excluding investments accounted for using the equity method (see&#160;Note&#160;D.19.1.)</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BiopharmaSegmentMember_380144e8-8525-4a92-99ae-4d86dc8e2e72_terseLabel_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma</link:label>
    <link:label id="lab_sny_BiopharmaSegmentMember_label_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:label id="lab_sny_BiopharmaSegmentMember_documentation_en-US" xlink:label="lab_sny_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BiopharmaSegmentMember" xlink:to="lab_sny_BiopharmaSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestIncome_576df8b3-9852-43be-8d1f-37ade39a3816_terseLabel_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_sny_InterestIncome_label_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income</link:label>
    <link:label id="lab_sny_InterestIncome_documentation_en-US" xlink:label="lab_sny_InterestIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome" xlink:href="sny-20231231.xsd#sny_InterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestIncome" xlink:to="lab_sny_InterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember_9417e9cf-2c28-4522-9481-da17ba7d1199_terseLabel_en-US" xlink:label="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash-generating units</link:label>
    <link:label id="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember_label_en-US" xlink:label="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash-generating units [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember" xlink:to="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_97ab26e8-79e1-4c31-9c5e-8ac8d941aa97_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about finance income expense [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent detailed information about finance income expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_23900f9b-af95-4e51-9e46-cf75a57cfe58_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">to shareholders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid to equity holders of parent, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpairmentOfAssetsAbstract_2dd46ed2-e5f8-4095-857d-08ff2dbe3fca_terseLabel_en-US" xlink:label="lab_sny_ImpairmentOfAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Assets [Abstract]</link:label>
    <link:label id="lab_sny_ImpairmentOfAssetsAbstract_label_en-US" xlink:label="lab_sny_ImpairmentOfAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Assets [Abstract]</link:label>
    <link:label id="lab_sny_ImpairmentOfAssetsAbstract_documentation_en-US" xlink:label="lab_sny_ImpairmentOfAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentOfAssetsAbstract" xlink:href="sny-20231231.xsd#sny_ImpairmentOfAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpairmentOfAssetsAbstract" xlink:to="lab_sny_ImpairmentOfAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards_f76046d7-7098-4471-9d6d-44acfba943d1_terseLabel_en-US" xlink:label="lab_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets for tax loss carryforwards</link:label>
    <link:label id="lab_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards_label_en-US" xlink:label="lab_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Deferred Tax Assets For Tax Loss Carryforwards</link:label>
    <link:label id="lab_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards_documentation_en-US" xlink:label="lab_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets for tax loss carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards" xlink:href="sny-20231231.xsd#sny_TotalDeferredTaxAssetsForTaxLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards" xlink:to="lab_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_bc7cb31b-6015-45f2-aade-a22b5004188b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_0109c308-2731-41ce-a76a-c86a1b7c99dc_terseLabel_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in other current assets and other current liabilities</link:label>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Change In Other Current Assets And Other Current Liabilities</link:label>
    <link:label id="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:href="sny-20231231.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:to="lab_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_43c70e49-f4f5-4fcf-b944-a4e106879ee8_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life, intangible assets other than goodwill (in years)</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_a29de255-ad0b-40eb-b0fa-49aa58611787_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock_aba1fd63-60aa-4762-9e5c-7173cf4d6425_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Trends in Net Income Attributable to Non-Controlling Interests</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information About The Amounts Attributable To Non-Controlling Interests Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information About The Amounts Attributable To Non Controlling Interests Explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_7f74a48e-ffb0-40c1-a751-19c75583bebe_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal_c01d627b-425b-4b80-b0ed-1c9822092f9d_terseLabel_en-US" xlink:label="lab_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs who filed notices to appeal</link:label>
    <link:label id="lab_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal_label_en-US" xlink:label="lab_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Plaintiffs Who Filed Notices To Appeal</link:label>
    <link:label id="lab_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal_documentation_en-US" xlink:label="lab_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Plaintiffs Who Filed Notices To Appeal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal" xlink:href="sny-20231231.xsd#sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal" xlink:to="lab_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a4546766-b2a9-4c00-a4f7-b6b5632bdd6d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TwoThousandFourteenAmendedInvestmentAgreementMember_78c27749-3d7c-4c58-ae9a-bc309ebf1b73_terseLabel_en-US" xlink:label="lab_sny_TwoThousandFourteenAmendedInvestmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Amended Investment Agreement</link:label>
    <link:label id="lab_sny_TwoThousandFourteenAmendedInvestmentAgreementMember_label_en-US" xlink:label="lab_sny_TwoThousandFourteenAmendedInvestmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Amended Investment Agreement [member]</link:label>
    <link:label id="lab_sny_TwoThousandFourteenAmendedInvestmentAgreementMember_documentation_en-US" xlink:label="lab_sny_TwoThousandFourteenAmendedInvestmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand fourteen amended investment agreement,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TwoThousandFourteenAmendedInvestmentAgreementMember" xlink:href="sny-20231231.xsd#sny_TwoThousandFourteenAmendedInvestmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TwoThousandFourteenAmendedInvestmentAgreementMember" xlink:to="lab_sny_TwoThousandFourteenAmendedInvestmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurLimitedMember_24f2e7e4-6fa3-435a-ac31-f859ba331e43_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Limited</link:label>
    <link:label id="lab_sny_SanofiPasteurLimitedMember_label_en-US" xlink:label="lab_sny_SanofiPasteurLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Limited [Member]</link:label>
    <link:label id="lab_sny_SanofiPasteurLimitedMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurLimitedMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurLimitedMember" xlink:to="lab_sny_SanofiPasteurLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_e75adff6-38a9-40e1-81bf-7359d2fe7a58_terseLabel_en-US" xlink:label="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular milestone payments for projects under collaboration agreements</link:label>
    <link:label id="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_label_en-US" xlink:label="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular Milestone Payments For Projects Under Collaboration Agreements</link:label>
    <link:label id="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_documentation_en-US" xlink:label="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regular Milestone Payments For Projects Under Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:href="sny-20231231.xsd#sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:to="lab_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_27870a38-3146-458f-960a-bd39aa6ddb8a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BioverativUSLLCMember_e42489f5-ff5b-4de2-b8be-ffa11e4edc88_terseLabel_en-US" xlink:label="lab_sny_BioverativUSLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ U.S. LLC</link:label>
    <link:label id="lab_sny_BioverativUSLLCMember_label_en-US" xlink:label="lab_sny_BioverativUSLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ US LLC [member]</link:label>
    <link:label id="lab_sny_BioverativUSLLCMember_documentation_en-US" xlink:label="lab_sny_BioverativUSLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ US LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativUSLLCMember" xlink:href="sny-20231231.xsd#sny_BioverativUSLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BioverativUSLLCMember" xlink:to="lab_sny_BioverativUSLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfJointOperationsLineItems_36f63cf5-0058-41a6-b0f5-10f343922a7f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of joint operations [line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfJointOperationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of joint operations [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointOperationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfJointOperationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfJointOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock_e03f81c8-3f04-42c9-97d1-db3844095912_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Changes In Property, Plant And Equipment [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of changes in property, plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock" xlink:to="lab_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_eae3eaf5-d976-4f3d-b78d-42cd363a6c5e_terseLabel_en-US" xlink:label="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#8364;1,750 million bonds maturing March 2023</link:label>
    <link:label id="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_label_en-US" xlink:label="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Billion Seven Hundred Fifty Million Bonds Maturing March 2023 [Member]</link:label>
    <link:label id="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_documentation_en-US" xlink:label="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Billion Seven Hundred Fifty Million Bonds Maturing March 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:href="sny-20231231.xsd#sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:to="lab_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowingsMember_3fd581dc-3456-433f-8c8b-c9e13fc67680_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowingsMember_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term borrowings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowingsMember" xlink:to="lab_ifrs-full_LongtermBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AR_6766a63d-05ab-404b-8c49-2e83da01b09a_terseLabel_en-US" xlink:label="lab_country_AR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Argentina</link:label>
    <link:label id="lab_country_AR_label_en-US" xlink:label="lab_country_AR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARGENTINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AR" xlink:to="lab_country_AR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_54b77d6a-546e-42bd-97c0-0345f050b33d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Characteristics of Restricted Share Plans</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths_150d4b35-63de-4400-b848-7c5a07e94a32_terseLabel_en-US" xlink:label="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions, expected utilized amount in 2022</link:label>
    <link:label id="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths_label_en-US" xlink:label="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified Environmental Risks Provisions Expected Utilized Amount Next Twelve Months</link:label>
    <link:label id="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths_documentation_en-US" xlink:label="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified environmental risks provisions expected utilized amount next twelve months.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths" xlink:href="sny-20231231.xsd#sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths" xlink:to="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseOfBorrowings_3813ced9-8ddd-43d9-b824-21c351384e52_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_sny_IncreaseDecreaseOfBorrowings_label_en-US" xlink:label="lab_sny_IncreaseDecreaseOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Of Borrowings</link:label>
    <link:label id="lab_sny_IncreaseDecreaseOfBorrowings_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Of Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfBorrowings" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseOfBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseOfBorrowings" xlink:to="lab_sny_IncreaseDecreaseOfBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MinimumPlan2Member_035033f8-bab1-4fe9-a8f3-7b3639496215_terseLabel_en-US" xlink:label="lab_sny_MinimumPlan2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum plan 2</link:label>
    <link:label id="lab_sny_MinimumPlan2Member_label_en-US" xlink:label="lab_sny_MinimumPlan2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Plan 2 [Member]</link:label>
    <link:label id="lab_sny_MinimumPlan2Member_documentation_en-US" xlink:label="lab_sny_MinimumPlan2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Plan 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinimumPlan2Member" xlink:href="sny-20231231.xsd#sny_MinimumPlan2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MinimumPlan2Member" xlink:to="lab_sny_MinimumPlan2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlusTwentyFiveBasisPointsMember_1bbec7f7-88bf-4a47-8212-70a70ab80bd1_terseLabel_en-US" xlink:label="lab_sny_PlusTwentyFiveBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">+25&#160;bp</link:label>
    <link:label id="lab_sny_PlusTwentyFiveBasisPointsMember_label_en-US" xlink:label="lab_sny_PlusTwentyFiveBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus Twenty Five Basis Points [Member]</link:label>
    <link:label id="lab_sny_PlusTwentyFiveBasisPointsMember_documentation_en-US" xlink:label="lab_sny_PlusTwentyFiveBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus twenty five basis points.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlusTwentyFiveBasisPointsMember" xlink:href="sny-20231231.xsd#sny_PlusTwentyFiveBasisPointsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlusTwentyFiveBasisPointsMember" xlink:to="lab_sny_PlusTwentyFiveBasisPointsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MinusHundredBasisPointsMember_00c316c3-75e3-4ab1-b506-255173055e82_terseLabel_en-US" xlink:label="lab_sny_MinusHundredBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-100&#160;bp</link:label>
    <link:label id="lab_sny_MinusHundredBasisPointsMember_label_en-US" xlink:label="lab_sny_MinusHundredBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minus Hundred Basis Points [Member]</link:label>
    <link:label id="lab_sny_MinusHundredBasisPointsMember_documentation_en-US" xlink:label="lab_sny_MinusHundredBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minus hundred basis points.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinusHundredBasisPointsMember" xlink:href="sny-20231231.xsd#sny_MinusHundredBasisPointsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MinusHundredBasisPointsMember" xlink:to="lab_sny_MinusHundredBasisPointsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EvotecMember_2bf4e608-4ac0-4db8-bf9b-21f91143bd27_terseLabel_en-US" xlink:label="lab_sny_EvotecMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evotec</link:label>
    <link:label id="lab_sny_EvotecMember_label_en-US" xlink:label="lab_sny_EvotecMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evotec [Member]</link:label>
    <link:label id="lab_sny_EvotecMember_documentation_en-US" xlink:label="lab_sny_EvotecMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evotec.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EvotecMember" xlink:href="sny-20231231.xsd#sny_EvotecMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EvotecMember" xlink:to="lab_sny_EvotecMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets_dd75fbcb-7fa5-4a94-b4a6-1a4ae6d733ed_terseLabel_en-US" xlink:label="lab_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and other increases</link:label>
    <link:label id="lab_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets_label_en-US" xlink:label="lab_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions Other Than Through Business Combinations, Property, Plant and Equipment, Right Of Use Assets</link:label>
    <link:label id="lab_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets_documentation_en-US" xlink:label="lab_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions Other Than Through Business Combinations, Property, Plant and Equipment, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets" xlink:href="sny-20231231.xsd#sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets" xlink:to="lab_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e2599dad-bc9f-475d-8f16-d59f3db970f0_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember_62fd1908-01fe-4ac6-a69c-86bd3ecfb0de_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases in US dollar, commercial paper</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In US Dollar, Commercial Paper [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In US Dollar, Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember" xlink:to="lab_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParent_3d224585-e7f5-4e6b-9965-da034e5b953f_verboseLabel_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParent_9daac62d-bd02-4a43-ad4f-90bcb9320a5b_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SuppliersMember_bc8655ab-2385-4464-a270-6c7bd0397653_terseLabel_en-US" xlink:label="lab_sny_SuppliersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suppliers</link:label>
    <link:label id="lab_sny_SuppliersMember_label_en-US" xlink:label="lab_sny_SuppliersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suppliers [Member]</link:label>
    <link:label id="lab_sny_SuppliersMember_documentation_en-US" xlink:label="lab_sny_SuppliersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suppliers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SuppliersMember" xlink:href="sny-20231231.xsd#sny_SuppliersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SuppliersMember" xlink:to="lab_sny_SuppliersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowHedgesMember_6cb134bd-bc1e-41ac-b0ba-299acbd008b0_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges</link:label>
    <link:label id="lab_ifrs-full_CashFlowHedgesMember_label_en-US" xlink:label="lab_ifrs-full_CashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowHedgesMember" xlink:to="lab_ifrs-full_CashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_ac2643ae-1ff9-4c8e-8dae-664d0db4eb00_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New pronouncements issued by IASB and applicable from 2024 or later</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_fd6c3cbd-ec9f-4b2f-8d83-765d2ccdf61d_terseLabel_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference between actual return and interest income on plan assets</link:label>
    <link:label id="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_36530b27-929f-4037-957a-0ae546a26e21_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of associates [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of associates [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_JevtanaMember_0240e2f3-8ddd-4b07-aa75-e706da72c201_terseLabel_en-US" xlink:label="lab_sny_JevtanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JEVTANA</link:label>
    <link:label id="lab_sny_JevtanaMember_label_en-US" xlink:label="lab_sny_JevtanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jevtana [Member]</link:label>
    <link:label id="lab_sny_JevtanaMember_documentation_en-US" xlink:label="lab_sny_JevtanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jevtana.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaMember" xlink:href="sny-20231231.xsd#sny_JevtanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_JevtanaMember" xlink:to="lab_sny_JevtanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_fe79512b-7449-47f1-bd47-700668ccec17_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase)/decrease in inventories</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement_78af6b9a-cea1-4070-8fb2-fca57bfd3fde_negatedLabel_en-US" xlink:label="lab_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, options cancelled</link:label>
    <link:label id="lab_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Of Share Options Cancelled In Share Based Payment Arrangement</link:label>
    <link:label id="lab_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Of Share Options Cancelled In Share Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:to="lab_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiWinthropIndustriesMember_90a59172-2eb1-48b3-97fc-c8bc93eb5c77_terseLabel_en-US" xlink:label="lab_sny_SanofiWinthropIndustriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Winthrop Industrie</link:label>
    <link:label id="lab_sny_SanofiWinthropIndustriesMember_label_en-US" xlink:label="lab_sny_SanofiWinthropIndustriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Winthrop Industries [member]</link:label>
    <link:label id="lab_sny_SanofiWinthropIndustriesMember_documentation_en-US" xlink:label="lab_sny_SanofiWinthropIndustriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Winthrop Industries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiWinthropIndustriesMember" xlink:href="sny-20231231.xsd#sny_SanofiWinthropIndustriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiWinthropIndustriesMember" xlink:to="lab_sny_SanofiWinthropIndustriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries_4b862448-2c5c-4312-aeb1-b497d106b099_terseLabel_en-US" xlink:label="lab_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit of the financial statements of the parent company and its French subsidiaries</link:label>
    <link:label id="lab_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries_label_en-US" xlink:label="lab_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Of The Financial Statements Of The Parent Company And Its French Subsidiaries</link:label>
    <link:label id="lab_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries_documentation_en-US" xlink:label="lab_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit of the financial statements of the parent company and its French subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" xlink:href="sny-20231231.xsd#sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" xlink:to="lab_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock_5c7bafa9-f09f-4117-94f3-e50fcdce36bc_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Net Obligation in Respect of Sanofi's Pension and Other Post-Employment Benefit Plans</link:label>
    <link:label id="lab_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Net Defined Benefit Liability Assets Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of net defined benefit liability assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim_43c059f0-4d65-4ae3-9bb4-d51b42a6670c_terseLabel_en-US" xlink:label="lab_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claimant exposed who withdrawed their claim</link:label>
    <link:label id="lab_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim_label_en-US" xlink:label="lab_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claimant Exposed Who Withdrawed The Claim</link:label>
    <link:label id="lab_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim_documentation_en-US" xlink:label="lab_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claimant Exposed Who Withdrawed The Claim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim" xlink:href="sny-20231231.xsd#sny_NumberOfClaimantExposedWhoWithdrawedTheClaim"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim" xlink:to="lab_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProventionBioIncMember_a453bc93-db3e-455e-b26d-e08e139aea66_terseLabel_en-US" xlink:label="lab_sny_ProventionBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio, Inc</link:label>
    <link:label id="lab_sny_ProventionBioIncMember_label_en-US" xlink:label="lab_sny_ProventionBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio, Inc [Member]</link:label>
    <link:label id="lab_sny_ProventionBioIncMember_documentation_en-US" xlink:label="lab_sny_ProventionBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember" xlink:href="sny-20231231.xsd#sny_ProventionBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProventionBioIncMember" xlink:to="lab_sny_ProventionBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_d22d310a-b043-4cb5-8ff8-44fefa6ecbf4_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year 5 and later</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_634925e1-9c99-49d7-9729-9d889cf2c1f5_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More&#160;than 5&#160;years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_ccbd5953-9d59-4e82-a1ee-7d7828d1866d_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share plan 2022</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plan 2022 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2022Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plan 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2022Member" xlink:to="lab_sny_RestrictedSharePlan2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OthersCounterpartyMember_d76c3d0b-d78d-423d-9e6e-3448f49db9cf_terseLabel_en-US" xlink:label="lab_sny_OthersCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Others</link:label>
    <link:label id="lab_sny_OthersCounterpartyMember_label_en-US" xlink:label="lab_sny_OthersCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Others Counterparty [Member]</link:label>
    <link:label id="lab_sny_OthersCounterpartyMember_documentation_en-US" xlink:label="lab_sny_OthersCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Others Counterparty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersCounterpartyMember" xlink:href="sny-20231231.xsd#sny_OthersCounterpartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OthersCounterpartyMember" xlink:to="lab_sny_OthersCounterpartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossProfit_130a61d9-5fac-43f1-864c-535378b912f7_totalLabel_en-US" xlink:label="lab_ifrs-full_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_ifrs-full_GrossProfit_label_en-US" xlink:label="lab_ifrs-full_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossProfit" xlink:to="lab_ifrs-full_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesMember_35cca5f1-925f-447f-8d34-4dbf0d2061e5_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency sales</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesMember" xlink:to="lab_sny_ForwardCurrencySalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AtNotionalAmountMember_a9df20d3-2f79-465c-aecf-66b0e4938a6d_terseLabel_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_sny_AtNotionalAmountMember_label_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Notional Amount [member]</link:label>
    <link:label id="lab_sny_AtNotionalAmountMember_documentation_en-US" xlink:label="lab_sny_AtNotionalAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At notional amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember" xlink:href="sny-20231231.xsd#sny_AtNotionalAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AtNotionalAmountMember" xlink:to="lab_sny_AtNotionalAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfActionDeclaredTimeBarred_20a9840f-3f58-4441-bdba-1b96dca71a96_terseLabel_en-US" xlink:label="lab_sny_NumberOfActionDeclaredTimeBarred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of action declared time-barred</link:label>
    <link:label id="lab_sny_NumberOfActionDeclaredTimeBarred_label_en-US" xlink:label="lab_sny_NumberOfActionDeclaredTimeBarred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Action Declared Time-Barred</link:label>
    <link:label id="lab_sny_NumberOfActionDeclaredTimeBarred_documentation_en-US" xlink:label="lab_sny_NumberOfActionDeclaredTimeBarred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Action Declared Time-Barred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfActionDeclaredTimeBarred" xlink:href="sny-20231231.xsd#sny_NumberOfActionDeclaredTimeBarred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfActionDeclaredTimeBarred" xlink:to="lab_sny_NumberOfActionDeclaredTimeBarred" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_e61ffb57-3535-49de-94ef-9be69d2d3806_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other operating expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_3dc4dff8-7d99-4824-b3c7-89aafb3e499d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiManufacturingPteLtdMember_8d7302e6-4dcb-4e13-8045-7bfc9032133f_terseLabel_en-US" xlink:label="lab_sny_SanofiManufacturingPteLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Manufacturing Pte Ltd</link:label>
    <link:label id="lab_sny_SanofiManufacturingPteLtdMember_label_en-US" xlink:label="lab_sny_SanofiManufacturingPteLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Manufacturing Pte Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiManufacturingPteLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiManufacturingPteLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Manufacturing Pte Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiManufacturingPteLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiManufacturingPteLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiManufacturingPteLtdMember" xlink:to="lab_sny_SanofiManufacturingPteLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_3c591ba9-c11a-42f2-8619-34cbf66c721d_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income/(expenses), net related to Regeneron</link:label>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_21885788-2ebf-4973-9397-24d819e7e5ff_negatedLabel_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating (income)/expenses, net</link:label>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_7259163a-25f4-482f-87ab-6dd196b5ee76_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year 5</link:label>
    <link:label id="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_12d192f8-e59f-499f-86e6-f728596f3a69_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4 to 5 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than four years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_f49cb59a-c92f-4b6b-bc32-7ad99d7eafd1_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_3a4a4b3d-5601-4220-ab5c-591969264213_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Number&#160;of options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities_ff105634-be00-4ab4-843c-b03955c73993_verboseLabel_en-US" xlink:label="lab_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends received from non-consolidated entities</link:label>
    <link:label id="lab_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Received from Non-Consolidated Entities Classified As Operating Activities</link:label>
    <link:label id="lab_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities_documentation_en-US" xlink:label="lab_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends received from non-consolidated entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities" xlink:href="sny-20231231.xsd#sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities" xlink:to="lab_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherPropertyPlantAndEquipmentMember_1ee8b568-43db-4fad-a016-8f99b60b3569_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherPropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FabrazymeMember_abb4940c-8589-43d6-b858-062de94f8b3d_terseLabel_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FABRAZYME</link:label>
    <link:label id="lab_sny_FabrazymeMember_label_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fabrazyme [Member]</link:label>
    <link:label id="lab_sny_FabrazymeMember_documentation_en-US" xlink:label="lab_sny_FabrazymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fabrazyme [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember" xlink:href="sny-20231231.xsd#sny_FabrazymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FabrazymeMember" xlink:to="lab_sny_FabrazymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_302bdb98-dca0-4981-8fc9-aed948c4a61e_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProventionBioMember_7596aa19-41a4-4bba-af9b-f5031d5ae1c2_terseLabel_en-US" xlink:label="lab_sny_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio</link:label>
    <link:label id="lab_sny_ProventionBioMember_label_en-US" xlink:label="lab_sny_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio [Member]</link:label>
    <link:label id="lab_sny_ProventionBioMember_documentation_en-US" xlink:label="lab_sny_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioMember" xlink:href="sny-20231231.xsd#sny_ProventionBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProventionBioMember" xlink:to="lab_sny_ProventionBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_c400367f-9703-4051-818d-8cef91a3115d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInventoriesTable_a59374cb-78dc-481e-ba63-8ed0713ec3c4_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInventoriesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of inventories [table]</link:label>
    <link:label id="lab_sny_DisclosureOfInventoriesTable_label_en-US" xlink:label="lab_sny_DisclosureOfInventoriesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Inventories [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfInventoriesTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfInventoriesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInventoriesTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfInventoriesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInventoriesTable" xlink:to="lab_sny_DisclosureOfInventoriesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019_cb0e859f-0994-4d62-a50b-b63e9651f56d_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement age</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of retirement age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:to="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherProvisionsMember_d3c6a285-888e-4145-ab41-97dba5792fd6_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:to="lab_ifrs-full_MiscellaneousOtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockSubscriptionOptionPlanTenMember_1e74e2f8-c92c-41ff-bdc2-38ae0df7b356_terseLabel_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan ten</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanTenMember_label_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Option Plan Ten [Member]</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanTenMember_documentation_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan ten.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanTenMember" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockSubscriptionOptionPlanTenMember" xlink:to="lab_sny_StockSubscriptionOptionPlanTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock_aa53a7d5-9fe0-4ae0-823c-f17c3b0bf414_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Movements Share Capital</link:label>
    <link:label id="lab_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Statement Of Changes In Equity Of Parent [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of statement of changes in equity of parent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock" xlink:to="lab_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations_d9a7b933-99aa-4573-908a-f2a074cf828c_terseLabel_en-US" xlink:label="lab_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of profits and losses arising from commercial operations</link:label>
    <link:label id="lab_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations_label_en-US" xlink:label="lab_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Profits And Losses Arising From Commercial Operations</link:label>
    <link:label id="lab_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations_documentation_en-US" xlink:label="lab_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of profits and losses arising from commercial operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations" xlink:to="lab_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SyndicatedCreditFacilityCanceledMember_d28998b5-b9a2-49fb-b7a9-c77462b2374b_terseLabel_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syndicated credit facility canceled</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityCanceledMember_label_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syndicated Credit Facility Canceled [Member]</link:label>
    <link:label id="lab_sny_SyndicatedCreditFacilityCanceledMember_documentation_en-US" xlink:label="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Syndicated Credit Facility Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityCanceledMember" xlink:href="sny-20231231.xsd#sny_SyndicatedCreditFacilityCanceledMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SyndicatedCreditFacilityCanceledMember" xlink:to="lab_sny_SyndicatedCreditFacilityCanceledMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_89b58e09-d6bb-4e51-8e39-f3641177fcd6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_30fb172e-b570-458d-a1c1-661d101a3294_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top of range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FinancialInvestments_9be4685d-8327-419e-9214-c09e60882b14_terseLabel_en-US" xlink:label="lab_sny_FinancialInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial investments</link:label>
    <link:label id="lab_sny_FinancialInvestments_label_en-US" xlink:label="lab_sny_FinancialInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Investments</link:label>
    <link:label id="lab_sny_FinancialInvestments_documentation_en-US" xlink:label="lab_sny_FinancialInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of financial assets that are classified as financial assets available-for-sale, held-to-maturity investments or loans and receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInvestments" xlink:href="sny-20231231.xsd#sny_FinancialInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FinancialInvestments" xlink:to="lab_sny_FinancialInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_7c136e7c-111a-4227-a9bb-4cc06d63174b_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(decrease) in accounts payable</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareUKLimitedMember_f30de9ba-8c9e-47b6-b6cf-ff62cb741bab_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareUKLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare UK Limited</link:label>
    <link:label id="lab_sny_OpellaHealthcareUKLimitedMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareUKLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare UK Limited [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareUKLimitedMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareUKLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare UK Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareUKLimitedMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareUKLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareUKLimitedMember" xlink:to="lab_sny_OpellaHealthcareUKLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WriteDownMember_29e470ac-d5c6-4494-80c2-a5f5f2265860_terseLabel_en-US" xlink:label="lab_sny_WriteDownMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances</link:label>
    <link:label id="lab_sny_WriteDownMember_label_en-US" xlink:label="lab_sny_WriteDownMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-down [member]</link:label>
    <link:label id="lab_sny_WriteDownMember_documentation_en-US" xlink:label="lab_sny_WriteDownMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write down.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WriteDownMember" xlink:href="sny-20231231.xsd#sny_WriteDownMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WriteDownMember" xlink:to="lab_sny_WriteDownMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_d9e5de86-dbf6-44ad-95b4-59bcc7b0e320_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisRechercheEtDeveloppementMember_903b8e2e-2632-452b-8dc8-b627aef62c1b_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisRechercheEtDeveloppementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Recherche &amp; D&#233;veloppement</link:label>
    <link:label id="lab_sny_SanofiAventisRechercheEtDeveloppementMember_label_en-US" xlink:label="lab_sny_SanofiAventisRechercheEtDeveloppementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Recherche Et Developpement [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisRechercheEtDeveloppementMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisRechercheEtDeveloppementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi aventis Recherche et Developpement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisRechercheEtDeveloppementMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisRechercheEtDeveloppementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisRechercheEtDeveloppementMember" xlink:to="lab_sny_SanofiAventisRechercheEtDeveloppementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfClaimantExposed_12026a85-5325-4f20-bd37-1b991b309038_terseLabel_en-US" xlink:label="lab_sny_NumberOfClaimantExposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claimant exposed</link:label>
    <link:label id="lab_sny_NumberOfClaimantExposed_label_en-US" xlink:label="lab_sny_NumberOfClaimantExposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claimant Exposed</link:label>
    <link:label id="lab_sny_NumberOfClaimantExposed_documentation_en-US" xlink:label="lab_sny_NumberOfClaimantExposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claimant Exposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClaimantExposed" xlink:href="sny-20231231.xsd#sny_NumberOfClaimantExposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfClaimantExposed" xlink:to="lab_sny_NumberOfClaimantExposed" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PaymentRelatedToAttainmentOfGoal_e533de81-09c3-45be-acf2-4923f250d395_terseLabel_en-US" xlink:label="lab_sny_PaymentRelatedToAttainmentOfGoal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment related to attainment of goal</link:label>
    <link:label id="lab_sny_PaymentRelatedToAttainmentOfGoal_label_en-US" xlink:label="lab_sny_PaymentRelatedToAttainmentOfGoal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Related To Attainment Of Goal</link:label>
    <link:label id="lab_sny_PaymentRelatedToAttainmentOfGoal_documentation_en-US" xlink:label="lab_sny_PaymentRelatedToAttainmentOfGoal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Related To Attainment Of Goal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentRelatedToAttainmentOfGoal" xlink:href="sny-20231231.xsd#sny_PaymentRelatedToAttainmentOfGoal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PaymentRelatedToAttainmentOfGoal" xlink:to="lab_sny_PaymentRelatedToAttainmentOfGoal" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeLineItems_82208f69-4528-4766-8644-b211e74ac78f_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Operating Income [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Operating Income [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Operating Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeLineItems" xlink:to="lab_sny_DisclosureOfOtherOperatingIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod_a5121af5-8eaa-4458-b205-ded18e8b755f_terseLabel_en-US" xlink:label="lab_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in provisions recognized in profit or loss for the period</link:label>
    <link:label id="lab_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod_label_en-US" xlink:label="lab_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Provisions Recognized In Profit Or Loss For The Period</link:label>
    <link:label id="lab_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod_documentation_en-US" xlink:label="lab_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in provisions recognized in profit or loss for the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod" xlink:href="sny-20231231.xsd#sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod" xlink:to="lab_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_46332792-4781-401b-b5cd-dee0958202f8_terseLabel_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of debt instruments included in financial assets</link:label>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_label_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) On Remeasuring Debt Instruments, Before Tax</link:label>
    <link:label id="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_documentation_en-US" xlink:label="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) On Remeasuring Debt Instruments, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:href="sny-20231231.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:to="lab_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs_dcc18371-da18-4f0a-a54c-c9afeef3f6c6_terseLabel_en-US" xlink:label="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced amount of compensation claimed</link:label>
    <link:label id="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs_label_en-US" xlink:label="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced Amount Of Compensation Claimed By Filled Plaintiffs</link:label>
    <link:label id="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs_documentation_en-US" xlink:label="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced Amount Of Compensation Claimed By Filled Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs" xlink:href="sny-20231231.xsd#sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs" xlink:to="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b86046a8-e111-4771-a1a3-9fc46bf64c13_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_44d41ae7-226f-4d4a-875f-1c05101556b7_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty_877e192f-c18d-49c7-9a8c-48c8f73ae498_terseLabel_en-US" xlink:label="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase III costs, responsibility percentage for Regeneron</link:label>
    <link:label id="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty_label_en-US" xlink:label="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Second Part Of Development Costs Funded By Other Party</link:label>
    <link:label id="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty_documentation_en-US" xlink:label="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of second part of development costs funded by other party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty" xlink:href="sny-20231231.xsd#sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty" xlink:to="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CarraigInsuranceDACMember_57301948-a910-46da-9074-af7cfff37811_terseLabel_en-US" xlink:label="lab_sny_CarraigInsuranceDACMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carraig Insurance DAC</link:label>
    <link:label id="lab_sny_CarraigInsuranceDACMember_label_en-US" xlink:label="lab_sny_CarraigInsuranceDACMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carraig Insurance DAC [member]</link:label>
    <link:label id="lab_sny_CarraigInsuranceDACMember_documentation_en-US" xlink:label="lab_sny_CarraigInsuranceDACMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carraig Insurance DAC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CarraigInsuranceDACMember" xlink:href="sny-20231231.xsd#sny_CarraigInsuranceDACMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CarraigInsuranceDACMember" xlink:to="lab_sny_CarraigInsuranceDACMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsBioverativMember_6086c3aa-5ef7-495d-b3ec-975062cd60a7_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsBioverativMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsBioverativMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsBioverativMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Bioverativ [Member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsBioverativMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsBioverativMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Bioverativ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsBioverativMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsBioverativMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsBioverativMember" xlink:to="lab_sny_PrincipalMarketedProductsBioverativMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios_b0bc1522-2903-4806-b42e-a5cc6912eb38_terseLabel_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program, number of global warming scenarios</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios_label_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Number Of Global Warming Scenarios</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios_documentation_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Number Of Global Warming Scenarios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios" xlink:to="lab_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_e102a9e2-77c3-4d41-8631-47ea0847b619_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:to="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RoyaltyIncomePercentage_ef868999-91d0-421c-8fde-7449a9cf5199_terseLabel_en-US" xlink:label="lab_sny_RoyaltyIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty income percentage (percentage)</link:label>
    <link:label id="lab_sny_RoyaltyIncomePercentage_label_en-US" xlink:label="lab_sny_RoyaltyIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Percentage</link:label>
    <link:label id="lab_sny_RoyaltyIncomePercentage_documentation_en-US" xlink:label="lab_sny_RoyaltyIncomePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltyIncomePercentage" xlink:href="sny-20231231.xsd#sny_RoyaltyIncomePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RoyaltyIncomePercentage" xlink:to="lab_sny_RoyaltyIncomePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MultiemployerDefinedBenefitPlansMember_c72e9a06-f24f-4963-95ec-86f18bc04830_terseLabel_en-US" xlink:label="lab_ifrs-full_MultiemployerDefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multi-employer plan (Pensionskasses)</link:label>
    <link:label id="lab_ifrs-full_MultiemployerDefinedBenefitPlansMember_label_en-US" xlink:label="lab_ifrs-full_MultiemployerDefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multi-employer defined benefit plans [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MultiemployerDefinedBenefitPlansMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MultiemployerDefinedBenefitPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MultiemployerDefinedBenefitPlansMember" xlink:to="lab_ifrs-full_MultiemployerDefinedBenefitPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfComplaintsFiled_b5393952-1991-48fd-be6a-bdce839c93ce_terseLabel_en-US" xlink:label="lab_sny_NumberOfComplaintsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of complaints filed</link:label>
    <link:label id="lab_sny_NumberOfComplaintsFiled_label_en-US" xlink:label="lab_sny_NumberOfComplaintsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Complaints Filed</link:label>
    <link:label id="lab_sny_NumberOfComplaintsFiled_documentation_en-US" xlink:label="lab_sny_NumberOfComplaintsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Complaints Filed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfComplaintsFiled" xlink:href="sny-20231231.xsd#sny_NumberOfComplaintsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfComplaintsFiled" xlink:to="lab_sny_NumberOfComplaintsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember_4d901ecf-8a7f-492c-b7de-a57796f0f862_terseLabel_en-US" xlink:label="lab_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Euro and US dollar short-term interest rates</link:label>
    <link:label id="lab_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember_label_en-US" xlink:label="lab_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Euro And US Dollar Short-term Interest Rates [Member]</link:label>
    <link:label id="lab_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember_documentation_en-US" xlink:label="lab_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Euro and US dollar short-term interest rates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember" xlink:href="sny-20231231.xsd#sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember" xlink:to="lab_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Accruals_d17bfb96-5bd2-4af5-9406-58e2e96b85c1_terseLabel_en-US" xlink:label="lab_ifrs-full_Accruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals</link:label>
    <link:label id="lab_ifrs-full_Accruals_label_en-US" xlink:label="lab_ifrs-full_Accruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Accruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Accruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Accruals" xlink:to="lab_ifrs-full_Accruals" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_2d835a08-eaf4-4a9e-a129-0e8ed99428e9_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DefendantsMember_f02db68e-b078-46ef-9621-f5fe59038354_terseLabel_en-US" xlink:label="lab_sny_DefendantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defendants [Member]</link:label>
    <link:label id="lab_sny_DefendantsMember_label_en-US" xlink:label="lab_sny_DefendantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defendants [Member]</link:label>
    <link:label id="lab_sny_DefendantsMember_documentation_en-US" xlink:label="lab_sny_DefendantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defendant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantsMember" xlink:href="sny-20231231.xsd#sny_DefendantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DefendantsMember" xlink:to="lab_sny_DefendantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_ac998d7d-7b3f-4721-b199-edc2a8a70fea_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [axis]</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_29c51125-4806-4194-82f0-3aa2e3cbe9e3_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_059f731b-3c9a-412f-8670-42d5479dc41c_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisCanadaIncMember_adc7754d-2d9f-4090-bfc1-7f247f35972c_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisCanadaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Canada Inc.</link:label>
    <link:label id="lab_sny_SanofiAventisCanadaIncMember_label_en-US" xlink:label="lab_sny_SanofiAventisCanadaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Canada Inc [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisCanadaIncMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisCanadaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Canada Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisCanadaIncMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisCanadaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisCanadaIncMember" xlink:to="lab_sny_SanofiAventisCanadaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_efb4442a-6760-4eb8-ba0e-c1f7f38c7130_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2029 to 2033</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than five years and not later than ten years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SalesOfAntibodiesFirstAchievementMember_f04fcf04-f2da-4101-acae-dca3bc670f74_terseLabel_en-US" xlink:label="lab_sny_SalesOfAntibodiesFirstAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of antibodies, first achievement</link:label>
    <link:label id="lab_sny_SalesOfAntibodiesFirstAchievementMember_label_en-US" xlink:label="lab_sny_SalesOfAntibodiesFirstAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Of Antibodies, First Achievement [Member]</link:label>
    <link:label id="lab_sny_SalesOfAntibodiesFirstAchievementMember_documentation_en-US" xlink:label="lab_sny_SalesOfAntibodiesFirstAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Of Antibodies, First Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesOfAntibodiesFirstAchievementMember" xlink:href="sny-20231231.xsd#sny_SalesOfAntibodiesFirstAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SalesOfAntibodiesFirstAchievementMember" xlink:to="lab_sny_SalesOfAntibodiesFirstAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CambridgeMassachusettsMember_f0de7e0d-bacd-4819-b6c3-627bb7d7f890_terseLabel_en-US" xlink:label="lab_sny_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts</link:label>
    <link:label id="lab_sny_CambridgeMassachusettsMember_label_en-US" xlink:label="lab_sny_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_sny_CambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_sny_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CambridgeMassachusettsMember" xlink:href="sny-20231231.xsd#sny_CambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CambridgeMassachusettsMember" xlink:to="lab_sny_CambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock_f64ecb78-e6f6-40eb-b69c-4ce40857c3ee_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to business combinations and to non-controlling interests</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Non-Controlling Interests Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for liabilities related to business combination and to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_e626bafe-ceee-469a-8cf7-305c35bb2d0c_terseLabel_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not eligible for hedge accounting</link:label>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_label_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Eligible For Hedge Accounting [Member]</link:label>
    <link:label id="lab_sny_NotEligibleForHedgeAccountingMember_documentation_en-US" xlink:label="lab_sny_NotEligibleForHedgeAccountingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not eligible for hedge accounting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember" xlink:href="sny-20231231.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NotEligibleForHedgeAccountingMember" xlink:to="lab_sny_NotEligibleForHedgeAccountingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfIndividualCasesSettled_a01443ee-026f-4d08-94df-f9678c3179ec_terseLabel_en-US" xlink:label="lab_sny_NumberOfIndividualCasesSettled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual cases settled</link:label>
    <link:label id="lab_sny_NumberOfIndividualCasesSettled_label_en-US" xlink:label="lab_sny_NumberOfIndividualCasesSettled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Individual Cases Settled</link:label>
    <link:label id="lab_sny_NumberOfIndividualCasesSettled_documentation_en-US" xlink:label="lab_sny_NumberOfIndividualCasesSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Individual Cases Settled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfIndividualCasesSettled" xlink:href="sny-20231231.xsd#sny_NumberOfIndividualCasesSettled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfIndividualCasesSettled" xlink:to="lab_sny_NumberOfIndividualCasesSettled" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_5b01b126-8c18-4980-9c8e-a7d052db1d6b_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1_9a24f4a8-a727-4516-babc-10518e031034_terseLabel_en-US" xlink:label="lab_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual agreement for anti-programmed cell death protein</link:label>
    <link:label id="lab_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1_label_en-US" xlink:label="lab_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Agreement For Anti-programmed Cell Death Protein1</link:label>
    <link:label id="lab_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1_documentation_en-US" xlink:label="lab_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Agreement For Anti-programmed Cell Death Protein1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1" xlink:href="sny-20231231.xsd#sny_ContractualAgreementForAntiProgrammedCellDeathProtein1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1" xlink:to="lab_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f08b1a0e-23c9-4cbd-a86d-7fa80a8189e3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_c1d241de-96d3-4bba-a798-e1da092b304b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Legal and Arbitral Proceedings [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of legal and arbitral proceedings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_QuotedEuroDenominatedSeniorBondsMember_7082ace2-0541-4bc6-8578-a0164aad88eb_terseLabel_en-US" xlink:label="lab_sny_QuotedEuroDenominatedSeniorBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted euro denominated senior bonds</link:label>
    <link:label id="lab_sny_QuotedEuroDenominatedSeniorBondsMember_label_en-US" xlink:label="lab_sny_QuotedEuroDenominatedSeniorBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Euro Denominated Senior Bonds [Member]</link:label>
    <link:label id="lab_sny_QuotedEuroDenominatedSeniorBondsMember_documentation_en-US" xlink:label="lab_sny_QuotedEuroDenominatedSeniorBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted euro denominated senior bonds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedEuroDenominatedSeniorBondsMember" xlink:href="sny-20231231.xsd#sny_QuotedEuroDenominatedSeniorBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_QuotedEuroDenominatedSeniorBondsMember" xlink:to="lab_sny_QuotedEuroDenominatedSeniorBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxRateEffectOfForeignTaxRates_e7b220b5-917a-441e-ad39-1f4f6187adb0_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference between the standard French tax rate and the rates applicable to the Sanofi</link:label>
    <link:label id="lab_ifrs-full_TaxRateEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax rate effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxRateEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_00bf2beb-d29d-439f-aa0f-cffba8f93ac7_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired_b1e5a5ea-74ec-4d65-aabf-aa5e0e33ea6d_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
    <link:label id="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired_label_en-US" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllOtherSegmentsMember_26902738-e814-4f96-9cde-3dcbda15f048_verboseLabel_en-US" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_AllOtherSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllOtherSegmentsMember" xlink:to="lab_ifrs-full_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_bb95815e-b7e6-4ec5-92d2-a1c84bd58cf9_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes</link:label>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Allocation Of Income Tax Between Current And Deferred Taxes [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of allocation of income tax between current and deferred taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:to="lab_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_541d965c-da0f-44dd-b1f1-85f07bd2ed47_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property, Plant and Equipment Leased</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_3b7850b0-502b-47aa-a701-e6a2ba30b207_terseLabel_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Arbitral Proceedings [Domain]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_label_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Arbitral Proceedings [Domain]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsDomain_documentation_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Legal And Arbitral Proceedings [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain" xlink:href="sny-20231231.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain" xlink:to="lab_sny_LegalAndArbitralProceedingsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_bfbcb5b1-05bd-4ffc-8e39-35b49ad574ac_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrencyDerivativesMeasuredAtFairValue_7c7454d3-5ef0-47e8-aa89-bf43c52c7f1f_terseLabel_en-US" xlink:label="lab_sny_CurrencyDerivativesMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency derivatives measured at fair value (see Note&#160;D.20.)</link:label>
    <link:label id="lab_sny_CurrencyDerivativesMeasuredAtFairValue_label_en-US" xlink:label="lab_sny_CurrencyDerivativesMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Derivatives Measured At Fair Value</link:label>
    <link:label id="lab_sny_CurrencyDerivativesMeasuredAtFairValue_documentation_en-US" xlink:label="lab_sny_CurrencyDerivativesMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency derivatives measured at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesMeasuredAtFairValue" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesMeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrencyDerivativesMeasuredAtFairValue" xlink:to="lab_sny_CurrencyDerivativesMeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_d8c726a9-bd93-456c-a120-689e8d7aaeff_terseLabel_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper program in USA</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_label_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper Program In USA [Member]</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInUSAMember_documentation_en-US" xlink:label="lab_sny_CommercialPaperProgramInUSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper program in USA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember" xlink:href="sny-20231231.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercialPaperProgramInUSAMember" xlink:to="lab_sny_CommercialPaperProgramInUSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_09aa88f0-b494-4ff8-9d60-5db4fc58f242_terseLabel_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swedish Orphan Biovitrum AB</link:label>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_label_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swedish Orphan Biovitrum AB [Member]</link:label>
    <link:label id="lab_sny_SwedishOrphanBiovitrumABMember_documentation_en-US" xlink:label="lab_sny_SwedishOrphanBiovitrumABMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swedish Orphan Biovitrum AB</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember" xlink:href="sny-20231231.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SwedishOrphanBiovitrumABMember" xlink:to="lab_sny_SwedishOrphanBiovitrumABMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_74783ec8-32fd-4417-9910-72695f5c6e27_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted shares and vesting of existing restricted shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis_2c6ba53f-7995-4ebb-9a71-6308849bd75f_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [axis]</link:label>
    <link:label id="lab_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis_label_en-US" xlink:label="lab_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:to="lab_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CerezymeMember_18e8f672-8106-4cb1-a2c8-0a798cd03957_terseLabel_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEREZYME</link:label>
    <link:label id="lab_sny_CerezymeMember_label_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cerezyme [Member]</link:label>
    <link:label id="lab_sny_CerezymeMember_documentation_en-US" xlink:label="lab_sny_CerezymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cerezyme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember" xlink:href="sny-20231231.xsd#sny_CerezymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CerezymeMember" xlink:to="lab_sny_CerezymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember_ba3b68be-f2e0-48da-a4ba-6fb0d60fc8e6_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate and currency derivatives used to manage debt</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Interest Rate And Currency Derivatives Used To Manage Debt [Member]</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate and currency derivatives used to manage debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember" xlink:to="lab_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_bef86937-ac5e-439c-b3a4-42f490d4db72_terseLabel_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_label_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_sny_FinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_sny_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FinancialInstrumentsAbstract" xlink:to="lab_sny_FinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_b654eddb-2626-42ea-8ceb-feb6cde40c90_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_ifrs-full_Equity_85e1ba00-328f-4875-b2b5-6c55691a2423_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_Equity_0f3b489e-0bb4-42de-8bb6-55d9b9b80ae2_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PossibleIncreaseInMortalityTableInYears_17e841ec-f022-43b0-be7b-b1dc033c4214_terseLabel_en-US" xlink:label="lab_sny_PossibleIncreaseInMortalityTableInYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible increase in mortality table (in years)</link:label>
    <link:label id="lab_sny_PossibleIncreaseInMortalityTableInYears_label_en-US" xlink:label="lab_sny_PossibleIncreaseInMortalityTableInYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible Increase In Mortality Table In Years</link:label>
    <link:label id="lab_sny_PossibleIncreaseInMortalityTableInYears_documentation_en-US" xlink:label="lab_sny_PossibleIncreaseInMortalityTableInYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible increase in mortality table in years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PossibleIncreaseInMortalityTableInYears" xlink:href="sny-20231231.xsd#sny_PossibleIncreaseInMortalityTableInYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PossibleIncreaseInMortalityTableInYears" xlink:to="lab_sny_PossibleIncreaseInMortalityTableInYears" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PaymentOfDamagesClaimedByCounterparty_3e34249b-9cf7-458e-87f0-73e95c0cd076_terseLabel_en-US" xlink:label="lab_sny_PaymentOfDamagesClaimedByCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of damages claimed by the French CNAM (French Social Security)</link:label>
    <link:label id="lab_sny_PaymentOfDamagesClaimedByCounterparty_label_en-US" xlink:label="lab_sny_PaymentOfDamagesClaimedByCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Damages Claimed By Counterparty</link:label>
    <link:label id="lab_sny_PaymentOfDamagesClaimedByCounterparty_documentation_en-US" xlink:label="lab_sny_PaymentOfDamagesClaimedByCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Damages Claimed By Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentOfDamagesClaimedByCounterparty" xlink:href="sny-20231231.xsd#sny_PaymentOfDamagesClaimedByCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PaymentOfDamagesClaimedByCounterparty" xlink:to="lab_sny_PaymentOfDamagesClaimedByCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementCommitmentAmount_59918b8c-c703-4fa6-999e-70785cdcd532_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, commitment amount</link:label>
    <link:label id="lab_sny_CollaborationAgreementCommitmentAmount_label_en-US" xlink:label="lab_sny_CollaborationAgreementCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Commitment Amount</link:label>
    <link:label id="lab_sny_CollaborationAgreementCommitmentAmount_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Commitment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementCommitmentAmount" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementCommitmentAmount" xlink:to="lab_sny_CollaborationAgreementCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_78b2ecd0-38a9-434b-88c7-5238629ef59d_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_0e719444-3649-4601-93e7-c817efca408b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Operating Segments Reconciling Items [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of operating segments reconciling items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:to="lab_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialAssets_e5184220-89b5-4bc5-9293-b6361ccd2ea6_totalLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialAssets_287a181a-b736-412b-9b95-5c4457aefc82_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial assets</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialAssets" xlink:to="lab_ifrs-full_DerivativeFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember_5029732d-2ffe-4054-abf7-e9f0754db503_terseLabel_en-US" xlink:label="lab_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American&#160;Depositary&#160;Shares,&#160;each&#160;representing one half of one ordinary share, par value &#8364;2&#160;per&#160;share</link:label>
    <link:label id="lab_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember_label_en-US" xlink:label="lab_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares, NASDAQ Global Select Market [Member]</link:label>
    <link:label id="lab_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember_documentation_en-US" xlink:label="lab_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares, NASDAQ Global Select Market [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember" xlink:href="sny-20231231.xsd#sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember" xlink:to="lab_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_9179ef47-f06f-4362-a712-24a4e49932c5_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_dc84eef9-678d-4497-9e25-c74576a44661_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Acquisitions Of Property Plant And Equipment And Other Intangible Assets And Carrying Amount Of Investments In Associates And Joint Ventures By Operating Segment [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:to="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NewAgreementMember_28f6ed50-774d-4ca6-adb5-4c011006205d_terseLabel_en-US" xlink:label="lab_sny_NewAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New agreement</link:label>
    <link:label id="lab_sny_NewAgreementMember_label_en-US" xlink:label="lab_sny_NewAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Agreement [Member]</link:label>
    <link:label id="lab_sny_NewAgreementMember_documentation_en-US" xlink:label="lab_sny_NewAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NewAgreementMember" xlink:href="sny-20231231.xsd#sny_NewAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NewAgreementMember" xlink:to="lab_sny_NewAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements_99f3fd78-93b5-4197-a4d4-fab18bcef814_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments related to collaboration, discovery, development and commercialization agreements</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Collaboration, Discovery, Development And Commercialization Agreements</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Collaboration, Discovery, Development And Commercialization Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" xlink:to="lab_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_eb293d01-6b90-4a53-b9cb-ea0edcd9b194_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income)/cost</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment_5777a2c9-9f5a-4206-8534-07014c102c8c_negatedLabel_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals and other decreases</link:label>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals and retirements, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrument1Axis_dd58f776-39e3-4f6d-9c7e-6b47b958500b_terseLabel_en-US" xlink:label="lab_sny_DebtInstrument1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_sny_DebtInstrument1Axis_label_en-US" xlink:label="lab_sny_DebtInstrument1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument1 [Axis]</link:label>
    <link:label id="lab_sny_DebtInstrument1Axis_documentation_en-US" xlink:label="lab_sny_DebtInstrument1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrument1Axis" xlink:href="sny-20231231.xsd#sny_DebtInstrument1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrument1Axis" xlink:to="lab_sny_DebtInstrument1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisHoldingsIrelandLtdMember_9dca6d49-6c7b-4aef-a392-6643240a6255_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisHoldingsIrelandLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Holdings (Ireland) Ltd</link:label>
    <link:label id="lab_sny_SanofiAventisHoldingsIrelandLtdMember_label_en-US" xlink:label="lab_sny_SanofiAventisHoldingsIrelandLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Holdings (Ireland) Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisHoldingsIrelandLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisHoldingsIrelandLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Holdings (Ireland) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisHoldingsIrelandLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisHoldingsIrelandLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisHoldingsIrelandLtdMember" xlink:to="lab_sny_SanofiAventisHoldingsIrelandLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_74b46866-fcaf-4b4e-bd45-03bebf13345c_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_5164e150-412a-4e33-a340-052463125f68_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_874e081f-1729-445b-98b3-6cb963681dc1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:to="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ALTUVIIIOMember_8cd0af2a-2d39-4eb3-96bb-1b052f717f35_terseLabel_en-US" xlink:label="lab_sny_ALTUVIIIOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALTUVIIIO</link:label>
    <link:label id="lab_sny_ALTUVIIIOMember_label_en-US" xlink:label="lab_sny_ALTUVIIIOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALTUVIIIO [Member]</link:label>
    <link:label id="lab_sny_ALTUVIIIOMember_documentation_en-US" xlink:label="lab_sny_ALTUVIIIOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALTUVIIIO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ALTUVIIIOMember" xlink:href="sny-20231231.xsd#sny_ALTUVIIIOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ALTUVIIIOMember" xlink:to="lab_sny_ALTUVIIIOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_540f52e3-cfc1-4617-933f-7fc86aac7c65_terseLabel_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Euro Medium Term Notes (EMTN) bonds</link:label>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_label_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Euro Medium Term Notes [Member]</link:label>
    <link:label id="lab_sny_SanofiEuroMediumTermNotesMember_documentation_en-US" xlink:label="lab_sny_SanofiEuroMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Euro Medium Term Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember" xlink:href="sny-20231231.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiEuroMediumTermNotesMember" xlink:to="lab_sny_SanofiEuroMediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TranslateBioMember_b1a87e7f-a856-4dfd-8fcf-1a929ffa5c2a_terseLabel_en-US" xlink:label="lab_sny_TranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translate Bio</link:label>
    <link:label id="lab_sny_TranslateBioMember_label_en-US" xlink:label="lab_sny_TranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translate Bio [Member]</link:label>
    <link:label id="lab_sny_TranslateBioMember_documentation_en-US" xlink:label="lab_sny_TranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translate Bio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioMember" xlink:href="sny-20231231.xsd#sny_TranslateBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TranslateBioMember" xlink:to="lab_sny_TranslateBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_ade6fd99-934e-4452-a813-e857872910ee_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GoldBondProductLitigationInTheUSMember_66a02339-919f-46c0-be53-e773e7ce375e_terseLabel_en-US" xlink:label="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gold Bond Product litigation in the US</link:label>
    <link:label id="lab_sny_GoldBondProductLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gold Bond Product Litigation In The US [Member]</link:label>
    <link:label id="lab_sny_GoldBondProductLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gold Bond Product Litigation In The US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoldBondProductLitigationInTheUSMember" xlink:href="sny-20231231.xsd#sny_GoldBondProductLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GoldBondProductLitigationInTheUSMember" xlink:to="lab_sny_GoldBondProductLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BlackstoneLifeSciencesMember_cf47129f-7bac-4979-ae9e-665a94afb3be_terseLabel_en-US" xlink:label="lab_sny_BlackstoneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Life Sciences</link:label>
    <link:label id="lab_sny_BlackstoneLifeSciencesMember_label_en-US" xlink:label="lab_sny_BlackstoneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Life Sciences [Member]</link:label>
    <link:label id="lab_sny_BlackstoneLifeSciencesMember_documentation_en-US" xlink:label="lab_sny_BlackstoneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blackstone Life Sciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BlackstoneLifeSciencesMember" xlink:href="sny-20231231.xsd#sny_BlackstoneLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BlackstoneLifeSciencesMember" xlink:to="lab_sny_BlackstoneLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedMeasurementMember_b4d5dfa7-f1ff-4c29-b2b4-5dcd24776fa2_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated measurement</link:label>
    <link:label id="lab_ifrs-full_AggregatedMeasurementMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated measurement [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedMeasurementMember" xlink:to="lab_ifrs-full_AggregatedMeasurementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_954b3ce8-2279-4053-ae8a-019406a14016_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management of capital</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for issued capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockSubscriptionOptionPlanMember_73e1732c-4a1f-457d-bfe0-c6363afa4af9_terseLabel_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanMember_label_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Option Plan [Member]</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanMember_documentation_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanMember" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockSubscriptionOptionPlanMember" xlink:to="lab_sny_StockSubscriptionOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_aab9c9f6-9f70-4496-b9b2-595fdc612d61_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful lives or depreciation rates, property, plant and equipment (in years)</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember_b9ac46b9-92b7-48b8-a763-489bd7714f26_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset) [member]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset) [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityInvestmentSoldPercentage_4332996c-11a1-4b1a-a751-583296f97871_terseLabel_en-US" xlink:label="lab_sny_EquityInvestmentSoldPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate participation percentage of legacy companies in ACS</link:label>
    <link:label id="lab_sny_EquityInvestmentSoldPercentage_label_en-US" xlink:label="lab_sny_EquityInvestmentSoldPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Sold Percentage</link:label>
    <link:label id="lab_sny_EquityInvestmentSoldPercentage_documentation_en-US" xlink:label="lab_sny_EquityInvestmentSoldPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment sold percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInvestmentSoldPercentage" xlink:href="sny-20231231.xsd#sny_EquityInvestmentSoldPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityInvestmentSoldPercentage" xlink:to="lab_sny_EquityInvestmentSoldPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentsMember_f3f525e5-6ce2-4c5c-bd82-ccd8d5c32c90_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [member]</link:label>
    <link:label id="lab_ifrs-full_SegmentsMember_label_en-US" xlink:label="lab_ifrs-full_SegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsMember" xlink:to="lab_ifrs-full_SegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable_cc2640d1-f359-44d6-98e1-e8e238516b7b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-Based Payment [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-Based Payment [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-Based Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_HoechstGmbHMember_ffe536c3-fbae-4a94-86e8-415f013cf473_terseLabel_en-US" xlink:label="lab_sny_HoechstGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hoechst GmbH</link:label>
    <link:label id="lab_sny_HoechstGmbHMember_label_en-US" xlink:label="lab_sny_HoechstGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hoechst Gmbh [member]</link:label>
    <link:label id="lab_sny_HoechstGmbHMember_documentation_en-US" xlink:label="lab_sny_HoechstGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hoechst GmbH.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HoechstGmbHMember" xlink:href="sny-20231231.xsd#sny_HoechstGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_HoechstGmbHMember" xlink:to="lab_sny_HoechstGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_682bc456-81d8-4959-9a65-98c90749c078_terseLabel_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, ownership percentage</link:label>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_label_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage</link:label>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_documentation_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:href="sny-20231231.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:to="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProductLiabilitiesMember_79330216-baae-463d-9d96-d0e6eae5db7b_terseLabel_en-US" xlink:label="lab_sny_ProductLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liabilities</link:label>
    <link:label id="lab_sny_ProductLiabilitiesMember_label_en-US" xlink:label="lab_sny_ProductLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liabilities [Member]</link:label>
    <link:label id="lab_sny_ProductLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_ProductLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductLiabilitiesMember" xlink:href="sny-20231231.xsd#sny_ProductLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProductLiabilitiesMember" xlink:to="lab_sny_ProductLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_May252023Member_c3317fa9-0aaa-4df1-b2b1-28ec5bcc572c_terseLabel_en-US" xlink:label="lab_sny_May252023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 25, 2023</link:label>
    <link:label id="lab_sny_May252023Member_label_en-US" xlink:label="lab_sny_May252023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 25, 2023 [Member]</link:label>
    <link:label id="lab_sny_May252023Member_documentation_en-US" xlink:label="lab_sny_May252023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 25, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_May252023Member" xlink:href="sny-20231231.xsd#sny_May252023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_May252023Member" xlink:to="lab_sny_May252023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherCountriesInSegmentResultsMember_2f4db799-4ad0-4ed9-b867-52458d3c2f1b_terseLabel_en-US" xlink:label="lab_sny_OtherCountriesInSegmentResultsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other countries</link:label>
    <link:label id="lab_sny_OtherCountriesInSegmentResultsMember_label_en-US" xlink:label="lab_sny_OtherCountriesInSegmentResultsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries In Segment Results [Member]</link:label>
    <link:label id="lab_sny_OtherCountriesInSegmentResultsMember_documentation_en-US" xlink:label="lab_sny_OtherCountriesInSegmentResultsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other countries in segement results.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesInSegmentResultsMember" xlink:href="sny-20231231.xsd#sny_OtherCountriesInSegmentResultsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherCountriesInSegmentResultsMember" xlink:to="lab_sny_OtherCountriesInSegmentResultsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_354f70c6-fa6a-4f90-bc58-04b09e887b5f_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_915ef611-57a4-49e9-8f95-5de5b94cfa44_negatedLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of other equity investments</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of financial instruments, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainsLossesOnDerivativesUsedToManageDebt_f3772b36-d49d-44b6-a7b5-dad8ee7d2396_terseLabel_en-US" xlink:label="lab_sny_GainsLossesOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivatives used to manage debt</link:label>
    <link:label id="lab_sny_GainsLossesOnDerivativesUsedToManageDebt_label_en-US" xlink:label="lab_sny_GainsLossesOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) On Derivatives Used To Manage Debt</link:label>
    <link:label id="lab_sny_GainsLossesOnDerivativesUsedToManageDebt_documentation_en-US" xlink:label="lab_sny_GainsLossesOnDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain derivatives used to manage debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnDerivativesUsedToManageDebt" xlink:href="sny-20231231.xsd#sny_GainsLossesOnDerivativesUsedToManageDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainsLossesOnDerivativesUsedToManageDebt" xlink:to="lab_sny_GainsLossesOnDerivativesUsedToManageDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_99d36e3e-e1a9-4fd5-88da-a4cca3a6ee4a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Movement In Total Debt</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonINBRX101BusinessSpinCo.Member_85650ab8-1205-487d-baef-31d95defdd64_terseLabel_en-US" xlink:label="lab_sny_NonINBRX101BusinessSpinCo.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-INBRX-101 business (Spin Co.)</link:label>
    <link:label id="lab_sny_NonINBRX101BusinessSpinCo.Member_label_en-US" xlink:label="lab_sny_NonINBRX101BusinessSpinCo.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-INBRX-101 Business (Spin Co.) [Member]</link:label>
    <link:label id="lab_sny_NonINBRX101BusinessSpinCo.Member_documentation_en-US" xlink:label="lab_sny_NonINBRX101BusinessSpinCo.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-INBRX-101 Business (Spin Co.)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonINBRX101BusinessSpinCo.Member" xlink:href="sny-20231231.xsd#sny_NonINBRX101BusinessSpinCo.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonINBRX101BusinessSpinCo.Member" xlink:to="lab_sny_NonINBRX101BusinessSpinCo.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive_878eb3c5-b5d0-4d0c-b121-a7fb4559d216_terseLabel_en-US" xlink:label="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions, expected utilized amount in 2023 through 2026</link:label>
    <link:label id="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive_label_en-US" xlink:label="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified Environmental Risks Provisions Expected Utilized Amount Year Two To Five</link:label>
    <link:label id="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive_documentation_en-US" xlink:label="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified environmental risks provisions expected utilized amount year two to five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive" xlink:href="sny-20231231.xsd#sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive" xlink:to="lab_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_d81c9878-24a6-403d-ba58-c9f5c2c89101_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off balance sheet commitments</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of off-balance sheet commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiBVMember_4685fbeb-3562-44c7-acee-d410c771b49e_terseLabel_en-US" xlink:label="lab_sny_SanofiBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi BV</link:label>
    <link:label id="lab_sny_SanofiBVMember_label_en-US" xlink:label="lab_sny_SanofiBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi BV [Member]</link:label>
    <link:label id="lab_sny_SanofiBVMember_documentation_en-US" xlink:label="lab_sny_SanofiBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi BV.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBVMember" xlink:href="sny-20231231.xsd#sny_SanofiBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiBVMember" xlink:to="lab_sny_SanofiBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlanAssetsEffectOfAssetCeiling_709cefad-325d-4607-b682-3afdc6217e7b_terseLabel_en-US" xlink:label="lab_sny_PlanAssetsEffectOfAssetCeiling" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of asset ceiling</link:label>
    <link:label id="lab_sny_PlanAssetsEffectOfAssetCeiling_label_en-US" xlink:label="lab_sny_PlanAssetsEffectOfAssetCeiling" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets, Effect Of Asset Ceiling</link:label>
    <link:label id="lab_sny_PlanAssetsEffectOfAssetCeiling_documentation_en-US" xlink:label="lab_sny_PlanAssetsEffectOfAssetCeiling" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets, Effect Of Asset Ceiling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanAssetsEffectOfAssetCeiling" xlink:href="sny-20231231.xsd#sny_PlanAssetsEffectOfAssetCeiling"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlanAssetsEffectOfAssetCeiling" xlink:to="lab_sny_PlanAssetsEffectOfAssetCeiling" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFunded_7ac1966a-de25-46b2-83c7-8e4ba52a68fa_terseLabel_en-US" xlink:label="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFunded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase III costs, responsibility percentage</link:label>
    <link:label id="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFunded_label_en-US" xlink:label="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFunded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Second Part Of Development Costs Funded</link:label>
    <link:label id="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFunded_documentation_en-US" xlink:label="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFunded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Second Part Of Development Costs Funded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFunded" xlink:href="sny-20231231.xsd#sny_PercentageOfSecondPartOfDevelopmentCostsFunded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFunded" xlink:to="lab_sny_PercentageOfSecondPartOfDevelopmentCostsFunded" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock_4b4f89a3-b81b-4f6f-bcac-0c3ddef63ddb_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Cost for Pension and Other post-employment Benefit Plans, by Geographical Region</link:label>
    <link:label id="lab_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Service Costs Of Net Defined Benefits By Country [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of service costs of net defined benefits by country.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock" xlink:to="lab_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_45dbdc36-f612-46a8-82f6-5330621e4dad_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_69ae6a38-d3f2-4b59-9268-1a06fe355bce_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit/(loss) from investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_April2022EMTNISINFR0014009KQ0Member_424fce8e-f25b-4b8b-98bc-18a078ae15be_terseLabel_en-US" xlink:label="lab_sny_April2022EMTNISINFR0014009KQ0Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2022 EMTN ISIN FR0014009KQ0</link:label>
    <link:label id="lab_sny_April2022EMTNISINFR0014009KQ0Member_label_en-US" xlink:label="lab_sny_April2022EMTNISINFR0014009KQ0Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2022 EMTN ISIN FR0014009KQ0 [Member]</link:label>
    <link:label id="lab_sny_April2022EMTNISINFR0014009KQ0Member_documentation_en-US" xlink:label="lab_sny_April2022EMTNISINFR0014009KQ0Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2022 EMTN ISIN FR0014009KQ0</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2022EMTNISINFR0014009KQ0Member" xlink:href="sny-20231231.xsd#sny_April2022EMTNISINFR0014009KQ0Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_April2022EMTNISINFR0014009KQ0Member" xlink:to="lab_sny_April2022EMTNISINFR0014009KQ0Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_0162cf95-7901-47c4-8273-5eff113d630d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and impairment charged in the period</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AuditorsRemunerationForAuditRelatedServices_264633ec-2e23-42fe-ab6c-41347f06d23a_terseLabel_en-US" xlink:label="lab_sny_AuditorsRemunerationForAuditRelatedServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit-related services</link:label>
    <link:label id="lab_sny_AuditorsRemunerationForAuditRelatedServices_label_en-US" xlink:label="lab_sny_AuditorsRemunerationForAuditRelatedServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor's Remuneration For Audit Related Services</link:label>
    <link:label id="lab_sny_AuditorsRemunerationForAuditRelatedServices_documentation_en-US" xlink:label="lab_sny_AuditorsRemunerationForAuditRelatedServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor's remuneration for audit related services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsRemunerationForAuditRelatedServices" xlink:href="sny-20231231.xsd#sny_AuditorsRemunerationForAuditRelatedServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AuditorsRemunerationForAuditRelatedServices" xlink:to="lab_sny_AuditorsRemunerationForAuditRelatedServices" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GenzymeTherapeuticProductsLimitedPartnershipMember_41a3b55f-7def-43b3-9900-19e424d9792e_terseLabel_en-US" xlink:label="lab_sny_GenzymeTherapeuticProductsLimitedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Therapeutic Products Limited Partnership</link:label>
    <link:label id="lab_sny_GenzymeTherapeuticProductsLimitedPartnershipMember_label_en-US" xlink:label="lab_sny_GenzymeTherapeuticProductsLimitedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Therapeutic Products Limited Partnership [Member]</link:label>
    <link:label id="lab_sny_GenzymeTherapeuticProductsLimitedPartnershipMember_documentation_en-US" xlink:label="lab_sny_GenzymeTherapeuticProductsLimitedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Therapeutic Products Limited Partnership [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeTherapeuticProductsLimitedPartnershipMember" xlink:href="sny-20231231.xsd#sny_GenzymeTherapeuticProductsLimitedPartnershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GenzymeTherapeuticProductsLimitedPartnershipMember" xlink:to="lab_sny_GenzymeTherapeuticProductsLimitedPartnershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowings_4fd7e42e-a4db-41b8-ba3e-727937164511_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowings_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowings" xlink:to="lab_ifrs-full_LongtermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_2457d8f3-9068-4a31-b775-d946edc8c049_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends recognised as distributions to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:to="lab_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InsurancePoliciesMember_d2b65352-041c-4a18-83f7-99e29b550d76_terseLabel_en-US" xlink:label="lab_sny_InsurancePoliciesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance policies</link:label>
    <link:label id="lab_sny_InsurancePoliciesMember_label_en-US" xlink:label="lab_sny_InsurancePoliciesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Policies [Member]</link:label>
    <link:label id="lab_sny_InsurancePoliciesMember_documentation_en-US" xlink:label="lab_sny_InsurancePoliciesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InsurancePoliciesMember" xlink:href="sny-20231231.xsd#sny_InsurancePoliciesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InsurancePoliciesMember" xlink:to="lab_sny_InsurancePoliciesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TechnologicalPlatformsMember_4d124350-dce4-4036-aba7-e20c17650a18_terseLabel_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological platforms</link:label>
    <link:label id="lab_sny_TechnologicalPlatformsMember_label_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological Platforms [Member]</link:label>
    <link:label id="lab_sny_TechnologicalPlatformsMember_documentation_en-US" xlink:label="lab_sny_TechnologicalPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological Platforms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember" xlink:href="sny-20231231.xsd#sny_TechnologicalPlatformsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TechnologicalPlatformsMember" xlink:to="lab_sny_TechnologicalPlatformsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_46a790d7-02c8-43f5-9fa3-f98ed883145c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets that are either past due or impaired [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets that are either past due or impaired [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_139b9e94-d966-41d7-9bca-60181355205b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets that are either past due or impaired [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets that are either past due or impaired [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock_de83ca00-0321-4339-89cb-9a5d37edd659_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Personal Costs</link:label>
    <link:label id="lab_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Personnel Costs Details [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of personnel costs details.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfPersonnelCostsDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock" xlink:to="lab_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_c7694691-bb37-4153-ac9f-44abb9d727b2_terseLabel_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_label_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items Not Subsequently Reclassifiable To Profit Or Loss [Member]</link:label>
    <link:label id="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_documentation_en-US" xlink:label="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:href="sny-20231231.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:to="lab_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_624f6a6e-195d-43c6-a08b-9fe71792bcf8_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_JanssenPharmaceuticalsIncMember_52aca0de-74ea-4b36-aff6-f0982822c63e_terseLabel_en-US" xlink:label="lab_sny_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Inc</link:label>
    <link:label id="lab_sny_JanssenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_sny_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_sny_JanssenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_sny_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JanssenPharmaceuticalsIncMember" xlink:href="sny-20231231.xsd#sny_JanssenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_JanssenPharmaceuticalsIncMember" xlink:to="lab_sny_JanssenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember_f96e770b-829e-4046-9b13-c5cdb4d28b9f_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare T&#252;ketici Sa&#287;l&#305;&#287;&#305; Anonim &#350;irketi</link:label>
    <link:label id="lab_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare T&#252;ketici Sa&#287;l&#305;&#287;&#305; Anonim &#350;irketi [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare T&#252;ketici Sa&#287;l&#305;&#287;&#305; Anonim &#350;irketi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareTuketiciSalAnonimSirketiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember" xlink:to="lab_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_QuotedDebtSecuritiesMember_20336217-a12f-4aae-8a47-70f96aa95801_terseLabel_en-US" xlink:label="lab_sny_QuotedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted debt securities</link:label>
    <link:label id="lab_sny_QuotedDebtSecuritiesMember_label_en-US" xlink:label="lab_sny_QuotedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Debt Securities [Member]</link:label>
    <link:label id="lab_sny_QuotedDebtSecuritiesMember_documentation_en-US" xlink:label="lab_sny_QuotedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted debt securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedDebtSecuritiesMember" xlink:href="sny-20231231.xsd#sny_QuotedDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_QuotedDebtSecuritiesMember" xlink:to="lab_sny_QuotedDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeasedAssetsPercentage_47a9eaf5-d9df-40c9-b8e1-bbe4b25087d8_terseLabel_en-US" xlink:label="lab_sny_LeasedAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets, percentage</link:label>
    <link:label id="lab_sny_LeasedAssetsPercentage_label_en-US" xlink:label="lab_sny_LeasedAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased Assets, Percentage</link:label>
    <link:label id="lab_sny_LeasedAssetsPercentage_documentation_en-US" xlink:label="lab_sny_LeasedAssetsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased Assets, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeasedAssetsPercentage" xlink:href="sny-20231231.xsd#sny_LeasedAssetsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeasedAssetsPercentage" xlink:to="lab_sny_LeasedAssetsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems_8ce772da-1787-40a7-b065-cc844fedd1f4_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net income attributable to non-controlling interests [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Net Income Attributable To Non-Controlling Interests [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net income attributable to noncontrolling interests [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems" xlink:to="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral_b9f60d0c-a0fc-404b-97ad-36e31ff7ce71_terseLabel_en-US" xlink:label="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial collateral</link:label>
    <link:label id="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral_label_en-US" xlink:label="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects Of Other Netting Arrangements Not Fulfilling The IAS 32 Criteria For Offsetting Fair Value Of Financial Collateral</link:label>
    <link:label id="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral_documentation_en-US" xlink:label="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of other netting arrangements not fulfilling the IAS32 criteria for offsetting fair value of financial collateral.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral" xlink:href="sny-20231231.xsd#sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral" xlink:to="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_efa21018-0570-48eb-a0ee-6847ce0a75eb_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_1c9304f7-6659-455a-b317-d19a53e68b7e_verboseLabel_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of the workdown of acquired inventories remeasured at fair value</link:label>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_label_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value</link:label>
    <link:label id="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_documentation_en-US" xlink:label="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:href="sny-20231231.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:to="lab_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_96239cb0-f9b5-485f-8691-18ad086ecbc2_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible decrease in actuarial assumption</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of reasonably possible decrease in actuarial assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_13dc86d0-19a1-4d86-9edd-98815eeab046_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income for the period, net of taxes</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_646a1a51-995b-432b-8d37-d3c14217f001_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income for&#160;the&#160;period</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_45af1f84-f557-4e2d-8c9f-0b28ebd49add_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities related to business combinations and to non-controlling interests</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_label_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Liabilities Related To Business Combinations And To Non-Controlling Interests</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_documentation_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:href="sny-20231231.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:to="lab_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_May32022Member_b68c48d0-0024-4482-bab9-7581b885962a_verboseLabel_en-US" xlink:label="lab_sny_May32022Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 3, 2022</link:label>
    <link:label id="lab_sny_May32022Member_label_en-US" xlink:label="lab_sny_May32022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 3, 2022 [Member]</link:label>
    <link:label id="lab_sny_May32022Member_documentation_en-US" xlink:label="lab_sny_May32022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2, 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_May32022Member" xlink:href="sny-20231231.xsd#sny_May32022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_May32022Member" xlink:to="lab_sny_May32022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock_618df02b-2510-45a0-954b-280a1d217cc0_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information Of Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of detailed information of other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRevenue_a9de09c3-b17e-4866-9397-8c739d511e34_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_ifrs-full_OtherRevenue_label_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRevenue" xlink:to="lab_ifrs-full_OtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_d16145f0-a657-40d0-976f-51a6741a410f_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">to non-controlling interests, excluding BMS</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid to non-controlling interests, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7d6b96d2-77d0-4693-888f-104757cca339_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_dbf1bd57-fd81-4b2a-8636-fc77a44a472c_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UK</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SalesOfAntibodiesThirdAchievementMember_da517a12-35ea-4fa6-86e1-c5a1e66c103b_terseLabel_en-US" xlink:label="lab_sny_SalesOfAntibodiesThirdAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Of Antibodies, Third Achievement</link:label>
    <link:label id="lab_sny_SalesOfAntibodiesThirdAchievementMember_label_en-US" xlink:label="lab_sny_SalesOfAntibodiesThirdAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Of Antibodies, Third Achievement [Member]</link:label>
    <link:label id="lab_sny_SalesOfAntibodiesThirdAchievementMember_documentation_en-US" xlink:label="lab_sny_SalesOfAntibodiesThirdAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Of Antibodies, Third Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesOfAntibodiesThirdAchievementMember" xlink:href="sny-20231231.xsd#sny_SalesOfAntibodiesThirdAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SalesOfAntibodiesThirdAchievementMember" xlink:to="lab_sny_SalesOfAntibodiesThirdAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_e88597ac-c56d-43a9-b4c2-02ed0ea2b19f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Sensitivity for Pensions and Other Post-employment Benefits to Changes in Key Actuarial Assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_aca5cc9f-43fe-46fa-b3cc-c0b7bde98529_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SynthorxIncMember_62c0632a-323b-431c-8a48-5af76c1d3307_terseLabel_en-US" xlink:label="lab_sny_SynthorxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synthorx, Inc</link:label>
    <link:label id="lab_sny_SynthorxIncMember_label_en-US" xlink:label="lab_sny_SynthorxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synthorx, Inc [Member]</link:label>
    <link:label id="lab_sny_SynthorxIncMember_documentation_en-US" xlink:label="lab_sny_SynthorxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synthorx, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SynthorxIncMember" xlink:href="sny-20231231.xsd#sny_SynthorxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SynthorxIncMember" xlink:to="lab_sny_SynthorxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_88ceba23-11b0-4662-bbde-afb064cabb73_verboseLabel_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other gains and losses, and litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_8b3584f2-1288-4d25-a3ab-49b826319281_terseLabel_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other gains, (losses) and litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_c9a68217-40ac-4324-889e-05ea0d31fd2e_negatedTerseLabel_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other gains, (losses) and litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_label_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Gains, (Losses) And Litigation</link:label>
    <link:label id="lab_sny_OtherGainsLossesAndLitigation_documentation_en-US" xlink:label="lab_sny_OtherGainsLossesAndLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation" xlink:href="sny-20231231.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherGainsLossesAndLitigation" xlink:to="lab_sny_OtherGainsLossesAndLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_September2014EMTNISINFR0012146801Member_d2f7ec39-9ab1-47eb-95d6-25e405f85e72_terseLabel_en-US" xlink:label="lab_sny_September2014EMTNISINFR0012146801Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2014 EMTN ISIN FR0012146801</link:label>
    <link:label id="lab_sny_September2014EMTNISINFR0012146801Member_label_en-US" xlink:label="lab_sny_September2014EMTNISINFR0012146801Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2014 EMTNISINFR0012146801 [Member]</link:label>
    <link:label id="lab_sny_September2014EMTNISINFR0012146801Member_documentation_en-US" xlink:label="lab_sny_September2014EMTNISINFR0012146801Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2014 EMTN ISIN FR0012146801.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_September2014EMTNISINFR0012146801Member" xlink:href="sny-20231231.xsd#sny_September2014EMTNISINFR0012146801Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_September2014EMTNISINFR0012146801Member" xlink:to="lab_sny_September2014EMTNISINFR0012146801Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember_9369155b-d6fe-4472-8170-7ec6cb65a0f3_terseLabel_en-US" xlink:label="lab_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and provisions deductible at time of payments</link:label>
    <link:label id="lab_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember_label_en-US" xlink:label="lab_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Provisions Deductible At Time Of Payments [member]</link:label>
    <link:label id="lab_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember_documentation_en-US" xlink:label="lab_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and provisions deductible at time of payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember" xlink:href="sny-20231231.xsd#sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember" xlink:to="lab_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MerieuxCanadaHoldingsULCCanadaMember_ed3ae6b8-738e-4b17-9bdb-d264aee58183_terseLabel_en-US" xlink:label="lab_sny_MerieuxCanadaHoldingsULCCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merieux Canada Holdings ULC (Canada)</link:label>
    <link:label id="lab_sny_MerieuxCanadaHoldingsULCCanadaMember_label_en-US" xlink:label="lab_sny_MerieuxCanadaHoldingsULCCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merieux Canada Holdings ULC (Canada) [Member]</link:label>
    <link:label id="lab_sny_MerieuxCanadaHoldingsULCCanadaMember_documentation_en-US" xlink:label="lab_sny_MerieuxCanadaHoldingsULCCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merieux Canada Holdings ULC (Canada)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MerieuxCanadaHoldingsULCCanadaMember" xlink:href="sny-20231231.xsd#sny_MerieuxCanadaHoldingsULCCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MerieuxCanadaHoldingsULCCanadaMember" xlink:to="lab_sny_MerieuxCanadaHoldingsULCCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChattemIncMember_5bc7b9fe-c89a-484c-bc9a-df47b379d845_terseLabel_en-US" xlink:label="lab_sny_ChattemIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chattem, Inc.</link:label>
    <link:label id="lab_sny_ChattemIncMember_label_en-US" xlink:label="lab_sny_ChattemIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chattem Inc [member]</link:label>
    <link:label id="lab_sny_ChattemIncMember_documentation_en-US" xlink:label="lab_sny_ChattemIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chattem, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChattemIncMember" xlink:href="sny-20231231.xsd#sny_ChattemIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChattemIncMember" xlink:to="lab_sny_ChattemIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_eca64392-cb22-461d-a895-45042b2bf1fc_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_label_en-US" xlink:label="lab_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" xlink:to="lab_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AlprolixMember_a1b64a47-2c23-4e0f-b4a4-5ddae98f79c6_terseLabel_en-US" xlink:label="lab_sny_AlprolixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALPROLIX</link:label>
    <link:label id="lab_sny_AlprolixMember_label_en-US" xlink:label="lab_sny_AlprolixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alprolix [Member]</link:label>
    <link:label id="lab_sny_AlprolixMember_documentation_en-US" xlink:label="lab_sny_AlprolixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alprolix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AlprolixMember" xlink:href="sny-20231231.xsd#sny_AlprolixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AlprolixMember" xlink:to="lab_sny_AlprolixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_7f2c95ff-de27-4fc2-8e23-e444d1575b8d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Geographical Information on Net Sales and Non-Current Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of geographical areas [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_fb9baccb-e03c-40e8-aefa-d9c8655b81da_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other operating income [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareBrazilLtdaMember_8172c752-18d9-4113-979b-16c2cd0cc7f2_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareBrazilLtdaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Brazil Ltda.</link:label>
    <link:label id="lab_sny_OpellaHealthcareBrazilLtdaMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareBrazilLtdaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Brazil Ltda. [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareBrazilLtdaMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareBrazilLtdaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Brazil Ltda.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareBrazilLtdaMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareBrazilLtdaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareBrazilLtdaMember" xlink:to="lab_sny_OpellaHealthcareBrazilLtdaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentProvisionForEnvironmentRisks_32f4977d-543a-4613-b106-1a4fb662127a_terseLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionForEnvironmentRisks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental risks</link:label>
    <link:label id="lab_sny_NonCurrentProvisionForEnvironmentRisks_label_en-US" xlink:label="lab_sny_NonCurrentProvisionForEnvironmentRisks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Provision For Environment Risks</link:label>
    <link:label id="lab_sny_NonCurrentProvisionForEnvironmentRisks_documentation_en-US" xlink:label="lab_sny_NonCurrentProvisionForEnvironmentRisks" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environment risks.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionForEnvironmentRisks" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionForEnvironmentRisks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentProvisionForEnvironmentRisks" xlink:to="lab_sny_NonCurrentProvisionForEnvironmentRisks" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_26634bff-98c9-4928-8ab2-37b05de2b306_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and other receivables</link:label>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts receivable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurEuropeMember_6fea6a28-bdb1-451d-864b-41e79aa5cf44_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Europe</link:label>
    <link:label id="lab_sny_SanofiPasteurEuropeMember_label_en-US" xlink:label="lab_sny_SanofiPasteurEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Europe [Member]</link:label>
    <link:label id="lab_sny_SanofiPasteurEuropeMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurEuropeMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurEuropeMember" xlink:to="lab_sny_SanofiPasteurEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValueOfTheContingentConsideration_b697abd1-a929-4ffa-90be-622d7ee947d1_terseLabel_en-US" xlink:label="lab_sny_FairValueOfTheContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the contingent consideration</link:label>
    <link:label id="lab_sny_FairValueOfTheContingentConsideration_label_en-US" xlink:label="lab_sny_FairValueOfTheContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of The Contingent Consideration</link:label>
    <link:label id="lab_sny_FairValueOfTheContingentConsideration_documentation_en-US" xlink:label="lab_sny_FairValueOfTheContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfTheContingentConsideration" xlink:href="sny-20231231.xsd#sny_FairValueOfTheContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValueOfTheContingentConsideration" xlink:to="lab_sny_FairValueOfTheContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_33330b95-bd32-468f-824c-1f0ce4d33644_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs</link:label>
    <link:label id="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="lab_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_8672c5db-0655-4998-8031-e762a7186d42_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ManagedCareAndGPOProgramsMember_15c4e0d8-c930-4517-bba1-1c0ac80cb102_terseLabel_en-US" xlink:label="lab_sny_ManagedCareAndGPOProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care and GPO Programs</link:label>
    <link:label id="lab_sny_ManagedCareAndGPOProgramsMember_label_en-US" xlink:label="lab_sny_ManagedCareAndGPOProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care And GPO Programs [Member]</link:label>
    <link:label id="lab_sny_ManagedCareAndGPOProgramsMember_documentation_en-US" xlink:label="lab_sny_ManagedCareAndGPOProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care And GPO Programs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManagedCareAndGPOProgramsMember" xlink:href="sny-20231231.xsd#sny_ManagedCareAndGPOProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ManagedCareAndGPOProgramsMember" xlink:to="lab_sny_ManagedCareAndGPOProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentDerivativesMember_39605ab0-0a40-456f-9bd2-4b47a93d9b12_terseLabel_en-US" xlink:label="lab_sny_CurrentDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivatives</link:label>
    <link:label id="lab_sny_CurrentDerivativesMember_d40745ea-f6e6-460a-be6c-b59f89c715fa_verboseLabel_en-US" xlink:label="lab_sny_CurrentDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivatives</link:label>
    <link:label id="lab_sny_CurrentDerivativesMember_label_en-US" xlink:label="lab_sny_CurrentDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Derivatives [Member]</link:label>
    <link:label id="lab_sny_CurrentDerivativesMember_documentation_en-US" xlink:label="lab_sny_CurrentDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivatives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentDerivativesMember" xlink:href="sny-20231231.xsd#sny_CurrentDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentDerivativesMember" xlink:to="lab_sny_CurrentDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockSubscriptionOptionPlanFourMember_d64f3600-c0df-4404-9aa9-07b9f41d6db2_terseLabel_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan four</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanFourMember_label_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Option Plan Four [Member]</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanFourMember_documentation_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanFourMember" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockSubscriptionOptionPlanFourMember" xlink:to="lab_sny_StockSubscriptionOptionPlanFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfClaimant_88e30ab5-8b2f-4f8c-94be-94341f133e98_terseLabel_en-US" xlink:label="lab_sny_NumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claimant</link:label>
    <link:label id="lab_sny_NumberOfClaimant_label_en-US" xlink:label="lab_sny_NumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claimant</link:label>
    <link:label id="lab_sny_NumberOfClaimant_documentation_en-US" xlink:label="lab_sny_NumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claimant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClaimant" xlink:href="sny-20231231.xsd#sny_NumberOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfClaimant" xlink:to="lab_sny_NumberOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_690c68ed-8a40-4c41-accb-d27461bfe1ad_verboseLabel_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</link:label>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_label_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right-of Use Assets And Intangible Asset</link:label>
    <link:label id="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_documentation_en-US" xlink:label="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:href="sny-20231231.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:to="lab_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember_fdb1a75c-bc0e-42d8-89bf-03c8474d9751_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases in US dollar, US bond</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In US Dollar, US Bond [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In US Dollar, US Bond</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInUSDollarUSBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember" xlink:to="lab_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_1e84f4f1-4683-4366-abd4-313aabbf43f7_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous other operating income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForOtherServices_4c63c5ef-b38d-4b3e-bc91-8a4245b0b8c9_terseLabel_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForOtherServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForOtherServices_label_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForOtherServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor's remuneration for other services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForOtherServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForOtherServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationForOtherServices" xlink:to="lab_ifrs-full_AuditorsRemunerationForOtherServices" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_f5d0d369-c5b6-4919-a776-7a6641ad508a_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_7b690038-6c62-4977-8f23-ca0527470542_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisKoreaCoLtdMember_e385e31d-2ffa-4e85-bc7a-da141a7272ce_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Korea Co. Ltd</link:label>
    <link:label id="lab_sny_SanofiAventisKoreaCoLtdMember_label_en-US" xlink:label="lab_sny_SanofiAventisKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Korea Co Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisKoreaCoLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Korea Co. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisKoreaCoLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisKoreaCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisKoreaCoLtdMember" xlink:to="lab_sny_SanofiAventisKoreaCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurNVLMember_2575ec76-b1c2-4b32-8016-50612b087f48_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurNVLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur NVL</link:label>
    <link:label id="lab_sny_SanofiPasteurNVLMember_label_en-US" xlink:label="lab_sny_SanofiPasteurNVLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur NVL [Member]</link:label>
    <link:label id="lab_sny_SanofiPasteurNVLMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurNVLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur NVL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurNVLMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurNVLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurNVLMember" xlink:to="lab_sny_SanofiPasteurNVLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_April2016EMTNISINFR0013144003Member_c08d5847-1cfc-463d-a5d2-94f2f28f5596_terseLabel_en-US" xlink:label="lab_sny_April2016EMTNISINFR0013144003Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2016 EMTN ISIN FR0013144003</link:label>
    <link:label id="lab_sny_April2016EMTNISINFR0013144003Member_label_en-US" xlink:label="lab_sny_April2016EMTNISINFR0013144003Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2016 EMTNISINFR0013144003 [Member]</link:label>
    <link:label id="lab_sny_April2016EMTNISINFR0013144003Member_documentation_en-US" xlink:label="lab_sny_April2016EMTNISINFR0013144003Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2016 EMTN ISIN FR0013144003.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2016EMTNISINFR0013144003Member" xlink:href="sny-20231231.xsd#sny_April2016EMTNISINFR0013144003Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_April2016EMTNISINFR0013144003Member" xlink:to="lab_sny_April2016EMTNISINFR0013144003Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_9c5f9a3d-833d-48ce-9e43-bd3ac0eacae4_terseLabel_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency and interest rate derivatives</link:label>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency And Interest Rate Derivatives Used To Manage Debt Net Of Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:href="sny-20231231.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:to="lab_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativesMember_fc7eba49-c2d4-4605-ba14-e875711efae6_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_ifrs-full_DerivativesMember_label_en-US" xlink:label="lab_ifrs-full_DerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativesMember" xlink:to="lab_ifrs-full_DerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_919b27ee-c28a-40ae-90e2-0b14e914d57a_terseLabel_en-US" xlink:label="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development costs arising from commercial operations</link:label>
    <link:label id="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_label_en-US" xlink:label="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Costs Arising From Commercial Operations</link:label>
    <link:label id="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_documentation_en-US" xlink:label="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Costs Arising From Commercial Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:href="sny-20231231.xsd#sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:to="lab_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_2c7fe36f-da51-4a3b-b89a-1db3e965c7b8_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale or exchange</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets or disposal groups classified as held for sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:to="lab_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationPurchasePricePerShare_69f9b07b-6ba0-46fd-a8ee-c68362cc1f4a_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price per share (in euro/usd per share)</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePricePerShare_33ba36d9-6d34-499f-9ea1-abca75049088_verboseLabel_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in USD per share)</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePricePerShare_label_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Purchase Price Per Share</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePricePerShare_documentation_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare" xlink:href="sny-20231231.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationPurchasePricePerShare" xlink:to="lab_sny_BusinessCombinationPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BuildingsMember_564d7499-b43f-4670-8319-11858b4b4234_terseLabel_en-US" xlink:label="lab_ifrs-full_BuildingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_ifrs-full_BuildingsMember_label_en-US" xlink:label="lab_ifrs-full_BuildingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BuildingsMember" xlink:to="lab_ifrs-full_BuildingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory_0c2255bc-86a1-4f12-9796-2ae59b6a3df2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax position</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of deferred taxes [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ZantacLitigationInCanadaMember_eeae1c2e-0371-43b2-b60b-fd6727ee46cb_terseLabel_en-US" xlink:label="lab_sny_ZantacLitigationInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zantac litigation in Canada</link:label>
    <link:label id="lab_sny_ZantacLitigationInCanadaMember_label_en-US" xlink:label="lab_sny_ZantacLitigationInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zantac Litigation In Canada [Member]</link:label>
    <link:label id="lab_sny_ZantacLitigationInCanadaMember_documentation_en-US" xlink:label="lab_sny_ZantacLitigationInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zantac Litigation In Canada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacLitigationInCanadaMember" xlink:href="sny-20231231.xsd#sny_ZantacLitigationInCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ZantacLitigationInCanadaMember" xlink:to="lab_sny_ZantacLitigationInCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember_cfc01f2c-ded8-46b0-bae0-994c6852088c_terseLabel_en-US" xlink:label="lab_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees provided to banks in connection with credit facilities</link:label>
    <link:label id="lab_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember_label_en-US" xlink:label="lab_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees Provided To Banks In Connection With Credit Facilities [Member]</link:label>
    <link:label id="lab_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember_documentation_en-US" xlink:label="lab_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees provided to banks in connection with credit facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember" xlink:href="sny-20231231.xsd#sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember" xlink:to="lab_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_2349d0b0-d9fa-4d3c-a725-290a02899bfd_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation &amp; impairment</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_ad9405e9-19e9-43bc-b217-9578dac695d2_verboseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization&#160;&amp; impairment</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActuarialAssumptionOfMortalityTableMember_71909327-2dd9-47df-b5a9-c0614133263a_terseLabel_en-US" xlink:label="lab_sny_ActuarialAssumptionOfMortalityTableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortality table</link:label>
    <link:label id="lab_sny_ActuarialAssumptionOfMortalityTableMember_label_en-US" xlink:label="lab_sny_ActuarialAssumptionOfMortalityTableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumption Of Mortality Table [Member]</link:label>
    <link:label id="lab_sny_ActuarialAssumptionOfMortalityTableMember_documentation_en-US" xlink:label="lab_sny_ActuarialAssumptionOfMortalityTableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of mortality table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialAssumptionOfMortalityTableMember" xlink:href="sny-20231231.xsd#sny_ActuarialAssumptionOfMortalityTableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActuarialAssumptionOfMortalityTableMember" xlink:to="lab_sny_ActuarialAssumptionOfMortalityTableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherProductAndServicesMember_fab2b72e-fef7-45ce-9658-ff098c1690b0_terseLabel_en-US" xlink:label="lab_sny_OtherProductAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Others</link:label>
    <link:label id="lab_sny_OtherProductAndServicesMember_label_en-US" xlink:label="lab_sny_OtherProductAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product And Services [Member]</link:label>
    <link:label id="lab_sny_OtherProductAndServicesMember_documentation_en-US" xlink:label="lab_sny_OtherProductAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product And Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductAndServicesMember" xlink:href="sny-20231231.xsd#sny_OtherProductAndServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherProductAndServicesMember" xlink:to="lab_sny_OtherProductAndServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_c52f5313-60b9-4d7f-acb4-081bfc6d778c_negatedLabel_en-US" xlink:label="lab_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options cancelled (in shares)</link:label>
    <link:label id="lab_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Options Cancelled In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Options Cancelled In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:href="sny-20231231.xsd#sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:to="lab_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock_7d97bd78-04e1-4d65-8c20-00ea1b5d68fd_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Useful Lives of Property, Plant and Equipment</link:label>
    <link:label id="lab_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Estimated Useful Lives Of Property Plant And Equipment Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of estimated useful lives of property plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_f9882e69-9f01-4167-86ff-4ff96c37c31e_negatedLabel_en-US" xlink:label="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unwinding of discounting of provisions</link:label>
    <link:label id="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_label_en-US" xlink:label="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense arising from passage of time on other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lab_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_85a3f3cc-05b2-4b91-97e0-73ef543d6dd2_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_1c388aa4-1183-4bb5-aa23-b76c34034cbb_terseLabel_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_label_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items Subsequently Reclassifiable To Profit Or Loss [Member]</link:label>
    <link:label id="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_documentation_en-US" xlink:label="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items subsequently reclassifiable to profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:href="sny-20231231.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:to="lab_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock_8f9cb408-c53f-4285-ad07-353f858e4629_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Impairment Losses Recognised in Property, Plant and Equipment</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Impairment Losses of Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Impairment Losses of Property, Plant and Equipment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lab_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_cacce334-17fe-4422-97fa-71eda1dc3034_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1&#160;to&#160;3&#160;months</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one month and not later than three months [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:to="lab_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug_484de616-e22d-40e1-8e5f-bf881a15f045_terseLabel_en-US" xlink:label="lab_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of manufacturers with marketing authorization for generic version of drug</link:label>
    <link:label id="lab_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug_label_en-US" xlink:label="lab_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Manufacturers With Marketing Authorization For Generic Version Of Drug</link:label>
    <link:label id="lab_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug_documentation_en-US" xlink:label="lab_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Manufacturers With Marketing Authorization For Generic Version Of Drug</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug" xlink:href="sny-20231231.xsd#sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug" xlink:to="lab_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_71150877-d7b9-47d2-be24-6d197ab02bc9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionNumber_4a72ca28-1e54-4c69-92e7-604db9997e6a_terseLabel_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facilities, extension option, number</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionNumber_label_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facilities, Extension Option, Number</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionNumber_documentation_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facilities, Extension Option, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionNumber" xlink:href="sny-20231231.xsd#sny_CreditFacilitiesExtensionOptionNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CreditFacilitiesExtensionOptionNumber" xlink:to="lab_sny_CreditFacilitiesExtensionOptionNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_06741e3b-eeae-4c9f-902b-de5f998efc4e_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange for financial assets held to meet obligations to employees under post-employment benefit plans</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:to="lab_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_4c5dfe6d-684f-4750-b62c-99e76b866519_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainLossOnPurchaseOfTreasuryShares_b527ffb1-5111-4dee-a60e-0d44a6f8d4d7_terseLabel_en-US" xlink:label="lab_sny_GainLossOnPurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized on purchase of treasury shares</link:label>
    <link:label id="lab_sny_GainLossOnPurchaseOfTreasuryShares_label_en-US" xlink:label="lab_sny_GainLossOnPurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Purchase Of Treasury Shares</link:label>
    <link:label id="lab_sny_GainLossOnPurchaseOfTreasuryShares_documentation_en-US" xlink:label="lab_sny_GainLossOnPurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on purchase of treasury shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnPurchaseOfTreasuryShares" xlink:href="sny-20231231.xsd#sny_GainLossOnPurchaseOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainLossOnPurchaseOfTreasuryShares" xlink:to="lab_sny_GainLossOnPurchaseOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents_af61e637-0de8-4d97-9592-10a268ee3d2c_terseLabel_en-US" xlink:label="lab_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivatives used to manage cash and cash equivalents</link:label>
    <link:label id="lab_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) On Derivatives Used To Manage Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivatives used to manage cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents" xlink:href="sny-20231231.xsd#sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents" xlink:to="lab_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_fb158b47-2de6-4236-adeb-b01383e4168b_terseLabel_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in scope of consolidation</link:label>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_label_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</link:label>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_documentation_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combination, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:href="sny-20231231.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:to="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_948b606a-86e3-4c4e-8710-4264064f1c1a_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock_a00f6a3e-a68f-41bb-b872-9081bead022a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities measured at fair value</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities At Fair Value Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets and liabilities at fair value explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight_73a4b9f0-4aea-48c8-a9bf-92322082d6c4_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment per non-transferable contingent value right (in USD per share)</link:label>
    <link:label id="lab_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight_label_en-US" xlink:label="lab_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Cash Payment Per Non-Transferable Contingent Value Right</link:label>
    <link:label id="lab_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight_documentation_en-US" xlink:label="lab_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Cash Payment Per Non-Transferable Contingent Value Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight" xlink:href="sny-20231231.xsd#sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight" xlink:to="lab_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_ae5779b6-7406-4256-aef4-97d2e761a06e_negatedLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment_34d96d4b-4f85-4610-9542-581f51778a66_terseLabel_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in scope of consolidation</link:label>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combinations, Property, Plant And Equipment</link:label>
    <link:label id="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Scope Of Consolidation Through Business Combinations, Property, Plant And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="sny-20231231.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CoreAssetsMember_180282d9-1129-4db8-97ee-6f62b5487fef_terseLabel_en-US" xlink:label="lab_sny_CoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Assets</link:label>
    <link:label id="lab_sny_CoreAssetsMember_label_en-US" xlink:label="lab_sny_CoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Assets [Member]</link:label>
    <link:label id="lab_sny_CoreAssetsMember_documentation_en-US" xlink:label="lab_sny_CoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CoreAssetsMember" xlink:href="sny-20231231.xsd#sny_CoreAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CoreAssetsMember" xlink:to="lab_sny_CoreAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember_26fc3a3d-3702-4d5a-9488-00e6174f1993_terseLabel_en-US" xlink:label="lab_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration arising from acquisition of Amunix</link:label>
    <link:label id="lab_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember_label_en-US" xlink:label="lab_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Arising From The Acquisition Of Amunix [Member]</link:label>
    <link:label id="lab_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember_documentation_en-US" xlink:label="lab_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Arising From The Acquisition Of Amunix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember" xlink:to="lab_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_fdae2b3f-a048-40e7-a9a2-e26ab56a9830_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_b017e316-b0ac-4ca4-86c1-26a0ad7d8a3c_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_b9f0d1b3-7acf-4497-b53d-94535dc868ac_verboseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of net income attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated individually immaterial associates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:to="lab_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiIndiaLimitedMember_3d698040-e0dd-4898-b8c1-05d1c306ea11_terseLabel_en-US" xlink:label="lab_sny_SanofiIndiaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi India Limited</link:label>
    <link:label id="lab_sny_SanofiIndiaLimitedMember_label_en-US" xlink:label="lab_sny_SanofiIndiaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi India Limited [Member]</link:label>
    <link:label id="lab_sny_SanofiIndiaLimitedMember_documentation_en-US" xlink:label="lab_sny_SanofiIndiaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi India Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiIndiaLimitedMember" xlink:href="sny-20231231.xsd#sny_SanofiIndiaLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiIndiaLimitedMember" xlink:to="lab_sny_SanofiIndiaLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AventisIncMember_30479c23-97a6-4550-b676-7f58dd65359f_terseLabel_en-US" xlink:label="lab_sny_AventisIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Inc.</link:label>
    <link:label id="lab_sny_AventisIncMember_label_en-US" xlink:label="lab_sny_AventisIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Inc [member]</link:label>
    <link:label id="lab_sny_AventisIncMember_documentation_en-US" xlink:label="lab_sny_AventisIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisIncMember" xlink:href="sny-20231231.xsd#sny_AventisIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AventisIncMember" xlink:to="lab_sny_AventisIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FourBillionFacilityMaturingDecember2027Member_99a60be5-db49-4d69-b6a4-bc0fb5bdacd3_terseLabel_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingDecember2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#8364;4 billion facility maturing December 2027</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingDecember2027Member_label_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingDecember2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Billion Facility Maturing December 2027 [Member]</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingDecember2027Member_documentation_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingDecember2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Billion Facility Maturing December 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingDecember2027Member" xlink:href="sny-20231231.xsd#sny_FourBillionFacilityMaturingDecember2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FourBillionFacilityMaturingDecember2027Member" xlink:to="lab_sny_FourBillionFacilityMaturingDecember2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis_af4b3c64-defc-4be0-afa5-ace8265f62a1_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of contingent liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of contingent liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GuaranteesReceivedMember_66a8c3ad-3417-4c2b-9732-b4e5fed49053_terseLabel_en-US" xlink:label="lab_sny_GuaranteesReceivedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees received</link:label>
    <link:label id="lab_sny_GuaranteesReceivedMember_label_en-US" xlink:label="lab_sny_GuaranteesReceivedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees Received [Member]</link:label>
    <link:label id="lab_sny_GuaranteesReceivedMember_documentation_en-US" xlink:label="lab_sny_GuaranteesReceivedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GuaranteesReceivedMember" xlink:href="sny-20231231.xsd#sny_GuaranteesReceivedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GuaranteesReceivedMember" xlink:to="lab_sny_GuaranteesReceivedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_67a76f2f-de8d-46ff-9858-4fe399c214b5_totalLabel_en-US" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_label_en-US" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-derivative financial liabilities, undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_018e23b4-c527-4472-bed1-1b2b54b2a1d6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SpecialtyCareMember_9edf83e7-15ee-4a32-ab62-c42f68fdbe5f_terseLabel_en-US" xlink:label="lab_sny_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Care</link:label>
    <link:label id="lab_sny_SpecialtyCareMember_label_en-US" xlink:label="lab_sny_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Care [Member]</link:label>
    <link:label id="lab_sny_SpecialtyCareMember_documentation_en-US" xlink:label="lab_sny_SpecialtyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialtyCareMember" xlink:href="sny-20231231.xsd#sny_SpecialtyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SpecialtyCareMember" xlink:to="lab_sny_SpecialtyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock_23200f30-a1b9-479b-9d05-63a344170f85_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents</link:label>
    <link:label id="lab_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of sensitivity Analysis On Long-term Borrowings And Debt Securities Assuming A 1% Increase And Decrease In Interest Rates [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis on long-term borrowings and debt securities assuming a 1% increase and decrease in interest rates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock" xlink:to="lab_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_71e9094f-ff86-49c9-9fe2-3f657a8fafb5_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions during the period</link:label>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions through business combinations, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_3099ffe0-79e9-41d6-a5f8-9630791e2238_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From&#160;3&#160;to 5&#160;years</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than three years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_7928cbd6-975e-4eb8-b82c-4bc1dcc04efb_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains/(losses)</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_c1a47090-b627-4e34-aa87-e96ac29f7a4b_negatedLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial losses/(gains) due to changes in financial assumptions</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_923b326c-f969-4d81-a001-c0e712c6966b_verboseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains/(losses) on financial assumptions</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ParticipatingSharesMember_e67990c2-d4a3-487c-bf20-7810eefaf14f_terseLabel_en-US" xlink:label="lab_sny_ParticipatingSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1983 to 1987 participating shares issued</link:label>
    <link:label id="lab_sny_ParticipatingSharesMember_label_en-US" xlink:label="lab_sny_ParticipatingSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Shares [Member]</link:label>
    <link:label id="lab_sny_ParticipatingSharesMember_documentation_en-US" xlink:label="lab_sny_ParticipatingSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ParticipatingSharesMember" xlink:href="sny-20231231.xsd#sny_ParticipatingSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ParticipatingSharesMember" xlink:to="lab_sny_ParticipatingSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossOfAcquiree_e3fd4996-1a18-4b3e-bdb2-d495197ebf52_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from acquiree to net income</link:label>
    <link:label id="lab_ifrs-full_ProfitLossOfAcquiree_label_en-US" xlink:label="lab_ifrs-full_ProfitLossOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) of acquiree since acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossOfAcquiree" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossOfAcquiree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossOfAcquiree" xlink:to="lab_ifrs-full_ProfitLossOfAcquiree" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_25295e0d-214e-45ae-b35f-478024c128b9_terseLabel_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income and expenses</link:label>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_label_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous Other Operating Income (Expenses)</link:label>
    <link:label id="lab_sny_MiscellaneousOtherOperatingIncomeExpenses_documentation_en-US" xlink:label="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:href="sny-20231231.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:to="lab_sny_MiscellaneousOtherOperatingIncomeExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_857fec25-2a2c-4965-9216-6b633926a217_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShanghaiRonghengPharmaceuticalCoLtdMember_f5fe2a08-02e7-4217-bfd9-f91206b314bf_terseLabel_en-US" xlink:label="lab_sny_ShanghaiRonghengPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shanghai Rongheng Pharmaceutical Co, Ltd</link:label>
    <link:label id="lab_sny_ShanghaiRonghengPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_sny_ShanghaiRonghengPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shanghai Rongheng Pharmaceutical Co. Ltd [Member]</link:label>
    <link:label id="lab_sny_ShanghaiRonghengPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_sny_ShanghaiRonghengPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shanghai Rongheng Pharmaceutical Co. Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShanghaiRonghengPharmaceuticalCoLtdMember" xlink:href="sny-20231231.xsd#sny_ShanghaiRonghengPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShanghaiRonghengPharmaceuticalCoLtdMember" xlink:to="lab_sny_ShanghaiRonghengPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems_17b601eb-04a3-404b-9fca-48d4dcc128a7_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of acquisitions of property plant and equipment by operating segments [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of acquisitions of property plant and equipment by operating segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems" xlink:to="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_0b194249-e384-413b-92f9-464968f79145_terseLabel_en-US" xlink:label="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash-generating units [axis]</link:label>
    <link:label id="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_label_en-US" xlink:label="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash-generating units [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis" xlink:to="lab_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_847e5c87-36eb-45c2-aac9-a001ba7c7b18_netLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of shares awarded (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_122a49bf-1194-4b13-97ca-83b37234c236_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InnoventBiologicsMember_4f738ce3-17b0-4a54-9bf0-f47749b2e085_terseLabel_en-US" xlink:label="lab_sny_InnoventBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics</link:label>
    <link:label id="lab_sny_InnoventBiologicsMember_label_en-US" xlink:label="lab_sny_InnoventBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics [Member]</link:label>
    <link:label id="lab_sny_InnoventBiologicsMember_documentation_en-US" xlink:label="lab_sny_InnoventBiologicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InnoventBiologicsMember" xlink:href="sny-20231231.xsd#sny_InnoventBiologicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InnoventBiologicsMember" xlink:to="lab_sny_InnoventBiologicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture_a553c6cd-46dd-4d51-9320-2a7bb0085516_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of ownership interest in joint venture (in percent)</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of ownership interest in joint venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember_db0c0515-f043-4ab1-a603-6817368d7cb3_terseLabel_en-US" xlink:label="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of defined benefit obligation</link:label>
    <link:label id="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember_label_en-US" xlink:label="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of defined benefit obligation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:to="lab_ifrs-full_PresentValueOfDefinedBenefitObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_6d69f38d-db37-44cc-8cfa-768b92e7d033_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_646e50d3-b0c6-4bba-9d39-2c74c5a6973b_terseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities related to business combinations and to non-controlling interests</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_label_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities Related To Business Combinations And To Non-Controlling Interests</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_documentation_en-US" xlink:label="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:href="sny-20231231.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:to="lab_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember_3c66752c-5a51-4705-9432-0ac62363b11c_terseLabel_en-US" xlink:label="lab_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interests in subsidiaries and investments in other entities</link:label>
    <link:label id="lab_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember_label_en-US" xlink:label="lab_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interests In Subsidiaries And Investments In Other Entities [member]</link:label>
    <link:label id="lab_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember_documentation_en-US" xlink:label="lab_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interests in subsidiaries and investments in other entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember" xlink:href="sny-20231231.xsd#sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember" xlink:to="lab_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_16e5f652-3dc5-4e91-8670-fa54d0ea13fb_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures_f264a274-36d5-4575-9b4f-2b962ee306a4_totalLabel_en-US" xlink:label="lab_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Share Of Profit And Comprehensive Income Of Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" xlink:to="lab_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedCashFlowStatementsCaptionsLineItems_fa554727-16cb-487c-8305-c9ba3c61b7ac_terseLabel_en-US" xlink:label="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedCashFlowStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FixedInterestRateMember_027be86a-ee00-4942-9ce0-1a484d50b05e_terseLabel_en-US" xlink:label="lab_ifrs-full_FixedInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed-rate debt</link:label>
    <link:label id="lab_ifrs-full_FixedInterestRateMember_label_en-US" xlink:label="lab_ifrs-full_FixedInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed interest rate [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixedInterestRateMember" xlink:to="lab_ifrs-full_FixedInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_108cdfe5-5846-4bb3-9c9a-24f8fbb49df4_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of ownership interest in associate (in percent)</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_399c8d6e-5a13-4653-9af2-b9949e04edc9_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of ownership interest in associate (in percent)</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_abc64804-3ea2-49df-bd52-c8f33ea53694_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAuditFeesAndOtherServicesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of audit fees and other services [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfAuditFeesAndOtherServicesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Audit Fees And Other Services [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfAuditFeesAndOtherServicesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of audit fees and other services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfAuditFeesAndOtherServicesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems" xlink:to="lab_sny_DisclosureOfAuditFeesAndOtherServicesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b9f312f7-31c6-4a70-b9be-ae0ab84864c7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RelatedPartyAbstract_920d2f74-076f-443e-92bd-20736451a92d_terseLabel_en-US" xlink:label="lab_sny_RelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Abstract]</link:label>
    <link:label id="lab_sny_RelatedPartyAbstract_label_en-US" xlink:label="lab_sny_RelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Abstract]</link:label>
    <link:label id="lab_sny_RelatedPartyAbstract_documentation_en-US" xlink:label="lab_sny_RelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RelatedPartyAbstract" xlink:href="sny-20231231.xsd#sny_RelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RelatedPartyAbstract" xlink:to="lab_sny_RelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareHungaryKFTMember_e2c905f5-e2da-4f85-a928-0c8fe78d2d88_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareHungaryKFTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Hungary K.F.T</link:label>
    <link:label id="lab_sny_OpellaHealthcareHungaryKFTMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareHungaryKFTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Hungary K.F.T [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareHungaryKFTMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareHungaryKFTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Hungary K.F.T</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareHungaryKFTMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareHungaryKFTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareHungaryKFTMember" xlink:to="lab_sny_OpellaHealthcareHungaryKFTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_41d7aa93-fed5-464a-9087-4943f40e7800_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Principal Transactions and Balances with Related Parties</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainLossOnSaleOfTreasuryShares_0179c55e-d1cc-4249-962b-fcae99c67e99_terseLabel_en-US" xlink:label="lab_sny_GainLossOnSaleOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized on sale of treasury shares</link:label>
    <link:label id="lab_sny_GainLossOnSaleOfTreasuryShares_label_en-US" xlink:label="lab_sny_GainLossOnSaleOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Sale Of Treasury Shares</link:label>
    <link:label id="lab_sny_GainLossOnSaleOfTreasuryShares_documentation_en-US" xlink:label="lab_sny_GainLossOnSaleOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale of treasury shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnSaleOfTreasuryShares" xlink:href="sny-20231231.xsd#sny_GainLossOnSaleOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainLossOnSaleOfTreasuryShares" xlink:to="lab_sny_GainLossOnSaleOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock_98cffb9d-9ddf-458c-8439-07e04ecb8136_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Expense for Pensions and Other Post-employment Benefits Allocated between Income Statement Line Items</link:label>
    <link:label id="lab_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Expense For Pensions And Other Post Employment Benefits By Income Statement Line Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of expense for pensions and other post employment benefits by income statement line.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialLiabilitiesMember_64b657ca-0b6e-4160-b7e1-bd3aa56c795f_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:label id="lab_sny_DerivativeFinancialLiabilitiesMember_label_en-US" xlink:label="lab_sny_DerivativeFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Liabilities [Member]</link:label>
    <link:label id="lab_sny_DerivativeFinancialLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialLiabilitiesMember" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialLiabilitiesMember" xlink:to="lab_sny_DerivativeFinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_f367e93d-34a5-48d6-9bf1-8c98c9f7944c_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for impairment of assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCivilClaimsOnGoing_3897884d-3968-476f-b346-619c303fe2da_terseLabel_en-US" xlink:label="lab_sny_NumberOfCivilClaimsOnGoing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of civil claims on-going</link:label>
    <link:label id="lab_sny_NumberOfCivilClaimsOnGoing_label_en-US" xlink:label="lab_sny_NumberOfCivilClaimsOnGoing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Civil Claims On-Going</link:label>
    <link:label id="lab_sny_NumberOfCivilClaimsOnGoing_documentation_en-US" xlink:label="lab_sny_NumberOfCivilClaimsOnGoing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Civil Claims On-Going</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCivilClaimsOnGoing" xlink:href="sny-20231231.xsd#sny_NumberOfCivilClaimsOnGoing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCivilClaimsOnGoing" xlink:to="lab_sny_NumberOfCivilClaimsOnGoing" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket_8a2d388b-ea68-41e7-b831-4c70273b1793_terseLabel_en-US" xlink:label="lab_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities quoted in an active market</link:label>
    <link:label id="lab_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket_label_en-US" xlink:label="lab_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Contributed To Fair Value Of Plan Assets, Securities Quoted In An Active Market</link:label>
    <link:label id="lab_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket_documentation_en-US" xlink:label="lab_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Contributed To Fair Value Of Plan Assets, Securities Quoted In An Active Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" xlink:to="lab_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod_c8f34664-1c10-4971-bdb8-6dd04a632bc0_terseLabel_en-US" xlink:label="lab_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in subsidiary, minimum holding period</link:label>
    <link:label id="lab_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod_label_en-US" xlink:label="lab_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership Interest In Subsidiary, Minimum Holding Period</link:label>
    <link:label id="lab_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod_documentation_en-US" xlink:label="lab_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership Interest In Subsidiary, Minimum Holding Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod" xlink:href="sny-20231231.xsd#sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod" xlink:to="lab_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_March2019EMTNISINFR0013409844Member_468d3c6d-db43-42b5-bbcd-e49724eb4d77_terseLabel_en-US" xlink:label="lab_sny_March2019EMTNISINFR0013409844Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 EMTN ISIN FR0013409844</link:label>
    <link:label id="lab_sny_March2019EMTNISINFR0013409844Member_label_en-US" xlink:label="lab_sny_March2019EMTNISINFR0013409844Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 EMTN ISIN FR0013409844 [Member]</link:label>
    <link:label id="lab_sny_March2019EMTNISINFR0013409844Member_documentation_en-US" xlink:label="lab_sny_March2019EMTNISINFR0013409844Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 EMTN ISIN FR0013409844 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2019EMTNISINFR0013409844Member" xlink:href="sny-20231231.xsd#sny_March2019EMTNISINFR0013409844Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_March2019EMTNISINFR0013409844Member" xlink:to="lab_sny_March2019EMTNISINFR0013409844Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllowanceForCreditLossesMember_b9001054-6531-46f5-ac9e-c6c0b0c12872_terseLabel_en-US" xlink:label="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances</link:label>
    <link:label id="lab_ifrs-full_AllowanceForCreditLossesMember_label_en-US" xlink:label="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllowanceForCreditLossesMember" xlink:to="lab_ifrs-full_AllowanceForCreditLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable_f4120741-9ee9-4336-a741-1c38c706a080_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of finance lease payments receivable [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of finance lease payments receivable [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AventisCropScienceRetainedLiabilitiesMember_596b5703-0758-4d92-8980-3b27bab4e337_terseLabel_en-US" xlink:label="lab_sny_AventisCropScienceRetainedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Crop Science retained liabilities</link:label>
    <link:label id="lab_sny_AventisCropScienceRetainedLiabilitiesMember_label_en-US" xlink:label="lab_sny_AventisCropScienceRetainedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Crop Science Retained Liabilities [member]</link:label>
    <link:label id="lab_sny_AventisCropScienceRetainedLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_AventisCropScienceRetainedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis crop science retained liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisCropScienceRetainedLiabilitiesMember" xlink:href="sny-20231231.xsd#sny_AventisCropScienceRetainedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AventisCropScienceRetainedLiabilitiesMember" xlink:to="lab_sny_AventisCropScienceRetainedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_395315d0-fcb0-448b-882d-8698a8faa988_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial expenses and income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of finance income (cost) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_d284d200-981c-4a4b-87a5-9273d20804c0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MilestoneTypesAxis_9a11b26e-a35e-48ee-b2ba-2c12c62216ce_terseLabel_en-US" xlink:label="lab_sny_MilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Types [Axis]</link:label>
    <link:label id="lab_sny_MilestoneTypesAxis_label_en-US" xlink:label="lab_sny_MilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Types [Axis]</link:label>
    <link:label id="lab_sny_MilestoneTypesAxis_documentation_en-US" xlink:label="lab_sny_MilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Types</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MilestoneTypesAxis" xlink:href="sny-20231231.xsd#sny_MilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MilestoneTypesAxis" xlink:to="lab_sny_MilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ErnstYoungEtAutresMember_ad6db5ba-7342-4d61-9666-21c877162009_terseLabel_en-US" xlink:label="lab_sny_ErnstYoungEtAutresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ernst &amp; Young et Autres</link:label>
    <link:label id="lab_sny_ErnstYoungEtAutresMember_label_en-US" xlink:label="lab_sny_ErnstYoungEtAutresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ernst &amp; Young Et Autres [Member]</link:label>
    <link:label id="lab_sny_ErnstYoungEtAutresMember_documentation_en-US" xlink:label="lab_sny_ErnstYoungEtAutresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ernst &amp; Young Et Autres</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ErnstYoungEtAutresMember" xlink:href="sny-20231231.xsd#sny_ErnstYoungEtAutresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ErnstYoungEtAutresMember" xlink:to="lab_sny_ErnstYoungEtAutresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisHealthcarePtyLtdMember_1290e796-3b44-4d39-b4f9-004c400a55e3_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisHealthcarePtyLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Healthcare Pty Ltd</link:label>
    <link:label id="lab_sny_SanofiAventisHealthcarePtyLtdMember_label_en-US" xlink:label="lab_sny_SanofiAventisHealthcarePtyLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Healthcare Pty Ltd [member]</link:label>
    <link:label id="lab_sny_SanofiAventisHealthcarePtyLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisHealthcarePtyLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Healthcare Pty Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisHealthcarePtyLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisHealthcarePtyLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisHealthcarePtyLtdMember" xlink:to="lab_sny_SanofiAventisHealthcarePtyLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember_f7b933e1-cd3e-4c61-8933-58b91f1f53b7_terseLabel_en-US" xlink:label="lab_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value on redemption before derivative instruments</link:label>
    <link:label id="lab_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember_label_en-US" xlink:label="lab_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value On Redemption Before Derivative Instruments [Member]</link:label>
    <link:label id="lab_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember_documentation_en-US" xlink:label="lab_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value on redemption before derivative instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember" xlink:to="lab_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OutsideUnitedStatesMember_cc2a190b-db2c-42c6-a304-abe0ef1edb90_terseLabel_en-US" xlink:label="lab_sny_OutsideUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside the United States</link:label>
    <link:label id="lab_sny_OutsideUnitedStatesMember_label_en-US" xlink:label="lab_sny_OutsideUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside United States [member]</link:label>
    <link:label id="lab_sny_OutsideUnitedStatesMember_documentation_en-US" xlink:label="lab_sny_OutsideUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside United States.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OutsideUnitedStatesMember" xlink:href="sny-20231231.xsd#sny_OutsideUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OutsideUnitedStatesMember" xlink:to="lab_sny_OutsideUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_6b9f54e8-4b63-4364-8834-46734dc4ca03_terseLabel_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from out-licensing</link:label>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_label_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Resulting From Out-Licensing</link:label>
    <link:label id="lab_sny_IncomeResultingFromOutLicensing_documentation_en-US" xlink:label="lab_sny_IncomeResultingFromOutLicensing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Resulting From Out-Licensing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing" xlink:href="sny-20231231.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeResultingFromOutLicensing" xlink:to="lab_sny_IncomeResultingFromOutLicensing" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember_e737c71d-ac07-4cdf-9e4f-da421a93f48d_terseLabel_en-US" xlink:label="lab_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxotere mississippi attorney general litigation in the US</link:label>
    <link:label id="lab_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxotere Mississippi Attorney General Litigation In The US [Member]</link:label>
    <link:label id="lab_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxotere mississippi attorney general litigation in the US.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember" xlink:href="sny-20231231.xsd#sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember" xlink:to="lab_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_49236b43-9ee6-4e11-b168-8ade5b3607db_totalLabel_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before tax and investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_8666eca4-eabd-46a7-9d17-0a3d8e61bdc3_terseLabel_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before tax and investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_label_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Tax And Investments Accounted For Equity Method Investments</link:label>
    <link:label id="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_documentation_en-US" xlink:label="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before tax and investments accounted for equity method investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:href="sny-20231231.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:to="lab_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member_934143ac-f9e9-4fa1-b1e7-8982eda570be_verboseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_61c7049a-d635-4150-ba16-471b2db87a6e_terseLabel_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_label_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:label id="lab_sny_GeneralInformationAboutFinancialStatementsAbstract_documentation_en-US" xlink:label="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Information About Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:href="sny-20231231.xsd#sny_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:to="lab_sny_GeneralInformationAboutFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TotalUndiscountedCashFlow_c4e227f2-1eab-4baf-b347-75e5c301e3a8_totalLabel_en-US" xlink:label="lab_sny_TotalUndiscountedCashFlow" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_sny_TotalUndiscountedCashFlow_label_en-US" xlink:label="lab_sny_TotalUndiscountedCashFlow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Undiscounted Cash Flow</link:label>
    <link:label id="lab_sny_TotalUndiscountedCashFlow_documentation_en-US" xlink:label="lab_sny_TotalUndiscountedCashFlow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted cash flow.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalUndiscountedCashFlow" xlink:href="sny-20231231.xsd#sny_TotalUndiscountedCashFlow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TotalUndiscountedCashFlow" xlink:to="lab_sny_TotalUndiscountedCashFlow" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BioverativTherapeuticsIncMember_9d55cfca-9ff2-4a47-9c4a-8cff57e7b8fe_terseLabel_en-US" xlink:label="lab_sny_BioverativTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ Therapeutics Inc.</link:label>
    <link:label id="lab_sny_BioverativTherapeuticsIncMember_label_en-US" xlink:label="lab_sny_BioverativTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ Therapeutics Inc. [member]</link:label>
    <link:label id="lab_sny_BioverativTherapeuticsIncMember_documentation_en-US" xlink:label="lab_sny_BioverativTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativTherapeuticsIncMember" xlink:href="sny-20231231.xsd#sny_BioverativTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BioverativTherapeuticsIncMember" xlink:to="lab_sny_BioverativTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_03c82d07-a083-4f85-a384-dff17f3d5021_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisIsraelLtdMember_77fb1d92-5222-4f6e-947b-e49522fc58b5_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisIsraelLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Isra&#235;l Ltd</link:label>
    <link:label id="lab_sny_SanofiAventisIsraelLtdMember_label_en-US" xlink:label="lab_sny_SanofiAventisIsraelLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Israel Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisIsraelLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisIsraelLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Israel Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisIsraelLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisIsraelLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisIsraelLtdMember" xlink:to="lab_sny_SanofiAventisIsraelLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ConsiderationTransferredValuationPeriod_18d0811b-6c78-4292-bc02-03eaedd2ecdd_terseLabel_en-US" xlink:label="lab_sny_ConsiderationTransferredValuationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, valuation period</link:label>
    <link:label id="lab_sny_ConsiderationTransferredValuationPeriod_label_en-US" xlink:label="lab_sny_ConsiderationTransferredValuationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Transferred, Valuation Period</link:label>
    <link:label id="lab_sny_ConsiderationTransferredValuationPeriod_documentation_en-US" xlink:label="lab_sny_ConsiderationTransferredValuationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Transferred, Valuation Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsiderationTransferredValuationPeriod" xlink:href="sny-20231231.xsd#sny_ConsiderationTransferredValuationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ConsiderationTransferredValuationPeriod" xlink:to="lab_sny_ConsiderationTransferredValuationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_8d8c848e-1d4c-476e-8a01-fad158547444_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInKoreanWonMember_c293838a-55ef-4286-9e91-01c5af870d88_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In Korean Won</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInKoreanWonMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In Korean Won [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInKoreanWonMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In Korean Won</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInKoreanWonMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInKoreanWonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInKoreanWonMember" xlink:to="lab_sny_ForwardCurrencySalesInKoreanWonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiArabiaTradingCompanyLimitedMember_294cbb38-ace7-4c2e-86fe-53275025ab9d_terseLabel_en-US" xlink:label="lab_sny_SanofiArabiaTradingCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Arabia Trading Company Limited</link:label>
    <link:label id="lab_sny_SanofiArabiaTradingCompanyLimitedMember_label_en-US" xlink:label="lab_sny_SanofiArabiaTradingCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Arabia Trading Company Limited [Member]</link:label>
    <link:label id="lab_sny_SanofiArabiaTradingCompanyLimitedMember_documentation_en-US" xlink:label="lab_sny_SanofiArabiaTradingCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Arabia Trading Company Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiArabiaTradingCompanyLimitedMember" xlink:href="sny-20231231.xsd#sny_SanofiArabiaTradingCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiArabiaTradingCompanyLimitedMember" xlink:to="lab_sny_SanofiArabiaTradingCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1f800cdb-463f-4046-8cda-c4c8aaa8e405_negatedLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options forfeited (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_VehiclesMember_00340747-f07b-4d15-a139-66d20f49466c_terseLabel_en-US" xlink:label="lab_ifrs-full_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicle fleet</link:label>
    <link:label id="lab_ifrs-full_VehiclesMember_label_en-US" xlink:label="lab_ifrs-full_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_VehiclesMember" xlink:to="lab_ifrs-full_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_5dc762ea-7c88-4fd0-af00-5f8b300f70f3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmunixMember_dc5f0126-8525-4559-9849-ac6f3bfa9d39_terseLabel_en-US" xlink:label="lab_sny_AmunixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amunix</link:label>
    <link:label id="lab_sny_AmunixMember_label_en-US" xlink:label="lab_sny_AmunixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amunix [Member]</link:label>
    <link:label id="lab_sny_AmunixMember_documentation_en-US" xlink:label="lab_sny_AmunixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amunix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixMember" xlink:href="sny-20231231.xsd#sny_AmunixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmunixMember" xlink:to="lab_sny_AmunixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestCostsCapitalised_03639012-e583-48dc-a012-d5308e9140bb_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestCostsCapitalised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized interest</link:label>
    <link:label id="lab_ifrs-full_InterestCostsCapitalised_label_en-US" xlink:label="lab_ifrs-full_InterestCostsCapitalised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest costs capitalised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestCostsCapitalised" xlink:to="lab_ifrs-full_InterestCostsCapitalised" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DeferredTaxRelatingToRestructuringProvisionsMember_264fa507-85bb-447c-acf4-a0d5f550f0b6_terseLabel_en-US" xlink:label="lab_sny_DeferredTaxRelatingToRestructuringProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax relating to restructuring provisions</link:label>
    <link:label id="lab_sny_DeferredTaxRelatingToRestructuringProvisionsMember_label_en-US" xlink:label="lab_sny_DeferredTaxRelatingToRestructuringProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Relating To Restructuring Provisions [member]</link:label>
    <link:label id="lab_sny_DeferredTaxRelatingToRestructuringProvisionsMember_documentation_en-US" xlink:label="lab_sny_DeferredTaxRelatingToRestructuringProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax relating to restructuring provisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DeferredTaxRelatingToRestructuringProvisionsMember" xlink:href="sny-20231231.xsd#sny_DeferredTaxRelatingToRestructuringProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DeferredTaxRelatingToRestructuringProvisionsMember" xlink:to="lab_sny_DeferredTaxRelatingToRestructuringProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_adf0cca3-b12c-47e1-a4c1-279307d9e721_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Fair Value Measurement of Assets and Liabilities [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_label_en-US" xlink:label="lab_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Fair Value Measurement Of Assets And Liabilities [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:to="lab_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareKoreaIncMember_565c6500-cea7-41a2-8aa0-a65320e39a6d_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareKoreaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella healthcare Korea Inc.</link:label>
    <link:label id="lab_sny_OpellaHealthcareKoreaIncMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareKoreaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Korea Inc. [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareKoreaIncMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareKoreaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Korea Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareKoreaIncMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareKoreaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareKoreaIncMember" xlink:to="lab_sny_OpellaHealthcareKoreaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LonzaMember_7869095d-649a-4f14-aaae-95dbfd4d68fe_terseLabel_en-US" xlink:label="lab_sny_LonzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza</link:label>
    <link:label id="lab_sny_LonzaMember_label_en-US" xlink:label="lab_sny_LonzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza [member]</link:label>
    <link:label id="lab_sny_LonzaMember_documentation_en-US" xlink:label="lab_sny_LonzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LonzaMember" xlink:href="sny-20231231.xsd#sny_LonzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LonzaMember" xlink:to="lab_sny_LonzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_fdb6cdf7-b79d-4942-8146-b3a6ff6f985a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AuditorsRemunerationTableTextBlock_03f7d8fc-5516-48a2-9269-5ef88670f336_terseLabel_en-US" xlink:label="lab_sny_AuditorsRemunerationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Accountants' Fees and Services</link:label>
    <link:label id="lab_sny_AuditorsRemunerationTableTextBlock_label_en-US" xlink:label="lab_sny_AuditorsRemunerationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditors Remuneration [Table Text Block]</link:label>
    <link:label id="lab_sny_AuditorsRemunerationTableTextBlock_documentation_en-US" xlink:label="lab_sny_AuditorsRemunerationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditors remuneration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsRemunerationTableTextBlock" xlink:href="sny-20231231.xsd#sny_AuditorsRemunerationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AuditorsRemunerationTableTextBlock" xlink:to="lab_sny_AuditorsRemunerationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_54c4ba7e-f8b1-4cae-8d7a-43c325862627_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales_33944388-4bdb-42a6-9283-65a31e5a5c8d_terseLabel_en-US" xlink:label="lab_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to current period sales</link:label>
    <link:label id="lab_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales_label_en-US" xlink:label="lab_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Through New Provision Related To Current Period Sales</link:label>
    <link:label id="lab_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales_documentation_en-US" xlink:label="lab_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to current period sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" xlink:href="sny-20231231.xsd#sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" xlink:to="lab_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_c93adce2-47f0-4d3e-bb32-aed2127e80f7_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_7996af33-a960-4b78-9d36-18ec4d139116_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_f5377f92-6248-46c4-bb89-c86e041852d5_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_e425b4e8-3ac6-4821-b542-b0ac928aac86_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_8d795b00-cf3d-4371-a262-307d78fdd14c_totalLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_b044b5a2-0fa7-4345-98be-eca53f8b6c20_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisDeVenezuelaSAMember_6df4992b-3071-44d1-918e-36e8a341a2ac_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisDeVenezuelaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis de Venezuela SA</link:label>
    <link:label id="lab_sny_SanofiAventisDeVenezuelaSAMember_label_en-US" xlink:label="lab_sny_SanofiAventisDeVenezuelaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis De Venezuela SA [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisDeVenezuelaSAMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisDeVenezuelaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis de Venezuela SA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeVenezuelaSAMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeVenezuelaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisDeVenezuelaSAMember" xlink:to="lab_sny_SanofiAventisDeVenezuelaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_94b45da9-af22-4e58-bbab-a6a611b5e029_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLineOfCreditFacilityLineItems_79ac48a3-3446-4b89-b3c7-eaa28c06aded_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfLineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Line Of Credit Facility [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLineOfCreditFacilityLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfLineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of line of credit facility table line items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLineOfCreditFacilityLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfLineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLineOfCreditFacilityLineItems" xlink:to="lab_sny_DisclosureOfLineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockSubscriptionOptionPlanFiveMember_599ff4e5-36c4-4c3e-be7f-38bf6b1610a7_terseLabel_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan five</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanFiveMember_label_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Option Plan Five [Member]</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanFiveMember_documentation_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanFiveMember" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockSubscriptionOptionPlanFiveMember" xlink:to="lab_sny_StockSubscriptionOptionPlanFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_e7cbc6c2-10f8-4902-8b72-49860f8cdd92_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lab_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock_f45c6cf3-58d8-49cf-8825-37434e61e4db_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised</link:label>
    <link:label id="lab_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Stock Subscription Option Plans Under Which Options Were Exercised In The Year [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of stock subscription option plans under which options were exercised in the year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock" xlink:to="lab_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_2e81032a-fb1a-4a50-bf10-9052db8e43a5_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase)/decrease in accounts receivable</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_6449b6ae-385e-471f-9cd9-76e55a6f158b_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows related to derivative instruments</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial liabilities, undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiMedleyFarmaceuticaLtdaMember_d6b17567-e648-464c-9bf0-784bc245aa50_terseLabel_en-US" xlink:label="lab_sny_SanofiMedleyFarmaceuticaLtdaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Medley Farmaceutica Ltda</link:label>
    <link:label id="lab_sny_SanofiMedleyFarmaceuticaLtdaMember_label_en-US" xlink:label="lab_sny_SanofiMedleyFarmaceuticaLtdaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Medley Farmaceutica Ltda [Member]</link:label>
    <link:label id="lab_sny_SanofiMedleyFarmaceuticaLtdaMember_documentation_en-US" xlink:label="lab_sny_SanofiMedleyFarmaceuticaLtdaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Medley Farmaceutica Ltda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMedleyFarmaceuticaLtdaMember" xlink:href="sny-20231231.xsd#sny_SanofiMedleyFarmaceuticaLtdaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiMedleyFarmaceuticaLtdaMember" xlink:to="lab_sny_SanofiMedleyFarmaceuticaLtdaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_a64537bb-4a3b-4fff-9bcd-7aeb081c4194_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for determining components of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaterialReconcilingItemsMember_0d2c7768-b971-46dd-9a93-b7254919f5b4_terseLabel_en-US" xlink:label="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material reconciling items</link:label>
    <link:label id="lab_ifrs-full_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material reconciling items [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaterialReconcilingItemsMember" xlink:to="lab_ifrs-full_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_3fe0586f-dc0d-496a-a956-8edba193f29a_terseLabel_en-US" xlink:label="lab_sny_PercentageOfCumulativeDevelopmentCostsReimbursed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cumulative development costs reimbursed</link:label>
    <link:label id="lab_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_label_en-US" xlink:label="lab_sny_PercentageOfCumulativeDevelopmentCostsReimbursed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Cumulative Development Costs Reimbursed</link:label>
    <link:label id="lab_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_documentation_en-US" xlink:label="lab_sny_PercentageOfCumulativeDevelopmentCostsReimbursed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cumulative development costs reimbursed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed" xlink:href="sny-20231231.xsd#sny_PercentageOfCumulativeDevelopmentCostsReimbursed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed" xlink:to="lab_sny_PercentageOfCumulativeDevelopmentCostsReimbursed" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_b6e350ec-9578-4428-9473-f2c077c02e91_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US</link:label>
    <link:label id="lab_country_US_81735046-347a-4aad-8e45-b7df52b434cb_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfOperatingSegments1_0a5ca602-e50e-43b2-a1a3-631f5d7a354e_terseLabel_en-US" xlink:label="lab_sny_NumberOfOperatingSegments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_sny_NumberOfOperatingSegments1_label_en-US" xlink:label="lab_sny_NumberOfOperatingSegments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Segments1</link:label>
    <link:label id="lab_sny_NumberOfOperatingSegments1_documentation_en-US" xlink:label="lab_sny_NumberOfOperatingSegments1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments1" xlink:href="sny-20231231.xsd#sny_NumberOfOperatingSegments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfOperatingSegments1" xlink:to="lab_sny_NumberOfOperatingSegments1" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember_6191732c-6ffe-4dd3-a33c-b9bda36dbcfc_terseLabel_en-US" xlink:label="lab_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate before derivative instruments</link:label>
    <link:label id="lab_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember_label_en-US" xlink:label="lab_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Interest Rate Before Derivative Instruments [Member]</link:label>
    <link:label id="lab_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember_documentation_en-US" xlink:label="lab_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate before derivative instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember" xlink:href="sny-20231231.xsd#sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember" xlink:to="lab_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisRomaniaSRLMember_ff83a4f9-60b9-4d3e-aa36-80a8f0061418_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisRomaniaSRLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Romania SRL</link:label>
    <link:label id="lab_sny_SanofiAventisRomaniaSRLMember_label_en-US" xlink:label="lab_sny_SanofiAventisRomaniaSRLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Romania SRL [member]</link:label>
    <link:label id="lab_sny_SanofiAventisRomaniaSRLMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisRomaniaSRLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Romania SRL.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisRomaniaSRLMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisRomaniaSRLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisRomaniaSRLMember" xlink:to="lab_sny_SanofiAventisRomaniaSRLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MutualFundInvestmentsMember_88458d9a-8bb5-444c-bf27-718ae736af38_terseLabel_en-US" xlink:label="lab_sny_MutualFundInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual fund investments</link:label>
    <link:label id="lab_sny_MutualFundInvestmentsMember_label_en-US" xlink:label="lab_sny_MutualFundInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Fund Investments [Member]</link:label>
    <link:label id="lab_sny_MutualFundInvestmentsMember_documentation_en-US" xlink:label="lab_sny_MutualFundInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual fund investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MutualFundInvestmentsMember" xlink:href="sny-20231231.xsd#sny_MutualFundInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MutualFundInvestmentsMember" xlink:to="lab_sny_MutualFundInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NotionalRetirementAge_60618365-6f1d-4a0e-abd2-caec934b7607_terseLabel_en-US" xlink:label="lab_sny_NotionalRetirementAge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional retirement age</link:label>
    <link:label id="lab_sny_NotionalRetirementAge_label_en-US" xlink:label="lab_sny_NotionalRetirementAge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Retirement Age</link:label>
    <link:label id="lab_sny_NotionalRetirementAge_documentation_en-US" xlink:label="lab_sny_NotionalRetirementAge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional retirement age.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotionalRetirementAge" xlink:href="sny-20231231.xsd#sny_NotionalRetirementAge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NotionalRetirementAge" xlink:to="lab_sny_NotionalRetirementAge" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets_a350cc56-e4ad-4ba8-82ef-c02cecf735cc_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Net Exchange Differences, Property, Plant and Equipment, Right Of Use Assets</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Net Exchange Differences, Property, Plant and Equipment, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" xlink:to="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInExpenseOfRestructuringActivities_27745fe2-0157-441c-b504-133e531e448d_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in restructuring costs</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInExpenseOfRestructuringActivities_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Expense Of Restructuring Activities</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInExpenseOfRestructuringActivities_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Expense Of Restructuring Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInExpenseOfRestructuringActivities" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseInExpenseOfRestructuringActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInExpenseOfRestructuringActivities" xlink:to="lab_sny_IncreaseDecreaseInExpenseOfRestructuringActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotionalAmount_8ab0d04b-4ccb-4ee7-bc5a-4c39ee0fb6cb_terseLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facilities, amount drawable</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_539d38ad-acd9-4f33-aba5-70af1ebaeb64_verboseLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_95a6cec0-a70c-49f9-8e62-1b1aee08816d_netLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount of forward sales</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_label_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotionalAmount" xlink:to="lab_ifrs-full_NotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_102759c3-1ce9-4f52-8735-5251c4e25619_terseLabel_en-US" xlink:label="lab_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding arrangements of defined benefit plans [member]</link:label>
    <link:label id="lab_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_label_en-US" xlink:label="lab_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding arrangements of defined benefit plans [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:to="lab_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FourBillionFacilityMaturingMarch2029Member_503481c6-2a5d-4b1d-a78d-b270d5e7ae34_terseLabel_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#8364;4 billion facility maturing March 2029</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingMarch2029Member_label_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Billion Facility Maturing March 2029 [Member]</link:label>
    <link:label id="lab_sny_FourBillionFacilityMaturingMarch2029Member_documentation_en-US" xlink:label="lab_sny_FourBillionFacilityMaturingMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Billion Facility Maturing March 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingMarch2029Member" xlink:href="sny-20231231.xsd#sny_FourBillionFacilityMaturingMarch2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FourBillionFacilityMaturingMarch2029Member" xlink:to="lab_sny_FourBillionFacilityMaturingMarch2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ConsiderationTransferredMaximumAmount_25c1e361-9961-45b9-8f74-266dc7f86e19_terseLabel_en-US" xlink:label="lab_sny_ConsiderationTransferredMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, maximum amount</link:label>
    <link:label id="lab_sny_ConsiderationTransferredMaximumAmount_label_en-US" xlink:label="lab_sny_ConsiderationTransferredMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Transferred, Maximum Amount</link:label>
    <link:label id="lab_sny_ConsiderationTransferredMaximumAmount_documentation_en-US" xlink:label="lab_sny_ConsiderationTransferredMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Transferred, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsiderationTransferredMaximumAmount" xlink:href="sny-20231231.xsd#sny_ConsiderationTransferredMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ConsiderationTransferredMaximumAmount" xlink:to="lab_sny_ConsiderationTransferredMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AventisPharmaHoldingsLtdMember_2feb793b-b26d-434c-8e8c-83dcce6a4029_terseLabel_en-US" xlink:label="lab_sny_AventisPharmaHoldingsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma Holdings Ltd</link:label>
    <link:label id="lab_sny_AventisPharmaHoldingsLtdMember_label_en-US" xlink:label="lab_sny_AventisPharmaHoldingsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma Holdings Ltd [Member]</link:label>
    <link:label id="lab_sny_AventisPharmaHoldingsLtdMember_documentation_en-US" xlink:label="lab_sny_AventisPharmaHoldingsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma Holdings Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaHoldingsLtdMember" xlink:href="sny-20231231.xsd#sny_AventisPharmaHoldingsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AventisPharmaHoldingsLtdMember" xlink:to="lab_sny_AventisPharmaHoldingsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisNorgeASMember_9c8c7389-a8f8-43b9-9c87-76d59e55443d_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisNorgeASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Norge AS</link:label>
    <link:label id="lab_sny_SanofiAventisNorgeASMember_label_en-US" xlink:label="lab_sny_SanofiAventisNorgeASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Norge AS [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisNorgeASMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisNorgeASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Norge AS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisNorgeASMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisNorgeASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisNorgeASMember" xlink:to="lab_sny_SanofiAventisNorgeASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ParticipatingSharesCarryingAmount_f4ec37b6-e013-4bad-97be-63f8d5825061_terseLabel_en-US" xlink:label="lab_sny_ParticipatingSharesCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating shares carrying amount</link:label>
    <link:label id="lab_sny_ParticipatingSharesCarryingAmount_label_en-US" xlink:label="lab_sny_ParticipatingSharesCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Shares Carrying Amount</link:label>
    <link:label id="lab_sny_ParticipatingSharesCarryingAmount_documentation_en-US" xlink:label="lab_sny_ParticipatingSharesCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating shares carrying amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ParticipatingSharesCarryingAmount" xlink:href="sny-20231231.xsd#sny_ParticipatingSharesCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ParticipatingSharesCarryingAmount" xlink:to="lab_sny_ParticipatingSharesCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialAssets_0d1b6edf-57d7-4f03-9791-dfd92adf9cb8_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialAssets_bfe401f0-b694-49ed-935b-666e90a91a18_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current derivative financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:to="lab_ifrs-full_NoncurrentDerivativeFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_TR_b9f241b3-4f43-40f9-95d3-68d3d2399147_terseLabel_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Turkey</link:label>
    <link:label id="lab_country_TR_label_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">T&#220;RKIYE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_TR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TR" xlink:to="lab_country_TR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_63778a7f-2389-4f0a-b2d1-1d387db96c45_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_c233e146-eb01-451c-a006-4b1f93af34d2_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill_55a7d5e1-ab28-43ba-bedc-35d477174158_terseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease through loss of control of subsidiary, intangible assets and goodwill</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease through loss of control of subsidiary, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_15105221-9834-4754-b114-ac8157f69f4a_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_25001f0a-ce55-44bf-9ece-f4bf4c618c11_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim_210e01ff-fe04-48a8-bd12-fa3bfa0c0469_terseLabel_en-US" xlink:label="lab_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of indirect victim who withdrawed their claim</link:label>
    <link:label id="lab_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim_label_en-US" xlink:label="lab_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Indirect Victim Who Withdrawed The Claim</link:label>
    <link:label id="lab_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim_documentation_en-US" xlink:label="lab_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Indirect Victim Who Withdrawed The Claim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim" xlink:href="sny-20231231.xsd#sny_NumberOfIndirectVictimWhoWithdrawedTheClaim"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim" xlink:to="lab_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisDeMexicoSADeCVMember_9b6e010f-74af-4c7b-9baa-7102585b11dd_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisDeMexicoSADeCVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis de Mexico SA de CV</link:label>
    <link:label id="lab_sny_SanofiAventisDeMexicoSADeCVMember_label_en-US" xlink:label="lab_sny_SanofiAventisDeMexicoSADeCVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis De Mexico S.A. De C.V. [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisDeMexicoSADeCVMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisDeMexicoSADeCVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis de Mexico S.A. de C.V. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeMexicoSADeCVMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeMexicoSADeCVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisDeMexicoSADeCVMember" xlink:to="lab_sny_SanofiAventisDeMexicoSADeCVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_945eb941-fe45-4ceb-bd8e-5aeba3f7203b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Interest Rate Of Debt Net Of Cash And Cash Equivalent [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_label_en-US" xlink:label="lab_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Interest Rate Of Debt NetOf Cash And Cash Equivalent [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of interest rate of debt net of cash and cash equivalent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable" xlink:to="lab_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense_10de7ea9-f94d-4066-b8d8-3baf8242ebf1_terseLabel_en-US" xlink:label="lab_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount to be reimbursed for current and future environmental expense</link:label>
    <link:label id="lab_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense_label_en-US" xlink:label="lab_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount To Be Reimbursed For Current And Future Environmental Expense</link:label>
    <link:label id="lab_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense_documentation_en-US" xlink:label="lab_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount To Be Reimbursed For Current And Future Environmental Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense" xlink:href="sny-20231231.xsd#sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense" xlink:to="lab_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_USFDAApprovalMember_8d244d03-da03-4b05-abcf-f9bfa0500010_terseLabel_en-US" xlink:label="lab_sny_USFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US FDA Approval</link:label>
    <link:label id="lab_sny_USFDAApprovalMember_label_en-US" xlink:label="lab_sny_USFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US FDA Approval [Member]</link:label>
    <link:label id="lab_sny_USFDAApprovalMember_documentation_en-US" xlink:label="lab_sny_USFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US FDA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USFDAApprovalMember" xlink:href="sny-20231231.xsd#sny_USFDAApprovalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_USFDAApprovalMember" xlink:to="lab_sny_USFDAApprovalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d64be9a9-1e67-421f-bde7-0ce84e17ea07_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems" xlink:to="lab_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans_deb0ce60-8388-48f7-b747-8fbc7702fb6a_terseLabel_en-US" xlink:label="lab_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated payments</link:label>
    <link:label id="lab_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans_label_en-US" xlink:label="lab_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Timing Of Payments In Respect Of Unfunded Pension And Other Post-employment Benefit Plans</link:label>
    <link:label id="lab_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans_documentation_en-US" xlink:label="lab_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected timing of payments in respect of unfunded pension and other post-employment benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" xlink:href="sny-20231231.xsd#sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" xlink:to="lab_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales_953fa094-8f0b-4d3c-b5e7-e4b6eafa58d0_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in provision related to prior period sales</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Provisions Related To Prior Period Sales</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in provisions related to prior period sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" xlink:to="lab_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiMember_f93a43de-cdc1-49e4-870a-81e9a67ebd8f_verboseLabel_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sny_SanofiMember_6d3723d1-d7b5-4dbe-b4b8-fb31fbef98f8_terseLabel_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sny_SanofiMember_label_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [member]</link:label>
    <link:label id="lab_sny_SanofiMember_documentation_en-US" xlink:label="lab_sny_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember" xlink:href="sny-20231231.xsd#sny_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiMember" xlink:to="lab_sny_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_7b0d7f49-8092-458d-9fc8-59d192ae8f61_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_b20f1904-761b-44cb-aceb-3973d52abea8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of material accounting policy information [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements_d7a9c867-8c54-4c4c-9f6b-2da774cebc48_terseLabel_en-US" xlink:label="lab_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services other than statutory audit, percentage</link:label>
    <link:label id="lab_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements_label_en-US" xlink:label="lab_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Auditors Remuneration For Services Other Than Audit Of Financial Statements</link:label>
    <link:label id="lab_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements_documentation_en-US" xlink:label="lab_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services other than audit of financial statements, percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" xlink:to="lab_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChattemGBHoldingMember_9acfc7d1-e745-4204-a161-d6815e049ea4_terseLabel_en-US" xlink:label="lab_sny_ChattemGBHoldingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chattem (GB) Holding</link:label>
    <link:label id="lab_sny_ChattemGBHoldingMember_label_en-US" xlink:label="lab_sny_ChattemGBHoldingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chattem (GB) Holding [Member]</link:label>
    <link:label id="lab_sny_ChattemGBHoldingMember_documentation_en-US" xlink:label="lab_sny_ChattemGBHoldingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chattem (GB) Holding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChattemGBHoldingMember" xlink:href="sny-20231231.xsd#sny_ChattemGBHoldingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChattemGBHoldingMember" xlink:to="lab_sny_ChattemGBHoldingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SaleOfStockAxis_e5b5a382-79ca-476f-9c54-3e5b3190a224_terseLabel_en-US" xlink:label="lab_sny_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_sny_SaleOfStockAxis_label_en-US" xlink:label="lab_sny_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_sny_SaleOfStockAxis_documentation_en-US" xlink:label="lab_sny_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SaleOfStockAxis" xlink:href="sny-20231231.xsd#sny_SaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SaleOfStockAxis" xlink:to="lab_sny_SaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock_b314a222-f01e-4e3e-a8b1-2587525cce42_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Off Balance Sheet Commitments Relating to Property, Plant and Equipment</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments Of Property Plant And Equipment [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Off-Balance Sheet Commitments of Property Plant and Equipment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_0db978e9-ee03-4fe7-abc6-2aae6acea8a5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_22f95a6d-3a71-44ad-9ea7-300970c50264_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General inflation rate</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of expected rates of inflation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations_312e7999-6e54-4247-a8f8-9b65b04eb5d0_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments related to milestone payments, business combinations</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Milestone Payments, Business Combinations</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Milestone Payments, Business Combinations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations" xlink:to="lab_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TopUpDefinedBenefitPensionPlanMember_fb22c7da-884d-4184-b91e-9a580fe8eb55_terseLabel_en-US" xlink:label="lab_sny_TopUpDefinedBenefitPensionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top-up defined-benefit pension plan</link:label>
    <link:label id="lab_sny_TopUpDefinedBenefitPensionPlanMember_label_en-US" xlink:label="lab_sny_TopUpDefinedBenefitPensionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top-Up Defined-Benefit Pension Plan [Member]</link:label>
    <link:label id="lab_sny_TopUpDefinedBenefitPensionPlanMember_documentation_en-US" xlink:label="lab_sny_TopUpDefinedBenefitPensionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top-up defined-benefit pension plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TopUpDefinedBenefitPensionPlanMember" xlink:href="sny-20231231.xsd#sny_TopUpDefinedBenefitPensionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TopUpDefinedBenefitPensionPlanMember" xlink:to="lab_sny_TopUpDefinedBenefitPensionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_e0d0f0ec-5f5d-4d65-87ad-59a006e5b1ab_terseLabel_en-US" xlink:label="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_label_en-US" xlink:label="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations</link:label>
    <link:label id="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_documentation_en-US" xlink:label="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:href="sny-20231231.xsd#sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:to="lab_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_70f8dcab-62df-47d8-94ce-bf3893c54545_terseLabel_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period</link:label>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_label_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Years, Service Period</link:label>
    <link:label id="lab_sny_NumberOfYearsServicePeriod_documentation_en-US" xlink:label="lab_sny_NumberOfYearsServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Years, Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod" xlink:href="sny-20231231.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfYearsServicePeriod" xlink:to="lab_sny_NumberOfYearsServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_14a426f9-1636-4a58-9cff-dfd71a2d9080_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_594b21c2-6137-4784-9b47-7212d65934bd_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares not yet fully vested (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Restricted Shares Not Yet Fully Vested</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesNotYetFullyVested_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of restricted shares not yet fully vested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:href="sny-20231231.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:to="lab_sny_NumberOfRestrictedSharesNotYetFullyVested" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_29c8e381-c33c-4b3c-9759-0b4604ca5f6c_negatedLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of undistributed earnings from investments accounted for using the&#160;equity method</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for undistributed profits of investments accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_aeb8b0a2-5612-4ce2-8c52-611c4a43652f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_4d951632-1e75-4879-98d8-ed5cbe61c196_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_c26285b2-6f50-465d-afea-4bf16a3400eb_negatedLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_8da354b4-a4e9-48bd-b10d-25fc0533b8a2_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_9ef287ec-bbd3-48fb-8c33-a7adf396c7e6_terseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PainCareMember_a0d4fcc4-f3aa-4b47-91c1-41cd51e1d8af_terseLabel_en-US" xlink:label="lab_sny_PainCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pain Care</link:label>
    <link:label id="lab_sny_PainCareMember_label_en-US" xlink:label="lab_sny_PainCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pain Care [Member]</link:label>
    <link:label id="lab_sny_PainCareMember_documentation_en-US" xlink:label="lab_sny_PainCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pain Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PainCareMember" xlink:href="sny-20231231.xsd#sny_PainCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PainCareMember" xlink:to="lab_sny_PainCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_8fd81ca6-5b41-4347-a437-cdddf79adad0_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about major customers and credit risk [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information About Major Customers And Credit Risk [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about major customers and credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:to="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_538a4780-2667-46e8-a68b-ec30c176c13e_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisUkHoldingsLimitedMember_61cb321b-43c8-48bd-aaed-286cbc999d0f_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisUkHoldingsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis UK Holdings Limited</link:label>
    <link:label id="lab_sny_SanofiAventisUkHoldingsLimitedMember_label_en-US" xlink:label="lab_sny_SanofiAventisUkHoldingsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis UK Holdings Limited [member]</link:label>
    <link:label id="lab_sny_SanofiAventisUkHoldingsLimitedMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisUkHoldingsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis UK Holdings Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisUkHoldingsLimitedMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisUkHoldingsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisUkHoldingsLimitedMember" xlink:to="lab_sny_SanofiAventisUkHoldingsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmountsPayableForAcquisitionOfNonCurrentAssets_39665abb-b6d7-4d74-9b3a-0b45c1580d43_terseLabel_en-US" xlink:label="lab_sny_AmountsPayableForAcquisitionOfNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts payable for acquisitions of non-current assets</link:label>
    <link:label id="lab_sny_AmountsPayableForAcquisitionOfNonCurrentAssets_label_en-US" xlink:label="lab_sny_AmountsPayableForAcquisitionOfNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Payable For Acquisition Of Non-Current Assets</link:label>
    <link:label id="lab_sny_AmountsPayableForAcquisitionOfNonCurrentAssets_documentation_en-US" xlink:label="lab_sny_AmountsPayableForAcquisitionOfNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts payable for acquisitions of non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountsPayableForAcquisitionOfNonCurrentAssets" xlink:href="sny-20231231.xsd#sny_AmountsPayableForAcquisitionOfNonCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmountsPayableForAcquisitionOfNonCurrentAssets" xlink:to="lab_sny_AmountsPayableForAcquisitionOfNonCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PlanAssetsAtFairValue_98cee22f-8c80-4ff1-873e-8a7b35334d2b_terseLabel_en-US" xlink:label="lab_ifrs-full_PlanAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_ifrs-full_PlanAssetsAtFairValue_label_en-US" xlink:label="lab_ifrs-full_PlanAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets, at fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PlanAssetsAtFairValue" xlink:to="lab_ifrs-full_PlanAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInHungarianForintMember_8b35ab3d-ec65-4020-9a0b-8585117297d7_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInHungarianForintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases in Hungarian Forint</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInHungarianForintMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInHungarianForintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Hungarian Forint [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInHungarianForintMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInHungarianForintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases in Hungarian Forint.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInHungarianForintMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInHungarianForintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasedInHungarianForintMember" xlink:to="lab_sny_ForwardCurrencyPurchasedInHungarianForintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_HaleonUSLPMember_f56fc6a3-1fe7-46b0-82e6-c48e6e4319d0_terseLabel_en-US" xlink:label="lab_sny_HaleonUSLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Haleon US, LP</link:label>
    <link:label id="lab_sny_HaleonUSLPMember_label_en-US" xlink:label="lab_sny_HaleonUSLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Haleon US, LP [Member]</link:label>
    <link:label id="lab_sny_HaleonUSLPMember_documentation_en-US" xlink:label="lab_sny_HaleonUSLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Haleon US, LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HaleonUSLPMember" xlink:href="sny-20231231.xsd#sny_HaleonUSLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_HaleonUSLPMember" xlink:to="lab_sny_HaleonUSLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_16a8a9ff-b844-4008-a5c9-c457c252dd8d_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Currency Translation Before Tax Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in currency translation before tax excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InhibrxIncMember_302b2f8d-d880-4339-8daf-1f0a32dbedb5_terseLabel_en-US" xlink:label="lab_sny_InhibrxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inhibrx, Inc</link:label>
    <link:label id="lab_sny_InhibrxIncMember_label_en-US" xlink:label="lab_sny_InhibrxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inhibrx, Inc [Member]</link:label>
    <link:label id="lab_sny_InhibrxIncMember_documentation_en-US" xlink:label="lab_sny_InhibrxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inhibrx, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InhibrxIncMember" xlink:href="sny-20231231.xsd#sny_InhibrxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InhibrxIncMember" xlink:to="lab_sny_InhibrxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_6b1167a0-f91e-4d8c-a8a9-d4cc047bd680_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets and property, plant and equipment</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Impairment Of Intangible Assets And Property Plant And Equipment Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for impairment of intangible assets and property, plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_Patents1Member_d673689b-7cf6-433c-ac6e-88a3e920beb2_terseLabel_en-US" xlink:label="lab_sny_Patents1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_sny_Patents1Member_label_en-US" xlink:label="lab_sny_Patents1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents1 [Member]</link:label>
    <link:label id="lab_sny_Patents1Member_documentation_en-US" xlink:label="lab_sny_Patents1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_Patents1Member" xlink:href="sny-20231231.xsd#sny_Patents1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_Patents1Member" xlink:to="lab_sny_Patents1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseExtensionOptionsNumber_e96238f6-2ec3-43ab-a751-c7a11fd93737_terseLabel_en-US" xlink:label="lab_sny_LeaseExtensionOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, extension options, number</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsNumber_label_en-US" xlink:label="lab_sny_LeaseExtensionOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Extension Options, Number</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsNumber_documentation_en-US" xlink:label="lab_sny_LeaseExtensionOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Extension Options, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsNumber" xlink:href="sny-20231231.xsd#sny_LeaseExtensionOptionsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseExtensionOptionsNumber" xlink:to="lab_sny_LeaseExtensionOptionsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRateTypesMember_52e5df67-1959-48c8-9346-6deb6eef286c_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRateTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate types [member]</link:label>
    <link:label id="lab_ifrs-full_InterestRateTypesMember_label_en-US" xlink:label="lab_ifrs-full_InterestRateTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate types [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateTypesMember" xlink:to="lab_ifrs-full_InterestRateTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_fb0e41ac-6119-4d8e-bd93-04b56e0c0afa_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_45864d5d-25cd-4c69-9cc1-b3700ca10e29_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_ee737613-2594-42d7-9ac2-20b1fa2a6f07_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_5bbf27b0-88e4-48ff-915d-6a284e04d310_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations provided for</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisions" xlink:to="lab_ifrs-full_NoncurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsReceived_02baaec5-82a0-471d-b97c-37b1347c4fe4_negatedLabel_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsReceived" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irrevocable purchase commitments received</link:label>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsReceived_label_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irrevocable Purchase Commitments Received</link:label>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsReceived_documentation_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irrevocable purchase commitments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsReceived" xlink:href="sny-20231231.xsd#sny_IrrevocablePurchaseCommitmentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IrrevocablePurchaseCommitmentsReceived" xlink:to="lab_sny_IrrevocablePurchaseCommitmentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetAmountsAsReportedInTheBalanceSheet_7a4472a6-1618-4531-954a-6ba1c87af8a8_totalLabel_en-US" xlink:label="lab_sny_NetAmountsAsReportedInTheBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts as reported in the balance sheet</link:label>
    <link:label id="lab_sny_NetAmountsAsReportedInTheBalanceSheet_label_en-US" xlink:label="lab_sny_NetAmountsAsReportedInTheBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amounts As Reported In The Balance Sheet</link:label>
    <link:label id="lab_sny_NetAmountsAsReportedInTheBalanceSheet_documentation_en-US" xlink:label="lab_sny_NetAmountsAsReportedInTheBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts as reported in the balance sheet.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetAmountsAsReportedInTheBalanceSheet" xlink:href="sny-20231231.xsd#sny_NetAmountsAsReportedInTheBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetAmountsAsReportedInTheBalanceSheet" xlink:to="lab_sny_NetAmountsAsReportedInTheBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketedProductsMember_19ba13e9-1e80-4fea-9e93-f41a67d1da55_terseLabel_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed products</link:label>
    <link:label id="lab_sny_MarketedProductsMember_label_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed Products [Member]</link:label>
    <link:label id="lab_sny_MarketedProductsMember_documentation_en-US" xlink:label="lab_sny_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember" xlink:href="sny-20231231.xsd#sny_MarketedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketedProductsMember" xlink:to="lab_sny_MarketedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember_1c9c7f83-5aca-4881-8d02-f79114928a21_terseLabel_en-US" xlink:label="lab_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of acquired property, plant and equipment at fair value</link:label>
    <link:label id="lab_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember_label_en-US" xlink:label="lab_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition Of Acquired Property Plant And Equipment At Fair Value [member]</link:label>
    <link:label id="lab_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember_documentation_en-US" xlink:label="lab_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of acquired property plant and equipment at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember" xlink:href="sny-20231231.xsd#sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember" xlink:to="lab_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount_c66cad4a-5ff6-426d-af7b-e6c696475be0_terseLabel_en-US" xlink:label="lab_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest related to employee benefits, and unwinding of discount</link:label>
    <link:label id="lab_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount_label_en-US" xlink:label="lab_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Interest Related To Employees Benefits And Unwinding Of Discount</link:label>
    <link:label id="lab_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount_documentation_en-US" xlink:label="lab_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest related to employees benefits and unwinding of discount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" xlink:href="sny-20231231.xsd#sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" xlink:to="lab_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_a32c3dc5-1d95-4fbc-88ac-515b6aa60340_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average effective tax rate</link:label>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_8fae0cc6-337b-4bad-83e3-d1fa8023ac1f_totalLabel_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_label_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="lab_ifrs-full_AverageEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedCashFlowStatementTable_20cffb48-de51-4cf3-bf1f-83f88e1f8907_terseLabel_en-US" xlink:label="lab_srt_CondensedCashFlowStatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statement [Table]</link:label>
    <link:label id="lab_srt_CondensedCashFlowStatementTable_label_en-US" xlink:label="lab_srt_CondensedCashFlowStatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedCashFlowStatementTable" xlink:to="lab_srt_CondensedCashFlowStatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_e4271703-35f7-477a-a37c-8042deaabf25_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_b68367fc-6b7a-4576-b131-66abcb9c389b_terseLabel_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to debt measured&#160;at fair value</link:label>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_label_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Debt Measured At Fair Value [Member]</link:label>
    <link:label id="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember_documentation_en-US" xlink:label="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to debt measured at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:href="sny-20231231.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:to="lab_sny_AdjustmentToDebtMeasuredAtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LantusMember_b0e54a75-8308-49d3-8fe2-379590c835c2_terseLabel_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LANTUS</link:label>
    <link:label id="lab_sny_LantusMember_label_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lantus [Member]</link:label>
    <link:label id="lab_sny_LantusMember_documentation_en-US" xlink:label="lab_sny_LantusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lantus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember" xlink:href="sny-20231231.xsd#sny_LantusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LantusMember" xlink:to="lab_sny_LantusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_67695ab5-6945-41a0-95a3-ad33aa877800_verboseLabel_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share (in euros per share)</link:label>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_label_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:label id="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_documentation_en-US" xlink:label="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:href="sny-20231231.xsd#sny_BasicEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:to="lab_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_90643edf-6185-451b-8477-dfe31df44e9a_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis_f72fccd4-9bb7-45bd-b07b-6ce8a21b7447_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated purchase price on a fully-diluted basis</link:label>
    <link:label id="lab_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis_label_en-US" xlink:label="lab_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Estimated Purchase Price On A Fully-Diluted Basis</link:label>
    <link:label id="lab_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis_documentation_en-US" xlink:label="lab_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Estimated Purchase Price On A Fully-Diluted Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis" xlink:href="sny-20231231.xsd#sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis" xlink:to="lab_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets_8856c975-3ce0-4f1c-a5cc-512781299333_terseLabel_en-US" xlink:label="lab_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease through loss of control of subsidiary, net assets</link:label>
    <link:label id="lab_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets_label_en-US" xlink:label="lab_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease Through Loss Of Control Of Subsidiary, Net Assets</link:label>
    <link:label id="lab_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets_documentation_en-US" xlink:label="lab_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease Through Loss Of Control Of Subsidiary, Net Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets" xlink:href="sny-20231231.xsd#sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets" xlink:to="lab_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfOncologyTargetsUnderCollaborationAgreement_95fd9d1c-bcdc-40af-877f-e422279c8a91_terseLabel_en-US" xlink:label="lab_sny_NumberOfOncologyTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of oncology targets under collaboration agreement</link:label>
    <link:label id="lab_sny_NumberOfOncologyTargetsUnderCollaborationAgreement_label_en-US" xlink:label="lab_sny_NumberOfOncologyTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Oncology Targets Under Collaboration Agreement</link:label>
    <link:label id="lab_sny_NumberOfOncologyTargetsUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_sny_NumberOfOncologyTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Oncology Targets Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOncologyTargetsUnderCollaborationAgreement" xlink:href="sny-20231231.xsd#sny_NumberOfOncologyTargetsUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfOncologyTargetsUnderCollaborationAgreement" xlink:to="lab_sny_NumberOfOncologyTargetsUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RegeneronPharmaceuticalsIncMember_d8158b11-0fff-4bdc-9edd-c0b3f46fe279_terseLabel_en-US" xlink:label="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals, INC</link:label>
    <link:label id="lab_sny_RegeneronPharmaceuticalsIncMember_label_en-US" xlink:label="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals, INC [Member]</link:label>
    <link:label id="lab_sny_RegeneronPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RegeneronPharmaceuticalsIncMember" xlink:to="lab_sny_RegeneronPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_e9d3fd85-7477-4f4a-923e-f5d0326c139b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of initial application of standards or interpretations [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of initial application of standards or interpretations [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:to="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_720ec2bf-3db9-441a-88cc-a797651eea20_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareHungaryCommercialKFTMember_e27bd684-4752-4ae9-9d76-533d692c27db_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareHungaryCommercialKFTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Hungary Commercial K.F.T</link:label>
    <link:label id="lab_sny_OpellaHealthcareHungaryCommercialKFTMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareHungaryCommercialKFTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Hungary Commercial K.F.T [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareHungaryCommercialKFTMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareHungaryCommercialKFTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Hungary Commercial K.F.T</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareHungaryCommercialKFTMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareHungaryCommercialKFTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareHungaryCommercialKFTMember" xlink:to="lab_sny_OpellaHealthcareHungaryCommercialKFTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AtFairValueMember_1754240d-ec7b-4260-b738-b323b3e231fa_terseLabel_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_ifrs-full_AtFairValueMember_label_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At fair value [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtFairValueMember" xlink:to="lab_ifrs-full_AtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisSAMember_be2e5ea0-874f-4e68-80d0-6a110a1ec604_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis SA</link:label>
    <link:label id="lab_sny_SanofiAventisSAMember_label_en-US" xlink:label="lab_sny_SanofiAventisSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis SA [member]</link:label>
    <link:label id="lab_sny_SanofiAventisSAMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis SA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSAMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisSAMember" xlink:to="lab_sny_SanofiAventisSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2023ProgramMember_19571833-5885-4cb1-8729-5565d4f9fa7f_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2023ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_sny_ShareRepurchase2023ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2023ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase 2023 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2023ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2023ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase 2023 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2023ProgramMember" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2023ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2023ProgramMember" xlink:to="lab_sny_ShareRepurchase2023ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_766a8d9d-3b50-4767-a3e2-b10785d38f5b_terseLabel_en-US" xlink:label="lab_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_label_en-US" xlink:label="lab_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label id="lab_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_documentation_en-US" xlink:label="lab_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:href="sny-20231231.xsd#sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:to="lab_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_35f61dfe-07bb-412c-9bc5-97ba4acf0971_negatedLabel_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions utilized</link:label>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision used, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:to="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_4fa74553-8c66-45dd-829a-679aba6f4ed7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Treasury Shares Held</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member_375b24e5-36db-400f-aece-bd770e94bec2_verboseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps pay capitalized Eonia / receive 0.06%.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_VaccinesMember_137f586e-5dee-4856-b50d-2282f6d2e5d3_terseLabel_en-US" xlink:label="lab_sny_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines</link:label>
    <link:label id="lab_sny_VaccinesMember_label_en-US" xlink:label="lab_sny_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_sny_VaccinesMember_documentation_en-US" xlink:label="lab_sny_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesMember" xlink:href="sny-20231231.xsd#sny_VaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_VaccinesMember" xlink:to="lab_sny_VaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_166e2360-f74d-4a58-8d21-51263a21b7e2_negatedLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of property, plant and equipment and intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherRevenuePerformanceObligationNoLongerRequired_018579b1-0c56-48b1-ac3f-bd82fd515b86_terseLabel_en-US" xlink:label="lab_sny_OtherRevenuePerformanceObligationNoLongerRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue, doses no longer an obligation to be delivered</link:label>
    <link:label id="lab_sny_OtherRevenuePerformanceObligationNoLongerRequired_label_en-US" xlink:label="lab_sny_OtherRevenuePerformanceObligationNoLongerRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue, Performance Obligation No Longer Required</link:label>
    <link:label id="lab_sny_OtherRevenuePerformanceObligationNoLongerRequired_documentation_en-US" xlink:label="lab_sny_OtherRevenuePerformanceObligationNoLongerRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue, Performance Obligation No Longer Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRevenuePerformanceObligationNoLongerRequired" xlink:href="sny-20231231.xsd#sny_OtherRevenuePerformanceObligationNoLongerRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherRevenuePerformanceObligationNoLongerRequired" xlink:to="lab_sny_OtherRevenuePerformanceObligationNoLongerRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking_c1f44fc8-5251-4e35-98c0-949032ef8af9_terseLabel_en-US" xlink:label="lab_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fund reserves transferred</link:label>
    <link:label id="lab_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking_label_en-US" xlink:label="lab_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Transferred To Fund Reserve For Indemnification Undertaking</link:label>
    <link:label id="lab_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking_documentation_en-US" xlink:label="lab_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Transferred To Fund Reserve For Indemnification Undertaking</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking" xlink:href="sny-20231231.xsd#sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking" xlink:to="lab_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromNoncurrentBorrowings_db31fa34-31af-40fd-b715-6fc72e357d45_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional long-term debt contracted</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:to="lab_ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_30d977a4-2535-4d84-8b41-c1f99ce4b17d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Offsetting of Financial Assets and Liabilities [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off Setting Of Financial Assets And Liabilities [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of offsetting of financial assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems" xlink:to="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_73c57d32-da7a-4e99-9fe1-fec445de8510_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6&#160;to&#160;12&#160;months</link:label>
    <link:label id="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than six months and not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisGmbHMember_2f3f4563-4660-467e-94e5-fc3bd6420940_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis GmbH</link:label>
    <link:label id="lab_sny_SanofiAventisGmbHMember_label_en-US" xlink:label="lab_sny_SanofiAventisGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis GmbH [member]</link:label>
    <link:label id="lab_sny_SanofiAventisGmbHMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis GmbH.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisGmbHMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisGmbHMember" xlink:to="lab_sny_SanofiAventisGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpactOfChangeInInterestRateOnPreTaxIncome_52ca5463-e6f3-4b5f-b9fd-75b04ded144e_terseLabel_en-US" xlink:label="lab_sny_ImpactOfChangeInInterestRateOnPreTaxIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact on pre-tax net income</link:label>
    <link:label id="lab_sny_ImpactOfChangeInInterestRateOnPreTaxIncome_label_en-US" xlink:label="lab_sny_ImpactOfChangeInInterestRateOnPreTaxIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact Of Change In Interest Rate On Pre Tax Income</link:label>
    <link:label id="lab_sny_ImpactOfChangeInInterestRateOnPreTaxIncome_documentation_en-US" xlink:label="lab_sny_ImpactOfChangeInInterestRateOnPreTaxIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of change in interest rate on pre tax income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfChangeInInterestRateOnPreTaxIncome" xlink:href="sny-20231231.xsd#sny_ImpactOfChangeInInterestRateOnPreTaxIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpactOfChangeInInterestRateOnPreTaxIncome" xlink:to="lab_sny_ImpactOfChangeInInterestRateOnPreTaxIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_0952c56a-2ce8-414e-b9a8-fa79bb66f9ed_terseLabel_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term debt and other financial instruments</link:label>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_label_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</link:label>
    <link:label id="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_documentation_en-US" xlink:label="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:href="sny-20231231.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:to="lab_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_4e56a1fa-71e3-47f2-91fe-b6bc8f250709_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Finance Income Expense [table]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule disclosing information related to details of finance income (expense).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfGuaranteesTable_c82f0b00-0a76-41c6-a297-953dc08a5c9f_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfGuaranteesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Guarantees [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfGuaranteesTable_label_en-US" xlink:label="lab_sny_DisclosureOfGuaranteesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Guarantees [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfGuaranteesTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfGuaranteesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Guarantees [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfGuaranteesTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfGuaranteesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfGuaranteesTable" xlink:to="lab_sny_DisclosureOfGuaranteesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfAssetCeilingMember_b2b1618d-ef9e-41eb-92ec-94f8b6ea4a58_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfAssetCeilingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of asset ceiling</link:label>
    <link:label id="lab_ifrs-full_EffectOfAssetCeilingMember_label_en-US" xlink:label="lab_ifrs-full_EffectOfAssetCeilingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of asset ceiling [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfAssetCeilingMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfAssetCeilingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfAssetCeilingMember" xlink:to="lab_ifrs-full_EffectOfAssetCeilingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_a58e6fb2-3665-4375-87fb-6a45ac9ef50c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_label_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Non-Controlling Interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable" xlink:to="lab_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerTwoMember_1752d20f-9f4e-476d-bff5-c544df6f2a01_terseLabel_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer two</link:label>
    <link:label id="lab_sny_CustomerTwoMember_label_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [member]</link:label>
    <link:label id="lab_sny_CustomerTwoMember_documentation_en-US" xlink:label="lab_sny_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember" xlink:href="sny-20231231.xsd#sny_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerTwoMember" xlink:to="lab_sny_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ContingenciesArisingFromCertainBusinessDivestituresMember_7b70bc58-7cf3-496e-8205-136fe23ce83f_terseLabel_en-US" xlink:label="lab_sny_ContingenciesArisingFromCertainBusinessDivestituresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies arising from certain business divestitures</link:label>
    <link:label id="lab_sny_ContingenciesArisingFromCertainBusinessDivestituresMember_label_en-US" xlink:label="lab_sny_ContingenciesArisingFromCertainBusinessDivestituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies Arising From Certain Business Divestitures [Member]</link:label>
    <link:label id="lab_sny_ContingenciesArisingFromCertainBusinessDivestituresMember_documentation_en-US" xlink:label="lab_sny_ContingenciesArisingFromCertainBusinessDivestituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies Arising From Certain Business Divestitures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingenciesArisingFromCertainBusinessDivestituresMember" xlink:href="sny-20231231.xsd#sny_ContingenciesArisingFromCertainBusinessDivestituresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ContingenciesArisingFromCertainBusinessDivestituresMember" xlink:to="lab_sny_ContingenciesArisingFromCertainBusinessDivestituresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_d738eadc-df0e-4da5-bbd2-0f56fd0eb1f6_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:to="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WithMarketConditionMember_92fece82-89ae-4b61-be6e-f8b2a42705f3_terseLabel_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">With market condition</link:label>
    <link:label id="lab_sny_WithMarketConditionMember_label_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">With Market Condition [Member]</link:label>
    <link:label id="lab_sny_WithMarketConditionMember_documentation_en-US" xlink:label="lab_sny_WithMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">With Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember" xlink:href="sny-20231231.xsd#sny_WithMarketConditionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WithMarketConditionMember" xlink:to="lab_sny_WithMarketConditionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_5408886b-2663-45cc-86e7-efc7fa4e8e30_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefit indexation</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of expected rates of pension increases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareFranceSASMember_d4592b00-91b6-403a-9716-dc0163dcf3be_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareFranceSASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare France SAS</link:label>
    <link:label id="lab_sny_OpellaHealthcareFranceSASMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareFranceSASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare France SAS [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareFranceSASMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareFranceSASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare France SAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareFranceSASMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareFranceSASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareFranceSASMember" xlink:to="lab_sny_OpellaHealthcareFranceSASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RoyaltyExpensePercentage_aa18fbf8-12a5-4828-b3d3-8de0ab151b03_terseLabel_en-US" xlink:label="lab_sny_RoyaltyExpensePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense, percentage (percentage)</link:label>
    <link:label id="lab_sny_RoyaltyExpensePercentage_label_en-US" xlink:label="lab_sny_RoyaltyExpensePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense, Percentage</link:label>
    <link:label id="lab_sny_RoyaltyExpensePercentage_documentation_en-US" xlink:label="lab_sny_RoyaltyExpensePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltyExpensePercentage" xlink:href="sny-20231231.xsd#sny_RoyaltyExpensePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RoyaltyExpensePercentage" xlink:to="lab_sny_RoyaltyExpensePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares_0d123aa0-4a7b-4a70-becb-9247733bbc2e_terseLabel_en-US" xlink:label="lab_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares received (in shares)</link:label>
    <link:label id="lab_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares_label_en-US" xlink:label="lab_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Distribution, Shares Received Per Conversion Of Parent Shares</link:label>
    <link:label id="lab_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares_documentation_en-US" xlink:label="lab_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Distribution, Shares Received Per Conversion Of Parent Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares" xlink:href="sny-20231231.xsd#sny_SpecialDistributionSharesReceivedPerConversionOfParentShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares" xlink:to="lab_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory_4f835e39-a434-42e7-8b75-8835367b32f5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-controlling interests [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurSpZooMember_4d553d18-251b-4da6-b7e6-c2660338ffde_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurSpZooMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Sp. z.o.o.</link:label>
    <link:label id="lab_sny_SanofiPasteurSpZooMember_label_en-US" xlink:label="lab_sny_SanofiPasteurSpZooMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Sp z.o.o. [Member]</link:label>
    <link:label id="lab_sny_SanofiPasteurSpZooMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurSpZooMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Sp z.o.o.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurSpZooMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurSpZooMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurSpZooMember" xlink:to="lab_sny_SanofiPasteurSpZooMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ServicesOtherThanStatutoryAudit_531f9679-4610-410a-8442-59878bf9f3e1_totalLabel_en-US" xlink:label="lab_sny_ServicesOtherThanStatutoryAudit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services other than statutory audit</link:label>
    <link:label id="lab_sny_ServicesOtherThanStatutoryAudit_label_en-US" xlink:label="lab_sny_ServicesOtherThanStatutoryAudit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Other Than Statutory Audit</link:label>
    <link:label id="lab_sny_ServicesOtherThanStatutoryAudit_documentation_en-US" xlink:label="lab_sny_ServicesOtherThanStatutoryAudit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services other than statutory audit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ServicesOtherThanStatutoryAudit" xlink:href="sny-20231231.xsd#sny_ServicesOtherThanStatutoryAudit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ServicesOtherThanStatutoryAudit" xlink:to="lab_sny_ServicesOtherThanStatutoryAudit" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits_3c990918-04ff-4079-b8e1-5cea2bbe6b42_terseLabel_en-US" xlink:label="lab_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel</link:label>
    <link:label id="lab_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits_label_en-US" xlink:label="lab_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Management Personnel Compensation Termination Benefits And LumpSum Retirement Benefits</link:label>
    <link:label id="lab_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits_documentation_en-US" xlink:label="lab_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, termination benefits and lump sum retirement benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits" xlink:href="sny-20231231.xsd#sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits" xlink:to="lab_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AuditorsNameAxis_34cc8756-48bc-404d-9797-d7fcc3550d94_terseLabel_en-US" xlink:label="lab_sny_AuditorsNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditors Name [Axis]</link:label>
    <link:label id="lab_sny_AuditorsNameAxis_label_en-US" xlink:label="lab_sny_AuditorsNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditors Name [Axis]</link:label>
    <link:label id="lab_sny_AuditorsNameAxis_documentation_en-US" xlink:label="lab_sny_AuditorsNameAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditors Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsNameAxis" xlink:href="sny-20231231.xsd#sny_AuditorsNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AuditorsNameAxis" xlink:to="lab_sny_AuditorsNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_fcc53be1-e20a-46d7-8c25-1a283258f0ba_terseLabel_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other income</link:label>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_label_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties And Other Income, Related Party Transactions</link:label>
    <link:label id="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_documentation_en-US" xlink:label="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other income, related party transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:href="sny-20231231.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:to="lab_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_ed9ecbea-25a4-44b6-b1c8-04982d92d700_terseLabel_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">%&#160;of&#160;share&#160;capital for the period</link:label>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_label_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Share Capital For The Period</link:label>
    <link:label id="lab_sny_PercentageOfShareCapitalForThePeriod_documentation_en-US" xlink:label="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of share capital for the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfShareCapitalForThePeriod" xlink:href="sny-20231231.xsd#sny_PercentageOfShareCapitalForThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfShareCapitalForThePeriod" xlink:to="lab_sny_PercentageOfShareCapitalForThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockBasedCompensationStockOptionsExercisedPricePerShare_5926d5b3-1fec-4d2f-aa17-2c9b7b4b2386_terseLabel_en-US" xlink:label="lab_sny_StockBasedCompensationStockOptionsExercisedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in euros per share)</link:label>
    <link:label id="lab_sny_StockBasedCompensationStockOptionsExercisedPricePerShare_label_en-US" xlink:label="lab_sny_StockBasedCompensationStockOptionsExercisedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation Stock Options Exercised Price Per Share</link:label>
    <link:label id="lab_sny_StockBasedCompensationStockOptionsExercisedPricePerShare_documentation_en-US" xlink:label="lab_sny_StockBasedCompensationStockOptionsExercisedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation stock options exercised price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockBasedCompensationStockOptionsExercisedPricePerShare" xlink:href="sny-20231231.xsd#sny_StockBasedCompensationStockOptionsExercisedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockBasedCompensationStockOptionsExercisedPricePerShare" xlink:to="lab_sny_StockBasedCompensationStockOptionsExercisedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_2a59a4c9-090b-48c6-ae87-ed2ffe6ebf0b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InfluenzaVaccinesMember_41745612-90ef-4177-95c9-2de04b0e825c_terseLabel_en-US" xlink:label="lab_sny_InfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Influenza Vaccines</link:label>
    <link:label id="lab_sny_InfluenzaVaccinesMember_label_en-US" xlink:label="lab_sny_InfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Influenza Vaccines [Member]</link:label>
    <link:label id="lab_sny_InfluenzaVaccinesMember_documentation_en-US" xlink:label="lab_sny_InfluenzaVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Influenza Vaccines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfluenzaVaccinesMember" xlink:href="sny-20231231.xsd#sny_InfluenzaVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InfluenzaVaccinesMember" xlink:to="lab_sny_InfluenzaVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_38a33dce-1748-45f6-8961-b331f16ddb84_terseLabel_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in non-current provisions and other non-current liabilities</link:label>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_label_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Non-Current Provisions And Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for noncurrent provisions and other noncurrent liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:href="sny-20231231.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:to="lab_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisAustraliaPtyLtdMember_05456fc2-923e-4e2e-85e2-b893735b87fc_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisAustraliaPtyLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Australia Pty Ltd</link:label>
    <link:label id="lab_sny_SanofiAventisAustraliaPtyLtdMember_label_en-US" xlink:label="lab_sny_SanofiAventisAustraliaPtyLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Australia Pty Ltd [member]</link:label>
    <link:label id="lab_sny_SanofiAventisAustraliaPtyLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisAustraliaPtyLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Australia Pty Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisAustraliaPtyLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisAustraliaPtyLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisAustraliaPtyLtdMember" xlink:to="lab_sny_SanofiAventisAustraliaPtyLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet_1c8e73f4-f891-4c79-a84d-93cd4a427b9d_terseLabel_en-US" xlink:label="lab_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced</link:label>
    <link:label id="lab_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet_label_en-US" xlink:label="lab_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Leases, Low Value Asset Leases And Lease Contracts Committed But Not Started Yet</link:label>
    <link:label id="lab_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet_documentation_en-US" xlink:label="lab_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Leases, Low Value Asset Leases And Lease Contracts Committed But Not Started Yet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" xlink:href="sny-20231231.xsd#sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" xlink:to="lab_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_ca19d449-6cd6-48e5-9f92-f21e2c725fe2_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of Related Parties [Axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DigestiveWellnessMember_ce6aee59-3c83-46d4-8e0e-5ca58d82e596_terseLabel_en-US" xlink:label="lab_sny_DigestiveWellnessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Digestive Wellness</link:label>
    <link:label id="lab_sny_DigestiveWellnessMember_label_en-US" xlink:label="lab_sny_DigestiveWellnessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Digestive Wellness [Member]</link:label>
    <link:label id="lab_sny_DigestiveWellnessMember_documentation_en-US" xlink:label="lab_sny_DigestiveWellnessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Digestive [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DigestiveWellnessMember" xlink:href="sny-20231231.xsd#sny_DigestiveWellnessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DigestiveWellnessMember" xlink:to="lab_sny_DigestiveWellnessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsAventisMember_90bae6b1-7fef-461c-95c2-044d8247c928_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsAventisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsAventisMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsAventisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Aventis [member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsAventisMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsAventisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal marketed products aventis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsAventisMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsAventisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsAventisMember" xlink:to="lab_sny_PrincipalMarketedProductsAventisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock_8112f69b-6852-4aa7-a223-7ccddbef1003_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Other Provisions</link:label>
    <link:label id="lab_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Long Term Provisions [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of other long term provisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherLongTermProvisionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock" xlink:to="lab_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyLineItems_bdd009c5-f336-42d1-a7ab-a4a4e0be4399_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt By Currency [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt By Currency [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt By Currency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByCurrencyLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByCurrencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtByCurrencyLineItems" xlink:to="lab_sny_DisclosureOfDebtByCurrencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SynthorxMember_3ed02d8c-fcda-4895-b9d3-5defd5a16193_terseLabel_en-US" xlink:label="lab_sny_SynthorxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synthorx</link:label>
    <link:label id="lab_sny_SynthorxMember_label_en-US" xlink:label="lab_sny_SynthorxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synthorx [Member]</link:label>
    <link:label id="lab_sny_SynthorxMember_documentation_en-US" xlink:label="lab_sny_SynthorxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synthorx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SynthorxMember" xlink:href="sny-20231231.xsd#sny_SynthorxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SynthorxMember" xlink:to="lab_sny_SynthorxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_3cbf2e9c-f7df-47e6-8063-ea6d186c10f8_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_19e1e3d6-ad24-4441-bff7-3271dacc6bdc_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax relating to components of other comprehensive income that will be reclassified to profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:to="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod_d97f6da3-ddbd-4382-b174-bec140c64199_terseLabel_en-US" xlink:label="lab_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax charge on deemed repatriation attributable to accumulated earnings payable period</link:label>
    <link:label id="lab_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod_label_en-US" xlink:label="lab_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Charge On Deemed Repatriation Attributable To Accumulated Earnings Payable, Period</link:label>
    <link:label id="lab_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod_documentation_en-US" xlink:label="lab_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax charge on deemed repatriation attributable to accumulated earnings payable period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod" xlink:href="sny-20231231.xsd#sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod" xlink:to="lab_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_5b6237e9-cbb0-4e43-a90d-ec1759780b0a_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:to="lab_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FloatingInterestRateMember_c4fe0468-f952-4e65-89fb-51a2168f8317_terseLabel_en-US" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating-rate debt</link:label>
    <link:label id="lab_ifrs-full_FloatingInterestRateMember_label_en-US" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating interest rate [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FloatingInterestRateMember" xlink:to="lab_ifrs-full_FloatingInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsGiven_7a8d3ed6-891c-421c-b4b2-216606be9147_terseLabel_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsGiven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irrevocable purchase commitments given</link:label>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsGiven_label_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsGiven" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irrevocable Purchase Commitments Given</link:label>
    <link:label id="lab_sny_IrrevocablePurchaseCommitmentsGiven_documentation_en-US" xlink:label="lab_sny_IrrevocablePurchaseCommitmentsGiven" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Irrevocable purchase commitments given.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsGiven" xlink:href="sny-20231231.xsd#sny_IrrevocablePurchaseCommitmentsGiven"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IrrevocablePurchaseCommitmentsGiven" xlink:to="lab_sny_IrrevocablePurchaseCommitmentsGiven" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8d65f57d-f706-4682-a97e-b7f364593509_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PerformanceSharePlanOneMember_93d01905-0ea5-40f6-878e-e98755275b21_terseLabel_en-US" xlink:label="lab_sny_PerformanceSharePlanOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance share plan one</link:label>
    <link:label id="lab_sny_PerformanceSharePlanOneMember_label_en-US" xlink:label="lab_sny_PerformanceSharePlanOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Plan One [member]</link:label>
    <link:label id="lab_sny_PerformanceSharePlanOneMember_documentation_en-US" xlink:label="lab_sny_PerformanceSharePlanOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Plan One.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerformanceSharePlanOneMember" xlink:href="sny-20231231.xsd#sny_PerformanceSharePlanOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PerformanceSharePlanOneMember" xlink:to="lab_sny_PerformanceSharePlanOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiSynthelaboUKLtdMember_b77b29e0-0ca6-4340-8e09-44545f4e3bbd_terseLabel_en-US" xlink:label="lab_sny_SanofiSynthelaboUKLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Synthelabo UK Ltd</link:label>
    <link:label id="lab_sny_SanofiSynthelaboUKLtdMember_label_en-US" xlink:label="lab_sny_SanofiSynthelaboUKLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Synthelabo UK Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiSynthelaboUKLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiSynthelaboUKLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Synthelabo UK Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiSynthelaboUKLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiSynthelaboUKLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiSynthelaboUKLtdMember" xlink:to="lab_sny_SanofiSynthelaboUKLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_cd110aa2-7c7f-45bb-9a8f-4a87953a0460_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Detailed Information about Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_a56d498a-ab32-48dc-b887-5b3c27eb34b7_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInSingaporeDollarMember_07d830a2-049e-4ace-a21a-22c3ed434f54_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases in Singapore Dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInSingaporeDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Singapore Dollar [member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInSingaporeDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases in Singapore Dollar.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInSingaporeDollarMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInSingaporeDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasedInSingaporeDollarMember" xlink:to="lab_sny_ForwardCurrencyPurchasedInSingaporeDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfActuarialAssumptionsTableTextBlock_9bbbdd35-a416-4992-a195-aa4556b7e8d5_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfActuarialAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial and Demographic Assumptions</link:label>
    <link:label id="lab_sny_DisclosureOfActuarialAssumptionsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfActuarialAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Actuarial Assumptions [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfActuarialAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfActuarialAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Actuarial Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfActuarialAssumptionsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfActuarialAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfActuarialAssumptionsTableTextBlock" xlink:to="lab_sny_DisclosureOfActuarialAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_2407ae31-3a3b-47ad-bec2-d70117f93fde_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities related to assets held for sale or exchange</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities included in disposal groups classified as held for sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lab_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock_43836a7f-d132-4fa9-8e18-a65b53d62592_terseLabel_en-US" xlink:label="lab_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK</link:label>
    <link:label id="lab_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock_label_en-US" xlink:label="lab_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements Relating To The Recombinant Covid-19 Vaccine Candidate Developed By Sanofi In Collaboration With GSK [Policy Text Block]</link:label>
    <link:label id="lab_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock_documentation_en-US" xlink:label="lab_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreements Relating To The Recombinant Covid-19 Vaccine Candidate Developed By Sanofi In Collaboration With GSK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock" xlink:href="sny-20231231.xsd#sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock" xlink:to="lab_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SpecialDistributionPercentageOfShareCapitalDistributed_eb678c61-889e-4a46-8599-1760c3d646de_terseLabel_en-US" xlink:label="lab_sny_SpecialDistributionPercentageOfShareCapitalDistributed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special distribution, percentage of share capital distributed</link:label>
    <link:label id="lab_sny_SpecialDistributionPercentageOfShareCapitalDistributed_label_en-US" xlink:label="lab_sny_SpecialDistributionPercentageOfShareCapitalDistributed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Distribution, Percentage Of Share Capital Distributed</link:label>
    <link:label id="lab_sny_SpecialDistributionPercentageOfShareCapitalDistributed_documentation_en-US" xlink:label="lab_sny_SpecialDistributionPercentageOfShareCapitalDistributed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Distribution, Percentage Of Share Capital Distributed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialDistributionPercentageOfShareCapitalDistributed" xlink:href="sny-20231231.xsd#sny_SpecialDistributionPercentageOfShareCapitalDistributed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SpecialDistributionPercentageOfShareCapitalDistributed" xlink:to="lab_sny_SpecialDistributionPercentageOfShareCapitalDistributed" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsInterestRate_3e441778-d7d8-4c85-a45d-f49dedab9812_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_sny_InterestRateSwapsInterestRate_label_en-US" xlink:label="lab_sny_InterestRateSwapsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps, Interest Rate</link:label>
    <link:label id="lab_sny_InterestRateSwapsInterestRate_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsInterestRate" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsInterestRate" xlink:to="lab_sny_InterestRateSwapsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_a917b347-1d76-4f13-97ba-6fdbe2942479_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale or exchange and liabilities related to assets held for sale or exchange</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-current assets or disposal groups classified as held for sale [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember_f016519e-b0dd-464c-ad33-b5b4fd1e8f22_terseLabel_en-US" xlink:label="lab_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation adjustments (intragroup margin in inventory)</link:label>
    <link:label id="lab_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember_label_en-US" xlink:label="lab_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Adjustments Intragroup Margin In Inventory [Member]</link:label>
    <link:label id="lab_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember_documentation_en-US" xlink:label="lab_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation adjustments intragroup margin In Inventory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember" xlink:href="sny-20231231.xsd#sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember" xlink:to="lab_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_362bb2f5-ac72-44a9-a137-cb4782c3eaf6_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible increase in actuarial assumption</link:label>
    <link:label id="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_label_en-US" xlink:label="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of reasonably possible increase in actuarial assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lab_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfLossesArisingFromCommercialOperations_36d2c713-5617-48b9-a6a7-749cfb04d054_terseLabel_en-US" xlink:label="lab_sny_PercentageOfLossesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of losses arising from commercial operations</link:label>
    <link:label id="lab_sny_PercentageOfLossesArisingFromCommercialOperations_label_en-US" xlink:label="lab_sny_PercentageOfLossesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Losses Arising From Commercial Operations</link:label>
    <link:label id="lab_sny_PercentageOfLossesArisingFromCommercialOperations_documentation_en-US" xlink:label="lab_sny_PercentageOfLossesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Losses Arising From Commercial Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfLossesArisingFromCommercialOperations" xlink:href="sny-20231231.xsd#sny_PercentageOfLossesArisingFromCommercialOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfLossesArisingFromCommercialOperations" xlink:to="lab_sny_PercentageOfLossesArisingFromCommercialOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_f5808c3a-ba19-4e4f-a2d1-b6ce5bd05980_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_6ab692ee-f725-4588-af07-e7bdc971d18e_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of discount rates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_4478bc4f-76e8-4748-b7d4-d045d9e7f34a_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorBusinessCombinationMember_7afc4973-2b8b-46ba-a898-315b71cc8e04_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major business combination</link:label>
    <link:label id="lab_ifrs-full_MajorBusinessCombinationMember_label_en-US" xlink:label="lab_ifrs-full_MajorBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major business combination [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorBusinessCombinationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorBusinessCombinationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorBusinessCombinationMember" xlink:to="lab_ifrs-full_MajorBusinessCombinationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_ed177312-b44e-4a3e-a185-dbba8e5a72da_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard tax rate applicable in France</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_400bac0c-fdde-40f8-94ff-1c59619d6780_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains/(losses) on disposals of financial assets</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on available-for-sale financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:to="lab_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_7261d3ab-aa0d-4516-a1ac-a150945a9a2a_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3&#160;to&#160;6&#160;months</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than three months and not later than six months [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:to="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_7034fa65-db08-4560-bec1-867f33506035_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of preparation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisSingaporePteLtdMember_74610609-4f91-47b4-bba6-a400e5cd37a7_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisSingaporePteLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Singapore Pte. Ltd</link:label>
    <link:label id="lab_sny_SanofiAventisSingaporePteLtdMember_label_en-US" xlink:label="lab_sny_SanofiAventisSingaporePteLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Singapore Pte Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisSingaporePteLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisSingaporePteLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Singapore Pte Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSingaporePteLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisSingaporePteLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisSingaporePteLtdMember" xlink:to="lab_sny_SanofiAventisSingaporePteLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_17ed7f55-3b73-4060-84d4-a120078e80be_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Plans Assets relating to Pension Plans and Other Post-employment Plans</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value of plan assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForAuditServices_e80090fc-6ab2-4d0f-b1b5-e7abaf896b1b_terseLabel_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForAuditServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory audit of separate and consolidated financial statements</link:label>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForAuditServices_label_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForAuditServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor's remuneration for audit services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationForAuditServices" xlink:to="lab_ifrs-full_AuditorsRemunerationForAuditServices" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities_9a5960cc-4505-4043-a72b-474693141a91_terseLabel_en-US" xlink:label="lab_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities</link:label>
    <link:label id="lab_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities_label_en-US" xlink:label="lab_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Contributed To Fair Value Of Plan Assets, Other Securities</link:label>
    <link:label id="lab_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities_documentation_en-US" xlink:label="lab_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Contributed To Fair Value Of Plan Assets, Other Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities" xlink:to="lab_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_March2018EMTNISINFR0013324373Member_bf72c648-2220-4b6d-87ee-a314d2c3f4e6_terseLabel_en-US" xlink:label="lab_sny_March2018EMTNISINFR0013324373Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2018 EMTN ISIN FR0013324373</link:label>
    <link:label id="lab_sny_March2018EMTNISINFR0013324373Member_label_en-US" xlink:label="lab_sny_March2018EMTNISINFR0013324373Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2018 EMTN ISIN FR0013324373 [Member]</link:label>
    <link:label id="lab_sny_March2018EMTNISINFR0013324373Member_documentation_en-US" xlink:label="lab_sny_March2018EMTNISINFR0013324373Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2018 EMTN ISIN FR 0013324373.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2018EMTNISINFR0013324373Member" xlink:href="sny-20231231.xsd#sny_March2018EMTNISINFR0013324373Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_March2018EMTNISINFR0013324373Member" xlink:to="lab_sny_March2018EMTNISINFR0013324373Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_410f23b9-e998-46c2-845e-34dbda046479_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of treasury shares</link:label>
    <link:label id="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_label_en-US" xlink:label="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire or redeem entity's shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="lab_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_63a4247d-476b-4555-aa4e-1bbc191ca7f8_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity instruments included in&#160;financial assets and financial liabilities</link:label>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_label_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, entity's own equity instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:to="lab_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments_cafd6def-49e1-46b9-8621-fbb21ac01374_terseLabel_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains/(losses) on experience adjustments</link:label>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments_label_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Actuarial Gains (Losses) On Experience Adjustments</link:label>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments_documentation_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains/(losses) on experience adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" xlink:to="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_fe1f0ae5-7cfb-44fd-b8b7-e5a829d17d5f_terseLabel_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for other long-term benefits</link:label>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_label_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions For Other Long Term Benefits [member]</link:label>
    <link:label id="lab_sny_ProvisionsForOtherLongTermBenefitsMember_documentation_en-US" xlink:label="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for other long term benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:href="sny-20231231.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:to="lab_sny_ProvisionsForOtherLongTermBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock_1c222ddf-85f2-4e3f-ad62-f6ce041d103b_terseLabel_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs and similar items</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock_label_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Restructuring Costs And Similar Items [Policy Text Block]</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock_documentation_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The description of the entity's accounting policy for restructuring costs and similar items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock" xlink:to="lab_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_ae23f6f9-b32a-43a5-a6b4-e3c20f19916a_terseLabel_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization related expenses</link:label>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_label_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Related Expenses [Member]</link:label>
    <link:label id="lab_sny_CommercializationRelatedExpensesMember_documentation_en-US" xlink:label="lab_sny_CommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization related expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember" xlink:href="sny-20231231.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercializationRelatedExpensesMember" xlink:to="lab_sny_CommercializationRelatedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfProfitShareOnCounterpartiesProfit_12d69948-bc83-4d42-afea-d3edbd501f72_terseLabel_en-US" xlink:label="lab_sny_PercentageOfProfitShareOnCounterpartiesProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)</link:label>
    <link:label id="lab_sny_PercentageOfProfitShareOnCounterpartiesProfit_label_en-US" xlink:label="lab_sny_PercentageOfProfitShareOnCounterpartiesProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Profit Share On Counterparties Profit</link:label>
    <link:label id="lab_sny_PercentageOfProfitShareOnCounterpartiesProfit_documentation_en-US" xlink:label="lab_sny_PercentageOfProfitShareOnCounterpartiesProfit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of profit share on counter parties profit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitShareOnCounterpartiesProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit" xlink:to="lab_sny_PercentageOfProfitShareOnCounterpartiesProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsAbstract_98debfc8-50c0-4ebf-bc84-df4197a579b7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_b29377d0-349e-4302-809e-ae5203c0fbe7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other non-current assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_66ed4620-55a8-4f1a-8504-82cfaa7f7f12_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of initial application of standards or interpretations [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of initial application of standards or interpretations [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmountsPayablePartnersInCollaborationAgreements_349e05d4-7996-406d-86b5-a7273b6ac56f_terseLabel_en-US" xlink:label="lab_sny_AmountsPayablePartnersInCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts payable partners in collaboration agreements</link:label>
    <link:label id="lab_sny_AmountsPayablePartnersInCollaborationAgreements_label_en-US" xlink:label="lab_sny_AmountsPayablePartnersInCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Payable Partners In Collaboration Agreements</link:label>
    <link:label id="lab_sny_AmountsPayablePartnersInCollaborationAgreements_documentation_en-US" xlink:label="lab_sny_AmountsPayablePartnersInCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts payable partners in collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountsPayablePartnersInCollaborationAgreements" xlink:href="sny-20231231.xsd#sny_AmountsPayablePartnersInCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmountsPayablePartnersInCollaborationAgreements" xlink:to="lab_sny_AmountsPayablePartnersInCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_A340BDrugPricingProgramInTheUnitedStatesMember_d6481ae9-568a-47f1-9447-e924eb6dfa41_terseLabel_en-US" xlink:label="lab_sny_A340BDrugPricingProgramInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">340B Drug Pricing Program in the United States</link:label>
    <link:label id="lab_sny_A340BDrugPricingProgramInTheUnitedStatesMember_label_en-US" xlink:label="lab_sny_A340BDrugPricingProgramInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">340B Drug Pricing Program In The United States [Member]</link:label>
    <link:label id="lab_sny_A340BDrugPricingProgramInTheUnitedStatesMember_documentation_en-US" xlink:label="lab_sny_A340BDrugPricingProgramInTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">340B Drug Pricing Program In The United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_A340BDrugPricingProgramInTheUnitedStatesMember" xlink:href="sny-20231231.xsd#sny_A340BDrugPricingProgramInTheUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_A340BDrugPricingProgramInTheUnitedStatesMember" xlink:to="lab_sny_A340BDrugPricingProgramInTheUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1ed070a5-2eea-4a0d-8711-831d8829fc5c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfFirstInstanceRulings_bdc2854e-2708-4499-a886-078620b1ca32_terseLabel_en-US" xlink:label="lab_sny_NumberOfFirstInstanceRulings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of first instance rulings</link:label>
    <link:label id="lab_sny_NumberOfFirstInstanceRulings_label_en-US" xlink:label="lab_sny_NumberOfFirstInstanceRulings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of First Instance Rulings</link:label>
    <link:label id="lab_sny_NumberOfFirstInstanceRulings_documentation_en-US" xlink:label="lab_sny_NumberOfFirstInstanceRulings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of First Instance Rulings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfFirstInstanceRulings" xlink:href="sny-20231231.xsd#sny_NumberOfFirstInstanceRulings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfFirstInstanceRulings" xlink:to="lab_sny_NumberOfFirstInstanceRulings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_2cefdf15-1910-45f2-bae6-59a07fbfeaf1_terseLabel_en-US" xlink:label="lab_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholly or partly funded defined benefit plans</link:label>
    <link:label id="lab_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_label_en-US" xlink:label="lab_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholly or partly funded defined benefit plans [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:to="lab_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinanceLeaseReceivables_2387ba03-296d-4f85-8f45-7dfe3e2a05f0_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current finance lease receivables</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinanceLeaseReceivables_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current finance lease receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:to="lab_ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NewBusinessModelRolloutInVariousGeographiesMember_d1e0c0c2-ab4d-4ee4-b3b3-83c47a498a79_terseLabel_en-US" xlink:label="lab_sny_NewBusinessModelRolloutInVariousGeographiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New business model, rollout in various geographies</link:label>
    <link:label id="lab_sny_NewBusinessModelRolloutInVariousGeographiesMember_label_en-US" xlink:label="lab_sny_NewBusinessModelRolloutInVariousGeographiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Business Model, Rollout In Various Geographies [Member]</link:label>
    <link:label id="lab_sny_NewBusinessModelRolloutInVariousGeographiesMember_documentation_en-US" xlink:label="lab_sny_NewBusinessModelRolloutInVariousGeographiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Business Model, Rollout In Various Geographies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NewBusinessModelRolloutInVariousGeographiesMember" xlink:href="sny-20231231.xsd#sny_NewBusinessModelRolloutInVariousGeographiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NewBusinessModelRolloutInVariousGeographiesMember" xlink:to="lab_sny_NewBusinessModelRolloutInVariousGeographiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock_8381a95c-1525-4ee7-af99-88b98bfea991_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures</link:label>
    <link:label id="lab_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Profit Or Loss And Other Comprehensive Income Of Associates And Joint Ventures [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of profit or loss and other comprehensive income of associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock" xlink:to="lab_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrumentsMember_1f70cd83-342d-4741-8fe2-65f26842aad1_terseLabel_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments</link:label>
    <link:label id="lab_sny_DebtInstrumentsMember_label_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments [Member]</link:label>
    <link:label id="lab_sny_DebtInstrumentsMember_documentation_en-US" xlink:label="lab_sny_DebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember" xlink:href="sny-20231231.xsd#sny_DebtInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrumentsMember" xlink:to="lab_sny_DebtInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfPeopleExposed_43af2527-9b6d-4f4d-97df-6fb3df69b100_terseLabel_en-US" xlink:label="lab_sny_NumberOfPeopleExposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of people exposed</link:label>
    <link:label id="lab_sny_NumberOfPeopleExposed_label_en-US" xlink:label="lab_sny_NumberOfPeopleExposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of People Exposed</link:label>
    <link:label id="lab_sny_NumberOfPeopleExposed_documentation_en-US" xlink:label="lab_sny_NumberOfPeopleExposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of People Exposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPeopleExposed" xlink:href="sny-20231231.xsd#sny_NumberOfPeopleExposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfPeopleExposed" xlink:to="lab_sny_NumberOfPeopleExposed" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCancersAssociatedWithDismissedCases_9f1226db-310d-40cc-81d8-5cd1d6e841db_terseLabel_en-US" xlink:label="lab_sny_NumberOfCancersAssociatedWithDismissedCases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cancers associated with dismissed cases</link:label>
    <link:label id="lab_sny_NumberOfCancersAssociatedWithDismissedCases_label_en-US" xlink:label="lab_sny_NumberOfCancersAssociatedWithDismissedCases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Cancers Associated With Dismissed Cases</link:label>
    <link:label id="lab_sny_NumberOfCancersAssociatedWithDismissedCases_documentation_en-US" xlink:label="lab_sny_NumberOfCancersAssociatedWithDismissedCases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Cancers Associated With Dismissed Cases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCancersAssociatedWithDismissedCases" xlink:href="sny-20231231.xsd#sny_NumberOfCancersAssociatedWithDismissedCases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCancersAssociatedWithDismissedCases" xlink:to="lab_sny_NumberOfCancersAssociatedWithDismissedCases" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_3138c11c-6a62-445c-9823-39b452ca1172_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal changes in the scope of consolidation in 2023</link:label>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_226560e0-771b-4fc1-840c-1c1a46cc97df_verboseLabel_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal changes in the scope of consolidation in 2022 and 2021</link:label>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Impact Of Changes In The Scope Of Consolidation Due To Acquisitions And Divestments Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember_cc2e1873-93b8-44a5-90a8-5fa172b00a3e_terseLabel_en-US" xlink:label="lab_ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for decommissioning, restoration and rehabilitation costs</link:label>
    <link:label id="lab_ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember_label_en-US" xlink:label="lab_ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for decommissioning, restoration and rehabilitation costs [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember" xlink:to="lab_ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_30831237-8f4c-4333-8bbe-6ddbdd861731_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Currency Hedging Instruments</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Operating Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:to="lab_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee_b1bd2cbe-8a49-45a9-adff-454347c7b614_terseLabel_en-US" xlink:label="lab_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members</link:label>
    <link:label id="lab_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee_label_en-US" xlink:label="lab_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Pension Obligation In Favor Of Certain Corporate Officers And Of Members Of The Executive Committee</link:label>
    <link:label id="lab_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee_documentation_en-US" xlink:label="lab_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate pension obligation in favor of certain corporate officers and of members of the executive committee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee" xlink:href="sny-20231231.xsd#sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee" xlink:to="lab_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_99442c57-3b00-48a3-b4d9-f89b550ca361_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about credit exposures designated as measured at fair value through profit or loss [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UnquotedDebtSecuritiesMember_6ba0352e-b9e2-4956-952b-2427dd1b1fa4_terseLabel_en-US" xlink:label="lab_sny_UnquotedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unquoted debt securities not meeting the definition of equity instruments</link:label>
    <link:label id="lab_sny_UnquotedDebtSecuritiesMember_label_en-US" xlink:label="lab_sny_UnquotedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unquoted Debt Securities [Member]</link:label>
    <link:label id="lab_sny_UnquotedDebtSecuritiesMember_documentation_en-US" xlink:label="lab_sny_UnquotedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unquoted debt securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnquotedDebtSecuritiesMember" xlink:href="sny-20231231.xsd#sny_UnquotedDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UnquotedDebtSecuritiesMember" xlink:to="lab_sny_UnquotedDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_0308cf9f-b9f9-43d2-8804-0ad40930baa5_terseLabel_en-US" xlink:label="lab_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect at date of initial application [axis]</link:label>
    <link:label id="lab_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_label_en-US" xlink:label="lab_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect at date of initial application [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="lab_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmunixPharmaceuticalsIncMember_cc1c9b9e-17d0-4719-ac6d-838ac578c16b_terseLabel_en-US" xlink:label="lab_sny_AmunixPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amunix Pharmaceuticals, Inc</link:label>
    <link:label id="lab_sny_AmunixPharmaceuticalsIncMember_label_en-US" xlink:label="lab_sny_AmunixPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amunix Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_sny_AmunixPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_sny_AmunixPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amunix Pharmaceuticals, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixPharmaceuticalsIncMember" xlink:href="sny-20231231.xsd#sny_AmunixPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmunixPharmaceuticalsIncMember" xlink:to="lab_sny_AmunixPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_78bcf6a2-5aba-4e8b-9ddc-7ad2e1b6cafa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfExecutiveCommitteeMembers_d53d6d22-4607-442f-a514-93f24b026322_terseLabel_en-US" xlink:label="lab_sny_NumberOfExecutiveCommitteeMembers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average number of members of executive committee</link:label>
    <link:label id="lab_sny_NumberOfExecutiveCommitteeMembers_label_en-US" xlink:label="lab_sny_NumberOfExecutiveCommitteeMembers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Executive Committee Members</link:label>
    <link:label id="lab_sny_NumberOfExecutiveCommitteeMembers_documentation_en-US" xlink:label="lab_sny_NumberOfExecutiveCommitteeMembers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of executive committee members.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfExecutiveCommitteeMembers" xlink:href="sny-20231231.xsd#sny_NumberOfExecutiveCommitteeMembers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfExecutiveCommitteeMembers" xlink:to="lab_sny_NumberOfExecutiveCommitteeMembers" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees_a4934fe2-92e9-4084-a0f9-bcaddab71566_terseLabel_en-US" xlink:label="lab_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital increase reserved for employees (in shares)</link:label>
    <link:label id="lab_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees_label_en-US" xlink:label="lab_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Issues In Regards To Capital increase Reserved For Employees</link:label>
    <link:label id="lab_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees_documentation_en-US" xlink:label="lab_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Issues In Regards To Capital increase Reserved For Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees" xlink:href="sny-20231231.xsd#sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees" xlink:to="lab_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_bd0587c4-8d7a-4965-a649-880f26033420_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SocialSecurityContributions_544abc84-b6b0-4b30-92e6-636e5caf317f_terseLabel_en-US" xlink:label="lab_ifrs-full_SocialSecurityContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social security charges (including defined-contribution pension plans)</link:label>
    <link:label id="lab_ifrs-full_SocialSecurityContributions_label_en-US" xlink:label="lab_ifrs-full_SocialSecurityContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social security contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SocialSecurityContributions" xlink:to="lab_ifrs-full_SocialSecurityContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_da939e41-97d3-4bc1-adf3-52ad6467db0a_verboseLabel_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infraserv GmbH&#160;&amp; Co. H&#246;chst KG</link:label>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_label_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infraserv Gmbh And Co Hochst KG [member]</link:label>
    <link:label id="lab_sny_InfraservGmbhAndCoHochstKGMember_documentation_en-US" xlink:label="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infraserv GmbH and Co. Hochst KG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember" xlink:href="sny-20231231.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InfraservGmbhAndCoHochstKGMember" xlink:to="lab_sny_InfraservGmbhAndCoHochstKGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_a4427b3c-d016-4008-b086-1a3d0d2265fb_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions [member]</link:label>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember" xlink:to="lab_ifrs-full_OtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_JointVenturesAxis_fc335854-d30e-4e19-9ba1-38660c65af3d_terseLabel_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint ventures [axis]</link:label>
    <link:label id="lab_ifrs-full_JointVenturesAxis_label_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint ventures [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesAxis" xlink:to="lab_ifrs-full_JointVenturesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_db27e977-7481-450c-a46d-816ed2af682e_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable, other than corporate income taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current payables on social security and taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_QuotedDebtInstrumentsMember_f377e407-bcc0-4a5b-8aa1-376a5343aa86_terseLabel_en-US" xlink:label="lab_sny_QuotedDebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted debt instruments</link:label>
    <link:label id="lab_sny_QuotedDebtInstrumentsMember_label_en-US" xlink:label="lab_sny_QuotedDebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Debt Instruments [Member]</link:label>
    <link:label id="lab_sny_QuotedDebtInstrumentsMember_documentation_en-US" xlink:label="lab_sny_QuotedDebtInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedDebtInstrumentsMember" xlink:href="sny-20231231.xsd#sny_QuotedDebtInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_QuotedDebtInstrumentsMember" xlink:to="lab_sny_QuotedDebtInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock_9a2e29eb-44ca-4caa-a308-6169f0f44b0e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt by Maturity at Value on Redemption</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt By Maturity At Value Of Redemption Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of debt by maturity at value of redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GuaranteesGivenMember_a25c3959-a837-446c-a55a-cdfde57c8d76_terseLabel_en-US" xlink:label="lab_sny_GuaranteesGivenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees given</link:label>
    <link:label id="lab_sny_GuaranteesGivenMember_label_en-US" xlink:label="lab_sny_GuaranteesGivenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees Given [member]</link:label>
    <link:label id="lab_sny_GuaranteesGivenMember_documentation_en-US" xlink:label="lab_sny_GuaranteesGivenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees given.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GuaranteesGivenMember" xlink:href="sny-20231231.xsd#sny_GuaranteesGivenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GuaranteesGivenMember" xlink:to="lab_sny_GuaranteesGivenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BioverativIncMember_ec98962d-a458-4add-b134-a2d943d3f6e4_terseLabel_en-US" xlink:label="lab_sny_BioverativIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ Inc.</link:label>
    <link:label id="lab_sny_BioverativIncMember_label_en-US" xlink:label="lab_sny_BioverativIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ Inc. [member]</link:label>
    <link:label id="lab_sny_BioverativIncMember_documentation_en-US" xlink:label="lab_sny_BioverativIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativIncMember" xlink:href="sny-20231231.xsd#sny_BioverativIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BioverativIncMember" xlink:to="lab_sny_BioverativIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentAssetsMember_70ba52c3-d91c-43d7-8831-31af917c123a_verboseLabel_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_sny_NonCurrentAssetsMember_8c5ed905-754e-4e2c-98a7-dc3fa20bd4c9_terseLabel_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_sny_NonCurrentAssetsMember_label_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Assets [Member]</link:label>
    <link:label id="lab_sny_NonCurrentAssetsMember_documentation_en-US" xlink:label="lab_sny_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember" xlink:href="sny-20231231.xsd#sny_NonCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentAssetsMember" xlink:to="lab_sny_NonCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DefendantDomain_66ae0d7f-f0af-428c-b5f3-8d97450965a8_terseLabel_en-US" xlink:label="lab_sny_DefendantDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defendant [Domain]</link:label>
    <link:label id="lab_sny_DefendantDomain_label_en-US" xlink:label="lab_sny_DefendantDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defendant [Domain]</link:label>
    <link:label id="lab_sny_DefendantDomain_documentation_en-US" xlink:label="lab_sny_DefendantDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defendant [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantDomain" xlink:href="sny-20231231.xsd#sny_DefendantDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DefendantDomain" xlink:to="lab_sny_DefendantDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DepakineProductLitigationInIrelandMember_f4545af1-5057-49d7-9904-ed12928a29c0_terseLabel_en-US" xlink:label="lab_sny_DepakineProductLitigationInIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine product litigation in Ireland</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInIrelandMember_label_en-US" xlink:label="lab_sny_DepakineProductLitigationInIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Ireland [Member]</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInIrelandMember_documentation_en-US" xlink:label="lab_sny_DepakineProductLitigationInIrelandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Ireland</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInIrelandMember" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DepakineProductLitigationInIrelandMember" xlink:to="lab_sny_DepakineProductLitigationInIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForeignCurrencyTranslationDifferences_a9933c48-6007-4aac-a723-4c7d84b37522_terseLabel_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationDifferences" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_sny_ForeignCurrencyTranslationDifferences_label_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Differences</link:label>
    <link:label id="lab_sny_ForeignCurrencyTranslationDifferences_documentation_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationDifferences" xlink:href="sny-20231231.xsd#sny_ForeignCurrencyTranslationDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForeignCurrencyTranslationDifferences" xlink:to="lab_sny_ForeignCurrencyTranslationDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareGroupSASMember_f9288048-09e3-4eeb-af84-e39174c2a166_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareGroupSASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Group SAS</link:label>
    <link:label id="lab_sny_OpellaHealthcareGroupSASMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareGroupSASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Group SAS [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareGroupSASMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareGroupSASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Group SAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareGroupSASMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareGroupSASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareGroupSASMember" xlink:to="lab_sny_OpellaHealthcareGroupSASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_d078e99d-d927-42c0-b5f6-3c39054ed650_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual&#160;interest&#160;rate</link:label>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiSRLMember_3768f570-e2b3-4a1d-b2d4-76bff4f58811_terseLabel_en-US" xlink:label="lab_sny_SanofiSRLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi SRL</link:label>
    <link:label id="lab_sny_SanofiSRLMember_label_en-US" xlink:label="lab_sny_SanofiSRLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi SRL [Member]</link:label>
    <link:label id="lab_sny_SanofiSRLMember_documentation_en-US" xlink:label="lab_sny_SanofiSRLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Spa.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiSRLMember" xlink:href="sny-20231231.xsd#sny_SanofiSRLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiSRLMember" xlink:to="lab_sny_SanofiSRLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_86e997ed-2dc0-45f0-b188-3ddefdead71b_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_917c65a0-93dc-4aed-809e-a15a759aa6c7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in contingent consideration asset (liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:to="lab_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets_02a1cb27-bc1e-405c-922b-fd3320622f92_terseLabel_en-US" xlink:label="lab_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in scope of consolidation</link:label>
    <link:label id="lab_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets_label_en-US" xlink:label="lab_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Through Business Combinations, Property, Plant and Equipment, Right Of Use Assets</link:label>
    <link:label id="lab_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets_documentation_en-US" xlink:label="lab_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Through Business Combinations, Property, Plant and Equipment, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets" xlink:href="sny-20231231.xsd#sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets" xlink:to="lab_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030_3ae4f9d8-3b45-4fce-a0bb-cb30672c7dcd_terseLabel_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program, percentage of reduction in scope 3 greenhouse gas by 2030</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030_label_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Percentage Of Reduction In Scope 3 Greenhouse Gas By 2030</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030_documentation_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Percentage Of Reduction In Scope 3 Greenhouse Gas By 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030" xlink:to="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable_aced5fee-3cb6-43e8-a28e-154e9334fcc1_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Tax Losses Available For Carryforward [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable_label_en-US" xlink:label="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Tax Losses Available For Carryforward [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Tax Losses Available For Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfTaxLossesAvailableForCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable" xlink:to="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember_4393bcbd-50a8-4953-a71b-c75e22be0f8e_terseLabel_en-US" xlink:label="lab_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets held to meet obligations under deferred compensation plans</link:label>
    <link:label id="lab_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember_label_en-US" xlink:label="lab_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Held To Meet Obligations Under Deferred Compensation Plans [Member]</link:label>
    <link:label id="lab_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember_documentation_en-US" xlink:label="lab_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets held to meet obligations under deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember" xlink:href="sny-20231231.xsd#sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember" xlink:to="lab_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_746e6cb9-6e60-472d-aef4-9c7140419a22_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_7b004a28-2c2e-4536-8a88-7c99da12e2b8_terseLabel_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm orders of property, plant and equipment</link:label>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm Orders Of Property Plant And Equipment</link:label>
    <link:label id="lab_sny_FirmOrdersOfPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm orders of property plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:href="sny-20231231.xsd#sny_FirmOrdersOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:to="lab_sny_FirmOrdersOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_e35a849d-1091-43d4-a93c-2da0adb9ce83_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items not subsequently reclassifiable to profit or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcarePhilippinesIncMember_1479e067-2136-4786-9f48-4467f130cfc4_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcarePhilippinesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Philippines Inc.</link:label>
    <link:label id="lab_sny_OpellaHealthcarePhilippinesIncMember_label_en-US" xlink:label="lab_sny_OpellaHealthcarePhilippinesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Philippines Inc. [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcarePhilippinesIncMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcarePhilippinesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Philippines Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcarePhilippinesIncMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcarePhilippinesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcarePhilippinesIncMember" xlink:to="lab_sny_OpellaHealthcarePhilippinesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_0690ee6f-973f-467a-8403-de585f37ba03_terseLabel_en-US" xlink:label="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank credit balances</link:label>
    <link:label id="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank overdrafts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherOperatingIncomeExpense1Member_b4274fd4-9a9e-488d-ad80-6293e6b3863d_terseLabel_en-US" xlink:label="lab_sny_OtherOperatingIncomeExpense1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income (expense)</link:label>
    <link:label id="lab_sny_OtherOperatingIncomeExpense1Member_label_en-US" xlink:label="lab_sny_OtherOperatingIncomeExpense1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense)1 [Member]</link:label>
    <link:label id="lab_sny_OtherOperatingIncomeExpense1Member_documentation_en-US" xlink:label="lab_sny_OtherOperatingIncomeExpense1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpense1Member" xlink:href="sny-20231231.xsd#sny_OtherOperatingIncomeExpense1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherOperatingIncomeExpense1Member" xlink:to="lab_sny_OtherOperatingIncomeExpense1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations_8fcad642-8cc1-4c1a-a53f-a6558e59a2ac_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments relating to contingent consideration&#160;in connection with business combinations</link:label>
    <link:label id="lab_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations_label_en-US" xlink:label="lab_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Relating To Contingent Consideration In Connection With Business Combinations</link:label>
    <link:label id="lab_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Relating To Contingent Consideration In Connection With Business Combinations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" xlink:to="lab_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_3b5e9423-898d-4db1-8383-019d1fbfe258_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounts receivable [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_label_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Accounts Receivable [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Accounts receivable Table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable" xlink:to="lab_sny_DisclosureOfAccountsReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInformationOnIncomeStatementLineItems_747c13fc-6a5a-44f7-9864-3e7c36400f5c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInformationOnIncomeStatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information on income statement [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationOnIncomeStatementLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfInformationOnIncomeStatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information On Income Statement [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationOnIncomeStatementLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfInformationOnIncomeStatementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information on income statement line items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationOnIncomeStatementLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfInformationOnIncomeStatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInformationOnIncomeStatementLineItems" xlink:to="lab_sny_DisclosureOfInformationOnIncomeStatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiHongKongLimitedMember_5c03529b-74bf-46e8-a705-f68ed34a17e5_terseLabel_en-US" xlink:label="lab_sny_SanofiHongKongLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Hong-Kong Limited</link:label>
    <link:label id="lab_sny_SanofiHongKongLimitedMember_label_en-US" xlink:label="lab_sny_SanofiHongKongLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Hong-Kong Limited [Member]</link:label>
    <link:label id="lab_sny_SanofiHongKongLimitedMember_documentation_en-US" xlink:label="lab_sny_SanofiHongKongLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Hong-Kong Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiHongKongLimitedMember" xlink:href="sny-20231231.xsd#sny_SanofiHongKongLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiHongKongLimitedMember" xlink:to="lab_sny_SanofiHongKongLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareCzechSroMember_7177bdfd-6c17-4bff-9fae-529ecb7902dc_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareCzechSroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Czech s.r.o</link:label>
    <link:label id="lab_sny_OpellaHealthcareCzechSroMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareCzechSroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Czech s.r.o [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareCzechSroMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareCzechSroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Czech s.r.o</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareCzechSroMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareCzechSroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareCzechSroMember" xlink:to="lab_sny_OpellaHealthcareCzechSroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement_65b82751-65ed-4ba5-910d-a118b0aad65f_negatedTerseLabel_en-US" xlink:label="lab_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</link:label>
    <link:label id="lab_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement_label_en-US" xlink:label="lab_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains) Losses Related To Plan Amendments, Curtailments Or Settlement</link:label>
    <link:label id="lab_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement_documentation_en-US" xlink:label="lab_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains) Losses Related To Plan Amendments, Curtailments Or Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" xlink:href="sny-20231231.xsd#sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" xlink:to="lab_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionPeriod_53d18c04-0d07-4ea3-91b8-4510cfb638e2_terseLabel_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facilities, extension option, period</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionPeriod_label_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facilities, Extension Option, Period</link:label>
    <link:label id="lab_sny_CreditFacilitiesExtensionOptionPeriod_documentation_en-US" xlink:label="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facilities, Extension Option, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionPeriod" xlink:href="sny-20231231.xsd#sny_CreditFacilitiesExtensionOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CreditFacilitiesExtensionOptionPeriod" xlink:to="lab_sny_CreditFacilitiesExtensionOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MeasurementAxis_1726c6b7-d021-40cd-84d2-0c29213695e5_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement [axis]</link:label>
    <link:label id="lab_ifrs-full_MeasurementAxis_label_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis" xlink:to="lab_ifrs-full_MeasurementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiVietnamShareholdingCompanyLimitedMember_1677011d-ac1b-4b6b-8e3d-ddb1422fa701_terseLabel_en-US" xlink:label="lab_sny_SanofiVietnamShareholdingCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Vietnam Shareholding Company Limited</link:label>
    <link:label id="lab_sny_SanofiVietnamShareholdingCompanyLimitedMember_label_en-US" xlink:label="lab_sny_SanofiVietnamShareholdingCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Vietnam Shareholding Company Limited [Member]</link:label>
    <link:label id="lab_sny_SanofiVietnamShareholdingCompanyLimitedMember_documentation_en-US" xlink:label="lab_sny_SanofiVietnamShareholdingCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Vietnam Shareholding Company Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiVietnamShareholdingCompanyLimitedMember" xlink:href="sny-20231231.xsd#sny_SanofiVietnamShareholdingCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiVietnamShareholdingCompanyLimitedMember" xlink:to="lab_sny_SanofiVietnamShareholdingCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiOyMember_93bae24a-6b3d-4a91-91ad-9744711dd085_terseLabel_en-US" xlink:label="lab_sny_SanofiOyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Oy</link:label>
    <link:label id="lab_sny_SanofiOyMember_label_en-US" xlink:label="lab_sny_SanofiOyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Oy [member]</link:label>
    <link:label id="lab_sny_SanofiOyMember_documentation_en-US" xlink:label="lab_sny_SanofiOyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Oy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiOyMember" xlink:href="sny-20231231.xsd#sny_SanofiOyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiOyMember" xlink:to="lab_sny_SanofiOyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_27cd002a-d3c9-40e8-83d7-c1ba4fbea1d7_negatedTerseLabel_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_43c2b536-1a27-414d-aac4-0dd390c066d7_terseLabel_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exceptional supplementary dividends recognised as distributions to owners of parent</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_label_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_documentation_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:to="lab_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AwardsDateAxis_09dd2e32-0fc6-4f27-a0e0-e1e1b46561c9_terseLabel_en-US" xlink:label="lab_sny_AwardsDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Date [Axis]</link:label>
    <link:label id="lab_sny_AwardsDateAxis_label_en-US" xlink:label="lab_sny_AwardsDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Date [Axis]</link:label>
    <link:label id="lab_sny_AwardsDateAxis_documentation_en-US" xlink:label="lab_sny_AwardsDateAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Date 1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateAxis" xlink:href="sny-20231231.xsd#sny_AwardsDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AwardsDateAxis" xlink:to="lab_sny_AwardsDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_22a0315a-1abe-43e1-a1be-2abbffe3616b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Acquisitions and Capitalized Interest by Operating Segment</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_42d7cafb-c0bf-4b4e-b9a8-93de23b97cc0_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment owned and leased</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_98dd87a9-c5d0-4951-a21f-062923694697_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_9db8cb03-8aa2-4f0b-8353-a61380ae9108_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value on cash flow hedges excluding associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock_95d75a76-ddf5-4af1-97b4-7b6511192420_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Interest Rate of Net Debt at Value on Redemption</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt By Interest Rate At Value Of Redemption After Taking Account Of Derivative Instruments N1N2 [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of debt by interest rate at value of redemption after taking account of derivative instruments N1 N2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock" xlink:to="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AuditorInformationAbstract_label_en-US" xlink:label="lab_sny_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_sny_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_sny_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorInformationAbstract" xlink:href="sny-20231231.xsd#sny_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AuditorInformationAbstract" xlink:to="lab_sny_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2022ProgramMember_e349a02e-e007-4bf6-9a11-c773dece95c1_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_sny_ShareRepurchase2022ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase 2022 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2022ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase 2022 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2022ProgramMember" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2022ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2022ProgramMember" xlink:to="lab_sny_ShareRepurchase2022ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PlanAssetsMember_ec3542e4-8496-4281-8865-a66d2fdefd0a_terseLabel_en-US" xlink:label="lab_ifrs-full_PlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets</link:label>
    <link:label id="lab_ifrs-full_PlanAssetsMember_label_en-US" xlink:label="lab_ifrs-full_PlanAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PlanAssetsMember" xlink:to="lab_ifrs-full_PlanAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_9fcc7758-eda6-437a-98a6-866ab973e942_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityDerivativesMember_d21d4cd4-666e-4b16-a87e-1466a5f2d41b_terseLabel_en-US" xlink:label="lab_sny_EquityDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity derivatives</link:label>
    <link:label id="lab_sny_EquityDerivativesMember_label_en-US" xlink:label="lab_sny_EquityDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Derivatives [Member]</link:label>
    <link:label id="lab_sny_EquityDerivativesMember_documentation_en-US" xlink:label="lab_sny_EquityDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Derivatives [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityDerivativesMember" xlink:href="sny-20231231.xsd#sny_EquityDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityDerivativesMember" xlink:to="lab_sny_EquityDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_0a7fdf41-7785-409d-a5b8-97f9a3a8b599_totalLabel_en-US" xlink:label="lab_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_label_en-US" xlink:label="lab_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Expense For Pension And Other Post-employment Benefits Recognized Directly In Profit Or Loss</link:label>
    <link:label id="lab_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_documentation_en-US" xlink:label="lab_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized directly in profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:href="sny-20231231.xsd#sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:to="lab_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock_589e2972-bb0f-4408-a20c-37834f25d467_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Compensation Paid to Key Management Personnel</link:label>
    <link:label id="lab_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Compensation Paid To Key Management Personnel [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of compensation paid to key management personnel.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock" xlink:to="lab_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_f2f98ba7-4476-4871-946f-dde0c44ad7b5_terseLabel_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment plans:</link:label>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_label_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Payment Plans [abstract]</link:label>
    <link:label id="lab_sny_ShareBasedPaymentPlansAbstract_documentation_en-US" xlink:label="lab_sny_ShareBasedPaymentPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based payment plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract" xlink:href="sny-20231231.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract" xlink:to="lab_sny_ShareBasedPaymentPlansAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_c7b30abf-68cc-4032-80c0-256c2f428c6a_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences (investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Currency Translation Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in currency translation net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation_9c39ae4f-5c8d-4335-af4a-19161999885e_terseLabel_en-US" xlink:label="lab_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum penalty amount sought by plaintiffs for each violation</link:label>
    <link:label id="lab_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation_label_en-US" xlink:label="lab_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Penalty Amount Sought By Plaintiffs For Each Violation</link:label>
    <link:label id="lab_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation_documentation_en-US" xlink:label="lab_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum penalty amount sought by plaintiffs for each violation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation" xlink:href="sny-20231231.xsd#sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation" xlink:to="lab_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember_f6420eda-e0f8-48af-bdcc-0b65ec951db7_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim Consumer Healthcare</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Boehringer Ingelheim Consumer Healthcare [member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal marketed products Boehringer Ingelheim Consumer Healthcare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember" xlink:to="lab_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts_6bcca938-f750-4a16-ba6f-88c8234f4c8b_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments related to attainment of regulatory and sales milestones for commercialized products</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Attainment Of Regulatory And Sales Milestones For Commercialized Products</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Attainment Of Regulatory And Sales Milestones For Commercialized Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts" xlink:to="lab_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_bb8cedf6-5297-45a9-8a9d-ba827feb5db2_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Movements in Other Intangible Assets</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Changes In Other Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of changes in other intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_c4d8f800-392b-4149-bb83-022718ed05a0_terseLabel_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued immediately as employer's contribution (in shares)</link:label>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_label_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Further Shares As An Employers Contribution</link:label>
    <link:label id="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_documentation_en-US" xlink:label="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Further shares as an employers contribution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:href="sny-20231231.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:to="lab_sny_IssuanceOfFurtherSharesAsAnEmployersContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_2823e74b-c796-48ff-8186-e5cd4b192875_negatedLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:to="lab_ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CommercialPapersIssued_348ae05c-6572-4286-ba10-26b33658231b_terseLabel_en-US" xlink:label="lab_ifrs-full_CommercialPapersIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper programs</link:label>
    <link:label id="lab_ifrs-full_CommercialPapersIssued_label_en-US" xlink:label="lab_ifrs-full_CommercialPapersIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial papers issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommercialPapersIssued" xlink:to="lab_ifrs-full_CommercialPapersIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashEquivalentsMoneyMarketMutualFunds_19706869-c9c7-4be5-9b88-482815a9510a_terseLabel_en-US" xlink:label="lab_sny_CashEquivalentsMoneyMarketMutualFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, money market mutual funds</link:label>
    <link:label id="lab_sny_CashEquivalentsMoneyMarketMutualFunds_label_en-US" xlink:label="lab_sny_CashEquivalentsMoneyMarketMutualFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Money Market Mutual Funds</link:label>
    <link:label id="lab_sny_CashEquivalentsMoneyMarketMutualFunds_documentation_en-US" xlink:label="lab_sny_CashEquivalentsMoneyMarketMutualFunds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalent money market mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashEquivalentsMoneyMarketMutualFunds" xlink:href="sny-20231231.xsd#sny_CashEquivalentsMoneyMarketMutualFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashEquivalentsMoneyMarketMutualFunds" xlink:to="lab_sny_CashEquivalentsMoneyMarketMutualFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement_012a312b-c8c5-4ac6-86a9-e447489ec741_negatedLabel_en-US" xlink:label="lab_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, options forfeited</link:label>
    <link:label id="lab_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Of Share Options Forfeited In Share Based Payment Arrangement</link:label>
    <link:label id="lab_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of share options forfeited in share based payment arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement" xlink:to="lab_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiChinaInvestmentCoLtdMember_b55413f3-7dee-41d4-ba1c-342aa15c9303_terseLabel_en-US" xlink:label="lab_sny_SanofiChinaInvestmentCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi (China) Investment Co., Ltd</link:label>
    <link:label id="lab_sny_SanofiChinaInvestmentCoLtdMember_label_en-US" xlink:label="lab_sny_SanofiChinaInvestmentCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi China Investment Co Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiChinaInvestmentCoLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiChinaInvestmentCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi (China) Investment Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiChinaInvestmentCoLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiChinaInvestmentCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiChinaInvestmentCoLtdMember" xlink:to="lab_sny_SanofiChinaInvestmentCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UnquotedEquityInvestmentsMember_21b74fab-a771-4885-a4cb-f85dce291da7_terseLabel_en-US" xlink:label="lab_sny_UnquotedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unquoted equity investments</link:label>
    <link:label id="lab_sny_UnquotedEquityInvestmentsMember_label_en-US" xlink:label="lab_sny_UnquotedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unquoted Equity Investments [Member]</link:label>
    <link:label id="lab_sny_UnquotedEquityInvestmentsMember_documentation_en-US" xlink:label="lab_sny_UnquotedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unquoted equity investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnquotedEquityInvestmentsMember" xlink:href="sny-20231231.xsd#sny_UnquotedEquityInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UnquotedEquityInvestmentsMember" xlink:to="lab_sny_UnquotedEquityInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_a10308c3-4dcb-4e5b-aa34-c327013077e8_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_8e57b3e1-320a-4f20-a571-0cc63f1b82b5_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_0f590a12-7d1d-4595-8c00-f89b3767cf6d_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SspCoLtdMember_8fec2f5c-6a3d-4adc-9c44-cebc79ac72f9_terseLabel_en-US" xlink:label="lab_sny_SspCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SSP Co.,Ltd</link:label>
    <link:label id="lab_sny_SspCoLtdMember_label_en-US" xlink:label="lab_sny_SspCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SSP Co Ltd [member]</link:label>
    <link:label id="lab_sny_SspCoLtdMember_documentation_en-US" xlink:label="lab_sny_SspCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SSP Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SspCoLtdMember" xlink:href="sny-20231231.xsd#sny_SspCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SspCoLtdMember" xlink:to="lab_sny_SspCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_April2022EMTNISINFR0014009KS6Member_6b6c94d6-8817-4810-8363-f230eaca6da7_verboseLabel_en-US" xlink:label="lab_sny_April2022EMTNISINFR0014009KS6Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2022 EMTN ISIN FR0014009KS6</link:label>
    <link:label id="lab_sny_April2022EMTNISINFR0014009KS6Member_label_en-US" xlink:label="lab_sny_April2022EMTNISINFR0014009KS6Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2022 EMTN ISIN FR0014009KS6 [Member]</link:label>
    <link:label id="lab_sny_April2022EMTNISINFR0014009KS6Member_documentation_en-US" xlink:label="lab_sny_April2022EMTNISINFR0014009KS6Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2014 EMTN ISIN FR0012146777.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2022EMTNISINFR0014009KS6Member" xlink:href="sny-20231231.xsd#sny_April2022EMTNISINFR0014009KS6Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_April2022EMTNISINFR0014009KS6Member" xlink:to="lab_sny_April2022EMTNISINFR0014009KS6Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ContingentConsiderationTranslateBioMember_4c70a14c-f76a-4783-a3f3-fc627bd976f7_terseLabel_en-US" xlink:label="lab_sny_ContingentConsiderationTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire contingent consideration arising from the acquisition of Translate Bio</link:label>
    <link:label id="lab_sny_ContingentConsiderationTranslateBioMember_label_en-US" xlink:label="lab_sny_ContingentConsiderationTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Translate Bio [Member]</link:label>
    <link:label id="lab_sny_ContingentConsiderationTranslateBioMember_documentation_en-US" xlink:label="lab_sny_ContingentConsiderationTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Translate Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationTranslateBioMember" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationTranslateBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ContingentConsiderationTranslateBioMember" xlink:to="lab_sny_ContingentConsiderationTranslateBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress_1bc355cb-54c0-43fd-bc15-0be879553390_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development license agreements - contingent milestone payments in connection with development programs in progress</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Research And Development License Agreements, Contingent Milestone Payments In Connection With Development Programs In Progress</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Research And Development License Agreements, Contingent Milestone Payments In Connection With Development Programs In Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" xlink:to="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies_96e1148e-a345-40a3-b15b-606735f78872_terseLabel_en-US" xlink:label="lab_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, captive insurance and reinsurance companies</link:label>
    <link:label id="lab_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies_label_en-US" xlink:label="lab_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Captive Insurance And Reinsurance Companies</link:label>
    <link:label id="lab_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies_documentation_en-US" xlink:label="lab_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents captive insurance and reinsurance companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies" xlink:href="sny-20231231.xsd#sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies" xlink:to="lab_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement_6372fa2f-cd7d-450b-9163-d483f9e8fce8_terseLabel_en-US" xlink:label="lab_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of novel small molecule candidates developed</link:label>
    <link:label id="lab_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement_label_en-US" xlink:label="lab_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Novel Small Molecule Candidates To Be Developed Under Collaboration Agreement</link:label>
    <link:label id="lab_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Novel Small Molecule Candidates To Be Developed Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement" xlink:href="sny-20231231.xsd#sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement" xlink:to="lab_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UndrawnBorrowingFacilities_2f5dccf0-bc1c-4074-831d-21706f09846a_verboseLabel_en-US" xlink:label="lab_ifrs-full_UndrawnBorrowingFacilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total credit facilities</link:label>
    <link:label id="lab_ifrs-full_UndrawnBorrowingFacilities_a72ae0f9-9191-4b1d-899e-dc1ba5318641_terseLabel_en-US" xlink:label="lab_ifrs-full_UndrawnBorrowingFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General-purpose credit facilities</link:label>
    <link:label id="lab_ifrs-full_UndrawnBorrowingFacilities_label_en-US" xlink:label="lab_ifrs-full_UndrawnBorrowingFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undrawn borrowing facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UndrawnBorrowingFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UndrawnBorrowingFacilities" xlink:to="lab_ifrs-full_UndrawnBorrowingFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SubscriptionPricePerShare_89136961-d7b5-4132-bed1-a4f47964823a_terseLabel_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription price (in euros per share)</link:label>
    <link:label id="lab_sny_SubscriptionPricePerShare_label_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription Price Per Share</link:label>
    <link:label id="lab_sny_SubscriptionPricePerShare_documentation_en-US" xlink:label="lab_sny_SubscriptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare" xlink:href="sny-20231231.xsd#sny_SubscriptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SubscriptionPricePerShare" xlink:to="lab_sny_SubscriptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfProfitsArisingFromCommercialOperations_3ecc0042-2618-4d7d-9ed5-09c5472fa915_terseLabel_en-US" xlink:label="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of profits arising from commercial operations</link:label>
    <link:label id="lab_sny_PercentageOfProfitsArisingFromCommercialOperations_label_en-US" xlink:label="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Profits Arising From Commercial Operations</link:label>
    <link:label id="lab_sny_PercentageOfProfitsArisingFromCommercialOperations_documentation_en-US" xlink:label="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Profits Arising From Commercial Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitsArisingFromCommercialOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:to="lab_sny_PercentageOfProfitsArisingFromCommercialOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock_cad2ca96-60a2-44ca-9f6b-d73f95071688_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Weighted Average Duration of Obligation for Pensions and Other Long-term Benefits in Principal Countries</link:label>
    <link:label id="lab_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Weighted Average Duration Of Defined Benefit Obligation [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of weighted average duration of defined benefit obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock" xlink:to="lab_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_455255cb-a9f7-4212-bf76-bcf2a4ee5ef5_negatedLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate and currency derivatives used to manage debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate And Currency Derivatives Used To Manage Debt</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate and currency derivatives used to manage debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DengvaxiaProductLitigationInThePhilippinesMember_8da7838f-4466-41a5-8b79-b903bd48837e_terseLabel_en-US" xlink:label="lab_sny_DengvaxiaProductLitigationInThePhilippinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dengvaxia product litigation in the Philippines</link:label>
    <link:label id="lab_sny_DengvaxiaProductLitigationInThePhilippinesMember_label_en-US" xlink:label="lab_sny_DengvaxiaProductLitigationInThePhilippinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dengvaxia Product Litigation In The Philippines [Member]</link:label>
    <link:label id="lab_sny_DengvaxiaProductLitigationInThePhilippinesMember_documentation_en-US" xlink:label="lab_sny_DengvaxiaProductLitigationInThePhilippinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dengvaxia Product Litigation In The Philippines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DengvaxiaProductLitigationInThePhilippinesMember" xlink:href="sny-20231231.xsd#sny_DengvaxiaProductLitigationInThePhilippinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DengvaxiaProductLitigationInThePhilippinesMember" xlink:to="lab_sny_DengvaxiaProductLitigationInThePhilippinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TargeGenIncMember_e42081e5-9dc8-4cd2-aa92-2c95a08ead50_terseLabel_en-US" xlink:label="lab_sny_TargeGenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TargeGen Inc.</link:label>
    <link:label id="lab_sny_TargeGenIncMember_label_en-US" xlink:label="lab_sny_TargeGenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TargeGen Inc. [Member]</link:label>
    <link:label id="lab_sny_TargeGenIncMember_documentation_en-US" xlink:label="lab_sny_TargeGenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TargeGen Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TargeGenIncMember" xlink:href="sny-20231231.xsd#sny_TargeGenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TargeGenIncMember" xlink:to="lab_sny_TargeGenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_USLegalRestructuringMember_4474f718-3d33-4dcd-bc6c-d546f252b27f_terseLabel_en-US" xlink:label="lab_sny_USLegalRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US legal restructuring</link:label>
    <link:label id="lab_sny_USLegalRestructuringMember_label_en-US" xlink:label="lab_sny_USLegalRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Legal Restructuring [Member]</link:label>
    <link:label id="lab_sny_USLegalRestructuringMember_documentation_en-US" xlink:label="lab_sny_USLegalRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Legal Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USLegalRestructuringMember" xlink:href="sny-20231231.xsd#sny_USLegalRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_USLegalRestructuringMember" xlink:to="lab_sny_USLegalRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_7d00004c-655e-4f9a-822e-bc1bb6132193_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and other increases</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_4bc4f13e-b856-4a6e-810e-54d2a843afdb_negatedLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversals of unutilized provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Of Unused Provision Reversed, Other Provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease of unused provision reversed, other provisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:to="lab_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_34925442-4cf9-4257-bc69-58e12171c922_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounts receivable [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Accounts Receivable [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfAccountsReceivableLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Accounts Receivable [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems" xlink:to="lab_sny_DisclosureOfAccountsReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisGroupeMember_cac9eb3d-43b1-4a59-9a3d-28bd719a6b81_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisGroupeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Groupe</link:label>
    <link:label id="lab_sny_SanofiAventisGroupeMember_label_en-US" xlink:label="lab_sny_SanofiAventisGroupeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Groupe [member]</link:label>
    <link:label id="lab_sny_SanofiAventisGroupeMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisGroupeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Groupe.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisGroupeMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisGroupeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisGroupeMember" xlink:to="lab_sny_SanofiAventisGroupeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_June2018SNFISINUS801060AD60Member_e1afa2d4-e59f-4bfc-8242-04675ab1c3db_terseLabel_en-US" xlink:label="lab_sny_June2018SNFISINUS801060AD60Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2018 SNF ISIN US801060AD60</link:label>
    <link:label id="lab_sny_June2018SNFISINUS801060AD60Member_label_en-US" xlink:label="lab_sny_June2018SNFISINUS801060AD60Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2018 SNFISINUS801060AD60 [member]</link:label>
    <link:label id="lab_sny_June2018SNFISINUS801060AD60Member_documentation_en-US" xlink:label="lab_sny_June2018SNFISINUS801060AD60Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2018SNFISINUS801060AD60.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_June2018SNFISINUS801060AD60Member" xlink:href="sny-20231231.xsd#sny_June2018SNFISINUS801060AD60Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_June2018SNFISINUS801060AD60Member" xlink:to="lab_sny_June2018SNFISINUS801060AD60Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseInEffectiveTaxRate_9cbc4f15-8ee3-415f-8f43-a45805237fff_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseInEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in effective tax rate</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInEffectiveTaxRate_label_en-US" xlink:label="lab_sny_IncreaseDecreaseInEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Effective Tax Rate</link:label>
    <link:label id="lab_sny_IncreaseDecreaseInEffectiveTaxRate_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseInEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInEffectiveTaxRate" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseInEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseInEffectiveTaxRate" xlink:to="lab_sny_IncreaseDecreaseInEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerOneMember_757586b0-de70-4d42-b877-61a3a78de7eb_terseLabel_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer one</link:label>
    <link:label id="lab_sny_CustomerOneMember_label_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [member]</link:label>
    <link:label id="lab_sny_CustomerOneMember_documentation_en-US" xlink:label="lab_sny_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember" xlink:href="sny-20231231.xsd#sny_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerOneMember" xlink:to="lab_sny_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions_e71555c9-fcc9-4235-ad9d-7318e63da2de_terseLabel_en-US" xlink:label="lab_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in shareholders equity due to exercise of stock purchase option</link:label>
    <link:label id="lab_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions_label_en-US" xlink:label="lab_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder's Equity Increase Due To The Exercise Of All Stock Subscription Options</link:label>
    <link:label id="lab_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions_documentation_en-US" xlink:label="lab_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder's equity increase due to the exercise of all stock subscription options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions" xlink:href="sny-20231231.xsd#sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions" xlink:to="lab_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock_9116bae9-d4b7-43b4-8f76-63eddcbc6b16_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for discounts, rebates and sales returns</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Provisions For Discounts Rebates And Sales Returns [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for provisions for discounts rebates and sales returns.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock" xlink:to="lab_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_af07ab0c-95db-46b2-9a78-9b5c67863bfb_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restructuring Costs and Similar Items</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Restructuring Costs Details [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of restructuring costs details.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringCostsDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:to="lab_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_fc627d91-d26c-43ba-86a1-15f5bc046229_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal accountants' fees and services</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of auditors' remuneration [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_8a699522-6353-48d3-b13b-cb3564bb7f5a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, cash and cash equivalents and lease liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt Instruments Issued Explanatory [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of debt instruments issued explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:to="lab_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UniformPreTaxDiscountRates_8b0033ab-bfee-4696-be12-4f675254573a_terseLabel_en-US" xlink:label="lab_sny_UniformPreTaxDiscountRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uniform pre-tax discount rates</link:label>
    <link:label id="lab_sny_UniformPreTaxDiscountRates_label_en-US" xlink:label="lab_sny_UniformPreTaxDiscountRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uniform Pre-Tax Discount Rates</link:label>
    <link:label id="lab_sny_UniformPreTaxDiscountRates_documentation_en-US" xlink:label="lab_sny_UniformPreTaxDiscountRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uniform pre-tax discount rates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UniformPreTaxDiscountRates" xlink:href="sny-20231231.xsd#sny_UniformPreTaxDiscountRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UniformPreTaxDiscountRates" xlink:to="lab_sny_UniformPreTaxDiscountRates" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock_c8790f91-a73d-4957-9556-539cea412266_terseLabel_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Fair Value Remeasurement Of Contingent Consideration Liabilities Explanatory [Policy Text Block]</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The description of the entity's accounting policy for fair value remeasurement of contingent consideration liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock" xlink:to="lab_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_11e4ec30-afd9-4e7c-8409-4daf014f6918_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through transfers and other changes, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RPRUSLtdMember_be93ac03-6c70-460c-827a-74df5e6e14ff_terseLabel_en-US" xlink:label="lab_sny_RPRUSLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPR US Ltd.</link:label>
    <link:label id="lab_sny_RPRUSLtdMember_label_en-US" xlink:label="lab_sny_RPRUSLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPR US Ltd [Member]</link:label>
    <link:label id="lab_sny_RPRUSLtdMember_documentation_en-US" xlink:label="lab_sny_RPRUSLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPR US Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RPRUSLtdMember" xlink:href="sny-20231231.xsd#sny_RPRUSLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RPRUSLtdMember" xlink:to="lab_sny_RPRUSLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_940902ec-4b4d-4406-97dc-82e441a0ecce_negatedLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Currency Translation On Tax Effects</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnTaxEffects_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in currency translation on tax effects.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:to="lab_sny_ChangeInCurrencyTranslationOnTaxEffects" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_7ffa547f-417c-4e4b-9091-083dd993d2a1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_9672ab3b-8a42-4515-8c40-f25376e813ea_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Noncurrent Provisions [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non-Current Provisions [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Noncurrent Provisions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_f904930b-961b-484a-bb27-3adcbce4ebf5_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Non-current Assets [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_label_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Non-Current Assets [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule disclosing information related to other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:to="lab_sny_DisclosureOfOtherNonCurrentAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncontrollingInterests_c89fccba-ec06-4db4-888a-c25b58eeec6d_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_NoncontrollingInterests_f877776e-920a-4f0a-b639-777bf4ceca65_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_NoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_NoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncontrollingInterests" xlink:to="lab_ifrs-full_NoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodwillMember_fb699ce9-8d6c-4a13-bca7-48a7159f2b49_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_GoodwillMember_label_en-US" xlink:label="lab_ifrs-full_GoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodwillMember" xlink:to="lab_ifrs-full_GoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement_279215fe-e262-4f3b-982c-b4d947f78c9a_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments related to maximum payments for projects under collaboration agreement</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Maximum Payments For Projects Under Collaboration Agreement</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Maximum Payments For Projects Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement" xlink:to="lab_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsBeyfortusMember_9343545a-693b-46b9-9846-01780ee3bcca_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsBeyfortusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BEYFORTUS</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsBeyfortusMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsBeyfortusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Beyfortus [Member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsBeyfortusMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsBeyfortusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Beyfortus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsBeyfortusMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsBeyfortusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsBeyfortusMember" xlink:to="lab_sny_PrincipalMarketedProductsBeyfortusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_79028fa4-5f00-4f8f-bdc3-c9d1a22adbf8_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_00fae25d-70df-4819-8310-72ccd01e5574_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_fee7d82b-62a2-4b8b-a956-089e6ebe2bf3_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial currency hedging instruments in place</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_label_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments To Manage Financial Exposure</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments to manage financial exposure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:to="lab_sny_DerivativeFinancialInstrumentsToManageFinancialExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_8a3c79d5-0155-44f7-879b-15deac757175_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of changes in other provisions [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of changes in other provisions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInventoriesLineItems_2dab59e9-694e-45a7-9d56-b7fc3a52901a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInventoriesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of inventories [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfInventoriesLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfInventoriesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Inventories [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfInventoriesLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfInventoriesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInventoriesLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfInventoriesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInventoriesLineItems" xlink:to="lab_sny_DisclosureOfInventoriesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCases_0d690def-eb2c-43ee-875b-d2f7bf6785bf_terseLabel_en-US" xlink:label="lab_sny_NumberOfCases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cases</link:label>
    <link:label id="lab_sny_NumberOfCases_label_en-US" xlink:label="lab_sny_NumberOfCases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Cases</link:label>
    <link:label id="lab_sny_NumberOfCases_documentation_en-US" xlink:label="lab_sny_NumberOfCases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Cases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCases" xlink:href="sny-20231231.xsd#sny_NumberOfCases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCases" xlink:to="lab_sny_NumberOfCases" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MajorCollaborationAgreementMember_a93b949e-738e-4183-914a-0e471c4440f0_terseLabel_en-US" xlink:label="lab_sny_MajorCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Collaboration Agreement</link:label>
    <link:label id="lab_sny_MajorCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_MajorCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_MajorCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_MajorCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorCollaborationAgreementMember" xlink:href="sny-20231231.xsd#sny_MajorCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MajorCollaborationAgreementMember" xlink:to="lab_sny_MajorCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChinoinPrivateCoLtdMember_05770c96-8353-461f-a48e-6b7d66644169_terseLabel_en-US" xlink:label="lab_sny_ChinoinPrivateCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinoin Private Co. Ltd</link:label>
    <link:label id="lab_sny_ChinoinPrivateCoLtdMember_label_en-US" xlink:label="lab_sny_ChinoinPrivateCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinoin Private Co. Ltd [member]</link:label>
    <link:label id="lab_sny_ChinoinPrivateCoLtdMember_documentation_en-US" xlink:label="lab_sny_ChinoinPrivateCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinoin Private Co. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChinoinPrivateCoLtdMember" xlink:href="sny-20231231.xsd#sny_ChinoinPrivateCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChinoinPrivateCoLtdMember" xlink:to="lab_sny_ChinoinPrivateCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables_d98f821e-bf08-4eab-a61e-63ca9aa1dd3f_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognised in profit or loss, trade receivables</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognised in profit or loss, trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3a925fa8-21b1-4029-b06c-0ccbf66780d1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment_5c720dfb-e3ce-4fd0-ad9a-8f424fc939cf_terseLabel_en-US" xlink:label="lab_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PD1 sales milestone payment from Sanofi</link:label>
    <link:label id="lab_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment_label_en-US" xlink:label="lab_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti Programmed Cell Death Protein 1 Sales Milestone Payment</link:label>
    <link:label id="lab_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment_documentation_en-US" xlink:label="lab_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti programmed cell death protein 1 sales milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment" xlink:href="sny-20231231.xsd#sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment" xlink:to="lab_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock_9929570c-f5d0-4d99-91b1-fea8bad4a353_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Timing of Benefit Payments under Pension and Other Post-employment Benefit Plans</link:label>
    <link:label id="lab_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Expected Timing Of Payments Under Pension And Other Post Employment Benefit Plans [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of expected timing of payments under pension and other post employment benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock" xlink:to="lab_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_f7b98053-7918-4e57-a437-ba115449771f_terseLabel_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of consolidation</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Basis Of Consolidation [Policy Text Block]</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_documentation_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The description of the entity's accounting policy for basis of consolidation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:to="lab_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringProvisionsTableTextBlock_e4f8faed-12cc-4f54-bcc5-87af993efe16_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movements in Restructuring Provisions Classified in Non-current and Current Liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringProvisionsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Restructuring Provisions [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringProvisionsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of restructuring provisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringProvisionsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringProvisionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsTableTextBlock" xlink:to="lab_sny_DisclosureOfRestructuringProvisionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_e0a0aecb-2bf4-4904-8429-abb503e62bcd_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EmployeesShareOwnershipPlanMember_102bda68-c1dc-4214-83b5-132e91b9d14b_terseLabel_en-US" xlink:label="lab_sny_EmployeesShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees share ownership plan</link:label>
    <link:label id="lab_sny_EmployeesShareOwnershipPlanMember_label_en-US" xlink:label="lab_sny_EmployeesShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees Share Ownership Plan [member]</link:label>
    <link:label id="lab_sny_EmployeesShareOwnershipPlanMember_documentation_en-US" xlink:label="lab_sny_EmployeesShareOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees share ownership plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeesShareOwnershipPlanMember" xlink:href="sny-20231231.xsd#sny_EmployeesShareOwnershipPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EmployeesShareOwnershipPlanMember" xlink:to="lab_sny_EmployeesShareOwnershipPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_f2783ef4-bc41-499f-aa32-27e6d7a846fd_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New standards, amendments and interpretations</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of initial application of standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurHepatitisBVaccineMember_98166fc5-87ea-4fdc-a11a-fd8035d0f342_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurHepatitisBVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Hepatitis B Vaccine product litigation</link:label>
    <link:label id="lab_sny_SanofiPasteurHepatitisBVaccineMember_label_en-US" xlink:label="lab_sny_SanofiPasteurHepatitisBVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Hepatitis B Vaccine [Member]</link:label>
    <link:label id="lab_sny_SanofiPasteurHepatitisBVaccineMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurHepatitisBVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Hepatitis B Vaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurHepatitisBVaccineMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurHepatitisBVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurHepatitisBVaccineMember" xlink:to="lab_sny_SanofiPasteurHepatitisBVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpairmentTestingPercentage_7aa9c8ba-6d82-4144-a81f-c165000fcb8b_terseLabel_en-US" xlink:label="lab_sny_ImpairmentTestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate used for Impairment of goodwill</link:label>
    <link:label id="lab_sny_ImpairmentTestingPercentage_label_en-US" xlink:label="lab_sny_ImpairmentTestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Testing Percentage</link:label>
    <link:label id="lab_sny_ImpairmentTestingPercentage_documentation_en-US" xlink:label="lab_sny_ImpairmentTestingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Testing Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentTestingPercentage" xlink:href="sny-20231231.xsd#sny_ImpairmentTestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpairmentTestingPercentage" xlink:to="lab_sny_ImpairmentTestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_9b701cdf-e472-4900-adaa-ce9912392c23_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other movements</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through other changes, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingSegmentsMember_0aa691a5-1965-4a1e-9936-a0279cfd852e_terseLabel_en-US" xlink:label="lab_ifrs-full_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating segments</link:label>
    <link:label id="lab_ifrs-full_OperatingSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingSegmentsMember" xlink:to="lab_ifrs-full_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock_aaeba27d-5424-4261-8e8f-a3e635e94952_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Actual or Potential Effects of Netting Arrangements</link:label>
    <link:label id="lab_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Actual Or Potential Effects Of Netting Arrangements [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of actual or potential effects of netting arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock" xlink:to="lab_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_f6266e9d-978f-4c2c-a196-ee0c2d297536_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related expenses</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Of Restructuring Activities, Employee Related Expenses</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:href="sny-20231231.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImmunoOncologyCollaborationAgreementMember_0f8a6103-2929-4624-89cf-cc475105b59d_terseLabel_en-US" xlink:label="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno-oncology collaboration agreement</link:label>
    <link:label id="lab_sny_ImmunoOncologyCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno Oncology Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_ImmunoOncologyCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno oncology collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember" xlink:href="sny-20231231.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImmunoOncologyCollaborationAgreementMember" xlink:to="lab_sny_ImmunoOncologyCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReportableSegmentsMember_ac6723e7-d9c2-4a4f-b187-0e9b72e8e488_verboseLabel_en-US" xlink:label="lab_ifrs-full_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sanofi</link:label>
    <link:label id="lab_ifrs-full_ReportableSegmentsMember_3f9fad2e-2336-47b0-9c67-4bd6d4d9d711_terseLabel_en-US" xlink:label="lab_ifrs-full_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable segments</link:label>
    <link:label id="lab_ifrs-full_ReportableSegmentsMember_label_en-US" xlink:label="lab_ifrs-full_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable segments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReportableSegmentsMember" xlink:to="lab_ifrs-full_ReportableSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_e953764d-1431-4e07-929b-34af27242380_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurThailandLtdMember_621679bd-a9b3-46a6-b779-0c0e6a360489_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurThailandLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Ltd</link:label>
    <link:label id="lab_sny_SanofiPasteurThailandLtdMember_label_en-US" xlink:label="lab_sny_SanofiPasteurThailandLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Thailand Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiPasteurThailandLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurThailandLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Thailand Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurThailandLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurThailandLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurThailandLtdMember" xlink:to="lab_sny_SanofiPasteurThailandLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInJapaneseYenMember_c8b4509b-f4ce-49f7-80eb-3080efe10f4b_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency sales in Japanese Yen</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInJapaneseYenMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In Japanese Yen [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInJapaneseYenMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency sales in Japanese Yen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:to="lab_sny_ForwardCurrencySalesInJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_685acb0b-6fec-4a39-bcf5-a10af8ca1060_negatedLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_491746f3-2c3d-4c76-af54-5b2eca45f332_terseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfLawsuitsRuledOnMerit_2b400c4d-b6e9-42d0-a597-83e1d6855224_terseLabel_en-US" xlink:label="lab_sny_NumberOfLawsuitsRuledOnMerit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits ruled on merits</link:label>
    <link:label id="lab_sny_NumberOfLawsuitsRuledOnMerit_label_en-US" xlink:label="lab_sny_NumberOfLawsuitsRuledOnMerit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits Ruled On Merit</link:label>
    <link:label id="lab_sny_NumberOfLawsuitsRuledOnMerit_documentation_en-US" xlink:label="lab_sny_NumberOfLawsuitsRuledOnMerit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits Ruled On Merit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLawsuitsRuledOnMerit" xlink:href="sny-20231231.xsd#sny_NumberOfLawsuitsRuledOnMerit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfLawsuitsRuledOnMerit" xlink:to="lab_sny_NumberOfLawsuitsRuledOnMerit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_f0d8bdd7-0970-4888-9c0f-53a2e32844b0_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt and current portion of long-term debt</link:label>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowings and current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BorrowingDrawdown_b789057d-08c4-49e9-9e61-b6fc3048e119_terseLabel_en-US" xlink:label="lab_sny_BorrowingDrawdown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, drawdown</link:label>
    <link:label id="lab_sny_BorrowingDrawdown_label_en-US" xlink:label="lab_sny_BorrowingDrawdown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Drawdown</link:label>
    <link:label id="lab_sny_BorrowingDrawdown_documentation_en-US" xlink:label="lab_sny_BorrowingDrawdown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Drawdown</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingDrawdown" xlink:href="sny-20231231.xsd#sny_BorrowingDrawdown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BorrowingDrawdown" xlink:to="lab_sny_BorrowingDrawdown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInJointVentures_a2e591d8-1dc2-481f-8ef5-f516244feed1_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in joint ventures</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInJointVentures_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in joint ventures reported in separate financial statements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInJointVentures" xlink:to="lab_ifrs-full_InvestmentsInJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlanetCareProgramObjectivesNetEmissionsBy2045_f90d0d1c-e598-4768-9c8a-1d4a47c553b8_terseLabel_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesNetEmissionsBy2045" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program, net emissions by 2045</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesNetEmissionsBy2045_label_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesNetEmissionsBy2045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Net Emissions By 2045</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesNetEmissionsBy2045_documentation_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesNetEmissionsBy2045" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Net Emissions By 2045</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesNetEmissionsBy2045" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesNetEmissionsBy2045"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlanetCareProgramObjectivesNetEmissionsBy2045" xlink:to="lab_sny_PlanetCareProgramObjectivesNetEmissionsBy2045" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_fd9c1c57-489e-4270-9db0-a5d348ac49e3_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options&#160;and other&#160;share- based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_177da50e-6b01-40f7-805d-1eabc5e67fad_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_6d380ec6-e14a-4697-8eee-79a4b6c085a5_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:to="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates_cba00363-d41e-4679-8f2e-d4eb52810d25_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare cost inflation rate</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of medical cost trend rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates" xlink:to="lab_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_61ff4d50-5cb9-450e-b12a-8dc656ecc695_terseLabel_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</link:label>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_88500eb6-1462-4b85-9276-e9a1793c91a5_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains/(losses) arising during the period</link:label>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_eb5d502b-beca-4621-aa59-3e7e2671efeb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiaventisSpZooMember_9bcbef48-280a-405a-ac21-49f1d7e161c2_terseLabel_en-US" xlink:label="lab_sny_SanofiaventisSpZooMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Sp. z.o.o.</link:label>
    <link:label id="lab_sny_SanofiaventisSpZooMember_label_en-US" xlink:label="lab_sny_SanofiaventisSpZooMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Sp. zoo [member]</link:label>
    <link:label id="lab_sny_SanofiaventisSpZooMember_documentation_en-US" xlink:label="lab_sny_SanofiaventisSpZooMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Sp. z.o.o.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiaventisSpZooMember" xlink:href="sny-20231231.xsd#sny_SanofiaventisSpZooMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiaventisSpZooMember" xlink:to="lab_sny_SanofiaventisSpZooMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_b8ea7457-7a1f-4638-bf22-77c164e6b321_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_e260114c-f0b2-40ed-8108-672784c1dbf3_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_808ceb3e-d31c-4874-8326-d33bab15f00d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets at beginning of period</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_31b5f0ea-9fe2-446f-be51-8c48d2cdb7c5_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets at end of period</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BioverativMember_a55ba01f-fbe8-488e-a0a0-2e9f21fe1f96_terseLabel_en-US" xlink:label="lab_sny_BioverativMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ(c)</link:label>
    <link:label id="lab_sny_BioverativMember_label_en-US" xlink:label="lab_sny_BioverativMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ [member]</link:label>
    <link:label id="lab_sny_BioverativMember_documentation_en-US" xlink:label="lab_sny_BioverativMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativMember" xlink:href="sny-20231231.xsd#sny_BioverativMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BioverativMember" xlink:to="lab_sny_BioverativMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilities_057c51bc-fda4-4438-b3a8-10cc3253f603_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial liabilities measured at fair value</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TidalTherapeuticsMember_bcf347be-5b15-4960-a2d7-af3194874e31_terseLabel_en-US" xlink:label="lab_sny_TidalTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tidal Therapeutics</link:label>
    <link:label id="lab_sny_TidalTherapeuticsMember_label_en-US" xlink:label="lab_sny_TidalTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tidal Therapeutics [Member]</link:label>
    <link:label id="lab_sny_TidalTherapeuticsMember_documentation_en-US" xlink:label="lab_sny_TidalTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tidal Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TidalTherapeuticsMember" xlink:href="sny-20231231.xsd#sny_TidalTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TidalTherapeuticsMember" xlink:to="lab_sny_TidalTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CNY_99cecc7c-1750-471a-993b-913c1a069e62_terseLabel_en-US" xlink:label="lab_currency_CNY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese yuan renminbi</link:label>
    <link:label id="lab_currency_CNY_label_en-US" xlink:label="lab_currency_CNY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China, Yuan Renminbi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CNY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CNY" xlink:to="lab_currency_CNY" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisSouthAfricaPtyLtdMember_6380a0b0-ba77-42fb-8fe6-4898826a6817_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisSouthAfricaPtyLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis South Africa (Pty) Ltd</link:label>
    <link:label id="lab_sny_SanofiAventisSouthAfricaPtyLtdMember_label_en-US" xlink:label="lab_sny_SanofiAventisSouthAfricaPtyLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis South Africa (Pty) Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisSouthAfricaPtyLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisSouthAfricaPtyLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis South Africa (Pty) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSouthAfricaPtyLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisSouthAfricaPtyLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisSouthAfricaPtyLtdMember" xlink:to="lab_sny_SanofiAventisSouthAfricaPtyLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfVaccineDosesToBeSupplied_4f1f6f12-ace5-4e81-8a94-efb590ccd60c_terseLabel_en-US" xlink:label="lab_sny_NumberOfVaccineDosesToBeSupplied" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of vaccine doses to be supplied</link:label>
    <link:label id="lab_sny_NumberOfVaccineDosesToBeSupplied_label_en-US" xlink:label="lab_sny_NumberOfVaccineDosesToBeSupplied" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Vaccine Doses To Be Supplied</link:label>
    <link:label id="lab_sny_NumberOfVaccineDosesToBeSupplied_documentation_en-US" xlink:label="lab_sny_NumberOfVaccineDosesToBeSupplied" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Vaccine Doses To Be Supplied</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfVaccineDosesToBeSupplied" xlink:href="sny-20231231.xsd#sny_NumberOfVaccineDosesToBeSupplied"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfVaccineDosesToBeSupplied" xlink:to="lab_sny_NumberOfVaccineDosesToBeSupplied" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_2c7a114a-f9a3-44e3-90dd-0bd53d42c95f_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perpetual growth rates applied to future cash flows</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Growth rate used to extrapolate cash flow projections</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:to="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AventisPharmaSAFranceMember_9fb42145-4abe-4927-9104-6caee3e43b86_terseLabel_en-US" xlink:label="lab_sny_AventisPharmaSAFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma S.A.</link:label>
    <link:label id="lab_sny_AventisPharmaSAFranceMember_label_en-US" xlink:label="lab_sny_AventisPharmaSAFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma S.A. France [member]</link:label>
    <link:label id="lab_sny_AventisPharmaSAFranceMember_documentation_en-US" xlink:label="lab_sny_AventisPharmaSAFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma S.A. France.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaSAFranceMember" xlink:href="sny-20231231.xsd#sny_AventisPharmaSAFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AventisPharmaSAFranceMember" xlink:to="lab_sny_AventisPharmaSAFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParentMember_373dd50b-ee50-4329-964d-c80aabea0989_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attributable to&#160;equity holders of Sanofi&#160;</link:label>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParentMember_label_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiTaiwanCoLtdMember_a00f0cd2-0e43-4530-98c2-657ddd7b5ce1_terseLabel_en-US" xlink:label="lab_sny_SanofiTaiwanCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Taiwan Co., Ltd</link:label>
    <link:label id="lab_sny_SanofiTaiwanCoLtdMember_label_en-US" xlink:label="lab_sny_SanofiTaiwanCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Taiwan Co Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiTaiwanCoLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiTaiwanCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Taiwan Co Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiTaiwanCoLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiTaiwanCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiTaiwanCoLtdMember" xlink:to="lab_sny_SanofiTaiwanCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_fe9ff8b7-a4d3-4c98-a465-1f6e9625b792_terseLabel_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_label_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:label id="lab_sny_InterestsInOtherEntitiesAbstract_documentation_en-US" xlink:label="lab_sny_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract" xlink:to="lab_sny_InterestsInOtherEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurFranceSAMember_29d4b195-bd1d-468f-b243-2b422c6f5bf7_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurFranceSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur</link:label>
    <link:label id="lab_sny_SanofiPasteurFranceSAMember_label_en-US" xlink:label="lab_sny_SanofiPasteurFranceSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur (France) SA [member]</link:label>
    <link:label id="lab_sny_SanofiPasteurFranceSAMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurFranceSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur (France) SA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurFranceSAMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurFranceSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurFranceSAMember" xlink:to="lab_sny_SanofiPasteurFranceSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement_6700ff46-c098-43ee-9822-9045e5f923e9_negatedLabel_en-US" xlink:label="lab_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, options exercised</link:label>
    <link:label id="lab_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Of Share Options Exercised In Share Based Payment Arrangement</link:label>
    <link:label id="lab_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of share options exercised in share based payment arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:to="lab_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EuroapiMember_6f7fe050-0b14-461e-bbea-3cc4d7ff4acf_terseLabel_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EUROAPI</link:label>
    <link:label id="lab_sny_EuroapiMember_label_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euroapi [Member]</link:label>
    <link:label id="lab_sny_EuroapiMember_documentation_en-US" xlink:label="lab_sny_EuroapiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euroapi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EuroapiMember" xlink:to="lab_sny_EuroapiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AztecaVacunasSADeCVMember_31ed0879-4720-4f05-b9ef-8971338fc8b1_terseLabel_en-US" xlink:label="lab_sny_AztecaVacunasSADeCVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Azteca Vacunas, SA de CV</link:label>
    <link:label id="lab_sny_AztecaVacunasSADeCVMember_label_en-US" xlink:label="lab_sny_AztecaVacunasSADeCVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Azteca Vacunas, S.A. De C.V [Member]</link:label>
    <link:label id="lab_sny_AztecaVacunasSADeCVMember_documentation_en-US" xlink:label="lab_sny_AztecaVacunasSADeCVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Azteca Vacunas, S.A. De C.V</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AztecaVacunasSADeCVMember" xlink:href="sny-20231231.xsd#sny_AztecaVacunasSADeCVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AztecaVacunasSADeCVMember" xlink:to="lab_sny_AztecaVacunasSADeCVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_15539962-cfb4-4bf0-ac4e-99f3d107fc43_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Introduction</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_4dc535d4-8637-4bdf-a6a9-9c66bb19414d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InitialLeaseTerm_cb4b603b-c81a-4560-a3fa-52dff43583ad_terseLabel_en-US" xlink:label="lab_sny_InitialLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial lease term</link:label>
    <link:label id="lab_sny_InitialLeaseTerm_label_en-US" xlink:label="lab_sny_InitialLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Lease Term</link:label>
    <link:label id="lab_sny_InitialLeaseTerm_documentation_en-US" xlink:label="lab_sny_InitialLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InitialLeaseTerm" xlink:href="sny-20231231.xsd#sny_InitialLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InitialLeaseTerm" xlink:to="lab_sny_InitialLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChargebackIncentivesMember_0a6fb829-9179-43d0-b80b-f6f44d4d898e_terseLabel_en-US" xlink:label="lab_sny_ChargebackIncentivesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargeback incentives</link:label>
    <link:label id="lab_sny_ChargebackIncentivesMember_label_en-US" xlink:label="lab_sny_ChargebackIncentivesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargeback Incentives [Member]</link:label>
    <link:label id="lab_sny_ChargebackIncentivesMember_documentation_en-US" xlink:label="lab_sny_ChargebackIncentivesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargeback incentives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChargebackIncentivesMember" xlink:href="sny-20231231.xsd#sny_ChargebackIncentivesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChargebackIncentivesMember" xlink:to="lab_sny_ChargebackIncentivesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsAxis_81d21eb2-7557-4b8d-9afd-0fb6657997c6_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment consolidation items [axis]</link:label>
    <link:label id="lab_ifrs-full_SegmentConsolidationItemsAxis_label_en-US" xlink:label="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment consolidation items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis" xlink:to="lab_ifrs-full_SegmentConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_cd40a286-fdb3-4d01-be27-cbcf48c34606_terseLabel_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate information and statement of IFRS compliance [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_8bb49b18-21e7-40ac-837c-0d46ebde7d7f_negatedLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_88d4260a-8f75-4e70-9e6d-8eb31b58f807_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_66162671-c601-4742-a7a2-a9ff8dbdde12_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill recognized</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognised in profit or loss, goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MaximumPlan1Member_dd1dac01-d991-4361-8a9b-27d4f17dbc0a_terseLabel_en-US" xlink:label="lab_sny_MaximumPlan1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Plan 1</link:label>
    <link:label id="lab_sny_MaximumPlan1Member_label_en-US" xlink:label="lab_sny_MaximumPlan1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Plan 1 [Member]</link:label>
    <link:label id="lab_sny_MaximumPlan1Member_documentation_en-US" xlink:label="lab_sny_MaximumPlan1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Plan 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumPlan1Member" xlink:href="sny-20231231.xsd#sny_MaximumPlan1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MaximumPlan1Member" xlink:to="lab_sny_MaximumPlan1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GenzymeLuxembourgSarlMember_cbb35223-fdbd-4d17-9323-309271a49b5b_terseLabel_en-US" xlink:label="lab_sny_GenzymeLuxembourgSarlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Luxembourg Sarl</link:label>
    <link:label id="lab_sny_GenzymeLuxembourgSarlMember_label_en-US" xlink:label="lab_sny_GenzymeLuxembourgSarlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Luxembourg Sarl [Member]</link:label>
    <link:label id="lab_sny_GenzymeLuxembourgSarlMember_documentation_en-US" xlink:label="lab_sny_GenzymeLuxembourgSarlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Luxembourg Sarl</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeLuxembourgSarlMember" xlink:href="sny-20231231.xsd#sny_GenzymeLuxembourgSarlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GenzymeLuxembourgSarlMember" xlink:to="lab_sny_GenzymeLuxembourgSarlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ManufactureAndSupplyCollaborationAgreementMember_900de798-04f3-4ece-89e3-fc56e6127b97_terseLabel_en-US" xlink:label="lab_sny_ManufactureAndSupplyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacture and supply collaboration agreement</link:label>
    <link:label id="lab_sny_ManufactureAndSupplyCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_ManufactureAndSupplyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacture And Supply Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_ManufactureAndSupplyCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_ManufactureAndSupplyCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacture And Supply Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufactureAndSupplyCollaborationAgreementMember" xlink:href="sny-20231231.xsd#sny_ManufactureAndSupplyCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ManufactureAndSupplyCollaborationAgreementMember" xlink:to="lab_sny_ManufactureAndSupplyCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock_5af711a6-516c-4747-9edd-5222169cc1a4_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Amounts of Employer's Contributions to Plan Assets</link:label>
    <link:label id="lab_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Estimated Amounts Of Employer's Contributions To Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of estimated amounts of employer's contributions to plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock" xlink:to="lab_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments_b5e309d2-f99f-4ba3-90e3-372b2fe929d5_verboseLabel_en-US" xlink:label="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments_label_en-US" xlink:label="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects Of Other Netting Arrangements Not Fulfilling The IAS 32 Criteria For Offsetting Financial Instruments</link:label>
    <link:label id="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments_documentation_en-US" xlink:label="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of other netting arrangements not fulfilling the IAS32 criteria for offsetting financial instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" xlink:href="sny-20231231.xsd#sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" xlink:to="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_b0f286d1-0857-4d87-ada0-35fcf0dda2bb_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial interest in principal fully consolidated companies</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock_f6bae963-f7b7-462e-b2fe-b2fb9045215a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit/loss from investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share Of Profit (Loss) Of Associates And Joint Ventures Accounted For Using Equity Method [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share of profit loss of associates and joint ventures accounted for using equity method explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock" xlink:to="lab_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AtMarketValueMember_2539a09c-ea1b-4de9-aedb-02ba4230b8a4_terseLabel_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_sny_AtMarketValueMember_label_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Value [member]</link:label>
    <link:label id="lab_sny_AtMarketValueMember_documentation_en-US" xlink:label="lab_sny_AtMarketValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At market value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember" xlink:href="sny-20231231.xsd#sny_AtMarketValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AtMarketValueMember" xlink:to="lab_sny_AtMarketValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_6f51da22-6c48-4862-8739-35c4f8756880_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_2368b9d3-51ff-4bf4-98ed-2af6397623ac_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options exercisable (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_bc239b2d-e204-4d14-a04a-c52b350afa3a_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, number of options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxLossCarryforwardsOnAssetDisposals_e52b9def-a552-4698-b7ac-2623a93d40c9_terseLabel_en-US" xlink:label="lab_sny_TaxLossCarryforwardsOnAssetDisposals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss carry-forwards on asset disposals</link:label>
    <link:label id="lab_sny_TaxLossCarryforwardsOnAssetDisposals_label_en-US" xlink:label="lab_sny_TaxLossCarryforwardsOnAssetDisposals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Loss Carryforwards On Asset Disposals</link:label>
    <link:label id="lab_sny_TaxLossCarryforwardsOnAssetDisposals_documentation_en-US" xlink:label="lab_sny_TaxLossCarryforwardsOnAssetDisposals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss carryforwards on asset disposals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxLossCarryforwardsOnAssetDisposals" xlink:href="sny-20231231.xsd#sny_TaxLossCarryforwardsOnAssetDisposals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxLossCarryforwardsOnAssetDisposals" xlink:to="lab_sny_TaxLossCarryforwardsOnAssetDisposals" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss_3c2f222f-0d96-4db3-b0a2-d213eccb90b9_terseLabel_en-US" xlink:label="lab_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss_label_en-US" xlink:label="lab_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Discount Rate Above Rate Actually Used Would Not Cause Impairment Loss</link:label>
    <link:label id="lab_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss_documentation_en-US" xlink:label="lab_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of discount rate above rate actually used would not cause impairment loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss" xlink:href="sny-20231231.xsd#sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss" xlink:to="lab_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockSubscriptionOptionPlanThreeMember_d099bdf2-542e-49ce-80af-2c830b24d414_terseLabel_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan three</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanThreeMember_label_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Option Plan Three [Member]</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanThreeMember_documentation_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanThreeMember" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockSubscriptionOptionPlanThreeMember" xlink:to="lab_sny_StockSubscriptionOptionPlanThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfAdministrativeProceedings_f7491a1a-6c05-4261-81e7-b83a8917d47b_terseLabel_en-US" xlink:label="lab_sny_NumberOfAdministrativeProceedings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of administrative proceedings</link:label>
    <link:label id="lab_sny_NumberOfAdministrativeProceedings_label_en-US" xlink:label="lab_sny_NumberOfAdministrativeProceedings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Administrative Proceedings</link:label>
    <link:label id="lab_sny_NumberOfAdministrativeProceedings_documentation_en-US" xlink:label="lab_sny_NumberOfAdministrativeProceedings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Administrative Proceedings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfAdministrativeProceedings" xlink:href="sny-20231231.xsd#sny_NumberOfAdministrativeProceedings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfAdministrativeProceedings" xlink:to="lab_sny_NumberOfAdministrativeProceedings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestUndiscountedCashFlow_5a145f4d-e1e4-414a-a511-5ff757c33d42_terseLabel_en-US" xlink:label="lab_sny_InterestUndiscountedCashFlow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_sny_InterestUndiscountedCashFlow_label_en-US" xlink:label="lab_sny_InterestUndiscountedCashFlow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Undiscounted Cash Flow</link:label>
    <link:label id="lab_sny_InterestUndiscountedCashFlow_documentation_en-US" xlink:label="lab_sny_InterestUndiscountedCashFlow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest undiscounted cash flow.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestUndiscountedCashFlow" xlink:href="sny-20231231.xsd#sny_InterestUndiscountedCashFlow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestUndiscountedCashFlow" xlink:to="lab_sny_InterestUndiscountedCashFlow" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_438cced0-fe54-4157-855f-10e8bf490831_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_March2018EMTNISINFR0013324340Member_25d62b5d-22f0-4ae9-92cc-52ad5f2c87ea_terseLabel_en-US" xlink:label="lab_sny_March2018EMTNISINFR0013324340Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2018 EMTN ISIN FR0013324340</link:label>
    <link:label id="lab_sny_March2018EMTNISINFR0013324340Member_label_en-US" xlink:label="lab_sny_March2018EMTNISINFR0013324340Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2018 EMTN ISIN FR0013324340 [Member]</link:label>
    <link:label id="lab_sny_March2018EMTNISINFR0013324340Member_documentation_en-US" xlink:label="lab_sny_March2018EMTNISINFR0013324340Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2018 EMTN ISIN FR 0013324340.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2018EMTNISINFR0013324340Member" xlink:href="sny-20231231.xsd#sny_March2018EMTNISINFR0013324340Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_March2018EMTNISINFR0013324340Member" xlink:to="lab_sny_March2018EMTNISINFR0013324340Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageContributedToFairValueOfPlanAssets_196c075d-06f9-4ead-af92-960ea32f5045_totalLabel_en-US" xlink:label="lab_sny_PercentageContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_sny_PercentageContributedToFairValueOfPlanAssets_label_en-US" xlink:label="lab_sny_PercentageContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Contributed To Fair Value Of Plan Assets</link:label>
    <link:label id="lab_sny_PercentageContributedToFairValueOfPlanAssets_documentation_en-US" xlink:label="lab_sny_PercentageContributedToFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage contributed to fair value of plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssets" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageContributedToFairValueOfPlanAssets" xlink:to="lab_sny_PercentageContributedToFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_50c1b026-714a-48e5-8f57-08d704c60d0e_terseLabel_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in fair value of liability</link:label>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_label_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Increase In Fair Value Liabilities</link:label>
    <link:label id="lab_sny_PercentageIncreaseInFairValueLiabilities_documentation_en-US" xlink:label="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase in fair value liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities" xlink:href="sny-20231231.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageIncreaseInFairValueLiabilities" xlink:to="lab_sny_PercentageIncreaseInFairValueLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_b9ac77c8-3a6f-4dc8-b124-b29924213952_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for segment consolidation items [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for segment consolidation items [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lab_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AstraZenecaMember_ead215a3-0541-49aa-badd-5054d2615235_terseLabel_en-US" xlink:label="lab_sny_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_sny_AstraZenecaMember_label_en-US" xlink:label="lab_sny_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_sny_AstraZenecaMember_documentation_en-US" xlink:label="lab_sny_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AstraZenecaMember" xlink:href="sny-20231231.xsd#sny_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AstraZenecaMember" xlink:to="lab_sny_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_973c11ed-df9c-4241-8bb4-2ff3ff4d70ac_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_87df63d4-bad6-4db4-a19d-41986be2b231_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_68199fda-5530-444a-91d6-fd2b74c24590_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DefendantAxis_a46b1904-3dcc-4d21-a9a6-d8085dd13859_terseLabel_en-US" xlink:label="lab_sny_DefendantAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defendant [Axis]</link:label>
    <link:label id="lab_sny_DefendantAxis_label_en-US" xlink:label="lab_sny_DefendantAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defendant [Axis]</link:label>
    <link:label id="lab_sny_DefendantAxis_documentation_en-US" xlink:label="lab_sny_DefendantAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defendant [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantAxis" xlink:href="sny-20231231.xsd#sny_DefendantAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DefendantAxis" xlink:to="lab_sny_DefendantAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmountOfSharesRepurchased_86721750-ea84-4c7d-8318-0c035768856e_terseLabel_en-US" xlink:label="lab_sny_AmountOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value</link:label>
    <link:label id="lab_sny_AmountOfSharesRepurchased_label_en-US" xlink:label="lab_sny_AmountOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Shares Repurchased</link:label>
    <link:label id="lab_sny_AmountOfSharesRepurchased_documentation_en-US" xlink:label="lab_sny_AmountOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of shares repurchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountOfSharesRepurchased" xlink:href="sny-20231231.xsd#sny_AmountOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmountOfSharesRepurchased" xlink:to="lab_sny_AmountOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns_fd984523-a4ab-424d-863b-20667cf0206f_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Net Exchange Differences Provisions For Discounts Rebates And Sales Returns</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" xlink:to="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_c95359b8-a499-441d-ac18-b305d1cada38_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of outstanding options (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember_d5011701-7995-4bf4-962e-28bca578efe5_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments related to unquoted debt securities</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Unquoted Debt Securities [Member]</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Unquoted Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember" xlink:to="lab_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_538100da-a2fb-478e-a499-2d43a745ac17_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items</link:label>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_label_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments for non-cash items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7680dda7-d592-43eb-825b-9c0cb0230bdb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_792981be-0e73-49a5-b50b-e8ce75650f4c_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other employee expense</link:label>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other employee expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEmployeeExpense" xlink:to="lab_ifrs-full_OtherEmployeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationAbstract_f9949084-33fa-4ec1-9361-1e8819919587_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations 1 [Abstract]</link:label>
    <link:label id="lab_sny_BusinessCombinationAbstract_label_en-US" xlink:label="lab_sny_BusinessCombinationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination [Abstract]</link:label>
    <link:label id="lab_sny_BusinessCombinationAbstract_documentation_en-US" xlink:label="lab_sny_BusinessCombinationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationAbstract" xlink:to="lab_sny_BusinessCombinationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssociatesMember_30c835ce-8efa-4e73-89d5-e22cd37e8479_terseLabel_en-US" xlink:label="lab_ifrs-full_AssociatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Associates</link:label>
    <link:label id="lab_ifrs-full_AssociatesMember_label_en-US" xlink:label="lab_ifrs-full_AssociatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Associates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssociatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssociatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssociatesMember" xlink:to="lab_ifrs-full_AssociatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiMatureIPMember_a69fbcc9-fb2f-422f-a168-c9892b863ddb_terseLabel_en-US" xlink:label="lab_sny_SanofiMatureIPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Mature IP</link:label>
    <link:label id="lab_sny_SanofiMatureIPMember_label_en-US" xlink:label="lab_sny_SanofiMatureIPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Mature IP [Member]</link:label>
    <link:label id="lab_sny_SanofiMatureIPMember_documentation_en-US" xlink:label="lab_sny_SanofiMatureIPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Mature IP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMatureIPMember" xlink:href="sny-20231231.xsd#sny_SanofiMatureIPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiMatureIPMember" xlink:to="lab_sny_SanofiMatureIPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfPatentsAllegedlyInfringed_65ee4940-3ab3-49e2-b538-25714fa030f8_terseLabel_en-US" xlink:label="lab_sny_NumberOfPatentsAllegedlyInfringed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed</link:label>
    <link:label id="lab_sny_NumberOfPatentsAllegedlyInfringed_label_en-US" xlink:label="lab_sny_NumberOfPatentsAllegedlyInfringed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patents Allegedly Infringed</link:label>
    <link:label id="lab_sny_NumberOfPatentsAllegedlyInfringed_documentation_en-US" xlink:label="lab_sny_NumberOfPatentsAllegedlyInfringed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatentsAllegedlyInfringed" xlink:href="sny-20231231.xsd#sny_NumberOfPatentsAllegedlyInfringed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfPatentsAllegedlyInfringed" xlink:to="lab_sny_NumberOfPatentsAllegedlyInfringed" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeInstrumentAxis_3eadda36-c581-43fb-957a-46213efe56cd_terseLabel_en-US" xlink:label="lab_sny_DerivativeInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_sny_DerivativeInstrumentAxis_label_en-US" xlink:label="lab_sny_DerivativeInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_sny_DerivativeInstrumentAxis_documentation_en-US" xlink:label="lab_sny_DerivativeInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeInstrumentAxis" xlink:href="sny-20231231.xsd#sny_DerivativeInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeInstrumentAxis" xlink:to="lab_sny_DerivativeInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_1210e1f6-9972-4a54-8741-1b37e2902137_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Deferred Tax Position</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MSPVaccineCompanyMember_70aec962-225a-44d2-8f46-d18b1306fbd6_terseLabel_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSP Vaccine Company (formerly MCM company)</link:label>
    <link:label id="lab_sny_MSPVaccineCompanyMember_label_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSP Vaccine Company [Member]</link:label>
    <link:label id="lab_sny_MSPVaccineCompanyMember_documentation_en-US" xlink:label="lab_sny_MSPVaccineCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSP Vaccine Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember" xlink:href="sny-20231231.xsd#sny_MSPVaccineCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MSPVaccineCompanyMember" xlink:to="lab_sny_MSPVaccineCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_2f7740c3-ae04-4c55-a937-e2ea0503b564_terseLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss" xlink:to="lab_ifrs-full_NetForeignExchangeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiProdutosFarmaceuticosLdaMember_cfad2fd0-6cb6-4b73-9084-8988fbce6c73_terseLabel_en-US" xlink:label="lab_sny_SanofiProdutosFarmaceuticosLdaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Produtos Farmaceuticos Lda</link:label>
    <link:label id="lab_sny_SanofiProdutosFarmaceuticosLdaMember_label_en-US" xlink:label="lab_sny_SanofiProdutosFarmaceuticosLdaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Produtos Farmaceuticos Lda [member]</link:label>
    <link:label id="lab_sny_SanofiProdutosFarmaceuticosLdaMember_documentation_en-US" xlink:label="lab_sny_SanofiProdutosFarmaceuticosLdaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Produtos Farmaceuticos Lda.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiProdutosFarmaceuticosLdaMember" xlink:href="sny-20231231.xsd#sny_SanofiProdutosFarmaceuticosLdaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiProdutosFarmaceuticosLdaMember" xlink:to="lab_sny_SanofiProdutosFarmaceuticosLdaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InventoryTotalQuotasHeld_21d2644c-0c1b-4c23-ba6b-300045bf8e8b_terseLabel_en-US" xlink:label="lab_sny_InventoryTotalQuotasHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quotas held in inventory</link:label>
    <link:label id="lab_sny_InventoryTotalQuotasHeld_label_en-US" xlink:label="lab_sny_InventoryTotalQuotasHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Total Quotas Held</link:label>
    <link:label id="lab_sny_InventoryTotalQuotasHeld_documentation_en-US" xlink:label="lab_sny_InventoryTotalQuotasHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Total Quotas Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InventoryTotalQuotasHeld" xlink:href="sny-20231231.xsd#sny_InventoryTotalQuotasHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InventoryTotalQuotasHeld" xlink:to="lab_sny_InventoryTotalQuotasHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasMember_037d23d7-4c38-46be-8dd5-c44ef95d8518_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical areas [member]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasMember_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical areas [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasMember" xlink:to="lab_ifrs-full_GeographicalAreasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_e2d00334-149f-47e4-97e8-a22dacf9ca34_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_0a30add9-d990-487e-9eb1-8ed2a6e681e0_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgingInstrumentsMember_c975821e-acdc-47fe-89f0-436d6f543fe9_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging instruments [member]</link:label>
    <link:label id="lab_ifrs-full_HedgingInstrumentsMember_label_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging instruments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsMember" xlink:to="lab_ifrs-full_HedgingInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_c0df0ca2-d2c6-481f-88b1-17893069232d_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2f7e24fb-f4a2-4ec4-90ab-9ebe1f847e40_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised_a2df0dad-5a49-4622-a353-f7b5b6dbb79c_terseLabel_en-US" xlink:label="lab_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused capital losses for which no deferred tax asset recognised</link:label>
    <link:label id="lab_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Capital Losses For Which No Deferred Tax Asset Recognised</link:label>
    <link:label id="lab_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised_documentation_en-US" xlink:label="lab_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Capital Losses For Which No Deferred Tax Asset Recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="sny-20231231.xsd#sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfTreasuryShares_a347d8b0-68b2-4fdb-8df6-d6f03dfb18e5_negatedLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfTreasuryShares_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfTreasuryShares" xlink:to="lab_ifrs-full_PurchaseOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_5bba08bb-d1ef-407e-9a19-a76336626957_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges, gains or losses on assets</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Of Restructuring Activities, Related To Property Plant And Equipment And To Inventories</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense of restructuring activities related to property plant and equipment to inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:href="sny-20231231.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_713b4ecd-5b3c-4dfe-b9c6-42a7bfbef73e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates and judgments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherFinanceIncomeCost_9767d1bf-9721-432b-8340-50c7d1d4fa45_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherFinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceIncomeCost" xlink:to="lab_ifrs-full_OtherFinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_HealthcareCoverAndLifeInsuranceMember_b4a0a40a-38f7-4f57-a163-43594a4b8f65_terseLabel_en-US" xlink:label="lab_sny_HealthcareCoverAndLifeInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Cover And Life Insurance</link:label>
    <link:label id="lab_sny_HealthcareCoverAndLifeInsuranceMember_label_en-US" xlink:label="lab_sny_HealthcareCoverAndLifeInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Cover And Life Insurance [Member]</link:label>
    <link:label id="lab_sny_HealthcareCoverAndLifeInsuranceMember_documentation_en-US" xlink:label="lab_sny_HealthcareCoverAndLifeInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Cover And Life Insurance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HealthcareCoverAndLifeInsuranceMember" xlink:href="sny-20231231.xsd#sny_HealthcareCoverAndLifeInsuranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_HealthcareCoverAndLifeInsuranceMember" xlink:to="lab_sny_HealthcareCoverAndLifeInsuranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_e5caa3ab-ce15-40ca-af2b-0cc14f7b652a_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of intangible assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InfraservHoechstRetainedLiabilitiesMember_6b398210-f546-42b6-9e3d-718a69538ae7_terseLabel_en-US" xlink:label="lab_sny_InfraservHoechstRetainedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infraserv Hoechst retained liabilities</link:label>
    <link:label id="lab_sny_InfraservHoechstRetainedLiabilitiesMember_label_en-US" xlink:label="lab_sny_InfraservHoechstRetainedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infraserv Hoechst Retained Liabilities [member]</link:label>
    <link:label id="lab_sny_InfraservHoechstRetainedLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_InfraservHoechstRetainedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infraserv Hoechst retained liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservHoechstRetainedLiabilitiesMember" xlink:href="sny-20231231.xsd#sny_InfraservHoechstRetainedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InfraservHoechstRetainedLiabilitiesMember" xlink:to="lab_sny_InfraservHoechstRetainedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_9ef34165-3bf0-48f1-a503-ec22b5f1a260_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade Receivables [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfTradeReceivablesTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTradeReceivablesTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfTradeReceivablesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfTradeReceivablesTextBlock" xlink:to="lab_sny_DisclosureOfTradeReceivablesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyTable_9fa1d5d5-9f64-4e3c-b692-d9c7c4e3e84d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt By Currency [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyTable_label_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt By Currency [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt By Currency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByCurrencyTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByCurrencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtByCurrencyTable" xlink:to="lab_sny_DisclosureOfDebtByCurrencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurLtdMember_4847b8ae-0c61-4fae-9eac-810e7a40f185_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Ltd</link:label>
    <link:label id="lab_sny_SanofiPasteurLtdMember_label_en-US" xlink:label="lab_sny_SanofiPasteurLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiPasteurLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Ltd [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurLtdMember" xlink:to="lab_sny_SanofiPasteurLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisUSLLCMember_6bd8677a-8aff-4111-9746-9b15b9b1b9f4_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisUSLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis U.S. LLC</link:label>
    <link:label id="lab_sny_SanofiAventisUSLLCMember_label_en-US" xlink:label="lab_sny_SanofiAventisUSLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis US LLC [member]</link:label>
    <link:label id="lab_sny_SanofiAventisUSLLCMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisUSLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis US LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisUSLLCMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisUSLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisUSLLCMember" xlink:to="lab_sny_SanofiAventisUSLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DepakineProductLitigationInSwitzerlandMember_bcb39e89-96ad-4879-9306-c49f98b1838f_terseLabel_en-US" xlink:label="lab_sny_DepakineProductLitigationInSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine product litigation in Switzerland</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInSwitzerlandMember_label_en-US" xlink:label="lab_sny_DepakineProductLitigationInSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Switzerland [Member]</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInSwitzerlandMember_documentation_en-US" xlink:label="lab_sny_DepakineProductLitigationInSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Switzerland</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInSwitzerlandMember" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DepakineProductLitigationInSwitzerlandMember" xlink:to="lab_sny_DepakineProductLitigationInSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfShareSubscribed_0c52df1b-6b00-43bb-8f1d-440ad949c1d9_terseLabel_en-US" xlink:label="lab_sny_NumberOfShareSubscribed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares subscribed (in shares)</link:label>
    <link:label id="lab_sny_NumberOfShareSubscribed_label_en-US" xlink:label="lab_sny_NumberOfShareSubscribed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Subscribed</link:label>
    <link:label id="lab_sny_NumberOfShareSubscribed_documentation_en-US" xlink:label="lab_sny_NumberOfShareSubscribed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares subscribed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareSubscribed" xlink:href="sny-20231231.xsd#sny_NumberOfShareSubscribed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfShareSubscribed" xlink:to="lab_sny_NumberOfShareSubscribed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgedItemsMember_91794d17-1fcc-46c8-b253-50a8cb04efe0_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgedItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged items [member]</link:label>
    <link:label id="lab_ifrs-full_HedgedItemsMember_label_en-US" xlink:label="lab_ifrs-full_HedgedItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged items [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgedItemsMember" xlink:to="lab_ifrs-full_HedgedItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShelfRegistrationStatementProgramMember_d2cd03eb-896f-4a62-91b4-a55391c37a68_terseLabel_en-US" xlink:label="lab_sny_ShelfRegistrationStatementProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration statement program</link:label>
    <link:label id="lab_sny_ShelfRegistrationStatementProgramMember_label_en-US" xlink:label="lab_sny_ShelfRegistrationStatementProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement Program [Member]</link:label>
    <link:label id="lab_sny_ShelfRegistrationStatementProgramMember_documentation_en-US" xlink:label="lab_sny_ShelfRegistrationStatementProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration statement program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShelfRegistrationStatementProgramMember" xlink:href="sny-20231231.xsd#sny_ShelfRegistrationStatementProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShelfRegistrationStatementProgramMember" xlink:to="lab_sny_ShelfRegistrationStatementProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AuditorsNameMember_818801dd-94bc-4a3b-8154-0e6582a4c6a7_terseLabel_en-US" xlink:label="lab_sny_AuditorsNameMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditors Name [Member]</link:label>
    <link:label id="lab_sny_AuditorsNameMember_label_en-US" xlink:label="lab_sny_AuditorsNameMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditors Name [Member]</link:label>
    <link:label id="lab_sny_AuditorsNameMember_documentation_en-US" xlink:label="lab_sny_AuditorsNameMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditors Name [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsNameMember" xlink:href="sny-20231231.xsd#sny_AuditorsNameMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AuditorsNameMember" xlink:to="lab_sny_AuditorsNameMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_f217315d-d1c5-4e1d-bd79-d05037e22399_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of services obtained from employees</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Value Of Services Obtained From Employees</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of services obtained from employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution_62ca296a-10c6-4702-bad1-242f010fbd6c_terseLabel_en-US" xlink:label="lab_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized of which employers' contribution</link:label>
    <link:label id="lab_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution_label_en-US" xlink:label="lab_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense From Equity-Settled Share-Based Payment Transactions Of Which Goods Or Services Received Did Not Qualify For Recognition As Assets Employer Contribution</link:label>
    <link:label id="lab_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution_documentation_en-US" xlink:label="lab_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized in equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution" xlink:href="sny-20231231.xsd#sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution" xlink:to="lab_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_952fd4b1-0e5d-4166-a8cb-7e12813fe019_terseLabel_en-US" xlink:label="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development projects and technology platforms</link:label>
    <link:label id="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_label_en-US" xlink:label="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Projects And Technology Platforms [Member]</link:label>
    <link:label id="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_documentation_en-US" xlink:label="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:href="sny-20231231.xsd#sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:to="lab_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SalesOfAntibodiesSecondAchievementMember_29446a68-68ab-4793-8e50-a2068b494ca7_terseLabel_en-US" xlink:label="lab_sny_SalesOfAntibodiesSecondAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of antibodies, second achievement</link:label>
    <link:label id="lab_sny_SalesOfAntibodiesSecondAchievementMember_label_en-US" xlink:label="lab_sny_SalesOfAntibodiesSecondAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Of Antibodies, Second Achievement [Member]</link:label>
    <link:label id="lab_sny_SalesOfAntibodiesSecondAchievementMember_documentation_en-US" xlink:label="lab_sny_SalesOfAntibodiesSecondAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Of Antibodies, Second Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesOfAntibodiesSecondAchievementMember" xlink:href="sny-20231231.xsd#sny_SalesOfAntibodiesSecondAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SalesOfAntibodiesSecondAchievementMember" xlink:to="lab_sny_SalesOfAntibodiesSecondAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockSubscriptionOptionPlanEightMember_01989832-4529-4807-a35a-012babd6f198_terseLabel_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan eight</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanEightMember_label_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Option Plan Eight [Member]</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanEightMember_documentation_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanEightMember" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockSubscriptionOptionPlanEightMember" xlink:to="lab_sny_StockSubscriptionOptionPlanEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_8f43bb23-c3b7-4de4-910e-0bbb3238ba52_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit/(loss) from investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit (loss) of associates accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExscientiaMember_04c175c9-85f8-4523-a0f5-97e6b5ca0ace_terseLabel_en-US" xlink:label="lab_sny_ExscientiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exscientia</link:label>
    <link:label id="lab_sny_ExscientiaMember_label_en-US" xlink:label="lab_sny_ExscientiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exscientia [Member]</link:label>
    <link:label id="lab_sny_ExscientiaMember_documentation_en-US" xlink:label="lab_sny_ExscientiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exscientia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExscientiaMember" xlink:href="sny-20231231.xsd#sny_ExscientiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExscientiaMember" xlink:to="lab_sny_ExscientiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AfterTaxDiscountRates_aa6c260e-caf8-49d2-a798-8a82283788b5_terseLabel_en-US" xlink:label="lab_sny_AfterTaxDiscountRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After tax discount rates</link:label>
    <link:label id="lab_sny_AfterTaxDiscountRates_label_en-US" xlink:label="lab_sny_AfterTaxDiscountRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Tax Discount Rates</link:label>
    <link:label id="lab_sny_AfterTaxDiscountRates_documentation_en-US" xlink:label="lab_sny_AfterTaxDiscountRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After tax discount rates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AfterTaxDiscountRates" xlink:href="sny-20231231.xsd#sny_AfterTaxDiscountRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AfterTaxDiscountRates" xlink:to="lab_sny_AfterTaxDiscountRates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Borrowings_60742306-86f9-4131-ac72-1b81c37a36f6_totalLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_ifrs-full_Borrowings_710c22e9-1521-4e76-a3c0-76b269101c33_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Borrowings_ca991ba0-c0ad-48db-89f1-a67ec4de6b01_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings at end of period</link:label>
    <link:label id="lab_ifrs-full_Borrowings_354fa9aa-3979-4c33-a6c4-5e4b62e69981_terseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_ifrs-full_Borrowings_1ce799b6-c20f-42db-bcf2-18c506422f60_verboseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_ifrs-full_Borrowings_label_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MaximumPlan2Member_6cff155d-889a-40d6-ad23-95a08a454ad7_terseLabel_en-US" xlink:label="lab_sny_MaximumPlan2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum plan 2</link:label>
    <link:label id="lab_sny_MaximumPlan2Member_label_en-US" xlink:label="lab_sny_MaximumPlan2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Plan 2 [Member]</link:label>
    <link:label id="lab_sny_MaximumPlan2Member_documentation_en-US" xlink:label="lab_sny_MaximumPlan2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Plan 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumPlan2Member" xlink:href="sny-20231231.xsd#sny_MaximumPlan2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MaximumPlan2Member" xlink:to="lab_sny_MaximumPlan2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_c88237a4-28a6-4123-8dad-46ce5eb0a672_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_75187764-c289-4648-8f00-89b68049b280_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ContingentConsiderationRelatingToDivestmentsMember_ad0bf20c-7347-472c-89da-b7c36e88ab92_terseLabel_en-US" xlink:label="lab_sny_ContingentConsiderationRelatingToDivestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration relating to divestments</link:label>
    <link:label id="lab_sny_ContingentConsiderationRelatingToDivestmentsMember_label_en-US" xlink:label="lab_sny_ContingentConsiderationRelatingToDivestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Relating To Divestments [Member]</link:label>
    <link:label id="lab_sny_ContingentConsiderationRelatingToDivestmentsMember_documentation_en-US" xlink:label="lab_sny_ContingentConsiderationRelatingToDivestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration relating to divestments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationRelatingToDivestmentsMember" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationRelatingToDivestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ContingentConsiderationRelatingToDivestmentsMember" xlink:to="lab_sny_ContingentConsiderationRelatingToDivestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_d32e3328-8dcf-4f49-aa17-c718dbb6867c_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in subsidiaries, joint ventures and associates</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in subsidiaries, joint ventures and associates reported in separate financial statements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="lab_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_15138cf0-fe95-4f87-9386-e25acbcda067_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_24f5a718-0cc0-4151-a777-0bdf052524f8_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:to="lab_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_April2016EMTNISINFR0013143997Member_8b40755f-6c55-4beb-96ae-ba122cff1b2c_terseLabel_en-US" xlink:label="lab_sny_April2016EMTNISINFR0013143997Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2016 EMTN ISIN FR0013143997</link:label>
    <link:label id="lab_sny_April2016EMTNISINFR0013143997Member_label_en-US" xlink:label="lab_sny_April2016EMTNISINFR0013143997Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2016 EMTNISINFR0013143997 [Member]</link:label>
    <link:label id="lab_sny_April2016EMTNISINFR0013143997Member_documentation_en-US" xlink:label="lab_sny_April2016EMTNISINFR0013143997Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 2016 EMTN ISIN FR0013143997.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2016EMTNISINFR0013143997Member" xlink:href="sny-20231231.xsd#sny_April2016EMTNISINFR0013143997Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_April2016EMTNISINFR0013143997Member" xlink:to="lab_sny_April2016EMTNISINFR0013143997Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_470eea83-e942-4f64-84eb-e0609a249206_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit obligations</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_KymabMember_1101221b-f719-4142-a09f-7a1af3573c22_terseLabel_en-US" xlink:label="lab_sny_KymabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kymab</link:label>
    <link:label id="lab_sny_KymabMember_label_en-US" xlink:label="lab_sny_KymabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kymab [Member]</link:label>
    <link:label id="lab_sny_KymabMember_documentation_en-US" xlink:label="lab_sny_KymabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kymab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KymabMember" xlink:href="sny-20231231.xsd#sny_KymabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_KymabMember" xlink:to="lab_sny_KymabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_a0c3b343-e3d1-4765-9d2c-68bb4fd34ab8_terseLabel_en-US" xlink:label="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSD contingent consideration (European vaccines business)</link:label>
    <link:label id="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_label_en-US" xlink:label="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSD Contingent Consideration (European Vaccines Business) [Member]</link:label>
    <link:label id="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_documentation_en-US" xlink:label="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSD contingent consideration European vaccines business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:href="sny-20231231.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:to="lab_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_63d7314f-8c29-4150-bf0c-7e71a363e6cd_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit/(loss) from investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit (loss) of joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PensionObligationPercentageToPlanAssets_39f22c93-a691-44f1-b46a-79977410354f_terseLabel_en-US" xlink:label="lab_sny_PensionObligationPercentageToPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension obligations, percentage to plan assets</link:label>
    <link:label id="lab_sny_PensionObligationPercentageToPlanAssets_label_en-US" xlink:label="lab_sny_PensionObligationPercentageToPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Obligation, Percentage To Plan Assets</link:label>
    <link:label id="lab_sny_PensionObligationPercentageToPlanAssets_documentation_en-US" xlink:label="lab_sny_PensionObligationPercentageToPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension obligation percentage to plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionObligationPercentageToPlanAssets" xlink:href="sny-20231231.xsd#sny_PensionObligationPercentageToPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PensionObligationPercentageToPlanAssets" xlink:to="lab_sny_PensionObligationPercentageToPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment_99c06029-4397-440c-a9ef-a947ea608613_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in non-controlling interests</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Changes In Non-Controlling Interests Arising From Divestment</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease through changes in non-controlling interests arising from divestment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" xlink:to="lab_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansAxis_85d66669-29e0-40c7-88f5-7aba1881cd4a_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plans [axis]</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansAxis_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plans [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis" xlink:to="lab_ifrs-full_DefinedBenefitPlansAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LandMember_279d300a-caa5-41bc-a32a-02ca99fbe754_terseLabel_en-US" xlink:label="lab_ifrs-full_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_ifrs-full_LandMember_label_en-US" xlink:label="lab_ifrs-full_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LandMember" xlink:to="lab_ifrs-full_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RebatesAndDiscountsMember_fce84deb-8aba-4f1d-b334-48a706122302_terseLabel_en-US" xlink:label="lab_sny_RebatesAndDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and discounts</link:label>
    <link:label id="lab_sny_RebatesAndDiscountsMember_label_en-US" xlink:label="lab_sny_RebatesAndDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates And Discounts [Member]</link:label>
    <link:label id="lab_sny_RebatesAndDiscountsMember_documentation_en-US" xlink:label="lab_sny_RebatesAndDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and discounts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RebatesAndDiscountsMember" xlink:href="sny-20231231.xsd#sny_RebatesAndDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RebatesAndDiscountsMember" xlink:to="lab_sny_RebatesAndDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_7eddeab6-3c12-4d1b-8fd0-eb189007e851_terseLabel_en-US" xlink:label="lab_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized directly in profit or loss</link:label>
    <link:label id="lab_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_d9e2fe6b-75ea-4546-9a9c-1f60a62deca8_verboseLabel_en-US" xlink:label="lab_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense/(gain) recognized directly in profit or loss</link:label>
    <link:label id="lab_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_label_en-US" xlink:label="lab_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Expense For Pensions And Other Post-employment Benefits Recognized Directly In Profit Or Loss</link:label>
    <link:label id="lab_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_documentation_en-US" xlink:label="lab_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense for pensions and other post-employment benefits recognized directly in profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:href="sny-20231231.xsd#sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:to="lab_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DepakineProductLitigationInFranceMember_bc9fba52-74b9-47c6-84b3-0f639c46f185_terseLabel_en-US" xlink:label="lab_sny_DepakineProductLitigationInFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine product litigation in France</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInFranceMember_label_en-US" xlink:label="lab_sny_DepakineProductLitigationInFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In France [Member]</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInFranceMember_documentation_en-US" xlink:label="lab_sny_DepakineProductLitigationInFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInFranceMember" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DepakineProductLitigationInFranceMember" xlink:to="lab_sny_DepakineProductLitigationInFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock_7512d6f8-5796-45b5-a500-37d05f3a18e7_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of Net Defined-benefit (Asset)/Liability (Actuarial Gains and Losses)</link:label>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset By Country [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of remeasuresment of net defined benefit liability asset by country.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock" xlink:to="lab_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_ecc2b161-573f-409d-aeab-d82f0fbeba1e_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AtomwiseMember_a98c314b-9b68-4128-bb09-b0ee368898d2_terseLabel_en-US" xlink:label="lab_sny_AtomwiseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atomwise</link:label>
    <link:label id="lab_sny_AtomwiseMember_label_en-US" xlink:label="lab_sny_AtomwiseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atomwise [Member]</link:label>
    <link:label id="lab_sny_AtomwiseMember_documentation_en-US" xlink:label="lab_sny_AtomwiseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atomwise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtomwiseMember" xlink:href="sny-20231231.xsd#sny_AtomwiseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AtomwiseMember" xlink:to="lab_sny_AtomwiseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_19752bf0-bc75-4b48-ae35-82e5961f71c3_terseLabel_en-US" xlink:label="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity instruments designated at fair value through OCI</link:label>
    <link:label id="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="lab_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsChattemMember_f0d0b122-b34b-4f80-937a-e7040332a5d3_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsChattemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chattem</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsChattemMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsChattemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Chattem [member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsChattemMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsChattemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal marketed products chattem.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsChattemMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsChattemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsChattemMember" xlink:to="lab_sny_PrincipalMarketedProductsChattemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisSROMember_5cbad651-413c-4ad2-aff3-fb666b82eeec_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisSROMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis, s.r.o.</link:label>
    <link:label id="lab_sny_SanofiAventisSROMember_label_en-US" xlink:label="lab_sny_SanofiAventisSROMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis, S.R.O. [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisSROMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisSROMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis, s.r.o.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSROMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisSROMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisSROMember" xlink:to="lab_sny_SanofiAventisSROMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_JointVenturesMember_66b7ad13-a636-4116-9f80-a0592634e660_terseLabel_en-US" xlink:label="lab_ifrs-full_JointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint ventures</link:label>
    <link:label id="lab_ifrs-full_JointVenturesMember_label_en-US" xlink:label="lab_ifrs-full_JointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint ventures [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesMember" xlink:to="lab_ifrs-full_JointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory_a7ba9717-149e-44fa-a425-c3e273a03366_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale or exchange and liabilities related to assets held for sale or exchange</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for non-current assets or disposal groups classified as held for sale and discontinued operations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_adbded77-5293-4345-b305-7881d06cdf31_verboseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_8f0b388a-04a3-4e10-a96a-69a65e5094e2_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LandAndBuildingsMember_522866d8-78bd-4840-88ce-9fd979bd4a37_terseLabel_en-US" xlink:label="lab_ifrs-full_LandAndBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and industrial premises</link:label>
    <link:label id="lab_ifrs-full_LandAndBuildingsMember_label_en-US" xlink:label="lab_ifrs-full_LandAndBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and buildings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandAndBuildingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandAndBuildingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LandAndBuildingsMember" xlink:to="lab_ifrs-full_LandAndBuildingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_52654460-1d7d-4646-a03b-362fcc6e7d0f_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_692822ec-5c62-48db-b518-15fe963f4e51_terseLabel_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_859a5b5d-b3d0-447c-a177-01fe8bd9a8c0_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares_c7133031-4ff1-4402-b2fe-3d953773f6b9_terseLabel_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per share awarded for three year service period, additional shares (in euros per share)</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares_label_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Per Share Awarded For Three Year Service Period, Additional Shares</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares_documentation_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Per Share Awarded For Three Year Service Period, Additional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" xlink:href="sny-20231231.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" xlink:to="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_5785399e-b0f8-4657-8f61-b0c4be2d5c52_terseLabel_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross value of overdue receivables</link:label>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_c4ae12e7-b769-4de6-a494-1b3384b42ff5_verboseLabel_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overdue receivables gross value</link:label>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_label_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overdue Receivables Gross Value</link:label>
    <link:label id="lab_sny_OverdueReceivablesGrossValue_documentation_en-US" xlink:label="lab_sny_OverdueReceivablesGrossValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overdue receivables gross value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue" xlink:href="sny-20231231.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OverdueReceivablesGrossValue" xlink:to="lab_sny_OverdueReceivablesGrossValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_38f6aeda-b84f-4cef-b733-12e0d4724e1c_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customers [axis]</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customers [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersAxis" xlink:to="lab_ifrs-full_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssets_20c83d22-f03c-4c13-884c-fc4b257055db_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets measured at fair value</link:label>
    <link:label id="lab_ifrs-full_FinancialAssets_label_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets" xlink:to="lab_ifrs-full_FinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_JointOperationsAxis_f62d5642-62f1-4ca9-9ad0-b8b462fd69d8_terseLabel_en-US" xlink:label="lab_ifrs-full_JointOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Operations [Axis]</link:label>
    <link:label id="lab_ifrs-full_JointOperationsAxis_label_en-US" xlink:label="lab_ifrs-full_JointOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint operations [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointOperationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointOperationsAxis" xlink:to="lab_ifrs-full_JointOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_f3c29738-41d4-4d18-92f2-59a857b90bac_terseLabel_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_label_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation [Member]</link:label>
    <link:label id="lab_sny_ForeignCurrencyTranslationMember_documentation_en-US" xlink:label="lab_sny_ForeignCurrencyTranslationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember" xlink:href="sny-20231231.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForeignCurrencyTranslationMember" xlink:to="lab_sny_ForeignCurrencyTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement_0bb4c885-9ae3-4c4a-a230-bcb81ab10faf_terseLabel_en-US" xlink:label="lab_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, options exercisable</link:label>
    <link:label id="lab_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Of Share Options Exercisable In Share Based Payment Arrangement</link:label>
    <link:label id="lab_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of share options exercisable in share based payment arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" xlink:to="lab_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTemporaryDifferencesMember_160127d2-18bb-4921-8dc5-4d6a84acb836_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherTemporaryDifferencesMember_label_en-US" xlink:label="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other temporary differences [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTemporaryDifferencesMember" xlink:to="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember_15c8a826-b074-41e3-a6bd-a44ae3189d04_terseLabel_en-US" xlink:label="lab_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other contingent consideration arising from business combinations and acquisitions</link:label>
    <link:label id="lab_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember_label_en-US" xlink:label="lab_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contingent Consideration Arising From Business Combinations [Member]</link:label>
    <link:label id="lab_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember_documentation_en-US" xlink:label="lab_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other contingent consideration arising from business combinations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember" xlink:href="sny-20231231.xsd#sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember" xlink:to="lab_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ScribeTherapeuticsMember_64c3c37d-a8a1-48d5-81e5-fb0a0f1a4458_terseLabel_en-US" xlink:label="lab_sny_ScribeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scribe Therapeutics</link:label>
    <link:label id="lab_sny_ScribeTherapeuticsMember_label_en-US" xlink:label="lab_sny_ScribeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scribe Therapeutics [Member]</link:label>
    <link:label id="lab_sny_ScribeTherapeuticsMember_documentation_en-US" xlink:label="lab_sny_ScribeTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scribe Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ScribeTherapeuticsMember" xlink:href="sny-20231231.xsd#sny_ScribeTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ScribeTherapeuticsMember" xlink:to="lab_sny_ScribeTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_b1ded1e6-a0cb-4ecc-a992-a2c53f87d1c2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about credit exposures designated as measured at fair value through profit or loss [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareInternationalSASMember_eda49610-652b-4758-b833-4c7af4b53dc3_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareInternationalSASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare International SAS</link:label>
    <link:label id="lab_sny_OpellaHealthcareInternationalSASMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareInternationalSASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare International SAS [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareInternationalSASMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareInternationalSASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare International SAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareInternationalSASMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareInternationalSASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareInternationalSASMember" xlink:to="lab_sny_OpellaHealthcareInternationalSASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable_a2bf90e5-509a-442f-be22-32b7fc909a23_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock_8bdb978b-ca5d-4f40-9add-e12d454eac99_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt</link:label>
    <link:label id="lab_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Maturity Analysis Of Future Undiscounted Cash Flows Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of maturity analysis of future undiscounted cash flows.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForJointVenturesMember_2a6fde9f-42df-40ab-859b-90da7fc38081_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for joint ventures</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForJointVenturesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for joint ventures [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember" xlink:to="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill_c2f6f873-22f2-4d68-8d11-550e168e6652_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other movements during the period</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through other changes, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasurySharesMember_4a16b2da-caa8-487b-9be2-f55475192869_terseLabel_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasurySharesMember_label_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasurySharesMember" xlink:to="lab_ifrs-full_TreasurySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_VaxServeIncMember_2ca4cfb4-7cd4-420b-b319-c2f202971cdc_terseLabel_en-US" xlink:label="lab_sny_VaxServeIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VaxServe, Inc.</link:label>
    <link:label id="lab_sny_VaxServeIncMember_label_en-US" xlink:label="lab_sny_VaxServeIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VaxServe Inc [member]</link:label>
    <link:label id="lab_sny_VaxServeIncMember_documentation_en-US" xlink:label="lab_sny_VaxServeIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VaxServe, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaxServeIncMember" xlink:href="sny-20231231.xsd#sny_VaxServeIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_VaxServeIncMember" xlink:to="lab_sny_VaxServeIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_8295634f-10e2-45f4-a71d-9fa45485ddde_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_518e22d8-a578-49d2-b2b3-693fca701a53_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_d8946098-8fff-4a98-a4d2-6d120acef40e_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.92% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.92%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_90105a47-85e9-4ef2-97ab-8e41d3834685_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockSubscriptionOptionPlanSixMember_03fc3107-ee23-477d-8cdb-40a23d23c910_terseLabel_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan six</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanSixMember_label_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Option Plan Six [Member]</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanSixMember_documentation_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan six.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanSixMember" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockSubscriptionOptionPlanSixMember" xlink:to="lab_sny_StockSubscriptionOptionPlanSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_12bd77a1-4670-4d34-9ff8-109489d14560_negatedLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WagesAndSalaries_d177f3db-63a9-4636-8827-e72c16e8a17d_terseLabel_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries</link:label>
    <link:label id="lab_ifrs-full_WagesAndSalaries_label_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wages and salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WagesAndSalaries" xlink:to="lab_ifrs-full_WagesAndSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_a6cdbc54-7c93-4ed0-ad76-7200d0dd5f3b_terseLabel_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow And Fair Value Hedge</link:label>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_label_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow And Fair Value Hedge [Member]</link:label>
    <link:label id="lab_sny_CashFlowAndFairValueHedgeMember_documentation_en-US" xlink:label="lab_sny_CashFlowAndFairValueHedgeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow And Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember" xlink:href="sny-20231231.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashFlowAndFairValueHedgeMember" xlink:to="lab_sny_CashFlowAndFairValueHedgeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_5110b389-bc52-44ec-82e1-1af957c0b0c1_negatedLabel_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest cost related to employee benefits</link:label>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_label_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Interest Cost Related To Employee Benefits</link:label>
    <link:label id="lab_sny_NetInterestCostRelatedToEmployeeBenefits_documentation_en-US" xlink:label="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest cost related to employee benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:href="sny-20231231.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:to="lab_sny_NetInterestCostRelatedToEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_A.NattermannCie.GmbHMember_3ef98e58-d6f8-4989-8864-146eb1e5eaac_terseLabel_en-US" xlink:label="lab_sny_A.NattermannCie.GmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A. Nattermann &amp; Cie. GmbH</link:label>
    <link:label id="lab_sny_A.NattermannCie.GmbHMember_label_en-US" xlink:label="lab_sny_A.NattermannCie.GmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A. Nattermann &amp; Cie. GmbH [Member]</link:label>
    <link:label id="lab_sny_A.NattermannCie.GmbHMember_documentation_en-US" xlink:label="lab_sny_A.NattermannCie.GmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A. Nattermann &amp; Cie. GmbH [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_A.NattermannCie.GmbHMember" xlink:href="sny-20231231.xsd#sny_A.NattermannCie.GmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_A.NattermannCie.GmbHMember" xlink:to="lab_sny_A.NattermannCie.GmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRates_83f354bf-3900-402f-8ce1-defd7d234d3b_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRates_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BorrowingAverageDrawdown_70b615cb-1ffd-42f3-b34b-dbb80dbce1b5_terseLabel_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, average drawdown</link:label>
    <link:label id="lab_sny_BorrowingAverageDrawdown_label_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Average Drawdown</link:label>
    <link:label id="lab_sny_BorrowingAverageDrawdown_documentation_en-US" xlink:label="lab_sny_BorrowingAverageDrawdown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Average Drawdown</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown" xlink:href="sny-20231231.xsd#sny_BorrowingAverageDrawdown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BorrowingAverageDrawdown" xlink:to="lab_sny_BorrowingAverageDrawdown" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_23ca0e4f-c9b7-4ced-b7f5-a31f9f2c731c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Analysis of Financial Income and Expenses</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Income And Expenses Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for financial income and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SalesReturnMember_edfce702-176e-41a9-a364-bf2e48292314_terseLabel_en-US" xlink:label="lab_sny_SalesReturnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns</link:label>
    <link:label id="lab_sny_SalesReturnMember_label_en-US" xlink:label="lab_sny_SalesReturnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Return [Member]</link:label>
    <link:label id="lab_sny_SalesReturnMember_documentation_en-US" xlink:label="lab_sny_SalesReturnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesReturnMember" xlink:href="sny-20231231.xsd#sny_SalesReturnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SalesReturnMember" xlink:to="lab_sny_SalesReturnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_4a39c1d7-8149-4d25-9b75-3b59acd56caa_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock_c97e654d-98c9-4e15-a495-ebf072e44e86_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Undrawn Credit Facilities</link:label>
    <link:label id="lab_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Undrawn Borrowing Facilities [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of undrawn borrowing facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock" xlink:to="lab_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember_cc69a3c1-ff91-4ed7-b967-22d83efaf727_terseLabel_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for pensions and other post-employment benefits</link:label>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember_label_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions For Pensions And Other Post-Employment Benefits [Member]</link:label>
    <link:label id="lab_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember_documentation_en-US" xlink:label="lab_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for pensions and other post-employment benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember" xlink:href="sny-20231231.xsd#sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember" xlink:to="lab_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_c0711096-7725-4003-95c1-bfe1391222d0_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other cash flows</link:label>
    <link:label id="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other inflows (outflows) of cash, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember_2368a103-6fc0-403a-9cbb-de1b20bed30f_verboseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent</link:label>
    <link:label id="lab_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember_label_en-US" xlink:label="lab_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps receive capitalized Eonia / pay 1.48%.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember" xlink:to="lab_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_e9654274-aa10-496e-8553-b63978fb77d0_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognised in profit or loss</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCreditFacilities_004a82d5-810f-4021-a248-46503af0063e_terseLabel_en-US" xlink:label="lab_sny_NumberOfCreditFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of credit facilities</link:label>
    <link:label id="lab_sny_NumberOfCreditFacilities_label_en-US" xlink:label="lab_sny_NumberOfCreditFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Credit Facilities</link:label>
    <link:label id="lab_sny_NumberOfCreditFacilities_documentation_en-US" xlink:label="lab_sny_NumberOfCreditFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Credit Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCreditFacilities" xlink:href="sny-20231231.xsd#sny_NumberOfCreditFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCreditFacilities" xlink:to="lab_sny_NumberOfCreditFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_53bd50c0-17c9-4cb4-957a-ea850483d8af_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through transfers, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock_9121698b-1875-49e5-a1dd-a920db3c0c4d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Lease Liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Maturity Analysis Of Lease Payments [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Maturity Analysis Of Lease Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock" xlink:to="lab_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherLiabilities1Member_edd88901-ed19-4071-ab12-2a890f987d10_terseLabel_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sny_OtherLiabilities1Member_label_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities1 [Member]</link:label>
    <link:label id="lab_sny_OtherLiabilities1Member_documentation_en-US" xlink:label="lab_sny_OtherLiabilities1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member" xlink:href="sny-20231231.xsd#sny_OtherLiabilities1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherLiabilities1Member" xlink:to="lab_sny_OtherLiabilities1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_ec10e842-2241-45d4-ab9f-3318584631fb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IndustrialSalesMember_786616df-d5df-418a-b309-c6b79f3b7156_terseLabel_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industrial sales</link:label>
    <link:label id="lab_sny_IndustrialSalesMember_label_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industrial Sales [Member]</link:label>
    <link:label id="lab_sny_IndustrialSalesMember_documentation_en-US" xlink:label="lab_sny_IndustrialSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industrial Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember" xlink:href="sny-20231231.xsd#sny_IndustrialSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IndustrialSalesMember" xlink:to="lab_sny_IndustrialSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment_b6751b4e-41ec-481f-9d42-98c6d699129f_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements, development milestone payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment_label_en-US" xlink:label="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Development Milestone Payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Development Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementsDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:to="lab_sny_CollaborationAgreementsDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember_62aa2c6c-f33a-4502-825e-48f6febe73c4_verboseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia</link:label>
    <link:label id="lab_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember_label_en-US" xlink:label="lab_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps pay -0.57% / receivecapitalized Eonia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember" xlink:to="lab_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_f5d1d1c7-22c3-4eed-af53-f86d6e7c108b_verboseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_9db4701b-a850-45b1-b34a-da45a542ff18_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes_97925154-bcf4-4cb7-91ab-2c55baf3e9d0_terseLabel_en-US" xlink:label="lab_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revisions to tax exposures and settlements of tax disputes</link:label>
    <link:label id="lab_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes_label_en-US" xlink:label="lab_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate Effect Of Revisions To Tax Exposures And Settlements Of Tax Disputes</link:label>
    <link:label id="lab_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes_documentation_en-US" xlink:label="lab_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Rate Effect Of Revisions To Tax Exposures And Settlements Of Tax Disputes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:href="sny-20231231.xsd#sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:to="lab_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MinusTwentyFiveBasisPointsMember_6bd8bbda-fb19-41ce-abe2-ea2e23272832_terseLabel_en-US" xlink:label="lab_sny_MinusTwentyFiveBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-25&#160;bp</link:label>
    <link:label id="lab_sny_MinusTwentyFiveBasisPointsMember_label_en-US" xlink:label="lab_sny_MinusTwentyFiveBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minus Twenty Five Basis Points [Member]</link:label>
    <link:label id="lab_sny_MinusTwentyFiveBasisPointsMember_documentation_en-US" xlink:label="lab_sny_MinusTwentyFiveBasisPointsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minus twenty five basis points.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinusTwentyFiveBasisPointsMember" xlink:href="sny-20231231.xsd#sny_MinusTwentyFiveBasisPointsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MinusTwentyFiveBasisPointsMember" xlink:to="lab_sny_MinusTwentyFiveBasisPointsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProceedsFromCollaborationAgreements_094c9021-8b14-4268-a8ba-7e2e3a9404b7_terseLabel_en-US" xlink:label="lab_sny_ProceedsFromCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaboration agreements</link:label>
    <link:label id="lab_sny_ProceedsFromCollaborationAgreements_label_en-US" xlink:label="lab_sny_ProceedsFromCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaboration Agreements</link:label>
    <link:label id="lab_sny_ProceedsFromCollaborationAgreements_documentation_en-US" xlink:label="lab_sny_ProceedsFromCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProceedsFromCollaborationAgreements" xlink:href="sny-20231231.xsd#sny_ProceedsFromCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProceedsFromCollaborationAgreements" xlink:to="lab_sny_ProceedsFromCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ReservePercentageOfPandemicVaccines_5c1a5d6f-a26a-4a21-8099-8fff13a783f7_terseLabel_en-US" xlink:label="lab_sny_ReservePercentageOfPandemicVaccines" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of pandemic vaccines agreed to reserve</link:label>
    <link:label id="lab_sny_ReservePercentageOfPandemicVaccines_label_en-US" xlink:label="lab_sny_ReservePercentageOfPandemicVaccines" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve Percentage of Pandemic Vaccines</link:label>
    <link:label id="lab_sny_ReservePercentageOfPandemicVaccines_documentation_en-US" xlink:label="lab_sny_ReservePercentageOfPandemicVaccines" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve percentage of pandemic vaccines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReservePercentageOfPandemicVaccines" xlink:href="sny-20231231.xsd#sny_ReservePercentageOfPandemicVaccines"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ReservePercentageOfPandemicVaccines" xlink:to="lab_sny_ReservePercentageOfPandemicVaccines" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_1ed06964-3c9a-407e-9328-24454663c9f6_terseLabel_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity_98bc961b-f0d5-4803-a0cd-95626ba0e4c2_terseLabel_en-US" xlink:label="lab_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net pre-tax actuarial loss</link:label>
    <link:label id="lab_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity_label_en-US" xlink:label="lab_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Pretax Actuarial Loss Excluding Associates And Joint Ventures Recognized Directly In Equity</link:label>
    <link:label id="lab_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity_documentation_en-US" xlink:label="lab_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net pretax actuarial loss excluding associates and joint ventures recognized directly in equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity" xlink:href="sny-20231231.xsd#sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity" xlink:to="lab_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_7568b614-0ecb-4d70-a965-7dd81df31762_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivables, other than corporate income taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current receivables from taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AventisPharmaLimitedMember_129c1216-f474-4d59-8c76-bca6d6afc2e0_terseLabel_en-US" xlink:label="lab_sny_AventisPharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma Limited</link:label>
    <link:label id="lab_sny_AventisPharmaLimitedMember_label_en-US" xlink:label="lab_sny_AventisPharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma Limited [member]</link:label>
    <link:label id="lab_sny_AventisPharmaLimitedMember_documentation_en-US" xlink:label="lab_sny_AventisPharmaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventis Pharma Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaLimitedMember" xlink:href="sny-20231231.xsd#sny_AventisPharmaLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AventisPharmaLimitedMember" xlink:to="lab_sny_AventisPharmaLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EPICBPIFranceMember_0e6b55c7-fb34-4d9a-a643-0124fc66cfa9_terseLabel_en-US" xlink:label="lab_sny_EPICBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPIC BPIFrance</link:label>
    <link:label id="lab_sny_EPICBPIFranceMember_label_en-US" xlink:label="lab_sny_EPICBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPIC BPIFrance [Member]</link:label>
    <link:label id="lab_sny_EPICBPIFranceMember_documentation_en-US" xlink:label="lab_sny_EPICBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPIC BPIFrance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EPICBPIFranceMember" xlink:href="sny-20231231.xsd#sny_EPICBPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EPICBPIFranceMember" xlink:to="lab_sny_EPICBPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_March2020EMTNISINFR0013505112Member_f3d3b0db-cc78-4bd5-affb-f6ee32aaf175_terseLabel_en-US" xlink:label="lab_sny_March2020EMTNISINFR0013505112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2020 EMTN ISIN FR0013505112</link:label>
    <link:label id="lab_sny_March2020EMTNISINFR0013505112Member_label_en-US" xlink:label="lab_sny_March2020EMTNISINFR0013505112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2020 EMTNISINFR0013505112 [Member]</link:label>
    <link:label id="lab_sny_March2020EMTNISINFR0013505112Member_documentation_en-US" xlink:label="lab_sny_March2020EMTNISINFR0013505112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2020 EMTNISINFR0013505112</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2020EMTNISINFR0013505112Member" xlink:href="sny-20231231.xsd#sny_March2020EMTNISINFR0013505112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_March2020EMTNISINFR0013505112Member" xlink:to="lab_sny_March2020EMTNISINFR0013505112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_365c0d4e-959c-4d96-9991-4e65b2ec5fb3_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received/(made) on changes of ownership interest in a subsidiary without loss of control</link:label>
    <link:label id="lab_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_label_en-US" xlink:label="lab_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments from changes in ownership interests in subsidiaries that do not result in loss of control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="lab_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BondsAndSimilarInstrumentsMember_6c89a13d-6cb2-44c6-92bd-6a407e2d8635_terseLabel_en-US" xlink:label="lab_sny_BondsAndSimilarInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonds and similar instruments</link:label>
    <link:label id="lab_sny_BondsAndSimilarInstrumentsMember_label_en-US" xlink:label="lab_sny_BondsAndSimilarInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonds And Similar Instruments [member]</link:label>
    <link:label id="lab_sny_BondsAndSimilarInstrumentsMember_documentation_en-US" xlink:label="lab_sny_BondsAndSimilarInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonds and similar instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BondsAndSimilarInstrumentsMember" xlink:href="sny-20231231.xsd#sny_BondsAndSimilarInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BondsAndSimilarInstrumentsMember" xlink:to="lab_sny_BondsAndSimilarInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember_4920bcae-8742-4d9d-9008-22d32fad7346_terseLabel_en-US" xlink:label="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of other netting arrangements not fulfilling the IAS 32 criteria for offsetting</link:label>
    <link:label id="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember_label_en-US" xlink:label="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects Of Other Netting Arrangements Not Fulfilling The IAS 32 Criteria For Offsetting [Member]</link:label>
    <link:label id="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember_documentation_en-US" xlink:label="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of other netting arrangements not fulfilling the IAS 32 criteria for offsetting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember" xlink:href="sny-20231231.xsd#sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember" xlink:to="lab_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment_649719a6-c720-4c14-8b38-8c29af0becf7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses, net of reversals</link:label>
    <link:label id="lab_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-downs (reversals of write-downs) of property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_3e1fe92d-c2ba-4d7a-884c-4a28c7a37c54_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_0ee8bfac-f43a-4cc3-acf6-b92f120c9a99_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value (investments accounted for using the equity method, net of taxes)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:to="lab_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_1d330efd-233a-42fb-97c9-a9928f7de195_terseLabel_en-US" xlink:label="lab_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortisation period of intangible assets material to entity</link:label>
    <link:label id="lab_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_label_en-US" xlink:label="lab_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortisation period of intangible assets material to entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="lab_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_542d7bfa-7a9f-484d-98e1-7d070330dae2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Results</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member_1c632488-9f1f-4232-9039-2aa143151b9e_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisions_e35850e8-15e7-4ba1-9354-fa1c82890e1d_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions</link:label>
    <link:label id="lab_ifrs-full_OtherProvisions_label_en-US" xlink:label="lab_ifrs-full_OtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisions" xlink:to="lab_ifrs-full_OtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems_5f9752c0-215b-465a-8d5d-a7bea41f5324_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-Based Payment [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-Based Payment [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-Based Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesMember_8e82f953-8a54-4e56-8f00-a86fccae7748_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services [member]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesMember_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesMember" xlink:to="lab_ifrs-full_ProductsAndServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded_542d4650-2bf6-41a2-a2db-c4fcc5af6799_terseLabel_en-US" xlink:label="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced amount of compensation claimed, interest included</link:label>
    <link:label id="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded_label_en-US" xlink:label="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced Amount Of Compensation Claimed By Filled Plaintiffs, Interest Included</link:label>
    <link:label id="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded_documentation_en-US" xlink:label="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced Amount Of Compensation Claimed By Filled Plaintiffs, Interest Included</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" xlink:href="sny-20231231.xsd#sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" xlink:to="lab_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherTerritoriesMember_c41124a8-0386-4598-bfb4-eb9f41cf6e43_terseLabel_en-US" xlink:label="lab_sny_OtherTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other territories</link:label>
    <link:label id="lab_sny_OtherTerritoriesMember_label_en-US" xlink:label="lab_sny_OtherTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Territories [Member]</link:label>
    <link:label id="lab_sny_OtherTerritoriesMember_documentation_en-US" xlink:label="lab_sny_OtherTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Territories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherTerritoriesMember" xlink:href="sny-20231231.xsd#sny_OtherTerritoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherTerritoriesMember" xlink:to="lab_sny_OtherTerritoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss_0a80d150-2107-49a8-b08a-bced9f3eb85e_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value through profit or loss</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value through profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisDeutschlandGmbHMember_4b33d40b-0ecd-45b0-86a3-5b41bff1031a_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisDeutschlandGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Deutschland GmbH</link:label>
    <link:label id="lab_sny_SanofiAventisDeutschlandGmbHMember_label_en-US" xlink:label="lab_sny_SanofiAventisDeutschlandGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Deutschland Gmbh [member]</link:label>
    <link:label id="lab_sny_SanofiAventisDeutschlandGmbHMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisDeutschlandGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Deutschland GmbH.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeutschlandGmbHMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeutschlandGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisDeutschlandGmbHMember" xlink:to="lab_sny_SanofiAventisDeutschlandGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapitalMember_891d6bed-6597-47d4-83c4-ed17cdd0c9fc_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapitalMember_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapitalMember" xlink:to="lab_ifrs-full_AdditionalPaidinCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentFinanceLeaseReceivablesGross_1353257d-2d9a-4ff8-8d02-2f2f7e220943_terseLabel_en-US" xlink:label="lab_sny_NonCurrentFinanceLeaseReceivablesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current finance lease receivables, gross</link:label>
    <link:label id="lab_sny_NonCurrentFinanceLeaseReceivablesGross_label_en-US" xlink:label="lab_sny_NonCurrentFinanceLeaseReceivablesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Finance Lease Receivables, Gross</link:label>
    <link:label id="lab_sny_NonCurrentFinanceLeaseReceivablesGross_documentation_en-US" xlink:label="lab_sny_NonCurrentFinanceLeaseReceivablesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Finance Lease Receivables, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentFinanceLeaseReceivablesGross" xlink:href="sny-20231231.xsd#sny_NonCurrentFinanceLeaseReceivablesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentFinanceLeaseReceivablesGross" xlink:to="lab_sny_NonCurrentFinanceLeaseReceivablesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_75e91812-2ade-4c58-9aed-948c37358d08_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Non Current Assets [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Non-Current Assets [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:to="lab_sny_DisclosureOfOtherNonCurrentAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_2c2ae2b4-3160-4c65-ad34-a22785270522_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average exercise&#160;price per share, options forfeited (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentEquityDerivativesPayable_6169887b-5303-4d68-9172-44e986437f1c_verboseLabel_en-US" xlink:label="lab_sny_CurrentEquityDerivativesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity derivatives (see Note&#160;D.20.)</link:label>
    <link:label id="lab_sny_CurrentEquityDerivativesPayable_label_en-US" xlink:label="lab_sny_CurrentEquityDerivativesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Equity Derivatives Payable</link:label>
    <link:label id="lab_sny_CurrentEquityDerivativesPayable_documentation_en-US" xlink:label="lab_sny_CurrentEquityDerivativesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Equity Derivatives Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentEquityDerivativesPayable" xlink:href="sny-20231231.xsd#sny_CurrentEquityDerivativesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentEquityDerivativesPayable" xlink:to="lab_sny_CurrentEquityDerivativesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_f0147793-5115-4ccd-91ca-3624b0d99e78_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_fdb1d788-c739-480c-9ba6-2b71f4abc67c_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LumpSumRetirementBenefitPlansMember_5a4a1793-e1ff-48af-9021-5446850b958c_terseLabel_en-US" xlink:label="lab_sny_LumpSumRetirementBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lump-sum retirement benefit plans</link:label>
    <link:label id="lab_sny_LumpSumRetirementBenefitPlansMember_label_en-US" xlink:label="lab_sny_LumpSumRetirementBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lump-sum Retirement Benefit Plans [Member]</link:label>
    <link:label id="lab_sny_LumpSumRetirementBenefitPlansMember_documentation_en-US" xlink:label="lab_sny_LumpSumRetirementBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lump-sum retirement benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LumpSumRetirementBenefitPlansMember" xlink:href="sny-20231231.xsd#sny_LumpSumRetirementBenefitPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LumpSumRetirementBenefitPlansMember" xlink:to="lab_sny_LumpSumRetirementBenefitPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_e94caa94-d0a8-479d-89f2-a94a9276b5bc_terseLabel_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_sny_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_54076df4-ecf6-44be-90f9-2c6345ae01a4_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment pledged as security for liabilities</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, pledged as security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_6be7470c-cea7-4a84-ba55-327e4daba3bb_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase through remeasurement of financial liability</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Remeasurement, Other Current Liabilities</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:to="lab_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_6fa79af9-efb5-43c6-93d4-fc3ec3d2ef5b_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisPuertoRicoIncMember_747c4d09-a1ac-4d88-9d0d-27daf282cee9_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisPuertoRicoIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Puerto Rico Inc</link:label>
    <link:label id="lab_sny_SanofiAventisPuertoRicoIncMember_label_en-US" xlink:label="lab_sny_SanofiAventisPuertoRicoIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Puerto Rico Inc [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisPuertoRicoIncMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisPuertoRicoIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Puerto Rico Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisPuertoRicoIncMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisPuertoRicoIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisPuertoRicoIncMember" xlink:to="lab_sny_SanofiAventisPuertoRicoIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GenzymeCorporationMember_54aa70c9-c495-4e07-9c3a-624172699341_terseLabel_en-US" xlink:label="lab_sny_GenzymeCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Corporation</link:label>
    <link:label id="lab_sny_GenzymeCorporationMember_label_en-US" xlink:label="lab_sny_GenzymeCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Corporation [Member]</link:label>
    <link:label id="lab_sny_GenzymeCorporationMember_documentation_en-US" xlink:label="lab_sny_GenzymeCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeCorporationMember" xlink:href="sny-20231231.xsd#sny_GenzymeCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GenzymeCorporationMember" xlink:to="lab_sny_GenzymeCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForTaxServices_9fa64c14-9a82-4a26-be4e-ba3d9aa1beba_terseLabel_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForTaxServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_ifrs-full_AuditorsRemunerationForTaxServices_label_en-US" xlink:label="lab_ifrs-full_AuditorsRemunerationForTaxServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor's remuneration for tax services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForTaxServices" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForTaxServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemunerationForTaxServices" xlink:to="lab_ifrs-full_AuditorsRemunerationForTaxServices" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_8ca67cd6-19ce-4d9c-b173-28e3810b3905_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketConditionDomain_78a3cb9c-44f2-4dcd-ae2a-4331e70b5757_terseLabel_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:label id="lab_sny_MarketConditionDomain_label_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:label id="lab_sny_MarketConditionDomain_documentation_en-US" xlink:label="lab_sny_MarketConditionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Condition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain" xlink:href="sny-20231231.xsd#sny_MarketConditionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketConditionDomain" xlink:to="lab_sny_MarketConditionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Cash_0145ca4a-4302-4bdb-9454-3d2689fed0fc_terseLabel_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_ifrs-full_Cash_label_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash" xlink:to="lab_ifrs-full_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TypesOfAgreementAxis_3563c8c4-c111-4d43-aee9-4bf15d8e353a_terseLabel_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types Of Agreement [Axis]</link:label>
    <link:label id="lab_sny_TypesOfAgreementAxis_label_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types Of Agreement [Axis]</link:label>
    <link:label id="lab_sny_TypesOfAgreementAxis_documentation_en-US" xlink:label="lab_sny_TypesOfAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TypesOfAgreementAxis" xlink:to="lab_sny_TypesOfAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AllergyMember_a2c98152-ece8-45b6-ab41-e7e81be9da02_terseLabel_en-US" xlink:label="lab_sny_AllergyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergy</link:label>
    <link:label id="lab_sny_AllergyMember_label_en-US" xlink:label="lab_sny_AllergyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergy [Member]</link:label>
    <link:label id="lab_sny_AllergyMember_documentation_en-US" xlink:label="lab_sny_AllergyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergy, Cough And Cold [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AllergyMember" xlink:href="sny-20231231.xsd#sny_AllergyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AllergyMember" xlink:to="lab_sny_AllergyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RetirementAge_a84d560d-6a72-45c5-9374-6633fae07d0e_terseLabel_en-US" xlink:label="lab_sny_RetirementAge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement age</link:label>
    <link:label id="lab_sny_RetirementAge_label_en-US" xlink:label="lab_sny_RetirementAge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Age</link:label>
    <link:label id="lab_sny_RetirementAge_documentation_en-US" xlink:label="lab_sny_RetirementAge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement age.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RetirementAge" xlink:href="sny-20231231.xsd#sny_RetirementAge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RetirementAge" xlink:to="lab_sny_RetirementAge" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember_cd50952d-9f90-4367-8687-0694595b44c9_terseLabel_en-US" xlink:label="lab_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt and current portion of long-term debt</link:label>
    <link:label id="lab_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember_label_en-US" xlink:label="lab_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt And Current Portion Of Long-Term Debt [Member]</link:label>
    <link:label id="lab_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember_documentation_en-US" xlink:label="lab_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term debt and current portion of long term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember" xlink:href="sny-20231231.xsd#sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember" xlink:to="lab_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherBankBorrowings_53bb1058-5381-4bc7-a164-c12fe99af998_terseLabel_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other bank borrowings</link:label>
    <link:label id="lab_sny_OtherBankBorrowings_label_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Bank Borrowings</link:label>
    <link:label id="lab_sny_OtherBankBorrowings_documentation_en-US" xlink:label="lab_sny_OtherBankBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other bank borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings" xlink:href="sny-20231231.xsd#sny_OtherBankBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherBankBorrowings" xlink:to="lab_sny_OtherBankBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeStatementLocation1Axis_e52feb99-b890-4780-a1cc-400268853f0d_terseLabel_en-US" xlink:label="lab_sny_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_sny_IncomeStatementLocation1Axis_label_en-US" xlink:label="lab_sny_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_sny_IncomeStatementLocation1Axis_documentation_en-US" xlink:label="lab_sny_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Axis" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeStatementLocation1Axis" xlink:to="lab_sny_IncomeStatementLocation1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherDeductionsMember_d38aba1e-7c9e-4998-b6be-178b46e17fa2_terseLabel_en-US" xlink:label="lab_sny_OtherDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other deductions</link:label>
    <link:label id="lab_sny_OtherDeductionsMember_label_en-US" xlink:label="lab_sny_OtherDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Deductions [Member]</link:label>
    <link:label id="lab_sny_OtherDeductionsMember_documentation_en-US" xlink:label="lab_sny_OtherDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherDeductionsMember" xlink:href="sny-20231231.xsd#sny_OtherDeductionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherDeductionsMember" xlink:to="lab_sny_OtherDeductionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_45773ffd-45e3-4f5b-b519-53f9b8351f02_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non-current Provisions [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non-Current Provisions [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non-current Provisions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OneBillionBondsMaturingJune2023Member_26c93f2f-4f11-46e8-a706-a5a20e3097e3_terseLabel_en-US" xlink:label="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,000 million bonds maturing June 2023</link:label>
    <link:label id="lab_sny_OneBillionBondsMaturingJune2023Member_label_en-US" xlink:label="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Billion Bonds Maturing June 2023 [Member]</link:label>
    <link:label id="lab_sny_OneBillionBondsMaturingJune2023Member_documentation_en-US" xlink:label="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Billion Bonds Maturing June 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingJune2023Member" xlink:href="sny-20231231.xsd#sny_OneBillionBondsMaturingJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OneBillionBondsMaturingJune2023Member" xlink:to="lab_sny_OneBillionBondsMaturingJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherLongtermProvisions_eb139639-911f-482c-8a1a-70b5234a0633_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherLongtermProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_OtherLongtermProvisions_label_en-US" xlink:label="lab_ifrs-full_OtherLongtermProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLongtermProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLongtermProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherLongtermProvisions" xlink:to="lab_ifrs-full_OtherLongtermProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfTradingDaysPrecedingPlanApproval_8ee4a44a-06d3-4692-b7ca-23d58322ba79_terseLabel_en-US" xlink:label="lab_sny_NumberOfTradingDaysPrecedingPlanApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days preceding plan approval</link:label>
    <link:label id="lab_sny_NumberOfTradingDaysPrecedingPlanApproval_label_en-US" xlink:label="lab_sny_NumberOfTradingDaysPrecedingPlanApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Trading Days Preceding Plan Approval</link:label>
    <link:label id="lab_sny_NumberOfTradingDaysPrecedingPlanApproval_documentation_en-US" xlink:label="lab_sny_NumberOfTradingDaysPrecedingPlanApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Trading Days Preceding Plan Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTradingDaysPrecedingPlanApproval" xlink:href="sny-20231231.xsd#sny_NumberOfTradingDaysPrecedingPlanApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfTradingDaysPrecedingPlanApproval" xlink:to="lab_sny_NumberOfTradingDaysPrecedingPlanApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfOngoingTrials_54355f25-5357-4ae9-a301-2946601f1fb1_terseLabel_en-US" xlink:label="lab_sny_NumberOfOngoingTrials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ongoing trials</link:label>
    <link:label id="lab_sny_NumberOfOngoingTrials_label_en-US" xlink:label="lab_sny_NumberOfOngoingTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ongoing Trials</link:label>
    <link:label id="lab_sny_NumberOfOngoingTrials_documentation_en-US" xlink:label="lab_sny_NumberOfOngoingTrials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ongoing Trials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOngoingTrials" xlink:href="sny-20231231.xsd#sny_NumberOfOngoingTrials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfOngoingTrials" xlink:to="lab_sny_NumberOfOngoingTrials" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DupixentMember_34af4ab3-0ed5-4165-85bc-b35f9bd49174_terseLabel_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DUPIXENT</link:label>
    <link:label id="lab_sny_DupixentMember_label_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dupixent [Member]</link:label>
    <link:label id="lab_sny_DupixentMember_documentation_en-US" xlink:label="lab_sny_DupixentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dupixent [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember" xlink:href="sny-20231231.xsd#sny_DupixentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DupixentMember" xlink:to="lab_sny_DupixentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketedProductsTrademarksAndOtherRightsMember_2bb51868-4912-454e-b9d6-15eace5d0b28_terseLabel_en-US" xlink:label="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, trademarks and other rights</link:label>
    <link:label id="lab_sny_MarketedProductsTrademarksAndOtherRightsMember_label_en-US" xlink:label="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed Products Trademarks And Other Rights [Member]</link:label>
    <link:label id="lab_sny_MarketedProductsTrademarksAndOtherRightsMember_documentation_en-US" xlink:label="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketed products trademarks and other rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:href="sny-20231231.xsd#sny_MarketedProductsTrademarksAndOtherRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:to="lab_sny_MarketedProductsTrademarksAndOtherRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems_a5bc8f70-431c-49fd-ba63-748a8138496d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Maximum Amount Of Contingent Consideration Payable And Firm Commitments To Buy Out Non-Controlling Interests [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems" xlink:to="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_741a5d55-0e56-497a-9f59-bbee19d98d74_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_21c50913-4918-4145-8d5d-a77cce09c81c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Operating Income Expenses [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other operating income (expenses).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:to="lab_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ZantacLitigationInTheUSMember_4b4f49d4-acf6-4bb1-a478-5be1b5781c77_terseLabel_en-US" xlink:label="lab_sny_ZantacLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zantac litigation in the US</link:label>
    <link:label id="lab_sny_ZantacLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_ZantacLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zantac Litigation In the US [Member]</link:label>
    <link:label id="lab_sny_ZantacLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_ZantacLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zantac Litigation In the US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacLitigationInTheUSMember" xlink:href="sny-20231231.xsd#sny_ZantacLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ZantacLitigationInTheUSMember" xlink:to="lab_sny_ZantacLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiEgyptSAEMember_9ccd11b2-aa80-4e89-b8d4-d3dfad1e05cc_terseLabel_en-US" xlink:label="lab_sny_SanofiEgyptSAEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Egypt</link:label>
    <link:label id="lab_sny_SanofiEgyptSAEMember_label_en-US" xlink:label="lab_sny_SanofiEgyptSAEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Egypt S.A.E [Member]</link:label>
    <link:label id="lab_sny_SanofiEgyptSAEMember_documentation_en-US" xlink:label="lab_sny_SanofiEgyptSAEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Egypt S.A.E.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEgyptSAEMember" xlink:href="sny-20231231.xsd#sny_SanofiEgyptSAEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiEgyptSAEMember" xlink:to="lab_sny_SanofiEgyptSAEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_7ac49a95-e28d-453c-8a1e-c713f1039bc0_totalLabel_en-US" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets</link:label>
    <link:label id="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_label_en-US" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable assets acquired (liabilities assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_a9534fab-2e59-4798-8b8d-7b288004501b_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember_90131616-65a3-4d3a-8bc1-64d4ad5d5869_terseLabel_en-US" xlink:label="lab_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate after derivative instruments</link:label>
    <link:label id="lab_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember_label_en-US" xlink:label="lab_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Interest Rate After Derivative Instruments [Member]</link:label>
    <link:label id="lab_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember_documentation_en-US" xlink:label="lab_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate after derivative instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember" xlink:href="sny-20231231.xsd#sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember" xlink:to="lab_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_37c2e794-0e93-4ec2-a635-0956035b7650_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from sale of goods, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:to="lab_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcarePanamaSAMember_f10b6ff2-aab7-468c-ab48-7d55db60a3fa_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcarePanamaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Panama SA</link:label>
    <link:label id="lab_sny_OpellaHealthcarePanamaSAMember_label_en-US" xlink:label="lab_sny_OpellaHealthcarePanamaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Panama S.A. [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcarePanamaSAMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcarePanamaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Panama S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcarePanamaSAMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcarePanamaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcarePanamaSAMember" xlink:to="lab_sny_OpellaHealthcarePanamaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GenzymeFlandersBVBAMember_e6442e5c-8b43-453c-a028-03b6eebd46e6_terseLabel_en-US" xlink:label="lab_sny_GenzymeFlandersBVBAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Flanders BV</link:label>
    <link:label id="lab_sny_GenzymeFlandersBVBAMember_label_en-US" xlink:label="lab_sny_GenzymeFlandersBVBAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Flanders BVBA [member]</link:label>
    <link:label id="lab_sny_GenzymeFlandersBVBAMember_documentation_en-US" xlink:label="lab_sny_GenzymeFlandersBVBAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Flanders BVBA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeFlandersBVBAMember" xlink:href="sny-20231231.xsd#sny_GenzymeFlandersBVBAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GenzymeFlandersBVBAMember" xlink:to="lab_sny_GenzymeFlandersBVBAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_c7c1426b-4aae-468e-a68b-bd9e819b29ba_negatedLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes, net</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_91f10f31-a034-47ae-b14e-a53100049732_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes, net</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_1d9198d8-14b3-44cf-94eb-7fda7b3aee80_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ToujeoMember_9b890fcd-986f-45dd-a937-d982899fbeb7_terseLabel_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOUJEO</link:label>
    <link:label id="lab_sny_ToujeoMember_label_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toujeo [Member]</link:label>
    <link:label id="lab_sny_ToujeoMember_documentation_en-US" xlink:label="lab_sny_ToujeoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toujeo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember" xlink:href="sny-20231231.xsd#sny_ToujeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ToujeoMember" xlink:to="lab_sny_ToujeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlansMember_740fd468-bda7-4ebc-927f-eafe8c8aadb3_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share plans</link:label>
    <link:label id="lab_sny_RestrictedSharePlansMember_label_en-US" xlink:label="lab_sny_RestrictedSharePlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plans [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlansMember_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlansMember" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlansMember" xlink:to="lab_sny_RestrictedSharePlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WithoutMarketConditionMember_abb235c5-7595-4994-9348-0e40917756fe_terseLabel_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Without market condition</link:label>
    <link:label id="lab_sny_WithoutMarketConditionMember_label_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Without Market Condition [Member]</link:label>
    <link:label id="lab_sny_WithoutMarketConditionMember_documentation_en-US" xlink:label="lab_sny_WithoutMarketConditionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Without Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember" xlink:href="sny-20231231.xsd#sny_WithoutMarketConditionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WithoutMarketConditionMember" xlink:to="lab_sny_WithoutMarketConditionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock_705f9f25-f8a3-4e01-b2ad-24b9d8b5071f_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value of Derivative Instruments</link:label>
    <link:label id="lab_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Fair Value Of Derivative Instruments [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value of derivative instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock" xlink:to="lab_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_f3ca99be-5883-4ae7-bcb0-5f2b37f47108_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_7dfd7a44-2bbd-4040-a364-7a046d05a4dd_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average exercise&#160;price per share, options exercisable (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_5eb1ab88-d185-476d-8f8b-424ddda74b7a_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise&#160;price per share, Options exercisable (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments_64764e73-79a8-4c1c-879a-e62970c2e2b9_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development license agreements - commitments related to R&amp;D and other commitments</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Research And Development License Agreements, Other Commitments</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments related to R&amp; D licence agreements and other commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" xlink:to="lab_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsCurrent_d9ae3939-aaaa-4d38-9fe1-758719440174_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax assets</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax assets, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssetsCurrent" xlink:to="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiHangzhouPharmaceuticalsCoLtdMember_8da166ba-34d1-494a-9178-aded2ad697a2_terseLabel_en-US" xlink:label="lab_sny_SanofiHangzhouPharmaceuticalsCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi (Hangzhou) Pharmaceuticals Co., Ltd</link:label>
    <link:label id="lab_sny_SanofiHangzhouPharmaceuticalsCoLtdMember_label_en-US" xlink:label="lab_sny_SanofiHangzhouPharmaceuticalsCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Hangzhou Pharmaceuticals Co Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiHangzhouPharmaceuticalsCoLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiHangzhouPharmaceuticalsCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi (Hangzhou) Pharmaceuticals Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiHangzhouPharmaceuticalsCoLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiHangzhouPharmaceuticalsCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiHangzhouPharmaceuticalsCoLtdMember" xlink:to="lab_sny_SanofiHangzhouPharmaceuticalsCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_9e128d6b-f005-4d3c-9db6-108a4ddd48ba_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities other than liabilities included in disposal groups classified as held for sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lab_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock_a8400039-5d28-418b-bc9b-5f193fe773f3_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Fair Value Of Financial Assets And Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value of financial assets and liabilities explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_ca9a518e-0f69-427d-8b9f-ccd7583e6297_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total recognized in profit or loss</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_1018af66-6783-446f-bcc8-c4791eb9ce6d_totalLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_44b15502-0fa2-49d3-bcd2-135266638f49_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared_1c1f8e9b-dd3e-43eb-ba20-3dd2068bedf5_terseLabel_en-US" xlink:label="lab_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period before scheduled launch date</link:label>
    <link:label id="lab_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared_label_en-US" xlink:label="lab_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Before Launch Date During Which Commercial Expenses Of Antibodies Co-Developed Under License Agreement Are Shared</link:label>
    <link:label id="lab_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared_documentation_en-US" xlink:label="lab_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Before Launch Date During Which Commercial Expenses Of Antibodies Co-Developed Under License Agreement Are Shared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared" xlink:href="sny-20231231.xsd#sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared" xlink:to="lab_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_73cf4812-cee3-480d-9935-8f57c5b058ed_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock_ff5819b6-9aab-4992-9323-82283c567ced_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash and Cash Equivalents</link:label>
    <link:label id="lab_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Details [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of cash and cash equivalents details.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock" xlink:to="lab_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_KadmonCorporationLLCMember_5ccb0cf2-9c24-4a5d-b85a-b8bcd1b46231_terseLabel_en-US" xlink:label="lab_sny_KadmonCorporationLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kadmon Corporation, LLC</link:label>
    <link:label id="lab_sny_KadmonCorporationLLCMember_label_en-US" xlink:label="lab_sny_KadmonCorporationLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kadmon Corporation, LLC [Member]</link:label>
    <link:label id="lab_sny_KadmonCorporationLLCMember_documentation_en-US" xlink:label="lab_sny_KadmonCorporationLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kadmon Corporation, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KadmonCorporationLLCMember" xlink:href="sny-20231231.xsd#sny_KadmonCorporationLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_KadmonCorporationLLCMember" xlink:to="lab_sny_KadmonCorporationLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoods_76f586bd-246e-4fe3-b271-b9e4975aee98_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_ifrs-full_RevenueFromSaleOfGoods_label_en-US" xlink:label="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from sale of goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromSaleOfGoods" xlink:to="lab_ifrs-full_RevenueFromSaleOfGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherNonCoreAssetsMember_64c57b98-d342-4e5c-aff3-2e1a38e6496c_terseLabel_en-US" xlink:label="lab_sny_OtherNonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-core assets</link:label>
    <link:label id="lab_sny_OtherNonCoreAssetsMember_label_en-US" xlink:label="lab_sny_OtherNonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Core Assets [Member]</link:label>
    <link:label id="lab_sny_OtherNonCoreAssetsMember_documentation_en-US" xlink:label="lab_sny_OtherNonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Core Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherNonCoreAssetsMember" xlink:href="sny-20231231.xsd#sny_OtherNonCoreAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherNonCoreAssetsMember" xlink:to="lab_sny_OtherNonCoreAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_152e6818-2e79-4352-a9e6-c49eefaf6d7e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisDeColombiaSAMember_c7e66dda-30be-4398-ae20-628f60d02f79_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisDeColombiaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis de Colombia SA</link:label>
    <link:label id="lab_sny_SanofiAventisDeColombiaSAMember_label_en-US" xlink:label="lab_sny_SanofiAventisDeColombiaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis De Colombia S A [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisDeColombiaSAMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisDeColombiaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis de Colombia S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeColombiaSAMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeColombiaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisDeColombiaSAMember" xlink:to="lab_sny_SanofiAventisDeColombiaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_fb0fb079-ecba-4aa1-ba6c-0b303e964daf_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInKoreanWonMember_93bff6ef-4bdd-40f7-be31-1b77da91bc31_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Korean Won</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInKoreanWonMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Korean Won [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInKoreanWonMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInKoreanWonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Korean Won</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInKoreanWonMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInKoreanWonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasedInKoreanWonMember" xlink:to="lab_sny_ForwardCurrencyPurchasedInKoreanWonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TotalStockOptionPlansMember_20245f12-185b-4674-a010-e6ed8967fb67_terseLabel_en-US" xlink:label="lab_sny_TotalStockOptionPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock option plans</link:label>
    <link:label id="lab_sny_TotalStockOptionPlansMember_label_en-US" xlink:label="lab_sny_TotalStockOptionPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stock Option Plans [Member]</link:label>
    <link:label id="lab_sny_TotalStockOptionPlansMember_documentation_en-US" xlink:label="lab_sny_TotalStockOptionPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock option plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalStockOptionPlansMember" xlink:href="sny-20231231.xsd#sny_TotalStockOptionPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TotalStockOptionPlansMember" xlink:to="lab_sny_TotalStockOptionPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9730898f-f697-4b4c-ba13-a64e521d3ca1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock_391a5fd0-6766-4a09-a118-c3ed51c964af_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt by Interest Rate</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt By Interest Rate At Value Of Redemption And By Maturity Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of debt by interest rate at value of redemption and by maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_130aab76-613c-4317-af1b-9f65ec2e3634_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Legal and Arbitral Proceedings [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Legal And Arbitral Proceedings [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of legal and arbitral proceedings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:to="lab_sny_DisclosureOfLegalAndArbitralProceedingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c330eab3-76fe-4a98-9e07-3decbd27a67d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PriorDevelopmentBudget_91cbbab2-f19a-4350-aba9-49f51230e98d_terseLabel_en-US" xlink:label="lab_sny_PriorDevelopmentBudget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior development budget in total</link:label>
    <link:label id="lab_sny_PriorDevelopmentBudget_label_en-US" xlink:label="lab_sny_PriorDevelopmentBudget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Development Budget</link:label>
    <link:label id="lab_sny_PriorDevelopmentBudget_documentation_en-US" xlink:label="lab_sny_PriorDevelopmentBudget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior development budget.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PriorDevelopmentBudget" xlink:href="sny-20231231.xsd#sny_PriorDevelopmentBudget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PriorDevelopmentBudget" xlink:to="lab_sny_PriorDevelopmentBudget" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesHeld_aededbf4-db33-46de-a604-e85746163ae2_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesHeld_label_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Held</link:label>
    <link:label id="lab_sny_NumberOfSharesHeld_documentation_en-US" xlink:label="lab_sny_NumberOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesHeld" xlink:href="sny-20231231.xsd#sny_NumberOfSharesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesHeld" xlink:to="lab_sny_NumberOfSharesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_a95e908f-3715-49a4-83ab-dd1af4b1a5cb_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other profit or loss items with no cash effect on cash flows generated by operating activities</link:label>
    <link:label id="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_label_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments to reconcile profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:to="lab_ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements_a2ac214c-2eac-46ec-912e-ea7e1d599666_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Expenses</link:label>
    <link:label id="lab_ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements_label_en-US" xlink:label="lab_ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional information about share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements" xlink:to="lab_ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_b67c8cf8-e7fc-4916-b35f-b6afae2f992b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Instruments</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Interest Rates Hedging Instruments With Notional Amount By Expiry Date Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of interest rates hedging instruments with notional amount by expiry date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointOperation_2314fc6a-0eee-43c8-bfaa-1ad8d6ce34c9_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial interest in principal investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInJointOperation_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInJointOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of ownership interest in joint operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointOperation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInJointOperation" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInJointOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_402d9910-38af-46b4-bbf9-80d2187ab200_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_a6647f19-d1a6-41df-b063-02d429947eab_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_0b6a5805-16a7-4b2d-986d-afaf42d2554b_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year 4</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_347c0e9f-cba7-4b39-ba84-95cb1a60131a_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3 to 4 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than three years and not later than four years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MachineryAndEquipment1Member_1694895a-8b68-47cd-9dc3-08930b5b01dd_terseLabel_en-US" xlink:label="lab_sny_MachineryAndEquipment1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_sny_MachineryAndEquipment1Member_label_en-US" xlink:label="lab_sny_MachineryAndEquipment1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery And Equipment1 [Member]</link:label>
    <link:label id="lab_sny_MachineryAndEquipment1Member_documentation_en-US" xlink:label="lab_sny_MachineryAndEquipment1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery And Equipment1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MachineryAndEquipment1Member" xlink:href="sny-20231231.xsd#sny_MachineryAndEquipment1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MachineryAndEquipment1Member" xlink:to="lab_sny_MachineryAndEquipment1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture_e30b0398-1c7d-400b-b155-de224527a918_terseLabel_en-US" xlink:label="lab_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves likely to be distributed in the foreseeable future</link:label>
    <link:label id="lab_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture_label_en-US" xlink:label="lab_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves Likely To Be Distributed In The Foreseeable Future</link:label>
    <link:label id="lab_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture_documentation_en-US" xlink:label="lab_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves likely to be distributed in the foreseeable future.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture" xlink:href="sny-20231231.xsd#sny_ReservesLikelyToBeDistributedInTheForeseeableFuture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture" xlink:to="lab_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock_92735eb7-6903-4cd2-a78d-5425f409b8b3_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Pre-tax Actuarial Loss</link:label>
    <link:label id="lab_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Pre Tax Actuarial Loss Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Pre Tax Actuarial Loss Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1bbd099a-2f30-4d28-9408-fda1c9dd8eaf_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_b02e6132-e343-491b-b10d-e7615dda33fb_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_b265d99d-03a4-4c0c-a6c0-9add0f15ba46_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from changes in foreign exchange rates, net defined benefit liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_587f8f55-7372-4a35-b316-87e0b24cf88b_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in scope of consolidation</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Changes In Scope Of Consolidation, Other Provisions</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Changes In Scope Of Consolidation, Other Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:to="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_7725a9e7-a0f7-4db5-9199-f817f666738c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accounts Receivable</link:label>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Current Trade Receivables [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of current trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfCurrentTradeReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:to="lab_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_dc423571-3872-45f0-b9b8-6a52a7b1ef2a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsTZIELDMember_63490404-cbde-4634-af1c-7784ccfbd034_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsTZIELDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TZIELD</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsTZIELDMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsTZIELDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products TZIELD [Member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsTZIELDMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsTZIELDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products TZIELD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsTZIELDMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsTZIELDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsTZIELDMember" xlink:to="lab_sny_PrincipalMarketedProductsTZIELDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_8ea9aec5-a6b6-46a7-af3c-b53af171922d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_36b1b870-f7e7-48ac-a682-8667fa713e1e_negatedLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial losses/(gains) due to changes in demographic assumptions</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_2c95f304-74e2-4b58-b88e-c07f39cb8499_verboseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains/(losses) on demographic assumptions</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSustainableDevelopmentPerformanceIndicators_3a345539-4418-4125-b64d-85ef392f376d_terseLabel_en-US" xlink:label="lab_sny_NumberOfSustainableDevelopmentPerformanceIndicators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sustainable development performance indicators</link:label>
    <link:label id="lab_sny_NumberOfSustainableDevelopmentPerformanceIndicators_label_en-US" xlink:label="lab_sny_NumberOfSustainableDevelopmentPerformanceIndicators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sustainable Development Performance Indicators</link:label>
    <link:label id="lab_sny_NumberOfSustainableDevelopmentPerformanceIndicators_documentation_en-US" xlink:label="lab_sny_NumberOfSustainableDevelopmentPerformanceIndicators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sustainable Development Performance Indicators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSustainableDevelopmentPerformanceIndicators" xlink:href="sny-20231231.xsd#sny_NumberOfSustainableDevelopmentPerformanceIndicators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSustainableDevelopmentPerformanceIndicators" xlink:to="lab_sny_NumberOfSustainableDevelopmentPerformanceIndicators" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_3c06fd08-1909-45d5-8f02-0f4e7c0f96b5_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments at fair value through other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value through other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_84b31920-a1f8-43df-82fd-cafe2d4e6e49_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_67f81e5f-df06-4b14-8b12-417cb2415ab3_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_f71c7f96-77ff-42e5-8e44-1f389ce8ae88_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisVietnamCompanyLimitedMember_d00ebd43-0c59-45a8-9b6f-60466235b9d8_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisVietnamCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Vietnam Company Limited</link:label>
    <link:label id="lab_sny_SanofiAventisVietnamCompanyLimitedMember_label_en-US" xlink:label="lab_sny_SanofiAventisVietnamCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Vietnam Company Limited [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisVietnamCompanyLimitedMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisVietnamCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Vietnam Company Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisVietnamCompanyLimitedMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisVietnamCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisVietnamCompanyLimitedMember" xlink:to="lab_sny_SanofiAventisVietnamCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_30cbadf7-8e5c-48b0-ab07-ec5f76828d0c_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency sales in Singapore Dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In Singapore Dollar [member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInSingaporeDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency sales in Singapore Dollar.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:to="lab_sny_ForwardCurrencySalesInSingaporeDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_d797cb00-9a11-42a4-be2a-04d355dcf7e9_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price range two</link:label>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember" xlink:href="sny-20231231.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeTwoMember" xlink:to="lab_sny_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AventisubLLCMember_c186abef-45bd-47b1-9b25-bcfdeab56a1d_terseLabel_en-US" xlink:label="lab_sny_AventisubLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventisub LLC</link:label>
    <link:label id="lab_sny_AventisubLLCMember_label_en-US" xlink:label="lab_sny_AventisubLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventisub LLC [Member]</link:label>
    <link:label id="lab_sny_AventisubLLCMember_documentation_en-US" xlink:label="lab_sny_AventisubLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aventisub LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisubLLCMember" xlink:href="sny-20231231.xsd#sny_AventisubLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AventisubLLCMember" xlink:to="lab_sny_AventisubLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset_9ec79f05-894c-4396-8717-64d1d84264ec_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in scope of consolidation and transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from business combinations and disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_04d85977-8012-42c2-a28d-58bb4d3698f6_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MinimumPlan1Member_e624859c-173c-490c-8741-bce1e30decce_terseLabel_en-US" xlink:label="lab_sny_MinimumPlan1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Plan 1</link:label>
    <link:label id="lab_sny_MinimumPlan1Member_label_en-US" xlink:label="lab_sny_MinimumPlan1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Plan 1 [Member]</link:label>
    <link:label id="lab_sny_MinimumPlan1Member_documentation_en-US" xlink:label="lab_sny_MinimumPlan1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Plan 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinimumPlan1Member" xlink:href="sny-20231231.xsd#sny_MinimumPlan1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MinimumPlan1Member" xlink:to="lab_sny_MinimumPlan1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinishedGoods_0f7a17c9-1ce3-4f6e-9cbd-9928d8c2e247_terseLabel_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_ifrs-full_FinishedGoods_label_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current finished goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinishedGoods" xlink:to="lab_ifrs-full_FinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MCMVaccineBVMember_78abe004-c395-4dc9-a9a5-d0cd992dabb2_terseLabel_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MCM Vaccine BV</link:label>
    <link:label id="lab_sny_MCMVaccineBVMember_label_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MCM Vaccine BV [Member]</link:label>
    <link:label id="lab_sny_MCMVaccineBVMember_documentation_en-US" xlink:label="lab_sny_MCMVaccineBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MCM Vaccine BV.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember" xlink:href="sny-20231231.xsd#sny_MCMVaccineBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MCMVaccineBVMember" xlink:to="lab_sny_MCMVaccineBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ConcentrationRiskThresholdPercentage_f7162a86-0b6c-401b-b0b9-d5734dbee9b1_terseLabel_en-US" xlink:label="lab_sny_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_sny_ConcentrationRiskThresholdPercentage_label_en-US" xlink:label="lab_sny_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Threshold Percentage</link:label>
    <link:label id="lab_sny_ConcentrationRiskThresholdPercentage_documentation_en-US" xlink:label="lab_sny_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk threshold percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConcentrationRiskThresholdPercentage" xlink:href="sny-20231231.xsd#sny_ConcentrationRiskThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ConcentrationRiskThresholdPercentage" xlink:to="lab_sny_ConcentrationRiskThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_c506ffcb-835a-4812-95a1-af7656df4b70_terseLabel_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of other intangible assets, net of reversals (excluding software)</link:label>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Loss On Intangible Assets Other Than Goodwill</link:label>
    <link:label id="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_documentation_en-US" xlink:label="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss on intangible assets other than goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:href="sny-20231231.xsd#sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:to="lab_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_b496582d-1c52-48f8-bb45-80b108b3ec9d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcarePolandSpZOOMember_3ad331d8-1797-45c1-a28f-064bce04834d_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcarePolandSpZOOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Poland sp.z.o.o.</link:label>
    <link:label id="lab_sny_OpellaHealthcarePolandSpZOOMember_label_en-US" xlink:label="lab_sny_OpellaHealthcarePolandSpZOOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Poland sp.Z.O.O [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcarePolandSpZOOMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcarePolandSpZOOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Poland sp.Z.O.O</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcarePolandSpZOOMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcarePolandSpZOOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcarePolandSpZOOMember" xlink:to="lab_sny_OpellaHealthcarePolandSpZOOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock_55011fee-1e3b-4ee6-9b6a-218e03d26291_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Inventories [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of detailed information about inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UniformImpairmentTestingPercentage_780bc8f4-6687-4de8-863f-7ca189cf9213_terseLabel_en-US" xlink:label="lab_sny_UniformImpairmentTestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uniform impairment testing percentage</link:label>
    <link:label id="lab_sny_UniformImpairmentTestingPercentage_label_en-US" xlink:label="lab_sny_UniformImpairmentTestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uniform Impairment Testing Percentage</link:label>
    <link:label id="lab_sny_UniformImpairmentTestingPercentage_documentation_en-US" xlink:label="lab_sny_UniformImpairmentTestingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uniform impairment testing percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UniformImpairmentTestingPercentage" xlink:href="sny-20231231.xsd#sny_UniformImpairmentTestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UniformImpairmentTestingPercentage" xlink:to="lab_sny_UniformImpairmentTestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_87a420e9-e220-4cfc-9c77-6f706583b4e1_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year 2</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_aa3b8134-40bb-4641-afd9-cf7b137b3a3f_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1&#160;to&#160;2 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ContingentConsiderationLiabilities_51e4c2e2-8acf-4632-910c-249fb353bd40_terseLabel_en-US" xlink:label="lab_sny_ContingentConsiderationLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities</link:label>
    <link:label id="lab_sny_ContingentConsiderationLiabilities_label_en-US" xlink:label="lab_sny_ContingentConsiderationLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liabilities</link:label>
    <link:label id="lab_sny_ContingentConsiderationLiabilities_documentation_en-US" xlink:label="lab_sny_ContingentConsiderationLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationLiabilities" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ContingentConsiderationLiabilities" xlink:to="lab_sny_ContingentConsiderationLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeTable_35b758b9-26cf-4508-b5c1-e343fa51e32d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Operating Income [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeTable_label_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Operating Income [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherOperatingIncomeTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherOperatingIncomeTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Operating Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeTable" xlink:to="lab_sny_DisclosureOfOtherOperatingIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_09b4ba29-4efc-4d86-ac7d-d41077b0609a_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_18504775-e093-4be0-9f17-8276a606676f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1e04c2a8-5b87-4841-84ce-5d6b57153eeb_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WorldHealthOrganizationMember_bd9645ff-e787-431b-b2e6-1669f08bda69_terseLabel_en-US" xlink:label="lab_sny_WorldHealthOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">World Health Organization</link:label>
    <link:label id="lab_sny_WorldHealthOrganizationMember_label_en-US" xlink:label="lab_sny_WorldHealthOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">World Health Organization [member]</link:label>
    <link:label id="lab_sny_WorldHealthOrganizationMember_documentation_en-US" xlink:label="lab_sny_WorldHealthOrganizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">World Health Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WorldHealthOrganizationMember" xlink:href="sny-20231231.xsd#sny_WorldHealthOrganizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WorldHealthOrganizationMember" xlink:to="lab_sny_WorldHealthOrganizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SpecialDistributionNumberOfSharesConverted_64d0b9d3-f8f5-40f9-bec2-f2bbd6ea1e1d_terseLabel_en-US" xlink:label="lab_sny_SpecialDistributionNumberOfSharesConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special distribution, number of shares converted (in shares)</link:label>
    <link:label id="lab_sny_SpecialDistributionNumberOfSharesConverted_label_en-US" xlink:label="lab_sny_SpecialDistributionNumberOfSharesConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Distribution, Number Of Shares Converted</link:label>
    <link:label id="lab_sny_SpecialDistributionNumberOfSharesConverted_documentation_en-US" xlink:label="lab_sny_SpecialDistributionNumberOfSharesConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Distribution, Number Of Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialDistributionNumberOfSharesConverted" xlink:href="sny-20231231.xsd#sny_SpecialDistributionNumberOfSharesConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SpecialDistributionNumberOfSharesConverted" xlink:to="lab_sny_SpecialDistributionNumberOfSharesConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessOperatingIncome_4fe0261c-17d2-4061-aa7f-b4361265cdb5_totalLabel_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business operating income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_7b81d139-9892-4c6a-95ca-199aa3c21ee8_terseLabel_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business operating income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_label_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Operating Income</link:label>
    <link:label id="lab_sny_BusinessOperatingIncome_documentation_en-US" xlink:label="lab_sny_BusinessOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business operating income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome" xlink:href="sny-20231231.xsd#sny_BusinessOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessOperatingIncome" xlink:to="lab_sny_BusinessOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level1OfFairValueHierarchyMember_7790454c-5c5f-453e-a7ed-3e68fcd087da_terseLabel_en-US" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_ifrs-full_Level1OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock_c3ffd25f-731e-4ff5-8502-f86b418917f6_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets Held for Sale or Exchange, and Liabilities Related to Assets Held for Sale or Exchange</link:label>
    <link:label id="lab_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Assets Held For Sale Or Exchange And Related Liabilities [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of assets held for sale or exchange and related liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock" xlink:to="lab_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_6dc03135-6158-4b14-bbcf-9674784ef90b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hyperinflation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about hyperinflationary reporting [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:to="lab_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_aa696db6-59df-47c0-b74c-41c466b55290_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Subsidiaries [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2021Member_8cdcdb3b-b8f3-438f-a3b8-3d9f80e38b00_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share plan 2021</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2021Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plan 2021 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2021Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plan 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2021Member" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2021Member" xlink:to="lab_sny_RestrictedSharePlan2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_cf6ace5c-6154-433c-a9b3-425f3dae5984_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about Principal Alliances [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Principal Alliances [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about Principal Alliances [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems" xlink:to="lab_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiHealthcareIndiaPrivateLimitedMember_59222491-8e2d-452b-b4ee-2e0ba08dace7_terseLabel_en-US" xlink:label="lab_sny_SanofiHealthcareIndiaPrivateLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Healthcare India Private Limited</link:label>
    <link:label id="lab_sny_SanofiHealthcareIndiaPrivateLimitedMember_label_en-US" xlink:label="lab_sny_SanofiHealthcareIndiaPrivateLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Healthcare India Private Limited [Member]</link:label>
    <link:label id="lab_sny_SanofiHealthcareIndiaPrivateLimitedMember_documentation_en-US" xlink:label="lab_sny_SanofiHealthcareIndiaPrivateLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Healthcare India Private Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiHealthcareIndiaPrivateLimitedMember" xlink:href="sny-20231231.xsd#sny_SanofiHealthcareIndiaPrivateLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiHealthcareIndiaPrivateLimitedMember" xlink:to="lab_sny_SanofiHealthcareIndiaPrivateLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLineItems_edc75b02-311b-49de-9a07-533461106126_terseLabel_en-US" xlink:label="lab_dei_AuditorLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Line Items]</link:label>
    <link:label id="lab_dei_AuditorLineItems_label_en-US" xlink:label="lab_dei_AuditorLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLineItems" xlink:to="lab_dei_AuditorLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32_5c332dfe-65fa-42d5-99fe-909ad05f5b76_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts offset (in accordance with IAS 32)</link:label>
    <link:label id="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32_label_en-US" xlink:label="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Assets And Liabilities, Gross Amounts Offset In Accordance With IAS 32</link:label>
    <link:label id="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial assets and liabilities gross amounts offset in accordance with IAS 32.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" xlink:to="lab_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_72d3e2f6-b53c-4848-a642-e34fbf2fffd2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_12a3680d-7a9c-49a8-bbf4-48f6593614b4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RegeneronMember_70fc9d06-8e38-42a2-a487-8409e8ecd169_terseLabel_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron</link:label>
    <link:label id="lab_sny_RegeneronMember_label_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron [Member]</link:label>
    <link:label id="lab_sny_RegeneronMember_documentation_en-US" xlink:label="lab_sny_RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember" xlink:href="sny-20231231.xsd#sny_RegeneronMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RegeneronMember" xlink:to="lab_sny_RegeneronMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset_879f2442-714c-45cd-a350-74127a186088_totalLabel_en-US" xlink:label="lab_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense/(gain) for the period</link:label>
    <link:label id="lab_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Gain For The Period Net Defined Benefit Liability Asset</link:label>
    <link:label id="lab_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset_documentation_en-US" xlink:label="lab_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense/(gain) for the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" xlink:href="sny-20231231.xsd#sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" xlink:to="lab_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsReceivedForDevelopmentCosts_b3497551-8f18-4d51-8d56-7248359aeecf_terseLabel_en-US" xlink:label="lab_sny_CommitmentsReceivedForDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments received for development costs</link:label>
    <link:label id="lab_sny_CommitmentsReceivedForDevelopmentCosts_label_en-US" xlink:label="lab_sny_CommitmentsReceivedForDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Received For Development Costs</link:label>
    <link:label id="lab_sny_CommitmentsReceivedForDevelopmentCosts_documentation_en-US" xlink:label="lab_sny_CommitmentsReceivedForDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Received For Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsReceivedForDevelopmentCosts" xlink:href="sny-20231231.xsd#sny_CommitmentsReceivedForDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsReceivedForDevelopmentCosts" xlink:to="lab_sny_CommitmentsReceivedForDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AuditorsRemuneration_2e7db830-e240-41a2-b578-de1b78adb2e5_totalLabel_en-US" xlink:label="lab_ifrs-full_AuditorsRemuneration" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_AuditorsRemuneration_label_en-US" xlink:label="lab_ifrs-full_AuditorsRemuneration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor's remuneration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemuneration" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemuneration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AuditorsRemuneration" xlink:to="lab_ifrs-full_AuditorsRemuneration" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock_b5a6e3af-e7c1-4b62-9472-aff58d6f7dd7_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Information for Principal Marketed Products</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Principal Marketed Products [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of principal marketed products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfPrincipalMarketedProductsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock" xlink:to="lab_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReclassifiedItemsMember_890bf930-0bc5-42be-81b7-2ce416e5a065_terseLabel_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassified items</link:label>
    <link:label id="lab_ifrs-full_ReclassifiedItemsMember_label_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassified items [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassifiedItemsMember" xlink:to="lab_ifrs-full_ReclassifiedItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BenefitsPaidOrPayable_d5e32e30-0575-4006-b6bf-b021a9e31df8_negatedLabel_en-US" xlink:label="lab_ifrs-full_BenefitsPaidOrPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_ifrs-full_BenefitsPaidOrPayable_label_en-US" xlink:label="lab_ifrs-full_BenefitsPaidOrPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid or payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BenefitsPaidOrPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BenefitsPaidOrPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BenefitsPaidOrPayable" xlink:to="lab_ifrs-full_BenefitsPaidOrPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_be4a091c-4cec-4a31-9c66-6eaebc46a565_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of voting rights held in subsidiary</link:label>
    <link:label id="lab_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_label_en-US" xlink:label="lab_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of voting rights held in subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:to="lab_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_9aeefac0-9970-45b5-a6e2-7130c355b7a0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember_5aa6120c-a093-42a1-b63a-c758928d4323_terseLabel_en-US" xlink:label="lab_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shenzhen Sanofi pasteur Biological Products Co, Ltd</link:label>
    <link:label id="lab_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember_label_en-US" xlink:label="lab_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shenzhen Sanofi Pasteur Biological Products Co Ltd [Member]</link:label>
    <link:label id="lab_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember_documentation_en-US" xlink:label="lab_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shenzhen Sanofi Pasteur Biological Products Co, Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember" xlink:href="sny-20231231.xsd#sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember" xlink:to="lab_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DefinedBenefitPensionPlansMember_eef8f4d2-dbad-445a-b919-f068ec4eb5d4_terseLabel_en-US" xlink:label="lab_sny_DefinedBenefitPensionPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit pension plans</link:label>
    <link:label id="lab_sny_DefinedBenefitPensionPlansMember_label_en-US" xlink:label="lab_sny_DefinedBenefitPensionPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plans [Member]</link:label>
    <link:label id="lab_sny_DefinedBenefitPensionPlansMember_documentation_en-US" xlink:label="lab_sny_DefinedBenefitPensionPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit pension plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefinedBenefitPensionPlansMember" xlink:href="sny-20231231.xsd#sny_DefinedBenefitPensionPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DefinedBenefitPensionPlansMember" xlink:to="lab_sny_DefinedBenefitPensionPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_f5382931-a305-4f70-9440-03d76a2005d3_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount_b17c0417-b633-4c19-aac4-7e931689f0c3_terseLabel_en-US" xlink:label="lab_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal amount</link:label>
    <link:label id="lab_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount_label_en-US" xlink:label="lab_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Loss Recognised In Profit Or Loss, Intangible Assets Other Than Goodwill, Reversal Amount</link:label>
    <link:label id="lab_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount_documentation_en-US" xlink:label="lab_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Loss Recognised In Profit Or Loss, Intangible Assets Other Than Goodwill, Reversal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" xlink:href="sny-20231231.xsd#sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" xlink:to="lab_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OfficeSpaceCambridgeMassachusettsMember_16dbf0c8-f428-4a87-b011-e4199d4b5880_terseLabel_en-US" xlink:label="lab_sny_OfficeSpaceCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space, Cambridge, Massachusetts</link:label>
    <link:label id="lab_sny_OfficeSpaceCambridgeMassachusettsMember_label_en-US" xlink:label="lab_sny_OfficeSpaceCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space, Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_sny_OfficeSpaceCambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_sny_OfficeSpaceCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space, Cambridge, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OfficeSpaceCambridgeMassachusettsMember" xlink:href="sny-20231231.xsd#sny_OfficeSpaceCambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OfficeSpaceCambridgeMassachusettsMember" xlink:to="lab_sny_OfficeSpaceCambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisFranceMember_6db7cbe5-bf24-4202-9a5c-2e1c8f0d9c5e_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis France</link:label>
    <link:label id="lab_sny_SanofiAventisFranceMember_label_en-US" xlink:label="lab_sny_SanofiAventisFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis France [member]</link:label>
    <link:label id="lab_sny_SanofiAventisFranceMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis France.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisFranceMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisFranceMember" xlink:to="lab_sny_SanofiAventisFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurBiologiesCo.LtdMember_0394e6dc-60af-474c-8119-7a7490a393b5_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurBiologiesCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Biologies Co., Ltd</link:label>
    <link:label id="lab_sny_SanofiPasteurBiologiesCo.LtdMember_label_en-US" xlink:label="lab_sny_SanofiPasteurBiologiesCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Biologies Co., Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiPasteurBiologiesCo.LtdMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurBiologiesCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Biologies Co., Ltd [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurBiologiesCo.LtdMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurBiologiesCo.LtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurBiologiesCo.LtdMember" xlink:to="lab_sny_SanofiPasteurBiologiesCo.LtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GovernmentAndStateProgramsMember_ee40ea58-f564-4a30-8f3c-17c65f62d988_terseLabel_en-US" xlink:label="lab_sny_GovernmentAndStateProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and State Programs</link:label>
    <link:label id="lab_sny_GovernmentAndStateProgramsMember_label_en-US" xlink:label="lab_sny_GovernmentAndStateProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government And State Programs [Member]</link:label>
    <link:label id="lab_sny_GovernmentAndStateProgramsMember_documentation_en-US" xlink:label="lab_sny_GovernmentAndStateProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and state programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentAndStateProgramsMember" xlink:href="sny-20231231.xsd#sny_GovernmentAndStateProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GovernmentAndStateProgramsMember" xlink:to="lab_sny_GovernmentAndStateProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_3b732264-b760-49c7-bae4-f6075b6e803a_terseLabel_en-US" xlink:label="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions And Other Current And Non-Current Liabilities [Line Items]</link:label>
    <link:label id="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_label_en-US" xlink:label="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions And Other Current And Non-Current Liabilities [Line Items]</link:label>
    <link:label id="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_documentation_en-US" xlink:label="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions and other current and non-current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems" xlink:to="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CostOfDebtNet_24971dfe-50c3-43b5-a3b9-a8b974cd2f6a_negatedTotalLabel_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of net debt</link:label>
    <link:label id="lab_sny_CostOfDebtNet_label_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Debt Net</link:label>
    <link:label id="lab_sny_CostOfDebtNet_documentation_en-US" xlink:label="lab_sny_CostOfDebtNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of debt net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet" xlink:href="sny-20231231.xsd#sny_CostOfDebtNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CostOfDebtNet" xlink:to="lab_sny_CostOfDebtNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_0afb3654-e222-45da-b111-03e615e3e4e8_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsQunolMember_12ebfcc9-4f68-4dfd-b282-763d990ef20d_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsQunolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUNOL</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsQunolMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsQunolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Qunol [Member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsQunolMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsQunolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Qunol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsQunolMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsQunolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsQunolMember" xlink:to="lab_sny_PrincipalMarketedProductsQunolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_6ef3c4a7-ca5b-4925-b8b2-a84183b29a89_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of cash flow hedges</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on cash flow hedges, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementWithGSKMember_08b39132-f684-4037-bf15-d1ef54435d86_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementWithGSKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement with GSK</link:label>
    <link:label id="lab_sny_CollaborationAgreementWithGSKMember_label_en-US" xlink:label="lab_sny_CollaborationAgreementWithGSKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With GSK [Member]</link:label>
    <link:label id="lab_sny_CollaborationAgreementWithGSKMember_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementWithGSKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With GSK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementWithGSKMember" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementWithGSKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementWithGSKMember" xlink:to="lab_sny_CollaborationAgreementWithGSKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock_3e76aa63-b61e-412e-8f4f-5b523f917398_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Currency Translation Differences</link:label>
    <link:label id="lab_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reserve Of Exchange Differences On Translation [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of reserve of exchange differences on translation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock" xlink:to="lab_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_d6c71b72-7b20-4fe4-aecd-e7d8b620f8ac_terseLabel_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt at redemption</link:label>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_label_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Of Debt Instrument Issued</link:label>
    <link:label id="lab_sny_RedemptionOfDebtInstrumentIssued_documentation_en-US" xlink:label="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption of debt instrument issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued" xlink:href="sny-20231231.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RedemptionOfDebtInstrumentIssued" xlink:to="lab_sny_RedemptionOfDebtInstrumentIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_0a3eeb98-c087-4f36-99b4-37a546a7923f_verboseLabel_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixtures</link:label>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_c052651e-f3d8-4197-a965-4bd78258631d_terseLabel_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixtures, fittings&#160;and other</link:label>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_label_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixtures and fittings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixturesAndFittingsMember" xlink:to="lab_ifrs-full_FixturesAndFittingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlavixMember_53c2360f-63c4-4f25-90cd-a522d5636cd2_terseLabel_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLAVIX</link:label>
    <link:label id="lab_sny_PlavixMember_label_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plavix [Member]</link:label>
    <link:label id="lab_sny_PlavixMember_documentation_en-US" xlink:label="lab_sny_PlavixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plavix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember" xlink:href="sny-20231231.xsd#sny_PlavixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlavixMember" xlink:to="lab_sny_PlavixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_June2018SNFISINUS801060AC87Member_f3afb1bb-b941-4243-b564-291c7faa92a6_terseLabel_en-US" xlink:label="lab_sny_June2018SNFISINUS801060AC87Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2018 SNF ISIN US801060AC87</link:label>
    <link:label id="lab_sny_June2018SNFISINUS801060AC87Member_label_en-US" xlink:label="lab_sny_June2018SNFISINUS801060AC87Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2018 SNFISINUS801060AC87 [member]</link:label>
    <link:label id="lab_sny_June2018SNFISINUS801060AC87Member_documentation_en-US" xlink:label="lab_sny_June2018SNFISINUS801060AC87Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2018SNFISINUS801060AC87.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_June2018SNFISINUS801060AC87Member" xlink:href="sny-20231231.xsd#sny_June2018SNFISINUS801060AC87Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_June2018SNFISINUS801060AC87Member" xlink:to="lab_sny_June2018SNFISINUS801060AC87Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_KiadisMember_f12eb9f5-04c1-4796-9eab-f0a76ebd05f9_terseLabel_en-US" xlink:label="lab_sny_KiadisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kiadis</link:label>
    <link:label id="lab_sny_KiadisMember_label_en-US" xlink:label="lab_sny_KiadisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kiadis [Member]</link:label>
    <link:label id="lab_sny_KiadisMember_documentation_en-US" xlink:label="lab_sny_KiadisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kiadis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KiadisMember" xlink:href="sny-20231231.xsd#sny_KiadisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_KiadisMember" xlink:to="lab_sny_KiadisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level3OfFairValueHierarchyMember_f45bb1d7-f128-493f-a1ff-aa7b6ef4bc09_terseLabel_en-US" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_ifrs-full_Level3OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NorthAmericaMember_5621088b-6661-45cd-975d-77f52463ff43_terseLabel_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America</link:label>
    <link:label id="lab_srt_NorthAmericaMember_label_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfPatentsCoveringProduct_f65852fa-0795-4af1-a8fe-2e061c55d99f_terseLabel_en-US" xlink:label="lab_sny_NumberOfPatentsCoveringProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents covering product</link:label>
    <link:label id="lab_sny_NumberOfPatentsCoveringProduct_label_en-US" xlink:label="lab_sny_NumberOfPatentsCoveringProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patents Covering Product</link:label>
    <link:label id="lab_sny_NumberOfPatentsCoveringProduct_documentation_en-US" xlink:label="lab_sny_NumberOfPatentsCoveringProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patents Covering Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatentsCoveringProduct" xlink:href="sny-20231231.xsd#sny_NumberOfPatentsCoveringProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfPatentsCoveringProduct" xlink:to="lab_sny_NumberOfPatentsCoveringProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_87d30564-803e-4b56-ad6c-3187844529b3_terseLabel_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_label_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:label id="lab_sny_LegalAndArbitralProceedingsAxis_documentation_en-US" xlink:label="lab_sny_LegalAndArbitralProceedingsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Arbitral Proceedings [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis" xlink:href="sny-20231231.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis" xlink:to="lab_sny_LegalAndArbitralProceedingsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_5ab34068-73e8-4d37-a867-18928c705e54_terseLabel_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions and other current liabilities</link:label>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_c3164ccf-4e70-4678-9177-64cc6c4321b3_totalLabel_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions And Other Current Liabilities</link:label>
    <link:label id="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:href="sny-20231231.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:to="lab_sny_CurrentProvisionsAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationPurchasePrice_d1b7a372-3623-413c-85e9-74304776f272_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, purchase price</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePrice_label_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Purchase Price</link:label>
    <link:label id="lab_sny_BusinessCombinationPurchasePrice_documentation_en-US" xlink:label="lab_sny_BusinessCombinationPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePrice" xlink:href="sny-20231231.xsd#sny_BusinessCombinationPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationPurchasePrice" xlink:to="lab_sny_BusinessCombinationPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_06b49d77-2edb-4444-919e-f1e8ee62fca6_terseLabel_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per share awarded (in euros per share)</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_label_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Per Share Awarded For Three Year Service Period</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod_documentation_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per share awarded to a three year service period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:href="sny-20231231.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:to="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfSales_5818eb02-9af9-438b-828d-1f578146f17c_negatedLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_0059d817-b5de-46b0-9500-17f3e394cada_terseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_label_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales" xlink:to="lab_ifrs-full_CostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_00ab75dd-b28e-4ad8-bdca-1d7775fd3750_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year and not later than five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiBeijingPharmaceuticalsCoLtdMember_50c536ac-061a-4506-b8ab-cb3efd5214b0_terseLabel_en-US" xlink:label="lab_sny_SanofiBeijingPharmaceuticalsCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi (Beijing) Pharmaceuticals Co.Ltd</link:label>
    <link:label id="lab_sny_SanofiBeijingPharmaceuticalsCoLtdMember_label_en-US" xlink:label="lab_sny_SanofiBeijingPharmaceuticalsCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Beijing Pharmaceuticals Co Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiBeijingPharmaceuticalsCoLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiBeijingPharmaceuticalsCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Beijing Pharmaceuticals Co.Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBeijingPharmaceuticalsCoLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiBeijingPharmaceuticalsCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiBeijingPharmaceuticalsCoLtdMember" xlink:to="lab_sny_SanofiBeijingPharmaceuticalsCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_b3ea1304-ad10-4e08-bc54-dfacfa35480f_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US dollar</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_595e14d3-3500-4ccd-b35a-4c2a2c057e0a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off Setting Of Financial Assets And Liabilities [table]</link:label>
    <link:label id="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_label_en-US" xlink:label="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off Setting Of Financial Assets And Liabilities [table]</link:label>
    <link:label id="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off Setting Of Financial Assets And Liabilities [table].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable" xlink:to="lab_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImmunooncologyAllianceMember_ca433371-c095-499c-baea-fb95af7ead05_terseLabel_en-US" xlink:label="lab_sny_ImmunooncologyAllianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno-Oncology Alliance</link:label>
    <link:label id="lab_sny_ImmunooncologyAllianceMember_label_en-US" xlink:label="lab_sny_ImmunooncologyAllianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno-oncology Alliance [Member]</link:label>
    <link:label id="lab_sny_ImmunooncologyAllianceMember_documentation_en-US" xlink:label="lab_sny_ImmunooncologyAllianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno-oncology Alliance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunooncologyAllianceMember" xlink:href="sny-20231231.xsd#sny_ImmunooncologyAllianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImmunooncologyAllianceMember" xlink:to="lab_sny_ImmunooncologyAllianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations_7709ce44-2bb2-4a21-bf59-d58c24baf0df_terseLabel_en-US" xlink:label="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales arising from commercial operations</link:label>
    <link:label id="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations_label_en-US" xlink:label="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Net Sales Arising From Commercial Operations</link:label>
    <link:label id="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations_documentation_en-US" xlink:label="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Net Sales Arising From Commercial Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:href="sny-20231231.xsd#sny_PercentageOfNetSalesArisingFromCommercialOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:to="lab_sny_PercentageOfNetSalesArisingFromCommercialOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_b9b49ecc-2fc2-478d-87df-c0abb049522d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personnel costs</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about employees [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OneBillionBondsMaturingNovember2023Member_8d74ac9f-f1b4-4d37-a2e3-5b5664fbf9c6_terseLabel_en-US" xlink:label="lab_sny_OneBillionBondsMaturingNovember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#8364;1,000 million bonds maturing November 2023</link:label>
    <link:label id="lab_sny_OneBillionBondsMaturingNovember2023Member_label_en-US" xlink:label="lab_sny_OneBillionBondsMaturingNovember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Billion Bonds Maturing November 2023 [Member]</link:label>
    <link:label id="lab_sny_OneBillionBondsMaturingNovember2023Member_documentation_en-US" xlink:label="lab_sny_OneBillionBondsMaturingNovember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Billion Bonds Maturing November 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingNovember2023Member" xlink:href="sny-20231231.xsd#sny_OneBillionBondsMaturingNovember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OneBillionBondsMaturingNovember2023Member" xlink:to="lab_sny_OneBillionBondsMaturingNovember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans_64060168-a585-4ca5-81df-c691f0804bbe_terseLabel_en-US" xlink:label="lab_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains and losses on defined-benefit plans</link:label>
    <link:label id="lab_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans_label_en-US" xlink:label="lab_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Gains And Losses On Defined Benefit Plans</link:label>
    <link:label id="lab_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans_documentation_en-US" xlink:label="lab_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains and losses on defined-benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans" xlink:href="sny-20231231.xsd#sny_ActuarialGainsAndLossesOnDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans" xlink:to="lab_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentFinancialAssets_9ea9d7b7-f4db-43a7-a161-98f634849cd3_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current financial assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentFinancialAssets" xlink:to="lab_ifrs-full_OtherCurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_0612fbd2-0652-422b-abed-95b43f2a5d75_terseLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability risks, litigation and other</link:label>
    <link:label id="lab_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_3752c57e-7e4c-44f1-8b91-472ed793e744_verboseLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for product liability risks, litigation and other</link:label>
    <link:label id="lab_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_label_en-US" xlink:label="lab_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Provision For Product Liability Risks Litigation And Other</link:label>
    <link:label id="lab_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_documentation_en-US" xlink:label="lab_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability risks litigation and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" xlink:to="lab_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PublicOfferingMember_9694309b-5856-4f4e-ae31-310a04601d4e_terseLabel_en-US" xlink:label="lab_sny_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_sny_PublicOfferingMember_label_en-US" xlink:label="lab_sny_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_sny_PublicOfferingMember_documentation_en-US" xlink:label="lab_sny_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PublicOfferingMember" xlink:href="sny-20231231.xsd#sny_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PublicOfferingMember" xlink:to="lab_sny_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_76bdcd86-a04f-4e18-9f2b-08738d28673f_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Characteristics of Employee Share Ownership Plans Awarded</link:label>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Employee Stock Ownership Plan Awarded In Capital Increase Reserved Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_1e0518b8-142e-482a-be92-62f7574a482f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments and market risks</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of derivative financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030_c718c805-f12a-4743-9743-e6bb01942ad3_terseLabel_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program, percentage of reduction in scope 1 and 2 greenhouse gas by 2030</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030_label_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Percentage Of Reduction In Scope 1 And 2 Greenhouse Gas By 2030</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030_documentation_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Percentage Of Reduction In Scope 1 And 2 Greenhouse Gas By 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030" xlink:to="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOnRedemptionMember_4fb05bc1-bb55-4890-9620-a42050c7156e_terseLabel_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value on redemption</link:label>
    <link:label id="lab_sny_ValueOnRedemptionMember_label_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value On Redemption [Member]</link:label>
    <link:label id="lab_sny_ValueOnRedemptionMember_documentation_en-US" xlink:label="lab_sny_ValueOnRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOnRedemptionMember" xlink:to="lab_sny_ValueOnRedemptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_7923c959-b899-4753-a203-68052f32a88a_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementAnnualNetSalesTarget_a1c5f1f2-63fb-4474-acc1-8f9a0cb0c5d0_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementAnnualNetSalesTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, annual net sales target</link:label>
    <link:label id="lab_sny_CollaborationAgreementAnnualNetSalesTarget_label_en-US" xlink:label="lab_sny_CollaborationAgreementAnnualNetSalesTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Net Sales Target</link:label>
    <link:label id="lab_sny_CollaborationAgreementAnnualNetSalesTarget_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementAnnualNetSalesTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Net Sales Target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementAnnualNetSalesTarget" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementAnnualNetSalesTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementAnnualNetSalesTarget" xlink:to="lab_sny_CollaborationAgreementAnnualNetSalesTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsRecordedForFutureOperatingLosses_84263379-173b-467b-80af-76826db8656e_terseLabel_en-US" xlink:label="lab_sny_ProvisionsRecordedForFutureOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions recorded for future operating losses</link:label>
    <link:label id="lab_sny_ProvisionsRecordedForFutureOperatingLosses_label_en-US" xlink:label="lab_sny_ProvisionsRecordedForFutureOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions Recorded For Future Operating Losses</link:label>
    <link:label id="lab_sny_ProvisionsRecordedForFutureOperatingLosses_documentation_en-US" xlink:label="lab_sny_ProvisionsRecordedForFutureOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions recorded for future operating losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsRecordedForFutureOperatingLosses" xlink:href="sny-20231231.xsd#sny_ProvisionsRecordedForFutureOperatingLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsRecordedForFutureOperatingLosses" xlink:to="lab_sny_ProvisionsRecordedForFutureOperatingLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_34aeccd8-ebcd-4d43-a982-0eec2045b9fd_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of debt</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MedicareMember_cbccfbb9-c996-4e87-84eb-6ab293c211f8_terseLabel_en-US" xlink:label="lab_sny_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_sny_MedicareMember_label_en-US" xlink:label="lab_sny_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_sny_MedicareMember_documentation_en-US" xlink:label="lab_sny_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MedicareMember" xlink:href="sny-20231231.xsd#sny_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MedicareMember" xlink:to="lab_sny_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount_78941a29-206b-45c4-9bef-15cf57c02f57_terseLabel_en-US" xlink:label="lab_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax impact on other comprehensive income</link:label>
    <link:label id="lab_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount_label_en-US" xlink:label="lab_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Instruments At Fair Value Through Other Comprehensive Income (Loss), 10% Decline In Credit Prices, Pre-tax Amount</link:label>
    <link:label id="lab_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount_documentation_en-US" xlink:label="lab_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Instruments At Fair Value Through Other Comprehensive Income (Loss), 10% Decline In Credit Prices, Pre-tax Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount" xlink:href="sny-20231231.xsd#sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount" xlink:to="lab_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_85920c0f-304d-4937-9425-c91b7895f864_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value of plan assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value of plan assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_September2015EMTNISINFR0012969038Member_064cfc94-a613-4921-bbc5-80231ec7b17a_terseLabel_en-US" xlink:label="lab_sny_September2015EMTNISINFR0012969038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2015 EMTN ISIN FR0012969038</link:label>
    <link:label id="lab_sny_September2015EMTNISINFR0012969038Member_label_en-US" xlink:label="lab_sny_September2015EMTNISINFR0012969038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2015 EMTNISINFR0012969038 [Member]</link:label>
    <link:label id="lab_sny_September2015EMTNISINFR0012969038Member_documentation_en-US" xlink:label="lab_sny_September2015EMTNISINFR0012969038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2015 EMTN ISIN FR0012969038.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_September2015EMTNISINFR0012969038Member" xlink:href="sny-20231231.xsd#sny_September2015EMTNISINFR0012969038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_September2015EMTNISINFR0012969038Member" xlink:to="lab_sny_September2015EMTNISINFR0012969038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansMember_7987017c-fc4c-4ff8-bd3a-1d59a9ce9911_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plans [member]</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitPlansMember_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plans [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember" xlink:to="lab_ifrs-full_DefinedBenefitPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_c04adc0a-9cbd-4273-b8d1-26b5909bfe2b_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend paid out of earnings</link:label>
    <link:label id="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends recognised as distributions to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:to="lab_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_d13ed032-04a0-4b50-bf73-cc09472fb4d8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated shareholders' equity</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase_5dd071ee-54c5-48f5-8521-f15422cc8f1d_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments related to research and development relating to projects in research phase</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Research And Development Relating To Projects In Research Phase</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Research And Development Relating To Projects In Research Phase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase" xlink:to="lab_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentAssetsMember_87c7ef11-b44c-4c00-8551-6a0bbf5dace0_terseLabel_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_sny_CurrentAssetsMember_label_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets [Member]</link:label>
    <link:label id="lab_sny_CurrentAssetsMember_documentation_en-US" xlink:label="lab_sny_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember" xlink:href="sny-20231231.xsd#sny_CurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentAssetsMember" xlink:to="lab_sny_CurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_c0fa25b9-eae9-4be8-98b0-a5a9cc6cd30c_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TransferPercentageOfPandemicVaccines_e0b9bfb0-c84e-4203-817e-0178daf4f82c_terseLabel_en-US" xlink:label="lab_sny_TransferPercentageOfPandemicVaccines" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of pandemic vaccines agreed to transfer</link:label>
    <link:label id="lab_sny_TransferPercentageOfPandemicVaccines_label_en-US" xlink:label="lab_sny_TransferPercentageOfPandemicVaccines" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Percentage Of Pandemic Vaccines</link:label>
    <link:label id="lab_sny_TransferPercentageOfPandemicVaccines_documentation_en-US" xlink:label="lab_sny_TransferPercentageOfPandemicVaccines" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer percentage of pandemic vaccines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TransferPercentageOfPandemicVaccines" xlink:href="sny-20231231.xsd#sny_TransferPercentageOfPandemicVaccines"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TransferPercentageOfPandemicVaccines" xlink:to="lab_sny_TransferPercentageOfPandemicVaccines" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermRestructuringProvision_1d0af221-ed35-489f-928e-93407e317516_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermRestructuringProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classified in non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_LongtermRestructuringProvision_label_en-US" xlink:label="lab_ifrs-full_LongtermRestructuringProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restructuring provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermRestructuringProvision" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermRestructuringProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermRestructuringProvision" xlink:to="lab_ifrs-full_LongtermRestructuringProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices_655a4feb-6f14-49d8-8928-35baef6691e6_terseLabel_en-US" xlink:label="lab_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor's remuneration for comfort letters and attestation services</link:label>
    <link:label id="lab_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices_label_en-US" xlink:label="lab_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor's Remuneration For Audit Related Services, Comfort Letters And Attestation Services</link:label>
    <link:label id="lab_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices_documentation_en-US" xlink:label="lab_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor's Remuneration For Audit Related Services, Comfort Letters And Attestation Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices" xlink:href="sny-20231231.xsd#sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices" xlink:to="lab_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CapitalLossesCarryBackPeriod_1b3af961-eace-4a98-a93c-4f5379b5b26d_terseLabel_en-US" xlink:label="lab_sny_CapitalLossesCarryBackPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital losses, carry back period</link:label>
    <link:label id="lab_sny_CapitalLossesCarryBackPeriod_label_en-US" xlink:label="lab_sny_CapitalLossesCarryBackPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Losses, Carry Back Period</link:label>
    <link:label id="lab_sny_CapitalLossesCarryBackPeriod_documentation_en-US" xlink:label="lab_sny_CapitalLossesCarryBackPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Losses, Carry Back Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CapitalLossesCarryBackPeriod" xlink:href="sny-20231231.xsd#sny_CapitalLossesCarryBackPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CapitalLossesCarryBackPeriod" xlink:to="lab_sny_CapitalLossesCarryBackPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiASMember_73074a23-45e0-4473-977f-019d25eadf57_terseLabel_en-US" xlink:label="lab_sny_SanofiASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi A/S</link:label>
    <link:label id="lab_sny_SanofiASMember_label_en-US" xlink:label="lab_sny_SanofiASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi A/S [Member]</link:label>
    <link:label id="lab_sny_SanofiASMember_documentation_en-US" xlink:label="lab_sny_SanofiASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi A/S [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiASMember" xlink:href="sny-20231231.xsd#sny_SanofiASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiASMember" xlink:to="lab_sny_SanofiASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DepakineProductLitigationInNorthernIrelandMember_d01f7379-3179-47c2-9af5-6871e45e0b5d_terseLabel_en-US" xlink:label="lab_sny_DepakineProductLitigationInNorthernIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine product litigation in Northern Ireland</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInNorthernIrelandMember_label_en-US" xlink:label="lab_sny_DepakineProductLitigationInNorthernIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Northern Ireland [Member]</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInNorthernIrelandMember_documentation_en-US" xlink:label="lab_sny_DepakineProductLitigationInNorthernIrelandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Northern Ireland</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInNorthernIrelandMember" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInNorthernIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DepakineProductLitigationInNorthernIrelandMember" xlink:to="lab_sny_DepakineProductLitigationInNorthernIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_f80f5837-fa7d-44b7-8794-400bfbae0928_netLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense for restricted share plans</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_1daedf4d-e2df-45a9-93a0-14d7ae158bdc_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense from equity-settled share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockOptionPlanMember_525356c6-7a6a-4c09-b32f-5b4f497410ca_terseLabel_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_sny_StockOptionPlanMember_label_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan [member]</link:label>
    <link:label id="lab_sny_StockOptionPlanMember_documentation_en-US" xlink:label="lab_sny_StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember" xlink:href="sny-20231231.xsd#sny_StockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockOptionPlanMember" xlink:to="lab_sny_StockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DepakineProductLitigationInGreatBritainMember_3f6145d3-9bdd-4995-81d7-f71127a4d0f3_terseLabel_en-US" xlink:label="lab_sny_DepakineProductLitigationInGreatBritainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine product litigation in Great Britain</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInGreatBritainMember_label_en-US" xlink:label="lab_sny_DepakineProductLitigationInGreatBritainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Great Britain [Member]</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInGreatBritainMember_documentation_en-US" xlink:label="lab_sny_DepakineProductLitigationInGreatBritainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Great Britain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInGreatBritainMember" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInGreatBritainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DepakineProductLitigationInGreatBritainMember" xlink:to="lab_sny_DepakineProductLitigationInGreatBritainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_73e9be3b-8f2c-4c04-b51b-094d781ff889_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value of plan assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value of plan assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_3b238e61-14e7-44f4-83b8-17024c20efea_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Principal Companies and their Country of Incorporation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of interests in subsidiaries [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering_0bf03ee7-0eef-4db1-b42e-2176eb454048_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of issued and outstanding share capital tendered into the public offer</link:label>
    <link:label id="lab_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering_label_en-US" xlink:label="lab_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Proportion Of Issued And Outstanding Share Capital Tendered Into The Offering</link:label>
    <link:label id="lab_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering_documentation_en-US" xlink:label="lab_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Proportion Of Issued And Outstanding Share Capital Tendered Into The Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering" xlink:href="sny-20231231.xsd#sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering" xlink:to="lab_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock_9acb3b56-4718-469b-9070-9012c9a6b71d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Options Outstanding at Each Balance Sheet Date</link:label>
    <link:label id="lab_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Stock Options Outstanding At Each Balance Sheet Date And Of Changes During The Relevant Periods [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of stock options outstanding at each balance sheet date and of changes during the relevant periods.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock" xlink:to="lab_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_079b3eae-c513-4c99-9117-ab6990680c8b_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive069Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ErnstAndYoungMember_24c40e67-4b81-4f93-9dfa-79630dbdf8f7_terseLabel_en-US" xlink:label="lab_sny_ErnstAndYoungMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ernst&#160;&amp;&#160;Young</link:label>
    <link:label id="lab_sny_ErnstAndYoungMember_label_en-US" xlink:label="lab_sny_ErnstAndYoungMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ernst And Young [Member]</link:label>
    <link:label id="lab_sny_ErnstAndYoungMember_documentation_en-US" xlink:label="lab_sny_ErnstAndYoungMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ernst And Young.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ErnstAndYoungMember" xlink:href="sny-20231231.xsd#sny_ErnstAndYoungMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ErnstAndYoungMember" xlink:to="lab_sny_ErnstAndYoungMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SPMSDContingentConsiderationAssetMember_e63944a6-3d07-4337-9937-936cf905b4fd_terseLabel_en-US" xlink:label="lab_sny_SPMSDContingentConsiderationAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPMSD contingent consideration asset</link:label>
    <link:label id="lab_sny_SPMSDContingentConsiderationAssetMember_label_en-US" xlink:label="lab_sny_SPMSDContingentConsiderationAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPMSD Contingent Consideration Asset [Member]</link:label>
    <link:label id="lab_sny_SPMSDContingentConsiderationAssetMember_documentation_en-US" xlink:label="lab_sny_SPMSDContingentConsiderationAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPMSD contingent consideration asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SPMSDContingentConsiderationAssetMember" xlink:href="sny-20231231.xsd#sny_SPMSDContingentConsiderationAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SPMSDContingentConsiderationAssetMember" xlink:to="lab_sny_SPMSDContingentConsiderationAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_694103a6-328b-43c2-a3e2-21a39b71e17c_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_March2018EMTNISINFR0013324357Member_44c61842-b8dd-4d47-9e87-e570ccee0faf_terseLabel_en-US" xlink:label="lab_sny_March2018EMTNISINFR0013324357Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2018 EMTN ISIN FR0013324357</link:label>
    <link:label id="lab_sny_March2018EMTNISINFR0013324357Member_label_en-US" xlink:label="lab_sny_March2018EMTNISINFR0013324357Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2018 EMTN ISIN FR0013324357 [Member]</link:label>
    <link:label id="lab_sny_March2018EMTNISINFR0013324357Member_documentation_en-US" xlink:label="lab_sny_March2018EMTNISINFR0013324357Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2018 EMTN ISIN FR 0013324357.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2018EMTNISINFR0013324357Member" xlink:href="sny-20231231.xsd#sny_March2018EMTNISINFR0013324357Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_March2018EMTNISINFR0013324357Member" xlink:to="lab_sny_March2018EMTNISINFR0013324357Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherRestructuringCost_ea477b5f-d076-4b8e-bf0e-fea43911aa80_terseLabel_en-US" xlink:label="lab_sny_OtherRestructuringCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sny_OtherRestructuringCost_label_en-US" xlink:label="lab_sny_OtherRestructuringCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring Cost</link:label>
    <link:label id="lab_sny_OtherRestructuringCost_documentation_en-US" xlink:label="lab_sny_OtherRestructuringCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other restructuring cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCost" xlink:href="sny-20231231.xsd#sny_OtherRestructuringCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherRestructuringCost" xlink:to="lab_sny_OtherRestructuringCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisParticipationsSASMember_56d54638-b6c1-4d00-8086-bf558b420c22_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisParticipationsSASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Participations</link:label>
    <link:label id="lab_sny_SanofiAventisParticipationsSASMember_label_en-US" xlink:label="lab_sny_SanofiAventisParticipationsSASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Participations SAS [member]</link:label>
    <link:label id="lab_sny_SanofiAventisParticipationsSASMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisParticipationsSASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Participations SAS.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisParticipationsSASMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisParticipationsSASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisParticipationsSASMember" xlink:to="lab_sny_SanofiAventisParticipationsSASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_01276742-253c-46ac-972a-ac346d401303_terseLabel_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedges of net investments in foreign operations</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_label_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Currency Translation On Hedges Of Net Investments In Foreign Operations</link:label>
    <link:label id="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_documentation_en-US" xlink:label="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in currency translation on hedges of net investments in foreign operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:to="lab_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_3a14c82e-948c-4919-8113-f1a36eef5983_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Market Value of Net Debt</link:label>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Market Value Of Net Debt [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of market value of net debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfMarketValueOfNetDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:to="lab_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent_37d781dc-babb-4336-9e90-23ce62cb855a_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current income tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax liabilities, non-current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashAndCashEquivalents1Member_bc984695-92b9-456b-9291-6ad446c05b54_terseLabel_en-US" xlink:label="lab_sny_CashAndCashEquivalents1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_sny_CashAndCashEquivalents1Member_label_en-US" xlink:label="lab_sny_CashAndCashEquivalents1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents1 [Member]</link:label>
    <link:label id="lab_sny_CashAndCashEquivalents1Member_documentation_en-US" xlink:label="lab_sny_CashAndCashEquivalents1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalents1Member" xlink:href="sny-20231231.xsd#sny_CashAndCashEquivalents1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashAndCashEquivalents1Member" xlink:to="lab_sny_CashAndCashEquivalents1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_8a9f12b8-62b6-4599-aaf0-d6b8724f79d4_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of investments accounted for using equity method</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of investments accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_e7640954-b5e0-4c71-8f17-0ec258658b25_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax relating to cash flow hedges included in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:to="lab_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PolioPertussisHibVaccinesMember_7e73fe15-1d9c-4fa9-91b7-8670647e36b9_terseLabel_en-US" xlink:label="lab_sny_PolioPertussisHibVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polio/Pertussis/ Hib Vaccines</link:label>
    <link:label id="lab_sny_PolioPertussisHibVaccinesMember_label_en-US" xlink:label="lab_sny_PolioPertussisHibVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polio Pertussis Hib Vaccines [Member]</link:label>
    <link:label id="lab_sny_PolioPertussisHibVaccinesMember_documentation_en-US" xlink:label="lab_sny_PolioPertussisHibVaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Polio Pertussis Hib Vaccines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibVaccinesMember" xlink:href="sny-20231231.xsd#sny_PolioPertussisHibVaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PolioPertussisHibVaccinesMember" xlink:to="lab_sny_PolioPertussisHibVaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LovenoxMember_d5b48057-add1-4d19-beac-874ae1926767_terseLabel_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOVENOX</link:label>
    <link:label id="lab_sny_LovenoxMember_label_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lovenox [Member]</link:label>
    <link:label id="lab_sny_LovenoxMember_documentation_en-US" xlink:label="lab_sny_LovenoxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lovenox.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember" xlink:href="sny-20231231.xsd#sny_LovenoxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LovenoxMember" xlink:to="lab_sny_LovenoxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxExpense_77947aa2-59c4-442f-af38-7f1cf68d999a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in deferred taxes</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for deferred tax expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:to="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SECIPESASMember_6378920b-18ea-4524-921b-bc80f6d281d4_terseLabel_en-US" xlink:label="lab_sny_SECIPESASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SECIPE SAS</link:label>
    <link:label id="lab_sny_SECIPESASMember_label_en-US" xlink:label="lab_sny_SECIPESASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SECIPE SAS [Member]</link:label>
    <link:label id="lab_sny_SECIPESASMember_documentation_en-US" xlink:label="lab_sny_SECIPESASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SECIPE SAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SECIPESASMember" xlink:href="sny-20231231.xsd#sny_SECIPESASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SECIPESASMember" xlink:to="lab_sny_SECIPESASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiChimieMember_dedbd229-4cb2-48cd-986c-e3a8cfde0f17_terseLabel_en-US" xlink:label="lab_sny_SanofiChimieMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Chimie</link:label>
    <link:label id="lab_sny_SanofiChimieMember_label_en-US" xlink:label="lab_sny_SanofiChimieMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Chimie [member]</link:label>
    <link:label id="lab_sny_SanofiChimieMember_documentation_en-US" xlink:label="lab_sny_SanofiChimieMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Chimie.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiChimieMember" xlink:href="sny-20231231.xsd#sny_SanofiChimieMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiChimieMember" xlink:to="lab_sny_SanofiChimieMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_40b8dd7f-988f-46d6-b889-4a975af33d0d_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net financial income/(expenses)</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="lab_ifrs-full_FinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity_c69c9541-19b9-4274-9b82-fcffd7a7b6e5_terseLabel_en-US" xlink:label="lab_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized after-tax losses</link:label>
    <link:label id="lab_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity_label_en-US" xlink:label="lab_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains (Losses) On Securities Measured At Fair Value Through Other Comprehensive Income That Will Be Reclassified To Profit And Loss Recognized In Equity</link:label>
    <link:label id="lab_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity_documentation_en-US" xlink:label="lab_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments at fair value through other comprehensive income and Debt instruments at fair value through other comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity" xlink:href="sny-20231231.xsd#sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity" xlink:to="lab_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_a5e7566b-a841-4b84-8211-d35f94aa6012_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net impairment losses on property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock_6c33c808-f07c-4678-9de3-9eb3fcf09738_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Softwares Recognized in Income Statement</link:label>
    <link:label id="lab_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Amortization Of Software And Other Rights By Income Statement Line [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of amortization of software and other rights by income statement line.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock" xlink:to="lab_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Inventories_dd30d8c1-ec74-45ce-bd90-93ae31145faf_terseLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_Inventories_ffe0aeb1-1113-4cd6-857f-42f846cf8eed_totalLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_Inventories_label_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories" xlink:to="lab_ifrs-full_Inventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialAssets_3ca63655-b300-43ed-a953-0d971a1e768f_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialAssets" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_aeb9f824-b2b8-4342-9362-03c6d4113f9d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_da5e68cf-efb6-4bd9-b6d7-a1ea994e89f4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_1d5e6f8a-4eda-49a2-bd80-ad444c19e96b_negatedLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember_57c52b35-42f6-4b7f-ad87-0b495f21cff9_terseLabel_en-US" xlink:label="lab_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for pensions and other employee benefits</link:label>
    <link:label id="lab_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember_label_en-US" xlink:label="lab_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Pensions And Other Employee Benefits [member]</link:label>
    <link:label id="lab_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember_documentation_en-US" xlink:label="lab_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for pensions and other employee benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember" xlink:href="sny-20231231.xsd#sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember" xlink:to="lab_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_fefb9ff1-9af0-4db3-89c9-88938496ba20_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest in acquiree held before acquisition date</link:label>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfFamiliesWhoFiledACivilClaim_5a13d813-c5d9-4df6-93cf-fa00fa77ec0c_terseLabel_en-US" xlink:label="lab_sny_NumberOfFamiliesWhoFiledACivilClaim" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of families who filed a civil claim</link:label>
    <link:label id="lab_sny_NumberOfFamiliesWhoFiledACivilClaim_label_en-US" xlink:label="lab_sny_NumberOfFamiliesWhoFiledACivilClaim" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Families Who Filed A Civil Claim</link:label>
    <link:label id="lab_sny_NumberOfFamiliesWhoFiledACivilClaim_documentation_en-US" xlink:label="lab_sny_NumberOfFamiliesWhoFiledACivilClaim" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Families Who Filed A Civil Claim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfFamiliesWhoFiledACivilClaim" xlink:href="sny-20231231.xsd#sny_NumberOfFamiliesWhoFiledACivilClaim"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfFamiliesWhoFiledACivilClaim" xlink:to="lab_sny_NumberOfFamiliesWhoFiledACivilClaim" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_e1b75e79-b2ab-4c13-9cf3-4f676b82268f_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_27c956a6-bf69-40d7-84ea-349812e03148_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attributable to non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b3ca3d38-4f91-44c5-8613-fddd31ea0fd0_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_603f1bd1-3ad7-40f2-8fa5-793d146c2cd6_terseLabel_en-US" xlink:label="lab_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholly unfunded defined benefit plans</link:label>
    <link:label id="lab_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_label_en-US" xlink:label="lab_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholly unfunded defined benefit plans [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WhollyUnfundedDefinedBenefitPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:to="lab_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BorrowingMaximumDrawdown_23921e9b-8f34-4758-91ef-fbb222657c6f_terseLabel_en-US" xlink:label="lab_sny_BorrowingMaximumDrawdown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, maximum drawdown</link:label>
    <link:label id="lab_sny_BorrowingMaximumDrawdown_label_en-US" xlink:label="lab_sny_BorrowingMaximumDrawdown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Maximum Drawdown</link:label>
    <link:label id="lab_sny_BorrowingMaximumDrawdown_documentation_en-US" xlink:label="lab_sny_BorrowingMaximumDrawdown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum drawdown.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingMaximumDrawdown" xlink:href="sny-20231231.xsd#sny_BorrowingMaximumDrawdown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BorrowingMaximumDrawdown" xlink:to="lab_sny_BorrowingMaximumDrawdown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgingInstrumentsAxis_6d98263c-9afa-46a8-93b1-64b9dcf0426f_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_HedgingInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis" xlink:to="lab_ifrs-full_HedgingInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BioAtriumMember_6de64c8f-cc9d-4ae0-91de-fae908328142_terseLabel_en-US" xlink:label="lab_sny_BioAtriumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioAtrium</link:label>
    <link:label id="lab_sny_BioAtriumMember_label_en-US" xlink:label="lab_sny_BioAtriumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioAtrium [Member]</link:label>
    <link:label id="lab_sny_BioAtriumMember_documentation_en-US" xlink:label="lab_sny_BioAtriumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioAtrium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioAtriumMember" xlink:href="sny-20231231.xsd#sny_BioAtriumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BioAtriumMember" xlink:to="lab_sny_BioAtriumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract_a7d1cc32-b5dd-4297-9ee5-0c9b5e881c3d_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and goodwill [abstract]</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UnwindingOfDiscount_714c821f-88f2-4fe3-b72a-87124fbba5af_terseLabel_en-US" xlink:label="lab_sny_UnwindingOfDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unwinding of discount</link:label>
    <link:label id="lab_sny_UnwindingOfDiscount_label_en-US" xlink:label="lab_sny_UnwindingOfDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unwinding Of Discount</link:label>
    <link:label id="lab_sny_UnwindingOfDiscount_documentation_en-US" xlink:label="lab_sny_UnwindingOfDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unwinding Of Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnwindingOfDiscount" xlink:href="sny-20231231.xsd#sny_UnwindingOfDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UnwindingOfDiscount" xlink:to="lab_sny_UnwindingOfDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_035de09e-a4b4-4ee8-b7f2-8159b510d2ab_terseLabel_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment for restricted shares (in shares)</link:label>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_label_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Effect Of Share Options On Number Of Restricted Shares</link:label>
    <link:label id="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_documentation_en-US" xlink:label="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of share options on number of restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:href="sny-20231231.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:to="lab_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_e0751c09-c4ad-4b06-8418-dde5b269503c_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value through other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial assets at fair value through other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:to="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable_375f7f22-a372-45c8-a1ac-550b73aeaca3_terseLabel_en-US" xlink:label="lab_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets not recognized as future recovery not probable</link:label>
    <link:label id="lab_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable_label_en-US" xlink:label="lab_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Not Recognized As Future Recovery Not Probable</link:label>
    <link:label id="lab_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable_documentation_en-US" xlink:label="lab_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets not recognized as future recovery not probable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable" xlink:href="sny-20231231.xsd#sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable" xlink:to="lab_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiABMember_0368687b-edc5-440d-ba0c-11aa781132e3_terseLabel_en-US" xlink:label="lab_sny_SanofiABMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi AB</link:label>
    <link:label id="lab_sny_SanofiABMember_label_en-US" xlink:label="lab_sny_SanofiABMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi AB [member]</link:label>
    <link:label id="lab_sny_SanofiABMember_documentation_en-US" xlink:label="lab_sny_SanofiABMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi AB.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiABMember" xlink:href="sny-20231231.xsd#sny_SanofiABMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiABMember" xlink:to="lab_sny_SanofiABMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ConsumerHealthcareSegmentMember_91ba2624-43f1-4ca0-9f18-9191663e8bd1_terseLabel_en-US" xlink:label="lab_sny_ConsumerHealthcareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare</link:label>
    <link:label id="lab_sny_ConsumerHealthcareSegmentMember_label_en-US" xlink:label="lab_sny_ConsumerHealthcareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare Segment [Member]</link:label>
    <link:label id="lab_sny_ConsumerHealthcareSegmentMember_documentation_en-US" xlink:label="lab_sny_ConsumerHealthcareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ConsumerHealthcareSegmentMember" xlink:to="lab_sny_ConsumerHealthcareSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_b4d938df-ea75-4ff0-ba95-cad1fc1c7af2_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and other share-based payment [Member]</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PriorAgreementMember_9cdedbee-73fc-48ad-a9b5-0e8218d73d84_terseLabel_en-US" xlink:label="lab_sny_PriorAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior agreement</link:label>
    <link:label id="lab_sny_PriorAgreementMember_label_en-US" xlink:label="lab_sny_PriorAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Agreement [Member]</link:label>
    <link:label id="lab_sny_PriorAgreementMember_documentation_en-US" xlink:label="lab_sny_PriorAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PriorAgreementMember" xlink:href="sny-20231231.xsd#sny_PriorAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PriorAgreementMember" xlink:to="lab_sny_PriorAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_1a9a63ee-1f00-4f7d-88f8-5a404ff2c852_terseLabel_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43%</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_label_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.43% [Member]</link:label>
    <link:label id="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_documentation_en-US" xlink:label="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps Pay Capitalized Ester / Receive 3.43%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive343Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:to="lab_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DaiichiSankyoMember_e7ffcd44-d637-47c9-875c-37b78678d1c4_terseLabel_en-US" xlink:label="lab_sny_DaiichiSankyoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo</link:label>
    <link:label id="lab_sny_DaiichiSankyoMember_label_en-US" xlink:label="lab_sny_DaiichiSankyoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo [Member]</link:label>
    <link:label id="lab_sny_DaiichiSankyoMember_documentation_en-US" xlink:label="lab_sny_DaiichiSankyoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DaiichiSankyoMember" xlink:href="sny-20231231.xsd#sny_DaiichiSankyoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DaiichiSankyoMember" xlink:to="lab_sny_DaiichiSankyoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInTaiwanDollarMember_5158c3bf-e8a6-486f-9dc5-ac6dea9801c9_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInTaiwanDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Taiwan Dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInTaiwanDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInTaiwanDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Taiwan Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInTaiwanDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInTaiwanDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Taiwan Dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInTaiwanDollarMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInTaiwanDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasedInTaiwanDollarMember" xlink:to="lab_sny_ForwardCurrencyPurchasedInTaiwanDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentDerivativesMember_90fd2aa3-acf8-4d3c-b252-4623b36525ba_terseLabel_en-US" xlink:label="lab_sny_NonCurrentDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current derivatives</link:label>
    <link:label id="lab_sny_NonCurrentDerivativesMember_7ef18a54-635e-4550-91e8-36b08576dc1f_verboseLabel_en-US" xlink:label="lab_sny_NonCurrentDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current derivatives</link:label>
    <link:label id="lab_sny_NonCurrentDerivativesMember_label_en-US" xlink:label="lab_sny_NonCurrentDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Derivatives [Member]</link:label>
    <link:label id="lab_sny_NonCurrentDerivativesMember_documentation_en-US" xlink:label="lab_sny_NonCurrentDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current derivatives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentDerivativesMember" xlink:href="sny-20231231.xsd#sny_NonCurrentDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentDerivativesMember" xlink:to="lab_sny_NonCurrentDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_a1b3f63c-d804-4378-adf4-29ae3e390fd6_terseLabel_en-US" xlink:label="lab_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current and non-current assets and liabilities</link:label>
    <link:label id="lab_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_label_en-US" xlink:label="lab_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets And Current Liabilities As Of Acquisition Date</link:label>
    <link:label id="lab_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities as of acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate" xlink:href="sny-20231231.xsd#sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate" xlink:to="lab_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlavixRelatedLitigationInFranceMember_f828da1d-a139-4b68-a126-536c92a3235c_terseLabel_en-US" xlink:label="lab_sny_PlavixRelatedLitigationInFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plavix related litigation in France</link:label>
    <link:label id="lab_sny_PlavixRelatedLitigationInFranceMember_label_en-US" xlink:label="lab_sny_PlavixRelatedLitigationInFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plavix Related Litigation In France [Member]</link:label>
    <link:label id="lab_sny_PlavixRelatedLitigationInFranceMember_documentation_en-US" xlink:label="lab_sny_PlavixRelatedLitigationInFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plavix Related Litigation In France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixRelatedLitigationInFranceMember" xlink:href="sny-20231231.xsd#sny_PlavixRelatedLitigationInFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlavixRelatedLitigationInFranceMember" xlink:to="lab_sny_PlavixRelatedLitigationInFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationExpense_943d88d6-86be-4a28-92e5-e20b916b5cf7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationExpense_label_en-US" xlink:label="lab_ifrs-full_DepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationExpense" xlink:to="lab_ifrs-full_DepreciationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_2b07477c-5bb0-47b8-b764-d97ac69efee5_negatedLabel_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate and currency derivatives used to manage cash and cash equivalents</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_label_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent</link:label>
    <link:label id="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_documentation_en-US" xlink:label="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate and currency derivatives used to manage cash and cash equivalent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:to="lab_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030_253e13ff-4de2-45f5-92ef-382a1b662ced_terseLabel_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program, percentage of reduction in all scopes greenhouse gas by 2030</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030_label_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Percentage Of Reduction In All Scopes Greenhouse Gas By 2030</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030_documentation_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Percentage Of Reduction In All Scopes Greenhouse Gas By 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030" xlink:to="lab_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherCountriesMember_3f3b11cf-f87e-47a8-a56b-06fa93159f57_terseLabel_en-US" xlink:label="lab_sny_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sny_OtherCountriesMember_124ac3af-e53e-4811-bb41-f84e476742ce_verboseLabel_en-US" xlink:label="lab_sny_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other countries</link:label>
    <link:label id="lab_sny_OtherCountriesMember_label_en-US" xlink:label="lab_sny_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [member]</link:label>
    <link:label id="lab_sny_OtherCountriesMember_documentation_en-US" xlink:label="lab_sny_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other countries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherCountriesMember" xlink:to="lab_sny_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAssetsMember_e0167452-8d15-4370-848a-102d39d0fc96_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherAssetsMember_label_en-US" xlink:label="lab_ifrs-full_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAssetsMember" xlink:to="lab_ifrs-full_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans_31eafd1c-d2ae-4688-ac20-8566cd9a840f_terseLabel_en-US" xlink:label="lab_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future benefit payments under pension and other post-employment benefit plans</link:label>
    <link:label id="lab_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans_label_en-US" xlink:label="lab_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future Benefit Payments Under Pension And Other Postemployment Benefit Plans</link:label>
    <link:label id="lab_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans_documentation_en-US" xlink:label="lab_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future benefit payments under pension and other post-employment benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" xlink:href="sny-20231231.xsd#sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" xlink:to="lab_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_891d5da1-6b1b-48a9-a2f6-cf52d477b523_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement_cd86e21e-09b9-4207-96fa-bde88a37c4ce_periodStartLabel_en-US" xlink:label="lab_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, beginning balance</link:label>
    <link:label id="lab_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement_3273b6dd-038f-47c6-adfa-6908ff0531e6_periodEndLabel_en-US" xlink:label="lab_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, ending balance</link:label>
    <link:label id="lab_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Of Share Options Outstanding In Share Based Payment Arrangement</link:label>
    <link:label id="lab_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of share options outstanding in share based payment arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" xlink:to="lab_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLoansAndReceivables_aef2f0e8-ed54-4d28-91ff-adf30a5b6ca2_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLoansAndReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term loans and advances and other non-current receivables</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLoansAndReceivables_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLoansAndReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current loans and receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLoansAndReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLoansAndReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLoansAndReceivables" xlink:to="lab_ifrs-full_NoncurrentLoansAndReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_b0beff58-faa9-4916-ab8f-0ed12abfce0a_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for related parties</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentInterestRateDerivativesPayable_a6d82ff8-9698-44cd-b912-ff96eae78888_terseLabel_en-US" xlink:label="lab_sny_CurrentInterestRateDerivativesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate derivatives (see Note&#160;D.20.)</link:label>
    <link:label id="lab_sny_CurrentInterestRateDerivativesPayable_label_en-US" xlink:label="lab_sny_CurrentInterestRateDerivativesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Interest Rate Derivatives Payable</link:label>
    <link:label id="lab_sny_CurrentInterestRateDerivativesPayable_documentation_en-US" xlink:label="lab_sny_CurrentInterestRateDerivativesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current interest rate derivatives payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentInterestRateDerivativesPayable" xlink:href="sny-20231231.xsd#sny_CurrentInterestRateDerivativesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentInterestRateDerivativesPayable" xlink:to="lab_sny_CurrentInterestRateDerivativesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AwardsDateDomain_271c23c6-07d7-40f4-9678-300940a8a320_terseLabel_en-US" xlink:label="lab_sny_AwardsDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Date [Domain]</link:label>
    <link:label id="lab_sny_AwardsDateDomain_label_en-US" xlink:label="lab_sny_AwardsDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Date [Domain]</link:label>
    <link:label id="lab_sny_AwardsDateDomain_documentation_en-US" xlink:label="lab_sny_AwardsDateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateDomain" xlink:href="sny-20231231.xsd#sny_AwardsDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AwardsDateDomain" xlink:to="lab_sny_AwardsDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_bd12e74f-d7e3-4223-bcd7-0cb45cd3aa97_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_September2016EMTNISINFR0013201639Member_b7457a24-e26f-4e9d-9783-1681a88e34ce_terseLabel_en-US" xlink:label="lab_sny_September2016EMTNISINFR0013201639Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2016 EMTN ISIN FR0013201639</link:label>
    <link:label id="lab_sny_September2016EMTNISINFR0013201639Member_label_en-US" xlink:label="lab_sny_September2016EMTNISINFR0013201639Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2016 EMTNISINFR0013201639 [Member]</link:label>
    <link:label id="lab_sny_September2016EMTNISINFR0013201639Member_documentation_en-US" xlink:label="lab_sny_September2016EMTNISINFR0013201639Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2016 EMTN ISIN FR 0013201639.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_September2016EMTNISINFR0013201639Member" xlink:href="sny-20231231.xsd#sny_September2016EMTNISINFR0013201639Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_September2016EMTNISINFR0013201639Member" xlink:to="lab_sny_September2016EMTNISINFR0013201639Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement_6359653b-114e-48d9-9c26-a56de9ea5224_terseLabel_en-US" xlink:label="lab_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average exercise&#160;price per share, options cancelled (in euros per share)</link:label>
    <link:label id="lab_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Cancelled In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Cancelled In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:href="sny-20231231.xsd#sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:to="lab_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_ce0662c7-f80f-45e4-bfd9-548f36e6bbe1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_INBRX101BusinessRemainCo.Member_33d987e9-b5b4-4ad2-b219-c2b928454439_terseLabel_en-US" xlink:label="lab_sny_INBRX101BusinessRemainCo.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INBRX-101 business (Remain Co.)</link:label>
    <link:label id="lab_sny_INBRX101BusinessRemainCo.Member_label_en-US" xlink:label="lab_sny_INBRX101BusinessRemainCo.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INBRX-101 Business (Remain Co.) [Member]</link:label>
    <link:label id="lab_sny_INBRX101BusinessRemainCo.Member_documentation_en-US" xlink:label="lab_sny_INBRX101BusinessRemainCo.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INBRX-101 Business (Remain Co.)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_INBRX101BusinessRemainCo.Member" xlink:href="sny-20231231.xsd#sny_INBRX101BusinessRemainCo.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_INBRX101BusinessRemainCo.Member" xlink:to="lab_sny_INBRX101BusinessRemainCo.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfHedgesAxis_23b83f1e-4ba5-4d2d-a642-547830bb9a20_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of Hedges [Axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfHedgesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of hedges [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfHedgesAxis" xlink:to="lab_ifrs-full_TypesOfHedgesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems_3b825a1e-4814-4ac7-945b-f70e398d5a92_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Credit Risk Exposure [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of credit risk exposure [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="lab_ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseExtensionOptionsTerm_79fa51f7-65da-4e09-9187-2e03b4d8fc5f_terseLabel_en-US" xlink:label="lab_sny_LeaseExtensionOptionsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, extension options, term</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsTerm_label_en-US" xlink:label="lab_sny_LeaseExtensionOptionsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Extension Options, Term</link:label>
    <link:label id="lab_sny_LeaseExtensionOptionsTerm_documentation_en-US" xlink:label="lab_sny_LeaseExtensionOptionsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Extension Options, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsTerm" xlink:href="sny-20231231.xsd#sny_LeaseExtensionOptionsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseExtensionOptionsTerm" xlink:to="lab_sny_LeaseExtensionOptionsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrencyDerivativesOperatingMember_2d16ba99-4d51-4819-abcb-fee5a57fa40c_terseLabel_en-US" xlink:label="lab_sny_CurrencyDerivativesOperatingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">operating</link:label>
    <link:label id="lab_sny_CurrencyDerivativesOperatingMember_label_en-US" xlink:label="lab_sny_CurrencyDerivativesOperatingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Derivatives Operating [Member]</link:label>
    <link:label id="lab_sny_CurrencyDerivativesOperatingMember_documentation_en-US" xlink:label="lab_sny_CurrencyDerivativesOperatingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency derivatives, operating.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesOperatingMember" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesOperatingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrencyDerivativesOperatingMember" xlink:to="lab_sny_CurrencyDerivativesOperatingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_d836ae8c-7f05-4548-b711-56a180e7ec23_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Information About Major Customers and Credit Risk [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_label_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information About Major Customers And Credit Risk [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about major customers and credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:to="lab_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfAuditorRemunerationForStatutoryAudit_2ce9170b-e43e-4ec0-8089-e911bf553e08_terseLabel_en-US" xlink:label="lab_sny_PercentageOfAuditorRemunerationForStatutoryAudit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory audit of separate and consolidated financial statements, percentage</link:label>
    <link:label id="lab_sny_PercentageOfAuditorRemunerationForStatutoryAudit_label_en-US" xlink:label="lab_sny_PercentageOfAuditorRemunerationForStatutoryAudit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Auditor Remuneration For Statutory Audit</link:label>
    <link:label id="lab_sny_PercentageOfAuditorRemunerationForStatutoryAudit_documentation_en-US" xlink:label="lab_sny_PercentageOfAuditorRemunerationForStatutoryAudit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of auditor remuneration for statutory audit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorRemunerationForStatutoryAudit" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorRemunerationForStatutoryAudit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfAuditorRemunerationForStatutoryAudit" xlink:to="lab_sny_PercentageOfAuditorRemunerationForStatutoryAudit" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommoditiesMember_95fd5a9f-0c05-40db-b833-26dd5e314d4d_terseLabel_en-US" xlink:label="lab_sny_CommoditiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commodities</link:label>
    <link:label id="lab_sny_CommoditiesMember_label_en-US" xlink:label="lab_sny_CommoditiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commodities [Member]</link:label>
    <link:label id="lab_sny_CommoditiesMember_documentation_en-US" xlink:label="lab_sny_CommoditiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commodities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommoditiesMember" xlink:href="sny-20231231.xsd#sny_CommoditiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommoditiesMember" xlink:to="lab_sny_CommoditiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfAuditorsRemuneration_bf88ec78-1514-499d-9b49-b34e4c9ede7e_totalLabel_en-US" xlink:label="lab_sny_PercentageOfAuditorsRemuneration" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, percentage</link:label>
    <link:label id="lab_sny_PercentageOfAuditorsRemuneration_label_en-US" xlink:label="lab_sny_PercentageOfAuditorsRemuneration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Auditors Remuneration</link:label>
    <link:label id="lab_sny_PercentageOfAuditorsRemuneration_documentation_en-US" xlink:label="lab_sny_PercentageOfAuditorsRemuneration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor's remuneration, Total Percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorsRemuneration" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorsRemuneration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfAuditorsRemuneration" xlink:to="lab_sny_PercentageOfAuditorsRemuneration" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SaleOfStockDomain_0b641aa5-1c54-4d6e-81e7-1feed482e54e_terseLabel_en-US" xlink:label="lab_sny_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_sny_SaleOfStockDomain_label_en-US" xlink:label="lab_sny_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_sny_SaleOfStockDomain_documentation_en-US" xlink:label="lab_sny_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SaleOfStockDomain" xlink:href="sny-20231231.xsd#sny_SaleOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SaleOfStockDomain" xlink:to="lab_sny_SaleOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInJapaneseYenMember_8cbcf6ef-2f12-4d0b-8bb7-7021afbf0e50_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases In Japanese yen</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInJapaneseYenMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Japanese Yen [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInJapaneseYenMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In Japanese Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInJapaneseYenMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasedInJapaneseYenMember" xlink:to="lab_sny_ForwardCurrencyPurchasedInJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxLossesCarryforwards_be97629e-4dc1-4460-a6e5-09f8eda2adff_terseLabel_en-US" xlink:label="lab_sny_TaxLossesCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax losses available for carry-forward</link:label>
    <link:label id="lab_sny_TaxLossesCarryforwards_label_en-US" xlink:label="lab_sny_TaxLossesCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Losses Carryforwards</link:label>
    <link:label id="lab_sny_TaxLossesCarryforwards_documentation_en-US" xlink:label="lab_sny_TaxLossesCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax losses carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxLossesCarryforwards" xlink:href="sny-20231231.xsd#sny_TaxLossesCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxLossesCarryforwards" xlink:to="lab_sny_TaxLossesCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax_bc038439-e3c9-44bb-8421-ee50e37ff771_negatedTerseLabel_en-US" xlink:label="lab_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedges of net investments in foreign operations</link:label>
    <link:label id="lab_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax_label_en-US" xlink:label="lab_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedges Of Net Investments In Foreign Operations After Tax</link:label>
    <link:label id="lab_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax_documentation_en-US" xlink:label="lab_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedges of net investments in foreign operations after tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax" xlink:href="sny-20231231.xsd#sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax" xlink:to="lab_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_51234ee1-22f0-4eeb-a213-d1b89a5b6b92_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through net exchange differences, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_c8d02eb7-d49b-49a6-9ead-e3d72361e3f2_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average duration of defined benefit obligation</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_82dec9f1-25a9-4c8e-95de-353432349b3d_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average duration in main countries</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average duration of defined benefit obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:to="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_5aa7c1cd-7f57-4011-b89a-2c218905a1a8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OrigimmBiotechnologyGmbHMember_54e0f6a6-4989-4e0c-baa1-67b147374f44_terseLabel_en-US" xlink:label="lab_sny_OrigimmBiotechnologyGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Origimm Biotechnology GmbH</link:label>
    <link:label id="lab_sny_OrigimmBiotechnologyGmbHMember_label_en-US" xlink:label="lab_sny_OrigimmBiotechnologyGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Origimm Biotechnology GmbH [Member]</link:label>
    <link:label id="lab_sny_OrigimmBiotechnologyGmbHMember_documentation_en-US" xlink:label="lab_sny_OrigimmBiotechnologyGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Origimm Biotechnology GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OrigimmBiotechnologyGmbHMember" xlink:href="sny-20231231.xsd#sny_OrigimmBiotechnologyGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OrigimmBiotechnologyGmbHMember" xlink:to="lab_sny_OrigimmBiotechnologyGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateDerivativesMeasuredAtFairValue_add620d5-6572-4cc2-a05f-72915274bfdd_terseLabel_en-US" xlink:label="lab_sny_InterestRateDerivativesMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate derivatives measured at fair value (see Note&#160;D.20.)</link:label>
    <link:label id="lab_sny_InterestRateDerivativesMeasuredAtFairValue_label_en-US" xlink:label="lab_sny_InterestRateDerivativesMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivatives Measured At Fair Value</link:label>
    <link:label id="lab_sny_InterestRateDerivativesMeasuredAtFairValue_documentation_en-US" xlink:label="lab_sny_InterestRateDerivativesMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate derivatives measured at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateDerivativesMeasuredAtFairValue" xlink:href="sny-20231231.xsd#sny_InterestRateDerivativesMeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateDerivativesMeasuredAtFairValue" xlink:to="lab_sny_InterestRateDerivativesMeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_f0117476-c1df-4fa2-9332-0a3859f52959_terseLabel_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit or loss from commercialization of Zaltrap</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_label_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profit Or Loss From Commercialization Of Zaltrap [Member]</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_documentation_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit or loss from commercialization of Zaltrap.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:href="sny-20231231.xsd#sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:to="lab_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LongTermPrepaidExpenses_c9c6ecc6-f37b-477b-acb6-d0667dd6c26c_terseLabel_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term prepaid expenses</link:label>
    <link:label id="lab_sny_LongTermPrepaidExpenses_label_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Prepaid Expenses</link:label>
    <link:label id="lab_sny_LongTermPrepaidExpenses_documentation_en-US" xlink:label="lab_sny_LongTermPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term prepaid expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses" xlink:href="sny-20231231.xsd#sny_LongTermPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LongTermPrepaidExpenses" xlink:to="lab_sny_LongTermPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeStatementLocation1Domain_77df57bf-be49-4081-aba6-e6ac39ac8327_terseLabel_en-US" xlink:label="lab_sny_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_sny_IncomeStatementLocation1Domain_label_en-US" xlink:label="lab_sny_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_sny_IncomeStatementLocation1Domain_documentation_en-US" xlink:label="lab_sny_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Domain" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeStatementLocation1Domain" xlink:to="lab_sny_IncomeStatementLocation1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockPrice_3398078d-6efc-4860-b52b-63502d629abf_terseLabel_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price</link:label>
    <link:label id="lab_sny_StockPrice_label_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price</link:label>
    <link:label id="lab_sny_StockPrice_documentation_en-US" xlink:label="lab_sny_StockPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice" xlink:href="sny-20231231.xsd#sny_StockPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockPrice" xlink:to="lab_sny_StockPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_9bd57299-58f5-46c1-9462-cf04c3652dc3_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_bbf2f3ad-a811-4e26-90d2-19e45b470457_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashAndCashEquivalentsInvestedRate_db442592-38c7-4080-aeec-f0bf1fc234bd_terseLabel_en-US" xlink:label="lab_sny_CashAndCashEquivalentsInvestedRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, invested rate</link:label>
    <link:label id="lab_sny_CashAndCashEquivalentsInvestedRate_label_en-US" xlink:label="lab_sny_CashAndCashEquivalentsInvestedRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Invested Rate</link:label>
    <link:label id="lab_sny_CashAndCashEquivalentsInvestedRate_documentation_en-US" xlink:label="lab_sny_CashAndCashEquivalentsInvestedRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents invested rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalentsInvestedRate" xlink:href="sny-20231231.xsd#sny_CashAndCashEquivalentsInvestedRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashAndCashEquivalentsInvestedRate" xlink:to="lab_sny_CashAndCashEquivalentsInvestedRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtPercent_f3fa91bb-0688-4c9b-909e-888c9e2d8a14_terseLabel_en-US" xlink:label="lab_sny_DebtPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, percent</link:label>
    <link:label id="lab_sny_DebtPercent_label_en-US" xlink:label="lab_sny_DebtPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Percent</link:label>
    <link:label id="lab_sny_DebtPercent_documentation_en-US" xlink:label="lab_sny_DebtPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtPercent" xlink:href="sny-20231231.xsd#sny_DebtPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtPercent" xlink:to="lab_sny_DebtPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EloctateMember_033689a3-d6a5-4bfd-8127-3bb70c0b2917_terseLabel_en-US" xlink:label="lab_sny_EloctateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ELOCTATE</link:label>
    <link:label id="lab_sny_EloctateMember_label_en-US" xlink:label="lab_sny_EloctateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eloctate [Member]</link:label>
    <link:label id="lab_sny_EloctateMember_documentation_en-US" xlink:label="lab_sny_EloctateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eloctate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember" xlink:href="sny-20231231.xsd#sny_EloctateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EloctateMember" xlink:to="lab_sny_EloctateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GenzymeMember_7c524fd3-ad22-4a38-8bdd-d67ecad15dfd_terseLabel_en-US" xlink:label="lab_sny_GenzymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme</link:label>
    <link:label id="lab_sny_GenzymeMember_label_en-US" xlink:label="lab_sny_GenzymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme [Member]</link:label>
    <link:label id="lab_sny_GenzymeMember_documentation_en-US" xlink:label="lab_sny_GenzymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeMember" xlink:href="sny-20231231.xsd#sny_GenzymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GenzymeMember" xlink:to="lab_sny_GenzymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersMember_3db71aff-b653-42da-b072-c3b5f5a7ef0d_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers [member]</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersMember_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersMember" xlink:to="lab_ifrs-full_MajorCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetMember_4ba0eab1-36b8-4004-9baf-c7a976d96c02_terseLabel_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments included in financial assets</link:label>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetMember_label_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Instruments Included In Financial Asset [Member]</link:label>
    <link:label id="lab_sny_EquityInstrumentsIncludedInFinancialAssetMember_documentation_en-US" xlink:label="lab_sny_EquityInstrumentsIncludedInFinancialAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Instruments Included In Financial Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetMember" xlink:href="sny-20231231.xsd#sny_EquityInstrumentsIncludedInFinancialAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityInstrumentsIncludedInFinancialAssetMember" xlink:to="lab_sny_EquityInstrumentsIncludedInFinancialAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TevaPharmaceuticalsMember_764e3da3-fefe-476e-9bff-1b4a4b31b8d4_terseLabel_en-US" xlink:label="lab_sny_TevaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceuticals</link:label>
    <link:label id="lab_sny_TevaPharmaceuticalsMember_label_en-US" xlink:label="lab_sny_TevaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceuticals [Member]</link:label>
    <link:label id="lab_sny_TevaPharmaceuticalsMember_documentation_en-US" xlink:label="lab_sny_TevaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TevaPharmaceuticalsMember" xlink:href="sny-20231231.xsd#sny_TevaPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TevaPharmaceuticalsMember" xlink:to="lab_sny_TevaPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering_cba5c59b-bfad-4d3c-8ecc-c36af4f08213_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares included in public offer (in shares)</link:label>
    <link:label id="lab_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering_label_en-US" xlink:label="lab_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Shares Included In Public Offering</link:label>
    <link:label id="lab_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering_documentation_en-US" xlink:label="lab_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Shares Included In Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering" xlink:href="sny-20231231.xsd#sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering" xlink:to="lab_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_c93b01fb-3fa5-4bb4-8020-a917e4ddb4e0_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_9d971c88-74c6-4a67-bfa0-1527dc925be3_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MilestoneTypesDomain_e18b1fc2-ad79-4a1e-b2d7-8ceebdf6ac20_terseLabel_en-US" xlink:label="lab_sny_MilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Types [Domain]</link:label>
    <link:label id="lab_sny_MilestoneTypesDomain_label_en-US" xlink:label="lab_sny_MilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Types [Domain]</link:label>
    <link:label id="lab_sny_MilestoneTypesDomain_documentation_en-US" xlink:label="lab_sny_MilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Types [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MilestoneTypesDomain" xlink:href="sny-20231231.xsd#sny_MilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MilestoneTypesDomain" xlink:to="lab_sny_MilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SegmentsAxis_e01a2444-a909-4baf-ad02-85857e9d563d_terseLabel_en-US" xlink:label="lab_ifrs-full_SegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [axis]</link:label>
    <link:label id="lab_ifrs-full_SegmentsAxis_label_en-US" xlink:label="lab_ifrs-full_SegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SegmentsAxis" xlink:to="lab_ifrs-full_SegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanMember_05cfeba7-e027-453e-a9d3-d201bfd97845_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In Chinese Yuan</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In Chinese Yuan [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In Chinese Yuan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInChineseYuanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInChineseYuanMember" xlink:to="lab_sny_ForwardCurrencySalesInChineseYuanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_a136b512-3ae6-4164-acaa-d5dfd44beb7d_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActionForWhichWeArePlaintiffMember_77949d78-a6c6-467a-afe8-09c9239024e5_terseLabel_en-US" xlink:label="lab_sny_ActionForWhichWeArePlaintiffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Action for which we are a plaintiff</link:label>
    <link:label id="lab_sny_ActionForWhichWeArePlaintiffMember_label_en-US" xlink:label="lab_sny_ActionForWhichWeArePlaintiffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Action For Which We Are a Plaintiff [member]</link:label>
    <link:label id="lab_sny_ActionForWhichWeArePlaintiffMember_documentation_en-US" xlink:label="lab_sny_ActionForWhichWeArePlaintiffMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Action For Which We Are a Plaintiff.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeArePlaintiffMember" xlink:href="sny-20231231.xsd#sny_ActionForWhichWeArePlaintiffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActionForWhichWeArePlaintiffMember" xlink:to="lab_sny_ActionForWhichWeArePlaintiffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EmployeeBenefitsAbstract_9d833af0-f2aa-40d7-8e00-3dede678e1e5_terseLabel_en-US" xlink:label="lab_sny_EmployeeBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits [Abstract]</link:label>
    <link:label id="lab_sny_EmployeeBenefitsAbstract_label_en-US" xlink:label="lab_sny_EmployeeBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits [Abstract]</link:label>
    <link:label id="lab_sny_EmployeeBenefitsAbstract_documentation_en-US" xlink:label="lab_sny_EmployeeBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeBenefitsAbstract" xlink:href="sny-20231231.xsd#sny_EmployeeBenefitsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EmployeeBenefitsAbstract" xlink:to="lab_sny_EmployeeBenefitsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityInstrumentsMember_4ce649a7-bb00-42e2-9a01-bb4e3aca3060_terseLabel_en-US" xlink:label="lab_sny_EquityInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments</link:label>
    <link:label id="lab_sny_EquityInstrumentsMember_label_en-US" xlink:label="lab_sny_EquityInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Instruments [Member]</link:label>
    <link:label id="lab_sny_EquityInstrumentsMember_documentation_en-US" xlink:label="lab_sny_EquityInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsMember" xlink:href="sny-20231231.xsd#sny_EquityInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityInstrumentsMember" xlink:to="lab_sny_EquityInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CapitalLossesUsedAgainstCapitalGainsPercentage_269a92b6-ed6c-4e6e-a16e-029239acb5f3_terseLabel_en-US" xlink:label="lab_sny_CapitalLossesUsedAgainstCapitalGainsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of capital losses used</link:label>
    <link:label id="lab_sny_CapitalLossesUsedAgainstCapitalGainsPercentage_label_en-US" xlink:label="lab_sny_CapitalLossesUsedAgainstCapitalGainsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Losses Used Against Capital Gains, Percentage</link:label>
    <link:label id="lab_sny_CapitalLossesUsedAgainstCapitalGainsPercentage_documentation_en-US" xlink:label="lab_sny_CapitalLossesUsedAgainstCapitalGainsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Losses Used Against Capital Gains, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CapitalLossesUsedAgainstCapitalGainsPercentage" xlink:href="sny-20231231.xsd#sny_CapitalLossesUsedAgainstCapitalGainsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CapitalLossesUsedAgainstCapitalGainsPercentage" xlink:to="lab_sny_CapitalLossesUsedAgainstCapitalGainsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_49bc8962-ec7d-4bb1-a221-682bad2c6490_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average residual&#160;life (years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment_224a6783-147b-43c2-84a6-5d53522f3f71_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements, regulatory milestone payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment_label_en-US" xlink:label="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Regulatory Milestone Payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Regulatory Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementsRegulatoryMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:to="lab_sny_CollaborationAgreementsRegulatoryMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment_ef17d3bc-8761-45c2-b430-da7dcccd35cd_terseLabel_en-US" xlink:label="lab_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum sales of PD1 in 12-month period to be achieved for milestone payment</link:label>
    <link:label id="lab_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment_label_en-US" xlink:label="lab_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Sales Of Anti Programmed Cell Death Protein 1 In Twelve Month Period To Be Achieved For Milestone Payment</link:label>
    <link:label id="lab_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment_documentation_en-US" xlink:label="lab_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum sales of anti programmed cell death protein 1 in twelve month period to be achieved for milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment" xlink:href="sny-20231231.xsd#sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment" xlink:to="lab_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_c2d66106-fae3-490c-a195-4f55fa9f4fa5_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average exercise&#160;price per share, beginning balance (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_662ed5a7-077c-4ee7-96a9-da9ec1c821cf_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average exercise&#160;price per share, ending balance (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_c6134788-25ac-486b-84e3-59e47157d4c2_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_d557a87f-6239-43e0-b5fe-ab107e587cbf_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementPeriodAfterLossOfControl_a08909c4-03e2-4d61-901d-6b0b0ecb9455_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementPeriodAfterLossOfControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, period after loss of control</link:label>
    <link:label id="lab_sny_CollaborationAgreementPeriodAfterLossOfControl_label_en-US" xlink:label="lab_sny_CollaborationAgreementPeriodAfterLossOfControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Period After Loss Of Control</link:label>
    <link:label id="lab_sny_CollaborationAgreementPeriodAfterLossOfControl_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementPeriodAfterLossOfControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Period After Loss Of Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementPeriodAfterLossOfControl" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementPeriodAfterLossOfControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementPeriodAfterLossOfControl" xlink:to="lab_sny_CollaborationAgreementPeriodAfterLossOfControl" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsForDiscountsRebatesAndSalesReturns_0c5fe42a-4a47-4070-b6a7-1a0e4e32d96a_periodStartLabel_en-US" xlink:label="lab_sny_ProvisionsForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for discounts, rebates and sales returns, beginning balance</link:label>
    <link:label id="lab_sny_ProvisionsForDiscountsRebatesAndSalesReturns_c9dec97d-a362-4888-8f94-454a8d86c8fe_periodEndLabel_en-US" xlink:label="lab_sny_ProvisionsForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for discounts, rebates and sales returns, ending balance</link:label>
    <link:label id="lab_sny_ProvisionsForDiscountsRebatesAndSalesReturns_label_en-US" xlink:label="lab_sny_ProvisionsForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions For Discounts Rebates And Sales Returns</link:label>
    <link:label id="lab_sny_ProvisionsForDiscountsRebatesAndSalesReturns_documentation_en-US" xlink:label="lab_sny_ProvisionsForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for discounts, rebates and sales returns.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForDiscountsRebatesAndSalesReturns" xlink:href="sny-20231231.xsd#sny_ProvisionsForDiscountsRebatesAndSalesReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsForDiscountsRebatesAndSalesReturns" xlink:to="lab_sny_ProvisionsForDiscountsRebatesAndSalesReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfEntitysRevenue_77cc188e-36a3-4735-99c0-5d38fc86ffa2_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of entity's revenue (in percent)</link:label>
    <link:label id="lab_ifrs-full_PercentageOfEntitysRevenue_label_en-US" xlink:label="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of entity's revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfEntitysRevenue" xlink:to="lab_ifrs-full_PercentageOfEntitysRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_877fa560-bc35-47f2-b6db-5e76eba45360_terseLabel_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_label_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis" xlink:to="lab_ifrs-full_BusinessCombinationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_4c663fa6-1620-43ca-a397-7d518aea6768_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_5543f872-f1c5-4528-8ec0-36ad32daa2f6_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [table]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_2fc21888-3ba2-41b6-bf45-4de474565561_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee share ownership plan</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Employee Share Ownership Plans</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee share ownership plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_a3f4a8a5-78af-407b-94cc-7c1d0cf98a99_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_c2c7d269-fd39-4bcf-b99f-71cb26316d6a_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, beginning balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_63a84e6d-8fdf-4eeb-806a-2d8fa1a04790_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, ending balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_3f4eb229-3640-4d0e-b6a6-3acb640a2912_verboseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment owned</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_676f81ac-e4c9-4f9c-8ce6-624a1a6635a4_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of applying IFRIC agenda decision on IAS 19</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_1b8279fb-d1ed-45d6-a04a-614fcb62f0bf_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefit indexation</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of expected rates of pension increases [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_6f02dcfa-bd9c-4e65-b50b-df39cf43e923_terseLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflow for leases, excluding short-term leases</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForSubsidiariesMember_46196e76-c555-4693-aa24-244dbc8838a1_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for subsidiaries</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForSubsidiariesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for subsidiaries [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_e411b865-57fb-4bf1-8a00-5c84eb3e0b69_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items</link:label>
    <link:label id="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax rate effects for reconciliation between accounting profit and tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsAblynxMember_0d7e45a9-cdf6-46ca-bd04-ca8d77244dd8_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsAblynxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ablynx</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsAblynxMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsAblynxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Ablynx [Member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsAblynxMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsAblynxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Ablynx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsAblynxMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsAblynxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsAblynxMember" xlink:to="lab_sny_PrincipalMarketedProductsAblynxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis_e7017e62-3ef3-4a0e-96f4-8d1a3380fa70_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Associates [axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Associates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_4d71e8ee-bebc-4c5c-8070-2b8d7d76b798_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value (investments accounted for using the equity method, net of taxes)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value On Cash Flow Hedges Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value on cash flow hedges net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherEnvironmentRelatedProvisionMember_cbded8a3-2510-4ca8-8b0a-58aba49a2a35_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherEnvironmentRelatedProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other environment related provision</link:label>
    <link:label id="lab_ifrs-full_OtherEnvironmentRelatedProvisionMember_label_en-US" xlink:label="lab_ifrs-full_OtherEnvironmentRelatedProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other environment related provision [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEnvironmentRelatedProvisionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEnvironmentRelatedProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEnvironmentRelatedProvisionMember" xlink:to="lab_ifrs-full_OtherEnvironmentRelatedProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseLiabilitiesEffectOfDiscounting_8d48c91b-7624-41b4-93e7-c50d353b92a5_negatedTerseLabel_en-US" xlink:label="lab_sny_LeaseLiabilitiesEffectOfDiscounting" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounting effect</link:label>
    <link:label id="lab_sny_LeaseLiabilitiesEffectOfDiscounting_label_en-US" xlink:label="lab_sny_LeaseLiabilitiesEffectOfDiscounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liabilities, Effect Of Discounting</link:label>
    <link:label id="lab_sny_LeaseLiabilitiesEffectOfDiscounting_documentation_en-US" xlink:label="lab_sny_LeaseLiabilitiesEffectOfDiscounting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liabilities, Effect Of Discounting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseLiabilitiesEffectOfDiscounting" xlink:href="sny-20231231.xsd#sny_LeaseLiabilitiesEffectOfDiscounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseLiabilitiesEffectOfDiscounting" xlink:to="lab_sny_LeaseLiabilitiesEffectOfDiscounting" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember_5bc40cd6-1ef6-4656-8fcb-fb3d61e67218_terseLabel_en-US" xlink:label="lab_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax relating to capitalisation of R&amp;D expenses</link:label>
    <link:label id="lab_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember_label_en-US" xlink:label="lab_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Relating To Capitalisation Of R&amp;D Expenses [Member]</link:label>
    <link:label id="lab_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember_documentation_en-US" xlink:label="lab_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Relating To Capitalisation Of R&amp;D Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember" xlink:href="sny-20231231.xsd#sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember" xlink:to="lab_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030_aaef864c-c34f-4ecd-a28a-7a09dcf82509_terseLabel_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program, percentage of renewably-sourced energy in all sites by 2030</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030_label_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Percentage Of Renewably-Sourced Energy In All Sites By 2030</link:label>
    <link:label id="lab_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030_documentation_en-US" xlink:label="lab_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planet Care Program Objectives, Percentage Of Renewably-Sourced Energy In All Sites By 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030" xlink:to="lab_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_202a3e96-9bcd-4153-a113-c8da91333949_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average exercise&#160;price per share, options exercised (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets_04739912-000e-4fb1-aa41-d4227e3ebf21_negatedTerseLabel_en-US" xlink:label="lab_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals and other decreases</link:label>
    <link:label id="lab_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets_label_en-US" xlink:label="lab_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals And Retirements, Property, Plant And Equipment, Right Of Use Assets</link:label>
    <link:label id="lab_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets_documentation_en-US" xlink:label="lab_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals And Retirements, Property, Plant And Equipment, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" xlink:href="sny-20231231.xsd#sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" xlink:to="lab_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_1e18432d-42a6-44e6-a7e4-75f0f7ba88b1_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investments in Associates and Joint Ventures</link:label>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Investments In Associates And Joint Ventures [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure of investments in associates and joint ventures explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:to="lab_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember_aeea2227-5915-4ad0-b06e-3320533e1044_terseLabel_en-US" xlink:label="lab_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer contingent purchase consideration arising from the acquisition of Genzyme</link:label>
    <link:label id="lab_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember_label_en-US" xlink:label="lab_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Contingent Consideration Arising From The Acquisition Of Genzyme [Member]</link:label>
    <link:label id="lab_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember_documentation_en-US" xlink:label="lab_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer contingent purchase consideration arising from the acquisition of Genzyme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember" xlink:href="sny-20231231.xsd#sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember" xlink:to="lab_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_25e0dbf1-dccc-4d4d-96b1-bddd438e4d45_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisArgentinaSAMember_96fc62f7-4387-486e-a19f-ece54bd1d616_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisArgentinaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Argentina SA</link:label>
    <link:label id="lab_sny_SanofiAventisArgentinaSAMember_label_en-US" xlink:label="lab_sny_SanofiAventisArgentinaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Argentina S A [member]</link:label>
    <link:label id="lab_sny_SanofiAventisArgentinaSAMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisArgentinaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Argentina S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisArgentinaSAMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisArgentinaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisArgentinaSAMember" xlink:to="lab_sny_SanofiAventisArgentinaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisPrivateCoLtdMember_3e400ad6-c2ac-4b99-a683-b3615e65f59c_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisPrivateCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Private Co, Ltd</link:label>
    <link:label id="lab_sny_SanofiAventisPrivateCoLtdMember_label_en-US" xlink:label="lab_sny_SanofiAventisPrivateCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Private Co, Ltd [member]</link:label>
    <link:label id="lab_sny_SanofiAventisPrivateCoLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisPrivateCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Private Co, Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisPrivateCoLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisPrivateCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisPrivateCoLtdMember" xlink:to="lab_sny_SanofiAventisPrivateCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_b0278205-8d1c-4f04-8173-720fa1d04037_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital_01a612f7-b9e6-4da2-9658-a779dd8dbff4_terseLabel_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exceptional supplementary dividend proposed, percentage of share capital</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital_label_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exceptional Supplementary Dividend Proposed, Percentage Of Share Capital</link:label>
    <link:label id="lab_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital_documentation_en-US" xlink:label="lab_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exceptional Supplementary Dividend Proposed, Percentage Of Share Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital" xlink:to="lab_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_ebcf1673-31d4-45cc-bcab-a57809dca259_negatedLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options exercised (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7ed0285e-b794-4cb6-a4a8-4f063bc56c23_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfPreActionProtocolCases_ae68ce0b-14f8-488d-8666-03a7a3ae97c2_terseLabel_en-US" xlink:label="lab_sny_NumberOfPreActionProtocolCases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pre-action protocol cases</link:label>
    <link:label id="lab_sny_NumberOfPreActionProtocolCases_label_en-US" xlink:label="lab_sny_NumberOfPreActionProtocolCases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Pre-Action Protocol Cases</link:label>
    <link:label id="lab_sny_NumberOfPreActionProtocolCases_documentation_en-US" xlink:label="lab_sny_NumberOfPreActionProtocolCases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Pre-Action Protocol Cases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPreActionProtocolCases" xlink:href="sny-20231231.xsd#sny_NumberOfPreActionProtocolCases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfPreActionProtocolCases" xlink:to="lab_sny_NumberOfPreActionProtocolCases" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmortizedCostMember_969b570a-c83d-474d-ba63-198caa0a59ed_terseLabel_en-US" xlink:label="lab_sny_AmortizedCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_sny_AmortizedCostMember_label_en-US" xlink:label="lab_sny_AmortizedCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Member [member]</link:label>
    <link:label id="lab_sny_AmortizedCostMember_documentation_en-US" xlink:label="lab_sny_AmortizedCostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostMember" xlink:href="sny-20231231.xsd#sny_AmortizedCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmortizedCostMember" xlink:to="lab_sny_AmortizedCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_cb444492-6051-41b4-b963-5a6fe16e4513_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Options Outstanding and Exercisable</link:label>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of share based compensation shares authorized under stock option plans by exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:to="lab_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_7cca8eb3-fe0d-4552-8f5b-3a36dcc35845_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_716cb5c3-8159-4b87-9aa6-66e07b54cd89_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Movements in Non-current Provisions</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non-Current Provisions [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of noncurrent provisions explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:to="lab_sny_DisclosureOfNonCurrentProvisionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred_743031ac-440d-42c1-96f6-8ed8a587eb34_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding third-party debt liabilities incurred</link:label>
    <link:label id="lab_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred_label_en-US" xlink:label="lab_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Outstanding Third-Party Liabilities Incurred</link:label>
    <link:label id="lab_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred_documentation_en-US" xlink:label="lab_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Outstanding Third-Party Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred" xlink:href="sny-20231231.xsd#sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred" xlink:to="lab_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember_df530297-1a21-4e25-9459-e197e05ba18e_terseLabel_en-US" xlink:label="lab_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of computer software and other rights of an industrial or operational nature</link:label>
    <link:label id="lab_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember_label_en-US" xlink:label="lab_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Computer Software And Other Rights Of An Industrial Or Operational Nature [member]</link:label>
    <link:label id="lab_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember_documentation_en-US" xlink:label="lab_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of computer software and other rights of an industrial or operational nature.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember" xlink:href="sny-20231231.xsd#sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember" xlink:to="lab_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_b46c098b-4516-422b-ae45-b267b8b41bb1_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Gross Value of Overdue Receivables</link:label>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Overdue Receivables Gross Value [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of overdue receivables gross value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:to="lab_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_6f70da12-f565-4ab4-85ff-53c1f89cdd4f_negatedLabel_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses arising from the impact of acquisitions on inventories</link:label>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_label_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Arising From The Impact Of Acquisitions On Inventories</link:label>
    <link:label id="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_documentation_en-US" xlink:label="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses arising from the impact of acquisitions on inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:href="sny-20231231.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:to="lab_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7f7df0ca-c037-4c20-9c54-d7a3f3156789_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of exchange differences on translation</link:label>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of exchange differences on translation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForJointOperationsMember_f6cfef9c-4dee-4aec-8420-8c80a8164d37_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForJointOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's Total for Joint Operations [Member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForJointOperationsMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForJointOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for joint operations [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointOperationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember" xlink:to="lab_ifrs-full_EntitysTotalForJointOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_c86c0212-ea58-4af4-8900-23ee94cd13e4_verboseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_691e65db-936d-4153-bbc5-0220f0bfed82_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_label_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_8b0b4d4b-a52e-4c41-a01d-429574b8af75_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable_eb22f848-61a2-4e5c-bfc4-459388cd5892_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable_label_en-US" xlink:label="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Maximum Amount Of Contingent Consideration Payable And Firm Commitments To Buy Out Non-Controlling Interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable" xlink:to="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer_89596346-d7cf-491d-b0af-81be46c062d1_terseLabel_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per share awarded for three year service period, to chief executive officer (in euros per share)</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer_label_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Per Share Awarded For Three Year Service Period, To Chief Executive Officer</link:label>
    <link:label id="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer_documentation_en-US" xlink:label="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Per Share Awarded For Three Year Service Period, To Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" xlink:href="sny-20231231.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" xlink:to="lab_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInUSDollarMember_b85302d3-87ee-4538-a884-a45314681b0b_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases in US Dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInUSDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchased In US Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasedInUSDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasedInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases in USD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInUSDollarMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasedInUSDollarMember" xlink:to="lab_sny_ForwardCurrencyPurchasedInUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory_75508f78-27c7-4287-b54d-a845b410339b_terseLabel_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory_label_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Cost Of Sales [Policy Text Block]</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory_documentation_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for cost of sales explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory" xlink:to="lab_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_QuotedEquityInvestmentsMember_5319a6c6-29f7-4fe2-911c-b48a4c89c8a0_terseLabel_en-US" xlink:label="lab_sny_QuotedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted equity investments</link:label>
    <link:label id="lab_sny_QuotedEquityInvestmentsMember_label_en-US" xlink:label="lab_sny_QuotedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Equity Investments [Member]</link:label>
    <link:label id="lab_sny_QuotedEquityInvestmentsMember_documentation_en-US" xlink:label="lab_sny_QuotedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted equity investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedEquityInvestmentsMember" xlink:href="sny-20231231.xsd#sny_QuotedEquityInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_QuotedEquityInvestmentsMember" xlink:to="lab_sny_QuotedEquityInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_265ec2b4-d1a5-441b-855c-9c3c36fcd8b1_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_label_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued In Regards Of Capital Increase By Exercise Of Stock Subscription Options</link:label>
    <link:label id="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_documentation_en-US" xlink:label="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in regards of capital increase by exercise of stock subscription options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:href="sny-20231231.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:to="lab_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_52083661-f3c8-4c5d-8fc8-f3a70c695503_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareSpainSLMember_5384d5ed-eb24-4362-9e73-392de0ae2563_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareSpainSLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Spain, SL</link:label>
    <link:label id="lab_sny_OpellaHealthcareSpainSLMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareSpainSLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Spain, S.L. [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareSpainSLMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareSpainSLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Spain, S.L.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareSpainSLMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareSpainSLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareSpainSLMember" xlink:to="lab_sny_OpellaHealthcareSpainSLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_cd1ace8c-10ba-403b-9a64-9345798a264c_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year 3</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_72ade14d-3570-4f03-9537-c5cceab17ff3_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2 to 3 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than two years and not later than three years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_288f8a8b-9c2a-4ddf-a45a-413d1269aa12_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiKKMember_0e29cd32-7d45-4955-a2c4-9b3679184cd2_terseLabel_en-US" xlink:label="lab_sny_SanofiKKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi K.K.</link:label>
    <link:label id="lab_sny_SanofiKKMember_label_en-US" xlink:label="lab_sny_SanofiKKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi K.K [Member]</link:label>
    <link:label id="lab_sny_SanofiKKMember_documentation_en-US" xlink:label="lab_sny_SanofiKKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi K.K.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiKKMember" xlink:href="sny-20231231.xsd#sny_SanofiKKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiKKMember" xlink:to="lab_sny_SanofiKKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfAgreementsSigned_a669a6d7-8e86-4456-a260-784fc2e737e4_terseLabel_en-US" xlink:label="lab_sny_NumberOfAgreementsSigned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements signed</link:label>
    <link:label id="lab_sny_NumberOfAgreementsSigned_label_en-US" xlink:label="lab_sny_NumberOfAgreementsSigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Agreements Signed</link:label>
    <link:label id="lab_sny_NumberOfAgreementsSigned_documentation_en-US" xlink:label="lab_sny_NumberOfAgreementsSigned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Agreements Signed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfAgreementsSigned" xlink:href="sny-20231231.xsd#sny_NumberOfAgreementsSigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfAgreementsSigned" xlink:to="lab_sny_NumberOfAgreementsSigned" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInTaiwanDollarMember_e6b6dc79-17bb-4fbc-84b0-e5aec0138c90_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInTaiwanDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency sales in Taiwan Dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInTaiwanDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInTaiwanDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In Taiwan Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInTaiwanDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInTaiwanDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In Taiwan Dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInTaiwanDollarMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInTaiwanDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInTaiwanDollarMember" xlink:to="lab_sny_ForwardCurrencySalesInTaiwanDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_eb88c10f-f25a-4d75-952e-0ef49e5c67b9_terseLabel_en-US" xlink:label="lab_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense relating to short-term leases and low value assets</link:label>
    <link:label id="lab_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_label_en-US" xlink:label="lab_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Relating To Short-term Leases And Low Value Assets For Which Recognition Exemption Has Been Used</link:label>
    <link:label id="lab_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_documentation_en-US" xlink:label="lab_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Relating To Short-term Leases And Low Value Assets For Which Recognition Exemption Has Been Used</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="sny-20231231.xsd#sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="lab_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_6c6e0acc-b4d0-4273-8161-4fcaa6b9e19f_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax losses available for carry-forward</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DevelopmentOfCemiplimabREGN2810Member_b6ba4625-f3aa-4c6f-8960-772e1182cdb2_terseLabel_en-US" xlink:label="lab_sny_DevelopmentOfCemiplimabREGN2810Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development of cemiplimab (REGN2810)</link:label>
    <link:label id="lab_sny_DevelopmentOfCemiplimabREGN2810Member_label_en-US" xlink:label="lab_sny_DevelopmentOfCemiplimabREGN2810Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Of Cemiplimab (REGN2810) [Member]</link:label>
    <link:label id="lab_sny_DevelopmentOfCemiplimabREGN2810Member_documentation_en-US" xlink:label="lab_sny_DevelopmentOfCemiplimabREGN2810Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development of cemiplimab (REGN2810).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DevelopmentOfCemiplimabREGN2810Member" xlink:href="sny-20231231.xsd#sny_DevelopmentOfCemiplimabREGN2810Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DevelopmentOfCemiplimabREGN2810Member" xlink:to="lab_sny_DevelopmentOfCemiplimabREGN2810Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities_b8a1d6af-1cee-47bc-b90b-15de3ce212de_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities_cf7e8f76-c14a-4f12-83eb-cb9cbd41cfd2_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember_cb79fd1e-e708-4af5-95f0-c45097593376_terseLabel_en-US" xlink:label="lab_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct royalty agreement with SOBI on sales of BeyfortusTM in the United States</link:label>
    <link:label id="lab_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember_label_en-US" xlink:label="lab_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement With SOBI On Sales Of Beyfortus In The US [Member]</link:label>
    <link:label id="lab_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember_documentation_en-US" xlink:label="lab_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement With SOBI On Sales Of Beyfortus In The US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember" xlink:href="sny-20231231.xsd#sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember" xlink:to="lab_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareLLCMember_b0e8f1df-13dc-4d3c-9c59-33557a8ce44c_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare LLC</link:label>
    <link:label id="lab_sny_OpellaHealthcareLLCMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare LLC [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareLLCMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareLLCMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareLLCMember" xlink:to="lab_sny_OpellaHealthcareLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_98235135-8bc8-4270-8515-a6dcc38cc2ec_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans_442d37a5-49b2-4e8e-9641-3318b6bb29fd_terseLabel_en-US" xlink:label="lab_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average residual holding periods</link:label>
    <link:label id="lab_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans_label_en-US" xlink:label="lab_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Residual Holding Periods Under Various Early Retirement Plans</link:label>
    <link:label id="lab_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans_documentation_en-US" xlink:label="lab_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average residual holding periods under various early retirement plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans" xlink:href="sny-20231231.xsd#sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans" xlink:to="lab_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_42d79644-69ed-43d5-a462-3bdecd49f8d0_terseLabel_en-US" xlink:label="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of contributions expected to be paid to plan for next annual reporting period</link:label>
    <link:label id="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_label_en-US" xlink:label="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of contributions expected to be paid to plan for next annual reporting period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:to="lab_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_5129179a-cd59-430c-900b-511583f03f7c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Aggregate Amounts Payable to Key Management Personnel</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_3ddef536-3e93-4a87-8b44-577010877bb9_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, term deposits</link:label>
    <link:label id="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term deposits, classified as cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtLineItems_0d00ce22-3246-482f-a2be-634497bfdeac_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of debt [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtLineItems" xlink:to="lab_sny_DisclosureOfDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiResearchInvestLLCMember_2cf350af-fd64-4f05-a41b-a1f9a61b231e_terseLabel_en-US" xlink:label="lab_sny_SanofiResearchInvestLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Research Invest LLC</link:label>
    <link:label id="lab_sny_SanofiResearchInvestLLCMember_label_en-US" xlink:label="lab_sny_SanofiResearchInvestLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Research Invest LLC [Member]</link:label>
    <link:label id="lab_sny_SanofiResearchInvestLLCMember_documentation_en-US" xlink:label="lab_sny_SanofiResearchInvestLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Research Invest LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiResearchInvestLLCMember" xlink:href="sny-20231231.xsd#sny_SanofiResearchInvestLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiResearchInvestLLCMember" xlink:to="lab_sny_SanofiResearchInvestLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgedItemsAxis_a4940eb8-681a-40fa-9fb1-46be34ff2979_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged items [axis]</link:label>
    <link:label id="lab_ifrs-full_HedgedItemsAxis_label_en-US" xlink:label="lab_ifrs-full_HedgedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgedItemsAxis" xlink:to="lab_ifrs-full_HedgedItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisPhilippinesIncMember_e6def38e-6d86-499f-80b6-92e4bf2eea0c_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisPhilippinesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Philippines Inc.</link:label>
    <link:label id="lab_sny_SanofiAventisPhilippinesIncMember_label_en-US" xlink:label="lab_sny_SanofiAventisPhilippinesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Philippines Inc [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisPhilippinesIncMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisPhilippinesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Philippines Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisPhilippinesIncMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisPhilippinesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisPhilippinesIncMember" xlink:to="lab_sny_SanofiAventisPhilippinesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherGuaranteesGivenMember_ad6fde7a-81cb-4397-81b6-617224b4ab59_terseLabel_en-US" xlink:label="lab_sny_OtherGuaranteesGivenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other guarantees given</link:label>
    <link:label id="lab_sny_OtherGuaranteesGivenMember_label_en-US" xlink:label="lab_sny_OtherGuaranteesGivenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Guarantees Given [Member]</link:label>
    <link:label id="lab_sny_OtherGuaranteesGivenMember_documentation_en-US" xlink:label="lab_sny_OtherGuaranteesGivenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Guarantees Given</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGuaranteesGivenMember" xlink:href="sny-20231231.xsd#sny_OtherGuaranteesGivenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherGuaranteesGivenMember" xlink:to="lab_sny_OtherGuaranteesGivenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesMember_20f1a68a-cd56-4676-a31d-35f79c8a5706_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [member]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesMember" xlink:to="lab_ifrs-full_LiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValueMeasurementAbstract_6f09fe98-4400-49b2-8d46-ad6e0623c8d3_terseLabel_en-US" xlink:label="lab_sny_FairValueMeasurementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Abstract]</link:label>
    <link:label id="lab_sny_FairValueMeasurementAbstract_label_en-US" xlink:label="lab_sny_FairValueMeasurementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Abstract]</link:label>
    <link:label id="lab_sny_FairValueMeasurementAbstract_documentation_en-US" xlink:label="lab_sny_FairValueMeasurementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueMeasurementAbstract" xlink:href="sny-20231231.xsd#sny_FairValueMeasurementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValueMeasurementAbstract" xlink:to="lab_sny_FairValueMeasurementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockOptionsAndShareBasedPaymentsMember_2c66cdd6-2590-4835-9251-c4386d4a5df2_terseLabel_en-US" xlink:label="lab_sny_StockOptionsAndShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and other share-based payments</link:label>
    <link:label id="lab_sny_StockOptionsAndShareBasedPaymentsMember_label_en-US" xlink:label="lab_sny_StockOptionsAndShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Share Based Payments [Member]</link:label>
    <link:label id="lab_sny_StockOptionsAndShareBasedPaymentsMember_documentation_en-US" xlink:label="lab_sny_StockOptionsAndShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and share based payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionsAndShareBasedPaymentsMember" xlink:href="sny-20231231.xsd#sny_StockOptionsAndShareBasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockOptionsAndShareBasedPaymentsMember" xlink:to="lab_sny_StockOptionsAndShareBasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MyozymeOrLumizymeMember_38fbeee9-adbc-4c13-bc06-083e50e57b7a_terseLabel_en-US" xlink:label="lab_sny_MyozymeOrLumizymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYOZYME/ LUMIZYME</link:label>
    <link:label id="lab_sny_MyozymeOrLumizymeMember_label_en-US" xlink:label="lab_sny_MyozymeOrLumizymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myozyme Or Lumizyme [Member]</link:label>
    <link:label id="lab_sny_MyozymeOrLumizymeMember_documentation_en-US" xlink:label="lab_sny_MyozymeOrLumizymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myozyme or Lumizyme [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MyozymeOrLumizymeMember" xlink:href="sny-20231231.xsd#sny_MyozymeOrLumizymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MyozymeOrLumizymeMember" xlink:to="lab_sny_MyozymeOrLumizymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestructuringCostsReversedAndSimilarItems_badbd398-d452-4fb8-9ce0-05c46dcca7f1_verboseLabel_en-US" xlink:label="lab_sny_RestructuringCostsReversedAndSimilarItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_sny_RestructuringCostsReversedAndSimilarItems_label_en-US" xlink:label="lab_sny_RestructuringCostsReversedAndSimilarItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs (Reversed) And Similar Items</link:label>
    <link:label id="lab_sny_RestructuringCostsReversedAndSimilarItems_documentation_en-US" xlink:label="lab_sny_RestructuringCostsReversedAndSimilarItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs (Reversed) And Similar Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestructuringCostsReversedAndSimilarItems" xlink:href="sny-20231231.xsd#sny_RestructuringCostsReversedAndSimilarItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestructuringCostsReversedAndSimilarItems" xlink:to="lab_sny_RestructuringCostsReversedAndSimilarItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_c0ff908a-080f-4cda-81df-cca00a05242f_terseLabel_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Other Operating Expenses</link:label>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_label_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Expenses [Table Text Block]</link:label>
    <link:label id="lab_sny_OtherOperatingExpensesTableTextBlock_documentation_en-US" xlink:label="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Expenses [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpensesTableTextBlock" xlink:href="sny-20231231.xsd#sny_OtherOperatingExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherOperatingExpensesTableTextBlock" xlink:to="lab_sny_OtherOperatingExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_73f3f49b-fa2c-4fe3-be6a-b4f8d670ca70_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InventoriesPledgedAsSecurityForLiabilities_d329697e-4d01-43a3-bf09-a5e07008b90c_terseLabel_en-US" xlink:label="lab_ifrs-full_InventoriesPledgedAsSecurityForLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories pledged as security for liabilities</link:label>
    <link:label id="lab_ifrs-full_InventoriesPledgedAsSecurityForLiabilities_label_en-US" xlink:label="lab_ifrs-full_InventoriesPledgedAsSecurityForLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories pledged as security for liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InventoriesPledgedAsSecurityForLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoriesPledgedAsSecurityForLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InventoriesPledgedAsSecurityForLiabilities" xlink:to="lab_ifrs-full_InventoriesPledgedAsSecurityForLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings_667f4ed0-7d5d-438a-8262-1a8a2bf3f5e6_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in borrowings through change in scope of consolidation</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Change In Scope Of Consolidation, Borrowings</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Change In Scope Of Consolidation, Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings" xlink:to="lab_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ParticipatingSharesNumberOutstanding_37cc807c-4767-41c5-8e61-a64cfd0fe42a_terseLabel_en-US" xlink:label="lab_sny_ParticipatingSharesNumberOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of participating shares outstanding (in shares)</link:label>
    <link:label id="lab_sny_ParticipatingSharesNumberOutstanding_label_en-US" xlink:label="lab_sny_ParticipatingSharesNumberOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Shares Number Outstanding</link:label>
    <link:label id="lab_sny_ParticipatingSharesNumberOutstanding_documentation_en-US" xlink:label="lab_sny_ParticipatingSharesNumberOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating shares number outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ParticipatingSharesNumberOutstanding" xlink:href="sny-20231231.xsd#sny_ParticipatingSharesNumberOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ParticipatingSharesNumberOutstanding" xlink:to="lab_sny_ParticipatingSharesNumberOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_76141fec-63a7-454a-8d94-8a091cc70ae0_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency sales in US Dollar</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In US Dollar [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInUSDollarMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency sales in USD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInUSDollarMember" xlink:to="lab_sny_ForwardCurrencySalesInUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_b535d018-0f77-4c97-a1f2-71c0d829b241_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Provisional Purchase Price Allocation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_97424e61-7513-474e-b355-0d84472266b7_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Final Purchase Price Allocation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about business combination [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfBellweatherTrialsHeld_2aac4502-1868-4034-ab97-c663ab2257c5_terseLabel_en-US" xlink:label="lab_sny_NumberOfBellweatherTrialsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of bellweather trial held</link:label>
    <link:label id="lab_sny_NumberOfBellweatherTrialsHeld_label_en-US" xlink:label="lab_sny_NumberOfBellweatherTrialsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Bellweather Trials Held</link:label>
    <link:label id="lab_sny_NumberOfBellweatherTrialsHeld_documentation_en-US" xlink:label="lab_sny_NumberOfBellweatherTrialsHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Bellweather Trials Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBellweatherTrialsHeld" xlink:href="sny-20231231.xsd#sny_NumberOfBellweatherTrialsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfBellweatherTrialsHeld" xlink:to="lab_sny_NumberOfBellweatherTrialsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInOtherProvisions_62b4ed70-2c65-4058-b134-3739df492d06_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases in provisions</link:label>
    <link:label id="lab_ifrs-full_ChangesInOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_ChangesInOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInOtherProvisions" xlink:to="lab_ifrs-full_ChangesInOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock_41c799cd-da50-4da3-91ab-077517b628dd_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Profit (Loss) Attributable To Non-Controlling Interests [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for net income attributable to non-controlling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock" xlink:to="lab_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SAR444245Member_0ec3b9b0-39de-47fb-9a2c-9f4b8dbdfcd3_terseLabel_en-US" xlink:label="lab_sny_SAR444245Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SAR444245</link:label>
    <link:label id="lab_sny_SAR444245Member_label_en-US" xlink:label="lab_sny_SAR444245Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SAR444245 [Member]</link:label>
    <link:label id="lab_sny_SAR444245Member_documentation_en-US" xlink:label="lab_sny_SAR444245Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SAR444245</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SAR444245Member" xlink:href="sny-20231231.xsd#sny_SAR444245Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SAR444245Member" xlink:to="lab_sny_SAR444245Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AntibodiesAllianceMember_c3fe8905-516c-44e1-aa5f-baaaa5cd5b08_terseLabel_en-US" xlink:label="lab_sny_AntibodiesAllianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monoclonal Antibody Alliance</link:label>
    <link:label id="lab_sny_AntibodiesAllianceMember_label_en-US" xlink:label="lab_sny_AntibodiesAllianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antibodies Alliance [Member]</link:label>
    <link:label id="lab_sny_AntibodiesAllianceMember_documentation_en-US" xlink:label="lab_sny_AntibodiesAllianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antibodies Alliance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesAllianceMember" xlink:href="sny-20231231.xsd#sny_AntibodiesAllianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AntibodiesAllianceMember" xlink:to="lab_sny_AntibodiesAllianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan_c2ad511d-2d98-493d-9e65-d1f7fb9abd04_negatedLabel_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan amendments, curtailments or settlements not specified in the terms of the plan</link:label>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan_label_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Plan Amendments, Curtailments Or Settlements Not Specified In The Terms Of The Plan</link:label>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan_documentation_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Plan Amendments, Curtailments Or Settlements Not Specified In The Terms Of The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" xlink:to="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_7dca3f4f-0dfc-4fa1-9eed-71c44f9d80ba_terseLabel_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Of&#160;which recognized&#160;in&#160;equity</link:label>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_label_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Of Hedge Recognized In Equity [Member]</link:label>
    <link:label id="lab_sny_ValueOfHedgeRecognizedInEquityMember_documentation_en-US" xlink:label="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Of Hedge Recognized In Equity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember" xlink:href="sny-20231231.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOfHedgeRecognizedInEquityMember" xlink:to="lab_sny_ValueOfHedgeRecognizedInEquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfOngoingLawsuits_3a28fd1c-ffe7-4ced-95b5-a2549be50d5a_terseLabel_en-US" xlink:label="lab_sny_NumberOfOngoingLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ongoing lawsuits</link:label>
    <link:label id="lab_sny_NumberOfOngoingLawsuits_label_en-US" xlink:label="lab_sny_NumberOfOngoingLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ongoing Lawsuits</link:label>
    <link:label id="lab_sny_NumberOfOngoingLawsuits_documentation_en-US" xlink:label="lab_sny_NumberOfOngoingLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ongoing Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOngoingLawsuits" xlink:href="sny-20231231.xsd#sny_NumberOfOngoingLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfOngoingLawsuits" xlink:to="lab_sny_NumberOfOngoingLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod_7ed5409f-cce0-400e-b906-895f15e55514_terseLabel_en-US" xlink:label="lab_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified environmental risks provisions estimated obligation period</link:label>
    <link:label id="lab_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod_label_en-US" xlink:label="lab_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified Environmental Risks Provisions Estimated Obligation Period</link:label>
    <link:label id="lab_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod_documentation_en-US" xlink:label="lab_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified environmental risks provisions estimated obligation period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod" xlink:href="sny-20231231.xsd#sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod" xlink:to="lab_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_02f53e6e-93fd-47d4-9bb7-a8552863f5ea_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_5ce97db4-fc7b-4634-92b5-20fd888fb840_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income)</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_c5f4a88c-c8c5-4c86-ba62-8f4c24e252c8_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember_359638af-94f4-45a7-bf68-76c415b6c669_terseLabel_en-US" xlink:label="lab_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of other acquired intangible assets</link:label>
    <link:label id="lab_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember_label_en-US" xlink:label="lab_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Of Other Acquired Intangible Assets [Member]</link:label>
    <link:label id="lab_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember_documentation_en-US" xlink:label="lab_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of other acquired intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember" xlink:href="sny-20231231.xsd#sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember" xlink:to="lab_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_2d72ffd8-49ca-4606-a2c1-b761d9fd6fde_negatedLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_ab429c41-77d1-4367-b71d-5e036ad6efd6_verboseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_8db2effc-e46c-40a2-8748-072105d97fb0_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expense</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous other operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare_f0f87aa8-45ab-44e4-8d0b-ae1bbcb60e66_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of non-transferable contingent value right issued</link:label>
    <link:label id="lab_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare_label_en-US" xlink:label="lab_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Non-Transferable Contingent Value Right Issued Per Share</link:label>
    <link:label id="lab_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare_documentation_en-US" xlink:label="lab_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Non-Transferable Contingent Value Right Issued Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare" xlink:href="sny-20231231.xsd#sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare" xlink:to="lab_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PharmaceuticalsSegmentMember_d57de38b-3992-4c5a-a2f0-66794e2159f5_terseLabel_en-US" xlink:label="lab_sny_PharmaceuticalsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceuticals</link:label>
    <link:label id="lab_sny_PharmaceuticalsSegmentMember_label_en-US" xlink:label="lab_sny_PharmaceuticalsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceuticals Segment [member]</link:label>
    <link:label id="lab_sny_PharmaceuticalsSegmentMember_documentation_en-US" xlink:label="lab_sny_PharmaceuticalsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceuticals segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaceuticalsSegmentMember" xlink:href="sny-20231231.xsd#sny_PharmaceuticalsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PharmaceuticalsSegmentMember" xlink:to="lab_sny_PharmaceuticalsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember_69b3ea5e-bbec-4aa2-bfba-57c56a3f1d5b_terseLabel_en-US" xlink:label="lab_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments held to fund deferred compensation plan</link:label>
    <link:label id="lab_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember_label_en-US" xlink:label="lab_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Held To Fund Deferred Compensation Plan [Member]</link:label>
    <link:label id="lab_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember_documentation_en-US" xlink:label="lab_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Held To Fund Deferred Compensation Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember" xlink:href="sny-20231231.xsd#sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember" xlink:to="lab_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_5dc3554d-d8d9-46ca-83c0-4034db3ab7f3_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From&#160;1&#160;to 3&#160;years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year and not later than three years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries_45a882f8-58f6-4abd-87c5-d9b377bded03_terseLabel_en-US" xlink:label="lab_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit-related services charged to the parent company and its French subsidiaries</link:label>
    <link:label id="lab_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries_label_en-US" xlink:label="lab_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Related Services Charged To The Parent Company And Its French Subsidiaries</link:label>
    <link:label id="lab_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries_documentation_en-US" xlink:label="lab_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit-related services charged to the parent company and its French subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" xlink:href="sny-20231231.xsd#sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" xlink:to="lab_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_fe1bac2b-172c-4c17-a377-2c5f08a37080_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_label_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Purchases [Member]</link:label>
    <link:label id="lab_sny_ForwardCurrencyPurchasesMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencyPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency purchases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencyPurchasesMember" xlink:to="lab_sny_ForwardCurrencyPurchasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueOfAcquiree_5c11a4d9-61c7-468e-a339-f84c7e9567ff_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from acquiree to net sales</link:label>
    <link:label id="lab_ifrs-full_RevenueOfAcquiree_label_en-US" xlink:label="lab_ifrs-full_RevenueOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue of acquiree since acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueOfAcquiree" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueOfAcquiree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueOfAcquiree" xlink:to="lab_ifrs-full_RevenueOfAcquiree" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherCurrenciesMember_d06e3900-5469-4284-9429-e717da8b6c3d_terseLabel_en-US" xlink:label="lab_sny_OtherCurrenciesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other currencies</link:label>
    <link:label id="lab_sny_OtherCurrenciesMember_label_en-US" xlink:label="lab_sny_OtherCurrenciesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Currencies [Member]</link:label>
    <link:label id="lab_sny_OtherCurrenciesMember_documentation_en-US" xlink:label="lab_sny_OtherCurrenciesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Currencies [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrenciesMember" xlink:href="sny-20231231.xsd#sny_OtherCurrenciesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherCurrenciesMember" xlink:to="lab_sny_OtherCurrenciesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember_84d147de-67e0-4a75-a1e1-9ec088d95b83_terseLabel_en-US" xlink:label="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets excluding software</link:label>
    <link:label id="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember_label_en-US" xlink:label="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets Excluding Software [Member]</link:label>
    <link:label id="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember_documentation_en-US" xlink:label="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets Excluding Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:href="sny-20231231.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:to="lab_sny_OtherIntangibleAssetsExcludingSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InvestmentsInAssociatesAndJointVentures_f4c608ff-a417-4d38-af9f-02c2692d8570_terseLabel_en-US" xlink:label="lab_sny_InvestmentsInAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments accounted for using the equity method</link:label>
    <link:label id="lab_sny_InvestmentsInAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_InvestmentsInAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_InvestmentsInAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_InvestmentsInAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of investments, joint ventures and associates in an entity's separate financial statements. Long term equity interest, significant influence.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_InvestmentsInAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InvestmentsInAssociatesAndJointVentures" xlink:to="lab_sny_InvestmentsInAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_4194f5af-8132-4cce-9147-8bd71a5907b3_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price range four</link:label>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember" xlink:href="sny-20231231.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeFourMember" xlink:to="lab_sny_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MaximumOwnershipPercentageAllowedToAcquire_b8efc5c3-c16a-4d37-a0c8-fb9fe38801ef_terseLabel_en-US" xlink:label="lab_sny_MaximumOwnershipPercentageAllowedToAcquire" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage allowed to acquire</link:label>
    <link:label id="lab_sny_MaximumOwnershipPercentageAllowedToAcquire_label_en-US" xlink:label="lab_sny_MaximumOwnershipPercentageAllowedToAcquire" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Ownership Percentage Allowed To Acquire</link:label>
    <link:label id="lab_sny_MaximumOwnershipPercentageAllowedToAcquire_documentation_en-US" xlink:label="lab_sny_MaximumOwnershipPercentageAllowedToAcquire" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage allowed to acquire.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumOwnershipPercentageAllowedToAcquire" xlink:href="sny-20231231.xsd#sny_MaximumOwnershipPercentageAllowedToAcquire"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MaximumOwnershipPercentageAllowedToAcquire" xlink:to="lab_sny_MaximumOwnershipPercentageAllowedToAcquire" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_73b4e6d9-951f-4ae9-bf07-5a03b29f28f5_terseLabel_en-US" xlink:label="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net obligation</link:label>
    <link:label id="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_label_en-US" xlink:label="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:to="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseCategoriesDomain_e348f82d-7f4a-453d-953c-c79702a20db8_terseLabel_en-US" xlink:label="lab_sny_ExpenseCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Categories [Domain]</link:label>
    <link:label id="lab_sny_ExpenseCategoriesDomain_label_en-US" xlink:label="lab_sny_ExpenseCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Categories [Domain]</link:label>
    <link:label id="lab_sny_ExpenseCategoriesDomain_documentation_en-US" xlink:label="lab_sny_ExpenseCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Categories [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseCategoriesDomain" xlink:href="sny-20231231.xsd#sny_ExpenseCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseCategoriesDomain" xlink:to="lab_sny_ExpenseCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCountriesIncludedInPensionPlans_6dbdb76c-8d07-4d06-a477-240411cca1be_terseLabel_en-US" xlink:label="lab_sny_NumberOfCountriesIncludedInPensionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major countries included in pension obligations</link:label>
    <link:label id="lab_sny_NumberOfCountriesIncludedInPensionPlans_label_en-US" xlink:label="lab_sny_NumberOfCountriesIncludedInPensionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries Included In Pension Plans</link:label>
    <link:label id="lab_sny_NumberOfCountriesIncludedInPensionPlans_documentation_en-US" xlink:label="lab_sny_NumberOfCountriesIncludedInPensionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries included in pension plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCountriesIncludedInPensionPlans" xlink:href="sny-20231231.xsd#sny_NumberOfCountriesIncludedInPensionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCountriesIncludedInPensionPlans" xlink:to="lab_sny_NumberOfCountriesIncludedInPensionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany_1b640c52-a22e-44fe-b12d-d00c87fef77a_verboseLabel_en-US" xlink:label="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development expense funded by company</link:label>
    <link:label id="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany_label_en-US" xlink:label="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Future Development Expense Funded By Company</link:label>
    <link:label id="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany_documentation_en-US" xlink:label="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development expense funded by company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany" xlink:href="sny-20231231.xsd#sny_PercentageOfFutureDevelopmentExpenseFundedByCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany" xlink:to="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillMember_94bb83f2-6f89-412e-be6c-ba596e1ff4ff_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and goodwill [member]</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_df38d3c5-f21e-466f-88d0-20bc76e3f9aa_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current service cost</link:label>
    <link:label id="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in net defined benefit liability (asset) resulting from current service cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_5e186896-f8cc-44a5-8490-11d79d0e6f23_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount shown in the balance sheet at end of period</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_ec5ab1a6-fb36-49db-bfb8-960cd1c1c47e_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_5dca5e81-b819-41a6-aa34-70e7453f3058_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_96b380ff-f8d6-40cc-95bd-e8e3202f0c72_totalLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount shown in the balance sheet at end of period</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_40d9d5e1-cd41-4ce8-8722-ec950bb24d2e_verboseLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_12a8ec9b-ade2-4271-ad3e-b02632a016c5_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs and similar items</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Restructuring Costs And Similar Items [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure of restructuring costs and similar items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:to="lab_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_c35aa318-e0b9-48cd-a149-144a9568adaf_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_045d7e2c-36b8-4ad4-94b4-112eab50a5df_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2021ProgramMember_56f00747-336f-41db-8a3c-6759fb505114_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2021ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_sny_ShareRepurchase2021ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2021ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase 2021 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2021ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2021ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase 2021 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2021ProgramMember" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2021ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2021ProgramMember" xlink:to="lab_sny_ShareRepurchase2021ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_c4408b80-6fb0-4d85-bd0f-8ce55cf733d4_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [member]</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RestructuringProvisionAbstract_8e1e87b7-9704-4ee5-ab48-b3e580ead304_terseLabel_en-US" xlink:label="lab_ifrs-full_RestructuringProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Of which:</link:label>
    <link:label id="lab_ifrs-full_RestructuringProvisionAbstract_label_en-US" xlink:label="lab_ifrs-full_RestructuringProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring provision [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestructuringProvisionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestructuringProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestructuringProvisionAbstract" xlink:to="lab_ifrs-full_RestructuringProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_28135dfd-d59b-4783-9705-95357166e5d1_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_QRIMember_5c58081d-e057-4553-b146-ce165c35ee94_terseLabel_en-US" xlink:label="lab_sny_QRIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QRI</link:label>
    <link:label id="lab_sny_QRIMember_label_en-US" xlink:label="lab_sny_QRIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QRI [Member]</link:label>
    <link:label id="lab_sny_QRIMember_documentation_en-US" xlink:label="lab_sny_QRIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QRI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIMember" xlink:href="sny-20231231.xsd#sny_QRIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_QRIMember" xlink:to="lab_sny_QRIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod_61290b4d-9d4a-4e71-8e1c-7f49a6e3f1f9_terseLabel_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administration costs and taxes paid during the period</link:label>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod_label_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Administration Costs And Taxes Paid During The Period</link:label>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod_documentation_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Administration Costs And Taxes Paid During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" xlink:to="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_2fe94f87-0d97-461a-ab2d-4afacbece98e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DividendsPaidAbstract_adfd22c3-4290-4061-a7f6-f9c758a0c3ad_terseLabel_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid:</link:label>
    <link:label id="lab_sny_DividendsPaidAbstract_label_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Paid [Abstract]</link:label>
    <link:label id="lab_sny_DividendsPaidAbstract_documentation_en-US" xlink:label="lab_sny_DividendsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsPaidAbstract" xlink:href="sny-20231231.xsd#sny_DividendsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DividendsPaidAbstract" xlink:to="lab_sny_DividendsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures_30bcc84a-d717-4da4-baca-b109abf13c86_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures" xlink:to="lab_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_327a0fc8-2f6c-40c6-86fa-f7fb04c4dd3b_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for treasury shares [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCurrenciesDebtIsIssuedIn_6436f7ac-0866-4d62-84e0-536f4eabf81c_terseLabel_en-US" xlink:label="lab_sny_NumberOfCurrenciesDebtIsIssuedIn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of currencies debt is issued in</link:label>
    <link:label id="lab_sny_NumberOfCurrenciesDebtIsIssuedIn_label_en-US" xlink:label="lab_sny_NumberOfCurrenciesDebtIsIssuedIn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Currencies Debt Is Issued In</link:label>
    <link:label id="lab_sny_NumberOfCurrenciesDebtIsIssuedIn_documentation_en-US" xlink:label="lab_sny_NumberOfCurrenciesDebtIsIssuedIn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Currencies Debt Is Issued In</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCurrenciesDebtIsIssuedIn" xlink:href="sny-20231231.xsd#sny_NumberOfCurrenciesDebtIsIssuedIn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCurrenciesDebtIsIssuedIn" xlink:to="lab_sny_NumberOfCurrenciesDebtIsIssuedIn" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GainLossOnImpairmentOfTreasuryShares_d5ff40ff-d0c9-49e9-99ec-79a5d587e4b3_terseLabel_en-US" xlink:label="lab_sny_GainLossOnImpairmentOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized on impairment of treasury shares</link:label>
    <link:label id="lab_sny_GainLossOnImpairmentOfTreasuryShares_label_en-US" xlink:label="lab_sny_GainLossOnImpairmentOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Impairment Of Treasury Shares</link:label>
    <link:label id="lab_sny_GainLossOnImpairmentOfTreasuryShares_documentation_en-US" xlink:label="lab_sny_GainLossOnImpairmentOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on impairment of treasury shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnImpairmentOfTreasuryShares" xlink:href="sny-20231231.xsd#sny_GainLossOnImpairmentOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GainLossOnImpairmentOfTreasuryShares" xlink:to="lab_sny_GainLossOnImpairmentOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock_3a997557-b4a1-4c99-b2cd-e5c55ddb8089_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Repurchases program</link:label>
    <link:label id="lab_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share Repurchase Program Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share repurchase program explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiSaglikUrunleriLimitedSirketiMember_4cc960e7-77ec-41fd-b6e0-db23a761d86f_terseLabel_en-US" xlink:label="lab_sny_SanofiSaglikUrunleriLimitedSirketiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Saglik Urunleri Limited Sirketi</link:label>
    <link:label id="lab_sny_SanofiSaglikUrunleriLimitedSirketiMember_label_en-US" xlink:label="lab_sny_SanofiSaglikUrunleriLimitedSirketiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Saglik Urunleri Limited Sirketi [Member]</link:label>
    <link:label id="lab_sny_SanofiSaglikUrunleriLimitedSirketiMember_documentation_en-US" xlink:label="lab_sny_SanofiSaglikUrunleriLimitedSirketiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Saglik Urunleri Limited Sirketi [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiSaglikUrunleriLimitedSirketiMember" xlink:href="sny-20231231.xsd#sny_SanofiSaglikUrunleriLimitedSirketiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiSaglikUrunleriLimitedSirketiMember" xlink:to="lab_sny_SanofiSaglikUrunleriLimitedSirketiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_e0ed9c19-7169-427e-bafa-a61250cc0329_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="lab_ifrs-full_OtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_4e0fc79b-6307-432c-8cf5-eb0ab2f560bd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_67ac12b5-a220-4294-ad55-722d43c8ceb8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Movements in Goodwill</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxesAbstract_1440005e-b331-4c8f-8001-5f4e75c8298c_terseLabel_en-US" xlink:label="lab_sny_IncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:label id="lab_sny_IncomeTaxesAbstract_label_en-US" xlink:label="lab_sny_IncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:label id="lab_sny_IncomeTaxesAbstract_documentation_en-US" xlink:label="lab_sny_IncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxesAbstract" xlink:href="sny-20231231.xsd#sny_IncomeTaxesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxesAbstract" xlink:to="lab_sny_IncomeTaxesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringProvisionsLineItems_9f1921d9-1b57-4975-ad8b-668044294911_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Restructuring Provisions [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringProvisionsLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Restructuring Provisions [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringProvisionsLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of restructuring provisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringProvisionsLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems" xlink:to="lab_sny_DisclosureOfRestructuringProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentCurrencyDerivativesPayable_ad140ca1-3eb3-476f-a991-d56fb38aa32e_terseLabel_en-US" xlink:label="lab_sny_CurrentCurrencyDerivativesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency derivatives (see Note&#160;D.20.)</link:label>
    <link:label id="lab_sny_CurrentCurrencyDerivativesPayable_label_en-US" xlink:label="lab_sny_CurrentCurrencyDerivativesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Currency Derivatives Payable</link:label>
    <link:label id="lab_sny_CurrentCurrencyDerivativesPayable_documentation_en-US" xlink:label="lab_sny_CurrentCurrencyDerivativesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency derivatives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentCurrencyDerivativesPayable" xlink:href="sny-20231231.xsd#sny_CurrentCurrencyDerivativesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentCurrencyDerivativesPayable" xlink:to="lab_sny_CurrentCurrencyDerivativesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RegulatoryComplianceCostsMember_a06fc554-f1fe-444b-bd32-35eb744d2da6_terseLabel_en-US" xlink:label="lab_sny_RegulatoryComplianceCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory compliance costs</link:label>
    <link:label id="lab_sny_RegulatoryComplianceCostsMember_label_en-US" xlink:label="lab_sny_RegulatoryComplianceCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Compliance Costs [Member]</link:label>
    <link:label id="lab_sny_RegulatoryComplianceCostsMember_documentation_en-US" xlink:label="lab_sny_RegulatoryComplianceCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Compliance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegulatoryComplianceCostsMember" xlink:href="sny-20231231.xsd#sny_RegulatoryComplianceCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RegulatoryComplianceCostsMember" xlink:to="lab_sny_RegulatoryComplianceCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalAlliancesAxis_7041fbf8-8cf8-44f4-8119-f6b16b539ef5_terseLabel_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Alliances [Axis]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesAxis_label_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Alliances [Axis]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesAxis_documentation_en-US" xlink:label="lab_sny_PrincipalAlliancesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Alliances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalAlliancesAxis" xlink:to="lab_sny_PrincipalAlliancesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_4f3aec9f-a8d1-4bf8-820f-30eafbfa92ba_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of compensation paid to key management personnel [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActionForWhichWeAreDefendantMember_35316489-b5da-48f1-bff8-d53419c7cf6b_terseLabel_en-US" xlink:label="lab_sny_ActionForWhichWeAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Action for which we are defendant</link:label>
    <link:label id="lab_sny_ActionForWhichWeAreDefendantMember_label_en-US" xlink:label="lab_sny_ActionForWhichWeAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Action For Which We Are Defendant [member]</link:label>
    <link:label id="lab_sny_ActionForWhichWeAreDefendantMember_documentation_en-US" xlink:label="lab_sny_ActionForWhichWeAreDefendantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Action for which we are defendant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeAreDefendantMember" xlink:href="sny-20231231.xsd#sny_ActionForWhichWeAreDefendantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActionForWhichWeAreDefendantMember" xlink:to="lab_sny_ActionForWhichWeAreDefendantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsMadeToJointVenturesAndAssociates_dcda6f58-449b-4098-adb0-0e2b9c565f42_terseLabel_en-US" xlink:label="lab_sny_CommitmentsMadeToJointVenturesAndAssociates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding commitments to associates and joint ventures</link:label>
    <link:label id="lab_sny_CommitmentsMadeToJointVenturesAndAssociates_label_en-US" xlink:label="lab_sny_CommitmentsMadeToJointVenturesAndAssociates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made To Joint Ventures And Associates</link:label>
    <link:label id="lab_sny_CommitmentsMadeToJointVenturesAndAssociates_documentation_en-US" xlink:label="lab_sny_CommitmentsMadeToJointVenturesAndAssociates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments made to joint ventures and associates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsMadeToJointVenturesAndAssociates" xlink:href="sny-20231231.xsd#sny_CommitmentsMadeToJointVenturesAndAssociates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsMadeToJointVenturesAndAssociates" xlink:to="lab_sny_CommitmentsMadeToJointVenturesAndAssociates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_aaca7f2c-eb83-4fd3-8311-65f8fd514bab_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_87302228-db7c-4644-9030-f77b69d69341_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PricewaterhousecoopersMember_901254f8-e31d-4724-9e8b-f3dbb5cd8fdb_terseLabel_en-US" xlink:label="lab_sny_PricewaterhousecoopersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PricewaterhouseCoopers</link:label>
    <link:label id="lab_sny_PricewaterhousecoopersMember_label_en-US" xlink:label="lab_sny_PricewaterhousecoopersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PricewaterhouseCoopers [Member]</link:label>
    <link:label id="lab_sny_PricewaterhousecoopersMember_documentation_en-US" xlink:label="lab_sny_PricewaterhousecoopersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PricewaterhouseCoopers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PricewaterhousecoopersMember" xlink:href="sny-20231231.xsd#sny_PricewaterhousecoopersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PricewaterhousecoopersMember" xlink:to="lab_sny_PricewaterhousecoopersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForCashgeneratingUnitsMember_3bd829ec-c2fa-4ae5-85bd-bec013445bea_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForCashgeneratingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for cash-generating units [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForCashgeneratingUnitsMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForCashgeneratingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for cash-generating units [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForCashgeneratingUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForCashgeneratingUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForCashgeneratingUnitsMember" xlink:to="lab_ifrs-full_EntitysTotalForCashgeneratingUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_d2410813-a88c-4cdb-ab5f-7b3fdb418cf5_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of employee benefits (stock options and other share-based payments)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss_ca5b356d-6f09-475a-beda-c41d846c3a46_terseLabel_en-US" xlink:label="lab_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perpetual growth rate</link:label>
    <link:label id="lab_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss_label_en-US" xlink:label="lab_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Perpetuity Growth Rate Below The Rates Actually Used Would Not Cause Impairment Loss</link:label>
    <link:label id="lab_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss_documentation_en-US" xlink:label="lab_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of perpetuity growth rate below the rates actually used would not cause impairment loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:href="sny-20231231.xsd#sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:to="lab_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_b27c073f-4cdf-4ea1-8b78-82737f9be39f_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MajorTerritoriesMember_ac346cce-7284-4a2a-afa2-cd4603fb660d_terseLabel_en-US" xlink:label="lab_sny_MajorTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major territories</link:label>
    <link:label id="lab_sny_MajorTerritoriesMember_label_en-US" xlink:label="lab_sny_MajorTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Territories [Member]</link:label>
    <link:label id="lab_sny_MajorTerritoriesMember_documentation_en-US" xlink:label="lab_sny_MajorTerritoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Territories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorTerritoriesMember" xlink:href="sny-20231231.xsd#sny_MajorTerritoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MajorTerritoriesMember" xlink:to="lab_sny_MajorTerritoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember_98c723b5-aedc-48a4-a489-fa7cb623e2e9_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare cost inflation rate</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of medical cost trend rates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ImpactOfPreTaxIncomeRecognisedInEquity_01944c08-8bfb-4e27-9508-8404ff041b15_terseLabel_en-US" xlink:label="lab_sny_ImpactOfPreTaxIncomeRecognisedInEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact on pre-tax income/(expense) recognized directly in equity</link:label>
    <link:label id="lab_sny_ImpactOfPreTaxIncomeRecognisedInEquity_label_en-US" xlink:label="lab_sny_ImpactOfPreTaxIncomeRecognisedInEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact Of Pre Tax Income Recognised In Equity</link:label>
    <link:label id="lab_sny_ImpactOfPreTaxIncomeRecognisedInEquity_documentation_en-US" xlink:label="lab_sny_ImpactOfPreTaxIncomeRecognisedInEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of pre tax income recognised in equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfPreTaxIncomeRecognisedInEquity" xlink:href="sny-20231231.xsd#sny_ImpactOfPreTaxIncomeRecognisedInEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ImpactOfPreTaxIncomeRecognisedInEquity" xlink:to="lab_sny_ImpactOfPreTaxIncomeRecognisedInEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_3c0a579a-82c7-481f-b19e-0dd42d056a31_terseLabel_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity risk hedging instruments designated as fair value hedges</link:label>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_label_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Risk Hedging Instruments Designated At Fair Value Hedges</link:label>
    <link:label id="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_documentation_en-US" xlink:label="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Risk Hedging Instruments Designated At Fair Value Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:href="sny-20231231.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:to="lab_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfDrugTargetsUnderCollaborationAgreement_393b607a-9078-4d98-b8c3-0825c11b638c_terseLabel_en-US" xlink:label="lab_sny_NumberOfDrugTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of drug targets under collaboration agreement</link:label>
    <link:label id="lab_sny_NumberOfDrugTargetsUnderCollaborationAgreement_label_en-US" xlink:label="lab_sny_NumberOfDrugTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Drug Targets Under Collaboration Agreement</link:label>
    <link:label id="lab_sny_NumberOfDrugTargetsUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_sny_NumberOfDrugTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Drug Targets Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDrugTargetsUnderCollaborationAgreement" xlink:href="sny-20231231.xsd#sny_NumberOfDrugTargetsUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfDrugTargetsUnderCollaborationAgreement" xlink:to="lab_sny_NumberOfDrugTargetsUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_1204583c-38a6-4024-a774-71263abd3fa7_terseLabel_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share (in euros per share)</link:label>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_label_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:label id="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_documentation_en-US" xlink:label="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:href="sny-20231231.xsd#sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:to="lab_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfGuaranteesLineItems_4782489f-2403-410c-9f42-62b4fab83c51_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfGuaranteesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Guarantees [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfGuaranteesLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfGuaranteesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Guarantees [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfGuaranteesLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfGuaranteesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of guarantees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfGuaranteesLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfGuaranteesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfGuaranteesLineItems" xlink:to="lab_sny_DisclosureOfGuaranteesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests_3b2090fa-72aa-4e2d-890c-ec5fee962a36_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other movements</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Other Movements, Business Combinations And Non-Controlling Interests</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Other Movements, Business Combinations And Non-Controlling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" xlink:to="lab_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_e819c14c-0c30-4aeb-b686-0e8dcb30c899_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combinations and transactions with non-controlling interests</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for business combinations and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseCosts_b92963fa-028d-458b-8376-f819e63b2143_terseLabel_en-US" xlink:label="lab_sny_LeaseCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_sny_LeaseCosts_label_en-US" xlink:label="lab_sny_LeaseCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Costs</link:label>
    <link:label id="lab_sny_LeaseCosts_documentation_en-US" xlink:label="lab_sny_LeaseCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseCosts" xlink:href="sny-20231231.xsd#sny_LeaseCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseCosts" xlink:to="lab_sny_LeaseCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_fda1e49c-0cfb-4282-be2b-ceb55852345c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Financial Position</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Changes In Financial Position [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of changes in financial position [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfChangesInFinancialPositionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:to="lab_sny_DisclosureOfChangesInFinancialPositionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsMember_d17c7e56-aada-4e00-9e1c-0c79fb7df2b3_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [member]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember" xlink:to="lab_ifrs-full_ActuarialAssumptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OptionVestingPeriod_ffee77a1-8fc7-4951-acb8-af6a9921c92a_terseLabel_en-US" xlink:label="lab_sny_OptionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option vesting period (in years)</link:label>
    <link:label id="lab_sny_OptionVestingPeriod_label_en-US" xlink:label="lab_sny_OptionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Vesting Period</link:label>
    <link:label id="lab_sny_OptionVestingPeriod_documentation_en-US" xlink:label="lab_sny_OptionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option vesting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OptionVestingPeriod" xlink:href="sny-20231231.xsd#sny_OptionVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OptionVestingPeriod" xlink:to="lab_sny_OptionVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_8895b2d8-6854-407b-bdd7-393f8016af32_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherBorrowings_240891c3-bd36-4d31-97f9-36181b4bcc7c_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other borrowings</link:label>
    <link:label id="lab_ifrs-full_OtherBorrowings_label_en-US" xlink:label="lab_ifrs-full_OtherBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherBorrowings" xlink:to="lab_ifrs-full_OtherBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageSharePrice2019_de0e4c52-e4a8-49aa-9901-eb41a947ba7e_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePrice2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average share price (in EUR per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageSharePrice2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePrice2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average share price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePrice2019" xlink:to="lab_ifrs-full_WeightedAverageSharePrice2019" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RoyaltiesPayable_a9490b8b-935b-44f9-93e1-c9f215e6e072_terseLabel_en-US" xlink:label="lab_sny_RoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, payable</link:label>
    <link:label id="lab_sny_RoyaltiesPayable_label_en-US" xlink:label="lab_sny_RoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Payable</link:label>
    <link:label id="lab_sny_RoyaltiesPayable_documentation_en-US" xlink:label="lab_sny_RoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesPayable" xlink:href="sny-20231231.xsd#sny_RoyaltiesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RoyaltiesPayable" xlink:to="lab_sny_RoyaltiesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset_bfea2b54-ff18-4a06-ba26-9f44875177fe_negatedLabel_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan settlements specified in the terms of the plan</link:label>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Payments In Respect Of Settlements Specified In The Terms Of The Plan Net Defined Benefit Liability (Asset)</link:label>
    <link:label id="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset_documentation_en-US" xlink:label="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Payments In Respect Of Settlements Specified In The Terms Of The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" xlink:to="lab_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_68028c75-5f47-48ba-a863-7b8ea3846d45_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisGulfFZEMember_05e1f3c3-7318-477f-9b62-dde62bab11f9_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisGulfFZEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Gulf FZE</link:label>
    <link:label id="lab_sny_SanofiAventisGulfFZEMember_label_en-US" xlink:label="lab_sny_SanofiAventisGulfFZEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Gulf FZE [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisGulfFZEMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisGulfFZEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Gulf FZE.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisGulfFZEMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisGulfFZEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisGulfFZEMember" xlink:to="lab_sny_SanofiAventisGulfFZEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ManagedCareMember_45dd8140-63b1-40b8-a401-15b59fddc725_terseLabel_en-US" xlink:label="lab_sny_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care</link:label>
    <link:label id="lab_sny_ManagedCareMember_label_en-US" xlink:label="lab_sny_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care [Member]</link:label>
    <link:label id="lab_sny_ManagedCareMember_documentation_en-US" xlink:label="lab_sny_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManagedCareMember" xlink:href="sny-20231231.xsd#sny_ManagedCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ManagedCareMember" xlink:to="lab_sny_ManagedCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestRateDerivativesMember_cdf40c15-1f8d-4a56-9151-fa0239d7c9e9_terseLabel_en-US" xlink:label="lab_sny_InterestRateDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate derivatives</link:label>
    <link:label id="lab_sny_InterestRateDerivativesMember_label_en-US" xlink:label="lab_sny_InterestRateDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivatives [Member]</link:label>
    <link:label id="lab_sny_InterestRateDerivativesMember_documentation_en-US" xlink:label="lab_sny_InterestRateDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate derivatives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateDerivativesMember" xlink:href="sny-20231231.xsd#sny_InterestRateDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestRateDerivativesMember" xlink:to="lab_sny_InterestRateDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UncertaintiesOverIncomeTaxTreatmentsMember_45881c3c-e6fb-4383-9ee3-12425f1b4600_terseLabel_en-US" xlink:label="lab_sny_UncertaintiesOverIncomeTaxTreatmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertainties over income tax treatments</link:label>
    <link:label id="lab_sny_UncertaintiesOverIncomeTaxTreatmentsMember_label_en-US" xlink:label="lab_sny_UncertaintiesOverIncomeTaxTreatmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertainties Over Income Tax Treatments [Member]</link:label>
    <link:label id="lab_sny_UncertaintiesOverIncomeTaxTreatmentsMember_documentation_en-US" xlink:label="lab_sny_UncertaintiesOverIncomeTaxTreatmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertainties Over Income Tax Treatments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UncertaintiesOverIncomeTaxTreatmentsMember" xlink:href="sny-20231231.xsd#sny_UncertaintiesOverIncomeTaxTreatmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UncertaintiesOverIncomeTaxTreatmentsMember" xlink:to="lab_sny_UncertaintiesOverIncomeTaxTreatmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareRepurchase2020ProgramMember_afcfeadc-db5d-404b-a8e7-498e7365e10f_terseLabel_en-US" xlink:label="lab_sny_ShareRepurchase2020ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_sny_ShareRepurchase2020ProgramMember_label_en-US" xlink:label="lab_sny_ShareRepurchase2020ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase 2020 Program [Member]</link:label>
    <link:label id="lab_sny_ShareRepurchase2020ProgramMember_documentation_en-US" xlink:label="lab_sny_ShareRepurchase2020ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase 2020 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2020ProgramMember" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2020ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareRepurchase2020ProgramMember" xlink:to="lab_sny_ShareRepurchase2020ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForAssociatesMember_8730ac24-1eee-420d-a31f-93e88d5c6fd8_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for associates</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForAssociatesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for associates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember" xlink:to="lab_ifrs-full_EntitysTotalForAssociatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_adcb360c-317c-4952-b211-3a32971dc966_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAbstract_59a56f72-a085-41cf-a800-3c0f62759219_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) [abstract]</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAbstract" xlink:to="lab_ifrs-full_ProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_33ce86b8-74df-41df-a1c6-9c82f9912bda_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b3b22be9-b852-4fbd-ac02-9c45f120b187_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlavixLitigationCommonwealthInAustraliaMember_1e90fc37-0f60-4c76-b400-dab78680adc3_terseLabel_en-US" xlink:label="lab_sny_PlavixLitigationCommonwealthInAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plavix litigation (Commonwealth) in Australia</link:label>
    <link:label id="lab_sny_PlavixLitigationCommonwealthInAustraliaMember_label_en-US" xlink:label="lab_sny_PlavixLitigationCommonwealthInAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plavix Litigation (Commonwealth) In Australia [Member]</link:label>
    <link:label id="lab_sny_PlavixLitigationCommonwealthInAustraliaMember_documentation_en-US" xlink:label="lab_sny_PlavixLitigationCommonwealthInAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plavix litigation (commonwealth) In Australia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixLitigationCommonwealthInAustraliaMember" xlink:href="sny-20231231.xsd#sny_PlavixLitigationCommonwealthInAustraliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlavixLitigationCommonwealthInAustraliaMember" xlink:to="lab_sny_PlavixLitigationCommonwealthInAustraliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_d057d825-32db-42e2-8f46-acee530d5ba3_terseLabel_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_label_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Liabilities [Member]</link:label>
    <link:label id="lab_sny_NonCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_NonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember" xlink:href="sny-20231231.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentLiabilitiesMember" xlink:to="lab_sny_NonCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfLineOfCreditFacilityTable_036bb2bc-198b-44fd-964a-74e1723311b9_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfLineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Line of Credit Facility [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLineOfCreditFacilityTable_label_en-US" xlink:label="lab_sny_DisclosureOfLineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Line Of Credit Facility [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfLineOfCreditFacilityTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfLineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of line of credit facility table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLineOfCreditFacilityTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfLineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfLineOfCreditFacilityTable" xlink:to="lab_sny_DisclosureOfLineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrentLiabilitiesMember_ed9452e0-55fd-48b3-8a21-a04233de3b97_terseLabel_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesMember_label_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities [Member]</link:label>
    <link:label id="lab_sny_CurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_sny_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember" xlink:href="sny-20231231.xsd#sny_CurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrentLiabilitiesMember" xlink:to="lab_sny_CurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_April302021Member_e41bfbe4-9f82-4f7b-bfe6-9ce1a6015e7a_terseLabel_en-US" xlink:label="lab_sny_April302021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 30, 2021</link:label>
    <link:label id="lab_sny_April302021Member_label_en-US" xlink:label="lab_sny_April302021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 30, 2021 [Member]</link:label>
    <link:label id="lab_sny_April302021Member_documentation_en-US" xlink:label="lab_sny_April302021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">April 30, 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April302021Member" xlink:href="sny-20231231.xsd#sny_April302021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_April302021Member" xlink:to="lab_sny_April302021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsRezurockMember_058fe8c2-dd39-4ee0-954f-46a74f4b2381_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsRezurockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REZUROCK</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsRezurockMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsRezurockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Rezurock [Member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsRezurockMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsRezurockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Rezurock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsRezurockMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsRezurockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsRezurockMember" xlink:to="lab_sny_PrincipalMarketedProductsRezurockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerecognizedReceivables_03dbbd10-96b4-4b53-9069-ffa7417b0631_terseLabel_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derecognized receivables</link:label>
    <link:label id="lab_sny_DerecognizedReceivables_label_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derecognized Receivables</link:label>
    <link:label id="lab_sny_DerecognizedReceivables_documentation_en-US" xlink:label="lab_sny_DerecognizedReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derecognized receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerecognizedReceivables" xlink:href="sny-20231231.xsd#sny_DerecognizedReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerecognizedReceivables" xlink:to="lab_sny_DerecognizedReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_40478fa8-2159-4c06-8f71-7aa479d79693_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_986ad310-b3e0-4297-94e5-d1b25b7f795b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Number of Restricted Shares Not Yet Fully Vested</link:label>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number Of Restricted Share Plans Not Yet Fully Vested [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number of restricted share plans Not yet fully vested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:to="lab_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_6abbc116-f158-431b-bcf2-35991f8703f7_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_d822c06f-76dd-4697-9b58-1b1330d25e3b_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCoreAssetsMember_464896d6-a281-4d06-8728-62bb3ef2cb84_terseLabel_en-US" xlink:label="lab_sny_NonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Core Assets</link:label>
    <link:label id="lab_sny_NonCoreAssetsMember_label_en-US" xlink:label="lab_sny_NonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Core Assets [Member]</link:label>
    <link:label id="lab_sny_NonCoreAssetsMember_documentation_en-US" xlink:label="lab_sny_NonCoreAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Core Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCoreAssetsMember" xlink:href="sny-20231231.xsd#sny_NonCoreAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCoreAssetsMember" xlink:to="lab_sny_NonCoreAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_f5284b02-062e-42a7-9a21-34a36c9b5e6d_terseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_32380037-965e-4986-9b02-a155b1d569e3_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UpfrontPayments_617f771a-bf9c-4ef9-a2be-80977aab9a34_terseLabel_en-US" xlink:label="lab_sny_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_sny_UpfrontPayments_label_en-US" xlink:label="lab_sny_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments</link:label>
    <link:label id="lab_sny_UpfrontPayments_documentation_en-US" xlink:label="lab_sny_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments" xlink:href="sny-20231231.xsd#sny_UpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UpfrontPayments" xlink:to="lab_sny_UpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_a9d83db1-7d27-4458-acde-59915f252eeb_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Movements within Other Comprehensive Income</link:label>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Accumulated Other Comprehensive Income Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information of accumulated other comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_SGD_2664547f-6c7c-499b-ad8c-c765f99a7187_terseLabel_en-US" xlink:label="lab_currency_SGD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Singapore dollar</link:label>
    <link:label id="lab_currency_SGD_label_en-US" xlink:label="lab_currency_SGD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Singapore, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_SGD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_SGD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_SGD" xlink:to="lab_currency_SGD" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_4c6edc05-3f79-4b0a-b046-4db804cf08d5_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through transfers, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax_a9c9ab8a-3583-4cd5-bbe5-5679db4c7471_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of other comprehensive income from investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of other comprehensive income of associates and joint ventures accounted for using equity method, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax" xlink:to="lab_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AntibodiesMember_deb43006-750c-4cbd-be9d-eb3cc8183d2d_terseLabel_en-US" xlink:label="lab_sny_AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antibodies</link:label>
    <link:label id="lab_sny_AntibodiesMember_label_en-US" xlink:label="lab_sny_AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antibodies [Member]</link:label>
    <link:label id="lab_sny_AntibodiesMember_documentation_en-US" xlink:label="lab_sny_AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antibodies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesMember" xlink:href="sny-20231231.xsd#sny_AntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AntibodiesMember" xlink:to="lab_sny_AntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock_d611a8b7-7f53-43d9-b5f3-a3fa00e0468a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt by Currency After Derivative Instruments</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt By Currency At Value Of Redemption After Derivative Instruments [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of debt by currency at value of redemption after derivative instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock" xlink:to="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockOptionsWithNoDilutiveEffect_3149da43-6eff-418d-9493-e7339030c23c_terseLabel_en-US" xlink:label="lab_sny_StockOptionsWithNoDilutiveEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock option not taken for computing diluted earning per share (in shares)</link:label>
    <link:label id="lab_sny_StockOptionsWithNoDilutiveEffect_label_en-US" xlink:label="lab_sny_StockOptionsWithNoDilutiveEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options With No Dilutive Effect</link:label>
    <link:label id="lab_sny_StockOptionsWithNoDilutiveEffect_documentation_en-US" xlink:label="lab_sny_StockOptionsWithNoDilutiveEffect" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options with no dilutive effect.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionsWithNoDilutiveEffect" xlink:href="sny-20231231.xsd#sny_StockOptionsWithNoDilutiveEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockOptionsWithNoDilutiveEffect" xlink:to="lab_sny_StockOptionsWithNoDilutiveEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WorkInProgress_9aca3d15-40c2-4806-a8dd-cb437ba45664_terseLabel_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_ifrs-full_WorkInProgress_label_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current work in progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WorkInProgress" xlink:to="lab_ifrs-full_WorkInProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalAlliancesDomain_647a2067-e676-4bc3-a70a-7b33fc794906_terseLabel_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Alliances [Domain]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesDomain_label_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Alliances [Domain]</link:label>
    <link:label id="lab_sny_PrincipalAlliancesDomain_documentation_en-US" xlink:label="lab_sny_PrincipalAlliancesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Alliances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalAlliancesDomain" xlink:to="lab_sny_PrincipalAlliancesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_77c86648-b68e-43b9-8e9b-ecbd7d894399_terseLabel_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper program in France</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_label_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper Program In France [Member]</link:label>
    <link:label id="lab_sny_CommercialPaperProgramInFranceMember_documentation_en-US" xlink:label="lab_sny_CommercialPaperProgramInFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper program In France.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember" xlink:href="sny-20231231.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommercialPaperProgramInFranceMember" xlink:to="lab_sny_CommercialPaperProgramInFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_21240f33-d25c-48c0-9160-2e945dc22f7a_terseLabel_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan at the date of grant</link:label>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_label_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Plan At Date Of Grant</link:label>
    <link:label id="lab_sny_FairValueOfPlanAtDateOfGrant_documentation_en-US" xlink:label="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan at the date of grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant" xlink:href="sny-20231231.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValueOfPlanAtDateOfGrant" xlink:to="lab_sny_FairValueOfPlanAtDateOfGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal_37e2558c-9dd7-40fd-995d-38bd55ba8fd0_terseLabel_en-US" xlink:label="lab_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal_label_en-US" xlink:label="lab_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Issued In Transaction, Total</link:label>
    <link:label id="lab_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal_documentation_en-US" xlink:label="lab_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Issued In Transaction, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal" xlink:href="sny-20231231.xsd#sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal" xlink:to="lab_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_db55c4e5-28c0-4ced-89f6-9c84c16a6909_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CustomerThreeMember_cf4ef93f-1711-4504-ac09-72b4acddef10_terseLabel_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer three</link:label>
    <link:label id="lab_sny_CustomerThreeMember_label_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [member]</link:label>
    <link:label id="lab_sny_CustomerThreeMember_documentation_en-US" xlink:label="lab_sny_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember" xlink:href="sny-20231231.xsd#sny_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CustomerThreeMember" xlink:to="lab_sny_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_JevtanaRelatedPatentLitigationInTheUSMember_41cf988e-ce55-4912-8907-5dc37d82c02e_terseLabel_en-US" xlink:label="lab_sny_JevtanaRelatedPatentLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jevtana related patent litigation in the US</link:label>
    <link:label id="lab_sny_JevtanaRelatedPatentLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_JevtanaRelatedPatentLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jevtana Related Patent Litigation In The US [Member]</link:label>
    <link:label id="lab_sny_JevtanaRelatedPatentLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_JevtanaRelatedPatentLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jevtana Related Patent Litigation In The US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaRelatedPatentLitigationInTheUSMember" xlink:href="sny-20231231.xsd#sny_JevtanaRelatedPatentLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_JevtanaRelatedPatentLitigationInTheUSMember" xlink:to="lab_sny_JevtanaRelatedPatentLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_a6af7c7a-9d49-432f-b7c0-70f612bab6f6_negatedLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial losses/(gains) due to experience adjustments</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock_d901fbdf-cd64-465f-a794-6d0526517621_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Bond Issues</link:label>
    <link:label id="lab_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detail Of Bonds Issued Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detail Of Bonds Issued Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_d8ea3b1c-6e06-4246-b07d-3ad285be6297_terseLabel_en-US" xlink:label="lab_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opening balance before adjustment, cumulative effect at date of initial application [member]</link:label>
    <link:label id="lab_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_label_en-US" xlink:label="lab_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opening balance before adjustment, cumulative effect at date of initial application [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="lab_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems_e8c48d8e-72f7-4cec-abf2-2fbae5d25e5a_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of tax losses available for carryforward [line items]</link:label>
    <link:label id="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Tax Losses Available For Carryforward [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of tax losses available for carryforward.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems" xlink:to="lab_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneMonthMember_a8007f90-5d59-4931-b258-3b7866d505f2_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1 month</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneMonthMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not later than one month [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneMonthMember" xlink:to="lab_ifrs-full_NotLaterThanOneMonthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PropertyPlantAndEquipmentInProcessMember_226ceb4c-9ec4-45f4-bf7e-5dd9903473bc_terseLabel_en-US" xlink:label="lab_sny_PropertyPlantAndEquipmentInProcessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property,&#160;plant and&#160;equipment in process</link:label>
    <link:label id="lab_sny_PropertyPlantAndEquipmentInProcessMember_label_en-US" xlink:label="lab_sny_PropertyPlantAndEquipmentInProcessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment In Process [Member]</link:label>
    <link:label id="lab_sny_PropertyPlantAndEquipmentInProcessMember_documentation_en-US" xlink:label="lab_sny_PropertyPlantAndEquipmentInProcessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment in process.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PropertyPlantAndEquipmentInProcessMember" xlink:href="sny-20231231.xsd#sny_PropertyPlantAndEquipmentInProcessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PropertyPlantAndEquipmentInProcessMember" xlink:to="lab_sny_PropertyPlantAndEquipmentInProcessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiBelgiumMember_8e22da09-68c7-47ac-a017-34981bd61c60_terseLabel_en-US" xlink:label="lab_sny_SanofiBelgiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Belgium</link:label>
    <link:label id="lab_sny_SanofiBelgiumMember_label_en-US" xlink:label="lab_sny_SanofiBelgiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Belgium [member]</link:label>
    <link:label id="lab_sny_SanofiBelgiumMember_documentation_en-US" xlink:label="lab_sny_SanofiBelgiumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Belgium.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBelgiumMember" xlink:href="sny-20231231.xsd#sny_SanofiBelgiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiBelgiumMember" xlink:to="lab_sny_SanofiBelgiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty_bc88aa71-f2c0-4475-a091-643ad581c830_verboseLabel_en-US" xlink:label="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development expense funded by other party</link:label>
    <link:label id="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty_label_en-US" xlink:label="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Future Development Expense Funded By Other Party</link:label>
    <link:label id="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty_documentation_en-US" xlink:label="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development expense funded by other party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty" xlink:href="sny-20231231.xsd#sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty" xlink:to="lab_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_eb2d698a-ef4e-4557-bdc3-6c2b96dc5c1c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Other Non-current Assets</link:label>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Components Of Other Non-Current Assets [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of components of other noncurrent assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:to="lab_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TaxotereProductLitigationInTheUSMember_0e82dd07-45f8-4a25-b544-ec0fbd40a8ff_terseLabel_en-US" xlink:label="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxotere product litigation in the US</link:label>
    <link:label id="lab_sny_TaxotereProductLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxotere Product Litigation In The US [Member]</link:label>
    <link:label id="lab_sny_TaxotereProductLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxotere product litigation in the US.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereProductLitigationInTheUSMember" xlink:href="sny-20231231.xsd#sny_TaxotereProductLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TaxotereProductLitigationInTheUSMember" xlink:to="lab_sny_TaxotereProductLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RestructuringProvisionMember_19a20044-efc9-4bd5-a020-ff2b195a95ba_terseLabel_en-US" xlink:label="lab_ifrs-full_RestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Provision</link:label>
    <link:label id="lab_ifrs-full_RestructuringProvisionMember_label_en-US" xlink:label="lab_ifrs-full_RestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring provision [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestructuringProvisionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestructuringProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestructuringProvisionMember" xlink:to="lab_ifrs-full_RestructuringProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfBondIssuesRedeemed_af1864c8-b5e5-47f7-aec8-42fefad4d72e_terseLabel_en-US" xlink:label="lab_sny_NumberOfBondIssuesRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of bond issues redeemed</link:label>
    <link:label id="lab_sny_NumberOfBondIssuesRedeemed_label_en-US" xlink:label="lab_sny_NumberOfBondIssuesRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Bond Issues Redeemed</link:label>
    <link:label id="lab_sny_NumberOfBondIssuesRedeemed_documentation_en-US" xlink:label="lab_sny_NumberOfBondIssuesRedeemed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Bond Issues Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondIssuesRedeemed" xlink:href="sny-20231231.xsd#sny_NumberOfBondIssuesRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfBondIssuesRedeemed" xlink:to="lab_sny_NumberOfBondIssuesRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_5bab0dfc-301b-4e07-8c4f-6e35f26380d5_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_89d5d5bb-1051-49bd-943d-4c807ad7a376_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RamiprilCanadaPatentLitigationMember_22740339-c39c-4e4f-949b-5b150556ee00_terseLabel_en-US" xlink:label="lab_sny_RamiprilCanadaPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ramipril Canada Patent Litigation</link:label>
    <link:label id="lab_sny_RamiprilCanadaPatentLitigationMember_label_en-US" xlink:label="lab_sny_RamiprilCanadaPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ramipril Canada Patent Litigation [Member]</link:label>
    <link:label id="lab_sny_RamiprilCanadaPatentLitigationMember_documentation_en-US" xlink:label="lab_sny_RamiprilCanadaPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ramipril canada patent litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RamiprilCanadaPatentLitigationMember" xlink:href="sny-20231231.xsd#sny_RamiprilCanadaPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RamiprilCanadaPatentLitigationMember" xlink:to="lab_sny_RamiprilCanadaPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_6b3d3cbb-0815-40aa-a967-19a732b09a32_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_2d543b69-ac17-44e3-b732-cd4424c4315a_terseLabel_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer&#8217;s contributions</link:label>
    <link:label id="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from resulting from contributions to plan by employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_8f34ed42-6c31-46e2-9ba1-cab81cb17849_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsMember" xlink:to="lab_ifrs-full_ClassesOfAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EliminationOfIntersegmentAmountsMember_3f840e30-7231-4341-bcda-3fa727ad79b7_terseLabel_en-US" xlink:label="lab_ifrs-full_EliminationOfIntersegmentAmountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elimination of inter-segment amounts</link:label>
    <link:label id="lab_ifrs-full_EliminationOfIntersegmentAmountsMember_label_en-US" xlink:label="lab_ifrs-full_EliminationOfIntersegmentAmountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elimination of intersegment amounts [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EliminationOfIntersegmentAmountsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EliminationOfIntersegmentAmountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EliminationOfIntersegmentAmountsMember" xlink:to="lab_ifrs-full_EliminationOfIntersegmentAmountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TranslateBioIncMember_5b9de2a4-38ef-466f-83af-12654132cbc1_terseLabel_en-US" xlink:label="lab_sny_TranslateBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translate Bio, Inc.</link:label>
    <link:label id="lab_sny_TranslateBioIncMember_label_en-US" xlink:label="lab_sny_TranslateBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translate Bio, Inc [Member]</link:label>
    <link:label id="lab_sny_TranslateBioIncMember_documentation_en-US" xlink:label="lab_sny_TranslateBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translate Bio, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioIncMember" xlink:href="sny-20231231.xsd#sny_TranslateBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TranslateBioIncMember" xlink:to="lab_sny_TranslateBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_228cd90c-30e8-4e41-ae76-81742848f057_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share plan 2023</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plan 2023 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2023Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plan 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2023Member" xlink:to="lab_sny_RestrictedSharePlan2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_VaccinesSegmentMember_60448c3b-2e28-447d-9ccc-359eb5fca951_terseLabel_en-US" xlink:label="lab_sny_VaccinesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines</link:label>
    <link:label id="lab_sny_VaccinesSegmentMember_label_en-US" xlink:label="lab_sny_VaccinesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines Segment [member]</link:label>
    <link:label id="lab_sny_VaccinesSegmentMember_documentation_en-US" xlink:label="lab_sny_VaccinesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesSegmentMember" xlink:href="sny-20231231.xsd#sny_VaccinesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_VaccinesSegmentMember" xlink:to="lab_sny_VaccinesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfDefinedBenefitPlans_17bc01af-3eca-4ad2-802c-a090043141e4_terseLabel_en-US" xlink:label="lab_sny_NumberOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of types of defined-benefit plan</link:label>
    <link:label id="lab_sny_NumberOfDefinedBenefitPlans_label_en-US" xlink:label="lab_sny_NumberOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Defined Benefit Plans</link:label>
    <link:label id="lab_sny_NumberOfDefinedBenefitPlans_documentation_en-US" xlink:label="lab_sny_NumberOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defined benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDefinedBenefitPlans" xlink:href="sny-20231231.xsd#sny_NumberOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfDefinedBenefitPlans" xlink:to="lab_sny_NumberOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_d1cc6e71-419d-42d7-b5c0-781e398dd28b_verboseLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current provisions and other non-current liabilities</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_041c6624-e270-4616-b46b-99397d63b4a1_totalLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_2a0a5224-704e-4f82-be14-734e8a4f4771_periodStartLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_1c0b02fb-9ed9-4e96-8436-49cf0b407af4_periodEndLabel_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_label_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Provisions And Other Non-Current Liabilities</link:label>
    <link:label id="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_documentation_en-US" xlink:label="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:to="lab_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement_f9fefc0a-9a93-47fc-a955-3b1c2ed0a51a_terseLabel_en-US" xlink:label="lab_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of therapeutic targets under collaboration agreement</link:label>
    <link:label id="lab_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement_label_en-US" xlink:label="lab_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Therapeutic Targets Under Collaboration Agreement</link:label>
    <link:label id="lab_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Therapeutic Targets Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement" xlink:href="sny-20231231.xsd#sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement" xlink:to="lab_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_4b1cc0b2-de9f-4240-84a6-ca06e9141003_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock_b9b4177d-ef8b-4ecd-bfa8-ffa0c8702a35_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Goodwill</link:label>
    <link:label id="lab_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Goodwill By Operating Segments Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of goodwill by operating segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiBioverativHoldingsLLCMember_049d72ec-c77c-42e8-aa8f-6ce2b8921e9a_terseLabel_en-US" xlink:label="lab_sny_SanofiBioverativHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Bioverativ Holdings LLC</link:label>
    <link:label id="lab_sny_SanofiBioverativHoldingsLLCMember_label_en-US" xlink:label="lab_sny_SanofiBioverativHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Bioverativ Holdings LLC [Member]</link:label>
    <link:label id="lab_sny_SanofiBioverativHoldingsLLCMember_documentation_en-US" xlink:label="lab_sny_SanofiBioverativHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Bioverativ Holdings LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBioverativHoldingsLLCMember" xlink:href="sny-20231231.xsd#sny_SanofiBioverativHoldingsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiBioverativHoldingsLLCMember" xlink:to="lab_sny_SanofiBioverativHoldingsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesRepurchased_919836b3-1b12-4424-8159-38c144e61f97_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesRepurchased_label_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Repurchased</link:label>
    <link:label id="lab_sny_NumberOfSharesRepurchased_documentation_en-US" xlink:label="lab_sny_NumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares repurchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased" xlink:href="sny-20231231.xsd#sny_NumberOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesRepurchased" xlink:to="lab_sny_NumberOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_2e6ea6ea-9fec-4bfb-92eb-12fe26c76dc7_terseLabel_en-US" xlink:label="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government grant recognised as deduction from development expenses</link:label>
    <link:label id="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_label_en-US" xlink:label="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grant Recognised As Deduction From Development Expenses</link:label>
    <link:label id="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_documentation_en-US" xlink:label="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grant Recognised As Deduction From Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:href="sny-20231231.xsd#sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:to="lab_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_2bfd7335-136a-4ce9-a190-4d2393ca2d56_terseLabel_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Associates and joint ventures</link:label>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_label_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Associates And Joint Ventures [Member]</link:label>
    <link:label id="lab_sny_AssociatesAndJointVenturesMember_documentation_en-US" xlink:label="lab_sny_AssociatesAndJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Associates and Joint Ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember" xlink:href="sny-20231231.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AssociatesAndJointVenturesMember" xlink:to="lab_sny_AssociatesAndJointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AblynxMember_ff84b3ab-85d7-4c01-9a54-dba9aec72e18_verboseLabel_en-US" xlink:label="lab_sny_AblynxMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ablynx NV</link:label>
    <link:label id="lab_sny_AblynxMember_label_en-US" xlink:label="lab_sny_AblynxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ablynx [member]</link:label>
    <link:label id="lab_sny_AblynxMember_documentation_en-US" xlink:label="lab_sny_AblynxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ablynx.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AblynxMember" xlink:href="sny-20231231.xsd#sny_AblynxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AblynxMember" xlink:to="lab_sny_AblynxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_70971970-2b1a-4453-a62c-48982e9b3c64_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExplanatory_a1a51049-07f1-4029-b352-d269b3a22bb4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosures about major customers and credit risk</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of credit risk [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCreditRiskExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCreditRiskExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfPlaintiffs_4fce262a-21fd-41ae-9060-1278006865e1_terseLabel_en-US" xlink:label="lab_sny_NumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_sny_NumberOfPlaintiffs_label_en-US" xlink:label="lab_sny_NumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Plaintiffs</link:label>
    <link:label id="lab_sny_NumberOfPlaintiffs_documentation_en-US" xlink:label="lab_sny_NumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Plaintiffs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffs" xlink:href="sny-20231231.xsd#sny_NumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfPlaintiffs" xlink:to="lab_sny_NumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseCategoriesAxis_7464c6a3-f77a-477a-a043-0ed045845e1d_terseLabel_en-US" xlink:label="lab_sny_ExpenseCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Categories [Axis]</link:label>
    <link:label id="lab_sny_ExpenseCategoriesAxis_label_en-US" xlink:label="lab_sny_ExpenseCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Categories [Axis]</link:label>
    <link:label id="lab_sny_ExpenseCategoriesAxis_documentation_en-US" xlink:label="lab_sny_ExpenseCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Categories [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseCategoriesAxis" xlink:href="sny-20231231.xsd#sny_ExpenseCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseCategoriesAxis" xlink:to="lab_sny_ExpenseCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GenzymeIrelandLimitedMember_76c43045-f775-4521-b95e-8d7f1485500f_terseLabel_en-US" xlink:label="lab_sny_GenzymeIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Ireland Limited</link:label>
    <link:label id="lab_sny_GenzymeIrelandLimitedMember_label_en-US" xlink:label="lab_sny_GenzymeIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Ireland Limited [member]</link:label>
    <link:label id="lab_sny_GenzymeIrelandLimitedMember_documentation_en-US" xlink:label="lab_sny_GenzymeIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Ireland Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeIrelandLimitedMember" xlink:href="sny-20231231.xsd#sny_GenzymeIrelandLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GenzymeIrelandLimitedMember" xlink:to="lab_sny_GenzymeIrelandLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock_bc258c03-9384-4bdb-835a-6061b0f43fb9_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions and Other Current Liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Current Provisions And Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of current provisions and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_41b1e8df-5fc5-4497-9e5a-e7d8aff3c0a4_terseLabel_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring provisions</link:label>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_label_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Restructuring Provision [Member]</link:label>
    <link:label id="lab_sny_NonCurrentRestructuringProvisionMember_documentation_en-US" xlink:label="lab_sny_NonCurrentRestructuringProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring provisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember" xlink:href="sny-20231231.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonCurrentRestructuringProvisionMember" xlink:to="lab_sny_NonCurrentRestructuringProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_52e2425d-80f5-4203-ae2c-0f8763cd61d3_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisMarocMember_b2fb8a0b-5c39-42ee-b2cb-ef7ce1c4b081_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisMarocMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Maroc</link:label>
    <link:label id="lab_sny_SanofiAventisMarocMember_label_en-US" xlink:label="lab_sny_SanofiAventisMarocMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Maroc [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisMarocMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisMarocMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Maroc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisMarocMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisMarocMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisMarocMember" xlink:to="lab_sny_SanofiAventisMarocMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_7504d369-aaf0-4f35-a6e6-d4509df5eff4_verboseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year 1</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_954b68f8-4819-4c3a-bbc6-ba3fad85e281_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#160;than 1&#160;year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_20250f55-f7e3-452b-b06b-1d8ab40d20f9_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_499454a7-f070-4dc2-a9cc-6532e50231d4_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than 12 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_22b0859f-ad5a-406d-9764-34340885b7f2_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General inflation rate</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of expected rates of inflation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_KadmonMember_b1bc018d-185e-4a34-ae02-76a006a5c9ca_terseLabel_en-US" xlink:label="lab_sny_KadmonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kadmon</link:label>
    <link:label id="lab_sny_KadmonMember_label_en-US" xlink:label="lab_sny_KadmonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kadmon [Member]</link:label>
    <link:label id="lab_sny_KadmonMember_documentation_en-US" xlink:label="lab_sny_KadmonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kadmon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KadmonMember" xlink:href="sny-20231231.xsd#sny_KadmonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_KadmonMember" xlink:to="lab_sny_KadmonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember_0cfbb949-b7b8-4d4b-b900-f1374d9aff98_terseLabel_en-US" xlink:label="lab_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary differences subject to GILTI</link:label>
    <link:label id="lab_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember_label_en-US" xlink:label="lab_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Differences Subject To US Global Intangible Low Taxed Income [Member]</link:label>
    <link:label id="lab_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember_documentation_en-US" xlink:label="lab_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Differences Subject To US Global Intangible Low Taxed Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember" xlink:href="sny-20231231.xsd#sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember" xlink:to="lab_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_b074d312-dbe1-4376-b3a8-75b5d2c6ad14_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset) [axis]</link:label>
    <link:label id="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_label_en-US" xlink:label="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset) [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="lab_ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_26008372-ad49-4526-b3aa-27a03c2faee6_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Number of Shares Used to Compute Diluted Earnings Per Share</link:label>
    <link:label id="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Shares Used To Compute Diluted Earnings Per Share [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of shares used to compute diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:to="lab_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_31a2578b-a168-4dfb-935b-1aa535eb2cce_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other related parties</link:label>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRelatedPartiesMember" xlink:to="lab_ifrs-full_OtherRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_QRIBIntermediateHoldingsLLCMember_2412b1df-17e2-4851-a910-96ffd331fc05_terseLabel_en-US" xlink:label="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QRIB Intermediate Holding</link:label>
    <link:label id="lab_sny_QRIBIntermediateHoldingsLLCMember_label_en-US" xlink:label="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QRIB Intermediate Holdings, LLC [Member]</link:label>
    <link:label id="lab_sny_QRIBIntermediateHoldingsLLCMember_documentation_en-US" xlink:label="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QRIB Intermediate Holdings, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember" xlink:href="sny-20231231.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_QRIBIntermediateHoldingsLLCMember" xlink:to="lab_sny_QRIBIntermediateHoldingsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiaventisPlusPensionPlanMember_c0b9e5b2-e954-474e-af38-39f565d23f93_terseLabel_en-US" xlink:label="lab_sny_SanofiaventisPlusPensionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Plus</link:label>
    <link:label id="lab_sny_SanofiaventisPlusPensionPlanMember_label_en-US" xlink:label="lab_sny_SanofiaventisPlusPensionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis plus [member]</link:label>
    <link:label id="lab_sny_SanofiaventisPlusPensionPlanMember_documentation_en-US" xlink:label="lab_sny_SanofiaventisPlusPensionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Plus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiaventisPlusPensionPlanMember" xlink:href="sny-20231231.xsd#sny_SanofiaventisPlusPensionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiaventisPlusPensionPlanMember" xlink:to="lab_sny_SanofiaventisPlusPensionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests_b05fbe8f-7eb4-4561-adf1-7165271eb5fd_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Net Exchange Differences, Business Combinations And Non-Controlling Interests</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease through net exchange differences business combinations and noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" xlink:to="lab_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PretaxDiscountRateAppliedForGoodwill_f1a5c1cb-96c4-45b8-9895-770ad93bc048_terseLabel_en-US" xlink:label="lab_sny_PretaxDiscountRateAppliedForGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax discount rates</link:label>
    <link:label id="lab_sny_PretaxDiscountRateAppliedForGoodwill_label_en-US" xlink:label="lab_sny_PretaxDiscountRateAppliedForGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax Discount Rate Applied For Goodwill</link:label>
    <link:label id="lab_sny_PretaxDiscountRateAppliedForGoodwill_documentation_en-US" xlink:label="lab_sny_PretaxDiscountRateAppliedForGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax discount rate applied for goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PretaxDiscountRateAppliedForGoodwill" xlink:href="sny-20231231.xsd#sny_PretaxDiscountRateAppliedForGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PretaxDiscountRateAppliedForGoodwill" xlink:to="lab_sny_PretaxDiscountRateAppliedForGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1fddb62e-c99c-4cad-8b26-b2a3994a72b5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_189859b5-679f-4a70-9213-146c37a674e8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MedicaidMember_495879b4-3052-4614-95b9-9d7ba556877a_terseLabel_en-US" xlink:label="lab_sny_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_sny_MedicaidMember_label_en-US" xlink:label="lab_sny_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_sny_MedicaidMember_documentation_en-US" xlink:label="lab_sny_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MedicaidMember" xlink:href="sny-20231231.xsd#sny_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MedicaidMember" xlink:to="lab_sny_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashTransferred_5dbe599d-08db-4dcb-9d63-29a7155d3e41_terseLabel_en-US" xlink:label="lab_ifrs-full_CashTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash transferred</link:label>
    <link:label id="lab_ifrs-full_CashTransferred_label_en-US" xlink:label="lab_ifrs-full_CashTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashTransferred" xlink:to="lab_ifrs-full_CashTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock_049cb1f4-94dc-4be2-902f-0f717120025b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Off Balance Sheet Commitments Relating to Operating Activities</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments Relating To Operating Activities [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of off balance sheet commitments relating to operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount_0a6fb45f-ff76-4c8c-8c17-fb57282fbeb7_terseLabel_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income, transaction amount</link:label>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount_label_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Transaction Amount</link:label>
    <link:label id="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount_documentation_en-US" xlink:label="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Transaction Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount" xlink:href="sny-20231231.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount" xlink:to="lab_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CollaborationAgreementsUpfrontPayment_7b27af5d-2307-4268-97fb-407fc9f98f9c_terseLabel_en-US" xlink:label="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements, upfront payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsUpfrontPayment_label_en-US" xlink:label="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Upfront Payment</link:label>
    <link:label id="lab_sny_CollaborationAgreementsUpfrontPayment_documentation_en-US" xlink:label="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsUpfrontPayment" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CollaborationAgreementsUpfrontPayment" xlink:to="lab_sny_CollaborationAgreementsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_BusinessCombinationCapitalContribution_4109cd2f-35c4-4cb8-acc2-fd7e27017013_terseLabel_en-US" xlink:label="lab_sny_BusinessCombinationCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution</link:label>
    <link:label id="lab_sny_BusinessCombinationCapitalContribution_label_en-US" xlink:label="lab_sny_BusinessCombinationCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Capital Contribution</link:label>
    <link:label id="lab_sny_BusinessCombinationCapitalContribution_documentation_en-US" xlink:label="lab_sny_BusinessCombinationCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationCapitalContribution" xlink:href="sny-20231231.xsd#sny_BusinessCombinationCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_BusinessCombinationCapitalContribution" xlink:to="lab_sny_BusinessCombinationCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_865f3d45-19ed-4eda-a984-1a6041ca63fd_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in currency translation differences</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on exchange differences on translation of foreign operations, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharesMember_01aae5ea-e9af-417e-93b2-e914fc717a5a_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares</link:label>
    <link:label id="lab_sny_RestrictedSharesMember_label_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Shares [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharesMember_documentation_en-US" xlink:label="lab_sny_RestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember" xlink:href="sny-20231231.xsd#sny_RestrictedSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharesMember" xlink:to="lab_sny_RestrictedSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfHedgesMember_fc1b615e-0bee-4a4a-848e-4d5a7c311626_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedges [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfHedgesMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfHedgesMember" xlink:to="lab_ifrs-full_TypesOfHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_f70a9321-7fd2-457e-98fe-6ad27ad82b3c_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DefinedBenefitPlansVestingRightsPercentage_b632970d-ae70-4fcd-8341-a3c9c123fd98_terseLabel_en-US" xlink:label="lab_sny_DefinedBenefitPlansVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting right percentage</link:label>
    <link:label id="lab_sny_DefinedBenefitPlansVestingRightsPercentage_label_en-US" xlink:label="lab_sny_DefinedBenefitPlansVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans Vesting Rights Percentage</link:label>
    <link:label id="lab_sny_DefinedBenefitPlansVestingRightsPercentage_documentation_en-US" xlink:label="lab_sny_DefinedBenefitPlansVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plans vesting rights percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefinedBenefitPlansVestingRightsPercentage" xlink:href="sny-20231231.xsd#sny_DefinedBenefitPlansVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DefinedBenefitPlansVestingRightsPercentage" xlink:to="lab_sny_DefinedBenefitPlansVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2020Member_250325bc-7174-44af-a309-ae99f375b379_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share plan 2020</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2020Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plan 2020 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2020Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plan 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2020Member" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2020Member" xlink:to="lab_sny_RestrictedSharePlan2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PrincipalMarketedProductsGenzymeMember_c44ba0f7-4d91-43cb-9519-9ab64651d040_terseLabel_en-US" xlink:label="lab_sny_PrincipalMarketedProductsGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsGenzymeMember_label_en-US" xlink:label="lab_sny_PrincipalMarketedProductsGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Marketed Products Genzyme [member]</link:label>
    <link:label id="lab_sny_PrincipalMarketedProductsGenzymeMember_documentation_en-US" xlink:label="lab_sny_PrincipalMarketedProductsGenzymeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal marketed products genzyme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsGenzymeMember" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsGenzymeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PrincipalMarketedProductsGenzymeMember" xlink:to="lab_sny_PrincipalMarketedProductsGenzymeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_ea50f4c8-6ef9-421a-8e1a-2d047d6acb4d_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of acquisitions of property plant and equipment by operating segments [table]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_label_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable" xlink:to="lab_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RawMaterials_443087b9-25c5-4f49-a30f-f3debf70a256_terseLabel_en-US" xlink:label="lab_ifrs-full_RawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_ifrs-full_RawMaterials_label_en-US" xlink:label="lab_ifrs-full_RawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current raw materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RawMaterials" xlink:to="lab_ifrs-full_RawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_e630aeca-2773-424a-a157-49b33bdc2033_verboseLabel_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets recognised as of acquisition date</link:label>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_da5adcda-0c8c-4443-a1e7-5bc5ddac408d_terseLabel_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SeniorBondMember_adbfcc5b-9a7d-4b41-b124-5506ad2dab51_terseLabel_en-US" xlink:label="lab_sny_SeniorBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior bond</link:label>
    <link:label id="lab_sny_SeniorBondMember_label_en-US" xlink:label="lab_sny_SeniorBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Bond [Member]</link:label>
    <link:label id="lab_sny_SeniorBondMember_documentation_en-US" xlink:label="lab_sny_SeniorBondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior bond.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeniorBondMember" xlink:href="sny-20231231.xsd#sny_SeniorBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SeniorBondMember" xlink:to="lab_sny_SeniorBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitObligationAtPresentValue_205eb59d-056e-4301-a4df-696ea28c8c33_terseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee termination benefits</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitObligationAtPresentValue_7cabf02c-a03e-4814-94c9-ea9d040443e0_verboseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement of obligation</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitObligationAtPresentValue_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit obligation, at present value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:to="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PerformanceSharePlanTwoMember_e21a2614-ea0a-405d-85b7-3dba65bea79f_terseLabel_en-US" xlink:label="lab_sny_PerformanceSharePlanTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance share plan two</link:label>
    <link:label id="lab_sny_PerformanceSharePlanTwoMember_label_en-US" xlink:label="lab_sny_PerformanceSharePlanTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Plan Two [member]</link:label>
    <link:label id="lab_sny_PerformanceSharePlanTwoMember_documentation_en-US" xlink:label="lab_sny_PerformanceSharePlanTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance share plan two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerformanceSharePlanTwoMember" xlink:href="sny-20231231.xsd#sny_PerformanceSharePlanTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PerformanceSharePlanTwoMember" xlink:to="lab_sny_PerformanceSharePlanTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_ebf9c6d9-d0f8-4134-9f41-d1ef0ec9f3b5_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attributable to equity holders of Sanofi</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfPatentActionsInitiallyFiled_d3e2894b-457b-4cf3-84a5-a35f2e6f5301_terseLabel_en-US" xlink:label="lab_sny_NumberOfPatentActionsInitiallyFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patent actions initially filed</link:label>
    <link:label id="lab_sny_NumberOfPatentActionsInitiallyFiled_label_en-US" xlink:label="lab_sny_NumberOfPatentActionsInitiallyFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patent Actions Initially Filed</link:label>
    <link:label id="lab_sny_NumberOfPatentActionsInitiallyFiled_documentation_en-US" xlink:label="lab_sny_NumberOfPatentActionsInitiallyFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patent actions initially filed .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatentActionsInitiallyFiled" xlink:href="sny-20231231.xsd#sny_NumberOfPatentActionsInitiallyFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfPatentActionsInitiallyFiled" xlink:to="lab_sny_NumberOfPatentActionsInitiallyFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_f61cf206-8a79-4565-88c7-0433b44eedf4_terseLabel_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_label_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:label id="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_documentation_en-US" xlink:label="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:to="lab_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfPayments_8946ec03-afa4-4655-968f-91557964e15d_terseLabel_en-US" xlink:label="lab_sny_NumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of payments</link:label>
    <link:label id="lab_sny_NumberOfPayments_label_en-US" xlink:label="lab_sny_NumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Payments</link:label>
    <link:label id="lab_sny_NumberOfPayments_documentation_en-US" xlink:label="lab_sny_NumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPayments" xlink:href="sny-20231231.xsd#sny_NumberOfPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfPayments" xlink:to="lab_sny_NumberOfPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_9be32f24-2725-4018-ab2a-11ba8c12b7ae_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Average Effective Tax Rate And Applicable Tax Rate Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of average effective tax rate and applicable tax rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeInstrumentDomain_2b6e3a28-bb6a-4f53-a9da-93f752166e6e_terseLabel_en-US" xlink:label="lab_sny_DerivativeInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Domain]</link:label>
    <link:label id="lab_sny_DerivativeInstrumentDomain_label_en-US" xlink:label="lab_sny_DerivativeInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Domain]</link:label>
    <link:label id="lab_sny_DerivativeInstrumentDomain_documentation_en-US" xlink:label="lab_sny_DerivativeInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of derivative instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeInstrumentDomain" xlink:href="sny-20231231.xsd#sny_DerivativeInstrumentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeInstrumentDomain" xlink:to="lab_sny_DerivativeInstrumentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_732e77e0-4632-47a1-a558-068abc4a8f46_terseLabel_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:to="lab_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_c6af608a-bb32-4f87-b736-0e782bc751a2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of defined benefit plans [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of defined benefit plans [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_9af35f50-35fc-4eca-8e3c-261a021575e6_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_ed99eab1-6b09-4ae8-9db0-b31c2a42fea4_negatedLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_cdb729e6-b65a-4795-b30a-c83cea282990_terseLabel_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating foreign exchange gains/(losses)</link:label>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_label_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Operating Foreign Exchange Gains (Losses)</link:label>
    <link:label id="lab_sny_NonOperatingForeignExchangeGainsLosses_documentation_en-US" xlink:label="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating foreign exchange gains/(losses).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses" xlink:href="sny-20231231.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonOperatingForeignExchangeGainsLosses" xlink:to="lab_sny_NonOperatingForeignExchangeGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_d1772910-cfa1-4aba-b68d-9290f60783e4_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New borrowings</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfOtherManufacturersInvolvedInProceedings_f89acbd5-a47b-459e-b836-4ae6d24a852f_terseLabel_en-US" xlink:label="lab_sny_NumberOfOtherManufacturersInvolvedInProceedings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other manufacturers involved in proceedings</link:label>
    <link:label id="lab_sny_NumberOfOtherManufacturersInvolvedInProceedings_label_en-US" xlink:label="lab_sny_NumberOfOtherManufacturersInvolvedInProceedings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Other Manufacturers Involved In Proceedings</link:label>
    <link:label id="lab_sny_NumberOfOtherManufacturersInvolvedInProceedings_documentation_en-US" xlink:label="lab_sny_NumberOfOtherManufacturersInvolvedInProceedings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Other Manufacturers Involved In Proceedings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOtherManufacturersInvolvedInProceedings" xlink:href="sny-20231231.xsd#sny_NumberOfOtherManufacturersInvolvedInProceedings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfOtherManufacturersInvolvedInProceedings" xlink:to="lab_sny_NumberOfOtherManufacturersInvolvedInProceedings" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LeaseTerm_861a6293-949f-4ade-81ef-a5b2b13b7ded_terseLabel_en-US" xlink:label="lab_sny_LeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, term</link:label>
    <link:label id="lab_sny_LeaseTerm_label_en-US" xlink:label="lab_sny_LeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Term</link:label>
    <link:label id="lab_sny_LeaseTerm_documentation_en-US" xlink:label="lab_sny_LeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseTerm" xlink:href="sny-20231231.xsd#sny_LeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LeaseTerm" xlink:to="lab_sny_LeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_4e5ac1a8-fe0f-46b9-be4e-16a449c2fce3_terseLabel_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value (excluding investments accounted for using the equity method)</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_label_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</link:label>
    <link:label id="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_documentation_en-US" xlink:label="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:to="lab_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_414753d6-f69c-4da7-9abc-3aeafd1aea00_negatedLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and general expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_142d59ed-5686-4977-b292-08c38ed8a300_terseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and general expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6ed7f430-23ff-4ce4-8c85-70a6bd57aa01_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock_a604ed0a-95ce-4c6d-b481-184feeff5833_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Present Value of Pension and Other Post Employement Benefits</link:label>
    <link:label id="lab_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Pension And Other Post Employment Benefit Expense [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of pension and other post employment benefit expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock" xlink:to="lab_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_5411494f-7b8b-464b-919d-2ea2fd126d76_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bottom of range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockOptionPlansMember_cca5e1af-5abf-41b4-b7dc-cbb30cb22f0f_terseLabel_en-US" xlink:label="lab_sny_StockOptionPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option plans</link:label>
    <link:label id="lab_sny_StockOptionPlansMember_label_en-US" xlink:label="lab_sny_StockOptionPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plans [Member]</link:label>
    <link:label id="lab_sny_StockOptionPlansMember_documentation_en-US" xlink:label="lab_sny_StockOptionPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlansMember" xlink:href="sny-20231231.xsd#sny_StockOptionPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockOptionPlansMember" xlink:to="lab_sny_StockOptionPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiaventisAEBEMember_2aec3b87-a92a-41d8-bb94-56e4f66f6af0_terseLabel_en-US" xlink:label="lab_sny_SanofiaventisAEBEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis A.E.B.E.</link:label>
    <link:label id="lab_sny_SanofiaventisAEBEMember_label_en-US" xlink:label="lab_sny_SanofiaventisAEBEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis A.E.B.E. [member]</link:label>
    <link:label id="lab_sny_SanofiaventisAEBEMember_documentation_en-US" xlink:label="lab_sny_SanofiaventisAEBEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis A.E.B.E.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiaventisAEBEMember" xlink:href="sny-20231231.xsd#sny_SanofiaventisAEBEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiaventisAEBEMember" xlink:to="lab_sny_SanofiaventisAEBEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_e2d85e41-a72d-40a0-add0-6fd1b5fbd93a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of finance lease payments receivable [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of finance lease payments receivable [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LitigationAmountPayable_bf6ed117-5bcb-40ff-b3e6-68cf188c2c7a_terseLabel_en-US" xlink:label="lab_sny_LitigationAmountPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation amount payable</link:label>
    <link:label id="lab_sny_LitigationAmountPayable_label_en-US" xlink:label="lab_sny_LitigationAmountPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Amount Payable</link:label>
    <link:label id="lab_sny_LitigationAmountPayable_documentation_en-US" xlink:label="lab_sny_LitigationAmountPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Amount Payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LitigationAmountPayable" xlink:href="sny-20231231.xsd#sny_LitigationAmountPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LitigationAmountPayable" xlink:to="lab_sny_LitigationAmountPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurIncMember_dd75a716-e24b-436b-89a9-866a403bf930_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Inc.</link:label>
    <link:label id="lab_sny_SanofiPasteurIncMember_label_en-US" xlink:label="lab_sny_SanofiPasteurIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Inc [member]</link:label>
    <link:label id="lab_sny_SanofiPasteurIncMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurIncMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurIncMember" xlink:to="lab_sny_SanofiPasteurIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DepakineProductLitigationInSpainMember_2d951ebb-8e7d-452f-9ea9-ae4fb7015d7c_terseLabel_en-US" xlink:label="lab_sny_DepakineProductLitigationInSpainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine product litigation in Spain</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInSpainMember_label_en-US" xlink:label="lab_sny_DepakineProductLitigationInSpainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Spain [Member]</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInSpainMember_documentation_en-US" xlink:label="lab_sny_DepakineProductLitigationInSpainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Spain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInSpainMember" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInSpainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DepakineProductLitigationInSpainMember" xlink:to="lab_sny_DepakineProductLitigationInSpainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_30340af5-aba5-4af4-9a8e-e5165d2e8650_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OrdinarySharesNASDAQGlobalSelectMarketMember_0bc1b41f-6521-4ca2-8f85-12d1140da7d0_terseLabel_en-US" xlink:label="lab_sny_OrdinarySharesNASDAQGlobalSelectMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares, par value &#8364;2&#160;per share</link:label>
    <link:label id="lab_sny_OrdinarySharesNASDAQGlobalSelectMarketMember_label_en-US" xlink:label="lab_sny_OrdinarySharesNASDAQGlobalSelectMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares, NASDAQ Global Select Market [Member]</link:label>
    <link:label id="lab_sny_OrdinarySharesNASDAQGlobalSelectMarketMember_documentation_en-US" xlink:label="lab_sny_OrdinarySharesNASDAQGlobalSelectMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares, NASDAQ Global Select Market [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OrdinarySharesNASDAQGlobalSelectMarketMember" xlink:href="sny-20231231.xsd#sny_OrdinarySharesNASDAQGlobalSelectMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OrdinarySharesNASDAQGlobalSelectMarketMember" xlink:to="lab_sny_OrdinarySharesNASDAQGlobalSelectMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_24c19042-faed-4ef8-8e79-9f93476fbf03_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt by Type Valuation of Redemption</link:label>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt Net Of Cash And Cash Equivalents By Type At Value On Redemption Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of debt net of cash and cash equivalents by type at value on redemption.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_487c6be1-b7e1-44b3-a675-8a40e0564b37_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisDePanamaSAMember_63d98a25-f682-432f-8274-1a404dea5e99_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisDePanamaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis de Panama SA</link:label>
    <link:label id="lab_sny_SanofiAventisDePanamaSAMember_label_en-US" xlink:label="lab_sny_SanofiAventisDePanamaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis De Panama S A [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisDePanamaSAMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisDePanamaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis de Panama S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDePanamaSAMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisDePanamaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisDePanamaSAMember" xlink:to="lab_sny_SanofiAventisDePanamaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_05e33e62-f8e4-4c96-93ce-49bfca15596e_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals and other decreases</link:label>
    <link:label id="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals and retirements, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureTable_55e2a0bc-4403-46f6-8100-90d7e6bc01d5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Credit Risk Exposure [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCreditRiskExposureTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of credit risk exposure [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="lab_ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareRomaniaSRLMember_78fe788c-6039-4ea1-a993-eb9a60c0b044_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareRomaniaSRLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Romania SRL</link:label>
    <link:label id="lab_sny_OpellaHealthcareRomaniaSRLMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareRomaniaSRLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Romania S.R.L. [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareRomaniaSRLMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareRomaniaSRLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Romania S.R.L.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareRomaniaSRLMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareRomaniaSRLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareRomaniaSRLMember" xlink:to="lab_sny_OpellaHealthcareRomaniaSRLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_fbee4413-cf25-4157-9559-c72644b84ebe_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves and retained earnings</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_256e059e-f3c4-4db7-9811-d950d5a905d2_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services [axis]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock_8448e91a-5023-4126-9b5f-6161e899aff4_terseLabel_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other gains and losses, and litigation</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Other Gains And Losses And Litigation Explanatory [Policy Text Block]</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for other gains and losses, and litigation explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock" xlink:to="lab_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany_d455e332-8f05-4491-ab3e-32a20e4a994e_terseLabel_en-US" xlink:label="lab_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional funding for PD1 - part of each company</link:label>
    <link:label id="lab_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany_label_en-US" xlink:label="lab_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Additional Funding For Anti Programmed Cell Death Protein 1 Part Of Each Company</link:label>
    <link:label id="lab_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany_documentation_en-US" xlink:label="lab_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional funding for anti programmed cell death protein 1 part of each company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany" xlink:href="sny-20231231.xsd#sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany" xlink:to="lab_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GlobalPenaltyFeeIncurredByDefendants_0b391e11-bd9e-4a47-811e-6a674d88e4db_terseLabel_en-US" xlink:label="lab_sny_GlobalPenaltyFeeIncurredByDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total penalty fee incurred by defendants</link:label>
    <link:label id="lab_sny_GlobalPenaltyFeeIncurredByDefendants_label_en-US" xlink:label="lab_sny_GlobalPenaltyFeeIncurredByDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Penalty Fee Incurred By Defendants</link:label>
    <link:label id="lab_sny_GlobalPenaltyFeeIncurredByDefendants_documentation_en-US" xlink:label="lab_sny_GlobalPenaltyFeeIncurredByDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Penalty Fee Incurred By Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GlobalPenaltyFeeIncurredByDefendants" xlink:href="sny-20231231.xsd#sny_GlobalPenaltyFeeIncurredByDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GlobalPenaltyFeeIncurredByDefendants" xlink:to="lab_sny_GlobalPenaltyFeeIncurredByDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HeldtomaturityInvestments_83409b27-f1df-4cac-9053-14eb06917a5b_terseLabel_en-US" xlink:label="lab_ifrs-full_HeldtomaturityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets held for investments</link:label>
    <link:label id="lab_ifrs-full_HeldtomaturityInvestments_label_en-US" xlink:label="lab_ifrs-full_HeldtomaturityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HeldtomaturityInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HeldtomaturityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HeldtomaturityInvestments" xlink:to="lab_ifrs-full_HeldtomaturityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_bec74785-70e4-42c2-ad56-7271fe2512c6_totalLabel_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net debt</link:label>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_70210f9d-99df-4012-bf4e-64729f4cb94c_terseLabel_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net debt</link:label>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_label_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Net Of Cash And Cash Equivalents</link:label>
    <link:label id="lab_sny_DebtNetOfCashAndCashEquivalents_documentation_en-US" xlink:label="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt net of cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtNetOfCashAndCashEquivalents" xlink:to="lab_sny_DebtNetOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisSuisseSAMember_12e3a792-99c3-4ff9-bd11-5fa95c477822_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisSuisseSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis (Suisse) SA</link:label>
    <link:label id="lab_sny_SanofiAventisSuisseSAMember_label_en-US" xlink:label="lab_sny_SanofiAventisSuisseSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis (Suisse) SA [member]</link:label>
    <link:label id="lab_sny_SanofiAventisSuisseSAMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisSuisseSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis (Suisse) SA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSuisseSAMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisSuisseSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisSuisseSAMember" xlink:to="lab_sny_SanofiAventisSuisseSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_28ec062f-8c2d-428e-a54a-c82b4ddb30ea_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_6e726edc-a6f1-4317-8ff2-cf9702b5a88a_verboseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeBeforeTax_dd853fcd-017e-4a8f-b43e-2c9a675f7ae1_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income before tax</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_a65f2c54-3ad4-467f-87d0-65cbc328f2c5_terseLabel_en-US" xlink:label="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions And Other Current And Non-Current Liabilities [Table]</link:label>
    <link:label id="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_label_en-US" xlink:label="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions And Other Current And Non-Current Liabilities [Table]</link:label>
    <link:label id="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_documentation_en-US" xlink:label="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions and other current and noncurrent liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable" xlink:to="lab_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments_5a30abbf-8445-4a80-8844-9eaf61841487_terseLabel_en-US" xlink:label="lab_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments received in respect of disposals proceeds receivable and contingent consideration on divestments</link:label>
    <link:label id="lab_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments_label_en-US" xlink:label="lab_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Balance Sheet Commitments Received In Respect Of Disposals Proceeds Receivable And Contingent Consideration On Divestments</link:label>
    <link:label id="lab_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments_documentation_en-US" xlink:label="lab_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Balance Sheet Commitments Received In Respect Of Disposals Proceeds Receivable And Contingent Consideration On Divestments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments" xlink:href="sny-20231231.xsd#sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments" xlink:to="lab_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock_7cb84b5d-4af4-42c5-92e9-72e1258dc736_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt by Currency Before and After Derivative Instrument</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Debt By Currency At Value Of Redemption Before And After Derivative Instruments [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of debt by currency at value of redemption before and after derivative instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock" xlink:to="lab_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_b333aafa-42d1-44c5-ba55-66f656c80bbe_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfJointOperationsTable_bebefb1a-b2ff-4005-b82b-0a688d0978f5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Joint Operations [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfJointOperationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of joint operations [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointOperationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfJointOperationsTable" xlink:to="lab_ifrs-full_DisclosureOfJointOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PreFundedPensionObligations_09328735-f145-4003-89ca-1aa42e787f43_terseLabel_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-funded pension obligations</link:label>
    <link:label id="lab_sny_PreFundedPensionObligations_cd96cddb-a821-47e4-bc08-63e1c608bd45_verboseLabel_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-funded pension obligations</link:label>
    <link:label id="lab_sny_PreFundedPensionObligations_label_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Pension Obligations</link:label>
    <link:label id="lab_sny_PreFundedPensionObligations_documentation_en-US" xlink:label="lab_sny_PreFundedPensionObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-funded pension obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations" xlink:href="sny-20231231.xsd#sny_PreFundedPensionObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PreFundedPensionObligations" xlink:to="lab_sny_PreFundedPensionObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_TypesOfAgreementDomain_4b3c8a64-6cdc-46a8-97fd-1e70abab2f6d_terseLabel_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types Of Agreement [Domain]</link:label>
    <link:label id="lab_sny_TypesOfAgreementDomain_label_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types Of Agreement [Domain]</link:label>
    <link:label id="lab_sny_TypesOfAgreementDomain_documentation_en-US" xlink:label="lab_sny_TypesOfAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_TypesOfAgreementDomain" xlink:to="lab_sny_TypesOfAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GenzymeGlobalSarlMember_0680a42b-eab9-4ad4-8b22-693579699286_terseLabel_en-US" xlink:label="lab_sny_GenzymeGlobalSarlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Global Sarl</link:label>
    <link:label id="lab_sny_GenzymeGlobalSarlMember_label_en-US" xlink:label="lab_sny_GenzymeGlobalSarlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Global Sarl [member]</link:label>
    <link:label id="lab_sny_GenzymeGlobalSarlMember_documentation_en-US" xlink:label="lab_sny_GenzymeGlobalSarlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Global Sarl.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeGlobalSarlMember" xlink:href="sny-20231231.xsd#sny_GenzymeGlobalSarlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GenzymeGlobalSarlMember" xlink:to="lab_sny_GenzymeGlobalSarlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsNoncurrent_9786e203-753d-434c-b7a1-e6c02c70fde9_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current income tax assets</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsNoncurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax assets, non-current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:to="lab_ifrs-full_CurrentTaxAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod_7bc01660-f239-4ee1-bf62-1c1a6fc0abf5_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems_1ee7b310-0dc4-4c85-9965-a23521c35d56_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of operating segments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of operating segments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_cd6655d0-2405-48ef-8c05-bcf9b00f0e14_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockSubscriptionOptionPlanNineMember_cb11bfd1-4c76-4925-a022-e296fb6d2d67_terseLabel_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan nine</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanNineMember_label_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Option Plan Nine [Member]</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanNineMember_documentation_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan nine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanNineMember" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockSubscriptionOptionPlanNineMember" xlink:to="lab_sny_StockSubscriptionOptionPlanNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurAsiTicaretASMember_9b297d09-59fb-4d86-b649-f385f0e13841_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurAsiTicaretASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Asi Ticaret AS</link:label>
    <link:label id="lab_sny_SanofiPasteurAsiTicaretASMember_label_en-US" xlink:label="lab_sny_SanofiPasteurAsiTicaretASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Asi Ticaret A.S [member]</link:label>
    <link:label id="lab_sny_SanofiPasteurAsiTicaretASMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurAsiTicaretASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Asi Ticaret A.S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurAsiTicaretASMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurAsiTicaretASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurAsiTicaretASMember" xlink:to="lab_sny_SanofiPasteurAsiTicaretASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_7c1fc506-c563-4d6d-bd25-5ac7fb0ed725_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_32520ad7-50e3-49a0-909a-232008d7be84_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_684e83c8-a445-4610-844f-6795bf7a31f8_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RealEstate1Member_2ef6b1fc-20dc-4d75-85f6-1e43b68b75a2_terseLabel_en-US" xlink:label="lab_sny_RealEstate1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate</link:label>
    <link:label id="lab_sny_RealEstate1Member_label_en-US" xlink:label="lab_sny_RealEstate1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate1 [Member]</link:label>
    <link:label id="lab_sny_RealEstate1Member_documentation_en-US" xlink:label="lab_sny_RealEstate1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RealEstate1Member" xlink:href="sny-20231231.xsd#sny_RealEstate1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RealEstate1Member" xlink:to="lab_sny_RealEstate1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_8ed13a2d-a9f0-4419-a4e5-8d77b7ba8a4f_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Sanofi shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialInstruments_3146367f-dc6c-4a56-a42d-15ade060123f_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating currency hedging instruments in place</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstruments_bcd24b1e-df14-46a7-ba06-b9efd8209403_verboseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nominal value of interest rate swaps hedge fixed-rate bonds</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstruments_label_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_sny_DerivativeFinancialInstruments_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialInstruments" xlink:to="lab_sny_DerivativeFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_USGovernmentMember_ac1c63f2-da4c-4174-a258-53c1ec2a3233_terseLabel_en-US" xlink:label="lab_sny_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government</link:label>
    <link:label id="lab_sny_USGovernmentMember_label_en-US" xlink:label="lab_sny_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government [Member]</link:label>
    <link:label id="lab_sny_USGovernmentMember_documentation_en-US" xlink:label="lab_sny_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USGovernmentMember" xlink:href="sny-20231231.xsd#sny_USGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_USGovernmentMember" xlink:to="lab_sny_USGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_HedgeFunds1Member_614b9978-b3ea-4c9d-8492-8e4af7f19763_terseLabel_en-US" xlink:label="lab_sny_HedgeFunds1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge funds</link:label>
    <link:label id="lab_sny_HedgeFunds1Member_label_en-US" xlink:label="lab_sny_HedgeFunds1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge Funds1 [Member]</link:label>
    <link:label id="lab_sny_HedgeFunds1Member_documentation_en-US" xlink:label="lab_sny_HedgeFunds1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge Funds1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HedgeFunds1Member" xlink:href="sny-20231231.xsd#sny_HedgeFunds1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_HedgeFunds1Member" xlink:to="lab_sny_HedgeFunds1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember_e441c16c-cf80-46fa-92c9-d4dbf90ae5f4_terseLabel_en-US" xlink:label="lab_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent (Alirocumab)-related amgen patent litigation in the US</link:label>
    <link:label id="lab_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember_label_en-US" xlink:label="lab_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent (Alirocumab)-Related Amgen Patent Litigation In The US [Member]</link:label>
    <link:label id="lab_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember_documentation_en-US" xlink:label="lab_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent (Alirocumab)-Related Amgen Patent Litigation In The US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember" xlink:href="sny-20231231.xsd#sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember" xlink:to="lab_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_9c8fad65-5778-4c86-8125-862fcb01cdd9_terseLabel_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antibodies Collaboration agreement</link:label>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_label_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antibodies Collaboration Agreement [Member]</link:label>
    <link:label id="lab_sny_AntibodiesCollaborationAgreementMember_documentation_en-US" xlink:label="lab_sny_AntibodiesCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antibodies collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AntibodiesCollaborationAgreementMember" xlink:to="lab_sny_AntibodiesCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_63fc0741-fbdc-4354-9448-389e03180a97_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AOSanofiRussiaMember_0730bb6f-eeab-475a-a9d8-8ed88ee8ca52_terseLabel_en-US" xlink:label="lab_sny_AOSanofiRussiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AO Sanofi Russia</link:label>
    <link:label id="lab_sny_AOSanofiRussiaMember_label_en-US" xlink:label="lab_sny_AOSanofiRussiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AO Sanofi Russia [member]</link:label>
    <link:label id="lab_sny_AOSanofiRussiaMember_documentation_en-US" xlink:label="lab_sny_AOSanofiRussiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AO Sanofi Russia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AOSanofiRussiaMember" xlink:href="sny-20231231.xsd#sny_AOSanofiRussiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AOSanofiRussiaMember" xlink:to="lab_sny_AOSanofiRussiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReclassifiedItemsAxis_3c263e7a-46e2-420a-ba09-c511152f81d6_terseLabel_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassified items [axis]</link:label>
    <link:label id="lab_ifrs-full_ReclassifiedItemsAxis_label_en-US" xlink:label="lab_ifrs-full_ReclassifiedItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassified items [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis" xlink:to="lab_ifrs-full_ReclassifiedItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock_c279b088-53e2-405a-9ecf-87ba814d33e2_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests</link:label>
    <link:label id="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Maximum Amount Of Contingent Consideration Payable And Firm Commitments To Buy Out Non-Controlling Interests Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfPatientsToIndemnify_6519ddea-dd4c-4628-92f2-70319c6ae4c9_terseLabel_en-US" xlink:label="lab_sny_NumberOfPatientsToIndemnify" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients to indemnify</link:label>
    <link:label id="lab_sny_NumberOfPatientsToIndemnify_label_en-US" xlink:label="lab_sny_NumberOfPatientsToIndemnify" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients To Indemnify</link:label>
    <link:label id="lab_sny_NumberOfPatientsToIndemnify_documentation_en-US" xlink:label="lab_sny_NumberOfPatientsToIndemnify" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients To Indemnify</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatientsToIndemnify" xlink:href="sny-20231231.xsd#sny_NumberOfPatientsToIndemnify"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfPatientsToIndemnify" xlink:to="lab_sny_NumberOfPatientsToIndemnify" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_efd4bc69-bdb8-457e-adc3-23db3a508b9b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_0b5b5f50-0eab-4195-9c6a-df47c226b22c_negatedLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset/(liability)</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_RestrictedSharePlan2019Member_f6e5bd35-dc38-4144-bb50-1754a7998f50_terseLabel_en-US" xlink:label="lab_sny_RestrictedSharePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share plan 2019</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2019Member_label_en-US" xlink:label="lab_sny_RestrictedSharePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plan 2019 [Member]</link:label>
    <link:label id="lab_sny_RestrictedSharePlan2019Member_documentation_en-US" xlink:label="lab_sny_RestrictedSharePlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Plan 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2019Member" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_RestrictedSharePlan2019Member" xlink:to="lab_sny_RestrictedSharePlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GenzymePolyclonalsSASMember_41df97c5-edde-45ff-95eb-e46bcd6b27fe_terseLabel_en-US" xlink:label="lab_sny_GenzymePolyclonalsSASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Polyclonals SAS</link:label>
    <link:label id="lab_sny_GenzymePolyclonalsSASMember_label_en-US" xlink:label="lab_sny_GenzymePolyclonalsSASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Polyclonals SAS [Member]</link:label>
    <link:label id="lab_sny_GenzymePolyclonalsSASMember_documentation_en-US" xlink:label="lab_sny_GenzymePolyclonalsSASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Polyclonals SAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymePolyclonalsSASMember" xlink:href="sny-20231231.xsd#sny_GenzymePolyclonalsSASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GenzymePolyclonalsSASMember" xlink:to="lab_sny_GenzymePolyclonalsSASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisThailandLtdMember_8aba6835-e45b-43db-a37b-7f705fa0ac19_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisThailandLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis (Thailand) Ltd</link:label>
    <link:label id="lab_sny_SanofiAventisThailandLtdMember_label_en-US" xlink:label="lab_sny_SanofiAventisThailandLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Thailand Ltd [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisThailandLtdMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisThailandLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Thailand Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisThailandLtdMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisThailandLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisThailandLtdMember" xlink:to="lab_sny_SanofiAventisThailandLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3e4707cc-5abe-42f4-a5f7-63913d01cc22_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_7e316a28-8eeb-4c09-8e13-362c85126bb7_verboseLabel_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in other non-current assets</link:label>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_label_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Change In Other Non-Current Assets</link:label>
    <link:label id="lab_sny_NetChangeInOtherNonCurrentAssets_documentation_en-US" xlink:label="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in other non-current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets" xlink:href="sny-20231231.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetChangeInOtherNonCurrentAssets" xlink:to="lab_sny_NetChangeInOtherNonCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_c379ff0c-66f2-4537-ac17-79eac1a32fbb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [text block]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets_862e2523-aa7f-4a2b-a135-32b7f3f0a2e2_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments related to research and development payments contingent upon attainment of sales targets</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Research And Development Payments Contingent Upon Attainment Of Sales Targets</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments related to r and d payments contingent upon attainment of sales targets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets" xlink:to="lab_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurMerieuxSASMember_3e86682e-56a0-4d59-9936-9fdd52ab3557_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurMerieuxSASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Merieux SAS</link:label>
    <link:label id="lab_sny_SanofiPasteurMerieuxSASMember_label_en-US" xlink:label="lab_sny_SanofiPasteurMerieuxSASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Merieux S.A.S [Member]</link:label>
    <link:label id="lab_sny_SanofiPasteurMerieuxSASMember_documentation_en-US" xlink:label="lab_sny_SanofiPasteurMerieuxSASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur Merieux S.A.S</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurMerieuxSASMember" xlink:href="sny-20231231.xsd#sny_SanofiPasteurMerieuxSASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurMerieuxSASMember" xlink:to="lab_sny_SanofiPasteurMerieuxSASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_752e6e41-53fc-45fc-a5b0-d9b833fc27ad_terseLabel_en-US" xlink:label="lab_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value on redemption after derivative instruments</link:label>
    <link:label id="lab_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_label_en-US" xlink:label="lab_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value On Redemption After Derivative Instruments [Member]</link:label>
    <link:label id="lab_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_documentation_en-US" xlink:label="lab_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value on redemption after derivative instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionAfterDerivativeInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember" xlink:to="lab_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_f2b91b16-4cb2-4b8a-9d5a-03deb25b2dcd_terseLabel_en-US" xlink:label="lab_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New transactions</link:label>
    <link:label id="lab_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New liabilities, contingent liabilities recognised in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IGMBiosciencesIncMember_c1f0c655-2f1e-440f-b2a5-1a8a10aafb76_terseLabel_en-US" xlink:label="lab_sny_IGMBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IGM Biosciences, Inc</link:label>
    <link:label id="lab_sny_IGMBiosciencesIncMember_label_en-US" xlink:label="lab_sny_IGMBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IGM Biosciences, Inc [Member]</link:label>
    <link:label id="lab_sny_IGMBiosciencesIncMember_documentation_en-US" xlink:label="lab_sny_IGMBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IGM Biosciences, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IGMBiosciencesIncMember" xlink:href="sny-20231231.xsd#sny_IGMBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IGMBiosciencesIncMember" xlink:to="lab_sny_IGMBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock_b397a752-e504-46fe-ab80-25872d7773d0_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Impairment Losses of Other Intangible Assets</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Impairment Losses Of Other Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Impairment Losses Of Other Intangible Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock" xlink:to="lab_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_2150360c-afd1-4ac0-8a40-76787ca17800_negatedLabel_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs and similar items</link:label>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_c71e1ca7-7519-494b-b03e-6f7164646270_totalLabel_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ExpenseOfRestructuringActivities_label_en-US" xlink:label="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense of restructuring activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseOfRestructuringActivities" xlink:to="lab_ifrs-full_ExpenseOfRestructuringActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrencyDerivativesMember_2b5c36e4-be05-44de-91e1-d2d63cdbc481_terseLabel_en-US" xlink:label="lab_sny_CurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency derivatives</link:label>
    <link:label id="lab_sny_CurrencyDerivativesMember_label_en-US" xlink:label="lab_sny_CurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Derivatives [member]</link:label>
    <link:label id="lab_sny_CurrencyDerivativesMember_documentation_en-US" xlink:label="lab_sny_CurrencyDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency derivatives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesMember" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrencyDerivativesMember" xlink:to="lab_sny_CurrencyDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameMember_dd0ae4da-4236-4c8e-9a0e-af8b109aaf0b_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name [member]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameMember_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameMember" xlink:to="lab_ifrs-full_BorrowingsByNameMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement_1ada8ee5-0fd0-4537-a3cd-9d4f858b00dc_terseLabel_en-US" xlink:label="lab_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of immunology or inflammation targets under collaboration agreement</link:label>
    <link:label id="lab_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement_label_en-US" xlink:label="lab_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Immunology Or Inflammation Targets Under Collaboration Agreement</link:label>
    <link:label id="lab_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Immunology Or Inflammation Targets Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement" xlink:href="sny-20231231.xsd#sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement" xlink:to="lab_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_108c4235-2fe3-4fdb-aa47-bf5662b89133_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases and other expenses (including research expenses)</link:label>
    <link:label id="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of goods, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:to="lab_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_QuotedEquitySecuritiesMember_cb5d78b6-c992-4151-a9aa-3cd8abf0092c_terseLabel_en-US" xlink:label="lab_sny_QuotedEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted equity securities</link:label>
    <link:label id="lab_sny_QuotedEquitySecuritiesMember_label_en-US" xlink:label="lab_sny_QuotedEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Equity Securities [member]</link:label>
    <link:label id="lab_sny_QuotedEquitySecuritiesMember_documentation_en-US" xlink:label="lab_sny_QuotedEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedEquitySecuritiesMember" xlink:href="sny-20231231.xsd#sny_QuotedEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_QuotedEquitySecuritiesMember" xlink:to="lab_sny_QuotedEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfSharesIssuedByExerciceOfEachOption_0e351d07-e57c-4cd0-a5ec-285199b1aef8_terseLabel_en-US" xlink:label="lab_sny_NumberOfSharesIssuedByExerciceOfEachOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued by exercice of each option (in shares)</link:label>
    <link:label id="lab_sny_NumberOfSharesIssuedByExerciceOfEachOption_label_en-US" xlink:label="lab_sny_NumberOfSharesIssuedByExerciceOfEachOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued By Exercice Of Each Option</link:label>
    <link:label id="lab_sny_NumberOfSharesIssuedByExerciceOfEachOption_documentation_en-US" xlink:label="lab_sny_NumberOfSharesIssuedByExerciceOfEachOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued By Exercice Of Each Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedByExerciceOfEachOption" xlink:href="sny-20231231.xsd#sny_NumberOfSharesIssuedByExerciceOfEachOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfSharesIssuedByExerciceOfEachOption" xlink:to="lab_sny_NumberOfSharesIssuedByExerciceOfEachOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_1c8ec7eb-b834-4d47-aea2-e537398a43d3_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of consolidated undertakings and investments accounted for using the equity method</link:label>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_38e8e913-d649-47ab-9be1-2de82f07540a_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow on acquisition</link:label>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_dde13929-ecda-4a35-8bdb-17c8dacd5039_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_c7a28d0c-ae0d-49a2-8d16-5f5223d0c8a7_terseLabel_en-US" xlink:label="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated financial effect of contingent liabilities</link:label>
    <link:label id="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_label_en-US" xlink:label="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated financial effect of contingent liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:to="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LargestCustomersMember_67576fd4-1e26-4437-a39d-9976d906fa35_terseLabel_en-US" xlink:label="lab_sny_LargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest customers</link:label>
    <link:label id="lab_sny_LargestCustomersMember_label_en-US" xlink:label="lab_sny_LargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Customers [Member]</link:label>
    <link:label id="lab_sny_LargestCustomersMember_documentation_en-US" xlink:label="lab_sny_LargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LargestCustomersMember" xlink:href="sny-20231231.xsd#sny_LargestCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LargestCustomersMember" xlink:to="lab_sny_LargestCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_6bab5594-04f6-4939-96ec-069b673ea075_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax liabilities, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_StockSubscriptionOptionPlanSevenMember_d5920221-93db-4081-938a-194f4d43fc69_terseLabel_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan seven</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanSevenMember_label_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Option Plan Seven [Member]</link:label>
    <link:label id="lab_sny_StockSubscriptionOptionPlanSevenMember_documentation_en-US" xlink:label="lab_sny_StockSubscriptionOptionPlanSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription option plan seven.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanSevenMember" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_StockSubscriptionOptionPlanSevenMember" xlink:to="lab_sny_StockSubscriptionOptionPlanSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember_80b097a8-355a-4844-b70d-b80fb9012455_terseLabel_en-US" xlink:label="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plavix Attorney General Action in Hawaii</link:label>
    <link:label id="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember_label_en-US" xlink:label="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plavix Attorney General Action In Hawaii [Member]</link:label>
    <link:label id="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember_documentation_en-US" xlink:label="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plavix Attorney General Action In Hawaii</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:href="sny-20231231.xsd#sny_PlavixAttorneyGeneralActionInHawaiiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:to="lab_sny_PlavixAttorneyGeneralActionInHawaiiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_41695eba-d844-459e-aee9-0c191390f475_terseLabel_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from plan members</link:label>
    <link:label id="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_6edcd758-ecf2-41dc-92ad-5220381aa66e_negatedLabel_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from plan members</link:label>
    <link:label id="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from contributions to plan by plan participants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_c81eca4d-1629-4986-8e1f-1061dbaedf60_terseLabel_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital increase by issuance of restricted shares (in shares)</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_label_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Restricted Shares Issued In Regards Of Capital Increase</link:label>
    <link:label id="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_documentation_en-US" xlink:label="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of restricted shares issued in regards of capital increase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:href="sny-20231231.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:to="lab_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_161ef229-f09f-483a-b2d2-d81352fc0ccb_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and other increases</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_4357ca6e-8088-4f91-95c4-d23d69c1c167_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable_b9aea7af-4aa9-478f-9f35-4784a716e39b_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net income attributable to Non-controlling Interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable_label_en-US" xlink:label="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Net Income Attributable To Non-Controlling Interests [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net income attributable to Non-controlling Interests [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable" xlink:to="lab_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_02305636-b7fe-411f-a803-4da3190855a1_terseLabel_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_a90ed082-3384-4847-8bed-0e56afdbf7cd_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for risks</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for provisions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_4a3f5496-5ccd-4eb4-a9f3-6ef1c4f8db4c_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Sales by Segment and Geographical Area</link:label>
    <link:label id="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Net Sales By Segment And Geographical Area [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net sales by segment and geographical area.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:to="lab_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable_772ec886-de47-4cc5-9798-a9d13aeb5e51_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of stock subscription option plan outstanding and option exercised [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable_label_en-US" xlink:label="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Stock Subscription Option Plan Outstanding And Option Exercised [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of stock subscription option plan outstanding and option exercised [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable" xlink:to="lab_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns_bb142a9c-cf8c-4573-8757-e79e1d2004b5_negatedTerseLabel_en-US" xlink:label="lab_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made</link:label>
    <link:label id="lab_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns_label_en-US" xlink:label="lab_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease Through Payments Made Provisions For Discounts Rebates And Sales Returns</link:label>
    <link:label id="lab_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns_documentation_en-US" xlink:label="lab_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made for discounts, rebates and sales returns.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" xlink:href="sny-20231231.xsd#sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" xlink:to="lab_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorTable_8e615b0a-0006-4cf8-8736-d82c05e22116_terseLabel_en-US" xlink:label="lab_dei_AuditorTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Table]</link:label>
    <link:label id="lab_dei_AuditorTable_label_en-US" xlink:label="lab_dei_AuditorTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorTable" xlink:to="lab_dei_AuditorTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_c3eae7b0-f4d6-49ae-89eb-1ccf9b07455a_terseLabel_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock_500bc35f-e7df-449e-af79-45624df0a6f4_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Movement in Provisions for Discounts, Rebates and Sales Returns</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Changes In Provisions For Discounts Rebates And Sales Returns [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of changes in provisions for discounts rebates and sales returns.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock" xlink:to="lab_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfAverageOfQuotedMarketPricesOfShares_458c4a72-5bdc-4e08-a593-8c5a0479824d_verboseLabel_en-US" xlink:label="lab_sny_PercentageOfAverageOfQuotedMarketPricesOfShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription price (as a percent)</link:label>
    <link:label id="lab_sny_PercentageOfAverageOfQuotedMarketPricesOfShares_label_en-US" xlink:label="lab_sny_PercentageOfAverageOfQuotedMarketPricesOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Average Of Quoted Market Prices Of Shares</link:label>
    <link:label id="lab_sny_PercentageOfAverageOfQuotedMarketPricesOfShares_documentation_en-US" xlink:label="lab_sny_PercentageOfAverageOfQuotedMarketPricesOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of average of quoted market prices of shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAverageOfQuotedMarketPricesOfShares" xlink:href="sny-20231231.xsd#sny_PercentageOfAverageOfQuotedMarketPricesOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfAverageOfQuotedMarketPricesOfShares" xlink:to="lab_sny_PercentageOfAverageOfQuotedMarketPricesOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfPrincipalAlliancesTextBlock_8a4141ff-851d-4cd2-a7e4-f21d40b9da93_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAlliancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal alliances</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAlliancesTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAlliancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Principal Alliances [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfPrincipalAlliancesTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfPrincipalAlliancesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for principal alliances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAlliancesTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfPrincipalAlliancesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesTextBlock" xlink:to="lab_sny_DisclosureOfPrincipalAlliancesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NonQualifiedDefinedBenefitPensionPlansMember_b92c53bf-3a1e-4d55-a572-ba35230465b6_terseLabel_en-US" xlink:label="lab_sny_NonQualifiedDefinedBenefitPensionPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non qualified defined benefit pension plans</link:label>
    <link:label id="lab_sny_NonQualifiedDefinedBenefitPensionPlansMember_label_en-US" xlink:label="lab_sny_NonQualifiedDefinedBenefitPensionPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Qualified Defined Benefit Pension Plans [member]</link:label>
    <link:label id="lab_sny_NonQualifiedDefinedBenefitPensionPlansMember_documentation_en-US" xlink:label="lab_sny_NonQualifiedDefinedBenefitPensionPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non qualified defined benefit pension plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonQualifiedDefinedBenefitPensionPlansMember" xlink:href="sny-20231231.xsd#sny_NonQualifiedDefinedBenefitPensionPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NonQualifiedDefinedBenefitPensionPlansMember" xlink:to="lab_sny_NonQualifiedDefinedBenefitPensionPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_72ed4f52-405d-4d70-97ba-3327cc2f5ccc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of associates [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of associates [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReductionOfIssuedCapital_d4c41f5a-dae7-4efd-ba48-cb41667cca53_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ReductionOfIssuedCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share capital</link:label>
    <link:label id="lab_ifrs-full_ReductionOfIssuedCapital_label_en-US" xlink:label="lab_ifrs-full_ReductionOfIssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReductionOfIssuedCapital" xlink:to="lab_ifrs-full_ReductionOfIssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCommercialPaperPrograms_b18ba479-7a71-42d1-9a43-7c7bec83cabe_terseLabel_en-US" xlink:label="lab_sny_NumberOfCommercialPaperPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of commercial paper programs</link:label>
    <link:label id="lab_sny_NumberOfCommercialPaperPrograms_label_en-US" xlink:label="lab_sny_NumberOfCommercialPaperPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Commercial Paper Programs</link:label>
    <link:label id="lab_sny_NumberOfCommercialPaperPrograms_documentation_en-US" xlink:label="lab_sny_NumberOfCommercialPaperPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Commercial Paper Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCommercialPaperPrograms" xlink:href="sny-20231231.xsd#sny_NumberOfCommercialPaperPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCommercialPaperPrograms" xlink:to="lab_sny_NumberOfCommercialPaperPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShireHumanGeneticTherapiesIncMember_a64ba5d7-7af4-4692-beab-0d4686ca5952_terseLabel_en-US" xlink:label="lab_sny_ShireHumanGeneticTherapiesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire contingent consideration</link:label>
    <link:label id="lab_sny_ShireHumanGeneticTherapiesIncMember_label_en-US" xlink:label="lab_sny_ShireHumanGeneticTherapiesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire Human Genetic Therapies Inc. [Member]</link:label>
    <link:label id="lab_sny_ShireHumanGeneticTherapiesIncMember_documentation_en-US" xlink:label="lab_sny_ShireHumanGeneticTherapiesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire Human Genetic Therapies Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireHumanGeneticTherapiesIncMember" xlink:href="sny-20231231.xsd#sny_ShireHumanGeneticTherapiesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShireHumanGeneticTherapiesIncMember" xlink:to="lab_sny_ShireHumanGeneticTherapiesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_f24fd6da-99d1-4457-8679-23127c807cc8_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-employment benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, post-employment benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals_89dac6d0-873e-43c7-932e-449b45a76bff_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related liabilities</link:label>
    <link:label id="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals_label_en-US" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term employee benefits accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="lab_ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Goodwill_234d5c07-4d5e-4e1d-b041-d3f702a3751b_terseLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_Goodwill_label_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Goodwill" xlink:to="lab_ifrs-full_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_c63d82c0-e641-42c6-939c-f8bc065af496_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement_5db7e565-b683-4a87-af07-d0966560a334_periodStartLabel_en-US" xlink:label="lab_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, beginning balance (in shares)</link:label>
    <link:label id="lab_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement_0aeecf39-e3b6-47fc-a0cb-31c8ff608f68_periodEndLabel_en-US" xlink:label="lab_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, ending balance (in shares)</link:label>
    <link:label id="lab_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Outstanding In Share Based Payment Arrangement</link:label>
    <link:label id="lab_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share outstanding in share based payment arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement" xlink:href="sny-20231231.xsd#sny_NumberOfShareOutstandingInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement" xlink:to="lab_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_448e9d9e-2092-4ec0-af19-accb9357c6cf_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember_dc5dfef0-4243-4537-9a22-e3cdd057d19a_terseLabel_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire contingent consideration arising&#160;from&#160;the acquisition of Translate Bio</link:label>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember_label_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire Contingent Consideration Arising From The Acquisition Of Translate Bio [Member]</link:label>
    <link:label id="lab_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember_documentation_en-US" xlink:label="lab_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire Contingent Consideration Arising From The Acquisition Of Translate Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember" xlink:href="sny-20231231.xsd#sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember" xlink:to="lab_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember_6d2cef4b-2266-4adb-9d84-45645fee6672_terseLabel_en-US" xlink:label="lab_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Global Sarl Baar Intellectual Property Branch</link:label>
    <link:label id="lab_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember_label_en-US" xlink:label="lab_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Global Sarl Baar Intellectual Property Branch [Member]</link:label>
    <link:label id="lab_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember_documentation_en-US" xlink:label="lab_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genzyme Global Sarl Baar Intellectual Property Branch</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember" xlink:href="sny-20231231.xsd#sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember" xlink:to="lab_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_fa2d088e-5bce-4882-99c9-dd8ccc521af1_terseLabel_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and other post-employment benefits</link:label>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_label_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions And Other Post-Employment Benefits [Member]</link:label>
    <link:label id="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember_documentation_en-US" xlink:label="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and other post-employment benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:href="sny-20231231.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:to="lab_sny_PensionsAndOtherPostEmploymentBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_b554cf4d-505c-4ea8-b53f-aec95fca8e33_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non Current Provisions and Other Non-current Liabilities</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Provisions And Other Non-Current Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of provisions and other non current liabilities explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_6d4fde06-58c0-4e0a-8102-ff01545e8ef1_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_54b3e212-5387-496a-af8f-06396b3c733a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of analysis of other comprehensive income by item [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:to="lab_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_621e8f27-8d4e-41a3-9405-1f58edd8b041_terseLabel_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency sales in Chinese Yuan Renminbi</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_label_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Currency Sales In Chinese Yuan Renminbi [member]</link:label>
    <link:label id="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_documentation_en-US" xlink:label="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward currency sales in Chinese Yuan Renminbi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:to="lab_sny_ForwardCurrencySalesInChineseYuanRenminbiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesMember_131a1668-831a-483e-89b9-927836824cbc_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [member]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesMember_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesMember" xlink:to="lab_ifrs-full_CounterpartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_AubagioMember_c8049504-8053-42e0-a918-30c52b492cce_terseLabel_en-US" xlink:label="lab_sny_AubagioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AUBAGIO</link:label>
    <link:label id="lab_sny_AubagioMember_label_en-US" xlink:label="lab_sny_AubagioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aubagio [Member]</link:label>
    <link:label id="lab_sny_AubagioMember_documentation_en-US" xlink:label="lab_sny_AubagioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aubagio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AubagioMember" xlink:href="sny-20231231.xsd#sny_AubagioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_AubagioMember" xlink:to="lab_sny_AubagioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCivilIndividualActions_496c3708-2664-4f13-bc35-4603b2787c10_terseLabel_en-US" xlink:label="lab_sny_NumberOfCivilIndividualActions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of civil individual actions</link:label>
    <link:label id="lab_sny_NumberOfCivilIndividualActions_label_en-US" xlink:label="lab_sny_NumberOfCivilIndividualActions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Civil Individual Actions</link:label>
    <link:label id="lab_sny_NumberOfCivilIndividualActions_documentation_en-US" xlink:label="lab_sny_NumberOfCivilIndividualActions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Civil Individual Actions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCivilIndividualActions" xlink:href="sny-20231231.xsd#sny_NumberOfCivilIndividualActions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCivilIndividualActions" xlink:to="lab_sny_NumberOfCivilIndividualActions" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfRestructuringProvisionsTable_100c5489-4647-48ab-bba5-7d76e59a8e5e_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfRestructuringProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Restructuring provisions [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringProvisionsTable_label_en-US" xlink:label="lab_sny_DisclosureOfRestructuringProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Restructuring Provisions [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfRestructuringProvisionsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfRestructuringProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Restructuring provisions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringProvisionsTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringProvisionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsTable" xlink:to="lab_sny_DisclosureOfRestructuringProvisionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_f57013ad-8baa-46fd-a225-fd47adb26956_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial expenses and income</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for finance income and costs [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashEquivalents_58026caa-1f05-44f2-853a-e2807d06ec30_terseLabel_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalents" xlink:to="lab_ifrs-full_CashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns_60d3b711-3e30-4ed8-8010-8a104e273cb9_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in scope of consolidation</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Changes In Scope Of Consolidation In Provision For Discounts Rebates And Sales Returns</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in scope of consolidation in provision for discounts rebates and sales returns.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" xlink:to="lab_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock_278be09e-c165-45e7-947a-7799f127c619_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Future Termination Benefit Payments</link:label>
    <link:label id="lab_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Future Benefit Payments Explanatory [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of future benefit payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock" xlink:to="lab_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss_8ef7492f-bec6-453b-848c-e00790b5df16_terseLabel_en-US" xlink:label="lab_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating margin rate</link:label>
    <link:label id="lab_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss_label_en-US" xlink:label="lab_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Operating Margin Rate Below Rates Actually Used Would Not Cause Impairment Loss</link:label>
    <link:label id="lab_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss_documentation_en-US" xlink:label="lab_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of operating margin rate below rates actually used would not cause impairment loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:href="sny-20231231.xsd#sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:to="lab_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_47d610fc-f311-464c-87e7-18a356bf193c_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_be32efef-c918-4cfb-bdbd-7b469260d96b_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_a502b988-91e6-4ae0-90b7-c318466a168c_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_2f42b91d-5c25-40e4-a38f-bbcc7fe14ac3_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisMalaysiaSDNBHDMember_b598ad24-02ec-4c5b-ad54-75bc507b5622_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisMalaysiaSDNBHDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis (Malaysia) SDN. BHD.</link:label>
    <link:label id="lab_sny_SanofiAventisMalaysiaSDNBHDMember_label_en-US" xlink:label="lab_sny_SanofiAventisMalaysiaSDNBHDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Malaysia SDN. BHD [Member]</link:label>
    <link:label id="lab_sny_SanofiAventisMalaysiaSDNBHDMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisMalaysiaSDNBHDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis (Malaysia) SDN. BHD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisMalaysiaSDNBHDMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisMalaysiaSDNBHDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisMalaysiaSDNBHDMember" xlink:to="lab_sny_SanofiAventisMalaysiaSDNBHDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiBiotechnologyMember_4bd6a5da-9282-41f6-b591-d10796c3dbcc_terseLabel_en-US" xlink:label="lab_sny_SanofiBiotechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Biotechnology</link:label>
    <link:label id="lab_sny_SanofiBiotechnologyMember_label_en-US" xlink:label="lab_sny_SanofiBiotechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Biotechnology [Member]</link:label>
    <link:label id="lab_sny_SanofiBiotechnologyMember_documentation_en-US" xlink:label="lab_sny_SanofiBiotechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Biotechnology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBiotechnologyMember" xlink:href="sny-20231231.xsd#sny_SanofiBiotechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiBiotechnologyMember" xlink:to="lab_sny_SanofiBiotechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LaboratoryFacilitiesCambridgeMassachusettsMember_8a0d2011-769c-49d1-af9f-cb06458547d1_terseLabel_en-US" xlink:label="lab_sny_LaboratoryFacilitiesCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory facilities, Cambridge, Massachusetts</link:label>
    <link:label id="lab_sny_LaboratoryFacilitiesCambridgeMassachusettsMember_label_en-US" xlink:label="lab_sny_LaboratoryFacilitiesCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Facilities, Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_sny_LaboratoryFacilitiesCambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_sny_LaboratoryFacilitiesCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Facilities, Cambridge, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LaboratoryFacilitiesCambridgeMassachusettsMember" xlink:href="sny-20231231.xsd#sny_LaboratoryFacilitiesCambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LaboratoryFacilitiesCambridgeMassachusettsMember" xlink:to="lab_sny_LaboratoryFacilitiesCambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_cb396576-444b-47fb-b143-56febd86edca_terseLabel_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing &amp; Supply</link:label>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_label_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing And Supply [Member]</link:label>
    <link:label id="lab_sny_ManufacturingAndSupplyMember_documentation_en-US" xlink:label="lab_sny_ManufacturingAndSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing And Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember" xlink:href="sny-20231231.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ManufacturingAndSupplyMember" xlink:to="lab_sny_ManufacturingAndSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfCounterExpertiseExperts_d157bd07-dca1-4e57-934b-c2b3b8d47887_terseLabel_en-US" xlink:label="lab_sny_NumberOfCounterExpertiseExperts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of experts</link:label>
    <link:label id="lab_sny_NumberOfCounterExpertiseExperts_label_en-US" xlink:label="lab_sny_NumberOfCounterExpertiseExperts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Counter-Expertise Experts</link:label>
    <link:label id="lab_sny_NumberOfCounterExpertiseExperts_documentation_en-US" xlink:label="lab_sny_NumberOfCounterExpertiseExperts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Counter-Expertise Experts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCounterExpertiseExperts" xlink:href="sny-20231231.xsd#sny_NumberOfCounterExpertiseExperts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfCounterExpertiseExperts" xlink:to="lab_sny_NumberOfCounterExpertiseExperts" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_1704e46f-1eeb-4699-9eba-3cbd529f24f5_terseLabel_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments related to milestone payments for projects under collaboration agreements</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_label_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Milestone Payments For Projects Under Collaboration Agreement</link:label>
    <link:label id="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Related To Milestone Payments For Projects Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:to="lab_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiUSServicesIncMember_4a5f870b-5015-4d83-bcc1-96aafb3d6d36_terseLabel_en-US" xlink:label="lab_sny_SanofiUSServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi US Services Inc.</link:label>
    <link:label id="lab_sny_SanofiUSServicesIncMember_label_en-US" xlink:label="lab_sny_SanofiUSServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi US Services Inc [member]</link:label>
    <link:label id="lab_sny_SanofiUSServicesIncMember_documentation_en-US" xlink:label="lab_sny_SanofiUSServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi US Services Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiUSServicesIncMember" xlink:href="sny-20231231.xsd#sny_SanofiUSServicesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiUSServicesIncMember" xlink:to="lab_sny_SanofiUSServicesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CashEquivalentsCommercialPaper_abd9d4b6-e325-42a4-bf8e-338258bf6368_terseLabel_en-US" xlink:label="lab_sny_CashEquivalentsCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, commercial paper</link:label>
    <link:label id="lab_sny_CashEquivalentsCommercialPaper_label_en-US" xlink:label="lab_sny_CashEquivalentsCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Commercial Paper</link:label>
    <link:label id="lab_sny_CashEquivalentsCommercialPaper_documentation_en-US" xlink:label="lab_sny_CashEquivalentsCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalent commercial paper.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashEquivalentsCommercialPaper" xlink:href="sny-20231231.xsd#sny_CashEquivalentsCommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CashEquivalentsCommercialPaper" xlink:to="lab_sny_CashEquivalentsCommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling_f69abd73-f72a-4d82-ad34-54db7e20bd91_terseLabel_en-US" xlink:label="lab_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer's contribution percentage</link:label>
    <link:label id="lab_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling_label_en-US" xlink:label="lab_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer Contribute Percentage On Amounts Exceeding The Social Security Ceiling</link:label>
    <link:label id="lab_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling_documentation_en-US" xlink:label="lab_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribute percentage on amounts exceeding the social security ceiling.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling" xlink:href="sny-20231231.xsd#sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling" xlink:to="lab_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_e992822c-1ff1-4bb0-a536-629dd7ef8c30_terseLabel_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs related to transformation programs</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_label_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Of Restructuring Activities, Transformation Programs Costs</link:label>
    <link:label id="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_documentation_en-US" xlink:label="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Of Restructuring Activities, Transformation Programs Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:href="sny-20231231.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:to="lab_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_fd7666f9-66ec-4afc-8aa0-418fa6e977d9_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_label_en-US" xlink:label="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_18c49461-521f-4160-8686-19f328ceb4a9_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset_75984586-2d3b-444d-a368-b3294dcfc36e_terseLabel_en-US" xlink:label="lab_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest cost/(income) including administration costs and taxes paid during the period</link:label>
    <link:label id="lab_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense (Income) Including Administration Costs And Taxes Paid, Net Defined Benefit Liability (Asset)</link:label>
    <link:label id="lab_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset_documentation_en-US" xlink:label="lab_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense (Income) Including Administration Costs And Taxes Paid, Net Defined Benefit Liability (Asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" xlink:href="sny-20231231.xsd#sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" xlink:to="lab_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NetExposure_691f2a2a-a960-4133-a962-4bc973784f2c_totalLabel_en-US" xlink:label="lab_sny_NetExposure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exposure</link:label>
    <link:label id="lab_sny_NetExposure_label_en-US" xlink:label="lab_sny_NetExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Exposure</link:label>
    <link:label id="lab_sny_NetExposure_documentation_en-US" xlink:label="lab_sny_NetExposure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exposure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetExposure" xlink:href="sny-20231231.xsd#sny_NetExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NetExposure" xlink:to="lab_sny_NetExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_0437f3b8-1553-4aa8-9bf0-8291ce183c5e_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_ad7bc8bd-1eb4-4f78-afd8-a49b1decf28c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">List of principal companies included in the scope of consolidation during&#160;2023</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of subsidiaries [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DebtInstrumentDomain_4929c41a-33e3-44f3-8e7f-391fe0e6f650_terseLabel_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:label id="lab_sny_DebtInstrumentDomain_label_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:label id="lab_sny_DebtInstrumentDomain_documentation_en-US" xlink:label="lab_sny_DebtInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain" xlink:href="sny-20231231.xsd#sny_DebtInstrumentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DebtInstrumentDomain" xlink:to="lab_sny_DebtInstrumentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_7bf7bac5-ff19-4c65-b681-0d1b23dcad36_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effects on share-based payments</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Share-Based Payment Plans Tax Effects Of The Exercise Of Stock Options</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effects of the exercise of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:to="lab_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_c845e873-ba78-4bcf-80cd-08fbd0df7b4f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other current assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_e5131b76-b113-4ae2-a5ab-6f6996454550_terseLabel_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of class actions</link:label>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_label_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:label id="lab_sny_NumberOfClassActionLawsuits_documentation_en-US" xlink:label="lab_sny_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits" xlink:href="sny-20231231.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfClassActionLawsuits" xlink:to="lab_sny_NumberOfClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_9f0691f3-6753-4288-b8a5-a520ed9b2218_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_6fd0704e-19e8-47f6-b12a-efdeb6358821_terseLabel_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price range three</link:label>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_sny_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_sny_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember" xlink:href="sny-20231231.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ExercisePriceRangeThreeMember" xlink:to="lab_sny_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_05d3eab3-f83b-47e6-9248-ec10580d148c_terseLabel_en-US" xlink:label="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments for projects under collaboration agreements</link:label>
    <link:label id="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_label_en-US" xlink:label="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments For Projects Under Collaboration Agreements</link:label>
    <link:label id="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_documentation_en-US" xlink:label="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments For Projects Under Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:href="sny-20231231.xsd#sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:to="lab_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_0bfcecd0-c835-427e-974f-71e6f7ec56b3_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_label_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off-Balance Sheet Commitments [Table]</link:label>
    <link:label id="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable_documentation_en-US" xlink:label="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Off Balance Sheet Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:to="lab_sny_DisclosureOfOffBalanceSheetCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_04a6d29a-cb48-40d8-a42e-cb352363995f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_310c76e7-ddb3-4549-ae2b-305473e80e48_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_6fc86979-fd44-4020-a0ea-ac998ec5ec5f_negatedTerseLabel_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effects</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_label_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</link:label>
    <link:label id="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_documentation_en-US" xlink:label="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:to="lab_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ReportableGeographicalZonesMember_98f108e2-80b7-4942-831a-d380fbe59819_terseLabel_en-US" xlink:label="lab_sny_ReportableGeographicalZonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_sny_ReportableGeographicalZonesMember_label_en-US" xlink:label="lab_sny_ReportableGeographicalZonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Geographical Zones [Member]</link:label>
    <link:label id="lab_sny_ReportableGeographicalZonesMember_documentation_en-US" xlink:label="lab_sny_ReportableGeographicalZonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable geographical zones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReportableGeographicalZonesMember" xlink:href="sny-20231231.xsd#sny_ReportableGeographicalZonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ReportableGeographicalZonesMember" xlink:to="lab_sny_ReportableGeographicalZonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_cd3e0f8d-9a4b-4745-be34-1bed21cdb80a_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of other intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock_edd00f8c-36e2-4cf3-82a2-ce968be64833_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Tax Losses Available for Carry-forward</link:label>
    <link:label id="lab_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Availability Of Tax Losses Carry Forwards [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of availability of tax losses carry forwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock" xlink:to="lab_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIntangibleAssetsMember_bfb0f92c-8a57-4d34-ada6-6967cd852fa4_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIntangibleAssetsMember" xlink:to="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_a1a4cdbe-3b1b-4ef7-983a-54b13509516d_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_NumberOfLeaseAgreementsSigned_4457e18f-e972-445c-a1ae-146500d1424c_terseLabel_en-US" xlink:label="lab_sny_NumberOfLeaseAgreementsSigned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lease agreements signed</link:label>
    <link:label id="lab_sny_NumberOfLeaseAgreementsSigned_label_en-US" xlink:label="lab_sny_NumberOfLeaseAgreementsSigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lease Agreements Signed</link:label>
    <link:label id="lab_sny_NumberOfLeaseAgreementsSigned_documentation_en-US" xlink:label="lab_sny_NumberOfLeaseAgreementsSigned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lease Agreements Signed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLeaseAgreementsSigned" xlink:href="sny-20231231.xsd#sny_NumberOfLeaseAgreementsSigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_NumberOfLeaseAgreementsSigned" xlink:to="lab_sny_NumberOfLeaseAgreementsSigned" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DerivativeFinancialAssetsMember_71386d18-bfcc-4309-b167-07d9c81b8b75_terseLabel_en-US" xlink:label="lab_sny_DerivativeFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial assets</link:label>
    <link:label id="lab_sny_DerivativeFinancialAssetsMember_label_en-US" xlink:label="lab_sny_DerivativeFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Assets [member]</link:label>
    <link:label id="lab_sny_DerivativeFinancialAssetsMember_documentation_en-US" xlink:label="lab_sny_DerivativeFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialAssetsMember" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DerivativeFinancialAssetsMember" xlink:to="lab_sny_DerivativeFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermRestructuringProvision_dda021a1-4825-4d32-af6c-dc69e3cc1474_verboseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermRestructuringProvision" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classified in current liabilities</link:label>
    <link:label id="lab_ifrs-full_ShorttermRestructuringProvision_3c4948ab-c5cf-4dcb-bb10-9e8bac3fd9af_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermRestructuringProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring provisions (see Note&#160;D.19.2.)</link:label>
    <link:label id="lab_ifrs-full_ShorttermRestructuringProvision_label_en-US" xlink:label="lab_ifrs-full_ShorttermRestructuringProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restructuring provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermRestructuringProvision" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermRestructuringProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermRestructuringProvision" xlink:to="lab_ifrs-full_ShorttermRestructuringProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_March2019EMTNISINFR0013409851Member_4df8ea5b-67f4-4f84-86b3-768f0108fb23_terseLabel_en-US" xlink:label="lab_sny_March2019EMTNISINFR0013409851Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 EMTN ISIN FR0013409851</link:label>
    <link:label id="lab_sny_March2019EMTNISINFR0013409851Member_label_en-US" xlink:label="lab_sny_March2019EMTNISINFR0013409851Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 EMTN ISIN FR0013409851 [Member]</link:label>
    <link:label id="lab_sny_March2019EMTNISINFR0013409851Member_documentation_en-US" xlink:label="lab_sny_March2019EMTNISINFR0013409851Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 EMTN ISIN FR0013409851 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2019EMTNISINFR0013409851Member" xlink:href="sny-20231231.xsd#sny_March2019EMTNISINFR0013409851Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_March2019EMTNISINFR0013409851Member" xlink:to="lab_sny_March2019EMTNISINFR0013409851Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DepakineProductLitigationInBelgiumMember_da29faf6-1752-4746-aba7-754b99864952_terseLabel_en-US" xlink:label="lab_sny_DepakineProductLitigationInBelgiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine product litigation in Belgium</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInBelgiumMember_label_en-US" xlink:label="lab_sny_DepakineProductLitigationInBelgiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Belgium [Member]</link:label>
    <link:label id="lab_sny_DepakineProductLitigationInBelgiumMember_documentation_en-US" xlink:label="lab_sny_DepakineProductLitigationInBelgiumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depakine Product Litigation In Belgium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInBelgiumMember" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInBelgiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DepakineProductLitigationInBelgiumMember" xlink:to="lab_sny_DepakineProductLitigationInBelgiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets_05bea31c-9202-41b8-9c17-0e3f04961c66_terseLabel_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets_label_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Transfers, Property, Plant and Equipment, Right Of Use Assets</link:label>
    <link:label id="lab_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets_documentation_en-US" xlink:label="lab_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Transfers, Property, Plant and Equipment, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" xlink:to="lab_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ReclassificationFromNonCurrentToCurrent_6252e440-c794-4610-b908-d5d96f32c3ce_terseLabel_en-US" xlink:label="lab_sny_ReclassificationFromNonCurrentToCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from non-current to current</link:label>
    <link:label id="lab_sny_ReclassificationFromNonCurrentToCurrent_label_en-US" xlink:label="lab_sny_ReclassificationFromNonCurrentToCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification From Non-Current To Current</link:label>
    <link:label id="lab_sny_ReclassificationFromNonCurrentToCurrent_documentation_en-US" xlink:label="lab_sny_ReclassificationFromNonCurrentToCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from non current to current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReclassificationFromNonCurrentToCurrent" xlink:href="sny-20231231.xsd#sny_ReclassificationFromNonCurrentToCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ReclassificationFromNonCurrentToCurrent" xlink:to="lab_sny_ReclassificationFromNonCurrentToCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiAventisAlgerieMember_cbb36c35-b168-4fde-befc-1fac1b323c05_terseLabel_en-US" xlink:label="lab_sny_SanofiAventisAlgerieMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Alg&#233;rie</link:label>
    <link:label id="lab_sny_SanofiAventisAlgerieMember_label_en-US" xlink:label="lab_sny_SanofiAventisAlgerieMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Aventis Algerie [member]</link:label>
    <link:label id="lab_sny_SanofiAventisAlgerieMember_documentation_en-US" xlink:label="lab_sny_SanofiAventisAlgerieMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi-Aventis Algerie.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisAlgerieMember" xlink:href="sny-20231231.xsd#sny_SanofiAventisAlgerieMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiAventisAlgerieMember" xlink:to="lab_sny_SanofiAventisAlgerieMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_86da666e-0aea-45e6-ae7d-95a2bbd74122_negatedLabel_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recognised for estimated future royalties</link:label>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_label_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Recognised For Estimated Future Royalties</link:label>
    <link:label id="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties_documentation_en-US" xlink:label="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Recognised For Estimated Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:href="sny-20231231.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:to="lab_sny_LiabilityRecognisedForEstimatedFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_9c4445fc-0d1c-45ea-9408-0193f6d628d6_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_label_en-US" xlink:label="lab_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Interest Rate Of Debt Net of Cash And Cash Equivalent [Line Items]</link:label>
    <link:label id="lab_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_documentation_en-US" xlink:label="lab_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of interest rate of debt net of cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems" xlink:to="lab_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_GoodwillTaxDeductiblePeriod_55f07fb2-769d-4d2d-987b-171220ffd1ba_terseLabel_en-US" xlink:label="lab_sny_GoodwillTaxDeductiblePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, tax deductible period</link:label>
    <link:label id="lab_sny_GoodwillTaxDeductiblePeriod_label_en-US" xlink:label="lab_sny_GoodwillTaxDeductiblePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Tax Deductible, Period</link:label>
    <link:label id="lab_sny_GoodwillTaxDeductiblePeriod_documentation_en-US" xlink:label="lab_sny_GoodwillTaxDeductiblePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Tax Deductible, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoodwillTaxDeductiblePeriod" xlink:href="sny-20231231.xsd#sny_GoodwillTaxDeductiblePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_GoodwillTaxDeductiblePeriod" xlink:to="lab_sny_GoodwillTaxDeductiblePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_OpellaHealthcareItalySRLMember_ace4b626-b65b-45fc-a8ed-04633a14fa73_terseLabel_en-US" xlink:label="lab_sny_OpellaHealthcareItalySRLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Italy SRL</link:label>
    <link:label id="lab_sny_OpellaHealthcareItalySRLMember_label_en-US" xlink:label="lab_sny_OpellaHealthcareItalySRLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Italy S.R.L. [Member]</link:label>
    <link:label id="lab_sny_OpellaHealthcareItalySRLMember_documentation_en-US" xlink:label="lab_sny_OpellaHealthcareItalySRLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opella Healthcare Italy S.R.L.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareItalySRLMember" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareItalySRLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_OpellaHealthcareItalySRLMember" xlink:to="lab_sny_OpellaHealthcareItalySRLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_258e573d-e650-4d26-a32b-0876d40fbd88_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_83560e5d-5844-4cb3-b740-c6b0443bf94d_terseLabel_en-US" xlink:label="lab_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding arrangements of defined benefit plans [axis]</link:label>
    <link:label id="lab_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_label_en-US" xlink:label="lab_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding arrangements of defined benefit plans [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:to="lab_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_e37aa7fb-0526-47eb-9ee9-05838dab6862_terseLabel_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit or loss from commercialization of monoclonal antibodies</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_label_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profit Or Loss From Commercialization Of Monoclonal Antibodies [Member]</link:label>
    <link:label id="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_documentation_en-US" xlink:label="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit or loss from commercialization of monoclonal antibodies member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:href="sny-20231231.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:to="lab_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare_e6524d1d-5e2a-4595-86ae-eee5fe4c3020_terseLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid, ordinary shares per share (in EUR per share)</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid, ordinary shares per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:to="lab_ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember_9c57cf6a-3699-4d8e-ac3c-0d38accbb18c_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for business combinations [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for business combinations [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_5dbbffd0-92c4-4222-a7e8-d511d9524354_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Reconciliation of Carrying Amount to Value on Redemption</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of carrying amount to value on redemption [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:to="lab_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_SanofiPasteurS.A.deC.V.Member_72269b56-f810-4e88-9c78-dae8658c7b2c_terseLabel_en-US" xlink:label="lab_sny_SanofiPasteurS.A.deC.V.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur SA de CV</link:label>
    <link:label id="lab_sny_SanofiPasteurS.A.deC.V.Member_label_en-US" xlink:label="lab_sny_SanofiPasteurS.A.deC.V.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur S.A. de C.V. [Member]</link:label>
    <link:label id="lab_sny_SanofiPasteurS.A.deC.V.Member_documentation_en-US" xlink:label="lab_sny_SanofiPasteurS.A.deC.V.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur S.A. de C.V. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurS.A.deC.V.Member" xlink:href="sny-20231231.xsd#sny_SanofiPasteurS.A.deC.V.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_SanofiPasteurS.A.deC.V.Member" xlink:to="lab_sny_SanofiPasteurS.A.deC.V.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_MarketConditionAxis_cfb4384d-4215-4309-9d92-f4e0c5f375df_terseLabel_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Condition [Axis]</link:label>
    <link:label id="lab_sny_MarketConditionAxis_label_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Condition [Axis]</link:label>
    <link:label id="lab_sny_MarketConditionAxis_documentation_en-US" xlink:label="lab_sny_MarketConditionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Condition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis" xlink:href="sny-20231231.xsd#sny_MarketConditionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_MarketConditionAxis" xlink:to="lab_sny_MarketConditionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_10684f01-5cad-4541-8ed6-9b2bc1bf8f5f_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_ef810b5b-3c8c-4609-ba7f-54d4d4ae6d88_terseLabel_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other gains and losses, and litigation</link:label>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_label_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Gains And Losses, And Litigation [Text Block]</link:label>
    <link:label id="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_documentation_en-US" xlink:label="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure of other gains and losses, and litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:to="lab_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_CurrencyDerivativesFinancialMember_6564930f-1259-4d1d-bf0a-7f85cc621732_terseLabel_en-US" xlink:label="lab_sny_CurrencyDerivativesFinancialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">financial</link:label>
    <link:label id="lab_sny_CurrencyDerivativesFinancialMember_label_en-US" xlink:label="lab_sny_CurrencyDerivativesFinancialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Derivatives Financial [Member]</link:label>
    <link:label id="lab_sny_CurrencyDerivativesFinancialMember_documentation_en-US" xlink:label="lab_sny_CurrencyDerivativesFinancialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency derivatives, financial.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesFinancialMember" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesFinancialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_CurrencyDerivativesFinancialMember" xlink:to="lab_sny_CurrencyDerivativesFinancialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_EmployeeBenefitsExpenseGain_61da6956-93c5-4479-9918-fd6c98405def_terseLabel_en-US" xlink:label="lab_sny_EmployeeBenefitsExpenseGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense/(gain) for the period</link:label>
    <link:label id="lab_sny_EmployeeBenefitsExpenseGain_label_en-US" xlink:label="lab_sny_EmployeeBenefitsExpenseGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits Expense / (Gain)</link:label>
    <link:label id="lab_sny_EmployeeBenefitsExpenseGain_documentation_en-US" xlink:label="lab_sny_EmployeeBenefitsExpenseGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits Expense / (Gain)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeBenefitsExpenseGain" xlink:href="sny-20231231.xsd#sny_EmployeeBenefitsExpenseGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_EmployeeBenefitsExpenseGain" xlink:to="lab_sny_EmployeeBenefitsExpenseGain" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock_dd99ddf8-8734-47b6-85ab-d15c45312f89_terseLabel_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income and expenses</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Other Operating Income And Expenses Explanatory [Policy Text Block]</link:label>
    <link:label id="lab_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The description of the entity's accounting policy for other operating income and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock" xlink:to="lab_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_956bb055-f7db-4856-a411-310810f022fc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Events subsequent to December 31, 2023</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_5d0a9f97-a870-478e-a3b5-3949898694ac_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average number of shares after dilution (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_eb04ca75-01de-4af8-b5b4-cd8e99498454_totalLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average number of shares used to compute diluted earnings per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sny_FairValueOfSPMSDContingentConsiderationMember_3b8b38f3-59c6-4788-8f2c-e1bfa6857af9_terseLabel_en-US" xlink:label="lab_sny_FairValueOfSPMSDContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of SPMSD contingent consideration</link:label>
    <link:label id="lab_sny_FairValueOfSPMSDContingentConsiderationMember_label_en-US" xlink:label="lab_sny_FairValueOfSPMSDContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of SPMSD Contingent Consideration [Member]</link:label>
    <link:label id="lab_sny_FairValueOfSPMSDContingentConsiderationMember_documentation_en-US" xlink:label="lab_sny_FairValueOfSPMSDContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of SPMSD contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfSPMSDContingentConsiderationMember" xlink:href="sny-20231231.xsd#sny_FairValueOfSPMSDContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sny_FairValueOfSPMSDContingentConsiderationMember" xlink:to="lab_sny_FairValueOfSPMSDContingentConsiderationMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>sny-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:d2fc6364-8fcd-4586-a9d3-e16cd96a566e,g:f65f6c85-de12-4c7c-b6b2-ea3943f1a47f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sanofi.com/role/Coverpage" xlink:type="simple" xlink:href="sny-20231231.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c8dd7a3c-20cf-46e4-8505-b27c3339e0ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_63282cf8-9552-4776-a356-846159c5b2ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8dd7a3c-20cf-46e4-8505-b27c3339e0ec" xlink:to="loc_dei_EntitiesTable_63282cf8-9552-4776-a356-846159c5b2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_db442af4-7157-4aed-9a0a-f08f1d301e5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_63282cf8-9552-4776-a356-846159c5b2ba" xlink:to="loc_dei_EntityListingsExchangeAxis_db442af4-7157-4aed-9a0a-f08f1d301e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_ca8d302a-cd4a-4f17-8809-278b32abaeb1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_db442af4-7157-4aed-9a0a-f08f1d301e5f" xlink:to="loc_dei_ExchangeDomain_ca8d302a-cd4a-4f17-8809-278b32abaeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember_8c8839f1-3daa-44f6-83e3-249c2cf9388f" xlink:href="sny-20231231.xsd#sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_ca8d302a-cd4a-4f17-8809-278b32abaeb1" xlink:to="loc_sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember_8c8839f1-3daa-44f6-83e3-249c2cf9388f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OrdinarySharesNASDAQGlobalSelectMarketMember_a909b0fe-09ea-431f-842c-528aa2d4efb1" xlink:href="sny-20231231.xsd#sny_OrdinarySharesNASDAQGlobalSelectMarketMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_ca8d302a-cd4a-4f17-8809-278b32abaeb1" xlink:to="loc_sny_OrdinarySharesNASDAQGlobalSelectMarketMember_a909b0fe-09ea-431f-842c-528aa2d4efb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_6817344a-2e66-4742-b0dc-b42a85859912" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_63282cf8-9552-4776-a356-846159c5b2ba" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_6817344a-2e66-4742-b0dc-b42a85859912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_b05ccb02-f289-4330-8085-f0552f062b31" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_6817344a-2e66-4742-b0dc-b42a85859912" xlink:to="loc_dei_AddressTypeDomain_b05ccb02-f289-4330-8085-f0552f062b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_3d39dac7-c774-4d57-8be7-c412c22069f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_b05ccb02-f289-4330-8085-f0552f062b31" xlink:to="loc_dei_BusinessContactMember_3d39dac7-c774-4d57-8be7-c412c22069f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_63282cf8-9552-4776-a356-846159c5b2ba" xlink:to="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_bcf70f67-8fde-4815-a4a7-c006d4084aa3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentType_bcf70f67-8fde-4815-a4a7-c006d4084aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_50ff36dd-dfe8-4b8e-bdec-28fb5550e681" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentRegistrationStatement_50ff36dd-dfe8-4b8e-bdec-28fb5550e681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b7e98fa3-fd42-4d6e-a734-b1a6ff53832e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentAnnualReport_b7e98fa3-fd42-4d6e-a734-b1a6ff53832e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_778cd86c-68f5-4a3b-839c-e7d1ef5e63c6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_CurrentFiscalYearEndDate_778cd86c-68f5-4a3b-839c-e7d1ef5e63c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_929cff95-85f8-42c7-b405-ce4ee0392e15" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentPeriodEndDate_929cff95-85f8-42c7-b405-ce4ee0392e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_17015b9f-7752-42e6-bc79-4cc4e38e859e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentTransitionReport_17015b9f-7752-42e6-bc79-4cc4e38e859e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_74bbf6cd-d0ac-4bac-a384-66841733dc4f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentShellCompanyReport_74bbf6cd-d0ac-4bac-a384-66841733dc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b6aaa2b9-3f7a-4dad-9203-d4997cb71279" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityFileNumber_b6aaa2b9-3f7a-4dad-9203-d4997cb71279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_276619cd-a029-4416-8c3f-c697a65ebe0c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityRegistrantName_276619cd-a029-4416-8c3f-c697a65ebe0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_900a6a1a-e920-46e4-9c35-d5d28fd76427" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityIncorporationStateCountryCode_900a6a1a-e920-46e4-9c35-d5d28fd76427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_6df97151-5e91-4d4b-b526-123d43107d4c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_ContactPersonnelName_6df97151-5e91-4d4b-b526-123d43107d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ac31a46f-2c48-4c1a-bfdb-677fc1c3d30f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityAddressAddressLine1_ac31a46f-2c48-4c1a-bfdb-677fc1c3d30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b7a202c5-8294-45ae-a943-2613dbba639f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityAddressPostalZipCode_b7a202c5-8294-45ae-a943-2613dbba639f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_168ce81c-5773-4332-9e9b-5f8d61b9877e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityAddressCityOrTown_168ce81c-5773-4332-9e9b-5f8d61b9877e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_3a4afa11-d1d3-42d6-ab78-edb2b10c3b84" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityAddressCountry_3a4afa11-d1d3-42d6-ab78-edb2b10c3b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_408c0e72-426e-4834-9a94-c67264ccbfb7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_CityAreaCode_408c0e72-426e-4834-9a94-c67264ccbfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c10d332d-5418-481c-80f8-af9c881cb35e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_LocalPhoneNumber_c10d332d-5418-481c-80f8-af9c881cb35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5a4e42c4-1be5-4c38-9c45-b7f64402899a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_Security12bTitle_5a4e42c4-1be5-4c38-9c45-b7f64402899a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a8fedcc0-c7c7-44bf-ac4a-14e1468536fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_TradingSymbol_a8fedcc0-c7c7-44bf-ac4a-14e1468536fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d0b5d326-4e52-4568-a52f-4d6552672805" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_SecurityExchangeName_d0b5d326-4e52-4568-a52f-4d6552672805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7530f6f9-ad8a-4093-849a-689e1c4cb663" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7530f6f9-ad8a-4093-849a-689e1c4cb663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6021dbbd-eb17-4578-a686-be576628eb46" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_6021dbbd-eb17-4578-a686-be576628eb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f392f1a7-0e73-4c9c-8163-4f03551b628a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityVoluntaryFilers_f392f1a7-0e73-4c9c-8163-4f03551b628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4ba1fab0-6b5b-4325-a46c-ac7f4fd7330a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityCurrentReportingStatus_4ba1fab0-6b5b-4325-a46c-ac7f4fd7330a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_014ee22a-a531-476b-ab8f-46210dcafe1a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityInteractiveDataCurrent_014ee22a-a531-476b-ab8f-46210dcafe1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_996350c1-9113-4f9e-a5f3-5ad95fba93bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityFilerCategory_996350c1-9113-4f9e-a5f3-5ad95fba93bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_70cbef6e-41ec-492d-a274-7b38763f8ff7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityEmergingGrowthCompany_70cbef6e-41ec-492d-a274-7b38763f8ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_b2012084-1882-4076-b53e-badbf71e517d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_IcfrAuditorAttestationFlag_b2012084-1882-4076-b53e-badbf71e517d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_847b56a5-db49-420c-bce3-23933d839064" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_847b56a5-db49-420c-bce3-23933d839064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_e3cc20a3-8647-4902-9a5a-e69cb4a75421" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentAccountingStandard_e3cc20a3-8647-4902-9a5a-e69cb4a75421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_38145670-8248-4e35-8d58-04c7c1c91a68" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityShellCompany_38145670-8248-4e35-8d58-04c7c1c91a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_79cebc9c-2e18-434e-b345-28ed356c640d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_AmendmentFlag_79cebc9c-2e18-434e-b345-28ed356c640d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2762cbd2-2097-410b-baf6-109114fd889b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentFiscalYearFocus_2762cbd2-2097-410b-baf6-109114fd889b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3e9f4975-17ac-41a8-9256-ec1187646e89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3e9f4975-17ac-41a8-9256-ec1187646e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0ca123be-1a5f-44cd-8fe3-712a6290f849" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e1691303-641e-4d9d-8a3a-ee9fe6344519" xlink:to="loc_dei_EntityCentralIndexKey_0ca123be-1a5f-44cd-8fe3-712a6290f849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AuditInformation" xlink:type="simple" xlink:href="sny-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorInformationAbstract_128e8d2f-f26c-4e07-881c-190a3450db4b" xlink:href="sny-20231231.xsd#sny_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorTable_04790677-8977-4b1d-a49f-20e895528b85" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AuditorInformationAbstract_128e8d2f-f26c-4e07-881c-190a3450db4b" xlink:to="loc_dei_AuditorTable_04790677-8977-4b1d-a49f-20e895528b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bebc0b1b-8dc1-414b-b7f0-c486f2c2ea4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorTable_04790677-8977-4b1d-a49f-20e895528b85" xlink:to="loc_srt_CounterpartyNameAxis_bebc0b1b-8dc1-414b-b7f0-c486f2c2ea4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad83ff37-0b3d-4797-ba6f-8d6141551970" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bebc0b1b-8dc1-414b-b7f0-c486f2c2ea4c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad83ff37-0b3d-4797-ba6f-8d6141551970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ErnstYoungEtAutresMember_ee4cfc20-6864-44ef-b8f0-93c6e5496d68" xlink:href="sny-20231231.xsd#sny_ErnstYoungEtAutresMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ad83ff37-0b3d-4797-ba6f-8d6141551970" xlink:to="loc_sny_ErnstYoungEtAutresMember_ee4cfc20-6864-44ef-b8f0-93c6e5496d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLineItems_1413efae-ec16-458a-8c72-db461ea68b08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorTable_04790677-8977-4b1d-a49f-20e895528b85" xlink:to="loc_dei_AuditorLineItems_1413efae-ec16-458a-8c72-db461ea68b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_780d9c14-081b-4173-9296-1afce09482fe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_1413efae-ec16-458a-8c72-db461ea68b08" xlink:to="loc_dei_AuditorName_780d9c14-081b-4173-9296-1afce09482fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_afbe459e-48d1-4029-87d1-2e00283c0b3a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_1413efae-ec16-458a-8c72-db461ea68b08" xlink:to="loc_dei_AuditorLocation_afbe459e-48d1-4029-87d1-2e00283c0b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_5714d34a-0c40-4ecb-aa1c-5e33c6a1511a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_1413efae-ec16-458a-8c72-db461ea68b08" xlink:to="loc_dei_AuditorFirmId_5714d34a-0c40-4ecb-aa1c-5e33c6a1511a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedbalancesheets" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedbalancesheets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedbalancesheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_0ba46c9f-25bd-4caa-a1a5-f8eae652ed1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0ba46c9f-25bd-4caa-a1a5-f8eae652ed1e" xlink:to="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_8fd8e2da-74fd-4e06-a285-253d607d209f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_8fd8e2da-74fd-4e06-a285-253d607d209f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_fc162ae9-8217-438f-8562-eefd654bf750" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_RightofuseAssets_fc162ae9-8217-438f-8562-eefd654bf750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_3bbc4869-bc1d-418e-a1b4-c7240983ff11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_Goodwill_3bbc4869-bc1d-418e-a1b4-c7240983ff11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_be410fe7-7d0d-44b6-8248-206e0b5e32ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_be410fe7-7d0d-44b6-8248-206e0b5e32ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_814707a8-7408-4b86-b748-5e8afabaf782" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_814707a8-7408-4b86-b748-5e8afabaf782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_0a8dae46-8818-48dc-89cd-9dae665fc777" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_0a8dae46-8818-48dc-89cd-9dae665fc777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsNoncurrent_83521552-0c90-4444-8810-b33e38bea716" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_CurrentTaxAssetsNoncurrent_83521552-0c90-4444-8810-b33e38bea716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_bf6995f7-b4c4-4a68-88ea-5a21701549d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_DeferredTaxAssets_bf6995f7-b4c4-4a68-88ea-5a21701549d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_7b5b0d14-3b2d-49a3-a4c4-96955ad76e3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_NoncurrentAssets_7b5b0d14-3b2d-49a3-a4c4-96955ad76e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_a5896490-ddda-4ee4-848f-23f51e93872b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_Inventories_a5896490-ddda-4ee4-848f-23f51e93872b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_03c1306f-ea9d-4df3-b0f9-318a9e44916a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_CurrentTradeReceivables_03c1306f-ea9d-4df3-b0f9-318a9e44916a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_ff94722c-5099-47fe-a045-6eb36848559b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_OtherCurrentAssets_ff94722c-5099-47fe-a045-6eb36848559b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_eddafe2c-a620-4bf7-9a29-7991ad7877b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_eddafe2c-a620-4bf7-9a29-7991ad7877b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_fe510112-66e8-41c2-b8fb-350bc56493d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_CashAndCashEquivalents_fe510112-66e8-41c2-b8fb-350bc56493d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_bcc1240f-4a2f-4d0d-961a-a5806f21f149" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_bcc1240f-4a2f-4d0d-961a-a5806f21f149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_211035e9-4237-4f9c-bfc6-83c66f2316c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_211035e9-4237-4f9c-bfc6-83c66f2316c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_902dd59d-3ee9-48bb-9b22-df99877c149c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_551dff3d-6845-4118-a555-ce04b36dcaf3" xlink:to="loc_ifrs-full_Assets_902dd59d-3ee9-48bb-9b22-df99877c149c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_0ba46c9f-25bd-4caa-a1a5-f8eae652ed1e" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_0535a881-2a10-46a4-977e-5b13dd615ad5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_0535a881-2a10-46a4-977e-5b13dd615ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests_af70ad68-dcfe-40e4-9a1f-e26550522145" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_NoncontrollingInterests_af70ad68-dcfe-40e4-9a1f-e26550522145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_b5ffac1e-faf8-463b-bf4e-4ea2f41d9337" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_Equity_b5ffac1e-faf8-463b-bf4e-4ea2f41d9337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_4600114d-7aee-4c99-9228-88d0715f5996" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_LongtermBorrowings_4600114d-7aee-4c99-9228-88d0715f5996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_f54ec989-5840-4fa5-a597-59d4ae9bdbc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_f54ec989-5840-4fa5-a597-59d4ae9bdbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_f29009d6-bbc2-4f7a-8bda-ed5e9115b009" xlink:href="sny-20231231.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_f29009d6-bbc2-4f7a-8bda-ed5e9115b009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_a40dc074-45ae-421f-af08-785f3eb46c1d" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_a40dc074-45ae-421f-af08-785f3eb46c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_102b99cf-9777-4ccb-aa39-f3ae7f73fdfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_102b99cf-9777-4ccb-aa39-f3ae7f73fdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_d5cb1442-e73b-4a45-bc66-7a0d3ac0e768" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_d5cb1442-e73b-4a45-bc66-7a0d3ac0e768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_8673d352-5259-4b0c-98fa-7c0e1f446207" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_NoncurrentLiabilities_8673d352-5259-4b0c-98fa-7c0e1f446207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0c85b7d0-d990-4460-a324-353eb312bebc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0c85b7d0-d990-4460-a324-353eb312bebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_cdbbed1d-8f25-47a0-b8ab-2ac7518fd7cf" xlink:href="sny-20231231.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_cdbbed1d-8f25-47a0-b8ab-2ac7518fd7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_e7f13bea-c3bb-4169-ba61-561dbcba5406" xlink:href="sny-20231231.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_e7f13bea-c3bb-4169-ba61-561dbcba5406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_45fb510a-be3a-42be-8117-de43757899a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_45fb510a-be3a-42be-8117-de43757899a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_ce814ce9-9f34-48d7-bfef-0e3c344f2d91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_ce814ce9-9f34-48d7-bfef-0e3c344f2d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_09f71b32-9022-42c8-8cc8-4a54145aaad7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_09f71b32-9022-42c8-8cc8-4a54145aaad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_fb55ebfd-e154-4651-ace8-a8e59fff428d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_fb55ebfd-e154-4651-ace8-a8e59fff428d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_b02f9025-e483-4f45-9f1e-95328346bed3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_b02f9025-e483-4f45-9f1e-95328346bed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_85f82167-94ea-4777-856a-f3b247cc8e5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_49f8d5a1-d9d4-46c3-8d74-fc0ad81f1cf4" xlink:to="loc_ifrs-full_EquityAndLiabilities_85f82167-94ea-4777-856a-f3b247cc8e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedincomestatements" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedincomestatements"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedincomestatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_6e1fbb8f-574d-4c46-8f7e-ee676254e9c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_6e1fbb8f-574d-4c46-8f7e-ee676254e9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_850aab67-d650-42b9-a975-e26a274bfaeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_OtherRevenue_850aab67-d650-42b9-a975-e26a274bfaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_f098f6c4-deff-4f03-8282-3252f35d0411" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_CostOfSales_f098f6c4-deff-4f03-8282-3252f35d0411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossProfit_b8066aae-a764-4a1a-a0c5-d12ed95a5c9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_GrossProfit_b8066aae-a764-4a1a-a0c5-d12ed95a5c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_b77821a6-2557-42d8-ac34-46f16a17b6f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_b77821a6-2557-42d8-ac34-46f16a17b6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_6d094294-47ee-4519-8452-34a8174151ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_6d094294-47ee-4519-8452-34a8174151ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_221323dd-1b49-4b1f-8506-afb4cb28f523" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_221323dd-1b49-4b1f-8506-afb4cb28f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_c6f6597b-58ee-45c2-8e2b-56ccc866b00d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_c6f6597b-58ee-45c2-8e2b-56ccc866b00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_8e5b2c67-3328-4c60-a045-5493585a0a2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_8e5b2c67-3328-4c60-a045-5493585a0a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_d0b61a04-f31b-4eb1-9ce5-0645eb566e7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_d0b61a04-f31b-4eb1-9ce5-0645eb566e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_816581ed-7231-418d-a20d-52ece7d42488" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_816581ed-7231-418d-a20d-52ece7d42488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_a8a5bdf3-e75f-4b77-8683-257b9e8a1a66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_a8a5bdf3-e75f-4b77-8683-257b9e8a1a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_db96711f-e8ff-49f4-98fa-7968bc1460d7" xlink:href="sny-20231231.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_sny_OtherGainsLossesAndLitigation_db96711f-e8ff-49f4-98fa-7968bc1460d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_607e02fc-9a81-44a2-9ac2-344f5e00e0fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_607e02fc-9a81-44a2-9ac2-344f5e00e0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_d4534cec-77af-491c-b0eb-76fb7acabf03" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_FinanceCosts_d4534cec-77af-491c-b0eb-76fb7acabf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_080759e0-0e8c-49c0-9a22-02df70c96af0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_FinanceIncome_080759e0-0e8c-49c0-9a22-02df70c96af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_5ddafb6d-a063-45dc-a098-38fa5b2ac35e" xlink:href="sny-20231231.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_5ddafb6d-a063-45dc-a098-38fa5b2ac35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0c8504fd-317e-4234-b73e-9cda7eebc474" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_0c8504fd-317e-4234-b73e-9cda7eebc474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_2119f12f-026a-4e29-b272-043e989a464a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_2119f12f-026a-4e29-b272-043e989a464a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_4e69c882-f63b-4046-9a20-2f0ec6e6ba7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_ProfitLoss_4e69c882-f63b-4046-9a20-2f0ec6e6ba7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_43f7c5f4-5e8b-45d8-bdff-16bf57e9eb1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_43f7c5f4-5e8b-45d8-bdff-16bf57e9eb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_e54c0b28-8375-4cca-88bc-02a8f338f015" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_e54c0b28-8375-4cca-88bc-02a8f338f015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_3a15d1db-07e7-4bba-8e0b-2e55bcbcea1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_WeightedAverageShares_3a15d1db-07e7-4bba-8e0b-2e55bcbcea1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_20ae4110-dffa-47fb-a13c-1ade9feb6232" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_20ae4110-dffa-47fb-a13c-1ade9feb6232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_0a65a81c-690b-4c36-a1b6-f01e3c2f46a0" xlink:href="sny-20231231.xsd#sny_BasicEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent_0a65a81c-690b-4c36-a1b6-f01e3c2f46a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_037940e5-3a54-45d8-a8ef-846d2ed20061" xlink:href="sny-20231231.xsd#sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_bc33351f-1223-4c82-9da6-13957bda95c1" xlink:to="loc_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent_037940e5-3a54-45d8-a8ef-846d2ed20061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedincomestatements_1" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedincomestatements_1"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedincomestatements_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedstatementsofcomprehensiveincome"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_0e48b28c-b4fe-41f7-953f-db3ce8ab803a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_af351bde-759f-4804-b5d5-326c9631a53b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_0e48b28c-b4fe-41f7-953f-db3ce8ab803a" xlink:to="loc_ifrs-full_ProfitLoss_af351bde-759f-4804-b5d5-326c9631a53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_c1a12c2a-d60e-48b9-b6a7-849fa5825fd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_0e48b28c-b4fe-41f7-953f-db3ce8ab803a" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_c1a12c2a-d60e-48b9-b6a7-849fa5825fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_f003ba63-93a3-42a8-ae9e-096277a563e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_0e48b28c-b4fe-41f7-953f-db3ce8ab803a" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_f003ba63-93a3-42a8-ae9e-096277a563e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_0e48b28c-b4fe-41f7-953f-db3ce8ab803a" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_ca9f6842-7494-4143-91b5-145860113816" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_ca9f6842-7494-4143-91b5-145860113816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_f0a1c970-a64e-4504-ba4d-c0f8f943eb66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:to="loc_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments_f0a1c970-a64e-4504-ba4d-c0f8f943eb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_5647b03f-fccb-415e-b14e-e289553d440a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss_5647b03f-fccb-415e-b14e-e289553d440a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_cdb70835-2a2e-4236-a4f6-aa39b30c088f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_cdb70835-2a2e-4236-a4f6-aa39b30c088f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_b872fb22-e855-4eac-9ada-cea2eb65cd0f" xlink:href="sny-20231231.xsd#sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:to="loc_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax_b872fb22-e855-4eac-9ada-cea2eb65cd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_9bb8441f-c5eb-49a6-a3eb-025dcabc8f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_9bb8441f-c5eb-49a6-a3eb-025dcabc8f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_7c4b3328-26c7-4d01-984e-f74438a1f269" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_7c4b3328-26c7-4d01-984e-f74438a1f269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_4c3e90b2-28e5-4099-8ec0-9adcb4e0b346" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:to="loc_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss_4c3e90b2-28e5-4099-8ec0-9adcb4e0b346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_1c32bf61-86be-45f4-805e-2286ff4edf5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_1c32bf61-86be-45f4-805e-2286ff4edf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_8af1f165-00a0-43b8-90e0-63d006c243c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_77fbd8c9-d5aa-48e4-b629-10fe76084727" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_8af1f165-00a0-43b8-90e0-63d006c243c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_97a61986-1d8b-4121-9c60-9086a3183be8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_0e48b28c-b4fe-41f7-953f-db3ce8ab803a" xlink:to="loc_ifrs-full_ComprehensiveIncome_97a61986-1d8b-4121-9c60-9086a3183be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_d8efda61-8c02-47d8-91c9-e9fa68647999" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_0e48b28c-b4fe-41f7-953f-db3ce8ab803a" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_d8efda61-8c02-47d8-91c9-e9fa68647999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2b372a82-41e6-4c80-a0f6-eb4de4afe78b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_0e48b28c-b4fe-41f7-953f-db3ce8ab803a" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2b372a82-41e6-4c80-a0f6-eb4de4afe78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedstatementsofcomprehensiveincome_1"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedstatementsofchangesinequity"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_61c29f07-4b7c-4fdc-ae3a-6db3f9f8106f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_7bafa3bd-2ddc-48b2-8091-89946f95392a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_61c29f07-4b7c-4fdc-ae3a-6db3f9f8106f" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_7bafa3bd-2ddc-48b2-8091-89946f95392a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_11b2185c-0346-47d4-92d5-6811c22e4173" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_7bafa3bd-2ddc-48b2-8091-89946f95392a" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_11b2185c-0346-47d4-92d5-6811c22e4173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_5f8e19d0-cb17-4e83-bd96-04659777cf2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_11b2185c-0346-47d4-92d5-6811c22e4173" xlink:to="loc_ifrs-full_EquityMember_5f8e19d0-cb17-4e83-bd96-04659777cf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_5f8e19d0-cb17-4e83-bd96-04659777cf2f" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_1e3eeae3-de63-4035-811f-77213abd5422" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_IssuedCapitalMember_1e3eeae3-de63-4035-811f-77213abd5422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapitalMember_8940f240-d9b2-4762-ba59-f2a9cc165053" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_AdditionalPaidinCapitalMember_8940f240-d9b2-4762-ba59-f2a9cc165053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_fcc689eb-34d0-413a-aa56-f79c6aa9ea72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_TreasurySharesMember_fcc689eb-34d0-413a-aa56-f79c6aa9ea72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_e9e91e29-4da3-42a5-9f93-03d2b76c244e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_RetainedEarningsMember_e9e91e29-4da3-42a5-9f93-03d2b76c244e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_58b628fd-b2b2-4401-b288-88c1503b4896" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_58b628fd-b2b2-4401-b288-88c1503b4896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_09baad76-f830-42c9-aec9-458f7f42a012" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_4665d90b-81dc-48f8-8eb5-3cc69042b70c" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_09baad76-f830-42c9-aec9-458f7f42a012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterestsMember_5ae5a375-43b9-4a64-908a-4a4717c59228" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_5f8e19d0-cb17-4e83-bd96-04659777cf2f" xlink:to="loc_ifrs-full_NoncontrollingInterestsMember_5ae5a375-43b9-4a64-908a-4a4717c59228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_7bafa3bd-2ddc-48b2-8091-89946f95392a" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_130a2394-006c-472c-9cd9-92bd664b23c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_Equity_130a2394-006c-472c-9cd9-92bd664b23c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_e7b2d60f-8d3a-4f11-9f7a-a016395bf1f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_e7b2d60f-8d3a-4f11-9f7a-a016395bf1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_bf9ff57f-49fc-4a13-98c9-9c96b6516a55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_ProfitLoss_bf9ff57f-49fc-4a13-98c9-9c96b6516a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_7296f359-fc62-4705-b63e-31761b5e23dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_ComprehensiveIncome_7296f359-fc62-4705-b63e-31761b5e23dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_6b839d57-e80b-4777-bae9-66411a500ac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent_6b839d57-e80b-4777-bae9-66411a500ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_a3169403-a2b1-481e-a6ec-a4ba4e380dc2" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_a3169403-a2b1-481e-a6ec-a4ba4e380dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_5a39a013-35c8-48e2-ac8e-375a9ce05217" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests_5a39a013-35c8-48e2-ac8e-375a9ce05217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfTreasuryShares_e6f058d7-3ef5-4dae-ab8d-b502e720b515" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfTreasuryShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_PurchaseOfTreasuryShares_e6f058d7-3ef5-4dae-ab8d-b502e720b515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReductionOfIssuedCapital_6c4e00ae-5a7a-43f9-b4e3-b9d18babd4ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReductionOfIssuedCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_ReductionOfIssuedCapital_6c4e00ae-5a7a-43f9-b4e3-b9d18babd4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:href="sny-20231231.xsd#sny_ShareBasedPaymentPlansAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_a0b71e30-09b6-4072-97c4-c9bb44c19d71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_a0b71e30-09b6-4072-97c4-c9bb44c19d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_4203f77a-947e-4f1f-9584-47b8ca03be16" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares_4203f77a-947e-4f1f-9584-47b8ca03be16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_0cd078bf-0f32-401b-8fe9-c469a83ec3bc" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans_0cd078bf-0f32-401b-8fe9-c469a83ec3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_9dbe527c-249c-4b2d-a000-806c35a30a15" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees_9dbe527c-249c-4b2d-a000-806c35a30a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_33585a5d-af10-4002-b6d3-6c30a85ed615" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareBasedPaymentPlansAbstract_6be2d559-dc71-4b07-ab53-fd63c088019e" xlink:to="loc_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions_33585a5d-af10-4002-b6d3-6c30a85ed615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_23fcaf92-4e6f-4221-a6a6-b56d54192a95" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity_23fcaf92-4e6f-4221-a6a6-b56d54192a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment_a34d8c17-d36a-4d5f-ad0d-23156cc3ef1d" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment_a34d8c17-d36a-4d5f-ad0d-23156cc3ef1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_048d47f1-6e6f-4853-9767-6eae9fd9a523" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_048d47f1-6e6f-4853-9767-6eae9fd9a523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_7924d037-ec1b-4ebc-906e-9b6092f2a558" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_54426a33-63ee-4973-ae51-f27e69cfd7c8" xlink:to="loc_ifrs-full_Equity_7924d037-ec1b-4ebc-906e-9b6092f2a558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedstatementsofchangesinequityParenthetical"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_0857549c-9e41-4a12-8b18-c8da5bb84075" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_0d93a37c-358d-4357-871f-2d0a6326dde9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_0857549c-9e41-4a12-8b18-c8da5bb84075" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_0d93a37c-358d-4357-871f-2d0a6326dde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2a82c9e0-92b4-48d1-bb2d-05dda0fbed45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0d93a37c-358d-4357-871f-2d0a6326dde9" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2a82c9e0-92b4-48d1-bb2d-05dda0fbed45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c0ca3a7b-3682-4320-9ba5-64d05622eb1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_2a82c9e0-92b4-48d1-bb2d-05dda0fbed45" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c0ca3a7b-3682-4320-9ba5-64d05622eb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_8dec5ea3-e739-488c-b3c2-6549cd025382" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_c0ca3a7b-3682-4320-9ba5-64d05622eb1b" xlink:to="loc_sny_EuroapiMember_8dec5ea3-e739-488c-b3c2-6549cd025382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_2b41d346-a0c1-4953-af84-789e8c54f6ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0d93a37c-358d-4357-871f-2d0a6326dde9" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_2b41d346-a0c1-4953-af84-789e8c54f6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_b1260eed-88e9-4b5d-9995-1c6a36e9d573" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_2b41d346-a0c1-4953-af84-789e8c54f6ec" xlink:to="loc_ifrs-full_DividendsPaidOrdinarySharesPerShare_b1260eed-88e9-4b5d-9995-1c6a36e9d573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_a324da66-0544-4bc9-8ce7-597d24f80c63" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendPercentageOfShareCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_2b41d346-a0c1-4953-af84-789e8c54f6ec" xlink:to="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_a324da66-0544-4bc9-8ce7-597d24f80c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019_6b3e75fe-bf2a-4ef5-861a-94088e788706" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_2b41d346-a0c1-4953-af84-789e8c54f6ec" xlink:to="loc_ifrs-full_WeightedAverageSharePrice2019_6b3e75fe-bf2a-4ef5-861a-94088e788706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedstatementsofcashflows" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedstatementsofcashflows"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedstatementsofcashflows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_48b381ac-9201-4026-8ab5-540794b923e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_48b381ac-9201-4026-8ab5-540794b923e7" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_843237b8-2b82-4339-9af4-29a1d24f3d89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:to="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_843237b8-2b82-4339-9af4-29a1d24f3d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_4039466c-02c5-4280-b924-eab180aba253" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_4039466c-02c5-4280-b924-eab180aba253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_76f61f37-da89-401c-879a-d651038d2953" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:to="loc_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod_76f61f37-da89-401c-879a-d651038d2953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_7d638f86-cbf2-4725-9022-326b27832e78" xlink:href="sny-20231231.xsd#sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:to="loc_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset_7d638f86-cbf2-4725-9022-326b27832e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_dbffd84d-2403-43f2-8d49-5b41b3e92113" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:to="loc_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_dbffd84d-2403-43f2-8d49-5b41b3e92113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_5087e42e-6906-4566-ba34-8db99f346929" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_5087e42e-6906-4566-ba34-8db99f346929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_972b5682-d62e-4fd9-80b6-0748ccc64b93" xlink:href="sny-20231231.xsd#sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:to="loc_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities_972b5682-d62e-4fd9-80b6-0748ccc64b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_3d7ac670-037c-4616-82b3-100e6b85c2e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_3d7ac670-037c-4616-82b3-100e6b85c2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_5dfa4e35-72db-498b-aa99-2d252d1bd879" xlink:href="sny-20231231.xsd#sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:to="loc_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue_5dfa4e35-72db-498b-aa99-2d252d1bd879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_e3996648-adda-4818-8156-470fbf855be4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:to="loc_ifrs-full_OtherAdjustmentsToReconcileProfitLoss_e3996648-adda-4818-8156-470fbf855be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_27ce9f5c-bfe4-4ba8-af85-84ac9bf2dcc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_956bde2d-2218-4e69-a5fa-12bcaf5bf206" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_27ce9f5c-bfe4-4ba8-af85-84ac9bf2dcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_c5212138-e99c-4c01-86a3-91aeed2b5c88" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_48b381ac-9201-4026-8ab5-540794b923e7" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_c5212138-e99c-4c01-86a3-91aeed2b5c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_19b29881-3778-4cf8-8c0c-91112f26fb9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_c5212138-e99c-4c01-86a3-91aeed2b5c88" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_19b29881-3778-4cf8-8c0c-91112f26fb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_e659727a-87e7-4c4a-8276-c3d629012b40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_c5212138-e99c-4c01-86a3-91aeed2b5c88" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_e659727a-87e7-4c4a-8276-c3d629012b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_1eed719f-e29d-44b4-b930-915d558e0250" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_c5212138-e99c-4c01-86a3-91aeed2b5c88" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_1eed719f-e29d-44b4-b930-915d558e0250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_6f7443c2-af60-48ec-a9d8-c03e1073b4f4" xlink:href="sny-20231231.xsd#sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_c5212138-e99c-4c01-86a3-91aeed2b5c88" xlink:to="loc_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities_6f7443c2-af60-48ec-a9d8-c03e1073b4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_6c60c65a-5e93-4c72-8840-1bf41d95cfae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_c5212138-e99c-4c01-86a3-91aeed2b5c88" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_6c60c65a-5e93-4c72-8840-1bf41d95cfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_fb60ff7b-8971-4451-ab19-9b799f678d9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_48b381ac-9201-4026-8ab5-540794b923e7" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_fb60ff7b-8971-4451-ab19-9b799f678d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_d4062a7a-4e63-4313-a491-2d3b7519627a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_fb60ff7b-8971-4451-ab19-9b799f678d9d" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_d4062a7a-4e63-4313-a491-2d3b7519627a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_e5c5dd07-2363-4eae-a9c8-cd70d89872e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_fb60ff7b-8971-4451-ab19-9b799f678d9d" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_e5c5dd07-2363-4eae-a9c8-cd70d89872e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_62390c4c-e6e1-449a-9ad7-4cab4571e800" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_fb60ff7b-8971-4451-ab19-9b799f678d9d" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_62390c4c-e6e1-449a-9ad7-4cab4571e800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_b672af9b-98a9-4ab7-9e5c-8fe6931a08c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_fb60ff7b-8971-4451-ab19-9b799f678d9d" xlink:to="loc_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_b672af9b-98a9-4ab7-9e5c-8fe6931a08c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_2323a9a3-1ada-405a-8d85-2761ff91146c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_fb60ff7b-8971-4451-ab19-9b799f678d9d" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_2323a9a3-1ada-405a-8d85-2761ff91146c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetChangeInOtherNonCurrentAssets_8c88fefa-ecec-4152-bf60-b6270319fba4" xlink:href="sny-20231231.xsd#sny_NetChangeInOtherNonCurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_fb60ff7b-8971-4451-ab19-9b799f678d9d" xlink:to="loc_sny_NetChangeInOtherNonCurrentAssets_8c88fefa-ecec-4152-bf60-b6270319fba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_83e3dc30-4890-4cb8-85a9-fd907ad342eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_fb60ff7b-8971-4451-ab19-9b799f678d9d" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_83e3dc30-4890-4cb8-85a9-fd907ad342eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_9454d2c2-1e65-47fa-b799-8c7dbc032090" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_48b381ac-9201-4026-8ab5-540794b923e7" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_9454d2c2-1e65-47fa-b799-8c7dbc032090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_2d6a1471-33ba-456d-b599-24dab628a3a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_9454d2c2-1e65-47fa-b799-8c7dbc032090" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_2d6a1471-33ba-456d-b599-24dab628a3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsPaidAbstract_198f969e-afc4-43a6-8049-52397eca9b80" xlink:href="sny-20231231.xsd#sny_DividendsPaidAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_9454d2c2-1e65-47fa-b799-8c7dbc032090" xlink:to="loc_sny_DividendsPaidAbstract_198f969e-afc4-43a6-8049-52397eca9b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_fbfb8af4-4319-4d3b-84d6-1ef576fd0a74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DividendsPaidAbstract_198f969e-afc4-43a6-8049-52397eca9b80" xlink:to="loc_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_fbfb8af4-4319-4d3b-84d6-1ef576fd0a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_8c6f8c96-a00c-4846-bd38-1983c3ec4fb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DividendsPaidAbstract_198f969e-afc4-43a6-8049-52397eca9b80" xlink:to="loc_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities_8c6f8c96-a00c-4846-bd38-1983c3ec4fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_7902ecc2-f804-407b-8340-3e6818362e2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_9454d2c2-1e65-47fa-b799-8c7dbc032090" xlink:to="loc_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_7902ecc2-f804-407b-8340-3e6818362e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_e84d67f6-d771-4509-971b-0d651cd03399" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_9454d2c2-1e65-47fa-b799-8c7dbc032090" xlink:to="loc_ifrs-full_ProceedsFromNoncurrentBorrowings_e84d67f6-d771-4509-971b-0d651cd03399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_9a7e44bf-57a7-4306-bef0-da7382ecae81" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_9454d2c2-1e65-47fa-b799-8c7dbc032090" xlink:to="loc_ifrs-full_RepaymentsOfNoncurrentBorrowings_9a7e44bf-57a7-4306-bef0-da7382ecae81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_56e016e9-197f-46f3-a063-59d31b243864" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_9454d2c2-1e65-47fa-b799-8c7dbc032090" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_56e016e9-197f-46f3-a063-59d31b243864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_886e1a97-7c8e-4168-8e23-54a56f0e0a19" xlink:href="sny-20231231.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_9454d2c2-1e65-47fa-b799-8c7dbc032090" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_886e1a97-7c8e-4168-8e23-54a56f0e0a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_b7a22873-5feb-40a7-9350-63f669dde8f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_9454d2c2-1e65-47fa-b799-8c7dbc032090" xlink:to="loc_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_b7a22873-5feb-40a7-9350-63f669dde8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_8332de1b-6d9e-426e-a950-4d6dd65a903c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_9454d2c2-1e65-47fa-b799-8c7dbc032090" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_8332de1b-6d9e-426e-a950-4d6dd65a903c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_692c51ef-7f20-4640-a099-d28caa9fedc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_48b381ac-9201-4026-8ab5-540794b923e7" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_692c51ef-7f20-4640-a099-d28caa9fedc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_f090f046-d02b-492b-988d-7c21118fb811" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_48b381ac-9201-4026-8ab5-540794b923e7" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_f090f046-d02b-492b-988d-7c21118fb811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_f70578bb-1054-4f6d-ab75-fc4a3169a4b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_48b381ac-9201-4026-8ab5-540794b923e7" xlink:to="loc_ifrs-full_CashAndCashEquivalents_f70578bb-1054-4f6d-ab75-fc4a3169a4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_684a2df2-1254-4b13-a5da-5c2ba862475f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_48b381ac-9201-4026-8ab5-540794b923e7" xlink:to="loc_ifrs-full_CashAndCashEquivalents_684a2df2-1254-4b13-a5da-5c2ba862475f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedstatementsofcashflowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_136b19e8-5a19-4273-83e5-58ee2bd3536d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable_95ff321c-0dfe-4c04-a1e9-77fc65c33330" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_136b19e8-5a19-4273-83e5-58ee2bd3536d" xlink:to="loc_srt_CondensedCashFlowStatementTable_95ff321c-0dfe-4c04-a1e9-77fc65c33330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e688a65f-aeca-4464-b93e-bd9d86ef7d03" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementTable_95ff321c-0dfe-4c04-a1e9-77fc65c33330" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e688a65f-aeca-4464-b93e-bd9d86ef7d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_90fcd780-b5e0-4629-82d3-1cbbafa67d1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_e688a65f-aeca-4464-b93e-bd9d86ef7d03" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_90fcd780-b5e0-4629-82d3-1cbbafa67d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_10f39549-541f-48d4-803e-ccd35e131e70" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_90fcd780-b5e0-4629-82d3-1cbbafa67d1c" xlink:to="loc_sny_EuroapiMember_10f39549-541f-48d4-803e-ccd35e131e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1b07b115-59de-4474-a700-00dcce8f86ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementTable_95ff321c-0dfe-4c04-a1e9-77fc65c33330" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_1b07b115-59de-4474-a700-00dcce8f86ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_c00e8978-c97c-4a43-be39-dd0a675f0739" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1b07b115-59de-4474-a700-00dcce8f86ae" xlink:to="loc_ifrs-full_BorrowingsByNameMember_c00e8978-c97c-4a43-be39-dd0a675f0739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_98c09ff4-f71c-4df6-bc90-273c65d80538" xlink:href="sny-20231231.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_c00e8978-c97c-4a43-be39-dd0a675f0739" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_98c09ff4-f71c-4df6-bc90-273c65d80538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementTable_95ff321c-0dfe-4c04-a1e9-77fc65c33330" xlink:to="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_6842a529-23c3-4130-ac3d-3c188ccd20c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_6842a529-23c3-4130-ac3d-3c188ccd20c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_98cca87f-9548-479c-b0f4-bf84d7531c3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_98cca87f-9548-479c-b0f4-bf84d7531c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_d3be3566-d527-477b-82f7-d69de9919f84" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_d3be3566-d527-477b-82f7-d69de9919f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities_91ca24cb-0e05-4ccd-b09d-c55320876f63" xlink:href="sny-20231231.xsd#sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities_91ca24cb-0e05-4ccd-b09d-c55320876f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_ec299bce-1815-45ca-a9d5-0e715252e5b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_ec299bce-1815-45ca-a9d5-0e715252e5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_d45b18d8-365e-49ee-9025-99fe8edfd600" xlink:href="sny-20231231.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_38b5dffe-f64b-46c1-a971-5ae407174bba" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_d45b18d8-365e-49ee-9025-99fe8edfd600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Introduction" xlink:type="simple" xlink:href="sny-20231231.xsd#Introduction"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Introduction" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralInformationAboutFinancialStatementsAbstract_4ba80265-74cb-4e36-9ef6-c237e049dd4d" xlink:href="sny-20231231.xsd#sny_GeneralInformationAboutFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_8fca42d0-d158-4a73-a54c-35ca4827ba2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralInformationAboutFinancialStatementsAbstract_4ba80265-74cb-4e36-9ef6-c237e049dd4d" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_8fca42d0-d158-4a73-a54c-35ca4827ba2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Basisofpreparation" xlink:type="simple" xlink:href="sny-20231231.xsd#Basisofpreparation"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Basisofpreparation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_8958b2a0-eadd-4998-a5a6-709b110ef55d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_107af97e-a473-43cc-bc1f-a0d139249c7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_8958b2a0-eadd-4998-a5a6-709b110ef55d" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_107af97e-a473-43cc-bc1f-a0d139249c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="sny-20231231.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_1dd5a7de-dcc6-4a24-b750-1d48b5270722" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_bfdf896c-1d12-4759-8883-bc1c93a0e1fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_1dd5a7de-dcc6-4a24-b750-1d48b5270722" xlink:to="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_bfdf896c-1d12-4759-8883-bc1c93a0e1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalalliances" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalalliances"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Principalalliances" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_RelatedPartyAbstract_74af59e6-d73c-42a8-8aa0-c05d8699246d" xlink:href="sny-20231231.xsd#sny_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAlliancesTextBlock_26f8d3a5-b374-436a-bb4d-d7fb070e8830" xlink:href="sny-20231231.xsd#sny_DisclosureOfPrincipalAlliancesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_74af59e6-d73c-42a8-8aa0-c05d8699246d" xlink:to="loc_sny_DisclosureOfPrincipalAlliancesTextBlock_26f8d3a5-b374-436a-bb4d-d7fb070e8830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2023"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_99d2ea4c-22bc-4fdd-a688-c14708605e39" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_bb16b152-9b23-47aa-adf2-2fd203fa9dfd" xlink:href="sny-20231231.xsd#sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_99d2ea4c-22bc-4fdd-a688-c14708605e39" xlink:to="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_bb16b152-9b23-47aa-adf2-2fd203fa9dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2022and2021"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_dc3e1229-2d1f-4759-87f8-489cc3290843" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_02a11821-51bf-4e48-b3fe-d36801fd3bd4" xlink:href="sny-20231231.xsd#sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_dc3e1229-2d1f-4759-87f8-489cc3290843" xlink:to="loc_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock_02a11821-51bf-4e48-b3fe-d36801fd3bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="sny-20231231.xsd#Propertyplantandequipment"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Propertyplantandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_f97ece83-d528-4c2c-a613-aa54a8a2c85a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_6f06e6ba-f30c-44e1-90d5-152820d34575" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_f97ece83-d528-4c2c-a613-aa54a8a2c85a" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_6f06e6ba-f30c-44e1-90d5-152820d34575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Goodwillandotherintangibleassets" xlink:type="simple" xlink:href="sny-20231231.xsd#Goodwillandotherintangibleassets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Goodwillandotherintangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_65808cfc-e897-41a7-a8fc-1dd1c43da383" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_ecbe7e90-f9ae-47a5-b297-92053bf5dea2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_65808cfc-e897-41a7-a8fc-1dd1c43da383" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_ecbe7e90-f9ae-47a5-b297-92053bf5dea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Impairmentofintangibleassetsandpropertyplantandequipment" xlink:type="simple" xlink:href="sny-20231231.xsd#Impairmentofintangibleassetsandpropertyplantandequipment"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Impairmentofintangibleassetsandpropertyplantandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentOfAssetsAbstract_cd72fdf6-2e05-436d-904c-52e29ed1aa9d" xlink:href="sny-20231231.xsd#sny_ImpairmentOfAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_e73dc7a1-c0b3-4396-833f-6a3be2f73650" xlink:href="sny-20231231.xsd#sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ImpairmentOfAssetsAbstract_cd72fdf6-2e05-436d-904c-52e29ed1aa9d" xlink:to="loc_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock_e73dc7a1-c0b3-4396-833f-6a3be2f73650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod" xlink:type="simple" xlink:href="sny-20231231.xsd#Investmentsaccountedforusingtheequitymethod"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_24ed4754-867d-4c5d-b11b-eac0e7947772" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_3a9d9618-48ee-4c02-90ac-16ffdb63af94" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_24ed4754-867d-4c5d-b11b-eac0e7947772" xlink:to="loc_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_3a9d9618-48ee-4c02-90ac-16ffdb63af94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Othernoncurrentassets" xlink:type="simple" xlink:href="sny-20231231.xsd#Othernoncurrentassets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Othernoncurrentassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9bf6cc43-52b1-4fca-b479-cbd3a9e18dca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_e546cb67-54a7-4712-b6e1-58cf4833712c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9bf6cc43-52b1-4fca-b479-cbd3a9e18dca" xlink:to="loc_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory_e546cb67-54a7-4712-b6e1-58cf4833712c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Assetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchange" xlink:type="simple" xlink:href="sny-20231231.xsd#Assetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchange"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Assetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchange" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_cdb62706-ef1d-4618-b94a-899ac191ead9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_91e21ce9-28f4-418e-8939-800ca37edfa0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_cdb62706-ef1d-4618-b94a-899ac191ead9" xlink:to="loc_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_91e21ce9-28f4-418e-8939-800ca37edfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Inventories" xlink:type="simple" xlink:href="sny-20231231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_94027ef8-4b50-45e5-b588-ab1ae52d0160" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory_0688bd6e-ae11-4801-9e41-23a39e6a4c73" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_94027ef8-4b50-45e5-b588-ab1ae52d0160" xlink:to="loc_ifrs-full_DisclosureOfInventoriesExplanatory_0688bd6e-ae11-4801-9e41-23a39e6a4c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Accountsreceivable" xlink:type="simple" xlink:href="sny-20231231.xsd#Accountsreceivable"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Accountsreceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ccf2e328-8ff0-42a4-80dc-5bc5102d30bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTradeReceivablesTextBlock_c91beaa8-5d97-4838-8d15-1be10248a220" xlink:href="sny-20231231.xsd#sny_DisclosureOfTradeReceivablesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ccf2e328-8ff0-42a4-80dc-5bc5102d30bb" xlink:to="loc_sny_DisclosureOfTradeReceivablesTextBlock_c91beaa8-5d97-4838-8d15-1be10248a220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Othercurrentassets" xlink:type="simple" xlink:href="sny-20231231.xsd#Othercurrentassets"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Othercurrentassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_914b5daf-47bd-4f7e-9862-45d4307cbc25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_286d7029-434c-431e-9449-68b32483c6cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_914b5daf-47bd-4f7e-9862-45d4307cbc25" xlink:to="loc_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_286d7029-434c-431e-9449-68b32483c6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Financialassetsandliabilitiesmeasuredatfairvalue" xlink:type="simple" xlink:href="sny-20231231.xsd#Financialassetsandliabilitiesmeasuredatfairvalue"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Financialassetsandliabilitiesmeasuredatfairvalue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueMeasurementAbstract_27398971-dee3-4338-b7ae-cccf8fd278ec" xlink:href="sny-20231231.xsd#sny_FairValueMeasurementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock_3dccd543-53bc-465b-b947-1d297c4bc459" xlink:href="sny-20231231.xsd#sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FairValueMeasurementAbstract_27398971-dee3-4338-b7ae-cccf8fd278ec" xlink:to="loc_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock_3dccd543-53bc-465b-b947-1d297c4bc459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Cashandcashequivalents" xlink:type="simple" xlink:href="sny-20231231.xsd#Cashandcashequivalents"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Cashandcashequivalents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3bc72f04-6284-4161-b880-3dc07219772b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_2a722d6b-7ee0-4f3b-95ed-b38af6a0c6aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3bc72f04-6284-4161-b880-3dc07219772b" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_2a722d6b-7ee0-4f3b-95ed-b38af6a0c6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Netdeferredtaxposition" xlink:type="simple" xlink:href="sny-20231231.xsd#Netdeferredtaxposition"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Netdeferredtaxposition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxesAbstract_0680fed5-f6e8-4933-bf20-a32b61c253fa" xlink:href="sny-20231231.xsd#sny_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory_1edcb81f-14e9-47aa-90db-34f3c51415b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_0680fed5-f6e8-4933-bf20-a32b61c253fa" xlink:to="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory_1edcb81f-14e9-47aa-90db-34f3c51415b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Consolidatedshareholdersequity" xlink:type="simple" xlink:href="sny-20231231.xsd#Consolidatedshareholdersequity"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Consolidatedshareholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_2b985469-d4ac-422f-b619-761ad1e579af" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_79b7be46-b8b9-4c1d-bdc6-21f389f7b116" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_2b985469-d4ac-422f-b619-761ad1e579af" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_79b7be46-b8b9-4c1d-bdc6-21f389f7b116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Noncontrollinginterests" xlink:type="simple" xlink:href="sny-20231231.xsd#Noncontrollinginterests"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Noncontrollinginterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_be8d7984-cb7d-4e0b-b631-1a7345c94fb1" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory_8d81c624-81f2-4262-99a7-b7c4e871b862" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_be8d7984-cb7d-4e0b-b631-1a7345c94fb1" xlink:to="loc_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory_8d81c624-81f2-4262-99a7-b7c4e871b862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Debtcashandcashequivalentsandleaseliabilities" xlink:type="simple" xlink:href="sny-20231231.xsd#Debtcashandcashequivalentsandleaseliabilities"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Debtcashandcashequivalentsandleaseliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_052a79e5-2458-4023-b497-406e290321cd" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_dd3ccff6-1566-4c76-a5e8-d38e8b26ce22" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_052a79e5-2458-4023-b497-406e290321cd" xlink:to="loc_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock_dd3ccff6-1566-4c76-a5e8-d38e8b26ce22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests" xlink:type="simple" xlink:href="sny-20231231.xsd#Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_0b58a604-1b88-41d7-a68d-00ca50eedbf8" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock_282ca80f-0497-4a87-a71e-6858055cccc9" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_0b58a604-1b88-41d7-a68d-00ca50eedbf8" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock_282ca80f-0497-4a87-a71e-6858055cccc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Provisionsincometaxliabilitiesandotherliabilities" xlink:type="simple" xlink:href="sny-20231231.xsd#Provisionsincometaxliabilitiesandotherliabilities"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Provisionsincometaxliabilitiesandotherliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d9fc8c16-7217-4acd-b1e7-87c4bb246680" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock_6e9190d5-74bb-477e-a2c9-512765666b6b" xlink:href="sny-20231231.xsd#sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d9fc8c16-7217-4acd-b1e7-87c4bb246680" xlink:to="loc_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock_6e9190d5-74bb-477e-a2c9-512765666b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Derivativefinancialinstrumentsandmarketrisks" xlink:type="simple" xlink:href="sny-20231231.xsd#Derivativefinancialinstrumentsandmarketrisks"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Derivativefinancialinstrumentsandmarketrisks" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_21096347-d491-451a-b89f-5ce5ae8bd6eb" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_718a4305-0933-4c74-a8bd-9dda6f5511f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_21096347-d491-451a-b89f-5ce5ae8bd6eb" xlink:to="loc_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_718a4305-0933-4c74-a8bd-9dda6f5511f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Offbalancesheetcommitments" xlink:type="simple" xlink:href="sny-20231231.xsd#Offbalancesheetcommitments"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Offbalancesheetcommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_e4a48b33-bc09-4130-81e5-4899dee61fd8" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_59d6d5a4-6326-4e98-a298-847228f74ba4" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_e4a48b33-bc09-4130-81e5-4899dee61fd8" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock_59d6d5a4-6326-4e98-a298-847228f74ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Legalandarbitralproceedings" xlink:type="simple" xlink:href="sny-20231231.xsd#Legalandarbitralproceedings"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Legalandarbitralproceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_caf0a799-e887-49ab-bdec-f1fff732666d" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_c7812380-fcb8-47ee-868d-847886a5643d" xlink:href="sny-20231231.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_caf0a799-e887-49ab-bdec-f1fff732666d" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock_c7812380-fcb8-47ee-868d-847886a5643d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Provisionsfordiscountsrebatesandsalesreturns" xlink:type="simple" xlink:href="sny-20231231.xsd#Provisionsfordiscountsrebatesandsalesreturns"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Provisionsfordiscountsrebatesandsalesreturns" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_670d5cdd-5f44-4aad-8e48-7f0923250e3f" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock_d90da34b-1687-4334-869e-b53ea7a52277" xlink:href="sny-20231231.xsd#sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_670d5cdd-5f44-4aad-8e48-7f0923250e3f" xlink:to="loc_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock_d90da34b-1687-4334-869e-b53ea7a52277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Personnelcosts" xlink:type="simple" xlink:href="sny-20231231.xsd#Personnelcosts"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Personnelcosts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeBenefitsAbstract_6a331a32-13ff-4d75-8545-2479bdedfef8" xlink:href="sny-20231231.xsd#sny_EmployeeBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_74a9dba2-b941-46de-8ecd-89fb0e60f234" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_EmployeeBenefitsAbstract_6a331a32-13ff-4d75-8545-2479bdedfef8" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory_74a9dba2-b941-46de-8ecd-89fb0e60f234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Otheroperatingincome" xlink:type="simple" xlink:href="sny-20231231.xsd#Otheroperatingincome"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Otheroperatingincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4345bfd6-4f5e-4bff-abac-c3cfcc378fe3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_3ea1a6b3-dd39-4fc9-8e22-a52d29b07dcd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4345bfd6-4f5e-4bff-abac-c3cfcc378fe3" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_3ea1a6b3-dd39-4fc9-8e22-a52d29b07dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Otheroperatingexpenses" xlink:type="simple" xlink:href="sny-20231231.xsd#Otheroperatingexpenses"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Otheroperatingexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_09aa06d0-fa78-48e9-bc0d-f88dc2fc5db2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_470b5d14-a4ae-46e8-b5e2-fee6115a8559" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_09aa06d0-fa78-48e9-bc0d-f88dc2fc5db2" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_470b5d14-a4ae-46e8-b5e2-fee6115a8559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Restructuringcostsandsimilaritems" xlink:type="simple" xlink:href="sny-20231231.xsd#Restructuringcostsandsimilaritems"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Restructuringcostsandsimilaritems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_af0288fa-ff66-4139-89cb-621bc2b8e63d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_79170dfe-c7bd-4baf-a29f-6792c037acfd" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_af0288fa-ff66-4139-89cb-621bc2b8e63d" xlink:to="loc_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock_79170dfe-c7bd-4baf-a29f-6792c037acfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Othergainsandlossesandlitigation" xlink:type="simple" xlink:href="sny-20231231.xsd#Othergainsandlossesandlitigation"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Othergainsandlossesandlitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fc1e6077-e294-4ef4-a2bb-8650d975f4db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_37ac3013-9018-4303-a3c9-7d6323d92c71" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fc1e6077-e294-4ef4-a2bb-8650d975f4db" xlink:to="loc_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock_37ac3013-9018-4303-a3c9-7d6323d92c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Financialexpensesandincome" xlink:type="simple" xlink:href="sny-20231231.xsd#Financialexpensesandincome"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Financialexpensesandincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cad2466c-1201-47cf-86de-217f510e5d5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_ae7353f1-f0d1-4f53-b9c4-d9c6e01929ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cad2466c-1201-47cf-86de-217f510e5d5f" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_ae7353f1-f0d1-4f53-b9c4-d9c6e01929ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Incometaxexpense" xlink:type="simple" xlink:href="sny-20231231.xsd#Incometaxexpense"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Incometaxexpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxesAbstract_174f6f9a-d593-4e25-a824-71ebf11e3313" xlink:href="sny-20231231.xsd#sny_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_d7c486dc-4559-4822-ba90-a514bf3e967b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_174f6f9a-d593-4e25-a824-71ebf11e3313" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_d7c486dc-4559-4822-ba90-a514bf3e967b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Shareofprofitlossfrominvestmentsaccountedforusingtheequitymethod" xlink:type="simple" xlink:href="sny-20231231.xsd#Shareofprofitlossfrominvestmentsaccountedforusingtheequitymethod"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Shareofprofitlossfrominvestmentsaccountedforusingtheequitymethod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_194d6693-ad32-454b-b649-d8d2697bf299" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock_3537c2d0-1498-41e8-bfdf-0afc29c45b29" xlink:href="sny-20231231.xsd#sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_194d6693-ad32-454b-b649-d8d2697bf299" xlink:to="loc_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock_3537c2d0-1498-41e8-bfdf-0afc29c45b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Netincomeattributabletononcontrollinginterests" xlink:type="simple" xlink:href="sny-20231231.xsd#Netincomeattributabletononcontrollinginterests"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Netincomeattributabletononcontrollinginterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_0408a46e-2484-4875-9274-a06757119f5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock_0599ebce-56a2-48d6-8f68-da1b57881dec" xlink:href="sny-20231231.xsd#sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_0408a46e-2484-4875-9274-a06757119f5b" xlink:to="loc_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock_0599ebce-56a2-48d6-8f68-da1b57881dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Relatedpartytransactions" xlink:type="simple" xlink:href="sny-20231231.xsd#Relatedpartytransactions"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Relatedpartytransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_RelatedPartyAbstract_1fd7939f-869e-4e36-adfb-208f1182d51a" xlink:href="sny-20231231.xsd#sny_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_8dd022ab-289c-4b94-b6ce-ccb5a6a4cce0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_1fd7939f-869e-4e36-adfb-208f1182d51a" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_8dd022ab-289c-4b94-b6ce-ccb5a6a4cce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Disclosuresaboutmajorcustomersandcreditrisk" xlink:type="simple" xlink:href="sny-20231231.xsd#Disclosuresaboutmajorcustomersandcreditrisk"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Disclosuresaboutmajorcustomersandcreditrisk" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_db461a11-4b2b-4167-8f67-06d293521ea1" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExplanatory_9795ab26-d355-42c5-acd2-28b8f0a3567e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCreditRiskExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_db461a11-4b2b-4167-8f67-06d293521ea1" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExplanatory_9795ab26-d355-42c5-acd2-28b8f0a3567e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Segmentinformation" xlink:type="simple" xlink:href="sny-20231231.xsd#Segmentinformation"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Segmentinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingSegmentsAbstract_2bb5e9c2-1876-4de6-9655-d6b96043ae24" xlink:href="sny-20231231.xsd#sny_OperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_e1f6e2e8-6bb4-4fbe-889a-68fb957d9907" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_2bb5e9c2-1876-4de6-9655-d6b96043ae24" xlink:to="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_e1f6e2e8-6bb4-4fbe-889a-68fb957d9907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalaccountantsfeesandservices" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalaccountantsfeesandservices"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Principalaccountantsfeesandservices" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_0fb540a1-b456-47f1-82bc-3a15f31c4bc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_b8fa8333-5b4f-44ca-9666-77c129122f6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_0fb540a1-b456-47f1-82bc-3a15f31c4bc4" xlink:to="loc_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_b8fa8333-5b4f-44ca-9666-77c129122f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023" xlink:type="simple" xlink:href="sny-20231231.xsd#Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_773e6b66-f26f-49a7-a487-6ca419d83b1d" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_9c6d9ba2-1d40-4510-add4-28b1a8042afe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_773e6b66-f26f-49a7-a487-6ca419d83b1d" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_9c6d9ba2-1d40-4510-add4-28b1a8042afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/EventssubsequenttoDecember312023" xlink:type="simple" xlink:href="sny-20231231.xsd#EventssubsequenttoDecember312023"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/EventssubsequenttoDecember312023" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_7cabb3ca-c51b-4656-b9aa-5f814ec7ccea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2e22a3ee-5756-40bc-b6b4-f1e731fa428f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_7cabb3ca-c51b-4656-b9aa-5f814ec7ccea" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2e22a3ee-5756-40bc-b6b4-f1e731fa428f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance_8c3fa880-249c-47ff-a975-d675960afaa0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_StatementOfIFRSCompliance_8c3fa880-249c-47ff-a975-d675960afaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_8b3903f7-07ed-4108-9e5a-d2fd1be27e7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_8b3903f7-07ed-4108-9e5a-d2fd1be27e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_66350995-ea8c-45da-bb81-f19f5540022b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_66350995-ea8c-45da-bb81-f19f5540022b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_2269671a-4e41-4e6d-ad6d-5c084fd864a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_2269671a-4e41-4e6d-ad6d-5c084fd864a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_cc42f10e-6d9c-4f42-9a4a-5438074b5f4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory_cc42f10e-6d9c-4f42-9a4a-5438074b5f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock_9bafd796-52ec-4865-93df-57d77c09d349" xlink:href="sny-20231231.xsd#sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock_9bafd796-52ec-4865-93df-57d77c09d349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_e4462085-b8c2-4e23-8308-712cb9681043" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_e4462085-b8c2-4e23-8308-712cb9681043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_4dee29a5-41a2-49a4-b76b-86882a6e2237" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_4dee29a5-41a2-49a4-b76b-86882a6e2237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_86aace80-047f-4ee2-b816-95de9b0f9aba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_86aace80-047f-4ee2-b816-95de9b0f9aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_b8f46d43-1efa-43f0-a06a-9aee51bdf945" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_b8f46d43-1efa-43f0-a06a-9aee51bdf945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_8617c0fd-7c9e-4cd1-b79b-f8b886760554" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_8617c0fd-7c9e-4cd1-b79b-f8b886760554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_9821d395-0947-49bd-9d27-d8ad74f3fc6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_9821d395-0947-49bd-9d27-d8ad74f3fc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory_45f8fd65-98e8-4aae-ae3d-34206bb07d62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory_45f8fd65-98e8-4aae-ae3d-34206bb07d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_164b8569-4e48-481f-832b-55dc1b6691e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_164b8569-4e48-481f-832b-55dc1b6691e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_17f11abe-5b51-4ff4-88f2-045c8e418a15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_17f11abe-5b51-4ff4-88f2-045c8e418a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_dfbfcd04-4ae3-423f-9a7c-8c85ee419c8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_dfbfcd04-4ae3-423f-9a7c-8c85ee419c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_6d2a80e6-2db2-40b1-b4bc-56b102e48d84" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_6d2a80e6-2db2-40b1-b4bc-56b102e48d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_9aec5695-a10e-46a7-8816-f108a776d9c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_9aec5695-a10e-46a7-8816-f108a776d9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_4a94fa4d-e248-43d4-8f1b-5b494c407c8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_4a94fa4d-e248-43d4-8f1b-5b494c407c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory_7cd2c1f4-dfee-4329-9940-b9afdf732ff1" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory_7cd2c1f4-dfee-4329-9940-b9afdf732ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_abc44752-c20e-428f-9b9d-e06bf63d25e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_abc44752-c20e-428f-9b9d-e06bf63d25e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock_5e65bffe-f5bd-403c-b117-e1bf7206791a" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock_5e65bffe-f5bd-403c-b117-e1bf7206791a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_1b53841b-f742-4181-9c49-85cde95bb696" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_1b53841b-f742-4181-9c49-85cde95bb696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock_97b6a14e-1db8-4921-ad85-4714157d952f" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock_97b6a14e-1db8-4921-ad85-4714157d952f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock_69d744eb-ca87-4a12-966b-9701bff59b14" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock_69d744eb-ca87-4a12-966b-9701bff59b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock_58bb4c83-f005-474c-a283-ea884e433323" xlink:href="sny-20231231.xsd#sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock_58bb4c83-f005-474c-a283-ea884e433323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_658092c4-ae5e-48d2-b59a-2f8769081d24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_658092c4-ae5e-48d2-b59a-2f8769081d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_a43e4adc-18ce-47ae-9cfe-f758ae2d89e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_a43e4adc-18ce-47ae-9cfe-f758ae2d89e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_2ad0003b-dd29-45cc-bac6-50470c97a0ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_2ad0003b-dd29-45cc-bac6-50470c97a0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_6dd02a93-a214-4913-8a53-6ec892d55c41" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_6dd02a93-a214-4913-8a53-6ec892d55c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_390265ea-151f-49f7-b212-030c3b1226dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_390265ea-151f-49f7-b212-030c3b1226dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_e5f1ca4d-6f12-4dc0-bf1d-108ca1b73863" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_e5f1ca4d-6f12-4dc0-bf1d-108ca1b73863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_3a3fa17b-e394-415b-a22e-601ae3e0aa81" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_36a94786-43dd-4b04-81c4-d354f96e9feb" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_3a3fa17b-e394-415b-a22e-601ae3e0aa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_eb1cd64a-1412-4096-8a60-bae7b24d92aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock_5e52fa93-01bc-41d2-8bd5-a34ea5f806f6" xlink:href="sny-20231231.xsd#sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_eb1cd64a-1412-4096-8a60-bae7b24d92aa" xlink:to="loc_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock_5e52fa93-01bc-41d2-8bd5-a34ea5f806f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_3ac5ac98-d2f0-46d0-b112-2bc3052856a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_eb1cd64a-1412-4096-8a60-bae7b24d92aa" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_3ac5ac98-d2f0-46d0-b112-2bc3052856a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023Tables" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2023Tables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023Tables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_73f0ce73-dbfe-4f97-ae0c-e1c5f993f4ad" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_81bda0b9-fea8-42be-8453-0010901d6fcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_73f0ce73-dbfe-4f97-ae0c-e1c5f993f4ad" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_81bda0b9-fea8-42be-8453-0010901d6fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021Tables" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2022and2021Tables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021Tables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_1fe302c8-5303-486e-a493-bc57859e71ad" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_4decfd7a-d5a3-4d48-aa58-ac478b2a56a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_1fe302c8-5303-486e-a493-bc57859e71ad" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_4decfd7a-d5a3-4d48-aa58-ac478b2a56a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="sny-20231231.xsd#PropertyplantandequipmentTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_fa36bdef-016c-4e79-8d9c-39002621ec81" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock_078cf4d1-b14f-4fd2-9b58-b3563cbdb6ed" xlink:href="sny-20231231.xsd#sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_fa36bdef-016c-4e79-8d9c-39002621ec81" xlink:to="loc_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock_078cf4d1-b14f-4fd2-9b58-b3563cbdb6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_7bc01021-6097-4981-b010-77842d1ff3e6" xlink:href="sny-20231231.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_fa36bdef-016c-4e79-8d9c-39002621ec81" xlink:to="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock_7bc01021-6097-4981-b010-77842d1ff3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock_0760238c-0d65-4bcb-ae83-d4aa8fb0225f" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_fa36bdef-016c-4e79-8d9c-39002621ec81" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock_0760238c-0d65-4bcb-ae83-d4aa8fb0225f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock_dea07e65-7247-46c7-9e4f-2c2e1bdb640d" xlink:href="sny-20231231.xsd#sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_fa36bdef-016c-4e79-8d9c-39002621ec81" xlink:to="loc_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock_dea07e65-7247-46c7-9e4f-2c2e1bdb640d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_b535e35c-d8c8-4350-9c50-871e54ae1c54" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_fa36bdef-016c-4e79-8d9c-39002621ec81" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_b535e35c-d8c8-4350-9c50-871e54ae1c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_86a384d2-0db5-4fa6-aeb1-a8369a0ce7ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_022cf9e9-323d-49c2-9a93-b1f027d4c4cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_86a384d2-0db5-4fa6-aeb1-a8369a0ce7ca" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_022cf9e9-323d-49c2-9a93-b1f027d4c4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock_f7359e4a-477a-46dc-86c5-0e11acfcb06f" xlink:href="sny-20231231.xsd#sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_86a384d2-0db5-4fa6-aeb1-a8369a0ce7ca" xlink:to="loc_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock_f7359e4a-477a-46dc-86c5-0e11acfcb06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_f2ec6e52-5482-4824-be33-34452a571ff1" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_86a384d2-0db5-4fa6-aeb1-a8369a0ce7ca" xlink:to="loc_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock_f2ec6e52-5482-4824-be33-34452a571ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock_2ff40a56-8479-40ca-9e0e-a48bb2809227" xlink:href="sny-20231231.xsd#sny_DisclosureOfPrincipalMarketedProductsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_86a384d2-0db5-4fa6-aeb1-a8369a0ce7ca" xlink:to="loc_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock_2ff40a56-8479-40ca-9e0e-a48bb2809227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock_394d2263-fec1-4ba1-880a-f2ef62db21e5" xlink:href="sny-20231231.xsd#sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_86a384d2-0db5-4fa6-aeb1-a8369a0ce7ca" xlink:to="loc_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock_394d2263-fec1-4ba1-880a-f2ef62db21e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentTables" xlink:type="simple" xlink:href="sny-20231231.xsd#ImpairmentofintangibleassetsandpropertyplantandequipmentTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentOfAssetsAbstract_47c22341-ae50-44e1-bbf7-aa1e114bd971" xlink:href="sny-20231231.xsd#sny_ImpairmentOfAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock_0479e1ec-885e-4e77-82c5-a20b298b4efe" xlink:href="sny-20231231.xsd#sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ImpairmentOfAssetsAbstract_47c22341-ae50-44e1-bbf7-aa1e114bd971" xlink:to="loc_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock_0479e1ec-885e-4e77-82c5-a20b298b4efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables" xlink:type="simple" xlink:href="sny-20231231.xsd#InvestmentsaccountedforusingtheequitymethodTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_c0c6b875-f562-4bf4-87c9-5fe8e469d08b" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_b1d1abf6-be1d-4094-842d-28b1fd5e9e11" xlink:href="sny-20231231.xsd#sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_c0c6b875-f562-4bf4-87c9-5fe8e469d08b" xlink:to="loc_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock_b1d1abf6-be1d-4094-842d-28b1fd5e9e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock_bea25c81-723a-45df-b1f6-5f8818250fc3" xlink:href="sny-20231231.xsd#sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_c0c6b875-f562-4bf4-87c9-5fe8e469d08b" xlink:to="loc_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock_bea25c81-723a-45df-b1f6-5f8818250fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_662a1d61-9cdd-4f8f-9317-40e7e43874ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_c0c6b875-f562-4bf4-87c9-5fe8e469d08b" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_662a1d61-9cdd-4f8f-9317-40e7e43874ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthernoncurrentassetsTables" xlink:type="simple" xlink:href="sny-20231231.xsd#OthernoncurrentassetsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OthernoncurrentassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_fec2e6c8-7fec-4971-90f8-25b9b6e61f98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_33a398e8-6f18-4766-8fc6-870c4b15e499" xlink:href="sny-20231231.xsd#sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_fec2e6c8-7fec-4971-90f8-25b9b6e61f98" xlink:to="loc_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock_33a398e8-6f18-4766-8fc6-870c4b15e499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeTables" xlink:type="simple" xlink:href="sny-20231231.xsd#AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_04fa56d0-6157-4521-bc7a-f07e5deaa3a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock_8008da18-3633-44f2-8aee-56a14267318d" xlink:href="sny-20231231.xsd#sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_04fa56d0-6157-4521-bc7a-f07e5deaa3a8" xlink:to="loc_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock_8008da18-3633-44f2-8aee-56a14267318d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InventoriesTables" xlink:type="simple" xlink:href="sny-20231231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_00ba7863-604c-4942-b703-7d699c41c5e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock_979e3a11-aa06-4555-ab4d-2053c248ecde" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_00ba7863-604c-4942-b703-7d699c41c5e1" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock_979e3a11-aa06-4555-ab4d-2053c248ecde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableTables" xlink:type="simple" xlink:href="sny-20231231.xsd#AccountsreceivableTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsreceivableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_5e4e3bdc-661a-49d4-94d9-4499224231db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_9fcc3489-f758-4dc2-90d9-ca8a0db13baf" xlink:href="sny-20231231.xsd#sny_DisclosureOfCurrentTradeReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_5e4e3bdc-661a-49d4-94d9-4499224231db" xlink:to="loc_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock_9fcc3489-f758-4dc2-90d9-ca8a0db13baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_04780d90-f3fe-4a95-ad7a-35a7c8b48bb3" xlink:href="sny-20231231.xsd#sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_5e4e3bdc-661a-49d4-94d9-4499224231db" xlink:to="loc_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock_04780d90-f3fe-4a95-ad7a-35a7c8b48bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthercurrentassetsTables" xlink:type="simple" xlink:href="sny-20231231.xsd#OthercurrentassetsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OthercurrentassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_fe0ba958-bb17-4b12-9c76-8892df1088d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock_92d035b9-9118-4271-9232-82f9b3d5940b" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_fe0ba958-bb17-4b12-9c76-8892df1088d2" xlink:to="loc_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock_92d035b9-9118-4271-9232-82f9b3d5940b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueTables" xlink:type="simple" xlink:href="sny-20231231.xsd#FinancialassetsandliabilitiesmeasuredatfairvalueTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueMeasurementAbstract_d9553671-9842-4735-a077-32256652923e" xlink:href="sny-20231231.xsd#sny_FairValueMeasurementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock_86d3d8a0-19c9-4585-bfd5-3f41040668b7" xlink:href="sny-20231231.xsd#sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FairValueMeasurementAbstract_d9553671-9842-4735-a077-32256652923e" xlink:to="loc_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock_86d3d8a0-19c9-4585-bfd5-3f41040668b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/CashandcashequivalentsTables" xlink:type="simple" xlink:href="sny-20231231.xsd#CashandcashequivalentsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/CashandcashequivalentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_34c71c0c-4ba4-4fb2-84eb-42ac1a5de59e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock_6736e631-5668-4a40-82ed-5972b97b0f56" xlink:href="sny-20231231.xsd#sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_34c71c0c-4ba4-4fb2-84eb-42ac1a5de59e" xlink:to="loc_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock_6736e631-5668-4a40-82ed-5972b97b0f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NetdeferredtaxpositionTables" xlink:type="simple" xlink:href="sny-20231231.xsd#NetdeferredtaxpositionTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NetdeferredtaxpositionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxesAbstract_f61299c9-ef27-4e2a-870c-d699c2bbd130" xlink:href="sny-20231231.xsd#sny_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_61a94dd8-ab89-4f47-bef4-6ac5ddf4fb69" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_f61299c9-ef27-4e2a-870c-d699c2bbd130" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_61a94dd8-ab89-4f47-bef4-6ac5ddf4fb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock_22809ce8-77d5-4a62-adb8-f4d6622c0d16" xlink:href="sny-20231231.xsd#sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_f61299c9-ef27-4e2a-870c-d699c2bbd130" xlink:to="loc_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock_22809ce8-77d5-4a62-adb8-f4d6622c0d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityTables" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_e78c1d1f-e3fe-4039-8d6f-8f3f5f9da5bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_e78c1d1f-e3fe-4039-8d6f-8f3f5f9da5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock_4e251358-687e-4a16-9809-93f3d2d94e9f" xlink:href="sny-20231231.xsd#sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock_4e251358-687e-4a16-9809-93f3d2d94e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_1d12e757-7bdb-4aaa-93d0-31419c2087a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_1d12e757-7bdb-4aaa-93d0-31419c2087a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_c69cd43d-2a37-4edf-9934-a7be50605354" xlink:href="sny-20231231.xsd#sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock_c69cd43d-2a37-4edf-9934-a7be50605354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_4a4619f6-f30d-4d9c-90a3-144767dad2ae" xlink:href="sny-20231231.xsd#sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock_4a4619f6-f30d-4d9c-90a3-144767dad2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements_88c4281a-0036-48c5-9bf9-431808504104" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements_88c4281a-0036-48c5-9bf9-431808504104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock_3637edf5-79a9-499b-94af-079cfdadc028" xlink:href="sny-20231231.xsd#sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock_3637edf5-79a9-499b-94af-079cfdadc028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock_eb489db0-5893-43ee-93be-8797ddb60f2c" xlink:href="sny-20231231.xsd#sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock_eb489db0-5893-43ee-93be-8797ddb60f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_3e752104-44ad-4f9f-bf5c-25c8fd20dbc3" xlink:href="sny-20231231.xsd#sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock_3e752104-44ad-4f9f-bf5c-25c8fd20dbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock_5ac8e332-4a40-43ab-805a-07e07540a7ef" xlink:href="sny-20231231.xsd#sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock_5ac8e332-4a40-43ab-805a-07e07540a7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock_d71426fc-6c5a-45aa-be4c-982edb992131" xlink:href="sny-20231231.xsd#sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock_d71426fc-6c5a-45aa-be4c-982edb992131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_f2d7b8b1-6463-4c74-8845-46f378a35b17" xlink:href="sny-20231231.xsd#sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_f2d7b8b1-6463-4c74-8845-46f378a35b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_8b52e720-a5f5-4499-a811-ef0b3bfaca32" xlink:href="sny-20231231.xsd#sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_10da29c7-251e-4308-8449-e111adf30b8b" xlink:to="loc_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock_8b52e720-a5f5-4499-a811-ef0b3bfaca32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_5b1e024e-37f5-4992-8533-09f73a0ef4dd" xlink:href="sny-20231231.xsd#sny_DisclosureOfChangesInFinancialPositionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfChangesInFinancialPositionTableTextBlock_5b1e024e-37f5-4992-8533-09f73a0ef4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_87e6a2cd-117b-4145-852b-23108cff8d68" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock_87e6a2cd-117b-4145-852b-23108cff8d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_de460898-2dbc-455b-a319-25aee2f84779" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_de460898-2dbc-455b-a319-25aee2f84779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_42a09405-c79c-46d2-b9e2-4e7f7e38a7df" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock_42a09405-c79c-46d2-b9e2-4e7f7e38a7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock_4f4ac613-1d54-455e-a8ef-db671d26dc88" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock_4f4ac613-1d54-455e-a8ef-db671d26dc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock_43d64dc2-2fca-4cb7-8a67-1251b67817e5" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock_43d64dc2-2fca-4cb7-8a67-1251b67817e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock_2326bb07-a09e-4157-b8bd-2b8278fe179e" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock_2326bb07-a09e-4157-b8bd-2b8278fe179e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock_5f94da74-cc21-4290-9b74-d4493cbaab59" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock_5f94da74-cc21-4290-9b74-d4493cbaab59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock_8a4ed5c5-0449-42c2-99a7-584b9cbdc3ef" xlink:href="sny-20231231.xsd#sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock_8a4ed5c5-0449-42c2-99a7-584b9cbdc3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock_00ba2839-f1aa-414e-8937-e3fdf4c89dd8" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock_00ba2839-f1aa-414e-8937-e3fdf4c89dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock_42b9c379-19e5-451b-a16d-022c15175849" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock_42b9c379-19e5-451b-a16d-022c15175849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_1605adf5-9574-4acd-a7ae-cedf8cd7307e" xlink:href="sny-20231231.xsd#sny_DisclosureOfMarketValueOfNetDebtTableTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock_1605adf5-9574-4acd-a7ae-cedf8cd7307e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock_53019199-8c6b-4faa-8d4c-64a00993a2ff" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock_53019199-8c6b-4faa-8d4c-64a00993a2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock_d5627a0e-1bed-4134-a8eb-15ee961f0c12" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a9f59ee0-d278-4ae3-b50b-b20d8675e63f" xlink:to="loc_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock_d5627a0e-1bed-4134-a8eb-15ee961f0c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables" xlink:type="simple" xlink:href="sny-20231231.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_83869ac7-d9d6-4fd9-a232-2bd8e32fd4f1" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock_9401660c-4aaa-4ec2-83d0-c3cec7063801" xlink:href="sny-20231231.xsd#sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_83869ac7-d9d6-4fd9-a232-2bd8e32fd4f1" xlink:to="loc_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock_9401660c-4aaa-4ec2-83d0-c3cec7063801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock_9b3fecfd-b1cf-41e4-9f50-65f740b859c7" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_83869ac7-d9d6-4fd9-a232-2bd8e32fd4f1" xlink:to="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock_9b3fecfd-b1cf-41e4-9f50-65f740b859c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_2dd83fd2-f170-4928-b074-edda51ba9453" xlink:href="sny-20231231.xsd#sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock_2dd83fd2-f170-4928-b074-edda51ba9453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_425ce394-bac8-43aa-8d0c-096570b4ed5e" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTableTextBlock_425ce394-bac8-43aa-8d0c-096570b4ed5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfActuarialAssumptionsTableTextBlock_60eb5be6-864d-4de6-bcf1-528565ee47a3" xlink:href="sny-20231231.xsd#sny_DisclosureOfActuarialAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfActuarialAssumptionsTableTextBlock_60eb5be6-864d-4de6-bcf1-528565ee47a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock_4b5e649c-cd3e-4c5d-999e-b554e60696df" xlink:href="sny-20231231.xsd#sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock_4b5e649c-cd3e-4c5d-999e-b554e60696df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_6ec9e0b9-bf23-4f63-8a91-baccfb2a5e42" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_6ec9e0b9-bf23-4f63-8a91-baccfb2a5e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock_edd0f980-8cf6-4f4c-b4b4-186e1701bf5e" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock_edd0f980-8cf6-4f4c-b4b4-186e1701bf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock_b89ccabd-4611-4164-a932-e51a97dd1cae" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock_b89ccabd-4611-4164-a932-e51a97dd1cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_2a1d5dc8-a5bf-4011-bd7e-b60d98a93288" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory_2a1d5dc8-a5bf-4011-bd7e-b60d98a93288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock_93f3b433-defe-4720-885b-95328db2ef48" xlink:href="sny-20231231.xsd#sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock_93f3b433-defe-4720-885b-95328db2ef48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock_581d09ac-bcaa-4aee-a2f9-877e1c309879" xlink:href="sny-20231231.xsd#sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock_581d09ac-bcaa-4aee-a2f9-877e1c309879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock_9852ba14-086b-41fa-9845-07c00b6fd446" xlink:href="sny-20231231.xsd#sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock_9852ba14-086b-41fa-9845-07c00b6fd446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock_da06f7f3-69aa-49fe-a965-d997ffe41a59" xlink:href="sny-20231231.xsd#sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock_da06f7f3-69aa-49fe-a965-d997ffe41a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock_efaed692-795e-4db8-be4a-475fc37e9a06" xlink:href="sny-20231231.xsd#sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock_efaed692-795e-4db8-be4a-475fc37e9a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock_cadccf61-eb5a-4ede-9a37-7967f3e5eba1" xlink:href="sny-20231231.xsd#sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock_cadccf61-eb5a-4ede-9a37-7967f3e5eba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock_153ba4af-1e1a-479d-b15a-a572ab5e36b1" xlink:href="sny-20231231.xsd#sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock_153ba4af-1e1a-479d-b15a-a572ab5e36b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock_c7870656-18c9-425a-9c8d-c6432e384331" xlink:href="sny-20231231.xsd#sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock_c7870656-18c9-425a-9c8d-c6432e384331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringProvisionsTableTextBlock_f77990a1-e45f-4785-b4a2-873853fcc98f" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringProvisionsTableTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfRestructuringProvisionsTableTextBlock_f77990a1-e45f-4785-b4a2-873853fcc98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock_180dfc0b-6eb3-4b66-96a4-29b4003d69ca" xlink:href="sny-20231231.xsd#sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock_180dfc0b-6eb3-4b66-96a4-29b4003d69ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock_b80482d7-16a2-4f74-aecf-1e77764b7a8b" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherLongTermProvisionsTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock_b80482d7-16a2-4f74-aecf-1e77764b7a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock_32738a20-9253-4065-9418-35074ed34da4" xlink:href="sny-20231231.xsd#sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_67245b4e-7c61-43e5-9fba-10b69d6e83a4" xlink:to="loc_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock_32738a20-9253-4065-9418-35074ed34da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksTables" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_cc7d41ad-54ad-4ed9-9acb-817da902a9af" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock_5235c09c-92e4-455c-9c8d-eb046a45c560" xlink:href="sny-20231231.xsd#sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_cc7d41ad-54ad-4ed9-9acb-817da902a9af" xlink:to="loc_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock_5235c09c-92e4-455c-9c8d-eb046a45c560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_c3ce1823-e98a-48b2-b37b-9733c45cdb48" xlink:href="sny-20231231.xsd#sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_cc7d41ad-54ad-4ed9-9acb-817da902a9af" xlink:to="loc_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock_c3ce1823-e98a-48b2-b37b-9733c45cdb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_9c41cbc7-3d6d-4569-9715-0d9a614edd44" xlink:href="sny-20231231.xsd#sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_cc7d41ad-54ad-4ed9-9acb-817da902a9af" xlink:to="loc_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock_9c41cbc7-3d6d-4569-9715-0d9a614edd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_cc8d6675-c465-4988-a471-a601ed3722d1" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_cc7d41ad-54ad-4ed9-9acb-817da902a9af" xlink:to="loc_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock_cc8d6675-c465-4988-a471-a601ed3722d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock_01b10ebd-cea1-4b8a-b284-a0a79a304cda" xlink:href="sny-20231231.xsd#sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_cc7d41ad-54ad-4ed9-9acb-817da902a9af" xlink:to="loc_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock_01b10ebd-cea1-4b8a-b284-a0a79a304cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsTables" xlink:type="simple" xlink:href="sny-20231231.xsd#OffbalancesheetcommitmentsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_4511a7b7-14b3-4ed5-a7ac-e35e19b3e468" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock_3e3f1969-262a-45ae-bf5a-930fb71748d3" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_4511a7b7-14b3-4ed5-a7ac-e35e19b3e468" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock_3e3f1969-262a-45ae-bf5a-930fb71748d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock_33bf2dfe-d8e5-4031-abbe-580f93f23473" xlink:href="sny-20231231.xsd#sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_4511a7b7-14b3-4ed5-a7ac-e35e19b3e468" xlink:to="loc_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock_33bf2dfe-d8e5-4031-abbe-580f93f23473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock_2ab72167-ddc9-4a0e-b249-82a9e424ad0d" xlink:href="sny-20231231.xsd#sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_4511a7b7-14b3-4ed5-a7ac-e35e19b3e468" xlink:to="loc_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock_2ab72167-ddc9-4a0e-b249-82a9e424ad0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsTables" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsfordiscountsrebatesandsalesreturnsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_5b84a908-8d17-406d-90bd-e441eb969ace" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock_9a8ee584-0721-400d-9023-31493124db2f" xlink:href="sny-20231231.xsd#sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_5b84a908-8d17-406d-90bd-e441eb969ace" xlink:to="loc_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock_9a8ee584-0721-400d-9023-31493124db2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PersonnelcostsTables" xlink:type="simple" xlink:href="sny-20231231.xsd#PersonnelcostsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PersonnelcostsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeBenefitsAbstract_cba4c8e4-d0b1-4058-bbcc-46bf729e6286" xlink:href="sny-20231231.xsd#sny_EmployeeBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock_791c017f-7b50-4eac-8a68-259ce13c1a44" xlink:href="sny-20231231.xsd#sny_DisclosureOfPersonnelCostsDetailsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_EmployeeBenefitsAbstract_cba4c8e4-d0b1-4058-bbcc-46bf729e6286" xlink:to="loc_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock_791c017f-7b50-4eac-8a68-259ce13c1a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtheroperatingexpensesTables" xlink:type="simple" xlink:href="sny-20231231.xsd#OtheroperatingexpensesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtheroperatingexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9702a284-612f-4738-9705-2cdf25dc38b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingExpensesTableTextBlock_e7652486-c063-4e11-b7bd-76fa3a74c4e7" xlink:href="sny-20231231.xsd#sny_OtherOperatingExpensesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9702a284-612f-4738-9705-2cdf25dc38b4" xlink:to="loc_sny_OtherOperatingExpensesTableTextBlock_e7652486-c063-4e11-b7bd-76fa3a74c4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables" xlink:type="simple" xlink:href="sny-20231231.xsd#RestructuringcostsandsimilaritemsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e63aa5ed-1c23-405e-8693-545dd7646bd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_474d7621-5000-484b-b639-1b7eec5fc950" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringCostsDetailsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e63aa5ed-1c23-405e-8693-545dd7646bd4" xlink:to="loc_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock_474d7621-5000-484b-b639-1b7eec5fc950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeTables" xlink:type="simple" xlink:href="sny-20231231.xsd#FinancialexpensesandincomeTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialexpensesandincomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_7f77b80f-25fd-44f9-af52-054e1ef9f541" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_ac90c5bd-8abf-4db0-aa86-b486c742f7e6" xlink:href="sny-20231231.xsd#sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_7f77b80f-25fd-44f9-af52-054e1ef9f541" xlink:to="loc_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock_ac90c5bd-8abf-4db0-aa86-b486c742f7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncometaxexpenseTables" xlink:type="simple" xlink:href="sny-20231231.xsd#IncometaxexpenseTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncometaxexpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxesAbstract_39b3ac7c-d578-48b1-a951-371608a4c744" xlink:href="sny-20231231.xsd#sny_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_f5028e51-2f8a-4ab9-863b-713753c2484b" xlink:href="sny-20231231.xsd#sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_39b3ac7c-d578-48b1-a951-371608a4c744" xlink:to="loc_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock_f5028e51-2f8a-4ab9-863b-713753c2484b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_42bd980a-1e34-4fc1-bc18-b0acbd36c007" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_39b3ac7c-d578-48b1-a951-371608a4c744" xlink:to="loc_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock_42bd980a-1e34-4fc1-bc18-b0acbd36c007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsTables" xlink:type="simple" xlink:href="sny-20231231.xsd#NetincomeattributabletononcontrollinginterestsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_6b85d156-6483-4234-afc3-cd7fdce3b6bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock_363178db-ea3d-40ed-986f-f541d3318247" xlink:href="sny-20231231.xsd#sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_6b85d156-6483-4234-afc3-cd7fdce3b6bc" xlink:to="loc_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock_363178db-ea3d-40ed-986f-f541d3318247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RelatedpartytransactionsTables" xlink:type="simple" xlink:href="sny-20231231.xsd#RelatedpartytransactionsTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RelatedpartytransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_RelatedPartyAbstract_349e7c2b-445c-42b2-bbff-a02b1e8e170b" xlink:href="sny-20231231.xsd#sny_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock_e1321c9e-afe9-4bd4-be22-44ed7b9a3e7f" xlink:href="sny-20231231.xsd#sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_349e7c2b-445c-42b2-bbff-a02b1e8e170b" xlink:to="loc_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock_e1321c9e-afe9-4bd4-be22-44ed7b9a3e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_628c8b1a-67ec-4998-8b61-aae7ccf513af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_349e7c2b-445c-42b2-bbff-a02b1e8e170b" xlink:to="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory_628c8b1a-67ec-4998-8b61-aae7ccf513af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationTables" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingSegmentsAbstract_58c14735-3fad-4461-bd04-dea35946d9b5" xlink:href="sny-20231231.xsd#sny_OperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_f308b2f9-9fd1-4c38-bd83-31b565dff978" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_58c14735-3fad-4461-bd04-dea35946d9b5" xlink:to="loc_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock_f308b2f9-9fd1-4c38-bd83-31b565dff978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_da3e66d8-4443-4242-8524-26d8752aca98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_58c14735-3fad-4461-bd04-dea35946d9b5" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_da3e66d8-4443-4242-8524-26d8752aca98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_a4851d27-6d0d-4849-a4ef-5ed02b5e1da7" xlink:href="sny-20231231.xsd#sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_58c14735-3fad-4461-bd04-dea35946d9b5" xlink:to="loc_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock_a4851d27-6d0d-4849-a4ef-5ed02b5e1da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_99a90a58-8a82-4d48-8d8d-72a4b046b2b0" xlink:href="sny-20231231.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_58c14735-3fad-4461-bd04-dea35946d9b5" xlink:to="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock_99a90a58-8a82-4d48-8d8d-72a4b046b2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_b115144d-e73b-4c00-b2ff-34a55138be58" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_58c14735-3fad-4461-bd04-dea35946d9b5" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_b115144d-e73b-4c00-b2ff-34a55138be58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesTables" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalaccountantsfeesandservicesTables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_48eb959a-c8d1-4214-a516-8684e257a876" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsRemunerationTableTextBlock_1849fb69-c07e-48fb-bbf7-6e8c265d3936" xlink:href="sny-20231231.xsd#sny_AuditorsRemunerationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_48eb959a-c8d1-4214-a516-8684e257a876" xlink:to="loc_sny_AuditorsRemunerationTableTextBlock_1849fb69-c07e-48fb-bbf7-6e8c265d3936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023Tables" xlink:type="simple" xlink:href="sny-20231231.xsd#Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023Tables"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023Tables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_acc088ba-bbb1-48d5-8694-de8076b9721f" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_bfe2bd90-1980-4029-8140-5d6bdc769616" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_acc088ba-bbb1-48d5-8694-de8076b9721f" xlink:to="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_bfe2bd90-1980-4029-8140-5d6bdc769616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock_b9d94d5d-0e3c-429e-990b-e19aa15e4c29" xlink:href="sny-20231231.xsd#sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_acc088ba-bbb1-48d5-8694-de8076b9721f" xlink:to="loc_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock_b9d94d5d-0e3c-429e-990b-e19aa15e4c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/BasisofpreparationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#BasisofpreparationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/BasisofpreparationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_110ff5fb-9f0d-4b13-a34c-6256767a6177" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_110ff5fb-9f0d-4b13-a34c-6256767a6177" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_b2d57a9c-7689-4e68-91cb-ba83546329e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:to="loc_ifrs-full_GeographicalAreasAxis_b2d57a9c-7689-4e68-91cb-ba83546329e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_65e4d995-417b-4106-8c3f-25ab6532843a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_b2d57a9c-7689-4e68-91cb-ba83546329e3" xlink:to="loc_ifrs-full_GeographicalAreasMember_65e4d995-417b-4106-8c3f-25ab6532843a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AR_0809aa91-8809-4ef9-a759-44e94f526b7c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_65e4d995-417b-4106-8c3f-25ab6532843a" xlink:to="loc_country_AR_0809aa91-8809-4ef9-a759-44e94f526b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_869051ad-066c-4d72-928a-2bf35d3ee736" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_TR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_65e4d995-417b-4106-8c3f-25ab6532843a" xlink:to="loc_country_TR_869051ad-066c-4d72-928a-2bf35d3ee736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_6ff60dd5-090d-426c-828e-6187922a73ce" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:to="loc_sny_TypesOfAgreementAxis_6ff60dd5-090d-426c-828e-6187922a73ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_62ea85b1-2ca6-4b7e-9bdc-7fff753688f7" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementAxis_6ff60dd5-090d-426c-828e-6187922a73ce" xlink:to="loc_sny_TypesOfAgreementDomain_62ea85b1-2ca6-4b7e-9bdc-7fff753688f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementWithGSKMember_097a41e0-1711-4c5e-af46-f29bc5894bd0" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementWithGSKMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_62ea85b1-2ca6-4b7e-9bdc-7fff753688f7" xlink:to="loc_sny_CollaborationAgreementWithGSKMember_097a41e0-1711-4c5e-af46-f29bc5894bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_0054be0f-0825-46c8-aa76-3dde71c30736" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:to="loc_ifrs-full_CounterpartiesAxis_0054be0f-0825-46c8-aa76-3dde71c30736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_0a9406cd-760a-43e3-9689-43cb934a041f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_0054be0f-0825-46c8-aa76-3dde71c30736" xlink:to="loc_ifrs-full_CounterpartiesMember_0a9406cd-760a-43e3-9689-43cb934a041f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USGovernmentMember_bce85fda-3363-41f0-bb21-c5b1b486661c" xlink:href="sny-20231231.xsd#sny_USGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_0a9406cd-760a-43e3-9689-43cb934a041f" xlink:to="loc_sny_USGovernmentMember_bce85fda-3363-41f0-bb21-c5b1b486661c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_02cb42ab-d019-4639-92d2-a2477d8128af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:to="loc_srt_RangeAxis_02cb42ab-d019-4639-92d2-a2477d8128af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2958246b-9ed1-4d09-a093-4e2fa3eb8a20" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_02cb42ab-d019-4639-92d2-a2477d8128af" xlink:to="loc_srt_RangeMember_2958246b-9ed1-4d09-a093-4e2fa3eb8a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60611265-945e-4809-800a-5b08452b54f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2958246b-9ed1-4d09-a093-4e2fa3eb8a20" xlink:to="loc_srt_MaximumMember_60611265-945e-4809-800a-5b08452b54f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_c9a0cef2-a7f4-47b5-bb2e-f18776fa30b8" xlink:to="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_cfd5cb0b-ad27-49d0-a748-3a2a7a16b895" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_cfd5cb0b-ad27-49d0-a748-3a2a7a16b895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInEffectiveTaxRate_c2461929-6731-47ff-9869-873bad5ff0f0" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseInEffectiveTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_IncreaseDecreaseInEffectiveTaxRate_c2461929-6731-47ff-9869-873bad5ff0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesNetEmissionsBy2045_335b0e93-9336-440b-8f7c-5e1dd3045a68" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesNetEmissionsBy2045"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesNetEmissionsBy2045_335b0e93-9336-440b-8f7c-5e1dd3045a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030_cb165d26-41af-428c-9fd9-4608d1afa073" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030_cb165d26-41af-428c-9fd9-4608d1afa073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030_8cff0d0e-e514-4e30-af3c-adc562bfdc39" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030_8cff0d0e-e514-4e30-af3c-adc562bfdc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030_a53b7f01-3816-48e7-83d9-f2acba7948ad" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030_a53b7f01-3816-48e7-83d9-f2acba7948ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030_c7b561e9-1709-4dd4-9fe3-1548d75bd94c" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030_c7b561e9-1709-4dd4-9fe3-1548d75bd94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios_6ea20f27-5369-4489-9c76-0c81a0b1b2e8" xlink:href="sny-20231231.xsd#sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios_6ea20f27-5369-4489-9c76-0c81a0b1b2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears_eb9560ba-6451-4a87-b92b-c81432828958" xlink:href="sny-20231231.xsd#sny_CumulativeConsumerPriceInflationOverTheLastThreeYears"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears_eb9560ba-6451-4a87-b92b-c81432828958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfVaccineDosesToBeSupplied_df99360d-cc58-4791-9e3c-56346d9e17e8" xlink:href="sny-20231231.xsd#sny_NumberOfVaccineDosesToBeSupplied"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_NumberOfVaccineDosesToBeSupplied_df99360d-cc58-4791-9e3c-56346d9e17e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_1847b5e6-bd44-47cb-b51f-3aacfcc3cfa9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_ifrs-full_OtherRevenue_1847b5e6-bd44-47cb-b51f-3aacfcc3cfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_99f6b4e0-c3a2-452d-a4e2-4817a2b26aad" xlink:href="sny-20231231.xsd#sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses_99f6b4e0-c3a2-452d-a4e2-4817a2b26aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_a8818da8-d65c-44fb-b908-33f186b80d38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_ifrs-full_CurrentContractLiabilities_a8818da8-d65c-44fb-b908-33f186b80d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRevenuePerformanceObligationNoLongerRequired_8cc1a26b-4d31-4768-b5fd-d8a4a0ead029" xlink:href="sny-20231231.xsd#sny_OtherRevenuePerformanceObligationNoLongerRequired"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_f4292f1d-32b9-4680-a9df-640b44bfc6dd" xlink:to="loc_sny_OtherRevenuePerformanceObligationNoLongerRequired_8cc1a26b-4d31-4768-b5fd-d8a4a0ead029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_f231c2e6-fa5a-42ff-ba45-17dd3e3bc38a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_fa9b8f26-1356-40a4-9b0f-0cae4e83cada" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_f231c2e6-fa5a-42ff-ba45-17dd3e3bc38a" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_fa9b8f26-1356-40a4-9b0f-0cae4e83cada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_c138da3f-3e4f-48f2-a55f-1a50f532d4fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_fa9b8f26-1356-40a4-9b0f-0cae4e83cada" xlink:to="loc_ifrs-full_RangeAxis_c138da3f-3e4f-48f2-a55f-1a50f532d4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_da418f5d-ae2b-480c-8344-0bf4e1b99e93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_c138da3f-3e4f-48f2-a55f-1a50f532d4fc" xlink:to="loc_ifrs-full_RangesMember_da418f5d-ae2b-480c-8344-0bf4e1b99e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_c24d304b-0092-4aed-b3e5-c531863f658c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_da418f5d-ae2b-480c-8344-0bf4e1b99e93" xlink:to="loc_ifrs-full_BottomOfRangeMember_c24d304b-0092-4aed-b3e5-c531863f658c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_fba6d0e8-99fa-4df1-88fe-28fb44c336d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_da418f5d-ae2b-480c-8344-0bf4e1b99e93" xlink:to="loc_ifrs-full_TopOfRangeMember_fba6d0e8-99fa-4df1-88fe-28fb44c336d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_99ad1362-7de4-4971-b843-26c624b4b132" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_fa9b8f26-1356-40a4-9b0f-0cae4e83cada" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_99ad1362-7de4-4971-b843-26c624b4b132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_434fd109-11d8-40fc-a461-f8a366c692f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_99ad1362-7de4-4971-b843-26c624b4b132" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_434fd109-11d8-40fc-a461-f8a366c692f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_8d64745d-b3d4-4449-ac40-4054d2253305" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_434fd109-11d8-40fc-a461-f8a366c692f9" xlink:to="loc_ifrs-full_ComputerSoftwareMember_8d64745d-b3d4-4449-ac40-4054d2253305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8dc11af7-a8ea-4ef6-9dd7-6bb4065f0bab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_fa9b8f26-1356-40a4-9b0f-0cae4e83cada" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8dc11af7-a8ea-4ef6-9dd7-6bb4065f0bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_acbb0f9b-f4cb-4b4f-8b11-a12bc164f142" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_8dc11af7-a8ea-4ef6-9dd7-6bb4065f0bab" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_acbb0f9b-f4cb-4b4f-8b11-a12bc164f142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_1cdf6f43-4d04-4b92-861b-6b186430510c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d2716510-9e23-4b36-9bff-efeac730c8b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_1cdf6f43-4d04-4b92-861b-6b186430510c" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d2716510-9e23-4b36-9bff-efeac730c8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_c4e50ccd-7ca3-4219-a7ae-e844fb0dcc98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d2716510-9e23-4b36-9bff-efeac730c8b9" xlink:to="loc_ifrs-full_RangeAxis_c4e50ccd-7ca3-4219-a7ae-e844fb0dcc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_0741a82e-e3f3-4786-8a68-78a7c740cb68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_c4e50ccd-7ca3-4219-a7ae-e844fb0dcc98" xlink:to="loc_ifrs-full_RangesMember_0741a82e-e3f3-4786-8a68-78a7c740cb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_05fdd040-8cec-41a1-a395-91847daef187" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_0741a82e-e3f3-4786-8a68-78a7c740cb68" xlink:to="loc_ifrs-full_BottomOfRangeMember_05fdd040-8cec-41a1-a395-91847daef187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_848ab844-97c3-4347-9c65-a1e1b5d89b46" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_0741a82e-e3f3-4786-8a68-78a7c740cb68" xlink:to="loc_ifrs-full_TopOfRangeMember_848ab844-97c3-4347-9c65-a1e1b5d89b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_280a8866-82f6-4130-84a7-e9ac46aa33fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d2716510-9e23-4b36-9bff-efeac730c8b9" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_280a8866-82f6-4130-84a7-e9ac46aa33fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_280a8866-82f6-4130-84a7-e9ac46aa33fd" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_8e14c9db-3644-410d-9120-c08fb69896f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:to="loc_ifrs-full_BuildingsMember_8e14c9db-3644-410d-9120-c08fb69896f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_c2ee911c-b6c9-4618-8958-3dee3d1171bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_c2ee911c-b6c9-4618-8958-3dee3d1171bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MachineryAndEquipment1Member_50a4abcf-6384-48ef-98eb-68dc95bae8a9" xlink:href="sny-20231231.xsd#sny_MachineryAndEquipment1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:to="loc_sny_MachineryAndEquipment1Member_50a4abcf-6384-48ef-98eb-68dc95bae8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_4d036735-c421-453a-a243-1d7d633c439d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_fd08ad38-bac2-4aa8-b863-802642eb2c91" xlink:to="loc_ifrs-full_OtherPropertyPlantAndEquipmentMember_4d036735-c421-453a-a243-1d7d633c439d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_555ea92e-c56d-4975-97eb-fcb94bba886a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_d2716510-9e23-4b36-9bff-efeac730c8b9" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_555ea92e-c56d-4975-97eb-fcb94bba886a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_da250b30-61b3-4d92-b191-c2878ceebac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_555ea92e-c56d-4975-97eb-fcb94bba886a" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_da250b30-61b3-4d92-b191-c2878ceebac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTreasurySharesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesTreasurySharesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTreasurySharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_041aa385-5bf5-4cb5-9f11-59ebbe4bdb62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnPurchaseOfTreasuryShares_23f801e4-63df-46ab-9e10-4fb8e019cdf3" xlink:href="sny-20231231.xsd#sny_GainLossOnPurchaseOfTreasuryShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_041aa385-5bf5-4cb5-9f11-59ebbe4bdb62" xlink:to="loc_sny_GainLossOnPurchaseOfTreasuryShares_23f801e4-63df-46ab-9e10-4fb8e019cdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnSaleOfTreasuryShares_e55af87b-f811-4bc2-b26e-4029b6ff36e5" xlink:href="sny-20231231.xsd#sny_GainLossOnSaleOfTreasuryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_041aa385-5bf5-4cb5-9f11-59ebbe4bdb62" xlink:to="loc_sny_GainLossOnSaleOfTreasuryShares_e55af87b-f811-4bc2-b26e-4029b6ff36e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnImpairmentOfTreasuryShares_9c601109-3d0a-43f8-b077-71e0320dbbe1" xlink:href="sny-20231231.xsd#sny_GainLossOnImpairmentOfTreasuryShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_041aa385-5bf5-4cb5-9f11-59ebbe4bdb62" xlink:to="loc_sny_GainLossOnImpairmentOfTreasuryShares_9c601109-3d0a-43f8-b077-71e0320dbbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainLossOnCancellationOfTreasuryShares_dc950123-faa7-42fb-afb4-63d9d983897b" xlink:href="sny-20231231.xsd#sny_GainLossOnCancellationOfTreasuryShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_041aa385-5bf5-4cb5-9f11-59ebbe4bdb62" xlink:to="loc_sny_GainLossOnCancellationOfTreasuryShares_dc950123-faa7-42fb-afb4-63d9d983897b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesProvisionforRisksDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesProvisionforRisksDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesProvisionforRisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_3aa2667c-d339-4312-a5f2-52797829f9bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsRecordedForFutureOperatingLosses_4bf0db54-04fa-4a40-b3cb-bbcc805f2f5d" xlink:href="sny-20231231.xsd#sny_ProvisionsRecordedForFutureOperatingLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_3aa2667c-d339-4312-a5f2-52797829f9bd" xlink:to="loc_sny_ProvisionsRecordedForFutureOperatingLosses_4bf0db54-04fa-4a40-b3cb-bbcc805f2f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_8cd99cd4-7022-4769-8126-95bc010d9ad7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_b7fd2e62-5c4b-4c45-b2c7-34eb0c0c45f3" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_8cd99cd4-7022-4769-8126-95bc010d9ad7" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_b7fd2e62-5c4b-4c45-b2c7-34eb0c0c45f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis_f3934823-d849-49dc-964e-8ae096715907" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_b7fd2e62-5c4b-4c45-b2c7-34eb0c0c45f3" xlink:to="loc_ifrs-full_SegmentConsolidationItemsAxis_f3934823-d849-49dc-964e-8ae096715907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_6786a346-eda5-4433-8210-17246ae259c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_f3934823-d849-49dc-964e-8ae096715907" xlink:to="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_6786a346-eda5-4433-8210-17246ae259c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EliminationOfIntersegmentAmountsMember_b247e5a0-dbce-42d2-be43-ad23e245a650" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EliminationOfIntersegmentAmountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_6786a346-eda5-4433-8210-17246ae259c5" xlink:to="loc_ifrs-full_EliminationOfIntersegmentAmountsMember_b247e5a0-dbce-42d2-be43-ad23e245a650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5d0b4dd8-88f2-45f7-a539-6ee5237f0a29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_b7fd2e62-5c4b-4c45-b2c7-34eb0c0c45f3" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5d0b4dd8-88f2-45f7-a539-6ee5237f0a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_45828091-dc36-44ba-8cf5-33b5f9b83d7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5d0b4dd8-88f2-45f7-a539-6ee5237f0a29" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_45828091-dc36-44ba-8cf5-33b5f9b83d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember_7ce648b3-2efa-497a-96d2-31809d24ab39" xlink:href="sny-20231231.xsd#sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_45828091-dc36-44ba-8cf5-33b5f9b83d7f" xlink:to="loc_sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember_7ce648b3-2efa-497a-96d2-31809d24ab39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems_af3a43fe-0842-45d9-b49d-224d45de55b6" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable_b7fd2e62-5c4b-4c45-b2c7-34eb0c0c45f3" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems_af3a43fe-0842-45d9-b49d-224d45de55b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_c54e8b53-4be7-431b-a335-a805e19446ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems_af3a43fe-0842-45d9-b49d-224d45de55b6" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_c54e8b53-4be7-431b-a335-a805e19446ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_31c3c23b-25b3-478e-ad41-894663daead6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable_d333c313-1646-4903-810a-b7a5802e4f1b" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_31c3c23b-25b3-478e-ad41-894663daead6" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable_d333c313-1646-4903-810a-b7a5802e4f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6cb6327f-6080-4fa7-a59e-d84b0a7aeb20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable_d333c313-1646-4903-810a-b7a5802e4f1b" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6cb6327f-6080-4fa7-a59e-d84b0a7aeb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_fb563770-5566-40c7-a755-8e42a82a05d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6cb6327f-6080-4fa7-a59e-d84b0a7aeb20" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_fb563770-5566-40c7-a755-8e42a82a05d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlansMember_e296ef81-9f59-4b4f-b280-521595612787" xlink:href="sny-20231231.xsd#sny_StockOptionPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fb563770-5566-40c7-a755-8e42a82a05d9" xlink:to="loc_sny_StockOptionPlansMember_e296ef81-9f59-4b4f-b280-521595612787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlansMember_997dbf4d-84e1-44f3-ae71-669e9fa82324" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fb563770-5566-40c7-a755-8e42a82a05d9" xlink:to="loc_sny_RestrictedSharePlansMember_997dbf4d-84e1-44f3-ae71-669e9fa82324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems_df69b263-6ed8-402e-b07c-e0de2174c390" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable_d333c313-1646-4903-810a-b7a5802e4f1b" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems_df69b263-6ed8-402e-b07c-e0de2174c390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OptionVestingPeriod_bc1b3836-da33-4611-9892-d9083997a197" xlink:href="sny-20231231.xsd#sny_OptionVestingPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems_df69b263-6ed8-402e-b07c-e0de2174c390" xlink:to="loc_sny_OptionVestingPeriod_bc1b3836-da33-4611-9892-d9083997a197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_45b17ee3-8574-4d7d-854f-0d258683e5b7" xlink:href="sny-20231231.xsd#sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems_df69b263-6ed8-402e-b07c-e0de2174c390" xlink:to="loc_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_45b17ee3-8574-4d7d-854f-0d258683e5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SummaryofsignificantaccountingpoliciesSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_b3ffb01a-b712-431f-87a1-630784a55968" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments1_dedf2c83-e7f2-4df5-8bd7-342fe7f03dfe" xlink:href="sny-20231231.xsd#sny_NumberOfOperatingSegments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_b3ffb01a-b712-431f-87a1-630784a55968" xlink:to="loc_sny_NumberOfOperatingSegments1_dedf2c83-e7f2-4df5-8bd7-342fe7f03dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_RelatedPartyAbstract_3ecee270-2943-483d-9083-797d55d7da01" xlink:href="sny-20231231.xsd#sny_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_3ecee270-2943-483d-9083-797d55d7da01" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_696075d5-3d66-4580-a75c-91a46d2de6ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_ifrs-full_CounterpartiesAxis_696075d5-3d66-4580-a75c-91a46d2de6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_1342f330-3e1c-421f-8004-cf473b4712c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_696075d5-3d66-4580-a75c-91a46d2de6ee" xlink:to="loc_ifrs-full_CounterpartiesMember_1342f330-3e1c-421f-8004-cf473b4712c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_f02d6807-0dcc-45d8-93dc-c51a47670181" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_1342f330-3e1c-421f-8004-cf473b4712c8" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_f02d6807-0dcc-45d8-93dc-c51a47670181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_f93b6bec-85c5-498f-8e4b-567a574e5b3b" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_sny_PrincipalAlliancesAxis_f93b6bec-85c5-498f-8e4b-567a574e5b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_d7c44375-f81c-47fb-9531-fd8cf2b2f351" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_f93b6bec-85c5-498f-8e4b-567a574e5b3b" xlink:to="loc_sny_PrincipalAlliancesDomain_d7c44375-f81c-47fb-9531-fd8cf2b2f351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_7829df47-9427-4701-b064-db7ad64b7c3a" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_d7c44375-f81c-47fb-9531-fd8cf2b2f351" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_7829df47-9427-4701-b064-db7ad64b7c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember_759afa28-b4f4-41de-ad50-9d7ab5f03cad" xlink:href="sny-20231231.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_d7c44375-f81c-47fb-9531-fd8cf2b2f351" xlink:to="loc_sny_ImmunoOncologyCollaborationAgreementMember_759afa28-b4f4-41de-ad50-9d7ab5f03cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesMember_2931f056-21e4-48c0-a323-fe90fd96b29f" xlink:href="sny-20231231.xsd#sny_AntibodiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_d7c44375-f81c-47fb-9531-fd8cf2b2f351" xlink:to="loc_sny_AntibodiesMember_2931f056-21e4-48c0-a323-fe90fd96b29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_d5dafbd4-1bd0-4042-b2a2-82822106a97d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_ifrs-full_GeographicalAreasAxis_d5dafbd4-1bd0-4042-b2a2-82822106a97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_2f27affe-858f-4627-aa73-9c1859314594" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_d5dafbd4-1bd0-4042-b2a2-82822106a97d" xlink:to="loc_ifrs-full_GeographicalAreasMember_2f27affe-858f-4627-aa73-9c1859314594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_58e1dc1a-b952-4614-99b9-b16d0d2ee570" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2f27affe-858f-4627-aa73-9c1859314594" xlink:to="loc_country_US_58e1dc1a-b952-4614-99b9-b16d0d2ee570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OutsideUnitedStatesMember_d8c3109b-cbc6-45d5-9d77-0d2112d7ea45" xlink:href="sny-20231231.xsd#sny_OutsideUnitedStatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_2f27affe-858f-4627-aa73-9c1859314594" xlink:to="loc_sny_OutsideUnitedStatesMember_d8c3109b-cbc6-45d5-9d77-0d2112d7ea45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_76dfdfc1-df98-469b-a2ee-0ec5d1df6582" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_ifrs-full_RangeAxis_76dfdfc1-df98-469b-a2ee-0ec5d1df6582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_3325fd89-ba60-4b62-b731-bc75edd44edc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_76dfdfc1-df98-469b-a2ee-0ec5d1df6582" xlink:to="loc_ifrs-full_RangesMember_3325fd89-ba60-4b62-b731-bc75edd44edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_eafb538e-85bd-4f73-b371-9a27bec5ac37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_3325fd89-ba60-4b62-b731-bc75edd44edc" xlink:to="loc_ifrs-full_BottomOfRangeMember_eafb538e-85bd-4f73-b371-9a27bec5ac37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_3d802566-cb19-4e6d-8011-137351fa0d66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_3325fd89-ba60-4b62-b731-bc75edd44edc" xlink:to="loc_ifrs-full_TopOfRangeMember_3d802566-cb19-4e6d-8011-137351fa0d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_fbbd4189-d468-46ac-82ea-48169850ac28" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_sny_TypesOfAgreementAxis_fbbd4189-d468-46ac-82ea-48169850ac28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementAxis_fbbd4189-d468-46ac-82ea-48169850ac28" xlink:to="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesOfAntibodiesFirstAchievementMember_b8f6821f-6a1d-452f-9b44-90ec44670671" xlink:href="sny-20231231.xsd#sny_SalesOfAntibodiesFirstAchievementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:to="loc_sny_SalesOfAntibodiesFirstAchievementMember_b8f6821f-6a1d-452f-9b44-90ec44670671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesOfAntibodiesSecondAchievementMember_39130c34-5ee7-4fb2-b120-4a8cb8ff1674" xlink:href="sny-20231231.xsd#sny_SalesOfAntibodiesSecondAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:to="loc_sny_SalesOfAntibodiesSecondAchievementMember_39130c34-5ee7-4fb2-b120-4a8cb8ff1674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PriorAgreementMember_91ed8642-5871-45f6-abd1-f179b0acf7ca" xlink:href="sny-20231231.xsd#sny_PriorAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:to="loc_sny_PriorAgreementMember_91ed8642-5871-45f6-abd1-f179b0acf7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NewAgreementMember_44209a6c-2315-4a78-b7e2-21d8f552e4fb" xlink:href="sny-20231231.xsd#sny_NewAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:to="loc_sny_NewAgreementMember_44209a6c-2315-4a78-b7e2-21d8f552e4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesOfAntibodiesThirdAchievementMember_1d41e2f6-f001-46a0-984f-35deacce57bb" xlink:href="sny-20231231.xsd#sny_SalesOfAntibodiesThirdAchievementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_43f79340-902b-4311-9d82-77439e5da85b" xlink:to="loc_sny_SalesOfAntibodiesThirdAchievementMember_1d41e2f6-f001-46a0-984f-35deacce57bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_109c382d-b91f-4c3b-9f1c-fd08422f6619" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_srt_ProductOrServiceAxis_109c382d-b91f-4c3b-9f1c-fd08422f6619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7500fc9d-0fe9-44b3-8ccb-64d13a4f8f61" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_109c382d-b91f-4c3b-9f1c-fd08422f6619" xlink:to="loc_srt_ProductsAndServicesDomain_7500fc9d-0fe9-44b3-8ccb-64d13a4f8f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesAllianceMember_315b31aa-ce22-4985-bf5a-37b4da78ac7e" xlink:href="sny-20231231.xsd#sny_AntibodiesAllianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7500fc9d-0fe9-44b3-8ccb-64d13a4f8f61" xlink:to="loc_sny_AntibodiesAllianceMember_315b31aa-ce22-4985-bf5a-37b4da78ac7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesMember_b6bc3095-0ef8-4aeb-ab52-2ecf425dcfa7" xlink:href="sny-20231231.xsd#sny_AntibodiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7500fc9d-0fe9-44b3-8ccb-64d13a4f8f61" xlink:to="loc_sny_AntibodiesMember_b6bc3095-0ef8-4aeb-ab52-2ecf425dcfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_b13d1bc3-8cdc-47e2-9615-47ba4593e439" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_b13d1bc3-8cdc-47e2-9615-47ba4593e439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_4e93cfb1-0315-4a5e-b6a3-6792f9131eda" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_b13d1bc3-8cdc-47e2-9615-47ba4593e439" xlink:to="loc_ifrs-full_NonadjustingEventsMember_4e93cfb1-0315-4a5e-b6a3-6792f9131eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorCollaborationAgreementMember_bb8eee78-33c5-4fd6-9947-4b08b732df3b" xlink:href="sny-20231231.xsd#sny_MajorCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_4e93cfb1-0315-4a5e-b6a3-6792f9131eda" xlink:to="loc_sny_MajorCollaborationAgreementMember_bb8eee78-33c5-4fd6-9947-4b08b732df3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b28729e-dbac-4b8d-8ce4-87fadb9acd7c" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfAgreementsSigned_f5510613-a75a-40cf-8618-6e96d0916a1a" xlink:href="sny-20231231.xsd#sny_NumberOfAgreementsSigned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_NumberOfAgreementsSigned_f5510613-a75a-40cf-8618-6e96d0916a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFunded_56c81334-96de-4b03-af0c-55ed6d5f6f40" xlink:href="sny-20231231.xsd#sny_PercentageOfSecondPartOfDevelopmentCostsFunded"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFunded_56c81334-96de-4b03-af0c-55ed6d5f6f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty_6d9ac9a0-bb72-4195-adeb-ce12aadd504b" xlink:href="sny-20231231.xsd#sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty_6d9ac9a0-bb72-4195-adeb-ce12aadd504b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_80204b3f-8533-4540-98d2-d0246c8f2b21" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitShareOnCounterpartiesProfit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_80204b3f-8533-4540-98d2-d0246c8f2b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_556d0660-4891-4f2e-adc6-9465e60e9f7d" xlink:href="sny-20231231.xsd#sny_PercentageOfCumulativeDevelopmentCostsReimbursed"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_556d0660-4891-4f2e-adc6-9465e60e9f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared_dd494764-5588-4c6b-b433-036a960de9a5" xlink:href="sny-20231231.xsd#sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared_dd494764-5588-4c6b-b433-036a960de9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations_6ecedcac-8b21-4e14-96ef-5df2791a9459" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations_6ecedcac-8b21-4e14-96ef-5df2791a9459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_d533f53d-77bf-458d-80fb-6e77902e6615" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitsArisingFromCommercialOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_d533f53d-77bf-458d-80fb-6e77902e6615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfLossesArisingFromCommercialOperations_ddbb55a0-39dd-4262-a872-815fa5f9210e" xlink:href="sny-20231231.xsd#sny_PercentageOfLossesArisingFromCommercialOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PercentageOfLossesArisingFromCommercialOperations_ddbb55a0-39dd-4262-a872-815fa5f9210e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPayments_2d55cb2b-6a71-478a-bce4-8ce103c8f579" xlink:href="sny-20231231.xsd#sny_NumberOfPayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_NumberOfPayments_2d55cb2b-6a71-478a-bce4-8ce103c8f579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentRelatedToAttainmentOfGoal_ca1f1c28-a38b-401d-87ef-d05e6ab1956e" xlink:href="sny-20231231.xsd#sny_PaymentRelatedToAttainmentOfGoal"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_PaymentRelatedToAttainmentOfGoal_ca1f1c28-a38b-401d-87ef-d05e6ab1956e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_f4e9725d-dc77-491c-8bb3-27564aec507d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_f4e9725d-dc77-491c-8bb3-27564aec507d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltyExpensePercentage_377fe15c-a6a8-42f3-ab1f-da1dfa0fda6d" xlink:href="sny-20231231.xsd#sny_RoyaltyExpensePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_4c1683e4-2a3a-46f8-b55f-86895547cc87" xlink:to="loc_sny_RoyaltyExpensePercentage_377fe15c-a6a8-42f3-ab1f-da1dfa0fda6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_RelatedPartyAbstract_d7a07cd2-f94f-484d-9309-a9c0b652518b" xlink:href="sny-20231231.xsd#sny_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_d7a07cd2-f94f-484d-9309-a9c0b652518b" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_44b37ca2-52ad-4228-89c2-e9bc68415014" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_ifrs-full_CounterpartiesAxis_44b37ca2-52ad-4228-89c2-e9bc68415014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_18f1c6d5-0681-4707-8f74-d62cbedb83e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_44b37ca2-52ad-4228-89c2-e9bc68415014" xlink:to="loc_ifrs-full_CounterpartiesMember_18f1c6d5-0681-4707-8f74-d62cbedb83e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_43b140df-2689-41d9-84ec-ba5e5d43261b" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_18f1c6d5-0681-4707-8f74-d62cbedb83e7" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_43b140df-2689-41d9-84ec-ba5e5d43261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_11d2774e-e65e-48e8-ab08-d0079e8c3657" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_sny_PrincipalAlliancesAxis_11d2774e-e65e-48e8-ab08-d0079e8c3657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_822c8a73-9fcf-4ff1-abad-1355724429b7" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_11d2774e-e65e-48e8-ab08-d0079e8c3657" xlink:to="loc_sny_PrincipalAlliancesDomain_822c8a73-9fcf-4ff1-abad-1355724429b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember_216519d5-d788-4648-97e9-8be331166469" xlink:href="sny-20231231.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_822c8a73-9fcf-4ff1-abad-1355724429b7" xlink:to="loc_sny_ImmunoOncologyCollaborationAgreementMember_216519d5-d788-4648-97e9-8be331166469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_f74c8020-05ba-4415-bfeb-04d4b5cc5d54" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_sny_TypesOfAgreementAxis_f74c8020-05ba-4415-bfeb-04d4b5cc5d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_db4827e2-b86a-4ac4-a9fc-1634aa34bcd5" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementAxis_f74c8020-05ba-4415-bfeb-04d4b5cc5d54" xlink:to="loc_sny_TypesOfAgreementDomain_db4827e2-b86a-4ac4-a9fc-1634aa34bcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DevelopmentOfCemiplimabREGN2810Member_e59c7d3e-c900-4d73-977d-1ebafe141ae5" xlink:href="sny-20231231.xsd#sny_DevelopmentOfCemiplimabREGN2810Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_db4827e2-b86a-4ac4-a9fc-1634aa34bcd5" xlink:to="loc_sny_DevelopmentOfCemiplimabREGN2810Member_e59c7d3e-c900-4d73-977d-1ebafe141ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MilestoneTypesAxis_618917b6-cdfc-41a3-8b17-dd5e0bbf930c" xlink:href="sny-20231231.xsd#sny_MilestoneTypesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_sny_MilestoneTypesAxis_618917b6-cdfc-41a3-8b17-dd5e0bbf930c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MilestoneTypesDomain_cba2d50b-0f7f-4dd6-a722-7cb471cff12a" xlink:href="sny-20231231.xsd#sny_MilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MilestoneTypesAxis_618917b6-cdfc-41a3-8b17-dd5e0bbf930c" xlink:to="loc_sny_MilestoneTypesDomain_cba2d50b-0f7f-4dd6-a722-7cb471cff12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USFDAApprovalMember_0b045ae2-c9d6-4a2d-80a5-8847eed8acb8" xlink:href="sny-20231231.xsd#sny_USFDAApprovalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MilestoneTypesDomain_cba2d50b-0f7f-4dd6-a722-7cb471cff12a" xlink:to="loc_sny_USFDAApprovalMember_0b045ae2-c9d6-4a2d-80a5-8847eed8acb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_9557f18d-afb9-46f1-aeac-9e5c377a7adf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_9557f18d-afb9-46f1-aeac-9e5c377a7adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_e0df511b-8988-4465-afa6-a9e887e1c123" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_9557f18d-afb9-46f1-aeac-9e5c377a7adf" xlink:to="loc_ifrs-full_NonadjustingEventsMember_e0df511b-8988-4465-afa6-a9e887e1c123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorCollaborationAgreementMember_d040200e-1fef-4c25-83ae-f949ee91d5f1" xlink:href="sny-20231231.xsd#sny_MajorCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_e0df511b-8988-4465-afa6-a9e887e1c123" xlink:to="loc_sny_MajorCollaborationAgreementMember_d040200e-1fef-4c25-83ae-f949ee91d5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_27e8dcef-5dd2-4c6a-baf7-911571d69fed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_27e8dcef-5dd2-4c6a-baf7-911571d69fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_3ac43989-e8c4-4ac9-a9f3-d81698593b85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_27e8dcef-5dd2-4c6a-baf7-911571d69fed" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_3ac43989-e8c4-4ac9-a9f3-d81698593b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_831a7289-39ec-489c-8723-0a969c4dae2d" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_3ac43989-e8c4-4ac9-a9f3-d81698593b85" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_831a7289-39ec-489c-8723-0a969c4dae2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:href="sny-20231231.xsd#sny_DisclosureOfPrincipalAlliancesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_9f6ce388-3154-4272-817b-f0958dbfeda8" xlink:to="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfAgreementsSigned_932839ba-d867-48a2-b418-4c0f1c760178" xlink:href="sny-20231231.xsd#sny_NumberOfAgreementsSigned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_NumberOfAgreementsSigned_932839ba-d867-48a2-b418-4c0f1c760178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PriorDevelopmentBudget_fe021dba-0c82-4e9f-8e51-06645cd14044" xlink:href="sny-20231231.xsd#sny_PriorDevelopmentBudget"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_PriorDevelopmentBudget_fe021dba-0c82-4e9f-8e51-06645cd14044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1_cbbf31cb-e90d-4cfe-bf9b-8d8e8be1277f" xlink:href="sny-20231231.xsd#sny_ContractualAgreementForAntiProgrammedCellDeathProtein1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1_cbbf31cb-e90d-4cfe-bf9b-8d8e8be1277f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany_f862c8b3-2a31-43f4-b873-fab178f692e5" xlink:href="sny-20231231.xsd#sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany_f862c8b3-2a31-43f4-b873-fab178f692e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment_ed2090ac-0fb6-42bc-8605-4a0a8e5b2b0d" xlink:href="sny-20231231.xsd#sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment_ed2090ac-0fb6-42bc-8605-4a0a8e5b2b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment_51631d2a-15e6-439d-b812-a5bdf3b30503" xlink:href="sny-20231231.xsd#sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment_51631d2a-15e6-439d-b812-a5bdf3b30503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_2c13ead3-98a9-4244-ace5-03a4577603bf" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitShareOnCounterpartiesProfit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_2c13ead3-98a9-4244-ace5-03a4577603bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_3c664237-94cb-405d-b463-311fdfd2aa04" xlink:href="sny-20231231.xsd#sny_PercentageOfCumulativeDevelopmentCostsReimbursed"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_3c664237-94cb-405d-b463-311fdfd2aa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_40f63207-9447-42a8-83cc-cfcd0d28f7df" xlink:href="sny-20231231.xsd#sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_40f63207-9447-42a8-83cc-cfcd0d28f7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_3f2b4b58-abab-4836-851f-e52ab5abc8c2" xlink:href="sny-20231231.xsd#sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_3f2b4b58-abab-4836-851f-e52ab5abc8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltyIncomePercentage_54a2cadd-39cb-4e4e-86bb-a51ce1ee1e0e" xlink:href="sny-20231231.xsd#sny_RoyaltyIncomePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_RoyaltyIncomePercentage_54a2cadd-39cb-4e4e-86bb-a51ce1ee1e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_cad9c292-7671-4fe5-980c-5909868d2ebc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_cad9c292-7671-4fe5-980c-5909868d2ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProceedsFromCollaborationAgreements_254d688b-9087-419b-b798-fb1f8ddd2a69" xlink:href="sny-20231231.xsd#sny_ProceedsFromCollaborationAgreements"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_sny_ProceedsFromCollaborationAgreements_254d688b-9087-419b-b798-fb1f8ddd2a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_9b700ec7-12c0-4f64-a3f1-2cfde43a80be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_d83c7e33-22dc-48d3-9d15-1af56b5fb281" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_9b700ec7-12c0-4f64-a3f1-2cfde43a80be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_RelatedPartyAbstract_2433cbd8-f3a6-470d-8036-596ded23bbd4" xlink:href="sny-20231231.xsd#sny_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_2433cbd8-f3a6-470d-8036-596ded23bbd4" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_93cad380-90a3-4bf6-abac-57f55ab0960e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:to="loc_ifrs-full_CounterpartiesAxis_93cad380-90a3-4bf6-abac-57f55ab0960e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_424233e2-9071-4498-a3a6-384f690a8a81" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_93cad380-90a3-4bf6-abac-57f55ab0960e" xlink:to="loc_ifrs-full_CounterpartiesMember_424233e2-9071-4498-a3a6-384f690a8a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_dc61d26d-b6d4-42fe-a163-4c81676a2dcd" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_424233e2-9071-4498-a3a6-384f690a8a81" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_dc61d26d-b6d4-42fe-a163-4c81676a2dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_5ab4954f-7363-496c-9f03-68a0c521e597" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:to="loc_sny_PrincipalAlliancesAxis_5ab4954f-7363-496c-9f03-68a0c521e597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_6c84ae2b-1033-4e62-9043-0db1465a887f" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_5ab4954f-7363-496c-9f03-68a0c521e597" xlink:to="loc_sny_PrincipalAlliancesDomain_6c84ae2b-1033-4e62-9043-0db1465a887f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TwoThousandFourteenAmendedInvestmentAgreementMember_390b43e3-9d4e-46b7-9288-66db201ea468" xlink:href="sny-20231231.xsd#sny_TwoThousandFourteenAmendedInvestmentAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_6c84ae2b-1033-4e62-9043-0db1465a887f" xlink:to="loc_sny_TwoThousandFourteenAmendedInvestmentAgreementMember_390b43e3-9d4e-46b7-9288-66db201ea468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SaleOfStockAxis_4532f7e5-11e1-427e-9467-a7d4e54c09df" xlink:href="sny-20231231.xsd#sny_SaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:to="loc_sny_SaleOfStockAxis_4532f7e5-11e1-427e-9467-a7d4e54c09df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SaleOfStockDomain_67b64ba5-d5a9-49db-9f74-9a5beca7237b" xlink:href="sny-20231231.xsd#sny_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SaleOfStockAxis_4532f7e5-11e1-427e-9467-a7d4e54c09df" xlink:to="loc_sny_SaleOfStockDomain_67b64ba5-d5a9-49db-9f74-9a5beca7237b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PublicOfferingMember_a2698598-b5c5-417e-b92b-f56dbbc81f45" xlink:href="sny-20231231.xsd#sny_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SaleOfStockDomain_67b64ba5-d5a9-49db-9f74-9a5beca7237b" xlink:to="loc_sny_PublicOfferingMember_a2698598-b5c5-417e-b92b-f56dbbc81f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6916c5d4-62aa-410c-b788-6bc134b2d989" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6916c5d4-62aa-410c-b788-6bc134b2d989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_e0fc6501-3cf1-41d8-a51e-da071f26d26c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6916c5d4-62aa-410c-b788-6bc134b2d989" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_e0fc6501-3cf1-41d8-a51e-da071f26d26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_158c81aa-8d31-433b-b628-6f2ad0dda7f2" xlink:href="sny-20231231.xsd#sny_RegeneronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_e0fc6501-3cf1-41d8-a51e-da071f26d26c" xlink:to="loc_sny_RegeneronMember_158c81aa-8d31-433b-b628-6f2ad0dda7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_7a39d22e-16fd-4360-906c-f787416f4af7" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_5e8a7056-d766-4778-870d-2e630d670b2d" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_7a39d22e-16fd-4360-906c-f787416f4af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumOwnershipPercentageAllowedToAcquire_f6c4e2cc-465b-40fc-b5cc-feadd64e18ae" xlink:href="sny-20231231.xsd#sny_MaximumOwnershipPercentageAllowedToAcquire"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_7a39d22e-16fd-4360-906c-f787416f4af7" xlink:to="loc_sny_MaximumOwnershipPercentageAllowedToAcquire_f6c4e2cc-465b-40fc-b5cc-feadd64e18ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal_8f13135c-3af8-4bb4-b034-38bd20009855" xlink:href="sny-20231231.xsd#sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems_7a39d22e-16fd-4360-906c-f787416f4af7" xlink:to="loc_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal_8f13135c-3af8-4bb4-b034-38bd20009855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_RelatedPartyAbstract_9d465766-0cd3-4f59-a22e-5b628f4460e3" xlink:href="sny-20231231.xsd#sny_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_9d465766-0cd3-4f59-a22e-5b628f4460e3" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_0d449ccf-f9e8-46a9-8586-f53e630b730a" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:to="loc_sny_PrincipalAlliancesAxis_0d449ccf-f9e8-46a9-8586-f53e630b730a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_e0fb3bf2-e9c3-4f3c-adc2-df8d1d805d18" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_0d449ccf-f9e8-46a9-8586-f53e630b730a" xlink:to="loc_sny_PrincipalAlliancesDomain_e0fb3bf2-e9c3-4f3c-adc2-df8d1d805d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_919b6782-1aa2-48e9-9704-cbacdf99d362" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_e0fb3bf2-e9c3-4f3c-adc2-df8d1d805d18" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_919b6782-1aa2-48e9-9704-cbacdf99d362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_4e6f27f4-9507-4de2-8c2d-23361fc8f161" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:to="loc_ifrs-full_CounterpartiesAxis_4e6f27f4-9507-4de2-8c2d-23361fc8f161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_589a882c-a62b-44de-8871-a48b4f15decc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_4e6f27f4-9507-4de2-8c2d-23361fc8f161" xlink:to="loc_ifrs-full_CounterpartiesMember_589a882c-a62b-44de-8871-a48b4f15decc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AstraZenecaMember_ef909429-618a-46cf-a272-2b743b458614" xlink:href="sny-20231231.xsd#sny_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_589a882c-a62b-44de-8871-a48b4f15decc" xlink:to="loc_sny_AstraZenecaMember_ef909429-618a-46cf-a272-2b743b458614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_e89171be-0937-44ad-9ef5-8aee2a1bfaad" xlink:href="sny-20231231.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_589a882c-a62b-44de-8871-a48b4f15decc" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_e89171be-0937-44ad-9ef5-8aee2a1bfaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_98c1b14c-aa53-4f6f-a3f0-968a4018d2b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:to="loc_ifrs-full_GeographicalAreasAxis_98c1b14c-aa53-4f6f-a3f0-968a4018d2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_e10ac9e2-3976-4f29-ae65-f5989dcd64ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_98c1b14c-aa53-4f6f-a3f0-968a4018d2b7" xlink:to="loc_ifrs-full_GeographicalAreasMember_e10ac9e2-3976-4f29-ae65-f5989dcd64ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MajorTerritoriesMember_68ab5fdd-948b-42b9-b22b-92ff1d0c1ba5" xlink:href="sny-20231231.xsd#sny_MajorTerritoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_e10ac9e2-3976-4f29-ae65-f5989dcd64ab" xlink:to="loc_sny_MajorTerritoriesMember_68ab5fdd-948b-42b9-b22b-92ff1d0c1ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherTerritoriesMember_2bd32319-c271-42f4-ad01-da64ff9e42eb" xlink:href="sny-20231231.xsd#sny_OtherTerritoriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_e10ac9e2-3976-4f29-ae65-f5989dcd64ab" xlink:to="loc_sny_OtherTerritoriesMember_2bd32319-c271-42f4-ad01-da64ff9e42eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_89bc0ea3-ce1c-49a4-9a73-02d6be9e017c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_e10ac9e2-3976-4f29-ae65-f5989dcd64ab" xlink:to="loc_country_CN_89bc0ea3-ce1c-49a4-9a73-02d6be9e017c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a2982fb3-1aee-476b-ad2d-d4a5807b8174" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a2982fb3-1aee-476b-ad2d-d4a5807b8174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_81c519e9-a7e8-46ca-8a7f-83fc66c7ff3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a2982fb3-1aee-476b-ad2d-d4a5807b8174" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_81c519e9-a7e8-46ca-8a7f-83fc66c7ff3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_715b30c8-1d50-4b99-9a09-501b3dc00743" xlink:href="sny-20231231.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_81c519e9-a7e8-46ca-8a7f-83fc66c7ff3e" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_715b30c8-1d50-4b99-9a09-501b3dc00743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:href="sny-20231231.xsd#sny_DisclosureOfPrincipalAlliancesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_1bc10209-94fe-496f-a17d-2ebf7620ea68" xlink:to="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsUpfrontPayment_0d9f542c-1172-41fc-8e17-39f529c0f592" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_CollaborationAgreementsUpfrontPayment_0d9f542c-1172-41fc-8e17-39f529c0f592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_2d687618-4a8d-4282-a766-27e2dfc2541b" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementsDevelopmentMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_CollaborationAgreementsDevelopmentMilestonePayment_2d687618-4a8d-4282-a766-27e2dfc2541b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_6fe6f570-9130-4e26-acf6-bca19e79c22e" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementsRegulatoryMilestonePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_CollaborationAgreementsRegulatoryMilestonePayment_6fe6f570-9130-4e26-acf6-bca19e79c22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_2740fb50-e97b-478b-a4d7-e65f5f6eea7c" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_2740fb50-e97b-478b-a4d7-e65f5f6eea7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Accruals_1a4597b4-380f-4412-8ca9-20511b89bf45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Accruals"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_ifrs-full_Accruals_1a4597b4-380f-4412-8ca9-20511b89bf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_5eb6fed4-a7af-4363-bbbf-05e32952a8e7" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitsArisingFromCommercialOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_PercentageOfProfitsArisingFromCommercialOperations_5eb6fed4-a7af-4363-bbbf-05e32952a8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_ac32ac4c-4eed-417b-a5ed-19bb5434c277" xlink:href="sny-20231231.xsd#sny_PercentageOfNetSalesArisingFromCommercialOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_PercentageOfNetSalesArisingFromCommercialOperations_ac32ac4c-4eed-417b-a5ed-19bb5434c277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_cb2b5f34-7072-4c43-90ea-b891f00fff04" xlink:href="sny-20231231.xsd#sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations_cb2b5f34-7072-4c43-90ea-b891f00fff04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_466587bb-94ac-429c-8aa4-20674a70a6c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_466587bb-94ac-429c-8aa4-20674a70a6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_11a9e0f4-232e-4d69-801b-364e15f0461f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_11a9e0f4-232e-4d69-801b-364e15f0461f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_10d86b92-72cf-4a32-8080-46eeac2ab2f0" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfPrincipalAlliancesLineItems_8031c021-6ef6-4f62-8873-e09838574ca7" xlink:to="loc_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities_10d86b92-72cf-4a32-8080-46eeac2ab2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_a88279ea-7aee-4877-ac53-7c8124f60259" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ea1f9287-f0af-49ba-8a7b-f658a7359a8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_a88279ea-7aee-4877-ac53-7c8124f60259" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ea1f9287-f0af-49ba-8a7b-f658a7359a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_d1e7e741-314d-441c-8de4-e9ffbbdde3ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ea1f9287-f0af-49ba-8a7b-f658a7359a8a" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_d1e7e741-314d-441c-8de4-e9ffbbdde3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_859ed6b4-1fac-424f-a963-78730e2c77e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_d1e7e741-314d-441c-8de4-e9ffbbdde3ba" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_859ed6b4-1fac-424f-a963-78730e2c77e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_0110d12f-3729-4649-a175-15041646b7f5" xlink:href="sny-20231231.xsd#sny_ProventionBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_859ed6b4-1fac-424f-a963-78730e2c77e1" xlink:to="loc_sny_ProventionBioIncMember_0110d12f-3729-4649-a175-15041646b7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_73719dd7-cac6-4218-abbc-894d2a7a716b" xlink:href="sny-20231231.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_859ed6b4-1fac-424f-a963-78730e2c77e1" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_73719dd7-cac6-4218-abbc-894d2a7a716b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bec34f19-454e-4e62-bd52-1bb5eb13378d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ea1f9287-f0af-49ba-8a7b-f658a7359a8a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bec34f19-454e-4e62-bd52-1bb5eb13378d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_47b8a371-5586-4f9a-8a93-570b63c05556" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bec34f19-454e-4e62-bd52-1bb5eb13378d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_47b8a371-5586-4f9a-8a93-570b63c05556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_75b8ecf7-d2a9-426b-9366-9d6ddb0265c3" xlink:href="sny-20231231.xsd#sny_ProventionBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_47b8a371-5586-4f9a-8a93-570b63c05556" xlink:to="loc_sny_ProventionBioIncMember_75b8ecf7-d2a9-426b-9366-9d6ddb0265c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ea1f9287-f0af-49ba-8a7b-f658a7359a8a" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare_85ad2ff3-0903-480a-8acd-b0781a219b61" xlink:href="sny-20231231.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_sny_BusinessCombinationPurchasePricePerShare_85ad2ff3-0903-480a-8acd-b0781a219b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_8bee8e9b-4449-428d-851f-14b91b4193b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_CashTransferred_8bee8e9b-4449-428d-851f-14b91b4193b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_f5ecbd37-78d8-4a90-81be-ec6de1a7173b" xlink:href="sny-20231231.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_f5ecbd37-78d8-4a90-81be-ec6de1a7173b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_9ef3c090-aaeb-4781-90ae-522ca3d3eb58" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_9ef3c090-aaeb-4781-90ae-522ca3d3eb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_e9a8d13b-3772-42f5-a32d-7bd59859afa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_e9a8d13b-3772-42f5-a32d-7bd59859afa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_2df39ddc-3a89-4a62-9411-6d5d89854886" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_2df39ddc-3a89-4a62-9411-6d5d89854886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_9e6d0946-520b-45fb-a609-24cd4ce9bdea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_9e6d0946-520b-45fb-a609-24cd4ce9bdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePrice_08339f93-1cc3-4625-86d1-04ba8facfe7d" xlink:href="sny-20231231.xsd#sny_BusinessCombinationPurchasePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_sny_BusinessCombinationPurchasePrice_08339f93-1cc3-4625-86d1-04ba8facfe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoodwillTaxDeductiblePeriod_be1fdbf3-f64f-457c-9008-d47cb4455330" xlink:href="sny-20231231.xsd#sny_GoodwillTaxDeductiblePeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_sny_GoodwillTaxDeductiblePeriod_be1fdbf3-f64f-457c-9008-d47cb4455330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueOfAcquiree_ee2f00e1-bd71-4702-b432-202cb9e3ee38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueOfAcquiree"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_RevenueOfAcquiree_ee2f00e1-bd71-4702-b432-202cb9e3ee38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossOfAcquiree_e25411b5-16b4-4012-86bd-e7d2feac74db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossOfAcquiree"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_ProfitLossOfAcquiree_e25411b5-16b4-4012-86bd-e7d2feac74db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_d65e1e3e-92c6-4adc-9bc3-b687a2af0b7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_c554a936-0525-4d6f-834d-f04a1d5558e3" xlink:to="loc_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_d65e1e3e-92c6-4adc-9bc3-b687a2af0b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_bf0c9ddb-a163-459c-8d6d-be747be81880" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_b2a43033-e033-4f9d-941e-c15876ae83ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_bf0c9ddb-a163-459c-8d6d-be747be81880" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_b2a43033-e033-4f9d-941e-c15876ae83ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_47e1ad2f-5031-4a25-a155-3f9e22b8ac98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_b2a43033-e033-4f9d-941e-c15876ae83ce" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_47e1ad2f-5031-4a25-a155-3f9e22b8ac98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_6ac883b8-b7f9-4118-85e2-b3b4886c1cf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_47e1ad2f-5031-4a25-a155-3f9e22b8ac98" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_6ac883b8-b7f9-4118-85e2-b3b4886c1cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_6d772f3e-c397-42f2-b5f0-5eb0ab1e3d5e" xlink:href="sny-20231231.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_6ac883b8-b7f9-4118-85e2-b3b4886c1cf3" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_6d772f3e-c397-42f2-b5f0-5eb0ab1e3d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_b2a43033-e033-4f9d-941e-c15876ae83ce" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_2cf8b55e-e4d8-478e-b3fe-010d9b70432b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_2cf8b55e-e4d8-478e-b3fe-010d9b70432b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_5bb7f127-2be5-4802-9b95-c62638054e48" xlink:href="sny-20231231.xsd#sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_5bb7f127-2be5-4802-9b95-c62638054e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_31d8137d-5eb9-456b-bbce-aa67b796bb25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_31d8137d-5eb9-456b-bbce-aa67b796bb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_5ff6ef82-4883-4635-9a6b-d9828dd82257" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_5ff6ef82-4883-4635-9a6b-d9828dd82257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f2b9dbfc-e9be-4022-b638-ae95e8c98df4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f2b9dbfc-e9be-4022-b638-ae95e8c98df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_c62aa12b-39c2-430a-95a6-37f7d82bec45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_c62aa12b-39c2-430a-95a6-37f7d82bec45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_76ef74ce-2691-4515-9bb0-236350a74ec5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_f4a459d2-cd23-437c-8e50-0cd28d5b0268" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_76ef74ce-2691-4515-9bb0-236350a74ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_e388f112-c9c9-40ea-aa8b-162c775ee272" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_e388f112-c9c9-40ea-aa8b-162c775ee272" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_d99532a4-300b-4e5e-a44a-93395b20339b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_d99532a4-300b-4e5e-a44a-93395b20339b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_d99532a4-300b-4e5e-a44a-93395b20339b" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixPharmaceuticalsIncMember_8d2ab354-2c4a-4134-a213-843c06f4cbac" xlink:href="sny-20231231.xsd#sny_AmunixPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_AmunixPharmaceuticalsIncMember_8d2ab354-2c4a-4134-a213-843c06f4cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KymabMember_2d3636ab-391f-4993-a8a3-e1ab488a1a9e" xlink:href="sny-20231231.xsd#sny_KymabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_KymabMember_2d3636ab-391f-4993-a8a3-e1ab488a1a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KiadisMember_55da7907-48f5-4bee-a215-1e3469d812e8" xlink:href="sny-20231231.xsd#sny_KiadisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_KiadisMember_55da7907-48f5-4bee-a215-1e3469d812e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TidalTherapeuticsMember_99598765-5eb9-4f6b-9482-53b99e310a72" xlink:href="sny-20231231.xsd#sny_TidalTherapeuticsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_TidalTherapeuticsMember_99598765-5eb9-4f6b-9482-53b99e310a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioMember_8f9448e1-439c-40ae-9288-4d36fc8cb7cf" xlink:href="sny-20231231.xsd#sny_TranslateBioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_TranslateBioMember_8f9448e1-439c-40ae-9288-4d36fc8cb7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KadmonMember_f704348f-9799-4c6a-aaba-2c2d5d549627" xlink:href="sny-20231231.xsd#sny_KadmonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_KadmonMember_f704348f-9799-4c6a-aaba-2c2d5d549627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OrigimmBiotechnologyGmbHMember_87193874-c65b-4133-a27a-b0bf1a004693" xlink:href="sny-20231231.xsd#sny_OrigimmBiotechnologyGmbHMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_a908179e-e3d4-4372-be2a-d19b43d3371f" xlink:to="loc_sny_OrigimmBiotechnologyGmbHMember_87193874-c65b-4133-a27a-b0bf1a004693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_98f74a98-0c83-4518-be68-4c79bc19e745" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_98f74a98-0c83-4518-be68-4c79bc19e745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_367f8f0d-ae97-439c-866d-3141ecad3e27" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_98f74a98-0c83-4518-be68-4c79bc19e745" xlink:to="loc_ifrs-full_EquityMember_367f8f0d-ae97-439c-866d-3141ecad3e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_ec0c205a-a125-44f9-93d2-99ad02231014" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_367f8f0d-ae97-439c-866d-3141ecad3e27" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParentMember_ec0c205a-a125-44f9-93d2-99ad02231014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cf9523d2-20dc-40ea-9bb2-500aae6c4c12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cf9523d2-20dc-40ea-9bb2-500aae6c4c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_8328c06c-2a93-491c-a7a9-b4816e2d46c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cf9523d2-20dc-40ea-9bb2-500aae6c4c12" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_8328c06c-2a93-491c-a7a9-b4816e2d46c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_f331afad-aabd-415d-86e6-b21fe80a6219" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_8328c06c-2a93-491c-a7a9-b4816e2d46c4" xlink:to="loc_sny_EuroapiMember_f331afad-aabd-415d-86e6-b21fe80a6219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_ca411a85-ca30-4770-83a3-b145a45f6f38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_ca411a85-ca30-4770-83a3-b145a45f6f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_d43b3c28-dc93-4e1e-800e-25497a84bee6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_ca411a85-ca30-4770-83a3-b145a45f6f38" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_d43b3c28-dc93-4e1e-800e-25497a84bee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_a3d910ea-fe4e-47bc-a5cb-69cdead9d4ea" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_d43b3c28-dc93-4e1e-800e-25497a84bee6" xlink:to="loc_sny_EuroapiMember_a3d910ea-fe4e-47bc-a5cb-69cdead9d4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_df644065-3248-48e3-a864-8c848acf1890" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_CounterpartiesAxis_df644065-3248-48e3-a864-8c848acf1890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_5ed714d7-406a-4039-a4cf-8354e04b5a9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_df644065-3248-48e3-a864-8c848acf1890" xlink:to="loc_ifrs-full_CounterpartiesMember_5ed714d7-406a-4039-a4cf-8354e04b5a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EPICBPIFranceMember_8f52d986-30c8-4ae6-b0fe-d7a0bfc0cccb" xlink:href="sny-20231231.xsd#sny_EPICBPIFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_5ed714d7-406a-4039-a4cf-8354e04b5a9d" xlink:to="loc_sny_EPICBPIFranceMember_8f52d986-30c8-4ae6-b0fe-d7a0bfc0cccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_3a2c32f3-ab9d-40a2-8079-d303184af503" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_3a2c32f3-ab9d-40a2-8079-d303184af503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_01433e72-499b-46cd-b93f-dde017895174" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_3a2c32f3-ab9d-40a2-8079-d303184af503" xlink:to="loc_ifrs-full_OtherProvisionsMember_01433e72-499b-46cd-b93f-dde017895174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember_f6e0ab82-9df5-452a-b343-59dc8e0e3c08" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_01433e72-499b-46cd-b93f-dde017895174" xlink:to="loc_ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember_f6e0ab82-9df5-452a-b343-59dc8e0e3c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegulatoryComplianceCostsMember_4369ec9c-15c7-4fb2-86b4-265489e51462" xlink:href="sny-20231231.xsd#sny_RegulatoryComplianceCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_01433e72-499b-46cd-b93f-dde017895174" xlink:to="loc_sny_RegulatoryComplianceCostsMember_4369ec9c-15c7-4fb2-86b4-265489e51462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_73cade63-f06c-455d-93e0-410e3f27c3b4" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_sny_TypesOfAgreementAxis_73cade63-f06c-455d-93e0-410e3f27c3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_d571c544-e49c-4255-bc1a-10204f2cfb7d" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementAxis_73cade63-f06c-455d-93e0-410e3f27c3b4" xlink:to="loc_sny_TypesOfAgreementDomain_d571c544-e49c-4255-bc1a-10204f2cfb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufactureAndSupplyCollaborationAgreementMember_cd00e9e2-fb11-4922-898d-235918186d3d" xlink:href="sny-20231231.xsd#sny_ManufactureAndSupplyCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_d571c544-e49c-4255-bc1a-10204f2cfb7d" xlink:to="loc_sny_ManufactureAndSupplyCollaborationAgreementMember_cd00e9e2-fb11-4922-898d-235918186d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3d402907-4885-4329-a71b-77f00acbed19" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_9ed15688-ce5c-470d-acaa-bce756390f0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_CashTransferred_9ed15688-ce5c-470d-acaa-bce756390f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations_d3f9d799-afb6-40e5-ac87-25c084f6f929" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations_d3f9d799-afb6-40e5-ac87-25c084f6f929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_86264647-300f-4885-a130-f5bd222559f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_86264647-300f-4885-a130-f5bd222559f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_538238de-d757-4bf0-b2e3-aace48ab6cbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_538238de-d757-4bf0-b2e3-aace48ab6cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital_1bf769e0-82a6-4f96-8317-19f4e90bd4ad" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital_1bf769e0-82a6-4f96-8317-19f4e90bd4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfVotingEquityInterestsDivested_095b7dd2-5240-4e77-b9c5-33ce7768a952" xlink:href="sny-20231231.xsd#sny_PercentageOfVotingEquityInterestsDivested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_PercentageOfVotingEquityInterestsDivested_095b7dd2-5240-4e77-b9c5-33ce7768a952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsiderationTransferredMaximumAmount_c7c40e99-fbff-44d0-acdc-391535dbb6a8" xlink:href="sny-20231231.xsd#sny_ConsiderationTransferredMaximumAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_ConsiderationTransferredMaximumAmount_c7c40e99-fbff-44d0-acdc-391535dbb6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsiderationTransferredValuationPeriod_c6be73c7-fece-4785-9e6e-5f09194665e2" xlink:href="sny-20231231.xsd#sny_ConsiderationTransferredValuationPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_ConsiderationTransferredValuationPeriod_c6be73c7-fece-4785-9e6e-5f09194665e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_c0a5b879-3f23-46ee-ba54-5be325bb8e4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_c0a5b879-3f23-46ee-ba54-5be325bb8e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod_8d5b4a2b-fad8-4b08-8ef4-97c3ff819cf2" xlink:href="sny-20231231.xsd#sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod_8d5b4a2b-fad8-4b08-8ef4-97c3ff819cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_55d740db-2861-438f-b9ec-e425a9feb3cc" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendPercentageOfShareCapital"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital_55d740db-2861-438f-b9ec-e425a9feb3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares_1cd091c0-0f81-400d-8a54-d3c2da4638af" xlink:href="sny-20231231.xsd#sny_SpecialDistributionSharesReceivedPerConversionOfParentShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares_1cd091c0-0f81-400d-8a54-d3c2da4638af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialDistributionNumberOfSharesConverted_1e02fa74-8055-4b34-9857-a57edb26123f" xlink:href="sny-20231231.xsd#sny_SpecialDistributionNumberOfSharesConverted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_SpecialDistributionNumberOfSharesConverted_1e02fa74-8055-4b34-9857-a57edb26123f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialDistributionPercentageOfShareCapitalDistributed_29826f5b-b1e9-4fbe-9bd6-18c30ffc1d3c" xlink:href="sny-20231231.xsd#sny_SpecialDistributionPercentageOfShareCapitalDistributed"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_SpecialDistributionPercentageOfShareCapitalDistributed_29826f5b-b1e9-4fbe-9bd6-18c30ffc1d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_baf58271-068e-4758-92aa-5fc9137a070c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_baf58271-068e-4758-92aa-5fc9137a070c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets_57ddebc4-dfa2-49a5-aa8c-083f97d437bd" xlink:href="sny-20231231.xsd#sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets_57ddebc4-dfa2-49a5-aa8c-083f97d437bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill_69d7519e-8574-4f91-8afc-63075d8e4d68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill_69d7519e-8574-4f91-8afc-63075d8e4d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_2d615c96-e1cd-4a8f-9d83-74cbfb51ac9f" xlink:href="sny-20231231.xsd#sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent_2d615c96-e1cd-4a8f-9d83-74cbfb51ac9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019_fb58b1e5-c74f-447f-a681-d93f531d5ae2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_WeightedAverageSharePrice2019_fb58b1e5-c74f-447f-a681-d93f531d5ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_f4b9153c-42b0-4aa7-b90b-c73c5dca0e0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_InvestmentAccountedForUsingEquityMethod_f4b9153c-42b0-4aa7-b90b-c73c5dca0e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_b2743057-0b8d-4706-a072-1274d89cbf62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_b2743057-0b8d-4706-a072-1274d89cbf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_28025e97-a8da-4e17-92cb-bedb509b50d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisions"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_OtherProvisions_28025e97-a8da-4e17-92cb-bedb509b50d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_141eed15-264c-44d9-bcd8-ebbb4c9c5850" xlink:href="sny-20231231.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_OtherGainsLossesAndLitigation_141eed15-264c-44d9-bcd8-ebbb4c9c5850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b119abde-6e1c-4a33-9d74-bb2c65c2f77f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b119abde-6e1c-4a33-9d74-bb2c65c2f77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_25cf48d0-3d46-4a99-8697-aa2d2c3dbfee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_25cf48d0-3d46-4a99-8697-aa2d2c3dbfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementPeriodAfterLossOfControl_97b86516-70ed-4b48-8c81-49eb5c6e7fcd" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementPeriodAfterLossOfControl"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_CollaborationAgreementPeriodAfterLossOfControl_97b86516-70ed-4b48-8c81-49eb5c6e7fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementAnnualNetSalesTarget_3cac596d-34bc-433d-8f7f-d61617dfe466" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementAnnualNetSalesTarget"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_CollaborationAgreementAnnualNetSalesTarget_3cac596d-34bc-433d-8f7f-d61617dfe466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementCommitmentAmount_b7443b2f-cfe8-493c-bfe3-8c4c0b144757" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementCommitmentAmount"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_CollaborationAgreementCommitmentAmount_b7443b2f-cfe8-493c-bfe3-8c4c0b144757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_ab420b2c-7f7d-4bb5-8cda-bcf605391d98" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_ab420b2c-7f7d-4bb5-8cda-bcf605391d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_54444ebf-5600-4d3b-b3b0-6d70d1759f67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_54444ebf-5600-4d3b-b3b0-6d70d1759f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering_ada3b022-9752-4f9a-abfe-416eda575ede" xlink:href="sny-20231231.xsd#sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering_ada3b022-9752-4f9a-abfe-416eda575ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare_8f46a10e-9a11-44e1-846d-776bfb100a02" xlink:href="sny-20231231.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_BusinessCombinationPurchasePricePerShare_8f46a10e-9a11-44e1-846d-776bfb100a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering_ce9abc24-bd22-4937-b1cf-5304f5a63fb2" xlink:href="sny-20231231.xsd#sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering_ce9abc24-bd22-4937-b1cf-5304f5a63fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_8bb9e03b-c91c-4f11-83f5-c3e48f1fc686" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_8bb9e03b-c91c-4f11-83f5-c3e48f1fc686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired_65388710-80f1-4a60-846e-8fe265967c2b" xlink:href="sny-20231231.xsd#sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired_65388710-80f1-4a60-846e-8fe265967c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_04bb830c-3299-4475-83eb-4e5dbc16c749" xlink:href="sny-20231231.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_04bb830c-3299-4475-83eb-4e5dbc16c749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis_a09ca5fb-38c1-4fb9-b881-1f2f1db5229a" xlink:href="sny-20231231.xsd#sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_7834efac-ddcd-4a84-8e22-a5a4ddbcd9f5" xlink:to="loc_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis_a09ca5fb-38c1-4fb9-b881-1f2f1db5229a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_de3c763b-9e39-4f91-b671-a6b2471bd4b3" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_15854671-2da0-45ae-8e42-693dbda8b635" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_de3c763b-9e39-4f91-b671-a6b2471bd4b3" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_15854671-2da0-45ae-8e42-693dbda8b635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_cb530c32-c78f-4cc1-8436-16c51b8dbc4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_15854671-2da0-45ae-8e42-693dbda8b635" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_cb530c32-c78f-4cc1-8436-16c51b8dbc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_df393c82-9308-4de0-8115-3df81770a6b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_cb530c32-c78f-4cc1-8436-16c51b8dbc4b" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_df393c82-9308-4de0-8115-3df81770a6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixPharmaceuticalsIncMember_81639444-5eb1-4b88-a0bd-1b916c56a245" xlink:href="sny-20231231.xsd#sny_AmunixPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_df393c82-9308-4de0-8115-3df81770a6b0" xlink:to="loc_sny_AmunixPharmaceuticalsIncMember_81639444-5eb1-4b88-a0bd-1b916c56a245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioMember_8a96dfa1-94ea-4e2f-ac7a-7fc7117725f7" xlink:href="sny-20231231.xsd#sny_TranslateBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_df393c82-9308-4de0-8115-3df81770a6b0" xlink:to="loc_sny_TranslateBioMember_8a96dfa1-94ea-4e2f-ac7a-7fc7117725f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_15854671-2da0-45ae-8e42-693dbda8b635" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_777efb89-cbe7-4798-b65a-3da4c759a4aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_777efb89-cbe7-4798-b65a-3da4c759a4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_828adc2c-d6c4-4a32-b509-b785c7055bc4" xlink:href="sny-20231231.xsd#sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate_828adc2c-d6c4-4a32-b509-b785c7055bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_89911798-59af-462d-bd1a-06b10a3fb94e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_89911798-59af-462d-bd1a-06b10a3fb94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_fd785d6c-b5c5-44b9-a413-29b21bc74332" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_fd785d6c-b5c5-44b9-a413-29b21bc74332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_53a022ba-afd0-4329-9adb-aebd0a7bc030" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate_53a022ba-afd0-4329-9adb-aebd0a7bc030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_96dda491-278f-4a94-8e30-7baa5d53db4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_96dda491-278f-4a94-8e30-7baa5d53db4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_26b94672-d7f4-4192-9192-b69d04abd5ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_26b94672-d7f4-4192-9192-b69d04abd5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_7aee0651-6b2d-4940-8298-57301dfa1af6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_9b5da08e-a50a-496c-aa0f-4d51d0238888" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_7aee0651-6b2d-4940-8298-57301dfa1af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_090d1345-7162-4213-adfc-402c8eb67563" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3fe0523e-79cb-462d-91d9-bcdf49ab14fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_090d1345-7162-4213-adfc-402c8eb67563" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3fe0523e-79cb-462d-91d9-bcdf49ab14fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_85f95052-036a-4a70-95ae-c01489ccf708" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3fe0523e-79cb-462d-91d9-bcdf49ab14fb" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_85f95052-036a-4a70-95ae-c01489ccf708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_85f95052-036a-4a70-95ae-c01489ccf708" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandMember_aff10b88-4b71-48a4-8278-7c420f85988d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:to="loc_ifrs-full_LandMember_aff10b88-4b71-48a4-8278-7c420f85988d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_65c9976a-6e88-41f7-88c7-db727a58dee4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:to="loc_ifrs-full_BuildingsMember_65c9976a-6e88-41f7-88c7-db727a58dee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MachineryAndEquipment1Member_cafd2a5c-6d4a-4667-9f6d-17987ea54f62" xlink:href="sny-20231231.xsd#sny_MachineryAndEquipment1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:to="loc_sny_MachineryAndEquipment1Member_cafd2a5c-6d4a-4667-9f6d-17987ea54f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_e10d9345-cc88-4be8-bb8f-cabd7b664cc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_e10d9345-cc88-4be8-bb8f-cabd7b664cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PropertyPlantAndEquipmentInProcessMember_26275620-913f-4b9e-8860-4a63a2cc50f6" xlink:href="sny-20231231.xsd#sny_PropertyPlantAndEquipmentInProcessMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_43c0cf60-3297-4597-9391-3b6d01a8437b" xlink:to="loc_sny_PropertyPlantAndEquipmentInProcessMember_26275620-913f-4b9e-8860-4a63a2cc50f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506a5061-46e6-46d9-85c4-8c017a79cd4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3fe0523e-79cb-462d-91d9-bcdf49ab14fb" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506a5061-46e6-46d9-85c4-8c017a79cd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_5ea19592-8862-4d4c-9755-4bd82e0e879d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_506a5061-46e6-46d9-85c4-8c017a79cd4b" xlink:to="loc_ifrs-full_CarryingAmountMember_5ea19592-8862-4d4c-9755-4bd82e0e879d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_e2e94b78-4d39-49cb-9f8c-987e5dd7c476" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_5ea19592-8862-4d4c-9755-4bd82e0e879d" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_e2e94b78-4d39-49cb-9f8c-987e5dd7c476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_f6487b8f-39fa-4309-a425-ebe92a7ec23c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_5ea19592-8862-4d4c-9755-4bd82e0e879d" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_f6487b8f-39fa-4309-a425-ebe92a7ec23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3fe0523e-79cb-462d-91d9-bcdf49ab14fb" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_3324623a-2ca4-48b2-8782-34f06f347340" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_3324623a-2ca4-48b2-8782-34f06f347340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment_25b4d770-4f75-4e9a-b4cb-be17d2a9f25d" xlink:href="sny-20231231.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment_25b4d770-4f75-4e9a-b4cb-be17d2a9f25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationExpense_9da319b8-fa00-458d-ae56-927291f882fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_DepreciationExpense_9da319b8-fa00-458d-ae56-927291f882fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment_4a68ef09-8380-4f34-9590-fe6079e8cc94" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment_4a68ef09-8380-4f34-9590-fe6079e8cc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_83bec32a-e732-4287-8214-9e4ee52881a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_83bec32a-e732-4287-8214-9e4ee52881a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment_c64a6f04-f93d-4b84-aaff-f7b35ec286f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment_c64a6f04-f93d-4b84-aaff-f7b35ec286f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_ba324dad-eedc-43e6-9663-243f1725b910" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_ba324dad-eedc-43e6-9663-243f1725b910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_4d73fc7b-bf9d-4376-9f84-0a251df9c5a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_4d73fc7b-bf9d-4376-9f84-0a251df9c5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_855639d0-5a5b-4d85-9c06-031564993db8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_bf0c7b12-d152-4278-a940-35fbbfc6ecc8" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_855639d0-5a5b-4d85-9c06-031564993db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_cb6a2e4d-6e7f-4c8a-96b7-b8074f694f7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_040fe269-3e9d-44c9-b46e-52ed4fe88931" xlink:href="sny-20231231.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_cb6a2e4d-6e7f-4c8a-96b7-b8074f694f7f" xlink:to="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_040fe269-3e9d-44c9-b46e-52ed4fe88931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_b778d34d-12f6-48f9-a7d1-ffd824a3748e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_040fe269-3e9d-44c9-b46e-52ed4fe88931" xlink:to="loc_ifrs-full_SegmentsAxis_b778d34d-12f6-48f9-a7d1-ffd824a3748e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_b778d34d-12f6-48f9-a7d1-ffd824a3748e" xlink:to="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_40e536bc-0d5f-446c-9d03-b4c8247063d4" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:to="loc_sny_BiopharmaSegmentMember_40e536bc-0d5f-446c-9d03-b4c8247063d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaceuticalsSegmentMember_23d14567-2acc-44dd-a420-38fd2055c3b5" xlink:href="sny-20231231.xsd#sny_PharmaceuticalsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:to="loc_sny_PharmaceuticalsSegmentMember_23d14567-2acc-44dd-a420-38fd2055c3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesSegmentMember_49a28eac-5780-4b43-831d-afcc12b4ab83" xlink:href="sny-20231231.xsd#sny_VaccinesSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:to="loc_sny_VaccinesSegmentMember_49a28eac-5780-4b43-831d-afcc12b4ab83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_77ba1d40-deeb-4504-b5e9-20a466fa5ca8" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_839b7e65-8c8a-4154-bcac-dc5dd03dec79" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_77ba1d40-deeb-4504-b5e9-20a466fa5ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_6b098cd4-1142-43a0-9eef-934c65bf4fc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_040fe269-3e9d-44c9-b46e-52ed4fe88931" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_6b098cd4-1142-43a0-9eef-934c65bf4fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_e25c1d04-96d0-4a12-b6b7-a0c8f8e27121" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_6b098cd4-1142-43a0-9eef-934c65bf4fc4" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_e25c1d04-96d0-4a12-b6b7-a0c8f8e27121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManufacturingAndSupplyMember_3a13cd1e-25b8-4c05-884d-d960d7a09100" xlink:href="sny-20231231.xsd#sny_ManufacturingAndSupplyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_e25c1d04-96d0-4a12-b6b7-a0c8f8e27121" xlink:to="loc_sny_ManufacturingAndSupplyMember_3a13cd1e-25b8-4c05-884d-d960d7a09100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems_47b751e7-80cd-49c3-b7f6-feb75c171653" xlink:href="sny-20231231.xsd#sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable_040fe269-3e9d-44c9-b46e-52ed4fe88931" xlink:to="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems_47b751e7-80cd-49c3-b7f6-feb75c171653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_04b2b9ac-6f33-4a62-be9d-8595c53cc67a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems_47b751e7-80cd-49c3-b7f6-feb75c171653" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_04b2b9ac-6f33-4a62-be9d-8595c53cc67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestCostsCapitalised_17d7d7d0-0e84-45c3-b02a-7da9018858dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestCostsCapitalised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems_47b751e7-80cd-49c3-b7f6-feb75c171653" xlink:to="loc_ifrs-full_InterestCostsCapitalised_17d7d7d0-0e84-45c3-b02a-7da9018858dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofOffBalanceSheetCommitmentsRelatingtoPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PropertyplantandequipmentSummaryofOffBalanceSheetCommitmentsRelatingtoPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofOffBalanceSheetCommitmentsRelatingtoPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_4150ccdc-bff4-45f9-b270-2f5e402de895" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FirmOrdersOfPropertyPlantAndEquipment_f1287daf-39c5-4bfa-a4fc-a7a2c886200c" xlink:href="sny-20231231.xsd#sny_FirmOrdersOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_4150ccdc-bff4-45f9-b270-2f5e402de895" xlink:to="loc_sny_FirmOrdersOfPropertyPlantAndEquipment_f1287daf-39c5-4bfa-a4fc-a7a2c886200c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_08833d2d-107a-4599-a6bb-29681fd189fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_4150ccdc-bff4-45f9-b270-2f5e402de895" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity_08833d2d-107a-4599-a6bb-29681fd189fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofImpairmentLossesRecognisedinPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PropertyplantandequipmentSummaryofImpairmentLossesRecognisedinPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofImpairmentLossesRecognisedinPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_63a134b0-1a83-45d6-8bac-22203b5ad937" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_db92d101-797a-4f29-bb9a-d339b9d13ba9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_63a134b0-1a83-45d6-8bac-22203b5ad937" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_db92d101-797a-4f29-bb9a-d339b9d13ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_edb0c6cb-3c27-4c3d-807c-15b6bd1961ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_aae9ecca-8c7b-47e9-9f4d-0d10e7acd2cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_edb0c6cb-3c27-4c3d-807c-15b6bd1961ec" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_aae9ecca-8c7b-47e9-9f4d-0d10e7acd2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bb4c6037-7ad0-48b3-bfc3-1a5dc8f6f84d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_aae9ecca-8c7b-47e9-9f4d-0d10e7acd2cc" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bb4c6037-7ad0-48b3-bfc3-1a5dc8f6f84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_5dcfd018-243f-4161-b178-dcbfe19fbee0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bb4c6037-7ad0-48b3-bfc3-1a5dc8f6f84d" xlink:to="loc_ifrs-full_CarryingAmountMember_5dcfd018-243f-4161-b178-dcbfe19fbee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_2b5ca67e-2687-484f-a7f6-a377115ce5a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_5dcfd018-243f-4161-b178-dcbfe19fbee0" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_2b5ca67e-2687-484f-a7f6-a377115ce5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_50a58187-01c3-454e-8f94-83eb3aff3289" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_5dcfd018-243f-4161-b178-dcbfe19fbee0" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_50a58187-01c3-454e-8f94-83eb3aff3289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_38dabd5c-78b2-4c89-9124-f42d9e9457cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_aae9ecca-8c7b-47e9-9f4d-0d10e7acd2cc" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_38dabd5c-78b2-4c89-9124-f42d9e9457cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_8333746a-9b0d-4b78-8c96-33550ae27cd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_38dabd5c-78b2-4c89-9124-f42d9e9457cc" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_8333746a-9b0d-4b78-8c96-33550ae27cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CambridgeMassachusettsMember_752bbc63-3d74-46d6-9ca1-6ba22e1c52b3" xlink:href="sny-20231231.xsd#sny_CambridgeMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8333746a-9b0d-4b78-8c96-33550ae27cd1" xlink:to="loc_sny_CambridgeMassachusettsMember_752bbc63-3d74-46d6-9ca1-6ba22e1c52b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OfficeSpaceCambridgeMassachusettsMember_5b35d7f6-a000-4aaa-ba3e-8b2fe27e83d7" xlink:href="sny-20231231.xsd#sny_OfficeSpaceCambridgeMassachusettsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8333746a-9b0d-4b78-8c96-33550ae27cd1" xlink:to="loc_sny_OfficeSpaceCambridgeMassachusettsMember_5b35d7f6-a000-4aaa-ba3e-8b2fe27e83d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LaboratoryFacilitiesCambridgeMassachusettsMember_b2c8c116-06e4-4784-8066-1a91d6fab4e7" xlink:href="sny-20231231.xsd#sny_LaboratoryFacilitiesCambridgeMassachusettsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8333746a-9b0d-4b78-8c96-33550ae27cd1" xlink:to="loc_sny_LaboratoryFacilitiesCambridgeMassachusettsMember_b2c8c116-06e4-4784-8066-1a91d6fab4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_aae9ecca-8c7b-47e9-9f4d-0d10e7acd2cc" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_b1eb4e24-56e9-497a-8e30-ed11756240b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_ifrs-full_RightofuseAssets_b1eb4e24-56e9-497a-8e30-ed11756240b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets_ebba1693-f67f-4848-a052-071e32f58bd6" xlink:href="sny-20231231.xsd#sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets_ebba1693-f67f-4848-a052-071e32f58bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets_4182fa98-7796-4ebe-a376-722a01210891" xlink:href="sny-20231231.xsd#sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets_4182fa98-7796-4ebe-a376-722a01210891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_a19ac231-5138-4b9d-b63c-cd42cf0e22d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_a19ac231-5138-4b9d-b63c-cd42cf0e22d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets_2a45dd27-d6d9-48f7-9dab-110b71553358" xlink:href="sny-20231231.xsd#sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets_2a45dd27-d6d9-48f7-9dab-110b71553358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets_4ec5d06e-12a5-468e-99eb-cca31eeab995" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets_4ec5d06e-12a5-468e-99eb-cca31eeab995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets_b379c745-1197-481d-a5a4-ffa0332f0361" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets_b379c745-1197-481d-a5a4-ffa0332f0361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_4af009c9-b17c-47a2-ad2c-026b2a138f1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_ifrs-full_RightofuseAssets_4af009c9-b17c-47a2-ad2c-026b2a138f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLeaseAgreementsSigned_3a582881-2989-43cc-b3fa-c68834ff057d" xlink:href="sny-20231231.xsd#sny_NumberOfLeaseAgreementsSigned"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_NumberOfLeaseAgreementsSigned_3a582881-2989-43cc-b3fa-c68834ff057d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InitialLeaseTerm_38c9a9e1-3400-4122-a46a-fa8c0597f834" xlink:href="sny-20231231.xsd#sny_InitialLeaseTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_sny_InitialLeaseTerm_38c9a9e1-3400-4122-a46a-fa8c0597f834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_b37e9107-a70b-41a4-84b7-52c22c5d1e21" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_ifrs-full_RightofuseAssets_b37e9107-a70b-41a4-84b7-52c22c5d1e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_3ac25a65-f81d-4865-944d-864a07858efc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_ccb17c80-a959-4e4a-9381-99b24d81f39b" xlink:to="loc_ifrs-full_LeaseLiabilities_3ac25a65-f81d-4865-944d-864a07858efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PropertyplantandequipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_ff8fbd3e-ffd5-4c65-9d55-2ac2aa8ce415" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_753b0771-bda2-477f-a27a-62345133ac27" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_ff8fbd3e-ffd5-4c65-9d55-2ac2aa8ce415" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_753b0771-bda2-477f-a27a-62345133ac27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_17d9d851-1ecf-4304-a7a7-6c6d1457f6b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_753b0771-bda2-477f-a27a-62345133ac27" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_17d9d851-1ecf-4304-a7a7-6c6d1457f6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_d4382ef9-7f69-4a55-9226-f474aa1d886a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_17d9d851-1ecf-4304-a7a7-6c6d1457f6b0" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_d4382ef9-7f69-4a55-9226-f474aa1d886a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandAndBuildingsMember_1185bc8c-e33a-422f-a395-733a6eb90bab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandAndBuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_d4382ef9-7f69-4a55-9226-f474aa1d886a" xlink:to="loc_ifrs-full_LandAndBuildingsMember_1185bc8c-e33a-422f-a395-733a6eb90bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_a01d8717-a80f-4ea8-b821-9a29b1a77f86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_d4382ef9-7f69-4a55-9226-f474aa1d886a" xlink:to="loc_ifrs-full_VehiclesMember_a01d8717-a80f-4ea8-b821-9a29b1a77f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_006236c4-a6d1-410d-a059-80776e974490" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_753b0771-bda2-477f-a27a-62345133ac27" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_006236c4-a6d1-410d-a059-80776e974490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeasedAssetsPercentage_0337feae-2d16-4254-96a7-13fa5d3a43f2" xlink:href="sny-20231231.xsd#sny_LeasedAssetsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_006236c4-a6d1-410d-a059-80776e974490" xlink:to="loc_sny_LeasedAssetsPercentage_0337feae-2d16-4254-96a7-13fa5d3a43f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_1803d451-d0e7-4739-b57c-a635305d1258" xlink:href="sny-20231231.xsd#sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_006236c4-a6d1-410d-a059-80776e974490" xlink:to="loc_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_1803d451-d0e7-4739-b57c-a635305d1258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_a10c423c-f53c-43fb-916e-fbfaf1ab9806" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_006236c4-a6d1-410d-a059-80776e974490" xlink:to="loc_ifrs-full_CashOutflowForLeases_a10c423c-f53c-43fb-916e-fbfaf1ab9806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_39cbbb9e-09ee-4001-8625-96a21db8afbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_624e03e0-b1db-45d0-98f4-9b64b65afa4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_39cbbb9e-09ee-4001-8625-96a21db8afbf" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_624e03e0-b1db-45d0-98f4-9b64b65afa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_def3365f-77c0-4cfb-b599-2c88c3904f26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_624e03e0-b1db-45d0-98f4-9b64b65afa4d" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_def3365f-77c0-4cfb-b599-2c88c3904f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_9a33f9ed-3921-4960-ab29-0ee3592dd311" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_def3365f-77c0-4cfb-b599-2c88c3904f26" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_9a33f9ed-3921-4960-ab29-0ee3592dd311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_6b08ad31-a92b-4c34-816e-403f357faa85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_9a33f9ed-3921-4960-ab29-0ee3592dd311" xlink:to="loc_ifrs-full_GoodwillMember_6b08ad31-a92b-4c34-816e-403f357faa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_624e03e0-b1db-45d0-98f4-9b64b65afa4d" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_0138070d-e1e1-4bb0-839a-9b80f73ec16b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_0138070d-e1e1-4bb0-839a-9b80f73ec16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_6d34386c-8171-4e80-a776-64caff298963" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_6d34386c-8171-4e80-a776-64caff298963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill_2a328050-a633-4e50-8669-756b4a29d787" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill_2a328050-a633-4e50-8669-756b4a29d787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_566e6469-c3bc-4442-9e32-f7674325f109" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_566e6469-c3bc-4442-9e32-f7674325f109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_11dc76e6-e924-4176-8309-0bf96e5f05fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_8681de27-d5b4-4a14-b3e3-7f778d1a1636" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_11dc76e6-e924-4176-8309-0bf96e5f05fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_30ce58c2-4127-4f5e-bbc9-28a1518f1f77" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_871db5ea-b90c-475f-ac59-246647763613" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_30ce58c2-4127-4f5e-bbc9-28a1518f1f77" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_871db5ea-b90c-475f-ac59-246647763613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_1ea1b05f-8843-4f27-a16c-d81450d9b829" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_871db5ea-b90c-475f-ac59-246647763613" xlink:to="loc_ifrs-full_SegmentsAxis_1ea1b05f-8843-4f27-a16c-d81450d9b829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_0db619af-396a-4d21-9655-9ea8882e3292" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_1ea1b05f-8843-4f27-a16c-d81450d9b829" xlink:to="loc_ifrs-full_SegmentsMember_0db619af-396a-4d21-9655-9ea8882e3292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_3f70ecdd-8b66-42ba-87d6-5369382b1a73" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_0db619af-396a-4d21-9655-9ea8882e3292" xlink:to="loc_sny_BiopharmaSegmentMember_3f70ecdd-8b66-42ba-87d6-5369382b1a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_37c6b9a0-c642-4dc1-8a49-1bb2f4b12562" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_0db619af-396a-4d21-9655-9ea8882e3292" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_37c6b9a0-c642-4dc1-8a49-1bb2f4b12562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_f6b8fd4d-b37a-49bd-a122-a4a917c0fa16" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_871db5ea-b90c-475f-ac59-246647763613" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_f6b8fd4d-b37a-49bd-a122-a4a917c0fa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_7a3cdf53-d29e-4b9c-b1a0-940a807d126d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_f6b8fd4d-b37a-49bd-a122-a4a917c0fa16" xlink:to="loc_ifrs-full_Goodwill_7a3cdf53-d29e-4b9c-b1a0-940a807d126d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_fcd2e41b-ced8-478b-ae9c-c8308285ca96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_d558190f-3863-4651-b076-62bac3ba8fee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_fcd2e41b-ced8-478b-ae9c-c8308285ca96" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_d558190f-3863-4651-b076-62bac3ba8fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_941875be-c441-4517-af34-625420a61ee1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_d558190f-3863-4651-b076-62bac3ba8fee" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_941875be-c441-4517-af34-625420a61ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_e8b9c24d-ca44-4ccc-85ed-0740ac71dc62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_941875be-c441-4517-af34-625420a61ee1" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_e8b9c24d-ca44-4ccc-85ed-0740ac71dc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_0ca86b38-bbae-40ec-a268-f997edafcc57" xlink:href="sny-20231231.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_e8b9c24d-ca44-4ccc-85ed-0740ac71dc62" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_0ca86b38-bbae-40ec-a268-f997edafcc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixMember_58034244-397a-4128-bd1a-06712277cb72" xlink:href="sny-20231231.xsd#sny_AmunixMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_e8b9c24d-ca44-4ccc-85ed-0740ac71dc62" xlink:to="loc_sny_AmunixMember_58034244-397a-4128-bd1a-06712277cb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioMember_127a30d5-3aaa-4cd4-9ed5-579c4379957a" xlink:href="sny-20231231.xsd#sny_TranslateBioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_e8b9c24d-ca44-4ccc-85ed-0740ac71dc62" xlink:to="loc_sny_TranslateBioMember_127a30d5-3aaa-4cd4-9ed5-579c4379957a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_319dd287-e6bd-4ab3-92e2-709c96021448" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_d558190f-3863-4651-b076-62bac3ba8fee" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_319dd287-e6bd-4ab3-92e2-709c96021448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_319dd287-e6bd-4ab3-92e2-709c96021448" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_c123f3a6-e89b-43ca-aae8-821542629e42" xlink:href="sny-20231231.xsd#sny_MarketedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:to="loc_sny_MarketedProductsMember_c123f3a6-e89b-43ca-aae8-821542629e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TechnologicalPlatformsMember_5611e0d2-f576-44d8-a210-57160ae0c900" xlink:href="sny-20231231.xsd#sny_TechnologicalPlatformsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:to="loc_sny_TechnologicalPlatformsMember_5611e0d2-f576-44d8-a210-57160ae0c900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_20186ac5-1c14-4936-97e9-ac807bedf0e8" xlink:href="sny-20231231.xsd#sny_OtherIntangibleAssetsExcludingSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:to="loc_sny_OtherIntangibleAssetsExcludingSoftwareMember_20186ac5-1c14-4936-97e9-ac807bedf0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ALTUVIIIOMember_c47f0f62-5b85-476b-a726-45903efafacb" xlink:href="sny-20231231.xsd#sny_ALTUVIIIOMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_f4579554-f818-4aaf-9c7a-e56ed9bede61" xlink:to="loc_sny_ALTUVIIIOMember_c47f0f62-5b85-476b-a726-45903efafacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_30c6cb96-174b-4a49-ab0b-24624fda83d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_d558190f-3863-4651-b076-62bac3ba8fee" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_30c6cb96-174b-4a49-ab0b-24624fda83d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_a30ff506-0a3b-4f63-b1c5-4a961685ba5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_30c6cb96-174b-4a49-ab0b-24624fda83d9" xlink:to="loc_ifrs-full_CarryingAmountMember_a30ff506-0a3b-4f63-b1c5-4a961685ba5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_c4a12644-1538-43ab-bf5a-475e0ad97f15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_a30ff506-0a3b-4f63-b1c5-4a961685ba5d" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_c4a12644-1538-43ab-bf5a-475e0ad97f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_d558190f-3863-4651-b076-62bac3ba8fee" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments1_045cdfd4-32a0-49da-ae20-01ca50707180" xlink:href="sny-20231231.xsd#sny_NumberOfOperatingSegments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_sny_NumberOfOperatingSegments1_045cdfd4-32a0-49da-ae20-01ca50707180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_bfbb8b3c-4db7-4306-87da-86c170fbf3b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_bfbb8b3c-4db7-4306-87da-86c170fbf3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_67c65aeb-aec3-449a-9cc4-201c1769410e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_ifrs-full_Goodwill_67c65aeb-aec3-449a-9cc4-201c1769410e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_9981bf35-08f5-40d8-ae4c-53e19b886552" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_9981bf35-08f5-40d8-ae4c-53e19b886552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_c6f9d58d-6d3c-4241-ad3c-c911925ca211" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_c6f9d58d-6d3c-4241-ad3c-c911925ca211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_34498938-3622-4ad5-a4df-6d5a7b0fadca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_d849ae6b-2514-447e-b666-159c2a818fac" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_34498938-3622-4ad5-a4df-6d5a7b0fadca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_1e957486-604a-4194-be51-efa70326f954" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_1e957486-604a-4194-be51-efa70326f954" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a5c314b3-a75f-4223-a2dd-e96cb96372f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a5c314b3-a75f-4223-a2dd-e96cb96372f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_d32ebdbd-ea2a-4b1b-95fb-729e2a3d01a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a5c314b3-a75f-4223-a2dd-e96cb96372f7" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_d32ebdbd-ea2a-4b1b-95fb-729e2a3d01a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AcquiredRDMember_c2774a21-701a-4f6f-aeb0-8946e53f309d" xlink:href="sny-20231231.xsd#sny_AcquiredRDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_d32ebdbd-ea2a-4b1b-95fb-729e2a3d01a0" xlink:to="loc_sny_AcquiredRDMember_c2774a21-701a-4f6f-aeb0-8946e53f309d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_5cb9ccaf-cd62-4ef1-b600-a00a267df830" xlink:href="sny-20231231.xsd#sny_MarketedProductsTrademarksAndOtherRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_d32ebdbd-ea2a-4b1b-95fb-729e2a3d01a0" xlink:to="loc_sny_MarketedProductsTrademarksAndOtherRightsMember_5cb9ccaf-cd62-4ef1-b600-a00a267df830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_862eb23a-da84-4a1e-b2ab-a541faa792bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_d32ebdbd-ea2a-4b1b-95fb-729e2a3d01a0" xlink:to="loc_ifrs-full_ComputerSoftwareMember_862eb23a-da84-4a1e-b2ab-a541faa792bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_4c52ec54-ed25-4cef-b94a-741fcc388a24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_4c52ec54-ed25-4cef-b94a-741fcc388a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_e1fae8a8-ec15-4fd6-bf44-5b06ed9bbee5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_4c52ec54-ed25-4cef-b94a-741fcc388a24" xlink:to="loc_ifrs-full_CarryingAmountMember_e1fae8a8-ec15-4fd6-bf44-5b06ed9bbee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1f990801-e908-4c05-83ca-26d387ceb240" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_e1fae8a8-ec15-4fd6-bf44-5b06ed9bbee5" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_1f990801-e908-4c05-83ca-26d387ceb240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_7d3427a7-b36f-4b4b-9ed7-9b06a57e6d62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_e1fae8a8-ec15-4fd6-bf44-5b06ed9bbee5" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_7d3427a7-b36f-4b4b-9ed7-9b06a57e6d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_aeaac530-89de-47d1-b4e8-f49e0765cbb3" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:to="loc_sny_PrincipalAlliancesAxis_aeaac530-89de-47d1-b4e8-f49e0765cbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_7b6e14e4-66d8-40cb-ae78-d0c92d85037c" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_aeaac530-89de-47d1-b4e8-f49e0765cbb3" xlink:to="loc_sny_PrincipalAlliancesDomain_7b6e14e4-66d8-40cb-ae78-d0c92d85037c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IOLicenseAndCollaborationAgreementMember_fd7f0baf-36ae-470c-bf6d-21e3b7ed4b95" xlink:href="sny-20231231.xsd#sny_IOLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_7b6e14e4-66d8-40cb-ae78-d0c92d85037c" xlink:to="loc_sny_IOLicenseAndCollaborationAgreementMember_fd7f0baf-36ae-470c-bf6d-21e3b7ed4b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_81b2da00-9ec3-4060-ab69-a13d46e6d12a" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_7b6e14e4-66d8-40cb-ae78-d0c92d85037c" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_81b2da00-9ec3-4060-ab69-a13d46e6d12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_a8e05ed5-137a-4ec2-9b4e-a7195b0605e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:to="loc_ifrs-full_CounterpartiesAxis_a8e05ed5-137a-4ec2-9b4e-a7195b0605e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_eb1b2e74-d092-4319-a1d9-386723f76c88" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_a8e05ed5-137a-4ec2-9b4e-a7195b0605e3" xlink:to="loc_ifrs-full_CounterpartiesMember_eb1b2e74-d092-4319-a1d9-386723f76c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TevaPharmaceuticalsMember_6a792eeb-e336-4fbe-aae4-7baa170c3c71" xlink:href="sny-20231231.xsd#sny_TevaPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_eb1b2e74-d092-4319-a1d9-386723f76c88" xlink:to="loc_sny_TevaPharmaceuticalsMember_6a792eeb-e336-4fbe-aae4-7baa170c3c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JanssenPharmaceuticalsIncMember_248fe2f6-f2d3-48f3-b4a5-8f243db7e297" xlink:href="sny-20231231.xsd#sny_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_eb1b2e74-d092-4319-a1d9-386723f76c88" xlink:to="loc_sny_JanssenPharmaceuticalsIncMember_248fe2f6-f2d3-48f3-b4a5-8f243db7e297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_733fd0f4-f4ec-4541-874b-f502038b4589" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_91b4389a-0bfe-4bb1-992b-32ce2f22694b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_OtherIntangibleAssets_91b4389a-0bfe-4bb1-992b-32ce2f22694b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_f627c0b1-2faf-4e55-a318-6b7596ca6149" xlink:href="sny-20231231.xsd#sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets_f627c0b1-2faf-4e55-a318-6b7596ca6149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_89531309-6c9d-48b3-b65e-b4d65741e8fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_89531309-6c9d-48b3-b65e-b4d65741e8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_304e7deb-748b-4e5b-ae9d-ba266ad0aaa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_304e7deb-748b-4e5b-ae9d-ba266ad0aaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_2c2b6843-18fb-4538-98ab-cd1696c4a4c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill_2c2b6843-18fb-4538-98ab-cd1696c4a4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_42afec47-7f4c-41a7-99e2-2ca2e92857df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill_42afec47-7f4c-41a7-99e2-2ca2e92857df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_c100cdf1-00c0-4e5a-a8d3-5c3f4e07d8b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_c100cdf1-00c0-4e5a-a8d3-5c3f4e07d8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_54b117be-2747-48cf-8c83-8bd13c8b3afe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_54b117be-2747-48cf-8c83-8bd13c8b3afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssets_9ec574f0-5a73-4e23-a108-7910ecbc6502" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6556f032-47b6-4123-9d46-5f799e7ea563" xlink:to="loc_ifrs-full_OtherIntangibleAssets_9ec574f0-5a73-4e23-a108-7910ecbc6502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_91be055b-68d1-40fa-a74d-fab87ba86f4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_19432bb7-c387-4409-865f-5a7f29c70ee8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_91be055b-68d1-40fa-a74d-fab87ba86f4e" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_19432bb7-c387-4409-865f-5a7f29c70ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_ad11e782-76a4-44a7-8eca-6b718cbe794a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_19432bb7-c387-4409-865f-5a7f29c70ee8" xlink:to="loc_ifrs-full_RangeAxis_ad11e782-76a4-44a7-8eca-6b718cbe794a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_e9577280-3bc7-4ba2-94bf-25d2b42f0f15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_ad11e782-76a4-44a7-8eca-6b718cbe794a" xlink:to="loc_ifrs-full_RangesMember_e9577280-3bc7-4ba2-94bf-25d2b42f0f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_d19e08bc-523c-4f35-b33e-9f861b5fa28d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_e9577280-3bc7-4ba2-94bf-25d2b42f0f15" xlink:to="loc_ifrs-full_BottomOfRangeMember_d19e08bc-523c-4f35-b33e-9f861b5fa28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_637e64d1-d7f3-420f-a8d3-b7f20de509b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_e9577280-3bc7-4ba2-94bf-25d2b42f0f15" xlink:to="loc_ifrs-full_TopOfRangeMember_637e64d1-d7f3-420f-a8d3-b7f20de509b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_061d8595-9018-4e12-ba84-207d050e6957" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_19432bb7-c387-4409-865f-5a7f29c70ee8" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_061d8595-9018-4e12-ba84-207d050e6957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_1f3ac7a0-6e5b-403b-ac66-017d3805f6af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_061d8595-9018-4e12-ba84-207d050e6957" xlink:to="loc_ifrs-full_CarryingAmountMember_1f3ac7a0-6e5b-403b-ac66-017d3805f6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_f15897ee-4e12-4647-aac5-416624f47591" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1f3ac7a0-6e5b-403b-ac66-017d3805f6af" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_f15897ee-4e12-4647-aac5-416624f47591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_3cf10627-9143-4c28-9cc3-ed3dcb62a700" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_1f3ac7a0-6e5b-403b-ac66-017d3805f6af" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_3cf10627-9143-4c28-9cc3-ed3dcb62a700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5c925911-3821-40af-b572-dd627e3521af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_19432bb7-c387-4409-865f-5a7f29c70ee8" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5c925911-3821-40af-b572-dd627e3521af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3d43bd7f-a5cc-44c0-beab-4c2c3c294a01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_5c925911-3821-40af-b572-dd627e3521af" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3d43bd7f-a5cc-44c0-beab-4c2c3c294a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_842cb665-edb2-4b61-a00b-0bc60487e92d" xlink:href="sny-20231231.xsd#sny_MarketedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3d43bd7f-a5cc-44c0-beab-4c2c3c294a01" xlink:to="loc_sny_MarketedProductsMember_842cb665-edb2-4b61-a00b-0bc60487e92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_3d43bd7f-a5cc-44c0-beab-4c2c3c294a01" xlink:to="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsGenzymeMember_b4c534c7-e174-4ac9-baaa-70f00dd574dc" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsGenzymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsGenzymeMember_b4c534c7-e174-4ac9-baaa-70f00dd574dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember_fd83bafe-e58c-4d2a-8c5d-ad546d07cae4" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember_fd83bafe-e58c-4d2a-8c5d-ad546d07cae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsAventisMember_cdca3d90-d11c-46b7-a0a5-21771b228210" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsAventisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsAventisMember_cdca3d90-d11c-46b7-a0a5-21771b228210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsChattemMember_32c7e5fc-cada-4074-98d6-78703310de19" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsChattemMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsChattemMember_32c7e5fc-cada-4074-98d6-78703310de19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsProteinSciencesMember_2178d6c0-ce7e-4849-82f8-b2d62b10502b" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsProteinSciencesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsProteinSciencesMember_2178d6c0-ce7e-4849-82f8-b2d62b10502b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsAblynxMember_d7ed7a84-2cad-460f-9914-ad139abaf631" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsAblynxMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsAblynxMember_d7ed7a84-2cad-460f-9914-ad139abaf631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsBioverativMember_77f209eb-c8fd-4087-afdc-3ca1a5a0c2d2" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsBioverativMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsBioverativMember_77f209eb-c8fd-4087-afdc-3ca1a5a0c2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsRezurockMember_b1ecf614-9ee6-4028-a141-dfb79fd52214" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsRezurockMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsRezurockMember_b1ecf614-9ee6-4028-a141-dfb79fd52214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsTZIELDMember_c09ce4a3-692d-49c6-962b-15b613ba101a" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsTZIELDMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsTZIELDMember_c09ce4a3-692d-49c6-962b-15b613ba101a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsBeyfortusMember_3c17a9a1-6410-4724-bee1-0e24f35a23d9" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsBeyfortusMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsBeyfortusMember_3c17a9a1-6410-4724-bee1-0e24f35a23d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalMarketedProductsQunolMember_3ef9412e-bf52-4687-9a35-694cf10bb7ab" xlink:href="sny-20231231.xsd#sny_PrincipalMarketedProductsQunolMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalMarketedProductsMember_b1ccc34c-51cc-4ecb-98a1-a0828c28ea48" xlink:to="loc_sny_PrincipalMarketedProductsQunolMember_3ef9412e-bf52-4687-9a35-694cf10bb7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_19432bb7-c387-4409-865f-5a7f29c70ee8" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConcentrationRiskThresholdPercentage_3beafa2f-6a42-402e-b8c3-689284d203fd" xlink:href="sny-20231231.xsd#sny_ConcentrationRiskThresholdPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:to="loc_sny_ConcentrationRiskThresholdPercentage_3beafa2f-6a42-402e-b8c3-689284d203fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_9090772e-c449-46a8-9ef1-ff835543f92b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_9090772e-c449-46a8-9ef1-ff835543f92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_36c58013-f8b9-4672-b126-8347454e7ca2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_36c58013-f8b9-4672-b126-8347454e7ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_1a7f318e-8238-4f60-aa07-61ff5ea18299" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b70252d2-b867-4417-81a7-b57694ed2062" xlink:to="loc_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_1a7f318e-8238-4f60-aa07-61ff5ea18299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_0cb55516-b7bc-4c8a-afab-5e8769c4eb10" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c957cc70-4dae-4eed-8961-515725107a7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillAbstract_0cb55516-b7bc-4c8a-afab-5e8769c4eb10" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c957cc70-4dae-4eed-8961-515725107a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseCategoriesAxis_2bf4f1bc-e616-4917-88a5-75fcd4a57ea7" xlink:href="sny-20231231.xsd#sny_ExpenseCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c957cc70-4dae-4eed-8961-515725107a7c" xlink:to="loc_sny_ExpenseCategoriesAxis_2bf4f1bc-e616-4917-88a5-75fcd4a57ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseCategoriesDomain_7dcc8a80-16c8-448f-b3b1-73881fbc2284" xlink:href="sny-20231231.xsd#sny_ExpenseCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ExpenseCategoriesAxis_2bf4f1bc-e616-4917-88a5-75fcd4a57ea7" xlink:to="loc_sny_ExpenseCategoriesDomain_7dcc8a80-16c8-448f-b3b1-73881fbc2284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember_0d351fbd-1366-434c-b4c0-23351bb933ee" xlink:href="sny-20231231.xsd#sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ExpenseCategoriesDomain_7dcc8a80-16c8-448f-b3b1-73881fbc2284" xlink:to="loc_sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember_0d351fbd-1366-434c-b4c0-23351bb933ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c957cc70-4dae-4eed-8961-515725107a7c" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_51baa244-38e8-4e28-8b56-2f697a71fbe5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:to="loc_ifrs-full_CostOfSales_51baa244-38e8-4e28-8b56-2f697a71fbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_92b78982-51fd-4b35-a682-99555c5c481e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_92b78982-51fd-4b35-a682-99555c5c481e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_ce4898b8-c3db-4d93-80ab-8f86e1a58239" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_ce4898b8-c3db-4d93-80ab-8f86e1a58239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_8e2dbd8e-f3e6-48b3-920e-e3a16da72845" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_8e2dbd8e-f3e6-48b3-920e-e3a16da72845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_483fee4b-e04c-403a-a6a8-ba3b8dbeb055" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_6fd97063-114a-41b6-a429-fd56c5cd78b4" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_483fee4b-e04c-403a-a6a8-ba3b8dbeb055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentOfAssetsAbstract_d66a3f09-1f30-446f-839c-8424bececf71" xlink:href="sny-20231231.xsd#sny_ImpairmentOfAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ImpairmentOfAssetsAbstract_d66a3f09-1f30-446f-839c-8424bececf71" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_faf364db-7a35-4717-a862-5aa4ce1fc98c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:to="loc_ifrs-full_SegmentsAxis_faf364db-7a35-4717-a862-5aa4ce1fc98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_1415d5e2-cc33-4e28-9d08-3d8c21620673" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_faf364db-7a35-4717-a862-5aa4ce1fc98c" xlink:to="loc_ifrs-full_SegmentsMember_1415d5e2-cc33-4e28-9d08-3d8c21620673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_9dcd270a-07fd-4d92-946d-c7bfad854fdd" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_1415d5e2-cc33-4e28-9d08-3d8c21620673" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_9dcd270a-07fd-4d92-946d-c7bfad854fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_2b0dad7f-e34b-4398-b215-eff716a13adc" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_1415d5e2-cc33-4e28-9d08-3d8c21620673" xlink:to="loc_sny_BiopharmaSegmentMember_2b0dad7f-e34b-4398-b215-eff716a13adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_3855bef9-f83c-4cd8-b05b-1f39793e7cc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_3855bef9-f83c-4cd8-b05b-1f39793e7cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForCashgeneratingUnitsMember_60418347-0c0e-4474-8a99-175457599205" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForCashgeneratingUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_3855bef9-f83c-4cd8-b05b-1f39793e7cc4" xlink:to="loc_ifrs-full_EntitysTotalForCashgeneratingUnitsMember_60418347-0c0e-4474-8a99-175457599205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember_80c24125-30e9-4172-860d-ca673c5eac03" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForCashgeneratingUnitsMember_60418347-0c0e-4474-8a99-175457599205" xlink:to="loc_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember_80c24125-30e9-4172-860d-ca673c5eac03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cfebbe86-844b-4bf9-bf18-fe4f4752cdf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cfebbe86-844b-4bf9-bf18-fe4f4752cdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_837c1b1c-0e78-4cfe-8912-804b412869b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cfebbe86-844b-4bf9-bf18-fe4f4752cdf0" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_837c1b1c-0e78-4cfe-8912-804b412869b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_1f60ea44-5d54-474b-ab74-6d81c5b67f4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_837c1b1c-0e78-4cfe-8912-804b412869b5" xlink:to="loc_ifrs-full_GoodwillMember_1f60ea44-5d54-474b-ab74-6d81c5b67f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f4d442fb-27ea-44fb-90e8-ceaa12219261" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:to="loc_ifrs-full_RangeAxis_f4d442fb-27ea-44fb-90e8-ceaa12219261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_fb30afde-d49f-4817-baf5-0a9bfc687b86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_f4d442fb-27ea-44fb-90e8-ceaa12219261" xlink:to="loc_ifrs-full_RangesMember_fb30afde-d49f-4817-baf5-0a9bfc687b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_17f6e995-d4e5-4db1-9250-b08de6cce14c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_fb30afde-d49f-4817-baf5-0a9bfc687b86" xlink:to="loc_ifrs-full_BottomOfRangeMember_17f6e995-d4e5-4db1-9250-b08de6cce14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_d2de7290-61ae-4c4d-b6fc-8b3b365a6304" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_fb30afde-d49f-4817-baf5-0a9bfc687b86" xlink:to="loc_ifrs-full_TopOfRangeMember_d2de7290-61ae-4c4d-b6fc-8b3b365a6304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_1e17251a-7717-452b-be02-d3be58b79ffb" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentTestingPercentage_4c7d9cdf-00d5-4232-b665-11a7a6dac9cb" xlink:href="sny-20231231.xsd#sny_ImpairmentTestingPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_ImpairmentTestingPercentage_4c7d9cdf-00d5-4232-b665-11a7a6dac9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UniformImpairmentTestingPercentage_60e1559d-e0c6-4a02-bf9a-9b8be11d12e1" xlink:href="sny-20231231.xsd#sny_UniformImpairmentTestingPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_UniformImpairmentTestingPercentage_60e1559d-e0c6-4a02-bf9a-9b8be11d12e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments1_2891579d-f5a9-4208-87d8-b61ac616a99d" xlink:href="sny-20231231.xsd#sny_NumberOfOperatingSegments1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_NumberOfOperatingSegments1_2891579d-f5a9-4208-87d8-b61ac616a99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PretaxDiscountRateAppliedForGoodwill_82a9bc20-53f4-4550-84a8-30a5bded3292" xlink:href="sny-20231231.xsd#sny_PretaxDiscountRateAppliedForGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_PretaxDiscountRateAppliedForGoodwill_82a9bc20-53f4-4550-84a8-30a5bded3292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UniformPreTaxDiscountRates_a03ff356-b989-4e8a-88c2-1add63edf7dd" xlink:href="sny-20231231.xsd#sny_UniformPreTaxDiscountRates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_UniformPreTaxDiscountRates_a03ff356-b989-4e8a-88c2-1add63edf7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_ca0efe1f-f459-49ac-95c5-a296c8430f78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_ca0efe1f-f459-49ac-95c5-a296c8430f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss_39ed78b5-9004-4495-a802-268fe623baba" xlink:href="sny-20231231.xsd#sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss_39ed78b5-9004-4495-a802-268fe623baba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss_0b173e21-54c5-4a13-b3cf-41605beaa9db" xlink:href="sny-20231231.xsd#sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss_0b173e21-54c5-4a13-b3cf-41605beaa9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss_b22a50b3-80b2-49b2-bbfb-637da01763e2" xlink:href="sny-20231231.xsd#sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss_b22a50b3-80b2-49b2-bbfb-637da01763e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_4518d4ab-df09-494a-a3bd-701a515f2309" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_4518d4ab-df09-494a-a3bd-701a515f2309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AfterTaxDiscountRates_23d85066-bc26-48f9-88f8-3a658cadaeb7" xlink:href="sny-20231231.xsd#sny_AfterTaxDiscountRates"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_d86a0892-a46a-41b6-a7af-009158156a2f" xlink:to="loc_sny_AfterTaxDiscountRates_23d85066-bc26-48f9-88f8-3a658cadaeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentOfAssetsAbstract_315e0d55-61d3-43de-8625-0343d0e98061" xlink:href="sny-20231231.xsd#sny_ImpairmentOfAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ImpairmentOfAssetsAbstract_315e0d55-61d3-43de-8625-0343d0e98061" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_448d7249-0206-40c5-9c29-dfeba05e94ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:to="loc_ifrs-full_SegmentsAxis_448d7249-0206-40c5-9c29-dfeba05e94ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_65f28e17-de39-4751-95d2-b1ee15b6ba27" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_448d7249-0206-40c5-9c29-dfeba05e94ad" xlink:to="loc_ifrs-full_SegmentsMember_65f28e17-de39-4751-95d2-b1ee15b6ba27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_997fd8c2-9281-48e5-9036-da1e977fd70c" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_65f28e17-de39-4751-95d2-b1ee15b6ba27" xlink:to="loc_sny_BiopharmaSegmentMember_997fd8c2-9281-48e5-9036-da1e977fd70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_ee11ff11-74b6-4d01-8b1f-037702321759" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_65f28e17-de39-4751-95d2-b1ee15b6ba27" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_ee11ff11-74b6-4d01-8b1f-037702321759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0ad9bb67-37f9-4783-a730-da237d61f6d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0ad9bb67-37f9-4783-a730-da237d61f6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83b96020-596f-4c42-9e80-8df608bac85a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_0ad9bb67-37f9-4783-a730-da237d61f6d8" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83b96020-596f-4c42-9e80-8df608bac85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_93a6c0b2-48eb-42e9-a592-78b082f337a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83b96020-596f-4c42-9e80-8df608bac85a" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_93a6c0b2-48eb-42e9-a592-78b082f337a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_0cd0469f-66cd-4c0d-9881-e08740078df0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_0cd0469f-66cd-4c0d-9881-e08740078df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_a4768eb3-37cd-4ba1-be65-27c677730c38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_0cd0469f-66cd-4c0d-9881-e08740078df0" xlink:to="loc_ifrs-full_ProductsAndServicesMember_a4768eb3-37cd-4ba1-be65-27c677730c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketedProductsMember_1e5e79a1-0b41-45e7-b53d-492cee9bb6ad" xlink:href="sny-20231231.xsd#sny_MarketedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_a4768eb3-37cd-4ba1-be65-27c677730c38" xlink:to="loc_sny_MarketedProductsMember_1e5e79a1-0b41-45e7-b53d-492cee9bb6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_c711fced-a34c-41f8-8547-66530ed12df8" xlink:href="sny-20231231.xsd#sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_a4768eb3-37cd-4ba1-be65-27c677730c38" xlink:to="loc_sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember_c711fced-a34c-41f8-8547-66530ed12df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProductAndServicesMember_b9fd0d6d-931d-47a6-b5ed-9e177491d983" xlink:href="sny-20231231.xsd#sny_OtherProductAndServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_a4768eb3-37cd-4ba1-be65-27c677730c38" xlink:to="loc_sny_OtherProductAndServicesMember_b9fd0d6d-931d-47a6-b5ed-9e177491d983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8058959-63eb-4048-b349-480dae7d32bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:to="loc_srt_ProductOrServiceAxis_b8058959-63eb-4048-b349-480dae7d32bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_791117ba-4402-48bf-a3a0-3dec71d299b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b8058959-63eb-4048-b349-480dae7d32bb" xlink:to="loc_srt_ProductsAndServicesDomain_791117ba-4402-48bf-a3a0-3dec71d299b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_c6133345-8f93-4740-abe1-dbaac05b6129" xlink:href="sny-20231231.xsd#sny_EloctateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_791117ba-4402-48bf-a3a0-3dec71d299b2" xlink:to="loc_sny_EloctateMember_c6133345-8f93-4740-abe1-dbaac05b6129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SAR444245Member_b15923cf-b92b-4b91-a907-0c9f316aa954" xlink:href="sny-20231231.xsd#sny_SAR444245Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_791117ba-4402-48bf-a3a0-3dec71d299b2" xlink:to="loc_sny_SAR444245Member_b15923cf-b92b-4b91-a907-0c9f316aa954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NKCellAndProXTenTechnologyPlatformsMember_fc54d6f8-c518-48a1-a6d1-842eed176d41" xlink:href="sny-20231231.xsd#sny_NKCellAndProXTenTechnologyPlatformsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_791117ba-4402-48bf-a3a0-3dec71d299b2" xlink:to="loc_sny_NKCellAndProXTenTechnologyPlatformsMember_fc54d6f8-c518-48a1-a6d1-842eed176d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_acdec203-a6e5-47f9-ae93-fe8cb9807498" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable_4c791f83-ba2e-49ed-997b-00c38fbd33ca" xlink:to="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_acdec203-a6e5-47f9-ae93-fe8cb9807498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_e1228134-029b-458f-8435-caca2f09e860" xlink:href="sny-20231231.xsd#sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_acdec203-a6e5-47f9-ae93-fe8cb9807498" xlink:to="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_e1228134-029b-458f-8435-caca2f09e860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount_f3c48f27-96fb-45cc-8fa8-ddbf0aeefd22" xlink:href="sny-20231231.xsd#sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_acdec203-a6e5-47f9-ae93-fe8cb9807498" xlink:to="loc_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount_f3c48f27-96fb-45cc-8fa8-ddbf0aeefd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_71d80d26-da91-4f36-a4e6-a665053a6d1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems_acdec203-a6e5-47f9-ae93-fe8cb9807498" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_71d80d26-da91-4f36-a4e6-a665053a6d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_f958d452-17b4-4aa4-b3bf-d2043066150e" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7a9b7d1b-84bf-4efb-9c9a-1813a07c9420" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_f958d452-17b4-4aa4-b3bf-d2043066150e" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7a9b7d1b-84bf-4efb-9c9a-1813a07c9420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cc931b8d-4105-49f6-b9c1-40c447ecb163" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7a9b7d1b-84bf-4efb-9c9a-1813a07c9420" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cc931b8d-4105-49f6-b9c1-40c447ecb163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_93dff1d9-6d82-4500-afc1-470a19dce855" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_cc931b8d-4105-49f6-b9c1-40c447ecb163" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_93dff1d9-6d82-4500-afc1-470a19dce855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_995bcb99-2a33-4701-b574-1ec22c625212" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_93dff1d9-6d82-4500-afc1-470a19dce855" xlink:to="loc_sny_EuroapiMember_995bcb99-2a33-4701-b574-1ec22c625212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember_b75735e4-1d3f-44ce-9e62-4842ca7bab15" xlink:href="sny-20231231.xsd#sny_MCMVaccineBVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_93dff1d9-6d82-4500-afc1-470a19dce855" xlink:to="loc_sny_MCMVaccineBVMember_b75735e4-1d3f-44ce-9e62-4842ca7bab15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_b1d2ce54-a7a6-4426-a647-0408ed24cff3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7a9b7d1b-84bf-4efb-9c9a-1813a07c9420" xlink:to="loc_ifrs-full_JointVenturesAxis_b1d2ce54-a7a6-4426-a647-0408ed24cff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_d6195049-8894-45a0-b189-4e2e431cc117" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_b1d2ce54-a7a6-4426-a647-0408ed24cff3" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_d6195049-8894-45a0-b189-4e2e431cc117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember_8fd3f67f-b16c-4fed-b7c3-4ed0c4f7f53f" xlink:href="sny-20231231.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_d6195049-8894-45a0-b189-4e2e431cc117" xlink:to="loc_sny_InfraservGmbhAndCoHochstKGMember_8fd3f67f-b16c-4fed-b7c3-4ed0c4f7f53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_286336f8-a401-44e4-bde1-c6ffa899120b" xlink:href="sny-20231231.xsd#sny_MSPVaccineCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_d6195049-8894-45a0-b189-4e2e431cc117" xlink:to="loc_sny_MSPVaccineCompanyMember_286336f8-a401-44e4-bde1-c6ffa899120b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_30933fd1-6016-44df-afc3-a67d3d7597d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_d6195049-8894-45a0-b189-4e2e431cc117" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_30933fd1-6016-44df-afc3-a67d3d7597d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_43303ade-1ce8-498a-ab66-cd4b0bf78936" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7a9b7d1b-84bf-4efb-9c9a-1813a07c9420" xlink:to="loc_dei_LegalEntityAxis_43303ade-1ce8-498a-ab66-cd4b0bf78936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0820da73-d813-43ff-a6ba-cc6486f142d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_43303ade-1ce8-498a-ab66-cd4b0bf78936" xlink:to="loc_dei_EntityDomain_0820da73-d813-43ff-a6ba-cc6486f142d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_173c6de6-2b99-4bd3-aebc-a84696e788fc" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0820da73-d813-43ff-a6ba-cc6486f142d1" xlink:to="loc_sny_EuroapiMember_173c6de6-2b99-4bd3-aebc-a84696e788fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_b198cc31-6d10-4ece-b62f-85f9d03a5642" xlink:href="sny-20231231.xsd#sny_MSPVaccineCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0820da73-d813-43ff-a6ba-cc6486f142d1" xlink:to="loc_sny_MSPVaccineCompanyMember_b198cc31-6d10-4ece-b62f-85f9d03a5642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_7a9b7d1b-84bf-4efb-9c9a-1813a07c9420" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_06b9349f-38e9-49d5-abd9-c8321fa646b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInAssociate_06b9349f-38e9-49d5-abd9-c8321fa646b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_9df024e1-795e-4d4e-a669-532c1a76d12f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointVenture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointVenture_9df024e1-795e-4d4e-a669-532c1a76d12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVentures_ff82c817-26e8-447b-bfc3-5ba36169ccdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_ifrs-full_InvestmentsInJointVentures_ff82c817-26e8-447b-bfc3-5ba36169ccdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_2d19ce7b-7daf-418d-85a6-2445c401cc37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_2d19ce7b-7daf-418d-85a6-2445c401cc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_8503c1f7-93da-42ad-82e8-058a96794e3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_8503c1f7-93da-42ad-82e8-058a96794e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice_0524ed72-5925-4c42-8385-53acf4831a6e" xlink:href="sny-20231231.xsd#sny_StockPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e8f7aff4-a054-4180-b5d8-cc729a93a007" xlink:to="loc_sny_StockPrice_0524ed72-5925-4c42-8385-53acf4831a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_1a7a7601-3ffa-4162-aef8-32a4b06b98eb" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_19d62085-3b49-4696-9254-34ae4bd38063" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_1a7a7601-3ffa-4162-aef8-32a4b06b98eb" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_19d62085-3b49-4696-9254-34ae4bd38063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f16668c0-e964-472c-84a5-f8a2a4593ba8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_19d62085-3b49-4696-9254-34ae4bd38063" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f16668c0-e964-472c-84a5-f8a2a4593ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_363e8675-f422-4061-b5b6-2c19e2d57863" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f16668c0-e964-472c-84a5-f8a2a4593ba8" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_363e8675-f422-4061-b5b6-2c19e2d57863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssociatesMember_16927bf9-dbd7-4100-95e5-5546e465ac7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_363e8675-f422-4061-b5b6-2c19e2d57863" xlink:to="loc_ifrs-full_AssociatesMember_16927bf9-dbd7-4100-95e5-5546e465ac7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_f6a2016e-d3b9-4790-9ade-bd0c21d85da0" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_363e8675-f422-4061-b5b6-2c19e2d57863" xlink:to="loc_sny_EuroapiMember_f6a2016e-d3b9-4790-9ade-bd0c21d85da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_8217e0e2-f997-4b0d-9dd0-562dc8dccba2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_19d62085-3b49-4696-9254-34ae4bd38063" xlink:to="loc_ifrs-full_JointVenturesAxis_8217e0e2-f997-4b0d-9dd0-562dc8dccba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_1ddb818e-3a82-41b2-876a-17881bedc9e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_8217e0e2-f997-4b0d-9dd0-562dc8dccba2" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_1ddb818e-3a82-41b2-876a-17881bedc9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesMember_5e23acdb-fec9-47b1-8b04-4a44fec05c92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_1ddb818e-3a82-41b2-876a-17881bedc9e1" xlink:to="loc_ifrs-full_JointVenturesMember_5e23acdb-fec9-47b1-8b04-4a44fec05c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6b5002a5-e33c-47a3-9fdf-8fe62c70f8f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_19d62085-3b49-4696-9254-34ae4bd38063" xlink:to="loc_dei_LegalEntityAxis_6b5002a5-e33c-47a3-9fdf-8fe62c70f8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6308faf1-554c-4161-9d8d-955fc6457800" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6b5002a5-e33c-47a3-9fdf-8fe62c70f8f2" xlink:to="loc_dei_EntityDomain_6308faf1-554c-4161-9d8d-955fc6457800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_563e23ef-eed9-4fe9-ad61-1763812007a7" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6308faf1-554c-4161-9d8d-955fc6457800" xlink:to="loc_sny_EuroapiMember_563e23ef-eed9-4fe9-ad61-1763812007a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_19d62085-3b49-4696-9254-34ae4bd38063" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_0786e000-36a8-4f6f-a300-1a78c915b974" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:to="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_0786e000-36a8-4f6f-a300-1a78c915b974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax_8dab8ca4-8983-43a1-8aa4-a744123dba53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:to="loc_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax_8dab8ca4-8983-43a1-8aa4-a744123dba53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures_ec3322db-eaa6-42c6-ba52-fd2ab3c5d379" xlink:href="sny-20231231.xsd#sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:to="loc_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures_ec3322db-eaa6-42c6-ba52-fd2ab3c5d379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_d0002a07-8ef9-4ff7-8d14-3dd661fe8aed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_d0002a07-8ef9-4ff7-8d14-3dd661fe8aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockPrice_5982785f-bd1a-4fe9-9372-b30b8c8b02cd" xlink:href="sny-20231231.xsd#sny_StockPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8b7eacc2-bc4d-4669-971b-4a4b2e005891" xlink:to="loc_sny_StockPrice_5982785f-bd1a-4fe9-9372-b30b8c8b02cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_2e37f573-494f-45e7-9d35-48484658ff75" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_f9eb3031-07bf-4a9d-a5a7-1d2bc9e79b40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_2e37f573-494f-45e7-9d35-48484658ff75" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_f9eb3031-07bf-4a9d-a5a7-1d2bc9e79b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_5f6dbfe5-140c-49db-a049-e0a496317b2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_f9eb3031-07bf-4a9d-a5a7-1d2bc9e79b40" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_5f6dbfe5-140c-49db-a049-e0a496317b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_ca64e938-ba12-4bdf-8ee1-2d222dbe9de5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_5f6dbfe5-140c-49db-a049-e0a496317b2a" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_ca64e938-ba12-4bdf-8ee1-2d222dbe9de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_4995f126-a2d7-420c-be53-c8d263e8ae10" xlink:href="sny-20231231.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_ca64e938-ba12-4bdf-8ee1-2d222dbe9de5" xlink:to="loc_sny_AssociatesAndJointVenturesMember_4995f126-a2d7-420c-be53-c8d263e8ae10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_f9eb3031-07bf-4a9d-a5a7-1d2bc9e79b40" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_03d0ee03-5af0-4064-a310-351db496819b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_03d0ee03-5af0-4064-a310-351db496819b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_4c2ec866-fcf4-441e-8d5a-3763f1ae79bd" xlink:href="sny-20231231.xsd#sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:to="loc_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions_4c2ec866-fcf4-441e-8d5a-3763f1ae79bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_55e7daee-dcf1-45ad-b4e0-3f9999d32cc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_55e7daee-dcf1-45ad-b4e0-3f9999d32cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_3ca7a9f2-d040-4e68-8564-e4529f07aabe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:to="loc_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_3ca7a9f2-d040-4e68-8564-e4529f07aabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_50703511-863d-4eb1-b2e2-61d709476521" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_8568272e-923f-490b-8399-016bf7740b1d" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_50703511-863d-4eb1-b2e2-61d709476521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_af4ed915-c1cc-445c-8bce-58952f21ffda" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_04c0da55-9dc2-44f1-bf97-58f203ff8883" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_af4ed915-c1cc-445c-8bce-58952f21ffda" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_04c0da55-9dc2-44f1-bf97-58f203ff8883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ecf8f2c3-4d15-4659-8088-c27f179776f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_04c0da55-9dc2-44f1-bf97-58f203ff8883" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ecf8f2c3-4d15-4659-8088-c27f179776f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9e99ab55-bd23-47b7-8a7f-24f749b6f3de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_ecf8f2c3-4d15-4659-8088-c27f179776f5" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9e99ab55-bd23-47b7-8a7f-24f749b6f3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AssociatesAndJointVenturesMember_8f6dacba-7629-47a2-8b8b-23f57512f462" xlink:href="sny-20231231.xsd#sny_AssociatesAndJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9e99ab55-bd23-47b7-8a7f-24f749b6f3de" xlink:to="loc_sny_AssociatesAndJointVenturesMember_8f6dacba-7629-47a2-8b8b-23f57512f462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_d5b16b8c-420e-408e-b817-4ae7571ff1fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_04c0da55-9dc2-44f1-bf97-58f203ff8883" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_d5b16b8c-420e-408e-b817-4ae7571ff1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_21f2d9d4-a1fc-4d8f-ae5d-3d22845697b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_d5b16b8c-420e-408e-b817-4ae7571ff1fd" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_21f2d9d4-a1fc-4d8f-ae5d-3d22845697b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_6dad6b58-85cb-4aba-b0d5-f8a41e0f81a2" xlink:href="sny-20231231.xsd#sny_RegeneronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_21f2d9d4-a1fc-4d8f-ae5d-3d22845697b4" xlink:to="loc_sny_RegeneronMember_6dad6b58-85cb-4aba-b0d5-f8a41e0f81a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_dc046185-58f4-4338-9ccd-f607507181a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_04c0da55-9dc2-44f1-bf97-58f203ff8883" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_dc046185-58f4-4338-9ccd-f607507181a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsMadeToJointVenturesAndAssociates_f9739bc3-6645-44f8-be13-af74f12a6ff3" xlink:href="sny-20231231.xsd#sny_CommitmentsMadeToJointVenturesAndAssociates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_dc046185-58f4-4338-9ccd-f607507181a6" xlink:to="loc_sny_CommitmentsMadeToJointVenturesAndAssociates_f9739bc3-6645-44f8-be13-af74f12a6ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_051a6e1a-3dff-4057-9c3e-c292b35f4b13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_ff8aaad4-f5f5-4321-9c6d-e963e37b3e00" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_051a6e1a-3dff-4057-9c3e-c292b35f4b13" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_ff8aaad4-f5f5-4321-9c6d-e963e37b3e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_5ac0ae24-20c9-47de-9682-cf84ec541337" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_ff8aaad4-f5f5-4321-9c6d-e963e37b3e00" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_5ac0ae24-20c9-47de-9682-cf84ec541337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_c3f2a129-2567-4789-b4d4-16fbf04774eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_5ac0ae24-20c9-47de-9682-cf84ec541337" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_c3f2a129-2567-4789-b4d4-16fbf04774eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember_470f2ef8-7c6e-4494-858f-a1305f575f1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_c3f2a129-2567-4789-b4d4-16fbf04774eb" xlink:to="loc_ifrs-full_TradingEquitySecuritiesMember_470f2ef8-7c6e-4494-858f-a1305f575f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecuritiesMember_f4b91bbe-38b9-461d-9526-095f76b9c049" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_c3f2a129-2567-4789-b4d4-16fbf04774eb" xlink:to="loc_ifrs-full_DebtSecuritiesMember_f4b91bbe-38b9-461d-9526-095f76b9c049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_98d9304b-ca7a-4ea9-ba77-7d631e7a558c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_ff8aaad4-f5f5-4321-9c6d-e963e37b3e00" xlink:to="loc_ifrs-full_CounterpartiesAxis_98d9304b-ca7a-4ea9-ba77-7d631e7a558c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_a6e3adac-a44c-4e9b-8e66-8a0b4132fa1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_98d9304b-ca7a-4ea9-ba77-7d631e7a558c" xlink:to="loc_ifrs-full_CounterpartiesMember_a6e3adac-a44c-4e9b-8e66-8a0b4132fa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioAtriumMember_b9a08d8e-19bb-4fe1-ac2a-e8b869ab8bfc" xlink:href="sny-20231231.xsd#sny_BioAtriumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_a6e3adac-a44c-4e9b-8e66-8a0b4132fa1b" xlink:to="loc_sny_BioAtriumMember_b9a08d8e-19bb-4fe1-ac2a-e8b869ab8bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_ff8aaad4-f5f5-4321-9c6d-e963e37b3e00" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_fb855bd9-4e2e-4901-b7a5-f7b68e35c430" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_fb855bd9-4e2e-4901-b7a5-f7b68e35c430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss_1cf7eec1-2866-4ba8-90d7-d0574707103d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss_1cf7eec1-2866-4ba8-90d7-d0574707103d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_7624c329-fa8c-4396-bf20-707916cd64da" xlink:href="sny-20231231.xsd#sny_PreFundedPensionObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_sny_PreFundedPensionObligations_7624c329-fa8c-4396-bf20-707916cd64da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LongTermPrepaidExpenses_7a7e0553-b44d-4308-b73f-57482a818442" xlink:href="sny-20231231.xsd#sny_LongTermPrepaidExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_sny_LongTermPrepaidExpenses_7a7e0553-b44d-4308-b73f-57482a818442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLoansAndReceivables_f64ec9e7-7734-4e85-8e78-ea340546ff79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLoansAndReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_NoncurrentLoansAndReceivables_f64ec9e7-7734-4e85-8e78-ea340546ff79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_47cd4ba0-44a2-44ea-b94b-e3ec2290dbb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_47cd4ba0-44a2-44ea-b94b-e3ec2290dbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_26c23b2d-f7b1-48d6-9581-4509ff7b516b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_26c23b2d-f7b1-48d6-9581-4509ff7b516b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinanceLeaseReceivables_1127e0b7-1333-45b4-8919-b28f8f98ae48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_NoncurrentFinanceLeaseReceivables_1127e0b7-1333-45b4-8919-b28f8f98ae48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_ba505385-48f9-4245-9fa2-e9810e90dc6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_ifrs-full_OtherCurrentAssets_ba505385-48f9-4245-9fa2-e9810e90dc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentFinanceLeaseReceivablesGross_77f0aecf-df3a-4367-be64-45d16dd5cd94" xlink:href="sny-20231231.xsd#sny_NonCurrentFinanceLeaseReceivablesGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_a9c8144b-62b6-4886-b002-ba4ce52c1cbb" xlink:to="loc_sny_NonCurrentFinanceLeaseReceivablesGross_77f0aecf-df3a-4367-be64-45d16dd5cd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OthernoncurrentassetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_34aaf4c7-9f5e-40dd-8341-3625a72dbf87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherNonCurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_34aaf4c7-9f5e-40dd-8341-3625a72dbf87" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_6dbba4a1-0539-464e-b888-41c997a95f75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_6dbba4a1-0539-464e-b888-41c997a95f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_b5dbd526-22d5-410b-b2fb-754cdb65089b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_6dbba4a1-0539-464e-b888-41c997a95f75" xlink:to="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_b5dbd526-22d5-410b-b2fb-754cdb65089b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_325c8abf-8f1c-47a8-a239-12ebe1259ac7" xlink:href="sny-20231231.xsd#sny_RegeneronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_b5dbd526-22d5-410b-b2fb-754cdb65089b" xlink:to="loc_sny_RegeneronMember_325c8abf-8f1c-47a8-a239-12ebe1259ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InnoventBiologicsMember_0da0db3e-d83b-4621-8503-9326c7c6c6ec" xlink:href="sny-20231231.xsd#sny_InnoventBiologicsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_b5dbd526-22d5-410b-b2fb-754cdb65089b" xlink:to="loc_sny_InnoventBiologicsMember_0da0db3e-d83b-4621-8503-9326c7c6c6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioMember_2d99b0bd-2f0c-465a-8980-a0c200dfc914" xlink:href="sny-20231231.xsd#sny_TranslateBioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember_b5dbd526-22d5-410b-b2fb-754cdb65089b" xlink:to="loc_sny_TranslateBioMember_2d99b0bd-2f0c-465a-8980-a0c200dfc914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_25b1b6bd-b14b-44f3-b70e-b6fafe0af073" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_MeasurementAxis_25b1b6bd-b14b-44f3-b70e-b6fafe0af073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_fe37f44d-bb97-4515-8ad1-a05bfd31f56b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_25b1b6bd-b14b-44f3-b70e-b6fafe0af073" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_fe37f44d-bb97-4515-8ad1-a05bfd31f56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember_8b12a57b-dc30-4f0f-8ad7-c6540ba592d6" xlink:href="sny-20231231.xsd#sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_fe37f44d-bb97-4515-8ad1-a05bfd31f56b" xlink:to="loc_sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember_8b12a57b-dc30-4f0f-8ad7-c6540ba592d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_ad1fe893-10d8-4e70-910d-60e15b0d9636" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_ad1fe893-10d8-4e70-910d-60e15b0d9636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_ad1fe893-10d8-4e70-910d-60e15b0d9636" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradingEquitySecuritiesMember_036bcf02-f072-43b7-b6ca-8e149d0c1a79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradingEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_ifrs-full_TradingEquitySecuritiesMember_036bcf02-f072-43b7-b6ca-8e149d0c1a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnquotedEquityInvestmentsMember_695f13d5-9667-48f6-a3a5-1155eb8295b4" xlink:href="sny-20231231.xsd#sny_UnquotedEquityInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_UnquotedEquityInvestmentsMember_695f13d5-9667-48f6-a3a5-1155eb8295b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember_074067d2-ffe3-497f-8668-10f5358f1860" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember_074067d2-ffe3-497f-8668-10f5358f1860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_fec1d229-ee49-4dfe-99fd-b8a0194af040" xlink:href="sny-20231231.xsd#sny_DebtInstrumentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_DebtInstrumentsMember_fec1d229-ee49-4dfe-99fd-b8a0194af040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedDebtInstrumentsMember_2377ce6a-ffa9-464d-a526-7a9e5d4527e2" xlink:href="sny-20231231.xsd#sny_QuotedDebtInstrumentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_QuotedDebtInstrumentsMember_2377ce6a-ffa9-464d-a526-7a9e5d4527e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedEquitySecuritiesMember_3b5f6b6d-b2c2-499c-aea9-604b844ea57b" xlink:href="sny-20231231.xsd#sny_QuotedEquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_QuotedEquitySecuritiesMember_3b5f6b6d-b2c2-499c-aea9-604b844ea57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SPMSDContingentConsiderationAssetMember_aafc9d73-c514-4c9e-8806-1c2a8ef872fc" xlink:href="sny-20231231.xsd#sny_SPMSDContingentConsiderationAssetMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_SPMSDContingentConsiderationAssetMember_aafc9d73-c514-4c9e-8806-1c2a8ef872fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember_bb9b4eaf-34c0-4fc3-80d6-a23def2f0d8e" xlink:href="sny-20231231.xsd#sny_NonCurrentAssetsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_NonCurrentAssetsMember_bb9b4eaf-34c0-4fc3-80d6-a23def2f0d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnquotedDebtSecuritiesMember_f48814ca-7fe6-4f55-9263-5296eba7fb16" xlink:href="sny-20231231.xsd#sny_UnquotedDebtSecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_201e4d09-0b65-45f1-b3fe-f8a011572805" xlink:to="loc_sny_UnquotedDebtSecuritiesMember_f48814ca-7fe6-4f55-9263-5296eba7fb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_e79c4d78-cf37-4413-b0ce-626ab886b2f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_e79c4d78-cf37-4413-b0ce-626ab886b2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_40c3ef4e-3560-4a3c-ad68-095f55f23292" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_e79c4d78-cf37-4413-b0ce-626ab886b2f8" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_40c3ef4e-3560-4a3c-ad68-095f55f23292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedEuroDenominatedSeniorBondsMember_d78a5578-4011-4bb3-bebd-9c36ec4910a4" xlink:href="sny-20231231.xsd#sny_QuotedEuroDenominatedSeniorBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_40c3ef4e-3560-4a3c-ad68-095f55f23292" xlink:to="loc_sny_QuotedEuroDenominatedSeniorBondsMember_d78a5578-4011-4bb3-bebd-9c36ec4910a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SeniorBondMember_884e70b1-a02f-4eb2-ab8c-edb70822a218" xlink:href="sny-20231231.xsd#sny_SeniorBondMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_40c3ef4e-3560-4a3c-ad68-095f55f23292" xlink:to="loc_sny_SeniorBondMember_884e70b1-a02f-4eb2-ab8c-edb70822a218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember_23269efe-cad1-45f0-84ee-8c3caf30ceec" xlink:href="sny-20231231.xsd#sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_40c3ef4e-3560-4a3c-ad68-095f55f23292" xlink:to="loc_sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember_23269efe-cad1-45f0-84ee-8c3caf30ceec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2f474c3a-17b5-4e66-9648-2271a8a42fb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2f474c3a-17b5-4e66-9648-2271a8a42fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4412f3e1-bee1-4170-bade-91a69809c0d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_2f474c3a-17b5-4e66-9648-2271a8a42fb4" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4412f3e1-bee1-4170-bade-91a69809c0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_eb3b2fd6-b0f3-41ed-8f6e-7d4fa6bb8d3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4412f3e1-bee1-4170-bade-91a69809c0d7" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_eb3b2fd6-b0f3-41ed-8f6e-7d4fa6bb8d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis_c7e14908-bc3e-4bcd-bb4b-6f20f7bab699" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis_c7e14908-bc3e-4bcd-bb4b-6f20f7bab699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_f9e26735-0e4a-46dd-98d7-80faf3fde482" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis_c7e14908-bc3e-4bcd-bb4b-6f20f7bab699" xlink:to="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_f9e26735-0e4a-46dd-98d7-80faf3fde482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfSPMSDContingentConsiderationMember_5361b075-2e37-4c5c-b7ab-9fd8557aecfe" xlink:href="sny-20231231.xsd#sny_FairValueOfSPMSDContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember_f9e26735-0e4a-46dd-98d7-80faf3fde482" xlink:to="loc_sny_FairValueOfSPMSDContingentConsiderationMember_5361b075-2e37-4c5c-b7ab-9fd8557aecfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherNonCurrentAssetsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsTable_c4fe4d78-5b34-4203-9439-410862c25025" xlink:to="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_ef03167c-b25d-4a23-9590-5f724d8dc7e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_ef03167c-b25d-4a23-9590-5f724d8dc7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_b0bc2470-0574-489b-ba6b-4a43f9f5bfbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_b0bc2470-0574-489b-ba6b-4a43f9f5bfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount_12465bba-6730-438e-af90-3c3cec7eb966" xlink:href="sny-20231231.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount_12465bba-6730-438e-af90-3c3cec7eb966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_701c9442-30ef-4c9a-bb40-031a474cde82" xlink:href="sny-20231231.xsd#sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage_701c9442-30ef-4c9a-bb40-031a474cde82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount_24de5733-4cca-4d64-9ae6-a48a6a2a6c56" xlink:href="sny-20231231.xsd#sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount_24de5733-4cca-4d64-9ae6-a48a6a2a6c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_7b05ebad-84bb-4472-9329-c81b57179a7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_7b05ebad-84bb-4472-9329-c81b57179a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_1ac85c76-b113-4943-914f-12148114c03a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_1ac85c76-b113-4943-914f-12148114c03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_5f2b2b96-a36f-4381-a0ab-9e3e86f3c356" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts_5f2b2b96-a36f-4381-a0ab-9e3e86f3c356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HeldtomaturityInvestments_3b70e232-20c5-4d68-9115-0c1a88efcabb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HeldtomaturityInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_HeldtomaturityInvestments_3b70e232-20c5-4d68-9115-0c1a88efcabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTax_5d73b03c-9541-4f7d-af70-08a6622d9892" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTax_5d73b03c-9541-4f7d-af70-08a6622d9892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity_4ac4fc01-d91a-4c49-8581-4836c885fe84" xlink:href="sny-20231231.xsd#sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity_4ac4fc01-d91a-4c49-8581-4836c885fe84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfTheContingentConsideration_a83b523f-181c-44bb-85bc-191bac165325" xlink:href="sny-20231231.xsd#sny_FairValueOfTheContingentConsideration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_FairValueOfTheContingentConsideration_a83b523f-181c-44bb-85bc-191bac165325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInvestments_f546b7d3-dce1-467b-98f3-23d666381c79" xlink:href="sny-20231231.xsd#sny_FinancialInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_sny_FinancialInvestments_f546b7d3-dce1-467b-98f3-23d666381c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss_f9bb1f98-c33a-498b-96d2-8e865eeaab06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherNonCurrentAssetsLineItems_affe0424-a014-41d1-afa4-5e2cf39d2d99" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss_f9bb1f98-c33a-498b-96d2-8e865eeaab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeSummaryofAssetsHeldforSaleorExchangeandLiabilitiesRelatedtoAssetsHeldforSaleorExchangeDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeSummaryofAssetsHeldforSaleorExchangeandLiabilitiesRelatedtoAssetsHeldforSaleorExchangeDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeSummaryofAssetsHeldforSaleorExchangeandLiabilitiesRelatedtoAssetsHeldforSaleorExchangeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_7522e288-cb15-4ad0-879e-b87903a15d23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_86223294-72ed-4eb2-a31f-184a9af90010" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_7522e288-cb15-4ad0-879e-b87903a15d23" xlink:to="loc_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_86223294-72ed-4eb2-a31f-184a9af90010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_758bb8fa-005e-4919-ae8f-8ad2deb3ac28" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_7522e288-cb15-4ad0-879e-b87903a15d23" xlink:to="loc_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_758bb8fa-005e-4919-ae8f-8ad2deb3ac28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_5307380d-1bf6-41d6-9a5c-6b5be8703b63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInventoriesTable_4e5cd48c-93d2-45df-beb1-157ec9fb6278" xlink:href="sny-20231231.xsd#sny_DisclosureOfInventoriesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_5307380d-1bf6-41d6-9a5c-6b5be8703b63" xlink:to="loc_sny_DisclosureOfInventoriesTable_4e5cd48c-93d2-45df-beb1-157ec9fb6278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7355c367-a0b5-4049-8a84-e862ed0642a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInventoriesTable_4e5cd48c-93d2-45df-beb1-157ec9fb6278" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7355c367-a0b5-4049-8a84-e862ed0642a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_68851cc6-9d55-4e42-967b-1c3586c7c1c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7355c367-a0b5-4049-8a84-e862ed0642a5" xlink:to="loc_ifrs-full_CarryingAmountMember_68851cc6-9d55-4e42-967b-1c3586c7c1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_a9b41f26-beba-4df1-94a0-7ec74fd18edb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_68851cc6-9d55-4e42-967b-1c3586c7c1c9" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_a9b41f26-beba-4df1-94a0-7ec74fd18edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WriteDownMember_23be1407-224f-46fc-b9ca-1588b31f4591" xlink:href="sny-20231231.xsd#sny_WriteDownMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_68851cc6-9d55-4e42-967b-1c3586c7c1c9" xlink:to="loc_sny_WriteDownMember_23be1407-224f-46fc-b9ca-1588b31f4591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:href="sny-20231231.xsd#sny_DisclosureOfInventoriesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInventoriesTable_4e5cd48c-93d2-45df-beb1-157ec9fb6278" xlink:to="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials_1060dfb4-561f-41fe-a408-52f9959dc94b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:to="loc_ifrs-full_RawMaterials_1060dfb4-561f-41fe-a408-52f9959dc94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_ff752975-3685-46f0-b6f1-2c97a68765eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:to="loc_ifrs-full_WorkInProgress_ff752975-3685-46f0-b6f1-2c97a68765eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_d00c5b1a-051c-4489-a955-fce16aa5b08a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:to="loc_ifrs-full_FinishedGoods_d00c5b1a-051c-4489-a955-fce16aa5b08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_a29858ad-a221-46a5-9ae9-9a08809a887c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInventoriesLineItems_b9832e27-e9be-473d-80da-627e4646047c" xlink:to="loc_ifrs-full_Inventories_a29858ad-a221-46a5-9ae9-9a08809a887c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/InventoriesAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#InventoriesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/InventoriesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ffce9080-0d70-435a-bca4-b682343f7bae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InventoriesPledgedAsSecurityForLiabilities_4a92efd2-d625-4f05-acd1-5f92021e331d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoriesPledgedAsSecurityForLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ffce9080-0d70-435a-bca4-b682343f7bae" xlink:to="loc_ifrs-full_InventoriesPledgedAsSecurityForLiabilities_4a92efd2-d625-4f05-acd1-5f92021e331d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#AccountsreceivableSummaryofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_a5555a52-81d1-44e4-8079-430fe7765b4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableTable_bb80ef27-e9bc-418a-bfb6-b8fe265d8f2b" xlink:href="sny-20231231.xsd#sny_DisclosureOfAccountsReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_a5555a52-81d1-44e4-8079-430fe7765b4b" xlink:to="loc_sny_DisclosureOfAccountsReceivableTable_bb80ef27-e9bc-418a-bfb6-b8fe265d8f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_a018ec9f-515b-4012-b45a-c9f170c86df6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_bb80ef27-e9bc-418a-bfb6-b8fe265d8f2b" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_a018ec9f-515b-4012-b45a-c9f170c86df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_6cdc590e-2e97-4692-af88-6857afeac13d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_a018ec9f-515b-4012-b45a-c9f170c86df6" xlink:to="loc_ifrs-full_CarryingAmountMember_6cdc590e-2e97-4692-af88-6857afeac13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_8cbfd1ed-978d-47ce-89df-ca0ef0f2cf66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_6cdc590e-2e97-4692-af88-6857afeac13d" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_8cbfd1ed-978d-47ce-89df-ca0ef0f2cf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllowanceForCreditLossesMember_0da97186-6d8a-4c8c-bca0-aa9f4d720c15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllowanceForCreditLossesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_6cdc590e-2e97-4692-af88-6857afeac13d" xlink:to="loc_ifrs-full_AllowanceForCreditLossesMember_0da97186-6d8a-4c8c-bca0-aa9f4d720c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAccountsReceivableLineItems_fa378aee-c363-4a0d-8fa9-8119a323dbf5" xlink:href="sny-20231231.xsd#sny_DisclosureOfAccountsReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableTable_bb80ef27-e9bc-418a-bfb6-b8fe265d8f2b" xlink:to="loc_sny_DisclosureOfAccountsReceivableLineItems_fa378aee-c363-4a0d-8fa9-8119a323dbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_4bda234c-0e21-4a35-92fd-fec7de9ba5a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAccountsReceivableLineItems_fa378aee-c363-4a0d-8fa9-8119a323dbf5" xlink:to="loc_ifrs-full_CurrentTradeReceivables_4bda234c-0e21-4a35-92fd-fec7de9ba5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#AccountsreceivableAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dc69ed98-18fb-44a0-979e-c7adeb654ee3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables_59febd43-3904-44bf-9f46-444f1e221340" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dc69ed98-18fb-44a0-979e-c7adeb654ee3" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables_59febd43-3904-44bf-9f46-444f1e221340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue_125842f7-8d05-42e1-b453-83409d4c7720" xlink:href="sny-20231231.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dc69ed98-18fb-44a0-979e-c7adeb654ee3" xlink:to="loc_sny_OverdueReceivablesGrossValue_125842f7-8d05-42e1-b453-83409d4c7720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerecognizedReceivables_8486f92d-bf4a-49b1-ab02-377e71937b0a" xlink:href="sny-20231231.xsd#sny_DerecognizedReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dc69ed98-18fb-44a0-979e-c7adeb654ee3" xlink:to="loc_sny_DerecognizedReceivables_8486f92d-bf4a-49b1-ab02-377e71937b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_50c55700-e1e7-44fb-8d1f-032be871c686" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_3fc60a23-cebf-40e4-8060-7933d0f4743e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_50c55700-e1e7-44fb-8d1f-032be871c686" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_3fc60a23-cebf-40e4-8060-7933d0f4743e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_a5b58cf8-81d0-400d-af64-b87a7ff57191" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_3fc60a23-cebf-40e4-8060-7933d0f4743e" xlink:to="loc_ifrs-full_MaturityAxis_a5b58cf8-81d0-400d-af64-b87a7ff57191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_a5b58cf8-81d0-400d-af64-b87a7ff57191" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneMonthMember_69f69448-fbd5-4444-afce-4bd6861e2c75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneMonthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:to="loc_ifrs-full_NotLaterThanOneMonthMember_69f69448-fbd5-4444-afce-4bd6861e2c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_0ab57546-4132-4936-a9bc-d2cbebdd0657" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:to="loc_ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember_0ab57546-4132-4936-a9bc-d2cbebdd0657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_34575e3c-650a-490b-bb80-42bc7f7eecc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:to="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_34575e3c-650a-490b-bb80-42bc7f7eecc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_3b1d5f6f-2672-4e96-85ea-0609849d986b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:to="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_3b1d5f6f-2672-4e96-85ea-0609849d986b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_870b9e49-cd06-461e-b397-032a6531a1e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_7c6acf78-f2b5-43ac-86f6-b2a977f56d43" xlink:to="loc_ifrs-full_LaterThanOneYearMember_870b9e49-cd06-461e-b397-032a6531a1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_219f2008-c769-40c3-b2a6-4e8a31368701" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable_3fc60a23-cebf-40e4-8060-7933d0f4743e" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_219f2008-c769-40c3-b2a6-4e8a31368701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OverdueReceivablesGrossValue_c3c6dc44-d540-488f-90e2-cac49e64c7d9" xlink:href="sny-20231231.xsd#sny_OverdueReceivablesGrossValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems_219f2008-c769-40c3-b2a6-4e8a31368701" xlink:to="loc_sny_OverdueReceivablesGrossValue_c3c6dc44-d540-488f-90e2-cac49e64c7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthercurrentassetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OthercurrentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OthercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_662f90b6-1e05-4b04-8d41-a4b8e3452869" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_578739ac-0deb-41c6-813c-2ea4da69b367" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_662f90b6-1e05-4b04-8d41-a4b8e3452869" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_578739ac-0deb-41c6-813c-2ea4da69b367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_c50562ef-4a0b-44a9-b28e-b887553597eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_662f90b6-1e05-4b04-8d41-a4b8e3452869" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_c50562ef-4a0b-44a9-b28e-b887553597eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_0f898867-9bab-4112-90c9-8a1705d966af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_662f90b6-1e05-4b04-8d41-a4b8e3452869" xlink:to="loc_ifrs-full_OtherCurrentReceivables_0f898867-9bab-4112-90c9-8a1705d966af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateDerivativesMeasuredAtFairValue_91604efb-7aab-46b6-8b26-47d66cd17642" xlink:href="sny-20231231.xsd#sny_InterestRateDerivativesMeasuredAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_662f90b6-1e05-4b04-8d41-a4b8e3452869" xlink:to="loc_sny_InterestRateDerivativesMeasuredAtFairValue_91604efb-7aab-46b6-8b26-47d66cd17642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesMeasuredAtFairValue_aa426e43-1acd-4f9d-ac3e-faec29705ecc" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesMeasuredAtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_662f90b6-1e05-4b04-8d41-a4b8e3452869" xlink:to="loc_sny_CurrencyDerivativesMeasuredAtFairValue_aa426e43-1acd-4f9d-ac3e-faec29705ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_a1856f94-c411-4b08-9a82-6d03b6108128" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_662f90b6-1e05-4b04-8d41-a4b8e3452869" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_a1856f94-c411-4b08-9a82-6d03b6108128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_25e30e4b-dd14-4a60-b25d-e253e62da875" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_662f90b6-1e05-4b04-8d41-a4b8e3452869" xlink:to="loc_ifrs-full_OtherCurrentAssets_25e30e4b-dd14-4a60-b25d-e253e62da875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueMeasurementAbstract_65f1e35c-c4c2-4950-b8a6-4e9849dbab6d" xlink:href="sny-20231231.xsd#sny_FairValueMeasurementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_bf63c905-badc-4405-947f-53534720a715" xlink:href="sny-20231231.xsd#sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FairValueMeasurementAbstract_65f1e35c-c4c2-4950-b8a6-4e9849dbab6d" xlink:to="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_bf63c905-badc-4405-947f-53534720a715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4b62978d-6b6b-4005-a6be-83384c3c2514" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_bf63c905-badc-4405-947f-53534720a715" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4b62978d-6b6b-4005-a6be-83384c3c2514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26e25b8a-ed69-4c6c-971b-9ce222e502fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4b62978d-6b6b-4005-a6be-83384c3c2514" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26e25b8a-ed69-4c6c-971b-9ce222e502fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_df3765e6-2e15-45f5-ada0-1463134aae08" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26e25b8a-ed69-4c6c-971b-9ce222e502fc" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_df3765e6-2e15-45f5-ada0-1463134aae08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_b974e2f6-a077-4181-8cf9-ddef0eb0025c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26e25b8a-ed69-4c6c-971b-9ce222e502fc" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_b974e2f6-a077-4181-8cf9-ddef0eb0025c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_c7324e19-e5d5-450e-b097-5c3dd867e7ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_26e25b8a-ed69-4c6c-971b-9ce222e502fc" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_c7324e19-e5d5-450e-b097-5c3dd867e7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_579a3420-6535-4a7d-bffb-d5c3df5a9b91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_bf63c905-badc-4405-947f-53534720a715" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_579a3420-6535-4a7d-bffb-d5c3df5a9b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_579a3420-6535-4a7d-bffb-d5c3df5a9b91" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedEquityInvestmentsMember_dbd48ea8-828e-4c08-86fb-7398dd06a3c7" xlink:href="sny-20231231.xsd#sny_QuotedEquityInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_QuotedEquityInvestmentsMember_dbd48ea8-828e-4c08-86fb-7398dd06a3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnquotedEquityInvestmentsMember_29b3d727-94b8-4e46-81d3-7a152349220b" xlink:href="sny-20231231.xsd#sny_UnquotedEquityInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_UnquotedEquityInvestmentsMember_29b3d727-94b8-4e46-81d3-7a152349220b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QuotedDebtSecuritiesMember_417f0c6d-ef52-4ea0-8f0f-7fb2e7a78ca5" xlink:href="sny-20231231.xsd#sny_QuotedDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_QuotedDebtSecuritiesMember_417f0c6d-ef52-4ea0-8f0f-7fb2e7a78ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnquotedDebtSecuritiesMember_0224dc01-9a81-4674-b88e-80115a93436c" xlink:href="sny-20231231.xsd#sny_UnquotedDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_UnquotedDebtSecuritiesMember_0224dc01-9a81-4674-b88e-80115a93436c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationRelatingToDivestmentsMember_892cabc9-cf74-4f3e-8bd7-1b6733ba5dbc" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationRelatingToDivestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_ContingentConsiderationRelatingToDivestmentsMember_892cabc9-cf74-4f3e-8bd7-1b6733ba5dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember_f5e61bcb-ef25-495d-8f4b-1f0c65bebf70" xlink:href="sny-20231231.xsd#sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember_f5e61bcb-ef25-495d-8f4b-1f0c65bebf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentDerivativesMember_1bbe8cd9-ec19-4e1c-8ed0-ed1abc89bdc3" xlink:href="sny-20231231.xsd#sny_NonCurrentDerivativesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_NonCurrentDerivativesMember_1bbe8cd9-ec19-4e1c-8ed0-ed1abc89bdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentDerivativesMember_b8edfb68-6dbd-4a0a-8328-d8268708c71e" xlink:href="sny-20231231.xsd#sny_CurrentDerivativesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_CurrentDerivativesMember_b8edfb68-6dbd-4a0a-8328-d8268708c71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MutualFundInvestmentsMember_6a379760-78e9-4e76-87d1-3bfa9cf1e10c" xlink:href="sny-20231231.xsd#sny_MutualFundInvestmentsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_e088c32c-3b0a-453a-a906-de9d06effbed" xlink:to="loc_sny_MutualFundInvestmentsMember_6a379760-78e9-4e76-87d1-3bfa9cf1e10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_c35a65c4-5e4f-4d0c-ba89-525ea6e6f4ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_bf63c905-badc-4405-947f-53534720a715" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_c35a65c4-5e4f-4d0c-ba89-525ea6e6f4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_c35a65c4-5e4f-4d0c-ba89-525ea6e6f4ff" xlink:to="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember_18a61988-15b3-4325-84ba-75884ce22da9" xlink:href="sny-20231231.xsd#sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember_18a61988-15b3-4325-84ba-75884ce22da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_90250daf-1943-476f-be3d-a6ab0f6f3674" xlink:href="sny-20231231.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_90250daf-1943-476f-be3d-a6ab0f6f3674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationTranslateBioMember_e06adb61-9568-4a6b-afc6-6a82c80613b1" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationTranslateBioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_ContingentConsiderationTranslateBioMember_e06adb61-9568-4a6b-afc6-6a82c80613b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember_992c26f6-dbd9-40bb-8767-adfb51c91e2f" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember_992c26f6-dbd9-40bb-8767-adfb51c91e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember_52cbcaa4-2d9f-4aa0-9d23-a5940883d4b2" xlink:href="sny-20231231.xsd#sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember_52cbcaa4-2d9f-4aa0-9d23-a5940883d4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentDerivativesMember_88f6079b-1aff-4446-9973-b7e873c767d5" xlink:href="sny-20231231.xsd#sny_NonCurrentDerivativesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_NonCurrentDerivativesMember_88f6079b-1aff-4446-9973-b7e873c767d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentDerivativesMember_6b1b771c-8162-4c56-a634-de9cfcb06b3b" xlink:href="sny-20231231.xsd#sny_CurrentDerivativesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_546513c6-46de-43b8-9563-1f2f25c2acda" xlink:to="loc_sny_CurrentDerivativesMember_6b1b771c-8162-4c56-a634-de9cfcb06b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationOnIncomeStatementLineItems_cbd12861-19ca-4d27-805c-9d860438114c" xlink:href="sny-20231231.xsd#sny_DisclosureOfInformationOnIncomeStatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable_bf63c905-badc-4405-947f-53534720a715" xlink:to="loc_sny_DisclosureOfInformationOnIncomeStatementLineItems_cbd12861-19ca-4d27-805c-9d860438114c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_16154276-1bd0-4c5e-9803-dc2eb71381f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationOnIncomeStatementLineItems_cbd12861-19ca-4d27-805c-9d860438114c" xlink:to="loc_ifrs-full_FinancialAssets_16154276-1bd0-4c5e-9803-dc2eb71381f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_92d4e5b0-0339-4c96-9275-0b03a47eeb13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationOnIncomeStatementLineItems_cbd12861-19ca-4d27-805c-9d860438114c" xlink:to="loc_ifrs-full_FinancialLiabilities_92d4e5b0-0339-4c96-9275-0b03a47eeb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/CashandcashequivalentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#CashandcashequivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/CashandcashequivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_00a04bbf-14c0-4048-81a9-a2b1e1c1b0f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_3ffacf2b-4883-4afc-8fa2-5287e309bba7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_00a04bbf-14c0-4048-81a9-a2b1e1c1b0f1" xlink:to="loc_ifrs-full_Cash_3ffacf2b-4883-4afc-8fa2-5287e309bba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_94befd25-65cb-4f66-b7f6-8577e6e6206d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_00a04bbf-14c0-4048-81a9-a2b1e1c1b0f1" xlink:to="loc_ifrs-full_CashEquivalents_94befd25-65cb-4f66-b7f6-8577e6e6206d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_e91ba6d8-a277-4074-9e0d-9ee1f21fe1e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_00a04bbf-14c0-4048-81a9-a2b1e1c1b0f1" xlink:to="loc_ifrs-full_CashAndCashEquivalents_e91ba6d8-a277-4074-9e0d-9ee1f21fe1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashEquivalentsMoneyMarketMutualFunds_9513ac5d-1057-4fb1-b5b1-0dc20bf1cc47" xlink:href="sny-20231231.xsd#sny_CashEquivalentsMoneyMarketMutualFunds"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_00a04bbf-14c0-4048-81a9-a2b1e1c1b0f1" xlink:to="loc_sny_CashEquivalentsMoneyMarketMutualFunds_9513ac5d-1057-4fb1-b5b1-0dc20bf1cc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_1cd0bd26-08af-4d8b-acb2-bbf6fd78c7cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_00a04bbf-14c0-4048-81a9-a2b1e1c1b0f1" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_1cd0bd26-08af-4d8b-acb2-bbf6fd78c7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashEquivalentsCommercialPaper_41d35f4e-b79a-4c28-8953-a70940ba32fb" xlink:href="sny-20231231.xsd#sny_CashEquivalentsCommercialPaper"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_00a04bbf-14c0-4048-81a9-a2b1e1c1b0f1" xlink:to="loc_sny_CashEquivalentsCommercialPaper_41d35f4e-b79a-4c28-8953-a70940ba32fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies_e9087a10-c476-4f18-973e-d6baa0d31d23" xlink:href="sny-20231231.xsd#sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_00a04bbf-14c0-4048-81a9-a2b1e1c1b0f1" xlink:to="loc_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies_e9087a10-c476-4f18-973e-d6baa0d31d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxesAbstract_b716b21d-99c3-492c-beb5-8db3e9165176" xlink:href="sny-20231231.xsd#sny_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dfba40ba-8bb9-4669-bb80-b60b1207dab2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_b716b21d-99c3-492c-beb5-8db3e9165176" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dfba40ba-8bb9-4669-bb80-b60b1207dab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_61b4a269-15d4-4e43-8e60-3cb653b83662" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dfba40ba-8bb9-4669-bb80-b60b1207dab2" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_61b4a269-15d4-4e43-8e60-3cb653b83662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_61b4a269-15d4-4e43-8e60-3cb653b83662" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember_7a802477-2ded-41da-b4bd-c28b8bc537ae" xlink:href="sny-20231231.xsd#sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember_7a802477-2ded-41da-b4bd-c28b8bc537ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember_1075bfbe-a11b-4586-99b0-5f9ac5af7843" xlink:href="sny-20231231.xsd#sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember_1075bfbe-a11b-4586-99b0-5f9ac5af7843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember_16a07ae1-4a66-406f-b22e-d48ce84acb28" xlink:href="sny-20231231.xsd#sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember_16a07ae1-4a66-406f-b22e-d48ce84acb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember_577a75c6-7b9d-479e-ab95-94520b000eb6" xlink:href="sny-20231231.xsd#sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember_577a75c6-7b9d-479e-ab95-94520b000eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember_934c40fb-8e6e-4baf-9256-a143e311b801" xlink:href="sny-20231231.xsd#sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember_934c40fb-8e6e-4baf-9256-a143e311b801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_973ca4e2-6954-4575-82d2-c4bd7e3c77e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_973ca4e2-6954-4575-82d2-c4bd7e3c77e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionsAndShareBasedPaymentsMember_354ef9d4-1cdc-4527-973c-e2ad7c6c76e1" xlink:href="sny-20231231.xsd#sny_StockOptionsAndShareBasedPaymentsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_StockOptionsAndShareBasedPaymentsMember_354ef9d4-1cdc-4527-973c-e2ad7c6c76e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember_2add3933-f9c8-4429-ab73-57c584351573" xlink:href="sny-20231231.xsd#sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember_2add3933-f9c8-4429-ab73-57c584351573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_8c4dace0-e41a-42da-9e37-fa8f3658753c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_8c4dace0-e41a-42da-9e37-fa8f3658753c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DeferredTaxRelatingToRestructuringProvisionsMember_6a947cc5-8e21-47a0-82f0-66632db766d2" xlink:href="sny-20231231.xsd#sny_DeferredTaxRelatingToRestructuringProvisionsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_DeferredTaxRelatingToRestructuringProvisionsMember_6a947cc5-8e21-47a0-82f0-66632db766d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember_4cf94f91-761d-4132-bdd0-645c3beee0bd" xlink:href="sny-20231231.xsd#sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_3442ddf0-8cef-4d9b-962d-e3df59a93dac" xlink:to="loc_sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember_4cf94f91-761d-4132-bdd0-645c3beee0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1eaafa21-fa70-423a-a87e-56c5488272d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dfba40ba-8bb9-4669-bb80-b60b1207dab2" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1eaafa21-fa70-423a-a87e-56c5488272d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1eaafa21-fa70-423a-a87e-56c5488272d8" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativMember_ed246bef-7978-4302-94a6-a20418bb352b" xlink:href="sny-20231231.xsd#sny_BioverativMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_BioverativMember_ed246bef-7978-4302-94a6-a20418bb352b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipiaBiopharmaIncMember_ad3113cc-0ea9-4fd8-83c7-9a92e71e0217" xlink:href="sny-20231231.xsd#sny_PrincipiaBiopharmaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_PrincipiaBiopharmaIncMember_ad3113cc-0ea9-4fd8-83c7-9a92e71e0217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SynthorxMember_0067a1a8-d766-49a7-96ee-38ec8fc81a9c" xlink:href="sny-20231231.xsd#sny_SynthorxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_SynthorxMember_0067a1a8-d766-49a7-96ee-38ec8fc81a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeMember_86683552-c1b7-4fc1-b548-62caa8f00bc8" xlink:href="sny-20231231.xsd#sny_GenzymeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_GenzymeMember_86683552-c1b7-4fc1-b548-62caa8f00bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AblynxMember_0f2489a8-97ec-4850-bc68-27fe54f76764" xlink:href="sny-20231231.xsd#sny_AblynxMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_AblynxMember_0f2489a8-97ec-4850-bc68-27fe54f76764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixMember_c8c4e128-9ab2-4ef6-9097-ab25f5dc7b7f" xlink:href="sny-20231231.xsd#sny_AmunixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_b2bfb054-0e4d-4bc8-a397-28d9c67df0fb" xlink:to="loc_sny_AmunixMember_c8c4e128-9ab2-4ef6-9097-ab25f5dc7b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dfba40ba-8bb9-4669-bb80-b60b1207dab2" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_47354b6b-313f-45fb-ac94-a56b47ed6970" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_47354b6b-313f-45fb-ac94-a56b47ed6970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_b0ced0cd-9f42-4b13-86d0-1f329b91ecc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_b0ced0cd-9f42-4b13-86d0-1f329b91ecc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture_315d8092-e05d-4db1-ac84-ef8d48790027" xlink:href="sny-20231231.xsd#sny_ReservesLikelyToBeDistributedInTheForeseeableFuture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:to="loc_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture_315d8092-e05d-4db1-ac84-ef8d48790027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_50d45d18-8e94-45f9-b14a-dc1e9ac406d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_bc390457-a087-4428-a36b-70aab53735c4" xlink:to="loc_ifrs-full_DeferredTaxAssets_50d45d18-8e94-45f9-b14a-dc1e9ac406d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NetdeferredtaxpositionAdditionalinformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#NetdeferredtaxpositionAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NetdeferredtaxpositionAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxesAbstract_fccce7f7-a3a9-4375-9c72-5a7e1d0eda21" xlink:href="sny-20231231.xsd#sny_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_9d1f6abc-21b1-468c-b51b-734a5bf49e78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_fccce7f7-a3a9-4375-9c72-5a7e1d0eda21" xlink:to="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_9d1f6abc-21b1-468c-b51b-734a5bf49e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards_6a157ffb-c5d1-47ef-a7e5-ee63ae174229" xlink:href="sny-20231231.xsd#sny_TotalDeferredTaxAssetsForTaxLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_fccce7f7-a3a9-4375-9c72-5a7e1d0eda21" xlink:to="loc_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards_6a157ffb-c5d1-47ef-a7e5-ee63ae174229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_4541344b-b680-4540-b373-5f4569610bb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_fccce7f7-a3a9-4375-9c72-5a7e1d0eda21" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_4541344b-b680-4540-b373-5f4569610bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised_f2c41090-9942-473e-b219-56fbf83774fb" xlink:href="sny-20231231.xsd#sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_fccce7f7-a3a9-4375-9c72-5a7e1d0eda21" xlink:to="loc_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised_f2c41090-9942-473e-b219-56fbf83774fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable_f08bddad-e57e-41b6-8f87-f95d692bdf81" xlink:href="sny-20231231.xsd#sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_fccce7f7-a3a9-4375-9c72-5a7e1d0eda21" xlink:to="loc_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable_f08bddad-e57e-41b6-8f87-f95d692bdf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxesAbstract_8bad4639-8660-41db-8301-307b2837b270" xlink:href="sny-20231231.xsd#sny_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable_55f0afcd-080b-412b-ab95-16e56061b596" xlink:href="sny-20231231.xsd#sny_DisclosureOfTaxLossesAvailableForCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_8bad4639-8660-41db-8301-307b2837b270" xlink:to="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable_55f0afcd-080b-412b-ab95-16e56061b596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_52f60016-ff2a-487b-ba34-79b4a107b735" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable_55f0afcd-080b-412b-ab95-16e56061b596" xlink:to="loc_ifrs-full_MaturityAxis_52f60016-ff2a-487b-ba34-79b4a107b735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_52f60016-ff2a-487b-ba34-79b4a107b735" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_fc987503-38b8-4237-bf89-3889fa67d57a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_fc987503-38b8-4237-bf89-3889fa67d57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_707362c4-e4d2-48de-a77f-695332d1e192" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_707362c4-e4d2-48de-a77f-695332d1e192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_a7ad3167-fa0a-4943-94c9-32bea844e722" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_a7ad3167-fa0a-4943-94c9-32bea844e722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_4b6857fb-2a16-4311-a62c-d0428919c3cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_4b6857fb-2a16-4311-a62c-d0428919c3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_3838cc71-28d8-4094-9400-47d34555422e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_3838cc71-28d8-4094-9400-47d34555422e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_9fe9111c-1de3-4477-948f-9b7a62417afb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_fe7b78c5-bda6-4dec-8b8f-dd4ecabcc721" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_9fe9111c-1de3-4477-948f-9b7a62417afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems_facd0f4c-2c88-4a29-a2e1-3891f79bbfd8" xlink:href="sny-20231231.xsd#sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardTable_55f0afcd-080b-412b-ab95-16e56061b596" xlink:to="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems_facd0f4c-2c88-4a29-a2e1-3891f79bbfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxLossesCarryforwards_dd210181-0a0f-4467-afbd-795a5193ed27" xlink:href="sny-20231231.xsd#sny_TaxLossesCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems_facd0f4c-2c88-4a29-a2e1-3891f79bbfd8" xlink:to="loc_sny_TaxLossesCarryforwards_dd210181-0a0f-4467-afbd-795a5193ed27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxLossCarryforwardsOnAssetDisposals_b1930aff-0ccb-4bc6-81e7-39f6f64e14a4" xlink:href="sny-20231231.xsd#sny_TaxLossCarryforwardsOnAssetDisposals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems_facd0f4c-2c88-4a29-a2e1-3891f79bbfd8" xlink:to="loc_sny_TaxLossCarryforwardsOnAssetDisposals_b1930aff-0ccb-4bc6-81e7-39f6f64e14a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_275da421-b85f-4a97-b02c-45fa1ecc19e1" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_cc9363fc-29fe-47f2-b7b4-760f9c121410" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_275da421-b85f-4a97-b02c-45fa1ecc19e1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_cc9363fc-29fe-47f2-b7b4-760f9c121410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7f0b4d79-c768-4867-a831-a34d18bcf412" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_cc9363fc-29fe-47f2-b7b4-760f9c121410" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7f0b4d79-c768-4867-a831-a34d18bcf412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_72a2a314-815b-480f-a3c2-311c7c76ec06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_7f0b4d79-c768-4867-a831-a34d18bcf412" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_72a2a314-815b-480f-a3c2-311c7c76ec06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanMember_0f4989aa-53dc-4f22-bc81-a04b0b2f6c0f" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_72a2a314-815b-480f-a3c2-311c7c76ec06" xlink:to="loc_sny_StockSubscriptionOptionPlanMember_0f4989aa-53dc-4f22-bc81-a04b0b2f6c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateAxis_0f9f944e-85c5-4bea-9797-ea70cf12007a" xlink:href="sny-20231231.xsd#sny_AwardsDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_cc9363fc-29fe-47f2-b7b4-760f9c121410" xlink:to="loc_sny_AwardsDateAxis_0f9f944e-85c5-4bea-9797-ea70cf12007a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateDomain_4be7f9fc-f5ad-4262-9c7c-eeec39a36f57" xlink:href="sny-20231231.xsd#sny_AwardsDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AwardsDateAxis_0f9f944e-85c5-4bea-9797-ea70cf12007a" xlink:to="loc_sny_AwardsDateDomain_4be7f9fc-f5ad-4262-9c7c-eeec39a36f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_May252023Member_6ca07888-e915-4b1e-a15e-21e6938f98fd" xlink:href="sny-20231231.xsd#sny_May252023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AwardsDateDomain_4be7f9fc-f5ad-4262-9c7c-eeec39a36f57" xlink:to="loc_sny_May252023Member_6ca07888-e915-4b1e-a15e-21e6938f98fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_May32022Member_8688761d-d9dc-4558-8f71-7210c1af6ff9" xlink:href="sny-20231231.xsd#sny_May32022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AwardsDateDomain_4be7f9fc-f5ad-4262-9c7c-eeec39a36f57" xlink:to="loc_sny_May32022Member_8688761d-d9dc-4558-8f71-7210c1af6ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April302021Member_e2490167-3e4a-4806-b506-84fdb46eb8e2" xlink:href="sny-20231231.xsd#sny_April302021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AwardsDateDomain_4be7f9fc-f5ad-4262-9c7c-eeec39a36f57" xlink:to="loc_sny_April302021Member_e2490167-3e4a-4806-b506-84fdb46eb8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_cc9363fc-29fe-47f2-b7b4-760f9c121410" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_1a993f64-3f36-4d9e-a610-acda5d34f2d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_ifrs-full_IssuedCapital_1a993f64-3f36-4d9e-a610-acda5d34f2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_63b8168c-1157-4d7f-9991-f047695f12c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_ifrs-full_NumberOfSharesIssued_63b8168c-1157-4d7f-9991-f047695f12c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_48df5865-ecad-40ba-b274-2a7a01307242" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_ifrs-full_ParValuePerShare_48df5865-ecad-40ba-b274-2a7a01307242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PeriodOfShareRepurchaseProgram_b07f9976-9ec1-4ba0-adae-900ccead725b" xlink:href="sny-20231231.xsd#sny_PeriodOfShareRepurchaseProgram"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_sny_PeriodOfShareRepurchaseProgram_b07f9976-9ec1-4ba0-adae-900ccead725b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax_a9b94ba3-6b2e-4dd6-adb5-81f1a2003c39" xlink:href="sny-20231231.xsd#sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax_a9b94ba3-6b2e-4dd6-adb5-81f1a2003c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions_45cc510b-78eb-4be0-8645-1e7e9bf57ae0" xlink:href="sny-20231231.xsd#sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions_45cc510b-78eb-4be0-8645-1e7e9bf57ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedByExerciceOfEachOption_ebf685dd-84d7-4258-ba7c-1151a6a199bf" xlink:href="sny-20231231.xsd#sny_NumberOfSharesIssuedByExerciceOfEachOption"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_sny_NumberOfSharesIssuedByExerciceOfEachOption_ebf685dd-84d7-4258-ba7c-1151a6a199bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionsWithNoDilutiveEffect_71c0aaea-9ca1-4e75-9136-d2aefb83f6ce" xlink:href="sny-20231231.xsd#sny_StockOptionsWithNoDilutiveEffect"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e73bfe9e-c5fc-4e6a-ac3d-c294a1d830e1" xlink:to="loc_sny_StockOptionsWithNoDilutiveEffect_71c0aaea-9ca1-4e75-9136-d2aefb83f6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c8d890be-882e-4a12-9638-f99751fe4bd8" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesHeld_77b5c34a-ec37-4407-b31f-f7fdd8135f93" xlink:href="sny-20231231.xsd#sny_NumberOfSharesHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c8d890be-882e-4a12-9638-f99751fe4bd8" xlink:to="loc_sny_NumberOfSharesHeld_77b5c34a-ec37-4407-b31f-f7fdd8135f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfShareCapitalForThePeriod_7cc3f35e-b046-4599-9a1d-ba90eaf3c16a" xlink:href="sny-20231231.xsd#sny_PercentageOfShareCapitalForThePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c8d890be-882e-4a12-9638-f99751fe4bd8" xlink:to="loc_sny_PercentageOfShareCapitalForThePeriod_7cc3f35e-b046-4599-9a1d-ba90eaf3c16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_48f3da35-94ac-4fff-aa91-49ebb88e6e65" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_641c664b-4909-4d82-9f4b-d813f2c33a44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_48f3da35-94ac-4fff-aa91-49ebb88e6e65" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_641c664b-4909-4d82-9f4b-d813f2c33a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_6402e1b9-ea79-46d0-aab4-3a3a97d10f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_641c664b-4909-4d82-9f4b-d813f2c33a44" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_6402e1b9-ea79-46d0-aab4-3a3a97d10f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_df6f4920-2710-41ee-8411-36d3804f1006" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6402e1b9-ea79-46d0-aab4-3a3a97d10f1d" xlink:to="loc_ifrs-full_EquityMember_df6f4920-2710-41ee-8411-36d3804f1006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_7951b6bd-e959-4af6-b6a4-2a876e7f42fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_df6f4920-2710-41ee-8411-36d3804f1006" xlink:to="loc_ifrs-full_IssuedCapitalMember_7951b6bd-e959-4af6-b6a4-2a876e7f42fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_724e0829-465a-4907-a656-5e5915a30e15" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_641c664b-4909-4d82-9f4b-d813f2c33a44" xlink:to="loc_dei_LegalEntityAxis_724e0829-465a-4907-a656-5e5915a30e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f81dc610-cc74-416b-acd0-7067de02ed3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_724e0829-465a-4907-a656-5e5915a30e15" xlink:to="loc_dei_EntityDomain_f81dc610-cc74-416b-acd0-7067de02ed3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember_6b3b508e-8c30-42dd-a648-814bc4c9bda9" xlink:href="sny-20231231.xsd#sny_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f81dc610-cc74-416b-acd0-7067de02ed3e" xlink:to="loc_sny_SanofiMember_6b3b508e-8c30-42dd-a648-814bc4c9bda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_641c664b-4909-4d82-9f4b-d813f2c33a44" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_24d0a887-63d3-48d4-9d1f-a651fdb2ea37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_ifrs-full_NumberOfSharesIssued_24d0a887-63d3-48d4-9d1f-a651fdb2ea37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_668644c5-e094-4b7b-999f-c4c1932e5dea" xlink:href="sny-20231231.xsd#sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions_668644c5-e094-4b7b-999f-c4c1932e5dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_bf0dd41d-2b22-4d6f-b95a-287921998a44" xlink:href="sny-20231231.xsd#sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease_bf0dd41d-2b22-4d6f-b95a-287921998a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees_ce0371da-16c0-4903-9364-80cdbe3b3b82" xlink:href="sny-20231231.xsd#sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees_ce0371da-16c0-4903-9364-80cdbe3b3b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReductionOfSharesByCancellationOfTreasuryShares_1ff2220f-c757-42bb-97a4-2996c43e7273" xlink:href="sny-20231231.xsd#sny_ReductionOfSharesByCancellationOfTreasuryShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_sny_ReductionOfSharesByCancellationOfTreasuryShares_1ff2220f-c757-42bb-97a4-2996c43e7273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_b0b2f256-11a7-4d3f-a84e-a85d3243920b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9d0373b2-80d8-41d6-9bf5-30a9da1c8093" xlink:to="loc_ifrs-full_NumberOfSharesIssued_b0b2f256-11a7-4d3f-a84e-a85d3243920b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_efd1d619-37fc-45b4-9cb8-6d3371137458" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_9a9aa3e6-b42f-44a8-8348-484315163d86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_efd1d619-37fc-45b4-9cb8-6d3371137458" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_9a9aa3e6-b42f-44a8-8348-484315163d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1452ce22-d22b-41d2-b420-41a481aceb1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_9a9aa3e6-b42f-44a8-8348-484315163d86" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1452ce22-d22b-41d2-b420-41a481aceb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2bec8307-6947-424d-8306-e1d2a9a7c3f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1452ce22-d22b-41d2-b420-41a481aceb1d" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2bec8307-6947-424d-8306-e1d2a9a7c3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_b6874e0e-90c1-4d81-888e-7192c810383f" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2bec8307-6947-424d-8306-e1d2a9a7c3f6" xlink:to="loc_sny_RestrictedSharePlan2023Member_b6874e0e-90c1-4d81-888e-7192c810383f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member_812c2fe3-ba3c-45df-b781-6415dbec3d2c" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2bec8307-6947-424d-8306-e1d2a9a7c3f6" xlink:to="loc_sny_RestrictedSharePlan2022Member_812c2fe3-ba3c-45df-b781-6415dbec3d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2021Member_cf82e37f-a33e-4680-8c5e-e2648525549c" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2bec8307-6947-424d-8306-e1d2a9a7c3f6" xlink:to="loc_sny_RestrictedSharePlan2021Member_cf82e37f-a33e-4680-8c5e-e2648525549c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_1240c0e7-6576-47a6-b11c-e3761eefd123" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_9a9aa3e6-b42f-44a8-8348-484315163d86" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_1240c0e7-6576-47a6-b11c-e3761eefd123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_3354ea93-5c7f-4de3-8520-cee21731e325" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_1240c0e7-6576-47a6-b11c-e3761eefd123" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_3354ea93-5c7f-4de3-8520-cee21731e325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerformanceSharePlanOneMember_6c913eec-7b07-4de1-b230-fb405234c4a4" xlink:href="sny-20231231.xsd#sny_PerformanceSharePlanOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_3354ea93-5c7f-4de3-8520-cee21731e325" xlink:to="loc_sny_PerformanceSharePlanOneMember_6c913eec-7b07-4de1-b230-fb405234c4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerformanceSharePlanTwoMember_05f1aa27-6235-4283-9a44-56669169c15d" xlink:href="sny-20231231.xsd#sny_PerformanceSharePlanTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_3354ea93-5c7f-4de3-8520-cee21731e325" xlink:to="loc_sny_PerformanceSharePlanTwoMember_05f1aa27-6235-4283-9a44-56669169c15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis_675f2250-be72-42b2-b146-1fb1ea8b0ad2" xlink:href="sny-20231231.xsd#sny_MarketConditionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_9a9aa3e6-b42f-44a8-8348-484315163d86" xlink:to="loc_sny_MarketConditionAxis_675f2250-be72-42b2-b146-1fb1ea8b0ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_0b2cb4ed-2a94-4a68-ade1-4414642ec943" xlink:href="sny-20231231.xsd#sny_MarketConditionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionAxis_675f2250-be72-42b2-b146-1fb1ea8b0ad2" xlink:to="loc_sny_MarketConditionDomain_0b2cb4ed-2a94-4a68-ade1-4414642ec943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithoutMarketConditionMember_9f199d26-e314-4a7e-90d7-be374c0c0b76" xlink:href="sny-20231231.xsd#sny_WithoutMarketConditionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionDomain_0b2cb4ed-2a94-4a68-ade1-4414642ec943" xlink:to="loc_sny_WithoutMarketConditionMember_9f199d26-e314-4a7e-90d7-be374c0c0b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember_2e43b9cd-710e-4ea4-a557-51c6adfcedc0" xlink:href="sny-20231231.xsd#sny_WithMarketConditionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionDomain_0b2cb4ed-2a94-4a68-ade1-4414642ec943" xlink:to="loc_sny_WithMarketConditionMember_2e43b9cd-710e-4ea4-a557-51c6adfcedc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_9a9aa3e6-b42f-44a8-8348-484315163d86" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfYearsServicePeriod_a410a6dc-5ae0-4f7a-b4cb-da088438bec8" xlink:href="sny-20231231.xsd#sny_NumberOfYearsServicePeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_sny_NumberOfYearsServicePeriod_a410a6dc-5ae0-4f7a-b4cb-da088438bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_e3e76f5f-d839-4ba5-9a07-4d735c05a1d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_e3e76f5f-d839-4ba5-9a07-4d735c05a1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_a5ab7b06-d41f-4fae-8437-c231194c070b" xlink:href="sny-20231231.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriod_a5ab7b06-d41f-4fae-8437-c231194c070b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares_511d2b4e-bc5b-4f6c-8a1f-52a7d94b1674" xlink:href="sny-20231231.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares_511d2b4e-bc5b-4f6c-8a1f-52a7d94b1674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer_95fdf6a1-5d1a-4484-80c6-f3faee5ea7dd" xlink:href="sny-20231231.xsd#sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer_95fdf6a1-5d1a-4484-80c6-f3faee5ea7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FairValueOfPlanAtDateOfGrant_6805df77-bb8b-4304-92d9-e7925f29d207" xlink:href="sny-20231231.xsd#sny_FairValueOfPlanAtDateOfGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8b330200-0cde-4657-90c6-04d7c6cde5af" xlink:to="loc_sny_FairValueOfPlanAtDateOfGrant_6805df77-bb8b-4304-92d9-e7925f29d207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_d95ae9cb-eb57-4870-89e4-352a65b7b4ab" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d39a7185-7edb-4efc-b428-214ffeed37e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_d95ae9cb-eb57-4870-89e4-352a65b7b4ab" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d39a7185-7edb-4efc-b428-214ffeed37e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_98ba5370-316d-4c7e-9fc0-b265bb7d9d1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d39a7185-7edb-4efc-b428-214ffeed37e4" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_98ba5370-316d-4c7e-9fc0-b265bb7d9d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_4976aae0-34df-4a4c-9f78-ed30b950a8d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_98ba5370-316d-4c7e-9fc0-b265bb7d9d1c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_4976aae0-34df-4a4c-9f78-ed30b950a8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:href="sny-20231231.xsd#sny_RestrictedSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_4976aae0-34df-4a4c-9f78-ed30b950a8d4" xlink:to="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2023Member_489a9c05-2413-4f83-aec4-3f7304d1abaf" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:to="loc_sny_RestrictedSharePlan2023Member_489a9c05-2413-4f83-aec4-3f7304d1abaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2022Member_8a0efc88-d4bb-4c98-9abf-2659b8e5eb45" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:to="loc_sny_RestrictedSharePlan2022Member_8a0efc88-d4bb-4c98-9abf-2659b8e5eb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2021Member_18b71d19-158f-439c-8ca2-c91954d02ff2" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:to="loc_sny_RestrictedSharePlan2021Member_18b71d19-158f-439c-8ca2-c91954d02ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2020Member_e9596392-5552-4223-83de-787b11c03fbd" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:to="loc_sny_RestrictedSharePlan2020Member_e9596392-5552-4223-83de-787b11c03fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestrictedSharePlan2019Member_8593c38e-9501-4a0f-875c-c70f7e350356" xlink:href="sny-20231231.xsd#sny_RestrictedSharePlan2019Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RestrictedSharesMember_0d5b1a62-7862-423f-b944-09c45264b2ea" xlink:to="loc_sny_RestrictedSharePlan2019Member_8593c38e-9501-4a0f-875c-c70f7e350356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionAxis_2b98c3b9-e4e4-476a-8295-0346f9d95161" xlink:href="sny-20231231.xsd#sny_MarketConditionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d39a7185-7edb-4efc-b428-214ffeed37e4" xlink:to="loc_sny_MarketConditionAxis_2b98c3b9-e4e4-476a-8295-0346f9d95161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MarketConditionDomain_5c23f4ae-5982-485d-8148-c7d6d698c082" xlink:href="sny-20231231.xsd#sny_MarketConditionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionAxis_2b98c3b9-e4e4-476a-8295-0346f9d95161" xlink:to="loc_sny_MarketConditionDomain_5c23f4ae-5982-485d-8148-c7d6d698c082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WithMarketConditionMember_67ebfbde-8651-4613-84df-42e562b237b9" xlink:href="sny-20231231.xsd#sny_WithMarketConditionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_MarketConditionDomain_5c23f4ae-5982-485d-8148-c7d6d698c082" xlink:to="loc_sny_WithMarketConditionMember_67ebfbde-8651-4613-84df-42e562b237b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_b238d7e8-dfef-4abe-ad2d-6cac57d35c7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d39a7185-7edb-4efc-b428-214ffeed37e4" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_b238d7e8-dfef-4abe-ad2d-6cac57d35c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_aec75cf0-da53-4c36-b071-c348fa3a5992" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_b238d7e8-dfef-4abe-ad2d-6cac57d35c7a" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_aec75cf0-da53-4c36-b071-c348fa3a5992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PerformanceSharePlanOneMember_a1c525fb-7041-4f43-a6a3-d0edfd9b4ba5" xlink:href="sny-20231231.xsd#sny_PerformanceSharePlanOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_aec75cf0-da53-4c36-b071-c348fa3a5992" xlink:to="loc_sny_PerformanceSharePlanOneMember_a1c525fb-7041-4f43-a6a3-d0edfd9b4ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4afaffaa-71cd-46a0-acce-b73bb14bd1dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d39a7185-7edb-4efc-b428-214ffeed37e4" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4afaffaa-71cd-46a0-acce-b73bb14bd1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_429b0d9a-8286-4323-800e-6f6b09536439" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4afaffaa-71cd-46a0-acce-b73bb14bd1dd" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_429b0d9a-8286-4323-800e-6f6b09536439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_f76f2bd5-261f-47e3-aedf-29f910ce55c2" xlink:href="sny-20231231.xsd#sny_NumberOfRestrictedSharesNotYetFullyVested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4afaffaa-71cd-46a0-acce-b73bb14bd1dd" xlink:to="loc_sny_NumberOfRestrictedSharesNotYetFullyVested_f76f2bd5-261f-47e3-aedf-29f910ce55c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_4502dcf5-978b-4007-8d73-a454fd84c078" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4afaffaa-71cd-46a0-acce-b73bb14bd1dd" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_4502dcf5-978b-4007-8d73-a454fd84c078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_e8e31687-5686-4915-ae65-3f414bc0f46e" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e9d96aaf-acb3-4a94-bdde-23feccdab8f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_e8e31687-5686-4915-ae65-3f414bc0f46e" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e9d96aaf-acb3-4a94-bdde-23feccdab8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a4de4a6d-47dc-44fe-952e-f5df575aaa2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e9d96aaf-acb3-4a94-bdde-23feccdab8f8" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a4de4a6d-47dc-44fe-952e-f5df575aaa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_9ded9403-6b87-42b1-81b4-de96ee9eadd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a4de4a6d-47dc-44fe-952e-f5df575aaa2b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_9ded9403-6b87-42b1-81b4-de96ee9eadd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeesShareOwnershipPlanMember_fa4245e8-6f03-4a29-852e-e76b9074d080" xlink:href="sny-20231231.xsd#sny_EmployeesShareOwnershipPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_9ded9403-6b87-42b1-81b4-de96ee9eadd8" xlink:to="loc_sny_EmployeesShareOwnershipPlanMember_fa4245e8-6f03-4a29-852e-e76b9074d080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e9d96aaf-acb3-4a94-bdde-23feccdab8f8" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SubscriptionPricePerShare_15fdfb76-61e0-434e-ad39-b310ec71edbf" xlink:href="sny-20231231.xsd#sny_SubscriptionPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:to="loc_sny_SubscriptionPricePerShare_15fdfb76-61e0-434e-ad39-b310ec71edbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareSubscribed_646c65a4-08b4-4ba6-9756-6bf6681c4c3e" xlink:href="sny-20231231.xsd#sny_NumberOfShareSubscribed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:to="loc_sny_NumberOfShareSubscribed_646c65a4-08b4-4ba6-9756-6bf6681c4c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_9544c801-3f0e-4d0c-9642-09abb46c0de8" xlink:href="sny-20231231.xsd#sny_IssuanceOfFurtherSharesAsAnEmployersContribution"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:to="loc_sny_IssuanceOfFurtherSharesAsAnEmployersContribution_9544c801-3f0e-4d0c-9642-09abb46c0de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAverageOfQuotedMarketPricesOfShares_35c347eb-db9b-4ffb-b6ad-e1a95a0a3354" xlink:href="sny-20231231.xsd#sny_PercentageOfAverageOfQuotedMarketPricesOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:to="loc_sny_PercentageOfAverageOfQuotedMarketPricesOfShares_35c347eb-db9b-4ffb-b6ad-e1a95a0a3354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTradingDaysPrecedingPlanApproval_70368d63-c969-4e1e-93b3-19fd935a6760" xlink:href="sny-20231231.xsd#sny_NumberOfTradingDaysPrecedingPlanApproval"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5f4c350c-0233-4462-b87f-3a3f80efa349" xlink:to="loc_sny_NumberOfTradingDaysPrecedingPlanApproval_70368d63-c969-4e1e-93b3-19fd935a6760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_b2036227-fa00-485c-a523-bc82f18ad689" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_74a59dde-eaae-4a12-bd50-e9d49a5b9fc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_b2036227-fa00-485c-a523-bc82f18ad689" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_74a59dde-eaae-4a12-bd50-e9d49a5b9fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_864ac8b3-f194-4c76-a75e-4be6cf65c2ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_74a59dde-eaae-4a12-bd50-e9d49a5b9fc6" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_864ac8b3-f194-4c76-a75e-4be6cf65c2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_d87d6f3e-c03a-48b3-a51e-f74e141bcb40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_864ac8b3-f194-4c76-a75e-4be6cf65c2ba" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_d87d6f3e-c03a-48b3-a51e-f74e141bcb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeesShareOwnershipPlanMember_50fedabc-569d-4554-99d7-579fbd571681" xlink:href="sny-20231231.xsd#sny_EmployeesShareOwnershipPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d87d6f3e-c03a-48b3-a51e-f74e141bcb40" xlink:to="loc_sny_EmployeesShareOwnershipPlanMember_50fedabc-569d-4554-99d7-579fbd571681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_272572df-a2c5-46d9-a75d-fc797db32ba5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_74a59dde-eaae-4a12-bd50-e9d49a5b9fc6" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_272572df-a2c5-46d9-a75d-fc797db32ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a8b7ee46-9a13-4997-92fb-81f165d645de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_272572df-a2c5-46d9-a75d-fc797db32ba5" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a8b7ee46-9a13-4997-92fb-81f165d645de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution_a14a6a0b-7629-49db-8d5f-e4917338a3fd" xlink:href="sny-20231231.xsd#sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_272572df-a2c5-46d9-a75d-fc797db32ba5" xlink:to="loc_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution_a14a6a0b-7629-49db-8d5f-e4917338a3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_70092389-979f-4c59-9c95-5f77c3e07a66" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6433f5b1-f082-4e73-ba6c-9294fd2de1e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_70092389-979f-4c59-9c95-5f77c3e07a66" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6433f5b1-f082-4e73-ba6c-9294fd2de1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateAxis_0a031048-3998-469d-bdcb-9c1fdeac0c3f" xlink:href="sny-20231231.xsd#sny_AwardsDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6433f5b1-f082-4e73-ba6c-9294fd2de1e7" xlink:to="loc_sny_AwardsDateAxis_0a031048-3998-469d-bdcb-9c1fdeac0c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:href="sny-20231231.xsd#sny_AwardsDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AwardsDateAxis_0a031048-3998-469d-bdcb-9c1fdeac0c3f" xlink:to="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2023ProgramMember_dff6fe6f-738e-4d08-a83c-65a002b10a22" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2023ProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:to="loc_sny_ShareRepurchase2023ProgramMember_dff6fe6f-738e-4d08-a83c-65a002b10a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2022ProgramMember_e2e54ece-52f1-4720-96de-a20b0d853d1e" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2022ProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:to="loc_sny_ShareRepurchase2022ProgramMember_e2e54ece-52f1-4720-96de-a20b0d853d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2021ProgramMember_7f6ac938-9d37-47a1-8a1e-efcc9e3bec89" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2021ProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:to="loc_sny_ShareRepurchase2021ProgramMember_7f6ac938-9d37-47a1-8a1e-efcc9e3bec89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareRepurchase2020ProgramMember_3349357d-a67e-4cc8-8668-d52152ab1d16" xlink:href="sny-20231231.xsd#sny_ShareRepurchase2020ProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AwardsDateDomain_f261bf6b-6ea7-48ad-8993-a173167eb25a" xlink:to="loc_sny_ShareRepurchase2020ProgramMember_3349357d-a67e-4cc8-8668-d52152ab1d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8d6ef13c-b141-444b-bd4a-5c1d326482ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6433f5b1-f082-4e73-ba6c-9294fd2de1e7" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8d6ef13c-b141-444b-bd4a-5c1d326482ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSharesRepurchased_0db7c709-9562-4a60-8a44-b63d6d9e6ed7" xlink:href="sny-20231231.xsd#sny_NumberOfSharesRepurchased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8d6ef13c-b141-444b-bd4a-5c1d326482ea" xlink:to="loc_sny_NumberOfSharesRepurchased_0db7c709-9562-4a60-8a44-b63d6d9e6ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountOfSharesRepurchased_8ad58f8c-a877-47eb-9308-7410ae8aa7de" xlink:href="sny-20231231.xsd#sny_AmountOfSharesRepurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8d6ef13c-b141-444b-bd4a-5c1d326482ea" xlink:to="loc_sny_AmountOfSharesRepurchased_8ad58f8c-a877-47eb-9308-7410ae8aa7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_63027b8c-a8b3-43a6-a7f7-57b0e3dc167f" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e317b4f1-e188-413d-a85c-2f9c755a2917" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_63027b8c-a8b3-43a6-a7f7-57b0e3dc167f" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e317b4f1-e188-413d-a85c-2f9c755a2917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_cbf44912-e49a-40cd-978c-efc63c48c1ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e317b4f1-e188-413d-a85c-2f9c755a2917" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_cbf44912-e49a-40cd-978c-efc63c48c1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_043e4184-596b-4d11-907c-fbfa0644908d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_cbf44912-e49a-40cd-978c-efc63c48c1ef" xlink:to="loc_ifrs-full_EquityMember_043e4184-596b-4d11-907c-fbfa0644908d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_fa2f3a76-eee9-45d0-8b07-b2611079bb8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_043e4184-596b-4d11-907c-fbfa0644908d" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_fa2f3a76-eee9-45d0-8b07-b2611079bb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9888ff19-b6be-437f-9c8f-d04a2985ed63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e317b4f1-e188-413d-a85c-2f9c755a2917" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9888ff19-b6be-437f-9c8f-d04a2985ed63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_af980524-6c82-426f-8996-d2473e7144fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9888ff19-b6be-437f-9c8f-d04a2985ed63" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_af980524-6c82-426f-8996-d2473e7144fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncontrollingInterests_73058556-d4a0-4775-b5a0-e1ecac3ea7c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9888ff19-b6be-437f-9c8f-d04a2985ed63" xlink:to="loc_ifrs-full_NoncontrollingInterests_73058556-d4a0-4775-b5a0-e1ecac3ea7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_7d9bcac8-3310-45b7-8e50-9d088fa5e3a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9888ff19-b6be-437f-9c8f-d04a2985ed63" xlink:to="loc_ifrs-full_Equity_7d9bcac8-3310-45b7-8e50-9d088fa5e3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c15c84d0-9b40-4399-8f92-585fdc8d52ec" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c15c84d0-9b40-4399-8f92-585fdc8d52ec" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1ce21823-5a83-4fb2-9ed2-a0c919f2cf61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1ce21823-5a83-4fb2-9ed2-a0c919f2cf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_ebbffbdf-111a-4fdd-897f-d4d1e4fda1f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1ce21823-5a83-4fb2-9ed2-a0c919f2cf61" xlink:to="loc_ifrs-full_EquityMember_ebbffbdf-111a-4fdd-897f-d4d1e4fda1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_841805d8-0e54-48fb-bde8-6bf81c5789be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_ebbffbdf-111a-4fdd-897f-d4d1e4fda1f7" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_841805d8-0e54-48fb-bde8-6bf81c5789be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsAxis_4339477d-748c-4b18-ad72-56ea14155a98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:to="loc_ifrs-full_ReclassifiedItemsAxis_4339477d-748c-4b18-ad72-56ea14155a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassifiedItemsMember_158498b3-be8f-468f-8091-dad3d3aabd8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassifiedItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsAxis_4339477d-748c-4b18-ad72-56ea14155a98" xlink:to="loc_ifrs-full_ReclassifiedItemsMember_158498b3-be8f-468f-8091-dad3d3aabd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_bd909701-6dd8-4321-b5a7-2289ae46731c" xlink:href="sny-20231231.xsd#sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsMember_158498b3-be8f-468f-8091-dad3d3aabd8c" xlink:to="loc_sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember_bd909701-6dd8-4321-b5a7-2289ae46731c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_0dd02f80-684a-4404-a3bc-f3f9f8d5e81d" xlink:href="sny-20231231.xsd#sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReclassifiedItemsMember_158498b3-be8f-468f-8091-dad3d3aabd8c" xlink:to="loc_sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember_0dd02f80-684a-4404-a3bc-f3f9f8d5e81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f6fed796-5caa-4bf7-8a17-ab9cc76787b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f6fed796-5caa-4bf7-8a17-ab9cc76787b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_9f5e809f-bbc3-4793-8047-0f52d483f8e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_f6fed796-5caa-4bf7-8a17-ab9cc76787b2" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_9f5e809f-bbc3-4793-8047-0f52d483f8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_b22e31b4-197e-40be-b664-d7a271acf195" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_9f5e809f-bbc3-4793-8047-0f52d483f8e8" xlink:to="loc_sny_EuroapiMember_b22e31b4-197e-40be-b664-d7a271acf195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_3013393e-3f22-44a5-a5d9-33b0df168a61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_3013393e-3f22-44a5-a5d9-33b0df168a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_3013393e-3f22-44a5-a5d9-33b0df168a61" xlink:to="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsIncludedInFinancialAssetMember_f5c47a12-a978-49f9-a438-5ec398dd03c2" xlink:href="sny-20231231.xsd#sny_EquityInstrumentsIncludedInFinancialAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:to="loc_sny_EquityInstrumentsIncludedInFinancialAssetMember_f5c47a12-a978-49f9-a438-5ec398dd03c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentsMember_460256f9-3e2f-4d42-a717-1dca75bc9931" xlink:href="sny-20231231.xsd#sny_DebtInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:to="loc_sny_DebtInstrumentsMember_460256f9-3e2f-4d42-a717-1dca75bc9931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowAndFairValueHedgeMember_798428a4-be0d-4c26-91c6-61edee1238a5" xlink:href="sny-20231231.xsd#sny_CashFlowAndFairValueHedgeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:to="loc_sny_CashFlowAndFairValueHedgeMember_798428a4-be0d-4c26-91c6-61edee1238a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationMember_d81d396e-a3c0-4a37-b7a2-9a759e053f2f" xlink:href="sny-20231231.xsd#sny_ForeignCurrencyTranslationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_f342ec28-a64d-4910-a42d-b1a4877bda60" xlink:to="loc_sny_ForeignCurrencyTranslationMember_d81d396e-a3c0-4a37-b7a2-9a759e053f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable_8b4f29c7-3691-4347-b795-3ba07a4bfff6" xlink:to="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_f1edd936-40c4-4d47-abd7-68c25c6c3984" xlink:href="sny-20231231.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures_f1edd936-40c4-4d47-abd7-68c25c6c3984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_040f7195-b82d-4ccf-9cea-bc102b3770b5" xlink:href="sny-20231231.xsd#sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_040f7195-b82d-4ccf-9cea-bc102b3770b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_f527a22d-f0a3-4c62-a76c-11dc3223d747" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures_f527a22d-f0a3-4c62-a76c-11dc3223d747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_49d2ff29-48cf-46e9-b7d3-25a0fbb8a616" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures_49d2ff29-48cf-46e9-b7d3-25a0fbb8a616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_c0b10786-c15b-46e2-8f05-db6dab3f0eb8" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax_c0b10786-c15b-46e2-8f05-db6dab3f0eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_2991c693-7cb2-4646-b124-dd61bd111812" xlink:href="sny-20231231.xsd#sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges_2991c693-7cb2-4646-b124-dd61bd111812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_c7fb70ab-c2d5-49a0-849d-9cf19a284c14" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod_c7fb70ab-c2d5-49a0-849d-9cf19a284c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_4c507ecc-25af-4cb4-b902-540828796fbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_4c507ecc-25af-4cb4-b902-540828796fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_dffb19bb-11f1-4d1b-b03b-887c3be92263" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures_dffb19bb-11f1-4d1b-b03b-887c3be92263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures_8ad8154f-0520-4a37-a770-fbbb580382ff" xlink:href="sny-20231231.xsd#sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures_8ad8154f-0520-4a37-a770-fbbb580382ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_ba57c234-8b8d-4d56-acc7-6e67d8e57742" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures_ba57c234-8b8d-4d56-acc7-6e67d8e57742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_9f2dd6e8-aebb-4d7c-8e60-9a381d247c14" xlink:href="sny-20231231.xsd#sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures_9f2dd6e8-aebb-4d7c-8e60-9a381d247c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_63cf897f-a100-4fb7-a350-fcfbb9c3cc06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome_63cf897f-a100-4fb7-a350-fcfbb9c3cc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_1a0ce096-7699-4b1d-ad14-8075ef845999" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures_1a0ce096-7699-4b1d-ad14-8075ef845999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_e52d747f-5ab1-4827-8e44-d802a6e7624c" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures_e52d747f-5ab1-4827-8e44-d802a6e7624c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_1a4e86a0-239f-4ae4-b0d6-d20cd2654b39" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations_1a4e86a0-239f-4ae4-b0d6-d20cd2654b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_c317c135-7120-43f3-887f-b89cd8b7176a" xlink:href="sny-20231231.xsd#sny_ChangeInCurrencyTranslationOnTaxEffects"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_sny_ChangeInCurrencyTranslationOnTaxEffects_c317c135-7120-43f3-887f-b89cd8b7176a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_491ca491-d73e-4027-a9f1-65bc8b4205e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems_bdcc205d-1d3e-4861-8ca5-4c7fe9d824a6" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_491ca491-d73e-4027-a9f1-65bc8b4205e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c58c87c4-cac4-4b2f-a1ea-eb7be52b451b" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable_a2e2a8da-17fe-491f-9bea-ff0a217f2921" xlink:href="sny-20231231.xsd#sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_c58c87c4-cac4-4b2f-a1ea-eb7be52b451b" xlink:to="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable_a2e2a8da-17fe-491f-9bea-ff0a217f2921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_255e94f5-1d36-46ea-917a-a304baae47e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable_a2e2a8da-17fe-491f-9bea-ff0a217f2921" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_255e94f5-1d36-46ea-917a-a304baae47e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_dc8edc12-fb85-47f3-b87c-3508459c09e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_255e94f5-1d36-46ea-917a-a304baae47e9" xlink:to="loc_ifrs-full_EquityMember_dc8edc12-fb85-47f3-b87c-3508459c09e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_dc8edc12-fb85-47f3-b87c-3508459c09e6" xlink:to="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanThreeMember_c0951423-3dc7-43be-8cd2-ca7c7d84fb7e" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanThreeMember_c0951423-3dc7-43be-8cd2-ca7c7d84fb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanFourMember_dd435c63-8853-41e4-b547-8668eff2d3bf" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanFourMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanFourMember_dd435c63-8853-41e4-b547-8668eff2d3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanFiveMember_d7308cf9-15a8-4388-b0d0-f3300c2c4c4c" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanFiveMember_d7308cf9-15a8-4388-b0d0-f3300c2c4c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanSixMember_5f9800c3-1363-4ba3-b4a2-877df23cf39b" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanSixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanSixMember_5f9800c3-1363-4ba3-b4a2-877df23cf39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanSevenMember_c2f48e55-fe2e-42f9-b60e-382248762661" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanSevenMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanSevenMember_c2f48e55-fe2e-42f9-b60e-382248762661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanEightMember_220d8ce1-e891-47d6-b814-bf682f684a85" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanEightMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanEightMember_220d8ce1-e891-47d6-b814-bf682f684a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanNineMember_2d80a875-21f6-457c-979d-ea234a329779" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanNineMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanNineMember_2d80a875-21f6-457c-979d-ea234a329779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockSubscriptionOptionPlanTenMember_d9db98e1-0fcb-4943-9f85-157b15f9fd21" xlink:href="sny-20231231.xsd#sny_StockSubscriptionOptionPlanTenMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_StockSubscriptionOptionPlanMember_36b25537-7a1e-45cd-b01e-3dcbb592efbd" xlink:to="loc_sny_StockSubscriptionOptionPlanTenMember_d9db98e1-0fcb-4943-9f85-157b15f9fd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_88757ed2-e10c-4cdd-b18b-3f82b757c868" xlink:href="sny-20231231.xsd#sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable_a2e2a8da-17fe-491f-9bea-ff0a217f2921" xlink:to="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_88757ed2-e10c-4cdd-b18b-3f82b757c868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_35f43ef9-c459-43b9-be2c-c66b51c7551d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_88757ed2-e10c-4cdd-b18b-3f82b757c868" xlink:to="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_35f43ef9-c459-43b9-be2c-c66b51c7551d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockBasedCompensationStockOptionsExercisedPricePerShare_c24789da-9ec0-428b-9f23-8979e4462be7" xlink:href="sny-20231231.xsd#sny_StockBasedCompensationStockOptionsExercisedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_88757ed2-e10c-4cdd-b18b-3f82b757c868" xlink:to="loc_sny_StockBasedCompensationStockOptionsExercisedPricePerShare_c24789da-9ec0-428b-9f23-8979e4462be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_bab09ac5-c773-4458-ae22-45f4f2d79233" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems_88757ed2-e10c-4cdd-b18b-3f82b757c868" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_bab09ac5-c773-4458-ae22-45f4f2d79233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_eedc523e-b750-4480-8c4f-dbc48c143af1" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_27cd8772-406e-48ee-a5ec-7940532da9ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_eedc523e-b750-4480-8c4f-dbc48c143af1" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_27cd8772-406e-48ee-a5ec-7940532da9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_69f75679-9017-456a-9da0-25cb5a2f2b3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_27cd8772-406e-48ee-a5ec-7940532da9ed" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_69f75679-9017-456a-9da0-25cb5a2f2b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a39a107-4cb7-41d0-9b50-48c42ece855a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_69f75679-9017-456a-9da0-25cb5a2f2b3a" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a39a107-4cb7-41d0-9b50-48c42ece855a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalStockOptionPlansMember_f244b9a1-a2c4-4f50-9fd6-2e5d52f8d150" xlink:href="sny-20231231.xsd#sny_TotalStockOptionPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a39a107-4cb7-41d0-9b50-48c42ece855a" xlink:to="loc_sny_TotalStockOptionPlansMember_f244b9a1-a2c4-4f50-9fd6-2e5d52f8d150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_27cd8772-406e-48ee-a5ec-7940532da9ed" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement_7876134f-ac2b-47f3-b2e0-39268ea11956" xlink:href="sny-20231231.xsd#sny_NumberOfShareOutstandingInShareBasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement_7876134f-ac2b-47f3-b2e0-39268ea11956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_8b469ccf-695d-485f-b5ed-7f216eda68e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_8b469ccf-695d-485f-b5ed-7f216eda68e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_24006c06-fb58-460a-b2f9-bce6e2bcea9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_24006c06-fb58-460a-b2f9-bce6e2bcea9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_f3c13a92-ec26-4ec0-85de-fea1ae467e1b" xlink:href="sny-20231231.xsd#sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement_f3c13a92-ec26-4ec0-85de-fea1ae467e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_bc183da5-035d-4dca-b690-f3473dc8d2ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_bc183da5-035d-4dca-b690-f3473dc8d2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement_9b72abcc-f217-4757-9c5f-6f3fd836cf93" xlink:href="sny-20231231.xsd#sny_NumberOfShareOutstandingInShareBasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement_9b72abcc-f217-4757-9c5f-6f3fd836cf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_5104cc93-ba2c-4b48-ba6e-0fbd68c9397b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_5104cc93-ba2c-4b48-ba6e-0fbd68c9397b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_6798239f-0214-45af-a75b-8dbb3529909e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_6798239f-0214-45af-a75b-8dbb3529909e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_e444008d-1e76-429d-8709-c33ce1710988" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_e444008d-1e76-429d-8709-c33ce1710988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement_ce5f965b-f10d-4ddd-b260-e8b94ba8b83b" xlink:href="sny-20231231.xsd#sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement_ce5f965b-f10d-4ddd-b260-e8b94ba8b83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_b647a1ef-2b50-4db0-bdd2-c93d5bf4418b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_b647a1ef-2b50-4db0-bdd2-c93d5bf4418b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3f4cccf7-e4ef-40ce-aa99-a85e9ba0e813" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3f4cccf7-e4ef-40ce-aa99-a85e9ba0e813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement_5f68d36c-2214-48cb-9fd9-093a620b89af" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement_5f68d36c-2214-48cb-9fd9-093a620b89af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement_7ba8fab7-8f51-470b-9ab6-0791abd293d5" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement_7ba8fab7-8f51-470b-9ab6-0791abd293d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement_5afc2828-f7f1-45fa-8d62-32c42ec1485a" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement_5afc2828-f7f1-45fa-8d62-32c42ec1485a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement_0caba838-f523-4838-b7a8-43a71d93abf4" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement_0caba838-f523-4838-b7a8-43a71d93abf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement_3adabe4b-8d3c-46ac-881e-ddaa028beec2" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement_3adabe4b-8d3c-46ac-881e-ddaa028beec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement_59ba15db-96ef-4c28-bf85-0ed246cd75d3" xlink:href="sny-20231231.xsd#sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4fd3be5b-497b-45a1-9c34-30955aa3bc52" xlink:to="loc_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement_59ba15db-96ef-4c28-bf85-0ed246cd75d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_becdb838-33da-4dbf-b0f8-8015643e4ded" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2ac0df50-124e-4c9b-b6cf-556a314324a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_becdb838-33da-4dbf-b0f8-8015643e4ded" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2ac0df50-124e-4c9b-b6cf-556a314324a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_4ae283a5-3672-45d7-82a5-d6f005be5d7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2ac0df50-124e-4c9b-b6cf-556a314324a6" xlink:to="loc_ifrs-full_RangeAxis_4ae283a5-3672-45d7-82a5-d6f005be5d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_1b8479b4-4df1-40fb-8459-ead25f9b201a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_4ae283a5-3672-45d7-82a5-d6f005be5d7b" xlink:to="loc_ifrs-full_RangesMember_1b8479b4-4df1-40fb-8459-ead25f9b201a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_4402b974-19d2-4448-977a-9c6a1b61bea8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_1b8479b4-4df1-40fb-8459-ead25f9b201a" xlink:to="loc_ifrs-full_BottomOfRangeMember_4402b974-19d2-4448-977a-9c6a1b61bea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_e687f060-7d61-4495-8caf-e75df82bb0a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_1b8479b4-4df1-40fb-8459-ead25f9b201a" xlink:to="loc_ifrs-full_TopOfRangeMember_e687f060-7d61-4495-8caf-e75df82bb0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_843c1218-d1f7-4db7-850a-cb63f28a586e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2ac0df50-124e-4c9b-b6cf-556a314324a6" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_843c1218-d1f7-4db7-850a-cb63f28a586e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_c948729f-a7ec-4f57-9dc6-c0f4e952caac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_843c1218-d1f7-4db7-850a-cb63f28a586e" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_c948729f-a7ec-4f57-9dc6-c0f4e952caac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeTwoMember_82480155-ef57-4935-a9dc-06a752e6c137" xlink:href="sny-20231231.xsd#sny_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_c948729f-a7ec-4f57-9dc6-c0f4e952caac" xlink:to="loc_sny_ExercisePriceRangeTwoMember_82480155-ef57-4935-a9dc-06a752e6c137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeThreeMember_f4282a34-af49-4930-bc3b-68e8f5580c22" xlink:href="sny-20231231.xsd#sny_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_c948729f-a7ec-4f57-9dc6-c0f4e952caac" xlink:to="loc_sny_ExercisePriceRangeThreeMember_f4282a34-af49-4930-bc3b-68e8f5580c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExercisePriceRangeFourMember_12594b07-5048-438e-9623-843c7b6fecf9" xlink:href="sny-20231231.xsd#sny_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_c948729f-a7ec-4f57-9dc6-c0f4e952caac" xlink:to="loc_sny_ExercisePriceRangeFourMember_12594b07-5048-438e-9623-843c7b6fecf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_fa53a27e-3276-48db-8517-83527644351e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2ac0df50-124e-4c9b-b6cf-556a314324a6" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_fa53a27e-3276-48db-8517-83527644351e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_146d8065-1c1c-4730-8835-ddb622dd5529" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_fa53a27e-3276-48db-8517-83527644351e" xlink:to="loc_ifrs-full_EquityMember_146d8065-1c1c-4730-8835-ddb622dd5529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_StockOptionPlanMember_93c64f26-a579-4a7f-8a26-1dac07d459dc" xlink:href="sny-20231231.xsd#sny_StockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_146d8065-1c1c-4730-8835-ddb622dd5529" xlink:to="loc_sny_StockOptionPlanMember_93c64f26-a579-4a7f-8a26-1dac07d459dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_2ac0df50-124e-4c9b-b6cf-556a314324a6" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_097f22fc-a12c-4287-85d0-e66ac3a9f255" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_097f22fc-a12c-4287-85d0-e66ac3a9f255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_8ea61661-ba13-442c-a467-34156d05419f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_8ea61661-ba13-442c-a467-34156d05419f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dd398e28-9c2b-4f7c-aedc-47843d4c16b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dd398e28-9c2b-4f7c-aedc-47843d4c16b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_33f6e885-da5e-4b89-99c8-cf22247ffa53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_33f6e885-da5e-4b89-99c8-cf22247ffa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_0343475d-7d6c-4802-b00a-6a11014e20fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_0343475d-7d6c-4802-b00a-6a11014e20fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_1f8e3d0f-9245-4977-b974-4b4cf7cb283a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_09d36917-c15c-4d20-8051-f5d30596c57d" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_1f8e3d0f-9245-4977-b974-4b4cf7cb283a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_01e3e3d4-32fa-47c7-9c86-22b5d7a52c2e" xlink:href="sny-20231231.xsd#sny_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_b1315bb7-690e-4f8b-8eec-9f948d0fb5ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_01e3e3d4-32fa-47c7-9c86-22b5d7a52c2e" xlink:to="loc_ifrs-full_WeightedAverageShares_b1315bb7-690e-4f8b-8eec-9f948d0fb5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_93c5a8e1-d046-4ca2-b135-1b2edae9af37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_01e3e3d4-32fa-47c7-9c86-22b5d7a52c2e" xlink:to="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_93c5a8e1-d046-4ca2-b135-1b2edae9af37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_ac7e3837-df3e-4bfc-ad68-c66c3829f89b" xlink:href="sny-20231231.xsd#sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_01e3e3d4-32fa-47c7-9c86-22b5d7a52c2e" xlink:to="loc_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares_ac7e3837-df3e-4bfc-ad68-c66c3829f89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_a41119ab-6074-4697-814b-3df4c31f3937" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ShareCapitalReservesAndOtherEquityInterestAbstract_01e3e3d4-32fa-47c7-9c86-22b5d7a52c2e" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_a41119ab-6074-4697-814b-3df4c31f3937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_214e4c9e-94e7-465a-bb2c-86297a1463ac" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_f6777bf5-1b0d-40fe-9cff-c8d4101f7f89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_214e4c9e-94e7-465a-bb2c-86297a1463ac" xlink:to="loc_ifrs-full_LongtermBorrowings_f6777bf5-1b0d-40fe-9cff-c8d4101f7f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_1837b6b2-d7c4-43bb-9c23-a227f6b68776" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_214e4c9e-94e7-465a-bb2c-86297a1463ac" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_1837b6b2-d7c4-43bb-9c23-a227f6b68776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_f19beab5-0f32-4066-b490-f3b3b3b96773" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_214e4c9e-94e7-465a-bb2c-86297a1463ac" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_f19beab5-0f32-4066-b490-f3b3b3b96773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_2dcf64e2-6930-41c8-b3de-ccce5c896a5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_214e4c9e-94e7-465a-bb2c-86297a1463ac" xlink:to="loc_ifrs-full_Borrowings_2dcf64e2-6930-41c8-b3de-ccce5c896a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_6b845efe-0807-4336-918b-c8ecd89db589" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_214e4c9e-94e7-465a-bb2c-86297a1463ac" xlink:to="loc_ifrs-full_CashAndCashEquivalents_6b845efe-0807-4336-918b-c8ecd89db589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_0b942927-3fde-4923-b050-acb37d611edf" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_214e4c9e-94e7-465a-bb2c-86297a1463ac" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_0b942927-3fde-4923-b050-acb37d611edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_b58c297d-156a-4d16-8902-867411ad3cfa" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_214e4c9e-94e7-465a-bb2c-86297a1463ac" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_b58c297d-156a-4d16-8902-867411ad3cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_4001788c-b94c-471c-bdbe-ce5c0cf159f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_214e4c9e-94e7-465a-bb2c-86297a1463ac" xlink:to="loc_ifrs-full_LeaseLiabilities_4001788c-b94c-471c-bdbe-ce5c0cf159f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_85dbdd85-1727-4da6-a7ce-7f31443dd688" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_f2771df6-2a4f-4ec3-88d7-7e0b5a1f22c1" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_85dbdd85-1727-4da6-a7ce-7f31443dd688" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_f2771df6-2a4f-4ec3-88d7-7e0b5a1f22c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_7232f18d-f7b8-4983-b83f-f7fe7e551a11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_f2771df6-2a4f-4ec3-88d7-7e0b5a1f22c1" xlink:to="loc_ifrs-full_MeasurementAxis_7232f18d-f7b8-4983-b83f-f7fe7e551a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_7d529ffb-8aeb-4347-9ee6-469e33f1d653" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_7232f18d-f7b8-4983-b83f-f7fe7e551a11" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_7d529ffb-8aeb-4347-9ee6-469e33f1d653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizedCostMember_eb8efca9-50fe-425f-873f-836aae4eb81a" xlink:href="sny-20231231.xsd#sny_AmortizedCostMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d529ffb-8aeb-4347-9ee6-469e33f1d653" xlink:to="loc_sny_AmortizedCostMember_eb8efca9-50fe-425f-873f-836aae4eb81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_f34fbb78-160d-4d26-8aea-eda2f2ecc7b3" xlink:href="sny-20231231.xsd#sny_AdjustmentToDebtMeasuredAtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d529ffb-8aeb-4347-9ee6-469e33f1d653" xlink:to="loc_sny_AdjustmentToDebtMeasuredAtFairValueMember_f34fbb78-160d-4d26-8aea-eda2f2ecc7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_aaa0d9ea-32c6-4a71-9c8e-3b2bcf3f805e" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7d529ffb-8aeb-4347-9ee6-469e33f1d653" xlink:to="loc_sny_ValueOnRedemptionMember_aaa0d9ea-32c6-4a71-9c8e-3b2bcf3f805e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_f2771df6-2a4f-4ec3-88d7-7e0b5a1f22c1" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_bdc8eb2a-bcc9-4943-9ead-5e84739df49e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_ifrs-full_LongtermBorrowings_bdc8eb2a-bcc9-4943-9ead-5e84739df49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_bdc75cdf-b31e-4c6f-8492-beda7dda0aea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_bdc75cdf-b31e-4c6f-8492-beda7dda0aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_676d29a8-e8e4-40e0-9393-e5a5ae56068a" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_676d29a8-e8e4-40e0-9393-e5a5ae56068a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_a4e8d9c2-b7f7-4956-b911-a60ec4d12e9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_ifrs-full_Borrowings_a4e8d9c2-b7f7-4956-b911-a60ec4d12e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_ab4e44e3-3b0a-4d7e-a71e-90333306d146" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_ifrs-full_CashAndCashEquivalents_ab4e44e3-3b0a-4d7e-a71e-90333306d146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_57a25296-d180-4792-bde5-823dc143f546" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_57a25296-d180-4792-bde5-823dc143f546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_744f44d5-afc5-4270-a66f-82600865796b" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_50a44727-f419-4a27-977b-670d609fb745" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_744f44d5-afc5-4270-a66f-82600865796b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_d9a22845-e224-4645-9022-1dbfccb1ad13" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtTable_1691831f-df6f-4789-9968-5f4db472aa37" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_d9a22845-e224-4645-9022-1dbfccb1ad13" xlink:to="loc_sny_DisclosureOfDebtTable_1691831f-df6f-4789-9968-5f4db472aa37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_628fb555-244c-43cb-98c9-7c473b9f50da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtTable_1691831f-df6f-4789-9968-5f4db472aa37" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_628fb555-244c-43cb-98c9-7c473b9f50da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_c4592645-1b94-43e4-9227-736b626b4d85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_628fb555-244c-43cb-98c9-7c473b9f50da" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_c4592645-1b94-43e4-9227-736b626b4d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_f6b943da-a60d-4dc1-bc0c-016d4731819c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_c4592645-1b94-43e4-9227-736b626b4d85" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_f6b943da-a60d-4dc1-bc0c-016d4731819c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember_05027eca-e89f-4143-bf58-56e07a9dd265" xlink:href="sny-20231231.xsd#sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_c4592645-1b94-43e4-9227-736b626b4d85" xlink:to="loc_sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember_05027eca-e89f-4143-bf58-56e07a9dd265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember_6273b138-569a-4128-9fbf-5483528600f3" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_c4592645-1b94-43e4-9227-736b626b4d85" xlink:to="loc_sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember_6273b138-569a-4128-9fbf-5483528600f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_669f022d-a351-4884-a694-e534582d1e5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtTable_1691831f-df6f-4789-9968-5f4db472aa37" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_669f022d-a351-4884-a694-e534582d1e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_10e353b7-420a-42db-a434-01e46fa10d91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_669f022d-a351-4884-a694-e534582d1e5a" xlink:to="loc_ifrs-full_BorrowingsByNameMember_10e353b7-420a-42db-a434-01e46fa10d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_2227807a-505c-412a-9294-4e06695bbbe7" xlink:href="sny-20231231.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_10e353b7-420a-42db-a434-01e46fa10d91" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_2227807a-505c-412a-9294-4e06695bbbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtTable_1691831f-df6f-4789-9968-5f4db472aa37" xlink:to="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_226e98f9-d1b6-4c44-9a6a-b03c326976e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_ifrs-full_Borrowings_226e98f9-d1b6-4c44-9a6a-b03c326976e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_72ba9d60-7c04-41aa-8a1b-e3da65be50d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_72ba9d60-7c04-41aa-8a1b-e3da65be50d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_9d43ab31-68bd-4c91-8008-b7e65eadd369" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_9d43ab31-68bd-4c91-8008-b7e65eadd369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_5b7bb648-57be-4de8-a9b6-562284f09d32" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_5b7bb648-57be-4de8-a9b6-562284f09d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForeignCurrencyTranslationDifferences_f7698de1-b324-4a07-abeb-acef8a32bac6" xlink:href="sny-20231231.xsd#sny_ForeignCurrencyTranslationDifferences"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_sny_ForeignCurrencyTranslationDifferences_f7698de1-b324-4a07-abeb-acef8a32bac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReclassificationFromNonCurrentToCurrent_eccad586-e779-4d84-8e65-30ee1e382f78" xlink:href="sny-20231231.xsd#sny_ReclassificationFromNonCurrentToCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_sny_ReclassificationFromNonCurrentToCurrent_eccad586-e779-4d84-8e65-30ee1e382f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_4155fca8-8366-4cba-8331-9109d28a9ca6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_4155fca8-8366-4cba-8331-9109d28a9ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_2ac5bd8b-ebf4-4851-a771-05489cc39331" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_ifrs-full_Borrowings_2ac5bd8b-ebf4-4851-a771-05489cc39331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_b7786614-963c-40b5-91ea-cab897048457" xlink:href="sny-20231231.xsd#sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments_b7786614-963c-40b5-91ea-cab897048457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings_4d9d3edb-9c68-4f3f-860a-b0ae15c285fe" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtLineItems_7b414375-8749-4676-9ee7-d3740f7c8358" xlink:to="loc_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings_4d9d3edb-9c68-4f3f-860a-b0ae15c285fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_aaf4bc76-68df-4ed6-855f-0b1746bf5f7b" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5e43faa0-6063-47a3-8531-da8fcfcb56f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_aaf4bc76-68df-4ed6-855f-0b1746bf5f7b" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5e43faa0-6063-47a3-8531-da8fcfcb56f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_dec7ed3a-3996-467d-9185-1a7312567b19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5e43faa0-6063-47a3-8531-da8fcfcb56f5" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_dec7ed3a-3996-467d-9185-1a7312567b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_dec7ed3a-3996-467d-9185-1a7312567b19" xlink:to="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_f783167d-4b00-4430-800e-3fa3d2b1eca1" xlink:href="sny-20231231.xsd#sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member_f783167d-4b00-4430-800e-3fa3d2b1eca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingJune2023Member_d44e77af-6a55-4680-abfb-9329715d1947" xlink:href="sny-20231231.xsd#sny_OneBillionBondsMaturingJune2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_OneBillionBondsMaturingJune2023Member_d44e77af-6a55-4680-abfb-9329715d1947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OneBillionBondsMaturingNovember2023Member_101c13d4-26cf-4d74-ae2b-438517154109" xlink:href="sny-20231231.xsd#sny_OneBillionBondsMaturingNovember2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_OneBillionBondsMaturingNovember2023Member_101c13d4-26cf-4d74-ae2b-438517154109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingMarch2029Member_b9f81b4c-50a3-4130-a4fd-0998dab8912c" xlink:href="sny-20231231.xsd#sny_FourBillionFacilityMaturingMarch2029Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_FourBillionFacilityMaturingMarch2029Member_b9f81b4c-50a3-4130-a4fd-0998dab8912c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SyndicatedCreditFacilityCanceledMember_6cb91c53-2021-40eb-a1b1-3344d9597497" xlink:href="sny-20231231.xsd#sny_SyndicatedCreditFacilityCanceledMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_SyndicatedCreditFacilityCanceledMember_6cb91c53-2021-40eb-a1b1-3344d9597497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FourBillionFacilityMaturingDecember2027Member_bc11d497-5c0f-470b-bea8-d2cc73de27fd" xlink:href="sny-20231231.xsd#sny_FourBillionFacilityMaturingDecember2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_FourBillionFacilityMaturingDecember2027Member_bc11d497-5c0f-470b-bea8-d2cc73de27fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ParticipatingSharesMember_2a423ea3-7ab0-4226-b971-a6bcb1f157c7" xlink:href="sny-20231231.xsd#sny_ParticipatingSharesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_ParticipatingSharesMember_2a423ea3-7ab0-4226-b971-a6bcb1f157c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInFranceMember_7b94230e-b50b-44da-bcde-aabb71622637" xlink:href="sny-20231231.xsd#sny_CommercialPaperProgramInFranceMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_CommercialPaperProgramInFranceMember_7b94230e-b50b-44da-bcde-aabb71622637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercialPaperProgramInUSAMember_74e4edc8-3cbd-4a91-9803-965e5c11a2e4" xlink:href="sny-20231231.xsd#sny_CommercialPaperProgramInUSAMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_617a0554-307b-4a6f-9213-7d631786fcdf" xlink:to="loc_sny_CommercialPaperProgramInUSAMember_74e4edc8-3cbd-4a91-9803-965e5c11a2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrument1Axis_c5e6dffa-9f0b-4e9e-965b-fe34ea7f9993" xlink:href="sny-20231231.xsd#sny_DebtInstrument1Axis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5e43faa0-6063-47a3-8531-da8fcfcb56f5" xlink:to="loc_sny_DebtInstrument1Axis_c5e6dffa-9f0b-4e9e-965b-fe34ea7f9993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_c421a864-39f9-485e-b527-cfc768b8a168" xlink:href="sny-20231231.xsd#sny_DebtInstrumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrument1Axis_c5e6dffa-9f0b-4e9e-965b-fe34ea7f9993" xlink:to="loc_sny_DebtInstrumentDomain_c421a864-39f9-485e-b527-cfc768b8a168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_90b2377f-8153-4831-ab2e-0c3d9bab333f" xlink:href="sny-20231231.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentDomain_c421a864-39f9-485e-b527-cfc768b8a168" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_90b2377f-8153-4831-ab2e-0c3d9bab333f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_8bf3d59c-ef06-437e-8486-072399b9010a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5e43faa0-6063-47a3-8531-da8fcfcb56f5" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_8bf3d59c-ef06-437e-8486-072399b9010a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_5c251800-06ce-4d12-a17a-4733115877d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_8bf3d59c-ef06-437e-8486-072399b9010a" xlink:to="loc_ifrs-full_InterestRateTypesMember_5c251800-06ce-4d12-a17a-4733115877d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember_69231f5c-48c9-43f4-a2f3-cbab528f16a2" xlink:href="sny-20231231.xsd#sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_5c251800-06ce-4d12-a17a-4733115877d7" xlink:to="loc_sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember_69231f5c-48c9-43f4-a2f3-cbab528f16a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember_a266d4b9-5396-4656-a047-0bbd264c8b12" xlink:href="sny-20231231.xsd#sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_5c251800-06ce-4d12-a17a-4733115877d7" xlink:to="loc_sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember_a266d4b9-5396-4656-a047-0bbd264c8b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5e43faa0-6063-47a3-8531-da8fcfcb56f5" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBondIssuesRedeemed_db9feb5b-4d11-4eac-9d02-1b381e66fc0f" xlink:href="sny-20231231.xsd#sny_NumberOfBondIssuesRedeemed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_NumberOfBondIssuesRedeemed_db9feb5b-4d11-4eac-9d02-1b381e66fc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_fd2473fd-e1d4-4d4b-ab3c-4743f41105de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_ifrs-full_NotionalAmount_fd2473fd-e1d4-4d4b-ab3c-4743f41105de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionNumber_5e392628-8410-44e5-b5ba-819f7236802f" xlink:href="sny-20231231.xsd#sny_CreditFacilitiesExtensionOptionNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_CreditFacilitiesExtensionOptionNumber_5e392628-8410-44e5-b5ba-819f7236802f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CreditFacilitiesExtensionOptionPeriod_81730799-36a9-4b0a-954f-e3ac898b80ea" xlink:href="sny-20231231.xsd#sny_CreditFacilitiesExtensionOptionPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_CreditFacilitiesExtensionOptionPeriod_81730799-36a9-4b0a-954f-e3ac898b80ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCreditFacilities_1029bdf3-a6f8-4a1a-a4a5-83744bb61736" xlink:href="sny-20231231.xsd#sny_NumberOfCreditFacilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_NumberOfCreditFacilities_1029bdf3-a6f8-4a1a-a4a5-83744bb61736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfSustainableDevelopmentPerformanceIndicators_80ec4134-3290-4e32-8ff4-adb079e49a1a" xlink:href="sny-20231231.xsd#sny_NumberOfSustainableDevelopmentPerformanceIndicators"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_NumberOfSustainableDevelopmentPerformanceIndicators_80ec4134-3290-4e32-8ff4-adb079e49a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ParticipatingSharesNumberOutstanding_9825633e-5423-478d-849f-c20352d00a1d" xlink:href="sny-20231231.xsd#sny_ParticipatingSharesNumberOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_ParticipatingSharesNumberOutstanding_9825633e-5423-478d-849f-c20352d00a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ParticipatingSharesCarryingAmount_662c9b98-ae70-485e-a574-6211a0cb4fcd" xlink:href="sny-20231231.xsd#sny_ParticipatingSharesCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_ParticipatingSharesCarryingAmount_662c9b98-ae70-485e-a574-6211a0cb4fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCommercialPaperPrograms_2fc5a436-e9ba-41ed-a5e8-9287832ebcb3" xlink:href="sny-20231231.xsd#sny_NumberOfCommercialPaperPrograms"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_NumberOfCommercialPaperPrograms_2fc5a436-e9ba-41ed-a5e8-9287832ebcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommercialPapersIssued_526a14d1-0562-4a87-812a-4af1919036b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommercialPapersIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_ifrs-full_CommercialPapersIssued_526a14d1-0562-4a87-812a-4af1919036b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingAverageDrawdown_1147fe83-43b7-46b8-96ca-aeec7265b8d4" xlink:href="sny-20231231.xsd#sny_BorrowingAverageDrawdown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_BorrowingAverageDrawdown_1147fe83-43b7-46b8-96ca-aeec7265b8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingMaximumDrawdown_3539b0d4-a7b7-4426-9b1a-9d5b2d5b9140" xlink:href="sny-20231231.xsd#sny_BorrowingMaximumDrawdown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_BorrowingMaximumDrawdown_3539b0d4-a7b7-4426-9b1a-9d5b2d5b9140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BorrowingDrawdown_f9be7cf7-77c8-4f01-846b-f9358e3eca80" xlink:href="sny-20231231.xsd#sny_BorrowingDrawdown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_BorrowingDrawdown_f9be7cf7-77c8-4f01-846b-f9358e3eca80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCurrenciesDebtIsIssuedIn_953deb8f-4adb-41e8-8968-5de9983dfbf3" xlink:href="sny-20231231.xsd#sny_NumberOfCurrenciesDebtIsIssuedIn"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_NumberOfCurrenciesDebtIsIssuedIn_953deb8f-4adb-41e8-8968-5de9983dfbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_8acace23-dd51-415e-b51c-fc574ad1f8af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_ifrs-full_BorrowingsInterestRate_8acace23-dd51-415e-b51c-fc574ad1f8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalentsInvestedRate_b66eae4f-77cf-49fd-9cb5-898126e63207" xlink:href="sny-20231231.xsd#sny_CashAndCashEquivalentsInvestedRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b9ee67d9-33a8-4df0-a28f-6f09fa5094d6" xlink:to="loc_sny_CashAndCashEquivalentsInvestedRate_b66eae4f-77cf-49fd-9cb5-898126e63207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_0124b1c1-cf12-41c9-9b6e-cd86d2464a8f" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_0124b1c1-cf12-41c9-9b6e-cd86d2464a8f" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_5d24f9c7-e4ad-49c3-87ab-2e5a7be28b4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:to="loc_ifrs-full_MeasurementAxis_5d24f9c7-e4ad-49c3-87ab-2e5a7be28b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_a76a70c0-e1e0-47f0-a10a-ee371b732673" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_5d24f9c7-e4ad-49c3-87ab-2e5a7be28b4b" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_a76a70c0-e1e0-47f0-a10a-ee371b732673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_3951a1d6-9b72-4346-8818-3b7cfdc1f3a7" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_a76a70c0-e1e0-47f0-a10a-ee371b732673" xlink:to="loc_sny_ValueOnRedemptionMember_3951a1d6-9b72-4346-8818-3b7cfdc1f3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_c7cc84c6-c390-487b-b72e-0043f112e7a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_c7cc84c6-c390-487b-b72e-0043f112e7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_9232a6ec-66e1-4ee4-8641-d4b10de7c54a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_c7cc84c6-c390-487b-b72e-0043f112e7a4" xlink:to="loc_ifrs-full_LiabilitiesMember_9232a6ec-66e1-4ee4-8641-d4b10de7c54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesMember_aff558af-5f9d-49f1-99f6-fac3a30365b2" xlink:href="sny-20231231.xsd#sny_NonCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_9232a6ec-66e1-4ee4-8641-d4b10de7c54a" xlink:to="loc_sny_NonCurrentLiabilitiesMember_aff558af-5f9d-49f1-99f6-fac3a30365b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesMember_7ddeaba4-ab2b-4e91-89ea-7456011cdd31" xlink:href="sny-20231231.xsd#sny_CurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_9232a6ec-66e1-4ee4-8641-d4b10de7c54a" xlink:to="loc_sny_CurrentLiabilitiesMember_7ddeaba4-ab2b-4e91-89ea-7456011cdd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_9ab3767b-c83c-47f5-9780-e1cd582b19b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_9ab3767b-c83c-47f5-9780-e1cd582b19b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_36013d2b-afef-415c-b1b3-c05a886acf62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_9ab3767b-c83c-47f5-9780-e1cd582b19b6" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_36013d2b-afef-415c-b1b3-c05a886acf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentAssetsMember_a5b2becc-9647-4734-84ed-44987b8039d7" xlink:href="sny-20231231.xsd#sny_NonCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_36013d2b-afef-415c-b1b3-c05a886acf62" xlink:to="loc_sny_NonCurrentAssetsMember_a5b2becc-9647-4734-84ed-44987b8039d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentAssetsMember_3a90c6ab-0c51-4923-9f53-0d8a12d1b384" xlink:href="sny-20231231.xsd#sny_CurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_36013d2b-afef-415c-b1b3-c05a886acf62" xlink:to="loc_sny_CurrentAssetsMember_3a90c6ab-0c51-4923-9f53-0d8a12d1b384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_ea204372-a047-47f9-99b4-1ef0d36dcf23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:to="loc_ifrs-full_MaturityAxis_ea204372-a047-47f9-99b4-1ef0d36dcf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_ea204372-a047-47f9-99b4-1ef0d36dcf23" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_208739dd-56a4-44fa-8aa5-0de72c99bfa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_208739dd-56a4-44fa-8aa5-0de72c99bfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_ad13be56-d4ee-493b-b1fc-3c6f26a29db2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_ad13be56-d4ee-493b-b1fc-3c6f26a29db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_48c90606-99c8-4f4a-8bdd-8a676dffef3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_48c90606-99c8-4f4a-8bdd-8a676dffef3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_ff22db70-1c4a-4c8c-a77e-98c02a0e47ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_ff22db70-1c4a-4c8c-a77e-98c02a0e47ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_ffb7b537-54f8-4184-8c77-8bb754e59f74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_ffb7b537-54f8-4184-8c77-8bb754e59f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_41d75c07-a650-4666-9cde-fb5d6adfec6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_648eef27-981f-4d48-aa53-97f333af53da" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_41d75c07-a650-4666-9cde-fb5d6adfec6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:href="sny-20231231.xsd#sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable_bafdbcb5-f891-4bb6-b2b4-d7c658ce7cdf" xlink:to="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_683a9a6b-ead1-4ad9-a805-4c39796eddfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_ifrs-full_BondsIssued_683a9a6b-ead1-4ad9-a805-4c39796eddfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_fa8d9f79-dbb5-4436-bd1f-0e9fad54111e" xlink:href="sny-20231231.xsd#sny_OtherBankBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_sny_OtherBankBorrowings_fa8d9f79-dbb5-4436-bd1f-0e9fad54111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_6e25dd1a-30b3-4b15-8a09-6dbc7a578c48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_ifrs-full_OtherBorrowings_6e25dd1a-30b3-4b15-8a09-6dbc7a578c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_bb6aecaa-37ec-4ba5-b394-21d9d3c313d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_bb6aecaa-37ec-4ba5-b394-21d9d3c313d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_bd277c03-05a0-44d7-9f2b-69c58ba11cde" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_bd277c03-05a0-44d7-9f2b-69c58ba11cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_f3f8230d-6b3a-45e1-bee0-d5bcefdc4db7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_ifrs-full_Borrowings_f3f8230d-6b3a-45e1-bee0-d5bcefdc4db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_637f5591-4b2c-4571-801f-46ce2e199012" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_ifrs-full_CashAndCashEquivalents_637f5591-4b2c-4571-801f-46ce2e199012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_5293061f-43e7-4d55-ac15-3f7b2eeecba5" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_5293061f-43e7-4d55-ac15-3f7b2eeecba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_c3d01ff8-2fa6-4c80-bb23-d1d8f711d183" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems_f36aa82e-0b25-4536-bf28-0e468a99acf8" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_c3d01ff8-2fa6-4c80-bb23-d1d8f711d183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_1136b5b7-ceb1-4897-9864-af2cb0c435d8" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1d4907e9-f2a4-4e55-985f-6af70701eb92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_1136b5b7-ceb1-4897-9864-af2cb0c435d8" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1d4907e9-f2a4-4e55-985f-6af70701eb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrument1Axis_fb1fb3c5-a1f7-4b8d-8cb0-5a45fb8f3461" xlink:href="sny-20231231.xsd#sny_DebtInstrument1Axis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1d4907e9-f2a4-4e55-985f-6af70701eb92" xlink:to="loc_sny_DebtInstrument1Axis_fb1fb3c5-a1f7-4b8d-8cb0-5a45fb8f3461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_4cddc669-4f99-42aa-a557-ded70f5d8427" xlink:href="sny-20231231.xsd#sny_DebtInstrumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrument1Axis_fb1fb3c5-a1f7-4b8d-8cb0-5a45fb8f3461" xlink:to="loc_sny_DebtInstrumentDomain_4cddc669-4f99-42aa-a557-ded70f5d8427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_841c9caf-cddc-4a16-9d18-065920a5f6d5" xlink:href="sny-20231231.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentDomain_4cddc669-4f99-42aa-a557-ded70f5d8427" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_841c9caf-cddc-4a16-9d18-065920a5f6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShelfRegistrationStatementProgramMember_fda569c2-9a04-41b6-bb7e-0f1869a70f55" xlink:href="sny-20231231.xsd#sny_ShelfRegistrationStatementProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentDomain_4cddc669-4f99-42aa-a557-ded70f5d8427" xlink:to="loc_sny_ShelfRegistrationStatementProgramMember_fda569c2-9a04-41b6-bb7e-0f1869a70f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_4b3cb4ba-951a-4f03-b580-45e5d130d232" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1d4907e9-f2a4-4e55-985f-6af70701eb92" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_4b3cb4ba-951a-4f03-b580-45e5d130d232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4b3cb4ba-951a-4f03-b580-45e5d130d232" xlink:to="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2016EMTNISINFR0013143997Member_5887b558-c00b-4a91-91f8-c68098a04a0b" xlink:href="sny-20231231.xsd#sny_April2016EMTNISINFR0013143997Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_April2016EMTNISINFR0013143997Member_5887b558-c00b-4a91-91f8-c68098a04a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2020EMTNISINFR0013505104Member_e9714714-8481-48b6-9539-233a1eaa43a4" xlink:href="sny-20231231.xsd#sny_March2020EMTNISINFR0013505104Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2020EMTNISINFR0013505104Member_e9714714-8481-48b6-9539-233a1eaa43a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2022EMTNISINFR0014009KS6Member_32900e81-2e5c-4c46-9078-1d23d61a8a30" xlink:href="sny-20231231.xsd#sny_April2022EMTNISINFR0014009KS6Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_April2022EMTNISINFR0014009KS6Member_32900e81-2e5c-4c46-9078-1d23d61a8a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_September2015EMTNISINFR0012969038Member_46b08f51-6da3-45eb-a3e0-3455b59910f0" xlink:href="sny-20231231.xsd#sny_September2015EMTNISINFR0012969038Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_September2015EMTNISINFR0012969038Member_46b08f51-6da3-45eb-a3e0-3455b59910f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2018EMTNISINFR0013324340Member_70ef88bd-834d-4d84-8f36-6e828979ca59" xlink:href="sny-20231231.xsd#sny_March2018EMTNISINFR0013324340Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2018EMTNISINFR0013324340Member_70ef88bd-834d-4d84-8f36-6e828979ca59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_September2014EMTNISINFR0012146801Member_73bbe9b9-b09c-4b33-83a7-53e170003423" xlink:href="sny-20231231.xsd#sny_September2014EMTNISINFR0012146801Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_September2014EMTNISINFR0012146801Member_73bbe9b9-b09c-4b33-83a7-53e170003423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_September2016EMTNISINFR0013201639Member_2fd4a93e-ef14-454c-b1de-c10043905d53" xlink:href="sny-20231231.xsd#sny_September2016EMTNISINFR0013201639Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_September2016EMTNISINFR0013201639Member_2fd4a93e-ef14-454c-b1de-c10043905d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2016EMTNISINFR0013144003Member_23479da7-1b08-4643-a4d1-f8fcfa01202f" xlink:href="sny-20231231.xsd#sny_April2016EMTNISINFR0013144003Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_April2016EMTNISINFR0013144003Member_23479da7-1b08-4643-a4d1-f8fcfa01202f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2019EMTNISINFR0013409844Member_e955e9e3-9d8b-4642-82e6-e63c146b1422" xlink:href="sny-20231231.xsd#sny_March2019EMTNISINFR0013409844Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2019EMTNISINFR0013409844Member_e955e9e3-9d8b-4642-82e6-e63c146b1422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_April2022EMTNISINFR0014009KQ0Member_4a8a9ffb-0a59-49ba-8ba2-160612556df3" xlink:href="sny-20231231.xsd#sny_April2022EMTNISINFR0014009KQ0Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_April2022EMTNISINFR0014009KQ0Member_4a8a9ffb-0a59-49ba-8ba2-160612556df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2018EMTNISINFR0013324357Member_bef93696-a4b6-406b-ac1c-3de9d9abf96c" xlink:href="sny-20231231.xsd#sny_March2018EMTNISINFR0013324357Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2018EMTNISINFR0013324357Member_bef93696-a4b6-406b-ac1c-3de9d9abf96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2020EMTNISINFR0013505112Member_3225ceef-2956-4e6b-bfa7-2b9a9ca0bbb2" xlink:href="sny-20231231.xsd#sny_March2020EMTNISINFR0013505112Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2020EMTNISINFR0013505112Member_3225ceef-2956-4e6b-bfa7-2b9a9ca0bbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2019EMTNISINFR0013409851Member_b9c1a8af-284a-4f37-a83c-3b2fd17e5344" xlink:href="sny-20231231.xsd#sny_March2019EMTNISINFR0013409851Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2019EMTNISINFR0013409851Member_b9c1a8af-284a-4f37-a83c-3b2fd17e5344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_March2018EMTNISINFR0013324373Member_a08afe7d-c56f-4198-810e-5818f9258b46" xlink:href="sny-20231231.xsd#sny_March2018EMTNISINFR0013324373Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_March2018EMTNISINFR0013324373Member_a08afe7d-c56f-4198-810e-5818f9258b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_June2018SNFISINUS801060AC87Member_a48c419f-9198-416e-b9c5-1f98278ba9a6" xlink:href="sny-20231231.xsd#sny_June2018SNFISINUS801060AC87Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_June2018SNFISINUS801060AC87Member_a48c419f-9198-416e-b9c5-1f98278ba9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_June2018SNFISINUS801060AD60Member_86087cbe-a698-4d1d-89f9-49a697631d0f" xlink:href="sny-20231231.xsd#sny_June2018SNFISINUS801060AD60Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_753c04ae-999e-4de5-9f5d-34a875e315f4" xlink:to="loc_sny_June2018SNFISINUS801060AD60Member_86087cbe-a698-4d1d-89f9-49a697631d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f29540b5-2d5f-46be-ab7d-8279a811e70a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_1d4907e9-f2a4-4e55-985f-6af70701eb92" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f29540b5-2d5f-46be-ab7d-8279a811e70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_cd535c81-ba16-40b6-b0ed-96cc863e3bcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f29540b5-2d5f-46be-ab7d-8279a811e70a" xlink:to="loc_ifrs-full_BorrowingsInterestRate_cd535c81-ba16-40b6-b0ed-96cc863e3bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_a271c157-55ad-4ee1-b5b4-3e4faedb27de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_f29540b5-2d5f-46be-ab7d-8279a811e70a" xlink:to="loc_ifrs-full_NotionalAmount_a271c157-55ad-4ee1-b5b4-3e4faedb27de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_84a20162-75c5-41aa-8665-f640368a2a7c" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_84a20162-75c5-41aa-8665-f640368a2a7c" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_b37153a5-5e68-4c13-887e-b5d67217fbfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:to="loc_ifrs-full_MeasurementAxis_b37153a5-5e68-4c13-887e-b5d67217fbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_7c3cba0c-4005-43a3-b7e8-6bec76f8ac32" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_b37153a5-5e68-4c13-887e-b5d67217fbfb" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_7c3cba0c-4005-43a3-b7e8-6bec76f8ac32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_b46d708c-644a-4754-959c-bb2c9d449772" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_7c3cba0c-4005-43a3-b7e8-6bec76f8ac32" xlink:to="loc_sny_ValueOnRedemptionMember_b46d708c-644a-4754-959c-bb2c9d449772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_26f2a489-484d-4c16-a212-b48d2e884870" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:to="loc_ifrs-full_MaturityAxis_26f2a489-484d-4c16-a212-b48d2e884870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_26f2a489-484d-4c16-a212-b48d2e884870" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_02cbc534-f9fc-4437-856f-4d6c5969b19e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_02cbc534-f9fc-4437-856f-4d6c5969b19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_198a0388-a0e3-4208-b72b-fff34ab0da8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_198a0388-a0e3-4208-b72b-fff34ab0da8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_dddee576-cc42-4079-8076-e153b31c9a5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_dddee576-cc42-4079-8076-e153b31c9a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_db1fd94c-ecb5-47b8-9768-a6377ad4cd96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_db1fd94c-ecb5-47b8-9768-a6377ad4cd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_30018ed2-8e85-49f8-9cf5-03b6e90674ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_30018ed2-8e85-49f8-9cf5-03b6e90674ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_066c4d73-0a50-4c27-b857-d3dcb2df4155" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_bfcbd905-27f6-4f48-8786-5a8caa1ed81b" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_066c4d73-0a50-4c27-b857-d3dcb2df4155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrument1Axis_0db4d093-61fa-4b96-b8dd-37f2311892f9" xlink:href="sny-20231231.xsd#sny_DebtInstrument1Axis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:to="loc_sny_DebtInstrument1Axis_0db4d093-61fa-4b96-b8dd-37f2311892f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtInstrumentDomain_92267f69-74f6-4023-8c03-e5733f2e594a" xlink:href="sny-20231231.xsd#sny_DebtInstrumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrument1Axis_0db4d093-61fa-4b96-b8dd-37f2311892f9" xlink:to="loc_sny_DebtInstrumentDomain_92267f69-74f6-4023-8c03-e5733f2e594a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEuroMediumTermNotesMember_d266fc95-e887-4241-a051-06b696be9e9a" xlink:href="sny-20231231.xsd#sny_SanofiEuroMediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DebtInstrumentDomain_92267f69-74f6-4023-8c03-e5733f2e594a" xlink:to="loc_sny_SanofiEuroMediumTermNotesMember_d266fc95-e887-4241-a051-06b696be9e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_2bdd36fa-3220-4938-8f35-764bf1fef579" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_2bdd36fa-3220-4938-8f35-764bf1fef579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_f0e31b63-6f55-4aac-a1d4-9d1bfb784b6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_2bdd36fa-3220-4938-8f35-764bf1fef579" xlink:to="loc_ifrs-full_BorrowingsByNameMember_f0e31b63-6f55-4aac-a1d4-9d1bfb784b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember_5897ef47-07a1-46a1-8fd5-5a67e7d58125" xlink:href="sny-20231231.xsd#sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_f0e31b63-6f55-4aac-a1d4-9d1bfb784b6b" xlink:to="loc_sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember_5897ef47-07a1-46a1-8fd5-5a67e7d58125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0d13b82c-9e66-41c7-b65e-3b7cfdaaa059" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BondsIssued_f15f7d36-fd51-45b9-b41a-33f40453c986" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BondsIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_BondsIssued_f15f7d36-fd51-45b9-b41a-33f40453c986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherBankBorrowings_d4f31992-f945-4c0a-818e-baa61aa5fde8" xlink:href="sny-20231231.xsd#sny_OtherBankBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_sny_OtherBankBorrowings_d4f31992-f945-4c0a-818e-baa61aa5fde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherBorrowings_96ed2687-a69d-4abd-b14b-0b343d058d76" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_OtherBorrowings_96ed2687-a69d-4abd-b14b-0b343d058d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_8dd68bf6-2547-43eb-baf8-4f584efa93d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_8dd68bf6-2547-43eb-baf8-4f584efa93d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_f82b4857-50c7-4a69-bc61-232dea11427f" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt_f82b4857-50c7-4a69-bc61-232dea11427f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_c187f170-d4a9-4c9c-a7d2-555be9d5dafe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_Borrowings_c187f170-d4a9-4c9c-a7d2-555be9d5dafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_10c00f2e-f797-40aa-a0f8-9d9ebb9cd601" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_CashAndCashEquivalents_10c00f2e-f797-40aa-a0f8-9d9ebb9cd601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_2ededf18-35fb-4983-8a02-18cbc0ee992f" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent_2ededf18-35fb-4983-8a02-18cbc0ee992f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_f81fa868-e09d-4b1a-90a8-0ee070a33c19" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_f81fa868-e09d-4b1a-90a8-0ee070a33c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_f2e8d68d-0d7e-4672-a9a2-a8a70cc03592" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_LeaseLiabilities_f2e8d68d-0d7e-4672-a9a2-a8a70cc03592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_3aa1b059-ace3-44fa-86f6-ac56f2aa93fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_fc794b53-c7d8-433c-a8c1-c491d9743cb8" xlink:to="loc_ifrs-full_NotionalAmount_3aa1b059-ace3-44fa-86f6-ac56f2aa93fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_ee4849bb-8515-485d-be14-5a66096630e6" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_ee4849bb-8515-485d-be14-5a66096630e6" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_e36a9254-0a62-4a67-b4c1-0dc3b9e2457b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:to="loc_srt_CurrencyAxis_e36a9254-0a62-4a67-b4c1-0dc3b9e2457b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_ba8fa326-2b29-4c23-96ef-61ceca0e3c53" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_e36a9254-0a62-4a67-b4c1-0dc3b9e2457b" xlink:to="loc_currency_AllCurrenciesDomain_ba8fa326-2b29-4c23-96ef-61ceca0e3c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_f0cf0446-da97-479d-b231-51f52a1d2fd9" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_ba8fa326-2b29-4c23-96ef-61ceca0e3c53" xlink:to="loc_currency_EUR_f0cf0446-da97-479d-b231-51f52a1d2fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_56ab2e47-cb27-4dfc-a33e-f12c8f4b2f26" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_ba8fa326-2b29-4c23-96ef-61ceca0e3c53" xlink:to="loc_currency_USD_56ab2e47-cb27-4dfc-a33e-f12c8f4b2f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_SGD_b2b683dc-ff7f-4d54-a015-bfb345f3c3ff" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_SGD"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_ba8fa326-2b29-4c23-96ef-61ceca0e3c53" xlink:to="loc_currency_SGD_b2b683dc-ff7f-4d54-a015-bfb345f3c3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_4d6b461c-8427-4cc9-9001-1e31ce0adb1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:to="loc_ifrs-full_MaturityAxis_4d6b461c-8427-4cc9-9001-1e31ce0adb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_4d6b461c-8427-4cc9-9001-1e31ce0adb1c" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_e059508b-4c23-4527-886b-8471b7869f05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_e059508b-4c23-4527-886b-8471b7869f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_e059c6ad-b377-424c-bcbf-511555edc286" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_e059c6ad-b377-424c-bcbf-511555edc286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2fad621f-a4a3-4290-b901-8851c6b98eae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_2fad621f-a4a3-4290-b901-8851c6b98eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_6b9dc782-74f5-4098-9d27-ab15e6b6d530" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_6b9dc782-74f5-4098-9d27-ab15e6b6d530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_64a3ea77-6da9-4601-9f56-f8edac26eb60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_64a3ea77-6da9-4601-9f56-f8edac26eb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_d9c0c68c-108a-4c8d-845d-f0410ef13a2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_9595abd0-f2ca-4487-bc74-6041f3d045ee" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_d9c0c68c-108a-4c8d-845d-f0410ef13a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_50f094aa-d253-4eb7-a85c-358bdb25cdc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:to="loc_ifrs-full_MeasurementAxis_50f094aa-d253-4eb7-a85c-358bdb25cdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_01f8c3a0-88ec-436a-93b6-beb79722daf6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_50f094aa-d253-4eb7-a85c-358bdb25cdc9" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_01f8c3a0-88ec-436a-93b6-beb79722daf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember_061b132b-df5a-4833-a5d7-50324b17d9b7" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_01f8c3a0-88ec-436a-93b6-beb79722daf6" xlink:to="loc_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember_061b132b-df5a-4833-a5d7-50324b17d9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_a3902da2-745e-48ce-aeb0-c98ca302bd40" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionAfterDerivativeInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_01f8c3a0-88ec-436a-93b6-beb79722daf6" xlink:to="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_a3902da2-745e-48ce-aeb0-c98ca302bd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_85f8bf13-8e4b-4053-bd4f-385fdca44b5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_85f8bf13-8e4b-4053-bd4f-385fdca44b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_77d3213b-aa24-474b-85de-0870ca7aabb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_85f8bf13-8e4b-4053-bd4f-385fdca44b5d" xlink:to="loc_ifrs-full_InterestRateTypesMember_77d3213b-aa24-474b-85de-0870ca7aabb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_daa6d0f2-248d-46d1-b5bc-b9cea28b4c2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_77d3213b-aa24-474b-85de-0870ca7aabb4" xlink:to="loc_ifrs-full_FixedInterestRateMember_daa6d0f2-248d-46d1-b5bc-b9cea28b4c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember_35cbeb7d-e6bd-401d-8787-f74b5de2d457" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_77d3213b-aa24-474b-85de-0870ca7aabb4" xlink:to="loc_ifrs-full_FloatingInterestRateMember_35cbeb7d-e6bd-401d-8787-f74b5de2d457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_b17a237a-af9c-47b0-be21-da65a238356b" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfBorrowings_aeabfd52-d138-4bb8-9832-aea0a66f9a66" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseOfBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:to="loc_sny_IncreaseDecreaseOfBorrowings_aeabfd52-d138-4bb8-9832-aea0a66f9a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtPercent_93272b45-15d6-4665-8415-79bc02cdccf1" xlink:href="sny-20231231.xsd#sny_DebtPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:to="loc_sny_DebtPercent_93272b45-15d6-4665-8415-79bc02cdccf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_8c5597e1-a713-40a2-8150-8bf3f36b5ff2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:to="loc_ifrs-full_CashAndCashEquivalents_8c5597e1-a713-40a2-8150-8bf3f36b5ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_c24f558c-74b7-4974-95fe-c287e8bc7b83" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_9a453169-38b7-4d84-8a24-82cd4689cf46" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_c24f558c-74b7-4974-95fe-c287e8bc7b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_a1bdc7e1-179c-4544-8088-47d9356863f3" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_6142f25d-295e-465e-afe1-a41cde27380c" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_a1bdc7e1-179c-4544-8088-47d9356863f3" xlink:to="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_6142f25d-295e-465e-afe1-a41cde27380c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_0255add0-4dfe-4c24-9d55-bda7bba96ebf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_6142f25d-295e-465e-afe1-a41cde27380c" xlink:to="loc_ifrs-full_MeasurementAxis_0255add0-4dfe-4c24-9d55-bda7bba96ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_6760bac1-5038-4790-ae6d-96a18547857f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_0255add0-4dfe-4c24-9d55-bda7bba96ebf" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_6760bac1-5038-4790-ae6d-96a18547857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_8a7e9400-71c9-4fd0-a316-6077cba444df" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionAfterDerivativeInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_6760bac1-5038-4790-ae6d-96a18547857f" xlink:to="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_8a7e9400-71c9-4fd0-a316-6077cba444df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_dee69d64-46ef-4c97-a738-fa7716a97199" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_6142f25d-295e-465e-afe1-a41cde27380c" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_dee69d64-46ef-4c97-a738-fa7716a97199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_37bfa880-aa45-4bfb-a16b-151026b2053d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_dee69d64-46ef-4c97-a738-fa7716a97199" xlink:to="loc_ifrs-full_InterestRateTypesMember_37bfa880-aa45-4bfb-a16b-151026b2053d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_7dce270b-cc97-4a51-853c-6e38bcde837c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_37bfa880-aa45-4bfb-a16b-151026b2053d" xlink:to="loc_ifrs-full_FixedInterestRateMember_7dce270b-cc97-4a51-853c-6e38bcde837c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember_3901abbc-4c73-4c0d-b0c1-e66de99f5068" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_37bfa880-aa45-4bfb-a16b-151026b2053d" xlink:to="loc_ifrs-full_FloatingInterestRateMember_3901abbc-4c73-4c0d-b0c1-e66de99f5068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_6142f25d-295e-465e-afe1-a41cde27380c" xlink:to="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_b458d926-b134-4f6e-80ec-469e6964b4be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:to="loc_ifrs-full_Borrowings_b458d926-b134-4f6e-80ec-469e6964b4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_d0d7b4ad-a39f-448e-82e1-b58b30df7e8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:to="loc_ifrs-full_CashAndCashEquivalents_d0d7b4ad-a39f-448e-82e1-b58b30df7e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_7b299735-8757-4c79-bf5c-248a70329843" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_7b299735-8757-4c79-bf5c-248a70329843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtPercent_9b2a26cf-4349-4395-b2b5-ab80e8866a29" xlink:href="sny-20231231.xsd#sny_DebtPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_cd02580c-3787-466c-878f-94f544ebb429" xlink:to="loc_sny_DebtPercent_9b2a26cf-4349-4395-b2b5-ab80e8866a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_ec0084d7-b4ba-4e88-ac62-c0e0f07e9179" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_821bc404-7976-4969-aac9-64c177b90f5f" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_ec0084d7-b4ba-4e88-ac62-c0e0f07e9179" xlink:to="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_821bc404-7976-4969-aac9-64c177b90f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_bf183e94-f91f-4529-ad6e-c61e6e6c79e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_821bc404-7976-4969-aac9-64c177b90f5f" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_bf183e94-f91f-4529-ad6e-c61e6e6c79e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_bf183e94-f91f-4529-ad6e-c61e6e6c79e2" xlink:to="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlusHundredBasisPointsMember_33ad52eb-744c-4dd9-a10b-0f5d29fb2e4d" xlink:href="sny-20231231.xsd#sny_PlusHundredBasisPointsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:to="loc_sny_PlusHundredBasisPointsMember_33ad52eb-744c-4dd9-a10b-0f5d29fb2e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlusTwentyFiveBasisPointsMember_ecd7f625-dde2-4139-b66d-c801b33d8edb" xlink:href="sny-20231231.xsd#sny_PlusTwentyFiveBasisPointsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:to="loc_sny_PlusTwentyFiveBasisPointsMember_ecd7f625-dde2-4139-b66d-c801b33d8edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinusTwentyFiveBasisPointsMember_34815508-1954-4ae0-948f-1510125847b6" xlink:href="sny-20231231.xsd#sny_MinusTwentyFiveBasisPointsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:to="loc_sny_MinusTwentyFiveBasisPointsMember_34815508-1954-4ae0-948f-1510125847b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinusHundredBasisPointsMember_bd934b32-d762-4f1d-ba45-6c2ed00eff6c" xlink:href="sny-20231231.xsd#sny_MinusHundredBasisPointsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_9487dfb6-b99d-4bd2-a4a1-c2ca1771f7d7" xlink:to="loc_sny_MinusHundredBasisPointsMember_bd934b32-d762-4f1d-ba45-6c2ed00eff6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_10f7fe21-f0e4-49fc-84c5-fc31c5346813" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_821bc404-7976-4969-aac9-64c177b90f5f" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_10f7fe21-f0e4-49fc-84c5-fc31c5346813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_60c4a018-019f-4e96-a1d9-1a5e1d5dcc77" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_10f7fe21-f0e4-49fc-84c5-fc31c5346813" xlink:to="loc_ifrs-full_BorrowingsByNameMember_60c4a018-019f-4e96-a1d9-1a5e1d5dcc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember_ef00adce-ca0e-4877-837d-d5cb7bbcd11c" xlink:href="sny-20231231.xsd#sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_60c4a018-019f-4e96-a1d9-1a5e1d5dcc77" xlink:to="loc_sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember_ef00adce-ca0e-4877-837d-d5cb7bbcd11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_ac86df26-b18b-4659-84ac-835f149c97a5" xlink:href="sny-20231231.xsd#sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable_821bc404-7976-4969-aac9-64c177b90f5f" xlink:to="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_ac86df26-b18b-4659-84ac-835f149c97a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfChangeInInterestRateOnPreTaxIncome_43e271bf-4087-4703-bb55-0338a9c8f887" xlink:href="sny-20231231.xsd#sny_ImpactOfChangeInInterestRateOnPreTaxIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_ac86df26-b18b-4659-84ac-835f149c97a5" xlink:to="loc_sny_ImpactOfChangeInInterestRateOnPreTaxIncome_43e271bf-4087-4703-bb55-0338a9c8f887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpactOfPreTaxIncomeRecognisedInEquity_3605ace8-f895-44ad-822d-c9e03f69d726" xlink:href="sny-20231231.xsd#sny_ImpactOfPreTaxIncomeRecognisedInEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems_ac86df26-b18b-4659-84ac-835f149c97a5" xlink:to="loc_sny_ImpactOfPreTaxIncomeRecognisedInEquity_3605ace8-f895-44ad-822d-c9e03f69d726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_6ff8e5c3-9f55-4c56-95f1-1307df6301bd" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByCurrencyTable_48f95cb9-27cd-4822-8065-7db5ba98c44e" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByCurrencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_6ff8e5c3-9f55-4c56-95f1-1307df6301bd" xlink:to="loc_sny_DisclosureOfDebtByCurrencyTable_48f95cb9-27cd-4822-8065-7db5ba98c44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_09e4bacf-4e57-490c-a860-c74eea459bd9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtByCurrencyTable_48f95cb9-27cd-4822-8065-7db5ba98c44e" xlink:to="loc_srt_CurrencyAxis_09e4bacf-4e57-490c-a860-c74eea459bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_09e4bacf-4e57-490c-a860-c74eea459bd9" xlink:to="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_0accc8c1-ebdd-4a16-b49a-703ca856e2a3" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_currency_EUR_0accc8c1-ebdd-4a16-b49a-703ca856e2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_0187c3a9-44c4-4575-981e-bf8c78c6c54f" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_currency_USD_0187c3a9-44c4-4575-981e-bf8c78c6c54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_SGD_6e31a908-e5d8-465e-9574-8d70e39d50ed" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_SGD"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_currency_SGD_6e31a908-e5d8-465e-9574-8d70e39d50ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_ff129047-45c9-43d4-9b21-2408888fa056" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_currency_GBP_ff129047-45c9-43d4-9b21-2408888fa056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CNY_fd3f0506-e98a-46c0-8f4c-fcd753b21c16" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CNY"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_currency_CNY_fd3f0506-e98a-46c0-8f4c-fcd753b21c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCurrenciesMember_c113f21c-d66c-4b6b-8598-a4cb11a23a38" xlink:href="sny-20231231.xsd#sny_OtherCurrenciesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6d324c31-b346-471c-adb7-8149995d9d0e" xlink:to="loc_sny_OtherCurrenciesMember_c113f21c-d66c-4b6b-8598-a4cb11a23a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_93680ce2-6619-422a-adbe-1ef6e889c004" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtByCurrencyTable_48f95cb9-27cd-4822-8065-7db5ba98c44e" xlink:to="loc_ifrs-full_MeasurementAxis_93680ce2-6619-422a-adbe-1ef6e889c004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_cf9ef94f-0c83-4ca2-a728-4945535757a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_93680ce2-6619-422a-adbe-1ef6e889c004" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_cf9ef94f-0c83-4ca2-a728-4945535757a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember_15037e71-9bd7-44d3-b5b6-800821623600" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_cf9ef94f-0c83-4ca2-a728-4945535757a5" xlink:to="loc_sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember_15037e71-9bd7-44d3-b5b6-800821623600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_7f1cd380-7f0b-4df4-949f-02b6dce28690" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionAfterDerivativeInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_cf9ef94f-0c83-4ca2-a728-4945535757a5" xlink:to="loc_sny_ValueOnRedemptionAfterDerivativeInstrumentsMember_7f1cd380-7f0b-4df4-949f-02b6dce28690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDebtByCurrencyLineItems_941b0f6f-b003-4df6-9af8-060169a02e75" xlink:href="sny-20231231.xsd#sny_DisclosureOfDebtByCurrencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtByCurrencyTable_48f95cb9-27cd-4822-8065-7db5ba98c44e" xlink:to="loc_sny_DisclosureOfDebtByCurrencyLineItems_941b0f6f-b003-4df6-9af8-060169a02e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DebtNetOfCashAndCashEquivalents_9532a818-6519-4ce3-8be8-067c8833c834" xlink:href="sny-20231231.xsd#sny_DebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDebtByCurrencyLineItems_941b0f6f-b003-4df6-9af8-060169a02e75" xlink:to="loc_sny_DebtNetOfCashAndCashEquivalents_9532a818-6519-4ce3-8be8-067c8833c834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_01faa4a6-fb08-484c-9b68-47854ac33a7f" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_ce7648f2-b424-4ccf-80f3-53f59a99e1ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_01faa4a6-fb08-484c-9b68-47854ac33a7f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_ce7648f2-b424-4ccf-80f3-53f59a99e1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_527760a2-b7dc-45c2-b9c9-9e45bde4df4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_ce7648f2-b424-4ccf-80f3-53f59a99e1ab" xlink:to="loc_ifrs-full_MeasurementAxis_527760a2-b7dc-45c2-b9c9-9e45bde4df4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_3dc0f04c-1bf6-4e1d-92ea-e933f8b3459b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_527760a2-b7dc-45c2-b9c9-9e45bde4df4f" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_3dc0f04c-1bf6-4e1d-92ea-e933f8b3459b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtMarketValueMember_b7fc6cd6-85aa-4705-bb0d-4f8cd1afd669" xlink:href="sny-20231231.xsd#sny_AtMarketValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_3dc0f04c-1bf6-4e1d-92ea-e933f8b3459b" xlink:to="loc_sny_AtMarketValueMember_b7fc6cd6-85aa-4705-bb0d-4f8cd1afd669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOnRedemptionMember_dcc20016-09d2-4523-abfc-cdd54a6657fc" xlink:href="sny-20231231.xsd#sny_ValueOnRedemptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_3dc0f04c-1bf6-4e1d-92ea-e933f8b3459b" xlink:to="loc_sny_ValueOnRedemptionMember_dcc20016-09d2-4523-abfc-cdd54a6657fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9c493e0d-73e6-40f5-af71-121591784e1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_ce7648f2-b424-4ccf-80f3-53f59a99e1ab" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9c493e0d-73e6-40f5-af71-121591784e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_ce62a135-bfd4-4579-ad3e-a23c5dc8a332" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9c493e0d-73e6-40f5-af71-121591784e1b" xlink:to="loc_ifrs-full_Borrowings_ce62a135-bfd4-4579-ad3e-a23c5dc8a332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RedemptionOfDebtInstrumentIssued_01e05d13-6da6-48b6-b253-255dec9ec72d" xlink:href="sny-20231231.xsd#sny_RedemptionOfDebtInstrumentIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_9c493e0d-73e6-40f5-af71-121591784e1b" xlink:to="loc_sny_RedemptionOfDebtInstrumentIssued_01e05d13-6da6-48b6-b253-255dec9ec72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_07f3dbc5-cb10-4943-bd68-e21364948b60" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_746113ff-a30d-4e1a-8cb0-b403d2a21ff0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_07f3dbc5-cb10-4943-bd68-e21364948b60" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_746113ff-a30d-4e1a-8cb0-b403d2a21ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_e26f509a-62e1-4297-9e02-1e78704cb8b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_746113ff-a30d-4e1a-8cb0-b403d2a21ff0" xlink:to="loc_ifrs-full_MaturityAxis_e26f509a-62e1-4297-9e02-1e78704cb8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_e26f509a-62e1-4297-9e02-1e78704cb8b1" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_77882879-b7b6-41a8-b40a-0687b0a1a462" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_77882879-b7b6-41a8-b40a-0687b0a1a462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_4a30e93a-9a7b-4edc-929d-3283ff818f59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_4a30e93a-9a7b-4edc-929d-3283ff818f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_452c7ed0-afeb-4622-9949-d12e1c8a8aaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_452c7ed0-afeb-4622-9949-d12e1c8a8aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1cbb1aa9-ee02-475a-a801-f5a540c444bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_1cbb1aa9-ee02-475a-a801-f5a540c444bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_fef2b5a8-a8d9-44f6-8d6c-de164c622c7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_fef2b5a8-a8d9-44f6-8d6c-de164c622c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_2c28f70e-6952-49c7-b0b4-54786c4c9a1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_97783515-fdda-4b49-a822-99ae985c8c9f" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_2c28f70e-6952-49c7-b0b4-54786c4c9a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_746113ff-a30d-4e1a-8cb0-b403d2a21ff0" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_9ad30cb1-e046-4e91-9af4-5f8aadf515a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_9ad30cb1-e046-4e91-9af4-5f8aadf515a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalUndiscountedCashFlow_1404b372-a2d8-4558-9269-c6a6da629fc8" xlink:href="sny-20231231.xsd#sny_PrincipalUndiscountedCashFlow"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:to="loc_sny_PrincipalUndiscountedCashFlow_1404b372-a2d8-4558-9269-c6a6da629fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestUndiscountedCashFlow_211b0353-2d87-43fa-b008-687a4dcd9877" xlink:href="sny-20231231.xsd#sny_InterestUndiscountedCashFlow"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:to="loc_sny_InterestUndiscountedCashFlow_211b0353-2d87-43fa-b008-687a4dcd9877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_866ed996-b4a5-48d2-9798-c47a31444c57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_866ed996-b4a5-48d2-9798-c47a31444c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalUndiscountedCashFlow_6bb07c1e-bfac-4fc6-b035-06ce87928ebd" xlink:href="sny-20231231.xsd#sny_TotalUndiscountedCashFlow"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_c105e09c-b918-4c3e-b0a0-65cffe1f994e" xlink:to="loc_sny_TotalUndiscountedCashFlow_6bb07c1e-bfac-4fc6-b035-06ce87928ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_8b95b5ff-f3c7-4c78-8a1c-97eaaeefc534" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable_55bf40ac-b25d-471d-ae58-440386cb7af5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_8b95b5ff-f3c7-4c78-8a1c-97eaaeefc534" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable_55bf40ac-b25d-471d-ae58-440386cb7af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_3f083024-ace6-4f85-bda2-848a6e5b459f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable_55bf40ac-b25d-471d-ae58-440386cb7af5" xlink:to="loc_ifrs-full_MaturityAxis_3f083024-ace6-4f85-bda2-848a6e5b459f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_3f083024-ace6-4f85-bda2-848a6e5b459f" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_4b5e5c89-8eb7-4003-830c-d10664ad22c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_4b5e5c89-8eb7-4003-830c-d10664ad22c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_af15c2d9-a08f-475f-bd8d-db05468f10a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_af15c2d9-a08f-475f-bd8d-db05468f10a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_d4e49998-64ca-4ea3-97da-4cd8fb0ba889" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_d4e49998-64ca-4ea3-97da-4cd8fb0ba889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_11a2b6cc-f166-4939-92a1-1444b8d347b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_680362c0-e540-4656-a657-b3cfa80fde4a" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_11a2b6cc-f166-4939-92a1-1444b8d347b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_526dd989-0f22-4079-af58-dbb9b24ec148" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable_55bf40ac-b25d-471d-ae58-440386cb7af5" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_526dd989-0f22-4079-af58-dbb9b24ec148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_0bcd534a-cc92-4dc2-8c0f-045aa3255d86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_526dd989-0f22-4079-af58-dbb9b24ec148" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_0bcd534a-cc92-4dc2-8c0f-045aa3255d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CambridgeMassachusettsMember_81ad36b8-1a9a-40ec-9103-1c5797094512" xlink:href="sny-20231231.xsd#sny_CambridgeMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_0bcd534a-cc92-4dc2-8c0f-045aa3255d86" xlink:to="loc_sny_CambridgeMassachusettsMember_81ad36b8-1a9a-40ec-9103-1c5797094512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_31387131-997d-4f8a-a5df-1eab206efc59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable_55bf40ac-b25d-471d-ae58-440386cb7af5" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_31387131-997d-4f8a-a5df-1eab206efc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_66b4899d-511d-44a9-bbc7-27ea29f9c709" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_31387131-997d-4f8a-a5df-1eab206efc59" xlink:to="loc_ifrs-full_LeaseLiabilities_66b4899d-511d-44a9-bbc7-27ea29f9c709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseLiabilitiesEffectOfDiscounting_50109ba2-ea4a-45b5-97af-543a5a5d2e9a" xlink:href="sny-20231231.xsd#sny_LeaseLiabilitiesEffectOfDiscounting"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_31387131-997d-4f8a-a5df-1eab206efc59" xlink:to="loc_sny_LeaseLiabilitiesEffectOfDiscounting_50109ba2-ea4a-45b5-97af-543a5a5d2e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InitialLeaseTerm_900dcd2b-083a-4793-a70b-ee3f42a11646" xlink:href="sny-20231231.xsd#sny_InitialLeaseTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems_31387131-997d-4f8a-a5df-1eab206efc59" xlink:to="loc_sny_InitialLeaseTerm_900dcd2b-083a-4793-a70b-ee3f42a11646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_3e204809-0337-4d76-af7b-47deeae828d3" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_17b88e43-a463-4507-ba76-b5ed44f9a9cc" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_3e204809-0337-4d76-af7b-47deeae828d3" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_17b88e43-a463-4507-ba76-b5ed44f9a9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_7fa66585-6f26-4c48-af51-ac8dd0b40c32" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_17b88e43-a463-4507-ba76-b5ed44f9a9cc" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_7fa66585-6f26-4c48-af51-ac8dd0b40c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_7fa66585-6f26-4c48-af51-ac8dd0b40c32" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember_bd0b3783-3f10-4fe0-af38-8f7a9e9bd467" xlink:href="sny-20231231.xsd#sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember_bd0b3783-3f10-4fe0-af38-8f7a9e9bd467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_c9edaf2d-835b-4f13-88d9-a2fd18f00b4f" xlink:href="sny-20231231.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_c9edaf2d-835b-4f13-88d9-a2fd18f00b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember_316dd29b-db99-485c-83c7-27ef1f585e31" xlink:href="sny-20231231.xsd#sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember_316dd29b-db99-485c-83c7-27ef1f585e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixMember_37a821f7-4ffc-4fdd-b3af-d2d124db3a1e" xlink:href="sny-20231231.xsd#sny_AmunixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_AmunixMember_37a821f7-4ffc-4fdd-b3af-d2d124db3a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherLiabilities1Member_30a74be9-dfd6-4e76-9409-05a66526b810" xlink:href="sny-20231231.xsd#sny_OtherLiabilities1Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_OtherLiabilities1Member_30a74be9-dfd6-4e76-9409-05a66526b810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioMember_88debb28-b0c7-4ef1-a1fa-ca5cfd7e94e1" xlink:href="sny-20231231.xsd#sny_TranslateBioMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fc781978-9b28-4e8d-bac7-614a0b4fc023" xlink:to="loc_sny_TranslateBioMember_88debb28-b0c7-4ef1-a1fa-ca5cfd7e94e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_17b88e43-a463-4507-ba76-b5ed44f9a9cc" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_a04cf3cd-95d2-4c54-9c83-3de9f1851933" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_a04cf3cd-95d2-4c54-9c83-3de9f1851933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_6681f40c-213c-4d2d-b4e0-293d3b83b57e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_6681f40c-213c-4d2d-b4e0-293d3b83b57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_33710821-4b87-4847-afda-bac0c7496236" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination_33710821-4b87-4847-afda-bac0c7496236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_040d0c73-d4fa-40d2-a28b-574d0fc4ed20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_040d0c73-d4fa-40d2-a28b-574d0fc4ed20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests_07409d24-ba58-47cf-8868-3eb10d18bfb1" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests_07409d24-ba58-47cf-8868-3eb10d18bfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests_f1b8eef2-11d7-424d-bcec-942cd74a7159" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests_f1b8eef2-11d7-424d-bcec-942cd74a7159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_ca3240d6-db47-4c8d-b407-7711da80e2f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_ca3240d6-db47-4c8d-b407-7711da80e2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_be80114c-3856-48b6-82a4-5a00d5894c79" xlink:href="sny-20231231.xsd#sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_be80114c-3856-48b6-82a4-5a00d5894c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_d9d2d9a1-bf75-4122-80dc-58941aba733b" xlink:href="sny-20231231.xsd#sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests_d9d2d9a1-bf75-4122-80dc-58941aba733b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingentConsiderationLiabilities_3f7c8d1d-0eb5-4bf9-87ab-bdd6bd9ecc21" xlink:href="sny-20231231.xsd#sny_ContingentConsiderationLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_f378f127-3b7c-4ff3-8611-9accd19b4f86" xlink:to="loc_sny_ContingentConsiderationLiabilities_3f7c8d1d-0eb5-4bf9-87ab-bdd6bd9ecc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_ae87e193-832a-4ac0-8c2f-700de507d4dc" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_83d22b0f-b070-497f-ac2a-d312211b49d1" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_ae87e193-832a-4ac0-8c2f-700de507d4dc" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_83d22b0f-b070-497f-ac2a-d312211b49d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_6e764e06-c6f5-4f69-9163-cff3bc505175" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_83d22b0f-b070-497f-ac2a-d312211b49d1" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_6e764e06-c6f5-4f69-9163-cff3bc505175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_6e764e06-c6f5-4f69-9163-cff3bc505175" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_fd1fb0ce-f3e1-4299-96f3-703e27e4af04" xlink:href="sny-20231231.xsd#sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:to="loc_sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember_fd1fb0ce-f3e1-4299-96f3-703e27e4af04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember_97478fe9-36b0-4ab4-9905-fe4f36d4d006" xlink:href="sny-20231231.xsd#sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:to="loc_sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember_97478fe9-36b0-4ab4-9905-fe4f36d4d006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShireHumanGeneticTherapiesIncMember_09288179-aa26-4d1c-8a5c-278b7804d87e" xlink:href="sny-20231231.xsd#sny_ShireHumanGeneticTherapiesIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:to="loc_sny_ShireHumanGeneticTherapiesIncMember_09288179-aa26-4d1c-8a5c-278b7804d87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixMember_cf853866-f497-4a2c-b00b-f14503feac63" xlink:href="sny-20231231.xsd#sny_AmunixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fae3ca7d-4699-4130-bbbf-814f5673f7d9" xlink:to="loc_sny_AmunixMember_cf853866-f497-4a2c-b00b-f14503feac63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_b95d847f-fce3-4e51-be9d-bb1eb3cd39ba" xlink:href="sny-20231231.xsd#sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable_83d22b0f-b070-497f-ac2a-d312211b49d1" xlink:to="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_b95d847f-fce3-4e51-be9d-bb1eb3cd39ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageIncreaseInFairValueLiabilities_b5c1a388-f0ad-42ce-b9fa-799d914ba107" xlink:href="sny-20231231.xsd#sny_PercentageIncreaseInFairValueLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_b95d847f-fce3-4e51-be9d-bb1eb3cd39ba" xlink:to="loc_sny_PercentageIncreaseInFairValueLiabilities_b5c1a388-f0ad-42ce-b9fa-799d914ba107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_6c8b29e0-7ebc-4eb0-bd09-52d8ca6d76c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_b95d847f-fce3-4e51-be9d-bb1eb3cd39ba" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_6c8b29e0-7ebc-4eb0-bd09-52d8ca6d76c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations_1561a4ff-a786-4920-951e-ef6b4c2a9eb0" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems_b95d847f-fce3-4e51-be9d-bb1eb3cd39ba" xlink:to="loc_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations_1561a4ff-a786-4920-951e-ef6b4c2a9eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationAbstract_d51177c3-6608-4978-8aa7-afc5df763d20" xlink:href="sny-20231231.xsd#sny_BusinessCombinationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable_50734351-eb27-4437-a079-02882afd7df4" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_BusinessCombinationAbstract_d51177c3-6608-4978-8aa7-afc5df763d20" xlink:to="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable_50734351-eb27-4437-a079-02882afd7df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_bce07a67-59f8-40e9-a265-e383c9198443" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable_50734351-eb27-4437-a079-02882afd7df4" xlink:to="loc_ifrs-full_MaturityAxis_bce07a67-59f8-40e9-a265-e383c9198443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_bce07a67-59f8-40e9-a265-e383c9198443" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_0aaeff43-09e8-4da4-9caa-483edcbc2a97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_0aaeff43-09e8-4da4-9caa-483edcbc2a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_9f955834-9c4f-4ab1-84ce-84b6fc8c7868" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_9f955834-9c4f-4ab1-84ce-84b6fc8c7868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_ca9e7f90-3e09-41c9-9f23-51bba04ace9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_ca9e7f90-3e09-41c9-9f23-51bba04ace9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_038d9476-5180-49e3-9e6f-fe56bd67418c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c51822dc-ecc8-4e61-8221-d83b909e9d09" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_038d9476-5180-49e3-9e6f-fe56bd67418c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems_e6b18dc2-6782-4009-8baa-e1afe4a71f48" xlink:href="sny-20231231.xsd#sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable_50734351-eb27-4437-a079-02882afd7df4" xlink:to="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems_e6b18dc2-6782-4009-8baa-e1afe4a71f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations_019ab0ae-b304-4505-9f29-b05895ecfc85" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems_e6b18dc2-6782-4009-8baa-e1afe4a71f48" xlink:to="loc_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations_019ab0ae-b304-4505-9f29-b05895ecfc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d3cfc182-8c26-44b6-a8b5-05dc442d06c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_6e06637e-17b7-4e93-996a-0bcfbf76c40d" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d3cfc182-8c26-44b6-a8b5-05dc442d06c7" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_6e06637e-17b7-4e93-996a-0bcfbf76c40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_687f41bf-86c3-4504-afb2-c83c0872f726" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_6e06637e-17b7-4e93-996a-0bcfbf76c40d" xlink:to="loc_sny_PrincipalAlliancesAxis_687f41bf-86c3-4504-afb2-c83c0872f726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_e2d4c7f9-65f2-40c2-b4ff-22c9d59de0b4" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_687f41bf-86c3-4504-afb2-c83c0872f726" xlink:to="loc_sny_PrincipalAlliancesDomain_e2d4c7f9-65f2-40c2-b4ff-22c9d59de0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_2c8e52e0-9b64-47df-a211-76b0ffc48e44" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_e2d4c7f9-65f2-40c2-b4ff-22c9d59de0b4" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_2c8e52e0-9b64-47df-a211-76b0ffc48e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_c814c1f4-3f80-4d52-9644-d857f9548152" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_6e06637e-17b7-4e93-996a-0bcfbf76c40d" xlink:to="loc_ifrs-full_CounterpartiesAxis_c814c1f4-3f80-4d52-9644-d857f9548152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_13fec41d-10a0-4935-a69c-8dbcaead0021" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_c814c1f4-3f80-4d52-9644-d857f9548152" xlink:to="loc_ifrs-full_CounterpartiesMember_13fec41d-10a0-4935-a69c-8dbcaead0021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SwedishOrphanBiovitrumABMember_f67c8507-4edf-4654-905b-5feccbc7b862" xlink:href="sny-20231231.xsd#sny_SwedishOrphanBiovitrumABMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_13fec41d-10a0-4935-a69c-8dbcaead0021" xlink:to="loc_sny_SwedishOrphanBiovitrumABMember_f67c8507-4edf-4654-905b-5feccbc7b862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_fdb03f76-343a-4688-aaea-fe0cdab901d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_6e06637e-17b7-4e93-996a-0bcfbf76c40d" xlink:to="loc_ifrs-full_MaturityAxis_fdb03f76-343a-4688-aaea-fe0cdab901d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ebbced3d-48b1-4d5f-9e86-1a938aa3b54b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_fdb03f76-343a-4688-aaea-fe0cdab901d4" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ebbced3d-48b1-4d5f-9e86-1a938aa3b54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_a964a21d-e1e6-4ca5-a954-2b30edbf04ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ebbced3d-48b1-4d5f-9e86-1a938aa3b54b" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_a964a21d-e1e6-4ca5-a954-2b30edbf04ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_215d61b1-a7f8-4a91-b657-d231e9034ee2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ebbced3d-48b1-4d5f-9e86-1a938aa3b54b" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_215d61b1-a7f8-4a91-b657-d231e9034ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_6e06637e-17b7-4e93-996a-0bcfbf76c40d" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_ac1ed249-6b27-4fa9-9e71-69bc8cdb991e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:to="loc_ifrs-full_NoncurrentProvisions_ac1ed249-6b27-4fa9-9e71-69bc8cdb991e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_1456afc6-0d99-47ef-b242-9ff26862831a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_1456afc6-0d99-47ef-b242-9ff26862831a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_31fb20d8-4197-4ade-a124-2bda9d060c47" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_31fb20d8-4197-4ade-a124-2bda9d060c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_d7463160-b0b0-431c-8f71-ffe169f96950" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_f00ff666-3605-4dca-812e-6210024d7bcd" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_d7463160-b0b0-431c-8f71-ffe169f96950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_1861f38e-92f7-4dfe-bcae-59d707d19ca3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsTable_34cbc0c4-5509-4ace-a56a-c33d468825dc" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_1861f38e-92f7-4dfe-bcae-59d707d19ca3" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsTable_34cbc0c4-5509-4ace-a56a-c33d468825dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_79afe6a4-9c55-4903-8ec2-9834a12f8566" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_34cbc0c4-5509-4ace-a56a-c33d468825dc" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_79afe6a4-9c55-4903-8ec2-9834a12f8566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_79afe6a4-9c55-4903-8ec2-9834a12f8566" xlink:to="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember_0cdaa7e9-2fed-4c28-ba38-311fcef2d37e" xlink:href="sny-20231231.xsd#sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:to="loc_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember_0cdaa7e9-2fed-4c28-ba38-311fcef2d37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForOtherLongTermBenefitsMember_103f5c68-01c7-4136-bd9d-e8148dc321fb" xlink:href="sny-20231231.xsd#sny_ProvisionsForOtherLongTermBenefitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:to="loc_sny_ProvisionsForOtherLongTermBenefitsMember_103f5c68-01c7-4136-bd9d-e8148dc321fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentRestructuringProvisionMember_936d0f11-9199-4962-ad95-66a1c3fab217" xlink:href="sny-20231231.xsd#sny_NonCurrentRestructuringProvisionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:to="loc_sny_NonCurrentRestructuringProvisionMember_936d0f11-9199-4962-ad95-66a1c3fab217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherProvisionsMember_341d60c5-e225-4ca2-ae0a-95ff9c50f210" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherProvisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_46bd43cc-7f72-4af1-aa46-0133849a39a0" xlink:to="loc_ifrs-full_MiscellaneousOtherProvisionsMember_341d60c5-e225-4ca2-ae0a-95ff9c50f210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_55faa2b8-9383-4595-91dd-a124b3a817fe" xlink:href="sny-20231231.xsd#sny_DisclosureOfNonCurrentProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsTable_34cbc0c4-5509-4ace-a56a-c33d468825dc" xlink:to="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_55faa2b8-9383-4595-91dd-a124b3a817fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNonCurrentProvisionsLineItems_55faa2b8-9383-4595-91dd-a124b3a817fe" xlink:to="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_2f7e804c-cf66-4297-8f70-a9ca4a2003a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_ifrs-full_NoncurrentProvisions_2f7e804c-cf66-4297-8f70-a9ca4a2003a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_c0fd20b0-4e86-41db-ba74-f998098fd31e" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions_c0fd20b0-4e86-41db-ba74-f998098fd31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInOtherProvisions_846c4ab1-a68f-4232-b827-6885e8bb51ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInOtherProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_ifrs-full_ChangesInOtherProvisions_846c4ab1-a68f-4232-b827-6885e8bb51ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_c40dcca6-bbf7-41f7-93bb-a30bfa5affaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_c40dcca6-bbf7-41f7-93bb-a30bfa5affaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_c776faa5-98ff-4168-91d7-e6f9e785ef2d" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions_c776faa5-98ff-4168-91d7-e6f9e785ef2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_09cd4461-7d09-45e7-866b-adc4721b1c92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_09cd4461-7d09-45e7-866b-adc4721b1c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount_b4a62014-2893-4e0a-b38c-01559fc0b2b7" xlink:href="sny-20231231.xsd#sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount_b4a62014-2893-4e0a-b38c-01559fc0b2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_1815135a-b305-4dd8-837e-8ac7e7393fd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_1815135a-b305-4dd8-837e-8ac7e7393fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans_d3b21ac5-4722-4650-a8ef-034b27152f9f" xlink:href="sny-20231231.xsd#sny_ActuarialGainsAndLossesOnDefinedBenefitPlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans_d3b21ac5-4722-4650-a8ef-034b27152f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_e05277f4-9450-45ea-9179-06d847d1fc19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract_b77acf84-b9eb-4717-ad85-0faa8b30a4ad" xlink:to="loc_ifrs-full_NoncurrentProvisions_e05277f4-9450-45ea-9179-06d847d1fc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_c891edf4-5678-48df-989e-5e121a533f24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_c891edf4-5678-48df-989e-5e121a533f24" xlink:to="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_d64f8516-3e43-4bcc-bb47-afcc2836ef7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_d64f8516-3e43-4bcc-bb47-afcc2836ef7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_d64f8516-3e43-4bcc-bb47-afcc2836ef7c" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LumpSumRetirementBenefitPlansMember_4bf8a67d-55ee-45cb-8d27-26b662b4f8a5" xlink:href="sny-20231231.xsd#sny_LumpSumRetirementBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_sny_LumpSumRetirementBenefitPlansMember_4bf8a67d-55ee-45cb-8d27-26b662b4f8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefinedBenefitPensionPlansMember_0516e6bd-a3ba-4e37-a93f-2b8344b6cb73" xlink:href="sny-20231231.xsd#sny_DefinedBenefitPensionPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_sny_DefinedBenefitPensionPlansMember_0516e6bd-a3ba-4e37-a93f-2b8344b6cb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TopUpDefinedBenefitPensionPlanMember_01707777-f279-4fae-b2dc-e7495c40754a" xlink:href="sny-20231231.xsd#sny_TopUpDefinedBenefitPensionPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_sny_TopUpDefinedBenefitPensionPlanMember_01707777-f279-4fae-b2dc-e7495c40754a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiaventisPlusPensionPlanMember_eb668ad2-cf58-4451-b94c-d4e60dfe7a8d" xlink:href="sny-20231231.xsd#sny_SanofiaventisPlusPensionPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_sny_SanofiaventisPlusPensionPlanMember_eb668ad2-cf58-4451-b94c-d4e60dfe7a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MultiemployerDefinedBenefitPlansMember_f46582f1-0852-4884-9039-97cf2e9c801f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MultiemployerDefinedBenefitPlansMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_ifrs-full_MultiemployerDefinedBenefitPlansMember_f46582f1-0852-4884-9039-97cf2e9c801f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HealthcareCoverAndLifeInsuranceMember_2693b21a-0e3d-4566-80f1-74ac28884550" xlink:href="sny-20231231.xsd#sny_HealthcareCoverAndLifeInsuranceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_c4d61aae-ff8d-4a58-8284-a46c874a69a5" xlink:to="loc_sny_HealthcareCoverAndLifeInsuranceMember_2693b21a-0e3d-4566-80f1-74ac28884550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_688c132d-161a-4901-976d-5d5f96fa7906" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_GeographicalAreasAxis_688c132d-161a-4901-976d-5d5f96fa7906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_688c132d-161a-4901-976d-5d5f96fa7906" xlink:to="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_5122bc24-95ca-4bf8-aa87-dc5717273e9b" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:to="loc_country_FR_5122bc24-95ca-4bf8-aa87-dc5717273e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_6bcce49e-4f2b-428c-9af7-58c4ee2703e5" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:to="loc_country_DE_6bcce49e-4f2b-428c-9af7-58c4ee2703e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7ce71bd4-1a00-4d2f-bc63-e4c909ddc530" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:to="loc_country_US_7ce71bd4-1a00-4d2f-bc63-e4c909ddc530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_2d077a58-9832-48c8-bba9-2e02ff194df5" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_32698707-c223-4a34-8dc8-3b3d1207a739" xlink:to="loc_country_GB_2d077a58-9832-48c8-bba9-2e02ff194df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_fff40302-6197-4677-8c3b-93c9ea87ad41" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_RangeAxis_fff40302-6197-4677-8c3b-93c9ea87ad41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_56cdf88f-97a9-4edc-bb25-4249ed2c5b72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_fff40302-6197-4677-8c3b-93c9ea87ad41" xlink:to="loc_ifrs-full_RangesMember_56cdf88f-97a9-4edc-bb25-4249ed2c5b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_51b19af3-a4ae-4e87-916c-5c4739807ba7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_56cdf88f-97a9-4edc-bb25-4249ed2c5b72" xlink:to="loc_ifrs-full_BottomOfRangeMember_51b19af3-a4ae-4e87-916c-5c4739807ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_4f0bf0d3-80ba-402b-aa62-5b97897a97c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_56cdf88f-97a9-4edc-bb25-4249ed2c5b72" xlink:to="loc_ifrs-full_TopOfRangeMember_4f0bf0d3-80ba-402b-aa62-5b97897a97c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_21d45091-c6b4-4e36-b7a7-febe8e00ad48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_21d45091-c6b4-4e36-b7a7-febe8e00ad48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_21d45091-c6b4-4e36-b7a7-febe8e00ad48" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QualifiedDefinedBenefitPensionPlansMember_c0787548-0b71-4234-8b4a-8d8e299cefd1" xlink:href="sny-20231231.xsd#sny_QualifiedDefinedBenefitPensionPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:to="loc_sny_QualifiedDefinedBenefitPensionPlansMember_c0787548-0b71-4234-8b4a-8d8e299cefd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonQualifiedDefinedBenefitPensionPlansMember_7ef170a7-860d-4f69-b4b5-015fea937448" xlink:href="sny-20231231.xsd#sny_NonQualifiedDefinedBenefitPensionPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:to="loc_sny_NonQualifiedDefinedBenefitPensionPlansMember_7ef170a7-860d-4f69-b4b5-015fea937448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_36c92980-2e36-4c62-a20a-2a088b0dcca7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:to="loc_ifrs-full_PlanAssetsMember_36c92980-2e36-4c62-a20a-2a088b0dcca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UncertaintiesOverIncomeTaxTreatmentsMember_05654d7f-8b47-42e8-a614-2fc63766c275" xlink:href="sny-20231231.xsd#sny_UncertaintiesOverIncomeTaxTreatmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_912b8f4d-22bf-459a-b052-d100cc90301f" xlink:to="loc_sny_UncertaintiesOverIncomeTaxTreatmentsMember_05654d7f-8b47-42e8-a614-2fc63766c275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_176d8ec2-6e02-417b-a428-29fbdb0c94ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_176d8ec2-6e02-417b-a428-29fbdb0c94ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_31dc99bc-64e5-4453-845a-f5af4834d92b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_176d8ec2-6e02-417b-a428-29fbdb0c94ec" xlink:to="loc_ifrs-full_OtherProvisionsMember_31dc99bc-64e5-4453-845a-f5af4834d92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NewBusinessModelRolloutInVariousGeographiesMember_759bd1de-cf49-4ba2-86d6-db14a446abdd" xlink:href="sny-20231231.xsd#sny_NewBusinessModelRolloutInVariousGeographiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_31dc99bc-64e5-4453-845a-f5af4834d92b" xlink:to="loc_sny_NewBusinessModelRolloutInVariousGeographiesMember_759bd1de-cf49-4ba2-86d6-db14a446abdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEnvironmentRelatedProvisionMember_e68d82ea-9a1b-4655-a902-e8817b44b334" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEnvironmentRelatedProvisionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_31dc99bc-64e5-4453-845a-f5af4834d92b" xlink:to="loc_ifrs-full_OtherEnvironmentRelatedProvisionMember_e68d82ea-9a1b-4655-a902-e8817b44b334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_8b1d91c1-37b7-4404-9700-5b8f162b990a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_8b1d91c1-37b7-4404-9700-5b8f162b990a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_5eef6f53-dc2c-4c0b-ac04-f618a9e342ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_8b1d91c1-37b7-4404-9700-5b8f162b990a" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_5eef6f53-dc2c-4c0b-ac04-f618a9e342ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EvotecMember_da0ec3e1-5e87-4360-9fe6-1cda0e5e8281" xlink:href="sny-20231231.xsd#sny_EvotecMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_5eef6f53-dc2c-4c0b-ac04-f618a9e342ca" xlink:to="loc_sny_EvotecMember_da0ec3e1-5e87-4360-9fe6-1cda0e5e8281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_5a22572a-98c0-4e93-861d-a781ab632171" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_MaturityAxis_5a22572a-98c0-4e93-861d-a781ab632171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_d42b3962-7ee0-446e-9c23-ceb51882f3ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_5a22572a-98c0-4e93-861d-a781ab632171" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_d42b3962-7ee0-446e-9c23-ceb51882f3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_17c2ab30-638b-4607-8e7f-6023b914a49a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d42b3962-7ee0-446e-9c23-ceb51882f3ee" xlink:to="loc_ifrs-full_LaterThanOneYearMember_17c2ab30-638b-4607-8e7f-6023b914a49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_6409055b-662c-40f9-a3c6-0d12bde1483a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_6409055b-662c-40f9-a3c6-0d12bde1483a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_c5167015-ea7c-4451-b65f-5f3a758415fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_6409055b-662c-40f9-a3c6-0d12bde1483a" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_c5167015-ea7c-4451-b65f-5f3a758415fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_USLegalRestructuringMember_28ec9c6e-898f-4af1-8856-2dc893e5aaf7" xlink:href="sny-20231231.xsd#sny_USLegalRestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_c5167015-ea7c-4451-b65f-5f3a758415fd" xlink:to="loc_sny_USLegalRestructuringMember_28ec9c6e-898f-4af1-8856-2dc893e5aaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_46828255-b377-49b4-8379-69317fcaf142" xlink:to="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCountriesIncludedInPensionPlans_e230d453-ef4c-4090-a3fd-ea6131b24990" xlink:href="sny-20231231.xsd#sny_NumberOfCountriesIncludedInPensionPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_NumberOfCountriesIncludedInPensionPlans_e230d453-ef4c-4090-a3fd-ea6131b24990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionObligationPercentageToDefinedBenefitLiability_0f3e51a4-8041-4806-abe7-cc2102b0eef9" xlink:href="sny-20231231.xsd#sny_PensionObligationPercentageToDefinedBenefitLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_PensionObligationPercentageToDefinedBenefitLiability_0f3e51a4-8041-4806-abe7-cc2102b0eef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionObligationPercentageToPlanAssets_d5042d9b-c5da-469d-872a-f07489f869a1" xlink:href="sny-20231231.xsd#sny_PensionObligationPercentageToPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_PensionObligationPercentageToPlanAssets_d5042d9b-c5da-469d-872a-f07489f869a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling_2413016d-4534-46cc-bca8-6f4dd47d7436" xlink:href="sny-20231231.xsd#sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling_2413016d-4534-46cc-bca8-6f4dd47d7436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_657f0451-1bae-4284-a16a-56dd22f46106" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_657f0451-1bae-4284-a16a-56dd22f46106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDefinedBenefitPlans_6ac7d8fd-6829-4e27-ad7f-f04472d8d429" xlink:href="sny-20231231.xsd#sny_NumberOfDefinedBenefitPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_NumberOfDefinedBenefitPlans_6ac7d8fd-6829-4e27-ad7f-f04472d8d429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_4f098c4e-f608-494d-99cb-e22d26cec4ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_4f098c4e-f608-494d-99cb-e22d26cec4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefinedBenefitPlansVestingRightsPercentage_384929dc-561a-4b64-be43-52b0a8d1a5f2" xlink:href="sny-20231231.xsd#sny_DefinedBenefitPlansVestingRightsPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_DefinedBenefitPlansVestingRightsPercentage_384929dc-561a-4b64-be43-52b0a8d1a5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RetirementAge_5326649b-1a0c-45de-be17-8a8527d92bc2" xlink:href="sny-20231231.xsd#sny_RetirementAge"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_RetirementAge_5326649b-1a0c-45de-be17-8a8527d92bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotionalRetirementAge_b4857dbd-7faa-45a2-81c6-a2ea948920c4" xlink:href="sny-20231231.xsd#sny_NotionalRetirementAge"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_NotionalRetirementAge_b4857dbd-7faa-45a2-81c6-a2ea948920c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans_d152a109-26e4-47a3-ae9a-53a79779fce1" xlink:href="sny-20231231.xsd#sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans_d152a109-26e4-47a3-ae9a-53a79779fce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod_05440518-e5b9-48b7-84e0-7a95802e3c0f" xlink:href="sny-20231231.xsd#sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod_05440518-e5b9-48b7-84e0-7a95802e3c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths_5bec066d-78ce-42a9-83fa-6360b1e3bec4" xlink:href="sny-20231231.xsd#sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths_5bec066d-78ce-42a9-83fa-6360b1e3bec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive_e56a1efa-9795-4ccc-9a03-d471056a3e3a" xlink:href="sny-20231231.xsd#sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive_e56a1efa-9795-4ccc-9a03-d471056a3e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InventoryTotalQuotasHeld_470521f1-bdc1-4c5d-b529-cc4ae5c55c2f" xlink:href="sny-20231231.xsd#sny_InventoryTotalQuotasHeld"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_InventoryTotalQuotasHeld_470521f1-bdc1-4c5d-b529-cc4ae5c55c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_89bff345-fe5a-4275-a370-e41b3fabb86f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_89bff345-fe5a-4275-a370-e41b3fabb86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_661d91eb-5267-45b0-b552-021e6379222a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_661d91eb-5267-45b0-b552-021e6379222a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognizedRepresentingEstimatedCost_a4d1de4f-d4f5-4c47-8355-5b6ea4b2dc10" xlink:href="sny-20231231.xsd#sny_LiabilityRecognizedRepresentingEstimatedCost"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_LiabilityRecognizedRepresentingEstimatedCost_a4d1de4f-d4f5-4c47-8355-5b6ea4b2dc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod_8efeb2f9-518f-4d18-8a05-95d6ec53c2ec" xlink:href="sny-20231231.xsd#sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod_8efeb2f9-518f-4d18-8a05-95d6ec53c2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised_c7f69d58-bb1b-41d5-93fb-0daa0b040524" xlink:href="sny-20231231.xsd#sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised_c7f69d58-bb1b-41d5-93fb-0daa0b040524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CapitalLossesCarryBackPeriod_4d481628-dfd9-47f9-b6d7-5fc4aa1cc0f5" xlink:href="sny-20231231.xsd#sny_CapitalLossesCarryBackPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_CapitalLossesCarryBackPeriod_4d481628-dfd9-47f9-b6d7-5fc4aa1cc0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CapitalLossesUsedAgainstCapitalGainsPercentage_fb99f819-da19-4b1a-8979-484ea67a41e1" xlink:href="sny-20231231.xsd#sny_CapitalLossesUsedAgainstCapitalGainsPercentage"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_a5a1c1cd-ffe8-4e26-b39c-af82b22aacab" xlink:to="loc_sny_CapitalLossesUsedAgainstCapitalGainsPercentage_fb99f819-da19-4b1a-8979-484ea67a41e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dea098b6-54e4-47e9-a40d-cbb433e5cac4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f7085afe-e8ea-4f04-aff6-84cfaa4210b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dea098b6-54e4-47e9-a40d-cbb433e5cac4" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f7085afe-e8ea-4f04-aff6-84cfaa4210b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_621f57be-6301-4238-b66b-1a74a1fe358d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f7085afe-e8ea-4f04-aff6-84cfaa4210b4" xlink:to="loc_ifrs-full_GeographicalAreasAxis_621f57be-6301-4238-b66b-1a74a1fe358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_621f57be-6301-4238-b66b-1a74a1fe358d" xlink:to="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_e0d8fd76-bdd2-4897-ba4c-a86070da676e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:to="loc_country_FR_e0d8fd76-bdd2-4897-ba4c-a86070da676e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_9445173e-99f0-45a4-83fe-047cd2699e49" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:to="loc_country_DE_9445173e-99f0-45a4-83fe-047cd2699e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b8d2851a-98e7-41c9-bdc4-7106cde4d4a8" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:to="loc_country_US_b8d2851a-98e7-41c9-bdc4-7106cde4d4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_0bd8d214-c628-40a8-a8d4-9c0a58e34311" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_71118bfd-e514-47d9-b98c-41090f85b7a7" xlink:to="loc_country_GB_0bd8d214-c628-40a8-a8d4-9c0a58e34311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_b2d024d3-8a9b-4a7e-a255-dd26920e966f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f7085afe-e8ea-4f04-aff6-84cfaa4210b4" xlink:to="loc_ifrs-full_RangeAxis_b2d024d3-8a9b-4a7e-a255-dd26920e966f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_b2d024d3-8a9b-4a7e-a255-dd26920e966f" xlink:to="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_be38d468-5d68-488a-a3ad-1057463e2d55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_ifrs-full_BottomOfRangeMember_be38d468-5d68-488a-a3ad-1057463e2d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_61294a04-d280-4dcf-a0c6-12dbb1978b76" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_ifrs-full_TopOfRangeMember_61294a04-d280-4dcf-a0c6-12dbb1978b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinimumPlan1Member_73cd3d92-b6f6-438a-8cd8-aa695224d2cf" xlink:href="sny-20231231.xsd#sny_MinimumPlan1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_sny_MinimumPlan1Member_73cd3d92-b6f6-438a-8cd8-aa695224d2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumPlan1Member_39a9dc8b-fa4d-477a-b009-6668dfb87f5c" xlink:href="sny-20231231.xsd#sny_MaximumPlan1Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_sny_MaximumPlan1Member_39a9dc8b-fa4d-477a-b009-6668dfb87f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MinimumPlan2Member_952fd100-31e1-4184-a5b4-e65b55a80db2" xlink:href="sny-20231231.xsd#sny_MinimumPlan2Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_sny_MinimumPlan2Member_952fd100-31e1-4184-a5b4-e65b55a80db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumPlan2Member_5a9d613f-bd95-4828-b39f-03018a992017" xlink:href="sny-20231231.xsd#sny_MaximumPlan2Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_c8320a37-2f60-4357-8f1f-29b2d9597671" xlink:to="loc_sny_MaximumPlan2Member_5a9d613f-bd95-4828-b39f-03018a992017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f7085afe-e8ea-4f04-aff6-84cfaa4210b4" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_3e56b96f-dd4d-4f76-bd23-d416dd23cf30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_3e56b96f-dd4d-4f76-bd23-d416dd23cf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_f97e2efa-d7a9-4f7e-91aa-197c8bf927a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation_f97e2efa-d7a9-4f7e-91aa-197c8bf927a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_4c71d33d-1a69-44f4-8d86-1ea7dd9cd566" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_4c71d33d-1a69-44f4-8d86-1ea7dd9cd566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates_e4e2af12-49ac-4160-9e6e-f50d51e42386" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates_e4e2af12-49ac-4160-9e6e-f50d51e42386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_cd6673f8-ac60-4717-9da0-99e965761b08" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_cd6673f8-ac60-4717-9da0-99e965761b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_5c03fbad-e4b8-487d-a845-936cbfa0aa35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_45f74a22-75c9-4e3a-a9a6-6fd4a57d7586" xlink:to="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_5c03fbad-e4b8-487d-a845-936cbfa0aa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_438cfbff-b9ba-440b-a649-d3c1fe512135" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7b1ebae3-8aca-473b-9322-6b1be914ec57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_438cfbff-b9ba-440b-a649-d3c1fe512135" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7b1ebae3-8aca-473b-9322-6b1be914ec57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_157b8218-3727-46e4-998d-6ab864410546" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7b1ebae3-8aca-473b-9322-6b1be914ec57" xlink:to="loc_ifrs-full_GeographicalAreasAxis_157b8218-3727-46e4-998d-6ab864410546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_157b8218-3727-46e4-998d-6ab864410546" xlink:to="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_b2c8c07b-d95b-484d-ac09-9d2137ea7be6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:to="loc_country_FR_b2c8c07b-d95b-484d-ac09-9d2137ea7be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_38df537e-2830-4472-80a9-4b8ad7cb831e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:to="loc_country_DE_38df537e-2830-4472-80a9-4b8ad7cb831e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_da97e99f-95ca-4c71-8ae9-d48b514502d3" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:to="loc_country_US_da97e99f-95ca-4c71-8ae9-d48b514502d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_59fe8ce5-f1b1-4db5-b4ac-40f415c6ebee" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_0083ca76-0399-4275-92d4-bcd843f8f7de" xlink:to="loc_country_GB_59fe8ce5-f1b1-4db5-b4ac-40f415c6ebee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_7479fce0-d6c2-48b4-8427-9589e3196f59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7b1ebae3-8aca-473b-9322-6b1be914ec57" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_7479fce0-d6c2-48b4-8427-9589e3196f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_c3e93656-f02d-458b-bd86-e026c58e19e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_7479fce0-d6c2-48b4-8427-9589e3196f59" xlink:to="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_c3e93656-f02d-458b-bd86-e026c58e19e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_bd576758-9bd8-4ba4-9400-601b35d287d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1ec06ed0-eca2-4274-b2ba-c53bd1846eee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_bd576758-9bd8-4ba4-9400-601b35d287d5" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1ec06ed0-eca2-4274-b2ba-c53bd1846eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_aca9fea1-080b-46a0-ad02-cd7c90eca1bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1ec06ed0-eca2-4274-b2ba-c53bd1846eee" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_aca9fea1-080b-46a0-ad02-cd7c90eca1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_aca9fea1-080b-46a0-ad02-cd7c90eca1bc" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_60de853a-71bd-440c-a6f5-a111bd86b5ca" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:to="loc_country_FR_60de853a-71bd-440c-a6f5-a111bd86b5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_771667c7-aee2-4a52-985e-41e58d05920c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:to="loc_country_DE_771667c7-aee2-4a52-985e-41e58d05920c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_5a2b402a-fab8-4a99-a92c-7325047a9a8d" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:to="loc_country_US_5a2b402a-fab8-4a99-a92c-7325047a9a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_5f1b08aa-084d-44c1-a793-a8317acc23c5" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_e92d5005-6ee0-4b80-ac8d-247ed490bf61" xlink:to="loc_country_GB_5f1b08aa-084d-44c1-a793-a8317acc23c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_3a5ddea5-7224-4030-9f05-892eec001c20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1ec06ed0-eca2-4274-b2ba-c53bd1846eee" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_3a5ddea5-7224-4030-9f05-892eec001c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_3a5ddea5-7224-4030-9f05-892eec001c20" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_f8751d1f-d852-4eac-b556-7b047bd8e68a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_f8751d1f-d852-4eac-b556-7b047bd8e68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_e248aee7-8ff0-4166-ae8b-0d9a5cd263a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember_e248aee7-8ff0-4166-ae8b-0d9a5cd263a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_14e2045f-e429-499c-9241-a5b07bfb4e1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_14e2045f-e429-499c-9241-a5b07bfb4e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember_b714a08b-81db-4154-bb63-81a2abe23bca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:to="loc_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember_b714a08b-81db-4154-bb63-81a2abe23bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActuarialAssumptionOfMortalityTableMember_a90850b7-21e5-45b8-8753-86920d47e2cd" xlink:href="sny-20231231.xsd#sny_ActuarialAssumptionOfMortalityTableMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_8ea747b2-d3a0-408b-b158-80700c9cde89" xlink:to="loc_sny_ActuarialAssumptionOfMortalityTableMember_a90850b7-21e5-45b8-8753-86920d47e2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_1ec06ed0-eca2-4274-b2ba-c53bd1846eee" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_cc4ad276-89e7-4191-8cbb-4e2985e7a108" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption_cc4ad276-89e7-4191-8cbb-4e2985e7a108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_940b36b6-b69c-41e1-85db-e9fd34c216b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:to="loc_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption_940b36b6-b69c-41e1-85db-e9fd34c216b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_9ff55d9e-85c1-410d-9c27-d5e8e6a926e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:to="loc_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_9ff55d9e-85c1-410d-9c27-d5e8e6a926e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PossibleIncreaseInMortalityTableInYears_91cc31e7-234f-4be2-9430-9f041800c827" xlink:href="sny-20231231.xsd#sny_PossibleIncreaseInMortalityTableInYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_23a2a6a8-09a5-4234-ba15-5e64b3d74147" xlink:to="loc_sny_PossibleIncreaseInMortalityTableInYears_91cc31e7-234f-4be2-9430-9f041800c827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_7a49210f-8d9e-453d-8e94-1912394e4d96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_7a49210f-8d9e-453d-8e94-1912394e4d96" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_ab142e2e-c06d-4678-8a1a-0412da178461" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_ab142e2e-c06d-4678-8a1a-0412da178461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_bec9cdc2-91c4-4af7-af6c-8769b047510d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_ab142e2e-c06d-4678-8a1a-0412da178461" xlink:to="loc_ifrs-full_OtherProvisionsMember_bec9cdc2-91c4-4af7-af6c-8769b047510d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember_7bf95bb0-7d83-4117-9789-196dcc4c8e2f" xlink:href="sny-20231231.xsd#sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_bec9cdc2-91c4-4af7-af6c-8769b047510d" xlink:to="loc_sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember_7bf95bb0-7d83-4117-9789-196dcc4c8e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_647abf2b-a0b2-4642-951e-054c07931830" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_647abf2b-a0b2-4642-951e-054c07931830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_06c70d65-0e87-4c56-bbb0-cd31d656c582" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_647abf2b-a0b2-4642-951e-054c07931830" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_06c70d65-0e87-4c56-bbb0-cd31d656c582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_1fb16b85-4c6d-41b0-8ad4-f75c2d10591f" xlink:href="sny-20231231.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_06c70d65-0e87-4c56-bbb0-cd31d656c582" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_1fb16b85-4c6d-41b0-8ad4-f75c2d10591f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6a1746ac-459b-4576-8e47-b2fb77a4ec98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6a1746ac-459b-4576-8e47-b2fb77a4ec98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fb554368-fd93-411e-9a4a-d314b5a14982" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_6a1746ac-459b-4576-8e47-b2fb77a4ec98" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fb554368-fd93-411e-9a4a-d314b5a14982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_3f5d41e7-7953-4a14-bf73-2e3839485fa5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fb554368-fd93-411e-9a4a-d314b5a14982" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_3f5d41e7-7953-4a14-bf73-2e3839485fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsMember_641d5a6d-3102-43ab-8de9-ad9fb8985429" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fb554368-fd93-411e-9a4a-d314b5a14982" xlink:to="loc_ifrs-full_PlanAssetsMember_641d5a6d-3102-43ab-8de9-ad9fb8985429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfAssetCeilingMember_78166727-42a5-4fb7-9111-cd5fad6a2ab9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfAssetCeilingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_fb554368-fd93-411e-9a4a-d314b5a14982" xlink:to="loc_ifrs-full_EffectOfAssetCeilingMember_78166727-42a5-4fb7-9111-cd5fad6a2ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_511b8fe7-1fae-487c-8628-a1bea6747f64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:to="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_511b8fe7-1fae-487c-8628-a1bea6747f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_f98c0e62-d2f4-4bc5-9f4f-0aceaf564dc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_511b8fe7-1fae-487c-8628-a1bea6747f64" xlink:to="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_f98c0e62-d2f4-4bc5-9f4f-0aceaf564dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_1881f0e3-57f5-4a29-bd91-55017485c81e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_f98c0e62-d2f4-4bc5-9f4f-0aceaf564dc7" xlink:to="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_1881f0e3-57f5-4a29-bd91-55017485c81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_ef4d04f7-3ba6-423d-b12c-a715dbdac7e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:to="loc_ifrs-full_GeographicalAreasAxis_ef4d04f7-3ba6-423d-b12c-a715dbdac7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_aa1b4336-26ef-4c84-a95b-910363cf4d31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ef4d04f7-3ba6-423d-b12c-a715dbdac7e9" xlink:to="loc_ifrs-full_GeographicalAreasMember_aa1b4336-26ef-4c84-a95b-910363cf4d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_4b89fe51-6b2f-4939-a2a0-482bb716bf64" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_aa1b4336-26ef-4c84-a95b-910363cf4d31" xlink:to="loc_country_GB_4b89fe51-6b2f-4939-a2a0-482bb716bf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_6d9906db-ec06-4edd-94f3-7584fc655349" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_b5bbe19a-b66b-46f9-b966-d412de5fa09a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_b5bbe19a-b66b-46f9-b966-d412de5fa09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_9a08015d-36bb-406c-bea5-965ab9ab9578" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_9a08015d-36bb-406c-bea5-965ab9ab9578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_e0ebfee1-fe5e-4ada-9484-3d0d8e2e9686" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_e0ebfee1-fe5e-4ada-9484-3d0d8e2e9686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_5e47fdcf-3579-40de-bc6f-e87cbca80ab8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_5e47fdcf-3579-40de-bc6f-e87cbca80ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_a7698bf9-4a41-41b2-b378-4ba98347e920" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_a7698bf9-4a41-41b2-b378-4ba98347e920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_eadeea87-461b-4a88-a32b-eb1d7e797ad6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_eadeea87-461b-4a88-a32b-eb1d7e797ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan_e2c3d85c-4209-43fb-a88a-e6469b7aaf91" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan_e2c3d85c-4209-43fb-a88a-e6469b7aaf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset_d51e21d8-a6a2-4c38-84dd-2536fa28ec97" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset_d51e21d8-a6a2-4c38-84dd-2536fa28ec97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BenefitsPaidOrPayable_d0c57f31-9e7f-4e93-b74b-732c863def5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BenefitsPaidOrPayable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_BenefitsPaidOrPayable_d0c57f31-9e7f-4e93-b74b-732c863def5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset_18ca26f4-784e-4f9c-bc1a-8d9ec2304f71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset_18ca26f4-784e-4f9c-bc1a-8d9ec2304f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_91a4a3ae-349e-4622-8af4-2996b147b9d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_91a4a3ae-349e-4622-8af4-2996b147b9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_e4a0b049-d5c9-451b-a3f9-1fa2c4ccf936" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_e4a0b049-d5c9-451b-a3f9-1fa2c4ccf936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod_4eb38a50-27ec-468f-9f96-278256ffb99d" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod_4eb38a50-27ec-468f-9f96-278256ffb99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_6b0c65ee-5a4a-44bd-bc3d-d98bc76b80c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_6b0c65ee-5a4a-44bd-bc3d-d98bc76b80c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_754bc410-7978-4b36-831c-9f5915351c6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_754bc410-7978-4b36-831c-9f5915351c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_957d97dd-05cb-4d72-8852-05b2f81c6c3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_957d97dd-05cb-4d72-8852-05b2f81c6c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_f1b47880-5955-4dcb-9fba-24ab20af7bcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_f1b47880-5955-4dcb-9fba-24ab20af7bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PreFundedPensionObligations_4671a96d-3919-4cda-9be3-3836d2e7a4f4" xlink:href="sny-20231231.xsd#sny_PreFundedPensionObligations"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_PreFundedPensionObligations_4671a96d-3919-4cda-9be3-3836d2e7a4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_c9d42b2c-c1d8-4528-8809-b7f46acf2d2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_NoncurrentProvisions_c9d42b2c-c1d8-4528-8809-b7f46acf2d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_548ceda2-f360-4651-a40a-7d6b307629eb" xlink:href="sny-20231231.xsd#sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_548ceda2-f360-4651-a40a-7d6b307629eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_d89a5762-4769-446b-bb4e-e02d9bda0574" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_d89a5762-4769-446b-bb4e-e02d9bda0574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_79bc2192-15bf-48fd-8153-4ed0fbc2c361" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_79bc2192-15bf-48fd-8153-4ed0fbc2c361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeBenefitsExpenseGain_e93aab95-c0e6-4f61-8570-e47239f9cd51" xlink:href="sny-20231231.xsd#sny_EmployeeBenefitsExpenseGain"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_92fe5d7e-9143-4f55-ac26-949f4340b5ee" xlink:to="loc_sny_EmployeeBenefitsExpenseGain_e93aab95-c0e6-4f61-8570-e47239f9cd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b926d580-2afd-4863-9c09-638b65919652" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f00e0961-74d5-4193-b488-5b1c6000d516" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b926d580-2afd-4863-9c09-638b65919652" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f00e0961-74d5-4193-b488-5b1c6000d516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_dec1ae08-4f38-4922-b083-83f2a3ad9f6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f00e0961-74d5-4193-b488-5b1c6000d516" xlink:to="loc_ifrs-full_GeographicalAreasAxis_dec1ae08-4f38-4922-b083-83f2a3ad9f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_dec1ae08-4f38-4922-b083-83f2a3ad9f6d" xlink:to="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_0f9f6d55-bfde-4719-890f-57e751da9573" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:to="loc_country_FR_0f9f6d55-bfde-4719-890f-57e751da9573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_b849f979-d7e5-4cbf-8593-9acce0082d76" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:to="loc_country_DE_b849f979-d7e5-4cbf-8593-9acce0082d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c1bfe499-4f6c-426d-98b1-8680e711b68f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:to="loc_country_US_c1bfe499-4f6c-426d-98b1-8680e711b68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_3fe0a4df-fffa-4676-ad72-70f380123f54" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:to="loc_country_GB_3fe0a4df-fffa-4676-ad72-70f380123f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_0ebb4da2-6472-4591-b46e-604bcb50e393" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_bec99f36-14f0-442d-a160-a494014c5d3e" xlink:to="loc_sny_OtherCountriesMember_0ebb4da2-6472-4591-b46e-604bcb50e393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_8301d0b8-5f9a-459a-9b4d-21336ca82052" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f00e0961-74d5-4193-b488-5b1c6000d516" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_8301d0b8-5f9a-459a-9b4d-21336ca82052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_9df7e86f-8c06-4edd-97cf-8c0bf7110e79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_8301d0b8-5f9a-459a-9b4d-21336ca82052" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_9df7e86f-8c06-4edd-97cf-8c0bf7110e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_25d1049c-0b0c-4fb9-ad30-8b9ab01a03b4" xlink:href="sny-20231231.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_9df7e86f-8c06-4edd-97cf-8c0bf7110e79" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_25d1049c-0b0c-4fb9-ad30-8b9ab01a03b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_f00e0961-74d5-4193-b488-5b1c6000d516" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_d61457d9-97c8-450d-9646-437baa305b51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_d61457d9-97c8-450d-9646-437baa305b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PlanAssetsAtFairValue_96effc1b-6a57-472e-b423-d3f9ddbb5ef4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PlanAssetsAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:to="loc_ifrs-full_PlanAssetsAtFairValue_96effc1b-6a57-472e-b423-d3f9ddbb5ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlanAssetsEffectOfAssetCeiling_aade5de5-d75d-4998-b673-c0703907400c" xlink:href="sny-20231231.xsd#sny_PlanAssetsEffectOfAssetCeiling"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:to="loc_sny_PlanAssetsEffectOfAssetCeiling_aade5de5-d75d-4998-b673-c0703907400c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_7f28e1a5-e68a-4a42-9ce1-12161ed48ec6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_95820071-44fb-420c-b7bf-bedeb21f7619" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_7f28e1a5-e68a-4a42-9ce1-12161ed48ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_5646dc0d-183e-4330-8b06-6523a9f8ec38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_c28a6f8f-919d-4858-8b2f-b689e690aa8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_5646dc0d-183e-4330-8b06-6523a9f8ec38" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_c28a6f8f-919d-4858-8b2f-b689e690aa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_3acbf6f3-0210-48a5-b9c1-b64f9cac5cf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_c28a6f8f-919d-4858-8b2f-b689e690aa8c" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_3acbf6f3-0210-48a5-b9c1-b64f9cac5cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_3acbf6f3-0210-48a5-b9c1-b64f9cac5cf8" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CashAndCashEquivalents1Member_97e5be46-1b01-4477-8549-a3db5a6f1c2f" xlink:href="sny-20231231.xsd#sny_CashAndCashEquivalents1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_CashAndCashEquivalents1Member_97e5be46-1b01-4477-8549-a3db5a6f1c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInstrumentsMember_fa9d13ca-aa02-411a-8232-d8e6f364d2be" xlink:href="sny-20231231.xsd#sny_EquityInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_EquityInstrumentsMember_fa9d13ca-aa02-411a-8232-d8e6f364d2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BondsAndSimilarInstrumentsMember_75777d5a-3583-427f-89e8-2ab2765fc620" xlink:href="sny-20231231.xsd#sny_BondsAndSimilarInstrumentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_BondsAndSimilarInstrumentsMember_75777d5a-3583-427f-89e8-2ab2765fc620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RealEstate1Member_102b86a7-1049-469b-89fb-9512af94bb9b" xlink:href="sny-20231231.xsd#sny_RealEstate1Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_RealEstate1Member_102b86a7-1049-469b-89fb-9512af94bb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_6b75a3c1-a421-43b4-9f6f-1a3195b528a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_ifrs-full_DerivativesMember_6b75a3c1-a421-43b4-9f6f-1a3195b528a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommoditiesMember_52e463ca-daee-4687-b7c0-238536eb9849" xlink:href="sny-20231231.xsd#sny_CommoditiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_CommoditiesMember_52e463ca-daee-4687-b7c0-238536eb9849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAssetsMember_a33f8c6d-7bc6-485b-9a57-014f3dfe61be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssetsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_ifrs-full_OtherAssetsMember_a33f8c6d-7bc6-485b-9a57-014f3dfe61be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HedgeFunds1Member_607fa5e7-3dc5-4e61-87bc-dbaddf0d4303" xlink:href="sny-20231231.xsd#sny_HedgeFunds1Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_HedgeFunds1Member_607fa5e7-3dc5-4e61-87bc-dbaddf0d4303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InsurancePoliciesMember_e38ea1a8-baaa-4821-a0a2-44144ebcf9c5" xlink:href="sny-20231231.xsd#sny_InsurancePoliciesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_bd50ae35-24dc-42fe-9aab-13fc29dd9ff4" xlink:to="loc_sny_InsurancePoliciesMember_e38ea1a8-baaa-4821-a0a2-44144ebcf9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_686f2627-2961-476a-9a18-c5a83d3ffe39" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_c28a6f8f-919d-4858-8b2f-b689e690aa8c" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_686f2627-2961-476a-9a18-c5a83d3ffe39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket_b2d52de9-cf8b-403c-b6e5-4db3f18034aa" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_686f2627-2961-476a-9a18-c5a83d3ffe39" xlink:to="loc_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket_b2d52de9-cf8b-403c-b6e5-4db3f18034aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities_63c2de71-0330-42dc-a220-9cc98a551fa2" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_686f2627-2961-476a-9a18-c5a83d3ffe39" xlink:to="loc_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities_63c2de71-0330-42dc-a220-9cc98a551fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageContributedToFairValueOfPlanAssets_4c618caa-e036-402d-9e49-216340ab92ec" xlink:href="sny-20231231.xsd#sny_PercentageContributedToFairValueOfPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_686f2627-2961-476a-9a18-c5a83d3ffe39" xlink:to="loc_sny_PercentageContributedToFairValueOfPlanAssets_4c618caa-e036-402d-9e49-216340ab92ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_c33dc2be-6da5-47da-8fbc-a580c28559e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_68901fe2-cf84-4bff-93dd-e4e3c8eae105" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_c33dc2be-6da5-47da-8fbc-a580c28559e4" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_68901fe2-cf84-4bff-93dd-e4e3c8eae105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_f4ea43df-6be7-483a-864f-5f4e077d28b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_68901fe2-cf84-4bff-93dd-e4e3c8eae105" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_f4ea43df-6be7-483a-864f-5f4e077d28b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_bbcc6825-6a8f-4f56-b678-939e93b3ccc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_f4ea43df-6be7-483a-864f-5f4e077d28b7" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_bbcc6825-6a8f-4f56-b678-939e93b3ccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_28ab539d-f230-439f-b744-e389cea93bda" xlink:href="sny-20231231.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_bbcc6825-6a8f-4f56-b678-939e93b3ccc2" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_28ab539d-f230-439f-b744-e389cea93bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_ab6d0bd7-945a-44e2-b254-a5e48178938d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_68901fe2-cf84-4bff-93dd-e4e3c8eae105" xlink:to="loc_ifrs-full_GeographicalAreasAxis_ab6d0bd7-945a-44e2-b254-a5e48178938d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ab6d0bd7-945a-44e2-b254-a5e48178938d" xlink:to="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_fa440ab7-2fe1-4d60-808e-996b53bdc592" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:to="loc_country_FR_fa440ab7-2fe1-4d60-808e-996b53bdc592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_2525c0cc-ff4e-49b2-ab6d-ee5f7ad58ca5" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:to="loc_country_DE_2525c0cc-ff4e-49b2-ab6d-ee5f7ad58ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_543a5dbd-6a33-4a30-b9d5-3eff8e03474e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:to="loc_country_US_543a5dbd-6a33-4a30-b9d5-3eff8e03474e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_8bfbcf3a-b14c-4d40-8dc4-38cdea6c53a0" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:to="loc_country_GB_8bfbcf3a-b14c-4d40-8dc4-38cdea6c53a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_0e34c660-ab80-44cd-a83c-ff6ff3a85dcc" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_70c5578b-9b9c-4aa8-8a92-64b56950f798" xlink:to="loc_sny_OtherCountriesMember_0e34c660-ab80-44cd-a83c-ff6ff3a85dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_68901fe2-cf84-4bff-93dd-e4e3c8eae105" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_c95583e5-7988-43d3-933b-2875f2480d29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_c95583e5-7988-43d3-933b-2875f2480d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement_6fb08c47-c9b4-4fbd-bb49-237f6adfd01f" xlink:href="sny-20231231.xsd#sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement_6fb08c47-c9b4-4fbd-bb49-237f6adfd01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset_a8182946-fa77-47c8-8448-f702b377f6d5" xlink:href="sny-20231231.xsd#sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset_a8182946-fa77-47c8-8448-f702b377f6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_0098441a-5359-4d5f-bc31-b734c3650ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_0098441a-5359-4d5f-bc31-b734c3650ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_99b5972e-d604-4cf9-80c1-9d9304208cde" xlink:href="sny-20231231.xsd#sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_99b5972e-d604-4cf9-80c1-9d9304208cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a1ecb945-b04d-45b0-bd52-d2f74df60910" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a1ecb945-b04d-45b0-bd52-d2f74df60910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset_c37f42fc-de7c-4295-b483-3de555a9d00f" xlink:href="sny-20231231.xsd#sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_ed31aa4a-cbb6-4a27-97b9-ca557359e32e" xlink:to="loc_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset_c37f42fc-de7c-4295-b483-3de555a9d00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_578cfc73-4c3b-45a3-aecc-c5eab7a479fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_e277e021-2c71-45cb-9de3-50743e470ae0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_578cfc73-4c3b-45a3-aecc-c5eab7a479fb" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_e277e021-2c71-45cb-9de3-50743e470ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_ef121a30-04e6-49d6-974b-7288eaa75b3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_e277e021-2c71-45cb-9de3-50743e470ae0" xlink:to="loc_ifrs-full_GeographicalAreasAxis_ef121a30-04e6-49d6-974b-7288eaa75b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_ef121a30-04e6-49d6-974b-7288eaa75b3c" xlink:to="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_2222104b-22c4-4b7a-a1b6-42bbfc9183ad" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:to="loc_country_FR_2222104b-22c4-4b7a-a1b6-42bbfc9183ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_863692b6-7b89-42b7-9c1c-4a6896718dc4" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:to="loc_country_DE_863692b6-7b89-42b7-9c1c-4a6896718dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0f3ed8a8-141c-40d1-a771-36c782e92c2f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:to="loc_country_US_0f3ed8a8-141c-40d1-a771-36c782e92c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_18776ad1-4102-4509-9836-13fd1e07d883" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_3fe42880-6b6d-4805-82a8-4ff05da518b0" xlink:to="loc_country_GB_18776ad1-4102-4509-9836-13fd1e07d883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_e277e021-2c71-45cb-9de3-50743e470ae0" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_529bf6fc-53de-46cb-9967-c28e08a09bea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_529bf6fc-53de-46cb-9967-c28e08a09bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments_8eb37f78-eddf-4d97-b46a-a12f577f0c99" xlink:href="sny-20231231.xsd#sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:to="loc_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments_8eb37f78-eddf-4d97-b46a-a12f577f0c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_9a36d477-ae94-4c8f-bfe2-faddd4f36f79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_9a36d477-ae94-4c8f-bfe2-faddd4f36f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_fa11a2ef-a525-4614-a536-9c3f46945a9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_53b3a487-629b-4721-9d85-015ceac94469" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_fa11a2ef-a525-4614-a536-9c3f46945a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNetPretaxActuarialLossDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNetPretaxActuarialLossDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNetPretaxActuarialLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b61b5aa3-f255-4420-881b-f9918de8912e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity_d93abb56-6581-4b98-bae3-1a3debe460a3" xlink:href="sny-20231231.xsd#sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b61b5aa3-f255-4420-881b-f9918de8912e" xlink:to="loc_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity_d93abb56-6581-4b98-bae3-1a3debe460a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_8d115e20-2c67-402e-9db0-865e1a176ffc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_a55dd250-100a-4fd8-bdc7-07bcef355ba2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_8d115e20-2c67-402e-9db0-865e1a176ffc" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_a55dd250-100a-4fd8-bdc7-07bcef355ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_e8fd4961-2a51-4164-9a88-d49cc9628472" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_a55dd250-100a-4fd8-bdc7-07bcef355ba2" xlink:to="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_e8fd4961-2a51-4164-9a88-d49cc9628472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_fefe1705-f7c4-4f1e-a226-43f02bca3334" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis_e8fd4961-2a51-4164-9a88-d49cc9628472" xlink:to="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_fefe1705-f7c4-4f1e-a226-43f02bca3334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_7ba1f1a9-ae3c-4cc3-98f3-a52c319e8f7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_fefe1705-f7c4-4f1e-a226-43f02bca3334" xlink:to="loc_ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember_7ba1f1a9-ae3c-4cc3-98f3-a52c319e8f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_32f9b1e7-5167-4a88-ad69-3312111a25b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WhollyUnfundedDefinedBenefitPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember_fefe1705-f7c4-4f1e-a226-43f02bca3334" xlink:to="loc_ifrs-full_WhollyUnfundedDefinedBenefitPlansMember_32f9b1e7-5167-4a88-ad69-3312111a25b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_0ed6e8bb-c0f6-4f1e-9b2c-d8f7242f0a49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_a55dd250-100a-4fd8-bdc7-07bcef355ba2" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_0ed6e8bb-c0f6-4f1e-9b2c-d8f7242f0a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_eb5055ed-916c-45d2-a2fc-d7d277b8ce04" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetAxis_0ed6e8bb-c0f6-4f1e-9b2c-d8f7242f0a49" xlink:to="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_eb5055ed-916c-45d2-a2fc-d7d277b8ce04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_1240a0ac-c54e-416f-808b-8b42656573fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentValueOfDefinedBenefitObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NetDefinedBenefitLiabilityAssetMember_eb5055ed-916c-45d2-a2fc-d7d277b8ce04" xlink:to="loc_ifrs-full_PresentValueOfDefinedBenefitObligationMember_1240a0ac-c54e-416f-808b-8b42656573fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_345afaa1-3f77-4373-9df0-e3c83278a164" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_a55dd250-100a-4fd8-bdc7-07bcef355ba2" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_345afaa1-3f77-4373-9df0-e3c83278a164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_7348657a-66d8-4a22-b122-92362bfb9f58" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_345afaa1-3f77-4373-9df0-e3c83278a164" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_7348657a-66d8-4a22-b122-92362bfb9f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_8c898c67-ac4c-4c78-85a0-07705da357ec" xlink:href="sny-20231231.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_7348657a-66d8-4a22-b122-92362bfb9f58" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_8c898c67-ac4c-4c78-85a0-07705da357ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_b700d284-62a9-458c-a9fd-edb1d990bd7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable_a55dd250-100a-4fd8-bdc7-07bcef355ba2" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_b700d284-62a9-458c-a9fd-edb1d990bd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_ec9efc65-7b37-49f2-aa93-087b6811e5c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems_b700d284-62a9-458c-a9fd-edb1d990bd7e" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_ec9efc65-7b37-49f2-aa93-087b6811e5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_7aa464cc-b36d-4dac-a389-e305a2366a0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_27d5a4f6-b684-4167-ba79-607854c5c9e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_7aa464cc-b36d-4dac-a389-e305a2366a0c" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_27d5a4f6-b684-4167-ba79-607854c5c9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansAxis_8d2d85a1-c742-40eb-80e6-f796b55533f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_27d5a4f6-b684-4167-ba79-607854c5c9e8" xlink:to="loc_ifrs-full_DefinedBenefitPlansAxis_8d2d85a1-c742-40eb-80e6-f796b55533f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitPlansMember_2f34ab52-24d8-479f-9661-bf3b0bf10add" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansAxis_8d2d85a1-c742-40eb-80e6-f796b55533f6" xlink:to="loc_ifrs-full_DefinedBenefitPlansMember_2f34ab52-24d8-479f-9661-bf3b0bf10add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_694af423-d339-4e27-8cae-bd843e05b942" xlink:href="sny-20231231.xsd#sny_PensionsAndOtherPostEmploymentBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefinedBenefitPlansMember_2f34ab52-24d8-479f-9661-bf3b0bf10add" xlink:to="loc_sny_PensionsAndOtherPostEmploymentBenefitsMember_694af423-d339-4e27-8cae-bd843e05b942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_27d5a4f6-b684-4167-ba79-607854c5c9e8" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_33199781-9c46-46b3-b28f-0aa41695030e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_ifrs-full_CostOfSales_33199781-9c46-46b3-b28f-0aa41695030e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1a3d877f-9a66-4202-ae0a-2975b81f2d0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_1a3d877f-9a66-4202-ae0a-2975b81f2d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1e1d6b1a-98d7-4848-a5aa-789ac7fbe370" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_1e1d6b1a-98d7-4848-a5aa-789ac7fbe370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_0f69d178-a888-4a91-ab4f-54030b0b402a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_0f69d178-a888-4a91-ab4f-54030b0b402a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RestructuringCostsReversedAndSimilarItems_0edcf299-30ff-41a3-abaf-c0fbde7dfb6a" xlink:href="sny-20231231.xsd#sny_RestructuringCostsReversedAndSimilarItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_sny_RestructuringCostsReversedAndSimilarItems_0edcf299-30ff-41a3-abaf-c0fbde7dfb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_a51e9c31-e7f5-4ac9-ad0c-da44f2b7b726" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_ifrs-full_FinanceCosts_a51e9c31-e7f5-4ac9-ad0c-da44f2b7b726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_ab73ab74-f06c-4814-91d8-fc1412611bfb" xlink:href="sny-20231231.xsd#sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fb0c7da9-a61b-46bb-8f28-8b660ffd0a4e" xlink:to="loc_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss_ab73ab74-f06c-4814-91d8-fc1412611bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_41e04e04-8901-440f-a80e-4bb1f6f409ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_70d64836-a078-4553-9de1-f22e4402dfe1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_41e04e04-8901-440f-a80e-4bb1f6f409ff" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_70d64836-a078-4553-9de1-f22e4402dfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_49646f25-108f-4c97-aa5b-f1ce9f1f0fa4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_70d64836-a078-4553-9de1-f22e4402dfe1" xlink:to="loc_ifrs-full_MaturityAxis_49646f25-108f-4c97-aa5b-f1ce9f1f0fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_d7f44e3b-1cf1-4fd0-b634-1274138b5c4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_49646f25-108f-4c97-aa5b-f1ce9f1f0fa4" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_d7f44e3b-1cf1-4fd0-b634-1274138b5c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_ee1799f8-0c92-455e-8eae-a63f08b7bf51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d7f44e3b-1cf1-4fd0-b634-1274138b5c4b" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_ee1799f8-0c92-455e-8eae-a63f08b7bf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_7eb1afa8-7a3d-47ed-84ee-bb791b59f4dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_70d64836-a078-4553-9de1-f22e4402dfe1" xlink:to="loc_ifrs-full_GeographicalAreasAxis_7eb1afa8-7a3d-47ed-84ee-bb791b59f4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_7eb1afa8-7a3d-47ed-84ee-bb791b59f4dd" xlink:to="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_e3e9b7a9-7ae6-4ce3-9795-9f5cea558907" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:to="loc_country_FR_e3e9b7a9-7ae6-4ce3-9795-9f5cea558907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_6583925b-af80-4df1-b99a-3bf551dd1f9f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:to="loc_country_DE_6583925b-af80-4df1-b99a-3bf551dd1f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c9ace286-6439-4ced-9859-e4403de9857d" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:to="loc_country_US_c9ace286-6439-4ced-9859-e4403de9857d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_9b3478f1-ae4a-485e-8371-aa28bcf70c94" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:to="loc_country_GB_9b3478f1-ae4a-485e-8371-aa28bcf70c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_cdd7b302-df1a-44ed-a469-26f806f5fbe6" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_497d191a-7f15-4e5f-888c-c659b4317fb5" xlink:to="loc_sny_OtherCountriesMember_cdd7b302-df1a-44ed-a469-26f806f5fbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_bdefc291-6226-477b-9131-317970c76873" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsTable_70d64836-a078-4553-9de1-f22e4402dfe1" xlink:to="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_bdefc291-6226-477b-9131-317970c76873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_6295c5fc-681b-4118-a37d-ac18677dd1f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems_bdefc291-6226-477b-9131-317970c76873" xlink:to="loc_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan_6295c5fc-681b-4118-a37d-ac18677dd1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_4bb212e6-154e-4112-bb5c-d3812f8fc661" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_77d3c64f-354d-475d-ad6e-3f51e5a734fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_4bb212e6-154e-4112-bb5c-d3812f8fc661" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_77d3c64f-354d-475d-ad6e-3f51e5a734fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_17272ed2-3211-4c8d-a5eb-bf91b148b648" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_77d3c64f-354d-475d-ad6e-3f51e5a734fc" xlink:to="loc_ifrs-full_GeographicalAreasAxis_17272ed2-3211-4c8d-a5eb-bf91b148b648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_17272ed2-3211-4c8d-a5eb-bf91b148b648" xlink:to="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_c7ad791e-357c-46bb-8b0b-e1ba662843e6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:to="loc_country_FR_c7ad791e-357c-46bb-8b0b-e1ba662843e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_ff056a15-d2d7-4415-b402-7c542de76a29" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:to="loc_country_DE_ff056a15-d2d7-4415-b402-7c542de76a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_dff3e63a-5050-40a6-a491-d9fc23681e12" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:to="loc_country_US_dff3e63a-5050-40a6-a491-d9fc23681e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_0d4aba01-a896-494f-a651-fbf6f4e192d7" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:to="loc_country_GB_0d4aba01-a896-494f-a651-fbf6f4e192d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_2c4ae2ca-fef1-4832-aee2-7f4c9b56cd9f" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_589655f1-9f51-422b-a078-4428923948c3" xlink:to="loc_sny_OtherCountriesMember_2c4ae2ca-fef1-4832-aee2-7f4c9b56cd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_1b708b50-4881-4e79-ba2b-3f55d4921906" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_77d3c64f-354d-475d-ad6e-3f51e5a734fc" xlink:to="loc_ifrs-full_MaturityAxis_1b708b50-4881-4e79-ba2b-3f55d4921906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_1b708b50-4881-4e79-ba2b-3f55d4921906" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_d0bb4c6d-4df6-48c6-a708-9b3b6c660eb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_d0bb4c6d-4df6-48c6-a708-9b3b6c660eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c68bb4e7-e6fd-4649-9c08-d68df92d28b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c68bb4e7-e6fd-4649-9c08-d68df92d28b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_aec65f16-9c42-4451-8bb5-b825258c5424" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_aec65f16-9c42-4451-8bb5-b825258c5424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_b77b7126-e996-4cb5-ad78-464d2063ae05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_b77b7126-e996-4cb5-ad78-464d2063ae05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_c35a0516-138c-4adb-bbeb-5715b54d0b25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_c35a0516-138c-4adb-bbeb-5715b54d0b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_b6b0e810-4e28-4974-abb8-02c5e547b683" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_82aa26e4-4a6e-4878-943e-26e87047966f" xlink:to="loc_ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember_b6b0e810-4e28-4974-abb8-02c5e547b683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_cb44161b-7a4a-4fc3-9f3a-f9bebe185a44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_77d3c64f-354d-475d-ad6e-3f51e5a734fc" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_cb44161b-7a4a-4fc3-9f3a-f9bebe185a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans_c518fd41-7ef4-4552-be0b-11d7178ba853" xlink:href="sny-20231231.xsd#sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_cb44161b-7a4a-4fc3-9f3a-f9bebe185a44" xlink:to="loc_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans_c518fd41-7ef4-4552-be0b-11d7178ba853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_0fbc2b9f-59a2-488b-ab76-650144a099df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7e7d9a37-92a0-4e7a-9f97-7d37f0acc598" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_0fbc2b9f-59a2-488b-ab76-650144a099df" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7e7d9a37-92a0-4e7a-9f97-7d37f0acc598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_ee0f7ce8-6ded-43c9-8428-6a59a21d72ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7e7d9a37-92a0-4e7a-9f97-7d37f0acc598" xlink:to="loc_ifrs-full_MaturityAxis_ee0f7ce8-6ded-43c9-8428-6a59a21d72ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_ee0f7ce8-6ded-43c9-8428-6a59a21d72ae" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_13496d8e-c9cf-438d-bc0b-ae19f5467614" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_13496d8e-c9cf-438d-bc0b-ae19f5467614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_dc1384a8-97a4-4026-b5ca-55af506553dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_dc1384a8-97a4-4026-b5ca-55af506553dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_f5a5caa1-38d0-4bb1-a804-6abd773a7739" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_f5a5caa1-38d0-4bb1-a804-6abd773a7739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_2a67b0ba-cbe1-4add-a353-8b709e62c55f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_b8b35936-ffb1-4c83-8919-0e3e96e484e3" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_2a67b0ba-cbe1-4add-a353-8b709e62c55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fa15f4a4-c9fc-4fab-91cc-bd33662a5195" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_7e7d9a37-92a0-4e7a-9f97-7d37f0acc598" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fa15f4a4-c9fc-4fab-91cc-bd33662a5195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans_b720941e-b944-4b07-a3d0-ef292c0a2f71" xlink:href="sny-20231231.xsd#sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_fa15f4a4-c9fc-4fab-91cc-bd33662a5195" xlink:to="loc_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans_b720941e-b944-4b07-a3d0-ef292c0a2f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3d2e1a0d-4a90-4975-bdc2-ce0935713178" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringProvisionsTable_0d513a08-df0b-40b2-8045-a6a774902ab5" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3d2e1a0d-4a90-4975-bdc2-ce0935713178" xlink:to="loc_sny_DisclosureOfRestructuringProvisionsTable_0d513a08-df0b-40b2-8045-a6a774902ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_a423ec1c-297c-4783-9cfb-d3e783f966cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsTable_0d513a08-df0b-40b2-8045-a6a774902ab5" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_a423ec1c-297c-4783-9cfb-d3e783f966cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_6f7b191a-311e-4c2e-99cd-52bc04f18cf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_a423ec1c-297c-4783-9cfb-d3e783f966cc" xlink:to="loc_ifrs-full_OtherProvisionsMember_6f7b191a-311e-4c2e-99cd-52bc04f18cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestructuringProvisionMember_f603c2f9-5941-44e6-8fcd-09397876d4cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestructuringProvisionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_6f7b191a-311e-4c2e-99cd-52bc04f18cf0" xlink:to="loc_ifrs-full_RestructuringProvisionMember_f603c2f9-5941-44e6-8fcd-09397876d4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:href="sny-20231231.xsd#sny_DisclosureOfRestructuringProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsTable_0d513a08-df0b-40b2-8045-a6a774902ab5" xlink:to="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_0450f2bd-9d1d-4703-b8b2-23b6fcf7c3b5" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_0450f2bd-9d1d-4703-b8b2-23b6fcf7c3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestructuringProvisionAbstract_87006ed1-4f14-4e9d-b300-3e84cbced079" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestructuringProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_ifrs-full_RestructuringProvisionAbstract_87006ed1-4f14-4e9d-b300-3e84cbced079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermRestructuringProvision_b8d19ce5-f40e-4f1d-8af6-9cf4b5d6a1d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermRestructuringProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RestructuringProvisionAbstract_87006ed1-4f14-4e9d-b300-3e84cbced079" xlink:to="loc_ifrs-full_LongtermRestructuringProvision_b8d19ce5-f40e-4f1d-8af6-9cf4b5d6a1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermRestructuringProvision_a3e30ba2-03b6-4887-9d7b-646220a1ba51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermRestructuringProvision"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RestructuringProvisionAbstract_87006ed1-4f14-4e9d-b300-3e84cbced079" xlink:to="loc_ifrs-full_ShorttermRestructuringProvision_a3e30ba2-03b6-4887-9d7b-646220a1ba51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod_e3edab22-c25b-4474-a7cf-b61654cc3471" xlink:href="sny-20231231.xsd#sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod_e3edab22-c25b-4474-a7cf-b61654cc3471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_0c7f4cf1-3655-40eb-9e55-5840a6cb9b34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_0c7f4cf1-3655-40eb-9e55-5840a6cb9b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_251a9552-a221-4300-b35c-6622f6e6ca7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_251a9552-a221-4300-b35c-6622f6e6ca7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UnwindingOfDiscount_5d423037-918b-4e9b-a88c-6c0a09e03586" xlink:href="sny-20231231.xsd#sny_UnwindingOfDiscount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_sny_UnwindingOfDiscount_5d423037-918b-4e9b-a88c-6c0a09e03586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_a63dbc03-54d5-411d-94bf-6f57a915ac7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_a63dbc03-54d5-411d-94bf-6f57a915ac7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_70601ed4-33f0-4715-ad21-4feacd10e41f" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfRestructuringProvisionsLineItems_87bb794e-ca98-45de-9b5b-05c1d73a2caa" xlink:to="loc_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities_70601ed4-33f0-4715-ad21-4feacd10e41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_1c2984a9-592a-4092-a6bf-2dbc4a22dd59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f3068181-ba65-44b7-b8c7-a2932144b201" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_1c2984a9-592a-4092-a6bf-2dbc4a22dd59" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f3068181-ba65-44b7-b8c7-a2932144b201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_60fcdcaf-ef50-483f-84af-d24368954fb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f3068181-ba65-44b7-b8c7-a2932144b201" xlink:to="loc_ifrs-full_GeographicalAreasAxis_60fcdcaf-ef50-483f-84af-d24368954fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_6ce8710b-4676-41d5-a8ba-812fb4465522" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_60fcdcaf-ef50-483f-84af-d24368954fb7" xlink:to="loc_ifrs-full_GeographicalAreasMember_6ce8710b-4676-41d5-a8ba-812fb4465522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_45a6e0f4-5149-4fc1-91ec-5c6d7cabeba6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_6ce8710b-4676-41d5-a8ba-812fb4465522" xlink:to="loc_country_FR_45a6e0f4-5149-4fc1-91ec-5c6d7cabeba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_cc8512b9-f83d-4018-a01e-67addf1fbaed" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_6ce8710b-4676-41d5-a8ba-812fb4465522" xlink:to="loc_sny_OtherCountriesMember_cc8512b9-f83d-4018-a01e-67addf1fbaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_f7c75156-4160-4731-81f4-e71532aa9849" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f3068181-ba65-44b7-b8c7-a2932144b201" xlink:to="loc_ifrs-full_MaturityAxis_f7c75156-4160-4731-81f4-e71532aa9849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_f7c75156-4160-4731-81f4-e71532aa9849" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_55381cfd-d419-462c-b84f-fb353df22207" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_55381cfd-d419-462c-b84f-fb353df22207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_afe999e1-8845-46fd-a23d-3bf04b67b4ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_afe999e1-8845-46fd-a23d-3bf04b67b4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_b519b09b-b324-4fbd-9a5f-2e4785899e6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_b519b09b-b324-4fbd-9a5f-2e4785899e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_77e22068-ea98-4ee2-a23b-8224d1d446eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_d2834202-c359-4b9a-8fbe-9b7bcd92afd9" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_77e22068-ea98-4ee2-a23b-8224d1d446eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_9b8cd62b-448e-4acf-9c75-c67656ac427c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_f3068181-ba65-44b7-b8c7-a2932144b201" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_9b8cd62b-448e-4acf-9c75-c67656ac427c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_6a4c5e19-2e96-4eb0-b5af-6a0b07b975d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_9b8cd62b-448e-4acf-9c75-c67656ac427c" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_6a4c5e19-2e96-4eb0-b5af-6a0b07b975d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b139e813-530a-4ee2-ad4c-e3c9f405892d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_523556d3-1673-49af-b640-256a5111891d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b139e813-530a-4ee2-ad4c-e3c9f405892d" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_523556d3-1673-49af-b640-256a5111891d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionForEnvironmentRisks_50539acf-c3f9-4a9a-928d-7f7922d37fe1" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionForEnvironmentRisks"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_523556d3-1673-49af-b640-256a5111891d" xlink:to="loc_sny_NonCurrentProvisionForEnvironmentRisks_50539acf-c3f9-4a9a-928d-7f7922d37fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_6ecfc06e-1e27-4c2a-a792-e1d64a685201" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_523556d3-1673-49af-b640-256a5111891d" xlink:to="loc_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_6ecfc06e-1e27-4c2a-a792-e1d64a685201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLongtermProvisions_fd3b2744-c921-4c8d-8a8d-4fd243b9074e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherLongtermProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsAbstract_523556d3-1673-49af-b640-256a5111891d" xlink:to="loc_ifrs-full_OtherLongtermProvisions_fd3b2744-c921-4c8d-8a8d-4fd243b9074e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_396a62d6-745b-4bb2-b40d-8557e9873652" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_86185204-bab6-4fce-9768-773e25c3e345" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_396a62d6-745b-4bb2-b40d-8557e9873652" xlink:to="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_86185204-bab6-4fce-9768-773e25c3e345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementAxis_595d2c41-7cf3-4d49-8bde-4653e415c349" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_86185204-bab6-4fce-9768-773e25c3e345" xlink:to="loc_sny_TypesOfAgreementAxis_595d2c41-7cf3-4d49-8bde-4653e415c349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TypesOfAgreementDomain_7fa4cde1-e12c-4f3e-b114-3c7dfdcb4426" xlink:href="sny-20231231.xsd#sny_TypesOfAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementAxis_595d2c41-7cf3-4d49-8bde-4653e415c349" xlink:to="loc_sny_TypesOfAgreementDomain_7fa4cde1-e12c-4f3e-b114-3c7dfdcb4426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CollaborationAgreementWithGSKMember_e4042e6b-4204-4cee-9027-42beb46dca7d" xlink:href="sny-20231231.xsd#sny_CollaborationAgreementWithGSKMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_7fa4cde1-e12c-4f3e-b114-3c7dfdcb4426" xlink:to="loc_sny_CollaborationAgreementWithGSKMember_e4042e6b-4204-4cee-9027-42beb46dca7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember_07126f38-8e02-46d0-9eb8-1d009f6a35f6" xlink:href="sny-20231231.xsd#sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_TypesOfAgreementDomain_7fa4cde1-e12c-4f3e-b114-3c7dfdcb4426" xlink:to="loc_sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember_07126f38-8e02-46d0-9eb8-1d009f6a35f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_86185204-bab6-4fce-9768-773e25c3e345" xlink:to="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_6e5a86b9-e31c-467c-8aca-a9c4de5e308e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_6e5a86b9-e31c-467c-8aca-a9c4de5e308e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_a3d79bfb-0020-413e-b316-242f5f24613b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsAccruals_a3d79bfb-0020-413e-b316-242f5f24613b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermRestructuringProvision_28cf096f-d51f-45db-b806-c8c11e339e88" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermRestructuringProvision"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_ShorttermRestructuringProvision_28cf096f-d51f-45db-b806-c8c11e339e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentInterestRateDerivativesPayable_ed2f4f1f-9473-4446-aeac-46e8671762fb" xlink:href="sny-20231231.xsd#sny_CurrentInterestRateDerivativesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_CurrentInterestRateDerivativesPayable_ed2f4f1f-9473-4446-aeac-46e8671762fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentCurrencyDerivativesPayable_c1dfa0ae-db5c-41f8-aa1b-96bf13c6ed2a" xlink:href="sny-20231231.xsd#sny_CurrentCurrencyDerivativesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_CurrentCurrencyDerivativesPayable_c1dfa0ae-db5c-41f8-aa1b-96bf13c6ed2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentEquityDerivativesPayable_5496f789-b7be-4dff-bca6-76a9ce5f6748" xlink:href="sny-20231231.xsd#sny_CurrentEquityDerivativesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_CurrentEquityDerivativesPayable_5496f789-b7be-4dff-bca6-76a9ce5f6748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountsPayableForAcquisitionOfNonCurrentAssets_d3b60522-7664-43ea-a905-2bbfd7c12793" xlink:href="sny-20231231.xsd#sny_AmountsPayableForAcquisitionOfNonCurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_AmountsPayableForAcquisitionOfNonCurrentAssets_d3b60522-7664-43ea-a905-2bbfd7c12793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_4c0f2e22-f606-46c9-b1ea-ef4690807a38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_CurrentContractLiabilities_4c0f2e22-f606-46c9-b1ea-ef4690807a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_75cd0432-8525-4587-932d-fdc620762318" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_75cd0432-8525-4587-932d-fdc620762318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_6292ccfd-cbdb-4bcd-aed2-1828c8bb5b4c" xlink:href="sny-20231231.xsd#sny_CurrentProvisionsAndOtherCurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_CurrentProvisionsAndOtherCurrentLiabilities_6292ccfd-cbdb-4bcd-aed2-1828c8bb5b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_6ec8a74d-1595-4f70-a6e3-94a052a56a85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_ifrs-full_OtherRevenue_6ec8a74d-1595-4f70-a6e3-94a052a56a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RoyaltiesPayable_3138a1ba-3e4e-4756-bc49-7b2bdcc6a9a6" xlink:href="sny-20231231.xsd#sny_RoyaltiesPayable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_f664c95d-b3ad-4fbc-a1a6-828c564bf92e" xlink:to="loc_sny_RoyaltiesPayable_3138a1ba-3e4e-4756-bc49-7b2bdcc6a9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_4f6ba06b-7945-407b-b53d-87dec69d6adb" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_dbabc657-d238-407d-a26b-0bac989d25ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_4f6ba06b-7945-407b-b53d-87dec69d6adb" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_dbabc657-d238-407d-a26b-0bac989d25ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_d52854b9-7187-4bc2-a838-32d6fe5ba396" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_dbabc657-d238-407d-a26b-0bac989d25ca" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_d52854b9-7187-4bc2-a838-32d6fe5ba396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_d52854b9-7187-4bc2-a838-32d6fe5ba396" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesMember_b94883c3-de6d-4bfe-bcc9-20f743efe92c" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:to="loc_sny_CurrencyDerivativesMember_b94883c3-de6d-4bfe-bcc9-20f743efe92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesOperatingMember_9cee2896-5613-4520-b743-696caab0d65a" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesOperatingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:to="loc_sny_CurrencyDerivativesOperatingMember_9cee2896-5613-4520-b743-696caab0d65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyDerivativesFinancialMember_9c6b7ebb-b2ca-4f28-a753-3d3a0781d507" xlink:href="sny-20231231.xsd#sny_CurrencyDerivativesFinancialMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:to="loc_sny_CurrencyDerivativesFinancialMember_9c6b7ebb-b2ca-4f28-a753-3d3a0781d507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateDerivativesMember_518747a0-5b7c-4607-8485-7b7e84ee6702" xlink:href="sny-20231231.xsd#sny_InterestRateDerivativesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:to="loc_sny_InterestRateDerivativesMember_518747a0-5b7c-4607-8485-7b7e84ee6702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityDerivativesMember_86c25e97-a735-4014-ad6a-974d85f83c60" xlink:href="sny-20231231.xsd#sny_EquityDerivativesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_5dc2d191-2b85-444c-a755-61bdb616a30b" xlink:to="loc_sny_EquityDerivativesMember_86c25e97-a735-4014-ad6a-974d85f83c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureTable_dbabc657-d238-407d-a26b-0bac989d25ca" xlink:to="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_0ca71ff6-f2e0-4401-bd3a-38e7cf5e58da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialAssets_0ca71ff6-f2e0-4401-bd3a-38e7cf5e58da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets_a159d67c-d093-468b-860e-b5686bb8fc49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialAssets_a159d67c-d093-468b-860e-b5686bb8fc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_27d23520-c6c9-4d1b-9bd3-bffd56bff1be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_DerivativeFinancialAssets_27d23520-c6c9-4d1b-9bd3-bffd56bff1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_f558fe0f-6504-43a3-812a-124dfb4d3be2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_f558fe0f-6504-43a3-812a-124dfb4d3be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_e6d4a8b9-5c55-4238-b384-190a499955a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_e6d4a8b9-5c55-4238-b384-190a499955a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_7421bd2e-73fc-416f-8c7c-88551dd2cf7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_7421bd2e-73fc-416f-8c7c-88551dd2cf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_132736d9-a061-41a0-b20f-0a8bb86ecba0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfCreditRiskExposureLineItems_53f4d17a-2f65-4514-a846-5beba6bb2a2b" xlink:to="loc_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue_132736d9-a061-41a0-b20f-0a8bb86ecba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_c0f5e5a1-f955-4240-9fb0-6ca63777b6f3" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_fa20864a-bdea-4e55-82dc-e44d6d5a62fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_c0f5e5a1-f955-4240-9fb0-6ca63777b6f3" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_fa20864a-bdea-4e55-82dc-e44d6d5a62fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_0e3fe47c-c756-4e3e-a6be-8d7c0c562381" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_fa20864a-bdea-4e55-82dc-e44d6d5a62fe" xlink:to="loc_ifrs-full_MeasurementAxis_0e3fe47c-c756-4e3e-a6be-8d7c0c562381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_0fed53bf-0376-4002-9064-6020bd161e9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_0e3fe47c-c756-4e3e-a6be-8d7c0c562381" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_0fed53bf-0376-4002-9064-6020bd161e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_37e446bf-6970-4272-ad08-6148642d80e8" xlink:href="sny-20231231.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_0fed53bf-0376-4002-9064-6020bd161e9e" xlink:to="loc_sny_AtNotionalAmountMember_37e446bf-6970-4272-ad08-6148642d80e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_9e699dd3-555a-4706-9103-4c44ef3992ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_0fed53bf-0376-4002-9064-6020bd161e9e" xlink:to="loc_ifrs-full_AtFairValueMember_9e699dd3-555a-4706-9103-4c44ef3992ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_1b10de0d-8882-4bd0-a5c6-c530f8f5fa1c" xlink:href="sny-20231231.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_0fed53bf-0376-4002-9064-6020bd161e9e" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_1b10de0d-8882-4bd0-a5c6-c530f8f5fa1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_0e402936-caf2-41e3-8027-1dbe43f0036c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_fa20864a-bdea-4e55-82dc-e44d6d5a62fe" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_0e402936-caf2-41e3-8027-1dbe43f0036c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_fc2ea1ec-b9b9-420a-9c1f-da61dadb70f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_0e402936-caf2-41e3-8027-1dbe43f0036c" xlink:to="loc_ifrs-full_TypesOfHedgesMember_fc2ea1ec-b9b9-420a-9c1f-da61dadb70f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_3c9b2d2a-4397-4da4-a4de-fd9918e42146" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_fc2ea1ec-b9b9-420a-9c1f-da61dadb70f9" xlink:to="loc_ifrs-full_CashFlowHedgesMember_3c9b2d2a-4397-4da4-a4de-fd9918e42146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NotEligibleForHedgeAccountingMember_79953801-7864-4cfa-9b0c-82fa404d1fb2" xlink:href="sny-20231231.xsd#sny_NotEligibleForHedgeAccountingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_fc2ea1ec-b9b9-420a-9c1f-da61dadb70f9" xlink:to="loc_sny_NotEligibleForHedgeAccountingMember_79953801-7864-4cfa-9b0c-82fa404d1fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_2ad05c5a-fa87-471b-8804-550ac0a3674e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_fa20864a-bdea-4e55-82dc-e44d6d5a62fe" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_2ad05c5a-fa87-471b-8804-550ac0a3674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_6589164a-c9ec-43be-99f2-941f3975f25d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_2ad05c5a-fa87-471b-8804-550ac0a3674e" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_6589164a-c9ec-43be-99f2-941f3975f25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_6589164a-c9ec-43be-99f2-941f3975f25d" xlink:to="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_f26aaf50-02ce-4798-9c27-e16b4d9c5a9f" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_f26aaf50-02ce-4798-9c27-e16b4d9c5a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_10e6d022-4d89-420b-9421-c265184f128f" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInChineseYuanRenminbiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanRenminbiMember_10e6d022-4d89-420b-9421-c265184f128f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_2b0b558a-173c-4db8-940d-55953993515a" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_2b0b558a-173c-4db8-940d-55953993515a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInJapaneseYenMember_305a673f-956e-4abe-be0b-46168237fd2d" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInJapaneseYenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInJapaneseYenMember_305a673f-956e-4abe-be0b-46168237fd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInKoreanWonMember_677229a3-6f5c-4aad-b34b-66692e222ba6" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInKoreanWonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInKoreanWonMember_677229a3-6f5c-4aad-b34b-66692e222ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInTaiwanDollarMember_4a0ad8c0-c43f-4378-a233-094c6e227021" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInTaiwanDollarMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_71d5817b-d444-461d-b428-bcb7b508b6c6" xlink:to="loc_sny_ForwardCurrencySalesInTaiwanDollarMember_4a0ad8c0-c43f-4378-a233-094c6e227021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_6589164a-c9ec-43be-99f2-941f3975f25d" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInUSDollarMember_b2d43e04-08c1-4ff7-90fb-f8af7715c932" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInUSDollarMember_b2d43e04-08c1-4ff7-90fb-f8af7715c932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInSingaporeDollarMember_4946f79a-cd25-40c1-9a2f-e12d75d97504" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInSingaporeDollarMember_4946f79a-cd25-40c1-9a2f-e12d75d97504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember_9fcefc7f-80e3-4bf2-900b-cdd8dfd62dab" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember_9fcefc7f-80e3-4bf2-900b-cdd8dfd62dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInKoreanWonMember_77de5474-72ea-49c4-ae70-b7d283de4860" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInKoreanWonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInKoreanWonMember_77de5474-72ea-49c4-ae70-b7d283de4860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInJapaneseYenMember_aea853dc-5139-4895-83bb-6a7bb4e4f240" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInJapaneseYenMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInJapaneseYenMember_aea853dc-5139-4895-83bb-6a7bb4e4f240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInTaiwanDollarMember_d046da23-0f65-46a0-9c4b-e6a79db93da9" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInTaiwanDollarMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInTaiwanDollarMember_d046da23-0f65-46a0-9c4b-e6a79db93da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInHungarianForintMember_ac4aa2e1-4a18-421e-b6ee-809e4ace6049" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInHungarianForintMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInHungarianForintMember_ac4aa2e1-4a18-421e-b6ee-809e4ace6049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInRussianRoubleMember_4c417d44-ae2a-4a0e-80fc-1cf8ee808a5a" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInRussianRoubleMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_9388e176-c46c-40c5-92bf-6ab435b08c7a" xlink:to="loc_sny_ForwardCurrencyPurchasedInRussianRoubleMember_4c417d44-ae2a-4a0e-80fc-1cf8ee808a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_26011cb1-284c-46c8-b63d-fedb8296af24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable_fa20864a-bdea-4e55-82dc-e44d6d5a62fe" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_26011cb1-284c-46c8-b63d-fedb8296af24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments_82841e54-3aee-43a9-b1b9-e460b612ad44" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialInstruments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems_26011cb1-284c-46c8-b63d-fedb8296af24" xlink:to="loc_sny_DerivativeFinancialInstruments_82841e54-3aee-43a9-b1b9-e460b612ad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_6e6e5ddd-150f-40bd-84ef-fe2ac52b58aa" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_30cf6538-0ff5-4909-921d-85c7a5928b44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_6e6e5ddd-150f-40bd-84ef-fe2ac52b58aa" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_30cf6538-0ff5-4909-921d-85c7a5928b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_41f32f09-ad9b-4045-a364-f83ebe568f3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_30cf6538-0ff5-4909-921d-85c7a5928b44" xlink:to="loc_ifrs-full_MeasurementAxis_41f32f09-ad9b-4045-a364-f83ebe568f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_2ab78ff9-db80-4745-a6d4-aada94fca341" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_41f32f09-ad9b-4045-a364-f83ebe568f3d" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_2ab78ff9-db80-4745-a6d4-aada94fca341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_ecc4b003-149b-468e-a1da-5d0a14a0e2f9" xlink:href="sny-20231231.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_2ab78ff9-db80-4745-a6d4-aada94fca341" xlink:to="loc_sny_AtNotionalAmountMember_ecc4b003-149b-468e-a1da-5d0a14a0e2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_41ba778d-491d-496c-bcd2-2d92596f6417" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_2ab78ff9-db80-4745-a6d4-aada94fca341" xlink:to="loc_ifrs-full_AtFairValueMember_41ba778d-491d-496c-bcd2-2d92596f6417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_5ba76cf8-7a56-42b1-9e42-fb110d9f10e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_30cf6538-0ff5-4909-921d-85c7a5928b44" xlink:to="loc_ifrs-full_MaturityAxis_5ba76cf8-7a56-42b1-9e42-fb110d9f10e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ff4b1096-02dd-47ce-941e-d4768b9c3bc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_5ba76cf8-7a56-42b1-9e42-fb110d9f10e5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ff4b1096-02dd-47ce-941e-d4768b9c3bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_6dca7a9d-6d8b-40d4-afe5-de27bc597569" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ff4b1096-02dd-47ce-941e-d4768b9c3bc1" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_6dca7a9d-6d8b-40d4-afe5-de27bc597569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_1f074568-fb34-42fd-8e44-45b67aaa336a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_30cf6538-0ff5-4909-921d-85c7a5928b44" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_1f074568-fb34-42fd-8e44-45b67aaa336a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_1f074568-fb34-42fd-8e44-45b67aaa336a" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesMember_a65b4f89-f99b-4e5a-b6f1-7fd09dd3ab69" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:to="loc_sny_ForwardCurrencySalesMember_a65b4f89-f99b-4e5a-b6f1-7fd09dd3ab69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInUSDollarMember_183b2a4b-b363-4106-9b52-37d9677371e1" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_a65b4f89-f99b-4e5a-b6f1-7fd09dd3ab69" xlink:to="loc_sny_ForwardCurrencySalesInUSDollarMember_183b2a4b-b363-4106-9b52-37d9677371e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_da56eab4-1d49-4449-b1d1-32a957348d8e" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_a65b4f89-f99b-4e5a-b6f1-7fd09dd3ab69" xlink:to="loc_sny_ForwardCurrencySalesInSingaporeDollarMember_da56eab4-1d49-4449-b1d1-32a957348d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencySalesInChineseYuanMember_4a8e5984-915b-41c2-a24e-6f79fe0c8064" xlink:href="sny-20231231.xsd#sny_ForwardCurrencySalesInChineseYuanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencySalesMember_a65b4f89-f99b-4e5a-b6f1-7fd09dd3ab69" xlink:to="loc_sny_ForwardCurrencySalesInChineseYuanMember_4a8e5984-915b-41c2-a24e-6f79fe0c8064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasesMember_ebba4cd4-e401-4eba-9a38-111977ab26ec" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:to="loc_sny_ForwardCurrencyPurchasesMember_ebba4cd4-e401-4eba-9a38-111977ab26ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInUSDollarMember_0de51e8d-bf93-41b5-aef6-304edbdbeab1" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInUSDollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_ebba4cd4-e401-4eba-9a38-111977ab26ec" xlink:to="loc_sny_ForwardCurrencyPurchasedInUSDollarMember_0de51e8d-bf93-41b5-aef6-304edbdbeab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInSingaporeDollarMember_b1b7bf60-89a0-49b8-90f5-1cbb91251c89" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInSingaporeDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_ebba4cd4-e401-4eba-9a38-111977ab26ec" xlink:to="loc_sny_ForwardCurrencyPurchasedInSingaporeDollarMember_b1b7bf60-89a0-49b8-90f5-1cbb91251c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInJapaneseYenMember_5837e857-cf98-47d1-b29e-a943bd77c661" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInJapaneseYenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ForwardCurrencyPurchasesMember_ebba4cd4-e401-4eba-9a38-111977ab26ec" xlink:to="loc_sny_ForwardCurrencyPurchasedInJapaneseYenMember_5837e857-cf98-47d1-b29e-a943bd77c661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember_5fc7b2ae-2223-41aa-ae44-bda05f703884" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInUSDollarUSBondMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:to="loc_sny_ForwardCurrencyPurchasedInUSDollarUSBondMember_5fc7b2ae-2223-41aa-ae44-bda05f703884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember_8e5c83ad-3ba9-4d54-8414-d607d6d772ac" xlink:href="sny-20231231.xsd#sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_19c214fe-25cc-44de-955b-38ac66fd88ff" xlink:to="loc_sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember_8e5c83ad-3ba9-4d54-8414-d607d6d772ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable_30cf6538-0ff5-4909-921d-85c7a5928b44" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_00c58fc2-47c0-4bbb-8d60-53fb36948704" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialInstrumentsToManageFinancialExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:to="loc_sny_DerivativeFinancialInstrumentsToManageFinancialExposure_00c58fc2-47c0-4bbb-8d60-53fb36948704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_3ade63d6-f761-4ca0-b1e1-ad579dd9a256" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:to="loc_ifrs-full_NotionalAmount_3ade63d6-f761-4ca0-b1e1-ad579dd9a256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialAssets_796b2a38-14c6-4671-a929-592de172d23a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:to="loc_ifrs-full_DerivativeFinancialAssets_796b2a38-14c6-4671-a929-592de172d23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_a8ea35bb-abba-490f-b188-c9cbb05b71b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_a8ea35bb-abba-490f-b188-c9cbb05b71b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_99fd2a86-8186-42ac-82d9-7d7a111b5362" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems_45c9cb5e-90e1-4ddc-a420-d3176219a8f6" xlink:to="loc_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax_99fd2a86-8186-42ac-82d9-7d7a111b5362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_33a7392b-81eb-4b25-8e46-4ddd2a167e4b" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_33a7392b-81eb-4b25-8e46-4ddd2a167e4b" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_bfbc2f1e-3cc6-4568-b755-f0e2f6b7d847" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_bfbc2f1e-3cc6-4568-b755-f0e2f6b7d847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_bfbc2f1e-3cc6-4568-b755-f0e2f6b7d847" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member_39717edc-a99c-4372-b01e-6fbaa8b906ca" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member_39717edc-a99c-4372-b01e-6fbaa8b906ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member_1dae4335-d80b-4c31-89e3-96024e2b6869" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member_1dae4335-d80b-4c31-89e3-96024e2b6869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_5dcf598a-d3d1-4843-bc18-ebe0d6c2ce7c" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive069Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive069Member_5dcf598a-d3d1-4843-bc18-ebe0d6c2ce7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_0256c234-9f4d-4e9c-8031-b2e2b387258b" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive092Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive092Member_0256c234-9f4d-4e9c-8031-b2e2b387258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_f76bafe7-5a91-407e-b7fd-45c8f0be9b04" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEsterReceive343Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEsterReceive343Member_f76bafe7-5a91-407e-b7fd-45c8f0be9b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member_ccd6b926-916a-47b7-8508-57f8b60c16d9" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member_ccd6b926-916a-47b7-8508-57f8b60c16d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember_07d59206-999e-4005-b6ae-84146f986ec3" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember_07d59206-999e-4005-b6ae-84146f986ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember_bebce6c7-7724-4686-a368-5fda4218c8de" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_516daebd-22f7-4176-beff-70270986ad1d" xlink:to="loc_sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember_bebce6c7-7724-4686-a368-5fda4218c8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_fc46b097-9238-49a9-be90-8a9fc0407a90" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:to="loc_ifrs-full_MeasurementAxis_fc46b097-9238-49a9-be90-8a9fc0407a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_1d1dfb56-0db7-45e1-bb95-f32bc10d92fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_fc46b097-9238-49a9-be90-8a9fc0407a90" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_1d1dfb56-0db7-45e1-bb95-f32bc10d92fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtNotionalAmountMember_4cef8acd-0f9a-4c50-b882-fa95630decee" xlink:href="sny-20231231.xsd#sny_AtNotionalAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1d1dfb56-0db7-45e1-bb95-f32bc10d92fe" xlink:to="loc_sny_AtNotionalAmountMember_4cef8acd-0f9a-4c50-b882-fa95630decee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_0ba02217-f412-418a-84f9-75cab087b047" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1d1dfb56-0db7-45e1-bb95-f32bc10d92fe" xlink:to="loc_ifrs-full_AtFairValueMember_0ba02217-f412-418a-84f9-75cab087b047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ValueOfHedgeRecognizedInEquityMember_777eaceb-0dfe-4f96-abe7-feeffeb9344a" xlink:href="sny-20231231.xsd#sny_ValueOfHedgeRecognizedInEquityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_1d1dfb56-0db7-45e1-bb95-f32bc10d92fe" xlink:to="loc_sny_ValueOfHedgeRecognizedInEquityMember_777eaceb-0dfe-4f96-abe7-feeffeb9344a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_0af56552-ea70-4ba3-94b3-0e2cb81f56d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:to="loc_ifrs-full_MaturityAxis_0af56552-ea70-4ba3-94b3-0e2cb81f56d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_0af56552-ea70-4ba3-94b3-0e2cb81f56d6" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_715ebc43-e8f5-4800-ab89-9cfcd2a6a850" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_715ebc43-e8f5-4800-ab89-9cfcd2a6a850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c6b69124-83aa-4a79-b386-123a1b3655a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_c6b69124-83aa-4a79-b386-123a1b3655a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_04404ae7-4d46-4a14-9253-797ac941e55a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember_04404ae7-4d46-4a14-9253-797ac941e55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_305df9c3-804c-4023-95c8-ebf538abb973" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember_305df9c3-804c-4023-95c8-ebf538abb973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_7c181904-4893-4db6-99c8-5ad3cdf70f50" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember_7c181904-4893-4db6-99c8-5ad3cdf70f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_d07e3959-99ee-4768-8a26-c4f4b400b945" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_0749e34b-f6a3-4ddb-a61d-22822195f324" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_d07e3959-99ee-4768-8a26-c4f4b400b945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesAxis_d8678702-3a40-4413-ba18-f0e8618f3c47" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:to="loc_ifrs-full_TypesOfHedgesAxis_d8678702-3a40-4413-ba18-f0e8618f3c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfHedgesMember_3dec50fd-bb33-42f0-8157-c9c521c6de8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesAxis_d8678702-3a40-4413-ba18-f0e8618f3c47" xlink:to="loc_ifrs-full_TypesOfHedgesMember_3dec50fd-bb33-42f0-8157-c9c521c6de8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FairValueHedgesMember_fd48a549-fb4d-4694-a8ed-3d8b5b1f108f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FairValueHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_3dec50fd-bb33-42f0-8157-c9c521c6de8c" xlink:to="loc_ifrs-full_FairValueHedgesMember_fd48a549-fb4d-4694-a8ed-3d8b5b1f108f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowHedgesMember_d92710c1-aab7-47c8-8a51-94fb991f59de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowHedgesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfHedgesMember_3dec50fd-bb33-42f0-8157-c9c521c6de8c" xlink:to="loc_ifrs-full_CashFlowHedgesMember_d92710c1-aab7-47c8-8a51-94fb991f59de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65e4c39c-8b8d-4792-9c5d-8d37584e0367" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_c40c0bf2-12b5-482e-99be-dc4a04176652" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65e4c39c-8b8d-4792-9c5d-8d37584e0367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateSwapsInterestRate_03dca2f6-ec33-45a6-aee1-6830f3e23207" xlink:href="sny-20231231.xsd#sny_InterestRateSwapsInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65e4c39c-8b8d-4792-9c5d-8d37584e0367" xlink:to="loc_sny_InterestRateSwapsInterestRate_03dca2f6-ec33-45a6-aee1-6830f3e23207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_3e0c7363-12ee-4b51-bea0-f6a96e777246" xlink:href="sny-20231231.xsd#sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65e4c39c-8b8d-4792-9c5d-8d37584e0367" xlink:to="loc_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents_3e0c7363-12ee-4b51-bea0-f6a96e777246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialInstruments_9cfad909-ec73-472b-bace-14ac8dd63d44" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_65e4c39c-8b8d-4792-9c5d-8d37584e0367" xlink:to="loc_sny_DerivativeFinancialInstruments_9cfad909-ec73-472b-bace-14ac8dd63d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_29a79a4b-ee15-4ad7-9209-e68f9c8f0260" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_82101ac0-ed9c-4257-a5f8-aed234a72550" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_29a79a4b-ee15-4ad7-9209-e68f9c8f0260" xlink:to="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_82101ac0-ed9c-4257-a5f8-aed234a72550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_bd4ad79c-277a-457a-a75a-46271148e926" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_82101ac0-ed9c-4257-a5f8-aed234a72550" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_bd4ad79c-277a-457a-a75a-46271148e926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_3bb0aaf9-0a24-4d85-a59a-2495f83f0f40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_bd4ad79c-277a-457a-a75a-46271148e926" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_3bb0aaf9-0a24-4d85-a59a-2495f83f0f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialAssetsMember_6a8bbc2f-6f46-4e7a-aa6a-eba4162e3e24" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_3bb0aaf9-0a24-4d85-a59a-2495f83f0f40" xlink:to="loc_sny_DerivativeFinancialAssetsMember_6a8bbc2f-6f46-4e7a-aa6a-eba4162e3e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialLiabilitiesMember_da6082d5-5187-43a1-8628-481aa4add155" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_3bb0aaf9-0a24-4d85-a59a-2495f83f0f40" xlink:to="loc_sny_DerivativeFinancialLiabilitiesMember_da6082d5-5187-43a1-8628-481aa4add155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeInstrumentAxis_563daaaf-a739-4143-ad45-c8baa72846ba" xlink:href="sny-20231231.xsd#sny_DerivativeInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_82101ac0-ed9c-4257-a5f8-aed234a72550" xlink:to="loc_sny_DerivativeInstrumentAxis_563daaaf-a739-4143-ad45-c8baa72846ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeInstrumentDomain_1b0bfc2d-d026-4c2b-a852-b5c3effed5a0" xlink:href="sny-20231231.xsd#sny_DerivativeInstrumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DerivativeInstrumentAxis_563daaaf-a739-4143-ad45-c8baa72846ba" xlink:to="loc_sny_DerivativeInstrumentDomain_1b0bfc2d-d026-4c2b-a852-b5c3effed5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember_441cb859-4f21-4f5c-93f4-c690cc4351f0" xlink:href="sny-20231231.xsd#sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DerivativeInstrumentDomain_1b0bfc2d-d026-4c2b-a852-b5c3effed5a0" xlink:to="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember_441cb859-4f21-4f5c-93f4-c690cc4351f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable_82101ac0-ed9c-4257-a5f8-aed234a72550" xlink:to="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset_2f22a933-48ab-4d4c-b855-aaadbee986f9" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset_2f22a933-48ab-4d4c-b855-aaadbee986f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32_da29c275-d317-4eb4-b214-1b29879e0336" xlink:href="sny-20231231.xsd#sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32_da29c275-d317-4eb4-b214-1b29879e0336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetAmountsAsReportedInTheBalanceSheet_68f24b60-aeb9-4ec9-b8e4-16214cd7c788" xlink:href="sny-20231231.xsd#sny_NetAmountsAsReportedInTheBalanceSheet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_NetAmountsAsReportedInTheBalanceSheet_68f24b60-aeb9-4ec9-b8e4-16214cd7c788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral_901de762-5663-4852-aa17-812f71dfbf2d" xlink:href="sny-20231231.xsd#sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral_901de762-5663-4852-aa17-812f71dfbf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments_4aafe789-cce1-4a90-9f2b-62e05e5af328" xlink:href="sny-20231231.xsd#sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments_4aafe789-cce1-4a90-9f2b-62e05e5af328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetExposure_e50077b9-cf55-429e-ae4a-74235612cba6" xlink:href="sny-20231231.xsd#sny_NetExposure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems_557fcaa1-cbea-45a8-94f4-3eb76aafb025" xlink:to="loc_sny_NetExposure_e50077b9-cf55-429e-ae4a-74235612cba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1c895dc5-da09-4ebd-a6c9-0460d5893b7f" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1c895dc5-da09-4ebd-a6c9-0460d5893b7f" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_9ab3624b-b545-4d7f-8b20-32e05224d2a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:to="loc_ifrs-full_JointVenturesAxis_9ab3624b-b545-4d7f-8b20-32e05224d2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_a766ee55-5f11-433e-aa41-3aabc5c2f613" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_9ab3624b-b545-4d7f-8b20-32e05224d2a8" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_a766ee55-5f11-433e-aa41-3aabc5c2f613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesMember_2ff421f6-b7e4-4349-a576-8114a3f0590a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_a766ee55-5f11-433e-aa41-3aabc5c2f613" xlink:to="loc_ifrs-full_JointVenturesMember_2ff421f6-b7e4-4349-a576-8114a3f0590a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_851f1d64-0d2f-4379-96f4-30f9ff89b437" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_851f1d64-0d2f-4379-96f4-30f9ff89b437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8c9472b6-9293-42a4-94bb-e5b97da88cf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_851f1d64-0d2f-4379-96f4-30f9ff89b437" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8c9472b6-9293-42a4-94bb-e5b97da88cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SuppliersMember_d9fa09f3-b04b-43ce-91bd-3e709e0e8374" xlink:href="sny-20231231.xsd#sny_SuppliersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8c9472b6-9293-42a4-94bb-e5b97da88cf4" xlink:to="loc_sny_SuppliersMember_d9fa09f3-b04b-43ce-91bd-3e709e0e8374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_c7ebaad9-10d0-4489-b5ed-69c48d3731b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:to="loc_ifrs-full_MaturityAxis_c7ebaad9-10d0-4489-b5ed-69c48d3731b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_c7ebaad9-10d0-4489-b5ed-69c48d3731b3" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_fb669f6f-d993-42d7-9591-c2d10ecab478" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_fb669f6f-d993-42d7-9591-c2d10ecab478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_5431f87d-87e6-4621-9a88-fa9ebd478178" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_5431f87d-87e6-4621-9a88-fa9ebd478178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_32328268-c754-4fb9-9ec2-23b4c9889855" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_32328268-c754-4fb9-9ec2-23b4c9889855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_1df3a840-a905-461c-8e45-099aa510e1be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_2962162a-8297-4869-9166-1e7f3337cae4" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_1df3a840-a905-461c-8e45-099aa510e1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b7175773-c553-4579-ace5-702ce52dfc0f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:to="loc_srt_RangeAxis_b7175773-c553-4579-ace5-702ce52dfc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b2659b6-74fe-4b2c-a0cf-74f3fa9bc410" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b7175773-c553-4579-ace5-702ce52dfc0f" xlink:to="loc_srt_RangeMember_3b2659b6-74fe-4b2c-a0cf-74f3fa9bc410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2e2d07a4-e89f-42a9-82c8-305292b12219" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b2659b6-74fe-4b2c-a0cf-74f3fa9bc410" xlink:to="loc_srt_MinimumMember_2e2d07a4-e89f-42a9-82c8-305292b12219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b09b8525-f0ef-4834-9be8-65b4914f192d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b09b8525-f0ef-4834-9be8-65b4914f192d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_a6d70682-d2b4-4061-aaa7-2131ef2acac5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_b09b8525-f0ef-4834-9be8-65b4914f192d" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_a6d70682-d2b4-4061-aaa7-2131ef2acac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_83c71954-11ee-4c59-ab0f-94a44c22d98a" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_a6d70682-d2b4-4061-aaa7-2131ef2acac5" xlink:to="loc_sny_EuroapiMember_83c71954-11ee-4c59-ab0f-94a44c22d98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:href="sny-20231231.xsd#sny_DisclosureOfOffBalanceSheetCommitmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsTable_16e070f2-eb95-4114-88a8-4a5268272791" xlink:to="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet_c9e85566-42a3-48e9-85b8-da9d9b15b753" xlink:href="sny-20231231.xsd#sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet_c9e85566-42a3-48e9-85b8-da9d9b15b753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsGiven_955aba27-87f2-4193-a5b8-fc447ccc7dbd" xlink:href="sny-20231231.xsd#sny_IrrevocablePurchaseCommitmentsGiven"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsGiven_955aba27-87f2-4193-a5b8-fc447ccc7dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IrrevocablePurchaseCommitmentsReceived_2409ee34-6b4d-4864-b2cb-e8eda839442e" xlink:href="sny-20231231.xsd#sny_IrrevocablePurchaseCommitmentsReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_IrrevocablePurchaseCommitmentsReceived_2409ee34-6b4d-4864-b2cb-e8eda839442e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments_146577ac-2c74-4f68-ac6c-1a7487b594b9" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments_146577ac-2c74-4f68-ac6c-1a7487b594b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress_5b415bf1-5be6-4e36-8b2c-3ad84dd6061a" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress_5b415bf1-5be6-4e36-8b2c-3ad84dd6061a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TotalOffBalanceSheetCommitments_0dfcc23c-3eb5-4ccb-ba4d-acb48a6396a7" xlink:href="sny-20231231.xsd#sny_TotalOffBalanceSheetCommitments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_TotalOffBalanceSheetCommitments_0dfcc23c-3eb5-4ccb-ba4d-acb48a6396a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseTerm_f7ab12bd-9c0c-4d3d-b570-de957b946ca7" xlink:href="sny-20231231.xsd#sny_LeaseTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_LeaseTerm_f7ab12bd-9c0c-4d3d-b570-de957b946ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseCosts_8113278e-d6e6-41b4-a7db-6e1ab7e7f53b" xlink:href="sny-20231231.xsd#sny_LeaseCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_LeaseCosts_8113278e-d6e6-41b4-a7db-6e1ab7e7f53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsNumber_18a90061-4596-4928-9d3c-3110e1f3c65e" xlink:href="sny-20231231.xsd#sny_LeaseExtensionOptionsNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_LeaseExtensionOptionsNumber_18a90061-4596-4928-9d3c-3110e1f3c65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LeaseExtensionOptionsTerm_db05dd9a-f65a-4ba2-b3ce-d77f77b6bd40" xlink:href="sny-20231231.xsd#sny_LeaseExtensionOptionsTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems_df0d0f79-d90b-455c-86ef-59b5103ca9e3" xlink:to="loc_sny_LeaseExtensionOptionsTerm_db05dd9a-f65a-4ba2-b3ce-d77f77b6bd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OffbalancesheetcommitmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_39aeaf1d-8fd3-4d6a-be7b-8322b72ca8a8" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_39aeaf1d-8fd3-4d6a-be7b-8322b72ca8a8" xlink:to="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_930c9d7d-d0a7-4e67-bc19-db995fa7fc22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_930c9d7d-d0a7-4e67-bc19-db995fa7fc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fbf04ef3-e505-4182-a53c-e82aed9e48cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_930c9d7d-d0a7-4e67-bc19-db995fa7fc22" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fbf04ef3-e505-4182-a53c-e82aed9e48cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AblynxMember_46af2528-68cf-4b10-830c-76da7c1094f9" xlink:href="sny-20231231.xsd#sny_AblynxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fbf04ef3-e505-4182-a53c-e82aed9e48cd" xlink:to="loc_sny_AblynxMember_46af2528-68cf-4b10-830c-76da7c1094f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KymabMember_61dc3263-4fe0-4c06-9a04-25e03ae4c2f8" xlink:href="sny-20231231.xsd#sny_KymabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fbf04ef3-e505-4182-a53c-e82aed9e48cd" xlink:to="loc_sny_KymabMember_61dc3263-4fe0-4c06-9a04-25e03ae4c2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioMember_5e03733c-54fe-4a32-9e1c-4cf7f111586c" xlink:href="sny-20231231.xsd#sny_ProventionBioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_fbf04ef3-e505-4182-a53c-e82aed9e48cd" xlink:to="loc_sny_ProventionBioMember_5e03733c-54fe-4a32-9e1c-4cf7f111586c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_1a66c16e-e4d4-4704-87fc-b273a7be21f3" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_sny_PrincipalAlliancesAxis_1a66c16e-e4d4-4704-87fc-b273a7be21f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_2c0051a1-69e7-4646-9442-12c1e636f5da" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_1a66c16e-e4d4-4704-87fc-b273a7be21f3" xlink:to="loc_sny_PrincipalAlliancesDomain_2c0051a1-69e7-4646-9442-12c1e636f5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_a758f39a-bc95-485b-a47b-d0e02577d5de" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_2c0051a1-69e7-4646-9442-12c1e636f5da" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_a758f39a-bc95-485b-a47b-d0e02577d5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_a9d75441-eeee-4b05-a71d-e7ad7e0d8b47" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_ifrs-full_CounterpartiesAxis_a9d75441-eeee-4b05-a71d-e7ad7e0d8b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_a9d75441-eeee-4b05-a71d-e7ad7e0d8b47" xlink:to="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ScribeTherapeuticsMember_36465f48-f0cb-483d-8700-143529578b8f" xlink:href="sny-20231231.xsd#sny_ScribeTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_ScribeTherapeuticsMember_36465f48-f0cb-483d-8700-143529578b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JanssenPharmaceuticalsIncMember_45e38aeb-b40b-40c9-83e0-219b4b90a574" xlink:href="sny-20231231.xsd#sny_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_JanssenPharmaceuticalsIncMember_45e38aeb-b40b-40c9-83e0-219b4b90a574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TevaPharmaceuticalsMember_828a08e2-cb9d-4e8f-928f-bc1057e81dd5" xlink:href="sny-20231231.xsd#sny_TevaPharmaceuticalsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_TevaPharmaceuticalsMember_828a08e2-cb9d-4e8f-928f-bc1057e81dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioIncMember_b4362c4f-88eb-4067-a9d2-0088057f60d4" xlink:href="sny-20231231.xsd#sny_ProventionBioIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_ProventionBioIncMember_b4362c4f-88eb-4067-a9d2-0088057f60d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExscientiaMember_b2bce415-906b-4c42-9c37-af5da0672829" xlink:href="sny-20231231.xsd#sny_ExscientiaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_ExscientiaMember_b2bce415-906b-4c42-9c37-af5da0672829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BlackstoneLifeSciencesMember_865cbf3f-4a7c-4d49-b1cb-69b4880a9257" xlink:href="sny-20231231.xsd#sny_BlackstoneLifeSciencesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_BlackstoneLifeSciencesMember_865cbf3f-4a7c-4d49-b1cb-69b4880a9257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IGMBiosciencesIncMember_e5e28358-4a3b-40f7-a027-a63e07ed9c3e" xlink:href="sny-20231231.xsd#sny_IGMBiosciencesIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_IGMBiosciencesIncMember_e5e28358-4a3b-40f7-a027-a63e07ed9c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AtomwiseMember_c531f47a-fa54-445c-8f90-da311d32ee30" xlink:href="sny-20231231.xsd#sny_AtomwiseMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_AtomwiseMember_c531f47a-fa54-445c-8f90-da311d32ee30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InsilicoMedicineMember_7e0b45cf-c655-4c69-a5d2-e1b684d07c14" xlink:href="sny-20231231.xsd#sny_InsilicoMedicineMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_InsilicoMedicineMember_7e0b45cf-c655-4c69-a5d2-e1b684d07c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_02092633-cb79-42dd-aa5a-ad53a2b0f807" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_02092633-cb79-42dd-aa5a-ad53a2b0f807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LonzaMember_58dd11a4-61b3-451e-977f-5a68fea06c20" xlink:href="sny-20231231.xsd#sny_LonzaMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_6defea7a-8a09-417e-af28-1c2b74d32fa2" xlink:to="loc_sny_LonzaMember_58dd11a4-61b3-451e-977f-5a68fea06c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_987130e9-f661-4c40-88bb-1f4ebb2990a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_ifrs-full_JointVenturesAxis_987130e9-f661-4c40-88bb-1f4ebb2990a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_764448b4-6714-4bb6-817b-5d89ed2b4802" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_987130e9-f661-4c40-88bb-1f4ebb2990a7" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_764448b4-6714-4bb6-817b-5d89ed2b4802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesMember_83b0ff20-6433-4ffe-85fe-2f39d7b9a660" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_764448b4-6714-4bb6-817b-5d89ed2b4802" xlink:to="loc_ifrs-full_JointVenturesMember_83b0ff20-6433-4ffe-85fe-2f39d7b9a660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e7677915-5a49-4613-a22a-7714c5a70aa4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e7677915-5a49-4613-a22a-7714c5a70aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9588ba0b-deee-4781-98e1-a1af1c7eaf3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_e7677915-5a49-4613-a22a-7714c5a70aa4" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9588ba0b-deee-4781-98e1-a1af1c7eaf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_WorldHealthOrganizationMember_13049d7c-b0b2-42a6-9534-e11daf7ad8cf" xlink:href="sny-20231231.xsd#sny_WorldHealthOrganizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_9588ba0b-deee-4781-98e1-a1af1c7eaf3a" xlink:to="loc_sny_WorldHealthOrganizationMember_13049d7c-b0b2-42a6-9534-e11daf7ad8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6fb65b6b-d716-4bf3-ab6e-8eeaabf29352" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_srt_RangeAxis_6fb65b6b-d716-4bf3-ab6e-8eeaabf29352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63fad515-9fad-41c7-82db-56e79b28f258" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6fb65b6b-d716-4bf3-ab6e-8eeaabf29352" xlink:to="loc_srt_RangeMember_63fad515-9fad-41c7-82db-56e79b28f258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_46be5e43-ce2d-4a5e-b604-1c86eb0aea6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_63fad515-9fad-41c7-82db-56e79b28f258" xlink:to="loc_srt_MaximumMember_46be5e43-ce2d-4a5e-b604-1c86eb0aea6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:href="sny-20231231.xsd#sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable_d4bd4e55-23f4-4c72-9a51-3bf91a279ed8" xlink:to="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase_8a053d00-23c3-457a-aa1c-20cf8bf279c2" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase_8a053d00-23c3-457a-aa1c-20cf8bf279c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets_b234bd91-0e71-464b-9544-95523e7ec83f" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets_b234bd91-0e71-464b-9544-95523e7ec83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements_8ad95944-de4c-4f12-9763-00bf5c9d2dc5" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements_8ad95944-de4c-4f12-9763-00bf5c9d2dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts_4bd6becb-961a-44b9-a5a3-476fbae47830" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts_4bd6becb-961a-44b9-a5a3-476fbae47830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPayments_db69ce53-badd-4bfb-a748-33358eee77bf" xlink:href="sny-20231231.xsd#sny_UpfrontPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_UpfrontPayments_db69ce53-badd-4bfb-a748-33358eee77bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_f46673fc-4a6f-4f9f-af45-61baec45bd4d" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement_f46673fc-4a6f-4f9f-af45-61baec45bd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement_f8087afd-98c4-4e45-894e-7adb8ff49ee0" xlink:href="sny-20231231.xsd#sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement_f8087afd-98c4-4e45-894e-7adb8ff49ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement_887dbe37-e8ed-4c8c-bc05-ea8bbcfa1169" xlink:href="sny-20231231.xsd#sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement_887dbe37-e8ed-4c8c-bc05-ea8bbcfa1169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOncologyTargetsUnderCollaborationAgreement_538a8efd-f345-4fe2-8136-8bee54abaa43" xlink:href="sny-20231231.xsd#sny_NumberOfOncologyTargetsUnderCollaborationAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_NumberOfOncologyTargetsUnderCollaborationAgreement_538a8efd-f345-4fe2-8136-8bee54abaa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement_4c7c9ac4-7519-407d-8ffc-42df454888b7" xlink:href="sny-20231231.xsd#sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement_4c7c9ac4-7519-407d-8ffc-42df454888b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfDrugTargetsUnderCollaborationAgreement_817bc53e-1ba2-4950-92b9-8a360a6ac30f" xlink:href="sny-20231231.xsd#sny_NumberOfDrugTargetsUnderCollaborationAgreement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_NumberOfDrugTargetsUnderCollaborationAgreement_817bc53e-1ba2-4950-92b9-8a360a6ac30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement_a4351099-06e8-49b0-9cb3-37c7ff5d5b94" xlink:href="sny-20231231.xsd#sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement_a4351099-06e8-49b0-9cb3-37c7ff5d5b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_b5c5726d-ad18-4e8b-9237-08d959dcd8ad" xlink:href="sny-20231231.xsd#sny_PercentageOfProfitShareOnCounterpartiesProfit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_PercentageOfProfitShareOnCounterpartiesProfit_b5c5726d-ad18-4e8b-9237-08d959dcd8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_379841eb-c388-45c3-b588-2d4eb256e38d" xlink:href="sny-20231231.xsd#sny_PercentageOfCumulativeDevelopmentCostsReimbursed"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_PercentageOfCumulativeDevelopmentCostsReimbursed_379841eb-c388-45c3-b588-2d4eb256e38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsReceivedForDevelopmentCosts_74396709-72c9-4f51-8385-a7a44184ddc9" xlink:href="sny-20231231.xsd#sny_CommitmentsReceivedForDevelopmentCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CommitmentsReceivedForDevelopmentCosts_74396709-72c9-4f51-8385-a7a44184ddc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CumulativeDevelopmentCostsIncurred_7d702a53-1be6-41d2-89a9-1592a8840ae1" xlink:href="sny-20231231.xsd#sny_CumulativeDevelopmentCostsIncurred"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_CumulativeDevelopmentCostsIncurred_7d702a53-1be6-41d2-89a9-1592a8840ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVentures_f2f96706-e70c-4622-a0d3-7e11567b3b85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInJointVentures"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_ifrs-full_InvestmentsInJointVentures_f2f96706-e70c-4622-a0d3-7e11567b3b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany_f03844e5-bc0b-4ce5-81ea-2cfb61b839c4" xlink:href="sny-20231231.xsd#sny_PercentageOfFutureDevelopmentExpenseFundedByCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany_f03844e5-bc0b-4ce5-81ea-2cfb61b839c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty_4de6ee02-4b38-4205-8d22-c5bbdfcc649d" xlink:href="sny-20231231.xsd#sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty_4de6ee02-4b38-4205-8d22-c5bbdfcc649d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmountsPayablePartnersInCollaborationAgreements_d0decb42-bd00-46ca-8a24-2a97d693c72c" xlink:href="sny-20231231.xsd#sny_AmountsPayablePartnersInCollaborationAgreements"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_AmountsPayablePartnersInCollaborationAgreements_d0decb42-bd00-46ca-8a24-2a97d693c72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TransferPercentageOfPandemicVaccines_b13b9aff-96e6-405c-b35d-e4748346567b" xlink:href="sny-20231231.xsd#sny_TransferPercentageOfPandemicVaccines"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_TransferPercentageOfPandemicVaccines_b13b9aff-96e6-405c-b35d-e4748346567b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReservePercentageOfPandemicVaccines_734dde7a-03fc-4a0e-8702-553eb196d758" xlink:href="sny-20231231.xsd#sny_ReservePercentageOfPandemicVaccines"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_ReservePercentageOfPandemicVaccines_734dde7a-03fc-4a0e-8702-553eb196d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_dcfd2264-49fd-4e19-93c0-309f91014c9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UndrawnBorrowingFacilities"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_dcfd2264-49fd-4e19-93c0-309f91014c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments_1366f4ea-5f8a-4cf4-beda-67a34ea9ab86" xlink:href="sny-20231231.xsd#sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems_d4855f77-3202-428a-9317-7c75f1f03f0c" xlink:to="loc_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments_1366f4ea-5f8a-4cf4-beda-67a34ea9ab86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_5ab418fb-ea7b-4c45-8ab9-3dac3215ec51" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLineOfCreditFacilityTable_9b4a1e2c-5c48-411d-a77d-f49e375d479e" xlink:href="sny-20231231.xsd#sny_DisclosureOfLineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_5ab418fb-ea7b-4c45-8ab9-3dac3215ec51" xlink:to="loc_sny_DisclosureOfLineOfCreditFacilityTable_9b4a1e2c-5c48-411d-a77d-f49e375d479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_d965546c-fb67-429e-8bc2-ee13636315e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLineOfCreditFacilityTable_9b4a1e2c-5c48-411d-a77d-f49e375d479e" xlink:to="loc_ifrs-full_MaturityAxis_d965546c-fb67-429e-8bc2-ee13636315e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_d965546c-fb67-429e-8bc2-ee13636315e6" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_b75ff6cf-e263-4951-ad69-d3fb6d1ce7f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_b75ff6cf-e263-4951-ad69-d3fb6d1ce7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_26295da7-3971-46ea-b43c-d33c5c96558d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_26295da7-3971-46ea-b43c-d33c5c96558d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_c4d80b6a-da52-4cb0-bc63-61a028aaaa06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_c4d80b6a-da52-4cb0-bc63-61a028aaaa06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_781e6033-d77e-4b76-b37a-0e8f764d599a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_cc79a666-949b-4904-a8f4-5c82df1bedb0" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_781e6033-d77e-4b76-b37a-0e8f764d599a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLineOfCreditFacilityLineItems_629859f2-381e-4ef4-9246-2a848f3f1764" xlink:href="sny-20231231.xsd#sny_DisclosureOfLineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLineOfCreditFacilityTable_9b4a1e2c-5c48-411d-a77d-f49e375d479e" xlink:to="loc_sny_DisclosureOfLineOfCreditFacilityLineItems_629859f2-381e-4ef4-9246-2a848f3f1764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_d98c89f9-84a5-4eb8-b1d4-617a50657852" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UndrawnBorrowingFacilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLineOfCreditFacilityLineItems_629859f2-381e-4ef4-9246-2a848f3f1764" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_d98c89f9-84a5-4eb8-b1d4-617a50657852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_fd78c815-f815-4645-8ed3-49e95f88476d" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfGuaranteesTable_e60ab289-6098-40bc-98b9-4db91013a560" xlink:href="sny-20231231.xsd#sny_DisclosureOfGuaranteesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_fd78c815-f815-4645-8ed3-49e95f88476d" xlink:to="loc_sny_DisclosureOfGuaranteesTable_e60ab289-6098-40bc-98b9-4db91013a560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_43c6e663-a5d7-42c5-b9a7-4b5b6527c342" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfGuaranteesTable_e60ab289-6098-40bc-98b9-4db91013a560" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_43c6e663-a5d7-42c5-b9a7-4b5b6527c342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_7372a2b3-c1e2-43c1-9863-6f750f7677dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_43c6e663-a5d7-42c5-b9a7-4b5b6527c342" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_7372a2b3-c1e2-43c1-9863-6f750f7677dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GuaranteesReceivedMember_72619669-2348-49b0-ab78-8bd28bc68988" xlink:href="sny-20231231.xsd#sny_GuaranteesReceivedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_7372a2b3-c1e2-43c1-9863-6f750f7677dc" xlink:to="loc_sny_GuaranteesReceivedMember_72619669-2348-49b0-ab78-8bd28bc68988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GuaranteesGivenMember_d85868bb-353c-4fa4-a631-5c0c10169fd2" xlink:href="sny-20231231.xsd#sny_GuaranteesGivenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GuaranteesReceivedMember_72619669-2348-49b0-ab78-8bd28bc68988" xlink:to="loc_sny_GuaranteesGivenMember_d85868bb-353c-4fa4-a631-5c0c10169fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember_26ff1431-3cc9-4543-a301-7b52fb84d3a1" xlink:href="sny-20231231.xsd#sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GuaranteesGivenMember_d85868bb-353c-4fa4-a631-5c0c10169fd2" xlink:to="loc_sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember_26ff1431-3cc9-4543-a301-7b52fb84d3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGuaranteesGivenMember_57a6b8e8-1726-4ca0-82f5-1cd7a8850bf0" xlink:href="sny-20231231.xsd#sny_OtherGuaranteesGivenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GuaranteesGivenMember_d85868bb-353c-4fa4-a631-5c0c10169fd2" xlink:to="loc_sny_OtherGuaranteesGivenMember_57a6b8e8-1726-4ca0-82f5-1cd7a8850bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfGuaranteesLineItems_18ff4301-4756-47dd-934e-d46d77b34e1d" xlink:href="sny-20231231.xsd#sny_DisclosureOfGuaranteesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfGuaranteesTable_e60ab289-6098-40bc-98b9-4db91013a560" xlink:to="loc_sny_DisclosureOfGuaranteesLineItems_18ff4301-4756-47dd-934e-d46d77b34e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_3a96713a-089c-410a-ab98-7f5fffc43139" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfGuaranteesLineItems_18ff4301-4756-47dd-934e-d46d77b34e1d" xlink:to="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_3a96713a-089c-410a-ab98-7f5fffc43139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/LegalandarbitralproceedingsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#LegalandarbitralproceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/LegalandarbitralproceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_22b099da-da75-41ea-89c5-0c2b4128108b" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:href="sny-20231231.xsd#sny_DisclosureOfLegalAndArbitralProceedingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_22b099da-da75-41ea-89c5-0c2b4128108b" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsAxis_34dc58f5-c4ed-434d-b097-b6c143d6ae44" xlink:href="sny-20231231.xsd#sny_LegalAndArbitralProceedingsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_sny_LegalAndArbitralProceedingsAxis_34dc58f5-c4ed-434d-b097-b6c143d6ae44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:href="sny-20231231.xsd#sny_LegalAndArbitralProceedingsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsAxis_34dc58f5-c4ed-434d-b097-b6c143d6ae44" xlink:to="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurHepatitisBVaccineMember_091e213d-3f23-47d3-b928-d113faebb14f" xlink:href="sny-20231231.xsd#sny_SanofiPasteurHepatitisBVaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_SanofiPasteurHepatitisBVaccineMember_091e213d-3f23-47d3-b928-d113faebb14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereProductLitigationInTheUSMember_af05690b-d3a2-4341-9d31-2ae936d54743" xlink:href="sny-20231231.xsd#sny_TaxotereProductLitigationInTheUSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_TaxotereProductLitigationInTheUSMember_af05690b-d3a2-4341-9d31-2ae936d54743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember_95a1c260-5e4e-495d-8f35-c33adc266f21" xlink:href="sny-20231231.xsd#sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember_95a1c260-5e4e-495d-8f35-c33adc266f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacLitigationInTheUSMember_75b481ca-7145-42d4-80fa-dbfcf1af3fcc" xlink:href="sny-20231231.xsd#sny_ZantacLitigationInTheUSMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_ZantacLitigationInTheUSMember_75b481ca-7145-42d4-80fa-dbfcf1af3fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ZantacLitigationInCanadaMember_a2430e47-cb14-4a90-9877-4c43c3137218" xlink:href="sny-20231231.xsd#sny_ZantacLitigationInCanadaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_ZantacLitigationInCanadaMember_a2430e47-cb14-4a90-9877-4c43c3137218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GoldBondProductLitigationInTheUSMember_ee515140-2697-44c4-9b54-05234e9c8ac7" xlink:href="sny-20231231.xsd#sny_GoldBondProductLitigationInTheUSMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_GoldBondProductLitigationInTheUSMember_ee515140-2697-44c4-9b54-05234e9c8ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInFranceMember_34931760-980b-4a98-b3bd-ad38bf1ac157" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInFranceMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInFranceMember_34931760-980b-4a98-b3bd-ad38bf1ac157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInSwitzerlandMember_55f3e6ae-0601-42f9-9bf9-490430931518" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInSwitzerlandMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInSwitzerlandMember_55f3e6ae-0601-42f9-9bf9-490430931518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInSpainMember_e0a4229a-823d-4eb0-85bc-a71b1c3acde6" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInSpainMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInSpainMember_e0a4229a-823d-4eb0-85bc-a71b1c3acde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInBelgiumMember_cd9de0a9-93eb-4af9-be42-aa35e36899a5" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInBelgiumMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInBelgiumMember_cd9de0a9-93eb-4af9-be42-aa35e36899a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInIrelandMember_e16dff60-6196-44f1-85ab-3316f0299194" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInIrelandMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInIrelandMember_e16dff60-6196-44f1-85ab-3316f0299194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInGreatBritainMember_3d8c9417-94c0-42f3-8109-8dc091bde888" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInGreatBritainMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInGreatBritainMember_3d8c9417-94c0-42f3-8109-8dc091bde888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DepakineProductLitigationInNorthernIrelandMember_f46ac8db-4e3d-435a-93c7-77521037c983" xlink:href="sny-20231231.xsd#sny_DepakineProductLitigationInNorthernIrelandMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DepakineProductLitigationInNorthernIrelandMember_f46ac8db-4e3d-435a-93c7-77521037c983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DengvaxiaProductLitigationInThePhilippinesMember_a7239cf2-31e7-45e8-a93b-e4354360c66a" xlink:href="sny-20231231.xsd#sny_DengvaxiaProductLitigationInThePhilippinesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_DengvaxiaProductLitigationInThePhilippinesMember_a7239cf2-31e7-45e8-a93b-e4354360c66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RamiprilCanadaPatentLitigationMember_ef201123-4a49-4b16-ac61-6c6eddfdb7c3" xlink:href="sny-20231231.xsd#sny_RamiprilCanadaPatentLitigationMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_RamiprilCanadaPatentLitigationMember_ef201123-4a49-4b16-ac61-6c6eddfdb7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember_13fe4cf9-7c79-4eac-a3ee-a044bcea3730" xlink:href="sny-20231231.xsd#sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember_13fe4cf9-7c79-4eac-a3ee-a044bcea3730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaRelatedPatentLitigationInTheUSMember_c1785738-678a-432e-91ce-dc904d105125" xlink:href="sny-20231231.xsd#sny_JevtanaRelatedPatentLitigationInTheUSMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_JevtanaRelatedPatentLitigationInTheUSMember_c1785738-678a-432e-91ce-dc904d105125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixLitigationCommonwealthInAustraliaMember_87947178-d970-487f-83e5-088e160bcfc7" xlink:href="sny-20231231.xsd#sny_PlavixLitigationCommonwealthInAustraliaMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_PlavixLitigationCommonwealthInAustraliaMember_87947178-d970-487f-83e5-088e160bcfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_6dffee9d-0e5c-4c74-a9aa-8e50e945a0d8" xlink:href="sny-20231231.xsd#sny_PlavixAttorneyGeneralActionInHawaiiMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_PlavixAttorneyGeneralActionInHawaiiMember_6dffee9d-0e5c-4c74-a9aa-8e50e945a0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixRelatedLitigationInFranceMember_b99fd71f-647e-4a86-afc3-2ccae884214e" xlink:href="sny-20231231.xsd#sny_PlavixRelatedLitigationInFranceMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_PlavixRelatedLitigationInFranceMember_b99fd71f-647e-4a86-afc3-2ccae884214e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_A340BDrugPricingProgramInTheUnitedStatesMember_3ef09bca-53b5-43cd-90f6-7ed14b5c932c" xlink:href="sny-20231231.xsd#sny_A340BDrugPricingProgramInTheUnitedStatesMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_A340BDrugPricingProgramInTheUnitedStatesMember_3ef09bca-53b5-43cd-90f6-7ed14b5c932c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisCropScienceRetainedLiabilitiesMember_734d09a4-312c-46a3-b9bf-faf041376d4f" xlink:href="sny-20231231.xsd#sny_AventisCropScienceRetainedLiabilitiesMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_AventisCropScienceRetainedLiabilitiesMember_734d09a4-312c-46a3-b9bf-faf041376d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservHoechstRetainedLiabilitiesMember_98e088a6-4ce3-4b51-80f4-baef5cfb714e" xlink:href="sny-20231231.xsd#sny_InfraservHoechstRetainedLiabilitiesMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_LegalAndArbitralProceedingsDomain_f87e51df-9a67-4eab-852d-0c02688746be" xlink:to="loc_sny_InfraservHoechstRetainedLiabilitiesMember_98e088a6-4ce3-4b51-80f4-baef5cfb714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantAxis_e965c3c1-3d3f-4386-9bc5-a3b547b1c888" xlink:href="sny-20231231.xsd#sny_DefendantAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_sny_DefendantAxis_e965c3c1-3d3f-4386-9bc5-a3b547b1c888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantsMember_1cad0676-99d6-4247-8132-56df8516c763" xlink:href="sny-20231231.xsd#sny_DefendantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DefendantAxis_e965c3c1-3d3f-4386-9bc5-a3b547b1c888" xlink:to="loc_sny_DefendantsMember_1cad0676-99d6-4247-8132-56df8516c763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeAreDefendantMember_a5452264-27a0-4ad8-85be-77f2307ee314" xlink:href="sny-20231231.xsd#sny_ActionForWhichWeAreDefendantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DefendantsMember_1cad0676-99d6-4247-8132-56df8516c763" xlink:to="loc_sny_ActionForWhichWeAreDefendantMember_a5452264-27a0-4ad8-85be-77f2307ee314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ActionForWhichWeArePlaintiffMember_144bda1b-46a9-4bc2-8c6c-e0bc6f5f08d4" xlink:href="sny-20231231.xsd#sny_ActionForWhichWeArePlaintiffMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DefendantsMember_1cad0676-99d6-4247-8132-56df8516c763" xlink:to="loc_sny_ActionForWhichWeArePlaintiffMember_144bda1b-46a9-4bc2-8c6c-e0bc6f5f08d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DefendantDomain_189d9dcc-cfdb-4bc4-a246-e2c913d592d3" xlink:href="sny-20231231.xsd#sny_DefendantDomain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DefendantAxis_e965c3c1-3d3f-4386-9bc5-a3b547b1c888" xlink:to="loc_sny_DefendantDomain_189d9dcc-cfdb-4bc4-a246-e2c913d592d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_2258cf65-63c3-4383-9ff9-6025636af4d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_2258cf65-63c3-4383-9ff9-6025636af4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_0f555464-dcb6-4212-abad-eaa47c18b33f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2258cf65-63c3-4383-9ff9-6025636af4d3" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_0f555464-dcb6-4212-abad-eaa47c18b33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ContingenciesArisingFromCertainBusinessDivestituresMember_6dca5915-27b2-465a-b5ee-7f8589419187" xlink:href="sny-20231231.xsd#sny_ContingenciesArisingFromCertainBusinessDivestituresMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_0f555464-dcb6-4212-abad-eaa47c18b33f" xlink:to="loc_sny_ContingenciesArisingFromCertainBusinessDivestituresMember_6dca5915-27b2-465a-b5ee-7f8589419187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1e288657-2ca5-492d-8cdb-7c52302515be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1e288657-2ca5-492d-8cdb-7c52302515be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesMember_ab36291c-cc45-4ce2-abef-3e3b830e899f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_1e288657-2ca5-492d-8cdb-7c52302515be" xlink:to="loc_ifrs-full_ContingentLiabilitiesMember_ab36291c-cc45-4ce2-abef-3e3b830e899f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProductLiabilitiesMember_249b0d59-d0b2-4194-a0c3-cf2d175535da" xlink:href="sny-20231231.xsd#sny_ProductLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ContingentLiabilitiesMember_ab36291c-cc45-4ce2-abef-3e3b830e899f" xlink:to="loc_sny_ProductLiabilitiesMember_249b0d59-d0b2-4194-a0c3-cf2d175535da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_823d4030-ebbb-4ce9-90cf-135ecdeac8ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_ifrs-full_RangeAxis_823d4030-ebbb-4ce9-90cf-135ecdeac8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_f3ec29dd-e176-4122-a87c-9254ee2b310b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_823d4030-ebbb-4ce9-90cf-135ecdeac8ee" xlink:to="loc_ifrs-full_RangesMember_f3ec29dd-e176-4122-a87c-9254ee2b310b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_23f6a475-a26f-48d4-b159-613e572ae584" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_f3ec29dd-e176-4122-a87c-9254ee2b310b" xlink:to="loc_srt_MinimumMember_23f6a475-a26f-48d4-b159-613e572ae584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70d28cbf-24c2-4677-9bd8-d6d4b5b334b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_f3ec29dd-e176-4122-a87c-9254ee2b310b" xlink:to="loc_srt_MaximumMember_70d28cbf-24c2-4677-9bd8-d6d4b5b334b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_8f01e581-d3f5-46ab-9c4f-8fb31037e0a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_8f01e581-d3f5-46ab-9c4f-8fb31037e0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_036435f6-87d7-4637-ae93-f27f7d267843" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_8f01e581-d3f5-46ab-9c4f-8fb31037e0a6" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_036435f6-87d7-4637-ae93-f27f7d267843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_Patents1Member_b272bb6c-35d9-4137-a4a9-f5b3b1045ded" xlink:href="sny-20231231.xsd#sny_Patents1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_036435f6-87d7-4637-ae93-f27f7d267843" xlink:to="loc_sny_Patents1Member_b272bb6c-35d9-4137-a4a9-f5b3b1045ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:href="sny-20231231.xsd#sny_DisclosureOfLegalAndArbitralProceedingsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsTable_47913113-aaf3-42f7-9451-814733a6baed" xlink:to="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_21375f95-5483-411b-b312-b706c62ed099" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther_21375f95-5483-411b-b312-b706c62ed099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCurrentProvisionForEnvironmentRisks_67d74fb6-afa4-47e4-ae97-1c4708892577" xlink:href="sny-20231231.xsd#sny_NonCurrentProvisionForEnvironmentRisks"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NonCurrentProvisionForEnvironmentRisks_67d74fb6-afa4-47e4-ae97-1c4708892577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCivilIndividualActions_1f2a9d5e-1d10-439d-9f0a-1471ec9bb96c" xlink:href="sny-20231231.xsd#sny_NumberOfCivilIndividualActions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfCivilIndividualActions_1f2a9d5e-1d10-439d-9f0a-1471ec9bb96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOngoingLawsuits_cc69607b-3b44-4f48-a439-cf2e3957c72f" xlink:href="sny-20231231.xsd#sny_NumberOfOngoingLawsuits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfOngoingLawsuits_cc69607b-3b44-4f48-a439-cf2e3957c72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffs_0a22794c-9c58-418e-87a3-e598cd7beaec" xlink:href="sny-20231231.xsd#sny_NumberOfPlaintiffs"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPlaintiffs_0a22794c-9c58-418e-87a3-e598cd7beaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfBellweatherTrialsHeld_d9df637c-0c26-4065-aabf-b08f864659e0" xlink:href="sny-20231231.xsd#sny_NumberOfBellweatherTrialsHeld"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfBellweatherTrialsHeld_d9df637c-0c26-4065-aabf-b08f864659e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfIndividualCasesSettled_cc61a13d-edd0-4c3b-8f7d-a0acbe3e460f" xlink:href="sny-20231231.xsd#sny_NumberOfIndividualCasesSettled"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfIndividualCasesSettled_cc61a13d-edd0-4c3b-8f7d-a0acbe3e460f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation_4416b53a-2fa9-4bc1-a42d-b531da0b3493" xlink:href="sny-20231231.xsd#sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation_4416b53a-2fa9-4bc1-a42d-b531da0b3493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCancersAssociatedWithDismissedCases_834874fe-41e3-450e-94c0-037dab7ddeb2" xlink:href="sny-20231231.xsd#sny_NumberOfCancersAssociatedWithDismissedCases"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfCancersAssociatedWithDismissedCases_834874fe-41e3-450e-94c0-037dab7ddeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal_9108d191-4d88-4149-98fc-10041d408671" xlink:href="sny-20231231.xsd#sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal_9108d191-4d88-4149-98fc-10041d408671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfComplaintsFiled_6260ab1e-1e66-43c2-8c10-c71ec003a5f4" xlink:href="sny-20231231.xsd#sny_NumberOfComplaintsFiled"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfComplaintsFiled_6260ab1e-1e66-43c2-8c10-c71ec003a5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClassActionLawsuits_bd6f6482-b14d-4f53-8462-35f9faa53492" xlink:href="sny-20231231.xsd#sny_NumberOfClassActionLawsuits"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfClassActionLawsuits_bd6f6482-b14d-4f53-8462-35f9faa53492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOngoingTrials_2eb9562a-1fe3-451d-8ebc-975770b7b3f5" xlink:href="sny-20231231.xsd#sny_NumberOfOngoingTrials"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfOngoingTrials_2eb9562a-1fe3-451d-8ebc-975770b7b3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPeopleExposed_c8da6d10-a126-4624-ab22-3a4825ec53e4" xlink:href="sny-20231231.xsd#sny_NumberOfPeopleExposed"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPeopleExposed_c8da6d10-a126-4624-ab22-3a4825ec53e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfLawsuitsRuledOnMerit_eb769a23-7146-4248-970e-4459e25bc31f" xlink:href="sny-20231231.xsd#sny_NumberOfLawsuitsRuledOnMerit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfLawsuitsRuledOnMerit_eb769a23-7146-4248-970e-4459e25bc31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfFirstInstanceRulings_3fa177aa-e77a-40a5-b5d9-8f13ed1b1edb" xlink:href="sny-20231231.xsd#sny_NumberOfFirstInstanceRulings"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfFirstInstanceRulings_3fa177aa-e77a-40a5-b5d9-8f13ed1b1edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LitigationAmountPayable_71790136-15bf-4cd2-b92a-e0f7ad880228" xlink:href="sny-20231231.xsd#sny_LitigationAmountPayable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_LitigationAmountPayable_71790136-15bf-4cd2-b92a-e0f7ad880228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfFamiliesWhoFiledACivilClaim_6e3910c1-898f-4f86-ac7d-5d7193839727" xlink:href="sny-20231231.xsd#sny_NumberOfFamiliesWhoFiledACivilClaim"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfFamiliesWhoFiledACivilClaim_6e3910c1-898f-4f86-ac7d-5d7193839727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClaimant_5e71db26-38c3-48f2-88fc-c7064096a373" xlink:href="sny-20231231.xsd#sny_NumberOfClaimant"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfClaimant_5e71db26-38c3-48f2-88fc-c7064096a373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClaimantExposed_807cb4a7-981c-4665-953c-c9fbeb85144d" xlink:href="sny-20231231.xsd#sny_NumberOfClaimantExposed"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfClaimantExposed_807cb4a7-981c-4665-953c-c9fbeb85144d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim_f0e2e2b0-4375-4709-b0ab-a73b312ba498" xlink:href="sny-20231231.xsd#sny_NumberOfClaimantExposedWhoWithdrawedTheClaim"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim_f0e2e2b0-4375-4709-b0ab-a73b312ba498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim_5f027ccf-d918-49bf-9a7b-014a92236e8d" xlink:href="sny-20231231.xsd#sny_NumberOfIndirectVictimWhoWithdrawedTheClaim"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim_5f027ccf-d918-49bf-9a7b-014a92236e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCounterExpertiseExperts_bd6e6389-4ccd-4b51-83e1-8e512bb4a3cb" xlink:href="sny-20231231.xsd#sny_NumberOfCounterExpertiseExperts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfCounterExpertiseExperts_bd6e6389-4ccd-4b51-83e1-8e512bb4a3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfAdministrativeProceedings_a77a1846-ab85-42bb-ad3e-f63260cf6fe3" xlink:href="sny-20231231.xsd#sny_NumberOfAdministrativeProceedings"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfAdministrativeProceedings_a77a1846-ab85-42bb-ad3e-f63260cf6fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfActionDeclaredTimeBarred_659ef074-553b-418f-8fc4-aabd05218238" xlink:href="sny-20231231.xsd#sny_NumberOfActionDeclaredTimeBarred"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfActionDeclaredTimeBarred_659ef074-553b-418f-8fc4-aabd05218238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatientsToIndemnify_37de7cbf-f868-4458-9431-d3c8d24c0e35" xlink:href="sny-20231231.xsd#sny_NumberOfPatientsToIndemnify"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPatientsToIndemnify_37de7cbf-f868-4458-9431-d3c8d24c0e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPreActionProtocolCases_147510b7-6b82-42a7-a06e-d3ffcbd3d677" xlink:href="sny-20231231.xsd#sny_NumberOfPreActionProtocolCases"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPreActionProtocolCases_147510b7-6b82-42a7-a06e-d3ffcbd3d677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCivilClaimsOnGoing_2b6d5cad-1b9c-430a-b320-ac00b241bd74" xlink:href="sny-20231231.xsd#sny_NumberOfCivilClaimsOnGoing"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfCivilClaimsOnGoing_2b6d5cad-1b9c-430a-b320-ac00b241bd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfCases_e4afee00-fb95-46d4-8c21-999eaf561a33" xlink:href="sny-20231231.xsd#sny_NumberOfCases"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfCases_e4afee00-fb95-46d4-8c21-999eaf561a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug_7f4800f2-3fb7-451b-8150-da8ce712e549" xlink:href="sny-20231231.xsd#sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug_7f4800f2-3fb7-451b-8150-da8ce712e549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatentActionsInitiallyFiled_99aec6d8-4da9-490f-9869-f246041bc4a4" xlink:href="sny-20231231.xsd#sny_NumberOfPatentActionsInitiallyFiled"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPatentActionsInitiallyFiled_99aec6d8-4da9-490f-9869-f246041bc4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatentsAllegedlyInfringed_d9023c69-ec29-4551-8172-e28dcd4a1303" xlink:href="sny-20231231.xsd#sny_NumberOfPatentsAllegedlyInfringed"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPatentsAllegedlyInfringed_d9023c69-ec29-4551-8172-e28dcd4a1303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfPatentsCoveringProduct_0b932012-0bf3-4278-8816-1090fdc1e5c4" xlink:href="sny-20231231.xsd#sny_NumberOfPatentsCoveringProduct"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfPatentsCoveringProduct_0b932012-0bf3-4278-8816-1090fdc1e5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs_31fef068-dd1f-46b4-992a-b9a9974ea8d0" xlink:href="sny-20231231.xsd#sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs_31fef068-dd1f-46b4-992a-b9a9974ea8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded_5255d6f5-c155-4f32-ba39-bd044d35d7c9" xlink:href="sny-20231231.xsd#sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded_5255d6f5-c155-4f32-ba39-bd044d35d7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GlobalPenaltyFeeIncurredByDefendants_047b3815-a860-49d1-8ebd-974e6a74a1a7" xlink:href="sny-20231231.xsd#sny_GlobalPenaltyFeeIncurredByDefendants"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_GlobalPenaltyFeeIncurredByDefendants_047b3815-a860-49d1-8ebd-974e6a74a1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PenaltyFeeIncurred_5d533cc0-224b-45a9-a18d-7c4ee1da38d5" xlink:href="sny-20231231.xsd#sny_PenaltyFeeIncurred"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_PenaltyFeeIncurred_5d533cc0-224b-45a9-a18d-7c4ee1da38d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PaymentOfDamagesClaimedByCounterparty_da9d362f-b7f9-4c72-83b4-fd16e92a031a" xlink:href="sny-20231231.xsd#sny_PaymentOfDamagesClaimedByCounterparty"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_PaymentOfDamagesClaimedByCounterparty_da9d362f-b7f9-4c72-83b4-fd16e92a031a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOtherManufacturersInvolvedInProceedings_20e25ac3-dd1b-4d13-9eaa-8c4a10862b09" xlink:href="sny-20231231.xsd#sny_NumberOfOtherManufacturersInvolvedInProceedings"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_NumberOfOtherManufacturersInvolvedInProceedings_20e25ac3-dd1b-4d13-9eaa-8c4a10862b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EquityInvestmentSoldPercentage_372417fe-3150-4b0d-8fba-deb402341abe" xlink:href="sny-20231231.xsd#sny_EquityInvestmentSoldPercentage"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_EquityInvestmentSoldPercentage_372417fe-3150-4b0d-8fba-deb402341abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking_b13023a6-ffa1-4dc5-9e68-d3f3b621263b" xlink:href="sny-20231231.xsd#sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking_b13023a6-ffa1-4dc5-9e68-d3f3b621263b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense_84c0a55d-8954-4c1d-837c-fd329990ea9f" xlink:href="sny-20231231.xsd#sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfLegalAndArbitralProceedingsLineItems_c2cc7e44-2bb3-4298-b01c-f760308f93a1" xlink:to="loc_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense_84c0a55d-8954-4c1d-837c-fd329990ea9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_bc16cdf1-71a1-4a6e-be5e-7c1f5d7b9595" xlink:href="sny-20231231.xsd#sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a65050e-468c-4cb8-ad8f-d65d70226a15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_bc16cdf1-71a1-4a6e-be5e-7c1f5d7b9595" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a65050e-468c-4cb8-ad8f-d65d70226a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d5c2aeb4-9654-481e-86c0-edf51382e316" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a65050e-468c-4cb8-ad8f-d65d70226a15" xlink:to="loc_srt_CounterpartyNameAxis_d5c2aeb4-9654-481e-86c0-edf51382e316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02cad831-b4b5-4ac9-ad0f-b5ae55d09a8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d5c2aeb4-9654-481e-86c0-edf51382e316" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02cad831-b4b5-4ac9-ad0f-b5ae55d09a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MedicaidMember_e1e2352e-1c14-4c58-8e4a-5b0d00889e91" xlink:href="sny-20231231.xsd#sny_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02cad831-b4b5-4ac9-ad0f-b5ae55d09a8e" xlink:to="loc_sny_MedicaidMember_e1e2352e-1c14-4c58-8e4a-5b0d00889e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MedicareMember_ad066566-e978-405e-b2b0-da788c255313" xlink:href="sny-20231231.xsd#sny_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_02cad831-b4b5-4ac9-ad0f-b5ae55d09a8e" xlink:to="loc_sny_MedicareMember_ad066566-e978-405e-b2b0-da788c255313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_8b418b8f-7889-4932-99a7-5ab1ff1454e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a65050e-468c-4cb8-ad8f-d65d70226a15" xlink:to="loc_ifrs-full_GeographicalAreasAxis_8b418b8f-7889-4932-99a7-5ab1ff1454e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_67bdaf8e-c3da-4c52-b196-c54b68fa7fae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_8b418b8f-7889-4932-99a7-5ab1ff1454e9" xlink:to="loc_ifrs-full_GeographicalAreasMember_67bdaf8e-c3da-4c52-b196-c54b68fa7fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_39e1ef87-bb3a-47f4-88c0-fe1f9ab0cc79" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_67bdaf8e-c3da-4c52-b196-c54b68fa7fae" xlink:to="loc_country_US_39e1ef87-bb3a-47f4-88c0-fe1f9ab0cc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_60326fbb-c69c-4e31-8e14-5b1f16ac013c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a65050e-468c-4cb8-ad8f-d65d70226a15" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_60326fbb-c69c-4e31-8e14-5b1f16ac013c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_60326fbb-c69c-4e31-8e14-5b1f16ac013c" xlink:to="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GovernmentAndStateProgramsMember_2d525f42-9a25-4fa4-9295-df9dfc858a7b" xlink:href="sny-20231231.xsd#sny_GovernmentAndStateProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_GovernmentAndStateProgramsMember_2d525f42-9a25-4fa4-9295-df9dfc858a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManagedCareAndGPOProgramsMember_3578c231-20c1-4d96-941b-74ff625c0614" xlink:href="sny-20231231.xsd#sny_ManagedCareAndGPOProgramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_ManagedCareAndGPOProgramsMember_3578c231-20c1-4d96-941b-74ff625c0614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChargebackIncentivesMember_c87c20b0-4c87-4c95-90de-2e04c6137fc2" xlink:href="sny-20231231.xsd#sny_ChargebackIncentivesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_ChargebackIncentivesMember_c87c20b0-4c87-4c95-90de-2e04c6137fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RebatesAndDiscountsMember_8a909ea1-44a2-40df-a7db-9cd83558790b" xlink:href="sny-20231231.xsd#sny_RebatesAndDiscountsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_RebatesAndDiscountsMember_8a909ea1-44a2-40df-a7db-9cd83558790b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SalesReturnMember_f1e039c7-8c20-45df-b0bb-c773acb872de" xlink:href="sny-20231231.xsd#sny_SalesReturnMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_SalesReturnMember_f1e039c7-8c20-45df-b0bb-c773acb872de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherDeductionsMember_23ccf82a-7dae-4c5f-99e7-b6bebd67f092" xlink:href="sny-20231231.xsd#sny_OtherDeductionsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_OtherDeductionsMember_23ccf82a-7dae-4c5f-99e7-b6bebd67f092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ManagedCareMember_bae21d1b-8e94-4256-9f94-daea043ea2f8" xlink:href="sny-20231231.xsd#sny_ManagedCareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_a07347c1-2008-4fb6-abe6-5701cd996eca" xlink:to="loc_sny_ManagedCareMember_bae21d1b-8e94-4256-9f94-daea043ea2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_6a65050e-468c-4cb8-ad8f-d65d70226a15" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForDiscountsRebatesAndSalesReturns_ee1cbe35-64dd-439d-acbe-a50584df8a91" xlink:href="sny-20231231.xsd#sny_ProvisionsForDiscountsRebatesAndSalesReturns"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_ProvisionsForDiscountsRebatesAndSalesReturns_ee1cbe35-64dd-439d-acbe-a50584df8a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns_a8d13c5f-63d3-49c8-8b27-46045b2e13a8" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns_a8d13c5f-63d3-49c8-8b27-46045b2e13a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales_88b6d6f2-6f42-4e6a-b59a-0a69f196e8f8" xlink:href="sny-20231231.xsd#sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales_88b6d6f2-6f42-4e6a-b59a-0a69f196e8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales_967203c6-e6e8-4100-afff-e71c95a57c39" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales_967203c6-e6e8-4100-afff-e71c95a57c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns_cc47839c-e827-4e0b-a408-a55d2d0cd0cf" xlink:href="sny-20231231.xsd#sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns_cc47839c-e827-4e0b-a408-a55d2d0cd0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns_63e40ef6-0882-4421-b45c-1a589e1c5222" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns_63e40ef6-0882-4421-b45c-1a589e1c5222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProvisionsForDiscountsRebatesAndSalesReturns_986d8169-66f7-423a-9ab2-be289609c83b" xlink:href="sny-20231231.xsd#sny_ProvisionsForDiscountsRebatesAndSalesReturns"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_bb6237cf-6ebc-4944-be8b-cc8eba42beaa" xlink:to="loc_sny_ProvisionsForDiscountsRebatesAndSalesReturns_986d8169-66f7-423a-9ab2-be289609c83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PersonnelcostsSummaryofPersonalCostsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeBenefitsAbstract_ca164530-88ca-4465-a6d1-1115281382d5" xlink:href="sny-20231231.xsd#sny_EmployeeBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_1d0fc44d-9aeb-4158-b439-9f199cf9816f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_EmployeeBenefitsAbstract_ca164530-88ca-4465-a6d1-1115281382d5" xlink:to="loc_ifrs-full_WagesAndSalaries_1d0fc44d-9aeb-4158-b439-9f199cf9816f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions_c2b765c1-3231-4eb8-9e38-e0cdd13a62ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_EmployeeBenefitsAbstract_ca164530-88ca-4465-a6d1-1115281382d5" xlink:to="loc_ifrs-full_SocialSecurityContributions_c2b765c1-3231-4eb8-9e38-e0cdd13a62ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_5b310e1a-9d87-4d6d-928f-84fa30c976a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_EmployeeBenefitsAbstract_ca164530-88ca-4465-a6d1-1115281382d5" xlink:to="loc_ifrs-full_OtherEmployeeExpense_5b310e1a-9d87-4d6d-928f-84fa30c976a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_b1694b0b-21b0-4741-97ca-06e1334908f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_EmployeeBenefitsAbstract_ca164530-88ca-4465-a6d1-1115281382d5" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_b1694b0b-21b0-4741-97ca-06e1334908f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PersonnelcostsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PersonnelcostsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PersonnelcostsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_EmployeeBenefitsAbstract_29c8821b-2d86-4caf-835e-49c569342663" xlink:href="sny-20231231.xsd#sny_EmployeeBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_e6e0e044-103f-4f13-a265-1f6a8a1d2c33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_EmployeeBenefitsAbstract_29c8821b-2d86-4caf-835e-49c569342663" xlink:to="loc_ifrs-full_NumberOfEmployees_e6e0e044-103f-4f13-a265-1f6a8a1d2c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtheroperatingincomeDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OtheroperatingincomeDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtheroperatingincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fad91ae5-ce01-40fd-b6c0-632adab51d08" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeTable_6325dafb-b0eb-4ed2-aa12-ed87638b51a0" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fad91ae5-ce01-40fd-b6c0-632adab51d08" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeTable_6325dafb-b0eb-4ed2-aa12-ed87638b51a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2cffbbca-b52d-4e45-b5fc-8391f975c331" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeTable_6325dafb-b0eb-4ed2-aa12-ed87638b51a0" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2cffbbca-b52d-4e45-b5fc-8391f975c331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_d56677a8-de37-4f44-b0f2-93c4ebaf9098" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_2cffbbca-b52d-4e45-b5fc-8391f975c331" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_d56677a8-de37-4f44-b0f2-93c4ebaf9098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_80b0753c-283e-4530-92d1-aac7f8f6e282" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_d56677a8-de37-4f44-b0f2-93c4ebaf9098" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_80b0753c-283e-4530-92d1-aac7f8f6e282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DaiichiSankyoMember_13fe255a-111c-414e-a61b-fd0922aaf4fa" xlink:href="sny-20231231.xsd#sny_DaiichiSankyoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_d56677a8-de37-4f44-b0f2-93c4ebaf9098" xlink:to="loc_sny_DaiichiSankyoMember_13fe255a-111c-414e-a61b-fd0922aaf4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6f75f28b-20b8-4f44-8319-48f4220c987b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeTable_6325dafb-b0eb-4ed2-aa12-ed87638b51a0" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6f75f28b-20b8-4f44-8319-48f4220c987b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_2a442ac7-16f1-4e79-b201-a27b4cd4d3a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_6f75f28b-20b8-4f44-8319-48f4220c987b" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_2a442ac7-16f1-4e79-b201-a27b4cd4d3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_18b5fe57-5b8f-4d5e-876e-dc44da064f03" xlink:href="sny-20231231.xsd#sny_RegeneronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_2a442ac7-16f1-4e79-b201-a27b4cd4d3a5" xlink:to="loc_sny_RegeneronMember_18b5fe57-5b8f-4d5e-876e-dc44da064f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Axis_05bf4f04-20e1-4a9e-89bc-5a8df6a5b6da" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Axis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeTable_6325dafb-b0eb-4ed2-aa12-ed87638b51a0" xlink:to="loc_sny_IncomeStatementLocation1Axis_05bf4f04-20e1-4a9e-89bc-5a8df6a5b6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Domain_55cc5d5e-c5fe-4a5a-b3cd-616af4e66999" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeStatementLocation1Axis_05bf4f04-20e1-4a9e-89bc-5a8df6a5b6da" xlink:to="loc_sny_IncomeStatementLocation1Domain_55cc5d5e-c5fe-4a5a-b3cd-616af4e66999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpense1Member_107d13c1-bcf4-4dde-8966-d8fc157356e5" xlink:href="sny-20231231.xsd#sny_OtherOperatingIncomeExpense1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeStatementLocation1Domain_55cc5d5e-c5fe-4a5a-b3cd-616af4e66999" xlink:to="loc_sny_OtherOperatingIncomeExpense1Member_107d13c1-bcf4-4dde-8966-d8fc157356e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeLineItems_0249197d-8776-415c-9096-e4681f838929" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeTable_6325dafb-b0eb-4ed2-aa12-ed87638b51a0" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeLineItems_0249197d-8776-415c-9096-e4681f838929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_48f8f32b-9f3c-419e-bb22-6d5803d3a18a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeLineItems_0249197d-8776-415c-9096-e4681f838929" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_48f8f32b-9f3c-419e-bb22-6d5803d3a18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsOnDivestmentOfProducts_caa073af-b6a0-432b-9032-0061250366e7" xlink:href="sny-20231231.xsd#sny_GainsOnDivestmentOfProducts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeLineItems_0249197d-8776-415c-9096-e4681f838929" xlink:to="loc_sny_GainsOnDivestmentOfProducts_caa073af-b6a0-432b-9032-0061250366e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtheroperatingexpensesAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OtheroperatingexpensesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtheroperatingexpensesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_48d300bd-1cda-4419-8453-11a11b9454dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_de9793fd-3a4e-4015-aa5c-46c723cb1c42" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_48d300bd-1cda-4419-8453-11a11b9454dd" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_de9793fd-3a4e-4015-aa5c-46c723cb1c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OtheroperatingexpensesOtherIncomeandExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_68f93821-9560-4a6f-9d04-74e619ac12a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_68f93821-9560-4a6f-9d04-74e619ac12a5" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_27585492-052d-4f1e-aab9-a7b42482b668" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:to="loc_srt_CounterpartyNameAxis_27585492-052d-4f1e-aab9-a7b42482b668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91ce62d7-3f0c-4b7d-a783-1fe5c1d4e67a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_27585492-052d-4f1e-aab9-a7b42482b668" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91ce62d7-3f0c-4b7d-a783-1fe5c1d4e67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesAllianceMember_d28c1b7b-07bc-4f51-a737-7f8562b28104" xlink:href="sny-20231231.xsd#sny_AntibodiesAllianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91ce62d7-3f0c-4b7d-a783-1fe5c1d4e67a" xlink:to="loc_sny_AntibodiesAllianceMember_d28c1b7b-07bc-4f51-a737-7f8562b28104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunooncologyAllianceMember_381023e2-6bc4-4be5-a20b-16574d842310" xlink:href="sny-20231231.xsd#sny_ImmunooncologyAllianceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91ce62d7-3f0c-4b7d-a783-1fe5c1d4e67a" xlink:to="loc_sny_ImmunooncologyAllianceMember_381023e2-6bc4-4be5-a20b-16574d842310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OthersCounterpartyMember_b1fdab9d-1191-4f2f-996f-a1fdcecc14fc" xlink:href="sny-20231231.xsd#sny_OthersCounterpartyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91ce62d7-3f0c-4b7d-a783-1fe5c1d4e67a" xlink:to="loc_sny_OthersCounterpartyMember_b1fdab9d-1191-4f2f-996f-a1fdcecc14fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Axis_1e72930d-a5b0-45d7-ba45-d15877d77fa7" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Axis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:to="loc_sny_IncomeStatementLocation1Axis_1e72930d-a5b0-45d7-ba45-d15877d77fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:href="sny-20231231.xsd#sny_IncomeStatementLocation1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeStatementLocation1Axis_1e72930d-a5b0-45d7-ba45-d15877d77fa7" xlink:to="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_8b0992d7-6d9f-4ee2-b9a1-2d4f2762224d" xlink:href="sny-20231231.xsd#sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember_8b0992d7-6d9f-4ee2-b9a1-2d4f2762224d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_0e23bc1e-f637-4c7d-b534-681edb1228ad" xlink:href="sny-20231231.xsd#sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:to="loc_sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember_0e23bc1e-f637-4c7d-b534-681edb1228ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommercializationRelatedExpensesMember_1e5eabc9-2631-4e1e-a098-8abe6381b817" xlink:href="sny-20231231.xsd#sny_CommercializationRelatedExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:to="loc_sny_CommercializationRelatedExpensesMember_1e5eabc9-2631-4e1e-a098-8abe6381b817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherOperatingIncomeExpense1Member_746374e0-15b4-4f8d-8795-96f8edc66e40" xlink:href="sny-20231231.xsd#sny_OtherOperatingIncomeExpense1Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeStatementLocation1Domain_6ccf5a20-8013-4cbc-8fa4-d155e0ee289c" xlink:to="loc_sny_OtherOperatingIncomeExpense1Member_746374e0-15b4-4f8d-8795-96f8edc66e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_0ece645b-7065-4baf-bda8-df92f4b30252" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_0ece645b-7065-4baf-bda8-df92f4b30252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_b0322897-6e4c-44f4-bdaf-558b18cb6b5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_0ece645b-7065-4baf-bda8-df92f4b30252" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_b0322897-6e4c-44f4-bdaf-558b18cb6b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronMember_00278c35-b3f6-4c26-b8ab-6bdb611cecbd" xlink:href="sny-20231231.xsd#sny_RegeneronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_b0322897-6e4c-44f4-bdaf-558b18cb6b5c" xlink:to="loc_sny_RegeneronMember_00278c35-b3f6-4c26-b8ab-6bdb611cecbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_4047a23d-f238-4384-98de-7031eb8ad78f" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:to="loc_sny_PrincipalAlliancesAxis_4047a23d-f238-4384-98de-7031eb8ad78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_6bf9f6f6-6560-45e1-bf04-afda85123dec" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_4047a23d-f238-4384-98de-7031eb8ad78f" xlink:to="loc_sny_PrincipalAlliancesDomain_6bf9f6f6-6560-45e1-bf04-afda85123dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AntibodiesCollaborationAgreementMember_66c99143-555b-4691-bc50-71c9537bd950" xlink:href="sny-20231231.xsd#sny_AntibodiesCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_6bf9f6f6-6560-45e1-bf04-afda85123dec" xlink:to="loc_sny_AntibodiesCollaborationAgreementMember_66c99143-555b-4691-bc50-71c9537bd950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_8e98ebdd-d930-483e-8208-34a3451e2e7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:to="loc_ifrs-full_CounterpartiesAxis_8e98ebdd-d930-483e-8208-34a3451e2e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_465acba7-f2ad-4f76-b717-089e07c823d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_8e98ebdd-d930-483e-8208-34a3451e2e7a" xlink:to="loc_ifrs-full_CounterpartiesMember_465acba7-f2ad-4f76-b717-089e07c823d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_07103fd8-23be-42ee-a719-0d1b85af8ef8" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_465acba7-f2ad-4f76-b717-089e07c823d3" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_07103fd8-23be-42ee-a719-0d1b85af8ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:href="sny-20231231.xsd#sny_DisclosureOfOtherOperatingIncomeExpensesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesTable_e3580afe-5b44-4ab4-8cca-fa68571d1ccb" xlink:to="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_f0dd2a7b-21a2-4677-a762-b82e8142af73" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_f0dd2a7b-21a2-4677-a762-b82e8142af73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_bb455d1e-21a6-49bd-9648-6068cc4531cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_bb455d1e-21a6-49bd-9648-6068cc4531cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_a2ddc426-2912-4537-ada8-f34c57c9e5d9" xlink:href="sny-20231231.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_a2ddc426-2912-4537-ada8-f34c57c9e5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_ab0c72f8-48a0-45be-931d-ed6090381355" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_ab0c72f8-48a0-45be-931d-ed6090381355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CommitmentsReceivedForDevelopmentCosts_48e95fb0-4335-45b2-9abd-3822eee3f1a1" xlink:href="sny-20231231.xsd#sny_CommitmentsReceivedForDevelopmentCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems_e4fbec86-145a-4f8a-b1c2-f12c6b2be9c2" xlink:to="loc_sny_CommitmentsReceivedForDevelopmentCosts_48e95fb0-4335-45b2-9abd-3822eee3f1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_19e8f3d0-81e3-479a-93aa-bd947990e43b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_1d77ab0c-f174-4c06-ae53-e0bc962defcc" xlink:href="sny-20231231.xsd#sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_19e8f3d0-81e3-479a-93aa-bd947990e43b" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses_1d77ab0c-f174-4c06-ae53-e0bc962defcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_d468118b-6c94-4d57-99a0-d169b2cbaffe" xlink:href="sny-20231231.xsd#sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_19e8f3d0-81e3-479a-93aa-bd947990e43b" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories_d468118b-6c94-4d57-99a0-d169b2cbaffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_5613fe41-b502-4458-834e-2a50ae24cc78" xlink:href="sny-20231231.xsd#sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_19e8f3d0-81e3-479a-93aa-bd947990e43b" xlink:to="loc_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts_5613fe41-b502-4458-834e-2a50ae24cc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherRestructuringCost_38bfcb54-d5f9-48dd-8fcd-0f4d4901a1b3" xlink:href="sny-20231231.xsd#sny_OtherRestructuringCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_19e8f3d0-81e3-479a-93aa-bd947990e43b" xlink:to="loc_sny_OtherRestructuringCost_38bfcb54-d5f9-48dd-8fcd-0f4d4901a1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_4185d450-ae83-4292-9a2a-801b03d44eeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_19e8f3d0-81e3-479a-93aa-bd947990e43b" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_4185d450-ae83-4292-9a2a-801b03d44eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#RestructuringcostsandsimilaritemsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RestructuringcostsandsimilaritemsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ad32554d-f78e-48d4-bfca-f38f355b5861" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncreaseDecreaseInExpenseOfRestructuringActivities_0f60d012-f79f-4fa6-91af-961f6647e0ea" xlink:href="sny-20231231.xsd#sny_IncreaseDecreaseInExpenseOfRestructuringActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ad32554d-f78e-48d4-bfca-f38f355b5861" xlink:to="loc_sny_IncreaseDecreaseInExpenseOfRestructuringActivities_0f60d012-f79f-4fa6-91af-961f6647e0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#OthergainsandlossesandlitigationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_6bab5666-f4a8-4d41-b57a-33cbd21fd621" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_f636f708-878c-4e56-b286-27112a548ba5" xlink:href="sny-20231231.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_6bab5666-f4a8-4d41-b57a-33cbd21fd621" xlink:to="loc_sny_OtherGainsLossesAndLitigation_f636f708-878c-4e56-b286-27112a548ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#FinancialexpensesandincomeDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialexpensesandincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ee46798a-97a3-4c79-afdc-cca9122096d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e05c8efb-a80d-49f7-96a5-8cc4b1f5f064" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ee46798a-97a3-4c79-afdc-cca9122096d8" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e05c8efb-a80d-49f7-96a5-8cc4b1f5f064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsAxis_f618d9f1-236a-4cba-9774-4f5c371983cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e05c8efb-a80d-49f7-96a5-8cc4b1f5f064" xlink:to="loc_ifrs-full_HedgedItemsAxis_f618d9f1-236a-4cba-9774-4f5c371983cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgedItemsMember_3e7ba616-38e8-4ae2-89be-c4b9d34b12c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsAxis_f618d9f1-236a-4cba-9774-4f5c371983cd" xlink:to="loc_ifrs-full_HedgedItemsMember_3e7ba616-38e8-4ae2-89be-c4b9d34b12c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestRateAndCurrencyDerivativesMember_1fae7689-b299-4cf9-82ff-e25f9a2aacd4" xlink:href="sny-20231231.xsd#sny_InterestRateAndCurrencyDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgedItemsMember_3e7ba616-38e8-4ae2-89be-c4b9d34b12c1" xlink:to="loc_sny_InterestRateAndCurrencyDerivativesMember_1fae7689-b299-4cf9-82ff-e25f9a2aacd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:href="sny-20231231.xsd#sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable_e05c8efb-a80d-49f7-96a5-8cc4b1f5f064" xlink:to="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_57cec60a-503f-4c23-bc12-34d4505f7cbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_57cec60a-503f-4c23-bc12-34d4505f7cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestIncome_6ec19886-bff1-4244-8a53-2d5b87864c3c" xlink:href="sny-20231231.xsd#sny_InterestIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_InterestIncome_6ec19886-bff1-4244-8a53-2d5b87864c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CostOfDebtNet_a936ce8e-e93a-47f6-a1ce-642e61b31b71" xlink:href="sny-20231231.xsd#sny_CostOfDebtNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_CostOfDebtNet_a936ce8e-e93a-47f6-a1ce-642e61b31b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonOperatingForeignExchangeGainsLosses_31d62177-a158-4dc6-9e0d-a2230762b08c" xlink:href="sny-20231231.xsd#sny_NonOperatingForeignExchangeGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_NonOperatingForeignExchangeGainsLosses_31d62177-a158-4dc6-9e0d-a2230762b08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_613a3a3f-66c7-4716-a20b-6397fc7177be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions_613a3a3f-66c7-4716-a20b-6397fc7177be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NetInterestCostRelatedToEmployeeBenefits_85caa58b-1365-4117-ac70-8d72bb8a9b64" xlink:href="sny-20231231.xsd#sny_NetInterestCostRelatedToEmployeeBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_NetInterestCostRelatedToEmployeeBenefits_85caa58b-1365-4117-ac70-8d72bb8a9b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_7640f2f2-041c-4f97-ae43-57265b892d6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets_7640f2f2-041c-4f97-ae43-57265b892d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_86355e2d-a23f-4b60-876c-77712eb073d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_86355e2d-a23f-4b60-876c-77712eb073d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncomeCost_c759c974-2334-4e4e-b14e-5ccf85e698a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_OtherFinanceIncomeCost_c759c974-2334-4e4e-b14e-5ccf85e698a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_b4da615e-6ec9-4910-b74b-b38a9637a4a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_ifrs-full_FinanceIncomeCost_b4da615e-6ec9-4910-b74b-b38a9637a4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_a01bb568-e1c0-4652-b314-43d4db788d7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinanceIncomeCost_b4da615e-6ec9-4910-b74b-b38a9637a4a9" xlink:to="loc_ifrs-full_FinanceCosts_a01bb568-e1c0-4652-b314-43d4db788d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_6a3a366c-8890-49ac-8c3b-5f9fe1285e68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinanceIncomeCost_b4da615e-6ec9-4910-b74b-b38a9637a4a9" xlink:to="loc_ifrs-full_FinanceIncome_6a3a366c-8890-49ac-8c3b-5f9fe1285e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnDerivativesUsedToManageDebt_eaa0836a-17f9-4c9c-91aa-db5548121e3d" xlink:href="sny-20231231.xsd#sny_GainsLossesOnDerivativesUsedToManageDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_GainsLossesOnDerivativesUsedToManageDebt_eaa0836a-17f9-4c9c-91aa-db5548121e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents_bbd674ff-d35b-4f4b-8100-9124283814f5" xlink:href="sny-20231231.xsd#sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents_bbd674ff-d35b-4f4b-8100-9124283814f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_6b1cf5bb-c5fe-448d-abe7-5f69b11201f4" xlink:href="sny-20231231.xsd#sny_LiabilityRecognisedForEstimatedFutureRoyalties"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems_6c2bf87b-6fe8-4db2-aa72-d2d5ca7b81a1" xlink:to="loc_sny_LiabilityRecognisedForEstimatedFutureRoyalties_6b1cf5bb-c5fe-448d-abe7-5f69b11201f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1" xlink:type="simple" xlink:href="sny-20231231.xsd#FinancialexpensesandincomeDetails_1"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxesAbstract_803f28ae-7cf2-4913-873f-fe165e390f6e" xlink:href="sny-20231231.xsd#sny_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_a4087348-e361-4e9c-b3c0-3e60241b53e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_803f28ae-7cf2-4913-873f-fe165e390f6e" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_a4087348-e361-4e9c-b3c0-3e60241b53e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_81fe5bd6-d172-4601-b1c9-13aaaeb3c9e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_803f28ae-7cf2-4913-873f-fe165e390f6e" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_81fe5bd6-d172-4601-b1c9-13aaaeb3c9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_cefa428d-f18f-4442-b6de-a65a849704a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_803f28ae-7cf2-4913-873f-fe165e390f6e" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_cefa428d-f18f-4442-b6de-a65a849704a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_c849199b-2a98-4d6e-9857-62b0b97340b8" xlink:href="sny-20231231.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_803f28ae-7cf2-4913-873f-fe165e390f6e" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_c849199b-2a98-4d6e-9857-62b0b97340b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeTaxesAbstract_467b622e-6413-4c95-8b2c-03235909d353" xlink:href="sny-20231231.xsd#sny_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_b99bee0b-f624-455e-af60-f9a9423db5e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_467b622e-6413-4c95-8b2c-03235909d353" xlink:to="loc_ifrs-full_ApplicableTaxRate_b99bee0b-f624-455e-af60-f9a9423db5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_8559e796-2b2d-41e7-b608-eb33f1653a62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfForeignTaxRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_467b622e-6413-4c95-8b2c-03235909d353" xlink:to="loc_ifrs-full_TaxRateEffectOfForeignTaxRates_8559e796-2b2d-41e7-b608-eb33f1653a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes_ab426d13-c0c7-406c-9ce8-b5403ca90e8f" xlink:href="sny-20231231.xsd#sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_467b622e-6413-4c95-8b2c-03235909d353" xlink:to="loc_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes_ab426d13-c0c7-406c-9ce8-b5403ca90e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_e3c76c4b-3c5f-489f-9133-82d5e49c5ee8" xlink:href="sny-20231231.xsd#sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_467b622e-6413-4c95-8b2c-03235909d353" xlink:to="loc_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments_e3c76c4b-3c5f-489f-9133-82d5e49c5ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_88a85f7f-5a31-4a59-b4e3-e843edc1dc26" xlink:href="sny-20231231.xsd#sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_467b622e-6413-4c95-8b2c-03235909d353" xlink:to="loc_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations_88a85f7f-5a31-4a59-b4e3-e843edc1dc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_9b4de6bd-d5b5-49a4-afee-84392d55b4ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_467b622e-6413-4c95-8b2c-03235909d353" xlink:to="loc_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_9b4de6bd-d5b5-49a4-afee-84392d55b4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_67360b8a-8842-4957-8bd9-b9690e0a0348" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_IncomeTaxesAbstract_467b622e-6413-4c95-8b2c-03235909d353" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_67360b8a-8842-4957-8bd9-b9690e0a0348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_868f8b2e-4b2b-4872-8cdb-735584b12a7e" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_93020f3d-9f75-4f7a-a701-33bedaf01ebb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_868f8b2e-4b2b-4872-8cdb-735584b12a7e" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_93020f3d-9f75-4f7a-a701-33bedaf01ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1b4d4318-8b01-4fc7-97f1-82ddd45da1bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_93020f3d-9f75-4f7a-a701-33bedaf01ebb" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1b4d4318-8b01-4fc7-97f1-82ddd45da1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_6bbfcbca-39d3-43e0-b341-de99d918d8f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_1b4d4318-8b01-4fc7-97f1-82ddd45da1bb" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_6bbfcbca-39d3-43e0-b341-de99d918d8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_bd8f0ae4-7437-495a-b5a2-e6f3a05bba62" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_6bbfcbca-39d3-43e0-b341-de99d918d8f3" xlink:to="loc_sny_EuroapiMember_bd8f0ae4-7437-495a-b5a2-e6f3a05bba62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_40e06983-79f1-4e19-acf0-9e7a4abc1e87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_93020f3d-9f75-4f7a-a701-33bedaf01ebb" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_40e06983-79f1-4e19-acf0-9e7a4abc1e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_da055633-89d0-46cc-8d76-7cdc148c19e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_40e06983-79f1-4e19-acf0-9e7a4abc1e87" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_da055633-89d0-46cc-8d76-7cdc148c19e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_cd087c98-16d0-43d0-8f6c-442855629f9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_40e06983-79f1-4e19-acf0-9e7a4abc1e87" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_cd087c98-16d0-43d0-8f6c-442855629f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#NetincomeattributabletononcontrollinginterestsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_07edee4c-fc93-4528-92d4-eda23b1d722c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable_1b3ee640-5e98-4b5c-a2e3-92d1b62819e7" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_07edee4c-fc93-4528-92d4-eda23b1d722c" xlink:to="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable_1b3ee640-5e98-4b5c-a2e3-92d1b62819e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_82cddb8e-bbe5-4b06-804d-b2cff916da0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable_1b3ee640-5e98-4b5c-a2e3-92d1b62819e7" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_82cddb8e-bbe5-4b06-804d-b2cff916da0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_2ef02dcb-a748-4ab0-b899-67d517d71452" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_82cddb8e-bbe5-4b06-804d-b2cff916da0a" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_2ef02dcb-a748-4ab0-b899-67d517d71452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_4fbedaec-6904-4895-b832-085b2829b134" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_2ef02dcb-a748-4ab0-b899-67d517d71452" xlink:to="loc_ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember_4fbedaec-6904-4895-b832-085b2829b134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems_22c9d146-403a-4c45-9f93-bdeb565459de" xlink:href="sny-20231231.xsd#sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable_1b3ee640-5e98-4b5c-a2e3-92d1b62819e7" xlink:to="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems_22c9d146-403a-4c45-9f93-bdeb565459de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_db524729-7e87-4b3d-b678-41f9f0e0d99b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems_22c9d146-403a-4c45-9f93-bdeb565459de" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_db524729-7e87-4b3d-b678-41f9f0e0d99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RelatedpartytransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#RelatedpartytransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RelatedpartytransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_RelatedPartyAbstract_06408b1d-2c2a-4636-8dd3-ce00f6416377" xlink:href="sny-20231231.xsd#sny_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfExecutiveCommitteeMembers_54312140-65a8-4b5c-b79b-cb67fa99f2fd" xlink:href="sny-20231231.xsd#sny_NumberOfExecutiveCommitteeMembers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_06408b1d-2c2a-4636-8dd3-ce00f6416377" xlink:to="loc_sny_NumberOfExecutiveCommitteeMembers_54312140-65a8-4b5c-b79b-cb67fa99f2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_RelatedPartyAbstract_8dbd9a2b-7666-49fe-bb94-be2a5a8a7279" xlink:href="sny-20231231.xsd#sny_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_467b8f0a-f2e5-44b9-adc3-8cc90eaa9ad0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_8dbd9a2b-7666-49fe-bb94-be2a5a8a7279" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_467b8f0a-f2e5-44b9-adc3-8cc90eaa9ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_b515bf56-34a6-48f8-9d76-72fe7a3c4e5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_467b8f0a-f2e5-44b9-adc3-8cc90eaa9ad0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_b515bf56-34a6-48f8-9d76-72fe7a3c4e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_b6edc4b2-7bb6-455d-b650-0c51be9ed900" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_467b8f0a-f2e5-44b9-adc3-8cc90eaa9ad0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_b6edc4b2-7bb6-455d-b650-0c51be9ed900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_ed2e9ec0-ab74-4bc0-b433-68bfe699aea7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_467b8f0a-f2e5-44b9-adc3-8cc90eaa9ad0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_ed2e9ec0-ab74-4bc0-b433-68bfe699aea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_efc78980-afc5-4eaf-8c1b-fbc9ff51b3fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_467b8f0a-f2e5-44b9-adc3-8cc90eaa9ad0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_efc78980-afc5-4eaf-8c1b-fbc9ff51b3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/RelatedpartytransactionsSummaryofaggregateamountsPayabletoKeyManagementPersonnelDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#RelatedpartytransactionsSummaryofaggregateamountsPayabletoKeyManagementPersonnelDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/RelatedpartytransactionsSummaryofaggregateamountsPayabletoKeyManagementPersonnelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_RelatedPartyAbstract_5a7b1f45-d1b8-4864-bdb5-37aa649605cb" xlink:href="sny-20231231.xsd#sny_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee_6a396109-29d0-465a-a595-9ae575c17089" xlink:href="sny-20231231.xsd#sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_5a7b1f45-d1b8-4864-bdb5-37aa649605cb" xlink:to="loc_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee_6a396109-29d0-465a-a595-9ae575c17089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits_15fc97df-184e-4d5b-9476-4fbfe0355494" xlink:href="sny-20231231.xsd#sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_RelatedPartyAbstract_5a7b1f45-d1b8-4864-bdb5-37aa649605cb" xlink:to="loc_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits_15fc97df-184e-4d5b-9476-4fbfe0355494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#DisclosuresaboutmajorcustomersandcreditriskDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_FinancialInstrumentsAbstract_951fab2e-795e-482c-a0e4-f214431b24e0" xlink:href="sny-20231231.xsd#sny_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_86c223c7-98ae-4089-adaa-b74cf50fd648" xlink:href="sny-20231231.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_FinancialInstrumentsAbstract_951fab2e-795e-482c-a0e4-f214431b24e0" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_86c223c7-98ae-4089-adaa-b74cf50fd648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_b7a4867b-f01a-42ce-b6b9-af859fa1dd4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_86c223c7-98ae-4089-adaa-b74cf50fd648" xlink:to="loc_ifrs-full_MajorCustomersAxis_b7a4867b-f01a-42ce-b6b9-af859fa1dd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersAxis_b7a4867b-f01a-42ce-b6b9-af859fa1dd4b" xlink:to="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LargestCustomersMember_d14ccc02-89eb-40a6-8064-76cbde282d47" xlink:href="sny-20231231.xsd#sny_LargestCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:to="loc_sny_LargestCustomersMember_d14ccc02-89eb-40a6-8064-76cbde282d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerOneMember_79a402eb-0855-4934-a354-a3a5140ffc3e" xlink:href="sny-20231231.xsd#sny_CustomerOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:to="loc_sny_CustomerOneMember_79a402eb-0855-4934-a354-a3a5140ffc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerTwoMember_76c9e912-81e3-483c-91e8-d1e1a98ebd40" xlink:href="sny-20231231.xsd#sny_CustomerTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:to="loc_sny_CustomerTwoMember_76c9e912-81e3-483c-91e8-d1e1a98ebd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CustomerThreeMember_df6b7529-1bc6-4c3d-9bed-5408a492cae8" xlink:href="sny-20231231.xsd#sny_CustomerThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_bc0b02ed-aed5-4239-bd52-0ce67d2bcee8" xlink:to="loc_sny_CustomerThreeMember_df6b7529-1bc6-4c3d-9bed-5408a492cae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_0676e1da-fd80-4c3c-b6f0-9b7c62e199cd" xlink:href="sny-20231231.xsd#sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable_86c223c7-98ae-4089-adaa-b74cf50fd648" xlink:to="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_0676e1da-fd80-4c3c-b6f0-9b7c62e199cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfEntitysRevenue_01d3654f-b610-471d-8023-53e3c1140e7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems_0676e1da-fd80-4c3c-b6f0-9b7c62e199cd" xlink:to="loc_ifrs-full_PercentageOfEntitysRevenue_01d3654f-b610-471d-8023-53e3c1140e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingSegmentsAbstract_fa78ee51-7d7b-449f-bb35-ec8580403582" xlink:href="sny-20231231.xsd#sny_OperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments1_d054c139-e7a5-41be-887c-c2752b3a526a" xlink:href="sny-20231231.xsd#sny_NumberOfOperatingSegments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_fa78ee51-7d7b-449f-bb35-ec8580403582" xlink:to="loc_sny_NumberOfOperatingSegments1_d054c139-e7a5-41be-887c-c2752b3a526a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingSegmentsAbstract_7617601b-b8b8-436b-aa02-a152698a349e" xlink:href="sny-20231231.xsd#sny_OperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_b1a48f04-7adc-4180-927f-2aa375100a1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_7617601b-b8b8-436b-aa02-a152698a349e" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_b1a48f04-7adc-4180-927f-2aa375100a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_d86dbb47-3068-46c0-8b96-cfe4316701fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_b1a48f04-7adc-4180-927f-2aa375100a1d" xlink:to="loc_ifrs-full_GeographicalAreasAxis_d86dbb47-3068-46c0-8b96-cfe4316701fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_ccaf0a56-50e4-4feb-bcb1-dd023ec49aba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_d86dbb47-3068-46c0-8b96-cfe4316701fb" xlink:to="loc_ifrs-full_GeographicalAreasMember_ccaf0a56-50e4-4feb-bcb1-dd023ec49aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_3f4e3f19-58c5-47a5-8cfe-abcbed9c37b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_ccaf0a56-50e4-4feb-bcb1-dd023ec49aba" xlink:to="loc_srt_EuropeMember_3f4e3f19-58c5-47a5-8cfe-abcbed9c37b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b5b12ddf-f821-48fa-866f-96e5531cec69" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_ccaf0a56-50e4-4feb-bcb1-dd023ec49aba" xlink:to="loc_country_US_b5b12ddf-f821-48fa-866f-96e5531cec69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesInSegmentResultsMember_4ad8a628-aef2-43f2-a367-673dbd3a98b1" xlink:href="sny-20231231.xsd#sny_OtherCountriesInSegmentResultsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_ccaf0a56-50e4-4feb-bcb1-dd023ec49aba" xlink:to="loc_sny_OtherCountriesInSegmentResultsMember_4ad8a628-aef2-43f2-a367-673dbd3a98b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_dc4a22d6-2996-47f1-bb8f-1fd378158b29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_b1a48f04-7adc-4180-927f-2aa375100a1d" xlink:to="loc_ifrs-full_SegmentsAxis_dc4a22d6-2996-47f1-bb8f-1fd378158b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_28cb5e5e-c8a0-4f18-a022-c18f36d845c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_dc4a22d6-2996-47f1-bb8f-1fd378158b29" xlink:to="loc_ifrs-full_SegmentsMember_28cb5e5e-c8a0-4f18-a022-c18f36d845c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_0d0b9a11-9d15-4d1b-9e76-d0c7228863a6" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_28cb5e5e-c8a0-4f18-a022-c18f36d845c2" xlink:to="loc_sny_BiopharmaSegmentMember_0d0b9a11-9d15-4d1b-9e76-d0c7228863a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_b1e33332-9d5b-48bb-a1ad-56dd2df3366c" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_28cb5e5e-c8a0-4f18-a022-c18f36d845c2" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_b1e33332-9d5b-48bb-a1ad-56dd2df3366c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_61a800c4-37c1-404e-98e5-ea33a352e2a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_b1a48f04-7adc-4180-927f-2aa375100a1d" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_61a800c4-37c1-404e-98e5-ea33a352e2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_61a800c4-37c1-404e-98e5-ea33a352e2a1" xlink:to="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:href="sny-20231231.xsd#sny_SpecialtyCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DupixentMember_2cd2d67c-b082-4853-a3c7-5b87a6763b0c" xlink:href="sny-20231231.xsd#sny_DupixentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_DupixentMember_2cd2d67c-b082-4853-a3c7-5b87a6763b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AubagioMember_96123dd7-e536-4c21-9971-89e1b8bfdec7" xlink:href="sny-20231231.xsd#sny_AubagioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_AubagioMember_96123dd7-e536-4c21-9971-89e1b8bfdec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CerezymeMember_5e4da4c8-1e4c-4d0e-9691-74667cb9c18b" xlink:href="sny-20231231.xsd#sny_CerezymeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_CerezymeMember_5e4da4c8-1e4c-4d0e-9691-74667cb9c18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_FabrazymeMember_982582d9-d130-4d08-854f-8bc5d8976161" xlink:href="sny-20231231.xsd#sny_FabrazymeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_FabrazymeMember_982582d9-d130-4d08-854f-8bc5d8976161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MyozymeOrLumizymeMember_a81c515c-151d-4cf2-9461-d087fa74c1cd" xlink:href="sny-20231231.xsd#sny_MyozymeOrLumizymeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_MyozymeOrLumizymeMember_a81c515c-151d-4cf2-9461-d087fa74c1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_JevtanaMember_a639e5a7-faf2-4823-ae22-abd20dc8a871" xlink:href="sny-20231231.xsd#sny_JevtanaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_JevtanaMember_a639e5a7-faf2-4823-ae22-abd20dc8a871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AlprolixMember_183dca33-cb22-4e2d-9f22-3882405a6941" xlink:href="sny-20231231.xsd#sny_AlprolixMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_AlprolixMember_183dca33-cb22-4e2d-9f22-3882405a6941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_b9233d97-31fe-404c-b0c8-08b14f265a92" xlink:href="sny-20231231.xsd#sny_EloctateMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_SpecialtyCareMember_07299c6c-319c-422f-81fb-1bcf31560d0e" xlink:to="loc_sny_EloctateMember_b9233d97-31fe-404c-b0c8-08b14f265a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GeneralMedecinesMember_3d47fc26-c3ec-4e66-8a1b-7a8cec90a873" xlink:href="sny-20231231.xsd#sny_GeneralMedecinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_GeneralMedecinesMember_3d47fc26-c3ec-4e66-8a1b-7a8cec90a873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CoreAssetsMember_cbd2df30-f098-4d29-84aa-7504dcbcbac7" xlink:href="sny-20231231.xsd#sny_CoreAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralMedecinesMember_3d47fc26-c3ec-4e66-8a1b-7a8cec90a873" xlink:to="loc_sny_CoreAssetsMember_cbd2df30-f098-4d29-84aa-7504dcbcbac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LovenoxMember_8174b587-1376-441f-8b77-a6f2dcb5b572" xlink:href="sny-20231231.xsd#sny_LovenoxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_CoreAssetsMember_cbd2df30-f098-4d29-84aa-7504dcbcbac7" xlink:to="loc_sny_LovenoxMember_8174b587-1376-441f-8b77-a6f2dcb5b572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ToujeoMember_20c34687-97d5-47bd-9ab8-073645729600" xlink:href="sny-20231231.xsd#sny_ToujeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_CoreAssetsMember_cbd2df30-f098-4d29-84aa-7504dcbcbac7" xlink:to="loc_sny_ToujeoMember_20c34687-97d5-47bd-9ab8-073645729600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PlavixMember_d4f7d1e2-25e8-40c6-9d33-89b944a39e26" xlink:href="sny-20231231.xsd#sny_PlavixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_CoreAssetsMember_cbd2df30-f098-4d29-84aa-7504dcbcbac7" xlink:to="loc_sny_PlavixMember_d4f7d1e2-25e8-40c6-9d33-89b944a39e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonCoreAssetsMember_82ea56d9-d570-4723-b472-32460b17cfc3" xlink:href="sny-20231231.xsd#sny_NonCoreAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralMedecinesMember_3d47fc26-c3ec-4e66-8a1b-7a8cec90a873" xlink:to="loc_sny_NonCoreAssetsMember_82ea56d9-d570-4723-b472-32460b17cfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_LantusMember_8eff31d4-0ee3-4b71-8a63-935cf74d6ebf" xlink:href="sny-20231231.xsd#sny_LantusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_NonCoreAssetsMember_82ea56d9-d570-4723-b472-32460b17cfc3" xlink:to="loc_sny_LantusMember_8eff31d4-0ee3-4b71-8a63-935cf74d6ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherNonCoreAssetsMember_8bb735d6-b49c-4b29-9b9c-47e4439adead" xlink:href="sny-20231231.xsd#sny_OtherNonCoreAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_NonCoreAssetsMember_82ea56d9-d570-4723-b472-32460b17cfc3" xlink:to="loc_sny_OtherNonCoreAssetsMember_8bb735d6-b49c-4b29-9b9c-47e4439adead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IndustrialSalesMember_49cad975-bf2e-483f-9571-612cc00060a5" xlink:href="sny-20231231.xsd#sny_IndustrialSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_GeneralMedecinesMember_3d47fc26-c3ec-4e66-8a1b-7a8cec90a873" xlink:to="loc_sny_IndustrialSalesMember_49cad975-bf2e-483f-9571-612cc00060a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesMember_e5dbfda1-4d8c-4881-95d8-d72a38dbfd55" xlink:href="sny-20231231.xsd#sny_VaccinesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_VaccinesMember_e5dbfda1-4d8c-4881-95d8-d72a38dbfd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PolioPertussisHibVaccinesMember_3d809853-0e55-45fd-a98c-d00101b716af" xlink:href="sny-20231231.xsd#sny_PolioPertussisHibVaccinesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_VaccinesMember_e5dbfda1-4d8c-4881-95d8-d72a38dbfd55" xlink:to="loc_sny_PolioPertussisHibVaccinesMember_3d809853-0e55-45fd-a98c-d00101b716af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfluenzaVaccinesMember_c5dc3c00-c04e-480f-8258-67ed06720ffe" xlink:href="sny-20231231.xsd#sny_InfluenzaVaccinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_VaccinesMember_e5dbfda1-4d8c-4881-95d8-d72a38dbfd55" xlink:to="loc_sny_InfluenzaVaccinesMember_c5dc3c00-c04e-480f-8258-67ed06720ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AllergyMember_7b46cafe-7b93-4186-86c8-594c1cf8a0bb" xlink:href="sny-20231231.xsd#sny_AllergyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_AllergyMember_7b46cafe-7b93-4186-86c8-594c1cf8a0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PainCareMember_0bbb3a65-52d6-4c8a-9988-7977c702a629" xlink:href="sny-20231231.xsd#sny_PainCareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_PainCareMember_0bbb3a65-52d6-4c8a-9988-7977c702a629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DigestiveWellnessMember_7499c8e9-2ade-4ae4-ba44-80c8ef955d29" xlink:href="sny-20231231.xsd#sny_DigestiveWellnessMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_b9d38011-943d-401c-9207-f1745b695f14" xlink:to="loc_sny_DigestiveWellnessMember_7499c8e9-2ade-4ae4-ba44-80c8ef955d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_19e17268-a445-440f-8007-42d157af6f6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_b1a48f04-7adc-4180-927f-2aa375100a1d" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_19e17268-a445-440f-8007-42d157af6f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_ef22becf-d561-4c86-adf8-bc3af23f1324" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_19e17268-a445-440f-8007-42d157af6f6f" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_ef22becf-d561-4c86-adf8-bc3af23f1324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments1_966874d5-6d43-4625-85b9-751b6a603ad0" xlink:href="sny-20231231.xsd#sny_NumberOfOperatingSegments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_19e17268-a445-440f-8007-42d157af6f6f" xlink:to="loc_sny_NumberOfOperatingSegments1_966874d5-6d43-4625-85b9-751b6a603ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationScheduleofSegmentResultsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingSegmentsAbstract_7dbbfc48-40f7-4ebb-9929-b1d48b4ae657" xlink:href="sny-20231231.xsd#sny_OperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_3c6db461-58ff-4d8b-addf-9f6df526d93d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_7dbbfc48-40f7-4ebb-9929-b1d48b4ae657" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_3c6db461-58ff-4d8b-addf-9f6df526d93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_1907db83-654b-42cc-8fce-0de680510f02" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_3c6db461-58ff-4d8b-addf-9f6df526d93d" xlink:to="loc_ifrs-full_SegmentsAxis_1907db83-654b-42cc-8fce-0de680510f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_08f23aed-5490-4f74-b467-b6e24a39d2f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_1907db83-654b-42cc-8fce-0de680510f02" xlink:to="loc_ifrs-full_SegmentsMember_08f23aed-5490-4f74-b467-b6e24a39d2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_08f23aed-5490-4f74-b467-b6e24a39d2f3" xlink:to="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_0b582692-b29e-46f1-8091-db769e7a7630" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:to="loc_sny_BiopharmaSegmentMember_0b582692-b29e-46f1-8091-db769e7a7630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaceuticalsSegmentMember_0818e87f-5035-4bb1-88b2-176c45fd2e11" xlink:href="sny-20231231.xsd#sny_PharmaceuticalsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:to="loc_sny_PharmaceuticalsSegmentMember_0818e87f-5035-4bb1-88b2-176c45fd2e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesSegmentMember_832d0b7e-0ceb-46fd-bd07-8d638189557f" xlink:href="sny-20231231.xsd#sny_VaccinesSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:to="loc_sny_VaccinesSegmentMember_832d0b7e-0ceb-46fd-bd07-8d638189557f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_5530a193-0ec3-4bc4-97c0-dff6e9586580" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_5530a193-0ec3-4bc4-97c0-dff6e9586580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllOtherSegmentsMember_5e20d67f-e443-4f11-83a5-dc97d562db30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllOtherSegmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_f30f8a1b-6d61-42ea-a25d-131ec0693408" xlink:to="loc_ifrs-full_AllOtherSegmentsMember_5e20d67f-e443-4f11-83a5-dc97d562db30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_3c6db461-58ff-4d8b-addf-9f6df526d93d" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_6db49d0d-9e37-46af-8cf4-c316909600d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_6db49d0d-9e37-46af-8cf4-c316909600d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_b48c914f-2df7-4e68-be54-391c029b971e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_OtherRevenue_b48c914f-2df7-4e68-be54-391c029b971e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_2c36d6a0-2455-450e-bce6-574c73569def" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_CostOfSales_2c36d6a0-2455-450e-bce6-574c73569def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_2627000c-a19b-4b91-9e7a-1b8ccb99fcb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_2627000c-a19b-4b91-9e7a-1b8ccb99fcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_6cdb273c-45ba-4d19-8f57-2e0fab1e6d64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_6cdb273c-45ba-4d19-8f57-2e0fab1e6d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_b4933d81-26d6-4c1d-8faa-c1ee626a0349" xlink:href="sny-20231231.xsd#sny_MiscellaneousOtherOperatingIncomeExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_sny_MiscellaneousOtherOperatingIncomeExpenses_b4933d81-26d6-4c1d-8faa-c1ee626a0349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_6d209c4d-d316-4209-8954-af11fce2a818" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_6d209c4d-d316-4209-8954-af11fce2a818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1de00692-52ba-497f-b9f6-195d1e3dc664" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_1de00692-52ba-497f-b9f6-195d1e3dc664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_debaf6dd-bccb-466e-a9d4-13f27ed00382" xlink:href="sny-20231231.xsd#sny_BusinessOperatingIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_sny_BusinessOperatingIncome_debaf6dd-bccb-466e-a9d4-13f27ed00382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NumberOfOperatingSegments1_023b5ab3-bcc1-477a-a0b3-c905952799b1" xlink:href="sny-20231231.xsd#sny_NumberOfOperatingSegments1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_c636168c-3880-4b75-bac3-f3921cf0cb96" xlink:to="loc_sny_NumberOfOperatingSegments1_023b5ab3-bcc1-477a-a0b3-c905952799b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingSegmentsAbstract_3498e142-ef26-4cd7-a444-d6a1a233d03a" xlink:href="sny-20231231.xsd#sny_OperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_3498e142-ef26-4cd7-a444-d6a1a233d03a" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentConsolidationItemsAxis_a6987667-cdba-48ad-92cf-49567e1c3914" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_ifrs-full_SegmentConsolidationItemsAxis_a6987667-cdba-48ad-92cf-49567e1c3914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_3939c222-b453-420f-9131-f29f9dfa2ae3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentConsolidationItemsAxis_a6987667-cdba-48ad-92cf-49567e1c3914" xlink:to="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_3939c222-b453-420f-9131-f29f9dfa2ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingSegmentsMember_bbf58987-67ac-4123-95dc-94098c75c724" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_3939c222-b453-420f-9131-f29f9dfa2ae3" xlink:to="loc_ifrs-full_OperatingSegmentsMember_bbf58987-67ac-4123-95dc-94098c75c724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaterialReconcilingItemsMember_23ae8782-b0c9-41e9-b07e-0996b707561c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_3939c222-b453-420f-9131-f29f9dfa2ae3" xlink:to="loc_ifrs-full_MaterialReconcilingItemsMember_23ae8782-b0c9-41e9-b07e-0996b707561c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bf5cadce-464d-41c5-9e0c-1cf59b76bd99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_srt_ProductOrServiceAxis_bf5cadce-464d-41c5-9e0c-1cf59b76bd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3f639f5a-fa9b-4ea6-beca-0689107e9e95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bf5cadce-464d-41c5-9e0c-1cf59b76bd99" xlink:to="loc_srt_ProductsAndServicesDomain_3f639f5a-fa9b-4ea6-beca-0689107e9e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EloctateMember_1dcf491e-e7d1-4b96-b559-7ca164e7e102" xlink:href="sny-20231231.xsd#sny_EloctateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3f639f5a-fa9b-4ea6-beca-0689107e9e95" xlink:to="loc_sny_EloctateMember_1dcf491e-e7d1-4b96-b559-7ca164e7e102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_689b1e05-5459-49b9-b1df-4004ac1e4389" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_689b1e05-5459-49b9-b1df-4004ac1e4389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_b3cf3b3e-eddd-4a63-9667-e1f8678700f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_689b1e05-5459-49b9-b1df-4004ac1e4389" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_b3cf3b3e-eddd-4a63-9667-e1f8678700f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_46e5843b-a255-46d2-a825-42eed5ee5e41" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_b3cf3b3e-eddd-4a63-9667-e1f8678700f0" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_46e5843b-a255-46d2-a825-42eed5ee5e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_838630b3-1b12-41af-893b-2b6d4574e41b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_838630b3-1b12-41af-893b-2b6d4574e41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_af1be0e2-7381-461d-ba0d-02a4b232dc25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_838630b3-1b12-41af-893b-2b6d4574e41b" xlink:to="loc_ifrs-full_ProductsAndServicesMember_af1be0e2-7381-461d-ba0d-02a4b232dc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NKCellAndProXTenTechnologyPlatformsMember_c4a49298-e512-4c5f-b9c5-7b0bec62f727" xlink:href="sny-20231231.xsd#sny_NKCellAndProXTenTechnologyPlatformsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_af1be0e2-7381-461d-ba0d-02a4b232dc25" xlink:to="loc_sny_NKCellAndProXTenTechnologyPlatformsMember_c4a49298-e512-4c5f-b9c5-7b0bec62f727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SAR444245Member_460121fa-7c1e-4fd8-a7a6-64a22dee4b3b" xlink:href="sny-20231231.xsd#sny_SAR444245Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_af1be0e2-7381-461d-ba0d-02a4b232dc25" xlink:to="loc_sny_SAR444245Member_460121fa-7c1e-4fd8-a7a6-64a22dee4b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesAxis_5a3413a3-3e48-4dba-a724-0b851222e1e1" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_sny_PrincipalAlliancesAxis_5a3413a3-3e48-4dba-a724-0b851222e1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipalAlliancesDomain_51ca70ec-1100-429f-9b0f-c3a100a5d32b" xlink:href="sny-20231231.xsd#sny_PrincipalAlliancesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesAxis_5a3413a3-3e48-4dba-a724-0b851222e1e1" xlink:to="loc_sny_PrincipalAlliancesDomain_51ca70ec-1100-429f-9b0f-c3a100a5d32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImmunoOncologyCollaborationAgreementMember_fbb8bba6-3674-47f0-8592-2923cb4f86b7" xlink:href="sny-20231231.xsd#sny_ImmunoOncologyCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_PrincipalAlliancesDomain_51ca70ec-1100-429f-9b0f-c3a100a5d32b" xlink:to="loc_sny_ImmunoOncologyCollaborationAgreementMember_fbb8bba6-3674-47f0-8592-2923cb4f86b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_85549ccf-2111-4366-a97d-8358ee9a655a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_ifrs-full_CounterpartiesAxis_85549ccf-2111-4366-a97d-8358ee9a655a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_1a78bacc-ef64-472c-bb28-419ff375b01e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_85549ccf-2111-4366-a97d-8358ee9a655a" xlink:to="loc_ifrs-full_CounterpartiesMember_1a78bacc-ef64-472c-bb28-419ff375b01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegeneronPharmaceuticalsIncMember_4b1019dd-b7ef-4376-ac6f-8fb444585c6a" xlink:href="sny-20231231.xsd#sny_RegeneronPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_1a78bacc-ef64-472c-bb28-419ff375b01e" xlink:to="loc_sny_RegeneronPharmaceuticalsIncMember_4b1019dd-b7ef-4376-ac6f-8fb444585c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_a7c246c4-7ae4-4785-8670-0724bf5c088c" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessOperatingIncome_cf13cf69-d7e2-4f3a-8cc0-3c2dafe32d0f" xlink:href="sny-20231231.xsd#sny_BusinessOperatingIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_BusinessOperatingIncome_cf13cf69-d7e2-4f3a-8cc0-3c2dafe32d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_fceda395-5bdc-492b-99e0-955eb775d5fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_fceda395-5bdc-492b-99e0-955eb775d5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_84d20ff2-a061-4790-a104-9f130a5975bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_ProfitLossAttributableToNoncontrollingInterests_84d20ff2-a061-4790-a104-9f130a5975bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_a2220647-3e22-4943-8aa8-e20d706727ce" xlink:href="sny-20231231.xsd#sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill_a2220647-3e22-4943-8aa8-e20d706727ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_ffdc9624-55b1-4a24-b7ea-6f44c60a68af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability_ffdc9624-55b1-4a24-b7ea-6f44c60a68af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_0c823fff-1555-43f0-bb23-af1379352b8a" xlink:href="sny-20231231.xsd#sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories_0c823fff-1555-43f0-bb23-af1379352b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseOfRestructuringActivities_0024353f-a3bf-4a1c-908d-865a42d5f27e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseOfRestructuringActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_ExpenseOfRestructuringActivities_0024353f-a3bf-4a1c-908d-865a42d5f27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherGainsLossesAndLitigation_6e018816-4047-4eec-833e-9a6204a1f386" xlink:href="sny-20231231.xsd#sny_OtherGainsLossesAndLitigation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_OtherGainsLossesAndLitigation_6e018816-4047-4eec-833e-9a6204a1f386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeResultingFromOutLicensing_924ef0fb-355c-47d0-9970-2eee89d684d1" xlink:href="sny-20231231.xsd#sny_IncomeResultingFromOutLicensing"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_IncomeResultingFromOutLicensing_924ef0fb-355c-47d0-9970-2eee89d684d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_099f63ae-35a4-4fc8-aae8-21d96979e802" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_099f63ae-35a4-4fc8-aae8-21d96979e802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_451dae27-bfdf-428b-9bda-3d56f61a8abc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_FinanceCosts_451dae27-bfdf-428b-9bda-3d56f61a8abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_65f50bf1-0d32-42fa-b149-b7f11b948623" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_ifrs-full_FinanceIncome_65f50bf1-0d32-42fa-b149-b7f11b948623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_c8f437b2-9fe3-4eed-a4b8-b46daba37c0b" xlink:href="sny-20231231.xsd#sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments_c8f437b2-9fe3-4eed-a4b8-b46daba37c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount_eab52c4d-6662-4c1f-be42-d0554f2df4b8" xlink:href="sny-20231231.xsd#sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount_eab52c4d-6662-4c1f-be42-d0554f2df4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_f378a02f-b01c-4e51-8adb-21d27d9992ab" xlink:href="sny-20231231.xsd#sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill_f378a02f-b01c-4e51-8adb-21d27d9992ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_201ac633-6cdd-49e8-9614-0eda78002c70" xlink:href="sny-20231231.xsd#sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements_201ac633-6cdd-49e8-9614-0eda78002c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_dc75bc35-f1ba-424a-96ae-2fd0c2211c68" xlink:href="sny-20231231.xsd#sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_f3b948d2-0b82-49f2-99fd-26a9d765bcc0" xlink:to="loc_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements_dc75bc35-f1ba-424a-96ae-2fd0c2211c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingSegmentsAbstract_189d2fc2-3663-4b73-b511-af2e56cab913" xlink:href="sny-20231231.xsd#sny_OperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_88a7d95c-6cac-45ce-af23-e8b653ea3e9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_189d2fc2-3663-4b73-b511-af2e56cab913" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_88a7d95c-6cac-45ce-af23-e8b653ea3e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsAxis_a377f6b8-cead-4922-90b0-0cdd1176102c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_88a7d95c-6cac-45ce-af23-e8b653ea3e9b" xlink:to="loc_ifrs-full_SegmentsAxis_a377f6b8-cead-4922-90b0-0cdd1176102c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SegmentsMember_dbc0e98c-0234-43f7-9e64-84f43958ff3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsAxis_a377f6b8-cead-4922-90b0-0cdd1176102c" xlink:to="loc_ifrs-full_SegmentsMember_dbc0e98c-0234-43f7-9e64-84f43958ff3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SegmentsMember_dbc0e98c-0234-43f7-9e64-84f43958ff3b" xlink:to="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PharmaceuticalsSegmentMember_bc953226-cf50-4ba4-9ba6-d8dd7762103a" xlink:href="sny-20231231.xsd#sny_PharmaceuticalsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:to="loc_sny_PharmaceuticalsSegmentMember_bc953226-cf50-4ba4-9ba6-d8dd7762103a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaccinesSegmentMember_249e899c-fb63-42d0-8ab2-53507354fb05" xlink:href="sny-20231231.xsd#sny_VaccinesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:to="loc_sny_VaccinesSegmentMember_249e899c-fb63-42d0-8ab2-53507354fb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BiopharmaSegmentMember_e98f5d27-c9db-47d5-8f19-9474558827e0" xlink:href="sny-20231231.xsd#sny_BiopharmaSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:to="loc_sny_BiopharmaSegmentMember_e98f5d27-c9db-47d5-8f19-9474558827e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ConsumerHealthcareSegmentMember_10834494-674f-4da9-8668-a9d043d0f36e" xlink:href="sny-20231231.xsd#sny_ConsumerHealthcareSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReportableSegmentsMember_e2b76659-3987-4773-8a88-28103c682692" xlink:to="loc_sny_ConsumerHealthcareSegmentMember_10834494-674f-4da9-8668-a9d043d0f36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_230c010c-81eb-45fb-89be-4106a6b5601f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_88a7d95c-6cac-45ce-af23-e8b653ea3e9b" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_230c010c-81eb-45fb-89be-4106a6b5601f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InvestmentsInAssociatesAndJointVentures_b4325504-86dd-4f28-872c-3074d0905c40" xlink:href="sny-20231231.xsd#sny_InvestmentsInAssociatesAndJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_230c010c-81eb-45fb-89be-4106a6b5601f" xlink:to="loc_sny_InvestmentsInAssociatesAndJointVentures_b4325504-86dd-4f28-872c-3074d0905c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4c3475f0-c063-4db5-9b19-01c2526d483f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_230c010c-81eb-45fb-89be-4106a6b5601f" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_4c3475f0-c063-4db5-9b19-01c2526d483f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_fb2c2067-8ab7-4156-ac45-f88ef1093a8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_230c010c-81eb-45fb-89be-4106a6b5601f" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_fb2c2067-8ab7-4156-ac45-f88ef1093a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_OperatingSegmentsAbstract_86451a5d-18b7-47d2-9133-fb9f49ee9b98" xlink:href="sny-20231231.xsd#sny_OperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_d9c7ca8c-ca4a-4941-b5a0-beeb600d207b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_OperatingSegmentsAbstract_86451a5d-18b7-47d2-9133-fb9f49ee9b98" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_d9c7ca8c-ca4a-4941-b5a0-beeb600d207b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_e8c7e833-42a7-42c7-8347-30637437a24f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_d9c7ca8c-ca4a-4941-b5a0-beeb600d207b" xlink:to="loc_ifrs-full_GeographicalAreasAxis_e8c7e833-42a7-42c7-8347-30637437a24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_0577e3b7-0056-4077-8c24-ec4992823301" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_e8c7e833-42a7-42c7-8347-30637437a24f" xlink:to="loc_ifrs-full_GeographicalAreasMember_0577e3b7-0056-4077-8c24-ec4992823301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ReportableGeographicalZonesMember_4ce1d438-12a2-47cd-b1d2-8db44b1bce0d" xlink:href="sny-20231231.xsd#sny_ReportableGeographicalZonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_0577e3b7-0056-4077-8c24-ec4992823301" xlink:to="loc_sny_ReportableGeographicalZonesMember_4ce1d438-12a2-47cd-b1d2-8db44b1bce0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_8fe0e9c1-b535-4921-9cb1-00caeb6cc400" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ReportableGeographicalZonesMember_4ce1d438-12a2-47cd-b1d2-8db44b1bce0d" xlink:to="loc_srt_EuropeMember_8fe0e9c1-b535-4921-9cb1-00caeb6cc400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_1cab799a-5725-41b1-a8ea-f43a665589d9" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EuropeMember_8fe0e9c1-b535-4921-9cb1-00caeb6cc400" xlink:to="loc_country_FR_1cab799a-5725-41b1-a8ea-f43a665589d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_00241120-0704-4264-a2d3-3d1fce599c39" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ReportableGeographicalZonesMember_4ce1d438-12a2-47cd-b1d2-8db44b1bce0d" xlink:to="loc_srt_NorthAmericaMember_00241120-0704-4264-a2d3-3d1fce599c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_84b9501c-a68f-40fb-a4a2-92668282f7dc" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NorthAmericaMember_00241120-0704-4264-a2d3-3d1fce599c39" xlink:to="loc_country_US_84b9501c-a68f-40fb-a4a2-92668282f7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_f25ac134-2630-4053-bca2-977770dfd95f" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ReportableGeographicalZonesMember_4ce1d438-12a2-47cd-b1d2-8db44b1bce0d" xlink:to="loc_sny_OtherCountriesMember_f25ac134-2630-4053-bca2-977770dfd95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_d9c7ca8c-ca4a-4941-b5a0-beeb600d207b" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromSaleOfGoods_f5609dae-9cfb-4f83-b06f-da7100efd6f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:to="loc_ifrs-full_RevenueFromSaleOfGoods_f5609dae-9cfb-4f83-b06f-da7100efd6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_aa533da6-9edc-439b-9e62-f18cb458f3e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_aa533da6-9edc-439b-9e62-f18cb458f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_7134fedf-a681-496e-98c2-aca4f4cc22e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:to="loc_ifrs-full_Goodwill_7134fedf-a681-496e-98c2-aca4f4cc22e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_29a35da1-fde4-451e-8a7a-216ba34a5bf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_101a8816-7762-4869-921b-042b2959fc1a" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_29a35da1-fde4-451e-8a7a-216ba34a5bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#PrincipalaccountantsfeesandservicesDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e1232ced-afaf-4655-871b-b44d59f7ffca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAuditFeesAndOtherServicesTable_2ac9596b-068e-4c44-ac60-2f5211c1d9d6" xlink:href="sny-20231231.xsd#sny_DisclosureOfAuditFeesAndOtherServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e1232ced-afaf-4655-871b-b44d59f7ffca" xlink:to="loc_sny_DisclosureOfAuditFeesAndOtherServicesTable_2ac9596b-068e-4c44-ac60-2f5211c1d9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsNameAxis_4106d539-3c62-41db-a72d-966fbb851ef2" xlink:href="sny-20231231.xsd#sny_AuditorsNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesTable_2ac9596b-068e-4c44-ac60-2f5211c1d9d6" xlink:to="loc_sny_AuditorsNameAxis_4106d539-3c62-41db-a72d-966fbb851ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsNameMember_a8fe76f6-777e-4d84-a95d-6f0a9fc41df8" xlink:href="sny-20231231.xsd#sny_AuditorsNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AuditorsNameAxis_4106d539-3c62-41db-a72d-966fbb851ef2" xlink:to="loc_sny_AuditorsNameMember_a8fe76f6-777e-4d84-a95d-6f0a9fc41df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ErnstAndYoungMember_ba861fa2-a647-4473-a098-20d65b571b32" xlink:href="sny-20231231.xsd#sny_ErnstAndYoungMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AuditorsNameMember_a8fe76f6-777e-4d84-a95d-6f0a9fc41df8" xlink:to="loc_sny_ErnstAndYoungMember_ba861fa2-a647-4473-a098-20d65b571b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PricewaterhousecoopersMember_5bffff80-212b-4ed3-a20e-c7fb1d5f19f0" xlink:href="sny-20231231.xsd#sny_PricewaterhousecoopersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_AuditorsNameMember_a8fe76f6-777e-4d84-a95d-6f0a9fc41df8" xlink:to="loc_sny_PricewaterhousecoopersMember_5bffff80-212b-4ed3-a20e-c7fb1d5f19f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:href="sny-20231231.xsd#sny_DisclosureOfAuditFeesAndOtherServicesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesTable_2ac9596b-068e-4c44-ac60-2f5211c1d9d6" xlink:to="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForAuditServices_3d730012-b70b-46a8-bb79-daf3d9c8484c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForAuditServices"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_ifrs-full_AuditorsRemunerationForAuditServices_3d730012-b70b-46a8-bb79-daf3d9c8484c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ServicesOtherThanStatutoryAudit_94e325f5-a47d-41ba-8a38-4cd32b8b67e2" xlink:href="sny-20231231.xsd#sny_ServicesOtherThanStatutoryAudit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_ServicesOtherThanStatutoryAudit_94e325f5-a47d-41ba-8a38-4cd32b8b67e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsRemunerationForAuditRelatedServices_9287d1f6-a8a0-4c50-beba-600a1e75e380" xlink:href="sny-20231231.xsd#sny_AuditorsRemunerationForAuditRelatedServices"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ServicesOtherThanStatutoryAudit_94e325f5-a47d-41ba-8a38-4cd32b8b67e2" xlink:to="loc_sny_AuditorsRemunerationForAuditRelatedServices_9287d1f6-a8a0-4c50-beba-600a1e75e380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForTaxServices_6f3dc2ec-e9f0-4e39-a5bd-6956bb1bc63b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForTaxServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ServicesOtherThanStatutoryAudit_94e325f5-a47d-41ba-8a38-4cd32b8b67e2" xlink:to="loc_ifrs-full_AuditorsRemunerationForTaxServices_6f3dc2ec-e9f0-4e39-a5bd-6956bb1bc63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemunerationForOtherServices_1ff47991-1896-4c98-9920-a2de818227a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemunerationForOtherServices"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_ServicesOtherThanStatutoryAudit_94e325f5-a47d-41ba-8a38-4cd32b8b67e2" xlink:to="loc_ifrs-full_AuditorsRemunerationForOtherServices_1ff47991-1896-4c98-9920-a2de818227a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AuditorsRemuneration_47741e76-cb02-4aa2-8477-919c121e749c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AuditorsRemuneration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_ifrs-full_AuditorsRemuneration_47741e76-cb02-4aa2-8477-919c121e749c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorRemunerationForStatutoryAudit_008813b5-7adc-4825-8fd9-37561a1dd996" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorRemunerationForStatutoryAudit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_PercentageOfAuditorRemunerationForStatutoryAudit_008813b5-7adc-4825-8fd9-37561a1dd996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements_7c713e8b-bd19-4b06-bacd-e541359cccf7" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements_7c713e8b-bd19-4b06-bacd-e541359cccf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PercentageOfAuditorsRemuneration_92d39bbe-8b37-4538-a519-d958b44521f3" xlink:href="sny-20231231.xsd#sny_PercentageOfAuditorsRemuneration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_PercentageOfAuditorsRemuneration_92d39bbe-8b37-4538-a519-d958b44521f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries_2792b25f-bc0f-4708-b8a0-c0b3646b47bc" xlink:href="sny-20231231.xsd#sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries_2792b25f-bc0f-4708-b8a0-c0b3646b47bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries_446e4ce1-02c4-4cbb-95ac-92eecafd9d0c" xlink:href="sny-20231231.xsd#sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries_446e4ce1-02c4-4cbb-95ac-92eecafd9d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices_aa449094-58ba-4891-b4df-3dc34492cd09" xlink:href="sny-20231231.xsd#sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_DisclosureOfAuditFeesAndOtherServicesLineItems_bc7e604d-9ea7-49f7-a568-b825d2e9a724" xlink:to="loc_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices_aa449094-58ba-4891-b4df-3dc34492cd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_2c9a70be-01e7-4979-8e37-828033781340" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ce2fe308-fdf1-4b32-a631-65886079da0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_2c9a70be-01e7-4979-8e37-828033781340" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ce2fe308-fdf1-4b32-a631-65886079da0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_58c6c269-a06a-4722-a7d3-188369fe94e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ce2fe308-fdf1-4b32-a631-65886079da0c" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_58c6c269-a06a-4722-a7d3-188369fe94e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_58c6c269-a06a-4722-a7d3-188369fe94e7" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HoechstGmbHMember_1a7ab509-302a-4f64-9e7a-352c32d239c9" xlink:href="sny-20231231.xsd#sny_HoechstGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_HoechstGmbHMember_1a7ab509-302a-4f64-9e7a-352c32d239c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeutschlandGmbHMember_f73ffdf6-d21a-4cda-a908-2d4dd1524acf" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeutschlandGmbHMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisDeutschlandGmbHMember_f73ffdf6-d21a-4cda-a908-2d4dd1524acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_A.NattermannCie.GmbHMember_30a76c3c-0609-4be2-8c0b-c675def98168" xlink:href="sny-20231231.xsd#sny_A.NattermannCie.GmbHMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_A.NattermannCie.GmbHMember_30a76c3c-0609-4be2-8c0b-c675def98168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisGmbHMember_782e24f2-a6ff-491b-b1ba-782346d15a89" xlink:href="sny-20231231.xsd#sny_SanofiAventisGmbHMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisGmbHMember_782e24f2-a6ff-491b-b1ba-782346d15a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBelgiumMember_6ef3c612-29a9-491f-a63f-1336c291b91f" xlink:href="sny-20231231.xsd#sny_SanofiBelgiumMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiBelgiumMember_6ef3c612-29a9-491f-a63f-1336c291b91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AblynxMember_591b7ad9-4fb2-4170-857d-d41fb4846a9c" xlink:href="sny-20231231.xsd#sny_AblynxMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AblynxMember_591b7ad9-4fb2-4170-857d-d41fb4846a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeFlandersBVBAMember_6924f87c-559b-4c01-9d87-00ee7ddbd933" xlink:href="sny-20231231.xsd#sny_GenzymeFlandersBVBAMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeFlandersBVBAMember_6924f87c-559b-4c01-9d87-00ee7ddbd933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiASMember_7644619c-2399-4430-981f-4ec98dcd6873" xlink:href="sny-20231231.xsd#sny_SanofiASMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiASMember_7644619c-2399-4430-981f-4ec98dcd6873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSAMember_e191d5e7-63c5-45a8-949d-958943ed1595" xlink:href="sny-20231231.xsd#sny_SanofiAventisSAMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisSAMember_e191d5e7-63c5-45a8-949d-958943ed1595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareSpainSLMember_9a41d12c-b6ec-4c80-a0d9-1f7c234de040" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareSpainSLMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareSpainSLMember_9a41d12c-b6ec-4c80-a0d9-1f7c234de040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiOyMember_ecd23f59-e038-4a0f-8bf8-984f03c54530" xlink:href="sny-20231231.xsd#sny_SanofiOyMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiOyMember_ecd23f59-e038-4a0f-8bf8-984f03c54530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMember_ddebf05d-1614-4e63-b9af-0b1d182c3777" xlink:href="sny-20231231.xsd#sny_SanofiMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiMember_ddebf05d-1614-4e63-b9af-0b1d182c3777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisFranceMember_3ece6a02-7ef1-4d9c-ba57-1d239fac4cf5" xlink:href="sny-20231231.xsd#sny_SanofiAventisFranceMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisFranceMember_3ece6a02-7ef1-4d9c-ba57-1d239fac4cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiWinthropIndustriesMember_3167fd5e-fa35-4784-a044-c874cd6cee40" xlink:href="sny-20231231.xsd#sny_SanofiWinthropIndustriesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiWinthropIndustriesMember_3167fd5e-fa35-4784-a044-c874cd6cee40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisRechercheEtDeveloppementMember_310e1ddc-b4f3-461e-9cea-0249eee8c05a" xlink:href="sny-20231231.xsd#sny_SanofiAventisRechercheEtDeveloppementMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisRechercheEtDeveloppementMember_310e1ddc-b4f3-461e-9cea-0249eee8c05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisGroupeMember_87e7bd90-7272-4aae-ba47-5ba75992185d" xlink:href="sny-20231231.xsd#sny_SanofiAventisGroupeMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisGroupeMember_87e7bd90-7272-4aae-ba47-5ba75992185d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiChimieMember_ae01a701-276f-4901-a770-02cc0b175509" xlink:href="sny-20231231.xsd#sny_SanofiChimieMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiChimieMember_ae01a701-276f-4901-a770-02cc0b175509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisParticipationsSASMember_72b16f2a-d397-4dcd-abe4-0ae3849bf1b8" xlink:href="sny-20231231.xsd#sny_SanofiAventisParticipationsSASMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisParticipationsSASMember_72b16f2a-d397-4dcd-abe4-0ae3849bf1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurFranceSAMember_a471ace3-1a87-4aa9-addd-43d5900e6ef0" xlink:href="sny-20231231.xsd#sny_SanofiPasteurFranceSAMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurFranceSAMember_a471ace3-1a87-4aa9-addd-43d5900e6ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaSAFranceMember_3728e222-c3a3-4251-9e38-4f39855e1591" xlink:href="sny-20231231.xsd#sny_AventisPharmaSAFranceMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisPharmaSAFranceMember_3728e222-c3a3-4251-9e38-4f39855e1591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBiotechnologyMember_e056218a-669d-4fe7-b86d-1e950d01a5c9" xlink:href="sny-20231231.xsd#sny_SanofiBiotechnologyMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiBiotechnologyMember_e056218a-669d-4fe7-b86d-1e950d01a5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMatureIPMember_63516574-dad0-41e4-b63d-f4847a5db1dd" xlink:href="sny-20231231.xsd#sny_SanofiMatureIPMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiMatureIPMember_63516574-dad0-41e4-b63d-f4847a5db1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurNVLMember_f5b3a002-8f85-4a07-8c60-d6e921a78c12" xlink:href="sny-20231231.xsd#sny_SanofiPasteurNVLMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurNVLMember_f5b3a002-8f85-4a07-8c60-d6e921a78c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurEuropeMember_065becab-787f-42f7-a2bf-ae18b6ec5371" xlink:href="sny-20231231.xsd#sny_SanofiPasteurEuropeMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurEuropeMember_065becab-787f-42f7-a2bf-ae18b6ec5371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SECIPESASMember_bb052e90-be13-42bc-9e56-42d0d50117bf" xlink:href="sny-20231231.xsd#sny_SECIPESASMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SECIPESASMember_bb052e90-be13-42bc-9e56-42d0d50117bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurMerieuxSASMember_6df85f08-d4d9-41e9-8cdc-ce2cbae4b9a9" xlink:href="sny-20231231.xsd#sny_SanofiPasteurMerieuxSASMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurMerieuxSASMember_6df85f08-d4d9-41e9-8cdc-ce2cbae4b9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareInternationalSASMember_58542b3c-5ed0-426b-8505-d293dd75e4bd" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareInternationalSASMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareInternationalSASMember_58542b3c-5ed0-426b-8505-d293dd75e4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareFranceSASMember_bd72f6e9-c623-402d-90e1-447c32a6d172" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareFranceSASMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareFranceSASMember_bd72f6e9-c623-402d-90e1-447c32a6d172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareGroupSASMember_d9d3ce4b-cfeb-45ff-bc88-e974b546e5b7" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareGroupSASMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareGroupSASMember_d9d3ce4b-cfeb-45ff-bc88-e974b546e5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymePolyclonalsSASMember_4608f89d-c80c-49ec-b6b9-d6dd9453cde4" xlink:href="sny-20231231.xsd#sny_GenzymePolyclonalsSASMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymePolyclonalsSASMember_4608f89d-c80c-49ec-b6b9-d6dd9453cde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiaventisAEBEMember_d05ed9e5-4d1b-4ace-a562-c328e970ba08" xlink:href="sny-20231231.xsd#sny_SanofiaventisAEBEMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiaventisAEBEMember_d05ed9e5-4d1b-4ace-a562-c328e970ba08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisPrivateCoLtdMember_20f0faf4-c1dd-4d6b-b256-c2af95ad4e8f" xlink:href="sny-20231231.xsd#sny_SanofiAventisPrivateCoLtdMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisPrivateCoLtdMember_20f0faf4-c1dd-4d6b-b256-c2af95ad4e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChinoinPrivateCoLtdMember_4eb66500-eee7-4a3d-9d23-4e57c5e8557f" xlink:href="sny-20231231.xsd#sny_ChinoinPrivateCoLtdMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ChinoinPrivateCoLtdMember_4eb66500-eee7-4a3d-9d23-4e57c5e8557f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareHungaryCommercialKFTMember_a7565f67-fbfb-4342-82f1-a90f9da60979" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareHungaryCommercialKFTMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareHungaryCommercialKFTMember_a7565f67-fbfb-4342-82f1-a90f9da60979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareHungaryKFTMember_a94e2646-1e92-480b-907c-5a6661039fc3" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareHungaryKFTMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareHungaryKFTMember_a94e2646-1e92-480b-907c-5a6661039fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_CarraigInsuranceDACMember_8a55b8b3-ea14-4cfa-a674-f93edb64e06f" xlink:href="sny-20231231.xsd#sny_CarraigInsuranceDACMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_CarraigInsuranceDACMember_8a55b8b3-ea14-4cfa-a674-f93edb64e06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeIrelandLimitedMember_46a9ef43-e02a-4b5d-a3e8-cc4393dec80c" xlink:href="sny-20231231.xsd#sny_GenzymeIrelandLimitedMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeIrelandLimitedMember_46a9ef43-e02a-4b5d-a3e8-cc4393dec80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisHoldingsIrelandLtdMember_a6a9959e-8fb7-4287-a564-aa8396735b20" xlink:href="sny-20231231.xsd#sny_SanofiAventisHoldingsIrelandLtdMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisHoldingsIrelandLtdMember_a6a9959e-8fb7-4287-a564-aa8396735b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiSRLMember_6a31cb5a-9e13-4644-aac1-5d5e1283d161" xlink:href="sny-20231231.xsd#sny_SanofiSRLMember"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiSRLMember_6a31cb5a-9e13-4644-aac1-5d5e1283d161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareItalySRLMember_347e8504-9911-4a8e-9316-8566f8b4cf13" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareItalySRLMember"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareItalySRLMember_347e8504-9911-4a8e-9316-8566f8b4cf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeGlobalSarlMember_bc7bbd97-3667-4754-b32e-eb1998496d5a" xlink:href="sny-20231231.xsd#sny_GenzymeGlobalSarlMember"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeGlobalSarlMember_bc7bbd97-3667-4754-b32e-eb1998496d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeLuxembourgSarlMember_9c6c1aa9-7b62-4d31-af3f-ad581b9e7346" xlink:href="sny-20231231.xsd#sny_GenzymeLuxembourgSarlMember"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeLuxembourgSarlMember_9c6c1aa9-7b62-4d31-af3f-ad581b9e7346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisNorgeASMember_b2289aa3-ef7f-42cf-a020-e13cc97c03ed" xlink:href="sny-20231231.xsd#sny_SanofiAventisNorgeASMember"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisNorgeASMember_b2289aa3-ef7f-42cf-a020-e13cc97c03ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBVMember_43909773-87b4-460f-b5d3-0b3e69272515" xlink:href="sny-20231231.xsd#sny_SanofiBVMember"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiBVMember_43909773-87b4-460f-b5d3-0b3e69272515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiForeignParticipationsB.V.Member_ea6bc878-325c-4c58-9417-5c910dbf798a" xlink:href="sny-20231231.xsd#sny_SanofiForeignParticipationsB.V.Member"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiForeignParticipationsB.V.Member_ea6bc878-325c-4c58-9417-5c910dbf798a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiaventisSpZooMember_cc86b906-529a-4940-8cfc-8a6f59b3e157" xlink:href="sny-20231231.xsd#sny_SanofiaventisSpZooMember"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiaventisSpZooMember_cc86b906-529a-4940-8cfc-8a6f59b3e157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcarePolandSpZOOMember_d50b587a-8760-424d-977a-53e3519278a6" xlink:href="sny-20231231.xsd#sny_OpellaHealthcarePolandSpZOOMember"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcarePolandSpZOOMember_d50b587a-8760-424d-977a-53e3519278a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurSpZooMember_a662b206-2564-4ac9-bba9-e91498819685" xlink:href="sny-20231231.xsd#sny_SanofiPasteurSpZooMember"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurSpZooMember_a662b206-2564-4ac9-bba9-e91498819685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiProdutosFarmaceuticosLdaMember_03fe1e0b-a5aa-4075-9405-7b104b341426" xlink:href="sny-20231231.xsd#sny_SanofiProdutosFarmaceuticosLdaMember"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiProdutosFarmaceuticosLdaMember_03fe1e0b-a5aa-4075-9405-7b104b341426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSROMember_5ac3d254-a68b-4a4a-a148-6666ec0396b4" xlink:href="sny-20231231.xsd#sny_SanofiAventisSROMember"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisSROMember_5ac3d254-a68b-4a4a-a148-6666ec0396b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareCzechSroMember_425521c4-7f36-4a4a-8a47-024a6a3070f6" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareCzechSroMember"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareCzechSroMember_425521c4-7f36-4a4a-8a47-024a6a3070f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisRomaniaSRLMember_12899cd2-0c43-4079-98a8-e24230753c68" xlink:href="sny-20231231.xsd#sny_SanofiAventisRomaniaSRLMember"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisRomaniaSRLMember_12899cd2-0c43-4079-98a8-e24230753c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareRomaniaSRLMember_6c74bb9b-5425-4b98-99f4-37d09f0cb32d" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareRomaniaSRLMember"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareRomaniaSRLMember_6c74bb9b-5425-4b98-99f4-37d09f0cb32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisUkHoldingsLimitedMember_af4a1f3b-dc45-4132-8ccd-2b22563e0e84" xlink:href="sny-20231231.xsd#sny_SanofiAventisUkHoldingsLimitedMember"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisUkHoldingsLimitedMember_af4a1f3b-dc45-4132-8ccd-2b22563e0e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaLimitedMember_81cdffb6-87e0-45fd-98d0-0b00945018d7" xlink:href="sny-20231231.xsd#sny_AventisPharmaLimitedMember"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisPharmaLimitedMember_81cdffb6-87e0-45fd-98d0-0b00945018d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiSynthelaboUKLtdMember_1a1be2e6-f964-40d9-86d3-ed69242583ab" xlink:href="sny-20231231.xsd#sny_SanofiSynthelaboUKLtdMember"/>
    <link:presentationArc order="56" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiSynthelaboUKLtdMember_1a1be2e6-f964-40d9-86d3-ed69242583ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaHoldingsLtdMember_90284b01-43f4-48e2-a704-8f846f965594" xlink:href="sny-20231231.xsd#sny_AventisPharmaHoldingsLtdMember"/>
    <link:presentationArc order="57" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisPharmaHoldingsLtdMember_90284b01-43f4-48e2-a704-8f846f965594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareUKLimitedMember_1a98719d-f4df-4f5d-8717-3534504825de" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareUKLimitedMember"/>
    <link:presentationArc order="58" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareUKLimitedMember_1a98719d-f4df-4f5d-8717-3534504825de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AOSanofiRussiaMember_5f046975-eccd-4f69-a7cc-e444b0c4cd95" xlink:href="sny-20231231.xsd#sny_AOSanofiRussiaMember"/>
    <link:presentationArc order="59" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AOSanofiRussiaMember_5f046975-eccd-4f69-a7cc-e444b0c4cd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareLLCMember_fbd85746-644f-4163-bb66-5f8a0b864f92" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareLLCMember"/>
    <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareLLCMember_fbd85746-644f-4163-bb66-5f8a0b864f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiABMember_eae0138e-3c2a-4548-a0d1-c401ae289954" xlink:href="sny-20231231.xsd#sny_SanofiABMember"/>
    <link:presentationArc order="61" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiABMember_eae0138e-3c2a-4548-a0d1-c401ae289954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSuisseSAMember_b24e4142-e7ad-423d-83bb-b3f80d1d848f" xlink:href="sny-20231231.xsd#sny_SanofiAventisSuisseSAMember"/>
    <link:presentationArc order="62" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisSuisseSAMember_b24e4142-e7ad-423d-83bb-b3f80d1d848f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember_403f913b-afef-4a59-bfbc-a4fe792bff51" xlink:href="sny-20231231.xsd#sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember"/>
    <link:presentationArc order="63" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember_403f913b-afef-4a59-bfbc-a4fe792bff51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiIlacSanayiVeTicaretASMember_29de1eba-0658-49e8-8c98-bcca04dded94" xlink:href="sny-20231231.xsd#sny_SanofiIlacSanayiVeTicaretASMember"/>
    <link:presentationArc order="64" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiIlacSanayiVeTicaretASMember_29de1eba-0658-49e8-8c98-bcca04dded94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurAsiTicaretASMember_1d621f45-08b7-4857-a56f-42977a0c0b6f" xlink:href="sny-20231231.xsd#sny_SanofiPasteurAsiTicaretASMember"/>
    <link:presentationArc order="65" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurAsiTicaretASMember_1d621f45-08b7-4857-a56f-42977a0c0b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember_e2ed0f2d-88f8-49fe-ab63-e0810527126f" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareTuketiciSalAnonimSirketiMember"/>
    <link:presentationArc order="66" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareTuketiciSalAnonimSirketiMember_e2ed0f2d-88f8-49fe-ab63-e0810527126f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiSaglikUrunleriLimitedSirketiMember_7fef6842-b9b0-4f64-b95f-a65bdb24d6ae" xlink:href="sny-20231231.xsd#sny_SanofiSaglikUrunleriLimitedSirketiMember"/>
    <link:presentationArc order="67" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiSaglikUrunleriLimitedSirketiMember_7fef6842-b9b0-4f64-b95f-a65bdb24d6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeTherapeuticProductsLimitedPartnershipMember_fddbfd6a-0889-4923-901d-177d87356c12" xlink:href="sny-20231231.xsd#sny_GenzymeTherapeuticProductsLimitedPartnershipMember"/>
    <link:presentationArc order="68" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeTherapeuticProductsLimitedPartnershipMember_fddbfd6a-0889-4923-901d-177d87356c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisIncMember_1f226b18-0134-45ca-bd33-bed3f709c508" xlink:href="sny-20231231.xsd#sny_AventisIncMember"/>
    <link:presentationArc order="69" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisIncMember_1f226b18-0134-45ca-bd33-bed3f709c508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiUSServicesIncMember_3fc2c1bb-07cc-4acb-8857-0b61010e6f5e" xlink:href="sny-20231231.xsd#sny_SanofiUSServicesIncMember"/>
    <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiUSServicesIncMember_3fc2c1bb-07cc-4acb-8857-0b61010e6f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisUSLLCMember_34a2763c-a719-4b71-9f7e-1b89a632bd9f" xlink:href="sny-20231231.xsd#sny_SanofiAventisUSLLCMember"/>
    <link:presentationArc order="71" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisUSLLCMember_34a2763c-a719-4b71-9f7e-1b89a632bd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChattemIncMember_2aebdce1-a245-4450-9ac6-c394d41d4daf" xlink:href="sny-20231231.xsd#sny_ChattemIncMember"/>
    <link:presentationArc order="72" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ChattemIncMember_2aebdce1-a245-4450-9ac6-c394d41d4daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisubLLCMember_9ba625cf-c0ce-4101-b8c6-cacf162dca0c" xlink:href="sny-20231231.xsd#sny_AventisubLLCMember"/>
    <link:presentationArc order="73" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisubLLCMember_9ba625cf-c0ce-4101-b8c6-cacf162dca0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_GenzymeCorporationMember_1b99e702-36a0-499b-b361-d195a81993fb" xlink:href="sny-20231231.xsd#sny_GenzymeCorporationMember"/>
    <link:presentationArc order="74" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_GenzymeCorporationMember_1b99e702-36a0-499b-b361-d195a81993fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurIncMember_968c4cd3-2b94-4133-add3-daba4a2b662f" xlink:href="sny-20231231.xsd#sny_SanofiPasteurIncMember"/>
    <link:presentationArc order="75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurIncMember_968c4cd3-2b94-4133-add3-daba4a2b662f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_VaxServeIncMember_1b73a921-b3d7-4963-9855-419473853049" xlink:href="sny-20231231.xsd#sny_VaxServeIncMember"/>
    <link:presentationArc order="76" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_VaxServeIncMember_1b73a921-b3d7-4963-9855-419473853049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativIncMember_0940bdca-1bdf-4e2d-af6b-12c7fbf40c27" xlink:href="sny-20231231.xsd#sny_BioverativIncMember"/>
    <link:presentationArc order="77" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_BioverativIncMember_0940bdca-1bdf-4e2d-af6b-12c7fbf40c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativUSLLCMember_3e04c317-494b-4824-8e61-a731645c0672" xlink:href="sny-20231231.xsd#sny_BioverativUSLLCMember"/>
    <link:presentationArc order="78" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_BioverativUSLLCMember_3e04c317-494b-4824-8e61-a731645c0672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BioverativTherapeuticsIncMember_e61f8954-576f-416f-931c-13fc156257ed" xlink:href="sny-20231231.xsd#sny_BioverativTherapeuticsIncMember"/>
    <link:presentationArc order="79" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_BioverativTherapeuticsIncMember_e61f8954-576f-416f-931c-13fc156257ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_PrincipiaBiopharmaIncMember_c0205645-4491-42b7-8fbf-ace84f071e20" xlink:href="sny-20231231.xsd#sny_PrincipiaBiopharmaIncMember"/>
    <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_PrincipiaBiopharmaIncMember_c0205645-4491-42b7-8fbf-ace84f071e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiResearchInvestLLCMember_04f094f1-f000-4290-9e39-80329fa476c4" xlink:href="sny-20231231.xsd#sny_SanofiResearchInvestLLCMember"/>
    <link:presentationArc order="81" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiResearchInvestLLCMember_04f094f1-f000-4290-9e39-80329fa476c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBioverativHoldingsLLCMember_6b125643-fcf2-4385-991f-af098def9462" xlink:href="sny-20231231.xsd#sny_SanofiBioverativHoldingsLLCMember"/>
    <link:presentationArc order="82" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiBioverativHoldingsLLCMember_6b125643-fcf2-4385-991f-af098def9462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_RPRUSLtdMember_f2fe1d98-e99a-42d8-87f8-bf0d2b939620" xlink:href="sny-20231231.xsd#sny_RPRUSLtdMember"/>
    <link:presentationArc order="83" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_RPRUSLtdMember_f2fe1d98-e99a-42d8-87f8-bf0d2b939620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_KadmonCorporationLLCMember_487d3fd4-ec93-4cbe-a104-7b4899330a47" xlink:href="sny-20231231.xsd#sny_KadmonCorporationLLCMember"/>
    <link:presentationArc order="84" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_KadmonCorporationLLCMember_487d3fd4-ec93-4cbe-a104-7b4899330a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AmunixMember_751bf9a3-e2fd-4401-8f06-ef2832db4417" xlink:href="sny-20231231.xsd#sny_AmunixMember"/>
    <link:presentationArc order="85" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AmunixMember_751bf9a3-e2fd-4401-8f06-ef2832db4417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SynthorxIncMember_31dd0a1e-e0f3-4fbd-a6b3-e688c753b62c" xlink:href="sny-20231231.xsd#sny_SynthorxIncMember"/>
    <link:presentationArc order="86" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SynthorxIncMember_31dd0a1e-e0f3-4fbd-a6b3-e688c753b62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ProventionBioMember_38c76a5f-c82f-4f3f-b11b-50eb8721acc7" xlink:href="sny-20231231.xsd#sny_ProventionBioMember"/>
    <link:presentationArc order="87" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ProventionBioMember_38c76a5f-c82f-4f3f-b11b-50eb8721acc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIBIntermediateHoldingsLLCMember_610f4a71-a61b-4021-946c-c60f2f9aaedc" xlink:href="sny-20231231.xsd#sny_QRIBIntermediateHoldingsLLCMember"/>
    <link:presentationArc order="88" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_QRIBIntermediateHoldingsLLCMember_610f4a71-a61b-4021-946c-c60f2f9aaedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_QRIMember_535e0f0c-cbb3-45c2-852e-a20f14d87937" xlink:href="sny-20231231.xsd#sny_QRIMember"/>
    <link:presentationArc order="89" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_QRIMember_535e0f0c-cbb3-45c2-852e-a20f14d87937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TargeGenIncMember_df26de3c-4e93-44a6-8c10-10104760f661" xlink:href="sny-20231231.xsd#sny_TargeGenIncMember"/>
    <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_TargeGenIncMember_df26de3c-4e93-44a6-8c10-10104760f661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ChattemGBHoldingMember_55a95701-a8b1-4acd-b1ba-eb43167485aa" xlink:href="sny-20231231.xsd#sny_ChattemGBHoldingMember"/>
    <link:presentationArc order="91" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ChattemGBHoldingMember_55a95701-a8b1-4acd-b1ba-eb43167485aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_TranslateBioIncMember_35a44280-99de-4d01-8075-ac2739a05501" xlink:href="sny-20231231.xsd#sny_TranslateBioIncMember"/>
    <link:presentationArc order="92" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_TranslateBioIncMember_35a44280-99de-4d01-8075-ac2739a05501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSouthAfricaPtyLtdMember_fc322da9-cf56-4741-8241-4f4553e28c71" xlink:href="sny-20231231.xsd#sny_SanofiAventisSouthAfricaPtyLtdMember"/>
    <link:presentationArc order="93" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisSouthAfricaPtyLtdMember_fc322da9-cf56-4741-8241-4f4553e28c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisAlgerieMember_c8f1427f-5b44-4e82-a765-801d2a34e12c" xlink:href="sny-20231231.xsd#sny_SanofiAventisAlgerieMember"/>
    <link:presentationArc order="94" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisAlgerieMember_c8f1427f-5b44-4e82-a765-801d2a34e12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiArabiaTradingCompanyLimitedMember_5163f9d9-8f27-442d-9563-e007ea771b24" xlink:href="sny-20231231.xsd#sny_SanofiArabiaTradingCompanyLimitedMember"/>
    <link:presentationArc order="95" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiArabiaTradingCompanyLimitedMember_5163f9d9-8f27-442d-9563-e007ea771b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisArgentinaSAMember_78135f9b-4386-4674-9ce4-54af1faaba26" xlink:href="sny-20231231.xsd#sny_SanofiAventisArgentinaSAMember"/>
    <link:presentationArc order="96" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisArgentinaSAMember_78135f9b-4386-4674-9ce4-54af1faaba26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisHealthcarePtyLtdMember_1714bd95-0790-43ea-9de3-43ad658fee2d" xlink:href="sny-20231231.xsd#sny_SanofiAventisHealthcarePtyLtdMember"/>
    <link:presentationArc order="97" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisHealthcarePtyLtdMember_1714bd95-0790-43ea-9de3-43ad658fee2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisAustraliaPtyLtdMember_44d0d8a1-31fd-49dc-98e4-3539a9f7de3e" xlink:href="sny-20231231.xsd#sny_SanofiAventisAustraliaPtyLtdMember"/>
    <link:presentationArc order="98" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisAustraliaPtyLtdMember_44d0d8a1-31fd-49dc-98e4-3539a9f7de3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiMedleyFarmaceuticaLtdaMember_6329fae8-1b3f-4232-9076-cee761903c2a" xlink:href="sny-20231231.xsd#sny_SanofiMedleyFarmaceuticaLtdaMember"/>
    <link:presentationArc order="99" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiMedleyFarmaceuticaLtdaMember_6329fae8-1b3f-4232-9076-cee761903c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareBrazilLtdaMember_22e69630-0a4c-451e-8b81-2b31d9604750" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareBrazilLtdaMember"/>
    <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareBrazilLtdaMember_22e69630-0a4c-451e-8b81-2b31d9604750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisCanadaIncMember_42199202-1b52-43b1-b889-1395512df30c" xlink:href="sny-20231231.xsd#sny_SanofiAventisCanadaIncMember"/>
    <link:presentationArc order="101" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisCanadaIncMember_42199202-1b52-43b1-b889-1395512df30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurLimitedMember_a5a31789-53ea-44f6-a4f8-25996dcf8b7d" xlink:href="sny-20231231.xsd#sny_SanofiPasteurLimitedMember"/>
    <link:presentationArc order="102" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurLimitedMember_a5a31789-53ea-44f6-a4f8-25996dcf8b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MerieuxCanadaHoldingsULCCanadaMember_e3a4cd49-84d4-4813-8f32-76e59e61b21d" xlink:href="sny-20231231.xsd#sny_MerieuxCanadaHoldingsULCCanadaMember"/>
    <link:presentationArc order="103" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_MerieuxCanadaHoldingsULCCanadaMember_e3a4cd49-84d4-4813-8f32-76e59e61b21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiHangzhouPharmaceuticalsCoLtdMember_cea21204-a1d7-497d-a025-1099c09a8f49" xlink:href="sny-20231231.xsd#sny_SanofiHangzhouPharmaceuticalsCoLtdMember"/>
    <link:presentationArc order="104" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiHangzhouPharmaceuticalsCoLtdMember_cea21204-a1d7-497d-a025-1099c09a8f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiChinaInvestmentCoLtdMember_3c70b2c2-e4dd-49eb-bbd5-6faa111f7951" xlink:href="sny-20231231.xsd#sny_SanofiChinaInvestmentCoLtdMember"/>
    <link:presentationArc order="105" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiChinaInvestmentCoLtdMember_3c70b2c2-e4dd-49eb-bbd5-6faa111f7951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiBeijingPharmaceuticalsCoLtdMember_b194e847-f2a1-4d3d-884a-bfc36c04fc04" xlink:href="sny-20231231.xsd#sny_SanofiBeijingPharmaceuticalsCoLtdMember"/>
    <link:presentationArc order="106" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiBeijingPharmaceuticalsCoLtdMember_b194e847-f2a1-4d3d-884a-bfc36c04fc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurBiologiesCo.LtdMember_30e61a07-6436-4459-a0f8-ee0002e8c91d" xlink:href="sny-20231231.xsd#sny_SanofiPasteurBiologiesCo.LtdMember"/>
    <link:presentationArc order="107" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurBiologiesCo.LtdMember_30e61a07-6436-4459-a0f8-ee0002e8c91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember_3c25ecf3-7aac-43b5-8f5d-25e86b82d071" xlink:href="sny-20231231.xsd#sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember"/>
    <link:presentationArc order="108" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember_3c25ecf3-7aac-43b5-8f5d-25e86b82d071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_ShanghaiRonghengPharmaceuticalCoLtdMember_a14fe677-19ae-4979-8f9e-2c1167dc0aca" xlink:href="sny-20231231.xsd#sny_ShanghaiRonghengPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="109" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_ShanghaiRonghengPharmaceuticalCoLtdMember_a14fe677-19ae-4979-8f9e-2c1167dc0aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeColombiaSAMember_a82dcbe7-173e-4e2d-a14c-12e5ff37683a" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeColombiaSAMember"/>
    <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisDeColombiaSAMember_a82dcbe7-173e-4e2d-a14c-12e5ff37683a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisKoreaCoLtdMember_fa58aa7b-bd13-44cf-8a11-fd7d2990813f" xlink:href="sny-20231231.xsd#sny_SanofiAventisKoreaCoLtdMember"/>
    <link:presentationArc order="111" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisKoreaCoLtdMember_fa58aa7b-bd13-44cf-8a11-fd7d2990813f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurLtdMember_19c03800-4e12-4479-a7b9-8311665e4c2e" xlink:href="sny-20231231.xsd#sny_SanofiPasteurLtdMember"/>
    <link:presentationArc order="112" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurLtdMember_19c03800-4e12-4479-a7b9-8311665e4c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcareKoreaIncMember_7982b156-6c6a-4aa7-842a-394d81c91ce4" xlink:href="sny-20231231.xsd#sny_OpellaHealthcareKoreaIncMember"/>
    <link:presentationArc order="113" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcareKoreaIncMember_7982b156-6c6a-4aa7-842a-394d81c91ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisGulfFZEMember_4daa9270-5a59-4c1d-a799-1e9d3bfa3939" xlink:href="sny-20231231.xsd#sny_SanofiAventisGulfFZEMember"/>
    <link:presentationArc order="114" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisGulfFZEMember_4daa9270-5a59-4c1d-a799-1e9d3bfa3939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiEgyptSAEMember_c5457b01-b27e-43f5-8369-1ccc21ddc6d2" xlink:href="sny-20231231.xsd#sny_SanofiEgyptSAEMember"/>
    <link:presentationArc order="115" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiEgyptSAEMember_c5457b01-b27e-43f5-8369-1ccc21ddc6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiHongKongLimitedMember_2dbbcb4f-db9f-4540-a544-00244735e9cc" xlink:href="sny-20231231.xsd#sny_SanofiHongKongLimitedMember"/>
    <link:presentationArc order="116" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiHongKongLimitedMember_2dbbcb4f-db9f-4540-a544-00244735e9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiIndiaLimitedMember_5ca6513a-7b35-47bc-bb06-02c79b627658" xlink:href="sny-20231231.xsd#sny_SanofiIndiaLimitedMember"/>
    <link:presentationArc order="117" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiIndiaLimitedMember_5ca6513a-7b35-47bc-bb06-02c79b627658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiHealthcareIndiaPrivateLimitedMember_41749335-0b6d-4d51-ae5f-0a7bf02787f4" xlink:href="sny-20231231.xsd#sny_SanofiHealthcareIndiaPrivateLimitedMember"/>
    <link:presentationArc order="118" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiHealthcareIndiaPrivateLimitedMember_41749335-0b6d-4d51-ae5f-0a7bf02787f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisIsraelLtdMember_299bcf75-b5cc-4440-9105-aaaa4357f24c" xlink:href="sny-20231231.xsd#sny_SanofiAventisIsraelLtdMember"/>
    <link:presentationArc order="119" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisIsraelLtdMember_299bcf75-b5cc-4440-9105-aaaa4357f24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiKKMember_b92243f9-38ca-4b92-8554-f635a5a74d91" xlink:href="sny-20231231.xsd#sny_SanofiKKMember"/>
    <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiKKMember_b92243f9-38ca-4b92-8554-f635a5a74d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SspCoLtdMember_e72114fa-b9da-4d80-baeb-2aac77e119b0" xlink:href="sny-20231231.xsd#sny_SspCoLtdMember"/>
    <link:presentationArc order="121" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SspCoLtdMember_e72114fa-b9da-4d80-baeb-2aac77e119b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisMalaysiaSDNBHDMember_dacaa564-34d6-4947-8b1a-304398984dcd" xlink:href="sny-20231231.xsd#sny_SanofiAventisMalaysiaSDNBHDMember"/>
    <link:presentationArc order="122" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisMalaysiaSDNBHDMember_dacaa564-34d6-4947-8b1a-304398984dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisMarocMember_6bce2515-5d90-4103-aa7a-623dd69ca2ed" xlink:href="sny-20231231.xsd#sny_SanofiAventisMarocMember"/>
    <link:presentationArc order="123" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisMarocMember_6bce2515-5d90-4103-aa7a-623dd69ca2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeMexicoSADeCVMember_7b0639a2-1eff-45f1-9580-0dbb42ffe360" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeMexicoSADeCVMember"/>
    <link:presentationArc order="124" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisDeMexicoSADeCVMember_7b0639a2-1eff-45f1-9580-0dbb42ffe360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurS.A.deC.V.Member_27c58445-5600-4480-a68f-3b6a62bf6c63" xlink:href="sny-20231231.xsd#sny_SanofiPasteurS.A.deC.V.Member"/>
    <link:presentationArc order="125" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurS.A.deC.V.Member_27c58445-5600-4480-a68f-3b6a62bf6c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AztecaVacunasSADeCVMember_defe1fc0-789f-43dd-9c94-c4065c345bd7" xlink:href="sny-20231231.xsd#sny_AztecaVacunasSADeCVMember"/>
    <link:presentationArc order="126" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AztecaVacunasSADeCVMember_defe1fc0-789f-43dd-9c94-c4065c345bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDePanamaSAMember_736fa05e-fd91-4d3f-a302-476d7371e219" xlink:href="sny-20231231.xsd#sny_SanofiAventisDePanamaSAMember"/>
    <link:presentationArc order="127" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisDePanamaSAMember_736fa05e-fd91-4d3f-a302-476d7371e219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcarePanamaSAMember_24a10b33-bddb-467f-ad2f-f72ccc93fd21" xlink:href="sny-20231231.xsd#sny_OpellaHealthcarePanamaSAMember"/>
    <link:presentationArc order="128" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcarePanamaSAMember_24a10b33-bddb-467f-ad2f-f72ccc93fd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisPuertoRicoIncMember_464cf959-38d5-4ea7-b6e4-aaa1b868b83e" xlink:href="sny-20231231.xsd#sny_SanofiAventisPuertoRicoIncMember"/>
    <link:presentationArc order="129" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisPuertoRicoIncMember_464cf959-38d5-4ea7-b6e4-aaa1b868b83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisPhilippinesIncMember_d6c02812-e78c-487e-b402-385906865b81" xlink:href="sny-20231231.xsd#sny_SanofiAventisPhilippinesIncMember"/>
    <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisPhilippinesIncMember_d6c02812-e78c-487e-b402-385906865b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OpellaHealthcarePhilippinesIncMember_8c23df6c-3c2e-4f83-bbb2-d5e6b64e0a62" xlink:href="sny-20231231.xsd#sny_OpellaHealthcarePhilippinesIncMember"/>
    <link:presentationArc order="131" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_OpellaHealthcarePhilippinesIncMember_8c23df6c-3c2e-4f83-bbb2-d5e6b64e0a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisSingaporePteLtdMember_5de0e20a-f697-4a48-b990-c002a370040a" xlink:href="sny-20231231.xsd#sny_SanofiAventisSingaporePteLtdMember"/>
    <link:presentationArc order="132" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisSingaporePteLtdMember_5de0e20a-f697-4a48-b990-c002a370040a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_AventisPharmaManufacturingPTELTDMember_fe8ec031-08c8-48ac-b1cc-d05d9f506924" xlink:href="sny-20231231.xsd#sny_AventisPharmaManufacturingPTELTDMember"/>
    <link:presentationArc order="133" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_AventisPharmaManufacturingPTELTDMember_fe8ec031-08c8-48ac-b1cc-d05d9f506924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiManufacturingPteLtdMember_23b1a676-613e-4205-869f-8c87809c632f" xlink:href="sny-20231231.xsd#sny_SanofiManufacturingPteLtdMember"/>
    <link:presentationArc order="134" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiManufacturingPteLtdMember_23b1a676-613e-4205-869f-8c87809c632f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiTaiwanCoLtdMember_17da57a8-2183-4f26-a52b-8b02aa6644fd" xlink:href="sny-20231231.xsd#sny_SanofiTaiwanCoLtdMember"/>
    <link:presentationArc order="135" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiTaiwanCoLtdMember_17da57a8-2183-4f26-a52b-8b02aa6644fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisThailandLtdMember_e2513c77-2c45-41f8-81d9-0046e46c3e88" xlink:href="sny-20231231.xsd#sny_SanofiAventisThailandLtdMember"/>
    <link:presentationArc order="136" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisThailandLtdMember_e2513c77-2c45-41f8-81d9-0046e46c3e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiPasteurThailandLtdMember_15895ea5-8964-46a7-8208-dd4dca2cf39d" xlink:href="sny-20231231.xsd#sny_SanofiPasteurThailandLtdMember"/>
    <link:presentationArc order="137" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiPasteurThailandLtdMember_15895ea5-8964-46a7-8208-dd4dca2cf39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisDeVenezuelaSAMember_1c1cd16f-97ce-4de3-8b36-dde110659068" xlink:href="sny-20231231.xsd#sny_SanofiAventisDeVenezuelaSAMember"/>
    <link:presentationArc order="138" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisDeVenezuelaSAMember_1c1cd16f-97ce-4de3-8b36-dde110659068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiAventisVietnamCompanyLimitedMember_cfb16c34-37d8-4744-ac84-102e94790d15" xlink:href="sny-20231231.xsd#sny_SanofiAventisVietnamCompanyLimitedMember"/>
    <link:presentationArc order="139" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiAventisVietnamCompanyLimitedMember_cfb16c34-37d8-4744-ac84-102e94790d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_SanofiVietnamShareholdingCompanyLimitedMember_1ce88a9d-0ee2-4306-8efb-7cb059f83a24" xlink:href="sny-20231231.xsd#sny_SanofiVietnamShareholdingCompanyLimitedMember"/>
    <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_ea31da7c-0950-42d6-92b4-59c385259c71" xlink:to="loc_sny_SanofiVietnamShareholdingCompanyLimitedMember_1ce88a9d-0ee2-4306-8efb-7cb059f83a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_a3565864-ac05-457f-954f-0da2643f82fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ce2fe308-fdf1-4b32-a631-65886079da0c" xlink:to="loc_ifrs-full_GeographicalAreasAxis_a3565864-ac05-457f-954f-0da2643f82fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasMember_29671df4-2c42-462d-b9af-5d7eaba4b620" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_a3565864-ac05-457f-954f-0da2643f82fd" xlink:to="loc_ifrs-full_GeographicalAreasMember_29671df4-2c42-462d-b9af-5d7eaba4b620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_5c41e616-92f1-4262-8b47-3260c6af0c1c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_29671df4-2c42-462d-b9af-5d7eaba4b620" xlink:to="loc_srt_EuropeMember_5c41e616-92f1-4262-8b47-3260c6af0c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_59613e2a-2d79-492c-a1ce-67d40236fb3e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_29671df4-2c42-462d-b9af-5d7eaba4b620" xlink:to="loc_country_US_59613e2a-2d79-492c-a1ce-67d40236fb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_OtherCountriesMember_ffb8c486-4fcf-4421-aeeb-c56ad91eb76c" xlink:href="sny-20231231.xsd#sny_OtherCountriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasMember_29671df4-2c42-462d-b9af-5d7eaba4b620" xlink:to="loc_sny_OtherCountriesMember_ffb8c486-4fcf-4421-aeeb-c56ad91eb76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_88bad13d-193e-4880-9ef3-6c7f93593ce3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ce2fe308-fdf1-4b32-a631-65886079da0c" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_88bad13d-193e-4880-9ef3-6c7f93593ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_843e28e1-d03d-4db8-bc6c-aa99501a7be4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_88bad13d-193e-4880-9ef3-6c7f93593ce3" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_843e28e1-d03d-4db8-bc6c-aa99501a7be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="simple" xlink:href="sny-20231231.xsd#Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sny_InterestsInOtherEntitiesAbstract_c0ca5474-c54c-433f-ad99-d0f8bc6a783a" xlink:href="sny-20231231.xsd#sny_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointOperationsTable_64c5809c-407d-4391-a59f-b3bc1be4a2a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sny_InterestsInOtherEntitiesAbstract_c0ca5474-c54c-433f-ad99-d0f8bc6a783a" xlink:to="loc_ifrs-full_DisclosureOfJointOperationsTable_64c5809c-407d-4391-a59f-b3bc1be4a2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointOperationsAxis_1a18e36c-e356-417a-b42d-74eb7a1405f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_JointOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointOperationsTable_64c5809c-407d-4391-a59f-b3bc1be4a2a8" xlink:to="loc_ifrs-full_JointOperationsAxis_1a18e36c-e356-417a-b42d-74eb7a1405f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForJointOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointOperationsAxis_1a18e36c-e356-417a-b42d-74eb7a1405f6" xlink:to="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_HaleonUSLPMember_069ba7af-88a5-4c6e-b5be-a5881652d8da" xlink:href="sny-20231231.xsd#sny_HaleonUSLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_HaleonUSLPMember_069ba7af-88a5-4c6e-b5be-a5881652d8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InfraservGmbhAndCoHochstKGMember_6f6cdbbd-fb13-4ea1-b576-10043f53b767" xlink:href="sny-20231231.xsd#sny_InfraservGmbhAndCoHochstKGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_InfraservGmbhAndCoHochstKGMember_6f6cdbbd-fb13-4ea1-b576-10043f53b767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MapharMember_c5e72f8d-671e-4e3b-8909-ce293bdbdc2f" xlink:href="sny-20231231.xsd#sny_MapharMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_MapharMember_c5e72f8d-671e-4e3b-8909-ce293bdbdc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MCMVaccineBVMember_6279b298-5701-4eb7-b7af-8efeb9ce097b" xlink:href="sny-20231231.xsd#sny_MCMVaccineBVMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_MCMVaccineBVMember_6279b298-5701-4eb7-b7af-8efeb9ce097b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_MSPVaccineCompanyMember_c237124b-dd90-4b1c-9f9c-e7ce22733607" xlink:href="sny-20231231.xsd#sny_MSPVaccineCompanyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_MSPVaccineCompanyMember_c237124b-dd90-4b1c-9f9c-e7ce22733607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_EuroapiMember_c2f47064-c59b-44ad-aee3-b17da039beb9" xlink:href="sny-20231231.xsd#sny_EuroapiMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointOperationsMember_d30ce7a0-92dc-4156-abc9-f054c3169da1" xlink:to="loc_sny_EuroapiMember_c2f47064-c59b-44ad-aee3-b17da039beb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointOperationsLineItems_691ded62-0509-44bc-83e9-213a4b847e76" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfJointOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointOperationsTable_64c5809c-407d-4391-a59f-b3bc1be4a2a8" xlink:to="loc_ifrs-full_DisclosureOfJointOperationsLineItems_691ded62-0509-44bc-83e9-213a4b847e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInJointOperation_a7d43cf8-442e-4b94-9d0c-e8454f516a40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInJointOperation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointOperationsLineItems_691ded62-0509-44bc-83e9-213a4b847e76" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInJointOperation_a7d43cf8-442e-4b94-9d0c-e8454f516a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sanofi.com/role/EventssubsequenttoDecember312023Details" xlink:type="simple" xlink:href="sny-20231231.xsd#EventssubsequenttoDecember312023Details"/>
  <link:presentationLink xlink:role="http://www.sanofi.com/role/EventssubsequenttoDecember312023Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_b196ac5f-bdb0-4263-9cec-a1a1c84a8095" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_b196ac5f-bdb0-4263-9cec-a1a1c84a8095" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_4313d9d2-2271-4a3e-9c4c-5eae7d0c7020" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_4313d9d2-2271-4a3e-9c4c-5eae7d0c7020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_41cda943-f580-414b-8c24-975ae7b6f472" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_4313d9d2-2271-4a3e-9c4c-5eae7d0c7020" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_41cda943-f580-414b-8c24-975ae7b6f472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_InhibrxIncMember_7f9b2228-0f3a-481f-9b32-f10ec5d5598c" xlink:href="sny-20231231.xsd#sny_InhibrxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_41cda943-f580-414b-8c24-975ae7b6f472" xlink:to="loc_sny_InhibrxIncMember_7f9b2228-0f3a-481f-9b32-f10ec5d5598c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a35b6634-dcf8-4613-ae07-03de66f18d69" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a35b6634-dcf8-4613-ae07-03de66f18d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_0328ddfe-517b-4b2d-8ba8-9faad425fe8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a35b6634-dcf8-4613-ae07-03de66f18d69" xlink:to="loc_ifrs-full_NonadjustingEventsMember_0328ddfe-517b-4b2d-8ba8-9faad425fe8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorBusinessCombinationMember_021c9dae-f1b0-4335-a7c5-ed69a0a2e7e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorBusinessCombinationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_0328ddfe-517b-4b2d-8ba8-9faad425fe8a" xlink:to="loc_ifrs-full_MajorBusinessCombinationMember_021c9dae-f1b0-4335-a7c5-ed69a0a2e7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_ad32a8bd-f2d1-4eda-b97f-ab023b45b28b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:to="loc_ifrs-full_RangeAxis_ad32a8bd-f2d1-4eda-b97f-ab023b45b28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_06abd1f7-5726-4a39-afb1-0a388b0de3cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_ad32a8bd-f2d1-4eda-b97f-ab023b45b28b" xlink:to="loc_ifrs-full_RangesMember_06abd1f7-5726-4a39-afb1-0a388b0de3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_0e5ea3b3-8937-4a15-a4d0-5e82dea704ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_06abd1f7-5726-4a39-afb1-0a388b0de3cd" xlink:to="loc_ifrs-full_TopOfRangeMember_0e5ea3b3-8937-4a15-a4d0-5e82dea704ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63ad0d8d-cb08-4b0f-833d-65edb1181980" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63ad0d8d-cb08-4b0f-833d-65edb1181980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b6a1b29b-2d41-43b9-a8fb-314b38f3b12e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63ad0d8d-cb08-4b0f-833d-65edb1181980" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b6a1b29b-2d41-43b9-a8fb-314b38f3b12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_NonINBRX101BusinessSpinCo.Member_16a1eb93-7d0f-4604-9b46-f894aa6771be" xlink:href="sny-20231231.xsd#sny_NonINBRX101BusinessSpinCo.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b6a1b29b-2d41-43b9-a8fb-314b38f3b12e" xlink:to="loc_sny_NonINBRX101BusinessSpinCo.Member_16a1eb93-7d0f-4604-9b46-f894aa6771be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_c39ee905-4758-4137-8ae3-f26fb6e93253" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_c39ee905-4758-4137-8ae3-f26fb6e93253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_6939739d-0d83-40cd-b9bb-26f24af23b78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_c39ee905-4758-4137-8ae3-f26fb6e93253" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_6939739d-0d83-40cd-b9bb-26f24af23b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_INBRX101BusinessRemainCo.Member_981a9155-e762-44e2-b677-4ed7b67b9d61" xlink:href="sny-20231231.xsd#sny_INBRX101BusinessRemainCo.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_6939739d-0d83-40cd-b9bb-26f24af23b78" xlink:to="loc_sny_INBRX101BusinessRemainCo.Member_981a9155-e762-44e2-b677-4ed7b67b9d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_aa1a0525-c386-4edc-95d5-a98a5f215e46" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationPurchasePricePerShare_3f2ffa8d-6c3f-42b3-aef8-80d5c68e6400" xlink:href="sny-20231231.xsd#sny_BusinessCombinationPurchasePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_sny_BusinessCombinationPurchasePricePerShare_3f2ffa8d-6c3f-42b3-aef8-80d5c68e6400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_b1391cdd-fa94-411a-8910-c7a32ee3150e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_ifrs-full_CashTransferred_b1391cdd-fa94-411a-8910-c7a32ee3150e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare_96a646a9-c9c9-460b-a0b3-658cf15107df" xlink:href="sny-20231231.xsd#sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare_96a646a9-c9c9-460b-a0b3-658cf15107df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight_37416546-d43d-4437-80bd-159d67fcfadd" xlink:href="sny-20231231.xsd#sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight_37416546-d43d-4437-80bd-159d67fcfadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_72ea4672-f1a8-4a99-8100-6a9fa80327d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_72ea4672-f1a8-4a99-8100-6a9fa80327d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred_22218186-5819-49d3-95d6-d14647d3e16e" xlink:href="sny-20231231.xsd#sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred_22218186-5819-49d3-95d6-d14647d3e16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sny_BusinessCombinationCapitalContribution_2e479cc2-17cb-4ba5-824d-a6ecf1918033" xlink:href="sny-20231231.xsd#sny_BusinessCombinationCapitalContribution"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_sny_BusinessCombinationCapitalContribution_2e479cc2-17cb-4ba5-824d-a6ecf1918033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_52d68095-50c1-4663-99eb-325b4a6b1224" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_52d68095-50c1-4663-99eb-325b4a6b1224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_a44f4a85-77a6-4856-8841-69b61ce8f8cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_7d6ca746-099f-4644-b761-d3bb1ea1fc38" xlink:to="loc_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary_a44f4a85-77a6-4856-8841-69b61ce8f8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>sny-20231231_g1.jpg
<TEXT>
begin 644 sny-20231231_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(
M    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0
M  ($    %')865H   (8    %&=865H   (L    %&)865H   )     %&1M
M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4
M)&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\
M   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT
M("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M
M,BXQ
M          !865H@        \U$  0    $6S%A96B
M    6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA9
M6B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N
M:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                     &1E<V,
M        +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E
M("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@                            !D97-C
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0                                  =FEE
M=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6
M %    !7'^=M96%S          $                        "CP    )S
M:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R
M #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\
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M>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$?^6
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MIB=7&87C9':69__:  P# 0 "$0,1 #\ O\
M
M
M
M
M
M
M
M       *Z?%[_B!>LG_,'T\?Z+[$*T/"3-UDY@KDX
M
M
M
M
M
M         9=3_@R?M"_N<#XUUE(YB
M
M
M
M
M
M
M
M   "NCQ?SG'Q O63["Y-_P# #Z>/['=^3_X%]B_^2-@5X>$F;K)S.\;^+/\
MWT_\<5R<=XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_
M (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X
M=XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\
M6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\
MOI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_X
MX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =X
MW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?
M^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_
M (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X
M=XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\
M6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\
MOI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_X
MX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =X
MW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?
M^^G_ (X =XW\6?\ OI_XX X^)GMP7PS]N<9SCY4_V"Y+C/\ Y_\ ]=@* Y=X
MW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?
M^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_
M (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X
M=XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\
M6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\
MOI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_X
MX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =X
MW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?
M^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_
M (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X
M=XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\
M6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\
MOI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_X
MX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =X
MW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?
M^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_
M (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X
M=XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\
M6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\
MOI_XX =XW\6?^^G_ (X =XW\6?\ OI_XX =XW\6?^^G_ (X =XW\6?\ OI_X
MX =XW\6?^^G_ (X =XW\6?\ OI_XX _S)\XQG.4S]F,9SGY4_P!C'R__ "84
M!_O>-_%G_OI_XX =XW\6?^^G_C@!WC?Q9_[Z?^. '>-_%G_OI_XX =XW\6?^
M^G_C@!WC?Q9_[Z?^. '>-_%G_OI_XX =XW\6?^^G_C@!WC?Q9_[Z?^. '>-_
M%G_OI_XX =XW\6?^^G_C@!WC?Q9_[Z?^. '>-_%G_OI_XX =XW\6?^^G_C@!
MWC?Q9_[Z?^. '>-_%G_OI_XX =XW\6?^^G_C@!WC?Q9_[Z?^. '>-_%G_OI_
MXX =XW\6?^^G_C@!WC?Q9_[Z?^. '>-_%G_OI_XX =XW\6?^^G_C@!WC?Q9_
M[Z?^. '>-_%G_OI_XX =XW\6?^^G_C@!WC?Q9_[Z?^. '>-_%G_OI_XX =XW
M\6?^^G_C@!WC?Q9_[Z?^. '>-_%G_OI_XX =XW\6?^^G_C@!WC?Q9_[Z?^.
M'>-_%G_OI_XX =XW\6?^^G_C@!WC?Q9_[Z?^. '>-_%G_OI_XX =XW\6?^^G
M_C@!WC?Q9_[Z?^. '>-_%G_OI_XX =XW\6?^^G_C@!WC?Q9_[Z?^. '>-_%G
M_OI_XX =XW\6?^^G_C@!WC?Q9_[Z?^. '>-_%G_OI_XX R^G_!I_M"_N<#XE
MUE(YB
M
M
M
M
M
M
M                                       "NGQ>_P"(%ZR?\P?3Q_HO
ML0K0\),W63F"N3@
M                                                        <,_P
MI/\ )J_NDA'@!S$
M
M                                         <5/X,_[0W[G(BFL'(0
M
M              !EU/\ @R?M"_N<#XUUE(YB
M
M
M
M
M
M
M
M          "NGQ>_X@7K)_S!]/'^B^Q"M#PDS=9.8*Y.
M
M                         !PS_"D_R:O[I(1X <Q
M
M
M         '%3^#/^T-^YR(IK!R$
M                                           9=3_@R?M"_N<#XUUE
M(YB
M
M
M
M
M
M
M                                     "NGQ>_X@7K)_P P?3Q_HOL0
MK0\),W63F"N3@
M                                                      <,_P *
M3_)J_NDA'@!S$
M
M                                       <5/X,_P"T-^YR(IK!R$
M
M              9=3_@R?M"_N<#XUUE(YB
M
M
M
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MTK1%<U$5:(JT330A+;7,";4T;V-5=;FJG]*&Q@MA0
M
M
M                                                 #5[;'.#A9H6
MW*Z_WGR^XO:8OB$>REEJ3MC?^J-=6Y&*DRG/'22M;N%LAYE./D")&R@ME'":
MN"YR7.>S(NUG@..XC#TG#[*[GMZJFU'#(]M4UIM-:J53A2I]$=I=3-VX8I',
M\J-54]*(;*Q\@PEV#&5BGS.3BY-FVD(V2CW*+UA(,'J)'+-\Q>-CJMW;-VW5
M*HDJF8Q%"&P8N<XSC(M;FN8Y6/14>BT5%T*BIK14\I05%1:+K/V"4@
M         5T^+W_$"]9/^8/IX_T7V(5H>$F;K)S!7)P
M
M                        .&?X4G^35_=)"/ #F(
M
M
M        XJ?P9_VAOW.1%-8.0@
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M3]H7]S@?&NLI',0
M
M
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MB
M
M                        'FR?&+?UFFC/]Q/67_B Y.CJ#<I_V5N/_:#_
M /S,!G.6?^ ?_ME_U6&#^-/PLW4#Y4<?]/<C]>[AX<0]'W;KZM;(JL5<M@[K
MC[7'P=ICD9./:6!C"<>[#$-)9%!;&%DVSYVB4_;@JI\?*+ABF]K+F$8C/AES
M!?.N()',<K61*U5:M%HJS-6GDJB+YBK/F"SMYG0/;*KV.5%HC::/)ZR%GSH
M]%3E-TFMB\E+[R,OV@[K#[6U]3*]7FNC[%LZVR[-Y5)V:F9%25C[;J2@F\%=
MJ_(5N5F9XNJKC)?#Q^3DVJ-XN>L(SC;6MOAD=Q&^&1RNYUL;45'(B)16R/\
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MX
M                                          '#/\*3_)J_NDA'@!S$
M
M
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MSU$155R->YKG)1%7U46NBFM*R-PZ]= MPD:\RB5JM$T>5$545?J0QISNZTO
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M_@R?M"_N<#XUUE(YB
M
M
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MMFFQ][3L[.SP4IH,W6XF3".E5_;]'1U:)][8K6E*:^"E"_GOCASQ(Z*7 /J
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MDYV]>B(KMEK:HU$1-#&M;H1*:$^DP6XN)KJ59IUVI%IIHB:M' B(;#"VE$
M
M
M                     /-D^,6_K--&?[B>LO\ Q <G1U!N4_[*W'_M!_\
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M%]B%:'A)FZR<P5R<
M                                                         #AG
M^%)_DU?W20CP YB
M
M                                         .*G\&?]H;]SD136#D(
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M:*52NG6A3Q*WM;:XYNS?SD6RBUJCM.G15J(A*$,3+>
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M?#E:DZL7;K3955U4UU1/*2K#$"W@
M       %3OJ7?% ^SMYM;JX=?<>^N#ZG_JX_^"+]Y;ZO_G%]8&I:'M+_ *(_
M=_N_FCS1\]_(?^='7E'DOC?O?B>$GN#*VZCQ+@,&-]/YCG]OU.8V]G8D?'][
MGFUKLU^ZE*TTTJ9%88!TVU9<\[L[5=&S6E%5->TGD\AHI_;5_P#VVG_WR?\
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MTBM:JKML1&K155-")JIK/@O8H8;I\5N[;A1="U1:Z$X4T+I-S!8SY0
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MPC-M?6T;*+M<%:F1RX=A#+-9F3UN$CJC=MGWJ:J4KKX-9;;&G#'
MZM>;O4M:4NW;%OT_&U2C4.M3EQN-GF%\-HFNU>M1CF9GIN2<9P;P6,7%LU5E
M3=F<X(3/9C.?D%:W@FNIV6UNU7W$CT:UJ:W.<M$1/.JK0F8QTCT8Q*O5:(GE
M52FGQ7^(1ZF74KY^RW&K@;H#BM!Z*6L<G,-]C[NU[N>W6C6VAX%^RC9#9^S5
MZ=OF@0+R<DS.$S,(5HU9X4D9!K&>5&[%)'.[L7W;Y5RMEU,4S#<W;L0V438B
M?$UKY5152-FU$]41.%RJOJHKZ:FF3W&#6%C9\_>/D6:FIJM1%=Y$JU?3Y$KY
MBZBEA4J26%SIJ+X3)A91)(R*2BN"XPH=)$ZK@Z29C]N2ERH?)<?)DV?V1HQ:
M5T:C%C^@@  *MG70ZJ/57Z5%UJVP-5:JX@;.X@;-=-:_4KM<];;G=WNB;!0B
MU7DA0=BNZ[R%KL'(+33>/<R,-)-(YBBY;$6:G0*LSRLZVUD#*.4,WP/MKR:]
MBQJ)*N:U\6P]E:(]B.A<J4JC7-5RJBT6M'43(,)P_#\08K)'2MN6Z51%;14\
MJ5:OT*E?Z2:?IO<\]9=2'B5KGE!K1+S0:P)N*[L2D+.BO)#6^TZ^BT+<:0_<
ME(EETFR5>(NV#DQ$C/8EZT=932RMX9<%S/EZ[RQC,N$W7K;/K,?J1\:_=<GT
MT5%3@<CDJM*EJOK.2QN76\FFFE%\J+J7].&IO8,?/D
M                        \GCXEW^NTYJ?_2X_^$O0X[!W6_\ 82Q_??\
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MM?\ 4R%''6)?\QG_ -L__64UU-_C/_O+_29>'Q%(\I>R_P#$\MO_ *MQ5/\
MQK0PZ\B_^2E?_8+O_K5383?^0_\ U*O^H>A[UD?ZJGJ"?[J6XO\ 5)^.;,D_
M]K\-_P"N1_ZR&%X9_P PA_VC?Z2H9\&-_M(<UOYD=<?Z^2(W-OP_Y98?[=_^
MHADF:/\  B_OK_0:A_%R?UJT)_NI:A_UMVF+UN:_[(._ZY)_JQGTY;_Y>O\
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MADT?*4P
M                     #S9/C%OZS31G^XGK+_Q <G1U!N4_P"RMQ_[0?\
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MDM.F;4?-<WMTJM:4K_5I6GG^LGL&O"S@
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MV&H#'@
M                                   #BI_!G_:&_<Y$4U@Y"      /
M(=YQ;$F]0=77E_MFM-8M]8]7]1WD!L2 93B#MS"/)ND\FK;98IK,-F#Z,?.(
MMP^C$R."(.6ZQT<FP15,V<&QV;@%M'>Y,LK.552*7#(6*J4JB.@:U:514K1=
M%45*\!LBT8DN&QQNKLN@:B_6U$)@_P"UW=27_P!27!__ -C;?/ZRHPK\F<K^
M_O\ EQ?^@+;X;L?Z\OI;[):8X"]75MM+I6/>H]SA=:TU1'UNQ;&C+,EK&&LD
M; NDJQ9S5RK0=5KUJM]RGI6XVEXHBU;ML2!L.7BQ<%PDGWLEU+F+)BVF;DRQ
M@"2S.>UBMYQ6JOK-VG*Y6M:B-:E55::$3A,?O,-YO$.@VFTY51*5I72E5JJ(
MFA"G12HSDW\2GU2LO[@O-4W3D/V2,ZG$J*2-;XY<<(.1P1I7(-9]DL>[O]U=
M'PCA?*??DYYZN]RW(P:G1;;LG?A6Z[*6S!LOO7:$KH=-,J?>6FG8;KI^JQ$;
M7:6JY,Y8,#P^C:+*OI<[R_0GV)HUJ?UV+6>3WPUO5&8S]-=3%MTO/K*R5:.Y
M65CZUR)XYRLJB:9I%@63(LR:7VE*Y(W65RF92-FVK:031,R<HE<0MI<*WHY3
M6.=&LOFZ'<+H9D30].%6.UI_6:JMKM(M(,=!CEA1U$E37Y6N\J>9?M31K+,'
M7-Y,:BY@= RY<B='61&SZYV38="2T6X_>TY*(?)[?JS6;J]B8IJK9B[/5Y=%
M9C(-<F-X+E V"F.3NG-JS(&%7N"[Q&89?MV+F)LR+Y%3FW4<U>%KDHJ+Y%+%
MA,$EMC"02I1[4=_JKI3S+P%9_HW]8':'2RX]\@W,1PGM?(G65TV35927VTUO
M%AUW2==6E&O^8V=9L<^VU%L6ONGLT5VU5;MU7L:Y^7)2X4\4AB;3SMDNTS;B
M5LC[]EM=1Q.1(]A'N>VM5<U.<8M$TU6CD^BA?<3PV/$)F5E1DB-711%54KK1
M*HO])U;4W'OFY\0SU#7N^;I096LZNN=KJ_UK[0B(64B]3ZAT_5/)(%.GTJ:F
M3F;6*WI0$0HV81Z"ZSV0EU%G;DJ*'E:Z%6\Q+ =VV6DP^"1'W;&.YN-519))
M':=IR)]UM5JJJB(C:-2J[*+-)-:8+9<RQ:R(BT3A<Y>%?(GG\FCR%U_K5],)
MQU"^##33&G4X.O;8T;,1%_T+'/E4HR$E%ZU6Y*L.]7+RC@^$(2.M-:?^"U75
M,5LC)M&1G"B;<JJA=%9%S6F6\?6^O=IUG<-5DRII5-IR.YRG"K7)5432K5=2
MJT0Q;"[_ *%=\[+58WI1WUK6OU+]E2H!P*ZJ//OH11]NXW\A^']ML6HG]TEI
MMGKW:R-ITW/UR[N8TC>4<ZXVBK4[;7I6M6%-JU>KHECI9H[*B5PQ7;X<+JK[
MIS#E'+N\%S,4PV]8V]2-$5\>S*CFUT;<>TU4<W2B+M-5*T<BT1$R6\P^SQ=4
MGAE1)::THZJ>=*HM4^E/.2A:S^(;ZC_4!WAHO7?#GA#(ZPU=+[JUM"[FO=;A
M+9R6FX6D$NE.+?RN;PIK^HZWH,&C59D^9-U(0R[AFV>(JI.FJG<5/B=UNVRQ
MERPN+G&[]);ML#UB8Y6P(K]EVQZFVY[UVD]5$<B*J*BHNHM\F"V-G$]]S+M2
M(Q=E%HW31::*JJZ=6GTF4?B7^C[O/E%:*?S=XJTB3VC<:I0&NNMS:EJ,>K(W
MV<@J]*2TK5+Y2H%KXLC=I=FC.KQLA&,DU)(S9!D=J@O@KCPODW69TP_"87X#
MB\B10/DVXI'+1B*J(CF.74U%HCD<OJU5U53163 L2BMVK:W"[+5=5JKJJNM%
M\GE1=6NI'QQB^*%Y+\,-$5#BYR%X:([(V)IJF05!K%LLFPK+I2U-JW!P2#*F
M%V-1YC65Q>3THRABLRF=(.8<[]JF4Y\>,H9P;),5W3X7CF(/Q;#;[FK:=ZO<
MUK&RMVE6KMAZ/:B(JUT*CJ+YDH?9/@$%U,MQ#+LL<M51$1R5X:+5/\M"S'T3
M.7G.'FOK'D+NGF=K.8U*V?;G2C=%4EYK"6US!Q.NV598)R+:KO+)&-;1>F3:
MR%72=RKQR]P:1(NBD9 J66R.J\]X+@&!7=M8X'*V94@K*Y)$>JO5RTVD:NRQ
M=FE&HB>K15K6JV+%;:TM9&16KD=ZOK+6NFO#30FC@\A0SU\XY,="3J65G:6R
M-"R[N5TG>-E0L)!6Q&:J]*W'0YZMV&BOY.A[ -%S#5VPD:I;4WK&1:DD/(G)
MD<.D3F*LV-T)<IA6\#*SK2UN&HR>-BJK:.=&]'->B/95**CFT5JTJE:+J4RY
M_,8O8K'&]*/1-6E6K5%TI]*:M'F+B6H]I7'XDKIC\P:I>]3P?&-I,[%CX#CD
M\4D+%<V[">H,;4[E"6J;N;N#KR-JCE[ZW>PLDXB8=IAM''<MRI*.DS&-I6]M
M(-U^:K*:WF==JV)5F2C6U1ZN:K4;5=E=BCFHYRU=1:HBF-21MP._B<QRR4;5
MVI-=4I2JTT:4JNLK,\/>3W4K^'<V[M&L[:XIV62U+=)."0V13+RPGH?7]G?P
MCIRU@;GJ7>E?C+!46\L\9KN6)'J!9E@Y24RFX9G<MDO)]IXUA.5MY5E%+9WC
M$O(T78<Q45[476V2)51U$6BT795-:.HJUOMS!8XU&UT<B<XFI4I5/*BM6B_T
M?222W'XGWJ#<NHEWKGI\]/Y[6MC/"I1SZR0!KGRWM5?/)-I1=D^K]:K^K:)7
M(>5\*+6614FF,PQRBT<&.V.4IC)8O!NHRY@STNLQXBC[5-*-79MVK2E45RR/
M<J:43U5:M533Y?A;@-G;+MWLU6>1:,1?I555?10WG^)4Z;^^.8'&SCQR7U%3
MYB_[@XX5N9C]M4& C\O+C9*-=(VM2DO,U^OQJ)CS$I0K3 JJ*QS!+QU6DFX4
M3(?#8I!8-UV9\/P7%+G"KU[8[*Z<BQO5:-:]JN1$55U(]JIZRZ*M1%UGR8%?
M0VT[X)51L;UT*NI%2NOZ4X?,1 ]+OX@?EMQAT%4> 54X1/\ E/LK7[N;J.GC
M0MDN4#=X%*4M$BX2J]XU[$:_N<I;?FY9Y_R)#R=W ';M"I-5<^(7QLYIFS=Q
M@V+8B_,4U^EI:R(CI*M:K%HU/68]7M1NTU*K5'U6JIHT%RO\&MIYEO'2\W&[
M2[0BIJUHM4I5/I(\.D5)6R9ZX_&Z8OL2V@+U*\G]@25T@F2:B3.%MCZ.O[JQ
MQ+1)5[)*IMHZ85613*9RX-@A,8RH?/Y6<ESFV%F0;IENJNMTM&(U5UJU%9LK
MJ36E%U)]!]N)(U,)>C%JQ(TI]&BAZJ@Y%-?  >6]\/5_7B<6/_>]R>_\,F^Q
MUGO(_P"P-W_=@_\ /PF?XU_RJ3Z&_P"NTN2_$V_U06]O^OFB?Z7*H-([J_\
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M9#</BC6K&N5$7RHGT&RXM10             #+J?\&3]H7]S@?&NLI',0
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M:('UT>14^VB\'U^8J+\%/^):K'_U1O?O^O.T1N7,'_R6O_\ 9D/^I&9)=_\
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MA'=]%A&BK$B9I=BP8LXQ1!QVND47>3.\,QK%=U^/X%=28?;1VF,QP*Z)JQI
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M(J,^YDQ/)A?KO-.ZRSO),'N\(2-8U6-SUM(4I1*5KM<]IX';.TM4=YSZI+_
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MF6!K[9ERW[S74^IW_=1/2>B6.:C"@
M                  "/GJOTNX[&Z:G..B:]J=EO=XMO&C:T#5:;38*4L]KL
MTY(U=\WCX:OUV$:OI>:EGRY\$1;MD5%E3YQ@I<YSV#),GSP6V:;"XN7LCMV7
M4:N<Y4:UJ(Y*JKEHB(G"JK0^S#G-9?1/>J(Q)$JJZ$33PJ5:_A+N)'*SCAO[
MEW,\A^,G(30T/9=/T&,KDKN?3&Q]71L_),[H_=/(^$?7BMP;65?-6I\**)(&
M44(GG!C8QC/:-L[XL9PC$\.LF8;=VUP]DSU<D4K)%1%:E%5&.6B?29!F.YMY
MX8DAD8]4<M=ER+31YE+S0T$8F
M                    44/C5_\ \FG_ /3D_P#XJHZ W%__ *4_^IO_ ,X,
MMRM_T_\ F?\ ?G;>AP;H;DZ6&OS\Z<=,?.\22V\37G'( G&E3D-FNEOEJS X
MRG:BFW$=U\U\(^9<-,9>92\'R''>\(4<_>/O%TGA_M7H%(MCF>?YG:V&U^[^
MS^]7:KHK7:X27%NUNT'=$Z1S7JTV=K9K1/)ZNO7]I4YO4!JJ[=4U>M=.Q*<0
MU;9N8M;BN*94T)]Q(-6LELN);T5>%;S)/G7YG:3"I%(PDAC,F2/*CAUG+C"A
ML[AMY+N#*7.YFV5NV63EN-5-#%VZT]6M/O4]6M::*&1,=(S#]J]ISB1+MZO)
MI\WT\%3T!OB7>>_++I^<5M";(XB[7^J2Z77D$6D6:9^8NM;[YRJ^=<W2>S&>
M;MFTZZ1+/_E:);J^,W02<?O?=\3N&,7/.>ZW+N#YCQ>XM<9AYZ".VVVIMO91
MVVU*UC<U5T*NA5IYC#L"L[:\N'QW+=IB,JFE4TU3R*AE[H=<S^2O,'I3N^2?
M(O9/UB;J2L>^6!+I\SZ#4NZTI9EL5I+YNT6K5BIY\VX)C\K+#O+?_+<G'Q9^
MP/"\%S>F%X9%S5CLQ+L[3W?>^]ZSW.=I^G1P%+%K6"VQ#F(&[,5&Z*JNO7I5
M54JR],KK7=?'FKR:QQYUCNW5VZ;M<M;7W,(SW+K?1&M-=Z[79,&QS[8G)/66
MIZ[<YY:F)GSEG%-CNTG3UPD9PT=-DE43;:S5D7=W@6%=I7<$T$#)656)\KWO
MJO\ AHDDCFIM<+EI1$6CD544R"_PK![6#GI&.8Q')]U7*J^;2JII\OVF+>H3
M>_B%^D%O?6VT.0_.[9-YSM)]+SE/L='W/==D\;[!+UA2#=6:FOM.WNMU&F0"
MS)O)M,F8GJC%JN@LH9B=3N.#)_9ENWW;9TP^6TPW#XH^91$<U\363HCJ[+DD
M8YSEK1=/.*J*B;5-%:EDS!<2A='!"U-G6BM1')74NTBJOV_27(=1]9O5=@Z.
M33JL;'KI8M&OZ^DB7C64)(E;K/MWP-K4UEC7U<?/DW1V;&[["PV-&K+$<J,X
MJ1277PIE)7&=)7N1[N/.RY0M755TB;#U35$K><VW(E*JQE=I$I5S51-:&,R8
M7(W$^SF+K=H7^S2M5^A-?G0JH<?MP_$*]?RY[>O_ !XY6%XL:<UU98IIAM4-
MJWKCAK*IR;MA+/(;7T)/:;KECW!L"63BGZCN06E#R"63+-C.54BECD4=NXE9
M;MMW4$-MB5GTN^E8J^M&R:1R51%>J2N;&Q*I1NS34M$7UE7(9HL&P=K63Q\Y
M*Y.%$<J^>CE1J>:E/Z3%T)U1NL5T/.<K'CWSCW;;^2]#@)"O3&Q*1L'8$ANQ
MC?\ 5MK7.8MWU+M>[I%V5"2B3(CH\6FZ79HIOFWD\A'9(3*1?KDRGDG/N +B
M6 0,M;AR*C',8D2LD;^I)&SU%2M-JB*M%JUW"5%P_#,6M.>M&)&]:T5$V:*G
M J)H^G[%+0/Q-L_$6OHG;AM%?>IR<#9+/QPGX222(JFE(1$QM6E2,:]23732
M7(F[9."*%P<A3XP;LSC&?D&J-U4;X<]P12)21K)D5/(J1N14])8,!16XJUKM
M:([^A2/OX,O_ &6^9/\ /]2OZ.TQD>_#_F]C_P!6=_KGV9G_ .(B_N+_ $FG
M?$_K8]3C9?7#@>'UVY,>>N.CWFIM[4CG7?U,\?HWQ-?5>UWV-@J_\[8G5+"]
M$\A90K8GE99/#Y7PNU18YC'R:]XQD3*MKD%V-06NSB:6,<FWSLR^NYK%5=E9
M%9I55T;-/(A]-QA5A'A*W+(Z3\TU:[3M:HFFE:?83:?$N\]^673\XK:$V1Q%
MVO\ 5)=+KR"+2+-,_,76M]\Y5?.N;I/9C/-VS:==(EG_ ,K1+=7QFZ"3C][[
MOB=PQBYP3=;EW!\QXO<6N,P\]!';;;4VWLH[;:E:QN:JZ%70JT\Q:\"L[:\N
M'QW+=IB,JFE4TU3R*A7-U3S-^**ZI/&! G',]_G=?5N8M3.V<@M9%T7QHO>Q
M)--;Q3P,->,RFHTU6],9N4VR2-+;-GIG.5/+5W*Q4R-]F7F![I\I8M_ZSYMM
MRYK5;#)SL[&)Y5923[RZ?VJJE*;*(E:WN2UP##[C]OLH]42C5VG(GU:=?]KZ
MCJW0\ZSO4"U;U#=4<3.4VZMP;QUMNW;".B+O3>0=JL%[OVN-E3<DM4Z]+0-N
MO*TO=J\^K]VRBSDH@[OS>NU4<%.W*Z(W71K9]R/ER[RU-C&$006]U!#SK'0M
M1C'L1-IR*UE&N16U5KJ51:::519L6PNSDLG7-NQK)&-VD5J414UKH31JU+K+
M8?7CZOBG2GX\U)76\' VSDMOF2GZ_J&*LOBN*W4XFLM8]:X[+LL6T7;.YEK7
MCS;!JQ8>,W([?OB'.<R#9=)33V[W):9OQ)Z73G,PNW1%D5OWG*ZNRQJKJK15
M5:+1$\JHJ8[A&&]HS+MJJ0,IM4UK74B?25I-'<//B<^H_HN%YJP/4'N^NX#8
MD!)V37E&<<IMJ\>YR_P.)*:?,).M:WT-4([5%=;V)^HJ2,4E5X;O,S-OE2CR
M-C$VG?XUNJRQB#L"DPV.62)R->_H\<R,6B(J.?,Y9';*?>V4=IKK=4OLMS@-
MC,MJL*.<U:*NPCJ?2KEJM.&E?29NZ!G7)YG27-B,Z=G/JYS&U4;S,7#7E-N=
MY;1RNSM6;AH;*:=JU"R6>&;$<7. LCBO/(Q0\CY<^;2QVITWA&F%R9^#>)D'
M V8$N9<NL;"L;6O<UE>;DC>J)M-:OW5;M([U:(K:^K6A1QC";5+7IMFB-HB*
MJ)J5J\*)P*E:Z.#@J7QQSV8B8!Y7MMTO>+?)1GQN,X)R)=Z!W&VT(=H[KC!T
M3=*^N[&EJTS9]<%FU29."WD[')%911..3-V&<F*C@^<7'!UL6XM:NQ2G9B7,
M?/?>7]EMMYS0WUE]2OW?6\FDK6_-)<1K/_@;;=K7]VJ5U:=7DTE,!STA/BF-
MHQ[F_P!LZF[Z@V55CG!M?-N<'(RER!\Q[(N6S9M#Z5H2^IVSY^;]ZPJ5\GA1
M;&3KJE+GQ,[Q3.FZ6T<EM#A2215^_P!%A<FE?+*_G*)]&K4G 90F)9?C78;!
M5OEYMJ_ZRU-&^$?63ZK'3\ZB%1X;\V]LW7>%1C-T5?0FZ]=[:L4=M"S0&+)8
MF<*A>*3MM8TK;I"6A4K&G)-L*RKIC+LNZW73*;R=9K?\>R1E#,>6GXW@,,=O
M,L#IHGQM6-J[+578='H:B+L[*^JBM72BZT7Z[K#,.O+);JU:C';"N:J)1-":
ME35P4U:/Z;&GQ'?61W/TSZ'I[4O&)I#Q.]N0#.WS9=IV*"CK,RU?2Z>XAH]1
MY7*U.(/*Y-7.?F)C!$#2;5_',VK1?*K191= R6L]V.2;'--Q/>8JKG8?;*U.
M;:JM61SJK1SDHY&HB:=E4<JJE%1$6MDP3#(K][I+BJPLIH3155\JZZ)YM) _
MQ>X2?$9=0O0<-S+U/U6I1M7[ZS?2,31B<ZN0M/L7ED S102@'%*U+5I'4])L
M$AAND4T>[?1RA%EL*ORH>*94VP<6Q[=GEO$78'>8.BR1JB*_HD+FT5=>U(Y)
M'(GE1':$HVM*%WN+O!+*9;62W]9O#S;53TJM5^G3YBRIT8K/U2]8ZNY=UOJX
MO;S+3NC;##3.M+9/Q-%EVEAUTI6K39K5(U'8>OHULRV2UPZ9D/@CQX[D8O"B
M3-4C3&"-R:NSQ%E*ZN[*7)J1I'<-5'M17HJ/VFM:CF/6K-? B-=I<FUK+%BC
M</DDC=AM$1Z:4TZ%JB)5%U?T+KTE3^2ZMO5OZUG-!#CEQ9Y.1/">FWV2ET]4
MTB&V<XT.QAH&+?,W<?BU;CJ$:_V]=-@S#=DUPNSBU5R.5LN$H^-1;K.$C[@;
MDW)N1<#[3Q:T6_GC1.<<L?.JJJBHNS&Y4C:Q*K174HE%<Y51%,B3#L-PJUY^
MXCYUR:UIM:?,U?51/I^M3?IEPI^*:X%WJC[ C^7=_P"6FOSW.CGV0PI>]+?R
MD4C*L[FW4)/I9UGR@IC.U/DT(9^J=UFMQ3Q9+"[=T4V%&?C,\==CNZ3,-O);
M.LH[.YV'["NB;!5U*IZ\#E:FE-&VY$T*FIU'?&MUE^\8K%B2-]%I5J,T_2Q:
M>E?-PZ9-/B)>N/>^FY'TGC7Q;+ I\H]KU)Q>978$]'1MD8Z5UXM(R$#!3$95
M99N]@IZ\VJ:B7OD)91%S',6T<=1PS=>4H8)BN[3(-OFATF*8MM=DPOV$8BJU
M97T1517)148U%2NRJ.5741R44^#!<)9?*L]Q7H[5I35M+]/D3S:?.0OR73Z^
M*'MO'Q;FO(<^=JQSI;7T=MXF@XWF+NVH;/6KD?7F,RT;(ZOK,+%:'832U>;E
M<N8A2706<+853<I'?**)*9PS,>Z>'$NPFX="K><6/GEMHG1[2JJ+^T<JRJFU
MH1VRJ(E%1=E*ET2\P!LW14A;][9VMAJI6OE7UM?#3["0OX:CK@<@^:&Q+KPM
MYBV='9&Q(:A2&R]/;B<1,;$6>?B*U(1,9:]?W8E?8L(F:DF3&80D8R2RV0=*
M(-7Q'J[E4S;.,;WI9"PW [:/'<$9S5LZ1&21U56HKD56O;555$545KFU5*JW
M91$J?%CN%0VK$NK9-EBK1S>#3J5*^A4^BA5IZ]OM!OO[S7M$O^G/S0D?N^_]
MB?\ LH_7-N+ZJ/\ L-_Y'_YX\]_\]_\ OR?_ #9^1Y.-M;O/#GAUOAK_ (?;
M3GO\7_B.:CYS_%TZMG[OJ?U>$R#!^A=#3H7W*^M][[^RVOWOJU:/(6;>C1_:
M3/K#X*?7E_5E?5Q2O"_V"_\ L#^I=?ZG/^B'_P"$!_ ^8OV?^6O_ )N^7R@:
MJSQ^5_1L0Z!_VJYUW6_\;G?VOWOV/]?^S_5X"PXGV'L3<S_Q^TOO/O;7K:_5
M\OF\A=)&C3%P
M                                   Z1LQHZ?ZWV"Q8MG#UZ]I%K:,V
M;1%1RZ=NG,"_1;MFS=$IUEW"ZQ\$(0F,F,;.,8QG.17M51MU&YRHC4D;5?K0
MG9H>BKJJAYYWPS'!_FGH7JA5[8&\^(/*'3%#0TCMZ)6NVV- ;7UU449638PY
M(Z-5LEPJ</#)R$@=(V$$<K845R7."XSV9'26]3'L"Q'*;K;#[VTGN.D1KLQS
M1O=1%6J[+7*M$X5H9GCUW:S6"LAEC<_;30CD5?0BGHT#F8PD
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M%:M?Z"PIP)ZEO*_J:=)'?.P]#QL3$=1#4\98M6QI(%I1X^#LFSVT+#SE&O\
M$1NT#+:WB6]LB)/)7+234S'HRC-WDJ:+4S9/&M\PY6P?*N<K>VQ!7.RU,K9%
MKMJK8ZJCV*L?KKLJFA6Z5:K=:U4LUY8V]AB+&3:;)U%X="<*:-.CS::4*$4=
M]]WVEJGF_P#K%OOHROB?]DG^V#]<SSSG_#__  #/^U[Q?V/_ 'U__D/\R[!T
M,_L'PMZW_9GH*>\_X;FDI_X7_#I_X3_.,O7HO0=/_!<UY_N;/*^[]?UGH9='
M+VW7SGWO[6__ *-^8:']2/\ LD?\^><+/\]_]F?_ #__ -T/-O\ SO\ O/\
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M'!Y"5$8B6\
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MQ+58_P#JC>_?]>=HC=V8/_DM?_[,A_U(S)[O_D2_[!O]"%D;XR?_ &'>+?\
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MY%1=*+])B;FN8Y6N14<G NL^Z*9
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M;JY")_$[K)IE*0A.MM:B$(0N"D(0O-68P4I2XQC!2EQCLQC'R8P-W2Z=U/\
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M%4^A%EK_ $H6C*ZIMS)PT;_WQ86Z%$O%S?2)X%O(A9-=HCHV/B%3I&4.4LI
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M6#=PL,_^-LVS?\Y',5?L13/,9]7!ME_WJ,3ZZH>G,.5# P
M
M                                   "BA\:O_\ DT__ *<G_P#%5'0&
MXO\ _2G_ -3?_G!EN5O^G_S/^_(\^EQ\,U[2CAM0>6WWU_J7^?-@OT%]7_W;
M_K&\U_,>XR]3\J^=?U]43RWSIYJ\H[GFU'P/$[G>4[O?SDN;-Z?A?&Y,&Z!S
M_-M8NWS^Q7;:CON\R^E*T^\M?,?;B&.]!NG6W-;5$33M4UI75LK_ $EL+I=?
M#P\/.FC=V.[TIZT\B.1L;$JQD)L_8<9#PT!1%)&/Q'S\CK+7T9F00J\M-H*+
MH&?/9&8D6S%8[9!RFFLZ\HT_FS>5C>:8%L%:RVPQ5JL;%55?1:HDCUIM(FA:
M(UK55*JBJB4QW$,:N;]G-41D%=2</DJO#Z$0CU^,G_V'>+?^]:3^B'8HR3<C
M_P _N_\ J?\ ]$8?;EC_ (N3_9_]\AG[X:/^HT?_ /6_E#^Z<"V[TO\ M\G]
MR HX[_S;ZF%77X41PW1ZN=1367124=Z'W:W:)JJD3.Z<%AXMV9!N0YL&66*U
M:JJY*7M-A-,QNSL+G.-L[WT5<FO5$T)<15]*H7_,7_+5_OM)<_C(>1NH9NH\
M4>,D!<8"P;@K-_N>T;M5X=^SD92AUD]7:5R!+:R-ESJ0;RV/)191FU5+A99&
M/45,4A/"RKANY+#+V.:\Q61CFV3XVQM<J*B/=M;2[/E1J(E5U(JHGEI;<LP2
MHZ2=R*D2M1$7RK6NCZ/\IK@EQIW#_9!UI5*&DE,+;\-R64A,IJ+21=/);;)3
M#S*3$[<ZS>-(9O\ . QB9*7S3WG>3^$8V,W-<5LOSGV%<G_#\Q7@YSF]JE?+
M^I_>]765^?B\24K^IL_YU*_]SZ2.+H3=.WII]2";V;I_EYR"W-IGD)'3$ \T
MQ5:%L74]#A]J5.30\@E8R!3V/JB]N+%?X.?*F8T>S>).7#%V11!JH5NZ53R?
M>!F7-.6(XKW!;:"?#5:J2N>R1ZQN32BKL2,V6*G"J414HJI5$/NQ>]OK%&RV
MS&NAIZRJBK1?J5*)3A)]^27PTW0MX?4IUL'DWSFY2Z7K"#=9PW6NF[^.C*9G
M#(IK*F8U*J-^,CJUW28.FW4RFQB&3UXKA,W<2-W<]FNL+WI9_P :G2VPK#[2
M>55_5BF5$\[G<_LM3SN5$\Y9X,=Q:Y?L00QN=YFN^U=JB?62 _$?PM>K?0CO
M5=J3Y])U2 6XK0M9DI/L\Y2%>B]AT%C"OI#NLHTOESN-0345[&S?'B&S^]D_
MP<8YNQ?)+O!CEF1$F=TA7(FI%5CU5$TKHKYU^D^+ U<[%VN=]Y=NOTT4T=^#
M+_V6^9/\_P!2OZ.TQ?\ ?A_S>Q_ZL[_7/KS/_P 1%_<7^DKT<%/^):K'_P!4
M;W[_ *\[1&R<P?\ R6O_ /9D/^I&7J[_ .1+_L&_T(61OC)_]AWBW_O6D_HA
MV*-8;D?^?W?_ %/_ .B,+'EC_BY/]G_WR&WOPIG]4/1/Y[MW_P"LC867>]_V
MSD_V$7^J?-F'_F3O[C?Z"FW5R$3^)W633*4A"=;:U$(0A<%(0A>:LQ@I2EQC
M&"E+C'9C&/DQ@;NET[J?_P"0M_\ K5#)G?\ (?\ ZE3_ %"7_P",[UK<T]F\
M(]P^0N%]>/:)M#6OG-)'OM8NYQE@@K1EB_7*CCR9Q/0<MXC,AU,^.6.<Y(7'
MA*9SA6X^Z@6UO[*J=)22-]/*U45M4^A4T^3:3RH6W*\C>;EB_7JB_52GZ?2=
M)Z0G0HZ0W4UXIT/91N3_ "A9\C(V'<,^0&FJ=MC0\7(4.V1DAY YDXZES^@9
M^VMJ!/HN&KF,D%7+YL?#GR?+H[I!=-/Z,Z;P,YY5Q>2UZ):+ABNK#*Z.54>U
M4K17),C=M-*.2B+HK2BHJSXEB^)6%PL?-Q\Q7U7*CM*?2CJ5\J$I''SHI=%G
MI^\_N+ZU7YK[XE.8##8*\EJ#0EKVYI.Z2L]/QE8LL@O\]*1KWC]&VVNUHL+&
MOSX?/WD,S47;^"1SE;.$C8EB6>L\YCRY=I-86Z8*L=))FQRM1$5S4]5[YE:Y
MU530B.6BUI326^;%<4O+.3:B9T:GK.1')PIJ5745?26V1IPQPB+ZX?.?9O3S
MZ=^U>0.EVD:?;*\[2]<4*9F8U.9B*A-7F:*Q7M[R'<MG,=*+04,W=*,T'F/(
ME)#+?"Y5DN\W5S/(6 6N9,RPX=?*O0]ESWHBT5R,2NRBZTJM*JFG9K2BZ4N6
M$VD=[>MAE_PZ*J^>G!^G 4\^DAPAV[UYXKD)LWFMU.>2*D;K^?K]3FM2,=D.
M+%9)RKR/;;GLRYC;A8)&JTG7"#ERX;1C9O7EX[$EE=0N$_)C(N-U9RQZRW>O
MMK7 L*M=N1JN2164:CD]5$JU$<Y^I7*KT=LT336J9+B5U'A"LCM8(ZN15K3A
MU<"55?+IK0AHVYH_2W&OJ[L]$<=[\^VAIG5W+O455HU[D[54[M)3S)G;Z2I)
M'D+/1XF"JLH^83BSIJKEFS;D240RD8F%"'&;V=_?8IDQ<0Q.-(KZ6RD<]B-<
MU$56NI1KU5R(J472JZZZBZ1RRSX;STZ;,KHG*J45.!>!=)?\ZYW$3IV\^G^A
MN-7)[EA6.)'*9I'VZW\:+U9,L4&<M"3S^#@;C6'[*U2-1IUX9R\K#QYD8=.?
MC9TKMLFHT/A%1RFXYTR!C.9<NMN,4PFS?>80JM;.QM:HJ(JM<BM1SF*B*ZKM
MAS**J.TT5,.PFYO;-'SV\:R6^A'(GV+HJJ<.FBIY2HIR_P#AX>>O3=T_>N8E
M)Y0Z)LFJ*+ 1S]S<M5[6O&K]G2-:GD&&5U(R.E(*&K\JS>OU2)MF<=9G[R4)
MX1T6QCF\(FYL%WE9>S1>QX)/:7#;R1RILR1LDC1R5UJBJJ*B:U=&B-TU7A,D
MML:L[Z5+9\;TD5=2HBI7^GTIH)VOA>NI]R0Y+ZZY?ZFYD;'M.Z:3QTI54V9#
M[=V*N_N=PA*C,M[:SM]-N4XJTDK)?FJS2M9D&!WIWLG^]O4<G73,W20U]O8R
MIA>%7-E>8)$R">YD<Q8V4:U7)LJUS4T-9]ZBTHW[JZ%JJVC'[""!\4EJU&/>
MJI1-"5T45.!-=/)J(_-C_#1\<.:CZP;HZ074)X_WS7-J6?6*'TSL65DWJNMD
MW<E%K*5U_=:42VWZ*C8MM+*$19SU0;R[ J;1!TJZ4<G<I9):[TL4P)K;'.F&
MW,=TRC5E8B)MZ%]9&NV6*JTTJR16KI5$1$HOV,QV>U1(L2A>CTT;2</GHM$]
M#J:Z$/M@W1U/NA#R_P Z3;<FGR=DU4:G/IS75)V_+[/X]W2HD44D(FM3]'EC
MMH]HQ>1:SA(K9[$Q4]%-WIE6^&BBQ%<YI'8Y4W@X+T];5.:FVD1[HTCF:[4K
MD>FE51::4<YCE2B[5*%S;%88O;<[S?JNKI5M'(OEK_W51?.;8_%1UB\K=0[7
M6[;)6I*O5C?_ !0TK=*>@]+XI8Q:,9RL/:J>Y?$:-$UYZKRY,'=IYQE0B3YN
M?."D53+BS[HY;=,M2V$3D=+;7DK74X:JBM=3R.35]"^13YLON9T)T35JYDCD
M7_(OUDN7!#X<7HO\^..6N]\:<Y7<O[0K/U*MO=@U: W%QW6G=8WE_'_^_!2K
MA7C\;7$U6)*,FFCM)N1Z7'EC9$KEN==NHFL?#<P[SL\Y=Q.7#[VSLF(U[D8Y
M8YJ2,1=#FKS]'(J4K34NA:*BH6Z[QO%+.=T,L<245:*K7:4X%1=K22&]-KI:
M=(#@'U#64;Q>YD[:V[S!B=2[&,]TO9MI:CV4PK]'<'K4;:9.Z-M6:1K!Z;.-
M#R[#+)K*3#%RY(OE1)LX3*8Q,:S1FW.F8LM*[%K&&'!5F925L<C%5_K*U&\Y
M*[:1:+56M5$I1513XK[$,2O+*MQ$UMLKD]9$5*KII2KEK]2%>SXQAJN3J5:&
M>F3[&SC@WKMJBKWB9[Z[/??))5RGW,&RH7PTWR6>W.,8SWODSG.,]FR-R:IX
M6N&\*8@_[88.(O.65_W%Z</.K_JM+PO39VWJQYT[NG2NAL:D9)<^+7'BD5$J
MUHAFR]FNM<TO7FUAIT$V<O$G$I:X%Q7GZ;V-1*=XU.Q<853+E%3NZ%S19W;<
MRXFBQ2>I=S/=ZJ^JUTJ[+ET:&KM)1RZ%JE%TH8I?1R)>S^JNB1RKHU(KEHOT
M:=9(>,:/B
M
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M,5CC6DK[E)434JL>KD2B>9=?DJGE/BR_,Q[IT3[ROVOJ6O\ 1_E/N=)?H?\
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M*U'47954I5$74JI5*IK2J& [+D;M*B[*K2O =C%(E
M                     .&?X4G^35_=)"/ #F(    *L'Q=W]6UI+_?@UM_
M0-R5&W-S/_:B?_J#_P#SL!D&6_\ CG_[)?\ 6:1J=+G@JZZA/PZ?*'1M7C6D
MCMN&Y?;$VAHS#MY'QN#[5H^JM+N8F%)*2RS:+C/GM"/)" ,Y=+(-6Y97Q55$
MR)Y.7*,V9@3+>\RTQ"552S=9,CEHBK^S?)+5:)I795$?1$55V:(FD^_$+OH6
M-1RN_P -8D1WT*KOZ-"_4;)_#R=$#D_Q$Y07SE#S>U"RUG-T*BGJNA8):^:O
MV X>V6^9>1]SNR2^M+?<VT,M6ZBS4BDBNUFYW!)];)"'\+)BVO>3GW"<9PF/
M"<!F66.23:F78D91K**UOKM;7:<NUH1:;">4^?&L5@N8$M[1VTBK5VA4T)J3
M2B:UT_45NN@1_6^\)?\ KY<_Z(]AC9^\3_L7?_[-O_G&%\QC_ELOT)_K(6IO
MB=^I_P G.'3/17'+C)<Y34<AN>L6Z[;!VI6<F:7E.!A9>.@X2JTJQ9;^-4E7
M#W+IS(/F"I)/N%;)I*MTS+8<:CW4Y4PK&W7&)XJQ)FP/:UD;M+*JBJKG)^MH
MHB(OJZU5%6E,?P&P@N5?/.FTC%1$1=7TJG#_ $&@O'[HOZ@Y8]/*'Z@?.3J3
M[RV!\X-97W;[EDXVS6$ZG0KPY9O'B,#;=A[><[*\LM>)-EX4_@R,8\6>./)\
M9(='QE\BQ+/-[@^979<P#"[>/9E9'7FW;3V:$JUD>Q1M%]32Y$1*\-$^R;%)
M+:]6SM(&-HY&ZEJJ>9&TT>36:#_"Q_UKM;_F(W-_\X0HR+>W_P!CW_\ 6(OZ
M5/KS!_R]?[[?\I(9\8W_ -I_!+_J'O?_ %AUB,:W)_\ "8A_M(OZ)#XLL_<F
M^EO^4E8I?_"NO/\ ZG)??_0EC&(S_P#RN)_[39_2TM[_ /M!^_3^E"'OX/#_
M &B>9?\ ,MKS_7F1&:;ZO^66/^W?_J(7/,O^#%_>7^@P-\780I>I-I7)2E+E
M3A#K8Y\XQC&3FQO?DF3!CYQCM,;!"8QVY^7LQC']P7'<S_V7G_Z^_P#\U 5L
MM_\  O\ ]JO^JTO/]/+_ & >#?\ N>\9OZ%J2- 9D_[17_\ UV?_ ,ZXQ.]_
MXR;_ &KO]93<(64^4\OOJH_\0SL[_>TXW?\ H/38ZORC_P#)M%_U.?\ IE,]
MP_\ Y*W_ &;_ .EQ<(^)M_J@M[?]?-$_TN50:5W5_P#;2W_V<O\ YMQC6!?\
MR9]#O]52//X/3_9CY?\ \^]-_H^3&2[ZO^:V7_5W?ZY]N9?^(C_N+_25Y/B$
MR%)UP^4^"%*3&;!QD/G!<8+C)E.,VACG-G&,8QWCG-G.<_LYSGM&R=V__8&T
M_NS_ /GYB]8+_P JC^AW^LXL@?%^U6PR/#CC%;V+%PXK=8Y'/8JP.T>\=./?
M6C7%D4@5'29,9\-NX^;[M/"QNPA%3$3[>\J7&=8[EYHFXW=PN6DK[5%3SHU[
M:_TIHXBQY;<U+J1J_>5FCZE0S!\*7N?55@Z<LUJ2)LM<:[-U9N?9$Q?ZF>18
M-K*G!V<E?EX&\O(LSCRY6MO6;CS<G(&3*AY1&JH=[O)?+\6]ZQNX\S-O'M<M
MK- Q&.HNS5M45E=6TB^M371R+PE/,,4C;U)%1>;<U*+P:-:?3PT\Y5#YQVFL
M77K\WNS4VQP-MK<GSOU3YML%9EX^>@Y#R.XT*/>>12T4X=L'?DC]HJ@IX:AO
M#63.0W88N<8V_@$,L&[N.*=KF2IA\E4<BHJ5:]4JBZ=6GZ#(;1KF8.C7(J.Y
ME="_0I9C^+__ -BGC%_O1E_HFV"-6;E_^>W?_5/_ *(PL66_^+D_V?\ E0S-
M\.Y4IB_=#.R42O+)MY^ZS7*>I0:ZJI4$D)BQMWL/&K*+F*<J*:3UX0QCY+G!
M<8[>S(^'>7,RVS\RXD_PXVV[E^ANE?L0I8TY&8LCW:D1B^@JD_#\[KUQQ,ZK
MVM'O(A_&:WC'T3M+3;^Q7=9"#CM>WV=AW,9&_.-[(F11@/*9N,-"+++F33;*
M/^U8Q$L*'+M[>-876,9/E;AJ+*]%CE1K=*O8BU791->A=I$3731I,AQF)]SA
MSD@]9:HZB<*>;R^7ZCTL]\<HN//&+6;S<6_-PT76&MVD=F43LMBFD,)S#;N-
MCI)U:-8^63-PD7>'J.&[.*;/';DRQ"I)G,<N,\N8?A.)8K=)98=!)+=*M-EJ
M:O[RK1&IH6JN5$2FE3!H;>:XDYJ%JN?Y$_R^3ZRL9\2QU6^1'&&J\<-+\1[[
M*:Q:<B:#.;3M&X:RBZBKRXIA'<.RJE?I4R]9-Y&E*R!G*[N0=M<H3!"8;)$.
MV(98J^U=UV4,-Q6:ZOL9C25;:1(VQNTLVJ*KE<B+1U-"(BU;K73HI?L"P^&X
M<^6Y3:V%HC5U5X57R_T&C?'[HOZ@Y8]/*'Z@?.3J3[RV!\X-97W;[EDXVS6$
MZG0KPY9O'B,#;=A[><[*\LM>)-EX4_@R,8\6>./)\9(='QE[_B6>;W!\RNRY
M@&%V\>S*R.O-NVGLT)5K(]BC:+ZFER(B5X:)]<V*26UZMG:0,;1R-U+54\R-
MIH\FLT'^%C_K7:W_ #$;F_\ G"%&1;V_^Q[_ /K$7]*GUY@_Y>O]]O\ E,X?
M%X-5R=1O1CPQ.QLOPFU^U24[Q,]]=IO7D6JX)W,&RH7PTWJ6>W.,8SWODSG.
M,]EOW,JGAFX;PI?O^V*'B*66_P#@7_[5?]5I=7Z=&U]8.^GYT]UD-A4ON7#C
M%Q^I=4*K9H=LM9+E7M.0#:?J$&W</$G$G:8-Q /B/(Y$IWC4[)?"J9<HJ=W1
M>9K.[;F/$D6*3U+N9SO57U6K(M'+HT-6J4<NA:I1=*&+WT<B7LWJKHD<JZ-2
M*[0OT:=9Y_G51_XAG9W^]IQN_P#0>FQT9E'_ .3:+_J<_P#3*9AA_P#R5O\
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MW+5P7=PZ'$?5DBPKFW(O]=8=A&<M4898].C8,K9M#FV]%^G9I3TZ"9+XQO\
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M54T>9>,L/C6I90
M                            #BI_!G_:&_<Y$4U@Y"
M
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M4T::UX(8?C<UA%S",:^*M=:HNG7ITI]A%EKGX+C649:&CO;G/Z]W>ED\+R^
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MU=*+M._H1/Z5]!>F&@#$@
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MB5K<V[7+1%EB?&BKY$VVI7ZBK+;W$"(LT;V(O]9JI_2AL +<40
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MBNCA3[K[,"WELZV2+9VN':KPUU;*%L\:=,=
M                                                  /A6:TUBE0;
M^SW*QP52K465 \G8;-+Q\#!QQ'+E!DV,_EI5PU8,RN'CE-$F5%"X.JH4N.TQ
ML8S4BAEGD2*!KGRKJ1J*JKPZ$32N@BUKGKLM15<O AJE5>HST]KU.-*Q2.=W
M#6XV60*Y.PKU5Y/Z1L,X](S;+/7AFD3$7AX_<E:LVZBRF2)FP1(AC&["XSG%
MXFRSF2WC66XP^^9$FMSH)6HE="556(FO0?2ZRO6)M/AE1OE5CD_R&Y0L9\H
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MUIIK0KV^-\Q9)9\U6C52NU377@V?/Y2:/J/\-/:"<,-R\1/K'^J3ZV_J\_\
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M30C4X$^E5JJJJX]<7$UU*LTZU>OZ43S&QHM90
M                                                    .*G\&?\
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MOI.TBB2@
M
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M
M
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MU&HBZ%55X,DQ3$XL.E:JQ;<SFZZHE$KJK15U\%#0]IKOEQTV.IE/<=-&;O\
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M'Q,5J<VCD145:Z=I[]/T*A5OK^:_>U\R-16I3U:I_2JDD8Q<^$
M
M               X9_A2?Y-7]TD(\ .8@
M
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M<Q
M
M
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M_*(_H?\ Z[CU:!R&:]
M
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MP5R<
M                                             #AG^%)_DU?W20CP
M YB
M
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M(1R88                          9=3_@R?M"_N<#XUUE(YB
M
M
M
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M^C0:,<FNB_TON8%S?[&W[P\UQ9;],2"DM8+G4Y.\:AL]IEEO*/'E;A-Z<ME
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M56E:)HH5X,5O[:%((9-F)*T39:NM55=*HJZU)6AB!;@
M
M
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MVWLT_P .'9I6OW>;V:_VJ;5-%:'W]MXIM;7.K6E/NMIZ-FGUZS<SA_TR^"'
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M%]B%:'A)FZR<P5R<
M                                                         #AG
M^%)_DU?W20CP YB
M
M                                         .*G\&?]H;]SD136#D(
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M72?3VI?<QT;G/V&QLTV6_=I2E:5U<-:DI Q(MX
M  !EU/\ @R?M"_N<#XUUE(YB
M
M
M
M
M
M
M                                                          "N
MGQ>_X@7K)_S!]/'^B^Q"M#PDS=9.8*Y.
M
M             !PS_"D_R:O[I(1X <Q
M
M                                                         '%3
M^#/^T-^YR(IK!R$
M                               9=3_@R?M"_N<#XUUE(YB
M
M
M
M
M
M
M
M                         "NGQ>_X@7K)_P P?3Q_HOL0K0\),W63F"N3
M@
M                                          <,_P *3_)J_NDA'@!S
M$
M
M                           <5/X,_P"T-^YR(IK!R$
M
M  9=3_@R?M"_N<#XUUE(YB /BV2Q0U0KL];+&^3BZ]6(64L4])JIK*I1T-"L
M5Y*4?*)-DEG"B;1BV.IDJ9#GS@O84N<]F!4BB?-*V&)*R/<C43RJJT1/K4BU
MJN<C6Z7*M"'O^T,=&O\ ')1?H%NG[-!FGY;9W[ODY<7MES[%Q/W*^EO&/[0Q
MT:_QR47Z!;I^S0/RVSOW?)RXO;'8N)^Y7TMXQ_:&.C7^.2B_0+=/V:!^6V=^
M[Y.7%[8[%Q/W*^EO&/[0QT:_QR47Z!;I^S0/RVSOW?)RXO;'8N)^Y7TMXQ_:
M&.C7^.2B_0+=/V:!^6V=^[Y.7%[8[%Q/W*^EO&/[0QT:_P <E%^@6Z?LT#\M
ML[]WR<N+VQV+B?N5]+>,?VACHU_CDHOT"W3]F@?EMG?N^3EQ>V.Q<3]ROI;Q
MC^T,=&O\<E%^@6Z?LT#\ML[]WR<N+VQV+B?N5]+>,?VACHU_CDHOT"W3]F@?
MEMG?N^3EQ>V.Q<3]ROI;QC^T,=&O\<E%^@6Z?LT#\ML[]WR<N+VQV+B?N5]+
M>,?VACHU_CDHOT"W3]F@?EMG?N^3EQ>V.Q<3]ROI;QC^T,=&O\<E%^@6Z?LT
M#\ML[]WR<N+VQV+B?N5]+>,?VACHU_CDHOT"W3]F@?EMG?N^3EQ>V.Q<3]RO
MI;QC^T,=&O\ ')1?H%NG[- _+;._=\G+B]L=BXG[E?2WC']H8Z-?XY*+] MT
M_9H'Y;9W[ODY<7MCL7$_<KZ6\8_M#'1K_')1?H%NG[- _+;._=\G+B]L=BXG
M[E?2WC']H8Z-?XY*+] MT_9H'Y;9W[ODY<7MCL7$_<KZ6\8_M#'1K_')1?H%
MNG[- _+;._=\G+B]L=BXG[E?2WC']H8Z-?XY*+] MT_9H'Y;9W[ODY<7MCL7
M$_<KZ6\8_M#'1K_')1?H%NG[- _+;._=\G+B]L=BXG[E?2WC']H8Z-?XY*+]
M MT_9H'Y;9W[ODY<7MCL7$_<KZ6\8_M#'1K_ !R47Z!;I^S0/RVSOW?)RXO;
M'8N)^Y7TMXQ_:&.C7^.2B_0+=/V:!^6V=^[Y.7%[8[%Q/W*^EO&/[0QT:_QR
M47Z!;I^S0/RVSOW?)RXO;'8N)^Y7TMXQ_:&.C7^.2B_0+=/V:!^6V=^[Y.7%
M[8[%Q/W*^EO&/[0QT:_QR47Z!;I^S0/RVSOW?)RXO;'8N)^Y7TMXQ_:&.C7^
M.2B_0+=/V:!^6V=^[Y.7%[8[%Q/W*^EO&/[0QT:_QR47Z!;I^S0/RVSOW?)R
MXO;'8N)^Y7TMXQ_:&.C7^.2B_0+=/V:!^6V=^[Y.7%[8[%Q/W*^EO&/[0QT:
M_P <E%^@6Z?LT#\ML[]WR<N+VQV+B?N5]+>,?VACHU_CDHOT"W3]F@?EMG?N
M^3EQ>V.Q<3]ROI;QC^T,=&O\<E%^@6Z?LT#\ML[]WR<N+VQV+B?N5]+>,?VA
MCHU_CDHOT"W3]F@?EMG?N^3EQ>V.Q<3]ROI;QC^T,=&O\<E%^@6Z?LT#\ML[
M]WR<N+VQV+B?N5]+>,?VACHU_CDHOT"W3]F@?EMG?N^3EQ>V.Q<3]ROI;QC^
MT,=&O\<E%^@6Z?LT#\ML[]WR<N+VQV+B?N5]+>,?VACHU_CDHOT"W3]F@?EM
MG?N^3EQ>V.Q<3]ROI;QC^T,=&O\ ')1?H%NG[- _+;._=\G+B]L=BXG[E?2W
MC']H8Z-?XY*+] MT_9H'Y;9W[ODY<7MCL7$_<KZ6\8_M#'1K_')1?H%NG[-
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MQV+B?N5]+>,?VACHU_CDHOT"W3]F@?EMG?N^3EQ>V.Q<3]ROI;QC^T,=&O\
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M_<KZ6\8_M#'1K_')1?H%NG[- _+;._=\G+B]L=BXG[E?2WC']H8Z-?XY*+]
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M;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\
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M;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\
MXV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)
MRX_;'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH
M_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9T
MZA)RX_;'8^)>Z7TMXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[
M?WH__C9H_P!!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y
M=9TZA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TM
MXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9
MP'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z
M7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__ (V:/]!=
MQ_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9P'Y=9TZA)RX_;'8^
M)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/
M]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)RX_;
M'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_P#X
MV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9TZA)R
MX_;'8^)>Z7TMXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_
M_C9H_P!!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZ
MA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?
MWH__ (V:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9P'Y=
M9TZA)RX_;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMX
MQ[?WH_\ XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__ (V:/]!=Q_9P
M'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9P'Y=9TZA)RX_;'8^)>Z7
MTMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/]!=Q
M_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)RX_;'8^)
M>Z7TMXQ[?WH__C9H_P!!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_P#XV:/]
M!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9TZA)RX_;'
M8^)>Z7TMXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__C9H
M_P!!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX
M_;'8^)>Z7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__
M (V:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9P'Y=9TZA
M)RX_;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?W
MH_\ XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__ (V:/]!=Q_9P'Y=9
MTZA)RX_;'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ
M[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/]!=Q_9P'
MY=9TZA)RX_;'8^)>Z7TMXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7T
MMXQ[?WH__C9H_P!!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_
M9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>
MZ7TMXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__C9H_P!!
M=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8
M^)>Z7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__ (V:
M/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9P'Y=9TZA)RX_
M;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\
MXV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)
MRX_;'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH
M_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9T
MZA)RX_;'8^)>Z7TMXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[
M?WH__C9H_P!!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y
M=9TZA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TM
MXQ[?WH__ (V:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9
MP'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z
M7TMXQ[?WH_\ XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__ (V:/]!=
MQ_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH__C9H_P!!=Q_9P'Y=9TZA)RX_;'8^
M)>Z7TMXQ[?WH_P#XV:/]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXQ[?WH_\ XV:/
M]!=Q_9P'Y=9TZA)RX_;'8^)>Z7TMXSB?K^=(#)#XQS9I';DIL8_]\7<?[.<9
M_P#O< F[K.G4).7'[8['Q+W2^EO&<O;^]'_\;-'^@NX_LX#\NLZ=0DY<?MCL
M?$O=+Z6\8]O[T?\ \;-'^@NX_LX#\NLZ=0DY<?MCL?$O=+Z6\8]O[T?_ ,;-
M'^@NX_LX#\NLZ=0DY<?MCL?$O=+Z6\8]O[T?_P ;-'^@NX_LX#\NLZ=0DY<?
MMCL?$O=+Z6\8]O[T?_QLT?Z"[C^S@/RZSIU"3EQ^V.Q\2]TOI;QCV_O1_P#Q
MLT?Z"[C^S@/RZSIU"3EQ^V.Q\2]TOI;QCV_O1_\ QLT?Z"[C^S@/RZSIU"3E
MQ^V.Q\2]TOI;QCV_O1__ !LT?Z"[C^S@/RZSIU"3EQ^V.Q\2]TOI;QCV_O1_
M_&S1_H+N/[. _+K.G4).7'[8['Q+W2^EO&/;^]'_ /&S1_H+N/[. _+K.G4)
M.7'[8['Q+W2^EO&/;^]'_P#&S1_H+N/[. _+K.G4).7'[8['Q+W2^EO&/;^]
M'_\ &S1_H+N/[. _+K.G4).7'[8['Q+W2^EO&/;^]'_\;-'^@NX_LX#\NLZ=
M0DY<?MCL?$O=+Z6\8]O[T?\ \;-'^@NX_LX#\NLZ=0DY<?MCL?$O=+Z6\8]O
M[T?_ ,;-'^@NX_LX#\NLZ=0DY<?MCL?$O=+Z6\8]O[T?_P ;-'^@NX_LX#\N
MLZ=0DY<?MCL?$O=+Z6\8]O[T?_QLT?Z"[C^S@/RZSIU"3EQ^V.Q\2]TOI;QC
MV_O1_P#QLT?Z"[C^S@/RZSIU"3EQ^V.Q\2]TOI;QCV_O1_\ QLT?Z"[C^S@/
MRZSIU"3EQ^V.Q\2]TOI;QCV_O1__ !LT?Z"[C^S@/RZSIU"3EQ^V.Q\2]TOI
M;QCV_O1__&S1_H+N/[. _+K.G4).7'[8['Q+W2^EO&/;^]'_ /&S1_H+N/[.
M _+K.G4).7'[8['Q+W2^EO&/;^]'_P#&S1_H+N/[. _+K.G4).7'[8['Q+W2
M^EO&/;^]'_\ &S1_H+N/[. _+K.G4).7'[8['Q+W2^EO&/;^]'_\;-'^@NX_
MLX#\NLZ=0DY<?MCL?$O=+Z6\8]O[T?\ \;-'^@NX_LX#\NLZ=0DY<?MCL?$O
M=+Z6\8]O[T?_ ,;-'^@NX_LX#\NLZ=0DY<?MCL?$O=+Z6\8]O[T?_P ;-'^@
MNX_LX#\NLZ=0DY<?MCL?$O=+Z6\8]O[T?_QLT?Z"[C^S@/RZSIU"3EQ^V.Q\
M2]TOI;QCV_O1_P#QLT?Z"[C^S@/RZSIU"3EQ^V.Q\2]TOI;QCV_O1_\ QLT?
MZ"[C^S@/RZSIU"3EQ^V.Q\2]TOI;QCV_O1__ !LT?Z"[C^S@/RZSIU"3EQ^V
M.Q\2]TOI;QCV_O1__&S1_H+N/[. _+K.G4).7'[8['Q+W2^EO&/;^]'_ /&S
M1_H+N/[. _+K.G4).7'[8['Q+W2^EO&/;^]'_P#&S1_H+N/[. _+K.G4).7'
M[8['Q+W2^EO&/;^]'_\ &S1_H+N/[. _+K.G4).7'[8['Q+W2^EO&/;^]'_\
M;-'^@NX_LX#\NLZ=0DY<?MCL?$O=+Z6\8]O[T?\ \;-'^@NX_LX#\NLZ=0DY
M<?MCL?$O=+Z6\8]O[T?_ ,;-'^@NX_LX#\NLZ=0DY<?MCL?$O=+Z6\8]O[T?
M_P ;-'^@NX_LX#\NLZ=0DY<?MCL?$O=+Z6\8]O[T?_QLT?Z"[C^S@/RZSIU"
M3EQ^V.Q\2]TOI;QCV_O1_P#QLT?Z"[C^S@/RZSIU"3EQ^V.Q\2]TOI;QCV_O
M1_\ QLT?Z"[C^S@/RZSIU"3EQ^V.Q\2]TOI;QCV_O1__ !LT?Z"[C^S@/RZS
MIU"3EQ^V.Q\2]TOI;QCV_O1__&S1_H+N/[. _+K.G4).7'[8['Q+W2^EO&/;
M^]'_ /&S1_H+N/[. _+K.G4).7'[8['Q+W2^EO&32ZEVG0-X:QH>X-5V-M<-
M;[)JT/<:1:6;:09-9^M3K-)]$RK=I+,X^3;I/&JI3E(N@DJ7&>PQ<9^08+>6
MEQ87<EE=M5EU$]6O:M%HY%HJ51531YE+5)&^)ZQ2)21JT5/(ID,?,2'R9^"B
M+3!359L#!"5@;%$R,%-Q;K!C-9*(EV:T?),')2F*8R#QDX.F?&,XSDIL_*)X
MY'Q2-EC6DC5147R*BU1?J4BU5:J.;H<BD6?L+>D7^ K1/Z*F_3@RWQ_G/O&X
M]*<1<.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P
M%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(
M=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^B
MIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+W
MS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^
MG \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<
M0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_S
MGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI
M%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]
M*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\
M!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=
MKXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_H
MJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS
M_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#
MQ_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G
M$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SG
MWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ
M1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*
M<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:
M)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=K
MXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ
M;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_
M +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q
M_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%
MO2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GW
MC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1
M?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<
M0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)
M_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7
MOG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOT
MX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_
M[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_
MG/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A
M;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-Q
MZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@
M*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G
M$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_
M14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE
M[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX
M'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LX
MA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?
MYS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;
MTB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<
M>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*
MT3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[
M7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?
MT5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[
MY_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].
M!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA
M["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/
MO&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86
M](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>
ME.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"
MM$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7
MQ+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14
MWZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y
M_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!
MX_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(
M>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O
M&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_
M  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E
M.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M
M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q
M+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14W
MZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9
MQ#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_
M #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>
MPMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&
MX]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_
MP%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XA
MVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^
MBIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\
M2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ
M<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V
M<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.
M?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["W
MI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[Q
MN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P
M%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(
M=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^B
MIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+W
MS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^
MG \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<
M0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_S
MGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI
M%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]
M*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\
M!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=
MKXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_H
MJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS
M_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#
MQ_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G
M$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SG
MWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ
M1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*
M<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:
M)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=K
MXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ
M;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_
M +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q
M_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%
MO2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GW
MC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1
M?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<
M0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)
M_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7
MOG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOT
MX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_
M[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_
MG/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A
M;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-Q
MZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@
M*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G
M$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_
M14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE
M[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX
M'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LX
MA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?
MYS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;
MTB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<
M>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*
MT3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[
M7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?
MT5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[
MY_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].
M!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA
M["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/
MO&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86
M](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>
ME.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"
MM$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7
MQ+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14
MWZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y
M_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!
MX_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(
M>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O
M&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_
M  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E
M.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M
M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q
M+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14W
MZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9
MQ#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_
M #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>
MPMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&
MX]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_
MP%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XA
MVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^
MBIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[QN/2G$.U\
M2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ
M<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V
M<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.
M?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["W
MI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^G \?YS[Q
MN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P
M%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(
M=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^B
MIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]*<0[7Q+W
MS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\!6B?T5-^
MG \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<
M0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_HJ;].!X_S
MGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXA["WI
M%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#Q_G/O&X]
M*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G$/86](O\
M!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SGWC<>E.(=
MKXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ1?X"M$_H
MJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS
M_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:)_14WZ<#
MQ_G/O&X]*<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_ #GWC<>E.(=KXE[Y_P!G
M$/86](O\!6B?T5-^G \?YS[QN/2G$.U\2]\_[.(>PMZ1?X"M$_HJ;].!X_SG
MWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*<0[7Q+WS_ +.(>PMZ
M1?X"M$_HJ;].!X_SGWC<>E.(=KXE[Y_V<0]A;TB_P%:)_14WZ<#Q_G/O&X]*
M<0[7Q+WS_LXA["WI%_@*T3^BIOTX'C_.?>-QZ4XAVOB7OG_9Q#V%O2+_  %:
M)_14WZ<#Q_G/O&X]*<0[7Q+WS_LXB#OCYTMNGS:.M)U2./\ 8.*6K)73.F]-
M<(Y_5^O'3"3-7Z7,[#U].2EUD(9$LH5=)Q8Y!L15QDZA\9,7'9C JQ9^SBM:
MXA<>E.(F;BV(KKF>2[>Q%Z3WX%]'_HN9]-"MX\SAWA<>E.(F[5Q'WSQ[$7I/
M?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_]%S/IH/'F<.\+CTIQ#M7
M$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_T7,^F@\>9P
M[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_
M $7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_ *+F?30>/,X=X7'I3B':N(^^
M>/8B])[\"^C_ -%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X=X
M7'I3B':N(^^>/8B])[\"^C_T7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_HN
M9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7
MI/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_\ 1<SZ:#QYG#O"X]*<
M0[5Q'WSQ[$7I/?@7T?\ HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/\ T7,^
MF@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TG
MOP+Z/_1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVK
MB/OGCV(O2>_ OH_]%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X
M=X7'I3B':N(^^>/8B])[\"^C_P!%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1
M_P"BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_P#1<SZ:#QYG#O"X]*<0[5Q'
MWSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_]%S/IH/'F<.\
M+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_T7
M,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+
MTGOP+Z/_ $7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_ *+F?30>/,X=X7'I
M3B':N(^^>/8B])[\"^C_ -%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?
M30>/,X=X7'I3B':N(^^>/8B])[\"^C_T7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3
MWX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_1<SZ:#QYG#O"X]*<0[5
MQ'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_\ 1<SZ:#QY
MG#O"X]*<0[5Q'WSQ[$7I/?@7T?\ HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+
MZ/\ T7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC
M[YX]B+TGOP+Z/_1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>
M%QZ4XAVKB/OGCV(O2>_ OH_]%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+
MF?30>/,X=X7'I3B':N(^^>/8B])[\"^C_P!%S/IH/'F<.\+CTIQ#M7$??/'L
M1>D]^!?1_P"BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_P#1<SZ:#QYG#O"X
M]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_]%S/
MIH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B])
M[\"^C_T7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=J
MXC[YX]B+TGOP+Z/_ $7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_ *+F?30>
M/,X=X7'I3B':N(^^>/8B])[\"^C_ -%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^
M!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_T7,^F@\>9P[PN/2G$.U<1
M]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_1<SZ:#QYG#O
M"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGG#/1&Z3_B%Q]Q
M?1_9DBF<X\US/[.#)XQ__6O[G;D/'F<*?\PN/2G$.U<1]\\Y^Q%Z3WX%]'_H
MN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_1<SZ:#QYG#O"X]*<0[5Q'WSQ[$
M7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_]%S/IH/'F<.\+CTIQ
M#M7$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_P!%S/IH
M/'F<.\+CTIQ#M7$??/'L1>D]^!?1_P"BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>
M_ OH_P#1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAV
MKB/OGCV(O2>_ OH_]%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,
MX=X7'I3B':N(^^>/8B])[\"^C_T7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'
M_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_ $7,^F@\>9P[PN/2G$.U<1]\
M\>Q%Z3WX%]'_ *+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_ -%S/IH/'F<.
M\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_T
M7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B
M+TGOP+Z/_1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4X
MAVKB/OGCV(O2>_ OH_\ 1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?\ HN9]
M-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/\ T7,^F@\>9P[PN/2G$.U<1]\\>Q%Z
M3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_1<SZ:#QYG#O"X]*<0[
M5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_]%S/IH/'F
M<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C
M_P!%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_P"BYGTT'CS.'>%QZ4XAVKB/
MOGCV(O2>_ OH_P#1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'
M>%QZ4XAVKB/OGCV(O2>_ OH_]%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z
M+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_T7,^F@\>9P[PN/2G$.U<1]\\>Q
M%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_ $7,^F@\>9P[PN/2
MG$.U<1]\\>Q%Z3WX%]'_ *+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_ -%S
M/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B]
M)[\"^C_T7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=
MJXC[YX]B+TGOP+Z/_1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS
M.'>%QZ4XAVKB/OGCV(O2>_ OH_\ 1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7
MT?\ HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/\ T7,^F@\>9P[PN/2G$.U<
M1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_1<SZ:#QYG#
MO"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_]
M%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8
MB])[\"^C_P!%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_P"BYGTT'CS.'>%Q
MZ4XAVKB/OGCV(O2>_ OH_P#1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?^BY
MGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_]%S/IH/'F<.\+CTIQ#M7$??/'L1>
MD]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_T7,^F@\>9P[PN/2G$.
MU<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_ $7,^F@\
M>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_ *+F?30>/,X=X7'I3B':N(^^>/8B])[\
M"^C_ -%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N
M(^^>/8B])[\"^C_T7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SA
MWA<>E.(=JXC[YX]B+TGOP+Z/_1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?^
MBYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_\ 1<SZ:#QYG#O"X]*<0[5Q'WSQ
M[$7I/?@7T?\ HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/\ T7,^F@\>9P[P
MN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_1<
MSZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O
M2>_ OH_]%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B'
M:N(^^>/8B])[\"^C_P!%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_P"BYGTT
M'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_P#1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/
M?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_]%S/IH/'F<.\+CTIQ#M7
M$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_T7,^F@\>9P
M[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_
M $7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_ *+F?30>/,X=X7'I3B':N(^^
M>/8B])[\"^C_ -%S/IH/'F<.\+CTIQ#M7$??/.)^B+TGL$/G'!?1^,X*;./^
M2YG]G&,__P!Z!,^9PK_S"X]*<0[5Q'WSSE[$7I/?@7T?^BYGTT'CS.'>%QZ4
MXAVKB/OGCV(O2>_ OH_]%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30
M>/,X=X7'I3B':N(^^>/8B])[\"^C_P!%S/IH/'F<.\+CTIQ#M7$??/'L1>D]
M^!?1_P"BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_P#1<SZ:#QYG#O"X]*<0
M[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_]%S/IH/'
MF<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B])[\"^
MC_T7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[Y
MX]B+TGOP+Z/_ $7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_ *+F?30>/,X=
MX7'I3B':N(^^>/8B])[\"^C_ -%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_
MZ+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_T7,^F@\>9P[PN/2G$.U<1]\\>
MQ%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_1<SZ:#QYG#O"X]*
M<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_\ 1<SZ
M:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?\ HN9]-!X\SAWA<>E.(=JXC[YX]B+T
MGOP+Z/\ T7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(
M=JXC[YX]B+TGOP+Z/_1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'C
MS.'>%QZ4XAVKB/OGCV(O2>_ OH_]%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?
M1_Z+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_P!%S/IH/'F<.\+CTIQ#M7$?
M?/'L1>D]^!?1_P"BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_P#1<SZ:#QYG
M#O"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ OH_
M]%S/IH/'F<.\+CTIQ#M7$??/'L1>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/
M8B])[\"^C_T7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E
M.(=JXC[YX]B+TGOP+Z/_ $7,^F@\>9P[PN/2G$.U<1]\\>Q%Z3WX%]'_ *+F
M?30>/,X=X7'I3B':N(^^>/8B])[\"^C_ -%S/IH/'F<.\+CTIQ#M7$??/'L1
M>D]^!?1_Z+F?30>/,X=X7'I3B':N(^^>/8B])[\"^C_T7,^F@\>9P[PN/2G$
M.U<1]\\>Q%Z3WX%]'_HN9]-!X\SAWA<>E.(=JXC[YX]B+TGOP+Z/_1<SZ:#Q
MYG#O"X]*<0[5Q'WSQ[$7I/?@7T?^BYGTT'CS.'>%QZ4XAVKB/OGCV(O2>_ O
MH_\ 1<SZ:#QYG#O"X]*<0[5Q'WSQ[$7I/?@7T?\ HN9]-!X\SAWA<>E.(=JX
MC[YX]B+TGOP+Z/\ T7,^F@\>9P[PN/2G$.U<1]\\EVUCK>BZ>UY2]6:RK,;3
M->Z_KD55*94X8BB457J[#-$V<7$1Z:JBRI&C)JF4A,&,;."X_9&&7=U<7MS)
M=W3U?<R.5SG+K<Y=*JOG4MLDCY7K)(M7N6JKY5.]#YR0
M
M
M
M
M
M
M
M                 *Z?%[_B!>LG_,'T\?Z+[$*T/"3-UDY@KDX
M
M                                '#/\*3_)J_NDA'@!S$
M
M
M                <5/X,_[0W[G(BFL'(0
M                                                 !EU/^#)^T+^
MYP/C764CF(
M
M
M
M
M
M
M                                            *Z?%[_B!>LG_ #!]
M/'^B^Q"M#PDS=9.8*Y.
M
M!PS_  I/\FK^Z2$> ',0
M
M                                             !Q4_@S_ +0W[G(B
MFL'(0
M                    !EU/^#)^T+^YP/C764CF(
M
M
M
M
M
M
M
M               *Z?%[_B!>LG_,'T\?Z+[$*T/"3-UDY@KDX
M
M                              '#/\*3_)J_NDA'@!S$
M
M
M              <5/X,_[0W[G(BFL'(0
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MH;N>Z2CD8FVC6M574>M7(E=A*(M-*Z-*EJL>/QSP
M
M
M
M
M
M
M   %=/B]_P 0+UD_Y@^GC_1?8A6AX29NLG,%<G
M
M                    X9_A2?Y-7]TD(\ .8@       -:.6G,3C?P8T^]W
MURIV8UU1JEA/0=76L[BN7&VJJ6"R+JH0T4QKE"KUJM4FZ=Y04/G#9BKA%!)1
M53)$DSG+!51J574*T->^%W5MZ>G4,NMMUSP_Y$,]N7>C59.ZV:N'UON'7L@Q
MJJDLS@C3;7&T]>TA&89MI>2;(+Y9'<&;G<H^+@F%4\F@CFNU!%1=1(V)@=5O
M%[H^L:C8-@;*N54U[0ZE&KS-JNUXL,14ZC68=KC&7,K8+)/O(^&AHUO@V.^N
MY632)V_*;  Z-I?D5Q]Y(04K:..^]=.;ZK,%+>8)RQ:7V=2=I04-.^1MI'S+
M*R]'FYV/CI;S>\17\F64(MX*I#]WNF+G)%1=0,Q@            .IWZ\U;6
M%%NFRKS*>8Z3KRIV.\W":\BD9/S/5JE#O)^P2GFZ':2$M(>;XF/65\!J@NY5
M[G=33.?)2Y:@:.<*^JYP$ZB%EN]/X=[Z^N"Q:X@XVR7..^JW=&O_ #-"R[]6
M+CGOE>T==4EC(^4/D3$\-HJNJ3L[QBE+V9$J.:[4$5%U$AXF
M%=':W7Z^K'K-1?2,^Z;Y[\Y;)TUKW[P7U[^;?!^MS4E&VEYW^JCZFG_B?-_Y
MZ>0^3_.4OE?DWC>(CXGA$IK)1^S0A730L7"H1
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MCM01474;I"(
M      .*G\&?]H;]SD136#D(
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M\RC28
M
M
M
M
M
M                            5T^+W_$"]9/^8/IX_P!%]B%:'A)FZR<P
M5R<
M                                            #AG^%)_DU?W20CP
MYB        H,_%T<B++O_DQPMZ7VGS+3UGQ-0>P[+76:CE5*5V[NB7+K#2-;
M6;M_$SB:B81Q)N,8P@JIEM9D?#SVF.3-&5:JC4)':Z$>>O**M\/-\0WJ2D25
MADG&A9E:A5J1M\T;"2%DT-R+K3*IV&T26$\HK9B=9[3([=YQ^4H96JXSV+=O
M8I+_ (<GF'W5/3R'T$Y"=U]>0.A===,[F/J78.[M147:NT^.-Z1UCK.Y;)IM
M8V#L94BC1H=*ATR;FF-CMZA'><)9+'MG&<*9[O[/R"5ZHC51=="#M1 -\)/S
M'XA\;^&G)6K\B.5/&_0MFG>39I^#KNZ-XZQU;.S,%]5=!CO/45$7BT04A(Q/
MG!FLAY2BF='QDCD[W>*;&*<2HC=*\)!JEQ_2W,+B1R2F)BO<=N4G'/?D_78U
M.9L$'I;=VL]IS$%#K.B,4968C*-9YU[&1JKU4J)5UR$2,J;!,&[V<8%5%1=2
MDU3-=KMM4H=;FKE>;-7J94*U'N):Q6NUS4;7:W 130G?=2<U.3#EG%Q4>V)\
MJBRZJ:9,?+G.!$$-5W^(VZ+&O[0]J$]SHIS^6CU")+NZ1K#?>S*NH93/87+*
M[ZWU3:Z7)IXSC\H[:05(7^[G DYQGE(;2$F7'/ECQGY=U%[>^,>]=8;SJT6^
MQ%S<EK>W1%D4KLH?"ID8NSQK)P:5K$DZ01RLBWD$&RR[?)5DRF2.0YID5%U$
M:U-@Q$&N6MN8O$;<U\G]5Z?Y3\<=K;/JK.9D;1KC6V[]97J^5N/KDFUA;"^G
MZA5[/*6&'9P,R^0:/57#=,C5RL1)7)3G*7,$5%T(ND50T*W=U^.C[QZN3N@[
M)YR:T6L\>LX:R+;65<V?O2-C7K3"'ED?(V/1U$V+6X^29J.,)+-EG9%TER*I
M')A1%4A(+(Q.$A5#??C-RZXR<RJ$;9G%S=^O-W4QNZ+'RDE19]O(O:Y)J$,L
ME#V^OJ^3V.FS2S;&%R,I5HS=';G(L5/*1R'-%%1=*$:U.][PI%/V9I7;^M]A
M3CBLT'8&KM@4B\61I)1<*[K]/M=3EH&RSC:8FVC^%B7$3"OUUR.7B"S5 R>#
MJIG3*8N8KJ!!WT4^G/TJN&=]WM=^G-S6=<M)^UU"G57:3 G(_CEOAE2(?$S+
MR]8>.&NBZ/5GM:=3KU@\(BI(JJ).B-5<)$[R1S8D8UJ?=6I!$1-184$Y$C\Y
M:=57IX<&I%6 Y1\K]7:SMR#-M(N=?HNIB^[-:1[UU'LV+YYK#6D1<=@M&;Y2
M2(=!56-(19!-=8F3(MG)TH*YK=:BJ(8$TKU].CYO^Q$JFO>=>J&4VLZ;,6R.
MTXK86A63UX\;OG#5M'S&]:7KB&D%E\1YTRE0<*9RX410_AG"":D$>Q>$A5"7
M*.D8^7CV,M$OF<I%2C-K(QDG'.D'L?(Q[U CEF^8O&QU6SMF[;*E4253,8BA
M#8,7.<9QD3$3]@  ##&]^1>AN+]">;0Y$[?UYI:@,EBM3VG8UIB:M&.9!0AU
M$(F,/)N4%9F:=D3-X#)H1=VOG&<)IFS\@*J)I4$6=1^(TZ+-VM2--AN=--92
MZZSA CRW:SWQK^JE.V-DJAEKW?-5UND-D39Q^]J*2)4UL?*F8V,XR).<9Y2&
MTA4NWQ=:;L?XPK7=YU[;:Q?*39N0?#&4K=PID]%6BK6&,5XEZ/*E(P=@@W;Z
M)EF*IB&P59!91,V<9[,_(*2_XOUH2_K'I"#Z"<Q)N[?>D^-6O9;;'(':] TU
MK>%,1%_<]CVF(J<%AZLBNLSB&;R7=-L2<])X;'*SCVN%GSU4OAH)**9P7)51
M-*Z@1,I?$B=%):V9I9.<M;Q,8G%J]EXKI_D4A4_+T'AV)W&+\MJ!.BF@S+IY
M,24Q(^;%$>Q8J^4LX/F3G&>4AM(2Z:@W3J+D#087:>C=F4;;FN+$F8\-==>6
M:(ME<?'3P7REJ64AG3MLE(,3GPFY;*9(X;*XRFJ0A\9+B=%1=*$3EMG=&G="
M4]QL/>FV-::6H#1\QBW5YVS>ZMKFGMI.45RA&1SBS7"5AH5%](K%R1!$R^%%
MC8["8SD%5$U@XZ_W7IK;.N4-PZKVWK+9>I'3>;=M=I:_OE5N6N7+2M.WT?8W
M2%WKDK)5E9O /XMR@].5UDK59NJ17)3)GQ@BHNE-0,,5/GUP3ONQ&.H:-S4X
MEW3;,G-/:U&ZOJ?([3MBV)(6*.\J\X0#&E0]R>65W-,/(5O&:IMC+I>"?O%Q
MW#=D-INJJ5%4.V[JY><3N-DG!PO(OE!QWT%,69BYE*W$[JW7K;5DG8(QDX*T
M>2,&PO-E@G4LQ:.CX2560(HFFIG!39QG/8"JB:U%3'7++J'<)>#,#$V#E;R2
MUIIY&P,5I6M0DQ*.9R\6F);D6,XEZIKFHL[#?[1$H'1\,[J/C'+<BYTTLGPJ
MJD0Y7-;K451##7$[K'],SG!<T]<\9N6] O6PG1GA(NASL/>]57.PG8-47STM
M4J^WZE0INW&:LELK'Q&(.\E226/_ (*"V4X(]KM2D*HIMUR#Y0\=.*%+)L/D
MINS6FD*:NZRP83>R+;$5A&8DL$PIF*K[:1<I/[%+81SXF6C%)PXPGC)^YW2Y
MSB951-*D:T(W=4?$)]&[=-W8:\H_.2A-[-**)(,/K!HVY=/UUTX7D644W:)W
M7;NMZ-2_+'#R03PFCF0PJ=/OJE+E)-0Y)4D8O"0VD)E45DG"22Z"J:Z"Z9%D
M5D3E42624+@Z:J2A,F(HFH0V,E-C.<9QGMP)B)KAR0YD<4N'T-#3W*+D1J#0
M[&S%E#51#9E[@*Q,W'$$X@VL_BEUQ^]3L-Q-7U++'YD,1C5WEBF\247PFF?!
MLP5436*T(OYGXEKHD04M)0KWG!&KO(E\ZCG2T-H;E%8HE5PS6.@JI&S]?TC*
M04TQ.<F<I.F;E=LN3L.FH<F<&S+SC/*0VD)$^+/4 X6<V6LDOQ6Y+:HW2\A6
MK5_-URJV5!.[04>]0:KM9*<H,P2+NT-&K9>%2PX=1Z2/E1%6_>\=%9,DR.1V
MHC5%-E+W?J+JVH6#86S;I4M=4&IQZDM:KQ>['#U&H5J*1,0BLG8++8'D?"PT
M>D=0N#+.5TTRY-C&<_+@1U:P>:O7N1G'M#XL5QR,6WOII'CV;D=9YS&]U=GT
MA/3681QQTEH-"8QM \YBD9BUYI0K,CCR[P3.C82P;*F<%'SU3G:\!)^L7[H[
MJ@=-&7D&,3$]0_@Q*2LH\:QT9&1W+703V0D9!ZN1LS8L6;;8"KEV\=N52II)
M)E,=0YL%+C.<XP*^TWRH3U0Q#U=^*/#'F)Q*)J_GCR!<<:-#1.T:9=U=G([6
MU3II-"X13*PPM<@W=TW)7+/34F\OBQ.,8;9;E=.%2$PDICL,4T'HBI1VA""H
MBZSL?2CXO<2.(O#BI:HX0[Q=<B^/*EOOEJK.UW&R]9[=2G9B8L"[:TLV-ZU'
M7ZU2)1K"3T8LSRFW;>*V71426.90AL8-1$2C=1%*4T%);XP+D#H7>O(7B,AI
M'=VHMQKZ\UUMVL7]'5>R:;L)6C64MW@"&KUP3J,U+GK,Y@[);&6CW"#CM1/C
MN?DF[*4JHJI0D=K+KVL.J-TS(_6FO&#_ *BG!1D^94:I-'K)WRYT V=M';:
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M_@.,)+8RGB9'-74I&J*;UB(
M             .*G\&?]H;]SD136#D(
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M)!H^=9,]RDV=D<+*]C?!-N?/=\K>4<EX+#OHW76L5E@4L\<5_:0(C;:/G_\
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MNE'1JNM8WI5M=6E-+56B55JJFA3<\:*,6
M
M
M
M
M
M                                                     *Z?%[_B
M!>LG_,'T\?Z+[$*T/"3-UDY@KDX
M
M        '#/\*3_)J_NDA'@!S$      ?)GYZ'JT%-6>Q2+6'K]<B9&>G9=\
MIA%E%P\0S6D).1>+9^1)JQ9-SJJ&S_@D+G( \[GHF0DMU;OB".0O42ND8LZU
MQIB>N6](-G+'67+&.Y?+G5?%ZFNO$,9?SE4Z:T\Z(G+X2.'58[>Z4IBHYH,]
M>3:X"1-*U) _C*.&I+GH3CUSDK,292>TM:W&D]GOFQ<945UOLE527H\E)F-C
M.2,:GL&/79H=S)<Y7M)N]@V.[DD9DT;1%R<)/ST1.9:?.CIG<9MR2,GYSV!
MTY#3^WCJG,=[]9VITD*G.R<EG)U,8>7".:,I_LP;LPE+$^0O^#BHQ=IJ*11:
MH1Y_$L],?0O*?B?L_FSL&V[=A]J\-N/-^>ZQK]-GJ;'Z^G55Y1E.'+?(J;H-
MAL<FGAVG@N,1\M%Y\/Y.WM_*$LC45*KK1 Y-%2M%\/OT'N(?5<XW;JW#R(V-
MR0IEFUQN_.M8-CI>WZQKL$Z@L4.IVCRN5;7C3^Q9!>6\X3RQ/$1=((^"4F/"
M[V#'-3C8CDJI*B5+DW3$Z%?$CI/['V3M#CML3D9<Y_:5(94*P,]TVW6=BAV<
M.PGFMA1<P[>C:BUR];R1GK0I3'7<.$LI9SC">#=AL56L1JU0F1*%6OK><E>1
MG5\ZME)Z-7'&XK5G3%!V6QUW8D$3OS0%FVK7X5Q:]P;1V RBU2.)V!T;!L'[
M9C''QV(N(AZX3SA5V3*5-ZJ]^PFHE5:K0GTU/\*=T>Z)K)C3+]IW8.[KP2/.
ME*;@N&[-M56T.91Q'H-EWT96=8W.EZ]C&;1^F=RR;+1+TZ7B>&X6=E+CMG2)
MA-LH5>>?_$S=GPQ/4#T+RHX;;!M]KXZ;3=2:T+ V^3R1:<C*U)1*^S>.&WGD
M.P;1-B@9>$E&CJ&E<M$7A/$RLDEA]%>6*TW(L;JIJ)5394]';1NX*;R$TOJ;
M>^NWAG]$W+KBE[/J#I0N4UU*[>:['V6)*[1-@JC9\BSDB$71/@JB*Q3$.4IB
MYQCZ$6J5)SRNN 7!;:_47ZL',+B]K??\EQTK%K?<DY/?5KAO.[B8M>B8S?E;
M1M6NHZ(BW4<VGUK/8W\.8[21=MHW*+8ZJ_CX2*T<?*UJN<J)H*:)52['2?A4
M^C55M??,V?TCLO9-ERQ5:FVS<-][6CKYARJP0:8DDHO7UDH^KRNF[E(SI,AJ
MX=#QE#%.F='!$BU^:83[*%4*]4O9'PPO6IUT6D;&M]FXK["1J=ADUYHV$7&Q
M>,%VLKVNW"L7UE"L<P\Q>]4RL4\<M'35HCE5XP9O4V[8CPS3%)?V;_,2Z6J>
MC_R;.13C1R#43,4Y#Z+VP<AR&P8AR&H$^8IBF+G.#%-C/;C./DS@5UU*3\!2
M&^"7_P"E74<_ZO\ %;_TER#%&'A)&ZR>SXB_J@6OIK<(FZFFY4L-R0Y'6)_J
M_4D[A!!RO18IC%XD]B;-:-W6#-5I*JQ+IJSC^^53",M+M'!DU4D5"9J2.V4T
M:R9RT0@MZ)_PUFG^5&AZCSNZE4IL?:DWR)16V51].8N]EK24G2K(]+*1&R=K
MWV%D&>Q+)9ME-\FE&B;&59$2BWR2[A9PZ<9392,C14VG<)*C:Z5)4N2GPE/2
MLV[5W;/1D+M7B=<DV:186PT?9-QVE7/.*.)/&'%IJ6[+!>)&:CW7G!+*[>.F
M(14V6*'A+H]KGRF98FKJT$VRA-%TW>*]EX1\(./7%*WVB#NM@TE4I*I/;96V
M[]G#3Z6;989>.DVK*333>L%'$9)HY6;GRIA!?OIE56(4JIYVILMH130AN\(@
MZ[<+97Z%4K1>;9)(P]5I==F[999=QWLMXJOUR,<S$S)+X(4Q\HL8YFHJ;LQG
M/=+GLP /-0T=K'?7Q4G5)VE==O;&N^N>(&DD7<LC'PZD:N_U%IV:G';#7.K]
M?Q3Y-_6F.T]H>8U'4M-.6KQ+*K!VZ53<IM63 WSI65VG42:7*6OU?A;>BLI4
M<5LG&*VH3.&:+7.P$N0W(#-N,NFL14\CEDMLA:A^6."$RF<N(3#?!#9R5(I^
MPV*O-L\A-LH4]]=<,]<]/KXHG1/$34EAN=JUUJ;DYQY4J\WL%W"O[BX9["TW
M0MI.&TV^KT)7(9XM%R%V6:)JHL6V%$$"&,3!\FSFC39DHGE):4=0]/:YVZO:
M_I]KOMND4X>J4FMSMNL\LL155*+KU;BW4S-2*J:!%%E$V4:R55,4A3&S@O9C
M&<_(/I)SSN^->C-Z?%4]03=._>1FR;WK3@1QUEDHBH4"L/FC62@("R.)+-$U
ME0&<@C+5N-O=FAX,TQ=;.JUD5_$*BV(GA!:-(QH(BRNJOW21/64LF3GPLO1<
MEJ(YJ+#CA=ZQ8%XEM&I;2@^0>\G%[9O$/ \6?;1]EOEAUD:6>>$;Q"+5Q5AC
MQ3>&V)V$[E3FF>0FV4*UO F5W1T ^O2SZ>LMLJ4N_%WDG?:#K\Z,DNFQBK7#
M;H20CM$;46AT3NV%?V#3;E(MX67<)IHIN6R+]/'=;J-E4J;:QOV>!25-"TX"
MPO\ %D?U/=]_GRT9_K,Y$\OW"9VHJ@=.?IY=83JV<--3\=Z?LYKH'IKZDDK^
M6M35P=RM<I>S[=-; N%LM4@A5JL@XLV[):"N4RX8%</S-Z_#X;G1;JE?I.B+
M4FM>Y*)]TD1%7Z"P+P*^$W^Y#S"T%RP^_P!?6=]1UY1N?S!^ZQ\R_G1X49(Q
MWFWYT_>.MGF3O><._P"-YN=]G<[.Y\O;BHV*BUJ3(VBD:?QJ7^TIPC_F-V3_
M *^QHEFUH0<2_P#%;X7W0%Y2QR#ZJFUME\[.3>SFK2PWE-78][I&K8%5_&J9
M:UZ!D*G)5394XUKY'::;9;,C$QR:+1!!M%-&Q#)*3)&FMVE2*-\I"#\1[T:^
M/72W@^-W-+@86]Z3B)'<<;KR5IZ%YMEJ;4G94; RVR-:W_7UTMLW-;"@IK&:
M'*'<)N)-\3"[9LLTRTRFH5:61B-HYI!R4U&_O3OZ,UFZSM5U[U1>KMR=O/(E
MOMZ'?/-1Z U_,K4:H5.EP]CF*[YELDQ"-F"M<BUWD0L?S'5$XA8BY<.WLJ[=
MKNDBQ:S;]9ZD42NE3]W7&^'%Z?VCN ^Y.3_#'6UBT9LOCY"QUZD8%':&R=@5
M"_4YO/1["XLIEOM:U7J6BY:+@))5\R7CW;5,RC+"*J1\+94(?&U&U36%:E-!
M(7\*-RNO/)+I?I4O8LQ)6"?XO;?LNC(&:EG*KY\\UNG6ZE>J*T</EL>*H6M(
M6]S#-4C&/EO'1C8F,]WNE+-$JJW3P!NHW-ZK_1=TYU=;;Q>?;RV[LG7=&XX-
M]V87K6JV%9;6B\/-O'U'E!4MSM;&RQ=89UPFKCE41\QR"C[,AC)56OD_8O%S
M$?2I%4J84K/PO'1.@89K%RO$Z>NKYN9P96QV;D5R2:S+["SA59,CI"F[8J5>
M(5HFIA%/P6".<ID+D^3J=XYG-L\@V4*A_6VZ=270,Y<\2.3? ;:>Q:E!;!<6
MVR4)K8)HLQ8M>7[4#NF9L\$YGVR4<>UZ^NT+>FA%(Z105\=#RYJY4<MU2D+2
M>W85%:2JE%T'H/; UIKWJ6<!_F#L-S;:AK?F%Q]IDI85J))13&WP$%LBLP%O
M\*OREDKMBB49!GAV1,JCJ-<$SC&>\EVY^2O3:;IX2?6AYF\/TK./<AU^ENE8
MM<=REX]I[FG-=XN*5AI!=RYA(S3DAL-!UFPGUX>D>=#S30J1S_-WP<M<Y+A+
M"G8ICY]A.<V> ITTT+=5,^#ZZ:-&N%4NL3O#G.XE:?98*TQC>1V7H)6/7D*_
M*-99FB^2;<96CE5FJY:%*J5-5(YB9S@IRY[,XJ<TWSD^RAEWXLC^I[OO\^6C
M/]9G(C+]P.U&4?A=_P"I/XH_]8.1/_B0VL(Q?<0-U%,#XEGICZ%Z<O(_4\EI
M&V[=M*_*%GN#;]_)M2>ILVE$652]LUS,:>6HT&CGCX/![ MC"3TT@X["D_?O
MD-WJ,C4:NCA)7)12R'1O@[.F99J53[(_WESK1?6"K5^;>I--F: 3:).Y:):/
MW";4BW&-PL1N19QG!,'4.;!<8[39S\HJ<TWSD=E"0SJ,<7*!PJ^'OY1<6=63
M%QG]?:8XLV:K5>8V!(0LK<G\>K9TYDRT_(5VOU6$=/,.I10N#-X]J3P\%QW.
MW&39F<FS&J(170A'Y\&1_5V<D/\ ?3M/]!NBA+#]U?I(--"/BX.4.WK]RUXI
M]-:OWMQKW2ELI6O]G;!,>05CZ[;;ILS:]EHE7?WQ)!9/SI5]6LZ-YQ:HJG*B
M5V_67.0RK=JJE+*JUV> @Y=-";73/PJG1WUS0H>L;&TE>>05O:-V^9K95_W=
MN6HS$P_\E03>G;5W3U\US48F+4=D.H@AAFNX1(IW%'*_=P?,Z1,)ME#7%O\
M"G<>=%<P.+/++AKN>\TAKHOD-I3:]OTQN!PC>:Y.UK7UTKLU96]'O$7&1MJK
MTX[C(E5P@WE4IINZD%<I>4L&QB> YI$5%0ALZ=!;)%0F
M                                  .*G\&?]H;]SD136#D(
M
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MJCTX$0J[ZI(WYKA8RFVRQ8COI62541?J5%^LG?'GB:@
M
M
M
M
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MK7-6BI5JJE45*Z%,MC#"V@
M
M                %=/B]_Q O63_ )@^GC_1?8A6AX29NLG,%<G
M
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M+I]A"-VB::+1"(9Z]KK>-1:I)$322;I,DR%(4I2E*7&,8QC'R"NFHG349Y
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MV6JT<11WE+KHJDP
M    !Q4_@S_M#?N<B*:P<A
M                                      &74_X,G[0O[G ^-=92.8@
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M&:\<=F/,%SBZU2.1]&(O!&U$:Q/IV415\ZJ;5#3YCH
M
M
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M!?GZ?/.+5'48XDZEY;Z=2>QE9V7%.RR]3EW+5S/4&[5^0<P=RH\ZJT[J2KV
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M^TV?>Y8>R-_V5/JAIGEW]7]_VK>>;;\[_P#:9_\ @C_\T>:O\#_DW^)_+\8
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M^+W_ ! O63_F#Z>/]%]B%:'A)FZR<P5R<
M
M              #AG^%)_DU?W20CP YB      /.?^(SV18>I3UI.,'35U7+
MK.X75,M0-*/%F*AGS")VQOB:K]DVM:S83QY*9K2->>8DW^.Q0[1:&>D.;!BG
M2)0D7:>C4)':5H>A=KF@534^O:'JRB12,'1]:TRKT"FPC8I2MX>J4V$8UVO1
M2!2%(0J,?$1R*)<8QC&"DQV8P*^K03G<@!YI76"KTQT>_B'];\V*7&OFVNME
MWNE\L&[:);Y:XDHRV/GU%Y049L[:G9MUY:SJIS[A5/\ )RFULC;"V%,&R97Y
MW^I)M$BZ%+SG4RHDCRJZ6_,&HZ:.6Y26V^)^P9C6!84JCO-V6=4A>VU%A"%(
MGE1PM;\-D&[/\G'>.Z)V]F.W.*SM+5IY"9=*%/\ ^$LZEW$/C'KKDIQ=Y+[I
MU]H"P7#9,3N37UNVW9HRB4"T,34UG5;5 JWVQN8^H0,Y YK#)=!M(/&JLD5_
MDK3"YT52DI1.1$HI*U4+K^C>?/"_DYLNT:AXX\E]1;YO=+JZ5SM#'3]M8;&@
MX>MKO8N.1?N;K4C2U),HJ^F4$BMR2)W65/%QX?:@OX=9'(JT12>J%#/J=4_<
M'0OZ]];ZC=4I4I8./>\]HS^YVJ\2S\DB+2SVBSD(KD]IQ>1<85B&-]*K8925
MC/&_>TBR$<]*7)D52I4'59)M<!(NA:\!<PU+UP.D[N'5C+;4/SPXWTV)<1JS
M][4=M;0J>J-IPSAG'I/Y&(>ZOO<K"79[),LJY0)F/9O6SYP0Q6*SK'=-FLCV
MKIJA-5"EMUS>?OMU^9_%S@3T[HJ4VE1Z3;9B*KUT4CI:$B-E[4O!HZ.G;B5M
M(1Q96$U-JRIPIU5)IXW;]J*TDZ,CY(DV66HO=MJC6DJK5:(>@]Q/X^UOBAQE
MT)QIJ*_ED!HW4U%UDTE#($;+3J]3KS&*D[*\03_>TY"S2J"\@YP7L+Y0Y/G&
M,8^05T2B4)TT(>;QT6.:W&O@GUO>6.T>4^Q$]6:YNR?)_4<;<GD#8YZ'C[G9
M^0=.GH-&?Q6(J9?PT.[;5-T12050PR:'R0[E1%'OJD^=BHUZJI(FA2^W9>LM
MTHJI15=BRG4.XCNJ^C$MIH\?6MVTBYWK+-VV(Z212U=3Y6=V8O+%24QA1@2(
M,_14[4U$2J8R7%?;;Y4)JH49]@VFV_$V]<G7^-<T^WL.'&HT:C7Y&2FH@B)Z
MEQJU].2%JN-CN7DRBT=$6_=UKD7[&)0.99PEF18-U<+)L%SEH_XC]&HE^\OF
M/12Y-D(GQHY!IIE*0A-%[8(0A"X*0A"T"?*4I2EQC!2EQCLQC'R8P*ZZE)^
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MG1ASC:T32HVDU&)OBR/ZGN^_SY:,_P!9G(A+]P.U&4?A=_ZD_BC_ -8.1/\
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MCW^J2+I70>G8/H)P
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M4\JND1:+K^HA5R+I/2W'T$X
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MM.1OW=NFA&I1%1C="*E55RHE)9!QL:Y
M
M
M                                                 "NQ\15M4T%H
M31VGFC_"+G8FRY6XR;1+.<K.H/7,#Y&5%SV&[",SS5W:JEP;':HJVQDN?WL^
M!Z;_ ,L;)Z8CO%S!G>:/:BPS"H[:-RZFRWLVU5OE<D5K(U:+H;(M4]9#=NY'
M#N>QB[Q-R5;! C$7R.E=71Y]F-4\R+YT,^=!;52=#X+M+LNQ.A)[EV3<[B9T
MN3!%UX6!<-Z!$($Q\A\,4G%4=KI=[&,FRZ.?':0Y<C7/\Q3.#LQ?,&_ 8Y$=
M:8'A5K;;*+H269'7DB^3;5MQ&QU-21M:NE%+-OAQ%;S-RVB+6.U@8RGD<Y%D
M=]='M1?H1-:$C'(WE/K;C&34Z5Z:6:;FMU[7J^G:!6*:TA7\_*6BU+Y;-GJK
M:<GJZU1KT8L=(KUSA8QD3.42X3.90N,\P[L-T.:=[#L9?EY]I;V& X-<8E>3
MW+I60QP6Z;3F(Z*&9RS2)M+%'LHCD8]5<U&JIA&!Y>OL?6Y6T6-D5I;/FD>]
M7(U&,TJE6M<NTNG92FFBZ4H8IY \'Z_OSE)Q7Y,2%PQ NN-3^<?KU4M6)+*7
MP[A=E*59(]B4GV!:VG59]L=WC_,'YG/C&)C*&<84&8;MM_V);N=T>;]U-M8]
M(BS5'$Q+CI"QI:(U'1W"\RD+^?6XA<D?^-"C-E%7G$]4N.#9LFP?+^(X"R+;
M;?HU-O;IS=*H_P!797:VVK3[S:4KIU'Q.474^X=<2921JNR-D*3NQ8Q,YWFL
MM<QBEON314K)%\DSE_"695JL/W:#I#**,O),%%2KE4+C*6#G)<-TGRF;[]\U
MI%C&5L+2WRQ*J;-]>R);6SDVE8KHZHZ>=C5:_:=;P3-:K5:J[:M:ZKE_(&9\
MR1MN+&#8L7:I95V&+II5NMST2BU5C7(E*:Z(O8N&?4)XZ\YX^QJ:<D+-%66H
MD0<V2@WZ(8P5PC(MXZ<-&$T5")F+#!2D2[6;YQE5D_<Y;&.F5P5$ZJ936S?G
M\M.\[Y?;FU;GB*TFPJ]56P7EG(^6V?(UJ.?%62.&6.1J.^[+"S;1'+$KVL<J
M4<T9+QO*+V)BC8W02U1LD;E<Q51$56Z6M<BI74YJ5T[-4138K=N\M5\=-=3>
MUMR7"-I-(@<)$=RC_"ZZ[MZYR;#*(AXQDDYDYN:?F(;"#1JDJNI@IC8+W2&,
M76.0MW^;]YV9[?)^1[&6_P ?N:[,;*(C6M^])+(Y6QQ1,JFU)(YK$JB5JJ(M
MCPK"<1QN^9AV%Q.ENWZD3@1-:N5:(UJ<*JJ(:@</.J%QFYMW^VZSU*GL.%ME
M4A75E39; KL/!I6>N,91E$/9JM+0]FL>%4&KJ3:Y.@\PR>83<8/A'."*^'NO
M?=\I.];<'ERRS7G-<,GP:\G; KK.:258)WQND;%.DD$%%<V.2CXN=BVF*G.5
M<S:R;,V[_'LJ6<=_B7,/MI'HVL;G.V'*BN1KMIK=:(NENTVJ4KI2O=>I/M53
M3/!?DM=FSXD?)J:VDZ="NLGR5=*:V*X:4"-798+VG,^:.++A=/LQG!,I=\WY
M!39Q8?E8R>W//S!Y5P&6-9;1,5CN96TT+%9(Z\>CN#8<V#8=Y4=LII5#Y<BX
M<F*9NL+1R;4?/H]R?V8D61:^94;1?IIK*]_PZFJDY[?.\MPNV)UD-=:VB*=%
MNE"8\G;36QITSU1=N;/88SY.&H[E'/=[<$1=&P;L[Y.WTJ_F<YP=AV[O+^2(
M9$;)B>*R7,C472Z*RAV41?["RW;':=;HTI]UQNC?=B*PX/:88U:+/.YZIPJV
M)M/1M2(OTIYE+>0\5CFH\ZKDDQQO[GINR(U.S0E3;:Y17J$H:48F8S>;<6S9
M4C&0L@W(D3O>'-N'9'6<]WMQA;.<_P!T?IRW67"[N/EUP"]SD]T*8-E&TENU
MD73$EO8LDE8JJNN)&K&FG]5$0[;P)_8V3[27$55O1L/C=)76U&1(KD7^ZB4^
MH]$UHW\D:-6OB'6\F;HM_%4_PU?!3*GXA_V?RS]WMS_\?(_,E-)STSYJ(W;<
MJT34E5K1/H.)G+M.5VJJE$/G7)/>775;O=*C':\DVL>^:;Q^@?(.PQ6C.N2,
M%K![E@8^3I80Q+,GCPRN<^#DZIU>W!,_)^AOY>K6#<M\G>'8]=L;%+:Y=N<8
MFV_UG3LFOV[=*+7FW11HVFU1K6:7(=>Y0C9EK=U#=2(C7,LWW#J\*N1TJ5^I
M6I37H1-9>VC(UA#1L?#Q;5)C&13%I&QS)N7NH,V#%!-JS:HE[<]U)NW2*0N/
M[F,#\\]W=7%]=2WMX]TEW-(Y[W+K<]ZJYSE\ZJJJOG4Y#DD?+(Z61561RJJJ
MO"JZ57ZU->M:\I];;9WUO;CW3&EF?VCCLE3B[$LQVD+BCDEKJS=/8ZNPTFWG
MG,R]FX\L>Y3>D4CT$6Z[95+Q#')G V7FK=#FG)N[K+V\K'7VD>$9G=<]"@1T
MO2^;M7-:^:6-86Q,B?ML=$K9GN>Q['["-6I>K_+U]AN#V>-72QI;WROYME7<
MY2-417.391J-6J*VCE545%I13%/"W@_7^&\IR)E(:X8MJF^]O2FR$T"58E82
MIU?4<2;BOT=/.)^P*3F(#,TZQY=G+3"^%,=C9+.,][,-^V_[$M^-IEBTOK'H
M3<N8+'9*JW"SK<S(V-LUTO[&%(N>YJ->:I(K*+65]4I<<TYLFS1'8QRQ<VEG
M;)%]_;VW41'2?=;L[6RGJZ:4^\I7\ZXW..Q[5VRGPIU')/5Z71I..:[-1@C+
M*+W_ &HZ7;J1].42;E,H_C*0H=$F&Y<YPM-+*E43R=FW-CTC_E__ "_X7D_)
MJ[^<Z11MQ[$(GNL5EHB6>'M1R/N45VADETFTNVOW;5K%:Y&SR(;FW2Y2@P[#
M?%6)-1+J9JK%M:HX41:OTZEDTZ>!B)1:.<6$.GYQ KG"_C;3-8M&+'-]DV+2
MS[=L*!457,_L&3:I*RJ&7Z7;Y5#5GO8C8W&.PGDC;"O=\594Q_-7YDM]F*;]
M=Z5]FR:23PY%(Z##H5JC8;.-RI&NPOW99_\ 'GUKSCU9788Q&Z7SGF:?-..R
MW[E7H;55D+5U-C1=&C@<[[SO.M-2)3=P:#,3--.HC5H^X\%.6L3)I)JMFF@]
MDVE,JI,'+B0HM:?7:(5P7/["B,K7D3DS_P":<N,_W!O+Y9<7N<#^83)E[:*K
M97YCL;=:+3U+N=EK(GT+',Y%3A150RC)-P^US=ALD>ARWD3/JD<D:_8Y36#H
MD:O^K?I\ZRD5T#MI+:ECO.T)-$^.S/\ RE.J5:#7QGOGP8CVI5&.7+G'=["J
M8QG';C.<[:^?C-OBGYE,6M8W(^UP>UM+"-4_L1)<2IJ_5N+F9BZ]+:UH9!O7
MQ#IV=+AB+6.W9'$GU-VW>A[W)]1+4.,S6Y$AO#K:\#=*S3FNL[G:]T3$>^\@
MDT])5YA9HEFI@JN3K(VVQSU/IDXT3RF7&58R1?%R90N,=O8?N=GY ^0GYB,^
M6#,3GL;/ K*2/;8N*3/@D<FBB+;P0W-U$Y:JNS/#$M$6M*MVMDX3NISABL23
MNBCM8G)5.?<K%7_,:U[VKYGM;J^BN]G&3D[J7ESJF-W%IF7?2=6>R#Z$?-)>
M/-%3U>L,85LI(U^>CLJN$VLFT0>H*_O2JZ"J*Z:B:AR'*;//6]C=-G/<OG&7
M)&>8(XL7CB9*QT;^<AFADVD9-"^C5=&Y6O;ZS6O:YCFO:US50Q#'\ Q++6(N
MPS%&HVX1J.16K5KFK6CFKHJBT5-*(J*BHJ(J'6^7',72W"K6S?9FZ)":PPE)
M<D!6ZW58YO,6VTS)FR[Y1C"1[R0B8_&&K)L=59P[=M6J6.Z4RN#J)E/=-R^Y
M#/>_C-+LJ9%C@Z3# LT\]P]T=O;Q;2,1\KVLD?ZSG(UK(XY)':51BM:Y6U\M
MY8Q7-5\MAA36;;6[3G/798QM:5<J(JZ56B(B*J^2B+3['%?E3J/F)J:/W%IN
M0E'%><23R"EHBPL$HNS5:QQZ+5R^KUB8-G<BQ1DF[1^W6P9LZ=-E45R'35.7
M/:/BWO[H,Z;D,Y29(SQ%"W$VQ-ECDA>LD%Q ]7-9-"]S6/5BN8]M)(XY&N8Y
MKF-5"EF'+V)98Q)V&8HUJ3HU'(YJU8]JU1'-541:514THBHJ*BHAL*]>LXUF
M[D9%VUCX^/:KO7[]ZNDU9LF;5(Z[IV[=+G30;-6R"9CJ*',4A"%SG.<8P-9P
M03W4[+6U8^2YD>C6,:BN<YSEHUK6I57.<JHB(B*JJM$TEE8QTCD8Q%<]RT1$
MTJJKJ1$X54C M75ZXIMKTKK;3D-O#EE<VGBY?Q'%K5KS9N&J38CI5VZ;OWDI
M6HV>CVB3<ICNHM9^V[%B]U3/=5\/K7"/DJWPRY>3-.>)\ R;@3Z;$F/W[;':
M5RM1K58V.=\+W*JHD=PV*3U5JU*LVL_M]VF8G6B7^*.M,-M5U.NY4BK6E$5$
M1RM5:ZGHU=&K57\4=UD>&D=)R%=W*INGC-<(QF=^\I&_-+76N6Q-N599-//F
MNI,[MCQ'2:.5$294P94N>Z7&5,&(6O<_([OSN;2+$\C)@.:\$E>C&W6$8I:S
M6ZNHBK^TN'6NAJKLN6E&KI7U51RSOW89H?&V?"^BW]JY:));SQN97Z7K'JU+
MY/HTFU/$[F/J'FA5[C=M*)7!Q4J9;2TIS/6B 3K[68F\0438'9(1LI(.9)1"
M/9S;<JV7*#4V%#_D%.3.#YT_ODW'9UW%8O8X#GQ;)N-7UETIL,$RS.BBYV2%
MJRN1C6(KW1/5J1OD3932J.JU,=S'E?$\K7$5IBJQ)<RQ[:-8[:5K=I6IM+1$
MTJU:45='D70;1O7K.-9NY&1=M8^/CVJ[U^_>KI-6;)FU2.NZ=NW2YTT&S5L@
MF8ZBAS%(0A<YSG&,#4<$$]U.RUM6/DN9'HUC&HKG.<Y:-:UJ55SG*J(B(BJJ
MK1-)C[&.D<C&(KGN6B(FE55=2(G"JD9ECZM7&'%NDJ+I2M[YY<6>#RGY^8\5
M=22FT6T0D?RWO/#S#E_7(64C4\M"X\JCW#QN?*Q,)G/DJWA=787\F>]GL6+,
M.?+K+N2\)N*\R_,&(QV#I%39]5(VLGEC>NTO[.9D3TV5VFMK'MY[!NXQ_HS;
MO%9+/#;=_P!U;N9(E75HV41SD73J<C5T+5$T5[/H3JA<8][[/SHY8FS-([M,
M[7CVVI^0-%6UW<'<DW\0RD2CA.1G(-*;.B0JB3!9ZD^7(?'A(G,50I+3O&^4
MG>QN\RE^8#%PG'\@["/=B.#W:7MLUCJ4D6K(I5B1:M=,V)T3%1=M[45JN^?&
M-W^/X/A_:R='N\)I59K>3G6(B\.IKMG@5R-5J<*IHK(L.8C"#0K?W4GXJ<?+
MAC5\M:Y[9FY#N%62.F=)UE_LK8AI))HL[Q$.6,49&$B)M;PR$(Q?/VKO.5B*
M93PCA14G16[CY6=\&\K!/%ME9V^%9&1J/7$\4G98V6PKD;SC7R5EDB2JJLL4
M,D?JN;M<XK6.S#!LBYBQJU[0CC9;X72O/SO2*.E:;2*OK.;_ &FM5-"I6M$7
M#"76#XXUZWP=.WMJOE3Q3=6;PLP$MR3T>\H<+)D47.U,Y15B9ZT2"4>V=E*F
MN[5;)M&^3X,HJ4A5#$SM_P DN]#$L$N,<W>XQD_.,5I7GH\#Q5MW+&J(CME4
MDAMV*]S:N9&UZR/I1K%<K4==5W98Y-;/NL(N,.Q%L?WDM9TD<G#32UB55-*(
MBU7@2M*[J;VY8<>.-=$B=D;EVE7*G4[&3O51VFHYGGMP[6))(F:E$UYO*REB
M2,R624RLU140(19,QSE*H3.=#[O=S>\S>IF&;*V1L(NKS&;5?]X:J-A;;>NK
M%Z1),L<<*[2.39D<UZJUZ-:JM<B8KA&7,;QV\=8X7;ODN6??30U&::>NKE1&
MZ:I151="T30I']J_KD<(=I[9@M3QQML5A>SS3*O0%YN5.A(RAR,Q*/&K"*:G
M>,+A+62*3D7CLI"KOHMJV2[N3+*)%[#9Z1S;_+^W^Y0R;<9RN4P:[CM('336
MEM<RR7;(XVN?(Y&OMHX)%8UJJK(KB1[JHD;7K5$S/$-TN;,/PY^(OZ-(D;%<
MZ-CW+(C4155:*Q&K1$U->JKP(I*#MG;^L=%4>5V3MZZP5!I$+E!-_8)]SE!L
M5P[4\)HR:()$6>R4D\5_)1;-DE7"N<9[A,]F1R5DW).;-X6/PY6R587&)8_/
M560PMJ[9:E7/<JJC6,:FETCW-8W]9R&O\-PR_P 7NVV.&1/FNW5HUJ::)K5>
M!$3A551$X5(G3=>_@5\^V5/26W&O!NWZ3)39Q=>LT*(P254.3,D]:O+.UV(5
M@EW<&/X< JM@I\=B>>PW=['3^7/\Q7AZ3&WMP-N(,C5R6'3'+=O5$1=AKFP.
MLMM=2;5XUM47UM5=C?D[G#H:W*I:I,B5YKG%YQ?,BHQ8Z_3(B><D7Y#<O..W
M%JE-+YNK9L#6(F7;F7K$>V44G+'<<^3X<)$J==AB/92:26P=/&72:>&2'BD,
MNLD0V#CF+=IN5WF[W<>?EW(>$W%W>0NI.]R)%!;::*MQ-*K8XE2B_LU7G7[+
MDCC>Y-DPC!<M8WF&[6SPJW?)(U:/5?5:S33UW.HC?HKM+1:(JZ".6F=>[@I;
MKRSIKQ#<U(8/Y3S6A?[G2ZTTHQ,G>D9-I!XX@[U/V6-BW.%,+>,YBTL((8R9
M?".<9QCI_'?Y='S"8+E]^.0.P*_N8X><6SM;J=UVM&JYS&I+:0P/D;39V63N
MVW42-7U13.+K<[FZVM%NFK:RO1M>;8]RR:JJB(Z-K55-5$>M5U5)IFSEL];-
MWC-P@[9NT$G+5TV537;.6RZ954'#==(QTED%DCX,0Y<Y*8N<9QGL'",L4L$K
MH)VN9.QRM<UR*CFN1:*UR+I1470J+I1="FJW-<QRL>BHY%HJ+H5%3@4_),3,
M17HJ1G9^5C8.#B&;B1EIF8?-8R*BX]HD99T^D9%ZJ@T9,VR),G455.4A"XSG
M.<8P*UC8WN)WD6'X;#+<8A.]K(XHF.DDD>Y:-8QC45SG.5:-:U%55T(A-%%+
M-(V&%KGRN5$1K45555U(B)I55X$0C'?]7/C9+V:7JFBM?\E^6DE7<Y^<2W&+
M2,QL*.A$N_A$CQV]E9&JIKQJ[K.4DG3;RANL?':0YBY*;/6%M\EN].RPF#&-
MX6)94R9:W7^"F/8K%9OE6E=EK8V7"H]&^LZ-^P]J?>:BU1,^9NUQV*W;<XO-
M88;&_P"[TJ=L:N\R(B/TTTJBT5.%#(7%[J;<7>5EU=:LJ4E=->[@9^=L+:EW
M#5\4R[F5@5WJ4PR;)M9&<@'DM&(,C.%V*+\[Y%OWCG1+X2^$L:WM_*AO<W/8
M"S-^-16&)Y)?S=,1PVXZ5:TF1JQ.<KF13-C>KT8R5T*1.?1K7KMQ[?Q9@R%F
M#+MHF(7+8I\,6G[:%^W'ZU-E5JC7(BUHCE;LJNA%TI60@<U&%@
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M)BYEH1RFUEXYE)MDWB!VKM-N_;).D2.FJN,*-G)$U<8.F;\HANW&?EP /H@
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M93]IRF-D"2H  !Y^73@_XQ+G/_[T>5__ ,Y5< >@:
M  *Z?%[_ (@7K)_S!]/'^B^Q"M#PDS=9.8*Y.
M
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MN,HH]Z,B2Q\<NHW37604<XRL:=K6MU$R(B$C(F
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M:JN3Y.KWZ$:*YVVI(B56IZ&(KDX
M        &74_X,G[0O[G ^-=92.8@
M
M
M
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M[V-BZ_*1;1](/]ISZR*4W+$10@8N!2(V8.I!^W,JX OJ
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MY(Q$1+N#+JJ0NF-#LIC,@SUE5I,K=2%F.0FWT\+N7;G!%?"<*J.U"FC8UHT
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MXOS1AJE+>?OG/\P-;]SSA\Z?#\E\W9\+P.]XQ^_V$ E<
M  5T^+W_ ! O63_F#Z>/]%]B%:'A)FZR<P5R<
M
M                  #AG^%)_DU?W20CP YB
M"NATS^@)[.OGYO'G)][+ZX?KFJVWZU]5_P!1'U??-OZUMH5/9'EOSV^N6[^>
M/,/S7\B\/S0U\J\?QN\CW/"/3;'LNVJD$;1:EB\5"(
M
M                                        <5/X,_[0W[G(BFL'(0
M       5R.OYUP*7TT=.RND]-ST?/<X=LU9=.C0S3+:01TC69DB['ZX+J@H1
M=JG((E(K\W(M<ILOWQ,.%DS,D%2K2/?LI1/O$'+3Z2.SX7GHY;$U&]?]4'E]
M%3#?<6U*_+8X\U.Y9D%;K7ZU?L.CW3=EYS+X-*)W'9T6[,VBBK'\H+"O7CES
MXAI%'R>6)E/6760:G"I-U\07Y;[&SGEY!X?C_55!^)XO9W?(OK*HWG+L[?\
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M>4F:R-B<*I1Z:IC'9Q2#5KC.2(%%5K=E*$Z)1#>T1
M                       &74_X,G[0O[G ^-=92.8@
M
M
M
M
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MN9<.JM)9+9R1MED1BI_@I=MF;')IVG\XBHB-:KNJ=SO36Y56.Z1&P+.]T/\
M65BT1RT_J\XCD1>%:^1*W =#RE*G-'Z=FM;Q;&$U[+ZMH,I1X6-SDT?$5*0J
ML4[KT6SR;\O+=A$JI)%R;\KL)\OR]H\3=XEICV'Y_P <L,TS27&98,7O([N5
M_P!^2Y9<2-FD=_:?(CG+31IT:#F?&([J+%KJ*^<K[UMQ(DCEUN>CU1RKYU6J
MF5QAQ;BF!\0/M=.Y<Q:OK5FK@S33FJ8)A()>+WS)6>\.W=O?9R3!LE1PI674
M-G&,EP?/9G.<Y+DO9[J_RVLG.P/<A=YJG2DV.8Q*]BTI6"T:VV9IX:3MN>&G
M E%1:]2;F,.6URQ)?N^]=7#E3^Y&B,3_ $D?^E2U?P]U7G2/%?C[JI9KY'(T
MS4M)C9]#NF)_[]2T&TD+<MX9\8.EY39WCM3NF_*+W^S/RX'CWONS@F?M[^9<
MX,?MVM]C-T^%=?\ NZ2N9;)5-"[,#8VU30M*G/&9L1[6S#>XBBU9+<R*W^YM
M*C/0Q$0V0&KBQ  15=:+:Z>K>GWMMN17"4KM%_5=40W>5\/"BEDF$Y2>2[,&
M(=7)Z97Y3L+C/[/RFQDF#8SV#\B>3G9N^9/!97)6SPB.XQ"716B01K'"O"B4
MNIH-*_0E%5%-A[K,.7$,YVSE_P .W1\SO\UM&_Z;F?\ VR-?X<35)TXKDIO!
MVAVI/9"G:I@'/AFQW3QC9Y;K>AXN<=TW?++P9NZ7Y2]WM-^R4=3?S0LX-?>9
M5R!"[UXXKG$)FUX)'-MK9:>;F[I*KKKHU*9WOQQ%%DL,):NE&OF<GTJC&?T2
M%@'E/J:5WOQNWEIN!4@D;!LO5]RI]>=691VC ,K#-0CMI!2$LNPCY9\V9QTL
M=%<RJ#5PLGX?>(F8V,8SYO;H<Y6>[S>EE_/.(I<.PW"L7MKF9L"-69\,4K73
M,C1[XV.<^-',1KI&-=6CG(BJIIG+V(QX1CMIBDVVL,%PQ[D;3:5K7(KD2JHB
MJK:I151%KI4QUQGUO \'>%^NZ)LBS5R*BM&ZS>2NR;8S6>YJS21*>2M]\EX]
MP[8,I-W$XFY)X=N8[1%TX)DN? *H?P\9/O6S3B/S ;]<3S#E:TNIKS,&+-CL
M;=R-Z0YE&6UI&]&O?&V3FF1H]$D=&Q:_M%:W:/NQZ^FS;FF>\L8Y'27=PB1,
M6FVJ:&1M5$541=E&UTJB>6B5.M\DKY5^0?3NY#W_ %#*.+/5-A\7]S2E-DS0
M\_7W$ZP/0K.DD9"'L<7$3K;S@9L<B)7#9+QBF*;'[V<ILW3=;EW%]VOS-99R
MYG6%MIC&&9MPR.YCYV&9(7I=P*M9())(G;&TBN5DCME45%]9JH5\"L[C!<[6
M5GB;4CN(,0@1Z;37(U><9^LU5:M*Z:*M/I0JH="J4CX_J%T5H]RGAS-Z_P!H
MQ<1@Y<9,:02JSB:5PCG)3=U3S5$.LYSVX_(P;';\O9GV$_F$6ES<_+1B$T%>
M:M\2L))*?U%N&Q)7S<Y)'Y=-/I.B-[L;WY*F<S[K)HE7Z-M&_P!+D+R@_/T<
ME  ?&FK%7ZVDR7L4[#0*$G)LX6-6FI-E%I2$S(F,2/B62CY= CN3?'(;"*">
M3*JYQG!2Y[!]UAAF)8H^2/#+>>YDBB=*](HW2*R)FE\CT8BJV-B*FT]:-;72
MJ%6*":=52!CGJUJN7915HU-:K34B<*ZD/LCX2D !4M^(OVX:8VQH#14>[RHE
M3:5/;&FV;?.3E4E;Y,$K\(DZP7)NUXPCJ6X.F3LP8J3_ +V>W"A>SV8_EB9+
M2QR;F3>%<LH^^OX;*)RZ*1VD:S2JW^R]]TQ'+J5T--"M4Z/W(X;S6'7N+O33
M+*V)JKY(V[3J>95>E?.WS%DOB5J0NB.,FB-1&;F;/:+J^H0\XF;&"F-:,Q#=
MY;%S$QG.$\NK*Z=JY+VY[O?[.W/9VCRSWS9S7>'O8S%G5';=OB&+W,L2_P#@
M.<<VW2O#LP-C;7AI6B&B\R8EVOC]YB5:LFN'N;_<JJ,]#41#\7,C94'J#BGR
M%V)8'*#9A7M27;P,.,YPF]FY:$=0=9AR]AT\Y7G+))M&26.\7&5%RXSG'[./
MHW'95Q#.V^'+66,-:YUQ<XU:UIK;%'*V6>3AT101R2NT+ZK%T+J)LKV$V)YB
MLK&!%5[[F/ZFHY'/=_FM17+YD-'.!%&D>%G2F3N,JQ\BMS#4&T>2UC:/&N$#
MIR3^M2UU@FL@USWE2N&-0BXMLX(I^^841-C)2]G<+T!\Q>8+7?O\X:X'9R<Y
M@LF-V&!P.:ZJ*QD\=K*YCM6R^YDG>Q6Z*.145?O+EN<;MF:MXG18UK;.N8K5
MJHO CD8Y47R*]7JE/+PZR"#H+4M/8O/>6O=C7/)RNN]2[#V"V?R!U7;US9[%
M*UZB.'RBRBG?4=KQMZD#G5/W\Y,;/R=XV#8]#OYBF.NRQ\N<.7<+:D5GB>,V
M5FYC$1K6P0QS7;6(B)1&H^TA1&I30GD2B[?WPW2V.3FV<";,<]S'&J)H1&-1
MTB)]%8VZ"ZL/!TY6*9_73O4ENGGM1=$5M4CM;7M.HM":,"&RIV7S:$F6R+Y-
MW<=I3NH>=A$\DQC.<>%V]O:;LQ[F_P O?+UKD3Y=,0WAXJBL9B=]=W;GKH_W
M2PCYA/J;)#=.K_:IP57J'=':1X5DZ;%Y]"32R2*O_@XDV4]#FR+]9;\HU3A-
M7Z[I]&B/WFN:[I=?J<7^]8)X4)48-I#LOWA#!L%\-C'E_()C/9V=F!XGY@QF
M_P VYFOLP7OK8IB=_-<2::UEN972.TKY7O72OTJ<T7=S+B%[+=RZ9YY7/7^\
M]RN7[5*4/2HDL[SZL%)V1;3+/9*P6S=^VW97GAN5'%ADZC>9M!5RH;&<>*SE
M)4K@IRX[<*HE[.P>\_S@VJ;OODXO\K8-LQVMM9X5AS=FK42&.YM(E1J>1T<:
ML5%_5<M3JO>)'V1NYEL;:B,9'!"E-%&H^-JT^E$I]"EY(?G[.2@ *.W6EMKK
M9W4KM=*>O'6(RC1&HM8Q:F<][#-C+5V'N<CEFBI@N"X3FKZ[SV9^0ZF,Y[<E
MS@>__P B.#0Y3^5:SQZ!C.EXA/B5_(G]9\<TEJS:5/+%9QIYDHFM%.L]UELV
MPR)'=L1.<F=-*OG5KG,2O^;&GU%WJ*C&,)%QL-&-TVD;$,&<9'M$2E(DU8L&
MZ;5HW2(7&"D31;I%*7&,8QC&!X$WEW<7]W+?7;E?=32.D>Y=*N>]RN<Y5\JJ
MJJIR?)(^61TLBUD<JJJ^556JJ?O'S$A\*T6*,J%:L5LFE\-H:KP4O8I9R;_!
M;QD+'N))^N;LQG/8DU;'-GY/[@N&$X9=XUBMK@U@W;OKNXCAC;Y9)7HQB?6Y
MR(5K>"2YG9;1)661Z-1/.Y41/M4II]%ZJ2W(SJ2V7>]I:^5+T^,VGNV;<JF.
MNU^>>P)%:O,T3G4*8R[O+J\O'B&3]F>\RRIV]XF.WW*^>O&+/=A\K5KN\PA^
MQ'>RX?A434HCNBV;$F<J(FINS:11OIP2HVE'*=0;TKF/ \BQX/;K1)710-3A
MV(TVE^JD;6K_ 'J<)=)'A*<LE)JHD6YE=<G,GG&).&3Y/R,_A93PUFKJB\="
MJK0GE7?3,EEG*US6;1OX><9[WE!4\9SG.,CWKQI6;C?Y?O1/\*^7*3(:)5'-
MN\:HDNS1:[4<]](^O!L*ZE$H=67*IE?=+S?W9>ST;YTDN?O4\Z.E5:^:I=E'
M@H<IE)3G6JKS0ZQ1M2LSY=P2>V-:\?$<86,IYO@JFYCF&Q5C&34[2)QTXO/.
M3$3[IBE+G'9XG;G/O=\O3&;BODA3.<Z;&(K@U]C*Z*;<MPU[[)-*:5?$EHQ%
M6J*JU^[2G5N4$3*V['M)VB;HTMS]+GHJQ>EO-II_H+A6^[N?4>@=T;'C$TT%
M-8Z>V+=X]%%$F$D3TNES$\T320*0R>$TS1I<%)@N<=F.SL[/D'B1NZP!N=-X
M^!97NU5S<6QNRM7JJK54NKJ*%RJM:U7;6JUKPU.9<'M$Q+&;6QDTI<744:_Y
M[VM7^DI7](#8DQKCE/9]I,-$[LY(7)AK>Q,:]!ZJA6TTZC++;)V!;OK5>[%+
MR#5I6X4]>))M\/%\J^.]=IIYQC)\G+[O_.QEBQS1NAM,HW&8<!RM@<F*0OFE
MQ"5T39(+>&9S+>TAC8YT\J3+ _FF;.Q%&YWZNRO5&\RQBOLO1X>^\M+&U6=J
MN=,Y6HK6-=1D;415<[:V5V4I1J*O!0L17^?ZL_*R#>5#7VI]=<":-/(*(R.P
M+[LQGL?<SF!<Y1[IZO'T6.=LJ3+OH]P<JR#QNC(-%"F\%\V5(113S*RWAWR:
M[GL09C>9<9Q3>+F"V<BLL[2Q=988V9M=$[[M[774;'HBM?&]T,C53;MY6.<U
MND[*'=QEV9+F]N9\8NV+HCCB6*!')_761461J*FA6JK7)K8Y%5$S%P.Z7VC^
M#)7]IBY&2VGNB<9G8S>V+5'M&#EHR7P3+Z,I5?07D"5.+DE2>(YR=X_?N#9R
M11V='!$B81\Q'S:Y_P#F"6/"+N*+",B6[]N+#K=[GM<Y*[$EU,J,6XD8BT92
M.&%B:6PM>KGNMF<,_P"+9MI;R-;;X4Q:MA8JJBKP+([1MJFI/5:U-:-1:JLE
MHY5,#   "/CJD:2YC\CN$VV=)<#MNUW0?(V_N:5'5S<5@V'L75JM$K\9=8&P
M7%[7KIJNJW"Z1-BFJ]#KQ2)FS4G8B_5SE9/)2YR!4*]@7\4U[ZC_ .&-]13[
M' !8&Z'73TZEO"!IR(ENI/SAL7,"U;&<:[CM3QYN27(K?53UW7ZPE;7-L>H)
M;WK]4S"V*W24ZQ(J9DS6[6T6GC*V.^8@ GV   >9[\5I,;1YN=9[C]P9X_P2
MVP=AZ]T_K36%4U^A(P# TANC=4[,;&>I*RECD8JNPK20HDK5<KK2;ELT;(MS
M+KJD0SDQ0-O4:_\ ',RC1*JK.TZW"2+8E?5?,W724A$8&*=I8CCNVKVH)YL<
M0G%M%,G(K%D\N;X3P9MCQ2DP ,W\2/A9^3O(SD+'\M>N/RH<\A)UG(MGF=(U
MJ\VV_P C<&,6Y3<Q%<V!M>90KS>FT-JYPN0U9J;-1%1DL3"$FP-XB  [)\:-
MN=KKWA[PIX;45@TB&^V]R35U;U:L1R#5LVIO'^F1]2@:JQAXU,B,?$+3FWX\
MS%JBB0ISQ12(]A43$R!;*X-Z#;\6>&G%CCD@R18+Z6T%JG7<NBADF2KV6MTN
M'86N25.D8R2KN8LR;MVN<N>Z=98QL?)D 5[OC$][--9]*%AJ8BG?F.2'(C6%
M**S*9+!\5R@EF-O3$H<JA<F.V9SE'B&YL$S@^%'J>>WN][&0)6.ACQZ6XP=)
M3@IJM_%)PT\MHR"V;:6&$S)NVUHW:\D=QSC65RIVJGE8U[>3-%\9R;"9D/#)
MGPR$Q@"6$      <3EP<AB&R;!3E,7.2'.F?&#8SC.2J)F*H0W9GY,ESC.,_
M+C/: *V&]/A/.C9M:CV&"H.E-A:!ODL5ZZCMKT;?&[;O8H^870<Y0=2,%NO8
M.RZI.L#2"Q5W21V:+IQ@F2D=(Y-DX AI^%>Y\<K*GS>Y&])CD'L^Q;GUYJZN
M[67UG+V:9D+0^UM<]$[%C:39*]59F0</WR&M[A%RCERFR5=*M(]W'M\,R)^5
MN<J 7YP              80Y&<D-(\2M.77?W(G8U=U9J:@1V)&R6VRN_)VR
M9EE"-HZ)C&B957\Y8IQ^JFUCHYFDN]?NU2(H)**'*7('GD<F>5'4%^*TY4H<
M3^'%5GM(]/?5]F82]KG;29=O7&+!NX<ECMM<@9&*4\&PW.01;J&JU&CE7.&Z
M^>]WU/!=R[<"]#TV>FIQJZ77'B)T%QVKQO%<F:3&S]H3B+52_P"X+LDT\F<6
MJX2*!"E(B@4YTXV,0[K"*:FRF@3OG656 D% 'FF?%Z4&Q<>>K'Q/Y?1T<Y=0
M5XU%KFPQ2SDBA6;W87'39\FM8H5JNJB=H9-M6IJLJJ$QDYB&>Y,<F"G)DX'H
M_:VV'4=N:[HFU=?S+2Q4795.K5]IL\Q61<,YFK6Z&9S\#*-EVZJR"J+Z+?I*
M%R0YBYP;Y,Y $ OQ4V^H32O1FY!UUZ]1;6/D!:-4:1IC8[U)LN]D)"^PU]LQ
M$4,G(X>E2U]0)C)R)XSV=N,G_(P;M UJ^#ET-+:MZ5=BVG.QBS)SR/Y)[%O=
M<=+IF2S(4.EPE2U3%JIE42(8Z)+C2[!W#XR8AL&[<?W0!/USJY[<9NG/H6>Y
M#<H;ZTJ%1CC*1M;@6N6[V[[*MQF;AY'477-:.Y;.+):)))J<^$RF3;M&Y%'+
MM9NU167(!00C*EU&?BX>7[6XV=&7XT]-?2-H<M8\Y%%I&H4)D?+;#Z&JV7#=
M@WW'R7M<,J7RR1.@G&034_Y>&C<[9F_ ]"+B)Q#T!P8T)2>-O&FAL*!J^C-#
M%;,T<^535BFW94LS5RN4XH0KVRW&Q.$L*O7R^<F/V$23*F@DBBF!LN   \[3
MXJGFSL/G%S3T1T;N*:;NZJTN_4U38D- >5GS<.36P4,Q=-ICM9L99JM!ZLI5
MC*Z>K]W*31_+NRN>X>,[2@7=NG?PHU[T\>'&C^).M_#>1NK:J1&RV7P$D7=X
MV%..5Y[8%V?Y(BBJ=2Q6N1=+-R*=XS1CX#4IO#0)C &ZH    //RZ<'_ !B7
M.?\ ]Z/*_P#^<JN /0-                     %=/B]_Q O63_ )@^GC_1
M?8A6AX29NLG,%<G
M                                                         X9_
MA2?Y-7]TD(\ .8@
M
M                                        #BI_!G_:&_<Y$4U@Y"
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MR>43$5CNZ6C$E55ZDC4TU/0)%<G
M          #+J?\ !D_:%_<X'QKK*1S$
M
M
M
M
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MVH^KS?7MGO\ I]\\Z?\ 4=_LG_\ 1#S'*_.W_94_Y&_YZ\E_YW_SK^)_>^^
M)4N4-MWC1./.X+7QHU27=_(&(HTTIIW5JUEJ=08VS8+E#R&M-YBQWBPU2LQE
M?C9%R1[(F7D&ZBC%LJFAD[@R29@*AOP[/0HYA\?>9F[>H9U1-?J5W?;92>-I
MJ/F]B:JVA+V#8&W3S3C;^[9N4U?:[K%1DTE%/U8I@11VBJKY[D5#-RX3:J9
MNU@     "KOQ,Z)O*G0_7KY(=4FWW_C[(\?]PN]VKUFGUNU;&>;B8DV2WADH
M+$[7Y/5,/2FQFAHX_E?D]A=83QDOA^+VY[ +1                      K
MI\7O^(%ZR?\ ,'T\?Z+[$*T/"3-UDY@KDX
M
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MV"H1
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M;UP^:(-S&[YUDRXR;$[JJU4363+J/.UX@]&OXE3@=LEUN'BQQ8K>N=GN(=S
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M"_N<#XUUE(YB
M
M
M
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MX1*D5VK%9M;#'^JJHJHB2-<B5HFE$KP5HJUTK]B[TT?PV?\ T8M^_:F-\?\
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M,1'MRYR8V$&C1--/*JRF<J*JF[RJRIC'4,8YC&SP]F+,>/YMQF?,.9[RXO\
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M;HI-VZ2:"""9$4$$2%21112+@B:229,%(FFF0N,%+C&,8QCLP /Z
M
M*Z?%[_B!>LG_ #!]/'^B^Q"M#PDS=9.8*Y.
M
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M%C),I/)I$[EX1''^:GSBE$U:[2DK4X2\R*Q,
M
M                      !Q4_@S_M#?N<B*:P<A
M                                                        &74_
MX,G[0O[G ^-=92.8@
M
M
M
M
M
M
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M[8KR.P@X*BD57!"UVKM)5"=%JANZ(@
M
M                #BI_!G_:&_<Y$4U@Y"
M                                                  ,NI_P9/VA?
MW.!\:ZRD<Q
M
M
M
M
M
M
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M4U54ZISC+)@&[%+&5R]*6U@MM*Z5<J-1Z<AK]'^0N4#P<.5@
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M4ICY9RE8K<PPCGB1C&,5XU5[>[_@EG8E&HBD42B$O@F(@
M
M                               <5/X,_P"T-^YR(IK!R$
M
M      9=3_@R?M"_N<#XUUE(YB
M
M
M
M
M
M
M
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M1^MLUY5O\I8ET"]5'Q.;M1R-T->W56FMKD70YJZEU*K515VZ&CS&
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MK=&2.<+-).9=X;I.2X=DCTG9$5D9VQHFE=*A&^4M)"H3
M
M                                !Q4_@S_M#?N<B*:P<A
M
M      &74_X,G[0O[G ^-=92.8@
M
M
M
M
M
M
M
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M;VSKG#NO4[.$59/8FWZPQ014[<*HQ=;BIZR24DA^3G&<H/F;)N;';C/==_\
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M&*JUHAOG?7;1OR_:WBTYZ.\1J?0^-ZN1/K8U?J+:X\3#F<
M                 #AG^%)_DU?W20CP YB
M
M
M .*G\&?]H;]SD136#D(
M                                   RZG_!D_:%_<X'QKK*1S$
M
M
M
M
M
M
M
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MM*(UJZ4<E-I;[<6C5MG@<:UD1SIGIY-"LC]-9/J1/*68QY(G/X
M                     '#/\*3_ ":O[I(1X <Q
M
M
M      '%3^#/^T-^YR(IK!R$
M                                        9=3_ (,G[0O[G ^-=92.
M8@
M
M
M
M
M
M
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M,6KLQN^+@Z?9;@Z?&=9<^9Z1&S=ADVT,P;MTU</W:K=)V5REEL58OB&2\/\
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MVQS(J.I55DVU25J?K(U'(BHFENS1=%%6?:I]1WA!;J*VO[;DIJN#CEFA'+B
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M                               !PS_"D_R:O[I(1X <Q
M
M
M               '%3^#/^T-^YR(IK!R$
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M#F]?7 X\>CP\+92_$-O\--QCH%AUQG(</:8=4CW#F]?7 X\>CP\+92_$-O\
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M6'7&<AP]IAU2/<.;U]<#CQZ/#PME+\0V_P --QCH%AUQG(</:8=4CW#F]?7
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M#F]?7 X\>CP\+92_$-O\--QCH%AUQG(</:8=4CW#F]?7 X\>CP\+92_$-O\
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M5X55552S/>^1ZR2*KI%6JJJU55\JJNL_6*!(
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MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\
M\P#PQE7O^W^'FXQT&PZVSD.'M(>IO[C7>'K:\?\ \P#PQE7O^W^'FXQT&PZV
MSD.)U-,V^YW_ %/KN[;$UI)::O5IJ,'.6W5,Q/15HE=>ST@Q2<252D+%!E)#
MS3N%<G,B=RVQA%7)>\7Y,C7]]#!;7DL%M*D]NQZHV1$5J/1%T.1JZ4KKHNE"
MSRM:R1S&.VF(NA=5?/0R8/E)
M
M
M
M
M
M
M                                                          KI
M\7O^(%ZR?\P?3Q_HOL0K0\),W63F"N3@
M
M             <,_PI/\FK^Z2$> ',0
M
M                                                        !Q4_
M@S_M#?N<B*:P<A
M                              &74_X,G[0O[G ^-=92.8@
M
M
M
M
M
M
M
M                         KI\7O\ B!>LG_,'T\?Z+[$*T/"3-UDY@KDX
M      &K[/F]PND=M?4%'\O.+[[>OSB=4_ZE6>_M4.MM?.UEXWEE7^KA"V'N
M/SB:>3J>*Q\C\I3[AN\3'=SV0JE:52HJAM (@
M                           ZK>+W1]8U&P; V5<JIKVAU*-7F;5=KQ88
MBIU&LP[7&,N96P62?>1\-#1K?!L=]=RLFD3M^4V !T#2O)+CKR3BIJ=XZ[\T
MMOR#K<@A$V*9TKM.C;3BH"5<ML/&T9-2-&G9UI%R#AIGQ2(KG34.G^5C&2_*
M"*BZ@9I                                      <,_PI/\FK^Z2$>
M',0
M
M                            !Q4_@S_M#?N<B*:P<A
M
M  &74_X,G[0O[G ^-=92.8@
M
M
M
M
M
M
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M#J%^\5B<                                    #AG^%)_DU?W20CP
MYB
M
M                            .*G\&?\ :&_<Y$4U@Y"
M
M   ,NI_P9/VA?W.!\:ZRD<Q                &.[YM[4VJU()+9^T-=ZX5
MM#[,964[Y=:U4%+%)%RB4T?!$L,G'&EWQ3.$\92;^(IC)R_)\N.W)LNY*SEF
M]MP_*6$8GBC+2/G)UM+6>Y2%FGUY5AC?S;-"^L_930NG0I]MGAF)8BCUP^WG
MG2-*NYN-S]E/*[91:)YUH9#*8IRE.0V#%-C!BF+G!BF*;';@Q<X[<9QG&?DR
M,:5%:M%T*A\6K0IB>R[[T72VTH\N.Z-35-I"+F;33JR[&I\$VB')'96!F\HO
M*3#5*/7*^/A')%<D-A7."=G>SV#,<*W=;P<=EA@P/ L9O)KANU$V"RN9G2-V
M=NL:1Q.5Z;"*ZK:IL^MJTER@P?%[IS6VMK<R.>E6HV)[E<E*U2C5KHTZ.#29
M%@YR$L\)#V6M3$78:Y88N/G("?@Y!I+0DY"2S1%_%3$/*L%G#&3BY-BX36;N
M$5#HK(G*<ALESC.<9Q##[_";^?"L5@FML4MIGQ30RL='+%+&Y6212QO1'QR1
MO16O8Y$<UR*UR(J*A\,T,MO*Z"=KF3L<K7-<BHYKD6BM<BT5%14HJ+I1="GU
M!\93          .JV&]TBHJMD+9<JK6%WB9UF:-AL,1"JNDDC8(HJV3DGC8Z
MZ:9S8P8Q<9QC.>S(O&&9>Q_&F/DP:QO+N-BHCEAADE1JKI1'*QKD1534BGT0
M6=W<HJVT4DB)KV6N=3Z:(I\FB[9U7M$T^36>R]?[%-5)+S-:"T6Y5RW&K<OV
MK8\U3^*_)2&8>2[6ZG[PX\-7][-^3^3GL^S,.3<WY12V7->%8EAB7D7.V_2[
M:>VY^/1^TAYYC.=9ZR>NS:;I33I0JWF&XAA^PM_!-!SC=IG.,<S:;Y6[2)M)
MI32E4,@#&SX@                  ZY;;C4:!7I*W7NU5RE52&2*XF+/;9R
M,K=>B4#JD0(M)34RZ91K%(ZRI28,JJ3&3&QC]G.!=,%P/&LR8G%@N7K.ZO\
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MN5NRBZ4T5KI,IC$"W@
M
M
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M1J0
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MNE,IC),%392=[<G1R4V#8.H?.>SY,BC+H<BDCM9?4%8G
M                     X9_A2?Y-7]TD(\ .8@
M
M
M    #BI_!G_:&_<Y$4U@Y"
M                                      ,NI_P9/VA?W.!\:ZRD<Q
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MRMO/([)<XUMY.W>*NU/*?$(D9)-4Y +:_(S^T7>Q_P"(OW?OZV/ZWF?WK/\
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M-;%,5INYP@YL^OYN#E)*&NT-&Y61P^(GEM(L3*X,LT*AE-=0";H
M
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M:8]$<E6JBI5$JBHNI2TRPRP2+%.US)4UHY%14X=*+I31I/J#XRF
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MI-%7GW\7_MBZ^5^>*-PV>7AWA"/4-EO&M..% B-%-42N>\4Y4T>0-J3>N/\
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M!7;3;WQ?6[IVZ(IR3NH<IN>C2 3=83RF1WJJI[?US55O!-@Q5E(F$A$U4/\
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MM!6)@                                    .&?X4G^35_=)"/ #F(
M      "##KW]66V=)OBU0=AZCKVO+EOC;FTV5(U_5]H1=EF*>2MPT2\L&PK5
M+QU4ME'F72,,T(P8HE1DT3%>R[=0Q%4B*E$CW;*:-9!5H1>=#+XCCD9U$.:<
MIQ%Y>:ST#K:1LNMK78-2/-0579-2EY"^T7R:>L%1L3/86U=AX=)N:"A*2*.6
MZ;55 T2?!_$*KC*4K)%<M%((ZJEQ(528      "N1TY_B OO_=1#<? G[I7U
M3?5+'[J??6M]?/S\^<'U/WZ)HWA?,7ZF:9YJ^<7G3RKO>>7/DGA^'V+=[Q,2
M-?M.V:$$=5:%C<3D2H]\7)R2Y%<;.-?$F=XZ[\W3H.<LF\;A$V*9TKM.\ZLE
M9^*;4)1XVC)J1HT[!.Y2/;N\>*1%<ZB9%/RL8P;Y12E541*$KB?#I;W"V[!Z
M;7 V]7VT6*[W>X<1^/\ 9;;<;?-R=EM5IL4SK&MOYB?L=AF7+V7FYJ5?KG7<
MNG*RJZZQS'.8QLYR*C?NI]!%-1OB(D0
M
M                             XJ?P9_VAOW.1%-8.0@
M
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MRU;VUQ>3MMK2-\MR]:-8QJN<Y?(C6HJJOT(:^_?BX5?C XN>L!J?^5HV5_\
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M[OK&1+=J*JJUT<E$36KDB>]41/*J(E*KP*;ZCG4P\
M           \R;X-C^MZY2?[D6[O_$YQ? 'IL@  /,FZ@G_&;T+_ 'W>F9_0
MUQ1 'IL@  /,FZ-__%I[]_WF>II_\^[O 'IL@#S0OC3M5ZVHW.OC'M:F1S"!
MV;MC03]QLQS$>&R>3:VO[HM#4:V2A&V$U5)PT6[6C2O3Y\51I$MTL&[&Q<8
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M0$IC+B+6IEJV5;",8-,BIDW$+CQFG>20P8H'ID
M
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M;2.)J<_*Q$YQSU2NSMZ7;2(J*YZKMU7916HU474CKQT_COHJ[\=:CH?36O\
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M?[DM*JW2B;542J(7-QX7G+@
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M5)5GDDE&HC=*A'42G"8>6^*CZL7%N_UEOU"NFC4M=TFQ)I+M:\MJ/DGQ:O\
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M&16)C[0
M                                              .*G\&?]H;]SD13
M6#D(
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MOW(8T<Y45Z_KN3SZ=AE5M<:DU5H/IK<37\8Q<>9]=ZIKDK=]A7%VW;_."Z6
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M:L^K&Y2UKKSN911([?0;:T-H%=-!<YRMUC9,E@GB*]X"S9TDM?V?5O2_Z?\
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M<:HX=+$2CD?#A62#K*T4D5D[356 F6
M
M                     %#3DF?'-3JV6JKMG#B5A-A\FZUJ!N[1.H9,E*J<
MU"ZU>2K/+8R:B48A7:\L_P &3R53*7:IG]\SG.?T2;K$7</\F5GB\K6PW^&9
M3GQ)6JB56ZN(I;YL;MJJ+(LTS8:.JFU1OW40[ P+_P"%=V\=PY$;+!8.FI_;
M>UTJ(M>':<C=/#HU$M?5!Z/N@-?<9)O;W$C63FDV_5#HUJNT,C<=A7#%LUR1
MN=&Q&;M[K:+-AE)5/'AR>#M\H8.Q1=E/A4^4,$XR^4KYVMY&9=Z]ODK?/BS+
M_!<89T>UE6VL[;H]ZKD6&KK6W@VF7&F"C]NDKH5:K&\Y76^0-YF,WN/LPS,E
MPDMM<IL1NV(V;$M?5JL;&U1_W--?65M*)6OS_A\.55?<P5ZXDV0D6PM<<N\V
M%K>3PU;-9"R5Q14REIJKAVFFFI(+UB5>'DVA%#**Y0D7F2]B:'9CZ?YE.Y_$
MHL0P_?/A:S28/*UMG?1[3G,@G1*6]PUJJJ,2>-J02*B(W;AAK5TFFIOHR[,V
M:',D&TMNY$CE2JJC7?J/1.#;1-E=25:WA4LX#R?-!F%=I\B--Z4M&IJ9LZZ)
M5BS;SN*-!U7%'A;)+*VNV+NHMDG%IKP4/*-(@F7<VT3RY?J-6A3+E[RN/E[,
M\RANRSQGS"<9QW*=@Z[PG+]BMYB$B2P1I;VZ-D>LBI-+&Z1=F*149"DDBHQ:
M,4NN'X)BF*V]S=6$2R6]I%SDR[34V&45:^LY%=H:NAM5T:C)]DK-;N4')5BW
MU^$M5:F6^6DQ7K)%,)R#E6F3D4RUDHF3;NF#YOE1,INXJF<O:7&>SMP,2PO%
M<4P/$(L6P6YN+/%8';4<T$CXI8W4IM,DC5KV.HJI5JHM%+?!<3VLS;BV>^.=
MBU:YJJUR+Y45**B_0I#/R:Z%/$7<C63F=0(2W':]K-SG9GJ:RTWKMW(8*?PU
M):BS+E7+%N?'<)DD,]BTB8+W_".?)^_W/NH_F$[Z<CRQ6.=70YGR\UR(Y+A$
MBO6LT52.[B:FVY-*UN8KARUV=MK4;L[1P'>[F7"W-BQ-6WMFBZ=OU9$3^S(U
M-*_WVO7@JB4I5_H=VW[TPN9#UNHY6A[QJ.XH5_8-=C9!1:N;"IIUF4@[B7.,
M^ 22KEQK;A%XQ46337;^.@X*5%PF7N>M&8L!W<?-GN.CD:QL^7\:L5FLYGL1
M)[.Y1',;(W6K)[:=KHY6M<K'[$D2K)$Y=K?UY:8-G_*Z.1$=:7,6U&Y4]:-^
ME$5/(YCD5KD151:*W2U=/H7-UTG2"+E W?0<))KHG[IB]])4A5$S=T^"G+WB
M&QGLSC&<?W1^:22-\4CHI$I(URHJ>146BZM&LXL5%:JM76BD4'6VI1[?T[=N
MO44?*'=%GM;W5LGC&._@C:\PE?DEB9-V8QY+"V)RJ;Y<9\,AL8[<]F,]C?(1
MCR8)\S6"P2.V8<0M[VU<O!ZUI+,Q%_O2PQM3SJG!I-B[J;I+;.ULQ5HV9DK%
M^N-SD]+FHA'A\.!>"J5KE3KIPKA,L5-:RO#$IU,8*<LTPMT'-*]W/9@F&V*\
MQ[QNWY?$Q^QV#IG^:+E]6XKD_,\256:"^M'T35S3[:6)//M<]+1/[*^4S;?E
M:*D^'7S?UF2QK_FJQS?3M.]!L_K1/VG7.MWO1Z3SGPSX1SSJJZ9;K%\:"W!O
M<ODSV9O6$38RF[C*VH1HZ0-G.2Y00BC%+_G3Y/&I<UN_^:=\O3-WL"\UOSS]
M;MN,3<FB;#<)]9L5I76V2=%DC>FO;?>(J_L;=RV"_7P#E!,(;ZN:,68CYU_6
MAM]*-C\RNTHOG63^JQ2=0>>YJ(   *\'Q%.U/F_QZTCJ!NKE)ULK:$G;GF"'
M4P9>#UE7_)7#18I<^&9!6:OS!;&#_+WVQ<E_8SG'IE_+'RAVEO+Q_.TK:PX5
MA$=LVJ)HEOIMI')PU2*SF;HX'K76E=U[DL.Y[&KO$W)ZL%NC$_O2NJB\F-R?
M6;K]&G5AM7=/C2OE37#66V+FS[3EL83RGEP6W3[SYN.C9,4AU,KTF/B\][/]
MSLQC.2X+D:&^>7-Z9N^93'N9?MV6&<QA\>FM.C0MY]OFI=/N-'IHM3%=Z&(=
MH9TNME:QP;$2>;8:FTG_ (Q7G4NM_M976? "_1+-<C>1VW:Z7JUHKE0I5L-G
M\BK;9U-%,V?W[RNN4]VV/C&,]U-<QODSC&<7GY \GLS7\R&&WD[5=:X+9W5^
MY*:-IC$MHE5>#9GN8WIY7,1.$^G=/AR7^<H9')5EM&^5?I1-AOH<]J_2A@GX
M>[5AJGQ'O>S'C7"+[;6VY3R%SX>2F=U6AQ,? 1V<J&*7*F$+.YFRXQC.2E^7
MLSWLFQC8?\RO-Z8SOHP[*D+]JWP;!8]MM?NW%W(^9^C@K VU7@5?HH7??3B'
M2<R0V#5JRVMDJGD?(JN7_01ANGU8MP(Z9X#<@I<KOR:7NU6QJ: 2*;!%W;W9
MCE.K2:;<^<9P15G5GTB[SGMP;!&QN[GO=T:(^3?)+\]?,;EJR5FU96%YVC,O
M UMBU;B-7)PHZX9#'Y*O2NBIBN[G#%Q3.-E%2L<4G/.\R1)MI7Z7HU/K(SOA
MS]/8BM6;\WN]9G*YN5T@]:0+E4RA<XBJ1$XL$XHU2_)(HW?R=P;)F4S@W[XP
MR4N2Y*?!NK/YGF=UO,WY<W>6[T6*QL);Z9J4_P 2ZDYF)'+K1S([9ZHW1ZLU
M5K5M,]WWXGSF(6>#L7U8HG2N3SR+LMKYT1BK3R.KY"R2/+4T64-.29\<U.K9
M:JNV<.)6$V'R;K6H&[M$ZADR4JIS4+K5Y*L\MC)J)1B%=KRS_!D\E4REVJ9_
M?,YSG]$FZQ%W#_)E9XO*UL-_AF4Y\25JHE5NKB*6^;&[:JBR+-,V&CJIM4;]
MU$.P,"_^%=V\=PY$;+!8.FI_;>UTJ(M>':<C=/#HU$M?5!Z/N@-?<9)O;W$C
M63FDV_5#HUJNT,C<=A7#%LUR1N=&Q&;M[K:+-AE)5/'AR>#M\H8.Q1=E/A4^
M4,$XR^4KYVMY&9=Z]ODK?/BS+_!<89T>UE6VL[;H]ZKD6&KK6W@VF7&F"C]N
MDKH5:K&\Y76^0-YF,WN/LPS,EPDMM<IL1NV(V;$M?5JL;&U1_P!S37UE;2B5
MK\_X?#E57W,%>N)-D)%L+7'+O-A:WD\-6S60LE<45,I::JX=IIIJ2"]8E7AY
M-H10RBN4)%YDO8FAV8^G^93N?Q*+$,/WSX6LTF#RM;9WT>TYS()T2EO<-:JJ
MC$GC:D$BHB-VX8:U=)IJ;Z,NS-FAS)!M+;N1(Y4JJHUWZCT3@VT3974E6MX5
M+. \GS08 $&_2SRMN?EAU)>7#LN'4?:-TM=-423_ 'U0QJUK\SXIT<.#&RF;
M"U70K!LD+V^'W,8Q^3DH] ?F[2/(NYS=9N7A78N;3 78G=QZ$_;WFQ1::]$Z
MWZ57[U?+4VUO"IA>7,"RVW0^.U6>1/[4E/\ O^=^DFBNE.KFPZ?::%<(MO-U
M.Z5Z8JUDAW9>\VDX.>CW$9*,5L?LX(Y9.3E[<=F2]O;C.,XP.%,!QO%,LXW9
MYBP29UOC-A<Q7$$C?O1RPO22-Z>=KFHOD74N@U9:W4]E<QWEJY67,3VO:Y-:
M.:J*B_4J%%"GRMZZ2O4B4:RYY)Y":UNJT!8#E3R0VP-%7+""J<FFD1(C=R\>
MU-XVD4DR=Y)O,M"IYSWD#=GZ%,;L\O?.9\KB3621,O\ %;!)H=->AXM;518U
M555S6LN&OA<Y:.?:R*Y$I(AUW<QVF\C(VU%LI+/%M-_\'<,X/*B(]%:JZU8M
M>$GZZB\S'<CN7_2YX\5.1;6&IVO8!^2%APP5PZ9S5%K*<5.P<JCW3X3RPD:G
M!6+!%C8SC)%>TO[!BF\X?EBL;G=?N3WN;S,9B?;8S9X:F"0[:;+HKN=9(I8U
MT5VV7$ME5J+K;IX%33>2(GX'EG,&-W+59<QP]%;70K9'5:Y/I1[HM'FTD[8\
M\S4)K+R_Y.TOB#H"][PN:B"^*^P,QJ5>.OA!S<KW)I+(U6J,N[WELYD7Y.^Z
M43(H9I'HN'1BY(@<;7W)[IL=WU[R,.R!@2.;TF3;N)D2K;:TC5%N+AW!ZC%I
M&URHDDSHHD5'2-+]EG +K,V,PX3:U3;6KW<#(T^^]?H34BTJY6MUJA"-P>B.
MHOI"7VQR)LW3H?[TW-R?E&5VFMHS?*G2VKGK"DRC1G,05)C*)8$;%.U)FT7<
M>(NU<K-W!2(M&JS9++ F!WSO_O?EBS_98-NRPK>?'E[(N4H7VL5A%E_%+]C[
MJ-SHIKJ2[A6&&X<Y$HR1C7L5733,E>ERY3;&;9<D8M%;8)!CB6F%X>U8VQ-M
M)Y461%5KI%D;LM>JHFA414TN<CEVU,_<OMM]0K=7&'>>LK=TP5*;6[1KJP)R
MUO2YGZ,M2E6;Q3;SX6PDK+"$:/[!F&6C"N/(T%4UW/A^&F;!S%R-<;E,F?+3
MD/>SE_-F"[VDOL4M,4A6.V7+&+6Z7"R.YKF5G?*YD/.I(K.=>US&;6TY%:BE
MFRUAN2L*Q^TO[;'^=GCG;1G0;AFVJKL[.TKE1NU6FTJ*B5JN@C9^'1O!8SD9
MO;7:BJB9;CIQC:DB>)@J"[JAW&*CB)F3_94=%:WM<Z>?_-3*I_Y1U-_,[R^M
MWNPR]F9J(JV../MU6FE&W=M(]5KP-VK1J+Y55IG6^ZTYS [.]1/\*Z5GGI(Q
M5]%8TK]1;['B@<T  0%?$2+O$^'6J44C*E9..2=9P\P0N<)**I:RVL=HFLIC
M'^4,4F<]ALE[W9G),9QZ-_RRHX';[\8D>C5G;E:?9KK1%O\ #T<J)Z$5>"M*
MZ=.X]R:-7,]RJTVTL'T_\;#4Q-\.#",T-6\G[&0A,2$K?]?0CE3">,*&9U^N
MS[]B0RO;VG(FO97&2E[,=W)LY^7O?)F7\T2_GDS=E+"W*O1H<-O)6I71M330
ML>M.!52!E5X:)Y"Y;\I7+B&'P+]QL,CD^ESFHO\ JH63AY9&B@ *F?Q%VZFT
MQLC0V@8QZ13-(K,_LFU-D<Y.4LG=7;:$K+=UGL[J;MA%5EXL4F,][P9$IC8[
M#$'LI_+$R'+8Y6S%O'NXU3M"[AL;=R^[M6NEG<WRM?)/&U5U;4*HFE''1NY'
M"G16-YC,B?XLC8F+YF(KG*GF57-3Z6_22I]$OCS(:+X0UF=L4>O'6K>D_(;>
M?-G9<E=-:Y*LH^'HJ&2]PG<;/JM#H2B1<]XV/.9NW.,_D%Y ^?;>7;;PM_MW
MA^&2MEP?+ULS#6.;]UT\;GRW:ZUJYEQ*^W<NA/V"43A77N];&F8OFR2&!R.M
M[1B0HJ:E<BJZ3ZT>Y6+_ '/K7ZO50Y0WK7](JG%/CDT<67E;RK5=4RD0,.[;
M-I>M4AVFY8V>YG>N7C)G *N$RJ,F#UXNU;-NZ\?96*2-5'Q_*%NDR]F3'[S?
M#O0>VUW.Y/:VZNII6N='/=-5KX+5&M:]TR(NS++%&R21]8+=(U6Z84]WF7[2
M]NY,Q8XJ1Y=PY$?(YR*K72)16,HB*KJ:'.:U%5?593UT,%<2)#GIQ T-2=&4
M/I/>7-*VT.[L5E5YP<?V#^ZW*3[B]EMTDV+"O3-U95[CL0;F7<>1,4D&I53I
MH$R-A;Y[;Y==]F\2_P!X.8M\G-S73T;# F5<8>RUMHZI!;,=SK=I(V_?>C&<
M[*Z296-=(Y"[YD9D_,V,2XO>9CHZ1:-;T"X5&,30UB+M)6B:UHFTY5=1%530
M[K+W#E_N30VO;%O7@TIQQJ^N-BX40OI>2>K-Q$=.+;#.XWYO*UNG1L=,,</W
M#!!7#S.3H$RW\,Y>U4AB]$?(S@FY/(^\3$\,W>[P4S1B^*871;3L/$,,5J6\
MK7\\D]R]\3]AKW-YJB/5'[2+1CD7+]U]MEG"\8F@PC%^G7$\'^'T6:&B,<B[
M6T]5:M$54V=>FJ:E)%>@3>"VG@B>MF54,MK7<=_JN$55,&\-K+-J_?$5$"?L
MIM57-O7QC']U4BF1S%_,;R^N$?,,F*(B;&*X'9W%436Z-TUHJ*O"Y&VS/\U6
MF$;X[3H^;^?IHGM8W_6BNCT^>C$^JA-J."35( %+7KQ;2G-H\YH?3+5W@\5J
M"E4ZKQ47E7)6R-LV2V87.8DU<GQV(N9.+F89!3..TO@LDL]G;WNWW;_EWY1P
M_*7R^SYZF92\QN_N;B22GK+;V+GVL<:4UMCDBN7MKIVI7IJH=3;H,/AP_*+L
M4<G[2YE>]5X=B)58U/H16O5/.Y2XMK>CP^LM>436]>1(W@:!3JS2X5!,I2$2
MBJO#,H1@3!2E*7'8U9%_N8^4>(.:,P7V;,S8CFG$W*[$<2OI[J55TUDN)72O
M7E/4YCOKN6_O9KZ=:S32N>[Z7N5R_:IA'D/PMXO\K7E5DM_ZCA=@R=*RMBN2
MBTK9J[*,VSA4BZT:ZDJC.0#V7A3.">)Y"]4<,\*&,;"6#'/DV?;L]^^]K<[!
M>6N[?&I\-M+^G/QI'!-&YS4HCVLN8IF1RT]7G8D9+LHB*^C41+M@F:LP9=;)
M'@UR^&.7[R4:Y%5.%$>UR-=31M-HZG#H0A[Z_>S$]0<6-&<;Z&U:56L;*LSA
M!:%A4"L8Y&@Z7C*^=C56K1O@C9O$MYVQPZY$\%QW<L$\%^3O#MO^7#E1V=M[
MV8-Z.8GOO,6PJT14EE7;>MYBDDR/N'.=5SI%B@N6JZNGGG*NFALW<W8+B>8;
MO'+Q5DN((T]9RU7G)U=5ZJNE55K7I7^TIL5T(-6,:)P+K]T(U33EMS; OEU?
MNC)EP[49P,TKKB):**9+A7R- E+5713SG),9=J*%_A<YSK+^8=F^XS#\Q5S@
M3GJMG@6&VEJQM?51TT27LCD35M*MTUCEU_LVM7[B4LF]_$'WF<'VJK^SM88V
M(G!5S>=5?I]=$7Z$3@)G!PL:M**&QO'VOUJGC:K9*Z4?<ZZW$HN69<*))H5#
M9T/%R\KC*!NQ1JP;0"[I10N<Y,FF8V.W.1^A3+'-Y.^0]DN+^HV/=[/(K7:%
M5;FPDDCCTZG/=,R-$74YR(==6-,.W5HZXT(F$.6B_P!N)RM3Z55R)]*EVO;V
MP6.IM3[.VG)$(I'ZVU]<KZ]24R?!%FM0KLC/KHY\/M4SXR<?DO87M-G.>S'R
M]@\$<E9:N,Y9RPG*%JJI<XKB5M:,5*51US,R%%TZ-"OKIT>70<I899/Q+$;?
M#X_OSS,C3Z7N1O\ E*D/0$H$AL?F?LK<LZ4\AG7FL[#*+2BY3++8N^RYUG$M
MESK'P;NJOH$D[DQLF[YOEQ\N,F[/9_\ F/9DMLK[BL*R-AZI%VGBL,:1IH3H
MMC"Z1R(B<#)EM*)2B:-2T.DM\EZRQRM!A</J\_.U*?\ @XFJJ^AW-_I0N0F,
M4A3'.;!2EQDQC&S@I2E+CMR8V<]F,8QC'RY'AVB*Y:)I53F#7H0I1<#,N>8'
M63/MMXD1_");2VSO9QG&,.4H^"KQ9G.OBHJ8*<AD8N:>P3=-0V<?DDP;&<G[
M.WWF^8E(MR?R.)DR!5COUPC#L)3]57RS<UTRJ:%K)$V[>YJ<*JE*5IU5G#9R
MSNO[-;HE6WAM_)5SMGG/2U)%5/\ (77AX,'*I2>AL-^=/6^,^3P>:J"G(5:2
M\8JAR,WNN^/4=@K!8RJ6"&;1]AAM=($+V9(H8[TI>W"I^T>]%\LGR^?(&ENZ
MD&-IEE&4HBN;>XR_UTHM=I\,MZ]5UHB1*M%8VAU7+7*.Z?87U+GH5/.DERNG
MZ5:Z5?-ZOD0NI2LFQA(N2F9-PFTC8A@\DY!VL8I$FK%@W4=.W"IS9P4B:+=(
MQC9SG&,8P/""SM+B_NXK&T:K[J:1L;&II5SWN1K6HGE551$.5XXWRR-BC2LC
ME1$3RJJT1"F3T@XU[R8ZIMIWO,,L*^9L;LW]*)O385PWE;Q)N:\P3^0WAJO&
MDEL;"J6/EP7+?)R]F28SCW/^=:Z@W4_*'9[O+&2G/]EX/&K=&U':1MF>OE1K
MF66R[R[>ROWE1>HMY<C<!W>QX1$M-KF+=*<*1HCE^I4BHOTTX2Z*/"<Y:*=?
MQ%$VP=\K-.P*&4SOX70;!Y(&(4W?3),W^[X9(*J=_),Y*2,.I@F"XR7"O;G.
M<&QV>WO\LBPN8=SV.8C)5+:?,;VL\BK%9VNTJ)KUR(E:T56T2E%KTYN2B>W+
MMU,OW'WBHG^;''7^G["1WGCL2U<9>BQIJC).7<9;[YJ7CUQ[DG!E3Y=L,2>M
M&\G>(Q,Z><8*D[K5/DHSLSVX*W7SC&>]C&1R]\N^6<'WK_/?CF8'L9+@N'8S
MC.,L2B;+^;OECM)%1>%L]S!/7A>Q%U50P;)]E;X]O4NKM41UM#<W-RB<"TE5
M(U^ISVN^E#&_PYFK&,=ISD!NE5JGF5MFR(?6C-VJF7*Z$51*TRLSM-H<Q>^F
MUD'VP$_&[N>ZJHS)@W;E+'9E/\S[-]Q<YXRWD1CUZ'9X7+?.:BZ%DNYW0-5R
M:E<QEF[9KI:DCJ:'K7[]]^(/?BEEA2+^SC@=*J<%9'*Q*^=$C6GDVE\I8_'E
MT:-*,_6RD<W?J17ZMUY+SI*Q5>U-2DFC+":BSJ<?5&&E46!,DSV*N\JV-)'.
M,Y[Q3_D9[.[V#] _R%6R8!\K>&XIB:\S9S7.(W2N?5$;$RYEC5ZUU-I YWD5
M/636=;;J6=$R-#/.NS&Y\SZKP-1[DK]'JJOVEX&OQRL/ PD2NMARO%Q$;'+.
M"][!5U63)%LHL7!^T_8J=+)L=OR_+\H\!<2NF7N(W%[&W9CFG>]&^1'N5R)H
MT:$6AR=,])9GR(E$<Y5IY*K4^N/B*0
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MNCX2(FE@B9:J(B)1"=$H;(B(
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MQE=@6K9,N,]TB:12EP4N,8Q6C^XA,W43#"8B
M
M              '%3^#/^T-^YR(IK!R$
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MVCHN+9-8Z-CV:1$&C%@Q03;,V;5!/!4T6S9ND4A"%QC!2EQC'R #]H
M "$'XC;;&J]4]&WFIG:CJ*\+9&OV>I]?PTD<OE-BVI<IV-+2&L(U[Y57LK77
MK \_DI.W*#2'7<&QX:)\X B^^"\UM>JETTMSWJQ^5M*?M?EA;IG7D>OVX0>L
M*KKW75,LEJ98[O<\&3LD.M&&SWN]E6$-C.,8P7)@+?X
M                         #2VZ=23IV:WFLUO8G/?A;0K%AH@_P P-TY2
MZ-JTUABZRIAJ\S%SEZ8OO)'.4C834\/N'[N>S.>S( V,U?N'4>[JRWNNE]I:
MYV]3796YVEMU?=ZS?ZRZ([;)/6IF\]5).6BEBN6:Y%D\E5S@Z1RFQVESC( R
M,   UFW+S4X;\<YAK7N0G+3C-HB?>^)Y'![EWQJS6$P[\)JQ?*^2QEWM4&]7
M\-E*-EC=PF>Q)PD?/Y*A,Y R)J3>VD-_US%PT1N356ZZEGN=EIU)L.H[(KF?
M%5=()]DW3I>9C,^(NQ7(7]]^4Z)\8^4ANP#*H  #2VZ=23IV:WFLUO8G/?A;
M0K%AH@_S W3E+HVK36&+K*F&KS,7.7IB^\D<Y2-A-3P^X?NY[,Y[,@#8S5^X
M=1[NK+>ZZ7VEKG;U-=E;G:6W5]WK-_K+HCMLD]:F;SU4DY:*6*Y9KD63R57.
M#I'*;':7.,@#(P
M   ,4[UV='Z5TMM?;DHH@1EK;7EONARN,]B;E:O03V29L"E[Y,JKR+QNF@DF
M7.#***%(7Y<X&8;O<IW.?,]X-DNS1RSXKB=M:I36U)I6,<_AHC&JKW*NAK6J
MJZ$+CA%@_%<5ML-CKM3SL9HX-IR(J_4BJJKP(E2FUT,-<.-H<_XJ[2Z*DL35
ME%O^RW[YZKE3!IN500H[!TX,H53RM^=]=SN$\9S@V%$<K8SVI#W'_F"YHCRE
M\M\V 63DA=C&(6=BQC4I^RC5;I[6TILLV+5&.751R,I1YT_O;OFX?DUUI$NR
MMQ-'$B)_53]HJ)Y$I'1?,M.$NYNVC20:.F#]JW>L7K=9H]9.T4W+1VT<IF1<
M-73=8IT7#=PB?)#D/C)3ESG&<9QD>!L,TUM,RXMWNCN(W(YKFJK7-<U:M<UR
M45'(J(J*BU1=*'*+7.8Y'L54>BU14T*BIJ5%\I0UY<ZFN_2ZZ@C:<U?EU'0]
M9M$7M_2+YR=P=K(T:6>.<+5.0<?D*/6;$Q)"O2)<F\1RU(8YNS"^,Y_1'N7S
ME@'S;_+8[#\V[$M]=VDF&XJQJ-1S+N-K:7#&Z4:Y]8;V%:49(J(FF-3K_+6)
M6F\#)BPXA1TLD:PSHE*I(B)ZZ)P*OJR-\B_07;>/F\J1R2TUK_=FO7R3RM7Z
MO,Y=- CA-RYA)3)? G:Q*'3*0I)FLS*2[%V7LQC"Z!LE[2Y+G/@AO*W?X_NM
MSSB60LRQN9BN'7+HU56JULL>N*>.NN*>)62QK7[CTKIJAREC6$W>!8I-A5ZB
MI/"]6UI1')^J]/[+VT<GF4K/==WD ]IW-/B<V@W!W;WCW7H3<#9HFL0A&MGF
M]BMY4C;M.V4P@[78ZTCE#'SXI?#43_)^3.#>K'\O+=O;XYN(SE+B#49!F6YE
MPUSE2JN@BLG1J[0Y*M1]].U$]5:H[3I2F^-T.#,NLJXDZ9*-O7NA5?*QL2I7
M7JK*Y.#4I:-UEL>H[?U[3-HT*52FJ=?:Y%6BNR*1D\Y6C9=HFZ22<II**X:R
M#/)\HND#&\1NY3.D?&#D-C'D=FO*^-9*S+?91S%"Z#',.NI+>9BUT/C<K55J
MJB;3'4VHWHE'L5KVU:Y%.?K^QN<,O9</O&JRZAD5CD\[5IH\J+K1>%%14T*=
MY&/GR%+SDQK#VAO66NVOM7M235.:VZF5_8-GCS>-&Q]/U56ZO7=GV%X^;X*@
M0C9_&.HQB;Q.Z[=Y:I$/WEB8Q[K[J<V__-G^1JPS+FUZP8V^RNIK.!^A[[G$
M)[B:PA:Q=*JYDD<\J;-8X^=>YM&..I<!Q#P5NOBO<078NEB>Z-BZU?,Y[HFH
MB^5%1[M&A-I530I="*4I"E(0N"E+C!2E+C!2E*7'9@I<8[,8QC&/DP/"E55R
MU72JG+6O2IJESKHY]C\,N4-/13.L]D]&[(<Q2),XQE>;A*Q(3T&AG.?D*1:8
MC$"FS_<+G(W#\O6/IE??GE'&WJC8(LP639%7@BEG9#*OTI'(]4\Z&191NTL<
MT8?=+H8V[B1?[KGHUW^BJE(#@?=-_GNE]XY<=4>Y=.7%19:7=3I'#ELO38!6
MQ1D[:+859N0^4&C"F,)1N\6[,*MV3I99#/CIIXS[\_,1@.[=N X=O0WG.K@6
M2[UV*-A5K7)<S)#)%;V]'*E7/NGV[XV_=?+&QDB<VYZIUCF^UP9+6'',;7_=
M<-E6=&T1=MVRK6,T\*O5BM34KD1%T*I?"XZ:&H_&72] TCKQIA"MT2#;QN'A
MT4D7L_+J9,ZGK/+82[2'E[',++/'&<9[A5%LD)C"92EQ^>'>=O$S!O7SWB6?
MLS/VL4Q&X5^RBJK(8T]6&".NE(X(D;&SA5&U=5RJJ\@XWC%WCV*S8M>K6>9Z
MK3@:W4UB?V6MHU/HJNDS6,"+4   %-#KS7J1VKSHH>EJ^L5XIK[7E,J:$;CM
MSE.\;*EW-B7P;*655,9?04K!X[O<[W83&<8SVX[?<S^79E^VR?\ +YB.>\2;
ML-Q+$[JX5_EM+&-L*:Z)ZDL=VM:TTTJE%.H=S]HS#LHS8K,E$FG>^O\ X.)J
M-^QR2%O?65&C-7ZVU[K2%[/,VNZ/4Z-$]TGAE\V5*!80##NIY,?),>2QY.S'
M;GL_8[<CQ2S9F"[S;FG$\U7_ /QV)XA<7<FFO[2XF?,_3P^L]=)S3?W<F(7T
M]_+_ (L\SY%^E[E<OVJ5EOB.]J95F^-6D6CO&,,8NY[4L#'M+DQ\RCMC4J>[
MSC!^\3"7F><)CM+V&[^>S/Y.<#U=_E>Y0V+#-6?IF:9)K7#X7^3FVON;ENKA
MYVT77HII32AOK<=A](K_ !9R:W,B:OT(KWI_I1D\G 35"FD>&/&[6SE##:2A
M]65Z5G6Q2]W#:RW%-2ZV=M_]?EO8;"Y)DWR=_..]V8[>P>=WS'9Q;G[?IFG-
M,3MNUGQ>:.)W]:"V5+6!WUPPL6G!6G :?SEB*8MFF^OFK6-UPY&KY6L]1B\E
MJ$*GQ'6U%VE0XVZ3:JJ>!.V*X[0G$<'P5+OUB.8U6L&,3&<F4RI\ZY;]GLP7
MN8[.]G/Y/>/\K[*$<V-9IS[,U.<M[6VL(EIII.]]Q/IX*='M_.M>"FG:NX[#
MD=<WV*N32QC(F_YZJ]_^HPE,Z2=$AZ#T]^.#.)PF<]DJLC>Y=T3)#*.YBYV*
M7GG&5S)YR4RD>W=I,B_^<5-J4IORL9'(?SFYAO<Q_,KFB>\JC;6\9:1M6M&Q
MVL,<+:5X'JUTJ\"ND54T*AKW>1>2WF=+YTFJ.1(VIY&L:UJ>FBN^E5-QMZ[.
MC]*Z6VOMR440(RUMKRWW0Y7&>Q-RM7H)[),V!2]\F55Y%XW3023+G!E%%"D+
M\N<#1^[W*=SGS/>#9+LT<L^*XG;6J4UM2:5C'/X:(QJJ]RKH:UJJNA#&,(L'
MXKBMMAL==J>=C-'!M.1%7ZD555>!$J4VNAAKAQM#G_%7:714EB:LHM_V6_?/
M5<J8--RJ"%'8.G!E"J>5OSOKN=PGC.<&PHCE;&>U(>X_\P7-$>4OEOFP"R<D
M+L8Q"SL6,:E/V4:K=/:VE-EFQ:HQRZJ.1E*/.G][=\W#\FNM(EV5N)HXD1/Z
MJ?M%1/(E(Z+YEIPEW-VT:2#1TP?M6[UB];K-'K)VBFY:.VCE,R+AJZ;K%.BX
M;N$3Y(<A\9*<N<XSC.,CP-AFFMIF7%N]T=Q&Y'-<U5:YKFK5KFN2BHY%1%14
M6J+I0Y1:YS'(]BJCT6J*FA45-2HOE*&O+G4UWZ774$;3FK\NHZ'K-HB]OZ1?
M.3N#M9&C2SQSA:IR#C\A1ZS8F)(5Z1+DWB.6I#'-V87QG/Z(]R^<L ^;?Y;'
M8?FW8EOKNTDPW%6-1J.9=QM;2X8W2C7/K#>PK2C)%1$TQJ=?Y:Q*TW@9,6'$
M*.EDC6&=$I5)$1/71.!5]61OD7Z"[;Q\WE2.26FM?[LUZ^2>5J_5YG+IH$<)
MN7,)*9+X$[6)0Z92%),UF9278NR]F,870-DO:7)<Y\$-Y6[_ !_=;GG$LA9E
MC<S%<.N71JJM5K98]<4\==<4\2LEC6OW'I735#E+&L)N\"Q2;"KU%2>%ZMK2
MB.3]5Z?V7MHY/,IT+FCON)XS\7]R[@D9-"-D*Y2IEO4"J.4&SB1ODPS6BZ9&
M,,+&QE=TO/ND3&*0ISD0344[N2D,,BW$[N;S>MO:P/)-K$Z6VNK^)US1JN1E
MI$Y)+I[Z:FI"UR(JJB*]6MJBN0^S*V#R8]C]KAC&JYCY6J_15$C:M7JOFV47
MZZ)PFCG0L@XV*Z>U&DV2Z2SVV;!VE8)[!%<**I2R%J<UE,CO&#&,FX/#5QHI
MV&[,Y3.0W9V&QG/0/\P?$+J\^9;$+2=KFP6>&V$,-4HBQK;MG56^5J2SR)HT
M;2*G!0RW>Y-))G2:-Z*C(X8FM^C81^CS;3E3Z:DPHXC-9%<WX@;B<:Z:OI7+
M"IQ.%K!JA1*D[+6:HY,Z>:ZL,C@U<E7>2)F,HA4K<].CCY<=U.:4.;\A+\GT
M]_EM;Y$P'-M_N<QF;9PW&$6ZL4<OJMO86?MXVU70MS;-1WG=:M:GK/T[OW,Y
MCZ+B$N7+EU(;G]I%74DK4]9$_OL2OTL1-:FHO0?9W3=W*5YLB]SCN?C>+_&]
M#5E$,[S@Z\-'VFUR.:Q"D5[.T\?&0[NP)I%S^40ATRXSW2=F=T_S#Y\!R#NB
M9E;+UNRVNLVYI7$+O9U2OM[=G/RJG ^21MFYRZE5'*J5=4R7>^ZUPG+R6-FQ
M&28A?<[)3]96,3;=]*N2.OU^4MSN'"#5!9TZ62;-FR2CAPX<*$10001)E199
M993)4TDDDRY,8QLXP7&.W/R#Q<CCDFD;#"USI7.1&M1%5555HB(B:555T(B:
M54YL:U7*C6HJN5:(B<)7'C;JPZM74EC(>,<H3?#/A)G%P2(4QCQ&U+_F0291
M,FY1P=1%_%6"QQQ\LL*$,W7KT.X[?#/(')GU NL!N?DS^5F6]NF.M]^>?O\
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M>1*HY<-G)&3<WA%43[^96M1NA*T((E"403$0
M                         #3/G/PQB>>&D93C_;-_<C-$Z^M!EF]]QQOL
MVNZ;8MA5]=+":M/L]CN^K]D22%4<FQVN6L6:-R_3,9!V==L<Z!H.3:2@5*G2
M.G9TR^*G3 T^^U#QCK,P3%AE,3=]V7?'L5/[6V3*H>.G%KW.S1,'7(]=G ,W
M!D(]@Q8,8YF4ZJB;?"[ARLL:U&I1""(B$@8B1
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M]=(QVJ';C]Y2[L)&M1NA"#D1$)R/AW?ZF'@E_-]>/Z9=DB:/[B$6ZB:43D0
M
M                                     XJ?P9_VAOW.1%-8.0@
M
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MK%<2N,8Q*?%+M:W$\BO7R)5=")YFI1$\R(90&)%O
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MJ.WSQ<QW#UZNJNL8RBAS9 S
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M:D.!YD7&[8/*+<O7.Z?^]>82EJ7W;OKGEP9W/(O+>R-$OG]3V%O76$[07T+
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M?\T[L,W6>=\FW+K7'[*3:8ZE6N:J;+XI6+H?%*Q59(Q=;5T*CD14QG"<6O\
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M82%FN%DJNN6>G7Q];),%9W,%8(S:TQ=7)799$GDGE%>:Y4S@WB>%V8[0)A0
M                   !73XO?\0+UD_Y@^GC_1?8A6AX29NLG,%<G
M
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M$.'$>]17(1P@F8Z*I#XQDIBYS69H:E29NHEP$Q$
M
M                 .*G\&?]H;]SD136#D(
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MDWHE*'L"UWU&[:-8Z1LY\G4^=3ZOK$;KM+$=?.#+.(M]&X=]]4SDBRRN5L=
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M#9X:F+
M
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MQ@OE#M8_RY.8 71P
M
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MGY39 &P0  #S\NG!_P 8ESG_ />CRO\ _G*K@#T#0
M !73XO?\0+UD_P"8/IX_T7V(5H>$F;K)S!7)P
M
M                  .&?X4G^35_=)"/ #F(
M
M
M  XJ?P9_VAOW.1%-8.0@
M                                   #+J?\&3]H7]S@?&NLI',0
M
M
M
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MN3%)(JZQURVEY+#9(V>PR+-39Z9,K%+W3J9,3O9,D;!0+LH
M
M
M              #0;J.=1WCATP^.5@Y#<B+&5%(A7<3K?7$4X0->MOWS#)5U
M&TFEQRG>,=9<Q2G>OU2X8Q33)G#DY28+@X%"'A'PFY>?%#\^K/SVYK%EZ)PK
MIE@;UUXG"N9"*B756K+E=_7N,.A'*Z9'*R+3R[*MHL*>"';G>N71CXDGB*>
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M8/IX_P!%]B%:'A)FZR<P5R<
M
M    #AG^%)_DU?W20CP YB
M
M                                                .*G\&?\ :&_<
MY$4U@Y"
M                       ,NI_P9/VA?W.!\:ZRD<Q
M
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MS-PL'!,IO8W:&U7R]WLM<D"]N2>6T<DLA ',3\@_FK!L=O;VY EA
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MB-1S*5JFTY]:4T5J611Y;FC
M
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M_P"8/IX_T7V(5H>$F;K)S!7)P
M
M      .&?X4G^35_=)"/ #F(                   /ESDY"UB%F++99B+K
MU=KT7(3D_/SD@TB86#A8EHL_E9B8E7ZS=C&1<8Q;J+.'"RA$D4B&.<V"XSG
M&+M+<C>/?)&%E[+QVWOIK?==K\H6#GI_2VT*1M*%A)H[1%^2'EY6C3DZQC90
MS%PFMANLH17*2A3]WNFQG)%1=0,R@              Z;L+8VO=24R>V-M:]
MTS66O:JU3?6>^;"M$)2Z97&2SINQ2>3UHLCZ-A(=JJ]=)(E4<+ID,JH0F,]X
MV,95II4'QM3;HT[ONGM]AZ+VQK3=- =OGT6UO.IKW5MC4]S)Q:N$)..;V:GR
MLS"K/HY8V"+HE7RHB;/8?&,@BHNH&2P
M
M               <5/X,_P"T-^YR(IK!R$
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M-GX64J6OJ_5ZTUL&HMC,S1\DLDP;9.C,L"&\18BRI@+4P
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M$R(_KUZ;%4F8NNUO7\NW5*HWF)5\T;O4\*89%=JI'1P!7'B/CC-:+7S$=/\
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MB>D"$8-749R1USG7C9;+PY2,FOF[D[4_)EE<FSC+-+OJ&(93.2@>@: *I76
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ME&E5I37].*DID[&=94F4?*6RYO4LF9N[*X;1J95V67"+0"^\
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M?%[_ (@7K)_S!]/'^B^Q"M#PDS=9.8*Y.
M
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M".D[NHU4P;)O#\#"9<]PA<8F8E&HA%-1*8)B(
M
M                    <5/X,_[0W[G(BFL'(0
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MR3:6'DQLC:6^IK!DC%>>1+SI-75 JZQ^W*C9U3=8L7R!2Y\,A7V<XQ@YU,Y
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M_9@YLY[^<@>@6
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M3-E(CIXI@GY.,8 &RX
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MX"_B
M                                             *Z?%[_B!>LG_,'T
M\?Z+[$*T/"3-UDY@KDX
M
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M]!.
M                                            !Q4_@S_M#?N<B*:P
M<A
M                  &74_X,G[0O[G ^-=92.8@         H';79$ZR_P 5
M_#:>L*9K+QFZ;+1QF:@%"8>0[L_'I_'2US1F(],F6!RV;E1;&-?DBKF/EW"L
M4TE.WNE0*!?Q $0?7MY"$XS=(;G3L)&7-#S4_I>4T[6'#<V,2)K#O60CM/L\
MQ6.^17#]BWNBSS"B>?$;)-CKX_@LYP!0<Z._1CZTG);BZXY1=/SG!!\/=5;6
MN,U79"';<GN4F@[%L![J]\]@2V*7B]&:TL<#8(B*E9"19,%W3Y1PBL1V3":6
M#9RH!OSR ^'&^)2V9K&>@-H]2.N\H:V1,KC.G+'SNY?W-"T++=L<JBSB-TZS
MKVN3.2,7RV3FD'[1/+?Q"8.8QL)G S#\,GU(W7%?E-*]&?D;Q!U=QPVM-SUF
MJZ&PZ55'U9V;8=QZOK\U+OJMR&DI"9LN;\YEX:+DE8&:;.T6+=54C=F@HS?(
M*(@>@* *"7QM>\'DP^X"<0*PH[D9>5?[*WA8JTSR9=P]>/5H#6&IU&[!$QU7
M#MVZ6M;=+M)VY-^2GG.3'Q@"[+Q%T7%<8N*_'+CK#-DVK#2&D-8:N*1/*1\K
MN:538> D'ZZJ&3).7LG(L57+A;&3>,NJ=3.<Y-G.0/M<F-UPG&SCIOGD+8\M
MLP6CM.[)VS)I.E3)(NFNOJ?,6H[')B?OIE)#,7A!,B?:HHHI@I,9-G&,@>17
MTC.=/+KCKL3E(EPDTS;]Z]0GE[3&>M-;W>$K*U^G-?5.1L$SL7>5V8U!FQ=K
M3MS?R4% N62SO&(9AEJX>/DURHI(* 3H_"+5?A7R#Y9<@]K\I'%@V?U,JS.*
M;,U9([KG4+''OZX^-G-YV32(^91/*RV]:Y:EC&EW\DNZ=L8]VU<1A43EDEB@
M>CB (1_B+^0B''+HX<U;"1\LTG-E:]::!K:+5;R=U(/-Y3T9KJ=;(J]F<%*U
MH\W+/%L=N,G;M5"ESWLE &J_PF''I;2'1YUK<)**3C)SDIM7:N\WO?3,607B
M33#75=36>'/VY\G?5K6+9\T(3/A>3O2J8Q@ZBG:!9@ %!#J(M?K>^,7X'TRO
MX4?R6MV7&YU-MXW'CN6GS#A]A[ZDLO$^ZIX2;:JN".EODQW6F>_VX_P@!?O
M
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M!1%NI)L*]>ZY),V[HR21G*"!%<IDR?), 4)_AL_^(ZYI?]7>;W_B$J  ]*8
M4B_C=_\ 9-X2_P"\1>?Z-50!93Z.O]4_TW?]R+C-_1#4P!UWK9?U1O49_P!T
M3=7^ITB *[_P1O\ L;\S/]YFM?T608 ^=\;O_LF\)?\ >(O/]&JH LI]'7^J
M?Z;O^Y%QF_HAJ8 U$^)F_J.N=_\ U=TK_P")?3  TB^#?_JC9[_>[W-_J=J4
M 6==O?\ 9-M#^;NZ_P"K4F //A^!_P#]H7GI_,SI[_7>U@#.OQ:'4GY.K\B]
M1=*#C':+!2X*_4ZB63;AZA*K5NS;6N6U[3+UFA:G>V!%VS6;49FP8-W;QMA9
M)M)N90A'?>29DQD#:CAW\&%PQI5"KTKS3W#N+=VWGL+@]IKFLK!%ZPTY 2CX
MK9PHP@RIUZ5V)8G-?4*=LG)KS#%L_)DRQHQ#)B)I :$?$E]$CIO=-SIO:WV[
MQ2T?-5#;[WE%KW6LULJP[;VY=9F=IU@U_N6QRD8_KUDNS[7C51:2K,?DKAE"
MM'!"-<%*?'B+>(!:"^'!_J3> _\ -W>_Z:MF@";H  !'?SBZ47 3J12VNYSF
MCH7ZYI75$=8HF@.OK2W1KOS#'VQS$O+ W\#5&Q:*WE/+W,$U-WWI')TO"[$\
MDP8^# :(_P!EQZ%'X&?^\SS#_6" $G_"K@5Q.Z=NK)_2G#K5/U/ZRM&P)7:4
M[6OGSLG8'EU[FZY5:G)SOGG:5QNU@;>4U^DQ;?R5%VFS)Y+WR)%445.H!M^
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MNV+ R1S^_2+EL3)("H1KE9;S3 M3F:1R2F<G.Y=J.'C@"3L
M
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M;<K&V2ZN$1=3XXI(HHG(BI^VFTHYB4^;<QEJ*XFFS+=-1R0NYJ&J:GT17O\
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MTW;OU:90X1BWBX\RI4LNE$G#_*+=1\HB0"7X
M
M                 5T^+W_$"]9/^8/IX_T7V(5H>$F;K)S!7)P
M
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MPDFV=8.8Q<$/G%"32]$362.UGH4BN3@
M
M            <5/X,_[0W[G(BFL'(0
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MD))+%2 %]0
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M49,W!S"I\58M27:5*&6<22K4KEN9=)J8F%4\F[^ +M(
M
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M'$ARQ><4^,SJ,405CG''[32K%1MW<-S-3ZZKF4,HX+C!2I^'V=F.S'9CY.S
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MLHDIY.NYI^O8<Z[Y/7^N6[U'"F&:*JKZ04*55^Z<Y2;)M@)JP
M
M                               %=/B]_P 0+UD_Y@^GC_1?8A6AX29N
MLG,%<G
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M&RE<BWBWB9<RF$U"*J.HYR?$D:*YVVI*U*K4O4"L3@
M
M                       <5/X,_P"T-^YR(IK!R$
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MNW!>F2"K=/8NYK4BS6O-L22<$2<)Q1%&;>,B4U2X60A(UFDKDRI#G,!(R
M
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M^;/>-V@;G
M
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M0_?3]_MQ@#-@
M                                                     KI\7O\
MB!>LG_,'T\?Z+[$*T/"3-UDY@KDX
M
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MK\#',X>#A(>-;IM(Z*B(F/1;L(V-8-$2)(((ID223+@I2XQC&!4(GU@
M
M                                     '%3^#/^T-^YR(IK!R$
M
M           9=3_@R?M"_N<#XUUE(YB         "GOUQ^DISIL74;XE=5OI
M3ZS8;"Y#45_ ([JJ"NP=9ZY1DGNL/)&U*L\B\V;<Z/'6"(O&OW3NGV!HW>F<
M>:F;0A$<E574(!;,U?9K;<]<TBUWW6\UIZ[V&LP\K;=66&P5&US.O[$\9)*R
M]4?V>A35BIMA4AGQCHE>QSQ9LY(7"A>[WLD*!WP                   $5
M/58W!U-Z)I=2E]+?B.MO;>U[8/66-O6+9G'RDZ]T>S/@[928Q6MN;4ILY?+\
M;!L'C&A8]6"0SGQWBZWA>;W &A_0DZ'SW@$VM_,#F+/)[GZD'(3SI-['O$Q+
M8N6-1-+:]6F;-5*]:W"CH]DOEK?N?%M5C(H<KI4F&3$^69%W,D!9&
M
M
M
M
M                                                         !4"
MY<=+CG9U5>N-JS9O,/1GU<]*_A]Y;]4Z,SLW3MJ+N_YLR<3,O_&HU)V#8[S!
M_7Y>6S-9_P"=8V.\&EP:+1SY-)9(D<"WV0A$R%33*4B9"E(0A"X*0A"XP4I2
ME+C!2E*7'9C&/DQ@ <@
M
M        5T^+W_$"]9/^8/IX_P!%]B%:'A)FZR<P5R<
M
M                        #AG^%)_DU?W20CP YB
M
M
M        .*G\&?\ :&_<Y$4U@Y"
M                                           ,NI_P9/VA?W.!\:ZR
MD<Q
M
M
M
M
M
M
M                                     !73XO?\0+UD_P"8/IX_T7V(
M5H>$F;K)S!7)P
M                                                      .&?X4G
M^35_=)"/ #F(
M
M                                      XJ?P9_VAOW.1%-8.0@
M
M           #+J?\&3]H7]S@?&NLI',0
M
M
M
M
M
M
M
M      5T^+W_ ! O63_F#Z>/]%]B%:'A)FZR<P5R<
M
M                      #AG^%)_DU?W20CP YB
M
M
M      .*G\&?]H;]SD136#D(
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M5'LFN;7OQ>=GT7U+Z+#QA@/<&'\J3C':-IU2'TJ/9-<VO?B\[/HOJ7T6'C#
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M7#V5G,_WUW.#Z,ZJ]%AXNP/N*PY4G&.T+7JL7I</96<S_?7<X/HSJKT6'B[
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M*PY4G&.T+7JL7I</96<S_?7<X/HSJKT6'B[ ^XK#E2<8[0M>JQ>EP]E9S/\
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M6HUJK6B:D\R&3!\I3
M
M
M
M
M
M
M                                                  "NGQ>_X@7K
M)_S!]/'^B^Q"M#PDS=9.8*Y.
M
M     !PS_"D_R:O[I(1X <Q
M
M                                                 '%3^#/^T-^Y
MR(IK!R$
M                       9=3_@R?M"_N<#XUUE(YB
M
M
M
M
M
M
M
M                 "NGQ>_X@7K)_P P?3Q_HOL0K0\),W63F"N3@
M
M                                  <,_P *3_)J_NDA'@!S$
M
M
M                   <5/X,_P"T-^YR(IK!R$
M                                                      9=3_@R
M?M"_N<#XUUE(YB
M
M
M
M
M
M
M                                                "NGQ>_X@7K)_
MS!]/'^B^Q"M#PDS=9.8*Y.
M
M   !PS_"D_R:O[I(1X <Q
M
M                                               '%3^#/^T-^YR(
MIK!R$
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M%ZWY(:<O,BU6EEU&L4DX95BY2CE!23<HG3;E,7&5CER4G;G&< #;<
M!6RY;_%9])?B?L>8U8WMFX.3-EK4FO"VE]Q?I%5N5.@I5KXN'3-.]W_86L*?
M:RMCD*0[B >R[7"A_#\7OD5*F!NWTL>M+Q%ZO#/;:G&6"W55)?27S04OE:W3
M3:S5Y=JSO:MF1K$A'.J;>M@UV2;2"E0?XR4C_P ='PL>(F3OD[0)<@
M
M
M
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MN56N15I7956.<C74JNRZCJ(NC0IM,-0F/
M
M5T^+W_$"]9/^8/IX_P!%]B%:'A)FZR<P5R<
M
M                #AG^%)_DU?W20CP YB
M
M
M.*G\&?\ :&_<Y$4U@Y"
M                                   ,NI_P9/VA?W.!\:ZRD<Q
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MC=FN5\OMQJXO=N=RQMYKF=GUWZ5;M\Z[[J([3L:::DKHFD'"1JP
M         *7772E/K6ZB-5UE5F#56QU_6FJ]9*>3^&9Y(V:W3T[:HM!T8N2Y
M+G#"]L2)D/\ E8*;O=O=/CL]V/Y?%IX.^66\S9B\CTPNYQ7$+Y*UV606T,5O
M(K?\^TE5RIHJE*5:M>I=T<?9V29+^X5>8?/-+IU(UC6L6GUQNK_W"XOK^F1.
MN*'2=>0)>Y!T.HUNF0Q/#(EW(FKPS*#CB^$G^]I]UFQ)CNE^3'[&!X@YDQV\
MS1F*_P S8BM<0Q&]GNI5JJ_M+B5TK]*Z5]9ZZ5TJ<QWMU)?7DM[-_C32N>[Z
M7N5R_:IVX64^8 "'GGWT?]><X=LUW<B.U9K4=L0B(RN7<K.IMKDPN,+#+*YC
M%FJ#FQ5P]=L3=DX,UR[[SUN=%-'M:]Y,YE>W/ER^=G,VX#)MUD:3!X,:P9T\
MD]KM7#K9]M+*B<XCE;#.DT*N:DG-TB>CG/I-1R(S9N3MYE[E+#7X6MNRYME<
MKHZO5BL<[76C7;3:I6GJK55]:BI23_4&JZAH[5]$U#06CAE3M=UF+JL D\7P
M[?J,HMN5'RR1=E31*ZDY!;!W#E7!"%475.;!2XS@N.2\ZYPQO>!FW$<ZYC>V
M3',3NY+B96ILL1TCJ[+&U79C8E&,:JJK6-:BJJI4P#$\1N<6Q";$[Q46ZGD5
M[J)1*JNI$X$34B<"(AD<8N?"               1!=<N]1-0Z>>PX211;K/=
MF7;6=%@/*"$/X4LVM;38*ZR!3D/_ )P2!H;WNYQDN2]N38S\G9GM?^7YEZ\Q
MOYE\,O[9SFP8587UW-LJJ5C=;NLT1:*GJK-=Q532BZJ::ILO=):27.=8)6*J
M-MXI9'4\BL6/T;4C3"/P]VK#5/B/>]F/&N$7VVMMRGD+GP\E,[JM#B8^ CLY
M4,4N5,(6=S-EQC&<E+\O9GO9-C&??S*\WIC.^C#LJ0OVK?!L%CVVU^[<7<CY
MGZ."L#;5>!5^BA=M].(=)S)#8-6K+:V2J>1\BJY?]!&$]8\ZC3P
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MS9N]2,QGJX_DHIV55F\26+E-4V#)*D-C\DQ<Y [J
M
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MS2*YR\X[9:J.HJJUFEKZ(Q&I1=-:(3WCSH-.@
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M+G&<8B<Z\G@>MLFTYNPB,=L24:J;2N=16HY%:K41:*CBQR/+XT>
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MP-F$X,YTTDDC7O<K',2-&U]7UT:JN55_5JU$KZVHLNCRI-#@
M
M              5T^+W_ ! O63_F#Z>/]%]B%:'A)FZR<P5R<
M
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M22GC5VE':R9M>$LOBH1
M                                     #BI_!G_ &AOW.1%-8.0@
M
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M7N<LM+E3''X4DG.P[#7L<J456N\J:JHJ*FC0M*Z*T2.GG#U2.1NET>1=%C.
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M#*>2<9S=.J6*)'9,6CYGUV&KKV4II<^GZJ:M&TK45%-9->[RZP>_:X39FO\
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MK7L<BZ4<UR*BHNE%2AHN2-\4CHI45LC55%1="HJ+145/*BG[Q\Y(
M                           >;5\:_N>R6CFIQ!XTM'KUQ7-?\<W6UFL,
MB?!62MRW-LZU4YRHHD4^,N)%.&TZP*GE0N<(IN,^'G'BJX 'H)\3] UCBKQD
MT%QNIK9%M7=(:DH>M&.4"]WRU2IUQA%2,PXSDQS*OYR3;K/7*IC&.JX7.<V<
MF-G( V"   0M?$0;LF=!=&;G7=JZ_>QLY.ZR@M2,74>91-X1OO'8E-T].^"X
M3,GEKW:U=WIC*=XIBE+GN=I^Z7($&WP2N@(&#XE<N>3ZK-H:V;)Y!1>D6SQ1
M#)I!I5-0Z^K-UR1JY-VX283$YN)3"I"=W*BL<3*G;X:78!=N   >7?U'H?V>
MWQ6]+VAK=-.-A[=RFXS[V5C6*/DIEHS?)JI%[PBS91*FGE2W2TQ9^TY2YQ@D
MACO8.;!N\!?OZQ7]4_U(O]R+DS_1#; !5H^!V_[)NH?_ #B<=O\ 5K;0 O8/
M'C2/:.G[]TV8L&+9=X]>O%TFS1FT;)&6<NG3E8Q$6[9NB0QSG.;!2%QG.<XQ
M@ >79Q-L3/G[\6EC=''GNV76B7+V^[=0MT4J4T*\U5I>L2,>O?"O42G3\QW?
M-<;99'SV>4*3#9//897Y +??Q5']1URV_P"L7&__ ,2^I0!K-\&__5&SW^]W
MN;_4[4H M<@"+KK0\2*=S4Z97+O3=IBVC^7C]/W':>L7ZY,%<5[;FIX"2O.O
MI5D\*4SA@5U,Q&(Y\=+\M6*?NT,X,18Y# 5;/@BN1]FDZMS=XFS+YV\JM2D]
M9;XH+115RJA#R%N3L%'V2B3"JQVS9&3^;5<5232(GVJD<'-D^3X[H%]@  !0
MN^+DZ2OGZ(V9U=?K_P#)/F55-":;^[Y]57C^<_*[Q\T?G']:_P!9"/D7A_.W
MRCR/YM*]OD_A^/CQ.^0"*+I(?"\>U,X7U/EY]^/ZBOG1<[_4?J]^[/\ 6=Y#
M\QI]6#\X?.S[P.O?*?.GA>+X7FQ/P.WN]]3_  @!;PI]6J?PP714V;\YMHMN
M3<GJ:Q7&P:Z>.:*IJ5/8>T]R6)FQH5&7K:%XV(Z913&;<$7DW:,DHL6);.ER
M)%,G@F0*N?33Z0'*KXCFXW[J*]1GD_L:!TS)7F2JE85K2<<[NUX6AWR*MGJF
MGHVPIR5'TQJREX=>0M%TXF30/)$63*R4.BY7,!O#SW^#CJFH-.SN[.FIR'W[
M.;MU)&*7Z'U?N>4I,K/WR1JAEIPK/66Q-9TS52U+OR1&:9X4CE@[2<R29$S.
MV>%<+H@2+?"T=9?8_4"U)L/B?RDM#VX<H.-4-&66%V'.N45+/M[23Y^WKI9:
MT=]7,A,7?6UF7;1\Q*JD*9^WEXQ1<RKW+M=8#+WQ=?\ 4T; _GWT/_K0Z %1
M'IU['Z[/.S@SK'IO]-BJ635'&O2RVS$-K[]JM@4U2C<YG9-]NVQGM=MF\I5U
M'.8Y@Q9VXD?BLU4RDBZ2/Y1(X6:K$(V EMZ:'PLG4DX@]1/C;S'W9OCB%=:O
MJK:Z^P]A8J.T-\V/8]E(_C)UM*N&'SMX]UF/F9R2>R^5%SOI1OA;O',=3)L]
MA@- OB2'VVXOXC324GH&*CIW>T<VX3OM*0<QE@6)F=MM+HDXUQ%2AI20B8S$
M=(W%-FBOERZ;(>$<WB*ID[3X FCHOPFEEY<2TAR)ZQ'/OD%NSD_?V"3FR--&
MR]-B(>D&[R"\?4H^Z;*H%\9R]?@"+.DT6$/7*Y$LC+%29I811[[@" 'J#\2]
MV?"U]1WCGO3A]O&VWG6.Q8B7M=,:7G.(N3MM:J<W%16U-"[L1JZ$55K]7W\?
M-1K@D@V9L#)J/T7"+-F]CVSM0":O3_00YL]:UW6><_6GY?W.H0&RJ[&W#2O&
M'CLX@2YUUKNY1K*=KI(Q]9FMSUQJE-:+70.:-;1%DEWZ1TUI:4+($72 $7G7
M*^'P@^C5K#5G.O@WR)WN_@*KMFK52=)?9>NH[5UE:)=E)25.V-5-C:UKNN6O
MF[$Y"&8JH>:D'35P[:F(NL4RO< O2]&/FA8.H!TT.*W)Z[+(K[(MM*DJMM)P
M@V19%?[(U?:)W6MNGO(6W^:L2VZ3JIIA-!+!4DDI A2E)C'<*!6RZ]O4MYE\
ML>==,Z%_2[LTC6[M:7+"N<BMB5"=>UV;DYJ?KREHG-=N;Q$IJOZ5JK6NN3'E
M[L\CO$?O<95C<XPFT=LI #OFFO@F.$,71(IOR$Y7<JKQLS*:2LW,::<:CU71
M"+';HY6915;N^KMQV!5-LZ\3!72TJ3*Z?=SENCGM* (3>4/&OF3\)MS<T=O?
MCSNV>W/Q7W8]=-Y&-E6+FLPVRHFJNHQ6]:8W'5&;Z5K25J;04RF[KEA;Y*O@
MYE'+5) S9TWR!Z8FI]F53=6K-:;DH;M20HVVM?TW9E,?K$236>U2^5R-M-==
MJD06<H$4<P\JB<V"**$QDWR&-CY<@>1#P^Y@<PN'?51YCS? W4YMO<H]X6#D
MIQYUK"H5.3ODA7'ESWQ#6I[=HFF1Z2C>P2=?940_A%D.R):>-EV]*JV;J(*@
M2K7#X87K]\]5TMY<O.1FD?K*FW*[\];Y-<C-H7&YUS$M'0R[E!BTU=JC;>N:
MM'$*W19>014BD@AF.PF1$K=-N8P%^#IF\9=@<-.!'%CBUM29J5AV%H[5$-0[
M7-421FI:G2$G&.'IS+5V1L<!5YQU&817(5,SF/:*?D]GAXQC  WH
M
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MF!@
M                 %=/B]_Q O63_F#Z>/\ 1?8A6AX29NLG,%<G
M
M                                  X9_A2?Y-7]TD(\ .8@     "H-
M\9O_ %=G&_\ WTZM_0;O44IONI])*XE4^'=_J8>"7\WUX_IEV2)H_N(1;J)"
M^:ECH]1X><J;+LMQ%MM?0_'7<[RY*396ZD6I7":[L195H\0=9\%XF^:&,AA#
M/;EP93">,9R;&,S+JTZB*ZBC-\%;5+.YY#\WKPW9NLTR&TQK.J2TAC*A61;/
M9;Q*R]>9F+\B2SI2*J<H?&?E,D0N?V,*?+1AUJO 2-/03MO_ $5LW_5^9_\
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M]44V!$0
M                            !Q4_@S_M#?N<B*:P<A
M
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MS9<RJITVV%U">POSUY;S?O:GRAN,R)&LV,8G?SXA<5JD5O;6D;8$N;IZ(NQ
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MJB(E%=-*]_E5'(JJJJIKG>7:Q6F=[^.*FPY['_YTD3'NK]+G*OUDDXY8,%
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M'[R7>(0V/RL$S@"R7\77_4T; _GWT/\ ZT.@!E7X5?\ J.N)/_6+DA_XE]M
M"Q  /-JZXW_%7<)/YU>F]_3-  #TE0!0?^.5;H&K?30=F3+ERA.<N&Z2V?\
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M-$4\*LGKAOG!<=P^<8[, 49_A@/^(1YV_P U7,?_ ,4^HP!Z2H
M
M                           "._J3\O7W%;1J3#7B1YGD/NV63U?H.JLD
M/+I9Y;YT[>.5L;:.Q@QG1*QB21.B0Q3IKR:[- Y<E6-V=-?*SN4M]\&\!USF
M94@W9X!"M_B]P]=B-MM"CGI Y_ZJS[#D<J*BM@9/(U45B&;9%RTS,.+*^]]7
M!+1O.W#UT(C&U795>#;HM>%&(Y4U';NGUQ&:</./<)291QY[VM<7:FP-VV]=
MR:2?V/9-@015ED32ZQE',A&5\N,,FJAC?O\ X2CHQ<+.5LFLGS)[Z)M]V\NX
MQ^T;T?)UBQ+/"K9&[#(;&%52->;2C623:99$1/4VFPHJLB93YLZ9E=F?&GW<
M:;&'1)S<#*41L3=7JZD5WWE\E4;J:A4GUCC/&?K*Q$8N9..CZQS0FJ>1<W=3
M10J=ZO,G4VKT^$BID10-5K218V,8P4A<YQV=F.P>S>;%_-;Y&IKN-%EN;O(D
M5RJ:U6XM+2.X<U*U55Z1;JU.%5X:G2%__P"OMU[I&^L^3"FO_P ^.-'JG+90
MO=#\\IR$0O\ 6=YXS_$O2T%KC5,R>&W3N[SJRCIYBNJC+4.AQ::2-BM<6NAG
MQ&-A?O'J+",6SDADLF<N$386:E'=?R+?+OAN^;/=QFC.$"3Y$P#FW/A>B+'=
MW<BJL-O(BZ'PL:UTT[=*.1(HGIL3*;2W6Y/AS)BK[[$6[6%6E%5JZI)%^ZQ:
MZVHB*YZ</JM70X_9T;.$\!Q_X[US>5OB$)#>^_H5K>)>R2B7E<S7*+9$T96J
MU1@[=%\J8YDHM1&3E?\  76?.?"6R<K5'NT/GCW]8EO(WFW6[_!)W1;O,MSN
MM(X(UV8I[N!5CN+A[6^J_8D1T%OK8V*/;C1JS/K+O0S7-C.-OPBV<K<'LWK&
MUJ:&ND;H>]430M%JQG C4JE-I2/#XC*Q['?6OC3KYM7IOZM"1-GL;2:;1KE6
M*L.QY>21A,5XKU,JB:TW7H"-(JDV+@JF4Y<QNQ3&<>'TS_+"PO*]O@^:LRRW
M-OXJ6:"!T3GM22&RC8LO/;*T5(IIGJUSUJW:MD3U:+M9KN0@L66]_>N>SI^T
MQJM54JV)J;6U3^JYRT5=56<'#-;TY=562E<*N*L/N&NIYV;2M?O#L3V2,;K6
M>F1EGEI*1B()!=XB>0@73*G.8Y@Y;D,D<F&N$5"]J?=QP;\S^<,*Q[?QG"]R
M1<KX4O\ $FH]()%2"ZD@C8R254:J,F:ZY;-*QZHY%617M7UJKJO/&(P76:L1
MEPQ_^X2S)795=AZL1$<[1H<BO1SD73KJFLJG<WZ8??76&V%KK4"S:K2MUWYK
M>C1\S#M2&2K]O9P=)KMSN2S=B9B95U&6J/D99]DIR+'6(J8Q\J9R?/L)N!QU
MN[KY(\,S/G9K[RSL,N7UV^*5RUFMG2W4UK;(Y^W1LEN^&WBJBM1JL1&[*(TZ
M(RG=)@^[*"^Q-%DCBLY9%:Y?O,5TCF,JM="L5K&\%*:*%Q/0/%+4G'IJ\D:W
M%+VC9UDR5YL/=]Z5+9MO;(G#HE3>2UINC\BDGE!8V#91CVQD(UF4V2(()ESG
MM\1-X^^'.>\N9EKBDS;3*=KZMEA5HG,8;8Q(M6QV]JQ4CJFC:F>CYY53:DD<
MM*<QXSF+$L:<C)W)'81Z(X(_5AB;P(QB:/I<M7.UJJE/CK'T*IQG4@M-4U!"
MQL+-V*-U:O+Q-<13C$"[*M$6Q5*X2:LBI(L9*7:.XYVL9(I3*N'!ES=JBIS&
M]M?D>S%C-W\KMGC&=IY9["UEOTCDG59%Z#;R/395SZJ]D;FS1M1RJC6,2-*,
M8B)TUNPO+F3(T=SB;W/B8Z6BNT_LF*NBJZT:J.1*ZD2FI$+QOBI1D;XTD^2*
MC'L?%?R;LZ;5 J31#ONGSI153PFR6")F4.8QNZ3';G.>S':/S_;#[NZYNUC<
MKY9*,C:BN6KEHUC41*N72B(B)55U(<ET622D:+5RZ$33KU(GE\A3[NNR;[UJ
M^H+7]+1,_/5_BAK^3EYUK%QZJC=-OKZI*9:3.QY-H;*C<]YO[A\C&QRRR:N(
ME*312P3)2NCK^VF Y6R[\AWRV7.>[RVM[G?%B44<+I'HCE6\N4VHK*-VAR6E
MFUCIYFM<WI#H)'JY%6%L?3%K8V>ZK);\5D8Q^8YFM:JKIK(_2V)%U\W&B*YR
M(J;:M5:_=1+;U)I-%U'1H.CT:!A*/0:3#DCX6$BTDHZ&A(AD0ZRALY,;&,=N
M<G7<.%CF565.=94YE#'/GQ@Q['\PYTS!<9@S!<W&(9COY]N6615?++(]41/\
MC6,:B-:U&L8U&HB)S==W=WB5V^[NWOFO)75<Y=+G.7]*(B:$2B(E*(4Z>G/(
MOMH=::P;"U!C.*#);6Y0[$>N(Y R<2WU19"WXL29TV0*@DE&NGUDB&S;&28(
MD[7;YP7&2X[/;[YGK6WRE\B-MEK.O_:.+!\!LF(]:R.Q"#H?.;+EJJO:R"Y>
M_2JNC9*E=*G3F=V,P_=8RRQ/_C&V]I&E5TK,WFZT5>%$:]5\J(XNE#PD.63Y
M<U!PEDC7$-8H>+GX=WEN9W$S4>TE(UT9HY1>M3.&+Y%=JMEL\;IJIY,3/<5(
M4V.PQ<9Q]EAB%_A=TV^PR>:VOF5V9(GNC>W::K7;+V*CDVFN5JT72U51="J5
M(II8)$E@<YDJ:E:JHJ52BT5-.E%5/H*J'Q'\G63[$XKP+)C'HVV,I.RY.;?(
MI-R23BLS$Y4F538NE")%<&CX^3@9D[8ACF3(HX7R0I<F/DWL'_*ZM,6;EG-^
M(SR2NP66_L8XF*JJQ)XXKAUP]J*M-M\<ULDBHB*J,CVE5$;3HC<;'<)98C,]
M7+;.EB1J::;;6O5ZIP55',KPZ$KP$J73:X-5ZC:"T+LO>RBFW]K_ %7UYW1&
ME\8,Y*O:$J-H8I6%K2]<5=VBM%0$^5O)X),S14\RKYQE1+*^&V,)9Y ^:7Y@
M<2S!O'S%E7=XB8)D[M>9MVZT>YDV+W-N]8775[<-5))H:QUMK57='B9LOYM9
M?737F>LVS7>,WEA@_P#NV'=(<DBQJJ.N'L795\KTTN;5/4978:E%IM:32CXC
M*LZ^3U%H&WJ0L:EM)QLN5@&$^BT:I2KRC)521?3L8]>$*5X]9LYSS6HW(?)T
MVYE5<D[N53=_?/\ +"Q;,CLZ9DP1L\JY1;A4<SX5<Y8VW:W#&12,:OJM<Z+G
MVO5**]&LK5&)3*MR%Q>KB5Y;(]W9Z0(Y6U6B2;:(U434BJW;1>%:)Y#)W1\X
M<LK=Q8TKM_D4_=[6BXY6W27'G4-T:M9#7&GH1W<[$H]MK*IN$E(J=OEMG#NI
M!O+/DW"\>P7;IM,HY[^<XI\[6_"?!=[V/9)W8QLP>[E2V9C.)6KG,O<2E;:P
MHVV=<-5)(K2WB2.%]O$K&33-D=,DB40^#>9F=UMF&ZPS!$2VD=L)<S,54EF<
MC&T8KTTMC8VC58U41SD575T'V/B":UK]3AM4[1-P\9\^(O<M1@:).8;(DEVQ
M)."MSR<A4GA"E<YAW</&++*MLYRAE=NBIDO?(3./A_ELXKF1N_&\PBPGE[ F
MP.YFNXMI5C=L2VS8I5:OJ\ZV61K6OIM[#WMKLN<BTMS$]ZF:)+>)SNB.M7ND
M;7U5HYB-=35M(Y41%UT54U*IV3X?^%F(K@E)OI-551E9-\;!FJZ110QR(0Z$
M!1JZNDW+G'8BEFP0#X^2X^3*AS&_9-D6O^9#?V-Y\PT5O:(U)[7+MG%,J)15
ME6:[F15\J\S-$E?(B)P%#?++%)F]K(T3;CLXVN\[MJ1W^JYI-Z8Q2%,<YL%*
M7&3&,;."E*4N.W)C9SV8QC&,?+D<"(BN6B:54U/KT(>? IN36FT>I2KOC;EE
M)#Z>F>5:NQ[#-K1TS.I-];P]_--Q4;YOKD9)3;]):LQC9@7R=JHKDIL&[,=F
M<X_2FW(^:LI?*NF[O)=JL^=X,GI90Q(^*)77TEGS4C]N>1D3%2=[YEVY$;5%
M2JZ$7M%,+O\ #\B)@^&Q[6)LP[FFMJUM971[*K5RHU/757:5H6I[YUR.GA4Z
M\ZEZUL^U;/ED<'PVJE/U=L.)EG:F$E#IYP^V'7*17D$#*D*0QC/>^7OXS@AL
M8SV>0&7?Y?WS,XSB;++%<)L\)LW4VKBYO[*2-J51%]2RGNIE6BJJ(D5%I3:1
M:'/-GNESM<SI%/;QV\:ZWOEC5$^J-TCO]'ZS0+:G"?GEU7=P5O9W(5C!<7..
M->PNEK>F+3T3=;:VJ4DY9K/Y6+BZ\Z<-)&SVI%JGE:1E%HY'":*)F[91N5/"
MO1V4-_7R[?)UDFZRGNTDN,W;T+FBWUTD,EK;.N&-<C(Y))FHYD%NKEV88&S.
M5SGI)*V57;&98=FO)^[K#),/P57XACC_ /%?LN8Q7HBT15<B*C&5T-8CEJJ[
M3D=6E@WCYQ_UCQAU/5],ZB@\PE-JR"W@Y<K8>3$S)O53.96PV&3\)$\I.R[L
M^5%E<E(0N.ZDD1)!-)(GFOO*WD9LWLYQN\\YTN.D8Y>.2NRFS%%&U-F.&%E5
MYN*-J4:VJJNE[W/D<][M+XUC.(8_B,F*8D_;NI%X-#6HFA&M3@:B:D^M5555
M5S"[=M6#1T^>N$FC)DW6=NW3@Y4D&S5LF99PX64/G!4TD4B9,8V<]F,8[1A,
M,,MS,RWMVN?/(Y&M:B55SG+1$1.%5541$X5+8UKGN1C$57JM$1.%5U(0D]%-
MI(;!@.8/+29+WG_)7DQ9G\<X51,FY7K-84?2L;E/OY,9"/:R5[>M$4/D\'R3
M)>SL[H[W^?&:VRUB.2-S-BM+;*N5(&/:BU:D\Z,C?6FM[F6D4CG_ *W.(NNI
MM;>HYEE-AF6XON6%@U%3@VWT1?K5(VJJ\-2/3X@CB+\W+I3>85/B^Y$7SR+7
MFVO)$/R&UQB8\_S*L[OPDS&_]^"ML#QJRI\E334BFI?E4<?+TM_+9WT]J8#?
M;DL;FK>X=MWN';2Z76TCTZ5 VJ_]#.])VM2KE2XE70V+1FNYC,O/VLN6;IW[
M2&LD->%BKZ[$_NN7:1-:[;N!I,'TB^7/WKN)-8^<4GY=M/3OD>LMB^.KXC^1
M\ULB?-&W..]C"BOSGKJ1/&6-_"R35YV?(4<2_.EN6_)W?/=]F1<WE#'-J^LJ
M)1C.<<O2;9O G,3*NRU/NP20>4UGO*RUX=S))S#:8?=5EB\B57UV)_<=J3@:
MK3 '*_!]Z]7[@GI1LXP\@^/U-M'(:UH8(15O%RR[AV\@LN$\Y_+?^=:-!]S)
ML?YNF^*H3/:8V!LC<XK=WOR4;P\^RMV,0S)?6^#6ZUHLD:-:V6B\#.;N[NM/
MOK$K7)1$4O.7*81NTQ?%7)26]E9;,\JI1$=]5))/IV:*3BCS_-2GQ;)8H*H5
MZ<MEGE6<'6ZS$2,_/S4BMA!A$PT0T6?R<B\6-\B39DS0.H<W]PI<C[\+PS$,
M;Q*WP;"87W&*7<[(88F)5\DLCD8QC4X7.<J-1/*I5@@FN9V6UNU7SR.1K6IK
M5SEHB)YU700@\'X"P<^^5]RZD&S8Y^WU!KIY,:PX84V6(<K-*/C5GT58ME*1
MB^3)8E,G45+E;L4_Y6=."%,7,4U[O?>_[$<-^7'<Y8_*[E.6-V=L39'?YGN8
MU3:5[T9)#8H]-/-T1J[/J_[O'&Y45+R6NV,V30Y-RY%D:P<BXG.C9;YZ:ZK1
M6Q5\FK1H]1$7_I'&G'Q(%".G+\6]GH)8,F[C=DT*47[I,&3/'NJO88!+)L$\
M0^%RR<EG&,FS@OAY[,8[V>W>'\KK,3766;LI2.]9DMC=QIITH]MQ#,OD2G-P
M)JJM=.I#*-QMXBQ8AAZKI1T4B?6CVN_H;Z283I*7LFP>GGQKDLKD6=0-3EJ(
M\3+G.3M3T*USU28H*XSG.2G-#Q+94N/V/#4+G'9C/8.)?G-RZ[+7S+YJM4:K
M8;F\CNVKP.2\MX;AZIYN<D>U?.U366\BS6RSK?QTHU\B2)Y^<8UZKRE5/I0D
M;'+Y@X &L?*-IK2D<:^4-NL-7K"4,^U#L2?O><PD60]M5C:1)HM,3>?)>].2
M2B:"39MEQXJG>\,A/_-P-L;HYLU8_O3RE@N&7=VM]'C5E#:?M9%2W1]U&KN:
M];]DQ%5SW[&RVFTYW"I?\ONO[O'</MH)).=2YC;'ZR^I61*[.GU4UJM*)K52
ML[\.GKN0EN1V\=I8*IYFI&G&U,7/@F<)>>=B7"&EHS!E.WL[2QVNWWY'9GM[
M<9[<=F.WU8_F=9FMK/=?E_**JG3K_''72)73S5E;2QR:/[][%I^KAT;XWW7K
M(\#M,/\ ^EENE?\ YL;'(OVR-+4._-.P/(+2^S=*6=Z^C(39E.F:F\E(WN^<
M(DTFU,FTEF9%,X17<1;W";@J2G[TKE/N'QDAC8'D'NYSOB.[;/>$Y\PF..6_
MPJ^BN&QO^Y)S;JNC<J:4;(S:8KD]9NUM-]9$.>L&Q.;!<5M\5MT1TMO*UZ(N
MI:+I1?,J52J:4K5-)5.Z-ND;QI7JD[3U/:44#SVG-=;9@[4Z8**J1KE!C9*A
M!,I5BH8A#J1LRM)-'#;Q2IJ916+DQ2GQDN/87YX\_9?SY\HV#YRPASDP[',4
MPZ6W:]$1[5?!<RNC>E51'Q(R1C]E53::M%5JHJ]$[S\6M,5W?6^(VZKS-U/"
MYB+K2K7N5%\[:*BTJE4\A)]UHNHC/<6J-#:(TW,YB-U[8A74G+69BN4LKKG7
M1UW$7F4B^S&3M++;'S=RU8.L9P=FDU<K)]Q?#=0O)GR)_++AV]W,$^\//,'/
M9#P:=L<<#T_9WMZB))S<G Z"W8YDDT:Z)7211NK'SC5P#=9DF',-V[&,49M8
M5;/1$8NJ66E:+Y6L145R?K*K46J;2'=.D#P!K7'/3=<WYL&#+*<C=RP"-HDI
MN;+AY)T6HV9,LE$U:),XP9:-E)2,72=32V>QTJZ6RV4-X:&,9L7SL?,?BN\_
M/-UNYRU<<SNOP*Y6!D47JQW=S NQ)<2;.A\<<B.CM6_X;8VI*U-J153Y=YF<
MI\;Q23!K)^S@=J_81K="2/9H5ZTUHBU1B:D1-I-*F>NKF2FXZ>/)%W=HYG(L
MV5:@CP.739-PJPN3^X5Z%J,C'F.0RC5XWG)1'&54\E-A$ZA<Y[ACXSKKY+G8
MY_\ .8RM#@,KXIY+J5)MERM1]LRVFEN6/IH<UT4;O56J;2-5/61I9MVRW7C6
MQ;:.5KED=M46E6(QSGHOE16HNA>&G#0B9^'$U4EA#DIN]VEWES*T[54"OX)L
M>$D0CRW6U+R@Q.X?QSJ0F>X0W:7P^T^/RD\CLG^:%G!_.95R!"O[-&W.(3)7
M6JJVVMUV:U2B)=)54T[5&KH<;'WXXBM;#"6KHH^9WV,9HY?IT<)D_KI<\;=K
MAG \.M,3+Z+MFQ($DWMN:@%W:4\TJ$RX5C*_0(Q=CG"R+BZY1<*21"&*N:.*
M@CV&1>J8SB?\OCY=\%S1-<[[\]01S8-AEQS6'13(U877,2))->2(_0K;6K&P
M*J*Q)ED?5'V[5+?NCR?;7SGYGQ1J.MH'[,+74V5>U*ND6O!'H1O!M576Q"3W
MIT<)ZEPJX^5>IIQ$:;;5GBXZ>W);DTD5I*7MCM'RI: 2DL%\0]:IYG!F+!(G
M<2-A([G),+.%3&Y,^9W?UC6_C>5=XRZ>5,F6DSX<,ME549';M79296:DGN=E
M)9G+5R*YL2.YN-B)@.=\UW.:L:DN5<[LV-RM@9P-8FC:I_6?3:<NO2C:T:A7
M(Z[[G;VQ^==1UPE3+2[AXG7=3KVGX]A"/G1;T\L2RTS992M%0374F7V9]_B*
M<%1_@S1A"Y)C/:<_J!_+QBR5E?Y>KW-#[ZS9?38G<38D]\K&]$;"B101SU5$
MB9S+%N&*[[R3N5'+]UN\-T#<,L<HRWRRQI*Z=[IE5R)S:-]5J.K]U-E-M*Z]
MM=/ DYO,[EG;>G_T_-<R$P\;2O(V5U_KW4U;\YJ%DL*[+0I3!"Y7-_C&5B2#
M:L$CW;[)C]Y!P^,V14SW5^T>?>XO<U@WS(_,EBEM91OAW80XE>8C/S:;%+%;
MIZVUJS4K'3J^.*B4>R))9&I6,U)E;+EMG/.<[(D5N!MFDF=31^RVUV&)Y%?5
MK?*C=I4U&HW1 XD%EZI.\^=X8=7S<6X+%8SZ_L5O65FYF(@F4H_B;-=O*I/Q
M76+5=+$@\1RZ/WE21K4F45,)O%L&W1\_F^=;+&+?Y<\@;&'9(P2U@2\AMD2*
M*25T;)(+79CHWH]K"L;N;2C5GD=MM5T#%3)-[&9.;N69.PFD.%VS&\XUGJM<
MY416QT31L,;LK35M*M4JU#[7Q#EJV!&<8M55.O0LLM0K3M([_8MD9,5EXV,4
MK41D]/K\R])WD6"5AE9=9TA@^,957B2X*?'9DA_A_EG8/EN[WLXQC.)SPMS%
M9X0C+*!ST1\B3R?[S-$Q=+UACC;&^BKLLN%56K6K:6Y2WLI,?N+F=[4O([>D
M3572NT[UW-3AV4:B+Y$?JX4SCT5]16R&Z?<)7-U5?+J%N.Q;9<ZC4;M$).T&
M])<N:^O"*JP4PW5(BU>6N%>2[3Q$L=[+A-R3_#(?.O\ Y[\Z8-??,G<8ID.[
MV+^QPNWM;FYM9%:JW36S)*B31*BJYMO+%;24=HV'1.^ZYI:=ZF)6TN<WSX5)
M26*!C'OC=2LB([:]9JZT8YK'47@5JZE0C2^)!E:RML3BQ"-&C$ERCZ7LZ5GG
MR:+<LDYK,S.5%I4FCMP4N'2K%E*P4V=N0YLID4<+9)C&3J=O57\KFSQ9F6<W
MW\SY%P.6_L(X6*J[#9XHKEUPYJ?=1[HY;5'JB55&1HZJ-;3.]QL=PEEB,KE7
MHKI8D:FFB/:UZO5."JHYE>'0E=2$[G 74;:J<"N,^M;U!1\N0^I:G/3=?L#%
MO+LTWUG5Q?RL7["217;G<0\A+DQ@IBFPBNACN9_(+D>>7S&YTEQCYB\UYJR]
M<2PN3&;B&*:%[HW*R!.A[;'L5'(V5D:Z45%<QZ[7WE0U#G'$G7&<;^_LWN:O
M27M:YJJBT9^SJBIIHY$^M%TZR"'XC^3K)]B<5X%DQCT;;&4G9<G-OD4FY))Q
M69B<J3*IL72A$BN#1\?)P,R=L0QS)D4<+Y(4N3'R;T._E=6F+-RSF_$9Y)78
M++?V,<3%558D\<5PZX>U%6FV^.:V2141%5&1[2JB-IM_<;'<)98C,]7+;.EB
M1J::;;6O5ZIP55',KPZ$KP$I736X%4S7FA-![0W81YM_<1M;P<Q33['P:>A]
M#UFVMDK0SH>L*Q*'>1-3>1Y)/&)&113\X.GAEBX6(V[B!>1?FH^8K'<S;Q<Q
MY2R$K,$R0F*2QW*67[&7%Y[=RP.N[^>-&R7#7K'^PA<O,QQHQ58Z7:D77V>\
MX75[C%YA^%4ML,Y]S7\UZKKA[%V%DE>E%>BT]5J^JB4T*ZJFA7Q'%6UZUJ7'
M"X8B(AIM&6M5TA2S3=L@WFIFEQ<)#N'[21<I$(M)LX67>,?)_&R?R3+I3"?=
MPLIWNBOY7^+YEFQK-&"+/,_*,-G:R\TKE=%%=22RM8YC5JD;I8VR[>S3G.;:
MKJ[#:9AN/N+UUS?6NTY</;&QVRJU:UZN<B*B<"N1'5IKHE=2$G/1TAYJ$Z<7
M&]O.J+F<O(V_3#-)QDYC-X6:VI>)2"3(<YC&,@K$.D5D\?)@A%<%QCL+C.>3
MOG?OK"_^:'-,N'HU(F2V<3E3]:6+#[2.551.%)&N:OE5M5TJ8#O.EBESQ?.A
MILHZ-J^=S88T=_I(J?417]:+FYL2^[5ANG?QV?2!'L](5FO;8<0#O+>1N5HO
M?D2-;U(@];K%\.!RTF&RLP3O8P[7<D:J]U)!PFMU]\B>X/+&7<GS_,SO-CB6
MWMXIYL.29NTRVM[3:6?$5:Y-,VU$]MLM/V;6.F95\D3H]A[K,J65GASL[8VC
M=AC7.AVDJC&1UVIE1?UJM5&>1$5R:5:J3A\(>'&N^%&CX#5U.9L'EG<-FDEL
MV^)M")2M]N64CF>2+IP8A7.(6,4<*-XIH;/=9L\8Q^4LHNJKP#O]WX9FW\Y_
MN<W8V^2/"6O<RPM%<JQVEM5-EC4KL\[(C4?<2)IDEKJ8V-C-2YLS/>YKQ9^(
M72JENBJD4==$;.!$35M+1%>OZSO,B(E7SK@SB6R>H]3J?J7&9+85<UUJ;6[A
M&O9+B57VE)W"U6*!8I+M<$44G"1MRAT29[QE$S8(GVXR3!2^M7R!8>_*WRNW
MV-YS_99:NL4Q&^19O\-+".VMX9GJCJHD2OMKERZ$:Y%<ZB[55W_NFB6QR-+<
MXEZMD^>:5-K5S2,8URZ?U:L>OD72O"7.F!'B;%DG(K).) C1L1\X;IY207>%
M1(5TLBEG.<I)*KX,8I?_ #<9[!X6W+H'7$CK9KFVRO<K$5:JC:KLHJ\*HE$5
M>%3EQZM5ZJQ%1E5HB^3@/UBB2@
M                                      !73XO?\0+UD_Y@^GC_ $7V
M(5H>$F;K)S!7)P
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ML@X.FZR@TK,?M)IUDR+4L1B<B
M                                           '%3^#/^T-^YR(IK!R
M$
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MRF32<&K]=CHYE!Q&5BD7-%1;=18N%SJ]H$H(  "M[\6'_4F\A_YQ./']-5-
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MM,E4,HDI@H$Z/Q=?]31L#^??0_\ K0Z &5?A5_ZCKB3_ -8N2'_B7VT +$
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MU1K2ON[/=[O9W>6D/!0[3)$_$4\,BSM\_?.UDFK)DU27>R#U=)LV25<*I)'
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MO_OL_P#M(X L_=%3JM^V#XL7[DO]0OW=_F/R M.B_F5]:/UM^=/FSKK55_\
MG3\X_JZUEY%Y;]9ODGD/D"WA^1>+Y0;QO#2 E^
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M>M5^[&V..D:8KFO.6+YNNDFQ!49;1_X<3*[#//I55<Y>%R_0B-30;O#01B8
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M]UNUDO,+5R_=F:W:N[9M>"2-G28VI1&NCN%TNE,:W,YHYJ:3*UV[]G)62"O
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MGQ>_X@7K)_S!]/'^B^Q"M#PDS=9.8*Y.
M
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MRF(;$*K\O;W>WYXOO*O!0D;K/2;'T$X
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MZBA#;$E]8M-72;&SJ.4T8]\C-G8NW1\-TEC+Y\,2[3:[/"*IJ)'1,
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MMU6C7#6$;JEZ^T-9F=KJ"4W!S^G;-;G+22D61"214)UL=9'.<(&;F[#X FX
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MB:IIVE61J[9S=8;I,S.)9T1-J=0JA5E,E5(!-P
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MJ5J?ZL=.1/F5.CMH%2KE^?<)KV-V7(^:SO5<]KN97ROWOW[Q.S'8!<*
M                %=/B]_Q O63_ )@^GC_1?8A6AX29NLG,%<G
M
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MI%;1T>V339QS0F"$*94ZZZ]9K4:E$)D2AOR(@
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MNX?VMCUGAJI5DUS&UW]U7)M>AM5*SWPY^K/.^Z-_;D<LB*(4;7<!0HUVM_\
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MJ*B/G>]R(J-:FA=36IP(5+W$<0Q*1)<1GFN)4U+(]SUX.%RJO GH0[^,</C
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M0YRH9M&!%J
M
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M\YC+1-DK4VR<QTFR4SXC-^U61-\I,Y &>0
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M%7-.E%JG_JW"/)3N_P BEV_-+/?7O_(V_P#Z(X^Q=Z:/X;/_ *,6_?M3$?\
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MHC6HB(B&L;N\N[^X==WLCY;IZU<YZJYRKYU7[/(FA-!VT68^8
M              H _%U]4N!VBXIW20XWJ+;"N1-A5*V\C7-03S85R7%H<Z6L
M./L(PC$'[N9N*TY*H2TNW;XPNT=HQK(GB.%'J" %H3H7]/\ F^FSTV](<>[T
MFV2V_+^>=N[N0:*M'#:-V?LA9O(R%9([98,W?J4:NM8R!5<D5<).EHLZJ2F4
M3IX*!1X^(@D4K?\ $J:IK,CWG#"$L'!6GJHF\3LPQE9:K6)R@3Q3JI]U3-K4
M-^04I.T^>TN3=XQ@/4! $-OQ!T$TL71BZ@<>\P7*+?29)TG>(8^/*ZM=JE9F
M&<8*JEG!L/HA/.,]N<%SV9R4V,9+D"#+X(Z8>K\,N9-?464-&QG)VOS#1OD^
M,HI/9W55=92"Q"=S&2J+H5UL4V>]GO83+\F.SY0+KX  #S1/B4^?4QU:.=FA
M>F'P<CE-NPFGMFO:<A*59PUD(O;/)6XG:UF5Q"R*6%&:5#U##MG+-:;.NDP\
M1>6=*F\@:H.U +_W 3BA"\&N&/&[B9!R*,REH[5E>J$O/-D,-FMCN&4U)>^6
M9HV\!N=LTLEVE)!\DF<N52)N,%4,<^#',!MZ /G3$O%5^)E)Z=D641"0D<]E
MYB6DG*3..BXJ-;*O9"1?NUS$0:LF31$ZJJAS8(0A<FSG&, #S-:$UL7Q.OQ
M[NY3+*3D.#''QVWDCQT@B[8Q[7BQJ>R*XJ=7>-5._AI:.25Z?Y7DFOC$>MV<
MP_,B<R<63!0/339LVD>T:L&#5LQ8,6R#-DR9H)-FC-HV2*BV:M6R)2(MVS=$
MA2$(0N"D+C&,8QC  P9O+E7Q>XP(UIQR5Y(Z$X\H71261IR^\MPZ\U*C;%H
ML<>=2K2E^L5?).J0I)AIEV5KE7+;#I'*G=\0G> U[]K%TLO>6< /7(XZ_:,
M*.G 3E=Q;IOQ6',KD1;^2>@JKQ_M#_DR>L[TLFX]=P>G;$2>:5PL$:"V;)V-
MK2I<LT9 ^&F6[Y3#G)#>'WNS( O%^UBZ67O+. 'KD<=?M& &U&F]\Z-Y%U%3
M8''S<VJ-[4-*7>U]6[:;V)4-GU%.?C46CF1A%+)29B<AB2[!O((*+-LK862(
MNF8Q<8.7.0,K@                 *Z?%[_ (@7K)_S!]/'^B^Q"M#PDS=9
M.8*Y.
M                                              !PS_"D_P FK^Z2
M$> ',0                             5+NN=TN^:O5,ZB7!"FPNI7&.
MFFX]H;<.Y5MG:PBL1J^PKTUD=RMH:@+7J.VD\D,:_H,&Q9N6L8H51^Z_)R1)
M%1;-)[5<Y/ZI*J*J^8M?PT/%5V'BJ_!1[6)A(*-8P\/%L42MV4;%1C5)E'Q[
M- F,$0:LVB!$TR8^0I"XQC]@528^D
M
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M)
M                                         #&>W-U:;T!2W>R-\;:U
MEI/7;!['QKZ^[<OE6UO2V4C+.,-(M@[M-RE8:#;/9)T;"3=(ZY3K*9[I,9S\
M@ :CW5IO?]+:;(T/MK66[-=OWLA&L;[J.^5;9%+>R,2XRTE&#2TTV5F8-R]C
M71<I.$B+F.BICNGQC/R #)@
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M3(910Q2)D*8YSG-@I"$+C)C&,8V<%*4I<=N<Y^3& !1%ZZW7^OW(:^K=*/I
M.)[:FR=HS2FK=I;PU"HM+2MDD9 QFDIJ30$S#N,)KME&Z:Z=BMJ2A62#$JY&
M:^$2K/DP)<N@/T"Z%TK-?$W1N=.!V#SGV/7?(;=:61BR=:TI6)/"#EUJ[6;I
M0A2NGJYDD\3TZ4I3R"J?D[;N,B9,Z LE     KI?%1:1UGM7HS\D+K=XB*5M
MFA975&R]56AXW2S(UBUR&VZ+0)1".>9)XZ:=LJ=P?1:J.#835.Y2.;&3(IY*
M!I%\%E<K7/=-3?%6F7#UW6J+S$M[*FJ.<*F;1S>>U/J.?G(*/5,7")6R$P[.
M_.D7.3$6DCG-V>(7M N%
M
M
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ME-L)TEX4;=.6:M<BLF[<'<?,;4NOG3YR3&3YP9MX]RPD4V"X[5$E,=N>[V%
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M"]9/^8/IX_T7V(5H>$F;K)S!7)P
M
M        .&?X4G^35_=)"/ #F(
M
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MF[;;)@R::\_;;(_R9R^>*8+WU#8(F1)!-)).NB(U*)J)]1IQUPZ3([ Z1W4
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M/@G=^4 ;-@
M              K-_%O?U+^V/YYM!?Z_-0 ^$A_J7]3_ ,\V_?\ 7YT +,@
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M:OYF:DI%,GJ.3)RC>DUF+BJZ1Z4V2/B0^'!,$(J5,@$MP
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M,<3\K*8<^;XJMK[SI&N&5DDWBC0R9&[!5PME8Z27=\19$IP)?
M
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MB^Q"M#PDS=9.8*Y.
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MGE&I'>8"Z5">9QMBK4IX)LF3PY;E1=IERJV461SA3,Z.1R50F1:FVPB
M
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M9L2^V",J='HE;F[A<+1-.2LXBNUBMQKF8G9N3='_ "6["+C&:JRI_E[I"9R
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M=LAY 2VLXEYO#;3!*,G&L(HSR?%63?L5V1U6RAWZF0(U+C\$]N^RQ$C?G_5
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M-L:5N/>2$@PK[6QWBI3LPW@V+^6=KHM"+8026=*G*3!E#YR!B3V3O2R]VGP
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MM-LDJWJ&Y.2.OH(A6B";9++:KT+<E:K+)0R:>,JG1:)G64SDZF3',8V0-_\
MB7TX."O!5LNGQ,XNZFTM)/(IG!2-NK]?\Y[%F(9BU9-$(R=V=9W$[L.=9&Q'
MIK*IO)-<J[O)W*O?<*JJG W9
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MKMGBR[9@_M&M;O$UC8=;C)-PU5(T=/HM!NZ.D?")SY(;L W7        >?\
M\_?C*-QZ[V9R"X_\5>)&MZ]+:PVCMC4M=WMLS9DYLIG8F=,N;^HP^Q(S5D-3
M-<MX%[)1\2L^18/)R9;(KN4,*Y<)(*IN@/T?!J4.[[VY$=1CJ%;EL$C>=GV!
MM4M8N;Y8%?+9^S6?;-HEML;:D7CG!4DFZBCREUT_<3)@G=7[A"IIIX*8"_P
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MA1155RLQ,LH?)U#8P!.2
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M-I2;CJ' P#.5D6[/'A)KKD45(E^3@V"_( ,W
M      KI\7O^(%ZR?\P?3Q_HOL0K0\),W63F"N3@
M
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M4ZB<DWC&DKG=%D[WA*)F(U/$ZP-'.\FP9,Q'_A&Q^^X%65:,^DF<N@USZ?\
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M47WEIJ)6ZST8A7)P
M
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M:F<8P7'?.;/9VYSG(%HH
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M3&^7.0!0K^'SXV:'Y,=?[EE![_U74-NP&M&7*S;M,KMYC<3E<C-C5OD?1(&
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MB--E[>.ADK@I&L9L/:-OEZN1+#@W;DKBHX8.#9(1-/*BQN[@V/WPX$^8
M  Q)OZ"V?:-$[HK.DI6#@MRV+5&PX'4T[9IJ=KE=A-DS%1EXZCS$[8*M%S=F
MA(B+LSALNY=1[-T^013,=!(ZN"ER!YP//+HO_$.:3TO*[9Y3\G;%U'./.M64
MG>MN::AN;O*S9K)O1JZ@1_9).7IVU&^K)J09(1:2BZAZ]F0?-TVQECHY23-@
MP%HCX9'E'T\N0O#>W5SA#QFK_$>[ZLL%;C^1VHVLV\O-BDK%.Q4@>H[(?;4G
M\JW+8U;M:43)H1JTN<KJ,68.V14B()(JK@640
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MGBF"?DXQ@ ;+@
M
M                                          KI\7O^(%ZR?\P?3Q_H
MOL0K0\),W63F"N3@      =$ONTM9:KCD)?9^QJ)KB)=*'2:R=]M]?I\<Y5(
M=!,Z:#VPR$<V64(HZ2+G!39SC*A<?LFQVY)EO)V;LY73K'*&%8EBMZQ*NCL[
M::Z>U%15159 Q[D14:Y:JFIJ^13[;+#L0Q)ZQ8=!-/*FM(V.>J:^!J*O OH4
M_11MD:[VA#?.+6E]I>Q*_P",HV\^T:TP=MAO*$3G250\YP#Z09>,DHF8IB]_
MO%,7.,X[<9%+,65,T9/O^R\VX;?X7B>RCN9N[>:VEV51%1>;F8Q]%145%I14
M5%);RPOL.EYC$(98)Z5V9&.8ZGEHY$4[F+ ?(                    ?E?
M/F48S=2,D\:Q\>Q;JNWKY\X2:,V;5 F5%W+ITN=-!NW13+DQSG-@I2X[<Y[!
M6M[>XNYV6MI&^6YD<C6,8U7.<Y5HC6M1%5SE70B(BJJZ$)V,?(](XT5SU6B(
MB5557@1$UJ8O=;^T0QEZ[7WNZ]2,YZWRC>#J<(ZV/3F\O:)IVZ:,FL/78U69
M(\FY1R\?H(IMVQ%53JK)DP7)CEQG,8=VF\>XL;K$[?+^-OPVQA=-<RML;IT5
MO$UKGNEGD2)6Q1M:Q[G/D5K4:URJM&JJ7!N"XR^*2=EI<K#$U7/<D3U:QJ(J
MJYR[-&HB(JJJT2B*O 9:&$%L,?XVSJO-]-JK&R]?YV@5IYP-K?%RKF;Z5AY/
MAWY::GXDOG#AIY*;"GB^3]SP\][M[/E&3KDK.29:3.:X3B?@]7['3NBS]#V]
MK9V.E<WS&UM>KL[==K12I]W9N(]"[2Z//V=6G.[#N;K6E-NFS6NBE=9D 8P?
M"                !TZ<V)K^L/#1UEO5.KT@1$CD[&<L\)$O"-U,&RFN9L_
M?-URHJ8+GL-DO=SV9[,B_8=E;,V+P)=83AU_=6RN5J/AMY9&JY-:;3&.2J<*
M5J?7#8WMPSG+>&61E:5:QSDKY*HBBC;$U_M""Q:-:7JG;#K)G;B/+8J-9X2V
MP1G[3P_*V6)> ?2$?EVU\4OB)^)WR=[';C';@,Q96S-D_$>Q\VX=?X7BZ,:_
MF+NWEMIMAU=E_-3,8_9=1=EVS1:+1= O+&]PZ;H^(0RP7%$79D8YCJ+J79<B
M+1>!:'<183Y                                        #AG^%)_DU
M?W20CP YB      -&>;/4IX3].F/UW)\R=W-].--L/+*PU]@U"VC?W=C<4Y"
M$<6;P8_5U(NT@R;PZ=D8>*LZ201[SI,I39-GL$%<UNL*J)K(_P#^TW]#[\;?
M_=MY=?8&)><9Y2&TA+#Q:Y5Z'YIZ5K/(CC3=G&QM.7)Y86%8N:U.O=&3F7%4
MGY&KS_DD)L6LU&R9;QU@B733*QF945%4#X3,;!<Y$R*BI5-1%%J;"B(  \UC
MI[\C>/&\_B:N0_-CD%NO2VGM14&\\EK]0[CO/:M-UW6)UO$-5./VGXV'G+Y8
M8F)E;1FH3[:5;,4%EC()1ZJR!<)M<&)\[519%5=1(GWJEU7=/6\Z3>BZB^N%
MFY[<:[@W:L7[QO Z6V?6-ZVZ468X;%+',:SJ.0N,FD^?KO$TV_E1&R!^TYS*
M%11742K*]J<*$U4*8]3BMM_%"]9: W:VUK8*1P1XX*4>(L#FS($,E#:2I=F>
MVI"C34FR(Z@'&X=\STB_/F/;+.<QD>Y4-XCIM%Y66H_XCZ_JH2_>4W.^+;LM
MHY%\P>F;TZJ&\3+/WB0-9<L$"9?.%[1OW94#I77#QZPPHAG*<0K49C*.,*I^
M*5VKWLEP4IL32Z51I%VNA.=PI^&^Z8G$FLL3W?2E?Y?[<<IG7N&U^3\'&;(;
M3TJ[1<E?GB=53Q9365<B\.'RQVQ3,'LH3M3RXD':R*:Q9TC:GG4BC40JI_%@
M<'>,'%7D3PUG>(>G*=I2W[QJVR$K?0--0;*G5IU,4>QZ_94"P5ZAUE!C#5R<
MEW%L?-3GCF[8CL[)(W<RL0YSTI6HBI0E<FG0>CE1VUA94JGL[<Z\NM;2K5]M
M9WO[U_GEA0B6B4TZ_>%%4?\ .)(BI_R#F+\OR9SCY1]!.=H      $6O5[Y8
M\PN'7$]KLW@OQNFN4G("9VG4*5$ZZB],;=WC'Q]9DHZQS5GM=CJVEYB MD;$
MQK* *V2?G=I-$W[QLD?!S+$*)7JJ)5NE2"JJ:BD=R!ZRG4@Y?[%0X;=3;<]@
MZ/>F]B,VL1L0FON'&VZ_,3-:ERE924=<F6P-@.-VQE6FXY[W7/D#PT8Z06.5
MXB9O^0>BKW*M':$)555T*7INF!P.XA<!>+E2H'#OR6ST:_L878\SNI:9C[38
M=ZOYN$9*16P)2TQ9$XE]$O84Z68IK&D0B6C53.6Z6#K+JK5VM1J40F1$1-!(
MJ(D0
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M=O:OYSI$#&ON]V8[OE7<^7N=[(%A,
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MUY.W0K9)5/Q<85=.4\F(9,Q3 7T@
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MNG2<G5J-]=$E0W;0O?1(7;^T,434^/*R8.W6;--*U"4;]N,E.X4[JA?R<'P
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M.?WZ1<MB9) 5"-<K+>:8%J<S2.24SDYW+M1P\< 2=@
M
M
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M1J.JY$39:C7.]715554JJ)ZN@F,'"1JP                    U2Y3\+]
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MI8QLM7T\SIHI7K315RFD-XF(=HYROI47U(Y>:3S<TB1KZ7-<OTJ;_#F8PD
M                                      X9_A2?Y-7]TD(\ .8@
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ME1-P>/QGND+&';X2QA'"8C']Q"+=1/D)R(
M
M                    '%3^#/\ M#?N<B*:P<A
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M"W=FAMB<P=3UB[.T2*';(5Z+U_M^\,&[S*?R)%=6ZIQAB&/^]]]'!?\ #,0
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MTJPC)S6A=XLXIN^LFJKNNU*4F5"]J#J;H-C5;((ST+XZ1'[9,BB9T'C=HZ0
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M%I"<L4_*.5GLC(.E%73YZX576.90YLY SF
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MW2=4C(: <^-@N%<^!?;C:T/#SG)2>%WBY[3FQ@#1SKV]='J5Z.ZLF>#W3TY
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MOX NT@
M
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M64[QSF,<QLYKHE$HA.=^
M
M        <5/X,_[0W[G(BFL'(0
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M*FHU=F< 6?@
M
M
M                                                          '6
M;K:6U&IMMNKV)LT^SI]9GK2[@J57):XW*:;5^*=RR\34JC -GL[:K-))-,HL
M(UDBJ[?.CIHHD,H<I<@4S^C/PFY8\YNJ[R<ZSO4@T'M[1+NF69U5N)>D-\4.
MYT">KKAW#8B*U)Q%3V!#Q$@>J:AU:X29-G[=JFRE;5+.WZ1BO&;C  NK
M
M
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MRQVFBN>[9<U6Z48J?=HE4I306=J1TL> &OY]&R0/&JHOY%!NY;$;W>;O&S(
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MZL\:N:CV_P!6KDK1/U7*VM%4NU#\^AR0
M          '#/\*3_)J_NDA'@!S$
M
M                                                      <5/X,_
M[0W[G(BFL'(0
M                           !EU/^#)^T+^YP/C764CF(         (B>
MJ1T5N(G5L6TU*\B)W<VOKAHMS8C4J_Z$L],J%R5B[,:*<OJ[.2%SUYL5C(0K
M24AD'K/!&R+EDZ\0R*Q"KKD4 DZU?2GVM]<TB@26P+YM5]3*S#UIQLC:#RO2
M.QKJ:'9),BV*[R54K5/KTE9I(B.%'CEK&,R.%LF4RG@YC9R!WP
M                                  'X)5FXD(R18-)5_!.WS!XS;3<4
MG&+2<.X<MU$496.2FXZ8AE7\>H?"R)7;1TU,H3&%454^\0P$&W'_ .'OX6Z9
MYJR/4"V+LCD[S$Y-.Y5>SQMMY<WK6M]B:Q=CJ)^07>NUNAZ?U?&-9ZM-$L-X
M1)8KB-@4BI&CFK55LU50 G8
M
M
M
M
M
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M4A3$0IT4VKD#ARGC/BF1>KW)\8F,_D9.TSG/:8I>ST8_EBY.;<YGS-GV9O\
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MM6.$+)B<VBNREHVL#O)_QC[9*Z*5JFE$0LV[+#%Q/.-K5*Q6]9G>;FT]5?\
MQBL-,>@'J8D!HG;NY'C-(DAL;832I1;DZ>#.3US7\21?*J"V>W*35W/VIVD<
MA>[WU&6,FQGNI]F^_P"9AG5V)[Q\#R' ]RVN%86ZYD:B^JD][(J45.%S8;>-
MR*M:)*J)2KJY5OJQ-9\9M<*:J[$$"O5.#:D=_2C6-7_.T<)KW\0;MB25M.@=
M&-G2B,0PK\[MB:9%/^]2$E+R+BGUATNG_<4B&L)+D2-CL[</E,9[>S'9L_\
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M #F(
M
M                              XJ?P9_VAOW.1%-8.0@
M
M   #+J?\&3]H7]S@?&NLI',0
M
M
M
M
M
M
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M,8^BZ8X6HE$=_;DHE4U[-57[S56TD/'4YU
M            #AG^%)_DU?W20CP YB
M
M                                                        .*G\
M&?\ :&_<Y$4U@Y"
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M2S5W9B'P\WL#L^_]Q-R'<0]J/TR_>*\$_6YX_P#V@AX2S5W9B'P\WL#L^_\
M<3<AW$/:C],OWBO!/UN>/_V@AX2S5W9B'P\WL#L^_P#<3<AW$/:C],OWBO!/
MUN>/_P!H(>$LU=V8A\/-[ [/O_<3<AW$/:C],OWBO!/UN>/_ -H(>$LU=V8A
M\/-[ [/O_<3<AW$/:C],OWBO!/UN>/\ ]H(>$LU=V8A\/-[ [/O_ '$W(=Q#
MVH_3+]XKP3];GC_]H(>$LU=V8A\/-[ [/O\ W$W(=Q#VH_3+]XKP3];GC_\
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M2S5W9B'P\WL#L^_]Q-R'<0]J/TR_>*\$_6YX_P#V@AX2S5W9B'P\WL#L^_\
M<3<AW$/:C],OWBO!/UN>/_V@AX2S5W9B'P\WL#L^_P#<3<AW$/:C],OWBO!/
MUN>/_P!H(>$LU=V8A\/-[ [/O_<3<AW$/:C],OWBO!/UN>/_ -H(>$LU=V8A
M\/-[ [/O_<3<AW$/:C],OWBO!/UN>/\ ]H(>$LU=V8A\/-[ [/O_ '$W(=Q#
MVH_3+]XKP3];GC_]H(>$LU=V8A\/-[ [/O\ W$W(=Q#VH_3+]XKP3];GC_\
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M2S5W9B'P\WL#L^_]Q-R'<0]J/TR_>*\$_6YX_P#V@AX2S5W9B'P\WL#L^_\
M<3<AW$/:C],OWBO!/UN>/_V@AX2S5W9B'P\WL#L^_P#<3<AW$/:C],OWBO!/
MUN>/_P!H(>$LU=V8A\/-[ [/O_<3<AW$/:C],OWBO!/UN>/_ -H(>$LU=V8A
M\/-[ [/O_<3<AW$/:C],OWBO!/UN>/\ ]H(>$LU=V8A\/-[ [/O_ '$W(=Q#
MVH_3+]XKP3];GC_]H(>$LU=V8A\/-[ [/O\ W$W(=Q#VH_3+]XKP3];GC_\
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M2S5W9B'P\WL#L^_]Q-R'<0]J/TR_>*\$_6YX_P#V@AX2S5W9B'P\WL#L^_\
M<3<AW$/:C],OWBO!/UN>/_V@AX2S5W9B'P\WL#L^_P#<3<AW$/:C],OWBO!/
MUN>/_P!H(>$LU=V8A\/-[ [/O_<3<AW$/:C],OWBO!/UN>/_ -H(>$LU=V8A
M\/-[ [/O_<3<AW$/:C],OWBO!/UN>/\ ]H(>$LU=V8A\/-[ [/O_ '$W(=Q#
MVH_3+]XKP3];GC_]H(>$LU=V8A\/-[ [/O\ W$W(=Q#VH_3+]XKP3];GC_\
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M2S5W9B'P\WL#L^_]Q-R'<0]J/TR_>*\$_6YX_P#V@AX2S5W9B'P\WL#L^_\
M<3<AW$/:C],OWBO!/UN>/_V@AX2S5W9B'P\WL#L^_P#<3<AW$/:C],OWBO!/
MUN>/_P!H(>$LU=V8A\/-[ [/O_<3<AW$/:C],OWBO!/UN>/_ -H(>$LU=V8A
M\/-[ [/O_<3<AW$/:C],OWBO!/UN>/\ ]H(>$LU=V8A\/-[ [/O_ '$W(=Q#
MVH_3+]XKP3];GC_]H(>$LU=V8A\/-[ [/O\ W$W(=Q#VH_3+]XKP3];GC_\
M:"'A+-7=F(?#S>P.S[_W$W(=Q#VH_3+]XKP3];GC_P#:"'A+-7=F(?#S>P.S
M[_W$W(=Q#VH_3+]XKP3];GC_ /:"'A+-7=F(?#S>P.S[_P!Q-R'<0]J/TR_>
M*\$_6YX__:"'A+-7=F(?#S>P.S[_ -Q-R'<0]J/TR_>*\$_6YX__ &@AX2S5
MW9B'P\WL#L^_]Q-R'<0]J/TR_>*\$_6YX_\ V@AX2S5W9B'P\WL#L^_]Q-R'
M<0]J/TR_>*\$_6YX_P#V@AX2S5W9B'P\WL#L^_\ <3<AW$/:C],OWBO!/UN>
M/_V@AX2S5W9B'P\WL#L^_P#<3<AW$/:C],OWBO!/UN>/_P!H(>$LU=V8A\/-
M[ [/O_<3<AW$/:C],OWBO!/UN>/_ -H(>$LU=V8A\/-[ [/O_<3<AW$/:C],
MOWBO!/UN>/\ ]H(>$LU=V8A\/-[ [/O_ '$W(=Q#VH_3+]XKP3];GC_]H(>$
MLU=V8A\/-[ [/O\ W$W(=Q#VH_3+]XKP3];GC_\ :"'A+-7=F(?#S>P.S[_W
M$W(=Q#VH_3+]XKP3];GC_P#:"'A+-7=F(?#S>P.S[_W$W(=Q#VH_3+]XKP3]
M;GC_ /:"'A+-7=F(?#S>P.S[_P!Q-R'<0]J/TR_>*\$_6YX__:"'A+-7=F(?
M#S>P.S[_ -Q-R'<0]J/TR_>*\$_6YX__ &@AX2S5W9B'P\WL#L^_]Q-R'<0]
MJ/TR_>*\$_6YX_\ V@AX2S5W9B'P\WL#L^_]Q-R'<0]J/TR_>*\$_6YX_P#V
M@AX2S5W9B'P\WL#L^_\ <3<AW$/:C],OWBO!/UN>/_V@AX2S5W9B'P\WL#L^
M_P#<3<AW$/:C],OWBO!/UN>/_P!H(>$LU=V8A\/-[ [/O_<3<AW$/:C],OWB
MO!/UN>/_ -H(>$LU=V8A\/-[ [/O_<3<AW$/:C],OWBO!/UN>/\ ]H(>$LU=
MV8A\/-[ [/O_ '$W(=Q#VH_3+]XKP3];GC_]H(>$LU=V8A\/-[ [/O\ W$W(
M=Q#VH_3+]XKP3];GC_\ :"'A+-7=F(?#S>P.S[_W$W(=Q#VH_3+]XKP3];GC
M_P#:"'A+-7=F(?#S>P.S[_W$W(=Q#VH_3+]XKP3];GC_ /:"'A+-7=F(?#S>
MP.S[_P!Q-R'<0]J/TR_>*\$_6YX__:"'A+-7=F(?#S>P.S[_ -Q-R'<0]J/T
MR_>*\$_6YX__ &@AX2S5W9B'P\WL#L^_]Q-R'<0]J/TR_>*\$_6YX_\ V@AX
M2S5W9B'P\WL#L^_]Q-R'<0]J/TR_>*\$_6YX_P#V@AX2S5W9B'P\WL#L^_\
M<3<AW$/:C],OWBO!/UN>/_V@AX2S5W9B'P\WL#L^_P#<3<AW$/:C],OWBO!/
MUN>/_P!H(>$LU=V8A\/-[ [/O_<3<AW$/:C],OWBO!/UN>/_ -H(>$LU=V8A
M\/-[ [/O_<3<AW$/:C],OWBO!/UN>/\ ]H(>$LU=V8A\/-[ [/O_ '$W(=Q#
MVH_3+]XKP3];GC_]H(>$LU=V8A\/-[ [/O\ W$W(=Q#VH_3+]XKP3];GC_\
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M2S5W9B'P\WL#L^_]Q-R'<0]J/TR_>*\$_6YX_P#V@AX2S5W9B'P\WL#L^_\
M<3<AW$/:C],OWBO!/UN>/_V@AX2S5W9B'P\WL#L^_P#<3<AW$/:C],OWBO!/
MUN>/_P!H(>$LU=V8A\/-[ [/O_<3<AW$/:C],OWBO!/UN>/_ -H(>$LU=V8A
M\/-[ [/O_<3<AW$/:C],OWBO!/UN>/\ ]H(>$LU=V8A\/-[ [/O_ '$W(=Q#
MVH_3+]XKP3];GC_]H(>$LU=V8A\/-[ [/O\ W$W(=Q#VH_3+]XKP3];GC_\
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MV%HCL3M;BW:_[O.QOCVJ:Z;;4K2J5IJJA(^WN(-,\;V(NK::J5^BJ%@\?*2
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MO]UU[;DGJ"W61I%-[HUS2&UZ@I]U"QC>&82[1EBTTUW#R9XMDW2<9\H<(K>
M4^$R*&4.?HKY?/GKS)N1R-'N_P 4P.'',$M'R+:NZ6ZSFA;+(Z5\3G]'NFRQ
MI(][F)L,<S;5NTYJ-:W,,H[TKS+&%MPF>U;=6L:JL:\XL;FHY5<K578>CDJJ
MJFA%2M*JE$3;KC-PHB^/;R+L5AWKR"WW<X>'?P4/*;>V;8IZLUB+D,-$%VE.
MHJC]6$@TS,6"*.3JF>+EQ@^$U$TS83+I#>W\P%YO/@FPO"\N98RU@$\[)I8\
M,L((;BXD9M*CKJ[1B2S*CWO=1J1,7U=ICG(KUQC,&;9,<:Z""SL;*T<]'.2"
M)K7O5*Z7R4VG:55=&RFJJ*NDQ>OTL>/C[E67E]*V_<,OLHFR&VT4H*0GJ.>B
MHV".72<0S5.+0UVWG<14&HV0RU+F3RX+Y.GDZQS8-DV81_./O.M]S*[C;*QP
M*#*:X4[#UF9#=I>+"]%;*Y9%O70\Y,CG\XO,;"[;D:QJ41+BF\;&V9;\+QQ6
MK;#F%AVD;)SFRNARUYU6U=5:^I32M$0DJ')A@!&GR+Z5_'KE!O3&_=F6W<&+
M+A*JM<UF"G:,TI1H^IIH)M8U2/DM=RTVJRDC)',[P:0R<YEU,)F3+W"DZTW6
M?.3O/W/[NORTRC8X%V36X=TB:&[==[=RJJZ1'LOHXD?'5$CI"B(C&[2/7:5V
M?X%O&QS+V#]BX?%:]']==MS9%DJ^M5JDK6U3]7U>!*UTUDL')9@!J)RYX1:,
MYJ5FOU_<+&P-7U2=O7=5N%-DVD/;(#$H5J279LW4E&3<2XCY8K!#*Z+IFX)W
MD"')@ARX,-X[D/F$WB[@,7NL3R+);/M[UC&W%K=1NEMIN;VEB<YL<D4C7Q[;
M]A\<K%H]S7;35H91EC-V,93N'SX6K%9*B(]CT5S'4KLJJ(K7(K:K14<FM46J
M&$^/'2=X:<<K!#7*"I<YL&\UUZWDH"W[5G269_#2;*1-)L)6.A(N/KU+;R\:
MY*AEJ\Q%^5-LMDSI*$5RJHIL#>A\Z>_G>IAEQ@.)8A;X9EVZC='-;8="L#)8
MWLYM\;Y9'SW3HI&[?.1+<<W)SCFO:YB,:V[8YO*S5CL#[6:5D%G(BHYD+=A'
M(J45%<JND5JI6K=NBU5%14HB;8<C^-^JN56KI74FWH9:4K<@Y:R3%_&KIL;#
M69YAA4K"Q5F44;NRQLPT3753[QDE4EFZRJ"R:J"JB9M+;JMZV<]S.<(<[9'N
M&PXK$QT;V2(KX+B%]-N"XC1S><B<J-=1'-<U[621N9(QCDQK <>Q++F(MQ/"
MWHVX:BHJ+I:]JZVO2J5:NA=:*BHBHJ*B*D36K^BM9=3ST@VIO/3?U,U=./4U
M['1M9-I'7,U/MBH$;*(R=HB-@.8!XZ.W[Z>%EJ^K@J9L%[F<8SWNU<X?/]A.
M=<-BFQ[=MEF_SA;QJD%W?N9?10NJKD6.WELFS-:CJ.V&WK:N2NUIT;+Q'>S;
MXE"UUW@UE+B+$HV254E:U:UT,=&CD2NFB2IIX21RT<$.,EMX]&XR2.OTV^L\
MR:5D*=A(.T;;\^$\'P?83BVJG<2\G>7?BG*Y?O#N#ND5#(+8.W-E(<K8/\Q^
M]W!-YZ;W;7$U=F[F5@H]C5MNB+2EDVV1&Q1VC:(L<,2,2-S4D8K94VS!+?.6
M8+;'/$$<]<0V=C2B;'-^Z1GW4C3@:VE%1')1VDU7U!T5N#^J9_%ADX&];C<H
M&(K'Q^W[+&2\ P7)DO[[F J-;I43-%,7&2Y1E$G[?.#9SX?>P4Q=R9Y^?[YA
MLZ8;V7:7.'8%"Y%1[\,@DBF>B\'/7,]W)%P*CK=T+]%-JBJBY'BF]G-^)0\Q
M&^&U:NM8&*UR_P"<]TCF_2Q6KYR2W86L-?[7HLWK+8E3A[70[%'%BY:LR3?/
MF]=FGE,S;"'DQD'$>Y8JI$4;+MCI+M54R*(G(<A38Y+ROF_,V2\QV^;LK7L]
MEF2UEYR.XC=ZZ.6NU7:JCVO15;(QZ.9(U7->US7*BX!8XA>X;>,Q"QE=%>1N
MJUZ+IKPUK5%1=2HM45%5%144BRIG2HN''JQ34SPSYJ;7X_Q=B?*/)>I6:CU'
M<]77P9!1% F(*:>5B&<N8XJIDVKQZV>/4D,%+E8Q\95-V/CWSFX%O/PNWL-_
M60,%S->6L:-BN;>[N<*N$THJKST3;B5K7T1TD44D43GU5&(VC$V+=[R+7'(&
M19KPFVO9(THU[)'P/Y34>Y$76K6JUJKP(F@[+[+)IM>ZP]^YK<DMG<LY2NJG
M4@ZL[B8O4VL6A5')G"A#4>I/I#"'C9P3"WD3QB5P4F"K%43P5,MI_P#GCSY+
MP"?+7R_Y3PC)-G=(B37#9),2OW4;LHO2[EC*TT[/.Q2JQ556*URJY:'YBNPV
MT?992L+?#(Y$]9Z.6:5=%/\ $>B?5M-=36E%TDI\)!PM9AXVO5N'BZ_ 0S)O
M&P\'"1[2*AXJ/:)E2:L(V-8(MV3%DV2+@J:21"$(7&,8QC XVQ#$<0Q>^EQ3
M%9YKK$KB1SY9I7NDED>Y:N?)(]7/>]RZ7.<JJJZ54US--+<2NGG<Y\SU57.<
MJJY576JJM555X54^H/C*0                                      :
M[[AY<<4N/=@B:UOWDYQZT?8YJ'/.P]?W!NC6^M)N6A#/5&!9B,BKI985^_BC
M/V2R&'"29T<K(G)WN\0V,7.RP;&,2C67#K2YN(FNHJQQ/>B+2M%5K51%HJ+3
M712O%;7$R;4,;WM3A:U5_H0Q1[3?IM>\'X/^MAH;^7P^SPKFCNV_^'E]@J=
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M_6PT-_+X/"N:.[;_ .'E]@= OO<R\AW$/:;]-KW@_!_UL-#?R^#PKFCNV_\
MAY?8'0+[W,O(=Q#VF_3:]X/P?];#0W\O@\*YH[MO_AY?8'0+[W,O(=Q#VF_3
M:]X/P?\ 6PT-_+X/"N:.[;_X>7V!T"^]S+R'<0]IOTVO>#\'_6PT-_+X/"N:
M.[;_ .'E]@= OO<R\AW$/:;]-KW@_!_UL-#?R^#PKFCNV_\ AY?8'0+[W,O(
M=Q#VF_3:]X/P?];#0W\O@\*YH[MO_AY?8'0+[W,O(=Q#VF_3:]X/P?\ 6PT-
M_+X/"N:.[;_X>7V!T"^]S+R'<0]IOTVO>#\'_6PT-_+X/"N:.[;_ .'E]@=
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M_6PT-_+X/"N:.[;_ .'E]@= OO<R\AW$/:;]-KW@_!_UL-#?R^#PKFCNV_\
MAY?8'0+[W,O(=Q#VF_3:]X/P?];#0W\O@\*YH[MO_AY?8'0+[W,O(=Q#VF_3
M:]X/P?\ 6PT-_+X/"N:.[;_X>7V!T"^]S+R'<0]IOTVO>#\'_6PT-_+X/"N:
M.[;_ .'E]@= OO<R\AW$/:;]-KW@_!_UL-#?R^#PKFCNV_\ AY?8'0+[W,O(
M=Q#VF_3:]X/P?];#0W\O@\*YH[MO_AY?8'0+[W,O(=Q#VF_3:]X/P?\ 6PT-
M_+X/"N:.[;_X>7V!T"^]S+R'<0]IOTVO>#\'_6PT-_+X/"N:.[;_ .'E]@=
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M_6PT-_+X/"N:.[;_ .'E]@= OO<R\AW$/:;]-KW@_!_UL-#?R^#PKFCNV_\
MAY?8'0+[W,O(=Q#VF_3:]X/P?];#0W\O@\*YH[MO_AY?8'0+[W,O(=Q#VF_3
M:]X/P?\ 6PT-_+X/"N:.[;_X>7V!T"^]S+R'<0]IOTVO>#\'_6PT-_+X/"N:
M.[;_ .'E]@= OO<R\AW$/:;]-KW@_!_UL-#?R^#PKFCNV_\ AY?8'0+[W,O(
M=Q#VF_3:]X/P?];#0W\O@\*YH[MO_AY?8'0+[W,O(=Q#VF_3:]X/P?\ 6PT-
M_+X/"N:.[;_X>7V!T"^]S+R'<0]IOTVO>#\'_6PT-_+X/"N:.[;_ .'E]@=
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M_6PT-_+X/"N:.[;_ .'E]@= OO<R\AW$/:;]-KW@_!_UL-#?R^#PKFCNV_\
MAY?8'0+[W,O(=Q#VF_3:]X/P?];#0W\O@\*YH[MO_AY?8'0+[W,O(=Q#VF_3
M:]X/P?\ 6PT-_+X/"N:.[;_X>7V!T"^]S+R'<0]IOTVO>#\'_6PT-_+X/"N:
M.[;_ .'E]@= OO<R\AW$/:;]-KW@_!_UL-#?R^#PKFCNV_\ AY?8'0+[W,O(
M=Q#VF_3:]X/P?];#0W\O@\*YH[MO_AY?8'0+[W,O(=Q#VF_3:]X/P?\ 6PT-
M_+X/"N:.[;_X>7V!T"^]S+R'<0]IOTVO>#\'_6PT-_+X/"N:.[;_ .'E]@=
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M,O(=Q'/VF_3:]X/P?];#0W\O@\*YH[MO_AY?8'0+[W,O(=Q#VF_3:]X/P?\
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MW,O(=Q#VF_3:]X/P?];#0W\O@\*YH[MO_AY?8'0+[W,O(=Q#VF_3:]X/P?\
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MW,O(=Q#VF_3:]X/P?];#0W\O@\*YH[MO_AY?8'0+[W,O(=Q#VF_3:]X/P?\
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M\I98VFX# UK7/70LVQJ1$73L;2;2JM'/=I5$1/6F8'!9JD
M
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M,CIM>[XX/^J?H;^0(>*LT=Y7_P 1+[8Z??>^EY;N,>S(Z;7N^.#_ *I^AOY
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M,CIM>[XX/^J?H;^0(>*LT=Y7_P 1+[8Z??>^EY;N,>S(Z;7N^.#_ *I^AOY
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M0
M
M
M
M
M
M
M                                  KI\7O^(%ZR?\P?3Q_HOL0K0\),
MW63F"N3@
M                                                 <,_PI/\FK^Z
M2$> ',0
M
M                                !Q4_@S_M#?N<B*:P<A
M
M      &74_X,G[0O[G ^-=92.8@
M
M
M
M
M
M
M
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M-6B:2574+-FMK%8+?KJ@VVVU7YBVJT4JK6*S4CSJI._,ZP3<$PDYFJ^>UHF
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MF[.=3NJH)$I,<[:5KM9*BK6BEN4528
M      #AG^%)_DU?W20CP YB
M
M                                                  .*G\&?]H;]
MSD136#D(
M                        RZG_  9/VA?W.!\:ZRD<Q
M
M
M
M
M
M
M
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MOG:2>3%P;.<%6B54*M"BSTB.%FTNMCR7YQ=6OE]7RR-9GX7;>M./U/F/+'L
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M
M
M                          XJ?P9_VAOW.1%-8.0@
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MF33VUM!!-;L:L4C41'N=M-1$<_[TFW6GK*[75**E2YH/# Y=
M
M
M
M
M
M
M                    KI\7O^(%ZR?\P?3Q_HOL0K0\),W63F"N3@  !59^
M+=YA2>@^GA6>.U2D%F-QYE;'3I4CAJJ5%X?4FMDXZX[#*T,0IW1S25B=5J*<
M)DP4JS&3<)G-W3>&I3E6C:>4E<N@F+Z2W#")X#]/KC9QR0BTXZW0E"C;=MM;
MP,HO)+<=^13M>QUGRA\8<.?-5@DE(MH97]\3C8]LEV%*F4A9FMV6T)D2B$C8
MF!0U^(&Y-[4ZIG4&T5T/N'DN60A*UL>)<[ZGX[QW,&?:R,8ZD)H]F<L%NQ[2
M..&O5WLG+MR&[339G#<Z9GL<VP6C(JN=L-)%6JT0NB\3^,FKN&O'/47&/3,5
MYIUWIZG1]5AO%(CB0F7:>5'M@MDZHW321<V6Y6-X[E9)8I2%5?/%3%*4N<%Q
M51$1*)J)T2A1;^'!4=\;^OMU#>+KTB;6/<0_*G7:+)N50B'G_3?(^N*PCAMW
ML]T\>6LLI7PL]GY9%DS%-V=N#48]#U0D;K+0WQ"N_D>/'2"YESY'JS2:V/0&
MFAJZBV6\!R_>;MG(W7TXW15[,X*5M29J5=JX^3)T&QRESWLX%61:,4F=J-!/
MA9>GMHS4/3ZU%S&F]25!UR:W\ZV)8B[2FX4TC>*UK=K=9ZEU2LUB1F/*<5:)
MFX:M8DUS11&F9).03\I,OA)+N2Q-1&UX2#4T5)5NMK.4VO=)/J#/[VUCWD(X
MXP[)@V*4F5$[8ERL\7\VM<ND\+E.3$@QV%+1:[3.,=\KM-/),X-C&<3/^ZM?
M(1740Y?!T:GEJ;TW=M;-E/*$D-Q\HK:\KK<^/\V6KE$I%%J7G1OG"ANU1S:$
M95LI^27./(B_+G^Y)$GJ_60;J(]N;BQ.?GQ;'%[1:+,MCI7$QUI^-F4<8PG#
M^3Z6K<]RTMYY,^4ETUT<6F?Q"N2JE*5TLB1IV]AB&S!=,J)Y""Z7%]X5B<H/
M_$NN%^:76-Z9W3P@?*)AI'IT5I:69%EL,(I]R0VU%Q]N.Z20[CA'S-K+7#"3
M=KDSG)6:I>Y^40V!1D]9Z-)':5H6W^ICSJJ?3)X4;.Y82]$1V"CK8U(@*GJQ
MG94:'FY3ENM\#3XNO1]AQ7+2C!HQK&36D%#EC77<9L%<%3SGL%5SME*DZK1"
MII_;<?\ VV5_WS__ &D\4N>\Q+M$]W1/ZT5DZP[7D#.FXE_=RJ&BW&OHE&Q*
M[Q/MGYZV2\IVMXYA63+&G-9DBOFS%UM)=TKE=SDWG%N7">.W)L3L?M\!%%J5
M::HDESP^,!E4[JJC.5G3W*"[H-&3CQ5F$8CPBUI-M:FP:M.\=),I=CZJ:KKD
M_)34=KKJGQDQS%-3^]+]9+K<>CH*Y.   'GC:$69=0_XO/8&PL94G:!QYVK?
MIM$S<F7L<UC^(VN&^G:;+,%%5%T&T6]W'"1DD1<G:199WDZ>"F6*8M!/6E)-
M;CT.17)P /.3Z7*#7F#\5SO3?NN\FE=<ZTVWS(V^>:89,NRD:2R@[=HBIV(K
MG&"^"QL5@OT0Z2P;';DCC"><=N<YQ0;IEKP:21-+B07D=S Y@_$:[MMW!7IM
MN[!H[IN4R8Q <I.94S&RL6?:</C&<2-?CFA%8U^XK=B;=XL13T5D9*PH'3=3
MJD;&*+MV\559%V6_=(U5VA-1:;X)\">-O3JT/!Z XTTI&N5QF9.2M=G?^3O;
MSLRW&:I-G]UV!84V[=6;GGI$<$(7!4VC%N4C9HB@V332+5:U&I1"9$H4JNA(
MG]_;XB[FQSBE3LY6O:S4Y#[*HLBF;RU)O\_+:326J&#-?&"$63;:;EY%,KGL
MQW\-<9P3'B=I*+/6D5Q(FE:DL'Q@F_G.M>FO1=*1BJA'O)'D%48:;3PKE-):
MCZOC9/9$D4Y"GP9=0EWC*X8I#%RGC&#&SG!BD[9Y5HVGE(NU$F70 T&RX\=(
M?A16DHTK&5O^K$-[6-<Q$2NY62WI)/MGQSU^9'/8=9K5;)',DN]V*)M6B29\
M8,3(F8E&(1;J).-\[8@]"Z/W)O&SJ(I5S3FK-@;2G5'!\IHXB*!5):U2&%#X
M_**4S6*-CY/ROE^3Y1,JT2I%2B?\&?JJP7?D/SPY<6-$SEPQHE1U46PKIE*>
M6L&W+P]V9<T6IBI9QDS4^M(Q=T7!B8+EVA^2;M[24(4TJI(TZ'U@U"=0#XGG
MBOQ-8JFL52U'8N,FH+9%8+AW%E@V,HMR+W0H@@D11%=TVI-K<MGACXSV*Q_@
MJF*1'\@_UI$0+I=0]$,5R<   *'_ ,5HU^L_J/=)/1<+A1Y:)MXBU1C8_'C2
MJGUJ[WU_3X'"#;NJ9,H^D:LY3;_DY[ZA#8[,]G8*,NER)PDCM9? %8G
M                                X9_A2?Y-7]TD(\ .8@     "!G^T
MW]#[\;?_ ';>77V!B3G&>4AM(/[3?T/OQM_]VWEU]@8<XSRC:0?VF_H??C;_
M .[;RZ^P,.<9Y1M(9-TQ\09TA>0NV->:.T_RX^=^T=K6R&HU!J_U"<G(#S]:
M; \381$7Y[M&EX6NQ?E;M4I/'>NVS9/M[3J%QVY$4D8JT1=(VD)F1,1
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M\V4:BW3YQ>??JZUKY!X_SU\F\D\C6[ODWB>-GQ.XG!CMM*D$6I+X)B(
M   :];KY<\4.-<A!1/(OD[QYT#*VAF\D:S&;KW3K?5<A8H^/72;/WT$SO5E@
MG,NS8N5R)K*MRJ$2.<I39QG.,""JB:U%4,^M';20:-7[!TW>L7K=%VR>M%DW
M+1VT<IE6;NFKA$QT7#=PB?!R')G)3ESC.,YQD1!^@
M                                                !Q4_@S_M#?N<
MB*:P<A
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M>2SB^XQTCG,9HIZK556MT:-")H,B#&3X@
M
M
M
M
M
M
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M;/"E=0+NR-XF.+Y<P9NEWL<=9--RFBJH0AH;245?(*H4_P#X-34TW>=F\_\
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MZ;N9!LJQAM?[9BZ/=).0QB,66*W18'7.T*5R4F6YR*F(]JZE%4))Q,1
M                                                  .*G\&?]H;]
MSD136#D(
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MF=964UA@EA%%#"R-\JLC8UB>LJ,8M&HB:.;<B?\ VBQF/,$T@
M
M
M
M
M
M
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MKK6[DLQ:[+96RIR(MG"121Y384+DYB"$;%;6NL(E"RF*A$   (#>M7T(-/\
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MI ZK=RQU7#R*[=91-19%>;>22Z"IFZR."F-V6^<-2B$X8G(@
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MG->SLU%&[#8Q@K[O9P;NX+F21*L(.U$?7P<&XK)=.GON[4DXX6>1FE.2DO\
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ME6D0I)RR;O:]4[4%RLO.)I2?PFV;HGRQ67\=5>"Q)P!6^0N#"J3
M                                              '%3^#/^T-^YR(I
MK!R$
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MQ$EQ,E.#9N;F9J^56UJ6+>OB*W^<YXT6L=LR.)/J;MN]#WN3ZC\77!V[]6'
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M?2M%54,8WI8AT_.ETB?X<",B3_-:BN_TU=_]LE/'(1KT
M
M
M
M
M
M
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M?)Q<BV3>,)!B[0,=!TS>M%B*)*$-DAR&P;&<XR*Q.?0
M                                     !Q4_@S_ +0W[G(BFL'(0
M
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M+<SOF5/-3;I1-"<!S1B=X[$<2N,0?]^>=\B_Y[E=_E,CC%SX0
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MWR8Q835H]-VQ0HEJRJ&G63:=SETS?'45<9QV9*3!#@6DP
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MB]^\U74.YM<[*LE+)A^M%9-;(.F62:E*Z7SHW4;=KQ)''CD,G_AESC &P0
M
M
M
M                                       KI\7O^(%ZR?\ ,'T\?Z+[
M$*T/"3-UDY@KDX
M                                                       '#/\
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M&KU*?=E7;K.$%RN96(5/@Y%#D-C/;@V<9[<UT2B(A.FHV/$0
M                                         '%3^#/^T-^YR(IK!R$
M
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M%N<2D>[%Y[:BN<M7<[<JJJGF6-'NHB:&HRB:$1"[@/ XY1
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MA$?ZR'JO_P#O./\ T\6\ >@:
M
M
M
M     *Z?%[_B!>LG_,'T\?Z+[$*T/"3-UDY@KDX
M
M                    '#/\*3_)J_NDA'@!S$       !J3S+X*\5^H+K"!
MTSR\U;];FMJS?8O9T)6_GOL:A>17B&KUHJL;-^>-8V^ESSGR:!NDFAY,LZ49
MG\I[YTC*)I')!6HY*+J"I769%XV\;M+<1-)T;CKQXIGU>Z;ULWF6M*IWSBM=
ML\RH6&R3-NET_G!>)VRVF1\KL-@=N.UV^7,GXWADR5(I"%BB(B434-1G$ 5
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MS6-;JUD41$);A,1
M          .*G\&?]H;]SD136#D(
M                                            RZG_  9/VA?W.!\:
MZRD<Q
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M'M5797@DD70K_P"ZB>JSS;3OUJ),P.&35P
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MKTOSUY3\W/*/$\UM.YXWA]TW<[Y@-W0
M
M
M
M        %=/B]_Q O63_ )@^GC_1?8A6AX29NLG,%<G
M
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M%YB\[^;/'\D\O>>3]_N>,IV=_,R)1*$4T)0V)$0
M
M                                          '%3^#/^T-^YR(IK!R$
M
M                9=3_ (,G[0O[G ^-=92.8@
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MRRNNNPW99HX/5T<%#9X:F+
M   47/C3^9KF%UAQ?Z?%+=N%;!MJQ*<A-GQL?G)WR]-J+J1I6J8)1FEA5P^9
M6R]NIAY@A2ESAW6D.[WLYSC &N.M?@@+;:-=4&S7[J*(Z[O5BI55G;IK]MQ%
M-:V]&MLO!,)"QTY"T'Y/5L]D1K,PX69$?YCF&7A4,+9;(=_PB@=U_L,?_MT3
M_N3?^U< ".GH^2-VZ'_Q%$WP?VI;C2]-V%;7_$.VVA2./5(VY1NS$H"Z<;-F
M)UB2DI-O#.[-8U:T8J?ESH\>QG7B23IR7)O' ]0QRV;O&Z[-X@BZ:.D56SIJ
MY2(NW<MUR&270705*9)9%9(V2G(;&2F+G.,X[ !!'R>^&HZ._*6:E+9.<66F
MH+O,K++R%KX\6VR:C(L=QF976/\ ,&'>N=1%=K24SETHZ^;OEBJC9!,ZQFQ,
MH& IN]<WX>>)Z.&LM><W^'?)[;,K3HO;U6HYXJ\O(R$W5K>V2\9-SE3O51VC
MK9C26$FFD_K:J"A48F)?1ZRB"J2C@IE<MP+W/1/Y8[#YO]+3AYR8VTX\OV;>
MM?ST#>YK+=)JK9[/JG8ESU!+W%RV;HMFC=[<G="-*KD033;E6>&PD0J?=+@"
ME%\-R<C;XC_F<@X,5!=6#YPMDT5C8254<)\@*JLH@1,^2G.L1%NH?),8[V"D
M-G..S&>P#TJ !2+^-W_V3>$O^\1>?Z-50!93Z.O]4_TW?]R+C-_1#4P!UWK9
M?U1O49_W1-U?ZG2( KO_  1O^QOS,_WF:U_19!@#YWQN_P#LF\)?]XB\_P!&
MJH LI]'7^J?Z;O\ N1<9OZ(:F -1/B9OZCKG?_U=TK_XE], #2+X-_\ JC9[
M_>[W-_J=J4 6==O?]DVT/YN[K_JU)@#SX?@?_P#:%YZ?S,Z>_P!=[6 ,:_%F
M[(V7R.ZNG&+@](7!_6-25ZE:4A:S''4<.*^QO6_KY)1EIV<[B?*&S=_)MX8T
M:PQG)BY(WBS$(8F5ELF NR\.^C%TU^$5"KU0U%Q.T[,6.(A<14QM_9M$K.R=
MQV]=P5L>:?3FP+?%RTVV;3C]L5PI&1ZC.&;GP4C=HBF0A"@0H_&-5RO5'I#:
MCKE4@86L5Z+YLZF1C(&O1;&%AHY%34_(9PHDPBXU!LQ:)J.%CG,5,A<9.?)L
M_+G.0!)W\.#_ %)O ?\ F[O?]-6S0!-T           *?7QGG(5QKKISZ=T%
M&.? D.1_(B(5FT_*B)^64/3D!(6^5;>1X6(X<]V]RE96[_=.BEX78?L.=+(
M[#TS/AF>E/>^G[Q!V'RFXHJ;%W_LO1%#VALRV+;YY)U59W,[+B4KTTC%:_0=
MPU6H1JE9AK UBS%9,42&RS[Y\JJ&.LH!-+Q>Z+G2SX:V*%N7'GA3IVI7>M.'
M+VM7RS-;!MJ_5I\Z4,HK(5V\[AG;[;(&1*50Z2;AH\161;G.BF8J)S$R!\;K
MB<AT^+W29YV[5)(>:YA;0EIUA4WJ:YD'K6Y;PRUTS5G\9DF#**2,/-7M%\GC
M&#8+Y-DY^Q,I\X B@^#PX]H:IZ4KO<+EBLE-\G=^[(O*<@X1\$SBH:].PU!
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M$Q\KR="U ]L9KE;&ILYR9PRLVQK M'&.KG*GE%:4R7&"F[R@%V<
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MBM<BZ6;D4[QFC'P&I3>&@3& -U0    >?E\(C_60]5__ -YQ_P"GBW@#T#0
M
M
M
M                                       !73XO?\0+UD_Y@^GC_1?8
MA6AX29NLG,%<G
M                                                       X9_A2
M?Y-7]TD(\ .8@
M
M                                      #BI_!G_:&_<Y$4U@Y"
M
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MC;$/6:[L6L3K.-C9EDXE8>IW"\PN86P1,HFNP=(2*Z:_<53-W%D%DDP)'0
M                 47MD=';J2\[?B*8CFMRPX[EH/!G7.\8.9IECE]LZ(M2
M<CJ'C>P.[TW!):]I^T;->DT=R76MM9&4:NV"?D1)]]EQA/P\-P!>A   4EOB
M9>B/S7YF<L^./,?IX:F-L+9#"@_,S;AHC9^J-6RU8G]7V9&QZDOS5YM"[T-*
M3EWK6R/&.5F+EPLU)!-,'33QDAS 2 ]7;B=U;.;G!O@KLSBH53COSZT-(Q>V
M=M4*(WA 4"Y-;N_U4M 76CT#85-F)'5<^VD+@91/"#^?90;V.5(5PKW,JI%
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M7B*;1ZA!-_)XR"KT(U3:,6B.,Y.LX6,0GB+N%C*.'2YSK+'.J<YS 9&
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M/D"T0
M
M
M                                              *Z?%[_ (@7K)_S
M!]/'^B^Q"M#PDS=9.8*Y.
M
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M[*5UA-1+<)B(
M                                                       <5/X,
M_P"T-^YR(IK!R$
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MJX6\?)73VHTJ5EZ>DOG!LK.GRA3%*?/[V!Z"(
M
M
M
M
M
M                                            "NGQ>_X@7K)_S!]/
M'^B^Q"M#PDS=9.8*Y.
M                                                           !
MPS_"D_R:O[I(1X <Q              !YX7-K"_43^+3TCI5%%Q+TSCQL72-
M'<).&Q%6RE.XXU]YR7VE&/$'"?@H1;NW.K!'=I\FPMXQ<D[3*D(*"^M+0D72
MX]#T5R<\USXMJ@T*7ZJ7'Z T9"Q_W@-C:.UTSV QIR35G,3]^F-EVNNZK=S1
MHTJ2ZU]D(8C5J1=<V79HU"-+V^$1$?/+][1K)':R9[XQ'>[W7?3[X\\>4Y=/
M,]OG>K&4L':?&%9RG:3J+J4GNXAG)3^'B^6ZMN3'[,X)DA2YQVGQG$\JT;0B
M[4:%\1.I)U>-I\,N.?$3HD\%["OK?1FFH#6ULY<;8K=19Q]RVM'P3IWLB8UG
M);0LE3T)7HYO>U9)RU:2SJQ2;@AVF7K9FLN9FI!'.5*,30015I1#%T5UZ.NA
MTN.5M(UCU<:<WO=$M2D)*6BK6;7.DJY8DM=.Y!2-E[AI397&Z/A*!9IB%6(8
MZK=VI.-55&YF9_(U52N48;;VK1XJJ:ST/(N38349'3,4[1?Q<LQ:2<:^;F[[
M=ZP?MTW3-V@?Y.^BY;JE.7/]TN<"N3G[@     !U^JU*JT2O1=1I%9K]-JD&
MWRTA*Q58:-KU>AVN55%\MHN%B&S.-CV^5ECGR1%(A>\;.>SMSD :-=5;D#JK
MC-T[N7FT-QJ1JU1^HS8=);5R2,TSB]6G8U9DJ14Z$U:.\]Q^M:YV=1:J)X*I
MA-J=58Y<I)*9Q!RHC550NHK!_!<\<KG6M5\R>4L_'.F%-VI9M8ZDUVX<)'0+
M.+ZM0N<]?I1KA3LR[C6SV]Q;))<F,I>5-G:7>R=(Y24H4T*I*WRF&OC1M]E>
M7C@WQ6)*E91<=";!WW=D$"X>O<%L4O&ZYHLKYNRJV[2QS>M6@J6,JEPY.L8O
M>)X><Y3+J0@XR:TZ@_Q"7,W5U.B.COP.EN-'$#7=0JM%T[L79\9H]ILN]4FF
M14)!0,XPEN3DU7-12\*]AXM-(J%:@Y5JR.HY0Q*.U$,*HMJ1WW$HA&KN Z5T
MY/B%NHUI'GO4N!?6$K157>P+O5]8/+7:-:5/4FT-27:_.42:\G)=CK^'J^O[
M-K2R.9^/17=D8)X2C5DI-!ZJDDLF[->Y';+R".6M%+YPK$X
M
M                            '%3^#/\ M#?N<B*:P<A
M
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MOC .GDZJIE#2\K]TQU8<)*%*8B9K!?X:;+GL\'.$_F0R*8Y<F-DQ,Y_9[<$
M%_P
M
M
M
M
M
M          !73XO?\0+UD_Y@^GC_ $7V(5H>$F;K)S!7)P
M
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M[=<E]BQ=)=/,)Y*51T1UA=-!0W[[DB129SW")X+0E^^GE)':ST/Q7)P
M
M                                    .*G\&?\ :&_<Y$4U@Y"
M
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M7M3RJW*90P%^4
M
M
M
M
M
M                    !73XO?\ $"]9/^8/IX_T7V(5H>$F;K)S!7)P
M
M                                     .&?X4G^35_=)"/ #F(
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MS0;Z\FUP(2)I6IZ#XKDX
M
M '%3^#/^T-^YR(IK!R$
M                                   9=3_@R?M"_N<#XUUE(YB
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MUDLAA/'@>43=*,\E&>#%R8N&QU<YPL3!@!Z!( \_2X)YZ@'QF-8B,L2RFO\
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M<2MON/S;2XMSA8#YV6R3>R/D67SXS;RGPS.7!BY6.!MO_;G/_;7?_?9_]I'
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MD'.IZ].><"F?MK%/EL4C99/!SX7SF9;-W1"N&1L8 L_
M
M
M
M
M
M                                                   *Z?%[_B!>
MLG_,'T\?Z+[$*T/"3-UDY@KDX
M
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M!!*JB(U*)J)D1$-IA$
M
M<5/X,_[0W[G(BFL'(0
M                                 !EU/^#)^T+^YP/C764CF(
M   //?YW+N.A)\2SKGG@[CEH[B-SL6G)?8\DT;G,S9--CFAZWR326\G*1=[+
MTC9:L7L11$A,Y<(OVZ!<G4R?. /0/AYB)L,3%S\!*1TY!3D<RF(6:AWK:3B9
MB)DVR3V.E(N19*K,Y".D&:Q%4%TCG252.4Q39+G&0!]$           ?G>,V
MD@T=,'[5L^8/FR[-ZR>().6CQHY2,BY:NFRQ3HN&SA$YB'(<N2G+G.,XSC(
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M&9UBQO7\5 D;O$6Z=GH,',H>572>4;I(VZ;+B+03\W-G#2/ OG@
M
M
M
M
M
M
MKI\7O^(%ZR?\P?3Q_HOL0K0\),W63F"N3@
M
M               <,_PI/\FK^Z2$> ',0
M
M                                                          !Q
M4_@S_M#?N<B*:P<A
M                                &74_X,G[0O[G ^-=92.8@
M  PCN_C-QOY-1,) <D>/ND.04%69%>8K<+N_5%#VO$U^6=-LLG,I"1U\@9]G
M%2+AGGPE%T")JG2_)R;)?D &0Z-1*/K"H5S7NM:;5->4&GQ36"J5'HU>B*E4
M*M!L2>$RAJY6H!G'PL)%,T\=U)NV0213+\A2XP .U@
M                                                 -<=W\.N(O)N
M3@IODEQ8XX\@YFKL'4569?=^C]9;8DZ[&/7!7;V.@G]\K$^[B&#MV0JJJ+<Z
M::BF,&-C.<=H SK7*Y7J?7X2IU&!A:M5JU%,(*N5JN1;&$K]?@XIJDQBX:$A
MHQ!K'145&LD"(MVZ"::**1"D(7!<8P /L@
M
M
M
M
M
M                                           KI\7O^(%ZR?\ ,'T\
M?Z+[$*T/"3-UDY@KDX
M                                                           '
M#/\ "D_R:O[I(1X <Q
M
M                                            '%3^#/\ M#?N<B*:
MP<A
M                   &74_X,G[0O[G ^-=92.8@
M
M
M
M
M
M
M
M              KI\7O^(%ZR?\P?3Q_HOL0K0\),W63F"N3@
M
M                             <,_PI/\FK^Z2$> ',0
M
M
M            !Q4_@S_M#?N<B*:P<A
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M6'7&<AP]IAU2/<.;U]<#CQZ/#PME+\0V_P --QCH%AUQG(</:8=4CW#F]?7
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M#F]?7 X\>CP\+92_$-O\--QCH%AUQG(</:8=4CW#F]?7 X\>CP\+92_$-O\
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M6'7&<AP]IAU2/<.;U]<#CQZ/#PME+\0V_P --QCH%AUQG(</:8=4CW#F]?7
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M.'M(>IO[C7>'K:\?_P P#PQE7O\ M_AYN,=!L.MLY#A[2'J;^XUWAZVO'_\
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M=X>MKQ__ # /#&5>_P"W^'FXQT&PZVSD.'M(>IO[C7>'K:\?_P P#PQE7O\
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M.'M(>IO[C7>'K:\?_P P#PQE7O\ M_AYN,=!L.MLY#A[2'J;^XUWAZVO'_\
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M=X>MKQ__ # /#&5>_P"W^'FXQT&PZVSD.'M(>IO[C7>'K:\?_P P#PQE7O\
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M#UM>/_Y@(>&,J]_V_P /-QCH-AUMG(</:0]3?W&N\/6UX_\ Y@'AC*O?]O\
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MAP]I#U-_<:[P];7C_P#F >&,J]_V_P /-QCH-AUMG(</:0]3?W&N\/6UX_\
MY@'AC*O?]O\ #S<8Z#8=;9R'#VD/4W]QKO#UM>/_ .8!X8RKW_;_  \W&.@V
M'6V<AP]I#U-_<:[P];7C_P#F >&,J]_V_P /-QCH-AUMG(</:0]3?W&N\/6U
MX_\ Y@'AC*O?]O\ #S<8Z#8=;9R'#VD/4W]QKO#UM>/_ .8!X8RKW_;_  \W
M&.@V'6V<AP]I#U-_<:[P];7C_P#F >&,J]_V_P /-QCH-AUMG(</:0]3?W&N
M\/6UX_\ Y@'AC*O?]O\ #S<8Z#8=;9R'#VD/4W]QKO#UM>/_ .8!X8RKW_;_
M  \W&.@V'6V<AP]I#U-_<:[P];7C_P#F >&,J]_V_P /-QCH-AUMG(</:0]3
M?W&N\/6UX_\ Y@'AC*O?]O\ #S<8Z#8=;9R'#VD/4W]QKO#UM>/_ .8!X8RK
MW_;_  \W&.@V'6V<AP]I#U-_<:[P];7C_P#F >&,J]_V_P /-QCH-AUMG(</
M:0]3?W&N\/6UX_\ Y@'AC*O?]O\ #S<8Z#8=;9R'#VD/4W]QKO#UM>/_ .8!
MX8RKW_;_  \W&.@V'6V<AP]I#U-_<:[P];7C_P#F >&,J]_V_P /-QCH-AUM
MG(</:0]3?W&N\/6UX_\ Y@'AC*O?]O\ #S<8Z#8=;9R'#VD/4W]QKO#UM>/_
M .8!X8RKW_;_  \W&.@V'6V<AP]I#U-_<:[P];7C_P#F >&,J]_V_P /-QCH
M-AUMG(</:0]3?W&N\/6UX_\ Y@'AC*O?]O\ #S<8Z#8=;9R'#VD/4W]QKO#U
MM>/_ .8!X8RKW_;_  \W&.@V'6V<AP]I#U-_<:[P];7C_P#F >&,J]_V_P /
M-QCH-AUMG(</:0]3?W&N\/6UX_\ Y@'AC*O?]O\ #S<8Z#8=;9R'#VD/4W]Q
MKO#UM>/_ .8!X8RKW_;_  \W&.@V'6V<AP]I#U-_<:[P];7C_P#F >&,J]_V
M_P /-QCH-AUMG(</:0]3?W&N\/6UX_\ Y@'AC*O?]O\ #S<8Z#8=;9R'#VD/
M4W]QKO#UM>/_ .8!X8RKW_;_  \W&.@V'6V<AP]I#U-_<:[P];7C_P#F >&,
MJ]_V_P /-QCH-AUMG(</:0]3?W&N\/6UX_\ Y@'AC*O?]O\ #S<8Z#8=;9R'
M#VD/4W]QKO#UM>/_ .8!X8RKW_;_  \W&.@V'6V<AP]I#U-_<:[P];7C_P#F
M >&,J]_V_P /-QCH-AUMG(</:0]3?W&N\/6UX_\ Y@'AC*O?]O\ #S<8Z#8=
M;9R'#VD/4W]QKO#UM>/_ .8!X8RKW_;_  \W&.@V'6V<AP]I#U-_<:[P];7C
M_P#F >&,J]_V_P /-QCH-AUMG(</:0]3?W&N\/6UX_\ Y@'AC*O?]O\ #S<8
MZ#8=;9R'#VD/4W]QKO#UM>/_ .8!X8RKW_;_  \W&.@V'6V<AP]I#U-_<:[P
M];7C_P#F >&,J]_V_P /-QCH-AUMG(<3J:9M]SO^I]=W;8FM)+35ZM-1@YRV
MZIF)Z*M$KKV>D&*3B2J4A8H,I(>:=PKDYD3N6V,(JY+WB_)D:_OH8+:\E@MI
M4GMV/5&R(BM1Z(NAR-72E==%TH6>5K62.8QVTQ%T+JKYZ&3!\I(
M
M
M
M
M
M
M
M                        %=/B]_Q O63_ )@^GC_1?8A6AX29NLG,%<G
M
M                                         X9_A2?Y-7]TD(\ .8@
M
M
M                        #BI_!G_:&_<Y$4U@Y"
M                                                          ,N
MI_P9/VA?W.!\:ZRD<Q
M
M
M
M
M
M
M                                                    !73XO?\
M$"]9/^8/IX_T7V(5H>$F;K)S!7)P
M
M         .&?X4G^35_=)"/ #F(
M
M                                                     XJ?P9_V
MAOW.1%-8.0@
M                          #+J?\ !D_:%_<X'QKK*1S$
M
M
M
M
M
M
M
M                      %=/B]_Q O63_F#Z>/]%]B%:'A)FZR<P5R<
M
M                                     #AG^%)_DU?W20CP YB
M
M
M                     .*G\&?]H;]SD136#D(
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M);O2K7-MT<UR>5')<*BIYT4D%XV<^.9G(R3U[)->FE:J-JBZ25=7D]IVKD'
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M@< +2NC5^GTFI?H/]$
M
M
M
M
M
M
M          !73XO?\0+UD_Y@^GC_ $7V(5H>$F;K)S!7)P
M
M                           .&?X4G^35_=)"/ #F(
M
M
M           XJ?P9_P!H;]SD136#D(
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M$Q.;"KE\;[B!^RY6*JMK1%6BN:U=%:+5J:47@TF7QA);
M
M
M
M
M
M
M                               *Z?%[_B!>LG_,'T\?Z+[$*T/"3-UD
MY@KDX
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M^(KJ(E(3X)?_ *5=1S_J_P 5O_27(,48>$D;K+]@KDX
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M                                    !Q4_@S_M#?N<B*:P<A
M
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MY@O;WOF)9F<^W;*&PGCN]SZQ53$QD^>WO'[,8[,YSO\ _E>Y@Z1DO-655?\
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M@X[Q.]?B6(W&(2??GF?(OTO<KO\ *9$&,GQ
M
M
M
M
M
M
M                      5T^+W_ ! O63_F#Z>/]%]B%:'A)FZR<P5R<
M
M                                      #AG^%)_DU?W20CP YB
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M*4N=E&'E4X<\UEN5SELWROA/OY33[W=Q71:I4G349M
M             '%3^#/^T-^YR(IK!R$
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M;*NUI0WYBJKE;=5S">K<)8,C\_.3T:^GG1TCG>71767>AX$G)X
M
M
M
M
M
M
M                                      5T^+W_ ! O63_F#Z>/]%]B
M%:'A)FZR<P5R<
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MVCXJ)BH]LF@V;()IHH(IE(0I2EQC$0?6
M   '%3^#/^T-^YR(IK!R$
M                                     9=3_@R?M"_N<#XUUE(YB
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M/BDN(%1'.C55956HZB*YK5T5HM6IZR*FE-)FT8$6D
M
M           QSL[<.H])UU>X;EVEKG4E2:HO7+FT[.N]9H5=;MXUHH_D5UYN
MU2<5&(HL&*)UESF5P5)$N3FS@N,Y &L%=ZGW33M\W&UJI]0[@S9[',.2LXBO
MUWEIH.:FY5V8ICE:QL5&W]R_?.3%)G."))F-G&,_)\@ W0@YV#L\1'V"M3,5
M88&6;$>14W!R+.6B))HIV^&ZCY)@LX9O&Q^S/8=,YBY[/DR /J@
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M]:F;SU4DY:*6*Y9KD63R57.#I'*;':7.,@#(P
M
M
M
M                               *Z?%[_B!>LG_,'T\?Z+[$*T/"3-UD
MY@KDX
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M^DE<3C=#O^J-Z?G^[;1__L;H3L^ZGT$4U%/7K8_\4=PN_G1Z=?\ 3# BB_\
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M4<%,\>(I8R1+.,JJD+_A&+C,-IJZE050V\$0
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M7-<_XLD.+?M7I5%1CIGX2Z58T5*MBV^;:M5:U%55+?A.]/ \"VEPC 88'/\
MO*VX]94\BN6W5U/(VM$X$,O<4>EOR=XC25:C]=]1ZV8U9&VF/F['J<^@81W7
M)^(-+-']HA8G%LVE<6%,?6AF@H@>18LO*$%%LKX*<^,X-A6^+YN=TV^BUNKG
M,VZZS\7RVCXH,13&)6SPR<VYD$LG1["V?=,@<K7)!++L/:WFU5K5T6S,6\'
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M7.<J^<TU<7%Q=S.N;I[Y;AZU<Y[E<YR^57*JJJ^=5/O"W%$
M                                               HZ?&E<Q7D#IKB
M_P!/^COUG%GW=<5]X[*@HHAG,LZI%$76JNL8)PT2.HX<,+GL.5?.T$TT3'4>
MU8F"G+W<D4 AKZ&\YMKHN]?%APLY'O$:ZGNMA$<:]DMD')LP2\_MFLU?9?'Z
M<:$=>"@X?O+H^A8DBQ39,V3FWA"&4[3%4 ]1\ 1O=8K^J?ZD7^Y%R9_HAM@
M\TCH==!+VS53Y$6C[UOW;_J$L6NX#R'ZB_K@^=?S^C;;(^5^4_7%JWS%YI^:
MW<\/PWGC^/V]Y/N=AP)RY#X+7DAJ(BMJXO\ 5)CFVQ#QTG'>/(:6OF@R*M%F
MY7#>-5NFO=V[1G,1TE*-4"NB>;S%23+A7!%CD*D8#6#'40^((^'AW+2:)SX5
MM'*SB_,RZ<9&OME6^1VQ3-APK=8[V51TYR:E&3C8E0NL;''6*TA[)@_DC9,A
ME8/+4K<^ +_W"7F=HWG_ ,:M;\IN/5@4F]>;%CEC^0R)6[:STVRQBYF-EHMT
MBF[EV6'M=8E$SHN$L**)+$\-RW46:KH+J ;7      #KMO\ ^B=H_P"KLW_Z
M-<@#S:O@EO\ ;TY9?[HA_P"F76@ ]+< 1O=8K^J?ZD7^Y%R9_HAM@ K%? __
M .SUST_GFT]_J1:P!8 ZZG5&]E#P7L&\JM%1%CW?L&T1^H=!U^>27=07U@3\
M5,S+BUV5DT51=.ZW2*U O9!5'!TB/'A&K(RJ7E6%"@4Z>F_T%.6_7=@TNH]U
M)^8.SXJB;3DYA*@&RW;6O<.QH"!G'\))25?)/91HFE]:M)I@Y:PC1I$O$5B-
MSG0CVK++5=R!,%=/@G>G8^A%&^N^3_-*K63*Q#)2MTGM&WZ$(WPDM@Z2E?@]
M)ZV?J+&6,F;"F),A2E*8O<SDV#$ T-XY= 'JO=(CJ"\0MC<>.0-HWGQ G>4F
MF(#?TAHJ:N>N)7.K)[8M8A[FYWMQ\-8)B,F*"XK^"J/W+-_96T8DVR[>&9IM
M$W6 /0<             :7]17E;C@[P9Y2\L46<-)3.D=.VRV4Z)L>')J]-[
M#4:8AM;04\1C(14@I"SE^E8UHZ*V<H.3(+&PB<JF2Y %'[3OQ-7Q%?(BH9V%
MQ^Z7>JMZ4'$J]@LWC3O";G-LVH8G(TC961ALV6E;[FX7$K'IO$3+M_'\9(JI
M,F+C!B]H';8WXN;J:<7MC1-7ZC_3+J]&CY-^V.I6XVC<@.*FQD8 K))25>Q,
M7O>6V@A8G[(LS'O4TLHL454,E0.JEY6F[0 O <-N8VB.>'&[7?*CCO9EI_5F
MQXQV[9YEVJ<18ZQ+Q#QQ&66H7.'PY=EA+15I=FLV>)%66;GR3"[9=PT50<*@
M5'OAN>6_*SJ)]5#J5\E;YR+Y$73C!3F]L6U7I.P[@V/*Z-H:V\MR2$EJ=I!:
MRE;"I48QQ5M7ZYDV3 J; F44UE5,X*KG!L@7A0         5R.NGUH.1/3>N
M_&SCEPSXML.47)ODO$7>Q0,'(1FQKI\WXVK2$%!PC.-U-JYFQM^QI.W2TJ[R
M4K2;CCL211BY27R[(=N!!7)[M^-TVK#.=JT[5K_5-32B%G9J3&:VX#5R9(2-
M:J2#EPVU[O=>R;K<R[MNI@A&A4U%%U281;H96[Q3 93Z17Q-G,"<YJTOIW]5
MC64+"7V[WN-TC$[-3H;C4&SJ3NQ^HT@*]5]Q:[QY'65VUVLV4615HR-A3L)"
M03/E!5F?&&P%[@                     5G_B ^E#S:ZL%TXA:FX];I9:7
MX[U>*W6^Y)RMEO-F:TZ2D9-_JDVM4'&I:P[PIL^S-4XJ9.P,\2;LH]/*_>>M
MSKD(L!I!K3X)?@1%5MLUW#RPY>WNWD18E>3FM%M,ZGK:[A-@V3DE6U5M&L=S
MRC1%W*%6603/,KF;H'(B8ZQR&74 @%ZE'33Y??#+[XT?R\X8\I+;/:HOEH-6
MH&WJLB5R:96Z#8&GW.I=W4QB^<4_9-.M\(V>.6ALI8;N4VKI-5HU6;H.' 'H
MU]._EU%\\^$G&SEU%Q"->-NW6L98YZO-5LN65>NL:Z>UC8%?CG)UEUG,9"7F
M"D6K914WC*-TB&4*53)BX A'^*%ZNU[Z<'%JDZ<XZ6GYJ\H>5KFRP\+<8XY<
MV#4VH:PU9H7N^U]4N%<P]SF9*<8P\$[4*0Z'BOWK10CR.3.0"&OIH?",5;E-
MQ^J'*;J/\A.0D#LKD% MMIQ^M]4254B+I78VZE:V&$F-KWW;%)V:^GKO8HMZ
M9Y)1Y8QHLP<.2IK.E5R+$ &E?4\Z4')?X;':VF^H#T^N2FQ)_3S_ & G2%9&
MT-6:5PIL\Z))3T/KG=#*LMXJE;6UE?X"$<(JN3QT8W.];F1.S;K'9+* >@GT
MX^:54ZA?"?C[R^J3!&#1V_2B/K+5T'1GI*?L&O23^I[&J)'2A4W#EI7[O!/V
M[5=5-)1TS(BODA<*XP (>OB ^E#S:ZL%TXA:FX];I9:7X[U>*W6^Y)RMEO-F
M:TZ2D9-_JDVM4'&I:P[PIL^S-4XJ9.P,\2;LH]/*_>>MSKD(L!I!K3X)?@1%
M5MLUW#RPY>WNWD18E>3FM%M,ZGK:[A-@V3DE6U5M&L=SRC1%W*%6603/,KF;
MH'(B8ZQR&74 @%ZE'33Y??#+[XT?R\X8\I+;/:HOEH-6H&WJLB5R:96Z#8&G
MW.I=W4QB^<4_9-.M\(V>.6ALI8;N4VKI-5HU6;H.' 'HU]._EU%\\^$G&SEU
M%Q"->-NW6L98YZO-5LN65>NL:Z>UC8%?CG)UEUG,9"7F"D6K914WC*-TB&4*
M53)BX @NZR'PS_M:^7+#E1]];Z@/(=0TS57S$^[A]:OB_-&9MLMY^^<_U\ZW
M[GG#YT^'Y+YNSX7@=[QC]_L(!%%_88__ &Z)_P!R;_VK@ :3=1+X4?6?3CX?
M;DY=;2ZG*DY$:R@4OFW2FG#E*(D]C;!GG:,)1*!&22O*R2S'*66QO4$G+TK1
MYYMC\.'ID%DVQR9 F#^">U3>ZOPSY8[8GH%S&4?:V^ZS$4"6=9*G\Y%=;TYP
MSMKV/;F[%E8J/DK,BS*YQCP5':#E$N<G;JX*!=2   0]=.;K9<5NIUNSD)H;
M0M Y!5&W\;$<KWF2V]5=<P-;E28MLE3<XJ;RF;6OTH^-YTBU%/\ /&;#'@9*
M;_#SDF )A0
M
M
M                                                  !73XO?\0+U
MD_Y@^GC_ $7V(5H>$F;K)S!7)P
M
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M=U)/\-LN'2Y\F47<JG4.8QC9SGZ$2B4)TT&6P
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M60*=L;)B-I!VGC&<=BF?E["+5*H$TFPHB
M        #+J?\&3]H7]S@?&NLI',0
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M7#W-U_<K1FO3]U$-C!K L8
M                       'FJZ7*GUROBI9S8SG_P!_'C;QFV!(76.4RU,[
M@%=*<1GS6 UF8C8ZAT7%=VMNQ2-D'"#DV,+M; Y[Z79WFX V(^,]XG3FNMQ<
M0.I'K8SF#?R::6A[S/Q)#-'4)L+7C^1V;I6SD=)%/A6:DHA>=;^,?N&13K[0
MN._C.,)@75.G=RRA.<W"+C+RMA%6AE-R:HK<_:&C+*66\+L1@@:O[-KB>$CG
M*4M;V%$2;''[&<E;XSDI>WLP!BSK%?U3_4B_W(N3/]$-L %6CX';_LFZA_\
M.)QV_P!6MM "]P -/N>_#36'/[B5NKBGM>-8.8/:-.E(Z G73)!X]H5^;M5G
M%$V+ F525.UG*992H/$C$_ADR*(*8.BLJF<"B7\&GR4OFH>:'*SI_P!V<.V=
M=O5!G-ELZXY<IK-Z_NK25IA*;9FS% B:A2.[%3K YP]7(K@JA:ZU+DI^PAB
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M=:U!S="PD:6V.*FQDGDTRJZ]CPVQ,*UUG,2#AVDR,MELFY745*3!SF-D#L0
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MLCM5QR;MD,U4:KR-2J%6IEUUE3',QC"WE<>G=Y._3'D9.YDJ^(18QLE[B??
ML==!'CY;N+_2!X+Z@OD<]A[<UU5*[$FX:22PWDH5SO'85SW@G"R37Q%#LY&(
M;;%3;+H*=U5%5(Q%"$.4Q"@2]   /.4^(MY.[(ZN/50X]=&SBG(IRE6U+M5O
M3+6^0PNXA9'D9--7#?95LGR)&[ZU9XT:Z2D4'1DR%<-G!; 7]]+X'8!?IXI<
M:];</..&F.,.HHXL;KW2=!@Z- 8RBFBZE#QJ'B3-FEL)?D*V"WSZ[J5DE<?*
MN_>+*9^4V0!L$   \_+X1'^LAZK_ /[SC_T\6\ >@:
M
M
M
M                       *Z?%[_B!>LG_,'T\?Z+[$*T/"3-UDY@KDX
M
M                                      '#/\*3_)J_NDA'@!S$
M
M                                                !^.1?)QD>^DE
MD7CA&/9NGRJ$<Q=R<@NFT0.N=%C&L$7#Z0>*%3R5)!%,ZJI\X*0N39QC(%*C
MX?'@9R,V1U*^;W55YH\?=RZ,M$K==BN]'53?>LK7K*SGLV_[%89FW66!@KK!
MQTF6/HFN%BUM!PU.9GX,VX;$,IX)O#HQM7:5RDJ)IJI=C%8F
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M</\ 5&R/^\EI7_[';Q3E^[]9!VHD3Z%']4)P!_W?:[_Z1EA,S[B!-1+()B(
M                                 !EU/^#)^T+^YP/C764CF(
M
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M6P_M'OWD-:>QP_V>OJ0BOK&_V$O^V;Y^7WSI_M2_^_O_ -"/,?\ [H_\E?\
MR'^<>4 "'#_XNN_]SV/( K\=(CVY_P!Y#E?[*7_:%\F-]Z+_ &/_ /W7^?DQ
MV_[1_P#[Y'_3?RO_ *._E?\ \OW !8'_ /BZ[_W/8\@"X_TX/OF?<FT'[0G_
M &R?F[/?7G_V5?\ /_SULWF3_L1_^!9_T.\V_P#,_P"\?QG[_P"* -W0
M
M
M
M                                 %=/B]_Q O63_F#Z>/\ 1?8A6AX2
M9NLG,%<G
M                                                  X9_A2?Y-7]
MTD(\ .8@
M
M                                 #BI_!G_ &AOW.1%-8.0@
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MU8W_ &6^=V_SN_[,/_@A_P#-7B?\R_\ */\ $_E]@G3G:Z=7U$?6+F0JDP
M                               9=3_@R?M"_N<#XUUE(YB
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MQB:[N970P*Z.G-M:KZ48CO5<KFN<K4]56K2M%552EG<>39H(
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M<;W49?P/ +O&)KNYE=# KHZ<VUJOI1B.]5RN:YRM3U5:M*T555*6=QY-F@@
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M.5'SY$I_#2\15,"P(   Z[;_ /HG:/\ J[-_^C7( \VKX);_ &].67^Z(?\
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MR7"S@J'?/V9[.]G( ^X           /.(XZ&1ZB_QBFQMA.72EIH/'3<6S;
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MZ!H
M
M
M                                            KI\7O^(%ZR?\P?3Q
M_HOL0K0\),W63F"N3@
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M6>47KS6D;%V*V=P[%C:V:1UUEV^<N<G3*0WAGSB5KD<E4"+4D7$P
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MJG\G-DR9,=WM-<CDJFH(M3<@1
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M4Y?N_60=J)$^A1_5"< ?]WVN_P#I&6$S/N($U$L@F(@
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MM?JH=,;WKJ/#,GPX3$J_MIHV(G]B)-I57RT<UGIKP%RP>&IR\
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M/37@+E@\-3EX
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M@I/7"CNTGT\349ZQ :W:W L=7V\?G9VT5)$K^1NKIRLMARU+G)$BY2-E,I\
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MXR?($PH
M
M
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M0;.G:]5SEEJNC9U(FFNO1N&-%&+
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MJ:CQ-@=LF99'O'QA='Q)D<UVI2-44WU$0
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MO>W\/)V]_%,5G"Z3BP/Z_ UB%=2!CN38,=M'M$\XQCL3Q\O:1*)1 F@V%$0
M                                  9=3_@R?M"_N<#XUUE(YB
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MT5U7;*H]*(Y56J+ITT2:0<)&K
M                         "N'\09TD^7?5WC.)6I-([,T5K31VK-A6:_[
ML<;-LFQ&-UEI25;P%9KSZ@U^J:VM]=EG=6J#FQ&(23?QV'#N023PHBEA50P$
M_FI]84K26K]=:<UO#-J[K[55(JVO*3!-$T4F\15:=",J_ L$R()((_YM&QZ9
M<Y*0N#&QG/9\H R
M
M
M
M
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MP;)69\P6BW^$6JRVB/5FUSD3/61$541)'M5:532B4K5*U1:86]L)TY_Q$?\
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M<NG98FAD;?ZK&\'G76[6Y54V.&JBP@
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M316QUE7""CDU-R;#TIJ)%2BGJ##Z"H
M                     !Q4_@S_ +0W[G(BFL'(0
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MA+$:0RD1J6)MUEP;_-T(Z5N:;G8-E\M44.8N%F4C85\.%.]W,G(;..PO9C'
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MAP
M
M
M
M
M
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M9U&.=3:8[2NP^E$551%5KD1-I$=ZJ4TRC#CPUT
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M21=+CT)17)P
M  .*G\&?]H;]SD136#D(
M                                    RZG_  9/VA?W.!\:ZRD<Q
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MUL[7P<U=IJTUT+H4V=OQQ"LMAA+5U-?*Y/I5&,7_ $9"SR/)HT$
M
M
M
M
M
M
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M1/N[;F=,E5/[2/NN;<NA?V:-U-0M.]O$5OLWR6Z+6.UA9&GDJJ<X[ZZOHO\
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MVV2%6?WN=:BT_P U7?47:!^?4Y)
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M#EV];-YHV*GK.^\H:G"I:R%0F
M                 XJ?P9_VAOW.1%-8.0@
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M\V90OI+_ ![..4\/R(V1R)>7LT]M-L(U7(KH'P\QSFC2Q+U4I5R.6FR:^O\
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M8YKD<UR-:BJJ.1514VW.HJ+J)-QR>8$
M
M
M
M
M
M
M       !73XO?\0+UD_Y@^GC_1?8A6AX29NLG,%<G   "IQIGES UGK6[4V%
M99HK6F;)O]WT ZL#AP@1DC%L#Q5+HKURX73;I(PRL]0H<IE#F3PV;'\0YS%3
M-WO:G/NY'$L7_E_8-EC";=7X]A.&6F,MA:U5>LCTDNKQC415594AO+I4:B.6
M21-AK45R4Z5Q7+$UQNEMK&W96[MX([E&T6M5VI)$1-/K;,C]&FJZ$33HMCCQ
M6.:CJ-_O%<UE1[=L.WR",55Z379>SSS]=0B9&\9#,5GSK)<J&*4ZQTT<E3)C
M/>44,4I<9-G&!?,LY=Q7-V8;'*^!Q.FQC$+J*WA8B*JNDE>C&ZM2(JU<NIK4
M55T(I]5E9SXA>16-JU77$TC6-1.%7+1/^[Y$*JO1#X^6+9?)^P\H'D(>+H.J
M6]K0B'N2'*R>;"OD8]B$X"+-DJ*3PD%4IQZNZ,3&?)LK-.\4N5R9Q[,?S"MY
M^%Y2W06NY^"X2;,N-.MW2LKZ[;*SD9*LTB556K-<PQ,C1?\ $V9Z*O-N1>C]
M[N-P8?EZ/+S'[5[<JQ7)PI%&J.VE\FT]K43RT=Y%) >I[R%F=U[+UQTTM"3[
M7YZ[ALT*PW=8&BN5DZ=5CJ(2Y*VZ.V6*?*I8=JM-3+<O8MB-:HH8P?RM0A>9
M?E"W7V&[_*6*_-IO)MG^'\"M)7X3"Y*+=7"(L7/M1R4ISKFVMJ]?56>1\BJW
MF&N7"=WN!Q83A\^?\:8O1+6-RV[5_7?]W:2O]I4C8NK;55T;**3+ZIUE4=,:
MWI.JJ''XBZC0J[&UN#:]I3+9:QZ!4SO'JV"ERZDY)QWW+I<V.^NY5.H;M,;.
M1P9G/-V-Y]S7B&<\R2\]CF)74D\SN#:>M4:Q-.S'&VC(V)H9&UK4T(AJK$L0
MN<5OYL2O';5U-(KW+YU74GD1$T(G B(AD 8P?"4F^JU'NM2]2C8UNB4"HF6E
M=5;0AD\?O.#O4JE5'#Q7*A2Y[,N+-#.CY/@N<XR;Y>W.,YS^@CY,+F'.WRG8
M5@=Z[:1L.(X?*NNC%N;EK4I_9MY8TI7@X$.MMV[VXGD&"UE6M&S0N^C;>B>A
MCD+IT!.1MG@82R0S@KN(L,1&SD4Z(9,Y',;+,T7[%P0Z1U$CE6:N"FQDIC%S
MC/R9SCY1X"XGAUWA&)7&$W[59?6L\D,C5JBMDC<K'M5%1%2CFJFE$7RH<G30
MR6\SX)4I*QRM5/(J+14]*$3_ %M=IHT#@[8:HFZPC*[@NU,HC---3)'>6$?)
M?/N:7(4ARG\CRSJ.&JYLX,3NO"IF_A,#M+^7UDZ3,WS#VN,N9M66!8?=7CE5
M/5VWQ]#B1:I3:VKGG&)H6L2N3[JFR=TF'+>YOCN52L=K"^1?)54YMOUU?M)_
M=KP&L?P^^L\1>H][;=<,L$<7&_05$CGJF<94-'T6"--/2MB9)@R399]>"E4/
M@V2K*-\%SC&41M[^9OFY;S.^7,CQ25BL,-FO'L35MWDW--VEKI<C+151%2K6
MO5?US(=]N(<YB=GAC5]6*%TBIYY';*5\](_J1?.3+<H- 5?D_HK8>D[65-)I
M<851*)E<IX.M7;0P4)(UBQ-L]TRA5(B;;(J*%+V970PHB;\A0V,\&;G]YF,;
MH-XV%[P,%JL]A<(LD=:)/;O167$#N"DL3G-15^X_9D3UF(J:JR]C5QE[&(,6
MMOO1/]9/ZS%T/:O]YJJGF6BZT0J&=/3D-9. 7,Y_3=JF4K50F[ [TWO".?JG
M295]S'S*S"-N"YLD[F4Z;/8RL9Q@IN]%.'?A_*J7(]P_F@W7X5\R^X2+'LF(
MEWCEO;-Q3"7L1%?,U\2/DMDX:W4-&HRJ4N&0[7W%0Z>SQ@<&=<J-N\-_:73&
M)/;JFMR*VJL_>-T4_KHVNHNV)*I+I)KH*)K(K)D5162.51)5)0N#IJ)J$SDB
MB:A,XSC.,YQG&>W _/H]CXWK'(BMD:JHJ*E%14T*BHNE%1=:')"HJ+1="H4_
M]B]0;1_(KE+*W3F;'[3N.@]2V:13T?H+5$15I>BS:["0<M&UNV6_L=\J*D\Z
M>M$"+*H)HJI.RK>!DZ;(JK9W[EY6^6+>'NMW.0X!N$EP:PWE8W:,7%L9Q&6X
MBO(D>QKG6U@R"SN4A:QRJUKW/:Z-6\YLON%9+#U!89(Q? LN-M,J.MHL:N8T
MZ1<S.>V1M4159$C8W[*(JT155%;3:HKZ.;)NVZ^7#%FW0:--7<D6K1JBDV:M
M6U)U4@W;-T"%210012W&5-%%%,N"E*7&"E+C&,8[!R)+_+5W]SRNGGQC*CYG
MN5SG.N\15SG*M5557"ZJJKI55TJNE37SMR^:W.5SKBP5RK5562:JKY5_8$+O
M5*YWT/G%?=5R>L(.]P%,UU4)IAEIL!E!1DJK9[+,IN)ERT85VRVJ/Q'FBH:-
M*58S@BRBA#E,G@J9#'[[^3KY<,R?+QEO&;3-]QAMSC^*WT3]JR?-)&EO!$K8
MFN?/!;OV^<EG56HQ6M:K51ZJYR-VQNZR;>Y0LKF/$'PONYY6K6-7*FPQM&HJ
MN8Q:U<_12B)33I5$G-Z=74;XV[$;:&X;ZIU_NYE8JWK)G GG[#6:*RJ2!Z'2
MSOK!.RKZ)V/,2Z2<[)1RF$SD8&RH]>IX.5,IC&)YU_-+\JV]?*TN9-^^=,3R
M])A5WB[IDA@N+Q]RJ7ETC(88V26,42K#&]NTBS(C8HGJU7JB([3V>LB8_8NO
M<U8E/:+!)<*[9:^17_M)*-:U'1-;ZJ*E?6T-:M*TTQ.[%Z@VC^17*65NG,V/
MVG<=!ZELTBGH_06J(BK2]%FUV$@Y:-K=LM_8[Y45)YT]:($6503152=E6\#)
MTV156SOM3*WRQ;P]UNYR' -PDN#6&\K&[1BXMC.(RW$5Y$CV-<ZVL&06=RD+
M6.56M>Y[71JWG-E]PK)8=E6&2,7P++C;3*CK:+&KF-.D7,SGMD;5$561(V-^
MRB*M$5516TVJ*^CFR;MNOEPQ9MT&C35W)%JT:HI-FK5M2=5(-VS= A4D4$$4
MMQE31113+@I2EQ@I2XQC&.P<B2_RU=_<\KIY\8RH^9[E<YSKO$5<YRK5555P
MNJJJZ55=*KI4U\[<OFMSE<ZXL%<JU55DFJJ^5?V!"[U2N=]#YQ7W5<GK"#O<
M!3-=5":89:; 9049*JV>RS*;B9<M&%=LMJC\1YHJ&C2E6,X(LHH0Y3)X*F0Q
M^^_DZ^7#,GR\9;QFTS?<8;<X_BM]$_:LGS21I;P1*V)KGSP6[]OG)9U5J,5K
M6JU4>JN<C=L;NLFWN4+*YCQ!\+[N>5JUC5RIL,;1J*KF,6M7/T4HB4TZ51)S
M>G5U&^-NQ&VAN&^J=?[N96*MZR9P)Y^PUFBLJD@>ATL[ZP3LJ^B=CS$NDG.R
M4<IA,Y&!LJ/7J>#E3*8QB>=?S2_*MO7RM+F3?OG3$\O285=XNZ9(8+B\?<JE
MY=(R&&-DEC%$JPQO;M(LR(V*)ZM5ZHB.T]GK(F/V+KW-6)3VBP27"NV6OD5_
M[22C6M1T36^JBI7UM#6K2M-,T(X%-4%*NL.VW,3K#L9,[QO)UZS<G',NQ<D6
M*X:RVO\ 3Z[B1AD2+*9[IT)6CZ_12QW<]F"J=A/_ #1[_8O!+N*^162S;&Z'
M$[3*#8GM5-ET=[B:-9*JHFIT=W>O=IX6U=PG65PUV5MUJQHBMGCP]&JFI6R3
MHB.^M))%7ZM)=4'@"<FFM')7B;J+EE&T*!W*VL,O6J!<D+NSK45.K0\-/R;=
MHNP*TLR3=$SE]&F9.EDLX15;+E(LI@BI>^;MVWNFWU9XW*7>)8ED)]K!BV)V
M"VCIY(4EEAC<Y'[5NKEV6/VVM=5[9&*K&JYB[*&08!F7$\M23384K&W$\2QJ
M]6[3FHJUJRNA%JB+I14T)5-!L!7Z] U.%C*W5X6*KE>A6B3"'@H./:141%L4
M,=U%G'QS%)!HS;)8_P $B9"EQ_Y!K/$\4Q+&L0FQ;&+B:ZQ2X>KY9IGNDED>
MNMSWO57.<O"KE52R3SS7,KKBX>Z2=ZU<YRJKE7RJJZ57Z2"SKUZ7I<SQ\I.\
MO-K%GL*D[ AZ>6<2032?3-1M3"94<P3]=,I57R<=+1J#IIA7)\-<&<X3P7QU
M.]Z+?RVL_8_8;SL0W=\[))EC$,,EN>9555D5S;OB1LS$70Q7QO?')LHG.4BV
MJ\VRFXMS.+7<6-S8/M*MC- Y^S70U[%;1R)P5:JHZFOU:_=0^AT";K8YSC'L
MVGRKEP[@Z+MM?%6RN=4Y8YK9J[%2LK#L^]^]),DY=-5[X9?EPN_5-G_#P/F_
MF69?PK#M[N$8[9,:S$<1P1.D41$VW6\\D<<KN%7K$K8JK^I"QJ?=4I[Z;2"'
M,-O=1HB336R;=.%6.5$<OGV:-KY&HG 1!\A817C1U?5[-<$O-T ERQI>[S2+
MPWA,W%.NU_BM@/Y-N[4.5'+=DE)NT#J=[N(N&JA#?P9BX[CW88@S>U\C;<(P
M)>=Q-<E76$[#=+FW5I9263(W-1*[3UCC>B4JYDC7)]Y%-H8',F8-UZ6]KZT_
M9LEO1-:/CC6-$5/*M$7SHJ+PEU4IBF+@Q<X,4V,&*8N<9*8N<=N,XSCY,XS@
M> *HJ+1="H<FD.76MY(P.I^*,MJ!K)M\["WRZ85V.BD5D#OV%*BI1E,6ZPN6
MQ\Y,G&N4H].)(;..TZK_ #E/MRBH8G=O\O\ W4XEG7?1!GF:%WA?+;'SOD5%
M1C[N2-\5M UR:Y&J];E4K1&PHCOOM1VT]TN S8EF5N*.:O0;)%<J\"R*BM8U
M%\J5V_H;IUI7JO1)XD3VCM(V/==^BEHBY[YS".H")>I'2?Q&LH9)RYKSIRDI
MW3M7-O>RBS[*6<?*R39GSG!C&(2\_P P;?;AN\/>%:[O\M3-GP#+?.MFD8J*
MR2_E5K9VM5-#FVS(VP[5?\5T[42B(YWT;V\S0XQB\>$V3D=:66TCE34Z5U$<
MB>5&(B-K_65Z>=8A>MGKJ;H'.J6V&LS4Q%;6J%!N$(^4*H=BY>5*!C:#)Q^%
M"FP7RED>I(*+)8R4Q4G21L]F%"YSW'_+[S3A^9?ES@RO'(G3<%OKRUF8BHCV
MMN9I+R-]/ZKTN7M:Y45%=&]/U51-G[I+Z&]R<VQ1?VEM+(QR<*(]RR(OT+MJ
MB+Y45. N&TNV1%\I]4O%?<I/(*XUR$M$,Z06371<1<_&MI1@LFLEDR2I%&KH
MN<&+GLS_ '!X68_@M]EO';W+V)L5F)6%W+;RM5%16R0R.C>BHNE%1S5T+I.7
M+NVEL[J2SG14FBD<QR:J*U51?M0TMZE/)&!XV<2=I3;J3;M[E>ZY,:WUO%X6
M0Q(R%HMT<XB#23)JKG/C-ZG&NU9-P8Q<IX*V*GGM.JF4^_?E-W4XEO8WVX/A
M\,+G8#AMW%?7TE%V&6]L]LO-O<FIUS(UMNQ$7:K(KD]5CE;EF0<!FQ_,UM"U
MJK:PR-EE7@1C%1U%7RO5$8G#IKP*13]"#B1/1![;RYNL4M',)R$=4'4*+U(Z
M:LJP7D45KG<4$S]W)&)7$4C&,EL=OC9\MQV8*4AC]G?S'M]N&WS;+<AE^9LM
MS;W#;S$U:J*D;T8J6MJJI^OLR.N)6Z-C_=]:JY&[(WR9FAE2++%HY'/8]))Z
M<"T_9L7ST<KW)P>IYZ63QY.F@P
M#AG^%)_DU?W20CP YB             Q_LC4NJMQU]>I[>UGK[:E5=-W[1U6
MMD4RN7BON6DJR6C91LO#6>-E(Y9O)1SA1NX(9/)5D#F(?&2YSC)41=8-=:=T
MYNGMKN=;6G7_  1X:46S,TUD6EBIW&#2-8G6J3DF4G"3:7A*.QD$$W">>Z<I
M5,8.7Y,]N!#9:FI$%$-RA$  :[;BX@<2^1#]I*\@.+O'7><I'_\ NA);BTGK
M39K]E^\IMO\ -'EUK,VX;?YND5/\@Q?R"X+^QC&!!41=:"B'<M1Z&T;Q_KQJ
MEH;3.J-)50YN^:LZCUW4-;5XQ_*Y"0[QH6FP\-&Y-Y?+.E^W*?;XSE4_^$H?
M.8HB)J!E<         &H=EZ?7 FZ7=?9MQX1<0[9LAU),YESL&R\:],SMW<3
M$=E T?++VR4I;J>6DF!FJ645S.,JI93+W38[N.R&RWR(*(;71<7&0D9'0L+'
M,8B'B&+2+B8F+:-V$9%QC!NFT81T<P:)I-63%DU2(DBBD0J::9<%+C&,8P(@
M_< /ES<'"V6)?P-CAXNP04JW.TE(6;CVDK$R313L\1J_CGZ*[-XW/V8[2*$,
M7/\ Y !IN^Z9O3>E)UY:)+I]\(I&S2,LXGY"Q/N*.AW<Z^G7;P\BZFGDNXH2
MD@YEG,@H9=1R=0RQUC9/DV39SD0V6^1!1#<*NUJNU"&95RIP$+5Z]&E6)'0-
M=BF,)#1Y'#A9VN5E%QJ#9BU*N[<**GPF0N#*',;/;G.<YB#[0  #KMII]2O,
M0I7[M5Z[<(%99!PM"6F$C+!$*N&I_$;+J1LLV=LSK-U/RB&R3)B9^7&<9 &H
ML#TS>F]5IB.L58Z??"*N6"'=)OHB=@>*.AXB8BWJ.>U%Y'2<?0F[UBZ2S\I5
M$CE.7^YD0V6^1!1#=".CH^(CV,3$L6<7%1;-K'1D9'-4&4?'1[) C9FQ8LVQ
M$FS1FT;)%3223*4B9"X*7&,8Q@1!^P
M      =1O6OJ%M"L2=)V92*AL2F32)V\Q4;U6H:W5B6;J)G240DX"?92$4_1
M.DH8N2JI'+DILX[.S.0!AK3W#+A]QYF7=CT#Q1XUZ-L+\J)'T]I[1>K]9S+P
MC=O(M&Y7<I2ZM"/G!4&DN[2)@Y\X*FZ6+CLPH?!H(B)J040V3$0
M                                            '%3^#/\ M#?N<B*:
MP<A
M                   &74_X,G[0O[G ^-=92.8@
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MN<OE<Y55?.IS7++)-*Z:55=*]RN55UJJK557Z5/I#Y2F
M
M
M
M
M
M
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M\:/_ &"-6_R5&J?S]W[?C7-O_P"6,0_B"P^+,T]YXA\1-[8^Y;PY_";QH_\
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MU?W20CP YB
M
M                                    .*G\&?\ :&_<Y$4U@Y"
M
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M0U/HTKK55729\&N2S
M
M
M
M
M
M
M                        5T^+W_$"]9/^8/IX_P!%]B%:'A)FZR<P5R<
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M9KE:5,S;Q+C%;!,"P2%+# &MV=AJ^N]J?JN5*(C5X6I7:T[3G(M"6$<6&M0
M                                                #AG^%)_DU?W2
M0CP YB
M
M                                .*G\&?\ :&_<Y$4U@Y"
M
M       ,NI_P9/VA?W.!\:ZRD<Q
M
M
M
M
M
M
M
M !73XO?\0+UD_P"8/IX_T7V(5H>$F;K)S!7)P
M
M                  .&?X4G^35_=)"/ #F(
M
M
M  XJ?P9_VAOW.1%-8.0@
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MPZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\
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MSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2
M>*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\ 'CT@'BG*7X>M_B9N(=/L.ILY
M;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'B
MG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[
M,_JD>_CWKZG_ !X](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIR
ME^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/
MZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_P >/2 >*<I?
MAZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J
M1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW
M^)FXAT^PZFSEN'LS^J1[^/>OJ?\ 'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>
M_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B
M9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CW
MKZG_ !X](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;
MB'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^
MI_QX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_P >/2 >*<I?AZW^)FXA
MT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?
M\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^P
MZFSEN'LS^J1[^/>OJ?\ 'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'
MCT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.I
MLY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_ !X]
M(!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.
M6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!X
MIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_P >/2 >*<I?AZW^)FXAT^PZFSEN
M'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<
MI?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS
M^J1[^/>OJ?\ 'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7
MX>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_J
MD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_ !X](!XIRE^'
MK?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'
MOX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?X
MF;B'3[#J;.6X>S/ZI'OX]Z^I_P >/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^
M/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)F
MXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>O
MJ?\ 'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(
M=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG
M_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_ !X](!XIRE^'K?XF;B'3
M[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_Q
MX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J
M;.6X>S/ZI'OX]Z^I_P >/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/
M2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFS
MEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\ 'CT@
M'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;
MA[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG
M*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_ !X](!XIRE^'K?XF;B'3[#J;.6X>
MS/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE
M^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/Z
MI'OX]Z^I_P >/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?A
MZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1
M[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\ 'CT@'BG*7X>M
M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_
MCWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9
MN(=/L.ILY;A[,_JD>_CWKZG_ !X](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]
MZ^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B
M'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I
M_P >/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT
M^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\
M>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\ 'CT@'BG*7X>M_B9N(=/L
M.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'C
MT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.IL
MY;A[,_JD>_CWKZG_ !X](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](
M!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6
MX>S/ZI'OX]Z^I_QX](!XIRE^'K?XF;B'3[#J;.6X>S/ZI'OX]Z^I_P >/2 >
M*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'
MLS^J1[^/>OJ?\>/2 >*<I?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\>/2 >*<I
M?AZW^)FXAT^PZFSEN'LS^J1[^/>OJ?\ 'CT@'BG*7X>M_B9N(=/L.ILY;A[,
M_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X
M>M_B9N(=/L.ILY;A[,_JD>_CWKZG_'CT@'BG*7X>M_B9N(=/L.ILY;A[,_JD
M>_CWKZG_ !X](!XIRE^'K?XF;B'3[#J;.6XTEZ86J=NZ;ZTO5BH.[.1-AY/[
M#K^B.$:EBW%9Z16:!,7-.P5&?EJXB\K%345A(LM,B"YCD<H&SETF;Q5>PXL^
M+XM@^)-8W"\.CL',5=I6RODVZTHB[>K9HNK74^:XN+>>B00MB5-='*M?3Y"R
MF+(?,     :M\S.8VB>!O'F]\E^15J+6=>T=JD1-LU(B[LURLTADZ5>HM(A5
M%VQYZWV1V3*;9O@Y$DDB*N7*B#-NX<)054:E5U!5HE2&#I"]17JO]4&Y3F_[
M3H?C#QHZ>*=EF$J#)V*D;@L^_=L139\[9H0='LAMQURDNTX,[?*4M;%:V2+\
MN(9LRCG2A766<C7.=IU-)455^@L([#V+0=24BS[+VC<ZQKS7M+B7,];;M<IN
M/KE8KD.TQC+B1F9J5<-6#!JGDV"]Y0Y>\<V"X[39QC-35I4F*I7+#XPO@GIV
M=EZMQIT_M?EE(Q!G2'SMR_8Z2U5+.T7C5NDG"6.RP]JOKQJ9##I0[A6JH(]J
M:&$<KD7.HWI+*U-6DEVD-;=3?&L:6F[&FSWAP-V7K6JG69)YG]8[QK6Y)A%)
M54Y'RZU;LVN-(MNZS2[IR%)(G,MVFQV$[N,F@DR<*#:+;?$7F1QQYU:8@M]\
M8-EP^R]>32AV+E=EA9C/56P-D4%I&I76M/TV\U5+3&$<)F5:.T4S'143<(Y5
M;+(K*545%2J$R*BZC9X1         5HNO_UI.1G2]N7$?5'$_7.F-G[1Y"FO
M[VP0VWZ]>K*1A&0\K1ZW0FE:CZ+LC7#DLE;+%8)%+)W"ZZ>,,"E*3&39-BF]
MZMHB$%6A9)@RS1(6')95HMS8R1<>6?<0;5VRA7$T5HCB56AV3]W(/FD6J^PH
M9NDLNNJFEDI3J'-C)LU")]0 0$]0WXC3@WTUN2$IQ<W=KKD]=MB0E2JEOEI'
M3U*U5/51BUN#-:1BHM9_==U:_E_/!(XB:ZQ"L3(%3<)]U4YLF*21TC6K1:D%
M<B&CG]LNZ8/_ *B>>?\ [&''O]:(2\\WSD-I!_;+NF#_ .HGGG_[&''O]:(.
M>;YQM(9JXX?%:]/OE)OW3?''6>BN;:=^WALFGZPJCJQ:[T.PKD=,7&;9PC:6
ML3Z/Y)2TBSKT/Y7ET^5;M';A-JBH9)!93!4S125JK321VD,C<X/B;NG_ ,"N
M3^S>)^TM=<J+UL/4JU;9VR=U'1]0SU&Q)66HP-R2BXZ6MN\Z/,NGT3'V%%N^
M*:/3(@](JE@Q_#R81=(UJT6H5R(35<5N2FMN8G'33W)[4)IK&N=UTB*N]9:V
M5DSC;-$H2!5$G]?LK".D9B,:6*N2S==@_(U>/&A7;93P'"Z7<5/,BHJ53413
M29!VOLJKZ8U;LK<-X<+-*5JB@7'95O=MRMSN&M7HM=D;18'"!73EFU,LC$Q:
MQBX4623R;&.\<N.TV(JM$J#0'IA=5W0'5AH&SMF<>->;UH]5U7<8NBS+K=M:
MH-<5F;!)PI9]1O7"479>R$G:<5'+MS.LN3M#$R[2[A5,9-DLK7([2@1:FM/4
MH^(,X4]+??<%QSWS0^1U[OLYK* VIEUI*I:MLM>AH6R6"UUZ-B)QW=MR:\E&
M=E,>HJNSMR,U4L,G393"V<J9(2#I$:M%(*Y$(^/[9=TP?_43SS_]C#CW^M$)
M>>;YR&T@_MEW3!_]1///_P!C#CW^M$'/-\XVD)0.HOUR>)?3$K_&Z;Y":_Y#
M3SWD[4K%<JA5-7536DW:J?%5IE1W;Y+8T?;MMT9I"O'"MZ1;-RLG$DFJY8O"
M]_&$2F4G<]&Z^$BJHA%__;+NF#_ZB>>?_L8<>_UHA)SS?.0VD)*N"/Q _32Z
M@MZ@M2ZHVC9]=[FM")3UG4V]*G\PK/8WGAN%EX2O34=*6?7L]8VZ3?O^;V<V
MN\7(;O-TUL$5RG,U[7:$UD4<BDUXG(@ 13]3;K$\3^E,TU*3D%&;5OEKW1*2
M[&FZXT9"4FV7_P W0B;?#VT2D'<=A:^1:5HTD]08(+$<*K.7JOAI)'PFN9*5
MST;K(*J(2F1SI1]'L7RS!Y%K/&;5TK&2/DGG".4<($6.P?>0.GS'RQF8^4U?
M!762[Y<]PYR]ALS$3]@    (N^I_U;N,O2:I6J[KR/KNW;>CN&T3U6J%?TS
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MIYJF3!\I(
M
M
M
M
M
M
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MF4U;A&O3%[^<GP7.,&SWNT5&K5J*3)J-VA$
M   !PS_"D_R:O[I(1X <Q
M
M                                               '%3^#/^T-^YR(
MIK!R$
M                     9=3_@R?M"_N<#XUUE(YB
M
M
M
M
M
M
M
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M1_<0-U$P@F(@                           !PS_"D_R:O[I(1X <Q
M
M
M                       '%3^#/^T-^YR(IK!R$
M                                                         9=3
M_@R?M"_N<#XUUE(YB
M
M
M
M
M
M
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M?W20CP YB
M
M                                   .*G\&?]H;]SD136#D(
M
M         RZG_!D_:%_<X'QKK*1S$
M
M
M
M
M
M
M
M   %=/B]_P 0+UD_Y@^GC_1?8A6AX29NLG,%<G   "AW\6O'26DN;W2WYEJQ
M,@]K-4<.(Y^[8&R?NR6D=N4_:C>)_*QANSD)2/M[@S7)S8RX\G5[/D0-G%&7
M0Y%)7:ZE["#FXFRPL/8X%^WE8*P1<?-PLHT/XC22B95HB_CG[53LQWV[QFN1
M0F>SY2FP*Q,?/N=.J^PZ?:Z!=X./L]+O-:G:=;ZU+(8<Q5AJ]FBW4+/P<FVS
MG&'$?+1+U9NL3/\ AIJ9Q_= 'GH[SZ%O5OZ0_+&5Y/=(F;MNW-7JN'^*^6E/
MZZ]V9$4F4?HRCC4VX]2VAT5EMJO-EV:*1'4<A)%>F:HOCMHUX5,J5!6/8M6:
MB2BHN@SQ&=9+XJ;846QUK7>EH^JMKDHU!BWV=)\$>4%,E$G4.T*_?3+Z<VGL
M%'2\7)32$:J4Y'4:DS46<91:()K';D*VY=5/L(U<9%XA_#D\V>;7(EGS)Z[>
MX):WNT7S9[GCZVO,39;9:T(]<CUC5K-8M<NL:VU/JS"ZA^]!4U;*JY%%2)J1
M9\^*>*1JJU>$:JZ5+L,BQ4HNNGT9K&G19U:=2G3'7NOH-"(KD*92O09V]3IT
M.V,XA8&!BS&9MV3<F56C-JEW<=]),O:6M]!,53OAI.E-S2X2[:YK<BN>VID]
M:[6W(SH]=H;@^P=4; D+ PF++<;SN"5=N-6W&ZLHE.0LB%=,1-==N=8Z2F<)
M&*0IL4HVJVJNUDK45-*EN4528H@]>SI6=0S7/4EA.K7TZZ/<]I3+U]K.[3,;
MJN$3N^R=:[;U35X2F,WI=6^#)RE^I%QJ]49>.BQ82*2BQGC9\W*BNCEQ1>UV
MUMM)%1:U0R#J3G?\6;S9C6FI:/PPUAQ#75,A$S_)#;?'S8.B)*O-T8Y%@]L3
MN.Y$7:X1\R5=Q+(NSEK5&E7.7"1O)6V$4'*1".E=HI0C5RF'N*W00ZEM5ZX.
MGN27*K-JY!Z$U=L^*VG:.7^Q]H:LE9R_W"CZU/9JV]B=<9VM:MJQ<"AO%JUC
MX1NXC4#,8ENBLHDU*3PB$8[;JNH@B+4G"^)/XG<VN<'".@<;^%.ES;>G)_?%
M<N>T2_6%JN@)PM'I-9M*D:V\?:-XH[.06E[C,1ZI<-%7"B16!^^0N#E-B>1%
M<VB$SD54T$IW3JXXON(G!/B;QMF6K=G9M1Z*U]6+NW:+-7+0NQ/,362V*HU<
MLEG+1RW7O,A(*$4344(<IL&P<V,][,S4HU$(IH0W.$0 !TO9,G<8375^F==U
MOYY; B*5:9.C5#RV+C?G5<6$$_=5FM^<9R2AH6/\^322#7QWCQHU2\7O*K))
MX,<H%3KX8[I(\S.!6RN8&\N<NIT]9;!V97]?TC7.76P]7[*F[!%.I^SV_:,L
M]EM9WF[MHU-U-L:_VD=JI+NUB'/W>Q+&34HVJVJN)6HJ:RWR*I,5".O%TP.=
M/4KZD'!-*AZ"+:.$6GFM#B=M;1>[.TY!I1:5_P!Q-WN\W2='G]B16Q9=C :R
MKD2?!6<0LN\7*JDW*J;!>VD]KG.3R$JHJKYBWJ0A$R%33*4A"%*0A"%P4A"%
MQ@I2E*7&,%*7&.S&,?)C JDQ$+UT^"=LZAW3<W/H?6%=;VC=L5(4_:.CXAS)
M5^%*]V)1YQ$ZD4G,VF1AH")<6:D24U$)N73UH@@>0P=17">#%-*]NTVB:R"I
M5" 3X:#HG\VN"G+_ '!R)YL:%;ZG;L]$O=>:E56V9IS8:DA9;I<*W(622:(:
MLV#=W$2XB:U53M,J/"MR*I2IRIY/GO\ <IQL5JU4@U%1=)NO\3]P<ZA/4(UK
MQ7TCPMT*XV]2JC>;YM3;4@;:FFM>M(NTLH",J.LV:+':&QZ2ZEW&8FRV4ZJK
M=%9-N4Z9>_C*ABB:1'.1$0.15U%@_AQHEMQ?XF\:^.K8J>,Z3T=K#6;U5)7"
MY7LQ4*=$0T[)Y7+V$64E9IJX<G,7!2&.KG)<%+V8Q.B41$)DU&R(B"!7XC#C
M5S1YC]/PG&7A/J%QMVV[*W+K]WL^.+L'6.O&D5J^CEE[IY0L^V=>*1'2CASL
M2%K^$FS=1P?!4U%3%+X9<YDD15;1"#JJF@VBZ+O#NW\$.FGQCXX;*@DZWM:N
M5NP6C:\*28A[ :+V#L2XV&\SL,M-5U_*5Z44K>)Y*+PLP<N&BA&1<IJJESXI
MXL39:B+K")1"3J4BXR;C)&%FHYC+P\NQ=Q<M$RC1N_C)2,?MU&C^.D6#M-5J
M]8O6JITED52&343-DIL9QG.!,1*,=&Z/?4]Z275VD.1G3-T4^Y!\([7)(.;-
M1F^[M*4!T\T_>)([FZZ+F(?:^TJ%)/[/K%\W\KJLOE)VSSA&,5<.%%LR+8M'
M8<U]6ZB6BHNC46G^IW+<]FW"?8QNFO5E)'F/,O* RUT5X^TJW/46*]R@7M\F
M'9-VRR6JI)PTI;5^R*BX4=X\H=$40(IE/!L57;5/5UDRUIHUE*+EOPX^+TYU
M:A7T/RGUZML_4[JQ0EK=5)*Z],RAD<SM<,Y/"NW$SK6UTZPKHLE'9SX;G=Y;
M'4[ISIF,F3):*I*Y*+J^HDHY3N/&_CA\8SQ+TQ0^.O'JEM=:Z:UNUDH^F5!"
M7Z6%A0@VTY8)6SRYU9JU2MBM$JL_L$Z[>++.W;E<ZJYL][/R8!$E1*)J^H>L
M6R>KKQBYC\GNFA>./'%J[1*W).7-I5XZN<K9<:PD[ ZUG>:??)Z5JMB@(QI'
M5*W3,_44'#7)/-C-'!E"%5;E[F!5>BJVB:R9454*K5#ZD'Q9/#%,NH]E<&=C
M\IWL&Q.R96:^<3]E[\40:LY%S%DR;;G$NS0,!;GQ%8E7L<R$G)O'3=4CDZBJ
M:[=8U+:E312I+5R'9;CQ1^(EZ^<I0J5S@K,#P5X<1MFA+C/UQU2E]:HX<$:%
M+F18::L%JLN\KO<HV,>J98LK3(1\,R=JG[5VRY3XPI))][0@]9=>HL*=2C@G
MM2J]%*V].OIMZ><7R=/1M:Z3IM6=7>A5)\G1F]W@9[9=OGK)L6RTJM/YRR14
M=(G?9PZ25<2,L=9-')<9)BHYOJ;+294T40RGT'^$.Q^G_P!-+2VA=TUU&I;M
M7FMB["VW7&\Q6["C"VFY7267C(O$[4I.;K\JM&4=E$-UEFSUVD9=(_<4[F"E
M+%C=EM%UA$HA(%RLY1:=X8<?MF\E]\V5.KZRU97U9N:=8P1:2E7JJJ3"!JU=
M8G41\Z6BV3KIO'1K7!B^,\<IE,8A.\<L55$2JZB*Z"HKT%>/FW>IUS_WMUY>
M64&HRK?SLLU/XE4Z0)EQ%M91G&GI&)"OI/$2(N:EI*@9Q ,GJ27=DK.X>O,G
M(_CW&3TF(KG*]25-*U4NWBL3                              '#/\*3
M_)J_NDA'@!S$
M
M                                      <5/X,_[0W[G(BFL'(0
M
M           !EU/^#)^T+^YP/C764CF(
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M5-:*BZ45.%#]P^<D
M
M
M
M
M
M
M                *Z?%[_B!>LG_ #!]/'^B^Q"M#PDS=9.8*Y.   $,G7IZ
M?#KJ+].K:FL:=$FE=VZM61WGH=NV;E7D9:_T6,E2.Z2SQCN*J+;$I\I)0S=/
MQ"(XD7;193MPAC E>W:;3A(.2J&'OAVM]\I+IP;JG'/F3QPY,:)W/Q9C8O7,
M-/[VT;M36,-M'4#1([76LE7K'?*S"QLQ8Z=#-<04DQ25.Z308-7AN]AV;PX1
MJNS1:U0-U44G\$Y$
M            #I>QKW%ZQHMIV!-0]UL$74H=W,O(/7-#N&SKU+)M2XSB/JU
MH,-8;A:9ATH;!$FK%FNJ;.>W.,$P8Q6H%*S9FA.I'\1=S6@*[R:T+R&Z?_2S
MX[65"Q):]W#1K=JC9&U^\X.D1VC#VV*BU+3M6XQ22K4L@BB[@*)&++%14<O5
MCXEJ-'2+IT-)-*KIU%TW6&L=?Z6UY3-3:IJ,+0];Z\KL74Z53JZT*RAJ]7H9
ML1I'QS)#&3'R5))/M.HH8ZRRF3**'.H8QLUM6A"<[T
M             .&?X4G^35_=)"/ #F(
M
M                                                         XJ?
MP9_VAOW.1%-8.0@
M                              #+J?\ !D_:%_<X'QKK*1S$
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MK5=1$15V52JHB(JZD34;#C699
M       *VO6YZD'5_P"$^Y-,T[IO\"_O;Z^N6LI*S;#M7W7.3^^OFK<FUI?1
M;.O^?-$7FJ0D'Y1"().?)'R2KH_?\0IL)YQ@ 5LM-?%E]=#D9;Y77W'O@;QD
MWO?H.#?6:;I&FN+W,#9]OAZW&2D7"25@E:U2.1TY-1\''S4XR:+NUD"().GB
M"1CX453*8"]UTX-V<D.1O";0>ZN7>H_J(Y'7VNSTCM'4OS"OFK_F7+,;K9H6
M,8_,/9TM.7NN^65R,9._"D7:RJGE'BDSA)0A< 5,^J3\2OU-.)/5)WEP!XJ<
M<.,FY6-,MNKZAJJ$EM0<@-B;GO$S?]3Z\N_F9*-UQO>MHV6<<V&W+MV3>-AD
ME3HE23[BBN#*' Q9[?3XIKW*_P#\+DZBGVQ@#]^H?C#.4>CMKPVK.J-T\C:O
M5.[43N+O64'LW3>QJA%FFG<9B;:Z0WR^L;^QEC%HQTT7;*6&+RLZ05R18ATC
M-C 7G-)[GUIR*U'KG>NF[2RNNK=L5"$O-%M# CA!"8KL^S3>L5U&CQ%N^CGJ
M15,I.6KE))RT<$.BL0BI#EP!6]^(\ZW/*SI 3G$6,XU:_P"/=X0W[%;O?7$^
M\JIL>RK1JVM7FJ6\$6M&H.V-9D9INR7EWEWAT5YE3*:/AY2[I\* 0_U_XA7X
MGRVP$):JKT<HBS5>S1$;8*W9*_T]NH/,P%@@)EDC)0\W"3$;NIS'2T1+1SE-
M=LY0441714*<AC%-C.0/W17Q>?4%XVV"OU[J%=+-M3%UI5[%V$L5'[LXR6#'
MA.F:ZYZ_4MW0VR3NI6OPCY,Z[!=^GY8J=/.7#)-3&2@6J>F3UFN$/59J\DZX
MZ7>1@MHU:.;25\T%LUJQK6V:JS7/X!IAM%MI&3B+E5".^Q,TI"/'[9L95$CS
MR5==-'($K@              (1=N_$;]&/1.U-CZ4VES-;5W9>I+O:-<;!KS
M70?*&SHP%UIDR\KUG@\6"I:3G:S+*1$U'K-U%F+QRV,HGGN*&Q\H ^#4/B8>
MA[=YUM78;GA664@[3<JI.+?IODCKZ"(5H@HY5PYM%]TW6JRR4,FGG"1%G:9U
ME,X(G@QS%+D":?7^Q-?[9IE>V/JN\T[9>O;:PQ*U2^:_LT+<J99XPRJJ!9&O
M6BN/9*#FF!ED3DPLV753R8AL=O;C( @]ZU77,C>D19.,.OX'C6MRGV9R7=W4
ML=2F.X4]1N*O&U=_386&?+/#ZPV<:76N4_;3M&:/@M2E-'KF,IGLP4 3S1JK
M]:.8+2K1M'RBK)JK),&;T\DT9/U$$S/&C6149QRC]LV<9,0BYFZ&52EP;*9,
MY[N /V@       ,7;HW;J'CGK*U[GWQLFF:CU31V2#^UW^_S\?6JS#)/'S6*
MC4'$E)+((J2,S,/F[%@T3[[I^_<HMFZ:JZR:9@*Y6[OB]>CWJ287B*A/\B.1
MF&LCYN7E-(Z92:0^.XU\9=\@\WC;M*F?QR#K&6WBMR+>,J7OHX4;Y*N8#+?#
M7XI#I/<R=@0.K&5\V?QSOUMG$Z[3H;DW286E1EFEW2C!&,9M;Q1KELK7D.M,
MNGN4&A):6CCKKHF2P7Q%&Y5@+%8
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M+3Z5]V9LIRZ>HN8TA43-UFI"DR;!B'SG!L 6/@
M
M
M
M                       !73XO?\0+UD_Y@^GC_1?8A6AX29NLG,%<G
M
M                                       X9_A2?Y-7]TD(\ .8@
M  "NCUI.HEU;>&.W]/5#IV<%_O7T&X:VDK)L"T?=DY+[U^:UP;6=[&,X'SUH
MV[5:%A/'A4$W'DKU)5T;O^(4V$\XP*;W/1?52J$%54U%<W3_ ,55UNN0MME*
M#H'@SQKWC>X2%>V69I6G^,O+?9EMB*[&R<9"R,_*5RE\AYN880K"8FF;1=TJ
MB1!)R[12,;!U2%-(DKUU(2[2EX[IW;GY%<AN&&B=R\LM3_4;R'O5>G)#9NJ?
MF+>=9_,Z58W*R0T:Q^8VRI2;O%>\LKT:S=>%(.EE%/*/%)G"1R%Q6:JJE5UD
MZ:M)54ZG7Q'?4FXI=3K=O WBYQWXU[@94ZUZSJ>KH65U)OK8&XKK,7S5>O[I
MYG2CM=[QKJ5DFG,_;%V[)O'0Z2IT2I$[BBF#'/2=(Y';*4)5<M:&,/;N_$]^
MYK_^%X]0?[7PVY/)]BBKO(?NU+\71R<TGM.(U?U-NG^;6:IW2B=O=ZVA-E:@
MV'4HPTR[C<33;2N]'MA?6$L:M&N6B[92P1F57*"N2+$,D9N8DJHM'(-KREW'
M3&XM<<A-3Z\WAJ"SL[GK':E2AKM2+.Q(X10EJ_.LTWC)<[1XDW?1[Q,JF4W#
M5PFDY:N"'16(10ABXK(M4JA-K*[/Q$/6EY2=)*:XG1O'&A:!NJ&]XO=+ZW'W
M;5MB6-6.5UP[U:A!EKAJ)M36Y&:;HEW=Y=X=%>9/E-+P\I=T_B4Y'JVE"555
M")" Z_GQ+UK@H6T5?I"Q-DK-DB8Z?KMB@. 7/N8@I^"F&:,C$34++QVY7,?*
MQ,K'N4UVSE!11%=%0IR&,4V,YEVY/)]BBKO(?NB_BS^?/'2>@8#G[TPV].76
ME'L98"Q;#<_&N>QX3EHNN>!JFZ8?8QW4I 0KU,ZS!=^GY8J=/.7#)-3&2N=<
MGWD&TO"6B.FOUA^%G5)K,BYX]W20@]FUB/;2-YT1LEJRKFU:NS7/X!I=M&-I
M"2B;A5B.^Q,TI#.WS9N95$COR5=9-'-1KT=J(HJ*2F"8B
M
M                                             <5/X,_[0W[G(BFL
M'(0
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MFG)=JJFY>F/W3&=*J9R4N<]W &^@
M     #KKJH5-]:(>[O:O77ETKT5,04!;G4)&N+1!P=B7C'-@AH>?6;'E8R*G
M7,*S4>-T52(NCM$3*%-E(F2@=B %*GXVR UNKPFXAVB18QV=O,.4SR I\F9H
MAF6)K>6U+>I'8[%!]G'E)(Y6SPM5452QG*9E2)FSV9+CM F/^&R=6]WT1N!2
MMX*Y+-$I&S6K+#I,Z:OS09;[VNRUZ8I5/RLMC4%O&91-_@G1R4Q?DS@ 5//C
M']U6W=O4'X@\(*O++'A:%JR"L)(<S@R,9G;7(?8#^M$5D6R1,9=+1]1I<(9!
M93*F6Z<@N5$J?B+95 ]"3CMHC7W&#1&H^/&JHAM!Z\TSK^L:\JK!LCA'MC:U
M%MX_S@\_+54<2LPX2.\>N%#J+.7:ZBJASJ',;(%?3XM3C'6]X](S8>V'$3'+
MWGBEL#7.UZA,*HYQ+-8>SW"$U3>X5D]3R4Y(Z3A+LF_=-SYR@NK$-SY+E5%$
MQ0/Q?".<DY/>W2.K5!GY-S)3?%W<VQ]&H'?'RJ\^:+@D%M>GX\8QSF5CHUAL
MI2+:8SV>$A&81*7!$R9R!9<=5"IOK1#W=[5ZZ\NE>BIB"@+<ZA(UQ:(.#L2\
M8YL$-#SZS8\K&14ZYA6:CQNBJ1%T=HB90ILI$R4#L0 I4_&V0&MU>$W$.T2+
M&.SMYARF>0%/DS-$,RQ-;RVI;U(['8H/LX\I)'*V>%JJBJ6,Y3,J1,V>S)<=
MH$Q_PV3JWN^B-P*5O!7)9HE(V:U98=)G35^:#+?>UV6O3%*I^5EL:@MXS*)O
M\$Z.2F+\F< "<<  !2S^+]ZESS5>C:-TS]+2JSS;O*4L9:=TLX KMU.PFD8Z
M?(C5*:@G'J$<EE]QWR*REX*>%CJQ$.[;K(^'(H&,!-MT(>FRQZ8W3WUAJ*=C
M44=Y[)*EN;D9(Y21R[+M"X1,;@U,PY*GXQXS6=>:,X-(G?,BHZ:.G:>"9=J8
M $RP  #S\OA$?ZR'JO\ _O./_3Q;P!Z!H
M
M
M
M              KI\7O^(%ZR?\P?3Q_HOL0K0\),W63F"N3@
M
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MM*!W$'>:IETBJL1=2I7:)D(TYLF[V3M<][!3=I<5VKM)4G1:H;7"(
M
M                                                   #BI_!G_:&
M_<Y$4U@Y"
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MU4VJ(U%IT1F:\E9NO?<8FNU=R8="CU76LLC8VJOT[;JZ/IU%Z@?GO.1@
M#'^V;ZRU7JS9.SI'P,L-=T*WWEYARIE%N=M5*_(3JQ%E<?E$34389+G./E[,
M_)\HR3)N79\WYOPK*=KM=)Q/$;:T;LI5VU<3,B143A5%?4^W#;-^(XA!8,KM
MSS,C2FNKW(W_ "E*SHN4)[NWJ,U6ZV/QY96A1&Q-TV!P9/&2.9E1L: 8/W9R
M]W".4[;=FKHN<?LK)E+V=W.1[P_/9F*#(7RPWF X7LPLQ&>RPN%M=+8D=SSV
M-3AK;VLD:U_5<JZZ'5&].\9A.2)+6"C4F=' U/(VNTJ)_F1JGT*7DQ^?HY*
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M95K56BTJ1=DZ5UZA+)3S^BQ<DU\2,D]][T7;).9PS)51"IPAFI557)FD?YS
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M)S\;6++<()JY4D:^L=/#>2=%R@8F<F*;)B% VF
M
M
M
M                5T^+W_$"]9/^8/IX_P!%]B%:'A)FZR<P5R<
M
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MX][QD4BJ;O$8,%;PO,J-&^/_ #$3RDLY7SC^,6-G^Z$7W W46214(@
M
M                                                   !Q4_@S_M#
M?N<B*:P<A
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M15<GD0V)OLM%ER];7B:XKM$7Z'L=I]+6I]9<5'B$<Q@
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MY%R<Z[V0>KN'SYRH==PLJJ<Y\@9@
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M"-T$RG76.?.,F.;.0.[@
M
M
M                                                         *Z?
M%[_B!>LG_,'T\?Z+[$*T/"3-UDY@KDX
M
M            '#/\*3_)J_NDA'@!S$       !YL'P?W];1R<_W+-T?^)7C,
M/GB^^OT$C=9Z3X^@G/-AY5_\8A5_]]+AK_0]HT?.O^+]9)^M]9Z3P^@G/BV5
M]7HRNS\E;G,2SJD?"RKZSO)\[1*":UYHQ77FG,TJ_P X8IQ*$:FJ9R9;]ZPC
M@V3_ )/: /-L^$3;RSOJQ;^DM>)OD=7(<7]N>>,)^,E&DKK[<.ILT=H[(^[R
MOEV7*21VY39\JPFBOGM[F%NWYXOO>:A(W6;@_&T?]*NG'_U?Y4_^DN/@C-P!
MVLN=<"/]A?A=_NF\<_Z'Z<*S?NI]!.FHVR$04)_BZNH73-K+Z:Z8NBI=385_
MKVT8S9N]&%,\2:5BKHE#2E2U7IXJ,3ATXF+@^4N+V1D(LA<JM%L1A>Z=PH8B
M-&5U?50E<O 6M^D5PX?<"NG5Q@XS6!LU;WNH40]BVCAJHFX(7:.Q9F3V!?&'
MEZ92><D:_8+(M%ME\X_+9L4>S&"X+C%1B;+40BB40DA$Q$
M
M                                            .*G\&?\ :&_<Y$4U
M@Y"
M                   ,NI_P9/VA?W.!\:ZRD<Q        8KW5NO6G'K6UE
MVQMNTQ]2I568JNWS]\LF5P]<E244:0D(R,<J\S89=1/PF;)#!UW*V<%(7/R]
MF89#R'FO>7FFUR;DRSEO<>O)$:QC$6C&U1'2RNI2*&-%VI97T8QM5<I<<*PJ
M_P :OH\.PV-TEU(M$1-2)PN<OZK4UN<NA$UD%O2W<27//EMO_J+;4RW5-1)
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MK_>!:28WD.X= QSI^:CF:U$JOJN:]VC7]S:\Y?1'YV#CX
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M1)%,O(7$TQ8VK6=V;M%!=PIY+*N6S)E&+'460;N'>&S] "VV
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MC,YRQ79.-9X3<M71SM55\IIY.7&2@6Z@
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MF\:PEMA[]VCB7)FW5ZN;!CHJ0-2--5<ZR<>0C91JUD'<9AHL4T:<A0/0-
M   %/7X<WI9\\.!_-GJ#[=Y6Z*^JO7F\&1DM76#ZSM.7CYSJ9VU8[-@OFG6^
MPKA.0O\ R&_27[9%LTQ^7W/X3!B8 N%
M
M
M
M            "NGQ>_X@7K)_S!]/'^B^Q"M#PDS=9.8*Y.
M
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M!4)@
M
M   #BI_!G_:&_<Y$4U@Y"
M                                     ,NI_P &3]H7]S@?&NLI',0
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M8G-Q\M)F6D%<N'\I*["U?(R+U?.,%RL[>O-+K.7*N2EQC)CF-GLQ^R.KK/\
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MB;&G768,=ES#?)?SV]K;R["-5((^;:ZBJNTY%<Y7/6M%<JZD:G ;'#5Y8P
M
M
M
M
M
M
M                          KI\7O^(%ZR?\P?3Q_HOL0K0\),W63F"N3@
M
M                                         <,_PI/\FK^Z2$> ',0
M
M
M                        !Q4_@S_M#?N<B*:P<A
M                                                          &7
M4_X,G[0O[G ^-=92.8@
M
M
M
M
M
M
M                                                     KI\7O\
MB!>LG_,'T\?Z+[$*T/"3-UDY@KDX
M
M         '#/\*3_ ":O[I(1X <Q
M
M                                                      '%3^#/
M^T-^YR(IK!R$
M                            9=3_ (,G[0O[G ^-=92.8@
M
M
M
M
M
M
M
M                        KI\7O^(%ZR?\P?3Q_HOL0K0\),W63F"N3@
M
M                                       <,_PI/\FK^Z2$> ',0
M
M
M                      !Q4_@S_M#?N<B*:P<A
M                                                        &74_
MX,G[0O[G ^-=92.8@
M
M
M
M
M
M
M                                                   KI\7O^(%Z
MR?\ ,'T\?Z+[$*T/"3-UDY@KDX
M
M       '#/\ "D_R:O[I(1X <Q
M
M                                                    '%3^#/\
MM#?N<B*:P<A
M                           &74_X,G[0O[G ^-=92.8@
M
M
M
M
M
M
M
M                      KI\7O^(%ZR?\P?3Q_HOL0K0\),W63F"N3@
M
M                                     <,_PI/\FK^Z2$> ',0
M
M
M                    !Q4_@S_M#?N<B*:P<A
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MH>7>L2?I^['W_P#XLCW5'$[]'3'Z\X>'-SW>]YZ4_A1T/+O6)/T_=C[_ /\
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MH>7>L2?I^['W_P#XLCW5'$[]'3'Z\X>'-SW>]YZ4_A1T/+O6)/T_=C[_ /\
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MH>7>L2?I^['W_P#XLCW5'$[]'3'Z\X>'-SW>]YZ4_A1T/+O6)/T_=C[_ /\
M%D>ZHXG?HZ8_7G#PYN>[WO/2G\*.AY=ZQ)^G[L??_P#BR/=4<3OT=,?KSAX<
MW/=[WGI3^%'0\N]8D_3]V/O_ /Q9'NJ.)WZ.F/UYP\.;GN][STI_"CH>7>L2
M?I^['W__ (LCW5'$[]'3'Z\X>'-SW>]YZ4_A1T/+O6)/T_=C[_\ \61[JCB=
M^CIC]></#FY[O>\]*?PHZ'EWK$GZ?NQ]_P#^+(]U1Q._1TQ^O.'AS<]WO>>E
M/X4=#R[UB3]/W8^__P#%D>ZHXG?HZ8_7G#PYN>[WO/2G\*.AY=ZQ)^G[L??_
M /BR/=4<3OT=,?KSAX<W/=[WGI3^%'0\N]8D_3]V/O\ _P 61[JCB=^CIC]>
M</#FY[O>\]*?PHZ'EWK$GZ?NQ]__ .+(]U1Q._1TQ^O.'AS<]WO>>E/X4=#R
M[UB3]/W8^_\ _%D>ZHXG?HZ8_7G#PYN>[WO/2G\*.AY=ZQ)^G[L??_\ BR/=
M4<3OT=,?KSAX<W/=[WGI3^%'0\N]8D_3]V/O_P#Q9'NJ.)WZ.F/UYP\.;GN]
M[STI_"CH>7>L2?I^['W_ /XLCW5'$[]'3'Z\X>'-SW>]YZ4_A1T/+O6)/T_=
MC[__ ,61[JCB=^CIC]></#FY[O>\]*?PHZ'EWK$GZ?NQ]_\ ^+(]U1Q._1TQ
M^O.'AS<]WO>>E/X4=#R[UB3]/W8^_P#_ !9'NJ.)WZ.F/UYP\.;GN][STI_"
MCH>7>L2?I^['W_\ XLCW5'$[]'3'Z\X>'-SW>]YZ4_A1T/+O6)/T_=C[_P#\
M61[JCB=^CIC]></#FY[O>\]*?PHZ'EWK$GZ?NQ]__P"+(]U1Q._1TQ^O.'AS
M<]WO>>E/X4=#R[UB3]/W8^__ /%D>ZHXG?HZ8_7G#PYN>[WO/2G\*.AY=ZQ)
M^G[L??\ _BR/=4<3OT=,?KSAX<W/=[WGI3^%'0\N]8D_3]V/O_\ Q9'NJ.)W
MZ.F/UYP\.;GN][STI_"CH>7>L2?I^['W_P#XLCW5'$[]'3'Z\X>'-SW>]YZ4
M_A1T/+O6)/T_=C[_ /\ %D>ZHXG?HZ8_7G#PYN>[WO/2G\*.AY=ZQ)^G[L??
M_P#BR/=4<3OT=,?KSAX<W/=[WGI3^%'0\N]8D_3]V/O_ /Q9'NJ.)WZ.F/UY
MP\.;GN][STI_"CH>7>L2?I^['W__ (LCW5'$[]'3'Z\X>'-SW>]YZ4_A1T/+
MO6)/T_=C[_\ \61[JCB=^CIC]></#FY[O>\]*?PHZ'EWK$GZ?NQ]_P#^+(]U
M1Q._1TQ^O.'AS<]WO>>E/X4=#R[UB3]/W8^__P#%D>ZHXG?HZ8_7G#PYN>[W
MO/2G\*.AY=ZQ)^G[L??_ /BR/=4<3OT=,?KSAX<W/=[WGI3^%'0\N]8D_3]V
M/O\ _P 61[JCB=^CIC]></#FY[O>\]*?PHZ'EWK$GZ?NQ]__ .+(]U1Q._1T
MQ^O.'AS<]WO>>E/X4=#R[UB3]/W8^_\ _%D>ZHXG?HZ8_7G#PYN>[WO/2G\*
M.AY=ZQ)^G[L??_\ BR/=4<3OT=,?KSAX<W/=[WGI3^%'0\N]8D_3]V/O_P#Q
M9'NJ.)WZ.F/UYP\.;GN][STI_"CH>7>L2?I^['W_ /XLCW5'$[]'3'Z\X>'-
MSW>]YZ4_A1T/+O6)/T_=C[__ ,61[JCB=^CIC]></#FY[O>\]*?PHZ'EWK$G
MZ?NQ]_\ ^+(]U1Q._1TQ^O.'AS<]WO>>E/X4=#R[UB3]/W8^_P#_ !9'NJ.)
MWZ.F/UYP\.;GN][STI_"CH>7>L2?I^['W_\ XLCW5'$[]'3'Z\X>'-SW>]YZ
M4_A1T/+O6)/T_=C[_P#\61[JCB=^CIC]></#FY[O>\]*?PHZ'EWK$GZ?NQ]_
M_P"+(]U1Q._1TQ^O.'AS<]WO>>E/X4=#R[UB3]/W8^__ /%D>ZHXG?HZ8_7G
M#PYN>[WO/2G\*.AY=ZQ)^G[L??\ _BR/=4<3OT=,?KSAX<W/=[WGI3^%'0\N
M]8D_3]V/O_\ Q9'NJ.)WZ.F/UYP\.;GN][STI_"CH>7>L2?I^['W_P#XLCW5
M'$[]'3'Z\X>'-SW>]YZ4_A1T/+O6)/T_=C[_ /\ %D>ZHXG?HZ8_7G#PYN>[
MWO/2G\*.AY=ZQ)^G[L??_P#BR/=4<3OT=,?KSAX<W/=[WGI3^%'0\N]8D_3]
MV/O_ /Q9'NJ.)WZ.F/UYP\.;GN][STI_"CH>7>L2?I^['W__ (LCW5'$[]'3
M'Z\X>'-SW>]YZ4_A1T/+O6)/T_=C[_\ \61[JCB=^CIC]></#FY[O>\]*?PH
MZ'EWK$GZ?NQ]_P#^+(]U1Q._1TQ^O.'AS<]WO>>E/X4=#R[UB3]/W8^__P#%
MD>ZHXG?HZ8_7G#PYN>[WO/2G\*.AY=ZQ)^G[L??_ /BR/=4<3OT=,?KSAX<W
M/=[WGI3^%'0\N]8D_3]V/O\ _P 61[JCB=^CIC]></#FY[O>\]*?PHZ'EWK$
MGZ?NQ]__ .+(]U1Q._1TQ^O.'AS<]WO>>E/X4=#R[UB3]/W8^_\ _%D>ZHXG
M?HZ8_7G#PYN>[WO/2G\*.AY=ZQ)^G[L??_\ BR/=4<3OT=,?KSAX<W/=[WGI
M3^%'0\N]8D_3]V/O_P#Q9'NJ.)WZ.F/UYP\.;GN][STI_"CH>7>L2?I^['W_
M /XLCW5'$[]'3'Z\X>'-SW>]YZ4_A1T/+O6)/T_=C[__ ,61[JCB=^CIC]><
M/#FY[O>\]*?PHZ'EWK$GZ?NQ]_\ ^+(]U1Q._1TQ^O.'AS<]WO>>E/X4=#R[
MUB3]/W9I?0Y;XFW7G,+DOS9A>F3I1UM3E34--4O84!*+,E]?0T7HZ!>UZIN*
M;%-.7+*QQ\A(,GQS2)WTK(IJJXQE$B!>TN9VY?W/MU8O>>E/X4BEIEU/_IB3
M]/W9M9]]?XKCW5O%K_0I+]=\3=A;H.][OTI_"D>BY>ZQ)^G[L??7^*X]U;Q:
M_P!"DOUWP["W0=[W?I3^%'1<O=8D_3]V/OK_ !7'NK>+7^A27Z[X=A;H.][O
MTI_"CHN7NL2?I^['WU_BN/=6\6O]"DOUWP["W0=[W?I3^%'1<O=8D_3]V/OK
M_%<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_T*2_7?#L+
M=!WO=^E/X4=%R]UB3]/W8^^O\5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ+E[K$GZ
M?NQ]]?XKCW5O%K_0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_Q7'NK>+7^A27
MZ[X=A;H.][OTI_"CHN7NL2?I^['WU_BN/=6\6O\ 0I+]=\.PMT'>]WZ4_A1T
M7+W6)/T_=C[Z_P 5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ+E[K$GZ?NQ]]?XKCW
M5O%K_0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_Q7'NK>+7^A27Z[X=A;H.][
MOTI_"CHN7NL2?I^['WU_BN/=6\6O]"DOUWP["W0=[W?I3^%'1<O=8D_3]V/O
MK_%<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_T*2_7?#L
M+=!WO=^E/X4=%R]UB3]/W8^^O\5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ+E[K$G
MZ?NQ]]?XKCW5O%K_ $*2_7?#L+=!WO=^E/X4=%R]UB3]/W8^^O\ %<>ZMXM?
MZ%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_T*2_7?#L+=!WO=^E/X
M4=%R]UB3]/W8^^O\5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ+E[K$GZ?NQ]]?XKC
MW5O%K_0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_Q7'NK>+7^A27Z[X=A;H.]
M[OTI_"CHN7NL2?I^['WU_BN/=6\6O]"DOUWP["W0=[W?I3^%'1<O=8D_3]V/
MOK_%<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_P!"DOUW
MP["W0=[W?I3^%'1<O=8D_3]V/OK_ !7'NK>+7^A27Z[X=A;H.][OTI_"CHN7
MNL2?I^['WU_BN/=6\6O]"DOUWP["W0=[W?I3^%'1<O=8D_3]V/OK_%<>ZMXM
M?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_T*2_7?#L+=!WO=^E/
MX4=%R]UB3]/W8^^O\5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ+E[K$GZ?NQ]]?XK
MCW5O%K_0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_Q7'NK>+7^A27Z[X=A;H.
M][OTI_"CHN7NL2?I^['WU_BN/=6\6O\ 0I+]=\.PMT'>]WZ4_A1T7+W6)/T_
M=C[Z_P 5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ+E[K$GZ?NQ]]?XKCW5O%K_0I+
M]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_Q7'NK>+7^A27Z[X=A;H.][OTI_"CHN
M7NL2?I^['WU_BN/=6\6O]"DOUWP["W0=[W?I3^%'1<O=8D_3]V/OK_%<>ZMX
MM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_T*2_7?#L+=!WO=^E
M/X4=%R]UB3]/W8^^O\5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ+E[K$GZ?NQ]]?X
MKCW5O%K_ $*2_7?#L+=!WO=^E/X4=%R]UB3]/W8^^O\ %<>ZMXM?Z%)?KOAV
M%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_T*2_7?#L+=!WO=^E/X4=%R]UB3
M]/W8^^O\5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ+E[K$GZ?NQ]]?XKCW5O%K_0I
M+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_Q7'NK>+7^A27Z[X=A;H.][OTI_"CH
MN7NL2?I^['WU_BN/=6\6O]"DOUWP["W0=[W?I3^%'1<O=8D_3]V/OK_%<>ZM
MXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_P!"DOUWP["W0=[W
M?I3^%'1<O=8D_3]V/OK_ !7'NK>+7^A27Z[X=A;H.][OTI_"CHN7NL2?I^['
MWU_BN/=6\6O]"DOUWP["W0=[W?I3^%'1<O=8D_3]V/OK_%<>ZMXM?Z%)?KOA
MV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_T*2_7?#L+=!WO=^E/X4=%R]UB
M3]/W8^^O\5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ+E[K$GZ?NQ]]?XKCW5O%K_0
MI+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_Q7'NK>+7^A27Z[X=A;H.][OTI_"C
MHN7NL2?I^['WU_BN/=6\6O\ 0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_P 5
MQ[JWBU_H4E^N^'86Z#O>[]*?PHZ+E[K$GZ?NQ]]?XKCW5O%K_0I+]=\.PMT'
M>]WZ4_A1T7+W6)/T_=C[Z_Q7'NK>+7^A27Z[X=A;H.][OTI_"CHN7NL2?I^[
M'WU_BN/=6\6O]"DOUWP["W0=[W?I3^%'1<O=8D_3]V?Y]]7XKCO8-[*[BWVX
MP8O_ +I279V&R7.?_P#=_P#^M#L+=!WO=^E/X4=%R]UB3]/W9_OWU_BN/=6\
M6O\ 0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_P 5Q[JWBU_H4E^N^'86Z#O>
M[]*?PHZ+E[K$GZ?NQ]]?XKCW5O%K_0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[
MZ_Q7'NK>+7^A27Z[X=A;H.][OTI_"CHN7NL2?I^['WU_BN/=6\6O]"DOUWP[
M"W0=[W?I3^%'1<O=8D_3]V/OK_%<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)
M^G[L??7^*X]U;Q:_T*2_7?#L+=!WO=^E/X4=%R]UB3]/W8^^O\5Q[JWBU_H4
ME^N^'86Z#O>[]*?PHZ+E[K$GZ?NQ]]?XKCW5O%K_ $*2_7?#L+=!WO=^E/X4
M=%R]UB3]/W8^^O\ %<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X
M]U;Q:_T*2_7?#L+=!WO=^E/X4=%R]UB3]/W8^^O\5Q[JWBU_H4E^N^'86Z#O
M>[]*?PHZ+E[K$GZ?NQ]]?XKCW5O%K_0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C
M[Z_Q7'NK>+7^A27Z[X=A;H.][OTI_"CHN7NL2?I^['WU_BN/=6\6O]"DOUWP
M["W0=[W?I3^%'1<O=8D_3]V/OK_%<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ
M)^G[L??7^*X]U;Q:_P!"DOUWP["W0=[W?I3^%'1<O=8D_3]V/OK_ !7'NK>+
M7^A27Z[X=A;H.][OTI_"CHN7NL2?I^['WU_BN/=6\6O]"DOUWP["W0=[W?I3
M^%'1<O=8D_3]V/OK_%<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*
MX]U;Q:_T*2_7?#L+=!WO=^E/X4=%R]UB3]/W8^^O\5Q[JWBU_H4E^N^'86Z#
MO>[]*?PHZ+E[K$GZ?NQ]]?XKCW5O%K_0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=
MC[Z_Q7'NK>+7^A27Z[X=A;H.][OTI_"CHN7NL2?I^['WU_BN/=6\6O\ 0I+]
M=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_P 5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ+
ME[K$GZ?NQ]]?XKCW5O%K_0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_Q7'NK>
M+7^A27Z[X=A;H.][OTI_"CHN7NL2?I^['WU_BN/=6\6O]"DOUWP["W0=[W?I
M3^%'1<O=8D_3]V/OK_%<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^
M*X]U;Q:_T*2_7?#L+=!WO=^E/X4=%R]UB3]/W8^^O\5Q[JWBU_H4E^N^'86Z
M#O>[]*?PHZ+E[K$GZ?NQ]]?XKCW5O%K_ $*2_7?#L+=!WO=^E/X4=%R]UB3]
M/W8^^O\ %<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_T*
M2_7?#L+=!WO=^E/X4=%R]UB3]/W8^^O\5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ
M+E[K$GZ?NQ]]?XKCW5O%K_0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_Q7'NK
M>+7^A27Z[X=A;H.][OTI_"CHN7NL2?I^['WU_BN/=6\6O]"DOUWP["W0=[W?
MI3^%'1<O=8D_3]V/OK_%<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7
M^*X]U;Q:_P!"DOUWP["W0=[W?I3^%'1<O=8D_3]V/OK_ !7'NK>+7^A27Z[X
M=A;H.][OTI_"CHN7NL2?I^['WU_BN/=6\6O]"DOUWP["W0=[W?I3^%'1<O=8
MD_3]V/OK_%<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_T
M*2_7?#L+=!WO=^E/X4=%R]UB3]/W8^^O\5Q[JWBU_H4E^N^'86Z#O>[]*?PH
MZ+E[K$GZ?NQ]]?XKCW5O%K_0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_Q7'N
MK>+7^A27Z[X=A;H.][OTI_"CHN7NL2?I^['WU_BN/=6\6O\ 0I+]=\.PMT'>
M]WZ4_A1T7+W6)/T_=C[Z_P 5Q[JWBU_H4E^N^'86Z#O>[]*?PHZ+E[K$GZ?N
MQ]]?XKCW5O%K_0I+]=\.PMT'>]WZ4_A1T7+W6)/T_=C[Z_Q7'NK>+7^A27Z[
MX=A;H.][OTI_"CHN7NL2?I^['WU_BN/=6\6O]"DOUWP["W0=[W?I3^%'1<O=
M8D_3]V/OK_%<>ZMXM?Z%)?KOAV%N@[WN_2G\*.BY>ZQ)^G[L??7^*X]U;Q:_
MT*2_7?#L+=!WO=^E/X4=%R]UB3]/W8^^O\5Q[JWBU_H4E^N^'86Z#O>[]*?P
MHZ+E[K$GZ?NQ]]?XKCW5O%K_ $*2_7?#L+=!WO=^E/X4=%R]UB3]/W8^^O\
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M#8F3O; JNA1R[*KK5.!=2?T(9Y%O*(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
L                                                      !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>sny-20231231_g10.gif
<TEXT>
begin 644 sny-20231231_g10.gif
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MGNT\J#D+2<])EF::>^0D ?,IP80&ST3RQ("0 @:E"8;THABM:#DSVC!FNBR
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;V9TX.9WA:8O+29Y50E?GB9F7J9[MZ0\%   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>sny-20231231_g11.gif
<TEXT>
begin 644 sny-20231231_g11.gif
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M6O9Y'0B Q\=D'RB"RX1I$WB"9?: &]B"*PB"&H@V<H=_#21]+PB##FB"+!B
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M?:VPDOO7DBCYDF,8DP\YDZ-6DQ5YDTF8DS2(BSTYBCM9@+TGE);H"47Y=OR
-E$O)E$T%Z92'4   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>sny-20231231_g12.jpg
<TEXT>
begin 644 sny-20231231_g12.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
M 0 !_^)]$$E#0U]04D]&24Q%  $5  G\$$%$0D4"$   <')T<D--64M,86(@
M!]< !0 / !  '@ #86-S<$%04$P     041"10
M /;6  $     TRU!1$)%
M                       .9&5S8P   2P   !\8W!R=    :@    K=W1P
M=    =0    4=&%R9P   >@    8=&5C:    @     ,=G5E9    @P   !>
M=FEE=P   FP    D03)",    I   5]F03)",@   I   5]F03)",0 !8?@
M 5]F0C)!,  "P6   CBT0C)!,0 $^A0  CBT0C)!,@ ',L@  CBT9V%M=  )
M:WP  )"19&5S8P         B0V]A=&5D($9/1U)!,SD@*$E33R Q,C8T-RTR
M.C(P,#0I
M                                                     '1E>'0
M    0V]P>7)I9VAT(#(P,#<@061O8F4@4WES=&5M<RP@26YC+@  6%E:(
M     -A%  #@3P  ON9T97AT     $E#0TA$050@1D]'4D$S.0!S:6<@
M &]F9G-D97-C          1$-3
M
M              !V:65W      )EU"L"?)ZI @TES !ZQ D ?U+O &D'CP
M  %M9G0R      0#"P   0                    $
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M">[D[\#PF_%U\D_S*?0#]-WUM_:2]VSX1ODA^?OZUONQ_(S]9_Y$_R'__P
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MMWTYK+J0%WTPJ#=];WTOH\AJ;GU%GY57!GU>FY]#!'UAF @MK7TTE3X5,WQ
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M+HS6?T)*JXM2?XLX8XGZ?^,D/(DG@%X-%H@%@2F\$I>QAGFL8I5EA=*<B)-
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MB&6GC9T$O/Z9&IG9N+6*F9;KM%M\ 91=K^EM>I($J[I>]X^ZI[50!8V;H^=
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M5)!\@Q,<#(]&@[T(^8NL@U"BE*;>B^&4R:-,BO:&VY_LB@EXLIS<B19J?IH
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MJ<_!*&\WICFO/G",HK6=0'&QGTZ+2G+9G"%Y1G/[F0AFUW40E@]3\G8/DSE
M:';=D)XK7W<QCLL3#'<2B<;1DFTYLV2_QVZLKQRM\7 !JN*<!W$IIL"*+G)4
MHMEX3'-ZGP=F!G22FUQ34762E]T_^'9AE*PK(W:RDD\3*G:1BU708VS8O1*^
MAVY$N"&LK&^4LSV:TW"WKF^)%''AJ=QW5',&I5QE.W0<H0-2N749G-T_E77E
MF1DJ[78ZE6\30W8DC*?/26R,QMJ]:VWQP42KE&\ZN[N9R'!7MD>(('& L0IV
M?'*BJ]]DC'.VIM52.72OH@4_0G5YG; JOW74F <36'7+C13.2&Q,T-"\>FVM
MRHRJL6[PQ%F8\' )OD*'6W$PN%AUSG)1LGYC_W-BK+]1T719IT(_ '4AH;,J
MFW6 FAP3:'6$C1_2D7PH;F?!57P[<!JOVGQ<<;2=_GR3<R6+_WS,=)%YWWT%
M=?YG/'U2=U-4#'VI>)5 %GWY>< J37XV>ID05GZ$>T'0BGHC>!J_5WI\>-"M
M[WK4>7R<.7LH>AJ*:GN >L5X?WO8>WIF"WQ!?"-3"GRN?,(_2GT/?54IS'U*
M?;<06GV'?B3.77A\@9F]37CX@6:L$7EQ@3::D7GD@0R(]7I7@/QW.GK*@/ED
M\WM)@/52('O*@/(^DWPW@.TI6'QP@-L077RG@,?,67<PBL>[<'?)B<6J77A6
MB-&9"GC3A_&'FGE8ARYV#'G>AG=C\7IOA<E12WK\A2,]\'MSA(<H\7NKA 00
M7WOA@QG*@78CD_RYKW;/DC>HN7=KD(67BW?PCNZ&0WB"C7=TX7D7C YB\WFT
MBK90?7I+B6\]6'K%B$ HFGKUAUH0>GL?A4K(U'56G2&X$78,FIFG,':RF"J6
M'W<^E>&$_'?8D[MSP7AUD:-B 7D:CZ5/O7FWC<(\SWHRC DH4WI2BM,0J'IF
MAT_'4'2UID2VI'5HHP:EVW8-G^"4Y':@G."#WW="F@=RR'?FESUA+WB3E)9/
M%WDUDA4\67FPC](H%GG$CE40SWG'B0G%ZW0TKW*U3G3?JXNDEG6!I[F3MG87
MI J"SW:^H(%QV7=EG0A@9W@5F;E.>WBZEIH[[7DTD] GWGE!D9$0\7E BH'$
MI'/-N+.T!W1PM#>C6'4-K\V2C76DJWR!P79*IT]PZW;OHS!?HW>>GSQ-YGA"
MFW\[B'BZF"\GJ'C&E&T1#7C-BXC#>G-UP@ZRYW02O02B172MN >1C'5#LQN
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M:(IP?91PI8E9?>-AQ8A-?D%2.H==?IE"#X:#?O(Q'87(?U(>.85F?[H)S80
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M@_> GG8=@Z!OYW;R@TY>GW?-@P-,QWB@@KLZ,GE0@G,ETWF?@B@.0WJ(@8_
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M#'6!KEZ@;G7KJNF1L79<IW2"Q';9H_]SNG=;H*MDGG?9G6A4[GAPFD]$N'D
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MI911=_]G>))X>+I;%Y"S>8A.EX[\>F)!5HUX>S,S8(PI? ,DB8LF?-H368L
M?;L$JH;)?[&)JI=J?3Y^-Y4]?:ERB),W??]F?)%L?C5:/(^O?H5-X(W\?N1
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M<7M.#J;Z<KY#W:.I=!HYFJ!U=84NG9V7=NTBW9LG>%$6 )E_>:,)$)4#?$T
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MXG6KA3EQ''9KA,1B-W<EA%I2IW?N@_5">WBP@Y4QCWE$@SP>Q7E2@O,*97L
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M5'^/AOM&D']SAE\X+W]>A=$I"7\TA6P7VW[0A4@':W["@RB217^ D>.&07^
MD+5Z!7]MCWIM<G\]CBI@EG\3C/-3F7[FB\E%]W[1BJLWO'Z\B:HHPGZ)B.X7
MT'X$B L'JWX9A**1%'[/F9*%)G[2E]5Y G[$E@ULBWZ;E#1?S'YXDG-2['Y2
MD,)%9GX_CR0W2WXGC;$H=WWKC*07O7U-BG8'X7V(A520!7XZH2>$''Y'GPEX
M!WX^G-5KK'X6FH!?"7WUF#]21WW1E@Q$V7V[D_(VUGV=DA,H(GU7D'T7GWRG
MC)<(#WT/A7..]WW,J."#*GW:IE)W,'W1HZMJ['VHH.!>8WV(GB!1NGUEFV]$
M8'U+F. V<'TFEJ$GUWS6D[D7A'P;CEP(-'RKA8R-^WU_L-&"6WV%K:IV@GUX
MJGEJ47U.ISE=W'TOH_M12'T,H,Y#_GSOG=,V'GS%FM$GFGQMEE 7;GNIC\<(
M4GQ;A:"0;8^%8OJ$A8X-9:!X5(RV:!EKL8N0:D]>UXI];'U1V(EW;JA#_(B=
M<*<U5X?Q<H(EOX>,=#$3JH?X=5$#X(4[><Z.W8U=:J:#*8PL;*-W(8L0;G9J
MF(H2< M=W(DA<:50_X@Y<T1#4H=Q=,DTZ(;-=C@EDX9A=XD3V(:;>'$$780R
M?!"-2(NV<BB!NHJC<X-UW(FA=+QIA(BW=<%<[8?<=M%0,X<)=^9"M895>.XT
M@H6_>>PE;852>ML4 (5B>XX$RX-(?A"+[8I#>9^ <(D_>E]TJXA.>P)H=X=W
M>WM<!(:I? 1/;X7A?)="(85#?1TT)(3#?: E2X1>?B44)(1+?JL%+()Z?]**
MD(D"@0=_*H@2@3AS@8<S@4YG<(9K@3Q;'H6J@4!.K83M@4]!B(1<@58SNX/F
M@6,E&8-]@8D4.(,^@=X%A8&H@7^)/(?PB"E]\X<=A^%R:(93AWIF>(66AN9:
M1(3@AF=-\80NA?1 [X.AA80S3(,IA2<DVH*RA/X4/X) A,,%U(#:@PZ(#H<2
MCV5\XH9+CI-Q=(6-C:1EH(39C(I9AX0NBX=-3H.%BI) :X+^B:LR[(*$B.8D
MI(( B'4418%DAST&&8 IA!^&]H9@EJM[X(6?E5APBH3ED^EDTH0WDE!8TH.3
MD,U,M(+PCUH_[()KC?TRB8'MC-,D9H%>C!@40("@B6<&4W^2A$>%\H76G?1Z
MYX46G#UOHH1<FF1D!8.LF%E8(8,,EE],'X)ME'8_;('EDJ@R'X%AD1TD&X#&
MCX04+G_QBTX&A'\3A&B$\85BI5EZ X2DHS-NV8/KH.MC5(,YGG-7B(*:G =+
MGH'^F:P^_H%TEW,QPX#JE80CV(!$DF 4&W]?C.(&K'ZKA(.$!83_K-]Y0(1&
MJBUN-X./IVABQ8+;I(57#8(]H:A+-X&CGN ^I8$8G$@Q>("(F3DCH7_:E*H4
M#'[JC8X&S'Y8A)F%9);@8P!Z0)3U98]NVY,D9_AC$I%[:BI7$(_I;%E*ZHYJ
M;H<]V8TE<(4O](PB<EXA#HN,= L/UXN==68"7X=(>I:$!I3G:D-Y%Y,H;#-M
MVI&#;@)B)) #;Z)6/8Z.<4E*-8TE<O,]4HON=($OIHKP=?@A XI+=U,0'8HI
M>(("WX8U?**"J9-0<6)WV)&P<K]LOI B= !A-(ZO=195;HU+=CA)AXOS=V(\
MT8K+>'TO7(G6>8X@^8DI>I,07(C<>YT#4H5!?G.!>)'J>')VL9!5>3UKJX[5
M>?)@08UT>H94G(P=>RU(V(K.>]T\48FX?($O%HC3?2$@\(@F?<L0DH>T?JX#
MMH1K@ N .I"S?X%UCH\N?\%JI8V]?^]?6HQJ@ 13TXL>@"Y(+XG9@&0[T8C.
M@)(NQ(?N@,@@UH<W@2 0NX:4@9,$$X.1@8]_$(^EAE%T?XX[AAUILHS=A=5>
MAHN2A7%3&HI0A2%'D(D5A-T[4H@.A)XN;(<JA'4@K(9@A(P0U86%A"T$:(*Z
M@O=^ H[,C2MSD(ULC'EHX(P8B[5=SHK4BM52>8F<B@E'!XAIB4PZYH=FB* N
M((9_B!P@B86EA_P0[(2<AF8$L(("@RQ]"(X=E MRJXS DN5H$(MOD:U=&8HM
MD%A1W(C\CQ=&@X?0C>8Z>8;/C,XMSH7DB_$@683[BUD0]H/1B%@$[H%F@U5\
M((V4FO!QR(PUF7-G.XKAE]Q<7XF<EA]1/8AOE'%%_H=)DM8Z"(9'D5<M<855
MD"8@&81?CF 0\(,=B@P%(H#B@WA[.(T0H?AP]HN[H!1F@HIJGA=;OHDBF_90
MLX?XF>%%BX;6E^(YI873E@0M'83;E#<?WH/:D.80Z(*'BVX%38!V@Y5Z8(R5
MJ2=P0XM1IKEE[(H*I$1;.XB^H<-00X>7GTM%+H9XG.TY585UFJLLVH1XEWP?
MKX-NDNT0X8(0BVH%;X ?@ZQZFIYY8P5P+)PE97)EB9G>9\9:DI>J:?1/9962
M;"9$$I.3;E@WR9'@<%DJH9"'<C$<9H_%<]L,?XZG=<0!$(D1>T1Y?)RN:>QO
M/9II:[]DO)@\;8)9TY8R;RY.NY0S<.)#A))#<IDW9I":=#$J=8] =;(<?8YF
M=Q@,VHT@>-T!E(?T?2)X89L8<+%N,YCW<?YCRI;D<SM9"93A=&-.#Y+O=9I"
M]9$+=MHW X]L> DJ28X6>2X<D8TJ>DL-*XO#>_,""H;X?LAW6YFY=UQM,I>A
M>"-BV)6:>.!8,I.I>9%-5I'">E5"78_F>R4VFHY4>^4J&XT&?*4<HXP1?70-
M<HJ0?L "<88:@#QV.)B*?A5L,I9^?E9A]Y2!?I17;9*<?M%,K)"_?R%!SX[L
M?WXV-(UB?],IXXP5@#,<HHL/@+X-JXEH@5@"TH4Y@9UU.I=WA)EK396&A&EA
M+9.=A#=6OI&]A -,%(_J@^%!4(X@@\XUTHR9@[\II(M&@\L<D(HHA"4-V(A2
M@Z\#*X1;@B1T39:ABQ=J@92XBG-@?I+4B<Y6)I#ZB2A+D8\PB)1 XHUNB! U
M?8OJAY\I;HJ1AUX<@HE?AW@-_8=EA:\#=X.>@EAS=)7SD95IN90)D(I?RY(F
MCWU5C)!-CFQ+#8Z)C6Q <XS/C'XU)(M-BZTI+HGOBQ\<8XBKBG0.%(:4AVX#
MN(+\@H1RL)5AF!-H\9-VEL%?"Y&0E6-4YX^SD_-*@8WTDI%  (Q!D44TPHJ_
MD!8HWXE;CS4<,(@(C2(.&X7<B/8#[H)T@JEQY93+GL!H-9+QG0Y>8I$3FU-4
M5X\PF8E*!XUUE\P_FXO(EB@T;(I&E*<HEXC=DL\;_X=^CUX.'85$B8L$&X($
M@L=Q))0XI9]GDY)[HV)=VI"LH3%3XH[%GQ%)I(T-G/\_28MFFPPT)XGDF/(H
M78AVE;(;V(<-D2D.'H3)B8P$/X&K@M]O[*9'8TEF%*--9;-<$*!X9_U1R)W9
M:AI'5)M5;$$\P)CM;FLQ19;D<&LDZY5-<D,79Y1Y<^():I$_=I\  (I[>^]O
M Z2.:=-E5Z&D:[%;<I[F;7A1-9QH;QU&U)GW<,T\69>:<H0Q!962="0DWI/M
M=:\7G9+Q=Q<)U(^L>;4 ;XF ?9)N(:+U<$9D@: R<:=:L9V/<O)0E9L9=!U&
M4)BR=5D[[Y9>=I\PPI18=]TDSY*L>147S)&1>D(*,8Y(?(8 YXA]?Q1M4*&:
M=IQCLY[C=XA9[9Q+>&)/Z9GB>2!%OI>">? [?)4P>LLP>9,R>Z DNY&(?'D7
M]I!9?64*@XT/?O\!48>9@&AL8*!T?0!BXIW$?7)9.9LU?==/3)C4?BE%.)9\
M?HT[$90O?OXP,I(S?W DH)"#?_,8$8\Z@*L*RXOA@4H!MH:Q@2AK@I]L@RUB
M))S0@S18EII.@R].P)?S@Q=$P96B@Q,ZL)-<@R O[Y%?@SDD@8^C@W88(8XX
MA (+"8K'@UP"$H7-@69JNYZ-B4AA?9O]B.58"IF$B'9.1Y<NA_9$6Y3DAXLZ
M7I*DAS0OMI"FAO<D9H[?AO,8+HU9ANX+/XG5A2 "884*@9QJ")W.CV=@VIM$
MCJ17>9C/C=1-RI9YC/)#\I0VC"8Z")']BW(O=H_^BN$D08XNBJ(8*HR1B8<+
M9HD AJP"I81D@<II:ITKE9%@-IJAE(96W)@JDVE-1)7/DC!#@9.2D0XYK)%A
MD @O+8]CCRHD#(V+CE(8%(O<B]T+?8A#A\4"WH/8@?!HO9R.F^%?FIH0FG=6
M49>>F0),SI4^EWI#'9,&E@HY7)#=E+LN[([>DXLCW(S_D6D7_(M"C= +CX>E
MA]$##8-F@A!H$IO^HE-?#YF3H&15X9<KGH-,;I3(G+)"S9*4FOLY&I!QF6XN
MMXYRESDCM8R.D^07ZHK%CV +G8<GA]H#,H,*@BEE4ZY]8Y1< JKX9>92DJ>D
M:!M(\*28:B8_,*&@;$(U5Y[);F8JJIQB<&@?'YJ&<D,27)F&<^$&NI-[=[\
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M?#$^F:<B?+$UX:.S?4$M)J!/?>$CRIU*?I@9N9JS?W(/$9?K@'T%^X_\@3P
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MB#P&97PSA%.'-W>AFU]\"7@]F;%PK7C#E_!E"WDGEA)9&'F$E$!- WG7DGE
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M6*)4=NU2]Y^O=^!*;ITH>,)!J9K.>8PXQYAT>EHOU)8F>S(F*90F? P;O)*
M?/,0<)#T?B@&AXL??[L  (8_@ !:IZ$A?*M2:YZ(?4!* )P-?<-!39F\?BPX
M?Y=K?J$OI)4B?R,F%Y,=?[$;SY%B@%\0K8^V@2@&V(H'@9@ .H6=@"=:&J %
M@EI1]YV @HI)H9L5@JM _9C-@K8X09:$@M(O>Y1!@P$F!Y(V@T8;WY!J@\ 0
MX8ZC@[H''8D8@S  BX3=@%Y9G)\)B =1AIR1A]U)/YHOAZ9 K)?KAUHX I6J
MAR0O3I-OAP<E\9%AAP4;Y8^&AS01!XVGA@8'5HA%A)< T(0Y@(U9)9XOC;M1
M$9NWC5!(TYE3C-1 59<.C#PWO)36B[XO&I*FBU\ETI"6BQ\;WHZMBFD1'HRZ
MB!\'@H>'A1,!"H.O@+18H)UHDX10GYKWDL-(=)B6D?A "99.D1XW@)0?D&$N
M[9'ZC\PEM8_HCPP;UHWTC1L1+HOPB> 'I8;HA2L!.H,^@-18'9RWF5)0.II5
MF!Q(*)?\EO(_RY6SE=PW3Y.+E.LNR)%OE XEGH];DC,;SXU>CT01/(M,BT@'
MP89JA3X!8(+D@.Y3*K(W7R9*[:[X87!"FJO.8[PZ):C$9@\QGZ6S:'4I J+#
M:N$?F*!<;2L5.YZT;SH+(IM,<@D"XY*0=U   (=%?;%2\K 190=*MJSU9MA"
M9:GJ:+8Y]*;X:J<Q@*/U;*HH_:$*;K0?M9Z5<+$5AIS%<HP+B9E5=2H#6I#P
M>=,  (;K?M%2C*XA:MQ*2ZLQ;#E"!:A#;:TYMJ55;T(Q6Z);<.(H\)]T<HL?
MR)ST=#<5Q)L&==4+Y)>1>$0#PX^ ? P  (:<?]!1^:QO<(Q)VJF9<99!L*:\
M<K0Y<Z/2<_$Q*Z#==3$HV)WX=G@?SYMU=\H5]YET>1X,,Y7_>U4$'XX\?@
M (97@ !1;JL4=A])=J@Z=MQ!:*5==ZDY.:)[>(PQ!9^->7,HR9RK>F0?X)H>
M>V86,I@!?'T,B92(?CT$?8T)?]$  (82@ !1.*G1>ZA).J<!>_U!+:0N?&<Y
M"J%7?/(PZ)YQ?8HHPIN1?C0?^9CV?O86<Y:X?^$,X9,S@-D$VHOL@7@  (70
M@ !0]*BB@0)(_J7H@/E ^Z,G@0@XX:!8@3PPSYUY@8DHO9J=@>X@#I?V@G,6
MJ96<@R@-+9(.@Q0%*8KY@N$  (67@ !0G*>4ADI(MJ3DA?= P:(JA;HXM)]A
MA: PKYR*A:8HKYFUA<\@&)<&AAL6TY25ABP-:I#_A1<%;(HA@ZL "X55@ =0
M,::KBY%(7J/OBP] >Z$OBITX?IYFBD(PAYN;B@THEIC1B@,@%I8<B@46[I.:
MB/0-G(_]AN\%HXE?@]  1H3(@"]/Q:7/D/!("Z,5D"9 /:!5CW,X3IV,CN P
M8YK*CGPH?I@+CDP@$953C6 7 Y+#BTL-PX\BB'P%T(B]@^X =H15@%!/9*4(
MEE1'Q*);E1] "I^CE!@X)YS:DU@P19HADM(H:I=KD?X@#I2QD!(7%)(5C2P-
MXXYPB60%](@ZA 8 G8/Y@&JS:V726MJC_6>-7AJ4CFE#84R%'&KQ9&-U@&RL
M9S-EQ&YE:>E5CG 0;(%$R'&<;O,S'G+<<2 ?-7,P<G<)%'>F= .Q!&(;9'BA
MX61"9L>2MV9=:1:#@&AH:V!T'FIE;7EDG6Q5;WY4E6XT<6E#]V_K<S4R?W%$
M=,D>WG%R=;,)/'9]=Q"NO%[U;>:?WF%U;U*0^&/><,B"!&8C<DMRVFA6<Z]C
MCVIZ=093L&R%=DA#.FY>=W(Q[V_'>'(>D&_3>/$)7W5W>A:LLEQ'=N.>$5\$
M=XN/9F&H>$" J60G>0AQL6:-><!BE&C?>G-2WFL*>Q5"CFSX>Z4Q<&YI?!@>
M2VY5?# )?G20?,FJVEH3?]><8%SZ?\2-X5_)?[]_56)U?]%PBV4$?]]AG6=[
M?^M2$FG!?^]![VO ?^DQ!6TX?]4>)FT<?Y@)Q7/%?U*I)5A1B*^:SUM9A]B,
M=%Y)AQM^$F$4AH1O<6/ A>Q@KV94A5-14FBOA+M!8&J\A"8PL&P\@Y4>'6PG
M@Q8*+7,8@:.GEU:ZD6B9:UGBC^6+.%SPCGM\^5_8C39N?6*@B_-?XF5-BK)0
MK&>[B7U Y6G5B%<P9FM=ATL>%FM6AI4*AG*$@YZF1%5DFAB8-%BGE_F*'EO.
ME>Y[^E[)D_]MGF&CDA9?)V1BD"]0%V;@CF! >FD'C*LP*6J7BR8>$6JBB>H*
MTG(&A4ZE,%15HK^7*E>MH!B)(%KDG7Q[#UWGFO-LSV#+F&U>>6.2E>I/D&8;
MDX1 '6A0D4,O^6GJCT8>#VH(C-L+$G&<AKND.E.*JVZ615;GJ#*(2UHCI0-Z
M2%TKH>5L(& 4GL9=YV+AFZA/'V5UF*X_T6>UE>,OTVE7DW$>#FF)CTT+1G%$
MAY^C8E+RM"25AE9*L#N'GUF$K&IYIUR1J+QKDE]^I0-=<&)/H4I.Q&3LG;P_
MDV<VFFTOM&C@EP,>#6DCD4(+<'#_A[RI4&NW6GN; &SE7;^,D&X:8/=][6]<
M9!=O''"P9N]@)W(%::Q0BW-<;$5 1W2A;K0O(G6I<-P;P77R<B<'/WH/=&NG
M&6@H8YZ9#&FW9@6*U6M.:&9\7&SQ:KYMOFZ%;.9? 7 .;OQ/F7&5</@_BG,
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ME#A*W&FODA@[^FN/D!PL:&S>CFT;$6T:B]H)?G0+ABZ:IUI5I\>-NET)I/V
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M9A!5EX?<:&)*Y8<^:K% "X:F;/PT-(8X;Q<G>H7[<0,9J(81<JL*U(4L=-
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MA;D5X(+.A94)S8%QA"0!IH!A@1YCBX;GC4-;&X8<C,A2?85>C$%)EX2SBZA
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M?[]##HRY@ PZ0XN%@%PQ7HI5@+<GKHE2@1(=.8AW@8L1SX>?@@P'=X2&@A<
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MDBTZD8^SD84RI(XJD/LJIHRHD(\A](L5CRP8C(F*C*(.N(<UB44&0H/HA#L
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M>@]/X&MF>K5"7VT]>TXT+F[8>]8E+F_9?$<4%W&G?&P%-7>3?>B,(UZ[?N*
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MBHT&R74%A):&XUB@I:1[L5N;HR=P4UYHH*!DL&#RG@A8SV->FWQ,TV6NF/U
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MF'Q(? T!L7W/?DMP/'0<>11FG74%>?=<T77@>KA2O7:F>TA(9W=9>]8][W@
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M8=E'H(F;9'D^*8CA9Q$TAX@Y::$IY(?*:_X>38>F;B 1C8?3;_4&1(6@= (
M ('7>OYA.(E08JM8K8B^91=/[H@D9V9&W(> :8H]AH;H:ZLT!89>;<DIE(8!
M;\0>.X7=<901P(7M<RP&EH0V=PX  (%Z?'1@$8;U:1Q7M8: :Q5/&H8';/-&
M(86*;J@\YX42<%DSB(2D<@@I1X1:<Y<>*(0\=081[80Y=E0&WH+Y>=T  ($H
M?;U?(X39;XU6WH2$<0Y.7(0K<GA%?H/+<[\\88-M=00S(H,4=D<I"8+;=W(>
M'(+!>(H2&8*M>9T'*('7?'X  (#M?O9>78,$=<U6)8+2=M9-MX*7=\Y$]X)/
M>*P[]8(#>8DRTH&X>F@HVX&,>SL>%8%T? P21(%5?/H'<X#4?N( *X!^@!U=
M=8%Z>^U5;H%:?(--*($R?0M$@H#_?7\[EX#$??0RCH"'?G HLX!F?NT>$(!1
M?WP2:8 O@#X'LG_X@.X ?'_3@%1<J( E@@-4R( 3@C=,HW_X@EU$&7_0@FP[
M1G^F@H R4W]Y@IXHD']B@L8>"'],@Q02A7\I@SL'YW\W@KP PG]!@(-<"W[\
MB Y4-G[YB 1,)7[GA^!#NGZ_AY4Z_GZFAU R('Z.AQDH<'Y\AN\=_GY>AOX2
MEWX^A?<($7Z/A%< _'[%@*M;?GWSCBQ3MGX'C<M+N7X!C5!#:WW8C*\ZPWW-
MC!<Q]WW)BY,H5GV[BR$=]'V6BHD2I'UYB$((,WX#A8L!+'Y@@,M; 'T-E$I3
M2WT\DVQ+8GU%DH9#*WT:D9$ZE'T<D*PQU7THC^0H07T=CR,=['SSC5\2KWS;
MBAD(3WV3A9X!4WX0@.59HY9U5;A1@Y3862))+9-57&5 AI'S7W WEY"O8G0N
M>(^.96XD6([+:",9,8Z.:H4->(VT;/P#Z8F.<A0  ()X>I]8WI-]6^Q0SY(8
M7MY(B9#.8:P_[(^G9$8W%XZ)9MLN&8V :6HD*8S%:\L9/HQW;>X-P8N#<# $
M28?R=1X  ((&?!Y7YI#G8B=/[X^Z9*%'QHZ;9OH_3XV/:2(VF8R-:T@MO(N<
M;6PC^8KJ;W,91XJ0<4\. 8F)<U@$GX:&=_D  (&B?7%6]XZ=:$Q/'XV.:EQ'
M$HR-;$P^LXN@;@PV&(JZ;\DM6XGA<80CQ8DZ<R@92XC8=*P..8?-=G($ZH5&
M>GP  (%*?IM6&XR6;F-.98NA< Q&=HJY<94^,8GE<NXUL8D5=$8M$HA/=9XC
MHX>P=N896H=%>!X.=H8]>; %.H0@?-8  ($(?[958XK"=$I-R8GS=8M%]8DI
M=J\]R8AG=Z<U8X>H>* LX(;O>9XCD895>I89<87@>Y$.M83??0$%BX,9?OL
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M\XWL=-P>+8S<=D44AHP;=Z +18E5>A$#B88<?2<  ($?@ !,=9+E<L-%;I&
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MB/\UL8H5B.@N,XD/B. FHX@1B/@>8X;\B0<5887KA_,,>(/<AB$$TH(:@T(
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MLU^VCA,7:&3CBK\(*G(TA86.ND)_ID2"H$=+HXIV;$O+H,IJ"T_<G@-=CE/
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M>K($_'>3?,J++E"1>YE_6%1>?"AS6E?6?)UG(%K2?.M:I5W)?3-.!F"J?7=
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M6)9!^H=^6_ XX8;Z7SDOCX:<8G E/8:"96(9Y(;)9_X-WH:;:I $#84O;ZL
M (  >0-:MH6_5]928(6-6OQ)YH5 7@A!,83.8.\X-82!8\4O"H1.9HPD[X1'
M:249VX2%:WL.&X1J;=,$:(.7<K@  (  >K19D(*+7E-1:H*2801)%8*!8Y9
M>(),9?LWFX(O:%HNE8(A:K(DJX(P;.H9U()L;O$.48)Z<0@$N8(N=<(  (
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M;;0X:X/V;U P88.T<.HH-H-\<H0?/X-2=! 58X-.=8$+N(*A=\\#KX(&>Z<
M (  ?WY.$X*F;Z1'$8*'<4(_QX)=<KDX%((F<_4P)8'Z=30H&('2=G@?18&O
M=[H5F(&=>/<,"8%!>R $"($"?=$  (  @ !-:(#$=55&C8#!=HL_98"P=YTW
MRH",>'HO\H!S>5\G_H!=>DT?2X _>T@5Q8 D?%0,3H 3?A,$5( C?ZL  (
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M8S,BZX]E9?P:&H[.:)\0@8Y2:R((-XKA;PD!4(?,=1D  ( 7?,)'@)(071%
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M?^0PQX/P@%HILH. @-LBAH,<@7,:KX*.@BT2'H'<@K<*3H$"@KD#<8"8@E0
M (  @ !#PX2!@XL]NX/DA#TW9X-(A+\PI(*IA/PIHH)&A44BC('QA:L:SH%L
MAB,25X#)A9,*BX WA)T#I8 *@G<  (  @ !#18,UB/$];8+ B2XW.X([B54P
MAX&>B6$IEH%%B7HBD(#]B;@:YX"!B602A'_MA]\*O'^5AB$#SW^8@I,  (
M@  ^S:&84/@X@)^%5($Q[)V05^LJ[IO'6RHCIIHT7F <+)C?88@3Z)?Q9'D+
M^I5=9_L%6(_A;-L  (J2<],  (#K?%D^.IX_5K8X'IQ16<<QLIJ$7,0JT)CG
M7Z4CJ)=J8H <5)8;95(4,94F: ,,4)*B:T8%M8V?;_   (F3=C   (!<?:(]
MS9K]7%TWLYEF7P<Q69?789\JG)919!XCEI3H9IT<8Y.E:1@499*G:X0,EI H
M;H4&!XN@<OP 5(@D>(   (  ?L0].)A&8=4W+I;:9#LPZI5N9H0J3Y0!:*8C
M9Y*Q:LH<5)& ;.\4?9!X;PL,SHWO<<(&3XG?=?\ GX;?>HD  (  ?\0\L97>
M9T4VR)2+:6$PHI,U:ULJ(I'9;20C5I"?;O0<8H]]<,L4LXYI<J$-'(OA=14&
MJ8A(>04 ]H6T?'4  (  @  \*)/#;'<V>Y*";DLP@)$[;_HJ$8_I<7<C78[
M<OT<B(VL=(\4_XR+=BT->XH4>&P'#H;B>\ !5(2I?C@  (  @  [[Y'3<9HV
M3Y"Q<Q8P8H]_=',J XXV=:4C9(T<=N,<J(P6># 5/XKM>9@-S8B)>ZH'9(6O
M?A8!I8/%?[H  (  @  [TI :=JXV+(\#=^4P08W;>/\I\HR8>>XC:(N->NL<
MQHJ3>_T5?HEF?3(.'8<A?ML'MX2=@#L![8+\@1(  (  @  [NHZ8>[0V"(UR
M?,PP'8Q"?;\IW8L%?GLC:8H$?T(<XXD5@"05OH?J@2X.<(7/@>,("X.C@D "
M+X),@7H  (  @  [@HT<@-(UVXP$@:HO_(K?@F8IRXFF@O@C:HBP@Y0<_(?*
MA% 5]8:DA-,.N(2RA'4(4H+1@_8"9X&Z@:   (  @  [.8NWA?0UK8K(AEPO
MXHF]AL@IO(B(ASLC:X>:A[0=$(:]B#(6(86;A[\.\8/-AH4(C((IA54"E(%%
M@;X  (  @ "2.U>M3'"%.5F_4*!X)%OR5,1J\EY<6--=H6"Z7+)0,6+\8'Q"
M+&5!8_\SB6<Y9S8D!F@P:?T28&TH:XD#E7GR;_&/P%(*5<2##E2L62)V2%=H
M7')I85I.7ZI<2UT98LQ/#E_ 9>)!/6).:+PRT&1O:U<CC&5=;902.VMS;M$#
MV7E_<Q*-D$T$7K"!,% J85)TM5-68^EH#5:+9G);)UFR:.%.%URY:T- <%^'
M;74R+V');W4C'F+2<2D2&VGQ<A<$%7D:=B^+NDB*9UA_H$P::59S9T^D:T5F
M^E,E;1Y:/5:@;M]-45G[<)(_R%S^<B$QIE]2<XDBO6"6=+D1_FB>=5P$27C"
M>/R*&T2W;]Q^,4BC<3)R*4R <GEE\%!%<ZE9850$=,9,H%>@==8_0EK.=LXQ
M3%TX=ZXBFU[5>&H2*&=Y>-8$LG@0>Z&(LT%^>!)\Z$7->+)Q!$G\>4YD]TW[
M>>-8EE'L>FI,"%6V>N@^W5D(>UHQ(%N.>\(BL%V'?!X2C&:&?&D%1'<9?@Z'
M3S[ @!=[N4-+@!IP!4>S@!=D($OI@ Q7YU )?_E+A5/^?^(^AE=S?\PP^5H4
M?[LBP5QI?[D2XF6U?^D%P79%@"*&*#QIB EZP$$>AWYO-$6TAN=C;DH>AD!7
M74YHA9I+*5*#A/4^5U87A%PP^%C3@]<B\5MT@W<3/V3X@R$&+'61@>>%3SIU
MC^%Z S],CMUND40(C<1BXDBAC(Q6^4T0BUY*]U%+BC<^4U3ZB24Q(5?/B"\C
M1%JDAW,3J&1'A@4&AG3Y@V6$P#CHEYYY=SW-EA9N#4*CE'5B<$=DDK%6JTOS
MD0!*U%!)CUH^6500C= Q35;\C&\CDUG[BU@4!6.RB&\&T'1]A)N$8C>QGR)Y
M#CR7G0EMHT%[FMMB%49>F(Y6;$L(EEE*N4]XE#0^7E-3DC8Q<593D'$CT5ET
MCIH44&,[BEX'"W09A,.)EEU'3(E]5U[I4*9P^V"H5+AD=6*86+A7T6257(Q+
M#&:&8$P]EVB)8\8O<&I/9O4@6VLM::T/6W#P:U@"/GPV<)N'8E?156![;UH&
M6+1O6UQ.7 -C%5ZU7TE6IF$98FY*$V-I98,\S&6P:%\NU6>;:OT?^VB/;38/
M66]$;IT"E7NB<[:%25+]7@UYIE6F8*UMWEA78T9AVEL49=15FUW4:$M),V!]
M:K4\%6,";/,N2F4,;P ?IF8_<+L/5VW*<=T"XWL?=JN#:T['9EYX$E'0:&)L
MC532:EQ@Q5?);$94KUK6;A=(:EW1;]H[<&")<7TMSF*G<OL?6V0X=#H/56Q]
M=1L#)WJL>46!V$L:;H1VM4YS;_)K8E&_<5%?Q53[<IE3V5A)<\Y'OUN!=/<Z
M\UYB=@PM@F"3=P@?2F*,=]L/C&M:>(L#DWGV>[Z @$?O=EMUC$N:=REJ8$\U
M=^Q>WU*Z>)]3'%8\>49'-%F=>>8ZFUR<>GPM8E[B>P<?;&$[>X0/\6IC?!<$
M''D.?@=_9$4D?B%TD$D-?D]I@4SH?G9>&%"Q?I!2>51C?J=&O%?K?KLZ3UL(
M?M$M1EUB?NP?B6 ;?Q,02&F0?W4$DGA'?_M^<4*WA=!SM$;7A6YHOTKHA0-=
M<T[FA(Y1^5+!A!I&9E9N@Z@Z)%FI@T,M25P;@O ?O%\D@L,0H6C5@G4$]G>=
M@:5]GD"FC5UR\D3\C(5H%DD[BZ!<\$U;BJ51G5%9B;)&-54IB,0Z'EB"A^LM
M;EL0AS @"UY4AK$1 &@LA20%2W<.@PQ\Z#[^E-]R3D-UDX!GBT?4DA1<ADP/
MD)=155 KCR=&$U0:C<(Z(%>.C'@ME5HWBUH@5%VJBFX14V>@AV$%D':9@\-\
M43VOG$1QR$(XFD%G&D:JF#]<,$K]EC]1'$\SE%-%]U,]DG@Z(E;)D,(MM%F(
MCT@@CETCC701EF<OB2P%QW8[@^B B6+W3+9T]F0Y4+II5F6=5+!=H&<V6))1
MN&C97%=%IFIR8 LXQVPK8WLK(FVV9IT<>FZ;:3\,>G2+:T< ]GY?<5E^KEW
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MIFQ+6'=+<FV27"I #F[97\PSRW V8R@FL'%O9C$8>')_:+$)TW??:U4  (
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M82=-%&KP8[U"Y6QV9D4XDFWM:,$M<V]9:QTAAW!_;444>W+C;P,(%W@+<@P
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M?^@5CVOF@&L)N7,@@,L!OGT.@0ID_U5KA9U;[%@>A2M2R%K+A,%)@UUQA&%
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M=[-$-69[>&8['FAK>1\Q]&H^>=XH%FO0>JT=@6T,>X81]G&<?'('A';L?FL
M?7\M?\]=M5Y;?,550F!H?/],J6)^?3Q#U62B?7TZV&:U?<PQR6BM?B@H#6I9
M?J =H&N\?S02/7"6?^\'T'8U@)L S'ZG@(I="UR1@R%4LEZC@PI,.6#!@NQ#
MBV+Q@L(ZIV4F@J\QKF='@K H$&D5@M0=Q&JI@R02@V^_@S8(%'6<@HX!#WXV
M@+=<C%KCB7M40%T4B/]+W%]'B'E#4&%_A^8Z@6/2AW<QFV88AR0H%6@'AOH=
MY6G*APL2OV\1A?8(374@A"X!1GW:@-Q<+UE<C[I3Z%N[CKA+D5X.C;E#(&!.
MC+XZ8V*ZB_@QC&4ABU@H&&<KBND=_VD8BF$2[VZ&B"H(>W2]A7L!<GV/@/I<
MW'PR37U3YWQ)42-*^7Q75,E"$WQ:6&TXTWRC6_@O6'T07VXD[WVK8J,9B'Y\
M97T-BG_ :$D#VH#F;7T  (  =U1;;'?85#=2KWA(5TY)Z'BQ6FU!#WD279@W
M\7FE8*HNIGI/8ZHD?7L+9GX997O8:0L-NGV6:YD$,G]/<),  (  >3A:,G.]
M6O51G'1W799(]G4T8#9 ,W7U8M4W.';.96DN%W>O9_(D)'B-:E\92WE?;)4-
MY'NL;MT$?WWG<Z,  (  >N19$G L8850N7$98[](/'(19?,_B7,9:!TVK'0G
M:CPMLG4S;%$CYW8S;DT9/7<3<!P."GG^<A$$PWRJ=J<  (  ?%Q7_6SM: !/
MX&X2:<]'DV]":Y4^^G"";4XV/7&];OTM9W+N<*8CQG0(<C\94'3]<[D.37AO
M=6T%&7N*>8H  (  ?<-7#&HI;C)/(&M^;YA&_6S:</,^AVY"<CTUZ6^A<X4M
M-'#P=,XCP'(;=A89?W,K=U0.J'<(>-T%?'J+?"X  (  ?P]64V?$=&Q.@FDT
M=5%&>VJQ=C$^(VP_=PLUH6V_=^TM"6\K>-8CNG!H><X9IW&=>M$.]G74?#@%
MT'FQ?G   (  @ !5KF6M>I=-]6<N>PQ&"FB^>W\]TFIE>^\U:6P$?&\LZVV1
M?/TCO&[F?:@9T'!,?G //G31?WT&&GCX@'   (  @ !5$F/;@*--<V5F@-5%
MI6;_@/@]DFBO@0@U0FIL@2\LVFP=@6HCR&V3@<H9_6\R@ED/A'/[@H &7'A>
M@CH ,G^K@")4H6(RAKM-#&/7AHQ%4F6!AE$]7F<VA@,U(VD.A=8LSFK@A<8C
MTVQVA>$:)&Y,AB /OG-,A0@&DW?@@[@ 9W]3@$5456"[C,),OV*$C U%#F1&
MBUT]-68 BK,U"V?NBC@LQ6G>B>0CW6N.B<4:0VV4B3$/[G+ AQ &OW=[A(\
MD'\,@&)4"H-!36I+S8+L40%#D8*05)H[4X(K6#DRLX(;6[XIU((Z7RP@"(*7
M8EH5+8-292@*L8-?:)P"6H-1;G\  (  >+92TG[F4\5*RG[S5MM"M'[U6?LZ
MA'[G72TR!'\=8$(I4G]V8T0?P'_K9AP5+H"7:*@*\H$V:]X"M(&Y<8H  (
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M9'8RSW\;9KLK'W]G:/LC27_":S8:HH :;5H1+X"$;V<(XX#A<M<!\($\>#
M (  ?B%'-GOM975 IGOX9YTYQGPE::@R<GR&:XDJX7SW;6DC+7UO;T@:KWW3
M<1D1:'YQ<N )-']2=A4"18 9>I$  (  ?TQ&B7DJ:Q- ('EJ;.<Y9'G";IHR
M+GH]<!\JNGK+<:<C)7M=<S0:TGO)=,,1N'R==ED)EGWO>6<"I7\7?,   (
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M828S"X7:8Z\L1X6?9@(E+H6&:%4=Y86%:J45T86!;.(-GH2R;W\&N(.Y<Z,
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M=KPKFWRC=\4D[7SX>-8>'WU:>?@6IWUG>S\.X7W??0H((7Z)?P "$G]4@$0
M (  @  ]$'KI>5TWFWJY>I<QSGJI>Z,KA'K$?&\D[WLL?4,>/WNE?BP6ZGO'
M?T(/.WR@@'H(>GVA@4H"5WZN@94  (  @  \MWE ?JTW77D3?Y\QJ'D'@&LK
M<7DE@00D\GF>@:(>6WHL@EH7)GIG@SP/B7N6@V0(QGS@@SH"D7XE@;P  (
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M<VTJQ(13=-XE%(.^=BD?!X.,=W88UX-V>-,2%X+.>FL+S(&S?.<&-X$9?O4
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M=#(     ! ,+   !                     0                    $
M  $   (   #6 :X"B@-J!% %/ 8M!R ($@D$"?8*Z O:#,L-NPZL#YT0CQ&"
M$G83:A1?%5462A=!&#<9*QH/&O0;VAS!':@>D1][(&8A4R)"(S(D)"48)@TG
M R?Z*/$IZ2KA*]@LSRW$+K@OJS"<,8LR>#-C-$PU-C8@-PDW]#C@.<TZNSNL
M/* ]E3Z-/X= @$%Z0G5#<D1Q17%&<D=U2'I)?TJ&2XU,EDV@3J=/K5"S4;I2
MP5/*5--5W5;G5_)8_5H)6Q5<(5TM7C1?.V!"84AB3V-69%UE9&9K9W)H>6F
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MI[*HWZH-JSNL::V8KL>O]+$2LC"S3K1LM8NVJK?)N.FZ"KLLO$^]<[Z8O[_
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M&F@C:2UJ-VM!;$UM66YE;W)P@7&/<I]SKW3!==-VYG?Z>0]Z)7L[?%%]:'Z
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M[>[O3O"O\A+S=?3:]C[WHOD$^F3[Q?TH_I#___\ @ "  .GS@ & #M3F@ .
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M]982E'.!I87#DBZ!B'65C_2!?V4\C=.!=E3?B[^!<$2FB:^!<C1ZA[R!@B5
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M1[<YB!IX_Z4]ATMYJI-#AG5Z>(%5A9Q[6F\JA.9\,ESMA$)]!DK*@YQ]U#C
M@O1^@2=*@D1_5]B<B26 U\<8B 6 I[5PAPB >Z./AD* 59' A8& 7H #A,"
M?&X'A"& F5OZ@Y& MDH/@O^ S#A0@F> RR<Z@<. V=:RA_")S\5 ANZ(R[.S
MA@R'TJ'YA5J&ZI!5A*R&,W[&@_Z%CVSX@W&$\EL<@O*$5DEH@F^#M#?M@>>#
M "<L@5""1-3JARZ2B,.-AC>0P+(7A5B/ Z!ZA*&-6H[\@_J+Z'V9@UF*B6OZ
M@M>)-5I0@F2'XTC4@>V&AS>5@72%'2<@@.J#E-,IAHB;:,'BA9N8U;"%A,&6
M49\%A 63YHVM@V.1MWQT@LF/F6L&@E"-BEF1@>6+?$A/@7:)83=/@0.'/B<J
M@'J$ZM&4A?BD*\!4A1J@V:\'A$>=F)VC@X>:<(QO@N>7A'M?@E*4IVHA@=Z1
MVECC@7B/#$?;@0N,,3<:@)>)5"=%@ :&.] DA:.L[;[UA+>HX:V\@]NDX9QP
M@QF@]HM;@GN=1GIO@>B9H6E;@7J6#UA,@1F2?$=W@*^.W#;L@#J+1"==?Z*'
M:,[,A6FUL;VGA&JP\ZQ^@X&L.YM.@KRGD(I7@AZC'7F,@8R>KVBA@1Z:4%?
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MJ;]X]V#^I4UYWU5QH-YZVTG*G'Q[WCY F!]\[#,)D\I^!B@3CY]_*QZ5BW"
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M 5%;D5U\P$19CK=]@C>BC!E^4BLOB:-_-2 ;AR& /IU=H=!_Q9"[GJ!_WX0
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MI=M_-WJIHCA_1&ZRGJ]_4F+:FTQ_AU<VE_!_STM:E)^ $3^,D5. 5S04CA"
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ML4A_ 7RYK-E_(W&4J(Q_/F9OI')_3EMSH'=_AU"SG']_U47/F(V (SL*E)N
M=S"HD*V U2:AC.&!/AX=B1F!NX</L&6%3WP!J_R$^'#UI[.$EF7HHY^$(UL
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MP!_0A2>'9WYSNUIRI'/QMAISY6EWL0AU%5\"K#YV*U3&IX]W;4K0HN)XR4#
MGCMZ)3;6F9)[ABU2E.=\[R0GD$Y^41Q[B]!_QGXJNBUX^'.EM0QYF&DKL!%Z
M-%ZWJU)ZQU2#IJU[ATJ9H@=\7D";G6!]/#;)F+-^(2UAE 9_"R1<CW%_[1S8
MBO> WWVNN1Y_$',MM Q_,VB^KQ]_3EYEJFQ_751"I<Y_F4IDH2Y_ZT!XG(Z
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MD4B /!ONC ^!#W-LP3)_HVEJN]E_=%^@MGA_7U8?L1)_;DSCJ[5_K4/WIDZ
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M?G95>%Z5<F7A>2F2;E5N>?N/9D4U>L:,4C4]>X:)1"94?#>%_,;&='"N#[:
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ML6T$>NJFX5X0>SV@]4\L>Z*:\T"2? .4[3)(?&2/ "52?*R)(KL4B:-M0:Q
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MG0A\ADR[F7)],T)TE>Y]XCA,DF]^F2Z'CO)_6"4=BXV &QTTB#J \'^DJP:
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ML@E[7U$3K1=[X$A[J"%\AT WHQ]]13?UGAM^%R_QF1!^\2A>E 5_Q2$OCQ"
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M>KJ":'Q">QR",FU<>X""!UXN>_Z!WD[V?(N!LC_W?1>!?3$K?9Z!+".$?B>
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M@"J!58,'?_V!+W3Z?]:!'V<&?[.!&5C,?ZN!$4J.?["!!3R1?[. ]"[-?[2
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MAO^ !H?=ABB $'K0A6: #FVSA*^ (V"S@_R 0E-N@V: 6D8K@MV ;SDQ@E.
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M>GXOD@:0/7-@D B.ZVALCC.->EURC&V,&E*CBJF*O4>GB0:)6SS%AVV'^#)
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MJ.AX440HI%]Y93R,G\AZC#3MFS=[RBV'EJ9]$":,DAE^2Q_IC9Y_9AJFB7J
M=F4PM0=[;UR%L*)[N501K#=\'$OEI\E\HD0%HS]]/CQ\GJ=]Z33QFB=^G2VB
ME:]_5R:^D3F #R RC-" N1L'B+Z!7F3/M R T%PTKY^ L%/.JS. IDNMILV
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MF2)^!E6>EH)^6DS"D]M^O40CD3!_*3M@CJQ_CS+!C#=_]RJ&B<" 9B*9AT^
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MHKE\Y%:XGUQ]94YWG"!]T$9FF-1^23Z@E8%^RC;(DDY_3"\?CR=_T2?>C *
M62#LB.> X!MCA@:!96:HI3&!P%YZH<F!WE9.GG:![$X>FT.!XD8@F .!YCYO
ME+J!\C:PD8V!_B\CCFN"#"?\BTJ"'2$AB#&"+QNOA5*"268>I$B' %X*H/.&
MK%7SG:Z&1TW1FH.%R$7DETR%5CY$E Z$[3:;D.>$@B\FC<F$&2@5BJN#MR%.
MAY6#6QOPA+F##V6AHWF,)UV;H"^+:%63G/.*DTV!F<R)HD6DEJ"(O3X6DVV'
MW3:!D$Z&^"\AC3.&%"@EBAN%.B%RAPR$;!PFA#>#O&4OHL61/UTIGWN0'E4I
MG#^.XDTKF1B-@T5?E?>,*CWBDM.*U#9@C[N);B\3C*:(!B@LB96&KB&-AI*%
M9QQ4@\J$4&2LHB&6/5RYGMV4IU3,FZ22^4S>F'V1+D4BE6:/8CVTDD^-ES9!
MCSZ+L2\%C"Z)R2@OB22']R&BABV&/QQY@W&$RV0GH9&;"EQ5GEB8Y%2 FR:6
MN$RAE_Z4@43QE/"21CV/D>20"C8ICMF-JR[ZB\R+3"@RB,B)#"&RA=R&\AR7
M@RJ%+U]JL\]EV%=IK[)G]4^)JXYJ(4?1IV1L8D!:HR)NRSDSGM=Q2S(!FJ-S
MU"L!EG=V821FDDMXXAX6CA][.QD<BE)]>E]%LAAKB5= KAYM(T]AJA9NU$>P
MI?QPI4!&H<QRESDQG9)TGC(3F69VMRLJE3YXV"2HD1UZZAYTC0M\T1F4B5=^
MGE[[L'EQ'U;VK)UR04\@J*]S?D>$I*MTX$ LH(MV6SDHG%YWZ#(?F#UYBBM-
ME")[-23BD!%\T1[&C!=^1QG\B'Q_IEY]KPQVE%:8JT9W4D[;IVEX*4=-HV]Y
M'T 'GU9Z)3D6FR][-C(DER!\5"MIDQU]>244CR1^EA\-BT%_G!I7A[R DEX+
MK>I[V59"JB)\-TZ:IDE\IT<9HEE]+S_CGDE]PCD&FBM^73(JEBE_ 2N'DC-_
MJ"5(CDB 31]3BG2 Y1JNAOR!=5W4K." Z%8'J2& UDY@I5& UD;HH6R [C_"
MG6B!%3CWF5:!1C(QE5F!?"NED6>!M"5[C8&!ZA^4B;."&1K^AD*"25V9J^.%
MRU7/J#J%1DXNI'J$TT:_H)^$?#^EG*6$.#CJF)V#_S(WE*:#QRN_D+B#DB6G
MC->#7A_,B0^#*1M!A:.# 5U.JP"*C%6.IV&)G4WWHZJ(P4:2G]6'_C^%F^B'
M3SC7E^Z&JS(WD_V& RO2D!2%727)C#N$O1_[B'Z$(1M[A1V#H5SRJCN/+E5
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M3#H[>TIX+RR_?%)YZB!^?69[PZ8D<7APUICG<J)R+(N1<\)S?'X/=-%TQ'"
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MAM!^1RLUA79^^2+OA"%_MAPE@MV =G%*D!U_E&BDCJ-_R5_HC2I_^E<$BZ^
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M=QF /UKW=_> 6%![>-* <46\>;F ?#L,>J6 @3"[>XB AR:[?%B CQX_?1V
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M>\U^XE[@?"U_(54*?(-_84M:?-=_HD%J?3U_U#>-?:B  BX4?@J -B3N?EJ
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MF[9\ED0NF0U]$SX1EF-]KC@TDYA^3S*KD,-^\RT@C>9_DB?#BQ2 +"*QB&:
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MMF6?;)27?5Q2;EF5*5+J<"J2T$FJ<?R0<$ K<[N-]3;'=7.+<"W2=RR(]B5
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M\TC-EOY?>T(-E-%BWCMEDIYF5C3\D&YIW2YUCE1M8B@9C$=PZ2(DBD5T:!R
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MT".L@F:$-AY]@8.#G!J&@+^#'5$7BSZ, $M;B@>+=D6,B,V*TS^<AXZ*#SG
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MDP9YN3I'D.!ZL#3VCKA[L2_RC(Y\MRKNBD]]OB82B!M^P"%SAAI_KASDA%Z
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M>!E_/80$5U"!47F&6OR!6V\ 7FV!4V1G88^!,EG)9+:!$4]59^2 \42E:R.
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M?;R @F)\<5)_;EL<<K)_PE.D<_I__TP&=2. '$1P=DZ /ST5=WJ 9S6:>+*
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M@9:!<$2PC&)\7T #BQI]8#M/B<=^.3:-B&9^W#'FAS1_>RV%A@Z %RDHA+V
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M_SQ[;,N%:#4];\6$U2XL<J^$0R=T=7J#JR#P>!R#!AO.>F2">6%'77>.#%G
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M;FA\BC^#<()]%CC9<IY]K#(@=+Q^5"N5=M1_!25D>-I_L1]I>LN 4!K ?'6
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MF!U;?TUZ/!D!@ U\LU7[=:=HH4^(=FIJM4C^=T-LR4)/>#INWSO$>3UP^S6
M>D1S'B\E>U)U3BCW?&)WAR,H?6UYNQV;?G-[XAE0?U5]X%4O<U1N-D[P=$5O
MXDB2=4YQB$(#=G9S*3N3=ZATT35I>-YV@B\L>A=X0BD<>U!Z"B-D?(1[RQWC
M?;)]>AFC?K5_!E2S<45SP4Z!<E]T[$@U<Y)V%4'"=.=W/3MI=D5X<C55=Z1Y
ML"\S>05[ 2D[>F5\6B.7>[U]J1X@?0Y^YQGJ?BZ "51#;WMY)TX;<+-YX4?B
M<@1ZF4&,<WI[3CM)=0!\$35)=HE\W2\]>!-]NRE:>9E^GB/&>Q1_=AY5?(.
M.AHE?;N [%/&;?)^64VV;SQ^RD>8<*!_*4%A<B=_;SLS<])_PC5%=8: '2],
M=SR @BEZ>.J Y2/R>H:!.QZ%? ^!=QI7?5N!L%-K;)B#@DUF;?J#AD=:;W&#
M>$$^<0>#43LB<M&#-S5#=*N#(R]:=H>#$"F6>%J"]R07>A."SQZK>[""BQJ
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M\QG"AS)VQQ;'AAIZ/$#BDY=6DCR@D:5:5C@UC]I>%C./CCYAV"[IC,)EI"J
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M6R\1?QB"KRM5?SB"\R>;?R"#(2/G?PF#,B L?R&#'QPC?WZ"TAD@?\N"E@
M__\  /__  #__P  ;69T,0     #!"$   $                    !
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M][VNA_>]KH?W_;1%(OVU3#O]LU-7_;!<=/NQ8(CSLV&9[;5AI^:W8K3ANF/
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MT&B\A\MIQ7S';<QWQG?.=\:&S7C'E\QYR*G+>L"KS'K J\QZP*O,>L"KS'K
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MP'C,9\-VS&_$=LQYPW?-A,)XS9#!><Z9P'G.F<!YSIG ><Z9P'G.F<!YSIG
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M<JV[X'6UN]AYN+K1?;BZRG^XNL6 N+O%@+B[Q8"XN\6 N+O%@+B[Q8"XN\6
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MO\E_M+_#@K6_O(.TP+B$M,"XA+3 N(2TP+B$M,"XA+3 N(2TP+B$M,"XA+3
MN(2TP+B$M,"XA+3 _YDC#?^;,B#_FCXV_YI)2O^B4%7_IU=A_ZI>;/^K8WC^
MJF>"^:AKC?2C;I?NG'*AZ)-ZJN&*@;+9@(F[TGF2P<]XGL+->JK"R7VRPL*!
MLL*\A+/"MH6RPK*%LL.RA;+#LH6RP[*%LL.RA;+#LH6RP[*%LL.RA;+#LH6R
MP[*%LL.RA;+#_YHC#?^;,A__FCXV_YM)2?^C4%3_J5=?_ZQ>:_^M8G7\K&:
M]JMJBO"I;Y3JHW.=XYQYIMN2@+#2AX:ZR7^-PL5\F,7#?:7%P("PQ;J#L<2U
MAK'$L(:QQ:V&L<6MAK'%K8:QQ:V&L<6MAK'%K8:QQ:V&L<6MAK'%K8:QQ:V&
ML<6MAK'%_YHC#?^;,A__FSXV_YU)2/^E4%/_JUA>_ZY>:?ZO87/YKV5]\ZYI
MA^VM;I#GJ7*9WZ-YH]68?J_+CH2YP86*PKN D\>X@:#'MX*MQ[*%K\>NAZ_'
MJHBOQZB(K\>HB*_'J(BOQZB(K\>HB*_'J(BOQZB(K\>HB*_'J(BOQZB(K\>H
MB*_'_YHC#?^<,A__FSXV_YY)1_^G4%+_K5A<_J]=9_RP8''WL61Z\+%H@^JQ
M;8SDL'*4VJAVHM">?*[%E8&XNHN'PK*%CLBNA)K*K(:HRJJ'K<JGB:W)I(FM
MR:*)KLFBB:[)HHFNR:*)KLFBB:[)HHFNR:*)KLFBB:[)HHFNR:*)KLFBB:[)
M_YLC#?^<,A__G#XV_Y])1O^H4%#_KEE;_;%<9?JR7V[TM&-W[;5G?^>V;(?@
MM&^3U:QSH<JD>:V_FW^XM)*$P:J*BLFEB)7,HHFBS*&*J\R?BJO,G8JLRYR*
MK,N<BJS+G(JLRYR*K,N<BJS+G(JLRYR*K,N<BJS+G(JLRYR*K,N<BJS+_YLC
M#?^=,Q__G#XU_Z%(1?^J44__L%E9_+)<8_FT7VOQMV)SZ[EG>N6\;(';N6N2
MT+%QH,6I=ZRZH7RWKIF"P*.0ALF;C(_.F(R<SY:-JL^6C*K.EHRJS9:+J\R6
MBZO,EHNKS):+J\R6BZO,EHNKS):+J\R6BZO,EHNKS):+J\R6BZO,_YLC#?^=
M,Q__G3XU_Z)(1/^K44[^L5A7^K1;8/:W7FCONF)OZ+]G=.'":(#6OFB1R[9N
MG[^N=*NTIWJVJ)]^P)V7@\F2D8G/C8^6T8N1I=&,CZC1C8ZISXZ-JLZ.C:K.
MCHVJSHZ-JLZ.C:K.CHVJSHZ-JLZ.C:K.CHVJSHZ-JLZ.C:K._YPC#/^>,Q__
MG3XU_Z1(0_^M4DS\LEA5^+9:7?2Y763LOV%IYL9G;=W)8G_1PV:0Q;MLGKFT
M<:JNK7:UHJ9[OY:>?\B)EX7/@I6/TX"6G]*"E:?2A9*HT(>0J<^'D*G/AY"I
MSX>0J<^'D*G/AY"ISX>0J<^'D*G/AY"ISX>0J<^'D*G/_YPC#/^>,Q__GC\U
M_Z9(0O^O4TK[M%=2]KA96?&]7%_JQ&!BX\QC:]C177[,R6./O\%IG;.Z;JFG
MLW.TFZUWO8ZF>\>"H(#.>YZ+TGF@F]%[GZG0?YFISX"6J<^ EJG/@):ISX"6
MJ<^ EJG/@):ISX"6J<^ EJG/@):ISX"6J<^ EJG/_YTC#/^?,Q[_GS\U_ZA)
M0/ZQ5$CYME5/]+M75.W"6ECFS&%8WM9;:M+76GW%SV&-N,AFG*S":ZB@NV^R
ME+5SO(>N=L5[JGS,=:F(SG2KF<UTK:O,>Z6LRWR?J\Q\GZO,?)^KS'R?J\Q\
MGZO,?)^KS'R?J\Q\GZO,?)^KS'R?J\Q\GZO,_YTD#/^?,Q[_H#\U_ZI*/ORS
M4T7WN%1*\+]53NC)64[@U5U1UN!7:,O>67N^UUV,L=!BFZ3*9Z>8Q&JQB[YM
MNWZX<<-TM7C)<+:&R7"XE\AONZO'=K*OQGBKKLAXJZ[(>*NNR'BKKLAXJZ[(
M>*NNR'BKKLAXJZ[(>*NNR'BKKLAXJZ[(_YXD#/^@-![_H3\U_ZU+//JU4D'S
MO%)$Z\531>+26$'8X%=/SN9:9L/D6WFVWUR*J-I?F9O48J6/SF2O@LEGN77%
M:\!NQ'7$:\:$Q&O(E<-JRZG"<,2TP'*YLL)RN;+"<KFRPG*YLL)RN;+"<KFR
MPG*YLL)RN;+"<KFRPG*YLL)RN;+"_Y\D"_^A-![_I$ S_[%-./>X4#OOP4\\
MY,Y1.-C>3D+/YE16Q>U8:;OJ6WFOYUV(H>-=EY/?7:.&V5ZM>=1AMF_09KQK
MSW*^:]!_O6S0C;QMT9V[;=&NNFS,M[MLS+>[;,RWNVS,M[MLS+>[;,RWNVS,
MM[MLS+>[;,RWNVS,M[MLS+>[_Z D"_^C-1W_J$$O^[1.,_.]3#3HR4LPVMM%
M-,_E2TG&[E%=N_)5;['O5WZE[%J,E^58F8O?6:. VENL==5=LV[38[=LTVVX
M;--XMVS3A+9MU)&U;M6?M&[5K+-NU:RS;M6LLV[5K+-NU:RS;M6LLV[5K+-N
MU:RS;M6LLV[5K+-NU:RS_Z(E"_^E-1W_K$,J^+A+*^W#1RC>U4$CT.1#.L;N
M24^\]DYCLO=2<ZCR5H*:ZU2.CN54F8/?5:)YVU>I<-A:KVO67[)HU6>S:-9P
MLFC6>;)IUX2Q:MB1L&K8FZ]JV)NO:MB;KVK8FZ]JV)NO:MB;KVK8FZ]JV)NO
M:MB;KVK8FZ]JV)NO_Z0E"O^G-AS^LD8C\KY&(>///AC2XCDIQ^U"0+WV2%6S
M_4UGJOE2=ISQ4(.0ZU".A>50F'OA49]SWE.E;-M7J6?:6ZQEVF*M9-IIK63:
M<*QEVGFK9=N#JV;;C*IFVXRJ9MN,JF;;C*IFVXRJ9MN,JF;;C*IFVXRJ9MN,
MJF;;C*IFVXRJ_Z8F"?^I.!OWN48:Z,@[$M3?+1G([#HPO?9"1;/^2%BJ_TUI
MG?A+=Y'R2X*&[$N,?.=,E'/D39MLX5"@9]]3HV3>5Z5BWEVE8=YBIF'>:*5A
MWF^E8=YXI&'??Z-AWW^C8=]_HV'??Z-AWW^C8=]_HV'??Z-AWW^C8=]_HV'?
M?Z-AWW^C_ZDG"/^Q.A/NP3L,U]L="LGK,1^^]CLUM/Y#2*K_2%J=_T9ID?E&
M=8;S1G]\[D>(<^M(CVOG2I1EY4R88N1/FE_C4YQ>XU>=7>)<G5SB89U<XV:=
M7.-MG%SC=)Q<XW2<7.-TG%SC=)Q<XW2<7.-TG%SC=)Q<XW2<7.-TG%SC=)Q<
MXW2<_ZTH!_2[.@?>TQD!R^DD#[_U-".U_CXXJO]!29S_0%F0_T!FAOM!<7SV
M0GIS\D.!:^]$AV7M1HM@ZTF.7>I,D%OI3Y%9Z5.26.A6DUCH6I-7Z%Z35^AD
MDE?I:9)7Z6F25^EIDE?I:9)7Z6F25^EIDE?I:9)7Z6F25^EIDE?I:9)7Z6F2
M_;,G!.7*'0#-YA4$P/0K$[7]-R:J_SLXG/\Y1Y#_.56%_SMA>_\\:W+[/7-J
M]S]Y8_1!?5[S0X%;\46#6/!(A%;P2X95[TZ&5.]1AU/O5(=3[U>'4N]<AU+O
M8(=2[V"'4N]@AU+O8(=2[V"'4N]@AU+O8(=2[V"'4N]@AU+O8(=2[V"'ZL$*
M ,_6!P#!\Q\&M_TP%:G_,B6;_S$UC_\Q0X3_,T]Z_S5:</\W8FC_.6EA_3MN
M7/L]<ECY/W55^$)W4_=$>%+W1WE1]TEY4/9,>D_V3GI/]E%Z3O95>DWV6'I-
M]EAZ3?98>DWV6'I-]EAZ3?98>DWV6'I-]EAZ3?98>DWV6'I-]EAZS,@$ ,'F
M!P"V_2 'J?\F%)O_)R*._R@P@_\J/7G_+4=O_R]09O\R6%__-%Y9_S9B5?\Y
M95+_.VA0_SUI3O] :DW_0FM,_D1L3/Y&;$O^26Q*_DMM2?Y.;4G^4&U)_E!M
M2?Y0;4G^4&U)_E!M2?Y0;4G^4&U)_E!M2?Y0;4G^4&U)_E!M_XP<"_^-*1S_
MBS<P_X9$1?^*3%+_C5)?_XQ8;/^(7G?^@F2#^7MLC?1T=)?Q;7R>[V>%H^YD
MC:7M9):F[62>INUEI:;M9:VF[6:TINYGO*7I:L"EY&W"I=YPQ*3:<L>DVG+'
MI-IRQZ3:<L>DVG+'I-IRQZ3:<L>DVG+'I-IRQZ3:<L>D_XP<"_^-*1S_BS<P
M_X9$1?^*3%+_C5)?_XQ8;/^(7G?^@F2#^7MLC?1T=)?Q;7R>[V>%H^YDC:7M
M9):F[62>INUEI:;M9:VF[6:TINYGO*7I:L"EY&W"I=YPQ*3:<L>DVG+'I-IR
MQZ3:<L>DVG+'I-IRQZ3:<L>DVG+'I-IRQZ3:<L>D_XP<"_^-*1S_BS<P_X9$
M1?^*3%+_C5)?_XQ8;/^(7G?^@F2#^7MLC?1T=)?Q;7R>[V>%H^YDC:7M9):F
M[62>INUEI:;M9:VF[6:TINYGO*7I:L"EY&W"I=YPQ*3:<L>DVG+'I-IRQZ3:
M<L>DVG+'I-IRQZ3:<L>DVG+'I-IRQZ3:<L>D_XP<"_^-*1S_BS<P_X9$1?^*
M3%+_C5)?_XQ8;/^(7G?^@F2#^7MLC?1T=)?Q;7R>[V>%H^YDC:7M9):F[62>
MINUEI:;M9:VF[6:TINYGO*7I:L"EY&W"I=YPQ*3:<L>DVG+'I-IRQZ3:<L>D
MVG+'I-IRQZ3:<L>DVG+'I-IRQZ3:<L>D_XP<"_^-*1S_BS<P_X9$1?^*3%+_
MC5)?_XQ8;/^(7G?^@F2#^7MLC?1T=)?Q;7R>[V>%H^YDC:7M9):F[62>INUE
MI:;M9:VF[6:TINYGO*7I:L"EY&W"I=YPQ*3:<L>DVG+'I-IRQZ3:<L>DVG+'
MI-IRQZ3:<L>DVG+'I-IRQZ3:<L>D_XP<"_^-*1O_BS<P_X=$1?^,2U+_CU)>
M_X]8:_^+7G;^A6."^7YKC?5W<Y;Q;WN>[FF#H^UFC*;M9)6G[&2>J.QEI:CM
M9JZG[6>UI^QHOJ?F:\"FX6_"IMMRQ:76=,>EUG3'I=9TQZ76=,>EUG3'I=9T
MQZ76=,>EUG3'I=9TQZ76=,>E_XT<"_^.*AO_C#<P_XE$1/^02U#_DU%<_Y-7
M:/^1773_C&* ^H1HB_5]<)7Q=7F=[FV!I.QHBJCK9I2JZV:=JNMFIJKK9Z^J
M[&BYJN=LOJG@;\"IVG+#J-1UQ:C/=L2ISW;$J<]VQ*G/=L2ISW;$J<]VQ*G/
M=L2ISW;$J<]VQ*G/=L2I_XX<"O^/*AO_C3<P_XM#0_^32T[_EU%:_Y=79O^6
M77+_DF)]^XMGB?:";I/R>G:<[G)_I.QKB*GJ9Y*LZF>=K>IGIZWJ:;*LZ6N\
MK.%OOZO:<\*KU';#JLUXPJO(><*LR'G"K,AYPJS(><*LR'G"K,AYPJS(><*L
MR'G"K,AYPJS(><*L_X\<"O^0*AO_CC<P_XY#0O^52DW_FE%9_YM79/^:7'#_
MEV%[_)%FAO>(;)'S@'2;[W=]H^MNAJKJ:9"NZ6><K^AHJ*_H:K.NXVZ\KMMR
MP*W4=L&MS7G!K<9ZP*[">\"OPGO K\)[P*_">\"OPGO K\)[P*_">\"OPGO
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M(0#4U @ QNT>!KOX,!6R_SPGI?\[.)?_.4>+_SE5@?\[8'?_/&IN^SYQ9OA
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M_Y,\,?^<13G_HDU!_Z942?>H6E+OJ5];Z:AC9>*D9V[:G6Q\T91SBLB,>9C
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MAE#OFX90[YN&4.^;AE#OFX90[YN&4.^;AE#OFX90[YN&_YL6 _ZP&0#8QP<
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M@_Y2RX/X5L^#\UG1@NY<U(+I7]:!Y&+:@>)CVX#B8]N XF/;@.)CVX#B8]N
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M>D_3Y'I/T^1Z3]/D>D_3Y'I/T^1Z_X<.!/^;#@#:K , T+H$ ,;( P"\UP<
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M./^S8#C_LV X_[-@UJ8  ,JU  "_Q $ M-$! *?> P"=_Q0#E/\?"XK_)A>
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ML))E8JB-:F^@B&]ZF(-SA)%^>8V,>H"3B'F*E89YE9:$>:*6@WJPEH%ZP9:
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MBUJ?VHM:G]J+6I_:BUJ?VHM:G]J+_W(."?^&$P3_EA4!]*00 -:P!@#/O 4
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M<D_/>W%.T(IP3M&:;TW2JVU,T[YL3-/8:TO2[6S_XGT024-#7U!23T9)3$4
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M2%1"^D]60/M75C[[858]_&Q5._QY5#G]AE,Y_I52./ZC43C_LU$W_\!0-__
M4#?_P% W_\!0-__ 4#?_P% W_\!0T*8  ,6T  "[P   K\P  *+5  "7Z04
MC?T3 X3_' I\_R,4<O\H'VC_*RE?_RXR5O\Q.4__-#])_SA$1?\]2$'_0DH]
M_TA+.O].3#C_5DPV_U]+-/]I2S/_=4HQ_X%)+_^-2"__FT@N_Z9'+O^F1R[_
MID<N_Z9'+O^F1R[_ID<N_Z9'QZ\  +R\  "QR   I-(  )?:  ",\00!@O\-
M!7G_%0IO_QL29O\?&UW_(R15_R<K3O\J,4C_+C9"_S(Z/O\V/#O_.SXX_T _
M-?]%0#+_3$ P_U- +O];0"W_9#\K_VX_*?]X/B?_@SXF_XT])O^-/2;_C3TF
M_XT])O^-/2;_C3TF_XT]OK@  +/%  "FSP  F-8  (O>  " \P !=O\&!6W_
M# IC_Q(06O\6%E+_&AQ,_QXB1?\B)T#_)BL[_RHN-_\N,#3_,C$R_S<R+_\\
M,RS_03,J_T<T*/]-,R;_53,D_UPS(O]D,B#_;3(?_W0R'_]T,A__=#(?_W0R
M'_]T,A__=#(?_W0RM<$  *C,  ":U   C-L  '_B  !T]  ":O\ !6'_ @I8
M_P</4/\+$TC_$!A"_Q0;//\7'C?_'"$S_R B,/\C)"W_)R0K_RLE*?\P)2;_
M-"4C_SDF(?\_)A__128=_TLF&_]1)1G_6"48_UXE&/]>)1C_7B48_UXE&/]>
M)1C_7B48_UXE_TT8$_]$(AK_/"T@_T$P(O]&."K_1T(U_T5,/O]!5D7_/6%+
M_SIN3O\X>E#_-X50_S>04/\WF5#_.*%0_SFI4/\YL$__.KA/_SO"3_\\S4[_
M/-A._SWD3?\^[TW_/_=,^D+Y3/9$^TOQ1_U+\$?]2_!'_4OP1_U+\$?]2_!'
M_4OP1_U+_TX8$_]%(AK_/RL?_T4N(O])-BK_2T T_TI+/?]%54;_05],_SUK
M4/\[>%'_.H-2_SJ.4O\ZEU+_.Y]2_SRG4O\\KE'_/;91_SZ_4/\_RE#_/]50
M_T#C3_U![D_[0O=.]D7Y3?)'^TWM2?Q.ZTG\3NM)_$[K2?Q.ZTG\3NM)_$[K
M2?Q._T\7$O]&(1G_0BD>_T@M(?].-2G_4#\S_TY)/?])4T7_15U,_T%I4?\^
M=5/_/8%4_SV+5/\]E53_/IU4_S^E4_\_K%/_0+13_T&]4O]"QU+]0M-1^T/A
M4?E$[5#W1?90\DCY3^Y*^T_H2_M1YDS[4>9,^U'F3/M1YDS[4>9,^U'F3/M1
M_U$7$O]'(1G_12@>_TPK'_]3-"?_53XQ_U-'._]/4D7_25M-_T5F4O]"<E7_
M07Y6_T"(5O] DE;^09M6_4*C5?Q#JE7[0[)5^T2[5/I%Q%3Y1M%3]T??4_5(
M[%+R2/91[DOY4>A,^E+B3OI4X4_Z5.%/^E3A3_I4X4_Z5.%/^E3A3_I4_U(7
M$O]((!G_228<_U$I'O]9,R7_6STO_UE&.?]53T/_3UE,_TEC4_]&;U?]1'I8
M^T2%6?I$CUGX19A8]T:@6/9'IU?U1Z]7]4BX5O1)PE;S2L]5\4O=5>Y,ZE3L
M3?54YT[X5>%0^5;;4OE8VE+Y6-I2^5C:4OE8VE+Y6-I2^5C:4OE8_U,7$?]*
M(!C_3B0;_U<H'/]@,B/_8SLM_V%$-_]<34'_5E=+_%!@4_E+:UCW27=;]4B!
M7/-(BUOQ291;\$J=6^]+I5KN3*U:[4VU6>Q.P%CK3\Q8ZD_<5^=0ZE?D4?57
MWE+W6=A4]UO25?A<T5;X7-%6^%S15OA<T5;X7-%6^%S15OA<_U46$?]+'QC_
M4R$9_UTG&?]F,2#_:CHI_VE#,_]D2SWZ7E1(]E==4O)1:%GO3G)=[4U]7NM-
MB%[I3I%>Z$^:7>=0HEWF4:I<Y5*S7.12OEOC4\M:X53;6MY5ZEG;5/5<U%;V
M7L]8]U_)6?=AR%KW8<A:]V'(6O=AR%KW8<A:]V'(6O=A_U86$?]-'QC_6!\7
M_V0F%_]M,!W_<3DF_W!!+_MM23GU9E%$[U];3^M89%CG4V]>Y%)Y8>)2A&'@
M4HUAWU.78-Y4GV#<5:A?VU:Q7]I6O%_95\E?UE?:7]19Z5_16/1AREKU8\5;
M]63 7?1EOUWT9;]=]&6_7?1EOUWT9;]=]&6_7?1E_U<6$/]/'A?_71X5_VDE
M%?]R+QK_=S@B_7A *O9U1S3O;T\_Z6=82N1A857?6VM>VU=U8]E6@&365XEE
MU%>39=-8FV716*1ET%FM9<Y:MV7-6L1ES%O39<E<Y67&7/-FP5[R:+Q?\FFX
M8/%JMV'Q:K=A\6JW8?%JMV'Q:K=A\6JW8?%J_U@6$/]3'!7_8AT3_V\D$O]X
M+A?_?3<>^7X^)?%\1B_J>$TYY')61-UK7U#89&A;TEYQ9,Y;>FC,6X1JREN-
M:LA<EFK&7)]JQ5VH:L1>LFK"7KYJP5_-:K]@WVJ\8.]KMV+O;;-C[VVP9.YN
MKV3N;J]D[FZO9.YNKV3N;J]D[FZO9.YN_UH5$/]7&A3_9QT1_W,C$/]]+13_
M@C4:]80](>V#1"GE@$PSWGM5/=AU74K0;&59RF9M9,5A=6O"8'YNP&"';[Y@
MD6^\8)IONF&C;[EBK6^X8KAOMF/'<+5CV7"R9.MPKF7L<:MF['*H9^MRIV?K
M<J=GZW*G9^MRIV?K<J=GZW*G9^MR_UL5#_];&1+_:QP/_W<C#O^!*Q'[AS06
M\8H\'.F*0R/AB$HLVH14-]%\6T?*=6-6PVYJ8[UH<6RY97IQMF2"<[1DBW2R
M9)5TL66>=*]EJ'2N9K-TK&;!=*MGTW6I:.9UIFGI=:-IZ7:@:NEVH&KI=J!J
MZ7:@:NEVH&KI=J!JZ7:@:NEV_UP4#_]>&!'_;QP._WLB#/^%*@_XBS,2[HXZ
M%^6/01W=CDDDU(E2-,R#6D3$?&%3O75G8+9O;FNQ:W5RK6E]=JMHAGBI:(]Y
MIVF9>:9IHWFD:JYYHVJ\>:%KS7F@:^%YG6SF>IMLYGJ9;>9YF6WF>9EMYGF9
M;>9YF6WF>9EMYGF9;>9Y_UP4#_]B%Q#_<AL,_WXB"_^(*0SUCS$/ZI,X$^*5
M/Q?9E$<@T(Y0,<>)6$&_@E]0N'QF7K%V;&JK<7)SIFYY>:-L@7N@;(M]GFR4
M?9UMGWV;;:I]FFVW?9ANR'V7;MQ^E6[C?I1OXWV2;^1]DF_D?9)OY'V2;^1]
MDF_D?9)OY'V2;^1]_UT4#O]E%0[_=1L+_X$A"?^+* KRDB\,YY<V#MZ:/1+5
MF$4>S)-/+\..5S^[B%Y.LX)D7*Q]:FBE=V]RGW-V>9MQ?7Z8<(: EF^0@91P
MFH&3<*:!D7"R@9!PPX*.<=B"C7'A@8QQX8&+<>& BW'B@(MQXH"+<>* BW'B
M@(MQXH"+<>* _UX4#O]G% W_>!H*_X0@"/R.)@COEBT)Y)LS"MN>. W1FT0<
MR)=.+;^25CVVC5Q+KHAB6:>":&:@?6UPF7ES>91U>8"0<X&#C7*+A8QREH6*
M<Z&%B'.NAH=SOH:&<]*&A7/>A85SWX2$<]^#A'/@@X1SX(.$<^"#A'/@@X1S
MX(.$<^"#_U\3#O]J% S_>QH(_X<?!OJ1)0;MF2L&X9\O!]BB-0O-GT(:Q)M,
M*[N753NSDEM)JHUA5Z.(9F2;@VMOE'YP>(UZ=8"(=WV&A76&B(-UD8F!=IV*
M@':JBGYVN8I]=LV*?';;B7UVW(=]==V&?G7=AGYUW89^==V&?G7=AGYUW89^
M==V&_V 3#O]M% O_?1D'_XH>!?>4(@3IG"<$WJ,J ]2E,PK)HT 8P)]+*+>;
M4SBOEEI'IY)@59^.96&7B6IMCX1N=XA_<X"!>WF'?7F!C'IYC(UX>9B-=GFF
MC75YM8US>LB-<WK9C'1YVHIV>-N)=GC<B'9XW(AV>-R(=GC<B'9XW(AV>-R(
M_V$3#?]P$PK_@!@&_XT<!/26'P+FGR("VZ<A ="H,0G%IC\6O*-))K.?4C:K
MFUE%HI=?4IJ39%^3CFAKBXIL=8.%<'][@76(='Y]CG!]AY!N?921;7ZBD&M^
ML9!J?L2/:7_7CFQ]V8UN?-J+;GS:BVY\VHMN?-J+;GS:BVY\VHMN?-J+_V(2
M#?]S$PC_@Q<%_Y ; O":' 'CHQH UJL; ,NL+P?!JCT4N*A')*^D4#2FH5="
MGIU=4):98EV.E&9IAI!J<WV,;GUTB'*';(1YCF>#@Y%E@Y"19(2>D6.$KI!B
MA<".8878CF.#V(UE@=F,9H#9C&: V8QF@-F,9H#9C&: V8QF@-F,_V,2#?]W
M$@?_AQ8#_I,8 >V>%0#>J L T:X8 ,:P+ :]KSL2LZQ%(:JI3C&BIE5 F:-;
M39&?8%J)FV1F@9=H<7B3;'MNCW"%98QVC&&+@(]?C(Z/7HR<C5Z-K(Q=C;^+
M7([6BEV+VHI?B-J*7X?:BE^'VHI?A]J*7X?:BE^'VHI?A]J*_V</"_][$07_
MBA0"^I<3 .*B"0#4JP8 R[(3 ,&T*02WM#@0KK)#'J6O2RZ<K%(]E*E82HRE
M75>$HF%C>Y]E;G*;:GAHF&Z!8)9UAUR5@(E;E8V)6Y:<AUJ7K(9:E[Z%69C5
M@UF5WH1:D=Z%6I#>AEJ0WH9:D-Z&6I#>AEJ0WH9:D-Z&_VP,"?]_#P/_CQ
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M8DC%]F)(Q?9B2,7V8DC%]F)(Q?9B_(@  -F8  #-I@  P[$  +J\  "OQ@$
MI,\$ )G9"0"4WB$#C-XN#(/=-QAZW#TF<-I",V;913]=UTE*5=9-4D_65%=,
MUEU92M=H6DG8=5E)V8-72=J25DC;HE5'W+-41]W)4D;=XE%$VO-40]KV54/:
M]E5#VO950]KV54/:]E5#VO95WY$  -&A  #&K0  O+@  +'#  "FS $ F]4$
M )+E$P"*Z"(&@^@L$'KH,AMPYS<G9N8Z,ESF/3Q4Y4%$3>5'2TGF3DY&YE90
M1>=@4$3H;%!#Z7E.0NJ'34+JETQ"ZZ9+0>RX2D'MRTE [N9(0.WL1T#M[$=
M[>Q'0.WL1T#M[$= [>Q'U9L  ,BI  "^M0  M,   *C*  "<T@$ D=L# (GP
M% *!\A\(>?,G$F_S+1QF\S$F7?(T,%3R.#A-\SP^2/-!0T3T1T9!]$]'/O57
M2#WV84<[]FQ'.O=Y1CGXB$4X^)9#./FF0C?YLT(W^LI!-_K00#?ZT$ W^M!
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M#O]I$ G_>!4%_X09 _2-' 'FDQX!VID@ =":,0?&F#\4O91)(K6043*MC%A
MI8A>39V#8UF7?FACD'IM;8IV<G2%<WEY@G*"?(!QC'U^<IA]?7*E?GMRLWYY
M<L1^>'+;?GERY'QY<N5[>G+F>GIRYGIZ<N9Z>G+F>GIRYGIZ<N9Z_UD1#?]L
M$ C_>Q0$_X<7 O&/& #CEA< UIP< ,R=+P;"G#T2N9A((+&54"^ID5<]H8U<
M2IJ)8E:2A&9BBW]K;(1[;W1^=W9[>G5^?W=UB(%U=92!<W6@@7)UKH%P=L"!
M;W;6@7!VXG]Q=>-^<G3D?')TY'QR=.1\<G3D?')TY'QR=.1\_UP0#/]O#@?_
M?A,#_XD5 >Z2$P#?F@T TI\9 ,BA+06^H#L0M9U&'JV93RVEEE4[G9);2):.
M8%2.BF5?AX5I:G^!;7-X?7)\<GIY@6YY@X1K>8^%:GJ<A&AZJX1G>KR#9GK2
M@V=ZX(%H>>& :GCB?VIXXG]J>.)_:GCB?VIXXG]J>.)__U\-"_]R#@7_@1$"
M^XP1 .>5"P#6G0< S:(5 ,.E*@2ZI#D.L:%$'*F>32JAFU0XF9=:19&37U&*
MD&-=@HQG:'J(:W)RA&][:H%V@F5_?X5C?XN&88"9A6" J(1?@+F#7X'/@E^
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M<U.6ZG-3ENIS4Y;J<U.6ZG-3ENIS_W(%!/R$! #;D0  T9P  ,BE  "^K0
MM+0  *RX&@"DN2P%G+@X$)2V0AV,M$DKA+)..'RO4T1SK5A/:JM<66*I8&-:
MIV9J5:9N;E.F>6Y2IX9M4J>5;%&HI&M0J+5I4*C*:$^HXFA-IO%J3J+P:TZB
M\&M.HO!K3J+P:TZB\&M.HO!K_W@# >F)  #5E@  RZ(  ,&K  "XL@  K;D
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M24'1^4E!T?E)V9$  ,N?  #!JP  M[4  *R]  "AQ0  E<P! (K4!0""X!(
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M920F_W$C)/]^(R+_BB(A_Y4A(?^@(2'_H"$A_Z A(?^@(2'_H"$A_Z AM[8
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M.O\Q[CG_,^TY_S/M.?\S[3G_,^TY_S/M.?\S_S8<%O\P)!G_.",:_SPE&_]
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M=5YYZG1>>>IT7GGJ=%YYZG1>>>IT_V($!O]U!@'P@0, V8L  -"3 @#(F@$
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M7TN=^5]+G?E?_'D  -N'  #/E   Q9X  +NF  "QK0  IK(  )RV"0"6N2
MC[DO!XBX.A& MT$<>;5(*'&S3#1HL5$^8+!51UFN6D]3K6!53ZUI6$VM=%E,
MK8!83*V.5DNNG55+KJU32J[ 4DJNV5%)K>Q21JOZ5$:K_55&J_U51JO]54:K
M_55&J_U5Y7\  -2.  #)F@  OZ0  +6L  "KL@  H+@  ).^ 0"-P1< A\(H
M!(#"- UYP3P8<;]"(VF^1RY@O$PX6;M005*Z5D=.N5U,2[EF3DFY<4Y(NGY,
M2+J+2T>[FDI'NZM(1KN^1T:\UT9%NNM&0[CY24*X_4I"N/U*0KC]2D*X_4I"
MN/U*VX<  ,V5  #"H0  N:L  *^R  "DN0  F+X  (S% 0""RPH ?LT? 7C-
M+ APS342:,P\'6#+02=8R48Q4LE+.$S(43Y(R%E!1LAB0D7);D%$R7I 1,J(
M/T/*F#Y"RZ@\0LR[.T',U#I!R^HZ/\GX/#[(^ST^R/L]/LC[/3[(^ST^R/L]
MTI   ,:>  "\J0  L[$  *BY  "<OP  D,4  (3+ 0!ZTP8 <MH3 &[;(P1G
MVBT,7]HU%EC9.A]1V3\H2MA%+D;83#-#V50U0MI>-4'::31 VW8S/]R$,C_<
MDS ^W:,O/MZU+CW>S"T\WN0L.MSS+SG;]S YV_<P.=OW,#G;]S YV_<PR9H
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M%Q__C!8>_Y@5'?^F%1W_JA4=_ZH5'?^J%1W_JA4=_ZH5L[4  *B]  ";Q
MC<H  '_0  !SU@  9]P  %SB  !4\0 !3?X !$?_!PA _PP,.O\2#S7_%A$P
M_QL4+?\@%2K_)18F_RH7(_\P%R#_-A<=_ST7&_]&%AC_3Q46_UH4%/]F$Q'_
M<A(._WX1#?^*$ W_C1 -_XT0#?^-$ W_C1 -_XT0JKP  )[#  "0R0  @L\
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MDF=L5X]F<UJ-97M<BV6$78EEC5V(99=>AF6B7H5EKEZ#9;U?@F717X%EYE^
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M9'%J]F-Q:O9C<6KV8W%J]F-Q:O9C_U<#!_]I!0+W=00 W'X  -2$ @#-B0,
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MF$I)J:A(2*FY1T>IT$5'J.=%1:;T2$2E_4E$I?U)1*7]242E_4E$I?U)W7\
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M(SG6QR(YU> A-]/O(S;2^"4VTO@E-M+X)3;2^"4VTO@EQ)D  +JE  "RK@
MI[4  )N[  ".OP  @L0  '?*  !KT   8=@% %O@$@%6X1X%4.$F"DKA+!%$
MX3,6/^$Z&SOA01XXXDD?-^-3'S;D71\UY&@>->5U'33E@QPSYI,;,N>D&C+H
MMADQZ,T8,.CB%S#F\1<PYO$7,.;Q%S#F\1<PYO$7O:,  +2M  "JM0  GKL
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M"@;_E0H&_Y4*!O^5"@;_E0H&_Y4*I[H  )K!  ",Q@  ?LP  ''2  !DV
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M3X->_TZ"7O].@E[_3H)>_TZ"7O]._TX"!_]?! +Z:@0 XG ! -AU @#1> 4
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MEEI0A:583X6V5TZ%RU5-A.)53(/R5TN"_5=+@?Y82X'^6$N!_EA+@?Y8\FL
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M/$6CR#M%H^ Z0Z'P/$*?_#Y!G_X^09_^/D&?_CY!G_X^UGX  ,B+  "^E0
MM9X  *RD  "AJ0  E:P  (BO  !]L@8 >+,; '2T*@-NM#0)9[,\$6&R0AI:
ML4<B5+!,*DZO4C%)KU@U1JY@-T6N:CA$KG8W0Z^"-D*OD#1"KZ S0:^Q,4"O
MQC! K]XO/ZWO,3VL^S,]J_TS/:O],SVK_3,]J_TSSH8  ,*3  "YG   L*0
M *:J  ";KP  CK(  (*V  !TN@  ;;T0 &J^(0%DOBT%7[XU#%B]/!12O$(;
M3+Q'(D>[32=$NU0J0;M=+$"[9RP_O'(K/KQ_*CV\C2@]O9TG/+VN)3N]PR0[
MO-PC.KOM)#BY^B<XN?PG.+G\)SBY_"<XN?PGQX\  +R;  "SI   JJL  )^P
M  "3M0  A[@  'N\  !NP0  8L@" %W*$P!9RR("5<LL!T_+,PU*RCH31,I
M&4#*1QT]RD\?.\I8(#K+8A\YRVT>.,QZ'3?,B1PWS9@;-LVJ&C7-OQ@TSM@8
M-,SL&#+*]QHRR?D;,LGY&S+)^1LRR?D;OY@  +:C  "NJP  H[(  )>V  "*
MN@  ?KX  '+#  !FR   7,X! %+4!@!,V1( 2=H? D3:* = VC +.]HW#SC;
M/Q(UVT<4--Q0%#/<6A0RW643,MYR$C'>@!$PWY 0+^"A#R[@M XMX<L.+.'B
M#2K>\@XJWO0/*M[T#RK>] \JWO0/N:(  +&K  "GL@  F[@  (Z\  "!P
M=,4  &G*  !=SP  4]4  $K; @!%Z P!0.@7 SOI'@<VZ24*,NHL#2_J,P\L
MZSL0*NM#$"GL3! G[5</)NYB#B7N< TD[W\,(_"/"R+PH0HA\;,)(/''"1_R
MX @?\N4('_+E"!_RY0@?\N4(LZH  *JR  ">N   D;T  (/"  !VQ@  :LL
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M /^=! #_G00 _YT$I+@  )>^  ")PP  >\D  &[.  !AU   5=H  $K?  !
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M-Y51_S>54?\WE5'_-Y51_S>54?\W_T$#"/]1 P3_6P4!\F$& .-C!@#:8P@
MT64: ,AF*P2_9#@-N&%#&+%<2R.L65,KJ%=;,:158S6B56LVH%5S-YY5>C><
M58$XFU6(.)E5D#B859DXEU6B.955K3F45;LZDE7,.I%5X#N/5?$[CE3\.XU4
M_SN-5/\[C53_.XU4_SN-5/\[_T4 !O]5 0+Y7P( XV0  -EH @#3: 4 RVH6
M ,)L* .Z:S8+LF= %:QC22"F8%$JH5U8,IU;7S>:668ZF%AN/)98=3R46'P]
MDUB$/9%8C#V06)4^CEB?/HU8JC^+6+<_BE?(/XA7W$"'5^Y AE?Z0(97_T"%
M5_\_A5?_/X57_S^%5_\__T@ !?]8  'P80  W&@  -1L 0#.;0, QF\3 +UQ
M)@&U<#,(KFT^$J=I1QVA9DXHG&-5,9=?7#B376(\D5QI/XY;<$&-6GA!BUJ
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MEEA;:Z186FNS6%EKQU=8:M]666KP55EJ^U19:O]366K_4UEJ_U-9:O]3_ET
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M3$R!PTM+@-M*2G_M2TE^^4Q(??],2'W_3$A]_TQ(??],XVD  --W  #'@0
MO8D  +2/  "JD@  G),  )25! "-EQ@ B)@H 8.7- =]ECT/=Y1$&'"32B%J
MD4\J8X]4,ER-6#I6C%U!48ID1DZ);$E,B7=)2XF#2$N*D$=*BI]%28JO1$F*
MPD-(BMI"1XCM0T:'^$5%AO]%18;_146&_T5%AO]%W6\  ,Y\  #"AP  N8X
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M)3JF]B<YIOTI.:;]*3FF_2DYIOTIR(4  +V1  "TF@  K*(  **G  "7J@
MBJT  'VP  !OLP  9K8' &&W&0!=MR<"6;<P!U.W. U.MCX32;9$&42U2AU
MM5$@/K5:(CRU8R([M6XA.K9[(#JVB!\YMI<=.+:H'#BVNQLWMM,:-K3H&C6S
M]1PTLOP=-++\'32R_!TTLOP=P8X  +B9  "PH@  IZ@  )NM  "/L   @[,
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M A;KZ@(6Z^H"L*D  *>P  ";M@  CKH  ("^  !SP@  9L8  %O+  !0T
M1M0  #S9   SW@  +>D" "KQ"@$G\A,#(_,:!"#S(04=]"<&&O0O!ACU. 85
M]4$&$_9,!0_V6 0+]V8$"OAV PGYAP,(^9D"!_FJ @;ZNP$&^LD!!OK) 0;Z
MR0$&^LD!J;   )ZV  "1NP  @[\  '7$  !HR   7,T  %'2  !&UP  /-P
M #+@   JY   )>\  "+Z  $>_P8#&_\- QC_$P05_QD%$?\@!0W_)P4)_R\%
M!O\X! +_1 0 _U # /]> @#_;P( _X ! /^/ 0#_G $ _Z8! /^F 0#_I@$
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MFD1O7*=$;ERU1&Q<R$5K6]]%:USP0VM<^T)K7/]!:US_06M<_T%K7/]!_U$
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M355GOTU49M9,56;K2U5F^$I69O])5F;_259F_TE69O])ZED  -IH  #,<@
MPGD  +A]  "O?P  I7X  )V #@"7@B  D8(M XN . J%?D 2?WQ&&WEZ3"-S
M>%$L;755-&=S6CQA<%]#7&YE25AM;4U5;'9/5&R"3U-LCDY2;)Q-46VK3%!M
MODM/;=1*3VSJ2D]K]TE/:_])3VO_24]K_TE/:_])Y5X  -5L  #)=@  OGT
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M.$.#]3I"@?\[0H'_.T*!_SM"@?\[UF\  ,AZ  "]A   M(L  *N1  "?D0
MDI,  (:5  !_EPH >I@< ':8*@)QES4':Y8]#6650Q5?E$D<69-.)%214RM.
MD%@Q2H]?-4>/:#9&CW(V18]]-42/BC1$CYDS0X^H,4./NC!"C]$O08[G+S^,
M]#$^B_XS/HO^,SZ+_C,^B_XST'4  ,.!  "YB@  L)$  *:6  ":EP  CI@
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M%"^L^Q0OK/L4O8T  +27  "LH   HZ4  )>I  "+JP  ?ZX  '*Q  !ELP
M6+<  $VZ P!(O!0 1KPA $.\*@,_O#(&.[PZ"3>\00PTO$@.,KQ1#S&]6@\P
MO64.+[UQ#2^^?@PNOHT++;Z="BR^L DJOL4)*;W>""B[[@DGNOD+)[KZ"R>Z
M^@LGNOH+MY<  *^@  "GIP  G*P  )"O  "#L@  =K0  &JW  !=N@  4KX
M $;"   [QP, -<H. #3+&P QRR4!+\LM RS,-@4JS#X%*<Q'!B?-408FS5L%
M)<YH!23.=00CSX0#(L^5 R#/J (>S[X"'=#8 AS.ZP(;S/8#&\SV QO,]@,;
MS/8#LJ   *NH  "@K0  E+$  (>T  !ZN   ;;H  &&^  !5P@  2L8  #_*
M   US@  +-," "38!P AW!  ']P; ![<) $<W2X!&]TX 1K>0@$9WTT!%]]9
M 1;@9P$4X78 $^&' !'BF0 .XJT #./%  KCW0 )X?$ ">#Q  G@\0 )X/$
MK:@  *2N  "8LP  BK<  'VZ  !PO0  8\$  %?%  !,R0  0<T  #;2   M
MU@  )=L  ![?   :ZP8 &.T/ !;M%P$3[1\!$>TG 0[N, $+[CL!">]& 0;P
M4P #\6(  ?%S  #QA   \98  /"I  #PNP  \-,  /#3  #PTP  \-, IZ\
M )NT  ".N   @+P  '/   !EQ   6<D  $W-  !"T0  -]4  "[:   EW@
M'N(  !?E   4\0  $?H"  W\"0$*_!$!!_P7 0/\'P$ _2@! /TR 0#]/@
M_4P  /U;  #];0  _'X  /N/  #[G0  ^JP  /JL  #ZK   ^JP GK4  )&Y
M  "#O0  =<(  &?'  !:S   3M$  $+5   WV@  +=X  "3B   <Y@  %>D
M  [L   +]@  "/X   7_  $"_P(! /\' 0#_#0$ _Q8! /\> 0#_*0$ _S4
M /]#  #_4P  _V0  /]T  #_@0  _XX  /^.  #_C@  _XX _P(B#O\#( [_
M " ._P B#?\ +0S_ #D*_P!&"/\ 4P?_ %\%_P!J!/\ = /_ 'T"_P"$ O\
MB@'_ (\!_@"5 ?T F@'[ )\ ^@"E /@ JP#W +$ ]0"Z /0 Q0#R -( \0#A
M /  [0#P /@ [P#_ .X _P#N /\ [@#_ .X _P#N /\ _P8@#_\''0[_!!P.
M_P @#?\ *PS_ #<+_P!$"?\ 40?_ %P&_P!H!?\ <@3_ 'L#_@"" OP B +Z
M (T!^0"3 ?@ F 'W )T!]0"C /0 J0#R +  \0"X .\ PP#N -  [0#? .P
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M(XQ(_B.+2/\DBTC_)(M(_R2+2/\D_SP  OI'  #B3@  V%4  ,]7  #)50$
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MC$148YE$4V.H1%)CN$-18\Y#46+E0E%B]$%28OU 4F+_/U)B_S]28O\_XUD
M --F  #&;P  O'8  +-Y  "H>0  G7@  )9Z" "/>QH BGLH 81Z,P9_>3L-
M>7="%'1U2!QN<TTD:'%2+&-N5C-=;%LZ6&IA/U5I:4-2:')$46A]15!HB41/
M:9=#3FFF0DUIMT%,:<Q 3&CC0$QG\T!,9_T_3&;_/TQF_S],9O\_WUT  ,]J
M  ##<P  N7D  +!]  "D?0  F7P  )%^ P"*?Q8 A8 D (!_, 1[?CD*=7U
M$F][1AEJ>4LA9'=0*5YU5#!9<UDW5'%?/5!P9T!-<'%"3&]\04MPB$!*<)8_
M2G"E/DEPMCU(<,L\2&_C/$=N\CQ';?P]1VW_/4=M_SU';?\]VV,  ,MO  "_
M=P  MGX  *R!  "@@@  E($  (N#  "%A!$ @(4@ 'N%+0-VA#8(<(,^#VN!
M1!9E@$H=7WY.)5E]4RQ4>U@S3WE>.$QX9CM*>&\\2'A[/$AXASI'>)4Y1GFD
M.$9XM39%>,HU1'?B-4-V\C="=?LX0G3_.$)T_SA"=/\XUF@  ,=T  "\?
MLH,  *B&  "<A@  CH8  (6(  !_B@H >HL; '6+*0%PBS,&:XH[#&6)0A)@
MAT<:6H9,(56$42=0@U8N2X)=,DB!931&@6XU18%Z-$2!AC-$@90Q0X&C,$.!
MM"]"@<HN08#A+4!_\2\_??LQ/GW_,3Y]_S$^??\QT&X  ,)Y  "X@@  KX@
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M$C.<[Q0RF_D5,9K]%C&:_18QFOT6OH0  +6.  "LE@  H9@  )6:  ")G
M?J   '*B  !EI@  6:@  %"J"0!-JQD 2JPE $>L+@-#JS8&/ZL]"CNK1 TX
MJDL/-JI3$32J6Q$SJV80,JMQ#S&K?@XPJXP-+ZN<#"^KK0LMJL$*+*K:"BNH
M[ LJI_<,*J;[#2JF^PTJIOL-N8T  +"6  "HG0  G)\  )"A  "$I   >:@
M &VJ  !@K0  4[   $BS   _M0L /+89 #JV)  WMBT"-+8T!#&V/ 8OMD0(
M+;9,""RW50@KMV (*K=K!RFW> 8HMX<&)K>6!26WJ 0CM[T$(K?5 R&UZ00@
MM/4%(+/Y!B"S^08@L_D&LY8  *R>  "DI   EZ8  (NJ  !_K0  <[   &:R
M  !9M   3;<  $&[   VO@  +<(& "K#$P HQ!X )L0G "3$, $CQ3@"(<5!
M B#%2P(>QE8!'<9A 1S&;P$:QWX &<>. !?'H  5Q[0 $\?- !/%Y0 3Q/,
M$L/X 1+#^ $2P_@!KYX  *BF  "=JP  D:X  (2Q  !VM   :;8  %VY  !1
MO   1;\  #K"   OQ@  )\L  ![/ @ 7T@< $]00 !'4&P 0U"0 #M4N  S5
M.0 +U44 "M91  G67P 'UFX !=9_  36D0 "UJ0  -:X  #7SP  UN(  -;J
M  #6Z@  UNH JJ8  *"L  "5L   A[0  'JW  !LN0  7[P  %/   !(PP
M/,<  #'+   HSP  (-,  !C6   1V@  "=T!  7C"  #XA(  >$;  #A)0
MX3$  .,]  #D3   Y5L  .5L  #F?0  YH\  .:A  #GL@  Y\,  .?-  #G
MS0  Y\T I*T  )BR  "+M0  ?;D  &^\  !BP   5<0  $G(   ]S   ,M
M "C3   @V   &-P  !'?   *X0   ^0   #M    \ (  .\*  #N$P  [AT
M .XH  #N-0  \$4  /)6  #S9P  ]'D  /2*  #UF0  ]:8  /6L  #UK
M]:P F[,  (ZW  "!NP  <K\  &3#  !7QP  2\P  #[0   SU0  *=D  !_=
M   7X0  $.0   CG   "Z0   .H   #S    ^P   /H   #Y 0  ^0D  /D4
M  #Y'P  ^BP  /P]  #^3@  _V$  /]R  #_@   _XP  /^1  #_D0  _Y$
M_P ?#/\ '0S_ !P+_P ?"O\ *PC_ #@&_P!%!/\ 4@/_ %T"_P!G ?\ <0'_
M 'D _0"  /H A@#X (P ]@"1 /4 E@#S )L \@"@ /$ I@#P *P \ "S .\
MO #N ,D [0#8 .T YP#M /$ [ #Z .P _P#K /\ Z@#_ .H _P#J /\ _P <
M#/\ &0S_ !D+_P >"O\ * C_ #4'_P!"!?\ 3P/_ %H"_P!E ?T ;@'Z '<
M^ !^ /4 A #S (H \0"/ .\ E #M )D [ "> .P I #K *H Z@"Q .D NP#H
M ,< YP#5 .8 Y #F /  Y0#Y .4 _P#D /\ X@#_ .( _P#B /\ _P08#/\#
M% S_ !0+_P <"O\ )0C_ #('_P _!?\ 2P3_ %<"^@!A ?< :P'T '0 \@![
M .\ @@#M (< ZP"- .D D@#G )< Y@"< .4 H@#D *@ XP"P .( N0#@ ,4
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M!O\A&@;X'R4&[QLP!><8/03A&$H"W1A5 =D97P'6&6D TQIQ -$;> #/''X
MSAR$ ,P=B@#+'8\ R1Z5 ,@>FP#&'J( Q1^J <,?LP'"(+\!P"#. ;XAWP&[
M(NX#N2+Z!+<B_P6V(O\%M2'_!K4A_P:U(?\&_QD""?\?  ;_* 4$_RL, _LJ
M% /O)QX#Y2,I!-T@-@/6(40"T2-0 LXE6P+*)F0"R"=L \4G= /$*'H#PBB
M \ IA@._*8L#OBF1 [PIEP.[*IX#N2JF [@JL .V*KL$M2O)!+,KVP2P*^L&
MKBOW!ZPK_PBK*_\)JBO_":HK_PFJ*_\)_Q\ !_\I  3_, ("^S,& ?(Q# #E
M+18!VRDA =(K, /,+3X%QBY*!L(P50:_,%\&O#%G!KHQ;@:Y,74&MS)[![4R
M@0>T,H<'LS*-![$RDP>P,YH'KC.B!ZTSK >K,[<(JC/%"*DSU@BF,^@*I#/U
M#*(S_PVA,_\-H#/_#J S_PZ@,_\._R4 !?\Q  +Z-P  ZC@  -XU @#;+PD
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MCS)G5)LR952I,V-4N3-B5,TT853D,V%4\S)A5/TP85/_,&%3_S!A4_\PYDL
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M.T]?LCI.7\8Z35_>.4U>\#A.7OHW3EW_-DY=_S9.7?\VW5@  ,UE  # ;0
MMW,  *MT  "@<P  EG$  (YR 0"(=!, @W4B 'YT+0-Y<S8(<W$]#VYP1!9I
M;DD=8VQ.)%YJ4RM9:%@Q569>-E%E93I/96\[361Y.TQEA3M+99(Z2V6A.4IE
ML3A)9<4W2&7<-TAD[S=(8_DV2&+_-DAB_S9(8O\VV5T  ,EI  "]<0  M'<
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M?P  AW\  'Z!  !W@P, <804 &V%(@!IA2X#9(4V!U^$/0U:@D,358%(&5"
M31],?U,D2'Y9*$5]82M#?6LK0GUV*D%]@BE ?8\H0'V>)C]]KB4^?<(D/GS:
M(SQ[[24[>?@F.WC_)SMX_R<[>/\GRFT  +UW  "S?P  IX(  )N#  "/@P
M@X4  '>'  !PB0  :HL- &:,'0!BC"D!7HPR!5F+.@E4BD /4(E&%4N(2QI'
MAU$>0X=8(4&&8",_AFDC/H9T(CV&@2$\AHX@/(:='CN&K1TZAL$<.H79&SB$
M[!TW@O<>-X'^'S>!_A\W@?X?Q'0  +E^  "PA@  HH<  ):'  "+B   @(H
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M!R.@^P<CH/L'M(L  *R4  "@E0  E)8  (B9  !]G0  <J   &:D  !:IP
M3JH  $.L   XKP, ,K 1 #"P'  OL28 +;$O 2JQ-@(HL3X#)K%' R6Q4 ,D
ML5H#(K%E R&Q<@(@L8 "'[&/ 1VQH0$;L;0!&K#+ !FOXP 9KO$!&*WY ABM
M^0(8K?D"L)0  *B;  ";G   CYX  (.B  !XI@  ;:H  &&M  !5KP  2;(
M #RT   QMP  *+H  ""\"@ >O18 '+T@ !N]*0 9O3( &+X[ !>^1  5OD\
M%+Y: !*_9P 0OW8 #;^&  N^F  )OJH ![V_  :\UP &O.D !KOS  :[\P &
MN_, JYT  *.B  "6I   BJ<  '^L  !SL   9K(  %FT  !-M@  0;D  #6\
M   JOP  (<(  !G&   1R ( ",L)  ;+%  %S!X !,PH  +,,P !S#X  ,Q*
M  #-5P  S68  ,UV  #-B   S9H  ,RN  #,P@  R]8  ,OE  #+Y0  R^4
MJ*4  )VJ  "1K0  A+   '>S  !IM@  7+@  %"[  !$O@  .,$  "W$   C
MR   &LP  !+/   *T0   ]0   #5!   U@T  -<7  #8(0  VBL  -LW  #<
M1   WE,  -YC  #?=0  WX<  .":  #?K   W[L  -_+  #?RP  W\L H:L
M )6O  "(LP  >K8  &RY  !?O   4K\  $;#   YQ@  +LD  "/-   ;T@
M$]4   K9   $V@   -T   #?    X0   .($  #C#0  Y1@  .<C  #I+P
MZSX  .U.  #O7P  \'(  /"$  #QE   \:(  /&L  #QK   \:P F+   (NT
M  !^N   <+P  &*_  !4PP  2,@  #O+   OSP  )-,  !K8   2W   "=\
M  +B    XP   .4   #G    Z0   .H   #L    [@(  / ,  #R&0  ]2<
M /@W  #[2   _%H  /UL  #^?   _XD  /^3  #_DP  _Y, _P <"O\ & G_
M !<(_P =!O\ *07_ #8#_P!# O\ 3P'_ %H _P!E /L ;@#W '8 ]@!] /4
M@P#T (@ \P"- /( D0#Q )8 \ "; .\ H #N *8 [0"M .T M0#L ,  Z@#.
M .@ WP#F .X Y@#Y .8 _P#F /\ Y@#_ .8 _P#F /\ _P 8"O\ %0G_ !,(
M_P ;!_\ )@7_ #,#_P!  O\ 3 '^ %< ^0!B /4 :P#R ', \ !Z .\ @ #M
M (4 [ "* .L CP#J )0 Z0"9 .@ G@#G *0 Y@"K .4 LP#D +T X@#, .
MW #? .L W@#U -X _0#> /\ W0#_ -T _P#= /\ _P 4"O\ $0G_ !$(_P 8
M!_\ (P7_ "\#_P ] OX 2 'X %0 \@!? .X : #K '  Z0!W .< ?0#F (,
MY0"( .0 C #C )$ X0"6 .  G #? *( W@"I -P L0#; +L V0#) -8 V@#5
M .< U0#S -0 ^P#3 /\ TP#_ -, _P#3 /\ _P(0"O\ "@C_  T'_P,7!O\!
M( 7_ "L#_@ X O8 1 'P %  Z@!; .4 9 #C &T X0!T -\ >@#= (  W "%
M -L B@#9 (\ V "4 -8 F0#5 *  U "G -( KP#0 +D S@#' ,T U@#, .8
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M -84,@#0&$  RQM, ,<<5P#$'6  P1YH +\?;P"^'W4 O"![ +L@@0"Y((8
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ME!MZ1Y\<>$>K''9&NQUU1LX==$;C'G-&\QUR1OT=<D;_'7)&_QUR1O\=ZCP
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M*U]0LBM=4,4K7$_<*UQ/[BI<3_HI7$__*%Q/_R=<3_\GX$L  -!8  ##8
MN64  *UD  "C8@  FU\  )-@!P"-81@ B&$E 8-@+P5^7S@+>5P_$75:11=P
M6$H<;%9/(6A5525E5%LH8U-B*F%3:BQ?4W,M7E-]+EQ3ARY:4Y,N65.A+U=3
ML"]64\(O55+9+U52[2U64ODL5E+_*U92_RI64O\JW4\  ,U<  #!9   MF@
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M+41@Z2U$7_8M1%[^+41>_RU$7O\MTEP  ,1H  "X;P  JW   )]P  "4<
MB6X  ()P  ![<0@ =G(8 ')S) !M<RX#:'(W"&1Q/0Y?;T,46FY(&E5L32!0
M:U(F3&E9*DEI8"U':&DO16AS+D1H?RY$:(PL0VB:*T)HJBI!:+TI06C3*$!G
MZ2D_9O4J/V7^*C]D_RH_9/\JSF$  ,!L  "U<P  IW0  )MT  "0<P  A',
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M%S)]_A<R??X7OW,  +1\  "G?P  F7\  (Z   "$@0  >8,  &R'  !CB0
M6HP  %2-#@!1CAP 3X\G $N., -'CC@&0XT^"D"-1 T\C$L0.8Q2$C>,6A,V
MBV,3-8MN$C2+>A$SBX<0,HN6#S&+I@XQB[@-,(K/#"^)Y0PNA_,.+8;\#RV&
M_0\MAOT/NGH  +"#  "A@P  E80  (J%  !_A@  =8D  &F-  !>D   5),
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M:P 7K'D %:N( !.KF0 1JZL #ZK!  VIV0 .J.P #J?V  ZG^  .I_@ K),
M )Z3  "3DP  AY8  'R:  !QG@  9:(  %JE  !/J0  1*P  #BO   ML
M([,  !JU P 4M@T $K<8 !"W(0 .MRH #+<S  NW/0 )MT< "+=2  :W7P $
MMVT  K=]  "VC@  MJ   +6S  "TR0  M-P  +/J  "S[0  L^T IID  )J9
M  "-FP  @I\  '>D  !LJ   8*P  %6P  !)L@  /;0  #&V   FN0  ';L
M !2]   +OP   \$(  #"$@  PAL  ,,E  ##+@  PSD  ,-$  #$4   Q%X
M ,1O  #$@   Q)(  ,2E  ##N   P\L  ,+<  #"X   PN  HJ   )6A  ")
MI0  ?JH  '.O  !FL@  6;0  $RW   _N0  ,[P  "B^   >P0  %<0   S'
M   $R0   ,L   #- @  S@H  ,\4  #0'0  T2<  -(R  #3/@  U4P  -9<
M  #6;P  UH(  -:5  #6IP  UK<  -;&  #6R@  ULH G:@  )&L  "%L
M=[,  &FV  !<N   3[L  $*^   UP0  *L0  !_'   6RP  #,\   72
MTP   -4   #8    V0   -L!  #="@  WQ0  .$?  #C*P  Y3@  .A'  #J
M6   ZFP  .J!  #JE   ZJ,  .JP  #JLP  ZK, E:X  (FR  ![M0  ;;@
M %^\  !1P   1,,  #?'   KR@  (,T  !71   ,U@  !-H   #=    W0
M -\   #A    XP   .4   #G    Z0   .P)  #O%@  \B,  /0R  #W0@
M^E0  /MF  #[>0  ^XD  /N6  #[F0  ^YD _P 6"/\ $P?_ !,%_P ;!/\
M)P+_ #,!_P!  /\ 30#\ %@ ^0!B /< :P#V '( ] !Y /, ?@#R (, \0"(
M /  C #O )$ [@"6 .T FP#K *  Z0"G .< K@#F +D Y0#& .0 U@#C .@
MXP#V ., _P#B /\ X@#_ .$ _P#A /\ _P 3"/\ #@?_  T%_P 8!/\ ) +_
M # !_P ] /L 20#V %4 \P!? /$ : #O &\ [0!V .P ? #K ($ Z@"& .D
MB@#H (X YP"3 .4 F #C )X X0"E -\ K #> +8 W #" -L TP#; .8 V@#S
M -D _0#8 /\ V #_ -@ _P#8 /\ _P 0"/\ "P?_  T%_P 7!/\ ( +_ "P!
M_  Y /0 1@#O %$ [ !; .D 9 #G &P Y0!S .0 >0#B 'X X0"# .  AP#>
M (P W0"1 -L E@#9 )P U@"B -4 J@#4 +, T@"_ -$ T #0 .( SP#P ,X
M^ #- /\ S #_ ,P _P#, /\ _P )"/\ ! ;_  H%_P 4 _\ '@+_ "@ ]  U
M .H 00#F $T XP!7 .  8 #> &@ W !O -H =0#8 'L U@"  -4 A #3 (D
MT0". ,\ DP#. )D S "@ ,L J #) +$ R "] ,8 S0#% -X Q #L ,, ]@#"
M /T P0#_ ,$ _P#! /\ _P "!_\   7_ P8$_P0/ O\ &0'X ", ZP O .(
M/ #= $@ V@!3 -8 7 #3 &0 T0!K ,\ <@#- '< RP!\ ,D @0#( (8 Q@"+
M ,4 D0## )< P@"> ,  I@"_ *\ O0"[ +P R@"[ -L N0#J +@ ]@"V ?X
MM@+_ +4"_P"U O\ _P, !?\'  /_#0$"_PT) ?D)$P#M QP WP H -D -@#3
M $( SP). ,L#5P#(!&  Q@1G ,0%;@#"!G0 P 9Y +\'?@"^!X, O >) +L(
MC@"Y")4 N B< +8)I0"U":\ LPJ[ +(*R@"Q"]P K@[N *P/^@"K$/\ JA'_
M *D1_P"I$?\ _P@ !/\2  +]%@  \A4! .P0"0#C"!, UP8@ - )+P#*#3P
MQ1%( ,$24@"^%%L NQ1C +D5:@"X%7  MA9V +46>P"S%H  LA>& +$7C "O
M%Y( KAB: *P8H@"K&:P J1FY *@9R "F&ML I!OL *(<^ &A'/\!H!O_ : ;
M_P&@&_\!_Q$  O\;  #K'0  X1X  -H; 0#5$P@ S109 ,49*0"_'3< NA]#
M +8@3@"S(5< L2%> *\B90"M(FP K")R *HC=P"I(WT J".# *<CB0"E(X\
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MF0>.-*,'C#2O!XLTO0B)-- (AS3D"88T\PJ%-/T*A#3_"H0S_PJ$,_\*\28
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M%7%"M!9P0L87;D+;%VU![A=M0?D6;$'_%FQ!_Q9L0?\6Y#P  -1)  #&4@
MNE4  *]3  "G3P  H$P  )I,# "43AP CTXH HI,,@>%2CL,@DE"$'Y'21-\
M1D\4>D96%GA%7!9V16(7=45I%W-%<1AQ17D8<$6!&6Y%BQEM198::T6C&FE%
ML1MH1<,;9D79'&5%[!ME1?@:943_&F5$_QIE1/\:X$$  -!.  ##5@  ME@
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M)U!.YR913O4D44[](U%._R-13O\CUD\  ,=:  "[80  K&$  *!@  "77P
MCUL  (A=  ""7@X ?5\< 'E?* )T7C$%;UPX"FI:/A!F6$0585=)&EY53AY:
M5%0B5U-;)5538B=34VLH4E-U*5!3@"E/4XPI3E.9*4U3J"E+4[DI2E+/*4I2
MYBA+4O0F2U'\)4M1_R5+4?\ETU,  ,1>  "W9   J60  )UC  "38@  BU\
M (-A  !]8@H >6,9 '1C)0%P8BX$:V$V"&9@/ YB7D(375Q'&5E;31Y565(B
M4EA8)D]88"E-5V@J2U=R*TI7?BI)5XHJ2%B7*4=8IRE&5[@H15?.*$57Y"=%
M5O,G15;\)D55_R5%5?\ESU<  ,%B  "T9@  I68  )IF  "090  AF,  ']E
M  !Y9@8 <V<5 &]H(@!K9RP"9V<T!V)E.PM=9$ 166-&%U5A2QQ07U A35Y6
M)4I>7BA'768I1EUQ*45=?"E$78@H0UV6)T)=IB9!7;<E05W,)4!<XR5 6_,E
M0%O[)4!:_R1 6O\DRUP  +YE  "P:0  HFD  )9I  ",:0  @F<  'II  !T
M:P( ;FP1 &IM'@!F;2D!8FPQ!5UL. E9:C\.56E$%%!H21E,9D\>2&55(D5D
M7"5#9&4F061O)4!D>R5 9(<D/V25(SYDI2$]9+8A/63,(#QCXR [8O(A.V'[
M(3M@_R$[8/\AQV$  +IJ  "L;   GFT  ))L  "(;   ?&P  '5N  !N<
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M;_X6OVL  +)S  "B<P  E70  (IT  " =0  =7<  &IY  !A?   6GX  %2
M#P!1@!P 3X$G $R!+P)(@#<&1( ]"4%_0PT]?DD0.GY0$CA^6!,V?6$3-7UK
M$C1]=Q$S?800,GV2#S)]H0XQ?+,-,'S(#3![X PO>O .+GGY#RUX_A M>/X0
MNG(  *QW  "==P  D7@  (9X  !\>@  <7P  &5_  !<@@  4X4  $R'!P!(
MB!4 1HDA $.)*@% B3(#/8@Y!3J(0 @WB$8*-(=.##*'5@PQAU\,,(=I"R^'
M=0LNAX(*+8>0"2R&GP@KAK$'*H7&!RF%WP8H@^\(*(+Y"2>!_0HG@?T*M7@
M *9[  "8?   C'P  ()]  !X?P  ;8(  &&&  !8B0  3HP  $2/   ^D0P
M.Y$9 #F2)  VDBP!-)$T C&1.P0OD4(%+9%*!BN14@8JD5L&*9%F!2>1<@4F
MD7\$)9"- R20G ,BD*X"(8_# B".VP(?C>T#'XSW!!^+_ 0?B_P$L(   *"
M  "3@   B($  'Z#  !SA@  :8D  %V-  !2D   29,  #Z6   TF0, +IL/
M "R;&@ JFR0 *)LL ">;- $EFSP!(YM$ 2&;30$@FU8!'YMA 1V;;0$<FWH
M&IN( !B:F  7F:H %9F^ !.8U@ 4E^H %);U !25^@$4E?H!J84  )J%  ".
MA@  A(<  'F*  !NC0  8Y$  %F4  !-F   0YP  #B?   NH0  )*0! !VE
M#  ;IA< &:8@ !BF*0 6IC$ %:8Z !.F0P 2IDT $*97  VF9  +IG$ ":6
M  >ED  %I*(  Z.U  *BR@ #HM\  Z'L  2A\@ $H?( HHH  )6+  "*C
M?XX  '22  !IE@  7IH  %.>  !(H@  /:4  #*H   HJ@  'ZP  !:N   ,
ML < !K 2  6P&P #L20  K$M  "Q-P  L4$  +!+  "P6   L&4  +!U  "P
MA0  KY<  *ZI  "NO@  K=,  *SC  "LZ0  K.D G)   )&1  "%DP  >I<
M &^;  !DH   6:0  $ZH  !#K   -Z\  "RQ   BLP  &+4  !"W   &N
M +H&  "Z#@  NQ@  +L@  "\*0  O#,  +P^  "]20  O5<  +YF  "^>
MO8D  +V<  "\L   N\,  +O4  "ZW@  NMX F)<  (R9  "!G0  =J(  &JG
M  !?JP  5*\  $BR   [M0  +[<  "2Y   :O   $+X   C     P0   ,,
M  #$ 0  Q0D  ,<2  #(&P  R24  ,HO  #+.@  S48  ,Y6  #/9P  SWH
M ,^-  #/GP  S[   ,^_  #.R0  SLD E)\  (BC  !]J   <JX  &:R  !8
MM   2[<  #ZZ   QO0  )K\  !K"   1Q0  ",@   #*    S    ,X   #0
M    T0   -,   #5!P  V!(  -H=  #<*   WC4  .!#  #B5   Y&8  .5[
M  #EC@  Y9X  .6J  #EL@  Y;( D*H  (6O  !XLP  :K4  %RX  !.O
M0;\  #/"   GQ0  ',@  !',   'T    -0   #6    UP   -D   #;
MW0   -\   #B    Y    .<&  #K$@  [A\  / N  #R/@  ]5   /5D  #V
M>   ]XD  />5  #WG   ]YP _P 2!O\ #@7_  T#_P 8 O\ ) #_ #$ _P ^
M /T 2@#[ %4 ^ !> /8 9P#T &X \P!U /$ >@#P '\ [P"# .T B #K (P
MZ0"1 .@ E@#G )P Y@"B .0 J@#C +( X@"_ .$ T #? .( W@#R -T _@#=
M /\ W0#_ -T _P#= /\ _P -!O\ "@7_  P#_P 5 ?\ ( #_ "T ^@ [ /8
M1P#T %( \0!; .\ 9 #M &L ZP!R .D =P#H 'P Y@"! .0 A0#B (H X ".
M -\ DP#> )D W0"@ -L IP#: +  V "\ -8 RP#4 -X TP#O -( ^P#2 /\
MT@#_ -( _P#2 /\ _P )!O\ !03_  H#_P 4 ?\ '0#[ "D \@ W .\ 0P#L
M $X Z0!8 .8 8 #D &@ X@!O -\ = #= 'D VP!^ -D @P#8 (< U@", -4
MD0#3 )8 T@"= -  I #. *T S0"X ,L QP#) -H R #L ,< ^ #& /\ QP#_
M ,< _P#' /\ _P "!O\   3_  <"_P 1 ?\ &0#R "4 Z@ Q .8 /@#B $D
MWP!4 -P 7 #9 &0 U0!K -, <0#1 '8 SP![ ,X ?P#, (0 RP") ,H C@#(
M )0 Q@": ,4 H@## *L P0"U +\ PP"^ -8 O0#H +P ] "[ /L NP#_ +L
M_P"[ /\ _P  !?\   /_  ,!_P , /D $P#G !X X0 L -P .0#8 $4 TP!/
M -  6 #, &  R@!G ,@ ;0#& ', Q !X ,, ? #! ($ P "& +\ BP"] )$
MNP"8 +H GP"X *@ M@"S +4 P0"S -( L@#C +$ \ "P /D L #^ *\ _P"O
M /\ _P   _\   '_ P  ^0 % /  "P#? !< V  E -$ ,P#, #\ R !* ,0
M4P#! %L OP!C +T :0"[ &\ N@!T +@ >0"W 'X M@"# +0 B "S (X L0"5
M *\ G0"N *< K "Q *L!OP"I M  J /B *<$\ "E!OH I ;_ *,'_P"C!_\
M_P$  O\)  #Q"@  Y0<  -X! @#6  \ SP > ,@!*P#"!#D O@9$ +H'3@"W
M"%< M0E> +,*90"Q"FL L MP *X+=@"M"WL K R  *L,A@"I#8P J V4 *8.
MG "E#J8 HP^Q *(0OP"@$-$ GA+D )P3\P";$_T FA/_ )H3_P":$_\ _PL
M ?$2  #D&   VAH  -(6  #,#04 Q@H6 +\0)0"Y%#, M!4_ + 720"M%U(
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M X8NM@2$+L<$@R[<!($N[@6 +OH&?R[_!G\M_P9_+?\&ZB4  -LS  #-.P
MP#T  +8Z  "O-P  JC$# *4Q%0"?-",!FS0O I<S.@24,T,%D3-+!8\S4@6-
M,UD%BS-?!8HS906(,VL%AS-Q!88S=P:$-'\&@S2'!H$TCP: -)H'?C2E!WTT
MLP=\-,0(>C39"'DT[ EW-/@)=S/_"78S_PEV,_\)Y2X  -8[  #(0P  ND,
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M20  F$8  ))%!P"-1A< B$<C 81&+02 1#8(?$,^"WE"10UW04L/=4%2$'-
M6!!Q0%X1;T!E$6Y ;!)L0'02:T%\$FE!AA-G09$49D&=%&1!JQ5C0;L584#0
M%F! YA5@0/058$#]%%] _Q-?0/\3V4   ,E-  "[40  K%$  *)0  ":30
ME$H  (U* P"(2Q, A$P@ ']+*@-[2C,'=T@Z"W-&00YP14@1;41.$FM$5!1I
M1%H4:$1A%69$:!9D1' 68T1Y%V%$@Q=@1(X87D2:&%U$J!E;1+D96D3-&EE#
MY!E90_,864/\%UE#_Q=90_\7UD4  ,91  "W5   J50  )Y3  "640  CTX
M (E.  "$3P\ ?U = 'M0* )V3C &<DTX"FY+/@YJ2D019TE*%&1(4!9B1U88
M8$==&5Y'9!I=1VT:6T=V&UI'@!Q82(L<5TB8'%5'IAU41[<=4T?+'5)'XAU2
M1O(;4D;[&E-&_QI31O\:TDH  ,-5  "T5P  IE<  )M6  "25   BU$  (52
M  !_4PL >E0: '94)0%R4RX$;5(U"&E0/ UD3D$184U'%%U,31=;2U,:64M:
M'%=+81U62VD>5$MS'U-+?1]12XD?4$N6($Y+I"!-2[4@3$K)($M*X!],2O$>
M3$G['4Q)_QQ,2?\<STX  ,%8  "P6@  HUH  )A9  "/6   AU0  (!6  ![
M5P@ =E@6 ')8(@!M6"L#:58S!V15.@M@4S\07%)%%%A12AA54% <4T]7'E!/
M7B!/3V8A34]P(DQ/>R)+3X<B24^4(DA/HB%'3[,A1D['(45.WR!&3O ?1DWZ
M'D9-_QY&3?\>S%(  +Y<  "M70  GUT  )5<  "+6P  @U@  'Q:  !V6P0
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M=1<W:($6-VB/%39HGA0U:*\3-&?#$C1GVQ(S9>T3,F3X%#%C_Q4Q8_\5O64
M *UH  "=:0  D6D  (9I  !]:@  <&L  &=M  !?<   67$  %1S#@!1<QH
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M!"6!F00D@:H#(X"^ R* U@(B?NL#(7WV!"%\_04A?/T%K7,  )QT  "/=
MA'4  'MV  !Q>   9GL  %I_  !1@@  2(4  #^(   UBP8 ,8L2 "^,'  M
MC"4 +(PM "J,-0$HC#T")HQ$ B2,30(CC%8"(8Q@ B",; $?C'@!'8N& 1N+
ME@ :BJ< &(J[ !>)T@ 7B.@ %X;T 1>%_ $7A?P!IG@  )=X  "*>0  @'H
M '=[  !L?@  88(  %:&  !,B0  0XP  #F/   OD@  )I0' "*5$P @E1P
M'I8E !V6+0 <EC4 &I8] !F61@ 7ED\ %99: !2690 2EG( $)6!  V5D  +
ME*$ "9.T  >2R@ (D=\ ")#M  F0]P )D/< GWT  )%]  "&?@  ?7\  '*"
M  !GA@  7(H  %*.  !'D@  /)4  #.7   IF@  'YP  !:?!  0H \ #J 9
M  V@(@ +H"H "J S  B@/  'H$8 !:!1  .@7  !H&D  )]X  "?B   GID
M )VK  ";P   FM8  )KD  ":[@  FNX F(,  (R#  "#A   >(<  &V*  !B
MC@  5Y(  $R6  !!F@  -IX  "RA   BHP  &:4  !&G   'J00  *H-  "J
M%P  JB   *LH  "K,0  JSL  *I%  "K40  JUX  *IM  "J?0  JHX  *FA
M  "HM   ILH  *7=  "EZ@  I>H DX@  (F)  !^C   <X\  &>4  !<F
M49P  $:A   [I   ,*@  ":J   <K   $Z\   JP   !L@   +,#  "T"P
MM!0  +4<  "U)   MBX  +8X  "V0P  MU   +=?  "W<   MX(  +>4  "V
MIP  M;H  +3,  "TW   M-P D(\  (21  !YE0  ;IH  &*>  !7HP  3*@
M $&L   UKP  *K(  !^T   5M@  "K@   .Y    NP   +P   "^    OP4
M , .  #!%P  PB   ,0I  #%-   QD   ,A/  #)8   R7(  ,F&  #(F0
MR*H  ,>Y  #'R0  Q\D BY<  (";  !UH   ::4  %ZJ  !3KP  1[,  #FV
M   MN   (;H  !:]   +P    L(   ##    Q0   ,8   #(    R@   ,L
M  #.!P  SQ   -(:  #4)   US   -H]  #=3@  WV   .!T  #@AP  X)D
M ."F  #?LP  W[, AZ$  'RG  !QK0  9[(  %FU  !+N   /;L  "^^   C
MP0  %\0   S'   "R@   ,T   #.    T    -(   #4    U@   -D   #;
M    WP   .$&  #D$P  YQ\  .DL  #M.@  \$P  /)?  #S<P  ](4  /22
M  #TG0  ])T _P ,!/\ "0/_  D!_P 4 /\ (0#_ "\ _@ [ /P 1P#Z %(
M]P!; /4 8P#R &L \ !Q .T =@#K 'L Z@"  .D A #H (@ YP"- .8 D@#D
M )< XP"= .( I0#@ *X W@"Y -L R #: -T V0#O -D _ #9 /\ V0#_ -D
M_P#9 /\ _P )!/\ !@/_  H!_P 3 /\ '0#[ "L ]P X /0 0P#R $X [P!8
M .P 8 #I &@ Y@!N .0 = #B 'D X0!] -\ @0#> (8 W0"* -P CP#: )0
MV0"; -< H@#4 *L T@"U -  Q #/ -@ S@#K ,T ^0#- /\ S #_ ,L _P#+
M /\ _P $!/\   +_  @!_P / /T &@#S "8 [P S .L /P#I $H Y@!4 .(
M70#> &0 VP!K -D < #8 '4 U@!Z -0 ?@#3 (, T@"' -  C #/ )( S0"8
M ,H GP#( *@ Q@"R ,4 P ## -( P@#F ,( ]@"_ /\ O@#_ +T _P"] /\
M_P  !/\   +_  4!_P * /, %0#K "( Y@ N .$ .P#= $8 V0!0 -4 60#2
M &  SP!G ,T ;0#, '( R@!W ,D >P#' '\ Q@"$ ,0 B0#" (\ P0"5 +X
MG "] *4 NP"O +D O "X ,T M@#B +0 \0"R /P L@#_ +( _P"R /\ _P
M _\   '_    _  % .D #@#B !P VP I -4 -@#0 $$ S !+ ,D 5 #& %P
MQ !C ,( :0#  &X O@!S +T =P"\ 'P N@"! +@ A@"W (P M0"2 +, F0"R
M *( L "L *X N "L ,D J@#= *D [0"I /< J #^ *@ _P"H /\ _P   ?\
M  #X    [    .  !P#7 !4 T  C ,D , #% #P P0!& +X 3P"[ %< N !>
M +8 9 "U &H LP!O +( = "P 'D KP!^ *X @P"L (D JP"/ *D EP"G *
MI@"J *0 M@"B ,8 H0#9 *  Z0"? /0 G@#[ )X _P"> /\ _P   /0   #G
M @  W@(  -4   #-  T Q0 ; ,  * "[ #4 MP!  +, 2@"Q %( K@!9 *P!
M8 "K 68 J0%K *@"< "G G4 I0)Z *0#@ "C X8 H02- )\$E0">!9X G :I
M )L&M0"9!L4 F ?8 )<(Z0"5"?8 E G^ )0*_P"4"O\ ^@,  .D-  #=%0
MTA4  ,@0  #"" , O@$3 +<%(0"R"2\ K@LZ *H-1 "H#4T I0Y5 *,/6P"B
M$&$ H!!G )\0; "=$7( G!%W )L1?0"9$H0 F!*+ )82DP"5$YT DQ.G )(3
MM "0%,4 CQ39 (T5ZP",%O@ BQ;_ (L6_P"*%O\ [@T  .$<  #4(P  QB0
M +T@  "W&0  M!$* *X4&P"I%RD I1DU *$:/P">&T@ G!M0 )H;5P"8'%T
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M!',NY05R+O0&<2W]!G$M_P9Q+?\&WRT  ,XY  "^/0  L#T  *<[  "@.
MFS0  )<Q"@"2,AH C3,F 8HS, *&,SH$A#-"!((S206 ,U %?C)6!7TR7 5[
M,F$%>C)H!7@S;@5W,W8&=3-^!G0SAP9R,Y$&<32=!V\TJ@=N,[H(;#/-"&LS
MXPEJ,_():3/\"6DR_PEI,O\)VC0  ,I   "Y0@  JT(  *)!  ";/@  E3L
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M$U0^_Q)4/O\2SD4  +Y,  "M30  H$T  )9-  ".2@  B$@  ()'  !]2 D
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M=!M 4( ;/U"-&CY0G!H]4*P9/%"_&3M/UA@[3NH8.T[V&#M-_A@[3?\8PE4
M *]8  "@6   DU@  (E8  " 6   =U8  '!8  !I60  9%H( %];%@!<6R
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M#C%DF0XP9*D-,&.\#"]CTPPN8>@-+6#U#BQ?_ \L7_\0M6   *-A  "480
MB&(  'YB  !U8P  :&4  &!G  !9:0  4FL  $UM!P!(;10 1FX> $-N)P!
M;B\"/6XV!#IM/ <W;4,)-6Q)"S-L40PQ;%H,,&QD#"]L;PLN;'L*+6R)"2QL
MEP@K:Z@(*FN[!REJT@<I:>@(*&?T"2=F_ LG9OX+KV0  )YE  "090  A&4
M 'MF  !Q9P  9&H  %QL  !5;@  37$  $5S 0! =0X /749 #MU(P Y=2L
M-G4R C-U.00Q=4 %+W5'!BUU3P<L=5@'*G5B!REU;08H=7D%)W2'!29TE@0E
M<Z8#)'.Y R-RT ,B<>8#(G#T!2%O^P8A;OX&J6@  )EH  "+:0  @&D  '=J
M  !M;   8F\  %AR  !0=   2'<  #]Z   W? < ,WT3 #%]'0 O?28 +7XM
M "M^-0$I?CP")WY$ R9^3 ,D?E4#(WY? B)]:@(@?7<!'WV$ 1U\DP$<?*0
M&WNV !EZS0 9>>0 &GCR 1EW^@(9=_T"HFP  )-M  "';0  ?&X  '-O  !I
M<0  7G0  %1X  !+>P  0WX  #F!   P@P  *(4* "6&%0 CAAX (H<F ""'
M+@ ?AS8 '8<^ !R'1P :AU  &8=: !>'90 5AW( %(:  !*&CP 0A:  #82R
M  R#R  +@MX #('O  V ^  -@/L FW$  (UQ  ""<0  >7(  &]T  !D=P
M6GL  $]_  !&@@  /(4  #.(   JBP  (8T  !F/"@ 6D!4 %) = !.0)0 1
MD"T $) V  Z0/@ ,D$@ "I!2  B07@ &D&L !)!Y  */B   CI@  (VJ  ",
MOP  B]0  (KE  "*[@  BO$ E78  (AV  !^=@  =7@  &I[  !??P  58,
M $N'  ! B@  -HX  "V0   CDP  &I4  !&7   (F0D  YH3  &9'   FB4
M )HM  ":-@  FC\  )I*  ":5@  FF,  )IQ  "9@   F)   )>B  "6M@
ME<P  )3@  "4ZP  D^X CWL  (1[  ![?   <'\  &6#  !:AP  4(P  $60
M   ZDP  ,)8  ":9   =G   $YX   J@   "H@(  *,*  "C$P  HQL  *0C
M  "D*P  I30  *4_  "E2@  I5<  *5F  "E=@  I(<  *.9  "BK   H<$
M *#5  "@Y   G^D BH   (&!  !VA   :X@  &",  !5D0  2I4  #Z:   T
MG0  *:   !^C   5I@  "Z@   2I    JP   *P   "M!P  K1   *X8  "O
M(   L"@  + R  "Q/0  L4H  +)9  "R:0  LGH  +&,  "PH   K[0  *[(
M  "MV   K=X AX<  'R)  !QC0  9I(  %J7  !/FP  1*   #BE   NJ
M(ZL  !FM   .L   !;(   "T    M0   +8   "W    N $  +D*  "Z$@
MNQL  +TD  "^+@  OSH  ,%)  #"6@  PVP  ,-_  #"D@  PJ0  ,&T  #!
MP@  P<< @X\  'B3  !LF   89T  %:B  !+IP  /ZP  #.P   HLP  ';8
M !&X   &N@   +T   "]    OP   ,    #"    PP   ,4   #' P  R0L
M ,L5  #.'P  T"H  -,W  #62   V5H  -EN  #9@@  VI0  -FC  #9K@
MV;, ?YD  '2>  !II   7JH  %.O  !'M   .;<  "NZ   >O   $K\   ?"
M    Q0   ,@   #(    R0   ,L   #,    S@   -$   #3    UP   -H$
M  #>#P  XAH  .4G  #H-0  [$<  .]:  #P;@  \($  /"0  #PFP  \)\
M_P ( _\ !@'_  < _P 2 /\ 'P#_ "P _0 X /H 1 #X $X ]0!8 /$ 8 #N
M &@ [ !N .H <P#I '@ Z !\ .8 @ #E (0 Y ") ., C@#B ), X "9 -X
MH #; *D V0"T -@ PP#5 -8 U0#M -0 ^P#0 /\ S@#_ ,T _P#- /\ _P $
M O\   '_  0 _P . /T &P#Y "@ ]0 U /( 0 #O $L ZP!5 .< 70#D &0
MX@!K .  < #? '4 W0!Y -P ?0#; (( V0"& -@ BP#6 )  TP"6 -$ G@#/
M *8 S0"P ,L O@#* -$ R0#G ,4 ]P#" /\ P@#_ ,( _P## /\ _P   O\
M  '_    _P ) /4 %P#P ", [  P .@ / #C $< X !1 -P 60#9 &$ U@!G
M -0 ; #3 '$ T0!V -  >@#. 'X S0"# ,L B #) (T QP"3 ,4 F@## *,
MP0"M +\ N0"] ,P N@#A +@ \@"X /\ N #_ +@ _P"X /\ _P   O\   #_
M    ]0 $ .P $@#F !\ X  K -H . #6 $, TP!, ,\ 50#, %P R@!C ,@
M:0#& &X Q !R ,( =P#! 'L P "  +X A0"] (H NP"0 +D EP"W *  M0"I
M +, M@"P ,8 KP#; *X [@"N /L K0#_ *T _P"M /\ _P   ?\   #^
MZP   .( # #: !D T@ F ,T ,@#) #X Q@!' ,, 4 #  %@ O0!> +L 9 "Y
M &H N !N +< <P"U '@ M !\ +, @0"Q (< L "- *X E "L )T J0"F *<
ML@"F ,$ I0#5 *0 Z0"C /8 HP#_ *, _P"B /\ _P   /L   #K    X0
M -8 !@#, !, Q@ @ ,$ + "^ #@ N@!" +< 2P"T %, L@!: +  8 "N &4
MK0!J *P ;P"J '0 J0!Y *@ ?@"F (0 I "* *, D0"A )H GP"D )X KP"<
M +T FP#0 )H Y "9 /$ F #Z )@ _P"8 /\ _0   .P   #A    TP   ,H
M  #"  L O  9 +@ )0"T #$ L  \ *T 10"J $T J !5 *8 6P"D &$ H@!F
M *$ :P"@ '  GP!U )X >@"< (  FP"' )D CP"8 )< E@"A )0 K0"3 +L
MD@#- )  X0"/ .\ C@'X (X!_0". ?\ \0   .,*  #5$   QPX  +X*  "Y
M @( M  1 *\ '@"K "H IP(V *0$0 "A!$@ GP50 )T&5@";!UP F@=B )@'
M9P"7!VP E@=Q )4'=P"3!WT D@B$ ) (C "/"98 C0F@ (P)K "*"KL B0K-
M (<+X@"&#/$ A0W[ (0-_P"$#?\ Z0T  -L:  #)'@  O1T  +0:  "N%
MK L' *<)%P"B#20 GQ P )L1.@"9$D, EA-+ )034@"3$U@ D1-= ) 38P".
M%&@ C11N (P4= "*%'H B16" (<5B@"&%90 A!:> (,6JP"!%KH @!?- 'X7
MX@!]&/( ?1C] 'P8_P!\&/\ XQH  -,E  #!*   M"<  *LE  "E(0  HAL
M )\6$ ":&1X EALJ ),<-0"0'#X CAU& (P=30"*'5, B!U9 (<=7P"&'60
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M!F,M_P9C+?\&TC,  +\Y  "O.P  HCP  )DZ  "2.   C34  (DQ  "%,1
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M=A!./H$133^-$4L_FQ%*/JH223Z\$D@^TQ)'/>@12#WU$4@\_1%(//\0PT8
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M%#E,EA,X3*83-TRX$C9+SA(V2^42-DKS$S9)^Q,V2?\3N$\  *50  "740
MBU(  (%2  !Y40  ;T\  &A1  !B4P  7%0" %A5#P!451H 454C $Y5*P)+
M53(%1U0X"$13/@M!4D0./E)*$3M241(Y45H3.%)C$S=2;A,V4GH2-5*'$352
ME1 T4J40,U*W#S)1S0\Q4.0/,4_S$#%.^Q$Q3O\1LU(  *%3  "35   B%4
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M R-FR@,B9>$#(F/Q!2%B^08A8?X'I%P  )1=  "'7@  ?%\  ')@  !I80
M76,  %9E  !/:   1VH  #]M   W;P< -&\3 #%P'  P<"0 +G L "QP,P$J
M<#H"*'!" R9P2@,E<%(#(W!< R)P9P(A<'0"('"! 1YOCP$=;Z !'&ZR !MM
MR  ;;.  &VOP 1IJ^0(::?T#GF$  (]A  "#8@  >&,  &YD  !E90  6F@
M %)K  !*;@  0G   #ES   Q=0  *G<+ "=X%@ E>!\ )'@F ")X+@ A>#8
M'W@^ !YX1@ <>4\ &WE8 !EY8P 8>'  %GA^ !1XC  3=YP $7:O !!UQ  .
M=-P $'/N !%R]P 1<?P F&4  (IE  !^9@  =&<  &MH  !A:@  5VX  $UQ
M  !%=   /'<  #-Y   K?   (G\$ !N #0 9@1< &($? !:!)P 5@2\ $X$W
M !*!/P 0@4D #H%3  R!7@ *@6H "(%X  : AP %?Y<  WZH  %]O0 !?-(
M GOD  )[[@ #>O4 DFD  (5J  !Z:@  <&L  &=M  !=<   4W0  $EX  !
M>P  -GX  "V!   DA   &X8  !.) P +B@T "(H7  >*'P %BB< !(HO  **
M.  !BD$  (I+  "*5@  BF,  (IQ  "*@   B9   (BB  "'M   A<P  (3A
M  "#Z@  @_  C&X  (!O  !V;P  ;7$  &)T  !8>   3GP  $.    Y@P
M,(<  ">)   >C   %8X   R0   #D@<  ),0  "3&   DQ\  ),G  "4+P
ME#@  )1#  "43@  E%L  )1I  "4>   DXD  )*:  "1K0  D,(  (_8  ".
MYP  CNX AG,  'QT  !S=0  :'@  %U\  !3@   2(4  #V)   SC0  *9
M ""2   7E0  #9<   69    FP   )P(  "<$   G!@  )T?  "=)@  GB\
M )XY  "?1   GU$  )]?  "?;P  GX   )Z1  "=I   G;@  )O-  ";W0
MF^< @GD  'EZ  !N?   8X$  %B%  !-B@  0H\  #>3   LE@  (ID  !B<
M   .G@  !J    "C    I0   *8   "F!   IPL  *@4  "H&P  J2,  *HL
M  "K-P  K$,  *Q2  "M8@  K'0  *N'  "KF@  JJT  *K   "IT   J=P
M?W\  '2"  !IA@  7HL  %.0  !'E0  .YD  #&=   FH0  &Z0  !&G   &
MJ0   *L   "M    K@   +    "Q    L@   +,&  "T#@  M1<  +<?  "X
M*0  N34  +M"  "\4P  O64  +UX  "]BP  NY\  +JQ  "YP   N<L >X<
M '"+  !DD   698  $Z;  !"H   -J4  "NI   @K0  %:\   JR    M0
M +<   "X    N0   +L   "\    O0   +\   #     P@<  ,00  #'&@
MR24  ,LR  #.0@  T50  -)H  #3?   TXX  -.>  #3J@  T[, =Y$  &N6
M  !@G   5:(  $JG   ^K0  ,K$  ">U   :N   #;L   *]    P    ,(
M  #"    Q    ,4   #'    R0   ,L   #-    T    -,   #8"@  W!4
M . A  #C+P  YT$  .E5  #J:@  ZWT  .R-  #LF0  [*  _P # ?\   #_
M  , _P 0 /\ &P#^ "@ _  U /< 00#T $P \0!5 .X 70#L &0 Z@!J .@
M< #G '0 Y0!Y .0 ?0#B ($ X0"% -\ B@#= (\ VP"6 -D G0#8 *4 U0"P
M -, O@#2 -$ S0#H ,H ^P#) /\ R0#_ ,D _P#* /\ _P   ?\   #_
M_P * /H & #V "0 \0 Q .T /0#K $@ Z !1 .4 60#B &$ WP!G -T ; #;
M '$ V0!V -8 >@#5 'X TP"" -( AP#0 (P SP"3 ,T F@#+ *( R0"L ,<
MN0#" ,L OP#C +\ ]@"_ /\ O@#_ +X _P"^ /\ _P   ?\   #_    ^  &
M /( % #K "  Y0 M .$ .0#? $, W !- -@ 50#4 %T T0!C ,X :0#- &X
MRP!R ,H =P#( 'L QP!_ ,4 A #$ (D P@"/ ,$ E@"_ )\ O "I +@ M0"V
M ,4 M0#< +0 \ "T /X LP#_ +, _P"S /\ _P   /\   #Y    [P " .<
M#@#= !P V  H -, - #0 #X S0!( ,D 40#& %@ PP!? ,$ 90#  &H O@!N
M +T <P"\ '< N@!\ +D @ "W (8 M0", +, DP"Q )L KP"E *T L "K +\
MJ@#5 *D Z@"I /@ J #_ *@ _P"H /\ _P   /\   #N    Y    -@ "@#0
M !8 R@ C ,4 +@#! #D OP!# +P 3 "Z %, MP!: +4 8 "S &4 L0!J +
M;P"N ', K0!X *L ?0"J (( J0"( *@ CP"F )@ I "A *, K "A +L H #-
M )\ XP"> /0 G@#^ )X _P"> /\ _P   .\   #C    UP   ,L ! #$ !$
MO0 = +D *0"V #, LP ] +$ 1@"N $X JP!5 *D 6P"G &  I@!E *4 :@"D
M &\ HP!T *$ >0"@ 'X GP"% )X C "< )0 F@"> )D J0"7 +8 E@#( )4
MW@"4 .\ DP#Z ), _P"2 /\ ]    .<   #6    R    ,    "Y  D LP 6
M +  (@"L "T J0 W *8 00"C $D H0!0 )\ 5@"> %P G !A )L 9@": &H
MF0!O )@ =0"6 'L E0"! )0 B0"2 )$ D "; (\ I@"- +, C #$ (L V0")
M .H B #U (@ _ "' /\ ZP   -P&  #*"0  O0<  +0%  "P  $ JP / *<
M&P"C "8 H  Q )T .P": $, F0!+ )< 40"5 %< DP!< )( 80"1 &8 CP!L
M (X <0"- '< C !^ (H A@") (\ AP"9 (4!I "$ ;$ @P'" ($#U@" !.@
M?P7T '\%^P!^!?\ XPP  - 6  # %P  LQ8  *L4  "F#@  HP8& * !$P";
M!"  EP8K )0'-0"2"#X D E& (X)3 ","E( BPI8 (D*70"("F, APIH (8+
M;@"$"W4 @PQ\ ($,A " #(T ?@V8 'T-I ![#;( >@W# 'D.V0!W$.P =A#W
M '80_@!V$/\ W!D  ,<?  "W(0  JR$  *(?  "='   FA8  )@."@"3$!D
MCQ(E (P3+P"*%#D B!5! (852 "$%4X @Q54 ($660" %E\ ?A9D 'T6:P!\
M%G$ >A=Y 'D7@0!W%XL =1B6 '08H@!S&+  <1C" ' 9UP!O&>L ;AKX &T:
M_P!M&?\ U2,  , G  "P*0  I"D  )PG  "6)0  D2$  (\;! ",&A0 B!L@
M (0<*@""'30 @!X\ 'X>0P!\'DH >QY0 'D>50!W'EL =AYA '4?9P!S'VX
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M>0->+8,#72V/!%LMG 1:+:H$62V[!5<MT056+>8%5BST!E8L_096+/\&PS0
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M:@\V2'8/-4B##C1(D0XS2*$-,DBR#3%'QPPQ1]X,,$;O#3!%^0XP1/\.K$<
M )Q)  ".2@  @TL  'E,  !Q2P  :$H  &!+  !:3   54T  %!." !,3Q0
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M'P W7"< -5PN 3)<- ,P6SL$+EM"!2Q;2@8K6U(&*5Q<!BA<9@8G7'(%)ER
M!25;C@0D6YX#(UJO R):Q ,B6=P#(5CM!"%7]P8@5OX'GU$  )!3  "#5
M>%4  &Y5  !E5@  6U@  %-:  !,7   15X  #Y@   X8@8 -&(1 #%C&P O
M8R, +F,J "QC,0$I8S@"*&-  B9C1P,D8U #(V-9 R)C9 (A8W "(&-^ 1YC
MC $=8IP!'&*M 1MAP@ ;8-H &U[L 1M=]P(:7?T#FE4  (M6  !_5P  =%@
M &I9  !A6@  5UT  $]?  !(80  06,  #EE   Q:   *VH+ "AJ%0 F:AX
M)&LE "-K+0 A:S0 (&L\ !YK1  =:TT &VM6 !IK80 8:VT %VM[ !9JB0 4
M:ID $VFK !)HOP 19]@ $F7K !-E]@ 39/T!E5D  (9:  ![6P  <%P  &9=
M  !>7P  5&$  $MD  !$9@  /&D  #1L   L;@  (W$$ !UR#@ ;<Q@ &G,@
M !AS)P 7<R\ %7,V !1S/P 2<T@ $7-2  YS7  -<V@ "W-V  ERA0 '<I0
M!G&F  5PN0 $;L\ !6WC  9L[P ';/@ CUX  (%>  !V7P  ;&   &-A  !:
M9   4&<  $=J   _;0  -G   "YR   F=0  '7@  !1Z!P .>Q  #'L9  I[
M(0 )>R@ "'LP  9[.  %>T(  WM,  )[5@  >V(  'MP  ![?P  >H\  'F@
M  !XLP  =\D  ';>  !UZ@  =/$ B&(  'QC  !Q9   :&4  %]G  !5:@
M3&T  $)Q   Y=   ,'<  "AZ   ??   %W\   V" 0 %A H  (03  "$&@
MA"(  (0I  "%,0  A#H  (1$  "$4   A5L  (1I  "$>0  @XD  (*:  "!
MK0  @,$  '_9  !^Z0  ??$ @V<  '=H  !N:   96H  %MM  !1<0  1W4
M #QY   S?   *G\  "&"   8A0  $(<   :*    C 4  (P,  ",%   C1L
M (TB  ".*0  CC$  (X[  ".1P  CU,  (]@  "/<   CH$  (Z3  "-I0
MB[D  (K0  ")X@  B.X ?6P  '1M  !K;@  8'$  %9U  !+>@  07X  #:"
M   LA0  (XD  !F+   0C@  ")    "2    E    )4%  "5"P  EA,  )<:
M  "7(0  F"@  )DQ  "9/   F4D  )I7  ":9P  FG@  )J*  "9G0  F*\
M )?$  "6UP  EN4 >G(  '%R  !F=0  6WH  %!^  !%@P  .H@  "^,   E
MD   &Y(  !*5   'EP   )H   "<    G@   )\   "? @  H D  *$1  "B
M%P  HQ\  *0G  "E,0  ICT  *9,  "G7   IVX  *>   "FD@  IJ8  *6X
M  "ER0  I-D =W<  &QZ  !A?P  5H0  $N)   _C@  -),  "F7   >F@
M%)T   F@    H@   *0   "G    J    *H   "K    K    *P#  "M"0
MKQ(  +$:  "R(P  M"X  +4\  "V30  MV   +9S  "UAP  M9H  +6K  "T
MN@  M,@ <W\  &>$  !<B0  48\  $64   YF@  +IX  "*B   8I@  #*D
M  &L    K@   *\   "Q    LP   +0   "V    MP   +D   "Z    O ,
M +X,  #!%@  PR   ,4M  #(/   RDX  ,QB  #-=@  S(D  ,J;  #)J@
MR+8 ;HD  &./  !8E   39H  $"@   TI@  **L  !VO   2L@  !K4   "X
M    NP   +T   "]    OP   ,    #!    PP   ,4   #'    R@   ,T
M  #0!0  U1   -D=  #<*P  X#P  .-0  #F90  YW@  .>)  #HE0  Z)\
M_P   /\   #_    _P , /\ & #Z "8 ]P R /4 /0#S $< [P!1 .L 6@#H
M &$ Y@!G .0 ;0#B '( X0!V -\ >@#> 'X W0"# -L AP#: (P V "2 -8
MF@#4 *( T@"L ,X N@#) ,X QP#F ,8 ^ #& /\ Q@#_ ,8 _P#' /\ _P
M /\   #_    _@ ' /< %0#P "( [0 N .H .0#G $, XP!- -\ 5@#< %T
MV@!C -@ :0#6 &X U !S -( =P#1 'L T "  ,X A #, (D R@"/ ,< EP#$
M )\ P@"I +\ M0"] ,< O #> +L \P"[ /\ NP#_ +L _P"[ /\ _P   /\
M  #\    ]0 # .H $0#E !T X  I -L -0#8 #\ U0!( -( 40#. %@ S !?
M ,H 90#( &H Q0!O ,, <P#! '@ OP!\ +T @0"\ (8 N@", +D DP"W )L
MM@"E +0 L "R ,  L0#5 +  [0"O /T KP#_ *\ _P"O /\ _P   /\   #S
M    YP   -X "P#7 !D SP D ,P , #) #H Q@!# ,, 3 "_ %0 O !: +D
M8 "W &8 M@!K +4 ;P"T ', LP!X +( ?0"P (( KP"( *X C@"L )< JP"@
M *D K "G +H I@#- *4 Y@"D /< I #_ *0 _P"D /\ _P   /0   #G
MV0   -  !P#' !0 P@ @ +X *@"Z #4 MP ^ +0 1P"Q $X KP!5 *X 6P"L
M &  JP!E *H :@"I &\ J !S *< > "E 'T I "# *, B@"A ), H "< )X
MIP"< +0 FP#' )H W@"9 /$ F0#] )D _P"9 /\ ]@   .D   #8    S
M ,(  @"[  X M@ : +$ )0"M "\ JP Y *D 00"G $D I0!0 *, 5@"B %L
MH0!@ )\ 90"> &H G0!O )P = "; 'D F0!_ )@ A@"7 (\ E0"8 ), HP"2
M +  D #! (\ U@". .L C0#X (T _P"- /\ [@   -P   #+    OP   +<
M  "P  < JP 4 *< 'P"D "D H0 S )\ / "= $0 FP!* )H 40"8 %8 EP!;
M )4 8 "4 &4 DP!J )( ;P"0 '4 CP![ (X @P", (L B@"5 (D H "' *T
MA@"\ (4 T0"$ .8 @P#T (, _ "" /\ Y    - !  #  @  M (  *P   "G
M    H@ , )\ & "< ", F0 M )8 -@"4 #X D@!% )  3 "/ %( C0!7 (P
M7 "+ &$ B0!F (@ :P"' '$ A0!X (0 ?P"" (@ @0"2 '\ G0!^ *H ?0"Y
M 'P S0![ .( >0#P 'D ^ !Y /T V@D  ,4.  "V$   JA$  *(.  "="@
MFP($ )< $0"4 !P D  G (T , "+ #D B0!  (<!1P"& DT A0)2 (,"6 ""
M UT @ -B '\#: !^ VX ?01U 'L$?0!Z!(8 > 20 '<%G !U!:D = 6Y '(%
MS !Q!^$ < ?O ' (^ !O"/T T!4  +T9  "N&@  HAL  )H9  "5%@  D1(
M ) )" ",!A4 B0@A (8)*@"#"C, @0L[ ( ,0@!^#$@ ?0U. 'L-5 !Z#5D
M> U? '<-90!V#FP = YS '(/? !Q$(4 ;Q"0 &X0G !L$:H :Q&Z &D1S@!H
M$N0 9Q+S &<2^P!G$O\ R1P  +4@  "G(P  G",  ),B  "-(   B1P  (<7
M  "%$@X @1,; 'X4)0!\%2X >18V '<6/@!V%D0 =!=* ',74 !Q%U4 <!=;
M &X780!M&&@ :QAP &H8>0!H&8( 9AF- &49F@!C&J@ 8AJX &$:S !@&N(
M7QOR %\;_ !>&O\ PB,  + F  "A*0  EB@  (TH  "')P  @B0  '\@  !]
M' @ >AP6 '<<( !T'2H <1XR &\>.0!N'D  ;!Y& &L>3 !I'U( 9Q]8 &8?
M7@!D'V4 8R!M &$@=@!@((  7B&+ %TAF !;(:8 6B&V %DAR@%8(>$!5R'Q
M 5<A^P)7(?\"O"@  *LL  "<+@  D2X  (@M  ""+   ?2H  'DG  !W(P0
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M; A#-7<(036#"4 UD D_-9\)/36O"3PUPPD[--H)/#3M"3PS^ D\,_X)K3<
M )PZ  "..P  @ST  'H]  !S/   ;3H  &<X  !A.   73D! %@Y#0!5.1<
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M"2Y$C DN1)L(+4.L""Q#P <K0]<'*T+K"2M ]@HK0/T*HD$  )-"  "%1
M>T4  '%%  !I10  844  %A%  !21@  34<  $A( @!$20T 04D7 #]*'P \
M2B8!.4HM C=),P0T23H%,DE!!S!)2 @O25 (+4E:""Q)9 @K2G '*DI]!RI*
MBP8I2IH&*$FK!2=)OP4F2-8%)D?J!B5&]@@E1?P(GD0  (]%  ""1P  =T@
M &Y(  !E20  74D  %-*  !-2P  1TT  $-.   ^3PD .D\3 #A0'  V4"0
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M !-<N@ 26]( $UGG !-8]  46/L!D4X  (-0  !W40  ;%(  &)3  !:5
M4E4  $E8  !"6@  .UP  #->   L80  )&,% !]E#@ =91< &V4? !EE)@ 8
M92X %F4U !5E/0 39D8 $F90 !!F6@ .968 #&5S  IE@@ )9)$ "&2B  =C
MM0 &8<L !V#A  A?[P )7_< BU(  'Y4  !R50  :%8  %]7  !76   3EH
M $5=   ]8   -F(  "YD   F9P  'FH  !9L!P 2;1$ $&T9  UM(  ,;2@
M"FTP  EM.  ';4$ !FU+  1M50 ";6$  &UN  !L?   ;(P  &N=  !KL
M:<8  &C;  !GZ0  9O$ A5<  'E8  !M60  9%H  %Q;  !370  2F   $%C
M   X9@  ,&D  "AK   @;@  &'$  !!S @ '=0H  G83  !V&P  =2(  '8J
M  !V,@  =CL  '5%  !U3P  =5L  '5H  !U=P  =(8  '27  !SJ@  <K\
M ''7  !PZ   ;^\ @%L  '1<  !I70  85X  %A@  !/8P  1F8  #QJ   S
M;0  *G   ")S   :=@  $G@   A[    ? @  'T/  !]%@  ?AT  'XD  !^
M*P  ?S,  '\]  !^20  ?E0  ']A  !^<   ?H$  'V2  !]I   >[@  'K/
M  !YY   >>X >F   &]A  !F8@  76,  %-F  !*:@  0&X  #9R   M=@
M)'@  !M[   2?@  "H    &#    A ,  (4*  "&$0  AA<  (<=  "()
MB"L  (DU  ")0   B$T  (E:  "):0  B7H  (B,  "'G@  AK$  (7'  "$
MW   A.@ =64  &MF  !C9P  6&H  $YN  !$<P  .7<  "][   E?P  '($
M !.$   )AP   8H   ",    C@   (\"  "/"   D X  )$5  "1&P  DB(
M )0J  "5-0  E4(  )50  "67@  EF\  )6"  "4E0  DZD  )*\  "1T
MD.$ <6L  &EK  !>;P  4W,  $EX   ]?0  ,H$  "B%   =B0  %(P   J.
M   !D0   )0   "6    F    )D   "9    F@4  )L+  "<$@  G1D  )\@
M  "@*@  HC8  *%$  "B5   HV4  *-X  "BC   HI\  *&R  "@PP  H-$
M;W   &1S  !9>   3GT  $."   WAP  *XP  "&0   6E   "Y<   &9
MG    )X   "@    H@   *,   "D    I0   *8!  "G!P  J X  *H7  "L
M'P  KBH  *\W  "O2   L5H  +%M  "Q@   L90  +"F  "PM@  L,, :G@
M %]]  !4@@  28@  #R.   QDP  )9@  !J<   .GP   Z(   "E    IP
M *D   "L    K0   *\   "P    L@   +,   "T    M@   +@'  "[$
MO1L  +\G  #"-@  Q$@  ,5>  #$<P  Q(<  ,28  ##IP  P[( 9H(  %N(
M  !0C@  1)0  #>:   KGP  (*0  !6H   (K    *X   "Q    M    +4
M  "W    N    +H   "\    O@   +\   #!    PP   ,8   #) @  S@L
M -(8  #5)@  VC<  -Y+  #A7P  XG,  .&&  #@E0  WZ  _P   /\   #_
M    _P ( /P %0#Y "( ]0 N /$ .@#P $, [ !- .D 50#F %T XP!C -\
M:0#< &X V0!S -< > #5 'P TP"! -( A@#0 (L SP"1 ,X F #, *  R@"J
M ,@ MP#& ,D Q #B ,, ]@#" /\ P@#_ ,, _P## /\ _P   /\   #_
M^0 % /, $@#M !X Z  J .4 -0#C #\ X !( -D 40#3 %@ SP!? ,T 90#+
M &H R@!O ,D = #( '@ QP!] ,8 @0#$ (< PP"- ,( DP#  )L O@"F +P
ML@"[ ,( N0#: +< \ "V /\ M@#_ +< _P"W /\ _P   /\   #Y    [0 !
M .8 #0#> !L V@ E -8 , #0 #H S !# ,@ 3 #% %, PP!: ,$ 8 "_ &4
MO@!J +P ;P"[ '0 N@!X +D ?0"X (( MP"( +4 CP"T )< L@"@ +$ K "O
M +L K0#1 *P Z0"K /L JP#_ *L _P"K /\ _P   /@   #K    X    -4
M"0#. !8 R0 A ,( *P"_ #4 O@ _ +L 1P"Y $X M@!5 +0 6P"S &  L@!E
M +  :@"O &\ K@!S *T > "L 'X JP"$ *D B@"H )( IP"; *4 IP"C +0
MH@#( *  X0"@ /4 H #_ )\ _P"? /\ ^@   .T   #=    T0   ,< !0#
M !  N  < +4 )@"R #  L  Y *\ 0@"L $D J@!0 *D 5@"G %L I@!@ *4
M90"D &D HP!N *( <P"A 'D GP!_ )X A@"= (T FP"7 )H H@"8 *\ E@#!
M )4 V "4 .\ DP#\ ), _P"2 /\ \    -X   #/    P@   +H   "R  L
MK0 6 *D (0"G "L I0 T *, / "A $0 GP!* )X 4 "< %8 FP!; )H 8 "9
M &0 F !I )8 ;P"5 '0 E !Z )( @0"0 (D CP"2 (T G@", *H B@"Z (D
MT ") .< B #W (@ _P"( /\ Y@   -(   #!    M@   *X   "G  4 HP 1
M )\ &P"= "4 FP N )D -P"7 #X E0!% ), 2P"2 %$ D !6 (\ 6P". &
MC !E (L :@"* '  B0!V (< ?0"& (4 A0"/ (, F@"" *< @0"V (  R@!_
M .$ ?@#R 'X _ !^ /\ V0   ,4   "V    J@   *,   "?    F@ * )8
M%0"4 !\ D0 I (\ ,0", #D BP!  (D 1@"( $P A@!1 (4 5@"$ %L @P!@
M (( 9@"! &P ?P!R 'X >@!\ (( >P", 'D EP!X *0 =P"S '8 Q0!U -P
M= #N '0 ^ !S /T S@(  +L'  "L"@  H@H  )H)  "5!0  D@ # (\ #@",
M !D B0 B (8 + "$ #, @@ [ ($ 00!_ $< ?@!- 'T 4@!\ %< >@!< 'D
M8@!W &@ =@!O '4 =P!S (  <0"* '  E0!O *( ;0"P &P PP!K -D :@#J
M &H ] !I /H Q0T  +,2  "D%0  FA4  )(4  ",$@  B0T  (<%!@"% 1(
M@0 < '\!)@!\ BX >@,V '@$/0!W!$, =@5( '0%3@!S!E, <099 ' &7P!O
M!F4 ;0=L &P'=0!J!WX : B( &<(E !E"*$ 9 BQ &,(PP!B"=D 80KJ & *
M]0!@"OL OA8  *L:  ">'   DQT  (L<  "%&P  @1<  '\3  !^"PD >PH6
M '<+( !U#"D <PTQ '$-. !O#C\ ;@Y% &P/2@!K$%  :1!6 &@07 !F$6,
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M;@!2(7@ 4"&# $\AD !.(IX!3"*N 4LAP0%*(=@!22'K 4DA]P))(/X"KB8
M )TI  "/*P  A"P  'PM  !U+   <"D  &PG  !H)0  92,' &(C$P!?(QP
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M!3DQB@4X,)D&-S"I!C8PO 8U,-,&-2_H!C4N]08U+OP&HC$  ),S  "&-0
M>S8  '(V  !K-@  9#4  %\R  !:,@  53,  %$S!P!-,Q$ 2C,: $@S(@!%
M,R@!0C,N C\R- ,^,CL$/#-"!3LS2@8Z,U(&.#1:!C<T9 8U-6\&-#5\!C,U
MB08R-9@&,36H!C TNP8O--$&+S/G!B\S] <P,OP'GS,  ) V  "#.   >#D
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M B%$N (@1,\"'T/E A]"\@0?0?H%E3P  (8_  !Z0   ;T$  &5"  !=0@
M5D,  $Y#  !%10  0$8  #M(   V20( ,DD, "]*%@ M2AX *TLE "E+*P G
M2S(!)4LY B1+00(B2TH"(4M3 B!+70(?2VD!'DQV 1U+A $<2Y,!&TND !M*
MMP :2<T &DCD 1I'\@(:1OH#D4   ()"  !V1   :T4  &)%  !:1@  4D8
M $I'  !"20  /$L  #9-   P3@  +% ( "A1$@ F41H )%$A ")1*  @4B\
M'U(W !U2/P <4D< &U)1 !E26P 84F< %U)T !92@@ 549$ %%&B !-0M0 2
M3\P $D[B !--\0 43?D!C40  ']&  !R1P  9T@  %Y)  !620  3TH  $=,
M   _3@  .5   #)2   L5   )%8$ !]7#0 =6!8 &U@= !I8)  86"P %U@S
M !59.P 4640 $EE- !!96  .66, #5AP  M8?@ *6(X "5>?  A6L0 (5<<
M"%3=  E3[0 *4_8 B$@  'I)  !N2P  8TL  %M,  !330  3$X  $10   [
M4P  -54  "Y7   G60  'UP  !=?!P 38!$ $6 8  ]@(  -8"< #& O  I@
M-P )8#\ !V!)  5@4P $8%\  E]K  !?>@  7XD  %Z9  !=K   7,$  %O8
M  !:Z   6?  @DP  '5-  !I3@  7T\  %=0  !040  2%(  $!5   W6
M,%L  "A=   A8   &6,  !)E @ ): L !6<4  -G&P !9R(  &<J  !G,0
M9SH  &=$  !G3@  9UH  &=F  !F=0  9H0  &:4  !EIP  9+L  &/3  !B
MY@  8>X ?5   '!2  !E4@  7%,  %54  !-50  1%@  #M<   R7P  *F(
M ")D   :9P  $VH   IL   #;@@  &\0  !O%@  ;QT  ' D  !P*P  <#0
M ' ]  !P2   <%0  '!@  !O;P  ;W\  &Z/  !MH0  ;;4  &S-  !JXP
M:NX =U4  &M6  !A5P  65<  %%9  !(7   /U\  #5C   L9@  )&D  !QL
M   4;P  #'$   1T    =@4  '8+  !W$@  =Q@  '@>  !Y)0  >2T  'DV
M  !Y00  >4T  'E:  !Y:   >'@  'B*  !WG   =Z\  '7&  !UW   =.H
M<5H  &9;  !>6P  5EP  $U?  !#8P  .6<  "]K   F;P  '7(  !5U   ,
M=P  !'H   !\    ?@$  'X'  !_#   @!,  ($9  ""'P  @B8  (0M  "$
M.0  @T4  (-3  "$80  A'$  (.#  ""E@  @:H  (&^  " U0  ?^4 ;%\
M &-?  !;8   46,  $=H   ];   ,G   "AT   ?>   %GL   Q^   $@
M (,   "%    AP   (@!  ")!@  B0P  (H2  "+&   C!X  (XE  "/+P
MCSP  (]*  "060  D&@  )![  "/CP  CJ,  (VW  ",RP  C-L :60  &%D
M  !6:   3&P  $%Q   V=@  *WH  "%_   7@@  #(4   .'    B@   (X
M  "0    D@   ),   "4    E0$  )8'  "7#0  F!0  )H;  "<(@  GBX
M )X]  ">3   GUT  )]O  "?@P  GI@  )VL  "<O@  F\T 9VD  %QM  !1
M<0  1G8  #I\   O@0  )(4  !B)   -C0   Y    "3    E@   )@   ";
M    G    )X   "?    H    *$   "B @  I D  *41  "H&   JB(  *PP
M  "L0   K5$  *YD  "N>0  K8X  *RA  "LL0  K+\ 8G$  %=V  !,?
M0($  #2'   HC0  ')$  !&6   %F0   )P   "?    H0   *0   "F
MIP   *D   "J    JP   *T   "M    KP   +$%  "S#@  MQ<  +DC  "[
M,@  O$4  +U9  "^;@  OX$  +^4  "_I   OJ\ 77L  %*!  !'AP  .HX
M "Z4   BF0  %YX   JB    I0   *@   "J    K0   *\   "R    LP
M +4   "W    N0   +H   "\    O@   ,    ##    R08  ,P3  #/(
MTS$  -=%  #97   V',  -:&  #8E0  V*  _P   /\   #_    _P & /H
M$@#U !\ \@ J .X -0#H #\ Y0!( .$ 4 #> %@ VP!> -D 9 #7 &D U0!N
M -, <P#2 '@ T0!] -  @@#. (< S0"- ,L E #* )T R "G ,< LP#% ,<
MPP#? ,$ ]0"_ /\ O@#_ +X _P"_ /\ _P   /\   #\    ]@ " .X $ #I
M !L X@ F -P ,0#: #L V !# -0 3 #1 %, S@!: ,L 7P#) &4 QP!J ,8
M;@#$ ', PP!X ,( ?0#! (, OP") +X D "] )@ NP"B +H K0"X +\ M@#6
M +4 [P"S /\ L@#_ +( _P"S /\ _P   /X   #R    Z    .  "@#8 !<
MSP A ,P + #* #8 R0 _ ,4 1P#" $X OP!5 +T 6@"\ &  N@!E +D :0"W
M &X M@!S +4 > "T 'X LP"$ +$ BP"P ), KP"= *T J "L +< J@#, *D
MYP"G /H IP#_ *< _P"G /\ _P   /$   #E    V0   ,\ !@#% !( P  =
M +T )P"[ #$ N0 Z +< 0@"T $D L@!/ +  50"O %H K0!? *P 9 "K &D
MJ@!N *@ <P"G 'D I@!_ *0 A@"C (X H0"7 *  H@"> +  G0## )P W@";
M /, F@#_ )H _P": /\ ]    .,   #4    R    +T  @"W  T L@ 8 *\
M(@"M "L JP T *H /0"H $0 I@!* *0 4 "B %4 H !: )\ 7P"= &0 G !I
M )L ;@": '0 F0!Z )< @0"6 (D E0"2 ), G0"2 *L D "[ (\ U ". .P
MC@#\ (X _P". /\ Y@   -4   #%    N@   +    "J  @ I@ 3 *, '0"A
M "< GP O )P -P": #X F !% )< 2P"5 %  E !5 ), 6@"2 %X D0!C )
M:0". &\ C0!U (P ?0"+ (4 B0". (@ F0"' *8 A0"U (0 R@"$ .0 @P#V
M (, _P"# /\ VP   ,8   "X    K0   *8   "@  ( FP - )@ & "5 "$
MDP J )$ ,@"/ #D C@!  (P 1@"+ $L B@!0 (D 50"' %H A@!? (4 9 "$
M &H @P!Q (( > "  ($ ?P"* 'T E0!\ *( >P"P 'H PP!Y -T >0#O 'D
M_ !Y /\ S@   +P   "M    H@   )L   "6    D@ ' (X $@"+ !P B0 D
M (< +0"& #0 A  [ (, 00"! $8 @ !+ '\ 4 !^ %4 ?0!: 'L 8 !Z &8
M>0!L '@ = !V 'T =0"& ', D0!R )X <0"L '  O@!O -4 ;P#K &X ^ !N
M /\ Q    +$"  "D!   F04  )$$  ", 0  B0 ! (8 "P"# !4 @0 ? '\
M)P!] "\ >P V 'H / !X $( =P!' '8 3 !T %$ <P!6 '( 7 !Q &( ;P!I
M &X <0!L 'H :P"$ &D CP!H )L 9P"I &8 NP!E -$ 90#G &0 \P!C /D
MNP8  *D+  "<#@  D1   (D0  "$#0  @ @  '\"! !\  X >@ 8 '< (0!U
M "D <P Q '$ -P!P #T ;@!# &T 2 !L $T :@!3 &D 6 !G %\ 9@!F &0
M;@!C '< 8@"" & !C0!? 9H 70&H %P!N@!< <\ 6P+C %H"[P!: _8 LP\
M *(4  "5%@  BA@  ((8  !\%@  >1,  '8.  !U!P< <P,2 ' #' !M!"0
M:P4L &D%,P!G!CD 9@8_ &4'1 !C!TH 8@A0 & (5@!?"5P 70ED %P); !:
M"G8 60J! %<+C0!6"YH 50NI %0+NP!2"]  4@OD %(,\0!1#/D K18  )T:
M  "/'   A!X  'T>  !V'0  <AH  &\7  !M$@  ; P+ &D,%@!F#1\ 9 XG
M &(.+@!@#C4 7@\[ %T000!<$$< 6A%- %D14P!7$EH 51)A %03:@!2$W0
M412  $\4C !.%)D 316I $L5NP!*%-$ 2A3F $H4] !*%/L J!L  )@>  "*
M(@  @",  '@C  !Q(@  ;"   &@=  !F&@  9!8% &(5$0!?%AH 7!8C %H6
M*@!8%S  5Q<W %47/0!4&$, 4AA) %$84 !/&5< 3AE? $P:: !+&G( 21M^
M $@;B@!'')@ 11RG $0<N0!#&\\ 0AOE $(;] !#&OP!HQ\  )0B  "&)0
M?"<  '0G  !M)P  9R4  &,B  !@(   71T! %H<# !8'!8 51P? %,=)@!1
M'2T 3QTS $X>.0!,'C\ 2QY& $D>30!('U0 1A]< $4@9@!$(7  0B%\ $$A
MB  _(I8!/B*F 3TAN $\(<X!.R'D 3L@\P$[(/P"H",  ) F  "#*   >2H
M ' K  !I*P  8RD  %XG  !;)0  5R(  %0B" !1(A, 3R(; $PB(@!*(RD
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M RHPM ,I+\H#*"_A RDN\ 0I+?H$EBP  (<O  ![,0  <#,  &<S  !?-
M6#,  %(R  !-,   2#$  $0R  ! ,@< /#(1 #DR&0 W,B  -3(F #(R+ $Q
M,S,"+S,Z RXS0@,M-$H$*S13!"HT700I-6@#*#5U R<U@@,F-9$#)36A R0U
MLP(C-,D"(S3@ B,S\ 0C,OD$DR\  (0R  !X-   ;34  &0V  !<-@  538
M $XV  !(-0  0S8  #XW   Z-P, -C@- #,X%@ Q.!T +S@D "TX*@$K.3$!
M*3DX B@Y0 ,G.4@#)CE1 R0Z6P,C.F<"(CIS B$[@0(A.I "(#J@ 1\ZL@$>
M.<@!'CG? 1TW[P(=-_D#CS(  ($U  !U-P  :C@  & Y  !8.0  43D  $LY
M  !$.@  /3L  #@\   T/0  ,#T) "T^$P K/AH *3XA "<_*  E/R\!)#\V
M 2(_/@$A/T8!($!/ 1] 6@$>0&4!'4!R 1Q @ $;0(\ &D"? !D_L0 8/L<
M&#[> !@][P$9//@"C#8  'XX  !Q.@  9CL  %T\  !5/   3CP  $<]  !
M/@  .4   #1!   N0@  *D,& "=$#P D11< (D4> "%%)0 ?12P 'D8S !Q&
M.P ;1D0 &49- !A&5P 71F, %D9P !5&?@ 41HT $T6> !)%L  11,4 $4/=
M !)"[@ 30?@!B#D  'H\  !N/0  8SX  %H_  !2/P  2T   $1    \0P
M-D0  #!%   K1P  )$D" "!*"P =2Q0 &TP; !E,(@ 73"D %DPP !5,.  3
M3$$ $DQ* !!,50 .3&  #4QM  M,>P *3(H "4N:  A*K  '2L$ "$G8  E(
MZ@ *1_4 @ST  '8_  !J00  7T(  %9"  !.0P  2$,  $%$   Y1P  ,DD
M "U*   F3   'T\  !E1!P 44@\ $E,7 !!3'@ .4R4 #%,M  M3-  )4ST
M!U-&  9340 $4UP  U-H  %2=@  4H8  %&6  !1J   4+P  $_3  !.Y0 !
M3>\ ?T$  '%#  !E1   6T4  %-&  !,1@  14<  #Y)   V2P  +TX  "A0
M   A4@  &E0  !-7 @ +6@H !UH3  5:&@ #6B$  EHI  !:,   6CD  %I"
M  !:3   65<  %ED  !9<@  68$  %B1  !8HP  5[<  %;/  !5XP  5.T
M>44  &Q'  !A2   6$D  %!)  !)2@  0DL  #I.   R40  *E0  "-6   ;
M60  %5L   Q> 0 %8 @  &$/  !A%@  8AT  &(D  !B*P  83,  &$]  !A
M1P  85,  &%?  !A;0  8'P  &"-  !?GP  7K(  %W)  !<X   7.T =$H
M &=+  !=3   5$P  $U-  !&3@  /5$  #54   L6   )5H  !U=   58
M#6,   9E    9P8  &@,  !H$P  :1D  &H?  !J)@  :BX  &HW  !J00
M:DT  &I9  !J9P  :7<  &B(  !HF@  9ZT  &;#  !FVP  9>H ;D\  &)0
M  !94   4E   $I1  !!50  .%@  "]<   F7P  'F(  !9E   .:   !FH
M  !M    ;P(  &\(  !P#@  <10  '(:  !S(   <R<  '0P  !T.@  =$8
M '-3  !S80  <W$  '*"  !QE0  <*@  '"\  !PU   ;^8 :%,  %Y4  !6
M5   3U4  $98   \7   ,F   "ED   ?:   %VL   UN   &<0   ',   !V
M    =P   '@#  !Y"   >@X  'L4  !\&@  ?2   'XH  " ,0  ?ST  ']+
M  !_60  ?VD  'Y[  !]C@  ?*(  'NV  ![S   >]X 8U@  %M9  !460
M2EP  $!A   U90  +&H  "%M   8<0  #G4   5X    >@   'T   !_
M@0   ((   "# @  A <  (4,  "&$@  B!D  (D@  "+)P  C#,  (M"  "+
M40  BV$  (QS  "*A@  BIL  (BO  "(Q   A]8 8%T  %E>  !/80  1&4
M #EJ   O;P  )'0  !EX   .?   !7\   ""    A    (<   ")    BP
M (P   "-    CP   ) %  "1"@  DA   )07  "6'P  F"@  )DW  "82
MF5@  )II  "9?0  F),  )BH  "6NP  ELX 7V(  %1F  !):@  /G   #)U
M   G>@  ''\  !&#   %AP   (H   ",    CP   ),   "5    EP   )D
M  ":    FP   )T   ">    H 0  *$*  "D$P  IQH  *DG  "I.   J4H
M *M<  "L<   JX4  *J:  "HK   J+P 6FL  $]O  !$=0  .'L  "R!   @
MA@  %(L   B.    DP   )8   "9    G    )X   "A    HP   *0   "F
M    IP   *D   "I    JP   *T   "P!P  LQ   +8<  "Y*@  N3T  +M0
M  "\90  O'H  +N/  "ZH   NJT 570  $IZ   ^@0  ,H<  "6-   9DP
M#)@   ";    GP   *(   "E    J    *H   "L    K@   *\   "Q
MLP   +0   "V    MP   +D   "\    P 8  ,41  #)'@  RRX  ,U$  #/
M6@  T6\  -&"  #2D@  TI\ _P   /\   #_    _0 # /@ $ #O !H ZP F
M .H , #H #H Y0!# .$ 2P#> %, VP!9 -D 7P#6 &0 U !I -, ;@#1 '(
MSP!W ,X ?0#, (, R@") ,D D0#' )D Q@"D ,0 L #" ,( P0#< +\ ]@"^
M /\ O0#_ +P _P"[ /\ _P   /\   #[    \@   .D "P#A !@ W0 A -L
M+ #9 #8 UP _ -, 1P#/ $X S !4 ,H 6@#( %\ Q@!D ,0 :0## &T P0!R
M +\ > "\ 'X N@"$ +D C "W )0 M0"> +0 J@"R +H L0#0 +  [@"P /\
ML #_ *\ _P"O /\ _P   /@   #M    Y    -8 !P#0 !, S  > ,D )P#'
M #$ Q@ Z ,, 0@"_ $D NP!/ +@ 50"V %H M !? +( 9 "Q &@ L !M *X
M<P"M 'D K !_ *H AP"I (\ J "9 *8 I0"E +, I #' *, Y0"B /H H0#_
M *$ _P"A /\ ^0   .L   #>    SP   ,4  P"_  X NP 9 +D (P"V "P
MLP U +  /0"M $0 JP!* *D 4 "H %4 IP!: *4 7@"D &, HP!H *( ;0"A
M ', GP!Z )X @0"= (H G "4 )H GP"9 *P F "^ )< VP"6 /, E0#_ )4
M_P"5 /\ ZP   -L   #,    O@   +8   "P  D K  4 *D '@"E "< I  O
M *, . "A #\ GP!% )T 2P"< %  F@!4 )D 60"8 %X EP!C )4 : "4 &X
MDP!T )$ ? "0 (0 CP". (X F@", *< BP"W (H T "* .L B0#] (D _P")
M /\ W@   ,L   "[    L0   *D   "C  0 G@ / )L &0"9 "( EP K )8
M,@"5 #H DP!  )$ 1@"/ $L C@!0 (T 5 ", %D BP!> (D 8P"( &D AP!O
M (8 =P"$ '\ A ") (( E0"! *( @ "Q '\ QP!^ .( ?@#U 'X _P!^ /\
MSP   +T   "O    I0   )X   "8    DP * )  % "- !T BP E (H +0")
M #0 B  [ (8 00"% $8 @P!+ (( 4 "! %0 @ !9 '\ 7@!^ &0 ? !K 'L
M<@!Y 'H >0"% '@ D !V )T =0"L '0 OP!S -@ <P#N ', _0!S /\ Q
M +$   "D    F@   )(   "-    B0 $ (8 #@"$ !@ @@ @ (  * !_ "\
M?@ V 'P / ![ $$ >@!& '@ 2P!W %  =@!5 '4 6@!S &  <@!F '  ;@!O
M '8 ;@"! &T C !L )D :@"H &D N0!I ,\ : #I &@ ]P!H /\ N0   *@
M  ";    D (  (D   "$    @0   'X " ![ !( >0 : '< (P!U "H =  Q
M ', -P!Q #P < !" &\ 1P!M $L ; !1 &L 5@!I %P : !C &8 :@!E ',
M9 !^ &, B0!A )8 8 "D %\ M !? ,H 7@#B %X \P!> /P L $  * &  "3
M"0  B L  ($*  !["   > 0  '8  P!S  P <0 5 &\ '0!M "4 :P L &H
M,@!H #@ 9P ] &4 0@!D $< 8P!- &$ 4@!@ %D 7P!? %T 9P!< '$ 6P![
M %D AP!8 ), 5P"B %8 L@!5 ,8 50#> %4 [@!4 /8 J0D  )H-  "+$@
M@A,  'H3  !T$0  < T  &T)  !L P8 :@ . &@ %P!E !\ 8P G &$ +0!@
M #, 7@ Y %T /@!< $0 6@%) %D!3P!8 E8 5@)= %4#90!3 V\ 4@1Y %$$
MA0!/!)( 3@2A $T$L0!,!,4 3 /: $L$Z@!+!/, HQ   )04  "&%P  ?!D
M '09  !M&   :18  &82  !D#@  8P@( &$%$@!>!AH 7 <B %H'*0!8!R\
M5P<U %4(.@!4"$  4PE& %$)3 !0"E, 3@I; $T+9 !+"VX 2@QY $@-A0!'
M#9, 10VB $0-LP!##,8 0PS< $(,[ !##/4 GA4  (X9  ""'   >!T  &\>
M  !H'0  8QP  %\9  !=%@  6Q(" %H."P!7#14 50X= %,/) !1$"L 4! Q
M $X0-P!-$3T 2Q%# $H22@!($E$ 1Q-9 $438@!$%&P 0A5X $$5A  _%9(
M/A6A #P5L@ [%<< .A3= #L4[P [%/@ FA@  (H>  !^(   ="$  &LB  !D
M(@  7B   %H>  !7&P  51D  %,6!@!1%1  3A89 $P6( !*%B< 2!<M $87
M,P!%%SD 0QA  $(81P!!&4X /QE6 #T:8  \&FH .AMV #D;@P X')  -AR@
M #4;L0 T&\4 ,QK< #0:[@ T&O@ EAP  (<A  ![(P  <"4  &<E  !@)0
M6B0  %4B  !2(   3QT  $P< @!*' P 1QP5 $4<' !#'", 01PJ #\<,  ]
M'38 /!T] #L>1  Y'TP .!]4 #8?7@ U(&@ -"%T #(A@0 Q(8\ ,"&? 2\A
ML $M(,0!+2#; 2T?[0$N'_@!DQ\  (0C  !X)@  ;2@  &0H  !<*   5B@
M %$F  !-)   2B(  $<A  !#(0@ 02$1 #XA&0 \(2  .2$F #<B+  V(C,
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M !PMZP$<+?8"B2D  'LL  !O+@  9#   %LQ  !3,0  3#$  $<P  !!,
M.S   #8Q   R,0  +C(& "LR#P I,A< )S,> "4S)  C,RL (C0R " T.@$?
M-$(!'C1, 1TU5@$<-6$ &S5N !HU>P 9-8H &#6: !<TK  6-,  %3/7 !8R
MZ@ 7,O8!ABP  '@O  !L,0  83(  %@S  !0,P  23,  $,S   ]-   -C4
M # V   L-P  *3<# "4X"P B.!0 (#D; !\Y(@ =.2D '#HP !HZ-P 9.D
M&#I* !<Z5  5.E\ %#ML !,[>@ 2.X@ $3J9  \ZJ@ ..;\ #3C5 ! WZ0 1
M-_4 @B\  '4R  !I-   7C4  %4V  !--@  1C8  $ W   Z-P  ,CD  "TZ
M   H.P  (ST  !\^"  </Q$ &C\8 !@_'P 60"8 %4 M !- -0 20#T $4!'
M  Y 40 -0%P #$!I  I!=P )0(4 "$"5  <_IP &/KH !CW0  <]Y  )//$
M?S,  '$U  !E-P  6S@  %$Y  !*.0  0SD  #TZ   W.P  +ST  "H^   E
M0   'T(  !E$!0 410P $D85 !!&'  -1B, #$8J  I&,0 )1CH !T9#  9&
M30 $1E@  T9E  )&<P  1H(  $:2  !%HP  1+8  $/-  !"X   0NT >S<
M &TY  !A.@  5SL  $X\  !'/   0#T  #H]   T/P  +$$  "9#   @10
M&T<  !1) 0 ,3 D "$T2  9-&0 $32   DTF  %-+@  338  $T_  !-20
M354  $UA  !-;P  37X  $R.  !+H   2K,  $G)  !(X   2.L =CL  &@]
M  !=/@  4S\  $L_  !$0   /D   #=!   P1   *48  ")(   <2P  %DT
M  Y/   '4@@  5,.  !4%0  5!P  %0C  !4*@  5#(  %0[  !410  5%$
M %-=  !3:@  4WH  %.*  !2G   4:\  %#%  !/W0  3NP <#\  &1!  !9
M0@  3T(  $A#  !"0P  .T0  #-'   L20  )$P  !U/   640  $%,   A6
M   !608  %D,  !:$@  6Q@  %L>  !<)0  7"T  %PV  !<0   6TL  %M8
M  !;9@  6W4  %N&  !:F   6:L  %C   !7V0  5NH :T,  %]%  !510
M3$8  $9&   _1P  -TH  "]-   G4   'U,  !=6   06   "%L   %>
M8 0  & )  !A#@  8A4  &,:  !D(0  9"@  &0P  !D.@  9$8  &13  !D
M8   9'   &.!  !BDP  8:<  &"\  !@TP  7^< 94@  %I)  !120  2DD
M $-*   Z30  ,E$  "E4   A6   &%L  !!>   )80   6,   !F    :
M &D%  !J"@  :Q   &P5  !M&P  ;B(  &\I  !O,P  ;S\  &],  !N6@
M;FD  &U[  !LC0  :Z$  &JV  !JS0  :>$ 7TT  %9-  !/30  2$X  #Y1
M   U50  +%D  ")=   980  $&0   AG   !:@   &P   !O    <    '(
M  !S!0  = H  '4/  !V%0  >!L  'DC  !Z*P  >C<  'I$  !Z4P  >6(
M 'ET  !WAP  =IL  '6O  !UQ0  =-L 6U(  %12  !-4@  0U4  #E:   O
M7@  )&(  !IG   1:P  !FX   !Q    =    '<   !Y    >P   'P   !]
M    ?P(  ( '  "!#   @Q,  (4:  "'(@  B2L  (@Y  "'20  AUD  (=K
M  "&?P  A9,  (2H  "#O   @M$ 6%8  %)7  !(6@  /5X  #)D   G:0
M'&T  !)R   &=@   'D   !\    ?P   ($   "$    A0   (<   "(
MB@   (L   "-!   C@H  ) 1  "2&0  E2$  )<N  "6/@  E5   )5B  "5
M=0  E(H  ).?  "2M   D<8 5UL  $U?  !"9   -FD  "MO   ?=   %'D
M  A]    @0   (0   "'    B@   (P   "/    D0   )(   "4    E0
M )<   "8    F@$  )P'  "?#P  H1@  *4B  "F,@  I$8  *58  "F:P
MIH   *26  "CJ@  H[T 4F0  $=I   \;P  ,'4  "1[   7@   "X4   ")
M    C    (\   "3    E@   )H   "<    G@   *    "B    HP   *4
M  "F    J    *H   "M 0  L H  +43  "X(@  N#0  +A(  "Z7   NW$
M +J&  "YF@  N*H 36X  $%T   U>@  *8$  !V'   0C    Y$   "5
MF0   )T   "@    HP   *8   "H    J@   *P   "M    KP   +$   "S
M    M    +8   "Y    O0   ,,'  #(%@  S"8  ,L[  #.40  T&8  ,]\
M  #-C@  S9T _P   /\   #_    _    /( # #O !< ZP A .H + #I #8
MYP _ .$ 1P#; $T U0!3 -( 60#0 %\ S@!C ,P : #+ &T R0!R ,< > #&
M 'X Q "$ ,( C #  )8 O@"B +T KP"[ ,$ N@#< +@ ]0"W /\ M@#_ +4
M_P"Q /\ _P   /\   #W    Z@   .0 " #? !0 W  > -H )P#4 #$ SP Z
M ,L 0@#( $D Q0!/ ,, 50#! %H OP!> +T 8P"\ &@ N@!M +D <@"W '@
MM@!_ +0 AP"R )  L "; +  J0"N +D K0#2 *L [@"K /\ J@#_ *H _P"G
M /\ _P   /,   #J    V@   -( ! #,  \ R0 : ,$ (P"_ "P O@ U +P
M/0"X $0 M@!+ +0 4 "R %4 L !: *X 7@"M &, JP!H *H ;0"H ', IP!Z
M *4 @0"D (H H@"5 *( H@"@ +$ GP#' )X Y0"= /L G0#_ )T _P"= /\
M\P   .4   #3    R    ,    "[  H LP 5 +  'P"N "@ K0 P *P . "I
M #\ I@!& *0 2P"C %  H0!5 *  60"? %X G@!C )P : "; &X F@!T )@
M? "7 (0 E0". )0 FP"4 *H D@"] )$ V@"1 /0 D #_ )  _P"0 /\ Y
M -,   #"    N    +    "H  4 I  0 *( &@"? ", G@ K )T ,P"; #H
MF0!! )@ 1@"6 $L E0!0 ), 5 "2 %D D0!> )  8P". &D C0!O (L =@"*
M '\ B ") (< E "' *0 A@"U (4 S@"$ .P A #_ (0 _P"$ /\ U    ,
M  "S    J0   *$   ";  $ EP + )0 %0"2 !X D  F (\ +@"/ #4 C0 [
M (L 00"* $8 B !+ (< 4 "& %0 A0!9 (0 7@"# &0 @0!J (  <@!^ 'H
M?0"# 'L CP![ )X >@"N 'H Q !Y ., > #X '@ _P!X /\ Q0   +0   "G
M    G0   )4   "/    BP & (@ $ "& !D A0 A (0 *0"# #  @@ V (
M/ !_ $$ ?@!& 'T 2P![ $\ >@!4 'D 60!X %\ =@!E '4 ;0!S '4 <0!_
M '  B@!P )@ ;P"H &X O !M -< ;0#P &P _@!L /\ N0   *D   "<
MD0   (H   "%    @0 " 'X "P!\ !0 >P < 'D (P!X "H =P Q '8 -@!T
M #P <P!! '( 1@!P $L ;P!0 &X 50!M %L :P!A &D :0!H '$ 9@![ &4
MA@!D )0 8P"C &, M0!B ,T 80#G &$ ]P!A /\ KP   *    "1    B
M (    !\    >0   '4 !@!S  X <0 7 &\ '@!N "4 ;0 L &L ,0!J #<
M:0 \ &< 00!F $8 90!+ &0 4 !B %8 80!= %\ 90!> &T 7 !W %L @P!:
M )  60"? %@ KP!7 ,0 5P#> %< \@!7 /T IP   )<!  "*!   @ 8  '@%
M  !S P  ;P   &T  0!J  D :  2 &8 &0!E "  8P F &( + !A #( 7P W
M %X / != $$ 6P!' %H 3 !9 %( 5P!9 %8 80!4 &H 4P!T %( @ !1 (T
M4 "; $\ JP!. +X 3@#8 $T [ !. /@ H ,  (\)  "##   >0T  '$-  !K
M#   9PD  &0%  !C  0 80 + %\ % != !L 6P B %D * !8 "X 5@ S %4
M. !4 #T 4P!# %( 20!0 $\ 3P!6 $T 7@!, &< 2@!R $D ?@!( (L 1P"9
M $8 J0!% +P 10#2 $4 YP!% /, F@D  (H.  !^$@  <Q0  &L4  !E$P
M8!(  %T.  !;"@  6@4& %@!#0!6 !8 5  = %( (P!0 "D 3P$O $X!- !,
M CH 2P(_ $H#10!( TP 1P14 $4$7 !$!68 0@5Q $$&?0! !HH /@:9 #T&
MJ0 \!;H / 30 #P#XP [ ^\ E0\  (84  !Z%P  ;Q@  &89  !?&   6A<
M %85  !4$@  4@X  %$*!P!/!Q  30<8 $L('P!)""4 2 @K $8),0!%"38
M0PD\ $(*0P! "TH /PM2 #T,6P \#&8 .@UQ #D-?@ W#HL -@Z: #0.JP T
M#;T ,PS2 #(,Y0 R#/  D!0  ((8  !V&@  :QP  &(=  !;'   51L  %$:
M  !.&   3!4  $H2 @!)$ H 1PX3 $0.&@!"#R$ 01 G #\0+0 ]$#, /!$Z
M #H200 Y$D@ -Q-0 #446@ T%&0 ,A5P #$5?  P%8H +A:9 "T5J@ L%+T
M*Q34 "L4Z  K$_, C!@  'X;  !R'@  9Q\  %X@  !7(   41\  $T>  !)
M'   1AH  $07  !"%@4 0!4. #T5%@ [%AT .18D #<6*@ U%C  -!<V #,7
M/@ Q&$8 ,!E. "\96  M&F( +!IN "H;>P I&XD )QN8 "8;J0 E&KP )!K3
M "09YP E&?0 B1L  'L>  !O(0  9"(  %LC  !4(P  3B(  $DA  !$(
M01X  #X<   [' $ .!L* #8;$P T&QH ,AL@ # ;)@ N'"T +1PT "P=.P J
M'D, *1Y, "@?5@ F'V  )2!L "0@>0 B((@ (2"7 " @J  ?'[L 'A_2 !X>
MY@ ?'O, AAT  'DA  !L(P  824  %@F  !0)@  2B4  $4E  ! )   /",
M #DA   U(0  ,B$' "\A#@ M(18 *R$= "@A(P G(2H )B(Q "4B.0 D(T$
M(R1* "$D5  @)%\ 'R5K !XE>  <)88 &R66 !HEIP 9)+H &"/1 !DCY@ :
M(O, @R   '8C  !I)@  7B@  %4H  !.*   1R@  $(H   \)P  ."<  #,F
M   P)@  +"8# "DF"P F)A, )"<: "(G(  A)R< ("@N !XH-@ =*3\ '"E(
M !LI4@ :*ET &2II !<J=P 6*H4 %2J5 !0JI@ 3*;D $BC0 !,HY0 4)_,
M@2(  ',F  !F*   6RH  %(K  !+*P  1"L  #XK   Y*@  -"H  "\J   J
M*P  )BL  ",L"  @+!  'BT7 !PM'@ ;+24 &2XL !@N-  7+CP %B]& !4O
M4  3+UL $B]G !$P=0 /,(0 #B^3  POI  ++K< "RW-  PMX@ -+/  ?24
M ' I  !C*P  6"T  $\M  !(+@  02X  #LN   V+0  ,"T  "HO   E,
M(3$  !TQ!0 :,@T &#,5 !8S'  4-"( $S0I !(T,0 0-#H #C1#  TT30 +
M-5@ "C5D  DU<@ (-8  !C20  4TH0 $,[, !#+)  4RW@ &,>P >B@  &PL
M  !@+@  52\  $PP  !%,   /C   #@P   S,   +3$  "<S   B-   '34
M !@W @ 4. H $3D2  XZ&0 ,.B  "CHG  DZ+@ (.C8 !SH_  4Z2@ $.E4
M CIA  $Z;@  .GT  #J-   YG@  .+   #C&   WW   -NH =BP  &DO  !<
M,0  4C(  $DS  !",P  .S,  #4S   P,P  *C4  "0W   ?.   &CH  !0\
M 0 -/@< "4 /  9 %@ $0!T  D D  % *P  0#,  $ \  ! 1@  0%$  $!=
M  ! :P  0'H  $"*   _FP  /JT  #W#   ]VP  /.H <C   &0R  !8-
M3C4  $8V   _-@  .38  #,V   M-P  )SD  " [   ;/0  %3\  !!"   (
M1 8  D4-  !&$P  1QH  $<@  !')P  1R\  $<X  !'0@  1TT  $99  !&
M9P  1G8  $:&  !&F   1*L  $/   !"V   0NH ;30  & V  !4.   2S@
M $,Y   \.0  -SD  #$Z   J/   (SX  !Q!   70P  $44   I(   #2@4
M $L+  !,$0  31<  $X=  !/)   3RL  $XT  !./@  3DD  $Y6  !.8P
M37(  $V#  !-E0  3*@  $J]  !)U@  2.D :#D  %LZ  !0.P  1SP  $ \
M   Z/   -#T  "T_   E0@  'D4  !='   22@  "DP   1.    400  %()
M  !3#@  5!0  %4:  !6(   5R<  %<O  !6.0  5D0  %91  !67P  56X
M %5_  !5D0  5:4  %.[  !1TP  4.@ 8CT  %8^  !,/P  1#\  #X_   X
M0   ,$,  "A&   @20  &$P  !).   *40  !%,   !6    6 $  %D&  !:
M"P  7!$  %T6  !>'   7R(  & J  !?-   7S\  %]+  !?6@  7FD  %YZ
M  !=C0  7:$  %RW  !:T   6>8 7$(  %%#  !)0P  0T,  #Q#   S1@
M*TH  "--   :40  $E0   M6   $60   %P   !?    8    &("  !C!@
M9 L  &41  !G%@  :!P  &DD  !J+0  :3@  &E%  !I4P  :&,  &AT  !G
MAP  9IL  &:P  !DR0  8^$ 5T<  $Y'  !'1P  04<  #=*   N3@  )5(
M !Q6   360  "5T   -@    8P   &4   !H    :@   &L   !L @  ;@8
M &\+  !P$   <A<  ',>  !U)@  =3$  '4]  !T3   =%P  '1M  !S@
M<94  '"J  !OP   ;M@ 4TL  $Q+  !&2P  .TX  #)3   H5P  'EP  !1@
M   )9    6<   !J    ;@   '    !S    =    '8   !W    >0   'H#
M  !\"   ?@X  ( 5  ""'0  A"8  (0S  "#0@  @U(  ()D  "!>   @(T
M 'ZB  !]MP  ?,T 44\  $M/  ! 4P  -5@  "M=   @8@  %6<   EK
M<    ',   !V    >0   'P   !^    @    ((   "$    A0   (<   ")
M    BP0  (T+  "/$P  DAP  )4F  "4-@  DT<  )):  "2;@  D8(  (^8
M  ".K   C<  4%0  $58   Z70  +V(  "-H   7;@  "W,   !W    ?
M '\   ""    A0   (@   "*    C    (X   "0    D0   ),   "5
MEP   )D"  "<"0  GQ(  *,;  "E*0  I#P  *)0  "B8P  HG@  *&-  "?
MH@  GK0 2ET  #]B   S:   *&X  !MU   .>@   H    "$    B    (L
M  ".    D0   ),   "6    F    )H   "<    G@   *    "B    HP
M *8   "I    K <  + 0  "T'0  M2\  +-%  "S60  M6T  +:"  "SEP
MLJD 16<  #EM   M=   (7L  !2!   &AP   (L   "0    DP   )<   ":
M    G@   *(   "D    I@   *D   "K    K    *X   "Q    L@   +4
M  "X    O    ,$"  #(#   SAT  ,TS  #-20  SUT  -%R  #/A@  SI<
M_P   /\   #_    ]P   /( " #O !0 Z0 > .0 )P#B #$ X0 [ -P 0P#8
M $H U !0 -  50#. %H RP!? ,D 8P#' &@ Q0!M ,, <P#" 'D P "  +X
MB "\ )$ N@"= +@ JP"V +X M@#@ +4 ^0"T /\ LP#_ *X _P"J /\ _P
M /X   #P    Z0   ., ! #; !  TP : -$ ) #/ "T S  V ,@ /@#$ $4
MP0!, +\ 40"] %8 NP!; +D 7P"X &, M@!H +0 ;@"S '0 L0![ *\ @@"M
M (L JP"6 *H I "H +0 J0#3 *@ \@"G /\ I@#_ *, _P"? /\ _    /$
M  #A    U@   ,X   ##  L P  6 +P ( "Z "D N  Q +< .0"T $$ L0!'
M *\ 3 "M %$ K !6 *H 6@"I %\ IP!D *8 :0"D &\ H@!U *$ ?0"? (8
MG0"0 )P G0": *P F@#$ )H Z ": /\ F0#_ )@ _P"5 /\ [0   -L   #-
M    PP   +<   "Q  8 K0 1 *H &P"I "0 J  L *< - "E #P H@!" *
M2 "? $T G0!1 )P 5@"; %H F0!? )@ 9 "7 &H E0!P ), > "2 (  D "*
M (X E@", *4 C "X (T W ", /@ C #_ (P _P"* /\ W0   ,@   "[
MKP   *<   "A  ( G0 + )L %@"9 !\ F  G )< +P"7 #8 E  \ ), 0@"1
M $< D !, (\ 4 "- %4 C !9 (L 7@"* &0 B !K (< <@"% 'L @P"% ((
MD "  )X ?P"O (  S@"  .X ?P#_ '\ _P!_ /\ R0   +@   "L    H
M )D   "3    D  ' (T $0"+ !H B@ B (H *0") #  B  W (8 / "$ $(
M@P!' (( 2P"! %  @ !4 '\ 60!] %\ ? !F 'L ;0!Y '8 =P"  '4 BP!S
M )@ <@"H ', P@!S ., <P#[ '( _P!R /\ O    *L   "=    E    (P
M  "'    A  # ($ # !_ !0 ?@ < 'T ) !] "L ?  Q 'H -P!Y #P > !
M '< 10!U $H = !/ ', 5 !R %H < !@ &\ : !M '$ :P![ &D A@!H ),
M9P"C &< N !F -8 9@#S &8 _P!F /\ L    )\   "2    B0   ((   !]
M    >0   '< !P!T !  <P 7 '( 'P!Q "4 <  K &\ ,0!M #8 ;  [ &H
M/P!I $0 : !* &< 3P!E %4 9 !; &, 8P!A &P 7P!V %X @0!< (X 7 ">
M %L L0!; ,H 6P#I %H ^P!: /\ I@   )4   ")    @    '@   !S
M<    &T  P!J  H :0 3 &< &0!F "  90 F &0 + !B #$ 80 V &  .P!?
M #\ 7@!% %T 2@!; %  6@!7 %@ 7P!7 &< 50!R %0 ?0!2 (H 4@": %$
MJP!1 ,$ 4 #> %  ] !0 /\ G0   (T   "!    > $  '    !J    9@
M &0   !A  8 7P - %T %0!< !L 6P A %H )P!9 "P 6  R %8 -@!5 #L
M5 !  %, 1@!1 $P 4 !3 $\ 6P!- &0 3 !N $H >@!) (< 20"6 $@ IP!'
M +L 1P#4 $8 [ !& /D E0   (<$  ![!@  <0@  &@(  !B!P  7@4  %L"
M  !9  $ 5P ( %8 $ !4 !8 4P = %$ (P!0 "@ 3P M $X ,@!, #< 2P \
M $H 0@!) $D 1P!0 $8 6 !$ &$ 0P!L $$ =P!! (4 0 "3 #\ HP ^ +4
M/0#, #X Y0 ^ /0 D 4  ($)  !U#   :PX  &(/  !<#@  5PP  %0*  !1
M!P  4 ,# $\ "@!- !( 2P 8 $H '@!( "0 1P I $8 +@!$ #, 0P Y $(
M/@!  $8 /P!- #T 50 [ %\ .@!I #D =@ X (, -P"1 #8 H0 U +( -0#(
M #4 WP U .\ BPD  'T.  !Q$@  9A,  %T4  !6%   41,  $T1  !+#@
M20H  $@'!0!& PP 10(3 $,!&@!! 2  /P(E #X"*P \ C  .P,V #H#/  X
M!$, -P5+ #4&4P S!ET ,@=I #$'=0 P!X( +P>1 "T'H  M!K( +03& "T#
MW  M NL APT  'D3  !M%0  8A<  %D7  !2%P  31<  $@6  !%%   0A$
M $$-  ! "@< /@@. #P(%@ Z"!P . @A #8))P U"2T ,PDS #(*.@ Q"T$
M+PQ) "X,4P L#5T *PUI "D.=@ G#X0 )@^3 "0.HP D#;0 (PW( "(,W0 B
M#.L A!(  '86  !I&   7AH  %4:  !.&P  21H  $09  ! &   /!8  #H4
M   Y$0( -Q ) #4.$0 S#A< ,0\> "\0)  N$"H +!$Q "L1.  I$D  *!-(
M "834@ E%%P (Q1H "(5=0 @%8, 'Q62 !X5HP =%+4 &Q/* !L3X  <$^X
M@14  ',9  !F&P  6QT  %(=  !+'0  11T  $ =   ['   -QH  #09   S
M%@  ,!8$ "X5#  L%1, *A4: "@6(  F%B8 )!<M ",7-0 B&#T (1A& !\9
M4  >&5H '1IF !L:<P :&X$ &1J1 !<:H@ 6&;0 %1G) !48WP 6&.\ ?A@
M ' ;  !C'@  6!\  $\@  !((   0B   #P@   W'P  ,QX  # =   M&P
M*AL! "<;"  D&Q  (AL6 " ;'  ?'", 'APK !T=,@ ;'3L &AY$ !D>3@ 8
M'UD %A]E !4?<@ 4((  $A^0 !$?H0 0'K, #Q[(  X=W@ 0'.X >QH  &T>
M  !@(   52(  $TC  !%(P  /B,  #DB   T(@  ,"$  "P@   H(   )"
M "$@!0 >( P '"$4 !HA&@ 8(2$ %R(H !8B,  5(S@ %"-" !,C3  1)%<
M$"1C  XD<  ,)7X "R2-  HDG@ )([  ""+$  @BV@ )(>H >!T  &H@  !=
M(P  4B0  $HE  !")0  .R8  #8E   Q)   +"0  "@D   C)   'R4  !PE
M @ 9)@D %B<1 !0G&  2)Q\ $2@F  \H+0 -*38 #"D_  LI20 **50 ""E?
M  <J;  %*GL !"J*  0IFP #**P  B?!  (FUP #)N< =2   &8C  !:)0
M3R<  $<H   _*   ."@  #,G   N)P  *2<  "4G   @*   &RD  !<J   3
M+ < #RT.  PM%@ *+1P "2XC  <N*@ &+C( !2\[  0N10 #+E   2Y<   O
M:0  +W@  "^(   NF   +:H  "R^   KU0  *^8 <2,  &,F  !7*   3"D
M $0J   \*P  -BH  # J   K*@  )RD  "(J   =+   &"T  !0O   .,08
M"#,,  4S%  #,QH  30@   T)P  -"\  #0X   T0@  -$T  #19   T9@
M-'4  #2%   SE@  ,J@  #&\   QTP  ,.< ;2<  %\I  !3*P  22P  $$M
M   Y+0  ,RT  "XM   J+   )"T  !\N   :,   %3(  ! T   )-@4 !#@+
M   Y$0  .1<  #H>   Z)   .BP  #LT   [/@  .DD  #I6   Z8P  .G(
M #J"   ZE   .*<  #>Z   VT@  ->8 :2H  %LM  !/+@  1B\  #TP   V
M,   ,2\  "PO   G,   (3$  !LS   6-0  $3<   HZ   %/ 4  #T*   _
M$   /Q4  $ ;  !!(0  02D  $$Q  !".@  048  $%2  ! 8   0&\  $!_
M  ! D0  0*4  #ZY   \T0  .^< 9"X  %<P  !+,@  0C,  #HS   T,P
M+S(  "HS   C-   '3<  !<Y   1.P  "SX   5     0@0  $0(  !%#0
M1A(  $@8  !)'@  224  $DM  !*-@  24$  $E.  !(7   2&L  $=\  !'
MC@  1Z(  $6X  !$T0  0N8 7S(  %(T  !(-0  /S8  #@V   S-0  +38
M "8X   ?.@  &#T  !)    +0@  !44   !'    20(  $L&  !,"@  3@\
M $\4  !1&@  4B   %(H  !2,@  4CP  %%)  !05P  4&<  $]X  !/B@
M3Y\  $ZU  !,SP  2^< 63<  $TX  !$.0  /#D  #<X   Q.0  *3L  "$^
M   900  $T0   M'   %2@   $P   !/    40   %(#  !4!P  5@L  %<1
M  !9%@  6QP  %PD  !<+0  6S<  %I#  !:4@  66(  %ES  !8A@  5YH
M %>P  !7RP  5.4 4SP  $D\  !!/0  .SP  #4\   L/P  )$(  !Q&   3
M2@  #$P   5/    4@   %4   !7    60   %L   != P  7@<  & +  !B
M$0  9!<  &4>  !F)P  9C$  &4]  !D2P  9%P  &-N  !B@   894  &&K
M  !@Q0  8.$ 3D   $9    _0   .4   #!#   G1P  'DL  !5/   +4P
M!58   !9    7    %X   !A    8P   &4   !F    : (  &D&  !K"P
M;A$  &\8  !Q(   <2H  '$V  !P1   <%0  &]F  !N>0  ;8X  &RD  !K
MNP  :]8 2T4  $1$   ^1   -$@  "M,   A4   %U4   Q9   #70   &
M  !C    9@   &D   !L    ;@   &\   !Q    <P   '0   !V!   > D
M 'H1  !\&   ?R(  '\M  !^.P  ?DL  'U>  !\<0  >X8  'J<  !XLP
M=\L 24D  $-(   Y3   +E$  "16   96P  #6    )E    :    &P   !O
M    <P   '8   !X    >@   'P   !^    @    ((   "$    A@   (@&
M  "+#0  CA<  )$B  "0+P  D$   (]2  "-9P  C'P  (N2  ")IP  A[P
M2$T  #U1   S5@  *%P  !QA   /9P   FP   !R    =@   'D   !]
M@    ((   "%    AP   (H   ",    C0   (\   "2    E    )8   "9
M P  G0P  * 6  "D(@  HS,  *)'  "@7   GW   )Z&  "=FP  FJX 0U8
M #=;   L8@  'V@  !-N   %=    'H   !_    @P   (<   "*    C0
M (\   "2    E    )8   "9    FP   )T   "?    H0   *0   "G
MJP$  *\*  "T%0  MR8  +4[  "R40  LF8  +)[  "RCP  KZ( /6$  #%G
M   E;@  &'4   E[    @@   (<   ",    D    ),   "6    F0   )P
M  ">    H0   *,   "E    IP   *H   "L    K@   +    "T    N
M +T   #$"0  RQD  ,HN  #'1P  R%L  ,IP  #,@P  R98 _P   /X   #\
M    ^    .\ ! #H !  Y@ ; .$ )0#? "X WP W -H /P#5 $< T@!- ,\
M4@#, %@ R@!< ,@ 80#& &8 Q !K ,( < #  '8 O@!] +P A0"Y (X M@":
M +0 J "R +L L #9 *X ]P"R /\ JP#_ *4 _P"B /\ _    /<   #O
MZ    -H   #4  L S@ 6 ,P ( #* "H R0 S ,8 .P#" $( OP!) +T 3@"[
M %, N0!8 +< 7 "U &$ M !F +( :P"P '$ KP!X *T ?P"J (D J "4 *8
MH0"D +( H@#, *$ [@"C /\ H #_ )L _P"8 /\ ]    .H   #=    S
M ,4   "]  8 N@ 2 +< ' "V "4 M0 N +0 -@"Q #T K@!# *P 20"J $X
MJ0!2 *< 5P"F %L I !@ *, 90"A &P H !R )X >@"< (, F@". )< FP"6
M *H E #  ), X@"4 /\ E0#_ )  _P". /\ Y0   -8   #(    N0   +
M  "K  ( J  , *4 %P"D "  HP H *, , "A #< G@ ] )P 0P"; $@ F0!-
M )@ 4@"7 %8 E0!; )0 8 "3 &8 D0!M (\ = ". 'X C "( (H E0"( *0
MA@"W (0 U "% /8 AP#_ (4 _P"# /\ T@   ,$   "Q    J    *    ";
M    EP ' )4 $0"4 !H DP C )( *@"2 #$ D  W (X /0"- $( BP!& (H
M2P") %  B !5 (< 6@"% %\ A !F (( ;@"! '< ?P"! 'T C@![ )T >@"N
M '@ R !X .L >0#_ 'D _P!X /\ P0   +$   "B    F0   )(   "-
MB0 # (8 # "% !4 A  = (0 ) "$ "L @@ Q (  -P!^ #P ?0!  'P 10![
M $D >@!. '@ 5 !W %H =@!@ '0 : !S '$ <0![ &\ AP!M )8 ; "F &L
MO0!K .  ; #^ &P _P!L /\ LP   *$   "5    C    (4   "     ?0
M 'H !P!X !  =P 8 '4 'P!U "8 =0 L ', ,0!R #8 <0 [ '  /P!O $0
M;0!( &P 30!K %0 :@!; &@ 8P!F &L 9 !V &, @0!A )  8 "@ %\ M !?
M -4 7P#U %\ _P!@ /\ I@   )8   "*    @0   'H   !U    <0   &X
M P!K  L :@ 3 &D &@!I "  :0 F &< + !F #$ 9  V &, .P!B #\ 80!$
M &  20!? $X 70!6 %P 7@!: &< 60!Q %< ? !5 (L 5 ": %, K0!4 ,H
M5 #K %0 _P!4 /\ G    (T   "!    >    '    !J    9P   &,   !A
M  8 8  - %X %0!= !L 70 A %P )P!; "P 6@ Q %D -@!8 #H 5P _ %8
M1 !4 $H 4P!0 %( 6@!0 &( 3@!M $T > !+ (8 2@"6 $D IP!* ,  2@#@
M $H ^ !* /\ E    (4   !Y    ;P   &<   !A    70   %H   !8  (
M5@ ) %4 $ !4 !8 4P < %, (@!2 "< 40 L %  ,0!/ #8 30 [ $P 0 !+
M $8 2@!, $@ 50!' %X 10!I $, = !! (( 0 "1 $$ I !! +D 00#5 $
M\ !  /X C    'X   !S 0  : ,  %\$  !9 P  50(  %(   !0    3@ %
M $T "P!, !( 2P 8 $H '@!) ", 2  H $8 +0!% #( 1  W $, / !! $(
M0 !) #\ 40 ] %L .P!E #D <0 X '\ -@". #@ H  X +, -P#, #< YP W
M /< AP   'D$  !L!P  8@D  %D)  !3"0  3@@  $H&  !( P  1P ! $4
M!P!$  T 0@ 4 $$ &0!  !X /P C #T *  \ "X .P S #D .0 X #\ -P!&
M #4 3P T %@ ,@!C #$ ;P P 'T , ", "\ G  O *X +@## "X W0 N .\
M@@0  '0)  !H"P  70T  %4.  !.#@  2 T  $0,  !!"0  /P<  #X$ P \
M  D .P / #D %0 X !H -@ ? #4 )  T "H ,@ O #$ -0 P #P +@!# "T
M3  L %8 *@!A "D ;0 H 'L )P") "< F0 F *H )0"^ "8 UP F .L ?P@
M ' ,  !D$   61$  % 3  !)$P  1!(  #\1   [#P  . T  #8*   U!P4
M- 4* #(#$  Q Q8 +P(< "X#(0 L R8 *P,L "D$,@ H!#D )P5! "4&2P D
M!U4 (P=@ "(';0 @"'H 'PB) !X(F0 =!ZD '06\ !T#TP = >< >PP  &T0
M  !@$P  5A0  $T6  !&%@  /Q8  #H5   V%   ,Q(  # 0   N#@$ +0L%
M "P)"P J"!( * D8 "8)'0 E"2, (PHI "(*,  A"S@ ( M! !X,2@ =#54
M&PUA !D.;@ 8#GT %@Z, !4.G  5#:P % R^ !0+TP 4"N0 >!   &D4  !=
M%0  4A<  $H8  !"&0  /!D  #88   R%P  +A8  "L5   I$P  )Q(" "40
M!@ C$ P (0\4 !\/&@ >$"  '! G !L1+P :$C< &1)  !<32@ 6%%0 %!1@
M !(4;0 1%7L $!6+  X4FP ,%*P "Q._  H2U  +$>< =1,  &86  !:&
M4!H  $<;   _'   .!L  #,;   N&@  *AD  "<8   D%P  (18  !\5 P <
M%0@ &A40 !@5%@ 7%AT %18D !07+  3%S4 $A@^ !$82  .&5( #!E>  L:
M:@ )&G@ "!J'  <9EP &&:@ !1B\  07T0 %%N, <A4  &,9  !7&@  31P
M $0=   \'@  -1X  # =   K'   )QP  ",;   @&@  '1H  !D:   7&@4
M%!L, !(;%  0'!L #APB  P<*0 +'3$ "ATZ  D>1  ('DX !AY:  0?9P #
M'W4  1^$  $>E0  ':8  !RY   <SP  &^( ;Q@  & ;  !4'0  2A\  $$@
M   Y(   ,R   "T?   H'P  )!X  " =   ='0  &AT  !4>   1( 0 #B *
M  HA$@ )(1@ !R$?  8B)@ $(BX  R,V  (C0  !(TL  "-7   C9   (W,
M "2"   CDP  (J0  "&W   @S0  '^, :QH  %T>  !1(   1R$  #XB   V
M(@  ,"(  "LA   F(0  (B   !X@   ;(   %R$  !(B   -) 0 "28)  4F
M$  #)Q8  "<=   G(P  *"L  "@S   I/0  *$@  "A4   H8@  *'   "B
M   ID0  )Z,  "6V   DS0  ).( :!X  %H@  !.(@  1"0  #LE   S)0
M+20  "@D   D(P  ("(  !TB   8(P  %"4   XG   ** 0 !2L)   L#@
M+10  "T:   M(0  +B@  "XP   O.@  +T0  "Y1   M7P  +FX  "U^   N
MCP  +J(  "RV   JRP  *>, 9"$  %8C  !*)0  0"<  #@G   Q)P  *R8
M "8F   B)0  'B4  !HF   5*   $"H   HL   %+@0  # (   Q#   ,Q(
M #08   T'@  -24  #4M   U-@  -4$  #5.   T7   ,VL  #-[   SC0
M,Z   #&U   PS0  +N, 7R4  %(G  !'*0  /2H  #4J   N*0  *2D  "4H
M   @*   &RD  !8K   1+0  "S    8R   !- ,  #8'   W"P  .1   #H5
M   [&P  /"(  #PJ   \,P  /#T  #U)   [6   .F@  #IX   YBP  .9X
M #FT   WS0  ->4 6B@  $XK  !#+   .2T  #(M   M+   *"L  ",K   =
M+0  &"\  !(Q   +-   !C8   $X    .P(  #P%   ^"0  0 T  $$2  !#
M&   1!\  $0F  !$+P  1#H  $1%  !#5   0F0  $!U  ! B   0)P  $"R
M   _S0  />< 52T  $DN   _,   -C   # O   L+@  )BX  !\P   9,P
M$S4   PX   &.P   #T   !     0@   $0#  !%!@  1PH  $D/  !+%0
M31L  $TB  !-*P  334  $U!  !,3P  2E\  $EQ  !)A   2)@  $BN  !(
MR0  1^8 4#$  $4R   [,P  -#,  "\Q   I,@  (C0  !HW   4.@  ##T
M  9     0@   $4   !(    2@   $P   !. P  3P<  %$+  !3$0  5A8
M %@=  !8)@  6#   %@[  !72   55D  %-L  !2?P  4I0  %&J  !1Q0
M4., 2C8  $ V   Y-@  ,S4  "TU   E.   '#L  !0_   -0@  !D4   !)
M    3    $X   !1    4P   %4   !7    60,  %L'  !="P  7Q$  &(8
M  !C(   8RH  &(V  !B0P  8%,  %]F  !=>P  7(\  %RE  !;O@  6MT
M1CH  #TZ  #_XGT024-#7U!23T9)3$4 "Q4W.0  ,CD  "D\   ?0   %D0
M  U(   &2P   $\   !2    50   %@   !:    70   %\   !A    8P
M &4"  !G!@  :0L  &P2  !N&@  ;R,  &\O  !N/   ;$P  &M>  !J<P
M:8@  &B>  !GM@  9M, 0CX  #P]   V/0  +4   "-%   920  #DX   52
M    5@   %H   !=    8    &(   !E    9P   &D   !K    ;0   '
M  !R    = 8  '<+  !Z$P  ?!P  'PG  ![-0  >D0  'E6  !X:P  =X
M ':6  !TK   <\4 04(  #M"   Q10  )TH  !Q/   15   !5D   !>
M80   &4   !I    ;    &\   !R    =    '8   !X    >@   'P   !^
M    @    (0"  "&"0  B1(  (P=  ",*@  BSH  (I,  ")8   AW8  (:,
M  "%H@  @[D 048  #9*   K4   (%4  !1;   '8    &8   !K    ;P
M ',   !V    >@   'T   "     @@   (4   "'    B0   (L   ".
MD    ),   "6    F@8  )T1  "B'0  H2P  )\_  ">5   G&H  )J   "8
ME0  EZH .T\  #!5   E6P  &&$   IH    ;@   '0   !Y    ?0   ($
M  "%    B    (L   ".    D    ),   "5    EP   )H   "<    GP
M *(   "E    J0   *X%  "S$0  N!X  +<R  "T1P  LEX  +!S  "OB
MKIL -5H  "EA   <:   #FX   !V    ?    ((   "'    BP   (\   "3
M    E@   )@   ";    G@   *$   "C    I@   *@   "K    K@   +
M  "T    N0   +\   #%!   SA$  -$D  #-.P  R%,  ,AH  #(?0  R(\
M^P   /<   #U    \@   .P   #E  L X@ 7 .  (@#? "L WP T -H / #6
M $, T@!* ,\ 3P#, %4 R@!: ,< 7@#% &, PP!H ,$ ;@"_ '0 O0![ +H
MA "X (X M@": +, J0"P +X K0#> *L ^@"J /\ H0#_ )X _P": /\ ]
M .\   #K    WP   -0   #/  < RP 3 ,D '0#( "8 QP O ,4 -P#  #X
MO0!$ +L 2@"Y $\ MP!4 +4 60"T %T L@!B +  : "O &X K0!U *L ?0"I
M (< IP"2 *4 H0"B +0 GP#2 )T ] "; /\ E@#_ ), _P"0 /\ ZP   .4
M  #3    Q@   +X   "Y  ( M@ - +0 %P"R "$ L0 I +$ ,0"N #@ K  ^
M *H 1 "H $@ I@!- *4 40"D %8 H@!; *  80"> &< G !N )L =@"9 '\
MEP"+ )4 F "4 *H D@#% )  Z@". /\ B@#_ (8 _P"% /\ X    ,X   "]
M    L@   *L   "F    H@ ' *$ $@"@ !L GP C )\ *P"< #( F0 X )<
M/@"5 $, E !' )( 2P"1 $\ D !4 (\ 60". &  C !H (H ;P") 'D AP"#
M (4 D0"$ *$ @@"V ($ VP"  /L @ #_ 'P _P![ /\ RP   +<   "J
MH0   )H   "5    D@ # )  # "- !4 C  > (P )0", "P B@ R (@ . "'
M #T A0!! (0 1@"# $H @@!. ($ 4P"  %D ?P!@ 'T :0![ '( >@!] '@
MB0!V )D = "L ', S !R /$ <0#_ '  _P!O /\ N    *<   ";    D@
M (L   "&    @P   '\ !P!^ !  ?0 8 'T 'P!] "8 >P M 'D ,@!X #<
M=P \ '8 0 !U $4 <P!) '( 3@!Q %0 < !: &\ 80!M &P :P!W &D @P!G
M )( 9@"C &4 O@!D .4 8P#_ &0 _P!C /\ J    )D   "-    A0   'X
M  !Y    =    '(  P!P  L ;P 3 &X &@!N "$ ;@ G &T + !K #( :@ V
M &D .P!H #\ 9P!$ &8 20!E $\ 8P!5 &( 7 !A &4 7P!R %T ?@!; (P
M60"= %< M !7 -8 5P#W %@ _P!9 /\ G0   (X   "#    >0   '(   !K
M    :    &4   !C  8 8@ - &( %0!B !L 8@ B &$ )P!@ "T 7P R %X
M-@!= #L 6P _ %H 10!9 $H 6 !1 %< 6 !5 &  5 !K %( >0!0 (< 3@"7
M $P K !+ ,D 2P#N $X _P!. /\ DP   (4   !Y    ;P   &8   !A
M70   %H   !9  ( 6  ) %< $0!7 !< 5P = %< (@!5 "< 5  L %( ,0!1
M #8 4  Z $\ 0 !. $4 3 !, $L 4P!* %P 2 !F $< = !% (( 0P"2 $$
MI@!  +\ 0 #D $, _@!$ /\ BP   'T   !Q    9@   %X   !7    4P
M %$   !/    3@ & $T "P!- !( 3  7 $P '0!+ "( 2@ G $@ *P!' #
M1@ U $0 .P!# $$ 00!( $  3P _ %@ /0!B #P <  Z 'X . "- #< H0 W
M +@ .0#; #H ]P Z /\ A    '8   !J    7P   %8   !0    3    $D
M  !'    10 " $0 !P!#  T 0@ 3 $( & !! !T 0  B #X )P ] "L .P P
M #H -@ X #T -P!$ #8 3  T %4 ,P!> #( ;0 Q 'H , "* "\ G  N +$
M, #. #$ [0 R /\ ?@   '    !D @  600  %$%  !*!0  100  $$"   ^
M    /0   #L !  Z  D .0 . #@ $P W !@ -0 = #, (@ R "< ,0 L #
M,0 O #@ +0!  "P 2  K %$ *@!< "D :0 H '< )P"' "< F0 G *P * #$
M "@ XP H /< >@   &P$  !?!@  5 @  $P)  !%"0  /PD  #L(   W!@
M-00  #," 0 R  4 ,  * "\ #P N !0 +0 9 "P '@ J ", *0 H "@ +@ G
M #0 )@ ] "4 10 C $\ (@!: "$ 9P @ '4 ( "% !\ E0 ? *< 'P"\ !\
MV0 ? .\ =@,  &<'  !;"@  4 P  $@-  ! #0  .@T  #4,   Q"P  +@D
M "P(   J!@, *0,& "@""P G 1  )@ 5 "0 &@ C !\ (@ E "  *P @ #(
M'P Z !X 0P = $T &P!8 !H!90 9 ', & "" !@ D@ 7 *, %P"W !8 SP 6
M .8 <@8  &0*  !7#0  31   $01   \$0  -A$  #$0   M#P  *0X  "8,
M   D"P$ (@D$ "$'!P @!0L '@41 !T%%@ <!1P &P4B !H%*  9!2\ & 4X
M !<%00 6!DP % =7 !,'9  1"'( $ B!  \'D0 .!J( #@6T  X#R@ / >(
M;@H  & ,  !4$   2A,  $$4   Y%   ,Q0  "T3   I$P  )1(  "$1   ?
M#P  ' X" !L,!0 9"P@ & H- !8)$P 5"1@ % H? !,*)@ 2"BX $0LW ! ,
M00 -#4P "PY8  D/9  (#W( !P^!  8.D0 &#:( !0RT  0+R0 %"=T :PT
M %T0  !1$P  1Q4  #T6   V%@  +Q8  "H6   E%0  (10  !X3   ;$@
M&!(" !81!  4$ 8 $0\)  X.#@ -$!8 #! =  L1)  *$BP "1(U  @3/@ '
M$TD !114  ,480 "%6\  15^   4CP  $Z   !*R   1QP  $-T :!   %H2
M  !.%0  1!<  #H8   S&0  +1@  "<8   B%P  'A8  !L5   8%0  %10"
M !,4!0 0$P8 #!0(  D5#  (%1, !A8:  46(0 $%R@  Q<Q  (8.P !&$4
M !A1   97@  &6T  !E]   9C0  &)\  !:Q   5QP  %-T 91,  %<5  !+
M&   01H  #@;   P&P  *AH  "0:   @&0  '!@  !D7   6%P$ $Q8# !$6
M!  ,%P4 "!@'  4:"P #&Q$  1L8   ;'@  '"8  !TN   =.   '4,  !Y.
M   =7   '6L  !U[   =C   '9X  !NQ   9Q@  &-X 8A4  %08  !(&@
M/AP  #4=   N'0  )QP  "(<   >&P  &AH  !<9   5& ( $1D"  T: P )
M&P0 !1T'  $>"@  (!   "$6   A'   (2,  "(K   B-0  (T   "-,   B
M6@  (FD  ")Y   ABP  (9T  "&Q   ?R   '=X 7A@  %$;  !%'0  .A\
M #(?   K'P  )1X  " =   <'   &1L  !8;   2&P  #AT   H> 0 %( ,
M 2(&   D"0  )@T  "<4   G&@  *"$  "@I   H,@  *#T  "E)   I5@
M)V<  "9X   FB0  )IT  ":Q   DR@  (N( 6AL  $T>  !!(   -R$  "\A
M   H(0  (R   !\?   <'@  &!X  !0>   /(   "B$   8C   ")0(  "<%
M   J"   + P  "X2   N&   +A\  "\F   O+P  +SH  "]&   P4P  +F0
M "QV   LAP  +)L  "NP   KR@  *.0 5A\  $DA   ^(P  -"0  "PD   F
M(P  (B(  !XA   :(   %2$  ! C   +)0  !B<   $I    + $  "X$   P
M!P  ,@H  #00   U%@  -AP  #8D   V+   -S<  #="   W3P  -F   #1R
M   RA0  ,ID  #&O   QR@  ,>8 42,  $4E   Z)P  ,2<  "HF   E)0
M(20  !TC   7)0  $B<   PI   &*P   2X    P    ,P   #4"   W!0
M.@@  #P,   ^$@  /Q@  #\@   _*   /S,  #\^   _2P  /UH  #QN   Z
M@P  .98  #FM   XR0  ..< 3"<  $ I   V*@  +BD  "@H   D)P  'R<
M !DH   3*@  #"T   <P   !,P   #8    X    .P   #T    _ @  004
M $,)  !&#@  2!4  $@<  !()   2"X  $@Z  !(1P  2%4  $5I  !#?@
M0I,  $&J  ! QP  0.8 1RL  #PM   S+0  +"P  "@J   B*@  &RP  !4O
M   -,@  !S4   $X    .P   #X   !!    0P   $4   !(    2@,  $P&
M  !."P  41$  %,7  !3(   4RD  %,U  !30@  4E   $]D  !->   2X\
M $JF  !*P0  2>, 0C   #@Q   P,   +"X  "8N   >,0  %S0   \W   '
M.P   #X   !!    1    $<   !*    3    $\   !1    4P   %4#  !7
M!P  6@P  %T3  !?&P  7R0  %\O  !>/   7DL  %Q<  !9<@  5X@  %:?
M  !5N0  5-H /30  #4T   P,@  *C(  "$U   8.0  $#P   =     1
M $@   !+    3@   %(   !4    5P   %H   !<    7@   &    !C 0
M9@4  &D+  !L$P  ;AP  &XG  !M-0  ;$,  &I4  !G:@  98$  &.9  !B
ML0  8<\ .C@  #0W   O-@  )3D  !L^   00P  "$<   !+    4    %0
M  !7    6@   %T   !@    8@   &4   !G    :0   &P   !N    <0
M '0&  !X#   >Q8  'P@  ![+0  >CP  'A,  !V80  ='@  '*1  !PIP
M;\$ .3L  #0[   I/@  'D,  !-)   '3P   %,   !7    7    %\   !C
M    9@   &D   !L    ;P   '$   !S    =@   '@   ![    ?0   ($
M  "$!0  B T  (L8  ",)   BC,  (A$  "&60  A'   (*(  "!G0  ?[0
M.3\  "Y#   C20  &$\   M5    6P   &    !D    :    &P   !P
M=    '<   !Z    ?0   '\   "!    A    (8   "(    BP   (X   "2
M    E@(  )D,  "=&0  G2@  )LY  "930  EV,  )9[  "4D   DJ8 ,TD
M "A.   <5   $%L   )B    :    &T   !R    =P   'L   !_    @P
M (8   ")    C    (\   "1    E    )8   "9    G    *    "D
MJ    *T   "R"P  MQH  +4K  "S0   L%8  *YM  "K@P  JI< +50  "%;
M   580  !F@   !O    =@   'T   ""    AP   (L   ".    D@   )4
M  "8    FP   )X   "A    HP   *8   "I    K    +    "T    N0
M ,    #(    T@L  -D;  #5,0  T$@  ,M@  #(=0  QH@
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MY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
M             0                    $    ! @,$! 4&!P@)"@L,# T.
M#Q 1$A,4%!46%Q@9&AL<'1X>'R A(B,D)28G*"DJ*BLL+2XO,#$R,S0U-C<X
M.3H[.SP]/C] 04)#1$5&1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A8F-D
M969G:&EJ:VQM;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1
MDI.4E9:7F)J;G)V>GZ"AHJ.DI::GJ*FJJZRMKJ^QLK.TM;:WN+FZN[R]OK_
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MH=K)DJ':R9*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':R9*AVO^F$P'_JRX._ZY
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MA\6(SX?%B,^'Q8C/A\6(S_RQ# #YN#0(][M"'?>\1SOIR4$]UMXS4<KJ.V[
M\$.%N.9,EK'?5*.LV5VMHM1>M)C17[N0SE_ B,Q@Q(/*8L=_R63)?LEHR7W)
M;<E]R7+)?<EYR'[*@,=^RH#'?LJ QW[*@,=^RH#'?LJ QW[*@,=^RH#'?LJ
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MA%'Q8H11\6*$4?%BA%'Q8H11\6*$4?%BA%'Q8H11\6*$4?%BA-2Z  #)S@,
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MF=ANSYG8;L^9V&[/F=ANSYG8;L^9V&[/F?^'" /_A1,(_X0A%?^!,BK_>T!
M_X!)3O^!45S_?UAJ_WI?=_YU9X+Y;W"-]6AYE?-C@9KQ8(J=\6"4G_!@G9_P
M8:6?\6*NG_%CMY_Q9,&>ZFC$GN1KQIW>;LF<V6_,G=)QS)W1<<R=T7',G=%Q
MS)W1<<R=T7',G=%QS)W1<<R=T7',G?^'" /_AA,'_X4A%?^#,BK_?D __X1(
M3?^&4%O_A5=I_X!>=OYZ98+Y=&Z,]6UVE?)G?YSP8XB@[V&2HN]BG*+O8J6B
M[V.OHN]EN:'L9\&AY6O$H-]OQZ#9<<J?TG+*H,QSRJ',<\JAS'/*H<QSRJ',
M<\JAS'/*H<QSRJ',<\JAS'/*H?^(!P/_AQ,'_X<A%?^$,BK_@C\]_XA(2_^*
M3UG_BE9G_X9==/^ 8X#Z>6R,]7)TE?%K?9WO9H:B[F.1I.YCG*7N9*6E[F6Q
MI>YFO*3G:\&DWV_$H]ERR*+2<\BCS'7'I,9VQZ3&=L>DQG;'I,9VQZ3&=L>D
MQG;'I,9VQZ3&=L>DQG;'I/^)!P+_B!,'_X@A%?^%,BG_AC\\_XQ'2?^/3U?_
MCU5E_XQ<<O^'8G[Z?VF*]7ARE?%P>IWN:82D[66/I^QDFZCL9::H[&>RJ.II
MOJ?A;\*GV7/%IM%UQJ;+=L6GQG?%J,!XQ:C >,6HP'C%J,!XQ:C >,6HP'C%
MJ,!XQ:C >,6HP'C%J/^*!P+_B!,'_XDA%/^&,BG_B3XZ_Y!'1_^43E7_E%5C
M_Y);</^.87S[AV>(]G]OD_)V>)WN;H&E[&B,J>MFFJOK9Z>KZVBUJ^1MOJK:
M<\.IT7;$J<IXPZK$><.KOWG"J[IZPJNZ>L*KNGK"J[IZPJNZ>L*KNGK"J[IZ
MPJNZ>L*KNGK"J_^*!P+_B1,&_XHB%/^(,BG_C3TY_Y1&1?^83E/_F55@_YA;
M;?^58'K]CV:%]X9LD?)]=9ON<W^DZVN*J^EGF:[I:*BNZ6JYK=QQOZW2>,*L
MR7G!K<)ZP*Z]>\"ON'S K[1\P*ZT?,"NM'S KK1\P*ZT?,"NM'S KK1\P*ZT
M?,"NM'S KO^+!P+_BA,&_XLB%/^),BG_D#TW_YA&0_^<3E#_GE5>_YY;:O^;
M8';[EV6"]H]KCO"%<IGK?'RCY7&&K.!LE+#>;:2QW'"VL-)UO[#(>[^PP'R^
ML;I]OK*U?KZRLGZ^LJY_OK&N?[ZQKG^^L:Y_OK&N?[ZQKG^^L:Y_OK&N?[ZQ
MKG^^L?^,!P+_BQ,&_XPB$_^*,BC_DSPV_YM&0?^@3T[_HU9;_Z-<9_RB87/V
MGF9^\)EKB>J0<97CAWJ@VWR#JM-SCK//<IZUS72OM<=XO+2^?;RTMW^\M;)_
MN[6N@+NUJX"\M:B O+2H@+RTJ("\M*B O+2H@+RTJ("\M*B O+2H@+RTJ("\
MM/^,!P+_C!,&_XTB$_^+,BC_ECTT_YY'/_^D3TO_IU=7_JA=8_BH8F_QIF=Y
MZZ)KA.2;<8_=DWJ;TH: J<A[B;3">)>XOWFHN;Q\N;BT@+FXKX&YN:N"N;BH
M@KFXI8*ZMZ."N[:C@KNVHX*[MJ."N[:C@KNVHX*[MJ."N[:C@KNVHX*[MO^-
M!@'_C!,%_XTB$_^,,BC_F#TR_Z%(/?^G4$C_JUA4^ZU?7_2M8VKMK&=TYJIL
M?M^E<(K5FG>:RI!]J+Z%A+2U?I"[L7ZAO:^ M;RJ@[:\IH2WO*.$M[RAA+>[
MGX2XNIV$N;B=A+FXG82YN)V$N;B=A+FXG82YN)V$N;B=A+FXG82YN/^-!@'_
MC1(%_XXB$_^.,2?_FSXQ_Z1(._^J44;]KEI0][!>6^^Q8F3ILF9MXK)J=MFK
M;(C.HG28PIE[IK6.@;.JA8F]I(.9P:&$K<">AK3 G(:TP)J&M;^9AK:]F(:W
MO)>%N+J7A;BZEX6XNI>%N+J7A;BZEX6XNI>%N+J7A;BZEX6XNO^.!@'_C1(%
M_X\B$_^0,27_G3XO_Z=).?^M4T+[L5E,\[1<5>RV8%WEN65EW;AD==*Q:8;'
MJ7&7NZ%WI:Z7?K*@C82^EH>1Q).)IL21B;'$D8BRPY&(L\&1A[3 D8>UOI&'
MM[R1AK>\D8:WO)&&M[R1AK>\D8:WO)&&M[R1AK>\D8:WO/^.!@'_CA(%_Y B
M$O^3,23_H#XM_ZI*-OVQ5#_XM%='[[A:3^B\7U7AP&)?U[]><\NW9H7 L&V5
MLZATHZ:@>K"7EH"]B(V)QX2-G<B#CJ_'A8NPQH>*L<2(BK+"B8FTP(N(M;Z+
MB+6^BXBUOHN(M;Z+B+6^BXBUOHN(M;Z+B+6^BXBUOO^/!@'_CQ(%_Y$B$O^5
M,2+_HS\J_ZQ+,_JS5#OTMU5"[+U81^7$7DK<REE=T<5<<<2^8X.XMVJ3K+!P
MHIZH=J^.GWN\?9:#QW>6E\EVF*_'>Y.OQGV/L,6 C;'#@HRSP8.*M+^$BK2_
MA(JTOX2*M+^$BK2_A(JTOX2*M+^$BK2_A(JTO_^0!@'_D!($_Y(C$O^8,B#_
MI3\H_K!,+_BV4C;QO%,[Z,16/>'-6436U%%;RLU9;[W%8(&QOV:1I+ALH)6Q
M<:V%J7:Z=:)^Q'"CE,5OIJW#=:"RPG>9LL-XE++">I&SP7R.M,!\CK3 ?(ZT
MP'R.M,!\CK3 ?(ZTP'R.M,!\CK3 ?(ZTP/^0!@'_D!($_Y,C$O^;,A[_J4 D
M^[-.*O2Z3R_LPE QY,U4,-K<3$'/VU!8PM16;;7.7'^HR&*/F\%GGHRZ:ZM\
MM'"W;K![OVNQDK]JM*R];ZZWO'&FMKYSG[6^=)JUOW:5M;YVE;6^=I6UOG:5
MM;YVE;6^=I6UOG:5M;YVE;6^=I6UOO^1!0'_DA($_Y0C$?^?,AO_K$$@][=,
M)/"_2R;FRDPEV]M-)M'C4#_'XE)6NMU4:JW76'R?T5V-DLQAFX+&9:ERP&JT
M9[]XN6;"D+AEQ*JV:<"\M6RTNK=NK+FX;Z6XN7&>N+IQGKBZ<9ZXNG&>N+IQ
MGKBZ<9ZXNG&>N+IQGKBZ<9ZXNO^2!0#_DQ(#_Y8C$?^C,Q?^L4(:\[M('.G&
M11O<V$(9T>-)+<CJ4$"_Z553L^589Z7A6'F6W5F)B-A;F'C37:5HT&.O8M%U
ML6#4C;!?UZBO8=7!K67&P*]HN[ZQ:K*]LVRJO+1LJKRT;*J\M&RJO+1LJKRT
M;*J\M&RJO+1LJKRT;*J\M/^4! #_E!$#_Y<D$/^H,Q+XMD,3[<) $M[3.@W1
MXCT?R.M'-+_P34>U[E):JNQ5:YSI5'J-YU.)?>13EF[@5J)CW%^I8-MPJF'<
MA:ABW9JF8]ZNI6#<Q*9AS\2I8\/#JV:YP:UFN,&M9KC!K6:XP:UFN,&M9KC!
MK6:XP:UFN,&M9KC!K?^5 P#_EA$"_YTC#/^N,PSRO#\+X\TQ!]+A+Q'(ZSTE
MO_1&.;7U2TRL]%!>G_-/;I'R37R#[DZ(=NA/E&GB4IUAWUNC7M]HI%[?>:->
MX(JA7^&;H%_AK9]>XK^>7=C)H5_+R*-?RLBD7\K(I%_*R*1?RLBD7\K(I%_*
MR*1?RLBD7\K(I/^7 @#_F1 "_Z0B!_FU, 7IQBX"U-\;!<CK,A:_]#XJMOM%
M/JW\2U"@^TE@D_M(;X;V2'M[\$F&;NI+CV/F3Y==XU:;6^-AG%KC;IQ:Y'R;
M6^2+FEOEFIA;YJB76^:ZEEKARIA:X,N86N#+F%K@RYA:X,N86N#+F%K@RYA:
MX,N86N#+F/Z9 0#_FQ !_ZL> N^^(@#6U@@ R>HC";_U-!JV_#\NK?]%0:#_
M0U&3_T)@B/Y";7WX1'AR\D6!9^Y'B5_J3(]:Z%*25^A;E%;H99-6Z'&35NE]
MDE;IB9%6ZI:/5NNDCE;KMHU6[+>-5NRWC5;LMXU6[+>-5NRWC5;LMXU6[+>-
M5NRWC?B<  #_H P [;4) -3*!@#*Z0X O_0I#+;\-QZL_STPG_\\09/_.U"'
M_SQ=??\^:'/[/W)I]T%Z8/-$@%KP2(16[TZ'4^Y5B5+N78E1[F:(4>]PB%'O
M>X=0\(6&4/"1A5#QH810\:*$4/&BA%#QHH10\:*$4/&BA%#QHH10\:*$4/&B
MA.^@  #@JP  T;T" ,?/! "^]1@"M?XL#JK_,AZ=_S0ODO\T/H;_-$M\_S97
M<O\X86C_.VE@_#UP6?E =57W1'A1]DI[3_50?$[U5GQ-]5U\3/5E?$OV;GM+
M]G=Z2O>!>DGWCGE)]XYY2?>.>4GWCGE)]XYY2?>.>4GWCGE)]XYY2?>.>>&D
M  #2M0  Q\8" +O6 @"P_Q0#I_\B#IO_)QR/_RDKA/\J.'K_+41P_S!.9_\R
M5U[_-5Y8_SAC4_\\9T__0&I-_D5L2_U*;4G]3VY(_55N1_U;;D;]8FY%_FEM
M1/YQ;4/^?&Q#_GUL0_Y];$/^?6Q#_GUL0_Y];$/^?6Q#_GUL0_Y];-2N  #'
MOP  O-   *[=  "B_PH"F/\6#(W_'!B"_Q\D=_\A,&W_)3IC_RE#7/\L2E7_
M+U!0_S)53/\V6$G_.EI'_S]<1?]#74/_2%Y"_TQ>0/]17C__5UX^_UQ>/?]C
M7CS_;%T\_VQ=//]L73S_;%T\_VQ=//]L73S_;%T\_VQ=//]L7<FY  "]R0
ML-<  *'G  "4_P(#B/\'"'[_#A)S_Q(<:?\7)F#_'"]8_R$V4?\E/$S_*$%(
M_RQ$1?\P1T+_-$E _S=*/O\[2SW_/TP[_T--.?](33C_3$TW_U%--O]6337_
M74TU_UU--?]=337_74TU_UU--?]=337_74TU_UU--?]=3;_#  "RT@  H]P
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M<D3[L7%$_,9P1/S&<$3\QG!$_,9P1/S&<$3\QG!$_,9P1/S&</F7  #6J@
MRKH  ,#) 0"UV ( JO\3 J+_(@R7_RD9C/\M*(+_+S5W_S!!:_\Q2V'_,U19
M_S=<4O\[8DW_0&9*_T9H1_]-:D7_56I$_UUJ0O]G:D'_<FD__WYH/O^*9SW_
MF6<]_ZAF/?^H9CW_J&8]_ZAF/?^H9CW_J&8]_ZAF/?^H9MJC  #,M   P<,
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MYG1.TN=W3\WG>$_-YWA/S>=X3\WG>$_-YWA/S>=X3\WG>/^&  'TE@  UJ<
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M4R__U%,O_]13+__44R__U%,O_]13+__44].C  #&L@  O,   +#,  "CU@
MEN(  (S_"0."_Q((>?\:$G#_'QQF_R,F7/\F+U/_*3=,_RP]1?\P0D#_-44\
M_SM(.?]"23;_24HS_U%*,O];2B__9DDM_W-)*_^ 2"G_CD<G_Y]')_^I1B?_
MJ48G_ZE&)_^I1B?_J48G_ZE&)_^I1LFN  "^NP  LLD  *32  "6VP  B><
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M_X0O%O^(.1[VBD(H[HE*,^>&43[@@%I+V7EC6=%P:VC+:71TQF5]>\)CB'[
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M:DO%\6I+Q?%J2\7Q:DO%\6I+Q?%J2\7Q:O^"  #=E0  SZ0  ,6Q  "\O
MLL@  *?2 P"=Z P ENP@!8[L+ ^%[#,<>^LX*G#J.S=DZ3Y#6>E!3E'I1U9+
MZ4];1^I:74;K:%U%['=<1.V)6T3NG%E#[[%80O#-5D+Q[E5"Y_571-WV6T3<
M]EM$W/9;1-SV6T3<]EM$W/9;1-SV6^B-  #3G@  QZP  +ZX  "TQ   J,X
M )W7 @"4\@\!B_4=!H/V)A%Z]BT=</8Q*67V-31;]3@^4O8[1DOV04U%]TE1
M0OA24S_Y75,]^6I2._IZ43K[C% Y_*!/./RU3CC]TTPW_NU+._?Y2CSV^DH\
M]OI*//;Z2CSV^DH\]OI*//;Z2MF7  #*J   P+4  +;   "JRP  G=,  )';
M  "(^@P"?_\7!W?_'Q!N_R4:9/\J)%O_+2Y2_S$V2O\U/43_.T% _T)%._])
M1CC_4D<V_UU'-/]J1C+_>D4P_XM$+_^>0R[_LT(M_\I!+?_M02W_\$ M__!
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MFRD6_YLI%O^;*;NW  "PP@  HLP  )/3  "%VP  >.$  &SJ  %C_0 $6O\
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M>U:5Y7M6E>5[5I7E>U:5Y7M6E>5[5I7E>_]I @7_?@  WHX  -.:  #*I0
MP:X  +FV  "OOP( J,,> :#$, J8PCP8C\!%*(:]2S=]NE!%<[A54FFU65Y?
MLUYI5[)F<%.Q<G)2LH%Q4;*2<%"SI&Y0M+IM3[3::TVQ[VU/JNUP4:7L<E*A
MZW-2H>MS4J'K<U*AZW-2H>MS4J'K<_]P  /RA0  V),  ,V@  #$JP  N[0
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M3#[6_TP^UO],/M;_3-V-  #-G0  PJH  +FU  "NO@  H\<  )?.  "+U@$
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M  "AQP  DLX  (/5  !TW0  9^,  %OI  !0\  !2/X !$#_  <X_P *,O\
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M&O]/-B#_34$I_TE,,_M%6#KW0V0_]$)Q0/)"?$'P0H=![D.00>U$F4#L1:%
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M_5BJ7/U8JES]6/]($ [_2A,0_U<.#/]D%@K_;!T)_W$D"O9S+ [M<S85Y7%
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M>V)ZYGIB>>9Y8GGF>6)YYGEB>>9Y8GGF>?]:!@C_;0 "]7T  -N(  #2D@
MRID  ,.@  "[I0\ M*<H JRG. VDI40;G*)-*Y2?5#F,FUI'A)A?4WR48V!R
MD&AK:(UL=6"*='Q;B7]_6HJ.?EF*GWQ9B[%[6(O*>5:*YGE8AN9Y6H/F>5N
MYWA<?^=X7'_G>%Q_YWA<?^=X7'_G>/]? @;_<@ !Y8$  -:-  #-E@  Q9X
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M94Z<]&5.G/1E3IST9?]R  #?@P  T9$  ,:=  "]I@  M:X  *NT  "?N@
ME< + )##(P*)PC$+@L$\%WJ_0R1QO4DR9[M./EZZ4DA6N%A14+=A5TVW;%E+
MMWI82[B)5TJYFE5*N:U42;K'4DBYYU%%MOM51K'^5T>K_%I(JOQ:2*K\6DBJ
M_%I(JOQ:2*K\6O%Z  #8BP  RY@  ,"D  "XK   KK0  *.Z  "8P0  C,@#
M (7-%P" S2D&><TT$7'+/!UHRD(J7LA'-5;'33]/QE-'2L9=2DC&:4M'QW=*
M1LB&24;(F$A%R:M&1,K%143)YT-!Q_I'/L7_2D"\_TU N_]-0+O_34"[_TU
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M%!'_?!,/_XT2#O^<$0[_KQ -_[,0#?^S$ W_LQ -_[,0#?^S$+2U  "HO@
MFL4  (S+  !]T@  <-@  &/?  !8Y   3NH  $?Y  ,__P &./\ "3+_ @PM
M_P<.*/\,$"3_$A$@_Q@2'?\>$QG_)!,5_RH3$?\Q$PS_.Q()_T41!?]1$ +_
M7@\ _VT. /]Z#0#_B@T _XT- /^-#0#_C0T _XT- /^-#:N\  "=Q   CLL
M '_2  !PV0  8^   %?F  !,ZP  0N\  3K]  ,S_P %+?\ ""C_  HB_P ,
M'O\ #1K_ PX6_P@/$_\-$!#_%! +_QD0!O\?$ +_)@\ _RX. /\Y#@#_1 T
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M:71L\VAU:_1F=6OT9G5K]&9U:_1F=6OT9O]0!0C_80 #_'   -]Z  #6@@
MSX@! ,F, @#!D!8 N9(L!+*0.PZJCD8<HXM/*YN'5CF4@UM%C7]A489Z9ER
M=FMF>G-R;75Q>G%R<(5S<'&2<VYQH'-K<;!S:G'%<FEQX7%J<>YO:V_O;&QN
M\6MM;O%I;6[Q:6UN\6EM;O%I;6[Q:?]3 P?_90 "\W,  -M]  #2A0  RXP
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M;%=\\&Q7?/!L5WSP;/]?  /U<0  VWX  ,^)  #&D@  OI@  +6=  "KH0(
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M'37EQ!PTY>8;,>+Z'B_@_R MW_\B+=__(BW?_R(MW_\B+=__(L:7  "\I
MLZX  *FU  "<NP  C\   (+%  !VR@  :]   &#8  !7X@0 4NT2 TSM&PA%
M[2,-/^XI$CGN,18U[SD9,N]"&C#P3!LN\5@:+?)E&2SS=!@K\X47*O28%BGU
MK14H]<H4*/;J$R;T^Q,E\O\3)?+_$R7R_Q,E\O\3)?+_$[ZB  "UK0  J[4
M )^\  "1P0  A,8  '?+  !KT0  8-@  %7>  !.ZP !2/H)!$+[$@<\^QD+
M-OP?#S'\)A(M_2T3*?TU%";^/A4C_T<4(?]3$Q__8!(=_W 1'/^"$!O_E0\:
M_ZH.&?_"#1G_X0P8__(,&/_R#!C_\@P8__(,&/_R#+BK  "NM   HKP  )3"
M  "&QP  >,T  &O2  !?V0  5=X  $OC  !#\  !/?T !#?_!P<R_PT*+?\4
M#"C_&@XD_R /(?\G$!W_+A 9_S80%O] #Q+_2P\/_U@."_]H#0C_>@L(_XP*
M!_^>"@;_L D&_\$)!O_!"0;_P0D&_\$)!O_!";&S  "ENP  E\(  (C(  !Y
MS@  ;-0  %_:  !4X   2>4  $#I   X]0 ",O\ !"S_  8H_P$((_\&"A__
M# L;_Q(,%_\8#1/_'@T._R4-"O\L#0;_-@P!_T$+ /]."@#_70D _VT( /]]
M" #_BP< _Y<' /^7!P#_EP< _Y<' /^7!ZB[  ":P@  B\@  'S.  !MU0
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MV&-N:?!@;FGY7F]H^UQP9_Q:<&?\6G!G_%IP9_Q:<&?\6O]/  7_7P !XVP
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M8U=T]V)9<OAA67+X8%ER^&!9<OA@67+X8/]9  +J:@  V7<  ,V!  ##B0
MNXX  +*2  "IE $ HI8; )R7+@26ECL-CY1%&8B23"6"CU(Q>XQ7/7.)7$=K
MAF!28X-F6UN!;&-7@'9F58"#9E2 D653@:%C4X&S85*!S&!0@.E@4'[X8%%[
M^&!3>/E?4WCY7U-X^5]3>/E?4WCY7_]>  #C;P  U'P  ,F&  "_C0  MY,
M *Z7  "CF0  G)L6 )>=*@*1G#@*BII"%8.82B%]EE M=9-5.&V16D-ECEY-
M78QD5E>*:UQ3B75?48F"7U&*D5U0BJ%;3XJS6D^*S%A-B>A82X?[6DR$_%I-
M@?Q;38#\6TV _%M-@/Q;38#\6_QC  #>=   SX$  ,2+  "[DP  LY@  *F<
M  "<GP  E:$. )"C) &*HC,'A*$^$7Z?1AQWGDTH;YM2,V>96#U?EUQ'6)5B
M3U*4:E1/DW563I."54Z4D%1-E*%23)2S4$R4S$Y*D^A/2)'[44>._U))BO]4
M28K_5$F*_U1)BO]428K_5.MI  #8>@  RH<  ,"1  "WF   KIX  *6B  "8
MI0  C:<% (BI'0"#JBT$?:DY#7>H0A=OID@B:*1.+6"C4S=8H5E 4I]?1TZ>
M:$M+GG1+2IZ!2DJ?CTE)GZ!'29^R1DB?RT1'GNA$19S[1T.:_TE#EO]*0Y;_
M2T.6_TM#EO]+0Y;_2^-Q  #2@0  Q8T  +N7  "RG@  JJ0  )^H  "3JP
MA*\  'ZQ$P![L28!=;$S"&ZP/!%GKT,;8*Y))5BM3B]2JU0W3*M</4FJ93]'
MJG$_1JI^/T:KC3U%JYX\1*NP.D.KR3A#JN@X0*CZ.SZF_SX]H_] /:/_0#VC
M_T ]H_] /:/_0-MZ  #+B   OY0  +:>  "NI0  I*H  )BN  ",L0  ?[4
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M&,&7  "XHP  L*P  *6R  "8MP  B[L  'Z_  !QQ   9<D  %K.  !0U
M1ML# $+E$ $]YAL$..8C"#/G*PPOYS0.+>@^#ROI2! IZ50/*.IA#R?K< XF
M[($-)>R4#"3MJ0LC[L4*(N_F"2'L^@D?Z?\*'NG_"Q[I_PL>Z?\+'NG_"[JA
M  "RJP  J+,  )NX  ".O0  @,$  '/&  !GRP  6]   %#5  !'VP  />$
M #CT!P(T]1$$+_88!ROV( DG]B<+(_<P#"#X.0P>^4,,&_E."QGZ7 H6^VP)
M%?M^"!3\D@<3_*@'$OW"!A'^X@40_?L%$/W]!1#]_040_?T%$/W]!;2J  "K
MLP  GKD  )"^  ""PP  =,@  &?-  !;T@  4-@  $;=   \X@  ,^@  "_X
M  (J_P4$)O\,!B+_$P<>_QH(&O\A"1;_* D3_S$)#O\["0K_1P@&_U0' O]D
M!@#_=P8 _XH% /^?! #_L@0 _\X# /_2 P#_T@, _](# /_2 ZZR  "AN0
MD[\  (7$  !VR@  :,\  %O5  !0VP  1>   #KD   QZ   *O   27[  (@
M_P $'/\ !1C_! 84_PH'$?\2!PO_& <'_Q\' O\G!P#_,0< _ST& /]*!0#_
M604 _VL$ /]] P#_C0, _Y\" /^A @#_H0( _Z$" /^A J2Y  "6OP  B,4
M 'C+  !JT0  7-@  %#>  !$Y   .>@  "_L   F[P  '_8  1K_  (5_P #
M$?\ ! W_  4)_P &!O\ !@+_!@8 _PP& /\4!@#_' 8 _R4% /\Q!0#_/@0
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M_Q_"-O\?PC;_'_\F$P__, L,_S<&"O] #@C_1!8(_T0?"OE!* WO/302Z#E
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MV$B#6^Y'@EO^1H%;_T6 6O]$@%K_1(!:_T2 6O]$@%K_1/]%  7_4P !ZUX
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M4VED_U%J8_]/:F/_3FIC_TYJ8_].:F/_3O]-  +S7   W6D  -%R  #'>0
MOWP  +=^  "O?PH J8$A **",0:<@#T0E7U&&X][3B>)=U0S@W19/7UQ7D9W
M;61.<FMJ56YI<EEK:7Q;:6B'7&=IDUME:*%;8VBQ6V%HQUI@:.-986CX5V%H
M_U1C9O]28V;_46-F_U%C9O]18V;_4?]/  'I7P  VFT  ,UV  #$?   NX
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M4TYU_U-.=?]33G7_4_1<  #=;0  SGD  ,*#  "YB@  L8X  *>1  ":D0
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M--1Y  #%AP  NY(  +*;  "JH@  H*8  ).H  "&JP  >JX  &NQ  !FLQ,
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M"BK2LPDITM$(*-#M"2;._ PDR_\.(\K_#R/*_P\CRO\/(\K_#[V7  "TH0
MK*H  *&O  "5LP  A[<  'JZ  !MO0  8<(  %7&  !*RP  0-   #76 P O
MW0L +=X9 2K?(P,GWRT%)> X!B3A0P8BX4\&(>)<!B#C:P4?Y'L%'N2.!!WE
MHP,;YKX#&N;@ QCC^ ,7XO\$%N'_!1;A_P46X?\%%N'_!;>A  "OJ@  I;
M )BU  "*N0  ?+T  &_   !BQ0  5\D  $S.  !!TP  -]@  "W=   HZ0,
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M  #_D0  _Z(  /^M  #_K0  _ZT  /^M *&W  "3O0  A<(  '7(  !GS@
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M /\ ^P#_ /L _P#[ /\ ^P#_ /\$)0__""$/_P@@#_\"(0__ "8._P R#?\
M/PO_ $T)_P!:"/\ 9P;_ '(%_P!\!/\ A0/_ (P#_P"3 O\ F +_ )X!_P"D
M ?\ JP'_ +,!_P"\ /T QP#\ -8 ^P#F /H \@#Y /P ]P#_ /8 _P#U /\!
M]0#_ ?4 _P'U /\!]0#_ ?\)(A#_#1T/_PP;#_\('0__ B,._P$O#?\ / S_
M $D*_P!7"/\ 8P?_ &\&_P!Y!?\ @@3_ (D#_P"0 _\ E@+_ )P"_@"B OT
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MVBF83.XKEDS]*Y1+_RR32_\KDTK_*Y-*_RN32O\KDTK_*_\X  ;_0@ "^$T
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M/'Q6_SM\5O\Z>U;_.7M6_SE[5O\Y>U;_.?]!  +Y3P  X5L  -1D  #+:0
MPVL  +QJ  "U:@\ KFPD :=L,PBA:CX2FV=''95D3R>0858QC%Y<-XE=8SR&
M6VL^A%MR0();>T&!6H1!?UJ-0GU:F4)[6J5">5JT0G=:R$-V6>%"=5GV0719
M_S]T6?\^=%G_/719_SUT6?\]=%G_/?]#  +P4@  W5\  -%H  #';0  OW
M +AO  "P;PL J7$A *-Q,0:=<#P/EVU%&I%J326,9U,OAV1:-X-A8#Y_7V="
M?5YN1'I>=D9X7G]'=UZ)1W5>E4=S7:)'<5VP2&]=Q$AM7-U';%WT16Q=_T-L
M7/]";5S_0&U<_T!M7/] ;5S_0/]&  'I50  VF,  ,UL  ##<0  NW0  +1S
M  "L<P< I74> )]V+@29=3H-DW)$&(UO2R*(;%$M@VE7-GYF73YY9&-$=6)J
M2')A<DIP87M,;F&%3&QAD4QJ89Y,:&"M3&9@P$QD8-I,9&#R261@_T=E8/]%
M95__1&5?_T1E7_]$95__1/]*  #E6@  UF<  ,IO  # =0  N'@  +!X  "G
M=P0 H7H; )M[+ .5>3@+CW="%8EU22"$<E J?F]5-'EL6CUS:6!$;F=F2FIE
M;DYG97=0962!4&-DC5!A9)M07V2J4%UDO4];9-9/7&3P3%QD_TI=8_](7F+_
M1UYB_T=>8O]'7F+_1_]-  #B7@  TVL  ,=S  "]>   M7L  *Q\  "C?
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MCBP#?8TX"7>,01)QBD<;:XE-)62'4BY=A5<W5X-</U*!8T5.@&U'3(!X2$N
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M)#V?M",\G\XA.YWJ(CF;_"4WFO\G-IC_*3:8_RDVF/\I-IC_*<UY  # A@
MMI   *Z8  "EG0  F)X  (N@  " HP  <Z8  &6I  !=JPD 6:P< %:M*0)2
MK3,&3:P[#$BK0A)#JTD8/ZM1&SRJ6AT[JV4=.JMQ'#FK?QLXJXX:-ZN?&3>K
MLA<VJ\P6-:GI%C.G^ADQIO\;,*3_'3"D_QTPI/\=,*3_'<:"  "ZCP  LI@
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M  W:\@ -V/\!#=;_ @W6_P(-UO\"#=;_ K.@  "LJ   HJX  )6R  "'M@
M>;D  &N\  !>OP  4L,  $?'   [RP  ,<\  "C4   ?V0  %]T  !/G"0 1
MZ!0 #N@>  OI*0 )Z34 !^I"  7K4  #[&   >QS  #KAP  ZIT  .JX  #K
MW   ZO,  .K_  #J_P  ZO\  .K_ *ZH  "EKP  F+0  (JX  !\NP  ;K\
M &##  !4QP  2,P  #S0   QU   )]D  !_=   7X0  #^0   OP   (^ 4
M!?@.  'Y%P  ^2$  /@L  #X.@  ^$D  /A;  #X;@  ]X0  /::  #WL0
M]\L  /CI  #XZ0  ^.D  /CI *BO  ";M0  C;D  '^^  !PP@  8L<  %7,
M  !(T0  /-4  #':   GW@  '>(  !;F   -Z0  !NP   /V    _@   /\
M  #_!0  _PT  /\7  #_(@  _S   /]   #_4P  _V@  /]]  #_D0  _Z,
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M +  _ "X /L P@#[ ,\ ^P#@ /H [@#Z /H ^@#_ /H _P#Z /\ ^@#_ /D
M_P#Y /\ ^0#_ /\ (0W_ 1T-_P <#/\ '@O_ "(*_P O"/\ /0?_ $L%_P!8
M _\ 9 +_ &\!_P!X ?\ @ #_ (< _P". /\ E #] )H ^P"@ /D I@#X *T
M]P"U /8 OP#U ,T ]0#= /0 [ #T /< ] #_ /0 _P#S /\ \P#_ /( _P#R
M /\ \@#_ /\$'@[_!AD-_P,8#/\ &0S_ " *_P L"?\ .@?_ $@%_P!5!/\
M80/_ &P"_P!U ?\ ?0'] (4 ^P"+ /D D0#W )< ]0"= /, I #R *L \ "S
M .\ O0#N ,H [@#: .T Z #M /4 [ #_ .L _P#J /\ Z #_ .< _P#G /\
MYP#_ /\)&@[_"A0-_P@3#/\"$PO_!!X+_P$I"?\ -@C_ $,&_P!1!/\ 70/^
M &@"^P!R ?@ >@'V (( ] "( /( CP#P )4 [@"; .T H0#K *@ Z0"P .@
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M N,5<P'@%GL!WA:# =T6B0';%Y !VA>6 -D8G0#7&*4 U1FM -0:MP#2&L0
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MW@JQ,^\-KS/]#ZTR_Q"K,O\1J3+_$:DR_Q&I,O\1J3+_$?\E 0C_*@ %_S0
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M(8]&_R&.1O\AC47_(8U%_R&-1?\AC47_(?\T  /_/@  YT8  -Q/  #24P
MRU,  ,9. 0"^4!8 MU(H [!1-@NJ3T$3I4U+&J%,5!^>3%TAG$QE(II,;2.9
M3'0DETQ\))9,@R243(LEDTR4)9%,GB6/3*DFCDRW)HQ,RB:*2^$GB$OT)X=+
M_R>&2O\GA4K_)H5*_R:%2O\FA4K_)O\V  +Y0@  XDT  -96  #,6@  Q5L
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M-&]5_S-O5?\S;U7_,_]   #F4   UUT  ,IE  # :0  N&L  +!I  "H9P4
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M.49\KS=%?,4U1'OB-4)Z]C9!>/\W0'?_.$!V_SA =O\X0';_.-QC  #+<
MOGH  +2"  "JA@  GH<  ).'  "$B0  ?8L  '>-#@!SCB  ;XXN VJ-. EE
MC$ 07XM&&%F*3"!4B%$G3H=7+DJ&7C)'A6<T185S-$2%?S-$AHTQ0X:=,$*&
MKBY!A<4L087B*SZ#]BX]@?\P.X#_,3M__S$[?_\Q.W__,=5I  #%=@  NH$
M +&(  "EBP  F8L  (Z,  ""CP  =9(  &^3!0!JE1D 9Y4H 6.5,P5>E#L+
M6)-"$E.22!E.D4X@29!5)46/72E"CV8J08]R*D"/?BE CXPG/X^<)CZ/KB0]
MC\0B/8[A(3J,]B0XB_\F-XG_*#>)_R@WB?\H-XG_*,YQ  # ?0  MH<  *V/
M  "AD   E9   (F2  !^E   <)@  &6;  !?G X 7)T? %F=+ )5G34'4)P]
M#$N;1!)'FDL80II2'#^96Q\]F60?/)EP'SN:?1XZFHL<.IJ;&SF:K!DXF<,8
M-YG@%S66]1HSE?\<,I3_'C*3_QXRD_\>,I/_'L=Y  "[A0  LH\  *F5  "<
ME0  D)8  (28  !YFP  ;)X  %^B  !5I0( 4*84 $ZF(@!+IBT"1Z8V!T*F
M/@L^I44/.J5-$CBE5A0VI6 4-:5L$S2E>1,TI8<1,Z68$#*EJ@\QI< .,*3>
M#2ZB]! MH/\2+)[_$RN>_Q0KGO\4*Y[_%,""  "VC0  KI8  *2;  "7FP
MBYT  '^@  !SHP  9Z8  %JI  !.K   0Z\$ #ZP%  \L2( .K$L C:Q-00S
ML3X',;%'"2^Q4 HML5L*++%F"2RQ= @KL8,(*K&3!RBQI@8GL;P%)K':!22N
M\@<CK?\)(JO_"B&K_PHAJ_\*(:O_"KJ+  "RE@  JIX  *"A  "2HP  A:4
M 'FI  !MK   8:\  %2Q  !(M   .[<  #"Z @ JO!  *;T= ">]*  EOC(!
M([X\ B*^1@(@OU$"'[]= AZ_:P$=OWL!',"+ 1K GP 9P+8 %[_4 !>]\ $6
MN_\"%+K_ Q2Y_P04N?\$%+G_!+65  "MGP  IJ8  )JI  "-K   @*\  '*Q
M  !ELP  6+8  $RX  ! NP  ,[\  "G#   @QP  %\L% !'-$  0S1P #LXG
M  W.,P +SD  "L]-  K/6P (SVL !M!]  70D0 $T*8  M#!  #/X@  SO@
M <S_  ++_P "R_\  LO_ +"?  "IIP  GJP  )*O  "$L@  =;4  &BW  !;
MN@  3KT  $+    VQ   *\@  "+,   9T   $=,   ?7   !V@<  -H4  #;
M'P  W"L  -TY  #>1P  WU<  .!I  #@?0  X9(  .&I  #AQ   XN,  .+V
M  #A^@  X?H  .'Z *RG  "BK0  E;$  (>U  !XN   :KL  %V^  !0P@
M1,8  #?)   LS0  (=$  !G6   1V@  "=P   '?    X@   .0   #E"@
MYA8  .@B  #J,   [$$  .]2  #P9@  \'L  /&0  #RI@  \KT  /+7  #R
MX0  \N$  /+A *6N  "8LP  BK<  'R[  !MO@  7L,  %''  !$RP  -\\
M "S4   AV   %]P   _@   'Y    .8   #G    Z@   /    #P    \
M /$)  #T%P  ]B8  /DY  #\3   _6$  /YV  #_BP  _YT  /^N  #_M0
M_[4  /^U )NT  ".N   ?[T  &_"  !AQ@  4\L  $71   XU0  +-L  "#?
M   6XP  #.8   7J    [    .\   #O    \0   /@   #\    _    /P
M  #]    _@H  /\<  #_+P  _T0  /]9  #_;0  _W\  /^.  #_DP  _Y,
M /^3 /\ (0O_ !T*_P <"?\ '0C_ ",&_P P!?\ /@/_ $P!_P!8 ?\ 9 #_
M &X _P!X /\ @ #_ (< _P"- /\ D@#^ )@ _0"= /P HP#\ *D ^P"P /H
MN@#Z ,8 ^0#5 /D YP#W /4 ]0#_ /0 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\ '0O_ !H+_P 8"O\ & C_ " '_P N!?\ .P/_ $D"_P!5 ?\ 80#_ &L
M_P!U /T ?0#[ (0 ^@"* /D CP#X )4 ]P"; /8 H #U *8 ] "N /0 MP#S
M ,( \@#1 /( Y #P /, [@#^ .X _P#N /\ [0#_ .T _P#M /\ [0#_ /\
M&@S_ !4+_P 4"O\ $PC_ !T'_P J!?\ . /_ $4"_P!1 ?\ 70#] &@ ^0!R
M /8 >@#T ($ \P"' /$ C0#P )( [P"8 .X G0#M *0 [0"K .P M #K +\
MZ@#. .D X #G /  Y@#Y .0 _P#D /\ Y #_ .0 _P#D /\ Y #_ /\$%0S_
M Q$*_P ."?\ $@C_ !H'_P F!?\ - 3_ $$"_P!. ?H 60#U &0 \0!N .X
M=@#L 'T Z@"$ .D B@#H (\ YP"5 .4 FP#D *$ XP"I .( L0#A +P X #+
M -X W0#= .L VP#W -D _P#9 /\ V #_ -@ _P#8 /\ V #_ /\($0O_" H*
M_P,&"/\%# ?_!Q<&_P,B!?\ +P3] #P"]P!) ?( 50#L &  Z !J .0 <P#C
M 'H X0"! -\ AP#> (P W0"2 -L F #: )\ V0"F -< KP#5 +H U #) -,
MV@#1 .L S@+X ,P$_P#+!?\ R0;_ ,@&_P#(!O\ R ;_ /\."@K_#@,(_PP
M!O\3" 7_$Q,%_Q$>!/L+*0/S!S<"[ 5$ >8%4 #B!%P W05F -L&;P#9!W8
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M!Z<L_PBE+/\)I"O_"J,K_PJC*_\*HRO_"O\?  ;_(P "_RT  .\O  #B+0
MW2@# -L@#0#1)B$ R2HQ L,M0 2^+TT%NS!7!K@R80:U,FD'LS-Q![(T> >P
M-'X(KS2%"*TUC BL-9,(JC6;":DUI FG-J\)IC:]":0VS@JB-N,+GS7T#)TU
M_PZ;-/\.FC3_#IDS_PZ9,_\.F3/_#O\E  3_*P !\3,  .(Y  #:.P  TS@
M ,\P!P#',QL OS8L [DW.P>T.$<*L#E2"ZTZ6PRK.V0-J3ML#:<\<PVF/'H.
MI#R #J,\APZB/8X/H#V7#YX]H ^=/:L/FSVX$)H]R1"8/=\1E3SR$I,\_Q.2
M._\3D3K_$Y Z_Q.0.O\3D#K_$_\H  +^,@  YSL  -M#  #21@  RD0  ,4^
M @"^/A8 MT$H [!!-@BK04(-IT%,$*1!5A*B0EX3H$)F$YY";A2<0G44FT-\
M%9E#@Q680XH5ED.3%I5#G!:30Z<6DD.T%Y!"Q1>.0ML7C$+O&(I!_AF)0?\9
MB$#_&8= _QB'0/\8AT#_&/\K  'R-P  X40  -5,  #+3P  PTX  +U(  "W
M1Q$ L$HD :E*,@>D23T.GTA($YQ(41>91UD9ET=A&I5':1J41W ;DD=W&Y%'
M?AR/1X8<CDB.'(Q(F!V*1Z,=B4>P'8='P!Z%1]8>@T;L'H)&_!Z!1?\>@$7_
M'H!%_QV 1?\=@$7_'?\O  #K/0  W$L  -!3  #&5@  OE8  +=0  "P3PP
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M/4]AJSQ.8;\[3&':.DQ@\CE-7_\W35__-DU>_S5-7O\U35[_->-1  #28
MPVL  +EQ  "M=   H7,  )AS  ".<@  B'0% (-U&0!_=B@!>G8T!W5T/ YP
M<D,6:G%)'F5O3R9?;50N6FM9-55I8#I19V@]3V=R/DUG?CY,9XL]2V>9.TIG
MJCI)9[XX2&?9-T=F\3='9?\V1V3_-4=C_S5'8_\U1V/_-=]6  #.90  P&\
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M(3M^[R,Y??XD.'O_)C=Z_R8W>O\F-WK_)L]I  # =0  M7\  *J#  "=A
MD80  (>%  !\AP  ;XL  &>-  !ACA$ 7H\A %N/+0)7CS8&4HX^#$Z-1!))
MC$H81(M1'$&+61\^BF(@/8IM(#R*>1\[BX8>.XN5'#J*IALYBKL9.(K6&#:(
M[QHUAOX<-(7_'3.$_QXSA/\>,X3_'LAQ  "[?   LH4  *6(  "8B   C8D
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M!1JD_P8:I/\&&J3_!K:+  "NE0  I)D  )>9  "*F@  ?IT  '*A  !FI
M6J<  $^J  !#K0  -K   "NR   AM08 ';84 !RV'P ;MRH &;<T !BW/P 7
MMTH %K=5 !2X8P 3N'( $;B#  ^XE0 -N*H "[?#  JVXP +M/@ "[/_  NR
M_P$+LO\!"[+_ ;*4  "KG0  H*   )*A  "%I   >*<  &RK  !@K@  5+$
M $>S   [M0  +K@  "2[   :O@  $<$   ?#"0 $Q!8  \0A  +%+0 !Q3D
M ,5%  #%4P  Q6(  ,5T  #%AP  Q9P  ,2R  #$SP  P^H  ,/Y  #"_P
MPO\  ,+_ *V>  "GI0  FJ@  (VK  " KP  <K$  &2S  !7M@  2K@  #V[
M   QO0  )L$  !S$   3R   "LH   '-    SP4  - 0  #1&P  TB8  -,R
M  #40   UD\  -A@  #8<P  V(D  ->@  #6N0  UM@  -;M  #5^   U?@
M -7X *JF  "?JP  DJ\  (2R  !UM0  9[@  %FZ  !,O0  /\   #/#   G
MQP  ',L  !//   *TP   M0   #8    V@   -P   #=!P  WQ(  .$>  #D
M*P  YCD  .E*  #J70  ZW(  .R(  #LH   Z[@  .O2  #JY@  ZN8  .KF
M **L  "5L0  B+0  'FX  !JNP  6[\  $[#  !!Q@  ,\H  "C-   <T@
M$]<   G;   !W@   -\   #B    Y    .8   #H    Z@   .P&  #O%
M\B(  /4R  #X1   ^E@  /MN  #\A   _9@  /VK  #]N@  _;H  /VZ )FR
M  "+M@  ?+H  &V^  !>PP  4,<  $+,   TT   *-0  !S:   1W@  !^(
M  #E    Z    .H   #K    [    .X   #P    \P   /4   #X    ^P@
M /X8  #_*@  _ST  /]2  #_9P  _WL  /^*  #_E@  _Y8  /^6 /\ ' G_
M !@(_P 7!_\ &07_ " $_P O O\ .P'_ $D _P!6 /\ 80#_ &L _P!T /\
M>P#_ (( _P"( /X C0#] )( _ "7 /P G0#[ *, ^@"J /@ L@#V +T ] #,
M /0 WP#S .\ \P#] /, _P#S /\ \P#_ /, _P#S /\ \P#_ /\ &0G_ !4(
M_P 2!_\ % 7_ !X$_P K O\ . '_ $8 _P!3 /\ 7@#] &@ _ !Q /H > #Y
M '\ ^ "% /< B@#V (\ ]0"5 /0 F@#S *  \@"G /  KP#N +H [ #( .L
MV@#K .P ZP#[ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\ %@K_ !((_P .
M!_\ #@;_ !L$_P G O\ -0'_ $( _@!/ /D 6@#V &0 ] !M /( =0#Q 'P
M\ "" .\ AP#N (P [0"2 .L EP#J )T Z "D .8 K #D +8 XP## .( U0#A
M .D X #W .  _P#@ /\ WP#_ -X _P#> /\ W@#_ /\ $0G_  L(_P (!_\
M#07_ !@$_P C O\ , '\ #X ]0!+ /  5@#M &  ZP!I .D <0#H '@ Y@!^
M .4 A #C (D X@"/ .$ E #? )H W0"A -L J0#9 +, UP#  -8 T@#5 .4
MU #S -, _0#2 /\ T0#_ -  _P#0 /\ T #_ /\""@G_  0'_P  !O\ "03_
M !4#_P @ O\ *P#T #D Z@!& .< 40#D %P X0!E -\ ;0#= '0 VP![ -D
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M .H%'0#= "L UP(Y -($1P#.!U( R@A< ,@*90#%#&T Q UT ,(.>P# $($
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M")0L_PB4+/\(E"S_"/\;  +[)   YRX  -PU  #2-@  RS,  ,8K P"_*A<
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M+&%1JRQ?4+XL75#6+%Q0[RI<3_XH7$__)UQ/_R5<3_\E7$__)>="  #64@
MQUT  +QC  "N8P  I&(  )M?  "470  CE\+ (IA'@"%82L#@& V"7Q>/A!W
M7$48<UI+'FY8421K5U<I:%9>+&5592YC56TP855W,%]5@3%=58PQ6U2:,5E4
MJ3!75+LP55/4,%53[2Y54_TL55+_*E92_RA64O\H5E+_*.1'  #25P  Q&$
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M+4-BZ2U"8?LM0F#_+$)?_RM"7_\K0E__*]E7  #'9   NVT  *YP  "A<
MEG   (QP  "!<   >W(  '5T#0!R=1X ;G4K FEU-0=E<ST-8')#%%IQ21M5
M;TXA46U4*$QL6BU):V(P1VML,$5K>#!$:X0N0VN3+4)KHRM!:[4I0&O.*#]J
MZ"@^:/HH/6?_*#UF_R@]9O\H/6;_*--<  ##:0  N'(  *IT  "==   DG0
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M%"Y__Q4N?_\5+G__%<-P  "W>P  JX$  )R!  "0@0  AH$  'N#  !PA@
M8XH  %J,  !0CP  2I$0 $B1'@!&D2D!0Y$S S^1.@<[D$(*.)!)#3604@XT
MD%L/,I!E#C&0<0XQD'\-,)"-#"^/G@LNC[$*+(_)"2N-Y0DJB_@+*8K_#"B)
M_PXHB?\.*(G_#KUX  "S@P  I88  )>&  ",A@  @8<  ':)  !KC   7Y
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M *Z4  "DF   EY<  (J9  !]G   <9\  &6C  !9I@  3JH  $*M   VL
M*K(  !^T   5MP  "[@   *Z"   NQ,  +L>  "\*   O#,  +P_  "\2P
MO5H  +UJ  "]?0  O9$  +RF  "[OP  NMX  +KQ  "Y^P  N?P  +G\ *N=
M  "@GP  DJ   (6C  !XIP  ;*H  &"N  !3L0  1K0  #FV   MN   (;L
M !>^   -P   !,(   #$    Q@0  ,<-  #(&   R2,  ,HO  #+.P  S$D
M ,Y9  #.;   SX$  ,^6  #.K0  SL@  ,WC  #,]   S/4  ,SU *>E  ";
MJ   C:H  ("N  !RL@  9+0  %:V  !(N0  .[P  "^^   CP0  &,4   W(
M   $RP   ,T   #/    T@   -,   #5!   V X  -L:  #=)@  WS0  .%$
M  #C5@  XVP  .2#  #DF@  Y;$  .7)  #DX0  Y.0  .3D *"K  "3KP
MA;(  ':U  !GN   6+L  $N^   ]P@  +\4  "/(   7RP  #=    /4
MV0   -D   #;    W@   .    #B    Y0   .@#  #K$   [AT  /$L  #T
M/0  ]E(  /=I  #W@@  ]YH  /BL  #XP   ^,,  /C# ):P  "(M   >K@
M &J[  !;OP  3<0  #[(   QS   ),\  !?3   *V    MT   #A    Y
M .0   #F    Z    .H   #L    [P   /$   #U    ^ 4  /P4  #_)0
M_S<  /],  #_8@  _WD  /^-  #_H   _Z(  /^B /\ %P?_ !0&_P 3!?\
M%0/_ !X!_P K /\ .0#_ $< _P!3 /\ 7@#_ &@ _P!P /\ =P#_ 'T _@"#
M /T B #\ (T ^P"2 /D F #W )X ]0"E /0 K0#S +8 \@## /( V #Q .L
M\0#Z .\ _P#O /\ [@#_ .\ _P#O /\ [P#_ /\ % C_  X&_P -!?\ #@/_
M !L!_P H /\ -@#_ $0 _P!0 /X 6P#\ &0 ^@!M /D = #W 'H ]@"  /4
MA0#T (H \@"/ /  E0#N )L [0"B .P J0#J +, Z0#  .D T@#H .8 Y@#V
M .4 _P#D /\ Y #_ .0 _P#E /\ Y0#_ /\ $0C_  L&_P )!?\ # /_ !<!
M_P D /\ ,@#[ #\ ^ !, /8 5P#T &  \@!I /  < #N '< [0!] .L @@#I
M (< YP", .4 D@#D )@ XP"> .$ I@#@ *\ WP"\ -T S #< .  V@#S -D
M_P#8 /\ V #_ -@ _P#9 /\ V0#_ /\ "P?_  4&_P !!/\ "@/_ !8!_P ?
M /H +0#S #L [P!' .T 4@#J %P YP!E .4 ;0#C ', X0!Y -\ ?P#= (0
MVP") -D CP#8 )4 U@"; -0 HP#3 *P T0"X -  QP#. -P S #O ,L _ #+
M /\ R@#_ ,H _P#* /\ R@#_ /\ ! ?_   %_P   _\ !@+_ !(!_@ ; .\
M)P#I #4 Y0!" .( 3@#? %@ W !A -D :0#6 &\ TP!V -$ >P#/ ($ S@"&
M ,P BP#+ )( R0"8 ,@ H #& *D Q "T ,( PP#! -< OP#J +X ]@"] /\
MO0#_ +P _P"\ /\ O #_ /\   ;_   $_P   O\  0'_  L ]0 4 .4 ( #?
M "\ V@ \ -4 2 #2 %, S@!< ,L 9 #) &P QP!R ,4 > ## 'T P@"# ,$
MB0"_ (\ O0"6 +P G@"Z *< N "R +< P0"U -, M #F +( ] "Q /\ KP#_
M *X _P"M /\ K0#_ /\$  3_   "_P@  ?@(  #Q P( Z0 + -P &0#5 "@
MSP V ,H 0P#& $X P@!8 ,  8 "^ 6@ O )N +H#=0"Y!'H MP2  +8%A@"T
M!HT LP>4 +$'G "P"*8 K@FR *T)P "K"M, J0OH *<-^ "D#_\ HP__ *,/
M_P"B#_\ H@__ /\(  /_#  !\Q$  .84  #?$0  V0@" -, $ #, A\ Q08O
M , +/0"[#4D N!!3 +427 "S%&, L15K + 5<0"N%G< K1=] *P8A "J&(H
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M  #D,P  U#\  ,A&  "[10  LD$  *P\  "H-P8 HCH: )P\*0*8/#4&E#Q
M"9$\20J//%$+C3Q9#(L]8 V)/6<-B#UM#88]= Z%/7P.A#V$#H(]C0Z /9</
M?SVC#WT]L0][/,(0>CS:$'<\[Q!V._X0=3O_$'0Z_P]T.O\/=#K_#^\I  #?
M.P  ST<  ,--  "V2P  K$@  *9$  "A0 ( G$(6 )9$)0*10S$&C4,\"HI"
M10Z'0DT0A4)4$8-"6Q*"0F(2@$)I$W]"<!-]0G@3?$* %'I"B11X0I04=T*@
M%75!K15S0;\5<4#6%6] [15N0/T5;3__%&P__Q-L/_\3;#__$^PP  #;0@
MRTT  +Y2  "Q40  ITX  *!*  ";1P  ED@2 )%+(@&,2BX%ATDX"H1(00^!
M1TD3?D90%7Q&5Q9Z1EX7>49E&'=&;!EU1G09=$9\&7)&AAIP1I :;D:<&FQ%
MJAIJ1;P;:$33&V9$ZQIE1/L994/_&&5#_Q=E0_\794/_%^@W  #62   QU(
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M*%!/Y2903O@D4$[_(E!-_R%03?\@4$W_(-Y'  #,5@  OE\  *]@  "B7P
MF%\  )!=  ")6P  @UT" 'Y>%0!Z8", =E\O!'%>-PIM73\0:%M%%V192QU@
M6% B7%96)EE572E7564K5%1N+%-4>2Q15(0L3U21*TU4H"M,5+$J2E/(*4E3
MXRA)4O<F25+_)$I1_R-*4?\B2E'_(MI,  #)6@  O&,  *QC  "?8P  E6(
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M'SAB_Q\X8?\?.&'_'\U<  "^:   L&T  *%M  "4;0  BFT  (%M  !T;P
M;7$  &=S 0!B=!( 7W4@ %QU*P)8=30&5'0\"T]S0A!+<D@51W!.&D-P51Y
M;UT@/F]F(#UO<A\\;WX>.V^,'3IOG!LY;ZT9.&_#&#=NWQ<U;/09-&K_&C-I
M_QHS:?\;,VG_&\AB  "[;0  K'$  )QQ  "0<0  AG$  'UR  !O=0  9W<
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M";EW  "L?@  G'\  (]^  "$?@  >H   &^"  !DA0  6(D  $Z,  !$CP
M.9(  #&4"P NE1@ +)4C "N5+  IE34!)Y4^ B651P(DE5$"(I5; B&59P(@
ME70!'Y6# 1V4DP$<E*4 &I.[ !B3V  8D? !&(__ A>._P,7CO\$%X[_!+2
M  "FA   EX0  (N#  " A   =88  &F)  !>C0  4Y   $>4   ]EP  ,ID
M "B<   >G@D &Y\5 !J?(  8GRH %Y\S !:?/0 5GT< $Y]2 !*@7P 0GVP
M#9][  R?C  *GI\ ")VT  ><S@ (F^D "9KZ  F9_P )F/\ "9C_ *^)  "@
MB@  DHD  (>)  ![BP  ;XX  &.1  !8E0  39D  $&<   UGP  *Z(  "&D
M   7IP  #:D%  6J$  #JAP  JHF  &J,   JCL  *I&  "J4P  JF$  *IP
M  "I@0  J90  *BH  "GP0  IM\  *7P  "E^P  I?\  *7_ *F1  ";D
MCX\  (*1  !VE   :9<  %V;  !2GP  1J,  #NF   OJ0  )*P  !JN   1
ML   !K(   "S!0  M \  +09  "U(P  M2T  +4X  "U1   ME(  +9B  "V
M=   MH<  +6<  "TLP  L]   ++J  "R^   L?T  +'] *27  "7E@  B9@
M 'V;  !PGP  9*,  %BG  !,J@  0*X  #2Q   HLP  ';4  !*X   (N@
M +L   "]    O@$  +\*  # %0  P1\  ,,I  #$-0  Q4$  ,91  #'8P
MQW<  ,>,  #&HP  QKT  ,7:  #$[@  Q/4  ,3U *">  "2GP  A:(  'BG
M  !KJP  7Z\  %.S  !%M0  -[@  "JZ   >O   $[\   C"    Q    ,4
M  #'    R0   ,L   #- P  SPT  -$9  #4)   UC   -D^  #<4   WF,
M -YZ  #?D0  WZ@  -Z_  #>V   WN0  -[D )NH  ".J@  @:\  '.S  !D
MM0  5;@  $>[   YO@  +,$  !_$   3QP  ",H   #-    T0   -$   #4
M    U@   -D   #<    WP   .("  #E#P  Z!P  .HK  #M.P  \$X  /)C
M  #S>P  ])(  /2F  #TMP  ],(  /3" )2O  "&L@  =[8  &>Y  !8O
M2L   #O$   MR   (,L  !/.   &T@   -<   #;    WP   -\   #A
MXP   .4   #G    Z@   .X   #R    ]@(  /D1  #\(@  _C4  /]*  #_
M80  _W@  /^-  #_G0  _Z4  /^E /\ $P;_  \$_P - _\ $ '_ !H _P I
M /\ -P#_ $0 _P!0 /\ 6@#_ &0 _P!L /\ <P#] 'D ^P!_ /D A #X (D
M]@". /4 DP#U )D ] "@ /, J #R +$ \0"^ .\ S@#M .4 [ #W .L _P#K
M /\ ZP#_ .P _P#L /\ [ #_ /\ #@;_  L$_P ) _\ "@'_ !< _P E /\
M- #_ $  _P!, /T 5P#Z &  ^0!I /< < #T '8 \@!\ /  @0#O (8 [@"+
M .T D #K )8 Z@"= .D I #H *T Y@"Y .0 R0#B .  X0#S .  _P#@ /\
MX #_ .$ _P#A /\ X0#_ /\ "P;_  8$_P # _\ "@'_ !4 _P A /P +P#Y
M #P ]@!( /0 4P#Q %P [P!E .P ; #I ', YP!Y .4 ?@#D (, XP"( .$
MC0#@ ), WP"9 -T H0#< *H V0"T -8 Q #5 -D TP#M -, _0#2 /\ T@#_
M -$ _P#0 /\ T #_ /\ ! 7_   $_P   O\ " '_ !  ^0 = /, *@#O #<
M[ !# .D 3@#F %@ X@!A -\ : #< &\ VP!U -D >@#7 '\ U0"$ -0 B@#2
M (\ T0"6 ,\ G0#, *8 R@"P ,@ OP#' -( Q0#H ,4 ^0#$ /\ P0#_ ,
M_P#  /\ P #_ /\   7_   #_P   ?\ ! #_  H [P 6 .D )0#D #( X  ^
M -P 2@#8 %0 U != -$ 9 #/ &L S0!Q ,L =@#* 'P R "! ,< A@#% (P
MPP"2 ,$ F@"_ *, O0"M +L NP"Z ,P N0#C +< ] "U /\ LP#_ +, _P"R
M /\ L@#_ /\   3_   "_P   /\   #V  , Y@ 0 -X '@#8 "L T@ Y ,T
M10#* $\ QP!8 ,0 8 #" &< P !M +X <P"] '@ NP!] +H @P"X (D M@"0
M +4 EP"S *  L0"K *\ MP"N ,D K #? *H [P"I /L J #_ *@ _P"G /\
MIP#_ /\   +_   !^@   .P   #D    W  ( -, %P#, "4 Q@ R ,( /P"^
M $D NP!3 +@ 6P"V &( M !I +, ;P"Q '4 L !Z *\ @ "M (8 K "- *H
ME0"I )X IP"I *4 M@"C << H@+; * #[0"?!/L G@7_ )T%_P"<!?\ G 7_
M /\   '[ P  ZPL  .$0  #8"P  T (  ,D #@#" !T O0 K +@ . "T T0
ML05. *X'5P"L"5X JPIE *D*:P"H"W$ I@QW *4,?@"D#80 H@Z, *$.E "?
M$)T GA"H )P1M@":$<< F1'= )83\0"5$_\ DQ/_ ),3_P"2$_\ DA/_ /\$
M  #O$0  XAP  -<A  #+'P  PQ<  +X- @"Z!Q4 M TD *\2,@"K%#\ IQ9)
M *484@"C&5H H1IA )\;: ">'&X G1QT )L=>@":'8$ F1V) )<>D0"6'IL
ME!ZF )(>LP"1'L0 CQ[: (T?[P"+'_T!BA[_ 8D>_P*('O\"B![_ OD,  #I
M'@  VRD  ,XO  #!+   N2<  +0?  "Q%PT JQP? *8?+0"B(CH GB1% )PE
M3@":)E8 F"9= )8G9 &5)VH!E"AQ 9(H=P&1*7X!D"F% 8XIC@&,*9@!BRFC
M 8DIL *(*<$"ABG6 H0I[ ."*/P#@"C_!( G_P1_)_\$?R?_!/(7  #C*0
MU#0  ,4Y  "Y-@  L#(  *LM  "H)0< HB@: )TK*0"9+#4!EBY  I,N20.1
M+U(#CS!9 XXP7P2,,&8$BS%L!(HQ<P2(,7H$AS&"!(4QBP6$,I0%@C*@!8 Q
MK05_,;T&?3'3!GLPZ@9Y,/L'>"__!W<O_P=W+O\'=R[_!^XA  #>,@  SCX
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M%6$_XA1@/_837S[_$E\^_Q%?/?\17SW_$>(X  #01P  P5   +!/  "D3@
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M'5=(GQU52*\=4T?#'5)&WAU11O,;44;_&5%%_QA11?\7447_%]M"  #)40
MN58  *E6  "=50  DU0  (Q2  "&4   @%(  'Q3$@!X5"$ =%0L W!3-0AK
M4CP.9U!#$V1/21=@3D\;7DU5'5M-7!]9360@5TQM(55,=R%43((A4DR.(5!,
MG"%.2ZTA3$O!($M*W"!*2O(>2TG_'$M)_QI+2/\:2TC_&M='  #&50  MED
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M'#I;V!LY6N\;.%C^&SA7_QLX5_\;.%?_&\M7  "]8@  JV,  )QC  "08@
MAF(  'UC  !R8P  :V4  &9G 0!A:!$ 7FD? %MI*@%8:3,%5&@Z"D]G0 ]+
M94841V1,&$1C4QQ!8UH>/V-D'SUC;AX\8WL=.V.(&SICEQHY8Z@8.&.\%S9B
MUA8U8.\6-%_^%S->_Q@S7?\8,UW_&,=<  "Y9@  IF8  )AF  ",9@  @F8
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M!R-V_PDB=?\*(G7_"KEO  "H<@  F'(  (MR  "!<P  =W,  &UU  !B>
M5WP  $Y^  !%@0  .H0" #6&$  SAAP ,88F "^&+P$MAC<"*X8_ RF&2 0G
MAE$$)H9;!"6&9@,DAG,#(H:! B&%D (?A:$!'H2V 1R$T $<@NL!&X#\ QI_
M_P0:?O\%&G[_!;1W  "B=P  DW<  (=W  !]=P  <WD  &A[  !=?@  48(
M $B%   ^B   -(L  "J. P DCQ  (H\; "&/)0 ?D"X 'I W !V00  ;D$H
M&I!5 !B08  7CVT %8][ !./BP 1CIT #XZQ  V-R@ -B^< #HKZ  Z)_P$.
MB/\!#HC_ :U]  "<?0  CGP  (-\  !Y?0  ;G\  &*"  !7A@  3(H  $&-
M   WD   +9,  ".5   9EP( $9D-  ^9&0 -F2, #)DL  N9-@ )F4  ")E+
M  :95P $F64  IES  "8@P  F)4  )>H  "6P   E=L  )3O  "3^P  D_\
M )/_ *:#  "6@@  BH(  (""  !TA   :(<  %R+  !1C@  1I(  #J5   P
MF   )IL  !N=   2H   !Z("  "C#   HQ<  *,A  "D*@  I#0  *0_  "D
M3   I%D  *1H  "D>0  HXL  **?  "AM@  G],  )[L  ">]@  GOT  )[]
M )^)  "2B   AX@  'N*  !NC0  8I   %:4  !+F   /YP  #.?   HH@
M'J4  !2G   *J0   :L   "L @  K0L  *X5  "N'P  KR@  *\S  "O/@
ML$L  +!;  "P;   L'X  *^2  "OJ0  K<0  *SC  "J]   JOT  *K] )J/
M  "/C@  @I   '63  !HEP  7)L  %"?  !$HP  .*<  "VJ   BK0  %[
M  RR   #M    +4   "W    N    +D&  "Y$   NQH  +PD  "]+P  OCL
M +]*  # 7   P&\  ,"$  # F@  O[(  +_.  "^Y@  O?0  +WT )>6  "*
MEP  ?9H  '"?  !CHP  5Z@  $NL   _L   ,K0  ":V   9N   #KH   .]
M    O@   +\   #!    PP   ,0   #&    R D  ,H4  #-'@  SRH  -$X
M  #520  V%P  -AR  #8B0  UZ$  ->W  #6SP  UN,  -;C )*?  "%H@
M>:<  &RL  !?L0  4K4  $2W   UN@  *+T  !N_   -P@   \4   #(
MR@   ,L   #,    S@   -$   #3    UP   -H!  #>#   XAD  .4F  #H
M-   [$<  .Y<  #O=   \(L  /"A  #PLP  \,0  /#$ (^J  ""KP  =+,
M &6V  !6N0  1[T  #?    IQ   ',<   [*   "S0   -$   #5    V
M -@   #:    W0   -\   #B    Y0   .D   #M    \ 0  /,2  #V(0
M^C$  /Y%  #_7   _W,  /^(  #_F0  _Z8  /^F /\ #@3_  H#_P ( ?\
M" #_ !@ _P F /\ - #_ $$ _P!, /\ 5P#_ &  _@!H /L < #Y '8 ^ ![
M /< @ #V (4 ]0"* /0 CP#S )4 \@"< /$ HP#O *P [0"X .L R #I -\
MZ0#S .@ _P#H /\ Z #_ .4 _P#D /\ XP#_ /\ "@3_  <#_P $ ?\ " #_
M !0 _P C /\ , #_ #T _@!) /L 4P#X %T ] !E /$ ; #P ', [@!X .T
M?0#L (( ZP"' .H C #I )( Z "8 .8 GP#D *@ X0"T -\ PP#= -@ W0#O
M -P _P#: /\ U@#_ -4 _P#4 /\ U #_ /\ !@3_  $"_P   ?\ ! #_ !$
M_0 > /D + #V #D ] !$ /$ 3P#L %D Z0!B .< :0#E &\ XP!U .( >@#@
M 'X WP"# -X B #< (X V@"5 -@ G #5 *4 TP"O -$ O0#/ -$ S@#I ,L
M^@#( /\ Q@#_ ,8 _P#' /\ QP#_ /\   3_   "_P   ?\   #\  H ]  :
M .\ )@#L #0 YP!  ., 2P#@ %4 W != -H 9 #8 &L U0!Q -0 =@#2 'L
MT "  ,\ A0#, (L R@"1 ,@ F #' *$ Q0"K ,( N #! ,L O@#B +H ]0"Z
M /\ N@#_ +H _P"Z /\ N@#_ /\   /_   !_P   /\   #Q  4 Z@ 4 .0
M(0#= "X V  [ -0 1@#1 $\ S@!8 ,L 8 #) &8 Q@!L ,0 <@## '< P0!\
M ,  @0"^ (< O0"- +L E0"Y )T MP"G +4 M "R ,4 L #; *\ \ "N /X
MK@#_ *T _P"M /\ K0#_ /\   +_    _P   /4   #G    W@ - -4 &P#/
M "D R@ U ,8 0 ## $H P !3 +T 6P"[ &( N0!H +< ;@"V ', M !X +,
M?@"R (0 L "* *\ D@"M )H J@"D *@ L "F +\ I0#5 *0 ZP"C /D H@#_
M *( _P"A /\ H0#_ /\   '_    \    .4   #<    T@ & ,D %0## "(
MO@ O +H .P"W $4 M !. +$ 5@"O %T K0!D *P :@"K &\ J0!U *@ >@"G
M ($ I0"' *, CP"A )@ H "B )X K0"= +P FP#1 )H Y0"8 /4 EP#_ )<
M_P"6 /\ E@#_ /\   #R    Y@@  -H*  #.!0  Q0   +\ # "Z !H M0 G
M +$ - "M #\ J@!) *< 40"E %D I !@ *(!9@"A FP GP-R )X#=P"=!'X
MFP2% )H%C0"8!98 EP:@ )4&K "3!KL D@?/ ) (Y0"."?8 C0K_ (P*_P",
M"O\ C K_ /@   #J$   W1H  ,T=  #"&   NA$  +8( 0"R !( K ,@ *@'
M+@"D"CH H0Q$ )\.30"<$%4 FQ%< )D28@"8$F@ EQ-N )43=0"4%'L DA2"
M )$5BP"/%90 CA6? (P5JP"*%;L B17/ (<6YP"%%_@ A!?_ (,7_P""%_\
M@A?_ /(+  #C'0  U2<  ,0I  "X)0  L"$  *L:  "I$0@ I!,: )\7* ";
M&34 F!L_ )8<20"4'5$ DAY8 ) >7@"/'V0 CA]K (P@<0"+('@ B2&  (@A
MB "'(9$ A2&< (,AJ0""(;@ @"', 'XAY %\(?8!>R'_ GH@_P)Z(/\">B#_
M NT8  #=*   S#(  +PR  "P,   J"P  *,G  "@( ( G!\5 )<B) "3)#
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M"FHWH0IH-[ *9C;#"V0VW MB-?$+837_"V$T_PI@-/\*8#/_"M\Q  #-00
MNT0  *M$  "?1   ET$  )$^  ",.P  B#H& (0[%P" /20!?#TO!'@\. =V
M/$ )<SQ("G$\3@MP/%4,;CQ;#6P\8@UK/&H-:3QR#F<\>PYE/(4.9#R1#F(\
MG@]?.ZT/73O #ULZV0]:.O /63G_#EDX_PY9./\-63C_#=LX  #)1@  MT@
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M&D5&TAE%1NP8147\%T5$_Q9%1/\514/_%=!(  "_4@  K%(  )U2  "24@
MB%(  (%0  !Z3@  =%   '!1" !L4Q@ :%,D 653+@1A4C8(75$\#5E00A%5
M3T@54DY.&%!-51M-3%P<2TQE'4E,;QU(3'H=1DR''$1,E1Q#3*4;04NW&C]+
MT!D_2NH9/DG[&#])_Q<_2/\6/TC_%LQ-  "[50  J%4  )I5  ".50  A54
M 'U4  !V4@  ;U4  &I6! !F6!0 8U@A &!8*P)<6#,&6%<Z"U150 ]05$84
M35-,&$I24AM'45H=15%B'D-1;1Y!47@=0%&%'#]1DQL]4:,:/%&V&3I1SQ<Y
M4.D7.$_[%SA._Q<X3?\7.$W_%\E2  "W6   I5@  )=9  "+6   @E@  'I8
M  !P5P  :EH  &1;  !@71  75X= %I>* %773$$4UTX"$];/@U+6D021UE*
M%D184!E!6%@;/UAA&SU7:QL\6'<:.UB$&3I8DA@X6*,6-U>U%397SA0T5ND4
M,U3Z%3-3_Q4R4O\5,E+_%<56  "S6P  H5P  )-<  "(7   ?EP  '9<  !J
M70  9%\  %YA  !:8@H 5V,9 %1D) !19"T"36,U!DIB.PI&84$.0F!($C]?
M3A4\7U87.E]?%SA?:A8W7W85-E^#%#5?D1,T7Z(1,UZU$#)>S0\P7>@/+UOZ
M$2Y9_Q(M6/\3+5C_$\%<  "N7P  G5\  (]?  "$7P  >V   ')A  !E8P
M7F4  %=G  !3: 4 3VD4 $UJ'P!*:BD!1VHQ T-I. = :#\*/&=%#3EG31 W
M9U41-6=>$31G:! S9W0/,F>"#C!GD TO9J$,+F:T"RUES HL9.<**F+Y#"EA
M_PXH7_\/*%__#[UA  "I8P  F6,  (MC  " 8P  =V0  &YE  !B:   6FH
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M JIP  "9<   BW   ']P  !U<   :W(  &!T  !6>   2WP  $)^   X@0
M+H0  "6'   <B0@ &(H4 !>*'@ 5BB< %(HP !.*.0 1BD, $(I-  V*60 +
MBF4 "8IS  >)@P %B90 !(BF  *&O0 "A=@  H7M  .#^P $@O\ !(+_ *-V
M  "3=0  AG4  'QU  !R=@  9G@  %M[  !0?P  18,  #N&   QB0  )XP
M !Z.   4D0  "I,(  24$P "DQT  9,F  "3+P  DSD  )-$  "34   DUT
M )-K  "3>P  DHP  )&>  "0M   C]   ([H  "-]0  C?T  (W^ )Q[  ".
M>P  @GH  'A[  !L?0  8(   %6$  !*B   /XL  #./   JD@  ()0  !:7
M   ,F0   IL   "<"@  G!0  )T=  "=)@  GB\  )XZ  ">10  GE,  )YB
M  "><0  G8,  )V6  "<JP  FL4  )GC  "8]0  E_X  )?_ ):!  ")@
M?X   '."  !GA@  6HD  $^.  !#D@  .)4  "V9   BG   &)X   V@   $
MHP   *4   "F    IP@  *<2  "H&@  J2,  *HM  "J.   JD4  *M4  "K
M9   JG<  *F+  "IH0  J+D  *?8  "F[@  I?H  *7\ )&'  "'AP  >HD
M &V,  !AD   590  $F8   \G0  ,:   ":D   :IP  $*D   6K    K0
M *\   "Q    L@   +,#  "S#   M!8  +8?  "W*@  N#8  +E$  "Z50
MNV@  +M\  "ZD0  N:H  +?&  "VXP  M?,  +7V (^.  ""CP  =9,  &B7
M  !;FP  3Z   $.E   VJ0  *ZT  !^P   3LP  "+4   "X    N0   +H
M  "\    O0   +X   #     P@4  ,0/  #'&0  R24  ,LR  #.0P  SU8
M -%L  #1@@  T9@  -"O  #0Q@  S]T  ,_B (J7  !]F@  <)\  &.D  !7
MJ0  2ZX  #ZR   QM@  )+D  !>[   )O@   ,    ##    Q    ,4   #'
M    R    ,L   #-    T    -,   #8"   W!0  . @  #C+P  YT$  .I7
M  #J;@  ZX8  .N<  #KKP  Z\   .O% (:B  !YIP  ;:T  &&R  !3M@
M1+D  #2]   EP   &,,   K&    R0   ,T   #0    T0   -(   #3
MU0   -@   #;    WP   .,   #G    ZP$  / -  #S'   ]RP  /M   #]
M5@  _VX  /^%  #_EP  _Z8  /^J /\ "0/_  <!_P # /\ !@#_ !4 _P C
M /\ ,0#_ #T _P!) /\ 5 #] %X ^P!F /D ; #W '( ]@!X /4 ?0#T ((
M\P"& /( BP#Q )$ [P"8 .T GP#K *@ Z@"S .@ PP#G -H Y0#P .0 _P#@
M /\ W0#_ -P _P#; /\ V0#_ /\ !@+_  $!_P   /\ ! #_ !( _P @ /\
M+0#_ #D ^@!& /< 4 #T %H \@!B /  :0#N &\ [ !T .L >@#J 'X Z "#
M .< B #E (T XP"4 .$ FP#? *0 W0"O -L O0#9 -( UP#J -( _0#/ /\
MSP#_ ,\ _P#/ /\ SP#_ /\   +_   !_P   /\   #_  T ^P ; /@ * #R
M #8 [P!! .T 3 #I %4 Y@!= .0 90#A &L WP!Q -T =@#; 'L V0"  -@
MA0#5 (H U "0 -( F #0 *  S@"J ,P N #) ,H Q #D ,( ^ #" /\ P@#_
M ,( _P#" /\ P@#_ /\   +_   !_P   /\   #W  < \0 6 .H (P#E #$
MX@ \ -\ 1P#; %  U@!9 -, 8 #1 &< SP!M ,T <@#+ '< R@!\ ,@ @0#'
M (8 Q0"- ,, E #! )P OP"F +P LP"X ,0 MP#< +8 \@"U /\ M0#_ +4
M_P"U /\ M0#_ /\   '_    _P   /4   #L  , Y  1 -L 'P#6 "L T@ W
M ,X 0@#* $L QP!4 ,0 6P#" &( P !H +X ;0"] ', NP!X +H ?0"X ((
MM@") +0 D "R )@ L "B *X K@"L +T JP#3 *H ZP"I /P J #_ *@ _P"H
M /\ J #_ /\   '_    ]@   .H   #@    U  + ,T &0#( "4 P@ Q +\
M/ "\ $8 N0!. +8 5@"T %T L@!C +  :0"N &X K0!T *L >0"J '\ J0"%
M *@ C "F )4 I "> *, J@"A +@ H #, )X Y "= /8 G0#_ )P _P"< /\
MFP#_ /\   #V    ZP   -T   #1    R  $ ,$ $@"[ !\ M@ K +, -@"P
M $  K0!) *H 40"H %@ I@!? *0 90"C &H H@!O *$ =0"@ 'L GP"! )T
MB0"< )$ F@"; )@ I@"7 +0 E0#& )0 W@"3 /$ D0#] )  _P"0 /\ D #_
M /L   #M    X 4  ,\%  #$    O0   +< "@"Q !@ K0 D *H , "F #L
MHP!$ *  3 "> %0 G0!: )L 8 ": &8 F0!L )@ <0"6 '@ E0!^ )0 A@"2
M (\ D "9 (\ I "- +( BP#$ (H V@"( .X AP'Z (8"_P"% O\ A0+_ /,
M  #E#@  U!<  ,05  "Y$@  L0P  *T# 0"I !  I0 = *$ *@"= 34 F@,_
M )@%2 "6!D\ E =6 ),(7 "1"&( D EH (\);@"-"G4 C I\ (L+A ")"XT
MAPN8 (8+I "$"[( @@S$ ($,W !_#O  ?@[^ 'T._P!\#O\ ? [_ .T,  #=
M'   RB(  +LB  "O'P  J!L  *,5  "A# 8 G0D6 )D-) "5$"\ DA(Z ) 3
M0P"-%4L C!52 (H660")%U\ AQ=E (88:P"%&'( @QEY ((9@@" &8L ?QF6
M 'T9H@![&;  >AG# '@9VP!V&O  =1K_ '0:_P!S&?\!<QG_ ><8  #6*
MPBL  +,K  "H*0  H"8  )LB  "8&P  EA80 )$:'P"-'"L BAXV (<?/P"%
M($< A"%/ ((A50"!(EL ?R)B 'XC: !](V\ >R-W 'HC?P!X)(@ =R23 '4C
MH !S(ZX <2/  &\CV %M(^X!;"+^ FLB_P)K(?\":B'_ N(B  #/,0  NS(
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M"E8UT M5->D+5#3Z"E,S_PI3,O\*4S+_"M0Y  # 0   K4$  )]"  "400
MBT   (4]  " .P  ?#D  '@Z#0!T/!P <#TG 6T\, 1I/#@'9SQ "64\1@IC
M.TT+83M3#%\[6@U>.V$-7#MJ#5H[<PU8.WT.5CN)#E0[E@Y2.Z0.4#JV#DXY
MS0Y-.><.33CY#4TW_PU--O\-33;_#- ^  "\1   J44  )M&  "010  AT0
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M$CE$_Q(Y0_\2.4/_$L9,  "P3@  GT\  ))/  "'3P  ?D\  '9.  !N3
M:$X  &-0  !>40T 6U(; %E3)@%54BX$4E(U!TY1.PM+4$$/2$]'$D5.3A5"
M35460$U>%SY-:!<]37,6.TV %3I-CA0X39X3-TVO$C5-QA$T3.(1,TOV$3-)
M_Q(S2?\2,TC_$L)0  "M40  G%(  (Y2  "#4@  >E(  ')2  !I40  8E0
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M"K-;  "?7   D%P  (-<  !Y70  ;UX  &9?  !;80  5&,  $UF  !%:
M/FH& #IK$P X:QX -FLG #1K+P$Q:S8#+VL^!"UJ104K:DX&*FM7!BAK804G
M:VT%)6IZ!"1JB0,B:ID#(6FK B!HP0$>:-X!'6;S QQD_P4<8_\&&V+_!JU@
M  ":8   C&   ']A  !U80  :V(  &)C  !79@  3VD  $AK   _;@  -G
M #!R"P M<Q< *W,@ "IS*0 H<S$ )G,Y 21S00$C<TH"(7-4 B!S7@$><VH!
M'7-X 1MRA@ 9<I8 %W&H !9POP 4;]L %6WR !5L_P$4:_\"%&K_ Z=D  "5
M9   AV0  'ME  !Q90  :&8  %YH  !3;   2VX  $)Q   Y=   ,'8  "=Y
M @ @>PT 'GL8 !Q[(0 ;>RH &7LR !A\.P 7>T0 %7M. !1[60 2>V4 $'MS
M  U[@@ +>I( "7FD  =XN0 &=], !W;K  AT^P )<_\ "7/_ *!I  "0:0
M@FD  '=I  !N:@  9&L  %EN  !/<0  174  #QX   R>@  *7T  ""    7
M@P( #H4-  N%&  *A"$ "(0J  >$,@ &A#P !(1'  .$4@ !A%X  (1L  "$
M>P  @XL  (*=  "!L@  ?\T  '[E  !]]   ??P  'S_ )EO  "*;@  ?FX
M '1N  !J;P  7W(  %1U  !)>0  /GP  #5_   K@@  (H4  !B'   /B@
M!8P%  "-#P  C1@  (TA  ".*0  CC(  (X]  ".20  CE4  (YC  ".<P
MC80  (R6  "+J@  BL,  (CB  "']   AOH  (;^ )-T  "%<P  >W,  '%T
M  !E=@  67D  $Y]  !#@0  -X4  "V(   CBP  &HX  !"0   'D@   )4
M  "6!P  EA   )88  "7(   F"D  )@S  "8/@  F$L  )E9  "9:0  F7L
M )B.  "7H@  EKD  )38  "3[P  DOL  )+_ (UZ  "">0  >'D  &M[  !?
M?P  4X,  $B'   \BP  ,(\  ":2   ;E0  $I<   >:    G    )X   "?
M    H 8  * .  "A%P  HA\  *,H  "D,P  I#\  *5.  "E7P  I7$  *6#
M  "DF   HZ\  *++  "AYP  H/4  *#[ (F   !_?P  <X$  &:%  !9B0
M38X  $&2   UE@  *9H  !Z=   3H   "*(   "E    IP   *D   "K
MK    *T   "M"   KA$  + :  "R)   LS   +0^  "U3P  MF$  +1W  "S
MC   LZ,  +*\  "QV@  L>T  +#U (>&  !ZB   ;8L  &"0  !4E0  1YD
M #J>   NH@  (J<  !>J   +K    *\   "Q    L@   +0   "V    N
M +D   "Z    O (  +X+  # %0  PB$  ,4M  #'/0  R5   ,ME  #+>P
MRY$  ,BJ  #&Q   Q=P  ,7H (*/  !UDP  :)<  %N<  !/H0  0J<  #6L
M   IL   ';,  !&V   $N@   +P   "^    OP   ,    #"    PP   ,8
M  #(    R@   ,T   #1 P  U@X  -H<  #=*@  X3P  .12  #E:0  YH
M .>6  #FJ@  YKH  .;& 'Z:  !QGP  9*4  %BJ  !,L   /[4  #&Y   A
MO   %+\   7"    Q0   ,@   #+    RP   ,T   #.    SP   -(   #5
M    V@   -X   #B    Y@   .P(  #P%P  \R8  /@[  #Z4@  ^VL  /N"
M  #\E0  _*0  /RL /\ !@'_  ( _P   /\ !0#_ !( _P @ /\ +0#_ #L
M_P!& /\ 40#] %H ^P!B /D :0#V '  ] !U /, >@#Q '\ \ "$ .X B0#M
M (X [ "4 .H G #H *0 YP"O .4 O@#D -0 WP#M -H _P#8 /\ V0#_ -H
M_P#5 /\ T0#_ /\   '_    _P   /\   #_  X _P < /T *@#Z #< ^0!"
M /< 3 #S %8 [P!> .P 9@#J &P Z !R .< =P#E 'P Y "  .( A0#A (L
MWP"1 -X F #; *$ V0"K -< N #2 ,T S0#G ,L ^@#+ /\ RP#_ ,P _P#+
M /\ R #_ /\   '_    _P   /\   #^  H ^  8 /( )@#O #( [0 ] .D
M2 #E %$ X0!: -X 80#< &@ V@!M -@ <P#6 '@ U0!] -, @@#1 (< SP"-
M ,T E #* )T QP"G ,0 LP#! ,8 OP#> +X ] "^ /\ O@#_ +T _P"] /\
MO0#_ /\   '_    _P   /H   #S  4 Z@ 4 .4 ( #@ "T W  Y -D 0P#5
M $P T0!5 ,X 7 #+ &, R !I ,4 ;@## ', P0!X +\ ?@"^ (, O ") +L
MD "Y )D N "B +8 K@"T +X L@#4 +$ [@"P /\ L #_ *\ _P"P /\ L #_
M /\   #_    _@   .\   #D  $ W  . -4 ' #. "< RP S ,@ /0#% $8
MP !/ +P 5P"Y %T MP!C +4 :0"T &X LP!S +( >0"Q 'X KP"$ *X BP"M
M )0 JP"= *D J0"H +< I@#+ *4 Y@"D /D HP#_ *, _P"C /\ HP#_ /\
M  #\    [P   .,   #5    S0 ) ,4 %@#  "( O  M +@ . "T $$ L0!)
M *\ 40"M %@ JP!> *D 9 "H &D IP!O *8 = "E 'H I "  *( AP"A (\
MGP"9 )X I "< +$ F@#$ )D W0"8 /, F #_ )< _P"7 /\ EP#_ /\   #R
M    Y    -(   #(    OP " +D $ "T !P KP G *L ,@"I #P I@!$ *0
M3 "B %, H !9 )\ 7P"= &0 G !J )L ;P": '4 F0!\ )< @P"6 (L E "5
M ), H "1 *T CP"^ (X U0"- .T C #[ (L _P"* /\ B0#_ /8   #H
MU0   ,8   "[    M    *X " "I !4 I0 A *( + "? #8 G  _ )H 1P"8
M $X E@!5 )4 6P"3 &  D@!F )$ ; "0 '( CP!X (T @ ", (@ B@"2 (D
MG0"' *H A0"Z (0 T "# .@ @0#W (  _P!_ /\ ?P#_ .X   #>#   RA
M +L/  "P"P  J0<  *4   "A  T G0 : )H )@"7 #  E  Z )$ 0@"/ $H
MC0!0 (P 5P"+ %P B0!B (@!: "' 6\ A0)V (0#?0"# X8 @0.0 '\#G !^
M ZD ? .Y 'H#S@!Y!>4 =P;V '8&_P!V!O\ =@;_ .@,  #4&@  P1P  +(;
M  "G&@  H!8  )L1  "9!P0 EP$2 )($( ".!BL C @U (D*/@"'"T8 A@Q-
M (0-4P"##ED @0Y? ( /9@!_$&P ?1!T 'P1? !Z$84 >1&/ '<1FP!U$:D
M<Q&Z '$1T0!P$ND ;A+Y &T2_P!M$O\ ;1+_ .$9  #+(P  N"4  *HE  "@
M(P  F"   ),=  "0%P  CQ * (L1&0"'%"8 A!8P ($7.@!_&$( ?AE) 'P:
M4 ![&E8 >1I< '@;8@!V&VD =1QQ ',<>0!R'(( <!R- &X<F0!L'*< :QRX
M &D;S@!G'.< 91SY &4;_P%D&_\!9!O_ =PC  #%*@  LBP  *0M  "9*P
MDBD  (PF  "((@  AQP$ (,<%0!_'B$ ?2 L 'HA-@!X(CX =B-& '0C3 !S
M(U, <219 ' D7P!O)&8 ;25N &LE=@!J)8 !:"6+ 68EEP%D):4!8B2V 6 D
MS %>).4!72/W EPC_P)<(O\#7"+_ ]8K  "_,   K3(  )\R  "4,0  C"\
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M"D<R_PI',?\)1S'_"<<[  "Q/0  H#\  ),_  "(/P  @#X  'H\  !T.@
M<#D  &LZ! !H.Q, 9#P? &$\* )>/#$$6SPX!E@[/@A6.T4*5#M+"U([4@Q1
M.UD,3SIA#4TZ:PU+.W4-23J!#4@ZC@U&.IP-0SFM#4(YP@U .-T,0#?S#$ W
M_PQ -O\,0#7_"\,_  "N0   G4(  )!"  "%0@  ?4(  '9   !P/@  :SX
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M#K=)  "C2@  DTL  (9,  !\3   <TP  &M,  !B3   6TX  %9/  !140,
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M!"1>A00C7I0#(5VF B!<NP(>7-8!'EKN QQ8_00<5_\&&U;_!ZA4  "650
MB%4  'Q6  !Q5P  9U<  %]8  !56P  3ET  $=?   _80  -V0  #)E#  O
M9A< +F8A "QF*0 J9C$!*&8X 29F0 (D9DD"(V92 B%F7 (@9F<!'F9T 1QE
M@P$;99( &62D !=CN0 58M0 %F'M !9?_ $57O\"%%W_ Z-8  "260  @UH
M 'A:  !M6P  9%P  %M=  !27P  26(  $)D   Y9P  ,6D  "EL!  D;1
M(FX: "!N(@ ?;BL '6XS !QN.P :;D0 &6Y. !=N6  5;F, $VUQ !%M?P .
M;8\ #&R@  MKM0 ):LX "FCH  MF^@ +9O\ #&7_ 9U=  ",70  ?UX  '->
M  !I7P  86   %=B  !.90  1&@  #QJ   S;0  *W   ")R   9=08 %'81
M !-V&P 1=B, #W8K  UV-  ,=CT "G9'  AV4@ '=EX !79K  )U>@  =8D
M '2;  !SK@  <<<  '#A  !O\@  ;OT  &W_ )9B  "'8@  >F,  &]C  !F
M8P  764  %-G  !):P  /FX  #5Q   M=   )'8  !MY   2?   "'X)  )_
M$P  ?QP  '\D  !_+0  ?S8  'Y   !^2P  ?E<  'YD  !^<P  ?8,  'V5
M  !\J   >L   'G>  !X\   =_D  ';_ )!G  ""9P  =F<  &QH  !B:
M5VL  $UO  !#<@  .'8  "]Y   F>P  ''X  !.!   )@P   (8$  "'#
MAQ4  (<=  "()   B"P  (DV  "(0@  B$X  (E<  "):P  B'P  (>/  "&
MH@  A+D  (/6  ""[P  @?L  (#_ (IM  !];   <VP  &EM  !=;P  4G,
M $=W   \>P  ,7X  ">"   =A   %(<   J*   !C    (\   "/!   D P
M ) 5  "1'   DB,  ),L  "3-P  DT0  )12  "480  E',  ).&  "2F@
MD;   (_,  ".Z0  C/@  (O_ (1R  !Z<@  <'(  &1U  !7>   3'P  $"!
M   TA   *8@  !Z,   5CP  "I$   *4    E@   )@   "9    F@(  )L*
M  "<$@  G1H  )XB  "?+   H#@  *!'  "A5P  H6D  *%\  "@D0  GZ<
M )[   "=W@  G/$  )O[ (%X  !X>   :WH  %Y^  !2@@  18<  #B,   M
MD   (I0  !:7   +F@   9P   "?    H0   *,   "D    I0   *8   "G
M!P  J X  *D7  "K(   K2P  *XY  "N2@  KUT  *]Q  "OA0  KIP  *ZT
M  "MT   K><  *ST ']^  !R@   980  %B)  !,C@  /Y,  #*8   FG
M&Z    ZC   #I@   *@   "K    K0   *\   "P    L@   +,   "T
MM@   +@'  "Z$0  O1L  +\H  #!-P  PTH  ,5?  ##=P  PHX  ,&E  #!
MO0  P-4  ,#H 'J(  !MBP  8)   %.5  !&FP  .:   "RE   @J@  %*T
M  >P    LP   +8   "X    N0   +L   "]    OP   ,$   ##    Q0
M ,<   #*    SPH  -(8  #6)@  VS<  -Y,  #A8P  X7H  .*1  #?IP
MW;L  -S0 '63  !IEP  7)T  $^C  !"J0  -:X  "BS   <MP  #KL   &^
M    P0   ,0   #&    Q@   ,@   #)    RP   ,X   #1    U    -@
M  #=    X0   .<$  #K$P  [R,  /,W  #V3@  ^&8  /E^  #YD@  ^J$
M /FN /\  0#_    _P   /\  @#_  X _P = /\ *P#_ #< _P!" /X 3@#[
M %< ^ !? /8 9@#T &T \P!S /$ > #P 'T [P"" .T AP#L (P Z0"3 .<
MF@#D *, X0"N -\ O #< -  UP#K -8 _@#5 /\ U0#_ -0 _P#/ /\ RP#_
M /\   #_    _P   /\   #_  L _P : /P )P#Y #, ]@ ^ /0 20#P %(
M[0!: .H 8@#G &@ XP!O .  = #> 'D W !^ -D A #7 (D U0"/ -0 E@#2
M )\ T0"I ,X M@#, ,@ R0#B ,@ ^ #' /\ QP#_ ,@ _P#% /\ P@#_ /\
M  #_    _P   /\   #Y  < ]  6 .\ (@#K "\ Z0 Z .< 0P#B $T VP!5
M -4 70#2 &, SP!I ,T ;P#, '0 RP!Y ,H ?P#( (0 QP"* ,8 D0#$ )D
MP@"C ,  L "^ ,  O #9 +H \0"Y /\ N0#_ +D _P"Y /\ MP#_ /\   #_
M    _P   /<   #L  , Y@ 1 -X '@#: "D V  T -$ /@#, $< R !0 ,4
M5P## %X P0!D +\ :0"] &\ O !T +L >0"Z '\ N "% +< C "V )0 M "=
M +( J@"P +@ K@#. *P Z0"L /T JP#_ *L _P"K /\ JP#_ /\   #_
M]    .@   #>    U  + ,T &0#( "0 P@ N +\ .0"] $( N@!* +< 4@"U
M %@ LP!> +$ 9 "P &D K@!O *T = "L 'H JP"  *D AP"H (\ IP"8 *4
MI "C +$ H0#% *  WP"? /< GP#_ )X _P"> /\ G@#_ /\   #U    Z
M -D   #-    Q  & +X $P"W !\ LP I +$ ,P"O #P K0!% *H 3 "H %,
MI@!9 *4 7@"C &0 H@!I *$ ;P"? '4 G@![ )T @@"< (H F@"3 )D GP"7
M *P E0"] )0 U@"2 .\ D0#_ )$ _P"1 /\ D0#_ /H   #L    V0   ,H
M  "_    MP   +  # "K !D J  D *4 +0"C #< H0 _ )\ 1P"= $X FP!4
M )D 60"8 %\ E@!D )4 :@"4 '  D@!V )$ ?0"/ (4 C@"/ (P F@"+ *<
MB0"W (@ S@"' .@ A@#Z (8 _P"& /\ A@#_ /$   #?    S    +T   "S
M    K    *8 !@"B !, G@ > )L * "9 #$ E@ Z )0 0@"2 $D D !/ (\
M50"- %L C !@ (H 9@") &P B !R (8 >@"% (( A ", (( EP"! *0 @ "S
M 'X QP!] .( ? #U 'L _P!Z /\ >@#_ .D   #3!P  P D  +((  "H!P
MH0(  )T   "9  L E@ 7 ), (@"0 "P C0 U (L /0"( $0 AP!+ (4 40"$
M %< @P!< ($ 8@"  &@ ?P!O 'X =P!\ '\ >P") 'D E0!W *$ =@"Q '0
MQ !S -T <0#P '  _ !P /\ < #_ .(,  #*$P  MQ4  *D6  "?%   F!$
M ),+  "1! , CP 0 (L ' "( "< A0 P ((".0"! T  ?P1' 'T%30!\!E,
M>P99 'D'7P!X!V8 =P=M '4(=0!T"'X <@B( ' (E !N"*$ ;0BP &L(Q !I
M"-P : KP &<*_0!F"O\ 9@K_ -D8  #!'   L!X  *(?  "8'@  D!L  (L8
M  "($P  APL' (0)%0"!"R$ ?@TK 'L.- !Y$#P >!%# '822@!T$U  <Q-6
M '$370!P%&, ;A1K &T4<P!K%7P :16' &<5DP!F%*  9!2P &(4Q0!@%-X
M7Q7S %X5_P!>%?\ 713_ -$@  "Z(P  J28  )PF  "1)0  BB,  (0A  "!
M'0  ?Q@  'T5#P!Y%QP =A@G '0:, !Q&SD <!M  &X<1P!L'$T :QU3 &D=
M6@!H'F  9AYH &4>< !C'GH 81Z% %\>D0!='I\ 7!ZO %H=PP!8'=P 5QWR
M 58=_P%5'/\!51S_ <LF  "U*0  HRL  )8L  ",*P  A"H  '\H  ![)0
M>"(  '8?"@!R(!@ ;R$C &TB+0!J(S4 :"0] &<D0P!E)4H 9"50 &(E5P%@
M)EX!7R9E 5TF;@%<)G@!6B:" 5@FCP%6)9T!5"6M 5(EP0%0)-L"3R3Q DXC
M_P-.(O\#3B+_ \4K  "P+@  GS   )(Q  "',   @"\  'HN  !U*P  <BD
M &\G!@!L)Q0 :2D@ &8J*0!C*C(!82LY 6 K0 )>*T<"7"Q- ELL5 -9+%L#
M6"QB U8L:P-4+'4#4BR  U LC 1.+)H$3"NK!$HKO@1(*MD$1RGP!$<H_P5'
M*/\%1R?_!<$O  "L,@  FS0  (XU  "$-0  ?#0  '8R  !Q,   ;2\  &DN
M @!F+A$ 8S < & P)@%=,2X"6S$V UDQ/017,4,$53%*!50Q4 52,5<&4#%?
M!D\Q: 9-,7(&2S%^!DDQB@9',9@&13"I!D,PO 9!+]8&0"[N!T M_@= +/\'
M0"S_![PS  "H-@  F#@  (LY  " .0  >#@  '(W  !M-   :#,  &0T  !@
M- P 7389 %HV(P!8-BL"538S!%,V.050-D &3C9&!TTV30A+-E0(239<"4<V
M90E&-G )1#9["4(VB E -98)/36G"3LTNP@Z--0(.3/M"#DR_0@Y,?\(.3#_
M"+@W  "D.@  E3L  (@\  !]/   =3P  &X[  !H.0  9#@  %\Y  !;.@D
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M"B]%@PDN19((+$6C!RM$MP<I1- &*$+J!R=!^P@G0/\))S__"JU!  ":0P
MBT4  ']&  !T1@  :T8  &-&  !<1P  4T<  $Y)  !*2@  1DP* $-,%@!!
M32  /TTH 3Q-+P,Y3#4%-DP\!S1,0P@R2TL),$M3"2Y+70DM3&@(*TQT!RI,
M@@<H2Y$&)TNB!25*M@0C2L\#(DGI!"%'^@8A1?\((47_"*A%  "61P  B$@
M 'M)  !Q20  9TH  %]*  !82P  3DT  $E/  !$4   /U(% #Q2$@ Y4QP
M-U,D #53+ $S4S,#,%,Z!"Y2004L4DD&*E)2!BE26P8G4F<%)E)S!"12@0,C
M4I #(5*A A]1M0(>4,X!'4_I AQ-^@0;3/\%&TO_!J-)  "22@  A$P  'A,
M  !M30  9$T  %Q.  !43P  2U(  $53   ^5@  .%@  #-9#  Q61< +UD@
M "U9*  K6B\!*5DW B=9/@(E64<#(UE/ R):60(@6F0"'UEQ 1U9?P$;68X
M&EB? !A7LP 65LP %E7G !94^0$64O\"%%+_ YY-  ".3@  @$\  '10  !I
M40  8%$  %A2  !04P  2%8  $%8   Y6P  ,ET  "I?!@ F8!$ )&$: "-A
M(@ A82L (&$R !YA.@ =84, &V%, !EA5@ 786$ %F%N !1@?  18(L #U^=
M  U>L  +7<@ "USD  U:]P -6?\ #5C_ 9E1  ")4@  ?%,  '!4  !E50
M754  %56  !,6   0UL  #Q>   T8   +&,  "1E   <: D &6@3 !=H'  5
M:"0 %&DL !-I-0 1:3T #FE'  QH40 *:%T "&AI  9G=P $9X<  F:7  %F
MJP  9,(  &/=  %A\  "8/P  U__ )-6  "$5P  =U@  &M8  !B60  6ED
M %%;  !(70  /F$  #9D   N9@  )FD  !UL   5;@  "W$*  AQ%0 &<1T
M!'$F  -P+@ "<#<  '!!  !P2P  <%<  '!C  !O<@  ;X$  &Z2  !NI0
M;;P  &O:  !I[0  :/@  &?_ (U;  !_7   <EP  &==  !?70  5EX  $QA
M  !#9   .&<  #!J   G;0  'G   !9R   -=0  !'@&  !X#P  >!<  'D?
M  !Y)P  >2\  'DY  !Y1   >5   'E=  !Y:P  >'L  '>-  !WH   =K8
M '33  !S[0  <OD  ''^ (=@  !Z80  ;F$  &1A  !;8@  464  $=H   \
M:P  ,F\  "AR   @=0  %W@   YZ   %?0   '\"  " "@  @!(  ($9  ""
M(   @B<  (,P  "#.P  @T@  (-5  "#9   @W0  (*'  "!F@  @+   '_,
M  !^Z   ?/@  'S_ (%F  !U9@  :V8  &%F  !6:0  2VT  $!P   U=
M*W@  "%[   7?@  #8    6#    A@   (@   ") @  B@D  (H1  "+&
MC!\  (TG  ".,   CCX  (Y,  "/6P  CVP  (Y_  "-E   C*H  (O#  ")
MXP  B/0  (C^ 'QL  !R:P  :&L  %QN  !0<@  1'8  #EZ   M?@  (H(
M !B%   -B    XL   ".    D    )(   "4    E0   )8&  "6#0  EQ4
M )D=  ";)0  G#$  )P_  "<3P  G6   )UT  "<B0  FZ   )JX  "9U
ME^T  )7Z 'EQ  !P<0  8W0  %9X  !*?   /8$  #&%   EB@  &HX   Z1
M   $E    )8   "9    FP   )T   "?    H    *$   "B @  HPD  *42
M  "G&@  J24  *HR  "J0P  JU4  *QI  "K?P  JY4  *JM  "IQP  J.$
M *CQ '=W  !J>@  77X  %&"  !$B   -HX  "J2   >E@  $IH   :=
MH    *(   "E    IP   *D   "K    K    *T   "N    L    +($  "T
M#0  MQ@  +DD  "Z,P  O$<  +U<  "]<@  O8@  +V?  "\MP  O-   +OE
M '*   !EA   6(D  $N/   ^E0  ,)L  "2?   7I   "J<   "J    K0
M +    "R    M    +8   "W    N0   +L   "]    OP   ,$   #$
MR08  ,P3  #0(   U#$  -A'  #<70  VG<  ->0  #7I@  UKH  -;- &V+
M  !AD   5)8  $><   XH@  *Z@  !ZM   2L@  !;4   "X    NP   +X
M  #!    P@   ,,   #%    Q@   ,D   #,    SP   -(   #6    W
M .(   #F#@  ZA\  .\R  #R20  ]6(  /9Y  #VC@  ]:   /2O /\   #_
M    _P   /\   #_  L _P : /\ * #_ #0 _P _ /\ 20#Z %, ] !; .\
M8P#L &D ZP!O .D =0#H 'H YP"  .8 A0#D (L XP"1 .( F #@ *$ W@"K
M -T N0#: ,\ UP#H -0 _0#2 /\ T@#_ ,\ _P#) /\ Q0#_ /\   #_
M_P   /\   #_  D _@ 6 /D ) #W "\ ]@ Z .\ 1 #I $X Y@!6 ., 70#@
M &0 W@!J -P < #: '4 V0!Z -@ @ #6 (8 U ", -, DP#1 )P SP"F ,T
ML@#+ ,8 R #@ ,8 ]P#$ /\ PP#_ ,, _P"^ /\ O #_ /\   #_    _P
M /T   #W  0 [P 3 .L 'P#G "H X  U -X /P#; $@ UP!1 -, 6 #1 %X
MS@!D ,P :@#* &\ R !U ,8 >@#% (  Q "& ,( C@#! )8 OP"@ +T JP"[
M +P N0#5 +< [P"U /\ M #_ +0 _P"T /\ L@#_ /\   #_    _    /
M  #H    X  - -D &P#1 "4 S@ P ,P .@#* $, Q@!+ ,, 4@#  %D O@!?
M +P 9 "Z &H N0!O +< = "U 'L M "! +, B "Q )  L ": *X I0"M +0
MJP#) *D Y@"H /L IP#_ *< _P"G /\ IP#_ /\   #[    [@   .$   #6
M    S@ ( ,0 %0#  "$ O0 J +L - "Y #T M@!% +, 3 "Q %, KP!9 *T
M7@"L &0 J@!I *D ;P"G '4 I0![ *0 @@"B (H H0"4 )\ G@"= *P G "_
M )L VP": /, F0#_ )@ _P"8 /\ F #_ /X   #P    W@   -    #%
MO  # +4 $ "Q !L K@ E *P +@"J #@ J !  *8 1P"C $T H0!3 )\ 60"=
M %X FP!D )H :0"9 &\ EP!V )8 ?0"5 (4 DP". )( F0"0 *< CP"W (X
MT "- .L C #^ (P _P", /\ C #_ /8   #B    T    ,$   "W    K@
M *D "@"E !4 H@ @ )\ *0"= #( FP Z )@ 0@"6 $@ E !. ), 5 "1 %D
MD !? (\ 9 "- &H C !Q (L > ") ($ B "* (< E "% *( A "Q (, Q@""
M ., @0#W ($ _P"! /\ @ #_ .P   #6    PP   +0   "J    I    )\
M! ": !  EP : )0 ) "1 "T CP U (T /0"+ $0 B@!* (@ 3P"' %4 A@!:
M (0 8 "# &8 @@!M ($ = !_ 'T ?@"& 'P D0![ )X >0"M '@ P !W -L
M=@#R '8 _P!V /\ =0#_ .    #)    N (  *H#  "@ @  F0   )8   "1
M  D C@ 4 (L '@"( "@ A@ Q (0 . "" #\ @0!& '\ 2P!^ %$ ? !7 'L
M7 !Z &( > !I '< <0!V 'D = "# ', C@!Q )L ;P"I &X O !M -4 ; #M
M &L ^@!J /\ :@#_ -8(  # #   K1   *$0  "7#@  D L  (L'  ")  $
MA@ - (, & "! "( ?@ L 'P - !Z #L > !" '< 2 !U $T = !3 '( 60!Q
M %\ < !F &X ;@!M '< :P&! &D!C !H )D 9@"H &0 N@!C -( 80'I &$"
M]P!@ O\ 8 +_ ,X1  "X%0  IA@  )H9  "0&   B!<  (,4  " #@  ?P<%
M 'T"$@!Z QT =P4G '0&+P!R!S< <0@^ &\)1 !N"DH ; I0 &L+5P!I#%T
M: QE &8,;0!D#'8 8PR! &$,C !?#)D 70RI %L,NP!9#-, 6 WJ %<-^0!7
M#?\ 5PS_ ,89  "Q'   H!\  ),@  ")(   @A\  'T<  !Y&0  =Q0  '8.
M"@!S#A< <!$B &T2*P!K$S, :10Z &<500!F%4< 9!9. &,65 !A%UL 8!=B
M %X7:P!<%W0 6A=_ %D7BP!7%Y@ 51>H %,7N@!1%M, 4!?L $\6_ !/%O\
M3Q;_ , ?  "K(P  FR0  (XE  "$)@  ?"4  '<C  !S(   <!T  &X9!0!L
M&!, :1H> &8;)P!D'#  8ATW & >/@!>'D0 71Y+ %L?40!:'U@ 6!]@ %<@
M: !5('( 4R!] %$@B0!/'Y8 31^F $L?N0!)'M$ 2![J 4@=^P%''?\!1QS_
M ;HD  "F*   ERD  (HJ  " *P  >"L  '(I  !M)@  :B0  &@A  !E(0X
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M!CLQ@P8Y,9$&-S"A!34OM 4S+\P%,B[F!3(M^08R+/\&,RS_!JXP  "<,P
MC#4  ( V  !V-@  ;38  &8V  !@-0  7#(  %<S  !3- , 4#40 $XV&P!+
M-B, 238K D8V,0-$-C@%0C8^!D V10<^-DT'/#95"#HV7@@X-F@'-C9T!S0V
M@0<R-8\&,36@!B\TL@8M-,H%+#/E!2PR^ 8L,?\'+3#_!ZHT  "8-@  B3@
M 'TY  !R.@  :CH  &(Y  !<.0  5S8  %(X  !..0  2SH, $@[%P!&/"
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M AY&KP$=1<<!'$3B 1M"]@,:0?\$&D#_!9\^  ".0   @$(  '-#  !I0P
M8$0  %A$  !110  248  $)(   ]2@  .$P  #1-"P Q318 +TX> "U.)@ K
M3BT!*4XT B=./ (E3D0#(TY- R).5@(@3F$"'TYN 1U.>P$;38H &4V; !A,
MK@ 62\4 %4KA !5)]0$51_\"%$;_ YI"  "*1   ?$4  '!&  !E1P  7$<
M %5(  !.20  14L  #]-   X3P  ,E$  "Q3!@ H5!$ )E0: "14(@ C5"D
M(54Q !]5.0 >54$ '%5* !I55  955\ %U1K !54>0 35(@ $5.9  Y2K  ,
M4<( "U#=  U/]  -3O\ #DW_ 99&  "%2   >$D  &Q*  !A2P  64L  %%+
M  !+3   0D\  #I2   T5   +58  "59   ?6PH '%L4 !I;'  86R0 %UPL
M !5<-  47#T $EQ& !!<4  -6UL "UMG  E;=0 '6H0 !5J4  -9IP "6+T
M E;8  -5[0 $5/L !5/_ )!+  "!3   <TT  &=.  !>3@  5D\  $]/  !'
M40  /E0  #97   O60  )UP  !]>   780, $&,,  UC%@ +8QX "6,F  AC
M+@ &8S< !6-   -C2P !8E8  &)B  !B<   87\  &&/  !@H@  7[<  %[4
M  !<Z@  6_<  %K^ (M/  !\40  ;U(  &-2  !:4@  4U,  $M4  !"5P
M.5H  #!=   H7P  (&(  !AE   09P  !VH'  %K$   :Q@  &L@  !K*
M:S$  &LZ  !J10  :E   &I<  !J:@  :7H  &F*  !HG0  9[(  &;.  !E
MZ@  8_8  &+] (54  !V5@  :E8  &!6  !85@  3U<  $9:   \70  ,V
M "ID   A9@  &6D  !%L   (;P   '$$  !R"P  <A,  ',:  !S(0  ="D
M '0R  !T/0  =$D  '-6  !S9   <W0  '*%  !QF   <:T  '#(  !NY@
M;?<  &S_ ']:  !Q6P  9EL  %U;  !56P  2EX  $!A   V90  +&@  ")L
M   9;P  $'(   AT    =P   'D   !Z!@  >@T  'L4  !\&P  ?2(  'XJ
M  !_-   ?D$  'Y.  !^7   ?FT  'U_  !\D@  >Z@  'O!  !YX0  >/0
M '?^ 'E?  !M8   8V   %I@  !/8@  1&8  #EJ   O;@  )'(  !IU   1
M>   !WL   !]    @    ((   "#    A 8  (4-  "&%   AQH  (@B  "*
M*@  BC<  (I%  "*5   BF0  (IW  ")BP  B*(  (>Z  "&V0  A/$  (/\
M '1E  !I90  864  %5H  !):P  /7   #)T   G>   ''P  !%_   '@@
M (4   "'    B@   (P   ".    CP   ) $  "1"@  DA$  )08  "5(
MERL  )<Z  "72@  F%L  )EM  "7@P  EYL  )6S  "3T0  DNH  )'W '!K
M  !H:@  6VT  $]Q  !"=@  -GL  "J    >A   $X<   >*    C0   )$
M  "4    E@   )@   ":    FP   )P   "=    GP4  *$,  "C%0  I1T
M *<J  "G.P  J$T  *E@  "I=@  J(X  *:F  "EP0  I-P  *3M &]P  !B
M<P  57<  $E\   [@@  +H<  "&,   5D0  "90   "7    F@   )T   "@
M    H@   *0   "F    IP   *D   "J    JP   *T   "O"   LA(  +4>
M  "X+0  N$   +E4  "Z:P  N8(  +F:  "XL0  M\L  +?A &IY  !=?@
M4(,  $.)   TCP  *)0  !N:   .G@   :$   "D    IP   *H   "L
MK@   +$   "S    M0   +<   "Y    N0   +P   "_    PP(  ,@-  #,
M&P  SBP  -!#  #17   T70  -&+  #2H@  T;8  -'* &6$  !8B@  2Y
M #V6   PG0  (J(  !6G   (JP   *\   "R    M@   +@   "Z    O
M +X   #     P@   ,0   #'    R@   ,P   #0    U    -P   #A"@
MYAH  .HM  #N1   \ET  /!W  #OCP  [:0  .ZS /\   #_    _P   /\
M  #_  @ _P 8 /\ ) #_ #  _  [ /H 10#W $X ] !7 /$ 7@#O &0 [0!K
M .L < #I '8 YP![ .8 @0#D (< XP". .$ E@#@ )\ W@"I -P MP#: ,L
MV #G -0 _0#2 /\ SP#_ ,H _P#$ /\ P #_ /\   #_    _P   /\   #_
M  8 ^P 4 /< ( #Q "L [P V .X 0 #K $D YP!1 .0 60#A %\ WP!E -P
M:P#; '  V0!V -8 >P#4 ($ T@"( -$ D #/ )D S0"C ,L L #) ,$ QP#;
M ,4 ]P## /\ P #_ +\ _P"Y /\ M@#_ /\   #_    _P   /L   #R  (
M[0 0 ., &P#A "8 WP Q -T .P#: $0 U@!, -( 4P#0 %D S0!? ,L 90#)
M &H QP!P ,4 =0## 'L P "" +X B@"\ ), N@"= +@ J0"V +@ M0#. +0
M[@"S /\ L@#_ +  _P"O /\ K #_ /\   #_    ]0   .P   #C    U@ *
M -$ %P#- "$ RP K ,D -0#( #X Q !& ,$ 30"] %, N0!9 +< 7P"T &0
ML@!J +$ ;P"O '4 K@!\ *P A "K (T J0"6 *@ H@"F +  I #$ *, XP"B
M /H H0#_ *$ _P"A /\ H #_ /\   #V    YP   -H   #/    Q  % +\
M$@"[ !T N0 F +< +P"T #@ L !  *T 2 "J $X J0!4 *< 60"E %X I !D
M *, :0"A &\ H !V )X ?@"= (8 G "0 )H G "9 *D EP"Z )8 V "5 /(
ME #_ ), _P"3 /\ DP#_ /D   #F    U@   ,@   "\    M0   *\ # "L
M !< J0 A *4 *@"C #, H@ [ )\ 0@"= $D FP!. )H 5 "8 %D EP!> )4
M9 "4 &H D@!P )  > "/ (  C@"* (P E@"+ *, B@"S (@ RP"( .D AP#]
M (< _P"' /\ AP#_ .\   #:    QP   +@   "O    J    *, !P"> !(
MF@ < )@ )0"6 "X E0 V ), /0"0 $0 C@!* (T 3P"+ %0 B@!9 (D 7P"'
M &4 A@!K (4 <P"# 'L @@"% ($ D "  )T ?@"M 'T P0!\ -\ ? #V 'L
M_P![ /\ >P#_ .(   #,    N@   *P   "C    G0   )<  0"2  P CP 7
M (T ( "+ "D B0 Q (< . "% #\ A !% (( 2@"! %  @ !5 'X 6@!] &
M? !G 'H ;@!Y '< > "! '8 C !U )D <P"H '( N@!Q -0 < #O '  _P!P
M /\ < #_ -8   #     K@   *(   "8    D0   (T   ")  8 A@ 1 (0
M&P"! "0 ?P L 'X ,P!\ #H >@!! 'D 1@!W $P =@!1 '0 5P!S %T <@!C
M '  :P!O ', ;0!] &P B !J )4 :0"D &< M !F ,T 9@#H &4 ^@!E /\
M9 #_ ,P!  "V!@  I@@  )D*  "/"@  B <  (0#  "!    ?@ * 'P %0!Y
M !\ =P G '4 +P!S #8 <0 \ '  0@!N $@ ;0!. &L 4P!J %D : !@ &<
M: !F '$ 9 ![ &, A@!A )( 7P"A %X L@!< ,@ 7 #D %L ] !: /X 6@#_
M ,,*  "N$   GA(  )$4  "'%   @!(  'P.  !X"@  =P0$ '4 #@!S !D
M<  B &T *@!K #( :0$Y &@"/P!F T4 90-+ &,$40!B!%< 8 5> %\%9@!=
M!6\ 7 5Y %H%A0!8!9$ 5@6@ %0%L0!3!,< 4@7@ %$%\0!1!?T 407_ +P2
M  "H%@  F!D  (L;  "!&P  >AH  '08  !Q%   ;Q   &X)!P!L!Q, :0D=
M &8*)@!D"RX 8@PU &$-.P!?#4( 7@Y( %P/3@!;$%4 61!< %<090!6$&X
M5!%Y %(1A0!0$9( 3A"A $P0LP!*#\H 20_C $D/]0!(#O\ 2 [_ +88  "B
M'   DQX  (8A  !\(0  ="   &X?  !J'   :!D  &85  !E$@T 8A,9 %\5
M(@!=%2H 6Q8Q %D7. !8%S\ 5AA% %482P!3&%( 41E: % 98@!.&6P 3!EW
M $H9@P!(&9  1AF@ $08L0!"&,@ 01?C $$7]@!!%_\ 01;_ + =  ">(0
MCB,  ((E  !X)@  <"4  &DD  !E(@  8A\  %\=  !>&PD 6QL5 %@<'P!6
M'2< 5!XN %(?-0!1'SP 3Q]" $X@20!,(%  2R!7 $D@8 !'(&H 12!U $,@
M@0!!((\ /R"> #T?L  ['\8 .1[A 3D>]@$Y'?\!.1S_ :PB  ":)0  BB<
M 'XI  !T*@  ;"H  &4I  !@)P  724  %HC  !7(@4 52(1 %(C&P!0)"0
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M R@PK ,G+\(")2[= B4M\P,E+/\$)BO_!*$M  "0+P  @3(  '4S  !K-
M8C0  %LT  !4-   3S,  $LR  !'-   0S0& $ U$0 ^-AL /#8B #DV*0$W
M-C "-38V S,V/@0Q-D4%+S9.!2XV5P4L-F$$*C9M!"@V>@0F-H@#)#:9 B,U
MJP(A-<$!(#3< 1\S\@,?,?\$'S#_!)XP  ",,P  ?C4  '(V  !G-P  7S<
M %<W  !1-P  2S<  $4X  !!.0  /3H" #H[#0 W/!< -3P@ #,\)P$Q/"T"
M+SPT RT\.P,K/$,$*3Q,!"@\500F/& #)#QK R(\>0(A/(<"'SN8 1T[J@$;
M.L  &CG; !HX\@(9-_\#&3;_!)HT  ")-@  >S@  &\Y  !D.@  6SH  %0[
M  !-.P  1SL  #\]   [/P  -T   #-!"0 P010 +T(< "U")  K0BL!*4(R
M 2=".0(E0D$"(T)* B)"4P(@0EX"'D)J 1Q"=P$:0H8 &$&6 !9!J0 50+\
M$S_: !0^\0 4//\!%#O_ I8W  "%.@  >#P  &L]  !A/0  6#X  %$^  !*
M/P  1$   #M"   V1   ,44  "U'!0 I2 \ )T@8 "5((  C22< (4DO "!)
M-@ >23X!'$E' !M)40 925P %TEH !5)=0 32(0 $4>4  Y'IP ,1KP "T76
M  Q$[P -0OT #4'_ 9([  "!/@  =#\  &A   !=00  54$  $U"  !'0@
M0$0  #A&   S2   +4H  "9,   A3@H 'D\4 !Q/'  :3R, &$\K !=/,@ 5
M3SL %$]$ !)/3@ 03UD #4]E  I/<@ (3H$ !DZ1  5-HP #3+<  DO1  -*
MZ0 %2?D !4C_ (U   !]0@  <$,  &1$  !:10  444  $I%  !$1@  /4@
M #1+   N30  *$\  "%1   95 0 $U8- !%6%@ .5AX #58F  M6+@ *5C8
M"%8_  9620 $5E0  E5@  !5;0  57P  %2,  !3G@  4K,  %'.  !0Y@
M3_4  $_] (A$  !Y1@  :T<  &!(  !62   3D@  $A)  !!2@  .$T  #!0
M   I4@  (E0  !I7   36@  "ET(  1=$0 "71D  %TA  !=*0  73$  %TZ
M  !=1   74\  %U;  !<:0  7'@  %N(  !;F@  6JX  %G)  !8Y@  5O0
M %7\ ())  !S2P  9DP  %Q,  !33   3$P  $1-   \4   ,U,  "M6   C
M6   &UL  !1>   +8    V,%  !D#0  910  &4;  !E(P  92L  &4T  !E
M/@  94D  &55  !E8P  9'(  &.#  !CE0  8JH  &'$  !@X@  7_4  %[]
M 'Q.  !N4   8E   %A0  !14   25$  #]3   V5@  +5H  "1=   ;8
M$V,   ME   #:    &H"  !K"0  ;!   &P6  !M'0  ;B0  &\M  !O-P
M;D(  &Y/  !N70  ;FT  &U^  !LD   :Z4  &N^  !JW@  :?,  &?^ '94
M  !I50  7E4  %94  !.50  1%<  #E;   P7@  )F(  !QE   3:   "FL
M  -N    <    ',   !T P  =0D  '80  !W%@  >!T  'DE  !Z+@  >CH
M 'E'  !Y5@  >64  'AW  !WBP  =J   '6X  !UU@  <_$  '/\ '!9  !D
M6@  7%D  %-9  !)7   /5\  #)C   H:   'FL  !1O   )<@   G4   !W
M    >@   'P   !]    ?P(  ( (  "!#@  @A4  (0<  "%)0  AR\  (8]
M  "%30  A5T  (5O  "$@P  @YH  (*Q  "!SP  @>L  '_Z &M?  !B7@
M65X  $YA  !"90  -FD  "MN   ?<@  %78   EZ    ?0   '\   ""
MA    (8   "(    B0   (L   ",!@  C0P  (\4  "1&P  DR0  )0R  "3
M0P  DU0  )1F  "3>P  DI(  )&K  "/QP  CN4  ([U &AD  !@9   5&<
M $AK   [<   +G4  ")Z   6?@  "H(   "%    B    (L   "-    D
M )(   "4    E@   )<   "8    F@(  )P)  ">$0  H1D  *,D  "D-0
MHTD  *1;  "E;P  I(<  *.A  "AO   G]T  )WP &=J  !:;0  3G$  $%V
M   T?   )H$  !J&   ,B@   8X   "1    E0   )@   ";    G@   *
M  "B    HP   *4   "G    J    *H   "L P  KPP  +,6  "V)0  MC@
M +9,  "X80  MWH  +:3  "TK   L\8  +/? &)S  !5=P  2'T  #J#   M
MB0  'XX  !*4   $F0   )P   "?    H@   *4   "H    J@   *P   "N
M    L    +(   "S    M    +<   "Y    O0   ,()  #&&   RBD  ,H^
M  #,50  S6X  ,V&  #-G0  S;,  ,S( %U^  !0@P  0HH  #21   FEP
M&9T   NB    I@   *D   "L    KP   +(   "U    N    +H   "\
MOP   ,$   #$    Q@   ,@   #,    T    -@   #=!0  X14  .4H  #I
M0   ZEP  .AW  #IC0  ZJ(  .JR /\   #_    _P   /\   #_  @ _P 4
M /\ ( #_ "P _@ W /P 00#Y $H ]@!2 /0 60#R &  \ !F .X :P#L '$
MZ@!V .@ ? #F (, XP"* .  D@#= )P VP"G -@ M@#5 ,H U #G -, _ #3
M /\ SP#_ ,4 _P"_ /\ NP#_ /\   #_    _P   /\   #_  , ]0 1 /,
M&P#R "< \  R /  / #L $4 Z0!- .4 5 #A %H W !@ -D 9@#5 &L T@!Q
M -  =@#. 'T S "$ ,H C #( )4 Q@"A ,0 K@#" ,$ P #< +X ]0"\ /\
MO #_ +@ _P"T /\ L0#_ /\   #_    _P   /<   #N    Y@ , ., & #@
M "( W@ L -T -@#7 #\ SP!' ,P 3@#) %0 Q@!: ,0 8 #" &4 P !K +\
M< "] '< NP!] +D A0"W (X M0"9 +0 IP"R +< L #0 *X [0"M /\ K #_
M *H _P"F /\ I #_ /\   #\    \@   .@   #9    TP ' ,X $P#+ !X
MQ@ G ,$ ,0#  #H O0!" +H 20"W $\ M0!5 +, 6@"Q %\ KP!E *T :@"K
M '  J@!W *@ ?P"F (@ I "2 *, GP"B *\ H #$ )\ X@"> /L G0#_ )T
M_P"; /\ F0#_ /\   #N    X    -(   #'    OP " +H #0"T !D L0 C
M *\ *P"N #0 K  \ *D 0P"F $H I !/ *( 50"A %H GP!? )X 9 "< &H
MFP!Q )D >0"7 ($ E@"+ )0 EP"4 *< D@"Y )$ U0"/ /, CP#_ (X _P".
M /\ C@#_ /$   #@    S@   +\   "V    KP   *@ " "D !0 H0 = )\
M)@"= "\ G  W )H /@"8 $0 E@!* )0 3P"3 %0 D0!: )  7P". &4 C0!K
M (L <P") 'L B "% (8 D "& *  A0"Q (0 R0"# .D @@#^ (( _P"" /\
M@@#_ .<   #0    O0   +    "H    H0   )H  P"7  X E  8 )$ (0"0
M "H C@ Q (T .0"+ #\ B0!% (@ 2P"& %  A0!5 (, 6@"" &  @ !F '\
M;@!] '8 ? "  'L BP!Z )D >0"I '@ O@!W -T =@#V '8 _P!V /\ =@#_
M -D   ##    L0   *0   ";    E    (\   "+  D B  3 (8 ' "$ "4
M@P L (( - "  #H ?@!  'T 1@![ $L >@!0 '@ 5@!W %L =0!B '0 :0!R
M '$ < ![ '  AP!O )0 ;0"C &P M@!K -$ :@#M &H _P!J /\ :@#_ ,P
M  "V    I@   )H   "0    B0   (8   ""  0 ?P - 'P %P!Z "  >0 H
M '< +P!V #4 =  \ '( 00!Q $< ;P!, &X 40!M %< :P!> &D 90!G &T
M9@!W &4 @P!D )  8@"? &$ L !@ ,< 7P#D %\ ^0!? /\ 7P#_ ,(   "M
M    G@0  ) &  "'!0  @ ,  'P   !Z    =@ ( '0 $@!R !L ;P C &X
M*@!L #$ :@ W &D /0!G $, 9@!( &0 3@!C %0 80!: &  8@!> &H 70!T
M %L @ !: (P 6 "; %< JP!5 ,  50#= %4 ] !5 /\ 5 #_ +D$  "F"0
ME@P  (D/  !_#P  > T  '0*  !P!0  ;P # &P # !J !4 :  > &8 )@!D
M "T 8@ S &  .0!? #\ 7@!% %P 2P!; %$ 60!8 %@ 7P!6 &@ 50!R %,
M?@!1 (H 3P"9 $T J0!, +T 3 #9 $L [@!* /H 2@#_ +$+  "?$0  CQ0
M (,6  !Y%@  <A8  &P4  !I$   9@L  &8&!@!D A  80(9 %\#(0!=!"D
M6P4O %D&-@!8!CP 5@=" %4(2 !3"$\ 4@A6 % )7@!."6< 30EQ $L)?0!)
M"8H 1PF9 $4(J0!$![T 0@;6 $$'ZP!!!_D 00?_ *P2  ":%@  BAH  'X;
M  !T'   ;!P  &8:  !B&   7Q4  %X1  !="P@ 6PL4 %@-'0!6#B4 5 \L
M %,0,P!1$3D 3Q$_ $X21@!,$DT 2Q)4 $D37 !'$V8 11-Q $,3?0!!$XH
M/Q.9 #T2JP [$<  .1#: #D0[P Y$/P .1#_ *<7  "5&@  AAX  'H@  !P
M(0  9R$  &$@  !<'@  61L  %<9  !6%@, 5!4/ %$6&0!/%R$ 31<I $P8
M+P!*&38 2!D\ $<90P!%&DH 1!I2 $(:6@! &F0 /AIO #L:>P Y&HD -QJ8
M #49J0 S&;X ,1C9 #$8\  R%_X ,A;_ *,;  "1'@  @R(  '<D  !L)0
M9"4  %TD  !8(P  5"$  %(>  !0'   31P+ $L=%@!)'AX 1QXF $4?+ !#
M'S, 0B Y $ @0  _($@ /2%/ #LA6  Y(6( -R%M #0A>0 R(8< ,""6 "X@
MJ  L'[T *A[8 "H>[P$K'?X!*QS_ 9\?  "-(@  ?R4  ',G  !I*   8"@
M %DH  !4)P  4"8  $TC  !*(@  1R,' $4C$@!#)!L 024C #\E*@ ])3
M.R8V 3DF/0$X)D4!-B9- 30F5@$R)F !,"9K 2XF> $L)H8!*B:5 2<EIP$E
M)+P!)"36 20C[@$D(OT!)2'_ IPB  "*)@  ?"@  ' J  !E*P  72P  %8K
M  !0*P  3"H  $@H  !%*   02D# #\I#@ \*A@ .BL@ #@K)P V*RT!-"LT
M 3(K.P(Q*T("+RQ+ BTL5 (K+%X"*2QI B<L=@(E+(0!(RN4 2$KI@$?*KL
M'BG5 !XI[0$>*/T"'B?_ I@F  "'*0  >2L  &TM  !B+@  6B\  %(O  !-
M+@  2"X  $,M   _+@  .R\  #@O"@ V,!4 -# = #(Q)  P,2L!+C$Q 2PQ
M. (J,4 "*3%) B<Q4@(E,5P"(S%H B$Q=0$?,8,!'3&3 1LPI0 9+[D &"_4
M !@N[0 8+?P!&"S_ I4I  "$+0  =B\  &HP  !?,0  5C(  $\R  !),@
M1#(  #\R   Y-   -30  #(U!P O-A$ +38: "PW(0 J-R@ *#<O 28W-@$D
M-SX!(C=& 2$W4 $?-UH!'3=F 1LW<P 9-X( %S:1 !4VHP 3-;@ $332 !(S
M[  3,OP!$S'_ 9$M  "!,   <S(  &<S  !<-   4S4  $PU  !&-0  0#8
M #HW   S.0  +SH  "P[ P H/ T )CP6 "0]'@ C/24 (3TL !\],P >/3L
M'#U$ !H]3@ 8/5@ %CUD !0]<0 2/8  $#R0  P[H0 *.[4 "3K.  HYZ  +
M./D ##?_ (TQ  !]-   ;S4  &,W  !9-P  4#@  $DX  !#.0  /3D  #8[
M   P/0  *SX  "9    A0@D 'D(2 !Q#&@ ;0R$ &4,I !=#,  61#@ %$1!
M !)#2P 00U8 #4-A  M#;@ )0WT !T*,  1!G@ "0+$  3_+  (^Y  $/?4
M!3S_ (DU  !Y.   ;#D  & Z  !5.P  33L  $8\  ! /   .CT  #,_   M
M00  )T,  "%%   :1P0 %DD- !-*%@ 12AT #THE  U*+  +2C0 "4H]  A*
M1P &25( !$E=  %):@  27D  $B)  !'F@  1JX  $7'  !$X@  0_(  $/[
M (0Z  !U/   9ST  %P^  !2/@  2C\  $,_   ]/P  -T$  "]#   H1@
M(D@  !Q*   530  #4\(  A0$0 %4!D  U$A  )0*   4#   % Y  !00@
M4$T  %!9  !09@  3W4  $^%  !.EP  3:L  $S#  !+X0  2O(  $G[ '\^
M  !P0   8T$  %A"  !/0@  1T(  $%"   Z0P  ,D8  "M(   C2P  '$T
M !90   .4@  !E4&  !7#0  5Q4  %@<  !8(P  6"L  %<S  !7/0  5T@
M %=4  !780  5W   %:!  !6DP  5:@  %/   !2W@  4?,  %'] 'I#  !K
M10  7D8  %1&  !,1@  144  #Y&   U20  +4P  "5/   =40  %E0   Y6
M   '60   %P$  !="@  7A$  %X7  !?'@  8"4  & N  !@-P  8$(  %]/
M  !?7   7VL  %Y\  !>CP  7:0  %R[  !:VP  6O(  %G^ '1(  !F2@
M6DH  %%*  !*20  0DH  #E-   P4   )U,  !Y6   660  #EL   9>
M80   &,   !D!@  90P  &82  !G&0  :"   &DG  !I,0  :3P  &E)  !I
M5P  :&8  &AW /_B?1!)0T-?4%)/1DE,10 /%0!GB@  9I\  &6V  !DU0
M8_   &+] &U.  !A3@  5TX  $].  !'3@  /5$  #-4   J5P  (%L  !9>
M   ,8@  !60   !G    :@   &P   !M    ;P8  ' +  !Q$@  <A@  '0@
M  !U*   =3,  '5   !T3P  =%X  '-P  !RA   <9D  '"Q  !OSP  ;^L
M &[[ &A3  !=4P  5%,  $U2  !"50  -ED  "Q=   A80  %V4   QI   #
M;    &\   !Q    =    '8   !W    >0   'H$  !\"@  ?1$  '\8  "
M(   @BH  ((W  "!1@  @5<  (!H  " ?0  ?I(  'RJ  ![Q@  >^8  'OW
M &-9  !:6   4U@  $=:   [7P  +V,  "1H   8;   #'    )T    =P
M 'H   !]    ?P   ($   "#    A0   (8   "( 0  B@<  (L-  ".%@
MD!\  )(J  "1.@  D$P  )!?  "/<P  CHH  (RB  "+O@  BMX  (GS &!>
M  !970  36   $!E   S:@  )V\  !IT   .>    GT   "     @P   (8
M  ")    BP   (T   "/    D0   ),   "4    E@   )@$  ":"P  G14
M * >  "B+0  H$$  *!4  "@:0  H'\  )Z9  "=M   F],  )KM &!C  !3
M9@  1FL  #EP   L=@  'WP  !*!   %A0   (D   ",    CP   )(   "5
M    F    )L   "=    GP   *$   "C    I    *8   "I    K <  + 0
M  "T'@  M#$  +-'  "T6P  MG$  +2+  "SI0  L<$  *_= %IL  !-<0
M0'<  #)]   D@P  %XD   B.    D@   )8   ":    G@   *$   "D
MI@   *@   "K    K0   *\   "Q    L@   +0   "W    NP   +\$  #%
M$   RB$  ,DV  #+30  S60  ,Q^  #*EP  R+   ,?& %5W  !'?0  .H0
M "N+   =D0  #I<   &=    H0   *4   "H    JP   *X   "P    LP
M +4   "W    N@   +P   "^    P0   ,(   #&    R@   ,\   #7 P
MW!0  -\F  #A/P  XUD  .5R  #EB0  YI\  .:Q /\   #_    _P   /\
M  #_  0 _P 1 /\ ' #_ "@ _P S /\ /0#Y $8 \@!- /  5 #M %L ZP!A
M .D 9@#G &P Y0!R ., > #A 'X WP"% -T C@#: )@ UP"D -0 LP#3 ,P
MT #K ,X _P#+ /\ Q #_ +H _P"U /\ LP#_ /\   #_    _P   /\   #Z
M    ]P - /0 &0#S ", [P M .H . #G $$ XP!) -\ 4 #< %8 V@!< -<
M80#4 &8 T0!L ,\ <@#, '@ R@!_ ,< AP#% )$ P@"< +\ JP"^ +\ O0#@
M +L ^@"Z /\ MP#_ *\ _P"K /\ J #_ /\   #_    _0   /(   #J
MY0 ( .( % #: !\ U@ H -4 ,@#3 #P S@!$ ,D 2P#& %$ PP!6 ,  7 "^
M &$ O0!F +L ; "X '( MP!Y +4 @0"R (H L "5 *X H@"L +, K0#1 *L
M\0"I /\ J #_ *, _P"@ /\ G@#_ /\   #Z    [@   -\   #6    SP #
M ,8 #P#" !H P  D +T +0"[ #8 N  ^ +4 10"S $L L !1 *\ 5@"M %L
MJP!A *H 9@"H &P I@!S *0 >P"B (, H ". )X F@"< *H G0#" )P Y0":
M /\ F0#_ )< _P"4 /\ D@#_ /<   #I    V@   ,L   #!    N    +(
M"@"O !4 JP ? *H * "I #  IP X *4 0 "B $8 H !, )X 40"= %8 FP!;
M )H 80"8 &< E@!M )0 =0"2 'T D0"' (\ DP"- *$ C0"V (P U@"+ /8
MBP#_ (H _P") /\ AP#_ .L   #8    Q    +@   "O    I@   *( !0">
M !  FP 9 )H (@"8 "L EP S )4 .@"3 $  D0!& )  2P". %  C0!6 (L
M6P"* &$ B !G (< ;P"% '< @P"! ($ C !_ )H ?P"M '\ QP!^ .L ?0#_
M 'T _P!] /\ ? #_ -P   #&    M0   *D   "@    F0   ),   "0  H
MC0 4 (L '0"* "4 B0 M (@ - "& #H A !! (, 1@"! $L @ !0 'X 5@!]
M %P >P!B 'H :@!X '( =@!\ '0 AP!R ), <P"F '( O !Q -T < #Y '
M_P!P /\ < #_ -    "Y    J0   )P   "3    C0   (@   "$  4 @0 /
M '\ & !^ "  ?0 H 'P +P!Z #8 >  [ '< 00!U $8 = !+ '( 40!Q %<
M< != &X 9 !L &T :@!W &@ @@!G (X 9@"? &4 LP!E -  9 #O &, _P!C
M /\ 9 #_ ,(   "N    GP   )$   "(    @@   'X   !Z  $ =P * '4
M$P!S !L <@ C '  *@!O #  ;0 V &P / !J $$ :0!' &@ 3 !F %( 90!8
M &, 8 !A &D 8 !R %X ?0!< (H 7 ": %H K !9 ,0 6 #D %@ ^0!8 /\
M60#_ +<   "E    E    (@!  !_    >0   '0   !Q    ;@ % &P #@!J
M !< :  > &8 )0!E "P 9  R &( -P!@ #T 7P!" %T 2 !< $X 6P!5 %D
M7 !7 &4 5@!N %0 >0!3 (< 4@"5 %  IP!/ +P 3@#9 $X \P!. /\ 3@#_
M *\   "= P  C0@  ($)  !X"0  < @  &L%  !H 0  9@ ! &0 "0!B !(
M8  : %X (0!< "@ 6P N %D - !8 #D 5@ _ %4 10!4 $L 4@!1 %$ 60!/
M &( 30!L $P =P!* (0 20"3 $< HP!& +8 10#2 $4 [ !% /P 10#_ *D&
M  "6"P  APX  'L1  !Q$@  :1$  &0.  !@"P  7@@  %T#! !;  P 60 5
M %< '0!5 "0 4P J %( , !0 #8 3P \ $X!0@!, 4@ 2P)/ $D"5P!' F
M10)J $0"=@!" H, 0 *1 #X!H0 ] +0 / #, #P YP [ /8 .P#_ *,+  "0
M$@  @A0  '86  !L%P  9!<  %X6  !:%   5Q$  %4-  !4"08 4P8/ %$&
M& !.!R  30@G $L(+0!*"3, 2 HY $<*/P!%"T8 0PM. $(+5@! "U\ /@MJ
M #P+=@ Y"X, -PN2 #4+H@ T";4 ,PC, #$(Y  Q"?0 ,0C] )\0  ",%@
M?AD  '(;  !H'   7QP  %D:  !4&0  41@  $\5  !.$@  30\) $L/$P!(
M$!P 1A$C $42*@!#$C  01,V $ 3/0 ^%$0 /!1, #H45  X%%X -A1I #04
M=0 R%(, +Q22 "T3HP K$K< *1+0 "D2Z0 I$?< *A'_ )H4  "(&@  >QT
M &X?  !D(   6R   %4?  !0'@  3!T  $D;  !(&   1A<% $07$ !"%Q@
M0!@@ #X9)P \&2T .AHT #@:.@ W&D( -1M* #,;4@ Q&UP +QMG "T;=  K
M&X$ *!N0 "8:H@ D&;4 (AG/ "(8Z0 B&/H (Q?_ )88  "%'0  =R   &LB
M  !@(P  6",  %$C  !,(@  2"$  $0@  !#'0  0!T! #T>"P ['A4 .1\=
M #<?)  U'RH ,R Q #(@.  P(#\ +R%( "TA4  K(5H *2%E "8A<@ D(8
M(B"/ " @H0 >'[0 '![- !P>Z  <'?D '!W_ ),;  ""(   =",  &@E  !=
M)@  5"8  $XF  !()@  1"4  $ D   ](P  .2,  #<D"  T)!( ,B4: #$E
M(0 O)2@ +28N "LF-0 J)CT!*"9% 28F3@$D)E@!(B9D " F<  >)G\ '":.
M !DEGP 7)+, %B3, !8CYP 6(OD %R+_ (\?  !_(P  <28  &4H  !:*0
M42D  $LI  !%*0  0"D  #LI   W*   -"D  #$J!  N*@X +"L7 "HK'@ I
M*R4 )RPL "4L,P C+#L!(2Q# 2 L3  >+%< '"QB !HL;P 7+'T %2N- !,K
MG@ 1*K( #BG+  XHY@ 0*/@ $2?_ (LC  !\)@  ;BD  &(K  !7+   3BP
M $<L  !"+   /"T  #<M   R+0  +B\  "LO 0 H, H )3$4 ",Q&P B,2(
M(#(I !XR,  =,C@ &S)! !DR2@ 7,E4 %3)@ !,R;0 1,GP #3&+  LPG  )
M+Z\ !R_&  @NX  )+?0 "BS_ (@G  !Y*0  :RP  %XN  !4+P  2R\  $0P
M   ^,   .3   #0P   N,@  *30  "0U   A-@< 'C<0 !PW&  :-Q\ &3<F
M !<X+0 5.#4 %#@^ !(X2  0.%( #3A>  HW:@ (-W@ !C>(  0VF  !-:P
M #3#  $SW0 ",O   S+\ (0J  !U+0  :"\  %LQ  !1,@  2#(  $$S   [
M,P  -C,  #$T   J-@  )3<  " Y   ;.P, %ST+ !0]%  2/AL $#XC  X^
M*@ ,/C( "CXZ  @^1  &/4X !#U:  (]9@  /74  #V$   \E@  .ZD  #K
M   YW0  ..\  #?Y ( O  !Q,0  9#,  %@T  !--0  138  #XV   Y-@
M,S8  "XW   G.@  (3P  !L^   60   #T,'  I$$  '1!@ !40?  1$)@ "
M1"X  40V  !$0   1$H  $-6  !#8P  0W$  $.!  !"DP  0:8  $"]   _
MVP  /O$  #WZ 'PS  !M-0  7S<  %0X  !*.0  0CD  #PY   V.0  ,#H
M "H\   B/@  '$$  !=#   110  "4@&  )*#   2A0  $L;  !+(@  2RH
M $LR  !+.P  2D8  $I2  !*7P  2FT  $I^  !)D   2*0  $:[  !%V0
M1/$  $3\ '<X  !H.@  6SL  % \  !'/   0#P  #H\   S/0  +#\  "5!
M   =1   %T8  !%)   *2P   DX$  !/"@  4!$  %$7  !2'@  4R4  %,M
M  !2-@  4D$  %)-  !16P  46D  %%Z  !1C   4:$  $^Y  !-U@  3/
M $O] '$]  !C/P  5D   $Q   !$0   /C\  #=    O0@  )T4  !](   7
M2P  $4T   E/   #4@   %4"  !6!P  5PT  %@3  !:&0  6R   %LH  !;
M,0  6SP  %I(  !:5@  6F4  %EV  !9B   69T  %>V  !5U0  5.\  %/]
M &M"  !>0P  4D0  $E$  !#0P  .T,  #)&   J20  (4P  !A/   04@
M"54   )7    6@   %P   !> P  7P@  & -  !B%   8QH  &0B  !E*P
M9#4  &1!  !D3P  8U\  &-P  !B@P  8I@  &&P  !?T   7NT  %W\ &5(
M  !92   3T@  $A'  ! 1P  -DH  "U-   C40  &E0  !!8   (6@   %T
M  !@    8P   &4   !G    : ,  &H(  !K#0  ;10  &X;  !P(P  <"X
M ' Z  !O2   ;U@  &YJ  !M?0  ;),  &NK  !JR   :>D  &C[ %]-  !5
M30  34P  $9,   [3P  ,%,  "96   ;6@  $5X   9B    90   &@   !K
M    ;@   '    !R    =    '4   !W!@  >0L  'H3  !\&P  ?B0  'XP
M  !^/@  ?4\  'QA  !\=0  >XL  'BC  !WOP  =N(  '7W %M3  !34@
M3%$  $!4   T6   *5T  !UA   19@  !6H   !N    <0   '0   !W
M>@   'P   !^    ?P   ($   "#    A0,  (<)  ")$@  BQL  (XF  "-
M-   C44  (M8  "+;0  BH,  (><  "&M@  A-@  (/Q %E7  !25@  1EH
M #E>   L8P  'VD  !-N   &<P   '<   ![    ?@   ($   "$    A@
M (D   "+    C0   (\   "1    DP   )4   "8!@  FPX  )X9  "A)0
MH#@  )Y,  "=80  G7@  )N0  "9JP  E\H  );I %A=  !,8   /V4  #%J
M   D<   %G8   A[    @    (4   "(    BP   (X   "1    DP   )8
M  "8    F@   )P   "?    H    *,   "F    J00  *P-  "Q&   LRH
M +!   "O5@  L&T  +"%  "MH   K+P  *O= %)F  !&:P  .'$  "IX   <
M?@  #80   ")    C0   )$   "5    F    )L   "?    H@   *4   "H
M    J@   *T   "O    L0   +,   "V    N@   +\   #'!@  S!@  ,PM
M  #*10  S5P  ,]T  #+C@  R:<  ,?  $UQ   _>   ,7X  ".%   5C
M!9$   "6    FP   *    "D    J    *L   "M    L    +(   "U
MMP   +H   "\    OP   ,$   #%    R0   ,\   #8    W@L  .0>  #B
M-P  Y$\  .=I  #D@P  XIL  .*P /\   #_    _P   /\   #_  ( _P -
M /\ &0#^ "0 _0 O /T .0#Y $, ]0!+ /$ 4@#M %@ Z@!> .@ 8P#F &@
MY !N .( <P#? 'H W0"" -H B@#7 )0 U "@ -$ KP#. ,8 RP#I ,P _P#&
M /\ N@#_ +0 _P"O /\ JP#_ /\   #_    _P   /\   #[    ^  ) .\
M%0#M "  [  J .H - #E #X X0!& -T 30#: %, UP!9 -0 7@#2 &, T !I
M ,T ;@#+ '4 R ![ ,4 A #" (T P "9 +T IP"Z +H N #: +< ^P"X /\
MK@#_ *@ _P"C /\ H0#_ /\   #^    ^0   /    #I    X  $ -H $0#6
M !P T@ F -$ +P#0 #@ RP!  ,< 2 #$ $X P0!4 +\ 60"\ %\ N@!D +D
M:0"W '  M0!V +( ?@"P (< K0"2 *L H "H +  I@#* *0 [0"G /\ H@#_
M )T _P"9 /\ E@#_ /P   #U    Y@   -P   #2    Q@   ,$ "P"] !8
MNP @ +D *@"X #, M@ [ +, 0@"P $@ K@!. *P 4P"J %@ J != *< 8P"E
M &D HP!P *$ > "? ($ G0"+ )H F "8 *< E@"] )0 W@"6 /\ E0#_ )$
M_P". /\ BP#_ /,   #E    T0   ,4   "X    L0   *P !@"I !$ IP ;
M *4 ) "E "T I  T *$ .P"? $( G0!( )L 30"9 %, EP!8 )8 70"4 &,
MD@!J )$ <@"/ 'L C0"% (H D@"( *  A@"R (4 S0"' /@ AP#_ (4 _P""
M /\ @ #_ .0   #-    O@   +(   "G    H    )L  0"8  L E@ 5 )0
M'@"3 "< D@ O )$ -@"/ #P C0!! (L 1P"* $P B !1 (< 5P"& %T A !C
M (( :P"! '0 ?P!^ 'T BP![ )@ >0"I '< P !X .L > #_ '@ _P!V /\
M=0#_ -0   "^    K@   *    "8    D0   (T   ")  8 AP 0 (4 &0"$
M "$ A  I (, , "! #8 ?P [ 'X 0 !\ $4 >P!+ 'D 40!W %8 =@!= '0
M9 !R &T <0!W &\ A !M )$ ; "B &H M@!K -T :@#[ &H _P!J /\ :@#_
M ,4   "Q    H    )0   "+    A0   ($   !]  ( >P + 'D % !X !P
M=P C '4 *@!S #  <0 V '  .P!O $  ;0!% &P 2P!K %$ :0!8 &< 7P!F
M &@ 9 !R &( ?@!@ (L 7P"; %X K@!> ,T 7@#P %T _P!= /\ 70#_ +D
M  "F    E0   (D   "!    >P   '8   !R    <  ' &T #P!K !< :@ >
M &D )0!H "L 9@ Q &4 -P!C #P 8@!! &$ 1@!? $T 7@!3 %P 6@!; &,
M60!M %< >0!6 (8 5 "5 %0 J0!3 ,$ 4@#E %( _0!1 /\ 40#_ *\   ";
M    C    ($   !X    <0   &P   !I    9@ " &, "@!A !, 8  : %\
M(0!> "< 7  M %L ,@!9 #< 6  ] %< 0@!5 $@ 5 !/ %( 5@!1 %\ 3P!I
M $T =0!, (( 2@"0 $H HP!) +D 2 #9 $@ ] !' /\ 2 #_ *<   "4
MA0,  'D%  !P!0  : 0  &,"  !?    70   %L !@!9  T 5P 5 %8 ' !5
M ", 4P I %( +@!1 #0 3P Y $X /@!- $4 2P!, $H 4P!( %P 1@!F $0
M<0!" 'X 0@"- $$ G@!  +( /P#- #X ZP ^ /X /@#_ *    ".!@  ?PD
M ',+  !I#   80L  %L*  !7"   504  %0! 0!2  D 4  1 $\ & !- !\
M3  E $H *P!) #  2  V $8 .P!% $( 0P!) $( 4 !  %D /@!C #L ;P Z
M 'P .0"+ #@ FP V *X -0#% #4 Y  U /< -0#_ )H&  ")"P  >P\  &X1
M  !D$@  7!(  %81  !1$   3@T  $P*  !,!@0 2@,+ $D!% !' 1L 10(A
M $,")P!" RT 0 ,S #\$.0 ]!$  / 5' #H%3P X!5@ -@5B #0%;@ R!7L
M,06* "\$F0 M!*L + +" "P WP L /( + #] )4,  "$$0  =A0  &H6  !?
M%@  5Q8  %$6  !,%0  2!0  $82  !%#@  1 L& $,)#@!!"1< /PH> #T*
M)  ["RH .@LQ #@,-P V##X -0U& #,-3@ Q#5@ +@UC "P-;P J#7T * V+
M "4-FP D#*T (PK# "$*W0 @"N\ ( KZ )$0  "!%0  <Q@  &8:  !<&@
M4QH  $T:  !'&@  0QD  $ 7   _%0  /A(! #P1"0 Z$1, .!(: #83(0 T
M$R@ ,Q0N #$4-0 O%#P +A5$ "P530 J%5< )Q5A "45;@ C%7P (!6+ !X4
MG  <$Z\ &A/& !D2X0 :$O( &A+] (T4  !]&   ;QL  &(=  !8'0  4!X
M $D>  !$'0  /QT  #L<   Y&@  -Q@  #48!0 S& X ,1D7 "\9'@ N&B4
M+!HK "H:,@ H&SH )QM" "4;2P C&U4 (1M@ !X;;  <&WH &AN) !<:F@ 5
M&:X $QG% !,8X  3&/4 %!?_ (H7  !Z&P  ;!X  %\@  !5(0  32$  $8A
M  ! (0  .R$  #<@   T'P  ,AX  "\> @ M'@L *Q\4 "D?&P G("( )2 H
M "0@,  B(3< ("%  !XA20 <(5, &B%> !@A:P 5(7D $R"( !$@F0 .'ZP
M#!["  L>W0 ,'?( #1S_ (<:  !W'@  :2$  %PC  !2)   220  $(D   \
M)   -R0  #,C   P(P  +",  "DD   F) @ )"41 "(E&  @)A\ 'R8F !TF
M+0 ;)C4 &B8] !@F1P 6)E$ %"9< !$F:0 .)G< "R:&  DEE@ ()*D !B._
M  4CV0 &(NX !R'\ (0=  !T(0  9B0  %DE  !/)@  1B<  #\G   Y)P
M-"<  # G   L)P  )R@  ",I   @*@0 '2L- !LK%0 :+!P &"PC !8L*@ 5
M+#( $RT[ !$L1  .+$\ #"Q:  DL9@ '+', !"R#  (KDP  *J8  "F[   H
MV   )^P  2?X ( @  !Q)0  8B<  %8H  !,*0  0RH  #PJ   V*@  ,2H
M "TJ   I*@  (BT  !XN   :+P$ %S ) !0Q$@ 2,AD $#(@  XR)P ,,B\
M"C,W  @R0  &,DL !#)6  (Q8@  ,7   #&    PD0  +Z,  "ZY   MU@
M+>P  "SX 'TD  !M*   7RH  %,L  !)+   0"T  #DM   T+0  +RT  "LM
M   F+@  'S   !LR   6-   $38&  LX#@ ).!8 !S@=  4X)  #."L  C@S
M   X/0  .$<  #=2   W7P  -VT  #=]   WC@  -:(  #2W   SU   ,NT
M #+Y '@H  !I*P  6RX  $\O  !%,   /3   #<P   Q,   +2\  "@P   B
M,@  '#0  !<V   2.   "SL%  0]#   /A,  #X:   ^(0  /B@  #XP   _
M.0  /D,  #Y/   ]7   /6H  #UZ   ]C   /*   #JV   YTP  ..T  #C[
M '0M  !E+P  5S(  $PS  !",P  .C,  #0S   P,@  *C,  "0U   =-P
M%SD  !(\   +/@  !4 $  !""@  0Q   $06  !%'0  1B0  $8K  !&-
M1CX  $5+  !$6   1&8  $1W  !$B0  0YT  $*T  ! T@  /^X  #[\ &\R
M  !@-   4S4  $@V   _-@  .#8  #,U   M-@  )C@  !\Z   8/0  $C\
M  M"   %1    $<"  !(!P  2@P  $L3  !,&0  3A\  $XG  !.,   3CH
M $U&  !,4P  3&,  $MS  !+A0  2YH  $NR  !(T0  1NX  $7] &DW  !;
M.0  3CH  $0Z   ].@  -SD  # Y   H.P  (#X  !A!   20P  "T8   5)
M    2P   $X   !/!   40D  %(.  !4%   5AL  %<B  !7*P  5S4  %9
M  !53@  55X  %1O  !4@0  4Y8  %.O  !1SP  4.X  $W^ &,\  !5/0
M2CX  $(^   [/0  -#T  "P_   C0@  &D4  !)(   +2P  !$X   !1
M4P   %8   !7    604  %L)  !=#P  7Q4  & <  !A)0  82\  & Z  !@
M2   7U@  %YJ  !>?0  79(  %RJ  !<R@  6>T  %C^ %U"  !10@  1T(
M $!!   Y00  +T,  "9'   <2@  $TX   I1   #5    %<   !:    7
M %\   !A    8@   &0$  !F"0  :!   &H6  !L'@  ;2@  &PT  !K00
M:E$  &ID  !I=P  :(P  &>E  !FP@  9N<  &/\ %='  !-1P  1D8  #]%
M   T2   *4P  !]0   45   "5@   %;    7@   &$   !E    9P   &H
M  !L    ;0   &\   !Q @  <P<  '4-  !W%@  >A\  'HK  !Y.   >$@
M '=;  !V;P  =84  '2>  !RN@  <=\  '#X %-,  !,2P  14H  #E-   M
M4@  (E8  !9;   *7P   &0   !G    :P   &X   !Q    =    '8   !X
M    >@   'P   !^    @    (,%  "%#   B!8  (H@  "*+@  BCX  (E0
M  "(90  AGL  (64  ""KP  @=$  '_O %)1  !+4   /E,  #)8   E7@
M&&(   MH    ;    '$   !U    >0   'P   !_    @0   (0   "&
MB    (L   "-    CP   )$   "4 @  EPH  )H5  ">(@  G3(  )M%  "9
M6P  F'(  )>*  "5I0  DL(  )'D %%6  !%60  -UX  "ID   <:@  #G
M  !V    >P   (    "#    AP   (H   "-    D    )(   "5    EP
M )H   "<    GP   *$   "D    J    *P'  "P%   M"(  +(W  "O3@
MKF4  *U^  "LEP  J;(  *?2 $M@   ^90  ,&L  ")R   3>0  !'X   "%
M    B@   (X   "1    E0   )@   ";    G0   *    "C    I0   *@
M  "J    K0   *\   "R    M@   +L   #!!P  R!0  ,HI  #&0@  Q5H
M ,9R  #'B@  PJ4  ,#! $5K   W<@  *7D  !J    *AP   (T   "2
MEP   )H   ">    H@   *8   "K    K@   +    "S    M@   +D   "\
M    OP   ,(   #&    RP   -$   #8    XP$  .D5  #G+@  YT<  .E@
M  #J>0  YY(  .6H /\   #_    _P   /\   #_  $ _P ) /\ %@#_ "$
M_0 L /P -@#Y $  ]0!( /( 3P#O %8 [ !< .H 8@#H &< Y0!M ., <P#A
M 'D W@"  -L B #8 )( U "? -  KP#, ,8 R #H ,4 _P"] /\ M #_ *P
M_P"G /\ I #_ /\   #_    ^P   /H   #Z    \@ % .X $@#K !T Z@ H
M .D ,0#F #L X@!# -X 2P#; %$ V !7 -4 7 #2 &$ T !G ,T ; #+ ',
MR !Z ,8 @@## (P P "8 +P IP"X +H M0#; +, ^@"P /\ IP#_ *$ _P"=
M /\ F@#_ /T   #W    \P   .\   #A    W    -0 # #2 !@ T  B ,\
M+ #/ #4 R@ ] ,8 1 ## $L P !1 +T 5@"[ %P N0!A +< 9P"U &T LP!T
M +  ?0"N (8 K "2 *D H "E +, HP#- *$ \ "? /\ FP#_ )8 _P"2 /\
MCP#_ /4   #M    Y    -4   #(    P    +P !P"Y !, MP = +8 )@"U
M "\ LP W +  /@"M $0 JP!* *D 3P"H %4 I@!: *0 8 "C &8 H0!M )\
M= "= 'X FP") )@ EP"6 *@ DP#  )  Y ". /\ C #_ (H _P"' /\ A0#_
M .H   #<    S    +L   "R    JP   *<  0"D  P H@ 7 *$ ( "A "@
MH0 P )X -P"< #T F0!# )< 2 "5 $P DP!2 )$ 6 "/ %X C0!E (P ;0"*
M '8 B "! (8 C@"% )T @P"S (( TP"  /8 ?P#_ 'T _P![ /\ >@#_ -L
M  #'    MP   *D   "@    F@   )8   "2  < D  1 (\ &@"/ "( C0 J
M (L ,0") #< AP ] (8 0@"$ $8 @P!+ (( 4 "  %8 ?P!> 'T 9@![ &\
M>@!Z '@ A@!V )4 = "I '( PP!Q .H <0#_ '$ _P!O /\ ;@#_ ,H   "W
M    I0   )D   "1    BP   (<   "#  , @0 + '\ % !^ !P ?0 D 'T
M*P![ #$ >0 W '@ / !V $$ =0!& ', 2P!R %  < !7 &X 7P!M &D :P!S
M &D ?P!G (T 90"@ &0 M@!C -H 8P#] &0 _P!C /\ 8P#_ +P   "G
MF    (T   "$    ?P   'H   !V    <P ' '$ #P!P !< ;P > &X )0!M
M "P :P Q &D -P!H #P 9P!! &8 1@!D $P 8P!2 &( 60!@ &0 7@!N %P
M>0!: (< 6 "9 %< K0!6 ,L 5P#S %< _P!8 /\ 5P#_ +    "<    C0
M ((   !Z    <P   &X   !J    9P " &4 "@!D !, 8@ : &( ( !A "<
M7P L %X ,@!= #< 6P \ %H 00!9 $< 6 !- %8 5 !5 %X 4P!I %$ = !/
M ($ 30"2 $P I0!+ +\ 3 #H $P _P!- /\ 3 #_ *8   "3    A0   'D
M  !P    :0   &,   !@    70   %L !@!9  X 6  5 %< ' !7 "( 50 H
M %0 +0!3 #, 4@ X %$ /0!/ $, 3@!) $T 4 !+ %H 20!D $< < !% 'T
M0P"- $$ GP!" +@ 0@#; $( ^ !" /\ 0@#_ )T   "+    ?0   '(   !H
M    8    %H   !7    5    %(  P!1  H 3P 1 $X & !. !X 30 D $L
M*0!* "\ 20 T $< .0!& #\ 10!% $, 30!! %8 /P!@ #T ;  [ 'D .0")
M #< F@ Y +  .0#. #@ [@ X /\ . #_ )8   "% 0  =P0  &L'  !A!P
M60<  %,&  !/!   3 (  $L   !)  8 2  - $< % !& !H 10 @ $, )0!!
M "L 0  P #\ -@ ] #P / !" #H 2@ X %, -@!= #0 :0 R '8 ,0"& #$
MEP P *H +P## "\ XP O /D +P#_ )$!  "!!@  <@D  &8+  !<#   5 T
M $T,  !)"P  10D  $,&  !" P( 00 ) $  $  ^ !8 /0 < #L (@ Z "<
M.  M #< ,P U #D - !  #( 2  P %$ +@!; "T 9P K '4 *@"# "@ DP G
M *8 )@"\ "4 V0 F /, )@#_ (T&  !\"P  ;@X  &$0  !7$0  3Q(  $D2
M  !#$0  0 \  #T-   ["P  .@@$ #H%"P X!!( -@09 #0$'P S!20 ,04J
M # &,  N!C< +08^ "L'1P I!U  )P=; "4'9@ C!W0 (0>" !\'D@ =!J0
M' 2Y !P"U  < .X '0#[ (@*  !Y#P  :A,  %X4  !3%0  2Q8  $06   _
M%0  .A0  #<3   U$@  - \  #,,!@ R"PT , L5 "X,&P M#"( *PTH "D-
M+P H#C8 )@X^ "0.1P B#E$ 'PY< !T/:  ;#W8 & Z% !8.E0 4#:8 $PRZ
M !,+TP 2"ND $@KV (4.  !U$P  9Q8  %H7  !0&   2!D  $$9   [&0
M-A@  #,7   P%@  +A4  "T3 0 K$P@ *A,1 "@4&  F%!\ )!4E "(5+  A
M%30 'Q4\ !T510 ;%D\ &19: !869@ 4%G0 $16$  X5E  ,%*8 "A.Z  D3
MU  )$NL "A'Y ((2  !R%@  8QD  %<:  !-&P  1!P  #T=   W'   ,QP
M "\;   L&@  *1H  "<9   E&04 (QD- "$:%0 ?&AP '1LB !P;*@ :&S$
M&!LZ !8;0P 4&TT $AM8  \;90 ,&W( "1N   <;D  %&J( !!FW  (8T0 #
M%^@ !!?V '\5  !O&0  8!P  %0=  !*'@  01\  #H?   T'P  ,!\  "P>
M   H'@  )1X  "$>   ?'@( '1\* !H@$@ 8(!D %R @ !4A)P 3(2\ $2$W
M ! A00 -(4L "B%5  @A80 %(6X  R%]  $@C@  'Z   !ZU   =SP  '.@
M !SU 'L8  !K'   71\  %$@  !'(0  /B(  #<B   Q(@  +2$  "DA   E
M(0  (2$  !TB   9)   %B0' !,F#@ 1)A8 #R8=  TG)  +)RL "2<T  <G
M/0 &)D< !"92  $F7@  )FP  "9[   FC   ))X  ".S   BS0  (>D  "#V
M '@<  !H'P  6B$  $XC  !$)   .R4  #0E   O)   *B0  "8D   B)
M'R0  !HF   5*   $2H%  PK#  )+!0 !RP:  4L(0 #+"@  2PP   M.0
M+$,  "Q.   K6P  *VD  "MX   KB@  *YT  "BR   GS   )N@  "7X '0?
M  !D(P  5B4  $LF  !!)P  ."@  #$G   L)P  *"8  "0F   @)@  &R@
M !8J   2+   #"X$  8Q"@ ",1$  #(7   R'@  ,B4  #(M   S-0  ,S\
M #)+   Q6   ,68  #%V   PAP  ,)L  "ZQ   MS   *^H  "OY ' C  !@
M)@  4B@  $<J   ]*@  -2H  "\J   J*0  )BD  "(I   =*@  %RP  !(O
M   ,,0  !S,$  $U"0  -@X  #<5   X&P  .2(  #DI   Y,@  .3L  #E'
M   X5   -V,  #=S   WA0  -ID  #:P   TS0  ,NH  #'[ &LG  !<*@
M3BP  $,M   Z+@  ,RT  "TL   I*P  )"P  !XM   8+P  $S(   PT   '
M-@   3D"   [!P  / P  #X2   _%P  0!X  $ E  ! +@  03@  $%#   _
M40  /F   #UP   ]@P  /9<  #VO   [S0  .>P  #C\ &8K  !7+P  2C
M $ Q   W,0  ,3   "PO   F+P  'S$  !DS   3-0  ##@   <Z   !/0
M #\!  !!!0  0PD  $0.  !&%   2!H  $DA  !)*@  23,  $D^  !(3
M1UL  $5M  !%?P  190  $2L  !$S   0>T  #_^ & Q  !2,P  1C0  #TT
M   U-   ,#(  "HR   B-   &C<  !0Y   ,/   !C\   !"    1    $<
M  !) @  2@8  $P*  !.$   4!8  %(<  !3)0  4RX  %,Y  !21@  458
M $]H  !.>P  3I   $VI  !-R   3.T  $G_ %HV  !-.   0C@  #HX   T
M-@  +C8  "4X   <.P  %#X   Q!   %1    $<   !*    30   $\   !2
M    5 $  %8%  !8"@  6A   %T6  !?'@  7B@  %XS  !=0   6U   %IB
M  !9=P  6(P  %>D  !7PP  5NH  %7_ %0\  !)/   /SP  #D[   R.@
M*#T  !Y    51   #$<   5+    3@   %$   !4    5@   %D   !;
M70   %\   !B!0  9 H  &<1  !I&   :R(  &HM  !I.@  :$D  &9;  !E
M<   9(8  &.>  !BNP  8>0  &'] $]!  !%00  /D   #@_   M0@  (D4
M !=*   ,3@  !%$   !5    6    %L   !>    80   &0   !F    :
M &L   !M    ;P,  '()  !U$0  =QH  '@E  !W,@  =4$  '14  !S:0
M<8   '"8  !OLP  ;=L  &WX $M&  !$10  /D0  #)'   F2P  &E    Y5
M   "6@   %T   !A    9    &<   !K    ;@   '$   !S    =0   '<
M  !Y    ?    'X   ""!P  A!   (<;  "'*   AC<  (1)  "#7@  @G8
M (".  !^J0  ?,P  'OO $I*  !$20  -TT  "M2   >5P  $EP   1A
M9@   &H   !O    <@   '8   !Y    ?    '\   "!    A    (8   "(
M    B@   (T   "0    DP8  )<1  ";'0  FBL  )D^  "84@  EFH  )2"
M  "2G0  D;L  (W@ $I/   ]4P  ,%@  "-?   59   !FH   !P    =@
M 'H   !_    @@   (4   ")    C    (X   "1    E    )8   "8
MFP   )X   "A    I0   *D$  "M$   LAX  + Q  "N1@  K%X  *IW  "H
MD   IZL  */* $19   V7P  *64  !IL   *<P   'H   "     A0   (H
M  ".    D@   )4   "8    FP   )X   "A    I    *8   "I    K
M *\   "R    MP   +P   ## 0  RPT  - @  #+.   QE(  ,1J  ##@P
MPYP  +VW #UE   O;   (7,  !%[   !@@   (D   "/    E    )@   "<
M    GP   *,   "F    J    *L   "N    L0   +0   "W    NP   +X
M  #"    QP   ,X   #5    X    .<2  #G*@  X4<  .-?  #D=P  Y8\
M .&I /\   #_    _    /H   #[    _@ ( /\ $P#_ !\ _@ J /X - #\
M #T ^ !% /4 30#R %0 [P!: .T 8 #J &4 Z !K .4 <0#C '@ X !_ -T
MB #: ), U@"@ -( L0#. ,P R #Q ,0 _P"V /\ JP#_ *, _P"@ /\ G #_
M /X   #X    ]    /,   #T    \  ! .T #0#K !H Z@ D .H +@#H #@
MXP!  -\ 1P#< $T V0!3 -8 60#3 %X T0!D ,X :@#, '  R0!X ,< @ #$
M (H P "6 +T IP"Z +T M@#B +$ _P"G /\ G@#_ )@ _P"6 /\ DP#_ /8
M  #O    ZP   .<   #=    U@   -( " #0 !0 S@ ? ,T *0#- #$ R0 Y
M ,8 0 ## $8 P !+ +P 4 "Y %4 MP!: +0 80"R &@ KP!P *T > "J ((
MJ "- *8 G "D *\ H@#. *$ ]P"; /\ D@#_ (P _P"* /\ B #_ .P   #D
M    W@   ,X   #"    O    +@  @"U  X M  9 +0 (@"R "H K@ R *L
M.0"H $  I@!% *4 2@"C $\ H@!4 *  60"? %\ G0!F )L ;P"9 'H E@"&
M )0 DP"2 *0 CP"] (T Y0"+ /\ A@#_ ($ _P!^ /\ ?0#_ .    #6
MP0   +4   "L    I@   *(   "@  @ G0 2 )L &P"; "0 FP L )@ ,P"6
M #D E  _ )( 1 "0 $D C@!. (T 4P"+ %D B0!? (@ 9P"& '  A !^ ((
MBP"  )L ?P"P 'T T@![ /P > #_ '0 _P!S /\ <@#_ -$   #     K@
M *(   ":    E    )    ",  , B0 , (D %0"( !X AP E (8 + "$ #,
M@@ Y ($ /@!_ $, ?@!( 'T 30![ %, >@!9 '@ 8 !W &D =0!T ', A !P
M ), ;@"F &P P0!K .\ :@#_ &< _P!G /\ 9@#_ ,,   "L    G0   ),
M  "+    A0   (    !\    >@ ' '@ $ !W !@ =P ? '< )@!U "T <P S
M '( . !Q #T < !" &\ 2 !M $T ; !4 &H 6P!I &, 9P!M &4 >P!B (P
M8 "= %X M !< -\ 7 #_ %L _P!< /\ 6P#_ +,   "?    D0   (8   !]
M    =P   '$   !N    :P " &H "@!I !, :0 : &D (0!H "@ 9P N &4
M,P!C #@ 8@ ] &$ 0@!? $@ 7@!. %P 50!; %X 6@!G %@ <P!6 (4 5 "6
M %$ JP!/ ,X 3P#V $\ _P!1 /\ 40#_ *8   "4    A@   'L   !R
M:@   &4   !A    7P   %X !@!=  X 70 6 %P ' !< "( 6@ H %@ +0!7
M #( 5@ X %0 /0!3 $, 4@!) %  4 !/ %D 30!B $P ;@!* '\ 2 "/ $8
MH@!$ ,  0P#J $8 _P!' /\ 1P#_ )P   "+    ?@   '(   !G    8
M %H   !7    50   %,  P!2  H 4@ 1 %$ %P!0 !T 3P C $X * !, "T
M2P S $D . !( #X 1P!% $4 3 !$ %0 0@!> $$ :0 _ 'H /0"* #H G0 Y
M +8 . #= #P _@ \ /\ /0#_ )0   "$    =@   &H   !?    5P   %(
M  !.    3    $H   !)  8 2  , $< $P!& !D 1@ ? $0 ) !" "D 00 N
M #\ -  ^ #H / !! #L 2  Y %  . !: #8 9@ T '4 ,@"% #$ F  P *\
M,0#1 #( ]  S /\ ,P#_ (X   !^    <    &,"  !9 P  40,  $L"  !'
M    1    $(   !   , /P ) #X #P ] !4 /  : #L (  Y "4 .  J #8
M+P U #8 ,P ] #( 1  P $T +P!7 "T 9  K '$ *@"! "D DP H *D *0#$
M "D Z0 I /\ *0#_ (@   !Y 0  :@4  %X'  !4"   2P@  $4(  ! !P
M/ 4  #H#   X 0  -P & #8 "P U !$ -  7 #, '  Q "$ +P F "X +  M
M #( *P Z "H 00 H $H )P!4 "4 80 C &\ (@!^ "$ D  @ *, ( "[ !\
MW0 ? /8 'P#_ (0!  !T!@  9@@  %D+  !/#   1PT  $ ,   Z#   -@L
M #,)   Q"   , 8# # #"  N 0T +0$3 "L!&0 J !X *  D "<!*0 F #
M) $W ",!/P A $@ ( %3 !X!7P < &T &P!\ !D C  8 )\ %P"T !8 T0 5
M .T %@#_ ( %  !P"0  8@P  %8.  !+$0  0Q$  #P1   V$0  ,A   "X/
M   L#0  *@P  "D*!  I" D )P<0 "4&%@ D!QL (@<A "$()P @""X '@@V
M !P(/@ ;"$@ &0E2 !8(7@ 4"&P $@A[ ! (BP .!IT #06Q  T#RP - >@
M#@#Y 'T)  !M#0  7A   %(2  !(%   /Q4  #@5   R%   +A0  "H3   G
M$P  )1(  ",1 @ B#@4 (0X+ " -$@ >#AD ' X? !L.)@ 9#BX %PXV !4/
M/P 3$$D $!!4  T08  *$&P "1![  <0BP &#IT ! VP  ,,R0 ""^,  PGS
M 'H,  !I$0  6Q,  $\5  !%%P  /!@  #47   O%P  *A<  "86   C%@
M(14  !\5   =% ( &Q0' !D4#@ 7%18 %A4= !05)  2%2L $!8T  T6/0 +
M%D8 "190  867  $%FD  A9X   6B   %9L  !.N   2QP  $>,  !'S '<0
M  !F%   6!8  $P8  !"&@  .1H  #(:   L&@  )QH  ",9   @&0  '1@
M !L8   8&0$ %1D$ !,:"P 0&Q, #AL:  P;(0 *&R@ "!LO  8;.  $'$(
M AM-  $;60  &V8  !MV   ;A@  &ID  !FN   7Q@  %N,  !7U ',3  !C
M%P  51D  $D;   ^'0  -AT  "\=   I'   )1P  "$<   >&P  &QL  !@;
M   5'   $!X#  P?"0 )(!$ !B 7  4@'@ #(20  2$L   A-0  (3X  "%)
M   @5@  (&0  "!T   ?A0  'Y@  !ZM   <QP  &N4  !KV &\6  !?&@
M41P  $8>   ['P  ,Q\  "P?   G'P  (AX  !\>   <'0  &1T  !4>   1
M(   #"(#  <D"  #)0X  "45   F&P  )B(  "8I   F,@  )SL  "=&   F
M5   )6(  "5R   DA   ))<  "2M   AR   '^4  ![X &L:  !;'0  3A\
M $(A   X(@  ,"(  "HA   D(0  (2   !T?   :'P  %B   !(B   ,)
M""8#  ,H"   *@P  "L3   L&   +!\  "PF   L+P  +3@  "U#   M3P
M*U\  "IP   J@@  *98  "FL   HR0  )N@  "3Y &<>  !7(0  2B,  #\E
M   U)0  +20  "<D   C(P  ("(  !PB   7(P  $B4   TG   (*0   RL#
M   M!P  +PH  #$0   S%@  ,QP  #,C   T*P  -#4  #1    T3   ,EP
M #%M   P?P  ,)0  "^K   OR0  +.L  "K\ &(B  !3)0  1B<  #LH   R
M*   *R<  "8F   B)0  'B0  !@F   3)P  #2H   @L   #+P   #(!   T
M!   -@@  #@,   Z$@  .Q@  #L?   [)P  .S$  #P\   \2   .U<  #EI
M   W?0  -Y(  #:J   VR0  ->P  #+_ %TG  !.*0  0BL  #<K   O*P
M*2D  "4H   @*   &BD  !0K   -+@  !S$   (S    -@   #@    [ @
M/04  #\)  !!#@  0Q0  $0;  !$(P  1"T  $0X  !$1   1%(  $%E   _
M>0  /XX  #ZG   ]Q@  />P  #O_ %<L  !*+@  /B\  #0O   M+0  *2L
M ",K   <+0  %2\   XR   '-0   3@    [    /0   $    !"    10(
M $<&  !)"@  2Q   $X6  !.'@  3B@  $XS  !./P  3DT  $M@  !)=0
M1XL  $>D  !&Q   1>L  $7_ %$Q  !%,@  .C,  #(R   M,   )R\  !XQ
M   6-   #C<   <Z    /@   $$   !#    1@   $D   !+    3@   % "
M  !2!@  50L  %<2  !:&0  6B(  %HM  !9.@  64@  %A9  !5;P  4H8
M %*>  !1O   4.8  %#_ $PV  ! -P  .#8  #(T   K,P  (38  !<Y   /
M/0  !T    !$    1P   $H   !-    4    %,   !6    6    %H   !=
M 0  8 4  &(+  !F$P  :!L  &@F  !H,@  9T$  &51  !B:   8(   %Z8
M  !=M0  7-\  %O\ $<[   ].P  -SD  # X   E.P  &C\   Y#   &1P
M $L   !/    4P   %8   !9    7    %\   !B    9    &<   !I
M;    &\$  !R"P  =A0  '<?  !V*P  =3H  '-*  !P8   ;G@  &R2  !K
MK   :=,  &CV $-    ]/P  -CT  "M    >10  $DH   5/    4P   %@
M  !<    7P   &(   !E    :0   &P   !N    <0   ',   !V    >0
M 'P   !_ P  @PL  (86  "'(@  A3$  (-"  "!5P  ?V\  'R*  ![I
M><8  '?M $-$   \0P  ,$<  "1+   740  "5<   !<    8    &4   !I
M    ;    '    !S    =P   'H   !\    ?P   ((   "$    AP   (H
M  ".    D0$  )4*  "8%P  F"4  )8W  "42P  DF,  )!]  ".EP  C+4
M (K< $-)   V30  *5(  !M8   -7@   &0   !J    ;P   '0   !X
M?    (    "$    AP   (H   "-    D    )(   "5    F    )L   "?
M    HP   *<   "L"@  LA@  +$I  "O/@  K%4  *EO  "FB0  HZ4  *'$
M #Q3   O60  (6   !)F   ";0   '0   !Z    @    (4   "*    C0
M )$   "4    F    )L   ">    H0   *0   "G    J@   *T   "Q
MM@   +P   ##    S H  -09  #0+P  RT@  ,9B  #$>P  P94  +ZO #5?
M   G9@  &&X   =V    ?0   (0   "+    D0   )4   ":    G0   *$
M  "D    IP   *L   "N    L0   +4   "X    O    ,$   #%    RP
M -(   #;    Y    .X(  #P(   ZSL  .57  #D<   Y(@  ..@ /X   #Y
M    ]0   /0   #U    ^  % /P $0#_ !P _P G /\ ,0#^ #H ^P!" /@
M20#V $\ \P!4 /  6@#M %\ Z0!D .8 :@#C '( WP!Z -P A #8 (\ U "<
M -  K #- ,< RP#P ,0 _P"P /\ HP#_ )L _P"5 /\ DP#_ /<   #Q
M[    .L   #M    [P   .T "0#K !8 ZP A .P *@#I #0 X0 \ -L 0P#8
M $D U !. -( 5 #0 %D S@!> ,L 8P#) &H QP!P ,0 >0#! (4 O@"4 +H
MI "W +D LP#@ +  _P"B /\ F #_ )$ _P", /\ B0#_ .X   #G    X@
M .    #:    U    ,\ ! #. !  RP : ,< ) #( "T Q0 U ,$ / "^ $,
MO !( +@ 30"V %, LP!8 +$ 70"O &, K !J *H <@"H 'L I@"& *0 F0"A
M *X GP#- )T ]P"5 /\ B@#_ (4 _P"" /\ ?P#_ .,   #:    U    ,@
M  "^    N    +0   "N  D K@ 4 *X '@"M "8 J@ O *< -@"D #P H@!"
M *$ 1P"? $P G@!2 )P 5P"; %T F0!D )< :P"5 '4 DP!_ )$ C "/ *(
MC "^ (D Z "& /\ ?P#_ 'D _P!V /\ = #_ -4   #*    NP   +    "H
M    H@   )L   "9  , EP - )4 %P"6 "  E@ H )0 +P"1 #8 D  \ (\
M00". $< C0!, (L 40"* %< B !> (< 90"% &X @P!Y ($ A0"  )0 ? "S
M 'D UP!V /X <0#_ &P _P!J /\ : #_ ,8   "U    IP   )T   "4
MC0   (D   "%    A  ( (, $0"$ !H A0 C (0 *@"" #  @  V 'X .P!]
M $  >P!% 'D 2P!X %  =@!7 '4 7@!S &< <0!R &\ ?@!N (T ;0"A &H
MQ0!F /( 8P#_ %\ _P!= /\ 70#_ +<   "E    EP   (P   "$    ?0
M '@   !U    =  # '4 # !T !4 =  < '0 (P!R "D <  N &X - !L #D
M:P ^ &D 1 !H $H 9@!1 &0 6 !B &$ 80!K %\ =P!> (8 70"7 %L MP!9
M .( 5@#_ %, _P!2 /\ 4@#_ *D   "8    B@   '\   !U    ;@   &D
M  !G    9@   &4 !P!D  X 9  6 &0 '0!C ", 80 H %\ +0!= #, 7  X
M %H /0!9 $, 5P!) %8 4@!4 %L 4@!E %$ <0!0 '\ 3P"0 $T K !+ -
M20#Y $< _P!' /\ 1P#_ )T   "-    ?P   ',   !I    80   %T   !;
M    60   %<  @!7  D 5@ 1 %8 %P!6 !T 5  B %( * !0 "P 3@ Q $P
M-P!* #P 20!# $@ 2@!' %0 1@!@ $0 :P!# 'H 0@") $  I  _ ,( /0#N
M #P _P \ /\ /P#_ )0   "$    =@   &D   !?    5P   %,   !/
M30   $P   !+  4 2@ + $D $@!( !@ 1@ = $0 (@!# "< 00 L $  ,@ ^
M #@ /0 ^ #L 10 Z $X . !: #< 9@ W '0 -@"$ #0 G  S +< ,@#D #(
M_P R /\ -@#_ (P   !]    ;@   &$   !7    4    $H   !&    0P
M $$   !   ( /@ ' #P #0 \ !, /  8 #H '@ X ", -P H #8 +0 T #,
M,P Z #( 00 P $H +P!6 "X 8@ L '  *P"  "H E@ I *X *0#6 "D ^P K
M /\ +0#_ (8   !V    :    %L   !1    20   $(    ]    .@   #<
M   U    -  $ #, "0 S  X ,P 4 #$ &@ P !\ +@ D "T *0 L #  *P V
M "D /@ H $8 )P!2 "4 7@ D &P (P!^ "$ D0 A *@ (0#) "$ \@ B /\
M) #_ ($   !Q    8@   %8"  !, P  0P0  #P$   W P  ,P(  "\"   M
M    +  " "P !@ K  L *P 1 "H %@ H !L )P @ "8 )@ D "P (P S "(
M.P A $, 'P!/ !X 6P = &D &P!Z !H C  : *, &0"_ !D Y0 9 /\ &@#_
M 'P   !L    7@0  %$&  !'"   /@@  #<(   Q"   +0@  "D'   G!@
M)@0  "4"!  D  @ (P , ", $P A !@ (  = !\ (P > "D '  P !L .  :
M $$ &0!- !< 60 6 &< % !W !( B0 1 )T $0"T !$ U@ 1 /4 $ #_ '@
M  !H!   6@@  $T*  !#"P  .@P  #,,   M#   * P  "4+   B"@  ( D
M !\( P >!@8 '04* !P$#P ;!!4 &@0: !@$(  7!"8 %@0N !4$-@ 4 T
M$@)+ !$"5P . V0 "P-T  D"A0 ( 9@ " "N  @ RP ( .P " #_ '4$  !E
M!P  5@L  $H-   _#P  -A   "\0   I$   )1   "$.   >#@  ' T  !H,
M @ 8"P4 %PH' !<)#  5"1( % D8 !,)'@ 1"20 $ DL  X)-0 ,"3\ "@E*
M  @*5@ %"V,  @IS   *@P  "98   >J   %PP   ^(   #X '$'  !A"@
M4PT  $<1   \$@  ,Q,  "P3   F$P  (A(  !X2   ;$0  &!$  !80 @ 4
M$ 0 $@\' !$."0 .#@X #0\5  L0'  *$", "! J  <0,P %$#T !!!(  (1
M5   $6$  !!Q   0@@  #I4   VJ   +P@  "M\   GS &X*  !=#0  4!$
M $04   Y%0  ,!4  "D5   C%0  'Q4  !L4   8%   %1,  !,3 P 1$@4
M#Q('  L3"  )% P !Q43  85&0 $%2   A8G  $6+P  %CH  !9%   640
M%5\  !5O   5@0  %)0  !.J   1Q   #^(   WV &H-  !:$0  310  $ 7
M   V%P  +1@  "88   A%P  '1<  !D6   6%@  %!4" !(4!  /%04 "Q8%
M  @7!P $&0H  1H0   :%@  &QT  !LD   ;+0  &S8  !M"   ;3@  &UP
M !IM   9@   &90  !BJ   7Q0  %>4  !/X &81  !7%   21<  #T:   S
M&@  *QH  "0:   ?&0  &Q@  !<8   5%P  $Q8# ! 7 P ,& , "!D$  0;
M!@  '0D  !\-   @%   (!L  " B   A*@  (3,  "$_   @3   (%H  !]L
M   >?P  '9,  !VJ   <Q@  &^@  !G[ &(5  !3&   1AH  #H<   P'0
M*!P  "(<   =&P  &1H  !<9   4& $ $!D   P:   (' $ !!X"   @!
M(@<  "4+   F$@  )A@  "<?   G)P  )S$  "<[   G20  )U<  "9H   C
M?0  (Y$  "*I   AQP  (>L  ![^ %X8  !/&P  0AX  #8?   M'P  )1\
M " >   <'0  &1L  !8;   1'   #!T   @?   #(0   ",    F P  * 4
M "L)   M#@  +14  "X<   N)   +BX  "XX   N1@  +E0  "UD   J>@
M*)$  "BH   GQP  )^P  "?_ %D<  !+'P  /B(  #,B   J(@  (R$  !\@
M   ;'@  %QX  !,?   -(   ""(   ,E    )P   "D    L 0  +P,  #$'
M   T"P  -A(  #89   V(0  -BH  #8U   V0@  -E   #9@   R=P  ,(X
M "^F   NQ@  +NT  "[_ %0A  !&)   .28  "\E   H)   (B,  !XA   :
M(0  %"(   TD   ()@   BD    L    +@   #$    S    -@$  #D%   [
M"0  /@\  #\6   _'@  /R<  #\Q   _/@  /TP  #]<   ]<   .8H  #:D
M   VPP  ->T  #7_ $\F  !!*   -2D  "TI   F)P  (B4  !TD   6)@
M#B@   @K   "+0   #$    S    -@   #D    \    /P   $$"  !$!@
M1PH  $H1  !*&0  2R$  $HL  !*.0  2D<  $E7  !(:@  0X4  $"@  !
MO@  /^H  #[_ $DK   \+0  ,BT  "LK   F*0  ("@  !@J   1+   "#
M  $S    -P   #H    ]    0    $,   !&    20   $L   !. 0  404
M %0+  !7$P  5QP  %8F  !6,P  5D$  %51  !49   3W\  $R:  !*MP
M2>4  $C_ $,Q   X,@  ,#   "HN   D+0  &R\  !(R   )-@   3H    ^
M    00   $0   !(    2P   $X   !1    4P   %8   !9    7 $  %\&
M  !B#   918  &4@  !D+   9#L  &-+  !A70  77@  %F3  !6L0  5ML
M %7] #\V   U-0  ,#,  "DQ   >-   %#@   H\    00   $4   !)
M30   %    !3    5P   %H   !=    7P   &(   !E    9P   &L   !N
M!P  <@\  '09  !T)@  <S0  '-#  !Q50  ;6\  &F)  !FJ   9<P  &3U
M #LZ   U.   +S<  ",Z   6/P  "D0   !(    30   %(   !6    6@
M %X   !A    90   &@   !K    ;@   '$   !T    =P   'H   !^
M@@4  (</  ")'   ARH  (4[  ""3@  ?68  'J   !WG@  =;T  '3I #L^
M   U/   *4   !M%   ,2P   %(   !6    6P   &    !D    :    &L
M  !O    <P   '8   !Y    ?    '\   ""    A0   (D   ",    D0
M )8&  ":$@  FB   )<Q  "41   D5P  (YV  "+DP  B+   (;9 #M"   O
M1@  (4P  !-2   $60   %\   !E    :@   &\   !S    =P   'H   !^
M    @@   (8   ")    C    (\   "1    E0   )@   "<    H0   *8
M  "J!0  KQ0  *XD  "J.   J$\  *5I  "BA0  GZ   )R_ #5-   H4P
M&5D   EA    9P   &X   !T    >@   '\   "$    B    (P   "1
ME0   )@   ";    GP   *(   "E    J    *P   "Q    MP   +T   #%
M    S00  -85  #1*   S$   ,=:  #!=@  O9   +FJ "Y9   @80  $&@
M  !P    =P   '\   "&    C    )$   "6    F@   )X   "B    I@
M *H   "N    L@   +4   "Y    O@   ,,   #)    T    -H   #C
M[    /0$  #Y%P  ]#   .],  #I9P  YH$  ..9
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M[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0
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MK8KYQJV*^<:MBOG_JQT#_ZTH"O^L,A;_JCPF_ZU$-_^W3$C_O%1=_K]<<_K
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M@/2JL8#TJK& ]*JQ@/2JL8#TJK& ]*JQ@/2JL8#TJK& ]*JQ@/2JL8#TJK&
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MP&S8?<!LV'W ;-A]P&S8?<!LV'W ;-A]P&S8?<!LV'W ;-A]P&S8?<!LV'W
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MTF&YG<UBPI+(9,J&Q&;2>\!JV'; >-EUP(78=<"%V'7 A=AUP(78=<"%V'7
MA=AUP(78=<"%V'7 A=AUP(78=<"%V'7 A=AUP(78=<"%V'7 A=C_J!D"_ZDE
M"/^I+Q/_K#@>_+E */+'1CCIUDM*X>A-8MSQ4'K+ZU:._^)]$$E#0U]04D]&
M24Q% ! 5N^);GJW;7:J@U%^UE,]@OHK+8L5_QV/,=L1HTG'$=-)PQ(#2<,2
MTG#$@-)PQ(#2<,2 TG#$@-)PQ(#2<,2 TG#$@-)PQ(#2<,2 TG#$@-)PQ(#2
M<,2 TG#$@-+_J1D"_ZHE"/^J+Q+_L#@<][U )NS-1C3AWTI'V>U,8M#T3WC
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M5%],_U1?3/]47TS_5%],_U1?3/]47TS_5%__GA@$_YTB"O^;+!7_EC8B_YI
M+_^B23W_I%1-_Z->7_^A:''^G'&"]Y9ZDO"/@J#KAXFKYX&0M.1\F+GC>I^\
MXGJHON%ZLK_3=+/!Q&RRPL!JLL/ :K+#P&JRP\!JLL/ :K+#P&JRP\!JLL/
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MQ&RRPL!JLL/ :K+#P&JRP\!JLL/ :K+#P&JRP\!JLL/ :K+#P&JRP\!JLL/
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M]Y9ZDO"/@J#KAXFKYX&0M.1\F+GC>I^\XGJHON%ZLK_3=+/!Q&RRPL!JLL/
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M2_]<8DO_7&)+_UQB2_]<8DO_7&+2PP( Q]<$ +G[%P.J_QP+F_\>%(W_(1Z
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M@*W)AX"RPX> LL.'@++#AX"RPX> LL.'@++#AX"RPX> LL.'@++#AX"RPX>
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M_Y8<"/^3)1'_FRX5_Z8W&O^O/B/YN44P\L-+0.O.4%+CU59GV=)<?,S*8XW
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M7=N)V5W;B=E=VXG97=N)V5W;B=E=VXG97=N)V5W;B=E=VXG_B! &_X4:#/^
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M4$'_;T]!_V]/0?]O3T'_;T]!_V]/0?]O3T'_;T]!_V]/0?]O3T'_;T_.N
MP\D! +;9  "I_ D!F_\1!H[_%0V"_Q@5=_\<'6S_("5A_R0M6?\G,U+_+#A-
M_S \2?\T/T;_.$%#_SQ"0?] 0T#_1$0^_TA$/?]+1#S_4$0[_U1$.O]:0SG_
M7T,Y_U]#.?]?0SG_7T,Y_U]#.?]?0SG_7T,Y_U]#.?]?0SG_7T/$P@$ N-(
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MEGJHE8]^L8R)A+B'AX^[A(B=NX.)K+M_A[>[>H*YN7R!OK%\@,*L?(#"K'R
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M2H3U0UAZ]4=D</1+;F;T3W=>]%1]6/);@57R9()4\G""4_)\@E+SB8%2\Y>
M4?2F?U#TN'Y/]<=]3_7'?4_UQWU/]<=]3_7'?4_UQWU/]<=]3_7'?4_UQWW_
ME D!_Z$, -JT @#0Q04 R-@' +SV(@6Q_BP/I?XR')G^-BJ._CDXA/X\1'K^
M/U!O_4);9OU&8U[^2VI8_5%O5/M8<E+Z8'-0^FES3_IT<T_[?W).^XMQ3OR8
M<$W]J&]-_;5N3?VU;DW]M6Y-_;5N3?VU;DW]M6Y-_;5N3?VU;DW]M6[_F <
MVZP  -"\ @#'S00 O/(. +'_(0>E_R@0F/\L'(W_,"B"_S0T>/\W/F[_.DAE
M_SU17/] 6%;_15U2_TQ@3_]38TW_6F1+_V)D2_]J9$K_<V-)_WUB2?^(84C_
MEV!(_Z%@2/^A8$C_H6!(_Z%@2/^A8$C_H6!(_Z%@2/^A8$C_H6#DI   T;4
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M.C+_8CHR_V(Z,O]B.C+_8CHR_V(Z,O]B.C+_8CK P@  L]   *7;  "7ZP
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M4T/_LE-#_[)30_^R4T/_LE-#_[)30_^R4T/_LE/:I   S+0  ,+# 0"WT0
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MYF"%=^-?D'OA7II\WUZC?MY=K7_<7KB VU_&@-I@V(#27N* RE_D?,1@Z'?
M8>MRNV+O;;MB[VV[8N]MNV+O;;MB[VV[8N]MNV+O;;MB[VW_;@T)_V@7$/]G
M'17_=",5_WTL%_^"-!W_A3TE_89&,/>&3SWQ@5I+['IE6^9R;FGA:7=VW&.
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M_X4J$_^+,QC^CSL?]I)$*N^33#?HD%=&X8I@5MF":&?1>7!VRG%W@L1L?XK
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MB7V:HH=]J**&?K>AA'[)H8%[S)Z >M"7@'G5D(!YUI" >=:0@'G6D(!YUI"
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M<$W4ZG!-U.IP3=3J<$W4ZG!-U.IP3=3J<$W4ZG#_A0,"]9@! ->H  #-M@$
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MR6A*V.-G2]3Q94O.]&-+SO1C2\[T8TO.]&-+SO1C2\[T8TO.]&/_A@  WI@
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M/3K_SCPZ_\X\.O_./#K_SCPZ_\X\.O_./#K_SCS/I   Q+(  +J^  "NR@
MH=,  )7;  "*] 8!@?\0!7?_& QM_QT39/\B&UO_)B)3_RLI3/\O+T;_-#-!
M_SHV/?] .#K_1SDX_TXY-O]7.#7_83@T_VPW,O]Y-3'_AC0P_Y,S,/^A,C#_
MK3$P_ZTQ,/^M,3#_K3$P_ZTQ,/^M,3#_K3'%K@  O+H  +#'  "CT   E=@
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MA*"08X6PCV*&Q(YBAMJ+8X/>A6. XH!C@.-_8X#C?V. XW]C@.-_8X#C?V.
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M64G+_%=)R?U72<G]5TG)_5=)R?U72<G]5TG)_5?UA@  V9<  ,RE  ##L
MNKH  *_$  "DS0( F=8& )+B&0&*XR<(@>(P$WCA-R!NX#TM9-]!.5O=1D13
MW4M-3=U24DK=7%1(WFA42-]V4T?@A5%'X)501N&G3T7BNDU$X]5,1.'N2T/@
M_$I#W_]*0]__2D/?_TI#W_]*0]__2D/?_TK>CP  T)\  ,6L  "\MP  LL$
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M)RO_N2<K_[DG*_^Y)RO_N2?!K@  N+D  *S$  "?S   D=,  (3:  !XX0
M;_<  F;_!P9=_PT+5?\3$4W_&!9&_QT;0/\A'SK_)B(V_RLD,O\Q)B__-R8L
M_SXG*O]%)BC_3B8F_U<E)/]B)"+_;B,A_WHB'_^&(1[_E2 >_Y@?'O^8'Q[_
MF!\>_Y@?'O^8'Q[_F!^ZM@  K\(  *'*  "3T0  A=@  'C?  !LY0  8OD
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M _Z"! #CC@  UI<! ,^? P#)I@( OZH: +>J, >NJ#X4I:5((YVB4#.5GE=
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M;%2;\FE4F/-G5)CS9U28\V=4F/-G5)CS9U28\V?_;P "]H(  -J/  #0FP
MQZ0  +ZL  "ULP  J[D& *2\(@&<NS(*E+D^&(RW1B:$M4PT>[)207*O5DQI
MK5I88*M?85FI9FA4J&]L4JA[;%&IB&M1JIAJ4*JH:$^JNV=/J]-E3ZKK8T^H
M]V%0I/E?4*3Y7U"D^5]0I/E?4*3Y7U"D^5__=@ !X8<  -25  #*H   P:H
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M/D#6_SY UO\^0-;_/D#6_S[9CP  RYX  ,"K  "XM   K;T  *+%  "6RP
MBM,! '_=!@!ZZ!D#<N@D"FGH*Q-@YS$=5^<V)D_F/"])YD(U1.=*.4'G5#M
MZ%\[/^EK.C[I>3@^ZH@W/>N9-CWLJS0\[, S.^W;,COL\3$ZZ?\Q.NG_,3KI
M_S$ZZ?\Q.NG_,3KI_S'/F0  PZ<  +JR  "PO   I,0  )?+  "+T0  ?]@
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M@1.NO@  H<8  )+-  "#U   ==L  &CA  !<YP  4>P  4G\  -!_P &.?\
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M<EU][FY>>_)I7GKR:%YZ\FA>>O)H7GKR:%YZ\FC_80 %_W(  >F   #8B@
MT),  ,B9  # GP  MZ(3 *^C*@.HHCH-GY]$&YB<32F0F50VB9590H&27DYZ
MCF)9<8MF8VB(:FQAA7!T7(1Z=UJ$AG=9A)1V6(6C=5>%M'-7ALIR5X;E;UB%
M\&M8@O-G6('T9EB!]&98@?1F6('T9EB!]&;_90 $_G8  -Z$  #4C@  RY<
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M4TZ@_U-.H/]33J#_4TZ@_U/Y=@  W(8  ,^3  #%G@  O*8  +.M  "ILP
MG;@  ).[$ ".O28"A[PT"X"Z/1=XN40C<+=*,&>U3SM>LU-%5[%935&P8%--
ML&E53+!U54NP@U1+L9%32K&B44FQLU!)LLM.2+'F34BO]DM(KO]*2*[_2DBN
M_TI(KO]*2*[_2DBN_TKD?@  U(T  ,F:  "_I   MZP  *VS  "BN0  EKX
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M)C;B_R;*F0  OZ8  +:P  "LN0  H,   )/%  "'RP  >]$  '#8  !GZ0<
M8>\5!%KO'0I2\"002_ J%T3P,!T^\#<A.O ^)#?Q1R4U\E$E-/-<)#/S:2,R
M]'<B,?2'(3#UF!\O]:L>+_; '2[WV1PN]_$;+O;U&B[V]1HN]O4:+O;U&B[V
M]1K!I   N:\  *^X  "COP  EL8  (C+  !\T0  <-<  &7>  !=\0,!5OP-
M!5#\%0I)_1L/0OTA%#O])Q@V_BT;,OXT'"__.QTL_T0>*O]-'2G_6!PG_V0;
M)?]S&B3_@Q@C_Y07(O^E%B'_MQ4A_\\4(?_8%"'_V!0A_]@4(?_8%"'_V!2[
MK0  L;<  *:_  "8Q0  BLL  'W1  !PUP  9=T  %KC  !3]0 "3/\$!47_
M"PD^_Q$-./\7$3+_'!,N_R(5*_\H%R?_+A<D_S48(/\]%Q[_1A<;_U$6&?]=
M%1?_:Q,4_WL2$_^*$1+_F! 2_Z@/$O^M#Q+_K0\2_ZT/$O^M#Q+_K0^TM0
MJ+X  )O%  ",RP  ?M$  ''8  !DW@  6>,  $[H  !'^  "0/\ !3G_  @T
M_P4++O\*#BG_$! E_Q41(O\;$A__(1,;_R83%_\M$Q/_-!(/_ST2"_]'$0C_
M4Q %_U\/ O]L#@#_>0T _X<, /^*# #_B@P _XH, /^*# #_B@RKO0  G<0
M (_+  " T0  <M@  &3>  !8Y   3>D  $/N  $[^P #-/\ !2[_  @I_P *
M)/\ #"#_ @T<_P<.&/\+#Q7_$@\2_Q@/#?\<#PC_(@\$_RD/ /\Q#@#_.PT
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MT4FP,L])NC+.2<@SS$K9,\A*Z3/&2_<PQ$S_+L)-_RS!3?\JP$[_*<!._RG
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MQEJ*8MQ:BF/P5(IE_%"*9?],B67_28EE_TF)9?])B67_28EE_TG_3@<)_UT
M!/]K P'X= 4 YWL$ -I^!0#6@0@ S(,A ,*#- FZ@$$5L7M+)*IW4C*C<UD^
MG&]?2)=J95&39VQ6CV9S6HUE>UR+9(1=BF2-78AEF%Z&9:->A66P7H-EP5^"
M9==?@F;M6H)G^E6":/]1@6?_3H%G_TZ!9_].@6?_3H%G_T[_404(_V   _]N
M 0#N=P  VWX  -6" P#1A 8 R(<? +Z',@>UA#\3K8%)(:9\42^?>%<[F'1=
M1I)P8U"-;&E7B6EO7(9H=U^#9W]A@F>)8H!GE&)^9Y]C?6>L8WMGO6-Y9])D
M>FGJ7WMJ^5I[:O]5>FG_4GII_U)Z:?]2>FG_4GII_U+_4P,'_V,  OQQ  #B
M>@  V($  -&& @#,B 0 PXL< +J+, 6QB3T1J85('J*"3RR;?E8YE'E;1(UU
M84Z(<697@VYL77]L<V)\:WME>FJ$9GAJCV=V:IMG=&JI9W)JN&AP:LYH<6SF
M9')M]UYR;/Q:<FO_5G)K_U9R:_]6<FO_5G)K_U;_5@$&_V<  ?1S  #=?0
MU(0  ,V) 0#'C $ OH\9 +:/+02NC3P/IHI&')Z'3BF7@U0VD']:08EZ7TR#
M=F15?7-I7GAP;V1T;G=H<6Z :F]NBVMM;I=K:VZE:VENM6MG;LEK:&_C:&IP
M]6)J</I=:F[\6FIN_%IJ;OQ::F[\6FIN_%K_60 %_VH  >IV  #:@   T8<
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M6U9__%M6?_Q;5G_\6U9__%O_9  !ZG4  -F!  #.BP  Q9,  +V9  "SG0
MJ9\% **A'P"<H3$&E9\]$8V<1QV&FDXI?Y=3-7B46#]PD5Q*:(]A5&",95Q9
MBFQC58EU9E.)@693BH]E4HJ>8U&*KF)1B\)@4(O=7E&*\5M2BOU84HC_5E*(
M_U92B/]64HC_5E*(_U;_:0  X7D  -2&  #*D   P9@  +B>  "NH@  HZ4
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M/T6H_S_>?@  SXP  ,28  "[H@  LJD  *BO  "=LP  D;<  (.\  !\OQ,
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M'3?>I1PVW[L;->#8&C3=[QLRV_H<,=K_'3':_QTQVO\=,=K_'3':_QW%F0
MNZ4  +.O  "IM@  G;P  )#!  "#Q0  =\H  &O0  !@UP  5^,& %+J% -,
MZAT(1NHE#3_J*Q(ZZC,6-NL[&3/K1!HQ[$X;,.U9&B_N91DN[G08+>^$%BSO
ME14K\*D4*_' $RKQW1(I\/ 1*.[]$2CN_1$H[OT1*.[]$2CN_1&^HP  M:X
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M"0#_>P@ _XD' /^4!P#_E < _Y0' /^4!P#_E >HNP  FL(  (S(  !]S@
M;]0  &';  !5X0  2>8  #_J   U[@ !+_H  BG_  0C_P &'_\ !QK_  D6
M_P$)$_\&"@[_"PL+_Q$+!_\7"P+_'0H _R0* /\M"0#_. D _T0( /]0!P#_
M6P< _V8& /]P!@#_< 8 _W & /]P!@#_< ;_&204_QDF%/\;)17_&R@6_Q8N
M%_\.-Q?_#447_PQ3%?\+813_"VX2_PIZ$?\*A!#_"XT._PR5#O\-G W_#J,,
M_PZI"_\0L O_$+@*_Q' "O\2RPG_$MD(_Q/F"/\3\0?_$_@'_Q/_!OT3_P;[
M$O\&^Q/_!OL3_P;[$_\&^Q/_!OL3_P;_&B04_QLC%/\>(Q7_'B46_QHK%_\6
M-1C_%4,8_Q-1%_\37A7_$FP4_Q%X$O\2@A'_$XL0_Q23#_\4F@[_%:$-_Q6G
M#?\6K@S_%[4+_Q>^"_\8R0K_&=8*_QGD"?X9[PC\&?<(^AG_!_@9_PCW&?\(
M]QG_"/<9_PCW&?\(]QG_"/<9_PC_&R,4_Q\@%/\B'Q7_(B$5_Q\G%_\>,QC_
M'$ 9_QM-&/\:6Q?_&6@6_QEU%/\9?Q/_&H@2_QN0$?\;EQ#_')X/_QVE#O\=
MJP[_'K,-_Q^[#?\?Q@S^(-,,^R'B"_D@[ KV(?8*\R'^"O(A_PKQ(?\*\2'_
M"O$A_PKQ(?\*\2'_"O$A_PK_'"(4_R,<%/\G&Q3_*!T5_R<D%O\H,!G_)3P:
M_R-*&O\B5QG_(608_R%Q%O\A?!7_(H44_R.-$_XDE!+]))L1_"6B$?LFJ1#Z
M)K 0^2>X#_@HPP_W*- .]"G>#O$IZ@WN*?4-["G^#>LI_PWJ*?\-Z"K_#>@J
M_PWH*O\-Z"K_#>@J_PW_(1X4_R@8$_\M%A+_+Q@3_S$A%?\Q+!C_+SD;_RQ%
M'/\J4QS_*F ;_2EL&?LJ>!CY*X$7]RR*%O4LD17T+9@5\RV?%/(NIA3Q+ZT3
M\"^U$^\PP!+N,<T2ZS';$N@QZ1'E,?42XS+^$N$Q_Q+?,O\1W3+_$=TR_Q'=
M,O\1W3+_$=TR_Q'_)1D3_R\5$?\U%!#_.180_SP>$O\\*1;_.30:_S5!'?TR
M3A[X,EL>]#)H'?(R<QSO,WT;[32&&NPUCAGJ-949Z3:<&.@VHQCF-ZH8Y3>S
M%^0XO1?C.,H7X3C9%]TYZ1?:.?47V#G^%]0Z_Q?3.O\6TCK_%M$Z_Q;1.O\6
MT3K_%M$Z_Q;_*A82_S42$/\\#P[_0A4-_T<=#_]&)A+_0S 7^S\\'/0[22#O
M.58AZSEB(><Z;B#E.WD?XCN"'N$\BA[?/9$>W3V9'=P]H!W:/J@>V3ZP'M@^
MNA[6/\<>U#_6']$_YQ_-0/4>RD'_'<E!_QS'0?\<QD'_&\5!_QO%0?\;Q4'_
M&\5!_QO_,!01_SL.#O]""@O_2Q,*_U ;"_]0) [\32P2\T@W&.M#0Q_E0% C
MX$!=)-Q!:2390G0DUD)])-1"A2320XTET4.4)<]$FR7-1*,ES$2K)LI%M";)
M1< FQT70)L1%XB?!1O$FOT?\)+U'_R.[2/\ANDC_(+I(_R"Z2/\@NDC_(+I(
M_R#_-A$/_T *"_]*"0G_5!$'_U@8!_]9( GU5RD-ZU(S$^--/QK;2DPBU4A8
M)]%'8RK-1VXKRDAW+,A(?RS&28<MQ$F.+<-)EBW!2ITMOTJF+;Y*KRZ\2KHN
MNTO)+KE+VR^V2^PMM$SY*[)-_RFQ3?\GKT__)JY/_R:N3_\FKD__)JY/_R;_
M.PT-_T8&"?]1!P;_6PX%_V 5!/IA'07N8"4'Y%PN#-I8/!/25$@?RU!3*<9.
M72_"36<ROTUQ,[Q->32Z3H$TN4Z)-+=.D#2U3Y@UM$^@-;)/J36Q3[0UKT_"
M-JY0U#:K4.@UJ5'V,J=3_S"F5/\NI53_+*54_RNE5/\KI53_*Z54_RO_/PH,
M_TL#!_]7!@3_80L"_V81 O1H& +H9R #W60J!M-B.0_*7D4<PEE/*;Q56#*X
M4V(WM%)K.;)2=#JP4GP[KE.#.ZQ3BSNJ4Y,[J52;/*=4I3RF5*\\I%2\/*-4
MSCVA5.(]GU;S.9Y7_C:=5_\TG%C_,IQ8_S&<6/\QG%C_,9Q8_S'_0@@*_T\
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M3(5@^$>%8/]$A6'_085A_T"%8?] A6'_0(5A_T#_30 &_UL  OIH  #A;P
MV74  -)X 0#.>00 Q'L< +M\+P6S>3T0JW5'':1Q3RJ=;58VF&E</Y-F8D:/
M8VE,BV)P3XEA>%"'88!1AF&)4H1ADU*#89Y3@6&J4X!ANE-^8<Y4?6'F47YB
M]DQ^8_](?F3_17YD_T1^9/]$?F3_1'YD_T3_4  %_UX  ?)J  #=<P  U7D
M ,Y\  #(?0( OW\9 +> +02O?CL.IWI%&J!W32>9<U0SDV]:/8UK7T:):&5,
MA65L48)D<U2 9'M6?F.$5WQDCU=[9)I8>62G6'=CMEAV8\E9=63B5W9E]%%V
M9O]-=V;_27=F_TEW9O])=V;_27=F_TG_4P $_V(  >AM  #:=@  T7P  ,J
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M46=L_U!G;/]09VS_4&=L_U#_6  "^&@  -YS  #3?   RH,  ,*'  "ZB0
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M.T6GJ#E$I[LX0Z?5-D.E[39"I/HU0J+_-4*B_S5"HO\U0J+_-4*B_S79?0
MRHL  +^6  "WGP  KJ8  *2K  "9K@  C+$  'ZT  !TMPH <+@? &NX+05E
MN#8,7K<^%5BU1!Y1M$DF2[10+$>S5S%$LV S0K-L,T&S>#)!M(8P0+25+S^T
MIBT_M+HL/K35*CVR[2H\L?LJ.Z__*SNO_RL[K_\K.Z__*SNO_RO0A@  Q),
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M"B3KVPHCZ?$)(>;_"B'F_PHAYO\*(>;_"B'F_PJZHP  LZP  *FT  "<N@
MC[X  ('"  !TQP  :,P  %S1  !2U@  2-P  $#F   [\PL"-O,4!3'T&P@L
M]",**?0J#"7U,@TC]CL-(/9%#1[W4 P<]UT+&?AM"ACY?@D7^9 (%OJD!Q7Z
MNP85^M8&%/OP!1/[] 43^_0%$_OT!1/[] 6UK   J[0  )^Z  "2OP  A,0
M ';)  !IS@  7=,  %+9  !(W0  /N(  #;M  $Q^@$#+/\(!2C_$ <D_Q8(
M(/\="1S_) H9_RL*%?\T"A+_/@D-_TD)"O]6" ;_90<$_W<& _^)!0+_G 4!
M_ZT$ ?_"! '_QP,!_\<# ?_' P'_QP.NLP  HKH  )3   "&Q0  =\H  &K0
M  !=U0  4=L  $?@   \Y   ,^@  "SR  $G_0 #(O\ !![_ @8:_P@'%_\.
M!Q/_%0@._QL("O\B" 7_*@@!_S0' /\_!@#_3 8 _UL% /]K! #_? , _XL#
M /^: P#_G0, _YT# /^= P#_G0.EN@  E\   (G&  !ZS   ;-$  %[8  !1
MW@  1N,  #OG   QZP  *.X  "'W  $<_P #&/\ !!3_  41_P &#/\ !@C_
M! 8$_PH' /\1!P#_& 8 _Q\& /\I!0#_- 4 _T$$ /].! #_6P, _V@# /]V
M @#_> ( _W@" /]X @#_> +_#"<2_Q,D$O\4)!/_$"83_P@L$_\"-A+_ 401
M_P!2$/\ 7P[_ &P,_P!X"_\ @@K_ (L)_P"2"/\ F0?_ * '_P"F!O\!K0;_
M ;0%_P*\!?\"Q@3_ M,$_P+A _\"[0/_ O8"_P+^ OT"_P+[ O\"^P+_ OL"
M_P+[ O\"^P+_ OL"_P+_$242_Q8A$O\7(1/_%2,3_PTI$_\)-!/_"$(2_P=0
M$?\%70__ VH-_P)V#/\#@ O_!(@*_P60"?\&EPC_!YX'_P>D!_\(J@;_";$&
M_PFZ!?\*PP7_"M $_PK?!/T*ZP/["O0#^0K] _<*_P/V"O\#]@K_ _8+_P3V
M"_\$]@O_!/8+_P3_%2(2_QH>$O\;'1+_&A\3_Q4E%/\4,13_$CX4_Q!,$O\.
M6A'_#&8/_PMR#?\,?0S_#88+_PZ-"O\0E G_$)L)_Q&A"/\2J C_$J\'_Q.W
M!OX4P ;]%,T%^A3;!?<4YP7T%/,$\A3\!/ 5_P7P%?\%[Q7_!>\5_P7O%?\%
M[Q7_!>\5_P7_&1X2_QX9$O\@&!+_'QH2_Q\B$_\>+A3_&SL5_QE(%/\85A+_
M%V,1_Q9O#_\6>0[_&((-_1B*#/P9D0O[&I@*^AN>"OD;I0GX'*P)]QRT"/4=
MO0CT'LD'\A[8!^\>Y0;L'O$&ZA[\!^@?_P?G'_\'Y2#_".0@_PCD(/\(Y"#_
M".0@_PC_'1H2_R,5$?\G%!#_)A40_RH?$O\I*Q3_)C<6_R-$%O\A417^(5X3
M^R!J$?@@=1#V(7\/]"*'#O,CC@WQ))4,\"2;#.\EH@ON)JD+[2:Q"NLGNPKJ
M*,<*Z2C4">4HY GB*/$*X"C\"MXI_PO;*O\+VBG_"]DI_PO9*?\+V2G_"]DI
M_PO_(A81_RH2#_\N$ [_,A0._S4=#_\T)A+_,3,5_RT_%_HK3!?U*ED5\2IF
M%.XK<1+L*WL1ZBR#$.@MBQ#F+I(/Y2Z8#^0OGP[B+Z8.X3"N#N QN [>,<0-
MW3'3#=HQXP[6,O$/TS+\#] R_P_.,O\/S3+_#\PR_P_,,O\/S#+_#\PR_P__
M*!,0_S$-#?\V"@S_/1$+_T :#/\_(P__.RT2^#<Z%O$S1QCK,E08YS-A%^,T
M;!7@-784WC9_%-PVAQ/:-XX3V3>5$]<WG!/5.*03U#BK$](YM131.< 4SSG.
M%,TYWQ3).N\5QCK[%<0Z_Q3"._\4P#O_%, Z_Q/ .O\3P#K_$\ Z_Q/_+A .
M_S<)"_\^!PG_1@\(_TH7"/])( KX12D.[T T$^<\01?A.DX9W#M;&=@\9QC4
M/7$9TCUZ&<\^@AK-/HD:S#Z0&LH_EQK(/YX:QS^F&\5 KQO#0+H;PD#'&\!
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M,)E2^BZ84O\KF%+_*I=2_RB74O\HEU+_*)=2_RC_00$(_TT  _]9  'T8
MY6,! -QC! #980H SV0A <5C,@F\7S\4M5M)(*]84BFJ55HPIE1C,Z14:S6A
M5',VGU1[-IY4@C><5(HWFU22-YE4FS>85*4XEE2Q.)54P#B35-0YDE3I-Y%5
M^#205O\QCU;_+X]6_RZ/5O\NCU;_+H]6_R[_10 &_U$  OQ=  #F8P  VV@
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M/GE?_SQY7_\\>5__/'E?_SS_3@ #_5P  .)G  #8;P  SG4  ,=W  # =P
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M34R"HTM,@K1*2X++2$N"Y4=+@?9$2X'_0TN _T)+@/]"2X#_0DN _T+F:
MUG<  ,F"  "_BP  MI$  *Z5  "DF   E)<  (V9"@"'FB  @IDO!'V8.@MV
MED(5<)5)'FF33BABD5,Q6X]8.56-74!0C&1%38MM1TN+>$=*BX5&2HR314F,
MHT-(C+1!2(S+0$>+YC]'BO8]1XG_/$>)_SM'B?\[1XG_.T>)_SO@;P  T'P
M ,2'  "[D   LY<  *J;  "?G@  DI\  (6@ 0" H1@ >Z$I G:@-0APGSX0
M:9U%&6.;2R)<FE K5IA6,U"77#E,EF,]299M/DB6>#Y'EH4]1Y:4.T:6HSE%
MEK4X1);,-T25YC5#E/<U0Y/_-$.2_S1#DO\T0Y+_-$.2_S3:=@  RX,  ,".
M  "WE@  KYT  *:A  ":I   C:8  'VG  !VJ T <ZDA &ZI+P1HJ#@+8J=
M$UNE1AQ5I$PD3Z-2*TJB63!'HF$S1:%K-$.A=S-#HH0R0J*2,$*BHB]!HK0M
M0*+,+#^AYBL_G_<K/IW_*SZ=_RL^G?\K/IW_*SZ=_RO2?0  Q8H  +N5  "S
MG0  JZ,  *"G  "4J@  B*P  'JN  !ML0$ 9[(6 &2R)@%?LC$'6;$Z#5.P
M0!5-KT<<2*Y-(D2N529!KETH/ZYH*#ZN="<]KH$F/:Z0)#RNH2,[KK,A.J[+
M(#JMYA\XJ_<@-ZK_(3>I_R$WJ?\A-ZG_(3>I_R'+A@  OY(  +><  "OI
MI:D  )JM  "-L   @+(  '2U  !FN   6[P' %>]&@!4O2<"3[TQ!TJ\.0U%
MO$ 30+M'&#R[4!LZNUD<.;QD&SB\<!HWO'X9-KR-&#:]GA<UO;(6-+S*%#.[
MYA0QN?<6,+C_%R^W_Q<OM_\7+[?_%R^W_Q?#CP  NIL  +*D  "JJP  GZ\
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M 0CS^0$(\_D!"//Y 0CS^0&RJP  J;(  )RX  "/O   @<   '/%  !ER0
M6<X  $[3  !#V   .=P  "_A   GY0  (_0  2#]!@(<_@X#&?X6!!7^'001
M_B4%#?\N! G_. 0%_T0$ ?]1 P#_80( _W0" /^( 0#_G $ _[ ! /_%  #_
MV0  _]D  /_9  #_V0"KL@  G[@  )*]  "#P@  =,<  &?,  !:T0  3M8
M $/;   XX   +N0  "7G   >[   &OD  1;_  (3_P ##_\& PO_#00&_Q0$
M O\<! #_) , _RX# /\Z @#_2 ( _UD! /]L 0#_?@$ _X\  /^?  #_J0
M_ZD  /^I  #_J0"BN   E;X  (;#  !WR0  :<X  %O4  !.VP  0N   #?D
M   MYP  (^L  !KN   4\P  $/T  0O_  ('_P "!?\  P'_  , _P,# /\(
M P#_$0, _QD# /\C @#_+P( _SX! /]. 0#_7P$ _V\  /]\  #_A0  _X4
M /^%  #_A0#_""00_PLB$/\*(A#_!"00_P J#_\ -0[_ $,,_P!1"_\ 7@G_
M &L'_P!W!O\ @ 7_ (D$_P"0!/\ EP/_ )T#_P"C O\ J0+_ *\"_P"W ?\
MP '_ ,P!_P#; /\ Z0#_ /, _P#] /T _P#[ /\ ^P#_ /L _P#[ /\ ^P#_
M /L _P#_#"(0_P\?$/\.'A#_"B$0_P F$/\ ,@__ $ -_P!.#/\ 6PK_ &@(
M_P!T!_\ ?@;_ (8%_P".!/\ E 3_ )L#_P"A _\ IP+_ *T"_P"T O\ O0'_
M ,D!_@#8 ?T Y@#[ /$ ^ #\ /8 _P#U /\ ]0#_ ?4 _P'U /\!]0#_ ?4
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M*(I1_R:*4?\FBE'_)HI1_R;_0@ $_TX  .M7  #=7P  U6,  ,YD  #*8 (
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M.WQ6[CA\5_PT>U?_,GM7_S![5_\P>U?_,'M7_S#_1P "]54  .!@  #5:
MS&T  ,1N  "];   M6P2 *UN)@&F;#0(GVD_$IEF1QV38DXFCE]5+HI=6S2&
M6V(XA%IH.H)9<#R 67@\?EF /7U9B3Y[690^>5F?/WA9K3]V6;Y =%C40'19
MZSUT6OHY=%K_-G1:_S1T6O\T=%K_-'1:_S3_2@ ![%@  -UD  #1;   R'$
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M05YD_SY>9/\^7F3_/EYD_S[Y5   X60  --O  #(=@  OWL  +9^  "M?@
MHWT" )Q^&0"6?BH"CWTW"8EZ0!*#=T<<?75-)7AR4BYR;U<W;&Q</F9J845B
M:&A*7F=P35QG>DY:9X5.6&>23E=GH4Y69[%-5&?&3%1GX$I5:/1&5FC_0U=H
M_T!7:/] 5VC_0%=H_T#O6   W6@  ,]R  #%>@  O'\  +."  "I@P  GX(
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M.4=\_SG@:   T'8  ,2   "ZB   LHX  *F2  "?DP  CI(  (:3 @" DQ@
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M)CZ=G24]G:XC/)W$(CR<WR$[FO,A.IG^(CF8_R(YF/\B.9C_(CF8_R+-?0
MP(D  +>3  "OFP  IZ   )VD  "1I@  @Z<  ':I  !FJ@  7ZP- %NL'P!8
MK"L#4ZPU"$ZK/ Y)JD,41*E*&4"I4AP]J5H>.ZED'CJI<!TZJ7T<.:F+&SBI
MFQHWJ:T8-JG#%S:HWA8TIO(7,Z7^&#.C_QDSH_\9,Z/_&3.C_QG&A@  NY$
M +.:  "KH@  HJ<  ):J  "*K   ?:X  &^O  !AL@  5+4  $ZV$0!,MR
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M !+;T@ 1V>T $=?Z 1'5_P(1U?\"$=7_ A'5_P*TH@  K:H  *.P  "6M
MB;@  'N[  !NO@  8<$  %7%  !)R0  /LT  #/2   JU@  (ML  !OD!0 9
MZ!  %^@: !3I) $2Z2X!$.HY 0WJ1@$*ZU, ".MC  ;L=  $[8@  >R=  #K
MM0  Z]<  .KP  #I_P  Z?\  .G_  #I_P"OJ@  IK$  )FV  ",N@  ?KT
M '#!  !BQ0  5LD  $K.   ^T@  --8  "K;   BWP  &N,  !3K   1^ ,
M#?D+  KY% $&^1P! ODF 0#Z,0$ ^CX  /I,  #Y70  ^7   /B$  #WF0
M]J\  /;'  #WY   ]^0  /?D  #WY "IL0  G;8  (^[  "!OP  <L0  &3(
M  !7S0  2M(  #[6   SVP  *=\  "#C   8Y@  $>H   OQ   '^P  !/\
M  '_! $ _PH! /\3 0#_' $ _R<  /\U  #_1   _U8  /]I  #_?0  _Y
M /^A  #_L@  _[,  /^S  #_LP"@MP  DKP  (3!  !TQ@  9LL  %C1  !+
MU@  /MP  #+@   HY   'N<  !7J   .[@  !O    +W    _P   /\   #_
M  $ _P ! /\  0#_" $ _Q(  /\=  #_*@  _SH  /],  #_7P  _W$  /^
M  #_CP  _X\  /^/  #_CP#_ R(._P0?#O\!'P[_ "(-_P H#/\ ,PK_ $$(
M_P!0!O\ 707_ &D$_P!U _\ ?@+_ (4!_P", ?\ DP'_ )D _P"? /\ I0#_
M *L _P"R /\ NP#^ ,8 _ #4 /L XP#[ /  ^P#Z /L _P#[ /\ ^@#_ /H
M_P#Z /\ ^@#_ /H _P#_!Q\._P@<#O\&' [_ !X-_P D#/\ ,0O_ #X)_P!-
M!_\ 6@;_ &8$_P!R _\ >P+_ (,"_P"* ?\ D '_ )8!_P"< /\ H@#^ *D
M_ "P /H N #Y ,, ]P#1 /8 X #U .T ]0#X /4 _P#T /\ ] #_ /0 _P#S
M /\ \P#_ /, _P#_"QL/_PP7#O\*%P[_!1D-_P B#?\ +@O_ #L*_P!)"/\
M5@;_ &(%_P!N!/\ > /_ ( "_P"' ?\ C0'] )0!^P": /H H #X *8 ]@"M
M /4 M0#S ,  \0#- .\ W0#O .L [@#W .T _P#L /\ ZP#_ .D _P#H /\
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MR NT-=H+L37L#*XU^@VL-?\-JC;_#:DV_PVH-O\-J#;_#:@V_PW_+0 (_S,
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M'Y!(\!Z/2/T=CDC_'(U(_QN-2/\:C4C_&HU(_QK_.P #_T4  .9-  #<50
MU%@  ,U8  #)40( P%09 +=5*@2P4S<,J5!"%*1.2QN@350?G$Q=(9I,9"*8
M3&PBEDQS(I5,>B.33($CDDR((Y!,D22/3)HDC4RE)(Q+LB6*2\,EB4O9)H=+
M[22&3/LBA4S_(85,_R"%3/\?A4S_'X5,_Q__/0 "]TD  .)4  #86P  SE\
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M+VY6_RUN5O\M;E;_+6Y6_RW^2   Y58  -=B  #,:0  PFT  +IN  "R;
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M.%-D_SCH6   V&8  ,IP  "_>   MWP  *Y^  "D?@  F'L  )![#@"*?"$
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M.49ZF#=&>JDV17J\-$1ZU3-#>>TR0WC[,4-W_S!#=_\P0W?_,$-W_S#;:
MRW0  +]^  "VA@  K8L  *6.  ":CP  BHT  '^-  !XC1$ =(XB &^-+P-J
MC#@)9(M $%^)1AA9B$L?4X91)DZ%5BQ*A%TQ1X-F,T6#<#-$@WPR1(.),4.#
MF"]"A*@M082\+$"#U2I @NTJ/X'[*CZ _RH^?_\J/G__*CY__RK4;@  QGH
M +N$  "SBP  JI$  *&4  "7E0  B94  'J4  !PE @ ;)0; &B5*0%CE#0&
M7I,\#%B20Q-3D$D:3H].($F.5"5%CEPI0XUE*D&-<"I C7PH0(V))S^-F"4^
MC:@D/8V\(CR-U2$[C.TA.HK[(CJ)_R(YB?\B.8G_(CF)_R+.=0  P8$  +>*
M  "OD@  IY<  )Z:  "2FP  A9P  '6<  !HG   89T2 %Z=(@!;G2X#5IPW
M"%&;/@U,FD431YE,&4.84AU F%H?/IAD(#R8;Q\\F'L>.YB('3J8EQLYF*@:
M.)B\&3>7UA@VENT8-93[&323_QHTD_\:-)/_&C23_QK'?0  O(@  +21  "L
MF   I)T  )F@  "-H@  @*,  '&C  !BI   5Z8& %.F%P!0IR4 3*8O TBF
M. A$I3\-/Z5&$3RD3A0YI%<5-Z1@%C:D:Q4UI'@4-:2&$S2DE1(SI*80,J2[
M#S&CU0XPH>T/+I_[$2V>_Q(MG?\2+9W_$BV=_Q+!A0  MY   +"9  "HGP
MGZ0  ).F  "&J   >:D  &NJ  !=K   4*X  $:P" !"L1@ 0+$E #VQ+P,Y
ML3<&-; _"3.P2 LQL%$,+[!;#"ZP9PLML70*+;&""2NQD@@JL*,'*;"X!R>P
MTP8FKNP'):S["22K_PHCJO\*(ZK_"B.J_PJ[C@  LY@  *R@  "CI@  F*H
M (NL  !^K@  <:\  &.Q  !6LP  2K8  #VY   RO 8 +[X5 "Z^(0 KOBL!
M*;XU B>^/@,EOTD$)+]3 R._7P,BOVP#(;][ A^_C (>OYX!'+^T 1J_SP$9
MO>L!&;OZ A>Z_P,6N?\$%KG_!!:Y_P2VF   KZ$  *>G  "<K   D*\  (*R
M  !UM   9[8  %NX  !.NP  0KX  #;"   LQ@  (LH! !O."0 8SQ8 %L\A
M !7/+  4T#@ $M!$ !'04  0T5X #=%N  O1?P )T)( "-"G  ;0P0 $S^$
M!<[U  7,_P %R_\ !<O_  7+_P"QH0  JZ@  *"N  "3L@  AK4  'BX  !J
MN@  7;T  %'   !%PP  .<<  "[+   ESP  '-,  !36   +VP( !=T*  /=
M%P "W2,  -XO  #?/   X$L  .!;  #A;0  X8   .&4  #AJ@  X<0  .'A
M  #A\@  X?@  .'X  #A^ "MJ0  HZ\  )>S  ")MP  >[H  &V]  !?P0
M4\0  $;(   ZS   +]   "34   <V0  %-P   S?   $X@   .L   #K!@
MZA   .D:  #I)@  ZS0  .U%  #O5@  [VD  /!]  #PD@  \:<  /&\  #Q
MTP  \M\  /+?  #RWP"FKP  FK4  (RY  !^O0  ;\   &'$  !4R0  1\T
M #K1   OU0  )-H  !K>   3X@  "N4   /G    Z0   /$   #W    ]@
M /8&  #U$0  ]1P  /8K  #Y/0  _%   /UD  #]>   _HP  /Z=  #_K0
M_[0  /^T  #_M "=M0  C[H  (&^  !QPP  8\@  %7-  !(T@  .]@  "[<
M   DX   &>,  !#G   (Z@   >T   #O    \    /8   #^    _P   /\
M  #_    _P4  /\2  #_(0  _S,  /]'  #_7   _V\  /^   #_C0  _Y0
M /^4  #_E #_ !\,_P =#/\ '0O_ !\*_P D"/\ ,@?_ $ %_P!. _\ 6P+_
M &8!_P!Q /\ >@#_ (( _P") /\ D #_ )8 _P"< /\ H0#^ *< _0"M /T
MM0#\ +\ ^P#+ /L VP#Z .P ^@#X /H _P#Y /\ ]P#_ /8 _P#V /\ ]@#_
M /8 _P#_ AP-_P$9#/\ &0O_ !L*_P A"?\ +P?_ #T%_P!+!/\ 6 +_ &,!
M_P!N ?\ =P#_ '\ _P"' /X C0#\ ), ^@"9 /D G@#X *0 ]P"K /8 L@#V
M +L ]0#' /0 V #T .@ \P#U /, _@#Q /\ \ #_ .\ _P#N /\ [@#_ .X
M_P#_!A@-_P44#/\!% O_ !8*_P ?"?\ *PC_ #D&_P!'!/\ 5 /_ & !_P!K
M ?\ = #] 'P ^@"$ /< B@#U )  \P"6 /( FP#Q *$ \ "H .\ KP#N +@
M[0#$ .P TP#K .0 ZP#Q .H ^P#H /\ YP#_ .4 _P#E /\ Y0#_ .4 _P#_
M"Q0,_PH0"_\'#@K_ A(*_P,<"?\ * C_ #4&_P!#!/\ 4 /_ %P"_ !G ?@
M< #U 'D \@"  .\ AP#M (T Z@"3 .D F #H )X YP"E .8 K #D +4 XP#
M .( SP#A -\ X #N -\ ^@#< /\ V@#_ -D _P#9 /\ V0#_ -D _P#_$0\,
M_Q$)"O\-!PG_#@T)_Q 9"/\,(PC_!S '_P,^!?H 2P/U %<"\0!B >X ; #K
M '4 Z0!] .8 @P#C (D X0"/ -\ E0#> )L W0"B -L J0#: ;( V0&^ -<"
MS #5 ]X U 7O - )_ #-"O\ S O_ ,L+_P')#/\!R0S_ <D,_P'_%PD+_Q@#
M"?\7 0?_' D&_QP4!_\9'P?^%2L&]1 Y!>\,1@/I#5("Y0Q> >(-: #?#7$
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M!JHN] >G+_\(I2__"*0N_PBC+O\(HR[_"*,N_PC_*  %_RT  O\V  #S.
MZ3<  .4R!P#>+!( U"TC <LO,P3%,4(&OS).![LS6 BX-&$(M31J"+,U<0BQ
M-7@)L#5^":XVA0FM-HL)JS:2":HVF@FH-Z,*IS>M"J4WN@JC-\L+H3?@"YXW
M\0R<-_X,FS?_#)HV_PR9-O\,F3;_#)DV_PS_+@ #_S4  ?,\  #C/P  W$$
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M&X!'_QI_1_\9?T?_&7]'_QG_.0  ZD4  -U1  #16   R%L  ,!;  "Z5
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M.U!@ECM/8*8Z36"X.DQ@T#E,8.DV36#Y-$Y?_S).7_\P3E__,$Y?_S#B6
MTF4  ,5O  "[=0  LGD  *E[  "?>@  D74  (EU!P"#=1H ?G4I 7ET- =T
M<CP-;G!#%6EN21QC;$XD7FI3*UEH6#%49UXV469F.DYE;SM-97H[3&6'.DMF
ME3E*9J4X26:W-TAFSC9'9N@T2&7Y,DAE_S%(9/\P2&3_,$AD_S#>70  SFH
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M(CU_S2$\?N<A.WWX(3I\_R(Y>_\B.7O_(CE[_R+/;@  P7D  +>"  "NB0
MIHT  )V0  "3D0  A9   ':/  !IC@$ 8X\4 &"/(P!<CRX#6(XW!U.-/@U.
MC$0228M*&$6*41Q!B5@?/XEA(#V):R \B7<?.XF$'CN)DAPZB:(;.8FU&CB)
MS1DWB.<8-H;X&C6%_QHUA/\;-83_&S6$_QO)=0  O8   +.(  "KCP  HY0
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M!!RE_P4<I/\&'*3_!ARD_P:WC@  L)<  *F>  "@HP  E:8  (BI  ![J@
M;:L  %^L  !2K@  1;   #FR   NM0  );<+ ".X&0 BN"0 (+@N !ZX.  =
MN$(!'+A- !JX6  9N64 %[ET !:XA  4N)8 $KBJ !"XPP .MN( #K3V  ZS
M_P$.LO\!#K+_ 0ZR_P&SEP  K)\  *2E  "9J0  C*P  '^N  !RL   9+(
M %>S  !*M@  /K@  #&[   GO@  '<(  !3% P ,QPT "L<:  G')0 'QS$
M!L<\  7'20 $QU8  \=E  ''=P  QXD  ,:=  #&LP  Q<\  ,3I  ##]P
MP_\  ,/_  ##_P"NH   J*<  )VK  "0KP  @[(  '6T  !GM@  6K@  $V[
M  !!O@  -,$  "G$   ?R   %LP   W.   $T0   -,(  #3$P  U!X  -4J
M  #6-@  UT0  -E3  #99   V7<  -F+  #9H   V+@  -?5  #6ZP  UO<
M -;W  #6]P"KIP  H*T  )2Q  "&M   >+@  &JZ  !<O0  3\   $+#   V
MQ@  *LH  !_.   7T@  #M4   ;8    VP   -T   #?    X H  .$6  #C
M(0  Y2\  .<^  #J3@  ZV$  .MU  #LB@  [*   .RV  #KS0  Z^(  .OB
M  #KX@"CK@  E[(  (FV  ![N@  ;+T  %[!  !1Q0  1,D  #;,   KT
M(-0  !;9   ,W0  !>    #A    Y    .8   #H    Z0   .L   #M"@
M\!<  /(F  #U-@  ^$@  /I<  #[<0  _(8  /R9  #]J0  _;8  /VV  #]
MM@":M   C;@  'Z\  !OP0  8,4  %/)  !%S@  -](  "O7   ?W   %-\
M  OD   "YP   .D   #K    [    .T   #P    \0   /,   #U    ^
M /L,  #^'   _RX  /]"  #_5@  _VH  /]]  #_BP  _Y<  /^7  #_EP#_
M !P+_P :"O\ & G_ !L'_P B!O\ , 3_ #X"_P!+ ?\ 6 #_ &0 _P!O /\
M> #_ '\ _P"& /\ C #_ )( _P"7 /X G #^ *( _0"H /P KP#[ +@ ^P#$
M /H TP#X .0 ]@#T /4 _P#U /\ ]0#_ /4 _P#V /\ ]@#_ /8 _P#_ !D+
M_P 6"O\ %0G_ !8'_P ?!O\ +03_ #L"_P!( ?\ 50#_ &$ _P!K /\ =0#]
M 'P ^P"# /H B0#Y (\ ^0"4 /@ F0#W )\ ]@"E /4 K #T +4 \P#  /(
MS@#P .  [@#Q .T _0#M /\ [0#_ .T _P#M /\ [0#_ .T _P#_ 10+_P 2
M"O\ $0G_ ! (_P <!O\ *03_ #@"_P!% ?\ 40#_ %T _ !H /@ <0#U 'D
M] "  /, A@#R (L \ "1 .\ E@#N )P [0"B .P J0#K +$ Z@"[ .@ R0#F
M -P Y #M ., ^0#C /\ X@#_ .( _P#B /\ X@#_ .( _P#_!1 *_P,+"?\
M"0C_  \'_P 9!O\ )03_ #,#_P!  ?X 30#X %D \P!D .\ ;0#M '4 ZP!\
M .D @@#H (@ YP"- .8 DP#D )@ XP"> .( I@#@ *X W@"W -P Q0#: -<
MV #H -@ ] #6 /X U0#_ -0 _P#4 /\ TP#_ -, _P#_"@D*_P@$"/\" 0?_
M!@H&_P86!?\!(03_ "X#_  [ ?4 2 #N %0 Z !? .4 :0#C '$ X0!X -\
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M O@9%0+N$R(!Y0TN -X*/ #7"TD T@U5 ,X/7P#+$6@ R1)P ,83=@#$%'T
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M")4P_PB4+_\(E"__")0O_PC_)@ "_"X  .@V  #>/   U3T  ,\X  #+, 4
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M*F)0F2I@4*<K7E"X*UQ0SRQ<4.@J7%#Y)UQ0_R5<4/\C7%#_(UQ0_R/F2@
MUE@  ,EB  "^9P  M6H  *QJ  "B9P  EV$  (]A#0"*81\ A&$L W]?-@EZ
M73X0=5I$%G!82AQL5D\A:%55)6546RAC4V(J85-J+%]3<RU=4WXN7%.)+EI3
MEBY84Z0O5E.U+U53S"]44^8M55/X*E53_RA54_\F55/_)E53_R;C3@  TUP
M ,9E  "[:P  LFX  *EN  "?;   DV8  (ME"0"%9AP @&4I GMD,P=V8CP.
M<6!"%&Q=2!MG6TT@8UI3)E]86"I<6%\M65=G+UA7<#%65WLQ5%>&,5-7DS%1
M5Z(Q4%>S,4Y7R3%.5^0O3E?W+$]7_RI/5_\I3U;_*$]6_RC@4P  T&   ,-I
M  "X;P  KW(  *9S  "<<0  CVH  (9J!0" :A@ ?&HF 7=I,05R9SD+;&5
M$F=C1AEB84L?7F!1)5E>5BI675TO4UQD,5%;;3-/6W@S3EN$,TQ<D3)+7* R
M2ERR,4A<R#!(7.,O2%OV+$E;_RM)6_\J25O_*4E;_RG<6   S&0  ,!M  "V
M<@  K78  *1W  "9=@  BV\  ()O  ![;A0 =V\C ')N+@1M;3<):&L^#V-J
M1!9>:$H=669/(U5D5"E08UHM36)B,4MA:S))878R2&*",4=BD#!&8I\O16*P
M+D1BQBU#8N$L0V'U*D-A_RE#8/\I0V#_*$-@_RC87   R&D  +UQ  "S=@
MJGH  *%\  "7>P  AW4  'UT  !U= X <70? &UT*P)H<S4'8W(\#5YP0A-9
M;T@956U-(%!K4B5,:EDJ2&E@+49I:BY%:74N1&F!+4-ICRM":IXJ06JP*$!J
MQB<_:>$F/FCT)CYG_R8^9_\E/F;_)3YF_R738@  Q6T  +EU  "P>P  J'\
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M$C" _Q,O?_\4+W__%"]__Q3#=   N'X  *^&  "GC0  GY$  ):3  "*DP
M?9,  &V2  !@D0  4I$" $V2$P!+DB$ 2)(K 421- 1 D3P(/9!#"SF02@XV
MCU(/-(];$#./90\RCW$/,8]^#C"/C POCYP++HZM"BV.Q DLC=\)*XOS"RJ*
M_PPIB?\-*8G_#BF)_PZ^>P  M(8  *R-  "EDP  G9<  )*9  "%F@  >)D
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M  2L_P"OE@  J9X  **C  "6IP  B:D  'RK  !NK   8*T  %.O  !&L0
M.;,  "VU   BN   &+H   Z\   %O@H  ;X6  "_(0  ORL  +\W  "_0P
MOT\  +]>  "_;@  OX   +Z3  "]J   O<   +S=  "[[P  NOD  +K[  "Z
M^P"LGP  I:4  )JI  "-K   @*\  '*Q  !DL@  5K0  $FW   \N0  ,+L
M "2^   :P0  $<0   ?&    R0   ,H&  #+$   S!L  ,TE  #.,0  SCX
M ,],  #07   T'   -"$  #0F0  SZ\  ,[)  #.XP  S?(  ,WT  #-] "H
MI@  G:L  )&N  "#L0  =;0  &:W  !9N0  3+P  #Z_   RP0  )L0  !O(
M   2RP  ",\   #0    TP   -4   #7    V0<  -L2  #='0  WRD  .$W
M  #D1P  Y5D  .5O  #EA@  Y9T  .6R  #ER@  Y-\  .3C  #DXP"@K
ME+   (>T  !XMP  :;H  %N^  !.P0  0,4  #/(   GRP  &\X  !'3   '
MV    -L   #<    W@   .    #B    Y    .8   #I!P  [!0  .\A  #R
M,0  ]4(  /=5  #X:P  ^(,  />:  #WK@  ]\   /?$  #WQ "7L@  BK8
M 'RZ  !LO@  7L(  %#&  !"R@  -,X  "?2   ;U@  #]L   ;@    XP
M .4   #F    Z    .D   #K    [0   /    #R    ]0   /D)  #\&
M_RD  /\\  #_4   _V4  /]Z  #_C   _YT  /^@  #_H #_ !@)_P 5"/\
M% ;_ !<%_P @ _\ +@'_ #L _P!) /\ 5@#_ &( _P!L /\ = #_ 'P _P""
M /\ B #_ (T _P"2 /X EP#^ )T _0"C /P J@#Y +( ]P"\ /8 S #U -\
M] #O /0 _0#T /\ ] #_ /, _P#R /\ \@#_ /( _P#_ !4)_P 1"/\ #P?_
M !(%_P = _\ *P+_ #@ _P!& /\ 4P#_ %X _@!H /T <0#\ '@ ^@!_ /D
MA0#X (H ^ "/ /< E #V )H ]0"@ /, I@#P *X [@"X .T QP#L -D ZP#K
M .L ^@#J /\ Z0#_ .@ _P#H /\ Z #_ .@ _P#_ !$)_P -"/\ "P;_  X%
M_P : _\ )P+_ #0 _P!" /T 3P#Y %H ]P!D /4 ;0#S '4 \@![ /$ @0#O
M (< [@", .T D0#L )8 Z@"< .@ HP#F *L Y "U ., P@#A -( X #G -\
M]@#> /\ W0#_ -P _P#< /\ W #_ -P _P#_  L)_P &!_\  P;_  P%_P 7
M _\ (P+_ #  ^P ^ /0 2@#Q %8 [@!@ .L :0#I '$ Z !W .8 ?0#E (,
MXP"( .( C0#@ ), W0"9 -L GP#9 *< V "Q -8 O0#4 ,T TP#B -$ \@#0
M /P SP#_ ,X _P#- /\ S0#_ ,T _P#_! 0(_P  !O\   7_  <$_P 4 _\
M'P'] "H \@ X .H 10#G %$ XP!; .  9 #> &P W !S -H >0#8 '\ U0"$
M -, B@#1 (\ SP"5 ,T G #, *0 R@"M ,@ N0#' ,D Q0#< ,0 [ #" /@
MP0#_ ,  _P"_ /\ OP#_ +\ _P#_"0 &_P4 !/\(  /_"@("_P<- ?X!&0'T
M "0 Y@ Q .  /P#; $L V !6 -0 7P#1 &@ S@!O ,P =0#* 'L R "! ,8
MA@#$ (P PP"2 ,$ F0"_ *$ O@"J +P M@"Z ,4 N0#8 +< Z0"U O@ LP3_
M +($_P"P!O\ KP;_ *\&_P#_$  %_PP  O\4  ']%0  ^!$% /,*$0#H AP
MVP J -4 .0#0 48 RP-1 ,<$6@#$!6, P@=J +\(<0"^"'< O E] +H*@P"Y
M"HD MPN/ +8+EP"T#)\ LPRI +$-M0"O#L0 K@[8 *L1ZP"I$_L IA3_ *44
M_P"D%/\!I!3_ :04_P'_%0 #_Q@  ?@=  #H'   XAD  -X0! #:!A  T@DA
M ,H-,0#$$C\ OQ5+ +L650"X%UX MAAF +09;0"R&G, L!IY *\;?P"M&X4
MK!R, *H<DP"H')P IQVE *4=L0"D'L  HA[3 * ?YP"='_<!G!__ IL?_P*:
M'_\"F1__ ID?_P+_&0 !_"$  .DG  #@+   V"L  -(D  #/&0@ QQH; +\>
M+ "Y(3H M"-& + D40"M)5D!JR9A :DF: &G)V\!I2=U :0H>P&B*($!H2B(
M 9\HCP&>*9@!G"FA 9HIK0*9*;L"ERG- I4IXP.3*?4$D2G_!) I_P6/*/\%
MCRC_!8\H_P7_'@  [B@  .(S  #8.0  SSD  ,@T  ##*P( O"<5 +4K)@"O
M+#4"JBY! Z8O2P.C+U0#H#!<!)XP8P2<,6H$FS%P!)DQ=@28,7P$EC&#!)4Q
MBP63,9,%DC&=!9 RJ06/,K8&C3'(!HLQWP>),?('AS'_"(8Q_PB%,?\(A3#_
M"(4P_PC])0  Z3(  -P]  #10P  QT0  ,!   "Z.0  LS,/ *PV(0"F-B\#
MH38[!9TW1@>9-T\'ES=7")4W7@B3-V0(D3=K") W<0B..'@)C3A_"8LXA@F*
M.(\)B#B9"H<XI J%.+(*A#C$"X(XV@N ..\,?C?^#'TW_PQ]-_\,?3?_#'TW
M_PSS*@  Y#P  -9&  #+3   P4T  +E*  "R0P  JST) *4_'0">/RL#F3XV
M!Y0]00J1/4H+CCU2#(P]60R*/5\-B#UF#8<]; V%/7,-A#UZ#H(]@@Z!/8L.
M?SV5#WX]H0]\/:X/>SV_$'D]UA%W/>P1=CW\$'4\_Q!U//\0=#S_#W0\_P_O
M,P  WT,  -%-  #%4P  O%0  +11  "L2P  I44$ )Y&& "81B<"DD4R!XU$
M/ N)0D4.AD)-$(1!5!&"05H1@$%A$G]!9Q)]06X2?$%V$GI!?A-Y08<3=T&1
M%'5!G11T0:L5<D&[%7!!T19O0>D5;4'Z%6U!_Q1L0/\3;$#_$VQ _Q/K.@
MVTD  ,U3  #!6   N%D  +!8  "G4@  GTP  )A+% "232,!C$LO!8=*.0N#
M2$$/?T=($GU&3Q1Z1585>$5<%G=%8Q9U16H7<T5Q%W)%>AAP18,8;T6-&6U%
MF1EK1:<::46X&FA%S1MF1>8:947X&65$_QAE1/\7943_%V5$_Q?G0   V$X
M ,E8  "^70  M5X  *Q=  "C6   FE(  ))0$ "-4B  AU$L!()/-@E]33X/
M>4M%$W9*3!9S25(8<4E8&F](7QIM2&8;:TAM'&I(=AQH2'\=9DB*'F5)EAYC
M2*0?84BU'U](RB!>2.0?7DCV'5U(_QQ=2/\;74C_&EU(_QKD10  U%,  ,9<
M  "[80  LF,  *EB  "@7@  E5@  (U5"P"(5AT @E8I WU4,PAX4CL-=%!"
M$G!/2!=L34X::4Q4'&=,6QYE3&(?9$QI(&),<B%@3'PB7TR'(EU,DR-;3*$C
M64RR)%A+QR162^$C5DOU(59+_Q]72_\>5TO_'5=+_QWA2@  T%<  ,-@  "X
M9   KV<  *9F  "<8P  D5T  (E:!P"#6AD ?ELG 7E9,09T5SD+;U5 $6I3
M1A9F4DL:8U!1'F!05R%>3UXC7$]F)%I/;R593WDF5T^$)E5/D2=43Y\G4D^O
M)U!/Q"=/3]XG4$_S)%!/_R)03O\A4$[_(%!._R#=3@  S5L  ,!C  "V:
MK6L  *1K  "::   CF$  (1? P!^7Q8 >5\D 75>+@1P7#<):UH^#V991!5A
M5TD:755.'EI45")74ULE55-C)U-3;"E14W8I4%.!*4Y3CBE-4YTI2U.M*4I3
MPBE)4]PH25/R)DE3_R1*4O\C2E+_(DI2_R+:4P  RE\  +UG  "S;   JFX
M *%O  "7;   BF8  (!C  !Y8Q( =60@ '!C+ -K8C4'9F \#6)>0A-=74<8
M65M-'E5:4B-16%DF3UA@*4Q7:2I+5W,K25A_*DA8C"I'6)LI1EBL*$18P"A#
M6-LG0UCQ)4-7_B1$5_\C1%;_(T16_R/65P  QF,  +MJ  "Q<   J',  )]S
M  "5<0  AFL  'MH  !T: T ;V@= &MH*0%G9S(%8F8Z"UUE0!!98T865&%+
M'%!@4"%,7U<E25Y>*$=>9RE%7G(I1%Y^*$->BR="7IHF05^K)4!?OR0_7]HC
M/E[P(CY=_B(^7/\B/ES_(CY<_R+27   PV<  +AO  "N=   IG<  )QX  "2
M=P  @W$  'AO  !N;@@ :6X8 &5N)0!A;B\$76TW"%EK/@Y4:D034&A)&4MG
M3QY'9E4B1&5=)$)E9B5!97$E0&5])#]FBB(^9IDA/6:J(#QFOQX[9MD=.F3P
M'CEC_1XY8_\>.&+_'SAB_Q_-80  OVP  +5S  "L>   HWP  )I]  "0?
M@7@  '9V  !H= ( 8G03 %]T(0!;="P"6'0T!E-S.PI/<4$02W!'%49O31E#
M;E0=0&Y;'SYM91\\;7 >/&Y\'3MNB1PZ;ID;.6ZI&3ANOA@W;MD7-FSO&#5K
M_1DT:O\:-&G_&C1I_QK(9P  O'$  +)X  "I?@  H8(  )B#  "-@P  ?X
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M"2.$_PFY>P  L(0  *F+  "AD0  F94  (Z6  ""E@  =)4  &64  !6E
M294  #R5   TE@X ,I8< #"6)@ NEB\!+)8X BJ60 ,HE4D#)I52 R6570,C
ME6@#(I5U B&5@P(?E9,!'I2D 1R3N0 :D]0 &I'M 1F0_ (8C_\#&([_!!B.
M_P2U@P  K8P  *:3  "?F   E9L  (F<  ![G   ;9P  %^<  !0G   0YT
M #>>   KH   (Z$- "&A&@ ?H20 ':$M !RA-P ;H4  &:%* !BA50 6H6$
M%*!N !*@?0 0H(T #I^@  N>M  )G<T "ISH  N:^0 +F?\ "YG_  N9_P"P
MC   J90  *.:  ":G@  CJ   (&B  !TH@  9J,  %BC  !*I   /*8  #"G
M   EJ0  &JL  !"L"  ,K!0 "JP?  FL*0 'K#0 !JP^  2L2@ "K%8  *QD
M  "K<P  JX0  *J6  "IJ@  J,(  *?=  "G[P  IOD  *;^  "F_@"LE0
MIIP  )^A  "3I   AJ8  'BH  !JJ   7:D  $^K  !"K   -:X  "BP   >
ML@  %+0   FU    MP<  +<2  "X'   N"8  +@Q  "X/   N$@  +A6  "X
M9@  N'@  +B*  "WGP  MK4  +71  "SZ@  L_8  +/[  "S^P"IG0  HZ,
M )>G  "*J@  ?:P  &ZM  !@KP  4[   $6R   XM   ++<  ""Y   6NP
M"[X   ._    P0   ,($  ###0  Q!@  ,4B  #&+0  QCD  ,=&  #)50
MR6<  ,E[  #)D   R*8  ,>_  #&VP  Q>T  ,7U  #%]0"FI0  FZD  (ZL
M  "!KP  <K$  &.S  !5M0  2+@  #JZ   NO0  (K\  !?"   ,Q0   \@
M  #)    S    ,X   #/    T04  -,0  #5&P  UR<  -DT  #;0P  WE0
M -]H  #??@  WY0  -^J  #?P0  W]@  -[D  #>Y ">JP  DJX  (2Q  !U
MM0  9K<  %BZ  !*O0  /,   "_#   CQ@  %\D   S-   "T0   -4   #5
M    V    -H   #<    WP   .$   #D!   Z!$  .H>  #L+0  [SX  /%2
M  #R9P  \W\  /25  #TJ0  ]+D  /3%  #TQ0"5L   A[,  'FW  !JNP
M6[X  $W"   ^Q@  ,,H  "3-   7T0  "M4   ':    W@   .$   #A
MXP   .4   #G    Z0   .P   #O    \@   /8&  #Z%0  _24  /\W  #_
M30  _V0  /]\  #_D   _Y\  /^G  #_IP#_ !,'_P 1!O\ $03_ !,#_P >
M ?\ *P#_ #D _P!( /\ 5 #_ %X _P!H /\ <0#_ '@ _P!^ /\ @P#_ (D
M_P". /T DP#[ )@ ^0"> /< I0#V *T ]0"W /0 Q #T -@ \P#L /( ^P#P
M /\ [P#_ .\ _P#O /\ \ #_ /  _P#_ ! '_P ,!O\ "P3_  P#_P ; ?\
M)P#_ #8 _P!$ /\ 4 #_ %L _@!E /P ;0#[ '0 ^0![ /@ @ #W (4 ]0"+
M /0 D #R )4 \ "; .\ H@#M *H [ "S .L OP#J -( Z0#F .< ]@#E /\
MY0#_ .4 _P#D /\ Y #_ .0 _P#_  P'_P '!O\ !@3_  P#_P 7 ?\ ) #_
M #( _  _ /H 3 #X %< ]0!A /, :0#Q '$ \ !W .X ?0#L (( Z@"' .@
MC #F )( Y0"7 .0 G@#B *8 X0"O -\ NP#> ,L VP#@ -D \@#8 /\ V #_
M -8 _P#6 /\ UP#_ -< _P#_  4'_P  !?\   3_  D"_P 5 ?\ 'P#Y "T
M\P [ /  1P#N %( ZP!< .@ 90#F &P Y !S .$ >0#? 'X W0"# -L B0#:
M (X V "4 -8 F@#4 *( T@"J -$ M@#. ,4 S #9 ,L [0#) /L R #_ ,@
M_P#( /\ R #_ ,@ _P#_   &_P  !/\   /_  4"_P 1 ?P &@#N "< Z0 U
M .8 0@#B $T WP!7 -P 8 #9 &@ U0!O -( =0#0 'H SP!_ ,T A0#+ (H
MR@"0 ,@ EP#& )X Q "G ,( L@#  +\ O@#3 +T Z "\ /8 NP#_ +H _P"Y
M /\ N #_ +@ _P#_ 0 $_P   _\   '_    _P * /, $@#D "  WP N -H
M/ #5 $@ T0!2 ,T 6P#* &, QP!J ,4 <0## '8 P@!\ ,  @0"^ (8 O0",
M +L DP"Y )L MP"D +4 K@"S +P L@#. +  X0"O /$ K@#\ *L _P"J /\
MJ@#_ *H _P#_!@ #_P8  ?T*  #R"   [ (  .8 "0#; !@ U  G ,X -0#)
M $( Q !- ,  5@"] %X NP!F +D ; "W '( M0!X +0 ?0"R (, L ") *\!
MD "M I@ JP*A *H#K "H!+D IP3* *4&WP"C"/$ H0K^ * *_P"?"O\ G@K_
M )X*_P#_"@ !_A$  .L5  #C&   W10  -@* 0#2  X RP$> ,,$+@"^!SP
MN0E' +4+40"R#%D L YA *X.: "L$&X JA!T *D1>@"G$8  IA*& *02C0"C
M$Y4 H1.? )\4J@">%;@ G!7) )H6WP"8%_( EA?_ )48_P"4%_\!E!?_ 907
M_P'_$0  [QH  .0D  #:*   T28  ,L?  #'% 0 P! 7 +D5)P"S&#4 KAI"
M *H;3 "G'%0 I1U< *,>8P"A'FD H!]O )X?=0"<('P FR"" )H@B@"8()(
MER"; )4AI@"3(;0 DB'% ) AV@".(N\!C"+^ HLB_P**(O\#B2'_ XDA_P/Z
M&   Z2<  -TQ  #1-0  R#4  ,$P  "[)@  MAX1 *\B(@"I)3  I"8] *$G
M1P&=*% !FRE7 9DI7@&7*64!EBEK 90J<0&3*G<!D2I^ 9 JA0&.*HX"C2J7
M HLKH@*)*Z\"B"O  H<KU@.$*^P$@BO\!($K_P6 *O\%@"K_!8 J_P7R(@
MY#$  -8[  #*0   P4   +D[  "S-   K"L* *8M' "@+RL!FS W I<P0@.4
M,4L$DC%2!) Q602.,6 $C#%F!(LQ; 2),7,$B#)Z!88R@06%,HH%@S*3!8(R
MGP6 ,JP&?S*\!GTRT0=[,ND'>3+Y"'@Q_PAX,?\(=S'_"'<Q_PCM*@  WCH
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M%&) Q15A0-\58$#S%%] _Q-?/_\37S__$E\__Q+A0   T4T  ,-5  "Y60
MKUL  *=9  "=5   E$X  (M*"0"&2AH @4LG GQ),09X2#D*=$9!#G!%1Q%N
M1$X2:T14$VE$6A1H1&$59D1I%F5$<19C1'L7842%%V!$D1A>1)\87$2N&5I$
MPAE90]P:6$/Q&%A#_Q=80_\66$/_%5A#_Q7>10  S5(  ,!9  "V7@  K5\
M *1>  ":60  D%,  (=/!0"!3Q< ?% D 7=.+@5R33<);DL^#FI*1!%G2$H4
M9$A0%F)'5AA@1UT97D=E&EU';1I;1W<;6D>"&UA'CAQ61YP<54>L'5-'OQU1
M1]D=44?P'%%'_AI11O\944;_&%%&_QC:20  RE8  +Y=  "S80  JF,  *%B
M  "77@  C%D  ()4 0!\4Q, =U0A ')3+ -N4C0(:5 [#&5.01%A34<474Q-
M%UM+4QI92UH<5TMA'55+:AY42W0?4DM_'U%+BR!/2YD@34NI($Q+O2!*2]8@
M2DON'DI*_1U+2O\<2TK_&TM*_QO73@  QUH  +MA  "Q90  J&<  )]G  "5
M8P  B5T  'Y9  !W6 \ <E@> &Y8*0)I5S(&9%4Y"V!4/Q!<4D446%%*&%50
M4!Q23U<>4$]>($Y/9R%-3W$B2T]\(DI/B2)(3Y<B1T^H(49/NR%$3]0A1$_M
M'T1._!Y$3O\=14[_'$5._QS34@  Q%T  +AD  "O:0  IFL  )UK  "2:
MAF(  'I>  !R70L ;5T: &E=)@%D7"\$8%LW"5Q9/0Y76$,35%9(%U!53AQ-
M5%0?2E1<(4A492)&5&\C151Z(D14AR)#5)8A056F($!5N2 _5=,?/E3L'CY3
M^QX^4_\=/E+_'3Y2_QW05P  P6$  +9H  "L;0  I'   )IP  "0;@  @F@
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M%"YE_Q3#9@  MV\  *YV  "E>P  G7\  )2   "*?P  ?'P  &]Z  !A>
M5'4% $]U%0!,=B$ 2G8K 49U,P1#=#H'/W1 "SQS1PXY<TX0-G)6$35R8!$S
M<FH0,G)V#S%RA XQ<I(-,'*C#"]RM@LM<L\*+''I"RMO^0TJ;O\.*6W_#REM
M_P^^;   M'4  *M\  "C@0  FX4  )*&  "(A@  >H0  &N!  !=@   3WX
M $9]#0!#?1L 07XE #Y]+@$[?38$.'T]!C5\1 @S?$P*,7Q5"B]\7@HN?&D*
M+7QU"2Q\@P@K>Y$'*7NB!BA[M04G>LX%)GGI!25X^0<D=O\)(W7_"B-U_PJZ
M<@  L'L  *B"  "AB   F8L  )"-  "$C   =HL  &:)  !8B   2X<  #V&
M!  WAA( -8<> #2')P QAS !+X8X BV&0 0KADD%*891!2>&6P0FAF8$)89S
M R2%@ ,BA8\"(86@ A^$M $>A,P!'8+H 1R!^0,<@/\$&W__!1M__P6U>@
MK8,  *6*  ">CP  EI(  (N3  !_DP  <9$  &&0  !3D   1I   #B0   L
MD < *) 4 ":0'@ DD2@ (Y$Q "&1.@ @D4,!'I!, 1V05@ ;D&( &I!N !B0
M?  6CXP %(^= !*.L0 0C<D $(SE !&+]P 1BO\!$(G_ 1")_P&Q@@  J8H
M *.1  "<E@  DI@  (69  !XF0  :I@  %N7  !,F   /Y@  #.9   GF0
M&YL& !:;$@ 5FQT $YLF !*;,  1FSD #IM#  R;3@ *FUH ")MG  >:=0 %
MFH4  YF6  "8J@  E\$  );;  "5[@  E/H  9/_  &3_P"MBP  IY(  *"8
M  "8G   BYX  'Z?  !PGP  8IX  %2?  !&H   .*$  "RB   @HP  %J0
M  NF!  #I@\  *<:  "G)   IRX  *<X  "F0P  ID\  *9=  "F:P  I7P
M *6-  "DH0  HK<  *#3  "?ZP  G_4  )_\  "?_ "JE   I)H  )R?  "0
MH@  @Z,  '6D  !GI0  6:4  $NF   ]J   ,*D  "2K   9K   #ZX   6O
M    L 0  +$.  "Q&   LB(  +(L  "R-@  LD(  +)/  "S7P  LG   +*"
M  "QE@  L*L  *_%  "MXP  K/,  *O]  "K_0"GG   H*(  )6E  "(IP
M>JD  &NJ  !=JP  3ZP  $&N   TL   )[(  !RT   1M@  ![<   "Y
MN@   +L!  "\"0  O10  +X>  "_*   P#,  ,$_  #"3@  PV   ,-S  #"
MB   PIX  ,&U  # T0  O^<  +[U  "^]0"CHP  F*<  (RJ  !^K   ;ZX
M &"P  !2L@  1+0  #:V   IN   ';L  !*]   'P    ,(   ##    Q
M ,8   #(    R@0  ,P-  #.&   T",  -(O  #4/   V$T  -E@  #:=@
MVHT  -FD  #8NP  V-(  -CG  #8YP";J0  CZP  (&O  !RL@  8[0  %6W
M  !'N0  .+P  "N_   >P@  $L4   ?(    RP   ,X   #.    T    -,
M  #5    V    -L   #>!   X1$  .0=  #F*@  ZCD  .U,  #O80  \'@
M /&/  #QHP  \+4  /#'  #PQP"2K@  A;$  ':U  !GN   6+L  $F_   Z
MP@  +,8  !_)   3S   !=    #4    V    -P   #<    W@   .    #B
M    Y0   .@   #L    [P   /,%  #U%0  ^"0  /LV  #^2@  _V   /]W
M  #_C   _YP  /^I  #_J0#_  \&_P ,!/\ "P/_  X!_P : /\ *0#_ #@
M_P!% /\ 40#_ %L _P!E /\ ;0#_ '0 _P!Z /X @ #\ (4 ^P"* /D CP#X
M )0 ]P": /< H0#V *D ] "S /, OP#R -$ [P#G .X ^0#M /\ [0#_ .T
M_P#M /\ [0#_ .T _P#_  P&_P )!/\ " /_  H!_P 7 /\ )0#_ #0 _P!!
M /\ 30#_ %@ _0!A /L :0#Y '$ ]P!W /4 ?0#S (( \0"' /  C #O )$
M[@"7 .T G0#L *4 Z@"N .D N@#F ,H Y #A ., ] #A /\ X0#_ .$ _P#A
M /\ WP#_ -X _P#_  8%_P #!/\  0+_  H!_P 4 /\ (0#] "\ ^@ \ /@
M20#V %, \P!= /$ 90#N &T ZP!S .D >0#G 'X Y@"# .4 B #D (T X@"3
M .$ F0#? *$ W0"J -H M0#7 ,0 U@#: -0 [@#3 /T T@#_ -  _P#- /\
MS #_ ,L _P#_   %_P   _\   +_  <!_P 0 /D ' #S "H \  X .T 1 #K
M $\ Z !9 .0 80#A &D W@!O -P =0#: 'H V0!_ -< A #5 (D U "/ -(
ME0#/ )T S0"F ,H L #( +X QP#2 ,4 YP#$ /D P #_ +X _P"] /\ O0#_
M +T _P#_   $_P   O\   '_  ( _@ ) .\ %@#I "0 Y0 R .$ /P#> $H
MV@!4 -4 70#2 &0 SP!K ,T <0#+ '8 R@![ ,@ @ #& (4 Q "+ ,( D0#
M )D O@"A +P K "Z +D N #* +8 X0"S /, L0#_ +$ _P"P /\ L #_ +
M_P#_   #_P   ?\   #\    \P " .4 #P#? !X V0 K -0 .0#/ $0 RP!/
M ,< 6 #$ %\ P@!F +\ ; "^ '( O !W +H ? "X (( M@"' +4 C@"S )4
ML0"> *\ J "M +0 J@#% *@ VP"G .X I@#Z *4 _P"E /\ I #_ *0 _P#_
M   !_P   /$   #I    X0   -L !P#4 !8 S0 E ,< ,@#" #\ O@!) +H
M4@"W %H M0!A +, 9P"Q &T KP!S *X > "L 'X J@"$ *D B@"G )( I0";
M *, I0"A +$ H #! )X U0"= .D FP#W )H!_P"9 ?\ F0'_ )@!_P#_
M\0@  .82  #=%   U0X  ,\%  #)  T P@ < +T *@"W #@ LP!# *\!30"L
M U4 J@1< *@%8P"F!6D I 9N *,&= "A!WH H >  )X(AP"<"8\ FPF8 )D*
MHP"7"J\ E@J_ )0+U "2#>H D0[Z (\/_P"/#_\ C@__ (X/_P#Y"0  ZA@
M -XA  #3)   RB(  ,,;  "^#@  N084 +(*(P"M#C$ J!$] *421P"B$T\
MGQ17 )T57@";%60 FA9J )@6< "7%G8 E1=] )07A "2%XP D1B5 (\8H "-
M&*P C!B\ (H9T0"(&N@ AQOY (4;_P&%&_\!A!K_ 80:_P'R%@  Y"4  -8N
M  #*,@  P3$  +HK  "T(0  KA8+ *@9'0"C'"L GAXW )L?0@"8($L E2!2
M ),A60"1(5\ D"%E (XA; "-(G( BR)Y (HB@ "((X@ AR.1 (4CG "$(ZD
M@B.X ($DS0%_).0!?23W GPD_P)[)/\#>R/_ WLC_P/M(0  WB\  ,\X  ##
M/   NSP  +,W  "L,   IB4% )\D%P":)R8 E2@R )(I/0&/*48!C"I. 8HJ
M50&(*EL!ARIA 84J9P&$*VX!@BMT H$K? )_*X0"?BR. GPLF0)[+*4#>2RU
M W@LR -V+.$$="SU!7,K_P5R*_\%<BO_!7$J_P;H*@  V#D  ,E"  "^10
MM44  *U!  "E.@  GC(  )<M$@"2,"$ C3 M 8DQ. .&,4$#A#%)!((Q4 2
M,58$?C%<!'TQ8@1[,6D$>C%P!7@R> 5W,H %=3**!7,RE09R,J(&<#*Q!F\R
MQ0=M,MT':S+R"&HQ_PAI,?\(:3'_"&DQ_PCC,@  TT   ,5(  "Z3   L4P
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M$U,^_!-3/O\24SW_$5,]_Q'81   QU   +M7  "Q6P  J%P  )]:  "550
MBU   (%*  !Z2!$ =4D? '%(*0)L1S(&:$4Y"61$0 QA0T8/7T-,$5Q"4A);
M0ED364)@%%A":1560W(554-]%E-#B1910Y864$.F%TY#N!=,0M 73$+J%TQ"
M^Q5,0?\53$'_%$Q!_Q3420  Q%0  +A;  "N7P  IF   )Q?  "26P  B%4
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M%SE._Q?)5@  O&   +%F  "H:@  GVT  )9L  ",:@  ?F0  '-A  !F70
M7UP0 %Q<'0!87"<!55LO!%%;-@A-63P,25A"$$972!1#5D\70%96&3Y67QD\
M5FD9.U9T&3I7@1@Y5Y 7.%>@%C=7LA4V5\H4-5?E%#15]Q4S5/\6,U3_%C-3
M_Q;&6P  N60  *]J  "F;P  G7$  )1Q  "*<   ?&L  '%H  !D90  66(+
M %5B&0!38B0 3V(L DQA- 5(8#H)15] #4%>1A ^7DT3.UU5%3E=7A4X76@5
M-UYT%#9>@1,U7H\2-%Z?$3->L1 R7LD/,5WD#R]<]Q$N6O\2+EK_$RY9_Q/"
M8   MFD  *QO  "D=   FW8  ))W  "(=@  >G(  &]O  !A;   5&D% $YH
M% !,:1\ 26DI 49H,0-"9S@&/V<^"CQF10TY9DP/-F54$#1E71 S96<0,F9S
M#S%F@ XP9HX-+V:>#"YFL0LM9<@*+&7D"BMC]@PJ8O\.*6'_#RE@_P^^90
MLVX  *IT  "B>0  F7P  )!]  "&?   >7D  &QV  !>=   4'$  $9P#0!$
M<!H 07 D #]P+0$[;S0$.&\[!C5N0@@S;DH*,6Y2"R]N6PLN;F4*+6YQ"2QN
M?P@K;HT'*FZ=!RENL 8G;<<%)FWC!25K]@<D:?\)(VC_"B-H_PJZ:P  L',
M *=Z  "??P  EX(  (^#  "%@P  =X   &A]  !:>P  3'H  #YX!@ Y>!0
M-W@> #5X*  S># !,7@X RYW/P0L=T<%*W=0!2EW604H=V0%)G=P!"5W?00D
M=XP#(G>< B%VK@(?=L4!'W7B 1YS]0,=<O\%'''_!AQQ_P:U<@  K'H  *6!
M  "=A@  EHD  (V*  "!B0  <X<  &.%  !5@P  2((  #J!   O@0H +($7
M "J!(  H@2H )X$R "6!.@$C@4,!(8%, 2"!5@$?@6 !'8%M 1N!>@ :@(D
M&("9 !9_K  4?L, $WW? !1\]  4>_\!%'K_ A1Z_P*Q>0  J8$  **(  ";
MC0  E(\  (B0  !\CP  ;8X  %Z,  !0BP  0HL  #6+   HB@  'XL+ !R+
M%P :BR  &8LI !>+,@ 6BSL %8M% !.+3P 1BUH #XMG  V+=0 *BH0 "(F4
M  :(IP $A[T !(;6  2&[  %A/H !H/_  :#_P"M@0  IHD  *"/  "9DP
MCY4  (.6  !UE0  9I0  %B3  !)DP  .Y,  "^4   CE   &)4   R6"@ )
MEA8 !Y4@  :6*0 %EC(  Y4\  *51P  E5,  )5@  "5;@  E'T  )..  "3
MH   D;4  )#0  "/YP  C_0  ([[  "._@"JB@  I)$  )Z6  "5F0  B9L
M 'N;  !MFP  7IL  %";  !!FP  -)P  "B=   <G@  $I\   :@ 0  H L
M * 6  "@'P  H"@  *$R  "A/0  H$D  *!6  "@90  H'4  )^&  ">F
MG:T  )S'  ":Y   F?0  )G[  "9_0"GDP  H9D  )F=  ".GP  @:$  '*A
M  !DH0  5:(  $>B   YI   +*4  ""F   5IP  "J@   "I    J@$  *L*
M  "K%   JQT  *PF  "L,   K3P  *U)  "M6   K6@  *UZ  "LC@  JJ0
M *F\  "HV@  I^\  *;Z  "F_0"DFP  G:   )*C  "%I0  =Z8  &BG  !:
MJ   2ZD  #VJ   PK   (ZT  !>O   +L    K$   "S    M    +4   "V
M!0  MQ   +@9  "Y(@  NBT  +LZ  "\2   O5D  +UL  "]@   O)4  +NL
M  "YR   M^0  +;T  "V^ "AH@  EJ4  (FH  ![J@  ;*L  %VM  !/K@
M0+   #*R   EM   &+8   RX   "N@   +P   "]    O@   ,    #!
MPP   ,4(  #'$P  RAT  ,PI  #.-@  T4<  -):  #2<   TX8  -*<  #2
MLP  T<H  -'@  #1Y@"9J   C:H  '^M  !OL   8+$  %*S  !#M@  -+@
M ">[   :O0  #,    +#    Q@   ,<   #(    R0   ,L   #.    T
M -,   #6 0  V@P  -X8  #B)0  Y3,  .E&  #K6P  ['(  .R*  #LH
M[+,  .S$  #LRP"0K   @J\  '.S  !DM0  5;@  $:[   WOP  *,(  !O%
M   -R    <L   #/    T@   -0   #4    U@   -D   #;    W@   .$
M  #E    Z0   .T%  #Q$@  ]"   /@P  #\10  _EL  /]R  #_B   _YH
M /^H  #_K0#_  L$_P ) O\ !P'_  @ _P 8 /\ )P#_ #4 _P!" /\ 30#_
M %@ _P!A /\ :@#_ '$ _ !W /L ?0#Z (( ^0"& /@ BP#W )$ ]@"7 /4
MG0#T *4 \P"N /$ N@#N ,L [ #B .L ]@#K /\ Z@#_ .@ _P#E /\ X@#_
M -X _P#_  <$_P $ O\  P'_  @ _P 4 /\ (P#_ #$ _P ^ /\ 2@#^ %0
M^P!> /@ 9@#U &X \P!T /( >0#P 'X [P"# .X B #M (T [ "3 .L F0#I
M *$ YP"J .0 M0#B ,4 X #: -\ \0#> /\ V@#_ -8 _P#4 /\ U #_ -0
M_P#_  $$_P   O\   '_  , _P 1 /X '@#[ "P ^  Y /8 10#T %  \ !:
M .P 8@#I &H Z !P .8 =0#E 'L XP!_ .( A #@ (D WP"/ -T E0#: )T
MV "E -4 L #3 +X T0#2 ,\ ZP#+ /P QP#_ ,8 _P#& /\ Q@#_ ,8 _P#_
M   #_P   O\   #_    ^P * /0 &0#P "< [0 T .H 0 #G $L X@!6 -\
M7@#< &4 V@!L -@ <0#6 '8 U ![ -( @ #1 (4 S@"+ ,P D0#* )@ R "A
M ,4 JP## +@ P0#+ +T XP"Z /8 N0#_ +D _P"Y /\ N0#_ +@ _P#_   "
M_P   ?\   #_    \  % .H $P#E "( X0 O -P .P#7 $< TP!0 -  60#-
M &  R@!G ,@ ;0#& '( Q !W ,( ? #  ($ OP"' +T C0"[ )0 N0"= +<
MIP"S +, L #$ *\ V@"N /  K0#_ *P _P"L /\ JP#_ *L _P#_   !_P
M /L   #O    Y@   -\ # #9 !L T@ H ,T -@#) $$ Q0!+ ,( 5 "_ %L
MO !B +H : "X &T M@!S +0 > "S 'T L0"# *\ B0"M )  JP"9 *@ H@"F
M *X I0"] *, T@"B .D H0#Y *  _P"? /\ G@#_ )X _P#_    ]@   .P
M  #C    VP   -, !0#, !0 Q0 B ,  +P"\ #L N !% +4 3@"Q %8 KP!=
M *T 8P"K &D J@!N *@ <P"F 'D I0!_ *, A0"A (P GP"5 )T G@"< *H
MF@"X )@ S "7 ., E0#S )0 _@"3 /\ DP#_ )( _P#Z    [ 8  .$.  #7
M$   S@D  ,<   #!  L NP : +4 )P"Q #, K0 _ *D 2 "F %  I !7 *(
M7@"@ &0 G@!I )T ;P"; '4 F@![ )@ @0"6 (D E0"1 ), FP"1 :< CP&U
M (X"R ", ]X BP7Q (D&_@"(!_\ AP?_ (<'_P#R"   Y1<  -@?  #,(@
MPQX  +T6  "W"@  L0 1 *L 'P"F!"T H@<X )\(0@"<"4L F0I2 )<+60"6
M#%\ E QE )(,:@"1#'  D UW (X-?@",#H8 BPZ/ (D.F@"(#Z8 AA"U (00
MR "#$>  @1/T ( 4_P!_%/\ ?A3_ 'X3_P#M%@  WB,  - L  #$+P  NRP
M +0G  "M'0  J!$& *(/& "<$R8 F!4R )46/0"2%T4 D!A- (T85 ",&5H
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M!60L_ 5C*_\&8RO_!F,K_P;=,@  S#\  +]&  "U20  K$D  *-%  ";/P
MDC@  (HO!P"$+Q< @# D 'PP+@)Y,3<#=C%  W0Q1P1R,4T$<#%3!&\Q601M
M,6 %:S%G!6HQ;P5H,7<%9S&!!64RC 9D,ID&8C*H!V RN@=>,M$(73+J"%PQ
M^PA;,?\(6S#_"%LP_PC8.0  R$4  +Q+  "Q3@  J$\  )],  "71@  CD
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M$$<\_Q#-20  OU(  +18  "J7   H5T  )A;  ".5P  @U$  'E,  !N1P8
M:$85 &1'(0!@1BH"7$4Q!5E$. A50SX+4D)##5!"2@].05$134%8$DM"81)*
M0FH32$)U$T="@1-%0X\41$.>%$)#L!1 0L84/T+B$S]"]A,_0?\20$#_$D!
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M%3I,?A0Y38L3.$V;$S=-K1(U3<,1-$W?$3-,]!(S2_\2,TK_$S-*_Q/$50
MMUX  *UD  "D:   FVH  ))I  "(9P  >V$  '!>  !C6@  6%8) %16%@!1
M5B$ 3E8J DI5,01'5#<(1%0]"T!31 X]4DH0.U)2$CE26A,W4F03-E)P$C53
M?!$T4XL0,U.:#S)3K XQ4\(.,%/>#2]2\P\N4/\0+E#_$2U/_Q' 6@  M&(
M *MH  "B;   F6\  )%N  "&;   >6@  &YE  !A80  4UT$ $U<$@!+7!T
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M R)IJ0(@:;\"'VC; 1YG\0,=9?X%'63_!AQC_P>U:@  K'(  *1X  "<?0
ME'\  (N   ""@   ='T  &5Z  !7>   278  #MT   Q<@P +G(7 "QR(0 J
M<RD *',R "=S.0$E<T$"(W-* B)S4P(@<UX!'W-J 1UR=P$<<H4 &G*5 !AQ
MIP 7<;T %7#9 !9N\  6;?X!%6S_ A5L_P.Q<0  J7@  *%_  ":A   DX8
M (J'  !^A@  <(0  &"!  !2@   1'X  #9\   J>P, (GL0 "![&@ >>R,
M'7PK !M\-  :?#P _^)]$$E#0U]04D]&24Q% !,5&'Q% !=\3P 5?%H %'QF
M !)\<P 0>X( #7N2  MZI  )>;D "'C2  AWZP *=?H "G7_  IT_P"N>
MIH   )^&  "8B@  D8T  (:-  !YC   :HH  %N(  !,AP  /X8  #&&   E
MA0  &84$ !&&$  0AAD #88C  R&*P *AC0 "88^  B%2  &A5, !(9@  *%
M;0  A7P  (2,  "#G@  @K(  (#-  !_Y   ?_,  '[[  !]_P"J@   I(@
M )V-  "7D0  C),  ("3  !RD@  8Y$  %20  !%CP  .(\  "N/   ?CP
M%(\   B0!@  D!$  ) :  "0(P  D"P  ) V  "00   D$P  )!8  "09@
MCW4  (^&  ".F   C*P  (O$  ")X@  B/(  (CY  "'_@"GB0  H9   )N5
M  "2EP  AI@  'B8  !JF   6Y<  $R7   ]EP  ,)@  "28   8F   #)D
M  *:    F@@  )H2  ":&P  FB0  )LL  ";-P  FT(  )M/  ";70  FVT
M )I^  "9D   F*0  )>\  "6V0  E/   )/Z  "3_P"DD0  GY<  )>;  "+
MG0  ?IX  &^>  !@G@  4IX  $.?   UH   **   !RA   0H@  !:,   "D
M    I0   *4&  "E$   IA@  *8A  "G*P  IS8  *="  "G40  J&(  *=T
M  "GAP  IIL  *6R  "DS@  HND  *+V  "A_0"BF@  FYX  )"A  "#H@
M=*,  &6D  !6I   2*4  #FG   KJ   'JD  !*J   &K    *P   "N
MKP   *\   "P @  L0L  +(5  "S'@  M"@  +4T  "V00  MU(  +=E  "W
M>0  M8X  +2F  "SP   L]T  ++O  "Q]P"?H0  DZ0  (:F  !XJ   ::D
M %JJ  !+JP  /*T  "ZN   @L   %+(   >T    M0   +8   "X    N0
M +H   "\    O0   +\$  # #@  PQ@  ,4D  #',0  R4$  ,M4  #-:0
MS7X  ,V5  #,K   R<8  ,C>  #'[ "6I@  BJD  'RK  !MK0  7JX  $^P
M  ! L@  ,+4  ".W   6N0  ![P   "^    P0   ,$   ##    Q    ,8
M  #(    R@   ,T   #0    TP<  -D3  #<'P  WRT  .-   #E50  YFP
M .>$  #HF@  YZX  .>_  #GS "-JP  @*T  '&P  !AL@  4K4  $.X   S
MNP  )+X  !?!   )PP   ,<   #*    S0   ,X   #/    T    -$   #4
M    V    -P   #@    Y    .@   #M#   \1L  /0J  #X/P  ^U8  /QN
M  #\A0  _)D  /RG  #\L0#_  <"_P % ?\  0#_  8 _P 5 /\ ) #_ #(
M_P ^ /\ 2@#_ %4 _P!? /X 9P#\ &X ^P!T /H >@#Y '\ ^ "# /< B #V
M (T ]0"3 /0 F0#R *$ [P"J .T M@#L ,< Z@#> .D \P#G /\ X@#_ -X
M_P#> /\ V0#_ -8 _P#_  ("_P   ?\   #_  , _P 2 /\ ( #_ "T _P Z
M /\ 1@#[ %$ ]P!; /0 8P#R &H \0!P /  =@#N 'L [0"  .P A #K (D
MZ0"/ .< E@#E )T XP"F .$ L0#? ,  W0#5 -H [ #4 /\ T0#_ -  _P#0
M /\ T #_ ,T _P#_   "_P   ?\   #_    _P , /L &P#X "D ]@ V /,
M0@#O $T ZP!7 .D 7P#G &8 Y0!L ., <@#A '< X !\ -X @0#< (8 V@"+
M -@ D@#5 )D TP"A -$ K #/ +D RP#- ,8 Y@#$ /H PP#_ ,( _P#" /\
MP@#_ ,( _P#_   !_P   /\   #^    ]@ ' /$ %@#M ", Z0 Q .0 /0#A
M $@ W@!2 -L 6@#8 &( U0!H -, ;0#1 ', SP!X ,T ?0#+ (( R0"' ,<
MC0#% )4 PP"= ,$ IP"] +0 N0#% +< W@"V /, M0#_ +0 _P"T /\ M #_
M +0 _P#_   !_P   /\   #S    ZP " .4 $ #@ !X V0 K -0 . #1 $,
MS@!- ,L 50#( %P Q0!C ,( :0#  &X OP!S +T > "[ 'T N@"# +@ B0"V
M )  LP"8 +  H@"N *X K "] *H U "I .L J #\ *< _P"G /\ IP#_ *8
M_P#_    _P   /    #H    X    -@ "@#0 !@ RP F ,8 ,@#" #T OP!'
M +P 4 "Y %< M@!> +0 9 "R &D L0!N *\ = "M 'D K !^ *D A0"G (P
MI@"4 *0 G0"B *@ H "W )X R@"= ., G #V )L _P": /\ F@#_ )D _P#_
M    \0   .<   #=    TP   ,L  P#$ !( OP ? +H *P"U #< L@!! *\
M2@"L %( J@!8 *< 7P"F &0 I !J *( ;P"A '0 GP!Z )X @ "< (< F@"/
M )@ F0"6 *0 E "Q ), PP"1 -P D #P (\ _0"- /\ C #_ (P _P#U
MZ 0  -P+  #0"P  QP8  ,    "Z  D M  7 *X ) "J "\ IP Z *, 1 "A
M $P G@!3 )P 60": %\ F0!E )< :@"6 &\ E !U ), ? "1 (, CP"+ (T
ME0"+ *  B@"N (@ OP"& -4 A #K (, ^0"" /\ @@#_ ($ _P#M!P  X!4
M -$=  #&'@  O1H  +81  "P!0  J@ . *4 ' "@ "@ G  S )D /0"6 $8
ME %- )("5 "0 UH C@-? (T$90"+!&L B@1Q (@%> "&!8  A0:( (,&D@"!
M!IX @ :L 'X&O !]!], >PGJ 'H+^@!Y"_\ > O_ '@+_P#G%0  V"(  ,DJ
M  "^*P  MB@  *XC  "G&0  H0P$ )L%% "6"2( D@LM (\,-P",#D  B@](
M (@03P"&$%4 A!%; (,180"!$F< @!)M 'X2= !]$WP >Q.& 'H3D !X$YP
M=A.J '44O !S%-, <1;K ' 6_ !O%O\ ;Q;_ &\6_P#A(0  T"T  ,,T  "X
M-@  KS0  *@O  "@)P  F1T  )(3# "-%1P B1<H (49,@"#&CL @1I# '\;
M2@!]&U  >QM6 'H<7 !X'&( =QQI '4<<0!S'7D <AV" ' =C0!O'9D ;1ZG
M &P>N0!J'L\ :!_H &<?^@%F'_\!9A[_ F4>_P+;*0  RC8  +X\  "S/@
MJCT  *(Y  ":,P  DBH  (H@!P"%'Q8 @2$C 'TB+0![(S< >",_ '8C1@!T
M)$P <R12 '$D6 !O)%\ ;B1E &PD;0!K)74 :25_ 6@EB@%F)I8!9":E 6,F
MM@%A)LP"7R;F EXF^ -=)O\#727_!%TE_P36,@  QCT  +I#  "P1@  IT4
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M"T<U] M'-/\+1S3_"T<S_PK*1   O$P  +%2  "H50  GU8  )93  ",3@
M@DD  'A#  !M.P0 9SH3 &,['@!?.R<!6SHO U@Y-@56.3P'4SA""%$X2 E0
M.$\*3CA7"DTY7PM+.6@+2CES#$@Z?PQ'.HP,13J;#4,ZK U".L$-0#G<#4 Y
M\PU ./\-0#C_#4$W_PS'2   NE$  *]6  "F60  G5H  )18  ")4P  ?TX
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M#BU%_PZ^5   LUP  *EB  "@9@  EV<  (YF  "$8P  =UX  &Q;  !@5P
M4U(" $Q0$ !)4!L 1E D $-0+ ) 3S($/4\X!SI./PDX3D8+-4Y-##1.5@TR
M3F -,4YK##!/> LO3X8++D^5"BU/IPDL3[L(*D_6""E.[@DH3/T+*$O_#"A+
M_PV[60  L&$  *=F  ">:@  EFP  (UK  "#:0  =F0  &MB  !>7@  45H
M $96"P!"5A< 0%8A #U6*0$Z5C #-U8V!355/0<R540(,%5,"2]550DM55\)
M+%9J"2M6=P@J5H4'*5:4!BA6I@8G5KH%)5;5!"14[@8C4_T((E+_"2)1_PJX
M7@  KF8  *5K  "<;P  E'$  (MQ  "!;P  =&L  &EI  !<9@  3F(  $!>
M!@ Z71( .%T< #9=)0 S72T!,5TT B]=.P0M74(%*UU*!2E=4P8H75T%)UUI
M!25==00D78,#(UV3 R)=I (@7;D"'US4 1Y;[0,=6?P%'5C_!AQ8_P>U8P
MJVL  *-Q  ";=0  DW<  (IW  " =@  <W,  &9P  !8;0  2FH  #QG   R
M90P +V47 "UE(  K92@ *64P 2=E. $E94 ")&5( B)E40(A95L"'V5F 1YE
M<P$=98(!&V61 !IDHP 89+< %V/2 !=B[  78/L"%F#_ Q5?_P2Q:0  J'$
M *!V  "9>P  D7T  (E^  !_?0  <7H  &)W  !4=   1G(  #AO   K;@4
M)&T1 ")M&@ A;2, 'VTK !YM,P <;3L &VU$ !EM30 8;5@ %FUC !1M<  2
M;7\ $&V.  YLH  ,:[0 "FK-  MIZ  ,:/D #6?_  UF_P&N<   IG<  )Y]
M  "7@0  D(0  (>%  ![@P  ;(   %U^  !/?   07H  #-X   G=P  &W8(
M !9V$P 4=AP $G8D !%V+  /=C4 #78^  QV2  *=E, "'9>  9V;  $=GH
M G6*  !UFP  =*X  '+'  !QX0  </(  &_\  %N_P"J=P  HWX  )R$  "6
MB   CHL  (.*  !VB0  9X<  %>%  !)A   .X(  "Z!   A@   %H    F
M"0 $@!0  H =  & )@  @"X  ( W  " 0@  @$T  (!9  " 9@  ?W4  '^%
M  !^E@  ?:D  'O!  !ZW@  >>\  'CY  !X_@"G?P  H88  )N,  "4CP
MBI   'V0  !OCP  8(T  %&,  !"BP  -(L  ">*   ;B@  $(H   2+ P
MBPP  (L6  "+'@  BR<  (LO  "+.@  BD4  (I1  "+7P  BFX  (I^  ")
MD   AZ,  (:[  "$V   @^\  (+[  ""_P"DB   GXX  )F3  "0E0  @Y8
M ':5  !GE   6)0  $F3   ZDP  +9,  ""3   4E   ")0   "5    E04
M )4-  "5%@  E1X  )4G  "6,   ECL  )5(  "65@  EF4  )5V  "5B
ME)P  ).R  "1S@  D.D  ([X  "-_P"BD   G98  )69  ")F@  >YL  &R;
M  !=F@  3YH  #^;   QG   ))P  !>=   *G0   )X   "?    H    * #
M  "@#   H!4  *$=  "A)@  H3   *(]  "B2P  HEL  *)L  "B?P  H9,
M *"I  "?PP  GN$  )WR  "=_ "@F   F9P  (V>  " H   <:$  &*A  !3
MH0  1*(  #6C   GI   &J4   VF   !IP   *@   "I    J@   *L   "K
M    JP<  *P0  "M&0  KR(  + M  "P.P  L4T  +%@  "P=   L(@  +">
M  "OM@  KM,  *[I  "M]@"<GP  D:(  (2D  !UI0  9J8  %>G  !(J
M.:D  "JK   =K   #JX   *O    L0   +$   "S    M    +4   "V
MMP   +@!  "Z"@  O10  +\?  #!*P  PSL  ,5-  #'8@  QG@  ,20  #"
MJ   PL$  ,'9  #!ZP"4I   B*<  'JI  !KJ@  6ZP  $RM   \KP  +;$
M !^S   1M0   [<   "Z    O    +P   "^    OP   ,$   ##    Q0
M ,<   #*    S0,  -(-  #4&P  V"D  -P[  #?4   XF8  .)]  #CDP
MX:@  ."\  #?T0"+J0  ?JP  &ZN  !?L   4+(  $"U   PMP  (+H  !.]
M   $OP   ,(   #%    R    ,@   #*    RP   ,P   #/    T@   -8
M  #:    W@   .,   #I!P  [18  / E  #T.@  ]E(  /AJ  #Y@0  ^94
M /JD  #YL0#_  (!_P   /\   #_  0 _P 2 /\ ( #_ "X _P [ /\ 1P#_
M %( _@!< /P 9 #[ &L ^@!Q /@ =@#W 'L ]@"  /4 A0#T (H \@"/ /
ME@#N )X [0"G .L L@#J ,$ Z #9 .0 \0#> /\ VP#_ -P _P#9 /\ TP#_
M -  _P#_   !_P   /\   #_    _P . /\ ' #_ "H _0 W /H 0P#W $X
M] !8 /( 8 #P &< [P!M .T <P#L '@ Z@!\ .D @0#G (8 Y0", ., D@#A
M )H X "B -X K0#; +L UP#1 -$ Z@#. /T S0#_ ,T _P#- /\ R0#_ ,8
M_P#_   !_P   /\   #_    _0 ) /D %P#U "4 \0 S .T /P#K $D Z !3
M .4 6P#C &( X0!I -\ ;@#= '0 VP!X -D ?0#6 (( U0"( -, C@#1 )4
MSP"> ,T J #( +4 PP#) ,$ X@"_ /< OP#_ +X _P"^ /\ O@#_ +P _P#_
M    _P   /\   #Y    \@ $ .T $P#H "  X@ N -X .@#< $0 V0!. -4
M5@#2 %X T !D ,T :@#+ &\ R0!T ,@ >0#& 'X Q "# ,, B0#! )$ O@"9
M +H HP"W *\ M0#  +, UP"R /  L0#_ +  _P"O /\ KP#_ *\ _P#_
M_P   /<   #N    Y@   .  #0#8 !P T@ H ,X - #+ #X R !( ,4 40#!
M %D OP!? +T 90"[ &H N@!O +@ = "V 'D M0!_ +( A0"P (P K@"4 *P
MG@"J *D J "X *8 S "E .< HP#Z *( _P"B /\ H@#_ *( _P#_    ]@
M .P   #C    V@   -  " #) !8 Q  B ,  +@"\ #D N !" +8 2P"S %,
ML0!: *\ 8 "M &4 JP!J *D < "G '4 I@!Z *0 @ "C (< H0"/ )\ F "=
M *0 FP"Q )D PP"8 -T EP#S )8 _P"5 /\ E #_ )0 _P#Y    [    .$
M  #6    S    ,0  0"^  \ N  < +, * "O #, K  \ *D 10"F $T I !4
M *( 6@"@ &  G@!E )T :@"< '  F@!U )D >P"7 (( E0"* ), DP"1 )\
MCP"K (T O ", -, B@#L (D _ ") /\ B #_ (< _P#P    X@(  -4(  #)
M"   P0$  +H   "S  < K0 5 *@ (0"D "P H  V )T /P"; $< F0!. )<
M5 "5 %H DP!@ )( 90"0 &L CP!P (T =P"+ 'X B@"& (@ CP"& )H A "G
M (( MP"! ,T @ #F 'X ]@!] /\ ? #_ 'P _P#H!P  VA0  ,L;  # &@
MN!8  + ,  "J 0  I  , )X &0": "4 E@ O ), .0"0 $$ C@!( (P 3P"*
M %4 B0!; (< 8 "& &8 A !L (( <@"! 'H ?P"" 'T C !\ )< >@"D '@
MM !W ,@ =0'A '0"\P!S _\ <@/_ '(#_P#A%0  T"$  ,,G  "Y*   L"4
M *D?  "B%0  FP@" )4 $0"0 !X C (I (D#,P"&!3L A 9# (('20" "%
M?PA6 'T(6P!\"6$ >@EH '@);P!W"G8 =0I_ ',*B@!R"I4 < NC &\+LP!M
M"\@ :PWB &H.]0!I#O\ :0[_ &@._P#;(   RBP  +XQ  "S,P  JC$  *(K
M  ";)   DQD  (P-!P"'#!< @PXB '\0+0!]$34 >Q(] 'D31 !W%$L =111
M ',45P!R%%T <!5C &\5:P!M%7, ;!5\ &H6AP!H%I, 9Q:A &46L0!C%\<
M8ACA &$8]0!@&/\ 7QC_ %\8_P'4*@  Q30  +DZ  "N/   ICH  )TU  "5
M+P  C28  (4< 0!^%Q$ >AD= '<:* !T&S$ <ALY ' <0 !N'$< ;!U- &H=
M4P!I'5D 9QU@ &8>9P!D'G  8QYY &$?A !@'Y  7A^? %P?KP!;(,0 62#>
M %@@\P%7(/\"5Q__ E<?_P+/,@  P#L  +5!  "K0P  HD(  )D^  "1.
MB#   '\H  !W( L <R$9 &\B) !L(BT :B,U &@C/ !F)$, 9"1) &(D3P!A
M)%4 7R1< %TE9 %<)6P!6R5V 5DF@0%7)HX!5B:< 50FK )3)L$"42;; E F
M\@-/)O\#3R7_!$\E_P3*.0  O4$  +)'  "H20  GT@  )9%  "-/P  A#D
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M"CHS_PG!1P  M4\  *M4  "B5P  F5<  (]5  "%4   >TL  '!&  !E/P
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M"B]$= DN1($)+461""Q%H@<K1;8'*47/!BA$Z@<H0_L))T'_"B=!_PNY4P
MKEL  *5@  "<8P  E&0  (MC  "!8   =%L  &E8  !=5   44\  $5+"0!!
M2A4 /DH> #M*)@ Y2BT"-DHS!#1*.@4Q24$',$E)""Y*40@M2EL(+$IF!RI+
M<P<I2X &*$N0!2=+H04F2[4$)$O.!"-*Z04B2/H'(D?_"")&_PFW6   K%\
M *-D  ";:   DFD  (EH  !_9@  <V(  &A?  !<7   3U<  $%2!  Y41$
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M !!?G  .7[  #%[(  Q=Y  .6_< #EK_ 0Y:_P&M:   I6\  )UU  "6>
MCGH  (9[  !\>@  ;G<  %]T  !1<0  1&X  #5L   H:@  '&@) !EH$P 7
M:!P %6@D !1H+  2:#0 $6@]  YH1P -:%$ "VA<  EH:0 ':'< !6>'  -G
MEP "9JH  67"  )DW0 "8_   V+]  1A_P"J;P  HG8  )M[  "4?P  C8$
M (6"  !X@   :GT  %IZ  !,>   /G8  #!T   C<P  &'(   QQ"P )<14
M!W$>  9Q)@ $<2\  W$X  %Q0@  <4P  '%8  !Q9   <',  '""  !ODP
M;Z8  &Z\  !LV0  :NT  &GX  !I_@"G=@  H'T  )J#  "3A@  C(@  (&(
M  !SA@  9(0  %2!  !&@   -WX  "I]   >?   $GL   9[!P  >Q   'L9
M  ![(0  >RD  'LQ  ![.P  >D<  'M2  ![7P  >FX  'I^  !YC@  >*$
M '>W  !UTP  =.T  '/X  !R_0"D?@  GH4  )B*  "2C0  AXX  'J-  !L
MC   78H  $Z)   _B   ,8<  "2&   7A@  "X8   "& 0  A@D  (82  "%
M&@  A2(  (8I  "&,P  A3\  (5+  "%6   A6<  (1X  "#B0  @IP  (&Q
M  " S   ?^D  'WX  !]_P"BAP  G(T  )>1  "-DP  @9,  '.3  !DD0
M59   $:0   VD   *8\  !R/   0CP  !)    "0    D (  ) )  "0$@
MD!H  ) A  "1*@  D34  )!"  "13P  D5X  )%O  "0@0  CY4  (VJ  ",
MQ   BN,  (GT  ")_0"@CP  FY0  ).7  "&F   >)D  &F8  !:EP  2Y<
M #R8   MF   ()@  !.8   &F0   )H   ";    FP   )L   ";"   FQ
M )L8  "<(   G2H  )TV  "=1   GE0  )YE  ">>   G8P  )RB  ";N0
MFM8  )CN  "7^0">EP  EYL  (N<  !^G@  ;YX  %^>  !0G@  09X  #&@
M   CH0  %J$   BB    HP   *0   "E    I@   *8   "F    IP,  *<+
M  "H%   J1T  *HI  "J-P  JT<  *Q9  "L;   K($  *R7  "KK@  JLD
M *GC  "I\0":G@  CZ   (*B  !SHP  9*,  %2D  !%I0  -:8  ">H   9
MJ0  "JH   "K    K0   *T   "N    L    +$   "Q    L@   +,   "U
M!0  MP\  +D9  "[)0  O30  +Y(  "_7@  OG0  +Z*  "^H0  O;D  +W3
M  "\Y0"2HP  A:4  '>G  !HJ   6*D  $FJ   XK   *:X  !NP   ,L0
M +,   "U    MP   +<   "Y    N@   +P   "]    OP   ,$   ##
MQ@   ,L)  #.%@  TB,  -4T  #92@  W&   -QX  #9D0  V*@  -:]  #6
MT ")IP  >ZH  &NL  !<K@  3:\  #RQ   LM   ';<   VY    NP   +X
M  #!    PP   ,,   #%    Q@   ,@   #*    S0   -    #4    V0
M -T   #C P  YQ(  .LB  #O-0  \TP  /5D  #V?   ]I$  />B  #UKP#_
M    _P   /\   #_  $ _P . /\ '0#_ "L _P X /\ 1 #^ $\ _ !8 /H
M8 #Y &< ]P!M /8 <P#U '@ \P!] /( @@#P (< [P", .T DP#L )H Z@"D
M .D K@#G +T XP#4 -T [P#: /\ V0#_ -D _P#3 /\ S@#_ ,H _P#_
M_P   /\   #_    _P + /\ &0#] "< ^  T /8 0 #T $H \0!4 .\ 7 #M
M &, ZP!I .D ;P#G '0 Y0!Y .0 ?@#B (, X0") .  CP#> )8 W "? -H
MJ0#4 +< SP#, ,P YP#+ /L R@#_ ,D _P#( /\ PP#_ ,  _P#_    _P
M /\   #_    ^@ & /8 % #P "( ZP O .D .P#G $4 XP!/ .$ 5P#= %\
MVP!E -D :P#6 '  U0!U -, >@#2 '\ T "$ ,\ B@#- )( R@": ,4 I0#"
M +$ P ## +X W0"\ /0 N@#_ +H _P"Z /\ N #_ +4 _P#_    _P   /T
M  #U    [@ ! .@ $ #A !T W0 J -D -@#6 $  TP!* ,\ 4@#+ %H R0!@
M ,< 9@#% &L Q !P ,( =0#! 'L OP"  +T A@"Z (T MP"6 +4 GP"S *L
ML0"Z *\ T0"M .P K #_ *P _P"K /\ JP#_ *L _P#_    _    /(   #I
M    X0   -@ "@#1 !D S  D ,@ , #% #H P0!$ +X 30"[ %0 N0!; +<
M80"U &8 M !K +( <0"P '8 K@![ *T @0"K (@ J0"0 *@ F0"F *0 I "S
M *( Q@"@ .$ GP#X )X _P"= /\ G0#_ )P _P#^    \0   .8   #=
MT@   ,H !@## !, O@ ? +D *@"V #4 LP ^ +  1@"M $X JP!5 *@ 6P"F
M &$ I0!F *0 :P"C '  H0!V *  ? "> (, G0"* )L E "9 )\ EP"L )4
MO0"3 -8 D0#P )  _P"/ /\ CP#_ (\ _P#T    YP   -L   #.    Q0
M +X   "W  P L@ 9 *T ) "I "X I@ X *, 0 "@ $@ G@!/ )P 50"; %L
MF0!@ )@ 9@"7 &L E0!Q )0 =P"2 'X D "% (X CP", )D B@"F (@ M@"&
M ,T A0#H (0 ^P"$ /\ @P#_ (, _P#K    W0$  ,X&  #$!   NP   +,
M  "M  4 IP 2 *( '@"> "@ F@ Q )@ .@"5 $( DP!) )$ 3P"/ %4 C@!;
M (P 8 "+ &8 B0!K (@ <@"& 'D A "! (( B@"! )4 ?P"B 'T L0!\ ,4
M>@#@ 'D ]0!Y /\ =P#_ '< _P#C!@  TA,  ,48  "[%P  LA(  *L(  "D
M    G@ * )D %P"4 "$ D  K (T - "* #P B !# (8 2@"% %  @P!5 ((
M6P"  &$ ?P!G 'T ;0![ '4 >@!] '@ A@!V )$ = "> '( K0!Q ,  < #:
M &X [P!M /P ; #_ &P _P#;%0  RB   +XD  "T)0  JR$  *,;  "<$0
ME04  (\ #@"* !H A@ E (, +@"  #8 ?@ ^ 'P 1 ![ $H >0!0 '@ 5@!V
M 5P = %B '(":0!Q G$ ;P)Y &T#@P!L X\ :@.< &@#JP!G [X 9036 &0&
M[ !C!_L 8@?_ &('_P#3(0  Q"H  +@O  "N,   IBT  )XH  "6(   CA8
M (<*!0"!!!, ?04> 'H'* !W"#$ = DX '(*/P!Q"D4 ;PM+ &T,40!L#%<
M:@Q> &@-90!G#6T 90UW &,.@0!B#HT 8 Z; %X/JP!=$+\ 6Q#9 %H1[P!9
M$OT 61+_ %D1_P#-*0  OS(  +0W  "J.0  H3<  )DR  "0*P  B",  ( 9
M  !X$ L =!$8 ' 2(@!M$RL :Q0S &D4.@!G%4$ 915' &0630!B%E, 8!9:
M %\780!=%VH 7!=S %H8?@!9&(H 5QB8 %89J !4&;P 4AG5 %(:[@!1&OX
M41G_ 5 9_P'),0  NSH  + _  "G0   GC\  )4Z  ",-   @RT  'LD  !Q
M' 4 ;!D3 &@:'@!E&R< 8QPO &$<-@!?'3T 71U# %P=20!:'E  6!Y6 %<>
M7@!5'V< 5!]Q %(?? !1((@ 3R"6 $X@I@!,(+D 2R#3 4H@[ %)(/T"22#_
M DD?_P+%-P  N#\  *U$  "D1@  FT4  ))!  ")/   @#4  '8N  !L)0$
M9"$. &$A&@!>(B, 6R,K %DC,@!7(SD 52,_ %0D1@!2)$P!4213 4\E6P%.
M)60!3"5N 4LF>0%))H8!2":4 D8FI )$)K<"0R;0 D(FZP-!)OP#027_!$$D
M_P3"/0  M40  *M)  "A2P  F$L  (](  "&0@  ?#T  ',U  !H+@  7R@*
M %HH%@!7*!\ 5"DG %(I+P%0*34!3BD\ 4PI0@)+*4@"22E0 D@J6 )&*F$#
M12MK T,K=@-"*X,#0"R2!#XLH@0]++4$.RO.!#HKZ04Z*_L%.BK_!3HI_P6_
M00  LTD  *E.  "?4   ED\  (U-  "$2   >D,  &\]  !E-0  62\& %0M
M$@!1+AP 3BXD $LN*P%)+C$"1RXX T4N/@-#+D4$0BY-!$ O500_+UX%/2]H
M!3PP= 4Z,($%.3"0!3<PH 8U,+,&-##,!C,PYP8S+_D',R__!S0N_P>\10
ML4T  *=2  "=5   E50  (Q2  ""3@  >$@  &U#  !A/   5C8" $XS#@!+
M,QD 2#,A $4S* %",RX"/S(T SXR.P0\,T(%.S-*!CDS4@8X-%L&-C1F!C4U
M<@8S-7\&,C6.!C$UGP8O-;(&+C7*!BTUY@8M-/@'+3/_""TR_PBZ2@  KE$
M *56  "<6   DU@  (I7  " 4P  =4X  &I)  !>0P  4ST  $DY"@!%.!4
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M B!&FP(?1JX!'4;& 1U%X@$<1/8#&T/_!1M"_P:R5P  J%X  *!C  "79@
MCV8  (9F  !\9   <%\  &5=  !:60  350  #]/   R2PD +DL4 "Q+'  J
M2R0 *$PK "9,,@$D3#H!(TQ" B%,2@(@3%0"'TQ? 1Y-; $<37H!&TV) !E-
MF@ 83*T %TS% !9+X0 62O4!%DG_ A5(_P.O7   IF,  )YH  "6:P  CFP
M (5L  ![:@  ;V8  &1D  !78   25P  #M7   N5 0 )E(/ "12&  B4B
M(%,H !]3+P =4S< '%,_ !I32  94U( %U-= !93:0 44W< $E.' !%3F  /
M4ZL #5+"  Q1W@ .4/0 #T__ 0]._P&M80  I&@  )QM  "4<   C7(  (1R
M  !Z<0  ;FX  &%K  !39P  16,  #=@   J70  'EH) !I:$P 86AP %UHC
M !5:*P 46C, $EH[ !%:10 .6D\ #%M:  I;9@ )6G0 !UJ#  5:E  $6:8
M UF]  -7V  $5^T !5;\  95_P"J9P  HFX  )IS  "3=@  BW@  (-X  !Z
M>   :W0  %UQ  !/;@  06L  #-H   F9@  &60" !!C#  ,8Q8 "F,>  EC
M)@ '8RX !F,W  1C0  "8TL  &-6  !C8@  8G   &)_  !BD   8:(  &"W
M  !?U   7>H  %SW  !<_@"G;@  GW0  )AZ  "2?0  BG\  (*   !V?0
M9WH  %=W  !)=0  .W,  "UQ   @;P  %6T   AM!P !;!   &P9  !L(0
M;"D  &PQ  !L.P  ;$8  &Q1  !L7@  :VP  &M[  !JBP  :9X  &BS  !G
MS@  9ND  &3V  !D_0"D=0  G7P  )>!  "1A   B88  'Z%  !P@P  88$
M %%^  !#?   -'L  "=Y   :>   #G<   )W P  =PP  '84  !V'   =B,
M '8K  !V-0  =D   '5,  !U60  =6<  '1V  !TAP  <YD  '*N  !QR
M;^8  &[W  !N_P"B?0  FX,  ):(  "0BP  A8P  'B+  !IB0  6H<  $N%
M   [A   +H,  """   4@0  !X$   "!    @0<  ($.  "!%@  @!T  ( D
M  "!+0  @#@  (!%  " 4@  @&   (!Q  !_@@  ?I4  'VI  !\P@  >N$
M 'GT  !X_@"?A@  FHL  )6/  "+D0  ?Y$  '"0  !AC@  4HT  $*-   S
MC   )HP  !B+   +BP   (L   ",    C    (P&  "+#@  BQ4  (L=  ",
M)   C"X  (P[  ",20  C%@  (QH  "+>P  BH\  (FD  "'NP  AMD  (7Q
M  "$^P">C@  F9,  )"5  "$E@  =I8  &>5  !7E   2)0  #B4   JE
M')0   ^4   "E0   )4   "6    EP   )<   "6!   E@L  )<3  "7&P
MF"0  )@O  "8/@  F4T  )I>  "9<0  F84  )B:  "6LP  E-$  )/J  "2
M^ "<E@  E9D  (F:  ![FP  ;)L  %R;  !-FP  /9L  "Z<   ?G0  $IT
M  2>    G@   )\   "@    H0   *$   "B    H0   *((  "C$0  I!D
M *4C  "F,   ID$  *=2  "H90  J'H  *B0  "GIP  IL(  *7=  "D[@"8
MG   C)X  '^@  !PH0  8:$  %&A  !!H@  ,:,  ".D   5I0  !J8   "G
M    J0   *D   "J    K    *P   "M    K@   *X   "P 0  L0H  +04
M  "U(0  MC   +=$  "X6   N6X  +F$  "YFP  N+(  +C-  "XX@"0H0
M@Z,  '6E  !EI@  5J8  $:G   UJ0  ):L  !>M   (K@   *\   "Q
MLP   +,   "U    M@   +<   "Y    N@   +L   "]    P    ,0$  #(
M$   RQX  ,\N  #21   TUT  -%V  #2C0  TJ,  -&X  #1S "'I@  >:@
M &FJ  !:JP  2JT  #FO   IL0  &K,   FV    N    +H   "\    OP
M +X   #     P@   ,,   #&    R    ,L   #.    T0   -8   #=
MX@T  .8=  #K,   [D<  /)?  #R>   \)   .ZE  #NM #_    _P   /\
M  #_    _P * /\ &@#_ "@ _P U /\ 0 #\ $L ^@!4 /@ 7 #V &, ] !J
M /( ;P#P '4 [@!Z .T ?@#L (0 ZP") .H CP#I )< YP"@ .8 JP#A +H
MW #0 -D ZP#8 /\ U@#_ -4 _P#/ /\ R #_ ,0 _P#_    _P   /\   #_
M    _P ' /X %@#X "0 ]0 P /, / #Q $8 [@!0 .L 6 #H %\ Y0!F .,
M:P#B '$ X !U -\ >@#> (  W "% -L BP#9 )( U@"; -$ I@#- +0 RP#'
M ,H X@#( /D Q@#_ ,4 _P## /\ O0#_ +H _P#_    _P   /\   #]
M]P # /  $0#K !\ YP L .4 -@#B $$ W@!+ -H 4P#6 %L U !A -( 9P#0
M &P SP!Q ,T =@#, 'L RP"! ,D AP#% (X P@"7 ,  H0"^ *T O "] +H
MU@"X /$ M@#_ +4 _P"U /\ LP#_ +  _P#_    _P   /D   #Q    Z@
M .$ #0#< !H UP F -, ,@#/ #P RP!% ,@ 3@#% %4 PP!< ,$ 8@"_ &<
MO@!L +P <0"Z '< N !\ +4 @@"T (D LP"1 +$ FP"O *< K@"U *L RP"J
M .@ J #] *< _P"G /\ IP#_ *0 _P#_    ]P   .T   #D    V@   -$
M!P#+ !4 Q@ @ ,( + "^ #8 NP _ +@ 2 "U %  LP!6 +$ 7 "N &( K0!G
M *L ; "J '$ J0!W *@ ?0"G (0 I0"+ *, E0"A *  H "M )X P0"< -P
MF@#U )@ _P"7 /\ EP#_ )< _P#Z    [0   .$   #5    RP   ,0  P"]
M  \ N  < +, )@"P #  K0 Z *H 0@"G $H I !0 *, 5@"A %P H !A )\
M9@"= &P G !Q )L =P"9 'X F "& )8 CP"4 )H D@"G )  N "- -  C #L
M (L _P"* /\ B@#_ (H _P#O    X@   -0   #(    OP   +@   "Q  D
MK  6 *< (0"C "H H  S )T / "; $, F0!* )< 4 "5 %8 E !; )( 80"1
M &8 D !L (X <@"- 'D BP"! (D B@"' )0 A0"A (, L0"" ,4 @ #C '\
M^ !_ /\ ?@#_ 'X _P#E    U0   ,@#  "^ 0  M@   *X   "G  , H@ /
M )T &@"8 "4 E0 M )( -@"0 #T C0!$ (L 2@"* %  B !6 (< 6P"% &$
MA !G (, ;0"! '0 ?P!\ 'T A0!\ )  >@"< '@ JP!V +X =0#: '0 \@!S
M /\ <P#_ '( _P#<!P  S!$  , 5  "V%   K0X  *8%  "?    F  ( ),
M% ". !X BP G (< +P"% #< @P ^ ($ 10!_ $L ?@!0 'P 5@![ %L >0!A
M '@ : !V &\ = !X '( @0!P (P ;@"8 &T IP!K +D :@#2 &D [ !H /P
M9P#_ &8 _P#3%0  Q1T  +DA  "O(@  IAX  )X7  "7#0  D (  (H # "%
M !< @0 A 'X *@![ #$ >0 Y '< /P!U $4 <P!+ '$ 40!P %< ;@!= &T
M8P!K &L :0!T &< ?@!E (D 9 "5 &( I !@ +4 7P#. %X Y@!= /8 7 #_
M %P _P#-(   OR@  +,L  "J+0  H2H  )DD  "1'   B1,  ($( @!\  \
M=P : '0 ) !Q "P ;@$S &P".@!J D  :0-& &<$3 !E!5( 9 58 &(&7P!@
M!F< 7P9P %T&>P!;!X8 6@>3 %@'HP!6"+4 50C+ %0)Y0!3"O8 4PK_ %(*
M_P#'*   NC   *\U  "F-@  G30  )0N  ",)P  @R   'L7  !S# < ;@@4
M &H)'@!G"B8 9 LN &(,-0!@##L 7PU! %T.2 !<#DX 6@]4 %@07 !7$&0
M51!N %01>0!2$84 4!*2 $\2H@!-$K4 3!+- $L3YP!*$_D 2A/_ $H3_P##
M,   MC@  *P\  "B/0  F3P  )$W  "(,0  ?RH  '8B  !M&0  91(- &$3
M& !>%"$ 7!4I %H5, !8%C< 5A8] %471 !3%TH 41=1 % 86 !.&&$ 31AK
M $L9=@!*&8( 2!J0 $<:H !%&K( 1!K* $,:Y0!"&OD 0AK_ 4(:_P&_-@
MLSX  *E"  "@1   ET(  (X^  "%.0  >S(  '(K  !H(P  7AL( %H:% !7
M&QT 5!PE %(<+0!0'3, 3ATY $T=0 !+'D8 2AY- $@>50!''UX 11]H $0@
M<P!"((  02&. #\AG@$^(; !/"'( 3HAY $Z(/@".B#_ CH?_P*].P  L4,
M *='  "=20  E4@  (Q%  ""/P  >3H  &XR  !D*P  620$ %,A$ !0(1H
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M RHQF0,I,:P#)S#" R8PW@,F+_0$)B__!2<N_P6U2   JD\  *%4  "85@
MD%8  (94  !\4   <DL  &=&  !;0   4#L  $0U!  \,@X .3,8 #<S'P U
M,B8 ,C(L 3$S,P(O,SH#+C-" RPT2P0K-%0$*C5? R@U:P,G-7@#)C:' R0V
MF (C-JH"(C;! B VW0(@-?,#(#/_!2 S_P6S30  J%,  )]8  "76@  CEH
M (59  ![50  <%   &1,  !:2   3D,  $(]   W.0H ,S@5 #$X'  O.20
M+3DJ 2LY,0$I.3@"*#E  B8Z20,E.E(#)#I= B([:0(A.W<"(#N& 1\[E@$=
M.ZD!'#O  1L[W  ;.O("&CG_ QHX_P2P40  IU<  )Y<  "57@  C5\  (1>
M  !Z6P  ;E8  &-3  !83P  34L  $!%   R0 < +3\1 "L_&0 I/R$ )S\H
M "4_+P$C0#8!(D ^ 2! 1P$?0%$!'D!; 1Q!: $;074 &D&$ !A!E0 70:@
M%4&^ !1 V@ 5/_$!%3[_ A0]_P.N5@  I5P  )QA  "48P  C&0  (-C  !Y
M80  ;5T  &):  !85P  2U(  #U-   P2 , )D4- "-%%@ A1AX ($8E !Y&
M+  <1C0 &T8\ !I'10 81TX %T=9 !5'90 31W, $D># !!'DP .1Z8 #$:\
M  M&U@ -1?  #D3^  Y#_P&K6P  HV$  )IF  "3:   BVD  ()I  !X9P
M;&0  &)B  !57@  1UD  #E5   L40  'TT( !M-$@ 931H %TTA !9-*0 4
M33  $TTX !%-0@ /3DP #4Y7  M.8P )3G$ "$Z   9.D  %3:(  TVW  -,
MT0 $2^D !4KZ  9*_P"I8   H&8  )EK  "1;@  BF\  (%O  !X;@  ;&L
M %]H  !19   0V   #5=   H60  &U8# !)5#  .514 #%4=  M5)0 )52T
M"%4U  95/@ $54D  E54  %58   56T  %5\  !5C   5)X  %.S  !2S@
M4>8  %'U  !0_@"F9@  GFP  )=Q  "0=   B78  (%V  !W=0  :7(  %IN
M  !,:P  /F@  #!E   C8@  %V    M>!P $7A   5X9  !>(0  7BD  %XQ
M  !>.@  7D4  %Y0  !=7   76H  %UY  !<B0  7)L  %NO  !:R0  6>4
M %?T  !7_ "D;0  G',  )9X  "/>P  B'T  (!]  !S>P  9'@  %5U  !'
M<@  .&\  "IM   =:P  $FD   5H!   : P  &@5  !G'   9R0  &<L  !G
M-0  9T   &=+  !F6   9F4  &5U  !EA0  9)<  &2K  !BQ   8>(  &#U
M  !?_0"A=   FWH  )5_  ".@@  AX0  'R#  !N@   7GX  $][  ! >0
M,7<  "1U   7=   "W,   !S    <@@  '(0  !R%P  <1X  '$F  !Q+@
M<3H  '!&  !P4@  <&   '!P  !O@0  ;I,  &VG  !LOP  :]X  &GS  !H
M_@"??   F8(  )2&  "-B0  @XH  ':(  !GA@  5X0  $B"   X@   *G\
M !U^   0?0   WT   !]    ?00  'P*  !\$@  ?!D  'P@  !\)P  ?#(
M 'L_  ![3   >UH  'MJ  !Z>P  >8X  'BB  !WN0  =M@  '7P  !T_ "=
MA   F(H  )..  ")CP  ?(\  &Z-  !>C   3XH  #^)   PB0  (H@  !6'
M   'AP   (<   "(    B    (<#  "'"@  AQ$  (<8  "''P  AR@  (<U
M  "'1   AU(  (=B  "'=0  AH@  (2=  "#M   @M   ('K  " ^@";C0
MEY(  (Z4  ""E   =)0  &23  !5D@  19$  #61   FD0  &9$   J0
MD0   )$   "2    D@   )(   "2    D@<  )(.  "3%@  E!X  )0I  "3
M.   E$<  )58  "5:@  E'\  ).6  "1K@  D,D  (_F  ".]0":E0  DI<
M (:8  !YF0  :9D  %J8  !*F   .I@  "N9   <F0  #9D   ":    F@
M )L   "<    G0   )T   "=    G0   )T#  ">"P  H!,  *$=  "B*@
MH3H  *-,  "D7P  I',  *2*  "CH0  HKH  *#;  ">[P"6FP  BIP  'V>
M  !NG@  7IX  $Z>   ^GP  +J   !^A   1H@   J,   "D    I0   *8
M  "G    J    *D   "I    J@   *H   "K    K <  *X1  "O'0  L2L
M +(^  "T4@  M6<  +5^  "UE0  M*T  +3'  "SX ".GP  @:$  '*C  !C
MHP  4Z0  $.E   RI@  (:@  !.J   #JP   *P   "M    KP   *\   "Q
M    L@   +,   "T    M@   +8   "X    NP   +X   #""@  Q1D  ,8K
M  #(0@  RED  ,QP  #-AP  S9X  ,VT  #,R@"$I   =J8  &>G  !7J0
M1ZH  #:L   EK@  %K    :R    M    +8   "X    N@   +H   "\
MO0   +\   #!    PP   ,4   #'    RP   ,\   #7    W <  .$7  #E
M*@  Z4(  .M=  #I>   Z8\  .JC  #JM #_    _P   /\   #_    _P '
M /\ %P#_ "4 _@ Q /T / #Z $< ]P!0 /0 60#Q &  [P!F .T ; #L '$
MZP!V .H >P#H (  YP"& .8 C #E ), X@"< -T IP#9 +8 UP#* -4 Y@#4
M /T TP#_ -( _P#* /\ PP#_ +\ _P#_    _P   /\   #_    _P $ /D
M$P#U "$ \@ M /  -P#M $( Z0!, .4 5 #B %P X !B -X : #< &T VP!R
M -H =P#8 'P U@"! -4 B #1 (\ S0"8 ,H H@#) *\ QP#! ,8 VP#$ /8
MP@#_ ,$ _P"^ /\ N #_ +4 _P#_    _P   /\   #Z    \@   .L #@#F
M !P XP H .  ,@#< #T UP!' -, 3P#0 %< S@!= ,P 8P#* &@ R0!M ,<
M<@#% '@ P@!] ,  @P"^ (H O0"2 +L G "Y *@ N "X +8 SP"T .T L@#_
M +$ _P"Q /\ K0#_ *H _P#_    _@   /4   #M    XP   -P "@#6 !8
MT0 B ,P +@#) #< Q0!! ,( 2@"_ %$ O0!8 +L 7@"X &, M@!H +0 ;0"S
M ', L@!X +  ?@"O (4 K@"- *T E@"K *( J0"P *< Q "E .( I #[ *,
M_P"A /\ H #_ )T _P#^    \P   .@   #>    TP   ,P ! #% !( P  =
M +L * "X #( M0 [ +( 0P"O $L K !2 *H 6 "I %T IP!C *8 : "E &T
MI !R *, > "B '\ H "' )\ D "= )L FP"H )D N@"7 -4 E #R ), _P"3
M /\ D@#_ )( _P#U    YP   -H   #.    Q0   +X   "W  P L@ 8 *X
M(@"J "P IP U *0 /0"A $4 GP!, )X 4@"< %< FP!< )D 8@"8 &< EP!M
M )4 <P"4 'D DP"! )$ B@"/ )4 C "B (H L@") ,D AP#H (8 _@"& /\
MA0#_ (4 _P#J    VP   ,T   #"    N@   +(   "L  < I@ 3 *$ '0">
M "8 FP O )@ -P"6 #X DP!% )( 2P"0 %$ C@!6 (T 7 ", &$ B@!G (D
M;0"' '0 A0!\ (0 A0"" )  @ "< 'X JP!] ,  >P#= 'H ]P!Y /\ >0#_
M 'D _P#?    SP   ,,   "Y    L    *@   "B    G  , )< %P"3 "$
MCP I (P ,0"* #D B  _ (8 10"$ $L @P!1 ($ 5@"  %P ?P!A 'T : !\
M &\ >@!W '@ @ !V (L = "7 '( I@!Q +@ ;P#3 &X [P!M /\ ;0#_ &T
M_P#5!P  QPX  +L2  "P$0  J H  *$!  "9    DP % (X $0") !L A0 D
M (( *P!_ #, ?0 Z 'L 0 !Z $8 > !+ '8 40!U %8 <P!< '$ 8P!P &H
M;@!R &P ? !J (< :0"3 &< H@!E +( 9 #+ &, YP!B /L 80#_ &$ _P#-
M%   OQL  +0?  "J'@  HAH  )H4  "2"0  BP   (4 "0"  !0 ?  > '@
M)@!U "T <P T '$ .P!O $$ ;0!& &L 3 !J %$ : !7 &8 7@!E &8 8P!N
M &$ > !? (, 7@"0 %P G@!: *\ 60#% %@ X@!7 /4 5@#_ %8 _P#''@
MNB8  *\J  "E*@  G28  )0@  ",&0  A!   'T%  !W  P <@ 7 &X ( !K
M "@ :  O &8 -0!D #L 8P!! &$ 1P!? $T 7@!3 %P 6@!: &$ 6 !K %<
M=0!5 (  4P"- %( G !0 :T 3P'" $X!W !- O  3 +[ $P"_P#")P  M2X
M *LR  "A,P  F3$  ) K  "')   ?QT  '84  !N"04 : (0 &0"&0!A R(
M7@0I %P$, !:!38 608\ %<&0@!5!T@ 5 =/ %((5@!0"%X 3PEG $T)<@!,
M"GX 2@J, $@*FP!'"ZP 10K" $0+W !#"_$ 0PO^ $,+_P"^+@  LC8  *<Z
M  ">.P  E3D  (PT  "$+@  >B<  '$?  !H%@  7PP( %L+% !8#!P 50TD
M %,-*P!1#C$ 3PXW $X//@!,$$0 2Q%+ $D14P!'$5L 1A)E $03< !#$WP
M01.* #\4F@ ^%*P /!3" #L4W0 [%/, .Q3_ #L3_P"Z-0  KSP  *5   ";
M00  DS\  (H[  "!-@  =R\  &TH  !C(   6A@" %,4#0!/%!@ 314@ $L5
M)P!)%BT 1Q8S $47.@!$%T  0AA( $$83P _&5@ /AEB #P:;0 [&GH .1N(
M #<;F  V&ZH -!O  #,;VP S&_( ,QK_ 3,9_P&X.@  K$$  *-%  "91@
MD44  (A"  !^/   =3<  &LO  !@*0  52$  $P;"0!(&Q0 1AL< $,<(P!!
M'"D /QPP #T=-@ \'3T .QY$ #D>30 X'U8 -A]@ #4@:P S('@ ,B&& # A
ME@ O(:@ +2"^ 2L@V0$L(/$!+!__ BP?_P*U/P  JD4  *%)  "82P  CTH
M (9'  !\0@  <CT  &@W  !=,   4BD  $<B!0!!(1  /B$8 #PA'P Z(28
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M !@PU  9,.X!&2_] ADN_P.N3   I5(  )Q6  "35P  BU@  ()6  !X4P
M;$X  &)*  !710  3$$  $ [   S-@0 *S,- "@S%@ G,QT )3,D ",S*P A
M-#( (#0Z 1\T0P$>-4T!'#58 !LU8P 9-G$ &#:  !8VD  5-J, $S:X !(U
MTP 3->P %#3] 1,S_P*L4   HU8  )I:  "27   BEP  (%;  !W6   :U0
M &%1  !630  2TD  #]#   Q/@  )3H* "(Y$P @.1L 'CDB !TZ*0 ;.C
M&CHX !@[00 7.TL %3M5 !0[8@ 2/&\ $3Q^  X\CP ,/*$ "CNU  D[SP +
M.ND ##G[  TX_P&J5   H5H  )E?  "180  B6$  (!A  !V7@  :EH  &!8
M  !650  25   #M+   N1@  (4(& !I $  90!< %T ? !5 )@ 402T $D$U
M !%!/@ .04@ #$%3  M"7P )0FT !T)\  9"C  $09X  D&R  )!RP #0.0
M!3_V  8^_P"H60  GU\  )=D  "09@  B&<  ']G  !U90  :6$  &!?  !3
M6P  158  #=2   J3@  '4H! !1'"@ 01Q, #4@;  M((P *2"H "$@R  =(
M.P %2$4  TA0  ))7   26H  $EY  !)B0  2)L  $>N  !'QP  1N(  $7R
M  !$_ "E7P  G64  )9I  ".;   AVT  ']M  !U;   :6D  %UF  !/80
M05T  #-:   E5@  &5,   U0!@ &4!   U 8  %0'P  4"<  % O  !0.
M4$(  %!.  !060  4&<  %!V  !0A@  3Y@  $ZL  !-Q   3.$  $OQ  !+
M^P"C90  FVL  )1O  "-<@  AG0  'YT  !U<P  9F\  %AL  !*:   /&0
M "YA   @7P  %%P   A:!   6@P  %D5  !9'   62,  %DK  !9-   63\
M %E*  !85@  6&,  %AR  !8@@  5Y0  %:H  !5P   4]X  %+S  !2^P"A
M;   F7(  )-V  "->0  AGH  'Y[  !Q>   8G4  %-R  !$;P  -6P  "AI
M   :9P  #F8   )D 0  9 D  &,1  !C&   8Q\  &(G  !B+P  8CH  &)&
M  !B4@  85\  &%N  !@?P  7Y   %ZD  !=O   7-H  %OR  !:_0"><P
MF'D  ))]  ",@   A8(  'J   !K?@  7'L  $QX   ]=@  +W0  "%R   4
M<   !V\   !O    ;@4  &X,  !M$P  ;1H  &TA  !M*   ;#,  &Q   !K
M30  :UH  &MJ  !J>@  :8P  &B@  !GMP  9M4  &7O  !D_ "<>P  EX$
M )&%  "+B   @8<  '.%  !D@P  58$  $5_   U?0  )WL  !EZ   +>0
M 'D   !Y    >0   '@'  !X#0  =Q0  '<;  !W(@  =RL  '<X  !V1@
M=E0  '9D  !U=0  =(@  '.<  !RL@  <<X  '#L  !O^P";@P  EH@  )&,
M  "'C0  >HP  &N+  !<B0  3(@  #R&   MA0  'X0  !&#   #@P   (,
M  "#    @P   (,   "#!@  @@P  ((3  ""&@  @R(  (,O  ""/@  @DT
M ()<  "";@  @8(  ("7  !^K0  ?<@  'WF  !\]P"9C   E9   (R2  "
MD@  <9$  &*0  !2CP  0HX  #*.   CC@  %8T   >-    C0   (T   ".
M    C@   (X   ".    C@,  (X)  ".$0  CQ@  (\C  "/,0  CT(  )!2
M  "19   CWH  (Z0  "-IP  B\$  (K@  "*\P"9E   D)8  (27  !VEP
M9Y8  %>5  !'E0  -I4  ">5   8E@  "98   "6    EP   )<   "8
MF0   )D   "9    F0   )D   ":!@  FPX  )P7  "=(P  G30  )Y&  "?
M6   H&T  *"#  "?G   G+@  )O9  "9[P"4F0  B)L  'N<  !LG   7)L
M $N;   ZG   *IT  !N>   ,G@   )\   "@    H0   *(   "C    I
M *0   "E    I0   *4   "F    IP(  *H*  "K%P  K24  *TX  "O2P
ML6   +%W  "QCP  L:@  *_!  "OW0",G@  ?Y\  '"A  !@H0  4*$  #^B
M   NI   'J4   ZG    J    *D   "J    JP   *P   "M    K@   +
M  "Q    L@   +(   "S    M@   +@   "[!P  O18  +\G  #!/   Q5(
M ,=J  #(@@  R)D  ,BQ  #'QP""HP  =*0  &6E  !5I@  1*<  #*I   B
MK   $JT   *O    L0   +(   "T    M@   +8   "X    N0   +L   "]
M    O@   ,$   #"    Q0   ,D   #0    U0(  -L2  #>)@  X$   .);
M  #D<P  Y8H  .:@  #FL@#_    _P   /\   #_    _P $ /\ % #^ "$
M^P M /H . #W $, \P!- .\ 50#M %T ZP!C .D : #H &X Y@!S .4 =P#D
M 'T XP"" .$ B #= )  V0"9 -8 HP#4 +  TP#$ -$ X #0 /D S@#_ ,T
M_P#% /\ O@#_ +H _P#_    _P   /\   #_    ^P " /4 $ #Q !T [@ I
M .P ,P#H #X XP!( .  4 #= %@ V@!> -@ 9 #6 &D U0!N -, <P#1 '@
MS@!^ ,L A #( (P QP"4 ,8 G0#$ *H PP"[ ,$ U "_ /$ O@#_ +T _P"Y
M /\ M #_ +  _P#_    _P   /T   #V    [    .< "P#B !@ W@ D -D
M+P#5 #D T0!# ,T 2P#* %( R !9 ,8 7P## &0 P0!I +X ;P"\ '0 NP!Y
M +H ?P"Y (8 N ". +8 EP"U *, LP"R +$ R "O .< K@#_ *T _P"L /\
MIP#_ *, _P#_    ^@   /$   #F    W0   -8 !P#0 !, R@ ? ,8 *@##
M #, P  \ +P 10"Y $T M@!3 +, 60"Q %\ L !D *\ :0"N &X K0!T *P
M>@"J (  J0"( *@ D0"F )P I "K *( O0"A -H G@#W )P _P"; /\ F@#_
M )@ _P#Z    [@   .,   #6    S0   ,8  0"_  X N@ 9 +8 ) "R "X
MKP V *P /P"I $8 IP!- *4 4P"D %D H@!> *$ 8P"@ &@ GP!N )X = "<
M 'L FP"" )D BP"8 )8 E@"C ), M "1 ,T CP#N (X _P"- /\ C0#_ (P
M_P#Q    X@   -,   #(    P    +@   "Q  D K  5 *@ '@"D "@ H0 Q
M )\ . "< $  F@!' )D 30"7 %( E@!8 )0 70"3 &( D0!H )  ;@"/ '4
MC0!] (L A0") )  AP"= (4 K0"$ ,( @@#C ($ ^P"  /\ @ #_ (  _P#D
M    U    ,@   "]    M    *T   "G  0 H0 / )P &@"8 "( E0 K ),
M,P"0 #H C@!  (P 1@"+ $P B0!1 (@ 5P"& %P A0!B (, : "" &\ @ !W
M '\ @ !] (L >P"7 'D I@!W +H =@#6 '0 \@!T /\ <P#_ ', _P#8
MR0   +X   "S    JP   *,   "=    EP ) )( % ". !T B@ E (< +0"%
M #0 @P [ ($ 0 !_ $8 ?@!, 'P 40![ %< >0!< '< 8P!V &H = !R '(
M>P!P (8 ;@"2 &T H0!K +, :0#+ &@ ZP!G /X 9P#_ &< _P#/!0  P0P
M +8/  "L#0  HP<  )P   "4    C@ " (D #0"$ !< @  @ 'T )P!Z "X
M>  U '8 .P!T $$ <@!& '$ 3 !O %$ ;0!7 &P 70!J &4 : !M &8 =P!D
M (( 8@". &$ G !? *T 70## %P X@!< /< 6P#_ %L _P#'$P  NAD  *\<
M  "F&P  G1<  )40  "-!@  A@   (  !@![ !$ =@ : ', (@!O "D ;0 O
M &L -@!I #P 9P!! &4 1P!D $P 8@!2 &  60!> &  70!I %L <P!9 'X
M5P"* %8 F !4 *D 4P"^ %$ V@!1 /, 40#_ %  _P#"'0  M20  *HG  "A
M)P  F",  ) =  "'%@  ?PP  '@"  !Q  H ;  4 &@ ' !E "0 8@ J &
M, !> #8 70 \ %L 0@!9 $@ 5P!. %8 50!4 %P 4@!E %$ ;P!/ 'H 30"'
M $L E0!* *8 2 "Z $@ U !' .T 1@#Z $8 _P"])@  L"T  *8P  "=,
ME"T  (PH  "#(0  >AH  '(1  !I!@( 8P , %\ %@!; !X 6  E %8 *P!4
M #$ 4P W %$ /0!/ $, 3@!) $P!4 !* 5@ 2 )A $<"; !% W@ 0P.% $$$
ME ! !*0 /P.X #T#T0 \ ^@ / 3W #P$_P"Y+0  K30  *,W  ":.   D38
M (@Q  !_*P  =B0  &T<  !D%   6PH% %4%#@!2!1@ 3P4? $T&)@!+!RP
M20<R $<(. !&"#\ 1 E% $()30!!"E4 /PI? #T+:@ ["W8 .@R$ #@,DP V
M#*0 -0RX #,,T0 R#.H ,PSY #,,_P"V-   JCH  *$^  "8/@  CSP  (8X
M  !],P  <RP  &DE  !?'@  5A8  $T." !)#1( 1@T: $0.(0!!#B< 0 \N
M #X0-  \$#H .Q%" #D220 W$E( -A-< #039P S%'0 ,12" "\5D@ N%:,
M+!2X "H4T@ J%>P *Q3[ "P4_P"S.0  J#\  )]#  "61   C4(  (0_  !Z
M.@  <30  &<M  !<)@  4A\  $@8 P!!%0T /A46 #L5'0 Y%B0 -Q8J #86
M,  T%S< ,Q<^ #$81P P&%  +QE: "T990 L&G( *AN  "@;D  F&Z( )1JV
M ",:T  C&^H )!K\ "09_P&Q/@  ID,  )U'  "42   BT<  (-%  !X0
M;SH  &0T  !:+@  3R<  $0@   [' D -AL2 #0;&0 R&R  ,!LF "X<+0 M
M'#0 +!T\ "H>1  I'DT *!]8 "8?8P E('  (R!_ "$@C@ @(*  'B"U !P@
MS@ =(.D '2#[ 1X?_P&N0@  I$@  )M+  "330  BDP  (%*  !W10  ;4
M &([  !8-0  3"\  $$I   V(P4 ,"$- "TA%@ K(1P *"$C "<A*@ F(C$
M)2(Y ",C0@ B)$L (216 " E80 >)6X '"9] !LFC0 9)9\ &"6S !8ES0 7
M)>@ &"3Z 1<D_P&L1@  HTP  )I0  "140  B5$  (!.  !V2P  :T8  &!!
M  !6/   2S8  $ Q   T+ $ *B<* "8F$P D)QH (B<@ "$G)P ?*"\ 'B@V
M !TI/P <*4D &RI4 !DJ7P 7*VT %BM[ !0KBP 3*YT $2NR  \JRP 0*N<
M$2KY !(I_P&J2@  H5   )A4  "050  B%4  ']4  !U4   :4L  %]'  !5
M0P  2C\  #\Z   S-0  )B\' " M$  >+1< '"T> !LN)0 9+BP &"XT !<O
M/0 5+T< %"]2 !(P70 0,&L #C%Z  PQB@ *,)L "3"O  <PQP (+^( "B_W
M  LN_P"H3@  GU0  )=8  "/6@  AUH  'Y9  !T5@  :%$  %Y.  !42P
M24<  #U"   P/   (S<$ !HT#  7,Q0 %30; !0T(@ 2-"H $34Q  \U.@ -
M-40 "S5/  HV6P (-F@ !C=W  4WAP #-ID  3:L   VQ  !-=\  S3R  0S
M_P"F4P  GED  )5=  ".7P  AE\  'U>  !S7   9U@  %Y6  !44@  2$X
M #I(   M0P  'S\  !0["  0.A$ #3L9  L[(  ).R< "#PO  8\.  %/$(
M SQ-  $\60  /68  #UU   ]A0  /)8  #RJ   [P0  .]T  #KO   Y^@"D
M6   G%X  )1B  "-9   A64  'QD  !S8@  9U\  %Y=  !160  1%0  #9/
M   H2P  &T<  !!$!0 '0@T !$,6  )#'0  0R4  $,M  !$-0  0S\  $-*
M  !#5@  1&,  $1R  !$@@  0Y0  $*G  !!O@  0=P  $#O   _^0"B7@
MFF,  )-G  ",:@  A&L  'QK  !R:0  9V<  %MC  !-7P  /UL  #%7   C
M4P  %U    M- P !3 L  $L4  !,&P  3"(  $LJ  !+,@  2SP  $M(  !+
M4P  2V   $MO  !+?P  2I$  $FE  !(O   1]D  $;P  !%^@"@9   F&H
M ))M  "+<   A'(  'QR  !S<0  9&T  %9I  !(90  .6(  "M>   >6P
M$E@   56 0  5@D  %41  !5%P  51X  %0F  !4+@  5#D  %1$  !34
M4UT  %-L  !3?   4HX  %&B  !0N0  3M8  $WO  !-_ ">:@  EW   )%T
M  "*=P  @W@  'QY  !O=@  7W,  %!O  !";   ,VD  "5F   79   "V(
M  !A    8 8  %\-  !?%   7AH  %XA  !>*0  730  %U   !=3   7%H
M %QH  !;>0  6XH  %J>  !8M0  5],  %;N  !4_ "<<@  E7<  )![  "*
M?@  @X   '=^  !I>P  67@  $EU   Z<P  +'   !YN   1;0  !&L   !K
M    :@(  &H(  !I#P  :14  &@<  !H(P  :"T  &<Z  !G1P  9E4  &9D
M  !E=   9(8  &.:  !BL   8<T  %_K  !>^P":>@  E7\  (^#  ")A@
M?X4  '&#  !B@0  4GX  $)\   R>@  )'@  !9W   (=@   '4   !U
M=0   '0#  !T"0  <Q   ',6  !S'0  <R4  '(R  !Q0   <4X  '%>  !P
M;P  ;X(  &Z6  !MK   ;,<  &OF  !J^0"8@@  E(<  (^+  "%BP  >(H
M &F(  !9A@  284  #B#   I@@  &X$   V     ?P   '\   !_    ?P
M '\   !^ @  ?@@  'X.  !^%@  ?AP  'XH  !]-P  ?4<  'Y6  !]:
M?'L  'N0  !YI@  >,   'C@  !W]0"7BP  DX\  (J0  !]D   ;X\  %^-
M  !/C   /XL  "^+   @B@  $8H   .)    B0   (H   "*    B@   (H
M  "*    B0   (H%  "*#   BQ,  (L=  "+*P  BCP  (M-  "+7P  BW,
M (J)  "(H   A[D  (;:  "%\0"7D@  CI0  (*5  !TE0  9)0  %23  !$
MD@  ,Y,  "22   5D@  !9(   "3    DP   )0   "5    E0   )4   "5
M    E0   )4   "6 0  E@D  )@1  "9'0  F2X  )E   ";4@  G&8  )M^
M  "9F   E[$  );0  "5[ "2F   AID  'F:  !IF0  69D  $F9   WF0
M)YH  !B;   (FP   )L   "<    G0   )X   "?    H    *    "A
MH0   *$   "B    HP   *4%  "G$0  J!\  *@R  "J10  K%H  *UQ  "M
MB0  K:(  *N^  "IX "*G   ?9X  &V?  !>GP  3I\  #R?   KH0  &Z(
M  JD    I0   *4   "F    IP   *@   "J    JP   *P   "M    K0
M *T   "N    L    +(   "U P  N!$  +LA  "\-@  OTP  ,)D  ##?
MPY0  ,.L  #"Q " H0  <J,  &*C  !2I   0:4  "^G   >J0  #JL   "L
M    K@   *\   "Q    L@   +,   "T    M@   +<   "Y    N@   +P
M  "]    P    ,0   #*    S@   -(0  #3)   V#P  -U5  #@;0  X84
M .&<  #AL #_    _P   /\   #_    _P ! /X $0#[ !X ^0 I /8 - #R
M $  [@!) .L 40#H %D Y@!? .0 90#C &H X0!O .  = #> 'D VP!_ -@
MA0#4 (T T@"5 -$ GP#0 *L S@"] ,T V@#+ /8 R@#_ ,D _P#! /\ N@#_
M +4 _P#_    _P   /\   #^    ]@   /$ "P#M !D Z@ E .8 +P#B #H
MW@!$ -H 3 #7 %0 U !: -( 8 #0 &4 S0!J ,H < #( '4 Q0!Z ,0 @0##
M (< P@"/ ,$ F0#  *4 O@"T +P S0"Z .P N0#_ +@ _P"U /\ KP#_ *H
M_P#_    _P   /H   #P    Z    .( " #= !0 U@ @ -( *P#/ #0 RP ^
M ,< 1P#$ $X P0!5 +X 6P"[ &  N0!E +@ :@"W &\ M@!U +4 >P"T ((
MLP"* +$ DP"P )X K@"L *P P0"K .$ J0#[ *< _P"F /\ H0#_ )X _P#_
M    ]@   .P   #@    V    -   P#) !  Q  ; ,  )0"] "\ N@ X +4
M0 "R $@ KP!/ *X 50"L %H JP!? *H 90"I &H J !O *< =0"E 'P I "$
M *, C0"A )@ GP"E )X MP"; -( F #R )< _P"7 /\ E0#_ ), _P#U
MZ0   -P   #0    R    ,    "Y  L M  6 +  ( "L "D J0 R *8 .@"D
M $( H@!( *$ 3@"? %0 G@!9 )P 7@"; &0 F@!I )D ;P"7 '8 E@!^ )0
MAP"2 )$ D "> (X KP", ,8 B@#H (D _P"( /\ B #_ (< _P#K    VP
M ,T   ##    N@   +(   "L  8 IP 2 *( &P"? "0 G  L )H - "7 #L
ME0!" ), 2 "2 $T D !3 (\ 6 ". %T C !C (L :0") '  B !X (8 @0"$
M (L @@"8 (  J !_ +P ?0#< 'P ^ ![ /\ >@#_ 'L _P#=    S@   ,(
M  "W    KP   *@   "A  $ G  + )< %@"3 !X D  F (T +@"+ #4 B0 \
M (< 00"& $< A !- (, 4@"! %< @ != 'X 8P!] &H >P!R 'D >P!W (8
M=0"2 ', H@!R +0 < #0 &\ [P!N /\ ;0#_ &T _P#2    Q    +@   "O
M    I@   )\   "8    D@ & (T $0") !H A0 A (( * !_ "\ ?0 V 'P
M/ !Z $$ > !' '< 3 !U %( <P!7 '( 7@!P &4 ;@!M &P =@!J ($ : "-
M &< G !E *X 8P#% &( Y0!A /P 80#_ &  _P#)!   O H  +$,  "G"@
MGP0  )<   "0    B0   (0 "@!_ !0 >P < '@ ) !U "D <@ P '  -@!N
M #P ; !! &L 1P!I $P 9P!2 &8 6 !D &  8@!H &  <0!> 'P 7 ") %L
MEP!9 *@ 5P"] %8 VP!5 /4 50#_ %4 _P#"$0  M1@  *L:  "B&   F10
M )$,  ") P  @0   'L ! !V  T <0 6 &T '@!J "4 9P J &4 ,0!C #<
M80 \ %\ 0@!> $@ 7 !- %H 5 !8 %L 5@!C %4 ;0!3 '@ 40"% $\ DP!.
M *, 3 "W $L TP!* .X 2@#_ $H _P"\'   L"(  *8E  "=)   E"   (L:
M  "#$P  >PH  ',   !L  < 9P 1 &, & !? "  70 F %H + !8 #$ 5P W
M %4 /0!3 $, 4@!) %  3P!. %< 3 !? $H :0!) '4 1P"! $4 D !# *
M0@"S $$ S !  .D 0 #Z $  _P"X)   K"L  *(N  "9+@  D"H  (@E  !_
M'P  =A<  &T-  !E P  7@ * %D $P!6 !H 4P A %  )P!. "P 30 R $L
M. !) #X 2 !$ $8 2P!$ %, 0@!< $  9@ ^ '( /0!_ #L C0 Y )T . "P
M #< R  V ., -0#T #4 _@"T+   J3(  )\U  "6-0  CC,  (4N  ![*
M<B$  &D9  !?$0  5P@# % !"P!, !0 20 ; $< (0!% "< 0P M $$!,P _
M 3D /@)  #P#1P Z T\ . 19 #8%8P T!7  ,P5] #$%C  O!IP +@6O "T$
MQ@ L!>  *P;R "L%_0"Q,P  IC@  )T[  "4/   BSH  ((U  !Y,   ;RD
M &4B  !;&P  4A0  $D,!0!"!PT 0 85 #T''  ["", .0@I #<(+P V"34
M- D\ #(*1  P"TP +PM6 "T,80 K#&X *0U\ "<.BP E#IP ) VP "(-R  A
M#N( (@[T ",-_P"N.   I#T  )M!  "200  BD   ($\  !W-P  ;3$  &,J
M  !9)   3AT  $46   [$ < -@T0 #0.%P Q#AX ,! D "X0*@ L$#$ *Q$X
M "D200 H$DH )A-4 "437P C%&P (15Z !\5B@ >%9L '!2O !H4QP :%.,
M&Q7V !L4_P"L/   HD(  )E%  "11@  B$4  ']"  !U/0  :S@  &$Q  !6
M*P  2R4  $$>   W&0( ,!4+ "P5$P J%1H *!8@ "86)P D%BX (Q<U "(8
M/@ A&$< 'QE2 !X970 <&FH &AIY !D;B  7&IH %1JM !0:Q@ 3&N( %1KV
M !4:_P"J0   H48  )A)  "/2@  ATH  'Y'  !T0P  :3X  %\X  !5,@
M22T  #\G   T(@  *AT' "4;#P B&Q8 (!L< !\<(P >'"L '!TS !L=.P :
M'D4 &1Y0 !<?6P 5'V@ %"!W !(@AP 0()@ #B"L  P?PP ,']\ #A_U ! >
M_P"H10  GTH  )9.  ".3P  A4X  'U,  !S2   :$,  %T_  !3.@  2#0
M #TP   S*P  *"4# !\A"P <(1, &B$: !@A(0 7(B@ %B(P !4C.0 3(T,
M$B-. ! D60 .)6< #"5U  HFA0 ))98 !R6I  4EP  &)-L !R3Q  DC_P"G
M20  G4X  )52  "-4P  A5,  'Q1  !R3@  9DD  %Q%  !200  2#T  #TX
M   R,P  )BX  !HH"0 6)Q$ %"<8 !(H'P 0*"8 #BDN  TI-@ +*4  "BI+
M  @J5P &*V0 !2MS  ,L@P !*Y0  "NG   JO0  *M@  "GM  (I_ "E30
MG%(  )16  ",5P  A%@  'M6  !Q4P  94\  %Q,  !220  2$4  #Q    O
M.@  (C4  !8P!0 .+@T #"X6  HO'0 (+R0 !S L  4P-  $,#X  C!)  $Q
M50  ,6(  #)Q   R@   ,9(  #&E   PNP  ,-<  "_L   N^ "C4@  FE<
M )):  "+7   @UT  'I<  !P6@  958  %M3  !24   1DP  #A&   K00
M'CT  !(X P (-0L !#84  (V&P  -R(  #<J   W,@  -SP  #='   W4P
M-V   #AN   X?@  .)   #>C   VN0  -=4  #3L   T^ "A5P  F5P  )%@
M  "*8@  @F,  'IB  !P8   95T  %Q;  !05P  0E(  #1-   G2   &40
M  U! @ #/@H  #X2   ^&   /A\  #\G   _,   /SD  #Y$   ^4   /ET
M #]L   _?   /HX  #VA   \MP  .],  #OM   Z^ "?7   EV(  )!E  ")
M:   @FD  'EI  !P9P  964  %EA  !+70  /5@  "]4   A4   %4P   A)
M    2 @  $</  !'%@  1QT  $<D  !'+   1C8  $9"  !&3@  1EL  $9I
M  !&>0  1HL  $6?  !#M   0M$  $'L  ! ^@"=8P  EF@  (]L  "(;@
M@7   'EP  !P;P  8FL  %1G  !&8P  -U\  "E;   ;6   #E4   -3
M4@8  %$,  !1$P  4!H  % A  !/*0  3S,  $\^  !/2P  3E@  $YF  !.
M=@  3H@  $V<  !+L@  2<\  $CK  !'^P";:0  E&\  (YR  "(=0  @7<
M 'IW  !L=   77   $YM   _:0  ,68  ")C   580  "%X   !=    7 ,
M %L)  !;$   6A8  %D=  !9)   62X  %@Z  !81@  6%0  %=C  !7<P
M5H4  %69  !4KP  4LL  %#J  !/^P"9<0  DW8  (UZ  "'?   @7X  '5\
M  !F>0  5W8  $=S   X<   *6T  !MK   -:0   6@   !G    9@   &8%
M  !E"@  9!$  &08  !C'P  8R@  &,T  !B00  8D\  &%>  !@;P  8($
M %Z5  !=JP  7,8  %OF  !9^@"7>0  DGX  (V!  "(A   ?8,  &^!  !?
M?@  3WP  #]Y   O=P  (74  !-S   %<@   '(   !Q    <0   '    !P
M!0  ;PH  &\1  !N&   ;A\  &XL  !M.@  ;4D  &U8  !L:0  :GP  &F0
M  !HI@  9\   &;A  !E]P"6@0  DH8  (V)  "#B0  =H@  &:&  !6A
M1H(  #6    F?P  &'T   E\    >P   'L   !\    >P   'L   ![
M>@0  'H*  !Z$0  >A<  'HB  !Y,0  >4$  'E1  !Y8@  >'4  ':*  !U
MH   <[D  '+;  !Q\P"6B0  DHX  (B.  ![C@  ;8T  %V+  !-B@  /(D
M "R(   <AP  #88   "&    A0   (8   "&    A@   (8   "&    A0
M (4!  "%!P  A@X  (<7  "&)0  A3<  (9'  "&60  AFT  (6#  "$F@
M@K,  ('2  " [P"6D0  C9,  ("3  !RDP  8I(  %*0  !!D   ,)   ""0
M   1CP   H\   "/    CP   )    "1    D0   )$   "1    D0   )$
M  "1    D@0  )0*  "5%P  E2<  )0[  "630  EV$  )5Y  "4D@  DZL
M )'(  "0Z "0E@  A)<  ':8  !GEP  5Y8  $:6   TEP  ))@  !28   $
MF    )@   "9    F0   )H   ";    G    )T   "=    G0   )T   ">
M    GP   *    "C"@  I!@  *0L  "E0   J%0  *EK  "I@P  IY\  *6^
M  "CW0"(FP  >YP  &N<  !;G   2YP  #F=   HG@  &)\   >@    H0
M *(   "C    HP   *4   "F    IP   *@   "I    J0   *D   "J
MJP   *T   "Q    LPH  +8;  "V,   N48  +U>  "^=@  OH\  +ZH  "^
MP@!^GP  ;Z$  &"A  !0H@  /J,  "RD   ;IP  "J@   "I    J@   *P
M  "M    K@   *\   "Q    L@   +0   "U    M@   +@   "X    NP
M +T   #!    Q@   ,H+  #-'@  T38  -9/  #;:   W(   -R8  #<K@#_
M    _P   /\   #_    _P   /L # #X !H ]0 E /$ , #M #P Z0!% .8
M30#D %4 X0!; -\ 80#= &8 VP!K -@ <0#4 '8 T0!\ -  @@#. (D S0"1
M ,P FP#+ *< R@"W ,@ T@#& /$ Q0#_ ,0 _P"] /\ M0#_ +$ _P#_
M_P   /\   #Y    \P   .T !P#I !4 Y  A .  *P#= #8 V !  -0 2 #1
M $\ S@!6 ,H 7 #' &( Q !G ,( ; #! '$ P !V +\ ? "^ (, O0"+ +P
ME0"Z *  N0"N +< Q0"V .< M #_ +, _P"O /\ J #_ *0 _P#_    _P
M /4   #K    Y    -T !0#5 !$ T  < ,P )P#) #  Q0 Z ,$ 0@"\ $H
MN0!0 +< 5@"U %P M !A +, 9@"R &L L0!Q +  =P"O 'X K@"% *P CP"K
M )H J0"G *@ N@"F -D HP#W *$ _P"@ /\ G #_ )D _P#_XGT024-#7U!2
M3T9)3$4 %!7\    \@   .4   #;    T@   ,H   ##  P O@ 7 +H (0"W
M "L LP S *\ / "M $, JP!* *D 4 "H %4 I@!; *4 8 "D &4 HP!K *(
M<0"@ '@ GP!_ )X B "< ), F@"@ )@ L "5 ,L DP#N )( _P"2 /\ D #_
M (X _P#P    X@   -4   #+    P@   +H   "T  @ KP 3 *H ' "F "4
MI  M *( -0"? #T G0!$ )P 2@": $\ F0!4 )< 60"6 %\ E0!E ), :P"2
M '( D0!Y (\ @@", (T B@"9 (D J0"' ,  A0#B (0 _0"# /\ @P#_ ($
M_P#D    U    ,<   "]    M    *T   "G  ( H0 - )T %P": "  EP H
M )0 +P"2 #8 D  ] (X 0P"- $D BP!. (H 4P") %@ AP!> (8 90"$ &L
M@@!S ($ ? !_ (< ?0"3 'L H@!Y +< > #5 '8 ]0!U /\ =0#_ '4 _P#6
M    R0   +T   "R    J@   *,   "<    EP ( )( $P". !L BP B (@
M*0"& #  A  W (( /0"  $( ?P!( 'T 30!\ %( >@!8 'D 7@!W &8 =0!M
M ', =P!Q ($ < ". &X G0!L *\ :@#) &D ZP!H /\ 9P#_ &< _P#,
MOP   +,   "J    H0   )H   "3    C0 # (@ # "$ !8 @  > 'T ) !Z
M "H >  Q '8 -P!T #T <P!" '$ 1P!O $T ;@!2 &P 60!J &  : !H &8
M<0!D 'P 8@") &$ EP!? *D 70#  %P X !; /D 6@#_ %H _P#$ @  MP@
M *P)  "C!P  F@$  )(   "+    A    '\ !P!Z !$ =@ 9 '( ( !O "4
M;  K &H ,@!H #< 9P ] &4 0@!C $@ 8@!- &  5 !> %L 7 !C %H ; !8
M '< 5@"$ %4 D@!3 *, 40"X %  U0!/ /( 3@#_ $X _P"]$   L18  *<7
M  "=%0  E1$  (P)  "$ 0  ?0   '8  0!Q  H ;  3 &@ &@!D "$ 80 F
M %\ + != #( 6P X %H /0!8 $, 5@!) %0 3P!2 %8 40!> $\ 9P!- ',
M2P!_ $D C@!' )X 1@"Q $0 RP!$ .L 0P#] $, _P"W&@  K"   *(B  "9
M(0  D!T  (<7  !_$   =P<  &X   !H  4 8@ - %X %0!: !L 5P B %0
M)P!2 "P 40 R $\ . !- #X 3 !$ $H 2@!( %( 1@!: $0 9 !" &\ 0 !\
M #\ B@ ] )H .P"M #H Q0 Y ., .0#X #D _P"S(P  J"D  )\K  "6*P
MC2<  (0A  !['   <A0  &D*  !@    60 ' %0 #P!0 !8 30 < $H (@!(
M "@ 1@ M $4 ,P!# #D 00 _ #\ 1@ ] $T .P!6 #D 8  W &P -@!Y #4
MB  S )@ ,0"I #$ P  P -T , #S "\ _P"O*P  I3   )PS  "3,P  BC
M ($K  !W)0  ;AX  &47  !;#@  4P4  $P " !' !  1  7 $$ '0 ^ ",
M/0 I #L +@ Y #0 -P [ #4 0@ S $H ,0!3 "\ 7@ N &H + !W "L A0 I
M )8 )P"H "8 O0 F -D )0#N "0 ^@"M,0  HS<  )DY  "1.0  B#<  '\S
M  !U+0  ;"8  &(@  !7&0  3A$  $4* @ ^! D .@$2 #< &  U 1X ,P$D
M #$"*@ O C  +@,W "P#/@ J!$< * 50 "8%6P D!F< (P=U "$'A  ?")4
M'0>G !P&O0 :!M8 &0?L !D(^0"J-P  H3P  )<_  "//P  ACT  'TZ  !S
M-   :2X  %\H  !5(0  2QH  $$4   X#00 , @* "T'$@ K"!D *0D? "<)
M)0 E"2L ) HS "(*.P @"T0 'PQ. !T,60 ;#68 &0YT !<.A  5#I4 % ZH
M !(-O@ 1#=D $@[N !,-^P"H.P  GT   )9#  "-1   A4(  'Q   !R.@
M:#4  %XO  !3*0  2",  #X<   T%P  *Q(% "00#  A#Q0 'P\: !X0(  <
M$"@ &Q$O !H1.  8$D$ %Q-, !435P 3%&0 $11R ! 5@@ -%9, "Q6F  D5
MO  )%-8 "A3O  P4_0"F/P  G40  )1'  ",2   A$<  'M%  !Q0   9CL
M %PV  !2,   1RL  #PE   R(   *1L  !\7"  :%1  &!46 !<6'0 5%B4
M%!<L !,7-0 2&#\ $!A)  T950 +&F( "1MP  @;@  &&Y$ !1ND  ,:N0 #
M&M, !!GJ  89^P"E0P  FT@  )-+  "+3   @DP  'E*  !P1@  94$  %L\
M  !0-P  1C(  #LN   Q*0  )R0  !T?!0 4&PP $AL4 ! <&P .'"( #!TJ
M  L>,P *'CT "!]'  <?4P %(&   R!N  $A?@  ((\  ""B   ?MP  ']$
M !_I   >]P"C1P  FDT  ))0  "*40  @E   'A/  !O3   9$<  %I#  !0
M/P  1CL  #LV   Q,@  )2P  !DF @ .(@H "B(2  @C&0 '(R  !20H  0D
M,0 ")3L  25%   E40  )5X  "9L   G?   )XT  ":@   EM0  )-   "/H
M   C]@"A3   F%$  )%4  ")50  @58  'A4  !N40  8TT  %E*  !01P
M1D,  #P_   N.0  (3,  !4N   **@D !"D0  $J&   *A\  "LF   K+P
M+#@  "M#   K3P  +%P  "QJ   M>@  +(L  "R>   KLP  *LX  "GH   H
M]@"?4   EU4  (]8  "(6@  @%L  '=:  !N5P  8E0  %E1  !03@  14H
M #=%   J/P  '#H  !$V   %,@@  #(.   R%@  ,AP  #(D   R+0  ,S8
M #)!   R30  ,EH  #-H   S>   ,XH  #*=   QL0  ,,P  "_H   N]P"=
M50  E5L  (Y>  "'8   ?V   '=@  !M7@  8UL  %I9  !.50  0%   #)+
M   E1@  %T(   L^    .P<  #H-   Z%   .AH  #HB   Z*@  .C,  #H^
M   Y2@  .5<  #IF   Z=@  .H@  #F;   WL   -LL  #7H   U^ "<6P
ME&   (UD  "&9@  ?V<  '=F  !M90  8V,  %=?  !)6@  .U8  "U2   ?
M30  $DD   9&    1 8  $,+  !#$@  0Q@  $(?  !")P  0C   $(\  !!
M2   054  $%C  !!<P  084  $"9   ^K@  /<D  #SG   [^0":80  DV8
M (QJ  "&;   ?VX  '=N  !N;   8&@  %)E  !$8   -5P  "=9   950
M#%(   !/    3@,  $T)  !,#P  3!4  $L<  !+)   2BT  $HX  !*10
M25(  $E@  !)<0  28,  $B6  !'K   1<<  $/G  !"^0"8:   DFT  (QQ
M  "&<P  ?W4  'AU  !J<@  6VX  $QJ   ]9@  +F,  "!@   270  !5L
M  !9    6    %<%  !6"P  5A$  %48  !4'P  5"@  %0T  !300  4TX
M %)=  !2;0  47\  %&3  !0J@  3<4  $SE  !*^0"6<   D70  (MX  "%
M>P  ?WP  '-Z  !D=P  5',  $5P   U;0  )VH  !AH   )9@   &0   !C
M    8@   &(!  !A!P  8 P  & 3  !?&@  7B(  %XN  !>.P  74D  %U8
M  !<:0  6WL  %J/  !9I0  6,   %;B  !4^ "5=P  D'P  (N   "&@@
M>X$  &Q_  !=?   37D  #QW   M=   'G(  !!P   !;P   &X   !N
M;0   &P   !L 0  :P8  &H,  !J%   :AH  &DF  !I-   :$,  &A3  !G
M9   9G8  &6*  !DH   8KH  &'<  !@]0"4@   D(0  (N(  "!B   <X8
M &2#  !4@0  1'\  #)]   C?   %'H   5Y    >    '@   !X    >
M '<   !W    =@   '8%  !U"P  =1,  '8<  !U*@  =#L  '1+  !T7
M<W   '*$  !PFP  ;K0  &W4  !M\0"4B   D(P  (:-  !YC   :HH  %J)
M  !*AP  .88  "F%   9A   "8,   ""    @@   ((   "#    @P   ((
M  ""    @0   ($   "! P  @0H  ((1  ""'P  @3   (%"  ""4P  @F<
M (!]  !_E   ?:T  'S+  ![ZP"4D   BY$  'Z1  !PD   8(\  $^.   ^
MC0  +8T  !V-   -C    (P   ",    C    (T   "-    C@   (X   ".
M    C@   (T   "-    C@   ) %  "0$0  D"$  (\V  "020  D5T  )%S
M  "0BP  CJ4  (W!  ",Y ".E0  @I8  '26  !EE0  5)0  $.4   RE
M(94  !"5    E0   )4   "5    E@   )<   "8    F0   )D   "9
MF0   )D   ":    FP   )P   "?!   H!(  * E  "A.@  HT\  *5E  "C
M@   H9L  *"W  "?V "&F0  >)H  &F:  !9F@  2)H  #::   EG   %)P
M  .=    G@   )X   "?    H    *$   "B    I    *0   "E    I0
M *8   "F    IP   *D   "M    KP0  +$5  "Q*@  M$$  +A8  "Y<
MN8D  +FC  "XP@!\G@  ;9\  %Z?  !.GP  .Z   "FB   7I   !J4   "F
M    IP   *D   "J    JP   *P   "N    KP   +    "Q    L@   +,
M  "S    M0   +<   "Z    P    ,0%  #(&0  RC   ,])  #58@  UGL
M -:3  #6JP#_    _P   /\   #_    _    /@ " #U !8 \  B .T + #I
M #< Y0!! .$ 20#> %$ W !7 -@ 70#3 &, T0!H ,X ;0#, '( S !X ,H
M?@#) (4 R "- ,< EP#& *( Q "Q ,, R0#! .P P #_ +\ _P"Y /\ L0#_
M *L _P#_    _P   /X   #U    [P   .D ! #C !( W@ > -L )P#6 #$
MT@ [ ,X 1 #) $L Q0!2 ,( 6 #  %T O@!B +T 9P"\ &T NP!R +H > "Y
M '\ N "' +< D "U )P M "J +( O0"Q .  KP#] *T _P"I /\ HP#_ )\
M_P#_    ^P   .\   #F    WP   -8  @#/  P R@ 8 ,8 (P## "L O@ U
M +D /@"V $4 M !, +( 4@"Q %< KP!< *X 80"M &< K !L *L <@"J 'D
MJ "! *< B@"F )4 I "B *, LP"@ -$ G0#S )P _P"< /\ EP#_ )0 _P#X
M    [    -\   #5    S    ,0   "]  D N  3 +0 '0"P "8 K0 N *H
M-P"H #\ I@!% *0 2P"C %$ H@!6 *  6P"? &$ G@!F )T ; "; ', F@![
M )@ A "7 (X E "; )( JP"0 ,0 C@#I (T _P", /\ BP#_ (@ _P#K
MVP   ,\   #%    O    +4   "N  0 J0 0 *4 & "B "$ GP I )T ,0":
M #@ F  _ )< 10"5 $H E !0 )( 50"1 %H D !@ (X 9@"- &T BP!U (D
M?@"' (@ A0"5 (0 I "" +D @ #< '\ ^@!^ /\ ?0#_ 'P _P#>    SP
M ,(   "X    L    *D   "B    G0 * )@ % "5 !L D@ C (\ *P"- #(
MBP X (D /@"( $0 A@!) (4 3@"$ %0 @@!9 (  8 !_ &< ?0!O 'P > !Z
M (( > "/ '8 G@!T +$ <@#/ '$ \@!P /\ ;P#_ &\ _P#1    PP   +@
M  "M    I0   )X   "8    D@ % (T #@") !@ A@ > (, )0"! "L ?P R
M 'T . ![ #T >@!# '@ 2 !W $X =0!3 ', 6@!Q &$ < !I &X <@!L 'T
M:@") &@ F !F *H 9 ## &, YP!B /\ 80#_ &$ _P#'    N@   *\   "F
M    G0   )4   ".    B    (, "0!_ !( >P : '@ 'P!U "8 <@ L '
M,@!O #@ ;0 ] &L 0@!J $@ : !. &8 5 !D %L 8@!C &  ; !> '< 70"$
M %L D@!9 *0 5P"Z %8 VP!5 /< 5 #_ %0 _P"_ 0  L@8  *@&  "?!
ME@   (X   "&    @    'H ! !U  P <0 5 &T ' !I "$ 9P G &0 +0!C
M #, 80 X %\ /@!> $, 7 !) %H 3P!8 %8 5@!> %0 9P!2 '( 4 !_ $\
MC0!- )X 2P"R $D SP!( .\ 2 #_ $@ _P"X#@  K!0  *,5  "9$P  D T
M (@&  "     >    '$   !K  < 9P / &( %@!? !T 7  C %D )P!7 "T
M5@ S %0 . !2 #X 4 !$ $\ 2@!- %$ 2P!9 $D 8@!' &T 10!Z $, B0!!
M )D 0 "L #X Q@ ] .8 /0#\ #T _P"S&0  J!X  )X@  "5'@  C!H  (,4
M  ![#0  <@0  &H   !C  ( 70 * %@ $0!5 !< 40 = $X (P!- "@ 2P M
M $D ,P!' #@ 1@ _ $0 10!" $T 0 !5 #T 7@ [ &H .@!W #@ A0 V )4
M-0"H #, O@ S -\ ,@#V #( _P"N(@  I"<  )LI  "2*   B20  ( >  !W
M&0  ;A$  &4(  !<    50 % %  "P!+ !( 2  8 $0 '0!" ", 0  H #\
M+0 ] #, .P Z #D 00 W $@ -0!1 #, 6P Q &8 +P!T "X @@ M )( *P"D
M "H N0 J -8 *0#P "D _P"K*0  H2X  )@Q  "/,   ABT  'TH  !T(0
M:AP  &$4  !7"P  3P,  $< !@!#  P /@ 3 #L &0 X !X -@ D #4 *0 S
M "\ ,0 U "\ /0 M $0 *P!. "D 6  G &0 )@!Q "0 @  B )  (0"B !\
MM@ ? -$ 'P#L !\ ^@"I,   GS4  )8W  "--P  A#0  'LP  !R*@  :"0
M %X=  !4%P  2@X  $$(   Z 0< -0 - #( %  O !D +0 ? "L )0 I "L
M)P Q "4 .0 C $$ (0!+ !\ 50 > &( ' !O !H!?@ 8 8X %P&@ !8 M  5
M ,X % #H !, ]P"F-0  G3H  )0\  ",/   @SL  'HW  !P,0  9BL  %PF
M  !2'P  1Q@  #X2   T"P$ + 8( "@##@ E A0 (P(: "$#(  ? R8 '00M
M !P$-0 :!3X & 5( !<&4P 4!U\ $P=M !$(?0 ."(T #0>@  L'M  *!LP
M"0?E  D'] "D.0  FSX  )-!  "*00  @D   '@]  !N.   93(  %LL  !0
M)P  12$  #L;   R%@  *1$" " ,"  ;"0X &0@5 !<)&P 6"2( % HJ !,*
M,@ 1"SL #PQ&  P-40 *#EX " ]L  <0>P %$(P !!"?  ,0LP !#LL  0WD
M  (-]@"C/0  F4(  )%%  ")1@  @44  '=#  !M/@  8SD  %DT  !/+@
M1"D  #HD   P'P  )QH  !T6 P 4$0@ #@X.  T0%P ,$1\ "Q$G  D2+P (
M$SD !Q1#  443P #%5P  19J   6>0  %HH  !:<   5L0  %<D  !3C   3
M\P"A0@  F$<  )!)  "(2@  ?TD  '9(  !M1   8C\  %@Z  !.-0  1#
M #DL   P*   )R,  !T?   1&08 "18-  87%0 %&!T  Q@E  (9+0 !&C<
M !I!   :30  &UH  !MH   <>   '(D  !N;   ;KP  &L@  !GB   8\P"?
M1@  ETL  (]-  "'3P  ?TX  '9-  !L20  844  %=!  !./0  1#D  #HU
M   Q,0  )2P  !DE   ,( 8 !!X,   >%   'AL  !\C   ?*P  (#4  "!
M   @2P  (%@  "%F   A=@  (H<  "&:   ?K@  'L8  ![C   =\P">2@
ME4\  (Y2  "&4P  ?E,  '52  !K3P  8$L  %=(  !.10  14$  #L]   M
M-P  (#(  !0L   ()P8  "8,   E$P  )AD  "8A   F*0  )S(  "<]   F
M20  )U8  "=D   G=   *(4  ">8   EK   ),4  "/C   C]0"<3P  E%0
M (U6  "%6   ?5D  '58  !K50  8%(  %=/  !/30  1$@  #9#   I/0
M&S@   XS   #+P4  "X+   M$0  +1<  "T?   N)P  +C   "X[   M1P
M+50  "YB   N<@  +H0  "V7   LJP  *L0  "GB   I]@":5   DUD  (Q<
M  "$7@  ?5X  '1>  !K7   8%D  %A7  !-4P  /TX  #%)   C1   %C\
M  D[    . 4  #8*   V$   -14  #4=   U)0  -BT  #4Y   U10  -%(
M #1@   U<   -8(  #25   RJ@  ,<,  ##B   O]@"86@  DEX  (MB  "$
M9   ?64  '5D  !K8P  86$  %5=  !(6   .5,  "M/   =2P  $$8   1#
M    0 ,  #\(   _#0  /A,  #T:   ](@  /2H  #TV   \0@  /$\  #Q=
M   \;@  /(   #R3   ZJ0  .,(  #?B   V]@"78   D&4  (IH  "#:@
M?6P  '5L  !L:P  7F8  %!B  !"7@  ,UH  "56   74@  "4X   !,
M2@   $D%  !("@  2!$  $<7  !&'@  1B<  $4R  !%/P  14P  $1;  !$
M:P  1'T  $21  !"IP  0,$  #[A   ]]P"59P  CVP  (EO  "#<0  ?7,
M '9S  !H<   66P  $IH   [9   +&   !U=   .6@   U@   !5    5
M %,"  !2!P  4@P  %$3  !0&0  3R(  $\N  !/.P  3DD  $Y7  !-:
M37H  $V.  !+I   2KX  $?@  !%]P"4;@  CW,  (EV  "#>0  ?7H  '%X
M  !B=0  4G$  $)N   S:@  )&<  !9E   &8P   &$   !@    7P   %X
M  != P  7 @  %L-  !:%0  6AT  %DH  !9-0  6$0  %A3  !79   5G8
M %:*  !5H   4[H  %'>  !0]P"3=@  CGL  (E^  "$@0  >7\  &I\  !:
M>0  2G<  #ET   J<0  &V\   QM    ;    &L   !J    :0   &D   !H
M    9P(  &8(  !F#@  918  &4@  !D+@  9#T  &--  !C7@  87$  &"%
M  !?FP  7K0  %W7  !;] "2?P  CH,  (J&  !_A@  <80  &*!  !2?P
M07T  #!Z   @>0  $7<   )V    =0   '4   !T    =    ',   !S
M<@   '(!  !Q!P  <0X  '$6  !Q)   <#4  '!%  !O5P  ;VH  &U_  !K
ME0  :JX  &G.  !H[P"2AP  CHL  (6+  !WB@  :(@  %B&  !'A0  -H,
M "6"   6@0  !G\   !_    ?@   '\   !_    ?P   '\   !^    ?@
M 'T   !]    ?04  'X*  !^&   ?2D  'T\  !]3@  ?6$  'QW  !ZC@
M>:<  '?$  !VZ "2CP  B9   'R0  !NC@  78T  $V,   [BP  *HL  !J*
M   )B0   (@   "(    B0   (D   "*    B@   (H   "*    B@   (D
M  "*    B@   (L!  ","@  C!L  (HQ  "+1   C%<  (UM  "+A@  BI\
M (B[  "'W@"-E   @)0  '*4  !BDP  4I(  $&2   OD@  'I(   R2
MD@   )(   "2    DP   )0   "5    E0   )8   "6    E@   )4   "6
M    EP   )@   ":    G L  )P?  "<-0  GDH  )]A  ">>P  G94  )NP
M  ":T@"$F   =I@  &>8  !7F   1I<  #.8   AF0  $9H   ":    FP
M )L   "<    G0   )X   "?    H    *$   "A    H@   *(   "B
MHP   *4   "H    JP   *T.  "L)0  KSL  +)2  "U:@  M80  +*B  "P
MP@!ZG   :YT  %N=  !+G0  .9X  ":?   4H0   J(   "C    I    *4
M  "F    IP   *D   "J    K    *T   "M    K@   *\   "N    L
M +(   "U    NP   +\   #"$P  Q"L  ,E$  #.7   T'8  -&/  #1IP
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M________________________________________
M  $#! 4&" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X
M.3L\/3Y 04)$149'24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q
M<W1U=WAY>GQ]?H"!@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JK
MK*VOL+&SM+6VN+FZN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/D
MYN?HZ>OL[>[P\?+T]?;W^?K[_/[_________________________________
M_____________________P                     ! P0%!@@)"@L-#@\1
M$A,4%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*
M2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#
MA8:'B(J+C(Z/D)&3E)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]
MOK_!PL/$QL?(R<O,S<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V
M]_GZ^_S^____________________________________________________
M__\  0(#! 4&!P@)"@L,#0X/$!$2$Q05%A<8&1H;'!T>'R A(B,D)28G*"DJ
M*RPM+B\P,3(S-#4V-S@Y.CL\/3X_0$%"0T1%1D=(24I+3$U.3U!14E-45597
M6%E:6UQ=7E]@86)C9&5F9VAI:FML;6YO<'%R<W1U=G=X>7I[?'U^?X"!@H.$
MA8:'B(F*BXR-CH^0D9*3E)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["Q
MLK.TM;:WN+FZN[R]OK_ P<+#Q,7&Q\C)RLO,S<[/T-'2T]35UM?8V=K;W-W>
MW^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     # 2$
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M_______&="D     3[/_______________________________^A1P
M-Y_______________________________^]]%@      'H[_____________
M_________________]9'        !8C_____________________________
M_ZH^"0       (#______________________________\J#1!,      '#]
M_______________________________0G6@\-#-(9XKR________________
M_________________<RFGJ.WU/G_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________:M*"6M___________
M________________________\JMK02XC7=7_________________________
M________JF(=    ,J/________________________________)<RD
M$G[L______________________________^;0P       &'/____________
M_________________]%K"@       $FY____________________________
M_ZDP         #2G_____________________________WT          !Z6
M____________________________[#8           >(________________
M____________M@            !Z____________________________72
M          !F_?__________________________OG,P          !-[?__
M_________________________^&A7BH%       NV?__________________
M____________S95G4TY>=9"MU?_________________________________Z
MZ^W[________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________NU<2WJ\K_________________________________Y*%O44 R
M(V#E_______________________________7BT8*     #>U____________
M__________________:41P       !>/____________________________
M_[]?"0        !Q[____________________________Y,I          !9
MV/__________________________[F@           !%Q/______________
M____________PB0            QL___________________________D
M           ;H?__________________________/0             $D/__
M_______________________A                @?__________________
M______]?                :_________________________\B P
M        4?[______________________ZN>:RL             ,^?_____
M____________________^;]R-Q(        !%LS_____________________
M_______UNXQK651=:WF(E=K_________________________________^OG_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________PX=+Q____________
M____________________Z;*/=F151#-X____________________________
M___%>CL1      !"S____________________________\QT)P         8
MH?__________________________]HDU           "A?______________
M____________OU0             ;O[_________________________DAP
M            6>O________________________X9@              1]K_
M_______________________6(@              -,G_________________
M______^O                '[C_______________________]5
M        "*7_______________________\                  )/_____
M_________________Y8                  (#_____________________
M_P                   &/_____________________R0
M     $+______________________Q]&*@4              "WO________
M______________3_W:)C.1D       $.'"[G________________________
M____T:N,?WZ&D9VJN,7_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^C+M*"/?FUB
MR?_____________________________$A%0T' 4    ,D_______________
M_____________[-@%P          9/K_________________________RF81
M            .<O_________________________B"<             $:+_
M_______________________*3P               '__________________
M______^7&                %________________________]C
M         %#Y_____________________^$C                 $#K____
M_________________ZD                  "W;____________________
M_U0                  !?)_____________________P
M      "U____________________H                     "?________
M____________T                     "#_____________________P
M                  !Z_____________________RD
M  !Q_____________________X )#@                !K____________
M__________?,OYYW5STF&!0;)"\[1U1S____________________________
M_^W4S,S2V^3M^?______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________KFU,&MP?_____________________________G
MM)!S6T4Q&P8 9?G__________________________ZYB)P          -<G_
M________________________K5              !IO_________________
M_______280(              '#_______________________^,(@
M         $?M_____________________^!/                 "'*____
M_________________Z@9                  "J____________________
M_VP                   "+_____________________R8
M      !L____________________Q@                    !.________
M____________B0                     R____________________J@
M                   @\O__________________U
M   7Y____________________P                     5X___________
M_________R<                    1W/___________________VD
M               +TO___________________\8                    &
MR_____________________\\"08                !R/______________
M_______LT[^HC7AI86!G<'J$CYJEV/______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________^;*LIR'=%]'0=#_________________
M_________\J*6S@;        !)O_________________________IDX$
M         &K_______________________^S2P               #SD____
M_________________^9B                 !"Y____________________
M_YXC                  "0_____________________UP
M      !L____________________Y1\                   !)________
M____________GP                     F\?__________________>@
M                   $T?__________________E0
M    L___________________M0                      E___________
M________V@                      @O___________________P
M                >/___________________RT
M=O___________________V8                     <_______________
M_____ZD                     ;_____________________\<
M            :O____________________^%                    9?__
M____________________.B4E&PT!    !Q 9(RTW7?__________________
M________[-G+QLG0VN/J\_W_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___WXLVWH,+____________________________8KXUP5C\H$    ''_____
M____________________O&TR!0           #OC____________________
M__^H1@                BQ_____________________\Y-
M      "#_____________________W@                   !7________
M____________YBP                    N\___________________DP
M                   )T/__________________;0
M    K?__________________B0                      B___________
M________J                       :?__________________Q@
M                2?__________________YP
M+?___________________PH                     &_______________
M_____S4                     %/O__________________V<
M            $_7__________________Z$                     $_7_
M_________________^4,                    #.__________________
M__]=                    !.G____________________&!
M         .'_____________________A@                   -3_____
M_________________X]P:V-?7%]E;WB B9&:I-3_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________78OJ>1>V5-,T7Q________________________^;!]4S$2
M      VY______________________^]7A,               "$________
M_____________\I)                  !1_____________________V
M                   @XO__________________MPT
M    MO__________________7P                      C___________
M________=0                      :?__________________EP
M                1O__________________M0
M(___________________TP                       .W_____________
M____\@                       ,S__________________QL
M             +'__________________T(                      )[_
M_________________VT                      )7_________________
M_YX                      )'__________________]L%
M         )#___________________]*                     ([_____
M______________^<                     (?_____________________
M0P                   'O_____________________QQT
M     &C______________________\DF         PP4'"0M-5'_________
M________________^??Q[>WP]?O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________]^')L9?/________
M___________________AM9)T64$J$@    "*________________________
MGE<B              !4_____________________^!?!
M   >X/___________________UT                     K?__________
M________FP                      ??__________________40
M                4O__________________>@
M*?__________________H@                       ^C_____________
M____Q                        ,7_________________XP
M             */__________________PD                      ('_
M_________________RH                      &+_________________
M_T\                      $C__________________W@
M         #C__________________Z8                      ##_____
M_____________]H%                     "W___________________]
M                     "S___________________^'
M     "O____________________8(@                   !__________
M____________@@                    W______________________U8
M                  #_______________________]E
M  #?________________________N&9I;7)X@8B-E)^EK;78____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________JS[:?AV]5
M.R%6_________________________[B!5"\0           @Y/__________
M__________^>0@                  KO___________________W@#
M                >?__________________F
M1___________________10                      %O;_____________
M____>0                       ,S_________________IP
M             *3_________________SP                       '[_
M________________\P                       %K_________________
M_R                       #?__________________T$
M         !7__________________V,                       #_____
M_____________X8                       #O_________________ZX
M                      #=_________________]X-
M      #3__________________]"                      #-________
M__________]^                      #*___________________"#0
M                  #'____________________8
M  "_____________________P"4                   "L____________
M_________YL1                  "/______________________^F)@
M              !E_________________________7P4     @P4'"8M,SQ-
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Y,FM___________________________Q
MQ)Y]8$4K$@      KO_____________________YF%(=
M=O___________________[@Y                    0O______________
M____LA$                     #^W_________________.@
M             +O_________________=                        (W_
M________________J                        &+_________________
MU@                       #K__________________PP
M         !/__________________S(                       #X____
M_____________U<                       #7_________________WH
M                      "W_________________YT
M      ";_________________\(                       "&________
M_________^H8                      !V__________________]'
M                  !M__________________]^
M  !H__________________^\!@                    !D____________
M________3                     !?____________________G0$
M              !5_____________________V,                    \
M_____________________]].                   7________________
M_______M8P                  _________________________\%3   #
M$Q\L/%)LAZG4________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________$E6]:4$E!.C(J(1<.-/____________________^/+P
M             N7_________________]40                      +'_
M________________-0                       '__________________
M:0                       %#_________________J
M         "+_________________W                         #Z____
M_____________Q8                       #2_________________T(
M                      "M_________________VH
M      ")_________________X\                       !G________
M_________[,                       !)_________________]@&
M                   P__________________\M
M   <__________________]7                       /____________
M______^%                       &__________________^Y!
M                ___________________X0P
M____________________BP                      ________________
M____VS\                     _____________________Z 8
M            ^?____________________^.%0                  TO__
M____________________KSH              !(TO___________________
M______^877%_CZ&RQ-GT________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________\.39TLO&P;VWLJNFI_#_________________
M__N9;U$Y)Q@*             &K_________________C"$
M         #O_________________4@                        W_____
M____________H0                        #A________________X
M                      "V_________________QT
M      "+_________________T\                       !C________
M_________WH                        ]_________________Z,
M                   9_________________\D
M    _________________^\=                        ____________
M______]"                        ]_________________]J
M                Y/________________^5
MUO_________________##0                      S/______________
M___X0@                      Q?__________________?P
M            O___________________QRL                     M?__
M_________________WT                     HO__________________
M_^%2                    @?_____________________44P
M        3O______________________]G\<   )&"<W1UQSBZC.________
M___________________NTN;T____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________]UKJDD89]=6YH8EU74DU(14?_________________Q7]*
M(0@                   ##________________CP
M      "8________________W0                        !N________
M_________QP                       !$_________________U<
M                   ;_________________XD
M    _________________[4                         ^O__________
M_____]X,                        V?________________\S
M                NO________________]9
MH/________________]_                        B?______________
M__^G                        =__________________1&P
M            :___________________2@                      8O__
M________________@                       6___________________
MO!\                     4____________________V8
M        1O___________________[HR                    *_______
M______________^5'                    /______________________
MF"H            +(3E8>________________________\EB76Q[BINNPMCS
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________B."!)0T-?4%)/1DE,10 5%?__________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________/#H
MX=O6T,S(QL/#PL7O_________________]FE@VM71C@O)R :$PT&      !'
M________________U#\/                       >________________
M_Q(                         _________________U0
M            ^/_______________Y,                         TO__
M_____________\<                         K/________________,?
M                        B/________________])
M        9_________________]P                        2O______
M__________^7                        ,/________________^\!0
M                    &O_________________C+
M    "___________________5P                       /__________
M________A@                       /__________________O2
M                 /__________________^%T
M /___________________Z 9                     /______________
M______EL                     /_____________________96P
M            &NK_____________________X6H)  T9)C9'6W"(H\'E____
M_______________________(Q]KJ^?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________W\:VIYN0B81^
M>71P;&MJ;&]X_________________Y1D0B@5!                   S___
M_____________TT                         I________________Y<
M                        @?_______________]0
M        7/________________\M                        ./______
M__________];                        %?________________^&
M                     /________________^N
M     /_________________4'@                       /__________
M_______Z1                        /__________________:@
M                 /C_________________E
M .S_________________PR4                      ./_____________
M____^5P                      -C__________________YD2
M             ,K__________________]]7                     +/_
M__________________^I,P                   (G_________________
M____GS          #"$X4&R,KN+______________________[5;9W>'E:6X
MS>3^________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______CMY>+?W-K8UM76VN/K_________________^VZF7]N859-13\Z-3$L
M*"8E)2<I7O_______________YTP#@                      *?______
M_________]P                         !O________________\U
M                     /________________]J
M     /________________^9                         /S_________
M_______##                        .#________________L-0
M                 ,3_________________70
M *S_________________@P                       )C_____________
M____J@L                      (K_________________TS4
M             '___________________V,                      '3_
M_________________Y@1                     &;_________________
M_]1/                     %'___________________^5(
M         "[____________________P<PH             $BM(9I'_____
M________________Y' /&BHY2%AH>Y*LR.?_________________________
M__W!S=[P____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________Z];&
MNJ^GH9N6DX^+B8>)C9:AKO________________>!8DLY*Q\5#@<!
M     /________________\W                         .7_________
M______]W                         ,/_______________^L
M                 *3________________:(0
M (?_________________3                        &K_____________
M____=0                       %#_________________G
M             #C_________________PR0                      "?_
M________________ZDL                      !K_________________
M_W4                       [__________________Z,:
M          #__________________]5/                      #_____
M______________^+%P                    #____________________6
M70                 8,U?_____________________N4@     "QHK/E1N
MBJG*\/_______________________[=H>HR>K\+3YO__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________^^//OZ^?EX^;I\/K____________________5LIN+?7%I
M8EY955).2TI,4%9?:KG_______________^*-AX.
M &3________________                          $7_____________
M___S,@                       "K_________________8@
M              W_________________C0                        #_
M________________MA<                       #_________________
MW#X                       #__________________V0
M          #__________________XL"                      #_____
M_____________[4L                      #__________________^-:
M                      #___________________^.&
M      #Z___________________)5                   $C+X________
M____________G3,         %"I#7GR<O-S______________________8XO
M/4]@<(&4JL+>_______________________________-VNS_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^G9SL6]MK&MJJBFI::IK[G%U-[________________G@6Q<3T4]-2XI
M)!\<&AD9&ATB*C?_________________/@                        #_
M________________=                         #_________________
MI (                       #_________________SR\
M          #_________________]U@                       #I____
M_____________WX                       #5_________________Z0:
M                      #$_________________\Q#
M      "T__________________9M                      "G________
M__________^:)                     "3___________________*5P
M                !2.5____________________DBH           PD0%Y]
MG;SL____________________X705#B P0%%F?9:QT//_________________
M_________]6,F*N_T>3Y________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________^_/KX^_S_________________________
MT[>FFY.+A7YY=7)O<'!S>'^,GJS_________________EDHX*B$:$@L$
M          #)________________P!,                       "P____
M____________[48                       "9_________________W(
M                      "$_________________YH/
M      !N_________________\$W                      !:________
M_________^==                      !*__________________^%#@
M                   Z__________________^N-P
M   F___________________99                   "2E+____________
M________E2X            1+DULCK+9____________________UFL-   0
M(#%&77:1L=/V_________________________[IA9WJ-G[+(XOW_________
M_______________________K\/__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________QY=S6T<S'P\' P,7)S]?E^O__________________]92!
M<FEB7%=234I(1T=)3%->;X:F_________________UT?$ 4
M       G_________________XP                        4________
M_________[<L                        _________________]]4
M                    __________________]\!
M    __________________^C*P                      ____________
M_______(40                      ___________________P>!
M            '$%B____________________HST            -*TMND[O7
M____________________V&\2    #A\S2F-_H,/G____________________
M_____[!-0U=K?I*HP=SZ______________________________^^N]+G_/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^?)N[&JI)^<FIB8F)J@I;"]T^S__________________[UC5DQ%
M/CDU,"PJ*"<H+#(Y2FB+_________________]Q&
M    __________________]T                        ____________
M______^<(P                      ___________________#2@
M                ___________________I< <
M^___________________EBP                .-%Q_________________
M____O%,            5-%5[I,WM____________________Y'T?    !A<L
M0UU]GL+H_________________________[-2+D)6:G^5KLOJ____________
M__________________BEE*S"V>__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________?P[.CEY>/BY>KM]?__________________
M______^VFY&*A8%^?7IY>GN B)2CN-KT__________________^;0CDQ*B4B
M'QH5$A 0$A09*$ARY/________________^]0
MIO_________________D:P                      E?______________
M____DB<                   8NI/__________________MTT
M      8M4WN?W___________________W'$2          (B1FR3NN;_____
M_________________I8X    !QHO1V*$J,[V________________________
M_\%A(C=,8G:-J,7F______________________________F>?)6KP]OT____
M_______________________________]Z?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________XM;/R<?%Q<7(QLS4V^/R____________________
M___ZF'QT;FIH9V=I9VMQ>(.2I,+?]?__________________C2\A&A01#@L&
M 0      $3)>CO__________________M$D                  S%=@___
M________________VW 0             "=2>J/-Z___________________
M_I0U         !0X7XFTVO_______________________[96    #R0\5G*0
MN>'__________________________]I[)S9+8GJ3L,WN________________
M______________^K=(FANM3N___________________________________V
MT^?_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________^,"UKZRJK:VQM\#%T-GC^_______________________
M[XE@65945UE=8V5M=7Z1J,/L^?___________________Y<U#0D% @
M'4QYHLSW_____________________[Q< P      #3!7@JW8____________
M_____________]Q_)P &'#1/;(VNUO____________________________R?
M0SM2:X:AP./________________________________"?86@NM;V________
M___________________________^SM3S____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________S[^[N[_7\____________________
M______________.OFYJ;GJ6NNKS$U.;___________________________>7
M5$Q/5%ME;H"7P.?___________________________^N5  ;-E)PC*O+]O__
M___________________________*:S]C?YV\WOS_____________________
M___________GF8.LR.?_____________________________________V\SR
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________
M
M
M                                          #_________________
M____________________________________________________________
M____________________________________________________________
M_________________________________P   /_N !-!9&]B90!D      (%
M  ))1/_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(#
M @(" @,# P,# P,# P,# P,# P,# P,# P,#! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$_\  % @"3P)/! $1  (1 0,1 001 /_$ :(    & @,!
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M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO==%@/J?\
M#W[W[KW7'R+_ %_%_P"GYM;FW/OWOW7NN/D^OI/ N.0;C_56!O;^G]??O?NO
M=="0F_'%[ _CZV_)_K_R+W[W[KW76MKD<DBX-M(M?D'Z:@;'_'W[W[KW7*['
M^H_HMQJ^H )O^ ??O?NO=<?[0N2+BQO_ %&D<&Y%N;_XD_[;WOW7NO"XXMS>
MW)MQ] #P+W_K_4^_>_=>Z]IL+D<?3D VY ''%O\ 7]^]^Z]UW8DD6X-K7N>+
M"X87LQ!%_?O?NO==*&*ZB0QO>]^+ 6L+*/2#_L;?X^_>_=>Z[M8WTEB+W'^Q
M_'T]//Y]^]^Z]U[ZV]/U/^Q-C<W/'Z@?K[][]U[KLFWT)8&PO?Z#BQ^OUO\
M[?W[W[KW79+<V_J/J>0?]N5)O[][]U[KVH@\GCZ#Z7)'!_VQ']??O?NO==AS
M^5(_/X/'/T*DW^G^\^_>_=>Z]KL>01^?Q_2_-R/?O?NO==ZE^E_]]_K_ $]^
M]^Z]URO?D<CW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]UQ+*OU(!_I^?]M]3[][]
MU[K@95_'-_Z_3W[W[KW7F<@V/%Q<< ?@_DG^OOWOW7NL3'GG5P;@$VX/TY/%
MR/?O?NO==DJUKZC?3?ZW)) %C^>"?]A[][]U[KIB2+ V_'XO^H6)M^1;Z>_>
M_=>Z\B&U[$?J(L0";$BQM:]O]C[][]U[KLW"DEK6L;_6_ L?K<'GW[W[KW7-
M&)!;\?U'U_LC\\VX_J?^(]^]^Z]UT0;ZFLIO<'ZV%N+C@WN/K[][]U[KA9B2
M>"!<_6_ZBW-OR?Z>_>_=>ZY@'43:WT-O\?I^+C4;?C_8^_>_=>ZYVY)-@2.#
M]3I%K_[W_C[][]U[KKD<\\C_ %/-O]<6%_Z<>_>_=>Z[8<K8GBXO?_"_-^;V
M_P!;W[W[KW70M:PO;Z*!<W_J3];#_7^GOWOW7NN1'%N3R#<CGCD<_P"%OZ>_
M>_=>ZZYN#;C_ !^@!_HRW-A;_6Y]^]^Z]UYM5N%))_Q'!M_C^./?O?NO=<3R
M?SP3<W'T^HOQS<?\C]^]^Z]UWS;^OT'] !^;GD7_ -M[][]U[KP6Q6W%@;V^
ME^+FPO\ CZ7_ *^_>_=>Z[-[<?6Y O\ 3^GYN?I[][]U[KU[ W.KZ_2WT_'O
MWOW7NO7-A8V)/YNPL>.+D?G_ %_?O?NO==ZN0/K<V'X)_P!87-^/];Z>_>_=
M>ZY7_P!]_O/^M[][]U[KOW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO==$@
M?4_[#\_[ ?GW[W[KW6(S"QT DBU[\ 7-O]CQ?W[W[KW6/R/SJ!N"!8?X$<?T
MN;_0W^G^/OWOW7NN ));2#_L .3>U^2.>!:_]/?O?NO=<K,#;E@+W''(X_4=
M1MS];<>_>_=>ZY#DCAB>3_L5)TD7!N;<_4>_>_=>ZXD_V?7?\_ZCF]]1'(L1
M_6W'OWOW7NN2ZM(_4+?GZ7N%))%^+7_V_OWOW7NN@ 3S<DZM)-_T\@K86(%[
M6]^]^Z]UXGG42 ?]?@6!XX/%C[][]U[KF;, 26M<$$ VOIX)!4D'G@VX]^]^
MZ]UU^?Z#D?7DD"UQ]00!S[][]U[KE]%Y)Y-B0+FQ_' -N??O?NO==7L/J6Y)
M-[BY.K_ WO\ [:W^O[][]U[KUQ]&U']1) _!N23_ +;\>_>_=>ZY+:XM<V)_
MH.#8?U_'OWOW7NO$\:6)!O8&]C]/]58CZ'W[W[KW7K #DL >-)L0!8<"]R![
M][]U[KP (N+@_4&QN;W' )^O/^P/OWOW7NNQQ^"!_KDVNW^/^MQ;W[W[KW79
MX!/(O_L;<?C_ (GW[W[KW77-N"2;#Z\<CACP.3_@;^_>_=>ZZ'%@+_FUA>UK
MVM;@#_>#[][]U[KL7!YO8_6]^#_0?X?X^_>_=>Z\?J"+F]_J+?7^A(!N2?\
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M7]^]^Z]UQ!M:Q_+7(YY+"PL2#Q?\_7W[W[KW7/TV4@ #4W/#78"U[V'X-O\
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MP?P!]?P;W/T%A_MO?O?NO=>-^>/I^/Z:;_Z_!-O\/?O?NO=<=5B+$ EN/Z$
MD<_C\\_T/OWOW7NLZM?\6(X(_P ?S;^H]^]^Z]UR]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7B0!<\ >_>_=>ZP.X(*V!!!X/^'^/(Y'OWOW7NN(:RV L#R3
MR;@'D?B]AQ[][]U[KH *=0MZOJI4Z@?0">/S8W-_?O?NO=<O2!P!<'4!P;CC
MD$BQX;C@'W[W[KW7A^01?@?3Z ?6S?T/]![][]U[KDOZ;6!TVMP+?D6 %Q=;
M?[;W[W[KW7'3S>UR;$V']F_/-[WY_P +>_>_=>Z[$=OS?TVTD"X'' '^ ]^]
M^Z]UR7G^R% !_H0"?J#Q8'GW[W[KW7:@V'^JN;-I'(N;?6YMI/OWOW7NN[7_
M !Q>Q%@0?KSSS]3[][]U[KL <6%OS:P^G('XX/OWOW7NNP!^!]./]MQ_O'OW
MOW7NO<F_/'%N/]O_ *_OWOW7NN_?O?NO=>]^]^Z]U[_>?\?^1>_>_=>Z][][
M]U[J'7UU#CJ6>LR%1!34E-'Y9YZAT2**,$ ,[.0J@O8"_P!6L!S[][]U[HDG
M:OR:@,-31[9>.FP"/-!5Y&:?^'9#)P0S3T]3/2RU4]#'AL)Y(BC5LY4 7;24
MY/O?NO=5G]A_*C"8K+&CV;'D=R5>>KVVSA*;:F.J,ON+=%'-%(DC[>10F:K<
M'758DEIZN**EAK1"?"(Z,M52^]^Z]T#78&W=_'&+D>V=\R[!QU-7TBY3:NV<
MGCY=[8VIJZNG3'8BKJ,4^0KH<Q6TE3:2CAEI)Z:62,ZF\"02^]^Z]T3;<^^=
MR;JSLFU.D-C5F1WQ4QPSY/=^^J_"8W/[ V=MR'[AM[YO*9J2?&]<4>0R#PTF
M.I7CFR53E [K&9HH*FF][]U[IEVMM[I#KDU.V=YX^K^1/<FXLRVXLS2YEMRX
M_9^WG3*OE\3MK:^U9JN>KI-C4=53A37[GE3^)3P#(-AJQJF.1?>_=>ZL1IMP
M_(S?L.#PF(Q.0ZXVE12!<;LK:FW*2#!XC[=42E7&S46*QN HJBHC D:IQV/H
M[:2S2$O(&][]U[H8L3UONSQR5NX,EEZQH:PJPKMP-E:J8RPO%625U3/DJUX;
MD!I%F\4$::E "FQ][]U[J5'M?(4=?29=<?3T]TGAH::HJ,2\-5CJ>F3]RJHH
M)*FHG:2&.-@$B<Q0QPJ %#CW[W[KW3;'%@\?EDKJ-L5433&FK,1)M^@DP-9+
M44881)50I2XN@RVAZB2(N\*RB,D&0*JCW[W[KW2/QVPL1B<LTU%3QQ04-?63
MI'4QI$,92Y#)MEY<+%'$DZRQ4N2J*DP^E7B@D1'4L&M[W[KW2\3;.XMOSUB8
M/+Q8['NTB2TE%E*E%:(-*K5D%#'+)$E5YDCDB/B'B()++87][]U[IPEP>>S^
M.R%-DXL?N U]+2T"I+]XT]6'B85%94)05&)D^ZTAW,^DU(]9#$<^_>_=>Z4,
MCU.+I:.04$"9.HAEI),;D:5Z[ U;0QJM+>'(**BG,$%.R1NKM$1(%'U4K[W[
MKW4>HQ5+GL5EZ*&*!*+(QO\ >TN1Q\$DM/D2U92QPS5*3*0]/%7/ =40D$#G
MUGT>_>_=>Z7%/BJ&FHXHU^U%4*&-8WK:&..:N::>:&FQ4BO&U'D8X88$G6&5
M"REV:XL=7O?NO=/6,V/X8TI)YYY*=%QP>EQ]3E8):9::H\\)HX:*OCIWJJNJ
M%P&A((34W! ]^]^Z]TNIMLM LDXR*)7Y&NQYHJ6NB$M/EJ:G>FTT<J32)515
M=9>-/+3%F!76\;6 /O?NO=-?]VER;9';\V(HJ/)^=)*8Z!!!393)5576!89Y
MDI9)X8IHEE65 @,KWTJQ8+[W[KW0;[GZ=IGK5P'V$)HJ?'2/'25T44-#4U%-
M4(D4LE0\;24&2=*LQM4TX#2>)1*L@+>_>_=>ZK$[;^#53AXMJ;SZ2QM#2[^Z
MFW3N_=.W<9B\I_"$_NOV!12#?VR]P8:"2FILWA,Q4LU9%+34P^SGGEG\:R,V
MOWOW7NB=[Q^3F\^H=R8*MJI:GK?,4HQ]5LW)=@YK+KM#*T6&RU?C\IM_?KTB
MM4T.3H/*D292B.2H8V:DK&@2ED(C][]U[JV7;6Q]I?+'!4?=NTL(.C?DYBC)
M%6X_;NYZ*H@WG3T- M5/D-N[LV?D:FDW)M?+,RU=+-)',K*#:(*"A][]U[I:
M]1?*#MK8.6J-@=_05-;-A:DR4N;&$K(MP/BEB6:>LJJ.D @W+)A'CD,U1CY(
MJY*9%G:GECU'W[W[KW5E6T?D7C,G28^OI=Q87<>W*R&&L@W#0U/W3-25.M8)
M5,*FFJJ?R.+R(QX4JX1@0/>_=>Z-%MO=6-W)"_VDR_<PA6EB(Y:-@"E1#^)(
M7O:X^AX/OWOW7NE,#P+>JW'^)/\ K_CGZ^_>_=>ZPDDL;#D,4BN!93;4[W^N
MD?3_ 'CW[W[KW654"@< FY.JP_4?J?\ "_OWOW7NO,+VXN/K_6]_]<@?3W[W
M[KW717U7'-[ @C^GTY'/X_Q^OOWOW7NNC8'ZK;]0XN2;\@6^MN/?O?NO==?0
M&X_5]3]?J+*1^"?^-^_>_=>ZX:1P#;\@$+>]QQR;M]?K;\^_>_=>Z\ 1R"1:
MU^+?2W%K?2X^GOWOW7NLR/J']"/J/\/ZC_ ^_>_=>ZY^_>_=>Z][][]U[KWO
MWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z]
M[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7N
MO>_>_=>ZPR-<$?6Q%A_7\W/Y_'^'OWOW7NL:^D VN.#8?\B%R3_MO?O?NO=<
MK6XYL";D'B^HL1;F_!^I_I[][]U[KP!OQ]#<$WO<\@D<?T-_]?W[W[KW79Y
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MC[][]U[KP//Y!_Q^I_J#S];'W[W[KW7/_#_?6XO^;WY]^]^Z]U[@#^@_V/\
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M\T;6<!@"WO?NO=']C=9(TDC(*.BNA!NI5E!4AA<$$'W[W[KW7/W[W[KW7O\
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M8F^X4Q1<'45)')%[^_>_=>Z?IUHJZG2-Z+STQC\)<%9$I@D2QD%"S.B2^JS
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MCHRN57R@#0%,;.22WZ>+@GW[W[KW3_3JRI%(LCQ$Z'@,:JR>;_=B#QBT<A_
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M6,3DJ^%ON:6<TE2E1#+&:>JJ8XJSG3(3''2LT4(> HRE]#-^M55N?>_=>Z7
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M*8BRU,:5L9NMC*ZC[CTJ6 UFSBQMR??O?NO=/]N;W_V'^V_VWOWOW7NN(L>
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M^MQ_O?OWOW7NN8;2>"+78&X-@!S<F_((_I?W[W[KW7K :O4?H!RQ_K<6MP.
M/]A[][]U[KGJ(/Y-A_L>;6O8<W'U]^]^Z]UV&/%K_D?4D?ZPL!_QKW[W[KW7
M($#DGZ_7\@D \<\WM[][]U[KKFUQ<\_2Y']>./J?Z^_>_=>Z['-[DCU?UL?I
M;F__ !'OWOW7NHU?6T^-I)ZRH<)'!$7/^J=D4E451ZF=S8 "Y-_?O?NO=:,7
MSJW=7[Y^5O=>XMTY2LK,3UZFX-M+BIYGQ8K)MQ9>B&:I&9333:&VIC:JD$PT
M2%LE#XV-P5][]U[HA'5&#I>Q=SX[<^<HY(HLGN_'[AS,$2I3E=F9C,9K=>6H
M:S2Q3[S<..VI1Q0QPA(8:2H5 /$2Z^]^Z]U*W'NVMWE!M6.I@A:LW75=F=H2
M[32H9A0[U['VWN"GVOB:R/[M]=.I@I5KM'$E/B*6$0.=6KWOW7NFW?W8-'@:
MK9&P=M5296ODR&TL7DH<M2^:#+Y"OS,=-4U%?,!0U,>+AQ^*GJH_))%4S28N
MJ*RAX6 ][]U[H\>.R6S^D.@Z*CP61W/@L''3UE;7390T-9EILAN&63/[TRK9
M98<+35];)M3PFDE%''YZBHJ:PPQ>B&+WOW7NF+=V^1B]M;/V2U1D8<_E#4.V
M*3RUV4.\LM#A(=Q4&(H*)J+[G.T6(FBPU).644;M+() U353>_>_=>Z3$>#E
MEP>0J::AQ5*L%;AU7.Y"IR%7BYLM2U-9!EJ+$JE-?,4]'/E)4ADBADIJU:>:
MI+?;_;CW[W[KW2KQU=1XKQF2L6BQT%()))UQ+T%,\D52\AD:0U]1_#:6F8J2
M6%IB+DG\>]^Z]TJ*?<!KXL>4I*,T4$E6U9Y9'$%-,90M#5+*D*JU15A"YD9)
M$6Q90_U'O?NO="Y2YZD>**$U42P3C[F.I81RK5QED22&=X?)'&U/431_H 9I
M&72O#@>]^Z]USR61Q4D(JZA)9$EE^R9ZE)6KZF>)6)?&PQB\<;QO 0L4*^D6
MUJ+ >]^Z]TTT^Y\A@J/P5E+-B:<2Z[5T,T$M&4D*LB?>M%]K.D<@+A00K !?
MQ[][]U[H7,#O'#I3T"*M=/21.6FJL70UF5@HF9I%GG^ZHZ=Y(9F21]=_'$+M
MJLUA[][]U[J?'N7 5%?6T\&2I<9D8JBG5%JB4J#%.^J.29Z^)))98VD*$KK:
M10+7+@^_>_=>Z$_'92@8I%D\JM;3Q0I+3"AJ:N0RR3E::01PUR4@&J=;N'0J
M!H\:&P]^]^Z]THMO]>XN&LK:ZECJL49LA/D&)F@>L-8Y2>OJEHZASBXHGF'E
M4JD92Y4BZBWO?NO=#MA8=U3+)C*W*FII#4.!#6TN)R2U="BE&G>A"RT<LS0E
M6$4D3-&6]7C8'W[W[KW4QZ?&X6))?[MY)):)":>DQDLN1@GH)9' E_@-/)4J
M&+Z@P3PSD(%!YY][]U[IIH-UTOW(>#$KM_'S3,TT=?A<KCJ2C)&E9&CR<0%+
MY)'N&BE +W8D:@3[W[KW2AR&466.:NCJ/N;*67P04OVB1T[Z96J:R*24M'/3
M2%(WF)=@0%T@"WO?NO=,%-6[@J6DF:>BH7A:6MG::6.%)Z:1Y)H*@%8*5G-2
M']94ZE*!F5@Y5?>_=>ZD9:"*6C22GI%8R&66NQ\,.J0FK73,U+DD2E6%A.Q8
MRA8]40;4 .1[W[KW4:FC^T6+]FG$%,K4DJ8TP&6G191J^Y?[ZIDIZS'_ *"T
MQE+AE*DB_OWOW7NFK-8M:L_=T^6KU0+4TT=13RP2UI2IM%'3U5#64\U,QA5T
M9)$EC:344'I<@^]^Z]T&U3AZ6CF2HHL>:UUJ5:HI$SE=@<G.$D$4E;1T-%%%
M&"\D1!CJ?HI74;^H>]^Z]UEK:3#U$B;CIAD*&L6%H9':9\;5_<"7QR4E93T^
M(:G;(I"I_=A>02P2.[ E0X][]U[IODDK*5:R*JK9J.HIHF@I)JJJ26EKUJ(5
MIZ:6HGFAJ8@TLA +%HUM(>0+W][]U[IPPRUN,%0<A4U52LT@2>"6E?%2$.#
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M/Z>_>_=>ZXM4"Q"G]7)9RIU-S=C]!^D<7L/?O?NO==&H8?33IYOZB?U7L%X
M^H^MN/I[][]U[KDM0&L"2P0WN+H/H22!Q86;_7Y]^]^Z]UECJ1?U,&^@N=7K
M(4+;\@M<@G_6^OOWOW7NI/G_ *D:M05;78W.H7)4_2QO_6_OWOW7NLZR+Q?\
MW)U FYN2O!'UYYO:]N+^_>_=>ZY(X'-[J" "+\%C?4W] 0?\+^_>_=>ZXEP
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M.;Z01]!<_6YU7O?\?X>_>_=>ZPO4@$W<7!!YY!O:W-@!9?\ >O?O?NO=8S5
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M))U >]^Z]T82DVCG<O!03UE/38^6'5318ZFGIHJZK28@QR3T%,B0'[*GI[K
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MS96FPN FHJZ:%3)#/-X0KW=XU'O?NO=/-;#AX-Q=G[CCHY*FJI:&GVRM10U
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M1_B/?O?NO=,%17*&):2WJ !-K$W#'CZ7 _V)^GOWOW7NDW5Y-#J&HW.GZ'U
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M[H+<QFF0M>0?H)LIX'/U_4" U^/K[][]U[H*<UN0C5=R7OZ]+'58MJ-@2-)
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M -P/I[][]U[KHM)< %&L-/TM8\A1>_ 6]S?\W'^'OWOW7NN/DTA;D%F6]^
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MLL(<AMF@_,-)D*T@7]1JIJ>&.XO:X^R:QMQ<^_>_=>Z+\E>K*SZQ<D'_ #A
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ME82C5]!?5<,/H;!1<$?4_3\GW[W[KW0/Y*L9F/J&F^DCC4/5Z3RIL-0/^O\
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M9; V)4GDD'ZVM_O/OWOW7NDY)&6)]/Y^@!)&OZEKBZH>/ZW]^]^Z]TZ4,'*
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MOT'OWOW7NK">B^T=@93);2I%J&JMK]85E1O[)4T>(RF>?<F3PFW]MU&U.O\
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MID!)+7(M8:5+:E%N+-P?SR?]M[][]U[H-*VG=68%0& 8VLP(U  *%N?K>_\
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M:5-O\/?O?NO=21"19C]#8+]0P %KA/\ >3_MO];WOW7NI21'EB!ZOQXRJ@V
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M(/U_2/K87/UM];^_>_=>Z#RKHR'D%K@G4J@"S7"J0?I;D?[[Z^_>_=>Z99J
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M>&9<O@Y),A@9X@6\B$(U=A74*I6"KB!E')M*@X&HD>]^Z]TI!BJ3<M-2Y>6
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M@,;DHNDQJ>"0X)!!(.DA;Z;<?[S[][]U[H.4PP!4: .?7Z58$&]E7FP4#CD
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MAFBH?.'225R[A TC0ZV"L&4@KQRQ/OWOW7NGO(=CT88&%71*F.59Q KSP">
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M <BYX/'XO[][]U[I.5-2UG#%G4GZACSP2/K=K:A_O/U]^]^Z]TFZFL.EKEK
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MC@@_J"D$?[;W[W[KW0?9./46!"DG@>D6-[<?4G\6_P!<^_>_=>Z#7-4HE>S
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M6JFB0^>A9$E B#0E@$CM[W[KW1VX=S)B]7VM<JT+,JR.8P[M4$+I41VL0S
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MMK!K#WOW7NABV[F5,F2P4$$]1&8)L:F3:G%29Z.MB@J9&^VA68TTBM*YLUR
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M9*@DJ)LE1R9_+46*EHZ6N1IX5I)Z@EU%&/ FJ%""OCC9Q>X')'O?NO=)3:^
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M[W[KW3%@]DPX2IDA\,DS_P 22I>:-(A'55*2$U$])5TZIXS2R1!(B/*K$<7
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M?[;W[W[KW5;"T^@7Y\?X6P"_1EM9='XY_/OWOW7NL3!4%P+"X(L.3R1_2_\
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M"4-1(M?)+DF,LM+24K&:>GIPE4KK&U4Q@TIJ)$CQ$\L/?O?NO=#=L'>N$/\
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M]UA;/,5+7Y!9OJ;CZ<Z@0" >?]?W[W[KW3;-FSY+:]()!(L=-B+\@$J!JO\
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MS305M*&C-5'JJ'&I3&0-0][]U[IDFVY6T]520QPO+ERCUHFQ;2^&62EK)HQ
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MOW7NEA14ED"A2%X*_D@A4^A'^O<\W_Q]^]^Z]T^T]."!9#<GTW_M$ EB"/\
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MWOW7NL,NZ(BMO(22"/[5M0"A2PU-8+^!]/?O?NO=,=3N=2K*K?6]R#<:C?\
MUN ?Q;W[W[KW35_&EG-B=1L%%SI4V-P0P);A/Q[][]U[ISI#YG1E*W%K:N>
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M'^8=V5VF]3AMIU9ZTV1*T DP^/9SG,I12Q.)Z;.9]*B!Z M!J?QH8[*-0#6
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M,J)$=-@)-6KWOW7N@^S^Y815!J6HHGJO'+7(128N26&LQJFIBJ)IA6PQ/3U
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M&-"ZF^O'U-]0][]U[K&(XUBCB%$X9*A7EL*;6E,:@OX2JF1GE*KIU73TF_T
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M/+$2AC:X4C2201HY!.DGG\"]O?O?NO=/./R0*J)7L"6O>Y4BX(*MP]P/\?\
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MY@AIIOW8_+#*C&.-A*JL%*H\JW/OWOW7NN!CE4QB2$HBV9&8JJ%IU:=4DCM
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MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW04=Q?Z#?[HU/^S
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;^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>sny-20231231_g13.jpg
<TEXT>
begin 644 sny-20231231_g13.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
M!2$2,4%1!A-A(G&!%#*1H0<5L4(CP5+1X3,68O D<H+Q)4,T4Y*BLF-SPC5$
M)Y.CLS875&1TP]+B"":#"0H8&82414:DM%;352@:\N/SQ-3D]&5UA96EM<75
MY?5F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I.4E9:7F)
MF:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H " $!   _ /OYFS9LV;-FS9LV;-FS
M9LV;-FS9LV;-FP'>:CI^G)ZNH7]O8QTKSN)4B6@]W(&0J_\ S3\BV!*MKB74
M@_9M8Y)JT_RE4I_PV0R]_/C0(@PT_1KZ\8=/6,<"D_,-*?PR)W?Y]ZQ(3]0T
M"SMO#ZQ))/\ ?P]'(W=?G+YZN*^E=VEC7_?%NAI\O5]7"&X_,CSU<U]7S)=+
MRZ^D$AZFNWIHF$\WFWS5<$^MYDU23<FAO)J#Y#G0862:EJ<P FU&ZD -:/*[
M;_2QP'(\DQY2.SMTY,23]YQ/C3<X[B*=*Y7#;K]&"EO+Y&!CNYHV7H5D8$?(
M@X/BU_7X-H=<U"&AK\%S*N_CLXPTA\\^<X*%/-.I$@D_O+B23KM^V6PW@_-?
MS]:TIKS3(.HE@@>NU.IBK^.'5K^>?G2$@36^FWB]_4A=3]!CE0?ADIL_S^N1
MQ%_Y9CD_F>WN2E/DKQO_ ,2R5V7YZ>4[BBWEGJ%@W=C&DJ#Z4?E_PN3&P_,K
MR-J-!!YCM8F/47/*VH?"LRH/QR8VUU:WD8FM+F*ZB/1X75U/TJ2,$9LV;-FS
M9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS8G+-%!&\T\J
M0PQBKO(P55'B2: 9SS6/S6\EZ1R3])'5)UK^[L%]:M/"2JQ_\-G+]5_/F^D+
M)HFAPVPZ"6\=I6(\>">F ?\ 9'.;ZG^8_G;5599]>N((V_8M:6PIX5B",1\R
M<ALLDL[F2>1II6W9W8LQ^9.)<2<<%Z4[],OAC0!TIE\1W'RRN('O7+XY7$]M
MLOB0<P3*I4Y@O@/HR@.QS%:8SCR-/V1FX'PH,?PVZ4.-XFOV<KCOTQ>VN;FS
MD$UI<2VLPZ21.R,/I4@Y-M,_,WSQI?%8M=FNXQ2J7@6XK_LI S_<V=%TK\^K
MU.*:WH<,X.QDLW:(_/A)Z@/_  0SIVD?FSY)U8JC:DVES/TCOT](?3("T8^E
MLZ';W-O=Q)/:SQW,$@JLD3AT8>S*2#BV;-FS9LV;-FS9LV;-FS9LV;-FS9LV
M;-FS9LV;-FS9LV;-FS9LV0C7_P P_*GEWG'=ZDMS=I4?5;2DTM1V:AXJ?]8C
M.+:[^=^LW1>'0;"+2HMP)YZ3S'W ("#Y$-G)-5UW6=<D]35]4N=0:M0)7)1?
M]5?LCZ ,)^(\*UR^(^_+H?GE\?;MTRP@Z9?'QRZ?=E!?';,!W_#-Q.^7QV\#
MFIE<=CVIFX]AVS%:^&5QI3-QI_7$OB)I78;8H%IL.F6%\,W$9BOWXSC7<9N&
M^8)2OCFXC*I2M/HK@_3M5U72)C-I>HW.G2GJUO(T=?9N) (^>=5T/\Z_,VGA
M(M6MX-<@7J[?N)Z?ZZ+Q^]*^^=DT+\V/*&M<(Y;QM'NFV].^ C4GVE!*?>1G
M24=)$62-Q(C@,K*:@@]"",=FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS
M9LV;-C6945G=@B("68F@ '4DYROS)^;GES13);::3KM\M12!@+=3_E3;@_[$
M'YYP/S%^8OFKS&9(Y[XV5B^WU2SK$A'@QJ6;Z33VR"<1MFX_1EA=M_'-Q]]\
ML+OXY9'METJ?;*H,=QVR@*>W\<U#3;+X[Y@/:N-(_#-3?+IOMFZTVRJ4[9B-
MJXF:L:]L< 1ED=Z9J9=*C?QRN->V;CE<378YN!.65I\\:5^C,$&-X]LP6OS&
M230O-GF'RVP.CZI-;QUJT!/.$U\8FJM?>E<[AY<_.^SG,=OYFL#8R&@^MV@+
MQ?-HR2ZCY%OEG;-.U33M7MEO-,O8;ZV?820N& /@:=#['?!^;-FS9LV;-FS9
MLV;-FS9LV;-FS9LV;-FS9LV;-FSFGFO\T- \M^K:V[_IC55J/0MV'IHW_%LN
MX&_4"I]AGG#S-YY\Q>:79=0O#%8D_#9V]4@'A5:U8^[$^V1#P\,WMET[987*
M*^V:AV.72F72O4?V9J#KETS4/AFIETIVWR^V^:F;CX"F-*C+$>70 XP@#?&$
M%OECO3H0*;8[AX9?'[@,KA])IE!2,LC?*H>PZ9B"/HRZ >YQM*YN/TY7'ICN
M/AU'XXWCURN(K08WB1L>F&6E:QJFAW(O-(OIK&X% 6B:@8#LZFH8>Q!&=Z\K
M_G5'(8[3S5:^@U /KULI*?.2+<CW*U_U1G=;*^LM2MH[RPNHKRUE%4EA8.I\
M=Q7<=Q@K-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV$6O>9-'\M6GUS5KM8%
M:OIQCXI92.R(-S^H=SGFCS=^:6M^83+::<7T;2&JO"-OW\J_\62"E 1^RNWB
M3G+:;=,=3Z<U*GVRZ'OOEA?;KC@M?HS!0:UR^%!ME<.]*97'KME\>XRZ??E<
M:'+*[;;9J;4(R^.- .X(W'?QQW'MFX;^(&,>2.,;M0;5]JXR241!BZD!:==N
MOAVP/Z\3H\HD41Q_:.Y(\ :=_IQ\$D<X^!U=U)#!"#T-.QQ8-S8JA%%VV!8U
M]J=L<I)/Q"C+L1V^?TXXBM/',%W&;C7?KC>)^6^6!3;QRJ5V_5E4'3+X_P"8
MS!=Z4]L=QH/?&D#K3&\>V5PZ[&N;B>^45K]V5QK7#S0_,FM>6;KZSH]Z]L21
MZD9^**0#LZ'8_K'8YZ2\H_FOI&N^E9ZN$T;5&HHY-_HTK'^1R?A)_E;Z"<ZQ
MFS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LY+YU_-*PT'U=.T7T]2U=:J[UK! 1
MUY$'XF'\H.W<]L\T:EJ>H:S=RW^J7<EY=S'XGD/0>"@4  [ "F ..."_KS%=
MNF7Q\.N8+3+HH&72G?-Q[97'O7-3QRZ#;WRZ#;ME4IFIOWWRZ&O7+ )KMLOZ
M\1DF5* ?&S= "-_E_9D,\S^>_*_E"V>]\T>9M.T"&)Q$5E?G+R.ZIZ*,9F8T
MV"QU]LY1<_\ .2GY2LL<=KYWM;>YNG*0)>64]KZA5>7-6OH[9*4_F<?3@&+\
MU_,&OO"_ER3RX-%G3G%JM_>&59QZGIEH(H&MP0I!VY'E3;/(7YE_\Y5_FS%=
M2^5O+.NZ/I<=ZL*76MV5JJW%F91(6BM899[GDW%00[^*T +KG!K[\Y?S"_3\
M$>A^??.>IZNUI;R278UB>*"'G&LCJ?B9  T@Z@U->U!AQ=_\Y._FSH,T!U?\
MQ2[ &2:;6)H[_P! Q[T6!+:.5N1^'F>(KW&2S0O^<M]3N+>76-6%WJ.GK*/W
MPOY+>(**<VC9[=T4@FOP.203U.=@\C?\YW>1)9%T_6;&<1Q50K())94 %5/K
M1)'4T'0J<]>^7?S[_*/7--?5[/SQIUA9P1>I.M](UMZ2]>+>L2.7A0FIV&=#
M\O>>/*OFLWL?E_5DU"?3'1+N%XY;:YA]051GMKA(Y>+ _"W'BW[).2M3RW#!
MQTVVH1VQ]/HRCTS<1ME\>^U<JF6%[Y8%>HZ91!^C*H!VZY7'OE<0.U3FIOE<
M?',5_'&%1[97'QVSJ'DW\S]6\N>C8ZCSU71EHH1S^^A7_BISU _E.W@1GIW1
M=<TOS!9)J&DW:W5N^S4V=&[JZG=3[']6&V;-FS9LV;-FS9LV;-FS9LV;-FS9
ML2GGAM89;BYE2""!2\DDA"JJC<DD],\W^>?S2N=2,VE>7)'M-.W26[%5EG'0
MA.ZI^)]NF<7IMCE7I7J<OC_9FX>'?+XTIE\#X_?E@997Z-LJG?8Y5-]Q_9CJ
M=B,KKT'ME=?\]\U,HFI"+NW?V&$FO^8M'\L64E]K%WZ$<?2-07E=CT544$DF
MH[9P^^_,O\P-?=HO+&D1:#:,]$DN;<7%X]/M"02S+'"*#[; "N+)>>?+^(3O
MK5M,TIJ+07L=I-P6@K&##+#N:DD.P'0Y _S&\S?F'Y:\H:T\;ZQ'(UE<Q0S7
M441*3$4C9+NT:)0:,>/-*$@&HSYL_E#Y1T+SEJ5O8^9=3U+1?,&HF\BLM=M;
MR:WU"/4JQRVDK7H+* &+,[M7GQ %#U],>;?.?Y@?\X^HVC_FS;V'YF>3/,**
MNG:])%;1ZISE9GC.I6TS2?6W<@A34.J4:N_'/+_FK\]?+4E]3RYY+M?(-R+:
M9OKEFTL5Q.'EY)]:2-S:Q !0?A2K T;H,\^7VK:Q?7,MX^K2:K!<RM+*)OCF
M< EV6JCDW$FH! <=@=L,]3N[A-1\NV.H7*V_EKS)! !=0']V)MO2>>1#1^0
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M2,JLM31_B !Z#()<?\YH^7;Q[K3K?RMK*&+@ETUQ+;):QAE#49H>7(!17BK
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M9IG1H&*"9VY49C1F933BM?.VCV,[S3VVIZ[<6-H5"RSI*\HH!_=F(K1@*BI
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M=0?<<W$>%*98&:@VVRZ#-0XZE,L+VS4S4[]*95*=Z^^-IOE$^&V(R,521F(
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M+$<C4J3Q.W^WCY2S*%4@*M0 IVK[[#"US)5>8J!O4"I5]CM7:E,<K/6A6J@
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M1^77Y?6<ELUK)_AO39Y[9G]0Q2W$"2.>=!R8LQ+GN3RZYT_;ICJ&@[Y@.^.
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M:13VUF\4E&F_=VUN9!R(D8>I,Q'V$7B:,#DM\\Z4;^XNHKN_^I^5K*-)KYH
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MBAFC:(QP\:I.P6C(5'-UX]7!SSUYSLKKR:ZZ);+;:)J^F^DT\]N7CE?FH4K
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M<HH4AV$7"K*HY(.6W&M/;G_.$?E2SU;\^M 6]1]3T>SL+W61;3(2&) *1LA
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M5'A7/'_F/_G%GS;I9GOO)'GBSU^QO+2</;:CRMEFBOHQZZ13*9(V5Q0J6X]
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MIGEGS*]NT\,=W!:7UI>1R!>+VUUZ)62A-"O(%=Z@-OGDCS=^1GD"W@U:>_\
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MYC_,;S,NAZ?+=0W.O:@UO;6L:GD#=2E0$4+L:5V[9U<Z'JVAV*C6=&O-(:,
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MEY%"P^KW:#I1[6X64>%&';/H5Y@\EVEY]<NV@:3ZPK,]!5TD_P"*^I%2.F<
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M"NP!Y ;&O;[]H1KK&1@TJI)!>Q2%X9D1D*2,8SZB@L&Y4H0?A[&K5KP?5_\
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M6-#0@@TV-#C_ #3:)+;"(U-NG%I56G+@31CU%!UJ#M]YSGL-JUKSD>/@K=7
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MN/#3@]Y;I(P Z L14CV-1GF;S]90:9YWUBVM[:*SLR\$T$$"B*-(WAB("1H
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M)YMP>(],\@!4;A4R:>4//7GK4-9U32M1\PQZ)96E!I\FHV"QM<<F8BK.B\D
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M4\>V5\NA/3!NGQEYY *"EM<MO_DP2$_JQNH1E+^^CX\?3N)%IX4<BF!*=\<
M?IRZ4^>5]/SR^O7OF_CMFW_AF%>NV53K_#-3VRP-SX9?^8RO>N6?QS;CZ,V8
M#+IF[?TS'I3QRP >ORKETWP#JFEVVM:9?Z1>?[RZG;O;2-W4.*!Q[J:$?+/G
M[KUK<Z3=W5A> I>64TMM.S[\9(F*;CCT9MQ6@SF6JUF]4QKS:WX,3P%5H*L
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MOAFZ5[97MWS'PROEL,VY&Y]ZYJ5[_+-4YO?QS?/IFWS"E,NE=\:0.O7?*/\
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M[$\?$[_?B@M+&1VB]-))%^+<]AOXU&^P&%UW/(T;20K1+?@0M1U.WS&1[4Y
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M2I^[(Y>^> _Y]_FY^5]_(%NM+M])\S:+7[4MA?6D,5[&/'TKF/G\I/;)?6A
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M%MXXY"&"L2!)7[?(]@*^&Y%,DFD2WUW)2,1HB!0IWHU #45->E/G^&='TVR
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M)1!9HJ*KA"U !RHH([T)(\,<UF U&A^L-&!P%-JC^913< >&2*'A"D/.$&E
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M&UO*#&54,R(G%!7[)CBJ:MUV/;/*WYD>9I(A+!&\<4KTI+&!ZBBIXUV*\J=
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M60"H+&G1>(%1O4CK3OA=,J;_  @@\B16C<B/$C>@KMA7.G[MV<AS4J*D$$[
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M:@XA1LW,"H%0#7WPS$:L(3(H#P ET0L'8G8==JFO;MBRP,U$*@*QY%F &W$
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M2QHLK[A011E5@"I'7OL/8XZ2$"$1*5%6^P-WJ!6I9NE*G;IA6J+N_P )4/4
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MZ>&12_TUE8N%WQ>PN6!17^VFPKW'AAU-;K*O.,?:%?D>M,+UJCT-5->N=/\
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M%9&D].HXAY*^G'M7D:_9#4_2KH>B:3Y:T;2O+V@V$6EZ)HEI#8V-G .,4%O
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M69Z?/Z<_23_SB3_SCM8?\XX_E/I/EB9HK[SIJL<5[YGU%*,);PI06\34!,,
M/!/$\GH"Y&>H<V;-FS9LV;-FS9L^0G_/PC_G$YKL:C^?_P"7NGUGB3U?.>F6
MX"ET1335(@%.Z[>N!U%).TA/QU%JDD7K?7(Y6H6KS5>,8H#R'$CMUROJSL%E
MCIP(9B RFHI0?#N*K45RX5_?<BG)S1G;@$'*@)/PL=NWTX*:U9FE<HL2A"Z!
M6((K5BI_ TIO3+-LT,8X3?NU (,BE$5J_:!) WV^[WPMF+,LA=#&>)+,RT!2
MIIL!6M*@>)P.[-3X5!AI20EB14D@%MR:"I!H.^$=[:I)$Z&1) 4^-BHV&S4)
M K1:^.>>K:.33-6U?3A)Z$T<ZSQ*5JK1,W[SC7H0M#WK2E,['8.;B&)+=*B.
M/ERH32H/*FP&PZ5PXC7U1P<H)/A8E_BZ'BM*5IV_##:.W8J3+&W)7*?8KT'(
M"A IN?#[SEFT]28,6# *%"(CAJ5%06KMTZC DD0MX?41/3>&D;"2H<KOQXTJ
M*[]:_+"^[,CR D+(O'C*9J \J$4!% H VZG?.<:O92)(S2RK\19JU(-:;;=2
M#['(Y'&8^)Y^G(IW4 \C4\5*TKL? C.B: XI 2X1C\,;&M$/0J10&M=Z=L[E
MY(U.3RYYH\I^9U5XYO+^LV.I<F'$,L-PK2T-*[J6'7/MY^2NBQQ>?/--^+<C
M1;*3])M)U1I2@J!V^(@'.NB>634)Y9#REGD:5J]26))_7G2M+A6:-&%/B'7)
M)'94# [AJ$8C/IHD7IU'AD.U70N:L>/N,YQ=V4UA<*]*"OW_ #R4:%<+('C8
M_%;-0@]XVW4_1TP[\P>6_KUE]=M%K(@J0.^1SRAJ"VMW+87:>I:W"M#-&W1D
M<%64_,$C//GG?1CY<UW4M#EDD>*V<O$PHOJVS_'%)VK5"*FO4'.4W\\MW-::
M?ICR7$UY*EO!$FYEEE/&)%J?VF8;#/HK^4?Y2VWE/1=/BO8P]Q9J99305>[E
MH9I6IU8G8?RJ .N=Y2(*O$"@%*#$Y8]@:?/ L4 Y TZX9_5U*<2!WKG%_P R
M/*2ZK:\HHOB%>W?/'FM:9=:3/)#,A62,L\9[$J:C\1G'_P#GY!$-3_+;\D/-
M*N&MXM0U:T)KT-[9072'8&NT!SY-Z=*KQQ+(KD$?$ :/4FNV_CVVR96R55)!
M54]-60AB P4@4;F?'?Z:=L?)$T@$E:QJICY$G]BE P^$#8]/UX0W2(0J1DTH
M.;*&V5ARXDGK4]\#<50*'2JJH*$ D@5-=M^G3MO[XK' KM*'CK'(BJ\8( ?D
M=B-C4CD>M:90,4;7-6:0R$"!V' J 02'H0*D"@WZ[G;;!LB,&D<,TI],R+2G
M(#8?$14]6P3J5)M/ME9?5F+JJS#B*A>5$DI1OVNW?"2:*7C5DKX$D;4V))6G
M'>F(.CJQK10FZL&'*J@=2.X^\XY X(Y'ER%-B%4  +7OUZ5.+1RB"H>.2I_F
M'$*L9(92#M48=PRC[;/^Y;X0C%0K;5+$KR'C6O?K[#85:9HO5"BK;JIJ53KQ
M!H".QZ_1@:XAC#AC'ZRQ(3W8\A4@G8;#]7SI@7]VK49:Q\*"GPF/<<B: C;!
M+>LBNJ1D<44%WXE6W)^([;'K_#%Q+-'%R-76-XY2?AY<O BIV([$?=GV9_YP
M0_YQFF\KZ;!^<_GVQ_YV#6X.?EFPN4'.QLYA4WCJ:TEF!^#^6,UZO\/TRS9L
MV;-FS9LV;-FS8R2..:.2*6-98I5*.C@,K*PH00=B",^!W_.;?_.(MQ^3FM7?
MYE^0;)I/RKUN=I;BTB0,NA7DK;P.%7:VD)I >BG]VV_ O\]H8P;::5(THPH(
MP"A(8@]B.O?O^&.'/A\(J!RX!F8-38_ I%12O?M@Y&7F@D<\SQ("@,#(%W8[
M$DU.P]\S15/%5#%21\ (8 'H   ?>H[X374;EN=O(S/".0+J-A4?#44KOL,*
M7E>.LAMN:!3L2""&[T(VWW!'RP)+/*Y*5X(R1QLK,6=@I)7DM: _"!MMWZYQ
M7SM%^C?-.EZDB)(FH5MIQ*GP,K_ 0:GL&R:>6W::46'-K?\ 1Y:!XY?ADY1D
MJ0 P.^P._P \F%JC&22&:-4YLI-*EC0]3R-*U\<.8%;A&P=8Z(QY;N*JQ4@C
M:@)IWVQ=(:QH47U2%9(T?=:N/M"A!->Q'M] 9@TT#A@SJ2:@L%XL-J;$5:NW
MAA5+!Q56))9B"H05'P$&H)!J:>V]1D!UFV'JR*C^EZE*"H*DT/$#J:>/RR$.
MJ"9UA 9ZM]L4--J@GJ"-^W7)GH%R]0[%CUXQ-\2 D@=*$'J!G:=+0SV[1S#F
MTJ^D3)R))<$,/AVI\6U.IZY^@3_G'54O?R(\GZZ2'O?,NG07%[( ?B:!3;A:
MD#HT)KAY<2B&\#U_:SK?EQEF@6@^R:@?/.AI 1&&"D_#6GRQ\4<<@ Z[]#C)
M]*296'#MD!UWROZL3TC_  SF,,$^E:@2ZD'CQ8=F .=?\KWMNY6TF^*"X'[L
MGW_9^C(AYY\JOHFI1:K9I2UN&J2!L&_MSC/YY:<MQY=T?SE']K3..G7QZCT9
M27MW-.ZR<EK_ )0R=?D+^2Z:(MIYR\R6E?,U\AFL+65132[>85Y<:4%Q(#N?
MV%-!\5<]CK$D, B0<504H,I5_7B,P%">F(P@;'WIAAXC EQ:QW*,KJ&!\<Y%
MYY_+&Q\P6$XBI;W:AFBDIT:GWTSY)_\ .=_F:ZO?)7Y;_EX=(U&TU+RM<3WF
MJ/<6S+9CZO8RVRM#<5"ORKR''MUH<^8^BW'-8@12BJV]3TV!:A!H:'MX9/H5
M'&)^9X$*!4!B">K* %'X?3AK)-&J@M&49 2'#55>%:UK0D'Y;84WL@D _>?'
M+0R*4*GD2 "2.M*5'RPC(*E@#1FH"Y8 $@5'4D\O#?YXZ)><L<?'TBQ4%6#%
M:D@ BM/#!5RAYL6=9F55Y/2M6WK38"@\.OZ\71"+C@W/F4#<00!SKN-QTJ=N
M^#+U!);6\4<@-P9">/$"J*I->52:K38$TWPG, ])2C'DM&XR"JE202K?$?B]
ML0X,%J94C-4<*8RQ!ZFI"CH:# Q6C)&68%'"^P;:A(.Q-?HZ8HA _?1QNWQ
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MIE;TAQD(V\&;E6O0 'YX<V[&4@Q1JB*R!@M?5[_""1NI!KN*>^^.]*,++'%
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M^77&JR"DVT3A 2J@;;58<2?M;[8(A2-.;\#Z#ED?TU;<JQ*M4#?I3:H^_#5
MHV)=(T8R(H0552M=NH[>/A@_C*P>)OK!$G$.S!3R4FC<@*$BO4U]L#RP+,TD
MA6578D_"034F@J!0?:^[/77_ #B3_P XI:E^?/F&+7_,%G<Z7^56A7--2N^9
MB?4Y44%;.T=2U220)6&R+_E%<_0%I.DZ9H6F6&BZ-80:7I.E6\=K9VEL@CA@
MAB4*D<:*   !0###-FS9LV;-FS9LV;-FS9L)/,GEO0O-^@ZKY8\SZ5;ZWH&M
MV[VM]8W2\XIHGZ@C8@@[@@@@@$$$ Y^?_P#YRK_YQ'U_\@]8GUO0H[C6OREU
M*:MEJ0-9]/ED("65\RJ:-4TCDH%?V>HSQTH_>+&&-RRL#0@-5NK(3L!4T[]]
ML#,?4 16"LLC>*,*$D*:G?;;WP-/68*IED=QU>JL0P8%F 8 G<]C0857;R"1
MXI*2^F:J6BJ2"#5P>1.U"30>!)PID*(C\XDC J4=7X@$D\31QU%0",(->@M[
M^RN[=4<2A2H#3<N+,H'V1QY=.^<8\M/(+#7M!* MHMT-3AG/VT1:Q2HH!J P
M8$T[#[N\:->&;3?5FXREP"B DD4#5Y ;]R%_ADJMN4=J/A"^FK<D!J0#446A
MV!W'SIB[Q^JW)RT<-P-JL57X-NE.1-"34''?5?2Y\F8\G],J$%>(K1BW4GL1
MUQ"[X!&82GU9MB:H%'2A6NXY$;FOSR#ZS;U(!6I7<Q*O4 '92#6OCO\ +.;:
MA$\S\EXAT4GX:  +UH=SWV%!6F;2?22[<H"8[@UH>E0![DKMWZ9W3R\\[1I$
MJ * "*C[0)]J ;$9]>O^?>>N>G/^:7DJ5S34+#3M?MT+<@);626RN0E-J<9X
MR=SGK7SK;-%<2.5++4U_K\LD7Y;W/&Z5.1HPZ'/45O&'MU(\,*+VW*,21\-?
M? 4;-&P*D['#^"7F!4[T^G%BZ."K&E>E<*]2TBSU*W]&X0(P'POX'.<O8:GH
MNHP0P S>M((XF7HW(]#G2M.LGB:/FM5<EW(VY-W8^VV2?8#P&;D/'&<B*X$N
M&Y+0[?V8#BIR7PPS!J!X4S#^S$+H_NSGSI_YR^L%FT[3F*_"UPT;&E=I(W7Z
M>N?!/2D]*ZNK5V^S*%]-:\P0":DC[_HI[Y-;2.(N 49QTHP8*%4"K<M_N%:?
M+#R+U7C*N%DD^T.)+,H&^W2O@=S@._$@8@!O3^ Q(1V[$ ;G<[UW\<(Y=A(H
M)"#X?$DFM=ZMW\>F(Q>KR5U:0*A%:U/PJ3NQWK2N+\#&L,E>*$<@O[MA0]&H
M":5Z4V^G!O.7D\,D8E(I0L/B4-UIWJ0O3#J8*%ME]9?4"\T#D#DC,*AN5=M]
MCVK@$@0CU (X4C< !B"58ANI0FM0#@5FDGX+Z<7-A1'(H&'4U([=*;;X$G@/
MPJ$XM$YK3U&!]3>H !/T=L"R1S1/(A=ASXLRL:;]/M'Q)QJ^N.<*\A'%&119
M*':G$=Z U\>N&-JP+@FH,BA%>IV&P-&)"G<?Y]CM;6J!DV!3HVXY"@&QH0!L
M/'/67_.,7_.+&O?G]KHO]5M[O1?RWTF<#4M8(,;SO&:M:6+4"O*W1VW$:[M4
ME$;[Y>5O*WE_R3Y>TGRIY5TJ#1?+^AVXMK*SMQ1(XP23N22S,Q+,Q)9F)9B2
M2</\V;-FS9LV;-FS9LV;-FS9L*]:T32/,FDZCH.OZ;;ZQHNK0/;7EE=QK+#/
M#(*,CHP((.?#?_G+'_G"G6/REGOO/OY<P3ZW^632&:YM5#2WFB<V8D2TJ7MA
MM24[J-I/YV^?\QX,IH8V+\JJ!ZFW2M0-M_H]\ GBD)B=.5"@/*H'.F]6%=CX
MTPO80!F"J58(26I3X05:C;[T'WTPCU!EBJD3R@RK3XR"6WW0@**=/M?CA+>D
MH#($8IZ@')U',2)L "IV ([[[YP^55T;SI:3R2LMEK/J6EQ(*@%9_A>M:&A+
M"M<ZWY*FN;A+K3+M"!:W+I^[/%64-\+CF%(VW![YU"W"MS6)FK&Y 0<@ JGC
M2H J0#TV'B#MBABI$L0A"[AHW#[D#=10"H '<?+!+VH4J"@]0@!2_$ D?$2!
MOR8?@#B4\) <;M<)\#?%0M_(2I+4'0CY[UZ9$=4M3%R#Q^DGH'D*,U PI0D4
MVIOVZTSF&K(R^F'@C5EXJJAB5X@!0:G??8G_ &\+H6;ZP"ZF*-OA[<^* A=Z
M]ZT_V\[)Y8D,T()'!%0[AQ(S5)X@+MM4'K_'/H+_ ,X3^9FT/\_/)*-*GH>:
M(KSR]<J&W/UVV=X2P_XS01[[Y]7_ #Y9 .6X[FOS^61;R%<F#4TC.V]#3V[]
M<]A:4W*W4@U! WQUW&"AVR.,O%F44%#7!=NS#B??!4C[;]]J8$:[80DD[IMO
MWP/HJ/?W<T[[Q0'BO^LW4_0,.E82SR4;CQ)XCY'C0?=AZ!55#"IH*_/&,A'V
M._7$S5!OUKUP%.2:_/$H/M'\,,E^ROAF'6O@3B%S]@]-\\*_\Y76GJ^7(9J
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M+O/^D^IIS3A8TN8G,M%8\@HJ*D4ZD ;Y+/*E]%)?:;J*2"W@\P6,"E'E'][
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M6IH?CDY5-1X=0,-+%V]0%TDD92L@:M5XD<:':@\?'\<D,4:R^H(":R(./(D
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MW\S/SJU(:?Y!\JRZE"DJI<:G)^YTNT4%:FXNG"J"%8G@ TC#[*DC/L9^1/\
MS@9^6WY:/:>8_/D5M^8/G2,K*$FBIH]G**$&"V<5E92-GEJ.XC0Y[Q    %
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MX!W\?M[;YR+3(@PCX5!:I(^T>*H"?YCO2E!DVMV<I(A*SR2J0'8U<E@>*@J
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MK"('*!R9#R"[4*"J@FIH33>@P$EM+=W,<5G$]U/,ZI#!$7>60OT^"/D6)-0
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)FS9LV;-FS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>sny-20231231_g14.jpg
<TEXT>
begin 644 sny-20231231_g14.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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MS9LV;-FS9LV;-FSEWYG>=/\ #>F_H[3Y>.M:FA"%3\4$)J&E]B=POOOVSR<
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M-9T:!M7L7(Y\B]!QY]B*=/?/AYH27FFW^IZ)=Q3P7]A<":U7C\)]+X98SW#
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MB$DXGD&-"0OVJ827T:L)+:%JP,?@>N_'N-J"N$5[)";06].+6U70U))^[J<
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MKRC>RTCN*W6G\CTD _?1+\P.0'LWCGJS-FS9LV;.>_F7YB/E_P MSK!)PO\
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MXX8S56"]7=NE/\P.^=#LH9%1[0MRBBJ05'&E"*;^'CA_]6Y1L&G+2-5&C%0
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MV^C"B6.2H51^[*CE4;U(WW[8*N&0PLK0*:P#TS6C?YC"4VJ*/WH!$H0(3T
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M\*WD887 \"58\#^&='5;/S5IB+<FUU/2]1CWC=4N$-!\2L"2O+?Z,\U^<O\
MG'V&#44U_P#*W5V\JZQ%)R-M,[BU8_\ %31K(ZD_R\6&%_DG\X;RZUN#RAYJ
ML?T1YQT^Y,)G"B&WG>+K59&C=7<#8!37VSUGHWG=+J B*0PFV!!7X:E@:&GQ
M'< 9.M)L3JNI1W5V7=+N,7 B!.RT7B9>E-Q6G0^.=(U6[:YME!,BHTH*JE*O
MVW/A0?=G+;S4HA<W<R_"$Y<.+ D&N_<;>&-\DE)9K_4N81A&0S$BE5D8;_/O
M@76]:X2W5Z5'-VIQ5J  ; 4R$7/G00\S+(BR U9590%4>-2","#\SM+>546X
M1(W )1IH]C\N7W;Y++3SOI4PC59%>.0U)+QD,1T->9WR6V'F2RG(FA9T*GC*
M"4(9A3<?%WIG1[+5X6U*'4$/)VC"LJA=@:CEU^UQVKG38=)BELX[=)H8I)%B
M1 C\@PG:B-N.P2C;9T >7I[NWUJ>)89;>70WCN8SS(23BHCDC91M4@TJ,A=A
M=W,$%M:&#ZREE:QVZHZDB2:I7D#N>-3UZ^V=IT'2WBN#&662&=0T+J2:"X J
M"Q!Z =1AY^;-_)Y?\EV=I:/ROC<P0K(/B>DK!4]R*#?.#?F#H7Z._*J7689R
M\FG7LEH*_"0DE&Z"HZU[YXBN6J2U-V.XR/W+=:X0SN=_;"N5AN:X$9OUY@Q'
M0?/!T6Q4G:IZG#:W.XZ?+#VW(VR2V0V'MDUTU14&G?.H:,E NU.F=6T9=U'O
M3.N:&-DH,Z58=*_+#U3MTR>>0;VEY?V).TT2SK7QC/$_?S'W9U'&2R)#')+(
MW&.)2[,>RJ*DYX3OKMK^^O;^7:2]N))W\>4C%C^O$!0TQP%!B@QXZ=,>/ECQ
MCCT)Q'PRQ3Z,4'CBP[#OBR=ABX&.(Z'OC:YNO?;&'[L8<Y'^9,23?HZ-NAN8
MZ_21D:_.*9;?0K2*,D>E -Q\L\'ZOY@G4.B-1F/';#;R!Y6EUK5K9I5,\EQ*
MJ@==V.?1*WTN/1K*VLK:)8(;>!8@%V%0!4Y&]6GBYQJQ ,AI4?:HO>OSQ:.,
M-)# 3P])#(['?D1L!7\<-1=6\0CA!-+B@)[[=*>V/"3NLL4=I'>1*M3S/%P#
MM\.<N_-2.PO/RT\[Z+=&ZCM=4TB]@>TN4YPJ1$SH_,C:C*"*'/EI_P X;>14
M\R^:/.'G*[LXKV#R3I<4,*W#,D?UG4&9&)XD$D1H:#WSUGYS_+>#6Q]:\P7N
MI7.EVC*UIH\ %G9KQ/)O51#ZC,P^R6- .V=$D\AZ#I7EP7WE31[>SLM2T_T[
M>2&(<UC9*JI8K4DO]H^.>#?S8NM+\[W>N:Y#Y!@\M>8GL?2==-,T%C<RPK%!
MZJ6ZH*3#@S-3X6)WSS'IVAW-U!K-]]1ET2T@GA2VAN6<LLK$\BA:C4"_1G8?
M+&H7\7EZRN/,$+7.CS,T45Z0!,K D;^*[9T#14U+1G&H:1*9M-GI)+&AK%<1
MG8N!TJ!T(WSK;7,]Q9&:QB]4<0RM6IW\/EG&OS/_ "B7\P] U#6M+3AYY\MP
MM<VLT0*M=PPCFT#D=6 !,;=:[9S'\K?S<TJ\M;:Q\VWK:;Y@TZB1W3GA%>Q+
MM1S2BRCH:_:SWKY*\S:-<65H;:YCN)KM0Y>*568[?"KCEMV &377-7CM[>W9
M^+K$C!DAK\)I4GEX[YYOU?S1Z5W+%#O%,S"IWX&HV)ITWR]+\S/96=] )U1Y
M)%<?+]HCQ&V1C6?-I97<AI6?H%.RTZ$4SC^N:XI=_K%S B2$LZ>JB$D]2S$\
MLA'^(-$A]2-+^RA<$GD"K]-NI).2#3O,5K';D2>:(HXRZL@BHYW]@-OEDPT?
MSMJ$TBQP7<DT1JOU@_ VU*%@E1M_MYV7RMYGU>*\$GJR7$;<7].6@5Z=2A%*
M>U<]>>0M:DU>V6:;4IK2Y7U'@#\#,KI02Q@%"#QV(SW)Y!DMM7TB[O'N)5E3
M3?JLJ3Q*I>(\VY#B!]EFJ"<YNVF0_HK2[%&D%X([5^3KQ"2'XB_Z_A'?.Q^3
M+.274+R23TT:V,<77EPD6LDAH-A0&E.F>8?S<_-9;KSMK>A6Z&Y6R@B:+A1E
MA=93^]8^&PVR4ZC/I>O_ )8>9]'N9V-QJDJW<4A;X.82M%]@S;YX!OUDMYIH
M)1PEA8HP]QD:N7K7O\L(9WZ[_=A7(U:T.!BP'CN>V^.#>YJ<&PM4C:I/OAU;
M?+;#ZV[;U.2FQ'3>F3C2Q5E^C.IZ,M NV=5T=-TSKFBKLGT9T6Q788<]%\,-
M/+-W]3\QZ:W*BS2&!AX^J"@'_!$9WK(GY[O?T?Y0\P7'+B6M&@4^!G(A%/I?
M/&*U'?'@>^*"IV\<>/H-3CMOOQXH/HQ3IF8[8EM2E=\<-O?'@]-L67YXNG;Q
MQ:O;+\0<K*KX[8TXF?8YRW\R4(L/K*C>WD1_NH<@7YA))YA\L65S;DL3" U/
MEGS\UR)K35WM900RO2A^>>E_R2:"'5;2=B&:"5?A^>VV>T-69 7(-4"<OI89
MS&989[ID,?+B0/GO7#EX#)!<+(YXS$*"/V1MMAE#:0,?5DF+>C3DZK6E>@IX
MFF#KI+TP".&MBJU*F1E#%B*"K4)I4],Y?YWL?,X\L:U9WC6VKP7&F7<3^JW*
M1':%Z,C*%V%>A'TYXO\ ^?=VFQ7/E3\TTEMA*\FM01>HVX1[:UY("/?D:9[Z
MO/+_ .EOK.G2SKS@B4R59$+VY0'JRFH%".O7VS@;>8=4_+V_OM$O=,GOO+;R
M^J(&H9X YJ'2AH >X.W<9YM_,?REIWFN_G\Q>2]7CLYW=IY=+ORT'"4[,\)(
M('+N.GAG'A^6GF;6Y&77)[33[3G6?T91))(HI55(V4&F3W4M&T.ST46+BW6&
MVB]-( 5,84"@'7\<C7D#0KU[A++3&3]'W$K^K'<,?0@4 DGF _#Z12I%<Z3H
M^D7-IS-J/4LY&:.85%8W[ KO0G\<Z7^7WEV9]=N)V426J(0B$%27.V_:F?(?
M\T-%@T/\S_/VCVX5;>QU^]2-5Z -*S4'RY8;:!9^91:M^B;359 HY4MPVWOX
MX!G_ #*_-CRG).@UG5K."I7T;U3)&:]0>0/;WP[T+_G(R^CD_P"=ET-+\A @
MGLG]-A3N4:JFN&.K?GU9<'70=)F=F4<7NV 5*[THNYW[82V6G?F7Y[I<WU\=
M&TZ7=1(3$"I_DB3XB/GDQM?R4T","36O,D\C&A8CA"M>^[@G#!/RG_+P?!SU
M/4"2/BLYN9"UW/V./XX8G\@_(MY5+#S7J.FW+;K'=*H%#WJR#I\\0'Y ?F7H
MPGNO)GFJVU)H/B-L7*-(@Z$?:0XMH_YI>:/R_OH[+\SO*%Q:1L3QU2V2I!(H
M& Y%"/8'/8GY5?F9I^NK#/IES'>07$/HP7,>_!P"?WU""IIV(WSZ)_D9YGN+
MN@N%!6"UGBEBY%XYX@*,%I0UK2F=%:.&YU.W92EN;:.*2!@#3X8P?B5J$ #J
M3G#?SW_YR;\M?DQY)U72/)'_ #MOYDZA%(6CLOWA@>5JO<3E=@Q.P6F>5O('
MZ0B_)VY_,_\ ,$O'Y_\ S=O%GT^R2H$6CZ82)IR#T]2:1@OCQQ35_P S/KVA
M:)HFBP3"2P]1I6+$<B]*@_=AQY*TS4?,VLV\NK:9#<+,R\T IR[9T'\\?R%7
MRKY7M_/^@ IIKNL5_:5KZ)8T#+])SQ?<-2N^%3M^O$"P^_%$.XW)KO\ +!T)
MW!IWJ1AW:D=>U<D%KV&2VQ4?#VR>:4NZ[>&=5T=*!,ZIHJ[I\\Z[HR;+VSH-
MD/A&&I.W],+9)V@FBN$^W!(LB_-34?JSTQ]9B^J_7*GT/2]:O^1QY?JSE?YR
MWGU?RM!:@_%?WT:$5_817D)^]5SS O6N*>_AVQP[5[X\=.F^/'MB@[>^.&WO
MF;H-J8F3N,U>F*J=_8XJOZ]\70U/2N+5\-ZY=>N-Z>U<Q(\:8PUW[XP_V9!?
M/$"W.E7,9%28V_5G(?(FI_I*WN] NJ%K5B$#=UKB7F_\JO*4=I<ZN^E">^F4
MTD/4'VSSUY$6ZTW\P-$TBUJ(K^^2(\OV5K4_AGO[6$BA@F)W"BE?EMG*F"R7
M 9ZQA) Q8>'?[\&0W $DD3.0B;D=?A.XWR7VXV5@.*\15>N[;<1W)-<0GN[&
M.:M];37]UZ1$5M;U+'B33D 0  !XX27'^)9Q);1OIUA:2J4]*4"0I&15N;5Z
MD&F>"O\ G$:RO?(GYO\ _.1?Y1K=B#5].OHM:TU.D=W"DCJ>()W'IRJ<^B#V
MJ:M!;^I!^C]9M=Q#.#Q=1N4Y"@9?$9S_ ,X:5I]];3RW&@4>9G$L\?*8^HPH
M>7Q<J#J!GEW7/*$-S;PS>K(MW#<LY+PM&3!4@1@4[T&Y'?(&?+[V4E[=7NCQ
MSIR+(L1-50F@0J.FVXPI2?3(PD<VCPEU8\)#$#\)Z!@0=\%Z-J#PO>)I,T^C
MIJL?U>YAM/W,=Q&&K\86E17>G3.L?ESH-I;7$:1ZG"\%W<K<WC7"(K52J!!*
M_P 00[$CID^\V?F%H/D>\U$^7] FU/R_I]K!?>8M<C>)8=+>>J11QQ/\<[N1
M4A=E!KOGR#\@^6]4_.+\X/,.JVEL;HZIJUS=I45"F>9CZA_U$W^=,^L>D_EC
MHGDO1(K&*QMY&6 "24I^\+]V+^->V>2/SET;3F@O9+:TC])0P<<0=SN:[=-L
M\8_GO^7_ )9\O:'Y'\QZ%;K8W6NVW^G0I]AVH")./9O&FV1[\L/)JSVZ^9;Z
MV%R#(8["%Q5:H:-.0>M#LOWYW.2WU)45EE-NC;&1SV^G!5M_@ZV:.76=0^OS
M@%F]6LY6E#01K4=NN2"7\V]%6UN$T3R[>ZK#8NEO(\$2QI&TQ^%1T.]/ X0V
MWYX>59+IHKO0I[*2V;C)S^/B*T-01X]<ZAY5U?REK]PUYH^K-HVIPEO1G@;?
MBWVD:(_"RGPSI4HLK:2TL/S*TNRN=,UJ&EG?@"33[SF" LZ?%Z<@/[+4]LX;
MYY_(S5?R^23\S/R0UL6L^GJ;K4-#BD]1)($^)C%&^ST'VHS7;[.>IO\ G%S_
M )RJ\E>9(+BUUF#] ><X;012:9$Y"7B\A6:R>E6XTWC/Q#W&3C7OS*_-_P#.
M#7O,.C_E[#=6>FW5XFGS3JO&9P%6/B)/V10;T[9U._\ ^<?_ "U^6?E7RMY4
MN+B/4?S&_,W4>&H:Q<$L]K:01M+?31U)^&WMXW8,?V^.<O\ .T\>K:C=:_;*
MUAY8TNPBTG0=+I1;:PM%].V@7Q/$!F/=B3G.?+=B"7N+J-83NYD;95!-?OR:
M:;_SD!Y9\H7\&F:?ISWT]O(!)<\: -GL:7SI9_F7^1_GN,3*52T]94;>A"U_
MAGRLN&- .].WMA6YJ??VQ&NY\/;%4.^QZ]L'Q=>PWP]MCL-J5_5DCM%W6N3&
MP'3WR>Z4NZ]Z4SJNCK]@?+.JZ*NZ]\ZYHZT"')Y:;*,&LU!3":[;8YW&SO#=
M_ET]P&/)=&GCY [\H8GC)KXU3.;_ )XW9,OEZQ5J<$N)V'CR,:K_ ,1;.#CZ
M1CP?IQ0;#'#M7KBG>O?'#V[X_N/?KE-B???+Z8H.V+#%X]OGBXS?PRNWME'_
M &L8?D<8V_CD<U^V-Q#Z8W]12IKG!K#1+C1O-<5Q$C<)WXO3I0YW?6S9BPBB
MGA]6.0 #Z<@^FZ%Y3L;_ /3BZ>JWMH>43%=U8[5&V2J:Y%UIGUB4%0S;U^><
MXGA99)T6I60TB\6KUK@V&4"%O70?&.+E1_)T!^[#R%RMK%!$S"X:MRO(D@GI
M3\<-XV@T:RGN-3XS7$_PP11*2'+=$*#XF8D]S3"/] :EJ,5S+JCS6MK+3A;*
MX60@&H#2=OD,\"?\Y)^7[[\E?S)_+S_G)7RU9RW.BZ6\?EWSK#;EN;VTY9%D
M;<FGIOQK_,JY[OTWS,FJ:/IVN^7=3M_,7E;5K."^M6D(E8QS4HT; \M@=QU'
M3KA3Y@U.<*3^CYIT^$\T?U*"E5(XGE3WIG/)-;YL[0F#F:T4S$-7N '%1G/=
M7OKF=+@3+;PQFH"&XCJWA^T"<Y!JUA=LZ)96D4TP>I FCXH#UW!W/TX)TWR=
MYLN2_P!6L'12A=I 8W!'O0F@^6=R\H?E/J8MI=0\R3P16EK;O<P)4<6 0LI9
M^@!8 '/#/YS_ )FMH/Y<#\KX&G_Y6'^8MV^K^8ECBK*;YW5(;>-1T0* L=-N
M-/?/7G_.*'Y I^5/D>TUG6XE7S5K$?UB]# -]7C<5]$'Q'<COG5O/E]!'%-Z
M3GZH4:I<[FHH,\;^;K-M4M+I((_6C1&)WJ36NYSP;^>-U+=>5?(D4A;UHI;B
MU6O3C$>(H/GG58HI-(T'1-&T2..)["RA65G'&1B8P2%KMU)-<ANIVFO3R1M<
MI+=-&0SPR.&1A_DD4 R5:/;Z1</);/8)ITES0^C,*N!4$Q<MN0J-B#OD9U*T
ME\N:_P"8;+TTM[/6X5ECN"'$\:[\5A9'0?"^]"#O3.;V7E2[@N9;^\OX[B/A
M,H=P2S*]=V![YTCRAY3GN++]*P2RV5Q)*6LV W=(MPQ4$;5%!7MG8/+/F36+
MVVNO*'FQ1)8:NRP2,]&X.2 LG&I-17.J?E_H&IRZSK7D6[U%VG\OO+ )&Y$R
M(L?.$H1W9#05[['/%O\ SD%^7L_Y6_F#:RV#7%A'K40U6V(4VT]K=QO295"F
ML;!J,*':N=E_*'_GX!^;WY6VNG:/-;Z3K-E92L[7DEC&;R<RM\3W+@J9' Z-
M4'QKGOC\I_.]]^:;>;OS$U7SM%YX\Q:SIT>BZ5&\,MM=:787DWJWRW$#((8P
M8HQ&GIMO5C3)AKL-BNA7$]Y%72]+4A0O^[)?&OSSAF@2S^9;YX"OIVN](DZ<
M>V<&UVQ2R\RZM#$GP12E!GL/R'?WN@?DIYJO&:D5\JVZ_<*_KSR9._X[X7.W
M0^.)5[C?QKB\9J>N_2N&$-:GET/;OAY:FH'AL?EDFLNJ^.373Q]C)]I*[KMT
MIG5-(&Z?1G5M%6I2F=:T@?"N3>V^R.QP1(:#8X27C[-G4?*%W]8_+?S#$37Z
ME%J$5/ &'U/UR'.>?G+<^MYL@@KM:6$24_RF>1S^##.4CQQ8;]<<-_HQ_P \
M>/?PQPQU,ICB5=^N.!WQZG?%U[8NG>HQ<'VS5/;-O\\HGIX8TXQJBN%U_$9(
M6*_;CW&1#4846![B*,&:FQ[UQ2*]6]L;**?^]C8<B? 8:2061^+T>2"AV'4X
M&U-4N;"2"U/%4*N57L<@-Q&2WJHW%T0\%[DUZ_1E7,11XU6HX"I'8U%3^K#S
M2)FED/K\64 O%&HHW!=E ;P).^24R>A</=7[Q$ *((C1A"0#60 ]30]>V/N+
MM[J)^492"(5Y$\0ZH.P-#N?QR#Z]Y:T?S%HFNZ)YAT^.[TG6(GM;VPN?BCE@
MD6A0K3[0&X8;@[Y\\8;OSI_SA3KUYY;\Q6M]YZ_YQLU:\633-:@4R7GEZ6X_
M>"*0 F@%?B796^TM&J,]<:!YP\N^<+6UU3RQKEKYBT"^42Z=?VLO+TG;XC;R
MJ"'0^S $8I)^C-4DGAOE "-\+R*K,AK1@QXUV\<&1>0].>V$R!)U+$ +QY;;
MUW5OHIAK;>1=)9HT2X65;IN#0SQH&2HJ-U7\2,Z=HOES0=-@6.&SBBEG<6LU
M%!JZKR0T4?":;@]\\:?\Y+?\Y/>6?RRL[ORCH4R^9?/E]$((-,MF$B6\C'=[
M@("!2GV>^<6_YQ6_YQXU[S#YG/YU?FQ$UYK]U+]8TNVNP6"$_P"[F4UH%!^
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MO36M+FU/HLM!W 2OTXE#8""4 2/:."2@<40UZ"JTR;:3<0$A-6M(I'! 61Z
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MM4U!WIAGSB6(\A&LW%HXD*"G\I  J1V'7Q.!FMK8PQ6KA&>.'UW9Z<"U:L.
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MYOUKS+I6C0K'<0H)&+*KR54A3V--JDG.5:_KT>MB?TW4,"SOP4 .S@*@  %
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MG""&%._WY(;<4X[=0#DCLNH\<FNG=5['QSI6D#[/OG4M''V<ZOHP^SG3=-%
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M*NP9JI52#X@]L(6O);6X,]G=\/1(/U><D,&-"4Y4'T9.[?5(-7L1ZAX7,/\
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M;9.(/+P=B2=O'/47EHVOU6%Q%)"ZJ%D28=:]",ZM^7ED;OS#9AF=(F<^G2@
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MF"!0-Z;/&_WYZ)_/:R]?RK8WJBK6&H)R]DE1U/\ PP7/)X;MWQ53]PQ0-3%
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MIC)\#MG$K-E$;QUW(J2?',@F56DB(YJ34^.(^K+<L9)%8.PIQ'9A@,5!,-T
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MEIHPC_O% #1]E%>OADDAU".:99%G _=@N0/4H14_"I[U.#KS4$%F;I 9I(E
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MOGG;SK+=:>LA:.WBG]8O9B(*Z%N(5RS"H &]1\LY996)6.4W-LO.YN#2<-5
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MR2&O0%V51GZ)+.(0^DO0* ,=YATV/5](O+*0<A+&R_>,^:?F#39M)UW4='N
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M*[8HK??BJGL/EBJ@[]\28*H)D<(!UKMD:U;S=Y?T:-GNKY.2]@0>F<,\W_\
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M('%YKU"VFDA@EAO@%]/TG 65"@_;4TJ*]*85-YOM+JZ]2^G2W=%;C!*K)(E
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M:O**\AV]L99(TT84&I3ODDAM7:-0$J4WPX@M6^KN[QU8FE1AA;*T:5=B&4;
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MN.)7(YK0#J?'PP#J]LJHCQQGD-JCOB=I+;K;$.A9^E#VQQ1" 5%*[8LL')*
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MX%>2NT",DC*6 I0D;9$KNP22.82%O4^T":G?W.<5UQO2NF0&E#^.!K%&EF0
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MP*RQKZGGS2[5-W110:Q$BCJM*7('44E[2,?B+)Z)(C0\7"D%J[$#OC!+01Q
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M='C]?4;^&T116LC@?A7(]YI_YR%\L^7[:0Z5:76NSKT%O&2E1_E=,\C^:/\
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M-#22OY5>6KOEHVGW*T'F#4;=Z'DI'Q6D#K^\/21QZ>X$@'Z0@ H"J  !0 =
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MLV;-A%YG\L>7_.?E_5O*OFK2+;7?+NNVSVE_87:<XIHGZ@CJ"#0@@@J0"""
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M4B5Z/W\,]?>4)*QE#W&1CSY8K*9&*UVWSAV@73Z;KC6Q;BI:J_?GIK3KPR6
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MOZ>L%W-("JJMXBTV  EZ#C(:MGR[U:QU#3BB7Z?H]XY6AG@="KQRQ'BRW$#
M,C C>HP#>P+%QO)D4DL.+Q,6@8$=CU4X*CO_ %(=H_7F?[ F-&''_?<HR06\
MMY>(D/H,TTT?IPU;TITIX'8/\L"/#Z=Y S*L:P#A)-$E7Y+U$T!_6,(I[U.4
MDJQI&C3<A7XK=JGN.J9SGS?%Z3\HU,2\ZD \UW_WVX_4<[/_ ,XWWM-5U.#C
M5BJD'H>OAGU$_+2\]&YC4FA-!3/9OE67E/$0>H!R4^95/ >-,XWY@M_7L+@
M5(KMG(?+EZ^FZUQ)**ST/WYZ(2X%S:<@:D ';?/-_P#SD7^8EQY4\FCRKI=Q
MZ6I>;"4G*GXEM5^UO[Y\[IKAI[%H %]&"J(0*D]S4CKOC;3SQYRL-/M-/M-?
MN+>RTN.2&SB'$K"DA)<+R4]22<\^:[5KN220\I'=F9CU8DUJ<Z1Y)\XMY?\
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M95) V1DZY\./S]_YP-_//\D([[4!8?\ *Q/($:NS:YY<@D9X8UZ/?V'QR0T
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M)KO\NV))'179MT792-R<1B4@,ZD%#N0>N^#H+LHJQI%Q0;DCW\,'B.U=XI8
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MJ?[N2W5Z^X(SZ9>29S>:DBC<+3;/1\W[JQ/;BI_5GSJ_-^\$WFFYWZ/_ !R
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M7!5G^6W_ #@A8HHAU'R Z1MR'UCS6MP*^_K:I)4>QVPK;0O^?;6F7\CW\_Y
M2ZD*^I^E]1\NW<OQ?S"\N)3\J].V=_\ )?\ T+;RC_Y5Y_RK3G4^G_AW]#UK
H\%>/U3O]G\/;.X9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>sny-20231231_g15.jpg
<TEXT>
begin 644 sny-20231231_g15.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
M!2$2,4%1!A-A(G&!%#*1H0<5L4(CP5+1X3,68O D<H+Q)4,T4Y*BLF-SPC5$
M)Y.CLS875&1TP]+B"":#"0H8&82414:DM%;352@:\N/SQ-3D]&5UA96EM<75
MY?5F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I.4E9:7F)
MF:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H " $!   _ /OYFS9LV;-FS9LV;-FS
M9LV;-FS9LV;-FPFUGS'Y>\N0?6O,.O:=H-M0MZNHW4-JE!U/*5T&V<1\P?\
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MV"6"-+:20 Q2&>YG/3DP^!8: 4"@FNVWML,*;F_DO+TW49XAZK A)<Q1*?@
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M;-FS9LV;-FS9LV$'F?S/H7DW0M1\R^9=1BTK1M*B,MQ<2G8#HJJHJ69B0%4
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MW$MW>2?69Y&+R2S@N.1[E#]H^ .WT8\W$M^1ZLKQ6J,%;E5ZD#8&@JSD= *
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MU._I@CX5/0,6SS,%]NN7Q ZC'!3X5VRROTY73;+%6Z8H/P]\VU:??XXTC<G
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M['#9- ]:XBCTZ>.^YPK-6,@U#,P 4=?LKOM4=Q@J+2B?K,:Q>M,%941P*L[
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M.X0%. 4A%#KQ(45K6E OAUR-WGY36;P7#V\_U8R#CQ*D*O 5W6N[=@>WVER
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M>/B1OA5(M*[;]?[< OW-:;;?/ +@%F!Z'P_# <J!J4.%EQ#U%-N_OD=O[;D
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M$,3\QX8HRAUC<#[5 3[KN/PSH/DJ$K<K<!><TC".!.IJ=RWT9]8/R TQ]*M
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M]1F-1\QOD:\P^6;3S1_AF"\0R+H7FC1O,$2%>0=]-NED9&'@T;.I^>=]L_\
MG,;RAY5U\:5YE\O:TT4-PL-_J5JB3" ,.0?T PD8"N_$$^QSU9J=K^7/YO\
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MEK%WQWW^JPO'7I3;ZSD-_.FY-]^;GYD3.6)7S)J, Y=:07#PCIVHFV<R*B@
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M</*_!6TO54!ZU9]/N54?26I@FE*4Z'Z<<%VQO'?PQP7PZ^V8@4VQJC>I&V*
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M;F"WNKL#]U&\%O&CHO9F+D[#Z<][?\XN?E+:>4-$;5Y;8K?WS<89R*GTZ<9
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M<;'Q/7$YX2ZL%I[>]#OO7-!:P2)/;7,*SVLZ%)HG4,DJ$$%)%(8,I#4H01G
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MF9A_I#))L0'J:#L1A]H?DJWT]*K8@3'?U&!Y"FU*UIDJ_0#%$9HJ!>U-CM0
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MS9K$<,4R!P 8Z CP&]/I(%<\C^;=:]>>8>H"%)"@&GA3&^4]%]&NKWB_Z3<
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MU!SD^NZ:VCWE$!_1]XW^CN:D1N>L+'M7JI[].HWCLTI44XD+TJ=_HPIEX,2
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M<XGE=/IQ)C4[#;QRN.Q)I0XP^^].V4*;';*-?V>_X9EK2OCE_3L<82?'$R?
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M!E,???$R 3OC"H]CC:>V6"1T."(K@J:/N#W_ *X/!#+4&H.!IE)!\!B$;$$
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MD7?ZK;M2M>G-A]D=^1&?7;3]/LM*L;33--M(K'3["%+>VMX%"1Q11@*J(HV
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M63RD+>4DPD ;D@=>QQ5M'AB4Q>F!QW'A0]\\G?G1H3/;W(:( ,"*4\1G;_\
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M:*\M+R,Q3PR"JNAV-?\ /Y9XE_,'\O;[R)?N45[SR_?,5M+JF\;$?W,I'[8
MV/[0]ZYSE;56Y"G(GO2N_8' WZ-5F!9*JQ(6IKOVKA)J6C"2.5'0-&]"*;D$
M#/EO_P YC^1381:1K\%N?]'O9+2=@*42Y7G&3_LXJ?3D'_YP>_YR(G_YQ_\
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MA_\ .6GYER137?DBV_+C19S0WWG"[6S;B=S_ *#"+F\! I]J%03M7K3]&O\
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J1]5^IUWIZ7I^U:<<,LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>sny-20231231_g16.jpg
<TEXT>
begin 644 sny-20231231_g16.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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M<':2)E8=/'/2'D[_ )S-_P"<DO)0CCL_S-O]<M$I6W\P)%JH8#H#-=))./\
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M/TX_4XVN9+J">LK7+Q2ZBT7VI9_M16@ _9049OH&)>;+^3R]I;65E&)?,&N
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M%PK3N6F%" $HH1#MM4;GO\AGI6W$@C--F8DT]AO_  Q'5)RRSSH0?2B(!/\
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M8*!6@J<\>^=/SRT_6=(N+W0M>M= T6=!=:5KCA9&E:-O@N)S)58K5J$?%\;
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MIB9&)&F)'IB1IO7$6Q,^^&.@ZU=^7==T7S!8_P"]VA7]MJ%N:T_>VLJ2IO\
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MDE@" O)F)JS4SBTWY(?5[I[RSNY](OG4NMQ83-%*\I?=D=00*@$5(]CA??\
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M7J5J;;5#;O&55J(BCH??$]>:,0V1)XF+D@'6@WR)78'HP+R%0"<+(WXR"I^
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M@0K=*#L?; LVJ2_'4T8[D@_C0;9$-5U69@Y>0"( D#Q/RZ9PO5-!N/-VHBW
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MMB+8D3X"N(-TW\,1)PTT.OUV8_\ :OU'_J#N, +BRGPZ8H#X;XX$X\'>F/\
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M?XP=E\1COLT'ADC@MFGGTZRB?B;CB\G;[1H/PKGM/\B((I;'S1=H>%O!$D4
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M;$FST=_SC-IOU_6_S>NJ5_0WY.^?;SK2G+1;BUZ=_P#>GID@_P"<WM+;1_\
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MG5UIRM(VIX'^S#*/\S9":3Z<1L*\37^F&D7YC:2X'JQ2Q'IN/]O#RU\V:)>
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M'\-_L[';Z<<L83G4BO+IX4P#=;4 .YWP7Y:G"W=Y 3LU' ^BF3%F]^F>W/\
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M'%9?B%.]</XW#(%!H"*G%@71.%1P<U/O3&&I% -R>V/C)X\"M3XY@" 1T./
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M0RLRZ!: W]XJ\3>ZC.?4O+HUWH\K-Q!)XIQ3HHSL.;-FS9LV;-GPM_Y^-?\
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M%)8B1)&11D/N#E@AB144(^G \B@U-:^'MB2[K4;$'OW^6+*.0VV)&^.XL3Q
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M[O\ +0R6<C?6KRZ@YJAW])&+$ =]C6GMGR4\Q7QU"\N1$Y,=K%&B$'J */\
M/<X'MP$B1:4*@5Q[*0 >I.!V;XOB)Z;4QZK3<[5Z=]\4]9+9&FDV0=^Y/8#)
M#H]BZTU.[4_6)5JBD5]-.P^9P??MZL1(?:I.^<+\\T:]L87W4PL?O;IGI_\
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MM>#HU>O7;^&=5TPO15=257<?JR2Q(C1ER:&I IL!7K7QQ<PAU<-MR%/AIO\
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MB6K0 #K7IGUM_P"<//\ GW9J/FQM*_,O\_=-GTCRN"MQI?E&8-#>:B!0I+J
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M= "@*H  % !T R\V;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;/(7YT_\
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M(_*[_G!;\_/S)-O=W7EP?E[Y?G*N;_S/6VF*]^%DH:Y)(Z<D13_-GTJ_*?\
MY]Z_DOY#-IJ7G/U_S1U^W*O74U%OI:.O=-/C=@X\1,\BG^7/=6GZ=I^D65MI
MFE6%OIFG62"*WM;2)(8(D'18XXPJJ!X 8,S9LV;-FS9LV;-FS9LV;-FS9LV;
M-FS9LV;-FS9LV;-FS9LV; U[96>HVMQ8ZA:0W]C=H8Y[>XC66*1&ZJZ."I!\
M",\C_F-_S@I_SC;^8OK7#^2%\E:K-7_3O*L@TTJ34U^JA)+0FIZF&OOGA?S]
M_P ^M?-UCZUS^67YCZ;KT%"RV&OV\FGS@ [(+BW^M1NU.Y2,9X(_,S_G$G_G
M(_\ +L3S^8/RFUV;3X0[/>:/$-7M50#9WET]KD1K_K\<^>5S%)!<7,5Q&T<L
M4KI)'("KHRL05*FA!!Z@XT,I!05'OXY//RX\PMY0\Z^5_,BGC'IM_"9_>%FX
MR"GA0Y]I_P#G&3RO9ZW^2G_.?/Y(6I,^E:C9'S=Y>@;JT&L:5+-%Q4'HL]DJ
M[=\^+-A()8_5V(<!U^3 '!IW-=EVVIECX4#<QR/PGP^DXF>2\:;U^ZF. %-S
MU[=LS$DT*@@GKB1= 7 )-*;C+*;*0#2N^*J *;54_KS2E:@J*FG4=CB98J "
MU 2-_P"W%S1%Y!R2IPJNRMP)/4/&*-&9R-_A J1]V?0C_G,#1_-WD;\I?^<:
M[#S;YVU?6_S*\V>3(KOS&E[,K_5K A'L;)0$5E$*N4:I)9@S'<Y\Y[>,A22>
M1-3\7M@>Y!)^(!2.E>E,"CP!IM4XER!((V-0:?(YZ2\I>7]>\S7MOIWEO0=1
M\PZHZ*5M--MI;N<UITBA1V._MGN/\O/^<#/^<D//)@FOO*4/D73)>-;KS+<K
M:OXFMK$)[H$#^:(;]^M/<?Y>?\^P?(.EO#>_F9YXU/S=.*2'3M)C73;-6VJC
MS,UQ/(ONIB.>]_R^_);\J/RKA6+\O_(6C^6I%4J;N" 27KJ10B2\F,EPXI_,
MYSI^;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LY
MOYZ_)W\I_P SHVC_ ##_ "V\M>="P $NL:9:W<R4% 8YI(VD0@"E58'/&/GC
M_GUG_P XB^;VDETKROK7Y>74H/.7RWJTP4L>A]'41J,2T\%11[9Y.\W_ //F
M:S(FE\@_GC-&*D16?F#1UD^'MRN[2ZCW'>D'W4H5-&_YPQ_YS,_*^WN5\M:E
MY<US4;_2(_*\VJ>6M:DLKI]&]1F*3QZA;V2.R>HQ7XC2I ;/!GG?_G!C_G)C
M\O=8U?2H_P I/,/FC2+&<BRU'0[,ZDEQ;'=&"637#!@-F6G4;;$'//\ KOY?
M^>_*AE'F7R7KOEY8S5_TEIMU:!=@=S-$E-CD08'BP.RMVKB;"@4 GC04VQ1
M0O%@14U&/8$ JR4*[_(8FH!Y,%XTV(Q_<U'VNWM[91J593T'2@RSP$?%]CXY
M?%#1F6O$;5Q%]T;DW?IG>?\ G%[\JC^<?Y\?EEY!EM_6TS5=9BO-8'9=*TS_
M $R]+>S1P^G\W&>A/^<Z)/S _.O_ )R5\XP^4_)VM^:M-\LI!H>EIHNG75ZH
MCA7XJ"WBDW+ G;.+>5O^<'O^<L?-(4Z7^1WF.V]3<?IF.+1>P._Z4FLZ=>_Z
M\]&>6/\ GTU_SDKYB:&3S'J7D_R1;!@)A>:C/>W94_M)%96T\1IX&9<]1^2O
M^?-WD^U"2_F'^=&L:PST,EOY=TVWTW@.ZK<7<FH\O];TE_U<]A^0_P#GW-_S
MB-Y#:"X3\L$\WZC!3_2_-%Y<:F'I3[=H[I:'I_OC\,]D:#Y;\N^5K!-+\L:#
MIWES3(J<+32[6&S@6@H*10HBC;VPZS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L
MV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LX]YQ_Y4!RE_Y6!_RK[E7]Y_B'
M]%5KS/VOK?\ EUZ]_?//>L:5_P ^XM4>>/4I?^<?HI_WB3&"\\MV<O)S1^30
M31-RKW)J#TR":C^5'_/L#4@3=ZI^44:O'Z8^K><X+0<=]U^KZO$ =^HW]\AU
MU_SCM_SZMN(O3@\V?E]I[!@QD@_,J5F( (XGUM>F6F_A7WPKF_YQF_Y]=RQ2
M1Q?F7Y-MF=:"6+\QX"R>X$FINOW@X4?]"J_\^QJBOYT^6ZCI_P A$TS_ +*<
M'VG_ #C!_P ^P;8R&?\ -?RGJ/.E!<?F+9KQI7IZ-]#U]ZX;6O\ SCC_ ,^L
M[:3G/YW\AWZ$$".X_,DA:FFX,6M1-7Z<E6G_ )-_\^M],$8M]8_*B01-S'UO
MSVMW4]N7UC6Y:CV.V3?3- _Y]I:1Q^JS_P#./TO"H'UW4O+M[]KK7ZU<35/A
M7IVSTU^7O_*A_K!_Y53_ ("^M^C)7_"?Z+]3T:Q^I_O#OQKPY=OLU[9US-FS
;9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>sny-20231231_g17.jpg
<TEXT>
begin 644 sny-20231231_g17.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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M:6Z<2D#90-N7A2HJ/<Y"->UO3]-7U+_47DN_5$4D-FQ2-(_AYB:12H'6@Y,
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M^LL!()*$@%T8544([YQ^]FNHV4/,EH;<_NXY).3QD$[*!R--^AP79V]&BU&
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MV-:6\SG>91^RQ_F ^_Y]>G9LV;-FS9LV;-FS9LV<*_,?S=]:ED\OZ?+_ *+
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MZ?$3T&$UOY>U>^)DL_+EU:Q%>37S1M9QNH!-1),ZJ 3O0=<,;3R]:V;!7UF
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MEVBLQ2-45$0N>7II!'Z8+$CJ7;KX;8FOG[RIY>*V<$,\]Q"6*A(@TI<4Y/&
MJ(*5/Q-7VPKN//47F"0\[&ZU"I(1+JXF!"C>E0I4[#L=NPQ,6GDR\$RZIY52
M%9F Y_79GF5@*J"AC5B#VP$WD[0WBIINESJA%2C-<PG?[/)IN:4^5,$PZ#]3
MEC=1/I$84?\ 'S$ [4IN&J2#[4&*PZ%I<\I9-6BBO.8XJ'6O*O7DA"UIX@?/
M)EI]C:W/IV+ZM:O=D<DMYHN$XD!8DJ'*AB1O53X5KAY!HMCIKR&ZMKK47ACK
M(&(MZ!]BXY<G/P[^_3M0I0V'Z062:S]/30.58XH^8EYFE0-@-A4U"?ZR]Y/H
MVNZMY>N7M;ZRFU&RTW@L\$E&:-6!H562,-Z;=BK*1_E9VC2M7T/S':VZP:E=
M_60RM;V+N6FAY$<WLYF(E %:!27K^R <.KV*SO;DQ7P:]E<\8[R- +LE&*\)
M.;)R<=XWZ@U0UVP+:^K"#/87$7FC3)>=O-9Q.?4B5BP;ZN\I&X&YM9J$]BVV
M<_U+08.)N[-?J]K$5^JNG)?B;:BGA5&4@J490:\M^Q(=!UZSTF[-E,S6TUD2
MD,L0J 2S!J0T*LCAB&CVKU0T^ ];DBM[J"TO&BD'UGB\4UN%>1E(/)4=B4=N
M*AU4FK+7[+JXPH47UG]<-G<VMQ! _K-:_P!V6A('[R%6K2(G<C?@3T7< HU2
MZEN9KF\M*VZW 1+RPF<2+*".+2-PJ6H=^0W[2%MGR+R65E/;2!+Z6325'HS@
M(&O-/>I]-Q$W!Y;8K4AA]GZ"<A6NZ8\<=MIFO0QW-E<!OJ%];5>*> '^^MV%
M2#7[2=0>PKRR(0VVI^6YTDAD2723*7MKN  QI( 6X34^(%XP2I.QI\-#MGL_
M\F?S'TZVDF_3<4EWH&O216VL1,W/ZM.QI',M.J35)K^S(*]&SVI8?6M"N=/@
MM]1-S97EK"T&H6S!FFLR&2-YHP0LB $AE8 C8J13BO5],O)J I=?5_J9_=R%
M>7IL*BJM53Z3K12"/A;J*5 Z78WK7409E2:8 55?@#=]E-:?(G!JW,7V'!AD
MH2(Y!Q) Z\=R&^@G%%JJ*.I4 '%*U[UVR_\ ,97?KF\.^77H.GMFKM[9?XY7
MX"F:N^Y(IUP=IFHW6DWT%_9R<9H&KOT8=U;V.>E]'U:UUK3X-0M#\$HHR'[2
M./M(WN,-,V;-FS9LV;-FPMU?5+;1M.NM2NVI%;(6XUH7;HJ#W)VSREJNIW6L
M7]SJ-X_.:Y;D0.BJ-E5?8 4&%XH2#X9=-MMO?W^_+IWS4[5R_#ICATK[9N5
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M>S,O_&K9?*4T'HA34?M@CK\OX8!E:5I XF].!%*N8ANU2-D8UWKW ^6?-?\
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MGNHQBQ+7-C.4CN4=Y4H7:%TKR60"G-"-U<?$!L<!Z3*3+'+!*#)*:26A/)9
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M6A[$].^037?)&GZM$5EB#.@^'DQ!!Z$D]#UW.>8/S!_*&"[BG/HJ JFHVK0
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M2V9BNHWGL;J9!=QD?%"3O51[CPZCI_+CK9W\J7_IPRR7'EN9P[ 4D-J9""K
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M*47+,+Q8SQ4). 2R@; /\+#^5B/YMH]<0QPZA#)&A>>WN0)T2BEPS+*DQ7H
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MH/**"[J:M]8MVWW)6(2BN5--)+;32*:NU\0#2E?LT(^=,ZAY5T\0W$3EP/5
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M. VZURP #OX'+'MMF/3?L<U.Y/SR]NAI_;EUW\<WA3IURR"1L>-.^-;D $Y
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M9C\LNG:FQ\,JM=^OMX9NGSS4K['P]LWM^O-\^I_5GH:TNC<_EZ\X;=='GCY
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M=[=LFGVL!97>XYSU/\LDA(9?]4(* _C7(%KLKRM:V*J6!FY<5H"[U:I-:D
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MM>2E%4$,]*?$"M#X5-=Z],-8;^0% 7,9J0Z^_?KVPPCFA$1!+,KU*LE":TH
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M^8CIME5Z =\U2:YCMTS5ZU.;Z>OAF'3QSI_DR:OECSI;$[1V<DH'^O#*#_Q
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MBO?/4?EC1=)TR Q:5910V_#K$B* @(+ &@)Z4W/?)ZT:<69ZUF 55(XE!O\
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M&-]4-?10JPC2)XW/@$BC/]:9ZR\BSROIEF2"5EB!H %&U-@2:5W_ !R=22I
M+AI":&C$T-5JI-=OGD>GDUC556&REHI)$<3&-D'*M25-17YKDS\F_D]J^O3)
M)J,\49H%]>2,% 6W XJW"OA4?1GH.R_(GRM!';_I+4+B[DCJ'FDH O8!47X1
MU[#YY+['\AO(JQ$K9SM'RJ) [*37]HA6_7B>H?DGY1E A%M=*J\@A9J *.X)
M)K7MG(O-7_./MJU1H\XDX"I$PJ37L"O&GAG#-8_+35-*;@ T=RG(&1&Z[#>I
MJ.G^??"$IKNB.AM[J0O$]0HK]JG[:G;OUZ^&=M\C?FMJZFU34YAZ-5K6O-"H
MI5BQ;KT-<]<Z-YFBN;:"2,^BDTHFY"GQ T()J#N3V'3)K8:]"S*@EH(U59&J
M-^>^2R'5DF=57;@I%:@EVIWZ]*89_6755- ZL!4FG3MN,,(+SFIY1\E;JK=:
M4K4$8G=S!D7B0'1=@1O3H:4[87I>.0=SR.QH=MNOT_/ LVK!P6])1(C"IKP(
M(KN0!MMXYS+SCYF].%K?3KE8[N<A7=00 I-25/2O7L?XYQ*]@FO;J.*SMY[A
M"[/<<$^-Y& 5.I)6@]_QW,UT7R#=WBH+^W]"T0U6"G%3R/)@5I\-3]_[3'.R
M:?Y=L+ 1?7;J.&!&16<*Q;@!NI"FH ]A3#Z36O(^DJI;48E9=W@=I$C+]5HP
M%:BE?B## TGYAZ?'&TMIH[W#3?%#);B&5RAJ3(T<9YU/NFV"M%\^:9J<B)9Z
MC'/+,:!#(B2+)O52C4XD4-:[CODTCOTBB+.X=A4++]KXNM!7 EU=+.KSQE@%
M7X:@'?L3X]\B>N6$=Q'&\J*TJT)[5<]:C>M*;>&0E;3@LT1B#1CX%8"I/Q=^
MN<+_ #D_*^'7M)74H8#Z\85E9:!AQJ!N!M\1VKGA]]*O-"NKRSN;<W%@]&DA
M8442?$&9*[ T/4'J*?-#4(+CZBMW9A;^RF+QNTJ@<P ?@=J#XN+"C4%>M5:N
M$NGPVES),8':.2Z$<9BNE/K5BD#UY .& %0#U&Q)KA,]C;Q&2,W3&=I6].20
ME%%"QIZ?$,0I/4#O].3C2K"5-1^MHM+6^87D]0)(I Z5X1\6*J:R4H23X]-O
M:OD#RCI\'G;1!#:RG](:0EU"Y(,<DC*#ZC(U10_%NI%-R,X5YAM%M/ST_,&"
M" I9VK0I..!8%Q;Q.D8J/BKZ@ ]SGU:_)31?T=I7EE!!';CZE+<SQQ4XB>=Z
M4[D?""W7>N>D$)Y.:T-1O] QL9H63NM2OC2I'X8J!3Z*9CM[5ROI^_+\*>&;
MJ03N:9JBF50]QE]J=*=\PIWV.56E1N,WM7OE;T.7]^XR4>5Y/3EUQ*T];1;Y
M.M.D7+Z?LY"=8<RZMJDE/MWD[4^<C&G;QPN%!7+'6O;^.7OE4VRQ7I7OMCM^
MOCECL:5RZ]AOWQK[T0;%^_MWQX&VPV'0=J#&_9D4UH#3?PIN3]V0+5+-9_*E
MS)*8P\"U(9J!H_43U48GH"M?EMGPD_,2!T\Q^:K:2-HB;] Z=2%>5F%>^U?P
MSEMVT"I-R98E<M7<? 2X%" /!!WP1<V\-M8:-9B(6]:7$G)@')8 *#0]3W\!
M7(A>JRV%Z\A!,Z*D8!V578$D4VI2HH<Y/J,*QR&,5 9@!4C<,VW3VQ33[07.
MH7L[U]$T0&G7FX  ^ZGTYZH\@EY-/MW;B(PM(UITC XT ]]R3DVU!XE1O5(4
MNW&AH:TV J=LE/D[RXEW,LDC,@VD]4  N":\:CJ*^(SU?Y>^IV4*1K$$A*@.
MJU(85H3V%1G18TMQ"+J-?5M78 D5#1U(%3]'?)&MQ;:?9&[FN(H[>+DQ::01
MHH%2W*HZ 8.GEM'ABDO4"P2OQ!>M"PV"5 (&YVY,*]!@:_@\KP1R^K<6K1(Q
MCD*GC&&8A54,OPDU(ZL?ED3UO\N]%U>("W2.5. 9P#4+R%5^)Z5K0T-:9R?6
MOR.BE0RZ3>*DZU?TGX.E1N%&]3USE&J?EWY@\NTN+K0BZJP?U50=CLQ->^#;
M+SI+:/'#<J\7%J&,(RA*#=/ U[COG3]$\QQ7D:A5$4,2EOWWV@ #2I)VWZU'
M3)UY>\Q1RS>F&9]Z@,I!([-3Z-LZA9WL;(ZM*KQL?A(-"*]*$^^&:W<2Q@/(
MQX'9A\OGMU[X(%P)*.C?"-Z@_#7O7PKD=U>XHP,4@3I\8-'%?YAW&W7KD!U;
M4'!*!N1('Q*:@U^D'IA7:>6;K4I3+< B%VJJ%BK<3O\ #L?'.B:=HFD:);&6
M011T4UY +0;'<[&OX9PK\R/^<D/)WD:X?2(XKG5]5D4JL=N1&JCL)&<G;V"G
MQVSR/YA_YRK_ #(U35K:QT*\A\KB9GE1+*WYS2B( 5E=R>W7B!MOD/3_ )R3
M_."[9;RU\RWMII$5P$N;^*WA>60\ZHBAD=RIJ*M45KQR46/_ #E3^;/EJS0:
MU?V_F?4KPM=%+ZVBX+)<-R*+-"T+<06H &H/EC]"_P"<IXM5OX;[\Q=*2XUE
M%D6UGTB1/K23.W%Y5 W-0 $2I% 2Q);;T_\ ES^?A\Q0M"=3@U">)ZM!(#!<
M6Z5%4=&/Q%:;N!Q)K3/4=EYAANXX9?5 D8#BM-B2*\C[T[?3ARETEQ4<]QLQ
MZBAV'08VWTZLG#@4E+5XD?LG>I[#K@F_T@/8>C-'S]1:<#O\&YJ*5KXYY;_,
M;\I;2ZAO988T10HD60@,.XH2!7]6>,M:\O:EY3OKJ.:V:YTB^51/9LW$<R05
MDC)(H5)[;[UH17(W/906MQ#/'*;@6KQW<7( RQ*2"O(J22&8?: H?&NV$VKM
M81W,T<<AM[@.QCAA5S,0P)3THR4 J#N*[_ADM\K\S^B[IXI9!#'^] (;C#%(
MP/$@&I8R 5'@32F?2W\N;."[N_*,]O BC0O*]O;L66E*JH'MMX#J*YY9T[3I
M_-'YE><=<@7UTU;S->?5F8T]2*WD4PJ">U8@!3;XJ#/K/Y)T<:8D,896%M%'
M;IP X<4CV(-!78#[Z]\Z0H^UMU/ZO]K&=&4]*.R_\$*_K&*=,NG8Y1I7IMFR
MS_G\\K>OZLO8]!\_IS;[Y1&U/\_?-N ,WMT]LJA(&VPRZ&I'7#K09"EY=#;]
MYIVH+O\ \PDYV^[(7<.)+F=U/+E(S UK6I-#B0Z[]/U9?^UE[?V9A788[M\A
MUS>_\<WRZ>V76A[Y7[51N:4]O''[G?H?GB4Z\HI-S]D[_1A#>QH;.\L2H'UN
M"2O ?9'$@2*.X#$ CPIGP5_-Z*^M/.WG:WO5,%W'J2^JB_9+I.[L>()% *GZ
M<Y5<61;4+:'T44B1Y&7D67X2R@$FGL,*M;6YDU#E-&W[G<\2>)!H%.].A4#"
M"&.:6/ZGO'ZD;-(!2@8,".7@<YSJ\,GZ7"+$\3 ,Y0CN 0M/:E#UQ>WAY);6
MB-S$:^NRU #R)58EKT"K4L37Q]L]6>1[<0:59-R$A=*_"HWH :]MM^F3"XTM
MY%C9=JG:O<5-.HW&=#\JK]0BAC10B"CJH&X)/?.NZ+JZ1\N9X"4_9+$CH:^Z
MG!6K_F3I7EFRDN[_ %06L)C?F  W)$!))0D+2G5JTSQSYU_YR[-W,;#R5IDD
M3LLD#W6HL94*LK1DK"HDY5!J.@IUKG(;[\V/S<U&SMM-\Q^<M6LM)NX#%::;
M9QTDEAIQ7JI(5:"C,U138[8!>;\V=0A^LZKJ.NZC'#%S3UKV9ARY!O5]-I^H
MH.GM3)1:^:_S&\LR632ZCKL#K(@T^Z^LW$D04T5D,<LDRE20"O--CMMG?/(O
M_.3WYC:!J9T[S!:6WF58$6299(1:WT?(FJK\?HL13_)KGM#R=^<_DO\ ,"'A
M:7<#W\:UN+&[?T+J GM+ [+)U&_4>&%'GW\O-/URQN+G2D'K@'TAUC9^K$?"
M2#4^(SRW:W]]H>H2V<]H8;FV<JRLSK(#TJ59CX^^=B\JZHD_IRQ2,&3CR5C1
MJD[DGKW\/?/26D/=R1J9.1AE(X%22=^E2=J9T6QT02QU$<CLPW65:=M^-2M?
MNP-?Z*ULO)6>-*T*N#P^0K0]<A.J6LR!N2EF&U1[]*AJ$?1D#D=+*03,HFD6
MM>0%%)H>N&\?F@0V[W3@Q+!NZQ;\*5JQ+&E/ISRA^<G_ #D1K@670_)4\EO?
M3HR+<Q$/-(K?#\#!:A2?Y:D] 0-\X!^5_P#SC[^8WYRWMYKFH7WU#0"2MWJ%
MU62>9U8,YB=J_P#!*?:N/_Y5WY2L?,OF2._28:+Y0N)-.CE!)]:2!.5PSL#W
MY+2NP'COA?\ EE>>4?.?E[\T-=B'D_R[IOD&RLY(M/UO43;:KK+7TY@5-)L0
MC_6'C**SK5:54]3ACY=\O^5M)\[^5Y[G0)WT'S!>QZ?>6CN5C:*[XH9E IQD
M0N&!3;L=JYU;\]O^<.KSR=:ZEYG\C7+ZOI%M, UL:QS+'(O5S'0D [5%/'?/
M#UG#YBTG5;6Y^NMI=S9S^G&EN@$\0) *A^(IL=ZBGSSZ ?EO^;>J_4M+TGS+
M8'T4M^%MJU9&$Q&RJZ*#Q<;\@2 ?V?;V7Y%U1=0ABNHE)CE)4/QW:G7B/BH*
M>&_OG8K*R]=@44CU/B(-0S5Z%J]!^.&UW:QQPAI9:S)NI7:C"FVV]*9$-2TG
MG:S.-F<,2K?%44VV^6>4?S3\DV]YH[W4<!@EMIU(:(!2.17B: "H!I7[P:]?
M&&HZ48>%N\')BTQT^>&L:2LS<)8@RJ"DG(&L;#B2=UHW$A#82W4,D3Z;%>/&
MKQ1S3P(9(5!;E&KA_A^T.50.FZKTR>^2-$#SQ3-+(\4*N(VF39V2W?>56447
MD  IW.WL,^A>FR-Y9\D^8M31&N+^RMOJ-I' I+/) GU6%444K61*^'4Y"?R%
M_+N1;^35)[;U;/3UCA>5P )KR>0FJE:"HI(6<';H.U/H!I''=U%"4+E:4W9V
M*CMT0J/'QR1** *>P_V\:*^H_@*$#PJ*?PQXZBNV;VI3-X4[]\KK[Y?;-4GK
M^&^;Y$T'?-3P.W7*KT VRZ_(U[U\<JE.I.8=P=@/?* WWZ88Z8P2YE)J1]5N
MUVZU:WE'\<AJFOT[;8\'Z?\ /OFKOM\\V_7KMWQX'?-OOM7+'7<]LP^??[\N
MO?MVS"GSRQTKT[8V7^[:E>WRZC TENER#S)4Q4,3KLR.H/Q*37NWT]]L^.O_
M #F'Y4_0GYMW*^@D*^9+=;M'1>*.)$*2. .E62C"II3WSSAY3T1]7U"S<AS<
MGE$L4*DR%HP9&K3_ "5I7OWR->>+#]'71I;-ZD+RVY$G)3R8].((H=N_?.<6
MD\*W#"->-3Q$A/(&G;N0*[]<@_FUI%OY5C1A)*D<8 ZG933QWP4MGZLT-B@"
M<54W+4 ^R/LJ!U"UZ=SGL7R1IL36MG9,A60Q*$+$@U'9@.IH-\Z8-$]2*:VD
MH)X:[$= 14=1CQ9W%F[K+%(ETR<E )XN -^)_:\>M<*-2\P_HRQEN+VY6TLX
M?WCR3+Q,?B5DY+7PZ?1GBG\T//%[YUU-=%T6X];2(6$LDIW,CBM.<G@!OQZ
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MX&1/OTZ8[Z>O?+%?"AZ9?;YYOD,<#04'3+K7,-S3]>61UVRZ; =:Y9Z;[YF
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MB]:0PDR*SC?BO+=5.]!\7CG==$\O11R7&M3PB>]U%TB21R"ZVX<%8Z]JL.;
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MJ5,MNM0-A501T_KA,=(6)UF]+@:_%W(W(!PR32;=FCE].G)12@V#"M:@&H!
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MQ2TTV>*0\/JE[(#RJ1N%(._;KT^C/1OEZ^9N D X4_=!B*+W#$'N?PSK&F7
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MITBU.BDJER !'*:#;U!L2>X]\\3>7C);WLXD5HWN%96 '>+<4/O3.JZ/=\2
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MJ>YM'709X91NU@8B/VB\JJ"-MJT'^>^3O2E$.FZ<E/B$4:"IKNJA3OMW&'
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M2H4]JD=?<@8J&^=,L"JLM#O7[CA0G*;ZWONY52PV-"  /^!W^G"O48$]8V[
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MI82 :(Y(8J>VQ.WL<@FG7<ME+%=QC]W+LP!Z,/M#KX=,])>4O-<4L<"O+L0
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M?FFY5'8/+;46WB+@%5=E8&A -.1\:81WGEJT@"-)J^IR*2K%>:[EA4  H:5
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MSDMXT:2E68;@CXMZ?(5R%:C:*+AFC%$:A(I6G@1MOD7O=%L+^)K34+".]M)
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MV%#AY' C*338$T IL*],$HXB1> %3V^1Z=<3FG1FIWJ?U=,5MW6OP$"AIX4
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M,+I))28'C[$#;?";4+/T>A^/<@';D!]V$WJ@?Y(- /U]-Z8-L6#S'I0DA@?
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M6OTC)!%;JH/)1&14=14]&XBHZ5KCPQ0HO$E:;;4)'7KOL<MJ7%6C+,:$(5)
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MC#L:LRT[;?1GUB_YQ$_YS:3RS-IOY3_FQ=\_*$OH0^7O,UPY9]-:6)%%E=D
MAK8R1DI(=XR]')3['V/N5/I2A" Q0E2#4$A2R]/'VPJN +A+(H/AADC60-O]
MJ@=:&HWK3"'RK;/#:7-O'=-Z4&J7A1656X1B9BJ*S;_:!(ZY.XD6&*.-5XK&
MH4#Y"@Q[=0>GA_;E [T_5E'QIE]Z#*.W7&U[TV[99S<J=]Z91H/#;-4#[\L4
MWKFJ.AWIBD,4EQ-%!"ADFF<(BKU9V("@?,YZP\O:1'H>CV6FI0O!&#*P_:E;
M=V^\[>V'6;-FS9LV>+OS1\J'RSYFF>WC*:5J_*ZM2!\*$G][$#_DL=A_*1G.
M03TW&*AO'?W'MBBDCY^^*@G<^&+ [^%.E?EB@KL3U\<?7Z3CJ[?1WQX/X[;8
M]3O6F+"OW''J>II_F<4\ >G?'#_/??',E:$&C#H1V_S\,94U D''L*=#_GX8
MMTKW\<0FHJL1^WL?;M7"F!/2EU!:$E)ED ]G4&OW@XM<017D#QNBS13H496
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MSHT1+1:?YNUB.(GJ4^MRLA^RO9O#Y9S72=3GTJ]CNH'*E=F [@]<]/>4?/\
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M\A?^<L?S0_(]X[/0=1_2OE*2=&O-#OU,ML0NSBV9B3"QY?L['J0<^X_Y&_\
M.2OY;?GSIBR>6-1%AYB@C+7N@WC(M["5IR*IR/J(*[,M1GH+E7?K[Y=:T\!F
MJ:5&5R.W?&GKOXYWC\M_*!LHT\P:E%2[G3_0XV&\<;#^\(\6'3P'SSKF;-FS
M9LV;-FS9LV;*9592K ,K"A!W!!['/(_YH_ET_ENY?6=(A+:!>2'G&HVM)'_9
M-!LA)^$]OL^%>0U_M_MQX)((Z]3MBH._T5Q0-L-\4#=*8H"32IQ]>@QP.U:]
M/HKCU8&H![T/B3D3\S^??)WDF![OS9YCL- MHP"TE[.D0WZ;$@[TSP3^:_\
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MV?/[_G,/_GWO^5'_ #E/9WGF2S2+\O\ \X8H:6OFBRA!COBBT2#5K=2HF38
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+-FS9LV;-FS9L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>sny-20231231_g18.jpg
<TEXT>
begin 644 sny-20231231_g18.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
M!2$2,4%1!A-A(G&!%#*1H0<5L4(CP5+1X3,68O D<H+Q)4,T4Y*BLF-SPC5$
M)Y.CLS875&1TP]+B"":#"0H8&82414:DM%;352@:\N/SQ-3D]&5UA96EM<75
MY?5F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I.4E9:7F)
MF:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H " $!   _ /OYFS9LV;-FS9LV;-FS
M9LV;-FS9LV;-FPEUKS)Y=\MP?6O,6OZ;H-M0MZNHW4-JE!U/*9T&V</\P?\
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ML56GL1N/G@=K<-$@Y!I(>5(V%0!X@G^N!H;='-P))VBXT*\@0-Z;==\CEUI
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MAW\/?.?:Q: ,R-&#&[5H10;>*T]NV0W2[VZTK7TA]-Y;&.0S+Z:?9)V:M0&
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M(;W3K&Y0.X:%#\0+$ U&VQKXY%;_ $^ /P$Y83 !A0U&XITPJN=(92T5TX)
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M/'IA[;1(D@$O[R-*,0VQ92-MP0,F5E;0#A<7$"T( W^$<!T.VW3KDQMK!96
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M@+*GJKZP)^#ER5E.VU.N-^LA0T2D%:\00"U-M@=J_?@&T2Y5YG=E%:#B]>(
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MN8GM'T^Z2XA9+<::I$MF:"8K4D!E._ZJYR[SEY+\D7?FN_D\NI*^DHX)?TS
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M;0$H5:0JI(Y"A.VV%WF99T8Q1![:VD)$=N& XQ?LJ2.M.V0VRL_JFMZ*S$L
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M'3)7H6FW#AS-\"CNNYKAEK.BRB,NJ^HP^)7IQ)]CG%M;A>*5F<A'J#2E-QU
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M\L:6^1IC.53TI[Y8VVZ=\NHZ=,PQXQU?HRQOVQW?+Z_V9?AMF\<O^&V>N_\
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M4G92#3KQ';PPWMH4B]2B%%*@4K6K#<<=B#0CZ, W0E9XKA$<>DR+(J <F1V
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MAJM*U'4;?KR/A41'5'+_ %A^4;]21NP-!6G3QR7V NYK=(S(GK\B8F8[@D;
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M=<_6;81L 2C\9'8O7DFZ@;'(;JG.[DU=;)X[J_UNX:>.RAD@N63TJ2,':7@
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MD$I]&X4TVXO]EOIQ*1/@C/$O.(U'QGT)P2=^+CX6^G$>:,\88UF!<_%^YN*
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MA8T6M6=F"KU)&?8+\@?^<-O+/Y=7%CYT_,(P^<OS BXS6Z2?O-/TN0#[4$;
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MT B^0_O 2>QVQDC-;CU75K>"0M(\EL3=6I-"!S1BY7[Z]=C@*=1(5B'"*/\
M=Q[?O+*1B>="N[1MX_PS-3C&DRB( .8[:Y8LK&I!]"<';;?<_3BT0(NH_51V
M>-J!93Z=PBJM:QR4^*A(ZYU#\M_R@_,7\V[IK?R?Y6O]:"MZ,^K,HM(K1V()
M]>[DXQ;+OQJ6/[([9](?RI_YP'\J:*]MK/YL:HOG+5HF25-.T\26=C&4&RS2
MHR2ST(K_ +K'8JPSWUI6DZ7H>GVNDZ+IUMI.F6*".WM+2)(88D'14C0*H'R&
M&&;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV<9_,K_G'_P#*;\V(
M;D></*-M+J-T &U6QK9:A44"EKB#@STIL).2^V> /S+_ .?>/F"RBN[O\K/-
M%MKMFK++%HNL?Z%<U7:GUR(-'*Q_RUB&>*/-GY3?F/\ EQ=Q6OG;R=JFD11S
M"/\ ?P>EI9+[42\4F.7YJYR-:?"XN)+1Y7N>):"2WMOW<*\@0M6"DTWVJ.N]
M<0NDM5ACC%O90-%ZD/":3U90RFH0E785!ZFF>A?^<:'5O,>MN#;DM;PR$V_,
M"CL>H8#O6F?3SRI+6)!V&V=#&XKBJ 'MBJUK3%U7:N7*M4';/G]_SF1<S74O
MDKRU:21_6=1FN+@0/(8O4,2J%^,(].):N>"EBLH;@2WWJ^II;A)5B=5MFE0,
MK.JS!B:\02*@'\,[!^B%T*TM-7NKY]5BU^D=U:/#;PQNEQ&7JQ6,?$K4(*\?
M>IP4BZ=83VHLK1[/4+Z&**&Y$J7'I-,ZCX8YH2K?"-JUH?'?"7S!I7^'+I;"
M34299RD]O<6=J89827])N3)=(Q0K^SR%"/A\,[/_ ,XSZO/I?YG:',AFN[/5
MWN+":[DZ22R(Q;D-BKAE%00U0:\SGU7CHP%-ZXI*H,,E/Y3A!*-A@8G;&XU1
MO[XKX@XF>N.IMA/?KSY+GR6_YSACD7S[Y9,8E:MC(O&/;<.#N:']6>=[2&2T
ML0[G4;,&#B&<"5"2*,"@$=![[X@L;^F3  [1JB";3?@8U-3SA(4'IV ^>%J0
MW-[=*EA')-<S%R&LXC(9"?A59;>A/7P!^G/5/Y;?\X<?GAY^AMFN_+T?D70I
M1$SW&ODQQRJ/B+161Y72M2E*HJG^89]!/RS_ .<&?RD\E"&[\UB?\Q]5C;U
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M&Y'0;81IJ&HV9L]72SN]8ET]9H7MIH[E)(A<_$CJSQ.SJ0A%0-CUI7$/+5[
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(S9LV;-FS_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>sny-20231231_g19.jpg
<TEXT>
begin 644 sny-20231231_g19.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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M5%+V\ =$((H40/(#LRKUSX_?G)_SDW^;GYW3S1>:?,#Z?Y;9^47E[2B]MIJ
M&J^I'R9IF'7E*S$?LT&V>?J'IFI]^9:G^S,?OS 8H -CE'+ R^IRZ>&V9CQ4
ML>@ZXX ;8T,09 5)*'H!O0[],51[>=?2CEC2[0U_>,%612>G)J ,.U3O\\+K
MR_MM.E*7[M:)RIRD6@6OB?XXVYU2SM#$99HS'.G.*19$*2BM*QORH>H_5UP1
M+>V,1MC)=Q1)>+RA>5A$K]C1G(!H00? C'F:VX1.EW!,LI( BE1V!'^2"2?;
M*ED6-)'D/!8164BI,:]#R\/IP!<ZYHMNRK'JEO+(:5A+@,/DVRG[\N+6M,G5
MB+Z .A(*,ZJU1VH3@RWNH[CBT'[V-@?B!'4;TI7[L7+U"LHY UKX[=J>..#!
M@&7=3T(QK'*J<L$C*K].43TH,H5IOETQI!RJ5^G&XXC;]6-(_#&#)EY'_,/S
MQ^6NLQ^8/(GF>_\ +&K)Q#2V4G%9E4U$<\3<HY4KOQ=67VSZA_DI_P _'[*Z
M:UT+\\=%73I*",>9M%B=X2=ARN[$<W7;<M$6WZ1*,^GGESS-Y=\X:/9^8/*N
MMV7F'1+]>5O>Z?,D\+TV(#H2*@[$'<'8T.'F;-FS9LV;-FS9LV;-FS9LV;-F
MS9LV;-FS9LYC^:7YP_E]^3>@G7_/NOQ:7#)R%I9I^]O;V114QVUNIY.=Q4[*
MM1R91OGQD_/S_G.'\Q_S8:]T#RC)-^7OD2;E$;:SEIJ-[&:C_2[I.)564[Q1
MT7<JS2#?/$(&-.YV[=LL#;,-SCMA3&D^U,P../3*H>N/ITVS $F@&*-$P4L'
MB)H2!Z@'3OO3*O#"MVT=L)5@95*+<H%D(*CD:J>!%2:$'IBL5G(%B<Q-;QW+
MK%"T]8N<C;A*DA02.A.Q\<#6UJ+Z_:.*_FM[.8KQN_2=HN=>'&01EBIJ/'%;
MBQ\JV-S+-J5S9:I,Y*T>^FMB* <@/50)L>E0/GMB-O=Z;9))/%'J=QIDA81V
MUSZ-U;RQEJ<5:B1Q@] 0:UZX8P>8M$0"QGM=&TJ&5>9,3VT%RK <2/4?@Y;A
MUXD!P #7"C4?-7ENVL1I]I<>7K_A65HM1LH6]4&AJQ,LB@4._%@W@/"%6]Q;
M:Y<-IFF6>CZ?/%(LD#0W,2B0J.3^F#<.R**4 YFO\N(2Z=K,%]/!JVHV5F3'
MZC)!=2Q+$01LX2,U2AW^*G?(SJUAK[)-]033;F2,EB/JJFX!:IXTXS<TH!W^
MG(A8:1KEQ<3MJ-E:O'>,J1WL,WU189R.4/QE0(B:4_>H%/1F78X<Z7?ZAHL6
MI2OK,ME?6\JQ(74-&9%J&2Y@ZA6%*2+45Z'?)9I?YBPZE!>S/;A+S2UB-Q!
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MCM]&K<#+&4$)Y I0[]=NF$4RGUO3 #1N&-7'RVJ??K7"N>$! 0M>'Q$@?$5
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M]_G7.@: SF0SD4'$T%-S2@4]>FV=%TWDX?X:LNQ<'<*:DT^D4P]A>/U%B(+
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ME],NN_7'"G3,=\U/HS5Z#'#*)QO3KB@(/SRZT%.V-J.YRB?#KG0_RE_,"_\
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MB/?:7YU\RS)&[7.K6FFQ2S**,+:W:>8*3T/.Y%<]B:C:06S+:MQ6&4\(TI\
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M1?ZTKG+?S+MHYUNI[R8I9W\,>CQA11$^L55S)\/V69AO38T.>5/R_P!*N?\
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M**'D68?O-A(P!')MUK78TSY)?F/<GS#^?=]87#&6"7S6T;AR&I:VDO(J0?\
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M]::<L2.3. >.XV V';)[IFAW+*AND=;&",\YW"JBJ-U+U!533>A.V<\\Z_\
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M'JLQ0&O'U+N9J5VK2N0H8_85RUH>N;:OCE$[>^4&IMVRSOC>F:I^9QIV]CE
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M"@.$+'U [T]/BH/I"O)JUI3/DYYCN=>\@:PVM:%K-M8W(JR0N6:4Q@<PDH'
MUH>IH!^OL6@?\Y6SW5@MKYD>>RN+#@AN"K&,N0#17 KTH2".F#?^AE+<7+C]
M/FX]9.2B2*1@JM4#<IWKWPD\R?G#JWFR"WT33KV?TI9$CDFE5HXT#D)1*[DU
M(%:;9S6]T W-A.]QI[:9>V<WHB4-R43CDRDFC%5?AQ#_ &0QWV)R6:+?W>D6
MEMH^F6MM<PM)'<S/$3R,<L<"VUH%9BG+DYY $49@5I3;U?\ DAYNTV#7M'T[
M5-;G-O+:7XM9G0MZR112S^E\='#,IE1EJ>1%$<?9/K'0/S8T^6:\T&_BM %D
M%O=7$<C%3:24M(GMQ$004:)0RL0>:5^U2H77/..A:AY9UI9E2>:UN66TN7'J
MP(P9(UDC4G['JJQ(Y;J?AZL#P";S?KWY7ZO<ZC!*VJ>4(!#=7,$19KBT,DWH
MS!2_Q%ED=2T9W .W[-?:GDK\QK'S7IUK<:==(Y8UYNQ8 CJI4\>+#I38YT*X
MN(Q!,SD"41T9 6=E4_%6O(]>HPDO9VBCAC'[R4*?WU KMQJ%'$_/Q-37.>W5
MVDML]NC>I(CDA:%>0C8 T0&NQ/\ F,'W\JR62<2%'#=7^*BD5(-![&I&>8?/
M5U#]=DTV;3_4BDC=Y5;BGK($?]VS"M&( *MU/PJ#OGC[5H](U*^UO4[>)[AW
ML8;-[9F4SF"0&!;Y)U4,[Q)S4@BKCX&^QB%CYXU'ROJWF;3K%;>/4=2MUBF:
M%?@6,F*6*6E31^+  5^?3(>6+,S,Q=F8LQ.Y))J23FK7WQP;+#4[XZN;E[XX
M-6F.!KU[XI44]JYABR]?XXK\]L=3Z,47PS'M3K[XH !0GMCE([G[\?4=NN/#
M>VV-K0_+' @X[,3DD\H3Q6^K7<DS<$;1=<C!\6DTJ\11MXLP&!1FK]^422<L
M"O;,-L<36G;&DUQ/ET'WY8)&6&.8''5IFKE<J4[8ZM<;[XW??&,>V-_6,U:'
M*Y8TG)%ILMTWE[S596@:6>[M J1$J%5E/))$J:\^051VH=\@WDF*+R]Y@U;2
M?JY@OII;1M0]2BN[B)F*4I5N",.5"-SWSTUY"AK>)#&Y,1F:G'[+U!ZCW'09
MZ0BA6#3HY8:/Z"ANAJA)!!IVI7QR1Z=+]8DAB<O'ZREJ<=RK[-6NV==T#@$B
M@/PQD@J"?A8 #M[9T*&:"C<T$7$J!QH0WAMR&^WB,Y-^8OFN+0K.>:[(@4J5
M+49RM-^4@!8 G:A;Y;9Y?T;\Q"5F;2(WN[_4I?K%TCA5$-H$8F3=0313Q10?
MB<TI4@'SA^9?Y@WVL7%Q+J%_:6ML+&"U;3M.*3&3U8W(!D(9&>-: E034T7I
MGD34]%;4[:74!#-K!LI3=36<+(DUU$@EXS6ZL&=GCA3DS2*3QY,NX($*T_R?
M)J$.GZOJ*1PZ0 MU';P*S))]:GXJR*W)VJ*49JEJ,WQ9*=,_+;5)[+5/,E\I
MCDACN L9'QH(4!^-6H%)5T(KV/T9UKRUY%T^^M]*F]=8[>ZU2>"YD<BL-K;P
M>BLKA.3*H:,OL.Q]\'KINISP-I-]'%9ZUK.F7,]G._'T3(S#C .!J$DC^&(J
M>GQ&NY'+-2U"_NIX?*5K'!I7K3VMU->>L_*)]/)D>7T05"A)6:@[+\%/A!PR
MMM9DUR'S$"# FH2+?0F']RT$Z1&4QB(&BM.\B!0C?$?M+7BV'DWYI:C/-87=
M[<Q3WEQ=B]EU&/G$)9)0S3<H/@Y-\ 4H]:\0VY.='M?S$ETV6ZB8?5(1<6-W
M9R-(9K:^L[N.XCE>"1Q('C:0B@854AXW^-"<;<Z[=:KJ4"ZU'*)M;BCD$:5Y
MF- CPM%R'/DYD+=:@; K0')!Y7\P:OY-\Q:=K?E^[8Z/J;)%?V*S@K%=W4C/
M:ARY'[UAR1BU.3(0=QGTD\A^:H=>LUEE0+)(BK,')22+CU#QL %(Y;[_ "PR
MUJYDM;NW'*&\@NR(:N:"C!FKR&S$T%!U^GK$KA-/74;N:&U+7:*\I J&E9D7
MBU-RX9.WCM3!TUPC64,RRA[4Q2S<HJD\#6O'D =B!L!4';QSS;^86G:?J=U<
MQ2<+Z^BL4 'J1J667C03%PN[T"J?$#N,\5ZIJ^E>5/S!U/1= M)-3%I/*5N-
M1N9"KM<1I+.5XB%!7F%90W'D!(#L3D6U"\637!:P7(O+=+2.2"Z2(11SV[@>
MC\ 'PNBIZ4@J:,AWWP1OXXX$_1FKCP13-R(^6:N*@[8\=>N*"G?KCATQ0'^S
M%@VPKCE.YQP)\,=X$]L<3M[XX"AWWKCA7'BOTY=*XX"G;;'?KQI.&NBG_2YO
M^8#4/^H2?%R/#-VR\H'+_AE'&'?*->^8''?AF_#,/?-7Z,QW&8'?-R^[-7K[
M8P[G&$T-,K*Z;5RF_'#/1KV6SNR4:-1,A5O5KQ'<&HW%*5J.^<]O]7-YYTCN
MK1989V6</9R-4(8Y2B,TA()X(_Q%O#VSTWY$NUDEMA!<J9(U#N4)82*"M3VW
M-=J;5VSU-ZLC6'J1\E4! 5;8CHQJ#7PWP[TB<$R+4FYX")B]:54U # =#RVS
MJ>E7LT<JP.K2B5"RN*$*U=^0-#VZ=\FLE_'-;"[-UP3B"K*H^&O:K'OTSP!_
MSD+^94,-U'HUM=2*9)?](] *S",U ^$M3OR/@!4YYE\S>=+WR=Y9@T_3XXX[
MS5+XSM GPW,PB82BX9BO-(D^%$0BKMRV6F_#I7OKF7ZP;*XAM)KO4+6-&;ZN
MTEU^ZX06[,6)WH&;H&4]*!09>6K&Y\P)Y<T^QL$2]T]XI-8:56"N+:%;-@U*
M*$41ABG+X?B=M]LZ3J7E:>R\MI;7,4\WF2[U1O1/*/T[.TAM;>03,ZL8O6,%
MW&\:U 45;[0*YUO4+/RYI/DZ.QU:+36O;H7'.XL93<&&>YAFG4R*Q+%8K2.(
MT)8$R*5/P#"_R[:V^DZ1HEA;2!XM/U5;&[OR5B>>YNG2X=[?U0*<;=Z$R*#0
MC85^,\UR'2O-UKK">8+M+">]LUM=-N'5YA;):,9H6F$*"059F02JOPDK5>%#
MG&OS)\J'5M5UYO+UV/T=>7;B9'82LER!$)9ZJK54&(S%*T-2[**#."^9=)D,
M::AI%E/8Q6<]M ^F.=K>6R2".&0LA"-+)0L>'VD;;HU+TS1VU&74/JRVUK-=
MV4L]G>11HO)[6/ZP\3<@6^.-"BL0"I&Q[84"55T*XLGE>>/1K_U8B'=PB3B%
MW 4&A52KD4/SVST$NLSZE_ANXC4)JX]+5(+EBK0/ ;<"$1UY<-R 5WJ3QWVP
M=>^<I]/U.\$UG:IIGFOA;S3(L<4K>C'!(KB54Y53F\(/6H4C<4SVO^3&OZ=Y
MCTR2.YNKJ#S%ID@M.$R11S"1#&54!)*LO&1590#R!Y =E]'ZUIEO.;>).,T<
M%(R0.4?&'X@GPB3I0%&Z,*CVR*W4,5G>Q*MLOU^W],4:3X>!Y,%#&E:<:#O2
M@P-J6L3IIMU_HX$ZW $*SJR2D2%0Y2IH0>5>8\1G ?.\-O\ I 76IB:$3P-%
M6):1/5QP69/A^+8$;_USP3KB?Z=#K,%]#)J-NVII90WE8'D%JDL-QZ?*BDD?
M%0L*&(;$O3()H=CJ5E)>P?59;>TGO%F"2DDPD1CU/3-2K1NS$!@3Q(XGL<F2
MD A!VVH!0*!T&//3IE5S5/7+KC@>]<>&^[%%/;% >V*#'C%E-,L5K\\>O3WQ
M3MCE^_%",>/#Q&*4H <JN^5TWR]_EFH<D/E>T%WJ5U"7*!-(UB>H%?[C3;N6
MGT\*8O?VHL]0OK-6+I:7$L(9NI$;E03\Z8&_AC#48W]674],WSS=_GE$5QM-
M\OI]&6*?=F_KE8W+&8GWR@<::XS^&;IE'J/#VRJUQR-$DD<DX)@1P7530L/"
MON<)==MX+76M6]*.!;"[>&]F8(\CII[!(9'>5V<L>6YXA12M?'.H_ESJ;)/!
M#*Z-?FV24M]GU.87BM"VP 9?U4KGLNQF>333ZE"DO!Y.9!( "?" >M>1V/AA
MQ8730W$E7]1IBCJE*?"!QHU=@?AK_M9TW2YEO8S%.3#*9 M(V()B8$5(%#0[
MFOAB/G[S/:^5] U*^OY$AM;&%?W@Y;A@0$44'\H 'OGR1U?S//K_ )SU2[U1
M9(3<.+%9)W3G!)(Q(X 4%2SJ"#V%",)XUOM3U&_OQ \QM;>\5#.B31VX@IZ<
M[**-1I1OL?BIL0Q&7J_F;3Y=3U+0=.TF.[3S#$NL3ZC(]Q(8N,$TKF*&6I8S
M/+*J  ;,#2JTP^U>_P!2_+U-&O8UM-9-EH,&KJ[(9[">;5&*.LRJ"+E*JBL7
M/$D<#\)KDTOM7T_S#K>C6.F5%KJ&E7.KM:7!1U_2EY%$TJR2*SJ4AGC1T1ZD
MJK*PJ=P<-IK.JZYYEUE.>IPW5ZMU*SQ2&)S96RV4G$,0P5@ L=" I8[;8+\L
M:I9:?=.=274[>&;4%34-/DM_51XYW2%[^SYJ\1=!&(I8V 65 K \B5R8>8M&
MTGS1J&H?X=UCZKJ,7UV[M;AS+"TG&4^A$$D"/'2VE(#,33AQ8D<&SFOFFS\W
MVINXGA^KVVI1PW5PC-56O%#(M[$ H*GTV^,5/([4IOG+Q>:M<:3KC3!7O)XT
MN)XI27Y7<<;*EW"BA0'C#.*5H0QI0X%MH;[2KTW5@3H]UID O%N8F7U5F@DB
MN86C%'3D#52">)%.5*$9S?6KRV%W?Q6=_P#Z9=3&X$AC3T+H1HS*ZI&3&'Y5
MV I0\0 *#.D^6Q/-:Z!HNG,G^(=+F>RMGEF#6ZO(J7UM#"XW D)*_#]EN(KL
M*,\Q-I<=W:W5U82VL+F.0Q<@6$\$=N4D4H 0S/*0X)!!^+L,]#_DCJFMOJ%S
MKBWK6[MJ32_7"K>G)<PVIN#"P/Q,\@130'X*\C05SZ1:/?MJ^CCS)"YO9-:L
M;/4)?20((Y'4>J* T^&NU33C3Z"'5G>?4>,"E9H)HHRY7A7ENZ@-N H;:O7
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M9Z>\@006H D8<BP1I&!W"TKMGL'RM_SC]Y-:#3'6Q9Y*AI9I+F1G9?AXL6#
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MNC\0S;'FI:E"QF%W:6MQ<:F-3M;8VWEG5KE;E(HA [K(DB3^F#0QDM(U/3-
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M7EW_  Q_S[[U&P,?![W\JO,>KMM0M^E;&_OU)KN?AN!3V]L[%_SE?Y:/FO\
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M0Q_HV)KZ.*1O@>#[3! ?VDY5X].);KQPW]"]O/J5O>'ZX($D+1PTD+L?1$2
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MQZMBRG\<4!Q9&Q='Z8N'Z;XJK>.*AP*CQQXDH*=\<'RP=\64CQZX\?V8ZN*
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M<A\)N(2L-DH/\PN)DD'LAS]!.;-FSY)?\_*/RT]&^\D?FS8P4COD;RWJSJ*
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M(9;MZ(B@FK;5"CWV[]Y=U#3+J]O;S1[%I-)TZ*TMFNF+0PW)M7$D*Q6[B2<
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M(+_#O0@T-/HZ8"-4DB/J&(HW+DH^) :4-=M]LZ'H'G>2$BSUDM-"M!'=J/B
M.P]0=Q[YU"&:.>-)H9%EBD%5=#52/8X(#=/PQ8/3%A)MF5M]]AB]?NSZF?\
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MSG/YD:\+2QBT;3^4=YK#E)&'PLMNOVR!_E':O? /E:W-E:1M XMP$V8@G?Q
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MN+@<2:@U!"G\1@62UD5B'B9)"*49MF\"I'8UZUP.\8=F,S^FK+52NY# 4J5
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M8)5QS9F )%**:]:]R,8:U95 (Y4J_2O4]-J^!KB3K)(72.0KS4@ ;DUH2:U
M[=<XKY]DDN_,UKI\;"26PLTY[5XF5B33IX;8MIUC]7@'"-7DVJ6W-3\J=?QP
MZ8JB?$*2_:?;J#X'I6NV%US?%OA1'+?9$8/6A'VAUW\1@..R>0F252]&/$%J
MJ#W&^U0.^&T5@D2!45>9;BR[FM!T[4/A@CT5% B ,=@   HZJ/A-2:]<<5%>
M"QNP8?S"@-?BKT[#*%JK%456"QG8$<E)I0  _+;?&.E24 8F0_$S?M'IM7Y[
M^.!7A:-(XXT)D6H9&(;Y_+??,L$AJ6'[UJ*HI7B34]*>!Q.ZL+>[#?6)@TS
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M!4DFE32GW^V37TB%"QJP"4HG'<G>@\,WI>H_(@AGW2M %!Z4I[C!MM8UX\G
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MZ@K706T( G,9-I<1/0(PHO.04K2NW7?H?'/,'FFR\R'7)H/,DSW4Z,1%*IK
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M"IZ;.!0@?RUZ[_J.2?RAYGU[\MO-&D>=_*TB_I/1R>5O(2(;ZW.T]I/0_9D
MV/[+!6[9]A_)7G;0/S$\IZ-YR\N2F;1]<A]41R;20S E9K>8 [21R HX\?;)
M))$KF256;B?BD8U;CO3D&(H.H & MY?4/!HT.R%NY'2OOB$X8"BH'5SP &_)
MNPSY"_\ .6GYK#SUY[_PSI-T6\J^19);.*C?N[S4S\-W,*=0E/23Y,?VL\@&
M2K>K0AQRV-?C->I6M13?OOVZX^U0QLC.0/BZ,2*$#KVW_P Z8NZ<5Y1JQEDK
MS!'6H!I3L:^&/,C%PBGXV56VJ":=B/G_ )[8J%*&D?+@M Q VY=B/N^6"56C
M$T%*"A!IOTV\1_',&:W+.QV<UZ[U[5 %.VX^6!9G,,;E2LMQ<)5F/Q#XM@:T
MV_AD=U#2;'4+6'3;FDI5#)'*!\<,E:5!]Z;]J#QSG5SI,NGRIIC -/-\;SJ1
MQ,8Z%#X5R26<)BC18QZ4(2@KX#=JGWPWMUD1PPK7CR *_#Q%.NQZG#&WMI7*
MDB3A0%M@"2:[;U&V&\:JTG,HX4&I"@E1N/#I08,B?AZBE_B)]/9:[*:L!6E/
MOVQ)IU+_ !,G+9M@#\1^9KO@2>Y2!I/A61WW-3N":FJ^'T9'[^_$,8N 5Y-4
M(:[<2*[BM>^09VN-:N L(X6T6U1U(KUW)->^373=-ALXZD(%6M00">GVMS3O
MUZ[X?QP$DR%$$8)XD@5\ S4]]A[X*BC9WX@%7*@5 !^\&G3YXR^FMX%B+S*A
M*D>DF[]A7B:T^9V_A[4_YPR_YQ'UW_G(GS-%YB\P:?<:'^3V@7 &JZCS,4^I
MS1K4:?9$ ^(]5P:(O0B0KGZ/](TC2] TO3]$T2P@TK2-)MX[2SL[9!'#!!$H
M2..-%  50* 88YLV;-FS9LV;-FS9LV;-A#YI\K>7O.WE[6/*?FS1[;7_ "YK
M]L]I?V%VG.&>%^H(V(((!5@05(#*00#GYL_^<R?^<,_,?_.-^NOY@\O+/K_Y
M0:Y=<--U-_CGTZ:3DRV%]Q ^( 'TY*<9!X/5<\/1+4N6-$'3V]LS<F(#; F@
MH=P/'%*E%X+7?H.M?>F-50#4#XFW%/;KE@$ D'DK=":5P*6*'BP#'KX;'^F!
MY2!$P4\.7P4ZT'M@&/D[-2I2M%!WZ8.])';TU'($CV/OE\49F-!L:?,=!WRF
M:E=D)(.W3[J8&E*A3\(8@4% 17M7"N4 !54'XCT]P,(+L\J"M2!T\#XX41"L
MO&H(=A4TVSJ6FHBVR"G$CI3Y?=OC[BV^NZYHEGPH6N(V(%/$5K3YY]G-(*Z9
M;R7#I5=-@+H@!):9U58D%:=6H/ISX]_G5^9^HZM^=VJ:QI]R\MEY#E32K)U8
M_$UO*6O74^,DS.:^P\,ZM^=/DRW\^>3=#_.#RU&L\T\7#5XX5%/7"AY&%/\
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M=4%5C0@_ -NF]1^&V3K3]-AMXXD$'[QE -3N?:@Z9(HX8D1$;D"YK)6A!(W
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MN*\?K<ZFK#WC1N_[1R6!&2.,-3@%9B/AK0 *!L#M3&MR]-"5Y$J#1*@UK4;
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M^\E_F?Y:OO*'GWRY9^9_+VHK26TO$Y!6 (62)Q1XY%K\+H0R]B,^('_.2O\
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M"B4 @L?G4UZ@]M\$1R>GQ H)%W4B@J.A8[>/>F(35!9Y%*R,01R%/'[6_?\
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M=;E'4^%<*Y_^<<O^?:,L;QC\Q?)]O(2?WJ?F# 75]JGX]1=2?F#A:G_.,?\
MS[?#$Q_G#Y=Y5[>?M-.__21UP?9?\XV?\^W+5Y&E_-#ROJ!84I<>?[0!>M2!
M#>Q;GWKAK:?\X_?\^S[:<22^<O(]]\'PQS_F%04VH08]7C;\:8?V?Y1?\^R=
M.^KB/5ORLD]%R\7UOSNEU4UJ:_6-9DY#V-1DYTS0O^?=>DJHM)_R*E5.5/KF
MHZ#>_:ZU^M7$U?IZ9Z \H?\ 0O\ RC_P%_RKWG4\/T!^BJU^"M/JO?[/X9V+
=-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>sny-20231231_g2.jpg
<TEXT>
begin 644 sny-20231231_g2.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(                  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M P,# P,# P,#_\  $0@&%PQO P$1  (1 0,1 ?_$ 20  0 " @,! 0$!
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M6A.LSRZ+'J>R L2]GWYF>VAS3-[_ !>2-@C0A6-;HD1N*,0K!.(+O>UJ#/-
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MZJVA:<@-5;0HU)J(U2C$(H1A)0Q O:X@!OTAL&V4VKB71N0.:<)@"'%$E7$
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M%O362D<9EG>!/ABU.E,L%0$;<6 !GL &.WU5!!G_ &U;BR_R![__ ,5FNO\
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MT'BE<.O\[!QN_P MW6;_ #O1.@]M>@4"@4"@4"@4"@4"@4'CQ^IF_GQ=[_\
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MI3B&7=SN"XANZ-_0J&(L81 L!)(5 AV%U VL'K T'CQ^IF_GQ=[_ /&+"O\
MV:,,4'JP\?G^@7I'_)$UL_S-0N@J:]51_,=;;?XQ:W_]I?$M!JT>B6_T]-LO
MY(@_\\N-*#TMZ#RP/60?SN3#_)$PS^['+5!:7Z?3TSVI><-;,+;^;K.*W/@L
MNM2V78XUY0JG2,XJC+.AD+JSMR_)*YN.;Y3D.1''L@5%F\M0WL1 #!IU1#J
M5A@#>RQCB3%.$HFC@6&<98]Q'!F\0!H(7C&%QN Q-",M&D;P"1QR*MK2SIA
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M^U@T;PU!LL;88G@V>MU):T-DGE:K(S*SSF%8)7+R0+D\!QK&W9.X1H,@C #
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M+'<HQN%9LC&.6-OB$%R='LCFKDJ"9*(@RD)6!NR(QS$M/VZU$F2FO"9T5&N
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M\9B<=6)9P#&,;V8B\3;8R[IG$U8+("#%##'X\<W+F] KM<YW+'828DX-A=F
M=K!@#@E_GA.._P#E,P3^NJJ#VDZ#R_O57\2&:\$;C9*W_P 90203'5[8Y6V3
M"?2B.-BEU389R\- A99:W3L+>0:8Q1N;N*(MV;7=5U$ARYQ/0W&$THFQX10X
MY/5#\AO'YC&*X%7(\<[.X,A""S-"HSF1/(2)Q XXC;QI62)PS),9>$"TJ+LR
MBQ78)'E"]V2HB^YHQ)" DV)#9/P;ZVO3Z4GMR78C3S8+#1BP1A"MPQA+H'G=
ME:3S'9*E1*5I[Z'!SV>T 9S#5:PQ,W'JR#"K$$)577[2P;,VC7*!HOR.QQ6^
M:BY_BF2G5F:DKO+,>*2W*)Y5A*50:4D,-E&.94C:)2D;DSF;W3Q(E.H:%"CH
MLF5G@&6,83F?7=-'V-Y?EM^A&R-3B[J[]:P>A,VHSEI]^M>U[!Z"B;^S_P %
M!X2<6V#F$;V;CFU:]JC,ZG[!G=HV#6LD[1.+G#9C,&O("?(ZEJF3<S.L?=G"
M,R%Z(N2XDI%R%0:E.,"4>2.X3 AM#?[:MRF_Y ] /XK-BO\ V:J@?[:MRF_Y
M ] /XK-BO_9JJ"*N[GJE]_\ ??5K+FHV9,,Z9L6-<S-3&T2=XQYCO-39-&\F
M/2V/S1N4Q]PE6PDQ8$BT#S&D_2-0VJK6+ZW5L$?5&$);^BF<5I7)[L,TEJ3
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M.-W^6[K-_G>B=![:] H-;WU8?\R;L/\ PB:\?YZH;0:UGHC?],C<S^3-&O\
M.FQT'I*T"@A-OMR$:N<;&"7/8#:B>>5HN4INTQ6+LJ8EZR)DR5#)$>EAV.8H
M)6B,?WY06&XS!F')F] 182A<I2I@#."&A+MCZTK<Z>/;DUZ?X"P[K]!@K5 &
MR0Y,*=,RY46(B@E%(E9H@KHICQA,67L:<>CNT._8W&64!6.Q0S5 5;)^>CU
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M3%.,L4L))*=CQCCV%X]94Z8( )R&F%QMMC;<20 !*< "2D;: (+6+!:P;6Z
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M#>9DB$Q%%=D<"8\R<F;>TZQR2/YAQXT2HE#VII=[",(;9%8OK"![-[=-[?\
M!0>*A@"0+M'^0W"DIR&D$4Y:@[G8WD$Y0#*.*&6NP!G!F<9,D$1<LU06("B)
M'@N#J"':_L=%[^Q0>XVU.C:^-C<],RY(Z-#P@1NC4YH#RU2%Q;7!.6K0KD:D
MD0RE"16E."868&]PC *U[7Z+T'WT"@4"@4"@4"@4"@IR]02],#!PR\@JZ2C2
M%MQ^#ALJ82P8"R;O\DF$5CL4  1GU-U9DI=482 _U0C[@M;V;VH/.R]*PVOZ
M_G&U&5,Q*LUN98_LBY2L:>P[DIV W6;+K.F.7W#:X0I!2EV;2[7%T![<9=OS
M;VM</7:H% H%!Y,7JUW5Y<.:7,B1S-4&(F+$6O[5'0'A,L40S'8V:WL\I'<?
MU(D]Y \KAWN#ZGMACM_56O0;UWIBI5%I/PBZ5E1@])<4709EBLC0IQEW.:Y2
M@S]E%:Z$+RB[WN0K<BW(IQM870(9"TLS\P=J"^^@UG>?CT_&/N4B'+,^8()C
M^-MZX-'[IVJ0'%IVR,["1]F0B U8YR>K#<DM#)$)9($[!)C.N-$5U4*ZQJ"R
M8QM#R^9W)]H\ QC+&CN17?)N-(FAR\V2C+6NTF-7M36WYCQXWO470OKM%UEN
MS0R) U/)R<P\BP KR )1&W/"F1B*#U$?2C:TXUP/Q*XYG<.F$0G<RV6F<IS'
ME-YB3DD> 1I^ZZ:'L&+W58G4'&I'J!Q:.)?$4!P"1H7A<M!U+VO8TT-E>@4"
M@4%(OJ/OYDW?C^#N"?YZL94&A+Z2'^>@Q/\ P,Y]_<"JH/64H-,_U0O!!]UC
M"W[D+U+B';[.XUCI)F=<=1]%_9F>\91I (L$K9D*,D1CGEW'C2G  )?1V[XP
MD=V (:I"@3*0U>_3S\Y,FXM,W Q'F5U<WW1W-<D27R4SA+4NBW#DN5$EMB+,
MT*0%"$=<DH!9!$E;R B&XM9(3BBS%B-,6:'K,1F31V:QN/S&'OK1*8E+6-ID
MT6DT?<4CPP2..OR!.ZLCZR.R T]"Z-#NV*BE"9228,D\DP(P"N$5KT%(?J6<
M3N>7N%'=MH9$IBIXAT9QWEA. L%S.R;,5Y?@$WEZHP 0"'V::#,[F.XK7#8'
M1UA7ZH16N&C'Z0[.L<PWR_LD6D:I(A^Z+UYRY@IB5+#@IR;2.[G!\R-:4!@P
MW+NK=;X=&C(!<0;FGJ  #>XQ! (/5TH% H%!YM'K<,3.S1N7IQG0Q*=9CR#K
M(^XF1+;A%W<QVP[E22S!S2A'VH@6.)1YS2#O;J!O<)EOJA?F #8 ](%FQAR3
MQ$,>,T2],.0:[9WS! 7UJZQ(%R5),WLG,;(YF)PBN>-N<[9$4DD*!AL$PY$H
M*#>]R!= ;2] H/$HX=?YV#C=_ENZS?YWHG0>VO0>?#ZY/_ULXU?\7=L?\):[
M4%LOHW_YHU^_E=YF_<=B6@VN:#"&>M:=>MI84HQULAA/%V<82H+5@#'<HPB/
MS-"WG+20DFN+)=\0+#V!Y+L6 9*Y"-.M3FE@,*- 8  @A0=G7TE7#;F14Z+X
MMC+,6N;@[&!4J%&"LS/H4J=<-X5.RY6UL.8T.88RSEN!:JR.Z-*B);DJ,H 4
MB=,.US+AJO<N/I0LG:#X$R)MCKGL"3L'AS%C8CD61H+-(B1!\JPZ)EA1H7R4
MMCHUO+K%I^V-"XP2U66$AD5(V\=[ *6"3C-,#E?1Z[\Y0Q7O>/0UTDSF[8-V
M@B60GZ.PI:J5*6V(YHQI#'#(=I='2##AI6<4BQ]#G9"[ *+!X@,E ,P72D+M
M</3*E_\ ZIRC_%U[_P &J:#Q2N'7^=@XW?Y;NLW^=Z)T'MKT"@UO?5A_S)NP
M_P#")KQ_GJAM!K6>B-_TR-S/Y,T:_P Z;'0>DK0*#RA/5M[32S.?+1.<+*W=
M:=CW4B!P#&D+9+GEB:4T@G$+C.5<AR!*F)O<('5U=)6D;59H_P!-,*8TX+]
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M&8YRU987B/9$AT=;2U\EGNO:Y8?(U*MJ3DE#=7AUQ'(35CDG;R.L(UN>'0P
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MQQ11;L/-YY'7Z"NV=IM'9%%,1QE'*&I:P+3()$W4MCR#D65)+JQA)$K1M#,
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M<MC2X!)$0DR+GF 8@E!=CT21P!9;!\M/,)FC:()"X 1V4MY5RSPF$CL$XHT
M J)Y&?5E<?NKL+D4>U%D23<[8(Y --&DL22O2'!<9=52<8DCO.,DJT[47)6Q
MON(!HT$9NO.5BMW8Q6@$(1Y(:G^HW")R0\\$8VLY'\LY$+B<OGWB,EP_)<JL
MRE&5L_E%&>E2&QN-7).0DP7$,5C;1X&A>0)SFQ&J C0(R#$Z-<)$$5>+OE$V
M^X%MOIICW(4+F8<;AF88CMAJ?+A&-"^R]H, @/EL2(7CN@C^48^@N$QO<"Q=
MP>T'9D'F&)3$RE.'K):K;4X*W3P5 ]CM<9XV9#Q5D-L"O9GE +LEK<M*Z"G:
M,R9I-OWZ.RV.KNLF<6Y2$"A*H!<(K7M<(A!(:@4"@I%]1]_,F[\?P=P3_/5C
M*@T)?20_ST&)_P"!G/O[@55!ZRE H/-W]4KP/AP))91R4:A0OL,'39Y X;.X
MPC2$L"'#\Z?5A:>^5HVVI"P61XWGCRI!9V3@#<#,^*>U+Z$2P)2 /@]+MSU#
MUWDT5XW]P)B$& 9L^%M>M&49$MN$G"T[D;F*]L8R5P4WN6GQ9.7E?<;>K,&
MN/NYPK&WN@6"-;@]&;(D!B65L?SG%T^9DDC@N28=)H#-(\O+":A?8E,65;'9
M&S+"AA$ U(Z,[B<08&]KV$ =[7M0>,ER(Z,;,\+>^QL. XS&++,>SY)E74_8
M! 39 *;12.2(AY@.0(\ZIBKM@9;&U1"8EY1 M>[>ZDC+$7<@9(S0WMN,7U:N
MDFP^.8G"=[Y$7JALBULI*"42=S87IPP%DAW;D72JD45E# D>E./E+T!*:J-:
MI 2D1HS1A2I7%>8,L-PO0=N8#BD96-7(5G)+HR<@1(N_G)VG:7"S^^#(N$(N
MS21ABF3C)5ZWH%;^QB$ABCIZ;=3IM>U@H^WL]7_QYZ^-;Q'-2&J6[I95).=F
MM*M9V]ZQ?A%D<6ZXT8E;Q/IFR)I)*$G?Q6,2VCS(X-[FG),$!S3@&G-."U#@
MCW8S=R&<<^/=KMA%4;.R3D;)6<BE2&'L),;BT?88[E:4,,7C#"W!-5KA-D>8
MD!"4H]<J6N*@)?:*5)YHA&7#&7J$N+ERY1M"GR#XV2I#=CL'O@LQ8""I/*1@
MDKZW-:MNE>,#UR@0$Z0G(D:4&$I1FC*( ]I6XP\TM.6:*@\V_BMY6MJ>$;9B
M>.+- U;]&GY61!]E-8,CFO$#-D*N%N3@4D :K/:5[KCO)\)6+5R=&O.;5UD@
M5BDE0B4 ,N"P;H+;ZV'CG-BEUCOK'NNAG'<' RT=;8Y@MUBEW,L2GPI'>9JL
MY,SO9 M" FZA3X#<Q-<P=@$']F&Y@5 ;;^JEY$N1&3MVIW&%K](,!NF55YL3
M8G.%*UN5MJ)?=1TBOY2=FQI:(UB@F[6 \U>I1HUZ]L)+NJ)>4821FT&N9PZ_
MSL'&[_+=UF_SO1.@]M>@\^'UR?\ ZV<:O^+NV/\ A+7:@ME]&_\ S1K]_*[S
M-^X[$M!:MSB[<YGT0XOMDML=?'-C:<MXA<\ +XP?)6!%)X\K2R?9G#4&E3(]
M,J[JA5-DCATG<&\X9)B=806IN<E/3J2R3RPI8T5]8SHGFEF8HYNO$)GJ'DT1
M?=WF5M+*^Y;P2O5@+/L2L;G6(-[EDZ.^)G% MW18P*DR 1X;&.1Q8#% 0OMC
M/,+Q12UD12!JY)-'DB!P[SV">3;/X<A3V7W16H1&]]C,RE[#)&SK')A"+[RD
M*[8FX#2^L48 8@U]^>SU%?'X7I%L/J9JOF%CV=SCL1CV5884J<7E+7?&6/(C
M-"%$9F,K?LDJ&X$0?SC8Z:O):T;$I<U!BH9)QUTR81:@P*#?1ZZ79!R_R-F[
MAW8UZ3$6H\&G9)TO4)U!+4ZY6RY"'S&C)"6M4-/=.XN:>$2QX<UH"C.LB)*3
M7.ZO>T]C ]1>@\/N?Q_(G%_R5/#:%H.*R!H_MZC?HZWN1PDX'DW"N44DHA*X
M2NY"GM&B6M3*B5DG]D8$Y&K"9U1!%T7#UA=:>>7B;V7Q5&LG-N\6N>(5;RU-
MZI\QSL)EV!X.R+#GI22+Q*..T>R6^QDUT4LRTDP@:UL$N;%'4":G4&DFE&#"
M2> .3?07:S-[[KIK1M-BS/&7(U!I)DI\8<4N:Z;LB"$1*3P^&O;\*?L#>MQV
M>25(IZU$)RBG4:A<%2(Y,6<20H,*"JGU8?\ ,F[#_P (FO'^>J&T&M9Z(W_3
M(W,_DS1K_.FQT'I*T"@\I/U<&I$TP1RL2[/JIG5AQAN%"H3D&%2 !%@M I;C
MV%17%N2(F%0$HH-WQJ5QM \*2[]:]D\@3#ZU[CO8(;+G /ZAW1!^T@U\U2VN
MSC#M9\\ZX8]B.#TRG+BTJ&XTR!!((D2Q#'4FCN2%_4AK2<BAJ-M1NR5X6-RD
MM80<H+":DZ3@!>!EGG XB,,1DZ62WD3U1?&TDM09=#B;+D9SM)C.[  ,99,/
MPFKR!*C##.TM8NUD?Z9?IL'IZHN@-$'GT]28R\F>+GO3O5[#;G&-92I;&I=*
MLK9.3V*R?/%\+=AFLMV.*LSFO9,?PHQX.(.L8M4+G5?;L F ;A7-3&!GGT1O
M^F1N9_)FC7^=-CH/25H/*8]7IKS(\3\NDIS&M0*[1;:;#^)<A1]X%UAMZAVQ
MW#&C!\C9"#?ZD"]H(QPWJ3R?S0%.1!E_8-M0;1G )SYZ'S70?7W7'9C8_%VM
MN?\ 6C&\<PH[-V=9BS8TB4QA>.6H,<QW,(GD27F,<)<>^PEG1IEJ$U<6Z)G)
M.;81(R34JA2%UZGF/XL@Y$QGB9BWQULR'D7,,Y@F-<<Q7#N16K-J^0S?)<P;
MH'#&&YF(;S9&SG.DG=DY)AJ\U*G0D&=Z5&$)0B.L'U\Q7\T_R1?R(MF?\T,L
MH/-J])Y_/9:\?P=[#_YE9E0>MM0>?9ZQCBSF2R71'E'P[&%[[%S8O'\4[5I&
M5 :J.BJZ/G#;L89@=NPL<?X&\-*TF,.2D=BTS>:W-(?9$L&((8?].3ZDG%&I
M>)&'0W?Q[>HWB>)N*T. =@B&MVE#= V9\7GN2K&>3&MF3N,B(BB)Z5FFLSLC
M3+ H *A)519*(@H\D-TE5S*<3:.(AFQO)!I6-F&W(W2R)+L;BQ=+K)EUR+$E
M"@"*2J)X!Q!W@/;(Q-ME:?H%VI8.H/JAHG>H_P#458^Y X45I)I(HDBC65/*
M&N2YAR^^LR^+#SNXQA6E>(=&8G%GM.CDK1C6.R @IT/.=TB%R<G=$EN%*F3H
M^T7A:/Z/'BPEV(H7/>2S-D:5QY[S7$@XTUG8GI <D=?FB5KFN0S#+5B3QWZC
M9D=U;&]$QF7**/&W-BI2"YB-Q3F##>4H/'!]1]_/9;\?PB03_,KC*@]:72O_
M $-]2_Y,V!_\UD5H),T&I)ZSO^:?QE_+=Q'_ )H=@J"M[T,?_P %$_\ 8)O_
M *KB@W_*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!051\R'&'^-KU
M&0:K_/?\P'<<O0S*OGOYM?G5[7RBS2UI\!\L>?\ &_4\0\T]IWKQ&_9=AU>Q
M'U^D 01X1O3V?B;\R9FRW]UW]T9\[N,FW'7E_P"8+YH?+_ATI0R;QCQ7YZLH
M>+=MW+L.[]V3=7K=?M;]'5N&R50*##^?L"XFVAPSD77[.D-;)_B;*L;51::Q
M1V *Z9Q;5 RE*=0G/*$!2W.[0Y)B%K>M(&6I0KDY*@@8#2@#L&D2=Z( EFF1
MLFQURD2:&$-4F&^P0P[4P+A,HH2A=;N$8&;,F+9^( 729B 41<3FC;VNQJHK
MMRDZ;I"6 -V?6^"YAQCA''./L]YG;MA\K1".I&"5YI;L<WQ0+(A[;UDR.1NT
M'M-L@IVN1+6\LJ[B80Y"3JUMC3RB4P# IRP@QR=<.&EG*Y"VYHV*AR]CR;%$
M"E%CS/F.36]@RQ#2#KG'@9QNRIO<6^6PZZT\1PV9V3JT@####4W=5!EU%@TR
M\W>B/VZ9WX\.N&X^N.1(N8O-NF.S<Q9-PT_)6P25,:2$]-!(UGAO<%Y"TPY.
M*X3DQ9I10%%K%B-$F)#G=?\ T1FR;J\(CMI]SL'01@(=Q"<6W7^,3W++PZ,!
M(&XP)2)[R*S861,#NY&#5DW,&WN1*()9)W457,&04&YKQN<0^D7%?#'*/ZNX
MY5VFTG0)V_(&<,A.!$LS+D!,G-(/+0O,G @:VYCC]E"4DWP=B0M+,)02%0)*
M)3UCA!/K*6+<=9NQU,\1Y<AD?R'C3(<?<(M-85*6\ET89$PNA-R5C>X(SK7"
M((@WL(LP-PFDFA"86(!@ BL&DE./1+Q0.8'_ "%@+D@E^$8H3-SI;BJ+J=;E
M$WF>+DR=T"[1MO393;]DX"X/CK%5!9=DCJ%N0*^DDLP7Z=:Y@@W(]5<;YXQ%
M@N#8WV0S^U;094B#<%E=<X-^*+X973IO1  0U.4IAI>0\E(12^Z4'0X+TJU.
MG7G?IH4A KBL(-*V7^B"\URR42C\9UW#S)(GM_[C]Q;WKN7C#DI<>Z=Y^ZR3
M=Y[OWCJ=IV9?7Z.GJAZ>BP==_P!AC_\ [HG_ +Y-_P#C<4'=X+Z'+&[>XK#<
MF<C,WES2-%<M B@NL[#CMQ3./;E"LJ6.C_FO**9<B[M8P'8 1IQ]<01]MT!N
M 86PZH>DWXDM:WAGE<VA63=L98T]FK+%L9,D#G!BGBZ5L*4'DXTQ]'X#$WAE
M">C4#3M\A+?R@!7&6.&H$6F,)#9&B\6C$(CK+$(7'&&(1.-MR5GCL7B[0WL$
M=86E$78E&ULK(TITC:UMR0D-@%$$%%E%AMT!#:U!SU H% H%!1IS@<+_ ..6
MQY@6!_=)?<X?,A,YA+O%?F=^=_S/YL8VIF\/[C\Z>+O!>X>&=IVO;*^UZ_5Z
M@.KUK@X/^%_\33CS/4#^Z2^Z/^>^9P^7>*_,[\T'ECRFQNK-X?W'YT\H^-=_
M\3[3M>V2=EU.KU!];K6"\N@4"@4&DIFKT<WSP;>Y:VK_ !B_EWYTMD9YL'Y#
M^Y%\7\"\[9.=<C^4?-'W3S9XGX9XGW/O_AR?MNIVW=B^GLK!NUT&M[ZL/^9-
MV'_A$UX_SU0V@T;_ $\'%'KURV92VNPIGI_R%"SH+@Y@G..)WC9V;T3U%I8;
M/&UF,/6M+XV/#!)&-<A57*5)#R '"+Z>[J$IO0=8+-\O^B0W09W@)6 ]Q-8,
MC, E:X(U^7V?*V%W@E" "2[::%IAD4SVB4JU!@SPGEW6E )"46((S;FB"2&6
M]6_1'Y95R1K<=UMQL=QZ()%IYCU$-6V22S&22!N#8 $J5KR-EF+P5KB"TT1@
MC##S8J^ +L58NQ(^U[4D-Y#3+2#6/C_PHSX!U5Q>T8S@#:==R<[IAGN4FFDE
M.3)TSA,9Y*7$9[S*Y0Y%I2PC4J31!((++3IP$)222"PEA0*#60Y)_2O: ;Y2
MV2Y@QDOD&F^=Y8K<7:22?%+&U2#%LOD;F)2I5R:889<5C&B&^*W ZQZHYA=H
M]=<9<TU5VRDX2BP:V.0_1,;^MKR61BC:W3Z:QZY)@C73(:O-.,'D"BRH\!)1
M;%&\5Y=0FDF(0E&",NX@$ T8B[ $$%C1AVS$/HC-PGI98&>]T-:L:M_?3"[J
ML0Q7*.;UEFZR$9A2JR"9M.OA%UHW.P21$=YZ@2+W.L<(=K$"#9WXV?31\>O&
M_DN(9^CAV5\Y[%056[N$0RAE26@0MT.6O3.LCBPR)X^@B.,1@(1,+@H)L)ZL
M^*"S5)II9I=^P"0&PU0:>/)GZ3K\8MO%G?<W[OGYG?GL<84O^;?[EGYP?+/D
M_&D+QWV7G#[HV$>,^(^4.^=;PM)V/>.RZ!]GVHPVL=?<5?,3@7".$/'O-/S-
MXAQMBKS/X7X'YC^;R&,L1\>\%\1=_"/%_".\=U[VJ[OVG9]L9U>N((F<JFA/
MXS31W+>F7SK_ #)_.FXXW7_.1Y%^<CP+YOLEQ+(G9>3_ #C O$_%_*W<^MXH
MG[OV_:]!G4[(85:<)?IW/Q.F>LLYO^[ ^Z+^=#$(L5>6/N?_ )HO ^F9QF7>
M/>-?/;D_Q/\ ]7>[]U[HG_\ +=IVWU'4$&RW0:L',AZ9_P#&U[<H-J/NUOF
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MI$5GAZ[&NZ[Q73=2(K-:1ZD>2/(^BOF_DH% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M\%E)B/)%V3'^U#<"VMV&AVJ>N^6L_3EP2(6;'$.=GE(0J.))&^242<22)Q9
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MET?Z%T;LZMS$U.;X\+"6]H9F]:ZNB]2+J)T+<W)C%:Y8H'T7ZA*9,2(8[_\
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MV!9W-VUIUF87]O7.,:',,LY&8T;@0I5,ZYT1,T>QP%U1ISQF-RTYI/?#P 4
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M9;'K1;$>LQJZAW2_>]]UF\7S,SJ=3DR?L1??,VQ^Q$3$1'K1#3VYQWE+M)S
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M^D!UE?;H>F8TWO3#GR^UM\QI[O/Z[+$SQNL\Y;I\5DVU\>7'EQQXK[:1E+V
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MK"MTV]FU!R] H% H% H% H% H,-YWV&P;K!C]5E;8C*\&PQC5$YMC*KG&1)
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MP^0?*Y.#,0Y1E\$RVZEKCHC"LWPP6/U,\+:T2MR<P1!\3NL@BBYQ1-R(Q1=
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M_(.Y]P_]K]O^DA=UZ7_@Q\^?<?\ ,5]U%X5Y,R)F'_Z77YD^_>)>7?/^'_\
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M=!V#8(0AM:WL6M;V*#.= H% H% H% H% H% H% H% H% H% H% H% H% H%
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MKCSC%]-UL;JWB>:RN<X[0;*X_G\37S=.VAE#.T3S8*$NJ:,.[@T%I4#^I80
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M]2GP3<>&IO'2KVHU$PHGP%D'#N2,=,[Z6QS/(4D:9_"9^^)X0H:7IOG,IE0
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M5DG#_!&*0.\FE*AE4BE3I#5#--3DR%(DL).!O=F[H,&*YMS;=4(0C1ZBO0O
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M840409V9I8:DGI6US7..1R6:C9$:/.6 =S=8LW8AS?CE<X.2)BEL=8XY?(*
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MV3JGV/M+NH(3]<9O8$GN"10:43VI@A=0-[!ZPKWZ.F]!V!&C2-Z1*@0)4R%
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M O2IER!<F/1K42P@I2D6)%)0B5*54F.",E0F4$C$ 8!AN$8;WM>U[7H,81[
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M@T[%^TW8E'."LI(48;U-DQC[( SK7%T6O?HM[%KUQ=;_ )9'=G0Z+-K<F_\
M3LX\.*^^8B=968LMFZ8BNEI68C@^>;T=>J,.&_-=KM!-MELW3_QO6BO\VV0G
M)3ZD!L-+).EG",8(POM+7+QIO?T6MUA!Z+];+0;]/2&M:['MQWC?J._E3PE?
MQ:;V_2Y0/&_4=_*GA*_BTWM^ER@>-^H[^5/"5_%IO;]+E \;]1W\J>$K^+3>
MWZ7*!XWZCOY4\)7\6F]OTN4#QOU'?RIX2OXM-[?I<H'C?J._E3PE?Q:;V_2Y
M0/&_4=_*GA*_BTWM^ER@>-^H[^5/"5_%IO;]+E \;]1W\J>$K^+3>WZ7*!XW
MZCOY4\)7\6F]OTN4#QOU'?RIX2OXM-[?I<H'C?J._E3PE?Q:;V_2Y0/&_4=_
M*GA*_BTWM^ER@>-^H[^5/"5_%IO;]+E \;]1W\J>$K^+3>WZ7*!XWZCOY4\)
M7\6F]OTN4#QOU'?RIX2OXM-[?I<H'C?J._E3PE?Q:;V_2Y0/&_4=_*GA*_BT
MWM^ER@>-^H[^5/"5_%IO;]+E \;]1W\J>$K^+3>WZ7*!XWZCOY4\)7\6F]OT
MN4#QOU'?RIX2OXM-[?I<H'C?J._E3PE?Q:;V_2Y0/&_4=_*GA*_BTWM^ER@>
M-^H[^5/"5_%IO;]+E!S3;;U(;F0,\J7<(A80&B)O8S&N^'6N(( #O>W5RR*W
M1T&6H.0\.]21\L>$#^+7?+Z5Z!X=ZDCY8\('\6N^7TKT#P[U)'RQX0/XM=\O
MI7H'AWJ2/ECP@?Q:[Y?2O0/#O4D?+'A _BUWR^E>@>'>I(^6/"!_%KOE]*]
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M]L2$H=QAM8-^@,NO+PU1UG=9 ^N"5I9&)M7/#PZ+C@IT3:U-B4U:X."P\=[
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MJ44,=[!N%9.KG/5Q/;HYV@VM&M&UGSE9MR5YF\E0KYC-DH=XUY.ATAG\C_\
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MVA&2YM*,GPR9)RI7 BX$78AK9(]BY9$C4$^=9@]J$R$D2F2QY(C&HL:>=8D
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M9]$<(\1M[%A)"7:]Q7%]38/3T^Q0><7RG_<IF[\;7F\= )+?5^SXH-/NREG
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M$)P7"2A.L5=0=</:"#MU H% H% H% H% H% H% H% H% H% H% H% H% H%
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MPHZEQ#.,S0*SD+"@9XE&)1:28O2N G) V,ISFSR"Q*M.</NRDT)S<1J9.+U
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M@Q@)PR:\K$:?K!3'%6?(%LWB")".,9TZ=-8P$9*"&Y-A7 ('5* %Y'&+Q<8
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MGG(.:U4G4XP!C-.E3SV+06,'P\^,&SW))3D2B*A=S!JQ+2PJ J[EW3@L7UC
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M_P 4YEBA\6E*- J A=D5P*TCNQ2./KS4ZLEODT1DC8C=6Q082>40X(B1C*-
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M=NDPT8C#;F!*;YU?4+_>A<8'X4^?/H:H'SJ^H7^]"XP/PI\^?0U0/G5]0O\
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M0N,#\*?/GT-4#YU?4+_>A<8'X4^?/H:H'SJ^H7^]"XP/PI\^?0U0/G5]0O\
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M24Y8C316"&UQ6N(5[6M[-!U#YVL5?Y3,??MSCG[)4'?P# 8 )A8@C ,(1@&
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MX+%)\W;@:F-[JN4*!GXFGB".HGQN0KERQ59X.:8G((8G,$2*YPUC>Y&'!L8
MVQ8<OZIB41V$'</4TE[TW1N)Q#DVQ1*)1(GA46B:6&.L D#L]O3HL.N$E(W-
M;:D-//-'>P2RBQ"O[%J#N,@]8%Q ,>8+XP3K=EY%%"W<QJ/SY'\--AV'R22C
M%!9CS9$YSQKS0L:+"(M<(DT///,": 0"A6ZUPALQ8ZR)!LNP&&92QE*66<8[
MR'&6690B81U86X,<FB\B;R'1D>FI85?J'HG! I 8"_L7M871>UKVO:P=SH%
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M*M;7->D&<C/*N8$PL0;!%?,?J,.-C7;,FWN#L\RG)&*9GIT_0R+24,ABT==
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MI$5+FF*5-W<EC7<1A1PS["*#*.G/(%GN(>HPQ[M)L+Q]["<:6/N3:*HM7)G
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M@J 8YU=R_+H6[*X^UE PX\8VQJ\2.'S"##)()'&5,,7QQ&:44CN24<F3]T,
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M<S<O2&<F[8_V5&Q6.[B8O00-4K.&*Q2);F71UX?VEM3CM:Q32DD#B<JL,/2
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MU(7-J<SDBPL"#K')A]2P@]%KT'8,E:H[9Z4^DHW%UZW$@1V-,AQ3,^/G.*Q
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M.P.N>D&N& =H9' YAF?"^.F_&+_*<:R"32>)/K%"U*MA@*U(\S"'P61*7 ,
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MNAD(D>F^,,C.<2CR)(U1\<S?T6I3V]OI+:B()(*6NK_+79>>*UKW&K=%(_\
MVIT6#K?&9K]A'+'J,.<'(^3\50;(,WPI+<&N.))#,HZWR-7CMVED?<4K^^1(
MMU)5)&:0+DC&F)LX%%A6D$A&64: !IUAAD+U8BP^1X3XY<$RMV6L>!,Z\B&)
MXOG=>F/<&Q(HBZ9 XIB6YW>42E*!.W%H'QQ<K$#':XE+82I+N$:2P@AL=2G4
MG6&5:YJ=3I!@W%P]:?)BF"DX=)B+(V0%DBIC>J063,#*A2I4D;4H"%9IB98B
MLG5I% N\%&@.M8R@U!N#J2OB_P!-ARSP2[VME.-<.J.23'F$Y*J$(!#GCDW5
M]JF_7;4HN@):)9+)DYN(AE6L2)0XFAM;KEF7N%MOIC, X2QQQ%ZG96@N*H)%
M\GY@B$W>LHY&:8TV)YU/%Y.6IJTIO,TL[N)]=$2)N8$1*=*8?=*G G!V98>B
M@A3PH1",XEYZ.?3%N-6-LA..2WS#TB30J-HDS1&D3JL<9"^"-;VA"40B0$IW
M":.8B"20 *( K&  ;!Z+6#*_I_\ ^<']1E_K(7#]W.PM!'_TCF,L798PEMYO
MCD5BCLQW9R9NAEAFR3D&1-Z=UG\#;#XK#94*,LCJ\]^?6%%(WF?.ZI<>G.*L
MYA&!.?<WN(; #;>3XOQHDR KRPDQY!DN4U[&KC*[):>),!.0%D;7F1PU='U<
MR+;PR)0QK38<T"-2#4W(,$U([B!>Z8GJ!WF@TX/36/[9A+D$YS-+L@GIF'-+
M=MFY978&5=:R1?-,?))]E1E<),Q)CA64J65"GD<?7!'>WLI9$F,#TV$+JAN*
M+UZ%K0K'-S6)&YM;DBA>X."]02C0H$*,D:A6L6*U RTZ5(E3EB&88,00  &X
MA7M:U[T&DEP9.";/6=_4O[KP8:8_"&9LHY'C^+GIOZ/#Y>F3JMC)K=\!<JXT
M_>38C*6)>9<(S.L-Y%>U^CZH03N])#AS$L;XE,5YC8,9P-GRWD6;YO;)YD]N
MBC(ER#+VF/Y:D+6Q,\BF)2(,@=65F0M*<"5&<H$F([*P@ "*][W##.(X+#L"
M>KIRI%\ L;5$(OFWCS.G6>XI#6XA%&RYBI=XVJ&^.3(UEEM;"ZNZZ),*\Y1V
M11BA8Z&FBN(UP-$:'1\>Z@<QO##MINMEW3C47!'))K3MOF*2YX<5'SBL&*]H
MH*0]2UTDZZ%K)#+5[:Y/!@T;HH3#2-K?+4Z]84B<R"D1PES><%IW%-RCX.WE
MSYLEB&5Z5230_D*Q&QL;KL'B7(D:CHIS((6<O2B;GHG)2**PN539C:765)#_
M /SJU("[DOB)8BNI)67- $(/1Y_S9F=?Y?\ G?\ S:8'H.E<@."\.[$>JCXV
M\>YTQO$LL0(K0*;2XR%3II3R")KW^'R3:5^C2QYCR^QK2^DM3RD*4@3+2CTH
MCB@"&6*X;= 7Q<J#:W,W%#R.M#0@1-32U<>>WS:UM;:E(0MS:W(=;LAI42!
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M.32TI6 :M(J4IE @W,*-, (([A%?F*_FG^2+^1%LS_FAEE!J-\7FG_J8\O\
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M\H?\W5NI_)ORI^Y9?5[>C#^L1T7_ 'CT/T>U->W'Y>[1\88?=P\O&O3VV-%
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M/^9)?ZP70?;0*"&_(3BC8//&DVS&$-6)) X=G;,.*I!B^$RS)3[)HS$(T3/
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MC'SV>@5/,$QK!8:[J6HU0>V*7.,1=J9%Y[<<K2H59R Y6A&(D1I))@B[VN(
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M,U(M4687AW5-!ZE"0M0@5&F!#;RH% H% H% H% H% H% H% H% H% H% H%
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MDA$,8 [_ +@<;><M@>#!%QDPV58H;,\IM8-4,*#ELF?)>CQ%>58*<\,+9<X
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MZ&U^T^:,?YUYQ^0=ZW728X=?,[!K%CHMX9L#BD:EQ4.CB2M-4L\ 9TD46G&
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M*?.'^357_A>Z:?353_FG[!_8S6?TCC^TS_$KH?P1E^R+?I1^)3YP_P FJO\
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MHT:_?#0/N_>87\@-/_Z2C1K]\- ^[]YA?R T_P#Z2C1K]\- ^[]YA?R T_\
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M&OWPT#[OWF%_(#3_ /I*-&OWPT#[OWF%_(#3_P#I*-&OWPT#[OWF%_(#3_\
MI*-&OWPT#[OWF%_(#3_^DHT:_?#0/N_>87\@-/\ ^DHT:_?#0/N_>87\@-/_
M .DHT:_?#0/N_>87\@-/_P"DHT:_?#0/N_>87\@-/_Z2C1K]\- ^[]YA?R T
M_P#Z2C1K]\- ^[]YA?R T_\ Z2C1K]\- ^[]YA?R T__ *2C1K]\- ^[]YA?
MR T__I*-&OWPT#[OWF%_(#3_ /I*-&OWPT#[OWF%_(#3_P#I*-&OWPT#[OWF
M%_(#3_\ I*-&OWPT#[OWF%_(#3_^DHT:_?#0/N_>87\@-/\ ^DHT:_?#0/N_
M>87\@-/_ .DHT:_?#0/N_>87\@-/_P"DHT:_?#0/N_>87\@-/_Z2C1K]\- ^
M[]YA?R T_P#Z2C1K]\- ^[]YA?R T_\ Z2C1K]\- ^[]YA?R T__ *2C1K]\
M- ^[]YA?R T__I*-&OWPT#[OWF%_(#3_ /I*-&OWPT#[OWF%_(#3_P#I*-&O
MWPT#[OWF%_(#3_\ I*-&OWPT'1,I;A\PN4,9Y#QI?@SS= ;9"A$JA IQC_DT
MT#;IW#@2IC7,8Y/"W!_/DC&@E;$%==2WGJV]<F*5E%C,(-#:X!!&K0!9R(\;
M>L,*U0UYX!<U*L?PQQD[V.13[DYT >)[+I#+GU8^/$AF+Q'KQ1F<76]U):,H
M2=N2%$H$:<D(.@JU[A-#[OWF%_(#3_\ I*-&OWPT#[OWF%_(#3_^DHT:_?#0
M/N_>87\@-/\ ^DHT:_?#0/N_>87\@-/_ .DHT:_?#0/N_>87\@-/_P"DHT:_
M?#0/N_>87\@-/_Z2C1K]\- ^[]YA?R T_P#Z2C1K]\- ^[]YA?R T_\ Z2C1
MK]\- ^[]YA?R T__ *2C1K]\- ^[]YA?R T__I*-&OWPT#[OWF%_(#3_ /I*
M-&OWPT#[OWF%_(#3_P#I*-&OWPT#[OWF%_(#3_\ I*-&OWPT#[OWF%_(#3_^
MDHT:_?#0/N_>87\@-/\ ^DHT:_?#0/N_>87\@-/_ .DHT:_?#0/N_>87\@-/
M_P"DHT:_?#0/N_>87\@-/_Z2C1K]\- ^[]YA?R T_P#Z2C1K]\- ^[]YA?R
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MFU%UDPAN%D*5GO$E).R85CS$;=A]LA<57&(W'+#R_+LZ$RQIQT>78DY,8>R
M=E'?$Z<*#OIP$MP[ER7\_P!H]QG3*V&YL*=9KV'$E;5:K#&'&YI<'2*DO24A
M>R&Y D;\[,[)%Q/*!26<F1DW<'891Q)O<[$' .N$&M>_5L:)9,RVT8FSMA_/
M>IYL@7-S8WSC)#:POL*:5SH864B\[#85Y<HBK:J&H+ZJZS6K1$@%<U2:G( (
MVP6V<FW++KCQ38[Q;D[8*(YEG4=R[+'&'Q<O"#!!).X$.#:Q^8#5KJ";9'QV
MA*:ST/L%&)U"D8AWMT@L'ZJ@J,S3ZO3C=Q]$L>O.-()GW,TJFT?0R-]A"!BB
M,34XO+7@[4N.SR1+Y6ZQT^8 )&$9B1A/>TI'3<L]42<&Y5!9#J!SBZ<;G:;;
M*;C8S1Y+1-FH6.)EDO/V&7EECQ>78TR0V"27('_F)&&4!A\C)ES1$'$ID4^+
MI4RE4E&4I$C$ RP \^[&/+1CZ'<X;ER./9FP:W6%7L?ES+1.,D8F13D8$-G4
M?FC7'V<<,5Y(2X]"[-ZN0IAGI[/ETI02QW+.,$$%A!M\;3\^V ]I>&[<G8C5
MQIRCC!]=Y8ATB@_S^$X\QVZ_.CG)A:4BJ2L[C%\D3YE1M\+QQ)G-]LK4JTXR
M3&<P0RPD@N;08&@62-$M$>0KAU7:C[::O9DBDXUZ+XMMDF3!6<,9Y =ESL;9
MLEN$,N21FATJ?UYWFK.BM00M<EI*?N11Y1 #K@-"0 -R.@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&6VW^]R#_F27^L%T'VT"@4&I)S:1=OY
M-^5GC:X<C%RA1B",HICNQM^4T.!Y)A$28VA_8<?L2M6@,LH9W5>A:79OM;HN
M>&TO0*+7*+Z#!!DKTNV4); <&[<\7N7G$1N7N-':3(6-$R=48(L]?B:;RB2N
MD;>$!!ZE2)2V'SUEDIQ)J<8TH&]8AZE^J8 1@6?[S<Q6G/'3G[ & ]IW"<PD
MS82+Y F++EDEHBZG$<$9,<HCE;N/(3HLF3=-$Z]V-* E:TC,Q/:E>M/)( #M
M# AN%8\+]7KQ#3+-C?B$;AL9$8XZ/R1A19]FF*8\S83ZRXY*G3.S@>3D1?E-
MB8>W5=!JIPBJ4"4!0S3[%%![2X1[]8YM_C''>@T!U&=FF9N61-J)>@G^.9&Q
M((^L@#:QX%E<$=9:"5NZF3(GQ&M=DLW2>%60MKB2>(!O;&)[6!<P).\4_J1]
M&]XLK:X:%8GQ5M='LP/6,S&-+),AP;$+3C8M7B'$CA*)*8H>(WG26R@"9<WP
MU4!#<+.,1IQA5C0DA$,8 EOPLRWCCFK=O(Y\>6 <JX((8MQ)W"-D@93?7IZ.
MR!G:-D%J)!,XD%VS1F,"&*+0/%[)P$B9 WO>_2@+Z WH+NJ"G3G&T@U>V]T%
MV&F6Q&,?G"DFKNN>S69\%N/G3(<3\C9+9L+R-U;9)W.#RR,H)-W9?'D9G<W@
MIP0#['JB($$8[""M[TG>D&KV.>-O7_>6&8Q\&VEV"B&=('E[*'G3(;AYNBD/
MVLR>PQQJ\DNLL78[8/#FG'K.5V[8T(E)W<^L:8,9IXC ^+A&_GL?4<_P[X)_
MPOG^@VN:!0?BI4IT:<]8L/)2I$I)JE4J4F@(3IDY !&GGGGFB"42224&XAC%
M>P0AM>][]%!H@<O&9,J\UV =XLP8<E<BA'$KQVX[G3W$IDU@.;Q[[;<1=N$F
M3N32)38H1^#,.*G$)Y!PR325RFP!E]<]983&&S!P2_S/?'?_ "9H)_6E5!7%
MZDZ:RK/;5HUQ XH=E"+(')%LC%T&1U38;<2N,:Z8@>V653F1."<(#+ 1(GD:
M-Y#<83+'IHTM $HV]KVL&1/4&\=.FV0N*_)^0Y=AI,Y2_0C5F;M^ICFCFF1H
M\DQ(B*:84TEI4L>C,O9HS*TQ3?!VLH!;ZC<RRPI;6 $/7,ZX<MZ:K1K5K7OC
MKUZV<Q!B_P HYPVLP1 G;/DW\[9$?_/KA'G:4'-"CRU)Y<]1"+]T,=5%^HRM
M[< SM/J["L$/0$;O38_Z3?/Q_K0\F_YP,T4&US0*",VY$7VAFFL>88MI;D>&
M8BVD>8R6EPSDC(:%(Y0N)2BSNV'&N4@0KX'DY&I1"9RE15@F,#G;M# W[*U[
M=<(:7'&SA/D$P3ZG..QCDLV(B6S.Q[_I!D*: GL#D$A>X<U0)[4N*=@B$>;W
MS'&)T<00-;LVN*GPEJ8TC408M&:5UC3SKT&_!0:VL0]*CP=8T@2I'.L S/(H
MF9N/7.V4<I;)9IC[XE0MS,F*7NKI?&D[Q=CQ$F(N@.<3S+LY1)9QYO\ 4I@E
M$%!7[Z;_ !U; O)YRRZ\:?Y+EN7^+G&9T=2P"9N$A'+(.GSPH71A19BATE2%
M@C+^YL[,JDK4XN3=TF.B!F:E*D9H1I3!!NF4%4>^G,MIGQL9SP-A#:Y;D2&!
MS[%)_,VG*S7&F5\Q;!F/'20U2["GAI,J)R%=Q=3@ 2MB-ACSZJ7+#RB0%V&8
M&U!6;C;U?'$7D3,C5B96HV1QNR/+TF9$6;\DXMB;/ALL]:I2I$BYU7,N39%D
M*/LIARKI-6.$=2ITA18S5(R2@]>X<AGKU='$1A')BC'#$\; ;!IT#B-K=LD8
M%QG&7C&;>I)-3D*C4[[D;(V,W62MR<PXSH6,J!S2*0$#&G,. (D1H; NL6S&
M&-Q,#XWV4U\EY,ZQ%E9C&^1&1%HUK:>8!*O6,[NV.C4Y$)G!I?&!];5*!<E/
M+"8G5IC 7Z>KTW#4"Y-M<5G.QS+9STP9W<5\2<:VA>21)%J1Q$!I,W-SQ&DR
MF#)SUQ"I.F$%M>7B-F+$Q@RB@CA:],H-M<=RK!<!Z:C;5QVDXIL+1^9*%(<N
M:HN+YJ7E)J<QG@>FQ;B+NB>!A=$BX8G(E2+%;FQDGC._JUZ94$/1<L00!53M
M5N=KEH3ZH/*&Q6TF0TF.,7Q_BV:FFSB-O<WIV?Y*Z3%B-9(E%V!E2+G5]DCU
MW$WL""B^J$!1AQPRB"C30!85IWZJ#BSW)S[&]=8^MSOA693J1((ACA^S[ (A
M&(+/Y6[K3D#)'V>1PG).0Q,;B^J@%%(K/Q#.6H/4D)P#NI,L30;(5 H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H/D7KD;6A6.;BI)1-[<D4+ERQ28$I.D1I"1J%2D\T=[!+)((+$,8K^Q8-
MKWH-"S3C5*4^J2VAV'WMW?R)E%IX]<'Y9>,0ZFZUPN1*XPVO-T"1*[*C'!6(
MBQC,8DB#LSJI$Z(TQ;N^.SK=,4L1)&P*6@N'S)Z3'ACR-$53%CO"V3==)-<L
MX3;D#%N>LNR5]0K>DH:0XUJS?+<LQ94F3FD_5%A0DF#+,':QH!]F86$(.?B
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M E#<2KN#M4I9@ V4\)/<CDV&,1R28A.!+I!C" O<I I1B;U 9&ZQ1I7O@3T
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M1"M:X;7;.[M4@:6M^8G%$[LCVW(G=G=FU24L;G1J<DQ2UO<4"L@0R%2):D.
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M^*(-,,NXLY"I,QXRGTHCZ!_D&/4+[DK.;J\CA*AU*5EQ=S<EK.EN<N1 (6C
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M;.)LX("E#=DC$F089:)BBC XEX&S@\,:T9*]>$Y4WV95A0#PB*57&$/4")?
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M4<KO,,D&1,)X_/BDJ><>.+X[0MP<39._O03H^XR2.Q-\5(K)74L-Q*6Y(/M
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MGZ\G]O0._+?@E3]>3^WH'?EOP2I^O)_;T#ORWX)4_7D_MZ!WY;\$J?KR?V]
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MLQ]?@Y0PFKS,K1R)QM+D*+R1ZF,?:L@8M'&YU,CI+!C7:$*R1K%!:$PHPPD
MRK#'<(0M+H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!EMM_O<
M@_YDE_K!=!]M H% H% H% H% H% H% H% H% H%!UN8S*(8[B<DGN0)5&X+!
MH:QN<FE\TF+XUQB)Q2-LB,UP>9!))&]JD+.Q,;0@3F'JE:HXHA.2 0QC"&U[
MV#XL?Y$Q_EF&1[(^*YS#LEX]EJ"SK%)YC^3,LRADG;!&FD!<8]*(XM<F-Z0"
M.)&"QR8\TNX@"MT]-KT'<:!0*!0*!0*!0*!0*!0*!0*!08J!G;"!N7SM?"\R
M8J,SXGBEIVHP@#(<1'E\B#B/*3!F1V-0N]YF5%+J3P%V<1(K(^N,(>TZ;VM0
M95H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H.I3N?07%L.D60\FS2)8Y@$0;
M#WN63F=R-GB$.B[,EM:ZIVD4FD"QO961L36%;M%"D\HH'3[(K4'ZPF<0K)<1
MCF0,<2^+Y @<Q:$4@B,VA,@:97$92P.1(5+<]QR2,2M>S/C0X)QV,(4I3C23
M07L((KVOTT':*!08HQ]GG!N6I-DJ%8JS-BC)LRPS( 1/,$2Q]D2(3.38IE1B
MEW1%QK)3#''AR=8+(!K&!>39$Z%)5-S42@-@=8DRP0RO0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"!_*'_-U;J?R;\J?N67U>WHP_K$=%
M_P!X]#]'M37MQ^7NT?&&'W</+QKT]MC10*!060<0G\Y=IQ_# W?X)=ZQR]+K
M]6OK'XGO]WC0#NE^CW=O@D^S:])"0_WX6?\ 1_[5(KS-M=[A:!04&>IBR-D+
M%7$3G2:8OG<RQO,6^=X+3H)9 90]P^3(D[AEN*(UY"1^CRYN=$Q*Y&<,HX(#
M0A-+%<(K7#>]J#3AXM=#.7CE@PQDS,N$>2_(6/6[&N0CL:JV3*FRFSB1:Z/H
M8JR2HE6G4Q&TJ(3M)A#\44(P5A' &$=[%"M:W6#,<5Y4^:?@BV]9<"\@\OGN
MQF+#O!WI_B649DHRQY\QFN6JD8IY@7.<E$;+2G!#<"DLA,L6=R K3W2.* DT
ML(B WBL^<NG'QJ[A?7G8'/F?R8!BK:>,D2W!TE(QWE7( )@SFQV/2DPP27%D
M(G*EE.2M$I1","N"GMVA@BPW$,LRP0D_!]JL"9'UG2;APN>>,ZY+\9/68DN1
M/*\S;NUQQ'6MR>7B1>476.H9T#N;:T*#.Z";++S.SZH"!#$$(@CMI9RM:"\A
M\EF\0T\SU\[\BQRQMLDF;=\UV9\?^#,KNO-:VY;WO*..H2A<.\+B1 [-*:>:
M#HZP@A#T7H,0*^=CB?:\^SW6-]W C,6S-B^399AT^8)CCO-$-CD8DF#DLK5Y
M-;'#)<IQLT8ON)A!"'(L@TMY,)=5!)9#>-4<H3%G!@;&OJ6>'S*68$.'&399
M<QKWEZM'X].YUC6?0C%STYF'!(2!\Y2)B0IXZA6F7Z"UCT4V([=%NN:#K ZP
M8^]2;@G37-FHF$[;O[=O>FV+(UL>U7CF0F/"DWSHHDF0'C&62;-L,.C$!1N#
MTUDJ8ZUNB[OYA7=0"0V*$,)AQ5A!]/'-GGCHXKN'S!612=N)7E;3)=/\FI(?
MLV?K5GIM+=7R1Y<G;>XH9%CR,0&73."H6^;LS@SIUSPD1)%J@@JQ1@KJ4]C0
MM<TWW[U#Y ,?R3*&HF:6?+T,ATD,B4J6DQ^:0IVCSZ!N2NQ:=WBF1HU#Y8A1
MK&]6$Q*L,0A1*^H:$DTP1!UBPC)B/F^XO\][$-VJ6%]F3LGYW=I<^0ALAT,P
MAL6^-RU[C1Z\E]5)YXCQ&9CLR*MA;8>H-?K.W@=D1=U5E=TU[&W#(^\W*_H;
MQSD-J?:C.S/$)>^H[.$=QC'6MZG637M"(8RRW N'Q1 Z+V9G.&28$MP=+H&X
MPPL18#[F6L"X1'UG]1OQ,[29+9<1P_85= YQ*%R-JB23,L&DN-F23O"\X*9&
MS-TP=DAL02.RQ48 E.G7+D9JP\P!2>QI@K H)^;I<ANGO'C%87-MPLO?-!&,
MA2!=%H>Y^0,H3_Q=^;FZ[LM0=RQ?"9LX-_8M]NT[54402+^I".XO8H((YI]1
M?Q%82B6/9:Z;1)YR')T?0RR,1K&D$G4FFB:-.0.U0NLQBZA@:G+'1BLD0324
M,@"V.9Y(PFE)AE7Z]!,; ?)]H[LSJ[DW<7#N<FN3X)PG%Y?+\RO8(]+2)1B]
MG@4563:6>;<="8A3XA8W1AO/5D$IFY2-S+*OW#O72'I#1)QCSU31#SAN64IM
MOQF\?&(/8_+CTB;%BC,3CCFV&W&/S0G'Y(,/)8TIFY;26[*6VY""[)92E%8
MC"2[%BN$-FGD/YJ=3LJ<1>VF<=),YMN0%LH=D.F<3E#I'I_A].Q9=SFVHFM4
M<!3E^)P-62="\9/[C);+BB349(6V]QFA[,VY80C@62-$M$>0KAU7:C[::O9D
MBDXUZ+XMMDF3!6<,9Y =ESL;9LEN$,N21FATJ?UYWFK.BM00M<EI*?N11Y1
M#K@-"0 -R.@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&6VW^]
MR#_F27^L%T'VT"@4&I5ZAAF?.0K<?C6X381(G-A;\V2V2;5[+/3*859;%<.8
MV9I4U1=<8$T)B,87(#1+A)@*[=C=X1-M@@-,&"P0SCZ6[.LO=]'\J:-9@.,)
MSKQK;$9(UIFC0J,&->DB8I*_.\-4'!/(3*B$2&0)Y$PHRS0=8*5@![/1T! %
MSV=N0#3[63-N'M=\]YM8\7Y8SRQS.2XP9I*Q3(J//$>QXUK'J:/3UD1)&U6-
MX*V1]J0''G'/[NV%W++O<%Q>Q00ZA?J ^'/(6;&_7N([V8N=,F.[\DC#.$U@
MR:U8_>7U><E3-[>SYF>(*WX;=3'!4M*)3B3OYA9YPNS+$(=A!L$!/57[\!U&
MT&;,:8QV,R;K_M=FR;QUZPPIQ&]Y4@LT?H?C25Q8>6NZ9+QX0A;XRB;VN5(0
MJ$J]V0C<2U'4(+4=0P( FAQ^\Z'&=N*_8&U:PUM8MRCL[*<;H2S8BY8@V,9'
M%YD$%QN;*,@GKYS/<5,,0/6HD4><%)J@]U_LP95[%#.,,!88?'PJ8@XZ,7)-
MYUW'IGK+V=4LLV[F1NR!N5VI<U>0,]MA1ATEA$0 X85PV8LCK<6\6N \NSV0
M9TVZB\R]A4%X5!0[ZA#C;P;OOHSD?(.8)5E>-O.EF&]D=A\6IL:OD09VQ_FL
M?Q [/:)KGY,H@LQ5NL7-5Q1.$TAN.:E8BQF6"I#>X1 "M[TC_&W@W$>FF,N2
MN-RK*ZW.NU6.<PXQR%$WM\B"G$S,P0#:":QAF5PQB005MF#<[J4&*6X:DQ<_
M.)(SCE-P%%A&4 D,E<(W\]CZCG^'?!/^%\_T&US0*!0:07/#N%FSDHQ=O+KQ
MI/+? M$- ,92"<;P[(--SE+%GK-T<3V<(?J;C!V1B"CD3-&WXM.NE!Y1]B+&
M)KW,OV1* MY#88X)?YGOCO\ Y,T$_K2J@@1ZF;+\WD&MNN_&GA%P,(SORB;$
M0? K6%+?K'M.)F"2QEYR7)%H232E)3"F=7%A2.8KB)($S*UW:FA+".UPQ!ZA
M#A\U8FW%PQS_ ,;RO$%'%;J?-F/7"+0E[A39#GMN)8\;,I:?*"!W@#\\OH0)
ML<HA=9K7LQHS#E S!C$,-P!WGTN_&I@K5/2C'VYF/)7EEYR?O#A#&SYEAAF;
M[#W&!1Y7%'F8*&XO'C6QP2.R%I3'#?#;'6<G1V$*P0=40.@5Q!TCTV/^DWS\
M?ZT/)O\ G S10;7- H(S;D2C:&%ZQYAE.EN.(9EW:1FC):K#.-\AKDC;"Y;*
M+N[82:VR!<OGF,4:9$%G-5&V$8_MENT+#;M;WOU!!ID\<60^4#(7J8X4LY78
M=&\8Y\2:09/'!\609UQZZ0."XA<W!P6L*&+F8YG>2D%R5TDN[&FF.CTX/A@N
MBR@VY($P0!OGT&H>Z>D"UIS&F#)=PN0CD,V6S2,LRRO)KID2 I4R@Y4E2G+Q
MA9\HP/.,K++62.ZI8((I(9>Y1X"A"$:6-2<'!^GPD>S.M/)#R4<34GV&F.V6
MK>HC''Y!C+)LM6J'D>-Y.[O,;[#'"5<J<'<U@5NS7*G$AT9BU5V],^11<:D(
M3B-56,#<,H(7["<A^F&J.8L28%V-SS&</9*SBPS.48X13-JEC?%'&-X];53O
M,WV0Y-!'CL8P!J8&U$:<<?('AK+N %^I<5^BUPB!C;U!'#EEO,C5@2![T8W<
MLDOSTFCK$F=(KE:)PU[?%RE*B;VIGRK+L?L6*G1:YK5I1*0!#T9=4<+J%=<5
MKVL'(9ZY\N(#6C)BC#^7=Y,9-^0$+B-G=FB%1_)F7V^/NQ1J=.J:Y1*,/P:>
M1.+.* ]38M20XKDIJ48# FA!<DVP M&QGDW'F9\?Q'*N)II&\B8WGK&BDD-F
M\0=DCY&Y(QN!?:)7%J=$)IJ922/HN$5K7ZQ9@1 '8(PB#8-*CG6POD?F<Y1'
M3CGP^[.9<8X\]$\Q['S(#6/KDNFR^3(DVN&*( M)"2I)..>AK8.67:P3%MF]
MQ=NP+!V8C+A?/Z>_<4S=7BAU@G;VY&..1<5QT[7/*]U)P3W$$UPJ%+%T2UV-
ML H0W64P&S(^']8-AV&Z7L+K7MUA!5ID;,^)=?/5994RYG'(\,Q/C*'\3R=?
M))S/I VQF.-1'G>+@)+/<G10G),6K3KA*3)B[C4*CQA*) ,P807"YC5_G%XI
MMRLN$X(UUW(@<URRM4FHF.&O<7R=C)9+5Q%EHS&^"+LK0:$,\^<;$-YQMD[*
MH7G"(!VM@W+N$5PM<H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H/.AT!X*=2.7?<WF=G&R61-C(0[89Y'
M<XQ2+I\'R[&<;;E[=*<JY8=W Y_*GN(LE*52TE2V@"2).<E $%Q6$ =[V%8+
MVM7/28<<^I.Q>%MF\<9HW7>IY@G(T7R=$6B;9&P6Y1%Q?XFY$NK<DD:!BUPC
M;RK:#E!%K'EI5Z,X0+WL$T%_9H+J]S.1S2#CWCS-)-Q=C8'A0B2=J*,L3K9\
MDT]E"=,I3HUR^,8S@C/*<BR-J:U*PH"Q8B:STJ.YH.W,+ZUND.LZ8<IO'[R%
M&O*+3[9Z!Y@?H\B$YO,- CE<$R$A:"U@F\Q[,QQDR.PR=C82EO5+&N W"2 $
M<5:YENV*ZX=DW*Y']'>/IE9GO</8^ X4#(R5"J-,#M=[DD\DR)&I(1KG&-XV
M@[1*,@R!L0*E)9:A2C;#TZ<8[6,&&]Z#%&G?,=QG;\S'YNM4=M8'DK(@RWD]
M%CYS9)]C">/*:/-Z-U>E<=AN7(A Y+)43:V+;'F'-Z5258HE0+K7LE4W*"-F
M!,)\=+3SN;OYQQEGG,$BY))#K1 8WL;@!Y;%A.&H#B)PCNLJ>)RB)NAN%6)&
MMD#HU8WB9I@"IP]"+,<EG71E>P!&$I);R\\;F/YQLCCG(6V&/\>2_4AQBK-G
MQNR"VS2#)(B]S=,N611B9'V5Q=HC^27Y[2MJ@PI#%U3TJZI(KB+#T4'P:9<Q
M7&KR"S1TQOJ/M3$LHY":&Q4]'P5?%,EXQEZUH06($X.;!',NPF!N\G0-H5(+
MJC6TE6!,$72;<%K7O8)JYQSWA76?&K_F+8+*<&PYBZ,!(\;G.0Y&VQB/(SUA
MMD[>W@6N9Y 5CNZJQ!(1HB+&JUB@82B"S#!!#<*WM<.>[B(VQR:TX<P?NQ 7
MO)$@7I6F.1N9Q#+.'12=X7#/+0,D8=<S8_@#')'QP.(N6G1(5*A4>:,LLLL0
MS2PC":VV^ZFLVBF/8QE3:G)?S6P*99(C>(HV_>39_-_$LAR]"^.4=CWA>.8K
M+WE'X@BC:T?>U"<I"5V/0:< 0R[""#F5O4 \.F%<MG8/R!O;BQ)D)(Y^"N1$
M98\E9$B#([@7GM:ILD63L=P>58QCB]L7I3"EI2]X3C0"#?O%BK>S0?1S:2:-
MS7A8WRF$.D#'+8E*=3Y5((S*8R[('Z.R-@>&] O:7MB>VI0J;'=H=$)Y9R92
MG-,)/)&$8!"#>UZ" ^AW,IQD:%<7?'!CW:C;K'^.\@CU$P9=7 &5GGF5YTQ@
M6P1$M1'2J'8=B4_D<03+4A?:$&NB9&6< 8+@$+M =8-@C7797 VVV*(]G'6W
M*<2S#BF4"5DL\RAZ\2M -:W'73N34X)5!25T8WQL/MU%*!<0F6)Q7M8PH/3;
MI"JOBIPGQTXTV_Y=YOI9GG,&7,YY1VH"NWHAN1VQ8@BN&LV(\A; RB\/QB<J
MPKB\#C'[23($D(N<2[2PJZ9 DZ%O3TFJ@@7Z?;^<S]29_+_9_P#.7MK03WX5
M,0<=&+DF\Z[CTSUE[.J66;=S(W9 W*[4N:O(&>VPHPZ2PB( <,*X;,61UN+>
M+7 >79[(,Z;=1>9>PJ"3>Y/,#QKZ 29)!]L]LH#C&>*PMYHL?-S3.,GY";$C
MLB4.+4Y2&!XBBD\ET8:')$F$8G6.*)*E.L(NP#+W-+L,,IZ=\B^D._S([/FG
M^R..\VACZ9(MD<?8U3DQSR,H7 79H'"3XVF+;',A1MN7'!$42H7-B<DTXL98
M!7&6,(0FI0:9.X^PV^G-=R6YOXK]"<_OFHNF^H0;,FYFR4'4.":=2Z7V5K(_
M(H8V.,==V"1*VP;Z4OCZ..)W-K1.UVIU6NBA0E E2 #NXO1JZ/(>SFD;W-W]
M9,\6.3OAF6A9!Q$?UYJI/+4R24EMR##C/,BSGH\Y6,NUY,)62-181JI3<(^U
M"Y[BJTOVRT#Q9EW$FTVZTFW6AZ2;I7O ^1<A*)29/8?C(B.$%.,1E)4K=9:N
M2EMCL2,2,LE]=$P$O5"2%(6$*<(8&E/J8^#N'R);%W;>^-JW) )&$]3%L,;*
M3B.F77(TRXFZ*7PK#,@B3D$!*L 3KIUIMDYUAE&W :68 (6\8'V#PAM!C1DS
M'KQE2$9DQ?(C%J=HF^/W]#(6)2L;5 DCFW&J41@Q(G5L5 N4I2'A*4IS+=4P
M ;^Q05CYV]0IPVZWY#><5Y4WE@),WCBM6W/[;CZ#YDS4W,KHW*SF]R9G2386
MQOD"+(7QL7)C"5*(Q:%6G-!<)A8;VZ*#YM^>4W3QIXH=G=L<1[8Q]5#)9C#,
M>$,-9EPPYRZ1.#9LQ),:RUMQK&4#KC9M<Y-CV:D2L2,\A<M"V@:^T3K#5"<D
M9)X@JAX2O4+Z#M.BVGNOFX.\L\EN\+NXR2$S4C)L$VGRU.7R8S;.<V+QRWOV
M7AXUE\??#%47?68@A2:^G)T*:Y9!IA-B! +#8*FW*#H1C/,VP& ,D[*0S'64
M=6L=QS*N>&J>MDOAL=@<'EZ6**XLY&9#DD;;,<R-QD(9PTE(VQH=E[J>I6@3
M@37/L,L(4\[X[^<$?+7H/L/$,I[P9(:=8<&Y-P"JS=DK#.)\TQ^5P^73613$
MC#[<W@G.M$YO)VJ7N\)=2S3FED<RB"TMAG'I@&DC,#''J6MW(UH_Q;8CP?@#
M9O+>$]@,EDXM#K<^XX>\I03(\PQ9AY5!4<_7G9+QTU1YMC(BXQ(VP2Y*O6M(
MG'O0@$)C.H866%AW'[SH<9VXK]@;5K#6UBW*.SLIQNA+-B+EB#8QD<7F007&
MYLHR">OG,]Q4PQ ]:B11YP4FJ#W7^S!E7L4,XPP%AA\?"IB#CHQ<DWG7<>F>
MLO9U2RS;N9&[(&Y7:ES5Y SVV%&'26$1 #AA7#9BR.MQ;Q:X#R[/9!G3;J+S
M+V%09(V5YZ^(O47)3SA_.VZL#8<DQIQ<&:3Q:&0[+69546>VJZ<#HQ2E7A;'
MV06R-/S<>IL4>A7'IU11X#2A%V,)." )SZN[A:P;K8\-RKJIF^ YR@:5SNR.
MCU!W>RPY@? I$SA=BE#*K*1O\5?/#UI*CN;BE2J;D' ,ZG4&&]PDG0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!00/Y0_P";JW4_DWY4_<LOJ]O1A_6(Z+_O'H?H]J:]N/R]VCXP
MP^[AY>->GML:*!0*"R#B$_G+M./X8&[_  2[UCEZ77ZM?6/Q/?[O&@'=+]'N
M[?!)]FUZ2$A_OPL_Z/\ VJ17F;:[W"T"@UVO5/\ \S'L!_"#K_\ YY(A00-]
M&'_H,;4_RL1?YG\<4$)/6MRW'BR;<?L'1'-JC*S!&=AI/)"4RA,!V:H#*7/$
M39#KO*8*02M2A>Y!$WN[<(9X"TXT*SJEBN>(0 KSY;V*4QS@FX!F^8$+$[LH
MB>?'U(6N[6YXHM*3XA)H,>#M@A'W-3"7=O,3]'U/=Q@ZM[AZ+T&W5I!_NST2
M_P!6;FK_ #89'H-=KT6/^DINW_ =C;]WKE001UMUSPQMEZIO-> ]A(.CR1B&
M:[_<D2V5PIQ<'EL;WTR#6V<R%&R5RI@<6ES$C22N*(5!I 3PE*@$W)."8288
M6()7>JWXU=/-)P:>90U3Q$QX1.RDHRW"9]%(>->7$WL,+3P5ZC$@(:EJU64U
MOB:TF7IU1A/0%:3=/U[!$1UC S!S 9/FF8O2T\3L]R$J=%\M79UP2Q.3F]WZ
M[L\)X1@3;&#,SVO47_35RA[8XXF5W4F7$<J[;MC!",&(5POL]/IB'&V?O3VZ
MQX5S!$FN=XPR?%]J(;-XF\@,$A>6%ZVPS\E5D=J082L0K">M8U*K3&$JT:DL
ML\@PLXL PAH>[<E9UX2-S]Y=/-4]HCG*$Y$AAN(9C(H:\$'NZW%\R\,EK9%I
MD6C 6ACF9X8TK#6=<O1@*5H@K5_=!)0KC"P!NE>EGXV\$:\Z:Q7=I!(XGEC/
M^U$:$J<)FQ& <4.(H&E<C"OF69CSR@*4,H1O+=<R7&=4JYCH06C#8PA 4H4!
MIO8KV=GF=N93+&U&5=&9URD3%3DO+\L1ZJ,R:1.]ST3(J71R"A<HVPXPS,>Z
MP3#4>+1$$-BAF4(;61IK*#+A +M D;RJ8]VOY!YCB.=X&].]M/H;(H(TRIGG
MQN+==LR2!ORNG<5$:40M6YL\6U6PVULKM!O#7(NRRY2Y2O)<BRQC* C*",+*
MO4=/>7Y%PS\-[OL"QR^.9P/0Q8C++1D!G>(_.D\_;\ M3=*#IBQR!(A>FF3+
MW9(:H7)U))1I2DT81!MT4$EM6>$+C8R+P&@V;E. 1..QDKTGRIG [,9F0<D!
MDC3D>/0Z72..NK*TDRPF'H6UH<6!*&S?9MNC4D@&!2 [M3;C"$OHZXZR9,R%
MR-83GK>3*<394UTA$=R) 76YAL=ES(\/<RB3FWO"(!A?;DK(U*G%$.]KA%V"
MPP-KVZ:"">$]3]<G_P!3>\ZC/.((>XZU$;C; 00G#:I$<.&%Q"-1/)"UACX4
M7>+'V;VI6U)S"0]ITA$2'V?8H-T?*W!Q@^2;&::,6,,&ZS8_X[\&3C*>?L^:
M_#;GAT<\[[!/D!(Q_BQ2]0!\B,BQ^^0J&MZ()BOOSH48K+/.3B2& ZHZ#O7(
M!PBZF9^U1R;CS4;6#3_5_9\0HI*L$YT@V$X)AQW@61(3,&*5-*M5.L4X]-F3
M:RNA#4<@6=W3+>@E5<P) S2RQ!"Y#']IP&!0@.3K1T.20Q&-VR$&'K5SC$K3
MBS,BM++1=P<V>/.2^.V?N\=Q.4-Z$\U-U!&)R1WN6$.W4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4&6VW^]R#_ )DE_K!=!]M H%!YO>$_4"Z0
M8/YL>2;D V5A6?\ *UI6F:]9-0U&$(EC:8-D;PICYW!'Y)(E9F0,O8W QJ9\
M#'K(Z([H2UQ@[.SF$PP@)EP'AEOBZY>-7LF^I*R5DO6EFROC?7ODVQZTP2:P
M_-<>AD9=VK9F+QU.[QZ1HDT*R'D-N-22YZB*I.F,&X7,-<Y@K+$E+  @P(6"
M<\FLV(=QN<'A/ULSVQ+Y1B#)\7SZBG4<;7UWC*I]:F!,;+BFF[\P*V]];$C@
MX1\DI08B4)E7=Q#L4<4.X3 AWGU%O$_QV8CX==A,I80T_P  80R;@+YGY!C_
M "#BC%\5@\ROXKF?'$!?FN62B/-[=()TW/$3E2TH0'E4NZBH12JW2<5:]PPS
MS[L<9S%Z:K5#8_)L1B$USPEP[HP\M&7)%&&5XR+'%F6HIC-SR9:,S-R1JY+'
MTT[5IB1.Q:144%Q[ NRBQG9AZ V/M+M#=&\10/7_ #-B?3+5'&&8$F(H6L2Y
M6QYKMB&%9)3*Y/CQ$W254GG4;A[9*"5,A;W540N&%582LE2: VXPF#M<*:_2
MU_\ JGRR_P"M4SW_ (-CU!C=RW%]8N4XKRVSBCT$4-I:U4!O4'9%@X3CT0#S
M I#C0WY)R+V,-(L$0K7 #V;_ -3;\R@NSVN><RR/AAV3D.Q<3C\"V#?>,+,;
MSG:"Q-20LBL+S*Z:J2-=D^)QI6EDLT3*H_')L>N1HC"WAV+&F) (*Q5:]CQA
M#[TN/\Q1HS_[$S_VP]@J"(G"-_/8^HY_AWP3_A?/]!M<T&IWE#;GU=#5DO(;
M7BOBXT3DN,&V<RU!CB1O>0840\O\#1O[@GB#V[$'<BK <2YNL>+3GJ #0(A!
M-,%:Y!-_TL(=?YQ>3K>;3WB5U;!FJ+-6M>V>YCR1B/9B2834(Y$YZZ,H6M8\
M90.P4A3Y0D#.[S=?&PA2-:D<T$6CN<:,I<0JN0K1A2_E7GYX?(=P]Y@XNM+M
M==T(&"5X(D6-8G),B8XP$WHI%/9$4F&]9'RO(HIL$^.ZY^E+F4-2X*TS6HN#
MK )3IRTQ)))87V^F,Y5M>MJ]5\1:$X\AN9F;,&G&LT,^<Z23./0ANQJ^]V?"
MXT9Y#>&/(DBE#GTKG  [>(,[7^E6%?V!6L&X?%K6G%R.>H^VGV=5#,>\ <2&
M+DFIN&C1A)&S'[*SP$@095>$8!".1J'6+&J)BTKA%=906$AG-,&3T%%""S_G
M:_F>^1#^3-._ZTEH..X$?YG'CT_D[QS_  B[T%7GIL?])OGX_P!:'DW_ #@9
MHH-KF@U#W+<7UBY3BO+;.*/010VEK50&]0=D6#A./1 /,"D.-#?DG(O8PTBP
M1"M< /9O_4V_,H-I#7IYS+(\!8/D.Q<3C\"V#?</XT><[06)J2%D5A>972%L
MJ[)\3C2M+)9HF51^.38]<C1&%O#L6-,2 05BJU['C#6FE'^^ 8X_U7B[]T$\
MH-KF@J-Y9>./8OD6AN*(?@+D4S5Q_D0A;/;Y 48?;9TZDYE8YHU,+6FC<Q0P
MO.>$P*FIA UJA%E+1N9)EG T-BRND=S J)X$\DR#1?=;:'@RS/A'!$>RQBR*
ME[%,>S&!4\X"=L@S/1,,>%#[FE7D20RR5NV0!,V3$8TQXE25$@+2*F\M/T%$
MJE8;=%!IM<\FLV(=QN<'A/ULSVQ+Y1B#)\7SZBG4<;7UWC*I]:F!,;+BFF[\
MP*V]];$C@X1\DI08B4)E7=Q#L4<4.X3 AQ?J<N+SC[P3Q(RS+.!=1,"8-R1A
MC(F&2(G-L1XTC&/Y4O:Y1,F> O;1,Y#&6]M=Y\B6M#T(V]WLYP,"L* H"*QW
M6'<+0]3^!GB>2Z*X^QP?I;A63.&5L&15RE>5\@0]LGV:_,TYA"!P=9.PY5DI
M*R:PUQ3.;F,](4QK&M*CN (2"BP!M:@A?Z43-R.&\'$GGN4Y*H1X[UXS%LJX
MJW)Q5&J4L3QO%8_',KR6Z4L\RP$;<A4O[JM$4"X2^T-,'[%QBO04*<2/J,=(
M-.\H\@^T&VF*-I)MLUO1LNZ9)5NN(8/B:51J(89;+N#ECS'R9[G><L?O*96Q
MNDL=$YR9.W]UNA1-W2H/$78"<)T>F+Y#<#ROD]Y(];\#IIO$=;-N)5(MN-:H
M1E%HCS!+8A*FAU&IR)!;ML7ETS9RC#HW+K63!+<G"XVB(DFB,*-N<6()!;+:
M::V[Q^JV68HVGQH@RWC6,<=L6R@CA3PZO[8QKI?%Y*D;6-2^%1YT:%#TV(RI
M"H&- H,&B4BZMCRC2[7!<.3]3=QM:7ZV\?S?NIJCKYAW4W8K6;.>%9'!)YKC
MCN(876+O&9PC9+(G9L@#0PLSPM:'IQ1/*%<>F,<$2EK!8DX!(SRS V[,-S%?
MD3$.*L@.J=,D=)UC>#3%R2H^O9(F7R>,-;VL3I;&7$99,2H7""#K7O?JVMT^
MS09(H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H%!YT.@/&+MOOWN;S.R76WE7V,X[6G'?([G%BE$6P>FR8>W
M9+<7O*N6%[>_O]X%L9@],%:PID8TY/>$Z\?4/%U3"[=(1!>UJYP/\C&!MB\+
M9GR/Z@W=?86!XPR-%YI+L'39#G0N(Y68&%R)7.,&D8WW=:;,P6B0)RKIS[JF
MAR)Z@[]9.9;ZFX0\X[-5<#\J'-+S5;([S8]C>PZC3_8IJU9P+B?*R1/,L<0^
M(0V69;@I#PMQ\[$CC#ND5MN*23D"5:D4(.]NCFJ,*.6&V4A#A><W3?7/C'V<
MXL>1317%T*UCRQ?=O'>#Y[ ,$L+3CN&92@<J;U"IT1F8RBJ)LC*42V,L+DPN
MAS:0B$XII%>ROMCNP.*#D^4W4/8##7,T]<D.1^,);S!:9Y P!"\5M&((]&D>
M7)3@22LJ:.,2M6W807,,RO+5);N@<'0CMF)8T]C)E9UU:)4E$8$)0<7^X' U
MLANK!F+!.BA/'MR&PV/R0N!XSG&M\?UAE\@;3L=ORJ<EQM)AYR%CR9$BALF=
M3.[R E(]+42+OQ:'J($YJ<.7T_\ ]ZYY:/Y$6N7[CM6J"#VG''OJ'O%ZB+FD
MD^U^'&'-Y.OLSP\]8XB$U.6KH 4]SJ-*&YX<Y3#"U!+)-^P01THM,D=REC<6
M(T9HDXS@DF$AVCE=T^UKT8YDN ',^G6%\:ZSR+,VUCSB+)K/A*&,6,XA)XO:
M5X0B 3!Q&%I&.-H7-7$LMR%N7J"4@37)*M !0(820V$&4>7W'$>W\]0+Q9<:
MV?CG-UU.:-?<@[83#&Y#VX,K3DV9E?/L0F9'+PHU"L4")38-1)C3 'V4D,[D
MXEIAIQ*33!AGOG&X8^-Z_&#LWDO%.JN M;LJZT8?D^:,89.PACN'X>DP'G&S
M:1(1Q^3NL+9FH<\22]M91MEBGFRXT*E98].82KO8^P58\NN69?MKZ9OB7R1F
M1>ZOLRRAL1J.R9!?W(P9;Y*W%OQCGJ"O4L7JKW$(;K+@M G(T^UK6,.57,"$
M-A6#8-D]5P&<09F GC7AOT.U_:HX[1E7&RL@%PAM<L[M)BA$%*3(6S/CV!SS
M 1(D1Q8%!:B[R*US;7L,(BQF $&LKQZ9#FDI])=R?XUEKR<_-^M4MVOP- W,
MXY0<$^%H(YBG)I=DH5!I_=D!<GR@Z6() 8,LHJP0AO['18+<N$?AHXPE?&1J
MKE&<:78*S'DK8? T%R;E"<YS@K)F.1+9+-8XF6N5HNIR"D?B,>MB()UBDB=@
M+;0E6+L:*XU(C3S PEZ8Z&-N!]G^>/4N '+4.#]>]\DS7B>)*%BQ83&FU;*,
M]0RQ03EBE28J6^4,8L"(]4._;*K-I8S+WOT6"&4?3_\ \X/ZC+_60N'[N=A:
M#KOI]OYS/U)G\O\ 9_\ .7MK0=.].--%&-]?>;/(B-"2YJX%R);7S1*VJ31D
M)W!1%H2@?"$)YY01FDDJS4-BQC#:X@A%>]K=-!AWTU?&[J7N/J5->1[=O%..
M=SMHMH<ZY><);)MB(VQ9@:XVC89(:S&-Z:$S- [Q-!('EW*5N9RP:,:L*16D
M))&404 %PVAM>>/G2G4K(D]RIK#K5BS ,RR>QM<<G)N)6"T&CCVS,J]0Z-:3
MR)'SD4$;!(URHP834;:G.O8=PW'</U-!,:@TYO3&/2"#[L\[^OLX&)MSHT[G
M+IP[M[J,P+M)(JGR5G%@5/B"ZWLW)U;&I[7$G&JA%V+$!^2&!$+O-J"SOE S
M[S[XKS[$(]Q7:1:P;*:^+,/L#S,9UFN61MBE33F51-,@(9#$V](\;=X"4F1]
M#"6Z/+"C LZDNZE>>&RPRX1$)PQ5PO<ON<-TM:]Z<R\C,<UYP%?2[*\HQ_D@
M[&;5*VB%1F,P:&#?,AK)<?*,G9=+>3F1:D6%7-;5=TR@DNP2@'7$$0PI2D?)
MMQ69M#,VGC\]+D=O&PHA+VM',85H?B.#,KZU)5@&:02!M><58 S;,8LD2B6%
M"1'FI$CB$PXJQP$!][!"'=_3.1F=Y0QYS[Z[8UQ]-='SI3+6]IQ-@N=O,O<W
M[4B>YA@VQ421LKHLD<<B\O,=\=F,;*F/4JFE(ZFE,Q/;%W-!:@BWIP?AOB,P
M.3KWRU>G E66GG'+]-E\DW<AFK6'MN(]D-M<W:4OS(J7SS)2#R2R^",[=W4"
M))+R2BVA&%<-"G,$: T+ZV]LXB=F>"3?*0\?6*L22#6=%A_:O)M\?O,!7*DV
M+=G(3KDK,(?K0+)Z=U.QODJ+(&]F<$*IM*3EA&<6YHC1B5B5'!U7TYFA6C.1
MN(S1?..0M,-3YWFM4DR=(%68)EKIB"3Y24O\8V.RJCC3V?D![ARZ6'.\>2,R
M,I"I$KN<D+2$A*$ )0+!"%1F@FK>_'JJ.1".;88Z#EJ$X=UDUVRC&L?NKNZ(
M(<ZS.V*=<HL@72]M:%*!1)4#6W/RH12$\_N)IAG]D%'@MU*#/WJ:M3M6-7^%
M_8'[FC6G7_7?SQF;6?SK\Q>&\=8D\X>69\M\N>:?($<C_F#R_P"8%_<>]]MW
M3ORCLNKVQG6#]/5+8RQN_P#"!%\H/V/H0]Y+QXXZY,\ R([Q1A<IU!FF:.D2
M3S%KA\M6(#G^,MTL(:4H',A$H(*7@3%6/".Q8.@+R]+M#=&\10/7_,V)],M4
M<89@28BA:Q+E;'FNV(85DE,KD^/$3=)52>=1N'MDH)4R%O=51"X855A*R5)H
M#;C"8.UPI+],NUNCYBGF+96-Z.C;T[\FFRC6SR),58Y0P.CA&V=(WO1!(A "
M:<U*S0'@#>]K"$7:W304[::XY8N'N(Y&P;RT>GNE>X:QNR8_RD_?3&^N^.-T
M&:81-]NH$S!4.^2F95%8UV;E<H2< I*RKE:9QN%P;$S@@,LL#;"X6\I\5&9L
M!9%R+Q30V.XRQ])\D <LS8Q:H\]P5YA^4/+;4B3ER& .3@O9(\8NC"%+=.<Q
M"&RK %"[(XPXI18L+CZ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"!_*'_-U;J?R;\J?N67U>WH
MP_K$=%_WCT/T>U->W'Y>[1\88?=P\O&O3VV-% H%!9!Q"?SEVG'\,#=_@EWK
M'+TNOU:^L?B>_P!WC0#NE^CW=O@D^S:])"0_WX6?]'_M4BO,VUWN%H%!3'S[
MZGY_W7XRLP:]ZR0'YS,ORF8X?=6*(^:85#>_((MDN.2!]/\ '\@2.*1A+W%H
M0&G=4Y:6,WJ=0NPQW"&X:@^G''WZL3C_ ,>S'%FHF*#L006?28V92MG3Y$XX
M)FH<9,<R-\<&[$/F1)O+I TG69VI.4$*)4G* (NQ@0V,N(=PE=J;Z7[>#:79
MZ^T',?FE*[MA\B0O\VA*/(RK*.8<P#9PD 015\F;7T1+'>/.[$DI0V:URU84
MW$#0HTK<&Y"LD+L/43\2^2^1/3;$T<U298[?+NKDK/>\=8N-7LT09I?C]XC2
M:+R" QAP<U#5&(Z](@,[0I;.^J$C?V" U,(PNYI8PAKX:?Z?^J7<-6)=H2R$
M+->=6V+'V2HUV>6TV 02-Q8'YH?'%9AC'TC5V>9\J3SYR6GH$:NZE(TMMEX@
MFNJ)($ 0A8UZ87BEWZX\,W[22_</ OS01W(V*H1&X8X_.CAC('C+TT2Y<Z.*
M+NF+LBS9<W]W0G!'VBHH@H?3U0B$+IM0:V47.W#2^I'VA5Z")(6X[;H]YN21
M;B)LR$)G!$W4]&?LHIFC2O,D*I"QEK'7'13NG0B5J$R<+@81<9Q(;7- %C^;
M>*[U#7-%LOCI7R#Q"-X$QOC4M2QH9([.V+$&/,81I_<$2F8CQUC_ !S,);*)
MQ,)-X$4,2A0:<!2-*D)5.25(6F[,+XN>KBOS;GCBJU2T?X]<-BR*?KQG?#1[
M5#3)WCJ$J6W%..,"9NQV.0+I#D^6PIC=7(3S*6P*H(%1B]4H6C/[(00G# '(
M:KX@Y4M ^ O!NLVO^J!TJY!6P.<8A:*'Y=UU2L&#RLAY^S/.VO*;W)Y#E--C
M^9'-L0DB!2W-C8O<A"<EA 5I8"B%1=@JJXR?2R3+(6+MK9[RPM#Q&L]YJ:Y%
M$L3-:7(L9R#+,;25V<$TI<]C9#*X/)I5')+.7:4E%%I49KFI 8WW<0KRQ#7E
M]W#,_ OI7S:<5.R,PP3EG6<4]T*RG-W)')IA'\[:\K$,$DK>>)D8-B(-$%^7
M$T]O'9&SH$X7QGNTDO2AKNG.[H)<WEHCPPYR"< O(7J[OV[<C7#DZM[RX.TX
MD^8$V.D<EAL5GV,)E+S5QF0XXS-F1EC; <AXOE1+ZX=FUC46/L@4FM=T)X2R
M#% =@<MB/6&[!M*G%#%K-#\#JEQ9;.\95;8OA_'KL@2'_P!BK71-)<CY0DS.
M49V9)A@CV)N,6E=?KI A'<GH"4G./Q@<BVX_&WQGX'QE!SME-E< L,$3;)OZ
MC,$";E#M-VG T?ALVFI\XS9,H(IFQTDGR)6<)8(9C@K$==0>6&XQ7H+9=6-5
M<]XXX-X[IY-('X-L:@T9R?AU5COS1#''LLCR*"35F9X[YN:I$N@H^^.3NG+[
MV%SN@+[3K#/" (A!"F/TPO%+OUQX9OVDE^X>!?F@CN1L50B-PQQ^='#&0/&7
MIHERYT<47=,79%FRYO[NA."/M%11!0^GJA$(73:@A#R/<,7+!@CEQE'(UQ\X
MR:\\-<GS;?82"NJ)_P > <X1-GPKQ"40J?P.=RB+K7%G.=37$DA6W75)C6PX
MKM%"18,)80VK.)'(/*'D[#&2I9RG8JB.&\J*<GB28OAL/)AZ5$'&:**Q\DQT
M5(XM.)^L2JETPLY?4N:X"H0 6&62%,(@0PM=H% H% H% H% H% H% H% H%
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M*1$".+3$&*@)^^* O@H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H(4<D+22_:%;<,:E[9HTG><#
MY":E$CD1B\J/L!#@Q*4AKT^&M3>[NA;0UEFW/4W3)%2BQ)8NS),'U0"NKT<=
M7?H._'26NQX,VIR8=]TE\8<,63ERS9EBZ,>*+[\=DY+YCPV>.^RSQ3'BOMBL
MQ+^@,LX.MMKS6V7Y+K-;BNBRVGBNI=$^&WQ3;'BGU(K=$5GC,1Q><S]RK"_O
MU=/_ ([S]_[+W7HH_.GO/]B^K_G>U_UJSV_&75_@C=?XNF^VC[E6%_?JZ?\
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M7;*&X@!!/:#L#M3AV6BN HOIZ17M:_1:WYE"CL@1=:X[=40>H*P>D5NBP^D
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M#+4JB#>)V"OE4;QPK=RIB^1M$)A76.7)49J4NZ(_K#MV)G5#*= H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MHS9OCDC:&R9GOC\49;NK39M\5.']0%-<=KAL%0B3U5'#8IE!$?'FW)J-L.<
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MITS+@-Q;'-N5$+6]Q;UK^<I1KD*Q,,U,K1JTQH3"C2Q" 8 5A!O>U[7H.O\
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M)N;WC7W_ )LGQ9KYL$E'EQ<2N4M.*\B1B38VF<A3MJ,3@M%%"I2VHF28*DJ
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MZCZ<33 ^/]F<S-&(Y+LQ)'^)X9!(&"9JV*2/45M'12(+Q+V*-NT0@#8SERM
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MV/9]4?7ZX0:E\B_W4>Q63<!?,[Y&^;F/S1]\V?.#YF\9\H3F-PONO@7D>/\
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MI5+])\&96F^R^I&!LK9;GV8H:VY1G3A+\MX=8)7*%4/E,Q*=7;%J9,NE:@M
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MQN3*(9!X]M'IA E:)9$7G4S7TQEN@& 9",E)BN+-Y[08$O\ ]MEK&L2&(E)
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M:-<<39KC.9LD^=,>-?DU[ET,S&TQY%Y.>I8W3Z0^(.$J0%]HU-2XDKM^L:,
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MJ;7<ML;BY8 T%R[@-AY8K##<-ND+.N$?17\7KQNZ^X+?6T2#*[\QBS'GTY0
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M"8HKB^R['?..^*7VS,3'*8X2^NOD_DH% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\
MB59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@
MY_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\
MWH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[
M2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\
MB59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@
MY_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\
MWH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[
M2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\
MB59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@
MY_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\
MWH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[
M2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\
MB59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@
MY_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\
MWH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[
M2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\
MB59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@
MY_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\
MWH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[
M2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\
MB59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@
MY_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\
MWH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[
M2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\
MB59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@
MY_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\
MWH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[
M2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\
MB59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@
MY_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\
MWH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[
M2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\
MB59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@
MY_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\
MWH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[2A0\WH?@Y_\ B59[
M2A0\WH?@Y_\ B59[2A14YR \=R/D&V/T2R;D;,<B8, :897-S@\ZU$8;7/1&
M<LEH3VQ3$'229#'/FHF/M$5&T )"B\ON5E21:X$C,M96&Y HMC\WH?@Y_P#B
M59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y
M_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\W
MH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2
MA0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B
M59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y
M_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\WH?@Y_P#B59[2A0\W
MH?@Y_P#B59[2A1^J>4HE!Y*<*![ (\TLD(S6A644 1H[ L(TP0>J66&XND0K
M^Q:WLT*.R!%85QVM85NH*P;]-KVM>]P!'TAO_P"$'H'T=/\ W;7M_P %'X_J
M@4"@4"@4"@4"@4"@\@&O7BVGE H% H/7.QY_Z@0;_$^,_P"!45>2;J'[_P"N
M^&9OHES5WK_J[-\UO]U+N%=.XA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0<4^
MOK'%V9SD4E>6J.Q]E1'N3R^OKBC:69I;DI=S52]S<UYR=$@1)B@W$8::,  !
MMTWO:U!$J.<C''O,(U.YI$M[=-93#L7-C0]Y-ED<V?PD]QK'3-('M)&F%VG;
MZV3A4UQ%L>Y&O(;TBAP-3E*5IQ9!8A&C"&X2NC,FC<UC<?F4-D#'+8A+6-ID
MT5E49=D#]&Y-&WY G=6.01]\:E"MK>F-Z:U92E(K3&F$*2# &%C$ 5KW#G*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"% ]]L' VL!J#=/-+Y$&O\'\T
M!;&*^.+2#RE:87CUW[S+XQ=X"B$%+<NS;<(5XK$7%:_3>P37H% H()Y:WY@^
M*LT/F!DF$-E\NSZ.QMIECJFPGC5HGR9,Q/!209"XPDJ8MST2G3FKB23C3$8"
M0'&@!88KB#TAV3!N\6(<X3U=B:S#E#$67$;>-W!B[.$'/@$T<6HD!QQZYL0]
M^=D*L)"8KMA%6464=ATF6+N !H@!,B@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@@?RA_
MS=6ZG\F_*G[EE]7MZ,/ZQ'1?]X]#]'M37MQ^7NT?&&'W</+QKT]MC10*!060
M<0G\Y=IQ_# W?X)=ZQR]+K]6OK'XGO\ =XT [I?H]W;X)/LVO20D/]^%G_1_
M[5(KS-M=[A:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!09;;?[W(/^9)?ZP70?;0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0>0#7KQ;3R@4"@4'KG8\_\ 4"#?XGQG_ J*O)-U#]_]=\,S
M?1+FKO7_ %=F^:W^ZEW"NG<0H*'?4(<;>#=]]&<CY!S!*LKQMYTLPWLCL/BU
M-C5\B#.V/\UC^('9[1-<_)E$%F*MUBYJN*)PFD-QS4K$6,RP5(;W"( 5O>D?
MXV\&XCTTQER5QN5976YUVJQSF'&.0HF]OD04XF9F" ;036,,RN&,2""MLP;G
M=2@Q2W#4F+GYQ)&<<IN HL(R@$A=C,^;CBNQRHV&0Y W(Q[!W75G(SMB/,[%
M+6'(D=D;7DAB'(2G>)0B-NT,2/N9'-"9%EMA^3$\@*Z2P= []N1VH<CKCS2\
M66U\2R9.<*[K8?<8UAQHM(\FJ\@GR+!RV(1CMTB,4K<F3.3!CA],B1;@O3I!
MNI*8UO L4$IQ'6/-++$'1L'<]?$3L=G%KUQP_NQC^29=?WHR.1IB=(GE:#L$
MLD(7(AH2,,/R'/H!%\;RYZ>W)464UI6UW5'NPAV[D$^WLT$R-I]YM5])_F?O
ML_E9-BLO/636K#V*E"R)SR3)))D-Z[/PYC5+(5%I(EBZ8T)EA#<'<:!L(#TB
M-4 M:][!!%]]0_PN1S*ML-.6_F)C)A=U$S7=&ACR;(L7EK0'*"!#.SA'X(Z8
M5(;@F)A=*P<@"CL&X1=KU1@N(,F;2<WG%-IG)4D,V#W4Q='9<K3H58HQ"4,W
MS8_MB9S2#7MI\A:,'1/(Z^,%N" (3R;N):7M2#2C ](#BKC"<>NNRN!MML41
M[..MN4XEF'%,H$K)9YE#UXE: :UN.NG<FIP2J"DKHQOC8?;J*4"XA,L3BO:Q
MA0>FW2'2M/MU-9M^,/%Y\U,R7\Z^)3I,^0XN6>39_!>M(XW9&)Z;O LE16'2
M6W<K.!/Z=='8@SK_ *6,70+H#YTN[^KRW<!RT)39.[7;%HQ<7F=PQ3Y+R&#N
M^-#5"!*"2>>C(F#&QO6/<R ]S \"7VZ_3V'0$5[!BS('*AQ]8ES/G;7_ "OM
M! <793UH@T8R/FMHR.EE,%CT.BLU11A?$#B<A2F/-6.I6^24F9-@$+.RNSB\
M*5"L) $HC@C+"&--1^:[BYWIR@?A75[;J&9!RJ!,<J009XB>4,7/DE*2DKE2
MT,()RY!8&5/E+>B;3U*DED&O.3)2[GFA 3>P[A/'..>\*ZSXU?\ ,6P64X-A
MS%T8"1XW.<AR-MC$>1GK#;)V]O M<SR K'=U5B"0C1$6-5K% PE$%F&""&X5
MO:X<]W$1MCDUIPY@_=B O>2) O2M,<C<SB&6<.BD[PN&>6@9(PZYFQ_ &.2/
MC@<1<M.B0J5"H\T99998AFEA&%OE H*.L"83XZ6GG<W?SCC+/.8)%R22'6B
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M(23%*BQ9 !&6#'Y'J&N&!5F)+@M/OUB8^<K7DM@3.93)DL>*#'$Y/=25?Y_
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M7NT?&&'W</+QKT]MC10*!060<0G\Y=IQ_# W?X)=ZQR]+K]6OK'XGO\ =XT
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M%,X=S5:T<>D?68(@J-%@S,NZDLUXD[L)!*)^G59&009K>VQ$M87Y6$:$IR
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MUZ=[1:F[DZW[7X]UEY$]=VE]+UWRJ@D.?<$[!8UGKMJRDE<#D[(UY^>EN/\
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M8#+!/'>P;NE H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MSW_@V/4&-W+U&/*0B<5Z-/Z9G?M<0D6JDI"XEPV([%820>846J*ZF@IP.S4
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M?:(RTYIG6Z!B$&UK6"#&H,1V=GGI&X?#]-[R 6QC_JWDM! 4T16'()@Y(Q;
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M\!?TBUQ.4(/'H@\2",NG9EG@OVJ):I(OT^P.][7H(&<,.D&T.IVV_-9D[/\
MC'R#!]M]\IAF?7M[\Z8\E/S@8T=,F9XD""2>&PJ62-WBG;M$S;3NYO:=M7A[
MSU!$6&6:$ 5!X!TA]1=PW3?/&L7&EAK5O9_3#+6:'S)6-9WF271M"HQ$GEA#
M6P%KEC \9XP_-$#XSQIJ;@.R8A!*FU0<U74(RAF*#2C@E#QN\;'+=B?FS?\
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MIBE,_P"HNG3>N*-<RYFUNZ5Y990^QXQW?G:-EHI8T)GAX<'PQ$^/CBT-I!*
MAF)3V+"7?,O#MN^1O8[ O$AA?&^=\9:C31:S9:WXW$!CZ9L.*E^,8XJ)?$&
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MO'_-5_\ P/\ ^M__ &AE1_B8_P#1/_.?_*G^RD?_ (>G_OKG_P",53_FJ_\
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MA?YM!8KB?T_G*1,X;C3)*CU*V_:<B5QF&S@^.'%;$+R2"7UJ;7XQD-7CWQ(
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MOYK<:H\61WPO*WS\0";^,>'1YG)8O_05B;4[\W^8DE^V_3#+]TZ.H9TBH/\
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M5</'S[DJS9.X*1E/'DNQ\=-8.ZM[$!KF42+EK0T#D<4<ADCLG<4=CD9UPWL
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MYU"DGB[9]N$_]\7YU"DGB[9]N$_]\7YU"DGB[9]N$_\ ?%^=0I)XNV?;A/\
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M/VE"DGG&,?#2/]$/VE"DGG&,?#2/]$/VE"DGG&,?#2/]$/VE"DGG&,?#2/\
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M#^=0.S+_ %,'Z$/YU [,O]3!^A#^=0.S+_4P?H0_G4#LR_U,'Z$/YU [,O\
M4P?H0_G4#LR_U,'Z$/YU [,O]3!^A#^=0.S+_4P?H0_G4#LR_P!3!^A#^=0.
MS+_4P?H0_G4#LR_U,'Z$/YU [,O]3!^A#^=0.S+_ %,'Z$/YU [,O]3!^A#^
M=0.S+_4P?H0_G4#LR_U,'Z$/YU [,O\ 4P?H0_G4#LR_U,'Z$/YU [,O]3!^
MA#^=0.S+_4P?H0_G4#LR_P!3!^A#^=098;4Y%V]!>Y!-[W1);WO<L'L_I /_
M ,F@^WNZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_
MU GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#
MNZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#
MVM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)
M^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG
M_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0
M.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0
M/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U
MGZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ
M?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM
M [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M
M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4
M"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[
MI_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:
MT#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZ
MT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]
M0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [
MNG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]
MK0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?
MK0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_
MU GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#
MNZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#
MVM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)
M^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG
M_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0
M.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0
M/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U
MGZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ
M?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM
M [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M
M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4
M"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[
MI_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:
MT#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZ
MT#VM [NG_4"?K0/:T#NZ?]0)^M ]K0.[I_U GZT#VM [NG_4"?K0/:T#NZ?]
M0)^M ]K0?[8@BU[7L25:]KVO:]BP6O:]O9M>U[6Z;7M>@_6@4"@4"@4"@4"@
M4"@4&J=6,S3*4"@4"@VFV'^\3+_[J6[^TR:R4P_\&SY&/8;C=M^]VG^8V>YA
MRU?5S2@UN_52YSS9KSQ5K\AX!S#E/!L_!L-AYD!.</9!EN,YB!F<RY7=R:0R
M:%N[(]!;'"Z8OMT]C^R-[,/7#?JVZ X7@,VYV%:)YN%Q)[WY*EN3=N]%LC/K
MO#<H9)D#U(YSGC6V8OEE\<GBF02AV>I-)PLRU^1*"E2Q0,Q.Q21G1_FI3.@/
MK=\[9O*]4Q%M?"\R95+P&HXU5$[480!D.7 Q ?. R^1I@S([&H7>T,-E=DQ
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M)E6;XMQ&_:^DXIQK+LARZ2P#&)+TTR,QX*Q[#7EW6QV%ENQA !*0MJ9-8\0
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MZG3032H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M9%:D#U!Y;KKF5GDS>Y%7,2C;%./I!VJFUP"+/3*V\00J$Z@D99Z904 TH8#
M '8-$[5K53(6[GI-2G2*"<3LV:)["9FV'U?=&LDWS,TMV,96HG4[C\96I!V<
M[*7-LELD5(R">M<YX3(K6!<110@AM"0GF5Q^LX+TW+$]+&-P?6+742Z3QDH9
M:=$?M,UG%XN48W-1 &D4MR!^SP(I,1;J ,\'6%*RPB*&6(05<ZAX-VRX\O3;
M;/[5XI;Y$\<B.V$(D^ZT]E!#"4X9$:E&7'5C/(?@(;H#E W[&^"W!7+.Y&I;
M!;Y H7VN1T]>P@ITT<XZN"7??&.)<SYHYIMD6+D.F\9BKY.3\L["8FQ7*XWL
M.?X<2E:(XES?CA=.YXIC,W4D$MIC7-%BUY+(">D4)Q#O9.%A'J.N+6&XLX7<
M#Y&R%L;G/8/+?'X89CK%N29<^M1I.2X;L;G&$I#C,JDO:6:R9_=81!VYL:VA
M0W/S:EM9'VETUDXRD:<)W:#\!NGO'5@;*.ZF$\D;*RC*>6^.O(T4D;!E.88N
M>X B;LG8YC>0GXYD:HEAR$2),M2/463E(Q'NJD!:49@3 &F7"8 )&>E7_F.M
M2?\ &+9#_M+Y:H(S:2?[V7S+_P D36G_ #0Z94%9,"X_\O\ (ASM\V.(HUN;
ME[4K C7/,,N^Q35@D0&G)6;VQ5%UB.$PI#,1GE$Q9A:U87%4NNH)<T:NXBBC
M6\^_9GI0YU;H,H].UR]<5#=ISL/G>::V\@^67W7_ #!B?+TBC;MWI:-WQM"S
MW-\M"XWC^+/Q9!N5VYU9SPLQ3@UJV(P U!Q"FY0PGOR^9/VYW\Y4,"\(FKV?
M97JQB8_"OW26W.9<?#>6W("^.]]?.[PQ X-*]G<#V%,TH6PLE,2M3(7!UD8/
M$.U);PE"#G,.^DVUWU5R%CK+^H6^N^&%,FPV6Q.02%S43>#K8[.F:/NJ-P=X
M<ZM&,8;A60 C\G2%J42@D]Y6E=U5C ,LZUQV,"E;.?!AJ7L!ZE+,.F<RR'L4
MV8OS;A/(.[LJ?HS+<:(YZWY6R3,W>7/D?C[HZXC>8\DQZD<GDT"1(I:U;D60
M$%C%YHK7&()Y<T_&;@CBE].WG76S7B69;F4&D&W.),NK77,[]#I%+"I))WN"
M1A>B2KH/ L=,X&,E!"4@R2QH!GA.,-N(X81  6%D_.GO'G_4CCLU8Q5J2^&1
M'9W=_(&%=7,:3P@9Z1PQ\@ED5(.DDJ8'4I(NLU28X^S>SI%(2A*D('<U<DN%
M4C)&$(*NGI H6Q00S+N..17<A'R+(6%4_I=B%TR9FB$O.5PM2HL"VR1FCU\W
MQAE=%-R4@UOG=T<$J6XS>A1?H3V#Y\8;ZYBWZ]+3R 2;8Y:8Z[$:^0/.VLF8
MG]8G3HG:4R''S7#W]GDCVB2A G"_*HC-&]*Y*"[=DM=42H^U@W&(L 8.T(]-
MZV\CO'MJ?F#>[D"VUFC5(<#8\=]=,+XG=X;$<2:^8^O$B44'C88Y-HED)ND[
MXB:3;#<5[>DCRA68<86::H,ZRT\+"/3#9)SU%2N2_CMS=E*09G2<<FVJG$>,
MY_*%JQP=#H8Z/>3HGX*@.<'!R7(XN!SQ$:[-Z$XTT3=9Y-3A'V19910;55 H
M% H% H% H% H% H% H% H% H% H% H% H% H% H%!JG5C,TRE H% H-IMA_O
M$R_^ZEN_M,FLE,/_  ;/D8]AN-VW[W:?YC9[F'+5]7-*#6[]5+@S-FPW%6OQ
MY@'#V4\Y3\>PV'GL$&P]CZ6Y,F(V9L+E=G)V#&86T/;T)L;[J2^W46([(KM
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M*2,?S+:_TPW*T\QZ3HG2:8M6&)4,J:TM[MT<V7UG>G<XQDE\=L<==N03AA[
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MVVU6=],YY)HV_@AV!I/=^',XYBQ+-L:^45LV.DJ"/O)\H<E!JRZ@1S*P"L$
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M?>3'BFE#0NC\FY N/>1,+H3W=S9'W:W7!W:'%/UPF=@N;7">J$:LGM !%U3
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M#\,C77Z1J!^-BXLOREF@'X9&NOTC4#\;%Q9?E+- /PR-=?I&H'XV+BR_*6:
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M $/\6_O(I^*^Q?S'^_D^7/N]NO\ ._[MGRK9M8U)RQE9U:D?:*%36WJ3S.J
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M+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'=/\
M\&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\
M=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=
M!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ
M!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO
M^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P
M:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW
M3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$
M^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'
MXO703[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[
MRJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!H
MPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/
M_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[
MQW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B
M]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*
MH'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"
M_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__
M  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'
M=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+U
MT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@
M?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_
M +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\
M!HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T
M_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO70
M3[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^
M+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\
MO*H'XO703[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &
MC"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_
M /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/
MO'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO
M703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\
MJ@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,
M+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'=/\
M\&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\
M=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=
M!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ
M!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO
M^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P
M:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW
M3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$
M^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'
MXO703[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[
MRJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!H
MPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/
M_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[
MQW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B
M]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*
MH'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"
M_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__
M  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@?B]=!/O'
M=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_ +RJ!^+U
MT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\ !HPO^\J@
M?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T_P#P:,+_
M +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO703[QW3_\
M!HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^+UT$^\=T
M_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\ O*H'XO70
M3[QW3_\ !HPO^\J@?B]=!/O'=/\ \&C"_P"\J@?B]=!/O'=/_P &C"_[RJ!^
M+UT$^\=T_P#P:,+_ +RJ!^+UT$^\=T__  :,+_O*H'XO703[QW3_ /!HPO\
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MQ"#8IYGH7RHS;!>*V_B>EGE',23+-EF2%OCN+6#O.-/)\D)NE[SE9*K9SO\
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M23=R\@0EY>5D:AWB%[W[?PY,F[7I^JZ:#9QH% H-<[U*6ZNY.DVK&L,ETAS
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M*!0*!0*!0*#2HJ_E1E H% H-SR-?^KD?_P#=(U?V@15"Y?\ BW?)3[*V<?\
MP[?V(]AS=?-_90:M'K!OYGMQ_E,X0_K4RH*D=Z^5OU.&M^ 88@VIUHU1T.PQ
MF=^C6%T^VF.VQ1DI?C(N6-UT7C[PL@^R^S(H7W>/B/7 5&1@;B.Z0=FT U@
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MM9ESVWI)UBK)T=1=U:);&74 3RQ&]S*(-2+"Q!)*5$]>P;+_ *VW_P"!E_\
ML9W_ -2A08>UCX".5#<Z#<=NV>8MS\+2#%$+Q=J=/,$XED$GRFK^;S 48BL"
MD..(<UQYKQLCA4=E'D)(E)<!);'B4+[C-4K51HS#A!AWG!W&VQY/N6Q+Q1X5
MGKU!L(QK-\6UN9X:WNCJUQB6Y#6J6I#DG*N743086?*6F$.9RZR5*=922A9V
MH9Z8D*I6I[0+"LG^C7BD2QH&1ZJ[LY/0;-Q4E&\19WR(S,\;Q\[R1O&4;8*1
M? 4]YQC@1Q@1"3+BE+X8D,L&URS+=(PA5#ZOAN=&?D,U>:7M1WQZ:^.C"C<[
MJ^\&J^].B+-^RZ9>H[T?8)ZGMU90Q=H.UACZ>F_LWH-@GUE7\V'@G^7EC#_L
M^;0T$1<0[(;%ZJ>CRQ%EK6%V>(ID0IPRG$7'($=2*#I%CF%3;>C-,;D\M8%R
M>_3'7@!"\M G=>K<QM,76/($4J 0>4&MSQVXQX6<_P 8E[IRF[D[AX5V&D,_
M<_!GJ$,:1^QXXL*MO;#4+_+):;B#.LL=Y$ZR!4JLK-5A:$Z<HD(C#1!&(\(;
MR_!5H5A_5# &VH=:=[XCM_JSGQ4QJL3SAF6D@/Q(O9XU-D$V9)BU-S^X1]I?
MDUY*WJE1A7A*M1V5Q*D22X2KC#56GO'UZ;+7MO?(5G7EPV+S=G=J$K2N[SK)
MCEO=L>^/I.]@<32A$XGRU&7@D]R(N6 !,[N/K"L(9O4%<T(8^].=LK-->^93
M'VO>!<R2Z=:L9RF^7<<N;6\DO$49,E0QJADXD6-<DNV.%:Y>WQ7(:)1&FY7<
M5K*%2,LY8W@5#(4&&##U*:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!09;;?[W(/^9)?ZP70?;0*!0:7F']R=1\Z>I/W(VJV9VNUUPKC
M#CJP^CT\UA29MS7BS%5I'DE[5R-BS!*(@&>2=CO(PQUZ-G3:N4MX#A62N[8$
M\\ .Q),#].*/8_7_ %Z]0GR&:GX!SEAO,>LW(0QIMK\)R#">3('D>"M>;6I(
MXSC(<$2JX2^/C(RNXB7^9#-1$*0G ;F1L$), DTKL0_GU!.*,UYSYH>&K$.N
M^=%NL^7\@0/8J.Q7.[8SB?W?&B96WJ;RF0,C26M:SU3]Y.+<"$-REB$XI6<6
M86K2F!"H*"('+!P!-/%KJE.>5'5+>S=!XW"U\DV+YC-\@92G\5>%T^+E&2(1
MCM<N:W-CB$<E;<M0.,C2+CD[T[R)(O;D9B(XLVXPBH,[^IQQ#"MRN&73#DWG
M"Z7L>9(1C+!\BBT3CJ]B28Z4@W&:,1/^0"Y,TKH^ZR%:I8QL:<+3=&[(BR.L
M9VX55K@Z@6,<4_IN-&]'<K:X;ZXGRKM=(<P,N,S'Q+&\ASG$+MC8Q7E[$CA%
MY*6H9XW@N)2@:9"WS)4-#8+P 11Q95S1'!", PZ1Z6O_ -4^67_6J9[_ ,&Q
MZ@QNY>M(XMVMQ7MBC N_8SVY:J0GC)Q;KN(D1R0\Q.8(H0]IRQB+$,N]PWN$
M-[V_-M;\R@C[ZB3+L(W/3^G%>K-KXFU>W5V*QSEV0Q&>-[>F77A&4 :R*XXV
MSM UNS]'DKXAQYEYX2K4Y*U:G",U0$H\TH-S!!NW$DDIR2DZ<HL@@@L!)!!(
M E$DDE!L LHHL%@@+++ &U@AM:UK6MT6H/TH-4;A&_GL?4<_P[X)_P +Y_H-
MHK(,(B.3(%-\<3]H12"!Y B$EA$V87+I\.>XC*V9:PR1H7] @7[DY,R\XDWV
M;?4#O[-J#5/]&A(I Z<8N:XXM6F.<3@>[N5(Y 5IA74M9D5XNPG)UZ4@=KV
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MBC3@S%SXY,S>Y1F.1[&CS&I+*$D.C)Q"-.,+&^1H*@"6QQ"1%?J$%A/3TO\
MM%F?;SB@;"M@)=(II/,)9BREK6;.G]U&[3%\C479HA)XX<\OZ@Y8<[.L;9\@
MEM!*PVYAIJ=M)$:(TSKFF!KX;8<5OI>\3RN=+,\\T&U3WE]I4$,\C<R,X8QV
M:F3=)T2<MA;$TD08EU.F\M=U$8&WDIEB.RDE0@)3=@:8EZEK@"P+T[\U<N0?
M4GEIXV\J[5Y/VFU:@\@4X3PML<J+>X]EE[P!L9'LNQ<U>RBRXQODCC9P6N'A
M<VQN?T"_P14O-3=0U*642$*B^%STZFDW(Q]WA\]N4=IHM]R]M_--?X!\U<VQ
M*R>+PV.=Y[BYS#S;A&<>(28WL;=J<B\/2B]GJIPT%X&Z&(HWK_SE^FQP-#5K
MXYQ#"6"LMXBBKE)E*!9)'"-XVP^KAK&MD"QJ;69K5OBMK9BC%9B9&D(,/$,1
M9)0+V $.<Y?9?LWR-<JV!N$/ FP,OU?P:3@A7LON%DK'PG-'-Y8PFKW,IO@"
M4Q$K:C7!F2MR)K+((NL*;#W"2"/7D+/"DZ8801WNX/)3P-8$?^2OB>W*VB8Y
M/KV_0.2YDQ'F*31*413+&/ULN011:2\-V.81BY@DK*Q'R<D]<TO;>N*&V=\4
M)E*962GL,,Y^HIRK(]O=1>"'-6$7Y-C29;,[5:Y9)Q1)%I!3TGQS+LOXYCTC
MACHX(U"-24Y>2GV0)S%!!J<?:"2B ,J_3<%!T[?3TPK/CG53/V];ER+;KYCY
M!,!87GN>AYIG$R8DD9E3UBB*ON0GEFCK2%K<,I0(+R0W+$[08"<JBVD]2 0@
MF%V&&X2GR5R%[T3OTI\4W:P\\2M9M2\X98HK/\JQ=.:?/F..1#-*_">5LV-W
MAI9AZ.5*HG%5+FL=$H"ALPUI[H5W;N@1E!3WIWQ6<!FYD*QKE=FYLMAF?=Z:
M1N*/3XXY%S]AS$V1FW+3@C&B=6=M@.5,<-&57]SCRAL4M]K-DM<[FD$E*B%Q
MR)0E,.#?SUBQ#), Z]8;PG,,KRW.LGQ9CV-P=ZS%/#%YTTR0NC[>4WF2Z4'.
MCW)' Y\=[$V,4#-7JAB,O>]QWZ:#.M H% H% H% H% H% H% H% H% H% H%
M H% H% H% H*1?4??S)N_'\'<$_SU8RH)=\3O\UEQI_R --_^SKCF@I%R[_O
M@&K7^J\D/[H-C*#:YH%!JT>JC_ZD.,C_ %LNM/[D<JT&.^0HG\3QS0:X\I,?
M*\OZ?\@1C?J1OD4E!W2-1')II"86/<RO "[)FMO,4-[(D=%"GLS5(B8V_"N+
MMG6_6#(6L P&>K0Y'#"Q!&6/C<Q$, P"L( P"6:I""((@WN$01!OTVO;V+VH
M*!=LMZ-)N5'=S;N+\J_)]G'3W2[ >8)1A/7+437_ !OEQY4909( ]+&T[-,]
MD43PQF/'07-TE4?3N)93TUNKH6(T29+=O3I2#5 =KXZ-K-+N/;E,TJPAQ/\
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M"%OC40C66&-H)-$240 ]7=&B"(\[J6$<<(1@OJA7H-R6@4&I)Q _[PYS]_\
MNQQ5_A Z@G_ZF;^8ZWO_ ,7<*_\ :7PQ060\?G^@7I'_ "1-;/\ ,U"Z"7=
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M_6O>_309FH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M9GXOUOQ!C2:,6=G)'W1OD3Z]X"R>Z9)G1D,EY91YB9QB[B-S+3B1J$Q1:DX
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MH'>$_P"KD_70>VH'>$_ZN3]=![:@=X3_ *N3]=![:@=X3_JY/UT'MJ!WA/\
MJY/UT'MJ!WA/^KD_70>VH'>$_P"KD_70>VH'>$_ZN3]=![:@=X3_ *N3]=![
M:@=X3_JY/UT'MJ!WA/\ JY/UT'MJ!WA/^KD_70>VH'>$_P"KD_70>VH'>$_Z
MN3]=![:@=X3_ *N3]=![:@=X3_JY/UT'MJ!WA/\ JY/UT'MJ!WA/^KD_70>V
MH'>$_P"KD_70>VH'>$_ZN3]=![:@=X3_ *N3]=![:@=X3_JY/UT'MJ!WA/\
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MP2^2?&[X;#\@Y;S?.361 L:3,BHAIWZ!0"#.3Y9L/[BH0=H>G7*EIQR4*8)
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M.:O:[:7#[=C,QS5:F9#29>+QLYI)_B1P9(TU*#9)M=D.+V38Z<)"E7H>M&C
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M+I*UF.LA8>DLC"8E>2;.JAPE VN[QVI:!L 6C 98++H"R<A?!IJEO!L;N]R
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MB&$8^<@[!&X1QF9F^SBGR5B^))U]LKCC%YY9:1%2@M@#>_\ 7"WALGM>Q-K
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M9U,+RFOA[>Q.\>RU&CHU;RL>V39C?@6$>U]FVK%B-0I2$ITAQ!  O)H% H%
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MAZ[O<Y?&3(.#4LQD"?'[_D!E@>+-IT"9QE^*'-ENX)%PF:XW'OP1(DXNU;T
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M2B6.;2XF!*;[KG$)"P]6VGV,+L('6$&QEZVW_P"!E_\ L9W_ -2A0;:W%?\
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M*R5;,.<=-=>,G9/,$2-QFLKQE&U[W(AIB$Z5**7G]R+!-!)$B4LDF[L%;V1
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MV@4'0<GXJQ=FZ"ON+\SXW@.7<:2D+>"38[R?#X]/H+(@-+L@?FH+[$I6W.S
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MSHHQO#C\Q-T0,"L"9%4&33684U1QL87%1:Z$M<%+>QYG2#ZL72&6Z!08DA^
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MU:1,QQ?57/? H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M7B<:3IC^N,\03NOUPVM85K4%B5 H% H% H% H% H% H% H% H% H% H% H%
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M<ZY<PBD"O:F^P1IPW?BA"%?V"3OZF@E_ 5DO<(+"U^06I Q3U=$HXLF[(U&
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MZ>/'1X'204F7MRMOB"YM<$44LBE,<?6-(J+;8^QA[2/%F"L848G3H0[-*/\
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MJ(=F1(J"W*6PL24!AX7B<1V]_&=NAMW&KZ \)QFO<?C\0FKR9N^KT\P!AE'
MW$#(XLBR'MTVPM'YJB0NLU*4JVL!5Y0A&K3=[+$6.P1DC"*NZO/UQ=O$YF&'
MN6GALS^*>0AYE<%AZG(>NN%LG+'&-M#VZ(3I%C^8YN?,'SJ,-3LE4)W!(>T$
MVOU7'KA.#T@,.#LGILL*ORK>SD W#UEUBSCI=Q;9L@T*8,#86S4-V1'S/(Z%
M5$UY\_BS4\NSX<H8V<".2&!.1KG)H;O,UFM&N/"C&4F#<[H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H*V.8S^:KY!?Y)V:/W&.=2?HO\K=N^&8_=0Y6B^J\?R<>R\<>LT4T
M*!0*"V+@M_G=-"OX=FK_  (^5$.O?R.W#X//LPX>O^H\GR+UKY#_ 'X6?]'_
M +5(K#9#7"T"@HAYSN6+)G$G#]5LN0O&45RW#\CYCD$(RI#9 N<V!U<(N@AY
MKVGM#I>@"N31>1 6%7$ ]6W.B<P 1 $G_P##"%1&2/4*^GKW @;A(=M]*Y-*
MIXH;20N,>GVL6)Y_/C%H2^[#)AF5D$I"J2"())" E:8Z,9]R!6#U2^D1=@UW
M>$O6;(&U7,/'<S:8XHE$'U[P5G&<Y\;!21P<5[-BK&#4XR=]Q+B69S?O(K/<
MDDJ4;=&A$65B5.)9BE2,5DI2I04&"-!)OIE,>23*<VYYG'*;Y'%R7):B?GR9
M-EM8^6V502^/("6W+3;B^ULII6%B;4CXE&@0$WLF7ID24TBR(!I80^/DNFVA
M<]Y"\3/'&YBY=C#5Q&S8:8XY=3#I-"T$_D+/.GE)(<A,*&9JE$L<VEQ,"4WW
M7.(2%AZMM/L8780.L(-C+UMO_P #+_\ 8SO_ *E"@VUN*_\ FP^.+^0;J#_V
M?,>4&@;RQ07,7$?S^M6]S_ WJ3X?F^Q;-M+CM_(37*:)^P.ZI JS+C9"^*DQ
MS0VS=@4N3H@[N,8CTJ92@7B $M25TAL>9C]7;QF1+#JV98<:LUY=RVJ:1&QW
M#CG E>/+I7LVQ82$<XG;H8YQAG;4XAW$H/:!OQG0"]BRC+WM>@URO5]OHY1R
M'ZPR8Q,%&.1<=6%7T:0!MS@)1N^<-EW 28)P@%W-"1=1U;"N$-Q6MT]%OS*#
M8']95_-AX)_EY8P_[/FT-!@#4#;C7;3[TM.F$GVTU\5;,ZXY;R?F'!66\:-Z
MUK3NMHO,=J-H7\4G94+QW-$\OT<<(>0<@(LYL9Y*SLE1#DE/3%BN%!.W^$/3
M1R'!V2,JZ<[H;8XYSJGB4C>\=:SS?%$ZFT>>)B2V&'Q6#G25VQ2THHTUN#Q8
M"=:Z*YT[W2IQ". 6>,NQ1X2HX2'OD$@O#AS+SG"IF5TF/$.,(K; 2UM"ZJ$R
M#(!"J2$[%O\ AP@N]UB&11_$R\I2YK6RP+D+"D1MKB4I_P!+"#'"C*^#F/$9
MZE7+VADTFR*F7,CIA=$\,V;Y3!WANLC=#Y*F"APM=0H<9VZO!A=A7E 0,X2.
MS$6< VYPK!WCBP?,12?U)V&Y'@#'KMBC![[LYFMVQ)CE]8Q1EWB&.U^,\HJ8
MDSKH\):Y79CB60PD7=N\'=E85@]<71TW#U4J!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!09;;?[W(/\ F27^L%T'VT"@C?N'LC%=/M5]
M@MH9I8LV/X*Q--LCG-YAMB1OSC'614K8(LE,$,L-G&62"R5L2VN(%A*58+7$
M&U^FP:2O&/Z7S7+D;TXQQOEO/F7;5BV%VV=Y_G-^;<5S+$D;CHV"<SE_<HO(
M%*.;8/R$\J7>;M(@/QA]G#L1$N900E N 5Q!U??;B&POZ<3*&@G*)J!D+8R?
MPW&.V<?A.R;7F*10"6JTV,YZQ.*!Q%&;XYQ9C(QK3/L+221E5C6!< #7.C=V
M82[A$ \+:>2MW:I!ZB'T_P _,3BB=V1[AFQ[NSNS:I*6-SHU.4#?5K>XH%9
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MR:'7PTUH=F1<F-*5 $&Y=PL=VYWBU7]0?H+R2:-<=K]D#+N1H;A6!Y,;7]?
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MRR@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@^!U6#;FQQ<"TXE9B!
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M/Z#X'A^AVM4&X?5^?YM?[J7(5W+AE H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MLT%D<7BL7@\>9XC"HVPQ")QY"2V,$8B[.WQ^/,;:GMU4[>SLK2G2-K8A(#[
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M.,\0AT79DMKV2M,=C,?1M[*R-B:PK]FG3$%% Z?8#:@^?(N-<=9@A4@QKEJ
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M+$L=Y\)7GQ:12=Q=EK4RPY/+'V(8VE#)*'TY,$I$4\QIK2*UUQ(B5)BKL2U
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M>UKVO;HO0:\WJF\DBV+QYQ):=8RR0D5X3Y%MM8:8Y9#QW(&E\CLT@I2O%;%
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M?QU.-PLF)MV&ANWKUF0G%V3-XY$K,<9!/HU%TI8+7))$7()(DL&_6) C@0+
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MQ=*,%0IGP_CI/E=]RC&#W?(TJSJVE2=-DE>SDNNK&8X2GQJ_@5M:A'8I&VN
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MLSY-)>E$,A>%,ALN81N!$=C$LF3X8X/V-3I3%XX%LCD)<%!OB:U'U;A(+_\
M*K$99X:POIP]VM8.->$[@<7.\^8L>ZK[!8*W!R?(4[IGF2,^*XGDJ,/,<B3
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MY.327V?U-S68T81#+,+%03AX]/\ =+%G^K>WI_M+8J@F[Z<'^9-T'_@[G?\
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M85)Z5:02JZZM,H//#8QH% H% H% H% H% H% H% H%!I+;D\N\2Y<<Y3S0#
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M9*(7U=[A=;'];\PRP?8H+LL+ZI:W:[X5#KGA;">.\?X.$WN[8OQFSQM"=&)
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MKYK1K]J?CM+B;6O#N/<(XY2KU3M:)XYC+;&FQ6\+@D@6O;K9"26H>7Q84G*
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M?CAR=0J.R.8FNGL0,( I C[2]S+A"%P= H% H% H% H% H% H% H% H% H%
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M%,CSF5Y48W9EQ.SR=BA*=)!\A/\ $VDQN;9A,)V^E*5#<U%C47-<C@C/$*X
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M&(*0^Y:T\(2C#PL[H.,>SW9*S.RIA;4CP^)FQ>>RM"]S&RH75V)2FF-S:L>
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MY!B&5MG66&(D6:<BP%$E;H;+IL ]2)<\1Y"AA&-DB9N.($4$(2V)K#:X;_I
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MUBS' ,_OD)E4VR=.)9BF1-LUA\:2/3 S1V+1PN5L)JYB='Y\&<L/4)$JDTU
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M==*6'J"&$+<*<%& =S.!?0Q=KRS,>O.Z\4Q)"-I<*[(QP:UDF ]@)4W-,R?
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MP*^HYPG>E&E./TF2VSF8G*6.K6-7("6V1[F:;0[( $",M08<G5XGEVM['E-
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M;353Q_>E4QCJ2ZK$3A*,4R+ @YZL;17-;3<E3O+SCDC));8IN88):U(YU+W
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M<.\+B0C[144>:#HZH1!#TVH)Y1B-LL-C4>B$;1>&QV*,;3&V!N[PK6=P96-
MG:VI%WM>>J7*NZH4I8.T.-,-'U>L,0A7O>X5^[S<2V@O(P-M==J,"L\MG+$U
MV98_E.-N[[ \FM#4!0-20UBEL2<6I7(&=$>><-,@=PN*!*8H.,*( 8:,=PC+
MJOZ>#BCU%R0RY?Q]KNHF.28JZ(WJ&R3,$YEF2"(>ZMYI2I"Z,,5=W$$)"\(%
MR<M2E7J6Q0O0J"PC3'DWZ>D+BI] (+E6&27'.3(=&<@P"9-*IAEL*F;&VR2+
M25E6@ZBMK?&)W3*VUS0GA_JBSBQAO>UK]'3:UZ"AF:^ERX:9C*#),GUXF,+
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M7$;?"I]FW&L&"H(5B6@+)Q?CK)T5QHG0".%>PTI;0%*85T%#+$5:P*"U_!N
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MV*I'HZ1HXTAR?CUZB60DL?1/:Q4I(1 <PIB3%ZSJ #98JL<'1-/>&[C+T(F
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M%9;QC+TED<D@N0(ZV2B-NI99@3DIQS8ZIU)!:]O5  >D5%V I2*2P'$F%F@
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M'%J)SCSMD&:9@S8C8G=M4A6M;VSQW->1<A1EL?FI:6 ]*N)1@5ICRP&%& &
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M/_V;*NB_Q']TOKG2_8^/]QAI_B_[H_6VR_.,_P!M'XL/B\^\!Q3_ !Y;Q_\
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M-?/H1H'XH[9C\MOR?_M@U\^A&@?BCMF/RV_)_P#M@U\^A&@?BCMF/RV_)_\
MM@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_[8-?/H1H'XH[9C\MOR?\
M[8-?/H1H'XH[9C\MOR?_ +8-?/H1H'XH[9C\MOR?_M@U\^A&@?BCMF/RV_)_
M^V#7SZ$:!^*.V8_+;\G_ .V#7SZ$:!^*.V8_+;\G_P"V#7SZ$:!^*.V8_+;\
MG_[8-?/H1H'XH[9C\MOR?_M@U\^A&@?BCMF/RV_)_P#M@U\^A&@?BCMF/RV_
M)_\ M@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_[8-?/H1H'XH[9C\MO
MR?\ [8-?/H1H'XH[9C\MOR?_ +8-?/H1H'XH[9C\MOR?_M@U\^A&@?BCMF/R
MV_)_^V#7SZ$:!^*.V8_+;\G_ .V#7SZ$:!^*.V8_+;\G_P"V#7SZ$:!^*.V8
M_+;\G_[8-?/H1H'XH[9C\MOR?_M@U\^A&@?BCMF/RV_)_P#M@U\^A&@?BCMF
M/RV_)_\ M@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_[8-?/H1H'XH[9
MC\MOR?\ [8-?/H1H'XH[9C\MOR?_ +8-?/H1H'XH[9C\MOR?_M@U\^A&@?BC
MMF/RV_)_^V#7SZ$:!^*.V8_+;\G_ .V#7SZ$:!^*.V8_+;\G_P"V#7SZ$:!^
M*.V8_+;\G_[8-?/H1H'XH[9C\MOR?_M@U\^A&@?BCMF/RV_)_P#M@U\^A&@?
MBCMF/RV_)_\ M@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_[8-?/H1H'
MXH[9C\MOR?\ [8-?/H1H'XH[9C\MOR?_ +8-?/H1H'XH[9C\MOR?_M@U\^A&
M@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_ .V#7SZ$:!^*.V8_+;\G_P"V#7SZ
M$:!^*.V8_+;\G_[8-?/H1H'XH[9C\MOR?_M@U\^A&@?BCMF/RV_)_P#M@U\^
MA&@?BCMF/RV_)_\ M@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_[8-?/
MH1H'XH[9C\MOR?\ [8-?/H1H'XH[9C\MOR?_ +8-?/H1H'XH[9C\MOR?_M@U
M\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_ .V#7SZ$:!^*.V8_+;\G_P"V
M#7SZ$:!^*.V8_+;\G_[8-?/H1H'XH[9C\MOR?_M@U\^A&@?BCMF/RV_)_P#M
M@U\^A&@?BCMF/RV_)_\ M@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_[
M8-?/H1H'XH[9C\MOR?\ [8-?/H1H'XH[9C\MOR?_ +8-?/H1H'XH[9C\MOR?
M_M@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_ .V#7SZ$:!^*.V8_+;\G
M_P"V#7SZ$:!^*.V8_+;\G_[8-?/H1H'XH[9C\MOR?_M@U\^A&@?BCMF/RV_)
M_P#M@U\^A&@?BCMF/RV_)_\ M@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;
M\G_[8-?/H1H'XH[9C\MOR?\ [8-?/H1H'XH[9C\MOR?_ +8-?/H1H'XH[9C\
MMOR?_M@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_ .V#7SZ$:!^*.V8_
M+;\G_P"V#7SZ$:!^*.V8_+;\G_[8-?/H1H'XH[9C\MOR?_M@U\^A&@?BCMF/
MRV_)_P#M@U\^A&@?BCMF/RV_)_\ M@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V
M8_+;\G_[8-?/H1H'XH[9C\MOR?\ [8-?/H1H'XH[9C\MOR?_ +8-?/H1H'XH
M[9C\MOR?_M@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_ .V#7SZ$:!^*
M.V8_+;\G_P"V#7SZ$:!^*.V8_+;\G_[8-?/H1H'XH[9C\MOR?_M@U\^A&@?B
MCMF/RV_)_P#M@U\^A&@?BCMF/RV_)_\ M@U\^A&@?BCMF/RV_)_^V#7SZ$:!
M^*.V8_+;\G_[8-?/H1H'XH[9C\MOR?\ [8-?/H1H'XH[9C\MOR?_ +8-?/H1
MH'XH[9C\MOR?_M@U\^A&@?BCMF/RV_)_^V#7SZ$:!^*.V8_+;\G_ .V#7SZ$
M:!^*.V8_+;\G_P"V#7SZ$:!^*.V8_+;\G_[8-?/H1H'XH[9C\MOR?_M@U\^A
M&@?BCMF/RV_)_P#M@U\^A&@?BCMF/RV_)_\ M@U\^A&@?BCMF/RV_)_^V#7S
MZ$:#O&,>+W87'^2<>SQZY@.1?)C-"9Q$Y<[8WF[Y@PZ%Y!;(V_('E?")>4T8
M>;'4V+RM*B&@< I5*=0)(H,L6:6/JBL%N3>W'H5;ZI.=5[@6\.I+BE2++DW3
ML1!3(S- FIJL446,* Y2UF+16,N8/O2PZ]A=2X0A#E:!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!083V
M1_Z@\O\ \'\E_P &GUT_4'WDU?S"_P!B5?\ =;]&N^?%F?Z'+6ZK'YJE*!0*
M"0.JG^D1B;_&M/\ VJJKO>F?O]I?FL>Q*S>S7Z4=D^&V^YN7Q2'^_"S_ */_
M &J15^-IKA:!08(V1V:P5J%B9\SIL?D-MQ;B>-KF-M>YD[-[XYH6]=)'9*QL
MB<Q''&IY=3!.#JM*)#<"<00B':XKA#TWL'#ZM[=:Y;JXS.S'J[E%IRYC1/)G
M6&G2ME;)$THP29D2MJUU:;I9.S,;E<Y&E>$PQ"L1V5[&VZHKWM>U@D?0*"!?
M)%O_ (XXT-87G:7*D+FT^B+++HA#U$=Q]X%>1FK9BO,;T*HFTC=F5L[JE-+Z
MQO6/L/J_U-KW]B@<;N_^..2_6%FVEQ7"YM 8B]2Z7P]/'<@^!6D92V'+RV]<
MJ.M''9Z;.ZJC3.L5U3[CZO\ 56M?V*">E H*%]WN?_7'1?=^(Z+9!POFV7Y!
MF'S4]QE\.M!/)J;YVG4#0S=[N]RMK>[>&GCZRKJ)1?4?^3Z]_8H+Z*!0*!0*
M!05\XCY5./[/&Q;CJ5B39.+338EH>)TP..,4,<GZ-V2O&-+.MYRA&Y.T2;X\
M(R/V9%7:B"L$ SL;]E<?2'I#Y^3;D;QAQ=:WI-ELMP6>9"BJS)$8QF!@QU:/
M7D 764MDC=$:\7F9X8V[P].5&S0F=!W:=8P'5#>W3>P.,GD;QARBZWJ]EL20
M6>8]BJ/)$GQF-@R+:/6D G6+-D<=%B\/EEX?&[P]05)"@E])W:=8L?6#:W1>
MX6'4"@HKY4N>K7;B=R_CK#F8\-YIR0^9(QO;)C6Z8SM!KM2!JO)WV+=P7^:9
M4PJ_$.]L)AGZ66,OLQA^JZW3:P9CWGY@L)Z&Z/Z];U9$QAE*8X^V+>\3,<8A
M\+M$KS)C49=Q%+LPLIS]9\D+4R=BV,D//2JN[JCA=Z-!V=AE]8=@E7H%N?!>
M0G4C$VW^-8K+(3"LN^>_!8Q.;,]I2V>0<F3+&#CXI9@<G=I_LUVA1Z@CLE!G
M]CFE];JCZP0A,:@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@RVV_WN
M0?\ ,DO]8+H/MH% H-2B:^LKXPH),I;!W?!.^2EVALF?HHZ*&W&&OAS<>XQU
MU5M"TY :JVA1J341JE&(10C"2AB!>UQ #?I#8+%^-WU"''3R?Y$^9C"$ER5C
MC-RIL=7I@Q#GB&M4/ELO:F%.O7ORB).42E4_@KXK9F=O$O4(2GCQ$*"XE 4X
MBTZL2<(1;"^KKXV]:\^YPUTG6$MWW:;8!S!DO"DQ=(GC; RZ*N4JQ7-'J"R%
MPC2YXV48G=9'UCNQ'&(C52%&I,3" (T@D=Q%A##_ /MJW%E_D#W_ /XK-=?_
M &:J@FRT^IDT0>-,(+O.EQ-MN7B7(&WX=*F:.GP3#@<BILIBQZER59_<VDO/
M1L:)Q_X$K"5WHIW.<>]VN'N/9]!MPV'%BQ(WI%2]>J3(4"%,>L6K5AY29(C2
M)BA'*52I2<(!*=,G) (8QC%8( VO>][6M05HZ+<J^ ^1C(V=HMJ[CS.\JQ5@
M23'PMWVK>(K"&/6S(<M3C!UV'$4E,R,HG\Y4V37$I&<"-$(R$G8G''%EK6\2
ML+-J"N#&G*!@+*G)=L+Q71Z(9@1[!ZUX?9<USJ8O+!"T^&G:*OK5@]X2-\3D
M*'(#C-ET@+39]9PF%+(\@36,3++!/%8L@2@+'Z!059[X\EGW$NT?&]K9\RWS
MF_C!LW2/#?G3YQO)GS1^7U^,D/F/RYY#E?G[O?SC=;N??V7L^Y]';B[7I*"T
MR@CGMSL[ M,-:LR;391:)>_8^P?#%LYEC/ 4#,Z3)P:4!Z8@Y/'F^0O\69%;
MB(:H-P@4N*0J]K7Z3+>QTA!'/7+I L<<1#GRZ8NP[+\B8^,QWCW)$3P_/I&S
M8JF3LTS_ "E%,9DH9#((\CS R1MQ;!R42T5DQ;L4;9/8JPP]I<PL+'=?<J_/
MM@7".;_ ?*WSR8AQME7RQXIXYY<^<.&,LN\!\:\.:/%_"/%^[]Z[HE[QV?:=
MB7UNH$,NT%<'%_R@8"Y9<!2_8O72(9@A<)A>8'_"CHUYK8(7')4HE4<A>/YT
MN<&]#!<@9':#8^:T9'0EE&F+BE(E)1X1$! $LPT,XZ>;OZO;]8R?<Q:EY.^=
MC'$:R _8M>Y'Y+R'!.Y3N,MC"\/;%X1DN)PU]4]R;I.A,[T2E,1F=OU2S1B
M8$ 2NH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!JJYS]7SQK:_YLS#@
M:980WC<Y?A+*>0<12IRC.-<"+(VX23&TM=X:^+8^L==EV9T5L:MT9C3$ABE&
MD/,($ 1A)0[W $+#.-KGLX\>4>5*,9X FLUA.:2&-PDA>$\XQ9#!\@.C&TJ#
MBW-;&SV20S""RTYN2%!6*$C4]+%R="/MS20%E'W)"YZ@4%47,-R>?BGM98+L
M7\R'S^>==@('@OR=\Y7S6>&>=HS/)%YI\P^0,C=\\,\D]CW'N)7;=ZZ_>"^S
MZI@6NT"@4"@4"@B!OKNKBSCMU.RMN+FM@R!*,98?\C>96+%K5''N=KOG R3#
ML6LW@39+)5"8^I[M()LD.5=X=$O41EFC!VA@0%&!E_7K-<5V4P%@_8N"M\@:
M83G[#^-,UPYKEB5N0RIMBN5(6RSJ/-\E0L[J^M".0(VA])+6E)5RQ,6I",)1
MYP+!,$&8*!0*!0*"J?E0Y@-:>(B&XCG&R4'SG-VG,TFDD4BZ?!\:@,D<4#C%
MFIO=W Y_*GN3,:IDJ(Y,Y "2).<J&(=A6$ %K6%<+!\(YC@6PV',69XQ:[>.
MXXS'C^)9+A#J( 23UD8FC&BD#.)8F"8=W)Q+1KP@4IQ"N-.H",H?0(%[4%36
MU?/CI/J/O_BOC>F\;SO-L_92D6%8D%TQE%<>.^.H%),\R5!'X0S9 >9/E2(2
M9N6E(GAO>%H4#.Y6*:7!.85<XX0B A=M0*""/)GNQ^+IT=SON;\V?SQ?,FW0
MI?\ -OYS^;[S-YPR7"\=]EYP\J3?P;P[S?WSK>%J^V[OV70#M.U '"OW)1KE
MA_0?"?(1M3(ON?,/Y:Q5@G(;I?PB=Y8\F/&=XG'I$Q1#HQS!'.42+N*Y_LB\
M0+94Q1O9]L86G"+JA"=\<D+/+8\PRN/*_$&"3,K7(6-?W=4D[ZSO2$AR;%?=
M5Q"9:F[RB4@'V9Q99H.MT#"$5KVL%?.E/*!@+>_/N]6NF(HAF".3;CZS 3A3
M,SID=@A;1%9-*CYIE^"@<,8KHQD"7N[S'[.^%74RYKJA95/=E"078=<9Q9 6
M/T"@J:_&A_\ [X3\4_\ ,;_][-]T7\_GSF?_ "7L_)WS6?-__P#9\0\Q_P#1
MJ"V6@4"@Q[E?+&-,%8XF67\Q3B-XVQCCYC52.:3B7.:=GCT>9D?5L8K7KE(@
M@L(TXP!)!0.L<I4& )* ,TP !!J]Y$]95Q*0J5N<=C4/W(R\SH#! 2SS'>'<
M>MD4>@A--+L<V(\LYIQ?.2BQ@+L.UEC*D'U!AZ0V%U@A"Z'CUY:=&^4%MG"G
M43*+K+WO&1;0HR'#9/!9C!Y1$DDB6/*..+EA4B9TC,ZHGR[$H&4:V+5P2K!L
M ^Y)O278+):#IF1Y=\W^/)Y//#_%_),,E$N\*[WW#Q/RVQKGGP_OW=EO<N^]
MR[/M>Q-[/K=;J"Z.K<( <2'(K^-,TOB>WGS/?,5YHF<_B/S>_.#\YW<?(S^:
MQ^(>;/)&/>\^*=EVO9>&%]AT]7KF?U5!9E0*!0*!0*!05S['<G.!=8=T]1M%
M)]$<O.^7-S_&/FND40888OQRP^"*3TJOS\[O4^8),U]H81>Y?AS0Z](;VZ>K
M?V*"QB@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@PGLC_U!Y?_ (/Y+_@T^NGZ@^\FK^87^Q*O^ZWZ-=\^+,_T.6MU
M6/S5*4"@4$@=5/\ 2(Q-_C6G_M557>],_?[2_-8]B5F]FOTH[)\-M]S<OBD/
M]^%G_1_[5(J_&TUPM H-/+U=66MP&/5=JP_C_#4=D.FLX0Q209_S6L97L^1X
M^R P95CQN-8ZS/J>:MK$A2R5>046H*/8W(X81_4G$=-A6"FG@LW,YML&ZMH,
M<Z':,XPS_K NS_(G23Y2E4$GLB?VR4.Z.#HYLTI7&.9YQZVV)8V%(C4$EW:#
MC #.O<0S;7L (73\NWJ-LQ8(VR+X].-;#L=S3L<ADS-C^:3"5,,@F:4C)\A&
MF+1XLQ? XZZL1DCE368N(+7N*U4:B3+!&I+(S!$F'@"#>2.>CGIXR,E8S4\G
MVGV+E>+,G=<UO:4;9'XVZ/+<T]P4/Y,&RABN?3V%M4P;4CNG&H;GA&N.+",
M1IR+BN98+%O45;%XOVX]/\R;)X9=S'O&F8L@Z]S"+JU)04[@E*5R9<F<F-Y2
M ,. BD$:>DJEN<4]ACLG7)32["%U>M<._P#IA<C0K#_!R#+&29"AB>/<:9#V
M4G<WD[F(8$#!%(HON^/[NKN6$PT1*!L0FF7" (ACZO5"&XKVM<(&PKG,YH>5
M3,&4&;B U2Q1','X?.2"=I?F 3 MDZI.]'.">."ETEF<YB\$;':1$-AJE.PL
MZ-:N1@+-$<L/)#U[!E7CD]0KN(EY T/&3ROX2@.-\PR"=)<6,L\A"8R-N,:R
M?($25P@L6F;"BD$PB,J9<C#=$2=F>&-4D(ZR]&.Y:HA0)24%*?J69*HAG/7
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MI'(2V5AC8'W9O6QY!'8JW69XNP@=-3=B5H66-M 33[-;"UV/[!&FL,=B$Y8
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M<-B!%E!$'2C*6-<O>KBY#)5BG($,R7%DG&TT1<^30*3,\NCH9)%YCI2S2=B
M^,"Q>UG.L;>DQR%P( :(Q$N(-3G6 <486$-O6@U:/4/?Z9'IW_\ 6RX8_P Z
M>#J#*/,KP-*.3K:?4W/L(R*PXN9X[X?B/=AM5O4K87?-FK;3/&+([9#XV5$V
M1:E>Y6A?$;@266]*4J&W>TBGM>T;""30BSZC]H:H_MEZ=AA8FY$T,C)R(0UH
M9VEM3%(VYK:FW)6LB)O;D"0@("$J)$D) 446 -@  &P;6M:U!SW+-D.*8;]1
M3P1Y(R.[HHE!C8SL)!_-3\I*:8^5()RP23'[*B.>5PB6\HR\CGC64981ENS[
MX5<75L8&]PSSZK3.V%X9P\;/82E>5("P9CS + /S7XK<Y2SILA3LB-;08@EL
MA<(U#Q*O'G)H9(]$G%2J6@(ND(LE$ 9EC!  (,>\L7^ZC.?\B+0+]V.LE!%W
MFD2*5/I.M7SB"##2F_7_ (TE:TP ;B"E3#B&+D #SKV_J"Q+%I)5K_\ CF!M
M_P -!M(ZL9:Q9(M;]25S%D>#.J7*N%\?"QB:AE;&?\X7A6,V]\=BX6 "ZYDF
M.:69N4*U9:.QPTR=.:8;8 2QW"%"'I__ .<']1E_K(7#]W.PM!Q' +(&!-R1
M>HCC*A[:")(Z<B3\ZMD?.<D13VXMC9/L^$.3BA:AG!7JT#><N) ><66(LH1P
M+"O:XP](8TYJLAX]V1YI>!C5[!,D99]L/@#;=5G#,C7#593RXXKQ0P3/#\ZD
M[3,E[,)2)B<7F)X<>UBAK/$ XE$B+.5EE$*DPS@[?_\ %A/_ ,+-_P#<J@IT
MS+JOEG+7J)^2G"9O++E7B=R3E8S%^1<32.%+9XTH]GX6M@L9,8X@DDT>SO@!
MO6N,':U "T+<:L<C#CR'$E*4$2!1>X3ASWZ;#9IZ9H:FW"]25G.9X_:<@1R6
M1J.;,1F>/D*.G<>.,NQN#,W95WR<6"TK1E+SBDR@DD:LD"D80>P8*P@W=*".
MNQFW&M&HC/!9'L]FN X)B^2)RFQM$9=DQY+B\.6316Q/LF3,[I+G$!4;C 36
M2-+C[*G14B1_I%P=KV@@!$$/<R<7'$)MI'GC*62M0]0)VSOK=(ES]F6(1:&P
MYQ=D*9":Q/SRZYAQ<?&'Q:9'TK.,D*\UU$:TC2B$2:087<5@U?.'?&[#B+E\
MYEM+>-/)D@R)H21J5)UD0$VS]5*(!&MCW=IQ4S1-"R9 -7'(U[Y')/()DP(G
M:YXE"MM:1B/5*[H J1!8'Z0W-^%C..QYU13.S'$]G,(9US IS7B1X5%-&2!F
MOKZF.:9HLBJ_NSN<V)FLDE@./ 6,*58RC(.N6.P0W#8MSOE#&C_B[9?&[%D.
M#/61(I@K)#K*($TRU@<9I&VQ7$'Y&E<7^+(W Y\9T"E6"Y19R@@LL9EKAM>X
MK=%!J$<7<&G62/2"[50S&J-:Y3)VQ_NJ8VM3;W@3D\HVEZ='I^9&U.D*.4KW
M%ZCS<K2D)2PB$K-."3;_ ,I013XC.+G9S?'33#\ZU>]2WM1B5(S0Y$RRG5;'
M!^9^UUL=F<SPY;CDR+LN[<%$V1]I/L'PQ86PMB!Q0G$J$Q=BC0T%]O$?Q#/N
MA.]VP&?<J<L#GR"Y\R+@8G%^0XAD%@4I\QLS>VR['SA'9E,9#)-D\USA:@CC
M=% ,R1.M1IRB25H @/ $L))@8]](=_-<Y&_EN[ ?X Q?08DY-IY#M9_4Y\2>
MR>Q3P@B6O$GU;R3A2(3R5J;-\*AF9E2G/[&L=G%T<NQ8V<)]\RQ1$K6&' "B
M)6%J% BR2@F6"S3U!>R&O.(N(?;LK*\WA@+YYP9*\:X1CZE]1&.>2\B35L3)
M(4; VY*8H6RCRVXN*1]4&I"S2$C>D$I/&6G"(RP5WXTXRM<]T.&OB%URW"SJ
MZZQ[3P;#L4S%JM-F&?QC'V=XNYJ11%>8DA\6DRPATDB)C0SB&)70A&42XMCK
M=IZ%*-4,H)H1DW:R1S@<!&.(AL=-^37#?(KK:BG,<A3QA;8K%+3C3,LN+?O!
M"UKA$WUM5RW(CHO:"D*@@P_SDO(;BU ' ]L6=H<62$G^1.1$S#U!?IZI:G0.
M+41*,=[ R(AK>" IG9M)>\=/+F6@=$P##0)W%&!38L\%A"L T(K6O?HZ:"97
M(_Q48#WIV^Q]GG V]\HT=Y-<)0YKC;/-L,2^,R"8GX]-!(7QJ1Y$PD"6Q&6O
M"!2VN[B6 XMS;DKFR*%*1P*<$=B@)PKY8]O>73BLY'M#-+-V=ML(\BF#=X9N
M/$\5=6C'<=QKL9BLE.\1J(L\ZDS+%&QF5!:KKI,B6'+7=7*;.:=(\%=Y(4)B
M5!@;@U H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H%!A/9'_ *@\O_P?R7_!I]=/U!]Y-7\PO]B5?]UOT:[Y\69_H<M;JL?F
MJ4H% H) ZJ?Z1&)O\:T_]JJJ[WIG[_:7YK'L2LWLU^E'9/AMON;E\4A_OPL_
MZ/\ VJ15^-IKA:!084V-UYQ+M?@_).NN=8L3,\497CIL:F$?-4J4)JA)WE,X
MMZ]O<41A*QK>F)Y0IEZ!62,)J1:F*.!>P@6H-8I@]'3Q_P ;R"RS%OV)V[$S
ML,F;9$AC:A^P\8?<#6N)<4S8>^AQ&6(PFYY 0",LE"9<KIM[ _JZ"T'DWX)=
M'^4E[:\AY>;YKC+.#*SD,";,^'G-F99.]L:$0QM;+.6I_8I#')@WM=S1!3FG
M)BG,@F]B2E@";!+L%9VO7H_./G%.0F6<9<RQG?8AKCSDA=$F-Y$HB$*@;X:C
M.[:Z*:DQEC,E#XTG#"'K)TCHVA,#:X#;FEB$"@O>WQX[,#<@VJXM/<IKYSC;
M$);Q!G9M+P:JAL.>6(K'9@11IC8@2*$32,-D?2D  1W8MLZ $ " JY=K6H.0
MX^- L-\;6MC5JU@^19)EV/6F42R6D.F6W>+/\N.<)DM N=4RI=$8;!6,QO*-
M!U206;PC""][#&._LT%-VWWI1>-G9J?2/*$ <<M:M2B5.RY[>H_AYSBJK%)S
MDY![5<I;\?2R,.YD;":X6[<"5H<F]M)L8:66E "Y5B0^/3'TI>A>I6:<7;!.
MV5=A\TY(PY/XEDV I9$_Q*'P1MFD#DK?+(@]K6"(Q5+(G0YG>FE,;V!SU="H
MZ@@G)S"Q]2P2;W^]._I!R0[._=59_P @;,M4U-C<,B:Z)8VG.-8[ '%CA7;A
M1)E*1[P_*)<28Z$J1EK#$[R09<-^DBY K6%8(,L_H[.-)NR87+7#*FUL@@)+
MQ9U#B=RG$ 2M:I+V@#KQMPES+C5KF!D?Z_7*M=.I2NEDUPA[[<X(CQA>QLQQ
MR:V[,:)O_'4M;9!AO6UYC^.(LWM.#3XW%WZ),.+9_#\C1M!%U4GB\U8R.W?(
M4F M-5MRPY42<H%<=E!G> AP/&?QGX(XK,$2S7O7N69;F,+F.6W[,KFYYE?H
M=(901*)##H'"%J! MA$#QXU%,)35CQ$8448B-4!4&GB$>( BRRP_KDEXR-:.
M4G"+=A;8U)*&X,7D'FW'N0\?N;>S3Z 2020QO6*F1:[M+\SK&M[;S.[N"!:B
M4I5180#L$M20F4$A2C@_T@O'-CEIGR?)^1L_YM?9A$7^(QY\<G>%Q C&AC\@
M&WWFL/8VV)NC>NGS.6<8) I>O%6Q,;<)MF^YY99H0M1XMN&K6'B0^?/[G"=Y
MYFOW0/S9><OGND^/9)X9\U/SA>7?+/D3%^-NY=]^<E=WWO7?>T[(CLNQZIG:
MA"'>OTO6@6\&?IMLFHF.<<%Y#R<\*)+DEOQ4]0LV$RN5K_TQWE]X],(7(5C/
M)) LZ5#@-(M+2*E(AGW3V/---,#,\>]/?J S\;KMQC+,I['K<,2',Y&=WN<)
M)+C-OR@;-B/!K!1MR\_%3I$T,9N6Q$![L-I4*OZN_>>D5NJ$I]<^*#7;6/CX
MRIQLP*9YI=\&9>A^<H3))7+Y%!E^6$+5G^..T8F2AC?6;'+!#TS@V('@T;8-
M0Q*2R3@AN>6H#:X!!T_BVX:M8>)#Y\_N<)WGF:_= _-EYR^>Z3X]DGAGS4_.
M%Y=\L^1,7XV[EWWYR5W?>]=][3LB.R['JF=J&#,G>GITOROR(MO)C(LG;/HL
M[M><\1[ IXFRS3%*?$@YEAA9"UL7;#F%=A5QF(HRO-@J2R\D+\%4:$P[L5)%
MQ N6&2>3W@[U.Y8IOBV?;%9"V'ACQB.*O<0C:;"LLQM'6U:VO[N0]+#WLF<X
MER,J4KBU2>P2A$')B[%WO80!7^JH,M;Z\4&NW(EJCB'3W-<SS3%\9X6F$ FT
M6?,6R*#,DZ7NN.<;S'%[(G?W.68YFS J;U3!-E9RH"=L2F#6%E#+,*+",HP*
M7I9Z-[C<=&N.(HEFW;^)KV=*L2O+RMF>*),JEHE#FX."=P=4IN'VIN;W) F6
M%H2_#BD:4:-(5<P@:JYZDX+VN//C(U*XQ<7.V,=7(:Z-PI6L0.>0LB31V+DN
M3,D.;22I3M*N72$E"U(.[M)"PX*1 W(F]L2B/.,*3 -//&8%@5 H% H% H%
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M@NQ@N4,:911+'+&>1(+D1N;SP)5[A!9:P2Y$A4F!$,M.L51]P<"$QY@ 7N$
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M7;IL*P?8H,[..UFKK.L/;G?9+ ;6X)A=12@<<Q8\0K$X_P#Q#TJF1%'E"_\
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M/3QW(/@5I&4MAR\MO7*CK1QV>FSNJHTSK%=4^X^K_56M?V*">E H*%]WN?\
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MAO*2)Y R 7+X^^)9>[-9!XQ% 3QH\8$YUB$H!IC[V"[.;\Z#[,N!O(7+%KC
MX BS%CU5CZ'RC$F3 R*8P>(9,<,^8MQ1.F!V%%G^ 2!X;1Q:>V>F8TI<C-[!
M:B&H#>]CDX@H9B?K#]Q9!K^Y-S?J'AZ;[9CR*\FDNT2BN54V!(IAPN.Q,,;.
M=883E&69&E>0729&/@%0P/K$V)6\I%V=E!QAU@!,SD"]1OOAJ3JIQDYJB.']
M7%$_W)P9D#).7X_/L?YC-9HK*(E(HRSI&R$-39G&-O3&VB)>3KJ"716Z*+F!
M#U306L((@V IAO-EJ/\ "\DY%T<>QT;FU1Q\P?:\<65-,E'BRV1)-A"/Y*7L
MH60J7$RVT+*?74PHE-=\NN"D"$(E@C+7-N%+W%1SI<CW(_JWR79 9< :X238
MC52$X+=-<<;XO@N54C/D.8934YB*=&><-DBSF]N;PE(*QVD$D"WN;*(KKGW-
M-,M<'9AJ!:'9YY!\;\MLNS7K+KK#\H[U+L@;+N3[@5\CLC=8H@E,L!-_GA:B
MF)JR3%7XM/#0KW+NP12$P1/=@]H8IZ+]<-R/;;D7Y <;\*TRVNWYT6U.:]E8
MUM+&(,TZ_P";<+2J786/@3H!F2,<\-@[YF*2/!LHN8[N9*=<4_ *+[,0>PM]
M7UPD3QH<A<ZGG!1L=ORPX%U:PODG$N/MQ\F1[%V"\6O&.<#N$JP9 'R0QE6_
M0E'-5C\K\=51Q*4[F$/*92J3@ZI1J>]@""%*6K_JAN7;:R)YCA>%^/+'&PF=
MFXF'*X,YZ^8ISLY0?%T?5DS(J72'+S$9DK(+@]JG-P(9R8Z2!SCR7M"E_;FJ
MA7((L&1N+_U+&\4FW^@NCO([BN%LQ^4LHH,']\18]?<1Y3Q#E]^6ACT489/%
MG!Q/1.36\R\Y*V*4AZ-&O2&K;*0J#"RN[&!*3U+G)G*-!LXZSQZ,:A:'[&CR
M-BB6O+A(MM< N.7I1'P,$O*1(V6*.[?/8==J83+N!QYB88#[74#N,(@](K7#
MKWJLGD$CX4=(Y"6RL,; ^[-ZV/(([%6ZS/%V$#IJ;L2M"RQMH":?9K86NQ_8
M(TUACL0G+ #K7ZO305;:'\DO-/A3B=U^Q[Q\:#/#U@_ S/G%ZF^TDFQV_9&)
MG0UN=,N9(D-\:1X#I'FTZ-0Y+(1-;D<0F?E!CFW*BP#3"*&5<+W_ $^'/K-.
M3V03_6S9R+06*['0&&6R)%93 $Z]AC65X,WN;8PR2Q\8=G%WLS3:,+WE">>!
M&K$F<$BLPTE(E C.ZX;2] H% H% H% H% H% H% H% H% H% H% H% H% H,
MMMO][D'_ #)+_6"Z#[:!0*#00X!>8[C@XZL6;TXBW'V,^9[(<PY#,X9'CD?^
M:+.^0?$88NCF/XRE>?%L68PF[&D[5\C"XCNYZDI6'L.O<JQ8RQC#+.-LOZ@<
MQOJ/-7-EM()3CN*XZT^Q<\23*N1W\+)B/*^U,Y)(R)X*W8WP_)?+^7<AM3 U
M.Z8+L^KV@D3>T!4E*^QL%M+6!O+4&I)Z4K^]/+9_K(<C?VLIH'K ?]#?1C_6
M0X?_ ,UF:*#E]Y]F<K<V&U,SX>^/K))T*U?Q0)*;R?[CQ12E6!M&5:]2V7UN
MQ"O+&:F<W.2K&Q<@<CPW$4Y*TBA.*_A;<Y@<@V3=9M:<+:?X-QWKEKY"6['^
M)\8,)##&(^@ZQIP[!N(]P>GMR.N):^R:0.)IJUR<%(S%*Y:>8<:(0QWO09WH
M*8<#\BV;,H\VF\/&V_Q?%B/!NM&NN)\NP25,[)+4^5W:23M@PPZNZ*6OBV;N
M$07L:91D5<%,6C8D!X %$6&<9<)ES0K>VXYZMW,!\K>U/'5@715)N8NA.,,4
MNNO45Q8V3%BGH9E.<=XRG,HEN=I^;)93%T&+(F3+EW9A1QMK$>;9(F/<DO7&
MKN'3,1<X/+/K-NIK5K7S/Z!X;UTQQN--6K&N%\J8.?SG5%')@\OI$:;[2A[9
M\W[#PJ3$^8'UI3."*RV/.#2C5^)&%G)A +N'%^IVS43KCN/P.9W.@TSR=;$^
MSN:YN3CG';<%VG4Z5L:[6M4AB<2;1#!WU^?E@2TR<NW6$(PRW5",70 0="SS
MS=^H4UEC-]RL\<.6*,7Z"-SXTGRA@=YZL>MAHG%'U::S-P)8_,N61/D*5^+F
M$EC='G$R% 6,PHHTDFZH@=!L!;1\@PXCQ*Y&Y*M:$4;DUP:IMVRF(VO)#6\*
MX\M)D$;:9(RM<U9H^_QE\ZR4ET[!<F3N*0\I06,':!N&]!4URK[#S7;;TJ<_
MV;R.UQ=EGF=M:-4\G2YHA*)V;8BW/\LSQ@UU<4D<0/KW)'E(T$J#[V(+5+UA
MP06M81H[^S01(P9R;^H,F>J6NB_COX?HNX:W8AUUQ7$Q3[:9\3H,BYI003&,
M8:C)MC''(\[X%?RX^^B8EIC26VHY>)W3'I#4YO7-"G&%^W#ORG1GE7UJ>\GG
M8Z<\*9MQ'.5^)-AL+.YZU4?!<B-*4E5V[8J<VYI<S(^_I3;F$E*TQ2QO5DJD
M)_:#2W4'!"_CPY/N0WD'XF-C-L<480UYE^[,(S)DS%N#L1LB*0P[$4Q,A1F.
MCV\N4WR%G-O5$KSFR3N!AYUY8TIAB(*L"P+VN$T-87@7V$]0CC+3_)+#QEZ+
M:K[#X&5[/Y*>9=-<Q2Z,LDF:\RK(AC0B7Q- D=MQ<&*3(^U,*-G/(,"T*2Q&
MJC;66'7M<LD-H3DJYI\YZK9$P-HKJ)JC]UMR>9NQ<T3Y[Q*VK5GS9X43K&=4
M8K=YH-B=C5CTFL\-*TRR#QUI2I&4BZ]6\$E&)>^!"N.<\/*=HQF'$$8YTN//
M&^MV!LZR])"(]LCK](BGF%X[>7*]PI#9R)KS3L1&7(M$6A5K5Z'QQG>2F<HU
M<F1K I1%'A/;FXYA<J\5&4..Y)!\6QW+V-=G<F9+CN8HZCB$FF>9'*.0@S$8
M6=EP"E9,A0IBMD"3&Y 4IDH75.ZICU-TU@E!M8=C X'2/='GYV-V]Q6MV$XP
M\0ZG<=4[\_.$FDTLGC,][,0%G1X^G#ACDA[:#\^,$E(>7K([>QMRXD[&!!I:
M16<9<I.7>RHD-BF@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&J-Z;'_2;Y^/]
M:'DW_.!FB@AON47KW+O54<:!6C"6"*\WL**1/FZ3UA;PPE!=*0SSA2\CR@Y1
M8);,IG8,3"7IW4Q68-P/1*VU(I$*]TI5!)O(_/[OHQ\C.^7'Q@/0A!M_D;$$
MQA,7UC9\6-DGAZ5L:5;(!UGTYVFRC(9V_11DC[48YH"6L29LCJ)4H-&2H7)Q
M7*$8'.9^Y5^<#2/BXV)W WFU U$PEL5!<YX;@^&X.V'.,\QK*\<SI6G;)6_2
M9)C7;7(KN6_-SF:(M)_Y^:PAM:PA)C@_57"R'F0Y'<W\>?&(;NGA>+8JD^4@
M.N#T-F#*#'+GJ =CDMP;4KZ*[5%)S"I%VB0M8*Z2_BO06*UNTL;;IM<*<IGS
M4>H>R%BEPV^UFX<(#&M-XS&U,T<W'/#@]+\URV",")*O>)Q&,=)<VXDR"2T/
MC62H<&^S=$I00!&<6,A4Y$DB4'A_6,?4/<K'(S!F%1Q*<21<V?V!A; YER?L
M).$).#6C(/9IS7^$X_>U<]P(P2(M 4$9A!JB4D.XBU)0CFDD(+"4A9IPM\O.
M<]\IYM!J=NUKRQZR;OZC+V >1H-$Q/@(E(HZ_&J$!KNSM;X\2U8PG,;J4GL8
M&[X[)5Z)T1*D:DTH9G4#%6Y>U_J:XQL%D6*Z1\8.I\^UZC<H>6O'V4,JYBQ\
MND.28R4H#=DE%X_;<C"SG#Q*$M[A-1+6T9]S+=;]+M?J4';.*+F0V5V6VIRS
MQT\CNI2;4;>+%N/P940H(DI<%>,\BPE(H86M\5,!;B_3/NAB=8^DJVY6@D$@
M:G5")18"HLU"*RD(A9'Y_=]&/D9WRX^,!Z$(-O\ (V()C"8OK&SXL;)/#TK8
MTJV0#K/ISM-E&0SM^BC)'VHQS0$M8DS9'42I0:,E0N3BN4(P."SARV\^&B6L
ML&VQY"=)=0L5P%IVYQ_BO-,0Q^F>YQ)Q:]S=J1K#<C0N00'</*S!$Y(VOC.Y
M,H;O)2PD]P=6NX4=BRSN\!M#9>V6Q+AC6>>[:RB2I%&%X#A]WS<KDK<8$TEY
MA#=%S)8A4,?:=2ZU7(F_L@-Y5K==2>H*+#:XAVM00@X8-N-L=[]%X1MMMM!L
M38UD&:9-+I!BB%XFCDS8$;?A9O<O (@YR@R;9 GJ]ZD4D7M*]P+6)_#$I[6H
M1C D#<0C!A:Y0:HWIL?])OGX_P!:'DW_ #@9HH(;[E%Z]R[U5'&@5HPE@BO-
M["BD3YND]86\,)072D,\X4O(\H.46"6S*9V#$PEZ=U,5F#<#T2MM2*1"O=*5
M02;R/S^[Z,?(SOEQ\8#T(0;?Y&Q!,83%]8V?%C9)X>E;&E6R =9].=ILHR&=
MOT49(^U&.: EK$F;(ZB5*#1DJ%R<5RA&!)QFY:=^-$]"-AMO><35K$.!IU$L
MB16!:U8?UUE,=<%6=GF5,"Q8@CPW9'G[8AN97$#BV+52M4>J2B1,C<K4@1*Q
ME *-"";CS">I?AL&OMW.N&+#Y.FJ9C49"<XBCD3VV[&-..$[6J<5"Q\;A9Q?
MLAQM6VI4ABQ6I78H)[!&'K&)"PB";<-A?6#E)U:V;X]"^2=KD*N#8'9,>S6<
M91(E)8#)%BU=C$AP^<6(OB)MN>-R?&18UF 0@2!&-Y).2FI0"LK)"(-?*!\V
M//UO2-;GWC3XC,7/FEA3T>EC#_L1,4;-DK([$S.*M(YO$6>WK8'!4>6*' #8
M>2(IB9)4C:'&PDHEC@85^FA8=P>\LVVW)-FOD9Q=M=KUCG6EXTVF.$(@QXRB
MY<N63R./,\4YU;IS'\H2B02=Q992YLKCBI)9&>U-#(2$)QW7 ?818P!6QA;U
M"W*QL])=K-=-2^-R(;-;-XDV1RQCV)3*.)9!C/67'&'X>L.88:[YGF$^S")#
M(<JR&0-ZRXFLN0PQ*I0D=HE&(RQA986'3WF W$T6T-Q3/>2#42/BY+=ALP2_
M$>O&DNL3FE>R<I.2-4WAC+B0ZQ[)FPYB%H3(G5)XJ:D<'1=WQ>C3%(0#4=(
M@O,>7SU(FK3$Y;/;D\/6%4>E\>ZDFFQ&(YPE69M@6.%AX'8;Y)/!]C<O.C>9
M$HF Z[LJ<H,T(DRH'76W; 6$58+-M^><N":YZGZ7YOU3Q"_;999Y''6+,.G&
M(2%PHD=)UDF0QY2J4S$XE,\+VY;&%\M;&Q2TIRQ*3'A8%,,Y,6 Y42$#8QR*
M>J8QE)6B4[+<-&O\QPRI=42%W:->LA-RO*38B/6$N"QT+*B6SVR3TK+01E N
M!U 1(7:KS$X0B[00$BD)C<H_,!LQK_M9CCCFXV]2VS;S>3(.,%.7W5!-9$5'
M,88RA)ZEU:F%5(.TDD'+=E:E:VC6+KJI#'T2!!=-:ZDTU:'NP=#TDWO]00LV
M>Q3AOD?XJL68_P 194=W)K7YXUWF9+LQXD3I8X]NJ%VG"*-9JV;0*4B]X9@(
M.JJ7,(0"7%"N9[ 0G!*ANY'<WJ^=I]XPC(MBH. VO2HG8Y/+@,<NME\<X,D3
M,T":CG\4Y%#!12R9Q&*Q 8^%9U[!OWGHM>UPZ[QU\F.>LY\@W(SQT;@13$,)
MS'J9*VJ68.58JC\SC"?+&MDC5W$R3E\;IGD"?FCD1#%)(JM5B1')T@1/]B@E
M=) AB#G.2OD?SGKKN%QPZ)ZC17%$VSUNCE=T/R%?*S!,Y,S8QUMA)9!LZGJ9
MKA,W@;@5(!HK.2QN..4*T?91U<6<1UAE&!#J'*3S Y%U/S3CG1O1C5]\W:Y
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M J;DZ>/Q4DHBR(90.@+<EMU@W^H_\*X93H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MN1-GJ%<-.3DL2MS<W)=-%S@X+E!21$A1))@4H5+%BI0,LA,E3$%B&88,00
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MAR<48E#:F-4I51J=6 LP:8 +AC?D)TBCW'=Z6_/^J#.K;GI\Q]A"!+,F3!M
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M"L<CN$O^4#;\3?W70K'([A+_ )0-OQ-_=="L<CN$O^4#;\3?W70K'([A+_E
MV_$W]UT*QR.X2_Y0-OQ-_=="L<CN$O\ E V_$W]UT*QR.X2_Y0-OQ-_=="L<
MCN$O^4#;\3?W70K'([A+_E V_$W]UT*QR.X2_P"4#;\3?W70K'([A+_E V_$
MW]UT*QR.X2_Y0-OQ-_=="L<CN$O^4#;\3?W70K'([A+_ )0-OQ-_=="L<CN$
MO^4#;\3?W70K'([A+_E V_$W]UT*QR.X2_Y0-OQ-_=="L<CN$O\ E V_$W]U
MT*QR.X2_Y0-OQ-_=="L<CN$O^4#;\3?W70K'([A+_E V_$W]UT*QR.X2_P"4
M#;\3?W70K'([A+_E V_$W]UT*QR.X2_Y0-OQ-_=="L<CN$O^4#;\3?W70K'(
M[A+_ )0-OQ-_=="L<CN$O^4#;\3?W70K'([A+_E V_$W]UT*QR.X2_Y0-OQ-
M_=="L<CN$O\ E V_$W]UT*QR.X2_Y0-OQ-_=="L<CN$O^4#;\3?W70K'([A+
M_E V_$W]UT*QR.X2_P"4#;\3?W70K'([A+_E V_$W]UT*QR.X2_Y0-OQ-_==
M"L<CN$O^4#;\3?W70K'([A+_ )0-OQ-_=="L<CN$O^4#;\3?W70K'([A+_E
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M.7,;:J2XJSYKA!R9 D1/P2E(4;*K 38 4X%RDD@D5!:QQ4:R\T6JV><EX^Y
M-P8EN?JFLQ(C<,/Y!( V!R!'LL)'^+(UK/+!/<39,DC"X1T;D(%S7:1-A@$I
M2BYR18H-3B"^N@4"@4"@4"@4"@4"@4"@4"@4'2,D8XAF78/(\;Y#9O,,+EJ$
M+;(&;Q%U:?$$05!"L)/B+&N;79+T*$P!=8@\L?U/1T]%[VN$(OQ3N@'^0/\
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MG$ZWE9BH7?,N;8K-(_@=:DQM+#4.*6>;%Q^/)G=G3EV62UV3&%QQ'U4I5BR
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M<+(+IB=\+CLOD<+C\QV<?GZ A=SR%J1,QSA(W^'.-CDRHLQ$<8&Y0KWM>P8
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M4"@4"@4"@_P0K!M<0KV"$-KB$(5[6L&UK=-[WO?V+6M:@KC5;[2K(TGE$=U
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M8,.*FVQ^V"[*\3U=PS#<#.F>V/#[)DW.TXFZZ?)L(QE8O&G;S&2(-[2(J=N
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M%NR5?*PM^I!TD*=VYY)4!5&!D!9HA!4 $.Q@>D7U5J#<*H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M"@4"@4"@4"@4"@4"@4"@4"@B;O;*'R&Z>[$2&-JE"%Y38R?D:1<D%U%:(#R
MIE6*TIOL"3J$R%Q,& T%[&%"#88+V$&U[!^NC,/C\(T_UQ:(V0F)0KL0P>4J
MS$I998%KY,V%%*Y X#[, .T-6/3P>.XA=(^B]K"O>]J"5M!5%QD?^N&_G\LO
M)?\ A1RH/TY@VI&DU::<HHS0MD]Q!E> 2S'TA(OV3JTO)[N6WG!0*0]!@0C
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MOR-\W[-BQI\Q_.5Y\<?,WBWS:=IW/P!O[#OO5[<SL>DT.&Y3^+S\9?\ <?\
M_O<OF4^Y1V9BNQ?_ %9_./Y]\L]A_P"AW_6! _*W?>Q_OA_YQ[/I_P#;8=!S
M.^/&G]VUM'QO;)_/3\V7XOG-TCS)Y+^;GSG\[GF!?C)=Y<\Q^?(IY![I\W/5
M[YW!Z[3OG3V >RZ#0DUO;J[]VOI[L1J?YY^;3Y^\9/N.O/WEGSEY4\;"4'QC
MRMY@BGCO=NS_ /;?Q)'U^G_RH:")GXKS_P#<]_BG_GR_^]F^YT^?SYL__D79
M^<?FL^<#_P"SX?YC_P"DT'5,M<2OSI<,C5Q%?/\ ^!>&81PKAO[H/YJO$^W^
M9^9P.7>8_FH^<AO[/S%Y([OW/S*+NG>NT[<[L^H8%0*WTL.PK=%XYAO'O.OO
M=$-8R(['8]-,!+03=WB\@2)1D@E2".-['L3#<?16.O*%.64W-ZN,O06NX B.
M,7A#8%!L>:!:#Z\\;&MD6U>UJ97=O@S O<)$]O\ *'$AYFV09P]DHB)!/9P[
MI$+6@721Y);$Q(K)4B-$F2I2$R9.2G)**"&!>(;C3_%5:N2/6SYZ?GX\P9NR
M!F3SI\W/S7]T\]((NA\N>7//F1.W\+\M];OG?P=OVW1V!?4Z1!35D_TL+NGS
MSFJ=Z:\I^U&D> ]BYBJEV8M;L8MTG.;)"!]=7-?)HNDEL2S=B]J51<*-\6(V
M5._1V0&-28_J'&+P]<(PL-Y(>!O7SD*B>!WDK*>2-=-I=9H&QX_Q!M3BKL29
MDG8(ZVF)VEGFC(2X,ADC86YZ.-<T@$3FSN2%4>>%,O)*4J2S@AMKAZ8]N;-A
M<9;&\CG(CLORA27"#F2\XBB6<?-2*$,"]&X('EN*D*2?Y?SK(I"QHWU'WX;6
ME<FIM7* %66$*2 FDGA:COCQI_=M;1\;VR?ST_-E^+YS=(\R>2_FY\Y_.YY@
M7XR7>7/,?GR*>0>Z?-SU>^=P>NT[YT]@'LN@T+3*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!04PYBXZ<V9!YQ-3.2]EE&+$N"
M<#ZE3G TOB;H]RTG+3C+Y,HS8<@<HVQ)(0MARR-DAR0A[8Y4_(U0;E']5./J
ME]J%SU H% H% H(Y[;0W8W(.NN3X;J1F%AP%L4^-38GQAE^3Q)EG;%"74B1,
MRQS7N$2D3#)F5Z+6QU,L1A+/0J @,4!,M:P@6&$-6Z5<6_JDMHH\[X,VZY@=
M9([KSD) JCN3U&",?MP,@.$4=R#&I_9$J6):FZV.;NV.[&N4DJ4)DM0)%@!6
M*/L(L5[A#9YTIU&Q7HAJSA?4O"Y*^V/<+Q($=;7!W$F&^25W7."Z02Z92 :(
MA*B%()I+G=<ZK;$%$IPJ5@PDEEE6  (2DH% H% H% H% H% H% H% H% H.*
M?3'PIC>38PE:ETD+:G$R/(GU>L:F-8^ 1G":4KRZ-[:\KVUJ4+[%@4'D(U1Q
M)-Q# 2:*U@""F_A9XULN\?\ C;9&:[4S?'>5-S=Q=B)?G?8/).,5LC=HDO"K
M6+QPN*L;Q,(I#),L:F(QZ=G$):E 4%(L?%)!-QD@ 8,+I:!0*!0*!0*#BGU.
MZJV-Y2L2\MJ?%+4XIV9T.(+5$MKJ<C.+;EYJ4XLXI26C6" 8(L0!!'8/1>U[
M7Z*#4N?]&/5S/+VOC0^8;3GYM71?X0KE;?B&#1;(A,46F@3.#RV,<=T93W:I
M0F;S##4Q"24I[V4!"$+@3T]L +E.(_B[AW%EKJ_XR3Y'D&<<SY;GSME_8G.\
MJ)4IWK)V3'LHI.<K)2KW-]<T;&UI2NJ2%6O6JU*P]6M.-[56,  M2H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H*T.5^$3B?:K%,F/
MX3+Y^_$94@3L*/PB-N\J?1M[>8ZF+%9;2R)%BT2=/88;#,ZE@ N*W6O;IH.0
M7\@TF6)#TL,T,WO<I2H#8ID0S'")<&C"A<,0;  ]RXV0O13"AL'IN(\24X(;
MVM:]K=/38.Y\?.OL^P!AJ3%Y4"W(<C9:RE+<Q2R-LRHM<U1!?+"&E(3&4RT@
MPY,K.0HV<L9XRC#2@G&B+ :: L)HPZC#X/-4O*+EK("F(2A/ G+56.QUNFY\
M?=BHBOD!$QB:HYB124Q(%F5/!*9,88)* X1X2RQ"N'H#>]@_SE-@TSR)JBNC
M<#ATGG3\9D?'2VS!$8\ZR9W,0(GOM5ROPMF2+5HDB0GZHTSL^H6'V17M:@[]
MN=J8+8&+1^6XV=@8_P!B\/G^8<*Y"0BLA,1.2,9:KRF\GE %8R-/1A%@?5@-
M"C-%VEBS"A*"#PR%JCF7(69,8)U^7L433$&5HRJ%')W'9/$W^/LKF[HK"+%)
M8*YNR0M#((N]]E<TNZ50JLD'<10C# =BH/#]]?LWY!S [Y>;IQ@:8X52XYG:
MJ)Q9RE8WL:?)K,0I<R"Y@P>+PZ*%A:U!:$LP-DYC@5U5 >@Z]NBX@DI04Z;!
M/DYP[R513/)6 =A<MX^2:Q$P=0OPGBMXGHR9"X2^6J@HC%036QD+-2)KEF'E
MB66/+ <6+L[V':]!^.Q^5,V[SXT==:,2:E; 8Q;\AND32S?*&R4)+Q;'H8P-
M,F0R<YP;$(G1W42558Z/%!$!.,1P CN$)5S!E7H,K.F)I='N0W5ER:8Q+G?'
MF/\ 5600)PR!:/NIT:2.:#Q] WH7F1$)3&5 \N!%BC IS#PFC[6UPVO:]ND,
MN\B6"IAL1J=D7'F/TUG":@.CTGCK.(].FL^JXR]HW)4S 4JS"4Y*M>U@/"FN
M,8 "4]F$0@A$(5@BKG+93/\ L)K/E?&<.T>V.8IF\8P?VJ>+\BQDN(1MK$>U
MC(<0XV*":Y2C+3LM/ :2WHF]N(,&,PHPRX2NO>P?7F/ N6Y[QFZZ1&(0AU79
M3Q3'-?)P?CAV),C\C5K8*PHTK]&S4+O9&>B?$9"PX0DIP0GW&0(H(!'7 "X9
MU6S(W?G!V;<)N.#-BM?5SY 2$13WG;&=X8PCDS@(U6R^7E!CJK7R9,Q/[04<
MLL!*F'9+U;_I1AH+6#"N.=J]EL-X?CN#Y9I'L++<[X^BC= 8]((E&DKY@R7F
MQM 4Q1^2O.3TCD4F8DSBD0!/6%A(-Z!_F#*L;:Q0=4D&JF4L4<6F:,7+VAQG
M6<<DJE.29A'H.VKI.O4S.63B)+ES.SH68E:H=U#.RM1(%(TI8R1&D'#+N(JU
MC!!8X[LSP;JNZ1XMI<C'\S7Y:S%L8$*H;P-X'CDU"%I V!*NM$Y"6W[&Q%@=
MK<WZCJ];V*#'^@49DD-TZP+&)?'WR*R5GAYR5WCTD:5[&^-:F[\\'63N+2Z)
MTJ]"?<DT(NH:6$75%:_1T7M0<3M+E>:P%Y:&1VU'E&S>!)%&S S$4%8&6?R9
ME?QNHVTQN-QDZB/O*VM:S+@"O]0G 7:YEQ&B+L98H(8ZZX>53#=>'[!X6U:G
MFG^%HC Y:Q9!;,@1E'BQTRJ]2% Y)&EJ0XI;7!:D:F]D=3R%W>2@@3G=R+N*
MX1V)!<+I:"!W)K#Y;/=(,VQ."Q:1S25.WS;>%QJ)LCG(Y Y=QRY 7)=X>S,Z
M58XK.YMR,Y0;V98NS(*&,70$(KV"8./$JE% (,C6)STBQ)#XRE5I%11A"E*I
M(9411Z=00:$!I)Y)H+A& 5K""*U[7MTT%//*]#9K$9I@S-^$70EKRWD6TEU.
M6M9-B;.4L9,J,;PE9!HPA$4HLHCRU:LZBBUQW3JU2,RW5L3T#"SO&>'FO".N
M$=PQ%R;J4T)QH='"Q)21".>7H32I->76Q!981#6R*0*E"L80@MUCE%^@-O8M
M01YXO89,,?Z48HBD\BDEA,H;G#(@W"-RYB=(V_H +LD2M<B&L9WE*B<4H5:)
M26<5<98;&%&!&'I"*U[AAQ8@RWI-M#GG*#)A/)F>\ [+JV"9.(,,,J>69%QU
MD-H(6I7)*=#>]-RAX:G]8[''W4!,++*(N5TCN80;8T.=PY%LP;*;A->V^1,5
MRG!V+L1X_>8'AF%Y'3 :LF29VE=EI;[+I)&BE"@49+ U.AR<:<X8K=;L+%"-
MN \P(=$R-F!)-3G2+[4<6F7LC3U )R;&*20'$$9RY%71$->H0H5R+)85I#A!
M"W0#6F$<62J5&IB>@8AB+L7UPQLW:UYQQ_Q3YZQ:\PJ1G3*:21TE^/L-, W&
M?R6"P]\F,'6-4"3@:2W):ZKT%FU8XJ DV-& 2HRYO098VP0SCLCCK(+["N,=
M*R068O"J [$ZS/<Z3-48>W!1"V9A:6TM]=Y:2D0G&1QK93"Q!5J%EB2DP@WL
M8(-[4&6>4*&3#(&E&5XI XI)9M*'%PQV-OC<18G22/Z\"')$47+1HV=F2K7%
M4%(B3&'&W 6*Q918ABZ AO>P8\W-UQE<FGN MCHGAF)[$BQ4Q.D.R/@::HXX
MJ!,(4_)>N2Y1Q/+4*IGM)XFY*#U)99MKFFCN78H-[A& P,2MDEQU,7N+LN&^
M'UY8I2>\L]WB49JUHQ7B&(PI)9P0]]D#:^*TA@Y,I:2>W.*3E'-QY@BB[@%U
MA=6P7/4%;>WD"F<HW$XZY*P0R3R*,P>9YI6S.0,\==7=BB!+BRX^"S*Y.ZHD
M:AO8"URI ;9,8J,)L:82+J7O<%^@/@V]UTR%$\A-F[6J3=<W.T)1%I,DXZ1E
MG=SSYCHBR<#BQ*D*2US%\J0H$H+)^H&ZE4604$GK*TR, @Z=ML;.-A8IH1/8
MGB#+C<>DVOQ-,)O$'K'<N1RG&[:VJ3P2!3,FP]E)5-+,R*@B")S-++0&E6"<
M RY8PWN&6YK"IBJY,,,3Q+$I,I@S7K--F%SF:=A=3HHW/JN4.JA*RKY$6E$T
M(W9208$9:8PX)PP"M>P;VO:]!_FY$*F4HSSH4\1J)2:1-$/SRY/$N=&)A=79
MNBS08SMY0'21KD"50F9&X9@+AL>I$45<5KVZW3:@C;D*-R? N].9<\Y,U=RC
MM'CW*T3A*'%\EQ9CUORT_P",E$?9$K:^QL<36K$UH\0N4(Q#$L"(D)A8@7 ,
M9AZH 0[# ;YOR;R7PS-,RUWR+B.!$:O/409'&2)[/!5R"YM)EZ$,O>8^2MBD
M2F#D>X'BLQW<52HI&$@X0OT_J #F<N9G+>'^7P[:7C-RUEXUC?)2S0":8UP]
M&,\,<AA%G1T+CCV2\&K"W''KJM9%9)@R"59RDE08:8'L#.DDL,8X?T4R3+]*
M]H<,RED,PTDS3DQZR%@W%;U(12(>)FQM=VE_AK-('5,-R G"ZK60A,N 58X\
MM)TG##928,LL.-CK]C^(1UMAN6N'5_=LRMB=*S."[&6KV(YIB61NI'9MX'PK
M)*1$! RH'A44,\T(B%):$L5KB-,!]706E:SHW='A.&6?L*Q;7=U5>8' _#<-
M*8BF*%)G"4/2MJ2 \M$I6<QR7LYJ=8N&42G$-:H-N8229UB@!GB@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@Z5DB!,&4\?S3&TI)$?'9U&'N*O "^K8\*!\;SV\\]*,81!*6)@G]H2/HO<!
MH BM[-J"K/"&2=G-'(FGP#F76[+V?,>P92H:,3Y?UPC:6?N;S#S5#@J9VV50
M@+FA7L:EI*+N3VIIQ5B2^S)N$[JE*502SPUL/G/-.14!(=6,A8;PH0SNZUTF
M^:SFR,SQR=[#$G8F5LQJG<3G1IL886(Y0I/&J+[.W4Z"^L68:%?NLV7YSJID
M7<!MF>I&Y4V3Y'V=R-.(L_8OP*\22/+H\H?7-.C6ENCJYQT"DI>"UCB#$P3R
M#2!A&$R_309=E,0V$Y!YMCAMR;A=ZUWU+Q_*&;(3['<CJD(LHYB?VU)=2T,;
MA%DE[J(HP)R7*Y*M.JZ.KVAU[F&J0!(2A/[9#+$SPIB=[R% ,/R?.LF:US(E
M1XWAXW4#Z[$NCJE;UBM,)EC$P<+%-*90)2;U4!MNS+OUA MTBL&5HH[KI!%H
MT_.;,JCCD]L#.[N$>77.NN85SDW)EJMF674)4)]U36><(@SKD$CZY=^D +](
M;!^\A86J5,#Y%WU(6O8Y(SN;"\H3?_)+6IX1'M[BD,_^1J4B@8+_ /QKT%1^
M%7K9+CW:UV!YE@/*FR. &%]>56(,HX':$<SG3?'WQ>O>?+<KQ]9:@7]X3.:Z
MXC#[F)DZ81IH23%)-BK "56+-E\YYGR;%FYBU+REBO"W2\GSC(>>P-D$F!!9
M$>=?!&V.XT Z+'8U4MEY!!9BD1J@D""PC+@!<TL00CYISA*=+\+;]8WE\9DT
M 59?V"V,11E7+H\\,%G&/SJ*-S"URMJ Z("3'1@/,/&(I6G <0;V8NI<5[7M
M0=>U>SGL+A7#$-UA<=*,_O>9\:-ZR'H7ZS<QL^ 7DE*O/-:'I3F=:ZW:4Z&R
M%:7=19&F7WO<H?97&.]P #^M)T^QF!M')>Y-6!9!(,O-V;)4_@Q%)BUT =9%
M&W*41VTA4,:J4)FX\OICUUI[:HN0HLH,)#8!)XKV*$$>MB(JQ[8QBT'PKQLY
MEPUL,XOC$X)LS3+$[!@Z)PA2C?V0V0ORW)#.O3F3D)2%*80G*-($H$48)2E+
MN878L02ZV_@F681ES2K96,P&9YW3Z^^=8[E1C@#<%UG;F@F<4;(\*4,$<NI"
MJ>5(3K+3Q)R[]/:W*"8,!8A&@#C=D8=+-V\08US# <!35HFV!LOWDC?@7:>$
MLL*.RQ&DJ)NM*HZK8'A>^M9;9(R3"BT2E::44,Q*>&X0])1M!B=;,,7N:#R_
M">%N3J,JC$8B\-FNM&(X?BE(X%V.*-.^=M2T*&QP;"%-@7+-[HF*5%7%<)@+
M6L*X9TR_CV?+]V..F3H<<O!$:@L/RVCFZ^)QA>?!,>JW#' 6] S+G5J)6L4=
M0"7V[J@+-4! 98(0%"'['2%H-!A+9'#Q.?L$Y2PZ:X :39[$G!G;G0XNYR=M
M>P=FO8'!62$(C#D2-[1IS#@ Z#!E!%8 @BO85@KZQSM7LMAO#\=P?+-(]A9;
MG?'T4;H#'I!$HTE?,&2\V-H"F*/R5YR>D<BDS$F<4B )ZPL)!O0/\P95C;6*
M#A%NJ^3\2\7F;<8.;6OF^;\E$O\ D:7Q^%-ZV2KE,VF,CCRI4R,Z)H)6*'A6
MU-+804>)( 90SB31E7&5U1B"T3#2%<UX@Q4V.:-4W.3=C:#(7!O7)SDBY"N2
M1AK3JT:Q(H 6>E5)3RQ ,+&$(P##>U[6O:]J#O+L 9C4YEE@$888WK    -Q
M#&,28P(0 "&UQ"$(5^BUK>S>]!11H;L+/-5];&;$4XTJWF?9:TOTN>+J8IKR
M\J8Z>![<S5[>19P=W1G<RQ6"*P3A=Q%8N_3<-C.CV0DW$<69^VRV-QUGW8G'
M ,(X>P$M<G;#&'75X;W^;R.<GFIRBYY-36N]TC6!N4MA*E(G%U#"3$Q(2@F%
M#-5* [4B@TV!RK.^1!0Z4AQ^;I\5&2YR*/.UH<9)+9$:UMX^"372691OED18
MCNZ6/[?L@W'U.K:]Z#D=<83,V/>O?Z7O<1D[/$YE]SQY0E#HP.K?'97X) '!
M$\^6WI6D);7WPA8,)2KNIIO=S;V"/JBOT4'[XYA4R0\DFQ<Z6Q*3(X2]X&QD
MSLLQ5,+JGBKN[H%38)<UM<A-2@:'!Q1!+%<T@HX9I=@WZP;=%!A[:?7YXB6S
M_P!U01K1'-NL:RS'2.$Y0Q>NC<2ELWB+K'3BS6>>P!@E3<K*>SS6I*6B,1)>
MLK,O<RU^@(P"*#]<2O<)F.7\>EX;XL5V(&IM?DJZ5YCS%@+&F$WB")$Y2LT2
MV&-J8@;P^.I@PDEE*$:X!J<1HA7(,L#V0R)J[!IM']XN0.6OT.E+)%9FXX/'
M#Y,[QYV;8_*P-,5?4[J.-/*U(2W/H6Q0< "BZ4PVQ(Q6"/HO>UJ#C=X]=)1*
M\I84V2A^'(CL;;%J&0Q'(F"IDDC:TF9P>0!,-3ND9)E:%6RWDL5<%)ZHH!EA
M&&BN78H(KA& P,*MDEQU,7N+LN&^'UY8I2>\L]WB49JUHQ7B&(PI)9P0]]D#
M:^*TA@Y,I:2>W.*3E'-QY@BB[@%UA=6P2,9H3,RN4V6Y"-B,G+@*G2Y-%D\X
M,8'4$/42<.6(RY"CA,E$DLRFOP6Y.8?=&$^ZBQ(!#ZG5M>]!_NQT)F;YO7H#
M+V2(R=XB<-^Z'\WRAK8'5PCL4\;@#>B9O,CTD2'-K%XNL (I+WHTKO!MKA!U
MA6Z*#%N2E&2]8M[9]L0' F8LV8IS3B**P\Q9@N+AGDLC$MB@T1=DSI%@+T*@
MIN4(F<([JC#""/[(!8L9A@3"[!SFR*.;9CRWQL9-C>*,JMK,ARB\2V7MC_"7
M$A^QJU.K7&!IK9*2-5WA%#%(>Q&$P*M2$(# "!<76"*U@Q5D*-R? N].9<\Y
M,U=RCM'CW*T3A*'%\EQ9CUORT_XR41]D2MK[&QQ-:L36CQ"Y0C$,2P(B0F%B
M!< QF'J@!#L,!OF_)O)?#,TS+7?(N(X$1J\]1!D<9(GL\%7(+FTF7H0R]YCY
M*V*1*8.1[@>*S'=Q5*BD82#A"_3^H /Z6.V2=0=U=F\HK]=\ZYHQ9L<T8Q=(
MX_X&A8,B.[&_0A@$T.31(&,IU;QMA!ZI<K'8\XTOI" GLP&6,'V09%?6";3#
MD6UBR^EQQD-I@YNKDE"].KW%'%,EASV_F2%Q31"8NB0"]A8Y<F"O+*.0B6#'
M8[IL"X[= KAT]8@RWI-M#GG*#)A/)F>\ [+JV"9.(,,,J>69%QUD-H(6I7)*
M=#>]-RAX:G]8[''W4!,++*(N5TCN80;8T.=PY%LP;*;A->V^1,5RG!V+L1X_
M>8'AF%Y'3 :LF29VE=EI;[+I)&BE"@49+ U.AR<:<X8K=;L+%"-N \P(=^TI
MA4QBN6]['*41*31MNE^S+N_1->_L+JSHI0Q&HS0EO4=5.*5.0]-)@K] 5*81
MI-[_ )@J#_,<PJ9(>238N=+8E)D<)>\#8R9V68JF%U3Q5W=T"IL$N:VN0FI0
M-#@XH@EBN:04<,TNP;]8-NB@L*H% H% H% H% H% H% H% H% H% H%!A[8+
MN'S(Y3\4[WX9Y)??$>X6)NN[CW(SO?<N\7LG[WV'6[/K_4=?HZ?8KJM]\'W'
MU/G*^;\S=6GJTIQI7A6GJ(+W-][_ )O=Y]^>/WI]S\WC\%/'X/!/B\/B]KXJ
M5\->%:5X*!?_ 'AW_P U?_[D*H[_ /IO_B?]QK2__P >_P#K/_EC_P!X=_\
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M.;>])[+BTUU)%C SOF7DDP;@_?75GCNED5RNX9KVZB4VF6-Y1'6.(*\6LC9
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M/!?D[YROFL\,\[1F>2+S3YA\@9&[YX9Y)['N/<2NV[UU^\%]GU3 M=H% H%
MH%!$#?7=7%G';J=E;<7-;!D"48RP_P"1O,K%BUJCCW.UWS@9)AV+6;P)LEDJ
MA,?4]VD$V2'*N\.B7J(RS1@[0P("C R_KUFN*[*8"P?L7!6^0-,)S]A_&F:X
M<URQ*W(94VQ7*D+99U'F^2H6=U?6A'($;0^DEK2DJY8F+4A&$H\X%@F"#,%
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M-(7GS!62',3+CO-.)9Z\!#88FF%Y&ATI<P@N TRPQ(&-Y7*K!N60,73U.CH
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M1^9FIX;E+",\*(:@MU3EJ D&V-L *=X/RY>I:VUB3'LQI7Q$ZWG:E35.?((
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M8)EHHE--GL[/0F?%LS=4:=<!Q10D"[*^ HTUDJ5192EK-4RE:XN#9:R@36G
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MC'@.P.T45R?-6J8Y13$ON+].\?P=M1-Q\,CC@YY%SDWF23+;U;OJI:F.FK
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M!MNLE"6:&R<7L@ZMZ#\\)Z_XAS9R \@3KEB%-<_*@,IP,HCL?DUC72(A7O\
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M:Y$ZQ2/.3\V*$IJ)0W/2YH1JG1">B/ 4>D.2+C3"Q%#"$98@W#>UKVZ*#M=
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M$ED2B-H6!*:E$M&C(L<(?3<,B>BD_P"M7D!_@^U^_='E6@B]Z>#_ 'B+./\
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M%>*&"9X?G4G:9DO9A*1,3B\Q/#CVL4-9X@'$HD19RLLHA4F&<';_ /XL)_\
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M-;&YHRM-2R(BXNJ@U'"\A-K8WI"%BEX8&@39+&X2,9P1)P*2DYP2S"SABM[
M8VAF!>1["D0;,*XFS?K=)L5Q],0QP^?91BD[!EZ&Q8@^Y#>TH&9D+<(.^>7F
MDLLM)W\9EAVMV5^R* 7U0[YD'37*CFDPCDV Y[-;MKL+Q-1$5N69-&@.,?RV
MPNJDU>]Q^=QZZMP5)6@QP5J#D?8&G]RN<.P"^O<DU.'VQR"\CDQFD+59?RYK
M9CC'\9ED;D4B8< 1O(3P]Y":F5R"Z+HF[.N1A)%$?;7>Z0I.<:A/ZPR#3+&
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MCM?$.\=M['8=7ZN@CCCW5[=+6ETGT&UHR+KHLP9-YV_3MK'F1@R$LR+CU7*
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MOFHEC,CHLWY7F[O-L@^$K&A,TO"9 E3V8H!'!/\ V1QZXQI8V\9YBHPKILE
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MZ:HSBF)X[!+V,NQAS8M?&)[[DJ.N<$%QED7)#$?J+-:H+ISZ<U#JYC)VEK[
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M.\96M2=@<^_MJ\HSJHU2@977ZIE@"L(-@RG0*#^1C 6 9A@PEEEA$,8QBL$
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MGE);1=;D^$)9%=2>&PR4]F0]\+<[GG!O:X0=EUA6O[%J#,M H% H% H% H%
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MY*%(YG?Y?\GVWXY_N2A2.9W^7_)]M^.?[DH4CF=_E_R?;?CG^Y*%(YG?Y?\
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MY*%(YG?Y?\GVWXY_N2A2.9W^7_)]M^.?[DH4CF=_E_R?;?CG^Y*%(YG?Y?\
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M$HYB8<"-2%DD HUIZZQN0V97-$Y^"2%//Y@Z*&-UNB..LA=D[<[)3AIS.J:
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MSW"LF325Y>C4O.#(<<E0$FY36SLN*R8,[6R YS%\/2H"1&O["F1F*;&GFV)
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MB2D,SSIP#<@^*==A&75_/*4WY'=U/EY3>ZMH> L,PULQE!A&.+($2JY7FZQ
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M)'8LP7AS"#88T8DQI#<?HS[="T<;8T2%P<_TRYH1/#Q8L3N\C+%?H )4><(
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MHNX$43NW('5%9HV,7V2.2-.N2V7-,;>79J663JBS2K*VQT1$J4YG1UR5!(#
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MS+D4/C4@6O*50<:W$*4\:(+M8P26W0%V'*4F3JO4:<")2H@E24%CV34A+/*
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MWLJ!8(9EWOV#F>K^MDNS% &R,.\F8'>)($:&8(G5P8C"7Z2-S.L$I2LKU'W
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MMAK"\.C64QK4[VE:4R4]0W@LH"H0J1B!<5@"!>]KV"9- H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M9#(.N.<H]LAA6!9EC:438DF+1<]P8C5=ERB-R%O4GM<DCJA7W9$)6)F>T1Y
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M#-[%(D#.8^+&F*Y Q)*V:4.4=0A0KU*"0ITKB LHU2E,/"<:H#NO%[P%XVT
MSQ*MQLT[,YBWNW4EC"Y1@W/^:@K$@H^TO%[IG=;'&-[EN1Y1YK>V,LEM6.CK
M)'4^R$!A"4*0I2J+.#CN6S@^R=R2[.Z][4X;Y 9YHSDK7G&\@@$8D>,L8R"1
M3D!TC=WM6XOK#D**YZPT_P 2,5,S^H;3R4]C;GIC3 B-ZA@BZ""/^SB<IO\
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M"A\NTKU]<L-2/(F(L3$PS(>8I6='6UL;LIM<B5Y5?2<5+S7QF3K79O+2OEG
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MDQMNWLKI)GC#\5=XA#9Y@UW-)93FYS>2Y&0JD;(PO< F3BXM;X06:G&EDR
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MR#0*%,&,9O$KF3"%&1$25>]R639;\ZKB<AODTD-E;@IL3'&!,F-67+(*"26
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MN)G515KRRY&%FJ:2K)4ORIE#-"N%6@+G/Y+(C$C>TW/CALNGRMM21R)M"%"
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M,#V(=-8N)/$&28VF;54R4Q9LA\)"]'$D,R:3RF7O2%*Z.IB@91%T+&C">N&
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MZ%OYJM(LD,7F[U"(ZP-2AL.5%%6"W*#E!RD\HP=QE)S2J#8WH% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H,+;&F("L$9:,=5@FYL#!)!X@X
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M*-&OWPT#[OWF%_(#3_\ I*-&OWPT#[OWF%_(#3_^DHT:_?#0/N_>87\@-/\
M^DHT:_?#0/N_>87\@-/_ .DHT:_?#0/N_>87\@-/_P"DHT:_?#0/N_>87\@-
M/_Z2C1K]\- ^[]YA?R T_P#Z2C1K]\- ^[]YA?R T_\ Z2C1K]\- ^[]YA?R
M T__ *2C1K]\- ^[]YA?R T__I*-&OWPT#[OWF%_(#3_ /I*-&OWPT#[OWF%
M_(#3_P#I*-&OWPT#[OWF%_(#3_\ I*-&OWPT#[OWF%_(#3_^DHT:_?#0/N_>
M87\@-/\ ^DHT:_?#0/N_>87\@-/_ .DHT:_?#0/N_>87\@-/_P"DHT:_?#0/
MN_>87\@-/_Z2C1K]\- ^[]YA?R T_P#Z2C1K]\- ^[]YA?R T_\ Z2C1K]\-
M ^[]YA?R T__ *2C1K]\- ^[]YA?R T__I*-&OWPT#[OWF%_(#3_ /I*-&OW
MPT#[OWF%_(#3_P#I*-&OWPT#[OWF%_(#3_\ I*-&OWPT#[OWF%_(#3_^DHT:
M_?#0/N_>87\@-/\ ^DHT:_?#0/N_>87\@-/_ .DHT:_?#0/N_>87\@-/_P"D
MHT:_?#0/N_>87\@-/_Z2C1K]\- ^[]YA?R T_P#Z2C1K]\- ^[]YA?R T_\
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M&OWPT#[OWF%_(#3_ /I*-&OWPT#[OWF%_(#3_P#I*-&OWPT#[OWF%_(#3_\
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M&OWPT#[OWF%_(#3_ /I*-&OWPT#[OWF%_(#3_P#I*-&OWPT#[OWF%_(#3_\
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M AZ>D5K7"6M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$>=M/\
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MB(D(G18]-L?;V^Z@BQI]KG%]8/QXY?4A<<_)CFU-KIB,6;,39C>T#NX0>';
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M,"S1&Y-S@W)7= O1+FE<B(<D3HC5$*6Y8W*2 JDR]*M),&F4(E"883 &@%<
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M7V5S-0LUXQ^\9*RWA291QLC&;HU&&:.+I&:K3QL<C6Q>0IE06TY$6M;7I6V
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M?8<4X)BQ%B"$LJ*E7L"P[B&,(4<[7(L[\M[YQ6X%P0,F42"6X4Q[,Y9$8\>
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MYF8TJ,-FJ,EH768/Z(IN3A)++3H0D +L6B  L/G]*!D:'X>XA-MLMY#=RX_
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MCF+!\:?YRTNRX"9.;=U4F%^'@, F&:W%FI0XKD.QCZI#DXUY>M<ME>('1,3
MN7M3O&L@PO(>'$.6,9O36]-+N:\XTE<KY IBBC*][3M-FYQOW$\M:V*#DY@+
MV':X0E)S\X^ELIU>]/GBK::.%N,[D>V^IV/MC8B\.J%_)7RUWQY$(YEZ..CV
MPN;@VO1:IX4."4]4B6'D*;"$82<, @CN%_/)CK7@)/Q&;OX4:</8WCF*(3IG
ML"]0: 1B%QN/Q*#OD!Q!*Y%!GR(1YK;4S-'W6(/[.E6-YJ<@%TYY +V]CIM<
M*&<"NC@[^B^?5;FK.6J2M-=D&LLX\77&!O9,_9296E(&_P#P$M[4WDD%V_\
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M7.&/(WL7FR7F3YX,CYA:QU!8)!@>T$9U#%!XSPW%*#5&Y#/]Z-X1/X"-C_\
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M9)VN6R%^:"U!*H$?52EU=GTM@NI3&GI3E+8E6E@4B*&,GO?:]F(8.J,04Y8
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M1YP$_P 51W\*:) UOAX 7"BZ216[:UNFQ5C3 L$H% H% H% H% H% H% H%
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M^&F0YCR?,\JLLZ$JQXL.4/1A39%,+31@$G5 ,M9+>[F$0[_^4"7^;06!<X'
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M)$6$Z>./2'FIQ_L$@S[R<\G40SXQ,L4D<=1:X81@Y+%BYX<WA.<@:I8]/#'
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M=DC3KWA/$SS (+-I.Q.$>%E27RQ4X7<72,-KJ6B<AQE&T.QENW-*M<)A(+"
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M341/*<GRK*LB@I,[D H1*X_%<215EDK?+E;M,WB2-+20F/*71LL 0D7-*/
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MZ+Q2QUEE_'E$XG)&Y.[QZ3+<ML#ZU*P=HE<FAWELA;W%"H!_X1*I(H& 5O\
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MKU+>8J,&8C1GDEMHPE7-M<_L@MPH% H% H% H% H% H% H% H% H% H% H%
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M  6O_0D_9:!XB?\ !:_]"3]EH'B)_P %K_T)/V6@>(G_  6O_0D_9:!XB?\
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M"8CCQALT(U(5*E,G+;07+5."LRXQ".OT"BPKS(N^2K_];1^^Z%#S(N^2K_\
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MPMY9".R>R6R58Z$KQ199YD7?)5_^MH_?="AYD7?)5_\ K:/WW0H>9%WR5?\
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M]]T*'F1=\E7_ .MH_?="AYD7?)5_^MH_?="AYD7?)5_^MH_?="AYD7?)5_\
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M_?="AYD7?)5_^MH_?="AYD7?)5_^MH_?="AYD7?)5_\ K:/WW0H>9%WR5?\
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M;YG=[#4NJZE9% H%!*'2S_2IPA_CJE_M-;73[_\ >;4?,Y]F'8[1]\L/R?\
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MQE#,O[<Y+B;LO896;A!!'AP)I?&>P[O3"AE[P[EJ)4[,W8FV4B:6]:WE#),
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M=-$3L>DPJRWSRAR*4Y*NYQ59"_#3Q.!AJ@:,*<NRDH\U(84>,-=K+_K$N/F
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M].B74\EAU"V7<F0)W52N#N^8M9'4Y/UNCM3V='(W](F.ZGL]F%<:'I]CK_\
M#074: <XFD_(QC#,$ZPLJR$P3# D$79%RGA6?QYI9\E-L4;FY8L.?8W=OD+K
M#I<RJ5C>:D+/2NMAIU B++BD7>D_:!Y\V3N6C'TQYPVWD<9#-@T6L*38_$>6
MCL9+!,B;(PX;!8_"VN0,X(8DR0JQZ)V<%<>4C(3W?+)30F N8<6(0[!#T3^+
MWEZULY:(_F"2:YPC.,+0X3>(<R2HK-<:@4<5N"N;(I O:C(^""Y+R.2J3IR8
MX?91=28D$ 0R^H$RUQ7"%J= H% H% H% H% H% H% H% H% H% H% H% H%
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M:A.>3L"DD;*8M"0  U9KQBY Z'S%G3E]8LY8=(L6.;\B3)@#_37 U*+JF"+
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MIH7L)EAYEMX/BF&S'OZN/.$*3J;MY#8D5I)00H1W<7E]:>T-9'2Z="J1IS'
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MVZ%QBS#B:8.+)=@C"1O*96@30XE!4)KIR2[D'AL8"]AVZU!IER*=SF#>B"Q
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M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H(X[&8WSG/FJ(K,
MYM*PQ,8E(!.JD;G&"I;&)FTJDW<E<=D;6I5 (+3  /MRC[)U!P# =4JY(A]N
M6$9%$-Y596U"A[_E+3G'S6O2&-KADK'4=RT^9)1$#3&)AN;4R28+9#@NYW7[
M3I#=,$DWHN5</1:U!E1'HYC)ITY>].6=Q=$L8?(XXHELO5ITRY]52]<Y@D09
MJX);"2IUJA/)DY"@*7M"PV3$%I@F@"$([!'\G7GD5D6'G+ ,PSCKM'H*@@2^
M"M$T@L6FJ_*,W9TS*K9&AIF*J2I@Q2))WA$%.2Y+6Q N6%$B-['M#>@T8?Y+
M]'<RO>CVO.MC'+\=,^2L13R$2MVE"I3(7"(@+C#M)W U0R@O&BG-Y5E>,D#*
M3*DJ$H\18P#-*#T"N'W9!UYW\V(:!8=SIE_7:)X,<CD9,V>L)1S(!.5LA,3:
MM0*KLCBEEXSHU&+/]D=Q*C6]3U"1BN7<E2F$,BX2ISSJ=C'.^#$&"EY"F(LT
M331X>,7R-]4EVQJ]0]!9NBCM'[CO:W5;$%KI3";B!<Y&886$PHRX#BPKQV2R
M%R9ZCX(?)*[9+UTR)"8N='(^+*P(5-?GM3)7EP;F1+(G.,GB-QD(Y*M/ 6<8
M?WVYMS;#%89@_J0GWI_KM!,!8Y6*HM-566)'E9T^<2>YF<CB%+ADY\>2Q*27
MPLQ.K<24[+8E4,:-.!2HL#MC#!&F&FF&"#GL)QC9QCR/GUSSCD6&S+&DAEJ)
M9KY'HVA2)7B"Q #G+C5K5*CT\%BIJM><UK&<L(C5SP*PTAM^V#TW&<":1C9Q
M=L;BJ2PC(D.9]:FE@=4^6<?.*%(;+Y/(3DLD TKF-:9!756G2I5:IL$98#XW
M6N%.9TECZ;V-"2E!&C8Z";%RM)#WO6W+4;QO+8DM>U+BQS=@4/L(R B<FXHI
M(S2,23O"UI)1+TH!@5)DIZHH)H[EW#T7 :$9"-9-K<ZY7PW/=O9M@5NB^!9F
MER-#(+KTSSH8)#-6LY*J97.2R'(EPN2!,VJTP!"(2V,*/ 7U+A"(=S !]DVU
MDV=QSL?DS8+468X1(*SBVQ8C*&/\ZM\W\! ]Q% 8VMTB8'"!@-=#5)I!I@Q$
MF#3@"<I/%<1@1@"4']X5U-V"A^XSCLUE_+<-R>2^X(/QTXC:V95$7%ID2B5,
MST0SQR)I6I2U$P=G;VP19:M2['.2M48,TTH/:=4L.GQW7#>K#.4MC,@8,FVK
MZUFS?EUZG2:&97;\F+"4;:M%82!U4O\ $$32XH)"23<2<Q  "Q#U+W,L?<=[
M6"&>=8=89SCJ=Y#V!S]/&;)>P^5&QH8'=SC#4<TPJ"0YG"F,3P6#$K $.![0
M-<D)./4GDIC%0DY(QDV.L<<>&$8]JMMUK"^39MTUR/@MSP[-Y(YRY%BW89GG
M!*?&;P\&V-<DT*>L=V-6+VPT98+%%*;$$E%6"&Y1AP1J3@R)*=0LH9KU5REA
M+8S-"2<9&R5)S9DWS1EC0FV-X[<&\<=/BT;C3%=60-3&&D^.WL=>]DAZDM>H
MN*W;B$H,#$\WUXY&LS89F.&\GYNUQCS,JA+C'$3ACJ-391),GJ!H;I$*+),@
ME+<<BA;2K-*+-<#F!J4*3@"-) $-AV,L'?<DZ5SB=ZAZXX=:IO'8GFG6[YHI
M3$I<6G<'F'F3[&$=\&N4;VZ%$YF1]<><,PL\:*YP;EEB$GO;K%W#E9=KYLKM
M!KWE_"NVSY@1@7RH$:,QR_Z_HLBJR&1T87#QR[G+$V0528;B6-U0(R[)TG8V
M$E$HM<P(QE"+#'4BP3R09,PY-,)S[,>L,;CSCCM_A2*10**SUPF<^(61ET8T
MS5-U\I3"CT/:W\1B<MU5M#6L6%)CC[I0A-"6(0<GD_2O*<UXZ8CJ*U/\ 3Y)
M8&+'K8L>W!UD14'-41.1(7=Q&F<DT55OPR3DR802+C;0"$.]K"L"WU5@FWL+
MCYYRS@C,6+XXI;$3_D+&DTAK*L>SE:9G2NDCCZ]J0GNBA"B<EI* I0J"(T12
M<\P(+7N$ K]%KA&:0:6*9UJC@'##W,PPG+^O[#C1P@F58648[E1/)>/V%&V
M>&PEU3,JQYCBM00+M$YH48SP6+&*P#"PVL'3EL"Y4I&@\E..;-3H4R"$8D/R
MU"H7D!TRLH06L<2%;Y4D)!6/4;FL)-L,P*81-B#0![$VW1<5P[QL%J9/YG)<
M09OPCDY!"]DL+QDV(HI1+VI4[Q/)L85)#"U\9GR8DU<ZID2EP4J5):DGO9I
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M1M\<8"3CP-[2B$88*PA"[0TPT8NJ67V9)8=<PC">1N3:Q8.B,#RMK'%\7RC
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M]\66#,K^?I9D["&Q\*8\GY82>3X\HR'G5ADB,IP=6Z'MDM<HQ#&YR>";"+)
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M'(+*VIXD%D>,UX;E.BUG3=J:GM8^X1&"*#&/,-PY9:W<RY@;=O1_9 O4K?\
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M*?M\_P#S55N>_P#_ +G4?Q/_ &J\]Y_][A_C?^P^9;_YK.%/V^?_ )JI[_\
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M(=#6;Y9-QS*H2#9/42:X&Q/D21H8M',KJ<E0Z?$-CN]=6[&5/8U%T=CH,%6
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M6VM#Q/I*G7M7F14E+&/N79@Z+AN788C@'%E!WC7':DO-TAGF,IOC6180SGC
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M&6,0;]'L7H.5H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M"PA!MT_5!Z0M)H*M-G?YR;CK_P#=9L)^X%10<YAO^<_W&_@:P9_@AOH/XR@
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MQ-L?-6#-0I<EBLHPE%,929B;W>%V8C75@DIDVR[CMP:W92BD)"A&$"<\E42
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MR,XE GI9$%L5ET]A<B4LR$D*U2A3NXG$M".ZCN]RB%8DX5U__%A/_P +-_\
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MQ;B*32#YXL^SWQ+'DCQ+GB3/,>\)R;E29L:/OCY#&T_O:=,4N+[MU '!+,-
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M"YA&H:J@+.XQU2\MB,B+KG1<]+4BAA3.@(^Y+U;DXG&&."I*<X#M>P+GW
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MP=/U P]%J#H.<-2]<]D!H3\T8JC\T<&TBR1"]B/=X_)$Z()UE 4 9-%G)CD
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MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MA('QK WJ4JE$8EN4<G"&Y90:J_J;_P#ULX5_]:IA'_"310=;]5#$(UD('$#
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M-YCX5<,DT-QNW-$3&O#;(+<JL:4GNJ(< .)9ZE2 2:Q(;55 H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H(][-;
M)P?53&=\J9 9Y>^L/F%GC(6^$-[0YOIC@^=Z[F(M(]OL=1"3ANE%8=^\=>U[
MVZH!=/L!&-5R9XRC)S>?E?7W<+!457KTK:.?Y@P.KC,*;U:PXLD@M>Y()"]K
M@W%U[BZ"DIHNJ&_1:]^BUPL+1/C,XLB22H75O51Y<U$/B-[)5D#:E+,J2 7I
MW4I?8?=AMYR$=C@G=;L[EWZW3T>S00!<N2[#2MS?DF)L5[+['L\76GMS_-,
MX<6S:$MBY.78TP@V0+W>/$G@$&QERSR0F)C@%",+,&5<!@PDK@'9S#>S#&ZO
M.*).)S41U==LE49=V]6PRZ*.':'E 2R".N19*Y%VXDQEBS;6&08(L80CN,LP
M(0XK8';+"^M1;(ER*]N2J62KM;1#'<-95LLG\JN4(0!B:8ZVA$,M-UP" %2K
M,2I1&!N6$VYGU-!'O\9CB!@5(K9AP[M3KJRN*@"1#+,XX*>HQ&%2D0@@$26O
M9'&3J+7(&:58P0B0@!VP+WOT=-[!)Z5[#PJ'Y[Q7KJYM<H/FV7F"6R*-.B%$
MTFQ9"BAK:N='0I\6J'M*[)E1Z=O'9.%.A4@$.X;#$"U[WL'^;#['XVUFA)$T
MR&<[K1NKN@CL4AT40D/,YG$B<3RB$S'$&$Y:WA='#JF=H.PCBBP M]4.PA "
M(.K9CVWQQ@.$P2690C^161ZR1UT\5QDVQ4$JR*L>B6XMS5QPU#%'-ZC1+RC*
M.  RWBET]S1= #16"*X0QSCGD!Q+-<C1S$\SQ_GG7N=3:XBX&S;#XP4XZ\[J
M@F!)[E'%@'5[1G*C#Q=D6$\:>QQ_027<9PRRQA.F@4"@K,9^3^"2GS ?!M6M
MV<AM$9D+Q%G620'"+/+8V4],1@ N2/QAHGZA*6<04:6;<LRY9H230"$ -A6H
M)9:\[-XDV>C#G)L6/*Y0./.5V661E_;%#%+8@\=)_9MTB9576$E-/"G'<LPH
M9Q!EP#"$RXRS0@#B<"[$_/?--AXAY/\ +'S"Y86XP\0\P>->:^YD#.\<[IX(
MT^!=IU.CNW:K.C]5O027H% H%!&/:C;'&6H<'9)SDM#+'I+(I*5%V=B@[>T.
MTE6K1-CD[J5A:!Y?8\E\*;438*ZDZZC]+$84'HO<RU!F+&&18WES'4)R?#S5
M!L9GL99Y2R]\ 24O(1/"(I8!&Y$)U"LA,Z(!&7(4E -,"4>6,%A"Z.FX=ZH%
M H% H%!T_($O\@0J2S3RO,)KY;:E#IY3Q^R>9)J_]WM:_AT:8N\H_%'4_I_2
MR>U+ZW1^;:@_2"2OSU#8S,?+<LAWF5F0O/E6=L_EZ91_OQ 3O"I,Q]Y5^%/*
M/K=0\CM3.S':]NM>@[908OG69\:XTE&-H7-I)X+)<O/RJ,X[;?!W]R\POB(M
M(<J0]\:6I>@:>R+7%7[5<:F)%UO8'>]K] 90H% H(O;?;)?<IX=/RSY,\^=C
M*8O&O /,7E?K>9'#N/??%? I%U>Y?U?9]VOVGYG6#^;02AH.MR^81> 1A[F<
MU?FN,16.(#7-\?GE64B;6U$3T6$<H4&WL&UQC$$!8+=(S3!! "PAB"&X0%*Y
M,L9/!9[S!=?MQ<G8_(&;?YUH%K^ZN6.S$:8-C5KF!T<WEG=@($"6_;G7,0@,
M 5[/4O?V*"6V"-@<6[)0H^>XF?%3TQ('U;%G@MQ97=@=&.3MJ-N7.3"ZMCRC
M1J25Z)*[)QCN"QA(K&VZA@O9H,T4&)<QY8^9Z.-4C^;3+64O%9.UQGP+#D-\
M[R-M\33KU'F%U:_$6SN<8;^X=14KZXNR,.*MU+]?IL&-,G[+?-QLGKKKUY*\
M9^?U+D)3YO\ ,?AWE/R&P&/G4\ \!7>.^*]GV73WU'V'3UN@S^IH)2T"@4$6
ML>[+>>]H]@-:_)7A7S%L>.WGSIYC[]YI\^QEGD7=O+G@*/P3PGQ7L>OW]9V_
M9]?JE];JV"4M!B'-N>,4Z[0E3D'+TN0Q*.$GA1)3#RU"QQ>'0PHTXAH8VE"4
MH<79R/+)&*Q9)8NH (C#+@+"(80A\HY,,=M:<Q\DVN.Y\/@)05:@>4I-KZX(
M<?A;4Q"E24[B="']6Y ;5R=-<90Q(["" 5A&A+M8=PA/" 3V)91A<:R'!'@#
M_#I>TI7R.O):1>@"X-BP/6(/NA=$J%R1COT7L(I024<6*UPC"$5KVH.WT&)7
M7+'A68HQA_YM,M.7F:,+)-\Z+5#>^8=C_<Q.X?+TGFWB)?A4G5>$=)*3NIG7
MLJ3_ %=NT^I#'$0V2\U[69<UC\F=P^:R!Q&;>=_,7>O'?-1+4=X9Y:\"3>&=
MP\3Z.V[^H[7J?^3!UO8"4-!&S8';+"^M1;(ER*]N2J62KM;1#'<-95LLG\JN
M4(0!B:8ZVA$,M-UP" %2K,2I1&!N6$VYGU-!'O\ &8X@8%2*V8<.[4ZZLKBH
M D0RS.."GJ,1A4I$((!$EKV1QDZBUR!FE6,$(D( =L"][]'3>P6+T"@4"@Q?
M ,SXURA(,CQ:"R3QQ^Q))[PW(2'P=_;/+\DM91>[;WIX:F]&Z^PE,_3D)BDC
MZG^K]FW2&4*!08CAN6O..1,CX\^;/+D5^;DUK+\\S*&>!X[G?B@#1]ICB3>)
M*O-!3=V70JOV!'8B$&WL]-!ER@4&)<,Y8^>2)J97\VF6L5=V?G%B\M9FAOD:
M6*/#BTAGC*9F\1=.U85W>^JF4=I;M1%&6ZMNK[(9:H% H%!BS-F78W@;%<TR
M]+T3XY1J"M0'=W0QM,@6/BA,-:E0V W)G1R9T!Q_;*PWZ#5)(>K:_P!5T]%K
MA"(CE#Q@G:&F72[77<K'>-W=,C<"\K33 XTV.DS4Y(KKVMW-?F24OIJMM<TU
MP"3FI"%-C0F!&'I+Z1V"P^)RR-3N-,DRAKVW22+21N3.S$^M*D"MO<V]6"QA
M"E,>7?HO:]O8$&_0, [7"*UA6O:P=AH%!U.=SB+XTALFR!-G3P6(PYF72"1N
M_<G%R\.:&T@2A:K[@TI%[FK[$D%[]F02::+HZ AO?V*#]85,HWD2'QB>PYR\
M8B<R86J31MU[FO;_ !)C>T1+@V+NXNB5"Y(^\HU !]DH)*.!T] P!%:]K!V>
M@X&5/OE:,2.3>#/TC\N,+P^^7HJW>+R=]\(;U#AX-'&GMD_BC\Z=W[!&G[0'
M;J!@!U@];IL' XQG?SF02.SKR;/,?^84RA3Y.R='O*D[8^[KE2'N\BCW?%_A
MBD_NO;%@[8?6(, /IMUNBP=\H%!C/,F58]@_%TVRU+$;RX1R!,9[^\(H\G0J
MWM2C3C*+&4VIG)Q:4!RF]S;= 35)(.CI^JM0<O#)ZPS;'43R@B$>T1B70IBG
MJ0<@NC0*6MA?V)+(2!/8BEBMO1'HF]7:ZFX5!I)8@BZ#!!MUKA@K%&V\*S9%
M<L3S&L#RQ)8-BXR1I6^5HHTS&(,O.$72K%3BVX;;BY.9(I8I.$D"0F$I1-Y"
MA2>62 RYEC EAF[&,[^<R"1V=>39YC_S"F4*?)V3H]Y4G;'W=<J0]WD4>[XO
M\,4G]U[8L';#ZQ!@!]-NMT6#OE H% H% H% H*^95R.XH:95,XI \0[/YV/Q
MT_/47G3SA7"KG)X]%I!'3;)WEK=7-Y=(SU#42D)@+F%@,('8D1@1B*$488$F
M<"[#8JV3AADXQ0_F.[8B<U3&]MS@A4M$AC;XCZMU#1(&1: M8VK0EC",/6M<
MLTL5A $*WLT&;:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!01YVT_T9<[?P7R_
M_!"BNTV7[[Z;YM;[+@;I][LWS.[V&I=5U*R*!0*"4.EG^E3A#_'5+_::VNGW
M_P"\VH^9S[,.QVC[Y8?D_P#9+9HD/]^%G_1_[5(JF5EN%H%!^9Q)2@HT@\HL
M\@\L9)Q)P F%'%&!N PHTL=A ,+, *]A!O:]KVOT7H/.XSAZ.3<1]V&R:[80
MS;J9&M<'S*<B=<<-LMF.9"LCQ;%CM(E"UF9G1B:\'/$<5R*-,"D*4("WJZ=6
M8G"*YQ5C+]0-_" 8.QGC;!D.UPCT90FX@A&+&/#+5$G1.E6H%6/6&*IH8G8W
M9/9.2D7DK&!-8E5:Y00']<?2'ZJ]J#2LREZ8G?K378U_V(X<=P&7'[8M$\@8
MHA-YA)X'DB,QIW4EKS,<G2-+&YC"\KQ4E2C(L"[\%O[2Q) E!9YQ5U(@R-$.
M(KU&.TV1L3'[[<@L+;,'X]R3!YO)( V9">G,V6IHI*4<@[DIQ[BC'<'@,N,'
M9LZI8WQU#W:YX!%A%>PP@#.G/UP"[C<J>XV-=A->\E:T0Z%P[6B'8:<VS,LQ
MRE'I0?*(]E+,LW6KT"*$8:R&U&L)K5D-$64:8M*4"4%'A$0$ 2S# N=YI-&<
MM<C/']E#5/",AQU%LAS64XO>VIYRH[25DAB=)"I^Q2IU+<'&)1&</A2A0WM9
M@$]BVXT(SKAL,18;W'8('\67#HY:1\4NW>CW(3(L43R"YJR7E[*$Z=,)2.>/
M+*TXK?<,8BBYJTIVE&.X/(T$VC+GC!8YI[I6Q4 @1:0TL9IEQD@#6"QWPNP"
M#2I]R3IIZAW3/'6"'\DSQ/(*#8)7AS,""(I1#>O!IW"XID!J3J7*/HQDFFD+
MW1K[0=^WNF26$$%!$#B Q<Q.GJ#<"1+7^:R3/N/<?[&Y'?4&97I(,E=D&#8^
MC,U7/F7WBUAJO"F^9>'F+TH5)YIO2O3)QG'*3+",#:/Y^N 7<;E3W&QKL)KW
MDK6B'0N':T0[#3FV9EF.4H]*#Y1'LI9EFZU>@10C#60VHUA-:LAHBRC3%I2@
M2@H\(B @"688%H/.IQ,J^6;5B-X[@LSC^/LZ8?FIN0,1R&8 <?)CH<Y-![%*
M(1+U;.@=WAF8Y(C&F467)$2Q0F6MR?\ 23"A&AN&MGK!Z<SF_*Q/,]9\H;\A
MUZU9"PS@MMPUC[/V4Y/&YQ(7IM<%;?'C(JPLZ&-1G&DJE RQ/YIUU!H"SSCP
M,ZT\P=KA9SP/<#VV?&++]LGC8?)>NTG:L_86;<9Q@6&)/DJ4N#.ZIW1U5*G!
M^1SC%&-$Q;>%,X!N7W=0>8,8;AN$%N@5!#O'O%OZH_1=L+Q;J'R!XMR!AUJ)
M"W0U#)I4S2XN.L)=[!3-J&'[*8:G**!$I;(PW A9'!2C(";T%F7N,X-@SQQH
M^G,V7B6\R'DFY/=AH?E7.S-/%66&:#8O.<'4M_RB(L(669Y$F*F-0=K0IXLH
MM<](PL;6)$(TE)>ZP"<DU"<'6.87TY6V.R>_"GD'T&S1C2&3R3/6.)V^1O(<
MDE4(D<%RWC%MCC1'YYC>4,45EZ)42=:)-[@,E7W$Y"Y%F#)$>6: H@,]MW#A
MR>;L:$;4ZV\K.X43G.6)S.,3Y"U=ED1<C)8P8NDF+6^:$+"I@PH,<XT:0,<Y
MM*;(U=VVRE8$C^R1"N8G*3F!"'07A:]1'K"SNVJ<:WXQ=JSJ(]2A2]3%]QH[
MMV4978IT.3EOSE@X$BQ,WSV&/CL6F";>Q;U$21&7$<8(1UQ ,"2?"!Z?'<;C
M,WVE.SN;<K:Z3K'#KB7)F/6Y+CR;92D61E+E+Y1$'=G<WM)+<-09AN&Z*/&W
M7&EN1AEE!@>H P-Q""'3^87TY6V.R>_"GD'T&S1C2&3R3/6.)V^1O(<DE4(D
M<%RWC%MCC1'YYC>4,45EZ)42=:)-[@,E7W$Y"Y%F#)$>6: H@+JN(/ G*KA6
M-9R7<IFQT/S],9F^0;YJ$\.?QO"6$L$=028F3%K$J3&V.6!N42)<ZHS+72%J
MS#@I>D\8+A &X7'T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@RVV
M_P![D'_,DO\ 6"Z#[:!0*#5*VQ]/9L1C_:_(.]G"YNN9HOFK++BJD.4L.2M"
MXK,$S:5N#P?(W1QN8VL\U0HXH[2 7?3XT\1*3-92U0<8D[HF[-"$,&.G AS!
M\A,FA[-S2\J$9R/KQ"Y$WR%5@S5=DNS->03&H=KH@NUD.'M=H+''X(7!866]
MJHW)EZ,CI*3]G=1<U.%XO)EQV.&S7%!E[CGU'0XLQ )\@.(L>8?:I<KD,<Q=
M#8[C#)^.)80U+UL7C4WD:5(5&86<00,IO6G'*Q@N=>UAF'!"=VKN,7_"6LVN
MV&94K:'"48CP5B/&,D7Q]0M5L"U_@4 C\5>%;(J<F]I<5+0I<6DP:8P]*F.&
M2(-QE%BO<%@UHM@>%+E=P!NIM#M?PM[]8FUW8-UIFJR?GS%6P+ %Z:TF1'1W
M=I,_.T?,=L'[$QU[+<9=(71>C/$T,S@U$.AR$!YZ>W2,/R@/!ER<'\AV@&^.
MU7(A&=P9!K],\B2;-#5,RY!CICA;3($!R./1O6/&<0Q\L@__ )Q4+3E#ZJ5&
M14HZQ*,@E+U$@!#"QG\6IG7\?+^-%\UXF^8#[D#[G_RAX[,/GA\Y=MVGB?E_
MR)Y*\L]7_P!K>8.]=/\ \KT%WU!'7;#53!^[. ,C:S;$P\F;8IR<T!;'ULN<
M-$YMRQ(I)<6.31MV*L)0R2B,/*4A<WJR[7N2I)#U@C+N,L0:JL-X,>=KC_)5
MX[XJ>7V$)M?S'%V-C^-]IXG=03!&ER/2KK(F%G>,.;/PH#C=6G_LA4TMT;*4
M&"-/"G*NI.*N&>\'<%W)!F[:75K<'EQY.$6?YAJ-E%GS'BG#>$,;,C1 &Z;-
M4AA[R:$N4F0[%34W1UY+QVTA<DR.%)U2P77N6J3&!&:J"SOETX;\"<M>,H@T
MS64/V%L\XB6K7;!NQ<);$SK)H&N<#$AZUI?&0QP8C9C#%:UO3JQ( .;6K(6I
MRSDBU**YW;!3>R\;_JQ84B28FBO,QK<[X93EI8W>=3B-7E&<[15<F(1/;P8^
M2[4::SA?+V].<>)$:=/;JS3BRS/$4I@[F%!,J$<$>=U&C6U^O^<^3O/.4-IM
MO9CA?),EVW5L[VM><2RG"4J0S.&L&-6APR43)QPYF<DYB0LHE]9062"Z42=L
M#>Q  AFT\<7JR\-)"X-A3F4UHGL ;B4%FR29]CGFG)"LQ.U(&PP#L[9$T_V!
MDQX0%-Q=[F'296-4>(U2;:R@\X9@3[XP.$2;ZN;(R7D"WTVMDF\V^\FBZF$L
M4_=4;@WP?#T26(Q-#@UP4AV6'.+LYN#+VB4*RR1E1(4"U2D3MP;FGJE ;"M!
M2MS"\<6;^05\X]G/#,IQ5&2-3=U<=;'9%!DY\ES,<]0>(K$"AR:H4&*P:: <
M96>!**Q!"X3:C%>]NLI![-[ YA>.+-_(*^<>SGAF4XJC)&INZN.MCLB@R<^2
MYF.>H/$5B!0Y-4*#%8-- .,K/ E%8@A<)M1BO>W64@]F]@L?W Q%)-@-2]HL
M#0U:QMDOS;KKFW$45<I,I7HXVWR3).-)-#6-;(%C4VO+HD8TCH\E&*S$R-6>
M60$8BR31VL 05 8HXHMB()Z?%UXGW>9X74[$KL%9GQB5,VZ13@["P7_(N6YU
M/6169(E..D<YLT)6>3IRU1EHY<X"D!@2RC06"8,+/^/#7B:ZDZ,:GZR9'=(N
M]3S!."L>XQESO"5KLY1%Q?XFP)&IQ5QQ>^LD;>5;0<H(O<@Q4@1G"!>UQ% O
M[%!!7BYXV\Y:2[@<N&P.595BB00W?;9]!FO#[9CY\E[K)HW%4LOSB_F-^2D<
MC@L4:F>071Y,0!L4UK7A-VI2BUS[!"6(T/KX8N.+-_'6Q[OMF;)3BJ4'[+;J
MY-V.@H\6/DN>R6F#S1&U)VMJEHI;!H0-!*R!H1W4$(PKT8+7MU%(_9M8*4L3
M<'O/SJ%*-H,@:,\E6L6#%.P.RN5LI&8>=HVZSW'"Z+31^;G=CESZ_P"1]<LA
ME,^40HB[H%21!%SBDR="58IW. K/*("R/B_X7=A,';7R/DDY.=KR=S=\7:%+
M,=PA?'TJPG%6$HNZDGI7NT!$Y1^&CNK7-J]:A2IVZ/QIH;4CHY=5$>>O&>4$
ME<#\=.;,7<VF\/)(_P HQ8LP;LOKKB?$4$BK.]RU1E=IDD$8,,-3NMEK&MA#
M?$$#&I48Z7"3&(WU>>,!I%QDEW$98H(1<EG#7O\ S?D'0\G?$SN+CG6/9.68
ML;,/YB9<Q-JPZ(2&/LR!*U$.B141C#-3'(TCHT,;*2>Q/,8-3IUK*G<2%EE%
MBRR R=DKA4S=O+QC,VK?)/M;\YV[#!E&0YXA>V^.VY4>CQ9E%TNHNSM$58%#
M7CL"[&3.@6F-A[4B11Q.J3 *5)B6]840,@*[Y5PT^I$V,A*[4G:GF.Q$X:7O
MG3&Y:YPB/NSKGB;0 "T2<YIEZTO!&+Y?*"Y&Q*3P.;:[9'<D"OILF5"6D?56
M"\?,?%U'6'ATR7Q8:?#CL01+M=Y'A[&[UDUT<TK0JE$E6'O;]-LAO47C3ZXV
M<9=*W%<ZNAZ!I-M=8L,[%, OJEA"5G'AKQ-=2=&-3]9,CND7>IY@G!6/<8RY
MWA*UV<HBXO\ $V!(U.*N.+WUDC;RK:#E!%[D&*D",X0+VN(H%_8H)E4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4&LOR$>GE79FVK7\@_'-MK,^/O<U_4C6Y"=XLD=E6.\I.*X:
M!.].[F5''ID=XHZR-(F[9]!V+TSR(\@-U3:!0H5+C C);C6]53FI"=B_9'F0
MUDAN'WU 8UR9WPKC)D>9^>VK"?!W!#9.UZF:\.;LD5,:]5<TLV4IPJ#P%A,M
MTB[<D)V?[/=ALKAH>.(NV<YNZ)3GYRR3'\]N4<;$R]DR\9,139J?[8^;'0A$
MKAB=;;N2EG/<SU!R XZX%Q2FY!Y 0NQ!Q9^I84I6C >;^:G&\%U5CR)'%4<D
MP)!&UYV5705D4EHVY"BFSSK[B^9Q23+HZ58'BEYR\'MZBX>FZX!?U83[X<^(
M[(&CO'ILOHUMM*,?Y40;#9FS\_/;ACB42N3IWC$>:\8P;&RMMDKW-8# U]YN
MN0,*\2_LV\])UCP# <9<0P "J/!W!KS]Z>M;CJ5I[RZXAQ=H(;*Y0O8%3A!!
M.V>(>Q2AR7/2\Z,QYSPH^CCCTK=#['J2&3([*C-6*%*L'9&&C 8%BG"_PR9Z
MXP-K=\\KY.SXU;"P'95%B<B!3Z2S*9RS8"2NT//E;E,Y5FNT@A+,RH760/,E
M&:E"B>W\T)/06>I,,!<XT,+[F<%FZ$1W3RKR#\,6[,?TYS7L"*[EG;$^3&I0
MOPU.YBN<"%,@F)@BX/EEG5BD"E0K>#T#Q$7CL7\]0H2JDP%H@)@E+QN:1<TF
M/=A ; \H')E$M@&=GA4EB3+KG@Z)!8,4N+F^C1%M\VD"YDQ[@!C.=XXD0B[
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M  =>W50F6,/,N:$( A1J'A?;60Y@W5;H+NI\W;]&<ZC:LA2/[G'&DM^<V26
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M.\CH(R^C!8Q^BR3'<B<GM2M(2J+&]96 "8G]),$ XL0PT$O-Z-D<C8A?]?\
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MP66-;HD*4$&='6*.*",/0(-KV#J>=(1+- ,QN6W6$6%<\Z[9 <$Q>T^&F L
M01XT\RY9.6H8VVL6E3#2*E S51=K@ 6<:8 0@)50C4 9#W9Y#(Y@[$.)9%B1
MS8'MTV/3NU\;Y*=2U[CC^&L30&/6?IG(6UF0NDC=%K-:4)PE-9*$PVRD!ME
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MZ;B%9'Z0J);')Z-3A,!>X#+%=8-Q6O:]PDEL[_.3<=?_ +K-A/W J*"'&:\
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MBDB.%GIE*8\L(RS "L, [6O:]KVH(7;8PS)^!]H<?[U8I@+]E..)H,KQ/L!
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MJSW.(5&59:"23"+1]<:G K*1O<@:6I6:D,,-) J+3KU:<X:<9Q!@+#M:X;B
M*W3TVO0=IH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H,MMO][D'_ #)+_6"Z#[:!0*!0*!0*!0*#$WS^8*^>'[GCYZ<3?/\
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MN6IVLP(D+<1_8P@@%IOZ:O%O*+K'A#>SD.Y!-RMA,R[,XUBF9"E4"R' TS%
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M[0*RS.S/*+.+ZW5& (K7M8.>H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H%!YO_&EP4ZD<N^T/+K.-
MDLB;&0AVPSOWE:*1=/@^78SC;<O;I3D/)SNX'/Y4]Q%DI2J6DJ6T 21)SDH
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M[0T%F?K6_P#JJX_OX0=@?W.8JH+<](/]V>B7^K-S5_FPR/0:[7HL?])3=O\
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ME/[5(\P!=[+HM'84P%-4E9W<V4O-I(I2IC$B]O&G*.,/-4IR21GE!J<P7;;
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M< AJ!SE,^1GA<(PSQB"P!WD\=QOCQ ]="A<-S<!/*FR:Y?=C!+!N!(?+S/\
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M""8"3O.9\G8H:8F:BLD@[G+!)8BNV8P7D!*^-;]!4Q)*@^_<QDC-ZI9O6 8
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M17=9UUBQ2JN;8L-@?C-9N2=JP-*57*3+,)R78%_RN\O,1;<#)BB(C",/VA4
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M?[2'PE??[P#^+W./T74#_:0^$K[_ '@'\7N<?HNH'^TA\)7W^\ _B]SC]%U
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M?[2'PE??[P#^+W./T74#_:0^$K[_ '@'\7N<?HNH'^TA\)7W^\ _B]SC]%U
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MI0G;*+%'6@X\"@*:Q9,CD)K7'3NU.':Q5PJKA-#]4"X@^S01 YZ,5RS9/4O
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M:> ($]R;&C$,-K!O>]J"9C4ZMCZV-SVR.*!X9GA C=6AW:EB=P;'5L<$Y:M
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M!F,,2959$!&+F&"&SEFDDX?8F0J'.U9*[(D68FYP;V).% &_AZI4:6/V%!(
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M%A13E/(CQ'G5+9(%@=7MCB+JV$+BKD&MUW+O"89*@HDP =NPMZ2;B,AV#(]
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M84%,2:I*",=A& M<.U^I6TMVAVIU4U\R9IS!A94SKIWM)!]A&G&!!12IQF#
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ME+;81"<(W!K86XTU0IL$JY82JY?.$'3/-/'+M)%=4M%=9,9[(,N/3\AX;?\
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MH'=T_P"H$_6@>UH'=T_Z@3]:![6@=W3_ *@3]:![6@=W3_J!/UH'M:!W=/\
MJ!/UH'M:!W=/^H$_6@>UH'=T_P"H$_6@>UH'=T_Z@3]:![6@=W3_ *@3]:![
M6@=W3_J!/UH'M:!W=/\ J!/UH'M:!W=/^H$_6@>UH'=T_P"H$_6@>UH'=T_Z
M@3]:![6@=W3_ *@3]:![6@=W3_J!/UH'M:!W=/\ J!/UH'M:!W=/^H$_6@>U
MH'=T_P"H$_6@>UH'=T_Z@3]:![6@=W3_ *@3]:![6@=W3_J!/UH'M:!W=/\
MJ!/UH'M:!W=/^H$_6@>UH'=T_P"H$_6@>UH'=T_Z@3]:![6@=W3_ *@3]:![
M6@=W3_J!/UH'M:!W=/\ J!/UH'M:!W=/^H$_6@>UH'=T_P"H$_6@>UH'=T_Z
M@3]:![6@=W3_ *@3]:![6@=W3_J!/UH'M:!W=/\ J!/UH'M:!W=/^H$_6@>U
MH'=T_P"H$_6@>UH'=T_Z@3]:![6@=W3_ *@3]:![6@=W3_J!/UH'M:!W=/\
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M#+=Y[Y8ZZ?L/TSK]3V:"-D1W[T3R QSB30'=/4V=1W&+&7)\D/L,V*Q!*FF
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MPG;O?38S%NM&#'S'4A=HKD%@LYR1L=)9)(S(&%6A?&@P8BVV/FJ49@5)/F,
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M$]"@L1?]6&]K!UB:[S:38UR05AO(NX>K,!R\H4I$9&*IKL%B6*Y(.5N!YB5
ME*@[[+D$G,4K5)(RR062W$88&X0VO>U[4&4\;9SPGF5=/&S$&8<695<L62U?
M <G-^-L@Q*<KL<SIK./3N<+GB2,.[HHB$M;E"4T![:X!3K"1EB",NUPWM8.F
M9MVZU0UH4-*/8_9W7G7]6_D]Y8DN;<TXWQ2H>D]QJ2NW:2)W)6$UQ)[5$<'K
MDV&'K$CMT](1= =U3YPPJKQ0KSRDR_BY5@U!&7&:KLS)Y_$SL4(H:SI3USO+
M5>1"W84031EJ1)33E*\:RR4@HL0QF!"&][!K)\+G.7"\Q?=X?C".1/5EH\C[
M?S2):T?.IDW6'!??<#(^\^7E</\ #/F]^<.,CZH.R>S?$S#_ &.E4/IH+--D
M(4S9GWVXZ,VP3EI;,$Q%/'W:6172J)922WCG(-%75&.2H9+'VAGSY#VS(T?;
MH^J+4E+4T7EB:Z.P3@C 7>UZ"S249VPA!\CP'#LUS)BJ(9=RJ6YG8OQ9*,AQ
M&/Y'R02R$F*7DV P=V=TDFF!;0G)&8J$W)5%DX 7$9U;6O>@QNQ[M:92?*QF
M"(UMSK%(<X$K1MIN&F//F*G;*Q3B6 DTQ 9CM!*U$O M 6H+%<JZ.P[!&&_1
MT7MTA)V@BRZ;S:3,>5AX(>MP]66?.!;J)B,PTZ;!8E;\K ?  ,-&S#QVKEQ,
MO"ZA+)&*Z>Z/MK!#>_5Z+7H,IXFSGA//C,_R/!>8<69ICT5EKI 90^XFR#$L
MC,T;G3&E;5SW"W]TA[N\H6>6LZ%Y1G*FU0,M8G*5$C,+"$T%Q!E.@C!F'=W2
M_7AZ3QK/^W>L&#9$K$H E8,PY]Q3C-Z4C1IFU8K"G:IK+&1<<)*D>49IE@EW
MN M62(70$T%Q!DS$6<\)[ Q8N<X&S#BS-L)-.-3%3'$608EDF+&*"3CDYQ!<
MAAKN]-(SBCTY@! L=<01EBM>W2&]K!\JC8+ J/*CA@M7F[$*7-K3##LCNN'5
M&2881E1LQXG$ !\\<,>FO09:CAA(S V&Z&(PH0W%:US;=-!T?%FYVGN<YJ[8
MVPEM?K5F+(K!WWQV XLSKB[(,U9?#3CT[CXM%8E*7=];?#STQ@#^V(!V0RQ6
M%T7#>U@HR]05RF9$T-EF@L"U^VHQKAV<Y&VDQ^1L7"W0W"4CE@=8GQ8>WN4K
MDT<R6S25X@F/5:]K6D6DJ<EM  Y*< "T(BAV"%QK'N1IOM7&,K8YUNWJUFG$
MS3XJF3NZO.$-@\69(D^+(\:WW8C<J.#= YZ8ZLS+$'5Z2FB7F'HB"5 B@W4E
M#& 5!B#B.QFHQ3IA%HR?R*G<II1LUGSJCV\-F@Y^"4)U3X,@4132<>8L[!6D
MP96D-0W &0G!),"('8D"#<%!9I0:S/-#RO2K3/?3B:P5BG;K$F)85D?9.S7O
MM#'MSP6Y+H]@IRD^#? 7C*JS(#8]27"$2<XN^2,Y,]E*&'O"8)YP%0K)0C)"
M?NX>X>I&S?'?R1-&MNTNN>PCM%=%=HG*4->#\W8SRPXQMN<<'9"2MZ]_10*3
MOZEG1+E) RR35 2P&C ((;WO:]J"(G!;LGKIK5P:<>,BV,S[A7 ,??H1D%M8
MWW-F4X+BMF>7%/F?)!JA U.<Z?6%$XK2"C@"&42,8PA':][6M>U!?G ,B8_R
MQ#F'(>+)S#LEP"5("G6+SF 29EF4.DC8?;I(<6&31U:XLKP@.M;ZDY.>86+_
M (+T&-4FU>KR]-F!8@V1P(M2:]/5XYGY4DS#CQ2FP=(0K5C:)AS >3(AE8T>
M@N+<H(NE>KHC['$& ZO6 *U@YG"^Q&O^R$3<I]KOG/#N>H*S/RR+/$TPODV%
M92B;5)VYM:GIPCCE(X.]OK.A?D+.^HE9R,TX*@I,L(-$"P#2Q"#&<.WRT;R)
MD86'L?[FZHSK+8'%2SCQ;#MB<0R;(P79&M W+&L4(9)@MDP7%(X&!(,(NE[4
MLX5@"#85[6H) SN?07%L.D60\FS2)8Y@$0;#WN63F=R-GB$.B[,EM:ZIVD4F
MD"QO961L36%;M%"D\HH'3[(K4$?IOOEHWC.,P::Y(W-U1Q]#<H,*&4XTELWV
M)Q#%(SD.,.8#S&V1P9^?I@@:I:PN!:4T1"QO-4)S;%BN$=^K?H#)THV%P%",
M8)LVS3.&'XAAA8D)7I,N2C)<+8,8*D*@A0I3K$T^=GI)%#TAZ9(:8 P*NX!
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M:9*,3.6?$^W.L1^"F:3'PIWS23GS%1N)FJ9)2RCE,2<LC E8H>ADR<E06,:
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MAJ!T;3U*%666H)& 0BQBM88+AO[-KVH.:H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H%!'/;W_1=SY_!7,?\#J:B'7_ .1.Z? <
MON)6KV-_3%TS\<Z7Z+:U":P%;RR@4"@E1I#_ *6."_\ 'A+_ &DMJ<=MORZV
MSX3'L2IGTAOT*=1_%UWNK&T9(?[\+/\ H_\ :I%9XM(KA:!0:FOJU-.\+3_1
M%VW.D:"0'9OP"HQWCS'*]*_J4D=11W)&68VBE('./%E]W=5BE.L%8HTP723>
MUKAMT]/2%;?I4N+/4S93"%M],G,LV5;#:Y;P.K3C-V9IJO:(RD0X\QK@G(<=
M*=XN428A=Q!D4T7W.$.]A&DC"#IMU WH(9\<7^]]Y#_EY<J'[B=OJ#"WJI--
ML):E\@3$_P"'6Z0(''::'SG9G+0GV0*GTI=E3(V:\C+9.N9"E( V9&<\^UNR
M1E])9-O8M>@VO(;PB:':%:E;2;0:\QG(S3E>3<=>PT6=5LFR.\2AE&T3;"JM
M^?2R65<2%.2<8X,Y%RQVOTEAM<-O8O>@HM]%C_I*;M_P'8V_=ZY4$3N>S_>1
M&?\ A T:_P  XLH)B^L]+V1%GO5$Q7YQ'J&##RB\="F"NO 2MC+3:;@G!KN)
M.#PX,M,QJ;' M]U8KG=TLKLEM8-UG2$'\+Y;]*[F7&,9QAFK4[</4+*2ME96
MR1; 1[)\_P K-C<^A0EIG20%=7(LT;#R3G$0CQEAQI8JQ=@]F4#ZH%!;KZC'
M'6,L1>GNXY\987R<CS3B6#["ZY1W'&6$ V\:3(4-;]7]ERF"5%":E"IN_P#.
MS=U#!6)'<%A7O;H#_4V#).L_^YCR3^3]MG_VRLRT%"?![PD.?+K@W."^1[@3
M7!F,,2959$!&+F&"&SEFDDX?8F0J'.U9*[(D68FYP;V).% &_AZI4:6/V%!(
M 7+-#9/WKT;XH^/_ (LM*]-N2G9+*\HQ9KIE?*<^Q8TXS:DD4RIL+*99+,E2
MMY8?*363+UR.,Q%)F>X%:HAU:2BQDI1&N!(E $QP:H^]$[X2\NZ]S!3QU\>6
M[V&)[$#&(U%GF73202C&Q)*9\84KR7E!@?,MYH:T*=_:UJH@@:!:U#2N(T9G
M086(U((-E'TPN39M,.%3>F"R9]6/$<Q/,,^LV/D:TTP[RPP2C ;%+G6/MMQC
MN$AG'*G-<X@)"&W55N"D?3?M+6"&O#Z=OBTP=RFYGV#QUL+.LOQK'>+<>Q&<
M"C.)Y(S1D4Q?W&1.+$UWDJU[CLH(&A8"#E!A 24Q:CM3[]4X .T 8'6-KM6F
M/B;YZ,989UEG4X%'<7Y]U7F..WZ6."!7,&Y#D&V/Y"[QQ]<V5M8V]\;PFORY
MO%_8A-E;498E0$T0C1F!ZR% H% H% H% H% H% H% H% H% H% H% H% H%
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MTYE@JCU1ENTH,6^CG9$<:X[-L8XW7.$WQ_DLSLR(1*1A-471M6#=8D"6YY@
M%A,.N00'KBL$-KBZ;]%OS*#;0H-,+EUD7I2H9N!E>1[Y0-US9N7(U+0?F=MP
M]/MM7AU:G6.1!EC#"U2<K&V7H9AV*R(F.QY$C&UD')UQ RPFKB"A&W.&%67"
M/L3HV'U V%V+B8C6TF!]4MA<%9?C.;\&;".K0M)',83C[)N1V0<9.:\J9=7O
M<7:CHNT'(#GMT4.Z%88X  ==,JN"@GUO;H7COD=]4$]ZWY>G^4X1B@_CUA,Y
MR(UXFDH8F\9.CL3EJ$0<82)W&E7A!"I [N"52XEV(,.&%"#L!)U%BE1 8DYV
MN)G3OAUQ_I1R"\<L,E>O68L7[J8DAKDF297RC-FF7-[M'IW,BW1>+),KFJ]"
MXEK\?%MZE*C-2M;@U.BPE2G-MU W"1GJQ=0-=IEECC,SC),>>)91S%M=BG5;
M(\H\VSE'YCP*!W=GX,$\%029+'6CH=I<XF^*($B5Y_LCJ][ZA900!>'C7AQX
MX..J!;/9=TXUS^9[(<PUBRWCB1R#YW<[Y!\1ABYF#)E3-X3E/)\W8TG:OD80
MG]X(3%*P]AU+&V+&8 85I^GNS).M>_3=Q[-N,L)2W9&?XS5[.RN)X(@@W@N8
MY3>6_-$ONEB$=''XE.WH+FY7'>Q=TS.XF_4^P2*@_G''J%>3>:Y#@<-?_3<;
MW05BELSB\9>IL\+]@1-,.:7Y\0M3C*G2RW1)G1W;H\C5#5GV-5I2NR)%UCBP
M](PA%GU'VBNJV1.4[A<D<QQ;XP\[L[3(<&[.+/.^1F_YS,6P^4ZZQ..Q?N[7
M+T*6&>'1^;NB?OL? TN)W>NN:H&864,L+>LI\3''YQP: <H,KTPP#\S3_D[0
MC96/3A?\ZF:\A^-L[!A7)#DTI.ZY6R1.43;W1:N-'VB,M.:9UN@8A!M:U@IJ
MX-/3R\>6W''EK?MGN<QY7V?G.5X-(DT?BDOS+DV%0#$$2CN39DS,T3QXVXME
M<+D!" D]N5K# +'-2B$J<U RTI(A=:@S[Z=* F:9<D_-%QNX_E,F?M<,'Y Q
MI.\4,LK<@N2^*J7\3\E5V"I+3IBU3BYQEQ:D+@IZ@.]W8TYO4"(0^D(5:"\2
MVOO)SRA\X:_:^89=D6$,)\C,V7 UJAT^?X#C/)<UD&1<V=UEV2U497HI"Y*8
MTR-JA$V^'*&Q<E XJ;@6V :,H02+YCM3\4Z78SX]>%7CK:WS4G#7+#N^_P#S
M_.$=GN2YRY+XTT(\!XTGR8Y_R?.I?(K-#XS2IB4*V8A42A<@,%DXPA*5+0*@
ME5L;Z3/BQ/U6FT;UZQ[D;%6QT5@SJ\8XV#'FC)DGE"^?QMG7N$>.FD4D,LOB
MM0T/3V219Q TLK&> JW2C/1BMUKA'+#>XF3]U_2,[+Y'S3(5\QRG M?<Z82E
MTU=CCU+Q, XW>"$D4?GM8IN-0Y2 Z!N#42XK33#3EZ\DY4:.YIP[6#Y^);TU
M7&5L'QZZ[[#;41/*^Q68-CL%8_GATHE.9<C0]-BA&]0]&ECL1QFRXWD<30"8
MX8SEI24EI!9^M<::U@A*2=1&6%='!/P=ZN;NS?=2([AS?.>;L+:"[79+UUPM
M@%5E*41+&=RO,#X=()LY!A[@QO[2\R(UH*-4$L"IC)/4B,.4=O<0 E!/W5W4
M?%7$SZH7'6K&GH)) ]=-N-!I#DF38K<)9(9HTM"YL=,MF(D"=VF:]ZDJPEKD
M&"@K41ZQ:M7)K.BH@*CL#AE4&%<)\7.MW)SS[\T,?VI<<IO6*L+9*P;,CL.0
MG(#K H1E1\>XVM0(;9./CUDTG7H(VC;5-D-VQP:EQ W X0%0+"$$8<OR0\=F
MO?!-NKQ:;T\<C7+\(LN0-LHMK5G/#ELC3N<QF=0:?F-PWE(E<<C2.524DM_B
MB)Y3+$ZQ<N1 7^&K4I*8]%UC0L(Y0_\ >..!+_%W9S]QDBH(S>H)UH;MQ>:'
MAJUD><CY$Q,PYA@>Q47DD[Q.[$,60FN,!;U+I)6Z-.ZM.M1(%,H86Y0U'#/3
MJD_=EQEC4Z@NXB1AB'G)]/AQQ:/<8F4]L].\>3S"FPFL3KA^7L61TN:,M21T
MEUW7+T!@3A9\22F7/;$Q.J$B5"=4*Q@1,YY#FC)L$021"#8-P32C)<ES1IIJ
M3F*:* JYCEG63 N2Y8J  LL"F2SO%<4E+ZH"62624 )SHZFBM8( AM:_1:UK
M>Q02;H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H/-_P"-
M+"/-UEC:'EU6\3VX>N>LD*9]^\K)<P-&<(PP/[C*I0JR'DXV,N3 :\ZM;"&)
MT3<TEJ"C@@5-MA#,#>Y1M_JPAEGE_P!9?4TP/CDV5EF^7(?IYFK4QH:L>CR]
MC'&4)B;5.92B59>Q\@BI+"X-VC.)5J<QMG:IK6GW!(6WK)DQ@;B-M>Y!H2FY
M4-W9[J7Z<3B#Q[ )K-\8@VKUWT?Q/E/(V-0D"R''<$->J\.DF44,#[=XCA=I
M7)$Y*)$6 ;B@*4H3%24Q02!1<T 42J=@O2*F89/QHFT=Y3DV0!QLUG3[#CDD
M+490(>A#$:5+11F^Z)6#CW,H5[%W3>40MXB;='86,OVM!>#I[M/D;:7TB^[A
MV4)8_3M_P+!-@=>&J8RHP9TF?(3#VR$RV"%O9YBM>(Y3'HG/4C05>YYP@)6\
MH C#1!$8,,K\2WIJN,K8/CUUWV&VHB>5]BLP;'8*Q_/#I1*<RY&AZ;%"-ZAZ
M-+'8CC-EQO(XF@$QPQG+2DI+2"S]:XTUK!"4DZB,L*Z."?@[U<W=F^ZD1W#F
M^<\W86T%VNR7KKA; *K*4HB6,[E>8'PZ039R##W!C?VEYD1K04:H)8%3&2>I
M$8<H[>X@!*"?NKNH^*N)GU0N.M6-/022!ZZ;<:#2'),FQ6X2R0S1I:%S8Z9;
M,1($[M,U[U)5A+7(,%!6HCUBU:N36=%1 5'8'#*H.C:(Z)X>]0+O9R1[N\C)
ML\R]BK NRLLU0UIUR*GTM@4)AD'A0UXD9KJLQ](6&5)UJ%A.:5-R6EQ;4:Y^
M5.:U:%8)0 !(??GW2G'/ !RZ<7V9-"7><X\UIWWS85J7L5KX[3:232*%VDDE
MAT:C[ND6RMU>98^MC;?)'C"0"Y4M6M3C'^DI284X&I;!W7F!TX@V^_J1=#M7
M<GS;)D'QKD+CSF!L]4XFDI<2E4EB\;F.S<B<8*H>CD+F45&9G9L"@=BKIS+G
MMYII8+EC$$T =,YL> 3130S0B7;U\?,9R!J]LIIX_8PR9'YI'LT98E!TK#\X
MT-B:U0XWR#+IAY>D3+X[XPWJF.S6'OJ7L3 "(-M8H/KY_)>_;MZ,^GUGRJ0O
MF-)/MSL%JA+U,LB9MD,DQ^_9\Q!$7HZ0QHY">DLC?(HX2NZE$(DPKLSR 7 (
M/1:]@SAOCZ7GBPP_QP;43C'4#RB+8S"^N>7,QL&Q<SS5D:1SB63?%\#?I^$<
MYC%GI+B%4BFC@QW3N=T,71FEE*AF)KEF!#>@YR,9CGF>?1X2/)&2WQ?)9B?H
MGE>%N#\ZJS5[JZH,4Y%EV*8ZL=7!1<2IP<S8U"D?>%!PAGGG=8PP8QB$,09&
ME'^Z$IO]57$/W$LE!UW_ .(]O_A9O_N+06 Z!)==7#T^6KS1MPZQMEUB?N/&
M#QS.SA+Y4Y0>.AQE(\:$,4K2.4K979B?&0+DV. TQ9J!8G7W.. %,.QXBZ#4
M-V-RUZ+R/,,BBN--7-NYJZN)BUA;<C:\2'8L#S'!6)N,B8L*+:O9&'Q9:F":
M#LRBW%F7"$(72-'U/J[!L:^D4RW,\H\32AGE4LD4O9<-;.Y9Q!C!5*3Q'NS1
MC!KBV,IG'8[>PE;AW-$T+)RL"F2 4'$(B!!3D"[ HL(0VAJ#1^YEN0742W/[
MH+AW;_,A>-M5>.1E/V,R8I+BL[GI+ELW,&1).L41I=%\9Q":OYZEC(9H:Y@.
M4(S""42U<5:Y%U%QF!''</F'XZ%_.AQH\A^DNR"#)+>[H%.J.Z#29B_-N,$S
M;BN5O0XW',@/!^4L;P)#(PLB')*Q<99*H./('$F^Q@!%W#:@] ^@QGFD>+08
M>RI\^+LPL6&#<=S--EAXE$@%$XVVXX51UQ3318^R@#@TF1YJ)CIJBYZT"I.-
M,7TF!, (-A6#SO-ALH^BLQR5*(S!M7=D\PN1*LR-IY5KS,-JQ&HSE3:>(^61
M=9L3LICN*.B2/. >P"-4D6$*5-@F$IEB(5SKA='Z/3,+A.]+MJL:,\NR!*L(
M85VWDC/KJGR><WF3**XHEL99Y$U1UT3-"I>RLZ@Q1UW)8A;SS6\AV<%@D][@
M,ZP@K"].WP;:6\B&KLVV4W2OE?-K5%MD\TXVQ]@0>4IK \/PXI,VPURD$J2I
M\?O<;F(I1*5[JE&J,2NJ%,8%L3!.)4=7IH)M\<FN$(XNO4O;!:0:M+9,P:K9
MVTJ3YB%B=^DKO*$$1D3>Z1]R8@H'E^4+Y \^5E2=Y3-JAQ5*EP&U[-*4'J#
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M1,>1#,$#V,C,JE6*'Y/&)^EC9;8K=WQL8'U6WNR1O\RMC::V*A&I5!8T2PX
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MR4Q89V_5,-&$!80!+?G;U8:]A.8?A(U)CN2\D8"BTSQ5GC&X9YB%^4->2(K
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MW$US<E:GN9G8WZA)PZ#5JT64<QO!EN5DR.XZT8R%DJ>39I5XDD$(=,*9;R'
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M<4Q6[Y\6&/N$\%39YC*Y*VK<AS1\7X/9HC(E,B5.)[HZ*0Y*6"7.BM8Y 4#
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MN]+]EH4D\:9_A9L]WI?LM"DGC3/\+-GN]+]EH4D\:9_A9L]WI?LM"DGC3/\
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MOV6C\I)XTS_"S9[O2_9:/VDGC3/\+-GN]+]EH4D\:9_A9L]WI?LM"DGC3/\
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MN]+]EH4D\:9_A9L]WI?LM"DGC3/\+-GN]+]EH4D\:9_A9L]WI?LM"DGC3/\
M"S9[O2_9:%)/&F?X6;/=Z7[+0I)XTS_"S9[O2_9:%)/&F?X6;/=Z7[+0I)XT
MS_"S9[O2_9:%)/&F?X6;/=Z7[+0I)XTS_"S9[O2_9:%)/&F?X6;/=Z7[+0I)
MXTS_  LV>[TOV6A23QIG^%FSW>E^RT*2>-,_PLV>[TOV6A23QIG^%FSW>E^R
MT*2>-,_PLV>[TOV6A23QIG^%FSW>E^RT*2I6W*X_,K[#\L?&7O="I_A=KQ%I
MBU9A0Y0CDHE4D19'?CL@Q]U:F84!:&F&/<9="TRA< 2J[B\-=P M>Y=C+]%K
MBDKJ?&F?X6;/=Z7[+0I)XTS_  LV>[TOV6A23QIG^%FSW>E^RT*2>-,_PLV>
M[TOV6A23QIG^%FSW>E^RT*2>-,_PLV>[TOV6A23QIG^%FSW>E^RT*2>-,_PL
MV>[TOV6A23QIG^%FSW>E^RT*2>-,_P +-GN]+]EH4D\:9_A9L]WI?LM"DGC3
M/\+-GN]+]EH4D\:9_A9L]WI?LM"DGC3/\+-GN]+]EH4D\:9_A9L]WI?LM"DG
MC3/\+-GN]+]EH4D\:9_A9L]WI?LM"DGC3/\ "S9[O2_9:%)/&F?X6;/=Z7[+
M0I)XTS_"S9[O2_9:%)/&F?X6;/=Z7[+0I)XTS_"S9[O2_9:%)/&F?X6;/=Z7
M[+0I)XTS_"S9[O2_9:%)/&F?X6;/=Z7[+0I)XTS_  LV>[TOV6A23QIG^%FS
MW>E^RT*2>-,_PLV>[TOV6A23QIG^%FSW>E^RT*2>-,_PLV>[TOV6A23QIG^%
MFSW>E^RT*2>-,_PLV>[TOV6A23QIG^%FSW>E^RT*2>-,_P +-GN]+]EH4D\:
M9_A9L]WI?LM"DGC3/\+-GN]+]EH4D\:9_A9L]WI?LM"DGC3/\+-GN]+]EH4D
M\:9_A9L]WI?LM"DGC3/\+-GN]+]EH4D\:9_A9L]WI?LM"DO[ [M1@P%EN;>8
M88(("RP+4PQC&.]@A  (3;B$(0K]%K6]F]Z/RDOOM>U^FUKVO<-^@5K7Z>B_
M1871?_N7Z+VO_P#6O0?[0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"/NUR]<UZUYP<VQ8K;G)NQK*5S
M>X(%!R-<@7)&PY0D6(U:<99Z54E/+",LP @C ,-KVO:]K7J*==9<N#H[<LV&
MZZS-9H\EUMULS%UMT6S,3$QQB8GC$QQB5G]E=-I]9W:Z=T>LQV9=)EW;3V7V
M7VQ=9?9=DBVZVZVZ)MNMNB9BZV8F)B9B8HU4_GUS=_ECRI_&%+OV7K!W\9^I
M?PAKOG^7Y=N>_-QV]_ .S?86F^E'SZYN_P L>5/XPI=^R]/QGZE_"&N^?Y?E
MS\W';W\ [-]A:;Z4?/KF[_+'E3^,*7?LO3\9^I?PAKOG^7Y<_-QV]_ .S?86
MF^E'SZYN_P L>5/XPI=^R]/QGZE_"&N^?Y?ES\W';W\ [-]A:;Z4DIIYEC*<
MEV<PRPR/)>0) QNDQ3)G)F>YE(W5I<4PDBP5TZYN7N1Z-61<0;7N P @]-K>
MQ4S[>]0;]J>M=NT^IUVKR8+]1$76W9LEULQ2>$Q-TQ,>251=^NA>B=N[/=0:
M[;]GVK!K<6@NNLR8])I[+[+HNMI-M]N.+K9\L3$MCU]:FLEU5%E-J HL/8=4
MLM&G  /2F)%?H"$NP;=(KWO_ /7K-IIPK+B/#T'VBC]S$^TH5D\/0?:*/W,3
M[2A63P]!]HH_<Q/M*%9/#T'VBC]S$^TH5D\/0?:*/W,3[2A63P]!]HH_<Q/M
M*%9/#T'VBC]S$^TH5D\/0?:*/W,3[2A63P]!]HH_<Q/M*%9/#T'VBC]S$^TH
M5D\/0?:*/W,3[2A63P]!]HH_<Q/M*%9/#T'VBC]S$^TH5D\/0?:*/W,3[2A6
M3P]!]HH_<Q/M*%9/#T'VBC]S$^TH5D\/0?:*/W,3[2A63P]!]HH_<Q/M*%9/
M#T'VBC]S$^TH5D\/0?:*/W,3[2A63P]!]HH_<Q/M*%9/#T'VBC]S$^TH5D\/
M0?:*/W,3[2A63P]!]HH_<Q/M*%9/#T'VBC]S$^TH5D\/0?:*/W,3[2A63P]!
M]HH_<Q/M*%9/#T'VBC]S$^TH5D\/0?:*/W,3[2A63P]!]HH_<Q/M*%9/#T'V
MBC]S$^TH5D\/0?:*/W,3[2A63P]!]HH_<Q/M*%9/#T'VBC]S$^TH5D\/0?:*
M/W,3[2A63P]!]HH_<Q/M*%9/#T'VBC]S$^TH5D\/0?:*/W,3[2A63P]!]HH_
M<Q/M*%9/#T'VBC]S$^TH5D\/0?:*/W,3[2A63P]!]HH_<Q/M*%9/#T'VBC]S
M$^TH5D\/0?:*/W,3[2A63P]!]HH_<Q/M*%9/#T'VBC]S$^TH5D\/0?:*/W,3
M[2A63P]!]HH_<Q/M*%9/#T'VBC]S$^TH5D\/0?:*/W,3[2A63P]!]HH_<Q/M
M*%9/#T'VBC]S$^TH5EE!OC["- B&-D:!C&D3"$(3:C$(0A$@N(0A7)O<0A7O
MTWO?\VA67U^78_\  3-\6(OL%"LGEV/_  $S?%B+[!0K)Y=C_P !,WQ8B^P4
M*R>78_\  3-\6(OL%"LGEV/_  $S?%B+[!0K)Y=C_P !,WQ8B^P4*R>78_\
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M*R>78_\  3-\6(OL%"LGEV/_  $S?%B+[!0K)Y=C_P !,WQ8B^P4*R>78_\
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M*R>78_\  3-\6(OL%"LGEV/_  $S?%B+[!0K)Y=C_P !,WQ8B^P4*R>78_\
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M*R>78_\  3-\6(OL%"LGEV/_  $S?%B+[!0K)Y=C_P !,WQ8B^P4*R>78_\
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M\#J:B'7_ .1.Z? <ON)6KV-_3%TS\<Z7Z+:U":P%;RR@4"@E1I#_ *6."_\
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M&6+*D@/<7%YDN+I$Y9$8(<F4O3JX.CHZ($+IB1U4-EE9YJM"TK4J(8NS3%!
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M=H$-9N%,/!;N%#V'8+EDYSMRLD;M3UH1RZ:$P#$.<4D+Q%)WI*6O.Q\R!?\
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MS4( "&<2%QOJ?_YI_1+^6[IQ_FARY0;.NQO^CUGC^!G*'[B'R@T^>'K39QY
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MD<DKY,D>01QV>KFDP;<H20UQ$=<02R0'BO>]@D!QD\5NQVP6@O+?DK<V,*<
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M"@4"@4$<]O?]%W/G\%<Q_P #J:B'7_Y$[I\!R^XE:O8W],73/QSI?HMK4)K
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M+JAMUABN*_LWO>@Y#YU<7_Y2(%^W"/?LC0/G5Q?_ )2(%^W"/?LC0/G5Q?\
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M/_VY1S]DJ!\[.*_\I>/_ -N4<_9*@?.SBO\ REX__;E'/V2H'SLXK_REX_\
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M(AX@?O!,#?%+W^SE _$0\0/W@F!OBE[_ &<H'XB'B!^\$P-\4O?[.4#\1#Q
M_>"8&^*7O]G*!^(AX@?O!,#?%+W^SE _$0\0/W@F!OBE[_9R@?B(>('[P3 W
MQ2]_LY0/Q$/$#]X)@;XI>_V<H'XB'B!^\$P-\4O?[.4#\1#Q _>"8&^*7O\
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M[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU
M_$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-
MOY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/;
M'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_
ML]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q
M _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^
M3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\
M4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/
M4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/
MPV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]
ML ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#
M[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU
M_$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-
MOY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/;
M'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_
ML]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q
M _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^
M3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\
M4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/
M4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/
MPV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]
ML ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#
M[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU
M_$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-
MOY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/;
M'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_
ML]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q
M _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^
M3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\
M4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/
M4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/
MPV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]
ML ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#
M[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU
M_$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-
MOY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/;
M'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_
ML]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q
M _#;^3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^
M3VP!\4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\
M4/O[/4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/
M4#\0/PV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/
MPV_D]L ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]
ML ?%#[^SU _$#\-OY/; 'Q0^_L]0/Q _#;^3VP!\4/O[/4#\0/PV_D]L ?%#
M[^SU _$#\-OY/; 'Q0^_L]0=PQ[PC<3^*)_!\I8YT8PA$<A8UF$9G\$E;2UO
M1;K&)E#7I%(HO(6PPU[-* X,KVW$*2;B"(-C"K7O:]O8H+/4+.V-BIY6H$9*
M55(7(IX>CRK7L-Q<R&=J8"EBB][WL(X#,QI$]KVZ+=F0'_AZ;W#DJ!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!08OS7_ -4>1O\ %![_ +2-JA/2F_5QZV_NUKOH%Z<]L_T@[-\8X/=P
MI3KRS-F10*!09?P%_P!<F/?\8"?ZP?62GH>_K-]&?'-GT/(KONS^CC>/@D^Z
MM6GR'^_"S_H_]JD5Z@&MAPM H*EN;K=?,G'QQX94VAP*GAJK)<-E>*V5H)GS
M(MD,9NCF60F",.]U;4WO#$J.."VN1ER164@L SH%>PK6Z+A0_P #WJ/-A-\=
MRE&JFYB##C(/(\%>5^#WS&\8<8;<[(<0 -^=8D]@?)A( .(9%#"%RA&(GLS2
MU3;8JP#.\]8H+%O4.\RTXXJ<4818M?DT%>]D<W2YV7-S=/FA=(XY'<30E" $
MLD#DT-3RQK+.3O)'QK0M=C%!11P +S ]<240*#&GIO>7S;#E8^[+^Z?0XG1?
M,-]SOY'^:^'N\3[3YT?GS\R^.>*RJ3=_ZGS=-_=NS[#LNDWK=?KVZ@;*DMG<
M(@" MUG<RBL*:SCK)R7*6R%HC: U1?HZ""UCRL1IS#K]-OJ;"N+V?S*#]HI,
MH?.VFS]!Y7&YDQB4') O44?6N0M(E:;J]X2V<6A4L1W4$=</7!U^L'IMTVMT
MT'9*#I,FR7CB%.30RS+($)B3Q(!6 PM,FE;$PN3V,2@M($+0A=5Z14Y"$J.
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MR3).-(S,GQ%'T;JY/+HD8TCH\FEI"U*Q6>60$ 3#C1VN,02*H% H% H% H%
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ME3FKE;[KSG*?)EKE'XBA(3I2";H;&$=;JE"&88(/B^XW]9)^5BT _BY@W_\
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M9%8!%LG/Y#^Y296^V<H]$@0?$^8VG%^-L8-K4C"6U@3-QK@H<$Y@3S[DKKF
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M["OT!B3T6O\ HK;G_P H&$_YN2Z#='H% H% H% H% H% H% H% H% H% H%
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MXGB[+$NR\ERNT2YA0P+(I3 !JM>UW8QF2=U(3D]1O &EYN%B3A5X]X>OS;Q
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M]/):3A#!;9D!N;"&XR.R691141D+(D53IDI[0Q2U^D"1&D;[ )L%M&^&*D@
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M*5:C'3=GV%8?FT@+3G)EKC@K:^.(Y%'7$XFPP&H I,=JI@$11OZ4:H=2R3!
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M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&+\U_\
M5'D;_%![_M(VJ$]*;]7'K;^[6N^@7ISVS_2#LWQC@]W"E.O+,V9% H%!E_ 7
M_7)CW_& G^L'UDIZ'OZS?1GQS9]#R*[[L_HXWCX)/NK5I\A_OPL_Z/\ VJ17
MJ :V'"T"@UVO5/\ \S'L!_"#K_\ YY(A054^FGT^P_OGP6[AZJYU(?+XXRCO
M%/$KFY114U-\OCKBQX7U,D;#)(DZ/;+(FQLD#*\M))Q!IZ)42*UA%F%&%#&
M03QVAXL-:N*7@OY.<3:XNF390AR1CJ0S^62_+[Y%)#-W!<0BBT?:F.SA#(3
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M7'MIIPDY C1IKBN6"]^K8.4]7O\ SK['_).P]^Z[*M!O,<ZO\T-O[_)^D/\
MA%IH*&_1:_Z*VY_\H&$_YN2Z#='H% H% H% H% H% H% H% H% H% H% H%
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MZS?7861)(5#$(#D$;C\2):F @@Q&O>D"I4O4A*<3QIS2DX6'<P3AG3BPY?\
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M38[;,,0=-!7K(S@ZE/KKD-&%2HC:()C6Z1QK+1.+G9$8O%<LLY0%5,)CF ^
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M@!,%SD##D&\A;[]0H04R0GZDH20LJP>@?0:S>^?^\N<$O\#._7_9SRQ0;,E
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M.J,?T;TNUKU.CED1B?"6*HY%7MP;P=FC?YR>48^9(E1(.Q3WMYNR"[.;H+I
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M.%\X*>RGB-!?QN)ZQ?&XT-"80,796+"6985OJNM;\R@O H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H%!EMM_O<@_YDE_K!=!]M H%!H]
M8 YGO4M[LJ\XR72'C]T-S5B?#F=Y[@Y?*7)<L@CBED40-1+P-B]OR3OACQS<
M%OEI[;U!JI(@[B,:BX0"L, RP!:'Q9<Y>6-F-J9'QS\A^I[CI7O:PQ!1+XW'
MBC'>\"RTWLC.2[R,,6;W\UQ=V-;X02K>6VQ3H_M;@SHU(RW+M4U@J V0J!0*
M##^PKSF6.8"SA(==(G'Y[L&Q8?R6\X)@LL4D(XK-,RM<+>EV,(G)5:J2PM,E
MC\CFQ"%&M,,>&DL"8X8A+$MK7/ $;=4<W[3M>AC+G[DQQ?!,![&PZ&9BGNP6
M.,3KVQZA4.CL ET_71U1'5J/*.6&Q68Z8@86IS46M)EP0K51H!B37L),0&M#
MIQGKU-/+"7%=Z]=M@-1M0](YIE-Q(@V#9K%8T[R&5XK@N27>.241#\X:W9OF
M3D[GE,:QF5N!KY'"UB](-0A1H21A%8-CC7')/)/)=T]N81LKK[B''VD,/\'^
MX\S#$'IJ6Y&RMVRD@+UY^;$F;IPX-W=$HAB+[>+1OI$&W1U_S+A8Q0*!0:^G
M,]N_M#J=MOPIXQP!D[R#!]M]\H?AC81D\EX\E/S@8T=,F8'CZ^-^)36)R-WB
MG;M$S<B>^,BAM7A[SUPGV&64( ;!= H% H% H% H% H% H% H* =\MVMG<,<
MU7$=J3C7)OEO7S9YESJKSEC_ ,F8^>/.ZB&QEZ<(V9YK?XHZS:->&K$A8^AG
M<F\)W5Z#;##>]KA?]05P<H&2^2[%> HA(>*[7K#^RFP:S,# S3&"YK>FIBBK
M3AI1"\@+I#+&]6\9PP$F,D"&;-T>1E%A>%)ETR\\5D9E@B/3A8_0*!0*!0*!
M0*!0*!0*!05P<H&2^2[%> HA(>*[7K#^RFP:S,# S3&"YK>FIBBK3AI1"\@+
MI#+&]6\9PP$F,D"&;-T>1E%A>%)ETR\\5D9E@B/3A8_0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0:4\?YDO46;/[)[P8
MQX_M$M',[XQU$VDRI@)=(9,J<(1)$:**SV8Q^&"D L@[OXL(?7QUC\8[=6H:
MV\"/M[#Z"R+" 78)BZ&\ZNWQN\D&XU^7G2EJT_V5RXS+E^'9SCEQ6K<5SUW3
MGR$Y TD(%DMR2A\%?4L=5H4+VTRQ]1GO:2Z499/;V$0&TG0*"@[U$VZFS.BF
MG6"<J:K9+^:V>S+=G"6(I(_>38!-_$L>2^*93<I%'O"\C167LR/Q!;&T0^]I
MTY2XKL>@HX 1F6$%^-!'/;F2[)P_6K,DGT\Q]$,K;.LL,6K<+8ZGRU*W0V73
M8!Z8*%GD*Y=-\;)$S<<0(T0A&/K6&UPV_3P_F7!J-)=DYAK5AN3[AX^B&*=G
M7J&(EN:<=0%:E<8;$9L,]2%<SQY<AF^24BEN)("4((BWUT#>XK_IXOS+!(R@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4&+\U_\ 5'D;_%![_M(VJ$]*;]7'K;^[6N^@7ISVS_2#LWQC@]W"E.O+,V9%
M H%!E_ 7_7)CW_& G^L'UDIZ'OZS?1GQS9]#R*[[L_HXWCX)/NK5I\A_OPL_
MZ/\ VJ17J :V'"T"@UK/5*Z4Y[W*X\8V/7F*O>197@#-;1F618UC210YR>4P
MA/!YQ$7U9%&1)<:N0R.-#DQ"L"!.48J4(;*NP",X("30T^^+#U$FR'%!B1?J
MR;KGB[+&,&6>R:3#99 ;(,6958Y.]+$Y,J:W:5-R1Z1+NR/;;%@"Y,1[@C$'
ML;GB(*)3E!MT<;'-/QF\MVS&(AR/ 0<(;\XM2S5\PD=D-$QR!V4IW.!2&,3Y
MGQ;FB/)VA9(0F0-]<N^,CPA;0GIPW5)TQQB7M4X:>^9\Q8XU[]3/D/..7Y'Y
M1Q=BKDV>9S/I1X0^O_@,6C^43%[NZ>"QAK>I$Z=T2%"'V")(I4&='0 L5_8H
M+'/4V\OG'/R$X"P!B34:2'9HR5"LQBR&[Y=-Q;.8 3"X*5")=''?':-9E&'0
MV6KQ3>0/S4XGE(TXD ? 2A&C$;V5@!CO->/\SZJ^DLQ#&,C)I%'3MKMXX]+V
MZ++DJPI4V8HD35+I_#"GE,>?:S:TRA?A=+)$G0"P!V<THA L::(5@O>]'A"(
MRQ\9.3)JWMB<J43O;'(!<E>KE$]_7(8K ,7MT=:AJ@% /$UM%E:LX@D8AV*4
M+U(P]':WM0:Q.JZ$K53U2R*&X^$8QQUFY(LR8M8FYCN%,0A@.3YA.X.DC8BS
M07*&WH8M+P)#P]7ZH!0KE]474O8.-R2:W;'>J=<&O)2,Z1L2OE4CV/W9I?4I
M8R':.8?RVTP)G8ER-7962LCJAF@B9)V8K=12W=%K6!8=K!#9I]8_C-CDG'+A
M+)QJ5+:4XRVOBK6V.9I=Q*BXQD#&V2TDF9TH[6Z2PN3S'F529TWZM[-]K?F]
M7H"/W$MA WD0]+IG#4N3Y&;<?)FV99ABT3G<[<RT$+ABW'>0X5LU$#I&[=(#
M&: D3@\NSHH'VHTB,U28 !@0 )N&MMQ=<OFSW"U,LZPJ!P/$FQ^$'>?M*3*Z
M1N>CW*++Y&QV>6:.R3&N=(4%S;6\F4-B%1W(Q8C=42U*4(9:0!P#!!">W"DB
MPMRA<WTLWAV%S9CS!V4PYJ?MBL0ZG-!4EM*,G2MN+4NL=;&2<+V1HA:MIQTG
M)3+%Y1:LV12$QN4&>&)T@CU)8>EI0><YZIKD3D^WVUT!XP-;S7:7QG#4_9FF
M=L<5[1:?E+:F4&E1I@@B!(EZPG4[&I3Y=I+)M?I%('-:2,OKI"1T&YEQ'<>T
M7XS]'L5:XMQ;:MR$-**>YUEC>00&\OS-+$J,^6*[*R2RQN#3&BDR9B:33+6,
M$T-2:X[6,N/I"S&@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4&6VW^]R#_F27^L%T'VT"@4&@AP"\QW'!QU8LWIQ%N/L9\SV0YAR&9PR
M/'(_\T6=\@^(PQ=',?QE*\^+8LQA-V-)VKY&%Q'=SU)2L/8=>Y5BQEC&&<-0
M,T7YN_4:8MY%M:L<3Z,Z9:!:\O6*5>89C&P1P_)4S?(IF)O;6 0>V6!0N[@[
MY_5*"&SME"DJ/,EU2H*,UP+("%G?!)G/-F7MK^=R.99S#E/*$>Q#R<9:@.)F
M+(F09;-6;%\%;<D9C0MT+QVUR5W<T,*B2!"UIB26UM F1E%)R@!+L$L%K!P/
M(MGG.4(]0)PN89A>9LKQ##^4XEG=3D[%$7R)+V#&N1E#/&ID>TGSR"M+PDB\
MO.:STI0TXW!*H$0,L-P7#<-N@(O<N6:.3PGGITQUBXZ,["@,ERSHO)EWE#)\
MYEWW-+"YGRO8E')LV3+$:-<MATUG,'B;&6H9QK&-Y,$X(4(3$R@@GLK!FZ,<
M<'(EH)@CD5VRV!YEME]PGQ?QN;9-T>Q>Z$Y.@D/Q%F2\$0SYES%BY>=L'+V.
M/R2!G096@:%35&F%:44Z#/),2= TYH8DAL'V6WS]*SC:1JMT\YXVR\AP1F;-
M>2LV'RB?3S)&8HGBU\SLID.(9Q*3,EQ.3N\=R-'D)+0L-7N#BF+1%  8B5%
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MR-"='+TA1C>DN6<V&%7 H."<6Y.8^2V,YAT9]/IHUMXYOVSINOOSH[>\B.3
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M%U(+7)_!'T\LB]DZI6L$3<%!V_EY?.3/1/B#U59,X[R3&:;0D\C^)X,^;$X
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M#OP9N/A2.2!\X>MWIRV,FU>((Z0:XI-6<R/:]<<AGD%CR6UQM4?[$T]0T%D
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M8EWDJ4G6[%^V&-Y@SR0@"\QJ2Q>"%X^DNK4?<[.79*D04I"-  VQ03CRBPF
M"&P]Z8:=;9Y&XG\:R?;5]R!*G)3D2>)\$RS*0G8^=R;7).3'K0%W=W%^4K7E
MW;AOHGDIG4G'G@&QE(K)S#$H2!B#83H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M_P O0#&4/CT#A+%XJY+'ES\&BL5;FIB:_$7=P4*S^P(!VRD\PT?2,8A7#OE
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MA^)FB^O=W^S]5]-/G'<ODWCW^+^*?L73\]^^_@/HS_\ 7=H^U#\3-%]>[O\
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MM)E3 2Z0R94X0B2(T45GLQC\,%(!9!W?Q80^OCK'XQVZM0UMX$?;V'T%D6$
MNP34U<VI]5+*]B\+1O:OC5THQIK:^9&B[;F_($)G</7RZ'8U5.1)4JD$<1(]
M_,@*E3NVM@AF$ +9'48AVM:R8W^IN&T)0*"J++G)Y\UG+GJQQ7_,AX[]TOK_
M #+.GS[?.5X9Y*\HM^:EWE;YL/(#CYC\0^9_J]^\PH.R\1Z>[C[OT'!:[0*!
M0*"N?YR>2?\ &5?-C]S[B'\6-\S/C?W17C35\\?SU]RZ_E#P3Y[O%O+O?OJ.
MU\B]GU?_ )=_\*@L8H%!4URG\H?XM#[C_P#]X;\]?W5VS,5UT_ZS/FX\A>9N
MP_\ 3'_J_GGFGN7;?WO_ /-W:='_ +<@H+9:!0*!080V9S)]SIK?L%L'Y<\X
M_,3A#*^9/*/B_E[S3\V$#?IMY<\?\+?/ _'/ ^Z]\[DL[MVO:=@;U>S$& .,
MS=C\8MH[@C<WYL_F=^>QNFJ_YM_.?S@^6?)^2YICOLO.'E2$>,^(^4.^=;PM
M)V/>.RZ!]GVHPZ=C3)?)<Z<EVPN,,GZ]8?CG&%',/LKSKIL6S/34?F6>YE/:
ML'G/D3EC&3G!]=D<?1NS[.RBS#8(REW+94=[+!V& :\+'Z!0*!0:^GJ2=W]H
M=!=&<3YBU+R=\T^1Y+M_B;%KW(_)>/)WWV"2:#Y:>'MB\(R7$YDQ)N^N,80F
M=Z)2EK"^PZI9H C,",-@N@P_L+D!YQ-@+.&5(XF;%LAQIA_)>0&)&]DJE+,K
M>8;"WJ1M:9V3H5K:N/;#US: "@!*@@T15Q6 8 5["L&FCK#S">J>W(P'&]HM
M;N-;0W*>"Y7YK%'Y:VN*B.N+U:#R%YBTH3H(;+]_F.>76HGZ/+$I15VFYJH9
M=A)P' &7<87:</7-(7R0R?.6N&==?Y)J-N_K0(*K*^!Y,H<E12R-"=PL:B41
MR[VU,DA;1,#PK1I79O7IK"3"<D1I"E64IO<D+VJ!051<?7)Y]W9LUR3:Z?,A
M\UGXO38!'@OSC\Y7G?YWN]R;+4=\T^7O($0\@=G\UO;=Q[\]]/?NIWBW8]8T
M(U\M.ZFS.LN^G";A?"&2_).--N=IIKCC8:->38!)/G!AC0[X,2M[-XQ+HJ_O
M\3[N1,7(/>&-4VJQ]YZ1&BN65< 7XT"@4"@4"@4"@4"@KGV.R3R3QK=/4:$:
MU:^XAR#I#,/&/NP\PR]Z:D61L4]BI/"R^06Q7FZ#N#CWM*$ C.PBTDZ!"OT]
M3\RP6,4"@4%$O/QR7;-<8>MF \G:HP/#>1,G9FVDB& @1[-C-+'B-F(I9 LB
MR!()L#$LDXN/0/AT@BJ(@"A6X"1ED&F]H7:]PF%A6Y]V1ZR3\D[H!_&-!O\
M^)907\<:>1.1/)^NBN2<GF!L4:Z;) R-)FU'C_#;PV/D1-QJE;8Z;%Y 8M:<
MS9V2V=W)S4N19P/&PC"!.7>Z8KIL(P+!:!04J<O7-7A[BM:L=P-+CF4;);<9
MT$ G!VLT 4')W^1%*73P!%(Y,XHFF1.;-'W"06$WMI2-M<7)Z<BQIDB>X2E1
MZ8*I$G(MZLE:21E(GAIUF!AU08%Z+@ZN8I6_-H8T(_L;-1[8OV_32]+)K7_-
MN;!0&V#]7=#8'LT%X_%-R!Y%Y"\%3R;YGU1R1IIFC#V67+"^4,,9+N[7<4TD
M:H?#9@"0LMI#&(9(R&%Z;YB3<HE:VEF$#+& )RH%@J# L_H,9YJD+Q$L-Y:E
M<>5^'O\ &<93R0L:_NZ57W)X98LZN38K[JN(4HE/=EJ8 ^S.+,*'U>@81!O>
MUPI3X%]T-O-V^(U#LKFB8(,W[.KI!L"U1QT=8K 8$V2)WASLZ(L>Q]Q9<>M.
M.(FD0"5D)TQQP0HAC+%<1J@-^DRP6&<<\^WXR3K,SRCDGPEC#7W: Z6RU&\X
MXQ$[-KU#$D01KRRX>ZIUS5ES-R02]U;[B&H#9^-$$5O9))_J:"=E H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H,7YK_ZH\C?XH/?]I&U0GI3?JX];?W:UWT"].>V?
MZ0=F^,<'NX4IUY9FS(H% H,OX"_ZY,>_XP$_U@^LE/0]_6;Z,^.;/H>17?=G
M]'&\?!)]U:M/D/\ ?A9_T?\ M4BO4 UL.%H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!EMM_O<@_
MYDE_K!=!]M H(V;EXJE&==/]K,(0A2%%-,R:V9SQ5$%@SDJ<"249"QA*(BP*
M1'K;V1DA(=G<H5QG7L4&UND?U-KT&FQP,<XVB7&SIB5QX\@[GD+478/6;)^9
M&>7)I;AO)LN12-?(LE/DI-2JB<6P^:25DEL=4/IS8J3N: @CN[<482J-L:$H
ML/BQGR&ZS<@7JO\ 0[-.E:V8NF-U&L&:\,Y)G+Q WC'R#*BN&8IVVE2&3-K6
M^E().Y1L/0PI25;NA0*NW;2TXB 73@M0;%^POJ"^(;53-&0->L][<>0\P8L>
M@1Z>1#YA-G)1X$\&($3H!)X_#,+R*+N?2A<"1]HC6J"OJ^KUNM85K!U_:_,#
M+RT<1^Q.3N+'9K+:&6^7Y0]X*R[A)QS=K]/G/*>$G%-)E^.4%W!NQK/.Z3X#
M4='#2ST_<3O$[&AN(119@ R%PL;]-F\W%QK]LS-Y.F\Y1.!J\?;"OSXXV#=!
MDG#2,+'.95)'%8;<M-YK:D">4&#,,O8I,[!N,7L7Z A)P(Y2V.WI>>0;DDR9
ME_,A^$-E-@I3CC2?#TFG\Q<\8XOPABQ4O9")E#L7N;KY3C\@?U9B- XJDJ1$
MH4.C&O,$$'>C+C"O'9/B=W.Q6X228Y[]7?E7"D@+3-AIK?D*5OVML+(7FMZ=
M!&4RMC2;ZQJ,19$^#2E!$:F:!74F#,/N4H.&/M G_P"F^W_V9VRB>Z^N>U&:
M<=[03W1_-S) ([M!C)V8)#&,UP&:&3PF/OK?*(HG1QZ9-1:G'JH]M>"B25"Q
ML7)PJ@B4%&&FA@+TOCRUQQFYEY"^+26UE8>1_,3R\.*F]PIV]K:TKFN<%IX@
MV$*Q*5(0,P=[6O?JAO05EI-T-B^::0Y$SK+^?W7OA3UB;<@2)AUTUTBF?85!
M-BW2.Q5<>TMTQS"UH=@-?YV27+&Y>8>,2]^4H5"U/8:-H(2A2JAA8'PY;Z9_
MPQR1+N*O-?(OAGE>PYDW"KUES6C;;&V3(QD^:L+[!._^-8RR@],,OGCBD?G2
M(1IQ=%:!W?7U8D&2C/(7'%+S[%!$S7]HYK^03?WF3UKUMY&Y-K5K'C/>:=1F
M;9,F3[-,LY4QG& Y"RHU0S%.L,>>'_HQE&0-#8<J5 CSE#QVNW(R .%B>LGN
M&==6)!R4\/W,MJOH#M)OQDKD,U?WSATR6Q:;9C52URF\/G4=C3R:0I;TV09I
ME>5Q,31)HVD0FH4<G4,BYL>A+1D%KB[EEA"#DDXZ]H<H^IAPKAR(<EV>\33K
M:G#.5<Y8<S9&T^0Q2S4;'B-MV!5'X"QF!KSW&W@V&+28"Y%#$UNT90]61*>E
MN%:QME(;<W%IH;L=H1C3)L'V0Y"<V<ATAG,Y0RN/3W-Q$[(>8 S)6!(T'1!E
M#/,V9N7";%:Y.):*Y"Q$5VIE^DD0ND=PM%H/.AT!Y.MM]!-S>9V-:V\5&QG(
MDTY$Y'<XOLHE.#U.3"&[&CBR95RP@;V!_M M<\X)A+7Y,L&H)[PH0#ZA NJ6
M9;I$$+VM7.>#D8SSL7A;#&1_3Y;KZ]0/)^1HO"Y=G&;+LZ&1'%+ _.1*%QG,
MC ^Z4PEF$T1].;=0?94[MI/4!?K*"[?56#&>W.:]H.#KDSC>TN3<V;#9]XA]
MW9 3 ,IL64LE9%S(DT<R^Z+5+DV/,((F#O)%43QZ>J4J5J-$V7**4LEE[;=.
M8H:F3M0[[A?-.Q?-IR/K,HX,S9FK!_$#H=*W&((9-A;)LZQ*LY =@V\T@]Z3
MG26!/,?<I#@B.'$I!&$C/-3'MEB[ M8][/NU!3/R2<=>T.4?4PX5PY$.2[/>
M)IUM3AG*N<L.9LC:?(8I9J-CQ&V[ JC\!8S UY[C;P;#%I,!<BAB:W:,H>K(
ME/2W"M8VRD+1=SM7]V^)[@HY'G>6<I^U&VF:W!\PI,<;[ 2*49;QYE+#K8HS
M+AJ'.\5A$K<L^Y9EC2@>TBI6)2) Z-Q9I:PTH9(PC&(08OPOQG\[G(]KW@//
M&>^:;(6D+8_X7Q,Y8KQ+JTVY-?70^"K8*UG-,IS7D&,9XPL^R_*\M0FDNKRI
M7NDIL<O7&]10F 66E*"Q3E.XU=P=D\QGYCAO/!F3CAP:M)C#%'<0PQG?(C'4
M4M0QTQ,ZJ?G'CNTF#U<@5RD+8>OLVGIQED7+,& (KA&904]<?^X6TNBW+)JU
MHXOY?<9\RNI^XC=,HZ=-D&66C+F2,.3R.L;\_-RI\6D9+S3)8*XC?2R4Q"13
M*7!N>&<]1>R<A0A($0%JC1G;-YOJF)3KX9F3*IF T_&JGG:?" \ARX>(")P*
M7QQ,*9$XU$[WAA4KNF/&7=Q"BLLZ@Q![3HO>U! _?W(G+!DKU##_ *=\>FV2
MO"R*5Z+Q%]?DF49=+7_">*8RHD)/GO+D-PT;>001QS0$L"5 V*C&0\\??3+"
M.2V_LU,$<-Q(!R[^G^R#JYNU.>6/-7(#KYDS96'XAV!Q+EXB>HV!*FFB:1RI
MQ:HU"9?E?,D?9VYQB\9>@H'=F\".:'(E"6%*:0.Q%!VGU;.K.899L)QY9B9=
MMLE0^#96S9BC6R&X3:RI1>)XARL"1RAZOM#&1I,E-;.+(0T$H1H;A2M+8Y=B
MTD_^=NKU"R0M<UBTHV;X7(SM=O5N5RZ[2<BF(<9:KY'=!84R^5E%$UMC[&EL
M?G2*1QD^?[,9O9@3%U3Q,Z/HNJV)C.E[%TJ0E]H4:%$<&R5M-RG1=!M?LYZH
M36SBS'/CES_C+3W7_9"'Q)RQ;"754,E&P939X]M7KO($,H3)&I,>40_'R1U*
M J,N><B.&<DL%O?!GR5["RG*&\.@&RNQF*.0F;:@09LS9A#:O7J9QC(;=L!B
MIX1ISG.+GR:)FGM+Q*(P\OC0A"(SMG!.X+5:%4<?9&G/."I71=NY$.?]#.-B
M'7U LHT8GPLIRN-1_2/7!3*6&08^CH2;N#*2NA,(V&U^?W)C/8VD5VER5IY$
M<N B7&&K^^%.!80MCV@X\N3J.\+F\N%]HN4J59%E^-6[(6=X3FZ$,$D:9K.=
M><98/D#O,M;,H^&R* /B]JRHZ)%R=P4N;W*R.Y*0A.)5%ALF"%8_!APZ;S9P
MTOTFVWQ[S8;88$PHX21UFB73>&I,OCQ:VL$ S[,6R2P8@UDVPAL3\(R*KBRQ
M4NN&+%DV,=CNU3J1=<9P74ZKYSS9(?4Q<G>!G_,.4WS!L!T^P))H)AEXR#+7
M/%$*DCQ%-;E+O((ECM:[GQ"./CJH?5QBE6C1DGGC6'B&,5S3+B"M[8B5\P>P
MGJ">0/3/07<Y7@B (]><#/,H<LIR643B!8+@[GB_!*Z2R'!.('4<DA+)E.9R
M=]NG,<$;0F6@*<%9X%Z)0.RF@Q[DN.<JO 9NOH1,\K<HN9N1753<;8",:_YA
MBF<!3GO484O[^A;SS8S%LAY0SD&/*6]CDICPW.+ [-)JM8U70+4_=.R$:&S%
MREZ=[*[@8JBK%KUR0Y"XW$<).EK[E#(F/8HJ>ULMB1[2B&%,ODC?ES#SG DD
M4$V'++N2=Q[0)9AEKB+!UKB#3JVSF6[?"H%AV1PWZD6(<DDI@4\A*;+.EF;<
MT@E$TD,-D!Q1106O$LJV6V)D#DU."%YL)R5-Y<><6Y :6XIU(Q)RQ%A;MZM&
M5IIWQ*:L3A$G,2(YENIK/*TB0X=C#DJ:18=S:[D)S3+ +L,PDI98(K]4/3>W
MYEOS*#;DH(S;J?Z&^VG\F;/'^:R54&GGP*\]?%=HKQ,8(U]V2V47P_.>-U>>
M'>0XQ:L)Y\EKF9YES3DB;Q=N;I/&<8N>.E*^0,+TC&3<;T6G(,46 J-3W ;V
M89UX,%<TY$N9KD6YK8WB^7XIU2R-C-OUNP>IEK4G:'#*2MEOAB-'/XA)S525
MP6L\?P&2J>RTQRI,WNCV2A K/$B.H/OVYXG=QXK-)EDC./JP\R:PLZT1LA01
MR3.[]@"(Q2).S^M;HPG&F1[XXZCO<"EHK-@'02 LQ<H)Z!7$;]18,@<$6Z&W
M.S[AR5\:F>]R8-L_*-=(VD18&WZPI*4,]N\QS+K1+61-)&R=1%Q9038Z%.0V
MYS;E/B '9$O$L;S7 84J89 47\7/$/NWLEN!RX8IQ5S-[4:OS+5K9]!CC,&7
ML?),MF2;;25'R_.+47D[)08YM/CYU*D!"R&KUEK.CG)5/:OBCH5V%V@U 63<
MXF'MM-=YKZ;;">*<SD[+[EXVS)E6'0+.VP 7TI+DW+Z=9K>F89WD\#U,IM(+
M)!N9Y9ZP)[RYGW+*O:XS^GLQ!Q>^7']SSZ0Z[Y$Y-EW.9EG+F9<')DF4LEZ\
MLS'*H=KT-A*7^&R;RG$!S@S"TH1,R!P+5!9UN-&1">4$ZY?9*"$]C@MRV_YK
MI)@'@IPOR61J&,*G/>R6,L)L&,H0X@4*HD@S[EJ.'+'WM$83TKH^1V%AC[\Y
MI4A=PG.1;<42,1(#C#B@KQ:>%KU"4Y@0-F9?SO9DA>W+TQD34O6IN,GZ+7IL
ME2ML3&DP=Z41?([+B9D"D+.&G5EM^,5K.4O*Z2@GEWLJL$_>+;FEE>9.+K:C
M9K=F.)F+8/CF<<NP+:-H84S:S!G,BQ+%PR1L=FAL9@K6)C?IL:(3(>F2=*&S
M\B4&IBB49J<D 5::L:A<Y?-ICAKY \G<N&5>.C&>7'5]D.O& ]:F^?B:&_&I
M;ZI;FTZ0L<"S-@M,8W#&S]#:H?%LE=G!)TJ5 R+*>S$$DN":<[[,/+9RBZI;
MO;F9&VS?=><68+:42]TD<B38L3."E!'AIGZ$8M..21*&NZZ-JDI+HK1MY"QU
M7 /5K#5"E0<>:$#Y]OEGSF/SIG]X;.<_7?A;TIPYEF38GP5#TF=8/CS9G,B6
M)C3749=EC45G#"$]-CLN-"G,3#%(4[0F+,,1)4:HU,M7+0DSQ?[TY[U!Y-\,
M\;V3>5C#/,!K+MA")RMQ'L!$LGQK*.4<.97@S(_2L,;R,\L^0LKRAJ3S1O8S
M$9"!WD+V2<8H1GH#TEB' DP,9H5O,MN/S.<M^I6G6_+UKS@N#S?%@IY,\D2"
M89168.A:N-'W9HYJ[C%Y<7",Q%ZF[T<J,=C&WR\9<A  =G,@=@DJP[!"T_*#
MP><J?'E@K8'D<RWR*ZH<BDY>L,J!YL/G2^01B;%KH;%B53:@R%D?,KI"5<<D
MN18\M3'M[]W5X07<"#TA0P6. %D_(UG;-\'Y\>%##L*S)E6(8BRJP[$'90Q9
M%\ARZ/XXR0<R1)^4LQL^@[2[I(S,#&A02 Q*)Q2J+IQ@L(OJWM:]!T[F!WMW
MPR'OAKYPU<7TPC>'L[Y:Q[?-N>=E7PI"XCQ'B\M3)+%LC42N:GP#(OLSQ<YP
M6J"D1[DINXM25 :F&>H-L'1,.\*/-9K-D+'63,><_N:,]B;Y;$U.2L7;(QS)
M,C@C["$KJC-F+"RJ<FY=V5;2G-T9#%B9,K!'T"@!@BC0G$&! (H-K^@U(/6#
MOKC%],M'9*T,"V5NT=Y'<1/K7%FVY]G&2N+3BK-*]$P(+I43DILM>5*<*<KL
MTYX^N9;JECOT!N' _P"T=\IO_P#+'[__ !CL5_[(#07\<:>X><MX-=%>9]@]
M*LKZ%3Q/D:30LK!V9#I>=+E+ QML=7-TY+'-L48;>?"']0\GIR;6:!$]="9U
M5!E^L$L+!:!0:;&E$69MF_5D\E&6LLITTB>-/<*QZ+8%:UW9J$D(4'Q[%6/A
MR!F)-+N,I:!D?)"*]^FX2U,C4#M]5V=PAN3T%<7+/OHCXU-!<][;A96Z4RV#
MLK0PXPB3L<:4VR3*,\?FZ'PI,Z 3GI%:IA9W-W\5=22#B%)K2WJ0DF -N 5@
MUR,4<2//[MKB>&;EY2YS<R:^;!9,C[)E2,ZTP9/D1%@^+HGXA)*X=%YD3C[*
M4&QVUJRD3D$EW0)X&_HR+E]W$>Y%VN.@G=Q+\BFR.XVF7(SK?N^C: ;L<?1V
M5,#YU?F-*U-Z.<)3XCD1JC,R7(&%.ACQ#XL?H!($)YK6G):UQ+>2M3@!92(L
ML,4>F=<G%F]/4XN[0O6M3LU+=PW)K=&U4>A<6UQ0KI&J1+T"U*84I1K4:DH)
MA1I8@C+&&P@WM>UKT$P_3*9DR]GOB#P3DO.>5<D9HR.[SS.R-VR!EB<R?(LV
M=$C1EV6-K2E<97,'1X?5J9K;DQ:=. T\02""P@!8(0VM8+^J!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!08OS7_U1Y&_Q0>_[2-JA/2F_5QZV_NUKOH%Z<]L_T@[-
M\8X/=PI3KRS-F10*!09?P%_UR8]_Q@)_K!]9*>A[^LWT9\<V?0\BN^[/Z.-X
M^"3[JU:?(?[\+/\ H_\ :I%>H!K8<+0*#$6=\]8=UCQ/,<Y9\R#'\78G@+>6
MYRR:28\XIM;"#U1"!$040D(5.+HZ.CBJ*2HD2,D]8M5'%DD%&&C "X:GV5_6
M::8QF4JVC$>KFP.5(VC<"$EI=('F$8R*<T8330+W1F8QJ9FZC3V+" :0M;9
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M*PVBQ1/7MSE[UDW8&4O,3=6"7I6,O&[:V"39"3E+2WIZ:EB12C5 [$8 IS%
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M,R3S)TWB./X]#(/@',K&ZD/TT>VR/M-W1RRQ#L:14I$6Y.@ G#(<5 PA"*X
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M!J5J4/B"8]0%D*'U7?".K@A,N/V6G+9(#4%U@\7+M=L\&3M,HLH$3X4<X-L
M<,9"7W+MVW6+D9B7L[VMVW:=(+!$[>#-;MZBO@^W5E&H.!LS1.V+LS,+C@J/
MY&:T**8;$M^%",?9 F#I&H\S>,HK&.K#)GMO9FYO<710O>6P@BYA9QXTQ0=G
MU:]6!Q<(M1L>KMC)UDC$FR, QVQQ;(^OH,+9,DDE<I]#69&Q/Y4)DS#&E&,[
MM3Z[(336^SR^,J@@H=@+"TQ@1!H,8<%T(RUE_$?-9RJY1QV^8L8>2.43J6X-
MA\B*$0XVP_ HSF5U9I FN$A*6[-"^^3"FDERN6 +B>P'J20!(. ,T,C>FO\
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MBR.^R.K6N>P3M&41[;&W3-^$<9Y7<8^W*C[JE*!D6SR,/ZEJ1*%-^T,*($6
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M'UK1R2^G'B%I \Y_R;N=!,&:07"0ZF&/>N.Y;F2[R()B\D Q$(%,*(1D*_\
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M"M80K6O^9>_YM!JN>J[CLCC6NVB6V2>+.,RQWI_OOB/)^86=N1E.%DL&5B-
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M&C-=HL^IAI)!%78U&8(D:IN5)5 B17!<=PWO:@IG=/2O<,C@[EN23 60V-&
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MI2B0&"#<(T;4<(?%_NOF>0;";-ZQ_.9E^4M\?:GV7?/1L+#>_((LS(X^Q$>
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M&6>6,XJZ0B-K2PEF*!] ;9% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M_0$WH$$_,:Z0['*^0:#Y]SYF'6-;.4AWGR3PO&#[(D\S<&.,11-#D;NWPU;
MF,(FX;BJ;2%RU2I '^R;WL,8[EDB".NK<?8MO>67,V0Y2QMLOA,-=\CRTA#(
M4B1W:%S;%E*'&..S%B%:2I1JCTQ"A$M3DWL*Q)J2PPWO8KIN'"9)Q_!M@>9)
M!C1GA\;O 8Y,XPADS&C:&Q(Q/"/%L&2R29I7QN3)^X*2%KJSJ6PX!@;]X*L
MH71<75L'V\H</B.1=[L Z\8]B<>CIBAGQU#GD<;96UF$)RR%-U80$JP-24FU
MT3)'E"92 PSV"0J#;] 0VN(0=IY6AWS9O#K3K"R6,LW-+="8N-,F&$L#8ZY5
MEZ=,YV(*MTEIB4D4;&LZYE^CH#;V;6""UQ!E+FQ<,,Q+$&&,-Q!AAC-.R)X1
M(V]FC#2S-ZV.0-FBCZR'(C4K8F*.:VUZ='Q!=,3>P"U%T KA"+L>D(0#W@CN
M086P:%ZRS%U!&FQCU_B4F<2)<N<&^/1V;9,GLJ3R(<J4$$#-3)X@W-R1.H$
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MQUBGTW63N)ON2</KW)4I7K6>!.[1:/%KU8S#5*MH1O3*Y+V2YXSA]8E.JLD
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MK;K1$&=!A74,"$=@LWH% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
&H% H/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>sny-20231231_g20.jpg
<TEXT>
begin 644 sny-20231231_g20.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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M^9>JPER25LQ!:'=N6WU:**GM3Y9$;G\W_P U]0<M>_F7YIN1S+4?6+PHI/\
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M?^%/''%_B*,*L#6A.V]0.@]L=RY5KL>)ZT!Z]Z935^$_%0@G?;[_  Z90)/
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M-92)(K/^R90/4=SN:DR+MVZU+H-/TB*8+/YBN)Y0ADB;U%B,\1%0W(2R*_\
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MS9LV;-FS9LA_GOSWY8_+;RQJ/F[S=J*Z=H^FIN?M2S2M7A! E07D<BBJ/F:
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M].G' WY@?E]I_FN72_,^@W*Z/^8NEEKC0O,.F*L+WM5]3T7"543%5J8Z^G,
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M;Q4H% )/0GIMX^V(%>@IQZTVW.,)(-=P=Q4^/A4[XBVS?,[&FWW;8FU6JK*
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M%/GE[&@^T*'KMM]'SQ:PNKW3KNTO].NIK*]L9DGM;BW=HY898V#H\;+\08$
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MY8-Q]&J[[BF^PR-ZYY OC<JZVE+F"YE3D5 CW',QFI4TY, NVQ(4[,,YE?\
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M8SQ8T'$<> 5?;VZ9W;1_+,2$GTP_&C.9F!J:T!*C?M0#;.I:3HO%BS*68+Q
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MNG:UHMPWUFVN JO1';D'!;>A'?W!!]O# WF&6RUB#]&ZD[6DK+(B7(('I&0
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M !04V[5IC222 H :E"3[?3WRPM2W$\*[J/[/#?'\J#8U'6H]O??&#X2#TH?
M^V]#MF(%%/7<[U^[L>^8.>M?#H:TIV-3MC&^)0Q JHHO?O\ /&L-E)/(C?XJ
M[&OC]&!GY,>FXZGJ=\K<4&X--@W?K3K0C&<^5*=Z = :4QI;XMP!U._<;"A)
M[?1GTZ_Y]]_FH7/F7\I=4N2*\M=T-)&J1N([V!/^$D"C_+:G7/I[FS9LV<G_
M #P_,)/RO_*WS?YP$BI?V5FT&FAOVK^Z(AMMNX61PS?Y(.?GM=YIYY);B1IY
MIW:21W8L[.Q+,S$DUKWJ<:%Y&M*@B@!':FWAX??CBA  ;X*BA/7H:>^V5Q
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M'IM[XF58"A%012IZ@]A3>FV('K\+=QM\CU!J/QRPU5((I3IUIT[[^],]H?\
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MZ#MB(% "W8$\>NPWWVZ8\JQ!VH*5J-ST&VQS<=S0&HW(-=@1M\LNA-5Z%O8
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MV/;!"@@D%?BIMX=]]_<]L?0"E%! .XK3]>)&E#4U(KMX_(X@W5=]CW[;^/\
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MM7I@=JT%7/Q#H>O^=<:14@\BHK7MU]Z>^:M%>C\23L1L=S^JO;$Y 2QJ?VJ
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M4BF?;;RUYB?7_P#G"FYUA)V,T'Y8:M9&97J_JZ;I]U9LW,;\N5N2>]<\Z_\
M/Q/6RU[^5WEQ'VAAU/4ITK]KU&M883TVIZ<GWY\U>84#^:E:;4%:4Q(2$>P^
MR/"OZ^V7N1O7OL/;P_IC@[*:[$?PZ8D2[;&IWVWZ'YY0;XN+&I VKL.YZ?+P
MQ8&M3T)-:^QH*_/*Y!CO2I%%(VH/',6 /A6M3U\=SVZ 8V/[-":.!2OSKOCZ
M'E0 (M=ZTV[^V-&X)J#0KN/B 'CUVIE+TY5H:E2#OX;$^-.N/+%JJ-MSM[],
M<$-2.8 :O7KO\_?*,99: $D]3U%/8_3CO2Y5(-#X]QM7W\<=Q8<6^SRWW(_5
MTW.70'@ IWZEAM3Q)KUKMB<[N?3C5%2&*A$; ,2S=6?^8GI[=!MD5U^-YM+O
MKFXN1&EC(EP\TLNXB'P4"4I12W0$#?8>$*T2R1IQK5WI3:5]3#317<LG-@"
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MZZN8F+4!N=.N(KU"U:4Y*&3.1)<P7,_F729P)UDNHQ$@/IK#>VW&6("O+X6
MJA_EJO4')II5O#<:5 TYE>2VA>S+TY-%">)0/WHA6GC4^!SI?ET^E';I<:EQ
M]*5EG]).1>)CZ2U>@IT._N*]<,2\?&..UA,%LM"JD5<M_.YWJ=^G08F6- .(
M(!^77Z<>& &YW7K6E:^--O''$@D@[5IT["M#W]LM&(H*U!-#2@V^^G3MCE<$
ME!\'*E?GV\<>&;L*@[?QW[]\<"A/7TU_"GRKT'AC":T^%>.U>M.XKUQLE!5>
M('CVH<:E6-3NII0'Z-\4-*@*.!:E"WAOMOXXY=PP#T'^33J*[>XQKN* 4H:]
MAMVZUQ N5:HW7P(-=^Q^=,2=R/M#B*;&E>VQIXX'Y"OQ,:G\/G]^.YCJK':@
M&W<U']N>_P#_ )Q4U@R_\X^_\Y7:"S4-CY9O-11">IN]*U*)B/B[?55KMX;G
MMQC_ )R^U8ZG_P Y#_F*ZMRCLI;&SC (('U?3[:-P: 5_>!O<9YE%#78E2*G
MIV.^^V/'$#?]K8$ C<@90I7>@%=M_H^GKF+&AKV%-S0T'7QRRPIQ(X@&IIN0
M/G7IB9(XD*>);K0$5Z_CE%RIVZT_7N!N<09R:<6/2@^9_A[8T%A_DUJ1WIT^
M5<620-UWJ-Q\_8'K_GXXJK,: $AJT\3[;?+'AE)(+T%*\:4 I3KO[X[U:?$?
MA45%*;;FH^C!R0R/;"] _<+((RU5!#D BJ#??Q&(JRL>1)XGL0*5IOU^>*G[
M)-!P?8$=#2E-NO08SDQ/&M#T&^X]ONKBBN1\70D@'L178[$;Y7S!:FV_?IT[
M9J*Q%230]._7O[CWSJGE"6WTORSJ&L74S6>EM>@JQ-$_T>-^4AH23]LU)^CP
M"OG70]._,'RNY6>VU/2-5B^L6MW;U"HZ[*T,H%0:C=3T(^C/*%I-!HMM/:WV
MG-I4)]2QBM1-67ZJE3,Z<8E<>HS\7< ,>3?'OGM_\E))KWRI]?NK46TUY-6*
M!02(8J%HN8)KRX@$@]*CH,[G:6Q,3@E0 6X%22":58'<DU!_MP#(DEKJH%!Z
MER5C,98!0@/,.10'J-AD*\QSF.";F2Y0EXP6^$[A: $+0!6VSGD_G-K2Y+H\
M:(SB$1,0GI<5J=B14$ '8U[85:A^9MI C3+?\)%1J2I\0JH)910]&*]Q\\+%
M_,Z&>^M-/O5C@%]!ZJ,Y,0!B(4I5@O%F+A@"*4]B,E<VIZ4#;V]SJT)EN%YH
M\SAF9EJ K;*IV'4$GW'3$+C2YXY&;3O,)1#3D"ZRQFM".2R%2>O3?]65"OF>
MW;UUOHC)'\5/3X[;4J"S=AW.#TOR;B(ZUI:<P01<)5*%3458'85)[^(SOGD_
MS,(+&*Q$T]P'I21G#%8UZ)R\!TSKEGJ\30[R*2@6M/L  #<]^^^V&MOJ,<K/
M'Q'&/<,]?B8G8DU'C6@.WRIFO[V=)%;FW(+5HRQ-**1^UP[UIMA))K'I&:/F
MK$,:%B 2Q'@34BF(/YMMXHE,LP6,FAVX\BVP^'8]#]V>7?S+_,C5[W5[F&PM
M[FZBA:ELR;)N:,Q/IO0[5H0*$[>.<-OO,_FF9W9[N\TR!V,C&2[H^^VZGFE*
M'I6I/A3<L2<B:W,U_'<SS$-NBK(5K7<J/B- >A6M<Z#H\.GS213AVEJ[^F2#
MSJ"%^(@[TW!Y'VSLUE8:7!&&>S@4F.K54<Z5Y*I:A)!!K2N+M/I]5C:)5Z[E
M5*CCOOMUWZ81:IIUAJVFSV=Q&&A?XUD;JC>PIL1WSD*^M;SW$#)4;(#0*0W[
M,S*H4]>I'CUVIA;?([V=I$0WJW$<:J&)!/'D.3'8@CD-S3 =Q:"*  <&:6X*
M<@**%4D$F@I\(VH>NV>;?.^H?4_,-[(H6D6E:F8 .K-P6/TE;:I)<?0*YR"Z
M4#5[3S!"TGZ.U2*U%P\*EE6.8 VTT@4LPI0'G0\3_JYU30+TW#3Q &W>Q807
M?"C+.9>0)4J&JP)H5 !7X0>E3U2WMH+*.T^JN9#%"B.)1NX<%N16@I4$@CV]
M\%L: #;CN#4U.W:N^)D@F@J'WI7P^>]1C16@)Z$@"NPZ>.*(:@<MSN#3N-Q^
MO?'<@?M#H>H_&G7%.50-S0=O$]NW?' C;X?F .U,LOO7=>Y(/6@[CIB?J L*
M;@[^%3[C,2#N"0>70U('R]]LR;#B>_3;8?+>F/!)!Z[@$;5/S^6^-,H4@UXT
M/3>IZ;[X'EDZ[G8F@!K0^V_;&'J>NV]0*G?;;&,16H-&Y4.W7V'WXF%H5 :A
M3LOMO[8F_*HXFH&QKW/3I].>N_\ G%K5C'Y=_P"<G-%Y4^O?E3KE]PKU-I#)
M'7I_R]9R?\_KPZA^>'YLSO5BGFK5+=2VY'U6Y>$#;L!'M[4SC_+C0U-2: =*
M==^_AX8W8@'<\32FZ[[X\ 4-2:=!VI["@.77?8;]?O\ GB8 K4;@UXT_7X5Q
MBTJ!6@\*TZ]=P*XQB:BE2:#<T(-*_+**,225J?VJ=AUKM^O&D5 4$$D =:U\
M:C' <5*@TW- -M_8BN"@010U!"BNXJ?'KBQ0_$:@J"*4._\  [8GQ#%20Q V
MW&_;MC@2>7(&E"6]Q_M]L7!8DBE-R%H=_#H?IRUJ=R1Q)V7CX=#OBJJ0 .Q%
M 1VVZ=!CFVJ U/#_ ":#Q-/'&T"U%1VJ3O4UI^O'\4/(D$]ZC<U'?\<E<5M>
M^8?(?F[RS;7#&XCMEOE.U>#O-$R@;?[[6E,XC^3VI>:=,N+-+2XDET61X[?4
M[24\HF'J&,2J"?A=0.H^1VR0_FK!I[^:;'1H]+;5+ZYAC-O;CXC+$TTI!D H
M0M5-17XJ =CGN;\LO+EQH?EJTL[\K]?G)NKT0?"D'J(H2"BT^PB@T'M^U7.J
MP6A19"JM1U^($'B5&RT\=AVJ?$83:UQ:&.5(VDD23@PXDC@0P"M3B1R#'M\O
M;AWG/ZQ)I$%]IXDO]-MXY8KR*,L[K&U51@34'@!TV!4TJ"*CRWK^H7<B>KZT
M*AJ^E/)+6SOO2!#1U4N$E%"*$@[;?#0KYN\U_F9!#"7FU4S7JM)"L5L70#BP
M">JQ4J=@=QXCI4YRVT\SZUKMM)']=C;3-.CDJQ-P9XXD"_$*Q.13L%< ^V2C
M\N/+?F?\UM>D\M>4-)UOS5YB2"2_%L9H8Y'@A/.1D6>ZY2$=U3?<4&="\Q>6
M]7_+>ZAT;SCH>N>4/,]\!)IQDO)K*:XC4NKLB^N]NY#_  D<NH[;G.P>1/-G
MGCRX8WNM5_Q=Y:MR3]89?WD0''FLRD \E '0CV)&>K]&U>'6-*>]6*.>.3TP
MH9049G8 ;<GKUZ5V^C!E@SZ7?\+-_P!Q)*$*J6 2IJM :$K3;?IG?] U22[:
M.)%D)( <.*E3W%!V(\3G8M,L;I(S*Z/#PJI#A"H#$=5H&'('J1O[8K>6D:A7
M:"%8!T+BCM7H3U'&H%*GY*,XSYJU"WM$DFA9U522Q8$@A1N4J20 >AW&>:/,
MOYAW2S201&L@J$J3Q!;B>2$5+5!Z[_/.;/J.JZZTCS:E]2@0JK&,^)7ERD(8
M"G(=/'?.9:UJ/EW0HOK&O:X]O5EJK3LS,:U/I@_+M7KA-IWYJ?EKIPAA,]](
MMVYDD+65RT8(/PU9@*;E0>P_:.&G_*_O(6E>K%97T4IE>*.-U)MU0DOZGPO\
M96H6G4;]^F3[3/SUT6]1;:RU) 9!6/U'41EFWH*A10=R":GM3?))8_F):WUQ
M;Q0W)DN'Y? *<1_+Q^(U!(Z=\E,WFPO;,]K*EXJG;XZJ&534$@C9:?33(_!>
M1WT4LJTD//U"-@./38;^)ZY*Q9I-J44**H:W1G=7)4*[%CQ-23OON-Z#PIA/
MJ=C#]6D,G)9(HV)<  H&^*H-0#7B-QTSQQYT5+W4KY3*L,]O>,X<$JH#EHI#
MN&I0RQD^V^0_REH6N:NEI:B%;4VJ-8W*KQ;]P275T"@J:,Q /@*'/0R?E/96
ML%IKNF_68-0AFB&H@3.QNHCT:C'X64G;C3[Q@\"W,CN%,(8GA3XUI4#H344
M'0_1B;-\3T8,HJ0PJ 1^%,I:A@ 2#T![TKX99XT 7]GK3PW[_3CO:M-Q05Z;
M?V]<5%/A[ [UV KM2H^G+^$JRTVI0^.XW';QRP.((XC8$[#8>(.)UZ@-\7A7
MWWV[;>^/Y#>NP%>_<;#K[9OA<-PW  !VZ4WWIT]ACA4?%7[.Y/@,:6%-MUK3
M_/?M7$3N32H!IO7KM_GWQH4=2*L:D5/<#^F9C12OQ L-SUZ[  G$J;\B*<=Z
MUZT['OEDFC @$4JP'8;G88F0!14.R[5Z'MW&>@O^<>[SZGJ/YMV]>/Z5_*GS
MA:'XN/("P-Q2G[7]QT^GMG*_S#NVO?S!\]710(U[Y@U.4KUXF2ZF:E:5- :=
M,A1D8@T%#VJ*[UJ>U<L;$E/L@]>G3-R-:CK^!\3N.M!EK(*5)Z 5)V \<W+D
M5ZU.Q[_=TRPIZ;E234T%?IVQR BHXT85#;5[^^8DT-5H%V ^?7<5QI 9?B!V
MKMX=:T!QRUXMR!-".H^^N.6J]C53U&_4G;%0X7BK?::E:BI_"N],4.[$5)K4
M  5'@3MMCRH[@EC044=?;*"A:@;<NQZT\>^/6@  %>7Q;=O\ZX\N%_;Z[CQ(
M-??\,M22!U84KX=:=OEF+$*O(?[9\<&HANHT:WB9[F)5$L:#[8799%7;Y/\
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M_;%$81<)&Y_NB'K$WIR;;GBXH5-.ASL'E[S+/IOYD^7KJYTI4/F*VCATS4U
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MB)(FC#"@!)H6)5J?(')+HWUM)IDN11HF556I*A* \NI[G^RF=4TPB5#M5QN
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MWKC@*4Z%?"G0>/X8[D =GJ&/0]_8TQFYJ205V^5?\^V(\BQ6H)Z=!W))/;%
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MQ0#J"0#0_+&4(%=@=R 1W%!X8C6E>@V\?"M"OW8\$T#=Z;U-.G3P&V),QKQ
M KVZ?12E<Q9:-Q IM6O8]MQX8QW)'(;$4 _K45\,8PJRL!56Z^/3]7\,I5!J
M2">NQ.Z[FE-L:0PHVRL:GEL013M0910#B#]H<232E:UH:;;9:1$DL?V=@%[
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M^L[?1CMR!\55I](%.NW3?.[_ )!:>+K5?S-N:5.F?EAYRNNM*%M*FM_I_O\
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M@JP)(^FNV4"./4?#M2@/S[9=68<2:A>H'3H/<_3F<CIONI^'>E17[\=S.U
MPW/;8;TK]..0$TY"HH?$ #J>_7+KWIM4GX=SOOO6F8NE**O$$=]J#Y4Q!I8]
M@*GEL:G?[P>^5ZYH2#6I[#LO8[^V)F0@GC0[]A7^->YQQD+$ N=SQK784]J]
M/HQCFE"&*BO'?8;U&_?L<9$0A^&0U%._7<[D],68@?$U2*[,"34[T]N^>_O^
M<4-)*_D7_P Y;:XR@K-Y/N;"( F@,6F:K)*.M=_43[O?)?\ \_'M#:/7?RN\
MQHA(OK#4M-D<=%^J2V\T8;:@K]::F_8Y\T A#<J_L]MCO['?MBH-*E^@/7<#
M;M^&6HW^'=6\:FG3%0Q*TI7ON*U/^8^C%E<TXL:'PK4CZ!3+'<]*]Q7H??Z,
MU:C_ "3U%:D5[4S "K;<B.X\3VVQ0=":'EM2M.P'MCDIT8<64]Z=?>N*$GC]
MH&BFH'0==^OOFHRTV/Q';>FW8$9:@*HVXUW(8;GH??PS;U"E: 48 U%.ON1F
M =:TJOS.^XI4]O\ /[E.O;B1_-^!/3Y8T _:(WZCIM[DT]\N@&QH^]>0]J;#
MYXLK*H->^Y%=R/Q^[%0]14FII7K0=@*]?'!D8(I0 !V'O6A)IDT\N>5Y-<DN
M[JYNY-+T30[=M4U;4XUYM96=NR<I478O*SLD<,?[<KHG0DCN7E_\U+'6]0N8
M4M4T"QTR$VFEZ;<SJ\QBYF1KB:<L!-,^W-A3C]E5"@#'W_FOZSJ^DVEJZ7-Q
M<7T4*6T4D;2,_P 3<>()XT5226H!C+B$AV>>0M*/48F1W)2AV!>O],9 JH$!
MD1UX\:]%H21RJ=@!7I^%*X8P2R&)' 1R%"GCTVV%-R3[82ZEJ$D()))(4R$
MU%37>OR'W82)--Z(N)JK+.RJH45IRZ ;GK\^V272-.MTFM[JZ99)DHR44N:&
MNP^UUWZ]<[;H%U!$GH"HB5MU((/*G0U)WSKFFW=($#,&)) (H-@.E":=.V2$
M7D+ !G568?"3T-.N_B.^ )H(YN04+MR4'D%4DGP]_ ]<(KWRQ::DHBGB@N59
M13FBUW%&'$FAVWZ9S+5?RNT"2>:-M$M[?H8VME: L!0 <HRA&QK_ $SF'F#\
MD+2/UI;"ZU73Y0G-2M[*PW)JH5A*#\JY$+7\GKR64_6M1U>XMUH/CNRB@>%(
M^)(V]LF^D_EUI]@_IPVT04+5N2U;84!<GERJ1W\*YT*T\OK%QX *2H-:>--@
M!44&V^2.TLH[?TW*T,1I0BN_6HK6IKTR[KZLA@# /Q9I2N]&934$@$>.Q_'(
M9=WMO%\",BI&OQ(H+*:<A4)]E@!V-!^H SJ*R0R^O(5NX@ ^WP\6&PW8\J5W
M;N<@=]K#Q3DQNP*GCM1:B@-".A^6(3ZL9[<LK<F(YA0:&H% I/6F<ZUBY:6O
MQJO%M@*@J: BC=.AK3]60Z65FD:I7T@2ZD,S!0:@_%0E3TW&QZ866X5[FP@=
M.+3:A#*O%E^Q$KD#8"HY2G<>WMG1M>M?2O+:Y6A( +5H-O&M/?)OY@,&G^7+
M:=J!C'S:AIVJ2?OSQI/=&YO;R\1Z"XE9QU[L3T]^6)<U)4'<'?8;^'MO]&(E
MNGVB >YK2M3U%?'&,#2C+3PVH3M^'7QS&2E!RWV!!]NE,>6Z!CW%*_=O7*8E
M:J*=:T'45Z#MWQ)CMT-1TJ-B=NG;%5J0M=O$[&IWJ/N.6S<=SN5'?Z.@^G&5
M.[%=VK\7C7'-+N13=J]![[^W7KC3*&6M3T[=/'KB$AZD?#3H.@%>^)\JMNHX
MU-6Z]3U[=:8Y&Z  U'@.G<?[6.(4UHQ+;4Z=SOOW\,;P'Q#<$G8_M;;CK\O\
M^F;DI4FAZ=/M=CEJYH20?GL:@^VWZ\4%:44FGVB.@I3/JE_SC9HWZ/\ ^<*/
MSQU5DI+Y@T_S;<+)O\44&C_5EZFFSQ/G1_\ GX-H!U'\H?+^MQ(&E\O^9(!(
M3V@O()XF_P"2@CSXWE>QZ'JHV'S.XQAY"AW/M_9MM]&)U^*E-J[$=_'MBBBF
MZ @E20!MOX;;]\5%"V^Y3VZ#K0?V8]7.X7;>A-*T->N6"K$%0:B@(![=P#3V
M[X_<@_$PW(!IU-.H]NM<NA%*ACO4'J?'O7L,<HWV;K0"G6GSP2"A(5J"OQ;]
M 0.PZXJ0J _L@'\>P\,U%8UIR7:A[U/:G\<:PC)"C;EUZ=J=>GW92J 6/2E:
MU';W]MM\L#< $[]S6@!I^.41N2138[C8GO[>.7QK5=R-AT\.G;?%"/VB=Z\:
M_3T'3%XU!VY%C3_;]JX<Z;:27MPL4:F1I" #UI4]^NQSL_F<Q^5_RR\J>7;4
MRV^H^?PGFW5TFCDAF_1UM)-::#;/'($=02MS>%&0$,\=?LC.)S0PL0"H(8_9
M'M4]?PPP\N2PV7F;2;@-*OK3 ,T4AC(H06/(%#V\?GM7/2DZ(EW>Q<PWIR/^
M\C(YNI/)C6@(H.E <2MT=DJZ%#P5F]2J$4 VXDU 'N:^/<8=6H]4 M4R$!J#
M<-UIT'?88R_\O?7'+$#C(I*A>@(KL?EW'T8G'I8CT]6DAC>YM9"RAF!,BA2C
M!:FBOO\ 30&G7.>>;O.5GY.A_2%T[_4&JSN?4)Y;;!8@QK7VS@DO_.9'E/3[
M][&VU;ZG.GP^M<VUS%'3L3(R 5\"3\SG;]$_-^;5;."]E\TSFTN@'CDLOWD9
M[J5DC]1:;UJ#]^3[3_S&L[F*A\QWEZ$(VE4NU*;$ (HI\@,E$&MZ1JBH]OYV
MFLI6W',5HW_!?+Q^6:#4/-FGW4HTWS5;:F8ZOS,G"2A%1LU#3Z/OR5VGG[SM
M:F.&_P!.@N$*"4^HR\3NRTJW'X@1T'6M?' 6N_FYJED_HV7E07-VX4N\0!53
M0[ O*!N =@2?;(#<^=?/>KSB1K1K.V!Y*D2C@H8"@I&E.^^"+;S3KFG*JW#4
M=/V'XTZ_M5(/7)+:?F?]7BD:[M@[D@,RJ?B*GM0T  \/;!\7YM>79/@F<02C
M<-4CAUWHPJ<"7'G31;WBME?I/*P)DJP#!A1A11O4]O;.?WOF*LT-7;@I]1%'
M>C5(()VH -Z4]L&K=3:I+:21U@CG7UI"&+J.X-"06Y=.WL17 FJ6UTUXR!?4
M1V(:-JE2O&NX('Q [ 4H*X!M=-EBMHG,;GU5(YD<0O$T;KVJ!TWR':DI]1C2
M0#8,C4(<ABGQ*#O0FAV_KD4OAP$TD1].@6-!5@ROL*D@$$5/0^.0V^U6#2=8
M\IF>'TK626Y>XO.)X6\<A18S(P("J77>H^'8[+6OI-K>&\6*XD8^EQ#5(Y5!
M'6AV-?NSGOYH^9'E\M:5'!Z<D.H1^B'MP_&&C$212!P.$@%-M]F'@<\X4,0"
M%=UW-/$[GQZ5S%R: L/CH0![T_VLMF8$D>.S#MUZ#]65R+UY;4'A7QWW/OE4
M.Q)K7N3U!\?'%% 3C04#'<MV7N,S-P/4&AZ4%>]!^.),: D@@+5NO0CM7]66
M30;J.6X"CM6G>F;G6M-Z[BG<>W3-R(XBE0?AIT [C]>)]N1J!7PW7VH#7,02
M:-N6-">H-=JTK]V-/V0#7>O'N?\ /;$R%J2!1B.I/T=>F-!JIIN 14=2#X9?
M) "" NY  [TZG?Y8FSK0FI &U#L/#VZ9:M4[$E5.P]@?#Z1BZ$>P!W WJ:UV
MWZ]Z8\E1M4$$[$#\!X9]O/)&@#RY_P X*7]D8PAN_P L]?U5MJ<AJ=G>WJDU
MZ_#<#Z/;.J?\Y1>7#YI_(+\S=.1 \UII)U6.HJ0=+DCO3Q]RMN1[UIWS\_1V
MY=1X[]-JTV^G&]Z[ 5H' IUK0_CCN-#Q (W[>U=Z=^F76A+%?A!ZC8>'7,!S
MK04\/V?;VQO&E:\J[[=R!WWQ7DW$"M>Y\#W(.],61@H*KL*5.U*;=N@RP]5J
MK"K=02.]/HRD;B%*_%UI0;]Z[>_SQZLPXTV5B10[4^G>N+%S4;MR %*[#?\
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MNF6,\&H:A8BX2)JIZE?B>G5OI%1XY]$O)7E&#2;"WED@,,E%6(<>*JU.I %
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M.Q[['Y5 I@A"$H!45%*CKTW[_P"=,^C/_/N3RB=2\_\ GKSO-'SM_+.CPZ;
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M+,*UX_(5_IBSSQ $&G@6 Y+MO4A:_B,([F[=2  !RV%/AJN]=SW\-AA%=UE
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M&0G[AGBK\F$]'4[>;[(60 $^]0<]\Z1=MZ:HS,:4XBE!3W ]SD@4LEV'Y%Y
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MG.M?\XK>0I//_P"<^E7MS!STGR;"=9G'51,I].T7?J3(>7^QS[+V%MQUN^D
M^"WLH(5/NQYFN"[0&2[U.?\ 9C:.$4_XJ4LQ^]\H*8_+K5%'DMB:=/CE:I_%
ML,-2B_T2"V'5IK>&GMR6OX+@B])EN]/A4 AIFF8'^6)2?UG*<,VK6JUJ+:WD
ME([UD(0?A@CDKZHH&_U6U/('QE:@_!<$1.LFIS?M?5X$CJ/%SR(^[-(W.36I
M8S1VBAM$(.X9P1M7PYURY[?TSI<2BB)*H ]E  P7J**;2)6'^[XMO>IPROE
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MO)GD[UXUXK^ QD!9KNTB XB\FGO)0>ZK6.+O[5PYO8_W^G4_W\?U#-JB@00
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M_J06JQH?]+NWH#UI))N3\E'ZL8T<:O!;J:06:<S7QH0M?N)PJNP[VLA4\7N
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MEZ/H6HV.I>>="A%F]GKLN@ZW;H$6%IC&'BN8415 #@$'WW'<GA\NG">.="E
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,FS9LV;-FS9LV;/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>sny-20231231_g21.jpg
<TEXT>
begin 644 sny-20231231_g21.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
M!2$2,4%1!A-A(G&!%#*1H0<5L4(CP5+1X3,68O D<H+Q)4,T4Y*BLF-SPC5$
M)Y.CLS875&1TP]+B"":#"0H8&82414:DM%;352@:\N/SQ-3D]&5UA96EM<75
MY?5F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I.4E9:7F)
MF:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H " $!   _ /OYFS9LV;-FS9LV;-FS
M9LV;-FS9LV;-FPFUGS'Y>\N0?6?,.O:=H5M0MZNHW45JE!U/*5T&V<2\P?\
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MU)X:4'412VTU:G_+&=9T+_G._P#*74>*:OHOF'09"?B=K>"Y@44Z\HI_4/\
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MC ;U'B,#UH0*=34TQ_JFM%^$$[GVQ[EG H/;$Y#$D<CSN0L*&1UI]E1U9F)
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MY@].TU9CHFLL0"LP/IR'L0YZ5]\['R5N/IDR!A7D!4'8=QMEJ9.U2!]V8EV
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MXA$TH%?;(E-<1W=8K5HKE#7DL2.X%#TV-![UP NEWTM4]".R+[4BC5G/A^[
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M#Z+ILFB6TX\J65RO&[F=EN-7OD5>\$1<QHP.RDJM.ISE]_J=M(Z?5+]HK62
M-&MP3(%8;!GX_:VZ;T'[/C@?3KRPL2FHPWJZE>1$HMW=QE$22NWU6(@EOGQ
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MK%MF7D'DE9?V1_PI.&]_/,?TC=:A/>6UQ>RM!&A(:]F*@;QJ6?TD);8L>9[
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M5P]M;1F+4BX@ @D'E6G@#BZV#E"2M .XZ5Z@TQ6W)BE]%Z^G+NA(I1^X^G#
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M6VY57<]<X;J!>^UX+<'A!!6ZFVV/+I3J3\- ,[C^7VJ_OHDH3%<2@>EVXJ:
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M6B_EGY[;RCJ/EF&STJWU/S);K>VGF0-)ZFH3O';/ZENRE/W.PJK'HP"^C_\
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MJGVA4T([#PQ8T-#T./ !WY 4Z_+/J'_S[,\YBV\T_F1Y FEHFLZ9:Z[:(QH
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MS/:A'4A20[ 5^?4TSQ'^66F-HOYO6>D<W$=IJ$Z*U./*);GU" 3X*V>_]?\
M*T")I6I&,4CU &)2M> -.7+PV8 #/-7YC>F?.VOLL*Q1M,!PIT &PR$EN*D
M4I0?,8B16I&_]<!N":UI7$R.)JVU!T&!Y&8U(%-\2)H*T('OWP-(Q+;+Q4[8
MPAE4'L=O?$^F]*D]O#$FH#0CKX9347>E#W&7R! (%*_AB3 ^(J>XQT9(!!(^
M>.%10DU'>GABBK4,./%2?''K05(-=J8K\7$$T/MF!()))^7MGJ'_ )PY\W'R
MA_SD;^6EV[F*UUR^?09EK02#5(GM85/_ #WDC;Y@9^BO.#?\Y/\ F7_"?_./
M_P":VKK)Z4DFA3:;$U:$2:HRV"$>X-R",_.<C5H!45\<78D$@T*&@QE#N3U/
M2F4A*D$DFI[X(-138GYXHK'B33XABRL6 J-R*G'G<$CMV/ABZ$T('8;8^M-F
MZGICUIUJ<?0U7ELQQ=P %XGD.GN3CU%".U#O3I].+("7 )VZ[XNP%*G<=C[X
M^AX@ E1WQ)XJI*G"K3(4^@BE/QSSQ)Y?2QU/S3:<^+VTPFC10>+J.#$5'38]
M>V$%S%";BU:@:*Y]9%C'1J'EQI[KMD=UBV:.[-N1^XC5;@I6I(@)Y"O^JP.1
M6RN%M]1TJ=2:>H6K6FZFGZAGT6_*Z]@N=(LIE*RA@%Y#PI_G7/3&ELKVH!/V
M=QW^>&>H2/';RKSW]/X2!XCMBODNPG#+<<Z1.#)(K#E0***!7\<[WHZVEI%"
MZ*9)FW]0_%4MNS ':GODSLY.(IR=DK4;$U-2>F -=\U66A(MO%%+?:Q,.<=E
M" TC#O(['9(QW8_1G //WYR^5/)\,4OGSS'%?:E?./1T'3IF_=QG=6$:$,^]
M*<_M'HN<<D_YR=TVQGOIO+OY>V2:0D"7,@N[B&WN@ 2)'EA"M( ?V:BI.P&=
M3T+\WK;SSI?U^?\ +N_.E;1S7%M +I8J@$GTUBC=:"AJ=\G.GZII)MX[WRQY
MJCN8G*H;)I@55CMPEMYV+J1\@?#)S;>8=1$1N[JTYPHO!I[5A=1;$@M^Z-0-
MO TP)%J8:>66&56#&JA6ZCWJ <D5MK,EPFSA0#0D;GZ<5>Y29/3+ED8?'ZFU
M13MG*O,=@]NTYLI/5!/-58;T'52>^%WE'7+8R"VG0<X6*QH^Q5N]!385Z9T*
M'3[*_>=[A&BGG^&(,28]S5ASD4;^%*Y*K/1-(B*32(QJ@#58#XQU Y;4]Z'#
M466EIU@._0*T8 'SKC)8[,-6.#=110\JD#Y4. VAB-2[1I[ &0_<*#,MK;,>
M;1O.>Q>B@?):'!?I,5WC=1[/M^K":_BC],^K$'IMR  8?,CKG-=?B=XF 8S1
M5/%J_$OL#_#/-7G*-HV9A0CE4,!0 C/&OE'1_4_.W6;N5I5CL+JZE&WP+2-9
M% -1]HC[L]TOJDEUHGINQ*R7,+@>%2.O3K3/*_YF2!O.>O$*/[Q*;]^(SGSN
M /B&_MVQ)G;<"H'7YXF6JH % #O7OB#4K1C7K2AQ*1>E3]V!69M^]#MX4QC$
M[U'RI@<D;EOLCQRJB@/W4_IB;&C4(QK?S #D<:3UZ>%/#,K5%.HZ9A6M*5*]
MJ8^,58\CZ:]N^62:+7DP)P0 H 2E1WS$TZ"@[XNFYKL#[X<Z%K$_E_6]&URR
M/^FZ)?6]_ >E);:194W_ -91GZDO\0Z;_AO_ !7ZC?H?]&_I;U*#E]6]'U^5
M*]>'OGBC_GX=YA_17Y(:;HL;#U?-'F6SMW6M*P6T5Q<L:=Z211_?GQ,+@4 H
M3L-\S+S'LO7V.4I.U-SBH5B"II7KCU+<>M2-OH]\>M IJOQ#;%T\>HQ79@*+
M0=QUQRN5(H*>^/)Y4!WX]#BHH-ZU^6.H6;>H4FGT8(H JA:MXD]CBG$\ "3R
M/?+C) K4EJ]<&QC;Y'?[L64*17EN.V."$H0#\3; ]P<YUYHLWL]9BN8HO46_
MCX2D4)JJ[U!(KT&<^U"*6VDTQA$G"TN)(U!4GQ<-VJ2C4/RPD\TZ)+)80ZI:
MI\=L7$LD5:<"*#\*?/.(ZM2*6*> <!"SJ5/4.I'4#/;WY"ZVEUIB:>[J9+<5
M!7N-BV_S.>U]!DI&M22-JTZY*M0026B,-RM=Z;_*F2OR_;<(+>,(/3 4-VJ,
MZ!9S\9%0?&RU7CW49O,OF^'RIHIN^'UJ^N95MK"V'VY)G/4[[*HW8^ SP?\
MG=^;.H:5;OY8\O7@USS_ *[<A)!:W$D%Y;,1_>L8ROPK6@4_"!GE3SUY*\U>
M3KE8K^6>V\U:Q:1:C=:S<R275W)ZM>,<+R$^FBG8D?$>YPXA\Z?E&WF_RM?W
MWY:>;-:MH?+4NF>:X[OS.T-SK&O.L?H:G;7$,+?5X(2K@0@+R#+4? >7N/\
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MOQ3_ "FV[]<2)H.0-/\ )S5VZT)!V&)U+'B3M\L53EU8$=M\%HU!0$T(WQZ
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MI]L4J37?(MJ<8-2B>G(!4%AW]CD9L;IY+B0;J3\)\/\ ,X90ZO?Z1<^K$Y:
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MGJ;S1]4A<CXNWU1:[>&Y[<8_YS/U0ZM_SDK^9,L9#K8RV%C&-B!]7T^TC<5
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M.15GL8;E6NKC4$<(\4D(E=BW(&M1[G.4>4O*EOK/F277;JT%O)>3K<2QK0I
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M^E3L*U W/7%3Z@V6AH-ZY7 @<F((RN-#RI0D]\?LQ .QKWQ;@5JM:UZ4QP!
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M3R8]O84ZUS,0H(I]'OB5.X'7;%%([@8B0*CL">GOBG&E0PW/3$R.M0?<XWB
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MIB1&Q;IXUP,XK4TH!]PQG '9=JCZ,2?DH%/L':H\<HT4BOPKXCK7YX@H*FM
M:XRI4\CN,3E0.P:@"]*8PA:<2  -OF,#M2O$46F)M2AIN5\<09OAK2F([TH6
MZCOB)*B@)/3MTP(U*TIMB?!34T/$XWTB&&X([#&L *$$&IIC?3K6G;<DXGQI
M7]HG?+8$= "/'$Z&M:5WV)RC6NX)88X 5-14=<MU0"I.[=-L^E'_ #[4\EG4
M/S!\]^>;B+G!Y7T6+3("PV%SJDW/FA\5BLW4^S[]1GV7S9\O/^?CWDPFV_+K
M\Q((12&2X\NW\O>D@-W9CZ.%Q]^?+,, >(K4'L,OX>5'W\/GB@%37KBJ$"B[
M48TIBICV(I2G?'HH7B*=>M!^O'&,[[U/ABJ@J% 7PV[ 8*&R[;D[''T6FQ'R
M';+4 J#6O@,P!W( V[>^.7D&Y,=B.G],4^$G<5'7Y8]6H:'=3T]L6C"J6XUJ
M<$JZ$"@ )Q=6*_%7KU/;Y8NG+8U '4XYC4D4^6/Y5V*UKVS<C0\OA V![4SM
MGY6?DWK/GVXBO+N.33/+*L"]RX*O<4ZK#7M_E?=GT3\L^4-%\L:;;:9I-FEK
M:VB!411]Y/N>YR4BUC6OPU/7,T%*D=^HSBOYV:,]YY,N+A%+?HZ[M;P4ITAF
M1C6OM7.%W.C#](6EPB%HW7TP1]XR<64#1@5%5I0;5I3Q&2.UM5I^Z3[1J0V]
M/EBTUHH:C)1N@&(M9DEJQ_J_'"2YTY7)#J'[ @4!'7?(Y=:4%8L(@R]''2H[
M&F%-YH;W$=;:7T_%#2OS%<Y;YA\J7+QR")6:=SP[G[74FG;)7Y+_ "PBMK2-
MKF$-(U*L1^KKG7=/\GQ6R!$B5:[+3I[ Y(H/*RA$>6)1(=Z8+.B"*A2(**FO
M%:$G"J[MI859"H6HVJ*'Z,Y?K.EB[O(9".31O7OV[8CYC$-GH]Q)]DI&>I]L
M\47A9YYW;X><C,2.]3A=MR/7B#W[XE+0;]0=ML34%OA(HE:U(Q.0*:A10?3B
M1567B*A5VV.,(;A0BH'B,2H1T-5.!RJUH*]._P##&/MQ;J0=P/#$VJ3R*[#$
M7I0$BO4G Y+,:=,2D&QWJ?XX&-&Z=?ZXCW"@TIXXB]>1"GIT^G&!: <@3C&/
M4G8#&*-O8],MOA#&IQ*M=QV['$VJ=JD900[4/7Q\<>X;8BIVQIK3D=@3T&.(
M!"\?BXG;Y'/N]_S@#Y(/E;\A;77;F#T[[SYJMWJQ+"C_ %:$BSMU/L?J[.OL
M^>WLV>?O^<H_(A_,+\C?/FC00&?4M/LOTSIX45?ZQII^L<4%#4NB/'3_ "L_
M/HJ;'NU:4&V7T\.=<>=N@K7MF7<C;:NU<77DQ/CW Q52>55/;IBNZG?KXXLG
MQ=10^&"!OLQI0[?/-5=P1L0:>'S.. 5:,=MJ ]L:#3>O7<8N OVOUC'4^'<;
MGI7MCD50I)/T>&*(0%/<CI[X*4JW04'?Z,7'4*M*$;[?JQ:O'I\0\/ZY8):@
M'ACTYRR)&@YRR$*B1@LS$F@ 4;DG/4/Y7_D7<WSVVO><K1D@JKV^ED?:WJ#<
M=/\ @/OSV_I-K%9V\4"+'#'$ JQQ*%0*O0 #;MVR5121D?S;5KVV[8/4@@4(
MH.N.V(H-J'?;(UYPTS]*>7M7LV^+U[:0  =:@YYOL;-+S2K<&@>) E>X9=A^
M(PWL;-I0"5HRO^\6IV88?)"$(/"B@T!]^V'?H0RQJ'I0]?8COO7"^6QD 8HP
M=:].IV\-QA5<VC-M$P9MVX-L0!U'7"GZN9>?[++7KX=Q@6"R##C*E#4T![_+
M-<:3"RD-"H:M1XU'ODLTV )#& @'PT/@*>PP[MXHE!5I>3$D_$.GL,&^K$IX
M*0!L">XQ5DB,1+/R7L/]O(3K$B- TBOLP-*^&0BW199&)4$*2!X YSO\S[VW
MM=':,5YW+"(!=JU/;QSR'>6\BM-(L+< [>HRJ2H)\3A20FW&A!VKB9/<C<'I
M3[L83ON>O?PQ%E(#5(.^QQ 5IO6G>G?*+;<0.N^),"1R-!Q[COB+)0T84)%=
M_#$&4\6;; YWH2>E-AC6(*L>.YP,U&WY4XX'8GJ^Q/08B"JDU&_MC&4%B2*8
MAL#6GM3*"_":FH.X&)2*3Q\!U%,;Q<BM*U\<1:M*$5+=LW*@(XTVKC&7V (R
M@N]"QXCICBA+=_8=LW$T(-*TP?HFDWVN:KIFB:;#]8U/6+N"QM(@?[R>XD6*
M-?I9@,_4+Y+\L67DGRAY7\GZ< +'RQI5II<) IR6UA2+F?$MQJ3W)KDFS93*
MK*58!E84(.X(/4$9^<S\Z?(+_EC^:OG;R45*6FE:E(; ^-C< 7%H:T%3Z,J@
M^]<Y>..YZ-7J<<%)!(H? YC&M!\5#WIE"BU!Z@T.V+; J5 VQ9>A4@_%TKBR
M@"G=@*"F*,2% IOM3VKBI  7?X@.F;>H_:4>/3'*RL>+;@8ZK$'>M.A..1F(
MVZ?9&*(*DCH /EBBD*VP-.Y]L6^S\74#MBZ.#0 ;]NU,%V\%Q=SK:VEN]U<2
M?9CA4NQ]P!G>?)OY"^8M;6.]UPG3;0D'ZLI D=?>4U ]PH)SU!Y6_*_RSY8-
ME/;Z=$L]G<+(LJH.14"C$NW-R17K4?+/0*:;$@5U6M=P1X>-<MK2FX- -MM_
MPIB7"6)OLDT\>P."5N;A?M(VPJ**:4[>^"8KR:H_<GK\\%F5Y5D26,\64@CJ
M-\\QZ8K:=YF\W>6)U"RZ7J'K6Z]0]K>*)HF'@-V'T9+8K98F,JK1Y#\:?S4V
MIAA3X5X1MP/VZ;E:_=@ZW0-&7(VWY*U:&G3QQZ(O%F:+E7J._CTP#=VL,T?&
M6,!VW1EJ*$;COA;^CB@<2QD\OV_; 45AQ8\29(>0IWH/ '!$UFW$"G(#\/G@
MBS]2-54GH=C3K\\'F8EN=/HZ5IVI@.6XE9O@%2>H8=/84P'+>7$<96I#=@#L
M?HR,WS3RQ2,P)<UZX1:7&X6;U)2'Y4('AXBNV<1_-)N4UJJEI$5S0$_JR/>0
M+..?3]=5662:WGCG>%AR#V[ J^Q\",DFK?EQH&LQ-/#;?H^[E *W%LH )\6C
MV4_(9PCS3Y'UWRS*SW,(N]/Y42Z@!9?DX_9.08NC5K4[8C(2#PV"_?C/A- 3
M3;IX8FVQ^(FGOX8DY[K]D[TQ)CTVJ>QQ FH--R=CB+T%>/51^.($'B/$;T.,
M*ANM*G$7 Y;@;=,#2*36NX[4Q/D>A[>/?**4J:@\NQZXUT! J2'&(."*T%2?
MP^>8U Y []#C"-CR\=R/&N).H6FU6/CX8PA:$D;CPQ$+L-J=S[8X E>0.XVZ
MX[@:5.Y/;VSV-_S@M^7?^-_S\T/4KF 2Z3Y!MYO,-QR&QN(2L5F ?YA/*L@_
MU#GWSS9LV?+'_GXA^70BO?)GYI6<%([Q6\O:HZ[#U8P]Q9,=]RR>JI-/V5&?
M,LD%ZD=.W\<4+<0%V4=?GB=#6IV!\,51*UI\5.N.'PTJ<7!Y@5-?#'J"H^%A
MR!^>*\>=#RV_CCR&ZBFP[>'OB:\F%-QO6F**"5)!WK0XX [D&H Z5QZUJ*GC
MTQZ[5ZFOC@E2P%#W[D88:?INH:O=+9Z58SZC<M0+%;H7;W)IT'SST5Y1_P"<
M<]<N4M]0\Z7P\NV4M&6T2LEVZGK0 ?J'TYZJ\H_EKY3\MHB^7]#C0[![FY^.
M5B?VB"6W]S7.JV6B.S++-1B/A4D[T'2G],D2Z-:F/TVC 5A3_.F#K&W98S:2
M-5[;X5;N4_9)_5AEZ"(OPK4D[]\:8$H#Q&-%LA.PH0>HKO@A+5*UX_$>F9[=
MD&VP[YYE_,^)M'_,71-7MP5_2VF&"4C;D;22M/\ @),F$:QW-O$P)XL@8,-M
M_'%8T56*244J-NP)]^^+1D*3Q  9B#3H33Y=<3E 9@.6XW [;>]<3Y%^(96#
M@&E=P/E7,68K20#@":$;_A3 \8X-\"#B?#'BF[=233IC51"02M"&Z#?I@P1P
MT)XFIKQ;NOM@18XPU0@/*JUH:==\3N(X]AZ2G<=N_P!&$M_;(B.&8'U:FA]A
MT'MG/S,8C(I Z'>OQ$'H2/:F<!_,%TGO(2-T !!/COVKG.-(\Q1^5/,FEZG>
M7$=KIUS.=.GEE!]-6GH(O4;H$+T5CVKGJ73RD3(J"EI<$L@8U])ZT:)O=3DB
MDTBWO(7B:+U$<4;DHXFO;<9POS7^3.G:G)<'2)!H^M_$ZQL/]&N%ZUXC[)\2
M,\U:WY9U_P O3M#JVES6IC8@2 <XS3P=:C[\C?+<4-5/?&JS-5B3M7Y8@P8'
M9J@?J.,<F@XUH.N)@G<G?EN2?X8@YZT-?;$Z<@!Q/S&WWXF: 4/4'IX#$W59
M&!Z'KB34WI\/;_:Q,1"HY&HKW[XFRE3UH5[Y7[/(KR(-:XDP JW'9M\1%16@
MV;Q.-(7E6G]*XUSUJ: >.($@@"E>.WS.)MR)&WOMCH@3RY+3P&.'7<?9Z>!S
M[>?\^]?RX/E;\H]0\\WD'IZE^8]^9HB11OT=IQDM[<'<G>4S-VJ"I\#GOK-F
MS9R?\\?R[C_-/\K/./DOTT>_U&R:;36?;AJ%L1-:GEV!D0*Q_E)&?G6F@E@F
MEAN$:*:)VCDB<<61E)!5@>A!'3+!7J=R._ME5-1QZ'QQ0$ 'B=^I[4IBJJ&W
MJ3WKBB@]-J]\<0=FZ=JCO\L4%: @4KO7'DU%.1'ZQEK0"FY!/?%2BU8T^&F8
M4)''MXC%$5F!KVZ9)O+GE7S%YKNA9^7-(N-5F#!7,0_=H3M^\D:BC[\]2>3_
M /G%S]Y;W/Y@>8X;(,.3:3I[\Y^M KN 3]P'SSUOY7\D^3_)EAZ.@Z5;Z2J+
M_>N ;AC_ #5-=SXU)P9INFQW]Q/?S)ZSL3Q,E=@#0U\?EDRM+6(] -OY13;V
M.'\42(M56M!OTQQ7H*5KO\L#<?1N(IC7B:Q-0[;[J?O&&0-5J"5!V'OCPA-=
M^5*5R^(W)X@_PRA,$^(_%7;%_7B;:O%J5H<X3^>]M;V_EO2_-4A"Q^6-3@>9
M@":6UVPMY"U*[*SJ<":-*(X8XY>(A850_LJ>P]AX8?R012J&)+%35:$;'M45
MZ8@#0$ @@'H=@3_7&NJ%E /P[GQ 8>.:E20"01TH=\0D%&\:CY8@I/Q;]-_D
M,I#\+$=^GS]L<H*@#<'N>IP02!%6@/$;#^N(A2RBGQ,!4#H*_,UR_3+-\6P[
M@'\*X67=O&XY*!S564,0.7B17.8ZJ0@E" $T)!Z&ISSSY@C:XU!W9J-#L!V'
MT9R#S9HT&N:-KNBW<330W\95XXV*>HHW8<MR*C)I_P XZ?F7-K,>J_EKYKO5
MN/-7DQ(@;D'DNHZ0?@LM2B8_;9%'IST[K7QSVA8I- 0DE6( /(4H5[$=B,6U
M72X[^!90QCGB(:.5-F0_/N#WR&>E::U+)IM]!'!JT2D&.0!H[A#MR6H^):=>
MXSF7F#\E?*.LW!>*VDT6])HXMFX([>)6A%/<#.3^8OR \Q6"//H5RFI15)6W
MGI'*U.RR+\!/SIG"[_3M1TJ:6#5-.N-/E@8HZW$;1GD-CN10_0<+20I4$U!'
MS.-)!J :>'SQ,*!7?<;],8S&FWTXB=@32I&YQ%P*U/?PVQ)AV/;;;&L:45@:
M4\,;4-4G>HV[C$U#=*T/X8W</1MUI@68$'8;=^V8#X13H/QQ%D#$@["M<2<<
M:@UI[90V)'?I3++\:#N<E?D?RAJ?G[SAY8\F:,A.I^9M1M]/A/$N(_6<*TK
M?LQJ2S'LH)S]-_EGR]IGE+RYH/E;1H?0TGRYI]MIMG&=R(+6)8HZGN:**GN<
M/,V;-FSX<_\ .:/Y5C\O?S@O]:LH/3\O_F&)-:M   J798"_B[=)6$G382 9
MY#/Q4!/PD]!BH4+2AIQZ>^4_&E5V)ZC+2H)I4>Q[XH'-00*4I[XJ).1IN37Z
M!BR!CQ'0],5JM0#N>U<< O3I7H>V85:J\J@9(_+7EC7_ #5=FS\O:9+J3Q$"
M:91QMX0>\TS411\S7VSUUY"_YQGT>.:UN?/&K?IBX8+)^C[$-#:"NX5IVXM+
M7V &>GVTW1M"LK3RYY6TZVTH3?"%LE$;QKT)Y*!O38Y)K;08;=(H44+<* '<
M[L3XL>_7O@R]T\1VW!G5I''$;5-3\P33#FPM!;6<:K0%12@\?IQ>/IT-1M[?
M=AK$]0!U7PKVP1Q&YK]QI7$)X1(CJ">5*@CQ&X_''6X:6-)#6K ,0>E>AIM@
MU%/C3L-ZX^GP^![C$S%7;IRWIB;0(-NW&F_]N1GS1Y?M?,OEW7/+EZOJV.NV
M,]A,A-*K,A6M1N""001TSR/^37F349]&B\K>9^?Z;T!I-.:[(*K<+;.T2E@S
M/20<*,"2>C=&ST!&Q2-7%)8BI'(;$4[?1ENRRJ"6'Q>(WIC5-#X<33KN1[YB
M4))4UJ:T(VQ*0!@P*[D=:; ^V%S\@NQ(Y&G3\,6!XQA.XRN=./;H!XXO4&@*
MFHZ^&*<J;*#R\<8[ 5>N]*&E<)M1E0*26Z"M*YS36'HTBCJPV'T9Q+4X.!N)
MV%7=CG*-6+V\S-Q $J,V_2@'3/,_GW1=?\AII/YU>49I$U[R'-^EIXZ&1)--
MN9E2\MGVJ8_C#@$T7X@!OGU@_)WSGY>_,KRAH7F;0;A;C0_,$"O 1\1M+HK6
M6UDW-!RKP]LZM-IJP<D*EG';M7Y=,A?F#RRE\GUB)6BFB(DC>+X9(V'=2-\C
MD5U<12P6NL1AI%'%+OH"I_WY[_ADCMR;7BE%>)FJ%Z@*>O7IBVI>7=-U*%I3
M8PZA"5K);2JK CVY YR77O\ G';R'YJCDGT>*7RWJ W,EB %4]?WELQX'YCC
MG"M<_P"<7O/.FJ\NF:GINLH-T5R]HS^P9PR5]B1G!/,GE?S-Y0N5M/,^@WN@
MS.?W9NHBL4GNDHJC ]J-D<>@4D[^&)DKQIWZ&N!V#'GR[4V&)A2M=^O3&@[&
MIHP!Z>V(\Q7D-C[8FSBI !W[GIC3RZ$['&\AX5 Q-@3VV)QHHI"@\N.)$U)H
M*G*91N30,? XSTV!)J!05\:Y],/^?<WY4G5_-/F+\W-3M^5AY4C;1M&9A\+:
MC=1@W,B&O6*W<*0?]_>V?87-FS9LV>8?^<MORH;\U/RAU>/3;47'F?RD3K>D
M<5K)(8$/UBW6FY]6'D O=PGAGP77FPJJUIM3%%KRY=:#?'H Q+-2C;U&*$+Q
M)!-?U#'@T7V[X]5)2I&Q]^V+H2"!0>%<<Z@BI-*=NF3'RQY$\V^:QST?2))+
M3DJM>3_N+45Z<9'IS/L@;/4'DO\ YQ]\HZ21>>?KN\\R748Y#3[-7M;&H V9
MU/JR4Z$549ZK\H^4HH[>&:32K;2-)MMM/TZ!!''!%V/%:58^)J??.@7%A9LO
M[U^"!=QU(KX'QP-I&D6RW9O5A*+&I6,M0%O<]\/(HB\C./LUH-CL1BB6AFGY
MRJ:)]D?QP>T=!Q6@'0$#$ AK3?O2I\,$J.)]^H![X+0@[!:]:>'T8(1*T!WK
MUQL<;QO-'O\ :Y*>W%NPWWW&"DC9Z  M4GL<%"W9=FHAZT) KF/H"G[T-X!
M6/W@8@X0@LJ2M_L0*GZ3A5=51"PBD5E/<*:CY5SQ#KGES3--_,[S:3<2:6NK
M72ZHESPY>A>2Q(J3JI((4\>,E#3CU!SJ^A:WZI2QU-9+74 H$T3@@>H/LR+O
M0JXHPR9-$KT+ \E/?8D'$BO!AZ:;4WJ.F.5JBH-3\\28<B&-58=AEJ(C\1[=
MV.P^5,3D4$]#XTI2F F_O*FE(]A3QRBS<BQ)KT&W;QQ"XNFC4\#O7M@"2[N6
M0*&H/;YX477J.55V)J<CFI6I E=MV84%>PSE.M6C48 =>M,XYY@M))[&5XT,
MCVK,'X5J$.Q(IOMFTBTM=2#1JJ7D$FBWE%=0PEX(JA64HZTZ@U&_B.N%/Y'-
M:_D3YZ>+2Y6;\H_/TZP:GH[?9T/47;X)[9R=H&9MP?L&E/A.?5=+%]2L@8_3
MN98HP5E5^(GB/V)10-U[X1'3KJVE"-%S=MS4T_6,(=5\OVEX).5OP1MFX]0:
M=:?/(S86B6BFSD</*C$*&7JE>M>^2"."2T?G$:AA4QC;Z5Q=[5VXWMB0)@"?
MA(^,=U;#C3;^TO\ U(;B)(Y /WL1[^]#M@;5O+,5U936<5K:ZKI-QO/I>H(L
M]NZFM>',-Q/AGG#S1_SC)^6WF=Y)-"6\\A:K0L88"9K<L>H$4I*TK_*1GF3S
MC_SC3^97EAI9K*U@\V:?%6DNGGC-Q!VY02$&M.RDYP.]L[FQN7M;ZVFLKM">
M4-Q&T3BG^2X!PM=: ;]_'$F8E>)'Q$]L0>JL.A!'TXRI7X:4IOOEUJV_0C<U
MZ8F&)KT.V-YUV!.-8D;* #C*D5ILP'AC * L3\6Q.#=-TV_UG4+#1],MI+[4
M]5N8K.SMH162:>=Q''&@[EF8 9^E'\D?RRL_R@_*_P I^0K7TY+G2;0/J-Q&
M*"XU"<^K=2U.Y!D8A:[A0H[9U;-FS9LV;/A%_P Y=?D[_P JE_-2_N=+M?J_
ME+SIZFKZ056D44C-_I=H.@_=2,"H'1'3/+2$UJ'Y#OMB@!+$%?A&^V.-" !6
MM1\L>J[[J=_#O\\4Y@? 6')C15&Y;V &^='\N?E5^8/FI4DTGRY-';R$".:^
M_P!%1J]T#CFP^2Y[*_+'_G$NQM1;:OYSD&I7J?$+21?]'0]OW==_]D3\L]6V
M/Y;>7[ 1&WL?WT("H[&H4?RHO11\AAC)Y7M(G20P"3TGYA>JACM6@P4V_P (
M7BRY2Z?Z[@RH2M:T;I7PV]\-6B6.(I0*!T%!CK:+VJ2*[],'^D$7V8;DX$=:
MD[T/ZOEB'!00:[^.*@'CN.(IO[8Y'XJM:C?PVP>C @$"I[G!"JW-70JI52 2
M :@]M\%KR/VY&;L 6H/^%H,4CCB6E$4D>.*$BAZ4[8VH(ZB@P%<KS!!'O7/(
M'YSZ<MKYML;X?WE_8\ M*<O3>AKX[-TPML4-S8V]TDW^YC2D!>,QJ'N[52.,
M@G+*>4 K52-T I4YU?3[Z&ZM(IF8-4 D<@RTI6H8'\<6V=F9OVC\)K6@^>;@
MJEF'P@>)%/HQU :!C1NV.$- *@<5Z;[>^V-D7^6I#=>/0#W.!)(A4J:TC%68
M?J.(TX"H;XF%=_ ] ,+YU##92 QI7ITQ-U5 H^S3QZX "B1]Q0#QPJU:$%6D
MILH_'.7:E#S62BU!J/EG*QZ-G)?AXUE8DQ%6[E^WXY6A:!>Z7YDB0Q+^A!IU
M[ DL?Q&.L3,0>%#0D'<$;=33(KK6B-=Z5>0K;![&\C*7*C?X&!'):9/?^<3_
M /G(VZL?,0_(G\R-1/Z4@D>/R;K=X^]U&!MI]RSTJU!\#'[73KGT7U*!I$6Z
MC0K4\)$/56'4'(]-$[(W$!R.H) _SVR$ZK8\)8Y%!$O+DC ;!AV\,%V4HG15
M<4D ^,(*$&NY&#5!M[@&.,)&?MKV8>(VVIWQ]_I2W*I>6;>E.NZ4-/H([C%]
M.U1Q2"=>,B4!(( VVWKAU):V]W1V4,Y%108UK$JH4[J1T/49SGSO^6'E/SM8
MRVNOZ/;WRE2$FXA9XB>ACE4!E(/3?/FQ^;7Y):[^6UU->VWJZOY49CZ5_P *
MR0?Y%PJUH!V<;'O3.$D\B"?[,28DDJ*8PN5'B>_?&#>M=AUKB%3O047VR]P=
MP1E-RV(H!]V-"U!(.]-SE5I0=SVSZ&?\^^/R</FWS[?_ )J:S:%]"\@?N=,]
M1:I-K%PA 85J#]7B8L?!GC8=,^T^;-FS9LV;//W_ #DK^3L'YS_ECJFA6\*'
MS/I%=3T"5J*1>0J?W);;X9D)0U- 2K?LC/@MIV@ZUJ.J2:)IFD7=_J\4AA>Q
M@A=IHY%/%ED6GP$$4/*E,])>4/\ G%CS5J9AG\W:W;>6():,;*T7Z[?(/\LU
M6&,TZ59OEG8[3_G$;R4Y2NKZ_,$-&<S0J[=]D2&@R86G_.(OY;EHV>#5I5%*
M^K?-1O$$(JYVSRU^47D'R?'''H/E;3[*:-0#/Z(DF8C]HROS:OTYTJRTRUBD
M20P+ZRB@;8L!DBB0"FY_4-L$<001QJ0=AB#P@U)V([#"V6T3D74?%3\,4"!0
MHHI/08DZU85WZ#KBT2T( WK@@J*5VIX=<#\#U ZU/OE>EM0K_G[XJL-5Z5'^
M?CB#P%#R'C3QQ9 -ZJ=O?!JUHM-@1M7% "-]L>&WV-"=\5#G<UKE5I6O3KB4
MF]>X[9YM_/JR(M=!U:,<9(;F2$'WD4%0?:JY!?+4;36]O<2.3/;CDAI0JQ/X
MBG;PR66-B\.I3S:9<-%'=U$EG(J<?K9JWI(%-!R6K)MO]GKAK;2B541X^0:I
MJ 5XFO9?;#)3OQ)Y=R222*#%]J4.S8H@K\-"3[]\=Q4*>5 J[T\2, .*+N01
M(U2._COA<QK5B"Y)/R^6!RW)_BJ[)0C:@'L!C)$Y'D5^(]/ZXV" *S-2K5V]
M\+M83E"5/0G?WSFVI6P1":?8:I^G.-:Y:2)J**"K132?%7MDOTBW2V2TTJ27
MG$;.7^6A"0$D'F5%2WC7Y'"^;RVT,<;:?<JBW !>U?>-=CM4_$*YYQ_-?\G7
MUE!J"V4]GJ=NPGM+^P9CZ4J$,E2OQ*014&FQSW'_ ,XF_GEJ/YD^7[WR#^8%
MS7\SO)=NJ7DLR^DVK:;R].&^1:"LD>RS4ZU#=\]*7<;V\IAD'(I]Q7QPEN;9
M9U(8D=30;_CX9&(2UG.ZDE>+!=AN?#) ?WBI+7U!L&!(!'W8=6H$B^F=@0#7
M"G4;!H']1?LC[1I4&OOAGITVR[B@K4]!L/#)$$YH"10^.%\UM\+&E0>W3(=J
M^E6U]%)!<Q>K%*A1E8 JP.Q!!K4&N>$OS<_YQI]%;G7OR_A6,H"\^C<JK)U)
M-L?V6_R":>%,\42Q21220RQ-#+"[1R1N"KHZ[%6!Z$' ^^].@-*Y?:A(IT/O
MB'?VKVRR :T)Z]\3<4KMNF-0DK6H--Z=\./+?E_5_-NOZ-Y8T"T>^UK7[V&Q
MLH%ZO-.X1 3V%34D[ ;G;/TG?D[^66D_E!^7/EGR%I)64:/; WMT!0W=]+^\
MNK@UW^.1CQ!^RO%>V=-S9LV;-FS9LXIYG_+?RW;7UUJNG:%8Z?\ IF=[B^GM
M+:.&:2Z<\FED>-5+%SN2Q.]?'(C+H%O9,!R6196 4A0IJ>@8#;Z<$Q1B#X$0
M4K0#H!_3#2*->K&I.+BW4;@4).WAO@A8.-/@H:>%/ZXMQ(.XK3P_KCT/RW]^
MGRS$; [].HP'-U%*4Z5.U#@8]QW'OC@%-""0?#%T6@- IKCF!X[5-.W3$EW/
MC7KX8K&%^+Y=,51-S04\?[!BAB!_SVQJ0COW&"%C 4"NWC[X_P!,@4/7Q]\8
M4IXTZT\<PZ;C:N/H>M=]L:VWSSF7YIZ*FL>3M7C](R/:JEVBJ-^4+!]OH&<
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M2<1,A8$\.A[]SE>)I4]\^KW_ #[V_(=X!=_GGYELRK3+-IWE2*5:$*:QWE^
M1WWAC->GJ[;J<^JN;-FS9LV;-FQ&X@CNH);>8<HY5*G^HSCNK:?):W$]E,HH
MOV2*_$IZ,/#"58G4,64\DH&!.U.Q P?&2*5H*]>F#D2M/ =,5(%0"34]^V45
M'2OTY7'>IZ=JY5"*KN13 DJ@\@>P[]<#!?';?% -@3] IBJ@BE!\(QK&O0=_
M\^N4O4'I3% *$D#?K4XL/?<=C7%UZ'OBBJ"/GBP4;5&/H,Q44WV\,1X#J<I
M.Q->V/* #L:X5:E9K=6UQ;,/@N(GC/R<$?QSP'HHUC3;W4;&.-6^IW,L4RU+
M&B2$;5W[>.=#MO,EK#&XO(KF,$4(:)BIIUX\:[^&1^3SQH=I=2VC3QWFD7;
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MY^./[BHS4[CIX5S-X]:#&4%?"OAE@4V)'3;$94J#0#YYY"U;1_J_GWS)!'$
M/K0F!Z I,H;;Z3@ZYT]70U3?>M10@CIM_'(?J&@032AEC F/2H_#IBNBS/I"
MW-K,)&TZY8&\M"2(W!(JP"[C[(K3PR;17AMKCZA)Q,2*EQ;2FA$L,FZ.K#J"
M/I\1D@M)HG8*$X\S\ :M-^]<5F522-UJ1L/[<(I9/0>M:_%4D=,#W1#QEXSM
M_G7!>GT=>E:"E#T-<D$$(1%8[C]6*W2J8J]#3K7"ZVC4$D#[7M4X%U52+>0
M<O"@Z^V>>O/6G1W6FWD3HS;JW%?M$D[@>^%FE1LFFVA7TVA8O&?6X \6*CB
M_1O"@KX9.S'-&T<BR\?AV %.@VH#7+=U+#U)-FV)(_9 [C'&)742AR H^'V'
MCG+OS U"]TBTM?-&CL1K7E2\AU>U(JN]JW)XSX!TY+].>Z;#6=*\]^3_ "_Y
MNT.<7&D:]8PWMK(M"#%.@< D=2*D'W&0=V*^K ]"$)%.AKXXHB%D1Z[C[0K7
M[L.[!E>A6M%V(/WU'ODCM@0I&W&G7QPJU:*C)*!0J01XCWPPL7#(K#)# ?A
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MK4CKXX/T\A)2M2#3>OO3);;LKT(-2!U[>^;48?4@--^(^G;I@32GYQE:5,9
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MG9E1O\'3N*]3OG-+;3;.ZU2\T2^A$VFZ_;2V-Q&PJC"12-P=N^<4_P"<;_\
MG"JZO/S,UOS'^85F9/('DG5'CTBVF IK<T;!XBR[U@B!'/L[CAN X'U^
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MC?(1Y?TU-!_2GEM2?JUE.TUHI[6]Q\:CZ'##.3><K0V&MI=BBK<U0TVW7??
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M825 (WZ[=\Z+Y;T'5M?E5=.LVE16'J2'X(D-/VF.WT=? 9Z \O>0[#2ECGU
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MR4_F!'\,18;5R)ZPA2\C<@\94Z^XR1:'=.%B"D@J?M#K]/CG1K:<RQJ3\1H
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@?ABF;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>sny-20231231_g22.jpg
<TEXT>
begin 644 sny-20231231_g22.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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MME'8_,_JRJ>^54U--@,QJ3TH/#OC>)/>GO\ PRB#0DG&9O$>.*JI \*_3E@
M?PS5J"1OEBOMEY1/WXDRU.VU,9N.O7%,=E$9JTZ9L81\6.XXPBG3?)AY2_,+
MSKY$G,_E7S%=Z0';E) C"2VE:E*R6\@>)C3H2I([9[#\B?\ .8-G.T-C^8FB
M?49&(7]*:0&DAW( ,ML[%U %22C.3V3/7WESS3Y=\W:<FJ^6=9M=9L&H#);.
M&*,0&X2)LR-0[JP!]L/\V;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-GG
M/\RO^<DO)?DGZQIFB.OFWS%'53#:2#ZI ^P_?7(Y D5-53D:@JW#/!_GS\V/
M/'YC3L?,6KL-.#!HM+M*PV,96I4B(,>1%31G+-VY4SFY.W3&*V_MCO?H,W:E
M,I13?KCZ95/$9NG;*Z_1F.],NG?IFIC2!0@#&>)[YC3J-J;5_'&ENX/7QS5V
M^(_TRP#TH ,WA4>V6?H&-J21V\*YF%>NXVR]_&OSQ_X8T@_1X8VA WWVQA'M
MEC;+S96;,>F8"F8BH]\9E>/AAWH'F37O*VHQ:OY=U>YT?48MA-:R%"RU#<'
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M27]JU!-$?AN+:0]8IXCNC"GR/525(.2_-FS9LV;-FS9LV;-FS9LV;-FS9LV
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M0GB6X:[MMN,L=TI59P/AJZ,"?VZML.:6;R6US!/9W$AFAD!_T=FCFJK AXV
M!V(!'<'MMGU1_P"<:OSPE\[V6E:/YDN/K>L6[FT^OS%4>1HH:IZD8/PDKT:I
M!)/2A&>U,KK[C*IN!U]\U >G?&T VI[$Y5.M-@3C:$8W-[XT]/GE95-O&F8
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MD*MV+ 4ZY&]*\X>?O,OF2TT35OR^T'5XEBDE]?5-0#:F[M]E7-G"#'5:D_"
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M.#3X>/#8^YRK4:;;6]W8Q6C/ZI6:WG$##TV2H8%!RJKJ:;]" <C]WJ4D$8D
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M/'$(6:JLA-5J/]7":>WC7UH25X1HU6(KOUV&Q)(PK]/X)H5BY1VW4]#Q<U(
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M8!8+02Q,DI ^%EKM\.TCN-*CUZ+S+>V4@M?.-K:6R2RPS"2"XME9TM+J-&Y
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MH)J.C6,RLQ<1A) QJW-/A;\5.'_RROX96_SRC]V5FS97?*H*^)QV4?ORSE4
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MFE+B6[40R/&?BJZ U4D^)KXX)N-%2.V(AMUU.ZNVC7C /WHH*R*K<^A.W*H
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MN>[,L?PCB1N3^O([<J@XDT>XCAYAZBJHU14D^*G?(D7LN$LRRJ3)('X#XY5
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ME[>^6017TD+13I:6\0D9=R%9E*$,0NQJ3C[J^EO)I)9!?WD:NI>?4IRT)DJ
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M[:*RVNM6-O?PAOM".YC650?>C8:9L\0?\YA>9-_)_E"&8_[NUB[BIM_RSVK
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M2(+=IE$4:JW&0JW)B12I ;D>O6F^(_4K977U!);^BJLZ<ECV<L 2P(VK3M7
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M0M1^!R/WEFWU>7TV,\YN.$?'BB,&%2VP[=?]K(/J=MPAGEKZ8N>+,L:_%R4
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MAVUU?6S6]K,DU_;N46)J+56W5PX!H"IHU.^;7O+J3:?)96]O=V]W9DH\+O\
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M*QZEH4BI++#797M9&!]SN<X+YH\LZKYOU\VD7DG5-2T[4#Z>HZM>7,%N5M2
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M>9W;P\,]"_G9%>W%CY;T.22<IJ#F3T(3SCFMKL(TWH%:T ,:(*&E#D$_+?\
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MPVMV$4F")VJRJ&7<5(\#G;- U>R:+3M5@@^JR:E:Q27/**B+*&,<J@;F@=6
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M?/?D[7(I5L]'UM]3TUI%9$$-]M-&H;JH)+"A[G#>XC#P75GZAD2-I%68,-R
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MVW3-W_5E;?CE[=A2O8Y@*[9L8>N_7IFW.W88W+_CCT4R.L:(7=R%50*DD[
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M;>:6VFCK2DB20JU*[BJG8D9PW7M#U/RUK>K>7M9MC9ZMHEW-97<)WX30.4<
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M6&V/<]<W,>P]ZXQWI7<;=@<]2?\ .*GY?_XG\XS><-0M^>C>3N+0<UJLNHR
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MTU+ZWE#ZQ!Q6<R.%FAFKQ9%6E&%.A(WSKGEOS3=I]7(*\+F-Y4D6,1EH@X#
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M1&ZOH65_KS1ZQ"#S>.8.R-R'V P9>VY'C3!"W"I)#-!:K';VH+(L!#1LJ@*
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M-FS9LV&.D:1JFOZKIFA:'IUQJ^M:U=0V-A8VD;37%S<W#K'##%&@+,[NP55
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M0:A*8 2M"@WH-MCN:?3GR4_Y^%?G.OIZ9^2NC7,C2S&WUGS#(CC@(@"UE9L
M222W[YP:4I$16II\J\V;-FS9LV;-FS9LV;/T3_\ /J'_ )P>D\M6>G?\Y2?F
MMHYCUW6+7G^7VDW<=&L[*X4AM:E1A7U)XVI;5V$3&3?U(RGW5S9LV;-FS9LV
M;-FS8G+%%/%+!/$DT$R-')'(H9'1A1E934$$'<9\@O\ G)__ )QYG_*S5Y/-
MOE:V>;\O=:N"0B*6.DW$AK]7D(']RQ/[EC_J-\05G\A^H21M]Q\,>&J2#MVH
M<HNU#4=*YN?45KQ&_P##?'"0?:J3C"ZTI7WV[8'N[ZTT^UN;[4;N#3[*R4R3
MW-S(L,$:#<L\CD*!\SGE?S__ ,Y6^6-!DGT_R/9?XLU%"R&]G+PZ;&PJ/@ X
MRS4([<%(W5SGC#SO^:7GG\PIV?S-KLUS9\R\6GP_N+*+<E0D"44E:T#-5O%C
MG/LV;-FS9LV;-FS9]^/^?:?FJ77_ /G'V?R_.$4^2O,VH:?" :DV]VD.H*S"
MAZRW,HZ'I]WT(U728M4LF@GC]?U%(4$5-#L0IKRI_JL?EGPO_P"<V?\ G&;5
M?(VOW/YP^1;$PZ;]86YUR&T%)+2ZY\EU!%51LS4]78$-1SRY.RQ+R/\ F59^
M<-'L]7:YCMM7T[@M_:#BH$Y #D(QJ$DI4&OMU!ST?;20L !;HOP^F2* -$:,
M.!&]13':YY5L]9M94NX8D@N58,2HX#]K@I&X)'4?AGGC6/R,\MK>226^G,BO
M\$BJGPQL:U+!P"0 .HP-'^1GE7TA (HGEV)1E4*1Q)!1Q7[B,--&_(/25C2*
M2V21;B3G1$5:"O(!2&((]MCG3H_RLTBTM5@D-K ZJ6A%S$ YI]H*O)@?O.1P
M>5='MD46*6K7U6$TX4%%"D]"]*'; QTF"RMY+J.[$A848<%D5G8[!$4 %J]
M,(K*Q=G$\DR1+%)ZDL52KS;UY.14?(+@*6-=1N_4A'PE9#(Q#*C_ !4" 4_:
M[D#Y9(?RZ_+WSE^:7F"]\E>2M.CCT^S46NKZ[,I:QTQI@K-L"OK7)YBD2G:H
MYE1U^OGY*_D?Y._)[RY'H_ENT_?S,D^HW]QQ-U?3UH9IY !5BL6P "J-E &=
M:N'Y(L<-0QHM.F_'8_\ !3813R$DJK53]D[;;GB!_P )A;.Y"R*!QK\ )/[)
MVW^AQ]V<=_-GS[I7Y:^0_-'GK66KI_ERR>[]/D \TY81P6ZD[<I975!\\_-1
MYJ\SZUYT\QZUYK\QWKZAK>OW<EY=SN2:R2&O%02:(HHJJ-E4!1L,(,V;-FS9
MLV;-FS9LV?63_GVG_P X&W'_ #D#YEMOSD_-+2FC_)+RC>_Z%97*D?XHU.W?
M>W12-[.%E_TA^CM^Y7E^^,7ZED1(T6.-0B( JJHH !L  ,=FS9LV;-FS9LV;
M-FS85ZWHFD^8])U#0M=T^'5-(U2%K>ZM;A>4<D;=01^((W!W&^?&#_G(O_G'
M_6OR7UQK[3XY=2\@ZS<$:7J)JS6SFK"RNC^S(HKQ;I(HY#<.J^;.?(&GVB*D
M>^.:0G>FU*$8T."H-30@T/?O7&M(JJ\CD*D:EV9C10HW))[ >)SS3^8/_.3O
MDWRP)K+RJJ^<=9%1SA<IIT+4%"TXWEZ](]C_ #C/#?G;\R?.?Y@W9N?,^M37
M<"OS@L8R8[*W^U3TK=3P! 8CD06(ZL<@N;-FS9LV;-FS9LV;/J=_SZV\Z16'
MGW\R/(%R\E/,NCVNL6JEAZ0ETJ9HI %)'Q,E\#MV3<B@S[JV\8:,D_"#0M[^
M'($$5_U@/];(GYR\H6'F?2KO2=0LHKRUOX)()(9T#QRQ2J4="CD@JRFA 8@^
M&?G _P"<GOR!\P_\XV?F+]:T:&=/)6M3/-HEX29%A8'E)I\Y>I+)U7G]M*&I
M8/Q] _D[Y\A\X^5=,OH8/1O]//U:\B1MA<Q 4XLPVYHW):U'[).V>DM(NK.\
M=#Z4#Q!Z_5BXC97'=31N-.OA@N_N'MKE[>.2.ZA>BA98U:1Z]5$BU'';8_>,
M+5BTZ5[B2!7@] HQ=[=5***%@' JWM44P5:O!>0RM]8CNA\8E:&,1H6Z JH!
M:N_8X!N[EA#.B6\#VJ@K40DRFE/A\0-O'.87EI)&QN+^#U.;&5$$R1@4V4,!
MM11O\53A#?V[&!OJTAO7E<,?J\;,HY&E5Z"OATR+U#W1GEE@A@C)^-9!3D-E
M1MZ47NJUSJOY5_DSK_YS:C!<6<LFE?E_&SPWVMQLT5Q=2%N#P:>O'?>H:8&B
M4HG)J\?JIY \@>6_R_\ +^FZ!Y8TFVT;2M,B7T;>V0*BT#S,3M5F8D%F.['<
M[Y.Y7$:^BFY ]/;8]$BK][-A9<M4NZBAH2/"OQ./Q*X3W'%:@#[/V2!W&RCY
M_NAA5=,0F^XH=P? D ?=QSXV?\_$?SH?4=:TO\E]$OI%M]%*:IYH6,E5DO)$
M5K*U>A!;THV,C U')T_:3;YAYLV;-FS9LV;-FS9L^@G_ #@9_P X->9_^<LO
M.R:SKMO=Z'^1WE2["^8]<3]U)?3JHD&E::S*P>=PRF5A\,,9Y,>;1))^MSRS
MY9\O^3/+VC>4_*ND6N@>6_+UG%8:;IUG&(X+:V@4)''&HZ  ?3U.^'F;-FS9
MLV;-FS9LV;-FS83>8?+VB>:]$U+RYYCTV'5]$U>$P7=I.*I(AH1N""K*0"K
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M23_L8L1X<5 ;[06NWB$_YJERI K,0OQ -O3L"]/U1X532LL?ID;NE 1XE/\
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M)@BA :A"\".OQ<4CZ?.0XC*0\G)=E+5J=P 9"VWT1X4RS-%"!3F2G<]PG?\
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M\Y0PWNKZYHG^"OS*F3]SYR\OQI#>R2*G%/TA!017B;*#Z@]4*H5)8QGYTO\
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MW%U_1'H?F?0/-^A:7YI\I:[9^9?+6M0"ZL=4L7]2"=/C=J'J&1AQ=31E8%6
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M-U<?ES^?]K>W!E/U?3_,FAO:HL1#$>I?6=Y<DL#0;6P!W.U*'RAYS_Y]#?\
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+S9LV;-FS9LV?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>sny-20231231_g23.jpg
<TEXT>
begin 644 sny-20231231_g23.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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M/[R%JUKL 0X!!)PM2.],C1(TGJKTC/VC[!?'#;3-6:W=0\LJN#3E&U#X?$I
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M;:LLT@=@/ *-\C=M%+/>+%;VL,</(RN6D,LKLFREF9B-STVV^_!\X9;P*CM
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MJJ.)I55'*A-?A))&U=F_&3Z3:".XEMI^,SI^]B4[K<0"G+84/)>IIU%>X.=
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MKR^TL9%,\C^9_/GFC7]4:&ZG74-3F8QS6D;^O$CD[+*[!5'P_: 0;;=]RM-
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M<O/GF:34;X:-I%5"T@CB6GPJ-_B/8GJW]!A!%#9V%JMM;S>J7<>K(PXB:5J
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MXY)22)5NY4YL\=6H%0<20#N* [TH?>5H)KR>;2-2LU4/=25>,<5EYFBS1UH
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M^>50&=ZF5D45J0Q9%I_+\.&&L>6%UC08GNF%A;>99Y+FY$C<_2TZT_=M4BM
M>;U--Z<5%6KG+-%TV[\S>>O,_F.>V>WT/RMI\0ALB$2,+*ZBT@=J_ 56,2,*
M=\&ZE^7]W.MC#IU9KN2>*:^GD^)E4K-(/36BLH4U)-*DT]JD^I^1I8[O3-$$
M9CM=%LX[=5(*@M=*);J<JHX#@)>"BM>3/VWP+>^5K2VAT_38U"S:I+),(8JB
M4B*,! :_9!=@2?;8;$B+7OEZ[73];M;5XWNH(W2U85,-8Y CH%-:T5:UZFG7
M<#(!J6B!+N8+"0L$XA18S\?%0:-4A@I:G,GY=<./+FFIJVM^8+/293+=6[&&
MVAX,A80?%&Z=27H%!;N*=,GFB:<)M7U."XAF:[TM4:)48!I;!U,CIM2I*M*$
M)^RP;M3"/RIH5SI\/F#RG.TA73;B-K4L.*36=R.5E,BL#QY(_'8[#X?V<] _
MEG]3T;4].T:\D_>3FXT2\C"M(G#X)+1A4"M"Y6HZ<M]NG<U\MV<%A<1S\9]/
MM)$BO5-"9[.Y1[>4/6H/$%%.WX841V=YI?D^/2'OBWF'R1<216%X) 'EM4>E
MJ[BI)Z!2W<FO8YRG\Q+Y/,5IIVJ.1I]GJ<$#32H/WEC=Q-\$RKL2UO<$-_E1
MD^.>=-?/Z6CENV@%IJ$$XMKN$<:1W4;$)(O =%F0T)ZJ1G,=<M)'A6Y$01IE
MY *:A)/B#*/8\6&=&_*?7^$K1MO)!23C4AFX45Z>XV/WY[DL;@7MG;W('Q2(
M":=_?!@%:=LLKB++B17$2N^,*^V,9<19>FV)%>N)$;8BPQ(KGH?_ )QQ_.*3
M\K?-XLM6G;_!OF5X[?458GC:RUI%>*/\FM'\4/<JN?7A65U5T8,C %6!J"#T
M(.7FS9LV;-FS9L^0W_.9GYR_XX\XKY T.[]7RMY)G9;EHS5+K50&25ZCJ(03
M&O\ E<SN",\6@8\8IV&/&*@?3BE/#' #%1[XJ!7%0,648L!BH7%U&*JN+*N+
M*N&NGVQ=VGH2MOQ.PZNQHB_2<X?^:VIV+:OJ$E[>']"^7(G@4(2BR<%K+(&(
M- [U%>I&>*=(:]\ZZ_?^:=47UM%T=@D,1^&%W/\ =1;T  H&;Q%!XX3ZM+=Z
MUJ:Z?:.?K5U.U9&W$8W+RL!U(_9'4D[;TSJ=K8:7Y=TF#1;.*06UI\=TYKSN
M;Q5(G9N@/%CZ2G;?F>A&3+1KM4U*(,1'):HK7!X_#'<,I*1JW0+"M&/8D#QS
MK%CJ5EI^D7]S+&[O!I<=LQ<L&#W=[;,J;D\C((E+4Z\N)W8C(]YBU&_U"SBT
M&T+%G+1WCJU*S7C4G0%*4*+&8U&VZLQ-!AII_ERWTV1XP8X+[4W]:YXT]9(H
M8P(S(0!PB15H@[ ?"&(!P^TJ&34;YY(U+/(L<8Y*PHK&@'1ME4TZU^T2:G;J
M=M"NIW\.EZ:"MO<.K3W!(6,6@XF1NW'F  *?$0=J $X,U*>&"VO+;2YI+""P
M1DMI81RN1-*Q'UA5 51*0>$0_9J6VX9%;3R["ZVU@42&&,VL4H@-0D-O7C;0
M%C0 R$<V)JQ!)VV$F-G)J%W9:?9KS6.<6\5O; !))Y681[M4&C,68D4HHKTR
M6:UHJ:G_ +@]/Y7%N%M[2:4CX_0A>W0K7H$9G+MM4D$],#6GE2SN?,&H:-I8
M!TBRA.I:E+PXB:]N'0[G?EZ<494*?YCT[2-;>RTR.ZGO(T]:5H7ABE(,9%LH
M2$B0\@$Y4)ZU-?#>-RZ8+O46:56,LEF@("5942-2 BD KRW5J]%Y;5IA=:>2
MC>ZC:WMF!J-^UI+#;*$XD<5?XS6IY2S-)0UIQKT R!:SHMK9ZQ)%"ID6VMX8
M(119$E>Y=HO5J%H=C(6/9@"/>/:U^7$&FQ1SF[6>7ZJJNA.S( 8 0RDEF4%2
MPZFM!WSF_EK3+W0O/MKJ<L+6[RW]K'<E#Q ^M6;)<%=B5"R%=CV SHDN@"SU
M>>^B$9GTR;4;>9#R/*&:Y>:*I)K\)F8U/2,UK7(EJ@DLIH-1ED]5C97.AWDR
M(%>2WMB\JR\2Q4$".H;;P'6N3:>0VUA8:I9,9Q:3K(9H37]Y&98I"&VZ!$8<
MNO'P&_H3R_YSM=9\MW_I+&;Q5>T9U"JPD=28Y "*$<XR:[5#=.F1S7]5B2&#
M5HV,UMJ]F+*XMN)+.[!D5"0#0,RA=]Q7/.$NMP7"7FBWUV6BU&26&UN&^V+D
M(9(6)&P%Q;DU\)!['.5WUU)R>:[5(;M*VE\*_P!X0$C6Y'^5\,;_ $'QR/7J
M_6F,3_ Q!NHU'9N06>/Z'52/];(UH-\VD:T)H*I4K,HW'6O)?I!(SZ+>2;Z+
M4M'M9X&#1S1+(M/&F^W8^(R8!3X@G'%=NF),N(,N(%<:5Q)E[=L3*XB1^&),
M/QQ C[\288B1GT\_YQ)_-P^:_+;?E_KEUZGF#RI"#8R2-5[G300JC?JT!(0_
MY)3K1CGL7-FS9LV;-FSSM_SDW^;2?E1^6>HW%C<F'S3YE#Z7HH1BLD<LBTFN
ME(W'HHW('^?@.^?#]F9V9W8N[DEB=R2=R2?GEC'?QWQXQ08H!BH'W8H!TVQ0
M#%0,57%5'?%U7%U7%U'3QQ=5[XLJXL!DPTE8=-TK4=?N"QBTJW::-%Z273'A
M"#[*26]Z9\\OS]U2[@6Q\FVS"YU749EOK_@*EA(>,$2UW.Y\/?I3(5YS*_EW
MY8TCRFBJ]Y9@W5YQ-3-?W !X@4Z1B@R.^4],.GLVN:Q(;:6U*W=Q.!NLPWAB
M4 _:#$'K]K)5I5S)?QQ:H03;2/)=00,1R*0;(6)Z<W(H.^= \O:=(CV8;E--
M>.3S!!#%FK+<LI_U2 *]*9)- U,>8-0\PZO#&K:-H$H2WD_W_?PLLGP UJ(!
MP9J&A<HN/9X=.FBM$C-O<W+QF1I#0J98ZMR?>AX$ ^ Y$=,%&^N&+65@1*^H
MRPV[W14DMR^*AJ31NE-^M*THV=-T^[M;&*:VMI. LXY(><9V:%_@D=FY4!9M
MQ3??OUR3VFI+96%PBA;6.5#P#UHL.T?K,.[,1Q1:=!X5P/;31M<Q+/)Z,"O^
M[##=I%5E/*AH"H(H3U+4&&UE?16DT*Q,(WDDDFE*]1!3@I)HP)J:K3J*]L,_
M*5_%"\VJ-&4:U:=;*+X2"UPKJ9:U%.,3$U/2H/S[)Y>B1+2]O/45I[]>!:NX
M] LSJ%VK0EQ7H#3PP-HT::!I6M21']]=$0L7J [(5+ ,"*BL_5O 4&V1'4]0
MBU&5(942:>!3(.9/%%1:!R20 S,_(D["@.YQUI&=4O;R*TED@2*0+<2NQJA%
M(RK;@%R!T:@7;ODGN-9T[0['4+I8'DGO+9PL*!ZKS14C@C6E">(4'?IM^T<X
MC-#>*MG]<MQ>2V<2K<&*1C&;YF6906I4A# JN1W]1@:4P3=:O!<P6\J@POK,
MXM()*A0"X26-GY \6!6,%2-OA%/".RV10SR2QUO8X)4D(4[F."&-64#NI97/
MA4U-:C!VCPO>-:RW7*2YN?JW[F.@]26>%(36H!HXX+2GCWH<XCYJDA6\L"LW
MUA=46X9U H(>$S1!2E*CBU-ST (&2O1IEN;34-/B9&%W;VUR@5^-(9FEMI6/
MLLRI6O8FN^!/(GFV33M?NH9"?3FX2>FX^%9+<+*$H1LQ4'?MX9T&[U95AUVR
M68R"&XF] #[!0>E,C 4!'(,O$_*O3.&^:+0S3:H\#F*\MV)+(H8-*9/K>GST
MKL#SHX'\WL<@=_<+J266JJOH?6?]'F).R. : _ZI%*^W@<+Y)JO'/**!7C8C
MH/3D CD8'VZGMMD<UB!UG>D8$^G3O$RJ*5C:I4_[$T^8SUW^0VO&_L([)S6>
MS;T6(_;CD!:-J>*GX2?EGI=HMS3&^G0;=<19,#NM.V(%<85\,18#$67MB+#K
MB3#[L1*XDRX'9<D?DSS9JGD;S3HGFO1Y&6]T6Z2<('9%F0&DD+E:'A(A*L/
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M#NI;'ZO>3!%O-0<>FC&J)S8@<5(!XHK4)_:8_1DMTV='344GG51"I#$KMR+
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M&7$2N)LN(%?;$67$2OMB)%.V(L,19?;$&&>[O^<,_P S/JU]J7Y8:K=4@O\
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M=SV;F"2?GRZ_TP[T#[-E>*PC@NX%=(^-/]*0JM :[;G8>YP7YI\OEYFE5?\
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M6-7.] 14_AG(K[RV5@U: $B"24P+W?@8U90/8<<YOY1\L3R>9GF9&'UB&S+
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MLI!Z?KP"9%U:*&.&/C!;\K*)WKR95E25I*'Q#E1\L]=^2O*$TWDZS9(BKW-
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MW4MOW8[*!])K]&?*?6X3K/FF&S8,\%QJ\MY=U'("%+AI&4@FAY%54 ^.2?\
M,;493<VD5TB20VC?7+R,GE')-,0T5L:U# *$7H?A!SD/D96U;SO/=DM//;QN
M]7;H[IQ!!:IK5JU[9.;R]%_J5Y' %2!Y#! _A%"BPJ0 =@6!:F"O/]RD7Y?7
M;Q_ TDZ)&8C0\$(1&'3]I: >^<S\F>E)K<\45Q4S7#.A"L']$ L!*Q %*FE!
M7J<],W%A)>"!(CPF],LA ^+F.*U!'0^&=\_*?RQZ5Y9W<ULB-%&\DE54<7G4
M*2#3L?UYWB\G^MS16;+Z2Q<0S<:#DHZ55G\:],GOEZVL[!HYKHQL85#<BH)\
M-^Y]L,]5_,K0])59'M%AMPY19ZK'&'H:CFW%3T['8_:H-\C%M_SE-Y!MHC-<
M:KI\2Q?$L,D\K,&3]GC#;S@,1V!/O3"/6?\ G,GR%Z!G33YKNVD8QQSVT-4X
M)&'9Q$7#GJ*\@E3[UR.Z1_SDY^7FKWT<%Y'<Z89"I3Z[;21&0MNH5"K4'S;.
MCW^CZ'YMLH[O2[VS@CEC9H@ OQGOPXKU'0GMTR(:-8G3-16VG]))$<<I8Q\3
M ;@5%=]M\]G?E_>K)!$II'3QJ* #H*YW>V6.:V=48;A4+';K4>^].N%.J04C
M9ANZ<OLTKTH/GVIGG#\Q9WBMKD0@TEHOP&A##8D#;KG+_+-A%;Q+J>JA;A7)
MDH)(Q(. ('$2TK3J17H<@'YH_P#.1F@>486T6QLKYM3: K';::T:.RN:>HRQ
MRG@ =BS&GOGASS=_SD'^8^JWEO8P:M?0ZGJDL-O:Z=ILU]+/S=N$(,_UB*,M
M(6"T4$=*,<9^8GF;_G(/\J;JQTC\PM.\[>2M2U2&5K2VN]3Y,X'%BY2VOYJ<
M>0)WKT[X*TG_ )R#_,2SM-'U%>5_8E1&)KCZW6<(2I28_6V/*O<CWIVST[Y*
M_P"<E/+_ )AGMM(U:UFT+4I4,T)FD:YMKF1C5EAGC3DM/Y62H&=XN8(+K2X=
M5U.WEMK$FI:XCH\KL $BC5QR;D3X=,\]ZYY.EL;NXNVAC@,\CM)%Q52@E*DQ
MT -2*TSSMYOT22UFG,,87E'R I0#E2O0#IGF)KJ+3O,K:DKEW2YCD-F0>&\B
M1M(M *[4) %?GG3/-2)'J,/%0HE7G78 D+$[ >-.77&Z8!%-*O /'=<!\72O
M(-T^4N%7EZ1K?SG-&[42_MJ==AT_"C8M^61>R\X^7DY,SVVL0VSA:[GU.!';
MJM*Y]9H:-$K <58;#PH2*?ACU7XLIEZ^^!7&!V7$&7 S#$&'W8@1@=AB#KM@
M5AWQ%AN3@=A@=A]V(-WSZR?\XI>9?\0?D]I%I)(9+KRS=W.DREF+-Q5A/#UW
MH(IU4=ML](YL^)7_ #F!YJ_Q1^>WF>..7U;3RO#:Z';FO3ZNGJ3K3M2XGE&>
M8QB@Q9<57Y]<57%1BH&+ ;@G%EQ=?EBR^W48NM,$(N"%&+J.F"$'X8+13@E!
M@E%P3R98I0"2!&QV[D*<^8EC#$//,D=3-!823377'?G+7C'&E=B%YFI/[1)[
M#(=YKNYM5\PS07,_J1K)SF*FHZGD_A545Z> P#^6;AE\RZ[P"&[8K"M &5&J
MU!\E*K@ZQ ;5H+<DT9E)'M&C.Q^\_ABWYG:C'8Z5IUA/'RL6EM(9U7[8$[&9
MW%=N2GBP]Q\\A_Y>6%S=>93)'*)+6Q,\)E.R"DK.#[EE92,]P>7-%%_<QJZ\
M.4(&^Y6HWW]J9Z\_+O0E@M6#U=J%9PHI,J]5D WY AJ4P]U_38; )<VUQ%+9
M7$BJ[W/)4CD.RJ[T^ ':A;:O?.3_ )A>;;G\N=(;6/,&B7ATJ)@87@NHEAN6
MZFV$J.U6<?9X[]QWSP[)YG\U_G+K=Y:A[IK*8@Q6<?J-8Z?%%4QT8@!I!R.]
M-\@WG#RKJFFZEK44TUQJ?^'G6MD\KJ9UA56X.R$/\8]Z@'X<Z)K&J_E=^:-K
MH<OY9_D3%^3NFZ-"$U?5(M:NM3EU&Z*!9(RT[HHC1OCKQY5(4]-^\Q_DYJ5K
M^7V@^=]&,6L)=6A-]I5^3/$\;'>2*)C12ZJ"6&_T9)O)^E6_IK-^7^NM8ZA!
MQ-[Y2UZ0Q7,,9V5[6XF,7-6(J!R%>Y7IG8["P\RW^N:6]P#:3!6:>RN+2:"1
M%05)JR(AWH*JS>^>LO(DTD/%)3L>M#6G;<]<]'6%V@MN7)F9E(V4[#QKMA)J
MEZ?1%:EM^HXU &VWCGEO\RI+F_AN4LI)%NHT9P5I2JBO0_USS)YQO_.=O#::
M+HOE+7;J[OX0\U_ZRW$,-!O(Z6Z1@,0: /-L/V2-LX?I_P"6VOZMJT,NNV<_
ME_3-0O*7EM+(&U2^5!1YYYO[M0P"JJ*VRTVY8;?FC_SCU?\ G"_];R);:=::
M/=VL4:BYO%M)();97$A ,;$J!1@>M<YY9?\ .-_F.TA@U;S%^86G>9-4AY1R
M:C?:M<W")%#R B"3P2S'CP:JC?EVR9KY;T6+RK_A"WM9_,MW>2SW,UW86S6\
M0$P!"QO,"Q6B5Y?#OVSGUK^1?FG3-<L]0\OP:C>P;21:;+<JUX\A^%3;20+5
M&W%"QZ]=L]T^7/*OYJ:58VOZ>TJ6]U58@MO>>L]U+!$X-28I)&42T-"R[>&&
M.H_E]J+1B?4K1G4@L:W!Y\COR;C2ISS;YYT=8XY8VC]-@#QZ?"=MAW[9\^OS
M+TZ31;^2[ABD,S)0Q\R!)&*%BBC>H!)_U<ZEZJZCIWDR:5.;SQQ*&KRY1NKJ
M:^^V:"BOI,Q7E#=R!/"A!],!OEQ&1EI&MO-NF.6XO) X"G;^[Y(P/T4/T8:^
M5"(/S1L(6/&*?7;60T-*EI(Y W_)3/K9;(1;Q5W/#?YU.**OQ9;C CK]&!F7
M;$&7Z,#L!@9A@=AB+#[NF(NN!&'TX@PP.XZX'88@ZY[=_P"<)O,9M]>\Y^4I
M9/AU*R@U2W5C0![20PRA?=A<K7V7YY]%,#W=U!8VMS>W4@AMK2)YII&Z+'&I
M9F/R S\Y_F36KCS+YCU_S'= _6O,&I76I2UZ^I=3/,U?I?"@;XJ%Q51WQ4#%
M!WQ5<748J!TQ=14#%UQ48NHP0H]\$*,$*,%(,%(!L:8*08(08LT?*)XZ5]12
ME/$'8Y\W=2T^TT?6O,!<E+^\U2Z]&'H(;2W9@TGN2:*N_B<XIJ5_]2AU*8IS
MEN[>6W5J]#, '<GQ ) ^>&_DT+:>7TB XO.YF=A_*H!IX_RXOI;R#S-&RDD.
MTBHS"M.2RK3[VPK_ #@9IKNZL4/)#$8^)V"3A8@K5[4%1AY^4=M=1W%O&]D;
MF-HH9WD7=%E5./-:?:H$(I7MGNGR#:QR7U"S.5 V .Y:N]!0TSV=Y:TJ[-G&
MMK:,DRC]U-+Q0A3V^,<BIKTP^;R;YWO@S-^C%-PK1M%=N98V1@00"B$[@]#G
M%O.G_.).K^?'0:]YOMX(+61I[;3;7U%M;=G4@D%NCGK6FV0J'_G&K7_(T,$/
ME>[U/3X;=XW$EBPE4E6/+BY!(J"!Q(^6=*L/RU_,*_NK9=1T_2O-=N[@RS:A
MH<,LP15)H9#5JBM!4]=ZTZ]"L?R4UZYM1->Z1HECNJI';Z+86M%XUV"JX^T"
M&/$UZ['#R3\IKB>,V]S=^O;QCA'#&B11A32J_"J"E!0;?C@JT_)?2']-[JPM
M[F6(;-=HLK&GP@UHW84R6+Y%L]&M1:6EJMHELIDM8E!$49;>0**[!O; ^@DV
MLIJ20K$D#KX4WWVSL^E7B/#R:15('!-VKOV %:G"G6W/!EYJJML0M=CXCK^O
M..0V)O=3O#-O$$_:W!H>@ZUKG6[#R;ITUDDJ0K5^/$R+LU16M/$^'N,(M2\I
M6$4O[VPA1Y:%6)%!L./-BM!4=MS@.S\KZ5;2&(65J'J\A*D;$D=Q2F)W7E+R
MO(9A-#:A;BCW()4%I!0!J>-% ^C"P>0_*JD^C%&D<CAN,<0D/([5H%Z^)IA[
M;Z'H^D"2:UMI&N913U'0AJ5[*!L,#F\6GHH[\EZ\PQ*@=*@]#X4R-:W< QRJ
M"S[$FO&A!H">@'7_ #&>2OS)T[B\CF%:R@J/A\:]^M*?+/GQ^=%JMFI>2$/!
M9QK<A#$9:A7'+A\0(J/NPIT"["^4_+VIF(+Z*-$D0))261U((^0)49(8I/5\
ML:3=..#0W C<@?9'UEU!/N*C(%KBR6FN:'+([,$U":(U[+*[IN?DU<--!=%_
M,;RG)(I<2ZA:22(-FY(\: $=OLY]AD0*@%:@4I\B*_QS*O7&N,#.,#,,088%
M<=<#-WH.F!V&(,"#B1\,#L,"NN!W&!V&(,.O;.S_ /..FOGR[^<GDJ=I.$&I
MW3:5*M:!_KT;01J?^>KH?HS[#9Q;_G(KS!_AG\D/S*U,/Z;R:+-I\;="'U$K
M9*1[@W&V?!@#'@8J*8JOZ\4&*@;#%E&*CK3%AOBZXN!BR#VP0NV+J/NP2@P0
M@VP2H\,%(!M@I!@I /#!(<0CU6'+C3;QSYD_F8)X/S _,99'*M!$1#7<<)"H
M''L-Y,X?K<;2VT4;(2\LBJ .IJ.GSR<00+::=80**A(T#\.YYQCD?;DN^!=&
M1QKS\I HANHX@34E2[MT^@Y'O.HDU#S9*B,'%QZD@#&G,,Q7J1U!3[L[9^3M
MK9+/+;VDQGLX/4N4>.OII1/C4<@-ZFE:4WVKGL;\OD:/4(W29;>5@J[,&DY&
M@HM12OAMGN7RZJP6T(I5J+5B:ENU2QJ3OU/<Y/7N)$C$T+%HT^!V4D %NW]@
M^G%[2]:)J<6>,G?LE>N]-_GAS;R12R++&T2/'LO $[;FGPD5^[#R&Q>=_4+1
M.S4^-HI W^K0.N&\&D"(;M"$ZE8HV!H?#XB/GAM:Z7;;$R#D=F0-Q._3K0_=
MAE<V]G:1%E"+.%'P$"I)WZCP I\ZY M;N(W@DC<[J6"<0*J.VXZ^^<QD^"60
MA3&7]NM2,FF@W$AB>GQQOL$"^'7>A.;6I&^JL"Q/(\0#0 <MM@/U9S[3XO4O
MFJ-E/Q4W-%ZC.UZ+=O&B_6*25XGXMP.G*J[>WW4R2*]O)(#!QN"XX-R!6H )
M (% 2VU#7MVQ.32;.YX$VX(8A!Q8%6VI0@$4/@*T^_ \VC%"KHZ(1LJ!=S38
MTWW_ (81W1+(#%R"BH;XP1[L/ =AD3U&)0M7:216W!9FIN/ 9%+P@*!)14"@
ME1O2O@:$#(I?W,:AA2J$DM7<FFQKN34#KXC.$?F,@ET^X"4+PD2(M>W8;=3V
MK].?.G\]+F233+>2#G#=-<QQKQ()9FJ5!'O3?(1Y1^KW6E>7;0-5;J^-JW$'
MX)T#.K5-30-W_E.2:U5$\KZC$A9UMKS?8FM)4EI3Y Y _.B?Z+#=EBLJ2Q7=
M!XRO6OXY)_(ELUY^<'DF!/\ CXNK=Z,*]61F'Z\^O0%02-_B/W5VQRH>.^(2
M#K@1AVKB+# [CK@9Q@9@<088%9<1*^V(,,#N.OM@5A@=A^.(,*X(TV_GTG4]
M.U6VVN=,NHKN+>GQPNKKO\US[G?I>R_0OZ?YG]'?4OTASIOZ'I^K6E?Y??/(
M'_.=>N_HW\GM.TA&_>>8_,%K ZUI^YMXI[AC3O1XX_OSY"#_ #ICQVQRXL,5
M7:@Q9=L5&**,708(48(%<67\<67!*#QP4@]L$*,$(!@I0=J8,0#M@E!TQ5D)
M61CV1J>QH1GS]_/S34L?-OF6XXA6U:QL$!&XY<X^3T [ 9YOU&/E<:9)%(K-
M>79BA4?LL]46ONJ[GW(R:S((+*Z]).:QPW"?"*T]*YB6N^]/B&(>7H^7F5E*
MT:.\27?>@ >A_5D5O8'GU/ZW&XBN;>XNK1IZ5]/U2TD;UWIU89UK\M#)I=]'
M8NH@GU(O"2HVD0@D $;?:4U^>>VORSX_64E$:1R-Z?)G%6XTVX4!I4G/9EC,
M%$0YD>F@5@-@JCPZ =#]'SR>6=ZK0B.3X8Q'15/@=_HK]^#;'DC/&K TH02=
M^.2VPL$65'))8_$"-@">W?\ ')Q;+*OQ1+&G, %6Y5V[FC**X8\BJ_O >/VJ
M \=CU_9V/R&99A150+LQ(XJ*FIWY'I7(YJET82ZEJMRY5Z$BE1MUR$WT_$,\
MLI:OQ;C:OCL??(@LRS3EB>0Y$U\/#.B:#;^I;*RK3C4U)I6IVV^6):S;T0\&
M##?<#^OAG.X9!97S2 #B3]&=-TJ]@N0)XI 604*=>3'MMUR36<GK6[\5I(:C
M@]*CIN?##"*]$!JZF5Q\ 78*HI0BHKAP1!,K@LZE0&)&Q ;^4 'QW-<B&K_N
M9)%  CX\SQH.G0 #;KXY ]2G:AY&AIN :;D^&0>_E%"48D@FC5ZCN=^N^0/4
M;MDYD5##XA3[55W! ( Z?Q&<@\YW'*VD<#9X_A5ZT![+M0[$ #/GE^=;A/K4
M4MKS@3TWYU*BCU4J6H"H)8#EX]>^0+RQ%;6.DHD#$MH]93&Y',S2I(IH5IN#
M, *=:9T/3B)O)U_.$J)KF!G8?SK"ZD#_ (%6(]\YCYE#3:7''7U#) (B3U^%
M_P"P9T+\BK:;5/S?\IK"I9H7221V%2B!5=BI[4,0W\"<^M7IJ*@"@KC''8#
MLBX#=>N(,-A@=Q@=OOP.1@9QM@5L1; [# S4P,^!G&(,.V(M_M9]7-!UMM9_
MYQ4GU))298?(&I6GJ*Q+>I865Q:EN76O*#?WSR__ ,_!]9+WGY9>7D>@AAU+
M49DKU]5K:*$TIV].3OWSYQC'C%!B@Q48L,5&+#;%UZX(7]>+KBR_=BZ@X)0=
M*8)7!*#WP2@P6F"D&"T'O@D+56'B* 9XO_YR@TL12:3J$(/.]M6A<^\;J00?
M&ASQY<0-'JWD^!&Y&VNQSH-O6]4&0;_*GT9*IYHH;&5).18I+'53]AYI4>K;
MCNN!_+=QZ?FN-N06.8*K@[[DJ& ]ZJ<)45CJFJ1H>*O,X<=/LN60GW'8X;:(
MEZOF?0IHU>-X+U)7HW%:)4U*] =_ISZ*?E^PCLXKZ-""S+Q11T8'D?H',=\]
M8:)=":" \^;%.94#KT"U_P!8C_.F3.VG()Y-\1/7]>2BPN*R*W2GCN:9.[*4
MLBA3R$9K0FM*')U91M*%:5N(V+ _M#MT(VJ-\&W8/*BJ>)JSJYIT\=R*# ,D
MT=N0CU177[0  W/OL,@OF?6K:-?7W$<-$=E7:H[U)V!SB>M^;'OE*V)Y1KL0
MNYIT--\%Z8\W[L$U(%:=CG8/+\['TX^0')?B8[C;Y_+#35H%5%<QE48&A'0F
MF<<U6$Q/,.Y^R378GI3"2RU#6M,22_LBTGHU_=C<D#<TR?>4_P S-/OX#ZBK
M;3!BKQORJ7[EMP?D,Z'#KMA>J0LP@2.E1(OQ$GO44[^&'%K?)&FTZ/M1=Z"I
MVY&HKU/;"?5=0=H1Z8578D#<$@&M3UW!_5G/-4E(#;D[#84Z[;_?D$OKHCDK
ML"U-B!0'V_#.=:W=!%+@A"&H"*]=J#KG(O-$TLL+CD S(S =J4W7Z*9X'_.V
M[NK.2:9486DP>*;X#-&T9X\D->@[_P"UG'O*%U6UU.W,I)@FLT$A^*K)S)-=
M]MONSLGEU>?E3S&@<F"&ZME &R\VC=FI]!%<@^HHK:9:DG^\YBG@?6;?\<]#
M_P#.(&B+J7FOS)K9"JVE0*B;?$?44H?HW-<^D"U(ZUQC"N!G& W&!F&!F&YP
M.PIUQ!L#.,"N/' [C S# S8';$&'TX@PP.^^V?0G\EM5_2'_ #BE^9-D7J=#
MT_S+9A32H62P:Y&W@3<'/,7_ #G7JWU[\Y["P5O@T3RY96Y7L))9KJX)^965
M?NSQD,4!.*J-M\54??BBC\<648JHH1BP&+J.F+J.V+J,$*.F+KMBZ8*6N^"$
M]\%H,%H,%(/?!28*3MGG[_G(30FU#RVFI*A?_#H>_6G?]GB?;E0_(9\^5B_W
M):$K_O.%TSU)WJ:FOWX9:S"T$6J*"#ZUO!*A&_7U 2/I&$MG<_5?,.B7DCJ(
M9)X78G[(];X&)IX,IK@JZMVM//.H690I%.\AH3^VK D#[ZC)]86!M]0L;A4^
M-I53DXV(;8T/RSW5Y,M7AT*Y<MZH$B>BO0$EMR*?ZA.>@O*\Y6W4,Y+,0Q/A
M0 !:CH:?USH5N].)+4[CQ(ZTIDCL;FG7J34GK7VKD\TRZ:-2W)"Q4LH8T!/<
M5[4[9-DUZ,0<"R ABR\:FA'8U(VW[X07OF18:*KMR J''VA38"NYK].0;5O-
MSQ(P]6JL-ZM\1^^H._CG!O,WYA2:MJ=IY<L)N<MY($E/(MZ:]^AZFG;IG1+'
M2K6TLH[=$!< <F(')B*5/TX;65U:K<LID4,"0-^M1VSJ6@7%E"T4KNIC0;5/
MOUR2ZYK.GFV*QOS)0].@]^V<*US6;?U&C+KR)^'?PWZ=<VGW</U<5I\6_P N
MV<(_,N^E\N7]MYBTYU1R_H3Q[\9%H6!(4?:VV.&?E3\U!?PI2?U& H1L0K=Z
M=AG8].\X"\B65G]2B\:U))KW%#AS^FVD1']4EN@%=R._SPKN]0I&6#T9S4U.
MP]\A5[=$EVJ*;BA-2*;$CI3(!JLW..4.=Z4WIU/;\,Y5K4H=W5E!"CH=J BA
M(]Z^V>'?SVL9N5W=QIZJ)""':M% "MQIMUWW/]<X'Y#>D=W<EPL?J B/>C2Q
M\C]U&-<] ^7PH\EZY&1M)J5H%)J#\<3\S]^0/4J-IMM&:U:7@".X:6AIGT6_
MYQE_+RZ\C>4]9O;^T:&]\R7?KV_J+Q?ZG]J.M=P6!!H<]*JM*U/T93# KKUP
M*Z_=@5UP,XP.P&^!F';$&%>V!77K@=Q[],"..M,"N.N!V&!VIB+8'8=\]B_\
MX\ZD9/R9_P"<B='+;6F@W-XJGN;C3KZ-B-_^7<5V\,\P?\Y::E^D_P#G(#\P
M) P,=G+8V:4((7ZO8VR.*@#]L-^K/.JXJ/U8LIQ4#%!_F,67%5 Q=>V++^."
M$&"5&+J,7 Q=!TP4HZ8)5>F"4VP4ORP8GXG!2#<8,0=,)O,>C+K.DZC9R(LJ
M7-O)$RL*@AD*]/ISY47=A)IGF".PE3A=Z5?2VD@<5^S50:'Q7?'ZR5*6W+XA
M>6'IJ>P,4TH!^Y<YI>O(&B0.2L454!Z#BP<T'SWSH^H)-?ZOINO1*K74MO%=
MK&/VRBB.93\P <]0?EAY5M_.MM>SF(R&(_N@>BM2O3YYZ%T+3Y+/0I--N(%]
M2S"I(/\ *#CE7Z,Z-HE[';Q1BK"IXCDP%:$U"@;'YYT6+4?5"*% C ^,U)6I
M[&M23XY(+.]YIQ!(95!4[@^)R0VFIM&S%B7:@ IT->M0>N&#ZN$ /,([KPJ3
MU [9$]8\QM:QR2/.M5! 7H!_E=L\[^</S 9F6"TD:6>8A$CC')I&-?LTQ7R9
MY5OM&F_Q=JY;ZT%DD,)K1%8 T^@5R1^9?S:T70;/ZW<W@2- 2.(+DT[!5!).
M^<-M/^<G/)6I:O'9VVMR:=?^J%B^O6\MO#*:\0HD=>%37N1GI?0_S;M)K>'Z
MQ<+%*JCJ1O7H017;WPVN_P UK!;8J+GDS5V)J:GIU]S^.>9?/'YZ:!H%Y,&6
M[US5E<$VE@GJ,A_9$KNRHM.M":^(PE\L_P#.2>L:M<+!=>5[[2[2OP222QO0
M &@944?K.=>TWS%%YQECB55N5))8-N$V('CO\7CD6\Q>0K_1+AM9T N(T),M
MJC$*:UJ4[5KVP;Y8\Z2*(UFG99*F-E?D6J*[,*'?QZ9UNP\SK,JB68\7%%V'
M3;<FNYP^;4PR!/4+,.C-O3O7":YOU((5BPY4]ZFFQ)R%ZM> AZM4CLIIM7M7
M.7WUP)IYEHM/L[BO44V W\,\L?G$)YK22PAI&;JW/0 _$ 0I!Z"ASR5Y<E^J
M:KIVE!@L:Q3,RU-"W%@Y^9.>C]-#1^3)V8T6YU-)A7NA+K0?+C@#R?HP\R>:
M_(VA.?W>IZS;HQ[\&=G;\%S["VEOZ-O'&?V% %.P  7\ ,6*> W&(L!]V!7'
M7 L@Z^^!&'M@9Q]!P.1@=A@=@,08>V!'&!'&!F'A@=QUP*Z[G [#$",]&_D!
M?F/0_P ^-+K07GY=ZK=<?'ZM$Z5Z?\O.>8/SVNVO?SH_-29W>0IYIU6"LE*\
M;>YDA ^$ 4 CH/;KOG+!BB]0.IQ9<67%!BJ]A7%A_'%UQ=?UX(3I@E.W;!"X
ML,$JN"D^6"5&WO@A!2F"T'3!B#!:#I@M!XC!<8WSP1_SD?Y)_0'F^T\TV5JL
M6G>8D!D>/E1;N$@-RJ2 64[4IGGO7^)LM">GV)YD))ZUDJ!_R5SGVK((Q:2C
M_?77?[2DJP_#.C^3[A;ZRTV)'!NM/D:6+GL6CI21 ?$ UI[9[V_(/3HC9W4<
M*BWDN2\L3[_WJ[$$5SK6OH+>VNKB=:%@>87X6VXAC04[Y%;+6(%E>..4MQ54
M(Z%2Q_L_ADUM]6-/AE^%?"E:T'XDY+M/UCEQY2-R:A53W'6G3) FIE2)/48;
M"E*&E-B,3N]9 BDD2XX@"C5^(-3J*4(KG$O-OF.XE9K>&:1Y+D\8HE"@D_,=
M>M<E?Y>_EZK,NKZPL4NH.!\4A8LH!J HY4'T#.P>8-.#Z3/:(JH)860*"=ZU
MWZUVSY]>:_RX\[7.J7$::DLEES)CB>,$A17;D:GOXY";S\IK\I-]9L(20&#5
M4D G;? N@QZIY2/U&X%Q%IJBL:(6EC1MB>-:E-^PVR<0Z]#<1NB7,LLY%$ Y
M5 ([=*=.N!=)\L1N!QLT^T6KNS&IKN3U._CDMC\BM=(D?HLX8[JID44'8\6&
M=V_+[RF=&CB1;?TP#6M&_"I.=NO+>":UXSJ&15H*UW^@>^>9//?EV2RGEU32
M.,$]>;%:CG38*:DBM?;(GHWG"22-HFE>*Z4\6C>E5( ZFG0>/3)_:^:6D*&6
M9U4"K5IX > V[XK_ (DY$AY6EXU(('3IMLO<'"*\UP21L"Q(;?B"#QW[[>'7
M(P\WK2)(C4IQ?;>@!%=S3YYP3\Q98I+CT68&6W@8^F3T!+;AC3PZ9X4\O7,D
MWFNXE8F1()+Z&/:A!9D15I[<SGJJ*15\IP1&I]*\D8&IH/3#5-/F<G?Y!6)O
M_P W?)</'U7M)GD![*8X906V^G/JNZBIX]!L/E@<CKB#BG; CC?I@1P37 KC
M SC S?B,#N.OM@=OU8'; S],"N.N!7'MB#"N!W'M@1Q3 S['.N_DS=M;WWYB
MPB0K]?\ R]\S0$!@O("R:;B00:_W5:>U>V>9O/UP;SSYYVNRGIFZU_4I2H-:
M%[J5J5]JY%@!BBXH*XLIQ5??%EQ91BRC%U'W8(3[\%*.A]L67!28)7!";X*3
M?!2#<8*0=*X,C'3!:8*0=,&)G./SA\M1>9?RZ\R6CH&N+2U>]MF(J5D@^,4[
M[@'/F+J#/<:#&R']Y:7?,$T-"T8(._O%D:UZW9=&@O57[%TT#&E0GJJ'0_?7
M"_1KNY2SF-HWIWUFXO+?P]2-@60G;8AB#['/?W_.,OGC3-5TB^O[:1Q' [&2
M!JF2W>O%XV J?A8=?#/1?F#4+;7_ "_-?6%98)[IK=91LC/&JM)Q;VY5(&^<
M@BFO;.>Y+56WD+%' K*0/'8 ';I]'7#;3]8:-O\ 2&YL-^*L6I0=&)[T\,F-
MEY@C:,F)^14_;;<<C3Z>G?#T^:512%F4$@#<U\-]A^LY#==\TR!)2Y4*5W !
M#CY#8X#\DZ=/J6H_I6\(>X9ZQ@_$J+V -?I-<]6Z)(D21JU":>-.GM]&2"_^
MKLA)JJ%=UZG8_3D7FTBSF9Y/3'J UZ4.^$M]Y6@N#P"+R8;E@!M7<'8],A&L
M_E1:7B%HHN)-=PJ\>GLN0Z/\H4@</%#7EN"5"T)[;+DML?R^6TX\^25'6M "
M*=Z9,++1[.W)I'RH!78[&AW)-3A^DMK;* E/4'+B:;4!IUQ.XU&!P0ST \>P
M/;(-KJVEQ"T;48JOPCH#X=<\R>:]!FM)GOM."K.*D)6H(_D:G4'\,0TJ\N+R
M",IS(((()/(4 ! IUPT%M>/*8TMYXVX*Q%*@D&G3J*CP^C!K6%Y"PJ[4N "J
MO4D FFYVK6O?!$-J(H^/'A\#\>70"G<]-J[9S(2IJ7F75-,MM'M=:NM-L4OV
M9;7UKFTMHI1-<3AMJAVC2(U^RA913EGC77M=LO-GYLZI=66G6=B^GPI;WALP
M1%<7,3M+-*1O1N156-233?.FWLQ71]/C%.*PW4[5VJ%4H/QWST3_ ,XB>79K
MSS=>^9+A*QZ+8J8V V,USU'T*WXY]$^M:"G?$R,#.,"N,".,"N,"N,#.M,#.
M,#..^!F!\.N(,/? SK3 K#K@9AB#;UP*X_# KY._RSN#!Y@UA 5"W/E/S3$Q
M;P_06HN*;]:H!GF?59EN-5U.X23U4GNYI%>I/(-(QY5]ZX%&/!Q5<6&*KUQ=
M:?/%1]^++7M@A,$IV."5[5Q=1@E>@P2M,$)MTP2F"HS@R/M@Q!@M!@Q!TP6@
MZ5[XO+ MS;W%LP!6XB>(@BH(=2M"/ISY*>9=(;1SKVCLP-U9W;U0=%2.0<33
MP(<_=A'910ZAI&M:;-0K<Z>EY":;AX-S3W 4C.46-Y+87<G(@\2:AOL[BE?E
MOO[9ZE_YQ:_,>TLO,.I^13::;H]UYKOOTC'>3%8)I;N"'A-9M<2,J^FZKZBJ
MQ # FN^?0+STLOE7SCK?DR]U<:KJMCING7TPAFBN+6 7%LRPI$\!",_I1@$T
M!H$K78YS*:RY,O&1A,ZAF44^%RNQ.Q -&K_;D<N[6XB9A$KL) JU)!(XDACL
M *DCJ/'!EK#J<;2N*AF4@'8<1M\0!8#H/'MBP6ZE"Q(6G;E6+<D$46O';I3^
MS'2:?(\\<4QJTG4@5JV_C^.=3\OO:Z9:Q!*!R"'[5]^Y[YT*/S98VT#-/.EO
MP)'(T.XJ#UK]V$U_^;_EG3U#2ZLC!!OP^)OG0>V%A_/ORC**123SRH*#THR0
M1TH#M\\?;_GSI#RA/T;=K$3N_!?A'6HHQ'4=,F]G^<.B311 Z;?L"#0?5R>3
M4!7IR['_ #IBMW^;?EB6P^L6%M/<2!B6B55_=LO5& -16G?.>:]^;%VL+2PZ
M5Z<;&J&5P.HKT)'CG-K_ /.C4;")BJV)=B69>9;X>QV/3;(C>?\ .1ES8FL\
M5I%;*I+25<%^ ))^RQIUZ?/(7_T-]Y;>ZC@^M6;3\@O"*0EG+=-F1>HPVE_Y
MR2\H2/$+R>:.><_N[>*-VDD)^P(E4.3\QG74LM3\S:;%?6FE2V,%^!0W0"R2
M TH_ 5XC?OU\,ZEH'Y56]O:02>F&/$!BRA@3UJP([=1DH;R3IM@C2K%$KD@@
MTW''PWIV.W3Z>O-==@@AO9'"_#"@<^+4!"@^/4YS[7@+6&64N$6.)@ZT_E5%
M;;?;KGR4\\?F?Y[TGSCY@O=%\SZGY?N=3L)](NFTR\D@]73YW#R6CF,CE&Y1
M"P-0:+@S\I].FX-?RFLDK'F[U)9I3S'7J:*2?F,[1K-\5T^Z5:TM+ P*?%I9
M*?K;/HM_SB;I M/R]GU'A235+YZMXI B(OZCGJ8KN<8XIM^.!)!^K CU\,"O
M@9Q@=Q@5Q@5U[X%;$&P.PZX$? KX&?OB#?+ S[]\"N.N2'RA*MOK%V[@E6T3
M7(QQZUETJ]0>'=M\\W@X\8J,4!Q53BZXN#XXJ/;%UQ=,$IV'A@E.QP0O3!2#
M!*]JG!"],$H,%H-A@N/!B8,CV]L&1]L%H#M_#!D>QJ.QSY[_ /.1OEG]#^?Q
M?VR%(/,EM)&PI\)E6C#[PY^[/-6AW)M;NW>51QM;@PR*>\-P2:?\%R7Z<YUK
M5J;34=4L)4XSZ7.8J[T>!]X7K[J17(;K,)F$C0J97:(1W"CKL!Z4@]QT.>D/
M^<9_,_Z,UF32;;@WJP12W,L5:22%RO$LQ(8T[[?9';/HU:,MS##]E'X[%?BK
M0 C8^/3%;[39! MS%0QV<S+*%(IZ;!6Z]A4?CDBT2PL[OT@Z<HG"K\2]'6FV
MQ[CI].='T?R3IVYBCV<UV3XW\ YJ.E>AZ^&&U]^7UG)*Q^K*[ !@20"I WV'
M>G7.#?F9:>>O+L$5MY*\I7'F*=V8*(2B1P+_ #,\FU32@ J3X9X'\_>8/SHA
MN)8I_+EQ:7*J>2.3(5_R457'+_.F0OR?<^=?,<6KM=W3)>63(%B]%8BA96J&
M4KRZCOGLRR_)+6KSRYH/F'RYJ++)?BW>9"Y/PS*A9P*[;D].XH<G%W^17GC3
M[+1KRQU.6:#5+PP2DM62( J&?B*?S @')3#^3OGT+!$WF.2=%(X*T!)6E:;&
M0@=>V-T+\F_.FL0WAOM6N+)+&[GME2*,'F8&X.PY @;C84PT_P"A=-7\P:GH
MVDC6+F2&ZD9;R6\D)$<*@%6"JH&W?8X<><O^<3=&L9]#AL-8>Q!FD2[D8$M-
M"$)' ;E7JNU?'//OYV^3]#\L3Z#H6A6R7.HG3[R-(4HTA23@@J3T!-:G[\\L
M^4_^<6)K^[CN=>O?K6H2\ ;.U!")T^$.14D ]309](?R<_YQ\\H^3TL[C]"6
M]UJ_%0LTZ\PB#M\0.PSU&OER($*(Z*:BM!V(\*#:N^"+YXK",1(A<L*%:CN-
M_EMM7.:>8M2]-"R@D<>(&]:DTITWWSE4]H\KM/,.(FD78[_"AJ2*_+KX4S@G
MYN>8[/R]Y8\QZK=.%CLK.63XB-V?EQ4;5JVVV?&>1Y]>U5'D=YC=SU9F'Q'D
MQ/$^)%>OAGJ3RC'$EL]Q$@CLK&,"!"/M&3;U'/\ ,U"?84';#+5)N6ER.S ?
M6[R&(+XJG)V_XB,^PWY&Z.-'_*GR9;^GZ<DMBEU(".)+7'[S<?)AG50M:XDZ
MX#D&^^!'7 CBE<#.,#.*8&8?KP*XP(XP*Q[#$&W^C K[X$<8'?<8%<X@W4X@
MV&>@21Q:A,TC<5.G:F@_UGL;E5'TD@9YX4XJ-Z8J,>/GBJXNIQ8'%QBRG!*X
MNOX8*4XNN"TP2N"5'M@I!3WP8GRP4@^_!B#I@Q/??!B"@P:@I@M,\[_\Y*>4
M7UOR5<ZY:*QOO+:K?KQ%28X6XS#Z(Y"?HSYR:G']6U-I$(^KZA'SVZ?'1U._
M<,#A+YRMTD33-?5:I>6WU*[8>*[QLWN.GRSGCVOKQ2<0%N(:J4/^[$WK^&)^
M7+NX\M7T-Q;(GI6MU'+(SDJ8XPP8DD=:!?A[;Y]6O('F2/6](TW6 _K1R06[
ML3U'(#DO$DTXDU^6>A+:TM[B($*AM[D<9:4()(H"0#]&"+3339.\K*6:,D3
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M%%.^+BN+*,$KBRCIWP2OSP4F"%Q=<$)@I,%H,%I@Q!WP8E,%IVP6F#$_#!:
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MI H"HHP/[7WGKDRMXH^"!( B$4Y "I'N0*=<%QQVJ1-_HZ2$GD6XC;QIA==
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M>:DD6,K*2' (/+J1L14U%:?VY.;+S#;2A@91U!*>)6E"0=JCQ_ADMLM?C-Q
M6E-7/%B"./$FI4 ;'<]":YT?2M1'UB)F)*R(D;'J"!V->_A[?3AW=_'O&06%
M*=/BVV'8GZ,*XI/BX.>7$D[[[CYBN3+3'#LAHL9<!0J$_:/MV%.M.^3NUXR
M  "+C6FY/3<5(.Q/]F#)T)B9/ABXKR4\2P13V&_2G8Y&+ZZ4.VP3@@ '^2I
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M(_A1?LBHW!W/7W.";?S490RA^1)')&IL:; _V8I)KSM\*  N.(4;T)[5J/\
M/QQ6)IY@M9 C$U8L:F@'11WIA?J/F"&S%%?XP*)&-_BZ G. _F'^80A1K2UN
M1<W3@F1N55!%0:=J YYFO]1GOY79Y"W-RS,34LQ/6OSPJFD*J5K5AN=JC":)
M?5N:L:T;K\N^<1\\7B/YGGD::./ZJOHQACR)JHJ54=,[7^4/_.,7G/\ -866
MHZC#-Y3\EW7Q&_NA2\O8P=_0B.XC\#T/OGT3_+W_ )QQ_++\NPL^FZ.NI7L
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M35/RB=IXO)7G"PEL;_74B,FH(A=0\$2-6,1<%(<HS/N>-,\L_E7=^6]'\_\
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MSN:J*<MZ]QX[8-AMF/!R.3KO7]>*S6CD&D=!N26\<+!''$D@8<36F]-Z>/\
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MYZ9BGCK_ +M9>5/ #.)^6>7_ "L?RSHMU$GI^9=173A$HXHD5^PB9R.[.\H
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M*&'!7 J2"%_V\(KJ.>A7[(K4@&O(@_/MD9NB8)6=R:MU]AVK[X">5GA')2$
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MK4SN[B;2-9L(/,,4$WZ?G@M]/\R6CF2YCCU!FMUO'F"TG5=XV.T@)02\QQ?
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M*P1$4>+,0!GVL_*_R/;?EUY%\O\ E.#@\VGVX:]F0;37DOQW$E>I!=B%KT4
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MS2[K7?*=U?3*(Y;77K-I!(T\/V9+JUN/WL,Z\>BFA'6O>?>0-*TOR[^6]_\
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M)%?3[;4A:K&U/[X1*\I5@*-P5.+'QR+Z>DT,#R+)(?J=OZ0G7]VY@N+ADE4
M]VYT&'EO:)+=VM]KL:W3WXN%MA*:"*&Q0QISXC<"@^[!834=;TG18;J-)+WS
M+K,4LUP[? 75:*C=N*+OM@]+6UN]5\SZO/=!M(\N))80(5Y1")5,?IPC:A9^
MIP-!9W/^')KZ2[-J=/T-K=S(NSF=Z0PJ>Y(;8>V&-[<>GIEE9+\3:5ID*PVP
M7BHGN77D[5/<TW.3^ZBOM(GF2Z])+I-/,2649$@EDDC6)>)7W-2>F%'F/5Y?
M+WE"]TI$$UU?QQ+*PW+)+($8?2 :9RWS3=KJ>NZ!Y3N91!;7$$%JDD>S0L5,
MG(4/7D%&%]ZFJ74?EN6WDBFOVNG18^BC5;!C'^\\#-&N&TU_9ZI-]6M"UA8>
M:Y/TC9*!673?,%M\,L1IO1F7[L@NDZDEUY_LHKE7LK35FDL=0B&PBNYP4<K[
M>H WTY$M2N[V&>UT2XJEWY=EN;7ZURIZL<<A**?]7MDYT;S)??E]K6GZQ9,9
MM.U<1SW"C]M6H&;;N.^?37\C?(EQ^=7F;1=.TXO'H<T:WVIWL?2WLU(Y4)VY
MN3Q3KN:] <^T^FZ;8Z/I]CI.EVL=EIVFP1VUM;Q"B111*%1%'@ ,&YLV;-FS
M9LV;-GD?_G+W_G'2U_/OR-ILUA%7SAY&OX=8TZ-0A_24$#A[C3)/4*J1,H_=
MEC19 *D*SU_--JUQ+91>8].OM/ET_6=5\USK.EQRBGM_3N+H2Q21O0CBNU#N
M"*^&2;5;F2"WUW4-*L)'_35J@M9@K\/T9:V4#2SP+7J\=*FE&).U%P)J6G_I
M;_"VER".3S#YF%GIUI:V_P %MI>F!^,"1+RW9SSEE8GO6E3G3_,46DKJ\L%A
M=2S:9Y4MI=.<VR\A-=^H(YE6A6K?"D.P.[TZJ<E_EZ*3RU)H5OZ"^8O.7U.Z
MCG6/@(+(7,QFN8+,+QB4EF8RRON:[<0<.[;S!>:/<:D(E@U#7]*U"ZO-=N(A
M(EG^_E18[4*64FLWP(Z[IQ9@&KQ;J7EY/+'FCS!^D](BU&TU#2^<.JZ9<L()
M["\EX<Q(HY#C.@ZC]W,H5PZR1T/.[G1T\IZ[K-EIOK1:5YBN&L)FN2L2^N)U
MOM%N@(UY&%7:6!E%.B @<@,*/(K1:?/^;VERQM#;K(=;T:% 7DB:[224VSKM
M^ZCG>2$DD5W!J&R'S6>G^7-#\DZU8B=/+NJ:1##K(8F>"&\N!(+/46MR@3C3
MG#+&31D;@?MUR16=C?:9]1L+..9I-"9-0T>V6<23MZ9$\^C+*P"NI5&N=/D<
M5<+Z3;AQACH.JWFK_F+^8OF/2(^,A\J75_I<L$*K%<$VX-O.%^)UD:K@H!LP
M*GH<A.@6NG_X8\HRW=VPTK\Q[F\\KZY<,X4&2YC6?3KN95J!)!<B@;;;KN,A
M?F9/,:R:7YB>V,?F.SN9/+.HQP@LPN&1HP".3,"TH8KO\0D4C;)*][=MY7\L
M^9=)OPFI^4^"+ZH*E;=96AN8VV-5C6:-F%:J#OL,3\ZVM^7\A>:/J<EC8>9=
M:X:C:J%"->R(PGG@511?4526ZJQ"N17(SI7DNUTGS9^9'DZ&^MEE.MW$%K;3
M?[SA[6C,DTE0/WJOPB(V!!K2@P!J/EK4[-KF989KA=%95F(7E/:5 *I+$Y#<
M139NE._;"NQU*XCU![W3+^/3]8M%C_TKB5M;I).OUD%>$1/0%AZ9-%?^;)'I
MUY'!<ZC;6NBR/<&9AJ?E>ZA=H5N8V60?555TFA<T+)Z;,RM]FO(#)WJ5K=7^
MFQZJ&\N?F/I,RK"-/GN#!>QLU3Z,B3PP2)*#4=5Y$U(Y87Z3J/E/5)+NWTG5
M+OR/JVF@6VG7M["J3SPR1E6T_5"A5)>))2*4'D5'Q@C[(EK.\U%%M?-.F^LU
ML6-O>Z9-]:-N  W^ASLZ70H*$HRNM-Z4R1V=Q)>:=H=O9W$2>:='^N6T,Q6.
M/3];L[Q_48&0.!%<4&RFJD[AAO2,O#Y?NO,"22Z%>>2=?O*E6L)OT7>0&BJQ
M,<JK:3 4!+1\.0&Z$@MDRL_.&K6FJQ^7?.T\(@UM4M+36%MC')S/Q1&ZMF#Q
MB0'B6Y<E=.7%@*X-DL;JWN[S07U*'RT^HAXM1$MQ*^DWDB<72>"1)(@DA ^$
MJR2*30AZ YHH+[2[N>;1_1&JW4D1NY;*X,<\%&8P7+LBB"\M9J<.<D ='^!J
M\JX>SW=]JCI!K5Q%8R3)$UGYBM4Y6DC7!_=_78U*KQ=SQ$B,C*]%*JU.2$-U
MJ5WJ6IV$^M3>6_-NG72F_L=29IK"[)"B*Y3TA Z"4J#'<(!T/JH6Y F5R-7L
MKF'4U\NZQI,US)(VHW&B^AJ443NRM+<06Y"F6-R#ZB!!R:C( PWYW^8BV?G#
M2)Y/,T,0N=- ^H>;-+M)EYIQ6L6J64P$J[4XE68']D]L@'Y>:#9:9I.F7@:"
M[;3-5O))+W2O1GED5.!9D^LJ\8=XG"E74*>C#KG8?*WY$_E;^:*:3YH_)[\V
M[W\F_.-W<_4(+W44E_0$]U<L%73-5LP[7.E7$E2 K//9SD4A=6(CPEM8_-OY
M+?G TGYE36DVO6B266O?X=NXV]=51T:15N(H#%<1K 93;SHO-%#@A6#YZ^TW
M\X]+\M:VBZ7JUYKM]9Q+]3UORZ;5?K=O<()!'-INIRVDB@UXRPOZJ5Z,XHV%
MWF+\TM6U>]0>5/*6F^6-1F9VNK+S$\]O;P@#:YMH[9K@A).I@,A],_9<H1QE
MVDZG>76G6L>I7.C1WQC1+JZM4N+KUI*?&8H97ABC4GHK+(1XG.._F596?EV\
MM//*%]6N=+F5&CD*1NP)) MA'&L<3UZ$)3Q\<=YY_/>U\\Z9:Z+;Z/YHT7S'
M91)=Q-K*6[V,*64$U>=S%)Q(9I %H*5ZYY :\6:TBT7S#?:AH-FR<]0O[,AI
M?2Z,L1!H[D;*M:%J5VKD"_,DWGF[2?+:VEA/HODC18+B+RAY;MB9?JL*S^AZ
MTLE.5U?7EW4S3L.3%.*T154'GF.^M]!\G>8K6R$UEKVGV>GWNM6,,PDBL[^^
MC6VU".UFC92/4DA29E)(CDJ-Z9#)]3U_S9K/D2VM4^L7MAY-T;0+9F)"+;V5
MNZ&5RQ.X5V)/OGI6/T-$\M1WKR*M]:Z;;Z=IEK&#ZJV5O+62:9EJ%^LSN% Z
MML-S6D6\Q0"2>VDC1;;2M&B^L7@+*BI>ZA(_J1[UJ:0_1D4\H:E;W.LK)?2<
M[&9[5)$8<B\D<CS"B@[+5?B/A@B&XN86LY[^(RR:K;W\]O#*:11?6F_O!3?C
MU('MDCMHQI26=AJ5R;@Z%K\41GB)/&)X**5WV1J5 R/ZR9(X;#08;H7'UG7;
MJ2X2#=/3B=F,C = 2X&^2+7VLKO7UBO;V<Z/H]Q#96MI'599)(HE,C<!L*5/
M)C\A@N"UM;S6[WZY+]5&M*LUO:(>4T%E$O)'G K39!4'N<E0G(O/K*MS.NVD
M5K"P-6$D(8]^E.5=LA>J+'YBNK33;.XD86LB?6Y21NMM\)XGZ,Y_<VL][JR^
M9H8I);'1=?MK5GI4CDM5)IXG;*@N)U\O>8==*^DP\SVDXY UC<RR%N(^77%=
M9<V'G.T=8VBT>75+?74D=>*5G558T\.:[X2G2&OM2OKB65H-4NKVX F VCU%
M',UM2G19 * X'\[V0U._MM7LUXIK%G]=GC(XNEU$ EW'\U85ID<T32-;\V7>
ME>4=%M;G6-=U*Y2TTRRB')Y9IB%2&,#NQ.?J(_YQ0_(*+_G'G\I-%\HWMT-3
M\VWBK>^8+X'FINW%?JT+4!]& '@G\QY/0<Z#TQFS9LV;-FS9LV;-GQ[_ .?A
MW_.(,^M2Q_GI^6VG(LL=Q(_G73H5 ++<1K#^EXP*?8"@7%.W[WM(3\B+JZAG
M7S??>LUO9VOD[2M'MS'(PI=3Q6BM0D[#X'Y;T/;#?1]5^O27^OP*#K6L067E
MCR[ X!>%%C2*YDC^V:42A]C2H)R?Z*EIH>NZ/I"6WZ67RG8W/F&^L(I2S-+I
M](M/LF:I_NVF,SD=97=B2=\E9UY])\E^3+W3?])\X_F GUG4=1N4I$MQ-RNK
MB21DK2*VC)8*!T5:'? FDZ:;6W\BORDEB\X>8+#48H9*^JUI9/\ Z/\ 6P#7
MU.2M/*">*LQ4?9-)?K]QKK^?[Z\\K:FFF^;]/E$4<_PQ:;=6LT/UHV=Z 0IC
MD=05<UX5Y]'P]@UVU\U^3YO,,FG268LYX].U"TGK+<Z=.9T@FMF:A=2I9&B'
M7@R$;K4$&DIJMIYKU*^(A^OZSHE\ 7C5!++9$W0(52X/J*TJMXE%+4KD1\CW
M6ICR%;BRLVU"Q\K7MYI?F*T) %UI1D,?HF)J^JRH/4"T:OQ4!:BX+2U%M<MY
M:T2=[D1O^DO+5S;<ZO-"&ODM%E:K,DB(S0.36.5:%OAJYYJ#P:CH3^>_+,,6
MGZ[Y4FCU"<MS$-U#(B3NHBK3A*)!,-Z\RU>KUY_/IEO?Q^<=&TJV$.F:C!:Z
MYI:Q\C%;R7:-,>!9JA8[B*B[=#0X*TF(^8]'\M7][J9CTK\TDGT;5)I2W&'5
M+<5L[UN7&DB2<>,BFH#*HV6F-\N:]J L]<U;7M.BAFL)!IOGFQ9%01RQUMEO
MUC 8AU+4GH"LJ$L036H/6(+W3/*NIVMQ.\\7Y:>8=*NK.&ZYR(MK-=UA!!(<
M ^I)&:"M?M4(R.^<M$N'G_-P:0\MGJU_-%YR\N7Y)%R(9)9+E>!%5^)7DC=3
M44''HU#!M \ZW'F%-,M/-LP\I^=[F&5-&UJV'""[],+&5'$,U25HT8)._P"[
M!4F,2+2?*.MZ>]YJVL:-)>6IB9VU/0FBDDMF:H2\$(Y+- S_ &TX\& (JC X
M<:8UB[:1!YGF66WEX6VB>>/+S"-XVB!>.*<2A0778&.8*ZC=).*9TC5;Q+^R
MDU+7O+!OKVWG-FWF;0&:TU"VEJJ.E[&OJ(L@%"PEC*$497HW+"_1;5!)J$-Q
MK^FWD%W;$65VB(;6X]-@6T[5K0^HT;OQHHI0-^\B;B3R'W]EHT*+#!I$OD@/
M(SI:3,VH:1?2T)$<3DR!/LU7A(K'N,,=/U:"SMM3T+5]&:[81O<W.D7#AFM>
M3 &^LKFO&1/4JS.*4W$@5OWC:.PU^2UGN-)\Q:=?:.LBQW6G>98&G^K/&M3#
M- "7-!O0I45!5W7XL%VNK:%I5S8:?YD\LMI5M?.8OJCH;[1IPZ"GI+.*PMQ^
M,\2I[K3CD?F;7=!FU)=(6UU>>QD].+1=3F]?A;_#);K9SS)ZCB6-N2*]0?LE
MN8IDRTG5M&\WZ)-K%K+I^A>8O+[I$+28QR.]DZ>G<V\T<($D2N00:K\)^*@I
M7"5=;+IK,"*]IIMSJ=Q [S6PO$LKMT)NK:\LD7C/#, '*K]I2LB?L%1<FGZ%
MY@N+6V\TQWUQK;VK1Z!<VMPTUQ*@%#'::C&0;VT:E4#5FCW1^@?)+::-K_EX
M)<:'KMY9RV?&29-7MFG3E&2M6:$QR+'0G<D<=_' =OYIABU.TLM7YSV]X];S
M3IYY+B BX9F2]TZ[;DSVQ+$O [%HZ@@\<YO^9WDWREY?O[:SL_K?E6_UY>4E
M]"\D6C74P++);WUM&0JE !1U7WI0-3C%UYT\R_EIJD-WI=JVE^:98FL;F1Y?
M7T[5-/D0HR7$:/QE#5%&5NW)6Y#;K%IIEU^:_P"5UCJ=KYE,S^5]6BO[CS%<
MPM=WUS=P1&W6VU"X*RS2HL<06U)<%4Y0GDC  9^6OE_SIYKU&>Z_+?\ ,30/
M,/F?1;A;1?R^\Q70TW7G@>-371#JHACDHIX?5Q/\0 _=')3K/YU^??*9/E?S
M5;ZMI-_IK,QT/S5I:2S6C[KR@%RD5S&G4?N9C$1T3.\^7O-&DZQHEKYKTVS^
MN^4=0>.WBNX62-X+KXEDMMV!)1U*_O%1FVXER>.1'\W?,%@=-B\MZ#8ZGKGF
MRYF@FL+*UL+APK5Y*;B4QB-4*U[EB*T%1G-/S@OO.MA;:396'D;78+(^D^K7
MATRYA@/P\A CRQ*".>[>P SS8WF/5$UC3'U;RO>W.E)<QF[@%$_=DT9DY$?$
MH)(K\LF?FCSSHNIPZ"L2_HJ/0K=M,TBWTY"UTT,<LIBFN>)XK+(]R_[73.):
MC<76D^4]72X@EM-2_,#4 UG:S5,R:59,W*Z=?V0[FBUZTSL&E^3KBPUV3RE/
M,^EW<=I86VHW"D^K9Z;:V$5[>[FG&HD137OMGHZST31;.[TJ[$8CT&T2+4+"
MUE%7OYXHRRW-[<,U"L%>03X478[M09PG6=374_+_ )EUAV<)K6OL]LIJJ^E'
M&X4JON"-O?";2JZ?'>ZKI21P796XAMP0.2E;=1+P!##E^\^&N2&:PTKRKKUK
M9ZC)+<C3[.[M^1#/ZEQ)91F*"N^P:5J4\*X*UBMM%K<'I*$3RYITDTKJ4*7(
MWBXG>I^( ^.![BZ$VIV6DZ39K9ZQJMK:6\_HJ540DAF<<]ZR,%Y?+%+&_CM_
M-#7C21Z@+35VMUF:G"4ST$IZ=BNWMAI8V,"-J=U'%-?>8O-$]Y%:&$UHJ3^F
M2S; )05/RIAQ<1:3SNK*QO)+:T\I$>G=+4M+<!0LO(]E#,%^>1U9['2Y?,.H
MW+/#9Z5I@>)5-/4:9*5%/$G89&?*4EU:7U[Y6AN7.F>;]-&IQ<U#-]:52R%"
M>ZLN1?5'E@\E7UXYN+FT\SR!70[+::C:2TFY?ZP-5R4ZH\_Z3T/0C;B]L]-T
M*&UO$D8$QQWT8D>3DW0([ @GID7T\W%Q-%8S,\-U=:3=_OV/PS2:<[O;3QD;
M$CTZ$X[SGJ(BT^.>UB,%S?2VVKI(:$*NH6W">/Y%EKGV*_Y]T_\ .(\GDW2[
M#\^?S&TX#S5K=D/\*:?<+\6GV%PF]\ZL/AFG1J(.JQDGJ]%^LN;-FS9LV;-F
MS9LV;&21QRQO%*BR12*5=& *LI%""#L01GY_O^<Z_P#G"^Y_+&XN/-_Y:V,C
M?EOYSUVS6XMK="3Y?E;U28257BML\A5(6) 2HC/12WA/2M0TS3;R]UV%(YH?
M)I;0O+-BBE[B]U&<E9+HHAJ57F: >*+V)R?Z79S:1*FCR1)%K'EC0;K4/,,U
MS\16^U5Q<&)^##^[2(*O+8'<TY8+9YK_ $'\L?+_ *;RW\&@F*Y2 +)(WZ2,
M5M!& :_&4GD%.E%)IMA]?1RZWYGU^4:G+86&F3R:?;WB/R.FZ4M;69+9""\E
MS=S0M%$/V464@?$,=J8FTN33]%:!].O I>UT2VI+^CM.FD+$W+GGZEU*W!V9
MC\ 4+N%9@I=:A?:1Y<AN[5+B:&_MX+O6[)E;G=16=SPL;Q150?066.&9NK41
MJFF=&\T74-FVB^8[*P.L:*]E+2.V1P\B%;@R+$QWYO;RNZ[?$5X@[KD)MM+O
MO)ES9><S,^I:-!QN-6MFC7T;[3;A!;KJEIZ4KCGZ7I32P2$/&_(J2IKBU_:2
MZ1;:]I.FOZC^3KVU\Q:"%8A38WA-R(:@;A)58?ZE1[$V\MVE_I.E>:;66)9-
M'NH(K]:L(U:PCNH>;U+457M+Q%XTJ.##84R.?EE<1^7O+OG9)76ZURUN;CR[
M:JQ/J*]C#</ .U5D5#Q-35JC<FF<UDN[G1ORK_+."U4O8_I?49II224:X'H,
M8@&/51$0-Z#?OG2?,,=A=>9//FH2.PB\U?ELNI\):J]S=M:+$* */C *D$T!
M_7#=>T2UU_R1Y6>XN9K;S=YAM"\'!T^J7YL9(T6TE;E7U7(0J6[_ !=R<E$+
MZ7?Z/Y+\Q0RSV]QY<2X\M^9Q+&4FM)KDQ>F95D^% DD<=>0V#[CKG-=>\C0^
M9_(]M^7-[;P6^H:!<W6M^2]2FD6%+VWD),UF\A-3)'0Q,#\2L%;[.Y(/)WYA
MS^7K>?R]YXOM0@TZ.406VJR.\%UI=ZA0/'>!JE'J@42G]VZ_#-T#B3:KI;SW
M<C6L$<VH:O1KC35(B37HVFYB6U"$Q_65#?$HHV]4)-09+Y5\P6=GJ.HKJ.K:
MOY8_=+#97E_9OZ[I#\#6=S4H6XK55=16@*GL,E<4^M7MY)<264&H36L-S:B^
MT.UM+Q_VCZ<MLL4$DT+&@:(QNU >-'4'(EY8U6PDN%.B/:Q'47BMM<\K:E.8
M[.^]!QRCMIIS;K'+5?W)Y[.OQ!&^(3"POX)K+3([B_U"Y@TZ=I=!\PZ<%GU/
M1Y(:^I;ZE8G@\T1"@3!*L% =E79L*KS2Y_,.I65E]1T:_P#TH"(=4T&^,$,L
M"4=I4:1*\*H2%5V /[)&&%]/HD]Y'Y7L9[_0;._"Q-'<W U"VOWB8,C6K2RR
M6ZW$3#FO&2-@=@5^R4]4LKY9-'EO+B&Q\T6?+2-.UF4D:)J\**72RGEE4O9W
MJ?$$$B@-]DD?"Q1\QB[FF75O,FBW_DO7[8B,Z]I7&Z@$H4?#?/:M)R   YR"
MM*_'X"-3AU#1$L]4N]"6ZO+1(OT_;:-SN-,U71Y$#V]W:O"">2$AN+<6%?A.
MPR=69\LZIHMK%=+9^8-&FFFG%FH"N JJYNO3@/K0RJ64/(J\2WQ_ 23@"^\N
M>7U:#6;?2]?AF/[P7MA<WE]=VLH53Q6178@\6VW;E7XA0$89:=.OG/R_>Z!H
MM]IU[JUK=R7T0D]2VN8;Z2C+'=0LD#VTDX4L?@X$\Z,WV<,M.U#0M>TY+'7+
M"&X:&9;2YL=7+S1).01Z$S!7X7 D(5&- XXR)R5SGFKSSY$\K65Q<1RR:CY=
M^OJ'M6U2'ZU86]>L+S1?&HKLI4.H]JFD5_*[5K[\LM4UK3A=RZ=Y3U^!(=0L
MHI%:"6=WXVLT?(_%%RV9A_DUSL7EK4]0\W+>^6H?\,ZAIMC=+J]A!YE@%M;Q
MW]O-%+\.IP6DUS:._#[7-8ZC<COV37?RO_/>'1M+\Q>3].\Q_F-Y8$Y0^5]6
MGT_SO=Z+/*3(\ME>V]U*);.1B2LL,L;J=IH :$^?_P W-%_-O2;&#6O.OD37
M/RTT2*YC2&_2VL()UD,3"5'T^WE$GHR*J^HTB[T4%JTP@_+7_G+#SOY"UFTM
MM-\^W.AN8Q:6^KV0GHL2M40ZA9R+.)(NO$\6*=0"*Y)=?_-Q/./UF;S5Y.T'
M6FE<SSW^EB71KQBW62Y&GO-;S(W421PD?SHN^<F\P:%^7<RV^MW)\PZ7 O&3
M]'Q36-W:R*U2KK.JVXD2HILQ-=B!G/O+VC>1H_,PO+/3M:\U:]J$BQ6%EJ@@
MMM.$LC'B\D5N[,P6@ 0$ ]\["/*4[&Y\Y><YA/+=&&.9V4*/JH< Q1(**JK'
M4*HP-<^9=>\X>9?S!\U7):WN_/&L1O>QM4<;>^DD>WMMC4+Q1 P[A17/3&KZ
M%;OI&DV_F&13ID=LEI9:+;2&-A&L9 E=11I)9>+,H/PKO0%JG.&:G<W.K7%M
M;06T.EZ5Y>6ZCL;1%,9N'>15EDD9JECNO8<0N$\10/K,.EP?6M-MG6Q2]D8I
M$D]Y,JQR\OLU94:IZ4^62ZTGMK[7]*U,6B:BEQK^I230-)SB9+2*)%56ZLO$
M$@]QBDEU/J]B3=2M?3:S<?XHU)T58;=;6V#Q00%MJ\6"C@!3Z<*+Z_OK7S5I
M'F*]>&;5-1#7Q@5:11V@!@C) (H#2BK[5Q+RY92:_JTD%N#;:9Y82>^NG.T9
ME')F)._95"USH7EZ:?3O* U,"1-0_1%U<VSNM>!EG^T#[-**?V9'/,.DC2O)
MFG6=FKSWE[<QW&I7"FJO%R C6O>LAJ?<80>:+[T].T;RI"8YK[7;B!+KGM6*
M/D1&&\.IK@"&SU*\M+?2K5'37?+%Y,FD3(*?6([:KRP>H.I WIC;ITUB6Q@3
MC%HWG])?5M5),=IJ<7POQ&W$DT. [&>VN[K2+W6)8K7]-:?/Y3O9>1I!>0+Z
M<4DRTZ, *'"0P26]KI.D7K_5[W0KV]TBX'+["W2'TF7_ "2WZ\^DW_.$/_.)
M8_-:;0OS+_,K2 WY>>6K>&TL],ND*G5M4TRZDH64BC6T17X^SM\&X#C/N> %
M     H .@&7FS9LV;-FS9LV;-FS86:UHND^8M)U#0M=TZ#5M'U:![:\L[I!)
M#-%(*,CJ=B#GY^?^<B/^<0M?_P"<<?S!M_,GE*UN]=_*^>SU6Y\N7J@27&EZ
MK))Z\5E<RO7]X$=A"[?WG&M>8(SR'Y4U.UUBRE\M2O)IWZ5NI-5\VWKUDFY$
MR1VEH)5ZJ8@6XKL*R$U/')O?^<!I7FUVL+&;C/H[6^EZD8XS':Q6+7#7C6Z.
M KR\7(0U^"1QOMAU;7/Z$\RVK00QQ0^1K-KG4%D!8Q7$-KZ\Z<^,C$JACC!J
M?[QF!JS')'H^ESSZ9J/F":.6;S%KUEJ<UPTCB2%2]O(EI# X%4W]0$UKR-=@
M:!VB75G<Z]Y3L?6M=6M)?+\UC<1S !G_ $E>V\DJL$X* ZQ,H \/M=<%>78K
M^_TCSC^6.B-' UE&OF'R9J5U5V@@2:1XHF*U5C!<P^G4*04<UI08EH7F%[/R
MUYQ]#3HKC0K9K6]M].N@>=K9:E!*MU;/P^&2&SN8I8A2C!%VJ!N2ZV1IGFBY
MT^W5M1TG4/*5K;6C1$R_6HM):.0$,]#ZKV[-QI6K"@..TW7K_2M.M[U;:UUB
MVTZ%]&U73U4,LL4< +1!2Q_WHM(_7A-*&DD9^)HS@2TT\-YT$-A)//I_FK3;
MBYL+E7)+RZ:+2>QO)33XF$<B1RUK7@WVBV<_OK"T/D;\QM#EMQ"-%U*'6--5
M&;A''/"+\B-:TXB*0BO<?/)OJ.KVGF74/)/FTI%#8^9]+'EZ]]$LR6=Y!'$D
M939U(D$2G??9MP1A%:Z=;^6M*U'RSYI2:3R]H]\;/6U9PT^GN36QU>QD:)F5
M']1!(@J0=ZE.28:7":G#?WD/"V\R7]]9O9:_I9C>.YUC3TXK!?PQU/\ I4*2
M<945N5&4H74U(H6,&HZ-IV@Z5J4^O:!J5ROZ!N)HPM[I>HAU40W,JBO,@@(X
M/Q$!&I4@P_5+JUU^Y\O>==2M;.YFO+@^5_-$<\:R":2"0V<DO&J /&SQLM3]
MABK?"0!!M6LG_*7S9JWDG62/-GY9LL5_H\HK+-:64H5V]!$I*PA9V!56#*NZ
MENC= O5U)XY+[R>-/\[^7M4M(Y)M)U>1;EI+5TJC0S^H*N#3C(H1Z@J=^: 1
MY0O= 5H-'OKF_P#)_F6&0S0G5I7N=(O4DWBBDEH)K<54+ZM67^9=LE=S8V\V
MO7%PVIKY0\Y(CF;3-6"?5-2$S "WGE*E'C=4^"8!@10%B:<"/45T*VUB:;R_
M-+Y+U2:]1[ORI?1RM:BX'*D]LL2,\8-"591)0;J%&'UO>?EY<"YDU>PU?RKK
M-RW[E=-F6*PO+J2@9XYXA/$_(&H51RH/B/4"8ZKI-KI?Z9\JZE91^=V:QCU%
M%$EO!?W-I<,H]<'^ZN$1@4Y? R-QZ5R&W*VVD:7I5W%&?-7EO6(V2XTK4G^K
M7:,7:,V-XLS+&\L#H0/5*R&@*DC%+&0G1[77_(%VNC:S;RSQ:OY8U%B+BUGB
M9HPD0DY+1TI2.5B".A%0N!;"YN?+UM+YCT@W&F^7Y)FL?,NG6S,DF@W,Q4M>
M1(X+P+Z@YTIQ1J54H:!LT'F1_2O[72+3SHL-Q)+:ZUY>,=OJY!/$374:M$_Q
M\OWC!B#WY#;.I7/FV/3$MM/UK7[G2=8DE6L>L0_5XFHI++')';11\E!W8%@#
MV[Y'M?L8=0EAUS696TK4K.("Q\WZ-2\@,;#>*Y:!8V>WX;R*5!7[0HU&#[;7
MM)@U>WF\S:3.U['2Q_2.G-'<6NKV;K2*.:=VCCFC,BUA5Z,: JM>LC\T)(VF
M1:SI4%K,\@>WN;/4AZMM=L[AO1F]= D<I.P,@6I^$LDG$YXW_,'0+.[ME.GZ
M)>>5+B]%PTVGHC-;LJ DM9,Q<AHR@+Q<B *GX3L>R^3//>E:%Y0L5TN"V@U"
MYACENI[<U9[@J$G8LP#%6(W4].GOD1N_TY=75YJ[)Z,,Y>6P-@%@NHU<']V:
M<0\9WZ_3XF<^4=,\KW.EO<:EJXN=:E#))<W\L=M<QQL*FU, Y"1*&E6#!J5%
M!MG&O/WE+R/HMO=,?JTB7S@L\ Y3J">7IQ58\0:=5%?EG/O)?E27SIK \OZ7
M GE.;49XCHMZ\WI017\7(117D[?"AG#<>5:1MQ9_AKG1?^54^9;;4-3\O:_I
M#I-;2M->Z3>QB,P:E;GX_37]B4E:-3X6]Z@X2>9M&TZ'6O+FN>59P46SCD"1
MD"6&YBE)9'4;JZF@W&=9,][^;VJ6NE6$<D/DCR[+ZFHW94J+V\7_ '3%4;HA
MK4X1Z'#8:GY_LM$TM%N8Y]0DO;J-26]26P3TXBP(%%#?['KG:_--S#=:Q<WO
MJR)8^5DEF^M (#-/&@5 !\0*A(W[]_?..^9O6N=+TN[^MK-/J.DV\NH3*I"(
M+VYFD:"@Z4>B[=0OAA/<:79?7=*AMIZ:5<2VUA&4/ 2W$4"EY&BK4CG(=\&>
M5X;A=9TB\OW-LL=PBV^G054M;REDE<MT *@@GOVP\TCZM>,\$1633/+WEK4)
M-0A4CDC-<.\49!VJ.*GY8EY6>*P\QQZKY@2"ZM[30VN;9;CE)&@96:*,QBI)
M$E=C\\CL,IT7R?K4+W<J:YYBE9KSTJ^G'!*T;ISH-NX(K[9TV\U.>>UE/H"T
MTC1O*\L!B;O%-'&(I./=GD-5P!!<WTWE+3;6[11<W5O'I]O% #NZ+5R:]645
M+'^8C(%K&G16_FKR]ZYY0>7=2TV&]=R>0:=CZO*G@IIMAS#/>6[>?(M/C,.M
MZ%JC:M:1*"?3,<A#. =QRC('N,CUT;.ZUGR=KMK>&ST[7[J26>U4<?J6J$ L
M4)K57-&PO.G"_AO]#N(^%_K=U*WJ-U@UFQ+&@(_9E3/:7_.*O_.+M]_SDQYE
ML_.WF'39M*_*F&RCL_,-P)#%/>ZG8.JBVLW"D\FX@RN/L+W#E<_0/I>F:=HN
MG6.D:190Z=I>F01VUI:VZ!(H88E"HB*-@ !3!V;-FS9LV;-FS9LV;-FS84Z[
MH6C^9]'U'R_Y@TZ'5=&U6%K>[M+A>4<D;=CT(((!!!!! (((S\_W_.5'_.'^
MJ?\ ..NF^=]6\IV%QKOY7:M:"YL=9GD22[T_4;BZ96M[LT4J GI+&X'Q&O1F
M*CAVJV,=SYREF%JUOI/Y?Z)ID+P3(RA8.8DDA0\3_>)9*"2?VS3"R[MXH-!L
MKB<S'5_S#OKB_N H4HMC,;:]O S%2&*V]JB,4(XT(J0<Z-;WUQY=\R_E_H\C
M&[N-8T?47NK;B!1;F=$H"O)?MRQHA:M14GV2\FRZ/'KFKZ_J-K!;V-QJ4%GI
MTJ0I'';AQ,]L"5>)F9(4C;>I4.W3F28[Y5U&;3O,AU*\OY'TKRQYCU2TN&-5
M0:5J36DLDW(T+JES,K "AX!\GVG:.\4?F/2+/TK^\E]::"$GBMRT4R:@UNA
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M2WCT M$.0-SI<D;48GH#]FO>F&>DWMG-YULK>ZE>"S\OZ(HA@ ^%+C@\TM0
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M1"EK=7<$$Y%HTS;>K&QME>C>I'4)A2VK:QI>N:_;M/J_E>]FN"]U=\GK:NS
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M?S1Y$BTF^^MB[@TZUUB"2XTK4KAT_1D=^W(3V=W5:>A<HOP,P!^*O8C/2GY
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M_P XO_EC^:,-_<OIP\J^8[^2*:75M)1(GG>$IQ^LPBB2CBG$DT;CL&&?+/\
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M_P"< ?.?EQ;;5/RU\[)YYGTQ1I@MO,U+74[S09*!M/NKZ#C%<O"RJ\,Q6%P
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MI QY*RGU$VI)(!QR#W(T6[O;B+S 9=)U/S+Z^F:G%'&;BWN%D7G%- X Y,"
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MM(.B2HAH15UE5?V@Q"!3>".RNKO4K".WT;4[A[37[-$"O87\8"+>0U?EP4!
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5V;-FS9LV;-FS9LV;-FS9LV;-G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>sny-20231231_g24.jpg
<TEXT>
begin 644 sny-20231231_g24.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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MLV;-FS9LV1#SCY[\L>0]-_27F74DLT>H@@7X[BX8?LQ1#=O<]!W(SP;^9/\
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M8HU;U&C)+N4%65#3H -RH^["!?,FD.&-Q821,F[O(L06-  >0,C+R-"-P3U
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M;4^T1U\<4BLWMPP8Q,SGDW 4%1T(!:N"%B0>IZD($G,<)  #7KRXT'Z\8UH
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M-^V=,+?4[=4AB61Y#P  WX]?@&^P\<,M&T6>?4K6[O+<)/-3T4?<0Q@EB54
M?$?'MXYT^.W6CQPNMI:HW!NIYCK\ZGJ<,@9W9+>*G#D/C4D*H.XJ*BO^>V&-
MOZ4;L(2*L?C+#E0;;U/?KAG)ZY,310I< ,>1D/"G>M-ZC;I[XHJ^M  RF)T8
M-Z:-Q&YZ$J-Z]J=<5NX$) ,'*4\0$#&H->I[C<9<WUD&*&" W =N;R.3Q0#P
M4#?#V.&9DCDHK[\:!2#0;'L>^-DMKF) L<M'+;ADKM\J@=,?;R3."+BV]"+E
M4LP\#\) %>IP;;V<+3_%"K[BAVH >XW(PW2VD E]%&0 =*[5['$)8I&14D #
M _:VW![X7W$9$U3&S*Q ]0#D*;?=7 #J.<L?[MZ"OID[[C>H[86S6J, %)]5
M1R0U) (%.H-:?+ J642(0RE'E;=PM37O78[$C"&XMY(;N18561!O52>-#V:I
M.%-W% Y"K !(N[+2CGO45V/7(7K/EU9WD:W4NK@DLIHZC8#QV'OMGST_.[\G
MM:\@7%UYN\FPK?>7.8N=1TDQM.(6;XFDCB;DOIL*5 /P[T^';(MY#\]H;">_
MT_3T%U;O(CV%O=LUF\3D-(CV]T)3&Q5J+P=5-*TY9Z=\D>8_+7FV+EHEW<:+
MJ\(Y7.GL6B$B \2YC'.,L"M&% :]17.KP1ZG"41F%W;D5$IHQXGH59#O\B/E
M@YED0#DHHV]0:5_#*)VIB3(3O49C0+4BIQG(GJ*;9MC]&-H:DG<8ZA KC 30
M[=,=!<7%I<0WEI-);7-LZR0RQ,4='0@JRL*$$$5!&?2C\DOS7A_,;0S9ZE(D
M7FS1HU%]$*+]8CV5;J-104)V8#[+> *YV_-FS9LV;-FS9LV;/,W_ #DA^<@_
M+O04\N:'<</-_F2!_2D0BMC:UX/<'>H=MUCVZAF_9H?EN)B6-7+$DDDUJ23N
M3@D.&7;J?OQO+CT]]L>LAIL??%(V-33%!4GXB=_#!"$C?J >G]N">8)VQ4,%
M%34XHI!()J1@I0-C^.*JQZ@]-L4#[^X-/GF9F7B^_ "C#P'\WT=\6%:TS27,
M=NDC%P."EG)J0J@$EF[  "ISQ]^<7F^]NM52337MYT\M1"=K>ZX$P3W('HW-
MQ%5JDT'IQD5IN10MGE.75C'*_F#6)Q+JDY$,'UL.QENYF^ K#Q8GC7U&6GQG
MXF4TB4JV^E3SV]IJ$ML+S7=2//2;.YG*^E5N0O+J0< "%')R:@*&J17&+I4]
M^)]&CU*;6#J#J]Y?64#"XOUXJ ( O(*'+A4)V H?B/$9UC1- BT#1[G4XG2Y
MU.6-M*T>&)(WXBW8++):C>B12/P#U(EFJ:E(JOZ*_+#R>FC6%B+F-Y]2ND'K
M2.6D*T9B0"W6A)J3]H[YWO3(Q;NHC4J(BQ  ^T@%.7(^^'VEPMJFH27T[<>)
M(6)!\*H*=33KMV.3O3K>4WAD#M)5&*1(" -ZJ2WRZCODLMUD$?U>;B(YVKR5
M2:[?Y1."U2ZCI'"C>IU<D@GB=]ZU %!@V**;U^3J67CZC%JC=: D5WI[$X:E
MF6W%PH+4^P":J=ZDFE*_/!'IW$0CBCEXS7#AO4,9D8G^4=*>V&T%@IXO-19#
M7XPOQ?-NI&#([:3A+Z\2O'(:+\98,H ^UL*=]J?3AC;Q!$3X!# O4E3VWIOC
MRB. L5(UI4D] /:OCBZ6Z2E#Q_U6'MMO7!<-J$=RL9&P'+8*QZ[ =*8.C0_$
M&0,O0,.A\,8UM&6)'%6%:#O3"^2!PK5WZCB%[#M084O:K,Y>2(<A4$*:'CTZ
MT\, /9@56($#C16IN*?*GRPKN%:+GRCXS!@"=_C'7I7V[8!G>"?EZC4Y;*C4
M',GP) J=NF1K59;6T3ZQ=J888*O)(%(X+3=G(J1@4E9E29#&7*!DDC('-3T;
MIT(WR):SIL,]K,)XTF@G5E;NE0""O']?CGS%_.S\HY?R\\P_XI\KHUKH6JR,
MDL:LZ+!<2J>:,8Q_=E>E=J5%:Y"_*_F::*Y1X6FTO58) ]U96Y3_ $Q54<9H
M68(&)-2!OMW[9[5_+7\P[7S/:)IUQ<1PZ_ G-K.5FK-& 2983*B, >))0EJ;
M\25&W7G1XPHDC:(MNM1\+5[JPV.)D5^?SS;D;;XT@$[TKWQ/8$]LW#QW[Y@:
M$U&;KUZ8F=MAOOO7*.^^2'ROYFU;R=KFG^8M&G]"]T^3D 2>,J'9XI!W5AL1
M_'/J9Y(\XZ5Y\\MV/F/225AN@4E@<@R6\Z;21/3N#T\00>^2W-FS9LV;-FS9
MLBOG;S?I/D/ROK'FK6I.-EI,!D$8-'FE/PQ0IU^)W(4?.IVSXQ^;_.&K^?/,
MNK^:-;F]6_U28R%5KPB046.&,=E10%'X[Y&MB15B#CPX1N(-?F<$!Z_"-B>^
M* 4Z=:8J#QJ"=_Q^C%@36IV'MBZL!6F_<XK$0&%>O7Y>.+DBM/N&*A]AMT_5
M@E264;_+% WQ ';%X]S7IOOBRLHWZ'$ZM$/W=#&-^%:$?(T.WMG/O//F1;'2
M+IC,EG$D;.\D@5^7 %EC!Y<5YLHY%NB_,9\T-<\[7VK7ESJOKR16LEW)=0,S
M&22=D+5N&"'^\W)4D[*U1TKB^DVLLDZ76H6JSPP1O*UNI#5+!7:T!#>DK%$3
MU33^5-@/BG"PL+'6]8U;5+R>">QCBNBL!6Y%O),C_H:S>3@J-/P'JR$45"*[
M<\E'DORO/IUDNNZ[:M?Z[J\Y]6#3ZQM"TWQPV<<_V8_MJ%*#F RLH0_%DTMM
M+N+_ %'23>>C-/J$23VZZ=RABMM,M&,%G#;0@#TTFDYE1VC1?Y@<]9Z%8BWM
M(2623C"C.VSUDH.6PV(JQWPZF>98"8J-)=-MMTB&W&GX[9-]'<6MJD(4J .4
MKC;:O3IX'?.A:3$XM'<JRF61F!D/V@OB -A3;#*S=PS5D5I')+.N_44^!-_E
M4Y)K=8F@7U%#,QJ2!4'P!W_#!1AA#/-QYOQ->E">@VW!Q>"TE!YSR_6UD<$(
M/LHHZ+UZC#$K)"ZM(L<,-0 H8@LV] H -=NPPYA>!RP8H+A14H32@-:57?QP
M=;HX'JLK<0"K$]Q7;C7!:6<DG+U01&W?Q-*BNVV*PZ<8E+&17Y'DS;<F;L*>
MV.6"*.1BTBK++2@J3TKT&&$,3@G;FA)I3V^5<6], 4J "-CMR]N@_AE>D79@
MQ)(/?J <"O;$U*FO'=:FAVZCW^G"J:W5W9BQC>E"%- U>O:N!I;((C IQ"KR
M#*:D[&M=L*3I37"J3+\2BH/VB-MC4D]O#(Y=:;.LS(40F(CAS4<:KOU J/ZX
M4ZCZ@A7TK)KJ7:J1T->@(;D0"/UX27ELL;L?16()2-N7PGCN>.W:OW81M&LA
M, 9I/44T5SU(I45%?$;YRKSEY9TWS+H^I>7=4M_K.G:DC6TL;DGWC=2"#R1J
M>'SSY@:WI=]^7/FC4_*?F;3KUH+>3U++449Y%==UC>$79F!J"*@;$CC6N=V\
MJ_5=<;3M;TRM_>Q_5O5?3/W GA+ "[B5WK%+'*BUC-8RP-""S*WK/2IS-9\[
M:=28Y&BGAXLB+*I^)?3;>/<UX] -@,-4D1VX2!HW._2O^V,S(R'Z*BG3YUQ.
MC [_ -F-:GSIE\AU^[QQ(G<D=]\NH[_=MC2.6^4=ZTK_  QK58#V\<[7^1?Y
MFR?EYYF%KJ,Q_P +Z^R0WRD_#;R5I'<@?Y-:/XKXD+GTP5E90RD,K"H(W!!Z
M$'+S9LV;-FS9LV?+W_G*[\U_\8^:O\$Z/=!_+OE"9EG9#5+G4@"LK5':$$H/
M?GV(SR?"0M 3T[XYG)KW]_EC0=A3<G:O\,%*XVWW&"D!%&)!VVQZNHD-1N?
M8ORY4H!6F/\ B'3]G;%D-.-1OL<%K1EJ.ORQP &Y/WX*5@.AIX^V+H:]ZXJ*
M \J[8I7:O0GOB,D_I!B]* 5#5H-NQ/;/!G_.5/Y@Z>MSIWE9]0NI1?6_/T4Y
M+%(TM/@D#@CTR8@25'(CX0VYSS3:7,EQ%/>LR-HN@6T+7$O%:2RE(I8XOL\&
M,C5<['X%X@$-0RR&6:PU&P$J-::E?-ZLZ.@2VTVU0AV]7ES+F/U.4AV9YV7]
MH(,[/IVEM^9?F6RBGNFT[RYI=K+<6\B*IATR"*@N=5U"6@264JYXE>=9&*JU
M,F&L:W8:]YEL?+_EJQELO*=C'QM!*SB:"R0L@NG?>LTS GFV[-ZLB[+'G0-
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M)Q)((K05IMMOA9<V9<AHWXR5K\:AM_GOVQ&&SNCZ\DI65&I0;BAIN:=-\ -
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MR9*L4I^JPOS9%].< U^+[3$T[@5R9>6O4_24[P*@=K<,4W'M3Z!W]O?#ZWU
M3S3,Q8112"$(JE69J5^9'7_,YT/2+&>Y2*I,01:"-".);KN34DT/]<F5M8QP
M2,@ 4HJB1EVX,&H!4^/;]620R^I$D53Z2 R2'=BQ_9Z5[#MBZ(K(843FJNS,
M2O+K0UITKMXG#VTM4'*II45('MT%/#;^."DB$3!D8U<EJL#T/84K788+BX\J
MDEW(IRH*;_(X-DKL*%PHWIN?>HZ5]L2AB,[\GM^)+4W/0 5!-*4ZXL\ 8^FP
M6BKNPIL>G4U(VZ8)BMXA0#B1WH*-3IUQTEK"LD2\6W_9'[0I5ONQ,P\6HC$'
MN "3OXG?PQ5+8,U:A"I#  CB?O'Z\"7-HC\E5P&)J*$"HK6G8]\*N!C95,=:
MG@M*]S0TV.!Y9(HZ!VX-*S1T?:A I\J'"8R?OG#24(;D05HM*FE/IP#?(H]0
M-106^$UKQ'@?8';(W?0?8(/%Y%W /4KOM]K]61>\0&-C]@@TY&A )I0DD#Y9
M!M1LV^NHR1_9*U+"I%-CQ/T]<AFN0M;SW4"H6( G7K4*>H WVK6F>=_S@T;E
MI=EKELDC76CS.'HP5)8;A"A1]J\264GPW._3"?\ +5/TGI@6:5[28VR6D4,S
M-ZBR2"D2/S8LJR(R/#(IV=6C8@4SIWEN_.MZ<NIO'Z;WSR)*A!4^K&?1E!0T
M*U>/E3Q^6'(V+*P^,;U[D>)]^QQYH5Z ;TRC1:#,:=?PRJ;^%<LE3L<1<&M!
MT&,(W^++VZ 4 QAW)'0COE@&E:USU]_SBWY^]"[OOR_U&XI%><[W2N9Z3**S
MPK_K*.8 _E;QSVYFS9LV;-GG7_G)W\R3^7GY9W\=C<"'S!YL+:3IY!H\:2*3
M<SK3?X(Z@$=&93GQ^YT.W;[LP<-T''?IBJOL:&@7%4>M2-P.V9J&G$[4_5C@
M=@*5IEJ]#L-_?!/K=._C7!"R-MOL?XX81O0;]3[X-C.XJ!XFGC\\&!@%/$5K
MOCE:M=NO3! -"*T/X8MNU#_GOBZ.3M3;'2, I:A^'K05/W#.2_F=!<7.AZW,
M;<A[>U6VLT!'J!IPTTLU6^$<4B !WI7L=\^8VAZ%J,LQLXHKGS/<Z=$);R^]
M8F.UDN4E^!-I)'E(*H!MR;BH(6KGLFDV?EO\MVCO]41=1UJZBBM-(\NJ\:M8
MI$OJ12S&/FJ,26=V<",UXJC45EF&K13ZY%Y+\C7U_/=>:?S N&NYW]/]XNE-
M)21FCC#'A*RM1&'QJ%Y,>5,Z?K,>F6>L:N]K*)O\,26NA:8)Z-%'=0VK<V#*
M5'IQ1)OL22Q8],4T/2[K1_,%Y9"?ZQ87AMXVDDV8FTM(%)4&AHSH3O\ S$YW
M.SC?ZO EQ7U%B$LE:4(C%!TI^TV3ZP'J6.E&Y4,MO'4'<UEY%@?\_ 9(]#LK
M2U:]CB0+-=RS7<A<;L\AJQWV/@*].V3[R%;(][KLDIJX@6#D1X*6WIT KOA9
M/ZZW08(T<8D#$K[?:ZUW/<D9U?RQJ,\C%  1&RK"N[;GKR^63VVCBN79BP$7
MJ492O(RE@26)^8.21:Q@TD 445VH!UH0 !X8+0K$0CD<F/J%%ZD*>II3]>&]
MLZ5^&A#G<"E20*;5)[8*>1@'AC&TA^*K5X@_(4Q]LKHBB60N%/102=NGQ4&#
MEE!5553\1W"C[R=Z=,?',Q+I"73E\+-]G;N*UV';%Q."HX? $8TI1ZBO<GOO
MXX,2A*J3*Q3?EP%0>NU2>F*&0&.J0R.M=ZE%Z]"/O[8@TQ#+2';:M'(-3XA0
M13;'&XGC'(S"JFFR #_5K3$9I)'#L4C0U%#&I:H'V@5J1WKM3"8/= \>7JIN
M%1P"*TW6M!UZC"Z[XF5RJ_OY%#>FS5!%1\2U'4%NGA@(N&=PZ#CZ@()WZ[].
MHWP%-+#<(ZJ-HV &PW)VZ?,81W,0+41J<FH!U !H*C;(YJ2>G]89E[%4J-M^
ME=]]\@LC*))AP^!EH&'8K3EL?E49%/,<'$Z?=\N=:Q$UJ2&^)2#W&V<P\UZ<
MFJ:-J5C<1^HMU;3V]*+0,5/&NQ&Q -<X+^5VMJE]^B;V6!XK2-182W-(^=9*
M26=S0 \).14KMQ;A(A^/;NLUA#H^KW*VZM'I_F!%ND!J?1OD4LR/\1(=XMB*
M"I2HKOB]*_$1U[XG2A->_7&M3N!E DGQQ0"H(I0C$CU-1B=3U[>&8[#;&5H*
M 8T -7VRJ@5\?'!NDZM>Z)JNG:SILWH:AIEQ'=0.-Z/$P9:C:H)&X[C/K;Y4
M\QV/F[RYH_F33C6UU:V68+6IC?I)&Q\4<%3[C)#FS9LV;/CW_P Y6_F,?._Y
MIW^GV<YET3R6&T>T"GX6N$:MY*-NIE'"O=44YYG5RQV.V+*Y/>@I0_1XX\MQ
M.QZ^/?%D.W@>V*5X4H=_OR^9H0-L70\0 =SC^6] O7J,$1ECMVP?&X/4=/#K
M@M'8D5W&#HG+>/A@Q*;UZ@XJ#5J^'7! <'OMCU<4VZUWQS-Z4;/0N%W/$5-.
MM>V<A\\>;]*LM&UJY;3M7GN(+*ZBX):^JJK.HC]1ZOQ]*A/&E>IIWSYX^7?,
M]E+KFI)Y1TE+.2ZNI[B_NVEDEGBB9"J+;NR>FE%7@69F)4GB!\+$TTJ+1]-F
MU/S?YN-QJ%QJ$K-IEE=N/2N9&E/.ZDA-9'MXPC$%AQFX\%;TJ\_1/Y1:9J,G
MF37OS UDM)YN\URQ:!Y9MKD%YK?3@C->7DQVX#]VP3:C,O,;$5D=YHANY/*]
MBZSQQ:Q)K#3K#$&9A!Z$Q(56^T8H5K4T^*A!-:S!XKJ^\Q^=KI;)+2]LKNT>
M&%>]O,/38(-@:%$*T&P'2F=/1?4MHUMR)GE$4:3D$5Y L% .]=Z'P/B<Z'(P
M@EM["WJQLUCC?EN$Y;FH'7:I R4:=$'6%) RN'8%2>6XWIWW).3SR.WIZCYA
MAA(],*L8 IL62H)%:C;I@2ZM(H6<,I5EHP)W!X]!].2CRR[1QW5RU5D8*H0G
MH2*#[LZ?IER"A VF0;*GQ<B#6M#04WWR5112NK>J_J%F9E!_9K04I3VVQ_ID
M$%'9HUK6NS>U/IPPAD"%6KZ: GE3VV!K].#XN/J2'D2S@+2O&FWOBDLTT4)D
MCA>X =5].,T)%:-]KM]."6=V5X88V7D>)=?AIO2E20?ECH^4;F'U-E&PZT-*
M>.YQ1I /A24H@W(Z5/<M2OC@J&:/[:!4WY;T!/AMT/OBS,K-VDD0 U I0^]3
MM]&,>3D5(7XJEB%[5[@"A/O]^"K<D\@PJ:]>H.U:T-.WX8JY4*5,14$A@>@!
M[=R13QPLD26LCR-S2@-5H0R[D'Y[?>,*)T5UYH5 2CJ*U [54@;BG4833-)'
M42#E0_#3>E=]J=L*;F=8TX[,K,21]->F%[R$[U+FI(4TJ"-A6M<(K]VF=4*F
M.4DMR78&FX4Y!KDN6G29.!=R8D/0,I(Y BA /CD=U4+<:<8.84V]U$U0:DD[
M; []\A6H ^@ T9/']XP( !H*D'[L\3V>CW7_ "L+6-.T^2XL[X7<L-HT$H4E
M'D]:(H7Z?WG$]A]JE,]90:Q]9O;2SNB+>\O(XDN8:*><C 12JT8/P,DL893M
MNAZ%B"]20B.:#U-@#MO2IZ^&-='.]/N_L.,*G;Y=QE&JC:F^;D:TQK#QRBHI
ML"!B0!Z^&9P"/X8F!QVI7$VH-NW;$@1N:[C/:?\ SBIYU_X['D.]GK2NIZ:&
M/R6XC7_A6 _UCXY[0S9LV;.8_G)Y[3\M_P M?-7FP.%O;.T,.G@[\KVY(AM]
MNX#N&/\ D@Y\*)+B2=WDED>665C([N2S,S;L23N22>^*(X!W&^_7%:$GE78=
M*YB]2"#BH8BE37PQ7U 2!W[^&69./$]=_OP0LM:.-_[<?R^+ET(_C@Z-S2I!
M';%T)IUP9&?BJQV':N#8WZD-0CKO@R-BYW-#@Q&Z#KVQ0L>)".$?LU.5#XTV
MK]^,:[$ 'UE1"36DBGE$2!6I(^(?2/IS-<07,/$W$4'J@HC.ZF'F1\)Y\@II
MX$C/,/Y\:]ZVC6EF)WBM-:NG6WLXXU.HW[A&'*W1.12W!;BCT0-R!4,/BSR#
MK::?Y)TY=(MK..YUR^7U8[!)@K->2 TDU"57 00@_#""6:OQ")37#+R?Y-DU
MK7-3OM>U>"6"&XLXKN5;B%YW]&*LJJJLRQ@^GPY-0(.5!0 'TCY8\VMK-OI-
MRD1M7\S>9--\OZ1I*L(VBL&N"]U\>YJ]O9A&<FOQ]?'M4A33/,7Y:6\,LQU2
M#4;V6[D5:QF 73W-\Z*>(_>26<<*5 !W_P JD/\ (]WJ-[J6L75[&IGFM-/F
M6,UXJYC2-BJ]MX7)':H'49U**[,-]8 NM)!;-*A^PKN259CVJ6^^N=/M+9UN
M7^+F8Y!*[=2PD!^#8_=X#)3%<(D]G%$27D-%XTKO7QH12F3/R=:>GK6K3\5I
M=)&\@!-&5:AC3J3M3QIMA@7COYKJ9(R49T96 Z!B6V/:G3!Q=X:>FOQPO3_)
M;E]GOX>V3GRU<Q&3U2]3)\7+D2M0:L*^%!3.L1EO1612"M  #3<"N_A7?$96
M*@4%!4U*]0/'?YXV20A/A/(2,%%!N?I/3!4+,Q<GD6/PT -#QI3PPWM'<)2K
M2NII\(JJDC<]3^O!$4@C1?7E5&%:&HHH[ 4K2M<<TENH9U%"K>FJ@-V\3Q/C
M4XT %N2RQK([  ,QJ^U-PVV"@)AM04J34.#4?,$FM?#Y8+B^(&M %(4 $FII
MN"%Q8<2:23*B]JEP!7M\2CPWRT^K?$7E:6-317 Y<:=]SS\<IYK=D5C*R&M:
ML6'3N#Q [_=A<9D8D07"2N5KP8A=B:M3L=P:X7S);P(!%6&*M41@10=.2&GM
M0TR/7DCF4\2):5) (H5[4.$5RT-WR1D1O3);@:CXA6A%:"O7?[\+%EDIR8"L
MP9(Z=:4Z'?:E,)K[U4F4!O@<<=S0J=Q4^(PLOE#VTH9:2-R5#6@H* @5&<QN
MWHS1M'\0FA4,!2GQ5/?"775DAL+V6$&2<*LD0/2E1R7:O;/)6H:3>W?YI7(L
MEED%VT9(*!HXI$B#>F>0/(RQA@H(&U:'8YV[5O4A\P6MQZ<<Z7$$=Y97+\4,
M33Q $$M2J\A&6J!T)[8:V=W'?V5M?)#Z9E7XE( 9'!(DC--@5=2#3PQ?D#7Q
M'Z\;6HWWQ)A4_+$^)_''4J#XCOC&;8 5IXXPE:;&A.54FNV-;IML,1(Z^.,-
M/^!R3>2O,USY/\UZ%YDMN1?2;M)7130R0-\$T=?\N-F7Z<^NEI=6]]:6U]:2
MK/:WD23PR+NKQR*&5A[$&N",V;-GS?\ ^<ZO/8DO?*7Y<VD_P6L;:[J*@U'J
M2<X+133H542FG@RG/GL* [[5[8\LM 0*C^N.1W.W8G%1U\:'++4( W'A3'%F
M4]#MC@W(CJ/[,56H(\.NWA@M#L">QJ,$"0?=])P9"^X &X[8-!%*UK7PP0AI
M0]*"F"4-: $BF_\ F<&HYK0'O]V"XQ4@@[],&Q1$AR65445;DW';V[D^V%>I
MM2%HYW^J65P1#]<BB25Q(U66-5EK5V"GC13O[9X__/EX?)GE>^\Q^7K&+2IM
M3F^JQL])]1G6YD:-[JXNJ\T@4CBL$)5>1;G7MXMTR9==\Q0Q3Q<99O2/-U'.
M.*$&8B,=B?2+G^ VSO,T=S)Y>TC1;"$V5O?W+ZKJ,,:JCB**.-Q),J?O)9*-
M\(!I^\-!7?.Y_EEHX@\W>3I9[EX-+_++3[O4KV.)E66YUBZBD "(O)$=7FC7
ME7B!S85HN>A=6L40ZKYLO((GDE_1&CQK"XX^O]1:&*W27>E'FDE=B/B;WWSF
MF@6]U]:\TZXDB00&.(6_V5]2":XA0,NP^USY;=PWCDP:=XOK*6L9,<TL:I=R
M 45:1CTXE;XJFFY(^'Y].ZZ)<6UY:":-R&M>1< @ A !3I7OWP5HMO+<^8E*
MJ2EM:LRMO3D144/CDY\L3-<75U#(JI+,H5W WHC&@)J#U/\ ')-Q6.\B2$@0
M?%ZT=".-*AB.E!BUS;\U4(.3UK0?">%!O^.2GR\JQI)5>+NPIM0;5(%:9T:U
MOXV5$]41/*.,=-_EOALZAN08NU5[T(H!WQ$,CE&!/*+90F] :5I7;MAHB.]4
M9RO7D!X':@%<&Q!> MS\"CX:+4 #P VWVQ5PS>BX1DCB))WI0FHKMU^G%(@
M'**Q8D"JJ&IX^^/F2-%8F-G-1RJ:UJ: #D33Y8A($B9VX@4IT7EN-J;?/PP7
M'* CA )67;CR*@D[]:KOX;8*<<XT!'-]B%W.X/<CO[XB\S)1@Q8G8[&AW^_
MJW$C.0PW4\@R\E!\.I._O3+41U!4?$I)8'<CQ&_X;XBP:5-Z-PZ<D4?TR/W\
M7I1<V%2E"37:G85K7(Y.*4:/>9AR6O?EUJ:T';"Z<I%"5!$=:4%.A&Y]]JX4
M2,\MPL4<89*"K;]?A/ZS@:]C=+9U9A(4/(2$4VZ$BE?NSFBA))=0>A>MQ&X
MWI\0[^PR/:Q+QM+J/C6E(PM-Z4ZD]=JYY<>YF_Y7 ='MARGE73V<@@R&(SJ3
M&E:;D<BK5!4D$=\GGYEV]R%L=8T]KBY-HEG<V\C3-&&D@=)'#*:A@Y=D*D5&
M^].D@T.<2V4%Q+;SQ1ZI%#=\9&HT<\D8+KQ,8I7N">ON</S%&RUCE5B!4H?A
M8>PKL?H.!*@-^O+VK3MUQG(5XG[\Q )X@XDZ@==L3&Q_CCMR#4;=LH].E/[<
M0;:E.F---O#WS;5V%<^CW_.-OFP^8?R]ATNXEYW_ )5F-BP)JQMV_>6['<[
M$H/]3/06;-E,P4%F(55%23L !W.?!G\X/.C?F#^9OG'S8LOJV>HZA(MD:_\
M'G !!;?(^E&I/O7.<5Y$;U!&/Y"A W\<?&U :;5[8TS5)-:$>_CEI( :GJ<<
MTON:C'1L!U J3X_C^."(Y"#N-A]^"_4V!'?^-1BZ@DBG0^^#HBQ'6OSP54@C
M>A.U<&1FBU.X\,6!(;FN_AXX,C?8>/;W\,,HV  Z_P"W@V$H'4R<BM=^/7Y
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M@_UL^B^;-G%?^<B/./\ @?\ )WSOK$4WHWUS8G3+(C[7UB_(MU9*[519"_\
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M$U/HWY!J-Z_';M^O)-:_\Y6>73:_5+SR7J<=#M+#<V\AXG>AY<.FU/;#=/\
MG*3\OKBS2VO=/URR"2!JF&"2@%>2J1<$]#W%.V273?\ G(W\KS;Z5)<76IPZ
M=<:D;"&0V#R".?TTE])B)&('%JCKT/AG0O\ H8#R%922?5UU#4A$S>F;6V2
M$TXU9Y7Y4H.@ ^_"C5?^<C8=49/T-Y2OY&@4H6,T9V:O51&U#\CM[X$_Y6YY
MIU&W-K)^5#ZGIJJ@BA<W<01T^RRR6EK".6Y[]\GGES\U?SF,<5MI?Y+&]6%
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MD49BD8D*\:T XKLO1>M.^>JH/R"_*AK1HY?*5BSF*G, J]0.S*PWV\,^>_\
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MNL1&VBE5!^[= 6 *C>A^W4G<BF=PT;3K(Q@.#;M#^[$C1<5<\10L*#>I&_\
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M&\TZ'::YHK.UAJ 5H)'7@TBL P/ T(Z]\6IXUQK$G8;97Q,/B&V-?;?K3MC
M>8(I3?' ;4[>^45VK7?$1]KV\<:X)(Z'WRQM6HKX93%=Z#$O$8@2>6-K4TZ9
MN/B<]Q_E/J7UW_G&WS]:%J_H>QU^U"FE0KV1N!]%9SGB?_G/G5_K_P"=NGZ>
MK?N]#\LV5NR]A)+/=7!/S*RK]V>)^8V [90J2U1URZFM1[ XY7V-"1WS FG3
MXL>M105Q3E0=2*>&*;4KMBJFE37%>;;5I[@;C!4>^_08-1N)H-Z>^#DD&VVV
M#$;D1X?KPRB+;4^SVP=%L*#;PPVB&PHU=@:8/0]!4_QPTMYGA:.XBJ);=UD0
MC;XHSR7]6>G?S8U&U/Y<:9YO9?W#VR07#5!/"Y"@?<]!G+/*NFPO+9W4$:R+
M&B 5 K5U#-\(KV]^^=0UB74-0CDTW3U8I4]& )X[;[?=G)KSR1J=I'>ZMJC_
M %.TMP9>;&DAKT"UZ[CKTSF46OZ;KVGSW%M<0W;1SO;//$1030U1T/05!ZC"
M6*5DBC;TRHCE* +N!QKL#V'@<%1J22X<^F%H_0TH2"*]ZG#)8FXJ20 H''8T
M --C3PZX'O>**)0X_>)0.Q%*E@&/4;Y'-<U*PL+S17ND>>35;DV=LL=2%=(R
M]9#T (J>^^2VTM[>[A@%M66XGI5@>$:,M2*,0.@/3.D>5H]7YA[&<3&*DH<%
M1OV6G@*9R?R+;Z?Y=U3\P_R]U2Z#W6C>:M3U.VAB'-[FPUN4WT,P"CIRF9#X
M,I7]G))<^5- N;IKA])F5/A]*3T62II2A.QQFD>6Y8KZXTOZE-J<*N'LUE4B
M-69265G%#^[^?]<DT/DW4V*26%^NILY9+@1R+!&E*_ KTJQ4]:=#7?)KI1T?
M3I$34-0N].OH%*RI&#<H_058Q*0#M2FQP;/YJT.19H;!IKI&14D(M90X#;#J
MH( [5R,W)$L3.=.GEB8<5+KPY ]"6((4;]2!UZXZW>YMK<>K8QLHB8+ZTE)E
MV(7TWY<7 KO^K";5O,<^F:=*/0+SS0GBKCXV*@"H:K;CH>GA3/G#^9/^(_,7
MF/4O,/F.>9=)T?>U]-J\8:JJ1P(#M([,%J=ZD =L]=_\XT^2'T)+;6M3M8X;
MVXJ2QJ4]:0UD52:GBJT13X GOGTNT*<S52!E1D4!:[HU0*D4IWR5(0L<C<AR
M)YR4&RCH#_+7QIG&/S9L8O,7E'S#HQ#5O[66.J_;$KT,3(3T*NJD'QWSYM>2
M-3UGR?KGG'R=K9]--;>#S3IK1*7BFANE]*]92.@]6WJR_LL2NW?ND7F"&^=9
MHXS/<3B-'E="(R5#4"EF'*@ZCQ-,,-'B*CT#%+<Q\6X"1#6DE*JQ8T4=0>N3
MI-'@GL'6[MY2K$52WE9TY"GPN.0KT&_3"[4?+FEV-MZEN%7TZA6Y47K4!@/Y
M>E:9#KFTLK@-;LL2LRAI".@%2:D]J#H#OMGF/\RO+US<ZKHFL>6GAM=?\KO-
M<1O*?JZW-I-R5X%E H&;8@D$5"UPUTC7]4U2QN;:VTZ5KIJ>L][+&0K4J%_=
M!J@'PH,E_P"8XU7S+^6'Y/\ Y;:55)/,6L03ZJ@-2[VSRS"-J;%$/QD?(X3K
M;VM_^;GY>>799/K5A+YSTFPED%%#6VEEKV=_90M@Q^62?_G,N#5?/&EPZJ0\
M&C:-=D6-EOP4GE&9F&]7.X!/0'W.3[\IM(FTW\MM']>SEMS!%#$LDM0&8K6B
M ]:#J<G08'J-\HBF_AE5-*T]M^^-^UURJ4 (/7,Q/3L/#$JD8TD'WIEDK_M8
MQV&U#E;"I_5C&*U( Z#$"E#MN,3+5Z=<JI(^6>K/R.U O^5/YZZ43M:Z+<72
MKX^O8WB-05_XH%=L\+?\Y?ZL=4_YR*_,1E?E#92V%D@!!"_5["U1Q4 ?MANO
M3IVSS4*5Z&O<8HSUVQ@KN<>H&_;^W%%(KX>&/#5I3YYJE?GXXJ'._<> Q934
M[[5[8O2M*XNC;"@&"XC0&O3!:<J]>N&L0!(VZ^'^9PSCIM7;^&#T(- /PPPB
M)I2M!VPRA^&BUW/<_P <6A;E<R*WP^AQ0!AT9AR)I\B!G?;]CYI_YQQ\V:-(
M_&[L;*6% W57A<-&PK[JI!PJ_)"PN]4\HZ%J5W.'GN;1+ER=J [*#X[#)MYI
MGOO+J?I33XR_IA@Q^T.'@*=:9\UO^<FO^<CO.LUI_AG2-36SEU,LLLL53/Z%
M*,5! "$F@!W/AD!_YQ3FN8?\3:3K(DFL;L1:G:I,S,HN%;TYS0UJ7#*2>Y7/
M9+16Z0S"#X8&8LO*M/HZ8$LU6)44G:K$+VXD]#].&ZUN)0%Y!!Q)VH&! '$T
MWH-Z8C?^C/#*@I&8E9$DXU( ;?:M, V]DER\,4\RNK"21JJ!Q0="!OVH.F&<
M.D2-+ UI(8M.A7C.!N#RV1!U Z;T^6=7T@1WD2:5H=G6:VDCBFG8UA(H"5)'
M*K[UH.W7$O/'DJQN/T7>:?JDND_F'HYX:;J^GPK*HB9N36FI6YXI+;,S$LI8
M%?M(P-:D,NK>?-(C+>=_R]DO8(D"-JWEAY]3L4?H"]LD9O8QW_NW _FQ/2=:
MTWS)"6TO\P]-U6P+%#8:-<K->D @/'-&5%U&VU./!:'ODSBLKB!C.);O0]'M
M[<,MN\*IZG4G]V145^8)R9:/JFC3(]L6]1. =7 %!V/PL!4$G;:NQR?/8^79
M+07#^C(X4!6C :0/L?BVY?('"N>SBN))H=/1ED90CRNH(XL/Y3R[=OU8!N_)
MFGPQR2H/L#FQ>I5SN2U!\.QIN!G"?.KV^EWLES?7(B@C)Y23$1A>5 S%FH.J
M_3GG&/0+W\UO,NEWFFV;P>2-+E^LP/)$T3ZE=*U%NN)56]"%:^F2*NYYC[*Y
M[2\OZ5INA:6MA%"(5I4(!RH-PM":YV+RO=2FNWJ",!.*[&A"_9&]0.V='"E(
M>,<1:456E2%'?\:YQCSFS6Z.BQ<%".NQY5+-RXC?MGCK\Q/*]Y9P0^:-)LY-
M0UCR!=S:U'90J2U_H6H5_2EI&G[3 )Z@7^9/%L/=.\OVNI6FG^8_+=_^E] U
MNU6YL[N#XB\9J:DB@K^RP'V3L>F3/2?+-S(CO:^8CI[A2:21B0?$/A-6#@DU
M[[UV^4XA3SMI]HD0U+1]3] 4$5[&]L[<>H +R5KOT&16\N+2>%X]9T^6Q>/]
MX\Z2+=1KR-*OQ(*BNVZY'/T?I-R+Z"*[2XC@0O)(P95%:%0:4\-L@?F;2-&O
M[.Q-I##J$DL8#P1T<LR&F[;"O],B-KY<LH(KFTL()+)3]E OIM5ANM""" =Q
M]V=!\F6#MKNCWES'6V\DZ-J%UR/_ "T3.REO^!BH,AGY%^64\U>>3YVN5+Z-
MY/-Y#;2@@I>:O?I]7E]([\EM8&D5VZ>I+QZH].Z_F9H-IK=AY$\KK&7.L:I-
M<ST->=K:RGE4GQ;;)]YUM(-(M]!T6TC$-M!;F4(O0'91MV[YS\)W.6P^D'&'
MP&P.;MTQ,L 2.F,)[=:8PCQQA&VW;\<9LQJ!3+*TZ=_IQ,KW\,;3Z <8Q ^C
MKB; $;=?XXF3UW&W?.]_DE?!-&_.?3N1_P!*\B:E<\?^8>-DZ4_XOSP=_P Y
M 7QU#\\/S:F8L3'YKU2V^+K2VN9(!T[4CV]LY%OXU/B/\SE$G9:],4J#L/NS
M*216N_?WQ0=/\]\=7MUWQ8=-MZ=O?'JP V.X[Y?)B=A0]=O\SBZ.>G0 _P"W
M@E6\-ZTP7$Q<>]<,(NU.@[X:PFA'M[X/0<CUIVPP@512G4[&N&"$@4ZUZ_+#
M$&) KB9N(^T.!.WM0D[=<5,J65REY(5N;.X])9)(JL4*&B.PI7B0:$TVVR4>
M7_,$GZ+UK3+:99[+S/9O$&202)]84$@ @TWZ$9Z+_)K2!8^1]$?TF#-90CBP
M%0/3!(H-JC<'\,+OS?\ ,-EH'EZ^EDF5J1,Y+;T%"2#TH<^.5MY/UO\ -CSY
MJ>M^@6LD8N00Q$<*M12:#IOGO+\O/R8M/+=EIVI7L BOIXBT,,0J%1TH&D(I
MU%=L-]:LWMY'A"?LLO&G0 _T.142!4D*?L@ "NP '0?,X96-QRA?B"\H?XUK
ML 34FAZ8G<.A6IE*NTH+*=ZJ6 9:&E.V]<K2]/DO+RV>2,'C7X>0"E/V=^_L
M,ZU!8^M9+H=E;<TN%/J1TJ68BI-=J= *[^W3.DZ=ING^3M$AMK6$M<M$*#8,
M9)34EB:FORWP9H'ERZN))+MII);DJL9:B;4/*H'$CEMO3Z23DZCT)IXVA^OW
M3(["JD,@J #4T5*#;8UPAU[\GO+?F6XCNM;\M:=KD]LP,%Y/ JW4(V!I<I29
M0#N*-WKD/N/R,DLX73RYYS\V^6XW;FD0U']*V\1;?^XU*.YH-Q\(<>^%5U^5
M?YJQF&WTK\P-,U$B-_BU7R\(WCZ?"&LKN(&N^Y38]L,]*_+W\XXD 3S+Y%N;
MEA)Z:S6&K<U!5:%RMRJEE-2VP[ 4ZF5P>5?SE-N\4OGKR9:$)M)I?ER[E="P
M!(_TK4U5CL:$K3?VR-ZUY&\TBVE?S-^='F2ZBHY:VT&STW18"34*O**VGF(I
MX2 ^^<6_Y53Y974&N[;39=3N:\DO-=NKC59ZL>7)GNI)*[[[#PZ9W#R_Y231
M+02AFFG;B\DCJ Q 'MV%=L":LY0H(ZQ/7X:4W<_9J -JY./)MT?71%1Q&%*M
MON6V9NG;H*9VE9Q)%<1I0.&IQ)IU'8J3OOMOG)/-]I'=12L27G@8!H^I8 #H
MU=R:>'3.8W4)MY+#4[92ES9LR_!LS1.*%2?8BN$O_*H8[BZOM:_*[S'=?EIJ
M.JGZS?Z0L,6H>7KJYD-))GTN0QB%V+59K>2*M:G? NKZ5^:OE6&RN9_R[T_S
M;:S(\,]YY3U6.WE8J06Y:9J?U;DIY5XK.3UI4Y$+KS:^EAH=1M-6\MRVY92E
M_IMW RC?XN065/I#822^:;29#Z7GK1S%<,_P33K$Q) 6H#!/85PKEO\ RN3;
MR^8=>TVZ6VH(SIEU$RS(>@:..52>OOOO@*YO/*?UV&[\E7;)<LA]6*TAEF;D
M=@SQA"AKTV.XP79/YMU74(K&T\HFUN9HPR7.H3+9VY4M4/P FF;H30)7M7I@
M[5/*NI&%],UG7+Q(M5C-O?VVDNUI!/$S,1 TXK.8V)^/BR$]#0;9Z*T7_#E[
MY1T.'0O+UKH2Z/:Q65M!8Q"")(TVXJJ@"G4UI^.%6GP)>>?-)CFA-Q!IUL\*
M5&R%Y#(]#MN2P.*?F!<FX\R72DU6T1(13M05/Z\A'C4T!Q,TK[91(KTVQ*M-
M^V42#3L?'&TWI3KTQC4^1QI (I7$Q\)]LJI+;#IEUH*';VP.S@4 IB;;CP\,
M3(*[#?YY51X9U3\IKKT+KS['RI]>\B^88-FI4+:F7IW_ +KI]/;/ GYB7+7G
MY@^>KLKZ9N_,.J3% :TYW<K4K].1%3M]K?' BN^Q[9=:=37-6G;^F*+TZ4(Q
M134CP_S[8X"F_4'%/A<#??PQ56V.U,5"U^+L<$*"%%-Q7_/K@R$F@[#OAA$*
M4(Z5PSA*FAWV\<'0LS=Z89PD*Q]^_P!V#4^T:#YX80FE#W!K@M(TY!T9XF)K
M\!VK[C<5^C-';6UM=Q:DEO&EY'(LAECA1)'%=PS+0GZ<][?E>L(\IZ>>/-7#
ME4ZE16H'S [9XK_YRKEN+Z[L]'@F CN9ZR M12H-54,3N-\)_P F_*=OI=OZ
MEM:EYKA8X9'4 QJT_)55PQ!)(!*@>%3GKZYT^.")'D'%+:-8(J;<!QH,\X>=
M(Q;W.H.690O*G8LI /7.2.YA$@!JK2%C0UH#OM^&%J:@+:[6&.1U^NJ[JR@D
MA@?B5AV^%JCY8/DN6-P#+)\!X".,4HSJI+,W>AY=/;.E>6]*E>R.JW4Q)MXT
M4P@T"MR9B>^[$@4\/GG9/)MC#HT5GJNH.PNW!DY#=*,?M4W  V%3L,-+:&Z\
MP:I+J+@+:RGE&H.P2E!2M*D[DFF=BT6&.1UC')8[:-0]#4(10 4H!L:5--\E
MMM9V=Q,WILSS0MS9=_[R@&X)I]PR611JR^A12JU)\=Z>(^ZAP0+6-E$'IHVQ
MJ21QC '3>O\ MX%^HVI@]'^X8L8F)W/J FOQ]14&H)^BF^ [B&.U=6=2+5 2
MP4]0M* U K7;IUR%7^HW#46SI )254=Z%J@ #PID8O\ 1;F]+0!2]O#R+2,:
MU;WZ'IA6- T^Q>)Y&57@*OP%*DBO%=^PI7'W-]#);R3I\!B2H0B@WWI6E*'[
ML@9E%Q?KZJJ'BH^_V1N37;.AZ3%;Q1VS(SQ/$_)0.LE5VH2.AWSK-CZD0HT/
MJ%PTG*O$D&AK\NPKD'\RV/J&6X1"?A^.NQ"=J4-0=LY+_?"B@.CJS1^Z@CV\
M.XR:^5HH_K'IGBAHZ M\/)MBH!';:AR?""-HUG>XE>.0HJF-@"I!)JQ(VJ2!
M@>ZTJ5X$N((V6" !^ 9D<%QO3>HJ&[['"9]#]7TTF@@F:2M))8D<JI/PL*BM
M0>H\,)M2TBT@MS(^F003P.RUCC2@44%=A7L2:C.8Z[Y;:[#261EM)U*D2Q!4
M,9VHQ!H&%>Q!Q>PMRJ6[U$\EJ2"62OQ>] 1T[UPB\[0VY$#P4JYY;#X@S$
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M8FO4G8Y-?RTN3':Z(]Q;M%:_7Q-,YHRJ54K&=OG]Q\,].:XL,^E3M%OZJ5Y
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MK+49(A(4D<P$\Y5W*.P+54D=:?/PPJG\A:-=6D\<T*M L)5R5^*1&-3\(VH
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M954TW%0 :GW&26[(L;>8/\)>)FC  H!U%-O;(YIT;+I]_?T ]:XY**T^&!>
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M/O=4U*00V=C"\TC]31!6@'<GH!GSJ\^:I?\ F75K_6[R>FI:A&;F2UC^+ZI
MP$26WVNBIQ+ &M36G?/6G_.(GEU[7\D/..H-$AU+4-3OEEV)JJ<DXEU)Y=*=
M?ISB'DO41=QWSKZ9%A-,&60\09;:1BW3VVSMU@MM)K=LL2,=/U2W]7BQXQL5
M/(1J:@@DL?QSK.@J>1"3JDT=/50*51UJ2I7E2OV2/>A.#;^QCN4::WK'<Q2^
ML"E?B4K1@M2=S05PRLK]9K:V#T]>)J&JUIP!Z$_,4P#K$(N.$B0<U<$M7VV^
M>=%_)C6);'4;W1+BIBN2/1Y$U-*UIVZ?AA;^:?ERX\K>8W\XZ;(\MCJ02"ZC
MCJS(5:J..)V^(=??PR3^6?/%O-/;3I=B,W$2R,&HR*]%1R1TH0=OF<[_ !^8
M!:V 2-'>0H#53RHZT!%5%.U/I]LYOJ]T;N^29&^JW4 XR,S? :$%>150"*[_
M '=,Z3Y0U:247$UPO!0(_P!S%5G4'D*FHZ_#4J/GG3Q*(T4J")50"I[!MEZT
MZ^&!4BD:[K(GJ(5"AE^R &KW'?OMB<^B6DK,Q51\1H48CB%W4*0:"FWL<+)=
M+1KB7H'0\P_#D2>Q![;;BF.LH9)8X_2?C)4AE*K\?$;!@:TH??)"FG?6/524
MD"$AA0!J].M:]^NWXX#ET>*VD1[=A+=**R2/7@48TV56'2E14?/;"^[M9 \<
MULC.6C*\0M"*$L'V+5'CMA1)Z\<0]1C/((C%(=D"<J$+0$T/],BLD%O>L[AV
MA>.BNB <.-:J?B%:"@WI3YTR1:9#&T+*=U(1EH*CBP-#4GM3PPOO ?K9@DDY
M-"0[.#L4I7^.$RZB?K*PPU* ASZ9%*MVKL.N=$MO,$-O9(LCE5X\*I4GX0>X
MIL3T]^N0J.9]<U6.!(C'9[S7#5V6&.C<:FAY.P ^_P ,COY@:\'D2S$HD!K+
M(B]/A("** ?:8TSEB@A?B/)B2S'Q8FI/WY5:C?;&,-J_YFN)E*D5^[$W&Y\/
MUXUU&P&)[@4-=L:S$]MO#,&+ CL,HT;;Z<1:@J,JHI4['$R:^].N)'QS$[;?
MY^^4 ?F,SK1.NVWW8T;"AV/4XRE*U%2<=##<7MU;VENA>>ZE2&)1U+N0J@?,
MG/LM^@;7_#7^&.1^I?HS]%UIOZ7H^A6E?Y<&ZIIMKK&F:CI%\GJ66JVLUG<(
M/VHIT:-QN#U5CGY7?,6CW?EGS!KWEN_VO_+^HW.FW%!2DMK,T+[5/[2'"8/7
MIUW_ (XHIZ;[TKBP;N=SC^1I4'IB@;X03UQ=78]]O8TQ8,:COW&*H3\Z_P <
M$JQJ.U<%(U#3J#X8+1J4[$]=\'Q$M3M7#>'JM#O^.&<1W%?[<-(:?,X:0$?(
M_=AI%0].V&"+2FWW881$+[=!@[ER7L*;U/0#N2?#/'7YL_F7)YKN?T!Y>+S^
M7[26CR1T_P!/N(C4. 3_ ',9'PUV8[G;.5Q:);SP?5G N99 \AE+<5C>E3LQ
MZ\B&->HSZ'_\XF>6+B#\B]2M'42UO+QI)%:J!^95D#5/0C?<C/ ?E20Z1^;_
M .8ODV>-A%!KLTT<=0#Z4[U<*&IU]04ST=I$D:06-PDZ7"Z9=F!6C8%0B,/3
M)-30A7H?#.V6ES'+<&9@:R? ' !))W"GH!6GPCPPY*"(".5R'/Q(Q #,!XBM
M.GATP+>Q&V:.1%XQ.>6WPA33=:5!Z=/N[97KAV*>H#+P+*"?M"NY^=",!Z?=
MRZ9K5AJ5N>+P2 2QOL3Q(8&H\ #]^>O]3M]/\V>6B/3+43UE4<1RIN4*$D5H
M3USR[J7EU_+VL)8I0Z?J:?6[(R"@2XC8B6(C;V^@C/17DO6%U'3H(DE4SQ2<
M&*J9 W[ ) WZ=SV[Y!M9N9+'S,8U(2.\M)7EAXL"U""I((':FV3#R9KRR7>H
MVQE<7JD@"@H6'V7-:BE"2<] :;<"XA(JLLT77G4D,0*,!]'CAY' GJ#T6-5H
M)'+?M&O+YGVPP:R61@A8IS)!7;B? $ 4S)86TBI:[\D^)7H2&%/LU.WSW!P,
MWERW0*89 8F?U"H^%N>X^+P^_?!UO8O'&HH958U)>AH#MP9A7<>)'3KC+NV>
MAB9&8NS!8U#<FZ$G<TVV[9'KFUEY0<@R+&KQA@>I WI11X[X3/:)/'*L<;!C
MLQ<* E!NP!ZU%/'?"H:+%'-&5_<B4 LR#XV,9ZL?#>G3!E\6X0B,DSCX5 )^
MR>YV[X1ZDCVZR. LC.#SI0$,058$G;M7Y9Q.X\UB'4GM[.W?U;=-_A-:GXA\
M(W.Q^[!HU6Y>SCO+J=S:\0"5!C,C'944&GQ,3\(I\\FEIJ+:/H\MS=V[6DLM
M6=9*5954%56C'85XD]Z5[YR2>Z?4;V:\E4J2_*A-:$CX1] -?F<?4$?+;$SL
M/;WRB:4)ZY34(%.N(L3X[C$V8 BIZ#Z<19JUIC2:"N)\P>FWMEGH:?TQ(]0?
M'KC&8=M_?$ZTJ=SF!J:D]<HCP[8F&I_GX9BX&U<;4C<#;*+[9U+\E-%_Q!^:
M7DNR,?..WOUOY!2J\+(&Y^+M0F(#Z<^L>;/SO_\ .<'DS_!G_.1WG@0Q>C9>
M:_J_F.VVIR^O1CZP_P!-S'-GDT>/3^S%4J-^GOBP8]:T)Q0$FE1UV^>**YKX
M<L7#"@H>G6OCBT8WJ>VVV" 5IBR-N <%Q@=MQ@E&.W+>N&$<@J*?3XX;0OL3
MT\<-H'VW.YPRB;<=*?Y[X:Q$#>N&<#K4#;W^C#&,D$%3MTWP<K4&_0#?.'_F
M-YXFU*-O+?EZY*6TD@BU.]B)H54@O"&H!PH0'8'O0=\\]P6<S<+:.)'FD+<)
M5HH *L1Z: BGQ*%_7DITZP_1[7-Q]72-%"E:'=V8-1E3BS&J,1M0; 4SZ>_\
MX1VZ:CY(\Z:(M+A--U(2K(W+D1=1ABA5E!H"AH>_X#YK_P#.4WDR[_*7_G+/
M3-46'TM+\ZI:W$3.#P9PWHS ^X*JWTYU2""/Z[=:>IX+<*DTGI !2\8*AR!U
M) &PV)SM6A^G+9PAW/JQ1 R[55J[!B0!OX^%,.OJ\,R()E].> OPE'V"C"IW
MZBM.I[YBBW%M) $#%VXBAZ _9->@%>F126[%K(8I.2)]F&1J?M?"R&FP(K3\
M,$S1N8E8@S,NP-0*TW\?"N=[_+SS&RZ6T$SK+/$513T^#DPXDGN*=?HPRUZR
MAUJP*7#11O%<">U9J%TD4&B-TIRY"IKU IA'Y34:5=R'U0%E;U;61221ZHHX
M(K7?K3QK@GS=ZESK'E^Y:'BU7MI-^RBJG>O[2CKV.(:"MM9><Y;M.36EZJE5
M X.C4:A4;4HQZ#^&>EM)O$BN+.1I#)#*K J .*CC4D]A4#OD^2,,C72CE(5#
M*NQ:BTIW'W89Q72-$TL=)6C)!(/+8;GZ/?&BZH654$0IO0"I!';L*8*AG)=4
M63F%2I:E>2@;$D#<X*D7DC>H@ 84]_\ 9#;]6(LTBPH!('!85 -!44^D#;$'
ME1#(9VY1.*L#2FXI4;=?UY')75I8XX@T:A77U-E5RQ WH:B@'4X7^B([F.V/
MQ\D:0,:$']GXF\=N@P!?"3E (HA3XC0DJS#?IX5ID!\S:Y#;0/"6")OZS?LJ
M#2H\ *"E<XQ9V-H;C4M1EMXFG5U4M6JO&22@!!%>NWADJ\M:?];N&\P:G5[>
MS9HK!'VC0TXR3\=JG>BGYX2>;]<?4]2;3[(TBB-6K7]W0[!AML*5]]L*(U2-
M%0&H7N>I[DGW..7&LU-SB)<L<U>/7J>V)DDDGMB)H6IVQK&NPVQ \C\/AWQP
M4;>%<S$4XKVZX@U=QU&,V!%>M<S-TVS*@J#^.8LH_LQ(LI[=>V)D4(QE0=CX
M[#+84/S&>N/^<1-!%YYH\R>9'3E'HNGI9QEATFO9.7)?<);L#_K?+/?^;/DW
M_P _._(Q:V_+/\R[>$4ADNO+6H2^/J WEDOT<+C[\^1RL"*5Q2HKX?JQ53V-
M?IQ4-4;';%ATZ[XJ"![=L65QXTQ526Z[C_/QP6@IWKM@E&VX].VW?!"D CO3
MO@Z(BG4^!PV@8TH-_GAO"0 #UIO_ +6&D+ @4._AA@A)[_1AK$P-#2A&^&$<
MA*$#;C_#OG(?.WGYVCGTO0IF2#[%WJ,+ T&X:.W)V+'H6-5 KWSF\&D-&MQ+
MJ$+0VD2U".P*FC-$I(J%).QW([#?I@.ZMI(X(/J_-8Y!*_Q(\DCL#&YWXJ"$
M=^W<]-JDYT^UO)N#W=PEA:/9T1I2[2L\L:H#Z:*Y^&1.-:?"#TSZ)?\ . U]
M/;^</.WEZ:]FN(+[2K>\ACG7TRC0SRAU],D[4N!2GAO3 G_/SS\FVU?\M_+W
MYIZ58^IJ?Y9:W;W=U(@ 8:5=NL-P2?Y4?TWI['/%_ER^%[<Z%K+/PD+A'F>I
M'%@55@-Z$$T/XYZ-L(Q:!8S&7>29H[<5)#>L6ZD&M!W)^7?)!):"U#PMS%P2
M_P ;G8LV_(<J?#_DC8=,!F)OW%S'QBB+>E(KMO&4!'%@!T\.V1?5[""6:[MU
M9FYL)4!(8I+2A4$T"@CM]W09#_TU=:-+]5N0TU@ >+*"SQ ;C8_RUZ==LZ)Y
M<UN!)4N[.9+BSGHX9#4,XV- .^W3QSM]E?P:K;6QY$I*&=T.[(1PD1@O4BH\
M=LVF#T;R26=P\=S^_=5!XIR)6B@=B=ZC<5.%OF>XF"R1L!(8$5@:\GYA059:
M#8T^^E,(]%ODU*.YD+<[J-8KC:K!P*E^-:D;"N>D_+R7!M8W=EN)#&A5@."L
M50=JG<]/;IG3=&O888HEF2GJ+R/[05Q0!03N3OMAI:3!)9H'KN[1E:"G'H!U
M\/Q.7P994I\*Q#IM\0[$&M=L-;:Q6,+)%Q1FY,P HI-:FNPJWT]\-T53P63X
M%.ZUITZ[#?;OB5S$)(BR\O12K578?#3KXUK]^V1B^:8"595$D'IU()I(S5)(
M&X% !D>,MO%'QC?D9N-!0H30?:H>U!@HM)#"1-&'X]R*C?Q!KL0!OXX2:K?(
M*/&WV$H !L* L2<X[K5U%)#-SK':Q2<F(W#;@T(V]ZYSG2?K&I\+8MZ8GG8
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M5>W02YKZ5(Y[:1@651\2, ?L\@U3N*?*F=-TS6[0*\4#L\T[*I@=:T9 6HA
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M,+:&R>.:2UABG>XAAX2HK>M''('!5(S(P7[(5F!8 LJD/2I=#<7Y6*:&(PQ
MFS$A8D>G,I*$J!0#U000&/44/Q<F+(S<WJW*>EZ8BY1V[QDQ*DK0-+&['U(E
M#A8&#OR0[O([QD?6+7ZD?\XI^:YM:\@2Z)<NAD\JW?U2%05!2SG1;BU1D6&W
MX%$DX\3&AXA247D"WI76-)L-=TJ_TC5+5+W3M3MY;2ZMY-TEAF0I)&?]96(S
MXR7OD*^_)_SKYA_+>]$DUEI<XN],N265;K2[AF:W8LW5@GP/3HZL,ZAI\!N(
M/76;G-#6+G0?$E.4<@Z_:85_S&";C3(V$3R(I^JAA&JF@ (/*I%*D=Z>V$MQ
MHSL)N58[25CRB_:<;T8'I0]_EMD6U2TM/JTD##ZQS6D8/7B2?A\.V<TU..[4
M0P-(:.P5N2A^<:@['<4Y ?@,A-Y%:R>M9S'>!N%&JI5B2> /0D4_'"J*Q,,4
M8E!*,>-=NH-.A[TID9UC1P4YQKZ=QS;BXW!+5J#O7QQGEKS/<6<<VG7D9,<B
M!%]8&BNAK0@=>FV3F9[?6@LL5TUG*HW9 I53NP+;G;D.U-Z^.$WZ3\[^46"6
MLK:CI*%B0.,BG>K#>A KU';\</;+\]-3TV*0VDDVG7:D\XWYF*1AL2U>_$4V
M^>=$T'\]O+OF)88=2NVTW787903(DD)!)IP<LI(W-%._4=,ZGI7YF0VYA@>0
MQQV\7JB11R9C4_8D8D;@U'4^^'.H?FA]8AEY7*>C.E$]9N,NX)+3&@]NE=^F
M06^UJ\U56CEF>*TNTD,PMY"Q XD H7-0U#U \>^(_ICR]I,$44DDETT'HG@)
M#(J\MF=V?F J^^(6GY@^5+!I7U'4U$Z2!HU+D#<@A10#>M1O6@IA!J'YJ7]^
MPT[R];3W+ZC.Z%HHR()BXX\47CR/$=ZT \<D&C^4I;F3](>:%CO+AOB2QJ7@
MC]Y=R';V^R-NO:?1Q)%&D,<:Q1)LL: *JCV44 ^C%0E"=^N-8$#EV.,)Z;T]
ML2):M/NRJ<J8QMNAZ8P@L!N<IA04K7N?'$R=J?B,;R'0CZ<2<T.V,(/?-7H.
M^-!Z]/;*(V\*=<2VIN<812FW48SCW\<3)&V->AZ;D[XP"M-JXFQWIGT>_P"<
M4_*)T3R'=>9+F/C>>;;HR1D]?JEH6BB'TN9#\B,]19LV;..?G_\ EE%^;WY0
M^=_(@C1]1U.P:;2F?8)J5J1/:'E^R#+&%8_REAWS\R$T$UM-+;7$30SV[M'+
M&X(9'0T96!W!!%#C:U_ABPK0'J._T8HM#04H?ZX(&P\>F**=Q3M_MG!*FOL!
MM@E&VW&^+<S4 'OTP4K; 4K@Z/[(-/HQ<3QQ4+. Q;B!WV%=AU/3L,O3]8M+
MGA)=:;=+8W ,2!EIZCD L'!*%:*0=C45&U>AT+*UM)KN.ZMFL[F)S;16]>$5
MNZ@*G.X)9SZ04T#5J1T&*3GZJUU>M E]'+:L(+>X,J</4_WGF$<)!]1.18>I
M1:5^$_:'/_+6FW]UYEU30[0>J==N/521N +":.3B\C$G_=J<Q6E33P.=HT_R
MS:#66L]0,=CZ-L8*)$LO-Y[8"2, *_Q*Z \JG8GMDU\OZ"EO+%;Q-RF8R6LR
MHP])Y9H1%<1QJ0IWN.#("O4UIQ'!CW4?*=K;Q274@]>2UO[Q6%4]$>I)$'KR
M4DLTB[D_9'8;",U.G:C"D,$47HVUJEQ;QSRM&RQ)/<?6%JIC'(+&&'"H/Q%B
M?BD,B6G:??)'JL1M'1KCT;OUT64M!QGD 8E^41(>X-&9 $Z J[5P99Z)?)]=
MM[-X89K@JX=Y>#HW%6A*JAF8$-%R%!R8*'E!5(P/2'_.*NJ7.D^?VL?K#IIO
MF+2. MY&8@2Q$31!>=&^%3)0D#E6H!!#'Z4QM4#O[YY._P"<K?RS;S/Y8LO/
M&DQ$^8/(GJ3.$7DTVFR4-R@&Q)C($B_)O'/*OEEA=06TL9#*D3(R)4I+%Q_9
M/B-FR>"T;TS"(?6,**K14W>,"BNNW45_S[E-Y8D1^C$](8CR1S2J$;D-L-B>
MHSGFKZ(FH-),L;HK\6"';B]2*!@>0W%?NR$7FG-Z7I-ZDC"H&U&4-N#6@KT'
M;MMG)]6TI+<L$!G9 9966M0Z;[&N]0=A_$870R&4?#O5C2F^X'0CYG"^ZCWE
M?D"Q'%U8[*&'PC.?:Q:I%-RH4>@HI/$UVY=O&F2;2K:>[ACGM)C;74!%!2JM
MMU(!&QZ'YX.M6N;5KVUOWFE6YE,J+.PY*6_WT:#X33>O3H>V%]Y90%6+IZL;
M-50J5XMXU&0^_P#+VCREGDBCXL.1!4$D;;#8@_KP%96UG8,&M[BYM2I(C$4C
MA1OM\->(K3#9]0?=9-4N_B_9J":FE#7L1B]O<RNP,6J7JI7XBMS(IH3WHPQ:
M6QMYHD]2>>2A^!5ED(KWJ.0Z^V273-'JEK]5L(JR.J0*4$DDCL2 ?G6GTG/4
M7E;RS;>7M/A1HHY-4EC_ -+N0H+%FW,:-39%Z #K2N2V,4RV ZDD4RAL*_=E
M,3T[>^)BA;WRGH!M@8DBI&V-J=J[DY52.FU,2)-!ME$@;>V)MXGMB3&IWVRJ
MDCK7&D=*D_1E @ GMXXPG;IUQO(5!WVQLC;[XF&-#B;TK^O&$@; URP2?B)J
M*;X<^6]"O/-'F#1_+VGK6]UF[BM(S0D+ZC ,[ =E%6/L*Y]C]'TJST+2=,T7
M3X_2L=)M8;.W4[D1PH$6I[FB[G#+-FS9L_/S_P YX?E&WY9_G;J&NZ?;^EY;
M_,Q9->L^( 1+TL!J$.U-Q,PDZ;+(H[9XM5CV[8N#3Y=\>K<S3<8(2HZ],$(=
M]_I]\7C)9UC4K5CU8@ ?,G%V#0L%GK'5/4)IT2A-3X  8/MM1\OP6THU*29I
M)422%;9XN3%ASCY\ZE$9 3503RIRXBE0(U?2$N%M/5O9KH1H[+"B\.5 6!JI
M95WZT^>QKC]/UJ&6XA:XMIXK&) ;HK2.8L48_ 62556M":CN-ZD##^PM[BYG
M AN;6)+5:NL=(YI_K2T59'9N8"KNXH%H 17#)F@T^ZLS)#=BYB8>A$>'K<45
M3$1(W'F7/Q= ..P'?%(%6&"-]1MUE]?G,"MP A!8\S"H4_O9">->)H!QJ*$B
M1P6ZWAE;4+:CPQ3"!%.[RUY2<.5'E,2&A+;;; #J \QZ?#8V^G:Y8P^G;?68
MK(R$%8Y'N& 2(%10\''-F(H$?;D-LZ3IUW()M(?3;18WA1/JZLXD/K2UMY+G
MD#10KKQ'0%Z*!T;#K2+<B:%_56&UD>)976/U622:,Q+Z+K1:L26(ZU!H>8],
M]$^N07$6M0?6#<HT0NDA#QF(Q3>BBS1$R*A>1T 2IX-\3\A+^Z(2#7H%O_1]
M:-I)#+;S).9;AW(G598PS>H6H0#TY/4N5=_]%!Y:7VG\-/NIH_5:2YEB$DPM
MW6,22.A+$/;KR! +'UD 3BT<D,?.12J*=IF]"::>:;U8%E:02EXE:^E@-NB-
M:2D'UVW7T7!.YAFN62U@7_+OS3J/E[S9Y6UV(S\K"[T\R_'S/U5VN+>99%C5
MQ(TIA^$+)*78L5-W('G@^Q^FW45Q$DD,@EA<!D=2&#(P!5@P)!J#U&#[JWBN
MX)8)HUEAE1D='%5=6!#*P[@@T.?-#S+Y)N?RO\[:GY<5G.BR.-1T1ZFILY7I
MZ9( '[MO@I_D@]\E%E>$6P])1*L:L?AVD7E2C"M/A!.X^G$;NVEF0%0GQ(U5
M5@5Y4-:&F]:';QR%:AI\EN6$:\XGC)212/3:M 6>NX-!3;PR(ZQIR%7)9H[L
M JX<D*0 #U!\3MG-]1TR))GDGC  YB +N>7&H#$#CX@;=-NV<[O["6.Z::*'
MX1+P(  !V^(*#7H3A-JEH]97%4Y;5 \-ZFM>N0/6$:0*K1@ @5#FM=]@>I_9
MI^.'ODMIXWD9DYD/LNWV32@)'XD9UC5?+=MKEJLO!58H.E25<'K5:5VZD9S2
MZTS4+!6MS*)2KE !NS#L30^'7WPGFT)E >0A97-1R'($T.P !Z4Z8'E\NS)&
MO <XV!'+8"@%3532GAMG.[O3KU[@Q5)XM0*M#TVIO3?PKD\T7RR8K<7=S&R@
MI7B:<MN@--NV^^3*ST-8V2>2$)R6J*REB%3N17KMM7.X^4= 1"FL7=L([@)Z
M=HCK1HTW!DIM0L/L]Z5\<Z(JA1OV_P ]L<1T/AE<@>H[XF2 3F)J#7;&$]_\
MSB3$$**TIC& KL:XD>OL,39MJ8SXCWIE&E1MOC2IX[UKC* [=QB=*;$_/&DG
MH>_;&$4WS$_#N.F)BE:[#*8BN_<8E0U(!Q(GM2E#E #L=L:"0?\ /;/8O_.)
MGD?Z_K>K^?+R&MMHB'3]/8C8W<ZUF=3XI$P'_/3VSWSFS9LV;/)7_.:/Y.2_
MF_\ DGK,6D62W?F[R8WZ>T84/J2>@I^MVZ%023+ 6XKT:14KXC\[18 @$@5Z
M =SX#&0W4$THBAD]8T8D)O\ 9Z_=CK:>]N[@VMGILTMP@Y2)4#A&*DL3]F@&
M_7^&2-]-N.*2AFCA,P0\(N;%>3+5><D*G[/0FOM3%GTI!/;5U(I97+J1)PCC
M<QGH0AGD()^=*T%<UIY?N-0@DN?4E5;>14DF2,*S,?A"1KR=:NS@!>/O3889
M)Y4I=230R7%^LBD26XX&/V9PA+5%4W!H3T-<5'DCT[F&X9I;:LI>0)!Q5Y&9
M0JT"!2X(H!3H=P,D*>2HK"*[>]UB,7C2I"MM)ZCE^0;UD67D0/2CXN30\B*"
MA%5#R6VDPV?UA8X(H+0B%))%9I%E9R8X9&C+$3R."W5MJ]A7 Z:?J7I#48'3
MT[D+RX\'2)I)"I1C\2&1P#L16NU2<LRFYTZ5!<^O=2RN&5&$CIQ)'*=S(O&,
M%0(S4 [T6HR6Z3I5;2]OED:[@BFMXVGA<)#%$.0CA@0(0J %0STY<FX@8VRC
M>))8G>2-[)H50Q0*D:(M9%CF *\4^,M(35MP"K X8:M8W6H:3J5C'>W47UZ$
M02S%48122."CH"$57_=HR_9X #:H+9,O*&M)YIL;;6F+0S&"6.^M8XT6EQ:7
M*Q7?%26!I(%<;4/)A3BP&="MX83)/8-Z?IB,Q<%$95)$:4-R%6_:JU"&JO$.
M':G$O2-)[VWGDADOK<6?U*Z$D/$+((I4210T;AARHH5@:T?FTGPD&NH6B7K7
M%RJO#%=3S>I!&>;,76!)A^]J640QT4D$U!#^HH!4[M)9K>7ZPLBH$O4D984F
M)1WO.<NXE+<3(L;*0>5:NQ:2LN,NY86N;\0PQ>G<7-S#+%=0H%!EO$8B001&
M-D9$^.-5HQI& ]M^Y8KM;(7,K)&ICAFE9JR<YYIH9KN5I7?U5D21R_'U.8,;
MOQ$BR1(L4?U-_)_S2NO^2_+5X7]6=;1;2Y;<5GM@(9*U9^I2M:FM:^P[?$W)
M1\LXY^<OY;#S[H,<E@5A\Q:&SW.G.0#ZM5_>6K$D467B-^S '/&6CWDX]6SN
M8GAN%<6XC<E'CD%>5=B3TXM7^&3JUADDMUE;BW!N()X[<!U)4[5I0U&%E[;H
M_K3M''6V:D\#BCPE]ZDCD#M2OMOD*U2Q(C'IJT=NJBC\:TH"=Q0D5&VQH>^0
M75;-Q%P41L&7]V8UK53R I0GMM7?.:ZI9+,>$0 9) R<3RW3H34^V%FHZ,)[
M8W2BKM&W!:_:!(H:]*CJ">V<FU?0KB-ZRR*2RF0)3XOAVX]Z[]!@[RY!Z32!
M"9"8^6X() WIN>]>G^8ZYY;GCEM9(6<479>>S'8;4Z]_]O"^?0X[S4)YE0#@
M:DL-^5*5IMN!TQ&?2X(T$;CDQ/<"@^BA_5@:YT81IRD<^@P/P!:#VHP8T]]L
MYS#Y2@NKL4N3;RI,>"O&Q3D/B!ZBOTD#YY/;RRAM7CA4QGBH9^ V)K0+L3L2
M-Q7Z<E7EORO)?/%JFHM2V63E' RU,RBH!))V2OM\7^KUZH%4;@=<4H._^UE<
M@O\ 3$G9:[&E<2.U#RJ,3,A:E#3*+4J#]&,.XH33?&C8D@YMB.F(EMZ 5/W;
MXGW^64:@@TJ>V8N HV!.!]^I[Y0V!)WQ.AITW.7Q8FK=!E $5WKVQAIUK7?$
MV(5O$^&57NN]<2W)((IX[Y0VY5Z]\6M;.XU&[M;"R@>XO+V9+>WA05:265@J
M(H\2QH,^O?Y;>3H?(?DK0/+*",W-C;*U[)'NLMW+\<[AB 2.9(6H^R ,G.;-
MFS9LV? ?_G+O_G'71?RP_-K4KV.RD3RCYX,^KZ.R-Z:0/,W^E60J2"L,C<@
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M*WY?_IWS1<^=M0M^6E^5OW=GR'PR7\JFA'8^DA+'P9D.?1'-FS9LV;-G!O\
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M\[?1H2LINIQ)&B@QT^$%A1B.0K4 T&Q]L#ZG;J(HK9'#30DR&7B>)W!"<1N
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MD!B8S$Y=VE__ #C[=WEEYO\ S$\O77-5NX].UN$2 1L&*R6<H$2T15I;H:J
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MS@N=.NI)A'^D6E!@@)]1@$V/+<*E1L =\BLDA64K,QD<*W".'^Z++XL5KLH
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MUDG<G<[X89LV;-FS9LV;-FS9LV;-FS9LV-95=61U#HX(92*@@]01GC;\Z_\
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MI-UHGF'3HM3TV[6CQ25!4C=7C=2KHZD JZD,I *D$9\]?SB_YQ-U;17N-?\
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MC658P0RL 05/B#X$9PM-*?1)G%U&3#"=Y.)5B00%,S$;=:(.XRK35+RYU%P
M5MU)6W4?" @V%5&U54#?]9)R?::\ !>6Z1!)*R<7HE62GVCT%/$XCK[>E?6,
M26R_Z5^[65T4@L=^ .WTTP59NA_T<,9F%0QCJD;$_;'$"M<\^_\ .1/G/3_R
MT_+Z7SU<(BZKIY.DZ5*59W%_>LJ6R%UCF;BOQ2=#3CT8_"?D%Y\MXIT7S-5I
MX]1_TB9G8M()6XRDQD/(PJ9F!!+4!"\BRN1RBQGYWT:%2C7*'B2_&C)N X%
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MCOQ4YZ7    % ,V;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-GF_\T/\
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MX^7-4T"TA:6W?4G47'UI5-PP$%V8@LJ.SU+.06JSE0TD=O;Q&:>WTBT@M+"
M:=-*9W6V1IS*TK.ID>K%IN#\B3RWV"K1>(P#YBCAO8-,M1<7$2)!\<;"9Y(A
M.W)8HT1>5"SGEL/B+;LW*D FB;1[6.>>/ZO;F%XU>4!&1(W "":5J)4,"Q K
M7Q%6#+>6[:XD@?ZU<17XF)DFAN9(5DXT8Q\Y%4,2RD-^T*#X3DFCNI-/OD:6
MWBGCNT"&(PPRF/B%$BJQY+$5+4 [_M*W8[>Z<02S)';PV41?ZW';R^J\:R5)
M-6H6<"BL@<=6?<_%("\IR7_EGSSY4\PVUS,\.CZK:W_P1SO;NL-PDQ1U'IJ*
M+5N9+<0>X .?=@%"2T;!HR:J0:@J=P:_+% .E>_\<>1M\\(M2TBVOH)(I8U9
M&!!J*]<X!H[2^0?.UUY4U!F'E_S%RO\ 2)GJ$@F%%N+9F).S&CJ*]SG5=1M$
MFBK4!UW!_MPCM=0,+B*X)1AL'.X(%?M=<D<%\!QY*IIWKM3V-:')-9WB 0LE
M>#. *]1^/MGD#7H)8_,?G,S!@T=])S8L  M>0-=ZCXQG5ORAL;'RQY>N=8N(
MB=:\Z7GU]XQ_>"V11%:JW@!&O,_ZQSJKZC<S$B69+5>T<9Y/3W/WXO;R60J&
MCE<GJ[ GWVJ?;#>T:U#$)LW@PH<!^8M'M];LV@"(TZBJ<_LMO7B3VW&S=5.X
MSSSJ4%[H=\;29"+-Y^*2,OV.*5"RTKOR6H<_:W.Q-,,-)OC?W$D4%Z91&HW5
M_4^*E>07YGH#3.AP*L?IQ!:W$Y*I&H+ FE0"W&E:#?/E?_S\%_,[RU<>9O(G
MY1Z/K-GJ6K^3YY=;\QPVDG*XMKV9$CMH9&H43C$SGB#RW')145\0>6/,U_Y<
MUN-XY)IQ=I+!*K!_4/J?:$061FZ]'IL>+A25%$_S+\OW>E:I:ZL;.2/2=3_>
M1R2P"*OJ590L8=P@Y CCT0\HNL=<@VD6UW-?PVMG'+=7%T#;10Q#U)F<554H
M [<B.V],]T?EA_SAA^?'Y@VNGWD^B'R'IDR@RW/F=3;U0@@^G9AI;DL0:@M&
MBG^;/HI^4G_."?Y4?EZMI?>:);C\QM>@<3%[]?J^G"44W6RC=N8KVF>1?89[
M3L[*STZU@L=/M(;"RM5"0V]O&L44:CHJ(@"@>P&"<V;-FS9LV;-FS9LV;-FS
M9LV;-FS9LV;-FS9LV;-FS9LV;-FQ&XM[>[@EM;J".YMIU*2Q2J'1U;8JRL""
M#X'.$^9?^<:/R@\QRW5Y#Y8C\L:K=J5>^T/C:2;FNT?!X0:[U"5]\\V^=O\
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MY"TU)$D^N>8IDMGI]IE:V075T30T/*-0>E>N>_/*O_. /E"32K"V_-'S;?\
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/-FS9LV;-FS9LV;-FS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>sny-20231231_g25.jpg
<TEXT>
begin 644 sny-20231231_g25.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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MYR!U1 !:Z7/8L"&+"^FE4_[!UW^_(_<_G)YRO1_HFLWT*N?CDE$0ZFI*MP)
M'3J=L(+O\RO.5X/277KZ[4@H.<TLK$D[FG.A/R7;L,"O8^<=3#7>K7=Q86DB
M5>YOY/1'!?\ ):C'Y4Q.$:=86P/Z5N-2ED)5%BMRR[GJ))'4+4]=M\EVG_F5
M^8EE"MMI&I2Z=90T*%DB"KP\&XFE>AH:'),GYQ?FG&X=/,EM<.G6WEBH2?\
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M0?LYPFSFD66)HG8WDTBL)*_&C!P4 -#0EJ?=DAU._N-=U42WS"6%8([.)34
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MU^^N_P I/)U^?T)I4W#S%=PMM>741K]35@=XXF'Q^+BG1-_GZ: >&8$ ;G,
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M2+_*JW[%#\9>3,Y+L69B22>I)ZDX_8GKCAU]L=Q%30_1F8 4&6IQW #OFKE
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MRJ;[G&,*9+_(/GC7_P M_-FD><?+5T;;5-)F#A37TYHFVD@E (Y(Z[,/I%"
M<^]_Y8_F-H'YJ^3-)\Y^79*6NH)PN+9V!EM+I*>M;2TI\2$]:?$"&&Q&3_-F
MS9LV;-FS9LAOY@^>=%_+?R?KGG+7Y>%AHMN91&#1[B8_##;Q]?BD<A1X5J=@
M<^!WGWSMKOYC>;-:\Y>8YO6U+69S*5!/IPQBBQ01 UHD: *ORWWJ<A@7KX'O
MCP#U&6#_ &9:U\,M@6WRU4=>^*TKE<0">^-X4-?IS$"E>N5TZ[5QZ@#<'+WK
M[8^GWXPJ?IR]NXQH/AM@'5M3CTG3+[4Y_P"ZLHFE85 J%%2![[;9\V;V]AU?
M5=7UB^2:9)YO4G]&C2F69R8XDH2.;%>('8;[G;!M[#':C3]$EEGDU.0I+J\2
MH ()6<E;<'E\13CPVV4@]:'&W>I7=S?33:B@0>7K1HX50'B.,7&-=MBP+J-Q
MUKWSL&E745I9^7=$MH@DRQ?6-0E;<.(8))IN/(BM3S _R@M>F<>U>'ZU=1W1
MEDD].:.&%^):L$".PD6M!]H$A *Y+M,LK2:SO8F#P6.FW\,)169JRQQ--=-4
MFE>48W(J/IP'I>B7,QM9ID/US4;B42!:EC+*LA^,FM22#]^>N/R[\BJUG9W,
M419].NH)*&FX=.4@':@8DBOAGO;R#Y.M[5C=- '67C*2.-2:&I%14C;IGH30
MM+H;>9(U=*;]Z'OM[5SJ>FVBQ*VP/ D@#I0GIUR4Q1A57B !U) ZGPP9!0D5
M?@M=V._T#Z<'F-0VU-S\.U:4]NYQC@AC7XEZ4!W)]^@RG#,ZT "C?;K@-@O*
MAZL=S\L#M'7E4BA(I3J/GB$GIJ""M:[ 86RVR-R/'<^&%=SID$J5DC!&X%._
MA7(;-H5L7JL0^U6I&^QV-?;"#5-!@ ;X%>5D^,GK0&GAW&<VN?+JO-(50JJ_
M$I)[^ KV-,B&N^5@+>YD].L4X(N8B*JW\KJ.QKL<\P_F'Y!LI8H[FV7TZ;<:
M$J]:C<=OHSR9^8OD&*YTYGGMW$EH/C459@I&TB'N!O\ //'.H:))833HRB:.
M"0HS@_:1AR5E!\1XTPRT:9H0LDTDRVW!G=X34JB45G>)SQ(4;'N*U\,G4%G>
M2PV]M->&)YI9KZQGADHH1EBD:.,'C5"V_$BJD&G4YZ/\FFZO[/2VGN%CE^JH
MG'J6])0H].921\0&X.X[9V2T!CA5G2:&,['G24$?S!^-:>(/3#(*HHR$A?#]
MDCZ<6&XRZ?#0=<RCN1TR]CT&8#J>V40.V);U]\<J$=3MELH49ZA_YQ8_/-_R
M@\["PUFX8>1O-DD=MJBLQX6<U>,5\HZ#A6DE.J$]2JY]ME97571@Z. RLIJ"
M#N"",=FS9LV;-FS9L^0'_.9_YT'SQYS7\O\ 0KL2>5O(\[+<M&U4NM6 *2O7
MN( QC7_*YG<$9XM+?"*8D7[8Y#48HM-SFY"AIC@<<H))IE\34XX>%,JM?"F,
MY#H<W';?&FNWCTQU2N7SKWQ_+*Y!NN:H^C.7?FE),_EC45BN3!$4 E9 QDX$
M[+&J]6)^_IL,\&:A%^CU@&GR265IICD_6&8&6:_E!YRH@.S(IHM3\-#2IWP;
MH\%WJ,WUB:&1=-X5%S.P9_2C"0#@>*CDL50NVS.3UP[U_3KXW]U"EO\ 4WUN
M^98[<[F.W^N_#S4^R G?QR2:Q>6\ZZ3YB@O95M=1UJXT]?2JCQ65M"@E%!N%
M*$M3"V.&TN;G3[F&?AHMJ9Y4C<UH5^KQE5-0QY,-R>WTY(]!0V_DK6%J';4]
M11(R0&8K.T:R4ZC=&/XYU+R]Y9E^N:<(05N;2XCN$4#:0".Y/ L0: JM/GGO
M;\OM @M)+=S$(H9E5>"CB5E@*LH'A5>M1VSU5Y>T:-1%]50<9'4<0=J FM".
M@VSMEG8A%CD2E!M0"E#_ )],-[=D8!>?($?:&W0TIVPXA^)@QZ=J_17#6W0-
M2A 8-4=^+=L,0*\G!V HNU:_1@9P.5&K0]1C& W;I48#D0JW7[\",M:TW/\
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MWNU6M26&U?#Y4Q.2\#*W$;*/QQL-Q4^[4V&_RK@WU44DFM1].->6H)Y;TKW
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M-?NRU)/WX)78#%5-1U[X[H.M<>-_;%A^O';9= :BNV-(X^^634;'*!RZ_?F
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M:*HX+QJH[9.].B'KP#95:<H?'X=ZT\!3#/S<\UO8M':L$9_A9QM0.:5._CG
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M#7K2E,\C?\Y1?\X%:MJ.L3^<_P FKB+U[HCZYH-]*5CJ  )+6X/+@ /V&%/
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M>:+YL\@V+:/Y<\Q75SI]SI1D:6&UO;=4DK;M(S-Z;H_V23Q8&AIG,/\ G'A
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M!B*8\-0C'AB,6C)/7;!B4Q88XG;VS5Q0=/?+!WJ-\5#;8\5WKE@#Y8VM33'
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MR1E9=UIL!WJ<DMKJ$C"J:M;D>HR*&MPW,@A025==R=MAB5[?N2W^D6#*IJ.
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ME1RRM$FW)DWKO3XN1W%?QR4I<VMD%93Z,*,6EJ*@D[L6H/M'?MN/EAC#<&Y
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MMQJ*=<K8=<NN,K7MFWI3N,V]=N^8M3KWQK,"*=1C&Z5!^[&%B/GWRN5:XDS
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MS-I,L%VRCU+B(*R%ZU)H&Y4KOD!\Q?\ .3/Y?7%A<-%K<5D64?NYQ22J?9
MJ14[[ G.-:7^<MA+?V]]Z.IW%F9@R3R6T\498GJDC#8D;?+/>7D'\Q!J^EZ<
MQT](KBZ5$22-6%5&_P 3H" ">_VF/>FV=02Q,UP8XY/4D=U,Q4'A6H.P;N??
M#UH8[2"613SX+Z:?"#NU:D[[_P ?EGF;7KT>8_.$>CV0>6*U/K7%1\)H-@!7
MODQUR&'3M)N+J7:.QMRS4&Y(ZT'?XCGC;\T]9]5M)T*-BS7+!Y-C3@M&<5'B
M33($" =M@.V57PQ4-T Q4-TH:XH&VJ<54C%XZ ^.#$(I\L65SN/'%U;Z<64U
MZXH"?GBBM3%010>/CCE)ZXH&\>^8-6H&7MUKEJP[[X[D.V23RO<10ZG<O*_!
M6TC6(P2.K2:;=HHV\68#(WT &7RV RZ;>W7,-M\VVW:N6.H\,Q\!TS5VZY?,
M&G;,K5/7'G]6-/ME<OHQW+;<8VM>F5Q._CF&WOF)WRNGTXP-05ZY08G?,QKU
MQI(VWQ+F#7&%Z=>F)\^P.)EJ8F7).0;SK9R/9PZG *S:<U6(-"8VV8=.@ZX3
MZ!J?I74,BL6;9UK] ).>W/RO\SI)#%!)/RJ%92#0@KN:CO[C/3-E<Q7<;<7X
M_56Y+QV#(PVZ&N&4-Q*G- 16.AC9=PZG<"AKX8(L+U_5,8 *GD1QKR'+J!6F
MWSR3I_=UDC;T9EXD!02#W(^=,YUYDTV5(98;8.;>2M#.#ON :*.O]E,XG'^1
M<OGW4EN=2MI4TZV8D#C2(\>HJQ/8U &_B<E?F#_G&'\N;K2A:/Y?AKZ?".3@
MM0U*)^SL%KO]&>=M4_YQ#T32;@F***YBMI _H74*CUB*?NTE7B1M4[@Y*K;\
MA/RIGM(TNO*AL[YI.")!>2H&HRK448BM6%!W )P1<_\ .,7Y2Z[ L,#7L,2C
MDHFGD]6,E#)P2:&5" 5H>]20,.-#_P"<*/RLT^99K:6]:98@T<USJ-Q-&J2<
MMD7UB*]3T.'VC_\ .&_D.>ZFE;S+K#CT2\D;7!18B&(,7.M"".WXX#US_G%W
M\J-&MI+R\_2-W S$*TM\Y$G$_$0JD$*!]&<1\W_DW^3<:BQT;RPU[>R'C%/+
M//(S*RGI$7ZC:A\<)O(W_.-WEK4M:CU&^TF.RMK<J\=K%&I5 %)/,L"2U1M7
MW[9[1A_)GRL=';3[?1[<+=1J&0)\(%/M!?YA['"WRU^6U_Y8N?0LYY!8JW#T
M_36M"2*(Z[$?B,[=!IB:78,UQ3U:? K$FH[ T-2:YQK\Q/-\6A:'J,TTICBC
M0JA!"GFW8&O;8'(#^4&@3/977FK5 1J&M-ZJ*X/[N-J<0=MOA& OS;UJTL].
M^IF4 3RUIW].*C,2!U^( 9X,FU276M?U+4IB7CA/U>$D_#0'XB!V[8,#;]<6
M!'CCAO[8Y=CBP8TVQRL:X(1CXX+1ML$*:"O3%UD Z]<5$FVV*AS\^V/5O$XK
MRWJ,>'.+*1WQS4Z9MC6F/ [>&;8=,--(;_2I?'ZE?=O^76;"EG)%/NQRG;??
M'<B=A].70[[9:D$;9B=Z'$RYZ?1F)Z=LH_KRQ4'%0Q.Q.66 ^G&5%?U8X,",
MNH&W?MCP-_?*-/'&-L:Y1-<2K7;IEUQ-FQ.IH>_MB#'$W>HVQ-6ZU.XRZ@]?
M\QF:E-L!W$4=S#-;S+SBF0HP/@<XJ5DT759K9C_O/( IZU!'PL/HSMOD;S']
M6F1?4;@9%8 =5/('D/OSVUY4\S_6EA_?(Q9!X;D?3^O.ARW#2H6B95*['V)W
MV\*;XVRO)6D4LP>:%B/4'[8Z$&O3[LZ797'K6J(P^,?$>H-*[D;TP))=0M=<
M/3-UZ5)"LE=Z;#?IMD[M;Y/32&$HAX5!(HJ^*&GX8M=2V\T+&%ZR; [5%:^/
MCMD,F^K7;O'<</5)"E9C]L@]5+5&0C5O+^G,5>:T5A"]83QYJE"=N+5!Z[_A
MA1?:5Y8N+L2RWD]G<*G$,A(6E*B@!XD @[=!X8V&XL;4((]>BBYBFXC#1U9C
M4%2H%>76A/SP\M]=TV"WNY/TR@N)5C4AVY*0G(!"I)V^*OSSDWF*_M]3DE2?
M7B8HAQ<<ED5F*@!CR_U0!X9 [+3-$75A<VIEU*6$4^MLQ*K6A:A:@!)Z'?.N
M^6H99KJ"VA3B;F97+"I CJ*@>)-.N=M@U!+.,1KP=J4 /:O:OT8,L90L2RE@
M>1+.6%!3P&YV]\AOFG5APGDDG1+>",TKV5AU]]C]&>*]<U"7\S//5EY:LY"N
MDZ5(L][+3DG%22J4V&]*G/2&K:K:^7M%^K6O[B*V@Y$MLU*4!/WUSYU?FYY[
MDU"ZN8XK@R2.OHH2Q^%-ZD4[GOD!TBW-M8P(Y/(@.W^L=]\. 2-_#'B3;<4Q
M9' [UQX;OCPU1U^G%5/3QQ=&'?!2&M,$JWO[8\FO3%%.WCBG.FV+)6E:XH'/
M3PQ9&7QQ8/\ 1XY?.M!C@QKMOC^=.G;+YG;OAWY;@%WJ5Q$7X<=*U6:O7^YT
M^ZDI]/"F%M_;BSO[RU5N:VL\D(8]2$8J"?NQ"O3,"2<<3].6.YRN1+$>.,84
M->N^4#OTQV57?;OEBH'7?ICCOOF.VXS!AUKCRU309B6\?ORJ]JURB:FH\<JI
M&-K3?H!B324V'3&AQ3Q.)LV^VXQ-B#WQ)F'2GSQ,$;Y3'<Y7+:E:XQAU_4,Y
M9YZM/2O-/U%=EN$,$M/YDW4_<V%^C:DT$BL&+/&!45H13:OR.>GO(?F]554:
M<N1N=S\7C]U<]*Z?KWKV\<T?J&W= '9#\2DBE"*\L/[/44AN1&L@1SQ9-JDC
MJ*'.DVNI))%'( 0M?WBH:E3X\?##RSN:,S2E>+,&4<:DCM4'ODEB@I#ZUC(0
M5%61P!5.M4IX5P4MT3%Z<A42J"2-OC'=MJ?B< 7=K;7BCD_J2HW-64<NI[[;
M?K^_ 9T@E>7KLI1BLD9<'D/85![UR+:IY1GN6"VUZULTH92G'>HZ,BL&_77(
M7=_E==7/JB[U$A("#5(]VZT^(4._?(_>^3[X<[*UN2J1 59"IYU!H!\-2=]_
MPP-#^7^K1)Q%WZT:)]CTJL![["OR.&-MY8@M$$<TWK211G@E  K;DDTV/ADY
MT\QZ;"\O$&X=$/+Z12HVIURFU4S31HKU$LE P%0-Z%OPH,4N=;]=C!"XAMK4
M\9 G133['+V'7/,7YT_F2^DVDFA:5*T^IZB3'#%U=BW[;L/]K&_EKH,/D[RZ
M;J]<S:MJ/[^ZDJ 6+;\:TK0; #.5?FM^8TGISVL,Y593^]XGXI&H:(=SM]/;
M/'O-]8UB-9*\:\GKV4;TKG0%8*JJ.B@ ?(8N)*XY6RPQ!Q8;FN*BI^C!2T_4
M,71:CWP4G2N+#;?%A0C'"HQ=17>O7%5\<66G8;8\4!\:X[Y9N5",55O$X^M?
MEFKT\#DL\CV[W6M7L<9 =?+_ )AF):M.,.C7\C=*[T0TQWGBS^H>=O-^GF(0
MFRUO4+<Q@@A/3N95XU!(VI3(U0"N-V'08W<#+Z=.^8=<HG\,JNXJ.N/ZT_5E
MG;<#KE!O$;^.:N6 *?AC3L=LQ?H>F;U-LP8>.]<HMC"YKXXF3] Q,]2*8PM0
MYN6X!Q-FV^>)$UK7&@@=\8S$FO;&AB":'IE%R>^1;S3;+=::&H"UO,K;^!^$
M_KSG(M9()"ZBK ;^%,E^A:G+:R)*"8S%X FA'MGI#RKYP$B(LDA1J4?B=Z ;
M@ 'K4YUZQUB&Y2-GD"NI^VAH:]=P0:YV3RQJ0E4+,Z.RFC@CX67?<D'\<Z3#
M/;,CGU>!6OPN:]*=Z>&#;/43#175E5NA->*@?LFG3;#2*]@F1710TA< L-]B
M* C;ICI1,@1XXXYHWC(H-F(&QJ"._;%81/4!:*U>+,PI\NHH,&+97+LP)B81
MDTJ/C7:H-0?HP,^G.D+A[MVYL642-0KW&Y/3V%<BEUIAA:5X.22RJ&:1 '('
M^3] _P!O(_/;WBQIR6XECY!H0Q)/(="=Q7?M@6WL+N6262<41R =QO0C8'I3
M887ZE"]RSRH>,2,>4M/A#"G;;D1X#IA="1<7$=K9LRM&#),_&OIP_95AOQJ:
M?#7OO@'S/J6G^5O+-QJ$RK;6-G%(P0,3+*WQ$DFE"2<\=>6-*?S'KUYYU\P+
MZ,8=F@CD)(5>J(:]P*<ON\<-//7G=K:U,:3&/H(X1]H@>-#L<\=>9]<FN[ES
M(YEE?;X36A)/PBM>O3-Y<M#"DMQ)O))M7KOWR4 @XJ&)Q=3T&++BZXLI .+!
MO;%T8C!BGI@D#88]=C3[L745I@D*/HQ0K0;9EJ!BE:C;M^O-T6O?-OU[Y@3W
MZ8IS[Y9<4KWSIGY2V@O?,VLAD=H[;R7YSG<K7X?2\M:LR$^W,*,,?SOLAIOY
MR_FM9J%6.+S;K+1JM2%CDO)G0;[[*P&<LY'?WRJ4KE<AX[5S<CVRU.V]-\L$
M$$9J#' >^^-)-=C49>U<O8G;?&L:#KUQO(4K7&$XTDURJD;@Y8Z?/&MVIC&<
M]!C&-!N<2K7&,QZ>.-Y$BOAC3O3VQ)B1\\86IO\ AE<P!L:XSGM2N^ [N-9X
M)H6^(2*13WIL<C2:>)X$D" NHW/>O0C\*8BMB\<A>,<7 %"</M-O'MG1>9@D
M0"A/1M]C7.E6'F'4H!S>3U.0ZT44KU/3.G^6O/=Q:2+RE-"%6II4'P*TZ4/T
M9W[0_.L<X7A-1F I6A(/ATZ=17.E6.IW=]'&RO%Z<9J510NXZ_TITR46-Q&%
MA=>0^'J*4J0:K384&V2B&\CF!5(UBH>JT(I2O0]Z=J_+!IO+>-P[>DP<&K**
ME-Q3;W/B,3O-<L;!969" R5YN:(M>QIU\0:"F%J:G!?(TDMS!<6Q^.-6;@2.
MY) %>]-L#A1*H(1"3S/VBO%:;;UJ.OC7$/JT**LES&+GTQZ<:\J<F%0"M3[]
MOUX'GBMEMUD9%<0K5MB"2*[ 5IWI^.<Z\P7JJC4 8P*>$:J%W?8 "G?(YIS+
M:HY,JVUD L]_<5!:61!\,8[#PH-A\R<\L_FAYTN?-VO_ *%^M"/R]I<O[Q%H
M/5<'DH)(KL ._??(!K7G*"QLUM;"3TUMUXPQA:BBUJW(]@22223].>=O,7F>
MZO;IF69I7IUH*ECX'QPAMM+<+'=71_TFX<B)3^SW+')9$B1HJ1@!5% ,6!Q4
M-WKBZ/\ ABX>E"#BZO\ 1BBN2<%*1UP0N],%J:4IO@M&H!7%0:FI&+AML4!/
M4'%:FE:UQR-XXX]=L=U'7+! KWS<N1IC=QM7IVS&@%<[O^0-@U]K'YEW(9E&
MC?E?YSO" 0 P;2+BVH:@DC_2*[4^ZH,E_P"<MM/.E_\ .1'YE6Y!43WEK=@U
M)J+JRMIZ@D#O(?U9YP%23CRI VZ=\KCMO]^8#?;KE@>^6JXZG7?*Z#&U(->N
M:NYKB9)!J#E$UZFN)G;WRJGPRB:4RB3XY?*@'OE!^OCC237V&,KUJ<:3QZ=,
M3-#N<;6@&),].FV)%A4[XBQ^[$ZFF)UZ_P"=<:U.V^+:;;.QFB"$N&,R(PIS
MCD_EVZ5&";C3P&#JGPL*&G8]:?/ LNGAD!85=-J@=?#;Y95NT]J #(W!6VWW
M_'#$:A)%+T"FGVU^T*]Z9*M,\X3VY0+(5*_#6M!4GXM^O;/0WE'\P@HB9YJF
M/CZO/>A.V_?IG<K;6[>Z@98YPC_:=0]2I4].G3?;#^/5V<>I:SCF%/((2U0:
M5-*$$=_; X\QZI'(4EB959@L<H0<6KT#$ BA_'#:V\S6D"E;IEA;;U.2AMQ4
M@J#4;=ZXA/K]E?(S"!9I582"0&@!'1JJ%4T':GT890:[:);L6N>3!0Q5AN:[
M[A>- 2=A@?\ 32R3JJQM<J_QD@_"&)HJ^P]L)=7\R*ELL F6.8REV*L& 5>I
M-=MJ??TSED^N)<7)N5XL5Y.I8E0H_9W/^3[9P[\R/S.BT_39[&SG'/E0\2*$
MCQ^9WSR6_F":;UKAW/I,Q8ES1YG)^*I/;?Z<C^H7=S=O27E(\NR0*=S3NP'1
M<&:9Y5>-&O[[X744"G[*"O89&)O,=G<>9I-)'$?5X>"/44]2M2OW9( ].F^/
M#XK7%%(^D8N&KBJM@B-JG?!JFM*8)C)^C!B$>/A@A37^F+*W]N*^I7PWQZ-[
MXJK[TZ#%00"".M=\5V(QVY&4<WA_#,2=MZTRSN*'OGK+_G%O3?6TG_G)352*
MK8?D_P"8[;MLUU&K ^-:6YW&3#_G/32/T=^>PO0M/T]Y=T^^J.Y1KBT\3VM<
M\7T% *YCT K7&5/2N7[G-RKE<B-\W,UKCBQ-,;RJ01F8TQ(MX;Y3'PRO8XTD
M#IB9/3&GJ/?*KOOFKW&^9I*>^)B2I^>,9M^N)LU>]*8B6J>N,)W._?&'KB?(
M;93$=1TP.QH:X;>6]%N_,^OZ/Y?L@3<:K<I "/V5.[M]"@G.[_FMY;TO0?-W
ME_3M. @-KI"VLL2TJ%A?]VQ'N&.1*XT0.CR(O$K\4NU00 !S4;TVZY';S2W@
M856@K\P?I]\+OJ'/FI'(,.G\,O\ 12,*\:D=00=O?(_>:;);2EE5E$E-Z$C;
M^.&5AJMU8.*2%&4!13>J^!SI.@>=[RR<M)<2AQT:O,LK;\=@=Z9V#0?S#6%!
M$)HIW(8JLHX<JMRXK2E&6NWXX:S_ )M36"FV@E,D%PI^'@$51W!)ZT)IA7;^
M=K:<2*DT+23?;)JU.Y-!6AIMAK!YSMK0%DD784)8@J6(^T-MJ_+$E\[6:()6
MNE]2<^HY4U#MV'&M:?3OC'_,LVL2QI^[69C0DTKQK\7>@\:_+.?:K^84+F9K
MJX*6TA^&-=N9'=R-Z=S[4&<CUW\R+AO5CL2WIK51N=_YG(]^U<X;>3W.M7)1
MF:X<DLP5C3I3KV'O]PPZLO+]S)(L$$ N[]AMM^[MU/0D=/OWSHN@_E\E@OUR
M[7U;A@2SL*DTI4FO;VP!Y@@,L]KI%K0?6WJS@;A%W=]QT4?CGBST^6LWEY;D
MHINI9(6)^*@=BI^X9V+3KU;VUCF.TE )!X-W^_#$-CPY!W&V+!C7;%T;QQ8,
M3B\?C@R,_=[8.C8<=C@N,X)6M,5&^/ WV[8HNW7! IUKTQ92-J]L5^77'5H,
MOJ,WPC8[G+H#O7*&>_?^<3])X_D7_P Y;ZZP)$_DZYL8FKT]+3-6EE[_ /%B
M=LG?_/QG1O1US\K_ #$JU%]8ZEITC"NWU62WF0';O]::F_8Y\U]]\H&H]\U*
MY1!Z?:QHK6HV\<L[?Y],PKURB:'?I7-R WQK$4W.)AAUZY98'MC"WXXF6![Y
M1(IB9;\<2Y;FOXYA)URV<$?AB98;XPO3$#)4FN-9Z5[XPO4&IQ,O2N^)EA6N
M-9^E,834;]\]8_\ .(7E"/6_./F7S)-$)AY5TS]PI%1Z]S7>G<\(S]^<:_-W
MS; W_.0-M=2RL$UX"RC@8?"JI )*^->2],[IIFD+/#%*!S;8U Z@CM[;[C"K
M7O*;0Q%EA+PT(]D/\M>PKG,[O3'@<@I0C;I^O!5K LG%&Z^(V^C'7FE1B&1'
M4R=6'$5-/;WR'WVB/"[)T++RCJ-R/GOTR.20R1L&ADJT;;C8[CJI!'?%X]7G
MB >1/@ WWI0GH:;4.V:?6[B8,HDJK+1@VYVZ UKL,3M-3N8JR"Y$<E0>*&@_
MAUPV;S)?,@BN+EI8UKP^(+WK0T[[XB===I*R3 TJ%4<25KWZU[8'GU@/ZLLE
MUU4#DYJ6H1WKM\LB&J:M'*%,9>3I04X *.V$*VE]JK(JJ+:W)J**17QV/Z\Z
M3Y9\G27!6*TB9(6(]28+5FI_+6H)ST%Y>\DVMA; F 11M4L>KM[DX/U/29'"
M6]G;/(9F5((85+/-(QXHB* 2232GB< _G+^5[?DW^7%SYD\R2))Y\\PVTBM;
MQ4,=A$Z\(+:,]V#R N1W^6?,Z#360<0O%D ^GM7#O3BUBX#5]%_M ;_+Z<E*
MGH>H.X^G%0PQ0$GZ=L$*<$*>^"%;;PP5&>F#8S^.#4(^>+J^].GOBBDDD=L$
M T_5BRD8(4COWQ< =.F.#4Z??CMB,L>'OC3N>YIEU(._3%-J5W-,^J7_ #C;
MHOZ._P"<*/SQU5TI)Y@T[S9<*YJ*PP:.+=0-Z4#Q/O[YT?\ Y^#:"=0_*'R_
MKL2UE\O>9(/4/\L%W;W$;?\ )18\^-W,U^>.#@C^.7S_ +<>IJ#[Y6X!(.-!
M._?&G[AE>^)L:[=LJI.WAC:TJ/'-R VKC&I3$2:GK7,3V.V)\M_'&,_:E!_'
M$^73?,S;?+$&D/TXSD36M:XF6[TQ-G)/SQI.V-KVZXQF'X8WEE,>OC3/I9_S
M@[HK1^1O/FN,@(O]0$";;D6\(K^+YY"\]_ET_G+\Z[V4)]6C\HV5P;9-ZF=N
M<OJ&M=VK3Y9Z$_+A/K.CVD<_Q2B%&!(V-1V_4<Z!<Z,'617C#1NI4J=STZ$9
MQKS/Y8^K,K1CE":E2>U*U4_(Y!4TB42(T8^$-OWJ/ _UR31:4\B*IC*E0:;=
M?$5\<(-5T8AT 1N5=FZD>V1.\\M0LTL\:&-I#60*.XVWR.G07+.O$/&:FM-J
M=-\ RZ'&#Q$=>/7N=\*KC2&C-(T('05W'W85SZ?(B2,E3,*\54<02!TW'3 O
MZ/FI65E4FA(7<C;?XL1ETR.Y4(.?P@&I.X%1B\&AJ.)D'-J@*H'B>M,Z?Y;\
MCS:@5EGC:&V%""PIR_S&>@]#\NVMFD2PQA%4#M4@>(Z;X:ZG<66C6DMU=R+%
M# I8U_94"I)SO/\ SB[Y.O-<35/S:\V6 T_3(I6MO*UC,O%XXD'[_4)@>DCL
M>*#]E 3U;;Q'_P YR?F-'YS\XV/EW3[CU-/M7:0\#L\<!(!/LTAV_P!7/#]O
MIQ<A"@HQI4]0/X'#!]+ C570F, D5I7OW[X%@C9 (SN*GBU>W<$'%%]L74]/
M$8(7?%TWQ<'>F#4I2IP4@KN,%(":4."%.V+H:_UP0-QBJ*<$"HWK]&/#"N/K
M[]<>'H-MCEJ:]\6I7J:91._3;+#=1XY]N?(_E\>6_P#G!*_L3'P:\_++S!JK
M;4+?I.SOKT$UW/PW ^C.K?\ .4?EP^:/R!_,[3DC$DMII)U6.HJ0=+DCOB5[
MU*VY'TTS\^X8=?#&\MMLL$[^V.YD=]L=SK7?+#"F7LVPQC[4 WQI( Q+D ?;
M*)%-]\2Y5.-)Z[XE4CWS%J]<KM\\28$[[8F3L-]\86&,H&W&)DT)Q,MMXXF6
MVQ$DU]LQ/T8PD=]\:#3I@:ZN5MXS(?B/[*^)SZ^?\X4V<D?_ #CK#JC+1[[5
MM2=Z#J?6*?< HP+?>2=/L_/FMZC-:@2ZGI409Z;\@)$K](%,XQ^7]HLFEQP
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M))]M\()/*ML5^M/ R0)0(91\;4[A3T!P-?F.T\F:P1&;=8;M!&ZDJ6Y\>0\
M3V_LSRQ^;?YGZUY'\F:=Y8\G:>MIKOYAF6SM]08%72*44N+Q%ZJB*2$/[34/
MCG*/+GE>#2O+UKI5C&8Y;!$DMW;;E+'\0=R-R6)/+_6.3&">*XM8IH@(H9$)
M\"H.SJ1L*A@0<P$C<6H25.Q]T[?=@A@16E*5HP(Z\@"#\MLN3CZ3!@&8$.-M
MP12HI\L"L=^((/"@J:?L[BOT8D3&KN>/)  #PVJ&V[^'? H*\R0H(VJ-B 5V
M[=L&B))/W8 /,]?\EJ&I'SP4BHJ\V"@"K5#;$4H=Z9&_-RK^@;UP.0$'(=@"
M#R[_ "SC_F2191;(X:MS0E!4EJ*.U0=^62;RY;%!&>)"QU;XB:;B@[==\GD8
M()H!5%V"@CX?F#^/CE$U"R-5.52M=@W<=3A-?LQ:D=10$G8U[U KM3 4%L[M
MRIN1]IS_ )U'AABMJH"DE>*A>5!U/<&N"V14+\81^\0E0=B-Q1J>/A3"UG5&
M958%A6B("#]!/RQR,14T%8@/M;FIZCIVP8K*0-A\502U0!R/7O4?(8\#H Y
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MJC8[G8$8/=6K4@<7 %#].V,5"5'$@*HH3X$=\:D3R2%J&@(H*[DG#[3; R3
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M:@LY 84K0[ #I[8#N5-M?,:5M[SE)5@&I, /44*!T*T;KN0V*J.%#Z@8J=P
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M+!:\WI0 [ ]=L4AN#ZJJ:@D[?$"#MX&F'9@95(/Q @GXA7?VIL?;"Z]+U$$
M#SS[#D"%C'3F:>';Q.%SV*68$<;F1ZDNV_(LW4EJ;DX -NADJ%# DL5V'2AH
M#T\<ZS^06E17_P"<7DVSDB5_WEPRCM5(7=3M3IGU!\T:<14 'G':QNI_RDD'
M]<@>I0LUJ+I4Y-$"LJ>*,*,/NSTI^7'F+2]0T*SL(+UWO[6%0\-S*TLQ5 %#
MB1]W%*;[D=\DFN:/'KEN\<8":A #):R=/B'6-C_*V$7E&TL[V+5K34+-7,/I
M<XY5!X-\8(%1UP;<>4-*9VECLD16V44'08DF@VL% L*@5KT&"O3@@7HJJ,CN
MHZR &CMZ#K5ST'T9"[BVNM6?ZK&6$3FMQ+W*_P @^??VR9:9IHAC6%% 6,<0
M!L,%7UNEO;RNXI\).>0/S9UV.'1;;4+2Z1KBUENV2):L_K*KBK+3;BHJ&/T5
M[> M%LY IN[H&=[J1IF]3[9>1B['D=SN=JY-83Z7.0$JRT(#"I-=MO&@[X#O
MK-+U)1Q]*X1EDBE(7DLJGX&)WV Z[;U. +.1;BV5V3C-7TY5_ED1N-#6AV84
MZ>^+HJO0/4\C0<3LO+<@5'[+#'L6],@0%&9R:G>I&Y  .P88"F'+BM2 W$\U
MI6M.2FF_N,#%D)=P*H1SHFQV(#J*@CWQ:$5(:H'&CL3OR'V3T([4.&BGB.1X
MDAEJR@G9>FPKV& IY2[H@JSDA@ K'8=#N0*U/CA+YJ7ZQH6K0%0"]E<+78[F
M-J;@[;?Y^/ O*MOZ-G8@* _I)4@'8"@6FWAG9-+MN:U-$]05'(_#6FP.W7PZ
M>.2RVB4GXF(*$OU'*@&_$'C].V"6@5"28@R'[(-2-J@T.Y!';MB'I4X.8I&?
MDRD'BY4 T^+<U'>F )BB(X)(!?B8P3\1[$ 5H:G;".\E85"QLY-0.8!XG?M4
MFOSPA8D*)&8%F8GF#]D#K^.VV"[>"2<E@I=RX)H*FM!6H'T9*;+2(N!=*N5'
MVMOB8[ '>G0=O##);&2*20IRB+5H#U:,T%!3IT'4?JP'<11VJF:24)$3N7Z5
M4_LTZU-* 8R)+G4/B6/ZE:L0E?A^L/0>%>*BOS/R[>X_^<*_RE@UOSE>?F#?
MV?+2/);&.PD8'C<:G.A'.C#<PQDM[,R'MGU6S9LV;-FS9YW_ .<GOR8C_.S\
MK-5T&SCC'FO1C^E?+\S[?Z9"IY0$U6BSQEHS4T!*N0>.?GGN()[6>:UN89+:
MYMY&BFBE4HZ2(2K(RL 0010@Y%?,L[0VT,,9'.X>E#M\*BOOB&@51PQJQ)'M
MU\-LGFMVDCZ.US;Q\V@):15%24I\?P^P-<YU#&64'D1%)O6E*@]#@F,J)"&8
MD$C>FWMUSI&F6Q6,*0/CZ4WI4##H1F,!:\!X**=/GB14RM*H6@4@[B@.W0]\
M7$1>@9%Y( *5.Y/>N'%K:B154*!44Y=E->P\<DD40YJ/L<5W)-/L_*N+3%6#
M<"/BW:O8=M_GD;EU*#]-1:?<%8D: RP,2 )9 =U%?VE%-OI\<D% &#<6Y,*4
MIL0:D[^V(S1\BK!E4&@/3Z?UX#G:F]!P7:O<@==N_P!&)VYY-5-UK45 (%-N
M^&<J510XH@J2*5H3TZ;X4G3Q,2.5 *E13^;Y?+"*XLWMKL*S&E10%:J-]M\D
MDUR88(Z*TL[H%BAH/B:@[4VIW/88C;0.D8>1A)?/5I&0U![!02:4'8?VXC,@
M9F0(?C-%.^QI7^!PO>!5E4FK(CDFG@*[]:9VO_G'"(#\\_(;,-VDNE Z[?59
MMSGU/\R67*7I]JSE_P"%*G(#+I_IS/&RUCF%1X&HR&H+WR]JJQP2O;.A-Q93
M(:%#X _PSTUY*\SGS%I5OJLI1;N&7T+R./HDR[';L&!J,ETENEK=7US M)+W
MT_4IT+*"*_.F*>OZ<">H1RWK3I7([=ZK"I;XMAX>.1&_U5YR4C8T';H!\\+[
M6PGOG&Q].HW/?^S)M:Z;':Q+&B4/<]R>YPXL[4"I(ZG"'S.C/"UM%]N4<13W
MSRU^?'E[3O*7Y::IJ' ?I/798=+M=JFLY+2D'>G[M'SP5;TCY<0%92O$ ?#M
MX5('?%Y J\&9"RI]C8BG>OTXP3BCL2S?#Q)--PQW -/;"VX @F2<M^ZNV6*2
MHK^_ (1_L_RJ 3TV'CCHVX(6J&%.7$5K3HWTU%<:RDA@6 =B I+-2@W4[5^6
M!G9F9N" @K0D!J;[K7;QVQ %F*+(H<N?BH*=/MJ#AA"FP$:JRJ:D#KM16"CM
MTS7D_H1(ZLY)5A4"M3M2E3[>&V [2)I5]>5@!+7[1(5J[!MCO^&)ZO1;&_\
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M15>'D-N+CX=OPR.ZH_Z/B];<?5BK-_E*3N.W2N=>T%1<Z=;RI&71TK4FM%_
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MR-^5A>^7O,"VZ Q0:KSAFCWX2;$QL/\ *5NGM49U74?-T E:W@<O,U$4#IR
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M 7FP^VHK2G\WWY2)0@*H5&! VZ'K0]NF,>@%"6#5WKN:UIL!_7$FKR3@*DD
MD$'<;5I]V^+)'&07JPI]GQ'>A'TYW;_G'R-E_.#R!453Z\S@_P#/&44Z=,^N
M]^@:PA;^25#7Z<C.D%8[S48#7X9N5#X,*X8ZM8O,L7U6(2W&_$$T%/<Y$_\
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M_P"<7?R /GG48//_ )NL67RCI,_*QMI00-4NXFW)!I6&-A\1.SL./0-GU,
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M7-2GEO+C]IC).[2.*FG=ML .S%&0$R*IWVH=NM.G<8RGPLZ5.P^)MQ7IMO\
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MA^$ANV&H9.:<0P(W''K45V-?88&XU)D'P$N!39B*^_A7!BJQHW)0RU8@CJ<
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M0Q/&98)>7!@22*C[#@=00-N_T]0<LRO,ZFC<?A0,.=-AL5DX$5/N<? X17<
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M$\T?FIYWU=).=L=3DM[85H!!9@6Z#;L1%49RHR!@%62OJ-L:4I3<BF9U 'P
M\2E/BZK3ON: ?UQG%MF4A6DW<TK0=]NHW_AF#@EO4<GTB#4"J@D=.YR]N0XR
M<G8T'PU%#L17IV_#$I#0!S&:!2!L0:[@5-222??I[G&B8NO&,L&D^RA(:@8&
MF[$_[]%?EBB@HLLA59%!=UHU.56Y T%"..U*^%,HM7E7BRO1=A3B![_P\,H^
MFY"-&%4@!E/Q *HW->O[._\ G1B++P>4%F4/1>I^UWVQ2&0,H22DBE#L=N0-
M0=^_4[?YDF0I'=7ELC%FBD#(00&"$#B.49#[ ]P<!WAI&DI)D%0PH!T(JQ%
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M_C\L?ZS,#&Q52"&J-C3M4[_1OC^(^%S*68[5ILH4=:U]^F^V,JLOJ<5)( +
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,FS9LV;-FS9LV?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>sny-20231231_g26.jpg
<TEXT>
begin 644 sny-20231231_g26.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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M$EW?W4U]=3&LDT[M+(Y\69R2<25?'%0N73?%0,4"],> ,=C&&-I[UQX%.V.
M^C% ,651CN/MB;+B#"F)Y1S?1@_3=6U31;I+[1]2NM)O8_LW%E,\$J]]GC93
MV\<[SY6_YRO_ #]\I>FEK^85[K%LE*P:VD>I!@.QEN%>8?0XSTWY0_Y^)Z[
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MW3)5-M;2"HI>7@#(A!%"B!W!ZJO7/DS^;O\ SDE^:OYS3RQ^9]>:P\O,U8M
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ME(0,PH4:E>+=: COD9U* /)*0BAR SI0!@!T-=P=Q3;KG-]>T<1-+>VH!B0
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M(1<65:X6ZQ<?5[9(PP1[EP@)Y4 [D\=Z>.'GEN55Y,C,UTT?ILS/Q ?8 $D
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MI-.S%Z ,H+$%0*$^W7(ZPMGB2-U*<2KR!C3D*?VU&12[%LL+*.7I*S\#79*
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M:8*CM+N%@&<.6:I#"@/6AV.!I9I4F'/B."DGXC5>Y()I[Y';J<&Y,4CL]:R
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M2D= U?&G08:QZYZIG^)R&!4 $BB@[$$]?NPDN]361W>)6EE3BICC0\>1Y'D
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M48(4?1@E!7!2#;!*+TVP4JXLJ8(1/;!$:;[#/,WYC>=4L?,5Y-)-2WTV9K5
M>GP!:\10]6K\\ :/^;^E2FVM+S4FM"6XJPZCD:\JGP\,]5^3O..G^8X+*Q>\
MCO9KQFCCH/38>FA9-R*5JM=MSG"];T:Q\M^:=0TS3XQ:+<2G4D<$%3+.Q:0\
MAO1C4T/CD)\P('#E+4M'-M"X/;8D$AB.A\,K2HI+;TFX5#@HQ%1NOQ ,A\?\
MZ9*Y2T\,;0 ND^XC;HC&M>/TC?OD?DLI*RI).!Q())J#4_(>.3G0KD)(D$K\
MHT YT8.&0]Z?"?IR>0I;S2FYL[M2D85"&;J>U:D_?7!3ZTL#L.?U68=5;DI.
MW4'I3"34O.T[1F&6^Y1BAZCD"/ TSF'F;\Q],1)5NK^*!8P>1>0+](J<XW>?
MFWY7,IB.IJQ_9>-'=1\V"X=Z1^9>CW;)!;ZNDCFE%9BI-.G'E3IG4;#SS)Z:
M@W >,_"03N!X@Y,-/\U^HJ+ZP$= &>0^'<?/.W>7_-%OJ%K'!;R*?J_PHG4#
MH>YWKDK2&[O)A&8I#ZI%/3C+,">@H-M\D#>2+Y;)[_3IS97T=9/1G 6-Z 'C
M5=P?OR#+JMW:W$L.KPK#<Q-NLG4'K4,-B#[84:SYBGDC?XJP.U*,U/A)J2/]
M7L<@5SYHL]-026\_[]9/2N$+5H6V]0'?KM7(]=_F/(LK?O"I!!8G9OA%!0]0
M*8A!^<<UBP,*B=ZGB'%4 \"._P!XPZL/SBU._?T9G%DCCC((@L:N.@5V6NWM
MDVL)8-5E2YMU5W4<F$87C3JW%@=R<D<^E2Q6YGLV"J>7/B?C95!K4J "=_#;
M(U<VL&HQ\)K:)-62,20W"H>$H1AQ=379NQ![_/.*>:VDM9+J9H/JTETK1/&*
MD J *=C[=?EG*=+N^-[8$PA@+N-W*K5JF5-R*'>J['/>LHJS'W[X D3[\+Y5
MPOD& )1UPKF&%DHZX!=?;KB!7?$R.N),,088&;$3B+#$FQ/*Q-CM@:0Y]T?^
M<(/.9\V_D%H-G-)ZE[Y,O+K0)B3\7")EN+?;P$-RBC_5SUYFSX ?\YP><O\
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M1_GOG +GSU]6]1GF-2#R6O*OT9SW6/S<FCDX6UBUS(/YGX_?0'"ZU_."5?\
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MAU]-)J]/ &F0;5[?3],Y/>)J%I,0S"$K(4;?XC0L:$ = VWAG/\ 4]'U'S2
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MB] 2H4M0=:G(\VFVHX"7TW,9#"@%* @]QL-L9:>3;35&6Y@T] J2;EE!VJ
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M*RG:,2GX*@D \1X$@@[8*31FAA]:2XEDD:O)5'%5;H*4/\,T6EW21L+6X9Y
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M$'YX*3!D9P?&W3?!B-@V-\&QMN-\&HWOTP9&XP;&^#4?!T3U( J3TIG+//\
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MG!%!=1*!Z;OS4$;CG1@5.WCN,A/F2T"Q&[56Y(P9N7;:C?AD2>(E :;@UKW
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M<#,_O@9WK7$&:OO@<MB1/W8DQ.),V(EL19L09JXB3WQ,G/K7_P XPZ%^C?\
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M64]Z\0Y(*1JQ^TYV510YPBYDDN+AYI6Y2S.78^+$U.=-\KP&6V"_MP,+J/\
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M4PJN41IC&RO&U45.)W))Y':@_7BLEQ)$W!UY[$,>G7Q[#[\%P2 CEZKQD+Q
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M6 ((.Q'B,:6Q,MC2W?&$Y7*N,)ZXVOOB9.?1O_GW5^2Q\W?F#?\ YL:U9\]
M_+T>CI?J+5)]9N$(#"M0?J\+%SX.\;#IGV]S9LV;-FS9Y-_YS/\ ^<=[7_G(
M_P#)+7/*]I;QMYV\O\M;\J3L0I&HVZ-_HS,2!PN(RT1J:!BKG[ S\I<EA-87
M-Q9WMI);7EK(\,\%PC(\4L9*NDB, 592""#T.#+:.I(I2O<?V5PXB60%?W9
M4TKP)'XX;1L03R4@4IT _"F6?4"[*7(W'M_#$5,Q%#&Y(/7;Z>V*%V *\"&
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M ]\*[R_+R-964G.XCKZDK?%#"#7B\@%221T4;GV&%T20VP:-"SRFK2N^YFD
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MQ'#](:<"6"U/VG@8[=?@&?6Z6)2H* 5.Q'T>.%DD(4[;U'S_  ]L)[F%6JQ
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MQAC/S'(C]KB1GSGUJR2:WNPBBACJ/#[((S@3*4FD4]58C!(!Q5!@Z+IUI@H
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M-CN?I/3KCR40_#^\J=J=*C<>_P!.+*2:@&O([#N*T[?1@A&< 1CX2U>2KU+
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M^W?%%6A%>IZ$XLHV->FQ!&.< C8GIU. ^0,$Z'<T!W\/8X22]3B -#X8;6C
M$5Z X?1FNXZ4KMXX)8CA4]#M3ODA\C?EOYY_-OS5IOD;\N/+%[YK\T:JQ%O8
MV*58*M.<LKDJD<:5J\CLJJ-V(S]%?_.&7_/L_P D?D.VF?F'^;8L?S"_-R+C
M<6L(4RZ-H4HW!M4D5?7G4_[N=:*?[M5(YM]4,V;-FS9LV;-FS9LV;-FS9LV;
M-FS9LV;(9Y^_+OR3^:7EB_\ )WY@>6[+S3Y<U):36=['R"M0A9(G%'CD6OPN
MA#+V(SX/_P#.4'_/K[SOY$;4?./Y!RW7Y@^48PT\_EV<AM>L5W)%OQ"K=HHZ
M!0)>@X/NY^3=Y;W=C/=V-Y;365]:N\,L5RACEBD0E71D8 JP(H016N%9X58%
MN?I@T]R,L%=MO2'2B[L>NU,0=V#$K4D_#V.WMBAJ*5(JM*N32O3IW[X)H>0V
M^+??OTK6GACQ(@KS6K UKU4&O\<L2-Q#2'@OOWVP; S,X3^[CDV[%B>OT=,$
M(3Q!0*H.U>]0.YWK7*YJ1PC =Z&A%:#[L*M0B61%!W+=Z]]QT'RSZC_\^T_.
MWK:'^8_Y<SR$RZ3?0:[:H3_NF[7ZO<<17M)$A-/YL^H3+5-N)V[=_#"'4(0R
MM0 UWI3KX$82P Q,?A-$;MAG(M4.P)^U4>&X/OA)="*4,AV:E#7Q \?'(;/;
M /6,]":=ABL) *@L.0!Z^WSPUMG52XX&B&H&WTG$M1$[VDSV'%I%/!!UY%J#
MH.M :X?:)8);6L:LHH!O4?QP?K^IZ-Y<T6]US7=5@TC2=.C,]S>7#A(T0>))
M%3V &Y[9\R?S5_/S7/S9U&;0M!]?1_(44G%8F^&XU(*=I+GNJ&E5C^EM\KRI
MH*J8 Z4#;?.N"_-GEXV^IV/P_#+ :&G\K;_@<\J_\Y->6U7RSHNLHGQVEWZ+
M$?RR#O\ 2,\>6Z@H3C9$((H/"M#_ +6, H-_]K%%&Y%=_#%@* =Z;8]10C?I
MBY9B12OTXJ*BO<XL"Q0J=T:AI\NF_P!.!@8Q'<)Q-63]61^:E=NV!":D;=,,
M;=MP!U.'\!)6FVV^?0;_ )Q9_P"?>OYO?\Y%OI_F;6(I/RW_ "KF*RG7]3A;
MZSJ$-=QI=HW%I:_[]<K$.H9R.!_1E^0__..7Y3_\XX^5AY7_ "Q\N)IQN%0Z
MGJUR1/JFIRH/[V[N2H+;DD(H6-:G@BYW/-FS9LV;-FS9LV;-FS9LV;-FS9LV
M;-FS9LV>2/\ G(S_ )PL_)3_ )R2@>]\S:2_EGSL@'H^:M!6*#46X*56.[Y1
MNEQ'TV<<@!1'2ISX*_\ .1/_ #[[_/;\@Y+W6[;26_,GR!;\Y!KWEV&25[>)
M?VM0L?CE@H-V8<XQ_OVNV>$&Y&I*&IK[;_1E *?A:JJFXV%6K[=A@A9!P93U
MD/V4Z$CI4^V-CY"/B:\5K0_YTKCUJ55Z  =#XGQ Q5%$G'JS"M#UIVW[8(BD
M-"0P)!- =ZD>/RP8BJ]'E%:&A%:'PK3H!CWXH:$$\2&:IV)WH-OU85W1 79B
MM I"T'(^!([=<]'_ /.$GG-_)G_.1GEBV:0I8^=[:Z\NW )!#-<*)K<DT/26
M!?OIGWRB(930]>E=P:8A=)SC;:A W/\ GMD6I20UV'0ACU&#F)X@;@,I'?\
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MS9LV;-FS9LV;-FS9LV;-G._._P"47Y6?F5$T7Y@?EUY<\X\AQ$NKZ;;74R;
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>sny-20231231_g27.jpg
<TEXT>
begin 644 sny-20231231_g27.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2       4  DE$_]L
M0P " @(" @(" @(" P(" @,$ P,# P0%! 0$! 0%!04%!04%!04%!P@(" <%
M"0H*"@H)# P,# P,# P,# P,# P,_\  "P@"3P)/ 0$1 /_$ -(    ' 0$!
M 0$           0% P(& 0 '" D*"Q   @$# P($ @8' P0"!@)S 0(#$00
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MC\DO+Q\Q?F%YABTF&4,+.R3][?7TBBICM;93R<[BIV5:CDRC?/B)_P Y"_\
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MSXH_\Y5_\Y[ZQYW?4O(/Y+7MSY?\F5>VOO,*<H+_ %5=U9;<[-! WCM(XZ\
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MS9LV;(IYV\\>5?RY\LZGYO\ .FM6^@^7](C,D]U<-2I_9CC7[3R.=D1068[
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MKS:+^[C?2/)FB/)'Y?T4$'T(WH&GN"-GGD"CD>BCX5VJ6\T\:8ZG7J=J9BM
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M]&"+2YG>.75))/K6I7+*(-FD7U.ADD!Y \2/A7N?BWI@4^7M0F$]WJ]PEO$
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M81@4V!=C\AA)?7EG!1=,Y)91K\<RR$RL":$$\4-2>BB@&!X+.8SQ:W?@6EK
MM8X6JS%*TBAB&YW/<;\M]SAU/ILEW(\H(CAN#' ]M(2#*[BGH!D##E\-7(Z
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M3K&2=RB9^B)'21$DC<21R ,K*:A@=P01U!QV;-FS9LV;-FSX8_\ .??Y]_\
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MTLGG*"9E*I-)(Q"&63D\AZ4;DQ+;+\(J&.[RWM]'6**^E@G;U%GCT[U1'I\
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M-N*0H^R%B2QY$!CT@]Q^86H&5=(TP/'=3*S\8HO7N&9J</24U5%H*!F'*E:
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M".;2K#U75;?3KM)+F1B2RI!S;@E-F<L%"USREI/D6XU74IY;Y6L8KF2ZN/\
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M8#=ZT SG/F4&U963][4@$1[CO7?MN.F%-A<+ZYAE7DH4U"[#8U%3XY*+'DI
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M8&%7YVV(T_\ .'\T[(!5BC\V:NT:J20(WO)G05.^RL <YAQV]AMC@M-O''4
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MXTKON!^K$RN]:;XTK7MB3+7I@=D/;$&4 ].G<X'=:5P,5IO3K]V(N@&>EO\
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MY5GLHS_QCT[4Y).__%B=L-_^?A&C>GK?Y:>8 M?KMCJ.GNPKM]5D@E0';O\
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MI)!J*]L+KI]2:>6SD'"1'7CQ/*-5 JH.]*T%.^<Z_-[3IKKRGHVI3*OJ1ZS
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M:-A(U:UXG=5J!W.U!UP?8PI?FDL#1VD4GJ?$2LK.:<5\:;;TVR7:85DOHHU
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M94^PH#= QY$@>]3QZ&F)D2LT_#DLLD@-"5#  _$R']8]\%21K<+RF3X)!P'
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MT,"RCESMRL95=S1EZ _KP.&>Y9_6++&4#($8GC$O=@-J-U.^^&"2F;D*HB*
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ML*UV]\.;40EN5O(P8+QXDEC78DTH"#@CD*!I*=SR+5Z5KUH!G@'\_P#\P/\
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MI*Y53Q67>A4TI6I%!_4X%ECX,JJ*\OV1NH+=0Q^C*2=@I?G^Z%5*T[L?V?;
MY23U)$:82*^Q#&I'A7Y=L!SJ;F.2*6@900&!^,CIN03V^>$EUH^GW0#1#TI/
MM[456%-PPZ=>^V0J]TB\LG<M$3!6O,;\:BNX\/ X5*X&U>G48YFK6F)<NW?&
M%CXX+L+&]U2^L]-T^W>\O[^9(+>"(%GDED8*JJ/$DY]=_P EORLL_P K/*,&
MFL(Y_,&I<;K6+I-P\Y&T2-2OIQ@T7Q-6VY9U_-FS9LV;-FS9LV;/,OYV_EK]
M8%QYQT9"I*_[EX4WJBC:=5W'L^W^5XYY8LX!"PG=>=S,[1M'R.\:[_%R/$FN
MW3!]O-'(4YNRM*]6.ZJ56M *[]>VPP;.L9A]0QB>14]1E78\2:(M!2I[T.7&
M!;J\+J@6,@IR<AV<_LLR]@#L.O;!+%_2:(.UR58J ./$RD5[&E%KX_/$+*%E
M>-DD4\049F8'=:^I(M5IUVPRX2313#A&P2,4A% J(-D4T(J6[TWWPHDLO667
MUUAN)2_&0A11G._"BJ-H]NN<R\UZ*-/-M+ 7,=WR1S]E7(->1W( [#PR#QQ
MW;,[\GC!8.>5%+4KL2 30T&2RVD@^-0T@8H!68!> _9<BE2Q/OBUI/.K"X5S
MZD5"RJ@:J@DNI#<22P%.NV2R0QEE9>$EDPX@P CX9:$(0O4@-O3H>YP1HVHK
M?6<\!Y.=/62&BFC*L9._$'?8\-CL=ZY%K9IV(DE5DBE/,-(8ZAB:*325R:^
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MO,Q8,1%)SJ5"*U "QV)VWITZ8'E]8_4Q0_NC\1)HS4^T0OME>K'R5.<A$8-
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MKHH$T@=!(2^U7V8_/?IA9YG_ #(L/+$YTZ!!J%\BD2 'X(R=Z5 Z[[YRV_\
MS/\ -&K(+9KSZK;=%CB^$ >Y[Y$[W5;V8-)/=-)05^(USG.NWSLICY<01R-!
M4T^7\,^B/_.,G_./MK^5=I%^<'YE(C^:[ZTKH&DJ6673DG6LCL]12X:.JN"O
MP*?A/*I'6+S5(]1\S0^8M:L9-8D@CDXVB,8K57Y\5=)F#J#$6Y%*$OQ%-CGD
M+_G*[\][:PT6^_*GRK?SW.K:K6/593,TB:993$M+;QDGX))@:<?V(RW=@!X'
MT_3R(E)78  #L,G'ESRQ<ZW>);6R!$JIDE;[*)7<GW\,]Z_D7<Q^6?,"Z:O)
M=#NK5K?TN3\6GC%87**022QH?$'?:N>R%N$D*5!)3X1S 4TZ$GK4XV255!<F
MA<E>9!^&FP" 4W .!C+&CP2D.L:DHNVW-:?$:5-?PR<02>I'$6D5WJ#4K0U-
M:#OC(56 ,:$<7;8DDEJDDU[TP'([<J*S++Q*NS#D54FM?>O? 'UA'$\:R[PD
M<RVW*FX&PW^6 (EYW$I8E!)ON =^E12E3[8;PJ8RIX4;D0P4[4WHS*>P(P#(
MWJ2O+&U2 2NY'*O7J>AIBJ,R*W*,.7(4<3O0CKX;=,#J5/-:J2U4!!W*^-<9
M.R1&$/(B ,7J!\([#8]\!LS$@EV!6I5:$*P&Q)[UQ)X02 Q)=J5"U ]S7""9
MA'/=P2H5?B6 /Q;$=P-LZ_\ DK^1%[^:.N1ZQJB/9^2-/D'UZXCJC7S**K;P
M-39AL)&'1?\ *(SZEV%A9:796FFZ=:Q65A8Q)!;V\*A(XHXP%5%4;  #!>;-
MFS9LV;-FS9LV;-FS8#U#3[+5;*YT[4;9+RQO(S%-#(*JZGL?X'MVSPO^9_Y7
M7_D2ZEU&Q+7/EB=_W%PXJMJ6:OIS ;\NROT/L=LYU:RS*J^EZ@D=B0)*'G(U
M*?( 4()PRL(U"-'07#\%B>1@:<(_B=E'NVW7 T;%T9RW*C,S(G'U.3_#"M:[
M$#<@;X80/"8"8DX(:HM.(^",$R5%05JWWXH\MQZ4<L<8];9WH03ZLFT=6;<4
M#=*932%7@M*H>B @52K?;=7Z[4]ZGPSE?G6Q5[MKRG**Z%>/$#E)]E$I4$DJ
M*YS>\+(L<LK.@!XN 1R)X\2./A3L,9IT\R211%E2XY51*#BH%3R^'<D=  /I
MR3<C*%4@O"1P!;B1QV+$'J#4=<DN@:DK6_H%R9H&V,G18Y"?@!K550 ?.N'\
M$,L-Q]9FD"01/\%?@*0L0K$J30(*54 =>N'RMZ4;S3*@B@?X1N>2BGP_ %)Y
M U.W?H,5F@BD@ACA%1QC@C*L64U#AN0V.Y6I]R,*([P:1%?EXAZ4%M+/&H/)
MAP!9344VJ/NW&?!__G(#SAYD\W_G1YWNO,=W(TNBZG/I>GP^IRCM+6WD9E$1
M6@K([&5V JSL2<]\?\XK?G')JOE*P\J>8 8]9L4FCLKM8_4CN;:%BX>3H$D3
M<'LPWZUSWVD5Q=6MK<36TD!5:HL<BB1W/ B2HH#NE #V)H,T[6,TH@GO)##8
MP!0TT$4HH.5 7EH&!+"N_:F<S\V_DI^7GG*5)M8TC3[2V>91+=Z;%Z-[Z/I5
M/II&44$N >1Y=>F>$?-OD@_E[YKUC3](U626VT^XK:2.I'JVTGQ1EAU!X]<E
MNAZ[#K%L+*<>E?J0:+2C#Q1@:CIAC>:8TI8()G&_))6"N"-^AV(^G.5^9=%9
MHY*K*D=/B#NO%A7>E3T]LY?<Z)QF+A655Y-P D_9)[;C[LF.CV*^GM.3,U"5
M9A]P)-:COM@[S!YSC\M6<EK9A9-4G3A& W)HP?VWKTZYY\DDGF>2::1I)9F+
M-(34DDU.&%NS*M0M>([^.:5R$)8^H_CGJ#_G$7\HM*\X>9M:_,GS18_I3R[^
M7K VUJVWK:CP]7UZ$4<6RT8(=N1JWV1GL#\Q/-NFZYJ4,>AZE<:Q9B@=I81$
M4/(,L*J2S&H(J2?EMGG3\X_,'F3R/^7NK^8=!@X:A'<V]FLL@+_5/K193=<*
M4Y+L%'2IY'/E/<)<7VK*9Y9;FYO)FEFFE8O))([%F=V.Y)/4YUK2_+=Q<M;V
ML,)>68J@'NW>OA[YZ<\A^3M/T22UMM0F@@A+F2_N9D>2-552>(""K[]AWSK'
MDC1)YM>TR81.EF)>$3A0#\-6._38*6)/OL3GJDA?6,JOZ3R$[DU8J3X'Z=\>
M_,QDQR,7&X4[4'AMM7 BH&(]2I","C2;4V\#]H5/7)5:-ZD<2J&Y,RCDM.W3
MKOOX88L[4DC*-RB6NY^V":U;:G; $[.!Q!$J\:K(QH!W^R#M3KOA-<NT,M5!
M)J*%@J@]J[#[JTQT(*_O)&$DR$#9MCMR'3L.^#%D81S$#[5&90*<CVJW;Y8'
MNF?ASJRHPXLJ[G:GCM2F(^H:>F#4 !R0"&<4[MV^6/>4KR=$5 H%%(H_*HIL
M=L /"KF7GL 3\!W)((-=SE2;_9DYKR*AJ4(IV/O7'P/+(KQGD4CK&% W8>Q'
M?YG.E_E/^2VK?F?Y@.H7:7&E>4K)@+V\I0R2(=[>V8@AG/[1W"]3O13]--%T
M;2_+VEV6BZ+91:=I>G1B*WMXA146I)]R2222=R22=\,\V;-FS9LV;-FS9LV;
M-FS9L#7EG:ZA:SV5];QW=I=(8Y895#(Z-L00<\:?F7^3]QY4^LZOH/JW'EF4
M?OJ%Y;FR!8MN26)C'\YW'[7B>-P!UBCC/-(>1#+L[-&?B#5--S7:N#K1)$K(
M+<<8?B1DX-RD:H1?VB".K4]O?&,T33H9(%E:(E6/->)5&#5+<J_$S= .V#VF
M]0*DR<KA"/\ 49Y#M6/_ "5.]:=<6N D>\$JVT<0$5%(8K$-Y'VJ!4CQKVR*
M>9X6NM',L+\7]0%9"2%61CP3K3X@H\,XKJ"0QS<+4!U,O#TZ[%0:%J4-23W'
MTY'+@/#<P2!CP)&W%@:;A>+;[UZC)(EXG&!0." $=U**NY8J!W;_ #VPPTZ_
M>,BXCC,RQ,TKQLQ())X@,!M0UVKG5+-;6XMP]6E@=.:4-0Y;>LD9'(,M=^V*
M0R-QDAFA7E!(%KZ@J%-"%XG8%:[TZ5P9#(L; 2B62!0U.*\:%3RH  *UIU]\
M1U739KK3[BSLXD.IO:-#'":EGI%*BIR (J2@Z;;_ '_#?\__ "I8Z5^9/F&[
ML'N)['5KF2XD:X-9$NZTN%#4K0/T!W&ZGIGH_P#YP)TRVU#SUK<^I7YBL_*^
MD2W0@B*F6X%U*D(^%M@JUJ?'89]I+#3K>^M-+A=H"NK()K!'I%)(Q!8%13X6
MV-.U??/)?F)[FW_-"3R=?:A):W%_ILEY:LD7&"1(VD_8)^&0\6! -.0^6'%+
MB"QDM;,W&JWEQ./1@?[+L%!0\R13TRNU<X]^<GE9I]0TK4;MH5GU6S2WE%N2
MSK+&IJK!OM+L1R&VV>4]2TG4M#NY;B.%KJR8D*\8W1AXTZ4[D;')3HOF;ZQ&
MD5U=,@:@5F_>(>(( /*I&2.ZTD7\*S&2"2*A92&4*3TJ/LY#9O*W$R,MKQ:7
MD%K*W #8EJ>Y'RR):S>PZ)&RK##)?L#Q1!0*Q'PL6.^U,X[-:OJ%U-+/+)<W
MEQ(6=A5R6VV%!O\ JQ.[\O75K \]R5A'+B(R:O7P-,<NEWJ1*7MG@#+R4,*%
MAX[YWG\K/R;TSS#I4?G?SXFHOY5]=H=.T7255=0U8(2CSF5W00VJN"O/[3D$
M+2A.>HK:YTS0=#3RK^77E"?R3Y:8R_6V>8,]T9442F1N1+<N(K6I-.M!3%=,
MTZZ6W5#9&W@<EE)V<FE>1 H1N?O.275_*]GYC\OZIY;U:S6:RUR%[2Y5MV E
M04:O8J:,/<9\8M)\ONWGZ]T@UF_0\UQ [ 5J89&CK]/'/8WE3RL-,M1/+"K7
MLW'FW&OIK_+QJ34C8C.D:1Y<N=2NDC$4R6?J$<U%7)3B3Q4T#$!Q\EJ?;._>
M7-,LM(M((XXT2?TS#,]3Q4#<\:@&AI7?]HY(2[Q!8DK5E-!2@ !J2: D^.V,
MEN7HS,S+Q4,I(I4D&@!V!Q*"1B#ZPKS)WJ"M *CD/U[9*=/FD/VD64J RAF
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M\HT#2,Y%:[4^ #M385]\=J$CSK.8W402^G2+[- 0IZ%12@\<\U?\Y/:X=/\
MRZU+3[8CU=>F@TWX#L(23+*/G2.F<L_(+RJ5\DZ=IOI5FU*6XOY9)/A11ZG(
M%OB4T"[  U/T'/5,<,5AIT-K;<S9LX!;E53*RBK,0%JY"[MWP TA-T)[9T2#
MB(Z@\J\C7O\ UPPBV%3,)&=J\44E1MM6HW)[XX$JY5@22I 5AQK_ "D_+;!@
MC<ND2Q2*DI!#$47;]D5->I\.F#AIT@!X@^G"@;T]Z;FHIQ V[TPV,?'@[U9H
MZ"@H1N!T&QV['%9;J)=C"SQ&L:_$$!7;X@:[#Q/?(O>3%5]2/DW5:!OC4>!!
MK\_'#:W@40HG,B1T#,Q;D K=0=@*[]OGBTA"K)$K!&##9#4M38DU[#YX@L#1
MP#<"K_W9^&@&X5J^'7 UW.2K1,.88U2G[0KN?8?KPMD=9Q(D"E9B1^Z9Z#;8
MFA^1I7)#Y=\N:SYBU&#1]"LI=4U.]JL-O;4*!5^T[MML#3DQ(4=3GO?\I_\
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M9[&>P7U(9],NY;%N,3)(C $(L415F05%=V->OCD4\[+YCUB"QAUW2+#S4FG
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MCX@67DQJ&"TK4C;P\,()Y#.:\&44!)=@I)KT4 #IAW;_  6JH3Z8->;D[%O
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MC)(>'$HP.^X7XB":;4^?A@D%09&<<5/5UW9J[ 4VH#BGIJEM*YD$?J+ZFQ!
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MR4BM:TZ5P'9D3F7C&$=8WK'O1FJH#/0'NW?V[X6:K+Z[Q1QO(0J*W&( U#L
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M9LV;-FPHU'0-#U??5-(L]0;L\\*.XVI56()!IX'.>ZI^2OD/4@OIV5QIC("
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MT-%O5H*UVZ8:VODK_G%6TE)AO/*;S*Y=O5U\3-R+;\O5OGJ.78[5R0V6G_\
M.-%F$%M)^7[\:\?5N=.G.]>\LCU[YT/0_P#E6W_3-?X:^U_TK/J?VMO]\]^F
>3C-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>sny-20231231_g28.jpg
<TEXT>
begin 644 sny-20231231_g28.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
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M(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_XGT024-#7U!23T9)3$4  14
M"?P0041"10(0  !P<G1R0TU92TQA8B 'UP %  \ $  >  -A8W-P05!03
M  !!1$)%                        ]M8  0    #3+4%$0D4
M                                                      YD97-C
M   !+    'QC<')T   !J    "MW='!T   !U    !1T87)G   !Z    !AT
M96-H   "      QV=65D   "#    %YV:65W   ";    "1!,D(P   "D  !
M7V9!,D(R   "D  !7V9!,D(Q  %A^  !7V9",D$P  +!8  ".+1",D$Q  3Z
M%  ".+1",D$R  <RR  ".+1G86UT  EK?   D)%D97-C         ")#;V%T
M960@1D]'4D$S.2 H25-/(#$R-C0W+3(Z,C P-"D
M
M                        =&5X=     !#;W!Y<FEG:'0@,C P-R!!9&]B
M92!3>7-T96US+"!);F,N  !865H@        V$4  .!/  "^YG1E>'0
M24-#2$1!5"!&3T=203,Y '-I9R      ;V9F<V1E<V,         !$0U,
M
M                                             '9I97<      F74
M*P)\GJD"#27, 'K$"0!_4N\ :0>/     6UF=#(     ! ,+   !
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M^F3[Q?TH_I#___\ @ "  .FM@ & #]1,@ . ';[:@ . +*E/@ . .Y.>@ .
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MG6!]*CU+F?M]["U'EQ1^SAK^E9R  0@QD6>!H:#YM6R!=)+7L-&!$(2[K%F
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ME!1^78W#DA]^<GU\D$A^K6T?CGQ^^UPNC-9_0DJKBU)_BSACB?I_XR0\B2>
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MD*)[\%$.CM9\DD#[C3-],3 <B]%]VQTZBRQ^G D'B+> !*<NFLZ D9E4F#N
MI8L\E=> I7S"D[F AFXVD<. D5^6C^" L%!/CAZ RD!JC(" ZR_ BQN!)1TB
MBEV!I E5A]>!X:7+F>B(0Y@.EUZ'PXH5E0&'+7N\DNJ&=FU+D0*%\%['CRV%
M@4^DC7:%#C_IB]^$J"]NBGB$;AT,B:.$M F9AQ*#A*19F3&/_Y:]EK&.ZHCC
ME%J-OWJIDD2,<VQ5D&&+7EWPCI.*84[RC.")9C]BBTJ(@2\9B=J'W!SWB.6'
MY0GBACN%&*,EF*27G96#EC*5^(>PD^*4/7F1D<:28FM<C^*0P%T8CA./.DY
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MH5)YUUZ;GBAZDU&QFQ5[7T01F#9\(C7%E9E\Z"::DW-]QA4EDJY^W@5HC+"
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M=2B":9"I=A6",7W\=P""!FK9=^2!U5<U>+R!H$+9>7:!;"S8>>"!-A+2>>>
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M>7&!-IJ1>>2!#(CU>E> _'<Z>LJ ^63S>TF ]5(@>\J \CZ3?#> [2E8?'"
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M?U5_OJ(:?S)_M9&4?QI_KH#P?PA_PW P?OE_YU[0?P> #TS7?R* .CHD?SB
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M-9<UD@ZI=8J D!JFM'VGCD"CW'"2C(^@X6-8BPN>$%8-B9:;64@KB$.8QSG
MAP&6ABJNA<"4/1GHA)&/> E:@?2&4Y8ND<*Q4XF,C]&N'GS$C?>JTV_#C$"G
M9&*@BKFD&55NB4"@Z4>BA^J=Y3E/AJ2;*RI;A5N7+QG&A!R1"PE^@8:&:Y4]
MD7RY7(B[CY*UIWP-C;NQXF\;B_^N V(,BG:J/U3NB/JFFD<TAZ&C*CCSAEB?
M"2H7A0F9C!FK@[R16PF<@2Z&?Y71H$-L+8E=G7AM^7RHFM-OJ&^+F&=Q*F).
MEA]RM53VD^QT1T;5D>YUO3?YD"YW(B@UCM=X?!80CK=YI@4FBD=]*I2"GMYS
MI8@PG"]TQWN7F:1UU&Z.ETYVP&%KE1EWP%0RDO5XS$8ZD0%YR3>/CT5ZP"@%
MC>1[O!8SC9)\MP6<B3U_'Y,JG:MZZX;OFQ1[@'ITF)M[_6V6EE!\56"2E"=\
MS%-XD@]]4T6GD"9]U3<MCG!^7"?;C0E^^!92C(Q_RP8%B%* VI'MG*F"'(7$
MFAJ")GE@EZN"&&RBE6F!Z%^]DTF!W5+ D3B!Y$4:CUJ!Z#;1C:Z!^">VC$6"
M,19MBZ2"UP9@AX."8)"ZF\Z)8(2AF4V(VWA2EN>(0VNRE*F'C%[HDHZ&_E(*
MD(*&A42(CJJ&#39LC/^%K2>#BXN%C19]BKR%M :XAJ:#TX^NFQN0AX.5F*N/
M>G=1ED^.7&K+E!"-)%X<D?F,%E%9C_&+'T/XCAB*-#8!C&:);R=&BMZ)"!:$
MB=J(1@<)A<.$PHZAFI^7LX*?F"J6''9SE<J4=FH#DXJ2NEUKD7:1*E#!CW*/
MM4-\C9F.6#6EB^"-,B<2BDB,C1:)B1>*>@=/A0*$\8V>FCZ>[X&LE\"<V'62
ME5J:LFDXDQ>8>5RXD0.6;5 FCO^4?D+[C262L#5!BV>1+";2B<&/_A:!B&V,
M9@>*A%V%&8RJF>ZF18"VEVNCQ72DE/ZA-&AADK2>BUOYD)V<#$^"CI>9K$)N
MC+N7<C3.BOF5ER:!B4F3%Q9JA]B.%0>]@]&%.XNZF9JMP7_5EQZJU7/4E+.G
MV6>CDF*DQUM2D$BAV4[RCC^?#4'SC&&<<31HBIR9T28WB.*5K192AUN/& ?F
M@U^%5XK>F4>U<'\5EMJR W,KE':NDV<*DB"K&UK+D *GQ$Y^C?>DDD&/C!>A
M:305BD^=-"7[B(^7P!8_AO:/"P@'@P2%;8I/J#9L0GZ8I/=MYG*MH=%O?69S
MGL]P_5H:F_=RC$VIF3=T)$!EEKEUH#)?E(IW#2-EDN9X<!'SDK5YN .*C"5]
MLXE%IM=S4WVJHZYT6G'6H)YU7&6IG;1V6%EEFNQW9DT.F#AX?S_PE<!YBS(:
MDY%ZDB-9D=M[HQ(WD7!\S@0'BPY_>8@RI:MZ4'RAHIEZSG#CGYI[163<G+9[
ML5BUF?=\/4QWETM\VC^ E-M]<S'8DJY^%"-.D.M^T1)SD$U_WP1WBAB!#(<D
MI*^!'O_B?1!)0T-?4%)/1DE,10 "%7NAH:.!&V_WGJF!$F0-F\Z! 5@ F16!
M%4O>EF^!.S\/E B!7S&9D>"!DR-%D!6!^A*HCTR"H@38B4"";88GH\^(!GJM
MH-&'>V\2G>&&[V-"FPF&8E=.F%6%_4M'E;.%K#Z:DU"%7S%.D2:%+2,LCTN%
M2A+1CDN%+P4WB%J#AX5$HQ2.S'G+H"B-Q&XZG4.,OF*"FFJ+N%:DE[F*W$JV
ME1N*&#XFDK6)8C#]D(.(V",&CI"(OA+OC5.'? 61AW&#PX15HH^5D'CXGZ&4
M"VV G+J2B&';F=^1"%82ES&/M$HXE):.?3W"DB^-83"VC_2,@R+FC>Z,'!,)
MC'V)<P7=AJJ#]X-KHBJ<7W@AGS.::&R]G$68<V$LF6:6@%5XEKF4NTFUE!Z3
M%3U6D;:1E3!ECW60:2*WC5^/(1,3B\*+*@8>A@"$(X*.H=JC0W=$GMJ@]VOH
MF^2>IF!LF/V<353/EDV:($DED[&8%3S<D4B6-C !CP.4JB)TC."1V1,+BR",
MJ@95A7"$2(&UH7^J7W9XGHBGKFLKFY2D^U_"F*6B0U0ZE?.?LTBFDU2=2SQO
MD.J;&2^HCJ*87"(UC':4'Q, BIF,V0:"A/J$9X#MH1ZQOW7*GCVNAVJ2FU.K
M8%\XF%ZH3E/!E:FE8D@_DPFBICP7D)Z?BR]?CE2;4B(#C!^5\!+WBBN,TP:G
MA)R$?W\0L$]LN'/XK%EN6&BZJ)5OY%U I1UQ45&OH=!RUD8+GJ%T9SFBF\!U
MXRQYF3]W41Y.EV=XL@XAECMZ7 (<C<M^+7Y"KNUS:'-&JQET>V@=IW%U@%RL
MI IV<5$LH,EW?$6=G:)XECE3FK]YJBQ4F#%ZOQY@ECE[W0Y[E-M]; *AC*M_
MRGURK<1Z%7)]J@-ZHV=DIFI[)5P2HPQ[DU"IG])\)$4PG*]\RCD&F<U]<RPQ
MESI^*AYPE2M_ @[*DZ* +0,6BZN!-WR8K,> E'&SJ0F KV:MI72 O5MRHAV
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MGQI]?":)G!M^3AF,F;Q_10N6EFB =P'DC0F!1W)7M12 /V?XL,. 8UV%K*.
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MJ1E\K2N_I3!]@""/H:]^=!1:GO9_EPBJF-. NP#,CDB BF?WO;^ 9%WHN4:
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MDS=]_V9\D6Q^-5H\CZ]^A4W@C?Q^Y$#-C(=_/3,/BTA_FR1TBD> %!.(B?F
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M=RU\"#:5> )\FB*8>%-\X O6>A=];+>';:%_\JA1;Q9_]YCQ<'%__8E1<:.
M!'F#<LV #FF6<^^ '%D/=12 *4?R=B> ,S81=P: -")2=TV $@OY>4)_V[6H
M;!R(Y*:3;;2(*I=<;RR'=H?L<'2&SGA+<;2&+FB*<NR%DU@O=".$_D= =42$
M;S65=BB#YB(8=F&#; PP>'N")+0#:N&1J*4#;)F0-)7F;BJ.SH:;;W^-?'<@
M<-",-V>'<AB*^%=7<UR)R$:8=(6(IS4C=6N'GB'K=9.&X0QV=\:$/+*#:>J:
M9J.A:ZJ80Y2B;426+H5V;J:4+W8<< 620&:F<5V06E:=<JR.BT8'<]V,V#3
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M6TB-HR1N]S[?H#MPI34=G6QR7"J2FOMT!Q\VF01UGQ*QE]%W$@<OD>)ZCP
MB>5^560+JR9O\EKDI]QQ4%&;I+ERFT@>H<YSRCZ'GNYU"S3=G")V6"IUF:UW
MJ!]&EZ1X]1+[EDMZ.@>6D'A]#   B:M_9&-JJ<-U_5I)IHEV^%$,HW-WWT>B
MH)!XJSXBG;%YA323FN-Z;"I/F'![6!]/EF-\31,]E/!]70?QCSE_/ !7B.6
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MG4I^F!FYFK-_<@\1E^N ?07[C_R!/   B.:  %AIL#R _T_!K-Z \$<5J8&
M]CY@IB.!&S6WHKF!6BT2GU>!L"/4G$6"*!GKF9&"VP]EEJZ##P97CMF"V !
MB#2 *U@HKS2&<$^#J^R%^T;<J)V%H3XNI4:%;C64H>&%72T!GH"%;2/=FV.%
MJ1H5F)>&&P^ME9V%00:GC>"$. "4AVB 9%?5KDF+V$\ZJPF+#4:<I\&*7SWY
MI&R)W#5LH0Z)@RSHG;2)4B/<FI&)6AHRE[")#0_GE**'.0;IC0.$K #<AKN
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MGS'F=&5]Z!Z_=(I][@G8>!=^0ZM19HZ#9YT3:):#*(ZP:GB"ZH 5;"*"K'%
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M^0=4?6%V7::@<W-GQYC7=%!IZ8K.=2EK]'QB=?UMW&W4=L1OLE\H=X5Q@T_
M>%9S/C^H>25TX"ZY><]V4!NM>@EW) >F?$YY3J2'<0IP=Y;C<BEQQ(D.<SIS
M"GKN=#9T1&R6=2-U=5X;=@AVID[E=OMWS3\#=^5XY"Y0>)UYUAN+>+UZ3P?O
M>UM[ZZ+$;PIX_95%<%)YF(>9<8EZ+WFG<J1ZO6M[<[![35TJ=+-[X$XB=<)\
M:SYQ=L)\["WS=X9]5QMM=Y!]>0@P>H9^-Z#T;5"!9I.J;K^!6X8O<!:!2WAH
M<4N!,FID<G*!)%P]<X^!&TU@=+.!#SW>=<*! "V6=HN [AM6=GZ S A\>;V
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M=A1_OW"0=LA_S6-9=W-_YE7^>!> !4?L>,> &SDR>6R +"FJ>=V .Q@)>:^
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M"$-QH,-F:3HTGC=HUC#8F\EK1B:7F=1MAQMHF'=OD ].EUUQA@4+D)=V'0
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MH2%\JU)KGHA]0$H G U]PT%-F;Q^+#A_EVM^H2^DE2)_(R87DQU_L1O/D6*
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MJ3DYHGMXC#$%GXUY<RC)G*MZ9!_@FAY[9A8RF %\?0R)E(A^/01]C0E_T0
MAA*  %$XJ=%[J$DZIP%[_4$MI"Y\9SD*H5=\\C#HGG%]BBC"FY%^-!_YF/9^
M]A9SEKA_X0SADS. V03:B^R!>   A="  %#TJ**! DC^I>B ^4#[HR>!"#CA
MH%B!/##/G7F!B2B]FIV![B .E_:"<Q:IE9R#* TMD@Z#% 4IBOF"X0  A9>
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M>,I[V3V6>6Q\93 T>?U\XB'N>E5]5!%H>N-]N@0@?.-_!((,<\E_Y'<M=*:
M"FPE=7^ *V#<=E& 155 =P^ 84E^=\& @3SZ>&Z E"_'>0* IB&Y>5" QQ&
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M"&Y]>SY^<V0G>W=^S5F.>\Q_#$ZE?!)_3D.8?%!_DS?!?)I_RRLT?-N  QW
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MAZ-\6T&&AMQ\\#?DAAA]BBUGA81^$R(AA1%^H!71A+U_4PEN@Q2 40$2@:B
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M[%H,A+>8F%&<A ^72DCH@V"6!3_1@MN4Q#:1@F"3FRQJ@=J29"&"@4.0&A7
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MCP]ZI4-UC=%[53J5C)%\!S&9BU=\OR?/BD]];1TZB7I^)A&IB+E_&P<XA6J
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MB@&.\#EPB/..2C##A^R-O"=)ANB-.!T2A>J+[Q']A-")&P?Q@G&%7@$N@->
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MBC3<I+QB-2S/HB-D[22FGZEGI!NAG<-J*Q&SG'IL>0CHE]EP% &FC^9U[0
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MF*9]RR2"EE]^AQQ&E#A_51-(DD^ 30KPC<V!(P/3B%V!K@  @Q2  $EVH'R
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M;<A\]0:'=4A][Y5[6!* ](C76TZ!"7P77D>!#F\I8-R _&'[8VN ZU2J9>B
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M>TQ^]0(4?1)_]&\C<G5_Y66J<X& .EP!='N =%(,=5V B$?2=B: GCUW=MZ
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M9D;<AX!IBCV&ANAKJS0%AEYMR2F4A@%OQ!X[A=UQE!' A>US+ :6A#9W#@
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MK#UPAQA\0S4@AFA\WBRTA;M]@R."A29^+AF%A*I^\ [K@[1_] 71@C> T0
M@+*  %0'A^U_VDRSASF 644;AHJ O3T>A>. ^33CA4*!/2R.A*.!CR-UA!*!
M[AF4@X^">@\7@JB"G08,@7*"<   @)"  %.,ALR%ETP\AA>%WD2RA6F& #S1
MA,*%[32LA#"%XBQL@Z.%ZB-H@Q6& QF@@HF&+P\\@;.%#P8]@,2#XP O@"2
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MA"N N@  @+Z  $N!D 5]M42HCKQ^<#V1C8!_"C8=C%5_<RYYBS=_ZB;"BA^
M<QY4B0B!#Q4<B R!TPP7A:Z"& 1M@V&",   @)B  $LHCN&#(T1.C8N#K3U
MC$F$#S7CBR"$-"Y4B@^$9R:RB02$LQY=A^Z%%!5"AN:%)0Q,A+&$2 2D@J^#
M(P  @'>  $JRC;V(ID/QC':(Y#SZBSV(_S6QBA6(Z"XSB0^(X":CB!&(^!YC
MAOR)!Q5AA>N'\PQX@]R&(032@AJ#0@  @%V  $HOC*>.,$.8BX6-]CS!BF*-
MM#6)B3J-9BX:B#Z-+2:8ATN-&AYIAC>,/Q5ZA2"*,@R<@S*'FP3W@:.#6P
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M:89]Y$=G:SY^(3T&;-A^8C'P;D1^K28M;UI_ AF$<#I_:0OF=6V  0)Q>^"
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M"$$QA,Y@[S@UA(%CQ2\*A$YFC"3OA$=I)1G;A(5K>PX;A&IMTP1H@Y=RN
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MN3@4@B9S]3 E@?IU-"@8@=)V>!]%@:]WNA68@9UX]PP)@4%[( 0(@0)]T0
M@ "  $UH@,1U54:-@,%VBS]E@+!WG3?*@(QX>B_R@'-Y7R?^@%UZ31]+@#][
M2!7%@"1\5 Q.@!-^$P14@"-_JP  @ "  $S5?R=Z^T86?RY[VC\)?RA\E#>'
M?Q!]&2_&?PE]J2?J?P5^2!]4?O%^_Q7P?M%_W R.?PN P027?V*!4   @ "
M $Q??<6 ET6L?<F!03ZQ?<&!O3=,?:J!]B^B?;2".R?=?<6"E1]A?;R#"A8;
M?9V#EPS(?B&#/031?KJ"R@  @ "  $OG?'.&145*?(J&GCYG?(V&S3<;?':&
MOR^%?(^&P"?3?+.&W!]M?+:'&Q9 ?)F&PPSZ?5Z%5 4!?C"#8@  @ "  $MR
M>SJ+\$3T>W>+SCXK>Y&+F3;S>WF+2B]M>Z"+#B?+>]2*]A]V>^&*OA9=>\F)
M3@TB?,*' 04H?<*#?0  @ "  $C0F*A12$'<EO]4]SJGE7)8>S,.E Y;OBLF
MDN->]B,)D>QB'QH.D55E"A!(D.EGQ0?CC1UKY0#QB6IR,@  @)Y[6T@]E2]7
M*4%6D\E::#HPDGM=@3*LD5%@7RKBD$AC,R+KCV5E_!H:CLYHGQ"!CE)K(@@W
MBN%O"0%0A\QU&0  @!=\PD> DA!=$4"SD.I?YSFIC])BE#)$CL]E!"J:C>5G
M<R+%C1=IW1H=C(%L,1"QB_9N= B!B.9R(0&DAEUWK0  @ !^ $:_CV)BXT -
MCEQE7CD?C69GK#'6C(9IN2I)B[IKQB*5BP1MT1H4BG!OS1#6B=-QPPC"AREU
M+@'NA1MY\0  @ !_&$8!C/UHDC]\C!%JO#BRBS1LM#&$BFYN8BH2B;MP$R)^
MB1AQQQHEB(-S=!$1A]AU* D3A99X80)"@_-\$P  @ "  $5?BKUN#S\(B@1O
MXSADB4QQA#%,B)1RW"GUA_1T.B)^AV%UH!I+ALEW#!%=AA-XCPENA#)[= *>
M@NM^!P  @ "  $3FB-=S=3ZLB#UTZS@@AYQV,3$=AO)W-"G;AF1X0")^A>!Y
M6AIJA4AZAA&>A(E[W0F\@P)^%0+M@@E_LP  @ "  $2%ASIXT3Y:AJ5Y^3??
MA@MZ\3#QA6E[IRG%A.M\:"* A'=]/!J+@^)^+!'=@R1_50H&@?2 >P,R@42!
M,   @ "  $0SA=Q^)CX-A3-_(#>?A(]_Y##'@_" 6BFR@X" VR*&@QR!<QJO
M@HZ"+1(>@=R"MPI.@0*"N0-Q@)B"5   @ "  $/#A(&#BSV[@^2$/3=G@TB$
MOS"D@JF$_"FB@D:%12*,@?&%JQK.@6R&(Q)7@,F%DPJ+@#>$G0.E@ J"=P
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MCP-WY3!!C=MX_RGRC)AY[B-HBXUZZQS&BI-[_15^B69],@X=AR%^VP>WA)V
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M6XY[PB*P78=\'A*,9H9\:05$=QE^#H=//L" %WNY0TN &G %1[. %V0@2^F
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M:%U]D0N%<*!^H@)E>_-_LVX'4".!.V1%4U&!"%IJ5G& WU!E67Z QD8V7'"
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M87^'YCJ!8]*'=S&;9AB')"@5: >&^AWE:<J'"Q*_;Q&%]@A-=2"$+@%&?=J
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MFCM3@BM8.3*S@AM;OBG4@CI?+" (@I=B6A4M@U)E* JQ@U]HG ):@U%N?P
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MJ#)R?(9KB2KA?/=M:2,M?6]O2!JO?=-Q&1%H?G%RX DT?U)V%0)%@!EZD0
M@ !_3$:)>2IK$T @>6ILYSED><)NFC(N>CUP'RJZ>LMQIR,E>UUS-!K2>\ET
MPQ&X?)UV60F6?>]Y9P*E?Q=\P   @ "  $80=L)PM#^W=R=R&SD/=Z!S:#'T
M>#1TD"J8>-UUP2,?>8AV_!KP>?]X2Q']>PQYM GJ?,!\6P+W?CI^G@  @ "
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MHRN$>L1\;R3O>RQ]0QX_>Z5^+!;J>\=_0@\[?*" >@AZ?:&!2@)7?JZ!E0
M@ "  #RW>4!^K3==>1-_GS&H>0> :RMQ>26!!"3R>9Z!HAY;>BR"6A<F>F>#
M/ ^)>Y:#9 C&?."#.@*1?B6!O   @ "  #QI=[V#\#<I=ZJ$<S&)=ZZ$ZBMB
M=\^%5B3U>%>%Q1YR>/B&5A=5>4V&B0_(>L"%N@D$?$6$QP+ ?;B!W   @ "
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M)0  @ "     __\  /__  #__P  ;69T,@     $ PL   $
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M_2C^D/___P"  (  Z?.  8 .U.:  X =O]B  X KJLN  X ZE;Z  X!*@+&
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M*>V 0H2ZZ:&#<J.;U@^"QJ 1PHB"'YROKQ.!A)F.F\^!(9:QB*B TI/F=7.
MG9$Z8D* =(Z63RZ 28OB/$: '(DE*>%_WX85Z"6"VJS[U(:"0:BFP0"!IJ1X
MK:*!"Z")FH& JIS?AX* 7YE%='R ,)7-88" #I);3JA_YX[9/ -_NHM5*?5_
M=H=OYJ*"F[9DTQN!Y[%$OZR!.ZQ(K&* H*>$F5^ 0J,&AH1_^IZ5<Z=_T)I'
M8-I_M)8"3C1_D9&L.\A_9HU?*@=_'8BDY3Z"=K_,T<R!I[GMOG" Z;0JJS:
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M1(^!,9*3W8R6*"R.>(G#(%F)#H<UB3/ 6:MH?1JZ':>)<4:T$Z.D9=.N8I_
M6LRHYYP>4"2C;IB319V>&Y4-.V"8SI&+,9J3;(X6*$F.#(JX((Z(J(>UB)[
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MK2.!'(&EFCN [8&*AUJ O(& =$R H(%S83& C8%D3B^ >(%..U. 68$@*.B
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MG:.#AYIPC&^"YY>$>U^"4I2G:B&!WI':6..!>(\,1]N!"XPQ-QJ EXE4)T6
M!H8[T"2%HZSMOO6$MZCAK;R#VZ3AG'"#&:#VBUN">YU&>F^!Z)FA:5N!>I8/
M6$R!&9)\1W> KX[<-NR .HM$)UU_HH=HSLR%:;6QO:>$:K#SK'Z#@:P[FTZ"
MO*>0BE>"'J,=>8R!C)ZO:*&!'II05\" P)7N1QN 5Y%_-L)_Y8T<)W%_38AT
MS8J%/KYYO&*$+;D9JT2#.+.WFC&"<ZY5B5J!T:D@>+"!.J/J9^V RIZU5SJ
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MD"N'^+&/@'J&O*OY</R%B:9986R$>:"F4?.#=IKA0L*":I49,]Z!7H]M)CZ
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M)=^ ;(%)RT^"SXV&NM>"0HQ JD6!QHK_F8B!98G%B.&!%8B[>%* S(?#9W6
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M@UI^K:5P<X=^>J"X8X=^9YOV4X]^8I<D0]Y^59)'-(%^08UY)E-^#8B PK6
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M9:F X7=K5/R SGCB1'2 OGI8- J L'NU)'6 J7U!Q2*!#7;QM6J MG?*I8"
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M([5_H(0XL5:#'IZUHP>"IIP>E*V")YF"ACJ!GY;@=\V!,Y1B:8* SY'I6P"
MA(]N3(2 0XSM/E)_^(II,&I_HH?O(]1_,H5AL F"K::IH="",:-QDXR!L: N
MA32!*IS@=N: P9FO:+N 8):!6EV &I-.3 E_W9 3/@-_EHS5,$M_0XFF(^U^
MU89HKM>"8*Z.H*:!VZK*DG&!4Z;QA#" RJ+]=?^ 7Y\<9_5__9LW6;E_N)=$
M2XQ_?)-#/:]_.8\],"=^[HM() -^AH=.K:^"(;9LGYF!E+(6D7R!!ZVC@T^
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M)8#!3%F8DX#G0C25'8$*.#"1KX$P+I&.08%A)4>*XX&@'8&'EH'M?N:J(X;
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MDG:!2WJ*A$F!"GL4=A& TGNL9_& GWQ/68: ?GSR2Q. 9WV5/-Z 4GXT+N&
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M9WJ&6SB)&WM83K&'XGPG0BZ&LWSY-?R%AWW0*A&$:7ZF'Y&#27^3EJ6/*7Z
MBN.-@W[>?O>, 7\@<LB*M'\Z9H^);W]K6GJ(+7^H3B2'#'_=0=:%^H 1-=B$
MYH!**AZ#U("$']6"OX#-E4V.(H7$B:&,CH6(?=&+'(4Q<<:)VX2R9;"(H81,
M6;^':H/O392&6(.)07:%5H,?-:J$3X*Y*B&#0H)9(!""+H(!E :-5XS B'*+
MT(O^?+Z*:(L:<-2)+8H'9-Z'_XD*60R&TX@330>%R8<401*$RX80-7.#Q840
M*AR"MH09($.!G(,JDNN,J)/+AVR+*I)M>]")RI#P< .(E8]$9"B'<(VK6'*&
M3XP53(V%3(IY0+R$4HC:-42#38<_*A>"/86R(&Z!'X0RD=V,()K,AFZ*I)C7
M>N>)1I;";S6($Y2!8W6&])),5]R%V9 83!.$VHW90&*#XXN6-0V"X8E9*@R!
MTH<P(). M(4:D-6+P*&XA6^*/I\]>?>(VYR@;F&'IYG08K^&B9<"5T.%<)0M
M2Y6$<Y%%/_^#?(Y3-,R"?(MH*?F!<XB5(+& 6X7DC]:+8*B1A(>)Y*6)>2>(
MA*)=;:B'39[^8B"&,)N25K^%&)@92R>$&I2$/Z>#)9#A-)*")HU(*>>!)(G/
M(,J $8:-CO&+ J],@\.)E:NB>'Z(/:?9;1.'!*/F89^%YY_95E2$SYNX2LZ#
MTY=W/V&"W9,G-&*!X([J*=B XXK9(-]_UH<9C]V:OFA2A)B8-FJ)>2F5U&RG
M;7B3JFZ@8<J1D7"B5D"/?7*N2EB-@72I/FR+E7:F,M.)LGBT)XJ'[7K2':J&
M,GT?CJ"9&&^%@X*6LW$6>#24=7*2;)J2;W/P80>0<75>59V.=';82=^,C7A*
M/B6*LGG!,L&(WGM%)ZV')'S2'@N%;WZ"C5Z7OW:#@E:5=G=_=R:33GAE:[>1
M57DM8$:/9WH)5/V->WKS26N+J7O:/>*)XWS%,K"((7VZ)\R&<'ZT'F"$Q'_'
MC">6EGU9@3"46'W$=AF2/7X;:LR05'Y47WZ.<'ZE5%J,C7\#2/>*T']9/:&)
M)'^P,J&'>( .)^>%TH!V'JJ$+H#MBOV5EX0X@!B3:(0.=1F168/3:>V/>X-]
M7KZ-HH- 4[N+R8,-2("*&H+0/5B(?(*1,H:&V8):)_B%-X(M'NV#DX(.B>N4
MQXK<?Q:2J(HN="R0I8EK:1^.S(B+7@R,_8>^4R2++X;X2 R)AX8I/0F'ZX59
M,F"&2(2/* "$HH/1'R:"]X,AB.N4(9%Z?B^2!I ]<V"0"([K:&R.,XUZ77*,
M;8P:4J.*J8J]1Z>)!HE;/,6';8?X,D"%RX:;* >$(85.'U>"<H04A_23G)@(
M?4J1@)9"<I"/@91D9[B-K9)H7->+[9!T4B&*,8Z!1S^(DHR&/'J&^XJ',A:%
M6HB1* 6#L8:O'X&" (3IAP23-9Y_?&&1%)Q#<;6/$9GH9O>-.I=E7#.+?)3A
M49J)PY)71M"()X^Y/".&DXT3,=Z$](IX)_J#3H?V'Z2!H86AAA>2S*3M>XF0
MLZ(J</6.M)])9D^,V9P^6Z.+')DF422)9I8#1FZ'S9*_.]6&.H]P,:N$G8PQ
M)^Z"^XD6'\"!4X8\A3V29*M$>M*07J?><%F.:*1D9<:,BJ#/6R^*SIT@4,6)
M&IE@1A^'@Y5Z.Y:%\I&',8*$5XVN)^2"N8H'']>!%(:ZA22B)VAX>J*?'FJ1
M< B<+FR>94698FZ:6HF6J'"D3_>3\W*[10F16G3!.AN.T';++XF,4'CI)4^)
M\7L:'(F'HWUSA#*@D&]+><F=H7#!;T::T'(U9).8*'.E6>^5AG4E3WF2XW:P
M1+&06W@U.?*-X7G +Y"+;GM:)82)&7T '/.&TG[$@RJ?/77U>-&<:G;=;F:9
MK7? 8]F7$'B=65*4>GF23OJ1Y'J51%N/;GN5.<J-!WR;+Y:*I7VL);.(6G['
M'4^&&G_V@AN>&'Q==]6;37S ;8&8FGT?8Q&6#7UX6*J3@7WJ3G.0\WYJ1 &.
MD7[A.:&,07]:+YN)\W_=)=R'L8!M'9^%>H$,@1N='X+9=N>:78*O;*F7M(*$
M8E>5,()76 N2KH)#3?&0*H(Y0Z2-U((E.6Z+D8(1+Y*)2X(&)?N'#((('>B$
MU8(9@$"<08DI=A*9EHA[:^.6_(?-8:R4?(<>5WF2 X:!37B/BX7K0TF-.H5.
M.36*^(2P+WZ(LH0:)@^&;8.1'BB$,(,8?UR;H(]>=4R8]8XL:SF66XSX81F3
MWHO"5ON1;XJ:30^/ (EV0OJ,M8A-.02*=(<D+VV(+88$)B&%Y83S'EZ#HX/X
M?GV;&I5X=(*8:Y/,:H:5T)(;8'^34I!A5GB0Z8ZN3*..@HS]0J:,/(M#.,B)
M_HF(+U"'MX?7)BF%;X8X'HR#*X2\?:N:HIMP<[*7])EE:<&55Y='7]62U94.
M5>B0;Y+33"Z.#I"40D:+S(Y .'^)DHOE+R.'3HF8)B6%!X=E'K."QX5E?-2:
M+J%P<NZ7BI[H:1.4\IQ+7SZ2;)F356F0");.2\>-JY/_0?&+;I$..#V)-XX3
M+OF&]8LL)B"$L8AK'M."=(7R? J9Q*=O<D:7,*0\:(:4H*$&7L22%IW-50./
MM)I[2W2-6Y<<0:V+(9.1. >([8_\+MB&K8R')AR$;(E&'NR",X9E>L:ID6CR
M<-RESFL,9O&B-VT47/V>XV\#4R";G'$)27F85W,?/XV5+W4M-;.2$7= +#V.
M]7EA(R.+YWN&&X*(^'W#>?>H!6]D<#"D9'#G9E^@[7)A7'F=LW/-4K":?W5.
M22"727;?/U:4*WAQ-:21%7H++%>. 7NN(V>*_GU0&_.(&7\">36FKG6T;W2C
M*G:Q9;.?R7>C6^N<G7B'4CN9='F$2,662'J1/QZ3-WNC-9.0+WR\+&Z-*'W<
M(Z.*,7[Z'%6'58 D>%*ED'O*;JBB$7Q/9/^>N'S'6T^;F7TN4;J8=GVN2&*5
M3GXZ/N&237[%-8"/7']2+(*,:'_H(]>)?("$'*N&JX$I=X2DF('P;>JA(8'L
M9%2=T8'@6KR:N8'*44"7G8')2 &4?8'3/J&1AX'7-66.H('<+(V+M8'J) *(
MRX(!'/J%_((E=M>CNX?7;4&@6(=78[>=%(;/6C2: (8[4,V6[86Z1Z:3UH5"
M/F*0Y(3%-4:-_H1*+(Z+$8/5)":((X-J'4"%3X,1=@^C#XV2;)V?L(R<8R^<
M;XN96;^97HJ&4&N64XF#1U>318B&/BN05X>(-2J-<H:,+(^*A(67)$2'DX2N
M'7N$NX/?=56B?),X:_B?')'18I^;VY!96428RH[)4 25Q8U%1P22OXO$/>^/
MUHH_-0:,\XB[+(6*!H= )%B'%876':Z$/823=+6A]YC*:U.>EI<!8@&;4Y4>
M6+R8/I,63Y*5/Y$21JF208\-/:B/7HSY--6,?HKA+&^)E(C8)&*&IX;G'=B#
MU(4N= 6A=9Y9:K6>'IP4876:WYFU6$27QY<V3RZ4S)2P1EF1UI(F/6J.]X^"
M-*F,&HS8+%B)-(I$)&F&2X?3'?N#?86O<U2@_*/6:BB=MZ#L80.:@9W\5^.7
M9IL$3MV4;Y?^1AB1?Y3Q/3>.I)'!-(6+RHZ-+$:(YHMZ)&Z& 8B7'A:#.(87
M<*"Q*6F+9T.LR&N07?^HF&V(5-:DL6]K2]F@SG%N0QZ<Z7.%.CN9'76>,7J5
M5W>\*2*1C'G>(2*-P7OS&I:**GX,< *OJF^@9LNK;G$;7:&G6W*.5(.CA'/U
M2Y:?KW5Z0NZ;V'<1.B68$'BS,8642WI>*4Z0A7P)(72,R'VA&PZ)/G\[;X.N
M27669DVJ*':472VF+'>+5"6B:'AU2TR>GWE[0KJ:T'J3.@V7$7NX,8R35GSF
M*7:/FGX3(;R+ZW\P&W>(<(!-;M2M)7MD9;BI"GOU7*ZE%GQ[4[JA7'SP2O>=
MEGU\0GZ9QGX5.>^6%WZS,8Z2<W]5*9B.RW_[(?J+*H">&]*'O8%$;CRL+($R
M92VH%8%$7#2D)H%.4U&@<X%+2J.<LH%<0D"8YX%Y.<Z50H&4,8V1J(&R*;6.
M"H'6(C.*;H'_'":'!8(O;;RK3(:N9+&G0X9,6\&C7H7@4NV?L(5F2E*;]X4
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M]9493)%TI)%U/G!V4(W",))W](H.) MYCH9$L"AHI+*FH=AJ;*YTDXML&ZI
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M541UMIJJ1^QV_)7,.NQX/Y#I+D1Y>HP6(Q)ZI8=IJ)B!4&/ZFT*!#V:EC<*
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MN84Y212#&X2>/=&"B(/_,NJ![8-E*$^!1X+2'S> FH))BIN&S(ZI?^N& HW
M=12%/HRV:@"$A8M]7MF#THI04]B#(HDE2*."C8?R/86" H:\,L.!;(6,*%*
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M684S,IB*[X2=*I>(?X0/(N2&#X.-'*J#OX,?;AR<)(XI99.9=HT_7/N6U8Q
M5$:41XLF2ZB1OXH00TF/-XC].LZ,RH?B,GV*9(;'*I6'^86W(OV%CH2Y'-Z#
M0H/9;8B;A9.@9/R8UY)67&R6-9#N4\^3IH]?2T>1)XW.0OV.JXP[.I6,18J5
M,EF)Y(CJ*H>'?H=0(PR%&X7-'0F"V81Z;.::ZYD*9&N829='6^Z5KI5I4V>3
M')-F2O&0I9%90KJ.-(]'.F.+U(T5,C>)=HK=*GF'%HB[(Q>$O(:\'2V"A(3_
M;$>:79Y38^N7SYOV6XB5/YF/4Q*2K)<82JR0/)210H6-U)(#.CJ+>(]+,AN)
M'HR-*FZ&PHGQ(R"$<(>"'4F"/X5L:;>KXV4#81ZH&&=Y6(RD;6G<3_Z@\6PA
M1YB=;VZ#/W29ZG#X-R:6@G-K+ON3(W7D)SR/P7A?']J,7WK)&>*).GTM:1ZJ
M.FK^8*:FB&SP6"RB]V[33ZB?E'"?1U.<)G*%/T68LW1\-Q.5579\+PJ1_GB$
M)VR.IWJ*("N+6GQZ&E6(27YA:(>HI7#D8!BE&7)85Z^AI7._3T>>4W421PF:
M]'9[/Q*7CG?U-OZ4/7E[+Q60\WL*)Y>-K7R5('.*='X+&KF'=G]X9_*G3':A
M7XNCTG>H5R^@;7B@3MN=)WF 1K69T'IQ/M>6<WMM-N*3-'QO+QN0 'UV)[R,
MSWY](+&)J7][&Q"&OH!S9T>F+7Q47ORBN7SD5KB?7'UE3G><('W01F:8U'Y)
M/J"5@7[*-LB23G],+Q^/)W_1)]Z, H!9(.R(YX#@&V.&!H%E9JBE,8' 7GJA
MR8'>5DZ>=H'L3AZ;0X'B1B"8 X'F/F^4NH'R-K"1C8'^+R..:X(,)_R+2H(=
M(2&(,8(O&Z^%4H))9AZD2(< 7@J@\X:L5?.=KH9'3=&:@X7(1>273(56/D24
M#H3M-IN0YX2"+R:-R809*!6*JX.W(4Z'E8-;&_"$N8,/9:&C>8PG79N@+XMH
M59.<\XJ338&9S(FB1:26H(B]/A:3;8?=-H&03H;X+R&-,X84*"6*&X4Z(7*'
M#(1L'":$-X.\92^BQ9$_72F?>Y >52F</X[B32N9&(V#15^5]XPJ/>*2TXK4
M-F"/NXEN+Q.,IH@&*"R)E8:N(8V&DH5G'%2#RH109*RB(98]7+F>W92G5,R;
MI)+Y3-Z8?9$N12*59H]B/;223XV7-D&//HNQ+P6,+HG)*"^))(?W(:*&+88_
M''F#<83+9">AD9L*7%6>6)CD5(";)I:X3*&7_I2!1/&4\))&/8^1Y) *-BF.
MV8VK+OJ+S(M,*#*(R(D,(;*%W(;R')>#*H4O7VJSSV785VFOLF?U3XFKCFHA
M1]&G9&QB0%JC(F[+.3.>UW%+,@&:HW/4*P&6=W9A)&:22WCB'A:.'WL[&1R*
M4GUZ7T6R&&N)5T"N'FTC3V&J%F[41["E_'"E0$:AS'*7.3&=DG2>,A.99G:W
M*RJ5/GC8)*B1'7KJ'G2-"WS1&92)5WZ>7ONP>7$?5O:LG7)!3R"HKW-^1X2D
MJW3@0"R@BW9;.2B<7G?H,A^8/7F**TV4(GLU).*0$7S1'L:,%WY'&?R(?'^F
M7GVO#':45IBK1G=23MNG:7@I1TVC;WD?0 >?5GHE.1:;+WLV,B27('Q4*VF3
M'7UY)12/)'Z6'PV+07^<&E>'O("27@NMZGO95D*J(GPW3IJF27RG1QFB67TO
M/^.>27W".0::*WY=,BJ6*7\!*X>2,W^H)4B.2(!-'U.*=(#E&JZ&_(%U7=2L
MX(#H5@>I(8#63F"E48#61NBA;(#N/\*=:($5./>95H%&,C&568%\*Z619X&T
M)7N-@8'J'Y2)LX(9&OZ&0H))79FKXX7+5<^H.H5&3BZD>H331K^@GX1\/Z6<
MI80X..J8G8/_,C>4IH/'*[^0N(.2):>,UX->'\R)#X,I&T&%HX,!74ZK (J,
M58ZG88F=3?>CJHC!1I*?U8?^/X6;Z(=/.->7[H:K,C>3_88#*]*0%(5=)<F,
M.X2]'_N(?H0A&WN%'8.A7/*J.X\N54"FDXWH3;>BV8RN1F"?!XN$/UZ;*8IK
M.+V708E9,BZ36H@\*]R/=X<?)>2+J(8-("&'_(4%&ZN$K(0I7(^IA).N5/6E
MW9(!37^B(Y!@1C2>4X[2/SR:@XU/.*66K8O3,B62S8I#*^2.\8BR)?J++(<T
M($"'D(7(&]*$3X2:7#*HX9?S5+.E0Y7(35&ACY.V1A"=PI'&/R&9_8_@.)&6
M-(W_,AZ27(P#*^J.A8H))@N*R8@K(%B'.H9H&_*$!83VOS]JA&!VKUUL1F-F
MGXQMZV9#C\]O9FC^@!!P\6N(<&=RA&X(8*-T(W!\4.-URW+I04!W>G5+,9]Y
M,7=Y(NI[ GG0O--G=VH1K4MIBVP-G<-K@FX CCAM36_E?K)O%G&M;T5PX7-P
M7[%RM74H4!UTD';:0+%V;GB#,5=X2GH'(OUZ.'NBNJ9DSW. JT]G-W2+G %I
M=76;C+MK<7:S?6]M:W>[;CEO:'C!7M)Q:WF_3VMS<GJX0#%U>7NH,1AW>'Q\
M(PUYA'U8N*ABH'QTJ8=E-WRSFFYGI'SZBUUITGU,?$-K^7V=;3YN('WN7@1P
M27XX3LAR<GY[/[]TG'ZU,.!VNW[7(QMXY'[PMLM@U85=I]5CD837F.AF)(19
MB@9H>8/J>QIJQ(.!;$9M#8,973IO4X*L3B]QF8(Y/UQSWH&Z,+IV&8$I(T%X
M6X"%M2M?68XMIDIB0HS3EWID^HN.B+]G:(IF>?UIS8E&:U5L,(@D7'INC8<!
M3:)PZ(77/PAS0X2C,*1UE8-C(WAWZ8()LY1>+I;%I.)A)I2XECQC\)*ZAZ-F
M=I#3>09H\X[U:H9K;8T46]1MWXLT32EP38E//K]RNX=A,)%U(X5R(Z=WB8-E
MLBU=.Y],HZ)@.IR4E1YC#YGDAI]EI9=!>")H,I2E:<9JOI($6SUM08]E3+UO
MP8S /H%R08H1,(%TOH=E(\]W-X2;L0-<=J?&HHI??*1HE!AB5Z$-A:QD])VW
M=TQGBYIC:1)J()<$6K!LL9.C3%QO09 V/DQQTXR\,'1T98E (_%V\H6KL );
MR; >H9Q>VZP6DSMAP*@/A-UD8*0(=I5F_9_Y:'AIFIO96CEL-I>Q3 MNU)-Y
M/B!Q=8\R,&AT&XKG) QVNH:2KRE;,KA!H-A>5+.'DHAA0Z[,A#9CYZH2=@)F
MB:5#9_QI+*!=6=IKT9MK2\IN>Y9H/?UQ*I%;,%]SWXQ1)")VC8=1M+]P;5_K
MIAUQC6+REV5RI67CB(ESLFBP>:ATSVM):M]U]6W66]EW,G!53,UX?'+-/?)Y
MSG4]+SU[)G> (95\E7GOLI%M>6D8I#-N\&LSE;1P6VU"AOYQM6\\>%%S#'$:
M:<%T9G+T6O%UU'3'3!MW4':6/7QXS7A<+PQZ1WGY(;M[T'NSL'EK 7(,HD=L
MPG-1D_YN;'2.A8QO\G6]=QAQ=G;C:+UR_G@*6A]TF7DM2WMV/WI./1-WXWME
M+N%Y?7Q9(=Q[(GU9KHAH_GJYH(9JZWLWDG)LOGNRA#UN:7PI=?MP%7R=9\]Q
MQ'T365]S@WV%2NMU2WWR/+9W$7Y5+KMXR'Z;(?EZB'[@K,%G0H-1GN9I6H,/
MD/UK4X+.@OAM'8*-=.-NZ8)/9N9PN8(36*1RE8'22F!T>8&,/&!V68$[+J%X
M*H#6(B9Y_8!EJS5ESHNBG7)H%(JHCZ9J,(FR@<9L$8C"<]EM]H?79@9OX(;J
M5_%QTX7[2=YSRX4$/!1UOX0%+I!WHX+X(EYYAH'<J<1DKY/BG"9G 9(TCGQI
M+9")@+UK(H[D<O-M'XU%945O(8NC5U=Q*(G_26YS,HA6.])U.(:D+H)W+X3Q
M(HYY((,KJ'%CQYP1FO)F'IFXC6=H4Y=@?\9J5I4(<AUL8Y*U9))N=9!=5LEP
MC8X"20ARJ(N?.Y=TOXDU+G5VR(;-(K=XRH15ISUC"J0JF=)E9Z$WC%]GHIX]
M?MMIK)L\<5%KP)@X8^=MVI4J5D1O_Y(32*MR*8[O.V-T4(O +FEV;HB1(MEX
M@85:ICMB<JPSF-UDT:B9BWQG#Z3W?A%I'Z%+<*)K.)V38U9M5YG+5=-OA97T
M2%QQO)(+.S=S\HX7+EYV(HHC(O5X188WI6MA][09F!AD5J_$BL5FEZML?6YH
MJZ<1<!5JR**A8N!LZYX;57=O(IF"2!QQ9)36.Q1SIY D+E9UY8MZ(PMX%H;N
MJA)VHE^1G(=W,&*MCM=WPV6D@.MX7&AA<O9Y FL 91=YL6V;5N!Z?G E2)I[
M77*I.I9\074I+-=]+'>%($5^*'H.J"]SS&A/FLQTLVI\C4!UF&R6?W%V?6Z2
M<:MW6G""9 -X.')U5@9Y,W1B1_YZ/G9,.CM[2G@O++]\4GGJ('Y]9GO#IB1Q
M>'#6F.=RHG(LBY%SPG-\?@]TT73$<(!UV78(8PIVXG=054)X!GB81W)Y.7G?
M.>IZ:GL<+*E[CWPS(+!\NWU9I&UOBWDLEU=PX'G+BBIR)WIG?-AS67K\;W9T
MA'N58BYUL7PQ5)5V^7S+1O=X3GUB.:-YH'WN+)=ZX7Y=(-Q\)7[0HJIMXX%;
ME<IO8(%/B,]PRH$]>ZER&($C;G)S8H$1851TK8$#4^EV$8#P1GMW@H#7.5QX
M[8"U+(AZ1(!_(1![FH!%H1=L>HE"E%UN(HB,AXEOKH?1>HIQ$H<0;7ER=(99
M8(1SV86D4T-U4X3J1@1VUX0H.1=X4X-?+'UYNX**(4I['(&NG[]K49$:DR-M
M$8^YAFYNLHY4>9%P*8SG;*)QHHN&7]!S'HHE4K1TK(B_19UV0(=2.-UWS87?
M+'1Y1(1L(7IZL8+QGH]J;ICGD@5L,Y;CA6AMWI38>*EO9)+!:]IP[)"V7RER
M=XZH4C!T%(R213YUN(IT.*9W5(A0+&IXVX8Q(:1Z5H0/G8!IS*"ID/UKB9X/
MA'!M,YMH=\INP9BP:QIP4)7[7HMQXI- 4;-SBI!U1.1U.XV;.')VY8J[+%]X
M?X??(<9Z"H4*G(!I.:A%D!1J^*44@YMLIJ'2=PMN.IYY:G9OSIL97@-Q8Y>K
M44ES%)0G1)ATT)"0.$9VAXSR+%5X,8E<(>-YRX7>FYUHL*^ICTYJ>ZO9@O!L
M,J?U=G%MRZ/W:?%O8Y_F799P_)O$4/-RLY>'1%IT>9,V.")V.X[C+$UW\XJA
M(?EYF8:,GVU\_U]<DL=]&&)MA@%]-65<>05]5F@6:_Q]A&J]7PQ]N6UD4;E^
M!F_V1%E^87*!-T5^Q'4/*H!_,G>''P-_K'HLG;MZ3V>ID3%ZR&GFA(E[-VP+
M=ZU[EFX,:LY[^' +7@Y\77(/4/=\TG0+0]A]4'8$-P=]TW?\*H%^7'G8'U!^
M['O2F^1X$6_"CX!XS7$X@PEY='*D=FYY_7/^:<%ZB'5972Y[%G:Z4$M[L7@9
M0V9\5'EV-L]\^7K/*H)]G7P+'Y-^1'U9FDIV/W>LCA)W&WA[@<9WXGD^=5=X
MC'GP:-1Y-7JJ7&MYX'MI3[=ZHGPA0P-[;7S5-I]\-GV$*H-\\WX>'\Y]L'[
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M>]Z ]FN6;^^ S&V?8_B JV^M6"& CG'#2_" >7///[V ;'78,]Z 97?E*%*
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M=?%^U6%Z:J5^W&237T5^\V>A4_Y_$6JQ2$E_0&VD/(M_>G"0,2]_OG.$)C^
M$G9O'+> ;WE^BGI\06*:?YM\=64X=)Y\L6?$:6Y\^6HV7C9]2&RG4QY]FV\=
M1ZE]\G&&/#1^4'/M,1M^M795)F%_)GBK'1=_G'L9B-%YPVHT?AQZ/&P><T]Z
MMVX!:%M[-&_774Y[LW&M4F%\,W.*1R)\MG5@.^E]/'<U,0I]Q7D))G]^4WK'
M'6I^XGR4AWUWIW&F?/!X1G+S<DMXYW0Y9WMYC'5V7)1Z+W:V4<QZU'?[1KA[
MA7DT.ZQ\/'II,/M\\'N<)II]FGS!';-^/WWNABYUX'CI>[MVH'FB<35W9'I3
M9HQX+7KY6\EX\'ND42AYLWQ11C]ZAGSP.V%[7WV(,.!\,'X@)JU\\'ZS'?M]
MIW])A-ET67_E>GYU18 *<!9V,( I991W&8 _6O=W]X!84'MXTH!Q1;QYN8!\
M.PQZI8"!,+M[B("')KM\6("/'C]]'8";@YYS$(;6>61T%X9?;QUU'H7E9+YV
M)85H6D%W&X3J3^9X"X1K14MY!H/?.L-Z H-/,)QZ]H+#)L=[UH)!'GE\IX'(
M@HIR"(VR>&QS'HRN;D-T-HNE9 1U4HJ46:5V7(F!3VAW8(AI1.MX:8=".H%Y
M<H84,'QZ<X3N)LY[9(/8'JI\0X+1@:!Q091K=Y5R6I+X;81S>9%T8V-TH(_6
M62%UNXXM3P%VSXQ\1)IWXHJS.D5X\HC?,%MY_H<2)M%[ 857'M-[[X.X@,IP
MBIL5=MIQL9D?;.1RW)<38MUT#)3F6+1U-)*H3JUV6)!<1%=W<HWQ.A)XAXMW
M,#UYFXD%)M-ZKH:J'O5[JH1[@ MOX*&>=CUQ()\$;&-R79Q;8G%SDYF?6%UT
MQY;)3FEU]I/C1"%W%I#:.>IX,(W!,"9Y2XJT)M1Z;(?''Q![<X4;@G&%E5KL
M>"^$TEYI;=B$,F&\8UZ#QF3/6-2#96?>3FF#"VKR0XZ"Q6WH.+&"BW#;+C^"
M6W/:)$6"-W;;&[V"(7G[@-^"V6)9=MR";645;+6"&V>T8E.![FHK5^R!P&RE
M3:N!E&\H0PN!<W&<.'"!6W0/+CR!27:*)'&!0GC['!Z!1'N ?V2 A6F$=86
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M1E: ]7[*/3B RW\G-#" J7^"*XV ?G_D(SZ 1(!0'&V "X# <?J!*X*W:4F
MW(*U8(B H8*I5ZB ?X*13KF 4X)V1?: )8)://2 $((P- J  H($*XA_Z('A
M(UI_N('/'*I_AX'%<1* )(C.:(5_Y8A37^5_N8?*5R)_IX<P3DQ_C8:/1:)_
M<H7J/+=_;84S,^5_;(1Y*WY_7X/+(V]_/(,R'-Y_%H*K<$=_48Z\9]-_&XWG
M7TY^]HSW5JI^ZXO?3>U^XXJY15E^W(F+/(!^X(A!,\!^Y8;N*VY^X(6I(WU^
MSX1]'0I^N(-Q;Y)^E92>9SA^;Y-77LY^59'N5D1^39!939U^58ZN11U^8(SX
M/%)^:XL:,Y]^<HDO*U]^=8=7(XA^<X6?'2U^:X08;O=][YI?9KA]W9B 7F9]
MT9:*5?)]S91V35U]X9)(1.U]_) ,/"U^#(VA,X5^%8LH*U1^'HC((Y!^*H:1
M'4I^+82@;QB3&EN/9H>18U['7>*/PV'Q51>.0F4$3$:,Q&@C0YN+3&M-.G^)
M\FY8,6J(J7%B*,Z'9G1_(+.&+G>K&@F%%'K?;B20I&(09;6/'&2S72B-LF=.
M5&F,;FG<2[&+'&QV0R:)QV\<.CF(CW&R,5B'9'1+*.N&/W;P(/.%)GF5&FR$
M)GP\;0&.FVAR9*Z-0&J+7$6+^&R?4[2*R6ZK2QZ)EG#"0K.(9'+D.?2'2W3^
M,46&0'<;*06%.7E (2N$/'M?&L.#5'U[:_6,K6ZX8[V+='!36W"*37'I4OR)
M/W-Y2H2(+G410CR''W:Q.:R&)GA#,3"%.7G4*1N$4'MM(5R#;7T'&P^"GGZ=
M:PB*_W3S8N>)XG8-6K*(V'<D4ER'YW@W2@&&\GE/0=>%_GIK.6V%(GMW,1J$
M47Q_*2N#@'V0(8J"KWZH&UR![G^\:CZ)B7KV8BV(C7N06@Z'H'PJ4=2&QGS$
M296%YWU=08:%!WWY.3B$1'Z#,0.#BW\+*3."S'^;(;."!8 V&Z:!3(#1:6V(
M4(#*88"'9X#I68&&CH$'46"%R8$E23>$_8$_04"$+X%8.0J#@H%A,.^"WX%I
M*3N",H%[(=:!<X&=&^6 P8'%:*^'2(:!8-^&;88R6/N%H87=4/6$Z86!2..$
M+X4<00&#=H2T.-^"V80X,-F"1(.X*3R!I(-&(?* \H+H'!J 2X*::!"&:XP7
M8$J%FXMT6'F$UXJ]4)&$)(GK2):#?8D)0,B"VH@?.+:"1H<7,+^!MH8%*3:!
M'X4$(@: @(0<'$9_Z8-29W>%I9&@7\2$Z)".6 F$+X]E4#R#?HX=2%6"YXR_
M0)B"6(M6.).!S(G!,*F!/H@@*2^ KX:4(A6 ((4H'&M_F(/L9NN$]Y<"7U*$
M4)5>5Z^#II.O3_B"]Y'R2"&";I :0'*![XXU.'>!:8P:,): WHGS*2F 5(?H
M(B%_TX8('(A_5X1J9:Z:"UO[7<N7JE\T5=F5<F)<3<F3=&5J1<:1:VB)/?6/
M9&NV-=&-?F[/+<2+IW'I)BZ)TG4.'PR'_7@O&4Z&5GM&9/J7G6(E72N5;&33
M54B3:&=U34.1HFH'15>/P6RI/:.-VV]8-:B,$G( +<:*5W2L)E>(GW=<'U.&
MZGG^&;.%87R09!&5EF@R7%.3EFI>5(R1MFR"3+.0 &Z;1.:./'"_/5",=7+O
M-7R*R74?+<:)*7=4)GR'C7F)'Y*%]WNL&@N$B7V^8SB3MFX@6XZ1V6_84]^0
M&'&(3"".?G,L1&Z,V'36//>+,7:'-4R)H7@T+<&(&WGC)IV&FGN3'\F%(7TY
M&EB#S7[/8F>2%G/]6MN04W5!4TB.K'9[2Z*-*G>I1 N+GWC9/*^*$GH--2:(
MFGLY+;Z'*WQE)KJ%OWV3'_Z$6WZ^&J:#&'_=8;B0K'F96D6/!GIN4LF->'LW
M2SR,#'OQ0[V*EGRJ/'F)''UF-0J'N'X7+;V&6W[()M.% '][(#*#IX Q&O*"
M;H#@80R/>'\36;N-Y']R4EV,:G_&2N2+$H *0WF)KH!,/$N(1X"/-/*&](#&
M+;R%J(#\)NF$6X$X(%V##8%^&S*!WH'$8':.;X1S63N,YX1F4?.+>81+2I&*
M+80<0SJ(W(/H/!^'B(.S--F&0X-K+;>%!(,@)OB#Q(+@((""A8*O&VB!9(**
M7_R-CHFS6,.,"HE148B*H(C62D&)6H@X0OZ(&X>0._6&W(;B-+^%HX85+:V$
M:X5!)O^#-H1\()N"#(/+&Y: _8,V7WN,MX[>6%.+1HX/42N)Z(TF2?R(IHP;
M0LN'=XL .]&&3(G<-*B%&XB,+:.#Z(<P)P2"OH7J(+&!IX3!&[N J8/$7ON+
M\I/<5_"*GI*!4.&)4Y$92<2($X^A0J&&\HX6.[2%UXR -):$K8JS+9N#?XC;
M)PB"78<@(,*!586-&]F 9H0Y7'FA/%QB53&>/E^/3>>;<6*P1I.8Z66]/V"6
M16CB.&V3FVP6,4J1%&]#*DN.FW)R([J,(G6>'8F)J'BQ&*F'='NC6_Z>SF(\
M5,*< F3G38*99V>+1C:7$FHE/QB4DVS1.$&2"6^-,3Z/G'),*F&-/74/(_"*
MXG?*'=B(C'ID&0^&>'S=6T^<OF?[5!J:*6HI3/"7M6Q61<Z5;6Z /LZ3"'"U
M.!"0G'+V,2V.2G5 *G., W>0)"")Q'G5'AV'D'OX&6B%FWW[6JJ:Y6V54X68
M=&];3&^6'G$=1663ZW+8/GR1HG27-]B/5'9<,1>-&G@H*G^*['GW)$F(QWN]
M'EF&LGUK&;:$VG[]6?J95',54ON6]G1U3 .4M'7,10Z2EW<7/CR09WAA-Z^.
M,GFN,0N,#7K^*I")\7Q0)'2'X7V;'I:%XW[6&@6$'W_[67&7]'A84HR5K'E2
M2ZR3?WH_1,J1=WL:/@R/7'OV-Y:-.WS5,0F+)'VP*J:)%GZ*))^'%']A'M.%
M)H O&E*#<(#N6/"6O'UZ4BF4B7X$2V&2<7Z"1(^0?'[M/>2.='];-X",97_*
M,0>*7( Q*KB(68"6),.&9(#\'P:$A(%B&I2"VX'#6'^5JH)_4<J3@X*C2Q21
M=X*W1%6/D(*V/;N-FH*V-VF+GH*V,0&)HH*F*L2'JH*1)-^%PH*#'S&#]8)\
M&LN"7()]6"*4O8=B46Z2E(<V2L*0BX;O1!F.JX:&/9",R(89-TZ*X86K,/:(
M\84=*LF' X2()/2%*X/^'U.#=8."&OJ!\H,<5[B3TXPP4161O(N:2GJ/P(KK
M0^2-YHH</6J,$XE%-S:*0(AI,.R(6H=A*LV&=89.)06$JH5.'V^#"H1C&R"!
MFX.A5TR2]I#.4,21 H^O2D"/&XZ(0[J-1HU5/4R+@8P8-R*)O8K5,.2'X(E9
M*M"& H?3)1*$0H9H'X6"M(4>&SZ!580-4Q:HX5T"3$:EBE_A19BB0F+7/Q&?
M$67L.,2;K&D?,L68/&QE++>4ZV^O)MF1JG+X(5F.='8N'!F+17DQ& ^(?7O]
M4L"F>6*(3 6C2V3P16:@+F=T/N.=*VH>.*B9ZFS?,L&6EV^P+,R387*/)P:0
M.W5P(9N-)'@X'&^*'GK)&':'?'TG4D2D7V?X2X^A:6GL10.><6P!/JJ;>6Y#
M.(F847"2,K>5''+L+-J1_W59)RN.\W?)(=:+^GHA'+J)&GQ#&-&&FGXU4<NB
M@FT]2RR?L6[41+><U7"(/G&9[7)C.&.6X'0^,J63R78?+-^0Q'@2)TF-SWH'
M(@F*\GOG'/R(-7V<&1^%U'\H44NA G)?2M2>-7.>1'R;8W3S/D:8CW9C.$N5
MFW?/,J"2GGD_+/"/JWJ[)W",QGPW(D*)_GVB'4&'7'[N&6^%%( 740F?I7=M
M2IZ<Y'@Y1%*:(WD>/BF797HC.#Z4AWLI,J:1GWPS+0J.N'T_)YR+W7Y)(GZ)
M(G]&'8:&E8 M&;Z$7X#\4,6>6WPN2FN;MGR61"Z9#7T3/A&68WVN.#23F'Y/
M,JN0PW[S+2"-YG^2)\.+%( L(K&(9H# '<*%ZX%(&@&#Q8'#4'6=-("^2BZ:
MG8#51 .8!(#X/?*5:8$L."22LH%I,JJ/\8&H+2^-(('7)^&*6('^(MN'N8(F
M'?2%58)+&CF#0X)P4!B<-(4E2>:9EH4#0\R6_H3=/<V4;H2P. R1RX2(,I^/
M((1B+36,780<)_>)HH/,(OZ'%H.!'AV$SH,[&FF"U8,$3\B;+XF+2:68I8D)
M0YN6&XB#/:N3E8?X-_61 X=O,I2.:X;E+3B+M88N* B)!X5J(QJ&C(2T'C^$
M780)&H^"?(. 3XN:-XW/27.7TXS%0W258XO+/8^2Y(KE-^2088H ,HR-V8D9
M+3N++8?X*!:(B8;*(S&&'86T'EJ$ X2S&JZ"-(/DJ?IB3E:PF\)DCUJ'C9QF
MO5Y ?XMHT6'(<7]J^6498Y)M+6A?58EO?6N21Y)QWFZ\.=ET2''8+%UVN72W
M(!9Y/7>ZI[=>/6 ;F;YA &,$B]ACIF79?@AF(VB-<#AHGVL>8H9K(FVJ5+!M
MNG G1NEP87*:.6AS"G4%+"]UJW=$(#EX5WF;I8Y:R&DME]M=]6M#BCI@^&U)
M?*QCNF\W;Q1F?W$-899I2G+@4^UL(W2E1E)O!79D.0-QYG@<+ 9TMGFV(%=W
MBWM>HXA7Y7'MEB9;4W,\B,Q>EG1_>WAAG'6N;A!DHW;08,!GKW?O4S]JO7D$
M1<MMSWH1.*IPWGL9*^)SVGP,(')VUGT!H<95:WJ5E)59%WL?AVQ<EGNB>DQ?
MTWP8;1-C#WR&7_)F4'SR4IUIBWU615ALQ7VT.&EO_7X.*]IS(GY;(*QV0GZE
MH#%37(,%DR572(+!AB1:_H*">2]>98)*;"-ARH(+7S%E,8'(4@QHCX& 1/AK
MZX$T.#]O1H#D*^ERD("2(/UUT( YGL%1F(M"D>!5L8I&A0A9DHE1>#A='XAC
M:U-@J(=Q7HID,X9Z48YGLH6"1*9K+(2(.!MNIX.-*_5R$X*;(4-U<(&BG8A0
M(I-8D,A47)&WA ]86Y 7=UU<!XYW:IM?K(S37?EC4XLH425F[8E^1&9J@X?3
M. 5N&H8F+ 1QIH2'(7UU'X+BG(I.^IL]C]Q32ID/@S=77Y;5=II;'Y2,:?A>
MUY([77QBD(_@4-!F/XV$1#EI[8LA-_UMG8BZ+!9Q1X99(:YTVH/[FZ].&J,-
MCQ52;Z \@H-6CIU<=?9:7IIK:6]>)9=M711AZY1A4(MEK)%01!9I;XXU-_EM
M-HL4+"=P^8?W(=9THX3IFO1-<*JZCG%1P:<C@?)5XZ.+=7)9P)_Q:0%=DYQ#
M7,%A99B&4%-E-93!0_II"9#R-_9LXHT@+#1PNHE6(?9T=H6MH+)H#%::DW9I
MOUIIACIK:UX?>/=M#&&L:[ANR64#7IAPF&A043YRBFN*0^QTE&Z[-NMVIG'D
M*D5XNW37'NMZX'?OGHYD)U^%D9IF4V)YA)QH<F5:=XMJ?F@>:H%LCFJ_79IN
MI6U<4'5PW6_L0UES)W)V-I)U='3Y*BYWM7=0'Q]Y_GG G'9@X&@NC\!C<FID
M@P5EYVR%=CMH,FZ#:6EJA'!O7+5LX'):3\!O5G0]0M5QVW8<-D-T7'?U*AEV
MR'FL'TYY-GMRFJ5>!W"CCB1@[G(=@:!CJG.#=1!F*'3*:&YHM78'6^9K3W=#
M3QQM^WAY0EYPL'FJ-?US8'K6*@9U]7OK'W9XA7T$F/A;IGCRC*A>RGFW@%1A
MOWIH<_1D;GK\9WYG+GN,6R)I^7P<3H=LT'RF0?AOKGTL-<IRA7VN*@AU/WXC
M'[9W\'Z6EXM9HX#LBUQ=!8#^?RI@+X$!<NQC"H#M9IYE\H#96F]HY(##3@%K
MW("H0:)NUX")-:=QS8!H*AITJH!#( 9W=X <EBE8 8C)BBY;?X@M?B=>RX>#
M<@=AS8;#9=UDVH8$6=5G[X5$38YK!82 05AN'(.Z-8EQ+H+T*BIT*H(V($IW
M$8%WE.I6HI"%B1M:.(])?3I=G8W[<3I@O8R393)CYHLL64]G%8G"32UJ1(A3
M01YM=8;A-75PHH5P*CMSNX0,((-VNX*KD]=5>9@1B")9+)9.?%Y<J91O<(!?
MVY)I9)IC%9!=6-MF58Y*3-UIF8PO0/)LX(H+-6QP)H?E*DQS6X7)(+-V<X.X
MDO14DI^0AU!85)TN>Z1;WYJO;^-?'Y@)9!MB9I586'MELY*;3)QI"(_20-!L
M9(S\-69OOHHC*EQS"X=3(-MV.(2<DCY3XZ;NAJA7IZ/*>PU;.:"7;V5>A)U/
M8[5AUIGV6"UE+Y:/3&AHDY,90+1K_X^7-6%O:XP5*FARRXB@(/IV"858ERUM
MWE:/BLYO'UID?G%P7UX6<A)QG&&-9:YR[&3E665T2F@[3,EUTFM\0"UW=&ZU
M,_)Y'G'K*"UZR73V'<1\?W@CE2EJ25\+B1AK]6(+?/AMF63P<+MO-&>M9(9P
MSVI:6'1R<6T(3!!T.6^K/[%V%W),,[1W]G3G*"QYR'=:'@M[GWGDDT!G)F=1
MAUII*6F/>W%K'FNZ;WMM &W'8WQNW6_*5YIPOW'.2VIRPW///T%TV'7/,WQV
MZ7?)*"QXXGFA'DEZV7N%D:!D76]TA>5FLG#[>BEH[7)T;F-K!G/78HYM''4S
M5MAO-W:/2M9Q<7?G/MYSN'D],TMU]WJ.*"QX%7O''H!Z*WT&D !B$7=;A'MD
MH7@]>/%G$WD0;5AI6GG,8:UKGWJ#5B)MZGL[2DYP3GOM/H9RO'R<,R9U('U)
M*#AW87WH'L5YDWZ(CH=@+G[L@S!B]'\L=]%EE7]>;&!H G][8-YJ;7^657UL
MW7^P2=1O7G_%/CIQYW_6,PIT:'_F*$]VR7_R'Q-Y%7_^C3Y>A89J@A!A>(8%
M=M=D0862:XEFT(4*8"MI782%5.YK[X/^26INC(-R/?AQ+H+C,O-SQX)5*&)V
M1H'/'U9XJH%,C!Y=)XW,@1%@-XS0=?EC'8O!:LMEQXJ77XUH<(EQ5'-K'(A)
M21%MT(<9/<-PB87E,N%S.X2T*'1UU(./'XYX3X)TBR1<%I4'@"]?-9.*=3)B
M*Y'P:B%DZ9 M7P)GHXYI5 EJ8(R@2,AM*8K*/9EO]XCJ,M=RP(<**(5U<H4W
M'[YX X-VBD);/)PH?VQ>8IH9=(MA8I?I:9-D+Y6-7H]F^),K4[)IPY# 2(QL
MG(Y"/7=O?8NV,L]R68DK*)-U(H:M'^1WQ810B7Q:C*,??LE=M:!>= 1@O9V'
M:2!CEYJ17C)F;)>/4VQI0I2#2%ML*9%@/5QO&HXO,LER!HL#*)]TX8?I( -W
ME(4#C7%T!U:%@>=TXUI;=F9UMUX):NEV?V%V7V!W7F304_-X2F@K2"MY56MO
M/&5Z=6ZK,09[GW'K)B1\TG41'*Q^"WA5BZ1PDEZE@%%QY&&I=/QS(&22:9QT
M/6=27C]U8VH(4P=VCVS#1WYWTV]S._YY)G(B,.-Z?730)CQ[U7=B'05]*WH'
MB>-MD&:!?K=O-FC2<Y)PP6L.:')R)FTI749SB6\^4CUT\7%71NIV;'-N.Z5W
M\W6%,,1Y>'>9)E!Z\WF3'5-\9GN8B&5JZVXZ?6QLV&_E<G5NHW%]9WUP/7+X
M7'AQU'1P49AS;G7J1G%U'W=>.UIVVGC1,*EXCGI")F)Z*GNC'9=[NGT(AO-H
MP'7)?"9JW';2<5ILUW?*9HENGWBH6ZQP8GF$4/1R)WIB1?IT 'LX.Q)UXGP-
M,))WNGS@)GEY=GVM'>%[(7YZA9MF[7S]>N]I.WUK<$=K87W)99]M47X26NAO
M-WY94%AQ'GZ@18ES$W[B.L]U#7\A,'YW ']B)I1XVG^A'BYZG7_BA%YE5H0?
M>=MGR8/L;UIJ%8.M9--L)X-:6CYN+H,(3]%P-(*V12=R0H)?.I5T5(((,&UV
M7H&U)JIX4X%I'F]Z+8$C@T5D HLG>.=FD8IB;HEH]XF-9"-K)8BA6:UM1X>W
M3U]O9X;+1-5QBX79.F1SL83E,%YUT8/V)KYWWX,5'J=YSH(_@E-B])(&>!)E
ME)#+;=)H"H]T8XMJ28WU63-L@(QT3P)NMHKO1)-P[(E>.CUS)(?%,%)U5H8P
M)LYW?(2G'M5Y?X,V@8IB$9C3=V%DP9<+;3EG1I4D8PUID9,26,YKVI#[3K=N
M(H[=1%YP:(RK.AQRKHIM,$AT\8@T)MMW*X8*'OMY/H0'@.=A5)]Y=M%D$YT#
M;+YFI9IX8J=H^Y?16'QK4I4C3GIMJI)M1#-O_(^?.@)R3HS%,$!TGHGR)N9V
MZ8<U'QEY"H2R@[]Z95:J>0]ZT%IO;FE[+UX/8\M[?6%V61U[Y&333HU\6&@T
M0YQ\Y6M\.+!]@VZ_+C)^+7(,)#9^Y75,&ZQ_I'BE@?=W.UY+=XMX!F%7;1AX
MO61&8I1Y6F<+6 YZ FG.3;!ZLVR60P%[<6]5.%]\.W(4+B=]#737)&!]YW>&
M'!!^P'I%@%=T4V7,=A1U=&@K:\]V>FIU88-W66R?5RMX/&[(3/AY(W#W0H%Z
M%',E.!Q[#G54+AU\"7>$)(5]!'FA'&A]^7O$?P!QRVT?=/!S*F[F:MAT:G"9
M8*QU?W(M5G=VD7/!3&MWIG5:0A]XRW;L-^9Y^7A]+A5[(GH0)*5\/'N9'+1]
M2GTC?;QOM'1)<\YQ/75Z:=ERJ7:87]%S['>95<%U)WB:2]QV8GF>0;IWKWJ9
M-Z]Y GN4+@MZ3GR0),9[AGV*'0)\K'Z#?'YM\WLB<J]OIWN_:-MQ/'Q+7OER
MI7R_50YT 7TR2TYU6WVG055VPGX6-W=X+7Z$+@!YD7[U).5ZY7]G'4Y\(G_;
M>U5L8X'F<:UN/8'I9_]O]X'?7C]Q@X'!5'-R_8&C2M-T<X&&0/]U\H%F-T=W
M<X%&+?=X[H$K)0!Z6X$9'8][K8$,>E-K%XB2<,UM#(@)9S]NWX=Q79]PA(;#
M4_%R&885_^)]$$E#0U]04D]&24Q%  852FYSJH5F0+=U/82R-QYVTH/]+>UX
M88-/)19YY(*N'<9[28(9>7MJ%X\9< QL%HXB9IEM]8T/71EOJ(O54X9Q58J8
M2AYR_HE70'YTHX@*-OMV1H:W+>)WY85J)2=Y?H0K'?1Z]H,$>,%I-96/;VAK
M1I029@YM,Y)U7*MN\)"O4S!PL([C2=YR;XT20%!T(XLK-MYUT8D[+=EW?X=2
M)35Y*H5Y'AEZL8/*>")H;IO<;N)JEIFV99]LE)=]7%)N694I4NIP*I+02:IQ
M_)!P0"MSNXWU-L=U<XMP+=)W+(CV)4!XYX:2'C=Z>X1L>E2 T5;.<(R G5JQ
M9L. <%Y@7/" 3F' 4P^ 0V4=25& 16B /S6 8&O,-22 C&\7*XB Q')P(G&!
M"77%&L^!6'DM>-M]JEX9;T5]WF%"9:)^#F1&6^5^-V<04BE^:FG;2)A^HVRN
M/KA^ZV]Y-.I_0')&*XQ_G74;(J.  W?D&S* ;7JV=V]ZZ&4U;?M[;6>_9(![
MXVHG6O1\1FQ=46)\K6Z71_I]&'#9/DY]D',9-+E^$'5?*Y!^E'>H(L]_&WGC
M&XE_GWP@=AEXF6P8;.1Y0FX=8YMYXF_]6BYZ=W&G4+U[#'-31WI[HW4%/?E\
M2W:R-)%\^GA@*Y-]J'H2(O9^37N_&]5^ZGUJ=/!VE'+M:]YW8G1A8K=X*G6R
M66QXZW;24!UYI7?R1OYZ87D6/:9[+GHS-&E\ WM0*Y5\T7QR(QU]D7V5'")^
M17ZU<^YTV'ES:NMUTGI98=MVPWL@6+-WIGNY3X9X?WQ31HEY5WSO/5=Z/WV%
M-$)[+7X<*Y9\$WZX(T1\ZW]7'&]]LG_W<N9S47_F:@ET<( V81UUA(!K6!1V
MAH!Z3P1W?("*1B5X;H";/1-Y;H"I-"%Z<X"Y*Y=[<(#/(V1\7(#P'+!]-8$4
M<?IR!H9 :4!S0H8&8'5T;X6R5XMUB(4Z3I9VEX3 1=)WHX1'/-MXN(/(- -Y
MT(-**Y9ZWX+4(W][X8)K'.=\RX(0<39P^8QO:)%R28O,7^!SAHL#5Q9TJHH(
M3CMUSXD'18]V]8@$/*QX&X;S,^IY0(7=*Y)Z8(3/(Y1[=X//'15\<H+J<'YP
M'I* 9_=Q>Y%C7V-RPY =5K5S[XZ=3?%U*(T615EV9(N*/(=WF(GF,]1XR8@Z
M*XYY]H:8(Z5['X4''3M\*8.A;]9O:YA@9W1PTY:L7O]R))365F=S5Y+23;5T
MH)#'12UU[HZU/&EW+HR%,\-X:(I**XMYH(@?([-ZV(8,'5E[[X0W<0>'4%<M
M:!>&J5KS7R.& UZ/5B&%8&'N312$TV511"Z$4FB\.NN#ZVP1,;>#EF]G*/Z#
M3'+.(,F#$G8Z&@6"Z'FN;\Z$4EX 9PF$ &$C7C6#JF0F546#4&;[3%B"_&G4
M0YJ"KFRV.HV"<F^1,96"0W)Q*1&"'75;(0."!'@^&F>!]GLB;HR!N62W9>J!
MJV=(73R!DFF\5'>!:6P$2["!16Y30Q>!)7"L.CJ!%7,%,7:!#G5D*2*!#7?(
M(3:!%7HB&KV!(7QW;5-_@&L]9.I_D6U17&I_G6]%4\%_I'$*2QI_K'+40J1_
MMG2E.?)_T79P,5Q_]G@^*3& ''H2(6. 07OD&PB :'VN;$]]A7&[9 5]NG-%
M6Z-]['2R4QE^&W7U2I%^1W<[0CU^='B$.;)^M'G&,41^^WL)*3]_07Q2(9!_
M@'V?&U5_NW[D:WA[SG?R8SE\+7CU6NM\A7G=4H)\TWJB2AE]''MF0>-]9'PN
M.7E]P'SO,2]^(WVR*4Q^@7YZ(;U^U'](&Z)_(( 2:HIZ57X)8G5ZTGZ 6DU[
M2'[A4@![LW\C2;%\%7]E099\=G^I.4E\ZW_I,1Q]9X K*5=]VX!U(>1^08#(
M&^1^G($=:;1Y$H0$8<5YJ(/\6;UZ-(/>48YZLX.A25A[+8-B055[IX,C.1]\
M,8+=,0M\P(*8*5]]2()<(@-]P8(L'!M^+8(&:0EX HG482MXK8EO63MY2(CF
M42MYT(@N20UZ8(=O01]Z](:M./U[D(7;,/I\+84%*6)\Q(0X(AQ]4H-X'$E]
MSX+1:&AW((^)8*-WVXZS6,UX@XVU4-AY$(R!2,]YM8M$0/1Z8(H!..!["8BD
M,.Q[L8<^*6-\5H7C(C!\]H2;'&]]@H-[9]9V9I4-8"]W,).G6'1WXI(B4)9X
M=)!S2)UY*8ZZ0-%YYXSZ.,EZG8L8,.%[38DL*65[_8=0(D%\K(6-'(U]180&
M9_^-ZU>/7]V,TELI5[B+L5ZM3X6*@F(/1TN):&5[/SN(66CQ-M&'9VQ4+GR&
MAV^Y)J&%LW,O'T6$\7:M&5&$27HE9P&+&UWE7P:*/6#Z5OV)6V/Z3MB(=&;=
M1KJ'CVG'/LV&KVR\-I*%Y6^K+G"%*G*@)L.$>76>'X>#VWB7&;*#4GN%9>F(
MI60\7A.'_V;,5BZ'4&E(3BZ&DVNE1C&%VFX-/F6%)7" -E>$@W+T+F2#[G5N
M)N&#8G?L'\""Y7IA&@B">'S'9-F&<&IR73&%[FR(57&%9FZ)38N$U7!L1:R$
M1G)6/@&#NG1'-AZ#078S+EB"TG@C)ON":7H7'_.""WP)&E*!N7WK8_Z$>G":
M7&V$''(O5,B#N'.R3/Z#3'4;13N"X':'/;""=G?W-?""'WE@+E"!TWK*)Q6!
MB7PZ(">!1'VL&I^!!W\/8T>"QW:$6\:"D'>85#6"3GB>3(F" 'F.1.&!KWJ
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M)XQ[4S]B%(KA2!IF!HE$/1)I_H>D,GEM\88'*%5QS81Z'[UU<X+^B7E,CIF
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MYGKH&D=_BGT$9.AVEFV%71]WA&]G545X8'$K34MY)'+$165YZ71?/;MZL78
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M5K9_Z&C93WY__&LO2"-_^VUE0-R  F^A.=* $''F,J" *G0O*Y2 3G: )/"
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M(V: RWT0'>F OGYP&:V LW^Q4^^ KG9<3>F J'>=1\6 E7B]07" <GFQ.RZ
M6GJM-2R 1'NP+QB *GR\*2R %7W*(Y* #'[.'B& &G_"&?" )8"@4VU_0'N#
M38)_2GQ=1W=_2GT403I_/'V<.PQ_0'XI-1U_27Z[+QY_3']3*45_4G_K([I_
M9(!['E)_C(#[&BE_K8%P4P1^"("&329^%8$61RU^'(%V00I^&X&6.O!^.8&V
M-11^8H'9+R9^@8'W*5Y^HX(/(]]^SX(@'GQ_$8(?&EA_28(D4II\WX5V3-%]
M!(6?1NY]&X690.)](X53.ME]684*-0U]GH2_+RY]UH1D*7-^$(0 (_Y^5(.6
M'J!^K(,=&G]^]H*Z4C-[SHHY3(=\&8G71KQ\2HE70,)\68BO.L=\HX?_-0=\
M_X=,+S5]3(:!*81]F86J)!=]\(31'KQ^6X/O&IY^M8,U3^.6!51]2=Z4'5AX
M0\R20EQ9/:"0>& 3-X*.Q6/>,:2-'F>W*[N+?6N6)@.)Z6]V(*B(:7-)&XN'
M!G;R%Y^%VWI>3V*2V%HL26N1.EVQ0VJ/IV$>/5*.(F1I-U",I6?!,8Z++FLF
M*\*)NVZ<)B6(4W(5(.&' W5Y&]:%TWBI%_J$U'N<3KV0 %_:2.".J&+N0OJ-
M5&7F/0", VBW-QJ*MVN9,72);VZ)*\2()G&.)D&&Z'27(1.%Q'>''!B$Q'I
M&$F#[7R^3A6-D65H2%.,8F@70HB+.FJD/*F*&6T#-MV(_&]Q,5.'X7'K*[^&
MOG1U)E>%IG;_(3^$J'ER'%&#U'NV&(Z#(GW$37"+:&K(1]B*7&T90B^)6&]
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M(F^ )(,W'9^ !X+F&?E_[X*E2Q."Q(=Y1AR"48=Q0/R!TX=&.Z*!1(;P-EB
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M/WOO(79WY7U &YYZ07Z#:NQ<JWBW8D)?HWDI6:QBG7FP42IEF7I42,MHDGL
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M:%=E3_9W_5MI1W-XSE]N/QQYOV-]-I!ZVV>&+B]\%6N7)E)]66^S'PA^I7/
M&25_VW>_:)YR,59P7^AS*UG%5U1T*ETJ3NAU+V"C1HUV7F0</FIWHV>>-A]Y
M"FLG+@)ZA6Z\)F-\ G)7'T5]?'7>&8Q^UGE09UEN5%U;7KUOMF F5DAQ'F+[
M3@%RD&7>1=!T&&C&/=IUK6NY-<5W7&ZZ+=YY%W'))G%ZSG3;'WI\<W?:&>=]
M\'K!9C-K"V0*7<]LL69<58-N9FBR35%P,&L-14%R!&UK/7)SWV_0-81UTW)
M+<5WSG2\)GYYNG<\'ZA[B7FT&C9])GP191AH'VJ17/%J"&QI5-1L FY!3+YN
M$W 61,]P*''L/21R0G/)-5UT;76P+<5VG7>C)J%XNGF9'^5ZMGN,&HM\>'UE
M9#IEGG#07#9GR'(F5#MI_G-[3$AL1G3-1'END78D/.]PW7>"-4QS-7CP+=EU
MC7IH)M1WU'OA("MY_WU4&N1[YGZR8V=C@G;[6XUETG? 4[AH-'B(2^)JKGE3
M1"YM*7HI/,!OI7L(-3YR)7OZ+>MTHGSX)P!W#GWV(&9Y8G[N&R][:W_98JUA
MM7T%6OAD'7U&4T9FG'V*2Y!I/'W20_5KY7XI/)]NCWZ(-3=Q.'[\+?]SVW]Z
M)RIV:G_V()MXWX!K&VY[ H#<8A%@,(+<6G=BIH*[4N-E-X*12U!G[8);0\QJ
MP((T/(IMF8(7-3EP;8('+A=S-H'[)U)UY8'K(,EX<X'0&Z-ZJX&\89Q>PXB3
M6A!A7(?[4I%D"8=62QQFT8:@0ZUIQX7_/'MLRX5H-3UOQ835+BQRKX1#)W1U
M>H.K(/!X'(,&&\YZ9()Y84===XX,6<!@0HS@4D]C$HNQ2O-EZ(I]0Y-H_8EE
M/&]L)(A:-3]O/8=++CUR0H8Z)Y!U)(4G(0]WUH0)&_%Z*X,48>9\A$_<6;]\
MJ%/&4<A\R5>]2@U\Y%O"0DE]05_).K9]O&/;,OE^7&?N*VE_%&P-)%A_V' U
M'<> JG12&(Z!;WA58)5XD59S6*=Y&5G*4-AYGUTU22]Z)6"[09%ZW&0_.BU[
MJF?-,JA\CVMH*U-]@F\1)'9^?'*]'@=_?796&/& 9GG/7W5TXET$5[!UOU_?
M4 1VI&+$2'-WE&6W0/IXH6BR.;]YNVNY,FEZY&[3*T1\%''[))!]174D'D!^
M<7@X&4=_?GLJ7F]QN&->5N1RTF7*3V%S_F@Y1^-U0FJL0(AVE6TD.7%W\&^D
M,CYY6G(R*SMZR73,)*=\+W=G'G)]A7GX&9)^LGQF77)NWFF85B)P.6N/3LYQ
MIVV%1VMS+V]Z0"YTOW%R.3=V5'-P,B=W]'5[*T=YEW>1)-%[+7FG'K%\KGNW
M&>1]_GVE7)AL>&]]57=N"7$"3DMOK'*!1PEQ:'/Y/^IS*G5W.1%T[W;^,B-V
MNWB4*V-XB'HT)0AZ1GO2'OA[\GUF&CI]97[>6_!J:7595.IL'G923=IMZW=+
M1K5OUGA$/[!QQGE(./!SMGI6,A]UJWMX*WQWG7RC)3AY@'W+'S1[4G[I&H)\
MXW_R6UMHH7L05&QJ;WN/37=L67P-1G%N:'R*/X-P@GT6.-ERGGVL,B!TO'Y4
M*Y5VU'\%)61XVG^Q'VEZRX!0&L!\=8#D6LUG&("34_EH^8"\32!J]H#71CMM
M&(#=/V-O6H#S.,QQHX$1,BASZX$\*[%V*H%I)8UX48&-'Y=Z6H&@&O-\&(&V
M6F=ELH8"4YYGLX6X3-AIR85?1A!K^H3O/TMN7H21.,-PSH0\,C%S/H/J*\EU
MGX.5);%WXH,W'[YY_X+%&QU[S8)E6B-D=XLZ4UEFH(I=3)YHTHE^1>UK$8B:
M/S=MD8?,.+QP(H<),C=RL89!*]QU+X5T)<UWB82?']UYMH.X&SY[D8+U6=^"
M\5 I4H2"EU0-2U6"-E@"1%N!SUP-/5B!K6 ;-H:!JF0U+Y:!P6A6*-6![6R$
M(HB"*G"X'*6"?G3?& F"T'C>6,5_ E9?49]_$UF]2I9_&UTS0Z]_%V#)/,Y_
M361>-B9_FF?[+V9_\FNK*-: 5F]I(K* R',E'.J!3';*&&>!Q7I#5[M[C%R?
M4-9[U%^,2?E\*6*$0Q]\D&6+/%Q]&&B<-=I]KFN[+T)^1F[P*-E^Y7(S(M=_
MBW5P'2: /7B4&+F VWN*5M-X=F*M4"IX]V4R279YD&>[0JYZ1VI)/ =[$&S>
M-:5[XF]]+RM\NG(K*-]]EG3C(OA^<7>8'5M_37H\&0& #7RS5?MUIVBA3XAV
M:FJU2/YW0VS)0D]X.F[?.\1Y/7#[-8!Z1',>+R5[4G5.*/=\8G>'(RA];7F[
M'9M^<WOB&5!_57W@52]S5&XV3O!T16_B2))U3G&(0@-V=G,I.Y-WJ'31-6EX
MWG:"+RQZ%WA"*1Q[4'H*(V1\A'O+'>-]LGUZ&:-^M7\&5+-Q17/!3H%R7W3L
M2#5SDG850<)TYW<].VEV17AR-55WI'FP+S-Y!7L!*3MZ97Q:(Y=[O7VI'B!]
M#G[G&>I^+H )5$-O>WDG3AMPLWGA1^)R!'J908QS>GM..TEU 'P1-4EVB7S=
M+SUX$WV[*5IYF7Z>(\9[%']V'E5\@X Z&B5]NX#L4\9M\GY93;9O/'[*1YAP
MH'\I06%R)W]O.S-STG_"-45UAH =+TQW/(""*7IXZH#E(_)ZAH$['H5\#X%W
M&E=]6X&P4VMLF(."369M^H.&1UIO<8-X03YQ!X-1.R)RT8,W-4-TJX,C+UIV
MAX,0*99X6H+W)!=Z$X+/'JM[L(*+&H!]#()44S%K<8B 32QL[8?O1REN>H=>
M02)P&X;-.Q1R (9)-4)S^87-+V5U]H5**:UWYH2^)#5YMX0D'LM[9(-P&J!\
MS8+:4<F)0E";2U2(8%2<1/:'@UBC/K&&KERQ.&>&&&#&,E:%G63H+#N%*FD5
M)E.$PVU+(,^$;W%Y&Y>$-76(%Y*$"GE=4.>%?U9\2I^$^5H$1&:$>5V6/C>$
M 6$U. Z#N636,B&#A6B!+"R#3FQ")FB#'W -(0*# 7/(&]Z"_7=9%^N"_WJN
M4 >",%QA2?N!VU^%0^J!H&*C/<R!AV6Y-\"!BFC>,?2!EVP1+""!FV]>)GJ!
MHW*S(2Z!NG7U'!R!Z'D*&#F"$WOC3RQ_,6(N25M_$V3K0W5_&&>;/6Y_2VH[
M-WY_C6SI,=!_U6^C+!> $')N)HR 3G4_(5: EW?_'%. \WJ9&'Z!1'S[3GU\
M=V?/2-5\EFHF0Q)\UVQK/21]1&Z9-TY]OG#3,;Q^.W,6+!]^J'5I)JY_%'>^
M(8Q_BWH#')6 $WPF&,J B'X53>9Z&FT72&-Z=&\.0L%ZZ7#M/.][?W*N-S%\
M*'1Z,;=\TW9/+#5]:G@U)MQ]_WH>(<U^G'OR'-Y_37VD&1M_XW\K37UX#G)/
M2 IXEG//0GMY-74Z/,%Y\7:--QAZQ'?K,;-[F7E2+$A\5WK-)P1]#WQ)(@5]
MT'VR'1Q^I'[Z&6!_5X >31IV47=F1[EV\'A]0CUWJ'F /)IX@GIH-P9Y?'M;
M,;1Z>GQ5+%Y[7WUA)RU\/7YL(CI](7]B'51^%( V&9I^X(#S3+)TW'Q21VAU
M>WTC0@9V/7W2/'QW*GY6-OQX1W[?,;QY;7]M+'EZ?8 #)UA[A("3(FY\BH$,
M'89]FH%?&<M^?(&K3%1SAH$N1R-T-H&80==U!X'C/&-V X(%-O1W/X(H,<1X
MB8),+)%YOX)O)WUZZH*&(II\#X*'';!]-H)A&?)^*X)$3 AR5(791NIS(H6Y
M0;%T"86-/$]U$X51-NYV:(41,<MWT(31+*1Y)H2()YMZ;X0P(KY[K(/%'=%\
MY8,V&A)]ZH+!2=R/U5#L1$Z.6%4./L.,[UDL.3.+H%U$,Z:*B&%G+E:)AF66
M*1&(>&G3) "'<FX1'SV&AW(X&J6%OW8J%RB%'GG021N,.%:%0\.+!UHY/F*)
M[EWH..^(]&&3,X"((65&+DZ'7&D$*2.&BFS:)"B%O7"Q'WB%#71J&NZ$@7?B
M%WZ$$GL/2&^(_EP<0T6( E]P/@>'*V*R.*J&@V7=,U:%\FD:+D&%:FQF*2^$
MS6_-)$F$-G,U'ZN#NW9Z&RZ#9WEZ%\F#)7PS1ZB&#6&I0K*%2F28/9Z$LV=N
M.%V$4&HF,R6#_FSQ+BR#KF_)*3.#0W*T)&6"VG6>']F"CGAF&V:";7KR& J"
M57T[1R.#86;X0DF"V6F//5"">6P$."B"3&Y-,PJ",'"I+BJ"%7,/*4J!V'6'
M))&!FW?Z(!6!>WI,&ZF!B'QG&%6!EGY&1L*! &O\0?^ N6XW/1R C'!,. J
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MT'M(%Z"#3WUX/XR*IF8Y.XR)B&CG-VR(@VMY,QV'F6WI+L2&RW!O*J&& W,
M)H6%"'6A(HB$$G@S'K&#57J3&LV"YGRF%^B"CGYT/U2(=&K_.VB'=VU2-UB&
MD6^),QF%Q7&<+M*%)G._*L*$D77I)KB#OW@B(LJ"\'I-'OV"6GQ&&QF"%GWV
M&#6!X']K/R>&9V^<.TF%FW&)-TB$W7->,Q:$+747+MZ#N';7*MZ#4'B:)N2"
MHWIO(P.!]GPU'SV!A'W,&UJ!9'\@&':!3(!#/OZ$@G02.RZ#X76L-SF#17<M
M,Q."L'B/+NN"87GN*OV"(GM.)Q.!FWR[(S^!%'X7'WZ QG]&&Y6 RH T&*Z
MSX#_/M6"R'A>.Q."07G(-RN!P'L*,Q"!1'P;+OJ!&'T>*Q^ _7X;)TB H7\:
M(X" 1( "'\* '8"]&\V 18$X&-R 98&A/NB!/GRH.P^ UWVY-Q^ <7ZH,PV
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M4U?^L%UT^J]BBO*Q8YOKLF6JY;-FN-^S:,7:LV[/U;)TV-*Q>=_/L'WDS:^
MZ<JNA.[(K8?TQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OY
MQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G]M$0B_;5,//ZS4U?^
ML%UT^J]BBO*Q8YOKLF6JY;-FN-^S:,7:LV[/U;)TV-*Q>=_/L'WDS:^ Z<JN
MA.[(K8?TQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+
M^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G]M$0B_;5,//ZS4U?^L%UT
M^J]BBO*Q8YOKLF6JY;-FN-^S:,7:LV[/U;)TV-*Q>=_/L'WDS:^ Z<JNA.[(
MK8?TQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:M
MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G]M$0B_;5,//ZS4U?^L%UT^J]B
MBO*Q8YOKLF6JY;-FN-^S:,7:LV[/U;)TV-*Q>=_/L'WDS:^ Z<JNA.[(K8?T
MQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&
MK8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G]M$0B_;5,//ZS4U?^L%UT^J]BBO*Q
M8YOKLF6JY;-FN-^S:,7:LV[/U;)TV-*Q>=_/L'WDS:^ Z<JNA.[(K8?TQJV+
M^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OY
MQJV+^<:MB_G&K8OYQJV+^<:MB_G]M$0B_;5,//ZS4U?^L%UT^J]BBO*Q8YOK
MLF6JY;-FN-^S:,7:LV[/U;)TV-*Q>=_/L'WDS:^ Z<JNA.[(K8?TQJV+^<:M
MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+
M^<:MB_G&K8OYQJV+^<:MB_G]M$0B_;5,//ZS4U?^L%UT^J]BBO*Q8YOKLF6J
MY;-FN-^S:,7:LV[/U;)TV-*Q>=_/L'WDS:^ Z<JNA.[(K8?TQJV+^<:MB_G&
MK8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:M
MB_G&K8OYQJV+^<:MB_G]M$0B_;5,//ZS4U?^L%UT^J]BBO*Q8YOKLF6JY;-F
MN-^S:,7:LV[/U;)TV-*Q>=_/L'WDS:^ Z<JNA.[(K8?TQJV+^<:MB_G&K8OY
MQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&
MK8OYQJV+^<:MB_G]M$0B_;5,//ZS4U?^L%UT^J]BBO*Q8YOKLF6JY;-FN-^S
M:,7:LV[/U;)TV-*Q>=_/L'WDS:^ Z<JNA.[(K8?TQJV+^<:MB_G&K8OYQJV+
M^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OY
MQJV+^<:MB_G]M$0B_;5,//ZS4U?^L%UT^J]BBO*Q8YOKLF6JY;-FN-^S:,7:
MLV[/U;)TV-*Q>=_/L'WDS:^ Z<JNA.[(K8?TQJV+^<:MB_G&K8OYQJV+^<:M
MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+
M^<:MB_G]M$0B_;5,//ZS4U?^L%UT^J]BBO*Q8YOKLF6JY;-FN-^S:,7:LV[/
MU;)TV-*Q>=_/L'WDS:^ Z<JNA.[(K8?TQJV+^<:MB_G&K8OYQJV+^<:MB_G&
MK8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:M
MB_G]M$0B_;5,//ZS4U?^L%UT^J]BBO*Q8YOKLF6JY;-FN-^S:,7:LV[/U;)T
MV-*Q>=_/L'WDS:^ Z<JNA.[(K8?TQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OY
MQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G]
MM$0B_;5,//ZS4U?^L%UT^J]BBO*Q8YOKLF6JY;-FN-^S:,7:LV[/U;)TV-*Q
M>=_/L'WDS:^ Z<JNA.[(K8?TQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+
M^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G]M$0B
M_;5,//ZS4U?^L%UT^J]BBO*Q8YOKLF6JY;-FN-^S:,7:LV[/U;)TV-*Q>=_/
ML'WDS:^ Z<JNA.[(K8?TQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:M
MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G]M$0B_;5,
M//ZS4U?^L%UT^J]BBO*Q8YOKLF6JY;-FN-^S:,7:LV[/U;)TV-*Q>=_/L'WD
MS:^ Z<JNA.[(K8?TQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&
MK8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G&K8OYQJV+^<:MB_G]M$4B_;5,//VS
M4U?]L%UT^[!AB?.R8IKLLV.IY;5DMN"V9L/;MVK-U[=OU=2V=-O1MGC@T+=\
MX\RU?NO&L83RO:Z'][VNA_>]KH?WO:Z'][VNA_>]KH?WO:Z'][VNA_>]KH?W
MO:Z'][VNA_>]KH?WO:Z'][VNA_>]KH?WO:Z'][VNA_?]M$4B_;5,._VS4U?]
ML%QT^[%@B/.S89GMM6&GYK=BM.&Z8\#=O67)V;]JT-;!;];0O7/>RKEYY<:U
M?^S#LH7QMK"$];:PA/6VL(3UMK"$];:PA/6VL(3UMK"$];:PA/6VL(3UMK"$
M];:PA/6VL(3UMK"$];:PA/6VL(3UMK"$];:PA/7\M44B_+9,._VT4U?]L5QT
M^[)?A_2T7Y?MMV"FZ+I@LN._8;S?Q6+$V,9FS=# ;MC*O'3?QKE[Y<.V@>K
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MP'W9C,!]V8S ?=F,P'W9C,!]V8S ?=F,P'W9C,!]V8S ?=F,P'W9C,!]V8S
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MKFG97*YIV5RN:=E<KFG97*YIV5RN:=E<KFG97*[SOCT3X\\P$,WG*B? ]35
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M;/ZO8'G\L6*']K%ED_&R:9[MLFRGZ;)PL.6R=+?_XGT024-#7U!23T9)3$4
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M4(JYY%::L-U=IJC88K">TV.XD\]COHK,9,2#RF7(?\AHRGW(;LM]R';*?LF
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M>;;?7(JHVE^9F]1BI8_.9*^"R6>Y=<5KP&[$=<1KQH3$:\B5PVK+J<)PQ+3
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ML;Q\OK&\?+ZQO'R^L;Q\OK&\?+ZQO'R^L;Q\OK'_D!P*_Y$J&O^0."__DD)
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MY66FH>1FL:#C:+Z@WFO(G]9ORY_0<LN?RG/*H,1URJ' =<FBP'7)HL!UR:+
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MP*YRB\"N<HO KG*+P*YRB\"N<HO KG*+P*[_@A,(_X(>$?^0*A?_GC89_JE
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M?4ORTWW_D!$#_Z00 -FX! #/R 4 Q=H' +OR)P6R]S42I_@[(9OX/3&0^#Y
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M:#__=F<^_X!F/?^%9CW_A68]_X5F/?^%9CW_A68]_X5F/?^%9CW_A6;1L0
MQ< ! +K0 0"MW0( HO\2 YC_'0R._R,8@_\F)'C_*2]M_RHZ8_\L0EK_+4E4
M_S%/3O\T5$K_.%='_SU91?]!6T/_15Q!_TI=/_]/73[_5%T]_UI=//]@7#K_
M9UPY_V];.?]S6SG_<ULY_W-;.?]S6SG_<ULY_W-;.?]S6SG_<UO'NP  O,H
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MR:&%4\JRA%+*R(-3R>""5,#>A53 WH54P-Z%5,#>A53 WH54P-Z%5,#>A53
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MI6E"^+1H0?G-9T'YSF=!^<YG0?G.9T'YSF=!^<YG0?G.9T'YSF?NG   TZP
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M3"[_?TPN_W],+O]_3"[_?TPN_W],+O]_3"[_?TS"N@  M\<  *K2  "=VP
MD/(! 87_"01[_PX*<O\5$FC_&1M>_QTC5O\@*D[_(S%(_R8U0_\J.3[_+3P[
M_S$^.?\V/S?_.D T_S]!,O]$03'_24$O_T]!+O]502S_6T$K_V) *?]K0"G_
M:T I_VM *?]K0"G_:T I_VM *?]K0"G_:T"YPP  K,X  )_8  "1WP  A/(
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M5$U'_T]64/](8%C_0VQ>_T!X8?\^@V+_/8]B_SV98O\^HF+_/ZMB_T"R8O]
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M2C'_@4DO_XU(+_^;2"[_ID<N_Z9'+O^F1R[_ID<N_Z9'+O^F1R[_ID?'KP
MO+P  +'(  "DT@  E]H  (SQ! &"_PT%>?\5"F__&Q)F_Q\;7?\C)%7_)RM.
M_RHQ2/\N-D+_,CH^_S8\._\[/CC_0#\U_T5 ,O],0##_4T N_UM +?]D/RO_
M;C\I_W@^)_^#/B;_C3TF_XT])O^-/2;_C3TF_XT])O^-/2;_C3V^N   L\4
M *;/  "8U@  B]X  (#S  %V_P8%;?\,"F/_$A!:_Q864O\:'$S_'B)%_R(G
M0/\F*SO_*BXW_RXP-/\R,3+_-S(O_SPS+/]!,RK_1S0H_TTS)O]5,R3_7#,B
M_V0R(/]M,A__=#(?_W0R'_]T,A__=#(?_W0R'_]T,A__=#*UP0  J,P  )K4
M  ",VP  ?^(  '3T  )J_P %8?\""EC_!P]0_PL32/\0&$+_%!L\_Q<>-_\<
M(3/_("(P_R,D+?\G)"O_*R4I_S E)O\T)2/_.28A_S\F'_]%)AW_2R8;_U$E
M&?]8)1C_7B48_UXE&/]>)1C_7B48_UXE&/]>)1C_7B7_31@3_T0B&O\\+2#_
M03 B_T8X*O]'0C7_14P^_T%61?\]84O_.FY._SAZ4/\WA5#_-Y!0_S>94/\X
MH5#_.:E0_SFP3_\ZN$__.\)/_SS-3O\\V$[_/>1-_S[O3?\_]TSZ0OE,]D3[
M2_%'_4OP1_U+\$?]2_!'_4OP1_U+\$?]2_!'_4O_3A@3_T4B&O\_*Q__12XB
M_TDV*O]+0#3_2DL]_T551O]!7TS_/6M0_SMX4?\Z@U+_.HY2_SJ74O\[GU+_
M/*=2_SRN4?\]ME'_/K]0_S_*4/\_U5#_0.-/_4'N3_M"]T[V1?E-\D?[3>U)
M_$[K2?Q.ZTG\3NM)_$[K2?Q.ZTG\3NM)_$[_3Q<2_T8A&?]"*1[_2"TA_TXU
M*?]0/S/_3DD]_TE31?]%74S_06E1_SYU4_\]@53_/8M4_SV55/\^G53_/Z53
M_S^L4_] M%/_0;U2_T+'4OU"TU'[0^%1^43M4/=%]E#R2/E/[DK[3^A+^U'F
M3/M1YDS[4>9,^U'F3/M1YDS[4>9,^U'_41<2_T<A&?]%*![_3"L?_U,T)_]5
M/C'_4T<[_T]21?])6TW_1692_T)R5?]!?E;_0(A6_T"25OY!FU;]0J-5_$.J
M5?M#LE7[1+M4^D7$5/E&T5/W1]]3]4CL4O)(]E'N2_E1Z$SZ4N).^E3A3_I4
MX4_Z5.%/^E3A3_I4X4_Z5.%/^E3_4A<2_T@@&?]))AS_42D>_UDS)?];/2__
M648Y_U5/0_]/64S_26-3_T9O5_U$>EC[1(59^D2/6?A%F%CW1J!8]D>G5_5'
MKU?U2+A6]$G"5O-*SU7Q2]U5[DSJ5.Q-]53G3OA5X5#Y5MM2^5C:4OE8VE+Y
M6-I2^5C:4OE8VE+Y6-I2^5C_4Q<1_TH@&/].)!O_5R@<_V R(_]C.RW_840W
M_UQ-0?]65TO\4&!3^4MK6/=)=UOU2(%<\TB+6_%)E%OP2IU;[TNE6NY,K5KM
M3;59[$[ 6.M/S%CJ3]Q7YU#J5^11]5?>4O=9V%3W6])5^%S15OA<T5;X7-%6
M^%S15OA<T5;X7-%6^%S_5181_TL?&/]3(1G_72<9_V8Q(/]J.BG_:4,S_V1+
M/?I>5$CV5UU2\E%H6>].<EWM37U>ZTV(7NE.D5[H3YI=YU"B7>91JESE4K-<
MY%*^6^-3RUKA5-M:WE7J6=M4]5S45O9>SUCW7\E9]V'(6O=AR%KW8<A:]V'(
M6O=AR%KW8<A:]V'_5A81_TT?&/]8'Q?_9"87_VTP'?]Q.2;_<$$O^VU).?5F
M443O7UM/ZUAD6.=3;U[D4GEAXE*$8>!2C6'?4Y=@WE2?8-Q5J%_;5K%?VE:\
M7]E7R5_65]I?U%GI7]%8]&'*6O5CQ5OU9,!=]&6_7?1EOUWT9;]=]&6_7?1E
MOUWT9;]=]&7_5Q80_T\>%_]='A7_:245_W(O&O]W."+]>$ J]G5'-.]O3S_I
M9UA*Y&%A5=];:U[;5W5CV5: 9-97B6745Y-ETUB;9=%8I&706:UESEJW9<U:
MQ&7,6]-ER5SE9<9<\V;!7O)HO%_R:;A@\6JW8?%JMV'Q:K=A\6JW8?%JMV'Q
M:K=A\6K_6!80_U,<%?]B'1/_;R02_W@N%_]]-Q[Y?CXE\7Q&+^IX33GD<E9$
MW6M?4-AD:%O27G%DSEMZ:,Q;A&K*6XUJR%R6:L9<GVK%7:AJQ%ZR:L)>OFK!
M7\UJOV#?:KQ@[VNW8N]MLV/O;;!D[FZO9.YNKV3N;J]D[FZO9.YNKV3N;J]D
M[F[_6A40_U<:%/]G'1'_<R,0_WTM%/^"-1KUA#TA[8-$*>6 3#/>>U4]V'5=
M2M!L95G*9FUDQ6%U:\)@?F[ 8(=OOF"1;[Q@FF^Z8:-ON6*M;[ABN&^V8\=P
MM6/9<+)DZW"N9>QQJV;L<JAGZW*G9^MRIV?K<J=GZW*G9^MRIV?K<J=GZW+_
M6Q4/_UL9$O]K' __=R,._X$K$?N'-!;QBCP<Z8I#(^&(2BS:A%0WT7Q;1\IU
M8U;#;FICO6AQ;+EE>G&V9()SM&2+=+)DE72Q99YTKV6H=*YFLW2L9L%TJV?3
M=:EHYG6F:>EUHVGI=J!JZ7:@:NEVH&KI=J!JZ7:@:NEVH&KI=J!JZ7;_7!0/
M_UX8$?]O' [_>R(,_X4J#_B+,Q+NCCH7Y8]!'=V.2234B5(TS(-:1,1\85.]
M=6=@MF]N:[%K=7*M:7UVJVB&>*EHCWFG:9EYIFFC>:1JKGFC:KQYH6O->:!K
MX7F=;.9ZFVSF>IEMYGF9;>9YF6WF>9EMYGF9;>9YF6WF>9EMYGG_7!0/_V(7
M$/]R&PS_?B(+_X@I#/6/,0_JDS@3XI4_%]F41R#0CE QQXE80;^"7U"X?&9>
ML79L:JMQ<G.F;GEYHVR!>Z!LBWV>;)1]G6V??9MMJGV:;;=]F&[(?9=NW'Z5
M;N-^E&_C?9)OY'V2;^1]DF_D?9)OY'V2;^1]DF_D?9)OY'W_710._V45#O]U
M&PO_@2$)_XLH"O*2+PSGES8.WIH]$M6811[,DT\OPXY7/[N(7DZS@F1<K'UJ
M:*5W;W*?<W9YFW%]?IAPAH"6;Y"!E'":@9-PIH&1<+*!D'##@HYQV(*-<>&!
MC''A@8MQX8"+<>* BW'B@(MQXH"+<>* BW'B@(MQXH#_7A0._V<4#?]X&@K_
MA" (_(XF".^6+0GDFS,*VYXX#=&;1!S(ETXMOY)6/;:-7$NNB&)9IX)H9J!]
M;7"9>7-YE'5Y@)!S@8.-<HN%C'*6A8ISH86(<ZZ&AW.^AH9STH:%<]Z%A7/?
MA(1SWX.$<^"#A'/@@X1SX(.$<^"#A'/@@X1SX(/_7Q,._VH4#/][&@C_AQ\&
M^I$E!NV9*P;AGR\'V*(U"\V?0AK$FTPKNY=5.[.26TFJC6%7HXAF9)N#:V^4
M?G!XC7IU@(AW?8:%=8:(@W61B8%VG8J =JJ*?G:YBGUVS8I\=MN)?7;<AWUU
MW89^==V&?G7=AGYUW89^==V&?G7=AGYUW8;_8!,._VT4"_]]&0?_BAX%]Y0B
M!.F<)P3>HRH#U*4S"LFC0!C GTLHMYM3.*^66D>GDF!5GXYE89>):FV/A&YW
MB']S@(%[>8=]>8&,>GF,C7AYF(UV>::-=7FUC7-ZR(US>MF,='G:BG9XVXEV
M>-R(=GC<B'9XW(AV>-R(=GC<B'9XW(C_81,-_W 3"O^ & ;_C1P$])8? N:?
M(@+;IR$!T*@Q"<6F/Q:\HTDFLY]2-JN;646BEU]2FI-D7Y..:&N+BFQU@X5P
M?WN!=8AT?GV.<'V'D&Y]E)%M?J*0:WZQD&I^Q(]I?]>.;'W9C6Y\VHMN?-J+
M;GS:BVY\VHMN?-J+;GS:BVY\VHO_8A(-_W,3"/^#%P7_D!L"\)H< >.C&@#6
MJQL RZPO!\&J/12XJ$<DKZ10-*:A5T*>G5U0EIEB78Z49FF&D&IS?8QN?72(
M<H=LA'F.9X.#D66#D)%DA)Z18X2ND&*%P(YAA=B.8X/8C66!V8QF@-F,9H#9
MC&: V8QF@-F,9H#9C&: V8S_8Q(-_W<2!_^'%@/^DQ@![9X5 -ZH"P#1KA@
MQK L!KVO.Q*SK$4AJJE.,:*F54"9HUM-D9]@6HF;9&:!EVAQ>)-L>VZ/<(5E
MC':,88N CU^,CH]>C)R-7HVLC%V-OXM<CM:*78O:BE^(VHI?A]J*7X?:BE^'
MVHI?A]J*7X?:BE^'VHK_9P\+_WL1!?^*% +ZEQ, XJ() -2K!@#+LA, P;0I
M!+>T.!"NLD,>I:]++IRL4CV4J5A*C*5=5X2B86-[GV5N<IMJ>&B8;H%@EG6'
M7)6 B5N5C8E;EIR'6I>LAEJ7OH59F-6#697>A%J1WH5:D-Z&6I#>AEJ0WH9:
MD-Z&6I#>AEJ0WH;_; P)_W\/ _^/$ #KFPH U:8% ,VO! #$MPT N[HF [*Z
M-0VIN$ ;H+9(*Y>S3SF.L%5'AJU95'VJ7F!TIV)J:Z1F=&*B:WQ;H'.!6:!^
M@EB@C(%7H9N 5Z*J?E:BO7U5HM1\5:#D?5:;XG]7FN)_5YKB?U>:XG]7FN)_
M5YKB?U>:XG__<0D'_X4, O64"0#8H , SZL# ,:T @"]O < M, A :O!,0JB
MOSP8F;U%)Y"[2S:(N%%#?[554':R65QML%UF8ZYB;URL:'97JW%Y5:M]>E2L
MBGE4K9EW4ZVI=E*MNW52KM)S4:WH=%*GZ'92INAW4J;H=U*FZ'=2INAW4J;H
M=U*FZ'?_> @$_XL( -R9  #1I0$ R+ ! +^Y  "TPP$ K,@: *3)*P>;R#@4
MDL9!(HG$1S&!P4P_>+]12VZ]5%=ENUAA7+E=:5:X9&]2N&YP4;AZ<%"YB&]0
MN9=N3[JG;$ZZN6M.N]%J3;KG:DVU[VU-M.]M3;3O;4VT[VU-M.]M3;3O;4VT
M[VW_@ 8"ZY$  -6?  #+JP  P;4  +>_  "LR0, H] 0 )S3)063TC(0B]$[
M'H+/0BQYS4<Z;\M+1F7)3U%=QU-:5<9885'&8&5.QFMF3<=X94S(AF1,R)5C
M2\FE84O*MV!*R\]?2LKG7D?(]F%(Q?9B2,7V8DC%]F)(Q?9B2,7V8DC%]F+\
MB   V9@  ,VF  ##L0  NKP  *_& 0"DSP0 F=D) )3>(0.,WBX,@]TW&'K<
M/29PVD(S9ME%/UW724I5UDU23]945TS675E*UVA:2=AU64G9@U=)VI)62-NB
M54?<LU1'W<E21MWB443:\U1#VO950]KV54/:]E5#VO950]KV54/:]E7?D0
MT:$  ,:M  "\N   L<,  *;, 0";U00 DN43 (KH(@:#Z"P0>N@R&W#G-R=F
MYCHR7.8]/%3E041-Y4=+2>9.3D;F5E!%YV!01.AL4$/I>4Y"ZH=-0NJ73$+K
MIDM![+A*0>W+24#NYDA [>Q'0.WL1T#M[$= [>Q'0.WL1T#M[$?5FP  R*D
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M,"/_E"\C_Y<O(_^7+R/_ER\C_Y<O(_^7+R/_ER^ZMP  K\(  *++  "4T@
MA]D  'K@  !Q]  ":/\$!5__"@I7_Q /3_\4%$C_&!E"_QP</?\A'SC_)2(T
M_RDC,?\N)"[_,R4L_S@F*?\^)B?_128E_TPF(_]4)B'_724?_V8E'?]O)!O_
M>B0;_WTC&_]](QO_?2,;_WTC&_]](QO_?2.QP   I<D  )?0  ")UP  >]X
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M>GIRYGIZ<N9Z>G+F>GIRYGK_61$-_VP0"/][% 3_AQ<"\8\8 ..6%P#6G!P
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MA6-_BX9A@)F%8("HA%^ N8-?@<^"7X#A@6%^X8!B?>* 8GWB@&)]XH!B?>*
M8GWB@&)]XH#_8PL)_W8,!/^$#@'PD H V)D% -&@!0#(IA$ OJDH K6H-PRM
MID(9I:-+)YRA4C:5G5A"C9E=3X6685I^DF5E=8]I;VR+;7ADB'-_7H=]@UR'
MB8-<B)>"6XBF@5J)MW]:B<U^68CC?EJ%XWY<@^-^7(/C?ER#XWY<@^-^7(/C
M?ER#XW[_9P@(_WH+ ON("@#<DP( TYP# ,ND P#"J@P N:TD ;"M- JHJS\6
MH*E())>F3S*0HU4_B*!:2X"=7U=XFF-B;Y=G;&:4:W5>D7)[6I!\?EF1B'U8
MD9=\6)*F>U>2MWE6DLQX59+C>%:/YGE7C.9Z5XSF>E>,YGI7C.9Z5XSF>E>,
MYGK_; 8&_WX( >R, P#6EP$ SJ$" ,6H 0"[KP8 L[(? *NR, BBL3P3FJ]%
M(9*M3"^*JE(\@J=72'JE7%-RHF!>:9]D:&"=:7!:FW%U5YM[=U6;B'95G)9U
M59RE<U2<MG)3G<QQ4ISC<5*9ZW)3ENIS4Y;J<U.6ZG-3ENIS4Y;J<U.6ZG/_
M<@4$_(0$ -N1  #1G   R*4  +ZM  "TM   K+@: *2Y+ 6<N#@0E+9"'8RT
M22N$LDXX?*]31'.M6$]JJUQ98JE@8UJG9FI5IFYN4Z9Y;E*GAFU2IY5L4:BD
M:U"HM6E0J,IH3ZCB:$VF\6I.HO!K3J+P:TZB\&M.HO!K3J+P:TZB\&O_> ,!
MZ8D  -66  #+H@  P:L  +BR  "MN0  I+X2 )W!)@.5P#0-C;\]&86]129]
MNTHS=+E//VNW4TICM5=46[-<7%6R8F)1LFQE3[)W94ZRA&1.LY-B3;2B84VT
MLU],M,A>3+3A74JR\5])K_=A2:_W84FO]V%)K_=A2:_W84FO]V'^@   VY
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M.C_FY3D\X_4[/./U.SSC]3L\X_4[/./U.SSC]3O/F@  PZ@  +JS  "OO
MI,0  )?+  "+T@  @-L$ 'KK% )S[1X(:NTF#V+M+!A9[3$A4NTU*4OM.C!%
M[3\U0>Y&.#[N3CD\[U8Z._!@.3KQ;#DY\7DX./*'-S?SEC4W\Z<T-O2V,S;T
MR3,U]=TR-?7=,C7UW3(U]=TR-?7=,C7UW3+&I   O+   +*Z  "FPP  F<H
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M&!7_A1@5_X48%?^%&!7_A1BNO@  H<8  )/-  "%TP  =]H  &O@  !@Y@
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M83'_,6TR_S!Y,_\O@S/_,(PS_S"4,O\QG#+_,J,R_S*I,O\SL#'_,[<Q_S3
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M8?I=F6'Z79EA^EV98?I=F6'Z79EA^EW_2A00_UH."_]J% ?_=!D%^WL?!.V
M) 7B@BH&V8,T"L^ 01?'>TLFOW53-+AP6D&Q:V%-K&9H5:AD<%NE8WA>HV*
M7Z%BB%^?8Y%@GF.:8)QCI&";8Z]@F6.]89ACSV&69.-AE63R89-D]V&29/=A
MD63W89%D]V&19/=AD63W89%D]V'_31(/_UX."?]M$P;_=Q@$]W\< NJ$( +>
MAR4#U(<R",J%/Q3"@4DCNGQ1,;-V6#ZL<5]*IFUE5*%I;%R=9W-@FV9[8YEF
M@V279HQDE6:6991FH&629JMED6:X98]FRF:.9M]FC6;P9HMG]&6*9_5EBF?U
M98IG]66*9_5EBF?U98IG]67_4! -_V(-"/]P$@3_>A8"]((9 >:'&P':BQ\
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ML&Y4CL1M4X[<;%*,[FU3B>YN4XCN;E.([FY3B.YN4XCN;E.([F[_; $#]GT
M -J)  #/DP  QIP  +VB  "SIP  JZH9 *2K*P2<JS@-E:E"&8VG226&I4\Q
M?J)5/7>@64ANG5Y29IMB6UZ89V18EVYI599X:U.6A&M3EY%J4I>@:%*7L&=1
MF,1E49?<9$^6[69/D_-G3Y+S:$^2\VA/DO-H3Y+S:$^2\VC_<@ !XX(  -2.
M  #*F   P:$  +>G  "LK   I+ 2 )VR)@*6L30*C[ ^%8>N1B& K$PM>*I1
M.7"H54-HIEI-8*1>5EFB9%U4H6QB4:%V8U"A@F)/HI!A3Z*?7TZBKUY.H\)<
M3:/;6TRA[5U*G_E?2YWY7TN=^5]+G?E?2YWY7TN=^5_\>0  VX<  ,^4  #%
MG@  NZ8  +&M  "FL@  G+8) ):Y( "/N2\'B+@Z$8"W01QYM4@H<;-,-&BQ
M43Y@L%5'6:Y:3U.M8%5/K6E83:UT64RM@%A,K8Y62ZZ=54NNK5-*KL!22J[9
M44FM[%)&J_I41JO]54:K_55&J_U51JO]54:K_57E?P  U(X  ,F:  "_I
MM:P  *NR  "@N   D[X! (W!%P"'PB@$@,(T#7G!/!AQOT(C:;Y'+F"\3#A9
MNU!!4KI61TZY74Q+N69.2;EQ3DBZ?DQ(NHM+1[N:2D>[JTA&N[Y'1KS71D6Z
MZT9#N/E)0KC]2D*X_4I"N/U*0KC]2D*X_4K;AP  S94  ,*A  "YJP  K[(
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M)#/OZ20S[^DD,^_I)#/OZ23!I   N*X  *ZW  "BOP  E<4  (C+  !\T0
M<=@  &CC P!B\Q #6_,8"%3T'PY-]"031O0I&$#U+QT[]34@./8[(C7V0B,S
M]THC,?A3(S#Y72(O^6@B+?IV(2SZA" K^Y,?*ONB'BG\L1TI_,,=*?S)'2G\
MR1TI_,D=*?S)'2G\R1VZK0  L;8  *6^  "8Q0  B\H  '[0  !RU@  9]T
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M85"(Z&%.A_9B3X3V8T^$]F-/A/9C3X3V8T^$]F/_;  !X'L  -.&  #)D
MOY<  +:=  "KH   HZ,2 )RE)0&6I#,(CZ,^$8BA1AR!GTPH>IU2,W.;5SUK
MF%M&8Y9?4%R49%A6DFM=4I)T8%&2?V!0DHQ>4)*;74^3JEM/D[Q:3I/364V2
MZ%I+D/9;2X[[7$N.^UQ+COM<2X[[7$N.^USX<0  VX   ,Z+  #$E0  NYP
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M/D"Q_3Y L?T^0+']/D"Q_3[4AP  QY0  +V?  "TIP  JJX  )^S  "3N
MA[P  'O" P!VQ1@ <<8G!&O%,0MDQ3D47<0_'5;#1"5/PDDM2L%/,D;!5C9$
MPE\W0L)J-D+"=C5!PX0T0,.2,T#$HC$_Q+0P/L3++S[#Y"X]P?,P.\#\,CO
M_#([P/PR.\#\,CO _#+,D   P9P  +>F  "NK@  I+0  )>Y  "+O@  ?\,
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M$27WV!&VK   K;0  *&[  "4P0  A\8  'K+  !NT0  8]<  %C=  !0YP
M2_D' T7[$ 8__!8*.?P;#33\(1 P_282+?TL$RK^,Q0G_CD4)/]!%"+_2A0@
M_U03'O]@$AS_;A$:_WT/&?^+#AG_F@X8_Z<-%_^T#!?_M P7_[0,%_^T#!?_
MM RPLP  I+L  )?!  ")Q@  ?,P  &_1  !CV   6-T  $[B  !'[0 !0?L
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MLUAV8\19=&/:671D[5AT9/I6=&3_571D_U5T9/]5=&3_571D_U7_5  %_V0
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M8EQNYF!<;O5?76[Z7EYM^EU>;?I=7FWZ75YM^EW_7@ "[FP  -EW  #.@
MQ88  +V*  "TC , JXX: *6/*P.>CC<*EXQ!%)"*2!^*AT\I@X14-'V!6#YV
M?EU';WMA4&AX9EAB=FQ?7G1T8UMT?F19=(MD6'288U=TIV)7=+AA5G7-8%5T
MY&!5=/-?5G+Y7E=R^5Y7<OE>5W+Y7E=R^5[_8@ !XG   -5[  #+A   P8H
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M4$B*_U%(BO]12(K_44B*_U'C<   U'X  ,B)  "^D@  M9@  *N=  "?GP
ME:(# (ZD&0")I"D"@Z0U"7VC/A%VH44;;Z!+)6B>4"YAG%4W6IM:/U297T90
MF&9*39=O3$R7>TM+F(=*2IB524J8I$=)F+5&29C*1$B7X41&EO%&193\2$64
M_DA%E/Y(193^2$64_DC==P  SH0  ,./  "ZEP  L)X  *>C  ";I@  C:@
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M)SBY_"?'CP  O)L  +.D  "JJP  G[   ).U  "'N   >[P  &[!  !BR (
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M#23O?PPC\(\+(O"A"B'QLPD@\<<)'_+@"!_RY0@?\N4('_+E"!_RY0BSJ@
MJK(  )ZX  "1O0  @\(  ';&  !JRP  7]$  %36  !*W   0>$  #SS!0$W
M]@T$,_<5!B_X&PDK^"$*)_@G#"3Y+@PA^34-'_H]#!S[1@P:^U +%_Q<"A7]
M:@D4_7H)$_Z*"!+^F@<1_ZD&$/^Z!A#_O080_[T&$/^]!A#_O0:ML@  H;@
M )2^  "&PP  >,@  &S-  !?T@  5-@  $K=  !!X@  ..<  #/V  (O_P,$
M*O\)!B;_$ <B_Q4('_\:"1S_( H8_R8*%?\M"A+_-0H._SX)"O](" ;_5 @#
M_V(' /]Q!@#_@ 4 _XT% /^:! #_G00 _YT$ /^=! #_G02DN   E[X  (G#
M  ![R0  ;LX  &'4  !5V@  2M\  $#C   WZ   +^X  2KZ  (E_P $(?\
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MMS^*5\@_B%?<0(=7[D"&5_I AE?_0(57_S^%5_\_A5?_/X57_S__2  %_U@
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M3W!@YTYP8/5,<&#_2W!@_TMP8/]+<&#_2W!@_TO_4P "]&$  -QK  #1<@
MR7<  ,%Y  "Y>@D L'P> *E]+02B>SD,G'E"%95U22"/<D\JBF]5,X1K6CM_
M:%]">V9E2'=D:TQT8W-/<F-\4'!CA5%O8Y!2;6.<4FMCJ5)I8[E2:&+-4V=C
MY%)H8_10:&/^3VAC_TYH8_].:&/_3FAC_T[_5@ !ZV,  -EN  #.=0  Q7H
M +U]  "T?08 K( ; *:!*P.??S<*F'U $Y)Z2!V,=TXGAG13,8!Q6#I[;5U!
M=6MB2'%H:$YM9V]2:F9X5&AF@55F9HQ69&:95F-FIE9A9K968&;*5E]FX55@
M9O)38&;]4F%F_U%A9O]186;_46%F_U'_60 !XV8  -9Q  #+>0  PGX  +F
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M5%-O_U-3;_]34V__4U-O_U/V8   W&X  ,]X  #$@   NX4  +*)  "GB0
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M/4*/_CW6=@  R((  +Z-  "UE   K)H  *&>  "4GP  AJ(  '^D"0!ZI1P
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M'SFVEQTXMJ@<.+:[&S>VTQHVM.@:-;/U'#2R_!TTLOP=-++\'32R_!W!C@
MN)D  +"B  "GJ   FZT  (^P  "#LP  =K8  &JZ  !=OP  5<(+ %'#&P!.
MPR8"2<,O!T7#-@Q PST0/,-$%#G#3!8WPU06-L1>%C7$:18TQ'85,\6#$S/%
MDQ(RQ:01,<6W$##%S@\OQ.4/+L+S$2W!^A(MP?H2+<'Z$BW!^A*[F   LZ$
M *NI  "@KP  E+,  (>V  !ZN0  ;KT  &+!  !6Q@  3,L! $/0"0! TA<
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M PCYF0('^:H"!OJ[ 0;ZR0$&^LD!!OK) 0;ZR0&IL   GK8  )&[  "#OP
M=<0  &C(  !<S0  4=(  $;7   \W   ,N   "KD   E[P  (OH  1[_!@,;
M_PT#&/\3!!7_&041_R %#?\G!0G_+P4&_S@$ O]$! #_4 , _UX" /]O @#_
M@ $ _X\! /^< 0#_I@$ _Z8! /^F 0#_I@&AM@  E+L  (;   !XQ0  :LH
M %W0  !1U0  1ML  #O?   RXP  *><  "'J   =]  !&?T  A7_  (3_P #
M#_\%! O_"@0'_Q $ _\6! #_'00 _R4$ /\O P#_.@, _T8" /]4 @#_9 $
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MO".@2<PDGDK?))Q)[R::2?LGF4G_)YA(_RB82/\HF$C_*)A(_RC_.@ '_T@
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M-H-3YS>"4_8W@5/_-H%3_S:!4_\V@5/_-H%3_S;_1P #^50  .!<  #59
MS6<  ,9G  "^9PX MFHA *YI+P:G9SH.H61#&)MA2R&675(IDEM8+X]97S.,
M6&8VBE=M-XA6=#B'5GLXA5:#.816C#F"5I8Y@5:A.G]6K3I^5KP[?%;//'M6
MY3QZ5O0[>E;^.WI6_SIZ5O\Z>E;_.GI6_SK_2@ "\%<  -QA  #1:   R6L
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M161?_T1D7_]$9%__1&1?_T3\5   X&   --K  #(<@  OW8  +9W  "M=P
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M-$2/F3-#CZ@Q0X^Z,$*/T2]!CN<O/XST,3Z+_C,^B_XS/HO^,SZ+_C/0=0
MPX$  +F*  "PD0  II8  )J7  ".F   ?YP  'B= @!RGQ4 ;I\D &F?, 1D
MGS@*7IX_$%B=11=3G$L>3IM0)$F:5BE&F5XL1)EG+4*9<2U!F7TL09F)*D"9
MF"D_F:<G/YFY)CZ9T"4]E^8E/);T)SJ5_BDZE?XI.I7^*3J5_BG*?   OH@
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M"2J^Q0DIO=X(*+ON"2>Z^0LGNOH+)[KZ"R>Z^@NWEP  KZ   *>G  "<K
MD*\  (.R  !VM   :K<  %VZ  !2O@  1L(  #O' P UR@X -,L; #'+)0$O
MRRT#+,PV!2K,/@4IS$<&)\U1!B;-6P4ESF@%),YU!"//A ,BSY4#(,^H A[/
MO@(=T-@"',[K AO,]@,;S/8#&\SV QO,]@.RH   JZ@  *"M  "4L0  A[0
M 'JX  !MN@  8;X  %7"  !*Q@  /\H  #7.   LTP( )-@' "'<$  ?W!L
M'MPD 1S=+@$;W3@!&MY" 1G?30$7WUD!%N!G 13A=@ 3X8< $>*9  [BK0 ,
MX\4 "N/=  GA\0 )X/$ ">#Q  G@\0"MJ   I*X  )BS  "*MP  ?;H  '"]
M  !CP0  5\4  $S)  !!S0  -M(  "W6   EVP  'M\  !KK!@ 8[0\ %NT7
M 1/M'P$1[2<!#NXP 0ON.P$)[T8!!O!3  /Q8@ !\7,  /&$  #QE@  \*D
M /"[  #PTP  \-,  /#3  #PTP"GKP  F[0  (ZX  " O   <\   &7$  !9
MR0  3<T  $+1   WU0  +MH  "7>   >X@  %^4  !3Q   1^@( #?P) 0K\
M$0$'_!<! _P? 0#]* $ _3(! /T^  #]3   _5L  /UM  #\?@  ^X\  /N=
M  #ZK   ^JP  /JL  #ZK ">M0  D;D  (.]  !UP@  9\<  %K,  !.T0
M0M4  #?:   MW@  ).(  !SF   5Z0  #NP   OV   (_@  !?\  0+_ @$
M_P<! /\- 0#_%@$ _QX! /\I 0#_-0  _T,  /]3  #_9   _W0  /^!  #_
MC@  _XX  /^.  #_C@#_ B(._P,@#O\ ( [_ "(-_P M#/\ .0K_ $8(_P!3
M!_\ 7P7_ &H$_P!T _\ ?0+_ (0"_P"* ?\ CP'^ )4!_0": ?L GP#Z *4
M^ "K /< L0#U +H ] #% /( T@#Q .$ \ #M /  ^ #O /\ [@#_ .X _P#N
M /\ [@#_ .X _P#_!B /_P<=#O\$' [_ " -_P K#/\ -PO_ $0)_P!1!_\
M7 ;_ &@%_P!R!/\ >P/^ (("_ "( OH C0'Y ),!^ "8 ?< G0'U *, ] "I
M /( L #Q +@ [P## .X T #M -\ [ #M .H ]P#I /\ Z #_ .<!_P'G ?\!
MYP'_ ><!_P'_"QP/_PL8#O\(%PW_"AX-_PHH#/\)- O_!T *_P5-"/\$60?^
M V0%^P)O!/D#> /W!'\#]0:% O,'BP+R!Y$!\0>6 ? 'FP'O!J$![@:G .T&
MK@#L!K< Z@;! .D&S@#G!]X Y ?L .()]P#@"O\!WPO_ MT-_P+<#?\"W W_
M MP-_P+_$!<._Q$4#?\.$PW_%1L,_Q8E#/\4, S_$CT+_A!)"?D.5@?V#6$&
M\PUK!? -= 3N#GP#[!"# NL1B0+I$8X"Z!&4 ><1F0'F$9\!Y1&E >,2K0'B
M$K4 X1+  . 2S0#>$]T VA3K =@5]@+5%_\#TQC_!-(7_P31%_\%T1?_!=$7
M_P7_%10._Q</#/\:$ O_'QD+_R B"_\?+ O\'#@+_^)]$$E#0U]04D]&24Q%
M  D5]AI%"O 940CL&%T&Z1AG!><9<03D&7D#XAJ  ^$;A@+?&XP"WAN2 MP<
MEP+;')T!VARD =D<JP'7';0!U1V_ =0>S '2'MP!SQ_J \LA]@7)(?\&R"'_
M!\<@_PC&(/\(QB#_",8@_PC_&@X-_QP("_\D# G_*14)_RH>"?TH* KS)3,+
M[",_"N8B3 CB(E@'WR)C!=PC;039)'4$UR1] ]4E@P/4)8D#TB:. ]$FE 3/
M)YH$SB>A!,PHJ 3+*+ $R2B[!,@IQP3&*=<%PRKG!L J] B^*OX*O"G_"[LI
M_PNZ*?\,NBG_#+HI_PS_'PD+_R0#"/\O"@?_,Q$&_S09!O0Q(@?J+BT)XBLY
M"=PJ1@C8*U,'TRU>!] N: ?-+G 'RR]X!\DO?@?(,(0(QC"*",4PD C#,98(
MPC&=", QI B_,:P(O3*V"+PRPPFZ,M()N#+C"K4R\0RS,OP.L3'_#[ Q_Q"P
M,?\0L#'_$+ Q_Q#_)00)_R\"!O\X!P3_/ T#^3P4 NPZ' /A-28%V3,S!](T
M00G,-4T+R#98#,4V8@S"-VL,P#=R#+XX>0V\.( -NSB%#;DXBPVX.)(-MSF8
M#;4YH VT.:@.LCFR#K$YO@ZO.<X.K3G@#ZLY[Q&I.?H3ISG_%*4Y_Q6E.?\5
MI3G_%:4Y_Q7_*P '_S< !/\_! +Z0P< \4(, .,_% #9/1\!SSXN!L@]/ O"
M/4@/OCU2$;H]7!*X/F42M3YM$K0^=!*R/GH2L#Z!$J\^AQ*N/XT3K#^4$ZL_
MFQ.I/Z03J#^N%*8_NA2E/\D4HT#;%:% [!>>/_@8G3__&9P__QJ</_\:G#__
M&IP__QK_,  &_SX  OI%  #J1P  W48# -E#" #01AH QT@J!+]'-PNY14(1
MM$1-%;%#5A>N0U\8K$-G&*I$;QBH1'48IT1\&*5$@ABD1(@8HD2/&:%$EQF?
M1: 9GD6J&IQ%M1J;1<0;F476&Y=$Z1R61/8>E$3_'I-$_Q^30_\?DT/_'Y-#
M_Q__-P $_T,  >U)  #=3@  UE   -%-! #(3A8 OU$G KA/- FQ33X1K$M(
M%ZA)41NE25H<HTEB':%):1Z?27 >G4EW'IQ)?1Z:280>F4F+'YA)DQ^629P?
ME4FF()-)L2"22< AD$G2(8Y)YB*-2/0CC$C^(XM(_R2+2/\DBTC_)(M(_R3_
M/  "^D<  .).  #850  SU<  ,E5 0#"51$ N5@C ;)7, >K5#L/IE%$%Z%/
M31R=3E4@FTU=(IA-9".73&LCE4QR))1,>2223'\DD4R')(],CR6.3)@EC$RB
M)HM,KB:)3+PGB$S.)X9,XRB%3/,HA$S]*(-,_RB#2_\H@TO_*(-+_RC_0  !
M\$L  -U4  #36P  REX  ,-<  "\6PT M%T@ *Q=+@6F6SD-H%A"%9M521R7
M4U$BDU%8)9%17R>/4&8HC5!M*8Q/="F*3WLJB4^#*H=/BRJ&4)0KA%"?*X-/
MJBR!3[@M@$_*+7Y/X"Y]3_$N?4_\+7Q/_RU\3_\M?$__+7Q/_RW_1  !YDX
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M52Q\6UHQ>5E@-'989S9T6&\X<EAW.7!8@#EO6(HZ;5B5.FM8H3MI6*\[:%C
M/&98UCQF6.L[9ECX.F98_SEF6/\X9EC_.&98_SCP30  W5L  ,]E  #$:P
MNV\  +-O  "J;0  HFX3 )QO(P"6;R\%D&TY#(IJ012%9T<<@&1-)'MB4BMV
M7U<Q<EU=-6]<8SEL6VL[:EMS/6A;?#YF6X8^95N1/V-;GC]A6ZP_8%N]0%Y:
MTT!?6^@^7UOV/5]:_SQ?6O\[7UK_.U]:_SOI4   VE\  ,QH  #";P  N'(
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M0$QG_3],9O\_3&;_/TQF_S_?70  SVH  ,-S  "Y>0  L'T  *1]  "9?
MD7X# (I_%@"%@"0 @'\P!'M^.0IU?4 2;WM&&6IY2R%D=U I7G54,%ES63=4
M<5\]4'!G0$UP<4),;WQ!2W"(0$IPEC]*<*4^27"V/4APRSQ(;^,\1V[R/$=M
M_#U';?\]1VW_/4=M_SW;8P  RV\  +]W  "V?@  K($  *""  "4@0  BX,
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M*3J&_BG*=   OG\  +2(  "KC@  GH\  ).0  "'D0  >94  '"7  !IF T
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M#C"KC TOJYP,+ZNM"RVJP0HLJMH**ZCL"RJG]PPJIOL-*J;[#2JF^PVYC0
ML)8  *B=  "<GP  D*$  (2D  !YJ   ;:H  &"M  !3L   2+,  #^U"P \
MMAD .K8D #>V+0(TMC0$,;8\!B^V1 @MMDP(++=5""NW8 @JMVL'*;=X!BBW
MAP8FMY8%);>H!".WO00BM]4#(;7I!""T]04@L_D&(+/Y!B"S^0:SE@  K)X
M *2D  "7I@  BZH  '^M  !SL   9K(  %FT  !-MP  0;L  #:^   MP@8
M*L,3 "C$'@ FQ"< ),0P 2/%. (AQ4$"(,5+ A[&5@$=QF$!',9O 1K'?@ 9
MQXX %\>@ !7'M  3Q\T $\7E !/$\P 2P_@!$L/X 1+#^ &OG@  J*8  )VK
M  "1K@  A+$  ':T  !IM@  7;D  %&\  !%OP  .L(  "_&   GRP  'L\"
M !?2!P 3U!  $=0; !#4)  .U2X #-4Y  O510 *UE$ "=9?  ?6;@ %UG\
M!-:1  +6I   UK@  -?/  #6X@  UNH  -;J  #6Z@"JI@  H*P  )6P  "'
MM   >K<  &RY  !?O   4\   $C#   \QP  ,<L  "C/   @TP  &-8  !':
M   )W0$ !>,(  /B$@ !X1L  .$E  #A,0  XST  .1,  #E6P  Y6P  .9]
M  #FCP  YJ$  .>R  #GPP  Y\T  .?-  #GS0"DK0  F+(  (NU  !]N0
M;[P  &+   !5Q   2<@  #W,   RT   *-,  "#8   8W   $=\   KA   #
MY    .T   #P @  [PH  .X3  #N'0  [B@  .XU  #P10  \E8  /-G  #T
M>0  ](H  /69  #UI@  ]:P  /6L  #UK ";LP  CK<  (&[  !ROP  9,,
M %?'  !+S   /M   #/5   IV0  ']T  !?A   0Y   ".<   +I    Z@
M /,   #[    ^@   /D!  #Y"0  ^10  /D?  #Z+   _#T  /Y.  #_80
M_W(  /^   #_C   _Y$  /^1  #_D0#_ !\,_P =#/\ ' O_ !\*_P K"/\
M. ;_ $4$_P!2 _\ 70+_ &<!_P!Q ?\ >0#] (  ^@"& /@ C #V )$ ]0"6
M /, FP#R *  \0"F /  K #P +, [P"\ .X R0#M -@ [0#G .T \0#L /H
M[ #_ .L _P#J /\ Z@#_ .H _P#_ !P,_P 9#/\ &0O_ !X*_P H"/\ -0?_
M $(%_P!/ _\ 6@+_ &4!_0!N ?H =P#X 'X ]0"$ /, B@#Q (\ [P"4 .T
MF0#L )X [ "D .L J@#J +$ Z0"[ .@ QP#G -4 Y@#D .8 \ #E /D Y0#_
M .0 _P#B /\ X@#_ .( _P#_!!@,_P,4#/\ % O_ !P*_P E"/\ ,@?_ #\%
M_P!+!/\ 5P+Z &$!]P!K ?0 = #R 'L [P"" .T AP#K (T Z0"2 .< EP#F
M )P Y0"B .0 J #C +  X@"Y .  Q0#@ -, WP#B -X [P#= /D V@#_ -@
M_P#8 /\ V #_ -@ _P#_"10,_P@0"_\&$0K_"QH)_PPB"/\(+@?_!3L&^P-'
M!/8!4P+Q UX![@-H >P#<0#I W@ Z -_ .4#A0#C XH X0*/ -\"E0#> IH
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M/UP0IS]D$*4_:Q"C/W$1HC]W$: _?A&?/X01G3^+$9Q DA&:0)H2F4"D$IA
MKQ*60+T3E4#.$Y,_X121/_$6D#_\%H\__Q>./O\7CC[_%XX^_Q?_,@ "]3P
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M)'I+UR5Y2^HE>$OX)7=*_R5W2O\D=TK_)'=*_R3V/P  X$P  --7  #(70
MOU\  +==  "O6@0 J%L7 *%<)@*;6S('EE@[#I!50Q6,4TH;B%%1'X905R*#
M3UXD@4YD)8!.:R5^3G(F?4YZ)GM.@B=Z3HLG>$Z6*'9.H2EU3J\I<TZ_*G).
MTRIQ3N@J<$[V*7!._REP3?\H<$W_*'!-_RCM0@  W5$  ,];  #$80  NV,
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M-5I7_#1;5O\S6U;_,UM6_S/C3P  TUT  ,9F  "\;   LFX  *AL  ">:@
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M,T-I_S/48@  Q6T  +IU  "Q>P  I'L  )AZ  ",>@  A'P  'U]"0!X?AH
M='\G 6]^,01J?CD*97Q $%][11=:>DH=57A/)%!W5"I,=5LO275B,49T;#)%
M='8R1'2#,41TD"]#=)\N0G2O+4)TPRQ!=-LK0'+M+3]Q^"X_</\N/W#_+C]P
M_R[/9P  P7(  +=Z  "L?@  GWX  )1_  "'?P  ?H$  '># P!QA!0 ;84B
M &F%+@-DA38'7X0]#5J"0Q-5@4@94(!-'TQ_4R1(?EDH17UA*T-]:RM"?78J
M07V"*4!]CRA ?9XF/WVN)3Y]PB0^?-HC/'OM)3MY^"8[>/\G.WC_)SMX_R?*
M;0  O7<  +-_  "G@@  FX,  (^#  "#A0  =X<  '")  !JBPT 9HP= &*,
M*0%>C#(%68LZ"52*0 ]0B4852XA+&D>'41Y#AU@A089@(S^&:2,^AG0B/8:!
M(3R&CB \AIT>.X:M'3J&P1PZA=D;.(3L'3>"]QXW@?X?-X'^'S>!_A_$=
MN7X  +"&  "BAP  EH<  (N(  " B@  <XX  &F0  !BD@8 79,6 %J4(P!6
ME"X"4I,V!DZ3/0M)DD,/19%)%$&13Q<^D%8:/)!>&SJ0:!HYD',:.9!_&#B0
MC!<WD)L6-I"L%36/OQ0UC]@3-(WK%#.,]A8RB_T7,HO]%S*+_1>_>P  M84
M *N+  "=BP  DHP  (>.  !\D0  <)0  &27  !9F@  4YP- %"<' !-G"<
M2IPP T:<. 9"FSX*/IM%#CN;3! XFE,2-II<$C6:91(TFG 1,YI]$#*:B@\Q
MFID.,9JJ#3"9O0PNF=4++I?J#"V6]0TLE?T.+)7]#BR5_0ZZ@P  L(P  *60
M  "8D   C9(  (*5  !WF   :YL  %^?  !4H@  2:0" $2E$0!!IAX /Z8H
M #RF,0,XIC@%-:8_!S.E1@DPI4X*+Z57"BZE80HMIFP)+*9Y""NFA@<JII4'
M**6F!B>EN04FI-$%):/G!22A\P8CH/L'(Z#[!R.@^P>TBP  K)0  *"5  "4
ME@  B)D  'V=  !RH   9J0  %JG  !.J@  0ZP  #BO P RL!$ ,+ < "^Q
M)@ ML2\!*K$V BBQ/@,FL4<#);%0 R2Q6@,BL64#(;%R B"Q@ (?L8\!';&A
M 1NQM $:L,L &:_C !FN\0$8K?D"&*WY ABM^0*PE   J)L  )N<  "/G@
M@Z(  'BF  !MJ@  8:T  %6O  !)L@  /+0  #&W   HN@  (+P* !Z]%@ <
MO2  &[TI !F],@ 8OCL %[Y$ !6^3P 4OEH $K]G !"_=@ -OX8 "[Z8  F^
MJ@ 'O;\ !KS7  :\Z0 &N_, !KOS  :[\P"KG0  HZ(  ):D  "*IP  ?ZP
M '.P  !FL@  6;0  $VV  !!N0  -;P  "J_   AP@  &<8  !'( @ (RPD
M!LL4  7,'@ $S"@  LPS  ',/@  S$H  ,U7  #-9@  S78  ,V(  #-F@
MS*X  ,S"  #+U@  R^4  ,OE  #+Y0"HI0  G:H  )&M  "$L   =[,  &FV
M  !<N   4+L  $2^   XP0  +<0  "/(   :S   $L\   K1   #U    -4$
M  #6#0  UQ<  -@A  #:*P  VS<  -Q$  #>4P  WF,  -]U  #?AP  X)H
M -^L  #?NP  W\L  -_+  #?RP"AJP  E:\  (BS  !ZM@  ;+D  %^\  !2
MOP  1L,  #G&   NR0  (\T  !O2   3U0  "MD   3:    W0   -\   #A
M    X@0  .,-  #E&   YR,  .DO  #K/@  [4X  .]?  #P<@  \(0  /&4
M  #QH@  \:P  /&L  #QK "8L   B[0  'ZX  !PO   8K\  %3#  !(R
M.\L  "_/   DTP  &M@  !+<   )WP   N(   #C    Y0   .<   #I
MZ@   .P   #N @  \ P  /(9  #U)P  ^#<  /M(  #\6@  _6P  /Y\  #_
MB0  _Y,  /^3  #_DP#_ !P*_P 8"?\ %PC_ !T&_P I!?\ -@/_ $,"_P!/
M ?\ 6@#_ &4 ^P!N /< =@#V 'T ]0"# /0 B #S (T \@"1 /$ E@#P )L
M[P"@ .X I@#M *T [0"U .P P #J ,X Z #? .8 [@#F /D Y@#_ .8 _P#F
M /\ Y@#_ .8 _P#_ !@*_P 5"?\ $PC_ !L'_P F!?\ ,P/_ $ "_P!, ?X
M5P#Y &( ]0!K /( <P#P 'H [P"  .T A0#L (H ZP"/ .H E #I )D Z ">
M .< I #F *L Y0"S .0 O0#B ,P X #< -\ ZP#> /4 W@#] -X _P#= /\
MW0#_ -T _P#_ !0*_P 1"?\ $0C_ !@'_P C!?\ +P/_ #T"_@!( ?@ 5 #R
M %\ [@!H .L < #I '< YP!] .8 @P#E (@ Y ", ., D0#A )8 X "< -\
MH@#> *D W "Q -L NP#9 ,D U@#: -4 YP#5 /, U #[ -, _P#3 /\ TP#_
M -, _P#_ A *_P *"/\ #0?_ Q<&_P$@!?\ *P/^ #@"]@!$ ?  4 #J %L
MY0!D ., ;0#A '0 WP!Z -T @ #< (4 VP"* -D CP#8 )0 U@"9 -4 H #4
M *< T@"O -  N0#. ,< S0#6 ,P Y@#* /$ R0#[ ,@ _P#' /\ QP#_ ,<
M_P#_!@@)_P,"!_\*"0;_#1(%_PT=!/T()P/T!#,![0)  .<!3 #@ %8 W %@
M -H!:0#8 G  U0)W -,#?0#2 X( T .' ,\#C #. Y$ S 27 ,L$G@#)!*4
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MM &O(L$!KB/1 :LCXP*I(_(#IR/\ Z4D_P2E)/\$I"3_!*0D_P3_%P $_R(
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M#8XZV0V,.NL/BSKX#XHY_Q").?\0B3G_$(DY_Q#_+0  Z#8  -M   #01@
MQT8  ,!"  "Z/PP LD(> *Q"+ 2F03<(H4!!#)X_2PV;/U,.F3]:#Y<_80^5
M/V@/E#]N#Y(_= ^1/WL/D#^!$(X_B1"-/Y$0BS^;$8H_I1&(/[(2AS_!$H4_
MU1.$/^D4@C_V%($^_Q2!/O\4@3[_%($^_Q3X,0  XSX  -5(  #*3@  P4\
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M(FI)_"%J2?\A:DG_(&I)_R#F00  UE   ,E9  "^7@  M%X  *I;  "C5P
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M+5!5_RW:4P  RF   +YG  "R:P  IFH  )QI  "29@  BV<  (5H$0" :A\
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M+D1HC"Q#:)HK0FBJ*D%HO2E!:-,H0&?I*3]F]2H_9?XJ/V3_*C]D_RK.80
MP&P  +5S  "G=   FW0  )!S  "$<P  ?'4  '9V P!P>!, ;'D@ &AY*P)C
M>#0&7W<["UIV01%5=4874'-+'$QR42%(<5<F17!?*$-P:"E!<'(I07!^)T!P
MBR8_<)DE/W"I)#YPO",]<-,B/&[H(SMM]20[;/TE.FS_)3IL_R7)9P  O'$
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M#C&+N TPBL\,+XGE#"Z'\PXMAOP/+8;]#RV&_0^Z>@  L(,  *&#  "5A
MBH4  '^&  !UB0  :8T  %Z0  !4DP  2Y8& $>7%0!$ER$ 0I<J 3^7,@,[
MECD%.)9 "#661PHSED\+,997"S"580LOE6L++I5W"BV5A0DLE9,(*Y6C!RJ5
MM08HE,P&*)/C!B>1\@<FD/L()I#\"2:0_ FU@@  JH@  )R(  "0B0  A8H
M 'N-  !PD   9)0  %B7  !.FP  1)X  #N@"0 WH!< -:$A #.A*@ QH3("
M+Z Z RR@000JH$H%*:!2!2>@7 4FH&<$):!S!"2@@ ,CH(\"(:"? B"?L0$>
MG\<!'9[@ 1V<[P(<F_D#')K[ QR:^P.PB@  HXT  )>-  ",CP  @9$  ':5
M  !KF   7YP  %2@  !)HP  /J8  #.H   JJ@D )ZL5 "6K'P CJR@ (JLP
M ""K.  >JT$!':M* 1RL5  :K%\ &:QK !>L>0 5JX@ $ZN9 !&KJP /JL$
M#:G9  ZH[  .I_8 #J?X  ZG^ "LDP  GI,  ).3  "'E@  ?)H  '&>  !E
MH@  6J4  $^I  !$K   .*\  "VP   CLP  &K4# !2V#0 2MQ@ $+<A  ZW
M*@ ,MS, "[<]  FW1P (MU( !K=?  2W;0 "MWT  +:.  "VH   M;,  +3)
M  "TW   L^H  +/M  "S[0"FF0  FID  (V;  ""GP  =Z0  &RH  !@K
M5;   $FR   ]M   ,;8  ":Y   =NP  %+T   N_   #P0@  ,(2  #"&P
MPR4  ,,N  ##.0  PT0  ,10  #$7@  Q&\  ,2   #$D@  Q*4  ,.X  ##
MRP  PMP  ,+@  #"X "BH   E:$  (FE  !^J@  <Z\  &:R  !9M   3+<
M #^Y   SO   *+X  ![!   5Q   #,<   3)    RP   ,T"  #."@  SQ0
M - =  #1)P  TC(  -,^  #53   UEP  -9O  #6@@  UI4  -:G  #6MP
MUL8  -;*  #6R@"=J   D:P  (6P  !WLP  :;8  %RX  !/NP  0KX  #7!
M   JQ   '\<  !;+   ,SP  !=(   #3    U0   -@   #9    VP$  -T*
M  #?%   X1\  .,K  #E.   Z$<  .I8  #J;   ZH$  .J4  #JHP  ZK
M .JS  #JLP"5K@  B;(  'NU  !MN   7[P  %'   !$PP  -\<  "O*   @
MS0  %=$   S6   $V@   -T   #=    WP   .$   #C    Y0   .<   #I
M    [ D  .\6  #R(P  ]#(  /="  #Z5   ^V8  /MY  #[B0  ^Y8  /N9
M  #[F0#_ !8(_P 3!_\ $P7_ !L$_P G O\ ,P'_ $  _P!- /P 6 #Y &(
M]P!K /8 <@#T 'D \P!^ /( @P#Q (@ \ ", .\ D0#N )8 [0"; .L H #I
M *< YP"N .8 N0#E ,8 Y #6 ., Z #C /8 XP#_ .( _P#B /\ X0#_ .$
M_P#_ !,(_P .!_\ #07_ !@$_P D O\ , '_ #T ^P!) /8 50#S %\ \0!H
M .\ ;P#M '8 [ !\ .L @0#J (8 Z0"* .@ C@#G ), Y0"8 ., G@#A *4
MWP"L -X M@#< ,( VP#3 -L Y@#: /, V0#] -@ _P#8 /\ V #_ -@ _P#_
M ! (_P +!_\ #07_ !<$_P @ O\ + '\ #D ] !& .\ 40#L %L Z0!D .<
M; #E ', Y !Y .( ?@#A (, X "' -X C #= )$ VP"6 -D G #6 *( U0"J
M -0 LP#2 +\ T0#0 -  X@#/ /  S@#X ,T _P#, /\ S #_ ,P _P#_  D(
M_P $!O\ "@7_ !0#_P > O\ * #T #4 Z@!! .8 30#C %< X !@ -X : #<
M &\ V@!U -@ >P#6 (  U0"$ -, B0#1 (X SP"3 ,X F0#, *  RP"H ,D
ML0#( +T Q@#- ,4 W@#$ .P PP#V ,( _0#! /\ P0#_ ,$ _P#_  ('_P
M!?\#!@3_! \"_P 9 ?@ (P#K "\ X@ \ -T 2 #: %, U@!< -, 9 #1 &L
MSP!R ,T =P#+ 'P R0"! ,@ A@#& (L Q0"1 ,, EP#" )X P "F +\ KP"]
M +L O #* +L VP"Y .H N #V +8!_@"V O\ M0+_ +4"_P#_ P %_P<  _\-
M 0+_#0D!^0D3 .T#' #? "@ V0 V -, 0@#/ DX RP-7 ,@$8 #&!&< Q 5N
M ,(&= # !GD OP=^ +X'@P"\!XD NPB. +D(E0"X")P M@FE +4)KP"S"KL
ML@K* +$+W "N#NX K _Z *L0_P"J$?\ J1'_ *D1_P#_"  $_Q(  OT6  #R
M%0$ [! ) .,($P#7!B  T DO ,H-/ #%$4@ P1)2 +X46P"[%&, N15J +@5
M< "V%G8 M19[ +,6@ "R%X8 L1>, *\7D@"N&)H K!BB *L9K "I&;D J!G(
M *8:VP"D&^P HASX :$<_P&@&_\!H!O_ : ;_P'_$0 "_QL  .L=  #A'@
MVAL! -43" #-%!D Q1DI +\=-P"Z'T, MB!. +,A5P"Q(5X KR)E *TB; "L
M(G( JB-W *DC?0"H(X, IR.) *4CCP"D))< HB2@ *$DJ@&?);8!GB7% 9PE
MUP&:)>D"F"7V Y<E_P.6)?\#EB7_ Y8E_P/_&@ !\"(  .$I  #8+0  T"L
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M#GTY_ Y\.?\.?#G_#GPY_P[K+@  W3T  ,]&  #$2@  N4@  +%$  "K0 ,
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M,05O7#@*:EH^$&981!5A5TD:7E5.'EI45")74ULE55-B)U-3:RA24W4I4%.
M*4]3C"E.4YDI35.H*4M3N2E*4L\I2E+F*$M2]"9+4?PE2U'_)4M1_R734P
MQ%X  +=D  "I9   G6,  )-B  "+7P  @V$  'UB"@!Y8QD =&,E 7!B+@1K
M838(9F \#F)>0A-=7$<965M-'E594B)26%@F3UA@*4U7:"I+5W(K2E=^*DE7
MBBI(6)<I1UBG*497N"A%5\XH15?D)T56\R=%5OPF157_)455_R7/5P  P6(
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M&SILM1LY;,L:.&OB&C=I\1LV:/H<-F?_'#9G_QS#9@  MV\  *=P  ":<
MCG   (1P  !X<0  ;G0  &=V  !A=P8 7'D5 %EY(0!6>2L!4GDS!4YX.@E+
M>$ -1G=%$4-V2Q4_=5(8/'59&3MU8AHY=6T9.75X&#AUA1<W=),6-G2C%39T
MM!0U=,H3-'/A$S-Q\14R</H6,F_^%C)O_A:_:P  LG,  *)S  "5=   BG0
M (!U  !U=P  :GD  &%\  !:?@  5( / %& ' !/@2< 3($O DB -P9$@#T)
M07]##3U^21 Z?E 2.'Y8$S9]81,U?6L2-'UW$3-]A! R?9(/,GVA#C%\LPTP
M?,@-,'O@#"]Z\ XN>?D/+7C^$"UX_A"Z<@  K'<  )UW  "1>   AG@  'QZ
M  !Q?   97\  %R"  !3A0  3(<' $B(%0!&B2$ 0XDJ 4"),@,]B#D%.HA
M"#>(1@HTATX,,H=6##&'7PPPAVD++X=U"RZ'@@HMAY )+(:?""N&L0<JA<8'
M*87?!BB#[P@H@OD))X']"B>!_0JU>   IGL  )A\  ",?   @GT  'A_  !M
M@@  888  %B)  !.C   1(\  #Z1#  [D1D .9(D #:2+ $TD30",9$[!"^1
M0@4MD4H&*Y%2!BJ16P8ID68%)Y%R!2:1?P0ED(T#))"< R*0K@(AC\,"(([;
M A^-[0,?C/<$'XO\!!^+_ 2P@   H(   ).   "(@0  ?H,  '.&  !IB0
M78T  %*0  !)DP  /I8  #29 P NFP\ +)L: "J;)  HFRP )YLT 26;/ $C
MFT0!(9M- 2";5@$?FV$!'9MM 1R;>@ :FX@ &)J8 !>9J@ 5F;X $YC6 !27
MZ@ 4EO4 %)7Z 125^@&IA0  FH4  (Z&  "$AP  >8H  &Z-  !CD0  690
M $V8  !#G   .)\  "ZA   DI $ ':4, !NF%P 9IB  &*8I !:F,0 5ICH
M$Z9# !*F30 0IE< #:9D  NF<0 )I8  !Z60  6DH@ #H[4  J+*  .BWP #
MH>P !*'R  2A\@"BB@  E8L  (J,  !_C@  =)(  &F6  !>F@  4YX  $BB
M   ]I0  ,J@  "BJ   ?K   %JX   RP!P &L!( !; ;  .Q)  "L2T  +$W
M  "Q00  L$L  +!8  "P90  L'4  +"%  "OEP  KJD  *Z^  "MTP  K.,
M *SI  "LZ0"<D   D9$  (63  !ZEP  ;YL  &2@  !9I   3J@  $.L   W
MKP  ++$  "*S   8M0  $+<   :X    N@8  +H.  "[&   NR   +PI  "\
M,P  O#X  +U)  "]5P  OF8  +YX  "]B0  O9P  +RP  "[PP  N]0  +K>
M  "ZW@"8EP  C)D  (&=  !VH@  :J<  %^K  !4KP  2+(  #NU   OMP
M)+D  !J\   0O@  ",    #!    PP   ,0!  #%"0  QQ(  ,@;  #))0
MRB\  ,LZ  #-1@  SE8  ,]G  #/>@  SXT  ,^?  #/L   S[\  ,[)  #.
MR0"4GP  B*,  'VH  !RK@  9K(  %BT  !+MP  /KH  #&]   FOP  &L(
M !'%   (R    ,H   #,    S@   -    #1    TP   -4'  #8$@  VAT
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M '4 \0!Z /  ?P#O (, [0"( .L C #I )$ Z "6 .< G #F *( Y "J .,
ML@#B +\ X0#0 -\ X@#> /( W0#^ -T _P#= /\ W0#_ -T _P#_  T&_P *
M!?\ # /_ !4!_P @ /\ +0#Z #L ]@!' /0 4@#Q %L [P!D .T :P#K '(
MZ0!W .@ ? #F ($ Y "% .( B@#@ (X WP"3 -X F0#= *  VP"G -H L #8
M +P U@#+ -0 W@#3 .\ T@#[ -( _P#2 /\ T@#_ -( _P#_  D&_P %!/\
M"@/_ !0!_P = /L *0#R #< [P!# .P 3@#I %@ Y@!@ .0 : #B &\ WP!T
M -T >0#; 'X V0"# -@ AP#6 (P U0"1 -, E@#2 )T T "D ,X K0#- +@
MRP#' ,D V@#( .P QP#X ,8 _P#' /\ QP#_ ,< _P#_  (&_P  !/\ !P+_
M !$!_P 9 /( )0#J #$ Y@ ^ .( 20#? %0 W !< -D 9 #5 &L TP!Q -$
M=@#/ 'L S@!_ ,P A #+ (D R@". ,@ E #& )H Q0"B ,, JP#! +4 OP##
M +X U@"] .@ O #T +L ^P"[ /\ NP#_ +L _P#_   %_P   _\  P'_  P
M^0 3 .< '@#A "P W  Y -@ 10#3 $\ T !8 ,P 8 #* &< R !M ,8 <P#$
M '@ PP!\ ,$ @0#  (8 OP"+ +T D0"[ )@ N@"? +@ J "V +, M0#! +,
MT@"R ., L0#P +  ^0"P /X KP#_ *\ _P#_   #_P   ?\#  #Y  4 \  +
M -\ %P#8 "4 T0 S ,P /P#( $H Q !3 ,$ 6P"_ &, O0!I +L ;P"Z '0
MN !Y +< ?@"V (, M "( +, C@"Q )4 KP"= *X IP"L +$ JP&_ *D"T "H
M ^( IP3P *4&^@"D!O\ HP?_ *,'_P#_ 0 "_PD  /$*  #E!P  W@$" -8
M#P#/ !X R $K ,($.0"^!D0 N@=. +<(5P"U"5X LPIE +$*:P"P"W  K@MV
M *T+>P"L#(  JPR& *D-C "H#90 I@Z< *4.I@"C#[$ HA"_ * 0T0">$N0
MG!/S )L3_0":$_\ FA/_ )H3_P#_"P !\1(  .08  #:&@  TA8  ,P-!0#&
M"A8 OQ E +D4,P"T%3\ L!=) *T74@"K&%D J1A@ *<99@"F&6P I1ER *,:
M=P"B&GT H1J# )\;B0">&Y$ G!N9 )L<HP"9'*X F!R\ )8<S@"5'>$ DQWQ
M )(=_ &1'?\!D1W_ 9$=_P'[%   YQX  -LF  #1*0  QR8  , ?  "\&0\
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M%V!$CAA>1)H8742H&5M$N1E:1,T:64/D&5E#\QA90_P764/_%UE#_Q?610
MQE$  +=4  "I5   GE,  )91  "/3@  B4X  (1/#P!_4!T >U H G9., 9R
M33@*;DL^#FI*1!%G24H49$A0%F)'5AA@1UT97D=D&EU';1I;1W8;6D> '%A(
MBQQ72)@<54>F'51'MQU31\L=4D?B'5)&\AM21OL:4T;_&E-&_QK22@  PU4
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M(4)4LB!!4\8@0%/>'T!2[Q] 4OD>0%'_'D!1_Q[(5P  NE\  *I?  "<7P
MD5\  (A>  !_7   >%X  '%?  !L80\ 9V$< &1B)@%@82\$7& V"%=?/ Q3
M7D$13UQ'%DQ;3!I(6E,=15E:($-98B%"66PA05EW(4!9A" _6I$?/EJ@'CU:
ML1T\6<4=.UG='#M8[AT[5_D=.U;_'3M6_QW%6P  MF(  *9B  "98@  CF(
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M#"YM[0XN;/</+6O^$"UK_A"Y:@  J&P  )EL  "-;   @FT  'EN  !L<
M8W,  %MU  !3>   37D( $EZ%0!&>R  1'LI $%[,0(^>C@%.GH^"#=Z10HU
M>DP,,WE4##%Y7 PP>6<,+WER"RYY?PHM>8P)+'B<""MXK @J>,$'*G?9!REU
M[ @H=/<)*'/^"RAS_@NT;P  HG   )1P  "(<   ?G$  '5S  !J=0  7WD
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M  F0]P"??0  D7T  (9^  !]?P  <H(  &>&  !<B@  4HX  $>2   \E0
M,Y<  "F:   ?G   %I\$ !"@#P .H!D #: B  N@*@ *H#, "* \  >@1@ %
MH%$  Z!<  &@:0  GW@  )^(  ">F0  G:L  )O   ":U@  FN0  )KN  ":
M[@"8@P  C(,  (.$  !XAP  ;8H  &*.  !7D@  3)8  $&:   VG@  +*$
M "*C   9I0  $:<   >I!   J@T  *H7  "J(   JR@  *LQ  "K.P  JD4
M *M1  "K7@  JFT  *I]  "JC@  J:$  *BT  "FR@  I=T  *7J  "EZ@"3
MB   B8D  'Z,  !SCP  9Y0  %R8  !1G   1J$  #ND   PJ   )JH  !RL
M   3KP  "K    &R    LP,  +0+  "T%   M1P  +4D  "V+@  MC@  +9#
M  "W4   MU\  +=P  "W@@  MY0  +:G  "UN@  M,P  +3<  "TW "0CP
MA)$  'F5  !NF@  8IX  %>C  !,J   0:P  #6O   JL@  '[0  !6V   *
MN    [D   "[    O    +X   "_!0  P X  ,$7  #"(   Q"D  ,4T  #&
M0   R$\  ,E@  #)<@  R88  ,B9  #(J@  Q[D  ,?)  #'R0"+EP  @)L
M '6@  !II0  7JH  %.O  !'LP  .;8  "VX   AN@  %KT   O    "P@
M ,,   #%    Q@   ,@   #*    RP   ,X'  #/$   TAH  -0D  #7,
MVCT  -U.  #?8   X'0  ."'  #@F0  X*8  -^S  #?LP"'H0  ?*<  '&M
M  !GL@  6;4  $NX   ]NP  +[X  "/!   7Q   #,<   +*    S0   ,X
M  #0    T@   -0   #6    V0   -L   #?    X08  .03  #G'P  Z2P
M .TZ  #P3   \E\  /-S  #TA0  ])(  /2=  #TG0#_  P$_P ) _\ "0'_
M !0 _P A /\ +P#^ #L _ !' /H 4@#W %L ]0!C /( :P#P '$ [0!V .L
M>P#J (  Z0"$ .@ B #G (T Y@"2 .0 EP#C )T X@"E .  K@#> +D VP#(
M -H W0#9 .\ V0#\ -D _P#9 /\ V0#_ -D _P#_  D$_P & _\ "@'_ !,
M_P = /L *P#W #@ ] !# /( 3@#O %@ [ !@ .D : #F &X Y !T .( >0#A
M 'T WP"! -X A@#= (H W "/ -H E #9 )L UP"B -0 JP#2 +4 T #$ ,\
MV #. .L S0#Y ,T _P#, /\ RP#_ ,L _P#_  0$_P   O\ " '_  \ _0 :
M /, )@#O #, ZP _ .D 2@#F %0 X@!= -X 9 #; &L V0!P -@ =0#6 'H
MU !^ -, @P#2 (< T ", ,\ D@#- )@ R@"? ,@ J #& +( Q0#  ,, T@#"
M .8 P@#V +\ _P"^ /\ O0#_ +T _P#_   $_P   O\ !0'_  H \P 5 .L
M(@#F "X X0 [ -T 1@#9 %  U0!9 -( 8 #/ &< S0!M ,P <@#* '< R0![
M ,< ?P#& (0 Q ") ,( CP#! )4 O@"< +T I0"[ *\ N0"\ +@ S0"V .(
MM #Q +( _ "R /\ L@#_ +( _P#_   #_P   ?\   #\  4 Z0 . .( ' #;
M "D U0 V -  00#, $L R0!4 ,8 7 #$ &, P@!I ,  ;@"^ ', O0!W +P
M? "Z ($ N "& +< C "U )( LP"9 +( H@"P *P K@"X *P R0"J -T J0#M
M *D ]P"H /X J #_ *@ _P#_   !_P   /@   #L    X  ' -< %0#0 ",
MR0 P ,4 / #! $8 O@!/ +L 5P"X %X M@!D +4 :@"S &\ L@!T +  >0"O
M 'X K@"# *P B0"K (\ J0"7 *< H "F *H I "V *( Q@"A -D H #I )\
M] "> /L G@#_ )X _P#_    ]    .<"  #> @  U0   ,T #0#% !L P  H
M +L -0"W $  LP!* +$ 4@"N %D K %@ *L!9@"I 6L J )P *<"=0"E GH
MI .  *,#A@"A!(T GP25 )X%G@"<!JD FP:U )D&Q0"8!]@ EPCI )4)]@"4
M"?X E K_ )0*_P#Z P  Z0T  -T5  #2%0  R!   ,(( P"^ 1, MP4A +()
M+P"N"SH J@U$ *@-30"E#E4 HP]; *(080"@$&< GQ!L )T1<@"<$7< FQ%]
M )D2A "8$HL EA*3 )43G0"3$Z< DA.T ) 4Q0"/%-D C17K (P6^ "+%O\
MBQ;_ (H6_P#N#0  X1P  -0C  #&)   O2   +<9  "T$0H KA0; *D7*0"E
M&34 H1H_ )X;2 "<&U  FAM7 )@<70"7'&, E1QH )0<;@"3''0 DAQZ ) =
M@ "/'8@ C1V0 (P=F@"*'J4 B1ZR (<>P@"&']8 A!_I (,?]P&"'_\!@A__
M 8(?_P'I&@  VR<  ,LO  "^+@  M"L  *XG  "J( 0 IA\5 * B(P"<)#
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M!G(SD09Q-)T';S2J!VXSN@AL,\T(:S/C"6HS\@EI,_P):3+_"6DR_PG:-
MRD   +E"  "K0@  HD$  )L^  "5.P  D3@% (PY%0"'.B( @SDL X Y-05]
M.#T&>SA%!W@W2PAW-U$(=3=7"',W70AR-V0)<#=K"6\W<@EM.'L);#B$"FHX
MC@IH.)H+9SBG"V4XMPQD.,H,8CCA#&(W\0QA-_L,83?_#&$W_PS5.@  Q48
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M%T]#L!=.0\,734+;%TU"[19-0?D534'_%4U!_Q7+20  ND\  *I0  "=4
MDU   (M.  "$2P  ?DL  'A,!0!S310 ;TT? &M-*0)G3# %8DHW"5])/0Q;
M2$,/6$=($E9&3A141E464D9<%U%&91A/1FX93D9X&4Q'A!E+1Y 92D>?&4A'
MKAE'1L$91D;9&4=%[!A'1?@71T7_%T=%_Q?(30  MU(  *93  ":4P  D%,
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M%394ZA8V4_86-E+]%S92_Q>_60  K%H  )Q;  "06P  AEL  'U;  !R6@
M:EP  &1>  !>7P0 6F 2 %9A'0!3828!4&$N TQ@-09)7SL*15Y!#4)>1A$_
M74T4/%U4%3I<718X7&86-UUQ%3==?A0V78L3-5V:$S1<JA(T7+T1,US4$3):
MZ1(Q6?43,5C]%#%8_Q2Z70  IUT  )E>  ",7@  @E\  'E?  !L7P  9&(
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M!B%N_@:I:   F6@  (MI  " :0  =VH  &UL  !B;P  6'(  %!T  !(=P
M/WH  #=\!P S?1, ,7T= "]])@ M?BT *WXU 2E^/ (G?D0#)GY, R1^50,C
M?E\"(GUJ B!]=P$??80!'7R3 1Q\I  ;>[8 &7K- !EYY  :>/(!&7?Z AEW
M_0*B;   DVT  (=M  !\;@  <V\  &EQ  !>=   5'@  $M[  !#?@  .8$
M #"#   HA0H )885 ".&'@ BAR8 ((<N !^'-@ =ASX '(=' !J'4  9AUH
M%X=E !6'<@ 4AH  $H:/ !"%H  -A+( #(/(  N"W@ ,@>\ #8#X  V ^P";
M<0  C7$  ()Q  !Y<@  ;W0  &1W  !:>P  3W\  $:"   \A0  ,X@  "J+
M   AC0  &8\* !:0%0 4D!T $Y E !&0+0 0D#8 #I ^  R02  *D%( ")!>
M  :0:P $D'D  H^(  ".F   C:H  (R_  "+U   BN4  (KN  "*\0"5=@
MB'8  'YV  !U>   :GL  %]_  !5@P  2X<  $"*   VC@  +9   ".3   :
ME0  $9<   B9"0 #FA,  9D<  ":)0  FBT  )HV  ":/P  FDH  )I6  ":
M8P  FG$  )F   "8D   EZ(  ):V  "5S   E.   )3K  "3[@"/>P  A'L
M 'M\  !P?P  98,  %J'  !0C   19   #J3   PE@  )ID  !V<   3G@
M"J    *B @  HPH  *,3  "C&P  I",  *0K  "E-   I3\  *5*  "E5P
MI68  *5V  "DAP  HYD  **L  "AP0  H-4  *#D  "?Z0"*@   @8$  ':$
M  !KB   8(P  %61  !*E0  /IH  #2=   IH   'Z,  !6F   +J   !*D
M  "K    K    *T'  "M$   KA@  *\@  "P*   L#(  +$]  "Q2@  LED
M +)I  "R>@  L8P  +"@  "OM   KL@  *W8  "MW@"'AP  ?(D  '&-  !F
MD@  6I<  $^;  !$H   .*4  "ZH   CJP  &:T   ZP   %L@   +0   "U
M    M@   +<   "X 0  N0H  +H2  "[&P  O20  +XN  "_.@  P4D  ,):
M  ##;   PW\  ,*2  #"I   P;0  ,'"  #!QP"#CP  >),  &R8  !AG0
M5J(  $NG   _K   ,[   "BS   =M@  $;@   :Z    O0   +T   "_
MP    ,(   ##    Q0   ,<#  #)"P  RQ4  ,X?  #0*@  TS<  -9(  #9
M6@  V6X  -F"  #:E   V:,  -FN  #9LP!_F0  =)X  &FD  !>J@  4Z\
M $>T   YMP  *[H  !Z\   2OP  !\(   #%    R    ,@   #)    RP
M ,P   #.    T0   -,   #7    V@0  -X/  #B&@  Y2<  .@U  #L1P
M[UH  /!N  #P@0  \)   /";  #PGP#_  @#_P & ?\ !P#_ !( _P ? /\
M+ #] #@ ^@!$ /@ 3@#U %@ \0!@ .X : #L &X Z@!S .D > #H 'P Y@"
M .4 A #D (D XP". .( DP#@ )D W@"@ -L J0#9 +0 V ## -4 U@#5 .T
MU #[ -  _P#. /\ S0#_ ,T _P#_  0"_P   ?\ ! #_  X _0 ; /D * #U
M #4 \@!  .\ 2P#K %4 YP!= .0 9 #B &L X !P -\ =0#= 'D W !] -L
M@@#9 (8 V "+ -8 D #3 )8 T0"> ,\ I@#- +  RP"^ ,H T0#) .< Q0#W
M ,( _P#" /\ P@#_ ,, _P#_   "_P   ?\   #_  D ]0 7 /  (P#L #
MZ  \ ., 1P#@ %$ W !9 -D 80#6 &< U !L -, <0#1 '8 T !Z ,X ?@#-
M (, RP"( ,D C0#' ), Q0": ,, HP#! *T OP"Y +T S "Z .$ N #R +@
M_P"X /\ N #_ +@ _P#_   "_P   /\   #U  0 [  2 .8 'P#@ "L V@ X
M -8 0P#3 $P SP!5 ,P 7 #* &, R !I ,8 ;@#$ '( P@!W ,$ >P#  (
MO@"% +T B@"[ )  N0"7 +< H "U *D LP"V +  Q@"O -L K@#N *X ^P"M
M /\ K0#_ *T _P#_   !_P   /X   #K    X@ , -H &0#2 "8 S0 R ,D
M/@#& $< PP!0 ,  6 "] %X NP!D +D :@"X &X MP!S +4 > "T 'P LP"!
M +$ AP"P (T K@"4 *P G0"I *8 IP"R *8 P0"E -4 I #I *, ]@"C /\
MHP#_ *( _P#_    ^P   .L   #A    U@ & ,P $P#& "  P0 L +X . "Z
M $( MP!+ +0 4P"R %H L !@ *X 90"M &H K !O *H = "I 'D J !^ *8
MA "D (H HP"1 *$ F@"? *0 G@"O )P O0"; -  F@#D )D \0"8 /H F #_
M )@ _P#]    [    .$   #3    R@   ,( "P"\ !D N  E +0 ,0"P #P
MK0!% *H 30"H %4 I@!; *0 80"B &8 H0!K *  < "? '4 G@!Z )P @ ";
M (< F0"/ )@ EP"6 *$ E "M ), NP"2 ,T D #A (\ [P". ?@ C@'] (X!
M_P#Q    XPH  -40  #'#@  O@H  +D" @"T !$ KP > *L *@"G C8 I 1
M *$$2 "?!5  G096 )L'7 ":!V( F =G )<'; "6!W$ E0=W ),'?0"2"(0
MD B, (\)E@"-":  C FL (H*NP")"LT APOB (8,\0"%#?L A W_ (0-_P#I
M#0  VQH  ,D>  "]'0  M!H  *X4  "L"P< IPD7 *(-) "?$#  FQ$Z )D2
M0P"6$TL E!-2 ),36 "1$UT D!-C (X4: "-%&X C!1T (H4>@")%8( AQ6*
M (85E "$%IX @Q:K ($6N@" %\T ?A?B 'T8\@!]&/T ?!C_ 'P8_P#C&@
MTR4  ,$H  "T)P  JR4  *4A  "B&P  GQ80 )H9'@"6&RH DQPU ) </@".
M'48 C!U- (H=4P"('5D AQU? (8=9 "$'FH @QYP ($>=P" 'W\ ?Q^' 'T?
MD0!\'YP >B"H 'D@MP!X(,H =B#@ '4A\ %T(/L!="#_ 7,@_P+=)   RBX
M +HP  "M,   I"X  )XK  ":)@  ER$* )(B&0".)"4 BR4P (@E.0"&)4(
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M!V SL A>,\,(73+9"%PR[ E<,O@)6S+_"5LQ_PG..@  NCX  *H_  ">0
ME3\  (X\  "(.@  @S<  '\W"P![.!D =S@C 70X+ )P-S0$;C<\!FLV0@9I
M-DD'9S9/!V8V50AD-EL(8S9B"&$V:@E@-G()7C=\"5TWA@I;-Y(*6C>?"U@W
MK@M7-\ ,53;6#%4VZPQ5-O<,537^"U4U_PO*/P  MD(  *=#  ";0P  D4,
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M%$%!YQ-!0?430D#\$D) _Q*_20  K$L  )U,  "13   B$P  (!+  !Y2
M<DD  &Q*  !G2@D 8DL6 %]+( !;2RD"5THP!51)-@A02#L+34=!#4M'1Q!(
M1DX21D95%$5&711#1F<50D9Q%4%'?15 1XD5/D>7%#U'IQ0\1[D4.T;/%#M&
MYA0[1?03.T3\$SQ$_Q.[3   J4T  )I.  ".3P  A$\  'Q.  !T2P  ;4T
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M#BQ4_P^O50  G58  )!7  "$6   >E@  '%9  !D60  75P  %9=  !17P
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M B%P= (@<($!'F^/ 1UOH $<;K( &VW( !MLX  ;:_ !&FKY AII_0.>80
MCV$  (-B  !X8P  ;F0  &5E  !::   4FL  $IN  !"<   .7,  #%U   J
M=PL )W@6 "5X'P D>"8 (G@N "%X-@ ?>#X 'GA& !QY3P ;>5@ &7EC !AX
M<  6>'X %'B, !-WG  1=J\ $'7$  YTW  0<^X $7+W !%Q_ "890  BF4
M 'YF  !T9P  :V@  &%J  !7;@  37$  $5T   \=P  ,WD  "M\   B?P0
M&X - !F!%P 8@1\ %H$G !6!+P 3@3< $H$_ !"!20 .@5, #(%>  J!:@ (
M@7@ !H"'  5_EP #?J@  7V]  %\T@ ">^0  GON  -Z]0"2:0  A6H  'IJ
M  !P:P  9VT  %UP  !3=   27@  $![   V?@  +8$  "2$   ;A@  $XD#
M  N*#0 (BA< !XH?  6*)P $BB\  HHX  &*00  BDL  (I6  "*8P  BG$
M (J   ")D   B*(  (>T  "%S   A.$  (/J  "#\ ",;@  @&\  '9O  !M
M<0  8G0  %AX  !.?   0X   #F#   PAP  )XD  !Z,   5C@  #)    .2
M!P  DQ   ),8  "3'P  DR<  )0O  "4.   E$,  )1.  "46P  E&D  )1X
M  "3B0  DIH  )&M  "0P@  C]@  ([G  ".[@"&<P  ?'0  '-U  !H>
M77P  %.   !(A0  /8D  #.-   ID   ()(  !>5   -EP  !9D   ";
MG @  )P0  "<&   G1\  )TF  ">+P  GCD  )]$  "?40  GU\  )]O  "?
M@   GI$  )VD  "=N   F\T  )O=  ";YP"">0  >7H  &Y\  !C@0  6(4
M $V*  !"CP  -Y,  "R6   BF0  &)P   Z>   &H    *,   "E    I@
M *8$  "G"P  J!0  *@;  "I(P  JBP  *LW  "L0P  K%(  *UB  "L=
MJX<  *N:  "JK0  JL   *G0  "IW !_?P  =((  &F&  !>BP  4Y   $>5
M   [F0  ,9T  ":A   ;I   $:<   :I    JP   *T   "N    L    +$
M  "R    LP8  +0.  "U%P  MQ\  +@I  "Y-0  NT(  +Q3  "]90  O7@
M +V+  "[GP  NK$  +G   "YRP![AP  <(L  &20  !9E@  3IL  $*@   V
MI0  *ZD  ""M   5KP  "K(   "U    MP   +@   "Y    NP   +P   "]
M    OP   ,    #"!P  Q!   ,<:  #))0  RS(  ,Y"  #15   TF@  --\
M  #3C@  TYX  -.J  #3LP!WD0  :Y8  &"<  !5H@  2J<  #ZM   RL0
M)[4  !JX   -NP   KT   #     P@   ,(   #$    Q0   ,<   #)
MRP   ,T   #0    TP   -@*  #<%0  X"$  .,O  #G00  Z54  .IJ  #K
M?0  [(T  .R9  #LH #_  ,!_P   /\  P#_ !  _P ; /X * #\ #4 ]P!!
M /0 3 #Q %4 [@!= .P 9 #J &H Z !P .< = #E 'D Y !] .( @0#A (4
MWP"* -T CP#; )8 V0"= -@ I0#5 +  TP"^ -( T0#- .@ R@#[ ,D _P#)
M /\ R0#_ ,H _P#_   !_P   /\   #_  H ^@ 8 /8 ) #Q #$ [0 ] .L
M2 #H %$ Y0!9 .( 80#? &< W0!L -L <0#9 '8 U@!Z -4 ?@#3 (( T@"'
M -  C #/ ), S0": ,L H@#) *P QP"Y ,( RP"_ ., OP#V +\ _P"^ /\
MO@#_ +X _P#_   !_P   /\   #X  8 \@ 4 .L ( #E "T X0 Y -\ 0P#<
M $T V !5 -0 70#1 &, S@!I ,T ;@#+ '( R@!W ,@ >P#' '\ Q0"$ ,0
MB0#" (\ P0"6 +\ GP"\ *D N "U +8 Q0"U -P M #P +0 _@"S /\ LP#_
M +, _P#_    _P   /D   #O  ( YP . -T ' #8 "@ TP T -  /@#- $@
MR0!1 ,8 6 ## %\ P0!E ,  :@"^ &X O0!S +P =P"Z 'P N0"  +< A@"U
M (P LP"3 +$ FP"O *4 K0"P *L OP"J -4 J0#J *D ^ "H /\ J #_ *@
M_P#_    _P   .X   #D    V  * -  %@#* ", Q0 N ,$ .0"_ $, O !,
M +H 4P"W %H M0!@ +, 90"Q &H L !O *X <P"M '@ JP!] *H @@"I (@
MJ "/ *8 F "D *$ HP"L *$ NP"@ ,T GP#C )X ] "> /X G@#_ )X _P#_
M    [P   .,   #7    RP $ ,0 $0"] !T N0 I +8 ,P"S #T L0!& *X
M3@"K %4 J0!; *< 8 "F &4 I0!J *0 ;P"C '0 H0!Y *  ?@"? (4 G@",
M )P E ": )X F0"I )< M@"6 ,@ E0#> )0 [P"3 /H DP#_ )( _P#T
MYP   -8   #(    P    +D "0"S !8 L  B *P +0"I #< I@!! *, 20"A
M %  GP!6 )X 7 "< &$ FP!F )H :@"9 &\ F !U )8 >P"5 ($ E ") )(
MD0"0 )L CP"F (T LP", ,0 BP#9 (D Z@"( /4 B #\ (< _P#K    W 8
M ,H)  "]!P  M 4  +   0"K  \ IP ; *, )@"@ #$ G0 [ )H 0P"9 $L
MEP!1 )4 5P"3 %P D@!A )$ 9@"/ &P C@!Q (T =P", 'X B@"& (D CP"'
M )D A0&D (0!L0"# <( @0/6 ( $Z !_!?0 ?P7[ 'X%_P#C#   T!8  , 7
M  "S%@  JQ0  *8.  "C!@8 H $3 )L$( "7!BL E <U )((/@"0"48 C@E,
M (P*4@"+"E@ B0I= (@*8P"'"F@ A@MN (0+=0"##'P @0R$ ( ,C0!^#9@
M?0VD 'L-L@!Z#<, >0[9 '<0[ !V$/< =A#^ '80_P#<&0  QQ\  +<A  "K
M(0  HA\  )T<  ":%@  F X* ),0&0"/$B4 C!,O (H4.0"(%4$ AA5( (05
M3@"#%50 @199 ( 67P!^%F0 ?19K 'P6<0!Z%WD >1>! '<7BP!U&)8 =!BB
M ',8L !Q&,( <!G7 &\9ZP!N&O@ ;1K_ &T9_P#5(P  P"<  + I  "D*0
MG"<  )8E  "1(0  CQL$ (P:% "(&R  A!PJ ((=- " 'CP ?AY# 'P>2@![
M'E  >1Y5 '<>6P!V'F$ =1]G ',?;@!R'W8 <"!_ &\@B !M(), ;"&@ &HA
MK@!I(<  9R'5 &8AZ0%E(?8!92'^ F4@_P+-*@  N2X  *HO  "?,   EBX
M (\L  "+*0  AR4  (0B#@" (QL ?20F 'HE+P!X)3@ =B4_ '0E1@!S)4P
M<252 &\E5P!N)ET!;"9D 6LF:P%I)G,!:"=\ 68GA@%E)Y$!8RB> F(HK )@
M*+T"7RC3 EXHYP-=)_4#72?] UTG_P3(+P  M#,  *4U  ":-0  D3,  (HR
M  "%+P  @2P  'XJ"0!Z*A< =RLB ',K*P%Q*S,!;RL[ 6TK0@)K*T@":2M.
M F@K5 )F*UH"9"Q@ F,L: -A+' #8"UY UXM@P-=+8\$6RV<!%HMJ@19+;L%
M5RW1!58MY@56+/0&5BS]!E8L_P;#-   L#<  *$Y  "6.0  C3@  (8V  "
M-   ?#(  '@P!0!T,!, <#$> &TQ)P%J,2\"9S$W V4P/0-C,$0$83!*!& P
M4 1>,%8%73!=!5LQ9 5:,6T&6#%V!E<R@095,HP'5#*9!U,RJ =1,KD(4#'.
M"$\QY0A/,?,(3S#\"$\P_PB_.   K#H  )X\  "2/0  B3P  ((Z  !\.0
M=S<  ',U 0!O-0X :S8: &<W) %D-BP"834S!%XU.@5<-4 &6C5&!E@T3 =7
M-%('5359"%0U80A2-6H)435T"5 V?@E.-HH*33:7"DLVI@I*-K<+237-"T@U
MXPM(-/,+2#3["TDT_PJ[.P  J3X  )H_  "/0   AD   '\]  !X/   <SL
M &XZ  !I.PH 93L7 &([( !>.R@"6SHP!%@Y-@55.3P'4SE""%$X2 E/.$\*
M3CA6"TTY7@O_XGT024-#7U!23T9)3$4 "A5+.6<,2CEQ#$DZ? Q'.H@,1CJ5
M#40ZI U#.K4-0CG+#4(YX@U"./(-0CC[#4(W_PRW/P  I4$  )="  ",0P
M@D,  'M!  !U/P  ;SX  &D_  !D/P< 8$ 3 %Q '0!90"8!5C\M U(^,P5/
M/3D'33T_"4L]10M)/4P,1SU3#48]6PY$/60.0SYN#D(^>@Y /H8//SZ4#SX^
MHPX]/K0./#W)#CL]X X[//$./#SZ#CP[_PZS0@  HD0  )1%  ")1@  ?T8
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M"2Q-W@DL2^\+*TKX#"M)_PVH2@  F$P  (M-  " 3@  =D\  &U/  !D3P
M6U   %12  !/4P  2E0$ $95$ !#51H 054B #Y5*@$[53 #.%4W!355/0<S
M5$0),51+"C!45 HN5%T*+55H"2Q5= DL58$(*U6/!RI4GP<I5+ &*%/%!BA3
MW08G4>X()E#X"29/_@JD3@  E$\  (=0  !\40  <E(  &E2  !?4P  5E4
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M !-D_0&560  AEH  'M;  !P7   9ET  %Y?  !480  2V0  $1F   \:0
M-&P  "QN   C<00 '7(. !MS&  :<R  &',G !=S+P 5<S8 %',_ !)S2  1
M<U( #G-<  US:  +<W8 "7*%  =RE  &<:8 !7"Y  1NSP %;>, !FSO  =L
M^ "/7@  @5X  '9?  !L8   8V$  %ID  !09P  1VH  #]M   V<   +G(
M "9U   =>   %'H'  Y[$  ,>QD "GLA  E[*  (>S  !GLX  5[0@ #>TP
M GM6  ![8@  >W   'M_  !ZCP  >:   'BS  !WR0  =MX  '7J  !T\0"(
M8@  ?&,  '%D  !H90  7V<  %5J  !,;0  0G$  #ET   P=P  *'H  !]\
M   7?P  #8(!  6$"@  A!,  (0:  "$(@  A"D  (4Q  "$.@  A$0  (10
M  "%6P  A&D  (1Y  "#B0  @IH  (&M  " P0  ?]D  '[I  !]\0"#9P
M=V@  &YH  !E:@  6VT  %%Q  !'=0  /'D  #-\   J?P  (8(  !B%   0
MAP  !HH   ",!0  C P  (P4  "-&P  C2(  (XI  ".,0  CCL  (Y'  "/
M4P  CV   (]P  ".@0  CI,  (VE  "+N0  BM   (GB  "([@!];   =&T
M &MN  !@<0  5G4  $MZ  !!?@  -H(  "R%   CB0  &8L  !".   (D
M )(   "4    E04  )4+  "6$P  EQH  )<A  "8*   F3$  )D\  "920
MFE<  )IG  ":>   FHH  )F=  "8KP  E\0  );7  "6Y0!Z<@  <7(  &9U
M  !;>@  4'X  $6#   ZB   +XP  "60   ;D@  $I4   >7    F@   )P
M  ">    GP   )\"  "@"0  H1$  *(7  "C'P  I"<  *4Q  "F/0  IDP
M *=<  "G;@  IX   *:2  "FI@  I;@  *7)  "DV0!W=P  ;'H  &%_  !6
MA   2XD  #^.   TDP  *9<  !Z:   4G0  ":    "B    I    *<   "H
M    J@   *L   "L    K ,  *T)  "O$@  L1H  +(C  "T+@  M3P  +9-
M  "W8   MG,  +6'  "UF@  M:L  +2Z  "TR !S?P  9X0  %R)  !1CP
M190  #F:   NG@  (J(  !BF   ,J0   :P   "N    KP   +$   "S
MM    +8   "W    N0   +H   "\ P  O@P  ,$6  ##(   Q2T  ,@\  #*
M3@  S&(  ,UV  #,B0  RIL  ,FJ  #(M@!NB0  8X\  %B4  !-F@  0*
M #2F   HJP  ':\  !*R   &M0   +@   "[    O0   +T   "_    P
M ,$   ##    Q0   ,<   #*    S0   - %  #5$   V1T  -PK  #@/
MXU   .9E  #G>   YXD  .B5  #HGP#_    _P   /\   #_  P _P 8 /H
M)@#W #( ]0 ] /, 1P#O %$ ZP!: .@ 80#F &< Y !M .( <@#A '8 WP!Z
M -X ?@#= (, VP"' -H C #8 )( U@": -0 H@#2 *P S@"Z ,D S@#' .8
MQ@#X ,8 _P#& /\ Q@#_ ,< _P#_    _P   /\   #^  < ]P 5 /  (@#M
M "X Z@ Y .< 0P#C $T WP!6 -P 70#: &, V !I -8 ;@#4 ', T@!W -$
M>P#0 (  S@"$ ,P B0#* (\ QP"7 ,0 GP#" *D OP"U +T QP"\ -X NP#S
M +L _P"[ /\ NP#_ +L _P#_    _P   /P   #U  , Z@ 1 .4 '0#@ "D
MVP U -@ /P#5 $@ T@!1 ,X 6 #, %\ R@!E ,@ :@#% &\ PP!S ,$ > "_
M 'P O0"! +P A@"Z (P N0"3 +< FP"V *4 M "P +( P "Q -4 L #M *\
M_0"O /\ KP#_ *\ _P#_    _P   /,   #G    W@ + -< &0#/ "0 S  P
M ,D .@#& $, PP!, +\ 5 "\ %H N0!@ +< 9@"V &L M0!O +0 <P"S '@
ML@!] +  @@"O (@ K@". *P EP"K *  J0"L *< N@"F ,T I0#F *0 ]P"D
M /\ I #_ *0 _P#_    ]    .<   #9    T  ' ,< % #" "  O@ J +H
M-0"W #X M !' +$ 3@"O %4 K@!; *P 8 "K &4 J@!J *D ;P"H ', IP!X
M *4 ?0"D (, HP"* *$ DP"@ )P G@"G )P M "; ,< F@#> )D \0"9 /T
MF0#_ )D _P#V    Z0   -@   #,    P@ " +L #@"V !H L0 E *T +P"K
M #D J0!! *< 20"E %  HP!6 *( 6P"A &  GP!E )X :@"= &\ G !T )L
M>0"9 '\ F "& )< CP"5 )@ DP"C )( L "0 ,$ CP#6 (X ZP"- /@ C0#_
M (T _P#N    W    ,L   "_    MP   +  !P"K !0 IP ? *0 *0"A #,
MGP \ )T 1 "; $H F@!1 )@ 5@"7 %L E0!@ )0 90"3 &H D@!O )  =0"/
M 'L C@"# (P BP"* )4 B0"@ (< K0"& +P A0#1 (0 Y@"# /0 @P#\ ((
M_P#D    T $  , "  "T @  K    *<   "B  P GP 8 )P (P"9 "T E@ V
M )0 /@"2 $4 D !, (\ 4@"- %< C !< (L 80") &8 B !K (< <0"% '@
MA !_ (( B "! )( ?P"= 'X J@!] +D ? #- 'L X@!Y /  >0#X 'D _0#:
M"0  Q0X  +80  "J$0  H@X  )T*  "; @0 EP 1 )0 ' "0 "< C0 P (L
M.0") $  AP%' (8"30"% E( @P)8 ((#70"  V( ?P-H 'X#;@!]!'4 >P1]
M 'H$A@!X!)  =P6< '4%J0!T!;D <@7, '$'X0!P!^\ < CX &\(_0#0%0
MO1D  *X:  "B&P  FAD  )46  "1$@  D D( (P&%0")""$ A@DJ (,*,P"!
M"SL @ Q" 'X,2 !]#4X >PU4 'H-60!X#5\ =PUE '8.; !T#G, <@]\ '$0
MA0!O$)  ;A"< &P1J@!K$;H :1'. &@2Y !G$O, 9Q+[ &<2_P#)'   M2
M *<C  "<(P  DR(  (T@  ")'   AQ<  (42#@"!$QL ?A0E 'P5+@!Y%C8
M=Q8^ '861 !T%TH <Q=0 '$750!P%UL ;A=A &T8: !K&'  :AAY &@9@@!F
M&8T 91F: &,:J !B&K@ 81K, & :X@!?&_( 7QO\ %X:_P#"(P  L"8  *$I
M  "6*   C2@  (<G  "")   ?R   'T<" !Z'!8 =QP@ '0=*@!Q'C( ;QXY
M &X>0 !L'D8 :QY, &D?4@!G'U@ 9A]> &0?90!C(&T 82!V & @@ !>(8L
M72&8 %LAI@!:(;8 62'* 5@AX0%7(?$!5R'[ E<A_P*\*   JRP  )PN  "1
M+@  B"T  ((L  !]*@  >2<  '<C! !S(Q$ <",< &TD)@!J)"X :"4U &8E
M/ !E)4, 8R5) &$E3@%@)50!7B5; 5TF8@%;)FH!6B9T 5@G?@%7)XD"52>6
M E0HI )3)[0"42?( E GWP-0)_ #4";Z T\F_P2X+0  IC   )@R  "-,@
MA#(  'XP  !X+P  ="T  '$J  !M*0P :2H8 &8J(@!C*BH 82HQ 5\J. %=
M*C\"6RI% EHJ2P)8*E$"5RM8 E4K7P-4*V<#4BQQ U$L>P-/+(<$3BV4!$TM
MH@1++;(%2BS'!4DLW@5)*^\%22OZ!DDJ_P:T,0  HC0  )4U  ")-@  @38
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M"C4YV0HU..P*-C?W"C8W_@JI.@  F3T  (P^  "!/P  =S\  &\_  !I/@
M8CL  %T]  !7/0  4SX) $\^% !-/QT 2CXE 4<^*P)$/C$$03TW!C\]/@<]
M/44).SU,"CD]5 LX/ET+-SYG"S4^<PLT/G\*,SZ-"C(^G HR/JT),3[!"3 ]
MV DP/.L*,#SW"S [_0NF/0  EC\  (E!  !^0@  =$(  &Q"  !E00  7D
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M!2!+_ ::1P  BTD  ']*  !T2P  :DP  &%,  !930  3T\  $E0  !#4@
M/50  #=5!0 S5@\ ,588 "]6(  M5R@ *U<O 2E7-@$G5ST")5=$ R1730,B
M5U8"(5=A B!7;0(?5WH!'E>( 1U6F $<5JD!&U6] !I4U  ;4^@!&U+U AI1
M_ .62@  ATP  'M-  !P3@  9D\  %Y0  !540  3%,  $95   _5P  .%D
M #%;   L70H *%T4 "9='  D7B0 (UXK "%>,@ @7CH 'EY" !U>2@ ;7E0
M&EY> !E>:@ 77G< %EZ& !5=E0 47:< $URZ !);T@ 36>< $UCT !18^P&1
M3@  @U   '=1  !L4@  8E,  %I4  !250  25@  $):   [7   ,UX  "QA
M   D8P4 'V4. !UE%P ;91\ &64F !AE+@ 6934 %64] !-F1@ 29E  $&9:
M  YE9@ ,97, "F6"  EDD0 (9*( !V.U  9ARP '8.$ "%_O  E?]P"+4@
M?E0  ')5  !H5@  7U<  %=8  !.6@  15T  #U@   V8@  +F0  "9G   >
M:@  %FP' !)M$0 0;1D #6T@  QM*  *;3  "6TX  =M00 &;4L !&U5  )M
M80  ;6X  &Q\  !LC   :YT  &NP  !IQ@  :-L  &?I  !F\0"%5P  >5@
M &U9  !D6@  7%L  %-=  !*8   06,  #AF   P:0  *&L  "!N   8<0
M$',"  =U"@ "=A,  '8;  !U(@  =BH  '8R  !V.P  =44  '5/  !U6P
M=6@  '5W  !TA@  =)<  '.J  !ROP  <=<  '#H  !O[P" 6P  =%P  &E=
M  !A7@  6&   $]C  !&9@  /&H  #-M   J<   (G,  !IV   2>   "'L
M  !\"   ?0\  'T6  !^'0  ?B0  'XK  !_,P  ?ST  'Y)  !^5   ?V$
M 'YP  !^@0  ?9(  'VD  ![N   >L\  'GD  !Y[@!Z8   ;V$  &9B  !=
M8P  4V8  $IJ  ! ;@  -G(  "UV   D>   &WL  !)^   *@    8,   "$
M P  A0H  (81  "&%P  AQT  (@D  "(*P  B34  (E   "(30  B5H  (EI
M  ")>@  B(P  (>>  "&L0  A<<  (3<  "$Z !U90  :V8  &-G  !8:@
M3FX  $1S   Y=P  +WL  "5_   <@0  $X0   F'   !B@   (P   ".
MCP(  (\(  "0#@  D14  )$;  "2(@  E"H  )4U  "50@  E5   )9>  "6
M;P  E8(  )25  "3J0  DKP  )'0  "0X0!Q:P  :6L  %YO  !3<P  27@
M #U]   R@0  *(4  !V)   4C   "HX   &1    E    )8   "8    F0
M )D   ":!0  FPL  )P2  "=&0  GR   * J  "B-@  H40  *)4  "C90
MHW@  **,  "BGP  H;(  *##  "@T0!O<   9',  %EX  !.?0  0X(  #>'
M   KC   (9   !:4   +EP   9D   "<    G@   *    "B    HP   *0
M  "E    I@$  *<'  "H#@  JA<  *P?  "N*@  KS<  *](  "Q6@  L6T
M +&   "QE   L*8  +"V  "PPP!J>   7WT  %2"  !)B   /(X  #&3   E
MF   &IP   Z?   #H@   *4   "G    J0   *P   "M    KP   +    "R
M    LP   +0   "V    N <  +L0  "]&P  OR<  ,(V  #$2   Q5X  ,1S
M  #$AP  Q)@  ,.G  ##L@!F@@  6X@  %".  !$E   -YH  "N?   @I
M%:@   BL    K@   +$   "T    M0   +<   "X    N@   +P   "^
MOP   ,$   ##    Q@   ,D"  #."P  TA@  -4F  #:-P  WDL  .%?  #B
M<P  X88  ."5  #?H #_    _P   /\   #_  @ _  5 /D (@#U "X \0 Z
M /  0P#L $T Z0!5 .8 70#C &, WP!I -P ;@#9 ', UP!X -4 ? #3 ($
MT@"& -  BP#/ )$ S@"8 ,P H #* *H R "W ,8 R0#$ .( PP#V ,( _P#"
M /\ PP#_ ,, _P#_    _P   /\   #Y  4 \P 2 .T '@#H "H Y0 U .,
M/P#@ $@ V0!1 -, 6 #/ %\ S0!E ,L :@#* &\ R0!T ,@ > #' 'T Q@"!
M ,0 AP## (T P@"3 ,  FP"^ *8 O "R +L P@"Y -H MP#P +8 _P"V /\
MMP#_ +< _P#_    _P   /D   #M  $ Y@ - -X &P#: "4 U@ P -  .@#,
M $, R !, ,4 4P## %H P0!@ +\ 90"^ &H O !O +L = "Z '@ N0!] +@
M@@"W (@ M0"/ +0 EP"R *  L0"L *\ NP"M -$ K #I *L ^P"K /\ JP#_
M *L _P#_    ^    .L   #@    U0 ) ,X %@#) "$ P@ K +\ -0"^ #\
MNP!' +D 3@"V %4 M !; +, 8 "R &4 L !J *\ ;P"N ', K0!X *P ?@"K
M (0 J0"* *@ D@"G )L I0"G *, M "B ,@ H #A *  ]0"@ /\ GP#_ )\
M_P#Z    [0   -T   #1    QP % ,  $ "X !P M0 F +( , "P #D KP!"
M *P 20"J %  J0!6 *< 6P"F &  I0!E *0 :0"C &X H@!S *$ >0"? '\
MG@"& )T C0"; )< F@"B )@ KP"6 ,$ E0#8 )0 [P"3 /P DP#_ )( _P#P
M    W@   ,\   #"    N@   +( "P"M !8 J0 A *< *P"E #0 HP \ *$
M1 "? $H G@!0 )P 5@"; %L F@!@ )D 9 "8 &D E@!O )4 = "4 'H D@"!
M )  B0"/ )( C0"> (P J@"* +H B0#0 (D YP"( /< B #_ (@ _P#F
MT@   ,$   "V    K@   *< !0"C !$ GP ; )T )0"; "X F0 W )< /@"5
M $4 DP!+ )( 40"0 %8 CP!; (X 8 ", &4 BP!J (H < ") '8 AP!] (8
MA0"% (\ @P": (( IP"! +8 @ #* '\ X0!^ /( ?@#\ 'X _P#9    Q0
M +8   "J    HP   )\   ":  H E@ 5 )0 'P"1 "D CP Q (P .0"+ $
MB0!& (@ 3 "& %$ A0!6 (0 6P"# &  @@!F ($ ; !_ '( ?@!Z 'P @@![
M (P >0"7 '@ I !W +, =@#% '4 W !T .X = #X ', _0#. @  NP<  *P*
M  "B"@  F@D  )4%  "2  , CP . (P &0") "( A@ L (0 ,P"" #L @0!!
M '\ 1P!^ $T ?0!2 'P 5P!Z %P >0!B '< : !V &\ =0!W ', @ !Q (H
M< "5 &\ H@!M +  ; ## &L V0!J .H :@#T &D ^@#%#0  LQ(  *05  ":
M%0  DA0  (P2  ")#0  AP4& (4!$@"! !P ?P$F 'P"+@!Z S8 > 0] '<$
M0P!V!4@ = 5. ',&4P!Q!ED < 9? &\&90!M!VP ; =U &H'?@!H"(@ 9PB4
M &4(H0!D"+$ 8PC# &()V0!A"NH 8 KU & *^P"^%@  JQH  )X<  "3'0
MBQP  (4;  "!%P  ?Q,  'X+"0!["A8 =PL@ '4,*0!S#3$ <0TX &\./P!N
M#D4 ; ]* &L04 !I$%8 :!!< &818P!D$6H 8Q%S &$2?0!@$H< 7A.4 %T3
MH0!;$[$ 6A/$ %D3VP!8%.T 6!3X %@4_@"W'   IB   )@B  "-(P  A2,
M '\A  !Z'P  =QL  '47 P!S%!  <!4; &T6) !K%BP :18T &<7.@!E%T$
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M D,FU@-")NH#0B;W T(E_@.I*@  F2T  (PO  "!,   >3   '$P  !L+@
M9RP  &,J  !?*0( 7"@. %DI& !6*2$ 5"DH %$I+P%/*34!3BD[ DPI0@)*
M*4@"22I/ D@J5P-&*E\#12MI T,K<P-"+'\$02R,!#\LFP0^+*L$/2R^!#LK
MU 0[*^D%/"KV!3PJ_06F+@  EC   (DR  !^,P  =3,  &XS  !H,@  8R\
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M!RHV^P><-@  C3D  ( [  !U/   ;#P  &0\  !=/   5CL  % [  !+/
M1CT  $(]"@ _/A0 /#X< #D^(P W/BH!-3XP C(^-@0Q/CT%+SY%!BX^308L
M/E8&*S]A!BH_; 8I/WD%*#^'!2<_E@0G/Z8$)C^Y!"4^T ,D/>4$)#SS!B0[
M^P:9.0  BCP  'T]  !R/@  :3\  &$_  !9/P  4C\  $I   !%00  04(
M #Q#!@ X1!  -D09 #1$(  R1"< +T0N 2U$- (K1#L#*D1#!"A$2P0G154$
M)D5?!"5%:P0D17@#(T6% R)%E0(A1:4"(42X B!$SP(?0^4"'T+R!!]!^@65
M/   AC\  'I   !O00  94(  %U"  !60P  3D,  $5%  ! 1@  .T@  #9)
M @ R20P +TH6 "U*'@ K2R4 *4LK "=+,@$E2SD")$M! B)+2@(A2U,"($M=
M A]+:0$>3'8!'4N$ 1Q+DP$;2Z0 &TJW !I)S0 :2.0!&D?R AI&^@.10
M@D(  '9$  !K10  8D4  %I&  !21@  2D<  $))   \2P  -DT  #!.   L
M4 @ *%$2 "91&@ D42$ (E$H "!2+P ?4C< '5(_ !Q21P ;4E$ &5); !A2
M9P 74G0 %E*" !51D0 44:( $U"U !)/S  23N( $TWQ !1-^0&-1   ?T8
M ')'  !G2   7DD  %9)  !/2@  1TP  #].   Y4   ,E(  "Q4   D5@0
M'U<- !U8%@ ;6!T &E@D !A8+  76#, %5D[ !191  264T $%E8  Y98P -
M6'  "UA^  I8C@ )5Y\ "%:Q  A5QP (5-T "5/M  I3]@"(2   >DD  &Y+
M  !C2P  6TP  %--  !,3@  1%   #M3   U50  +E<  "=9   ?7   %U\'
M !-@$0 18!@ #V @  U@)P ,8"\ "F W  E@/P '8$D !6!3  1@7P "7VL
M %]Z  !?B0  7ID  %VL  !<P0  6]@  %KH  !9\ ""3   =4T  &E.  !?
M3P  5U   %!1  !(4@  0%4  #=8   P6P  *%T  "%@   98P  $F4"  EH
M"P %9Q0  V<;  %G(@  9RH  &<Q  !G.@  9T0  &=.  !G6@  9V8  &9U
M  !FA   9I0  &6G  !DNP  8],  &+F  !A[@!]4   <%(  &52  !<4P
M550  $U5  !$6   .UP  #)?   J8@  (F0  !IG   3:@  "FP   -N"
M;Q   &\6  !O'0  <"0  ' K  !P-   <#T  '!(  !P5   <&   &]O  !O
M?P  ;H\  &VA  !MM0  ;,T  &KC  !J[@!W50  :U8  &%7  !95P  45D
M $A<   _7P  -6,  "QF   D:0  '&P  !1O   ,<0  !'0   !V!0  =@L
M '<2  !W&   >!X  'DE  !Y+0  >38  'E!  !Y30  >5H  'EH  !X>
M>(H  '><  !WKP  =<8  '7<  !TZ@!Q6@  9EL  %Y;  !67   35\  $-C
M   Y9P  +VL  "9O   =<@  %74   QW   $>@   'P   !^ 0  ?@<  '\,
M  " $P  @1D  ((?  "")@  A"T  (0Y  "#10  @U,  (1A  "$<0  @X,
M (*6  "!J@  @;X  (#5  !_Y0!L7P  8U\  %M@  !18P  1V@  #UL   R
M<   *'0  !]X   6>P  #'X   2     @P   (4   "'    B $  (D&  ")
M#   BA(  (L8  ",'@  CB4  (\O  "//   CTH  )!9  "0:   D'L  (^/
M  ".HP  C;<  (S+  ",VP!I9   860  %9H  !,;   07$  #9V   K>@
M(7\  !>"   ,A0   X<   "*    C@   )    "2    DP   )0   "5 0
ME@<  )<-  "8%   FAL  )PB  ">+@  GCT  )Y,  "?70  GV\  )^#  ">
MF   G:P  )R^  ";S0!G:0  7&T  %%Q  !&=@  .GP  "^!   DA0  &(D
M  V-   #D    ),   "6    F    )L   "<    G@   )\   "@    H0
M *("  "D"0  I1$  *@8  "J(@  K#   *Q   "M40  KF0  *YY  "MC@
MK*$  *RQ  "LOP!B<0  5W8  $Q\  ! @0  -(<  "B-   <D0  $98   69
M    G    )\   "A    I    *8   "G    J0   *H   "K    K0   *T
M  "O    L04  +,.  "W%P  N2,  +LR  "\10  O5D  +YN  "_@0  OY0
M +^D  "^KP!=>P  4H$  $>'   ZC@  +I0  "*9   7G@  "J(   "E
MJ    *H   "M    KP   +(   "S    M0   +<   "Y    N@   +P   "^
M    P    ,,   #)!@  S!,  ,\@  #3,0  UT4  -E<  #8<P  UH8  -B5
M  #8H #_    _P   /\   #_  8 ^@ 2 /4 'P#R "H [@ U .@ /P#E $@
MX0!0 -X 6 #; %X V0!D -< :0#5 &X TP!S -( > #1 'T T "" ,X AP#-
M (T RP"4 ,H G0#( *< QP"S ,4 QP## -\ P0#U +\ _P"^ /\ O@#_ +\
M_P#_    _P   /P   #V  ( [@ 0 .D &P#B "8 W  Q -H .P#8 $, U !,
M -$ 4P#. %H RP!? ,D 90#' &H Q@!N ,0 <P## '@ P@!] ,$ @P"_ (D
MO@"0 +T F "[ *( N@"M +@ OP"V -8 M0#O +, _P"R /\ L@#_ +, _P#_
M    _@   /(   #H    X  * -@ %P#/ "$ S  L ,H -@#) #\ Q0!' ,(
M3@"_ %4 O0!: +P 8 "Z &4 N0!I +< ;@"V ', M0!X +0 ?@"S (0 L0"+
M +  DP"O )T K0"H *P MP"J ,P J0#G *< ^@"G /\ IP#_ *< _P#_
M\0   .4   #9    SP & ,4 $@#  !T O0 G +L ,0"Y #H MP!" +0 20"R
M $\ L !5 *\ 6@"M %\ K !D *L :0"J &X J !S *< >0"F '\ I "& *,
MC@"A )< H "B )X L "= ,, G #> )L \P": /\ F@#_ )H _P#T    XP
M -0   #(    O0 " +< #0"R !@ KP B *T *P"K #0 J@ ] *@ 1 "F $H
MI !0 *( 50"@ %H GP!? )T 9 "< &D FP!N )H = "9 'H EP"! )8 B0"5
M )( DP"= )( JP"0 +L CP#4 (X [ ". /P C@#_ (X _P#F    U0   ,4
M  "Z    L    *H " "F !, HP = *$ )P"? "\ G  W )H /@"8 $4 EP!+
M )4 4 "4 %4 DP!: )( 7@"1 &, D !I (X ;P"- '4 C !] (L A0") (X
MB "9 (< I@"% +4 A #* (0 Y "# /8 @P#_ (, _P#;    Q@   +@   "M
M    I@   *   @";  T F  8 )4 (0"3 "H D0 R (\ .0". $  C !& (L
M2P"* %  B0!5 (< 6@"& %\ A0!D (0 :@"# '$ @@!X (  @0!_ (H ?0"5
M 'P H@![ +  >@## 'D W0!Y .\ >0#\ 'D _P#.    O    *T   "B
MFP   )8   "2  < C@ 2 (L ' ") "0 AP M (8 - "$ #L @P!! ($ 1@"
M $L ?P!0 'X 50!] %H >P!@ 'H 9@!Y &P > !T '8 ?0!U (8 <P"1 '(
MG@!Q *P < "^ &\ U0!O .L ;@#X &X _P#$    L0(  *0$  "9!0  D00
M (P!  ")  $ A@ + (, %0"! !\ ?P G 'T +P![ #8 >@ \ '@ 0@!W $<
M=@!, '0 40!S %8 <@!< '$ 8@!O &D ;@!Q &P >@!K (0 :0"/ &@ FP!G
M *D 9@"[ &4 T0!E .< 9 #S &, ^0"[!@  J0L  )P.  "1$   B1   (0-
M  " "   ?P($ 'P #@!Z !@ =P A '4 *0!S #$ <0 W '  /0!N $, ;0!(
M &P 30!J %, :0!8 &< 7P!F &8 9 !N &, =P!B (( 8 &- %\!F@!= :@
M7 &Z %P!SP!; N, 6@+O %H#]@"S#P  HA0  )46  "*&   @A@  'P6  !Y
M$P  =@X  '4'!P!S Q( < ,< &T$) !K!2P :04S &<&.0!F!C\ 90=$ &,'
M2@!B"%  8 A6 %\)7 !="60 7 EL %H*=@!9"H$ 5PN- %8+F@!5"ZD 5 N[
M %(+T !2"^0 4@SQ %$,^0"M%@  G1H  (\<  "$'@  ?1X  '8=  !R&@
M;Q<  &T2  !L# L :0P6 &8-'P!D#B< 8@XN & .-0!>#SL 71!! %P01P!:
M$4T 61%3 %<26@!5$F$ 5!-J %(3= !1%(  3Q2, $X4F0!-%:D 2Q6[ $H4
MT0!*%.8 2A3T $H4^P"H&P  F!X  (HB  " (P  >",  '$B  !L(   :!T
M &8:  !D%@4 8A41 %\6&@!<%B, 6A8J %@7, !7%S< 51<] %080P!2&$D
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M S4D^P.<)@  C2D  ( K  !V+0  ;2X  &4N  !?+0  6BL  %8H  !2)P
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M!"DU: ,H-74#)S6" R8UD0,E-:$#)#6S B,TR0(C-. "(S/P!",R^023+P
MA#(  '@T  !M-0  9#8  %PV  !5-@  3C8  $@U  !#-@  /C<  #HW P V
M. T ,S@6 #$X'0 O."0 +3@J 2LY,0$I.3@"*#E  R<Y2 ,F.5$#)#I; R,Z
M9P(B.G,"(3N! B$ZD (@.J !'SJR 1XYR $>.=\!'3?O ATW^0./,@  @34
M '4W  !J.   8#D  %@Y  !1.0  2SD  $0Z   ].P  .#P  #0]   P/0D
M+3X3 "L^&@ I/B$ )S\H "4_+P$D/S8!(C\^ 2$_1@$@0$\!'T!: 1Y 90$=
M0'(!'$"  1M CP :0)\ &3^Q !@^QP 8/MX &#WO 1D\^ *,-@  ?C@  '$Z
M  !F.P  73P  %4\  !./   1ST  $ ^   Y0   -$$  "Y"   J0P8 )T0/
M "1%%P B11X (44E !]%+  >1C, '$8[ !M&1  91DT &$97 !=&8P 61G
M%49^ !1&C0 319X $D6P !%$Q0 10]T $D+N !-!^ &(.0  >CP  &X]  !C
M/@  6C\  %(_  !+0   1$   #Q#   V1   ,$4  "M'   D20( ($H+ !U+
M%  ;3!L &4PB !=,*0 63#  %4PX !-,00 23$H $$Q5  Y,8  -3&T "TQ[
M  I,B@ )2YH "$JL  =*P0 (2=@ "4CJ  I']0"#/0  =C\  &I!  !?0@
M5D(  $Y#  !(0P  040  #E'   R20  +4H  "9,   ?3P  &5$' !12#P 2
M4Q< $%,>  Y3)0 ,4RT "U,T  E3/0 '4T8 !E-1  137  #4V@  5)V  !2
MA@  498  %&H  !0O   3],  $[E  %-[P!_00  <4,  &5$  !;10  4T8
M $Q&  !%1P  /DD  #9+   O3@  *%   "%2   :5   $U<"  M:"@ '6A,
M!5H:  -:(0 "6BD  %HP  !:.0  6D(  %I,  !95P  660  %ER  !9@0
M6)$  %BC  !7MP  5L\  %7C  !4[0!Y10  ;$<  &%(  !820  4$D  $E*
M  !"2P  .DX  #)1   J5   (U8  !M9   56P  #%X!  5@"   80\  &$6
M  !B'0  8B0  &(K  !A,P  83T  &%'  !A4P  85\  &%M  !@?   8(T
M %^?  !>L@  7<D  %S@  !<[0!T2@  9TL  %U,  !43   34T  $9.   ]
M40  -50  "Q8   E6@  '5T  !5@   -8P  !F4   !G!@  : P  &@3  !I
M&0  :A\  &HF  !J+@  :C<  &I!  !J30  :ED  &IG  !I=P  :(@  &B:
M  !GK0  9L,  &;;  !EZ@!N3P  8E   %E0  !24   2E$  $%5   X6
M+UP  "9?   >8@  %F4   YH   &:@   &T   !O @  ;P@  ' .  !Q%
M<AH  ',@  !S)P  =#   '0Z  !T1@  <U,  '-A  !S<0  <H(  '&5  !P
MJ   <+P  '#4  !OY@!H4P  7E0  %94  !/50  1E@  #Q<   R8   *60
M !]H   7:P  #6X   9Q    <P   '8   !W    > ,  'D(  !Z#@  >Q0
M 'P:  !](   ?B@  ( Q  !_/0  ?TL  ']9  !_:0  ?GL  'V.  !\H@
M>[8  'O,  ![W@!C6   6UD  %19  !*7   0&$  #5E   L:@  (6T  !AQ
M   .=0  !7@   !Z    ?0   '\   "!    @@   (,"  "$!P  A0P  (82
M  "(&0  B2   (LG  ",,P  BT(  (M1  "+80  C',  (J&  "*FP  B*\
M (C$  "'U@!@70  65X  $]A  !$90  .6H  "]O   D=   &7@   Y\   %
M?P   ((   "$    AP   (D   "+    C    (T   "/    D 4  )$*  "2
M$   E!<  )8?  "8*   F3<  )A(  "96   FFD  )E]  "8DP  F*@  ):[
M  "6S@!?8@  5&8  $EJ   ^<   ,G4  "=Z   <?P  $8,   6'    B@
M (P   "/    DP   )4   "7    F0   )H   ";    G0   )X   "@!
MH0H  *03  "G&@  J2<  *DX  "I2@  JUP  *QP  "KA0  JIH  *BL  "H
MO !::P  3V\  $1U   X>P  +($  ""&   4BP  "(X   "3    E@   )D
M  "<    G@   *$   "C    I    *8   "G    J0   *D   "K    K0
M + '  "S$   MAP  +DJ  "Y/0  NU   +QE  "\>@  NX\  +J@  "ZK0!5
M=   2GH  #Z!   RAP  )8T  !F3   ,F    )L   "?    H@   *4   "H
M    J@   *P   "N    KP   +$   "S    M    +8   "W    N0   +P
M  # !@  Q1$  ,D>  #++@  S40  ,]:  #1;P  T8(  -*2  #2GP#_
M_P   /\   #]  , ^  0 .\ &@#K "8 Z@ P .@ .@#E $, X0!+ -X 4P#;
M %D V0!? -8 9 #4 &D TP!N -$ <@#/ '< S@!] ,P @P#* (D R0"1 ,<
MF0#& *0 Q "P ,( P@#! -P OP#V +X _P"] /\ O #_ +L _P#_    _P
M /L   #R    Z0 + .$ & #= "$ VP L -D -@#7 #\ TP!' ,\ 3@#, %0
MR@!: ,@ 7P#& &0 Q !I ,, ;0#! '( OP!X +P ?@"Z (0 N0", +< E "U
M )X M "J +( N@"Q -  L #N +  _P"P /\ KP#_ *\ _P#_    ^    .T
M  #D    U@ ' -  $P#, !X R0 G ,< ,0#& #H PP!" +\ 20"[ $\ N !5
M +8 6@"T %\ L@!D +$ : "P &T K@!S *T >0"L '\ J@"' *D CP"H )D
MI@"E *4 LP"D ,< HP#E *( ^@"A /\ H0#_ *$ _P#Y    ZP   -X   #/
M    Q0 # +\ #@"[ !D N0 C +8 + "S #4 L  ] *T 1 "K $H J0!0 *@
M50"G %H I0!> *0 8P"C &@ H@!M *$ <P"? 'H G@"! )T B@"< )0 F@"?
M )D K "8 +X EP#; )8 \P"5 /\ E0#_ )4 _P#K    VP   ,P   "^
MM@   +  "0"L !0 J0 > *4 )P"D "\ HP X *$ /P"? $4 G0!+ )P 4 ":
M %0 F0!9 )@ 7@"7 &, E0!H )0 ;@"3 '0 D0!\ )  A "/ (X C@": (P
MIP"+ +< B@#0 (H ZP") /T B0#_ (D _P#>    RP   +L   "Q    J0
M *, ! ">  \ FP 9 )D (@"7 "L E@ R )4 .@"3 $  D0!& (\ 2P". %
MC0!4 (P 60"+ %X B0!C (@ :0"' &\ A@!W (0 ?P"$ (D @@"5 ($ H@"
M +$ ?P#' 'X X@!^ /4 ?@#_ 'X _P#/    O0   *\   "E    G@   )@
M  "3  H D  4 (T '0"+ "4 B@ M (D - "( #L A@!! (4 1@"# $L @@!0
M ($ 5 "  %D ?P!> 'X 9 !\ &L >P!R 'D >@!Y (4 > "0 '8 G0!U *P
M= "_ ', V !S .X <P#] ', _P#$    L0   *0   ":    D@   (T   ")
M  0 A@ . (0 & "" "  @  H '\ +P!^ #8 ?  \ 'L 00!Z $8 > !+ '<
M4 !V %4 =0!: ', 8 !R &8 < !N &\ =@!N ($ ;0", &P F0!J *@ :0"Y
M &D SP!H .D : #W &@ _P"Y    J    )L   "0 @  B0   (0   "!
M?@ ( 'L $@!Y !H =P C '4 *@!T #$ <P W '$ / !P $( ;P!' &T 2P!L
M %$ :P!6 &D 7 !H &, 9@!J &4 <P!D 'X 8P") &$ E@!@ *0 7P"T %\
MR@!> .( 7@#S %X _ "P 0  H 8  ),)  "("P  @0H  'L(  !X!   =@ #
M ', # !Q !4 ;P = &T )0!K "P :@ R &@ . !G #T 90!" &0 1P!C $T
M80!2 &  60!? %\ 70!G %P <0!; 'L 60"' %@ DP!7 *( 5@"R %4 Q@!5
M -X 50#N %0 ]@"I"0  F@T  (L2  ""$P  >A,  '01  !P#0  ;0D  &P#
M!@!J  X :  7 &4 'P!C "< 80 M &  ,P!> #D 70 ^ %P 1 !: 4D 60%/
M %@"5@!6 ET 50-E %,#;P!2!'D 402% $\$D@!.!*$ 302Q $P$Q0!, ]H
M2P3J $L$\P"C$   E!0  (87  !\&0  =!D  &T8  !I%@  9A(  &0.  !C
M" @ 8042 %X&&@!<!R( 6@<I %@'+P!7!S4 50@Z %0(0 !3"48 40E, % *
M4P!."EL 30MD $L+;@!*#'D 2 V% $<-DP!%#:( 1 VS $,,Q@!##-P 0@SL
M $,,]0">%0  CAD  ((<  !X'0  ;QX  &@=  !C'   7QD  %T6  !;$@(
M6@X+ %<-%0!5#AT 4P\D %$0*P!0$#$ 3A W $T1/0!+$4, 2A)* $@240!'
M$UD 11-B $04; !"%7@ 016$ #\5D@ ^%:$ /!6R #L5QP Z%-T .Q3O #L4
M^ ":&   BAX  'X@  !T(0  :R(  &0B  !>(   6AX  %<;  !5&0  4Q8&
M %$5$ !.%AD 3!8@ $H6)P!(%RT 1A<S $47.0!#&$  0AA' $$93@ _&58
M/1I@ #P::@ Z&W8 .1N# #@<D  V'*  -1NQ #0;Q0 S&MP -!KN #0:^ "6
M'   AR$  'LC  !P)0  9R4  & E  !:)   52(  %(@  !/'0  3!P" $H<
M# !''!4 11P< $,<(P!!'"H /QPP #T=-@ \'3T .QY$ #D?3  X'U0 -A]>
M #4@:  T(70 ,B&! #$ACP P(9\!+R&P 2T@Q $M(-L!+1_M 2X?^ &3'P
MA",  '@F  !M*   9"@  %PH  !6*   428  $TD  !*(@  1R$  $,A" !!
M(1$ /B$9 #PA(  Y(28 -R(L #8B,P T(CH ,R-! 3(D20$Q)%(!,"5; 2XE
M9@$M)G(!+"9_ 2HFC@$I)IT!*"6O 2<EPP$F)=H!)R3L 2<C]P*0(@  @28
M '4I  !J*P  82L  %DK  !3*P  32H  $DH  !%)@  02<  #TG!  Z)PT
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M !DUB@ 8-9H %S2L !8TP  5,]< %C+J !<R]@&&+   >"\  &PQ  !A,@
M6#,  % S  !),P  0S,  #TT   V-0  ,#8  "PW   I-P, )3@+ "(X%  @
M.1L 'SDB !TY*0 <.C  &CHW !DZ0  8.DH %SI4 !4Z7P 4.VP $SMZ !([
MB  1.ID #SJJ  XYOP -.-4 $#?I !$W]0""+P  =3(  &DT  !>-0  538
M $TV  !&-@  0#<  #HW   R.0  +3H  "@[   C/0  'SX( !P_$0 :/Q@
M&#\? !9 )@ 50"T $T U !) /0 10$< #D!1  U 7  ,0&D "D%W  E A0 (
M0)4 !S^G  8^N@ &/=  !SWD  D\\0!_,P  <34  &4W  !;.   43D  $HY
M  !#.0  /3H  #<[   O/0  *CX  "5    ?0@  &40% !1%#  21A4 $$8<
M  U&(P ,1BH "D8Q  E&.@ '1D, !D9-  1&6  #1F4  D9S  !&@@  1I(
M $6C  !$M@  0\T  $+@  !"[0![-P  ;3D  &$Z  !7.P  3CP  $<\  !
M/0  .CT  #0_   L00  )D,  "!%   ;1P  %$D!  Q,"0 (31( !DT9  1-
M(  "328  4TN  !--@  33\  $U)  !-50  36$  $UO  !-?@  3(X  $N@
M  !*LP  2<D  $C@  !(ZP!V.P  :#T  %T^  !3/P  2S\  $1    ^0
M-T$  #!$   I1@  (D@  !Q+   630  #D\   =2"  !4PX  %05  !4'
M5",  %0J  !4,@  5#L  %1%  !440  4UT  %-J  !3>@  4XH  %*<  !1
MKP  4,4  $_=  !.[ !P/P  9$$  %E"  !/0@  2$,  $)#   [1   ,T<
M "Q)   D3   '4\  !91   04P  "%8   %9!@  60P  %H2  !;&   6QX
M %PE  !<+0  7#8  %Q   !;2P  6U@  %MF  !;=0  6X8  %J8  !9JP
M6,   %?9  !6Z@!K0P  7T4  %5%  !,1@  1D8  #]'   W2@  +TT  "=0
M   ?4P  %U8  !!8   (6P   5X   !@!   8 D  &$.  !B%0  8QH  &0A
M  !D*   9#   &0Z  !D1@  9%,  &1@  !D<   8X$  &*3  !AIP  8+P
M &#3  !?YP!E2   6DD  %%)  !*20  0TH  #I-   R40  *50  "%8   8
M6P  $%X   EA   !8P   &8   !H    :04  &H*  !K$   ;!4  &T;  !N
M(@  ;RD  &\S  !O/P  ;TP  &Y:  !N:0  ;7L  &R-  !KH0  :K8  &K-
M  !IX0!?30  5DT  $]-  !(3@  /E$  #55   L60  (ET  !EA   09
M"&<   %J    ;    &\   !P    <@   ',%  !T"@  =0\  '85  !X&P
M>2,  'HK  !Z-P  >D0  'I3  !Y8@  >70  '>'  !VFP  =:\  '7%  !T
MVP!;4@  5%(  $U2  !#50  .5H  "]>   D8@  &F<  !%K   &;@   '$
M  !T    =P   'D   ![    ?    'T   !_ @  @ <  ($,  "#$P  A1H
M (<B  ")*P  B#D  (=)  "'60  AVL  (9_  "%DP  A*@  (.\  ""T0!8
M5@  4E<  $A:   ]7@  ,F0  "=I   <;0  $G(   9V    >0   'P   !_
M    @0   (0   "%    AP   (@   "*    BP   (T$  "."@  D!$  )(9
M  "5(0  ERX  )8^  "54   E6(  )5U  "4B@  DY\  )*T  "1Q@!76P
M35\  $)D   V:0  *V\  !]T   4>0  "'T   "!    A    (<   "*
MC    (\   "1    D@   )0   "5    EP   )@   ": 0  G <  )\/  "A
M&   I2(  *8R  "D1@  I5@  *9K  "F@   I)8  *.J  "CO0!29   1VD
M #QO   P=0  )'L  !>    +A0   (D   ",    CP   ),   "6    F@
M )P   ">    H    *(   "C    I0   *8   "H    J@   *T!  "P"@
MM1,  +@B  "X-   N$@  +I<  "[<0  NH8  +F:  "XJ@!-;@  070  #5Z
M   I@0  '8<  !",   #D0   )4   "9    G0   *    "C    I@   *@
M  "J    K    *T   "O    L0   +,   "T    M@   +D   "]    PP<
M ,@6  #,)@  RSL  ,Y1  #09@  SWP  ,V.  #-G0#_    _P   /\   #\
M    \@ , .\ %P#K "$ Z@ L .D -@#G #\ X0!' -L 30#5 %, T@!9 -
M7P#. &, S !H ,L ;0#) '( QP!X ,8 ?@#$ (0 P@", ,  E@"^ *( O0"O
M +L P0"Z -P N #U +< _P"V /\ M0#_ +$ _P#_    _P   /<   #J
MY  ( -\ % #< !X V@ G -0 ,0#/ #H RP!" ,@ 20#% $\ PP!5 ,$ 6@"_
M %X O0!C +P : "Z &T N0!R +< > "V '\ M "' +( D "P )L L "I *X
MN0"M -( JP#N *L _P"J /\ J@#_ *< _P#_    \P   .H   #:    T@ $
M ,P #P#) !H P0 C +\ + "^ #4 O  ] +@ 1 "V $L M !0 +( 50"P %H
MK@!> *T 8P"K &@ J@!M *@ <P"G 'H I0"! *0 B@"B )4 H@"B *  L0"?
M ,< G@#E )T ^P"= /\ G0#_ )T _P#S    Y0   -,   #(    P    +L
M"@"S !4 L  ? *X * "M #  K  X *D /P"F $8 I !+ *, 4 "A %4 H !9
M )\ 7@"> &, G !H )L ;@": '0 F !\ )< A "5 (X E "; )0 J@"2 +T
MD0#: )$ ] "0 /\ D #_ )  _P#D    TP   ,(   "X    L    *@ !0"D
M !  H@ : )\ (P"> "L G0 S )L .@"9 $$ F !& )8 2P"5 %  DP!4 )(
M60"1 %X D !C (X :0"- &\ BP!V (H ?P"( (D AP"4 (< I "& +4 A0#.
M (0 [ "$ /\ A #_ (0 _P#4    P    +,   "I    H0   )L  0"7  L
ME  5 )( '@"0 "8 CP N (\ -0"- #L BP!! (H 1@"( $L AP!0 (8 5 "%
M %D A !> (, 9 "! &H @ !R 'X >@!] (, >P"/ 'L G@!Z *X >@#$ 'D
MXP!X /@ > #_ '@ _P#%    M    *<   "=    E0   (\   "+  8 B  0
M (8 &0"% "$ A  I (, , "" #8 @  \ '\ 00!^ $8 ?0!+ 'L 3P!Z %0
M>0!9 '@ 7P!V &4 =0!M ', =0!Q '\ < "* '  F !O *@ ;@"\ &T UP!M
M /  ; #^ &P _P"Y    J0   )P   "1    B@   (4   "!  ( ?@ + 'P
M% ![ !P >0 C '@ *@!W #$ =@ V '0 / !S $$ <@!& '  2P!O %  ;@!5
M &T 6P!K &$ :0!I &@ <0!F 'L 90"& &0 E !C *, 8P"U &( S0!A .<
M80#W &$ _P"O    H    )$   "(    @    'P   !Y    =0 & ', #@!Q
M !< ;P > &X )0!M "P :P Q &H -P!I #P 9P!! &8 1@!E $L 9 !0 &(
M5@!A %T 7P!E %X ;0!< '< 6P"# %H D !9 )\ 6 "O %< Q !7 -X 5P#R
M %< _0"G    EP$  (H$  " !@  > 4  ',#  !O    ;0 ! &H "0!H !(
M9@ 9 &4 ( !C "8 8@ L &$ ,@!? #< 7@ \ %T 00!; $< 6@!, %D 4@!7
M %D 5@!A %0 :@!3 '0 4@"  %$ C0!0 )L 3P"K $X O@!. -@ 30#L $X
M^ "@ P  CPD  (,,  !Y#0  <0T  &L,  !G"0  9 4  &, ! !A  L 7P 4
M %T &P!; "( 60 H %@ +@!6 #, 50 X %0 /0!3 $, 4@!) %  3P!/ %8
M30!> $P 9P!* '( 20!^ $@ BP!' )D 1@"I $4 O !% -( 10#G $4 \P":
M"0  B@X  'X2  !S%   :Q0  &43  !@$@  70X  %L*  !:!08 6 $- %8
M%@!4 !T 4@ C %  *0!/ 2\ 3@$T $P".@!+ C\ 2@-% $@#3 !'!%0 101<
M $0%9@!"!7$ 009] $ &B@ ^!ID /0:I #P%N@ \!-  / /C #L#[P"5#P
MAA0  'H7  !O&   9AD  %\8  !:%P  5A4  %02  !2#@  40H' $\'$ !-
M!Q@ 2P@? $D()0!(""L 1@DQ $4)-@!#"3P 0@I# $ +2@ _"U( /0Q; #P,
M9@ Z#7$ .0U^ #<.BP V#IH - ZK #0-O0 S#-( ,@SE #(,\ "0%   @A@
M '8:  !K'   8AT  %L<  !5&P  41H  $X8  !,%0  2A(" $D0"@!'#A,
M1 X: $(/(0!!$"< /Q M #T0,P \$3H .A)! #D22  W$U  -11: #049  R
M%7  ,15\ # 5B@ N%ID +16J "P4O0 K%-0 *Q3H "L3\P",&   ?AL  '(>
M  !G'P  7B   %<@  !1'P  31X  $D<  !&&@  1!<  $(6!0! %0X /146
M #L6'0 Y%B0 -Q8J #46,  T%S8 ,Q<^ #$81@ P&4X +QE8 "T:8@ L&FX
M*AM[ "D;B0 G&Y@ )ANI "4:O  D&M, )!GG "49] ")&P  >QX  &\A  !D
M(@  6R,  %0C  !.(@  22$  $0@  !!'@  /AP  #L< 0 X&PH -AL3 #0;
M&@ R&R  ,!LF "X<+0 M'#0 +!T[ "H>0P I'DP *!]6 "8?8  E(&P )"!Y
M "(@B  A()< (""H !\?NP >']( 'A[F !\>\P"&'0  >2$  &PC  !A)0
M6"8  % F  !*)0  124  $ D   \(P  .2$  #4A   R(0< +R$. "TA%@ K
M(1T *"$C "<A*@ F(C$ )2(Y "0C00 C)$H (214 " D7P ?)6L 'B5X !PE
MA@ ;)98 &B6G !DDN@ 8(]$ &2/F !HB\P"#(   =B,  &DF  !>*   52@
M $XH  !'*   0B@  #PG   X)P  ,R8  # F   L)@, *28+ "8F$P D)QH
M(B<@ "$G)P @*"X 'B@V !TI/P <*4@ &RE2 !HJ70 9*FD %RIW !8JA0 5
M*I4 %"JF !,IN0 2*-  $RCE !0G\P"!(@  <R8  &8H  !;*@  4BL  $LK
M  !$*P  /BL  #DJ   T*@  +RH  "HK   F*P  (RP( " L$  >+1< '"T>
M !LM)0 9+BP &"XT !<N/  6+T8 %2]0 !,O6P 2+V< $3!U  \PA  .+Y,
M#"^D  LNMP ++<T #"WB  TL\ !])0  <"D  &,K  !8+0  3RT  $@N  !!
M+@  .RX  #8M   P+0  *B\  "4P   A,0  '3$% !HR#0 8,Q4 %C,< !0T
M(@ 3-"D $C0Q ! T.@ .-$, #31-  LU6  *-60 "35R  @U@  &-)  !32A
M  0SLP $,LD !3+>  8Q[ !Z*   ;"P  & N  !5+P  3#   $4P   ^,
M.#   #,P   M,0  )S,  "(T   =-0  &#<" !0X"@ 1.1( #CH9  PZ(  *
M.B< "3HN  @Z-@ '.C\ !3I*  0Z50 ".F$  3IN   Z?0  .HT  #F>   X
ML   .,8  #?<   VZ@!V+   :2\  %PQ  !2,@  23,  $(S   [,P  -3,
M # S   J-0  )#<  !\X   :.@  %#P!  T^!P )0 \ !D 6  1 '0 "0"0
M 4 K  ! ,P  0#P  $!&  ! 40  0%T  $!K  ! >@  0(H  #^;   ^K0
M/<,  #W;   \Z@!R,   9#(  %@T  !.-0  1C8  #\V   Y-@  ,S8  "TW
M   G.0  (#L  !L]   5/P  $$(   A$!@ "10T  $83  !'&@  1R   $<G
M  !'+P  1S@  $="  !'30  1ED  $9G  !&=@  1H8  $:8  !$JP  0\
M $+8  !"Z@!M-   8#8  %0X  !+.   0SD  #PY   W.0  ,3H  "H\   C
M/@  '$$  !=#   110  "D@   -*!0  2PL  $P1  !-%P  3AT  $\D  !/
M*P  3C0  $X^  !.20  3E8  $YC  !-<@  38,  $V5  !,J   2KT  $G6
M  !(Z0!H.0  6SH  % [  !'/   0#P  #H\   T/0  +3\  "5"   >10
M%T<  !)*   *3   !$X   !1!   4@D  %,.  !4%   51H  %8@  !7)P
M5R\  %8Y  !61   5E$  %9?  !5;@  57\  %61  !5I0  4[L  %'3  !0
MZ !B/0  5CX  $P_  !$/P  /C\  #A    P0P  *$8  "!)   83   $DX
M  I1   $4P   %8   !8 0  608  %H+  !<$0  718  %X<  !?(@  8"H
M %\T  !?/P  7TL  %]:  !>:0  7GH  %V-  !=H0  7+<  %K0  !9Y@!<
M0@  44,  $E#  !#0P  /$,  #-&   K2@  (TT  !I1   25   "U8   19
M    7    %\   !@    8@(  &,&  !D"P  91$  &<6  !H'   :20  &HM
M  !I.   :44  &E3  !H8P  :'0  &>'  !FFP  9K   &3)  !CX0!71P
M3D<  $='  !!1P  -TH  "Y.   E4@  '%8  !-9   )70   V    !C
M90   &@   !J    :P   &P"  !N!@  ;PL  ' 0  !R%P  <QX  '4F  !U
M,0  =3T  '1,  !T7   =&T  '.   !QE0  <*H  &_   !NV !32P  3$L
M $9+   [3@  ,E,  "A7   >7   %&    ED   !9P   &H   !N    <
M ',   !T    =@   '<   !Y    >@,  'P(  !^#@  @!4  ((=  "$)@
MA#,  (-"  "#4@  @F0  (%X  " C0  ?J(  'VW  !\S0!13P  2T\  $!3
M   U6   *UT  "!B   59P  "6L   !P    <P   '8   !Y    ?    'X
M  "     @@   (0   "%    AP   (D   "+!   C0L  (\3  "2'   E28
M )0V  "31P  DEH  ))N  "1@@  CY@  (ZL  "-P !05   15@  #I=   O
M8@  (V@  !=N   +<P   '<   !\    ?P   ((   "%    B    (H   ",
M    C@   )    "1    DP   )4   "7    F0(  )P)  "?$@  HQL  *4I
M  "D/   HE   *)C  "B>   H8T  )^B  ">M !*70  /V(  #-H   H;@
M&W4   YZ   "@    (0   "(    BP   (X   "1    DP   )8   "8
MF@   )P   ">    H    *(   "C    I@   *D   "L!P  L!   +0=  "U
M+P  LT4  +-9  "U;0  MH(  +.7  "RJ0!%9P  .6T  "UT   A>P  %($
M  :'    BP   )    "3    EP   )H   ">    H@   *0   "F    J0
M *L   "L    K@   +$   "R    M0   +@   "\    P0(  ,@,  #.'0
MS3,  ,U)  #/70  T7(  ,^&  #.EP#_    _P   /\   #W    \@ ( .\
M% #I !X Y  G .( ,0#A #L W !# -@ 2@#4 %  T !5 ,X 6@#+ %\ R0!C
M ,< : #% &T PP!S ,( >0#  (  O@"( +P D0"Z )T N "K +8 O@"V .
MM0#Y +0 _P"S /\ K@#_ *H _P#_    _@   /    #I    XP $ -L $ #3
M !H T0 D ,\ +0#, #8 R  ^ ,0 10#! $P OP!1 +T 5@"[ %L N0!? +@
M8P"V &@ M !N +, = "Q 'L KP"" *T BP"K )8 J@"D *@ M "I -, J #R
M *< _P"F /\ HP#_ )\ _P#\    \0   .$   #6    S@   ,, "P#  !8
MO  @ +H *0"X #$ MP Y +0 00"Q $< KP!, *T 40"L %8 J@!: *D 7P"G
M &0 I@!I *0 ;P"B '4 H0!] )\ A@"= )  G "= )H K ": ,0 F@#H )H
M_P"9 /\ F #_ )4 _P#M    VP   ,T   ##    MP   +$ !@"M !$ J@ ;
M *D ) "H "P IP T *4 / "B $( H !( )\ 30"= %$ G !6 )L 6@"9 %\
MF !D )< :@"5 '  DP!X )( @ "0 (H C@"6 (P I0", +@ C0#< (P ^ ",
M /\ C #_ (H _P#=    R    +L   "O    IP   *$  @"=  L FP 6 )D
M'P"8 "< EP O )< -@"4 #P DP!" )$ 1P"0 $P CP!0 (T 50", %D BP!>
M (H 9 "( &L AP!R (4 >P"# (4 @@"0 (  G@!_ *\ @ #. (  [@!_ /\
M?P#_ '\ _P#)    N    *P   "@    F0   ),   "0  < C0 1 (L &@"*
M "( B@ I (D , "( #< A@ \ (0 0@"# $< @@!+ ($ 4 "  %0 ?P!9 'T
M7P!\ &8 >P!M 'D =@!W (  =0"+ ', F !R *@ <P#" ', XP!S /L <@#_
M '( _P"\    JP   )T   "4    C    (<   "$  , @0 , '\ % !^ !P
M?0 D 'T *P!\ #$ >@ W 'D / !X $  =P!% '4 2@!T $\ <P!4 '( 6@!P
M &  ;P!H &T <0!K 'L :0"& &@ DP!G *, 9P"X &8 U@!F /, 9@#_ &8
M_P"P    GP   )(   ")    @@   'T   !Y    =P ' '0 $ !S !< <@ ?
M '$ )0!P "L ;P Q &T -@!L #L :@ _ &D 1 !H $H 9P!/ &4 50!D %L
M8P!C &$ ; !? '8 7@"! %P C@!< )X 6P"Q %L R@!; .D 6@#[ %H _P"F
M    E0   (D   "     >    ',   !P    ;0 # &H "@!I !, 9P 9 &8
M( !E "8 9  L &( ,0!A #8 8  [ %\ /P!> $4 70!* %L 4 !: %< 6 !?
M %< 9P!5 '( 5 !] %( B@!2 )H 40"K %$ P0!0 -X 4 #T %  _P"=
MC0   ($   !X 0  <    &H   !F    9    &$ !@!?  T 70 5 %P &P!;
M "$ 6@ G %D + !8 #( 5@ V %4 .P!4 $  4P!& %$ 3 !0 %, 3P!; $T
M9 !, &X 2@!Z $D AP!) )8 2 "G $< NP!' -0 1@#L $8 ^0"5    AP0
M 'L&  !Q"   : @  &('  !>!0  6P(  %D  0!7  @ 5@ 0 %0 %@!3 !T
M40 C %  * !/ "T 3@ R $P -P!+ #P 2@!" $D 20!' %  1@!8 $0 80!#
M &P 00!W $$ A0!  ), /P"C #X M0 ] ,P /@#E #X ] "0!0  @0D  '4,
M  !K#@  8@\  %P.  !7#   5 H  %$'  !0 P, 3P * $T $@!+ !@ 2@ >
M $@ ) !' "D 1@ N $0 ,P!# #D 0@ ^ $  1@ _ $T /0!5 #L 7P Z &D
M.0!V #@ @P W )$ -@"A #4 L@ U ,@ -0#? #4 [P"+"0  ?0X  '$2  !F
M$P  710  %84  !1$P  31$  $L.  !)"@  2 <% $8## !% A, 0P$: $$!
M(  _ B4 /@(K #P",  [ S8 .@,\ #@$0P W!4L -093 #,&70 R!VD ,0=U
M # '@@ O!Y$ +0>@ "T&L@ M!,8 +0/< "T"ZP"'#0  >1,  &T5  !B%P
M61<  %(7  !-%P  2!8  $44  !"$0  00T  $ *!P ^" X / @6 #H('  X
M""$ -@DG #4)+0 S"3, ,@HZ #$+00 O#$D +@Q3 "P-70 K#6D *0YV "</
MA  F#Y, ) ZC "0-M  C#<@ (@S= "(,ZP"$$@  =A8  &D8  !>&@  51H
M $X;  !)&@  1!D  $ 8   \%@  .A0  #D1 @ W$ D -0X1 #,.%P Q#QX
M+Q D "X0*@ L$3$ *Q$X "D20  H$T@ )A-2 "447  C%&@ (A5U " 5@P ?
M%9( 'A6C !T4M0 ;$\H &Q/@ !P3[@"!%0  <QD  &8;  !;'0  4AT  $L=
M  !%'0  0!T  #L<   W&@  -!D  #,6   P%@0 +A4, "P5$P J%1H *!8@
M "86)@ D%RT (Q<U "(8/0 A&$8 'QE0 !X96@ =&F8 &QIS !H;@0 9&I$
M%QJB !89M  5&<D %1C? !88[P!^&   <!L  &,>  !8'P  3R   $@@  !"
M(   /"   #<?   S'@  ,!T  "T;   J&P$ )QL( "0;$  B&Q8 (!L< !\<
M(P >'"L '1TR !L=.P :'D0 &1Y. !@?60 6'V4 %1]R !0@@  2'Y  $1^A
M ! >LP /'L@ #AW> ! <[@![&@  ;1X  & @  !5(@  32,  $4C   ^(P
M.2(  #0B   P(0  +"   "@@   D(   (2 % !X@#  <(10 &B$: !@A(0 7
M(B@ %B(P !4C.  4(T( $R-, !$D5P 0)&, #B1P  PE?@ +)(T "B2>  DC
ML  ((L0 ""+:  DAZ@!X'0  :B   %TC  !2)   2B4  $(E   [)@  -B4
M #$D   L)   *"0  ",D   ?)0  '"4" !DF"0 6)Q$ %"<8 !(G'P 1*"8
M#R@M  TI-@ ,*3\ "RE)  HI5  (*5\ !RIL  4J>P $*HH !"F;  ,HK  "
M)\$  B;7  ,FYP!U(   9B,  %HE  !/)P  1R@  #\H   X*   ,R<  "XG
M   I)P  )2<  " H   ;*0  %RH  !,L!P /+0X #"T6  HM'  )+B, !RXJ
M  8N,@ %+SL !"Y%  ,N4  !+EP  "]I   O>   +X@  "Z8   MJ@  ++X
M "O5   KY@!Q(P  8R8  %<H  !,*0  1"H  #PK   V*@  ,"H  "LJ   G
M*0  (BH  !TL   8+0  %"\   XQ!@ (,PP !3,4  ,S&@ !-"   #0G   T
M+P  -#@  #1"   T30  -%D  #1F   T=0  -(4  #.6   RJ   ,;P  #'3
M   PYP!M)P  7RD  %,K  !)+   02T  #DM   S+0  +BT  "HL   D+0
M'RX  !HP   5,@  $#0   DV!0 $. L  #D1   Y%P  .AX  #HD   Z+
M.S0  #L^   Z20  .E8  #IC   Z<@  .H(  #J4   XIP  -[H  #;2   U
MY@!I*@  6RT  $\N  !&+P  /3   #8P   Q+P  +"\  "<P   A,0  &S,
M !8U   1-P  "CH   4\!0  /0H  #\0   _%0  0!L  $$A  !!*0  03$
M $(Z  !!1@  05(  $!@  ! ;P  0'\  $"1  ! I0  /KD  #S1   [YP!D
M+@  5S   $LR  !",P  .C,  #0S   O,@  *C,  ",T   =-P  %SD  !$[
M   +/@  !4    !"!   1 @  $4-  !&$@  2!@  $D>  !))0  22T  $HV
M  !)00  24X  $A<  !(:P  1WP  $>.  !'H@  1;@  $31  !"Y@!?,@
M4C0  $@U   _-@  .#8  #,U   M-@  )C@  !\Z   8/0  $D    M"   %
M10   $<   !) @  2P8  $P*  !.#P  3Q0  %$:  !2(   4B@  %(R  !2
M/   44D  %!7  !09P  3W@  $^*  !/GP  3K4  $S/  !+YP!9-P  33@
M $0Y   \.0  -S@  #$Y   I.P  (3X  !E!   31   "T<   5*    3
M $\   !1    4@,  %0'  !6"P  5Q$  %D6  !;'   7"0  %PM  !;-P
M6D,  %I2  !98@  67,  %B&  !7F@  5[   %?+  !4Y0!3/   23P  $$]
M   [/   -3P  "P_   D0@  '$8  !-*   ,3   !4\   !2    50   %<
M  !9    6P   %T#  !>!P  8 L  &(1  !D%P  91X  &8G  !F,0  93T
M &1+  !D7   8VX  &*   !AE0  8:L  &#%  !@X0!.0   1D   #]    Y
M0   ,$,  "='   >2P  %4\   M3   %5@   %D   !<    7@   &$   !C
M    90   &8   !H @  :08  &L+  !N$0  ;Q@  '$@  !Q*@  <38  '!$
M  !P5   ;V8  &YY  !MC@  ;*0  &N[  !KU@!+10  1$0  #Y$   T2
M*TP  "%0   750  #%D   -=    8    &,   !F    :0   &P   !N
M;P   '$   !S    =    '8$  !X"0  >A$  'P8  !_(@  ?RT  'X[  !^
M2P  ?5X  'QQ  ![A@  >IP  'BS  !WRP!)20  0T@  #E,   N40  )%8
M !E;   -8    F4   !H    ;    &\   !S    =@   '@   !Z    ?
M 'X   "     @@   (0   "&    B 8  (L-  ".%P  D2(  ) O  "00
MCU(  (UG  ",?   BY(  (FG  "'O !(30  /5$  #-6   H7   '&$   ]G
M   ";    '(   !V    >0   'T   "     @@   (4   "'    B@   (P
M  "-    CP   )(   "4    E@   )D#  "=#   H!8  *0B  "C,P  HD<
M *!<  "?<   GH8  )V;  ":K@!#5@  -UL  "QB   ?:   $VX   5T
M>@   '\   "#    AP   (H   "-    CP   )(   "4    E@   )D   ";
M    G0   )\   "A    I    *<   "K 0  KPH  +05  "W)@  M3L  +)1
M  "R9@  LGL  +*/  "OH@ ]80  ,6<  "5N   8=0  "7L   ""    AP
M (P   "0    DP   )8   "9    G    )X   "A    HP   *4   "G
MJ@   *P   "N    L    +0   "X    O0   ,0)  #+&0  RBX  ,='  #(
M6P  RG   ,R#  #)E@#_    _@   /P   #X    [P $ .@ $ #F !L X0 E
M -\ +@#? #< V@ _ -4 1P#2 $T SP!2 ,P 6 #* %P R !A ,8 9@#$ &L
MP@!P ,  =@"^ 'T O "% +D C@"V )H M "H +( NP"P -D K@#W +( _P"K
M /\ I0#_ *( _P#\    ]P   .\   #H    V@   -0 "P#. !8 S  @ ,H
M*@#) #, Q@ [ ,( 0@"_ $D O0!. +L 4P"Y %@ MP!< +4 80"T &8 L@!K
M +  <0"O '@ K0!_ *H B0"H )0 I@"A *0 L@"B ,P H0#N *, _P"@ /\
MFP#_ )@ _P#T    Z@   -T   #,    Q0   +T !@"Z !( MP < +8 )0"U
M "X M  V +$ /0"N $, K !) *H 3@"I %( IP!7 *8 6P"D &  HP!E *$
M; "@ '( G@!Z )P @P": (X EP"; )8 J@"4 ,  DP#B )0 _P"5 /\ D #_
M (X _P#E    U@   ,@   "Y    L    *L  @"H  P I0 7 *0 ( "C "@
MHP P *$ -P"> #T G !# )L 2 "9 $T F !2 )< 5@"5 %L E !@ ), 9@"1
M &T CP!T (X ?@", (@ B@"5 (@ I "& +< A #4 (4 ]@"' /\ A0#_ (,
M_P#2    P0   +$   "H    H    )L   "7  < E0 1 )0 &@"3 ", D@ J
M )( ,0"0 #< C@ ] (T 0@"+ $8 B@!+ (D 4 "( %4 AP!: (4 7P"$ &8
M@@!N ($ =P!_ ($ ?0". 'L G0!Z *X > #( '@ ZP!Y /\ >0#_ '@ _P#!
M    L0   *(   "9    D@   (T   ")  , A@ , (4 %0"$ !T A  D (0
M*P"" #$ @  W 'X / !] $  ? !% 'L 20!Z $X > !4 '< 6@!V &  = !H
M ', <0!Q 'L ;P"' &T E@!L *8 :P"] &L X !L /X ; #_ &P _P"S
MH0   )4   ",    A0   (    !]    >@ ' '@ $ !W !@ =0 ? '4 )@!U
M "P <P Q '( -@!Q #L <  _ &\ 1 !M $@ ; !- &L 5 !J %L : !C &8
M:P!D '8 8P"! &$ D !@ *  7P"T %\ U0!? /4 7P#_ &  _P"F    E@
M (H   "!    >@   '4   !Q    ;@ # &L "P!J !, :0 : &D ( !I "8
M9P L &8 ,0!D #8 8P [ &( /P!A $0 8 !) %\ 3@!= %8 7 !> %H 9P!9
M '$ 5P!\ %4 BP!4 )H 4P"M %0 R@!4 .L 5 #_ %0 _P"<    C0   ($
M  !X    <    &H   !G    8P   &$ !@!@  T 7@ 5 %T &P!= "$ 7  G
M %L + !: #$ 60 V %@ .@!7 #\ 5@!$ %0 2@!3 %  4@!: %  8@!. &T
M30!X $L A@!* )8 20"G $H P !* .  2@#X $H _P"4    A0   'D   !O
M    9P   &$   !=    6@   %@  @!6  D 50 0 %0 %@!3 !P 4P B %(
M)P!1 "P 4  Q $\ -@!- #L 3 !  $L 1@!* $P 2 !5 $< 7@!% &D 0P!T
M $$ @@!  )$ 00"D $$ N0!! -4 0 #P $  _@",    ?@   ',!  !H P
M7P0  %D#  !5 @  4@   %    !.  4 30 + $P $@!+ !@ 2@ > $D (P!(
M "@ 1@ M $4 ,@!$ #< 0P \ $$ 0@!  $D /P!1 #T 6P [ &4 .0!Q #@
M?P V (X . "@ #@ LP W ,P -P#G #< ]P"'    >00  &P'  !B"0  60D
M %,)  !."   2@8  $@#  !'  $ 10 ' $0 #0!" !0 00 9 $  '@ _ ",
M/0 H #P +@ [ #, .0 Y #@ /P W $8 -0!/ #0 6  R &, ,0!O #  ?0 P
M (P +P"< "\ K@ N ,, +@#= "X [P""!   = D  &@+  !=#0  50X  $X.
M  !(#0  1 P  $$)   _!P  /@0# #P "0 [  \ .0 5 #@ &@ V !\ -0 D
M #0 *@ R "\ ,0 U #  /  N $, +0!, "P 5@ J &$ *0!M "@ >P G (D
M)P"9 "8 J@ E +X )@#7 "8 ZP!_"   < P  &00  !9$0  4!,  $D3  !$
M$@  /Q$  #L/   X#0  -@H  #4'!0 T!0H ,@,0 #$#%@ O AP +@,A "P#
M)@ K RP *00R "@$.0 G!4$ )09+ "0'50 C!V  (@=M " (>@ ?"(D '@B9
M !T'J0 =!;P '0/3 !T!YP![#   ;1   & 3  !6%   318  $86   _%@
M.A4  #84   S$@  ,!   "X. 0 M"P4 + D+ "H($@ H"1@ )@D= "4)(P C
M"BD (@HP "$+.  @"T$ '@Q* !T-50 ;#6$ &0YN !@.?0 6#HP %0Z< !4-
MK  4#+X % O3 !0*Y !X$   :10  %T5  !2%P  2A@  $(9   \&0  -A@
M #(7   N%@  *Q4  "D3   G$@( )1 & ",0#  A#Q0 'P\: !X0(  <$"<
M&Q$O !H2-P 9$D  %Q-* !845  4%&  $A1M !$5>P 0%8L #A2;  P4K  +
M$[\ "A+4  L1YP!U$P  9A8  %H8  !0&@  1QL  #\<   X&P  ,QL  "X:
M   J&0  )Q@  "07   A%@  'Q4# !P5"  :%1  &!46 !<6'0 5%B0 %!<L
M !,7-0 2&#X $1A(  X94@ ,&5X "QIJ  D:>  (&H< !QF7  89J  %&+P
M!!?1  46XP!R%0  8QD  %<:  !-'   1!T  #P>   U'@  ,!T  "L<   G
M'   (QL  " :   =&@  &1H  !<:!0 4&PP $AL4 ! <&P .'"( #!PI  L=
M,0 *'3H "1Y$  @>3@ &'EH !!]G  ,?=0 !'X0  1Z5   =I@  '+D  !S/
M   ;X@!O&   8!L  %0=  !*'P  02   #D@   S(   +1\  "@?   D'@
M(!T  !T=   :'0  %1X  !$@!  .( H "B$2  DA&  '(1\ !B(F  0B+@ #
M(S8  B-   $C2P  (U<  "-D   C<P  )((  ".3   BI   (;<  "#-   ?
MXP!K&@  71X  %$@  !'(0  /B(  #8B   P(@  *R$  "8A   B(   'B
M !L@   7(0  $B(   TD!  ))@D !280  ,G%@  )QT  "<C   H*P  *#,
M "D]   H2   *%0  "AB   H<   *(   "F1   GHP  );8  "3-   DX@!H
M'@  6B   $XB  !$)   .R4  #,E   M)   *"0  "0C   @(@  '2(  !@C
M   4)0  #B<   HH!  %*PD  "P.   M%   +1H  "TA   N*   +C   "\Z
M   O1   +E$  "U?   N;@  +7X  "Z/   NH@  ++8  "K+   IXP!D(0
M5B,  $HE  ! )P  ."<  #$G   K)@  )B8  "(E   >)0  &B8  !4H   0
M*@  "BP   4N!   , @  #$,   S$@  -!@  #0>   U)0  -2T  #4V   U
M00  -4X  #1<   S:P  ,WL  #.-   SH   ,;4  ##-   NXP!?)0  4B<
M $<I   ]*@  -2H  "XI   I*0  )2@  " H   ;*0  %BL  !$M   +,
M!C(   $T P  -@<  #<+   Y$   .A4  #L;   \(@  /"H  #PS   \/0
M/4D  #M8   Z:   .G@  #F+   YG@  .;0  #?-   UY0!:*   3BL  $,L
M   Y+0  ,BT  "TL   H*P  (RL  !TM   8+P  $C$   LT   &-@   3@
M   [ @  / 4  #X)  ! #0  01(  $,8  !$'P  1"8  $0O  !$.@  1$4
M $-4  !"9   0'4  $"(  ! G   0+(  #_-   ]YP!5+0  22X  #\P   V
M,   ,"\  "PN   F+@  'S   !DS   3-0  ##@   8[    /0   $    !"
M    1 ,  $4&  !'"@  20\  $L5  !-&P  32(  $TK  !--0  34$  $Q/
M  !*7P  27$  $F$  !(F   2*X  $C)  !'Y@!0,0  13(  #LS   T,P
M+S$  "DR   B-   &C<  !0Z   ,/0  !D    !"    10   $@   !*
M3    $X#  !/!P  40L  %,1  !6%@  6!T  %@F  !8,   6#L  %=(  !5
M60  4VP  %)_  !2E   4:H  %'%  !0XP!*-@  0#8  #DV   S-0  +34
M "4X   <.P  %#\   U"   &10   $D   !,    3@   %$   !3    50
M %<   !9 P  6P<  %T+  !?$0  8A@  &,@  !C*@  8C8  &)#  !@4P
M7V8  %U[  !<CP  7*4  %N^  !:W0!&.@  /3H  /_B?1!)0T-?4%)/1DE,
M10 +%3<Y   R.0  *3P  !]    61   #4@   9+    3P   %(   !5
M6    %H   !=    7P   &$   !C    90(  &<&  !I"P  ;!(  &X:  !O
M(P  ;R\  &X\  !L3   :UX  &IS  !IB   :)X  &>V  !FTP!"/@  /#T
M #8]   M0   (T4  !E)   .3@  !5(   !6    6@   %T   !@    8@
M &4   !G    :0   &L   !M    <    '(   !T!@  =PL  'H3  !\'
M?"<  'LU  !Z1   >58  'AK  !W@   =I8  '2L  !SQ0!!0@  .T(  #%%
M   G2@  '$\  !%4   %60   %X   !A    90   &D   !L    ;P   '(
M  !T    =@   '@   !Z    ?    'X   "     A (  (8)  ")$@  C!T
M (PJ  "+.@  BDP  (E@  "'=@  AHP  (6B  "#N0!!1@  -DH  "M0   @
M50  %%L   =@    9@   &L   !O    <P   '8   !Z    ?0   (    ""
M    A0   (<   ")    BP   (X   "0    DP   )8   ":!@  G1$  *(=
M  "A+   GS\  )Y4  "<:@  FH   )B5  "7J@ [3P  ,%4  "5;   880
M"F@   !N    =    'D   !]    @0   (4   "(    BP   (X   "0
MDP   )4   "7    F@   )P   "?    H@   *4   "I    K@4  +,1  "X
M'@  MS(  +1'  "R7@  L',  *^(  "NFP U6@  *6$  !QH   .;@   '8
M  !\    @@   (<   "+    CP   ),   "6    F    )L   ">    H0
M *,   "F    J    *L   "N    L    +0   "Y    OP   ,4$  #.$0
MT20  ,T[  #(4P  R&@  ,A]  #(CP#[    ]P   /4   #R    [    .4
M"P#B !< X  B -\ *P#? #0 V@ \ -8 0P#2 $H SP!/ ,P 50#* %H QP!>
M ,4 8P## &@ P0!N +\ = "] 'L N@"$ +@ C@"V )H LP"I +  O@"M -X
MJP#Z *H _P"A /\ G@#_ )H _P#T    [P   .L   #?    U    ,\ !P#+
M !, R0 = ,@ )@#' "\ Q0 W ,  /@"] $0 NP!* +D 3P"W %0 M0!9 +0
M70"R &( L !H *\ ;@"M '4 JP!] *D AP"G )( I0"A *( M "? -( G0#T
M )L _P"6 /\ DP#_ )  _P#K    Y0   -,   #&    O@   +D  @"V  T
MM  7 +( (0"Q "D L0 Q *X . "L #X J@!$ *@ 2 "F $T I0!1 *0 5@"B
M %L H !A )X 9P"< &X FP!V )D ?P"7 (L E0"8 )0 J@"2 ,4 D #J (X
M_P"* /\ A@#_ (4 _P#@    S@   +T   "R    JP   *8   "B  < H0 2
M *  &P"? ", GP K )P ,@"9 #@ EP ^ )4 0P"4 $< D@!+ )$ 3P"0 %0
MCP!9 (X 8 ", &@ B@!O (D >0"' (, A0"1 (0 H0"" +8 @0#; (  ^P"
M /\ ? #_ 'L _P#+    MP   *H   "A    F@   )4   "2  , D  , (T
M%0", !X C  E (P + "* #( B  X (< /0"% $$ A !& (, 2@"" $X @0!3
M (  60!_ &  ?0!I 'L <@!Z 'T > ") '8 F0!T *P <P#, '( \0!Q /\
M< #_ &\ _P"X    IP   )L   "2    BP   (8   "#    ?P ' 'X $ !]
M !@ ?0 ? 'T )@![ "T >0 R '@ -P!W #P =@!  '4 10!S $D <@!. '$
M5 !P %H ;P!A &T ; !K '< :0"# &< D@!F *, 90"^ &0 Y0!C /\ 9 #_
M &, _P"H    F0   (T   "%    ?@   'D   !T    <@ # '  "P!O !,
M;@ : &X (0!N "< ;0 L &L ,@!J #8 :0 [ &@ /P!G $0 9@!) &4 3P!C
M %4 8@!< &$ 90!? '( 70!^ %L C !9 )T 5P"T %< U@!7 /< 6 #_ %D
M_P"=    C@   (,   !Y    <@   &L   !H    90   &, !@!B  T 8@ 5
M &( &P!B "( 80 G &  +0!? #( 7@ V %T .P!; #\ 6@!% %D 2@!8 %$
M5P!8 %4 8 !4 &L 4@!Y %  AP!. )< 3 "L $L R0!+ .X 3@#_ $X _P"3
M    A0   'D   !O    9@   &$   !=    6@   %D  @!8  D 5P 1 %<
M%P!7 !T 5P B %4 )P!4 "P 4@ Q %$ -@!0 #H 3P!  $X 10!, $P 2P!3
M $H 7 !( &8 1P!T $4 @@!# )( 00"F $  OP!  .0 0P#^ $0 _P"+
M?0   '$   !F    7@   %<   !3    40   $\   !.  8 30 + $T $@!,
M !< 3  = $L (@!* "< 2  K $< , !& #4 1  [ $, 00!! $@ 0 !/ #\
M6  ] &( / !P #H ?@ X (T -P"A #< N  Y -L .@#W #H _P"$    =@
M &H   !?    5@   %    !,    20   $<   !%  ( 1  ' $, #0!" !,
M0@ 8 $$ '0!  "( /@ G #T *P [ #  .@ V #@ /0 W $0 -@!, #0 50 S
M %X ,@!M #$ >@ P (H +P"< "X L0 P ,X ,0#M #( _P!^    <    &0"
M  !9!   404  $H%  !%!   00(  #X    ]    .P $ #H "0 Y  X .  3
M #< &  U !T ,P B #( )P Q "P ,  Q "\ .  M $  + !( "L 40 J %P
M*0!I "@ =P G (< )P"9 "< K  H ,0 * #C "@ ]P!Z    ; 0  %\&  !4
M"   3 D  $4)   _"0  .P@  #<&   U!   ,P(! #( !0 P  H +P / "X
M%  M !D +  > "H (P I "@ *  N "< -  F #T )0!% ", 3P B %H (0!G
M "  =0 @ (4 'P"5 !\ IP ? +P 'P#9 !\ [P!V P  9P<  %L*  !0#
M2 T  $ -   Z#0  -0P  #$+   N"0  + @  "H& P I P8 * (+ "<!$  F
M !4 )  : ", 'P B "4 (  K "  ,@ ? #H '@!# !T 30 ; %@ &@%E !D
M<P 8 (( & "2 !< HP 7 +< %@#/ !8 Y@!R!@  9 H  %<-  !-$   1!$
M #P1   V$0  ,1   "T/   I#@  )@P  "0+ 0 B"00 (0<' " %"P >!1$
M'046 !P%'  ;!2( &@4H !D%+P 8!3@ %P5! !8&3  4!U< $P=D !$(<@ 0
M"($ #P>1  X&H@ .!;0 #@/*  \!X@!N"@  8 P  %00  !*$P  010  #D4
M   S%   +1,  "D3   E$@  (1$  !\/   <#@( &PP% !D+"  8"@T %@D3
M !4)&  4"A\ $PHF !(*+@ 1"S< $ Q!  T-3  +#E@ "0]D  @/<@ '#X$
M!@Z1  8-H@ %#+0 ! O)  4)W0!K#0  71   %$3  !'%0  /18  #86   O
M%@  *A8  "45   A%   'A,  !L2   8$@( %A$$ !00!@ 1#PD #@X.  T0
M%@ ,$!T "Q$D  H2+  )$C4 "!,^  <320 %%%0  Q1A  (5;P !%7X  !2/
M   3H   $K(  !''   0W0!H$   6A(  $X5  !$%P  .A@  #,9   M&
M)Q@  "(7   >%@  &Q4  !@5   5% ( $Q0% ! 3!@ ,% @ "14,  @5$P &
M%AH !18A  07*  #%S$  A@[  $810  &%$  !E>   9;0  &7T  !F-   8
MGP  %K$  !7'   4W0!E$P  5Q4  $L8  !!&@  .!L  # ;   J&@  )!H
M " 9   <&   &1<  !87 0 3%@, $18$  P7!0 (& < !1H+  ,;$0 !&Q@
M !L>   <)@  '2X  !TX   =0P  'DX  !U<   =:P  '7L  !V,   =G@
M&[$  !G&   8W@!B%0  5!@  $@:   ^'   -1T  "X=   G'   (AP  !X;
M   :&@  %QD  !48 @ 1&0( #1H#  D;!  %'0<  1X*   @$   (18  "$<
M   A(P  (BL  "(U   C0   (TP  "):   B:0  (GD  "&+   AG0  (;$
M !_(   =W@!>&   41L  $4=   Z'P  ,A\  "L?   E'@  (!T  !P<   9
M&P  %AL  !(;   .'0  "AX!  4@ P !(@8  "0)   F#0  )Q0  "<:   H
M(0  *"D  "@R   H/0  *4D  "E6   G9P  )G@  ":)   FG0  )K$  "3*
M   BX@!:&P  31X  $$@   W(0  +R$  "@A   C(   'Q\  !P>   8'@
M%!X   \@   *(0  !B,   (E @  )P4  "H(   L#   +A(  "X8   N'P
M+R8  "\O   O.@  +T8  #!3   N9   +'8  "R'   LFP  *[   "O*   H
MY !6'P  22$  #XC   T)   +"0  "8C   B(@  'B$  !H@   5(0  $",
M  LE   &)P   2D    L 0  +@0  # '   R"@  -!   #46   V'   -B0
M #8L   W-P  -T(  #=/   V8   -'(  #*%   RF0  ,:\  #'*   QY@!1
M(P  124  #HG   Q)P  *B8  "4E   A)   '2,  !<E   2)P  #"D   8K
M   !+@   #     S    -0(  #<%   Z"   / P  #X2   _&   /R   #\H
M   _,P  /SX  #]+   _6@  /&X  #J#   YE@  .:T  #C)   XYP!,)P
M0"D  #8J   N*0  *"@  "0G   ?)P  &2@  !,J   ,+0  !S    $S
M-@   #@    [    /0   #\"  !!!0  0PD  $8.  !(%0  2!P  $@D  !(
M+@  2#H  $A'  !(50  16D  $-^  !"DP  0:H  $#'  ! Y@!'*P  /"T
M #,M   L+   *"H  "(J   ;+   %2\   TR   '-0   3@    [    /@
M $$   !#    10   $@   !* P  3 8  $X+  !1$0  4Q<  %,@  !3*0
M4S4  %-"  !24   3V0  $UX  !+CP  2J8  $K!  !)XP!",   .#$  # P
M   L+@  )BX  !XQ   7-   #S<   <[    /@   $$   !$    1P   $H
M  !,    3P   %$   !3    50,  %<'  !:#   71,  %\;  !?)   7R\
M %X\  !>2P  7%P  %ER  !7B   5I\  %6Y  !4V@ ]-   -30  # R   J
M,@  (34  !@Y   0/   !T    !$    2    $L   !.    4@   %0   !7
M    6@   %P   !>    8    &,!  !F!0  :0L  &P3  !N'   ;B<  &TU
M  !L0P  :E0  &=J  !E@0  8YD  &*Q  !ASP Z.   -#<  "\V   E.0
M&SX  !!#   (1P   $L   !0    5    %<   !:    70   &    !B
M90   &<   !I    ;    &X   !Q    = 8  '@,  ![%@  ?"   'LM  !Z
M/   >$P  '9A  !T>   <I$  '"G  !OP0 Y.P  -#L  "D^   >0P  $TD
M  =/    4P   %<   !<    7P   &,   !F    :0   &P   !O    <0
M ',   !V    >    'L   !]    @0   (0%  "(#0  BQ@  (PD  "*,P
MB$0  (99  "$<   @H@  (&=  !_M  Y/P  +D,  "-)   83P  "U4   !;
M    8    &0   !H    ;    '    !T    =P   'H   !]    ?P   ($
M  "$    A@   (@   "+    C@   )(   "6 @  F0P  )T9  "=*   FSD
M )E-  "78P  EGL  )20  "2I@ S20  *$X  !Q4   06P   F(   !H
M;0   '(   !W    >P   '\   "#    A@   (D   ",    CP   )$   "4
M    E@   )D   "<    H    *0   "H    K0   +(+  "W&@  M2L  +-
M  "P5@  KFT  *N#  "JEP M5   (5L  !5A   &:    &\   !V    ?0
M ((   "'    BP   (X   "2    E0   )@   ";    G@   *$   "C
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M_________________________________________P
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M_?[_;69T,0     #!"$   $                    !
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MB_G%K8OYQ:V+^<6MB_G%K8OYQ:V+^<6MB_G%K8OY[<0R!NK(-QOGRSLZYLQ
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M@.^HLX#OJ+. [ZBS@.^HLX#OJ+. [ZBS@.^HLX#OJ+. [ZBS@.^HLX#OJ+.
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MKHOXQ*Z+^,2NB_C$KHOX_+0@ ?>Z/Q#WNT4J^+M)2OBX4FWXMEF+\;I7G>K
M5*W?R$V_T,)6U<>Y;.;$LWWPQ*^&]L2OB??$KHKWQ*Z*^,.NBOB_KHGXO:Z)
M][NOBO:XKXOVN*^+]KBOB_:XKXOVN*^+]KBOB_:XKXOVN*^+]KBOB_:XKXOV
MN*^+]KBOB_:XKXOV^[4? ?>[/P_VO$0I][Q)2OBY46SUN56'[\!2E^;)3:;5
MSD3 R<-;T\.\;N#"MWKHPK6![,"SA.^ZLH+QM+& \K"Q@?.OL8/RK[*%\JZR
MB/&NLXKPKK.*\*ZSBO"NLXKPKK.*\*ZSBO"NLXKPKK.*\*ZSBO"NLXKPKK.*
M\*ZSBO"NLXKP^K8? ?:[/@_UO4,I]KU(2?>[4&SROT^ Z,E-C-O8.*C,STJ^
MP\9?SL# ;]F_O'G?O[I_Y+>X?.>NMGKIJ+5YZZ2U>NRBM7SLHK6 ZZ.VA.JC
MMH?JH[:'ZJ.VA^JCMH?JH[:'ZJ.VA^JCMH?JH[:'ZJ.VA^JCMH?JH[:'ZJ.V
MA^JCMH?J^;<? ?6\/0[TOD(G]+]'2/6]36KJR$IUV]@YCL_<.*C$T4^[OLEB
MR+S$;]&\P7C7M;YWVZN]==^CNW/AG;ISXYJZ=.28N7?DF+I[Y)BZ?^.9NH/B
MF;J#XIFZ@^*9NH/BF;J#XIFZ@^*9NH/BF;J#XIFZ@^*9NH/BF;J#XIFZ@^*9
MNH/B][@? /.^.PWRP$ F\L%%1N[%1U_=U3IPS^0WC\3=/Z:\U%*UN<YCP+C)
M;\BQQG#.J,-OTJ#";=:9P&W8E+]MVI"_;MN/OG';CK]UVXZ_>MJ/OWW:C[]]
MVH^_?=J/OWW:C[]]VH^_?=J/OWW:C[]]VH^_?=J/OWW:C[]]VH^_?=J/OWW:
M];H> /+ .0SPPCXD[\-#1.'2.T_0Y#1SQ.L]C;O@1Z"UV56ML]-CMZO/9KZA
MS&7$F<EER)+'9<R-QF7.B<5GT(?$:-&&Q&O1A<1OT87$<]&%Q7;0A<5VT(7%
M=M"%Q7;0A<5VT(7%=M"%Q7;0A<5VT(7%=M"%Q7;0A<5VT(7%=M"%Q7;0\KT<
M ._"-@KMQ3LAY<TZ-='C+E3$[SERN^Y$B+3E3IBOWEBDI-I9K9K56K.2TENY
MB]!;O8;.7,"!S5W"?\Q?Q'W+8<1[RV3%>LMGQ7K+:\5ZRV_%>LMOQ7K+;\5Z
MRV_%>LMOQ7K+;\5ZRV_%>LMOQ7K+;\5ZRV_%>LMOQ7K+;\5ZRV_%[\ 9 .O&
M,0CHRC8=T^ F-<7O,U6[^#]NL_-*@*SK4HZ?Y5"9E>!/HHS<4:F%V5*N?]94
MLGK45K5WTUBW==):N'/27;ERTF"Z<=%DNG'1:+IQTFRY<=)LN7'2;+EQTFRY
M<=)LN7'2;+EQTFRY<=)LN7'2;+EQTFRY<=)LN7'2;+EQTFRYZL45 .7+* 76
MW!H8Q^XK-[OY.5&S_D5FJ_E+=9_Q2H.4ZTJ.B>9*EX#B2IYYWTVD<]Q/J&_;
M4:ILVE2L:ME7K6G96JUHV5VN:-EAKFC99:YHV6FM:-EIK6C9::UHV6FM:-EI
MK6C9::UHV6FM:-EIK6C9::UHV6FM:-EIK6C9::UHV6FMY,P- -[3%P3)["$;
MO/DQ-;/_/TJK_T1;G_]#:I/X0W>(\D2"?NQ%C'7H1I-MY4B8:.-+G&7B3IYC
MX5&?8N%4H&'@6*%@X%NA8.!?H6#@8Z%@X&:@8.!FH&#@9J!@X&:@8.!FH&#@
M9J!@X&:@8.!FH&#@9J!@X&:@8.!FH&#@9J!@X&:@U](' ,SI$P>^^"<:M/\V
M+JO_.S^?_SM0D_\[7XC^/6Q]^#YW<_- @&KO0H=C[$6,7NI(CUSI3)%:Z5"2
M6>E3DEGH5I)9Z%F26.A=DECH89)8Z6226.EDDECI9))8Z6226.EDDECI9))8
MZ6226.EDDECI9))8Z6226.EDDECI9))8Z622_Z83 ?^K+@[_KD F_Z],0O^M
M66#_J6)[]Z1JDN^B;Z/HH'.QXYYYO-Z:?<;:E8'.V)&%T]6,B-?4BHS:TXF0
MV].*E=S3BYG<TXR=W-.-H-S.D*';RI*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':
MR9*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':_Z83 ?^K+@[_KD F_Z],0O^M66#_
MJ6)[]Z1JDN^B;Z/HH'.QXYYYO-Z:?<;:E8'.V)&%T]6,B-?4BHS:TXF0V].*
ME=S3BYG<TXR=W-.-H-S.D*';RI*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':R9*A
MVLF2H=K)DJ':R9*AVLF2H=K)DJ':_Z83 ?^K+@[_KD F_Z],0O^M66#_J6)[
M]Z1JDN^B;Z/HH'.QXYYYO-Z:?<;:E8'.V)&%T]6,B-?4BHS:TXF0V].*E=S3
MBYG<TXR=W-.-H-S.D*';RI*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':R9*AVLF2
MH=K)DJ':R9*AVLF2H=K)DJ':_Z83 ?^K+@[_KD F_Z],0O^M66#_J6)[]Z1J
MDN^B;Z/HH'.QXYYYO-Z:?<;:E8'.V)&%T]6,B-?4BHS:TXF0V].*E=S3BYG<
MTXR=W-.-H-S.D*';RI*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':R9*AVLF2H=K)
MDJ':R9*AVLF2H=K)DJ':_Z83 ?^K+@[_KD F_Z],0O^M66#_J6)[]Z1JDN^B
M;Z/HH'.QXYYYO-Z:?<;:E8'.V)&%T]6,B-?4BHS:TXF0V].*E=S3BYG<TXR=
MW-.-H-S.D*';RI*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':
MR9*AVLF2H=K)DJ':_Z83 ?^K+@[_KD F_Z],0O^M66#_J6)[]Z1JDN^B;Z/H
MH'.QXYYYO-Z:?<;:E8'.V)&%T]6,B-?4BHS:TXF0V].*E=S3BYG<TXR=W-.-
MH-S.D*';RI*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':R9*A
MVLF2H=K)DJ':_Z83 ?^K+@[_KD F_Z],0O^M66#_J6)[]Z1JDN^B;Z/HH'.Q
MXYYYO-Z:?<;:E8'.V)&%T]6,B-?4BHS:TXF0V].*E=S3BYG<TXR=W-.-H-S.
MD*';RI*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':R9*AVLF2H=K)DJ':R9*AVLF2
MH=K)DJ':_Z83 ?^K+@[_KD F_Z],0O^M66#_J6-[]Z5JDN^D;Z/HHG.QXI]Y
MO=Z<?<?:EX'.UY.$U-6.B-C4BXO;TXJ0W-.+E-W3C)C=TXV=W=&/H-W,D:#<
MR).@W,B3H-S(DZ#<R).@W,B3H-S(DZ#<R).@W,B3H-S(DZ#<R).@W,B3H-S(
MDZ#<_Z83 ?^L+@W_KT E_[!-0O^N6F#_JV-[]J=JD^^H<*/HIW2QXJ5YOMVB
M?<C9GH'0UIF$U].3A]O2CXK?T8V/X=&.E.'1CYCAT9"<X<R3G>'(E9W@PY6=
MX,.5G>##E9W@PY6=X,.5G>##E9W@PY6=X,.5G>##E9W@PY6=X,.5G>##E9W@
M_Z<2 ?^M+@W_L$$E_[%-0O^O6F#_K&1[]ZIKDN^J;Z/HJ7*QXJAWOMVH?LG8
MI('2U9^$V=*9AM[0DXGBSY&-Y,^1D^7/DYCES)6:Y<>7FN7#F)KDOY>;Y+^7
MF^2_EYODOY>;Y+^7F^2_EYODOY>;Y+^7F^2_EYODOY>;Y+^7F^2_EYOD_Z<2
M ?^M+PW_L$$E_[).0O^O66#_K&-\]ZMIDN^K;:/HJG"QXJEUOMRI?,K8J8'3
MU*2$VM&>A>#/F(CESI2,Z,V4DNG-EI?IQYF7Z,2;F.C FICHO)F8Y[R9F.>\
MF9CGO)F8Y[R9F.>\F9CGO)F8Y[R9F.>\F9CGO)F8Y[R9F.>\F9CG_Z@2 /^N
M+PW_L4(D_[).0?^P66#_K6-\]ZQHD>^L:Z+HJVZQXJIROMRJ><K8J7_4TZF$
MW-"DA>+.G8?GS)B+ZLR8D>S)FI7LQ9R5Z\&=E>N]G);KNIN6ZKF;ENJYFY;J
MN9N6ZKF;ENJYFY;JN9N6ZKF;ENJYFY;JN9N6ZKF;ENJYFY;J_Z@2 /^N+PW_
ML4(D_[-.0?^P66#_K6)\^*UGD.^M::'HK6RPXJQPOMRK=LK7JGW4TZJ"W-"I
MAN/-HH?IRYR*[<J;D._&GI/OPJ"3[KZ?D^Z[GI3MN)R5[+><E>RWG)7LMYR5
M[+><E>RWG)7LMYR5[+><E>RWG)7LMYR5[+><E>RWG)7L_Z@2 /^N+PS_LD(D
M_[-.0?^P6&#_K6)\^*YEC_"N:*'IKFJPXJUMO=RL=,K7K'K4TZN W<^JA>3,
MJ(?JRJ&)[\F?C_'$HI'QP**1\;RADO"YGY/OMIV4[;:=E.VVG93MMIV4[;:=
ME.VVG93MMIV4[;:=E.VVG93MMIV4[;:=E.VVG93M_ZD2 /^O+PS_LD,D_[--
M0?^Q6&#^K6)\^*YDC_"O9J#IKVFOXZ]KO-VN<,G8K7?4TZQ^W<^K@^7,JX?L
MR::)\<BBCO3"I8_TOJ20\[NBD/*WH)+PM)Z3[K2>D^ZTGI/NM)Z3[K2>D^ZT
MGI/NM)Z3[K2>D^ZTGI/NM)Z3[K2>D^ZTGI/N_ZD2 /^O+PS_LT,C_[1-0?^Q
M6&#^KF%[^:]CCO&P99_JL6>NX[%IN]VP;<C8KW33TZYZW,^M@.3,K(7LR*R)
M\L:GC/?!J(WVO::.];FCD/.UH9'QLIZ3[[*>D^^RGI/OLIZ3[[*>D^^RGI/O
MLIZ3[[*>D^^RGI/OLIZ3[[*>D^^RGI/O_ZD1 /^O, S^LT,C_K1-0?ZQ5V#^
MKV![^;!AC?&R8Y[JLF6LY+-GNMZS:,;9LV_1U+%VVM"P?.+,KX'JR:Z&\L:M
MB_F^J8WXNJ:.]K:DC_2RH9'RKY^2\*^>DN^OGI+OKYZ2[Z^>DN^OGI+OKYZ2
M[Z^>DN^OGI+OKYZ2[Z^>DN^OGI+O_ZH1 /^P, S^LT0C_K1,0/ZQ5V#]L%YZ
M^K)@B_*S89SKM6.JY;9DM]^X9</;N&G-UKEPUM.Y=MW.N'KFQK."\+NOAO>W
MK(WWLZ>.]K"DC_2NH9'RJY^2\*N>DN^KGI+OJYZ2[ZN>DN^KGI+OJYZ2[ZN>
MDN^KGI+OJYZ2[ZN>DN^KGI+O_ZH1 /^P, S^M$0C_K1,0/ZR5E_]L5UY^K->
MBO.U7YKLMV"HY[IAM.*]8K_>PV/'V,5IT,Z^<MW&N'OGPK2$[K.P@_2RL8OS
MK:R0\ZJFD/.HHI'QII^3[Z:?D^^FGY/OII^3[Z:?D^^FGY/OII^3[Z:?D^^F
MGY/OII^3[Z:?D^^FGY/O_ZH1 /^Q, O]M$0C_K5,0/ZR5E_\LEMW^;5<B/2X
M79?NNUVEZ<!>K^3'7[?9RU_%SL-JTL>]=-W"N7WEOK6#[*RR?_&LLXCPJ+./
M\*6LDO"CII+OH:&3[J&AD^ZAH9/NH:&3[J&AD^ZAH9/NH:&3[J&AD^ZAH9/N
MH:&3[J&AD^ZAH9/N_ZL1 /^Q, O]M44B_;5+0/VS55_[LUEU^+=9A?2[6I3O
MP%J?Z,A<I]S15;?/RE_'Q\-LT\*^=MR_NG[CM;=]Z::T?.VEM83MIK6+[*"U
MD^R>K97LG*:5[)REE>R<I97LG*65[)REE>R<I97LG*65[)REE>R<I97LG*65
M[)REE>R<I97L_ZL0 /^R,0O\MD4B_;9+/_VS55_ZME=S];I6@?# 5H[IR%>6
MW])1I]+24[G(RF+'PL1NTK^_>-J\O'[@K+EYY:"W>.F>MX#IH+>'Z)ZXCN>8
MMY;HEZZ8Z)>MF.B7K9CHEZV8Z)>MF.B7K9CHEZV8Z)>MF.B7K9CHEZV8Z)>M
MF.B7K9CH_ZP0 /ZS,0O[MT8A_+9+/_RT5%_XN5-O\L!2>^K(4X3@TTV5U-M&
MJLG15KK!RF3&O<5PT+O!>->ROGC<I+MTX9JY=>28N7SDF;J#XYJZBN*7NI'B
MD;J:XY&ZF^.1NIOCD;J;XY&ZF^.1NIOCD;J;XY&ZF^.1NIOCD;J;XY&ZF^.1
MNIOC_ZT/ /VS,@KZMT8A^[=*/ONV45SUO4]I[,=.<N#32G_4WT&8R=I)J\'2
M6;F\S&?$N<=QS+7#=M.HP'+8G+YPW)2\<M^2O'??DKU^WI2]A=V5OHW<D+Z4
MW9"^E=V0OI7=D+Z5W9"^E=V0OI7=D+Z5W9"^E=V0OI7=D+Z5W9"^E=V0OI7=
M_ZX. /RU,@KYN$4@^KA*/OBZ3%;OQ$M?XM%(9]3@/8/*Y$.:P-M,JKK37+:W
MSFC L\EOR*C&;LZ>PVW3E,%LUX[ ;MF,P'/9C,!YV8W ?]B.P8?7C\*/U8_"
MD-6/PI#5C\*0U8_"D-6/PI#5C\*0U8_"D-6/PI#5C\*0U8_"D-6/PI#5_Z\-
M /NV,PGXN40?^;I(/?+ 2$SESD5/U=\Y;,KI/X7 Y$>9N-Q0J+367K*PT6B[
MI<UGPIS)9LB3QV;,C,5GT(?$:M&&Q&[2A<1STH;$>=&&Q8#0A\6(SX?%B,^'
MQ8C/A\6(SX?%B,^'Q8C/A\6(SX?%B,^'Q8C/A\6(SX?%B,^'Q8C/_+$, /FX
M- CWNT(=][Q'.^G)03W6WC-1RNH[;L#P0X6XYDR6L=]4HZS97:VBU%ZTF-%?
MNY#.7\"(S&#$@\IBQW_)9,E^R6C)?<EMR7W)<LE]R7G(?LJ QW[*@,=^RH#'
M?LJ QW[*@,=^RH#'?LJ QW[*@,=^RH#'?LJ QW[*@,=^RH#'][,* /:[-@?T
MO4 ;[L1 +-G:*S7+Z355P/,^;[CR2(*QZ5&1J>-5G9W>5::4VE:MB]97LH73
M6+=_T5JZ>M!<O7?/7[YVSV*_=<]FOW7/:[YUSW&^==!XO770>+UUT'B]==!X
MO770>+UUT'B]==!XO770>+UUT'B]==!XO770>+UUT'B][[8' /.^-P7QP#T9
MWM,L&LWH+CK!]#E5M_I#:[#U37RG[E")FNA.E)#C39R'WTZC@-Q/J'G:4:QT
MV%.O<==5L6[66+)MUERR;-9?LVO68[-KUFBR:]9OLFO6;[)KUF^R:]9OLFO6
M;[)KUF^R:]9OLFO6;[)KUF^R:]9OLFO6;[)KUF^RXKH# /#!,P3ES"T+SN4C
M'\'T,3NW_#Y2L/](9:3Z27.8\T=_C>Y'B83I1Y%[YDB7=.-)G&_A2Y]KX$VB
M:-]0HV;>4J1EWE6E9-Y9I6/=7*9CW6&F8]YGI6/>9Z5CWF>E8]YGI6/>9Z5C
MWF>E8]YGI6/>9Z5CWF>E8]YGI6/>9Z5CWF>EV;X! .K&*P+1XA0)P_,I(;C\
M-CBO_T)+HO] 7)7_/VF+^D!T@?1!?7GP0H5Q[$2,:NE%D67H1Y1AYDJ67^5-
MF%[E4)E=Y5297.17FESD6YI<Y%^:7.1EF5SD99E<Y&697.1EF5SD99E<Y&69
M7.1EF5SD99E<Y&697.1EF5SD99E<Y&69UL," -36!P#$\1T+N?PM'Z[_-S*@
M_S9"E?\W48K_.5Z!_SMJ=_H\<V[V/GMF\T" 8/!"A5SO18A:[DF)6.U,BU?L
M3XM6[%.,5NQ6C%;L68Q5[%V,5>QCC%7L8XQ5[&.,5>QCC%7L8XQ5[&.,5>QC
MC%7L8XQ5[&.,5>QCC%7L8XQ5[&.,T<@# ,;O# "Y^R,+J_\F&J#_*BF5_RTX
MBO\P1H#_,E-V_S5?;/\W:&/\.F]=^3UT6/= >%7V1'I3]4A\4O5+?5'U3WU0
M]%)]4/15?4_T6'Y/]%Q]3O1B?4[T8GU.]&)]3O1B?4[T8GU.]&)]3O1B?4[T
M8GU.]&)]3O1B?4[T8GU.]&)]_YL, ?^@(@K_HC0?_Z%".?^>3E/_F5EL_Y1@
M?_B49X[RD6R<[8QRI^B'>+#E@7ZXXGR#O>!YB<'?=X_#WW>5Q-]XFL7?>9_%
MWWJEQ-][JL3??*_$VG^QP]2"LL/3@K+"TX*RPM."LL+3@K+"TX*RPM."LL+3
M@K+"TX*RPM."LL+3@K+"_YL, ?^@(@K_HC0?_Z%".?^>3E/_F5EL_Y1@?_B4
M9X[RD6R<[8QRI^B'>+#E@7ZXXGR#O>!YB<'?=X_#WW>5Q-]XFL7?>9_%WWJE
MQ-][JL3??*_$VG^QP]2"LL/3@K+"TX*RPM."LL+3@K+"TX*RPM."LL+3@K+"
MTX*RPM."LL+3@K+"_YL, ?^@(@K_HC0?_Z%".?^>3E/_F5EL_Y1@?_B49X[R
MD6R<[8QRI^B'>+#E@7ZXXGR#O>!YB<'?=X_#WW>5Q-]XFL7?>9_%WWJEQ-][
MJL3??*_$VG^QP]2"LL/3@K+"TX*RPM."LL+3@K+"TX*RPM."LL+3@K+"TX*R
MPM."LL+3@K+"_YL, ?^@(@K_HC0?_Z%".?^>3E/_F5EL_Y1@?_B49X[RD6R<
M[8QRI^B'>+#E@7ZXXGR#O>!YB<'?=X_#WW>5Q-]XFL7?>9_%WWJEQ-][JL3?
M?*_$VG^QP]2"LL/3@K+"TX*RPM."LL+3@K+"TX*RPM."LL+3@K+"TX*RPM."
MLL+3@K+"_YL, ?^@(@K_HC0?_Z%".?^>3E/_F5EL_Y1@?_B49X[RD6R<[8QR
MI^B'>+#E@7ZXXGR#O>!YB<'?=X_#WW>5Q-]XFL7?>9_%WWJEQ-][JL3??*_$
MVG^QP]2"LL/3@K+"TX*RPM."LL+3@K+"TX*RPM."LL+3@K+"TX*RPM."LL+3
M@K+"_YL, ?^@(@K_HC0?_Z%".?^>3E/_F5EL_Y1@?_B49X[RD6R<[8QRI^B'
M>+#E@7ZXXGR#O>!YB<'?=X_#WW>5Q-]XFL7?>9_%WWJEQ-][JL3??*_$VG^Q
MP]2"LL/3@K+"TX*RPM."LL+3@K+"TX*RPM."LL+3@K+"TX*RPM."LL+3@K+"
M_YP, ?^@(@K_HS0?_Z)".?^?3E/_FEEL_YAA?OF99X[REFR<[9%QI^B,=['D
MAWRYX8&"O]]\A\3>>HW'W7J4R-UZFLC=?*#(W7VER-U^J\C:@*['U(.OQ\Z%
MK\;-A:_&S86OQLV%K\;-A:_&S86OQLV%K\;-A:_&S86OQLV%K\;-A:_&_YT,
M ?^A(@K_HS4>_Z1".?^A3U/_G%EL_YUA?OF>9XWRG&R;[9=PI^B2=K'DC7NZ
MX(: P=Z!AL;<?8S*VWR3S-M]F<S;?Z#,VX"GS-J"J\O3A:S+SHBMRLB(K,K'
MB*S*QXBLRL>(K,K'B*S*QXBLRL>(K,K'B*S*QXBLRL>(K,K'B*S*_YT+ /^B
M(@G_I#4>_Z5"./^B3U/_G5EL_Z!A??FB9XWRH6R;[9UPI^B9=;'DDWJZX(Q_
MPMV&A,C;@8K-VG^2S]J F<_:@:'/VH.HS].&JL[.B:K.R(JJSL.+JL[!BZK.
MP8NJSL&+JL[!BZK.P8NJSL&+JL[!BZK.P8NJSL&+JL[!BZK._YX+ /^C(@G_
MI34>_Z9#./^C3U/_H%EK_Z1A?/JF:(SSI6V:[:-QINB>=+'DF7JZX))^P]R+
M@\K:A8G/V8*1TMB"F=+8A*+2U8>GTLZ+J-')C:C1PXVHT;Z-J-&]C:C1O8VH
MT;V-J-&]C:C1O8VHT;V-J-&]C:C1O8VHT;V-J-&]C:C1_YX+ /^C(@G_IC8>
M_Z9#./^D3U/_HEIK_Z=B>_JI:8OSJ6Z9[:=QINBC=+#DGWFZX)A^P]R1@LK9
MB8C0V(6/U-:$F=77AZ/5SXNFU,J/IM3$CZ;4OH^FU+J.IM2YCJ;4N8ZFU+F.
MIM2YCJ;4N8ZFU+F.IM2YCJ;4N8ZFU+F.IM2YCJ;4_Y\* /^D(PG_IC8=_Z=#
M./^E4%/_I5IJ_ZEB>ONK:(GTJFR8[JEPI>FH=*_DI'BYX)Y]PMR7@<K9CX;1
MUH>.UM6&F=C3B:/7RH^DU\20I->^D*37NI"DU[:0I-:UCZ36M8^DUK6/I-:U
MCZ36M8^DUK6/I-:UCZ36M8^DUK6/I-:UCZ36_Y\* /^D(PG_IS8=_ZA#./^E
M4%/_IUII_ZQC>?NL9HCTK&J7[ZMMH^FJ<:[EJ'6XX*5\P=R>@,K9E871U8J,
MV-2(F=K-C:+:Q9*BV;Z1HMJYD:+:M9&BV;*0H]BQD*/8L9"CV+&0H]BQD*/8
ML9"CV+&0H]BQD*/8L9"CV+&0H]BQD*/8_Y\* /^E(PG_IS8=_ZA#./^F4%/_
MJ5MH_ZUA=_RN9(?UKFB5[ZUKHNJL;ZSEJW.VX:EYP-VF@,C9G831U8^+V=.)
MFMW'D:#<OI.@W+B3H-RTDJ#<L9*AVZZ1HMJMD:+:K9&BVJV1HMJMD:+:K9&B
MVJV1HMJMD:+:K9&BVJV1HMJMD:+:_Z * /^E(PC_J#<=_ZE$-_^G4%/_JUMF
M_ZY@=OVO8X7VL&:3\+!IG^NO;*KGKW"TXJUUO=ZK?,;:IX//U9B*V-*+G-^_
ME)[?MY2>W[*4GM^ODY_>K).?W:J2H-NIDJ';J9*AVZF2H=NIDJ';J9*AVZF2
MH=NIDJ';J9*AVZF2H=NIDJ';_Z ) /^F(PC_J#<=_ZI$-_^G45/_K5QE_J]>
M=?RQ88/WLF21\;)GG>VS:J?HLVVQY+1QN>"R>,+<KX#*UJ2'UK^0D^*TE9SB
MKI6<XJN4G.&IE)W@IY.>WJ62H-VEDJ#<I9*@W*62H-REDJ#<I9*@W*62H-RE
MDJ#<I9*@W*62H-REDJ#<_Z ) /^F(PC_J3<<_ZI$-_^H45/_KEMD_;%=<_NR
M7X'XM&&.\[9DFNZW9Z3JNFNLY[UOL^3#=;G=OWG'R;"!U:Z;BN.DEYGFHY::
MY:.5F^.BE9SBH92=X*&3G]Z@DY_=H).?W:"3G]V@DY_=H).?W:"3G]V@DY_=
MH).?W:"3G]V@DY_=_Z$) /^F(PC_J3<<_ZM$-_^I45/_L%IC_+);<?JT77_W
MMU^+];IBEO&]99[NPVJEZ<QQJ=_0<;?1RW/&O+U[U*"I@N*0HYCHEIJ9YIB7
MFN6:EIOCFY6=X9N4GMZ;E)_>FY2?WIN4G]Z;E)_>FY2?WIN4G]Z;E)_>FY2?
MWIN4G]Z;E)_>_Z$( /^G(PC_JC@<_ZM%-_^K45+^L5AA^[19;_BW6GOUNUV'
M\K]@D.W&9);GT&R9W]ILIM+4<+;%RW7%L\-YTY.W>N"(N9;CD*B;XY&?F^.2
MFIOCDY>=X965GM^5E9[>E96>WI65GMZ5E9[>E96>WI65GMZ5E9[>E96>WI65
MGMZ5E9[>_Z$( /^G(PC_JS@<_ZQ%-O^M4E#^LE9?^K97;/:[6'?RP%J![,=?
MA^;19HG>W&68T]UII\C4<+2]S';#K<1XT8Z]==Z,O8O>B[N?WHRLGM^-HYW@
MC9V>X(Z9GMZ/F)_>CYB?WH^8G]Z/F)_>CYB?WH^8G]Z/F)_>CYB?WH^8G]Z/
MF)_>_Z(( /^H) ?_JS@;_ZU%-O^O4D[\M%-<^+E4:/*_5G+LQEEXY=%?>MS<
M6HW2X5R>R-IDK+[2;+BURW3%I,1ST8V_<]J-OX7:C\"6V(>]H=J)L*#<B:>@
MW(J@H-R*GZ#<BI^@W(J?H-R*GZ#<BI^@W(J?H-R*GZ#<BI^@W(J?H-R*GZ#<
M_Z,' /^I) ?_K#D;_ZY&-O^R44OZMU%8]+U28NW%5&GDT%AKVMU0?]'D5)+'
MX%BBO=ABK[;1:[JLRW#%FL5NSXK!<-:)P7[6B\*-U8K"F-6#P:36A;2CUX:J
MH]B&J*/8AJBCV(:HH]B&J*/8AJBCV(:HH]B&J*/8AJBCV(:HH]B&J*/8_:,'
M /^J) ?_K3D:_Z]'-?VT3T?WNT]2[\-/6>7.45S9W4EOT.5-A,;F4I:]WEBD
MM=ABL+#1:[JAS&K$DL=IS8?$;=*%Q'C2AL2$T8?%D-"%Q9K0@,2FTH&XI].!
MM:;3@;6FTX&UIM.!M:;3@;6FTX&UIM.!M:;3@;6FTX&UIM.!M:;3^Z0& /^K
M) ;_KSH:_[%(-?JW34+ROTQ*Y\M+3-G<0ES0Y4=TQNU,B+WE4IBTWEFEK]AC
ML*329;F7S67!BLEER8+':<V QG+-@,=]S('(A\N"R)'*@,B<RGO'J,QYQZO,
M><>KS'G'J\QYQZO,><>KS'G'J\QYQZO,><>KS'G'J\QYQZO,^:8% /^L)0;_
ML#L9_[-*-/:\2COJQT<]V]D^1M#E06'&[D=WO>U-B;3E4YBMWENDH]E>KIC4
M7[:-T&"]@\QAPWW*9<=ZRFW'>\IVQGO+?\5\RXC$?<R2PWS,GL-ZS*##>LR@
MPWK,H,-ZS*##>LR@PWK,H,-ZS*##>LR@PWK,H,-ZS*##]:<$ /^N)07_LCP8
M^K=(+._"1"_?U#POT>0Z2\;N066]]4AYM.Y/B:[F5I>BX%:AE]M8JHW66;&$
MTUJW?-!=O'?/8;]USF? =,YOOW7/=[]USW^^=M"(O7?1E+MWT9:[=]&6NW?1
MEKMWT9:[=]&6NW?1EKMWT9:[=]&6NW?1EKMWT9:[\*D" /^P)03\M3X7]+U#
M(>3-.1W2XC(UQ^\Z3[WV0V:T]TMXKN]3AZ+H4I.6XE&=C-Y2I8/:4ZM[UU6P
M==58M''47+9OTV*W;M-HMV[3;[9NU':V;]1^M6_5B+1OU8NS;]6+LV_5B[-O
MU8NS;]6+LV_5B[-OU8NS;]6+LV_5B[-OU8NSZ*L  /VS)@3YN$$5ZL<X$M3?
M)AW'[C0YO?<]4;3]1F6M^4]UH?)-@I7K3(V+YDR6@>),G7G?3J-SW5"G;=M3
MJFK:5ZQHV5RM9]EAK6;:9ZUGVFVL9]IUJV?;?:MGVW^J9]M_JF?;?ZIGVW^J
M9]M_JF?;?ZIGVW^J9]M_JF?;?ZIGVW^JW*\  /JW)P+PP#@)U]L5"<CL*B&]
M^#8ZM/Y!3ZS_2&&?_$9OD_9&>XGP1H6 [$>-=^A'DV_E2)AIXTN<9N).GF/A
M4J!AX%:A8.!;H6#@7Z%?X&2A7^%KH&#A<J!@X72?8.%TGV#A=)]@X72?8.%T
MGV#A=)]@X72?8.%TGV#A=)]@X72?VK(  /6[)P'>TP\ R>H>#;[W+R.T_SHY
MJO\_2IW_/EJ1_SYGA_L_<7WV0'IT\D&!;>]"AV;M1(MBZT:.7NI)D%SI39):
MZ%"26>A4DUGH6)-8Z%R36.AADUCI:))8Z6F26.EIDECI:9)8Z6F26.EIDECI
M:9)8Z6F26.EIDECI:9)8Z6F2U[8  -G)!0#+Z L!OO8E#K3_,R&G_S0SFO\U
M0X[_-5"$_S=<>O\X9G'].FYJ^CQT8_<]>%[U0'Q:]$)_6/)%@5;R28)4\4R#
M4_%/A%/Q4X12\5:$4O%;A%'Q8811\6*$4?%BA%'Q8H11\6*$4?%BA%'Q8H11
M\6*$4?%BA%'Q8H11\6*$U+H  ,G. P"^]Q(!LO\B#:7_)1R7_R@KC/\J.8+_
M+45X_S!1;_\S6F?_-6)@_SAI6OX[;5;\/G%3^D%S4?E$=%#Y2'5/^4MV3OA/
M=DWX4G=,^%9W3/A:=TOX8'=+^&%W2_AA=TOX87=+^&%W2_AA=TOX87=+^&%W
M2_AA=TOX87=+^&%WR<0" +S7  "N^@4!HO\2"97_%A6+_QPB@?\B+W?_)CMM
M_RI&9/\M3US_,5=6_S1=4?\X84[_/&1,_T!F2O]#9TG_1VA(_TIH1_].:4?_
M46E&_U5I1?]9:47_7FE$_V!I1/]@:43_8&E$_V!I1/]@:43_8&E$_V!I1/]@
M:43_8&E$_V!I_Y$* O^1&0C_DRD:_Y$Y,?^,1DG_A5%?_X59;O^#7WS[?V:)
M]GINE/%U=I[N;WVD[&N$J>MIBZSJ:9.MZFF:K>IJGZ[J:Z:MZFRLK>ILLJWJ
M;;FMYG"\K.%ROJS;=<&KVG;!J]IVP:O:=L&KVG;!J]IVP:O:=L&KVG;!J]IV
MP:O:=L&K_Y$* O^1&0C_DRD:_Y$Y,?^,1DG_A5%?_X59;O^#7WS[?V:)]GIN
ME/%U=I[N;WVD[&N$J>MIBZSJ:9.MZFF:K>IJGZ[J:Z:MZFRLK>ILLJWJ;;FM
MYG"\K.%ROJS;=<&KVG;!J]IVP:O:=L&KVG;!J]IVP:O:=L&KVG;!J]IVP:O:
M=L&K_Y$* O^1&0C_DRD:_Y$Y,?^,1DG_A5%?_X59;O^#7WS[?V:)]GINE/%U
M=I[N;WVD[&N$J>MIBZSJ:9.MZFF:K>IJGZ[J:Z:MZFRLK>ILLJWJ;;FMYG"\
MK.%ROJS;=<&KVG;!J]IVP:O:=L&KVG;!J]IVP:O:=L&KVG;!J]IVP:O:=L&K
M_Y$* O^1&0C_DRD:_Y$Y,?^,1DG_A5%?_X59;O^#7WS[?V:)]GINE/%U=I[N
M;WVD[&N$J>MIBZSJ:9.MZFF:K>IJGZ[J:Z:MZFRLK>ILLJWJ;;FMYG"\K.%R
MOJS;=<&KVG;!J]IVP:O:=L&KVG;!J]IVP:O:=L&KVG;!J]IVP:O:=L&K_Y$*
M O^1&0C_DRD:_Y$Y,?^,1DG_A5%?_X98;O^$7WS[@&:)]GMNE/%U=9[N<'VE
M[&N$J>IIBZSJ:9*MZFF9KNEJGZ[I:Z:NZFRLKNIMLJWJ;KFMYG"\K>!SOJS;
M=L&KVG;!J]IVP:O:=L&KVG;!J]IVP:O:=L&KVG;!J]IVP:O:=L&K_Y(* O^2
M&0C_E"H9_Y,Y,?^.1DC_BE%>_XM8;?^*7WO[AF6(]H%LE/%[<Y[M=7NFZV^"
MK.ELB:_H:Y&QZ&N8LNALG[+H;::RZ&ZML>AOM+'E<;JQX'2\L-IWOK#4>;^P
MTGF_L-)YO[#2>;^PTGF_L-)YO[#2>;^PTGF_L-)YO[#2>;^P_Y(* ?^3&0?_
ME2H9_Y0Y,?^01TC_CE!<_Y!8;/^07GK\C62(]H=JE/&!<9[M>GFGZG2 K>AO
MA[+F;8^TYFV7M>9NG[7F<*>UYG&OM>9RM[3@=;FTVGB\L]1[O;/-?+RTS'R\
MM,Q\O+3,?+RTS'R\M,Q\O+3,?+RTS'R\M,Q\O+3,?+RT_Y,* ?^4&0?_EBH9
M_Y4Y,/^11TC_DE!;_Y18:_^47GG\DF2']HUJD_&&;Y[M@'>GZ7E^KN=SA;3E
M<(ZWY6^7N.1PG[GE<JBXY7.PN.%VM[?:>;FWU'R[MLY]NK?(?KJWQGZZM\9^
MNK?&?KJWQGZZM\9^NK?&?KJWQGZZM\9^NK?&?KJW_Y0) ?^5&0?_ERH9_Y8Z
M,/^21TC_E5!:_YA8:?^97GC]EV2%]Y-IDO&,;IWMA76GZ7Y\K^9W@[7D<HRY
MXW&6N^-RG[OC<ZF[XW6SN]MYM[K4?;BYSG^XNLB N+K"@+BZP8"XNL& N+K!
M@+BZP8"XNL& N+K!@+BZP8"XNL& N+K!@+BZ_Y0) ?^6&0?_F"L8_Y<Z,/^3
M1TC_F%!9_YQ8:/^=7G;]G&2$]YEID?*3;9SMBW.FZ81ZKN9\@K;C=8J[XG.5
MON)SG[[B=:N^WGBTO=5]MKW.@+:]QX&VO<*"M;Z]@K6^O(*VOKR"MKZ\@K:^
MO(*VOKR"MKZ\@K:^O(*VOKR"MKZ\@K:^_Y4) ?^6&0;_F2L8_Y@Z,/^41TC_
MFU!7_Y]89O^A7G7^H62"^)YIC_.9;9KNDG&EZHIYKN:"@+;B>8B]X723P>!U
MH,'A=Z[!UWRTP,Z"M+_'@[3 P8.SP;R$L\&WA+/!MH2SP+:$L\"VA+/ MH2S
MP+:$L\"VA+/ MH2SP+:$L\"VA+/ _Y4) ?^7&0;_FBL8_YDZ,/^71T?_GE!6
M_Z-89?^E7G/_I62 ^:1IC?2@;9COFG&CZI%WK.:(?K7B?H:]X':2P]]VH<3<
M>K#$SX&RP\:$LL._A;'$NH6QQ+:&L<2RAK'#L8:RP[&&LL.QAK+#L8:RP[&&
MLL.QAK+#L8:RP[&&LL.QAK+#_Y8) ?^8&0;_FBL8_YHZ+_^91T;_H5!4_Z98
M8_^I7W'_JF5^^JEIBO6F;9;PH7"@ZYETJN>0?+/BA82]WWF0Q=YXH\?3?[#&
MQX6PQKZ&K\>XAZ_'M(>OQ["'K\>MA[#&K(>PQJR'L,:LA[#&K(>PQJR'L,:L
MA[#&K(>PQJR'L,:LA[#&_Y8) ?^8&0;_FRL7_YLZ+_^<1T7_I$]3_ZE88?^L
M7V[_K&-[_*QGA_:K;)+RJ'"=[:-TI^B9>K#BCH.[UX"-Q=!\GLK(@JW*O8>M
MRK:)K<JQB:W*KHFMRJN)K<FHB:[(IXFNR*>)KLBGB:[(IXFNR*>)KLBGB:[(
MIXFNR*>)KLBGB:[(_Y<) ?^9&0;_G"P7_YLZ+_^>1T/_IE!1_ZQ97_^N7FS^
MKV%X_:]EA/BO:8[RK6V9[*MRHN2E>:O:FH&XRXN(Q<""ELV\A:K.LXJJS:Z+
MJLVJBZO-IXNKS*6*K,NCBJW*HXJMRJ.*K<JCBJW*HXJMRJ.*K<JCBJW*HXJM
MRJ.*K<JCBJW*_Y<( ?^9&0;_G"P7_YPZ+_^@1D+_J5!/_Z]97?ZP7&G\LE]U
M^K-C?_.S9XGMM&R3Y[1RF]ZN=JC0HWVVP9:$Q+**CL^LBJ31J(RHT:2,J-"B
MC*G0H(RJSY^,JLV>BZS,G8NLRYV+K,N=BZS+G8NLRYV+K,N=BZS+G8NLRYV+
MK,N=BZS+_Y@( /^:&@;_G2P7_YTZ+_^B1D'_JU!-_[!86ORR6V;YM%YQ]K=B
M>^^Y9H/IO&R+XKUNE]6V<:?'K'FUMZ" PZ:3B-"<CYK5FH^EU9F.IM29CJ?2
MF8VHT9B-J<^8C*O-F(RKS9B,J\V8C*O-F(RKS9B,J\V8C*O-F(RKS9B,J\V8
MC*O-_Y@( /^;&@7_GBP7_YXZ+_^E1C__K5%+_;)76/JU6F/VN%UL\KQA=.O!
M9GOEQFJ#V\=HELV^;::^M'2TKJI[PIN>@L^*E8_8B96CUXR1I-:/D*;4D(^G
MTI&.J-"2C:K.DHVJSI*-JLZ2C:K.DHVJSI*-JLZ2C:K.DHVJSI*-JLZ2C:K.
M_Y@( /^;&@7_GBP6_Y\Z+O^G1CW_L%-)^[165/>X6%[SO%MF[L)@;.C+9V_?
MTF."T]!CE,3':J2UO7"RI+-VP)&I?,Y_H8C7?:2DUH2<I=6&EJ;4AY.FTXF1
MJ-&+CZG/BX^ISXN/J<^+CZG/BX^ISXN/J<^+CZG/BX^ISXN/J<^+CZG/_YD'
M /^<&@7_GRP6_Z [+O^J2#O]LE-&^;944/2[5ECNPEI>Y\M@8>#686O7WUN
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MF%SEC)A<Y8R87.6,F%SEC)A<Y8R87.6,F%SEC)A<Y8R8Y:@  /^M& 'LPAL
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M(@Z?_R8=D_\G+(C_*CI^_RU%=/\O3VO_,EAC_S1?7/\W9%?_.FA3_SQK4/Y
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M=_\0&F[_%R5E_QTO7/\B.%7_)C]/_RI%2_\N2D?_,DU$_S9/0O\Z44'_/E)
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M@;^PE8&_KY2!P*Z3@,&MDX#"K)* PZJ2@,.JDH##JI* PZJ2@,.JDH##JI*
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MB%35W(A4U=R(5-7<B%35W(A4U=R(_Y   /^6"@'CJ0( TKD# ,K*! #"[0X
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MF&"?T)A@G]"88)_0F&"?T)A@G]"8_WX! _]^"P;_D1 !^J$. -JP!0#4O@8
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M8#LE_VHZ(_]U.B'_@CD@_XHY(/^*.2#_BCD@_XHY(/^*.2#_BCD@_XHYO[@
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M4S<M_U-!./]03$/_2E=-_T1B5?]!;EK_/WM=_SV'7O\]DU[_/IU?_S^G7O]
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M:N5\_V8("/]@$P[_8A<0_W <#_][)!#_A"\6_X@Y'O:*0BCNB4HSYX91/N"
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ME6R"TI5L@M*5;(+2E6R"TI5L@M*5_VX%!O]N"PC_@0\$_X\3 ?N;$P#JIQ
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MH$\X_+5../W33#?^[4L[]_E*//;Z2CSV^DH\]OI*//;Z2CSV^DH\]OI*V9<
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M*AG_B"D6_YDI%O^;*1;_FRD6_YLI%O^;*1;_FRD6_YLIN[<  +#"  "BS
MD],  (7;  !XX0  ;.H  6/]  1:_P (4?\!#$G_!1%"_PH5._\/&#7_%!LQ
M_Q@=+?\>'RG_(B F_R@@(_\M(2#_,R$<_SH@&O]"(!?_2Q\5_U4>$_]?'1'_
M:AP-_W@<#?]Y' W_>1P-_WD<#?]Y' W_>1P-_WD<LL   *7*  "5T0  AMD
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M2C?_054__SYA1?\[;DC_.GM*_SF&2_\ZD4O_.YI+_SNC2_\\K$K_/;5*_S[
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M@'YTX8!^=.& ?G3A@'YTX8!^=.& _UX)"?]C"PG_=0P%_X(1 OZ-% #OE18
MX9T8 -:C(@',HS4,PJ!#'+J=3BVQF%8^J)1=3J"/8UR8BFAICX5M=8> <H"
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MN&%+P]E?2,'T84FY]61+L_-G3*_R:$RO\FA,K_)H3*_R:$RO\FA,K_)H_WD
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M.S?V[3HV]/\Z-N[_/#;N_SPV[O\\-N[_/#;N_SPV[O\\TI@  ,6G  "[L@
ML;P  *7%  "8S   C-,  (#;  !X] D!</D5!FCZ'0U?^B,45_HH'4_[+25'
M^S(L0?LY,3W\0#0Y_4@V-OU2-C3^738R_VHV,/]Y-2__BS0N_YXS+O^T,BW_
MS#$L_^HP+/_Y,"S_^3 L__DP+/_Y,"S_^3 L__DPR*,  +VP  "SN@  I\,
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M$P3_@Q,$_X,3!/^#$P3_@Q,$_X,3K[X  *''  "2S@  @]4  '3=  !GXP
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M3OE(T$W_2LE/_TS#4?],OE+_3;Y2_TV^4O]-OE+_3;Y2_TV^4O]-_T41#_]
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MBFZ)=HANE7>&;J%WA&ZP=X-NPW>!;MUW@&[I=8!NZG. ;NMR@&WL<(!M[7"
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ML7-4E<IR4Y3H<E20ZG-5C.IT5HCJ=%:'ZG16A^IT5H?J=%:'ZG16A^IT_V0
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M446V^U5&L?Y71ZO\6DBJ_%I(JOQ:2*K\6DBJ_%I(JOQ:\7H  -B+  #+F
MP*0  +BL  "NM   H[H  )C!  ",R , A<T7 (#-*09YS301<<L\'6C*0BI>
MR$<U5L=-/T_&4T=*QEU*2,9I2T?'=TI&R(9)1LB82$7)JT9$RL5%1,GG0T''
M^D<^Q?]*0+S_34"[_TU N_]-0+O_34"[_TU N_]-X(,  -"3  #$H   NZH
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M("KZ_R J^O\@*OK_("KZ_R J^O\@PZ,  +FN  "ON   H[\  )7&  "(RP
M>]$  '#8  !EWP  7?(! 5;_"P5/_Q,*2/\9#T'_'Q0[_R48-?\K&S+_,ATN
M_SD>*_]"'BG_3!XG_U<=)?]D&R/_=!HA_X49(/^7&!__JQ@>_\$7'?_?%QW_
MY1<=_^47'?_E%QW_Y1<=_^47NZP  +*V  "EOP  F,4  (G+  !\T0  ;]@
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MK'5@=L%T7W;><V%U['%C<^YO9'+O;65Q\&QE<?!L97'P;&5Q\&QE<?!L_U8
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M9$^.\V90B?-G48;S9U*$\VA2A/-H4H3S:%*$\VA2A/-H_V0  >1U  #6@P
MRXX  ,&7  "YG0  L*,  *2F  "=J18 F*HK Y&J. V*J$(9@Z9*)GRD4#)S
MH54^:Y]:26*<7U1:FF9<5)EN85*9>F-1F8AB4)F78%":J%Y/FKU<3IK:6TR8
M\UU,E/E?39#X8$V-]V%-C?=A38WW84V-]V%-C?=A_VH  -][  #0B0  QI0
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M/CJX_T ZN/] .KC_0#JX_T ZN/] V8,  ,J2  "_G@  MJ@  *VO  "BM0
MEKD  (F^  !^Q   <LL# &O0% !GT"0$8= O#%K/-Q52SSX?2\Y$)T;.3"U"
MSE4P0,]A,#_/;B\^T'TN/M&-+3W1GRL\TK4J.]/4*3K0[RHWSOXM-<S_,#3+
M_S(TR_\R-,O_,C3+_S(TR_\RSXT  ,*;  "YI@  L*X  *6U  "9NP  C+\
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M#!C_\@P8__(,N*L  *ZT  "BO   E,(  (;'  !XS0  :](  %_9  !5W@
M2^,  $/P  $]_0 $-_\'!S+_#0HM_Q0,*/\:#B3_( \A_R<0'?\N$!G_-A 6
M_T /$O]+#P__6 X+_V@-"/]Z"PC_C H'_YX*!O^P"0;_P0D&_\$)!O_!"0;_
MP0D&_\$)L;,  *6[  "7P@  B,@  'G.  !LU   7]H  %3@  !)Y0  0.D
M #CU  (R_P $+/\ !BC_ 0@C_P8*'_\,"QO_$@P7_Q@-$_\>#0[_)0T*_RP-
M!O\V# '_00L _TX* /]="0#_;0@ _WT( /^+!P#_EP< _Y<' /^7!P#_EP<
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M481?_T^$7_]/A%__3X1?_T^$7_]/_T8$"/]5  /_8P  YFP  -IR  #3=@$
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M76AJ^EUH:OI=_U, !/]C  #@;P  U'D  ,N!  ##A@  NXD  +.+"P"LCB0
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MH5M/BK-:3XK,6$V)Z%A+A_M:3(3\6DV!_%M-@/Q;38#\6TV _%M-@/Q;_&,
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M.$.JZ#A J/H[/J;_/CVC_T ]H_] /:/_0#VC_T ]H_] VWH  ,N(  "_E
MMIX  *ZE  "DJ@  F*X  (RQ  !_M0  =+D% &^Z&P!KNRH$9;LU"UZZ/!17
MN4,=4+A))DJW3RU&MU<Q0[=A,T*W;3)!N'LQ0+B*,$"XFR\_N*XM/KG'+#ZX
MYRL[M?HN.;/_,3>R_S0VLO\T-K+_-#:R_S0VLO\TTH,  ,21  "ZG   LJ4
M *BK  "=L   D;0  (2W  !XNP  ;,$  &+&"@!>QQT!6L<J!53',PQ.QCL4
M2,9"&T/%22$_QE(D/<9=)#S&:20[QW<C.LB&(CG(ER YR*L?.,G$'CC(Y1TU
MQ?D@,\/_(S'!_R8QP?\F,<'_)C'!_R8QP?\FR8T  +Z:  "UI   K*P  *&Q
M  "5M@  B+D  'N]  !OP@  9,<  %C. @!/U H 3-4: 4C6)@5#UB\+/M8X
M$#G6010VUTL6-=A6%C398A8TV7 5,]J %#+;D1,QVZ42,=R]$2_<WQ MV?03
M*]?_%2G5_Q<IU?\8*=7_&"G5_Q@IU?\8P9<  +BC  "PK   I;(  )BW  "+
MNP  ?K\  ''$  !ER0  6LX  %#4  !&VP, 0N40 3WF&P0XYB,(,^<K#"_G
M- XMZ#X/*^E($"GI5 \HZF$/)^MP#B;L@0TE[)0,).VI"R/NQ0HB[^8)(>SZ
M"1_I_PH>Z?\+'NG_"Q[I_PL>Z?\+NJ$  +*K  "HLP  F[@  (Z]  " P0
M<\8  &?+  !;T   4-4  $?;   ]X0  ./0' C3U$00O]A@'*_8@"2?V)PLC
M]S ,(/@Y#![Y0PP;^4X+&?I<"A;[; D5^WX(%/R2!Q/\J <2_<(&$?[B!1#]
M^P40_?T%$/W]!1#]_040_?T%M*H  *NS  ">N0  D+X  (+#  !TR   9\T
M %O2  !0V   1MT  #SB   SZ   +_@  BK_!00F_PP&(O\3!Q[_&@@:_R$)
M%O\H"1/_,0D._SL)"O]'" ;_5 <"_V0& /]W!@#_B@4 _Y\$ /^R! #_S@,
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M ,8$_P#4!/\ XP/_ .\#_P#X _\ _P/^ /\#_ #_!/P _P3\ /\%_ #_!?P
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M#@+U5A4"Z50> ]]0* ?53S<-SDQ$&,A)4"##25LEP$EE)[U);RB[27@IN4J
M*;=*ARJU2H\JM$N6*[)+GRNQ2Z@KKTNT*ZY,PBRL3-4LJ4SI+:=+^2^D2_\P
MHDO_,:%+_S&A2_\QH4O_,:%+_S&A2_\Q_S8'"_]!  ;_3@ #_U8$ ?9:" #N
M6PT X5D5 -=9) +-630*Q59!%K]23"&Z4%8IMD]?+;-/:3"P3W(QKD]Z,:U/
M@C*K4(HRJ5"2,JA0FC.F4*0SI5&O,Z-1O32A4<\TGU'E-9Q1]C:;4/\WF5#_
M-YE0_S:84/\VF%#_-IA0_S:84/\V_SH$"?]%  3_4P !]5L  .1>  #;7P,
MV5T) ,]A( #&8C$(OE\^$[=;21^R6%(JK55;,:I49#6G5&PWI51U.*-4?3FA
M5(4YH%6-.IY5ECJ<5: ZFU6K.IE5N#N85<H[EE7A.Y-4]#R25/\\D53_/)!4
M_SN/5/\[CU3_.X]4_SN/5/\[_SX!"/]+  /_5P  YUX  -MD  #59@$ T64%
M ,EH' # :2X&N&<\$+%C1QVK7T\IIEQ7,J):8#F>66@\G%EP/II8>#^86(!
MEUB(0)58D4"36)M!DEBG09!8M$&.6,5!C5C<0HM8\4*)6/]!B5?_08A7_T"'
M5_\_AU?_/X=7_S^'5_\__T$ !O]/  +V6P  WV,  -9I  #/:P  RVL" ,-M
M& "[;RP$LVTZ#JQJ1!JF9TTFH&-5,9MA7#J77F,_E%UK0Y)<<T607'M&CER$
M1HU<C4:+7)='B5RC1XA;L$>&6\%'A%O82(-;[D>"6_Y&@5O_18!:_T2 6O]$
M@%K_1(!:_T2 6O]$_T4 !?]3  'K7@  VV<  -)M  #+<   Q7   +UR%0"V
M="D"KW,X"ZAQ0Q>A;4LDFVI3+Y9F63F18V!!C6%G1HI@;TF(7W=+AE]_3(5?
MB4R#7Y-,@5^?37]>K$U^7KQ-?%[337M>[$QZ7OU+>5[_2GE=_TAY7?]'>5W_
M1WE=_T=Y7?]'_T@ !/]6  #C8@  V&L  ,YQ  #&=0  P'4  +EV$0"Q>2<!
MJG@V":1V016=<THAEW!1+9%L5SB,:5U!AV9D2(1D:DR!8G)/?V)[47UBA%)[
M8H]2>6*;4G=AJ%)U8;A2<V'/4G)AZ5%R8?M/<6'_37)@_TQR8/]+<F#_2W)@
M_TMR8/]+_TL  _Q9  #@90  U&\  ,IU  #">0  NWD  +1[#0"M?20!IGTT
M"*![/Q*9>$@>DW5/*HUR536';EL_@FMA2'UH9TYY9FY3=F5W571E@%=R98M7
M<&675VYEI5=L9+57:F3+5VEDYE9I9/E3:63_46IC_T]J8_].:F/_3FIC_TYJ
M8_]._TT  O-<  #=:0  T7(  ,=Y  "_?   MWX  *]_"@"I@2$ HH(Q!IR
M/1"5?48;CWM.)XEW5#.#=%D]?7%>1G=M9$YR:VI5;FER66MI?%MI:(=<9VF3
M6V5HH5MC:+%;86C'6F!HXUEA:/A786C_5&-F_U)C9O]18V;_46-F_U%C9O]1
M_T\  >E?  #:;0  S78  ,1\  "[@   LX(  *N#!0"DAAT GH8O!)B%.PV2
M@T48BX!,)(5]4C!_>E<Z>7=<1')T84UK<6=59FYN6V)M=UY?;8-?7FV/7EQM
MGEY:;:Y=66W$7%AMX%I8;?9866S_5EMJ_U5<:O]47&K_5%QJ_U1<:O]4_U,
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M3"1PCE$N:8Q6.&&*6T%:AV!*5(5G4%"$<5-/A'U33H6*4DV%FE!-A:M.3(7
M3$N%W4M)@_1-2(+_3DA__TY)??].27W_3DE]_TY)??].Z6(  -AS  #)?P
MOH@  +:/  "ME   HY8  )27  "-F0< B)L= (.;+@-^FCD+>)E"%'&721]J
MED\I8Y14,UR263Q5D%Y#4(]F2$V.<$I+CGQ*2X^*2$J/FD9)CZM%28_ 0TB/
MW4%&C?1$1(O_1D.)_T=$A_]'1(?_1T2'_T=$A_]'XVD  -%Y  #$A0  NHX
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M)32L_R<SJ_\H,ZO_*#.K_R@SJ_\HS((  +^0  "VF@  KJ(  *2H  "9K
MC*\  ("Q  !SM   9K@  %F\ P!5OA8 4K\D 4Z_+P9)OC<,0[X_$C^^1A8[
MOD\9.;Y9&CB^9!HWOW(9-K^ &#6_D!<UP*,5-,"Y%#/ UA,QO? 5+[O_&"ZZ
M_QHMN?\;+;G_&RVY_QLMN?\;Q(P  +F8  "QH@  J:D  )VN  "1L0  A+0
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M 03U_P$$]?\!L:D  *BQ  ";M@  C;L  '^_  !QPP  9,@  %?-  !,T@
M0=8  #;;   MX   )>0  "#O   <^P$!&?\) A;_$@,2_QD##?\A! G_*@,%
M_S4# ?]! P#_3P( _V " /]T 0#_B $ _YX! /^T  #_SP  _^,  /_C  #_
MXP  _^, J[$  )ZW  "0O   @L$  '/&  !ERP  6-   $S6  ! VP  -M\
M "SC   CYP  &^L  !?U   3_@ !#O\  @O_ @((_PD# _\0 P#_%P, _R #
M /\J @#_-P( _T8! /]8 0#_:P$ _W\  /^1  #_H@  _ZT  /^M  #_K0
M_ZT H;<  ).]  "%P@  =<@  &?.  !9U   3-H  $#@   TY   *N@  "'K
M   8[@  $?$   SZ  $(_P !!/\  @'_  ( _P " /\  P#_! , _PL" /\5
M @#_'P( _RP! /\\ 0#_3 $ _UX  /]O  #_?@  _X<  /^'  #_AP  _X<
M_P(F#_\$(P__ R(/_P D#O\ *@W_ #0,_P!""O\ 4 C_ %T'_P!I!?\ =03_
M '\#_P"' _\ CP+_ )0"_P": ?\ H '_ *<!_P"M ?\ M0#_ +X _P#* /\
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M!/\ B0/_ ) #_P"6 O\ G +^ *("_0"I ?P L 'Z +D!^0#% ?@ TP'V .(
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M0(\7N4"6&+A GABV0:<8M$&Q&;-!OAFQ0<\9KT'C&JQ!]!VI0/\>IT#_'Z5
M_R"E0/\@I4#_(*5 _R"E0/\@_RX$"?\W  7_0@ "_DD! ?1+!@#N2@P X4<5
M -=&) +.1C0*QD5!$L%$31B]1%@;N41B'+=%:QVU170>LT9['K%&@Q^P1HH?
MKD>1'ZU'F2"K1Z(@J4>M(*A'N2&F1\HAI$C?(:%'\22?1_\EG4;_)9Q&_R:;
M1?\FFT7_)IM%_R:;1?\F_S, "/\]  /_2  !\$X  .!0  #;3P, V$L) ,Y0
M'P'%43 'OD\]$;A,2!JS2U,@L$M<(ZU+9B6K2VXEJ4MV)J=+?B>F3(4GI$R-
M)Z),E2BA39XHGTVH*)Y-M"F<3<4IFDW:*9A,[BN63/TKE$O_+)-+_RN32O\K
MDTK_*Y-*_RN32O\K_S@ !O]"  +X30  XE,  -I8  #360  T%4% ,=8&P"^
M6BT%MU@Z#[!511FK4D\BIU%8)Z108"NA4&DLGU!Q+9Y1>2Z<48 NFE&(+YE1
MD"^749HOEE&D,)11L#"34, PD5#5,8]0ZS&-4/LQC$__,8M/_S&*3_\PBD__
M,(I/_S"*3_\P_SP !?]'  'L40  W5H  -1?  #-8   R%T! ,!?%P"X82H#
ML6 X#*I=0Q>E6DPAH%A4*9Q67"^9560REU5L,Y54=#245'PUDE2#-9!4C#:/
M5)8VC52@-HQ4K#>*5+PWB%30-X93Z#>%4_DWA%/_-H-3_S:#4O\U@U+_-8-2
M_S6#4O\U_S\ !/]+  #D5@  V5\  ,]D  #'9@  PF0  +IE$P"S9R<"K&8U
M"J5D0!2?84D?FEY1*99;63&26F VD%AG.(U8;SJ,6'<[BEA_.XA7B#R'6)$\
MA5></(-7J3V"5[@]@%?,/7Y6Y3U]5O<\?%;_.WQ6_SI[5O\Y>U;_.7M6_SE[
M5O\Y_T$  OE/  #A6P  U&0  ,MI  ##:P  O&H  +5J#P"N;"0!IVPS"*%J
M/A*;9T<=E61/)Y!A5C&,7EPWB5UC/(9;:SZ$6W) @EM[08%:A$%_6HU"?5J9
M0GM:I4)Y6K1"=UK(0W99X4)U6?9!=%G_/W19_SYT6?\]=%G_/719_SUT6?\]
M_T,  O!2  #=7P  T6@  ,=M  "_<   N&\  +!O"P"I<2$ HW$Q!IUP/ ^7
M;44:D6I-)8QG4R^'9%HW@V%@/G]?9T)]7FY$>EYV1GA>?T=W7HE'=5Z51W-=
MHD=Q7;!(;UW$2&U<W4=L7?1%;%W_0VQ<_T)M7/] ;5S_0&U<_T!M7/] _T8
M >E5  #:8P  S6P  ,-Q  "[=   M',  *QS!P"E=1X GW8N!)EU.@V3<D08
MC6]+(HAL42V#:5<V?F9=/GED8T1U8FI(<F%R2G!A>TQN885,;&&13&IAGDQH
M8*U,9F# 3&1@VDQD8/))9&#_1V5@_T5E7_]$95__1&5?_T1E7_]$_TH  .5:
M  #69P  RF\  ,!U  "X>   L'@  *=W! "A>AL FWLL Y5Y. N/=T(5B75)
M((1R4"I^;U4T>6Q:/7-I8$1N9V9*:F5N3F=E=U!E9(%08V2-4&%DFU!?9*I0
M762]3UMDUD]<9/!,7&3_2EUC_TA>8O]'7F+_1UYB_T=>8O]'_TT  .)>  #3
M:P  QW,  +UX  "U>P  K'P  *-\  "<?A< EW\I I%^-@F+?$ 2A7I('8!W
M3B=Z=5,Q=')8.FUO74-G;6-*8FIJ3U]I<U)<:7Y36FF*4UEIF%)7::=25FFZ
M451IU%!4:.Y.56C^3%9G_TI79O])5V;_25=F_TE79O])]E$  -]B  #/;@
MQ'<  +I\  "R@   J(   )Z   "7@A, DH0F 8V#- >'@CX0@8!&&7Q]3"1U
M>U$N;WA6-VAV6T!A<V!(7'%G3E=O<%)5;WM34V^'4E)OEE%1<*904'"X3D]P
MTDU.;^U,3F[^2TYM_TI0:_])4&O_25!K_TE0:_])[%8  -MG  #,<P  P'L
M +>!  "NA0  I(4  )B%  "2APT C8DA (B), 6"ASL-?89#%G>$2B!P@D\J
M:G]4,V-]63Q<>UY$5GAE2U)W;DY0=WE/3W>&3DYWE$Q->*5*3'BW24MXT4=*
M=NQ'277]2$ET_TA*<O]'2G+_1TIR_T=*<O]'YUP  -9L  #(=P  O8   +2&
M  "KB@  GXH  )**  "+C < AXX< (*.+ -]C3@)=XQ!$G&*1QMKB4TE9(=2
M+EV%5S=7@UP_4H%C14Z ;4=,@'A(2X"%1DJ!E$5*@:1#28&W04B!T$!'?^M
M17W\0D1\_T)$>O]#1'K_0T1Z_T-$>O]#XF(  -%R  ##?   N84  +"+  "F
MC@  FH\  (R0  "%D@  ?Y06 'R5)P%WE#0&<9,]#FN21!=ED$H@7H]0*5B-
M53%2C%LX38IB/4J*;#](BG<_2(J$/4>*DSQ&BJ0Z1HJV.$6*T#=#B>LX08?\
M.D"%_SL_A/\\/X3_/#^$_SP_A/\\W&H  ,MX  "_@P  M8L  *V1  "BDP
MEI0  (F6  !]F0  =YH- '.;( !OFRX#:ILX"F2:0!%>F4<:6)=-(E*64BI,
ME5DP2)1A-$:4:S5%E'<T1)2$,T.4DS%#E*,P0I2V+D&4T"U D^LM/9'\,#R/
M_S(ZCO\S.H[_,SJ._S,ZCO\SU7$  ,5^  "ZB0  LI$  *F8  "=F   D9D
M (6<  !VH   ;:(" &FC%P!EI"8!8:0R!5RC.PQ6HD(34*%(&TN@3B%&GU8F
M0Y]>*4&?:2E GW4I/Y^")SZ?D28^GZ$D/9^T(SR?SB$[G>HB.9O\)3>:_R<V
MF/\I-IC_*3:8_RDVF/\IS7D  ,"&  "VD   KI@  *6=  "8G@  BZ   ("C
M  !SI@  9:D  %VK"0!9K!P 5JTI E*M,P9-K#L,2*M"$D.K21@_JU$;/*I:
M'3NK91TZJW$<.:M_&SBKCAHWJY\9-ZNR%S:KS!8UJ>D6,Z?Z&3&F_QLPI/\=
M,*3_'3"D_QTPI/\=QH(  +J/  "RF   JJ   *"D  "2I0  AJ@  'JK  !N
MK@  8+   %.T  !+M@P 2;<= $:W*0)"MS(&/K<Z"CFW0PXVMTL0-+=5$3.W
M8!$RMVP0,;AZ#S&XB0XPN)L-+[BO#"VXR LMM^8+*[3Y#BFS_Q HL?\2*+'_
M$BBQ_Q(HL?\2OXP  +67  "NH   I:8  )JK  "-K0  @+   '.R  !FM
M6;<  $V[  !!OP  -\,) #7$&  SQ20!,,4N R[%. 4KQD$&*L9,!RC'5P8G
MQV0&)\AR!2;(@@4DR)0$(\BH!"+)P@,@R.,#'\7W!1W#_P<<P?\(','_"!S!
M_P@<P?\(N98  +&@  "IJ   GJT  )&P  "#LP  =K4  &FX  !<NP  4+\
M $7"   YQP  +\P  ";1!  ?U0P '=89 !S6)0 ;US  &M@\ !G82  8V54
M%]ID !7:=0 4VX< $MR< !#<M0 -W=@ #=KR  W8_P$-UO\"#=;_ @W6_P(-
MUO\"LZ   *RH  "BK@  E;(  (>V  !YN0  :[P  %Z_  !2PP  1\<  #O+
M   QSP  *-0  !_9   7W0  $^<) !'H%  .Z!X "^DI  GI-0 'ZD( !>M0
M  /L8  ![',  .N'  #JG0  ZK@  .O<  #J\P  ZO\  .K_  #J_P  ZO\
MKJ@  *6O  "8M   BK@  'R[  !NOP  8,,  %3'  !(S   /-   #'4   G
MV0  ']T  !?A   /Y   "_    CX!0 %^ X  ?D7  #Y(0  ^"P  /@Z  #X
M20  ^%L  /AN  #WA   ]IH  />Q  #WRP  ^.D  /CI  #XZ0  ^.D J*\
M )NU  "-N0  ?[X  '#"  !BQP  5<P  $C1   \U0  ,=H  "?>   =X@
M%N8   WI   &[    _8   #^    _P   /\%  #_#0  _Q<  /\B  #_,
M_T   /]3  #_:   _WT  /^1  #_HP  _[4  /^U  #_M0  _[4 GK4  )&Z
M  ""OP  <L4  &3*  !6T   2=4  #S;   PWP  )>,  !SG   2Z@  "^X
M  3P    \@   /P   #_    _P   /\   #_    _P(  /\+  #_&   _R4
M /\V  #_20  _UX  /]Q  #_@0  _Y$  /^1  #_D0  _Y$ _P D#?\ ( W_
M " ,_P A"_\ )@K_ #((_P! !O\ 3@3_ %L#_P!G O\ <0'_ 'L!_P"# /\
MB@#_ )  _P"6 /\ G #_ *( _@"I /T L #\ +@ ^P#" /L SP#[ .  ^@#N
M /H ^@#Z /\ ^@#_ /H _P#Z /\ ^0#_ /D _P#Y /\ _P A#?\!'0W_ !P,
M_P >"_\ (@K_ "\(_P ]!_\ 2P7_ %@#_P!D O\ ;P'_ '@!_P"  /\ AP#_
M (X _P"4 /T F@#[ *  ^0"F /@ K0#W +4 ]@"_ /4 S0#U -T ] #L /0
M]P#T /\ ] #_ /, _P#S /\ \@#_ /( _P#R /\ _P0>#O\&&0W_ Q@,_P 9
M#/\ ( K_ "P)_P Z!_\ 2 7_ %4$_P!A _\ ; +_ '4!_P!] ?T A0#[ (L
M^0"1 /< EP#U )T \P"D /( JP#P +, [P"] .X R@#N -H [0#H .T ]0#L
M /\ ZP#_ .H _P#H /\ YP#_ .< _P#G /\ _PD:#O\*% W_"!,,_P(3"_\$
M'@O_ 2D)_P V"/\ 0P;_ %$$_P!= _X : +[ '(!^ !Z ?8 @@#T (@ \@"/
M /  E0#N )L [0"A .L J #I +  Z "[ .< QP#F -< Y0#H .0 ]0#B /\
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M0IP7I$*F%Z)"LA>A0L 8GT+4&)Q"Z!F:0OD;F$'_')=!_QR60/\<ED#_')9
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MIBV%4+,MA$_&+8)/W2V 3_(M?T[_+7Y._RQ^3O\K?D[_*WY._RM^3O\K_SD
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M/FA8TCYG6.L\9UC\.F=8_SEG6/\W9UC_-V=8_S=G6/\W^T,  .-4  #380
MQVD  +UM  "U;P  JVT  *1L 0"=;A@ F&\I I)N-@F-;#\2AVE''()G325^
M9%,N>6)9-75@7SIQ7F8^;EUN0&Q==T%J78!":%V+0F9=F$)D7*9"8ERW0F!<
MSD)?7.E 7US[/E];_SQ@6_\[8%O_.F!;_SI@6_\Z\T8  -]9  #090  Q&P
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M04MI_T!+:/\_2VC_/TMH_S]+:/\_YE8  -1F  #&<0  NW@  +)]  "F?@
MFWX  )%^  "*@ 8 A8$; (&"*P)\@38(=X _$'%^1AAK?$LA97I0*E]X53-9
M=ELZ4W1A0$]S:D--<W1$3'.!0TMSCT)*<YY 27.O/DASQCU'<^(\1G'W/45P
M_SU%;_\]16[_/45N_SU%;O\]X5P  ,]K  #"=0  N'T  *Z"  "B@@  EX(
M (N#  "$A0  ?X<5 'N()@%VAS(%<88\#&N%0Q1E@TD=7X).)5F 4RU4?EDU
M3WU@.DM\:3U)?',]2'R /$=\CCI'?)TY1GRO-T5\Q35$>^(U0GKV-D%X_S=
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M*#>)_R@WB?\HSG$  ,!]  "VAP  K8\  *&0  "5D   B9(  'Z4  !PF
M99L  %^<#@!<G1\ 69TL E6=-0=0G#T,2YM$$D>:2QA"FE(</YE;'SV99!\\
MF7 ?.YI]'CJ:BQPZFIL;.9JL&3B9PQ@WF> 7-9;U&C.5_QPRE/\>,I/_'C*3
M_QXRD_\>QWD  +N%  "RCP  J94  )R5  "0E@  A)@  'F;  !LG@  7Z(
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M>P$<P(L!&L"? !G M@ 7O]0 %[WP 1:[_P(4NO\#%+G_!!2Y_P04N?\$M94
M *V?  "FI@  FJD  (VL  " KP  <K$  &6S  !8M@  3+@  $"[   SOP
M*<,  "#'   7RP4 $<T0 !#-'  .SB< #<XS  O.0  *STT "L];  C/:P &
MT'T !="1  30I@ "T,$  ,_B  #.^  !S/\  LO_  ++_P "R_\ L)\  *FG
M  ">K   DJ\  (2R  !UM0  :+<  %NZ  !.O0  0L   #;$   KR   (LP
M !G0   1TP  !]<   ':!P  VA0  -L?  #<*P  W3D  -Y'  #?5P  X&D
M .!]  #AD@  X:D  .'$  #BXP  XO8  .'Z  #A^@  X?H K*<  **M  "5
ML0  A[4  'BX  !JNP  7;X  %#"  !$Q@  -\D  "S-   AT0  &=8  !':
M   )W    =\   #B    Y    .4*  #F%@  Z"(  .HP  #L00  [U(  /!F
M  #P>P  \9   /*F  #RO0  \M<  /+A  #RX0  \N$ I:X  )BS  "*MP
M?+L  &V^  !>PP  4<<  $3+   WSP  +-0  "'8   7W   #^    ?D
MY@   .<   #J    \    /    #P    \0D  /07  #V)@  ^3D  /Q,  #]
M80  _G8  /^+  #_G0  _ZX  /^U  #_M0  _[4 F[0  (ZX  !_O0  ;\(
M &'&  !3RP  1=$  #C5   LVP  (-\  !;C   ,Y@  !>H   #L    [P
M .\   #Q    ^    /P   #\    _    /T   #^"@  _QP  /\O  #_1
M_UD  /]M  #_?P  _XX  /^3  #_DP  _Y, _P A"_\ '0K_ !P)_P ="/\
M(P;_ # %_P ^ _\ 3 '_ %@!_P!D /\ ;@#_ '@ _P"  /\ AP#_ (T _P"2
M /X F #] )T _ "C /P J0#[ +  ^@"Z /H Q@#Y -4 ^0#G /< ]0#U /\
M] #_ /4 _P#U /\ ]0#_ /4 _P#U /\ _P ="_\ &@O_ !@*_P 8"/\ ( ?_
M "X%_P [ _\ 20+_ %4!_P!A /\ :P#_ '4 _0!] /L A #Z (H ^0"/ /@
ME0#W )L ]@"@ /4 I@#T *X ] "W /, P@#R -$ \@#D /  \P#N /X [@#_
M .X _P#M /\ [0#_ .T _P#M /\ _P :#/\ %0O_ !0*_P 3"/\ '0?_ "H%
M_P X _\ 10+_ %$!_P!= /T : #Y '( ]@!Z /0 @0#S (< \0"- /  D@#O
M )@ [@"= .T I #M *L [ "T .L OP#J ,X Z0#@ .< \ #F /D Y #_ .0
M_P#D /\ Y #_ .0 _P#D /\ _P05#/\#$0K_  X)_P 2"/\ &@?_ "8%_P T
M!/\ 00+_ $X!^@!9 /4 9 #Q &X [@!V .P ?0#J (0 Z0"* .@ CP#G )4
MY0"; .0 H0#C *D X@"Q .$ O #@ ,L W@#= -T ZP#; /< V0#_ -D _P#8
M /\ V #_ -@ _P#8 /\ _P@1"_\("@K_ P8(_P4,!_\'%P;_ R(%_P O!/T
M/ +W $D!\@!5 .P 8 #H &H Y !S ., >@#A ($ WP"' -X C #= )( VP"8
M -H GP#9 *8 UP"O -4 N@#4 ,D TP#: -$ ZP#. O@ S 3_ ,L%_P#)!O\
MR ;_ ,@&_P#(!O\ _PX*"O\. PC_#  &_Q,(!?\3$P7_$1X$^PLI _,'-P+L
M!40!Y@50 .($7 #=!68 VP9O -D'=@#6"'T U0B$ -,)B@#2"9  T0F6 ,\*
MG0#."Z4 S RO ,L,N@#*#<D R _< ,03[0#!%/L!OQ7_ ;T5_P*\%/\"O!3_
M KP4_P*\%/\"_Q0$"?\5  ;_&@ $_QX# _\># /[&Q<#\!8C N<2, '@$3X
MVA%+ -835P#2%6$ SQ=J ,T8<P#+&7H R1J  ,<;AP#&'(T Q!V3 ,,=FP#!
M'J, P!^L +X?MP"]'\4!NR#8 ;@AZ@*U(?D#LB'_!+$A_P6P(/\%KB'_!JXA
M_P:N(?\&_QH !_\;  3_)  "_R@  ?<G!0#Q(PX Y1X; =P9)P#4'#< SB!&
M <HB4@'&)5T"PR9F L H;@*^*'8"O2E] [LJ@P.Z*HD#N"J0 [<KEP.U*Y\#
MM"RH!+(LLP2Q+,$$KRS3!*PLYP:J+/8'IRS_"*4L_PFD*_\*HRO_"J,K_PJC
M*_\*_Q\ !O\C  +_+0  [R\  .(M  #=* , VR - -$F(0#)*C$"PRU !+XO
M306[,%<&N#)A!K4R:0>S,W$'LC1X![ T?@BO-(4(K36,"*PUDPBJ-9L)J36D
M":<VKPFF-KT)I#;."J(VXPN?-?0,G37_#ILT_PZ:-/\.F3/_#IDS_PZ9,_\.
M_R4 !/\K  'Q,P  XCD  -H[  #3.   SS ' ,<S&P"_-BP#N3<[![0X1PJP
M.5(+K3I;#*L[9 VI.VP-ISQS#:8\>@ZD/( .HSR'#J(]C@^@/9</GCV@#YT]
MJP^;/;@0FCW)$)@]WQ&5//(2DSS_$Y([_Q.1.O\3D#K_$Y Z_Q.0.O\3_R@
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M)'U*TB1[2NHD>DK[)'E)_R-X2?\B>$G_(GA)_R)X2?\B_S0  .=$  #840
MRUD  ,%<  "X7   L5<  *I5" "D6!T GEDL!)A7. N354$3CU-)&XM142"(
M4%@CAE!?)81/9B>"3VXH@4]V*']/?BE^3X<I?$^1*7I/G"EX3ZDJ=DZY*G1.
MSBIS3N<J<DWY*7%-_RAP3?\G<$W_)G!-_R9P3?\F^3@  .-*  #45@  QUX
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M-EI7_S1:5_\R6U?_,5M7_S%;5_\QZD8  -E8  #*8P  OFH  +1M  "I;
MGVH  )=I  "1:@X C6PA (AL+@2#:S@+?FE!$WEG1QQT94TD;V)3*VI@6#)F
M7UXW8EYF.E]=;CQ=7'@]6UR#/5E<CSU77)T\5ERM/%1<P3M36]P[4UOS.%-;
M_S946O\U5%K_,U1:_S-46O\SYTP  -5<  #'9P  NVT  +%P  "E<   FV\
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M,D%J_S)!:O\RVEP  ,EJ  "]<P  LWH  *5[  ":>P  D'L  (-\  !]?@
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MA10UE903-)2E$3.4N1 RE-0/,9+N$"^0_1,NC_\4+8[_%2V._Q4MCO\5PG@
M +>$  "NC0  H(T  )2-  "(CP  ?9$  '*3  !EEP  69H  $^=  !'GPL
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M  VXJ@ +M\, "K;C  NT^  +L_\ "[+_ 0NR_P$+LO\!LI0  *N=  "@H
MDJ$  (6D  !XIP  ;*L  &"N  !4L0  1[,  #NU   NN   )+L  !J^   1
MP0  !\,)  3$%@ #Q"$  L4M  '%.0  Q44  ,53  #%8@  Q70  ,6'  #%
MG   Q+(  ,3/  ##Z@  P_D  ,+_  #"_P  PO\ K9X  *>E  ":J   C:L
M ("O  !RL0  9+,  %>V  !*N   /;L  #&]   FP0  ',0  !/(   *R@
M <T   #/!0  T!   -$;  #2)@  TS(  -1   #63P  V&   -AS  #8B0
MUZ   -:Y  #6V   UNT  -7X  #5^   U?@ JJ8  )^K  "2KP  A+(  '6U
M  !GN   6;H  $R]   _P   ,\,  "?'   <RP  $\\   K3   "U    -@
M  #:    W    -T'  #?$@  X1X  .0K  #F.0  Z4H  .I=  #K<@  [(@
M .R@  #KN   Z](  .KF  #JY@  ZN8 HJP  )6Q  "(M   >;@  &J[  !;
MOP  3L,  $'&   SR@  *,T  !S2   3UP  "=L   '>    WP   .(   #D
M    Y@   .@   #J    [ 8  .\4  #R(@  ]3(  /A$  #Z6   ^VX  /R$
M  #]F   _:L  /VZ  #]N@  _;H F;(  (NV  !\N@  ;;X  %[#  !0QP
M0LP  #30   HU   '-H  !'>   'X@   .4   #H    Z@   .L   #L
M[@   /    #S    ]0   /@   #["   _A@  /\J  #_/0  _U(  /]G  #_
M>P  _XH  /^6  #_E@  _Y8 _P <"?\ & C_ !<'_P 9!?\ ( 3_ "\"_P [
M ?\ 20#_ %8 _P!A /\ :P#_ '0 _P![ /\ @@#_ (@ _@"- /T D@#\ )<
M_ "= /L HP#Z *H ^ "R /8 O0#T ,P ] #? /, [P#S /T \P#_ /, _P#S
M /\ \P#_ /, _P#S /\ _P 9"?\ %0C_ !('_P 4!?\ '@3_ "L"_P X ?\
M1@#_ %, _P!> /T : #\ '$ ^@!X /D ?P#X (4 ]P"* /8 CP#U )4 ] ":
M /, H #R *< \ "O .X N@#L ,@ ZP#: .L [ #K /L Z@#_ .H _P#J /\
MZ@#_ .H _P#J /\ _P 6"O\ $@C_  X'_P .!O\ &P3_ "<"_P U ?\ 0@#^
M $\ ^0!: /8 9 #T &T \@!U /$ ? #P (( [P"' .X C #M )( ZP"7 .H
MG0#H *0 Y@"L .0 M@#C ,, X@#5 .$ Z0#@ /< X #_ .  _P#? /\ W@#_
M -X _P#> /\ _P 1"?\ "PC_  @'_P -!?\ & 3_ ","_P P ?P /@#U $L
M\ !6 .T 8 #K &D Z0!Q .@ > #F 'X Y0"$ ., B0#B (\ X0"4 -\ F@#=
M *$ VP"I -D LP#7 ,  U@#2 -4 Y0#4 /, TP#] -( _P#1 /\ T #_ -
M_P#0 /\ _P(*"?\ ! ?_   &_P )!/\ %0/_ " "_P K /0 .0#J $8 YP!1
M .0 7 #A &4 WP!M -T = #; 'L V0"! -@ A@#6 (P U "2 -( F #0 )\
MS@"G ,T L0#+ +X R@#. ,D X #' .\ Q@#[ ,0 _P## /\ P@#_ ,( _P#"
M /\ _P<$"/\$  ;_!0 $_PD$ _\(#P+_ QL!]0 E .D ,@#A $  W0!, -D
M5P#5 &$ TP!I -$ <0#/ '< S0!] ,L @P#* (D R "/ ,8 E@#% )T PP&E
M ,(!KP#  ;P OP/, +T$WP"[!O$ N0C^ +<)_P"V"?\ M0K_ +4*_P"U"O\
M_PT !_\*  3_$0 "_Q0  ?T3" 'U#!, Z@4= -T *P#7 CD T@1' ,X'4@#*
M"%P R IE ,4,;0#$#70 P@Y[ , 0@0"_$8< O1&- +P2E "Z$YP N1.D +<4
MKP"V%+P M!7, +(6X "O&/( K1C_ :L8_P&I&/\!J!C_ :@8_P*H&/\"_Q,
M!?\3  +_&P  \AT  .@9  #E$@< W@H3 -0+(@#-$3, QQ9! ,(930"_&U@
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M7P>D-6<'HC9N!Z V=0B?-GL(G3>"")PWB0B;-Y$)F3>:"9@WI F6-[ )E#?
M"I,WU J0-NH+CC;Z#(PU_PV+-?\-BC3_#(HT_PR*-/\,_Q\  >XK  #A.
MU#\  ,I!  #"/P  O#@  +<U$0"P.2,!JCHR!:4Z/@BB.TD*GSQ2"YP\6@R:
M/&(-F3UI#9<]< V6/7<.E#U^#I,]A0Z1/8T.D#V6#XX]H0^-/:T/BSV\$(D]
MT!"'/.<1A3SX$8,[_Q&"._\1@CK_$8(Z_Q&".O\1_R4  .HT  #;00  SDD
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M(6M(_R!K2/\?:DC_'FI(_QYJ2/\>[C8  -U)  #.5   P5L  +9<  "K6@
MI%8  )U4  "8510 DU<D 8Y7, :)53H-A%-"%(!22AI]4%$>>D]7(7A/7B-V
M3F4D=$YM)7-.=29Q3GXF;TZ()FU.DR=K3J G:4VN)V=-P2=E3-HH9$SP)F-,
M_R1C3/\C8TO_(F-+_R)C2_\BZSP  -E.  #*60  OE\  +)@  "G7@  GUL
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M*T]6_RM/5O\KX4P  ,];  #!90  MFH  *AI  "=:0  E&@  (MF  "%: ,
M@&H7 'UK)@%X:C$%<VDZ#&YG01-I94<:9&1-(5]B4BA;8%@N5U]>,E1>9C52
M77 V4%U[-DY=AS5-794T2UVE,TI=MS))7= Q2%SJ,$A;_"Y(6O\M25K_+$E:
M_RQ)6O\LW5$  ,M?  "^:0  LFT  *1M  "9;   D&P  (=K  " ;0  >V\3
M 'AP(@!S<"X$;V\X"6IM/Q!E;$478&I+'EIH4"569E8L465<,4YD9#1+8VXU
M2F-Y-4ECAC-(8Y0R1F.D,45CMB]$8\XM0V+I+4)A^RU"8/\L0E__*T)?_RM"
M7_\KV5<  ,=D  "[;0  KG   *%P  "6<   C'   (%P  ![<@  =70- ')U
M'@!N=2L":74U!V5S/0U@<D,46G%)&U5O3B%1;50H3&Q:+4EK8C!':VPP16MX
M,$1KA"Y#:Y,M0FNC*T%KM2E :\XH/VKH*#YH^B@]9_\H/6;_*#UF_R@]9O\H
MTUP  ,-I  "X<@  JG0  )UT  "2=   B'0  'QU  !U=P  ;WD' &M[&0!G
M>R<!8WLQ!%]Z.@I:>4 057A&%E!V3!Q+=5(B1W18)D1S82E"<VLI07-V*$!S
M@R<_<Y(E/G.B)#USM"(\<\T@.W+H(3EP^B(X;O\C.&W_(S=M_R,W;?\CSF(
M +]N  "U=P  IG@  )EX  ".>   A'D  '9[  !N?@  9W\  &*!$@!?@B$
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M"RZ/L0HLC\D)*XWE"2J+^ LIBO\,*(G_#BB)_PXHB?\.O7@  +.#  "EA@
MEX8  (R&  "!AP  =HD  &N,  !?D   5),  $F6   ^F00 .IH3 #B:(  V
MFBH -)HS C&:/ 0OFD0&+9I-!BN:5P<JFF(&*9IN!BB:>P4GFHH$)9J;!"29
MK@,CF<8#(9CC B"6]P4?E/\&'I/_!QZ3_P<>D_\'N($  *^+  "@BP  DXL
M (B,  !\C@  <9   &64  !9EP  39L  $.>   XH0  +:,# ">D$0 FI1T
M)*4G ".E,0 AI3L!(*5$ 1ZE3P$=I5H!'*5F !NE=  9I80 &*65 !:EJ  4
MI,  $Z/? !2A]0 3G_\!$I[_ A*>_P(2GO\"LXH  *F1  ";D0  CY$  (*3
M  !WE@  :YD  %^<  !3H   2*,  #RF   QJ0  )JL  !RN   4KPH $; 7
M !"P(@ -L"P #+ W  NP0@ )L$T "+%:  :Q:0 $L'D  ["+  &OG@  K[0
M *[0  "MZ@  K?D  :O_  &K_P !J_\ KI0  *28  "7EP  BID  'V<  !Q
MGP  9:,  %FF  !.J@  0JT  #:P   JL@  '[0  !6W   +N    KH(  "[
M$P  NQX  +PH  "\,P  O#\  +Q+  "]6@  O6H  +U]  "]D0  O*8  +N_
M  "ZW@  NO$  +G[  "Y_   N?P JYT  *"?  "2H   A:,  'BG  !LJ@
M8*X  %.Q  !&M   .;8  "VX   ANP  %[X   W    $P@   ,0   #&!
MQPT  ,@8  #)(P  RB\  ,L[  #,20  SED  ,YL  #/@0  SY8  ,ZM  #.
MR   S>,  ,ST  #,]0  S/4 IZ4  )NH  "-J@  @*X  '*R  !DM   5K8
M $BY   [O   +[X  "/!   8Q0  #<@   3+    S0   ,\   #2    TP
M -4$  #8#@  VQH  -TF  #?-   X40  .-6  #C;   Y(,  .2:  #EL0
MY<D  .3A  #DY   Y.0 H*L  ).O  "%L@  =K4  &>X  !8NP  2[X  #W"
M   OQ0  (\@  !?+   -T    ]0   #9    V0   -L   #>    X    .(
M  #E    Z ,  .L0  #N'0  \2P  /0]  #V4@  ]VD  />"  #WF@  ^*P
M /C   #XPP  ^,, EK   (BT  !ZN   :KL  %N_  !-Q   /L@  #',   D
MSP  %],   K8   "W0   .$   #D    Y    .8   #H    Z@   .P   #O
M    \0   /4   #X!0  _!0  /\E  #_-P  _TP  /]B  #_>0  _XT  /^@
M  #_H@  _Z( _P 7!_\ % ;_ !,%_P 5 _\ '@'_ "L _P Y /\ 1P#_ %,
M_P!> /\ : #_ '  _P!W /\ ?0#^ (, _0"( /P C0#[ )( ^0"8 /< G@#U
M *4 ] "M /, M@#R ,, \@#8 /$ ZP#Q /H [P#_ .\ _P#N /\ [P#_ .\
M_P#O /\ _P 4"/\ #@;_  T%_P . _\ &P'_ "@ _P V /\ 1 #_ %  _@!;
M /P 9 #Z &T ^0!T /< >@#V (  ]0"% /0 B@#R (\ \ "5 .X FP#M *(
M[ "I .H LP#I ,  Z0#2 .@ Y@#F /8 Y0#_ .0 _P#D /\ Y #_ .4 _P#E
M /\ _P 1"/\ "P;_  D%_P , _\ %P'_ "0 _P R /L /P#X $P ]@!7 /0
M8 #R &D \ !P .X =P#M 'T ZP"" .D AP#G (P Y0"2 .0 F #C )X X0"F
M .  KP#? +P W0#, -P X #: /, V0#_ -@ _P#8 /\ V #_ -D _P#9 /\
M_P +!_\ !0;_  $$_P * _\ %@'_ !\ ^@ M /, .P#O $< [0!2 .H 7 #G
M &4 Y0!M ., <P#A 'D WP!_ -T A #; (D V0"/ -@ E0#6 )L U "C -,
MK #1 +@ T #' ,X W #, .\ RP#\ ,L _P#* /\ R@#_ ,H _P#* /\ _P $
M!_\   7_   #_P & O\ $@'^ !L [P G .D -0#E $( X@!. -\ 6 #< &$
MV0!I -8 ;P#3 '8 T0![ ,\ @0#. (8 S "+ ,L D@#) )@ R "@ ,8 J0#$
M +0 P@## ,$ UP"_ .H O@#V +T _P"] /\ O #_ +P _P"\ /\ _P  !O\
M  3_   "_P ! ?\ "P#U !0 Y0 @ -\ +P#: #P U0!( -( 4P#. %P RP!D
M ,D ; #' '( Q0!X ,, ?0#" (, P0") +\ CP"] )8 O "> +H IP"X +(
MMP#! +4 TP"T .8 L@#T +$ _P"O /\ K@#_ *T _P"M /\ _P0 !/\   +_
M"  !^ @  /$# @#I  L W  9 -4 * #/ #8 R@!# ,8 3@#" %@ P !@ +X!
M: "\ FX N@-U +D$>@"W!(  M@6& +0&C0"S!Y0 L0>< + (I@"N";( K0G
M *L*TP"I"^@ IPWX *0/_P"C#_\ HP__ *(/_P"B#_\ _P@  _\,  'S$0
MYA0  -\1  #9" ( TP 0 ,P"'P#%!B\ P L] +L-20"X$%, M1)< +,48P"Q
M%6L L!5Q *X6=P"M%WT K!B$ *H8B@"I&9( IQF: *89I "D&K  HQJ_ *$:
MT@">&^< G!SW 9L<_P&:&_\!F1O_ ID;_P*9&_\"_PP  ?H5  #H'P  W20
M -0D  #-'0  R!,% ,(2& "[%RD M1LW +$>1 "N($X JR%8 *DB7P"G(V<
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M"WXV_PM]-?\+?37_"WPT_PM\-/\+\R   .0S  #4/P  R$8  +M%  "R00
MK#P  *@W!@"B.AH G#PI I@\-0:4/$ )D3Q)"H\\40N-/%D,BSU@#8D]9PV(
M/6T-ACUT#H4]? Z$/80.@CV-#H ]EP]_/:,/?3VQ#WL\PA!Z/-H0=SSO$'8[
M_A!U._\0=#K_#W0Z_P]T.O\/[RD  -\[  #/1P  PTT  +9+  "L2   ID0
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M&UU&_QI=1O\:Y#T  ---  #$5P  MEH  *E9  "?5P  EU0  )%2  ",4PD
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M@BU)69 L1UF?*T99L"E%6<8H0UCB)T-7]B9#5O\E0U;_)$16_R-$5O\CUE$
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M&SEOK1DX;\,8-V[?%S5L]!DT:O\:,VG_&C-I_QLS:?\;R&(  +MM  "L<0
MG'$  )!Q  "&<0  ?7(  &]U  !G=P  7WD  %I["P!7?!H 5'PG %%\, --
M>S@'27H_#$5Y11!!>4P4/GA3%SMX6Q@Y>&48.'AQ%S=X?18V>(L5-7B;$S1W
MK!(S=\(1,W;?$#%T]!(P<_\3+W'_%"YQ_Q4N<?\5PVD  +=S  "G=0  F'4
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M !B1\ $8C_\"%X[_ Q>._P07CO\$M(   *:$  "7A   BX,  ("$  !UA@
M:8D  %Z-  !3D   1Y0  #V7   RF0  *)P  !Z>"0 ;GQ4 &I\@ !B?*@ 7
MGS, %I\] !6?1P 3GU( $J!? !"?;  -GWL #)^,  J>GP (G;0 !YS.  B;
MZ0 )FOH "9G_  F8_P )F/\ KXD  *"*  "2B0  AXD  'N+  !OC@  8Y$
M %B5  !-F0  09P  #6?   KH@  (:0  !>G   -J04 !:H0  .J'  "JB8
M :HP  "J.P  JD8  *I3  "J80  JG   *F!  "IE   J*@  *?!  "FWP
MI?   *7[  "E_P  I?\ J9$  )N0  "/CP  @I$  ':4  !IEP  79L  %*?
M  !&HP  .Z8  "^I   DK   &JX  !&P   &L@   +,%  "T#P  M!D  +4C
M  "U+0  M3@  +5$  "V4@  MF(  +9T  "VAP  M9P  +2S  "ST   LNH
M ++X  "Q_0  L?T I)<  )>6  ")F   ?9L  '"?  !DHP  6*<  $RJ  !
MK@  -+$  "BS   =M0  $K@   BZ    NP   +T   "^ 0  OPH  , 5  #!
M'P  PRD  ,0U  #%00  QE$  ,=C  #'=P  QXP  ,:C  #&O0  Q=H  ,3N
M  #$]0  Q/4 H)X  )*?  "%H@  >*<  &NK  !?KP  4[,  $6U   WN
M*KH  !Z\   3OP  ",(   #$    Q0   ,<   #)    RP   ,T#  #/#0
MT1D  -0D  #6,   V3X  -Q0  #>8P  WGH  -^1  #?J   WK\  -[8  #>
MY   WN0 FZ@  (ZJ  "!KP  <[,  &2U  !5N   1[L  #F^   LP0  '\0
M !/'   (R@   ,T   #1    T0   -0   #6    V0   -P   #?    X@(
M .4/  #H'   ZBL  .T[  #P3@  \F,  /-[  #TD@  ]*8  /2W  #TP@
M],( E*\  (:R  !WM@  9[D  %B\  !*P   .\0  "W(   @RP  $\X   ;2
M    UP   -L   #?    WP   .$   #C    Y0   .<   #J    [@   /(
M  #V @  ^1$  /PB  #^-0  _TH  /]A  #_>   _XT  /^=  #_I0  _Z4
M_P 3!O\ #P3_  T#_P 0 ?\ &@#_ "D _P W /\ 1 #_ %  _P!: /\ 9 #_
M &P _P!S /T >0#[ '\ ^0"$ /@ B0#V (X ]0"3 /4 F0#T *  \P"H /(
ML0#Q +X [P#. .T Y0#L /< ZP#_ .L _P#K /\ [ #_ .P _P#L /\ _P .
M!O\ "P3_  D#_P * ?\ %P#_ "4 _P T /\ 0 #_ $P _0!7 /H 8 #Y &D
M]P!P /0 =@#R 'P \ "! .\ A@#N (L [0"0 .L E@#J )T Z0"D .@ K0#F
M +D Y #) .( X #A /, X #_ .  _P#@ /\ X0#_ .$ _P#A /\ _P +!O\
M!@3_  ,#_P * ?\ %0#_ "$ _  O /D / #V $@ ] !3 /$ 7 #O &4 [ !L
M .D <P#G 'D Y0!^ .0 @P#C (@ X0"- .  DP#? )D W0"A -P J@#9 +0
MU@#$ -4 V0#3 .T TP#] -( _P#2 /\ T0#_ -  _P#0 /\ _P $!?\   3_
M   "_P ( ?\ $ #Y !T \P J .\ -P#L $, Z0!. .8 6 #B &$ WP!H -P
M;P#; '4 V0!Z -< ?P#5 (0 U "* -( CP#1 )8 SP"= ,P I@#* +  R "_
M ,< T@#% .@ Q0#Y ,0 _P#! /\ P #_ ,  _P#  /\ _P  !?\   /_   !
M_P $ /\ "@#O !8 Z0 E .0 ,@#@ #X W !* -@ 5 #4 %T T0!D ,\ :P#-
M '$ RP!V ,H ? #( ($ QP"& ,4 C ## )( P0": +\ HP"] *T NP"[ +H
MS "Y ., MP#T +4 _P"S /\ LP#_ +( _P"R /\ _P  !/\   +_    _P
M /8  P#F !  W@ > -@ *P#2 #D S0!% ,H 3P#' %@ Q !@ ,( 9P#  &T
MO@!S +T > "[ 'T N@"# +@ B0"V )  M0"7 +, H "Q *L KP"W *X R0"L
M -\ J@#O *D ^P"H /\ J #_ *< _P"G /\ _P   O\   'Z    [    .0
M  #<  @ TP 7 ,P )0#& #( P@ _ +X 20"[ %, N !; +8 8@"T &D LP!O
M +$ =0"P 'H KP"  *T A@"L (T J@"5 *D G@"G *D I0"V *,!QP"B ML
MH /M )\$^P">!?\ G07_ )P%_P"<!?\ _P   ?L#  #K"P  X1   -@+  #0
M @  R0 . ,( '0"] "L N  X +0#1 "Q!4X K@=7 *P)7@"K"F4 J0IK *@+
M<0"F#'< I0Q^ *0-A "B#HP H0Z4 )\0G0">$*@ G!&V )H1QP"9$=T EA/Q
M )43_P"3$_\ DQ/_ )(3_P"2$_\ _P0  .\1  #B'   UR$  ,L?  ##%P
MO@T" +H'%0"T#20 KQ(R *L4/P"G%DD I1A2 *,96@"A&F$ GQMH )X<;@"=
M''0 FQUZ )H=@0"9'8D EQZ1 )8>FP"4'J8 DAZS )$>Q "/'MH C1_O (L?
M_0&*'O\!B1[_ H@>_P*('O\"^0P  .D>  #;*0  SB\  ,$L  "Y)P  M!\
M +$7#0"K'!\ IA\M *(B.@">)$4 G"5. )HF5@"8)ET EB=D 94G:@&4*'$!
MDBAW 9$I?@&0*84!CBF. 8PIF &+*:,!B2FP H@IP0*&*=8"A"GL X(H_ .
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M"FXT_PIN-/\*ZBD  -DZ  #)10  N48  *U%  "D0@  GCX  )DZ  "5.A
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M]1=80O\66$+_%5A!_Q180?\4WCT  ,Q,  "]4P  K5,  *!2  "740  D$X
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M'$5,_QM%3/\;TTP  ,-9  "R7   HUP  )=<  "-6P  A5H  'U9  !W6P
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M>18V:X<5-6N6$S1KIQ(S:KL1,FK5$#%H[A$O9OT2+F7_$RYD_Q0N9/\4PF(
M +1J  "B:@  E&H  (AJ  !_:@  =6L  &AN  !A<   67,  %)U! !.=A0
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M A^%H0$>A+8!'(30 1R"ZP$;@/P#&G__!!I^_P4:?O\%M'<  *)W  "3=P
MAW<  'UW  !S>0  :'L  %U^  !1@@  2(4  #Z(   TBP  *HX# "2/$  B
MCQL (8\E !^0+@ >D#< '9!  !N02@ :D%4 &)!@ !>/;0 5CWL $X^+ !&.
MG0 /CK$ #8W*  V+YP .BOH #HG_ 0Z(_P$.B/\!K7T  )Q]  ".?   @WP
M 'E]  !N?P  8H(  %>&  !,B@  08T  #>0   MDP  (Y4  !F7 @ 1F0T
M#YD9  V9(P ,F2P "YDV  F90  (F4L !IE7  2990 "F7,  )B#  "8E0
MEZ@  );   "5VP  E.\  )/[  "3_P  D_\ IH,  ):"  "*@@  @((  '2$
M  !HAP  7(L  %&.  !&D@  .I4  #"8   FFP  &YT  !*@   'H@(  *,,
M  "C%P  HR$  *0J  "D-   I#\  *1,  "D60  I&@  *1Y  "CBP  HI\
M *&V  "?TP  GNP  )[V  ">_0  GOT GXD  )*(  "'B   >XH  &Z-  !B
MD   5I0  $N8   _G   ,Y\  "BB   >I0  %*<   JI   !JP   *P"  "M
M"P  KA4  *X?  "O*   KS,  *\^  "P2P  L%L  +!L  "P?@  KY(  *^I
M  "MQ   K.,  *KT  "J_0  JOT FH\  (^.  ""D   =9,  &B7  !<FP
M4)\  $2C   XIP  +:H  "*M   7L   #+(   .T    M0   +<   "X
MN08  +D0  "[&@  O"0  +TO  "^.P  OTH  ,!<  # ;P  P(0  ,":  "_
ML@  O\X  +[F  "]]   O?0 EY8  (J7  !]F@  <)\  &.C  !7J   2ZP
M #^P   RM   )K8  !FX   .N@   [T   "^    OP   ,$   ##    Q
M ,8   #("0  RA0  ,T>  #/*@  T3@  -5)  #87   V'(  -B)  #7H0
MU[<  -;/  #6XP  UN, DI\  (6B  !YIP  ;*P  %^Q  !2M0  1+<  #6Z
M   HO0  &[\   W"   #Q0   ,@   #*    RP   ,P   #.    T0   -,
M  #7    V@$  -X,  #B&0  Y28  .@T  #L1P  [EP  .]T  #PBP  \*$
M /"S  #PQ   \,0 CZH  (*O  !TLP  9;8  %:Y  !'O0  -\   "G$   <
MQP  #LH   +-    T0   -4   #8    V    -H   #=    WP   .(   #E
M    Z0   .T   #P!   \Q(  /8A  #Z,0  _D4  /]<  #_<P  _X@  /^9
M  #_I@  _Z8 _P .!/\ "@/_  @!_P ( /\ & #_ "8 _P T /\ 00#_ $P
M_P!7 /\ 8 #^ &@ ^P!P /D =@#X 'L ]P"  /8 A0#U (H ] "/ /, E0#R
M )P \0"C .\ K #M +@ ZP#( .D WP#I /, Z #_ .@ _P#H /\ Y0#_ .0
M_P#C /\ _P *!/\ !P/_  0!_P ( /\ % #_ ", _P P /\ /0#^ $D ^P!3
M /@ 70#T &4 \0!L /  <P#N '@ [0!] .P @@#K (< Z@", .D D@#H )@
MY@"? .0 J #A +0 WP## -T V #= .\ W #_ -H _P#6 /\ U0#_ -0 _P#4
M /\ _P &!/\  0+_   !_P $ /\ $0#] !X ^0 L /8 .0#T $0 \0!/ .P
M60#I &( YP!I .4 ;P#C '4 X@!Z .  ?@#? (, W@"( -P C@#: )4 V "<
M -4 I0#3 *\ T0"] ,\ T0#. .D RP#Z ,@ _P#& /\ Q@#_ ,< _P#' /\
M_P  !/\   +_   !_P   /P "@#T !H [P F .P - #G $  XP!+ .  50#<
M %T V@!D -@ :P#5 '$ U !V -( >P#0 (  SP"% ,P BP#* )$ R "8 ,<
MH0#% *L P@"X ,$ RP"^ .( N@#U +H _P"Z /\ N@#_ +H _P"Z /\ _P
M _\   '_    _P   /$ !0#J !0 Y  A -T +@#8 #L U !& -$ 3P#. %@
MRP!@ ,D 9@#& &P Q !R ,, =P#! 'P P "! +X AP"] (T NP"5 +D G0"W
M *< M0"T +( Q0"P -L KP#P *X _@"N /\ K0#_ *T _P"M /\ _P   O\
M  #_    ]0   .<   #>  T U0 ; ,\ *0#* #4 Q@!  ,, 2@#  %, O0!;
M +L 8@"Y &@ MP!N +8 <P"T '@ LP!^ +( A "P (H KP"2 *T F@"J *0
MJ "P *8 OP"E -4 I #K *, ^0"B /\ H@#_ *$ _P"A /\ _P   ?\   #P
M    Y0   -P   #2  8 R0 5 ,, (@"^ "\ N@ [ +< 10"T $X L0!6 *\
M70"M &0 K !J *L ;P"I '4 J !Z *< @0"E (< HP"/ *$ F "@ *( G@"M
M )T O "; -$ F@#E )@ ]0"7 /\ EP#_ )8 _P"6 /\ _P   /(   #F"
MV@H  ,X%  #%    OP , +H &@"U "< L0 T *T /P"J $D IP!1 *4 60"D
M &  H@%F *$"; "? W( G@-W )T$?@";!(4 F@6- )@%E@"7!J  E0:L ),&
MNP"2!\\ D CE (X)]@"-"O\ C K_ (P*_P","O\ ^    .H0  #=&@  S1T
M ,(8  "Z$0  M@@! +( $@"L R  J <N *0*.@"A#$0 GPY- )P050";$5P
MF1)B )@2: "7$VX E1-U )04>P"2%(( D16+ (\5E ".%9\ C!6K (H5NP")
M%<\ AQ;G (47^ "$%_\ @Q?_ ((7_P""%_\ \@L  .,=  #5)P  Q"D  +@E
M  "P(0  JQH  *D1" "D$QH GQ<H )L9-0"8&S\ EAQ) )0=40"2'E@ D!Y>
M (\?9 ".'VL C"!Q (L@> ")(8  B"&( (<AD0"%(9P @R&I ((AN " (<P
M?B'D 7PA]@%[(?\">B#_ GH@_P)Z(/\"[1@  -TH  #,,@  O#(  + P  "H
M+   HR<  * @ @"<'Q4 ER(D ),D, "0)CL CB=% (LH30&**%0!B"E: 8<I
M80&%*F<!A"IN 8,J=0&!*WP"@"N% GXKC@)]*YD">RNF GDJM0)W*LD"=2KA
M W,I]01R*?\$<2C_!'$H_P1Q*/\$Z"(  -<Q  #%.0  M3D  *HX  "A-0
MG#$  )@L  "5*1  D"P? (PN+ &(+S<"AB]  X0P2 .",% $@#%6!'\Q701]
M,6,$?#%J!7LR<05Y,GD%=S*"!78RBP5T,I<&<C*C!G QLP9N,<8&;#'?!VHP
M\P=I+_\':"__!V@N_P=H+O\'Y"H  -$Z  # /P  L#\  *0^  "</   EC@
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M0 ( ?T(4 'M#(0!W0RP#<T(U!V]"/0IM040-:D%+#VA!41!F0%@194!?$6-
M9A)A0&\27T!X$EY @A-<0(X36D";$U@_JQ-6/[X35#[6$U,^[A)2/?X14CS_
M$5(\_Q!2//\0V#X  ,9+  "S3   I$P  )A,  "/2@  B4<  (-&  !^1@
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M>!U 484</U&3&SU1HQH\4;89.E'/%SE0Z1<X3_L7.$[_%SA-_Q<X3?\7R5(
M +=8  "E6   EUD  (M8  ""6   >E@  '!7  !J6@  9%L  &!=$ !=7AT
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M#2]FH0PN9K0++67,"BQDYPHJ8OD,*6'_#BA?_P\H7_\/O6$  *EC  "98P
MBV,  (!C  !W9   ;F4  &)H  !::@  4VP  $MO  !&< P 0W 9 $%Q)  _
M<2T!/' T!#AP/ 8U;T,(,V]*"C%O4@LO;UP++F]G"BUO<PDL;X (*V^/!REN
MGP8H;K(&)VW+!29LY@4D:OD'(VC_"2)G_PHB9_\*N&<  *1G  "49P  AV<
M 'UG  !S:   :FH  %YM  !6;P  3G(  $5T   \=P4 .'@2 #9X'0 U>"<
M,G@O 3!X-P(N>#\$+'A'!2IX4 4H>%D%)WAD!"9X< 0D=WX#(W>- R%WG0(@
M=K !'G7( 1YTY0$=<_@#'''_!!MP_P8;</\&L6L  )YL  "/:P  @VL  'EL
M  !P;0  96\  %IR  !1=0  2'@  #][   U?0  +8 ) "J %0 H@!\ )H$H
M "6!,0 C@3D (8%" 2"!2P$>@54!'8%@ 1N!;  :@'H &(") !9_F@ 4?ZT
M$G[% !)]X@ 3>_8 $WK_ 1-Y_P(2>?\"JG   )EP  "+<   ?W   '5P  !K
M<@  8'0  %9X  !+?   0GX  #B!   NA   )8<  !R)"  8BA0 %XH> !6*
M)P 4BC  $XHY !&*0P 0BDT #8I9  N*90 )BG, !XF#  6)E  $B*8  H:]
M  *%V  "A>T  X/[  2"_P $@O\ HW8  )-U  "&=0  ?'4  ')V  !F>
M6WL  %!_  !%@P  .X8  #&)   GC   'HX  !21   *DP@ !)03  *3'0 !
MDR8  ),O  "3.0  DT0  )-0  "370  DVL  )-[  "2C   D9X  )"T  "/
MT   CN@  (WU  "-_0  C?X G'L  (Y[  "">@  >'L  &Q]  !@@   580
M $J(   _BP  ,X\  "J2   @E   %I<   R9   "FP   )P*  "<%   G1T
M )TF  ">+P  GCH  )Y%  ">4P  GF(  )YQ  "=@P  G98  )RK  ":Q0
MF>,  )CU  "7_@  E_\ EH$  (F   !_@   <X(  &>&  !:B0  3XX  $.2
M   XE0  +9D  "*<   8G@  #:    2C    I0   *8   "G"   IQ(  *@:
M  "I(P  JBT  *HX  "J10  JU0  *MD  "J=P  J8L  *FA  "HN0  I]@
M *;N  "E^@  I?P D8<  (>'  !ZB0  ;8P  &&0  !5E   29@  #R=   Q
MH   )J0  !JG   0J0  !:L   "M    KP   +$   "R    LP,  +,,  "T
M%@  MA\  +<J  "X-@  N40  +I5  "[:   NWP  +J1  "YJ@  M\8  +;C
M  "U\P  M?8 CXX  (*/  !UDP  :)<  %N;  !/H   0Z4  #:I   KK0
M'[   !.S   (M0   +@   "Y    N@   +P   "]    O@   ,    #"!0
MQ \  ,<9  #))0  RS(  ,Y#  #/5@  T6P  -&"  #1F   T*\  -#&  #/
MW0  S^( BI<  'V:  !PGP  8Z0  %>I  !+K@  /K(  #&V   DN0  %[L
M  F^    P    ,,   #$    Q0   ,<   #(    RP   ,T   #0    TP
M -@(  #<%   X"   .,O  #G00  ZE<  .IN  #KA@  ZYP  .NO  #KP
MZ\4 AJ(  'FG  !MK0  8;(  %.V  !$N0  -+T  "7    8PP  "L8   #)
M    S0   -    #1    T@   -,   #5    V    -L   #?    XP   .<
M  #K 0  \ T  /,<  #W+   ^T   /U6  #_;@  _X4  /^7  #_I@  _ZH
M_P ) _\ !P'_  , _P & /\ %0#_ ", _P Q /\ /0#_ $D _P!4 /T 7@#[
M &8 ^0!L /< <@#V '@ ]0!] /0 @@#S (8 \@"+ /$ D0#O )@ [0"? .L
MJ #J +, Z ## .< V@#E /  Y #_ .  _P#= /\ W #_ -L _P#9 /\ _P &
M O\  0'_    _P $ /\ $@#_ "  _P M /\ .0#Z $8 ]P!0 /0 6@#R &(
M\ !I .X ;P#L '0 ZP!Z .H ?@#H (, YP"( .4 C0#C )0 X0"; -\ I #=
M *\ VP"] -D T@#7 .H T@#] ,\ _P#/ /\ SP#_ ,\ _P#/ /\ _P   O\
M  '_    _P   /\ #0#[ !L ^  H /( -@#O $$ [0!, .D 50#F %T Y !E
M .$ :P#? '$ W0!V -L >P#9 (  V "% -4 B@#4 )  T@"8 -  H #. *H
MS "X ,D R@#$ .0 P@#X ,( _P#" /\ P@#_ ,( _P#" /\ _P   O\   '_
M    _P   /< !P#Q !8 Z@ C .4 ,0#B #P WP!' -L 4 #6 %D TP!@ -$
M9P#/ &T S0!R ,L =P#* 'P R "! ,< A@#% (T PP"4 ,$ G "_ *8 O "S
M +@ Q "W -P M@#R +4 _P"U /\ M0#_ +4 _P"U /\ _P   ?\   #_
M]0   .P  P#D !$ VP ? -8 *P#2 #< S@!" ,H 2P#' %0 Q !; ,( 8@#
M &@ O@!M +T <P"[ '@ N@!] +@ @@"V (D M "0 +( F "P *( K@"N *P
MO0"K -, J@#K *D _ "H /\ J #_ *@ _P"H /\ _P   ?\   #V    Z@
M .    #4  L S0 9 ,@ )0#" #$ OP \ +P 1@"Y $X M@!6 +0 70"R &,
ML !I *X ;@"M '0 JP!Y *H ?P"I (4 J ", *8 E0"D )X HP"J *$ N "@
M ,P G@#D )T ]@"= /\ G #_ )P _P"; /\ _P   /8   #K    W0   -$
M  #(  0 P0 2 +L 'P"V "L LP V +  0 "M $D J@!1 *@ 6 "F %\ I !E
M *, :@"B &\ H0!U *  >P"? ($ G0") )P D0": )L F "F )< M "5 ,8
ME #> ), \0"1 /T D #_ )  _P"0 /\ ^P   .T   #@!0  SP4  ,0   "]
M    MP * +$ & "M "0 J@ P *8 .P"C $0 H !, )X 5 "= %H FP!@ )H
M9@"9 &P F !Q )8 > "5 'X E "& )( CP"0 )D CP"D (T L@"+ ,0 B@#:
M (@ [@"' ?H A@+_ (4"_P"% O\ \P   .4.  #4%P  Q!4  +D2  "Q#
MK0,! *D $ "E !T H0 J )T!-0": S\ F 5( )8&3P"4!U8 DPA< )$(8@"0
M"6@ CPEN (T*=0","GP BPN$ (D+C0"'"Y@ A@ND (0+L@""#,0 @0S< '\.
M\ !^#OX ?0[_ 'P._P!\#O\ [0P  -T<  #*(@  NR(  *\?  "H&P  HQ4
M *$,!@"="18 F0TD )40+P"2$CH D!-# (T52P",%5( BA99 (D77P"'%V4
MAAAK (48<@"#&7D @AF" ( 9BP!_&98 ?1FB 'L9L !Z&<, >!G; '8:\ !U
M&O\ =!K_ ',9_P%S&?\!YQ@  -8H  #"*P  LRL  *@I  "@)@  FR(  )@;
M  "6%A  D1H? (T<*P"*'C8 AQ\_ (4@1P"$(4\ @B%5 ($B6P!_(F( ?B-H
M 'TC;P![(W< >B-_ '@DB !W)), =2.@ ',CK@!Q(\  ;R/8 6TC[@%L(OX"
M:R+_ FLA_P)J(?\"XB(  ,\Q  "[,@  K#,  *$R  ":+@  E"L  ) G  ".
M(@H B20: (8F)P""*#( @"D[ 7XI1 %\*DL!>RI2 7DJ6 )X*UX"=BME G4K
M; )S*W,"<BQ\ G LA@)N+)$#;"N= VHKK -H*[X#9BK5 V4J[ 1C*?P$8BG_
M!6(H_P5B*/\%W2H  ,DW  "V.0  ISD  )PX  "4-0  CC(  (HO  "'*P4
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M>A)//X8233^3$DL_HA))/K021SW+$48]YA%&//@01CO_#T8Z_P]&.O\/S4,
M +A'  "F2   F$D  (U)  "$2   ?48  'A$  !R1   ;48& &E'%0!F2"$
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M%#A-GA,W3:\2-4W&$31,XA$S2_81,TG_$C-)_Q(S2/\2PE   *U1  "<4@
MCE(  (-2  !Z4@  <E(  &E1  !B5   754  %E7"0!56!< 4U@B %!8*P)-
M5S,%25<Y"496/PQ"5440/U1,$CQ45!0Z5%P5.51F%#=4<A,V5'\2-52-$3-4
MG1 R4Z\.,5/%#3!2X0TN4?4/+4__$"U._Q M3O\1OE0  *E4  "850  BU4
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M 1YHW@$=9O,#'&3_!1QC_P8;8O\&K6   )I@  ",8   ?V$  '5A  !K8@
M8F,  %=F  !/:0  2&L  #]N   V<   ,'(+ "US%P K<R  *G,I "AS,0 F
M<SD!)'-! 2-S2@(A<U0"('-> 1YS:@$=<W@!&W*& !ERE@ 7<:@ %G"_ !1O
MVP 5;?( %6S_ 11K_P(4:O\#IV0  )5D  "'9   >V4  '%E  !H9@  7F@
M %-L  !+;@  0G$  #ET   P=@  )WD" "![#0 >>Q@ ''LA !M[*@ 9>S(
M&'P[ !=[1  5>TX %'M9 !)[90 0>W, #7N"  MZD@ )>:0 !WBY  9WTP '
M=NL "'3[  ES_P )<_\ H&D  )!I  "":0  =VD  &YJ  !D:P  66X  $]Q
M  !%=0  /'@  #)Z   I?0  ((   !># @ .A0T "X48  J$(0 (A"H !X0R
M  :$/  $A$<  X12  &$7@  A&P  (1[  "#BP  @IT  (&R  !_S0  ?N4
M 'WT  !]_   ?/\ F6\  (IN  !^;@  =&X  &IO  !?<@  5'4  $EY   ^
M?   -7\  "N"   BA0  &(<   ^*   %C 4  (T/  "-&   C2$  (XI  ".
M,@  CCT  (Y)  ".50  CF,  (YS  "-A   C)8  (NJ  "*PP  B.(  (?T
M  "&^@  AOX DW0  (5S  ![<P  <70  &5V  !9>0  3GT  $.!   WA0
M+8@  ".+   :C@  $)    >2    E0   )8'  "6$   EA@  )<@  "8*0
MF#,  )@^  "82P  F5D  )EI  "9>P  F(X  )>B  "6N0  E-@  )/O  "2
M^P  DO\ C7H  ()Y  !X>0  :WL  %]_  !3@P  2(<  #R+   PCP  )I(
M !N5   2EP  !YH   "<    G@   )\   "@!@  H X  *$7  "B'P  HR@
M *0S  "D/P  I4X  *5?  "E<0  I8,  *28  "CKP  HLL  *'G  "@]0
MH/L B8   ']_  !S@0  9H4  %F)  !-C@  09(  #66   IF@  'IT  !.@
M   (H@   *4   "G    J0   *L   "L    K0   *T(  "N$0  L!H  +(D
M  "S,   M#X  +5/  "V80  M'<  +.,  "SHP  LKP  +':  "Q[0  L/4
MAX8  'J(  !MBP  8)   %25  !'F0  .IX  "ZB   BIP  %ZH   NL
MKP   +$   "R    M    +8   "X    N0   +H   "\ @  O@L  , 5  #"
M(0  Q2T  ,<]  #)4   RV4  ,M[  #+D0  R*H  ,;$  #%W   Q>@ @H\
M '63  !HEP  6YP  $^A  !"IP  -:P  "FP   =LP  $;8   2Z    O
M +X   "_    P    ,(   ##    Q@   ,@   #*    S0   -$#  #6#@
MVAP  -TJ  #A/   Y%(  .5I  #F@   YY8  .:J  #FN@  YL8 ?IH  '&?
M  !DI0  6*H  $RP   _M0  ,;D  "&\   4OP  !<(   #%    R    ,L
M  #+    S0   ,X   #/    T@   -4   #:    W@   .(   #F    [ @
M / 7  #S)@  ^#L  /I2  #[:P  ^X(  /R5  #\I   _*P _P & ?\  @#_
M    _P % /\ $@#_ "  _P M /\ .P#_ $8 _P!1 /T 6@#[ &( ^0!I /8
M< #T '4 \P!Z /$ ?P#P (0 [@") .T C@#L )0 Z@"< .@ I #G *\ Y0"^
M .0 U #? .T V@#_ -@ _P#9 /\ V@#_ -4 _P#1 /\ _P   ?\   #_
M_P   /\ #@#_ !P _0 J /H -P#Y $( ]P!, /, 5@#O %X [ !F .H ; #H
M '( YP!W .4 ? #D (  X@"% .$ BP#? )$ W@"8 -L H0#9 *L UP"X -(
MS0#- .< RP#Z ,L _P#+ /\ S #_ ,L _P#( /\ _P   ?\   #_    _P
M /X "@#X !@ \@ F .\ ,@#M #T Z0!( .4 40#A %H W@!A -P : #: &T
MV !S -8 > #5 'T TP"" -$ AP#/ (T S0"4 ,H G0#' *< Q "S ,$ Q@"_
M -X O@#T +X _P"^ /\ O0#_ +T _P"] /\ _P   ?\   #_    ^@   /,
M!0#J !0 Y0 @ .  +0#< #D V0!# -4 3 #1 %4 S@!< ,L 8P#( &D Q0!N
M ,, <P#! '@ OP!^ +X @P"\ (D NP"0 +D F0"X *( M@"N +0 O@"R -0
ML0#N +  _P"P /\ KP#_ +  _P"P /\ _P   /\   #^    [P   .0  0#<
M  X U0 < ,X )P#+ #, R  ] ,4 1@#  $\ O !7 +D 70"W &, M0!I +0
M;@"S ', L@!Y +$ ?@"O (0 K@"+ *T E "K )T J0"I *@ MP"F ,L I0#F
M *0 ^0"C /\ HP#_ *, _P"C /\ _P   /P   #O    XP   -4   #-  D
MQ0 6 ,  (@"\ "T N  X +0 00"Q $D KP!1 *T 6 "K %X J0!D *@ :0"G
M &\ I@!T *4 >@"D (  H@"' *$ CP"? )D G@"D )P L0": ,0 F0#= )@
M\P"8 /\ EP#_ )< _P"7 /\ _P   /(   #D    T@   ,@   "_  ( N0 0
M +0 ' "O "< JP R *D / "F $0 I !, *( 4P"@ %D GP!? )T 9 "< &H
MFP!O )H =0"9 'P EP"# )8 BP"4 )4 DP"@ )$ K0"/ +X C@#5 (T [0",
M /L BP#_ (H _P") /\ ]@   .@   #5    Q@   +L   "T    K@ ( *D
M%0"E "$ H@ L )\ -@"< #\ F@!' )@ 3@"6 %4 E0!; ), 8 "2 &8 D0!L
M )  <@"/ '@ C0"  (P B "* )( B0"= (< J@"% +H A #0 (, Z "! /<
M@ #_ '\ _P!_ /\ [@   -X,  #*$   NP\  + +  "I!P  I0   *$ #0"=
M !H F@ F )< , "4 #H D0!" (\ 2@"- %  C !7 (L 7 ") &( B %H (<!
M;P"% G8 A -] (,#A@"! Y  ?P.< 'X#J0!\ [D >@/. 'D%Y0!W!O8 =@;_
M '8&_P!V!O\ Z P  -0:  #!'   LAL  *<:  "@%@  FQ$  )D'! "7 1(
MD@0@ (X&*P","#4 B0H^ (<+1@"&#$T A U3 (,.60"!#E\ @ ]F '\0; !]
M$'0 ?!%\ 'H1A0!Y$8\ =Q&; '41J0!S$;H <1'1 ' 2Z0!N$OD ;1+_ &T2
M_P!M$O\ X1D  ,LC  "X)0  JB4  * C  "8(   DQT  ) 7  "/$ H BQ$9
M (<4)@"$%C  @1<Z '\80@!^&4D ?!I0 'L:5@!Y&EP >!MB '8;:0!U''$
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M?0-@+(@#7BR5 UPKHP-:*[0#6"O)!%8JXP15*O8$52G_!50H_P54*/\%T#(
M +DU  "H-P  FC<  (\W  "'-0  @3,  'TP  !Z+@  =BT+ ',O&@!O,"4
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M#48ZG U#.:T-0CG"#4 XW0Q -_,,0#?_#$ V_PQ -?\+PS\  *Y   "=0@
MD$(  (5"  !]0@  =D   ' ^  !K/@  9C\  &) #P!?0AP 7$(F 5E"+@16
M034&4T ["5! 0@M./T@-3#]/#DH_5@](/UX01C]H$$0_<A!"/WX/0#^+#SX^
MF@\]/JP..S[!#CD]W TY//(-.3O_#3DZ_PTZ.O\-OT(  *I$  ":10  C44
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M""I.V0<I3? )*$O^"R=*_PPG2?\,LDP  )]-  "03@  @T\  'E/  !O4
M9U   %U1  !54P  4%4  $M6  !'5PP 1%@8 $)8(@ _6"H!/%@Q SE8. 8V
M5S\(-%=&"C)63@HP5U8++E=@"BU7; DL5W@(*U>&!RE6E@8H5J<%)E6\!215
MV 0C4^\&(E'^"")0_PDA3_\*KE   )M1  ",4@  @%,  '53  !K4P  8U0
M %E6  !26   2UH  $1<   _7@8 .UX3 #E?'0 W7R8 -5\N 3)>-0,P7CP$
M+EY#!BQ>2P8J7E0&*5Y>!B=>:@4F7G<$)%Z%!"->E ,A7:8"(%R[ AY<U@$>
M6NX#'%C]!!Q7_P8;5O\'J%0  )95  "(50  ?%8  '%7  !G5P  7U@  %5;
M  !.70  1U\  #]A   W9   ,F4, "]F%P N9B$ +&8I "IF,0$H9C@!)F9
M B1F20(C9E("(69< B!F9P$>9G0!'&6# 1MED@ 99*0 %V.Y !5BU  68>T
M%E_\ 15>_P(47?\#HU@  ))9  "#6@  >%H  &U;  !D7   6UT  %)?  !)
M8@  0F0  #EG   Q:0  *6P$ "1M$  B;AH (&XB !]N*P =;C, '&X[ !IN
M1  9;DX %VY8 !5N8P 3;7$ $6U_  YMCP ,;*  "VNU  EJS@ *:.@ "V;Z
M  MF_P ,9?\!G5T  (Q=  !_7@  <UX  &E?  !A8   5V(  $YE  !$:
M/&H  #-M   K<   (G(  !EU!@ 4=A$ $W8; !%V(P /=BL #78T  QV/0 *
M=D< "'92  =V7@ %=FL  G5Z  !UB0  =)L  '.N  !QQP  <.$  &_R  !N
M_0  ;?\ EF(  (=B  !Z8P  ;V,  &9C  !=90  4V<  $EK   ^;@  -7$
M "UT   D=@  &WD  !)\   (?@D  G\3  !_'   ?R0  '\M  !_-@  ?D
M 'Y+  !^5P  ?F0  'YS  !]@P  ?94  'RH  !ZP   >=X  'CP  !W^0
M=O\ D&<  ()G  !V9P  ;&@  &)H  !7:P  36\  $-R   X=@  +WD  "9[
M   <?@  $X$   F#    A@0  (<,  "'%0  AQT  (@D  "(+   B38  (A"
M  "(3@  B5P  (EK  "(?   AX\  (:B  "$N0  @]8  (+O  "!^P  @/\
MBFT  'UL  !S;   :6T  %UO  !2<P  1W<  #Q[   Q?@  )X(  !V$   4
MAP  "HH   &,    CP   (\$  "0#   D!4  )$<  "2(P  DRP  ),W  "3
M1   E%(  )1A  "4<P  DX8  )*:  "1L   C\P  ([I  ",^   B_\ A'(
M 'IR  !P<@  9'4  %=X  !,?   0($  #2$   IB   'HP  !6/   *D0
M I0   "6    F    )D   ": @  FPH  )P2  "=&@  GB(  )\L  "@.
MH$<  *%7  "A:0  H7P  *"1  "?IP  GL   )W>  "<\0  F_L @7@  'AX
M  !K>@  7GX  %*"  !%AP  .(P  "V0   BE   %I<   N:   !G    )\
M  "A    HP   *0   "E    I@   *<'  "H#@  J1<  *L@  "M+   KCD
M *Y*  "O70  KW$  *^%  "NG   KK0  *W0  "MYP  K/0 ?WX  '*   !E
MA   6(D  $R.   _DP  ,I@  ":<   ;H   #J,   .F    J    *L   "M
M    KP   +    "R    LP   +0   "V    N <  +H1  "]&P  OR@  ,$W
M  ##2@  Q5\  ,-W  #"C@  P:4  ,&]  # U0  P.@ >H@  &V+  !@D
M4Y4  $:;   YH   +*4  ""J   4K0  ![    "S    M@   +@   "Y
MNP   +T   "_    P0   ,,   #%    QP   ,H   #/"@  TA@  -8F  #;
M-P  WDP  .%C  #A>@  XI$  -^G  #=NP  W-  =9,  &F7  !<G0  3Z,
M $*I   UK@  *+,  !RW   .NP   ;X   #!    Q    ,8   #&    R
M ,D   #+    S@   -$   #4    V    -T   #A    YP0  .L3  #O(P
M\S<  /9.  #X9@  ^7X  /F2  #ZH0  ^:X _P ! /\   #_    _P " /\
M#@#_ !T _P K /\ -P#_ $( _@!. /L 5P#X %\ ]@!F /0 ;0#S ', \0!X
M /  ?0#O (( [0"' .P C #I ), YP": .0 HP#A *X WP"\ -P T #7 .L
MU@#^ -4 _P#5 /\ U #_ ,\ _P#+ /\ _P   /\   #_    _P   /\ "P#_
M !H _  G /D ,P#V #X ] !) /  4@#M %H Z@!B .< : #C &\ X !T -X
M>0#< 'X V0"$ -< B0#5 (\ U "6 -( GP#1 *D S@"V ,P R #) .( R #X
M ,< _P#' /\ R #_ ,4 _P#" /\ _P   /\   #_    _P   /D !P#T !8
M[P B .L +P#I #H YP!# .( 30#; %4 U0!= -( 8P#/ &D S0!O ,P = #+
M 'D R@!_ ,@ A #' (H Q@"1 ,0 F0#" *, P "P +X P "\ -D N@#Q +D
M_P"Y /\ N0#_ +D _P"W /\ _P   /\   #_    ]P   .P  P#F !$ W@ >
M -H *0#8 #0 T0 ^ ,P 1P#( %  Q0!7 ,, 7@#! &0 OP!I +T ;P"\ '0
MNP!Y +H ?P"X (4 MP", +8 E "T )T L@"J +  N "N ,X K #I *P _0"K
M /\ JP#_ *L _P"K /\ _P   /\   #T    Z    -X   #4  L S0 9 ,@
M) #" "X OP Y +T 0@"Z $H MP!2 +4 6 "S %X L0!D +  :0"N &\ K0!T
M *P >@"K (  J0"' *@ CP"G )@ I0"D *, L0"A ,4 H #? )\ ]P"? /\
MG@#_ )X _P"> /\ _P   /4   #H    V0   ,T   #$  8 O@ 3 +< 'P"S
M "D L0 S *\ / "M $4 J@!, *@ 4P"F %D I0!> *, 9 "B &D H0!O )\
M=0"> 'L G0"" )P B@": ), F0"? )< K "5 +T E #6 )( [P"1 /\ D0#_
M )$ _P"1 /\ ^@   .P   #9    R@   +\   "W    L  , *L &0"H "0
MI0 M *, -P"A #\ GP!' )T 3@"; %0 F0!9 )@ 7P"6 &0 E0!J )0 < "2
M '8 D0!] (\ A0". (\ C ": (L IP") +< B #. (< Z "& /H A@#_ (8
M_P"& /\ \0   -\   #,    O0   +,   "L    I@ & *( $P"> !X FP H
M )D ,0"6 #H E !" )( 20"0 $\ CP!5 (T 6P", &  B@!F (D ; "( '(
MA@!Z (4 @@"$ (P @@"7 ($ I "  +, ?@#' 'T X@!\ /4 >P#_ 'H _P!Z
M /\ Z0   -,'  # "0  L@@  *@'  "A @  G0   )D "P"6 !< DP B )
M+ "- #4 BP ] (@ 1 "' $L A0!1 (0 5P"# %P @0!B (  : !_ &\ ?@!W
M 'P ?P![ (D >0"5 '< H0!V +$ = #$ ', W0!Q /  < #\ '  _P!P /\
MX@P  ,H3  "W%0  J18  )\4  "8$0  DPL  )$$ P"/ !  BP < (@ )P"%
M #  @@(Y ($#0 !_!$< ?05- 'P&4P![!ED >0=? '@'9@!W!VT =0AU '0(
M?@!R"(@ < B4 &X(H0!M"+  :PC$ &D(W !H"O  9PK] &8*_P!F"O\ V1@
M ,$<  "P'@  HA\  )@>  "0&P  BQ@  (@3  "'"P< A D5 ($+(0!^#2L
M>PXT 'D0/ !X$4, =A)* '034 !S$U8 <1-= ' 48P!N%&L ;11S &L5? !I
M%8< 9Q63 &84H !D%+  8A3% & 4W@!?%?, 7A7_ %X5_P!=%/\ T2   +HC
M  "I)@  G"8  )$E  "*(P  A"$  ($=  !_&   ?14/ 'D7' !V&"< =!HP
M '$;.0!P&T  ;AQ' &P<30!K'5, :1U: &@>8 !F'F@ 91YP &,>>@!A'H4
M7QZ1 %T>GP!<'J\ 6AW# %@=W !7'?(!5AW_ 54<_P%5'/\!RR8  +4I  "C
M*P  EBP  (PK  "$*@  ?R@  'LE  !X(@  =A\* '(@& !O(2, ;2(M &HC
M-0!H)#T 9R1# &4E2@!D)5  8B57 6 F7@%?)F4!729N 5PF> %:)H(!6":/
M 58EG0%4):T!4B7! 5 DVP)/)/$"3B/_ TXB_P-.(O\#Q2L  + N  "?,
MDC$  (<P  " +P  >BX  '4K  !R*0  ;R<& &PG% !I*2  9BHI &,J,@%A
M*SD!8"M  EXK1P)<+$T"6RQ4 UDL6P-8+&(#5BQK U0L=0-2+( #4"R,!$XL
MF@1,*ZL$2BN^!$@JV01'*? $1RC_!4<H_P5')_\%P2\  *PR  ";-   CC4
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M"3,YTPDS..P),S?\"C,V_PHS-?\*M#L  *$]  "1/@  A3\  'I   !Q0
M:C\  &0^  !>/0  6CX  %4_!0!20!, 4$$= $U")@%*02T#1T$T!45 .@A"
M0$$*0#]'"ST_3PP[/U<,.3]@##@_:PPV/W<,-#^%"S,_DPHQ/Z0),#ZX"2X^
MT0@M/>L)+3O["BTZ_PHM.O\*L#X  )Y   ".00  @D(  '=#  !N0P  9T,
M &!"  !90@  5$0  %!% 0!,1@X 2D<: $A'(P!%1RL"0D<Q!#]&. <\1CX)
M.45%"C=%30LU154,,T5?##)%:0LP178*+T6#"2Y%D@@L1:,'*T2W!RE$T 8H
M0NH')T'[""= _PDG/_\*K4$  )I#  "+10  ?T8  '1&  !K1@  8T8  %Q'
M  !31P  3DD  $I*  !&3 H 0TP6 $%-(  _32@!/$TO SE,-04V3#P'-$Q#
M"#)+2PDP2U,)+DM="2U,: @K3'0'*DR"!RA+D08G2Z(%)4JV!"-*SP,B2>D$
M(4?Z!B%%_P@A1?\(J$4  )9'  "(2   >TD  '%)  !G2@  7TH  %A+  !.
M30  24\  $10   _4@4 /%(2 #E3'  W4R0 -5,L 3-3,P,P4SH$+E)!!2Q2
M208J4E(&*5);!B=29P4F4G,$)%*! R-2D ,A4J$"'U&U AY0S@$=3^D"'$WZ
M!!M,_P4;2_\&HTD  ))*  "$3   >$P  &U-  !D30  7$X  %1/  !+4@
M15,  #Y6   X6   ,UD, #%9%P O62  +5DH "M:+P$I63<")UD^ B591P,C
M64\#(EI9 B!:9 (?67$!'5E_ 1M9C@ :6)\ &%>S !96S  65>< %E3Y 192
M_P(44O\#GDT  (Y.  " 3P  =%   &E1  !@40  6%(  %!3  !(5@  05@
M #E;   R70  *E\& "9@$0 D81H (V$B "%A*P @83( 'F$Z !UA0P ;84P
M&6%6 !=A80 686X %&!\ !%@BP /7YT #5ZP  M=R  +7.0 #5KW  U9_P -
M6/\!F5$  (E2  !\4P  <%0  &55  !=50  558  $Q8  !#6P  /%X  #1@
M   L8P  )&4  !QH"0 9:!, %V@< !5H)  4:2P $VDU !%I/0 .:4< #&A1
M  IH70 (:&D !F=W  1GAP "9I<  6:K  !DP@  8]T  6'P  )@_  #7_\
MDU8  (17  !W6   :U@  &)9  !:60  45L  $A=   ^80  -F0  "YF   F
M:0  '6P  !5N   +<0H "'$5  9Q'0 $<28  W N  )P-P  <$$  '!+  !P
M5P  <&,  &]R  !O@0  ;I(  &ZE  !MO   :]H  &GM  !H^   9_\ C5L
M ']<  !R7   9UT  %]=  !67@  3&$  $-D   X9P  ,&H  "=M   ><
M%G(   UU   $> 8  '@/  !X%P  >1\  'DG  !Y+P  >3D  'E$  !Y4
M>5T  'EK  !X>P  =XT  '>@  !VM@  =-,  '/M  !R^0  <?X AV   'IA
M  !N80  9&$  %MB  !190  1V@  #QK   R;P  *'(  "!U   7>   #GH
M  5]    ?P(  ( *  " $@  @1D  ((@  "")P  @S   (,[  "#2   @U4
M (-D  "#=   @H<  (&:  " L   ?\P  '[H  !\^   ?/\ @68  '5F  !K
M9@  868  %9I  !+;0  0'   #5T   K>   (7L  !=^   -@   !8,   "&
M    B    (D"  "*"0  BA$  (L8  ",'P  C2<  (XP  "./@  CDP  (];
M  "/;   CG\  (V4  ",J@  B\,  (GC  "(]   B/X ?&P  ')K  !H:P
M7&X  %!R  !$=@  .7H  "U^   B@@  &(4   V(   #BP   (X   "0
MD@   )0   "5    E@8  )8-  "7%0  F1T  )LE  "<,0  G#\  )Q/  "=
M8   G70  )R)  ";H   FK@  )G4  "7[0  E?H >7$  '!Q  !C=   5G@
M $I\   ]@0  ,84  "6*   :C@  #I$   24    E@   )D   ";    G0
M )\   "@    H0   *("  "C"0  I1(  *<:  "I)0  JC(  *I#  "K50
MK&D  *M_  "KE0  JJT  *G'  "HX0  J/$ =W<  &IZ  !=?@  48(  $2(
M   VC@  *I(  !Z6   2F@  !IT   "@    H@   *4   "G    J0   *L
M  "L    K0   *X   "P    L@0  +0-  "W&   N20  +HS  "\1P  O5P
M +UR  "]B   O9\  +RW  "\T   N^4 <H   &6$  !8B0  2X\  #Z5   P
MFP  ))\  !>D   *IP   *H   "M    L    +(   "T    M@   +<   "Y
M    NP   +T   "_    P0   ,0   #)!@  S!,  - @  #4,0  V$<  -Q=
M  #:=P  UY   ->F  #6N@  ULT ;8L  &&0  !4E@  1YP  #BB   KJ
M'JT  !*R   %M0   +@   "[    O@   ,$   #"    PP   ,4   #&
MR0   ,P   #/    T@   -8   #<    X@   .8.  #J'P  [S(  /))  #U
M8@  ]GD  /:.  #UH   ]*\ _P   /\   #_    _P   /\ "P#_ !H _P H
M /\ - #_ #\ _P!) /H 4P#T %L [P!C .P :0#K &\ Z0!U .@ >@#G (
MY@"% .0 BP#C )$ X@"8 .  H0#> *L W0"Y -H SP#7 .@ U #] -( _P#2
M /\ SP#_ ,D _P#% /\ _P   /\   #_    _P   /\ "0#^ !8 ^0 D /<
M+P#V #H [P!$ .D 3@#F %8 XP!= .  9 #> &H W !P -H =0#9 'H V "
M -8 A@#4 (P TP"3 -$ G #/ *8 S0"R ,L Q@#( .  Q@#W ,0 _P## /\
MPP#_ +X _P"\ /\ _P   /\   #_    _0   /< ! #O !, ZP ? .< *@#@
M #4 W@ _ -L 2 #7 %$ TP!8 -$ 7@#. &0 S !J ,H ;P#( '4 Q@!Z ,4
M@ #$ (8 P@". ,$ E@"_ *  O0"K +L O "Y -4 MP#O +4 _P"T /\ M #_
M +0 _P"R /\ _P   /\   #\    \    .@   #@  T V0 ; -$ )0#. #
MS  Z ,H 0P#& $L PP!2 ,  60"^ %\ O !D +H :@"Y &\ MP!T +4 >P"T
M ($ LP"( +$ D "P )H K@"E *T M "K ,D J0#F *@ ^P"G /\ IP#_ *<
M_P"G /\ _P   /L   #N    X0   -8   #.  @ Q  5 ,  (0"] "H NP T
M +D /0"V $4 LP!, +$ 4P"O %D K0!> *P 9 "J &D J0!O *< =0"E 'L
MI "" *( B@"A )0 GP"> )T K "< +\ FP#; )H \P"9 /\ F #_ )@ _P"8
M /\ _@   /    #>    T    ,4   "\  , M0 0 +$ &P"N "4 K  N *H
M. "H $  I@!' *, 30"A %, GP!9 )T 7@"; &0 F@!I )D ;P"7 '8 E@!]
M )4 A0"3 (X D@"9 )  IP"/ +< C@#0 (T ZP", /X C #_ (P _P", /\
M]@   .(   #0    P0   +<   "N    J0 * *4 %0"B "  GP I )T ,@";
M #H F !" )8 2 "4 $X DP!4 )$ 60"0 %\ CP!D (T :@", '$ BP!X (D
M@0"( (H AP"4 (4 H@"$ +$ @P#& (( XP"! /< @0#_ ($ _P"  /\ [
M -8   ##    M    *H   "D    GP $ )H $ "7 !H E  D )$ +0"/ #4
MC0 ] (L 1 "* $H B !/ (< 50"& %H A !@ (, 9@"" &T @0!T '\ ?0!^
M (8 ? "1 'L G@!Y *T > #  '< VP!V /( =@#_ '8 _P!U /\ X    ,D
M  "X @  J@,  * "  "9    E@   )$ "0". !0 BP > (@ * "& #$ A  X
M (( /P"! $8 ?P!+ 'X 40!\ %< >P!< 'H 8@!X &D =P!Q '8 >0!T (,
M<P". '$ FP!O *D ;@"\ &T U0!L .T :P#Z &H _P!J /\ U@@  , ,  "M
M$   H1   )<.  "0"P  BP<  (D  0"&  T @P 8 ($ (@!^ "P ?  T 'H
M.P!X $( =P!( '4 30!T %, <@!9 '$ 7P!P &8 ;@!N &T =P!K 8$ :0&,
M &@ F0!F *@ 9 "Z &, T@!A >D 80+W & "_P!@ O\ SA$  +@5  "F&
MFAD  ) 8  "(%P  @Q0  ( .  !_!P4 ?0(2 'H#'0!W!2< = 8O '('-P!Q
M"#X ;PE$ &X*2@!L"E  :PM7 &D,70!H#&4 9@QM &0,=@!C#($ 80R, %\,
MF0!=#*D 6PR[ %D,TP!8#>H 5PWY %<-_P!7#/\ QAD  +$<  "@'P  DR
M (D@  ""'P  ?1P  'D9  !W%   =@X* ',.%P!P$2( ;1(K &L3,P!I%#H
M9Q5! &851P!D%DX 8Q94 &$76P!@%V( 7A=K %P7= !:%W\ 61>+ %<7F !5
M%Z@ 4Q>Z %$6TP!0%^P 3Q;\ $\6_P!/%O\ P!\  *LC  ";)   CB4  (0F
M  !\)0  =R,  ',@  !P'0  ;AD% &P8$P!I&AX 9ALG &0<, !B'3< 8!X^
M %X>1 !='DL 6Q]1 %H?6 !8'V  5R!H %4@<@!3('T 42") $\?E@!-'Z8
M2Q^Y $D>T0!('NH!2!W[ 4<=_P%''/\!NB0  *8H  "7*0  BBH  ( K  !X
M*P  <BD  &TF  !J)   :"$  &4A#@!B(AH 7R,D %TD+ !;)30 624[ %@E
M00%6)4@!5"9. 5,F50%1)ET!4"9F 4XF;P%,)GH!2B:' 4@FE )&):0"1"6W
M D(DSP)!).D"0"/[ T B_P- (O\#MB@  *(L  "3+0  AB\  'PO  !T+P
M;2X  &DL  !E*@  8B@  %\H"@!<*1< 62HA %<K*0!5*S$!4RLW E$K/@)/
M*T0#3BQ+ TPL4@-*+%H#2"QC T<L;0-%+'@$0RR%!$$KDP0^*Z,$/"JU!#HJ
MS00Y*>@$.2CZ!#DG_P0Y)_\$LBP  )\P  "0,0  @S,  'DS  !P,@  :C(
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M!B8V_P<F-?\'IC<  )4Y  "&.P  >CP  &\]  !F/0  7ST  %D]  !2/
M33X  $D_  !%0 @ 0D$4 $!!'0 ]024!.T$L CA!,P0V03D%,T% !S%!2 <P
M05 '+D%:!RQ!90<K07$&*4%^!2=!C00F0)T$)$"P R(_R (A/N,#(#SV!2 [
M_P8@.O\'HSL  )$]  "#/P  =S\  &Q   !C0   7$$  %5!  !-00  1T,
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M7P 75&L %51Y !-4B  14YD #E*L  Q1P@ +4-T #4_T  U._P .3?\!ED8
M (5(  !X20  ;$H  &%+  !92P  44L  $M,  !"3P  .E(  #14   M5@
M)5D  !];"@ <6Q0 &EL< !A;)  77"P %5PT !1</0 27$8 $%Q0  U;6P +
M6V< "5MU  =:A  %6I0  UFG  )8O0 "5M@  U7M  14^P %4_\ D$L  (%,
M  !S30  9TX  %Y.  !63P  3T\  $=1   ^5   -E<  "]9   G7   'UX
M !=A P 08PP #6,6  MC'@ )8R8 "&,N  9C-P %8T   V-+  %B5@  8F(
M &)P  !A?P  88\  &"B  !?MP  7M0  %SJ  !;]P  6OX BT\  'Q1  !O
M4@  8U(  %I2  !34P  2U0  $)7   Y6@  ,%T  "A?   @8@  &&4  !!G
M   ':@<  6L0  !K&   :R   &LH  !K,0  :SH  &I%  !J4   :EP  &IJ
M  !I>@  :8H  &B=  !GL@  9LX  &7J  !C]@  8OT A50  '96  !J5@
M8%8  %A6  !/5P  1EH  #Q=   S8   *F0  "%F   9:0  $6P   AO
M<00  '(+  !R$P  <QH  ',A  !T*0  =#(  '0]  !T20  <U8  '-D  !S
M=   <H4  '&8  !QK0  <,@  &[F  !M]P  ;/\ ?UH  '%;  !F6P  75L
M %5;  !*7@  0&$  #9E   L:   (FP  !EO   0<@  "'0   !W    >0
M 'H&  !Z#0  >Q0  'P;  !](@  ?BH  '\T  !^00  ?DX  'Y<  !^;0
M?7\  'R2  ![J   >\$  'GA  !X]   =_X >5\  &U@  !C8   6F   $]B
M  !$9@  .6H  "]N   D<@  &G4  !%X   '>P   'T   "     @@   (,
M  "$!@  A0T  (84  "'&@  B"(  (HJ  "*-P  BD4  (I4  "*9   BG<
M (F+  "(H@  A[H  (;9  "$\0  @_P =&4  &EE  !A90  56@  $EK   ]
M<   ,G0  "=X   <?   $7\   >"    A0   (<   "*    C    (X   "/
M    D 0  )$*  "2$0  E!@  )4@  "7*P  ESH  )=*  "86P  F6T  )>#
M  "7FP  E;,  )/1  "2Z@  D?< <&L  &AJ  !;;0  3W$  $)V   V>P
M*H   !Z$   3AP  !XH   "-    D0   )0   "6    F    )H   ";
MG    )T   "?!0  H0P  *,5  "E'0  IRH  *<[  "H30  J6   *EV  "H
MC@  IJ8  *7!  "DW   I.T ;W   &)S  !5=P  27P  #N"   NAP  (8P
M !61   )E    )<   ":    G0   *    "B    I    *8   "G    J0
M *H   "K    K0   *\(  "R$@  M1X  +@M  "X0   N50  +IK  "Y@@
MN9H  +BQ  "WRP  M^$ :GD  %U^  !0@P  0XD  #2/   HE   &YH   Z>
M   !H0   *0   "G    J@   *P   "N    L0   +,   "U    MP   +D
M  "Y    O    +\   ## @  R T  ,P;  #.+   T$,  -%<  #1=   T8L
M -*B  #1M@  T<H 980  %B*  !+D   /98  #"=   BH@  %:<   BK
MKP   +(   "V    N    +H   "\    O@   ,    #"    Q    ,<   #*
M    S    -    #4    W    .$*  #F&@  ZBT  .Y$  #R70  \'<  .^/
M  #MI   [K, _P   /\   #_    _P   /\ " #_ !@ _P D /\ , #\ #L
M^@!% /< 3@#T %< \0!> .\ 9 #M &L ZP!P .D =@#G 'L Y@"! .0 AP#C
M (X X0"6 .  GP#> *D W "W -H RP#8 .< U #] -( _P#/ /\ R@#_ ,0
M_P#  /\ _P   /\   #_    _P   /\ !@#[ !0 ]P @ /$ *P#O #8 [@!
M .L 20#G %$ Y !9 .$ 7P#? &4 W !K -L < #9 '8 U@![ -0 @0#2 (@
MT0"0 ,\ F0#- *, RP"P ,D P0#' -L Q0#W ,, _P#  /\ OP#_ +D _P"V
M /\ _P   /\   #_    ^P   /(  @#M !  XP ; .$ )@#? #$ W0 [ -H
M1 #6 $P T@!3 -  60#- %\ RP!E ,D :@#' '  Q0!U ,, >P#  (( O@"*
M +P DP"Z )T N "I +8 N "U ,X M #N +, _P"R /\ L #_ *\ _P"L /\
M_P   /\   #U    [    .,   #6  H T0 7 ,T (0#+ "L R0 U ,@ /@#$
M $8 P0!- +T 4P"Y %D MP!? +0 9 "R &H L0!O *\ =0"N 'P K "$ *L
MC0"I )8 J "B *8 L "D ,0 HP#C *( ^@"A /\ H0#_ *$ _P"@ /\ _P
M /8   #G    V@   ,\   #$  4 OP 2 +L '0"Y "8 MP O +0 . "P $
MK0!( *H 3@"I %0 IP!9 *4 7@"D &0 HP!I *$ ;P"@ '8 G@!^ )T A@"<
M )  F@"< )D J0"7 +H E@#8 )4 \@"4 /\ DP#_ ), _P"3 /\ ^0   .8
M  #6    R    +P   "U    KP , *P %P"I "$ I0 J *, ,P"B #L GP!"
M )T 20"; $X F@!4 )@ 60"7 %X E0!D )0 :@"2 '  D !X (\ @ ". (H
MC "6 (L HP"* +, B #+ (@ Z0"' /T AP#_ (< _P"' /\ [P   -H   #'
M    N    *\   "H    HP ' )X $@": !P F  E )8 +@"5 #8 DP ] )
M1 ". $H C0!/ (L 5 "* %D B0!? (< 90"& &L A0!S (, >P"" (4 @0"0
M (  G0!^ *T ?0#! 'P WP!\ /8 >P#_ 'L _P![ /\ X@   ,P   "Z
MK    *,   "=    EP ! )( # "/ !< C0 @ (L *0") #$ AP X (4 /P"$
M $4 @@!* ($ 4 "  %4 ?@!: 'T 8 !\ &< >@!N 'D =P!X ($ =@", '4
MF0!S *@ <@"Z '$ U !P .\ < #_ '  _P!P /\ U@   ,    "N    H@
M )@   "1    C0   (D !@"& !$ A  ; ($ ) !_ "P ?@ S 'P .@!Z $$
M>0!& '< 3 !V %$ = !7 ', 70!R &, < !K &\ <P!M 'T ; "( &H E0!I
M *0 9P"T &8 S0!F .@ 90#Z &4 _P!D /\ S $  +8&  "F"   F0H  (\*
M  "(!P  A ,  ($   !^  H ?  5 'D 'P!W "< =0 O ', -@!Q #P < !"
M &X 2 !M $X :P!3 &H 60!H &  9P!H &8 <0!D 'L 8P"& &$ D@!? *$
M7@"R %P R !< .0 6P#T %H _@!: /\ PPH  *X0  ">$@  D10  (<4  "
M$@  ? X  '@*  !W! 0 =0 . ', &0!P "( ;0 J &L ,@!I 3D : (_ &8#
M10!E TL 8P11 &($5P!@!5X 7P5F %T%;P!<!7D 6@6% %@%D0!6!:  5 6Q
M %,$QP!2!>  407Q %$%_0!1!?\ O!(  *@6  "8&0  BQL  ($;  !Z&@
M=!@  '$4  !O$   ;@D' &P'$P!I"1T 9@HF &0++@!B##4 80T[ %\-0@!>
M#D@ 7 ]. %L050!9$%P 5Q!E %80;@!4$7D 4A&% % 1D@!.$*$ 3!"S $H/
MR@!)#^, 20_U $@._P!(#O\ MA@  *(<  "3'@  AB$  'PA  !T(   ;A\
M &H<  !H&0  9A4  &42#0!B$QD 7Q4B %T5*@!;%C$ 61<X %@7/P!6&$4
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M C(B_P(R(?\#J"8  )8I  "'*P  >RP  '$M  !H+@  82T  %PL  !8*@
M52@  %$H 0!/*0T 3"H8 $HJ(0!(*R@ 1BLO 40K-0)"*SP"0"M# S\L2@,]
M+%(#.RQ; SDL90,W+' #-"Q] S(KBP,Q*YL#+RJM RTJPP(K*=\"*RCT RPG
M_P0L)O\$I"D  ),L  "$+@  >#   &XP  !E,0  7C$  %@P  !4+P  4"T
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M8 ,D/&L#(CQY B$\AP(?.Y@!'3NJ 1LZP  :.=L &CCR ADW_P,9-O\$FC0
M (DV  ![.   ;SD  &0Z  !;.@  5#L  $T[  !'.P  /ST  #L_   W0
M,T$) #!!%  O0AP +4(D "M"*P$I0C(!)T(Y B5"00(C0DH"(D)3 B!"7@(>
M0FH!'$)W 1I"A@ 8098 %D&I !5 OP 3/]H %#[Q !0\_P$4._\"EC<  (4Z
M  !X/   :ST  &$]  !8/@  43X  $H_  !$0   .T(  #9$   Q10  +4<%
M "E(#P G2!@ )4@@ "-))P A22\ ($DV !Y)/@$<24< &TE1 !E)7  726@
M%4EU !-(A  11Y0 #D>G  Q&O  +1=8 #$3O  U"_0 -0?\!DCL  ($^  !T
M/P  :$   %U!  !500  34(  $="  ! 1   .$8  #-(   M2@  )DP  "%.
M"@ >3Q0 '$\< !I/(P 83RL %T\R !5/.P 43T0 $D]. !!/60 -3V4 "D]R
M  A.@0 &3I$ !4VC  -,MP "2]$  TKI  5)^0 %2/\ C4   'U"  !P0P
M9$0  %I%  !110  2D4  $1&   ]2   -$L  "Y-   H3P  (5$  !E4!  3
M5@T $586  Y6'@ -5B8 "U8N  I6-@ (5C\ !E9)  165  "56   %5M  !5
M?   5(P  %.>  !2LP  4<X  %#F  !/]0  3_T B$0  'E&  !K1P  8$@
M %9(  !.2   2$D  $%*   X30  ,%   "E2   B5   &E<  !-:   *70@
M!%T1  )=&0  72$  %TI  !=,0  73H  %U$  !=3P  75L  %QI  !<>
M6X@  %N:  !:K@  6<D  %CF  !6]   5?P @DD  '-+  !F3   7$P  %-,
M  !,3   1$T  #Q0   S4P  *U8  "-8   ;6P  %%X   M@   #8P4  &0-
M  !E%   91L  &4C  !E*P  930  &4^  !E20  954  &5C  !D<@  8X,
M &.5  !BJ@  8<0  &#B  !?]0  7OT ?$X  &Y0  !B4   6%   %%0  !)
M40  /U,  #96   M6@  )%T  !M@   38P  "V4   -H    :@(  &L)  !L
M$   ;!8  &T=  !N)   ;RT  &\W  !N0@  ;D\  &Y=  !N;0  ;7X  &R0
M  !KI0  :[X  &K>  !I\P  9_X =E0  &E5  !>50  5E0  $Y5  !$5P
M.5L  #!>   F8@  '&4  !-H   *:P   VX   !P    <P   '0#  !U"0
M=A   '<6  !X'0  >24  'HN  !Z.@  >4<  'E6  !Y90  >'<  '>+  !V
MH   =;@  '76  !S\0  <_P <%D  &1:  !<60  4UD  $E<   ]7P  ,F,
M "AH   >:P  %&\   ER   "=0   '<   !Z    ?    'T   !_ @  @ @
M ($.  ""%0  A!P  (4E  "'+P  ACT  (5-  "%70  A6\  (2#  "#F@
M@K$  ('/  "!ZP  ?_H :U\  &)>  !97@  3F$  $)E   V:0  *VX  !]R
M   5=@  "7H   !]    ?P   ((   "$    A@   (@   ")    BP   (P&
M  "-#   CQ0  )$;  "3)   E#(  )-#  "35   E&8  )-[  "2D@  D:L
M (_'  ".Y0  CO4 :&0  &!D  !49P  2&L  #MP   N=0  (GH  !9^   *
M@@   (4   "(    BP   (T   "0    D@   )0   "6    EP   )@   ":
M @  G D  )X1  "A&0  HR0  *0U  "C20  I%L  *5O  "DAP  HZ$  *&\
M  "?W0  G?  9VH  %IM  !.<0  078  #1\   F@0  &H8   R*   !C@
M )$   "5    F    )L   ">    H    *(   "C    I0   *<   "H
MJ@   *P#  "O#   LQ8  +8E  "V.   MDP  +AA  "W>@  MI,  +2L  "S
MQ@  L]\ 8G,  %5W  !(?0  .H,  "V)   ?C@  $I0   29    G    )\
M  "B    I0   *@   "J    K    *X   "P    L@   +,   "T    MP
M +D   "]    P@D  ,88  #**0  RCX  ,Q5  #-;@  S88  ,V=  #-LP
MS,@ 77X  %"#  !"B@  -)$  ":7   9G0  "Z(   "F    J0   *P   "O
M    L@   +4   "X    N@   +P   "_    P0   ,0   #&    R    ,P
M  #0    V    -T%  #A%0  Y2@  .E   #J7   Z'<  .F-  #JH@  ZK(
M_P   /\   #_    _P   /\ " #_ !0 _P @ /\ + #^ #< _ !! /D 2@#V
M %( ] !9 /( 8 #P &8 [@!K .P <0#J '8 Z !\ .8 @P#C (H X "2 -T
MG #; *< V "V -4 R@#4 .< TP#\ -, _P#/ /\ Q0#_ +\ _P"[ /\ _P
M /\   #_    _P   /\  P#U !$ \P ; /( )P#P #( \  \ .P 10#I $T
MY0!4 .$ 6@#< &  V0!F -4 :P#2 '$ T !V ,X ?0#, (0 R@", ,@ E0#&
M *$ Q "N ,( P0#  -P O@#U +P _P"\ /\ N #_ +0 _P"Q /\ _P   /\
M  #_    ]P   .X   #F  P XP 8 .  (@#> "P W0 V -< /P#/ $< S !.
M ,D 5 #& %H Q !@ ,( 90#  &L OP!P +T =P"[ 'T N0"% +< C@"U )D
MM "G +( MP"P -  K@#M *T _P"L /\ J@#_ *8 _P"D /\ _P   /P   #R
M    Z    -D   #3  < S@ 3 ,L '@#& "< P0 Q ,  .@"] $( N@!) +<
M3P"U %4 LP!: +$ 7P"O &4 K0!J *L < "J '< J !_ *8 B "D )( HP"?
M *( KP"@ ,0 GP#B )X ^P"= /\ G0#_ )L _P"9 /\ _P   .X   #@
MT@   ,<   "_  ( N@ - +0 &0"Q ", KP K *X - "L #P J0!# *8 2@"D
M $\ H@!5 *$ 6@"? %\ G@!D )P :@"; '$ F0!Y )< @0"6 (L E "7 )0
MIP"2 +D D0#5 (\ \P"/ /\ C@#_ (X _P". /\ \0   .    #.    OP
M +8   "O    J  ( *0 % "A !T GP F )T +P"< #< F@ ^ )@ 1 "6 $H
ME !/ ), 5 "1 %H D !? (X 90"- &L BP!S (D >P"( (4 A@"0 (8 H "%
M +$ A #) (, Z0"" /X @@#_ (( _P"" /\ YP   -    "]    L    *@
M  "A    F@ # )< #@"4 !@ D0 A )  *@". #$ C0 Y (L /P") $4 B !+
M (8 4 "% %4 @P!: (( 8 "  &8 ?P!N 'T =@!\ (  >P"+ 'H F0!Y *D
M> "^ '< W0!V /8 =@#_ '8 _P!V /\ V0   ,,   "Q    I    )L   "4
M    CP   (L "0"( !, A@ < (0 )0"# "P @@ T (  .@!^ $  ?0!& 'L
M2P!Z %  > !6 '< 6P!U &( = !I '( <0!P 'L < "' &\ E !M *, ; "V
M &L T0!J .T :@#_ &H _P!J /\ S    +8   "F    F@   )    ")
MA@   (( ! !_  T ?  7 'H ( !Y "@ =P O '8 -0!T #P <@!! '$ 1P!O
M $P ;@!1 &T 5P!K %X :0!E &< ;0!F '< 90"# &0 D !B )\ 80"P &
MQP!? .0 7P#Y %\ _P!? /\ P@   *T   ">!   D 8  (<%  "  P  ?
M 'H   !V  @ =  2 '( &P!O ", ;@ J &P ,0!J #< :0 ] &< 0P!F $@
M9 !. &, 5 !A %H 8 !B %X :@!= '0 6P"  %H C !8 )L 5P"K %4 P !5
M -T 50#T %4 _P!4 /\ N00  *8)  "6#   B0\  '\/  !X#0  = H  ' %
M  !O  , ;  , &H %0!H !X 9@ F &0 +0!B #, 8  Y %\ /P!> $4 7 !+
M %L 40!9 %@ 6 !? %8 : !5 '( 4P!^ %$ B@!/ )D 30"I $P O0!, -D
M2P#N $H ^@!* /\ L0L  )\1  "/%   @Q8  'D6  !R%@  ;!0  &D0  !F
M"P  9@8& &0"$ !A AD 7P,A %T$*0!;!2\ 608V %@&/ !6!T( 50A( %,(
M3P!2"%8 4 E> $X)9P!-"7$ 2PE] $D)B@!'"9D 10BI $0'O0!"!M8 00?K
M $$'^0!!!_\ K!(  )H6  "*&@  ?AL  '0<  !L'   9AH  &(8  !?%0
M7A$  %T+" !;"Q0 6 T= %8.)0!4#RP 4Q S %$1.0!/$3\ 3A)& $P230!+
M$E0 21-< $<39@!%$W$ 0Q-] $$3B@ _$YD /1*K #L1P  Y$-H .1#O #D0
M_  Y$/\ IQ<  )4:  "&'@  >B   ' A  !G(0  82   %P>  !9&P  5QD
M %86 P!4%0\ 4189 $\7(0!-%RD 3!@O $H9-@!(&3P 1QE# $4:2@!$&E(
M0AI: $ :9  ^&F\ .QI[ #D:B0 W&I@ -1FI #,9O@ Q&-D ,1CP #(7_@ R
M%O\ HQL  )$>  "#(@  =R0  &PE  !D)0  720  %@C  !4(0  4AX  % <
M  !-' L 2QT6 $D>'@!''B8 11\L $,?,P!"(#D 0"!  #\@2  ](4\ .R%8
M #DA8@ W(6T -"%Y #(AAP P()8 +B"H "P?O0 J'M@ *A[O 2L=_@$K'/\!
MGQ\  (TB  !_)0  <R<  &DH  !@*   62@  %0G  !0)@  32,  $HB  !'
M(P< 12,2 $,D&P!!)2, /R4J #TE,  [)C8!.28] 3@F10$V)DT!-"96 3(F
M8 $P)FL!+B9X 2PFA@$J)I4!)R6G 24DO $D)-8!)"/N 20B_0$E(?\"G"(
M (HF  !\*   <"H  &4K  !=+   5BL  % K  !,*@  2"@  $4H  !!*0,
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M !DW@@ 7-I$ %3:C !,UN  1--( $C/L !,R_ $3,?\!D2T  ($P  !S,@
M9S,  %PT  !3-0  3#4  $8U  ! -@  .C<  #,Y   O.@  +#L# "@\#0 F
M/!8 )#T> ",])0 A/2P 'STS !X].P </40 &CU. !@]6  6/60 %#UQ !(]
M@  0/)  ##NA  H[M0 ).LX "CGH  LX^0 ,-_\ C3$  'TT  !O-0  8S<
M %DW  !0.   23@  $,Y   ].0  -CL  # ]   K/@  )D   "%""0 >0A(
M'$,: !M#(0 90RD %T,P !9$.  41$$ $D-+ !!#5@ -0V$ "T-N  E#?0 '
M0HP !$&>  ) L0 !/\L  C[D  0]]0 %//\ B34  'DX  !L.0  8#H  %4[
M  !-.P  1CP  $ \   Z/0  ,S\  "U!   G0P  (44  !I'!  620T $TH6
M !%*'0 /2B4 #4HL  M*-  )2CT "$I'  9)4@ $25T  4EJ  !)>0  2(D
M $>:  !&K@  1<<  $3B  !#\@  0_L A#H  '4\  !G/0  7#X  %(^  !*
M/P  0S\  #T_   W00  +T,  "A&   B2   '$H  !5-   -3P@ "% 1  50
M&0 #42$  E H  !0,   4#D  %!"  !030  4%D  %!F  !/=0  3X4  $Z7
M  !-JP  3,,  $OA  !*\@  2?L ?SX  '!   !C00  6$(  $]"  !'0@
M04(  #I#   R1@  *T@  "-+   <30  %E    Y2   &508  %<-  !7%0
M6!P  %@C  !8*P  5S,  %<]  !72   5U0  %=A  !7<   5H$  %:3  !5
MJ   4\   %+>  !1\P  4?T >D,  &M%  !>1@  5$8  $Q&  !%10  /D8
M #5)   M3   )4\  !U1   65   #E8   =9    7 0  %T*  !>$0  7A<
M %\>  !@)0  8"X  & W  !@0@  7T\  %]<  !?:P  7GP  %Z/  !=I
M7+L  %K;  !:\@  6?X =$@  &9*  !:2@  44H  $I)  !"2@  .4T  #!0
M   G4P  'E8  !99   .6P  !EX   !A    8P   &0&  !E#   9A(  &<9
M  !H(   :2<  &DQ  !I/   :4D  &E7  !H9@  :'< _^)]$$E#0U]04D]&
M24Q%  \5 &>*  !FGP  9;8  &35  !C\   8OT ;4X  &%.  !73@  3TX
M $=.   ]40  ,U0  "I7   @6P  %EX   QB   %9    &<   !J    ;
M &T   !O!@  < L  '$2  !R&   ="   '4H  !U,P  =4   '1/  !T7@
M<W   '*$  !QF0  <+$  &_/  !OZP  ;OL :%,  %U3  !44P  35(  $)5
M   V60  +%T  "%A   790  #&D   -L    ;P   '$   !T    =@   '<
M  !Y    >@0  'P*  !]$0  ?Q@  ( @  ""*@  @C<  (%&  "!5P  @&@
M (!]  !^D@  ?*H  'O&  ![Y@  >_< 8UD  %I8  !36   1UH  #M?   O
M8P  )&@  !AL   ,<    G0   !W    >@   'T   !_    @0   (,   "%
M    A@   (@!  "*!P  BPT  (X6  "0'P  DBH  )$Z  "03   D%\  (]S
M  ".B@  C*(  (N^  "*W@  B?, 8%X  %E=  !-8   0&4  #-J   G;P
M&G0   YX   "?0   (    "#    A@   (D   "+    C0   (\   "1
MDP   )0   "6    F 0  )H+  "=%0  H!X  *(M  "@00  H%0  *!I  "@
M?P  GID  )VT  ";TP  FNT 8&,  %-F  !&:P  .7   "QV   ??   $H$
M  6%    B0   (P   "/    D@   )4   "8    FP   )T   "?    H0
M *,   "D    I@   *D   "L!P  L!   +0>  "T,0  LT<  +1;  "V<0
MM(L  +.E  "QP0  K]T 6FP  $UQ  ! =P  ,GT  "2#   7B0  "(X   "2
M    E@   )H   ">    H0   *0   "F    J    *L   "M    KP   +$
M  "R    M    +<   "[    OP0  ,40  #*(0  R38  ,M-  #-9   S'X
M ,J7  #(L   Q\8 57<  $=]   ZA   *XL  !V1   .EP   9T   "A
MI0   *@   "K    K@   +    "S    M0   +<   "Z    O    +X   #!
M    P@   ,8   #*    SP   -<#  #<%   WR8  .$_  #C60  Y7(  .6)
M  #FGP  YK$ _P   /\   #_    _P   /\ ! #_ !$ _P < /\ * #_ #,
M_P ] /D 1@#R $T \ !4 .T 6P#K &$ Z0!F .< ; #E '( XP!X .$ ?@#?
M (4 W0". -H F #7 *0 U "S -, S #0 .L S@#_ ,L _P#$ /\ N@#_ +4
M_P"S /\ _P   /\   #_    _P   /H   #W  T ]  9 /, (P#O "T Z@ X
M .< 00#C $D WP!0 -P 5@#: %P UP!A -0 9@#1 &P SP!R ,P > #* '\
MQP"' ,4 D0#" )P OP"K +X OP"] .  NP#Z +H _P"W /\ KP#_ *L _P"H
M /\ _P   /\   #]    \@   .H   #E  @ X@ 4 -H 'P#6 "@ U0 R -,
M/ #. $0 R0!+ ,8 40## %8 P !< +X 80"] &8 NP!L +@ <@"W 'D M0"!
M +( B@"P )4 K@"B *P LP"M -$ JP#Q *D _P"H /\ HP#_ *  _P"> /\
M_P   /H   #N    WP   -8   #/  , Q@ / ,( &@#  "0 O0 M +L -@"X
M #X M0!% +, 2P"P %$ KP!6 *T 6P"K &$ J@!F *@ ; "F ', I ![ *(
M@P"@ (X G@": )P J@"= ,( G #E )H _P"9 /\ EP#_ )0 _P"2 /\ ]P
M .D   #:    RP   ,$   "X    L@ * *\ %0"K !\ J@ H *D , "G #@
MI0!  *( 1@"@ $P G@!1 )T 5@"; %L F@!A )@ 9P"6 &T E !U )( ?0"1
M (< CP"3 (T H0"- +8 C #6 (L ]@"+ /\ B@#_ (D _P"' /\ ZP   -@
M  #$    N    *\   "F    H@ % )X $ "; !D F@ B )@ *P"7 #, E0 Z
M ), 0 "1 $8 D !+ (X 4 "- %8 BP!; (H 80"( &< AP!O (4 =P"# ($
M@0", '\ F@!_ *T ?P#' 'X ZP!] /\ ?0#_ 'T _P!\ /\ W    ,8   "U
M    J0   *    "9    DP   )  "@"- !0 BP = (H )0") "T B  T (8
M.@"$ $$ @P!& ($ 2P"  %  ?@!6 'T 7 ![ &( >@!J '@ <@!V 'P = "'
M '( DP!S *8 <@"\ '$ W0!P /D < #_ '  _P!P /\ T    +D   "I
MG    ),   "-    B    (0 !0"!  \ ?P 8 'X ( !] "@ ?  O 'H -@!X
M #L =P!! '4 1@!T $L <@!1 '$ 5P!P %T ;@!D &P ;0!J '< : "" &<
MC@!F )\ 90"S &4 T !D .\ 8P#_ &, _P!D /\ P@   *X   "?    D0
M (@   ""    ?@   'H  0!W  H =0 3 ', &P!R ", <  J &\ , !M #8
M;  \ &H 00!I $< : !, &8 4@!E %@ 8P!@ &$ :0!@ '( 7@!] %P B@!<
M )H 6@"L %D Q !8 .0 6 #Y %@ _P!9 /\ MP   *4   "4    B $  '\
M  !Y    =    '$   !N  4 ;  . &H %P!H !X 9@ E &4 + !D #( 8@ W
M &  /0!? $( 70!( %P 3@!; %4 60!< %< 90!6 &X 5 !Y %, AP!2 )4
M4 "G $\ O !. -D 3@#S $X _P!. /\ KP   )T#  "-"   @0D  '@)  !P
M"   :P4  &@!  !F  $ 9  ) &( $@!@ !H 7@ A %P * !; "X 60 T %@
M.0!6 #\ 50!% %0 2P!2 %$ 40!9 $\ 8@!- &P 3 !W $H A !) ), 1P"C
M $8 M@!% -( 10#L $4 _ !% /\ J08  )8+  "'#@  >Q$  '$2  !I$0
M9 X  & +  !>"   70,$ %L # !9 !4 5P = %4 ) !3 "H 4@ P %  -@!/
M #P 3@%" $P!2 !+ D\ 20)7 $<"8 !% FH 1 )V $("@P!  I$ /@&A #T
MM  \ ,P / #G #L ]@ [ /\ HPL  ) 2  ""%   =A8  &P7  !D%P  7A8
M %H4  !7$0  50T  %0)!@!3!@\ 4088 $X'( !-""< 2P@M $H),P!("CD
M1PH_ $4+1@!#"TX 0@M6 $ +7P ^"VH / MV #D+@P W"Y( -0NB #0)M0 S
M",P ,0CD #$)]  Q"/T GQ   (P6  !^&0  <AL  &@<  !?'   61H  %09
M  !1&   3Q4  $X2  !-#PD 2P\3 $@0' !&$2, 11(J $,2, !!$S8 0!,]
M #X41  \%$P .A14 #@47@ V%&D -!1U #(4@P O%)( +1.C "L2MP I$M
M*1+I "D1]P J$?\ FA0  (@:  !['0  ;A\  &0@  !;(   51\  % >  !,
M'0  21L  $@8  !&%P4 1!<0 $(7& ! &"  /ADG #P9+0 Z&C0 .!HZ #<:
M0@ U&TH ,QM2 #$;7  O&V< +1MT "L;@0 H&Y  )AJB "09M0 B&<\ (ACI
M "(8^@ C%_\ EA@  (4=  !W(   :R(  & C  !8(P  42,  $PB  !((0
M1"   $,=  ! '0$ /1X+ #L>%0 Y'QT -Q\D #4?*@ S(#$ ,B X # @/P O
M(4@ +2%0 "LA6@ I(64 )B%R "0A@  B((\ (""A !X?M  <'LT '![H !P=
M^0 <'?\ DQL  ((@  !T(P  :"4  %TF  !4)@  3B8  $@F  !$)0  0"0
M #TC   Y(P  -R0( #0D$@ R)1H ,24A "\E*  M)BX *R8U "HF/0$H)D4!
M)B9. 20F6 $B)F0 ("9P !XF?P <)HX &26? !<DLP 6),P %B/G !8B^0 7
M(O\ CQ\  '\C  !Q)@  92@  %HI  !1*0  2RD  $4I  ! *0  .RD  #<H
M   T*0  ,2H$ "XJ#@ L*Q< *BL> "DK)0 G+"P )2PS ",L.P$A+$,!("Q,
M !XL5P <+&( &BQO !<L?0 5*XT $RN> !$JL@ .*<L #BCF ! H^  1)_\
MBR,  'PF  !N*0  8BL  %<L  !.+   1RP  $(L   \+0  -RT  #(M   N
M+P  *R\! "@P"@ E,10 (S$; "(Q(@ @,BD 'C(P !TR.  ;,D$ &3)* !<R
M50 5,F  $S)M !$R?  -,8L "S"<  DOKP '+\8 ""[@  DM]  *+/\ B"<
M 'DI  !K+   7BX  %0O  !++P  1#   #XP   Y,   -#   "XR   I-
M)#4  "$V!P >-Q  '#<8 !HW'P 9-R8 %S@M !4X-0 4.#X $CA( ! X4@ -
M.%X "C=J  @W>  &-X@ !#:8  $UK   -,,  3/=  (R\  #,OP A"H  '4M
M  !H+P  6S$  %$R  !(,@  03,  #LS   V,P  ,30  "HV   E-P  (#D
M !L[ P 7/0L %#T4 !(^&P 0/B, #CXJ  P^,@ */CH "#Y$  8]3@ $/5H
M CUF   ]=0  /80  #R6   [J0  .L   #G=   X[P  -_D @"\  '$Q  !D
M,P  6#0  $TU  !%-@  /C8  #DV   S-@  +C<  "<Z   A/   &SX  !9
M   /0P< "D00  =$&  %1!\ !$0F  )$+@ !1#8  $1   !$2@  0U8  $-C
M  !#<0  0X$  $*3  !!I@  0+T  #_;   ^\0  /?H ?#,  &TU  !?-P
M5#@  $HY  !".0  /#D  #8Y   P.@  *CP  "(^   <00  %T,  !%%   )
M2 8  DH,  !*%   2QL  $LB  !+*@  2S(  $L[  !*1@  2E(  $I?  !*
M;0  2GX  $F0  !(I   1KL  $79  !$\0  1/P =S@  &@Z  !;.P  4#P
M $<\  ! /   .CP  #,]   L/P  )4$  !U$   71@  $4D   I+   "3@0
M $\*  !0$0  41<  %(>  !3)0  4RT  %(V  !200  4DT  %%;  !1:0
M47H  %&,  !1H0  3[D  $W6  !,\   2_T <3T  &,_  !60   3$   $1
M   ^/P  -T   "]"   G10  'T@  !=+   130  "4\   -2    50(  %8'
M  !7#0  6!,  %H9  !;(   6R@  %LQ  !;/   6D@  %I6  !:90  678
M %F(  !9G0  5[8  %75  !4[P  4_T :T(  %Y#  !21   240  $-#   [
M0P  ,D8  "I)   A3   &$\  !!2   )50   E<   !:    7    %X#  !?
M"   8 T  &(4  !C&@  9"(  &4K  !D-0  9$$  &1/  !C7P  8W   &*#
M  !BF   8;   %_0  !>[0  7?P 94@  %E(  !/2   2$<  $!'   V2@
M+4T  "-1   :5   $%@   A:    70   &    !C    90   &<   !H P
M:@@  &L-  !M%   ;AL  ' C  !P+@  <#H  &](  !O6   ;FH  &U]  !L
MDP  :ZL  &K(  !IZ0  :/L 7TT  %5-  !-3   1DP  #M/   P4P  )E8
M !M:   17@  !F(   !E    :    &L   !N    <    '(   !T    =0
M '<&  !Y"P  >A,  'P;  !^)   ?C   'X^  !]3P  ?&$  'QU  ![BP
M>*,  '>_  !VX@  =?< 6U,  %-2  !,40  0%0  #18   I70  '6$  !%F
M   %:@   &X   !Q    =    '<   !Z    ?    'X   !_    @0   (,
M  "% P  APD  (D2  "+&P  CB8  (TT  "-10  BU@  (MM  "*@P  AYP
M (:V  "$V   @_$ 65<  %)6  !&6@  .5X  "QC   ?:0  $VX   9S
M=P   'L   !^    @0   (0   "&    B0   (L   "-    CP   )$   "3
M    E0   )@&  ";#@  GAD  *$E  "@.   GDP  )UA  "=>   FY   )FK
M  "7R@  END 6%T  $Q@   _90  ,6H  "1P   6=@  "'L   "     A0
M (@   "+    C@   )$   "3    E@   )@   ":    G    )\   "@
MHP   *8   "I!   K T  +$8  "S*@  L$   *]6  "P;0  L(4  *V@  "L
MO   J]T 4F8  $9K   X<0  *G@  !Q^   -A    (D   "-    D0   )4
M  "8    FP   )\   "B    I0   *@   "J    K0   *\   "Q    LP
M +8   "Z    OP   ,<&  #,&   S"T  ,I%  #-7   SW0  ,N.  #)IP
MQ\  37$  #]X   Q?@  (X4  !6,   %D0   )8   ";    H    *0   "H
M    JP   *T   "P    L@   +4   "W    N@   +P   "_    P0   ,4
M  #)    SP   -@   #>"P  Y!X  .(W  #D3P  YVD  .2#  #BFP  XK
M_P   /\   #_    _P   /\  @#_  T _P 9 /X ) #] "\ _0 Y /D 0P#U
M $L \0!2 .T 6 #J %X Z !C .8 : #D &X X@!S -\ >@#= (( V@"* -<
ME #4 *  T0"O ,X Q@#+ .D S #_ ,8 _P"Z /\ M #_ *\ _P"K /\ _P
M /\   #_    _P   /L   #X  D [P 5 .T ( #L "H Z@ T .4 /@#A $8
MW0!- -H 4P#7 %D U !> -( 8P#0 &D S0!N ,L =0#( 'L Q0"$ ,( C0#
M )D O0"G +H N@"X -H MP#[ +@ _P"N /\ J #_ *, _P"A /\ _P   /X
M  #Y    \    .D   #@  0 V@ 1 -8 ' #2 "8 T0 O -  . #+ $  QP!(
M ,0 3@#! %0 OP!9 +P 7P"Z &0 N0!I +< < "U '8 L@!^ +  AP"M )(
MJP"@ *@ L "F ,H I #M *< _P"B /\ G0#_ )D _P"6 /\ _    /4   #F
M    W    -(   #&    P0 + +T %@"[ "  N0 J +@ ,P"V #L LP!" +
M2 "N $X K !3 *H 6 "H %T IP!C *4 :0"C '  H0!X )\ @0"= (L F@"8
M )@ IP"6 +T E #> )8 _P"5 /\ D0#_ (X _P"+ /\ \P   .4   #1
MQ0   +@   "Q    K  & *D $0"G !L I0 D *4 +0"D #0 H0 [ )\ 0@"=
M $@ FP!- )D 4P"7 %@ E@!= )0 8P"2 &H D0!R (\ >P"- (4 B@"2 (@
MH "& +( A0#- (< ^ "' /\ A0#_ (( _P"  /\ Y    ,T   "^    L@
M *<   "@    FP ! )@ "P"6 !4 E  > ), )P"2 "\ D0 V (\ / "- $$
MBP!' (H 3 "( %$ AP!7 (8 70"$ &, @@!K ($ = !_ 'X ?0"+ 'L F !Y
M *D =P#  '@ ZP!X /\ > #_ '8 _P!U /\ U    +X   "N    H    )@
M  "1    C0   (D !@"' !  A0 9 (0 (0"$ "D @P P ($ -@!_ #L ?@!
M 'P 10![ $L >0!1 '< 5@!V %T = !D '( ;0!Q '< ;P"$ &T D0!L *(
M:@"V &L W0!J /L :@#_ &H _P!J /\ Q0   +$   "@    E    (L   "%
M    @0   'T  @![  L >0 4 '@ ' !W ", =0 J ', , !Q #8 <  [ &\
M0 !M $4 ; !+ &L 40!I %@ 9P!? &8 : !D '( 8@!^ &  BP!? )L 7@"N
M %X S0!> /  70#_ %T _P!= /\ N0   *8   "5    B0   ($   ![
M=@   '(   !P  < ;0 / &L %P!J !X :0 E &@ *P!F #$ 90 W &, / !B
M $$ 80!& %\ 30!> %, 7 !: %L 8P!9 &T 5P!Y %8 A@!4 )4 5 "I %,
MP0!2 .4 4@#] %$ _P!1 /\ KP   )L   ",    @0   '@   !Q    ;
M &D   !F  ( 8P * &$ $P!@ !H 7P A %X )P!< "T 6P R %D -P!8 #T
M5P!" %4 2 !4 $\ 4@!6 %$ 7P!/ &D 30!U $P @@!* )  2@"C $D N0!(
M -D 2 #T $< _P!( /\ IP   )0   "% P  >04  ' %  !H!   8P(  %\
M  !=    6P & %D #0!7 !4 5@ < %4 (P!3 "D 4@ N %$ - !/ #D 3@ ^
M $T 10!+ $P 2@!3 $@ 7 !& &8 1 !Q $( ?@!" (T 00"> $  L@ _ ,T
M/@#K #X _@ ^ /\ H    (X&  !_"0  <PL  &D,  !A"P  6PH  %<(  !5
M!0  5 $! %( "0!0 !$ 3P 8 $T 'P!, "4 2@ K $D , !( #8 1@ [ $4
M0@!# $D 0@!0 $  60 ^ &, .P!O #H ?  Y (L . "; #8 K@ U ,4 -0#D
M #4 ]P U /\ F@8  (D+  ![#P  ;A$  &02  !<$@  5A$  %$0  !.#0
M3 H  $P&! !* PL 20$4 $<!&P!% B$ 0P(G $(#+0!  S, /P0Y #T$0  \
M!4< .@5/ #@%6  V!6( - 5N #(%>P Q!8H +P29 "T$JP L L( + #? "P
M\@ L /T E0P  (01  !V%   :A8  %\6  !7%@  418  $P5  !(%   1A(
M $4.  !$"P8 0PD. $$)%P _"AX /0HD #L+*@ Z"S$ . PW #8,/@ U#48
M,PU. #$-6  N#6, + UO "H-?0 H#8L )0V; "0,K0 C"L, (0K= " *[P @
M"OH D1   ($5  !S&   9AH  %P:  !3&@  31H  $<:  !#&0  0!<  #\5
M   ^$@$ /!$) #H1$P X$AH -A,A #03*  S%"X ,10U "\4/  N%40 +!5-
M "H55P G%6$ )15N ",5?  @%8L 'A2< !P3KP :$\8 &1+A !H2\@ :$OT
MC10  'T8  !O&P  8AT  %@=  !0'@  21X  $0=   _'0  .QP  #D:   W
M&   -1@% #,8#@ Q&1< +QD> "X:)0 L&BL *AHR "@;.@ G&T( )1M+ ",;
M50 A&V  'AML !P;>@ :&XD %QJ: !49K@ 3&<4 $QC@ !,8]0 4%_\ BA<
M 'H;  !L'@  7R   %4A  !-(0  1B$  $ A   [(0  -R   #0?   R'@
M+QX" "T>"P K'Q0 *1\; "<@(@ E("@ )" P "(A-P @(4  'B%) !PA4P :
M(5X &"%K !4A>0 3((@ $2"9  X?K  ,'L( "Q[=  P=\@ -'/\ AQH  '<>
M  !I(0  7",  %(D  !))   0B0  #PD   W)   ,R,  # C   L(P  *20
M "8D"  D)1$ (B48 " F'P ?)B8 '28M !LF-0 :)CT &"9' !8F40 4)EP
M$29I  XF=P +)H8 "266  @DJ0 &([\ !2/9  8B[@ '(?P A!T  '0A  !F
M)   624  $\F  !&)P  /R<  #DG   T)P  ,"<  "PG   G*   (RD  " J
M!  =*PT &RL5 !HL'  8+", %BPJ !4L,@ 3+3L $2Q$  XL3P ,+%H "2QF
M  <L<P $+(,  BN3   JI@  *;L  "C8   G[  !)_@ @"   '$E  !B)P
M5B@  $PI  !#*@  /"H  #8J   Q*@  +2H  "DJ   B+0  'BX  !HO 0 7
M, D %#$2 !(R&0 0,B  #C(G  PR+P *,S< "#)   8R2P $,E8  C%B   Q
M<   ,8   #"1   OHP  +KD  "W6   M[   +/@ ?20  &TH  !?*@  4RP
M $DL  ! +0  .2T  #0M   O+0  *RT  "8N   ?,   &S(  !8T   1-@8
M"S@.  DX%@ '.!T !3@D  ,X*P ".#,  #@]   X1P  -U(  #=?   W;0
M-WT  #>.   UH@  -+<  #/4   R[0  ,OD >"@  &DK  !;+@  3R\  $4P
M   ],   -S   #$P   M+P  *#   "(R   <-   %S8  !(X   +.P4 !#T,
M   ^$P  /AH  #XA   ^*   /C   #\Y   ^0P  /D\  #U<   ]:@  /7H
M #V,   \H   .K8  #G3   X[0  ./L ="T  &4O  !7,@  3#,  $(S   Z
M,P  -#,  # R   J,P  )#4  !TW   7.0  $CP   L^   %0 0  $(*  !#
M$   1!8  $4=  !&)   1BL  $8T  !&/@  14L  $18  !$9@  1'<  $2)
M  !#G0  0K0  $#2   _[@  /OP ;S(  & T  !3-0  2#8  #\V   X-@
M,S4  "TV   F.   'SH  !@]   2/P  "T(   5$    1P(  $@'  !*#
M2Q,  $P9  !.'P  3B<  $XP  !..@  348  $Q3  !,8P  2W,  $N%  !+
MF@  2[(  $C1  !&[@  1?T :3<  %LY  !..@  1#H  #TZ   W.0  ,#D
M "@[   @/@  &$$  !)#   +1@  !4D   !+    3@   $\$  !1"0  4@X
M %04  !6&P  5R(  %<K  !7-0  5D   %5.  !57@  5&\  %2!  !3E@
M4Z\  %'/  !0[@  3?X 8SP  %4]  !*/@  0CX  #L]   T/0  +#\  "-"
M   :10  $D@   M+   $3@   %$   !3    5@   %<   !9!0  6PD  %T/
M  !?%0  8!P  &$E  !A+P  8#H  &!(  !?6   7FH  %Y]  !=D@  7*H
M %S*  !9[0  6/X 74(  %%"  !'0@  0$$  #E!   O0P  )D<  !Q*   3
M3@  "E$   -4    5P   %H   !<    7P   &$   !B    9 0  &8)  !H
M$   :A8  &P>  !M*   ;#0  &M!  !J40  :F0  &EW  !HC   9Z4  &;"
M  !FYP  8_P 5T<  $U'  !&1@  /T4  #1(   I3   'U   !14   )6
M 5L   !>    80   &4   !G    :@   &P   !M    ;P   '$"  !S!P
M=0T  '<6  !Z'P  >BL  'DX  !X2   =UL  '9O  !UA0  =)X  '*Z  !Q
MWP  </@ 4TP  $Q+  !%2@  .4T  "U2   B5@  %EL   I?    9    &<
M  !K    ;@   '$   !T    =@   '@   !Z    ?    'X   "     @P4
M (4,  "(%@  BB   (HN  "*/@  B5   (AE  "&>P  A90  (*O  "!T0
M?^\ 4E$  $M0   ^4P  ,E@  "5>   88@  "V@   !L    <0   '4   !Y
M    ?    '\   "!    A    (8   "(    BP   (T   "/    D0   )0"
M  "7"@  FA4  )XB  "=,@  FT4  )E;  "8<@  EXH  )6E  "2P@  D>0
M458  $59   W7@  *F0  !QJ   .<    '8   ![    @    (,   "'
MB@   (T   "0    D@   )4   "7    F@   )P   "?    H0   *0   "H
M    K <  + 4  "T(@  LC<  *].  "N90  K7X  *R7  "IL@  I]( 2V
M #YE   P:P  (G(  !-Y   $?@   (4   "*    C@   )$   "5    F
M )L   "=    H    *,   "E    J    *H   "M    KP   +(   "V
MNP   ,$'  #(%   RBD  ,9"  #%6@  QG(  ,>*  #"I0  P,$ 16L  #=R
M   I>0  &H    J'    C0   )(   "7    F@   )X   "B    I@   *L
M  "N    L    +,   "V    N0   +P   "_    P@   ,8   #+    T0
M -@   #C 0  Z14  .<N  #G1P  Z6   .IY  #GD@  Y:@ _P   /\   #_
M    _P   /\  0#_  D _P 6 /\ (0#] "P _  V /D 0 #U $@ \@!/ .\
M5@#L %P Z@!B .@ 9P#E &T XP!S .$ >0#> (  VP"( -@ D@#4 )\ T "O
M ,P Q@#( .@ Q0#_ +T _P"T /\ K #_ *< _P"D /\ _P   /\   #[
M^@   /H   #R  4 [@ 2 .L '0#J "@ Z0 Q .8 .P#B $, W@!+ -L 40#8
M %< U0!< -( 80#0 &< S0!L ,L <P#( 'H Q@"" ,, C #  )@ O "G +@
MN@"U -L LP#Z +  _P"G /\ H0#_ )T _P": /\ _0   /<   #S    [P
M .$   #<    U  , -( & #0 "( SP L ,\ -0#* #T Q@!$ ,, 2P#  %$
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L !] *X A@"L )( J0"@ *4 LP"C
M ,T H0#P )\ _P"; /\ E@#_ )( _P"/ /\ ]0   .T   #D    U0   ,@
M  #     O  ' +D $P"W !T M@ F +4 +P"S #< L  ^ *T 1 "K $H J0!/
M *@ 50"F %H I !@ *, 9@"A &T GP!T )T ?@"; (D F "7 )8 J "3 ,
MD #D (X _P", /\ B@#_ (< _P"% /\ Z@   -P   #,    NP   +(   "K
M    IP ! *0 # "B !< H0 @ *$ * "A #  G@ W )P /0"9 $, EP!( )4
M3 "3 %( D0!8 (\ 7@"- &4 C !M (H =@"( ($ A@". (4 G0"# +, @@#3
M (  ]@!_ /\ ?0#_ 'L _P!Z /\ VP   ,<   "W    J0   *    ":
ME@   )( !P"0 !$ CP : (\ (@"- "H BP Q (D -P"' #T A@!" (0 1@"#
M $L @@!0 (  5@!_ %X ?0!F 'L ;P!Z 'H > "& '8 E0!T *D <@## '$
MZ@!Q /\ <0#_ &\ _P!N /\ R@   +<   "E    F0   )$   "+    AP
M (,  P"!  L ?P 4 'X ' !] "0 ?0 K 'L ,0!Y #< >  \ '8 00!U $8
M<P!+ '( 4 !P %< ;@!? &T :0!K ', :0!_ &< C0!E *  9 "V &, V@!C
M /T 9 #_ &, _P!C /\ O    *<   "8    C0   (0   !_    >@   '8
M  !S  < <0 / '  %P!O !X ;@ E &T + !K #$ :0 W &@ / !G $$ 9@!&
M &0 3 !C %( 8@!9 &  9 !> &X 7 !Y %H AP!8 )D 5P"M %8 RP!7 /,
M5P#_ %@ _P!7 /\ L    )P   "-    @@   'H   !S    ;@   &H   !G
M  ( 90 * &0 $P!B !H 8@ @ &$ )P!? "P 7@ R %T -P!; #P 6@!! %D
M1P!8 $T 5@!4 %4 7@!3 &D 40!T $\ @0!- )( 3 "E $L OP!, .@ 3 #_
M $T _P!, /\ I@   ),   "%    >0   '    !I    8P   &    !=
M6P & %D #@!8 !4 5P < %< (@!5 "@ 5  M %, ,P!2 #@ 40 ] $\ 0P!.
M $D 30!0 $L 6@!) &0 1P!P $4 ?0!# (T 00"? $( N !" -L 0@#X $(
M_P!" /\ G0   (L   !]    <@   &@   !@    6@   %<   !4    4@ #
M %$ "@!/ !$ 3@ 8 $X '@!- "0 2P I $H +P!) #0 1P Y $8 /P!% $4
M0P!- $$ 5@ _ &  /0!L #L >0 Y (D -P": #D L  Y ,X . #N #@ _P X
M /\ E@   (4!  !W!   :P<  &$'  !9!P  4P8  $\$  !, @  2P   $D
M!@!(  T 1P 4 $8 &@!% "  0P E $$ *P!  #  /P V #T /  \ $( .@!*
M #@ 4P V %T - !I #( =@ Q (8 ,0"7 #  J@ O ,, +P#C "\ ^0 O /\
MD0$  ($&  !R"0  9@L  %P,  !4#0  30P  $D+  !%"0  0P8  $(# @!!
M  D 0  0 #X %@ ] !P .P B #H )P X "T -P S #4 .0 T $  ,@!( #
M40 N %L +0!G "L =0 J (, * "3 "< I@ F +P )0#9 "8 \P F /\ C08
M 'P+  !N#@  81   %<1  !/$@  21(  $,1  ! #P  /0T  #L+   Z" 0
M.@4+ #@$$@ V!!D - 0? #,%)  Q!2H , 8P "X&-P M!CX *P=' "D'4  G
M!UL )0=F ",'=  A!X( 'P>2 !T&I  <!+D ' +4 !P [@ = /L B H  'D/
M  !J$P  7A0  %,5  !+%@  1!8  #\5   Z%   -Q,  #42   T#P  ,PP&
M #(+#0 P"Q4 +@P; "T,(@ K#2@ *0TO "@.-@ F#CX ) Y' "(.40 ?#EP
M'0]H !L/=@ 8#H4 %@Z5 !0-I@ 3#+H $PO3 !(*Z0 2"O8 A0X  '43  !G
M%@  6A<  % 8  !(&0  01D  #L9   V&   ,Q<  # 6   N%0  +1,! "L3
M"  J$Q$ *!08 "84'P D%24 (A4L "$5-  ?%3P '15% !L63P 9%EH %A9F
M !06=  1%80 #A64  P4I@ *$[H "1/4  D2ZP *$?D @A(  '(6  !C&0
M5QH  $T;  !$'   /1T  #<<   S'   +QL  "P:   I&@  )QD  "49!0 C
M&0T (1H5 !\:'  =&R( '!LJ !H;,0 8&SH %AM# !0;30 2&U@ #QME  P;
M<@ )&X  !QN0  4:H@ $&;<  AC1  ,7Z  $%_8 ?Q4  &\9  !@'   5!T
M $H>  !!'P  .A\  #0?   P'P  +!X  "@>   E'@  (1X  !\> @ ='PH
M&B 2 !@@&0 7("  %2$G !,A+P 1(3< $"%!  TA2P *(54 ""%A  4A;@ #
M(7T  2".   ?H   'K4  !W/   <Z   '/4 >Q@  &L<  !='P  42   $<A
M   ^(@  -R(  #$B   M(0  *2$  "4A   A(0  '2(  !DD   6) < $R8.
M !$F%@ /)AT #2<D  LG*P ))S0 !R<]  8F1P $)E(  29>   F;   )GL
M ":,   DG@  ([,  "+-   AZ0  (/8 >!P  &@?  !:(0  3B,  $0D   [
M)0  -"4  "\D   J)   )B0  "(D   ?)   &B8  !4H   1*@4 #"L,  DL
M%  '+!H !2PA  ,L*  !+#   "TY   L0P  +$X  "M;   K:0  *W@  "N*
M   KG0  *+(  "?,   FZ   )?@ =!\  &0C  !6)0  2R8  $$G   X*
M,2<  "PG   H)@  )"8  " F   ;*   %BH  !(L   ,+@0 !C$*  (Q$0
M,A<  #(>   R)0  ,BT  #,U   S/P  ,DL  #%8   Q9@  ,78  #"'   P
MFP  +K$  "W,   KZ@  *_D <",  & F  !2*   1RH  #TJ   U*@  +RH
M "HI   F*0  (BD  !TJ   7+   $B\   PQ   ',P0  34)   V#@  -Q4
M #@;   Y(@  .2D  #DR   Y.P  .4<  #A4   W8P  -W,  #>%   VF0
M-K   #3-   RZ@  ,?L :R<  %PJ  !.+   0RT  #HN   S+0  +2P  "DK
M   D+   'BT  !@O   3,@  ##0   <V   !.0(  #L'   \#   /A(  #\7
M  ! '@  0"4  $ N  !!.   04,  #]1   ^8   /7   #V#   ]EP  /:\
M #O-   Y[   ./P 9BL  %<O  !*,   0#$  #<Q   Q,   +"\  "8O   ?
M,0  &3,  !,U   ,.   !SH   $]    /P$  $$%  !#"0  1 X  $84  !(
M&@  22$  $DJ  !),P  23X  $A,  !'6P  16T  $5_  !%E   1*P  $3,
M  !![0  /_X 8#$  %(S  !&-   /30  #4T   P,@  *C(  "(T   :-P
M%#D   P\   &/P   $(   !$    1P   $D"  !*!@  3 H  $X0  !0%@
M4AP  %,E  !3+@  4SD  %)&  !15@  3V@  $Y[  !.D   3:D  $W(  !,
M[0  2?\ 6C8  $TX  !".   .C@  #0V   N-@  )3@  !P[   4/@  #$$
M  5$    1P   $H   !-    3P   %(   !4 0  5@4  %@*  !:$   718
M %\>  !>*   7C,  %U   !;4   6F(  %EW  !8C   5Z0  %?#  !6Z@
M5?\ 5#P  $D\   _/   .3L  #(Z   H/0  'D   !5$   ,1P  !4L   !.
M    40   %0   !6    60   %L   !=    7P   &(%  !D"@  9Q$  &D8
M  !K(@  :BT  &DZ  !H20  9EL  &5P  !DA@  8YX  &*[  !AY   8?T
M3T$  $5!   ^0   .#\  "U"   B10  %TH   Q.   $40   %4   !8
M6P   %X   !A    9    &8   !H    :P   &T   !O P  <@D  '41  !W
M&@  >"4  '<R  !U00  =%0  '-I  !Q@   <)@  &^S  !MVP  ;?@ 2T8
M $1%   ^1   ,D<  "9+   :4   #E4   ):    70   &$   !D    9P
M &L   !N    <0   ',   !U    =P   'D   !\    ?@   (('  "$$
MAQL  (<H  "&-P  A$D  (->  ""=@  @(X  'ZI  !\S   >^\ 2DH  $1)
M   W30  *U(  !Y7   27   !&$   !F    :@   &\   !R    =@   'D
M  !\    ?P   ($   "$    A@   (@   "*    C0   )    "3!@  EQ$
M )L=  ":*P  F3X  )A2  "6:@  E((  )*=  "1NP  C>  2D\  #U3   P
M6   (U\  !5D   &:@   '    !V    >@   '\   ""    A0   (D   ",
M    C@   )$   "4    E@   )@   ";    G@   *$   "E    J00  *T0
M  "R'@  L#$  *Y&  "L7@  JG<  *B0  "GJP  H\H 1%D  #9?   I90
M&FP   IS    >@   (    "%    B@   (X   "2    E0   )@   ";
MG@   *$   "D    I@   *D   "L    KP   +(   "W    O    ,,!  #+
M#0  T"   ,LX  #&4@  Q&H  ,.#  ##G   O;< /64  "]L   A<P  $7L
M  &"    B0   (\   "4    F    )P   "?    HP   *8   "H    JP
M *X   "Q    M    +<   "[    O@   ,(   #'    S@   -4   #@
MYQ(  .<J  #A1P  XU\  .1W  #ECP  X:D _P   /\   #\    ^@   /L
M  #^  @ _P 3 /\ 'P#^ "H _@ T /P /0#X $4 ]0!- /( 5 #O %H [0!@
M .H 90#H &L Y0!Q ., > #@ '\ W0"( -H DP#6 *  T@"Q ,X S #( /$
MQ #_ +8 _P"K /\ HP#_ *  _P"< /\ _@   /@   #T    \P   /0   #P
M  $ [0 - .L &@#J "0 Z@ N .@ . #C $  WP!' -P 30#9 %, U@!9 -,
M7@#1 &0 S@!J ,P < #) '@ QP"  ,0 B@#  )8 O0"G +H O0"V .( L0#_
M *< _P"> /\ F #_ )8 _P"3 /\ ]@   .\   #K    YP   -T   #6
MT@ ( -  % #. !\ S0 I ,T ,0#) #D Q@!  ,, 1@#  $L O !0 +D 50"W
M %H M !A +( : "O '  K0!X *H @@"H (T I@"< *0 KP"B ,X H0#W )L
M_P"2 /\ C #_ (H _P"( /\ [    .0   #>    S@   ,(   "\    N  "
M +4 #@"T !D M  B +( *@"N #( JP Y *@ 0 "F $4 I0!* *, 3P"B %0
MH !9 )\ 7P"= &8 FP!O )D >@"6 (8 E "3 )( I "/ +T C0#E (L _P"&
M /\ @0#_ 'X _P!] /\ X    -8   #!    M0   *P   "F    H@   *
M" "= !( FP ; )L ) "; "P F  S )8 .0"4 #\ D@!$ )  20". $X C0!3
M (L 60") %\ B !G (8 < "$ 'X @@"+ (  FP!_ +  ?0#2 'L _ !X /\
M= #_ ', _P!R /\ T0   ,    "N    H@   )H   "4    D    (P  P")
M  P B0 5 (@ '@"' "4 A@ L (0 ,P"" #D @0 ^ '\ 0P!^ $@ ?0!- 'L
M4P!Z %D > !@ '< :0!U '0 <P"$ '  DP!N *8 ; #! &L [P!J /\ 9P#_
M &< _P!F /\ PP   *P   "=    DP   (L   "%    @    'P   !Z  <
M>  0 '< & !W !\ =P F '4 +0!S #, <@ X '$ /0!P $( ;P!( &T 30!L
M %0 :@!; &D 8P!G &T 90![ &( C !@ )T 7@"T %P WP!< /\ 6P#_ %P
M_P!; /\ LP   )\   "1    A@   'T   !W    <0   &X   !K  ( :@ *
M &D $P!I !H :0 A &@ * !G "X 90 S &, . !B #T 80!" %\ 2 !> $X
M7 !5 %L 7@!: &< 6 !S %8 A0!4 )8 40"K $\ S@!/ /8 3P#_ %$ _P!1
M /\ I@   )0   "&    >P   '(   !J    90   &$   !?    7@ & %T
M#@!= !8 7  < %P (@!: "@ 6  M %< ,@!6 #@ 5  ] %, 0P!2 $D 4 !0
M $\ 60!- &( 3 !N $H ?P!( (\ 1@"B $0 P !# .H 1@#_ $< _P!' /\
MG    (L   !^    <@   &<   !@    6@   %<   !5    4P # %( "@!2
M !$ 40 7 %  '0!/ ", 3@ H $P +0!+ #, 20 X $@ /@!' $4 10!, $0
M5 !" %X 00!I #\ >@ ] (H .@"= #D M@ X -T / #^ #P _P ] /\ E
M (0   !V    :@   %\   !7    4@   $X   !,    2@   $D !@!(  P
M1P 3 $8 &0!& !\ 1  D $( *0!! "X /P T #X .@ \ $$ .P!( #D 4  X
M %H -@!F #0 =0 R (4 ,0"8 #  KP Q -$ ,@#T #, _P S /\ C@   'X
M  !P    8P(  %D#  !1 P  2P(  $<   !$    0@   $   P _  D /@ /
M #T %0 \ !H .P @ #D )0 X "H -@ O #4 -@ S #T ,@!$ #  30 O %<
M+0!D "L <0 J ($ *0"3 "@ J0 I ,0 *0#I "D _P I /\ B    'D!  !J
M!0  7@<  %0(  !+"   10@  $ '   \!0  .@,  #@!   W  8 -@ + #4
M$0 T !< ,P < #$ (0 O "8 +@ L "T ,@ K #H *@!! "@ 2@ G %0 )0!A
M ", ;P B 'X (0"0 "  HP @ +L 'P#= !\ ]@ ? /\ A $  '0&  !F"
M60L  $\,  !'#0  0 P  #H,   V"P  ,PD  #$(   P!@, , ,( "X!#0 M
M 1, *P$9 "H '@ H "0 )P$I "8 ,  D 3< (P$_ "$ 2  @ 5, '@%? !P
M;0 ; 'P &0", !@ GP 7 +0 %@#1 !4 [0 6 /\ @ 4  ' )  !B#   5@X
M $L1  !#$0  /!$  #81   R$   +@\  "P-   J#   *0H$ "D("0 G!Q
M)086 "0'&P B!R$ (0@G " (+@ >"#8 ' @^ !L(2  9"5( %@A> !0(;  2
M"'L $ B+  X&G0 -!;$ #0/+  T!Z  . /D ?0D  &T-  !>$   4A(  $@4
M   _%0  .!4  #(4   N%   *A,  "<3   E$@  (Q$" "(.!0 A#@L ( T2
M !X.&0 <#A\ &PXF !D.+@ 7#C8 %0\_ !,020 0$%0 #1!@  H0;  )$'L
M!Q"+  8.G0 $#;   PS)  (+XP #"?, >@P  &D1  !;$P  3Q4  $47   \
M&   -1<  "\7   J%P  )A8  ",6   A%0  'Q4  !T4 @ ;% < &10. !<5
M%@ 6%1T %!4D !(5*P 0%C0 #18]  L61@ )%E  !A9<  06:0 "%G@  !:(
M   5FP  $ZX  !+'   1XP  $?, =Q   &84  !8%@  3!@  $(:   Y&@
M,AH  "P:   G&@  (QD  " 9   =&   &Q@  !@9 0 5&00 $QH+ ! ;$P .
M&QH #!LA  H;*  (&R\ !ALX  0<0@ "&TT  1M9   ;9@  &W8  !N&   :
MF0  &:X  !?&   6XP  %?4 <Q,  &,7  !5&0  21L  #X=   V'0  +QT
M "D<   E'   (1P  !X;   ;&P  &!L  !4<   0'@, #!\)  D@$0 &(!<
M!2 >  ,A)  !(2P  "$U   A/@  (4D  "!6   @9   ('0  !^%   ?F
M'JT  !S'   :Y0  &O8 ;Q8  %\:  !1'   1AX  #L?   S'P  +!\  "<?
M   B'@  'QX  !P=   9'0  %1X  !$@   ,(@, !R0(  ,E#@  )14  "8;
M   F(@  )BD  "8R   G.P  )T8  "94   E8@  )7(  "2$   DEP  )*T
M "'(   ?Y0  'O@ :QH  %L=  !.'P  0B$  #@B   P(@  *B$  "0A   A
M(   '1\  !H?   6(   $B(   PD   ()@,  R@(   J#   *Q,  "P8   L
M'P  +"8  "PO   M.   +4,  "U/   K7P  *G   "J"   IE@  *:P  "C)
M   FZ   )/D 9QX  %<A  !*(P  /R4  #4E   M)   )R0  ",C   @(@
M'"(  !<C   2)0  #2<   @I   #*P,  "T'   O"@  ,1   #,6   S'
M,R,  #0K   T-0  -$   #1,   R7   ,6T  #!_   PE   +ZL  "_)   L
MZP  *OP 8B(  %,E  !&)P  .R@  #(H   K)P  )B8  "(E   >)   &"8
M !,G   -*@  ""P   ,O    ,@$  #0$   V"   . P  #H2   [&   .Q\
M #LG   [,0  /#P  #Q(   [5P  .6D  #=]   WD@  -JH  #;)   U[
M,O\ 72<  $XI  !"*P  -RL  "\K   I*0  )2@  " H   :*0  %"L   TN
M   ',0   C,    V    .    #L"   ]!0  /PD  $$.  !#%   1!L  $0C
M  !$+0  1#@  $1$  !$4@  064  #]Y   _C@  /J<  #W&   ][   ._\
M5RP  $HN   ^+P  -"\  "TM   I*P  (RL  !PM   5+P  #C(   <U   !
M.    #L    ]    0    $(   !% @  1P8  $D*  !+$   3A8  $X>  !.
M*   3C,  $X_  !.30  2V   $EU  !'BP  1Z0  $;$  !%ZP  1?\ 43$
M $4R   Z,P  ,C(  "TP   G+P  'C$  !8T   .-P  !SH    ^    00
M $,   !&    20   $L   !.    4 (  %(&  !5"P  5Q(  %H9  !:(@
M6BT  %DZ  !92   6%D  %5O  !2A@  4IX  %&\  !0Y@  4/\ 3#8  $ W
M   X-@  ,C0  "LS   A-@  %SD   \]   '0    $0   !'    2@   $T
M  !0    4P   %8   !8    6@   %T!  !@!0  8@L  &83  !H&P  :"8
M &@R  !G00  95$  &)H  !@@   7I@  %VU  !<WP  6_P 1SL  #T[   W
M.0  ,#@  "4[   :/P  #D,   9'    2P   $\   !3    5@   %D   !<
M    7P   &(   !D    9P   &D   !L    ;P0  '(+  !V%   =Q\  '8K
M  !U.@  <TH  '!@  !N>   ;)(  &NL  !ITP  :/8 0T   #T_   V/0
M*T   !Y%   22@  !4\   !3    6    %P   !?    8@   &4   !I
M;    &X   !Q    <P   '8   !Y    ?    '\#  "#"P  AA8  (<B  "%
M,0  @T(  (%7  !_;P  ?(H  'ND  !YQ@  =^T 0T0  #Q#   P1P  )$L
M !=1   )5P   %P   !@    90   &D   !L    <    ',   !W    >@
M 'P   !_    @@   (0   "'    B@   (X   "1 0  E0H  )@7  "8)0
MEC<  )1+  "28P  D'T  (Z7  ",M0  BMP 0TD  #9-   I4@  &U@   U>
M    9    &H   !O    =    '@   !\    @    (0   "'    B@   (T
M  "0    D@   )4   "8    FP   )\   "C    IP   *P*  "R&   L2D
M *\^  "L50  J6\  *:)  "CI0  H<0 /%,  "]9   A8   $F8   )M
M=    'H   "     A0   (H   "-    D0   )0   "8    FP   )X   "A
M    I    *<   "J    K0   +$   "V    O    ,,   #,"@  U!D  - O
M  #+2   QF(  ,1[  #!E0  OJ\ -5\  "=F   8;@  !W8   !]    A
M (L   "1    E0   )H   "=    H0   *0   "G    JP   *X   "Q
MM0   +@   "\    P0   ,4   #+    T@   -L   #D    [@@  / @  #K
M.P  Y5<  .1P  #DB   XZ  _@   /D   #U    ]    /4   #X  4 _  1
M /\ ' #_ "< _P Q /X .@#[ $( ^ !) /8 3P#S %0 \ !: .T 7P#I &0
MY@!J ., <@#? 'H W "$ -@ CP#4 )P T "L ,T QP#+ /  Q #_ +  _P"C
M /\ FP#_ )4 _P"3 /\ ]P   /$   #L    ZP   .T   #O    [0 ) .L
M%@#K "$ [  J .D - #A #P VP!# -@ 20#4 $X T@!4 -  60#. %X RP!C
M ,D :@#' '  Q !Y ,$ A0"^ )0 N@"D +< N0"S .  L #_ *( _P"8 /\
MD0#_ (P _P") /\ [@   .<   #B    X    -H   #4    SP $ ,X $ #+
M !H QP D ,@ +0#% #4 P0 \ +X 0P"\ $@ N !- +8 4P"S %@ L0!= *\
M8P"L &H J@!R *@ >P"F (8 I "9 *$ K@"? ,T G0#W )4 _P"* /\ A0#_
M (( _P!_ /\ XP   -H   #4    R    +X   "X    M    *X "0"N !0
MK@ > *T )@"J "\ IP V *0 / "B $( H0!' )\ 3 "> %( G !7 )L 70"9
M &0 EP!K )4 =0"3 '\ D0", (\ H@", +X B0#H (8 _P!_ /\ >0#_ '8
M_P!T /\ U0   ,H   "[    L    *@   "B    FP   )D  P"7  T E0 7
M )8 ( "6 "@ E  O )$ -@"0 #P CP!! (X 1P"- $P BP!1 (H 5P"( %X
MAP!E (4 ;@"# 'D @0"% (  E !\ +, >0#7 '8 _@!Q /\ ; #_ &H _P!H
M /\ Q@   +4   "G    G0   )0   "-    B0   (4   "$  @ @P 1 (0
M&@"% ", A  J (( , "  #8 ?@ [ 'T 0 ![ $4 >0!+ '@ 4 !V %< =0!>
M ', 9P!Q '( ;P!^ &X C0!M *$ :@#% &8 \@!C /\ 7P#_ %T _P!= /\
MMP   *4   "7    C    (0   !]    >    '4   !T  , =0 , '0 %0!T
M !P =  C '( *0!P "X ;@ T &P .0!K #X :0!$ &@ 2@!F %$ 9 !8 &(
M80!A &L 7P!W %X A@!= )< 6P"W %D X@!6 /\ 4P#_ %( _P!2 /\ J0
M )@   "*    ?P   '4   !N    :0   &<   !F    90 ' &0 #@!D !8
M9  = &, (P!A "@ 7P M %T ,P!< #@ 6@ ] %D 0P!7 $D 5@!2 %0 6P!2
M &4 40!Q %  ?P!/ )  30"L $L T !) /D 1P#_ $< _P!' /\ G0   (T
M  !_    <P   &D   !A    70   %L   !9    5P " %< "0!6 !$ 5@ 7
M %8 '0!4 "( 4@ H %  + !. #$ 3  W $H / !) $, 2 !* $< 5 !& &
M1 !K $, >@!" (D 0 "D #\ P@ ] .X / #_ #P _P _ /\ E    (0   !V
M    :0   %\   !7    4P   $\   !-    3    $L !0!*  L 20 2 $@
M& !& !T 1  B $, )P!! "P 0  R #X .  ] #X .P!% #H 3@ X %H -P!F
M #< =  V (0 - "< #, MP R .0 ,@#_ #( _P V /\ C    'T   !N
M80   %<   !0    2@   $8   !#    00   $   @ ^  < /  - #P $P \
M !@ .@ > #@ (P W "@ -@ M #0 ,P S #H ,@!! #  2@ O %8 +@!B "P
M<  K (  *@"6 "D K@ I -8 *0#[ "L _P M /\ A@   '8   !H    6P
M %$   !)    0@   #T    Z    -P   #4    T  0 ,P ) #, #@ S !0
M,0 : #  'P N "0 +0 I "P ,  K #8 *0 ^ "@ 1@ G %( )0!> "0 ;  C
M 'X (0"1 "$ J  A ,D (0#R "( _P D /\ @0   '$   !B    5@(  $P#
M  !#!   / 0  #<#   S @  +P(  "T    L  ( +  & "L "P K !$ *@ 6
M "@ &P G "  )@ F "0 +  C #, (@ [ "$ 0P ? $\ '@!; !T :0 ; 'H
M&@", !H HP 9 +\ &0#E !D _P : /\ ?    &P   !>!   408  $<(   ^
M"   -P@  #$(   M"   *0<  "<&   F!   )0($ "0 "  C  P (P 3 "$
M&  @ !T 'P C !X *0 < #  &P X !H 00 9 $T %P!9 !8 9P 4 '< $@")
M !$ G0 1 +0 $0#6 !$ ]0 0 /\ >    &@$  !:"   30H  $,+   Z#
M,PP  "T,   H#   )0L  "(*   @"0  'P@# !X&!@ =!0H ' 0/ !L$%0 :
M!!H & 0@ !<$)@ 6!"X %00V !0#0  2 DL $0)7  X#9  + W0 "0*%  @!
MF  ( *X " #+  @ [  ( /\ =00  &4'  !6"P  2@T  #\/   V$   +Q
M "D0   E$   (0X  !X.   <#0  &@P" !@+!0 7"@< %PD, !4)$@ 4"1@
M$PD> !$))  0"2P #@DU  P)/P *"4H " I6  4+8P ""G,   J#   )E@
M!ZH   7#   #X@   /@ <0<  &$*  !3#0  1Q$  #P2   S$P  +!,  "83
M   B$@  'A(  !L1   8$0  %A " !00!  2#P< $0X)  X.#@ -#Q4 "Q <
M  H0(P ($"H !Q S  40/0 $$$@  A%4   180  $'$  !""   .E0  #:H
M  O"   *WP  "?, ;@H  %T-  !0$0  1!0  #D5   P%0  *14  ",5   ?
M%0  &Q0  !@4   5$P  $Q,# !$2!0 /$@< "Q,(  D4#  '%1, !A49  05
M(  "%B<  18O   6.@  %D4  !91   57P  %6\  !6!   4E   $ZH  !'$
M   /X@  #?8 :@T  %H1  !-%   0!<  #87   M&   )A@  "$7   =%P
M&18  !86   4%0( $A0$  \5!0 +%@4 "!<'  09"@ !&A   !H6   ;'0
M&R0  !LM   ;-@  &T(  !M.   ;7   &FT  !F    9E   &*H  !?%   5
MY0  $_@ 9A$  %<4  !)%P  /1H  #,:   K&@  )!H  !\9   ;&   %Q@
M !47   3%@, $!<#  P8 P (&00 !!L&   ="0  'PT  " 4   @&P  ("(
M "$J   A,P  (3\  "!,   @6@  'VP  !Y_   =DP  ':H  !S&   ;Z
M&?L 8A4  %,8  !&&@  .AP  # =   H'   (AP  !T;   9&@  %QD  !08
M 0 0&0  #!H   @< 0 $'@(  " $   B!P  )0L  "82   F&   )Q\  "<G
M   G,0  )SL  "=)   G5P  )F@  "-]   CD0  (JD  "''   AZP  'OX
M7A@  $\;  !"'@  -A\  "T?   E'P  (!X  !P=   9&P  %AL  !$<   ,
M'0  "!\   ,A    (P   "8#   H!0  *PD  "T.   M%0  +AP  "XD   N
M+@  +C@  "Y&   N5   +60  "IZ   HD0  **@  "?'   G[   )_\ 61P
M $L?   ^(@  ,R(  "HB   C(0  'R   !L>   7'@  $Q\   T@   ((@
M R4    G    *0   "P!   O P  ,0<  #0+   V$@  -AD  #8A   V*@
M-C4  #9"   V4   -F   #)W   PC@  +Z8  "[&   N[0  +O\ 5"$  $8D
M   Y)@  +R4  "@D   B(P  'B$  !HA   4(@  #20   @F   "*0   "P
M   N    ,0   #,    V 0  .04  #L)   ^#P  /Q8  #\>   _)P  /S$
M #\^   _3   /UP  #UP   YB@  -J0  #;#   U[0  -?\ 3R8  $$H   U
M*0  +2D  "8G   B)0  '20  !8F   .*   ""L   (M    ,0   #,    V
M    .0   #P    _    00(  $0&  !'"@  2A$  $H9  !+(0  2BP  $HY
M  !*1P  25<  $AJ  !#A0  0*   $"^   _Z@  /O\ 22L  #PM   R+0
M*RL  "8I   @*   &"H  !$L   (,    3,    W    .@   #T   !
M0P   $8   !)    2P   $X!  !1!0  5 L  %<3  !7'   5B8  %8S  !6
M00  55$  %1D  !/?P  3)H  $JW  !)Y0  2/\ 0S$  #@R   P,   *BX
M "0M   ;+P  $C(   DV   !.@   #X   !!    1    $@   !+    3@
M %$   !3    5@   %D   !< 0  7P8  &(,  !E%@  92   &0L  !D.P
M8TL  &%=  !=>   69,  %:Q  !6VP  5?T /S8  #4U   P,P  *3$  !XT
M   4.   "CP   !!    10   $D   !-    4    %,   !7    6@   %T
M  !?    8@   &4   !G    :P   &X'  !R#P  =!D  '0F  !S-   <T,
M '%5  !M;P  :8D  &:H  !ES   9/4 .SH  #4X   O-P  (SH  !8_   *
M1    $@   !-    4@   %8   !:    7@   &$   !E    :    &L   !N
M    <0   '0   !W    >@   'X   ""!0  AP\  (D<  "'*@  A3L  ().
M  !]9@  >H   '>>  !UO0  =.D .SX  #4\   I0   &T4   Q+    4@
M %8   !;    8    &0   !H    :P   &\   !S    =@   'D   !\
M?P   ((   "%    B0   (P   "1    E@8  )H2  ":(   ES$  )1$  "1
M7   CG8  (N3  "(L   AMD .T(  "]&   A3   $U(   19    7P   &4
M  !J    ;P   ',   !W    >@   'X   ""    A@   (D   ",    CP
M )$   "5    F    )P   "A    I@   *H%  "O%   KB0  *HX  "H3P
MI6D  **%  "?H   G+\ -4T  "A3   960  "6$   !G    ;@   '0   !Z
M    ?P   (0   "(    C    )$   "5    F    )L   "?    H@   *4
M  "H    K    +$   "W    O0   ,4   #-!   UA4  -$H  #,0   QUH
M ,%V  "]D   N:H +ED  "!A   0:    '    !W    ?P   (8   ",
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M_____________________________________________________P
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M=#$      P0A   !                     0                    $
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M<;9BU'&V8M1QMF+4<;9BU'&V8M1QMO^M& '_KR0&_[(N#N_#-Q#>V3L7T.I
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M\(^"H.N'B:OG@9"TY'R8N>-ZG[SB>JB^X7JRO]-TL\'$;++"P&JRP\!JLL/
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MY'R8N>-ZG[SB>JB^X7JRO]-TL\'$;++"P&JRP\!JLL/ :K+#P&JRP\!JLL/
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MX7JRO]-TL\'$;++"P&JRP\!JLL/ :K+#P&JRP\!JLL/ :K+#P&JRP\!JLL/
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M_Z L$O^@-1[_JSXG_[1%-?J^2T;UQU):\,Y8<.O47(7EW6":VMIEJLW3:K?
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M8=*&N&'2AKAATH:X8=*&N/^G%0'_J"$&_ZHK#?>Z,P_GS#L3V.$](LSN0SO
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M94S_9F5,_V9E3/]F94S_9F5,_V9E3/]F94S_9F5,_V9E3/]F9=BX  #,RP0
MP/(, ++_' >D_R 0EO\B&8G_)21]_RDN<O\L.&C_,4!?_S1'6?\X3%3_/%!0
M_S]23?]#5$O_1E5*_TI62?]-5DC_4%='_U171O]95T;_7%=&_UQ71O]<5T;_
M7%=&_UQ71O]<5T;_7%=&_UQ71O]<5T;_7%=&_UQ71O]<5\W" @#!U0( M/\-
M J7_%0>7_Q</B?\:%WW_'2!Q_R$I9O\F,5W_*CA6_RX]4?\R04W_-D1*_SE&
M2/\\1T;_/TA%_T))1/]%24/_1TE"_TM*0?].2D#_44I _U%*0/]12D#_44I
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MM[22A,&JBHK)I8B5S*.)HLR=AZO,DGZKS(Y\K\:.?;3 CGVTP(Y]M,".?;3
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M13#RPTM Z\Y04N/55F?9TEQ\S,ICC<#":9RSNVZII[1SLYNM=[V.IGO'@:"
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MA?\3$7G_%AEN_QHA8_\>*5K_(R]3_R<T3O\L.$K_,#M&_S,]1/\V/T+_.C]
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MES0<_YX])/^D13#ZJDP^]:M53^^K76+IJ69TXJ-NAMF;=9;0DGRCQHB!KKV
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MMKQQA[>[<X:]LW2%P*]TA<"O=(7 KW2%P*]TA<"O=(7 KW2%P*]TA<"O=(7
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MBU'DT8M1Y-&+4>31BU'DT8M1Y-&+4>31B_^1"0+_F1,"_ZH2 -F^!@#2T08
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M$R!,_Q<E1_\=*4+_(BP^_R8N.O\J+SC_+3$V_S$Q-?\U,C/_.#(Q_SPR,/]
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MRH.%4\N4A%/,I8)2S;B!4<[1@%'*XWY2P.5[4L#E>U+ Y7M2P.5[4L#E>U+
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M:/\S,E__-CI7_SI!4/\^1TO_1$M'_TM-1/]33D/_74]"_V=.0?]S34#_?TQ
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M-"S_>3,K_X8R*_^',BO_AS(K_X<R*_^',BO_AS(K_X<R*_^',L&X  "VQ0
MJ=   )O9  "-X   @?4  G;_ 05L_P<+8O\,$%G_$190_Q4<2?\9($/_'20]
M_R(G.?\F*C7_*BLR_R\L,/\T+2W_.2TK_SXM*/]$+2?_2RPE_U(L(_]9*R+_
M82H@_VLI(/]K*2#_:RD@_VLI(/]K*2#_:RD@_VLI(/]K*;C!  "KS   G=4
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M?EB?XWY8G^-^6)_C?EB?XWY8G^-^6)_C?O]P"0?_@PD"_Y,) -^A @#4K0,
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M_U D'?]8(QS_8",:_VHB&?]Q(1G_<2$9_W$A&?]Q(1G_<2$9_W$A&?]Q(;7
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M@&. XW]C@.-_8X#C?V. XW]C@.-_8X#C?_]@#0O_= @%_X0, OV1#0#JFPH
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M:U*H\&M2J/!K4JCP:_]U  /XB0  VI<  -"C  #'K@  OK<  +7   "JR@8
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M(R'_>B(?_X8A'O^5(![_F!\>_Y@?'O^8'Q[_F!\>_Y@?'O^8'[JV  "OP@
MH<H  )/1  "%V   >-\  &SE  !B^0 #6O\ !E+_ PM*_P@/0_\,$SS_$A<V
M_Q8:,?\;'"[_(!TJ_R4>*/\J'R3_+Q\A_S4?'O\\'QS_1!X9_TT=%_]6'!;_
M8!P4_VH;$O]V&A'_>1H1_WD:$?]Y&A'_>1H1_WD:$?]Y&K&_  "DR   E=
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M<'=Q\&QW<?!L=W'P;'=Q\&QW<?!L=W'P;/]7#0S_:08&_W@+ _^$#@'WC0\
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M<5N$['%;A.QQ6X3L<?]E! ;_=P$!\X8  -J1  #2FP  RJ,! ,*J  "YKA4
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M-#SLP#,[[=LR.^SQ,3KI_S$ZZ?\Q.NG_,3KI_S$ZZ?\Q.NG_,<^9  ##IP
MNK(  +"\  "DQ   E\L  (O1  !_V   =^T' 6_T%05G]1X+7_4D$U;T*1I/
M]2\A1_4T)T+U.RP]]4(O.O9*,#CW5# W^%\O-OAL+C7Y>BTT^8DK-/J:*C/Z
MK"@S^[\G,OO8)C+\["4R_.PE,OSL)3+\["4R_.PE,OSL)<:D  "\L   LKH
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M$P?_@1,'_X$3!_^!$P?_@1,'_X$3!_^!$ZZ^  "AQ@  DLT  (/4  !UVP
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M0_\BY4/_(O\W&!3_-QL6_T 9%?]$&Q7_2207_TLN'/](."+_140H_T%1+?U
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M68QH_U6+:/]4BVC_5(MH_U2+:/]4BVC_5/].# S_7@4'_VT) _]X#0'\@!$
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M9&QQ]61L<?5D;''U9/]:!0C_:P #_GD" .2$  #8C   T9(" ,N7 P#"FAP
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M4$FRRTY(L>9-2*_V2TBN_TI(KO]*2*[_2DBN_TI(KO]*2*[_2N1^  #4C0
MR9H  +^D  "WK   K;,  **Y  "6O@  BL4$ (3'' !_QRP'>,8V$7#$/AUG
MPT0H7L%),U? 3CU0OU1$2[Y<2$F^9DE'OW-)1[^ 1T; CT9&P*!%1<"R0T3!
MRT)$P.=!0[[W0$.]_S]#O/\_0[S_/T.\_S]#O/\_0[S_/]R&  #-E0  PZ$
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M'"[W\1LN]O4:+O;U&B[V]1HN]O4:+O;U&L&D  "YKP  K[@  *._  "6Q@
MB,L  'S1  !PUP  9=X  %WQ P%6_ T%4/P5"DG]&P]"_2$4._TG&#;^+1LR
M_C0<+_\['2S_1!XJ_TT=*?]8'"?_9!LE_W,:)/^#&"/_E!<B_Z46(?^W%2'_
MSQ0A_]@4(?_8%"'_V!0A_]@4(?_8%+NM  "QMP  IK\  )C%  "*RP  ?=$
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M.142_T$4$/]'&!#_3" 2_TTI%?]*,QO^1CXA^$)*)_(_5RKN/V0KZS]P*^E
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M$ #2?R0!QWXV"KYZ0QBV=DPFKW%4-*AL6T"B:&)*G65I4)IC<%278GA6E6*
M5Y-BB5B28I)8D&*<68]BIUF-8K19C&+&6HIBW%J*8_!4BF7\4(IE_TR)9?])
MB67_28EE_TF)9?])B67_2?].!PG_70 $_VL# ?AT!0#G>P0 VGX% -:!" #,
M@R$ PH,T";J 016Q>TLDJG=2,J-S63Z<;U](EVIE49-G;%:/9G-:C65[7(MD
MA%V*9(U=B&687H9EHUZ%9;!>@V7!7X)EUU^"9NU:@F?Z58)H_U&!9_].@6?_
M3H%G_TZ!9_].@6?_3O]1!0C_8  #_VX! .YW  #;?@  U8(# -&$!@#(AQ\
MOH<R![6$/Q.M@4DAIGQ1+Y]X5SN8=%U&DG!C4(UL:5>):6]<AFAW7X-G?V&"
M9XEB@&>48GYGGV-]9ZQC>V>]8WEGTF1Z:>I?>VKY6GMJ_U5Z:?]2>FG_4GII
M_U)Z:?]2>FG_4O]3 P?_8P "_'$  .)Z  #8@0  T88" ,R(! ##BQP NHLP
M!;&)/1&IA4@>HH)/+)M^5CF4>5M$C75A3HAQ9E>#;FQ=?VQS8GQK>V5Z:H1F
M>&J/9W9JFV=T:JEG<FJX:'!JSFAQ;.9D<FWW7G)L_%IR:_]6<FO_5G)K_U9R
M:_]6<FO_5O]6 0;_9P !]',  -U]  #4A   S8D! ,>, 0"^CQD MH\M!*Z-
M/ ^FBD8<GH=.*9>#5#:0?UI!B7I?3(-V9%5]<VE>>'!O9'1N=VAQ;H!J;VZ+
M:VUNEVMK;J5K:6ZU:V=NR6MH;^-H:G#U8FIP^EUJ;OQ::F[\6FIN_%IJ;OQ:
M:F[\6O]9  7_:@ !ZG8  -J   #1AP  R8P  ,*0  "ZDA4 LI,K ZJ1.@VB
MCT09FHQ-)I.(4S.,A%@_A8!=27]\8E-X>69=<79L96QS<VIH<GQM97*';F-R
MDVYB<J)N8'.Q;5]SQFU?=.!J877S9&)T^&!B<OI<8G+Z7&)R^EQB<OI<8G+Z
M7/]=  3_;0  X'D  -:#  #-BP  Q9   +V4  "UEA$ K9<H J:6. N>E$,7
MEI%+(X^-4C"(BE<\@89<1GJ#8%%S?V1;:WQI9&1Z;VI@>'AN77B#;UQXD&];
M>9]N67FO;5AYPVM9>MYI6GKR9%MY^&!;>/I=6WCZ75MX^EU;>/I=6WCZ7?]@
M  +W<0  W7T  -*'  #)CP  P90  +F8  "OF@L J)PD :&;-0B:F4$4DI9)
M((N34"V$D%4X?8U:0W:*7DYNAV)89H1G85Z!;6A9@'9L5X"";%: CVM6@9YJ
M58&N:%2!PF=4@MUE58+Q85:!^EU6?_Q;5G_\6U9__%M6?_Q;5G_\6_]D  'J
M=0  V8$  ,Z+  #%DP  O9D  +.=  "IGP4 HJ$? )RA,0:5GST1C9Q''8::
M3BE_EU,U>)18/W"17$IHCV%48(QE7%F*;&-5B75F4XF!9E.*CV52BIYC48JN
M8E&+PF!0B]U>48KQ6U**_5A2B/]64HC_5E*(_U92B/]64HC_5O]I  #A>0
MU(8  ,J0  #!F   N)X  *ZB  "CI0  G*<9 ):G+ 2/I3D-B*-#&8&A2B1Z
MGU P<IQ5.VJ:6D5BF%]/6Y5D5U64:UQ2DW5>4).!7E"4CUQ/E)Y;3Y6N64Z5
MPU=-E=U63I3Q4TZ3_5%.DO]03I+_4$Z2_U!.DO]03I+_4/=O  #<?P  SXL
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M-4"V_C4_M?\U/[7_-3^U_S4_M?\U/[7_-=:&  #(E   OJ   +:I  "MKP
MHK4  )6Y  ")O0  ?<,  ''*! !LS!D 9\PG!6'+,@U:RCD64\D_'TS)1B='
MR$TM0\A5,$')7S! R6PP/\EY+S[*B"T^RI@L/<NJ*CS+P2D[R]\H.\GS*#G'
M_BDYQO\I.<;_*3G&_RDYQO\I.<;_*<V/  #"G0  N:<  +"O  "FM@  F;L
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M#!O_YPP;_^<,&__G#+>L  "NM0  HKP  )7"  "'QP  ><T  &S2  !AV
M5MX  $SC  !%\@ !/_X#!#G_"@<S_Q$*+O\7#2K_' XF_R,0(O\I$![_,!$;
M_SD0&/]"$!7_30\2_UH.#_]I#0S_>0P+_XH+"O^;"@K_J@D)_[D)"?^Y"0G_
MN0D)_[D)"?^Y";&T  "EO   E\(  (G(  ![S@  ;=,  &':  !5WP  2^0
M $'I   Z]@ "-/\ !"[_  8I_P0))?\)"B#_$ P<_Q4,&?\;#17_(0T1_R<-
M#/\O#0C_.0P$_T0+ /]0"@#_7@D _VT) /][" #_B0< _Y0' /^4!P#_E <
M_Y0' /^4!ZB[  ":P@  C,@  'W.  !OU   8=L  %7A  !)Y@  /^H  #7N
M  $O^@ "*?\ !"/_  8?_P '&O\ "1;_ 0D3_P8*#O\+"PO_$0L'_Q<+ O\=
M"@#_) H _RT) /\X"0#_1 @ _U ' /];!P#_9@8 _W & /]P!@#_< 8 _W &
M /]P!O\9)!3_&284_QLE%?\;*!;_%BX7_PXW%_\-11?_#%,5_PMA%/\+;A+_
M"GH1_PJ$$/\+C0[_#)4._PV<#?\.HPS_#JD+_Q"P"_\0N K_$< *_Q++"?\2
MV0C_$^8(_Q/Q!_\3^ ?_$_\&_1/_!OL2_P;[$_\&^Q/_!OL3_P;[$_\&^Q/_
M!O\:)!3_&R,4_QXC%?\>)1;_&BL7_Q8U&/\50QC_$U$7_Q->%?\2;!3_$7@2
M_Q*"$?\3BQ#_%),/_Q2:#O\5H0W_%:<-_Q:N#/\7M0O_%[X+_QC)"O\9U@K_
M&>0)_AGO"/P9]PCZ&?\'^!G_"/<9_PCW&?\(]QG_"/<9_PCW&?\(]QG_"/\;
M(Q3_'R 4_R(?%?\B(17_'R<7_QXS&/\<0!G_&TT8_QI;%_\9:!;_&744_QE_
M$_\:B!+_&Y 1_QN7$/\<G@__':4._QVK#O\>LPW_'[L-_Q_&#/X@TPS[(>(+
M^2#L"O8A]@KS(?X*\B'_"O$A_PKQ(?\*\2'_"O$A_PKQ(?\*\2'_"O\<(A3_
M(QP4_R<;%/\H'17_)R06_R@P&?\E/!K_(TH:_R)7&?\A9!C_(7$6_R%\%?\B
MA13_(XT3_B24$OTDFQ'\):(1^R:I$/HFL!#Y)[@/^"C##_<HT [T*=X.\2GJ
M#>XI]0WL*?X-ZRG_#>HI_PWH*O\-Z"K_#>@J_PWH*O\-Z"K_#?\A'A3_*!@3
M_RT6$O\O&!/_,2$5_S$L&/\O.1O_+$4<_RI3'/\J8!O]*6P9^RIX&/DK@1?W
M+(H6]2R1%?0MF!7S+9\4\BZF%/$OK1/P+[43[S# $NXQS1+K,=L2Z#'I$>4Q
M]1+C,OX2X3'_$M\R_Q'=,O\1W3+_$=TR_Q'=,O\1W3+_$?\E&1/_+Q41_S44
M$/\Y%A#_/!X2_SPI%O\Y-!K_-4$=_3).'O@R6Q[T,F@=\C)S'.\S?1OM-(8:
M[#6.&>HUE1GI-IP8Z#:C&.8WJACE-[,7Y#B]%^,XRA?A.-D7W3GI%]HY]1?8
M.?X7U#K_%],Z_Q;2.O\6T3K_%M$Z_Q;1.O\6T3K_%O\J%A+_-1(0_SP/#O]"
M%0W_1QT/_T8F$O]#,!?[/SP<]#M)(.\Y5B'K.6(AYSIN(.4[>1_B.X(>X3R*
M'M\]D1[=/9D=W#V@'=H^J![9/K >V#ZZ'M8_QQ[4/]8?T3_G'\U ]1[*0?\=
MR4'_',=!_QS&0?\;Q4'_&\5!_QO%0?\;Q4'_&_\P%!'_.PX._T(*"_]+$PK_
M4!L+_U D#OQ-+!+S2#<8ZT-#'^5 4"/@0%TDW$%I)-E"="360GTDU$*%)-)#
MC2710Y0EST2;)<U$HR7,1*LFRD6T)LE%P";'1= FQ$7B)\%&\2:_1_PDO4?_
M([M(_R&Z2/\@NDC_(+I(_R"Z2/\@NDC_(/\V$0__0 H+_TH)"?]4$0?_6!@'
M_UD@"?57*0WK4C,3XTT_&MM*3"+52%@GT4=C*LU';BO*2'<LR$A_+,9)ARW$
M28XMPTF6+<%*G2V_2J8MODJO+KQ*NBZ[2\DNN4O;+[9+["VT3/DKLDW_*;%-
M_R>O3_\FKD__)JY/_R:N3_\FKD__)O\[#0W_1@8)_U$'!O];#@7_8!4$^F$=
M!>Y@)0?D7"X,VE@\$])42!_+4%,IQDY=+\)-9S*_37$SO$UY-+I.@32Y3HDT
MMTZ0-+5/F#6T3Z ULD^I-;%/M#6O3\(VKE#4-JM0Z#6I4?8RIU/_,*94_RZE
M5/\LI53_*Z54_RNE5/\KI53_*_\_"@S_2P,'_U<&!/]A"P+_9A$"]&@8 NAG
M( /=9"H&TV(Y#\I>11S"64\IO%58,KA38C>T4FLYLE)T.K!2?#NN4X,[K%.+
M.ZI3DSNI5)L\IU2E/*94KSRD5+P\HU3./:%4XCV?5O,YGE?^-IU7_S2<6/\R
MG%C_,9Q8_S&<6/\QG%C_,?]"" K_3P &_UT$ _]E" 'Z:@L [FP1 .%L%P#6
M;"4"S&HV#,-F0QF[84TFM5U5,:]:73FK6&8^J%=N0*97=D&D5WY!HE>&0:%8
MCD&?6)9"G5B@0IQ8JD*:6+=#F5C(0Y=8W4.66?! E5K\/)5;_SF46_\WE%O_
M-I1;_S:46_\VE%O_-O]&!0G_4P $_V$! ?EI! #L;@4 X7 ' -MO"@#0<B(!
MQG$T";UN01:U:4HCKF13+ZA@6CFC7F) H%QJ1)U<<D6;6WE&F5N!1YA;B4>6
M6Y)'E5N;2)-;IDB26[)(D%O"28];V$F-7.Q&C5WZ0HU=_S^-7O\\C%[_.XQ>
M_SN,7O\[C%[_._]* @C_6  #_V0  .YL  #=<0  V'0# --T!P#*=Q\ P'<R
M![AT/A.P;T@@J6M1+:)G6#B=9%] F6%E1I5?;4F37G1+D5Y\3(]>A$R.7HU-
MC%Z738M>HDV)7JY.B%Z^3H9>TT^%7NE,A6#X1X5@_T2%8?]!A6'_0(5A_T"%
M8?] A6'_0/]-  ;_6P "^F@  .%O  #9=0  TG@! ,YY! #$>QP NWPO!;-Y
M/1"K=4<=I'%/*IUM5C:8:5P_DV9B1H]C:4R+8G!/B6%X4(=A@%&&88E2A&&3
M4H-AGE.!8:I3@&&Z4WYASE1]8>91?F+V3'YC_TA^9/]%?F3_1'YD_T1^9/]$
M?F3_1/]0  7_7@ !\FH  -US  #5>0  SGP  ,A] @"_?QD MX M!*]^.PZG
M>D4:H'=-)YES5#.3;UH]C6M?1HEH94R%96Q1@F1S5(!D>U9^8X17?&2/5WMD
MFEAY9*=8=V.V6'9CR5EU9.)7=F7T479F_TUW9O])=V;_27=F_TEW9O])=V;_
M2?]3  3_8@ !Z&T  -IV  #1?   RH   ,.!  "[@Q8 LX0K ZN".0RC?T08
MG'Q,))5X4C"/=%@[B7!=1(1M8DQ_:FA2>VAO5WAG=UIV9H!;=&:+7')GEEQP
M9Z-<;V>R76UFQ5UL9]Y;;6CR5FYI_E%O:?]-;VG_36]I_TUO:?]-;VG_3?]5
M  /_90  X7   -9Y  #.@   QH0  +^%  "VAQ, KX@H J>'-PJ@A$(5F(%*
M(I)]42Z+>58XA79;0G]R8$MY;V53=&QK67!K<UUM:GQ?:VJ&8&EJDF!G:J!@
M9FJN8&1JP6!C:]I?96SP669L_%5G;/]19VS_4&=L_U!G;/]09VS_4/]8  +X
M:   WG,  --\  #*@P  PH<  +J)  "RBPX JHPE :.+-0B<B4 3E89)'XZ"
M3RN'?U4V@7M:0'MX7DET=6-2;G)H66AP;U]E;GAB8FZ"8V!NCV-?;YQC76^K
M8UQOOF);;]9A77#N6UYQ^U=?</]37W#_4E]P_U)?</]27W#_4O];  'N:P
MVW<  -"   #'AP  OHL  +:.  "MCPD II B )^0,@:8CCX0D8M''(J(3B>$
MA5,S?8)8/79^7$9O>V%0:'AF6&)V;%]=='5C6G1_9%ETC&18=9IC5W6J8E9U
MO&%5=M5@5G;L6UAV^E=8=?]36'7_4UAU_U-8=?]36'7_4_]?  'D;@  UWL
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M24N.^D=+CO]%2X[_14N._T5+CO]%2X[_1>9O  #6?@  RHD  ,"3  "WF@
MKI\  *2B  "6I   C*8( (>G( ""IR\%?*8Z#76D0A=NHDDA9Z%.+&"?4S59
MG5D]4YM?1$Z:9TA,FG%)2YI]24J:BD=)FYE&29NI1$B;O$)'F]5!1YGL0$>8
M^C]'E_\^1Y?_/D>7_SY'E_\^1Y?_/N!V  #0A   Q(\  +N9  "SH   JJ4
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M(#2^_R TOO\@-+[_(,B/  "^G   M:4  *VM  "BLP  EK<  (FZ  !\O@
M<,(  &3(  !9S@, 4=,/ $[3'P)*TRD'1-,R##_3.A([TT(6.--,%S;45A@U
MU&(7-=5O%C35?A4SUHX4,M:@$S'7MA(PV-(1+]7K$2[3^!,LT?\4+-'_%2S1
M_Q4LT?\5+-'_%<&9  "XI   L*T  *:S  "9N   C+P  '_   !SQ0  9\D
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M ZZS  "BN@  E,   (;%  !WR@  :M   %W5  !1VP  1^   #SD   SZ
M+/(  2?]  ,B_P $'O\"!AK_" <7_PX'$_\5" [_&P@*_R((!?\J" '_- <
M_S\& /],!@#_6P4 _VL$ /]\ P#_BP, _YH# /^= P#_G0, _YT# /^= Z6Z
M  "7P   B<8  'K,  !LT0  7M@  %'>  !&XP  .^<  #'K   H[@  (?<
M 1S_  ,8_P $%/\ !1'_  8,_P &"/\$!@3_"@< _Q$' /\8!@#_'P8 _RD%
M /\T!0#_000 _TX$ /]; P#_: , _W8" /]X @#_> ( _W@" /]X O\,)Q+_
M$R02_Q0D$_\0)A/_""P3_P(V$O\!1!'_ %(0_P!?#O\ ; S_ '@+_P"""O\
MBPG_ )((_P"9!_\ H ?_ *8&_P&M!O\!M 7_ KP%_P+&!/\"TP3_ N$#_P+M
M _\"]@+_ OX"_0+_ OL"_P+[ O\"^P+_ OL"_P+[ O\"^P+_ O\1)1+_%B$2
M_Q<A$_\5(Q/_#2D3_PDT$_\(0A+_!U 1_P5=#_\#:@W_ G8,_P. "_\$B K_
M!9 )_P:7"/\'G@?_!Z0'_PBJ!O\)L0;_";H%_PK#!?\*T 3_"M\$_0KK _L*
M] /Y"OT#]PK_ _8*_P/V"O\#]@O_!/8+_P3V"_\$]@O_!/\5(A+_&AX2_QL=
M$O\:'Q/_%244_Q0Q%/\2/A3_$$P2_PY:$?\,9@__"W(-_PQ]#/\-A@O_#HT*
M_Q"4"?\0FPG_$:$(_Q*H"/\2KP?_$[<&_A3 !OT4S07Z%-L%]Q3G!?04\P3R
M%/P$\!7_!? 5_P7O%?\%[Q7_!>\5_P7O%?\%[Q7_!?\9'A+_'AD2_R 8$O\?
M&A+_'R(3_QXN%/\;.Q7_&4@4_QA6$O\78Q'_%F\/_Q9Y#O\8@@W]&(H,_!F1
M"_L:F KZ&YX*^1NE"?@<K GW'+0(]1V]"/0>R0?R'M@'[Q[E!NP>\0;J'OP'
MZ!__!^<?_P?E(/\(Y"#_".0@_PCD(/\(Y"#_"/\=&A+_(Q41_R<4$/\F%1#_
M*A\2_RDK%/\F-Q;_(T06_R%1%?XA7A/[(&H1^"!U$/8A?P_T(H<.\R..#?$D
ME0SP))L,[R6B"^XFJ0OM)K$*ZR>["NHHQPKI*-0)Y2CD">(H\0K@*/P*WBG_
M"]LJ_PO:*?\+V2G_"]DI_PO9*?\+V2G_"_\B%A'_*A(/_RX0#O\R% [_-1T/
M_S0F$O\Q,Q7_+3\7^BM,%_4J617Q*F84[BMQ$NPK>Q'J+(,0Z"V+$.8ND@_E
M+I@/Y"^?#N(OI@[A,*X.X#&X#MXQQ W=,=,-VC'C#M8R\0_3,OP/T#+_#\XR
M_P_-,O\/S#+_#\PR_P_,,O\/S#+_#_\H$Q#_,0T-_S8*#/\]$0O_0!H,_S\C
M#_\[+1+X-SH6\3-'&.LR5!CG,V$7XS1L%> U=A3>-G\4W#:'$]HWCA/9-Y43
MUS><$]4XI!/4.*L3TCFU%-$YP!3/.<X4S3G?%,DZ[Q7&.OL5Q#K_%,([_Q3
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M3G%?P4YP7]E/<&'O27%A_$5R8O]"<F+_0')B_T!R8O] <F+_0/]0  +V7P
MWVH  -1S  #+>   PWL  +Q[  "S>Q  K'TF :1\- B=>3\2EG9('9!R3BB*
M;U0SA&M:.W]H7T)[9F5(=V1K3'1C<T]R8WQ0<&.&46YCD5)M8YY2:V.L4FEC
MO5)G8M13:&3L36ED^TEJ9?]&:F7_1&IE_T1J9?]$:F7_1/]2  'M80  W&T
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M451R]TU4<O]+57+_255R_TE5<O])57+_2?E>  #?;0  T7@  ,>!  "^AP
MM8L  *N-  "@C0  F8X7 )..*0*-C38)AXM $H&)1QQZADTF=(12,&V!5SIF
M?EM"7WQ@2EEZ9U%5>&]54GAY5E%XAE50>9144'FC4D]YM5%.><M03GGE34]Y
M]DI/>?](4'C_1E!X_T90>/]&4'C_1NQB  #;<@  S7T  ,.&  "ZC   L9
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M-$.2_S1#DO\T0Y+_--IV  #+@P  P(X  +>6  "OG0  IJ$  )JD  "-I@
M?:<  ':H#0!SJ2$ ;JDO!&BH. MBIT 36Z5&'%6D3"1/HU(K2J)9,$>B83-%
MH6LT0Z%W,T.BA#)"HI(P0J*B+T&BM"U HLPL/Z'F*S^?]RL^G?\K/IW_*SZ=
M_RL^G?\K/IW_*])]  #%B@  NY4  +.=  "KHP  H*<  )2J  "(K   >JX
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M#KV9  "UHP  K:L  **Q  "6M0  B;@  'N\  !OOP  8L,  %?(  !,S
M0M(  #?8!@ SW1$ ,-X= BW>)P0JWC$&*-\[!R;?1@<EX%$').!=!R/A; 8B
MXGP%(>*-!2#BH00>X[D$'>38 QOA\0,:X/P%&=__!1G?_P49W_\%&=__!;>B
M  "PJP  IK(  )FW  ",NP  ?KX  ''"  !DQ@  6,L  $W/  !#U   .=H
M "_?   L[@@!*.X3 B7O&P0A[R,%'N\L!ASP-@89\4 &%_%,!13Q6 41\F@$
M$/-Y P_TC ,-]*("#/2Z @KUV0$)]? !"//Y 0CS^0$(\_D!"//Y ;*K  "I
ML@  G+@  (^\  "!P   <\4  &7)  !9S@  3M,  $/8   YW   +^$  "?E
M   C]  !(/T& AS^#@,9_A8$%?X=!!'^)04-_RX$"?\X! 7_1 0!_U$# /]A
M @#_= ( _X@! /^< 0#_L $ _\4  /_9  #_V0  _]D  /_9 *NR  "?N
MDKT  (/"  !TQP  9\P  %K1  !.U@  0]L  #C@   NY   )><  ![L   :
M^0 !%O\  A/_  ,/_P8#"_\-! ;_% 0"_QP$ /\D P#_+@, _SH" /]( @#_
M60$ _VP! /]^ 0#_CP  _Y\  /^I  #_J0  _ZD  /^I **X  "5O@  AL,
M '?)  !IS@  6]0  $[;  !"X   -^0  "WG   CZP  &NX  !3S   0_0 !
M"_\  @?_  (%_P # ?\  P#_ P, _P@# /\1 P#_&0, _R," /\O @#_/@$
M_TX! /]? 0#_;P  _WP  /^%  #_A0  _X4  /^% /\()!#_"R(0_PHB$/\$
M)!#_ "H/_P U#O\ 0PS_ %$+_P!>"?\ :P?_ '<&_P" !?\ B03_ ) $_P"7
M _\ G0/_ *,"_P"I O\ KP+_ +<!_P#  ?\ S '_ -L _P#I /\ \P#_ /T
M_0#_ /L _P#[ /\ ^P#_ /L _P#[ /\ ^P#_ /\,(A#_#Q\0_PX>$/\*(1#_
M "80_P R#_\ 0 W_ $X,_P!;"O\ : C_ '0'_P!^!O\ A@7_ (X$_P"4!/\
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MI$/_%_\V 0C_/@ %_TD  OY/ P'V40@ [U . .)-& '82R4"SDDU"\9'0A/
M1DX9NT58'+=%8AVU16L>LD9S'K!&>A^O1H$?K4>('ZQ'CQ^J1Y<?J$>?(*='
MJ2"E1[0@I$?#(:)(UB&@2.H@GDCX'YQ)_QZ;2?\=FTC_')M(_QR;2/\<FTC_
M'/\[  ?_1  #_T\  ?%4  #C5@  W%4$ -E0"P#/5"$!Q5,Q"+U1/A*V3DD;
ML4Q3(*U+7".K2V4DJ$MM):9+=26D2WPFHTR#)J%,BB:@3)(FGDR:)YQ-I">;
M3*\GFDR^*)A,T"B63.8HE4WV)9--_R233?\BDDW_(9)-_R&23?\ADDW_(?\_
M  7_20 !]U0  .)9  #:70  U%T! -%9!@#'7!T OEPN!K99.Q"O5D8:J5-/
M(J515R>B4& JGU!H*YU0;RR;4'<LF5!^+)A0A2R64(TME5"6+9-0H"V24*LN
MD%"Y+H]0RR^-4.$OC%#S+(M1_RF*4?\HBE'_)HI1_R:*4?\FBE'_)O]"  3_
M3@  ZU<  -U?  #58P  SF0  ,I@ @# 8AD N&,K!+!@.0VI74,7HUI,(9U7
M5"B:55LMEU1C,)14:C&34W(RD5-Y,H]3@#*.4X@SC%.1,XM3FS2)4Z<TB%.T
M-893QC6%4]TVA%3Q,H-4_2^#5/\M@E3_*X)4_RN"5/\K@E3_*_]%  /]4@
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M3E9GL4U49\9,5&?@2E5H]$96:/]#5VC_0%=H_T!7:/] 5VC_0.]8  #=:
MSW(  ,5Z  "\?P  LX(  *F#  "?@@  EX(5 )&#)P&+@C0'A7\^$']]11EY
M>TLB<WA0*VUV531G<UH\87%?0UMN94E7;6U-56QW3U-M@TY2;9!.46V?3%!M
MKTM/;L1*3V[?2%!N\T50;?Y"46W_0%%M_T!1;?] 46W_0.E=  #:;   S'8
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M-4.&\C1#A?XS0X3_,D.$_S)#A/\R0X3_,MMN  #+>P  P(8  +>.  "NE
MI9<  )N9  "-F@  ?YH  'B:$0!TFR, ;YHP!&J9.0IDF$$27I9'&EB532)2
ME%(I39-8+TF28#-&D6DT19%T-$21@#)#DHXQ0Y*=+T*2KBY!DL0L0)'>*S^0
M\BL_C_XK/H[_*SZ._RL^CO\K/H[_*]1U  #&@@  NXP  +.4  "KF@  HIX
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M$"JP_Q JL/\0*K#_$+^/  "VF0  KZ(  *>H  ";K0  CZ\  (*R  !UM
M9[8  %NY  !.O0  0L$! #O$#@ YQ1T -\4H C/%,00PQ3H'+L5$""S%3@DK
MQED(*L9E""G&<@<HQX(&)\>3!B7'I@4DQ[T$(\?;!"'$\04@POT''\#_"!_
M_P@?P/\('\#_"+F8  "RH@  JJD  )^O  "3L@  A;4  'BX  !KN@  7KT
M %+!  !'Q0  /,D  #'. 0 HU 8 )-82 "/6'@ AURD!']<T 1[80 $=V$L!
M'-E8 1O99@$9VG8 &-J( !;;G  4V[, $MO2 !'9[0 1U_H!$=7_ A'5_P(1
MU?\"$=7_ K2B  "MJ@  H[   ):T  ")N   >[L  &Z^  !AP0  5<4  $G)
M   ^S0  ,](  "K6   BVP  &^0% !GH$  7Z!H %.DD 1+I+@$0ZCD!#>I&
M 0KK4P (ZV, !NQT  3MB  ![)T  .NU  #KUP  ZO   .G_  #I_P  Z?\
M .G_ *^J  "FL0  F;8  (RZ  !^O0  <,$  &+%  !6R0  2LX  #[2   T
MU@  *ML  "+?   :XP  %.L  !'X P -^0L "OD4 0;Y' $"^28! /HQ 0#Z
M/@  ^DP  /E=  #Y<   ^(0  />9  #VKP  ]L<  /?D  #WY   ]^0  /?D
M *FQ  "=M@  C[L  (&_  !RQ   9,@  %?-  !*T@  /M8  #/;   IWP
M(.,  !CF   1Z@  "_$   ?[   $_P   ?\$ 0#_"@$ _Q,! /\< 0#_)P
M_S4  /]$  #_5@  _VD  /]]  #_D   _Z$  /^R  #_LP  _[,  /^S *"W
M  "2O   A,$  '3&  !FRP  6-$  $O6   ^W   ,N   "CD   >YP  %>H
M  [N   &\    O<   #_    _P   /\  0#_  $ _P ! /\( 0#_$@  _QT
M /\J  #_.@  _TP  /]?  #_<0  _X   /^/  #_CP  _X\  /^/ /\#(@[_
M!!\._P$?#O\ (@W_ "@,_P S"O\ 00C_ % &_P!=!?\ :03_ '4#_P!^ O\
MA0'_ (P!_P"3 ?\ F0#_ )\ _P"E /\ JP#_ +( _P"[ /X Q@#\ -0 ^P#C
M /L \ #[ /H ^P#_ /L _P#Z /\ ^@#_ /H _P#Z /\ ^@#_ /\''P[_"!P.
M_P8<#O\ '@W_ "0,_P Q"_\ /@G_ $T'_P!:!O\ 9@3_ '(#_P![ O\ @P+_
M (H!_P"0 ?\ E@'_ )P _P"B /X J0#\ +  ^@"X /D PP#W -$ ]@#@ /4
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M ?4!D0'T 9<!\@&= /$!HP#O :H [@&R .P!O0#J <H Z0': .<"Z@#E _8
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M.VE8LSMG6,<\9EC@.V98]#=G6?\T9UG_,6=9_S!G6?\P9UG_,/=+  #B6P
MU&8  ,AM  "_<0  MW(  *YQ  "E;@0 GF\: )AO*@.1;38)BVL_$H5H1AN
M94TC>V)2*W9?5S%R75TU;UQD.6Q;:SMJ6W,]:%M]/F9;ASYD6Y,_8UNA/V%;
ML#]?6\1 7EO=/U];\CI?7/\W8%S_-6!<_S1@7/\T8%S_-.].  #>7@  T6D
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M/TQJ[CQ,:?PZ3&G_.$UI_SA-:?\X36G_..1=  #4:P  QG0  +Q[  "T@0
MJX,  *&$  "3@   BX$) (6!'0" @2P">X V"'5^/Q!O?$48:7I+(&1X4"A>
M=E0P6'19-U-R8#Q/<6A 37!R04MP?4%*<8H_2G&9/DEQJ3U(<KP[1W+6.D=Q
M[3A'</LW1W#_-4=O_S5';_\U1V__->!B  #/;P  PWD  +F   "QA@  J(@
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M(CF)_R(YB?\B.8G_(LYU  #!@0  MXH  *^2  "GEP  GIH  )*;  "%G
M=9P  &B<  !AG1( 7ITB %N=+@-6G#<(49L^#4R:11-'F4P90YA2'4"86A\^
MF&0@/)AO'SR8>QX[F(@=.IB7&SF8J!HXF+P9-Y?6&#:6[1@UE/L9-)/_&C23
M_QHTD_\:-)/_&L=]  "\B   M)$  *R8  "DG0  F:   (VB  " HP  <:,
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M!+:8  "OH0  IZ<  )RL  "0KP  @K(  '6T  !GM@  6[@  $Z[  !"O@
M-L(  "S&   BR@$ &\X) !C/%@ 6SR$ %<\L !30.  2T$0 $=!0 !#17@ -
MT6X "]%_  G0D@ (T*< !M#!  3/X0 %SO4 !<S_  7+_P %R_\ !<O_ +&A
M  "KJ   H*X  ).R  "&M0  >+@  &JZ  !=O0  4<   $7#   YQP  +LL
M "7/   <TP  %-8   O; @ %W0H  ]T7  +=(P  WB\  -\\  #@2P  X%L
M .%M  #A@   X90  .&J  #AQ   X>$  .'R  #A^   X?@  .'X *VI  "C
MKP  E[,  (FW  ![N@  ;;T  %_!  !3Q   1L@  #K,   OT   )-0  !S9
M   4W   #-\   3B    ZP   .L&  #J$   Z1H  .DF  #K-   [44  .]6
M  #O:0  \'T  /"2  #QIP  \;P  /'3  #RWP  \M\  /+? *:O  ":M0
MC+D  'Z]  !OP   8<0  %3)  !'S0  .M$  "_5   DV@  &MX  !/B   *
MY0   ^<   #I    \0   /<   #V    ]@8  /41  #U'   ]BL  /D]  #\
M4   _60  /UX  #^C   _IT  /^M  #_M   _[0  /^T )VU  "/N@  @;X
M ''#  !CR   5<T  $C2   [V   +MP  "3@   9XP  $.<   CJ   ![0
M .\   #P    ]@   /X   #_    _P   /\   #_!0  _Q(  /\A  #_,P
M_T<  /]<  #_;P  _X   /^-  #_E   _Y0  /^4 /\ 'PS_ !T,_P ="_\
M'PK_ "0(_P R!_\ 0 7_ $X#_P!; O\ 9@'_ '$ _P!Z /\ @@#_ (D _P"0
M /\ E@#_ )P _P"A /X IP#] *T _0"U /P OP#[ ,L ^P#; /H [ #Z /@
M^@#_ /D _P#W /\ ]@#_ /8 _P#V /\ ]@#_ /\"' W_ 1D,_P 9"_\ &PK_
M "$)_P O!_\ /07_ $L$_P!8 O\ 8P'_ &X!_P!W /\ ?P#_ (< _@"- /P
MDP#Z )D ^0"> /@ I #W *L ]@"R /8 NP#U ,< ] #8 /0 Z #S /4 \P#^
M /$ _P#P /\ [P#_ .X _P#N /\ [@#_ /\&& W_!10,_P$4"_\ %@K_ !\)
M_P K"/\ .0;_ $<$_P!4 _\ 8 '_ &L!_P!T /T ? #Z (0 ]P"* /4 D #S
M )8 \@"; /$ H0#P *@ [P"O .X N #M ,0 [ #3 .L Y #K /$ Z@#[ .@
M_P#G /\ Y0#_ .4 _P#E /\ Y0#_ /\+% S_"A +_P<."O\"$@K_ QP)_P H
M"/\ -0;_ $,$_P!0 _\ 7 +\ &<!^ !P /4 >0#R (  [P"' .T C0#J ),
MZ0"8 .@ G@#G *4 Y@"L .0 M0#C ,  X@#/ .$ WP#@ .X WP#Z -P _P#:
M /\ V0#_ -D _P#9 /\ V0#_ /\1#PS_$0D*_PT'"?\.#0G_$!D(_PPC"/\'
M, ?_ SX%^@!+ _4 5P+Q &(![@!L .L =0#I 'T Y@"# ., B0#A (\ WP"5
M -X FP#= *( VP"I -H!L@#9 ;X UP+, -4#W@#4!>\ T G\ ,T*_P#,"_\
MRPO_ <D,_P')#/\!R0S_ ?\7"0O_& ,)_Q<!!_\<"0;_'!0'_QD?!_X5*P;U
M$#D%[PQ& ^D-4@+E#%X!X@UH -\-<0#<#7D V@V  -@-A@#6#HP U0Z2 -,0
MF0#2$*  T!&H ,X2L0#-$[P RQ/+ ,D5W0#%%^X PAC[ < 9_P*^&?\"O1G_
M KP8_P.\&/\#O!C_ _\< PG_'@ &_R, !?\H!03_)PX$_B09!/,@)07J&S($
MXQA  ]T830'9&5D!U!MC -$<;0#/'74 S!Y\ ,H?@@')'X@!QR". <4@E0'$
M(9P!PB*C < BK &^([@!O2/% ;LCV &X).D#M23X!+,D_P2Q)/\%L"3_!:XD
M_P6N)/\%KB3_!?\B  ?_)0 $_RT  O\Q 0'\, @!]"T2 >DH'0+?(BH#V"(Y
M M$E1P+,)U0#QRA> \0J9P/!*W $ORMW!+TL?02[+(0$NBV*!+@MD 2W+9<$
MM2V?!+0NJ 6R+K(%L"[ !:\NT06L+N4&JB[T!Z<O_PBE+_\(I"[_"*,N_PBC
M+O\(HR[_"/\H  7_+0 "_S8  /,X  #I-P  Y3(' -XL$@#4+2,!RR\S!,4Q
M0@:_,DX'NS-8"+@T80BU-&H(LS5Q"+$U> FP-7X)KC:%":TVBPFK-I()JC::
M":@WHPJG-ZT*I3>Z"J,WRPNA-^ +GC?Q#)PW_@R;-_\,FC;_#)DV_PR9-O\,
MF3;_#/\N  /_-0 !\SP  .,_  #<00  UCX! -,V" #*.1T P3HN!;HZ/ FU
M.D@,L3M2#:T\7 VK/&0.J#QL#J<\<PZE/7D.HSV #Z(]A@^@/8T/GSZ5#YT^
MGA"</JD0FCZU$)D^Q1&7/=H1E3WN$9,]_!&1/?\1D3W_$) ]_Q"0/?\0D#W_
M$/\Q  +].P  YT(  -Q*  #43   SDD  ,E"! #!1!D N$4I!+%#-PJK0D,/
MIT)-$:-"5A.A0EX4GD)F%)Q#;12;0W04F4-Z%9A#@1660X@5E4.0%9-#FA:2
M0Z06D$.P%H]#P!>-0M47BT+J%XI"^A:(0O\6B$+_%8="_Q6'0O\5AT+_%?\T
M  'Q0   X4L  -92  #.5   QE,  ,%,  "Y3!0 L4XF JI,,PBD2CX/GTE(
M%)M(41>81UD9ED=@&91':!J21V\:D$=U&H]'?!N-1X0;C$>,&XI'E1R)1Z <
MAT>L'89'NQV$1] >@T?F'8%']QR 1_\;@$?_&G]'_QE_1_\9?T?_&?\Y  #J
M10  W5$  -%8  #(6P  P%L  +I4  "R4@\ JU4B :14, >=4CL.F$]$%9--
M31J03%0=C4M<'HM+8Q^)2VD@B$MP((9+>""%2W\A@TN((8)+D2& 2YPB?TNH
M(GU*MR-\2LLD>DKC(WE+]2%X2_\@>$O_'GA*_QUX2O\=>$K_'?X]  #F3
MV5<  ,U>  #$80  O&$  +1<  "L60H I5H? )Y:+0686#@,DE5!%(U221J)
M45 ?AD]7(H1/7B."3F4D@$YL)7].<R9]3GLF?$Z#)GI.C2=X3I@G=TZE*'5.
MLRES3L<I<DW?*7%.\R9P3O\D<$[_(W!._R)P3O\B<$[_(O9!  #C40  U5P
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M-UE7[31:5_LQ6EC_+EM8_RU;6/\M6UC_+>E.  #970  RV<  ,!N  "W<0
MKG(  *5Q  ":;   DFP0 (QM(@"';"\$@6HX"WQG0!-V948:<6),(6Q@42AH
M7E<N9%U<,F!<8S9>6VLX7%MU.5I;?SI86XLZ5UN9.E5;J#I46[HZ4EO2.5-;
MZS936_HS5%O_,51;_R]46_\O5%O_+^93  #580  R&L  +UQ  "T=0  JW8
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M+4-K_RU#:_\M0VO_+=IB  #*;@  OG<  +5^  "L@@  HX4  )F%  ")@0
M?H   '> $0!S@2$ ;X N VI_-PAD?C\.7WQ%%5I[2AQ4>4\C3WA4*4MV6RY(
M=F,Q1G5M,41U>#%$=H4O0W:3+D)VHRQ!=K4K0';-*4!UYR@_=/@H/G/_*#YR
M_R@^<O\H/G+_*-1H  #%<P  NWP  +*#  "IB   H(H  ):+  "&B   >H<
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M%,)\  "XAP  L(\  *B6  "@F@  E9P  (F>  !\G@  ;9X  %Z?  !1H
M2J$0 $>A'@!%H2D!0:$S!#V@.P<ZH$(*-I]*#32?4PXRGUP.,9]G#C"?<PTP
MGX$,+Y^/"RZ?H HLGK,)*Y[+""J<Y@@IFO@**)G_"R>8_PPGF/\,)YC_#+V%
M  "TCP  K)<  *6=  ";H0  CZ,  (*D  !UI0  9Z4  %FG  !,J   /ZH
M #BK$0 VJQX -*PH #*K,@(OJSH$+:M#!2NK308IJU<&**MB!2>K;@4FJWP$
M):N+!".KG ,BJ[ "(*K( A^IY0(=I_<$'*7_!1RD_P8<I/\&'*3_!K>.  "P
MEP  J9X  *"C  "5I@  B*D  'NJ  !MJP  7ZP  %*N  !%L   .;(  "ZU
M   EMPL ([@9 "*X)  @N"X 'K@X !VX0@$<N$T &KA8 !FY90 7N70 %KB$
M !2XE@ 2N*H $+C#  ZVX@ .M/8 #K/_ 0ZR_P$.LO\!#K+_ ;.7  "LGP
MI*4  )FI  ",K   ?ZX  '*P  !DL@  5[,  $JV   ^N   ,;L  ">^   =
MP@  %,4#  S'#0 *QQH "<<E  ?',0 &QSP !<=)  3'5@ #QV4  <=W  #'
MB0  QIT  ,:S  #%SP  Q.D  ,/W  ##_P  P_\  ,/_ *Z@  "HIP  G:L
M )"O  "#L@  =;0  &>V  !:N   3;L  $&^   TP0  *<0  !_(   6S
M#<X   31    TP@  -,3  #4'@  U2H  -8V  #71   V5,  -ED  #9=P
MV8L  -F@  #8N   U]4  -;K  #6]P  UO<  -;W *NG  "@K0  E+$  (:T
M  !XN   :KH  %R]  !/P   0L,  #;&   JR@  '\X  !?2   .U0  !M@
M  #;    W0   -\   #@"@  X18  .,A  #E+P  YSX  .I.  #K80  ZW4
M .R*  #LH   [+8  .O-  #KX@  Z^(  .OB *.N  "7L@  B;8  'NZ  !L
MO0  7L$  %'%  !$R0  -LP  "O0   @U   %MD   S=   %X    .$   #D
M    Y@   .@   #I    ZP   .T*  #P%P  \B8  /4V  #X2   ^EP  /MQ
M  #\A@  _)D  /VI  #]M@  _;8  /VV )JT  "-N   ?KP  &_!  !@Q0
M4\D  $7.   WT@  *]<  !_<   4WP  "^0   +G    Z0   .L   #L
M[0   /    #Q    \P   /4   #X    ^PP  /X<  #_+@  _T(  /]6  #_
M:@  _WT  /^+  #_EP  _Y<  /^7 /\ ' O_ !H*_P 8"?\ &P?_ "(&_P P
M!/\ /@+_ $L!_P!8 /\ 9 #_ &\ _P!X /\ ?P#_ (8 _P", /\ D@#_ )<
M_@"< /X H@#] *@ _ "O /L N #[ ,0 ^@#3 /@ Y #V /0 ]0#_ /4 _P#U
M /\ ]0#_ /8 _P#V /\ ]@#_ /\ &0O_ !8*_P 5"?\ %@?_ !\&_P M!/\
M.P+_ $@!_P!5 /\ 80#_ &L _P!U /T ? #[ (, ^@") /D CP#Y )0 ^ "9
M /< GP#V *4 ]0"L /0 M0#S ,  \@#. /  X #N /$ [0#] .T _P#M /\
M[0#_ .T _P#M /\ [0#_ /\!% O_ !(*_P 1"?\ $ C_ !P&_P I!/\ . +_
M $4!_P!1 /\ 70#\ &@ ^ !Q /4 >0#T (  \P"& /( BP#P )$ [P"6 .X
MG #M *( [ "I .L L0#J +L Z #) .8 W #D .T XP#Y ., _P#B /\ X@#_
M .( _P#B /\ X@#_ /\%$ K_ PL)_P )"/\ #P?_ !D&_P E!/\ ,P/_ $ !
M_@!- /@ 60#S &0 [P!M .T =0#K 'P Z0"" .@ B #G (T Y@"3 .0 F #C
M )X X@"F .  K@#> +< W #% -H UP#8 .@ V #T -8 _@#5 /\ U #_ -0
M_P#3 /\ TP#_ /\*"0K_" 0(_P(!!_\&"@;_!A8%_P$A!/\ +@/\ #L!]0!(
M .X 5 #H %\ Y0!I ., <0#A '@ WP!^ -T A #; (H V@"/ -@ E0#6 )L
MU0"C -, JP#1 +4 SP#" ,T T@#, .0 R@#R ,D _@#' /\ Q0#_ ,0 _P#$
M /\ Q #_ /\1 PC_#P &_Q  !?\4!@3_$Q$$_P\= _D(* +Q!#4!Z@%# .,
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M O\=  7_'@ "_R8  ?<G  #O)0$ [B + .,9& #9%24 T1@U ,L<1 #%'E
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M"I0XO@J2.-$+D#CG"XXW]PR,-_\,BS?_#(LW_PR*-_\,BC?_#/\J  #N-
MXD   -9&  #.1P  QT0  ,$^  "Z.Q0 LCTE JL],P:F/3\)HCU)"YX]4PR<
M/5L-FCUB#9@]:0V6/6\.E3UV#I,]?0Z2/80.D#V+#H\^E ^-/I\/C#ZJ$(H]
MN1")/<P1ASWC$84]]1&#/?\0@SW_$((]_Q""//\0@CS_$/\P  #I/0  W$@
M -%.  #'40  P$X  +E'  "R1 X JT8A :1&+P:>1#H+F4-$#I9#31&30E42
MD4)=$H]"9!.-0FH3C$)Q$XI">!.)0G\4AT*'%(9"D!2$0IH5@T*F%8%"M!:
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M(FQ)[2!K2?P>:DG_'6I)_QQJ2?\<:DG_'.Q   #=3P  SUH  ,1@  "[8@
MLF$  *E=  "@6 $ F5@6 )-9)@&-5S$'B%4Z#8-30A1_44D9>T]0''A.5A]V
M35P@=$UC(G)-:B)P37(C;TU[)&U-A"1K38\E:DV<)6A-JB9F3;LG9$S2)V-,
MZR5C3?HC8TW_(6-,_R!C3/\@8TS_(.E%  #:5   S%X  ,%D  "W9@  KV8
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M*D]7_RE/5O\H3U;_*.!3  #08   PVD  +AO  "O<@  IG,  )QQ  "/:@
MAFH% (!J& !\:B8!=VDQ!7)G.0ML94 29V-&&6)A2Q]>8%$E65Y6*E9=72]3
M7&0Q45MM,T];>#-.6X0S3%R1,DM<H#)*7+(Q2%S(,$A<XR](6_8L25O_*TE;
M_RI)6_\I25O_*=Q8  #,9   P&T  +9R  "M=@  I'<  )EV  "+;P  @F\
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M(<]G  # <@  MGH  *V   "EA0  G(<  )&'  ""A   =H(  &F! @!C@10
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M#"^/G LNCJT*+8[$"2R-WPDKB_,+*HK_#"F)_PTIB?\.*8G_#KY[  "TA@
MK(T  *63  "=EP  DID  (6:  !XF0  :9D  %J9  !-F@  0IL( #Z;%P \
MFR, .9LM 3:;-0,SFST%,9I&!R^:3@@MFE@(+)IB""N:;@<JFGL&*)J)!2>9
MF04FF:P$))G" R.8W@,BEO,%(93_!B"3_P<@D_\'()/_![F$  "PC0  J94
M **:  "8G0  C)\  '^@  !QH   8Z   %6A  !(HP  .Z0  #"F"  LIA8
M*Z8A "FF*P GIC0!):8] B.F1P(BIE$"(*9< A^F: $>IG8!'*:% 1NEE0 9
MI:@ %Z2^ !6DVP 6HO$!%J#^ 12>_P(4GO\"%)[_ K2-  "LE0  IIP  )VA
M  "2HP  A:4  '>F  !IIP  7*@  $ZI  !!JP  -*T  "FO   ?L0, &;(0
M !>R'  6LB8 %+(P !.R.P 1LD4 $+)1  VR70 +LFP ";)\  BQC0 &L:
M!+"U  .OSP #KND !*WX  2L_P $K/\ !*S_ *^6  "IG@  HJ,  ):G  ")
MJ0  ?*L  &ZL  !@K0  4Z\  $:Q   YLP  +;4  "*X   8N@  #KP   6^
M"@ !OA8  +\A  "_*P  OS<  +]#  "_3P  OUX  +]N  "_@   OI,  +VH
M  "]P   O-T  +OO  "Z^0  NOL  +K[ *R?  "EI0  FJD  (VL  " KP
M<K$  &2R  !6M   2;<  #RY   PNP  )+X  !K!   1Q   !\8   #)
MR@8  ,L0  #,&P  S24  ,XQ  #./@  STP  -!<  #0<   T(0  -"9  #/
MKP  SLD  ,[C  #-\@  S?0  ,WT *BF  "=JP  D:X  (.Q  !UM   9K<
M %FY  !,O   /K\  #+!   FQ   &\@  !++   (SP   -    #3    U0
M -<   #9!P  VQ(  -T=  #?*0  X3<  .1'  #E60  Y6\  .6&  #EG0
MY;(  .7*  #DWP  Y.,  .3C *"L  "4L   A[0  'BW  !IN@  6[X  $[!
M  ! Q0  ,\@  "?+   ;S@  $=,   ?8    VP   -P   #>    X    .(
M  #D    Y@   .D'  #L%   [R$  /(Q  #U0@  ]U4  /AK  #X@P  ]YH
M />N  #WP   ]\0  /?$ )>R  "*M@  ?+H  &R^  !>P@  4,8  $+*   T
MS@  )](  !O6   /VP  !N    #C    Y0   .8   #H    Z0   .L   #M
M    \    /(   #U    ^0D  /P8  #_*0  _SP  /]0  #_90  _WH  /^,
M  #_G0  _Z   /^@ /\ & G_ !4(_P 4!O\ %P7_ " #_P N ?\ .P#_ $D
M_P!6 /\ 8@#_ &P _P!T /\ ? #_ (( _P"( /\ C0#_ )( _@"7 /X G0#]
M *, _ "J /D L@#W +P ]@#, /4 WP#T .\ ] #] /0 _P#T /\ \P#_ /(
M_P#R /\ \@#_ /\ %0G_ !$(_P /!_\ $@7_ !T#_P K O\ . #_ $8 _P!3
M /\ 7@#^ &@ _0!Q /P > #Z '\ ^0"% /@ B@#X (\ ]P"4 /8 F@#U *
M\P"F /  K@#N +@ [0#' .P V0#K .L ZP#Z .H _P#I /\ Z #_ .@ _P#H
M /\ Z #_ /\ $0G_  T(_P +!O\ #@7_ !H#_P G O\ - #_ $( _0!/ /D
M6@#W &0 ]0!M /, =0#R 'L \0"! .\ AP#N (P [0"1 .P E@#J )P Z "C
M .8 JP#D +4 XP#" .$ T@#@ .< WP#V -X _P#= /\ W #_ -P _P#< /\
MW #_ /\ "PG_  8'_P #!O\ # 7_ !<#_P C O\ , #[ #X ] !* /$ 5@#N
M &  ZP!I .D <0#H '< Y@!] .4 @P#C (@ X@"- .  DP#= )D VP"? -D
MIP#8 +$ U@"] -0 S0#3 .( T0#R -  _ #/ /\ S@#_ ,T _P#- /\ S0#_
M /\$! C_   &_P  !?\ !P3_ !0#_P ? ?T *@#R #@ Z@!% .< 40#C %L
MX !D -X ; #< ', V@!Y -@ ?P#5 (0 TP"* -$ CP#/ )4 S0"< ,P I #*
M *T R "Y ,< R0#% -P Q #L ,( ^ #! /\ P #_ +\ _P"_ /\ OP#_ /\)
M  ;_!0 $_P@  _\* @+_!PT!_@$9 ?0 ) #F #$ X  _ -L 2P#8 %8 U !?
M -$ : #. &\ S !U ,H >P#( ($ Q@"& ,0 C ## )( P0"9 +\ H0"^ *H
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MP "B'M, H!_G )T?]P&<'_\"FQ__ IH?_P*9'_\"F1__ O\9  '\(0  Z2<
M . L  #8*P  TB0  ,\9" #'&AL OQXL +DA.@"T(T8 L"11 *TE60&K)F$!
MJ29H :<G;P&E)W4!I"A[ :(H@0&A*(@!GRB/ 9XIF &<*:$!FBFM IDINP*7
M*<T"E2GC Y,I]021*?\$D"G_!8\H_P6/*/\%CRC_!?\>  #N*   XC,  -@Y
M  #/.0  R#0  ,,K @"\)Q4 M2LF *\L-0*J+D$#IB]+ Z,O5 .@,%P$GC!C
M!)PQ:@2;,7 $F3%V!)@Q? 26,8,$E3&+!9,QDP62,9T%D#*I!8\RM@:-,<@&
MBS'?!XDQ\@>',?\(AC'_"(4Q_PB%,/\(A3#_"/TE  #I,@  W#T  -%#  #'
M1   P$   +HY  "S,P\ K#8A *8V+P.A-CL%G3=&!YDW3P>7-U<(E3=>"),W
M9 B1-VL(D#=Q"(XX> F-.'\)BSB&"8HXCPF(.)D*ASBD"H4XL@J$.,0+@CC:
M"X X[PQ^-_X,?3?_#'TW_PQ]-_\,?3?_#/,J  #D/   UD8  ,M,  #!30
MN4H  +)#  "K/0D I3\= )X_*P.9/C8'E#U!"I$]2@N./5(,C#U9#(H]7PV(
M/68-ASUL#84]<PV$/7H.@CV"#H$]BPY_/94/?CVA#WP]K@][/;\0>3W6$7<]
M[!%V/?P0=3S_$'4\_Q!T//\/=#S_#^\S  #?0P  T4T  ,53  "\5   M%$
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M'%U(_QM=2/\:74C_&N1%  #44P  QEP  +MA  "R8P  J6(  *!>  "56
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M(]97  #&8P  NVH  +%P  "H<P  GW,  )5Q  "&:P  >V@  '1H#0!O:!T
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M'#INF1LY;JD9.&Z^&#=NV1<V;.\8-6O]&31J_QHT:?\:-&G_&LAG  "\<0
MLG@  *E^  "A@@  F(,  (V#  !_@   <GX  &1\  !;>PP 5WL< %5[)P!1
M>S$#37HX!TEY/PQ%>$4007A+%#YW4A<[=UH8.79D&#AV;Q<W=WL6-G>)%35W
MF!0U=ZD2-':]$3-VV! Q=>\2,'/]$R]R_Q0O<?\4+W'_%,-M  "X=@  KWX
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M !J3U  :D>T!&9#\ AB/_P,8CO\$&([_!+6#  "MC   II,  )^8  "5FP
MB9P  'N<  !MG   7YP  %"<  !#G0  -YX  "N@   CH0T (:$: !^A)  =
MH2T '*$W !NA0  9H4H &*%5 !:A80 4H&X $J!] !"@C0 .GZ  "YZT  F=
MS0 *G.@ "YKY  N9_P +F?\ "YG_ +",  "IE   HYH  )J>  ".H   @:(
M '2B  !FHP  6*,  $JD   \I@  ,*<  "6I   :JP  $*P(  RL%  *K!\
M":PI  >L-  &K#X !*Q*  *L5@  K&0  *MS  "KA   JI8  *FJ  "HP@
MI]T  *?O  "F^0  IOX  *;^ *R5  "FG   GZ$  ).D  "&I@  >*@  &JH
M  !=J0  3ZL  $*L   UK@  *+   !ZR   4M   ";4   "W!P  MQ(  +@<
M  "X)@  N#$  +@\  "X2   N%8  +AF  "X>   N(H  +>?  "VM0  M=$
M +/J  "S]@  L_L  +/[ *F=  "CHP  EZ<  (JJ  !]K   ;JT  &"O  !3
ML   1;(  #BT   LMP  (+D  !:[   +O@   [\   #!    P@0  ,,-  #$
M&   Q2(  ,8M  #&.0  QT8  ,E5  #)9P  R7L  ,F0  #(I@  Q[\  ,;;
M  #%[0  Q?4  ,7U *:E  ";J0  CJP  (&O  !RL0  8[,  %6U  !(N
M.KH  "Z]   BOP  %\(   S%   #R    ,D   #,    S@   ,\   #1!0
MTQ   -4;  #7)P  V30  -M#  #>5   WV@  -]^  #?E   WZH  -_!  #?
MV   WN0  -[D )ZK  "2K@  A+$  '6U  !FMP  6+H  $J]   \P   +\,
M "/&   7R0  #,T   +1    U0   -4   #8    V@   -P   #?    X0
M .0$  #H$0  ZAX  .PM  #O/@  \5(  /)G  #S?P  ])4  /2I  #TN0
M],4  /3% )6P  "'LP  >;<  &J[  !;O@  3<(  #[&   PR@  ),T  !?1
M   *U0   =H   #>    X0   .$   #C    Y0   .<   #I    [    .\
M  #R    ]@8  /H5  #])0  _S<  /]-  #_9   _WP  /^0  #_GP  _Z<
M /^G /\ $P?_ !$&_P 1!/\ $P/_ !X!_P K /\ .0#_ $@ _P!4 /\ 7@#_
M &@ _P!Q /\ > #_ 'X _P"# /\ B0#_ (X _0"3 /L F #Y )X ]P"E /8
MK0#U +< ] #$ /0 V #S .P \@#[ /  _P#O /\ [P#_ .\ _P#P /\ \ #_
M /\ $ ?_  P&_P +!/\ # /_ !L!_P G /\ -@#_ $0 _P!0 /\ 6P#^ &4
M_ !M /L = #Y 'L ^ "  /< A0#U (L ] "0 /( E0#P )L [P"B .T J@#L
M +, ZP"_ .H T@#I .8 YP#V .4 _P#E /\ Y0#_ .0 _P#D /\ Y #_ /\
M# ?_  <&_P &!/\ # /_ !<!_P D /\ ,@#\ #\ ^@!, /@ 5P#U &$ \P!I
M /$ <0#P '< [@!] .P @@#J (< Z ", .8 D@#E )< Y "> .( I@#A *\
MWP"[ -X RP#; .  V0#R -@ _P#8 /\ U@#_ -8 _P#7 /\ UP#_ /\ !0?_
M   %_P  !/\ "0+_ !4!_P ? /D +0#S #L \ !' .X 4@#K %P Z !E .8
M; #D ', X0!Y -\ ?@#= (, VP") -H C@#8 )0 U@": -0 H@#2 *H T0"V
M ,X Q0#, -D RP#M ,D ^P#( /\ R #_ ,@ _P#( /\ R #_ /\   ;_   $
M_P   _\ !0+_ !$!_  : .X )P#I #4 Y@!" .( 30#? %< W !@ -D : #5
M &\ T@!U -  >@#/ '\ S0"% ,L B@#* )  R "7 ,8 G@#$ *< P@"R ,
MOP"^ -, O0#H +P ]@"[ /\ N@#_ +D _P"X /\ N #_ /\!  3_   #_P
M ?\   #_  H \P 2 .0 ( #? "X V@ \ -4 2 #1 %( S0!; ,H 8P#' &H
MQ0!Q ,, =@#" 'P P "! +X A@"] (P NP"3 +D FP"W *0 M0"N +, O "R
M ,X L #A *\ \0"N /P JP#_ *H _P"J /\ J@#_ /\&  /_!@ !_0H  /((
M  #L @  Y@ ) -L & #4 "< S@ U ,D 0@#$ $T P !6 +T 7@"[ &8 N0!L
M +< <@"U '@ M !] +( @P"P (D KP&0 *T"F "K J$ J@.L *@$N0"G!,H
MI0;? *,(\0"A"OX H K_ )\*_P">"O\ G@K_ /\*  '^$0  ZQ4  .,8  #=
M%   V H! -( #@#+ 1X PP0N +X'/ "Y"4< M0M1 +(,60"P#F$ K@YH *P0
M;@"J$'0 J1%Z *<1@ "F$H8 I!*- *,3E0"A$Y\ GQ2J )X5N "<%<D FA;?
M )@7\@"6%_\ E1C_ )07_P&4%_\!E!?_ ?\1  #O&@  Y"0  -HH  #1)@
MRQ\  ,<4! # $!< N14G +,8-0"N&D( JAM, *<<5 "E'5P HQYC *$>:0"@
M'V\ GA]U )P@? ";((( FB"* )@@D@"7()L E2&F ),AM "2(<4 D"': (XB
M[P&,(OX"BR+_ HHB_P.)(?\#B2'_ _H8  #I)P  W3$  -$U  #(-0  P3
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M#&\W_PQO-O\,;S;_#.DS  #90@  RTL  ,!/  "V4   KDT  *9'  ">0
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M&-I)  #*5@  OET  +-A  "J8P  H6(  )=>  ",60  @E0! 'Q3$P!W5"$
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M(D-4EB%!5:8@0%6Y(#]5TQ\^5.P>/E/['CY3_QT^4O\=/E+_'=!7  #!80
MMF@  *QM  "D<   FG   )!N  "":   =V0  &UB!@!G8A8 9&(C &!B+0-;
M834'5V [#%->01%/74<52UQ,&DA:4QU%6EH@0UIC(4%:;2% 6GD@/UJ&'SY;
ME1X]6Z4=/%NX'#I;TALY6NL;.5G[&SA8_QLX6/\;.%C_&\M<  "^9@  LVP
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M"RURSPHL<>D+*V_Y#2IN_PXI;?\/*6W_#[YL  "T=0  JWP  *.!  ";A0
MDH8  (B&  !ZA   :X$  %V   !/?@  1GT- $-]&P!!?B4 /GTN 3M]-@0X
M?3T&-7Q$"#-\3 HQ?%4*+WQ>"BY\:0HM?'4)+'R#""M[D0<I>Z(&*'NU!2=Z
MS@4F>>D%)7CY!R1V_PDC=?\*(W7_"KIR  "P>P  J((  *&(  "9BP  D(T
M (2,  !VBP  9HD  %B(  !+AP  /88$ #>&$@ UAQX -(<G #&', $OAC@"
M+89 !"N&204IAE$%)X9;!":&9@0EAG,#)(6  R*%CP(AA: "'X2T 1Z$S $=
M@N@!'('Y QR _P0;?_\%&W__!;5Z  "M@P  I8H  )Z/  "6D@  BY,  '^3
M  !QD0  89   %.0  !&D   .)   "R0!P HD!0 )I > "21*  CD3$ (9$Z
M ""10P$>D$P!'9!6 !N08@ :D&X &)!\ !:/C  4CYT $HZQ !"-R0 0C.4
M$8OW !&*_P$0B?\!$(G_ ;&"  "IB@  HY$  )R6  "2F   A9D  'B9  !J
MF   6Y<  $R8   _F   ,YD  ">9   ;FP8 %IL2 !6;'0 3FR8 $ILP !&;
M.0 .FT, #)M.  J;6@ (FV< !YIU  6:A0 #F98  )BJ  "7P0  EML  )7N
M  "4^@ !D_\  9/_ *V+  "GD@  H)@  )B<  "+G@  ?I\  '"?  !BG@
M5)\  $:@   XH0  +*(  ""C   6I   "Z8$  .F#P  IQH  *<D  "G+@
MIS@  *9#  "F3P  IET  *9K  "E?   I8T  *2A  "BMP  H-,  )_K  "?
M]0  G_P  )_\ *J4  "DF@  G)\  )"B  "#HP  =:0  &>E  !9I0  2Z8
M #VH   PJ0  )*L  !FL   /K@  !:\   "P!   L0X  +$8  "R(@  LBP
M +(V  "R0@  LD\  +-?  "R<   LH(  +&6  "PJP  K\4  *WC  "L\P
MJ_T  *O] *><  "@H@  E:4  (BG  !ZJ0  :ZH  %VK  !/K   0:X  #2P
M   GL@  '+0  !&V   'MP   +D   "Z    NP$  +P)  "]%   OAX  +\H
M  # ,P  P3\  ,).  ##8   PW,  ,*(  #"G@  P;4  ,#1  "_YP  OO4
M +[U *.C  "8IP  C*H  'ZL  !OK@  8+   %*R  !$M   -K8  "FX   =
MNP  $KT   ?     P@   ,,   #$    Q@   ,@   #*!   S T  ,X8  #0
M(P  TB\  -0\  #830  V6   -IV  #:C0  V:0  -B[  #8T@  V.<  -CG
M )NI  "/K   @:\  '*R  !CM   5;<  $>Y   XO   *[\  !["   2Q0
M!\@   #+    S@   ,X   #0    TP   -4   #8    VP   -X$  #A$0
MY!T  .8J  #J.0  [4P  .]A  #P>   \8\  /&C  #PM0  \,<  /#' )*N
M  "%L0  =K4  &>X  !8NP  2;\  #K"   LQ@  '\D  !/,   %T    -0
M  #8    W    -P   #>    X    .(   #E    Z    .P   #O    \P4
M /45  #X)   ^S8  /Y*  #_8   _W<  /^,  #_G   _ZD  /^I /\ #P;_
M  P$_P + _\ #@'_ !H _P I /\ . #_ $4 _P!1 /\ 6P#_ &4 _P!M /\
M= #_ 'H _@"  /P A0#[ (H ^0"/ /@ E #W )H ]P"A /8 J0#T +, \P"_
M /( T0#O .< [@#Y .T _P#M /\ [0#_ .T _P#M /\ [0#_ /\ # ;_  D$
M_P ( _\ "@'_ !< _P E /\ - #_ $$ _P!- /\ 6 #] &$ ^P!I /D <0#W
M '< ]0!] /, @@#Q (< \ ", .\ D0#N )< [0"= .P I0#J *X Z0"Z .8
MR@#D .$ XP#T .$ _P#A /\ X0#_ .$ _P#? /\ W@#_ /\ !@7_  ,$_P !
M O\ "@'_ !0 _P A /T +P#Z #P ^ !) /8 4P#S %T \0!E .X ;0#K ',
MZ0!Y .< ?@#F (, Y0"( .0 C0#B ), X0"9 -\ H0#= *H V@"U -< Q #6
M -H U #N -, _0#2 /\ T #_ ,T _P#, /\ RP#_ /\   7_   #_P   O\
M!P'_ !  ^0 < /, *@#P #@ [0!$ .L 3P#H %D Y !A .$ :0#> &\ W !U
M -H >@#9 '\ UP"$ -4 B0#4 (\ T@"5 ,\ G0#- *8 R@"P ,@ O@#' -(
MQ0#G ,0 ^0#  /\ O@#_ +T _P"] /\ O0#_ /\   3_   "_P   ?\  @#^
M  D [P 6 .D ) #E #( X0 _ -X 2@#: %0 U0!= -( 9 #/ &L S0!Q ,L
M=@#* 'L R "  ,8 A0#$ (L P@"1 ,  F0"^ *$ O "L +H N0"X ,H M@#A
M +, \P"Q /\ L0#_ +  _P"P /\ L #_ /\   /_   !_P   /P   #S  (
MY0 / -\ '@#9 "L U  Y ,\ 1 #+ $\ QP!8 ,0 7P#" &8 OP!L +X <@"\
M '< N@!\ +@ @@"V (< M0". +, E0"Q )X KP"H *T M "J ,4 J #; *<
M[@"F /H I0#_ *4 _P"D /\ I #_ /\   '_    \0   .D   #A    VP '
M -0 %@#- "4 QP R ,( /P"^ $D N@!2 +< 6@"U &$ LP!G +$ ;0"O ',
MK@!X *P ?@"J (0 J0"* *< D@"E )L HP"E *$ L0"@ ,$ G@#5 )T Z0";
M /< F@'_ )D!_P"9 ?\ F '_ /\   #Q"   YA(  -T4  #5#@  SP4  ,D
M#0#" !P O0 J +< . "S $, KP%- *P#50"J!%P J 5C *8%:0"D!FX HP9T
M *$'>@"@!X  G@B' )P)CP";"9@ F0JC )<*KP"6"K\ E O4 )(-Z@"1#OH
MCP__ (\/_P".#_\ C@__ /D)  #J&   WB$  -,D  #*(@  PQL  +X.  "Y
M!A0 L@HC *T.,0"H$3T I1)' *(33P"?%%< G15> )L59 ":%FH F!9P )<6
M=@"5%WT E!>$ )(7C "1&)4 CQB@ (T8K ",&+P BAG1 (@:Z "'&_D A1O_
M 84;_P&$&O\!A!K_ ?(6  #D)0  UBX  ,HR  #!,0  NBL  +0A  "N%@L
MJ!D= *,<*P">'C< FQ]" )@@2P"5(%( DR%9 )$A7P"0(64 CB%L (TB<@"+
M(GD BB*  (@CB "'(Y$ A2.< (0CJ0""([@ @23- 7\DY %])/<"?"3_ GLD
M_P-[(_\#>R/_ ^TA  #>+P  SS@  ,,\  "[/   LS<  *PP  "F)04 GR07
M )HG)@"5*#( DBD] 8\I1@&,*DX!BBI5 8@J6P&'*F$!A2IG 80K;@&"*W0"
M@2M\ G\KA )^+(X"?"R9 GLLI0-Y++4#>"S( W8LX01T+/4%<RO_!7(K_P5R
M*_\%<2K_!N@J  #8.0  R4(  +Y%  "U10  K4$  *4Z  ">,@  ERT2 )(P
M(0"-,"T!B3$X X8Q00.$,4D$@C%0!( Q5@1^,5P$?3%B!'LQ:01Z,7 %>#)X
M!7<R@ 5U,HH%<S*5!G(RH@9P,K$&;S+%!VTRW0=K,O((:C'_"&DQ_PAI,?\(
M:3'_".,R  #30   Q4@  +I,  "Q3   J$D  *!#  "8/   D#4, (LW'0"&
M-RD"@C<S!'\W/ 9\-T0'>C=+!W@V4@=V-E@(=#9>"',V90AQ-FP(<#=T"6XW
M?0EL-X<):S>2"FDWGPIG-ZX+9C?!"V0WV@QB-_ ,83;^#&$V_PQA-O\+83;_
M"]\Y  #.1@  P4X  +91  "M4@  I5   )Q*  "30P  BCT( (4]&0" /B4!
M?#TO!'@\. =U/$ )<CM'"G [30MN.U0+;#M:"VH[8 QI.V@,9SMP#68[>0UD
M.X,-8CN/#F$[G Y?.ZL/73N^#UL[UA!:.^X06CO]#UDZ_P]9.O\/63K_#ML_
M  #*3   OE,  +-6  "J5P  H54  )A0  "/2@  A4,# ']#%0![1"(!=D,L
M W)"-0=N03P*:T!##&@_20UF/T\.9#]6#V(_7!!A/V007S]L$5X_=A%</X 2
M6S^,$ED_F1-7/Z@353^[%%0_TQ13/^P34S[\$U,^_Q)3/?\14SW_$=A$  #'
M4   NU<  +%;  "H7   GUH  )55  "+4   @4H  'I($0!U21\ <4@I FQ'
M,@9H13D)9$1 #&%#1@]?0TP17$)2$EM"61-90F 46$)I%59#<A550WT64T.)
M%E%#EA900Z873D.X%TQ"T!=,0NH73$+[%4Q!_Q5,0?\43$'_%-1)  #$5
MN%L  *Y?  "F8   G%\  ));  "(50  ?4\  '5-# !P31L ;$TF 6=,+P5C
M2S8(7TD]#%M(0@]81T@25D9.%%1&51921ET74$9E&$]&;QE-1WH93$>&&4I'
ME!E)1Z091T>V&45'SAE%1N@914;Z&$5%_Q=%1?\61D7_%M!.  #!6   MEX
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M%397RA0U5^44-%7W%3-4_Q8S5/\6,U/_%L9;  "Y9   KVH  *9O  "=<0
ME'$  (IP  !\:P  <6@  &1E  !98@L 56(9 %-B) !/8BP"3&$T!4A@.@E%
M7T -05Y&$#Y>31,[7545.5U>%3A=:!4W7G04-EZ!$S5>CQ(T7I\1,UZQ$#)>
MR0\Q7>0/+USW$2Y:_Q(N6O\3+EG_$\)@  "V:0  K&\  *1T  ";=@  DG<
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M QUR_P4<<?\&'''_!K5R  "L>@  I8$  )V&  "6B0  C8H  (&)  !SAP
M8X4  %6#  !(@@  .H$  "^!"@ L@1< *H$@ "B!*@ G@3( )8$Z 2.!0P$A
M@4P!((%6 1^!8 $=@6T!&X%Z !J B0 8@)D %G^L !1^PP 3?=\ %'ST !1[
M_P$4>O\"%'K_ K%Y  "I@0  HH@  )N-  "4CP  B)   'R/  !MC@  7HP
M %"+  !"BP  -8L  "B*   ?BPL '(L7 !J+(  9BRD %XLR !:+.P 5BT4
M$XM/ !&+6@ /BV< #8MU  J*A  (B90 !HBG  2'O0 $AM8 !(;L  6$^@ &
M@_\ !H/_ *V!  "FB0  H(\  )F3  "/E0  @Y8  '65  !FE   6),  $F3
M   [DP  +Y0  ".4   8E0  #)8*  F6%@ 'E2  !I8I  66,@ #E3P  I5'
M  "54P  E6   )5N  "4?0  DXX  ).@  "1M0  D-   (_G  "/]   COL
M ([^ *J*  "DD0  GI8  )69  ")FP  >YL  &V;  !>FP  4)L  $&;   T
MG   *)T  !R>   2GP  !J !  "@"P  H!8  * ?  "@*   H3(  *$]  "@
M20  H%8  *!E  "@=0  GX8  )Z8  "=K0  G,<  )KD  "9]   F?L  )G]
M *>3  "AF0  F9T  (Z?  "!H0  <J$  &2A  !5H@  1Z(  #FD   LI0
M(*8  !6G   *J    *D   "J 0  JPH  *L4  "K'0  K"8  *PP  "M/
MK4D  *U8  "M:   K7H  *R.  "JI   J;P  *C:  "G[P  IOH  *;] *2;
M  "=H   DJ,  (6E  !WI@  :*<  %JH  !+J0  /:H  #"L   CK0  %Z\
M  NP   "L0   +,   "T    M0   +8%  "W$   N!D  +DB  "Z+0  NSH
M +Q(  "]60  O6P  +V   "\E0  NZP  +G(  "WY   MO0  +;X *&B  "6
MI0  B:@  'NJ  !LJP  7:T  $^N  ! L   ,K(  "6T   8M@  #+@   *Z
M    O    +T   "^    P    ,$   ##    Q0@  ,<3  #*'0  S"D  ,XV
M  #11P  TEH  -)P  #3A@  TIP  -*S  #1R@  T>   -'F )FH  "-J@
M?ZT  &^P  !@L0  4K,  $.V   TN   )[L  !J]   ,P    L,   #&
MQP   ,@   #)    RP   ,X   #0    TP   -8!  #:#   WA@  .(E  #E
M,P  Z48  .M;  #L<@  [(H  .R@  #LLP  [,0  .S+ )"L  ""KP  <[,
M &2U  !5N   1KL  #>_   HP@  &\4   W(   !RP   ,\   #2    U
M -0   #6    V0   -L   #>    X0   .4   #I    [04  /$2  #T(
M^#   /Q%  #^6P  _W(  /^(  #_F@  _Z@  /^M /\ "P3_  D"_P ' ?\
M" #_ !@ _P G /\ -0#_ $( _P!- /\ 6 #_ &$ _P!J /\ <0#\ '< ^P!]
M /H @@#Y (8 ^ "+ /< D0#V )< ]0"= /0 I0#S *X \0"Z .X RP#L .(
MZP#V .L _P#J /\ Z #_ .4 _P#B /\ W@#_ /\ !P3_  0"_P # ?\ " #_
M !0 _P C /\ ,0#_ #X _P!* /X 5 #[ %X ^ !F /4 ;@#S '0 \@!Y /
M?@#O (, [@"( .T C0#L ), ZP"9 .D H0#G *H Y "U .( Q0#@ -H WP#Q
M -X _P#: /\ U@#_ -0 _P#4 /\ U #_ /\  03_   "_P   ?\  P#_ !$
M_@ > /L + #X #D ]@!% /0 4 #P %H [ !B .D :@#H '  Y@!U .4 >P#C
M '\ X@"$ .  B0#? (\ W0"5 -H G0#8 *4 U0"P -, O@#1 -( SP#K ,L
M_ #' /\ Q@#_ ,8 _P#& /\ Q@#_ /\   /_   "_P   /\   #[  H ]  9
M /  )P#M #0 Z@!  .< 2P#B %8 WP!> -P 90#: &P V !Q -8 =@#4 'L
MT@"  -$ A0#. (L S "1 ,H F #( *$ Q0"K ,, N #! ,L O0#C +H ]@"Y
M /\ N0#_ +D _P"Y /\ N #_ /\   +_   !_P   /\   #P  4 Z@ 3 .4
M(@#A "\ W  [ -< 1P#3 %  T !9 ,T 8 #* &< R !M ,8 <@#$ '< P@!\
M ,  @0"_ (< O0"- +L E "Y )T MP"G +, LP"P ,0 KP#: *X \ "M /\
MK #_ *P _P"K /\ JP#_ /\   '_    ^P   .\   #F    WP , -D &P#2
M "@ S0 V ,D 00#% $L P@!4 +\ 6P"\ &( N@!H +@ ;0"V ', M !X +,
M?0"Q (, KP") *T D "K )D J "B *8 K@"E +T HP#2 *( Z0"A /D H #_
M )\ _P"> /\ G@#_ /\   #V    [    .,   #;    TP % ,P % #% "(
MP  O +P .P"X $4 M0!. +$ 5@"O %T K0!C *L :0"J &X J !S *8 >0"E
M '\ HP"% *$ C "? )4 G0"> )P J@": +@ F #, )< XP"5 /, E #^ ),
M_P"3 /\ D@#_ /H   #L!@  X0X  -<0  #."0  QP   ,$ "P"[ !H M0 G
M +$ ,P"M #\ J0!( *8 4 "D %< H@!> *  9 "> &D G0!O )L =0": 'L
MF "! )8 B0"5 )$ DP"; )$!IP"/ ;4 C@+( (P#W@"+!?$ B0;^ (@'_P"'
M!_\ AP?_ /((  #E%P  V!\  ,PB  ##'@  O18  +<*  "Q !$ JP ? *8$
M+0"B!S@ GPA" )P)2P"9"E( EPM9 )8,7P"4#&4 D@QJ )$,< "0#7< C@U^
M (P.A@"+#H\ B0Z: (@/I@"&$+4 A!#( (,1X "!$_0 @!3_ '\4_P!^%/\
M?A/_ .T6  #>(P  T"P  ,0O  "[+   M"<  *T=  "H$08 H@\8 )P3)@"8
M%3( E18] )(710"0&$T C1A4 (P96@"*&6  B!EF (<:; "&&G, A!IZ (,;
M@@"!&XL @!N6 'X;H@!]&[$ >QS$ 'D<W !X'?$ =AW_ 78=_P%U'?\!=1S_
M ><A  #8+@  R#8  +XY  "U.   K3,  *8K  "?(0  F1L2 ),>(0"/("T
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M!F0RF09B,J@'8#*Z!UXRT0A=,NH(7#'["%LQ_PA;,/\(6S#_"-@Y  #(10
MO$L  +%.  "H3P  GTP  )=&  ".0   A#@" 'XV$P!Z-R  =3<J G(V,P1O
M-CL%;#9"!FHV20=H-4\'9C55!V4U7 AC-6,(8C9K"& V= E?-GX)73:)"5LV
ME@I:-J4*6#:W"U8VS@M5-N@,5#7Z"U0U_PM4-?\+5#3_"]0_  #%2@  N5
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M%$!"QA0_0N(3/T+V$S]!_Q) 0/\20$#_$LI-  "\5@  L5P  *A@  "?80
MEF   (Q<  " 5P  =5(  &E, @!C2Q( 7TL> %M+)P%82B\$5$DU!U!(.PM-
M1T$-2T='$$A&3A)&1E441$9>%4-&:!5!1W,50$=_%3]'C14]1YP4/$>N%#I'
MQ!,Y1^ 3.4;U$SE&_Q,Y1?\3.47_$\=1  "Z6@  KV   *9D  "=90  E&0
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M"RE7_PTH5O\.*%7_#KU?  "R9P  J&T  *!Q  "8=   CW0  (5R  !W;@
M;&P  %YI  !090  1F,, $-C&0!!8R, /F,K 3MB,@,X8CD%-6% "#-A1PDQ
M84\*+V%8"BYA8@HM8FX)+&)[""MBB0<I8ID'*&&K!B=AP 4F8=P%)5_R!R1=
M_PDC7/\*(US_"[ED  "O;   IG(  )YW  "6>0  C7H  (-Y  !V=@  :7,
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M  J&-  )ACX "(5(  :%4P $AF   H5M  "%?   A(P  (.>  ""L@  @,T
M '_D  !_\P  ?OL  'W_ *J   "DB   G8T  )>1  ",DP  @),  '*2  !C
MD0  5)   $6/   XCP  *X\  !^/   4CP  ") &  "0$0  D!H  ) C  "0
M+   D#8  )!   "03   D%@  )!F  "/=0  CX8  (Z8  ",K   B\0  (GB
M  "(\@  B/D  (?^ *>)  "AD   FY4  )*7  "&F   >)@  &J8  !;EP
M3)<  #V7   PF   ))@  !B8   ,F0   IH   ":"   FA(  )H;  ":)
MFRP  )LW  ";0@  FT\  )M=  ";;0  FGX  )F0  "8I   E[P  );9  "4
M\   D_H  )/_ *21  "?EP  EYL  (N=  !^G@  ;YX  &">  !2G@  0Y\
M #6@   HH   '*$  !"B   %HP   *0   "E    I08  *40  "F&   IB$
M *<K  "G-@  IT(  *=1  "H8@  IW0  *>'  "FFP  I;(  *3.  "BZ0
MHO8  *'] **:  ";G@  D*$  (.B  !THP  9:0  %:D  !(I0  .:<  "NH
M   >J0  $JH   :L    K    *X   "O    KP   + "  "Q"P  LA4  +,>
M  "T*   M30  +9!  "W4@  MV4  +=Y  "UC@  M*8  +/   "SW0  LN\
M +'W )^A  "3I   AJ8  'BH  !IJ0  6JH  $NK   \K0  +JX  ""P   4
ML@  ![0   "U    M@   +@   "Y    N@   +P   "]    OP0  , .  ##
M&   Q20  ,<Q  #)00  RU0  ,UI  #-?@  S94  ,RL  #)Q@  R-X  ,?L
M ):F  "*J0  ?*L  &VM  !>K@  3[   $"R   PM0  ([<  !:Y   'O
M +X   #!    P0   ,,   #$    Q@   ,@   #*    S0   -    #3!P
MV1,  -P?  #?+0  XT   .55  #F;   YX0  .B:  #GK@  Y[\  .?, (VK
M  " K0  <;   &&R  !2M0  0[@  #.[   DO@  %\$   G#    QP   ,H
M  #-    S@   ,\   #0    T0   -0   #8    W    .    #D    Z
M .T,  #Q&P  ]"H  /@_  #[5@  _&X  /R%  #\F0  _*<  /RQ /\ !P+_
M  4!_P ! /\ !@#_ !4 _P D /\ ,@#_ #X _P!* /\ 50#_ %\ _@!G /P
M;@#[ '0 ^@!Z /D ?P#X (, ]P"( /8 C0#U ), ] "9 /( H0#O *H [0"V
M .P QP#J -X Z0#S .< _P#B /\ W@#_ -X _P#9 /\ U@#_ /\  @+_   !
M_P   /\  P#_ !( _P @ /\ +0#_ #H _P!& /L 40#W %L ] !C /( :@#Q
M '  \ !V .X >P#M (  [ "$ .L B0#I (\ YP"6 .4 G0#C *8 X0"Q -\
MP #= -4 V@#L -0 _P#1 /\ T #_ -  _P#0 /\ S0#_ /\   +_   !_P
M /\   #_  P ^P ; /@ *0#V #8 \P!" .\ 30#K %< Z0!? .< 9@#E &P
MXP!R .$ =P#@ 'P W@"! -P A@#: (L V "2 -4 F0#3 *$ T0"L ,\ N0#+
M ,T Q@#F ,0 ^@## /\ P@#_ ,( _P#" /\ P@#_ /\   '_    _P   /X
M  #V  < \0 6 .T (P#I #$ Y  ] .$ 2 #> %( VP!: -@ 8@#5 &@ TP!M
M -$ <P#/ '@ S0!] ,L @@#) (< QP"- ,4 E0## )T P0"G +T M "Y ,4
MMP#> +8 \P"U /\ M #_ +0 _P"T /\ M #_ /\   '_    _P   /,   #K
M  ( Y0 0 .  '@#9 "L U  X -$ 0P#. $T RP!5 ,@ 7 #% &, P@!I ,
M;@"_ ', O0!X +L ?0"Z (, N ") +8 D "S )@ L "B *X K@"L +T J@#4
M *D ZP"H /P IP#_ *< _P"G /\ I@#_ /\   #_    \    .@   #@
MV  * -  & #+ "8 Q@ R ,( /0"_ $< O !0 +D 5P"V %X M !D +( :0"Q
M &X KP!T *T >0"L 'X J0"% *< C "F )0 I "= *( J "@ +< G@#* )T
MXP"< /8 FP#_ )H _P": /\ F0#_ /\   #Q    YP   -T   #3    RP #
M ,0 $@"_ !\ N@ K +4 -P"R $$ KP!* *P 4@"J %@ IP!? *8 9 "D &H
MH@!O *$ = "? 'H G@"  )P AP": (\ F "9 )8 I "4 +$ DP## )$ W "0
M /  CP#] (T _P", /\ C #_ /4   #H!   W L  - +  #'!@  P    +H
M"0"T !< K@ D *H +P"G #H HP!$ *$ 3 "> %, G !9 )H 7P"9 &4 EP!J
M )8 ;P"4 '4 DP!\ )$ @P"/ (L C0"5 (L H "* *X B "_ (8 U0"$ .L
M@P#Y (( _P"" /\ @0#_ .T'  #@%0  T1T  ,8>  "]&@  MA$  + %  "J
M  X I0 < *  * "< #, F0 ] )8 1@"4 4T D@)4 ) #6@". U\ C01E (L$
M:P"*!'$ B 5X (8%@ "%!H@ @P:2 ($&G@" !JP ?@:\ 'T'TP![">H >@OZ
M 'D+_P!X"_\ > O_ .<5  #8(@  R2H  +XK  "V*   KB,  *<9  "A# 0
MFP44 )8)(@"2"RT CPPW (P.0 "*#T@ B!!/ (8050"$$5L @Q%A ($29P"
M$FT ?A)T 'T3? ![$X8 >A.0 '@3G !V$ZH =12\ ',4TP!Q%NL <!;\ &\6
M_P!O%O\ ;Q;_ .$A  #0+0  PS0  +@V  "O-   J"\  * G  "9'0  DA,,
M (T5' ")%R@ A1DR (,:.P"!&D, ?QM* 'T;4 ![&U8 >AQ< '@<8@!W'&D
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M!M$Y  #"0P  MTD  *U,  "D2P  FT@  ))"  ")/   ?S0  '<N# !S+QH
M;S E &LP+@%H,#8"9C ] V0P1 1B,$H$8#!0!%\P5P1=,%X%7#!F!5HP;P59
M,7D&5S&$!E8QD094,9\'4C&P!U$QQ@=/,>$(3C#U"$XP_PA.+_\(3B__",T_
M  "_2   M$X  *I1  "A40  F$X  (Y(  "%0P  >SP  '(U" !L-18 :38A
M &4V*@)A-3(#7S4Y!5PU0 9:-$8&6#1,!U<T4P=5-%H(5#5B"%,U:PA1-78)
M4#6!"4XVC@E,-IT*2S:N"DDUPPM(-=X+1S7T"T<T_PM'-/\+1S/_"LI$  "\
M3   L5(  *A5  "?5@  EE,  (Q.  ""20  >$,  &T[! !G.A, 8SL> %\[
M)P%;.B\#6#DV!58Y/ =3.$((43A("5 X3PI..%<*33E?"TLY: M*.7,,2#I_
M#$<ZC Q%.IL-0SJL#4(ZP0U .=P-0#GS#4 X_PU ./\-03?_#,=(  "Z40
MKU8  *99  "=6@  E%@  (E3  !_3@  =4D  &E"  !A/PX 74 ; %I ) %6
M/RP#4SXS!4\].0=-/3\)2SU%"TD]3 Q'/50-1CU<#D0]90Y#/G .03Y\#D ^
MB@X^/ID./#ZJ#CL^OPXZ/MH..3[Q#CD]_PXZ//\..CS_#L1,  "W5   K5H
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M"2Q/NP@J3]8(*4[N"2A,_0LH2_\,*$O_#;M9  "P80  IV8  )YJ  "6;
MC6L  (-I  !V9   :V(  %Y>  !16@  1E8+ $)6%P! 5B$ /58I 3I6, ,W
M5C8%-54]!S)51 @P54P)+U55"2U57PDL5FH)*U9W""I6A0<I5I0&*%:F!B=6
MN@4E5M4$)%3N!B-3_0@B4O\)(E'_"KA>  "N9@  I6L  )QO  "4<0  BW$
M (%O  !T:P  :6D  %QF  !.8@  0%X& #I=$@ X71P -ETE #-=+0$Q730"
M+UT[!"U=0@4K74H%*5U3!BA=704G76D%)5UU!"1=@P,C79,#(EVD B!=N0(?
M7-0!'EOM QU9_ 4=6/\&'%C_![5C  "K:P  HW$  )MU  "3=P  BG<  (!V
M  !S<P  9G   %AM  !*:@  /&<  #)E#  O91< +64@ "ME*  I93 !)V4X
M 25E0 (D94@"(F51 B%E6P(?968!'F5S 1UE@@$;99$ &F2C !ADMP 78](
M%V+L !=@^P(68/\#%5__!+%I  "H<0  H'8  )E[  "1?0  B7X  ']]  !Q
M>@  8G<  %1T  !&<@  .&\  "MN!0 D;1$ (FT: "%M(P ?;2L 'FTS !QM
M.P ;;40 &6U- !AM6  6;6, %&UP !)M?P 0;8X #FR@  QKM  *:LT "VGH
M  QH^0 -9_\ #6;_ :YP  "F=P  GGT  )>!  "0A   AX4  'N#  !L@
M77X  $]\  !!>@  ,W@  "=W   ;=@@ %G83 !1V'  2=B0 $78L  ]V-0 -
M=CX #'9(  IV4P (=EX !G9L  1V>@ "=8H  '6;  !TK@  <L<  ''A  !P
M\@  ;_P  6[_ *IW  "C?@  G(0  ):(  ".BP  @XH  ':)  !GAP  5X4
M $F$   [@@  +H$  "&    6@   "8 )  2 %  "@!T  8 F  " +@  @#<
M (!"  " 30  @%D  (!F  !_=0  ?X4  'Z6  !]J0  >\$  'K>  !Y[P
M>/D  'C^ *=_  "AA@  FXP  )2/  "*D   ?9   &^/  !@C0  48P  $*+
M   TBP  )XH  !N*   0B@  !(L#  "+#   BQ8  (L>  "+)P  BR\  (LZ
M  "*10  BE$  (M?  "*;@  BGX  (F0  "'HP  AKL  (38  "#[P  @OL
M (+_ *2(  "?C@  F9,  )"5  "#E@  =I4  &>4  !8E   29,  #J3   M
MDP  (),  !24   (E    )4   "5!0  E0T  )46  "5'@  E2<  )8P  "6
M.P  E4@  )96  "690  E78  )6(  "4G   D[(  )'.  "0Z0  CO@  (W_
M **0  "=E@  E9D  (F:  ![FP  ;)L  %V:  !/F@  /YL  #&<   DG
M%YT   J=    G@   )\   "@    H ,  * ,  "@%0  H1T  *$F  "A,
MHCT  *)+  "B6P  HFP  *)_  "ADP  H*D  )_#  ">X0  G?(  )W\ *"8
M  "9G   C9X  ("@  !QH0  8J$  %.A  !$H@  -:,  ">D   :I0  #:8
M  &G    J    *D   "J    JP   *L   "K!P  K!   *T9  "O(@  L"T
M + [  "Q30  L6   +!T  "PB   L)X  *^V  "NTP  KND  *WV )R?  "1
MH@  A*0  '6E  !FI@  5Z<  $BH   YJ0  *JL  !VL   .K@   J\   "Q
M    L0   +,   "T    M0   +8   "W    N $  +H*  "]%   OQ\  ,$K
M  ##.P  Q4T  ,=B  #&>   Q)   ,*H  #"P0  P=D  ,'K )2D  "(IP
M>JD  &NJ  !;K   3*T  #RO   ML0  '[,  !&U   #MP   +H   "\
MO    +X   "_    P0   ,,   #%    QP   ,H   #- P  T@T  -0;  #8
M*0  W#L  -]0  #B9@  XGT  ..3  #AJ   X+P  -_1 (NI  !^K   ;JX
M %^P  !0L@  0+4  #"W   @N@  $[T   2_    P@   ,4   #(    R
M ,H   #+    S    ,\   #2    U@   -H   #>    XP   .D'  #M%@
M\"4  /0Z  #V4@  ^&H  /F!  #YE0  ^J0  /FQ /\  @'_    _P   /\
M! #_ !( _P @ /\ +@#_ #L _P!' /\ 4@#^ %P _ !D /L :P#Z '$ ^ !V
M /< >P#V (  ]0"% /0 B@#R (\ \ "6 .X G@#M *< ZP"R .H P0#H -D
MY #Q -X _P#; /\ W #_ -D _P#3 /\ T #_ /\   '_    _P   /\   #_
M  X _P < /\ *@#] #< ^@!# /< 3@#T %@ \@!@ /  9P#O &T [0!S .P
M> #J 'P Z0"! .< A@#E (P XP"2 .$ F@#@ *( W@"M -L NP#7 -$ T0#J
M ,X _0#- /\ S0#_ ,T _P#) /\ Q@#_ /\   '_    _P   /\   #]  D
M^0 7 /4 )0#Q #, [0 _ .L 20#H %, Y0!; ., 8@#A &D WP!N -T = #;
M '@ V0!] -8 @@#5 (@ TP". -$ E0#/ )X S0"H ,@ M0## ,D P0#B +\
M]P"_ /\ O@#_ +X _P"^ /\ O #_ /\   #_    _P   /D   #R  0 [0 3
M .@ ( #B "X W@ Z -P 1 #9 $X U0!6 -( 7@#0 &0 S0!J ,L ;P#) '0
MR !Y ,8 ?@#$ (, PP") ,$ D0"^ )D N@"C +< KP"U ,  LP#7 +( \ "Q
M /\ L #_ *\ _P"O /\ KP#_ /\   #_    ]P   .X   #F    X  - -@
M' #2 "@ S@ T ,L /@#( $@ Q0!1 ,$ 60"_ %\ O0!E +L :@"Z &\ N !T
M +8 >0"U '\ L@"% +  C "N )0 K "> *H J0"H +@ I@#, *4 YP"C /H
MH@#_ *( _P"B /\ H@#_ /\   #V    [    .,   #:    T  ( ,D %@#$
M "( P  N +P .0"X $( M@!+ +, 4P"Q %H KP!@ *T 90"K &H J0!P *<
M=0"F 'H I "  *, AP"A (\ GP"8 )T I "; +$ F0## )@ W0"7 /, E@#_
M )4 _P"4 /\ E #_ /D   #L    X0   -8   #,    Q  ! +X #P"X !P
MLP H *\ ,P"L #P J0!% *8 30"D %0 H@!: *  8 "> &4 G0!J )P < ":
M '4 F0![ )< @@"5 (H DP"3 )$ GP"/ *L C0"\ (P TP"* .P B0#\ (D
M_P"( /\ AP#_ /    #B @  U0@  ,D(  #! 0  N@   +, !P"M !4 J  A
M *0 + "@ #8 G0 _ )L 1P"9 $X EP!4 )4 6@"3 &  D@!E )  :P"/ '
MC0!W (L ?@"* (8 B "/ (8 F@"$ *< @@"W ($ S0"  .8 ?@#V 'T _P!\
M /\ ? #_ .@'  #:%   RQL  , :  "X%@  L P  *H!  "D  P G@ 9 )H
M)0"6 "\ DP Y )  00". $@ C !/ (H 50") %L AP!@ (8 9@"$ &P @@!R
M ($ >@!_ (( ?0", 'P EP!Z *0 > "T '< R !U >$ = +S ',#_P!R _\
M<@/_ .$5  #0(0  PR<  +DH  "P)0  J1\  *(5  ";" ( E0 1 )  '@",
M BD B0,S (8%.P"$!D, @@=) ( (4 !_"%8 ?0A; 'P)80!Z"6@ > EO '<*
M=@!U"G\ <PJ* '(*E0!P"Z, ;PNS &T+R !K#>( :@[U &D._P!I#O\ : [_
M -L@  #*+   OC$  +,S  "J,0  HBL  )LD  "3&0  C T' (<,%P"##B(
M?Q M 'T1-0![$CT >1-$ '<42P!U%%$ <Q17 '(470!P%6, ;Q5K &T5<P!L
M%7P :A:' &@6DP!G%J$ 91:Q &,7QP!B&.$ 81CU & 8_P!?&/\ 7QC_ =0J
M  #%-   N3H  *X\  "F.@  G34  )4O  "-)@  A1P! 'X7$0!Z&1T =QHH
M '0;,0!R&SD <!Q  &X<1P!L'4T :AU3 &D=60!G'6  9AYG &0>< !C'GD
M81^$ & ?D !>'Y\ 7!^O %L@Q !9(-X 6"#S 5<@_P)7'_\"5Q__ L\R  #
M.P  M4$  *M#  "B0@  F3X  )$X  "(,   ?R@  '<@"P!S(1D ;R(D &PB
M+0!J(S4 :",\ &8D0P!D)$D 8B1/ &$D50!?)%P 725D 5PE; %;)78!62:!
M 5<FC@%6)IP!5":L E,FP0)1)ML"4";R T\F_P-/)?\$3R7_!,HY  "]00
MLD<  *A)  "?2   ED4  (T_  "$.0  >S$  '$H!P!L*!4 :"D@ &4I*0!B
M*3$!8"HX 5XJ/P%<*D4"6BI+ EDJ4@)7*ED"5BM@ E0K:0-3*W,#42M^ U L
MBP-.+)D$3"RJ!$LLO@1)+-D%2"OP!4@K_P9(*O\&2"K_!L<^  "Z1@  KTP
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M"C4ZN HT.M(),SGL"C,X_ LT./\+-#?_"[]+  "S4P  J5@  *!;  "76P
MCEH  (16  !Y4   ;DP  &%&  !60 0 4#X1 $T_&P!*/R0!1SXK D0^,01!
M/3<&/ST^"#T]10D[/4P*.3U5"S<^7@LV/FD+-3YU"S,_@PHR/Y(*,3^C"3 _
MMPDN/] (+C[K"2T]^PHM//\++CS_"[Q/  "Q5P  IUP  )Y?  "58   C%X
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M AQ/^00<3O\%'$W_!K1=  "J9   H6D  )EM  "1;@  B&X  'YM  !Q:0
M9V<  %EC  !,7P  /5L  #)8"P O6!8 +5@? "M8)P I6"X )U@U 258/0(D
M6$4"(EA. B%86 (?6&,!'EEP 1U9?@$;6(T &EB> !E8L@ 75\L %U;G !=5
M^0$65/\#%5/_!+!B  "G:0  GV\  )=R  "0=   AW0  'US  !Q<   8VT
M %9J  !(9@  .F,  "U@!0 E7Q$ (U\: ")?(@ @7RH 'V Q !U@.0 <8$(
M&F!+ !E@50 78&  %6!M !1@>P 28(L $%^<  Y?L  ,7L@ #%WD  Y;]P .
M6O\!#EK_ :UH  "E;P  G74  )9X  ".>@  AGL  'QZ  !N=P  7W0  %%Q
M  !$;@  -6P  "AJ   <: D &6@3 !=H'  5:"0 %&@L !)H-  1:#T #FA'
M  UH40 +:%P "6AI  =H=P %9X<  V>7  )FJ@ !9<(  F3=  )C\  #8OT
M!&'_ *IO  "B=@  FWL  )1_  "-@0  A8(  'B   !J?0  6GH  $QX   ^
M=@  ,'0  "-S   8<@  #'$+  EQ%0 '<1X !G$F  1Q+P #<3@  7%"  !Q
M3   <5@  '%D  !P<P  <((  &^3  !OI@  ;KP  &S9  !J[0  :?@  &G^
M *=V  "@?0  FH,  ).&  ",B   @8@  '.&  !DA   5($  $:    W?@
M*GT  !Y\   2>P  !GL'  ![$   >QD  'LA  ![*0  >S$  'L[  !Z1P
M>U(  'M?  !Z;@  >GX  'F.  !XH0  =[<  '73  !T[0  <_@  '+] *1^
M  ">A0  F(H  )*-  "'C@  >HT  &R,  !=B@  3HD  #^(   QAP  )(8
M !>&   +A@   (8!  "&"0  AA(  (4:  "%(@  ABD  (8S  "%/P  A4L
M (58  "%9P  A'@  (.)  ""G   @;$  (#,  !_Z0  ??@  'W_ **'  "<
MC0  EY$  (V3  "!DP  <Y,  &21  !5D   1I   #:0   ICP  '(\  !"/
M   $D    )    "0 @  D D  ) 2  "0&@  D"$  )$J  "1-0  D$(  )%/
M  "17@  D6\  )"!  "/E0  C:H  (S$  "*XP  B?0  (G] *"/  ";E
MDY<  (:8  !XF0  :9@  %J7  !+EP  /)@  "V8   @F   $Y@   :9
MF@   )L   ";    FP   )L(  ";$   FQ@  )P@  "=*@  G38  )U$  ">
M5   GF4  )YX  "=C   G*(  )NY  ":U@  F.X  )?Y )Z7  "7FP  BYP
M 'Z>  !OG@  7YX  %">  !!G@  ,:   ".A   6H0  "*(   "C    I
M *4   "F    I@   *8   "G P  IPL  *@4  "I'0  JBD  *HW  "K1P
MK%D  *QL  "L@0  K)<  *NN  "JR0  J>,  *GQ )J>  "/H   @J(  '.C
M  !DHP  5*0  $6E   UI@  )Z@  !FI   *J@   *L   "M    K0   *X
M  "P    L0   +$   "R    LP   +4%  "W#P  N1D  +LE  "]-   OD@
M +]>  "^=   OHH  +ZA  "]N0  O=,  +SE )*C  "%I0  =Z<  &BH  !8
MJ0  2:H  #BL   IK@  &[    RQ    LP   +4   "W    MP   +D   "Z
M    O    +T   "_    P0   ,,   #&    RPD  ,X6  #2(P  U30  -E*
M  #<8   W'@  -F1  #8J   UKT  -;0 (FG  ![J@  :ZP  %RN  !-KP
M/+$  "RT   =MP  #;D   "[    O@   ,$   ##    PP   ,4   #&
MR    ,H   #-    T    -0   #9    W0   .,#  #G$@  ZR(  .\U  #S
M3   ]60  /9\  #VD0  ]Z(  /6O /\   #_    _P   /\  0#_  X _P =
M /\ *P#_ #@ _P!$ /X 3P#\ %@ ^@!@ /D 9P#W &T ]@!S /4 > #S 'T
M\@"" /  AP#O (P [0"3 .P F@#J *0 Z0"N .< O0#C -0 W0#O -H _P#9
M /\ V0#_ -, _P#. /\ R@#_ /\   #_    _P   /\   #_  L _P 9 /T
M)P#X #0 ]@!  /0 2@#Q %0 [P!< .T 8P#K &D Z0!O .< = #E 'D Y !^
M .( @P#A (D X "/ -X E@#< )\ V@"I -0 MP#/ ,P S #G ,L ^P#* /\
MR0#_ ,@ _P## /\ P #_ /\   #_    _P   /\   #Z  8 ]@ 4 /  (@#K
M "\ Z0 [ .< 10#C $\ X0!7 -T 7P#; &4 V0!K -8 < #5 '4 TP!Z -(
M?P#0 (0 SP"* ,T D@#* )H Q0"E ,( L0#  ,, O@#= +P ] "Z /\ N@#_
M +H _P"X /\ M0#_ /\   #_    _0   /4   #N  $ Z  0 .$ '0#= "H
MV0 V -8 0 #3 $H SP!2 ,L 6@#) &  QP!F ,4 :P#$ '  P@!U ,$ >P"_
M (  O0"& +H C0"W )8 M0"? +, JP"Q +H KP#1 *T [ "L /\ K #_ *L
M_P"K /\ JP#_ /\   #\    \@   .D   #A    V  * -$ &0#, "0 R  P
M ,4 .@#! $0 O@!- +L 5 "Y %L MP!A +4 9@"T &L L@!Q +  =@"N 'L
MK0"! *L B "I )  J "9 *8 I "D +, H@#& *  X0"? /@ G@#_ )T _P"=
M /\ G #_ /X   #Q    Y@   -T   #2    R@ & ,, $P"^ !\ N0 J +8
M-0"S #X L !& *T 3@"K %4 J !; *8 80"E &8 I !K *, < "A '8 H !\
M )X @P"= (H FP"4 )D GP"7 *P E0"] ), U@"1 /  D #_ (\ _P"/ /\
MCP#_ /0   #G    VP   ,X   #%    O@   +< # "R !D K0 D *D +@"F
M #@ HP!  *  2 "> $\ G !5 )L 6P"9 &  F !F )< :P"5 '$ E !W )(
M?@"0 (4 C@"/ (P F0"* *8 B "V (8 S0"% .@ A #[ (0 _P"# /\ @P#_
M .L   #= 0  S@8  ,0$  "[    LP   *T !0"G !( H@ > )X * ": #$
MF  Z )4 0@"3 $D D0!/ (\ 50". %L C !@ (L 9@") &L B !R (8 >0"$
M ($ @@"* ($ E0!_ *( ?0"Q 'P Q0!Z .  >0#U 'D _P!W /\ =P#_ .,&
M  #2$P  Q1@  +L7  "R$@  JP@  *0   ">  H F0 7 )0 (0"0 "L C0 T
M (H / "( $, A@!* (4 4 "# %4 @@!; (  80!_ &< ?0!M 'L =0!Z 'T
M> "& '8 D0!T )X <@"M '$ P !P -H ;@#O &T _ !L /\ ; #_ -L5  #*
M(   OB0  +0E  "K(0  HQL  )P1  "5!0  CP . (H &@"& "4 @P N (
M-@!^ #X ? !$ 'L 2@!Y %  > !6 '8!7 !T 6( <@)I '$"<0!O GD ;0.#
M &P#CP!J YP : .K &<#O@!E!-8 9 ;L &,'^P!B!_\ 8@?_ -,A  #$*@
MN"\  *XP  "F+0  GB@  )8@  ".%@  APH% ($$$P!]!1X >@<H '<(,0!T
M"3@ <@H_ '$*10!O"TL ;0Q1 &P,5P!J#%X : UE &<-;0!E#7< 8PZ! &(.
MC0!@#IL 7@^K %T0OP!;$-D 6A'O %D2_0!9$O\ 61'_ ,TI  "_,@  M#<
M *HY  "A-P  F3(  ) K  "((P  @!D  '@0"P!T$1@ <!(B &T3*P!K%#,
M:10Z &<500!E%4< 9!9- &(64P!@%EH 7Q=A %T7:@!<%W, 6AA^ %D8B@!7
M&)@ 5AFH %09O !2&=4 4AKN %$:_@!1&?\!4!G_ <DQ  "[.@  L#\  *=
M  ">/P  E3H  (PT  "#+0  >R0  '$<!0!L&1, :!H> &4;)P!C'"\ 81PV
M %\=/0!='4, 7!U) %H>4 !8'E8 5QY> %4?9P!4'W$ 4A]\ %$@B !/()8
M3B"F $P@N0!+(-,!2B#L 4D@_0))(/\"21__ L4W  "X/P  K40  *1&  ";
M10  DD$  (D\  " -0  =BX  &PE 0!D(0X 82$: %XB(P!;(RL 62,R %<C
M.0!5(S\ 5"1& %(D3 %1)%,!3R5; 4XE9 %,)6X!2R9Y 4DFA@%()I0"1B:D
M D0FMP)#)M "0B;K T$F_ -!)?\$023_!,(]  "U1   JTD  *%+  "82P
MCT@  (9"  !\/0  <S4  &@N  !?* H 6B@6 %<H'P!4*2< 4BDO 5 I-0%.
M*3P!3"E" DLI2 ))*5 "2"I8 D8J80-%*VL#0RMV T(K@P- +)($/BRB!#TL
MM00[*\X$.BOI!3HK^P4Z*O\%.BG_!;]!  "S20  J4X  )]0  "63P  C4T
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M!2<Y^ <G./\')S?_"+=.  "L50  HUH  )I<  "270  B5L  ']8  !S4P
M9T\  %Q*  !110  1#\& #X^$@ \/AL .3XB #<^*0$T/C ",CXV!# ^/@4O
M/D4&+3Y.!BP_6 8K/V(&*4!O!2A ? 4G0(L$)D"<!"1 KP,C0,<#(D#C R$^
M]P4A/?\&(3S_![52  "J60  H5X  )EA  "080  AV   'U>  !Q6   9E4
M %M2  !/30  04<" #A%#0 U1!< ,T4@ #%%)P O12X!+44T BM%/ ,I140$
M)T5,!"9%5@0E1F$$)$9M R)&>P,A1HH"($:; A]&K@$=1L8!'47B 1Q$]@,;
M0_\%&T+_!K)7  "H7@  H&,  )=F  "/9@  AF8  'QD  !P7P  95T  %I9
M  !-5   /T\  #)+"0 N2Q0 +$L< "I+)  H3"L )DPR 21,.@$C3$("(4Q*
M B!,5 (?3%\!'DUL 1Q->@$;38D &4V: !A,K0 73,4 %DOA !9*]0$62?\"
M%4C_ Z]<  "F8P  GF@  )9K  ".;   A6P  'MJ  !O9@  9&0  %=@  !)
M7   .U<  "Y4!  F4@\ )%(8 ")2(  @4R@ 'U,O !U3-P <4S\ &E-( !E3
M4@ 74UT %E-I !13=P 24X< $5.8  ]3JP -4L( #%'>  Y0]  /3_\!#T[_
M :UA  "D:   G&T  )1P  "-<@  A'(  'IQ  !N;@  86L  %-G  !%8P
M-V   "I=   >6@D &EH3 !A:'  76B, %5HK !1:,P 26CL $5I%  Y:3P ,
M6UH "EMF  E:=  '6H, !5J4  19I@ #6;T  U?8  17[0 %5OP !E7_ *IG
M  "B;@  FG,  )-V  "+>   @W@  'IX  !K=   77$  $]N  !!:P  ,V@
M "9F   99 ( $&,,  QC%@ *8QX "6,F  =C+@ &8S< !&-   )C2P  8U8
M &-B  !B<   8G\  &*0  !AH@  8+<  %_4  !=Z@  7/<  %S^ *=N  "?
M=   F'H  ))]  "*?P  @H   '9]  !G>@  5W<  $EU   [<P  +7$  "!O
M   5;0  "&T'  %L$   ;!D  &PA  !L*0  ;#$  &P[  !L1@  ;%$  &Q>
M  !K;   :WL  &J+  !IG@  :+,  &?.  !FZ0  9/8  &3] *1U  "=?
MEX$  )&$  ")A@  ?H4  '"#  !A@0  47X  $-\   T>P  )WD  !IX   .
M=P   G<#  !W#   =A0  '8<  !V(P  =BL  '8U  !V0   =4P  '59  !U
M9P  ='8  '2'  !SF0  <JX  ''(  !OY@  ;O<  &[_ *)]  ";@P  EH@
M )"+  "%C   >(L  &F)  !:AP  2X4  #N$   N@P  (((  !2!   '@0
M ($   "!!P  @0X  ($6  " '0  @"0  ($M  " .   @$4  (!2  " 8
M@'$  '^"  !^E0  ?:D  'S"  !ZX0  >?0  'C^ )^&  ":BP  E8\  (N1
M  !_D0  <)   &&.  !2C0  0HT  #.,   FC   &(L   N+    BP   (P
M  ",    C 8  (L.  "+%0  BQT  (PD  ",+@  C#L  (Q)  ",6   C&@
M (M[  "*CP  B:0  (>[  "&V0  A?$  (3[ )Z.  "9DP  D)4  (26  !V
ME@  9Y4  %>4  !(E   .)0  "J4   <E   #Y0   *5    E0   )8   "7
M    EP   )8$  "6"P  EQ,  )<;  "8)   F"\  )@^  "930  FEX  )EQ
M  "9A0  F)H  ):S  "4T0  D^H  )+X )R6  "5F0  B9H  'N;  !LFP
M7)L  $V;   ]FP  +IP  !^=   2G0  !)X   ">    GP   *    "A
MH0   *(   "A    H@@  *,1  "D&0  I2,  *8P  "F00  IU(  *AE  "H
M>@  J)   *>G  "FP@  I=T  *3N )B<  ",G@  ?Z   '"A  !AH0  4:$
M $&B   QHP  (Z0  !6E   &I@   *<   "I    J0   *H   "L    K
M *T   "N    K@   + !  "Q"@  M!0  +4A  "V,   MT0  +A8  "Y;@
MN80  +F;  "XL@  N,T  +CB )"A  "#HP  =:4  &6F  !6I@  1J<  #6I
M   EJP  %ZT   BN    KP   +$   "S    LP   +4   "V    MP   +D
M  "Z    NP   +T   #     Q 0  ,@0  #+'@  SRX  -)$  #370  T78
M -*-  #2HP  T;@  -', (>F  !YJ   ::H  %JK  !*K0  .:\  "FQ   :
MLP  ";8   "X    N@   +P   "_    O@   ,    #"    PP   ,8   #(
M    RP   ,X   #1    U@   -T   #B#0  YAT  .LP  #N1P  \E\  /)X
M  #PD   [J4  .ZT /\   #_    _P   /\   #_  H _P : /\ * #_ #4
M_P!  /P 2P#Z %0 ^ !< /8 8P#T &H \@!O /  =0#N 'H [0!^ .P A #K
M (D Z@"/ .D EP#G *  Y@"K .$ N@#< -  V0#K -@ _P#6 /\ U0#_ ,\
M_P#( /\ Q #_ /\   #_    _P   /\   #_  < _@ 6 /@ ) #U #  \P \
M /$ 1@#N %  ZP!8 .@ 7P#E &8 XP!K .( <0#@ '4 WP!Z -X @ #< (4
MVP"+ -D D@#6 )L T0"F ,T M #+ ,< R@#B ,@ ^0#& /\ Q0#_ ,, _P"]
M /\ N@#_ /\   #_    _P   /T   #W  , \  1 .L 'P#G "P Y0 V .(
M00#> $L V@!3 -8 6P#4 &$ T@!G -  ; #/ '$ S0!V ,P >P#+ ($ R0"'
M ,4 C@#" )< P "A +X K0"\ +T N@#6 +@ \0"V /\ M0#_ +4 _P"S /\
ML #_ /\   #_    ^0   /$   #J    X0 - -P &@#7 "8 TP R ,\ / #+
M $4 R !. ,4 50## %P P0!B +\ 9P"^ &P O !Q +H =P"X 'P M0"" +0
MB0"S )$ L0"; *\ IP"N +4 JP#+ *H Z "H /T IP#_ *< _P"G /\ I #_
M /\   #W    [0   .0   #:    T0 ' ,L %0#& "  P@ L +X -@"[ #\
MN !( +4 4 "S %8 L0!< *X 8@"M &< JP!L *H <0"I '< J !] *< A "E
M (L HP"5 *$ H "@ *T G@#! )P W ": /4 F #_ )< _P"7 /\ EP#_ /H
M  #M    X0   -4   #+    Q  # +T #P"X !P LP F +  , "M #H J@!"
M *< 2@"D %  HP!6 *$ 7 "@ &$ GP!F )T ; "< '$ FP!W )D ?@"8 (8
ME@"/ )0 F@"2 *< D "X (T T ", .P BP#_ (H _P"* /\ B@#_ .\   #B
M    U    ,@   "_    N    +$ "0"L !8 IP A *, *@"@ #, G0 \ )L
M0P"9 $H EP!0 )4 5@"4 %L D@!A )$ 9@"0 &P C@!R (T >0"+ ($ B0"*
M (< E "% *$ @P"Q (( Q0"  ., ?P#X '\ _P!^ /\ ?@#_ .4   #5
MR ,  +X!  "V    K@   *<  P"B  \ G0 : )@ )0"5 "T D@ V )  /0"-
M $0 BP!* (H 4 "( %8 AP!; (4 80"$ &< @P!M ($ = !_ 'P ?0"% 'P
MD !Z )P > "K '8 O@!U -H = #R ', _P!S /\ <@#_ -P'  #,$0  P!4
M +84  "M#@  I@4  )\   "8  @ DP 4 (X '@"+ "< AP O (4 -P"# #X
M@0!% '\ 2P!^ %  ? !6 'L 6P!Y &$ > !H '8 ;P!T '@ <@"! '  C !N
M )@ ;0"G &L N0!J -( :0#L &@ _ !G /\ 9@#_ -,5  #%'0  N2$  *\B
M  "F'@  GA<  )<-  "0 @  B@ , (4 %P"! "$ ?@ J 'L ,0!Y #D =P _
M '4 10!S $L <0!1 '  5P!N %T ;0!C &L :P!I '0 9P!^ &4 B0!D )4
M8@"D &  M0!? ,X 7@#F %T ]@!< /\ 7 #_ ,T@  "_*   LRP  *HM  "A
M*@  F20  )$<  ")$P  @0@" 'P #P!W !H =  D '$ + !N 3, ; (Z &H"
M0 !I T8 9P1, &4%4@!D!5@ 8@9? & &9P!?!G  709[ %L'A@!:!Y, 6 >C
M %8(M0!5",L 5 GE %,*]@!3"O\ 4@K_ ,<H  "Z,   KS4  *8V  "=-
ME"X  (PG  "#(   >Q<  ',,!P!N"!0 :@D> &<*)@!D"RX 8@PU & ,.P!?
M#4$ 70Y( %P.3@!:#U0 6!!< %<09 !5$&X 5!%Y %(1A0!0$I( 3Q*B $T2
MM0!,$LT 2Q/G $H3^0!*$_\ 2A/_ ,,P  "V.   K#P  *(]  "9/   D3<
M (@Q  !_*@  =B(  &T9  !E$@T 81,8 %X4(0!<%2D 6A4P %@6-P!6%CT
M51=$ %,72@!1%U$ 4!A8 $X880!-&&L 2QEV $H9@@!(&I  1QJ@ $4:L@!$
M&LH 0QKE $(:^0!"&O\!0AK_ ;\V  "S/@  J4(  *!$  "70@  CCX  (4Y
M  ![,@  <BL  &@C  !>&P@ 6AH4 %<;'0!4'"4 4APM % =,P!.'3D 31U
M $L>1@!*'DT 2!Y5 $<?7@!%'V@ 1"!S $(@@ !!(8X /R&> 3XAL $\(<@!
M.B'D 3H@^ (Z(/\".A__ KT[  "Q0P  IT<  )U)  "52   C$4  ((_  !Y
M.@  ;C(  &0K  !9) 0 4R$0 % A&@!-(B( 2R(I $DB+P!'(S8 12,\ $0C
M0P%")$H!0212 4 D6P$^)64!/"5Q 3LF?@$Y)HP".":< C8FKP(T)L8",R;B
M C,F]@,S)?\#,R3_!+I   "N1P  I4L  )M-  "33   BDH  (!%  !V0
M;#H  &$S  !5+   32<+ $DG%@!&)QX 1"@E $$H+  _*#(!/2@X 3PH0 ([
M*4<".BE0 C@J60(W*F,#-2MO S,K? ,R*XH#,2N: R\KK0,M*\0#+"O@ RPJ
M]00M*O\$+2G_!;=$  "L2P  HU   )I2  "140  B$\  'Y+  !T1@  :4
M %XZ  !2,P  2"X( $,M$@! +1L /2TB #HM* $X+"\!-BTU C4M/0,T+D0#
M,RY- S$O5@,P+V$$+C!M!"TP>@,L,(D#*C&9 RDQK ,G,,(#)C#> R8O] 0F
M+_\%)R[_!;5(  "J3P  H50  )A6  "05@  AE0  'Q0  !R2P  9T8  %M
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M!+!1  "G5P  GEP  )5>  "-7P  A%X  'I;  !N5@  8U,  %A/  !-2P
M0$4  #) !P M/Q$ *S\9 "D_(0 G/R@ )3\O 2- -@$B0#X!($!' 1] 40$>
M0%L!'$%H 1M!=0 :080 &$&5 !=!J  50;X %$#: !4_\0$5/O\"%#W_ ZY6
M  "E7   G&$  )1C  ",9   @V,  'EA  !M70  8EH  %A7  !+4@  /4T
M #!( P F10T (T46 "%&'@ @1B4 'D8L !Q&-  ;1CP &D=% !A'3@ 71UD
M%4=E !-'<P 21X, $$>3  Y'I@ ,1KP "T;6  U%\  .1/X #D/_ :M;  "C
M80  FF8  )-H  "+:0  @FD  'AG  !L9   8F(  %5>  !'60  .54  "Q1
M   ?30@ &TT2 !E-&@ 732$ %DTI !1-,  333@ $4U"  ].3  -3E< "TYC
M  E.<0 (3H  !DZ0  5-H@ #3;<  TS1  1+Z0 %2OH !DK_ *E@  "@9@
MF6L  )%N  "*;P  @6\  'AN  !L:P  7V@  %%D  !#8   -5T  "A9   ;
M5@, $E4,  Y5%0 ,51T "U4E  E5+0 (534 !E4^  1520 "550  55@  !5
M;0  57P  %6,  !4G@  4[,  %+.  !1Y@  4?4  %#^ *9F  ">;   EW$
M )!T  ")=@  @78  '=U  !I<@  6FX  $QK   ^:   ,&4  "-B   78
M"UX'  1>$  !7AD  %XA  !>*0  7C$  %XZ  !>10  7E   %U<  !=:@
M77D  %R)  !<FP  6Z\  %K)  !9Y0  5_0  %?\ *1M  "<<P  EG@  (][
M  "(?0  @'T  '-[  !D>   574  $=R   X;P  *FT  !UK   2:0  !6@$
M  !H#   :!4  &<<  !G)   9RP  &<U  !G0   9TL  &98  !F90  974
M &6%  !DEP  9*L  &+$  !AX@  8/4  %_] *%T  ";>@  E7\  (Z"  "'
MA   ?(,  &Z   !>?@  3WL  $!Y   Q=P  )'4  !=T   +<P   ',   !R
M"   <A   '(7  !Q'@  <28  '$N  !Q.@  <$8  '!2  !P8   <'   &^!
M  !NDP  ;:<  &R_  !KW@  :?,  &C^ )]\  "9@@  E(8  (V)  "#B@
M=H@  &>&  !7A   2((  #B    J?P  '7X  !!]   #?0   'T   !]!
M? H  'P2  !\&0  ?"   'PG  !\,@  >S\  'M,  ![6@  >VH  'I[  !Y
MC@  >*(  '>Y  !VV   =?   '3\ )V$  "8B@  DXX  (F/  !\CP  ;HT
M %Z,  !/B@  /XD  #")   BB   %8<   >'    AP   (@   "(    AP,
M (<*  "'$0  AQ@  (<?  "'*   AS4  (=$  "'4@  AV(  (=U  "&B
MA)T  (.T  ""T   @>L  (#Z )N-  "7D@  CI0  (*4  !TE   9),  %62
M  !%D0  -9$  ":1   9D0  "I    "1    D0   )(   "2    D@   )(
M  "2!P  D@X  ),6  "4'@  E"D  ),X  "41P  E5@  )5J  "4?P  DY8
M )&N  "0R0  C^8  ([U )J5  "2EP  AI@  'F9  !IF0  6I@  $J8   Z
MF   *YD  !R9   -F0   )H   ":    FP   )P   "=    G0   )T   "=
M    G0,  )X+  "@$P  H1T  *(J  "A.@  HTP  *1?  "D<P  I(H  *.A
M  "BN@  H-L  )[O ):;  "*G   ?9X  &Z>  !>G@  3IX  #Z?   NH
M'Z$  !&B   "HP   *0   "E    I@   *<   "H    J0   *D   "J
MJ@   *L   "L!P  KA$  *\=  "Q*P  LCX  +12  "U9P  M7X  +65  "T
MK0  M,<  +/@ (Z?  "!H0  <J,  &.C  !3I   0Z4  #*F   AJ   $ZH
M  .K    K    *T   "O    KP   +$   "R    LP   +0   "V    M@
M +@   "[    O@   ,(*  #%&0  QBL  ,A"  #*60  S'   ,V'  #-G@
MS;0  ,S* (2D  !VI@  9Z<  %>I  !'J@  -JP  "6N   6L   !K(   "T
M    M@   +@   "Z    N@   +P   "]    OP   ,$   ##    Q0   ,<
M  #+    SP   -<   #<!P  X1<  .4J  #I0@  ZUT  .EX  #ICP  ZJ,
M .JT /\   #_    _P   /\   #_  < _P 7 /\ )0#^ #$ _0 \ /H 1P#W
M %  ] !9 /$ 8 #O &8 [0!L .P <0#K '8 Z@![ .@ @ #G (8 Y@", .4
MDP#B )P W0"G -D M@#7 ,H U0#F -0 _0#3 /\ T@#_ ,H _P## /\ OP#_
M /\   #_    _P   /\   #_  0 ^0 3 /4 (0#R "T \  W .T 0@#I $P
MY0!4 .( 7 #@ &( W@!H -P ;0#; '( V@!W -@ ? #6 ($ U0"( -$ CP#-
M )@ R@"B ,D KP#' ,$ Q@#; ,0 ]@#" /\ P0#_ +X _P"X /\ M0#_ /\
M  #_    _P   /H   #R    ZP . .8 ' #C "@ X  R -P /0#7 $< TP!/
M -  5P#. %T S !C ,H : #) &T QP!R ,4 > #" 'T P "# +X B@"] )(
MNP"< +D J "X +@ M@#/ +0 [0"R /\ L0#_ +$ _P"M /\ J@#_ /\   #^
M    ]0   .T   #C    W  * -8 %@#1 "( S  N ,D -P#% $$ P@!* +\
M40"] %@ NP!> +@ 8P"V &@ M !M +, <P"R '@ L !^ *\ A0"N (T K0"6
M *L H@"I +  IP#$ *4 X@"D /L HP#_ *$ _P"@ /\ G0#_ /X   #S
MZ    -X   #3    S  $ ,4 $@#  !T NP H +@ ,@"U #L L@!# *\ 2P"L
M %( J@!8 *D 70"G &, I@!H *4 ;0"D '( HP!X *( ?P"@ (< GP"0 )T
MFP"; *@ F0"Z )< U0"4 /( DP#_ ), _P"2 /\ D@#_ /4   #G    V@
M ,X   #%    O@   +< # "R !@ K@ B *H + "G #4 I  ] *$ 10"? $P
MG@!2 )P 5P"; %P F0!B )@ 9P"7 &T E0!S )0 >0"3 ($ D0"* (\ E0",
M *( B@"R (D R0"' .@ A@#^ (8 _P"% /\ A0#_ .H   #;    S0   ,(
M  "Z    L@   *P !P"F !, H0 = )X )@"; "\ F  W )8 /@"3 $4 D@!+
M )  40". %8 C0!< (P 80"* &< B0!M (< = "% 'P A "% (( D "  )P
M?@"K 'T P ![ -T >@#W 'D _P!Y /\ >0#_ -\   #/    PP   +D   "P
M    J    *(   "<  P EP 7 ), (0"/ "D C  Q (H .0"( #\ A@!% (0
M2P"# %$ @0!6 (  7 !_ &$ ?0!H 'P ;P!Z '< > "  '8 BP!T )< <@"F
M '$ N !O -, ;@#O &T _P!M /\ ;0#_ -4'  #'#@  NQ(  + 1  "H"@
MH0$  )D   "3  4 C@ 1 (D &P"% "0 @@ K '\ ,P!] #H >P!  'H 1@!X
M $L =@!1 '4 5@!S %P <0!C '  :@!N '( ; !\ &H AP!I ), 9P"B &4
ML@!D ,L 8P#G &( ^P!A /\ 80#_ ,T4  "_&P  M!\  *H>  "B&@  FA0
M )()  "+    A0 ) (  % !\ !X >  F '4 +0!S #0 <0 [ &\ 00!M $8
M:P!, &H 40!H %< 9@!> &4 9@!C &X 80!X %\ @P!> )  7 "> %H KP!9
M ,4 6 #B %< ]0!6 /\ 5@#_ ,<>  "Z)@  KRH  *4J  "=)@  E"   (P9
M  "$$   ?04  '< # !R !< ;@ @ &L * !H "\ 9@ U &0 .P!C $$ 80!'
M %\ 30!> %, 7 !: %H 80!8 &L 5P!U %4 @ !3 (T 4@"< % !K0!/ <(
M3@'< $T"\ !, OL 3 +_ ,(G  "U+@  JS(  *$S  "9,0  D"L  (<D  !_
M'0  =A0  &X)!0!H A  9 (9 &$#(@!>!"D 7 0P %H%-@!9!CP 5P9" %4'
M2 !4!T\ 4@A6 % (7@!/"6< 30ER $P*?@!*"HP 2 J; $<+K !%"L( 1 O<
M $,+\0!#"_X 0PO_ +XN  "R-@  ISH  )X[  "5.0  C#0  (0N  !Z)P
M<1\  &@6  !?# @ 6PL4 %@,' !5#20 4PTK %$.,0!/#C< 3@\^ $P01 !+
M$4L 21%3 $<16P!&$F4 1!-P $,3? !!$XH /Q2: #X4K  \%,( .Q3= #L4
M\P [%/\ .Q/_ +HU  "O/   I4   )M!  "3/P  BCL  ($V  !W+P  ;2@
M &,@  !:& ( 4Q0- $\4& !-%2  2Q4G $D6+0!'%C, 11<Z $070 !"&$@
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M [-#  "H2@  GTX  )9/  "-3@  A$P  'M(  !P0P  9CT  %LW  !/,0
M1"L! #LG"P X)Q4 -2<< #,G(P P)RD +R<P "XH-P$M*#\!*RE' 2HI40$I
M*EL!)RIG 28K= $D*X,!(RN3 2$KI0$@*[L!'BO6 !XK[P$?*OX"'RG_ [%'
M  "F3@  G5(  )53  ",4P  @U$  'E.  !N2   8T,  %@^  !-.0  0C,
M #8N!P Q+!$ +RP9 "TM(  K+2< *2TM "<N- $F+CP!)2Y% 20O3P$B+UD!
M(3!E 2 P<P$>,8$!'3&2 !LQI  :,+D &##4 !DP[@$9+_T"&2[_ ZY,  "E
M4@  G%8  )-7  "+6   @E8  'A3  !L3@  8DH  %=%  !,00  0#L  #,V
M!  K,PT *#,6 "<S'0 E,R0 (S,K "$T,@ @-#H!'S1# 1XU30$<-5@ &S5C
M !DV<0 8-H  %C:0 !4VHP 3-K@ $C73 !,U[  4-/T!$S/_ JQ0  "C5@
MFEH  ))<  "*7   @5L  '=8  !K5   85$  %9-  !+20  /T,  #$^   E
M.@H (CD3 " Y&P >.2( '3HI !LZ,  :.C@ &#M! !<[2P 5.U4 %#MB !(\
M;P 1/'X #CR/  P\H0 *.[4 "3O/  LZZ0 ,.?L #3C_ :I4  "A6@  F5\
M )%A  ")80  @&$  '9>  !J6@  8%@  %95  !)4   .TL  "Y&   A0@8
M&D 0 !E %P 70!\ %4 F !1!+0 2034 $4$^  Y!2  ,05, "T)?  E";0 '
M0GP !D*,  1!G@ "0;(  D'+  - Y  %/_8 !C[_ *A9  "?7P  EV0  )!F
M  "(9P  ?V<  '5E  !I80  8%\  %-;  !%5@  -U(  "I.   =2@$ %$<*
M !!'$P -2!L "T@C  I(*@ (2#( !T@[  5(10 #2%   DE<  !):@  27D
M $F)  !(FP  1ZX  $?'  !&X@  1?(  $3\ *5?  "=90  EFD  (YL  "'
M;0  ?VT  '5L  !I:0  768  $]A  !!70  ,UH  "56   94P  #5 &  90
M$  #4!@  5 ?  !0)P  4"\  % X  !00@  4$X  %!9  !09P  4'8  %"&
M  !/F   3JP  $W$  !,X0  2_$  $O[ *-E  ";:P  E&\  (UR  "&=
M?G0  '5S  !F;P  6&P  $IH   \9   +F$  "!?   47   "%H$  !:#
M614  %D<  !9(P  62L  %DT  !9/P  64H  %A6  !88P  6'(  %B"  !7
ME   5J@  %7   !3W@  4O,  %+[ *%L  "9<@  DW8  (UY  "&>@  ?GL
M '%X  !B=0  4W(  $1O   U;   *&D  !IG   .9@   F0!  !D"0  8Q$
M &,8  !C'P  8B<  &(O  !B.@  8D8  &)2  !A7P  86X  &!_  !?D
M7J0  %V\  !<V@  6_(  %K] )YS  "8>0  DGT  (R   "%@@  >H   &M^
M  !<>P  3'@  #UV   O=   (7(  !1P   ';P   &\   !N!0  ;@P  &T3
M  !M&@  ;2$  &TH  !L,P  ;$   &M-  !K6@  :VH  &IZ  !IC   :*
M &>W  !FU0  9>\  &3\ )Q[  "7@0  D84  (N(  "!AP  <X4  &2#  !5
M@0  17\  #5]   G>P  &7H   MY    >0   'D   !Y    > <  '@-  !W
M%   =QL  '<B  !W*P  =S@  '9&  !V5   =F0  '5U  !TB   <YP  '*R
M  !QS@  <.P  &_[ )N#  "6B   D8P  (>-  !ZC   :XL  %R)  !,B
M/(8  "V%   ?A   $8,   .#    @P   (,   "#    @P   (,&  ""#
M@A,  ((:  "#(@  @R\  ((^  ""30  @EP  ()N  "!@@  @)<  'ZM  !]
MR   ?>8  'SW )F,  "5D   C)(  ("2  !QD0  8I   %*/  !"C@  ,HX
M "..   5C0  !XT   "-    C0   (X   ".    C@   (X   ". P  C@D
M (X1  "/&   CR,  (\Q  "/0@  D%(  )%D  "/>@  CI   (VG  "+P0
MBN   (KS )F4  "0E@  A)<  ':7  !GE@  5Y4  $>5   VE0  )Y4  !B6
M   )E@   )8   "7    EP   )@   "9    F0   )D   "9    F0   )H&
M  ";#@  G!<  )TC  "=-   GD8  )]8  "@;0  H(,  )^<  "<N   F]D
M )GO )29  "(FP  >YP  &R<  !<FP  2YL  #J<   JG0  &YX   R>
MGP   *    "A    H@   *,   "D    I    *4   "E    I0   *8   "G
M @  J@H  *L7  "M)0  K3@  *]+  "Q8   L7<  +&/  "QJ   K\$  *_=
M (R>  !_GP  <*$  &"A  !0H0  /Z(  "ZD   >I0  #J<   "H    J0
M *H   "K    K    *T   "N    L    +$   "R    L@   +,   "V
MN    +L'  "]%@  OR<  ,$\  #%4@  QVH  ,B"  #(F0  R+$  ,?' (*C
M  !TI   9:4  %6F  !$IP  ,JD  "*L   2K0   J\   "Q    L@   +0
M  "V    M@   +@   "Y    NP   +T   "^    P0   ,(   #%    R0
M -    #5 @  VQ(  -XF  #@0   XEL  .1S  #EB@  YJ   .:R /\   #_
M    _P   /\   #_  0 _P 4 /X (0#[ "T ^@ X /< 0P#S $T [P!5 .T
M70#K &, Z0!H .@ ;@#F ', Y0!W .0 ?0#C (( X0"( -T D #9 )D U@"C
M -0 L #3 ,0 T0#@ -  ^0#. /\ S0#_ ,4 _P"^ /\ N@#_ /\   #_
M_P   /\   #[  ( ]0 0 /$ '0#N "D [  S .@ /@#C $@ X !0 -T 6 #:
M %X V !D -8 :0#5 &X TP!S -$ > #. 'X RP"$ ,@ C #' )0 Q@"= ,0
MJ@## +L P0#4 +\ \0"^ /\ O0#_ +D _P"T /\ L #_ /\   #_    _0
M /8   #L    YP + .( & #> "0 V0 O -4 .0#1 $, S0!+ ,H 4@#( %D
MQ@!? ,, 9 #! &D O@!O +P = "[ 'D N@!_ +D A@"X (X M@"7 +4 HP"S
M +( L0#( *\ YP"N /\ K0#_ *P _P"G /\ HP#_ /\   #Z    \0   .8
M  #=    U@ ' -  $P#* !\ Q@ J ,, ,P#  #P O !% +D 30"V %, LP!9
M +$ 7P"P &0 KP!I *X ;@"M '0 K !Z *H @ "I (@ J "1 *8 G "D *L
MH@"] *$ V@"> /< G #_ )L _P": /\ F #_ /H   #N    XP   -8   #-
M    Q@ ! +\ #@"Z !D M@ D +( +@"O #8 K  _ *D 1@"G $T I0!3 *0
M60"B %X H0!C *  : "? &X G@!T )P >P"; (( F0"+ )@ E@"6 *, DP"T
M )$ S0"/ .X C@#_ (T _P"- /\ C #_ /$   #B    TP   ,@   #
MN    +$ "0"L !4 J  > *0 * "A #$ GP X )P 0 ": $< F0!- )< 4@"6
M %@ E != ), 8@"1 &@ D !N (\ =0"- 'T BP"% (D D "' )T A0"M (0
MP@"" ., @0#[ (  _P"  /\ @ #_ .0   #4    R    +T   "T    K0
M *< ! "A  \ G  : )@ (@"5 "L DP S )  .@". $  C !& (L 3 ") %$
MB !7 (8 7 "% &( @P!H (( ;P"  '< ?P"  'T BP![ )< >0"F '< N@!V
M -8 = #R '0 _P!S /\ <P#_ -@   #)    O@   +,   "K    HP   )T
M  "7  D D@ 4 (X '0"* "4 AP M (4 - "# #L @0!  '\ 1@!^ $P ? !1
M 'L 5P!Y %P =P!C '8 :@!T '( <@![ '  A@!N )( ;0"A &L LP!I ,L
M: #K &< _@!G /\ 9P#_ ,\%  #!#   M@\  *P-  "C!P  G    )0   ".
M  ( B0 - (0 %P"  "  ?0 G 'H +@!X #4 =@ [ '0 00!R $8 <0!, &\
M40!M %< ; != &H 90!H &T 9@!W &0 @@!B (X 80"< %\ K0!= ,, 7 #B
M %P ]P!; /\ 6P#_ ,<3  "Z&0  KQP  *8;  "=%P  E1   (T&  "&
M@  & 'L $0!V !H <P B &\ *0!M "\ :P V &D / !G $$ 90!' &0 3 !B
M %( 8 !9 %X 8 != &D 6P!S %D ?@!7 (H 5@"8 %0 J0!3 +X 40#: %$
M\P!1 /\ 4 #_ ,(=  "U)   JB<  *$G  "8(P  D!T  (<6  !_#   > (
M '$ "@!L !0 :  < &4 ) !B "H 8  P %X -@!= #P 6P!" %D 2 !7 $X
M5@!5 %0 7 !2 &4 40!O $\ >@!- (< 2P"5 $H I@!( +H 2 #4 $< [0!&
M /H 1@#_ +TF  "P+0  IC   )TP  "4+0  C"@  (,A  !Z&@  <A$  &D&
M @!C  P 7P 6 %L '@!8 "4 5@ K %0 ,0!3 #< 40 ] $\ 0P!. $D 3 %0
M $H!6 !( F$ 1P)L $4#> !# X4 0024 $ $I  _ [@ /0/1 #P#Z  \!/<
M/ 3_ +DM  "M-   HS<  )HX  "1-@  B#$  '\K  !V)   ;1P  &04  !;
M"@4 504. %(%& !/!1\ 308F $L'+ !)!S( 1P@X $8(/P!$"44 0@E- $$*
M50 _"E\ /0MJ #L+=@ Z#(0 . R3 #8,I  U#+@ ,PS1 #(,Z@ S#/D ,PS_
M +8T  "J.@  H3X  )@^  "//   AC@  'TS  !S+   :24  %\>  !6%@
M30X( $D-$@!&#1H 1 XA $$.)P! #RX /A T #P0.@ [$4( .1)) #<24@ V
M$UP -!-G #,4=  Q%(( +Q62 "X5HP L%+@ *A32 "H5[  K%/L +!3_ +,Y
M  "H/P  GT,  )9$  "-0@  A#\  'HZ  !Q-   9RT  %PF  !2'P  2!@#
M $$5#0 ^%18 .Q4= #D6)  W%BH -A8P #07-P S%SX ,1A' # 84  O&5H
M+1EE "P:<@ J&X  *!N0 "8;H@ E&K8 (QK0 ",;Z@ D&OP )!G_ ;$^  "F
M0P  G4<  )1(  "+1P  @T4  'A   !O.@  9#0  %HN  !/)P  1"   #L<
M"0 V&Q( -!L9 #(;(  P&R8 +APM "T<-  L'3P *AY$ "D>30 H'U@ )A]C
M "4@<  C('\ (2". " @H  >(+4 '"#. !T@Z0 =(/L!'A__ :Y"  "D2
MFTL  )--  "*3   @4H  '=%  !M0   8CL  %@U  !,+P  02D  #8C!0 P
M(0T +2$6 "LA'  H(2, )R$J "8B,0 E(CD (R-" "(D2P A)%8 ("5A !XE
M;@ <)GT &R:- !DEGP 8);, %B7- !<EZ  8)/H!%R3_ :Q&  "C3   FE
M )%1  ")40  @$X  '9+  !K1@  8$$  %8\  !+-@  0#$  #0L 0 J)PH
M)B83 "0G&@ B)R  (2<G !\H+P >*#8 '2D_ !PI20 ;*E0 &2I? !<K;0 6
M*WL %"N+ !,KG0 1*[( #RK+ ! JYP 1*OD $BG_ :I*  "A4   F%0  )!5
M  "(50  ?U0  '50  !I2P  7T<  %5#  !*/P  /SH  #,U   F+P< ("T0
M !XM%P <+1X &RXE !DN+  8+C0 %R\] !4O1P 4+U( $C!= ! P:P .,7H
M##&*  HPFP ),*\ !S#'  @OX@ *+_< "R[_ *A.  "?5   EU@  (]:  "'
M6@  ?ED  '16  !H40  7DX  %1+  !)1P  /4(  # \   C-P0 &C0, !<S
M%  5-!L %#0B !(T*@ 1-3$ #S4Z  TU1  +-4\ "C9;  @V:  &-W< !3>'
M  ,VF0 !-JP  #;$  $UWP #-/( !#/_ *93  ">60  E5T  (Y?  "&7P
M?5X  '-<  !G6   7E8  %12  !(3@  .D@  "U#   ?/P  %#L( ! Z$0 -
M.QD "SL@  D[)P (/"\ !CPX  4\0@ #/$T  3Q9   ]9@  /74  #V%   \
ME@  /*H  #O!   [W0  .N\  #GZ *18  "<7@  E&(  (UD  "%90  ?&0
M '-B  !G7P  7ET  %%9  !$5   -D\  "A+   ;1P  $$0%  ="#0 $0Q8
M D,=  !#)0  0RT  $0U  !#/P  0TH  $-6  !$8P  1'(  $2"  !#E
M0J<  $&^  !!W   0.\  #_Y *)>  ":8P  DV<  (QJ  "$:P  ?&L  ')I
M  !G9P  6V,  $U?   _6P  ,5<  "-3   74   "TT#  %,"P  2Q0  $P;
M  !,(@  2RH  $LR  !+/   2T@  $M3  !+8   2V\  $M_  !*D0  2:4
M $B\  !'V0  1O   $7Z *!D  "8:@  DFT  (MP  "$<@  ?'(  '-Q  !D
M;0  5FD  $AE   Y8@  *UX  !Y;   26   !58!  !6"0  51$  %47  !5
M'@  5"8  %0N  !4.0  5$0  %-0  !370  4VP  %-\  !2C@  4:(  %"Y
M  !.U@  3>\  $W\ )YJ  "7<   D70  (IW  "#>   ?'D  &]V  !?<P
M4&\  $)L   S:0  )68  !=D   +8@   &$   !@!@  7PT  %\4  !>&@
M7B$  %XI  !=-   74   %U,  !<6@  7&@  %MY  !;B@  6IX  %BU  !7
MTP  5NX  %3\ )QR  "5=P  D'L  (I^  "#@   =WX  &E[  !9>   274
M #IS   L<   'FX  !%M   $:P   &L   !J @  :@@  &D/  !I%0  :!P
M &@C  !H+0  9SH  &='  !F50  9F0  &5T  !DA@  8YH  &*P  !AS0
M7^L  %[[ )IZ  "5?P  CX,  (F&  !_A0  <8,  &*!  !2?@  0GP  #)Z
M   D>   %G<   AV    =0   '4   !U    = ,  '0)  !S$   <Q8  ',=
M  !S)0  <C(  '%   !Q3@  <5X  '!O  !O@@  ;I8  &VL  !LQP  :^8
M &KY )B"  "4AP  CXL  (6+  !XB@  :8@  %F&  !)A0  .(,  "F"   ;
M@0  #8    !_    ?P   '\   !_    ?P   'X"  !^"   ?@X  'X6  !^
M'   ?B@  'TW  !]1P  ?E8  'UH  !\>P  >Y   'FF  !XP   >.   '?U
M )>+  "3CP  BI   'V0  !OCP  7XT  $^,   _BP  +XL  ""*   1B@
M XD   ")    B@   (H   "*    B@   (H   ")    B@4  (H,  "+$P
MBQT  (LK  "*/   BTT  (M?  "+<P  BHD  (B@  "'N0  AMH  (7Q )>2
M  ".E   @I4  '25  !DE   5),  $22   SDP  ))(  !62   %D@   ),
M  "3    E    )4   "5    E0   )4   "5    E0   )8!  "6"0  F!$
M )D=  "9+@  F4   )M2  "<9@  FWX  )F8  "7L0  EM   )7L )*8  "&
MF0  >9H  &F9  !9F0  29D  #>9   GF@  &)L   B;    FP   )P   "=
M    G@   )\   "@    H    *$   "A    H0   *(   "C    I04  *<1
M  "H'P  J#(  *I%  "L6@  K7$  *V)  "MH@  J[X  *G@ (J<  !]G@
M;9\  %Z?  !.GP  /)\  "NA   ;H@  "J0   "E    I0   *8   "G
MJ    *H   "K    K    *T   "M    K0   *X   "P    L@   +4#  "X
M$0  NR$  +PV  "_3   PF0  ,-\  ##E   PZP  ,+$ ("A  !RHP  8J,
M %*D  !!I0  +Z<  !ZI   .JP   *P   "N    KP   +$   "R    LP
M +0   "V    MP   +D   "Z    O    +T   #     Q    ,H   #.
MTA   -,D  #8/   W54  .!M  #AA0  X9P  .&P /\   #_    _P   /\
M  #_  $ _@ 1 /L '@#Y "D ]@ T /( 0 #N $D ZP!1 .@ 60#F %\ Y !E
M ., :@#A &\ X !T -X >0#; '\ V "% -0 C0#2 )4 T0"? -  JP#. +T
MS0#: ,L ]@#* /\ R0#_ ,$ _P"Z /\ M0#_ /\   #_    _P   /X   #V
M    \0 + .T &0#J "4 Y@ O .( .@#> $0 V@!, -< 5 #4 %H T@!@ -
M90#- &H R@!P ,@ =0#% 'H Q "! ,, AP#" (\ P0"9 ,  I0"^ +0 O #-
M +H [ "Y /\ N #_ +4 _P"O /\ J@#_ /\   #_    ^@   /    #H
MX@ ( -T % #6 "  T@ K ,\ - #+ #X QP!' ,0 3@#! %4 O@!; +L 8 "Y
M &4 N !J +< ;P"V '4 M0![ +0 @@"S (H L0"3 +  G@"N *P K #! *L
MX0"I /L IP#_ *8 _P"A /\ G@#_ /\   #V    [    .    #8    T  #
M ,D $ #$ !L P  E +T +P"Z #@ M0!  +( 2 "O $\ K@!5 *P 6@"K %\
MJ@!E *D :@"H &\ IP!U *4 ? "D (0 HP"- *$ F "? *4 G@"W )L T@"8
M /( EP#_ )< _P"5 /\ DP#_ /4   #I    W    -    #(    P    +D
M"P"T !8 L  @ *P *0"I #( I@ Z *0 0@"B $@ H0!. )\ 5 "> %D G !>
M )L 9 ": &D F0!O )< =@"6 'X E "' )( D0"0 )X C@"O (P Q@"* .@
MB0#_ (@ _P"( /\ AP#_ .L   #;    S0   ,,   "Z    L@   *P !@"G
M !( H@ ; )\ ) "< "P F@ T )< .P"5 $( DP!( )( 30"0 %, CP!8 (X
M70", &, BP!I (D < "( '@ A@"! (0 BP"" )@ @ "H '\ O !] -P ? #X
M 'L _P!Z /\ >P#_ -T   #.    P@   +<   "O    J    *$  0"<  L
MEP 6 ), '@"0 "8 C0 N (L -0") #P AP!! (8 1P"$ $T @P!2 ($ 5P"
M %T ?@!C 'T :@![ '( >0![ '< A@!U )( <P"B '( M !P -  ;P#O &X
M_P!M /\ ;0#_ -(   #$    N    *\   "F    GP   )@   "2  8 C0 1
M (D &@"% "$ @@ H '\ +P!] #8 ?  \ 'H 00!X $< =P!, '4 4@!S %<
M<@!> '  90!N &T ; !V &H @0!H (T 9P"< &4 K@!C ,4 8@#E &$ _ !A
M /\ 8 #_ ,D$  "\"@  L0P  *<*  "?!   EP   )    ")    A  * '\
M% ![ !P >  D '4 *0!R #  <  V &X / !L $$ :P!' &D 3 !G %( 9@!8
M &0 8 !B &@ 8 !Q %X ? !< (D 6P"7 %D J !7 +T 5@#; %4 ]0!5 /\
M50#_ ,(1  "U&   JQH  *(8  "9%   D0P  (D#  "!    >P $ '8 #0!Q
M !8 ;0 > &H )0!G "H 90 Q &, -P!A #P 7P!" %X 2 !< $T 6@!4 %@
M6P!6 &, 50!M %, > !1 (4 3P"3 $X HP!, +< 2P#3 $H [@!* /\ 2@#_
M +P<  "P(@  IB4  )TD  "4(   BQH  (,3  !["@  <P   &P !P!G !$
M8P 8 %\ ( != "8 6@ L %@ ,0!7 #< 50 ] %, 0P!2 $D 4 !/ $X 5P!,
M %\ 2@!I $D =0!' ($ 10"0 $, H !" +, 00#, $  Z0!  /H 0 #_ +@D
M  "L*P  HBX  )DN  "0*@  B"4  '\?  !V%P  ;0T  &4#  !>  H 60 3
M %8 &@!3 "$ 4  G $X + !- #( 2P X $D /@!( $0 1@!+ $0 4P!" %P
M0 !F #X <@ ] '\ .P"- #D G0 X +  -P#( #8 XP U /0 -0#^ +0L  "I
M,@  GS4  )8U  ".,P  A2X  'LH  !R(0  :1D  %\1  !7" , 4 $+ $P
M% !) !L 1P A $4 )P!# "T 00$S #\!.0 ^ D  / -' #H#3P X!%D -@5C
M #0%<  S!7T ,06, "\&G  N!:\ +03& "P%X  K!O( *P7] +$S  "F.
MG3L  )0\  "+.@  @C4  'DP  !O*0  92(  %L;  !2%   20P% $('#0!
M!A4 /0<< #L((P Y""D -P@O #8)-0 T"3P ,@I$ # +3  O"U8 +0QA "L,
M;@ I#7P )PZ+ "4.G  D#;  (@W( "$.X@ B#O0 (PW_ *XX  "D/0  FT$
M ))!  "*0   @3P  '<W  !M,0  8RH  %DD  !.'0  118  #L0!P V#1
M- X7 #$.'@ P$"0 +A J "P0,0 K$3@ *1)! "@22@ F$U0 )1-? ",4;  A
M%7H 'Q6* !X5FP <%*\ &A3' !H4XP ;%?8 &Q3_ *P\  "B0@  F44  )%&
M  "(10  ?T(  '4]  !K.   83$  %8K  !+)0  01X  #<9 @ P%0L +!43
M "H5&@ H%B  )A8G "06+@ C%S4 (A@^ "$81P ?&5( 'AE= !P::@ :&GD
M&1N( !<:F@ 5&JT %!K& !,:X@ 5&O8 %1K_ *I   "A1@  F$D  (]*  "'
M2@  ?D<  '1#  !I/@  7S@  %4R  !)+0  /R<  #0B   J'0< )1L/ "(;
M%@ @&QP 'QPC !X<*P <'3, &QT[ !H>10 9'E  %Q]; !4?:  4('< $B"'
M ! @F  .(*P #!_#  P?WP .'_4 $![_ *A%  "?2@  EDX  (Y/  "%3@
M?4P  '-(  !H0P  73\  %,Z  !(-   /3   #,K   H)0, 'R$+ !PA$P :
M(1H &"$A !<B*  6(C  %2,Y !,C0P 2(TX $"19  XE9P ,)74 "B:%  DE
ME@ '):D !27   8DVP ')/$ "2/_ *=)  "=3@  E5(  (U3  "%4P  ?%$
M ').  !F20  7$4  %)!  !(/0  /3@  #(S   F+@  &B@) !8G$0 4)Q@
M$B@? ! H)@ .*2X #2DV  LI0  **DL ""I7  8K9  %*W,  RR#  $KE
M*Z<  "J]   JV   *>T  BG\ *5-  "<4@  E%8  (Q7  "$6   >U8  '%3
M  !E3P  7$P  %))  !(10  /$   "\Z   B-0  %C %  XN#0 ,+A8 "B\=
M  @O)  ',"P !3 T  0P/@ ",$D  3%5   Q8@  ,G$  #*    QD@  ,:4
M #"[   PUP  +^P  "[X *-2  ":5P  DEH  (M<  "#70  >EP  '!:  !E
M5@  6U,  %)0  !&3   .$8  "M!   >/0  $C@#  @U"P $-A0  C8;   W
M(@  -RH  #<R   W/   -T<  #=3   W8   .&X  #A^   XD   -Z,  #:Y
M   UU0  -.P  #3X *%7  "97   D6   (IB  ""8P  >F(  '!@  !E70
M7%L  %!7  !"4@  -$T  "=(   91   #4$"  ,^"@  /A(  #X8   ^'P
M/R<  #\P   _.0  /D0  #Y0   ^70  /VP  #]\   ^C@  /:$  #RW   [
MTP  .^T  #KX )]<  "78@  D&4  (EH  "":0  >6D  '!G  !E90  66$
M $M=   ]6   +U0  "%0   53   "$D   !("   1P\  $<6  !''0  1R0
M $<L  !&-@  1D(  $9.  !&6P  1FD  $9Y  !&BP  19\  $.T  !"T0
M0>P  $#Z )UC  "6:   CVP  (AN  "!<   >7   '!O  !B:P  5&<  $9C
M   W7P  *5L  !M8   .50   U,   !2!@  40P  %$3  !0&@  4"$  $\I
M  !/,P  3SX  $]+  !.6   3F8  $YV  !.B   39P  $NR  !)SP  2.L
M $?[ )MI  "4;P  CG(  (AU  "!=P  >G<  &QT  !=<   3FT  #]I   Q
M9@  (F,  !5A   (7@   %T   !< P  6PD  %L0  !:%@  61T  %DD  !9
M+@  6#H  %A&  !85   5V,  %=S  !6A0  59D  %2O  !2RP  4.H  $_[
M )EQ  "3=@  C7H  (=\  "!?@  =7P  &9Y  !7=@  1W,  #AP   I;0
M&VL   UI   !:    &<   !F    9@4  &4*  !D$0  9!@  &,?  !C*
M8S0  &)!  !B3P  85X  &!O  !@@0  7I4  %VK  !<Q@  6^8  %GZ )=Y
M  "2?@  C8$  (B$  !]@P  ;X$  %]^  !/?   /WD  "]W   A=0  $W,
M  5R    <@   '$   !Q    <    ' %  !O"@  ;Q$  &X8  !N'P  ;BP
M &TZ  !M20  ;5@  &QI  !J?   :9   &BF  !GP   9N$  &7W ):!  "2
MA@  C8D  (.)  !VB   9H8  %:$  !&@@  -8   "9_   8?0  "7P   ![
M    >P   'P   ![    >P   'L   !Z!   >@H  'H1  !Z%P  >B(  'DQ
M  !Y00  >5$  'EB  !X=0  =HH  '6@  !SN0  <ML  ''S ):)  "2C@
MB(X  'N.  !MC0  78L  $V*   \B0  +(@  !R'   -A@   (8   "%
MA@   (8   "&    A@   (8   "%    A0$  (4'  "&#@  AQ<  (8E  "%
M-P  AD<  (99  "&;0  A8,  (2:  ""LP  @=(  (#O ):1  "-DP  @),
M '*3  !BD@  4I   $&0   PD   ()   !&/   "CP   (\   "/    D
M )$   "1    D0   )$   "1    D0   )$   "2!   E H  )47  "5)P
ME#L  )9-  "780  E7D  )22  "3JP  D<@  )#H )"6  "$EP  =I@  &>7
M  !7E@  1I8  #27   DF   %)@   28    F    )D   "9    F@   )L
M  "<    G0   )T   "=    G0   )X   "?    H    *,*  "D&   I"P
M *5   "H5   J6L  *F#  "GGP  I;X  */= (B;  ![G   :YP  %N<  !+
MG   .9T  "B>   8GP  !Z    "A    H@   *,   "C    I0   *8   "G
M    J    *D   "I    J0   *H   "K    K0   +$   "S"@  MAL  +8P
M  "Y1@  O5X  +YV  "^CP  OJ@  +[" 'Z?  !OH0  8*$  %"B   ^HP
M+*0  !NG   *J    *D   "J    K    *T   "N    KP   +$   "R
MM    +4   "V    N    +@   "[    O0   ,$   #&    R@L  ,T>  #1
M-@  UD\  -MH  #<@   W)@  -RN /\   #_    _P   /\   #_    ^P ,
M /@ &@#U "4 \0 P .T / #I $4 Y@!- .0 50#A %L WP!A -T 9@#; &L
MV !Q -0 =@#1 'P T "" ,X B0#- )$ S "; ,L IP#* +< R #2 ,8 \0#%
M /\ Q #_ +T _P"U /\ L0#_ /\   #_    _P   /D   #S    [0 ' .D
M%0#D "$ X  K -T -@#8 $  U !( -$ 3P#. %8 R@!< ,< 8@#$ &< P@!L
M ,$ <0#  '8 OP!\ +X @P"] (L O "5 +H H "Y *X MP#% +8 YP"T /\
MLP#_ *\ _P"H /\ I #_ /\   #_    ]0   .L   #D    W0 % -4 $0#0
M !P S  G ,D , #% #H P0!" +P 2@"Y %  MP!6 +4 7 "T &$ LP!F +(
M:P"Q '$ L !W *\ ?@"N (4 K "/ *L F@"I *< J "Z *8 V0"C /< H0#_
M *  _P"< /\ F0#_ /_B?1!)0T-?4%)/1DE,10 4%?P   #R    Y0   -L
M  #2    R@   ,, # "^ !< N@ A +< *P"S #, KP \ *T 0P"K $H J0!0
M *@ 50"F %L I0!@ *0 90"C &L H@!Q *  > "? '\ G@"( )P DP": *
MF "P )4 RP"3 .X D@#_ )( _P"0 /\ C@#_ /    #B    U0   ,L   #"
M    N@   +0 " "O !, J@ < *8 )0"D "T H@ U )\ /0"= $0 G !* )H
M3P"9 %0 EP!9 )8 7P"5 &4 DP!K )( <@"1 'D CP"" (P C0"* )D B0"I
M (< P "% .( A #] (, _P"# /\ @0#_ .0   #4    QP   +T   "T
MK0   *<  @"A  T G0 7 )H ( "7 "@ E  O )( -@"0 #T C@!# (T 20"+
M $X B@!3 (D 6 "' %X A@!E (0 :P"" ', @0!\ '\ AP!] ), >P"B 'D
MMP!X -4 =@#U '4 _P!U /\ =0#_ -8   #)    O0   +(   "J    HP
M )P   "7  @ D@ 3 (X &P"+ "( B  I (8 , "$ #< @@ ] (  0@!_ $@
M?0!- 'P 4@!Z %@ >0!> '< 9@!U &T <P!W '$ @0!P (X ;@"= &P KP!J
M ,D :0#K &@ _P!G /\ 9P#_ ,P   "_    LP   *H   "A    F@   ),
M  "-  , B  , (0 %@"  !X ?0 D 'H *@!X #$ =@ W '0 /0!S $( <0!'
M &\ 30!N %( ; !9 &H 8 !H &@ 9@!Q &0 ? !B (D 80"7 %\ J0!= ,
M7 #@ %L ^0!: /\ 6@#_ ,0"  "W"   K D  *,'  ": 0  D@   (L   "$
M    ?P ' 'H $0!V !D <@ @ &\ )0!L "L :@ R &@ -P!G #T 90!" &,
M2 !B $T 8 !4 %X 6P!< &, 6@!L %@ =P!6 (0 50"2 %, HP!1 +@ 4 #5
M $\ \@!. /\ 3@#_ +T0  "Q%@  IQ<  )T5  "5$0  C D  (0!  !]
M=@ ! '$ "@!L !, :  : &0 (0!A "8 7P L %T ,@!; #@ 6@ ] %@ 0P!6
M $D 5 !/ %( 5@!1 %X 3P!G $T <P!+ '\ 20". $< G@!& +$ 1 #+ $0
MZP!# /T 0P#_ +<:  "L(   HB(  )DA  "0'0  AQ<  '\0  !W!P  ;@
M &@ !0!B  T 7@ 5 %H &P!7 "( 5  G %( + !1 #( 3P X $T /@!, $0
M2@!* $@ 4@!& %H 1 !D $( ;P!  'P /P"* #T F@ [ *T .@#% #D XP Y
M /@ .0#_ +,C  "H*0  GRL  )8K  "-)P  A"$  'L<  !R%   :0H  &
M  !9  < 5  / %  %@!- !P 2@ B $@ * !& "T 10 S $, .0!! #\ /P!&
M #T 30 [ %8 .0!@ #< ;  V 'D -0"( #, F  Q *D ,0#  #  W0 P /,
M+P#_ *\K  "E,   G#,  ),S  "*,   @2L  '<E  !N'@  91<  %L.  !3
M!0  3  ( $< $ !$ !< 00 = #X (P ] "D .P N #D -  W #L -0!" #,
M2@ Q %, +P!> "X :@ L '< *P"% "D E@ G *@ )@"] "8 V0 E .X ) #Z
M *TQ  "C-P  F3D  )$Y  "(-P  ?S,  '4M  !L)@  8B   %<9  !.$0
M10H" #X$"0 Z 1( -P 8 #4!'@ S 20 ,0(J "\",  N S< + ,^ "H$1P H
M!5  )@5; "0&9P C!W4 (0>$ !\(E0 =!Z< ' :] !H&U@ 9!^P &0CY *HW
M  "A/   ES\  (\_  "&/0  ?3H  ',T  !I+@  7R@  %4A  !+&@  010
M #@-!  P" H +0<2 "L(&0 I"1\ )PDE "4)*P D"C, (@H[ " +1  ?#$X
M'0Q9 !L-9@ 9#G0 %PZ$ !4.E0 4#J@ $@V^ !$-V0 2#NX $PW[ *@[  "?
M0   ED,  (U$  "%0@  ?$   '(Z  !H-0  7B\  %,I  !((P  /AP  #07
M   K$@4 )! , "$/%  ?#QH 'A @ !P0*  ;$2\ &A$X !@200 7$TP %1-7
M !,49  1%'( $!6"  T5DP +%:8 "16\  D4U@ *%.\ #!3] *8_  "=1
ME$<  (Q(  "$1P  >T4  '%   !F.P  7#8  %(P  !'*P  /"4  #(@   I
M&P  'Q<( !H5$  8%18 %Q8= !46)0 4%RP $Q<U !(8/P 0&$D #1E5  L:
M8@ )&W  "!N   8;D0 %&Z0  QJY  ,:TP $&>H !AG[ *5#  ";2   DTL
M (M,  ""3   >4H  '!&  !E00  6SP  % W  !&,@  .RX  #$I   G)
M'1\% !0;#  2&Q0 $!P;  X<(@ ,'2H "QXS  H>/0 ('T< !Q]3  4@8  #
M(&X  2%^   @CP  (*(  !^W   ?T0  '^D  ![W *-'  ":30  DE   (I1
M  ""4   >$\  &],  !D1P  6D,  % _  !&.P  .S8  #$R   E+   &28"
M  XB"@ *(A( "",9  <C(  %)"@ !"0Q  (E.P !)44  "51   E7@  )FP
M "=\   GC0  )J   "6U   DT   (^@  "/V *%,  "840  D50  (E5  "!
M5@  >%0  &Y1  !C30  64H  %!'  !&0P  /#\  "XY   A,P  %2X   HJ
M"0 $*1   2H8   J'P  *R8  "LO   L.   *T,  "M/   L7   +&H  "UZ
M   LBP  +)X  "NS   JS@  *>@  "CV )]0  "750  CU@  (A:  " 6P
M=UH  &Y7  !B5   65$  %!.  !%2@  -T4  "H_   <.@  $38   4R"
M,@X  #(6   R'   ,B0  #(M   S-@  ,D$  #)-   R6@  ,V@  #-X   S
MB@  ,IT  #&Q   PS   +^@  "[W )U5  "56P  CEX  (=@  !_8   =V
M &U>  !C6P  6ED  $Y5  ! 4   ,DL  "5&   70@  "SX    [!P  .@T
M #H4   Z&@  .B(  #HJ   Z,P  .CX  #E*   Y5P  .F8  #IV   ZB
M.9L  #>P   VRP  ->@  #7X )Q;  "48   C60  (9F  !_9P  =V8  &UE
M  !C8P  5U\  $E:   [5@  +5(  !]-   220  !D8   !$!@  0PL  $,2
M  !#&   0A\  $(G  !",   0CP  $%(  !!50  06,  $%S  !!A0  0)D
M #ZN   ]R0  /.<  #OY )IA  "39@  C&H  (9L  !_;@  =VX  &YL  !@
M:   4F4  $1@   U7   )UD  !E5   ,4@   $\   !. P  30D  $P/  !,
M%0  2QP  $LD  !*+0  2C@  $I%  !)4@  26   $EQ  !)@P  2)8  $>L
M  !%QP  0^<  $+Y )AH  "2;0  C'$  (9S  !_=0  >'4  &IR  !;;@
M3&H  #UF   N8P  (&   !)=   %6P   %D   !8    5P4  %8+  !6$0
M51@  %0?  !4*   5#0  %-!  !33@  4ET  %)M  !1?P  49,  %"J  !-
MQ0  3.4  $KY )9P  "1=   BW@  (5[  !_?   <WH  &1W  !4<P  17
M #5M   G:@  &&@   EF    9    &,   !B    8@$  &$'  !@#   8!,
M %\:  !>(@  7BX  %X[  !=20  75@  %QI  !;>P  6H\  %FE  !8P
M5N(  %3X )5W  "0?   BX   (:"  ![@0  ;'\  %U\  !->0  /'<  "UT
M   ><@  $'    %O    ;@   &X   !M    ;    &P!  !K!@  :@P  &H4
M  !J&@  :28  &DT  !H0P  :%,  &=D  !F=@  98H  &2@  !BN@  8=P
M &#U )2   "0A   BX@  (&(  !SA@  9(,  %2!  !$?P  ,GT  "-\   4
M>@  !7D   !X    >    '@   !X    =P   '<   !V    =@4  '4+  !U
M$P  =AP  '4J  !T.P  =$L  '1<  !S<   <H0  '";  !NM   ;=0  &WQ
M )2(  "0C   AHT  'F,  !JB@  6HD  $J'   YA@  *84  !F$   )@P
M ((   ""    @@   (,   "#    @@   ((   "!    @0   ($#  "!"@
M@A$  ((?  "!,   @4(  ()3  ""9P  @'T  '^4  !]K0  ?,L  'OK )20
M  "+D0  ?I$  '"0  !@CP  3XX  #Z-   MC0  '8T   V,    C    (P
M  ",    C0   (T   ".    C@   (X   ".    C0   (T   ".    D 4
M ) 1  "0(0  CS8  )!)  "170  D7,  )"+  ".I0  C<$  (SD (Z5  ""
ME@  =)8  &65  !4E   0Y0  #*4   AE0  $)4   "5    E0   )4   "6
M    EP   )@   "9    F0   )D   "9    F0   )H   ";    G    )\$
M  "@$@  H"4  *$Z  "C3P  I64  *.   "AFP  H+<  )_8 (:9  !XF@
M:9H  %F:  !(F@  -IH  "6<   4G    YT   ">    G@   )\   "@
MH0   *(   "D    I    *4   "E    I@   *8   "G    J0   *T   "O
M!   L14  +$J  "T00  N%@  +EP  "YB0  N:,  +C" 'R>  !MGP  7I\
M $Z?   [H   *:(  !>D   &I0   *8   "G    J0   *H   "K    K
M *X   "O    L    +$   "R    LP   +,   "U    MP   +H   #
MQ 4  ,@9  #*,   STD  -5B  #6>P  UI,  -:K /\   #_    _P   /\
M  #\    ^  ( /4 %@#P "( [0 L .D -P#E $$ X0!) -X 40#< %< V !=
M -, 8P#1 &@ S@!M ,P <@#, '@ R@!^ ,D A0#( (T QP"7 ,8 H@#$ +$
MPP#) ,$ [ #  /\ OP#_ +D _P"Q /\ JP#_ /\   #_    _@   /4   #O
M    Z0 $ ., $@#> !X VP G -8 ,0#2 #L S@!$ ,D 2P#% %( P@!8 ,
M70"^ &( O0!G +P ;0"[ '( N@!X +D ?P"X (< MP"0 +4 G "T *H L@"]
M +$ X "O /T K0#_ *D _P"C /\ GP#_ /\   #[    [P   .8   #?
MU@ " ,\ # #* !@ Q@ C ,, *P"^ #4 N0 ^ +8 10"T $P L@!2 +$ 5P"O
M %P K@!A *T 9P"L &P JP!R *H >0"H ($ IP"* *8 E0"D *( HP"S *
MT0"= /, G #_ )P _P"7 /\ E #_ /@   #L    WP   -4   #,    Q
M +T "0"X !, M  = +  )@"M "X J@ W *@ /P"F $4 I !+ *, 40"B %8
MH !; )\ 80"> &8 G0!L )L <P": 'L F "$ )< C@"4 )L D@"K )  Q ".
M .D C0#_ (P _P"+ /\ B #_ .L   #;    SP   ,4   "\    M0   *X
M! "I !  I0 8 *( (0"? "D G0 Q )H . "8 #\ EP!% )4 2@"4 %  D@!5
M )$ 6@"0 &  C@!F (T ;0"+ '4 B0!^ (< B "% )4 A "D (( N0"  -P
M?P#Z 'X _P!] /\ ? #_ -X   #/    P@   +@   "P    J0   *(   "=
M  H F  4 )4 &P"2 ", CP K (T ,@"+ #@ B0 ^ (@ 1 "& $D A0!. (0
M5 "" %D @ !@ '\ 9P!] &\ ? !X 'H @@!X (\ =@"> '0 L0!R ,\ <0#R
M '  _P!O /\ ;P#_ -$   ##    N    *T   "E    G@   )@   "2  4
MC0 . (D & "& !X @P E ($ *P!_ #( ?0 X 'L /0!Z $, > !( '< 3@!U
M %, <P!: '$ 80!P &D ;@!R &P ?0!J (D : "8 &8 J@!D ,, 8P#G &(
M_P!A /\ 80#_ ,<   "Z    KP   *8   "=    E0   (X   "(    @P )
M '\ $@![ !H >  ? '4 )@!R "P <  R &\ . !M #T :P!" &H 2 !H $X
M9@!4 &0 6P!B &, 8 !L %X =P!= (0 6P"2 %D I !7 +H 5@#; %4 ]P!4
M /\ 5 #_ +\!  "R!@  J 8  )\$  "6    C@   (8   "     >@ $ '4
M# !Q !4 ;0 < &D (0!G "< 9  M &, ,P!A #@ 7P ^ %X 0P!< $D 6@!/
M %@ 5@!6 %X 5 !G %( <@!0 '\ 3P"- $T G@!+ +( 20#/ $@ [P!( /\
M2 #_ +@.  "L%   HQ4  )D3  "0#0  B 8  (    !X    <0   &L !P!G
M  \ 8@ 6 %\ '0!< ", 60 G %< +0!6 #, 5  X %( /@!0 $0 3P!* $T
M40!+ %D 20!B $< ;0!% 'H 0P") $$ F0!  *P /@#& #T Y@ ] /P /0#_
M +,9  "H'@  GB   )4>  ",&@  @Q0  'L-  !R!   :@   &,  @!=  H
M6  1 %4 %P!1 !T 3@ C $T * !+ "T 20 S $< . !& #\ 1 !% $( 30!
M %4 /0!> #L :@ Z '< . "% #8 E0 U *@ ,P"^ #, WP R /8 ,@#_ *XB
M  "D)P  FRD  )(H  "))   @!X  '<9  !N$0  90@  %P   !5  4 4  +
M $L $@!( !@ 1  = $( (P!  "@ /P M #T ,P [ #H .0!! #< 2  U %$
M,P!; #$ 9@ O '0 +@"" "T D@ K *0 *@"Y "H U@ I /  *0#_ *LI  "A
M+@  F#$  (\P  "&+0  ?2@  '0A  !J'   810  %<+  !/ P  1P & $,
M#  ^ !, .P 9 #@ '@ V "0 -0 I #, +P Q #4 +P ] "T 1  K $X *0!8
M "< 9  F '$ ) "  "( D  A *( 'P"V !\ T0 ? .P 'P#Z *DP  "?-0
MEC<  (TW  "$-   >S   '(J  !H)   7AT  %07  !*#@  00@  #H!!P U
M  T ,@ 4 "\ &0 M !\ *P E "D *P G #$ )0 Y ", 00 A $L 'P!5 !X
M8@ < &\ &@%^ !@!C@ 7 :  %@"T !4 S@ 4 .@ $P#W *8U  "=.@  E#P
M (P\  "#.P  >C<  ' Q  !F*P  7"8  %(?  !'&   /A(  #0+ 0 L!@@
M* ,. "4"%  C AH (0,@ !\#)@ =!"T ' 0U !H%/@ 8!4@ %P93 !0'7P 3
M!VT $0A]  X(C0 -!Z  "P>T  H&S  )!^4 "0?T *0Y  ";/@  DT$  (I!
M  ""0   >#T  &XX  !E,@  6RP  % G  !%(0  .QL  #(6   I$0( ( P(
M !L)#@ 9"!4 %PD; !8)(@ 4"BH $PHR !$+.P /#$8 # U1  H.7@ (#VP
M!Q![  40C  $$)\  Q"S  $.RP !#>0  @WV *,]  "90@  D44  (E&  "!
M10  =T,  &T^  !C.0  630  $\N  !$*0  .B0  # ?   G&@  '18# !01
M"  .#@X #1 7  P1'P +$2< "1(O  @3.0 '%$, !11/  ,57  !%FH  !9Y
M   6B@  %IP  !6Q   5R0  %.,  !/S *%"  "81P  D$D  (A*  !_20
M=D@  &U$  !B/P  6#H  $XU  !$,   .2P  # H   G(P  '1\  !$9!@ )
M%@T !A<5  48'0 #&"4  ADM  $:-P  &D$  !I-   ;6@  &V@  !QX   <
MB0  &YL  !NO   :R   &>(  !CS )]&  "72P  CTT  (=/  !_3@  =DT
M &Q)  !A10  5T$  $X]  !$.0  .C4  #$Q   E+   &24   P@!@ $'@P
M !X4   >&P  'R,  !\K   @-0  ($   "!+   @6   (68  "%V   BAP
M(9H  !^N   >Q@  'N,  !WS )Y*  "53P  CE(  (93  !^4P  =5(  &M/
M  !@2P  5T@  $Y%  !%00  .ST  "TW   @,@  %"P   @G!@  )@P  "43
M   F&0  )B$  "8I   G,@  )ST  "9)   G5@  )V0  "=T   HA0  )Y@
M "6L   DQ0  (^,  "/U )Q/  "45   C58  (58  !]60  =5@  &M5  !@
M4@  5T\  $]-  !$2   -D,  "D]   ;.   #C,   ,O!0  +@L  "T1   M
M%P  +1\  "XG   N,   +CL  "U'   M5   +F(  "YR   NA   +9<  "RK
M   JQ   *>(  "GV )I4  "360  C%P  (1>  !]7@  =%X  &M<  !@60
M6%<  $U3   _3@  ,4D  "-$   6/P  "3L    X!0  -@H  #80   U%0
M-1T  #4E   V+0  -3D  #5%   T4@  -&   #5P   U@@  -)4  #*J   Q
MPP  ,.(  "_V )A:  "27@  BV(  (1D  !]90  =60  &MC  !A80  55T
M $A8   Y4P  *T\  !U+   01@  !$,   !  P  /P@  #\-   ^$P  /1H
M #TB   ]*@  /38  #Q"   \3P  /%T  #QN   \@   /),  #JI   XP@
M-^(  #;V )=@  "090  BF@  (-J  !];   =6P  &QK  !>9@  4&(  $)>
M   S6@  )58  !=2   )3@   $P   !*    204  $@*  !($0  1Q<  $8>
M  !&)P  13(  $4_  !%3   1%L  $1K  !$?0  1)$  $*G  ! P0  /N$
M #WW )5G  "/;   B6\  (-Q  !]<P  =G,  &AP  !9;   2F@  #MD   L
M8   '5T   Y:   #6    %4   !4    4P(  %('  !2#   41,  % 9  !/
M(@  3RX  $\[  !.20  3E<  $UH  !->@  38X  $ND  !*O@  1^   $7W
M )1N  "/<P  B78  (-Y  !]>@  <7@  &)U  !2<0  0FX  #-J   D9P
M%F4   9C    80   &    !?    7@   %T#  !<"   6PT  %H5  !:'0
M62@  %DU  !81   6%,  %=D  !6=@  5HH  %6@  !3N@  4=X  %#W )-V
M  ".>P  B7X  (2!  !Y?P  :GP  %IY  !*=P  .70  "IQ   ;;P  #&T
M  !L    :P   &H   !I    :0   &@   !G @  9@@  &8.  !E%@  92
M &0N  !D/0  8TT  &->  !A<0  8(4  %^;  !>M   7=<  %OT ))_  ".
M@P  BH8  '^&  !QA   8H$  %)_  !!?0  ,'H  "!Y   1=P   G8   !U
M    =0   '0   !T    <P   ',   !R    <@$  '$'  !Q#@  <18  '$D
M  !P-0  <$4  &]7  !O:@  ;7\  &N5  !JK@  :<X  &CO )*'  ".BP
MA8L  '>*  !HB   6(8  $>%   V@P  )8(  !:!   &?P   '\   !^
M?P   '\   !_    ?P   'X   !^    ?0   'T   !]!0  ?@H  'X8  !]
M*0  ?3P  'U.  !]80  ?'<  'J.  !YIP  =\0  ';H )*/  ")D   ?)
M &Z.  !=C0  38P  #N+   JBP  &HH   F)    B    (@   ")    B0
M (H   "*    B@   (H   "*    B0   (H   "*    BP$  (P*  ",&P
MBC$  (M$  ",5P  C6T  (N&  "*GP  B+L  (?> (V4  " E   <I0  &*3
M  !2D@  09(  "^2   >D@  #)(   "2    D@   )(   "3    E    )4
M  "5    E@   )8   "6    E0   )8   "7    F    )H   "<"P  G!\
M )PU  ">2@  GV$  )Y[  "=E0  F[   )K2 (28  !VF   9Y@  %>8  !&
MEP  ,Y@  "&9   1F@   )H   ";    FP   )P   "=    G@   )\   "@
M    H0   *$   "B    H@   *(   "C    I0   *@   "K    K0X  *PE
M  "O.P  LE(  +5J  "UA   LJ(  +#" 'J<  !KG0  6YT  $N=   YG@
M)I\  !2A   "H@   *,   "D    I0   *8   "G    J0   *H   "L
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M____________________________________________________
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M%!46%Q@9&AL<'1X?("$B(R0E)B<H*2HK+"TN+S Q,C,T-38W.#DZ.SP]/C]
M04)#1$5&1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM
M;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:
MFYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'
MR,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T
M]?;W^/GZ^_S]_O]M9G0Q      ,!(0   0                    $
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M__________^C6Q<  "&"Z________________________________^J*-@4
M  5XY?_______________________________]IQ4#\K  !_[/__________
M_____________________\N@BXEY/5F&_/__________________________
M______?9VN3$G;GD____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________+"K[+_________
M____________________________U(Y0,UO*________________________
M___________=BT,  "R5]?________________________________:D6@\
M  EMSO_______________________________\9T*0    !/L___________
M_____________________Z%'       WG___________________________
M____[WT6       >CO______________________________UD<        %
MB/______________________________JCX)        @/______________
M________________RH-$$P      </W_____________________________
M_]"=:#PT,TAGBO+________________________________]S*:>H[?4^?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________]JTH):W___________________________________RJVM!
M+B-=U?________________________________^J8AT    RH___________
M_____________________\ES*0     2?NS_________________________
M_____YM#        8<______________________________T6L*
M2;G_____________________________J3          -*?_____________
M________________?0          'I;____________________________L
M-@          !XC___________________________^V             'K_
M__________________________]=(            &;]________________
M__________^^<S           $WM____________________________X:%>
M*@4      "[9_______________________________-E6=33EYUD*W5____
M______________________________KK[?O_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^[5Q+>KRO__________
M_______________________DH6]10#(C8.7_________________________
M_____]>+1@H     -[7_____________________________]I1'
M%X______________________________OU\)         ''O____________
M________________DRD          %G8___________________________N
M:            $7$___________________________")            #&S
M__________________________^0             !NA________________
M__________\]              20_________________________^$
M          "!_________________________U\               !K____
M_____________________R(#              !1_O__________________
M____JYYK*P             SY__________________________YOW(W$@
M      $6S/____________________________6[C&M95%UK>8B5VO______
M___________________________Z^?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________#ATO'________________________________ILH]V9%5$
M,WC______________________________\5Z.Q$      $+/____________
M________________S'0G         !BA___________________________V
MB34           *%__________________________^_5             !N
M_O________________________^2'             !9Z_______________
M__________AF              !'VO_______________________]8B
M           TR?_______________________Z\                ?N/__
M_____________________U4                (I?__________________
M_____P                  D_______________________E@
M        @/______________________                    8_______
M_______________)                    0O______________________
M'T8J!0              +>______________________]/_=HF,Y&0
M 0X<+N?____________________________1JXQ_?H:1G:JXQ?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________Z,NTH(]^;6+)____________________________
M_\2$5#0<!0    R3____________________________LV 7          !D
M^O_________________________*9A$            YR_______________
M__________^()P             1HO_______________________\I/
M            ?________________________Y<8                7___
M_____________________V,                 4/G_________________
M____X2,                 0.O_____________________J0
M        +=O_____________________5                   %\G_____
M________________                     +7___________________^@
M                     )_____________________0
M     (/_____________________                     'K_________
M____________*0                   ''_____________________@ D.
M                 &O_____________________]\R_GG=7/288%!LD+SM'
M5'/_____________________________[=3,S-+;Y.WY________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^N;4P:W!
M_____________________________^>TD'-;13$;!@!E^?______________
M____________KF(G           UR?________________________^M4
M           &F________________________])A @              </__
M_____________________XPB                1^W_________________
M____X$\                 (<K_____________________J!D
M         *K_____________________;                    (O_____
M________________)@                   &S____________________&
M                     $[___________________^)
M     #+___________________^J                     "#R________
M___________4                     !?G____________________
M                 !7C____________________)P
M !'<____________________:0                    O2____________
M________Q@                    ;+_____________________SP)!@
M              '(_____________________^S3OZB->&EA8&=P>H2/FJ78
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MYLJRG(=T7T=!T/__________________________RHI;.!L        $F___
M______________________^F3@0             :O__________________
M_____[-+                /.3_____________________YF(
M        $+G_____________________GB,                  )#_____
M________________7                    &S____________________E
M'P                   $G___________________^?
M     ";Q__________________]Z                      31________
M__________^5                      "S__________________^U
M                  "7___________________:
M  ""____________________                      !X____________
M________+0                    !V____________________9@
M              !S____________________J0                    !O
M_____________________QP                   !J________________
M_____X4                   !E______________________\Z)24;#0$
M   '$!DC+3==___________________________LV<O&R=#:X^KS_?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________?BS;>@PO__________________
M_________]BOC7!6/R@0    <?________________________^\;3(%
M        .^/______________________ZA&                "+'_____
M________________SDT                  (/_____________________
M>                    %?____________________F+
M     "[S__________________^3                      G0________
M__________]M                      "M__________________^)
M                  "+__________________^H
M  !I___________________&                      !)____________
M_______G                       M____________________"@
M               ;____________________-0                     4
M^___________________9P                     3]?______________
M____H0                     3]?__________________Y0P
M           ,[____________________UT                    $Z?__
M_________________\8$                    X?__________________
M__^&                    U/______________________CW!K8U]<7V5O
M>(")D9JDU/__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________]=B^IY%[94TS1?'_____
M___________________YL'U3,1(         #;G_____________________
M_[U>$P               (3_____________________RDD
M     %'_____________________8                    "#B________
M__________^W#0                    "V__________________]?
M                  "/__________________]U
M  !I__________________^7                      !&____________
M______^U                       C___________________3
M                [?_________________R
MS/__________________&P                      L?______________
M____0@                      GO__________________;0
M            E?__________________G@                      D?__
M________________VP4                     D/__________________
M_TH                     CO___________________YP
M        A_____________________]#                    >_______
M_______________''0                  :/______________________
MR28        ##!0<)"TU4?_________________________Y]_'M[?#U^___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________WX<FQE\___________________________^&UDG1902H2
M     (K_______________________^>5R(              %3_________
M____________X%\$                 ![@____________________70
M                  "M__________________^;
M  !]__________________]1                      !2____________
M______]Z                       I__________________^B
M               #Z/_________________$
MQ?_________________C                        H_______________
M____"0                      @?__________________*@
M            8O__________________3P                      2/__
M________________>                       ./__________________
MI@                      ,/__________________V@4
M        +?___________________T                      +/______
M_____________X<                     *____________________]@B
M                    '_____________________^"
M    #?______________________5@                   /__________
M_____________V4                  -________________________^X
M9FEM<GB!B(V4GZ6MM=C_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^K/MI^';U4[(5;_________________________
MN(%4+Q           "#D_____________________YY"
M  "N____________________> ,                   !Y____________
M______^8                      !'__________________]%
M               6]O________________]Y
MS/________________^G                        I/______________
M___/                        ?O_________________S
M            6O__________________(                       -___
M________________00                      %?__________________
M8P                       /__________________A@
M         .__________________K@                       -W_____
M____________W@T                      -/__________________T(
M                     ,W__________________WX
M     ,K__________________\(-                     ,?_________
M__________]@                     +_____________________ )0
M                 *S_____________________FQ$
M (_______________________Z8F                 &7_____________
M___________]?!0    "#!0<)BTS/$W_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________D
MR:W___________________________'$GGU@12L2      "N____________
M__________F84AT               !V____________________N#D
M              !"__________________^R$0                     /
M[?________________\Z                        N_______________
M__]T                        C?________________^H
M            8O_________________6                        .O__
M________________#                       $___________________
M,@                       /C_________________5P
M         -?_________________>@                       +?_____
M____________G0                       )O_________________P@
M                     (;_________________ZA@
M     ';__________________T<                      &W_________
M_________WX                      &C__________________[P&
M                 &3___________________],
M %____________________^= 0                   %7_____________
M________8P                   #S_____________________WTX
M             !?______________________^UC                  #_
M________________________P5,   ,3'RP\4FR'J=3_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________\25;UI024$Z,BHA%PXT
M_____________________X\O                   "Y?______________
M___U1                       L?________________\U
M            ?_________________]I                        4/__
M______________^H                        (O_________________<
M                         /K_________________%@
M         -+_________________0@                       *W_____
M____________:@                       (G_________________CP
M                     &?_________________LP
M     $G_________________V 8                      ##_________
M_________RT                      !S__________________U<
M                  ___________________X4
M  ;__________________[D$                      #_____________
M______A#                      #___________________^+
M              #____________________;/P                    #_
M____________________H!@                   #Y________________
M_____XX5                  #2______________________^O.@
M        $C2__________________________YA=<7^/H;+$V?3_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________PY-G2
MR\;!O;>RJZ:G\/__________________^YEO43DG& H             :O__
M______________^,(0                      ._________________]2
M                        #?________________^A
M         .'________________@                         +;_____
M____________'0                       (O_________________3P
M                     &/_________________>@
M     #W_________________HP                       !G_________
M________R0                        #_________________[QT
M                  #__________________T(
M  #W_________________VH                       #D____________
M_____Y4                       #6_________________\,-
M              #,__________________A"                      #%
M__________________]_                      "_________________
M___'*P                    "U____________________?0
M          "B____________________X5(                   "!____
M_________________]13                  !.____________________
M___V?QP   D8)S='7'.+J,[__________________________^[2YO3_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________W6NJ21AGUU;FAB
M75=234A%1__________________%?THA"                    ,/_____
M__________^/                         )C________________=
M                     &[_________________'
M     $3_________________5P                       !O_________
M________B0                        #_________________M0
M                  #Z________________W@P
M  #9_________________S,                       "Z____________
M_____UD                       "@_________________W\
M              ")_________________Z<                       !W
M_________________]$;                      !K________________
M__]*                      !B__________________^
M          !;__________________^\'P                    !3____
M________________9@                    !&____________________
MNC(                    K_____________________Y4<
M        ______________________^8*@            LA.5A[________
M________________R6)=;'N*FZ["V//_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^(X($E#0U]0
M4D]&24Q% !45________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________\\.CAV];0S,C&P\/"Q>______________
M____V:6#:U=&."\G(!H3#08      $?________________4/P\
M             ![_________________$@                        #_
M________________5                         #X________________
MDP                        #2________________QP
M          "L________________\Q\                       "(____
M_____________TD                       !G_________________W
M                      !*_________________Y<
M       P_________________[P%                       :________
M_________^,L                       +__________________]7
M                    __________________^&
M    __________________^](                       ____________
M_______X70                      ____________________H!D
M                ____________________^6P
M_____________________]E;                   :ZO______________
M_______A:@D #1DF-D=;<(BCP>7__________________________\C'VNKY
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________?QK:GFY")A'YY='!L:VIL;WC_________________
ME&1"*!4$                  #/________________30
M          "G________________EP                        "!____
M____________U                         !<_________________RT
M                       X_________________UL
M       5_________________X8                         ________
M_________ZX                         _________________]0>
M                    __________________I$
M    __________________]J                        ^/__________
M______^4                        [/_________________#)0
M                X__________________Y7
MV/__________________F1(                     RO______________
M____WU<                     L____________________ZDS
M            B?____________________^?,          ,(3A0;(RNXO__
M____________________M5MG=X>5I;C-Y/[_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________^.WEXM_<VMC6U=;:X^O_____
M____________[;J9?VYA5DU%/SHU,2PH)B4E)RE>________________G3 .
M                       I________________W
M       &_________________S4                         ________
M_________VH                         _________________YD
M                    _/_______________\,,
M    X/_______________^PU                        Q/__________
M______]=                        K/________________^#
M                F/________________^J"P
MBO_________________3-0                      ?_______________
M____8P                      =/__________________F!$
M            9O__________________U$\                     4?__
M_________________Y4@                    +O__________________
M__!S"@             2*TAFD?_____________________D< \:*CE(6&A[
MDJS(Y____________________________<'-WO#_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________KUL:ZKZ>AFY:3CXN)AXF-EJ&N________
M________]X%B2SDK'Q4.!P$             _________________S<
M                    Y?_______________W<
M    P________________ZP                         I/__________
M_____]HA                        A_________________],
M                :O________________]U
M4/________________^<                        ./______________
M___#)                       )__________________J2P
M            &O__________________=0                      #O__
M________________HQH                      /__________________
MU4\                      /___________________XL7
M         /___________________]9=                 !@S5_______
M______________^Y2      +&BL^5&Z*J<KP________________________
MMVAZC)ZOPM/F________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________[X\^_KY^7CYNGP
M^O___________________]6RFXM]<6EB7EE54DY+2DQ05E]JN?__________
M_____XHV'@X                     9/_______________\
M                1?________________,R
M*O________________]B                        #?______________
M__^-                         /________________^V%P
M             /_________________</@                       /__
M________________9                        /__________________
MBP(                      /__________________M2P
M         /__________________XUH                      /______
M_____________XX8                     /K__________________\E4
M                   2,OC___________________^=,P         4*D->
M?)R\W/_____________________]CB\]3V!P@92JPM[_________________
M_____________\W:[/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________Z=G.Q;VVL:VJJ*:EIJFON<74
MWO_______________^>!;%Q/13TU+BDD'QP:&1D:'2(J-_______________
M__\^                         /________________]T
M             /________________^D @                       /__
M_______________/+P                       /_________________W
M6                        .G_________________?@
M         -7_________________I!H                      ,3_____
M____________S$,                      +3_________________]FT
M                     *?__________________YHD
M     )/__________________\I7                   %(Y7_________
M__________^2*@          #"1 7GV=O.S____________________A=!4.
M(#! 469]EK'0\___________________________U8R8J[_1Y/G_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________[\
M^OC[_/_________________________3MZ:;DXN%?GEU<F]P<'-X?XR>K/__
M______________^62C@J(1H2"P0              ,G________________
M$P                       +#________________M1@
M         )G_________________<@                       (3_____
M____________F@\                      &[_________________P3<
M                     %K_________________YUT
M     $K__________________X4.                     #K_________
M_________ZXW                     ";__________________]ED
M               )*4O___________________^5+@           !$N36R.
MLMG____________________6:PT  ! @,49==I&QT_;_________________
M________NF%G>HV?LLCB_?_______________________________^OP____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________'EW-;1S,?#P<#
MQ<G/U^7Z___________________UE(%R:6)<5U)-2DA'1TE,4UYOAJ;_____
M____________71\0!0                   "?_________________C
M                     !3_________________MRP
M      #_________________WU0                       #_________
M_________WP$                      #__________________Z,K
M                  #__________________\A1
M  #___________________!X$                  <06+_____________
M______^C/0            TK2VZ3N]?____________________8;Q(    .
M'S-*8W^@P^?_________________________L$U#5VM^DJC!W/K_________
M_____________________[Z[TN?\________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________Y\F[L:JDGYR:F)B8FJ"E
ML+W3[/__________________O6-63$4^.34P+"HH)R@L,CE*:(O_________
M________W$8                       #__________________W0
M                  #__________________YPC
M  #__________________\-*                      #_____________
M_____^EP!P                    #[__________________^6+
M          XT7'____________________^\4P           !4T57NDS>W_
M___________________D?1\    &%RQ#77V>PNC_____________________
M____LU(N0E9J?Y6NR^K_____________________________^*64K,+9[___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________]_#L
MZ.7EX^+EZNWU_________________________[:;D8J%@7Y]>GEZ>X"(E*.X
MVO3__________________YM".3$J)2(?&A42$! 2%!DH2'+D____________
M_____[U                       "F_________________^1K
M              "5__________________^2)P                  !BZD
M__________________^W30              !BU3>Y_?________________
M___<<1(          B)&;).ZYO_____________________^EC@    '&B]'
M8H2HSO;_________________________P6$B-TQB=HVHQ>;_____________
M________________^9Y\E:O#V_3_________________________________
M__WI________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________BUL_)Q\7%
MQ<C&S-3;X_+_______________________J8?'1N:FAG9VEG:W%X@Y*DPM_U
M__________________^-+R$:%!$."P8!       1,EZ.________________
M__^T20                 #,5V#___________________;<!
M    )U)ZH\WK___________________^E#4         %#A?B;3:________
M________________ME8    /)#Q6<I"YX?__________________________
MVGLG-DMB>I.PS>[______________________________ZMTB:&ZU.[_____
M______________________________;3Y___________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________XP+6OK*JMK;&W
MP,70V>/[_______________________OB6!95E1765UC96UU?I&HP^SY____
M________________ES4-"04"       =3'FBS/?_____________________
MO%P#       -,%>"K=C_________________________W'\G  8<-$]LC:[6
M_____________________________)]#.U)KAJ' X___________________
M_____________\)]A:"ZUO;___________________________________[.
MU//_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__/O[N[O]?S_________________________________\Z^;FIN>I:ZZO,34
MYO__________________________]Y=43$]46V5N@)? Y_______________
M_____________ZY4 !LV4G",J\OV_____________________________\IK
M/V-_G;S>_/_______________________________^>9@ZS(Y___________
M___________________________;S/+_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________\
M
M
M             /______________________________________________
M____________________________________________________________
M____________________________________________________________
M____    _^X #D%D;V)E &2      /_; $,  0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,#
M __  !0( )<!A@0!$0 "$0 #$0 $$0#_Q !D  $  @(# 0$!
M"0H("P4&!P0" Q    8" @ $ 08)"P,$ @,   (#! 4& 0<("1$2$PH4(158
MV%D:(M46%Y>8J!DY,2.T-766ME?7&'A!B+@R))34-'>U)S?_V@ .! $  @ #
M  0  #\ O\"_P+_ O\
M
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ML_KF9X;)^EX'4*8Q,&  BP^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0
M^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]'
M=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]'=%'
MTYOV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]'=%'TYO
MV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N
M8?U?0  ^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U
M?0  ^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0
M ^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]'=%'TYOV9N8?U?0  ^]
M'=%'TYOV9N8?U?0 !S$-[G'HUGG:+)CSLAT%EU#)D/,Z'Y1UQH4Q$_4SE9_8
M=(1;%NGDN/#!U%"E,;\'&<F^0  2?Z YR\,N59TFW&SE7Q[WE*'C2RZU>UAM
MVBV^V1T>8A5,KS50AYMS9X$R1#8]1-ZT;J)9^0Y2Y^0  93@
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M3UNH.Z&)9&9:P<S.4FET&OG@;S4VZCB&+\VD<%6B) JJA\81\0 *Q@
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MDU4E"E.F<N2FQC.,X  'Q@ #T'5.V-F:+V+4=N:<O=IUGLZA2Z,[3KU2YA[
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M<V?:X>DEY^SGL#\_ID\WJ\A>Y?U?-Y<>;U?0BO0]3Q_]7D_ \?Y/D  ']/\
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M9U%;HJZTBS1V2G,REHM;S&:2#);!V<S 3+(ZK&3CG1%64G'.5VCE-5NLHF8
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MZS22-QJOM$CGC919%RQ?[;;(:F9OVJR"*RJ+IBYNQ5DCXP7R')C/G3QCSE
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M%8[GMSCY$U.URECH5+><B5(V1B=/ZM8Z%E&$A9;$^R\=L62BJ",7(1YE$6X
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MILV+;UW*KA](/%"IY5=/'*JSMZY447<*J+***&  ],     50?>2?PD*U_S
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M;8U;13,J$+KG>Z?DE-ET;TFV,MXN-MJKK-DAD\X13,5R_:-4_1C#>  %6
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MN3=U?LD7F$RM"UJ-T= 02J\65+.%"NL6B0(W6R<F$L(*D*4WG-D@ &OE
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M_P!\;:9[TG)9SENA"4;DC,SC9Y8Y-=51?X.#UO.3D;-+)%R?!&,/E%/'AY?
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M0OPZXR\1=A;FT54=T;*Y.Q%HI<]=-[WCC/&]N'+_ &_%2,\A69"K4'0^\;5
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MZ13MCT>8:V&E; JM>NU/GV)C&93E7M<0SG:_,,S&P4QFLG$OT5D\YQC.2'P
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M*^9!JWC58JF]=NX]M(DD$55G:SQ:7F8RXV:5*<N,H_$N\)ME$REQZ93F\3
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M(?;\(S6\B3@U)W34F-?5;L,8,7+QG#VS53Q=QG!,F05ET\'/Y542E  NR@
M  -<<[I$_P 7_<2=O?%*M638%%:<UN/'(/85"?ZRW:WXU3[RX3M-J?/1@:$W
MB^8S,?JMFK(4JS5I]+N&BS5E%OI N4R)FP=, "/6CL*5>=D+M=,QFF=E[X>+
M$=R!.*''_D1W)\VWZJYL$07GMF\L20/"ZIE.=(Q4;/4B&E(;.5'A4U%4D2Y
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MX=91?(JIJX-G*OR@ 0C        Y")_K6,_M!E_24P !OZ
M       '%S$'"V%D:-GX>+G(\RB:QF$Q'M)-D95+.<I*F:O45T,J)YSXE-Y?
M''_0  8:\B^"FAMM\>^0FIZ5I/0M.M^X=&[?U5"VS\U=0CBP\ILO7]BIS>3?
M/H6O8F",6[B;PHXRAYEC)8-Y<9-X8R !X]U7]3_&;J@T(TU1I&'3GMA61G$N
M]W;UFV"*-ZW!:X])?.'C_.%G>*[3X==ZN2%@6JIFD:W4,8YW+U9V]<@ 2?@
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MAXR:E55SC&5%,((%\QL_RY^4  =3     <A$_P!:QG]H,OZ2F  -_0
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M7 1-6K$%'HX\$6,/ 0;1C%1C-+'R%202(0N/Y,  #M
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MFJ>W=3UF?)M$Y!!L^<D1,J9'#?+558 "W"  -"/MG_\ U39?_P"P+E_B.2
M'GX    #D(G^M8S^T&7])3  &_H
M                 &OR]P+[;38%.OEJ[%NKZN3!3I3A=E;9XWZP;N(JYT*W
M1[HTX]V]QT:5WX1^LRQ)MB/W5=CBXDXQ_DSF*PJW/\(P  [ITS>[:@',;5.-
M7:O(.(.>CTV5;J?,*/B7+N+F/1PDR8M>0%<AVJSZ(F,F+A-6SQS=5HL8V%))
MLUP1S('  O3Z^V+K_;-.@=B:LO%1V10+4Q3DZS=J)8XBVU.P1RN<E(^A;# O
M'\3)M3&+G'G15.7S8SCQ\<9  '<@                       15=T?8-$]
M:?7KO#D2E(-4-GOHDVK] 1B^43*S&[K\R?L*@NDU7QE)\UIC9N\LCY WE]:.
MA7!"Y\YBXR !I:)"0D)>0?2TL^>2<I)O',A)24@Y6>R$A(/5CN7CY\\<G5<.
MWCMPJ91550QCJ'-DQLYSG.0 !\8          GDZK/<,<UNI[5ULT9J>M:AV
M[INRVIW>HZE[BB+6[5I%MDV;!A./Z;/5"V5:09QMA;QC<[R/=X>-<.4?7;%;
M*K.S.0 ,R+G[P?M<L.\:?M>M1_'6CTBI0,G N] Q^O;',:QO7SRO%.WDW>I&
M8NZ^Q'-B9N(DA8]Q$S4.1BV,HD5,WKNS.  ,D?OM'/KZ*/$#_P"/N?\ U1
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M,OZ2F  -_0
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M]'@  ^_%ZM^SLO\ ^L?7?]'@  ^_%ZM^SLO_ .L?7?\ 1X  /OQ>K?L[+_\
MK'UW_1X  /OQ>K?L[+_^L?7?]'@  ^_%ZM^SLO\ ^L?7?]'@ !6U[TN\FV]Q
M]UTJG%:NE-#Z4TE7YL\+K1]>$KP[G=CVMZ3%CODS+,:Y5&2GIU^-CXZ.:F:J
MG8E3=J%6_P#?*)D  @.
M '(1/]:QG]H,OZ2F  -_0
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M1\')G*:D@=,^,&+CY#8SC/\ UQX  "6H
M
E                                             '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>sny-20231231_g29.jpg
<TEXT>
begin 644 sny-20231231_g29.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
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M(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_XGT024-#7U!23T9)3$4
M 14 "?P0041"10(0  !P<G1R0TU92TQA8B 'UP %  \ $  >  -A8W-P05!0
M3     !!1$)%                        ]M8  0    #3+4%$0D4
M                                                          YD
M97-C   !+    'QC<')T   !J    "MW='!T   !U    !1T87)G   !Z
M !AT96-H   "      QV=65D   "#    %YV:65W   ";    "1!,D(P   "
MD  !7V9!,D(R   "D  !7V9!,D(Q  %A^  !7V9",D$P  +!8  ".+1",D$Q
M  3Z%  ".+1",D$R  <RR  ".+1G86UT  EK?   D)%D97-C         ")#
M;V%T960@1D]'4D$S.2 H25-/(#$R-C0W+3(Z,C P-"D
M
M                            =&5X=     !#;W!Y<FEG:'0@,C P-R!!
M9&]B92!3>7-T96US+"!);F,N  !865H@        V$4  .!/  "^YG1E>'0
M    24-#2$1!5"!&3T=203,Y '-I9R      ;V9F<V1E<V,         !$0U
M,
M                                                 '9I97<
M F74*P)\GJD"#27, 'K$"0!_4N\ :0>/     6UF=#(     ! ,+   !
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MBCQ\QY<WB1Y]-H/+B A]QV_QAQY^5EN8AE%^Y$:&A9=_;R_0A1%_UQ3WA2^
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MD JFLD0@C;"BY3.QBVB=U"&UB6F6O0XRADB)F:[OHA3+H)^TGG?&,)!IFP3
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MA*U\O4+OA#!]?2S*@]E^#A)U@_U^U]@2B4N VL8_B"N JK0WAS& ?J'@AG"
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M<">UIW1]=!JCH^!^E@Q3H"6 ! (_E""!.'>(RCY^[&P9Q*U^HV"^OR]^?E6
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M]LSX>''2<;MQ>(K,-JG>>*S&#9@Z>-[  (:]>2:Z W5#>6ZT"V-T><"N,5%
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ME40DAO.-!S,UA=V+Q""4A/:+,@PM@RB&[:U8D%6B'Y[.CJ^?:I BC1"<NX%
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MHL!_PXYLGZ1_WH$IG+!_ZG.8F?E_X&7TEW&  5@_E/Z .$G@DK. :CK@D)>
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MC+" HY WJMI_(H/8IT9_+G=:H\I_.FJIH'1_1EWFG5-_?5$5FDM_RD.7EW&
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MMVYUU45FLJAV\CK;K@MX+2_ J;MY:"/]I=]ZIA<NHM][Z GOGB=^# #ODD"
M"F_QQ59YG64QP$]YU%J"NU!Z(D_LMF!ZE$5EL:%[0CK<K09\$2_(J*I\\R07
MI+)][!=LH8)_"0I7G+: 6P%ND0R ^&^RQ"5_G64 OR=_:EI@NC1_4$_=M5)_
M745>L)E_H#K;J_R !"_/IYV B"0MHYN!-A>BH$N"+@JRFVV"90'?C_R!1&^
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M#(<DI*^!'O_B?1!)0T-?4%)/1DE,10 "%7NAH:.!&V_WGJF!$F0-F\Z! 5@
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MA#Q\J"VG@\U]2ALZ@Z5]SP@L@HE_$)^QB!U_])*-ASV !H4RAFJ $7>$A:^
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MGQ!WV$M[G$%XP4"3F89YN#3LEQ=ZKRB+E/Y[JQLMDVY\M0QID4%^6@'SBA2
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MI,1]8">NH55^'QT0GEI^_1&$F^& &0<YE&Z!!@!+B[> ,V 'MTV XE:?LT*
MPDU#KTF O$/WJVV V3J[IXF!$S&!H["!8R>OH#R!SATWG3*";!'8FIR"[@>=
MDS."Q0"ZBL" ?E^MMF6&9E9,LEJ%ZTSXKF.%B4.TJHR%2CJ&IJN%+S%@HM.%
M-">LGU.%8AU;G#"%W1(HF7&%= ?ZD@B$50$AB<F PU]GM8&+[E8(L8>+!TRW
MK9R*0$-YJ<F)ISI9I>N).S%$HA.(]B>JGHJ(ZQUZFU&)$1)LF'&'G0A*D0F%
MFP%XB/6 _E\8M+.1=56]L,"0+TQRK-J/#D,]J0>.(SHHI3"-;#$CH5V,Y">@
MG<^,J!V.FH2+\A*BEXB)B@B,D":%QP'"B$&!,%ZZM *7 %5GL 25>$PFK!64
M%$+\J$"2YCGRI'.1[3#YH*V1+R>,G1R0=1V7F<..E!++EK"+2 C"CUN%[ (!
MAZF!6UY9LU2<GE46KUB:QDOBJVJ9&T+#IY&7LCG"H\Z6A3#3H!:5?2=YG(.3
MIQV<F1Z0R!+LE?F,O@CNCK*&"@(UARR!?EX LK&B0E31KL6@ $NLJM^> 4*5
MIP.<;#F<HTF; S"UGYN9""=IG >6-AV@F)B2C1,&E6:,W0D1CBJ&(0)>ALB!
MFLD@;AME#+@9;Y=GBJ<*<.]I[I7M<A%L*(2J<S=N.W-'=%QP0F%\=8!R,$\M
M=IAT!3P'=XMUKB;1>!9VRPV]>91W>,:Y:UYN]+8";1YP>*4R;KIQ[Y0[<!YS
M48,K<7ATHW("<LMU\&!C=!9W*TX\=4UX4SM'=E5Y6R9:=M-Z  W->'=Z=,2"
M:0%XJ+/N:PAY.:-/;-QYSI*>;F1Z:('(;^5Z_W#4<5U[E5]@<LI\'TUA=!Q\
MGCJ;=35]"B7Q=:A].@W;=WM]9L)]9PR!\K(3:3B!M:&A:S*!@9$@;.&!68!Z
M;H*!.V^W<!B!(EYM<9^!!4R8<P> XSH!="V NB63=)> =PWH=IZ  \"'97N+
M/K!(9\**.Z !:=B)0X^I:Z2(7'\O;5Z'BVZ9;PN&P5U^<*6%_$O8<AN%/#EV
M<TF$@25*<ZB#VPX3==:"=+[;9#:4=ZZJ9J"2IIYX:-*0ZHY#:J^/4'WP;'N-
MSVV%;CB,5UR7;]Z*[4LE<5R)DCC\<HN(3B45<N"'50Y7=2>$K;TS8T&=E*TN
M9:Z;$)TC9^B8GXT,:=663'S;:[&4%VR5;7V1[5O0;RZ/VTJ)<+.-XSB2<>6,
M%R3H<C&*UPZ1=)&&D[NX8GVFMJO89.6CB9OL9Q^@;(OM:16=9GO::ON:@6NU
M;-*7J%L8;HJ4\4G]<!627C@U<4J0"B3 <9..0 [#=!*(,KIU8=^OY:JG9$"L
M&IK,9GBH7(K=:&^DLWKD:EBA*6K@;#*=K%IJ;?":4TE\;X"7)S?B<+F43B2;
M<0.11 [M<Z:)C[EF842Y%ZFE8Z^TL)G89>RP5XGV9^*L$7H2:<VGYFHI:ZFC
MQ5G5;6N?RTD/;O^<"#>=<#N8KB1]<(F3Q0\/<TZ*+[B'8+'"2JC38S"]19D2
M97FX3XDZ9VZS;WEI:5NNH6F5:SBIW%E>;/VE0$BW;I:@Z#=F;]6<=21E<":5
MQP\K<P>*0;WE=#%D2ZXC=01FXYXR=<QI8(WU=H1KL7V1=T%MTVT,=_UOY%OY
M>,9QVTI/>8YSM3?/>C]U8R-!>JQV@PM^?!MWJ+NP<9AMPZPK<K-O:IQJ<[UP
M_XQ-=*UR>GP8=99SXFO+=GMU1UKJ=VEVFTEQ>%!WWC<I>15X_B+H>7)YL NM
M>PEZI[F0;V%V^JHO<+AWR9J=<?5XC8J_<PIY0WK =!AY]VJE=1]ZKEGR=BQ[
M8$BG=RU\"#:5> )\FB*8>%-\X O6>A=];+>';:%_\JA1;Q9_]YCQ<'%__8E1
M<:. !'F#<LV #FF6<^^ '%D/=12 *4?R=B> ,S81=P: -")2=TV $@OY>4)_
MV[6H;!R(Y*:3;;2(*I=<;RR'=H?L<'2&SGA+<;2&+FB*<NR%DU@O=".$_D=
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M4VQ]<O2BXUX[<].?@4]9=,&<1C_K=9Z92R_8=C&6<AXA=?^1/@MJ>$Z'MZ-
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MJ$LW@:.>X#ZE@1B<2#%X@(B9.2.A?]J4JA0,?NJ-C@;,?EB$F85DEN!C 'I
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MEGY^5F'WE(%^E%=MDIQ^T4RLD+]_(4'/CNQ_?C8TC6)_TRGCC!6 ,QRBBP^
MO@VKB6B!6 +2A3F!G74ZEW>$F6M-E8:$:6$MDYV$-U:^D;V$ TP4C^J#X4%0
MCB"#SC72C)F#ORFDBT:#RQR0BBB$)0W8B%*#KP,KA%N")'1-EJ&+%VJ!E+B*
M<V!^DM2)SE8FD/J)*$N1CS"(E$#BC6Z($#5]B^J'GRENBI&'7AR"B5^'> W]
MAV6%KP-W@YZ"6'-TE?.1E6FYE F0BE_+DB:/?56,D$V.;$L-CHF-;$!SC,^,
M?C4DBTV+K2DNB>^+'QQCB*N*= X4AI2';@.X@OR"A'*PE6&8$VCQDW:6P5\+
MD9"58U3GC[.3\TJ!C?22D4  C$&1133"BK^0%BC?B5N/-1PPB B-(@X;A=R(
M]@/N@G2"J7'EE,N>P&@UDO&=#EYBD1.;4U17CS"9B4H'C767S#^;B\B6*#1L
MBD:4IRB7B-V2SQO_AWZ/7@X=A42)BP0;@@2"QW$DE#BEGV>3DGNC8EW:D*RA
M,5/BCL6?$4FDC0V<_S])BV:;##0GB>28\BA=B':5LAO8APV1*0X>A,F)C 0_
M@:N"WV_LID=C2684HTUELUP0H'AG_5'(G=EJ&D=4FU5L03S F.UN:S%%EN1P
M:R3KE4UR0Q=GE'ESX@EJD3]VGP  BGM[[V\#I(YITV57H:1KL5MRGN9M>%$U
MG&AO'4;4F?=PS3Q9EYIRA#$%E9)T)"3>D^UUKQ>=DO%W%PG4CZQYM0!OB8!]
MDFXAHO5P1F2!H#)QIUJQG8]R\E"5FQET'490F+)U63OOEEYVGS#"E%AWW23/
MDJQY%1?,D9%Z0@HQCDA\A@#GB'U_%&U0H9IVG&.SGN-WB%GMG$MX8D_IF>)Y
M($6^EX)Y\#M\E3!ZRS!YDS)[H"2[D8A\>1?VD%E]90J#C0]^_P%1AYF :&Q@
MH'1] &+BG<1]<EDYFS5]UT],F-1^*44XEGQ^C3L1E"]^_C RDC-_<"2@D(-_
M\Q@1CSJ JPK+B^&!2@&VAK&!*&N"GVR#+6(DG-"#-%B6FDZ#+T[ E_.#%T3!
ME:*#$SJPDUR#("_OD5^#.22!CZ.#=A@ACCB$ @L)BL>#7 (2A<V!9FJ[GHV)
M2&%]F_V(Y5@*F82(=DY'ERZ']D1;E.2'BSI>DJ2'-"^VD*:&]R1FCM^&\Q@N
MC5F&[@L_B=6%( )AA0J!G&H(G<Z/9V#:FT2.I%=YF,^-U$W*EGF,\D/RE#:,
M)CH(D?V+<B]VC_Z*X21!CBZ*HA@JC)&)APMFB0"&K *EA&2!RFEJG2N5D6 V
MFJ&4AE;<F"J3:4U$E<^2,$.!DY*1#CFLD6&0""\MCV./*B0,C8N.4A@4B]R+
MW0M]B$.'Q0+>@]B!\&B]G(Z;X5^:FA":=U91EYZ9 DS.E3Z7>D,=DP:6"CE<
MD-V4NR[LCMZ3BR/<C/^1:1?\BT*-T N/AZ6'T0,-@V:"$&@2F_ZB4U\/F9.@
M9%7AERN>@TQNE,B<LD+-DI2:^SD:D'&9;BZWCG*7.2.UC(Z3Y!?JBL6/8 N=
MAR>'V@,R@PJ"*653KGUCE%P"JOAEYE*2IZ1H&TCPI)AJ)C\PH:!L0C57GLEN
M9BJJG&)P:!\?FH9R0Q)<F89SX0:ZDWMWOP  BB9](V2NK,AIR5M_J5AKG5(G
MIAIM6TB-HR1N]S[?H#MPI34=G6QR7"J2FOMT!Q\VF01UGQ*QE]%W$@<OD>)Z
MCP  B>5^560+JR9O\EKDI]QQ4%&;I+ERFT@>H<YSRCZ'GNYU"S3=G")V6"IU
MF:UWJ!]&EZ1X]1+[EDMZ.@>6D'A]#   B:M_9&-JJ<-U_5I)IHEV^%$,HW-W
MWT>BH)!XJSXBG;%YA323FN-Z;"I/F'![6!]/EF-\31,]E/!]70?QCSE_/ !7
MB.6 .V*RJ)Y\#5FMI6A\G%"(HE9]&D<PGWI]@3W%G*!]^31/F=)^?RHLEUU_
M#Q]6E4-_NA-XDZV G A'C@>!0P"^A_B @6(&IYV!YED?I'""#E 2H6:"*4;*
MGH^"+3URF[N"2#01F/*"=BH,EG:"NA];E$B#+!.LDHJ#E@B5C.B#%P$>AP^
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MHLN30#41GX*2=BRFG$&1W2/#F1>0?AI0EAJ.!Q XDO"*A0=,BY>$[P%+A;&
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M8T*3G8!O\#F$FQ)QAC!<F+AS(R9GEKITN!N<E2]V/ _ND]1WTP7<C8Y[>
MAL1^_5P:H[%P^U.5H01R4DKOGG5SET(6G!%TPCD>F:UU\C 2EUEW*29$E5QX
M7!NKD\9YC1 PDE9Z[08RC$Y]K0  AH%_^%M8HE1V[5+WGZ]WX$ING2AXPD&I
MFLYYC#C'F'1Z6B_4EB9[,B8IE"9\#!N\DH!\\Q!PD/1^* :'BQ]_NP  AC^
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M"#CAH%B!/##/G7F!B2B]FIV![B .E_:"<Q:IE9R#* TMD@Z#% 4IBOF"X0
MA9>  %"<IY2&2DBVI.2%]T#!HBJ%NCBTGV&%H#"OG(J%IBBOF;6%SR 8EP:&
M&Q;3E)6&+ UJD/^%%P5LBB&#JP +A56 !U QIJN+D4A>H^^+#T![H2^*G3A^
MGF:*0C"'FYN*#2B6F-&* R 6EAR*!1;NDYJ(] V<C_V&[P6CB5^#T !&A,B
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M=*: "FPE=7^ *V#<=E& 155 =P^ 84E^=\& @3SZ>&Z E"_'>0* IB&Y>5"
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M>Q9^"&Y]>SY^<V0G>W=^S5F.>\Q_#$ZE?!)_3D.8?%!_DS?!?)I_RRLT?-N
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M'&$.BJY@-E:*B=9C$DN]B0]EY4"_B%AHKC2QA]=K+R>SAY=M<!F2A\9O70J
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MA6J 1P Q@Q2 (5OND+]^_E/BCT1_8TNAC>E_OT,.C+F ##I#BX6 7#%>BE6
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M6C1;H+1K3RR"GCIM1223F]%O/1O7F=AQ+1) F%US"@FBD\1V/P)VC-5ZN
MA"5_;DK\IB!K:T-BH[9LT#O"H5)N3#04GO=OZBQ0G(QQ@21YFB]S&!O@F#%T
MLQ)TEI]V20GOD@IY20+,BY%\L@  @]"  $IJI(QP[$+[HAUR!CM[G[MS,S/?
MG6MT>BPOFPQUN21RF+EV_!O[EJ]X21*WE0)YH@I&D'!\.@,GBF%^C   @X>
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MC$_?A?Y?JD68A8EBNCL=A2IEO2^<A/]H>2,EA1-J[!5TA9EL\@@3A)MP*
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M>$5^@\MSOSQA@VUU!#,B@Q1V1RD)@MMW<AX<@L%XBA(9@JUYG0<H@==\?@
M@.U^]EY=@P1US58E@M)VUDVW@I=WSD3W@D]XK#OU@@-YB3+2@;AZ:"C;@8Q[
M.QX5@71\#!)$@55\^@=S@-1^X@ K@'Z '5UU@7I[[55N@5I\@TTH@3)]"T2"
M@/]]?SN7@,1]]#*.@(=^<"BS@&9^[1X0@%%_?!)I@"^ /@>R?_B [@!\?].
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MA\E[K#UPAQA\0S4@AFA\WBRTA;M]@R."A29^+AF%A*I^\ [K@[1_] 71@C>
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M@P"/@#18@H:.[RPX@A>.@"-4@8^-RAFP@/:+V ]Q@$&(PP:%?\"$:0"%?VJ
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MER^TG?UC+2@FF_5EQB!YF@MH71?ZF)1JU0[]ENIM90=ED7]Q=P#[B\YW1
M@E5]_42QH<1A"3W#G[]C/C:UG<!E="]UF\EGKB@'F=!IZ2!YE_!L)!@=EG!N
M4P]!E+QPI@>ZCX%TA0%6BEYYC   @>5_%40HGW]FASU*G9QH=S90F[=J7R\K
MF<UL/B?6E^9N'"!CEA9O_!@ME(YQV ]WDLESXP@$C<!WBP&FB1E[C@  @8*
M $.7G9-L SSBF[=MIC8*F=MO/B[YE_UPQ2>\EB=R32!FE&1SVAA4DL]U;0_
MD/MW.0A<C"AZB '_A^Q]<0  @32  $,=F]MQ6CR6F@ERIS7?F#=SZ2[?EF9U
M'R>XE)YV7"!\DN-WI1B.D4!X^A 6CUUZE B]BK]]. )<AMQ_*P  @/J  $+:
MFC]VC#QCF(=W@C6ZELEX<B[(E0-Y5R>TDT=Z2R"0D95[41B^C^=\;!!AC?=]
MV0D/B8I_A0*LA?. I0  @,B  $*EF-%[ISPPER)\736/E6U]"BZLDZ]]J">J
MD?]^6B"<D%9_)!CGCJ" "1"DC*B _ E:B'&!G@+RA26!]@  @)Z  $)MEY6
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M)C9E8/*"MR=J8DF"61:R9KB"- <S<]2!,)$.1AR.(H2^2M"-'GA43R6,$FO
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M>-I^; >N>WA_O0![?S" 4UV ;^%_855I<21_NTT3<D9__D1?<SF (#ML="&
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M'#_5?_IK%#<4@ -M!"XQ@!1N[R1R@#QPO1G/@']R8PZ!@,9T+P4 @/%XCP
M@ !]@E>'?2YK"D_ ?8!LW$>V?<!ND3](?>5P'3:E?@QQHRWB?C=S)B1,?G!T
ME!G;?K9UZ0Z]?SMW>050?\][,0  @ !^PE;">OYQ)D\2>W9RAD<C>]ASSC[5
M?!AT\C9.?%=V%"VI?)5W.20X?-MX5AGT?1]Y;0\#?=UZV06F?LY]F   @ !_
MZU7L>1AW*$YL>:MX%4:D>B9X[3YQ>H!YJ#8#>M5Z9RUX>R1[+B0G>W=[_!H*
M>[M\V0\^?+)^&P7P??-_I@  @ "  %4R=VY]'TW6>!5]JD8P>*-^'SX;>0M^
M=S7$>75^V2U1>=A_1R0;>CE_R!H?>H" ; ]R>Z^!&08O?3:!>   @ "  %2A
M=?J#!4U4=K*#5$7$=TJ#@CW0=[6#@361>#*#CBTS>*Z#K"05>1V#XQHS>6B$
M40^?>LV#V@9E?).#&  O?[" (%0J=*^(_$SG=8"(\T5H=B:(RCV2=I"(=35G
M=QZ(,RT<=[*("B01>"Z'_QI$>'V'V _%>A.&*P:1? Z$<0!@?UZ 05/(<Y&.
M[$R.='^.9$4?=3:-T#U?=9^-*35&=CV,GBT)=N2,-20-=VR+Z1I2=[^*K _C
M>7Z(!@:U>Z.$B0"'?QN 6U)<D*Y1>DJACZ!5(D*[CI)8I3J0C8-;\C(1C*U?
M,2E<C 9B7Q^UB[%E3!3_B^-GW JMBA5K'P)DAW)PX@  @$IZ1%&$C317D4GD
MC&E:R$(3BYY=W3GXBM)@OS&6BBICDBD&B:)F61^0B5=H]!48B75K2 KVA]YN
M4@+!A==SZ   @ ![SE".BA1=OTD5B8)@B4%FB.UC*SEFB%5EE3$CA]1G^BBV
MAVIJ61]MARMLGA4MASINK LWA>EQ> ,4A&MVQ0  @ !]*D^<AUQCV$A0AN=F
M/$#%AG9H>#C<A@IJ>3"UA:QL=BAJA5UN<!]+A2MP4Q4^A3%R# MPA#%TD0-<
M@RMY20  @ !^6T['A.1IV4>CA))KW$ ZA$)MM#AK@_9O4#!A@[1PZB@V@WQR
MA!\_@U)T$!5C@TYU@0NX@J%WSP.O@@9[IP  @ !_?DX3@J9OI$<1@H=Q0C_'
M@EURN3@4@B9S]3 E@?IU-"@8@=)V>!]%@:]WNA68@9UX]PP)@4%[( 0(@0)]
MT0  @ "  $UH@,1U54:-@,%VBS]E@+!WG3?*@(QX>B_R@'-Y7R?^@%UZ31]+
M@#][2!7%@"1\5 Q.@!-^$P14@"-_JP  @ "  $S5?R=Z^T86?RY[VC\)?RA\
ME#>'?Q!]&2_&?PE]J2?J?P5^2!]4?O%^_Q7P?M%_W R.?PN P027?V*!4
M@ "  $Q??<6 ET6L?<F!03ZQ?<&!O3=,?:J!]B^B?;2".R?=?<6"E1]A?;R#
M"A8;?9V#EPS(?B&#/031?KJ"R@  @ "  $OG?'.&145*?(J&GCYG?(V&S3<;
M?':&OR^%?(^&P"?3?+.&W!]M?+:'&Q9 ?)F&PPSZ?5Z%5 4!?C"#8@  @ "
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MZRKNF\=;*B.FFC1>8!PLF-]AB!/HE_%D>0OZE5UG^P58C^%LVP  BI)STP
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M2^F #%?G4 E_^4N%4_Y_XCZ&5W-_S##Y6A1_NR+!7&E_N1+B9;5_Z07!=D6
M(H8H/&F("7K 01Z'?F\T1;2&YV-N2AZ&0%==3FB%FDLI4H.$]3Y75A>$7##X
M6-.#UR+Q6W2#=Q,_9/B#(08L=9&!YX5/.G6/X7H#/TR.W6Z11 B-Q&+B2*&,
MC%;Y31"+7DKW44N*-SY35/J))3$A5\^(+R-$6J2'<Q.H9$>&!0:&=/F#983
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M8GY]/$/59*)]?3K89K5]S#'):*U^*"@-:EE^H!V@:[Q_-!(]<)9_[P?0=C6
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M?P  @ !XME+2?N93Q4K*?O-6VT*T?O59^SJ$?N==+3($?QU@0BE2?W9C1!_
M?^MF'!4N@)=HJ KR@39KW@*T@;EQB@  @ !Z<%&I>P1:,TGE>SM<X4'[>WQ?
MC#G6>\]B-3%U?$=DU"CK?-)G:1^*?6)IXQ4T?@IL(0LK?TQO$0,$@%!TD0
M@ ![]E"F=X5@>DDA=^IBR4%C>&-E$#E->/AG3#$(>9]I?BBC>D]KIQ]H>OQM
MMQ4_>[YOE@M=?9UR-P-*?Q1W70  @ !]34^U=$QFM$AH=.MHFT#6=9IJ>3C:
M=F-L2S"S=S)N%2AP> %OVQ]?>,1QCQ5H>:ES(PNH?!%U@P.???-Y_P  @ !^
MDT[/<9ELF$>[<E]N(D!7<S1OH#A]="%Q"S!T=1!R=RA1=?ISXQ]J=LMU3Q6H
M=]5VK@P&>J]XY00 ?/-\:0  @ !_P4Y%;S)RB$<[<!ASF3_I<0YTI3@M<AUU
MJ3 ^<RIVM2@W="UWR1]S=0YX[A7?=D9Z&PQ6>7]\)013?!E^>0  @ "  $W&
M;19X94;&;A!Y$S^(;QMYO#?K<$!Z7S 5<6E[$2@F<HA[TQ^#<W]\L185=.]]
MK@R@>'Y_(P2<>U^ 3@  @ "  $TZ:T%^)492;$5^G3\P;5A_ C>V;H%_3R_X
M;\1_L2@@<0. *!^9<AJ Q!9,<\J!D@SG=Z:!Z03<>L*!]   @ "  $S3::.#
M_T7V:K>$&S[G:]6$*C>+;0"$)"_C;EJ$.B@>;[>$;Q^N<.V$T!9\<MJ%&PTB
M=O6$0 42>D*#5   @ "  $R1:$")TT6R:6J):#ZL:I6)!3=I:\2(KR_1;3&(
M@2@;;JB(>Q^^;_B(IA:B<AF'\ U2=FB&( 4]>=N#BP  @ "  $KZBFM-9$.0
MB:-1#SP.B.=4L31CB#E812Q5A^=;P"0)A\]?)!K;A_QB2Q#/B$QE, @<AKEI
M:@#_A8-OR@  @ !Y\$GYACA3;$*^A<)6ICM@A5=9VC/+A/E=!RO?A.!@&R.^
MA/-C'!K#A2QE]A#RA6EHGPAGA(=LG %:@^ARS   @ ![@TCY@GU9@D'^@BI<
M83K,@?5?*S-&@>IAV2MX@@ED@"-]@D-G'1JP@HQIHA$1@M!L!0BI@I9OP &I
M@GQUJ@  @ !\Z$?_?Q-?BT%#?NIB#3H_?N=D=C+/?QMFNRL??V=H^R-)?\)K
M-AJB@!IM6A$O@(1O9PCC@.%RUP'P@3QX,   @ !^(4<V>^UE=4"F>_AGG3G&
M?"5IJ#)R?(9KB2KA?/=M:2,M?6]O2!JO?=-Q&1%H?G%RX DT?U)V%0)%@!EZ
MD0  @ !_3$:)>2IK$T @>6ILYSED><)NFC(N>CUP'RJZ>LMQIR,E>UUS-!K2
M>\ETPQ&X?)UV60F6?>]Y9P*E?Q=\P   @ "  $80=L)PM#^W=R=R&SD/=Z!S
M:#'T>#1TD"J8>-UUP2,?>8AV_!KP>?]X2Q']>PQYM GJ?,!\6P+W?CI^G@
M@ "  $6>=+!V23]6=2-W53C$=:IX23'#=DUY'2J =Q!Y_2,A=]5Z[!L3>%U[
M_1)#>:Y].PHZ>[M_#0- ?7V 1P  @ "  $4E<O![RC[W<U=\I3B <]E]7C&<
M=(%]Z"IR=5I^@",M=CI_+AL^=MZ !1*->'F _ J)>MJ!D0.#?-R!R   @ "
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MZBMB=\^%5B3U>%>%Q1YR>/B&5A=5>4V&B0_(>L"%N@D$?$6$QP+ ?;B!W
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M"0%%@%B W   @ "  #2I@8M[Z"_+@11]'2JA@)=^."4,@!!_,!\Q?_R 'QE
M@ 2!*!+"?Z6"* R-?U>"J ;M?V&"S &!?\N!!   @ "  #3O?^V ]"_:?Y.!
MO"J5?RJ"C"4*?JF#:A]!?J&$-QEH?K>%$1,#?GR%* S6?GJ$Q@<P?L&$-@&R
M?UJ!)0  @ "     __\  /__  #__P  ;69T,@     $ PL   $
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MQ#R"KY3RL*^"'9*<G46!MY"*B?&!88Z0=HB!(HRN8R" [XK23]" NHCI/*>
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M.8RJ3@2-FHK(/WN*_(CK,2*(>H<E) J%R857M9"AQ:"BIGJ>1)W7EV::\IL
MB%&7[9@;>7B5*)5[:M:2<I+P7"2/SY!E38B-,(W;/R^*C8M6,0^'_XCI)#R%
M/89PM&.ABJA#I6V=^Z3-EG*:GJ%+AV^7E)V[>*Z4S9IP:B>2%9<V6Y6/<I0
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MU)F!1[Z/?Y4Q.O6,(Y#F+G:(W(RT(W:%7(BCIA:I1KK\F VD_[8.BA:@WK$
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MT9O+3Z&6P9?.0X22MI//-\&.I8_7+$R*LHOW(F2&D(A,F[6Q%[=$CEJL2;*
M@2NGCZVM=#FB^ZC+9Z:>N*0?6VB:A)^ 3S>6<)K;0SR29I8T-YV.59&4+$F*
M8XT)(H>&0XC.FR"P_KXBC;^L+KB?@(^G;;,7<Z:BS:V39R.>@*@\6OF:1:+P
M3N*6+YVA0P.2)9A4-X".%9,5+$>*(XWN(J*&!8DWF!F]"'L^BS:W:'N%?FRR
M GO4<<.L^WPQ95FH*7RX63*C7WU730J>I'X'00>9[W[&-4V50W^1*<&0QX!G
M'ZJ,.H%FEUR\&8'#BG>VFH%M?;JQ1X$K<3&L/H$&9-ZG;X$&6,JBJH$;3+2=
M](%(0,>90X&%-2F4EX')*<:0%X(0']Z+@8)WEI"[28AAB=*US8=X?2^PA(:>
M<*VKC87:9&>FR(5,6&2B"8383&*=6(1\0(N8JH0P-0F3_H/G*<N/>8.@( R*
MW(-PE=JZI([<B2BU+(U@?)2OYHOV<"6J\8JG8_"F,XF35_ZA>XB83!&<SH>J
M0%.8(8;'-.V3=87I*<^.[H44(#2*3(13E3NZ")4TB(&TG),X>^ZO6Y%';Y"J
M9(]L8VVEIHW/5Y"@[XQ*2[R<1(K,0!N7F(E4--:2Z8?C*>".6H:"('*)KH4U
ME)*YDIM>A]2T)YCF>T2NY)9T;O*IZ)0.8N6E)9'I5R&@:(_92VB;O8W./^67
M$HO(-,.27XG**?R-Q(??(,&)#(8.D_2Y1:&)ASJSRYZ$>K&N?9N$;FJI?9B2
M8F^DM97?5L&?])-!2Q^;2)"H/[:6G8X3-+21YXN(*A2-1(D8(02(@H;+DTVY
M":>OAIBS@:0B>A:N)J"8;=FI'9T78?"D3YG65EJ?AY:I2M*:VY-^/X:6,9!8
M-*21>HT\*B:,THH\(3R(#8=PDIFXU:W1A>>S1*G2>6FMWJ7(;3:HQ:&V86*C
M[IWC5>:?()HC2GZ:<I9C/U25R9*D-).1%([O*C2,;8M0(6N'JH?\D>FXG;/W
MA4.S#J]S>-&MHZK=;*6H?*8W8.2CG*'-57^>QYUV2C.:&)D=/R>5<93$-(20
MO9!X*C^,&8Q"(9*'6HAQD4VX:+H.A+JRW[3G>%6M<Z^S;#&H0*IT8'ZC6:5Q
M52R>?Z" 2?>9SYN./P25*9:A-'B0=Y'(*DB+U8T+(;&'&HC0C-[%,'Q%@,F^
MWWQX=-:XS7RR:1*S)7SW79.MK'UP4E^H.'X&1SBBU7ZM/$>==7]B,;"8$8 =
M)V*2PX#2'I:-<8&DC&W$)()N@$B]^X(.=%2X 8&\:*:R6(&"73>LXX%W4A"G
M<X&&1ONB%8&R/!Z<N8'O,:&758(K)W:2 X);'M*,K8*CB]'#28B:?]"]((>Q
M<_6W+X;4:$RQFX8+7.:L+X5Y4<NFQ(4#1L2A:H2M._J<$(1G,926K(0?)XF1
M68/*'P>+_X.+BW+"G8[!?W&\<XU(<YJVA8O@9_RP^(J37*"KD8F 49"F*HB'
M1I6@TX>D.]J;>X;,,8B6%X7V)YF0PX4>'S2+9H1<BPS!\Y2O?P&[TI*^<RFU
MZ)#99Y:P6X\(7$BJ](US44FEC(OW1F&@-XJ*.[R:X(DF,865>X?%)[B0(H9K
M'WJ*P84LBHK!:)I6?GV[2)?\<J>U6Y6D9QZOQY-26^.J6Y$]4/JD[H\^1BJ?
MFHU-.Z":18MC,8F4WXE_)^6/?X>F']&*&(7SBA[! Z .?@RZV)TL<C>TXII-
M9K>O1Y=X6XRIUY3@4+:D9I)=1?N?$X_F.XF9P(UW,8V46(L1* J.\XB_(!N)
MB(:@B:[ K*7!?9BZ=J)7<<2T=9[Q9DNNTIN76S"I7)A[4'"CYY5T1<V>E))W
M.W.91(^!,9*3W8R6*"R.>(G#(%F)#H<UB3/ 6:MH?1JZ':>)<4:T$Z.D9=.N
M8I_ 6LRHYYP>4"2C;IB319V>&Y4-.V"8SI&+,9J3;(X6*$F.#(JX((Z(J(>U
MB)[ ![#L?)RYSJR4<-BSP:@N96JN!*.^6G.H@I^53^&C!IN#17.=M)=S.U"8
M:I-H,:*3#(]M*&*-L8N+(+B(58@>B >_O;8^?"NYB[%><'^S?JQN916MMZ=Q
M6BRH,:*^3ZRBLIXH15&=89F2.T.8&94$,:B2OY".*'6-:8PY(-J($HAS@;S-
M6GX8=C#&Y7W.:O' <GVQ8!^Z"GW959JSS'Y"2V>MCW[,052G9']I-X6A-H 0
M+A^:^H"T)1>4OH%"'9..F8'A@63,9H/8==W%]H,*:J:_B()L7]ZY)H(756"R
M[8'^2S6LM8(%03"FCX(N-W6@98)G+B::*H*8)3N3[X*J'=>-R8+.@3G+@HF#
M=;#%"(@[:GB^G8<C7[.X5(9153JR)H6X2Q6K\84]01FESX3K-VF?J82J+BR9
M<81?)5N3-X/X'A&-$H.D@2G*S(\C=9_$18UM:F>]V(O?7Z2WG8J052VQ=(E\
M2PJK0HB"00^E)8>H-V2? X;;+C&8S88*)7>2E(4J'D6,<H1E@-_*"Y2@=6##
MB))\:C&]'I![7W*VY8ZQ506PO8TB2NZJBHNL0/^D<(I/-V*>4XC]+D.8'H>K
M)::1YH96'I*+Q84D@(?)5YGF=0G"W)=1:=V\<Y3<7R6V,I*<5,>P!I"62L.I
MT(ZG0.FCN8S/-V.=H(L"+E^7;8DV)>.1-(=P'O&+%87:@#+(S9\@=+K"3IP)
M:92[X)D77N*UEY9>5)*O9Y/?2I^I+Y%W0-:C&H\D-V2=!8S<+GB6U8J;)A>0
MG(AI'T&*?X9W?^W(4*1'='/!RZ"S:4V[5IU$7J"U!)H05%VNTI<92GVHF)0Y
M0,BBAI%K-VN<=HZH+I262HOQ)D>0%XE.'X6* 8;^?[K'UJE-=#+!3:53:02Z
MT:%Q7EFT=9V\5":N/YI-2EVH!9;Y0,"A^).P-WJ;[I!P+K:5RXT^)G2/HHHC
M'[^)EX=Q?V_':ZXI<^[ X*G!:,6Z7Z5I7ANS^J$R4_>MPIU+2D&GB)F$0+FA
M?I7"-XB;>Y()+M657XYC)IJ/08K9'^V)0(?0?Q;'$[++<ZS B*WD:)*Z ZD-
M7>JSEZ154]&M7)_Y2BNG(YO#0+2A')>.-Y.;'I-F+NV5"8]9)KF.\XMO(!*(
M^X@<]-U\KGIOX+M\Z7KBS)%],WMIN%Q]E'P+I"E]UGR>C_I^#7TO>[=^2WVQ
M9VY^C'XJ4RQ^R7ZA/O)^^7\$*MY_*'^ \GY[+(2>WGA[B(0"RF][\8-TMF%\
M:X+]HF!\QX*WCF=]%H*$>EA];()*9D)]Q8(+4CI^&8'&/DQ^9(%P*II^JX$4
M\#5Y^(Y/W$%Z<HR^R%EZZHM#M()[8HGOH+5[S8C:C.]\-(?=>1)\H(;B92]]
M#H7D46%]>(3>/;A]W(/**EQ^.X*2[CMY!9?=VE1YC95GQGUZ"9,3LL)Z<Y#U
MGQYZZ8\0BXE[9HT]=]][YHMX9#1\9XFT4)]\YH?E/31]888/*B9]UX/Y[&QX
M1:&;V(MXSIY!Q,-Y2IL0L2)YM)@AG:5Z-95JBCYZOY+ =L9[39 J8U%[W(V8
M3_A\:8KY/,Y\\8A<*A=]<H5HZN!WEJM4UO9X**<;PS-XKZ,/KZIY*)].G%)Y
ML9O&B11Z0)A(=<MZU93?8HM[;I%Y3VQ\ HX&/(9\D(J@*BA]$(;0Z59W%+3[
MU85WGZ_UP=AX)ZL7KF5XK*9\FRQY/*(<B!-YT)W!=/-Z;9E]8=][#94\3O-[
MJ)#O/$A\.XR^*CA\O(@5Y^!VRKZ:U"1W0+C0P(QWO[,IK2UX2JVZFA%XWJB"
MAQMY<J-,="=Z$)XJ849ZL9D'3HU[3I/8/!1[ZX['*D5\=(DWYH9VM\@OTM!W
M#L&QOT-W>;M-J_5X!;47F/9XEZ\0AB1Y)ZD"<V)YO:+\8+IZ5ISN3CEZ\I;-
M.^E[GI#"*E!\-XHVY5YVB-&^T:QVW,J/OB=W1<-QJNAWS[QUF )X7K69A4]X
MZJZK<KIY=Z>U8$5Z"*"N3?1ZH9F4.\9[79*,*EE\!HL/Y&UV0=M'T,!VI]-D
MO4%W&LN&J@YWH\.[ESQX+[O\A*)XM[0A<C)Y/JPK7^=YR*0A3;UZ7YP..ZI[
M)Y08*F![WHO#YYR#='CPU-B"Y7F+P?R"=GHKKO:".7K2F^&!\7N#B,N!IGP_
M=8V!<GSP8D&!27V:3P>!'GX_.]Z Z7[%*1. LW]LY7>!^X*@TLR!DX(\P J!
M1('EK2.!'(&EFCN [8&*AUJ O(& =$R H(%S83& C8%D3B^ >(%..U. 68$@
M*.B -8#WXV6 VHOIT,B AHJDOB& 1HEVJVB )(ALF+" !H>*A?]_Z8:Y<R%_
MX87M8#A_XH4B36Y_X(1..M9_UH-H*,)_Q()KX9Q__I42SPU_MY+[O'1_>Y#]
MJ<I_4X\GES9_/XU_A+1_,HOE<@=_.8I97U-_28C/3,)_5X<Z.F=_8(69**%_
M8(/'W]1_19YMS59_!YMWNM!^T9BCJ#U^IY8#E<]^FI.3@WI^F)$O</]^JH[=
M7H)^Q8R.3"Q^W8HR.A%^\(?0*)Y^]H4IWC9^L*>IR[E^>:/AN4!^2*!!ILU^
M(IS>E(5^&9FH@EE^')9Z< Y^-9-@7<=^6)!'2ZM^=8TA.=)^BHG]*+5^BH:&
MW*Y^1K#4RD9^!JQ+M^5]T*?EI8Y]K*.WDV9]J)^U@5]]KYNT;SY]SY?*725]
M^)/A2SU^&H_K.9Q^,8P#*,A^+X>_VT9]_+G\R.]]KK2_MJ%]<*^=I&%]3:JE
MDE=]2J75@'%]4:$";GM]<IQ"7))]G9>!2MQ]P9*Q.6U]WXWT*-A]X(C6V@-]
MS<,EQZ]]<+U(M6I]*;=VHSI]!;&[D4Q\_ZP@?XE] J9];<!]'J#@7 I]19LY
M2H9]:95_.4-]DH_4*.9]GHG+V.U]HLQCQIU]/<7:M%]\\;]1HCU\S+C/D&9\
MPK)D?L%\P*OH;1]\UJ5B6Y9\^)[)2C]]&Y@?.2!]4)&%*/)]:(J;V E]>-6R
MQ;Y]$LYILXA\P\<9H7%\G+_'CZU\D;A^?A]\BK$<;)Y\FZF@6SE\NJ(.2@9\
MW9IU.01]&Y+Z*/M]/(M'VHV*@W>(R/:)-GA'MSF(&GC_I3V'2WFJDT.&=7IX
M@56%G'M:;RJ$YGPR7.V$0GT&2LJ#G'W4.,""]'Z!)TJ"1']7V)R))8#7QQB(
M!8"GM7"'"(![HX^&0H!5D<"%@8!>@ .$P(!\;@>$(8"96_J#D8"V2@^"_X#,
M.%""9X#+)SJ!PX#9UK*'\(G/Q4"&[HC+L[.&#(?2H?F%6H;JD%6$K(8S?L:#
M_H6/;/B#<83R6QR"\H1626B";X.T-^V!YX, )RR!4()$U.J'+I*(PXV&-Y#
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MJ\B"M(/7FNB"0X-9BAF!XX,'>6*!B8+':%J!3(*&5S^!'H)$1E6 ZX'\-:R
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M[*HH@UI^K:5P<X=^>J"X8X=^9YOV4X]^8I<D0]Y^59)'-(%^08UY)E-^#8B
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MG!6&/9W0C,.%1)JR?8V$=9?";GR#LI3:7S6#!9'R3_2"78\#0/N!K(P1,E"
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MKZQDD#:+^*A3@AF*3Z0Q=!R(X: N9DV'@9PI6%*&-I@.2FN$[I/E/-F#G8_
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M]9$Y;UJ.]H]I8AV- HVE5*^+&XO31U")-8G].D.'3(@M+86%;(9V(C&#;X3
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MI8" ;WB3E4> 0GE&A1F &WH1=0-_]WKJ9*%_\GN_5"M_^WR10^* !'U>,\2
M"7X0)(Z $G[=PS)_@'_)LX]_67_ H\A_.'^WD\9_(G^Q@\E_$W_&<^-_"7_H
M8[%_&X .4V]_/( S0V!_6H!0,X5_=(!3)*1_C(!=P4Y^1XADL=Y^.X>CHD9^
M,H;ADFM^+H8>@IE^,X5]<MY^.X3J8ME^8(1:4L=^DH/'0NQ^PH,L,TU^[H)\
M)+=_%H' OXM]6I$!L#Q]5X^&H,9]6(X)D1%]8(R,@69]<HLU<==]B8GJ8@!]
MO(BC4B%]_(=80GU^.88#,QM^;X2@)-)^G(,BOAI\BYEUKL)\G9<[GU1\K)4&
MC\%\N9+6@#Q\U)#-<-9\]8[-82Y],XS148)]?8K00A9]P8C$,O!]^H:P)/%^
M)(1ZO*M[\:'DK6E\ Y[NGA1\%)O^CIY\)9D6?SI\2)94;_=\<I.88'A\NI#A
M4/E]#HXE0;U]68M?,LM]E(B9)0Q]O(6MNU1[>*I+K"5[A::FG.5[E*,#C8A[
MII]E?D-[SIOH;R)[_)AN7\I\2I3W4'9\I9%X06A\]XWM,J=].8IH)2)]9(:_
MNA][%K*@JO1[(*YGF[][+*HDC'=[/*76?4Y[8Z&A;D][D)UG7QU[X9DF3_5\
M0)37011\EY!Z,H)\Y(PB)39]&H>NN/AZU+KGJ>-ZTK8:FL)ZUK$XBXMZY*PY
M?'M[":=%;9A[-:)%7HA[AYTR3X5[Z9@*0,Q\19+7,F)\G8VM)45\W8AZM^YZ
MJ<,?J/MZE[VQF?5ZD+@DBLQZF[)L>]!ZOZRQ;01ZZJ;A7A![/:#U3RQ[HIKS
M0))\ Y3M,DA\9(\ )5)\K(DBNQ2)HVU!K$"(DV\2G3B'EG#'C=^&N7)3?HF%
M[G/C;TJ%*75]7[>$?W<%4!"#XGB(0):#27H/,4."NGN.(N^"*WU N46'_'75
MJHB''7;0FYV&2W>UC&B%BGA[?3R$W'E;;BN$-7I)7LN#HGLP3UR#&WP60"&"
MEGS],1>"&'W6(Q^!E7[/MX&&C'XTJ-:%TWY@F@N%(7Z%BPJ$>GZ>? N#Y'[3
M;26#4W\57?6"UW]63KF"9G^7/[B!]'_4,.^!AH $(TF!$8!"M;^%6X9VIT&$
MOH7MF*"$)(5>B<B#C(3$>O&#!H1.;#2"A8/E73&"'8-X3B>!P(,'/UN!8H*3
M,,V!!((7(VZ G8&8M!Z$<HZOI;F#XXUTESB#5(PSB(6"QHKJ>=2"2XG&:T"!
MUXBO7&J!?8>339.!+H9R/OV VX5,,*J A80C(Y* ((+MLKB#MI:WI%"#.)3,
ME=N"M)+>ATN"*I#L>+Z!MH\>:E&!2HU96ZB ^(N030* L8G!/J& 8H?N,(>
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MB%V'5ZHD>S"&**7H;@R%(J&O81*$)IUI4^:#1)D'1LZ":I23.A6!B) E+<"
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M>;1-FZ=PCJ^-C')QJZK-?4URTJ8';DYS_J$N7RYU0)Q'4!QVC9=,04MWV))
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MQ7AI+Q.!BWH](:B!6'Q$L!2#H'$0HB6#$W)_E >"FG/4A9V"0'4"=S:![G9
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M(;M_4(5.FO.$2J41CJ*#GZ(X@DF"]Y]%==^"5IPM:62!R9D970J!0)7]4'J
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MH81,6;^':H/O392&6(.)07:%5H,?-:J$3X*Y*B&#0H)9(!""+H(!E :-5XS
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MD6CR<-RESFL,9O&B-VT47/V>XV\#4R";G'$)27F85W,?/XV5+W4M-;.2$7=
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MC<* TFDN?_Z G&N%<C& <6W.9'N 3' 95FJ 07)12$J 1'2$.FB 37:Z+,*
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MU'Y)/J"5@7[*-LB23G],+Q^/)W_1)]Z, H!9(.R(YX#@&V.&!H%E9JBE,8'
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MY8/09@N4!)/;7D>2!I*65GV0"I$U3J&.$X^N1LV,-(X:/S6*6XR -W6(B(K
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M"HH"*)MXKX=.'^5Z/(3 B5=HL*5X?IYJB**%<^)L6I^$:1MN(9QM7CIOWYE
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M=86 6&N=:XF .VV@85V -V^$5R" ,W%L30: ,7-;0IJ -W5%.#> 0W<O+CF
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M8(SX/%)^:XL:,Y]^<HDO*U]^=8=7(XA^<X6?'2U^:X08;O=][YI?9KA]W9B
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M7U*$4)5>5Z^#II.O3_B"]Y'R2"&";I :0'*![XXU.'>!:8P:,): WHGS*2F
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M0GZEH#%37(,%DR572(+!AB1:_H*">2]>98)*;"-ARH(+7S%E,8'(4@QHCX&
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M<H4W'[YX X-VBD);/)PH?VQ>8IH9=(MA8I?I:9-D+Y6-7H]F^),K4[)IPY#
M2(QLG(Y"/7=O?8NV,L]R68DK*)-U(H:M'^1WQ810B7Q:C*,??LE=M:!>= 1@
MO9V':2!CEYJ17C)F;)>/4VQI0I2#2%ML*9%@/5QO&HXO,LER!HL#*)]TX8?I
M( -WE(4#C7%T!U:%@>=TXUI;=F9UMUX):NEV?V%V7V!W7F304_-X2F@K2"MY
M56MO/&5Z=6ZK,09[GW'K)B1\TG41'*Q^"WA5BZ1PDEZE@%%QY&&I=/QS(&22
M:9QT/6=27C]U8VH(4P=VCVS#1WYWTV]S._YY)G(B,.-Z?730)CQ[U7=B'05]
M*WH'B>-MD&:!?K=O-FC2<Y)PP6L.:')R)FTI749SB6\^4CUT\7%71NIV;'-N
M.Z5W\W6%,,1Y>'>9)E!Z\WF3'5-\9GN8B&5JZVXZ?6QLV&_E<G5NHW%]9WUP
M/7+X7'AQU'1P49AS;G7J1G%U'W=>.UIVVGC1,*EXCGI")F)Z*GNC'9=[NGT(
MAO-HP'7)?"9JW';2<5ILUW?*9HENGWBH6ZQP8GF$4/1R)WIB1?IT 'LX.Q)U
MXGP-,))WNGS@)GEY=GVM'>%[(7YZA9MF[7S]>N]I.WUK<$=K87W)99]M47X2
M6NAO-WY94%AQ'GZ@18ES$W[B.L]U#7\A,'YW ']B)I1XVG^A'BYZG7_BA%YE
M5H0?>=MGR8/L;UIJ%8.M9--L)X-:6CYN+H,(3]%P-(*V12=R0H)?.I5T5(((
M,&UV7H&U)JIX4X%I'F]Z+8$C@T5D HLG>.=FD8IB;HEH]XF-9"-K)8BA6:UM
M1X>W3U]O9X;+1-5QBX79.F1SL83E,%YUT8/V)KYWWX,5'J=YSH(_@E-B])(&
M>!)EE)#+;=)H"H]T8XMJ28WU63-L@(QT3P)NMHKO1)-P[(E>.CUS)(?%,%)U
M5H8P)LYW?(2G'M5Y?X,V@8IB$9C3=V%DP9<+;3EG1I4D8PUID9,26,YKVI#[
M3K=N(H[=1%YP:(RK.AQRKHIM,$AT\8@T)MMW*X8*'OMY/H0'@.=A5)]Y=M%D
M$YT#;+YFI9IX8J=H^Y?16'QK4I4C3GIMJI)M1#-O_(^?.@)R3HS%,$!TGHGR
M)N9VZ8<U'QEY"H2R@[]Z95:J>0]ZT%IO;FE[+UX/8\M[?6%V61U[Y&333HU\
M6&@T0YQ\Y6M\.+!]@VZ_+C)^+7(,)#9^Y75,&ZQ_I'BE@?=W.UY+=XMX!F%7
M;1AXO61&8I1Y6F<+6 YZ FG.3;!ZLVR60P%[<6]5.%]\.W(4+B=]#737)&!]
MYW>&'!!^P'I%@%=T4V7,=A1U=&@K:\]V>FIU88-W66R?5RMX/&[(3/AY(W#W
M0H%Z%',E.!Q[#G54+AU\"7>$)(5]!'FA'&A]^7O$?P!QRVT?=/!S*F[F:MAT
M:G"98*QU?W(M5G=VD7/!3&MWIG5:0A]XRW;L-^9Y^7A]+A5[(GH0)*5\/'N9
M'+1]2GTC?;QOM'1)<\YQ/75Z:=ERJ7:87]%S['>95<%U)WB:2]QV8GF>0;IW
MKWJ9-Z]Y GN4+@MZ3GR0),9[AGV*'0)\K'Z#?'YM\WLB<J]OIWN_:-MQ/'Q+
M7OERI7R_50YT 7TR2TYU6WVG055VPGX6-W=X+7Z$+@!YD7[U).5ZY7]G'4Y\
M(G_;>U5L8X'F<:UN/8'I9_]O]X'?7C]Q@X'!5'-R_8&C2M-T<X&&0/]U\H%F
M-T=W<X%&+?=X[H$K)0!Z6X$9'8][K8$,>E-K%XB2<,UM#(@)9S]NWX=Q79]P
MA(;#4_%R&885_^)]$$E#0U]04D]&24Q%  852FYSJH5F0+=U/82R-QYVTH/]
M+>UX88-/)19YY(*N'<9[28(9>7MJ%X\9< QL%HXB9IEM]8T/71EOJ(O54X9Q
M58J82AYR_HE70'YTHX@*-OMV1H:W+>)WY85J)2=Y?H0K'?1Z]H,$>,%I-96/
M;VAK1I029@YM,Y)U7*MN\)"O4S!PL([C2=YR;XT20%!T(XLK-MYUT8D[+=EW
M?X=2)35Y*H5Y'AEZL8/*>")H;IO<;N)JEIFV99]LE)=]7%)N694I4NIP*I+0
M2:IQ_)!P0"MSNXWU-L=U<XMP+=)W+(CV)4!XYX:2'C=Z>X1L>E2 T5;.<(R
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M9'PN.7E]P'SO,2]^(WVR*4Q^@7YZ(;U^U'](&Z)_(( 2:HIZ57X)8G5ZTGZ
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M6R&!.GS44[>!$'U=3"2 W'W31). HWY)/3J :W[!-;& 2W\T+DB -7^I)T.
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M4BN#O(X42\&#*HTG13:"A(P8/JB"!XK\.%&!EXG8,=B!&(B,*X& F(<U)8*
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MCIF ?J91)9>B<\55=I6C:,A999-U7<Q=7I%"4OYA7X\)1_IE:(S'/0]I>(J
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M_I5[7#QB_Y-#4LEF%)$4285I,H[F0!%L28RJ-K]O7(IH+==R9X@L)4IU7X8
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M7^I^Z5UT5Y9_$F#!3T5_&F/K1OQ_.V<6/N9_:FI*-IE_K&V!+FY__G#!)KN
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MPF9K5K9_Z&C93WY__&LO2"-_^VUE0-R  F^A.=* $''F,J" *G0O*Y2 3G:
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M5(>"7'$43ER"-'+)2!B" W1<0:Z!PW7!.U:!C'<N-3^!5WBB+Q2!('H>*1*
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M2W^#Y8,%1EZ#28.#02""L(/*.[B"&(/+-F&!L8/#,4V!68.X+#. Y8.;)SB
M=(-P(F^ )(,W'9^ !X+F&?E_[X*E2Q."Q(=Y1AR"48=Q0/R!TX=&.Z*!1(;P
M-EB \H:),5" KX8<+$* 4863)U)_]83[(H]_NH1;';Y_LH.H&AA_JX,81T2=
M7E3>0@::YEC"/+J8=5R;-UB6"V!E,A&3JV1%+1"15&@T*!Z.^&PN(UR,JG A
M'MZ*@7/S&GN(@W>$%RR&VWK$1LF:45IE0;:8#%W'/(V5TF$H-T*3I62',A*1
M=V?Y+2F/3&MY*$>-'V\-(Y*+ W*='R&)#G8%&LF'2GDB%X6%TGOR1FR78%_)
M05Z5=F*^/$:3@F6O-QN1@&B=,@:/?FN>+3.-@&ZN*&2+?''6([^)BG3['UN'
MPG?U&PZ&,WJ@%]*$Z7T$1?"4[F3V0/&3-6><.^^1;VHQ-N*/EFRQ,>6-P6]#
M+2F+[W'A*'**#G23(^*(/G<^'X^&G7G!&TJ%/GO_&!:$''W[17^2QFH-0)^1
M,&Q;.[>/C&Z1-L"-U7"F,=F,*'+,+3**@'3]*)"(OW<\)!.'#7ET'\Z%CWN%
M&X^$6GU9&&"#6W[T10R0Y&[:0&"/;'#/.YR-Y7*H-K2,1G1=,=Z*O78?+4J)
M.G?I*+N'EGF_)$^%_GN+(!2$GWTT&]F#C7ZD&*Z"JW_E1-V/,7.!0#V-W741
M.X6,<W:'-JF*ZW?<,>*)@7DZ+5^(('J>*."&EGP-)(&%%GUQ(%"#T7ZU'!B"
MWG_)&/""%8"X1,2-L'@#0"",;GD^.VR+&'I;-IR)I'M4,>6(5WQ2+7*'%'U2
M*0.%I7Y6)+.$0'].((J#&( I'%&"18#8&2>!EH%P1+",8GQ?0 .+&GU@.T^)
MQWXY-HV(9G[<,>:'-'][+86&#H 7*2B$O8"L).:#>($O(,."<(&7'(2!OH'6
M&5:!*X(.1(*+&("N/]^)Y8%6.S:(I8'8-G^'5((I,>>&.8)L+96%+8*G*4B#
M]X+.)1*"SH+@(/2!XX+;'*^!3X*Q&7R U(*21$6)XH35/[F(VX3[.R*'N843
M-G2&=H47,>>%;84"+:*$=X3C*6&#5X2C)36"1H1/(1N!<H/I'-& ]H-E&9N
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MR(RA=GU)C(NT;$M.4HJU8?A3'HF>5[!7]8B&39U<U(=M0UIAN895.3UFH85
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M. J @G(Q,P& E'0D+C> JG8@*6Z EG@N),F ?WHV(%N AGP=&_2 O7W.&*2
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M&*Z SX#_/M6"R'A>.Q."07G(-RN!P'L*,Q"!1'P;+OJ!&'T>*Q^ _7X;)TB
MH7\:(X" 1( "'\* '8"]&\V 18$X&-R 98&A/NB!/GRH.P^ UWVY-Q^ <7ZH
M,PV #']K+P=__8 5*SV  X"R)W9_S(%$([E_E8&\'_U_D8(*&_U_UH(9&0*
M#X(H/R!_\(##.QM_K(%6-Q9_88'?,PM_#H);+Q%_&(*O*U5_.(+S)YM_((,A
M(^=_"8,R("Q_(8,?'"-_?H+2&2!_RX*6  #__P  __\  /__  !M9G0Q
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M4U?^L%UT^J]BBO*Q8YOKLF6JY;-FN-^S:,7:LV[/U;)TV-*Q>=_/L'WDS:^
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MV5BMO-)DN+?-;<&SR7+(J<9PSI_#;].5P6[7CK]PV8R_=]J,P'W9C,!]V8S
M?=F,P'W9C,!]V8S ?=F,P'W9C,!]V8S ?=F,P'W9C,!]V8S ?=F,P'W9C,!]
MV8S ?=G_LCX:_;5+,OZS4$WZMU%<\[]09.C+4&?9W$9XS^5*C\3@3Z&[V5JN
MMM-EN++.;<"HRFS'G\=KS)?%:]"0PVO3BL)NU8C"<]:(PGG5B,)YU8C">=6(
MPGG5B,)YU8C">=6(PGG5B,)YU8C">=6(PGG5B,)YU8C">=6(PGG5B,)YU8C"
M>=7^LS\:_+5*,OVT3TSWNTY6[,9,6=W71F+0Y41\Q>E*D;O@4:&TV5RML=-G
MMJ?/9[Z=S&;#E<EFR(_'9LN)QF?.A<5JT(/%;]"#Q7/0@\5ST(/%<]"#Q7/0
M@\5ST(/%<]"#Q7/0@\5ST(/%<]"#Q7/0@\5ST(/%<]"#Q7/0@\5ST(/%<]#\
MM$ 9^[=*,?NW34GQP4I,X=)&2M+C/VC&[45_O.A,DK/@5*&NVE^KI-5@LYO1
M8;J3SV&_C,QAPX?+8L:"R6/(?\EFR7[(:LI]R&[*?<ANRGW(;LI]R&[*?<AN
MRGW(;LI]R&[*?<ANRGW(;LI]R&[*?<ANRGW(;LI]R&[*?<ANRGW(;LKZMT(8
M^KA(,/6]23_FS$,[U.$X4,?M0&N\\TB M.E0D:WB6)ZAW5BGE]A9KX_56K2(
MTENY@]!<O'_/7;Y[SE_ ><UAP7?-9<)WS6C"=\UHPG?-:,)WS6C"=\UHPG?-
M:,)WS6C"=\UHPG?-:,)WS6C"=\UHPG?-:,)WS6C"=\UHPG?-:,+XN4,7^+I'
M+NS&02_6W3$XR>PY5;WV0VVT\TQ_K>M4CI_E4IF4X%&BB]Q3J(395*U^UE6Q
M>M56LW?46+5TTUJV<M-<MW'27[APTF*X<-)BN'#28KAPTF*X<-)BN'#28KAP
MTF*X<-)BN'#28KAPTF*X<-)BN'#28KAPTF*X<-)BN'#28KCVNT$5\<!!)-O7
M*R#+ZC(]OO8\5[7\1VRM]4][G^Y-B)/H3).(Y$R;@.!-H7K>3J5UW%"H<=M1
MJF_:4ZMMVE6L:]E7K6G96:UIV5RN:=E<KFG97*YIV5RN:=E<KFG97*YIV5RN
M:=E<KFG97*YIV5RN:=E<KFG97*YIV5RN:=E<KFG97*[SOCT3X\\P$,WG*B?
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MIM/&CJ;3QHZFT\:.IM/&CJ;3QHZFT\:.IM/&CJ;3QHZFT\:.IM/_IC(7_ZA
M+?^H2T7_I%5?_ZE>;_^L9'WZK6>+]*QJF.ZK;J3JJG*NY:=VM^&C?+_>FX''
MVY.%S=B+B]+6A9+6UH6<UM&)I-;)CJ75P9"EUK^0I-:_D*36OY"DUK^0I-:_
MD*36OY"DUK^0I-:_D*36OY"DUK^0I-:_D*36OY"DUK^0I-;_IS,7_ZE +?^H
M2T7_I55?_ZM>;O^M8GS[KF6)]:YHEN^N;*+JK'"LYJITM>*H>KW?HG_%VYJ$
MS-B1BM+6B)+7U8:>V,N,H]C"D*/8NY&CV+F1H]BYD:/8N9&CV+F1H]BYD:/8
MN9&CV+F1H]BYD:/8N9&CV+F1H]BYD:/8N9&CV+F1H]C_IS,6_ZE +?^I2T7_
MIE5?_ZQ?;?ZN87O[KV2(];!GE?"P:J#KKVZJYZYRLN2L=[K@J7W"W**#RMF8
MB='3C)#7S8B;V\.-H=N[D:':M9*AVK.2H=NSDJ';LY*AV[.2H=NSDJ';LY*A
MV[.2H=NSDJ';LY*AV[.2H=NSDJ';LY*AV[.2H=O_IS,6_ZE +?^I2T7_IE9?
M_ZU>;/ZO8'G\L6*']K%ED_&R:9[MLFRGZ;)PL.6R=+?_XGT024-#7U!23T9)
M3$4 !Q7BKWN^WJN!QM:@AL_*E(S7OXV4W+F/G]VSDJ#=KI*@W:V2H-RMDJ#<
MK9*@W*V2H-RMDJ#<K9*@W*V2H-RMDJ#<K9*@W*V2H-RMDJ#<K9*@W*V2H-S_
MJ#,6_ZI +?^I2T7_IU9>_ZY=:_VP7WC[LF&%][-DD?*T9YSNMFNEZK=OK.>Y
M<[/DN7FZV[%]Q<ZG@\_"G(C7M)*.W:Z1G=^JDY[?J).>WZ>3GMZGDY[>IY.>
MWJ>3GMZGDY[>IY.>WJ>3GMZGDY[>IY.>WJ>3GMZGDY[>IY.>WJ>3GM[_J#,6
M_ZI!+?^J2T7_J%9=_Z]=:OVQ7G?ZLV"#^+5BC_.W9IGONFJA[+UNJ.G"<Z[@
MP'6YU+=YQ,>M?\ZZI(76K)F*WJ*4EN*@E)SAH).=X*"3G>"@DYW@H).=X*"3
MG>"@DYW@H).=X*"3G>"@DYW@H).=X*"3G>"@DYW@H).=X*"3G>#_J#,6_ZI!
M+/^J2T7_J59=_Z]<:ORR77;ZM%Z"][=AC?6Z9);QOFF>[,1NH^7)<:S;QW&X
MS;UVQ,"T?,VSJX'5I*"%W9:8CN.5F)OCEY6<XIB5G.&8E9SAF)6<X9B5G.&8
ME9SAF)6<X9B5G.&8E9SAF)6<X9B5G.&8E9SAF)6<X9B5G.'_J#,6_ZM!+/^J
M2T7_JE9<_K!;:?RS6W7YMEV ]KE@BO.^8Y/NPVF9ZLUPG.'1;:O4SFVXQL1S
MP[FZ><RLLGW5G:B!W8R?B..+H9OCD)J<XI&9G.*1F9SBD9F<XI&9G.*1F9SB
MD9F<XI&9G.*1F9SBD9F<XI&9G.*1F9SBD9F<XI&9G.+_J3,6_ZM!+/^K2T7_
MK%9;_K%:9_NT6G/XN%Q^]+Q>A_#"8X[KRFJ2Y=-MF]K9::K-TVRWO\MPPK+"
M=<RENGG4E;!]W(>JA>&%KIWAC*.=X(V@G>"-H)W@C:"=X(V@G>"-H)W@C:"=
MX(V@G>"-H)W@C:"=X(V@G>"-H)W@C:"=X(V@G>#_J306_ZM!+/^K3$7_K5=:
M_;)89OJV67'VNEI[\<!>@^S(8X?FU&R(WMUGFM+;::K&U&VVN<UPP:O(<LN=
MPG73C;EXVH.V@]Z!O)S=BJ^@W8JKG]V*JY_=BJN?W8JKG]V*JY_=BJN?W8JK
MG]V*JY_=BJN?W8JKG]V*JY_=BJN?W8JKG]W_J306_ZQ"+/^L3$7_KU=9_;-7
M9/FX5V[SO5EW[<5=?.;09'[?W&6)UN-EF<K<:JF_U&ZUM,YRP*C(<LJ9Q'+2
MB<!SV8*_@-N$OY+:AKZBV8>XHMF'N*+9A[BBV8>XHMF'N*+9A[BBV8>XHMF'
MN*+9A[BBV8>XHMF'N*+9A[BBV8>XHMG_JC05_ZQ"+/^M3$3_L%97^[558?:[
M5FOPPEAQZ,Q<=-_97GS6XEV.S.)AGL';:*NXU&ZVL,YRP*+)<<F4Q7#0B,)R
MUH;!?=:(PHO5B<.:U(?"GM6'PI[5A\*>U8?"GM6'PI[5A\*>U8?"GM6'PI[5
MA\*>U8?"GM6'PI[5A\*>U8?"GM7_JS05_ZU"*_^N3$3_LE14^;A37O*_5&7J
MR%9HX-59;=7A58+,YUF3PN!=HKC99:ZQTVRXILYMP9K);,B.QFS/AL-OTH3#
M>-.%Q(32A\61T8?%E="'Q970A\65T(?%E="'Q970A\65T(?%E="'Q970A\65
MT(?%E="'Q970A\65T(?%E=#_JS45_ZY#*_^O343]M%%1]KM16.W$4ESBTE5;
MUN!.<\SH4H;"YE:7N-Y<I;'89*^ITFFXG<YHP)+*:,>)QVC,@\9LSX'%<\^!
MQGW.@L:(S8/'B\V#QXO-@\>+S8/'B\V#QXO-@\>+S8/'B\V#QXO-@\>+S8/'
MB\V#QXO-@\>+S8/'B\W_K#84_Z]$*_^P3D3ZMT],\<!.4.;-3D_8WD=AS>A+
M=\+M4(JYY%::L-U=IJC88K">TV.XD\]COHK,9,2#RF7(?\AHRGW(;LM]R';*
M?LF R7[)@\E^R8/)?LF#R7[)@\E^R8/)?LF#R7[)@\E^R8/)?LF#R7[)@\E^
MR8/)?LF#R7[)@\G_KC84_[%%*OZS3D#UO$Q$ZLA*0]G</TW.Z$5GP_!+>[GL
M48VPY%>;J-U<IIW97:Z3U%ZUB]%?NX/.8+]^S6'">LQEQ'C+:L5XRW#%>,QX
MQ'G,>L1YS'K$><QZQ'G,>L1YS'K$><QZQ'G,>L1YS'K$><QZQ'G,>L1YS'K$
M><QZQ'G,>L3_L#<3_K-'*?JW2SGNPT<XW=8_-\_F/E/$\45KN?1,?K'K4XVH
MY%>:G-]6I)+:5ZN)UEBQ@M1:MGS26[EXT%Z\==!AO7//9;YSSVJ^<\]QO7/0
M<[UST'.]<]!SO7/0<[UST'.]<]!SO7/0<[UST'.]<]!SO7/0<[UST'.]<]!S
MO7/0<[W_LCD2_+9)*/.^1B[CSSTET>0W/L3Q/EBZ^$=ML?1/?JCL4XR;YE&7
MC^%0H(?=4J9_VE.K>=A5KW765[)RU5FS;]1<M6[47[5MU&2U;-1IM6S4:[5L
MU&NU;-1KM6S4:[5LU&NU;-1KM6S4:[5LU&NU;-1KM6S4:[5LU&NU;-1KM6S4
M:[7\M3L1^+E&(^G(/!S3X2THQN\X0[KY05JQ_DIMI_5.>YKN3(B/Z4R2A.1,
MFGSA3:!VWD^D<=U1IV[<4JEKVU6J:=I7JVC:6JQGVEZL9MIBK&;:8ZQFVF.L
M9MICK&;:8ZQFVF.L9MICK&;:8ZQFVF.L9MICK&;:8ZQFVF.L9MICK&;:8ZSX
MN#X/[\(\$];<(!3'[C$NN_DZ1;+_15FG_TEJF?A'=X[R1X*#[4>+>^E(DG/F
M2)=MY$J;:>),G6;A3I]EX5"@8^!2H&+@5:%AX%BA8.!;HF#@7:)@X%VB8.!=
MHF#@7:)@X%VB8.!=HF#@7:)@X%VB8.!=HF#@7:)@X%VB8.!=HF#@7:+TO#T,
MW-4:!<GK)QF]^#0PL_\^1*?_0E:9_T%EC?Q!<8+V07IY\D*"<>Y#B&KL18QF
MZD:/8NE(D6#H2I->Z$R47>=.E%SG4)5;YU*56N=5EEKG5I9:YU:66N=6EEKG
M5I9:YU:66N=6EEKG5I9:YU:66N=6EEKG5I9:YU:66N=6EEKG5I;ERR$!S.@9
M";_V+!RT_S<PI_\[09G_.E"-_SI>@O\[:'C[/'%O^#UX:/4_?6/S08!?\4*#
M7/!$A%KP1H99[TB&6.]*AU?O2XA6[DZ(5NY0B%7N48E5[E&)5>Y1B57N48E5
M[E&)5>Y1B57N48E5[E&)5>Y1B57N48E5[E&)5>Y1B57N48G_GRH2_Z X)O^?
M1#[_FT]5_YU79O^A7G3^HF.!^*%IC_.=;9KNEW&EZH]VKN:(?+7C@8*\X7J)
MP=]WD,/?=Y?$WW>>Q=]XI<3?>JS$VWRPQ-. LL//@[+#SX.RP\^#LL//@[+#
MSX.RP\^#LL//@[+#SX.RP\^#LL//@[+#SX.RP\^#LL/_GRH2_Z X)O^?1#[_
MFT]5_YU79O^A7G3^HF.!^*%IC_.=;9KNEW&EZH]VKN:(?+7C@8*\X7J)P=]W
MD,/?=Y?$WW>>Q=]XI<3?>JS$VWRPQ-. LL//@[+#SX.RP\^#LL//@[+#SX.R
MP\^#LL//@[+#SX.RP\^#LL//@[+#SX.RP\^#LL/_GRH2_Z X)O^?1#[_FT]5
M_YU79O^A7G3^HF.!^*%IC_.=;9KNEW&EZH]VKN:(?+7C@8*\X7J)P=]WD,/?
M=Y?$WW>>Q=]XI<3?>JS$VWRPQ-. LL//@[+#SX.RP\^#LL//@[+#SX.RP\^#
MLL//@[+#SX.RP\^#LL//@[+#SX.RP\^#LL/_GRH2_Z X)O^?1#[_FT]5_YU7
M9O^A7G3^HF.!^*%IC_.=;9KNEW&EZH]VKN:(?+7C@8*\X7J)P=]WD,/?=Y?$
MWW>>Q=]XI<3?>JS$VWRPQ-. LL//@[+#SX.RP\^#LL//@[+#SX.RP\^#LL//
M@[+#SX.RP\^#LL//@[+#SX.RP\^#LL/_GRH2_Z X)O^?1#[_FT]5_YU79O^A
M7G3^HF.!^*%IC_.=;9KNEW&EZH]VKN:(?+7C@8*\X7J)P=]WD,/?=Y?$WW>>
MQ=]XI<3?>JS$VWRPQ-. LL//@[+#SX.RP\^#LL//@[+#SX.RP\^#LL//@[+#
MSX.RP\^#LL//@[+#SX.RP\^#LL/_GRH2_Z X)O^?1#[_FT]5_YU79O^A7G3^
MHF.!^*%IC_.=;9KNEW&EZH]VKN:(?+7C@8*\X7J)P=]WD,/?=Y?$WW>>Q=]X
MI<3?>JS$VWRPQ-. LL//@[+#SX.RP\^#LL//@[+#SX.RP\^#LL//@[+#SX.R
MP\^#LL//@[+#SX.RP\^#LL/_GRH2_Z X)O^?1#[_FT]5_YU79O^A7G3^HF.!
M^*%IC_.=;9KNEW&EZH]VKN:(?+7C@8*\X7J)P=]WD,/?=Y?$WW>>Q=]XI<3?
M>JS$VWRPQ-. LL//@[+#SX.RP\^#LL//@[+#SX.RP\^#LL//@[+#SX.RP\^#
MLL//@[+#SX.RP\^#LL/_GRH2_Z X)O^?1#[_FT]5_YU79O^A7G3^HF.!^*%I
MC_.=;9KNEW&EZH]VKN:(?+7C@8*\X7J)P=]WD,/?=Y?$WW>>Q=]XI<3?>JS$
MVWRPQ-. LL//@[+#SX.RP\^#LL//@[+#SX.RP\^#LL//@[+#SX.RP\^#LL//
M@[+#SX.RP\^#LL/_GRH2_Z X)O^@1#[_G$]5_Y]79?^C7G/_I&2 ^:1IC?.A
M;9GNFW"DZI1UK>:->[7CA8&\X'V'P=]YC\7>>)?&WGB?QMYZIL;>>Z[&UG^P
MQ<^#L,7+A;#%RX6PQ<N%L,7+A;#%RX6PQ<N%L,7+A;#%RX6PQ<N%L,7+A;#%
MRX6PQ<N%L,7_H"H2_Z$Y)O^@1#W_G4]5_Z)79/^F7G'_J&1^^JAIB_2F;9?O
MHG"BZYMSJ^>4>K/CBX"[X(.&PMY\C<?=>9;)W7J@R=U[J<G7?Z[(SX2NR,B'
MKLC#AZ[(PX>NR,.'KLC#AZ[(PX>NR,.'KLC#AZ[(PX>NR,.'KLC#AZ[(PX>N
MR,.'KLC_H"H2_Z(Y)O^A1#W_GD]5_Z178_^I7G#_JV5]^ZMHB?6J;)7PIW&@
M[*)SJ>B:>++DDGZZX(F$P=Z C,?<>Y;+W'NAR]I]J\O0@ZW*R(BMRL&)K,N]
MB:S+O8FLR[V)K,N]B:S+O8FLR[V)K,N]B:S+O8FLR[V)K,N]B:S+O8FLR[V)
MK,O_H"H1_Z(Y)O^B1#W_GD]5_Z978O^K7V__K&-[_*QFA_:L:I/QJF^=[:=S
MI^FA=J_EF7VXX8^#P-Z%BL?:?97,V'VBS=*!J\W(AJO-P8FKS;J*JLVWBZK-
MMXNJS;>+JLVWBZK-MXNJS;>+JLVWBZK-MXNJS;>+JLVWBZK-MXNJS;>+JLW_
MH2L1_Z,Y)O^B1#W_H$]4_ZA78?^M7VW^KF)Y_:YEA?>N:9'RK6V;[JMQI.JG
M=:SFH'JUXI>"O=F-B<;0@Y#-RX&;T,F#J=# B*G0NHNIS[2,J="QC*G0L8RI
MT+&,J="QC*G0L8RIT+&,J="QC*G0L8RIT+&,J="QC*G0L8RIT+&,J=#_H2L1
M_Z,Y)O^C1#W_H4]3_ZE88/^N7FS^KV!X_+!C@_BP9X[TL&N8\*]OH>RL<ZGE
MJ'FQW:"!N]&4AL7'BHS-P(66TKZ&H]*XBJ?2LXRGTJZ-I]*LC:?2K(VGTJR-
MI]*LC:?2K(VGTJR-I]*LC:?2K(VGTJR-I]*LC:?2K(VGTJR-I]+_H2L1_Z,Y
M)O^C13W_HD]3_ZI87_^O76O]L%]V_+%B@?JR98SULVF5[[-NGNFR<Z7AKGFN
MUJ5^NLN;A,3 D8G-MXJ1T[.*G=2PC*;4K(ZFU*F.IM2GCJ;3IXZFTZ>.IM.G
MCJ;3IXZFTZ>.IM.GCJ;3IXZFTZ>.IM.GCJ;3IXZFTZ>.IM/_HBL1_Z0Z)?^C
M13W_I$]2_ZQ87O^P7&K]L5YU^[-@?_FU9(GRMFF2[+ANFN:Y<Z'=LW:MT:I[
MN<6A@<.YEX;,KX^,TZF,E]:GCJ36I(^DUJ*/I=6ACZ75H8^EU:&/I=6ACZ75
MH8^EU:&/I=6ACZ75H8^EU:&/I=6ACZ75H8^EU:&/I=7_HBL1_Z0Z)?^D13W_
MI4]1_ZU87?ZP6VC\LUUS^;5@??:W9(;PNFB.ZKUNE>*_<*#8N'*MS*]XN+^F
M?L.SGH/,J)6)U)^0D=B<D:'8FY"CV)N0H]>;CZ36FX^DUIN/I-:;CZ36FX^D
MUIN/I-:;CZ36FX^DUIN/I-:;CZ36FX^DUIN/I-;_HBL1_Z0Z)?^D13W_ID]1
M_ZY87/ZR6F?[M%QQ^+=?>O2Z8X/MOFB)Z,5OC][%;)_2O7"LQK5VM[FL>\*M
MI(#+H9R%TY64B]F0E)G:D9.AVI*1HMF4D:/8E)&CV)21H]B4D:/8E)&CV)21
MH]B4D:/8E)&CV)21H]B4D:/8E)&CV)21H]C_HRL1_Z4Z)?^E13W_IT]0_Z]8
M6_VS667YMEMO];I>=_&^8G[KQ&B#Y,IKCMK,:)[,PVVKP+ISM[.R>,&GJWW*
MFJ.!TXR;AMF&F9/<AIJAVXJ5HMJ,E*+9C)2BV8R4HMF,E*+9C)2BV8R4HMF,
ME*+9C)2BV8R4HMF,E*+9C)2BV8R4HMG_HRL1_Z4Z)?^E13W_J4]/_[!76?NT
M6&/WN%IL\[U=<^[#8GCHS&E[X--EC=/299W&R6JJN<%PMJRY=,"@LGG)DJM]
MTH6D@=A_HX_:@*6BV8:>H]B'FJ/8AYJCV(>:H]B'FJ/8AYJCV(>:H]B'FJ/8
MAYJCV(>:H]B'FJ/8AYJCV(>:H]C_HRL0_Z8Z)?^F13W_JD]-_K)55_JV5V#U
MNUEH[\%<;NG*8G'BU&5XVM]>C,W98IR_T6>ILLELM:7!<+^8NG3(BK-XT'^O
M?M9[L([6>K2DU8.JI=2#I*75@Z2EU8.DI=6#I*75@Z2EU8.DI=6#I*75@Z2E
MU8.DI=6#I*75@Z2EU8.DI=7_I"P0_Z8[)?^F13S_K%!,_;-45?BX5EWROEAC
MZ\=<9N/38V7;X%YWT>1?BL7@89NWV62HJ=%GLYS*:[Z/Q&['@KYRSWF\>])W
MOXS2=L.BT7ZXJ=!_L*C1?["HT7^PJ-%_L*C1?["HT7^PJ-%_L*C1?["HT7^P
MJ-%_L*C1?["HT7^PJ-'_I2P0_Z<[)/^G1CS_KU!)^[534?6[5%CMPU9<Y<];
M6]O=6F;2Y5YXR>IAB;WD8IFPW62GH]9GLI70:+R'RVG%?,=MS'?&=\YWQH;-
M>,>7S'G(J<MZP*O,>L"KS'K J\QZP*O,>L"KS'K J\QZP*O,>L"KS'K J\QZ
MP*O,>L"KS'K J\S_I2P0_Z@[)/^H1CS_LE%&^+A23?' 4E'GRU11W-I36-+D
M56S)ZUE^ONM<CK/C7YRIW&2HG-9ELI#19KN$S&;#>\IKQWG)=,AZRH#'>\N.
MQGS+G<5YRZ7&><NEQGG+I<9YRZ7&><NEQGG+I<9YRZ7&><NEQGG+I<9YRZ7&
M><NEQGG+I<;_IBT/_ZD\)/^J1CS\M%!"];Q/1NO'3T;>UDY'T^--7LGL4G*_
M\5:#M.E:DJKA79^?W%^ID]9@LHG28;I_SF/ >,QGPW;,;\1VS'G#=\V$PGC-
MD,%YSIG ><Z9P'G.F<!YSIG ><Z9P'G.F<!YSIG ><Z9P'G.F<!YSIG ><Z9
MP'G.F<#_J"T/_ZH](_^N2#CYN$X\[\)+/.+12C?4X45-R>M+9+_T3W>U[U2'
MK.=9E:#A6:"5W%NIBM=<L(+37;=ZT%^[=<]DOG//:K]RSW*_<\][OG30A;UT
MT(V\=-"-O'30C;QTT(V\=-"-O'30C;QTT(V\=-"-O'30C;QTT(V\=-"-O'30
MC;S_J2X._ZP^(OVS3#+TO4HSYLM%+M7?/3O*ZT13P/1):+;V3WJM[E6)HN=6
ME97A5)^+W5:G@ME7K7O66;)UU%RV<=)@N&_29;ENTFNY;M)SN&_3?+=OTX*W
M;]."MV_3@K=OTX*W;]."MV_3@K=OTX*W;]."MV_3@K=OTX*W;]."MV_3@K?_
MJR\._Z\_(OFX22GLQ4,EV-PS)\OI/$' ]$-8MOM*:Z[V47NC[E*(ENA1E(OC
M4)R"WU*C>MQ3J7395:UOV%BO;-=;L6K68+)IUF6R:=9KL6G6<K%IUWBP:==X
ML&G7>+!IUWBP:==XL&G7>+!IUWBP:==XL&G7>+!IUWBP:==XL&G7>+#_KC -
M_[)!(/&_0AS=U#$5S><T+L'S/4:W_$1;KOY,;*+V37J6[TR&B^I,D('E3)AY
MXDV><M]/HFW>4:5IW52G9]Q7J&7<6ZEDVU^I9-MDJ63<:JEDW&ZI9-QNJ63<
M;JEDW&ZI9-QNJ63<;JEDW&ZI9-QNJ63<;JEDW&ZI9-QNJ63<;JG_L3(+]KI"
M%.3-,0O/Y2D;PO(V,[?\/TBO_TA;HO]':I7X1G>*\D:!@.U'BGCI2)%PYDF6
M:N1+FF;C39QCXE">8N%3GV#A5I]?X5F@7^%=H%[A8J!>X66?7N%EGU[A99]>
MX66?7N%EGU[A99]>X66?7N%EGU[A99]>X66?7N%EGU[A99_\M30*Z\4R!M'A
M&PO$\2X@N/LY-:__0DBA_T%9E?] 9HG[07)_]D)[=O)#@F[N1(AH[$6,8^I'
MCV#I29%>Z$R37.A.DUOG491:YU.46>=7E5GG6Y59YUV56>==E5GG7959YUV5
M6>==E5GG7959YUV56>==E5GG7959YUV56>==E5GG797ROS$"U=H) <7O(P^Z
M^C(BL/\[-:'_.D64_SE4B?\Z8'[_/&IU^SUR;/<^>6;T0'UA\D*!7?%$@UKP
M1H59\$B&5^]*AU;O3(=6[TZ(5>Y1B%3N5(A4[E:(5.Y6B%3N5HA4[E:(5.Y6
MB%3N5HA4[E:(5.Y6B%3N5HA4[E:(5.Y6B%3N5HC7T0< Q^P5 [OY*A&P_S(A
MH?\Q,I3_,4"(_S--??\T6'3_-F%K_SAH9/TZ;E[[/'):^CYT5_A =E7X0G=4
M]T1X4_=&>5+W2'I1]DEZ4/9,>E#V3GM/]E![3_90>T_V4'M/]E![3_90>T_V
M4'M/]E![3_90>T_V4'M/]E![3_90>T_V4'O_EB(._Y<Q(/^6/C?_DDE-_Y11
M7/^76&G_EUYV_I5C@OB0:([SB&V9[X%UHNMZ?*KI<X.PYV^+L^9MD[7F;9JV
MYFZAMN9OJ;7F<*^UYG&VM>!TN;3:=[NTU7J]L]5ZO;/5>KVSU7J]L]5ZO;/5
M>KVSU7J]L]5ZO;/5>KVSU7J]L]5ZO;/_EB(._Y<Q(/^6/C?_DDE-_Y117/^7
M6&G_EUYV_I5C@OB0:([SB&V9[X%UHNMZ?*KI<X.PYV^+L^9MD[7F;9JVYFZA
MMN9OJ;7F<*^UYG&VM>!TN;3:=[NTU7J]L]5ZO;/5>KVSU7J]L]5ZO;/5>KVS
MU7J]L]5ZO;/5>KVSU7J]L]5ZO;/_EB(._Y<Q(/^6/C?_DDE-_Y117/^76&G_
MEUYV_I5C@OB0:([SB&V9[X%UHNMZ?*KI<X.PYV^+L^9MD[7F;9JVYFZAMN9O
MJ;7F<*^UYG&VM>!TN;3:=[NTU7J]L]5ZO;/5>KVSU7J]L]5ZO;/5>KVSU7J]
ML]5ZO;/5>KVSU7J]L]5ZO;/_EB(._Y<Q(/^6/C?_DDE-_Y117/^76&G_EUYV
M_I5C@OB0:([SB&V9[X%UHNMZ?*KI<X.PYV^+L^9MD[7F;9JVYFZAMN9OJ;7F
M<*^UYG&VM>!TN;3:=[NTU7J]L]5ZO;/5>KVSU7J]L]5ZO;/5>KVSU7J]L]5Z
MO;/5>KVSU7J]L]5ZO;/_EB(._Y<Q(/^6/C?_DDE-_Y117/^76&G_EUYV_I5C
M@OB0:([SB&V9[X%UHNMZ?*KI<X.PYV^+L^9MD[7F;9JVYFZAMN9OJ;7F<*^U
MYG&VM>!TN;3:=[NTU7J]L]5ZO;/5>KVSU7J]L]5ZO;/5>KVSU7J]L]5ZO;/5
M>KVSU7J]L]5ZO;/_EB(._Y<Q(/^6/C?_DDE-_Y117/^76&G_EUYV_I5C@OB0
M:([SB&V9[X%UHNMZ?*KI<X.PYV^+L^9MD[7F;9JVYFZAMN9OJ;7F<*^UYG&V
MM>!TN;3:=[NTU7J]L]5ZO;/5>KVSU7J]L]5ZO;/5>KVSU7J]L]5ZO;/5>KVS
MU7J]L]5ZO;/_EB(._Y<Q(/^6/C?_DDE-_Y517/^86&G_F5YV_I9C@OF2:([S
MBFV9[X-THNM[>ZKI=(.PYV^*M.9NDK;F;IJVYFZBMN9OJ;;F<+"VYG&WM=]U
MN;78>+RTTWN\M--[O+33>[RTTWN\M--[O+33>[RTTWN\M--[O+33>[RTTWN\
MM--[O+3_ER(._Y@Q(/^7/C;_DTE,_YA16O^<5V?_G5UT_YMC@/J8:(STDFR7
M\(ERH>R!>:GI>8"PYG.(M>5PD;CD;YJYY'"BN>1QJ[GE<K.XWW6WN-AYNK?1
M?;JWS'ZZM\Q^NK?,?KJWS'ZZM\Q^NK?,?KJWS'ZZM\Q^NK?,?KJWS'ZZM\Q^
MNK?_F"(._YDQ(/^8/C;_E$E,_YM16?^?5V;_H5UR_Z!B?ON=9XKUF&R5\9!P
MG^R(=ZCI?WZOYG>&MN1RC[KC<)F[XW&CN^-RK;O@=;6[V'FXNM%]N+K*?[BZ
MQ8"XN\6 N+O%@+B[Q8"XN\6 N+O%@+B[Q8"XN\6 N+O%@+B[Q8"XN\6 N+O_
MF",-_YHR(/^9/C;_EDE+_YY05_^B5V3_I%UP_Z1B?/RB9X?VGFN2\I=OG>V.
M=:;IA7RNYGR$M>-TC;OB<9F]XG*EON)SL;W9>+:]T7VWO,J M[S#@;:]OH*U
MOKZ"M;Z^@K6^OH*UOKZ"M;Z^@K6^OH*UOKZ"M;Z^@K6^OH*UOKZ"M;[_F2,-
M_YHR(/^9/C;_F$E*_Z!05O^E5V+_IUUN_ZAB>OVF9X7XHVN0\YUNFNZ5<Z/J
MC'NLYX*#M.%YB[O<=):_VG6CP-EWL+_1>[2_R7^TO\."M;^\@[3 N(2TP+B$
MM,"XA+3 N(2TP+B$M,"XA+3 N(2TP+B$M,"XA+3 N(2TP+B$M,#_F2,-_YLR
M(/^:/C;_FDE*_Z)05?^G5V'_JEYL_ZMC>/ZJ9X+YJ&N-]*-NE^Z<<J'HDWJJ
MX8J!LMF B;O2>9+!SWB>PLUZJL+)?;+"PH&RPKR$L\*VA;+"LH6RP[*%LL.R
MA;+#LH6RP[*%LL.RA;+#LH6RP[*%LL.RA;+#LH6RP[*%LL/_FB,-_YLR'_^:
M/C;_FTE)_Z-05/^I5U__K%YK_ZUB=?RL9H#VJVJ*\*EOE.JC<YWCG'FFVY*
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M>:";T7N?J=!_F:G/@):ISX"6J<^ EJG/@):ISX"6J<^ EJG/@):ISX"6J<^
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M=9"TRW2;MLEUI[;'=[2VPWJ[MKU]N[6X?[NVLX"[MK" N[:P@+NVL("[MK"
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MK5I7^:]?8/*O8VGKKV9QY*YK>=VI;H?3H7.6R9AZHK^/?ZVVAX2VKH&,O*J
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M;M"8TV[0F--NT)C3;M"8TV[0F--NT)C3;M"8TV[0F--NT)C_@Q8)_X,C%_^
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M%?^4,B+_H3XF_ZQ(*?>T42SMNU$LY,13*]O.2SC/RT]-P\578+B_77&MN6.
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M7O\L25?_+T]2_S)33?\U5TO_.5E(_SQ;1_\_7$7_0UU$_T9>0O]*7D'_35Y
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M;HZ1GW*9AIEVHWN3>JQRD(*R;H^/LVV0GK)LD:ZQ;)*_L&Z/OZ]QC,"O<HO
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M=T;XLW?_FPL V:X! ,Z^ P#$S@0 NO<2 +'[* FF_C$6F_\U)9#_-S.%_SA
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M7#K_9UPY_V];.?]S6SG_<ULY_W-;.?]S6SG_<ULY_W-;.?]S6SG_<UO'NP
MO,H  *_6  "B[0, EO\, XO_% N!_QH5=_\='VS_("EB_R,R6/\D.E+_*#],
M_RM$2/\O2$7_,TI"_S=,0/\[33[_/TX\_T-/._]'3SG_2U X_U!0-_]53S;_
M6D\T_V!/-/]C3S3_8T\T_V-/-/]C3S3_8T\T_V-/-/]C3S3_8T^]Q   L=$
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MXX%B8MUZ:V[6<7-YT&I[@\QF@XG)98V*QV:8B\5GHHO$9ZR+PFBXB\%IQHO
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M:D+XI6E"^+1H0?G-9T'YSF=!^<YG0?G.9T'YSF=!^<YG0?G.9T'YSF?NG
MTZP  ,B[ 0"^R0( L]8$ *CV%0&@^B0)EOLL%8S\,2*"_#0P=_PV.VS\-T9B
M_#E/6?T[5E']/EQ,_D-A2/Y)8T3_4&5"_U=E0/]@93[_:V0\_W=C.O^$8CG_
MD6(X_Y]A./^S8#C_LV X_[-@./^S8#C_LV X_[-@./^S8#C_LV#6I@  RK4
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M0"G_:T I_VM *?]K0"G_:T I_VM *?]K0"G_:T"YPP  K,X  )_8  "1WP
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M/RO_;C\I_W@^)_^#/B;_C3TF_XT])O^-/2;_C3TF_XT])O^-/2;_C3V^N
ML\4  *;/  "8U@  B]X  (#S  %V_P8%;?\,"F/_$A!:_Q864O\:'$S_'B)%
M_R(G0/\F*SO_*BXW_RXP-/\R,3+_-S(O_SPS+/]!,RK_1S0H_TTS)O]5,R3_
M7#,B_V0R(/]M,A__=#(?_W0R'_]T,A__=#(?_W0R'_]T,A__=#*UP0  J,P
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MBE^'VHI?A]J*7X?:BE^'VHK_9P\+_WL1!?^*% +ZEQ, XJ() -2K!@#+LA,
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M3$+KIDM![+A*0>W+24#NYDA [>Q'0.WL1T#M[$= [>Q'0.WL1T#M[$?5FP
MR*D  +ZU  "TP   J,H  )S2 0"1VP, B? 4 H'R'PAY\R<2;_,M'&;S,29=
M\C0P5/(X.$WS/#Y(\T%#1/1'1D'T3T<^]5=(/?9A1SOV;$<Z]WE&.?B(13CX
MED,X^:9"-_FS0C?ZRD$W^M! -_K00#?ZT$ W^M! -_K00#?ZT$#+I0  P+(
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M)!O_>B0;_WTC&_]](QO_?2,;_WTC&_]](QO_?2.QP   I<D  )?0  ")UP
M>]X  &_D  !E]@ "7/\ !53_  I,_P4.1?\)$C[_#14X_Q(8-/\6&C#_&APL
M_QX=*?\B'B?_)Q\D_RL?(?\P'Q__-1\<_SL>&?]"'A?_21T5_U$<%/]8'!+_
M8!L2_V,;$O]C&Q+_8QL2_V,;$O]C&Q+_8QO_0!H5_S<E&_\U+![_.2\@_SLU
M)/\]0"O_.TLT_SE6.O\V8CW_-6\__S-[0/\SA4#_,X] _S.80/\TGT#_-:=
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M?')TY'QR=.1\<G3D?')TY'S_7! ,_V\.!_]^$P/_B14![I(3 -^:#0#2GQD
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M84VTLU],M,A>3+3A74JR\5])K_=A2:_W84FO]V%)K_=A2:_W84FO]V'^@
MVY   ,^=  #$J   N[   +&X  "FOP  F\<( )7*'@&-RBT)ALDX%'[(/R%U
MQD4N;,1).6/"341;P5)-5,!75$^_7UA,OVE:2\!T64K @EA*P9!72L*@54G"
ML51(P\932,+?4D;!\5-$O_Q61+_\5D2__%9$O_Q61+_\5D2__%;BB   TY<
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M,S;TR3,U]=TR-?7=,C7UW3(U]=TR-?7=,C7UW3+&I   O+   +*Z  "FPP
MF<H  (W1  "!V   =^<$ '#W$01H^!D)8/@?$%CY)!91^2D=2ODN(T3Z,R@_
M^C@L._L^+CC[13 V_$PP-/U5,#+]7C Q_FHO+_YW+B[_A2TM_Y,L+?^A*RS_
MKRLK_[PJ*_^\*BO_O"HK_[PJ*_^\*BO_O"J^K@  M+@  *G!  "<R0  CL\
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M:(-I\FB#:?)H@VGR:(-I\FC_4PX,_V4,!_]S$0/_?10!\(45 .**% #6CAL
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ML&=1F,1E49?<9$^6[69/D_-G3Y+S:$^2\VA/DO-H3Y+S:$^2\VC_<@ !XX(
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M1D6ZZT9#N/E)0KC]2D*X_4I"N/U*0KC]2D*X_4K;AP  S94  ,*A  "YJP
MK[(  *2Y  "8O@  C,4! (++"@!^S1\!>,TL"'#--1)HS#P=8,M!)UC)1C%2
MR4LX3,A1/DC(64%&R&)"1<EN043)>D!$RH@_0\J8/D++J#Q"S+L[0<S4.D'+
MZCH_R?@\/LC[/3[(^ST^R/L]/LC[/3[(^SW2D   QIX  +RI  "SL0  J+D
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M'2G\R1TI_,D=*?S)'2G\R1VZK0  L;8  *6^  "8Q0  B\H  '[0  !RU@
M9]T  %[M  %8_0D$4?\1"$K_%PU$_QP1/O\A%3C_)A@T_RL:,?\Q'"[_-QPK
M_ST=*?]%'"?_3APE_U<;)/]C&B+_<!@@_WX7'_^,%A[_F!4=_Z85'?^J%1W_
MJA4=_ZH5'?^J%1W_JA6SM0  J+T  )O$  "-R@  ?]   '/6  !GW   7.(
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MK&U9>+]L6'G5:UAXZFM9=_%J6G;R:5IV\FE:=O)I6G;R:5IV\FG_8P #^7,
M -Q^  #1AP  R(X  ,"4  "WEP4 KID< *>:+@2@F3H-F9=#&)*52R.+DE$O
MA(]6.GV,6D1VB5Y.;H9C6&:#9V%?@6UH6G]U;%A_@&U7?XUL5H"<:U6 JVE5
M@+UH5(#49U-_Z6=3?O-H5'SS9U1\\V=4?/-G5'SS9U1\\V?_9P "[78  -B"
M  #-BP  Q),  +N8  "QFP  J9X7 **?*@*;GC<*E)U!%8V;22"&F$\L@)94
M-WB364%QD%U+:8YA5&&+95U:B6QC5HAT9U2(@&=3B(UF4XF;95*)JF-1B;UB
M48G385"(Z&%.A_9B3X3V8T^$]F-/A/9C3X3V8T^$]F/_;  !X'L  -.&  #)
MD   OY<  +:=  "KH   HZ,2 )RE)0&6I#,(CZ,^$8BA1AR!GTPH>IU2,W.;
M5SUKF%M&8Y9?4%R49%A6DFM=4I)T8%&2?V!0DHQ>4)*;74^3JEM/D[Q:3I/3
M64V2Z%I+D/9;2X[[7$N.^UQ+COM<2X[[7$N.^USX<0  VX   ,Z+  #$E0
MNYP  +&B  "EI@  G*D* ):K( "0JR\%B:HZ#H*I0AE[ITDC=*5.+FRC4SAD
MH5="79]<2E>>8E%2G&E63YQS5TZ<?U=-G8Q539V:5$R=J5),G;M12YW23TJ<
MZ%!)FO521YG^4T>9_E-'F?Y31YG^4T>9_E/D=P  U(8  ,F1  "_FP  MJ(
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M,CO _#([P/PR.\#\,CO _#+,D   P9P  +>F  "NK@  I+0  )>Y  "+O@
M?\,  '3) @!JT D 9M(; 6#2)P9:TC -5-(W%4W1/1U(T4,C0]%*)T#14BD^
MTELJ/=)F*3S3<B@\TW\G.]2.)CK5GB0ZU;$C.=;'(CG5X"$WT^\C-M+X)3;2
M^"4VTO@E-M+X)3;2^"7$F0  NJ4  +*N  "GM0  F[L  (Z_  ""Q   =\H
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ME0JGN@  FL$  (S&  !^S   <=(  &38  !8W@  3N,  $3H   \\P !-OX
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MKUUM9L!=;&;676QGZUML9_A:;6?]66UF_5AM9OU8;6;]6&UF_5C_5P $_F<
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M8%5TY&!5=/-?5G+Y7E=R^5Y7<OE>5W+Y7E=R^5[_8@ !XG   -5[  #+A
MP8H  +F.  "OD   IY(6 *"4* &:DS4(DY$_$8R/1QR&C4TF?XI2,7F(5SMR
MA5M$:H)?36-_9%5=?6I<6'MR855[?&)4>XEA5'R78%-\IEY2?+9=47S,7%%\
MXUQ0>_)<4'G[7%!Y^UQ0>?M<4'G[7%!Y^US^9@  WG0  -%_  #'B   O8X
M +22  "JE   H9<1 )N8) "5F#(&CI<]#XB511B!DTLC>Y%0+72.53=MC%E
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M2$64_DA%E/Y(193^2$64_DC==P  SH0  ,./  "ZEP  L)X  *>C  ";I@
MC:@  (:J$0"!K",!?*LP!G:K.@UOJD$6:*A'(&&G3"E:IE$Q5*56.4^C7#Y+
MHV1!2:-M0DBC>4%'HX5 1Z.3/T:CHCU%H[,\1:/(.T6CX#I#H? \0I_\/D&?
M_CY!G_X^09_^/D&?_C[6?@  R(L  +Z5  "UG@  K*0  *&I  "5K   B*\
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M&S+)^1N_F   MJ,  *ZK  "CL@  E[8  (JZ  !^O@  <L,  &;(  !<S@$
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M"A7]:@D4_7H)$_Z*"!+^F@<1_ZD&$/^Z!A#_O080_[T&$/^]!A#_O0:ML@
MH;@  )2^  "&PP  >,@  &S-  !?T@  5-@  $K=  !!X@  ..<  #/V  (O
M_P,$*O\)!B;_$ <B_Q4('_\:"1S_( H8_R8*%?\M"A+_-0H._SX)"O](" ;_
M5 @#_V(' /]Q!@#_@ 4 _XT% /^:! #_G00 _YT$ /^=! #_G02DN   E[X
M (G#  ![R0  ;LX  &'4  !5V@  2M\  $#C   WZ   +^X  2KZ  (E_P $
M(?\ !1W_ P8:_P<'%O\,"!/_$@@0_Q<("_\=" ?_(P@#_RL( /\T!P#_/@<
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MLT2"6L1%@%K917]:[$5_6OE$?EK_1'Y:_T-^6O]#?EK_0WY:_T/_3  $_UL
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M4V=CY%)H8_10:&/^3VAC_TYH8_].:&/_3FAC_T[_5@ !ZV,  -EN  #.=0
MQ7H  +U]  "T?08 K( ; *:!*P.??S<*F'U $Y)Z2!V,=TXGAG13,8!Q6#I[
M;5U!=6MB2'%H:$YM9V]2:F9X5&AF@55F9HQ69&:95F-FIE9A9K968&;*5E]F
MX55@9O)38&;]4F%F_U%A9O]186;_46%F_U'_60 !XV8  -9Q  #+>0  PGX
M +F   "P@0( J(,8 **$* *;A#4(E8$^$8Y_1AJ(?$PD@GE1+GUV5C=V<UM
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M44UU_U%-=?]1377_44UU_U'I9   V'(  ,M\  #!A   MXH  *Z-  "BC@
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M-#Z:_C30?0  PXD  +F3  "PFP  IZ   )RD  "/I@  @JD  ':L  !PK1,
M;*XC &>N+P5BK3<+7*P^$E:L1!E0JTH@2ZI/)D>I5BI$J5TM0JEG+4&I<BQ
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M$S/%DQ(RQ:01,<6W$##%S@\OQ.4/+L+S$2W!^A(MP?H2+<'Z$BW!^A*[F
MLZ$  *NI  "@KP  E+,  (>V  !ZN0  ;KT  &+!  !6Q@  3,L! $/0"0!
MTA< /=(B CG2*P4UTS,(,M,Z"C#30PLOU$P,+=16#"W580LLU6T**]9\"2K7
MBP@IV)T(*-BP!R;9QP8EV. &)-;N!R/5]0@CU?4((]7U""/5]0BUH0  KJD
M *.P  "7M   BK@  'V\  !QOP  9,0  %G(  !/S0  1=(  #O8 @ SX @
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M @#_@ $ _X\! /^< 0#_I@$ _Z8! /^F 0#_I@&AM@  E+L  (;   !XQ0
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MN"F63<@JE4W;*Y--[2R23?DLD4W_+9!,_RV03/\MD$S_+9!,_RW_/@ %_TP
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M/'M6Y3QZ5O0[>E;^.WI6_SIZ5O\Z>E;_.GI6_SK_2@ "\%<  -QA  #1:
MR6L  ,%L  "Y; H L6X> *IN+02C;#@,G6E!%9=F21Z28D\GC5]5+XE=6S2&
M6V(X@UIH.H%9;SR 67<]?EE_/7Q9B#Y[69(^>5F=/WA9JC]V6;E =%G,0'-9
MXD!S6?(_<UG]/G)9_SYR6?\^<EG_/G)9_S[_3@ !YED  -ED  #.:P  Q6\
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M2%UB_T==8O]'76+_1UUB_T?T5@  W60  ,]N  #%=0  NWD  +-[  "I>@
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M0D5Y_T+<:0  S74  ,%_  "WA@  KHL  *.-  "5C0  C8\  (:0$@"!D2(
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M*D"9F"D_F:<G/YFY)CZ9T"4]E^8E/);T)SJ5_BDZE?XI.I7^*3J5_BG*?
MOH@  +61  "LF   HIL  )6=  ")GP  ?*(  &^E  !HIPL 9*@< &"H*0);
MJ#(&5J<Z#%&F0!),ID881Z5,'4.D4R! I%HC/J1C(SVD;B,\I'HA/*2'(#NE
ME1\ZI*4=.J2W'#FDS1LXH^0;-Z'R'3:?_1\VG_T?-I_]'S:?_1_#A0  N8\
M +"8  "HGP  G:(  )"D  "$I@  >*D  &JL  !>KP  6+ 2 %6Q( !2L2L#
M3;$S!TFQ.@Q$L$$10+!'%3RP3A<ZL%89.+!?&3>P:A@WL'87-K"#%C6PDA4T
ML*(3,["T$C*PRA$RK^(1,:WP$R^L^Q0OK/L4+ZS[%"^L^Q2]C0  M)<  *R@
M  "CI0  EZD  (NK  !_K@  <K$  &6S  !8MP  3;H# $B\% !&O"$ 0[PJ
M S^\,@8[O#H)-[Q!##2\2 XRO%$/,;U:#S"]90XOO7$-+[Y^#"Z^C0LMOIT*
M++ZP"2J^Q0DIO=X(*+ON"2>Z^0LGNOH+)[KZ"R>Z^@NWEP  KZ   *>G  "<
MK   D*\  (.R  !VM   :K<  %VZ  !2O@  1L(  #O' P UR@X -,L; #'+
M)0$ORRT#+,PV!2K,/@4IS$<&)\U1!B;-6P4ESF@%),YU!"//A ,BSY4#(,^H
M A[/O@(=T-@"',[K AO,]@,;S/8#&\SV QO,]@.RH   JZ@  *"M  "4L0
MA[0  'JX  !MN@  8;X  %7"  !*Q@  /\H  #7.   LTP( )-@' "'<$  ?
MW!L 'MPD 1S=+@$;W3@!&MY" 1G?30$7WUD!%N!G 13A=@ 3X8< $>*9  [B
MK0 ,X\4 "N/=  GA\0 )X/$ ">#Q  G@\0"MJ   I*X  )BS  "*MP  ?;H
M '"]  !CP0  5\4  $S)  !!S0  -M(  "W6   EVP  'M\  !KK!@ 8[0\
M%NT7 1/M'P$1[2<!#NXP 0ON.P$)[T8!!O!3  /Q8@ !\7,  /&$  #QE@
M\*D  /"[  #PTP  \-,  /#3  #PTP"GKP  F[0  (ZX  " O   <\   &7$
M  !9R0  3<T  $+1   WU0  +MH  "7>   >X@  %^4  !3Q   1^@( #?P)
M 0K\$0$'_!<! _P? 0#]* $ _3(! /T^  #]3   _5L  /UM  #\?@  ^X\
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M *4 ^ "K /< L0#U +H ] #% /( T@#Q .$ \ #M /  ^ #O /\ [@#_ .X
M_P#N /\ [@#_ .X _P#_!B /_P<=#O\$' [_ " -_P K#/\ -PO_ $0)_P!1
M!_\ 7 ;_ &@%_P!R!/\ >P/^ (("_ "( OH C0'Y ),!^ "8 ?< G0'U *,
M] "I /( L #Q +@ [P## .X T #M -\ [ #M .H ]P#I /\ Z #_ .<!_P'G
M ?\!YP'_ ><!_P'_"QP/_PL8#O\(%PW_"AX-_PHH#/\)- O_!T *_P5-"/\$
M60?^ V0%^P)O!/D#> /W!'\#]0:% O,'BP+R!Y$!\0>6 ? 'FP'O!J$![@:G
M .T&K@#L!K< Z@;! .D&S@#G!]X Y ?L .()]P#@"O\!WPO_ MT-_P+<#?\"
MW W_ MP-_P+_$!<._Q$4#?\.$PW_%1L,_Q8E#/\4, S_$CT+_A!)"?D.5@?V
M#6$&\PUK!? -= 3N#GP#[!"# NL1B0+I$8X"Z!&4 ><1F0'F$9\!Y1&E >,2
MK0'B$K4 X1+  . 2S0#>$]T VA3K =@5]@+5%_\#TQC_!-(7_P31%_\%T1?_
M!=$7_P7_%10._Q</#/\:$ O_'QD+_R B"_\?+ O\'#@+_^)]$$E#0U]04D]&
M24Q%  D5]AI%"O 940CL&%T&Z1AG!><9<03D&7D#XAJ  ^$;A@+?&XP"WAN2
M MP<EP+;')T!VARD =D<JP'7';0!U1V_ =0>S '2'MP!SQ_J \LA]@7)(?\&
MR"'_!\<@_PC&(/\(QB#_",8@_PC_&@X-_QP("_\D# G_*14)_RH>"?TH* KS
M)3,+[",_"N8B3 CB(E@'WR)C!=PC;039)'4$UR1] ]4E@P/4)8D#TB:. ]$F
ME 3/)YH$SB>A!,PHJ 3+*+ $R2B[!,@IQP3&*=<%PRKG!L J] B^*OX*O"G_
M"[LI_PNZ*?\,NBG_#+HI_PS_'PD+_R0#"/\O"@?_,Q$&_S09!O0Q(@?J+BT)
MXBLY"=PJ1@C8*U,'TRU>!] N: ?-+G 'RR]X!\DO?@?(,(0(QC"*",4PD C#
M,98(PC&=", QI B_,:P(O3*V"+PRPPFZ,M()N#+C"K4R\0RS,OP.L3'_#[ Q
M_Q"P,?\0L#'_$+ Q_Q#_)00)_R\"!O\X!P3_/ T#^3P4 NPZ' /A-28%V3,S
M!](T00G,-4T+R#98#,4V8@S"-VL,P#=R#+XX>0V\.( -NSB%#;DXBPVX.)(-
MMSF8#;4YH VT.:@.LCFR#K$YO@ZO.<X.K3G@#ZLY[Q&I.?H3ISG_%*4Y_Q6E
M.?\5I3G_%:4Y_Q7_*P '_S< !/\_! +Z0P< \4(, .,_% #9/1\!SSXN!L@]
M/ O"/4@/OCU2$;H]7!*X/F42M3YM$K0^=!*R/GH2L#Z!$J\^AQ*N/XT3K#^4
M$ZL_FQ.I/Z03J#^N%*8_NA2E/\D4HT#;%:% [!>>/_@8G3__&9P__QJ</_\:
MG#__&IP__QK_,  &_SX  OI%  #J1P  W48# -E#" #01AH QT@J!+]'-PNY
M14(1M$1-%;%#5A>N0U\8K$-G&*I$;QBH1'48IT1\&*5$@ABD1(@8HD2/&:%$
MEQF?1: 9GD6J&IQ%M1J;1<0;F476&Y=$Z1R61/8>E$3_'I-$_Q^30_\?DT/_
M'Y-#_Q__-P $_T,  >U)  #=3@  UE   -%-! #(3A8 OU$G KA/- FQ33X1
MK$M(%ZA)41NE25H<HTEB':%):1Z?27 >G4EW'IQ)?1Z:280>F4F+'YA)DQ^6
M29P?E4FF()-)L2"22< AD$G2(8Y)YB*-2/0CC$C^(XM(_R2+2/\DBTC_)(M(
M_R3_/  "^D<  .).  #850  SU<  ,E5 0#"51$ N5@C ;)7, >K5#L/IE%$
M%Z%/31R=3E4@FTU=(IA-9".73&LCE4QR))1,>2223'\DD4R')(],CR6.3)@E
MC$RB)HM,KB:)3+PGB$S.)X9,XRB%3/,HA$S]*(-,_RB#2_\H@TO_*(-+_RC_
M0  !\$L  -U4  #36P  REX  ,-<  "\6PT M%T@ *Q=+@6F6SD-H%A"%9M5
M21R74U$BDU%8)9%17R>/4&8HC5!M*8Q/="F*3WLJB4^#*H=/BRJ&4)0KA%"?
M*X-/JBR!3[@M@$_*+7Y/X"Y]3_$N?4_\+7Q/_RU\3_\M?$__+7Q/_RW_1  !
MYDX  -I9  #.8   QF,  +YB  "V8 D KV(< *AB*P.A838*FUX_$Y9;1QN1
M6$XBC594)XI46RJ(4V(LAE-I+812<"Z#4G<O@5)_+X!2AS!^4I$P?5*;,7M2
MIS%Y4K4R>%+',G92W#-V4N\R=5+Z,G52_S%U4O\Q=5+_,752_S'_1P  XU,
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M0%Y:TT!?6^@^7UOV/5]:_SQ?6O\[7UK_.U]:_SOI4   VE\  ,QH  #";P
MN'(  *]R  "F<   GG(0 )AS( "2<RT$C'$W"H9O/Q*!;$4:?&I+(7=G4"EQ
M954P;&):-FAA8#ME7V<^8E]O06!?>$)>7X-"75^.0EM?FT):7ZI"65ZZ0E=>
MT$)77N=!6%[U/UA>_CY97O\^65[_/EE>_S[F5   UF(  ,EL  "_<@  MG8
M *QV  "B=   FG8+ )1W'0".=RL"B'4U"(-S/0]]<407>&])'W)M3R=M:E,N
M9VA8-6)F7CM>9&1 6V-L0UEC=4178X!%5F.,1%1CF4138ZA$4F.X0U%CSD-1
M8N5"46+T05)B_4!28O\_4F+_/U)B_S_C60  TV8  ,9O  "\=@  LWD  *AY
M  "=>   EGH( (][&@"*>R@!A'HS!G]Y.PUY=T(4='5('&YS321H<5(L8VY6
M,UUL6SI8:F$_56EI0U)H<D11:'U%4&B)1$]IET-.::9"36FW04QIS$!,:.-
M3&?S0$QG_3],9O\_3&;_/TQF_S_?70  SVH  ,-S  "Y>0  L'T  *1]  "9
M?   D7X# (I_%@"%@"0 @'\P!'M^.0IU?4 2;WM&&6IY2R%D=U I7G54,%ES
M63=4<5\]4'!G0$UP<4),;WQ!2W"(0$IPEC]*<*4^27"V/4APRSQ(;^,\1V[R
M/$=M_#U';?\]1VW_/4=M_SW;8P  RV\  +]W  "V?@  K($  *""  "4@0
MBX,  (6$$0" A2  >X4M W:$-@AP@SX/:X%$%F6 2AU??DXE67U3+%1[6#-/
M>5XX3'AF.TIX;SQ(>'L\2'B'.D=XE3E&>:0X1GBU-D5XRC5$=^(U0W;R-T)U
M^SA"=/\X0G3_.$)T_SC6:   QW0  +Q\  "R@P  J(8  )R&  ".A@  A8@
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M(#:0_B#$?   N88  +"/  "FDP  FI0  (Z5  ""F   =IL  &F>  !@H 0
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M!BBWAP8FMY8%);>H!".WO00BM]4#(;7I!""T]04@L_D&(+/Y!B"S^0:SE@
MK)X  *2D  "7I@  BZH  '^M  !SL   9K(  %FT  !-MP  0;L  #:^   M
MP@8 *L,3 "C$'@ FQ"< ),0P 2/%. (AQ4$"(,5+ A[&5@$=QF$!',9O 1K'
M?@ 9QXX %\>@ !7'M  3Q\T $\7E !/$\P 2P_@!$L/X 1+#^ &OG@  J*8
M )VK  "1K@  A+$  ':T  !IM@  7;D  %&\  !%OP  .L(  "_&   GRP
M'L\" !?2!P 3U!  $=0; !#4)  .U2X #-4Y  O510 *UE$ "=9?  ?6;@ %
MUG\ !-:1  +6I   UK@  -?/  #6X@  UNH  -;J  #6Z@"JI@  H*P  )6P
M  "'M   >K<  &RY  !?O   4\   $C#   \QP  ,<L  "C/   @TP  &-8
M !':   )W0$ !>,(  /B$@ !X1L  .$E  #A,0  XST  .1,  #E6P  Y6P
M .9]  #FCP  YJ$  .>R  #GPP  Y\T  .?-  #GS0"DK0  F+(  (NU  !]
MN0  ;[P  &+   !5Q   2<@  #W,   RT   *-,  "#8   8W   $=\   KA
M   #Y    .T   #P @  [PH  .X3  #N'0  [B@  .XU  #P10  \E8  /-G
M  #T>0  ](H  /69  #UI@  ]:P  /6L  #UK ";LP  CK<  (&[  !ROP
M9,,  %?'  !+S   /M   #/5   IV0  ']T  !?A   0Y   ".<   +I
MZ@   /,   #[    ^@   /D!  #Y"0  ^10  /D?  #Z+   _#T  /Y.  #_
M80  _W(  /^   #_C   _Y$  /^1  #_D0#_ !\,_P =#/\ ' O_ !\*_P K
M"/\ . ;_ $4$_P!2 _\ 70+_ &<!_P!Q ?\ >0#] (  ^@"& /@ C #V )$
M]0"6 /, FP#R *  \0"F /  K #P +, [P"\ .X R0#M -@ [0#G .T \0#L
M /H [ #_ .L _P#J /\ Z@#_ .H _P#_ !P,_P 9#/\ &0O_ !X*_P H"/\
M-0?_ $(%_P!/ _\ 6@+_ &4!_0!N ?H =P#X 'X ]0"$ /, B@#Q (\ [P"4
M .T F0#L )X [ "D .L J@#J +$ Z0"[ .@ QP#G -4 Y@#D .8 \ #E /D
MY0#_ .0 _P#B /\ X@#_ .( _P#_!!@,_P,4#/\ % O_ !P*_P E"/\ ,@?_
M #\%_P!+!/\ 5P+Z &$!]P!K ?0 = #R 'L [P"" .T AP#K (T Z0"2 .<
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M!.P-3P/G#EH!Y YD >$.;0#?#G4 W0Y\ -L.@@#:#H@ V V- -8.D@#5#I@
MU ^> -,0I0#1$*T T!&W ,X2PP#-$M( RA3C ,87\0'$&/P!PQC_ L(8_P+
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MJQB-1+D9C$3*&8I$WAJ(1.\;AT/[&X9#_QN&0_\;AD/_&X9#_QO_-P !Z4
M -Q+  #140  R%,  ,%0  "Z3@P LE ? *M0+ 6E3C<+H$Q!$9Q*21:825(9
MEDA9&I1(8!N22&<;D$AN&X](=!R-2'L<C$B"'(M(BAR)2),=B$B<'89(J!Z%
M2+4>@TC&'X)(VA^ 1^T@?T?Y(']'_R!^1_\@?D?_('Y'_R#^/   Y$<  -=1
M  #,5P  PUD  +Q7  "T5 @ K58; *96*0.@530)FE(^$)901A:23DT;CTU5
M'8Q,6Q^*2V(@B4MI((=+<"&&2W<AA$M^(8-+AB*!2X\B@$N9(WY+I"-]2[(D
M>TO")'I+UR5Y2^HE>$OX)7=*_R5W2O\D=TK_)'=*_R3V/P  X$P  --7  #(
M70  OU\  +==  "O6@0 J%L7 *%<)@*;6S('EE@[#I!50Q6,4TH;B%%1'X90
M5R*#3UXD@4YD)8!.:R5^3G(F?4YZ)GM.@B=Z3HLG>$Z6*'9.H2EU3J\I<TZ_
M*G).TRIQ3N@J<$[V*7!._REP3?\H<$W_*'!-_RCM0@  W5$  ,];  #$80
MNV,  +)A  "J7@  HU\4 )UA) &77R\%D5TY#(Q;0!.'6$<:@U9.((!45"1]
M4EHG>U)@*'E19RIW46XK=5%V*W-1?RQR48@M<%&3+6Y1GBYM4:PN:U&\+VI1
MT"]I4>8O:%'U+FA1_BUH4?\L:%'_+&A1_RSI1P  VE8  ,Q?  #!90  N&<
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M-U1:^S946O\U5%K_-51:_S7@5   T&$  ,-J  "Y;P  KW$  *1P  ":;0
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M+C]P_R[/9P  P7(  +=Z  "L?@  GWX  )1_  "'?P  ?H$  '># P!QA!0
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M&#B0C!<WD)L6-I"L%36/OQ0UC]@3-(WK%#.,]A8RB_T7,HO]%S*+_1>_>P
MM84  *N+  "=BP  DHP  (>.  !\D0  <)0  &27  !9F@  4YP- %"<' !-
MG"< 2IPP T:<. 9"FSX*/IM%#CN;3! XFE,2-II<$C6:91(TFG 1,YI]$#*:
MB@\QFID.,9JJ#3"9O0PNF=4++I?J#"V6]0TLE?T.+)7]#BR5_0ZZ@P  L(P
M *60  "8D   C9(  (*5  !WF   :YL  %^?  !4H@  2:0" $2E$0!!IAX
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M  F^J@ 'O;\ !KS7  :\Z0 &N_, !KOS  :[\P"KG0  HZ(  ):D  "*IP
M?ZP  '.P  !FL@  6;0  $VV  !!N0  -;P  "J_   AP@  &<8  !'( @ (
MRPD !LL4  7,'@ $S"@  LPS  ',/@  S$H  ,U7  #-9@  S78  ,V(  #-
MF@  S*X  ,S"  #+U@  R^4  ,OE  #+Y0"HI0  G:H  )&M  "$L   =[,
M &FV  !<N   4+L  $2^   XP0  +<0  "/(   :S   $L\   K1   #U
M -4$  #6#0  UQ<  -@A  #:*P  VS<  -Q$  #>4P  WF,  -]U  #?AP
MX)H  -^L  #?NP  W\L  -_+  #?RP"AJP  E:\  (BS  !ZM@  ;+D  %^\
M  !2OP  1L,  #G&   NR0  (\T  !O2   3U0  "MD   3:    W0   -\
M  #A    X@0  .,-  #E&   YR,  .DO  #K/@  [4X  .]?  #P<@  \(0
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M )L [P"@ .X I@#M *T [0"U .P P #J ,X Z #? .8 [@#F /D Y@#_ .8
M_P#F /\ Y@#_ .8 _P#_ !@*_P 5"?\ $PC_ !L'_P F!?\ ,P/_ $ "_P!,
M ?X 5P#Y &( ]0!K /( <P#P 'H [P"  .T A0#L (H ZP"/ .H E #I )D
MZ "> .< I #F *L Y0"S .0 O0#B ,P X #< -\ ZP#> /4 W@#] -X _P#=
M /\ W0#_ -T _P#_ !0*_P 1"?\ $0C_ !@'_P C!?\ +P/_ #T"_@!( ?@
M5 #R %\ [@!H .L < #I '< YP!] .8 @P#E (@ Y ", ., D0#A )8 X "<
M -\ H@#> *D W "Q -L NP#9 ,D U@#: -4 YP#5 /, U #[ -, _P#3 /\
MTP#_ -, _P#_ A *_P *"/\ #0?_ Q<&_P$@!?\ *P/^ #@"]@!$ ?  4 #J
M %L Y0!D ., ;0#A '0 WP!Z -T @ #< (4 VP"* -D CP#8 )0 U@"9 -4
MH #4 *< T@"O -  N0#. ,< S0#6 ,P Y@#* /$ R0#[ ,@ _P#' /\ QP#_
M ,< _P#_!@@)_P,"!_\*"0;_#1(%_PT=!/T()P/T!#,![0)  .<!3 #@ %8
MW %@ -H!:0#8 G  U0)W -,#?0#2 X( T .' ,\#C #. Y$ S 27 ,L$G@#)
M!*4 R 2N ,8%N #%!L8 PP?6 ,()YP"_"_4 O0S_ +P-_P"[#?\ NPW_ +L-
M_P#_# ((_PX !O\6!03_& P#_Q<7 _,3(0+I#BT!X@LY -P*1@#6"U$ T@Q;
M - .9 #-#VP RQ!S ,D1>0#'$G\ QA*$ ,43B0##$X\ PA.5 , 4G "_%*,
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ML .E++T#HRS-!*$MX 2?+? &G2W[!YPL_P>;+/\(FRS_")LL_PC_'P "_RH
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M$H4_U1.$/^D4@C_V%($^_Q2!/O\4@3[_%($^_Q3X,0  XSX  -5(  #*3@
MP4\  +I*  "S1P@ K$D: *5)* .@2#,(FD8]#9=%1A"31$X2D4-5$X]#7!2-
M0V,4C$-I%(I#<!2)0W84AT-]%89#A16$0XT5@T.7%H%#HA: 0ZX7?T.^&'U#
MTAA\0^89>D/U&7I"_AEY0O\8>4+_&'E"_QCM-0  WD4  -%/  #&5   O54
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M)F-,^R5C3/\D8TS_)&-,_R3C1@  TU0  ,9=  "\8@  L&$  *9?  "?6P
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M4%7_+5!5_RW:4P  RF   +YG  "R:P  IFH  )QI  "29@  BV<  (5H$0"
M:A\ >VDJ G9H,P=Q9CL,;&5!$V=C1AEB84P?7E]1)5I>5BI67%PN4UQD,5%;
M;3-06W<S3EN",TU;CS),6YTR2UNL,4I;OS%)6]4P25KJ,$E:]R]*6?\N2EG_
M+DI9_R[66   QV,  +MK  "O;0  HFT  )AL  ".:@  AFL  (!M# ![;AL
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M)T!PBR8_<)DE/W"I)#YPO",]<-,B/&[H(SMM]20[;/TE.FS_)3IL_R7)9P
MO'$  +%W  "C=P  EW<  (QW  " >   =GH  &]\  !I?@T 97\< &%_* %=
M?S$$67XY"%5]/PU0?$033'M*&$=Z3QQ$>58@07E=(C]Y9R(^>7$A/7E](#QY
MBA\[>9D>.WFH'3IXNQPY>-(;.7?H&S=U]!TW=/T>-G3^'C9T_A[$;0  N'8
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M!RJ5M08HE,P&*)/C!B>1\@<FD/L()I#\"2:0_ FU@@  JH@  )R(  "0B0
MA8H  'N-  !PD   9)0  %B7  !.FP  1)X  #N@"0 WH!< -:$A #.A*@ Q
MH3("+Z Z RR@000JH$H%*:!2!2>@7 4FH&<$):!S!"2@@ ,CH(\"(:"? B"?
ML0$>G\<!'9[@ 1V<[P(<F_D#')K[ QR:^P.PB@  HXT  )>-  ",CP  @9$
M ':5  !KF   7YP  %2@  !)HP  /J8  #.H   JJ@D )ZL5 "6K'P CJR@
M(JLP ""K.  >JT$!':M* 1RL5  :K%\ &:QK !>L>0 5JX@ $ZN9 !&KJP /
MJL$ #:G9  ZH[  .I_8 #J?X  ZG^ "LDP  GI,  ).3  "'E@  ?)H  '&>
M  !EH@  6J4  $^I  !$K   .*\  "VP   CLP  &K4# !2V#0 2MQ@ $+<A
M  ZW*@ ,MS, "[<]  FW1P (MU( !K=?  2W;0 "MWT  +:.  "VH   M;,
M +3)  "TW   L^H  +/M  "S[0"FF0  FID  (V;  ""GP  =Z0  &RH  !@
MK   5;   $FR   ]M   ,;8  ":Y   =NP  %+T   N_   #P0@  ,(2  #"
M&P  PR4  ,,N  ##.0  PT0  ,10  #$7@  Q&\  ,2   #$D@  Q*4  ,.X
M  ##RP  PMP  ,+@  #"X "BH   E:$  (FE  !^J@  <Z\  &:R  !9M
M3+<  #^Y   SO   *+X  ![!   5Q   #,<   3)    RP   ,T"  #."@
MSQ0  - =  #1)P  TC(  -,^  #53   UEP  -9O  #6@@  UI4  -:G  #6
MMP  UL8  -;*  #6R@"=J   D:P  (6P  !WLP  :;8  %RX  !/NP  0KX
M #7!   JQ   '\<  !;+   ,SP  !=(   #3    U0   -@   #9    VP$
M -T*  #?%   X1\  .,K  #E.   Z$<  .I8  #J;   ZH$  .J4  #JHP
MZK   .JS  #JLP"5K@  B;(  'NU  !MN   7[P  %'   !$PP  -\<  "O*
M   @S0  %=$   S6   $V@   -T   #=    WP   .$   #C    Y0   .<
M  #I    [ D  .\6  #R(P  ]#(  /="  #Z5   ^V8  /MY  #[B0  ^Y8
M /N9  #[F0#_ !8(_P 3!_\ $P7_ !L$_P G O\ ,P'_ $  _P!- /P 6 #Y
M &( ]P!K /8 <@#T 'D \P!^ /( @P#Q (@ \ ", .\ D0#N )8 [0"; .L
MH #I *< YP"N .8 N0#E ,8 Y #6 ., Z #C /8 XP#_ .( _P#B /\ X0#_
M .$ _P#_ !,(_P .!_\ #07_ !@$_P D O\ , '_ #T ^P!) /8 50#S %\
M\0!H .\ ;P#M '8 [ !\ .L @0#J (8 Z0"* .@ C@#G ), Y0"8 ., G@#A
M *4 WP"L -X M@#< ,( VP#3 -L Y@#: /, V0#] -@ _P#8 /\ V #_ -@
M_P#_ ! (_P +!_\ #07_ !<$_P @ O\ + '\ #D ] !& .\ 40#L %L Z0!D
M .< ; #E ', Y !Y .( ?@#A (, X "' -X C #= )$ VP"6 -D G #6 *(
MU0"J -0 LP#2 +\ T0#0 -  X@#/ /  S@#X ,T _P#, /\ S #_ ,P _P#_
M  D(_P $!O\ "@7_ !0#_P > O\ * #T #4 Z@!! .8 30#C %< X !@ -X
M: #< &\ V@!U -@ >P#6 (  U0"$ -, B0#1 (X SP"3 ,X F0#, *  RP"H
M ,D L0#( +T Q@#- ,4 W@#$ .P PP#V ,( _0#! /\ P0#_ ,$ _P#_  ('
M_P  !?\#!@3_! \"_P 9 ?@ (P#K "\ X@ \ -T 2 #: %, U@!< -, 9 #1
M &L SP!R ,T =P#+ 'P R0"! ,@ A@#& (L Q0"1 ,, EP#" )X P "F +\
MKP"] +L O #* +L VP"Y .H N #V +8!_@"V O\ M0+_ +4"_P#_ P %_P<
M _\- 0+_#0D!^0D3 .T#' #? "@ V0 V -, 0@#/ DX RP-7 ,@$8 #&!&<
MQ 5N ,(&= # !GD OP=^ +X'@P"\!XD NPB. +D(E0"X")P M@FE +4)KP"S
M"KL L@K* +$+W "N#NX K _Z *L0_P"J$?\ J1'_ *D1_P#_"  $_Q(  OT6
M  #R%0$ [! ) .,($P#7!B  T DO ,H-/ #%$4@ P1)2 +X46P"[%&, N15J
M +@5< "V%G8 M19[ +,6@ "R%X8 L1>, *\7D@"N&)H K!BB *L9K "I&;D
MJ!G( *8:VP"D&^P HASX :$<_P&@&_\!H!O_ : ;_P'_$0 "_QL  .L=  #A
M'@  VAL! -43" #-%!D Q1DI +\=-P"Z'T, MB!. +,A5P"Q(5X KR)E *TB
M; "L(G( JB-W *DC?0"H(X, IR.) *4CCP"D))< HB2@ *$DJ@&?);8!GB7%
M 9PEUP&:)>D"F"7V Y<E_P.6)?\#EB7_ Y8E_P/_&@ !\"(  .$I  #8+0
MT"L  ,HE P##(10 O"8D +4H,@&Q*3X"K2I( JHK4@*H*UD"IBQA J0L9P*B
M+&T"H2QS I\L>0*>+7X"G2V% ILMBP.:+9,#F"V< Y<MI@.5+;(#E"W!!),M
MTP21+><%CRWU!HXM_P:-+?\&C"W_!XPM_P?](0  YRL  -LU  #0.0  QS@
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M$G4]^Q)T/?\2=#W_$G0]_Q+G-0  V$0  ,I,  "_4   LTX  *Q*  "E1@
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M(%A+_R#:2@  RE<  +U>  "O7@  I%T  )I;  "36   C%D! (9:$@"!6Q\
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M*DE7BBI(6)<I1UBG*497N"A%5\XH15?D)T56\R=%5OPF157_)455_R7/5P
MP6(  +1F  "E9@  FF8  )!E  "&8P  ?V4  'EF!@!S9Q4 ;V@B &MG+ )G
M9S0'8F4["UUD0!%98T8756%+'%!?4"%-7E8E2EY>*$==9BE&77$I15U\*41=
MB"A#798G0EVF)D%=MR5!7<PE0%SC)4!;\R5 6_LE0%K_)$!:_R3+7   OF4
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M%39TM!0U=,H3-'/A$S-Q\14R</H6,F_^%C)O_A:_:P  LG,  *)S  "5=
MBG0  (!U  !U=P  :GD  &%\  !:?@  5( / %& ' !/@2< 3($O DB -P9$
M@#T)07]##3U^21 Z?E 2.'Y8$S9]81,U?6L2-'UW$3-]A! R?9(/,GVA#C%\
MLPTP?,@-,'O@#"]Z\ XN>?D/+7C^$"UX_A"Z<@  K'<  )UW  "1>   AG@
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M !27Z@ 4EO4 %)7Z 125^@&IA0  FH4  (Z&  "$AP  >8H  &Z-  !CD0
M690  $V8  !#G   .)\  "ZA   DI $ ':4, !NF%P 9IB  &*8I !:F,0 5
MICH $Z9# !*F30 0IE< #:9D  NF<0 )I8  !Z60  6DH@ #H[4  J+*  .B
MWP #H>P !*'R  2A\@"BB@  E8L  (J,  !_C@  =)(  &F6  !>F@  4YX
M $BB   ]I0  ,J@  "BJ   ?K   %JX   RP!P &L!( !; ;  .Q)  "L2T
M +$W  "Q00  L$L  +!8  "P90  L'4  +"%  "OEP  KJD  *Z^  "MTP
MK.,  *SI  "LZ0"<D   D9$  (63  !ZEP  ;YL  &2@  !9I   3J@  $.L
M   WKP  ++$  "*S   8M0  $+<   :X    N@8  +H.  "[&   NR   +PI
M  "\,P  O#X  +U)  "]5P  OF8  +YX  "]B0  O9P  +RP  "[PP  N]0
M +K>  "ZW@"8EP  C)D  (&=  !VH@  :J<  %^K  !4KP  2+(  #NU   O
MMP  )+D  !J\   0O@  ",    #!    PP   ,0!  #%"0  QQ(  ,@;  #)
M)0  RB\  ,LZ  #-1@  SE8  ,]G  #/>@  SXT  ,^?  #/L   S[\  ,[)
M  #.R0"4GP  B*,  'VH  !RK@  9K(  %BT  !+MP  /KH  #&]   FOP
M&L(  !'%   (R    ,H   #,    S@   -    #1    TP   -4'  #8$@
MVAT  -PH  #>-0  X$,  .)4  #D9@  Y7L  .6.  #EG@  Y:H  .6R  #E
ML@"0J@  A:\  'BS  !JM0  7+@  $Z\  !!OP  ,\(  "?%   <R   $<P
M  ?0    U    -8   #7    V0   -L   #=    WP   .(   #D    YP8
M .L2  #N'P  \"X  /(^  #U4   ]60  /9X  #WB0  ]Y4  /><  #WG #_
M !(&_P .!?\ #0/_ !@"_P D /\ ,0#_ #X _0!* /L 50#X %X ]@!G /0
M;@#S '4 \0!Z /  ?P#O (, [0"( .L C #I )$ Z "6 .< G #F *( Y "J
M ., L@#B +\ X0#0 -\ X@#> /( W0#^ -T _P#= /\ W0#_ -T _P#_  T&
M_P *!?\ # /_ !4!_P @ /\ +0#Z #L ]@!' /0 4@#Q %L [P!D .T :P#K
M '( Z0!W .@ ? #F ($ Y "% .( B@#@ (X WP"3 -X F0#= *  VP"G -H
ML #8 +P U@#+ -0 W@#3 .\ T@#[ -( _P#2 /\ T@#_ -( _P#_  D&_P %
M!/\ "@/_ !0!_P = /L *0#R #< [P!# .P 3@#I %@ Y@!@ .0 : #B &\
MWP!T -T >0#; 'X V0"# -@ AP#6 (P U0"1 -, E@#2 )T T "D ,X K0#-
M +@ RP#' ,D V@#( .P QP#X ,8 _P#' /\ QP#_ ,< _P#_  (&_P  !/\
M!P+_ !$!_P 9 /( )0#J #$ Y@ ^ .( 20#? %0 W !< -D 9 #5 &L TP!Q
M -$ =@#/ 'L S@!_ ,P A #+ (D R@". ,@ E #& )H Q0"B ,, JP#! +4
MOP## +X U@"] .@ O #T +L ^P"[ /\ NP#_ +L _P#_   %_P   _\  P'_
M  P ^0 3 .< '@#A "P W  Y -@ 10#3 $\ T !8 ,P 8 #* &< R !M ,8
M<P#$ '@ PP!\ ,$ @0#  (8 OP"+ +T D0"[ )@ N@"? +@ J "V +, M0#!
M +, T@"R ., L0#P +  ^0"P /X KP#_ *\ _P#_   #_P   ?\#  #Y  4
M\  + -\ %P#8 "4 T0 S ,P /P#( $H Q !3 ,$ 6P"_ &, O0!I +L ;P"Z
M '0 N !Y +< ?@"V (, M "( +, C@"Q )4 KP"= *X IP"L +$ JP&_ *D"
MT "H ^( IP3P *4&^@"D!O\ HP?_ *,'_P#_ 0 "_PD  /$*  #E!P  W@$"
M -8 #P#/ !X R $K ,($.0"^!D0 N@=. +<(5P"U"5X LPIE +$*:P"P"W
MK@MV *T+>P"L#(  JPR& *D-C "H#90 I@Z< *4.I@"C#[$ HA"_ * 0T0">
M$N0 G!/S )L3_0":$_\ FA/_ )H3_P#_"P !\1(  .08  #:&@  TA8  ,P-
M!0#&"A8 OQ E +D4,P"T%3\ L!=) *T74@"K&%D J1A@ *<99@"F&6P I1ER
M *,:=P"B&GT H1J# )\;B0">&Y$ G!N9 )L<HP"9'*X F!R\ )8<S@"5'>$
MDQWQ )(=_ &1'?\!D1W_ 9$=_P'[%   YQX  -LF  #1*0  QR8  , ?  "\
M&0\ M1T? *\@+0"K(CH IR)$ *0C30"B(U4 H"1< )XD8@"=)&@ FR1N )HE
M<P"9)7D ER5_ )8EA@"5)8X DR66 )(FH &0)JL!CB:Y 8TFR@&,)M\"BB;P
M H@F^P.()O\#AR;_ X<F_P/O&P  X2D  -0R  #(-0  OC(  +<M  "S)0D
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M07P2:4&&$V=!D11F09T49$&K%6-!NQ5A0- 68$#F%6! ]!5@0/T47T#_$U]
M_Q/90   R4T  +M1  "L40  HE   )I-  "42@  C4H# (A+$P"$3"  ?TLJ
M WM*,P=W2#H+<T9!#G!%2!%M1$X2:T14%&E$6A1H1&$59D1H%F1$<!9C1'D7
M842#%V!$CAA>1)H8742H&5M$N1E:1,T:64/D&5E#\QA90_P764/_%UE#_Q?6
M10  QE$  +=4  "I5   GE,  )91  "/3@  B4X  (1/#P!_4!T >U H G9.
M, 9R33@*;DL^#FI*1!%G24H49$A0%F)'5AA@1UT97D=D&EU';1I;1W8;6D>
M'%A(BQQ72)@<54>F'51'MQU31\L=4D?B'5)&\AM21OL:4T;_&E-&_QK22@
MPU4  +17  "F5P  FU8  ))4  "+40  A5(  ']3"P!Z5!H =E0E 7)3+@1M
M4C4(:5 \#61.01%A34<474Q-%UM+4QI92UH<5TMA'59+:1Y42W,?4TM]'U%+
MB1]02Y8@3DND($U+M2!,2LD@2TK@'TQ*\1Y,2?L=3$G_'$Q)_QS/3@  P5@
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M'CU:L1T\6<4=.UG='#M8[AT[5_D=.U;_'3M6_QW%6P  MF(  *9B  "98@
MCF(  (1B  !Z8   <F,  &QD  !F9@H 8F88 %YG(P!;9RP"5V8S!E-E.@I/
M9$ .2V-%$T=B2Q=$85$:06%8'3]@81T]8&L=/&!V'3MA@AP[89 ;.F&?&CE@
ML!DX8,08.&#<&#=>[ADV7?@9-ES_&C9<_QK!8   LF4  *)E  "590  BF4
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M!REU[ @H=/<)*'/^"RAS_@NT;P  HG   )1P  "(<   ?G$  '5S  !J=0
M7WD  %9[  !.?@  18$! #^"#@ \@QH .H,D #B#+ $U@S0",X,[!#&#0@4N
M@TD&+8-1!RN"6@<J@F0&*8)P!BB"? 4F@HH$)8&9!"2!J@,C@+X#(H#6 B)^
MZP,A??8$(7S]!2%\_06M<P  G'0  (]T  "$=0  >W8  '%X  !F>P  6G\
M %&"  !(A0  /X@  #6+!@ QBQ( +XP< "V,)0 LC"T *HPU 2B,/0(FC$0"
M)(Q- B.,5@(AC& "((QL 1^,> $=BX8!&XN6 !J*IP 8BKL %XG2 !>(Z  7
MAO0!%X7\ 1>%_ &F>   EW@  (IY  " >@  =WL  &Q^  !A@@  5H8  $R)
M  !#C   .8\  "^2   FE < (I43 ""5'  >EB4 '98M !R6-0 :ECT &99&
M !>63P 5EEH %)9E !*6<@ 0E8$ #960  N4H0 )D[0 !Y+*  B1WP (D.T
M"9#W  F0]P"??0  D7T  (9^  !]?P  <H(  &>&  !<B@  4HX  $>2   \
ME0  ,Y<  "F:   ?G   %I\$ !"@#P .H!D #: B  N@*@ *H#, "* \  >@
M1@ %H%$  Z!<  &@:0  GW@  )^(  ">F0  G:L  )O   ":U@  FN0  )KN
M  ":[@"8@P  C(,  (.$  !XAP  ;8H  &*.  !7D@  3)8  $&:   VG@
M+*$  "*C   9I0  $:<   >I!   J@T  *H7  "J(   JR@  *LQ  "K.P
MJD4  *M1  "K7@  JFT  *I]  "JC@  J:$  *BT  "FR@  I=T  *7J  "E
MZ@"3B   B8D  'Z,  !SCP  9Y0  %R8  !1G   1J$  #ND   PJ   )JH
M !RL   3KP  "K    &R    LP,  +0+  "T%   M1P  +4D  "V+@  MC@
M +9#  "W4   MU\  +=P  "W@@  MY0  +:G  "UN@  M,P  +3<  "TW "0
MCP  A)$  'F5  !NF@  8IX  %>C  !,J   0:P  #6O   JL@  '[0  !6V
M   *N    [D   "[    O    +X   "_!0  P X  ,$7  #"(   Q"D  ,4T
M  #&0   R$\  ,E@  #)<@  R88  ,B9  #(J@  Q[D  ,?)  #'R0"+EP
M@)L  '6@  !II0  7JH  %.O  !'LP  .;8  "VX   AN@  %KT   O    "
MP@   ,,   #%    Q@   ,@   #*    RP   ,X'  #/$   TAH  -0D  #7
M,   VCT  -U.  #?8   X'0  ."'  #@F0  X*8  -^S  #?LP"'H0  ?*<
M '&M  !GL@  6;4  $NX   ]NP  +[X  "/!   7Q   #,<   +*    S0
M ,X   #0    T@   -0   #6    V0   -L   #?    X08  .03  #G'P
MZ2P  .TZ  #P3   \E\  /-S  #TA0  ])(  /2=  #TG0#_  P$_P ) _\
M"0'_ !0 _P A /\ +P#^ #L _ !' /H 4@#W %L ]0!C /( :P#P '$ [0!V
M .L >P#J (  Z0"$ .@ B #G (T Y@"2 .0 EP#C )T X@"E .  K@#> +D
MVP#( -H W0#9 .\ V0#\ -D _P#9 /\ V0#_ -D _P#_  D$_P & _\ "@'_
M !, _P = /L *P#W #@ ] !# /( 3@#O %@ [ !@ .D : #F &X Y !T .(
M>0#A 'T WP"! -X A@#= (H W "/ -H E #9 )L UP"B -0 JP#2 +4 T #$
M ,\ V #. .L S0#Y ,T _P#, /\ RP#_ ,L _P#_  0$_P   O\ " '_  \
M_0 : /, )@#O #, ZP _ .D 2@#F %0 X@!= -X 9 #; &L V0!P -@ =0#6
M 'H U !^ -, @P#2 (< T ", ,\ D@#- )@ R@"? ,@ J #& +( Q0#  ,,
MT@#" .8 P@#V +\ _P"^ /\ O0#_ +T _P#_   $_P   O\ !0'_  H \P 5
M .L (@#F "X X0 [ -T 1@#9 %  U0!9 -( 8 #/ &< S0!M ,P <@#* '<
MR0![ ,< ?P#& (0 Q ") ,( CP#! )4 O@"< +T I0"[ *\ N0"\ +@ S0"V
M .( M #Q +( _ "R /\ L@#_ +( _P#_   #_P   ?\   #\  4 Z0 . .(
M' #; "D U0 V -  00#, $L R0!4 ,8 7 #$ &, P@!I ,  ;@"^ ', O0!W
M +P ? "Z ($ N "& +< C "U )( LP"9 +( H@"P *P K@"X *P R0"J -T
MJ0#M *D ]P"H /X J #_ *@ _P#_   !_P   /@   #L    X  ' -< %0#0
M ", R0 P ,4 / #! $8 O@!/ +L 5P"X %X M@!D +4 :@"S &\ L@!T +
M>0"O 'X K@"# *P B0"K (\ J0"7 *< H "F *H I "V *( Q@"A -D H #I
M )\ ] "> /L G@#_ )X _P#_    ]    .<"  #> @  U0   ,T #0#% !L
MP  H +L -0"W $  LP!* +$ 4@"N %D K %@ *L!9@"I 6L J )P *<"=0"E
M GH I .  *,#A@"A!(T GP25 )X%G@"<!JD FP:U )D&Q0"8!]@ EPCI )4)
M]@"4"?X E K_ )0*_P#Z P  Z0T  -T5  #2%0  R!   ,(( P"^ 1, MP4A
M +()+P"N"SH J@U$ *@-30"E#E4 HP]; *(080"@$&< GQ!L )T1<@"<$7<
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M"FHXC@IH.)H+9SBG"V4XMPQD.,H,8CCA#&(W\0QA-_L,83?_#&$W_PS5.@
MQ48  +1&  "G1@  G44  )9"  "00   BSX! (8^$0""/QX ?C\H GH^,05V
M/3D'=#Q "7$\1PIO.TT+;3M3"VL[60QJ.V ,:#MG#&<[;PUE/'<-9#R!#F(\
MBPYA/)</7SRE#UT\M1!</,@06SO>$%H[\!!:._H/6CO_#UHZ_P_20   P4D
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M&4A'KAE'1L$91D;9&4=%[!A'1?@71T7_%T=%_Q?(30  MU(  *93  ":4P
MD%,  (=1  " 3@  >4\  '-0 @!N41  :E(< &92)@%B42X$7E U!UI..PM6
M34 /4TQ&$E!+3!5.2U(83$I:&4I*8AI(2FL;1TMV&T9+@AM%2X\;0TN=&T)+
MK1I!2\ :0$K7&D!*ZQE!2?<904G^&$%(_QC%40  LU4  *-5  "750  C%4
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M$3):Z1(Q6?43,5C]%#%8_Q2Z70  IUT  )E>  ",7@  @E\  'E?  !L7P
M9&(  %YD  !890  4V8, %!G&0!-9R( 2F<K 4=G,@1#9CD'0&4_"CUE10TZ
M9$L0-V13$39D6Q$T9&41,V1P$#)D?0\R9(H.,629#C!DJ0TP8[P,+V/3#"YA
MZ TM8/4.+%_\#RQ?_Q"U8   HV$  )1A  "(8@  ?F(  '5C  !H90  8&<
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M AEW_0*B;   DVT  (=M  !\;@  <V\  &EQ  !>=   5'@  $M[  !#?@
M.8$  #"#   HA0H )885 ".&'@ BAR8 ((<N !^'-@ =ASX '(=' !J'4  9
MAUH %X=E !6'<@ 4AH  $H:/ !"%H  -A+( #(/(  N"W@ ,@>\ #8#X  V
M^P";<0  C7$  ()Q  !Y<@  ;W0  &1W  !:>P  3W\  $:"   \A0  ,X@
M "J+   AC0  &8\* !:0%0 4D!T $Y E !&0+0 0D#8 #I ^  R02  *D%(
M")!>  :0:P $D'D  H^(  ".F   C:H  (R_  "+U   BN4  (KN  "*\0"5
M=@  B'8  'YV  !U>   :GL  %]_  !5@P  2X<  $"*   VC@  +9   ".3
M   :E0  $9<   B9"0 #FA,  9D<  ":)0  FBT  )HV  ":/P  FDH  )I6
M  ":8P  FG$  )F   "8D   EZ(  ):V  "5S   E.   )3K  "3[@"/>P
MA'L  'M\  !P?P  98,  %J'  !0C   19   #J3   PE@  )ID  !V<   3
MG@  "J    *B @  HPH  *,3  "C&P  I",  *0K  "E-   I3\  *5*  "E
M5P  I68  *5V  "DAP  HYD  **L  "AP0  H-4  *#D  "?Z0"*@   @8$
M ':$  !KB   8(P  %61  !*E0  /IH  #2=   IH   'Z,  !6F   +J
M!*D   "K    K    *T'  "M$   KA@  *\@  "P*   L#(  +$]  "Q2@
MLED  +)I  "R>@  L8P  +"@  "OM   KL@  *W8  "MW@"'AP  ?(D  '&-
M  !FD@  6I<  $^;  !$H   .*4  "ZH   CJP  &:T   ZP   %L@   +0
M  "U    M@   +<   "X 0  N0H  +H2  "[&P  O20  +XN  "_.@  P4D
M ,):  ##;   PW\  ,*2  #"I   P;0  ,'"  #!QP"#CP  >),  &R8  !A
MG0  5J(  $NG   _K   ,[   "BS   =M@  $;@   :Z    O0   +T   "_
M    P    ,(   ##    Q0   ,<#  #)"P  RQ4  ,X?  #0*@  TS<  -9(
M  #96@  V6X  -F"  #:E   V:,  -FN  #9LP!_F0  =)X  &FD  !>J@
M4Z\  $>T   YMP  *[H  !Z\   2OP  !\(   #%    R    ,@   #)
MRP   ,P   #.    T0   -,   #7    V@0  -X/  #B&@  Y2<  .@U  #L
M1P  [UH  /!N  #P@0  \)   /";  #PGP#_  @#_P & ?\ !P#_ !( _P ?
M /\ + #] #@ ^@!$ /@ 3@#U %@ \0!@ .X : #L &X Z@!S .D > #H 'P
MY@"  .4 A #D (D XP". .( DP#@ )D W@"@ -L J0#9 +0 V ## -4 U@#5
M .T U #[ -  _P#. /\ S0#_ ,T _P#_  0"_P   ?\ ! #_  X _0 ; /D
M* #U #4 \@!  .\ 2P#K %4 YP!= .0 9 #B &L X !P -\ =0#= 'D W !]
M -L @@#9 (8 V "+ -8 D #3 )8 T0"> ,\ I@#- +  RP"^ ,H T0#) .<
MQ0#W ,( _P#" /\ P@#_ ,, _P#_   "_P   ?\   #_  D ]0 7 /  (P#L
M #  Z  \ ., 1P#@ %$ W !9 -D 80#6 &< U !L -, <0#1 '8 T !Z ,X
M?@#- (, RP"( ,D C0#' ), Q0": ,, HP#! *T OP"Y +T S "Z .$ N #R
M +@ _P"X /\ N #_ +@ _P#_   "_P   /\   #U  0 [  2 .8 'P#@ "L
MV@ X -8 0P#3 $P SP!5 ,P 7 #* &, R !I ,8 ;@#$ '( P@!W ,$ >P#
M (  O@"% +T B@"[ )  N0"7 +< H "U *D LP"V +  Q@"O -L K@#N *X
M^P"M /\ K0#_ *T _P#_   !_P   /X   #K    X@ , -H &0#2 "8 S0 R
M ,D /@#& $< PP!0 ,  6 "] %X NP!D +D :@"X &X MP!S +4 > "T 'P
MLP"! +$ AP"P (T K@"4 *P G0"I *8 IP"R *8 P0"E -4 I #I *, ]@"C
M /\ HP#_ *( _P#_    ^P   .L   #A    U@ & ,P $P#& "  P0 L +X
M. "Z $( MP!+ +0 4P"R %H L !@ *X 90"M &H K !O *H = "I 'D J !^
M *8 A "D (H HP"1 *$ F@"? *0 G@"O )P O0"; -  F@#D )D \0"8 /H
MF #_ )@ _P#]    [    .$   #3    R@   ,( "P"\ !D N  E +0 ,0"P
M #P K0!% *H 30"H %4 I@!; *0 80"B &8 H0!K *  < "? '4 G@!Z )P
M@ "; (< F0"/ )@ EP"6 *$ E "M ), NP"2 ,T D #A (\ [P". ?@ C@']
M (X!_P#Q    XPH  -40  #'#@  O@H  +D" @"T !$ KP > *L *@"G C8
MI 1  *$$2 "?!5  G096 )L'7 ":!V( F =G )<'; "6!W$ E0=W ),'?0"2
M"(0 D B, (\)E@"-":  C FL (H*NP")"LT APOB (8,\0"%#?L A W_ (0-
M_P#I#0  VQH  ,D>  "]'0  M!H  *X4  "L"P< IPD7 *(-) "?$#  FQ$Z
M )D20P"6$TL E!-2 ),36 "1$UT D!-C (X4: "-%&X C!1T (H4>@")%8(
MAQ6* (85E "$%IX @Q:K ($6N@" %\T ?A?B 'T8\@!]&/T ?!C_ 'P8_P#C
M&@  TR4  ,$H  "T)P  JR4  *4A  "B&P  GQ80 )H9'@"6&RH DQPU ) <
M/@".'48 C!U- (H=4P"('5D AQU? (8=9 "$'FH @QYP ($>=P" 'W\ ?Q^'
M 'T?D0!\'YP >B"H 'D@MP!X(,H =B#@ '4A\ %T(/L!="#_ 7,@_P+=)
MRBX  +HP  "M,   I"X  )XK  ":)@  ER$* )(B&0".)"4 BR4P (@E.0"&
M)4( A"9) ((F3P" )E4 ?R9; 'XF8 !\)F8 >R9M 'DF= %X)WP!=B>$ 74G
MC@%S)YD!<B>F 7 HM0)O*,@";BC= FPH[P-K)_H#:R?_ VLG_P38+   Q#0
M +0V  "G-@  GC4  )@R  "3+P  D"H% (LJ% "'*R$ @RPK 8 L-0%^+#T"
M?"Q$ GHL2P)Y+%$"=RQ7 G8L7 )T+&,"<RQI G$M< -P+7@#;BV! VPMBP-K
M+I<$:2ZD!&@NLP1F+L4%92[;!60M[09C+?D&8RW_!F,M_P;2,P  OSD  *\[
M  "B/   F3H  )(X  "--0  B3$  (4Q$ "!,AP ?3(G 7HR, )W,C@#=3)
M!',R1P1Q,4T$;S%3!6XQ605L,5\%:S)E!6DR;05G,G4&9C)_!F0SB09C,Y0'
M83.A!V SL A>,\,(73+9"%PR[ E<,O@)6S+_"5LQ_PG..@  NCX  *H_  ">
M0   E3\  (X\  "(.@  @S<  '\W"P![.!D =S@C 70X+ )P-S0$;C<\!FLV
M0@9I-DD'9S9/!V8V50AD-EL(8S9B"&$V:@E@-G()7C=\"5TWA@I;-Y(*6C>?
M"U@WK@M7-\ ,53;6#%4VZPQ5-O<,537^"U4U_PO*/P  MD(  *=#  ";0P
MD4,  (I   "$/P  ?SP  'H\!P!V/14 <CT@ &X]*0)J/#$$9SLX!F0[/PAB
M.D4)8#I+"EXZ40M=.E<+6SI>#%HZ9@Q8.F\-5SMY#54[A U4.Y .4CN=#E$[
MK ]/.[X/3CK4#TXZZ0]..?8.3CG^#DXX_P[&0P  LT4  *-&  "71P  CD8
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M%#M&YA0[1?03.T3\$SQ$_Q.[3   J4T  )I.  ".3P  A$\  'Q.  !T2P
M;4T  &=.  !A3P8 75 3 %I0'0!64"8!4U M T]/- 9,3CH*24T_#49,11!#
M3$P204M3%#]+6Q4]2V45/$QO%3M,>Q0Z3(@4.4R6$SA,IA,W3+@2-DO.$C9+
MY1(V2O,3-DG[$S9)_Q.X3P  I5   )=1  "+4@  @5(  'E1  !O3P  :%$
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M"B=:_PNJ60  F5H  (Q:  " 6P  =UP  &U<  !@7P  6F   %-B  !+90
M168! $!H#0 ]:!@ .V@A #AH*0 V:# ",V@W S%H/@4O:$4&+6A,!RMH50<J
M:%\'*6AJ!BAH=@4G:(,%)F>2!"5GH@0D9K0#(V;* R)EX0,B8_$%(6+Y!B%A
M_@>D7   E%T  (=>  !\7P  <F   &EA  !=8P  5F4  $]H  !':@  /VT
M #=O!P T;Q, ,7 < #!P)  N<"P +' S 2IP.@(H<$(#)G!* R5P4@,C<%P#
M(G!G B%P= (@<($!'F^/ 1UOH $<;K( &VW( !MLX  ;:_ !&FKY AII_0.>
M80  CV$  (-B  !X8P  ;F0  &5E  !::   4FL  $IN  !"<   .7,  #%U
M   J=PL )W@6 "5X'P D>"8 (G@N "%X-@ ?>#X 'GA& !QY3P ;>5@ &7EC
M !AX<  6>'X %'B, !-WG  1=J\ $'7$  YTW  0<^X $7+W !%Q_ "890
MBF4  'YF  !T9P  :V@  &%J  !7;@  37$  $5T   \=P  ,WD  "M\   B
M?P0 &X - !F!%P 8@1\ %H$G !6!+P 3@3< $H$_ !"!20 .@5, #(%>  J!
M:@ (@7@ !H"'  5_EP #?J@  7V]  %\T@ ">^0  GON  -Z]0"2:0  A6H
M 'IJ  !P:P  9VT  %UP  !3=   27@  $![   V?@  +8$  "2$   ;A@
M$XD#  N*#0 (BA< !XH?  6*)P $BB\  HHX  &*00  BDL  (I6  "*8P
MBG$  (J   ")D   B*(  (>T  "%S   A.$  (/J  "#\ ",;@  @&\  '9O
M  !M<0  8G0  %AX  !.?   0X   #F#   PAP  )XD  !Z,   5C@  #)
M  .2!P  DQ   ),8  "3'P  DR<  )0O  "4.   E$,  )1.  "46P  E&D
M )1X  "3B0  DIH  )&M  "0P@  C]@  ([G  ".[@"&<P  ?'0  '-U  !H
M>   77P  %.   !(A0  /8D  #.-   ID   ()(  !>5   -EP  !9D   ";
M    G @  )P0  "<&   G1\  )TF  ">+P  GCD  )]$  "?40  GU\  )]O
M  "?@   GI$  )VD  "=N   F\T  )O=  ";YP"">0  >7H  &Y\  !C@0
M6(4  $V*  !"CP  -Y,  "R6   BF0  &)P   Z>   &H    *,   "E
MI@   *8$  "G"P  J!0  *@;  "I(P  JBP  *LW  "L0P  K%(  *UB  "L
M=   JX<  *N:  "JK0  JL   *G0  "IW !_?P  =((  &F&  !>BP  4Y
M $>5   [F0  ,9T  ":A   ;I   $:<   :I    JP   *T   "N    L
M +$   "R    LP8  +0.  "U%P  MQ\  +@I  "Y-0  NT(  +Q3  "]90
MO7@  +V+  "[GP  NK$  +G   "YRP![AP  <(L  &20  !9E@  3IL  $*@
M   VI0  *ZD  ""M   5KP  "K(   "U    MP   +@   "Y    NP   +P
M  "]    OP   ,    #"!P  Q!   ,<:  #))0  RS(  ,Y"  #15   TF@
M --\  #3C@  TYX  -.J  #3LP!WD0  :Y8  &"<  !5H@  2J<  #ZM   R
ML0  )[4  !JX   -NP   KT   #     P@   ,(   #$    Q0   ,<   #)
M    RP   ,T   #0    TP   -@*  #<%0  X"$  .,O  #G00  Z54  .IJ
M  #K?0  [(T  .R9  #LH #_  ,!_P   /\  P#_ !  _P ; /X * #\ #4
M]P!! /0 3 #Q %4 [@!= .P 9 #J &H Z !P .< = #E 'D Y !] .( @0#A
M (4 WP"* -T CP#; )8 V0"= -@ I0#5 +  TP"^ -( T0#- .@ R@#[ ,D
M_P#) /\ R0#_ ,H _P#_   !_P   /\   #_  H ^@ 8 /8 ) #Q #$ [0 ]
M .L 2 #H %$ Y0!9 .( 80#? &< W0!L -L <0#9 '8 U@!Z -4 ?@#3 ((
MT@"' -  C #/ ), S0": ,L H@#) *P QP"Y ,( RP"_ ., OP#V +\ _P"^
M /\ O@#_ +X _P#_   !_P   /\   #X  8 \@ 4 .L ( #E "T X0 Y -\
M0P#< $T V !5 -0 70#1 &, S@!I ,T ;@#+ '( R@!W ,@ >P#' '\ Q0"$
M ,0 B0#" (\ P0"6 +\ GP"\ *D N "U +8 Q0"U -P M #P +0 _@"S /\
MLP#_ +, _P#_    _P   /D   #O  ( YP . -T ' #8 "@ TP T -  /@#-
M $@ R0!1 ,8 6 ## %\ P0!E ,  :@"^ &X O0!S +P =P"Z 'P N0"  +<
MA@"U (P LP"3 +$ FP"O *4 K0"P *L OP"J -4 J0#J *D ^ "H /\ J #_
M *@ _P#_    _P   .X   #D    V  * -  %@#* ", Q0 N ,$ .0"_ $,
MO !, +H 4P"W %H M0!@ +, 90"Q &H L !O *X <P"M '@ JP!] *H @@"I
M (@ J "/ *8 F "D *$ HP"L *$ NP"@ ,T GP#C )X ] "> /X G@#_ )X
M_P#_    [P   .,   #7    RP $ ,0 $0"] !T N0 I +8 ,P"S #T L0!&
M *X 3@"K %4 J0!; *< 8 "F &4 I0!J *0 ;P"C '0 H0!Y *  ?@"? (4
MG@", )P E ": )X F0"I )< M@"6 ,@ E0#> )0 [P"3 /H DP#_ )( _P#T
M    YP   -8   #(    P    +D "0"S !8 L  B *P +0"I #< I@!! *,
M20"A %  GP!6 )X 7 "< &$ FP!F )H :@"9 &\ F !U )8 >P"5 ($ E ")
M )( D0"0 )L CP"F (T LP", ,0 BP#9 (D Z@"( /4 B #\ (< _P#K
MW 8  ,H)  "]!P  M 4  +   0"K  \ IP ; *, )@"@ #$ G0 [ )H 0P"9
M $L EP!1 )4 5P"3 %P D@!A )$ 9@"/ &P C@!Q (T =P", 'X B@"& (D
MCP"' )D A0&D (0!L0"# <( @0/6 ( $Z !_!?0 ?P7[ 'X%_P#C#   T!8
M , 7  "S%@  JQ0  *8.  "C!@8 H $3 )L$( "7!BL E <U )((/@"0"48
MC@E, (P*4@"+"E@ B0I= (@*8P"'"F@ A@MN (0+=0"##'P @0R$ ( ,C0!^
M#9@ ?0VD 'L-L@!Z#<, >0[9 '<0[ !V$/< =A#^ '80_P#<&0  QQ\  +<A
M  "K(0  HA\  )T<  ":%@  F X* ),0&0"/$B4 C!,O (H4.0"(%4$ AA5(
M (053@"#%50 @199 ( 67P!^%F0 ?19K 'P6<0!Z%WD >1>! '<7BP!U&)8
M=!BB ',8L !Q&,( <!G7 &\9ZP!N&O@ ;1K_ &T9_P#5(P  P"<  + I  "D
M*0  G"<  )8E  "1(0  CQL$ (P:% "(&R  A!PJ ((=- " 'CP ?AY# 'P>
M2@!['E  >1Y5 '<>6P!V'F$ =1]G ',?;@!R'W8 <"!_ &\@B !M(), ;"&@
M &HAK@!I(<  9R'5 &8AZ0%E(?8!92'^ F4@_P+-*@  N2X  *HO  "?,
MEBX  (\L  "+*0  AR4  (0B#@" (QL ?20F 'HE+P!X)3@ =B4_ '0E1@!S
M)4P <252 &\E5P!N)ET!;"9D 6LF:P%I)G,!:"=\ 68GA@%E)Y$!8RB> F(H
MK )@*+T"7RC3 EXHYP-=)_4#72?] UTG_P3(+P  M#,  *4U  ":-0  D3,
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M"T@UXPM(-/,+2#3["TDT_PJ[.P  J3X  )H_  "/0   AD   '\]  !X/
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M#SX^HPX]/K0./#W)#CL]X X[//$./#SZ#CP[_PZS0@  HD0  )1%  ")1@
M?T8  'A$  !Q0@  :D(  &1#  !?1 , 6T00 %=%&@!412, 440J DU$,05*
M0S8'1T(\"45"0PM#0DD-04)1#C]"60\^0F(//$)L$#M"> \Z0X0/.4.2#SA#
MH@\W0K,.-D+(#C9"WPXV0? /-D#Y#S9 _P^P1   GT<  )%(  "&2   ?4D
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M!BA3W08G4>X()E#X"29/_@JD3@  E$\  (=0  !\40  <E(  &E2  !?4P
M5E4  %!7  !)6   1%H  #];"P \6Q8 .5P? #=<)P U7"X!,EPT S!;.P0N
M6T(%+%M*!BM;4@8I7%P&*%QF!B=<<@4F7( %)5N.!"1;G@,C6J\#(EK$ R)9
MW ,A6.T$(5?W!B!6_@>?40  D%,  (-4  !X50  ;E4  &56  !;6   4UH
M $Q<  !%7@  /F   #AB!@ T8A$ ,6,; "]C(P N8RH +&,Q 2EC. (H8T "
M)F-' R1C4 ,C8UD#(F-D B%C< (@8WX!'F., 1UBG $<8JT!&V'" !M@V@ ;
M7NP!&UWW AI=_0.:50  BU8  ']7  !T6   :ED  &%:  !770  3U\  $AA
M  !!8P  .64  #%H   K:@L *&H5 "9J'@ D:R4 (VLM "%K-  @:SP 'FM$
M !UK30 ;:U8 &FMA !AK;0 7:WL %FJ) !1JF0 3::L $FB_ !%GV  29>L
M$V7V !-D_0&560  AEH  'M;  !P7   9ET  %Y?  !480  2V0  $1F   \
M:0  -&P  "QN   C<00 '7(. !MS&  :<R  &',G !=S+P 5<S8 %',_ !)S
M2  1<U( #G-<  US:  +<W8 "7*%  =RE  &<:8 !7"Y  1NSP %;>, !FSO
M  =L^ "/7@  @5X  '9?  !L8   8V$  %ID  !09P  1VH  #]M   V<
M+G(  "9U   =>   %'H'  Y[$  ,>QD "GLA  E[*  (>S  !GLX  5[0@ #
M>TP  GM6  ![8@  >W   'M_  !ZCP  >:   'BS  !WR0  =MX  '7J  !T
M\0"(8@  ?&,  '%D  !H90  7V<  %5J  !,;0  0G$  #ET   P=P  *'H
M !]\   7?P  #8(!  6$"@  A!,  (0:  "$(@  A"D  (4Q  "$.@  A$0
M (10  "%6P  A&D  (1Y  "#B0  @IH  (&M  " P0  ?]D  '[I  !]\0"#
M9P  =V@  &YH  !E:@  6VT  %%Q  !'=0  /'D  #-\   J?P  (8(  !B%
M   0AP  !HH   ",!0  C P  (P4  "-&P  C2(  (XI  ".,0  CCL  (Y'
M  "/4P  CV   (]P  ".@0  CI,  (VE  "+N0  BM   (GB  "([@!];
M=&T  &MN  !@<0  5G4  $MZ  !!?@  -H(  "R%   CB0  &8L  !".   (
MD    )(   "4    E04  )4+  "6$P  EQH  )<A  "8*   F3$  )D\  "9
M20  FE<  )IG  ":>   FHH  )F=  "8KP  E\0  );7  "6Y0!Z<@  <7(
M &9U  !;>@  4'X  $6#   ZB   +XP  "60   ;D@  $I4   >7    F@
M )P   ">    GP   )\"  "@"0  H1$  *(7  "C'P  I"<  *4Q  "F/0
MIDP  *=<  "G;@  IX   *:2  "FI@  I;@  *7)  "DV0!W=P  ;'H  &%_
M  !6A   2XD  #^.   TDP  *9<  !Z:   4G0  ":    "B    I    *<
M  "H    J@   *L   "L    K ,  *T)  "O$@  L1H  +(C  "T+@  M3P
M +9-  "W8   MG,  +6'  "UF@  M:L  +2Z  "TR !S?P  9X0  %R)  !1
MCP  190  #F:   NG@  (J(  !BF   ,J0   :P   "N    KP   +$   "S
M    M    +8   "W    N0   +H   "\ P  O@P  ,$6  ##(   Q2T  ,@\
M  #*3@  S&(  ,UV  #,B0  RIL  ,FJ  #(M@!NB0  8X\  %B4  !-F@
M0*   #2F   HJP  ':\  !*R   &M0   +@   "[    O0   +T   "_
MP    ,$   ##    Q0   ,<   #*    S0   - %  #5$   V1T  -PK  #@
M/   XU   .9E  #G>   YXD  .B5  #HGP#_    _P   /\   #_  P _P 8
M /H )@#W #( ]0 ] /, 1P#O %$ ZP!: .@ 80#F &< Y !M .( <@#A '8
MWP!Z -X ?@#= (, VP"' -H C #8 )( U@": -0 H@#2 *P S@"Z ,D S@#'
M .8 Q@#X ,8 _P#& /\ Q@#_ ,< _P#_    _P   /\   #^  < ]P 5 /
M(@#M "X Z@ Y .< 0P#C $T WP!6 -P 70#: &, V !I -8 ;@#4 ', T@!W
M -$ >P#0 (  S@"$ ,P B0#* (\ QP"7 ,0 GP#" *D OP"U +T QP"\ -X
MNP#S +L _P"[ /\ NP#_ +L _P#_    _P   /P   #U  , Z@ 1 .4 '0#@
M "D VP U -@ /P#5 $@ T@!1 ,X 6 #, %\ R@!E ,@ :@#% &\ PP!S ,$
M> "_ 'P O0"! +P A@"Z (P N0"3 +< FP"V *4 M "P +( P "Q -4 L #M
M *\ _0"O /\ KP#_ *\ _P#_    _P   /,   #G    W@ + -< &0#/ "0
MS  P ,D .@#& $, PP!, +\ 5 "\ %H N0!@ +< 9@"V &L M0!O +0 <P"S
M '@ L@!] +  @@"O (@ K@". *P EP"K *  J0"L *< N@"F ,T I0#F *0
M]P"D /\ I #_ *0 _P#_    ]    .<   #9    T  ' ,< % #" "  O@ J
M +H -0"W #X M !' +$ 3@"O %4 K@!; *P 8 "K &4 J@!J *D ;P"H ',
MIP!X *4 ?0"D (, HP"* *$ DP"@ )P G@"G )P M "; ,< F@#> )D \0"9
M /T F0#_ )D _P#V    Z0   -@   #,    P@ " +L #@"V !H L0 E *T
M+P"K #D J0!! *< 20"E %  HP!6 *( 6P"A &  GP!E )X :@"= &\ G !T
M )L >0"9 '\ F "& )< CP"5 )@ DP"C )( L "0 ,$ CP#6 (X ZP"- /@
MC0#_ (T _P#N    W    ,L   "_    MP   +  !P"K !0 IP ? *0 *0"A
M #, GP \ )T 1 "; $H F@!1 )@ 5@"7 %L E0!@ )0 90"3 &H D@!O )
M=0"/ 'L C@"# (P BP"* )4 B0"@ (< K0"& +P A0#1 (0 Y@"# /0 @P#\
M (( _P#D    T $  , "  "T @  K    *<   "B  P GP 8 )P (P"9 "T
ME@ V )0 /@"2 $4 D !, (\ 4@"- %< C !< (L 80") &8 B !K (< <0"%
M '@ A !_ (( B "! )( ?P"= 'X J@!] +D ? #- 'L X@!Y /  >0#X 'D
M_0#:"0  Q0X  +80  "J$0  H@X  )T*  "; @0 EP 1 )0 ' "0 "< C0 P
M (L .0") $  AP%' (8"30"% E( @P)8 ((#70"  V( ?P-H 'X#;@!]!'4
M>P1] 'H$A@!X!)  =P6< '4%J0!T!;D <@7, '$'X0!P!^\ < CX &\(_0#0
M%0  O1D  *X:  "B&P  FAD  )46  "1$@  D D( (P&%0")""$ A@DJ (,*
M,P"!"SL @ Q" 'X,2 !]#4X >PU4 'H-60!X#5\ =PUE '8.; !T#G, <@]\
M '$0A0!O$)  ;A"< &P1J@!K$;H :1'. &@2Y !G$O, 9Q+[ &<2_P#)'
MM2   *<C  "<(P  DR(  (T@  ")'   AQ<  (42#@"!$QL ?A0E 'P5+@!Y
M%C8 =Q8^ '861 !T%TH <Q=0 '$750!P%UL ;A=A &T8: !K&'  :AAY &@9
M@@!F&8T 91F: &,:J !B&K@ 81K, & :X@!?&_( 7QO\ %X:_P#"(P  L"8
M *$I  "6*   C2@  (<G  "")   ?R   'T<" !Z'!8 =QP@ '0=*@!Q'C(
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M!$TMH@1++;(%2BS'!4DLW@5)*^\%22OZ!DDJ_P:T,0  HC0  )4U  ")-@
M@38  'HT  !T,P  ;S$  &LO  !G+P@ 8R\4 & P'@!=,"8!6B\N 5@O- )6
M+SL#5"]!!%(O1P11+TT$3R]4!4XP7 5,,&4%2S!N!DHQ>09(,84&1S&2!T8Q
MH =$,;$'0S'%!T(PW =",.X'0B_Y!T(O_P>P-   GS<  )(Y  "&.0  ?3D
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M"3 ]V DP/.L*,#SW"S [_0NF/0  EC\  (E!  !^0@  =$(  &Q"  !E00
M7D   %A!  !20@  3D,& $I#$0!'1!H 1$0B $)$*0$_0R\#/$,U!3E#/ <W
M0T((-4-*"31#4@HR0UL*,4-F"C!#<0HO1'X)+D2,"2Y$FP@M0ZP(+$/ !RM#
MUP<K0NL)*T#V"BM _0JB00  DT(  (5$  ![10  <44  &E%  !A10  6$4
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M AI1_ .62@  ATP  'M-  !P3@  9D\  %Y0  !540  3%,  $95   _5P
M.%D  #%;   L70H *%T4 "9='  D7B0 (UXK "%>,@ @7CH 'EY" !U>2@ ;
M7E0 &EY> !E>:@ 77G< %EZ& !5=E0 47:< $URZ !);T@ 36>< $UCT !18
M^P&13@  @U   '=1  !L4@  8E,  %I4  !250  25@  $):   [7   ,UX
M "QA   D8P4 'V4. !UE%P ;91\ &64F !AE+@ 6934 %64] !-F1@ 29E
M$&9:  YE9@ ,97, "F6"  EDD0 (9*( !V.U  9ARP '8.$ "%_O  E?]P"+
M4@  ?E0  ')5  !H5@  7U<  %=8  !.6@  15T  #U@   V8@  +F0  "9G
M   >:@  %FP' !)M$0 0;1D #6T@  QM*  *;3  "6TX  =M00 &;4L !&U5
M  )M80  ;6X  &Q\  !LC   :YT  &NP  !IQ@  :-L  &?I  !F\0"%5P
M>5@  &U9  !D6@  7%L  %-=  !*8   06,  #AF   P:0  *&L  "!N   8
M<0  $',"  =U"@ "=A,  '8;  !U(@  =BH  '8R  !V.P  =44  '5/  !U
M6P  =6@  '5W  !TA@  =)<  '.J  !ROP  <=<  '#H  !O[P" 6P  =%P
M &E=  !A7@  6&   $]C  !&9@  /&H  #-M   J<   (G,  !IV   2>
M"'L   !\"   ?0\  'T6  !^'0  ?B0  'XK  !_,P  ?ST  'Y)  !^5
M?V$  'YP  !^@0  ?9(  'VD  ![N   >L\  'GD  !Y[@!Z8   ;V$  &9B
M  !=8P  4V8  $IJ  ! ;@  -G(  "UV   D>   &WL  !)^   *@    8,
M  "$ P  A0H  (81  "&%P  AQT  (@D  "(*P  B34  (E   "(30  B5H
M (EI  ")>@  B(P  (>>  "&L0  A<<  (3<  "$Z !U90  :V8  &-G  !8
M:@  3FX  $1S   Y=P  +WL  "5_   <@0  $X0   F'   !B@   (P   ".
M    CP(  (\(  "0#@  D14  )$;  "2(@  E"H  )4U  "50@  E5   )9>
M  "6;P  E8(  )25  "3J0  DKP  )'0  "0X0!Q:P  :6L  %YO  !3<P
M27@  #U]   R@0  *(4  !V)   4C   "HX   &1    E    )8   "8
MF0   )D   ":!0  FPL  )P2  "=&0  GR   * J  "B-@  H40  *)4  "C
M90  HW@  **,  "BGP  H;(  *##  "@T0!O<   9',  %EX  !.?0  0X(
M #>'   KC   (9   !:4   +EP   9D   "<    G@   *    "B    HP
M *0   "E    I@$  *<'  "H#@  JA<  *P?  "N*@  KS<  *](  "Q6@
ML6T  +&   "QE   L*8  +"V  "PPP!J>   7WT  %2"  !)B   /(X  #&3
M   EF   &IP   Z?   #H@   *4   "G    J0   *P   "M    KP   +
M  "R    LP   +0   "V    N <  +L0  "]&P  OR<  ,(V  #$2   Q5X
M ,1S  #$AP  Q)@  ,.G  ##L@!F@@  6X@  %".  !$E   -YH  "N?   @
MI   %:@   BL    K@   +$   "T    M0   +<   "X    N@   +P   "^
M    OP   ,$   ##    Q@   ,D"  #."P  TA@  -4F  #:-P  WDL  .%?
M  #B<P  X88  ."5  #?H #_    _P   /\   #_  @ _  5 /D (@#U "X
M\0 Z /  0P#L $T Z0!5 .8 70#C &, WP!I -P ;@#9 ', UP!X -4 ? #3
M ($ T@"& -  BP#/ )$ S@"8 ,P H #* *H R "W ,8 R0#$ .( PP#V ,(
M_P#" /\ PP#_ ,, _P#_    _P   /\   #Y  4 \P 2 .T '@#H "H Y0 U
M ., /P#@ $@ V0!1 -, 6 #/ %\ S0!E ,L :@#* &\ R0!T ,@ > #' 'T
MQ@"! ,0 AP## (T P@"3 ,  FP"^ *8 O "R +L P@"Y -H MP#P +8 _P"V
M /\ MP#_ +< _P#_    _P   /D   #M  $ Y@ - -X &P#: "4 U@ P -
M.@#, $, R !, ,4 4P## %H P0!@ +\ 90"^ &H O !O +L = "Z '@ N0!]
M +@ @@"W (@ M0"/ +0 EP"R *  L0"L *\ NP"M -$ K #I *L ^P"K /\
MJP#_ *L _P#_    ^    .L   #@    U0 ) ,X %@#) "$ P@ K +\ -0"^
M #\ NP!' +D 3@"V %4 M !; +, 8 "R &4 L !J *\ ;P"N ', K0!X *P
M?@"K (0 J0"* *@ D@"G )L I0"G *, M "B ,@ H #A *  ]0"@ /\ GP#_
M )\ _P#Z    [0   -T   #1    QP % ,  $ "X !P M0 F +( , "P #D
MKP!" *P 20"J %  J0!6 *< 6P"F &  I0!E *0 :0"C &X H@!S *$ >0"?
M '\ G@"& )T C0"; )< F@"B )@ KP"6 ,$ E0#8 )0 [P"3 /P DP#_ )(
M_P#P    W@   ,\   #"    N@   +( "P"M !8 J0 A *< *P"E #0 HP \
M *$ 1 "? $H G@!0 )P 5@"; %L F@!@ )D 9 "8 &D E@!O )4 = "4 'H
MD@"! )  B0"/ )( C0"> (P J@"* +H B0#0 (D YP"( /< B #_ (@ _P#F
M    T@   ,$   "V    K@   *< !0"C !$ GP ; )T )0"; "X F0 W )<
M/@"5 $4 DP!+ )( 40"0 %8 CP!; (X 8 ", &4 BP!J (H < ") '8 AP!]
M (8 A0"% (\ @P": (( IP"! +8 @ #* '\ X0!^ /( ?@#\ 'X _P#9
MQ0   +8   "J    HP   )\   ":  H E@ 5 )0 'P"1 "D CP Q (P .0"+
M $  B0!& (@ 3 "& %$ A0!6 (0 6P"# &  @@!F ($ ; !_ '( ?@!Z 'P
M@@![ (P >0"7 '@ I !W +, =@#% '4 W !T .X = #X ', _0#. @  NP<
M *P*  "B"@  F@D  )4%  "2  , CP . (P &0") "( A@ L (0 ,P"" #L
M@0!! '\ 1P!^ $T ?0!2 'P 5P!Z %P >0!B '< : !V &\ =0!W ', @ !Q
M (H < "5 &\ H@!M +  ; ## &L V0!J .H :@#T &D ^@#%#0  LQ(  *05
M  ":%0  DA0  (P2  ")#0  AP4& (4!$@"! !P ?P$F 'P"+@!Z S8 > 0]
M '<$0P!V!4@ = 5. ',&4P!Q!ED < 9? &\&90!M!VP ; =U &H'?@!H"(@
M9PB4 &4(H0!D"+$ 8PC# &()V0!A"NH 8 KU & *^P"^%@  JQH  )X<  "3
M'0  BQP  (4;  "!%P  ?Q,  'X+"0!["A8 =PL@ '4,*0!S#3$ <0TX &\.
M/P!N#D4 ; ]* &L04 !I$%8 :!!< &818P!D$6H 8Q%S &$2?0!@$H< 7A.4
M %T3H0!;$[$ 6A/$ %D3VP!8%.T 6!3X %@4_@"W'   IB   )@B  "-(P
MA2,  '\A  !Z'P  =QL  '47 P!S%!  <!4; &T6) !K%BP :18T &<7.@!E
M%T$ 9!=& &(83 !A&%( 7QA8 %T97P!<&6< 6QEP %D:>@!8&H4 5AN2 %4;
MH !3&Z\ 4AO" %$;V0!1&^P 4!OX % ;_P&R(0  H24  )0G  "(*   @"@
M 'HG  !U)0  <2(  &X?  !L' L :1P7 &8=( !C'2@ 81TP %\>-@!>'CT
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M!#LKU 0[*^D%/"KV!3PJ_06F+@  EC   (DR  !^,P  =3,  &XS  !H,@
M8R\  %XN  !:+@  5BX* %,N%0!0+AT 32XE $LN*P%)+C$"1BXX T4N/@-#
M+D4$0BY,!$ O5 4_+UT%/C!F!3PP<04[,'T%.3&*!3@PF08W,*D&-C"\!C4P
MTP8U+^@&-2[U!C4N_ :B,0  DS,  (8U  ![-@  <C8  &LV  !D-0  7S(
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M!B0[^P:9.0  BCP  'T]  !R/@  :3\  &$_  !9/P  4C\  $I   !%00
M04(  #Q#!@ X1!  -D09 #1$(  R1"< +T0N 2U$- (K1#L#*D1#!"A$2P0G
M154$)D5?!"5%:P0D17@#(T6% R)%E0(A1:4"(42X B!$SP(?0^4"'T+R!!]!
M^@65/   AC\  'I   !O00  94(  %U"  !60P  3D,  $5%  ! 1@  .T@
M #9) @ R20P +TH6 "U*'@ K2R4 *4LK "=+,@$E2SD")$M! B)+2@(A2U,"
M($M= A]+:0$>3'8!'4N$ 1Q+DP$;2Z0 &TJW !I)S0 :2.0!&D?R AI&^@.1
M0   @D(  '9$  !K10  8D4  %I&  !21@  2D<  $))   \2P  -DT  #!.
M   L4 @ *%$2 "91&@ D42$ (E$H "!2+P ?4C< '5(_ !Q21P ;4E$ &5);
M !A29P 74G0 %E*" !51D0 44:( $U"U !)/S  23N( $TWQ !1-^0&-1
M?T8  ')'  !G2   7DD  %9)  !/2@  1TP  #].   Y4   ,E(  "Q4   D
M5@0 'U<- !U8%@ ;6!T &E@D !A8+  76#, %5D[ !191  264T $%E8  Y9
M8P -6'  "UA^  I8C@ )5Y\ "%:Q  A5QP (5-T "5/M  I3]@"(2   >DD
M &Y+  !C2P  6TP  %--  !,3@  1%   #M3   U50  +E<  "=9   ?7
M%U\' !-@$0 18!@ #V @  U@)P ,8"\ "F W  E@/P '8$D !6!3  1@7P "
M7VL  %]Z  !?B0  7ID  %VL  !<P0  6]@  %KH  !9\ ""3   =4T  &E.
M  !?3P  5U   %!1  !(4@  0%4  #=8   P6P  *%T  "%@   98P  $F4"
M  EH"P %9Q0  V<;  %G(@  9RH  &<Q  !G.@  9T0  &=.  !G6@  9V8
M &9U  !FA   9I0  &6G  !DNP  8],  &+F  !A[@!]4   <%(  &52  !<
M4P  550  $U5  !$6   .UP  #)?   J8@  (F0  !IG   3:@  "FP   -N
M"   ;Q   &\6  !O'0  <"0  ' K  !P-   <#T  '!(  !P5   <&   &]O
M  !O?P  ;H\  &VA  !MM0  ;,T  &KC  !J[@!W50  :U8  &%7  !95P
M45D  $A<   _7P  -6,  "QF   D:0  '&P  !1O   ,<0  !'0   !V!0
M=@L  '<2  !W&   >!X  'DE  !Y+0  >38  'E!  !Y30  >5H  'EH  !X
M>   >(H  '><  !WKP  =<8  '7<  !TZ@!Q6@  9EL  %Y;  !67   35\
M $-C   Y9P  +VL  "9O   =<@  %74   QW   $>@   'P   !^ 0  ?@<
M '\,  " $P  @1D  ((?  "")@  A"T  (0Y  "#10  @U,  (1A  "$<0
M@X,  (*6  "!J@  @;X  (#5  !_Y0!L7P  8U\  %M@  !18P  1V@  #UL
M   R<   *'0  !]X   6>P  #'X   2     @P   (4   "'    B $  (D&
M  ")#   BA(  (L8  ",'@  CB4  (\O  "//   CTH  )!9  "0:   D'L
M (^/  ".HP  C;<  (S+  ",VP!I9   860  %9H  !,;   07$  #9V   K
M>@  (7\  !>"   ,A0   X<   "*    C@   )    "2    DP   )0   "5
M 0  E@<  )<-  "8%   FAL  )PB  ">+@  GCT  )Y,  "?70  GV\  )^#
M  ">F   G:P  )R^  ";S0!G:0  7&T  %%Q  !&=@  .GP  "^!   DA0
M&(D   V-   #D    ),   "6    F    )L   "<    G@   )\   "@
MH0   *("  "D"0  I1$  *@8  "J(@  K#   *Q   "M40  KF0  *YY  "M
MC@  K*$  *RQ  "LOP!B<0  5W8  $Q\  ! @0  -(<  "B-   <D0  $98
M  69    G    )\   "A    I    *8   "G    J0   *H   "K    K0
M *T   "O    L04  +,.  "W%P  N2,  +LR  "\10  O5D  +YN  "_@0
MOY0  +^D  "^KP!=>P  4H$  $>'   ZC@  +I0  "*9   7G@  "J(   "E
M    J    *H   "M    KP   +(   "S    M0   +<   "Y    N@   +P
M  "^    P    ,,   #)!@  S!,  ,\@  #3,0  UT4  -E<  #8<P  UH8
M -B5  #8H #_    _P   /\   #_  8 ^@ 2 /4 'P#R "H [@ U .@ /P#E
M $@ X0!0 -X 6 #; %X V0!D -< :0#5 &X TP!S -( > #1 'T T "" ,X
MAP#- (T RP"4 ,H G0#( *< QP"S ,4 QP## -\ P0#U +\ _P"^ /\ O@#_
M +\ _P#_    _P   /P   #V  ( [@ 0 .D &P#B "8 W  Q -H .P#8 $,
MU !, -$ 4P#. %H RP!? ,D 90#' &H Q@!N ,0 <P## '@ P@!] ,$ @P"_
M (D O@"0 +T F "[ *( N@"M +@ OP"V -8 M0#O +, _P"R /\ L@#_ +,
M_P#_    _@   /(   #H    X  * -@ %P#/ "$ S  L ,H -@#) #\ Q0!'
M ,( 3@"_ %4 O0!: +P 8 "Z &4 N0!I +< ;@"V ', M0!X +0 ?@"S (0
ML0"+ +  DP"O )T K0"H *P MP"J ,P J0#G *< ^@"G /\ IP#_ *< _P#_
M    \0   .4   #9    SP & ,4 $@#  !T O0 G +L ,0"Y #H MP!" +0
M20"R $\ L !5 *\ 6@"M %\ K !D *L :0"J &X J !S *< >0"F '\ I "&
M *, C@"A )< H "B )X L "= ,, G #> )L \P": /\ F@#_ )H _P#T
MXP   -0   #(    O0 " +< #0"R !@ KP B *T *P"K #0 J@ ] *@ 1 "F
M $H I !0 *( 50"@ %H GP!? )T 9 "< &D FP!N )H = "9 'H EP"! )8
MB0"5 )( DP"= )( JP"0 +L CP#4 (X [ ". /P C@#_ (X _P#F    U0
M ,4   "Z    L    *H " "F !, HP = *$ )P"? "\ G  W )H /@"8 $4
MEP!+ )4 4 "4 %4 DP!: )( 7@"1 &, D !I (X ;P"- '4 C !] (L A0")
M (X B "9 (< I@"% +4 A #* (0 Y "# /8 @P#_ (, _P#;    Q@   +@
M  "M    I@   *   @";  T F  8 )4 (0"3 "H D0 R (\ .0". $  C !&
M (L 2P"* %  B0!5 (< 6@"& %\ A0!D (0 :@"# '$ @@!X (  @0!_ (H
M?0"5 'P H@![ +  >@## 'D W0!Y .\ >0#\ 'D _P#.    O    *T   "B
M    FP   )8   "2  < C@ 2 (L ' ") "0 AP M (8 - "$ #L @P!! ($
M1@"  $L ?P!0 'X 50!] %H >P!@ 'H 9@!Y &P > !T '8 ?0!U (8 <P"1
M '( G@!Q *P < "^ &\ U0!O .L ;@#X &X _P#$    L0(  *0$  "9!0
MD00  (P!  ")  $ A@ + (, %0"! !\ ?P G 'T +P![ #8 >@ \ '@ 0@!W
M $< =@!, '0 40!S %8 <@!< '$ 8@!O &D ;@!Q &P >@!K (0 :0"/ &@
MFP!G *D 9@"[ &4 T0!E .< 9 #S &, ^0"[!@  J0L  )P.  "1$   B1
M (0-  " "   ?P($ 'P #@!Z !@ =P A '4 *0!S #$ <0 W '  /0!N $,
M;0!( &P 30!J %, :0!8 &< 7P!F &8 9 !N &, =P!B (( 8 &- %\!F@!=
M :@ 7 &Z %P!SP!; N, 6@+O %H#]@"S#P  HA0  )46  "*&   @A@  'P6
M  !Y$P  =@X  '4'!P!S Q( < ,< &T$) !K!2P :04S &<&.0!F!C\ 90=$
M &,'2@!B"%  8 A6 %\)7 !="60 7 EL %H*=@!9"H$ 5PN- %8+F@!5"ZD
M5 N[ %(+T !2"^0 4@SQ %$,^0"M%@  G1H  (\<  "$'@  ?1X  '8=  !R
M&@  ;Q<  &T2  !L# L :0P6 &8-'P!D#B< 8@XN & .-0!>#SL 71!! %P0
M1P!:$4T 61%3 %<26@!5$F$ 5!-J %(3= !1%(  3Q2, $X4F0!-%:D 2Q6[
M $H4T0!*%.8 2A3T $H4^P"H&P  F!X  (HB  " (P  >",  '$B  !L(
M:!T  &8:  !D%@4 8A41 %\6&@!<%B, 6A8J %@7, !7%S< 51<] %080P!2
M&$D 41A0 $\95P!.&5\ 3!IH $L:<@!)&WX 2!N* $<<F !%'*< 1!RY $,;
MSP!"&^4 0AOT $,:_ &C'P  E"(  (8E  !\)P  ="<  &TG  !G)0  8R(
M & @  !='0$ 6AP, %@<%@!5'!\ 4QTF %$=+0!/'3, 3AXY $P>/P!+'D8
M21Y- $@?5 !&'UP 12!F $0A< !"(7P 02&( #\BE@$^(J8!/2&X 3PAS@$[
M(>0!.R#S 3L@_ *@(P  D"8  (,H  !Y*@  <"L  &DK  !C*0  7B<  %LE
M  !7(@  5"(( %$B$P!/(AL 3"(B $HC*0!((S  1R,V $4C/ !#(T,!0B1*
M 4$D40$_)5H!/B5C 3PF;@$[)GH".2>' C@GE0(W)Z4"-B:W C4FS (T)>,"
M-"7R S4D^P.<)@  C2D  ( K  !V+0  ;2X  &4N  !?+0  6BL  %8H  !2
M)P  3B@$ $LG#@!))Q< 1B@? $0H)@!!*"P /R@R 3TH. $\*#\".RE' CHI
M3P(X*E<"-RIA S4K; ,T*W@#,RN% S(KDP,Q*Z,#+RNU RXKRP,N*N(#+BGQ
M!"\I^@29*0  BBP  'TN  !S,   :C$  &(Q  !;,   5B\  %(L  !-+
M22T! $4M"@!"+10 0"T< #TM(@ Z+2D!."PO 38M-0(U+3P"-"Y$ S,N3 ,R
M+U4#,"]?!"\P:@0N,'8$+3"$ RPPD@,K,*(#*C"T RDOR@,H+^$#*2[P!"DM
M^@26+   AR\  'LQ  !P,P  9S,  %\T  !8,P  4C(  $TP  !(,0  1#(
M $ R!P \,A$ .3(9 #<R(  U,B8 ,C(L 3$S,P(O,SH#+C-" RTT2@0K-%,$
M*C1=!"DU: ,H-74#)S6" R8UD0,E-:$#)#6S B,TR0(C-. "(S/P!",R^023
M+P  A#(  '@T  !M-0  9#8  %PV  !5-@  3C8  $@U  !#-@  /C<  #HW
M P V. T ,S@6 #$X'0 O."0 +3@J 2LY,0$I.3@"*#E  R<Y2 ,F.5$#)#I;
M R,Z9P(B.G,"(3N! B$ZD (@.J !'SJR 1XYR $>.=\!'3?O ATW^0./,@
M@34  '4W  !J.   8#D  %@Y  !1.0  2SD  $0Z   ].P  .#P  #0]   P
M/0D +3X3 "L^&@ I/B$ )S\H "4_+P$D/S8!(C\^ 2$_1@$@0$\!'T!: 1Y
M90$=0'(!'$"  1M CP :0)\ &3^Q !@^QP 8/MX &#WO 1D\^ *,-@  ?C@
M '$Z  !F.P  73P  %4\  !./   1ST  $ ^   Y0   -$$  "Y"   J0P8
M)T0/ "1%%P B11X (44E !]%+  >1C, '$8[ !M&1  91DT &$97 !=&8P 6
M1G  %49^ !1&C0 319X $D6P !%$Q0 10]T $D+N !-!^ &(.0  >CP  &X]
M  !C/@  6C\  %(_  !+0   1$   #Q#   V1   ,$4  "M'   D20( ($H+
M !U+%  ;3!L &4PB !=,*0 63#  %4PX !-,00 23$H $$Q5  Y,8  -3&T
M"TQ[  I,B@ )2YH "$JL  =*P0 (2=@ "4CJ  I']0"#/0  =C\  &I!  !?
M0@  5D(  $Y#  !(0P  040  #E'   R20  +4H  "9,   ?3P  &5$' !12
M#P 24Q< $%,>  Y3)0 ,4RT "U,T  E3/0 '4T8 !E-1  137  #4V@  5)V
M  !2A@  498  %&H  !0O   3],  $[E  %-[P!_00  <4,  &5$  !;10
M4T8  $Q&  !%1P  /DD  #9+   O3@  *%   "%2   :5   $U<"  M:"@ '
M6A, !5H:  -:(0 "6BD  %HP  !:.0  6D(  %I,  !95P  660  %ER  !9
M@0  6)$  %BC  !7MP  5L\  %7C  !4[0!Y10  ;$<  &%(  !820  4$D
M $E*  !"2P  .DX  #)1   J5   (U8  !M9   56P  #%X!  5@"   80\
M &$6  !B'0  8B0  &(K  !A,P  83T  &%'  !A4P  85\  &%M  !@?
M8(T  %^?  !>L@  7<D  %S@  !<[0!T2@  9TL  %U,  !43   34T  $9.
M   ]40  -50  "Q8   E6@  '5T  !5@   -8P  !F4   !G!@  : P  &@3
M  !I&0  :A\  &HF  !J+@  :C<  &I!  !J30  :ED  &IG  !I=P  :(@
M &B:  !GK0  9L,  &;;  !EZ@!N3P  8E   %E0  !24   2E$  $%5   X
M6   +UP  "9?   >8@  %F4   YH   &:@   &T   !O @  ;P@  ' .  !Q
M%   <AH  ',@  !S)P  =#   '0Z  !T1@  <U,  '-A  !S<0  <H(  '&5
M  !PJ   <+P  '#4  !OY@!H4P  7E0  %94  !/50  1E@  #Q<   R8
M*60  !]H   7:P  #6X   9Q    <P   '8   !W    > ,  'D(  !Z#@
M>Q0  'P:  !](   ?B@  ( Q  !_/0  ?TL  ']9  !_:0  ?GL  'V.  !\
MH@  >[8  'O,  ![W@!C6   6UD  %19  !*7   0&$  #5E   L:@  (6T
M !AQ   .=0  !7@   !Z    ?0   '\   "!    @@   (,"  "$!P  A0P
M (82  "(&0  B2   (LG  ",,P  BT(  (M1  "+80  C',  (J&  "*FP
MB*\  (C$  "'U@!@70  65X  $]A  !$90  .6H  "]O   D=   &7@   Y\
M   %?P   ((   "$    AP   (D   "+    C    (T   "/    D 4  )$*
M  "2$   E!<  )8?  "8*   F3<  )A(  "96   FFD  )E]  "8DP  F*@
M ):[  "6S@!?8@  5&8  $EJ   ^<   ,G4  "=Z   <?P  $8,   6'
MB@   (P   "/    DP   )4   "7    F0   )H   ";    G0   )X   "@
M!   H0H  *03  "G&@  J2<  *DX  "I2@  JUP  *QP  "KA0  JIH  *BL
M  "HO !::P  3V\  $1U   X>P  +($  ""&   4BP  "(X   "3    E@
M )D   "<    G@   *$   "C    I    *8   "G    J0   *D   "K
MK0   + '  "S$   MAP  +DJ  "Y/0  NU   +QE  "\>@  NX\  +J@  "Z
MK0!5=   2GH  #Z!   RAP  )8T  !F3   ,F    )L   "?    H@   *4
M  "H    J@   *P   "N    KP   +$   "S    M    +8   "W    N0
M +P   # !@  Q1$  ,D>  #++@  S40  ,]:  #1;P  T8(  -*2  #2GP#_
M    _P   /\   #]  , ^  0 .\ &@#K "8 Z@ P .@ .@#E $, X0!+ -X
M4P#; %D V0!? -8 9 #4 &D TP!N -$ <@#/ '< S@!] ,P @P#* (D R0"1
M ,< F0#& *0 Q "P ,( P@#! -P OP#V +X _P"] /\ O #_ +L _P#_
M_P   /L   #R    Z0 + .$ & #= "$ VP L -D -@#7 #\ TP!' ,\ 3@#,
M %0 R@!: ,@ 7P#& &0 Q !I ,, ;0#! '( OP!X +P ?@"Z (0 N0", +<
ME "U )X M "J +( N@"Q -  L #N +  _P"P /\ KP#_ *\ _P#_    ^
M .T   #D    U@ ' -  $P#, !X R0 G ,< ,0#& #H PP!" +\ 20"[ $\
MN !5 +8 6@"T %\ L@!D +$ : "P &T K@!S *T >0"L '\ J@"' *D CP"H
M )D I@"E *4 LP"D ,< HP#E *( ^@"A /\ H0#_ *$ _P#Y    ZP   -X
M  #/    Q0 # +\ #@"[ !D N0 C +8 + "S #4 L  ] *T 1 "K $H J0!0
M *@ 50"G %H I0!> *0 8P"C &@ H@!M *$ <P"? 'H G@"! )T B@"< )0
MF@"? )D K "8 +X EP#; )8 \P"5 /\ E0#_ )4 _P#K    VP   ,P   "^
M    M@   +  "0"L !0 J0 > *4 )P"D "\ HP X *$ /P"? $4 G0!+ )P
M4 ": %0 F0!9 )@ 7@"7 &, E0!H )0 ;@"3 '0 D0!\ )  A "/ (X C@":
M (P IP"+ +< B@#0 (H ZP") /T B0#_ (D _P#>    RP   +L   "Q
MJ0   *, ! ">  \ FP 9 )D (@"7 "L E@ R )4 .@"3 $  D0!& (\ 2P".
M %  C0!4 (P 60"+ %X B0!C (@ :0"' &\ A@!W (0 ?P"$ (D @@"5 ($
MH@"  +$ ?P#' 'X X@!^ /4 ?@#_ 'X _P#/    O0   *\   "E    G@
M )@   "3  H D  4 (T '0"+ "4 B@ M (D - "( #L A@!! (4 1@"# $L
M@@!0 ($ 5 "  %D ?P!> 'X 9 !\ &L >P!R 'D >@!Y (4 > "0 '8 G0!U
M *P = "_ ', V !S .X <P#] ', _P#$    L0   *0   ":    D@   (T
M  ")  0 A@ . (0 & "" "  @  H '\ +P!^ #8 ?  \ 'L 00!Z $8 > !+
M '< 4 !V %4 =0!: ', 8 !R &8 < !N &\ =@!N ($ ;0", &P F0!J *@
M:0"Y &D SP!H .D : #W &@ _P"Y    J    )L   "0 @  B0   (0   "!
M    ?@ ( 'L $@!Y !H =P C '4 *@!T #$ <P W '$ / !P $( ;P!' &T
M2P!L %$ :P!6 &D 7 !H &, 9@!J &4 <P!D 'X 8P") &$ E@!@ *0 7P"T
M %\ R@!> .( 7@#S %X _ "P 0  H 8  ),)  "("P  @0H  'L(  !X!
M=@ # ', # !Q !4 ;P = &T )0!K "P :@ R &@ . !G #T 90!" &0 1P!C
M $T 80!2 &  60!? %\ 70!G %P <0!; 'L 60"' %@ DP!7 *( 5@"R %4
MQ@!5 -X 50#N %0 ]@"I"0  F@T  (L2  ""$P  >A,  '01  !P#0  ;0D
M &P#!@!J  X :  7 &4 'P!C "< 80 M &  ,P!> #D 70 ^ %P 1 !: 4D
M60%/ %@"5@!6 ET 50-E %,#;P!2!'D 402% $\$D@!.!*$ 302Q $P$Q0!,
M ]H 2P3J $L$\P"C$   E!0  (87  !\&0  =!D  &T8  !I%@  9A(  &0.
M  !C" @ 8042 %X&&@!<!R( 6@<I %@'+P!7!S4 50@Z %0(0 !3"48 40E,
M % *4P!."EL 30MD $L+;@!*#'D 2 V% $<-DP!%#:( 1 VS $,,Q@!##-P
M0@SL $,,]0">%0  CAD  ((<  !X'0  ;QX  &@=  !C'   7QD  %T6  !;
M$@( 6@X+ %<-%0!5#AT 4P\D %$0*P!0$#$ 3A W $T1/0!+$4, 2A)* $@2
M40!'$UD 11-B $04; !"%7@ 016$ #\5D@ ^%:$ /!6R #L5QP Z%-T .Q3O
M #L4^ ":&   BAX  'X@  !T(0  :R(  &0B  !>(   6AX  %<;  !5&0
M4Q8& %$5$ !.%AD 3!8@ $H6)P!(%RT 1A<S $47.0!#&$  0AA' $$93@ _
M&58 /1I@ #P::@ Z&W8 .1N# #@<D  V'*  -1NQ #0;Q0 S&MP -!KN #0:
M^ "6'   AR$  'LC  !P)0  9R4  & E  !:)   52(  %(@  !/'0  3!P"
M $H<# !''!4 11P< $,<(P!!'"H /QPP #T=-@ \'3T .QY$ #D?3  X'U0
M-A]> #4@:  T(70 ,B&! #$ACP P(9\!+R&P 2T@Q $M(-L!+1_M 2X?^ &3
M'P  A",  '@F  !M*   9"@  %PH  !6*   428  $TD  !*(@  1R$  $,A
M" !!(1$ /B$9 #PA(  Y(28 -R(L #8B,P T(CH ,R-! 3(D20$Q)%(!,"5;
M 2XE9@$M)G(!+"9_ 2HFC@$I)IT!*"6O 2<EPP$F)=H!)R3L 2<C]P*0(@
M@28  '4I  !J*P  82L  %DK  !3*P  32H  $DH  !%)@  02<  #TG!  Z
M)PT -R<5 #4G'  S)R, ,"<I "\G,  N*#<!+2@^ 2PI1P$J*5 !*2I: 2@J
M9 $G*W$!)2M^ 20KC $C*YP!(BJN 2$JP@$A*=D!(2GK 2$H]P*,)0  ?BD
M '(K  !G+0  7BX  %8N  !0+@  2BT  $4L  ! *P  .RP  #<L 0 T+ D
M,2P2 "\L&0 M+2  *RTG "DM+0 H+30!)BX\ 24N10$D+TX!(R]8 2(O8P$A
M,&\!(#!] 1\PBP$>,)L!'2^M !POP0 ;+M@ '"WK 1PM]@*)*0  >RP  &\N
M  !D,   6S$  %,Q  !,,0  1S   $$P   [,   -C$  #(Q   N,@8 *S(/
M "DR%P G,QX )3,D ",S*P B-#( (#0Z 1\T0@$>-$P!'356 1PU80 ;-6X
M&C5[ !DUB@ 8-9H %S2L !8TP  5,]< %C+J !<R]@&&+   >"\  &PQ  !A
M,@  6#,  % S  !),P  0S,  #TT   V-0  ,#8  "PW   I-P, )3@+ "(X
M%  @.1L 'SDB !TY*0 <.C  &CHW !DZ0  8.DH %SI4 !4Z7P 4.VP $SMZ
M !([B  1.ID #SJJ  XYOP -.-4 $#?I !$W]0""+P  =3(  &DT  !>-0
M538  $TV  !&-@  0#<  #HW   R.0  +3H  "@[   C/0  'SX( !P_$0 :
M/Q@ &#\? !9 )@ 50"T $T U !) /0 10$< #D!1  U 7  ,0&D "D%W  E
MA0 (0)4 !S^G  8^N@ &/=  !SWD  D\\0!_,P  <34  &4W  !;.   43D
M $HY  !#.0  /3H  #<[   O/0  *CX  "5    ?0@  &40% !1%#  21A4
M$$8<  U&(P ,1BH "D8Q  E&.@ '1D, !D9-  1&6  #1F4  D9S  !&@@
M1I(  $6C  !$M@  0\T  $+@  !"[0![-P  ;3D  &$Z  !7.P  3CP  $<\
M  ! /0  .CT  #0_   L00  )D,  "!%   ;1P  %$D!  Q,"0 (31( !DT9
M  1-(  "328  4TN  !--@  33\  $U)  !-50  36$  $UO  !-?@  3(X
M $N@  !*LP  2<D  $C@  !(ZP!V.P  :#T  %T^  !3/P  2S\  $1    ^
M0   -T$  #!$   I1@  (D@  !Q+   630  #D\   =2"  !4PX  %05  !4
M'   5",  %0J  !4,@  5#L  %1%  !440  4UT  %-J  !3>@  4XH  %*<
M  !1KP  4,4  $_=  !.[ !P/P  9$$  %E"  !/0@  2$,  $)#   [1
M,T<  "Q)   D3   '4\  !91   04P  "%8   %9!@  60P  %H2  !;&
M6QX  %PE  !<+0  7#8  %Q   !;2P  6U@  %MF  !;=0  6X8  %J8  !9
MJP  6,   %?9  !6Z@!K0P  7T4  %5%  !,1@  1D8  #]'   W2@  +TT
M "=0   ?4P  %U8  !!8   (6P   5X   !@!   8 D  &$.  !B%0  8QH
M &0A  !D*   9#   &0Z  !D1@  9%,  &1@  !D<   8X$  &*3  !AIP
M8+P  &#3  !?YP!E2   6DD  %%)  !*20  0TH  #I-   R40  *50  "%8
M   86P  $%X   EA   !8P   &8   !H    :04  &H*  !K$   ;!4  &T;
M  !N(@  ;RD  &\S  !O/P  ;TP  &Y:  !N:0  ;7L  &R-  !KH0  :K8
M &K-  !IX0!?30  5DT  $]-  !(3@  /E$  #55   L60  (ET  !EA   0
M9   "&<   %J    ;    &\   !P    <@   ',%  !T"@  =0\  '85  !X
M&P  >2,  'HK  !Z-P  >D0  'I3  !Y8@  >70  '>'  !VFP  =:\  '7%
M  !TVP!;4@  5%(  $U2  !#50  .5H  "]>   D8@  &F<  !%K   &;@
M '$   !T    =P   'D   ![    ?    'T   !_ @  @ <  ($,  "#$P
MA1H  (<B  ")*P  B#D  (=)  "'60  AVL  (9_  "%DP  A*@  (.\  ""
MT0!85@  4E<  $A:   ]7@  ,F0  "=I   <;0  $G(   9V    >0   'P
M  !_    @0   (0   "%    AP   (@   "*    BP   (T$  "."@  D!$
M )(9  "5(0  ERX  )8^  "54   E6(  )5U  "4B@  DY\  )*T  "1Q@!7
M6P  35\  $)D   V:0  *V\  !]T   4>0  "'T   "!    A    (<   "*
M    C    (\   "1    D@   )0   "5    EP   )@   ": 0  G <  )\/
M  "A&   I2(  *8R  "D1@  I5@  *9K  "F@   I)8  *.J  "CO0!29
M1VD  #QO   P=0  )'L  !>    +A0   (D   ",    CP   ),   "6
MF@   )P   ">    H    *(   "C    I0   *8   "H    J@   *T!  "P
M"@  M1,  +@B  "X-   N$@  +I<  "[<0  NH8  +F:  "XJ@!-;@  070
M #5Z   I@0  '8<  !",   #D0   )4   "9    G0   *    "C    I@
M *@   "J    K    *T   "O    L0   +,   "T    M@   +D   "]
MPP<  ,@6  #,)@  RSL  ,Y1  #09@  SWP  ,V.  #-G0#_    _P   /\
M  #\    \@ , .\ %P#K "$ Z@ L .D -@#G #\ X0!' -L 30#5 %, T@!9
M -  7P#. &, S !H ,L ;0#) '( QP!X ,8 ?@#$ (0 P@", ,  E@"^ *(
MO0"O +L P0"Z -P N #U +< _P"V /\ M0#_ +$ _P#_    _P   /<   #J
M    Y  ( -\ % #< !X V@ G -0 ,0#/ #H RP!" ,@ 20#% $\ PP!5 ,$
M6@"_ %X O0!C +P : "Z &T N0!R +< > "V '\ M "' +( D "P )L L "I
M *X N0"M -( JP#N *L _P"J /\ J@#_ *< _P#_    \P   .H   #:
MT@ $ ,P #P#) !H P0 C +\ + "^ #4 O  ] +@ 1 "V $L M !0 +( 50"P
M %H K@!> *T 8P"K &@ J@!M *@ <P"G 'H I0"! *0 B@"B )4 H@"B *
ML0"? ,< G@#E )T ^P"= /\ G0#_ )T _P#S    Y0   -,   #(    P
M +L "@"S !4 L  ? *X * "M #  K  X *D /P"F $8 I !+ *, 4 "A %4
MH !9 )\ 7@"> &, G !H )L ;@": '0 F !\ )< A "5 (X E "; )0 J@"2
M +T D0#: )$ ] "0 /\ D #_ )  _P#D    TP   ,(   "X    L    *@
M!0"D !  H@ : )\ (P"> "L G0 S )L .@"9 $$ F !& )8 2P"5 %  DP!4
M )( 60"1 %X D !C (X :0"- &\ BP!V (H ?P"( (D AP"4 (< I "& +4
MA0#. (0 [ "$ /\ A #_ (0 _P#4    P    +,   "I    H0   )L  0"7
M  L E  5 )( '@"0 "8 CP N (\ -0"- #L BP!! (H 1@"( $L AP!0 (8
M5 "% %D A !> (, 9 "! &H @ !R 'X >@!] (, >P"/ 'L G@!Z *X >@#$
M 'D XP!X /@ > #_ '@ _P#%    M    *<   "=    E0   (\   "+  8
MB  0 (8 &0"% "$ A  I (, , "" #8 @  \ '\ 00!^ $8 ?0!+ 'L 3P!Z
M %0 >0!9 '@ 7P!V &4 =0!M ', =0!Q '\ < "* '  F !O *@ ;@"\ &T
MUP!M /  ; #^ &P _P"Y    J0   )P   "1    B@   (4   "!  ( ?@ +
M 'P % ![ !P >0 C '@ *@!W #$ =@ V '0 / !S $$ <@!& '  2P!O %
M;@!5 &T 6P!K &$ :0!I &@ <0!F 'L 90"& &0 E !C *, 8P"U &( S0!A
M .< 80#W &$ _P"O    H    )$   "(    @    'P   !Y    =0 & ',
M#@!Q !< ;P > &X )0!M "P :P Q &H -P!I #P 9P!! &8 1@!E $L 9 !0
M &( 5@!A %T 7P!E %X ;0!< '< 6P"# %H D !9 )\ 6 "O %< Q !7 -X
M5P#R %< _0"G    EP$  (H$  " !@  > 4  ',#  !O    ;0 ! &H "0!H
M !( 9@ 9 &4 ( !C "8 8@ L &$ ,@!? #< 7@ \ %T 00!; $< 6@!, %D
M4@!7 %D 5@!A %0 :@!3 '0 4@"  %$ C0!0 )L 3P"K $X O@!. -@ 30#L
M $X ^ "@ P  CPD  (,,  !Y#0  <0T  &L,  !G"0  9 4  &, ! !A  L
M7P 4 %T &P!; "( 60 H %@ +@!6 #, 50 X %0 /0!3 $, 4@!) %  3P!/
M %8 30!> $P 9P!* '( 20!^ $@ BP!' )D 1@"I $4 O !% -( 10#G $4
M\P":"0  B@X  'X2  !S%   :Q0  &43  !@$@  70X  %L*  !:!08 6 $-
M %8 %@!4 !T 4@ C %  *0!/ 2\ 3@$T $P".@!+ C\ 2@-% $@#3 !'!%0
M101< $0%9@!"!7$ 009] $ &B@ ^!ID /0:I #P%N@ \!-  / /C #L#[P"5
M#P  AA0  'H7  !O&   9AD  %\8  !:%P  5A4  %02  !2#@  40H' $\'
M$ !-!Q@ 2P@? $D()0!(""L 1@DQ $4)-@!#"3P 0@I# $ +2@ _"U( /0Q;
M #P,9@ Z#7$ .0U^ #<.BP V#IH - ZK #0-O0 S#-( ,@SE #(,\ "0%
M@A@  '8:  !K'   8AT  %L<  !5&P  41H  $X8  !,%0  2A(" $D0"@!'
M#A, 1 X: $(/(0!!$"< /Q M #T0,P \$3H .A)! #D22  W$U  -11: #04
M9  R%7  ,15\ # 5B@ N%ID +16J "P4O0 K%-0 *Q3H "L3\P",&   ?AL
M '(>  !G'P  7B   %<@  !1'P  31X  $D<  !&&@  1!<  $(6!0! %0X
M/146 #L6'0 Y%B0 -Q8J #46,  T%S8 ,Q<^ #$81@ P&4X +QE8 "T:8@ L
M&FX *AM[ "D;B0 G&Y@ )ANI "4:O  D&M, )!GG "49] ")&P  >QX  &\A
M  !D(@  6R,  %0C  !.(@  22$  $0@  !!'@  /AP  #L< 0 X&PH -AL3
M #0;&@ R&R  ,!LF "X<+0 M'#0 +!T[ "H>0P I'DP *!]6 "8?8  E(&P
M)"!Y "(@B  A()< (""H !\?NP >']( 'A[F !\>\P"&'0  >2$  &PC  !A
M)0  6"8  % F  !*)0  124  $ D   \(P  .2$  #4A   R(0< +R$. "TA
M%@ K(1T *"$C "<A*@ F(C$ )2(Y "0C00 C)$H (214 " D7P ?)6L 'B5X
M !PEA@ ;)98 &B6G !DDN@ 8(]$ &2/F !HB\P"#(   =B,  &DF  !>*
M52@  $XH  !'*   0B@  #PG   X)P  ,R8  # F   L)@, *28+ "8F$P D
M)QH (B<@ "$G)P @*"X 'B@V !TI/P <*4@ &RE2 !HJ70 9*FD %RIW !8J
MA0 5*I4 %"JF !,IN0 2*-  $RCE !0G\P"!(@  <R8  &8H  !;*@  4BL
M $LK  !$*P  /BL  #DJ   T*@  +RH  "HK   F*P  (RP( " L$  >+1<
M'"T> !LM)0 9+BP &"XT !<N/  6+T8 %2]0 !,O6P 2+V< $3!U  \PA  .
M+Y, #"^D  LNMP ++<T #"WB  TL\ !])0  <"D  &,K  !8+0  3RT  $@N
M  !!+@  .RX  #8M   P+0  *B\  "4P   A,0  '3$% !HR#0 8,Q4 %C,<
M !0T(@ 3-"D $C0Q ! T.@ .-$, #31-  LU6  *-60 "35R  @U@  &-)
M!32A  0SLP $,LD !3+>  8Q[ !Z*   ;"P  & N  !5+P  3#   $4P   ^
M,   .#   #,P   M,0  )S,  "(T   =-0  &#<" !0X"@ 1.1( #CH9  PZ
M(  *.B< "3HN  @Z-@ '.C\ !3I*  0Z50 ".F$  3IN   Z?0  .HT  #F>
M   XL   .,8  #?<   VZ@!V+   :2\  %PQ  !2,@  23,  $(S   [,P
M-3,  # S   J-0  )#<  !\X   :.@  %#P!  T^!P )0 \ !D 6  1 '0 "
M0"0  4 K  ! ,P  0#P  $!&  ! 40  0%T  $!K  ! >@  0(H  #^;   ^
MK0  /<,  #W;   \Z@!R,   9#(  %@T  !.-0  1C8  #\V   Y-@  ,S8
M "TW   G.0  (#L  !L]   5/P  $$(   A$!@ "10T  $83  !'&@  1R
M $<G  !'+P  1S@  $="  !'30  1ED  $9G  !&=@  1H8  $:8  !$JP
M0\   $+8  !"Z@!M-   8#8  %0X  !+.   0SD  #PY   W.0  ,3H  "H\
M   C/@  '$$  !=#   110  "D@   -*!0  2PL  $P1  !-%P  3AT  $\D
M  !/*P  3C0  $X^  !.20  3E8  $YC  !-<@  38,  $V5  !,J   2KT
M $G6  !(Z0!H.0  6SH  % [  !'/   0#P  #H\   T/0  +3\  "5"   >
M10  %T<  !)*   *3   !$X   !1!   4@D  %,.  !4%   51H  %8@  !7
M)P  5R\  %8Y  !61   5E$  %9?  !5;@  57\  %61  !5I0  4[L  %'3
M  !0Z !B/0  5CX  $P_  !$/P  /C\  #A    P0P  *$8  "!)   83
M$DX   I1   $4P   %8   !8 0  608  %H+  !<$0  718  %X<  !?(@
M8"H  %\T  !?/P  7TL  %]:  !>:0  7GH  %V-  !=H0  7+<  %K0  !9
MY@!<0@  44,  $E#  !#0P  /$,  #-&   K2@  (TT  !I1   25   "U8
M  19    7    %\   !@    8@(  &,&  !D"P  91$  &<6  !H'   :20
M &HM  !I.   :44  &E3  !H8P  :'0  &>'  !FFP  9K   &3)  !CX0!7
M1P  3D<  $='  !!1P  -TH  "Y.   E4@  '%8  !-9   )70   V    !C
M    90   &@   !J    :P   &P"  !N!@  ;PL  ' 0  !R%P  <QX  '4F
M  !U,0  =3T  '1,  !T7   =&T  '.   !QE0  <*H  &_   !NV !32P
M3$L  $9+   [3@  ,E,  "A7   >7   %&    ED   !9P   &H   !N
M<    ',   !T    =@   '<   !Y    >@,  'P(  !^#@  @!4  ((=  "$
M)@  A#,  (-"  "#4@  @F0  (%X  " C0  ?J(  'VW  !\S0!13P  2T\
M $!3   U6   *UT  "!B   59P  "6L   !P    <P   '8   !Y    ?
M 'X   "     @@   (0   "%    AP   (D   "+!   C0L  (\3  "2'
ME28  )0V  "31P  DEH  ))N  "1@@  CY@  (ZL  "-P !05   15@  #I=
M   O8@  (V@  !=N   +<P   '<   !\    ?P   ((   "%    B    (H
M  ",    C@   )    "1    DP   )4   "7    F0(  )P)  "?$@  HQL
M *4I  "D/   HE   *)C  "B>   H8T  )^B  ">M !*70  /V(  #-H   H
M;@  &W4   YZ   "@    (0   "(    BP   (X   "1    DP   )8   "8
M    F@   )P   ">    H    *(   "C    I@   *D   "L!P  L!   +0=
M  "U+P  LT4  +-9  "U;0  MH(  +.7  "RJ0!%9P  .6T  "UT   A>P
M%($   :'    BP   )    "3    EP   )H   ">    H@   *0   "F
MJ0   *L   "L    K@   +$   "R    M0   +@   "\    P0(  ,@,  #.
M'0  S3,  ,U)  #/70  T7(  ,^&  #.EP#_    _P   /\   #W    \@ (
M .\ % #I !X Y  G .( ,0#A #L W !# -@ 2@#4 %  T !5 ,X 6@#+ %\
MR0!C ,< : #% &T PP!S ,( >0#  (  O@"( +P D0"Z )T N "K +8 O@"V
M .  M0#Y +0 _P"S /\ K@#_ *H _P#_    _@   /    #I    XP $ -L
M$ #3 !H T0 D ,\ +0#, #8 R  ^ ,0 10#! $P OP!1 +T 5@"[ %L N0!?
M +@ 8P"V &@ M !N +, = "Q 'L KP"" *T BP"K )8 J@"D *@ M "I -,
MJ #R *< _P"F /\ HP#_ )\ _P#\    \0   .$   #6    S@   ,, "P#
M !8 O  @ +H *0"X #$ MP Y +0 00"Q $< KP!, *T 40"L %8 J@!: *D
M7P"G &0 I@!I *0 ;P"B '4 H0!] )\ A@"= )  G "= )H K ": ,0 F@#H
M )H _P"9 /\ F #_ )4 _P#M    VP   ,T   ##    MP   +$ !@"M !$
MJ@ ; *D ) "H "P IP T *4 / "B $( H !( )\ 30"= %$ G !6 )L 6@"9
M %\ F !D )< :@"5 '  DP!X )( @ "0 (H C@"6 (P I0", +@ C0#< (P
M^ ", /\ C #_ (H _P#=    R    +L   "O    IP   *$  @"=  L FP 6
M )D 'P"8 "< EP O )< -@"4 #P DP!" )$ 1P"0 $P CP!0 (T 50", %D
MBP!> (H 9 "( &L AP!R (4 >P"# (4 @@"0 (  G@!_ *\ @ #. (  [@!_
M /\ ?P#_ '\ _P#)    N    *P   "@    F0   ),   "0  < C0 1 (L
M&@"* "( B@ I (D , "( #< A@ \ (0 0@"# $< @@!+ ($ 4 "  %0 ?P!9
M 'T 7P!\ &8 >P!M 'D =@!W (  =0"+ ', F !R *@ <P#" ', XP!S /L
M<@#_ '( _P"\    JP   )T   "4    C    (<   "$  , @0 , '\ % !^
M !P ?0 D 'T *P!\ #$ >@ W 'D / !X $  =P!% '4 2@!T $\ <P!4 '(
M6@!P &  ;P!H &T <0!K 'L :0"& &@ DP!G *, 9P"X &8 U@!F /, 9@#_
M &8 _P"P    GP   )(   ")    @@   'T   !Y    =P ' '0 $ !S !<
M<@ ? '$ )0!P "L ;P Q &T -@!L #L :@ _ &D 1 !H $H 9P!/ &4 50!D
M %L 8P!C &$ ; !? '8 7@"! %P C@!< )X 6P"Q %L R@!; .D 6@#[ %H
M_P"F    E0   (D   "     >    ',   !P    ;0 # &H "@!I !, 9P 9
M &8 ( !E "8 9  L &( ,0!A #8 8  [ %\ /P!> $4 70!* %L 4 !: %<
M6 !? %< 9P!5 '( 5 !] %( B@!2 )H 40"K %$ P0!0 -X 4 #T %  _P"=
M    C0   ($   !X 0  <    &H   !F    9    &$ !@!?  T 70 5 %P
M&P!; "$ 6@ G %D + !8 #( 5@ V %4 .P!4 $  4P!& %$ 3 !0 %, 3P!;
M $T 9 !, &X 2@!Z $D AP!) )8 2 "G $< NP!' -0 1@#L $8 ^0"5
MAP0  'L&  !Q"   : @  &('  !>!0  6P(  %D  0!7  @ 5@ 0 %0 %@!3
M !T 40 C %  * !/ "T 3@ R $P -P!+ #P 2@!" $D 20!' %  1@!8 $0
M80!# &P 00!W $$ A0!  ), /P"C #X M0 ] ,P /@#E #X ] "0!0  @0D
M '4,  !K#@  8@\  %P.  !7#   5 H  %$'  !0 P, 3P * $T $@!+ !@
M2@ > $@ ) !' "D 1@ N $0 ,P!# #D 0@ ^ $  1@ _ $T /0!5 #L 7P Z
M &D .0!V #@ @P W )$ -@"A #4 L@ U ,@ -0#? #4 [P"+"0  ?0X  '$2
M  !F$P  710  %84  !1$P  31$  $L.  !)"@  2 <% $8## !% A, 0P$:
M $$!(  _ B4 /@(K #P",  [ S8 .@,\ #@$0P W!4L -093 #,&70 R!VD
M,0=U # '@@ O!Y$ +0>@ "T&L@ M!,8 +0/< "T"ZP"'#0  >1,  &T5  !B
M%P  61<  %(7  !-%P  2!8  $44  !"$0  00T  $ *!P ^" X / @6 #H(
M'  X""$ -@DG #4)+0 S"3, ,@HZ #$+00 O#$D +@Q3 "P-70 K#6D *0YV
M "</A  F#Y, ) ZC "0-M  C#<@ (@S= "(,ZP"$$@  =A8  &D8  !>&@
M51H  $X;  !)&@  1!D  $ 8   \%@  .A0  #D1 @ W$ D -0X1 #,.%P Q
M#QX +Q D "X0*@ L$3$ *Q$X "D20  H$T@ )A-2 "447  C%&@ (A5U " 5
M@P ?%9( 'A6C !T4M0 ;$\H &Q/@ !P3[@"!%0  <QD  &8;  !;'0  4AT
M $L=  !%'0  0!T  #L<   W&@  -!D  #,6   P%@0 +A4, "P5$P J%1H
M*!8@ "86)@ D%RT (Q<U "(8/0 A&$8 'QE0 !X96@ =&F8 &QIS !H;@0 9
M&I$ %QJB !89M  5&<D %1C? !88[P!^&   <!L  &,>  !8'P  3R   $@@
M  !"(   /"   #<?   S'@  ,!T  "T;   J&P$ )QL( "0;$  B&Q8 (!L<
M !\<(P >'"L '1TR !L=.P :'D0 &1Y. !@?60 6'V4 %1]R !0@@  2'Y
M$1^A ! >LP /'L@ #AW> ! <[@![&@  ;1X  & @  !5(@  32,  $4C   ^
M(P  .2(  #0B   P(0  +"   "@@   D(   (2 % !X@#  <(10 &B$: !@A
M(0 7(B@ %B(P !4C.  4(T( $R-, !$D5P 0)&, #B1P  PE?@ +)(T "B2>
M  DCL  ((L0 ""+:  DAZ@!X'0  :B   %TC  !2)   2B4  $(E   [)@
M-B4  #$D   L)   *"0  ",D   ?)0  '"4" !DF"0 6)Q$ %"<8 !(G'P 1
M*"8 #R@M  TI-@ ,*3\ "RE)  HI5  (*5\ !RIL  4J>P $*HH !"F;  ,H
MK  ")\$  B;7  ,FYP!U(   9B,  %HE  !/)P  1R@  #\H   X*   ,R<
M "XG   I)P  )2<  " H   ;*0  %RH  !,L!P /+0X #"T6  HM'  )+B,
M!RXJ  8N,@ %+SL !"Y%  ,N4  !+EP  "]I   O>   +X@  "Z8   MJ@
M++X  "O5   KY@!Q(P  8R8  %<H  !,*0  1"H  #PK   V*@  ,"H  "LJ
M   G*0  (BH  !TL   8+0  %"\   XQ!@ (,PP !3,4  ,S&@ !-"   #0G
M   T+P  -#@  #1"   T30  -%D  #1F   T=0  -(4  #.6   RJ   ,;P
M #'3   PYP!M)P  7RD  %,K  !)+   02T  #DM   S+0  +BT  "HL   D
M+0  'RX  !HP   5,@  $#0   DV!0 $. L  #D1   Y%P  .AX  #HD   Z
M+   .S0  #L^   Z20  .E8  #IC   Z<@  .H(  #J4   XIP  -[H  #;2
M   UY@!I*@  6RT  $\N  !&+P  /3   #8P   Q+P  +"\  "<P   A,0
M&S,  !8U   1-P  "CH   4\!0  /0H  #\0   _%0  0!L  $$A  !!*0
M03$  $(Z  !!1@  05(  $!@  ! ;P  0'\  $"1  ! I0  /KD  #S1   [
MYP!D+@  5S   $LR  !",P  .C,  #0S   O,@  *C,  ",T   =-P  %SD
M !$[   +/@  !4    !"!   1 @  $4-  !&$@  2!@  $D>  !))0  22T
M $HV  !)00  24X  $A<  !(:P  1WP  $>.  !'H@  1;@  $31  !"Y@!?
M,@  4C0  $@U   _-@  .#8  #,U   M-@  )C@  !\Z   8/0  $D    M"
M   %10   $<   !) @  2P8  $P*  !.#P  3Q0  %$:  !2(   4B@  %(R
M  !2/   44D  %!7  !09P  3W@  $^*  !/GP  3K4  $S/  !+YP!9-P
M33@  $0Y   \.0  -S@  #$Y   I.P  (3X  !E!   31   "T<   5*
M3    $\   !1    4@,  %0'  !6"P  5Q$  %D6  !;'   7"0  %PM  !;
M-P  6D,  %I2  !98@  67,  %B&  !7F@  5[   %?+  !4Y0!3/   23P
M $$]   [/   -3P  "P_   D0@  '$8  !-*   ,3   !4\   !2    50
M %<   !9    6P   %T#  !>!P  8 L  &(1  !D%P  91X  &8G  !F,0
M93T  &1+  !D7   8VX  &*   !AE0  8:L  &#%  !@X0!.0   1D   #]
M   Y0   ,$,  "='   >2P  %4\   M3   %5@   %D   !<    7@   &$
M  !C    90   &8   !H @  :08  &L+  !N$0  ;Q@  '$@  !Q*@  <38
M '!$  !P5   ;V8  &YY  !MC@  ;*0  &N[  !KU@!+10  1$0  #Y$   T
M2   *TP  "%0   750  #%D   -=    8    &,   !F    :0   &P   !N
M    ;P   '$   !S    =    '8$  !X"0  >A$  'P8  !_(@  ?RT  'X[
M  !^2P  ?5X  'QQ  ![A@  >IP  'BS  !WRP!)20  0T@  #E,   N40
M)%8  !E;   -8    F4   !H    ;    &\   !S    =@   '@   !Z
M?    'X   "     @@   (0   "&    B 8  (L-  ".%P  D2(  ) O  "0
M0   CU(  (UG  ",?   BY(  (FG  "'O !(30  /5$  #-6   H7   '&$
M  ]G   ";    '(   !V    >0   'T   "     @@   (4   "'    B@
M (P   "-    CP   )(   "4    E@   )D#  "=#   H!8  *0B  "C,P
MHD<  *!<  "?<   GH8  )V;  ":K@!#5@  -UL  "QB   ?:   $VX   5T
M    >@   '\   "#    AP   (H   "-    CP   )(   "4    E@   )D
M  ";    G0   )\   "A    I    *<   "K 0  KPH  +05  "W)@  M3L
M +)1  "R9@  LGL  +*/  "OH@ ]80  ,6<  "5N   8=0  "7L   ""
MAP   (P   "0    DP   )8   "9    G    )X   "A    HP   *4   "G
M    J@   *P   "N    L    +0   "X    O0   ,0)  #+&0  RBX  ,='
M  #(6P  RG   ,R#  #)E@#_    _@   /P   #X    [P $ .@ $ #F !L
MX0 E -\ +@#? #< V@ _ -4 1P#2 $T SP!2 ,P 6 #* %P R !A ,8 9@#$
M &L P@!P ,  =@"^ 'T O "% +D C@"V )H M "H +( NP"P -D K@#W +(
M_P"K /\ I0#_ *( _P#\    ]P   .\   #H    V@   -0 "P#. !8 S  @
M ,H *@#) #, Q@ [ ,( 0@"_ $D O0!. +L 4P"Y %@ MP!< +4 80"T &8
ML@!K +  <0"O '@ K0!_ *H B0"H )0 I@"A *0 L@"B ,P H0#N *, _P"@
M /\ FP#_ )@ _P#T    Z@   -T   #,    Q0   +T !@"Z !( MP < +8
M)0"U "X M  V +$ /0"N $, K !) *H 3@"I %( IP!7 *8 6P"D &  HP!E
M *$ ; "@ '( G@!Z )P @P": (X EP"; )8 J@"4 ,  DP#B )0 _P"5 /\
MD #_ (X _P#E    U@   ,@   "Y    L    *L  @"H  P I0 7 *0 ( "C
M "@ HP P *$ -P"> #T G !# )L 2 "9 $T F !2 )< 5@"5 %L E !@ ),
M9@"1 &T CP!T (X ?@", (@ B@"5 (@ I "& +< A #4 (4 ]@"' /\ A0#_
M (, _P#2    P0   +$   "H    H    )L   "7  < E0 1 )0 &@"3 ",
MD@ J )( ,0"0 #< C@ ] (T 0@"+ $8 B@!+ (D 4 "( %4 AP!: (4 7P"$
M &8 @@!N ($ =P!_ ($ ?0". 'L G0!Z *X > #( '@ ZP!Y /\ >0#_ '@
M_P#!    L0   *(   "9    D@   (T   ")  , A@ , (4 %0"$ !T A  D
M (0 *P"" #$ @  W 'X / !] $  ? !% 'L 20!Z $X > !4 '< 6@!V &
M= !H ', <0!Q 'L ;P"' &T E@!L *8 :P"] &L X !L /X ; #_ &P _P"S
M    H0   )4   ",    A0   (    !]    >@ ' '@ $ !W !@ =0 ? '4
M)@!U "P <P Q '( -@!Q #L <  _ &\ 1 !M $@ ; !- &L 5 !J %L : !C
M &8 :P!D '8 8P"! &$ D !@ *  7P"T %\ U0!? /4 7P#_ &  _P"F
ME@   (H   "!    >@   '4   !Q    ;@ # &L "P!J !, :0 : &D ( !I
M "8 9P L &8 ,0!D #8 8P [ &( /P!A $0 8 !) %\ 3@!= %8 7 !> %H
M9P!9 '$ 5P!\ %4 BP!4 )H 4P"M %0 R@!4 .L 5 #_ %0 _P"<    C0
M ($   !X    <    &H   !G    8P   &$ !@!@  T 7@ 5 %T &P!= "$
M7  G %L + !: #$ 60 V %@ .@!7 #\ 5@!$ %0 2@!3 %  4@!: %  8@!.
M &T 30!X $L A@!* )8 20"G $H P !* .  2@#X $H _P"4    A0   'D
M  !O    9P   &$   !=    6@   %@  @!6  D 50 0 %0 %@!3 !P 4P B
M %( )P!1 "P 4  Q $\ -@!- #L 3 !  $L 1@!* $P 2 !5 $< 7@!% &D
M0P!T $$ @@!  )$ 00"D $$ N0!! -4 0 #P $  _@",    ?@   ',!  !H
M P  7P0  %D#  !5 @  4@   %    !.  4 30 + $P $@!+ !@ 2@ > $D
M(P!( "@ 1@ M $4 ,@!$ #< 0P \ $$ 0@!  $D /P!1 #T 6P [ &4 .0!Q
M #@ ?P V (X . "@ #@ LP W ,P -P#G #< ]P"'    >00  &P'  !B"0
M60D  %,)  !."   2@8  $@#  !'  $ 10 ' $0 #0!" !0 00 9 $  '@ _
M ", /0 H #P +@ [ #, .0 Y #@ /P W $8 -0!/ #0 6  R &, ,0!O #
M?0 P (P +P"< "\ K@ N ,, +@#= "X [P""!   = D  &@+  !=#0  50X
M $X.  !(#0  1 P  $$)   _!P  /@0# #P "0 [  \ .0 5 #@ &@ V !\
M-0 D #0 *@ R "\ ,0 U #  /  N $, +0!, "P 5@ J &$ *0!M "@ >P G
M (D )P"9 "8 J@ E +X )@#7 "8 ZP!_"   < P  &00  !9$0  4!,  $D3
M  !$$@  /Q$  #L/   X#0  -@H  #4'!0 T!0H ,@,0 #$#%@ O AP +@,A
M "P#)@ K RP *00R "@$.0 G!4$ )09+ "0'50 C!V  (@=M " (>@ ?"(D
M'@B9 !T'J0 =!;P '0/3 !T!YP![#   ;1   & 3  !6%   318  $86   _
M%@  .A4  #84   S$@  ,!   "X. 0 M"P4 + D+ "H($@ H"1@ )@D= "4)
M(P C"BD (@HP "$+.  @"T$ '@Q* !T-50 ;#6$ &0YN !@.?0 6#HP %0Z<
M !4-K  4#+X % O3 !0*Y !X$   :10  %T5  !2%P  2A@  $(9   \&0
M-A@  #(7   N%@  *Q4  "D3   G$@( )1 & ",0#  A#Q0 'P\: !X0(  <
M$"< &Q$O !H2-P 9$D  %Q-* !845  4%&  $A1M !$5>P 0%8L #A2;  P4
MK  +$[\ "A+4  L1YP!U$P  9A8  %H8  !0&@  1QL  #\<   X&P  ,QL
M "X:   J&0  )Q@  "07   A%@  'Q4# !P5"  :%1  &!46 !<6'0 5%B0
M%!<L !,7-0 2&#X $1A(  X94@ ,&5X "QIJ  D:>  (&H< !QF7  89J  %
M&+P !!?1  46XP!R%0  8QD  %<:  !-'   1!T  #P>   U'@  ,!T  "L<
M   G'   (QL  " :   =&@  &1H  !<:!0 4&PP $AL4 ! <&P .'"( #!PI
M  L=,0 *'3H "1Y$  @>3@ &'EH !!]G  ,?=0 !'X0  1Z5   =I@  '+D
M !S/   ;X@!O&   8!L  %0=  !*'P  02   #D@   S(   +1\  "@?   D
M'@  (!T  !T=   :'0  %1X  !$@!  .( H "B$2  DA&  '(1\ !B(F  0B
M+@ #(S8  B-   $C2P  (U<  "-D   C<P  )((  ".3   BI   (;<  "#-
M   ?XP!K&@  71X  %$@  !'(0  /B(  #8B   P(@  *R$  "8A   B(
M'B   !L@   7(0  $B(   TD!  ))@D !280  ,G%@  )QT  "<C   H*P
M*#,  "D]   H2   *%0  "AB   H<   *(   "F1   GHP  );8  "3-   D
MX@!H'@  6B   $XB  !$)   .R4  #,E   M)   *"0  "0C   @(@  '2(
M !@C   4)0  #B<   HH!  %*PD  "P.   M%   +1H  "TA   N*   +C
M "\Z   O1   +E$  "U?   N;@  +7X  "Z/   NH@  ++8  "K+   IXP!D
M(0  5B,  $HE  ! )P  ."<  #$G   K)@  )B8  "(E   >)0  &B8  !4H
M   0*@  "BP   4N!   , @  #$,   S$@  -!@  #0>   U)0  -2T  #4V
M   U00  -4X  #1<   S:P  ,WL  #.-   SH   ,;4  ##-   NXP!?)0
M4B<  $<I   ]*@  -2H  "XI   I*0  )2@  " H   ;*0  %BL  !$M   +
M,   !C(   $T P  -@<  #<+   Y$   .A4  #L;   \(@  /"H  #PS   \
M/0  /4D  #M8   Z:   .G@  #F+   YG@  .;0  #?-   UY0!:*   3BL
M $,L   Y+0  ,BT  "TL   H*P  (RL  !TM   8+P  $C$   LT   &-@
M 3@    [ @  / 4  #X)  ! #0  01(  $,8  !$'P  1"8  $0O  !$.@
M1$4  $-4  !"9   0'4  $"(  ! G   0+(  #_-   ]YP!5+0  22X  #\P
M   V,   ,"\  "PN   F+@  'S   !DS   3-0  ##@   8[    /0   $
M  !"    1 ,  $4&  !'"@  20\  $L5  !-&P  32(  $TK  !--0  34$
M $Q/  !*7P  27$  $F$  !(F   2*X  $C)  !'Y@!0,0  13(  #LS   T
M,P  +S$  "DR   B-   &C<  !0Z   ,/0  !D    !"    10   $@   !*
M    3    $X#  !/!P  40L  %,1  !6%@  6!T  %@F  !8,   6#L  %=(
M  !560  4VP  %)_  !2E   4:H  %'%  !0XP!*-@  0#8  #DV   S-0
M+34  "4X   <.P  %#\   U"   &10   $D   !,    3@   %$   !3
M50   %<   !9 P  6P<  %T+  !?$0  8A@  &,@  !C*@  8C8  &)#  !@
M4P  7V8  %U[  !<CP  7*4  %N^  !:W0!&.@  /3H  /_B?1!)0T-?4%)/
M1DE,10 +%3<Y   R.0  *3P  !]    61   #4@   9+    3P   %(   !5
M    6    %H   !=    7P   &$   !C    90(  &<&  !I"P  ;!(  &X:
M  !O(P  ;R\  &X\  !L3   :UX  &IS  !IB   :)X  &>V  !FTP!"/@
M/#T  #8]   M0   (T4  !E)   .3@  !5(   !6    6@   %T   !@
M8@   &4   !G    :0   &L   !M    <    '(   !T!@  =PL  'H3  !\
M'   ?"<  'LU  !Z1   >58  'AK  !W@   =I8  '2L  !SQ0!!0@  .T(
M #%%   G2@  '$\  !%4   %60   %X   !A    90   &D   !L    ;P
M '(   !T    =@   '@   !Z    ?    'X   "     A (  (8)  ")$@
MC!T  (PJ  "+.@  BDP  (E@  "'=@  AHP  (6B  "#N0!!1@  -DH  "M0
M   @50  %%L   =@    9@   &L   !O    <P   '8   !Z    ?0   (
M  ""    A0   (<   ")    BP   (X   "0    DP   )8   ":!@  G1$
M *(=  "A+   GS\  )Y4  "<:@  FH   )B5  "7J@ [3P  ,%4  "5;   8
M80  "F@   !N    =    'D   !]    @0   (4   "(    BP   (X   "0
M    DP   )4   "7    F@   )P   "?    H@   *4   "I    K@4  +,1
M  "X'@  MS(  +1'  "R7@  L',  *^(  "NFP U6@  *6$  !QH   .;@
M '8   !\    @@   (<   "+    CP   ),   "6    F    )L   ">
MH0   *,   "F    J    *L   "N    L    +0   "Y    OP   ,4$  #.
M$0  T20  ,T[  #(4P  R&@  ,A]  #(CP#[    ]P   /4   #R    [
M .4 "P#B !< X  B -\ *P#? #0 V@ \ -8 0P#2 $H SP!/ ,P 50#* %H
MQP!> ,4 8P## &@ P0!N +\ = "] 'L N@"$ +@ C@"V )H LP"I +  O@"M
M -X JP#Z *H _P"A /\ G@#_ )H _P#T    [P   .L   #?    U    ,\
M!P#+ !, R0 = ,@ )@#' "\ Q0 W ,  /@"] $0 NP!* +D 3P"W %0 M0!9
M +0 70"R &( L !H *\ ;@"M '4 JP!] *D AP"G )( I0"A *( M "? -(
MG0#T )L _P"6 /\ DP#_ )  _P#K    Y0   -,   #&    O@   +D  @"V
M  T M  7 +( (0"Q "D L0 Q *X . "L #X J@!$ *@ 2 "F $T I0!1 *0
M5@"B %L H !A )X 9P"< &X FP!V )D ?P"7 (L E0"8 )0 J@"2 ,4 D #J
M (X _P"* /\ A@#_ (4 _P#@    S@   +T   "R    JP   *8   "B  <
MH0 2 *  &P"? ", GP K )P ,@"9 #@ EP ^ )4 0P"4 $< D@!+ )$ 3P"0
M %0 CP!9 (X 8 ", &@ B@!O (D >0"' (, A0"1 (0 H0"" +8 @0#; (
M^P"  /\ ? #_ 'L _P#+    MP   *H   "A    F@   )4   "2  , D  ,
M (T %0", !X C  E (P + "* #( B  X (< /0"% $$ A !& (, 2@"" $X
M@0!3 (  60!_ &  ?0!I 'L <@!Z 'T > ") '8 F0!T *P <P#, '( \0!Q
M /\ < #_ &\ _P"X    IP   )L   "2    BP   (8   "#    ?P ' 'X
M$ !] !@ ?0 ? 'T )@![ "T >0 R '@ -P!W #P =@!  '4 10!S $D <@!.
M '$ 5 !P %H ;P!A &T ; !K '< :0"# &< D@!F *, 90"^ &0 Y0!C /\
M9 #_ &, _P"H    F0   (T   "%    ?@   'D   !T    <@ # '  "P!O
M !, ;@ : &X (0!N "< ;0 L &L ,@!J #8 :0 [ &@ /P!G $0 9@!) &4
M3P!C %4 8@!< &$ 90!? '( 70!^ %L C !9 )T 5P"T %< U@!7 /< 6 #_
M %D _P"=    C@   (,   !Y    <@   &L   !H    90   &, !@!B  T
M8@ 5 &( &P!B "( 80 G &  +0!? #( 7@ V %T .P!; #\ 6@!% %D 2@!8
M %$ 5P!8 %4 8 !4 &L 4@!Y %  AP!. )< 3 "L $L R0!+ .X 3@#_ $X
M_P"3    A0   'D   !O    9@   &$   !=    6@   %D  @!8  D 5P 1
M %< %P!7 !T 5P B %4 )P!4 "P 4@ Q %$ -@!0 #H 3P!  $X 10!, $P
M2P!3 $H 7 !( &8 1P!T $4 @@!# )( 00"F $  OP!  .0 0P#^ $0 _P"+
M    ?0   '$   !F    7@   %<   !3    40   $\   !.  8 30 + $T
M$@!, !< 3  = $L (@!* "< 2  K $< , !& #4 1  [ $, 00!! $@ 0 !/
M #\ 6  ] &( / !P #H ?@ X (T -P"A #< N  Y -L .@#W #H _P"$
M=@   &H   !?    5@   %    !,    20   $<   !%  ( 1  ' $, #0!"
M !, 0@ 8 $$ '0!  "( /@ G #T *P [ #  .@ V #@ /0 W $0 -@!, #0
M50 S %X ,@!M #$ >@ P (H +P"< "X L0 P ,X ,0#M #( _P!^    <
M &0"  !9!   404  $H%  !%!   00(  #X    ]    .P $ #H "0 Y  X
M.  3 #< &  U !T ,P B #( )P Q "P ,  Q "\ .  M $  + !( "L 40 J
M %P *0!I "@ =P G (< )P"9 "< K  H ,0 * #C "@ ]P!Z    ; 0  %\&
M  !4"   3 D  $4)   _"0  .P@  #<&   U!   ,P(! #( !0 P  H +P /
M "X %  M !D +  > "H (P I "@ *  N "< -  F #T )0!% ", 3P B %H
M(0!G "  =0 @ (4 'P"5 !\ IP ? +P 'P#9 !\ [P!V P  9P<  %L*  !0
M#   2 T  $ -   Z#0  -0P  #$+   N"0  + @  "H& P I P8 * (+ "<!
M$  F !4 )  : ", 'P B "4 (  K "  ,@ ? #H '@!# !T 30 ; %@ &@%E
M !D <P 8 (( & "2 !< HP 7 +< %@#/ !8 Y@!R!@  9 H  %<-  !-$
M1!$  #P1   V$0  ,1   "T/   I#@  )@P  "0+ 0 B"00 (0<' " %"P >
M!1$ '046 !P%'  ;!2( &@4H !D%+P 8!3@ %P5! !8&3  4!U< $P=D !$(
M<@ 0"($ #P>1  X&H@ .!;0 #@/*  \!X@!N"@  8 P  %00  !*$P  010
M #D4   S%   +1,  "D3   E$@  (1$  !\/   <#@( &PP% !D+"  8"@T
M%@D3 !4)&  4"A\ $PHF !(*+@ 1"S< $ Q!  T-3  +#E@ "0]D  @/<@ '
M#X$ !@Z1  8-H@ %#+0 ! O)  4)W0!K#0  71   %$3  !'%0  /18  #86
M   O%@  *A8  "45   A%   'A,  !L2   8$@( %A$$ !00!@ 1#PD #@X.
M  T0%@ ,$!T "Q$D  H2+  )$C4 "!,^  <320 %%%0  Q1A  (5;P !%7X
M !2/   3H   $K(  !''   0W0!H$   6A(  $X5  !$%P  .A@  #,9   M
M&   )Q@  "(7   >%@  &Q4  !@5   5% ( $Q0% ! 3!@ ,% @ "14,  @5
M$P &%AH !18A  07*  #%S$  A@[  $810  &%$  !E>   9;0  &7T  !F-
M   8GP  %K$  !7'   4W0!E$P  5Q4  $L8  !!&@  .!L  # ;   J&@
M)!H  " 9   <&   &1<  !87 0 3%@, $18$  P7!0 (& < !1H+  ,;$0 !
M&Q@  !L>   <)@  '2X  !TX   =0P  'DX  !U<   =:P  '7L  !V,   =
MG@  &[$  !G&   8W@!B%0  5!@  $@:   ^'   -1T  "X=   G'   (AP
M !X;   :&@  %QD  !48 @ 1&0( #1H#  D;!  %'0<  1X*   @$   (18
M "$<   A(P  (BL  "(U   C0   (TP  "):   B:0  (GD  "&+   AG0
M(;$  !_(   =W@!>&   41L  $4=   Z'P  ,A\  "L?   E'@  (!T  !P<
M   9&P  %AL  !(;   .'0  "AX!  4@ P !(@8  "0)   F#0  )Q0  "<:
M   H(0  *"D  "@R   H/0  *4D  "E6   G9P  )G@  ":)   FG0  )K$
M "3*   BX@!:&P  31X  $$@   W(0  +R$  "@A   C(   'Q\  !P>   8
M'@  %!X   \@   *(0  !B,   (E @  )P4  "H(   L#   +A(  "X8   N
M'P  +R8  "\O   O.@  +T8  #!3   N9   +'8  "R'   LFP  *[   "O*
M   HY !6'P  22$  #XC   T)   +"0  "8C   B(@  'B$  !H@   5(0
M$",   LE   &)P   2D    L 0  +@0  # '   R"@  -!   #46   V'
M-B0  #8L   W-P  -T(  #=/   V8   -'(  #*%   RF0  ,:\  #'*   Q
MY@!1(P  124  #HG   Q)P  *B8  "4E   A)   '2,  !<E   2)P  #"D
M  8K   !+@   #     S    -0(  #<%   Z"   / P  #X2   _&   /R
M #\H   _,P  /SX  #]+   _6@  /&X  #J#   YE@  .:T  #C)   XYP!,
M)P  0"D  #8J   N*0  *"@  "0G   ?)P  &2@  !,J   ,+0  !S    $S
M    -@   #@    [    /0   #\"  !!!0  0PD  $8.  !(%0  2!P  $@D
M  !(+@  2#H  $A'  !(50  16D  $-^  !"DP  0:H  $#'  ! Y@!'*P
M/"T  #,M   L+   *"H  "(J   ;+   %2\   TR   '-0   3@    [
M/@   $$   !#    10   $@   !* P  3 8  $X+  !1$0  4Q<  %,@  !3
M*0  4S4  %-"  !24   3V0  $UX  !+CP  2J8  $K!  !)XP!",   .#$
M # P   L+@  )BX  !XQ   7-   #S<   <[    /@   $$   !$    1P
M $H   !,    3P   %$   !3    50,  %<'  !:#   71,  %\;  !?)
M7R\  %X\  !>2P  7%P  %ER  !7B   5I\  %6Y  !4V@ ]-   -30  # R
M   J,@  (34  !@Y   0/   !T    !$    2    $L   !.    4@   %0
M  !7    6@   %P   !>    8    &,!  !F!0  :0L  &P3  !N'   ;B<
M &TU  !L0P  :E0  &=J  !E@0  8YD  &*Q  !ASP Z.   -#<  "\V   E
M.0  &SX  !!#   (1P   $L   !0    5    %<   !:    70   &    !B
M    90   &<   !I    ;    &X   !Q    = 8  '@,  ![%@  ?"   'LM
M  !Z/   >$P  '9A  !T>   <I$  '"G  !OP0 Y.P  -#L  "D^   >0P
M$TD   =/    4P   %<   !<    7P   &,   !F    :0   &P   !O
M<0   ',   !V    >    'L   !]    @0   (0%  "(#0  BQ@  (PD  "*
M,P  B$0  (99  "$<   @H@  (&=  !_M  Y/P  +D,  "-)   83P  "U4
M  !;    8    &0   !H    ;    '    !T    =P   'H   !]    ?P
M ($   "$    A@   (@   "+    C@   )(   "6 @  F0P  )T9  "=*
MFSD  )E-  "78P  EGL  )20  "2I@ S20  *$X  !Q4   06P   F(   !H
M    ;0   '(   !W    >P   '\   "#    A@   (D   ",    CP   )$
M  "4    E@   )D   "<    H    *0   "H    K0   +(+  "W&@  M2L
M +-   "P5@  KFT  *N#  "JEP M5   (5L  !5A   &:    &\   !V
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M_____________________________________________P
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M^OO\_?[_;69T,0     #!"$   $                    !
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M5<S!OVO;P+IXX\"W?^B^MH'KN+5_[+.T?>VOM'WNK+-\[ZJS?>^HLW[OJ+.
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M&0?_E2H9_Y0Y,?^01TC_CE!<_Y!8;/^07GK\C62(]H=JE/&!<9[M>GFGZG2
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M<HRYXW&6N^-RG[OC<ZF[XW6SN]MYM[K4?;BYSG^XNLB N+K"@+BZP8"XNL&
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MP>!UH,'A=Z[!UWRTP,Z"M+_'@[3 P8.SP;R$L\&WA+/!MH2SP+:$L\"VA+/
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MM[QNO[>\;K^WO&Z_M[QNO[>\;K^WO&Z_M[QNO[>\_YX$ /^B&0/_IB\4_[!
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MC%7L?HQ5['Z,5>Q^C%7L?HQ5['Z,5>Q^C%7L?HQ5['Z,W*L  -JX  #/S04
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M?Z3K:XJKZ6>9KNEHJ*[I:KFMW'&_K=)XPJS)><&MPGK KKU[P*^X?,"OM'S
MKK1\P*ZT?,"NM'S KK1\P*ZT?,"NM'S KK1\P*ZT?,"N_XL' O^*$P;_BR(4
M_XDR*?^0/3?_F$9#_YQ.4/^>55[_GEMJ_YM@=ON798+VCVN.\(5RF>M\?*/E
M<8:LX&R4L-YMI+'<<+:PTG6_L,A[O[# ?+ZQNGV^LK5^OK*R?KZRKG^^L:Y_
MOK&N?[ZQKG^^L:Y_OK&N?[ZQKG^^L:Y_OK&N?[ZQ_XP' O^+$P;_C"(3_XHR
M*/^3/#;_FT9!_Z!/3O^C5EO_HUQG_*)A<_:>9G[PF6N)ZI!QE>.'>J#;?(.J
MTW..L\]RGK7-=*^UQWB\M+Y]O+2W?[RULG^[M:Z N[6K@+RUJ("\M*B O+2H
M@+RTJ("\M*B O+2H@+RTJ("\M*B O+2H@+RT_XP' O^,$P;_C2(3_XLR*/^6
M/33_GD<__Z1/2_^G5U?^J%UC^*AB;_&F9WGKHFN$Y)MQC]V3>IO2AH"IR'N)
MM,)XE[B_>:BYO'RYN+2 N;BO@;FYJX*YN*B"N;BE@KJWHX*[MJ."N[:C@KNV
MHX*[MJ."N[:C@KNVHX*[MJ."N[:C@KNV_XT& ?^,$P7_C2(3_XPR*/^8/3+_
MH4@]_Z=02/^K6%3[K5]?]*UC:NVL9W3FJFQ^WZ5PBM6:=YK*D'VHOH6$M+5^
MD+NQ?J&]KX"UO*J#MKRFA+>\HX2WO*&$M[N?A+BZG82YN)V$N;B=A+FXG82Y
MN)V$N;B=A+FXG82YN)V$N;B=A+FX_XT& ?^-$@7_CB(3_XXQ)_^;/C'_I$@[
M_ZI11OVN6E#WL%Y;[[%B9.FR9FWBLFIVV:MLB,ZB=)C"F7NFM8Z!LZJ%B;VD
M@YG!H82MP)Z&M,"<AK3 FH:UOYF&MKV8AK>\EX6XNI>%N+J7A;BZEX6XNI>%
MN+J7A;BZEX6XNI>%N+J7A;BZ_XX& ?^-$@7_CR(3_Y Q)?^=/B__ITDY_ZU3
M0ONQ64SSM%Q5[+9@7>6Y967=N&1UTK%IAL>I<9>[H7>EKI=^LJ"-A+Z6AY'$
MDXFFQ)&)L<21B++#D8BSP9&'M,"1A[6^D8>WO)&&M[R1AK>\D8:WO)&&M[R1
MAK>\D8:WO)&&M[R1AK>\_XX& ?^.$@7_D"(2_Y,Q)/^@/BW_JDHV_;%4/_BT
M5T?ON%I/Z+Q?5>' 8E_7OUYSR[=FA<"P;96SJ'2CIJ!ZL)>6@+V(C8G'A(V=
MR(..K\>%B[#&AXJQQ(B*LL*)B;3 BXBUOHN(M;Z+B+6^BXBUOHN(M;Z+B+6^
MBXBUOHN(M;Z+B+6^_X\& ?^/$@7_D2(2_Y4Q(O^C/RK_K$LS^K-4._2W54+L
MO5A'Y<1>2MS*65W1Q5QQQ+YC@[BW:I.LL'"BGJAVKXZ?>[Q]EH/'=Y:7R7:8
MK\=[DZ_&?8^PQ8"-L<."C+/!@XJTOX2*M+^$BK2_A(JTOX2*M+^$BK2_A(JT
MOX2*M+^$BK2__Y & ?^0$@3_DB,2_Y@R(/^E/RC^L$PO^+92-O&\4SOHQ%8]
MX<U91-;445O*S5EOO<5@@;&_9I&DN&R@E;%QK86I=KIUHG[$<*.4Q6^FK<-U
MH++"=YFRPWB4LL)ZD;/!?(ZTP'R.M,!\CK3 ?(ZTP'R.M,!\CK3 ?(ZTP'R.
MM,!\CK3 _Y & ?^0$@3_DR,2_YLR'O^I0"3[LTXJ]+I/+^S"4#'DS50PVMQ,
M0<_;4%C"U%9MM<Y<?ZC(8H^;P6>>C+IKJWRT<+=NL'N_:[&2OVJTK+UOKK>\
M<::VOG.?M;YTFK6_=I6UOG:5M;YVE;6^=I6UOG:5M;YVE;6^=I6UOG:5M;YV
ME;6^_Y$% ?^2$@3_E",1_Y\R&_^L02#WMTPD\+]+)N;*3"7;VTTFT>-0/\?B
M4E:ZW51JK==8?)_178V2S&&;@L9EJ7+ :K1GOWBY9L*0N&7$JK9IP+RU;+2Z
MMVZLN;AOI;BY<9ZXNG&>N+IQGKBZ<9ZXNG&>N+IQGKBZ<9ZXNG&>N+IQGKBZ
M_Y(% /^3$@/_EB,1_Z,S%_ZQ0AKSNT@<Z<9%&]S80AG1XTDMR.I00+_I55.S
MY5AGI>%8>9;=68F(V%N8>--=I6C08Z]BT76Q8-2-L%_7J*]AU<&M9<; KVB[
MOK%JLKVS;*J\M&RJO+1LJKRT;*J\M&RJO+1LJKRT;*J\M&RJO+1LJKRT_Y0$
M /^4$0/_ER00_Z@S$OBV0Q/MPD 2WM,Z#='B/1_(ZT<TO_!-1[7N4EJJ[%5K
MG.E4>HWG4XE]Y%.6;N!6HF/<7ZE@VW"J8=R%J&+=FJ9CWJZE8-S$IF'/Q*EC
MP\.K9KG!K6:XP:UFN,&M9KC!K6:XP:UFN,&M9KC!K6:XP:UFN,&M_Y4# /^6
M$0+_G2,,_ZXS#/*\/POCS3$'TN$O$<CK/26_]$8YM?5+3*ST4%Z?\T]ND?)-
M?(/N3HAVZ$^4:>)2G6'?6Z->WVBD7M]YHU[@BJ%?X9N@7^&MGU[BOYY=V,FA
M7\O(HU_*R*1?RLBD7\K(I%_*R*1?RLBD7\K(I%_*R*1?RLBD_Y<" /^9$ +_
MI"('^;4P!>G&+@+4WQL%R.LR%K_T/BJV^T4^K?Q+4*#[26"3^TAOAO9(>WOP
M289NZDN/8^9/EUWC5IM;XV&<6N-NG%KD?)M;Y(N:6^6:F%OFJ)=;YKJ66N'*
MF%K@RYA:X,N86N#+F%K@RYA:X,N86N#+F%K@RYA:X,N8_ID! /^;$ '_JQX"
M[[XB -;6" #)ZB,)O_4T&K;\/RZM_T5!H/]#49/_0F"(_D)M??A$>'+R18%G
M[D>)7^I,CUKH4I)7Z%N45NAEDU;H<9-6Z7V25NF)D5;JEH]6ZZ2.5NNVC5;L
MMXU6[+>-5NRWC5;LMXU6[+>-5NRWC5;LMXU6[+>-^)P  /^@# #MM0D U,H&
M ,KI#@"_]"D,MOPW'JS_/3"?_SQ!D_\[4(?_/%U]_SYH<_L_<FGW07I@\T2
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M$0K_<AL2_VXM)?]S.#/_>4$__WI)3/]X4%G_<UAF_VQA<O]E:WS]7G6$^EB
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MK5A"YZ]>2N"N8536IV)HS*!J><*8<8FXD'>7K8A]I*. A:V>?I*PFW^CL9F
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MCUJLUH]:K-:/6JS6CUJLUH]:K-:/_X   O^%"0/_F H VZ@! -*U P#+PP,
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M3BP>_U8K'?]>*QO_:"L:_VXK&O]N*QK_;BL:_VXK&O]N*QK_;BL:_VXKML$
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MZU.\:>I4S&CH5=]HXUCM9]I:[FG17.]KRU[O;,5?[VW!8.YNP&'N;L!A[F[
M8>YNP&'N;L!A[F[ 8>YN_V,*"?]<%0__5!T6_V >%?]K)QC_<C(A_W4\+/]T
M13?^;TU#^&A64/-A8%SO66IEZU1V:^E3@6[F4XUOY528;N-6HF[B5ZUMX5FZ
M;-]:R6S=6]ULV%SL;<]?[6_'8.QQP6+K<KUCZW*X9.MSN&3K<[ADZW.X9.MS
MN&3K<[ADZW.X9.MS_V0)"?]=% __6!L4_V8=$_]Q)A7_>3$=_WP[)_]\1#/X
M>4P^\G)42^QJ75?G8F=CXEQR;-Y9?7'<68ARVEJ4<MA;GW+66ZIRU%RV<M-=
MQ7+17MISS6#K<\1CZ76^9.AVN&7H=[5FZ'>Q9^AWL&?H=[!GZ'>P9^AWL&?H
M=[!GZ'>P9^AW_V4)"/]>% [_71D2_VP=$?]V)1/_?S :_X,Z(_J#0R[S@4LY
M['Q21>9U6U+?;F5?VF9N:M1@>'/07H-WSEZ.>,M?F7G*8*1YR&&P><9BOGG%
M8]%YPF3G>;IFY7JT:.5[L&GD?*UJY'RJ:N5\J6KE?*EJY7RI:N5\J6KE?*EJ
MY7RI:N5\_V8("/]@$P[_8A<0_W <#_][)!#_A"\6_X@Y'O:*0BCNB4HSYX91
M/N" 6DO9>6-9T7!K:,MI='3&97U[PF.(?L!DDWZ^99Y_O&6J?[IFN'^Y9\I_
MMVCA?[%JXH"L:^& J&SA@*5MX8"C;>* HFWB?Z)MXG^B;>)_HFWB?Z)MXG^B
M;>)__V<("/]A$P[_9A8/_W4<#?^ ) W_B"X3^XXX&O*002/ID$DLXHY0-]N*
M6D32@F%6RGII9L-R<'.\;'A]N&F"@K5IC82S:9B$L6JEA*]KLH2N;,.$K&S;
MA*=NWH6C;]Z%H'#>A9YPWX2<<-^#G'#?@YQPWX.<<-^#G'#?@YQPWX.<<-^#
M_V@("/]B$PW_:A0-_W@;"_^#(PO_C2T0]Y(W%NZ60!WEET@FWI9/+]605T',
MB5]3Q()G8[QZ;G&T='5]KV]]A:MNAXBH;I.)IFZ?B:5OK(FC<+V)H7#4B9YR
MVXF;<MN)F7+<B)=RW(B6<MV&E7+=AI5RW8:5<MV&E7+=AI5RW8:5<MV&_V@'
M!_]C$@W_;10,_WP;"?^'(@G_D"P-])<V$NJ;/QCBG48?VIQ-*]"65C_'CUY0
MOHEE8;:";&^N?')\IW9YAJ)S@HR><HV.G'.:CIMSIXZ9=+>.EW3-CI5UV(Z3
M==B-D779C)!UVHN/=-N*CW3;B8]TVXF/=-N)CW3;B8]TVXF/=-N)_VD'!_]D
M$@W_<!,+_W\:"/^*( ?\E"H*\9LT#N>@/!+>HT,7U:!**<N;5#S"E5U.N8]D
M7["):FVH@W!ZH'UVAIEY?8Z5=H>2DG:4DY!VHI..=[*3C'?'DXMWU)**=]61
MBG?6CXEWV(Z)=MF,B7;9C(EVV8R)=MF,B7;9C(EVV8R)=MF,_VH'!_]E$0S_
M<Q,)_X(9!_^-'P7ZERD'[9\Q"N.E.0W:J#T4T*5()\>@4SJ]FUM,M)5B7*R0
M:&NCBFYXFH1SA9)^>8^+>X*5B'F.EX9ZG)>$>JR7@GO!EX%ZT9:!>M*5@GK4
MDX)YU9&#>=:/@WG6CX-YUH^#>=:/@WG6CX-YUH^#>=:/_VL&!_]F$0S_=A((
M_X48!?^0'@3VFR8%ZJ,N!N"J- C6K#D2S*E'),*E43BYH%E)KYM@6J>69VF>
MD6QVE(MQ@XN%=HZ#@'V7?7Z(FWI^EYQX?J>;=W^[FW9^SIIX?="8>7S2EGI\
MTY1\>]22?'O5D7Q[U9%\>]61?'O5D7Q[U9%\>]61_VP&!O]G$ O_>1$'_X@7
M!/^4' +RGB("YJ<H ]NO+ /1L#<0QZY%(KVJ3S6TI5='JJ%>5Z*<96:8EVIT
MCY)N@86,<XUZAGF7<H."G6^#D9YMA**>:X2VG6N%S9QN@L^:<(#0F')_T99T
M?M.4='[3E'1^TY1T?M.4='[3E'1^TY1T?M.4_VT%!O]K#@K_?1$%_XP5 OZ7
M&0'NHAL!X:P> -:U(0',M34.PK)"'[BO3#*OJU5$I:=<59RC8F23GF=QB9EL
M?G^4<(ISCG66:8M^G66+C9YDC)^<8XVSFV..SYEEB<^99X;0F&J$T9=L@M*5
M;(+2E6R"TI5L@M*5;(+2E6R"TI5L@M*5_VX%!O]N"PC_@0\$_X\3 ?N;$P#J
MIQ  VK() -"Y'0#&NC(+O+A ';.U2B^IL5)!GZU949:I7V&-I61N@Z%I>WB<
M;8=LF'.28Y5]F&"5C)E?EIZ77Y>REEZ8SI1@D]*488_2E6.+TI5EB-.498C3
ME&6(TY1EB-.498C3E&6(TY1EB-.4_V\$!?]S"0?_A0T"_Y0. .J@"@#7K 8
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MBT0O_YY#+O^S0BW_RD$M_^U!+?_P0"W_\$ M__! +?_P0"W_\$ M__! S:,
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M'1'_:AP-_W@<#?]Y' W_>1P-_WD<#?]Y' W_>1P-_WD<LL   *7*  "5T0
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ME18 X9T8 -:C(@',HS4,PJ!#'+J=3BVQF%8^J)1=3J"/8UR8BFAICX5M=8>
M<H" >WF(>WF#C'AYD(UV>9^-='JPC7)ZQHQR>MJ+='G;B75XW89V=]Z%=W;?
M@W=VWX-W=M^#=W;?@W=VWX-W=M^#_UX)"?]F"0C_> L#_X4. ?F0#P#JF X
MW*$* -&F'P#'IS,*OJ5!&;6B3"NLGE0[I)E<2YN585F3D69GBHQK<X&&<'YX
M@G6(<7]^CVU^BY!K?IJ0:7^KCV> P8YG?]B-:GW:BVQ\VXEN>MV';WG>A6]Y
MWH5O>=Z%;WG>A6]YWH5O>=Z%_V ("?]J!@?_>PH"_HD+ .N3" #9G 4 U*4&
M ,RJ&P#"JS$(N:H_%["G2BBHHU(YGZ!92):;7U:.EV5DA9)I<'N.;7QQB7*'
M:(9ZCF.%AY!BAI>/88>ICF"'OHQ?A]F+8H3:BF2!VXEF?]R(9W[=AV=^W8=G
M?MV'9W[=AV=^W8=G?MV'_V$("/]N! 7_?P@!\XP& -J7 @#3H 0 S:@$ ,6N
M%@"]L"X&M*\\%*NL1R6BJ5 UF:971)&B75.(GF)@?YIG;766:WEJDG"#88]X
MBEZ/A8Q=D):+7)"GB5N1O8=:D=R&7(S=AUV)W8=?AMV&8(3=AF"$W89@A-V&
M8(3=AF"$W89@A-V&_V('"/]R P/_A 0 X)   -6; 0#.I ( QZT" +ZS$0"W
MM2H$KK0Y$:6R1"&<L$TQE*U308NI64^"IEY=>:)C:6Z?:'5DFVU^7)IWA%J:
MA819FI6#6)NG@5B<O']7G-M^5Y?A@%B2X8%:CN""6HS@@EJ,X():C.""6HS@
M@EJ,X():C.""_V0'!_]W 0+QB   V94  -"@  #(J0  P+$  +>X"0"PO"4"
MJ+LU#9^Z01V6MTDMC;10/(2Q54I[KEI8<:M?9&:H8V]=IFIX6*5U?%:E@WM5
MII1Z5*>F>%2GNW=3J-MU4Z/G=U2=YGE6F.5[5I7E>U:5Y7M6E>5[5I7E>U:5
MY7M6E>5[_VD"!?]^  #>C@  TYH  ,JE  #!K@  N;8  *^_ @"HPQX!H,0P
M"IC"/!B/P$4HAKU+-WVZ4$5SN%52:;597E^S7FE7LF9P4[%R<E*R@7%1LI)P
M4+.D;E"TNFU/M-IK3;'O;4^J[7!1I>QR4J'K<U*AZW-2H>MS4J'K<U*AZW-2
MH>MS_W   _*%  #8DP  S:   ,2K  "[M   L;P  *?% @"?S!0 F,TI!I#,
M-A.'RC\A?\A&,77&2SYJPT]+8,%45U? 6F!1OV-E3[]P9DW ?V5-P9!D3,*C
M8DO#N&%+P]E?2,'T84FY]61+L_-G3*_R:$RO\FA,K_)H3*_R:$RO\FA,K_)H
M_WD  -Z,  #1F@  QJ<  +VQ  "TN@  J<(  )_+ P"4U0@ CM@? X?8+@U_
MUC@;=M4_*6O31#=AT4E#6-!.3E#/555,SU]92M!M64G1?%A)THU62-.@54?4
MME-&U=A21=/Q4T/.^U=%Q?M91L#[6T; ^UM&P/M;1L#[6T; ^UM&P/M;[X,
M -:4  #)H@  P*X  +:W  "LP   H<@  );1 P"+W @ AN,> W[D*@QUXS(8
M:^(W)&'A/#%7X$$\4.!'1$K@3TI'X5I,1>)G2T7B=DI$XX9)1.291T/EK49"
MY\=%0>?J1#WC_4<]W?]*/M;_3#[6_TP^UO],/M;_3#[6_TP^UO],W8T  ,V=
M  #"J@  N;4  *Z^  "CQP  E\X  (O6 0""[ L ?.X;!7/O) UK[RL78>XP
M(ECN-2Q/[CHU2.Y .T/O2$! \%%!/O%=0CSQ:D$[\GE .O.*/SGTGCXX];,\
M./;..S?V[3HV]/\Z-N[_/#;N_SPV[O\\-N[_/#;N_SPV[O\\TI@  ,6G  "[
ML@  L;P  *7%  "8S   C-,  (#;  !X] D!</D5!FCZ'0U?^B,45_HH'4_[
M+25'^S(L0?LY,3W\0#0Y_4@V-OU2-C3^738R_VHV,/]Y-2__BS0N_YXS+O^T
M,BW_S#$L_^HP+/_Y,"S_^3 L__DP+/_Y,"S_^3 L__DPR*,  +VP  "SN@
MI\,  )K+  ",T0  @-@  '7?  !L]P0"9/\-!US_% Q4_QH23?\?&$7_)!T_
M_RHB.?\O)37_-B<R_STI+_]&*BW_3RHJ_UHI*/]F*2;_=2@C_X8G(O^8)R+_
MJ28A_[\E(/_4)2#_U"4@_]0E(/_4)2#_U"4@_]0EOZT  +:X  "IP@  G,H
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M3RC_+%PL_RMI+_\J=C#_*8(Q_RF,,?\JE3'_*YXQ_RRF,?\LKC'_+;8Q_R[
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M;89K[VV&:^]MAFOO;89K[VV&:^]M_TX-#?]<!PC_; D$_W@- ?R"#P#MB!$
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ML&I1H<EI3Y_H:5";\&M1EN]M4I+N;E*1[FY2D>YN4I'N;E*1[FY2D>YN_VH
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M0T''^D<^Q?]*0+S_34"[_TU N_]-0+O_34"[_TU N_]-X(,  -"3  #$H
MNZH  +&S  "GN@  F\   (_'  "$S@, >=@( '7:'@)OVBL*9]HT%5[9.B!5
MV$ K3M=&-$C63CI%V%@\0]AE/$+9<SM"VH,Z0=N4.4'<J#= W< V/]SC-3S:
M]S@YV/\[.-3_/CC2_S\XTO\_.-+_/SC2_S\XTO\_UHT  ,B<  "]J   M+$
M *JY  ">P   D<8  (7,  ![U $ <>(( &SF&01DYR,*7.<K$U3G,1Q,YS<D
M1><^*T#G1B\]Z% Q.^E;,CKI:#$ZZG<P.>N(+SCLFBXW[:\L-^[**S;NZRHT
MZ_\K,>G_+C'I_R\QZ?\O,>G_+S'I_R\QZ?\OS)@  ,"E  "WL   K+D  *#
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M%QW_Y1<=_^47'?_E%QW_Y1<=_^47NZP  +*V  "EOP  F,4  (G+  !\T0
M;]@  &3>  !9Y   4O8  DO_ @9$_P@)/?\.#3?_%!$Q_QD3+?\?%BG_)A<F
M_RP8(O\S&!__.Q@<_T07&?]/%A?_7!44_VL4$?]\$P__C1(._YP1#O^O$ W_
MLQ -_[,0#?^S$ W_LQ -_[,0M+4  *B^  ":Q0  C,L  'W2  !PV   8]\
M %CD  !.Z@  1_D  S__  8X_P ),O\"#"W_!PXH_PP0)/\2$2#_&!(=_QX3
M&?\D$Q7_*A,1_S$3#/\[$@G_11$%_U$0 O]>#P#_;0X _WH- /^*#0#_C0T
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MJG1:?;YR67W;<5E[[7!;>>UO77?N;EYV[VU>=N]M7G;O;5YV[VU>=N]M_UH
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M6TR8\UU,E/E?39#X8$V-]V%-C?=A38WW84V-]V%-C?=A_VH  -][  #0B0
MQI0  +V<  "THP  JJ@  )ZL  "5KPT D+$D 8JQ,PF#L#X4?*Y%('2L3"QL
MJE$X8ZA60UNF6TQ4I6)44*1L5TZD>%A-I8973*6654REIU-+IKQ22J;94$BC
M\E)&H?]52)S_5DF9_EA)F?Y829G^6$F9_EA)F?Y8[W$  -B"  #+CP  P)H
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M,#3+_S(TR_\R-,O_,C3+_S(TR_\RSXT  ,*;  "YI@  L*X  *6U  "9NP
MC+\  (#$  !UR@  :M$! %_9!P!;WA@"5=\C!T[?*P](WS060M\['#W?1" Z
MX$XB.>!9(CCA9B(XXG0A-^.$(#;DEA\UY*H=->7$'#3EYALQXOH>+^#_("W?
M_R(MW_\B+=__(BW?_R(MW_\BQI<  +RD  "SK@  J;4  )R[  "/P   @L4
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M"0;_P0D&_\$)L;,  *6[  "7P@  B,@  'G.  !LU   7]H  %3@  !)Y0
M0.D  #CU  (R_P $+/\ !BC_ 0@C_P8*'_\,"QO_$@P7_Q@-$_\>#0[_)0T*
M_RP-!O\V# '_00L _TX* /]="0#_;0@ _WT( /^+!P#_EP< _Y<' /^7!P#_
MEP< _Y<'J+L  )K"  "+R   ?,X  &W5  !?W   4^(  $CG   ^ZP  -.\
M 2WZ  (G_P $(?\ !AW_  <9_P (%?\ "1'_ @H,_P<+"?\-"P7_% L _QH*
M /\A"@#_*@D _S4) /]!" #_3@< _UL' /]G!@#_<08 _W$& /]Q!@#_<08
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M2^8QN4KV,[9*_S6T2O\VLTG_-[!*_S>O2O\WKTK_-Z]*_S>O2O\W_S,2#_]
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M57YB_U-]8O]3?6+_4WUB_U-]8O]3_TD!!_]9  +X9@  WF\  -5V  #.>@
MR7P" ,%_%P"Z@2P#LH Z#JM]11ND>4XHG795-9=R6T&1;F%+C&IG4XAH;EB%
M9G9;@F: 78%FBEU_9I5>?6:A7GMFL%YY9<)>=V7<7G=E\UQW9?Q:=V7]67=D
M_E=W9/]7=V3_5W=D_U=W9/]7_TP !O]<  'O:0  VW,  -)Z  #*?@  Q(
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M7V%M^%]A;?A?_U8  _9F  #=<P  T7T  ,>%  "_B@  MXT  *Z/!P"HDB
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MH5),E+-03)3,3DJ3Z$](D?M11X[_4DF*_U1)BO]428K_5$F*_U1)BO]4ZVD
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M+#ZXYRL[M?HN.;/_,3>R_S0VLO\T-K+_-#:R_S0VLO\TTH,  ,21  "ZG
MLJ4  *BK  "=L   D;0  (2W  !XNP  ;,$  &+&"@!>QQT!6L<J!53',PQ.
MQCL42,9"&T/%22$_QE(D/<9=)#S&:20[QW<C.LB&(CG(ER YR*L?.,G$'CC(
MY1TUQ?D@,\/_(S'!_R8QP?\F,<'_)C'!_R8QP?\FR8T  +Z:  "UI   K*P
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M(>SZ"1_I_PH>Z?\+'NG_"Q[I_PL>Z?\+NJ$  +*K  "HLP  F[@  (Z]  "
MP0  <\8  &?+  !;T   4-4  $?;   ]X0  ./0' C3U$00O]A@'*_8@"2?V
M)PLC]S ,(/@Y#![Y0PP;^4X+&?I<"A;[; D5^WX(%/R2!Q/\J <2_<(&$?[B
M!1#]^P40_?T%$/W]!1#]_040_?T%M*H  *NS  ">N0  D+X  (+#  !TR
M9\T  %O2  !0V   1MT  #SB   SZ   +_@  BK_!00F_PP&(O\3!Q[_&@@:
M_R$)%O\H"1/_,0D._SL)"O]'" ;_5 <"_V0& /]W!@#_B@4 _Y\$ /^R! #_
MS@, _](# /_2 P#_T@, _](#KK(  *&Y  "3OP  A<0  ';*  !HSP  6]4
M %#;  !%X   .N0  #'H   J\  !)?L  B#_  0<_P %&/\$!A3_"@<1_Q('
M"_\8!P?_'P<"_R<' /\Q!P#_/08 _TH% /]9!0#_:P0 _WT# /^- P#_GP(
M_Z$" /^A @#_H0( _Z$"I+D  ):_  "(Q0  >,L  &K1  !<V   4-X  $3D
M   YZ   +^P  ";O   ?]@ !&O\  A7_  ,1_P $#?\ !0G_  8&_P & O\&
M!@#_# 8 _Q0& /\<!@#_)04 _S$% /\^! #_3 , _UH# /]H @#_> ( _WD"
M /]Y @#_>0( _WD"_Q$B$?\+)A'_#"42_PDG$O\#+!'_ #41_P!$#_\ 40[_
M %X,_P!K"O\ =PG_ ($(_P"*!_\ D@;_ )D&_P"?!?\ I@7_ *P$_P"S!/\
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M/)!4_SN/5/\[CU3_.X]4_SN/5/\[_SX!"/]+  /_5P  YUX  -MD  #59@$
MT64% ,EH' # :2X&N&<\$+%C1QVK7T\IIEQ7,J):8#F>66@\G%EP/II8>#^8
M6(! EUB(0)58D4"36)M!DEBG09!8M$&.6,5!C5C<0HM8\4*)6/]!B5?_08A7
M_T"'5_\_AU?_/X=7_S^'5_\__T$ !O]/  +V6P  WV,  -9I  #/:P  RVL"
M ,-M& "[;RP$LVTZ#JQJ1!JF9TTFH&-5,9MA7#J77F,_E%UK0Y)<<T607'M&
MCER$1HU<C4:+7)='B5RC1XA;L$>&6\%'A%O82(-;[D>"6_Y&@5O_18!:_T2
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MG%Q4=*Q;4W3"65)TWEA2<_584G'_5E1O_U55;O]456[_5%5N_U15;O]4_U@
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M21]JED\I8Y14,UR263Q5D%Y#4(]F2$V.<$I+CGQ*2X^*2$J/FD9)CZM%28_
M0TB/W4%&C?1$1(O_1D.)_T=$A_]'1(?_1T2'_T=$A_]'XVD  -%Y  #$A0
MNHX  +*5  "IF@  GIL  )&=  "%H   ?Z(5 'RC)P%VHC0'<*$]$&J@11EC
MGDLC7)U0+%6;5C10FET[2YEE/TF9<$!(F7P_1YF*/D>9F3Q&F:HZ19G .469
MW3="E_,Z0)7_/#Z4_SX^D_\_/I/_/SZ3_S\^D_\_W'$  ,N   "_BP  MI0
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M&"ZZ_QHMN?\;+;G_&RVY_QLMN?\;Q(P  +F8  "QH@  J:D  )VN  "1L0
MA+0  '>W  !JN@  7K\  %+$  !'R@, 0LP2 $#-( $\S2H$.,XT"#3./0LQ
MSD8-,,]1#2_/70TNT&H,+=!Y#"S1B@LKT9P**M*S"2G2T0@HT.T))L[\#"3+
M_PXCRO\/(\K_#R/*_P\CRO\/O9<  +2A  "LJ@  H:\  )6S  "'MP  >KH
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M  #_XP  _^, J[$  )ZW  "0O   @L$  '/&  !ERP  6-   $S6  ! VP
M-M\  "SC   CYP  &^L  !?U   3_@ !#O\  @O_ @((_PD# _\0 P#_%P,
M_R # /\J @#_-P( _T8! /]8 0#_:P$ _W\  /^1  #_H@  _ZT  /^M  #_
MK0  _ZT H;<  ).]  "%P@  =<@  &?.  !9U   3-H  $#@   TY   *N@
M "'K   8[@  $?$   SZ  $(_P !!/\  @'_  ( _P " /\  P#_! , _PL"
M /\5 @#_'P( _RP! /\\ 0#_3 $ _UX  /]O  #_?@  _X<  /^'  #_AP
M_X< _P(F#_\$(P__ R(/_P D#O\ *@W_ #0,_P!""O\ 4 C_ %T'_P!I!?\
M=03_ '\#_P"' _\ CP+_ )0"_P": ?\ H '_ *<!_P"M ?\ M0#_ +X _P#*
M /\ V0#^ .@ _0#S /T _@#\ /\ ^P#_ /L _P#[ /\ ^P#_ /L _P#[ /\
M_P0E#_\((0__"" /_P(A#_\ )@[_ #(-_P _"_\ 30G_ %H(_P!G!O\ <@7_
M 'P$_P"% _\ C /_ ),"_P"8 O\ G@'_ *0!_P"K ?\ LP'_ +P _0#' /P
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MUBV+"-4ND@G3+I@)TB^@"= OIPG/,+ *S3"["LPQR0K*,=L*QC+K#<,Q^1#
M,/\2OC#_$[TP_Q2\+_\4O"__%+PO_Q2\+_\4_R,,#?\K!0G_,@('_SH*!?\\
M$@7^.QH&\S<D".DS, OB,#X-W#!,#=<R60S3-&0-T#5N#LXV=P[,-W\/RC>&
M#\@XC0_'.)00Q3F;$,,YHQ#".:P1P#JV$;\ZQ!&].M42NCKH$[<Y]Q:T.?\8
MLCG_&;$X_QJP./\:L#C_&K X_QJP./\:_RD("_\Q  ?_.P $_T,& _]%# +V
M1!4"ZD >!. \*0?8.S@+T3M&$,L\4Q/'/5X4Q#YH%<(^<1; /WD6OC^!%[Q
MB!>[0(\7N4"6&+A GABV0:<8M$&Q&;-!OAFQ0<\9KT'C&JQ!]!VI0/\>IT#_
M'Z5 _R"E0/\@I4#_(*5 _R"E0/\@_RX$"?\W  7_0@ "_DD! ?1+!@#N2@P
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M1W-=HD=Q7;!(;UW$2&U<W4=L7?1%;%W_0VQ<_T)M7/] ;5S_0&U<_T!M7/]
M_T8  >E5  #:8P  S6P  ,-Q  "[=   M',  *QS!P"E=1X GW8N!)EU.@V3
M<D08C6]+(HAL42V#:5<V?F9=/GED8T1U8FI(<F%R2G!A>TQN885,;&&13&IA
MGDQH8*U,9F# 3&1@VDQD8/))9&#_1V5@_T5E7_]$95__1&5?_T1E7_]$_TH
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M3D]PTDU.;^U,3F[^2TYM_TI0:_])4&O_25!K_TE0:_])[%8  -MG  #,<P
MP'L  +>!  "NA0  I(4  )B%  "2APT C8DA (B), 6"ASL-?89#%G>$2B!P
M@D\J:G]4,V-]63Q<>UY$5GAE2U)W;DY0=WE/3W>&3DYWE$Q->*5*3'BW24MX
MT4=*=NQ'277]2$ET_TA*<O]'2G+_1TIR_T=*<O]'YUP  -9L  #(=P  O8
M +2&  "KB@  GXH  )**  "+C < AXX< (*.+ -]C3@)=XQ!$G&*1QMKB4TE
M9(=2+EV%5S=7@UP_4H%C14Z ;4=,@'A(2X"%1DJ!E$5*@:1#28&W04B!T$!'
M?^M 17W\0D1\_T)$>O]#1'K_0T1Z_T-$>O]#XF(  -%R  ##?   N84  +"+
M  "FC@  FH\  (R0  "%D@  ?Y06 'R5)P%WE#0&<9,]#FN21!=ED$H@7H]0
M*5B-53%2C%LX38IB/4J*;#](BG<_2(J$/4>*DSQ&BJ0Z1HJV.$6*T#=#B>LX
M08?\.D"%_SL_A/\\/X3_/#^$_SP_A/\\W&H  ,MX  "_@P  M8L  *V1  "B
MDP  EI0  (F6  !]F0  =YH- '.;( !OFRX#:ILX"F2:0!%>F4<:6)=-(E*6
M4BI,E5DP2)1A-$:4:S5%E'<T1)2$,T.4DS%#E*,P0I2V+D&4T"U D^LM/9'\
M,#R/_S(ZCO\S.H[_,SJ._S,ZCO\SU7$  ,5^  "ZB0  LI$  *F8  "=F
MD9D  (6<  !VH   ;:(" &FC%P!EI"8!8:0R!5RC.PQ6HD(34*%(&TN@3B%&
MGU8F0Y]>*4&?:2E GW4I/Y^")SZ?D28^GZ$D/9^T(SR?SB$[G>HB.9O\)3>:
M_R<VF/\I-IC_*3:8_RDVF/\IS7D  ,"&  "VD   KI@  *6=  "8G@  BZ
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M"!S!_P@<P?\(N98  +&@  "IJ   GJT  )&P  "#LP  =K4  &FX  !<NP
M4+\  $7"   YQP  +\P  ";1!  ?U0P '=89 !S6)0 ;US  &M@\ !G82  8
MV54 %]ID !7:=0 4VX< $MR< !#<M0 -W=@ #=KR  W8_P$-UO\"#=;_ @W6
M_P(-UO\"LZ   *RH  "BK@  E;(  (>V  !YN0  :[P  %Z_  !2PP  1\<
M #O+   QSP  *-0  !_9   7W0  $^<) !'H%  .Z!X "^DI  GI-0 'ZD(
M!>M0  /L8  ![',  .N'  #JG0  ZK@  .O<  #J\P  ZO\  .K_  #J_P
MZO\ KJ@  *6O  "8M   BK@  'R[  !NOP  8,,  %3'  !(S   /-   #'4
M   GV0  ']T  !?A   /Y   "_    CX!0 %^ X  ?D7  #Y(0  ^"P  /@Z
M  #X20  ^%L  /AN  #WA   ]IH  />Q  #WRP  ^.D  /CI  #XZ0  ^.D
MJ*\  )NU  "-N0  ?[X  '#"  !BQP  5<P  $C1   \U0  ,=H  "?>   =
MX@  %N8   WI   &[    _8   #^    _P   /\%  #_#0  _Q<  /\B  #_
M,   _T   /]3  #_:   _WT  /^1  #_HP  _[4  /^U  #_M0  _[4 GK4
M )&Z  ""OP  <L4  &3*  !6T   2=4  #S;   PWP  )>,  !SG   2Z@
M"^X   3P    \@   /P   #_    _P   /\   #_    _P(  /\+  #_&
M_R4  /\V  #_20  _UX  /]Q  #_@0  _Y$  /^1  #_D0  _Y$ _P D#?\
M( W_ " ,_P A"_\ )@K_ #((_P! !O\ 3@3_ %L#_P!G O\ <0'_ 'L!_P"#
M /\ B@#_ )  _P"6 /\ G #_ *( _@"I /T L #\ +@ ^P#" /L SP#[ .
M^@#N /H ^@#Z /\ ^@#_ /H _P#Z /\ ^0#_ /D _P#Y /\ _P A#?\!'0W_
M !P,_P >"_\ (@K_ "\(_P ]!_\ 2P7_ %@#_P!D O\ ;P'_ '@!_P"  /\
MAP#_ (X _P"4 /T F@#[ *  ^0"F /@ K0#W +4 ]@"_ /4 S0#U -T ] #L
M /0 ]P#T /\ ] #_ /, _P#S /\ \@#_ /( _P#R /\ _P0>#O\&&0W_ Q@,
M_P 9#/\ ( K_ "P)_P Z!_\ 2 7_ %4$_P!A _\ ; +_ '4!_P!] ?T A0#[
M (L ^0"1 /< EP#U )T \P"D /( JP#P +, [P"] .X R@#N -H [0#H .T
M]0#L /\ ZP#_ .H _P#H /\ YP#_ .< _P#G /\ _PD:#O\*% W_"!,,_P(3
M"_\$'@O_ 2D)_P V"/\ 0P;_ %$$_P!= _X : +[ '(!^ !Z ?8 @@#T (@
M\@"/ /  E0#N )L [0"A .L J #I +  Z "[ .< QP#F -< Y0#H .0 ]0#B
M /\ WP+_ -T$_P'=!/\!W03_ =T$_P'=!/\!_PX5#?\1$ S_#@P+_PX0"O\1
M&PK_$"4)_PLQ"/\'/P?\!4P%^ -9 _0#9 +P!FX"[@=W >P'?P'J"(8 Z0B,
M .<(D@#F")@ Y0B? .0(I@#B"*\ X FY -\)Q@#>"M@ VPSH -@.]@'4$O\!
MTA+_ M$2_P/0$O\#SQ+_!,\2_P3/$O\$_Q01#?\7"0O_%@4)_QL,"/\=%@C_
M'"$(_Q@L"/@4.@?Q$D<%[1%4!.D27P/E%&H"XQ5S > 6>P'>%H,!W1:) =L7
MD ':%Y8 V1B= -<8I0#5&:T U!JW -(:Q #1&]4!S1WF LD>]0/''_\%Q1[_
M!L,>_P?"'O\'P1[_!\$>_P?!'O\'_QD+#/\= PG_(  '_R<(!O\I$@7_)AL&
M]B,G!^T?,P?F'4$&X1U/!-T>6P/9(&8"UB%P M0C> +2)'\"T"2& \XEC /-
M)I,#RR>: \HGH0/(**D#QBBS!,4IP 3#*= $P"KB!;TJ\@>Z*?\)N"G_"K<I
M_PNV*/\,M2C_#+4H_PRU*/\,_Q\&"O\D  ?_+  $_S($ _\S"P+X,!4#["P@
M!.,H+ 7;)CL%U2E)!=$K5@7-+6 &RBYJ!\<O<P?%,'H'PS&!",(QB C ,H\(
MOS*5"+TSG0F\,Z4)NC.O";@SNPFW,\L*M33>"K$S[PVO,_T/K3+_$*LR_Q&I
M,O\1J3+_$:DR_Q&I,O\1_R4!"/\J  7_-  "_CH  ?4Z!0#N-PP XC(7 =DP
M) +0,C4&RC1#"<4V4 O!-UL,OCAE#;PY;0VY.74.N#I\#K8Z@PZU.HH/LSN1
M#[([F ^P.Z$/KSRK$*T\MA"K/,40JCS9$:<[[!.D._L5HCO_%J Z_Q:?.O\6
MGSK_%I\Z_Q:?.O\6_RH !_\Q  /_/   [C\  .!   #;/0( V#@* ,\]'P'&
M/C &OSX^#+H^2A"V/U42LT!?$[% :!2O07 5K4%W%:M!?A6J0H46J$*,%J="
ME!:F0IP7I$*F%Z)"LA>A0L 8GT+4&)Q"Z!F:0OD;F$'_')=!_QR60/\<ED#_
M')9 _QR60/\<_R\ !?\X  'T00  XD<  -E*  #220  ST,% ,9'&P"^22P%
MMT@Y#+%'11.M1E 7JD99&J=&8ANE1VH<HT=R'*)'>1V@1X =GTB('9U(CQZ;
M2)@>FDBB'IA(K1^72+P?E4?/'Y-'Y2"11_8ACT;_(8Y&_R&-1?\AC47_(8U%
M_R&-1?\A_S0  _\^  #G1@  W$\  -)3  #+4P  QDX! +Y0%@"W4B@#L%$V
M"ZI/01.E34L:H4Q4'YY,72&<3&4BFDQM(YE,="273'PDEDR#))1,BR633)0E
MD4R>)8],J2:.3+<FC$S*)HI+X2>(2_0GATO_)X9*_R>%2O\FA4K_)H5*_R:%
M2O\F_S8  OE"  #B30  UE8  ,Q:  #%6P  OU8  +A7$@"Q624"JEDS":17
M/A*>5$@:FE)0(9=16"6446 HDE!H*9!0;RJ/4'<KC5!_*XQ0ARR*4) LB5":
M+(=0IBV%4+,MA$_&+8)/W2V 3_(M?T[_+7Y._RQ^3O\K?D[_*WY._RM^3O\K
M_SD  >Y&  #>4P  TEP  ,A@  # 80  N5X  +)=#0"K7R(!I5\Q!Y]>/!"9
M6T49E%A-(9!652B-55PLBU1C+XE4:S"'4W(QA5-Z,813@S*"4XPR@5.6,G]3
MHC-]4[ S>U/",WE2VC1X4O S=U+_,G92_S%V4?\P=E'_+W91_R]V4?\O_SP
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M0F!<SD)?7.E 7US[/E];_SQ@6_\[8%O_.F!;_SI@6_\Z\T8  -]9  #090
MQ&P  +IQ  "Q<P  J'$  )]P  "9<A4 E',F 8YS,P>)<3T0@V]%&7YL3")Y
M:E$K=&=7-&]E7#MJ8V) 9F)J0V-A<D5A8'U&7V"(1EU@E49;8*-&66"T15A@
MRT577^9#6%_Z05A?_S]97_\]65__/5E?_SU97_\][4L  -Q=  #-:   P7
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M/45P_SU%;_\]16[_/45N_SU%;O\]X5P  ,]K  #"=0  N'T  *Z"  "B@@
MEX(  (N#  "$A0  ?X<5 'N()@%VAS(%<88\#&N%0Q1E@TD=7X).)5F 4RU4
M?EDU3WU@.DM\:3U)?',]2'R /$=\CCI'?)TY1GRO-T5\Q35$>^(U0GKV-D%X
M_S= =_\X0';_.$!V_SA =O\XW&,  ,MP  "^>@  M((  *J&  ">AP  DX<
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M'C*3_QXRD_\>QWD  +N%  "RCP  J94  )R5  "0E@  A)@  'F;  !LG@
M7Z(  %6E @!0IA0 3J8B $NF+0)'IC8'0J8^"SZE10\ZI4T2.*56%#:E8!0U
MI6P3-*5Y$S2EAQ$SI9@0,J6J#S&EP XPI-X-+J+T$"V@_Q(LGO\3*Y[_%"N>
M_Q0KGO\4P((  +:-  "NE@  I)L  )>;  "+G0  ?Z   '.C  !GI@  6JD
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M:P &T'T !="1  30I@ "T,$  ,_B  #.^  !S/\  LO_  ++_P "R_\ L)\
M *FG  ">K   DJ\  (2R  !UM0  :+<  %NZ  !.O0  0L   #;$   KR
M(LP  !G0   1TP  !]<   ':!P  VA0  -L?  #<*P  W3D  -Y'  #?5P
MX&D  .!]  #AD@  X:D  .'$  #BXP  XO8  .'Z  #A^@  X?H K*<  **M
M  "5L0  A[4  'BX  !JNP  7;X  %#"  !$Q@  -\D  "S-   AT0  &=8
M !':   )W    =\   #B    Y    .4*  #F%@  Z"(  .HP  #L00  [U(
M /!F  #P>P  \9   /*F  #RO0  \M<  /+A  #RX0  \N$ I:X  )BS  "*
MMP  ?+L  &V^  !>PP  4<<  $3+   WSP  +-0  "'8   7W   #^    ?D
M    Y@   .<   #J    \    /    #P    \0D  /07  #V)@  ^3D  /Q,
M  #]80  _G8  /^+  #_G0  _ZX  /^U  #_M0  _[4 F[0  (ZX  !_O0
M;\(  &'&  !3RP  1=$  #C5   LVP  (-\  !;C   ,Y@  !>H   #L
M[P   .\   #Q    ^    /P   #\    _    /T   #^"@  _QP  /\O  #_
M1   _UD  /]M  #_?P  _XX  /^3  #_DP  _Y, _P A"_\ '0K_ !P)_P =
M"/\ (P;_ # %_P ^ _\ 3 '_ %@!_P!D /\ ;@#_ '@ _P"  /\ AP#_ (T
M_P"2 /X F #] )T _ "C /P J0#[ +  ^@"Z /H Q@#Y -4 ^0#G /< ]0#U
M /\ ] #_ /4 _P#U /\ ]0#_ /4 _P#U /\ _P ="_\ &@O_ !@*_P 8"/\
M( ?_ "X%_P [ _\ 20+_ %4!_P!A /\ :P#_ '4 _0!] /L A #Z (H ^0"/
M /@ E0#W )L ]@"@ /4 I@#T *X ] "W /, P@#R -$ \@#D /  \P#N /X
M[@#_ .X _P#M /\ [0#_ .T _P#M /\ _P :#/\ %0O_ !0*_P 3"/\ '0?_
M "H%_P X _\ 10+_ %$!_P!= /T : #Y '( ]@!Z /0 @0#S (< \0"- /
MD@#O )@ [@"= .T I #M *L [ "T .L OP#J ,X Z0#@ .< \ #F /D Y #_
M .0 _P#D /\ Y #_ .0 _P#D /\ _P05#/\#$0K_  X)_P 2"/\ &@?_ "8%
M_P T!/\ 00+_ $X!^@!9 /4 9 #Q &X [@!V .P ?0#J (0 Z0"* .@ CP#G
M )4 Y0"; .0 H0#C *D X@"Q .$ O #@ ,L W@#= -T ZP#; /< V0#_ -D
M_P#8 /\ V #_ -@ _P#8 /\ _P@1"_\("@K_ P8(_P4,!_\'%P;_ R(%_P O
M!/T / +W $D!\@!5 .P 8 #H &H Y !S ., >@#A ($ WP"' -X C #= )(
MVP"8 -H GP#9 *8 UP"O -4 N@#4 ,D TP#: -$ ZP#. O@ S 3_ ,L%_P#)
M!O\ R ;_ ,@&_P#(!O\ _PX*"O\. PC_#  &_Q,(!?\3$P7_$1X$^PLI _,'
M-P+L!40!Y@50 .($7 #=!68 VP9O -D'=@#6"'T U0B$ -,)B@#2"9  T0F6
M ,\*G0#."Z4 S RO ,L,N@#*#<D R _< ,03[0#!%/L!OQ7_ ;T5_P*\%/\"
MO!3_ KP4_P*\%/\"_Q0$"?\5  ;_&@ $_QX# _\># /[&Q<#\!8C N<2, '@
M$3X VA%+ -835P#2%6$ SQ=J ,T8<P#+&7H R1J  ,<;AP#&'(T Q!V3 ,,=
MFP#!'J, P!^L +X?MP"]'\4!NR#8 ;@AZ@*U(?D#LB'_!+$A_P6P(/\%KB'_
M!JXA_P:N(?\&_QH !_\;  3_)  "_R@  ?<G!0#Q(PX Y1X; =P9)P#4'#<
MSB!& <HB4@'&)5T"PR9F L H;@*^*'8"O2E] [LJ@P.Z*HD#N"J0 [<KEP.U
M*Y\#M"RH!+(LLP2Q+,$$KRS3!*PLYP:J+/8'IRS_"*4L_PFD*_\*HRO_"J,K
M_PJC*_\*_Q\ !O\C  +_+0  [R\  .(M  #=* , VR - -$F(0#)*C$"PRU
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MIQ:20[07D$+%%XY"VQ>,0N\8BD'^&8E!_QF(0/\9AT#_&(= _QB'0/\8_RL
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M*G1.SBIS3N<J<DWY*7%-_RAP3?\G<$W_)G!-_R9P3?\F^3@  .-*  #45@
MQUX  +UA  "T80  K%T  *5;! "?71D FEXI Y1=-0F/6S\2BEE'&H963B&"
M554F?U1;*7U38BQ[4VHM>5)Q+GA2>BYV4H,O=%*-+W)2F2]P4J8P;E*V,&Q1
MRC!J4>0O:5'W+FE1_RQI4/\K:5#_*FE0_RII4/\J\3L  .!/  #06P  Q&(
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M.%-;_S946O\U5%K_,U1:_S-46O\SYTP  -5<  #'9P  NVT  +%P  "E<
MFV\  )-M  "-;PD B'$= (-Q*P-_<#8)>F\_$71M11EO:DLA:FA1*61F5C!?
M9%PW6V-B.UAA:SY5870_4V& /U)AC#Y189L]3V&K/$YAOSM,8=HZ3&#R.4U?
M_S=-7_\V35[_-4U>_S5-7O\UXU$  -)@  ##:P  N7$  *UT  "A<P  F',
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M+3QR_RT\<O\MU6,  ,5O  "Y>0  KW\  *%_  "6?P  BX   'V"  !VA
M;X8' &N'&0!HB"<!8X@R!5^'.PI9AD(15(1(&$^#31Y*@E,D1H%;*$.!8RI"
M@6XJ08%Z*4"!B"<_@9<F/H&G)#V!O",]@-8A.W[O(SE]_B0X>_\F-WK_)C=Z
M_R8W>O\FSVD  ,!U  "U?P  JH,  )V$  "1A   AX4  'R'  !OBP  9XT
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M@0HMH)$)+)^B"2N?M@@JG]$'*9SL"">;_0HFF?\+)9C_#"68_PPEF/\,O($
M +*,  "IDP  FY,  (^3  "#E0  >)@  &R;  !@G@  5*(  $FE   ]J
M-*H+ #*J&@ PJR4 +JLO 2RK. (JJT$$**M+!":K500EJV$$)*MM R.K? ,B
MJXL"(:N= A^KL@$>JLT!':GJ ANG^P,:I?\%&J3_!AJD_P8:I/\&MHL  *Z5
M  "DF0  EYD  (J:  !^G0  <J$  &:D  !:IP  3ZH  $.M   VL   *[(
M "&U!@ =MA0 '+8? !NW*@ 9MS0 &+<_ !>W2@ 6MU4 %+AC !.X<@ 1N(,
M#[B5  VXJ@ +M\, "K;C  NT^  +L_\ "[+_ 0NR_P$+LO\!LI0  *N=  "@
MH   DJ$  (6D  !XIP  ;*L  &"N  !4L0  1[,  #NU   NN   )+L  !J^
M   1P0  !\,)  3$%@ #Q"$  L4M  '%.0  Q44  ,53  #%8@  Q70  ,6'
M  #%G   Q+(  ,3/  ##Z@  P_D  ,+_  #"_P  PO\ K9X  *>E  ":J
MC:L  ("O  !RL0  9+,  %>V  !*N   /;L  #&]   FP0  ',0  !/(   *
MR@   <T   #/!0  T!   -$;  #2)@  TS(  -1   #63P  V&   -AS  #8
MB0  UZ   -:Y  #6V   UNT  -7X  #5^   U?@ JJ8  )^K  "2KP  A+(
M '6U  !GN   6;H  $R]   _P   ,\,  "?'   <RP  $\\   K3   "U
M -@   #:    W    -T'  #?$@  X1X  .0K  #F.0  Z4H  .I=  #K<@
M[(@  .R@  #KN   Z](  .KF  #JY@  ZN8 HJP  )6Q  "(M   >;@  &J[
M  !;OP  3L,  $'&   SR@  *,T  !S2   3UP  "=L   '>    WP   .(
M  #D    Y@   .@   #J    [ 8  .\4  #R(@  ]3(  /A$  #Z6   ^VX
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M )< _ "= /L HP#Z *H ^ "R /8 O0#T ,P ] #? /, [P#S /T \P#_ /,
M_P#S /\ \P#_ /, _P#S /\ _P 9"?\ %0C_ !('_P 4!?\ '@3_ "L"_P X
M ?\ 1@#_ %, _P!> /T : #\ '$ ^@!X /D ?P#X (4 ]P"* /8 CP#U )4
M] ": /, H #R *< \ "O .X N@#L ,@ ZP#: .L [ #K /L Z@#_ .H _P#J
M /\ Z@#_ .H _P#J /\ _P 6"O\ $@C_  X'_P .!O\ &P3_ "<"_P U ?\
M0@#^ $\ ^0!: /8 9 #T &T \@!U /$ ? #P (( [P"' .X C #M )( ZP"7
M .H G0#H *0 Y@"L .0 M@#C ,, X@#5 .$ Z0#@ /< X #_ .  _P#? /\
MW@#_ -X _P#> /\ _P 1"?\ "PC_  @'_P -!?\ & 3_ ","_P P ?P /@#U
M $L \ !6 .T 8 #K &D Z0!Q .@ > #F 'X Y0"$ ., B0#B (\ X0"4 -\
MF@#= *$ VP"I -D LP#7 ,  U@#2 -4 Y0#4 /, TP#] -( _P#1 /\ T #_
M -  _P#0 /\ _P(*"?\ ! ?_   &_P )!/\ %0/_ " "_P K /0 .0#J $8
MYP!1 .0 7 #A &4 WP!M -T = #; 'L V0"! -@ A@#6 (P U "2 -( F #0
M )\ S@"G ,T L0#+ +X R@#. ,D X #' .\ Q@#[ ,0 _P## /\ P@#_ ,(
M_P#" /\ _P<$"/\$  ;_!0 $_PD$ _\(#P+_ QL!]0 E .D ,@#A $  W0!,
M -D 5P#5 &$ TP!I -$ <0#/ '< S0!] ,L @P#* (D R "/ ,8 E@#% )T
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MK &J([@!J23( :<DW0&D).\"H23] Z D_P2?)/\$GB/_!)XC_P2>(_\$_Q@
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M$(D]T!"'/.<1A3SX$8,[_Q&"._\1@CK_$8(Z_Q&".O\1_R4  .HT  #;00
MSDD  ,1+  "[2   M$(  *\_# "I0A\ HT,M!9Y#.0J:0D0-ED)-$)1"51&2
M0ET2D$)D$X]":Q.-0G(4C$)Y%(I"@12)0XD5AT.2%85"G16$0JD6@D*X%H!"
MS!9^0>07?4'V%WM _Q9[0/\6>C__%7H__Q5Z/_\5^2H  .4\  #620  R5
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M)F-,_R1C3/\C8TO_(F-+_R)C2_\BZSP  -E.  #*60  OE\  +)@  "G7@
MGUL  )E9  "36A  CEPA (E<+@6$6S@+@%E $GQ71QEX54X?=%14)'%36B=O
M4F$I;5)I*FM1<2MI47HK9U&$+&51D"QC49TL85&K+%]0OBQ=4-8L7%#O*EQ/
M_BA<3_\G7$__)5Q/_R5<3_\EYT(  -92  #'70  O&,  *YC  "D8@  FU\
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M+$E:_RQ)6O\LW5$  ,M?  "^:0  LFT  *1M  "9;   D&P  (=K  " ;0
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M@AX[?)$=.GRA&SE\M!HX?,P8-WKH&35X^1LT=_\<,W;_'3-V_QTS=O\=R&D
M +MT  "P?   H7P  )1\  "*?0  @'X  '2   !I@P  7X8  %F("0!6B1H
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M!"29K@,CF<8#(9CC B"6]P4?E/\&'I/_!QZ3_P<>D_\'N($  *^+  "@BP
MDXL  (B,  !\C@  <9   &64  !9EP  39L  $.>   XH0  +:,# ">D$0 F
MI1T )*4G ".E,0 AI3L!(*5$ 1ZE3P$=I5H!'*5F !NE=  9I80 &*65 !:E
MJ  4I,  $Z/? !2A]0 3G_\!$I[_ A*>_P(2GO\"LXH  *F1  ";D0  CY$
M (*3  !WE@  :YD  %^<  !3H   2*,  #RF   QJ0  )JL  !RN   4KPH
M$; 7 !"P(@ -L"P #+ W  NP0@ )L$T "+%:  :Q:0 $L'D  ["+  &OG@
MK[0  *[0  "MZ@  K?D  :O_  &K_P !J_\ KI0  *28  "7EP  BID  'V<
M  !QGP  9:,  %FF  !.J@  0JT  #:P   JL@  '[0  !6W   +N    KH(
M  "[$P  NQX  +PH  "\,P  O#\  +Q+  "]6@  O6H  +U]  "]D0  O*8
M +N_  "ZW@  NO$  +G[  "Y_   N?P JYT  *"?  "2H   A:,  'BG  !L
MJ@  8*X  %.Q  !&M   .;8  "VX   ANP  %[X   W    $P@   ,0   #&
M!   QPT  ,@8  #)(P  RB\  ,L[  #,20  SED  ,YL  #/@0  SY8  ,ZM
M  #.R   S>,  ,ST  #,]0  S/4 IZ4  )NH  "-J@  @*X  '*R  !DM
M5K8  $BY   [O   +[X  "/!   8Q0  #<@   3+    S0   ,\   #2
MTP   -4$  #8#@  VQH  -TF  #?-   X40  .-6  #C;   Y(,  .2:  #E
ML0  Y<D  .3A  #DY   Y.0 H*L  ).O  "%L@  =K4  &>X  !8NP  2[X
M #W"   OQ0  (\@  !?+   -T    ]0   #9    V0   -L   #>    X
M .(   #E    Z ,  .L0  #N'0  \2P  /0]  #V4@  ]VD  />"  #WF@
M^*P  /C   #XPP  ^,, EK   (BT  !ZN   :KL  %N_  !-Q   /L@  #',
M   DSP  %],   K8   "W0   .$   #D    Y    .8   #H    Z@   .P
M  #O    \0   /4   #X!0  _!0  /\E  #_-P  _TP  /]B  #_>0  _XT
M /^@  #_H@  _Z( _P 7!_\ % ;_ !,%_P 5 _\ '@'_ "L _P Y /\ 1P#_
M %, _P!> /\ : #_ '  _P!W /\ ?0#^ (, _0"( /P C0#[ )( ^0"8 /<
MG@#U *4 ] "M /, M@#R ,, \@#8 /$ ZP#Q /H [P#_ .\ _P#N /\ [P#_
M .\ _P#O /\ _P 4"/\ #@;_  T%_P . _\ &P'_ "@ _P V /\ 1 #_ %
M_@!; /P 9 #Z &T ^0!T /< >@#V (  ]0"% /0 B@#R (\ \ "5 .X FP#M
M *( [ "I .H LP#I ,  Z0#2 .@ Y@#F /8 Y0#_ .0 _P#D /\ Y #_ .4
M_P#E /\ _P 1"/\ "P;_  D%_P , _\ %P'_ "0 _P R /L /P#X $P ]@!7
M /0 8 #R &D \ !P .X =P#M 'T ZP"" .D AP#G (P Y0"2 .0 F #C )X
MX0"F .  KP#? +P W0#, -P X #: /, V0#_ -@ _P#8 /\ V #_ -D _P#9
M /\ _P +!_\ !0;_  $$_P * _\ %@'_ !\ ^@ M /, .P#O $< [0!2 .H
M7 #G &4 Y0!M ., <P#A 'D WP!_ -T A #; (D V0"/ -@ E0#6 )L U "C
M -, K #1 +@ T #' ,X W #, .\ RP#\ ,L _P#* /\ R@#_ ,H _P#* /\
M_P $!_\   7_   #_P & O\ $@'^ !L [P G .D -0#E $( X@!. -\ 6 #<
M &$ V0!I -8 ;P#3 '8 T0![ ,\ @0#. (8 S "+ ,L D@#) )@ R "@ ,8
MJ0#$ +0 P@## ,$ UP"_ .H O@#V +T _P"] /\ O #_ +P _P"\ /\ _P
M!O\   3_   "_P ! ?\ "P#U !0 Y0 @ -\ +P#: #P U0!( -( 4P#. %P
MRP!D ,D ; #' '( Q0!X ,, ?0#" (, P0") +\ CP"] )8 O "> +H IP"X
M +( MP#! +4 TP"T .8 L@#T +$ _P"O /\ K@#_ *T _P"M /\ _P0 !/\
M  +_"  !^ @  /$# @#I  L W  9 -4 * #/ #8 R@!# ,8 3@#" %@ P !@
M +X!: "\ FX N@-U +D$>@"W!(  M@6& +0&C0"S!Y0 L0>< + (I@"N";(
MK0G  *L*TP"I"^@ IPWX *0/_P"C#_\ HP__ *(/_P"B#_\ _P@  _\,  'S
M$0  YA0  -\1  #9" ( TP 0 ,P"'P#%!B\ P L] +L-20"X$%, M1)< +,4
M8P"Q%6L L!5Q *X6=P"M%WT K!B$ *H8B@"I&9( IQF: *89I "D&K  HQJ_
M *$:T@">&^< G!SW 9L<_P&:&_\!F1O_ ID;_P*9&_\"_PP  ?H5  #H'P
MW20  -0D  #-'0  R!,% ,(2& "[%RD M1LW +$>1 "N($X JR%8 *DB7P"G
M(V< IB1M *0E= "C)7H HB:  * FAP&?)H\!G2>7 9PGH0&:)ZT!F2>[ 9<G
MS@&5)^0"DB?U Y$F_P./)O\$CR7_!(XE_P2.)?\$_Q,  .X?  #A+   U3(
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M$'8[_A!U._\0=#K_#W0Z_P]T.O\/[RD  -\[  #/1P  PTT  +9+  "L2
MID0  *%  @"<0A8 ED0E I%#,0:-0SP*BD)%#H="31"%0E01@T);$H)"8A*
M0FD3?T)P$WU">!-\0H 4>D*)%'A"E!1W0J 5=4&M%7-!OQ5Q0-85;T#M%6Y
M_15M/_\4;#__$VP__Q-L/_\3[#   -M"  #+30  OE(  +%1  "G3@  H$H
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M'E=*_QU72O\=X4(  ,]1  #!6P  LUT  *5<  ";6P  DUD  (U6  "'6 8
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M@2I$7XXI0F">)T%?KR9 7\4D/U_A(SY=]2,]7/\C/5O_(SU;_R(]6_\BTE<
M ,)C  "U:@  I6H  )AI  ".:0  A6D  'II  !S:P  ;FT' &EO& !F;R4
M8V\O!%YN. E:;3X.56Q$%%%J2AI,:5 ?2&A6)$5G7B9#9V@G06=S)D!G?R4_
M9XTD/F>=(CUGKB \9\0?.V;@'CED]1\X8_\?.&+_'SAA_Q\X8?\?S5P  +YH
M  "P;0  H6T  )1M  "*;0  @6T  '1O  !M<0  9W,! &)T$@!?=2  7'4K
M EAU- 94=#P+3W-"$$MR2!5'<$X:0W!5'D!O72 ^;V8@/6]R'SQO?AX[;XP=
M.F^<&SEOK1DX;\,8-V[?%S5L]!DT:O\:,VG_&C-I_QLS:?\;R&(  +MM  "L
M<0  G'$  )!Q  "&<0  ?7(  &]U  !G=P  7WD  %I["P!7?!H 5'PG %%\
M, -->S@'27H_#$5Y11!!>4P4/GA3%SMX6Q@Y>&48.'AQ%S=X?18V>(L5-7B;
M$S1WK!(S=\(1,W;?$#%T]!(P<_\3+W'_%"YQ_Q4N<?\5PVD  +=S  "G=0
MF'4  (QU  ""=@  >7<  &UY  !B?0  67\  %&" P!-@Q, 2X,@ $B#*@%%
M@S,#08,[!SZ"0@HZ@DD--X%0#S6!61 T@6,0,X%O#S*!? XQ@8H-,(&9#"^
MJPLN@,$*+7_>"2M]] LJ?/\-*7K_#BEZ_P\I>O\/OG   +-Y  "A>@  E'D
M (AZ  !^>@  ='P  &E_  !=@P  5(4  $J)  !"BP@ /HL7 #V,(@ ZC"P!
M-XLU S2+/04RBT0',(M-""Z+5@DMBV (+(ML""N+>0<JBX<&*(J7!2>*J04F
MBK\$)(G; R.'\@4BA?\'(H3_""&#_PDA@_\)N7<  *Q^  "<?P  CWX  (1^
M  !Z@   ;X(  &2%  !8B0  3HP  $2/   YD@  ,90+ "Z5&  LE2, *Y4L
M "F5-0$GE3X")95' B2540(BE5L"(95G B"5= $?E8,!'923 1R4I0 :D[L
M&)/8 !B1\ $8C_\"%X[_ Q>._P07CO\$M(   *:$  "7A   BX,  ("$  !U
MA@  :8D  %Z-  !3D   1Y0  #V7   RF0  *)P  !Z>"0 ;GQ4 &I\@ !B?
M*@ 7GS, %I\] !6?1P 3GU( $J!? !"?;  -GWL #)^,  J>GP (G;0 !YS.
M  B;Z0 )FOH "9G_  F8_P )F/\ KXD  *"*  "2B0  AXD  'N+  !OC@
M8Y$  %B5  !-F0  09P  #6?   KH@  (:0  !>G   -J04 !:H0  .J'  "
MJB8  :HP  "J.P  JD8  *I3  "J80  JG   *F!  "IE   J*@  *?!  "F
MWP  I?   *7[  "E_P  I?\ J9$  )N0  "/CP  @I$  ':4  !IEP  79L
M %*?  !&HP  .Z8  "^I   DK   &JX  !&P   &L@   +,%  "T#P  M!D
M +4C  "U+0  M3@  +5$  "V4@  MF(  +9T  "VAP  M9P  +2S  "ST
MLNH  ++X  "Q_0  L?T I)<  )>6  ")F   ?9L  '"?  !DHP  6*<  $RJ
M  ! K@  -+$  "BS   =M0  $K@   BZ    NP   +T   "^ 0  OPH  , 5
M  #!'P  PRD  ,0U  #%00  QE$  ,=C  #'=P  QXP  ,:C  #&O0  Q=H
M ,3N  #$]0  Q/4 H)X  )*?  "%H@  >*<  &NK  !?KP  4[,  $6U   W
MN   *KH  !Z\   3OP  ",(   #$    Q0   ,<   #)    RP   ,T#  #/
M#0  T1D  -0D  #6,   V3X  -Q0  #>8P  WGH  -^1  #?J   WK\  -[8
M  #>Y   WN0 FZ@  (ZJ  "!KP  <[,  &2U  !5N   1[L  #F^   LP0
M'\0  !/'   (R@   ,T   #1    T0   -0   #6    V0   -P   #?
MX@(  .4/  #H'   ZBL  .T[  #P3@  \F,  /-[  #TD@  ]*8  /2W  #T
MP@  ],( E*\  (:R  !WM@  9[D  %B\  !*P   .\0  "W(   @RP  $\X
M  ;2    UP   -L   #?    WP   .$   #C    Y0   .<   #J    [@
M /(   #V @  ^1$  /PB  #^-0  _TH  /]A  #_>   _XT  /^=  #_I0
M_Z4 _P 3!O\ #P3_  T#_P 0 ?\ &@#_ "D _P W /\ 1 #_ %  _P!: /\
M9 #_ &P _P!S /T >0#[ '\ ^0"$ /@ B0#V (X ]0"3 /4 F0#T *  \P"H
M /( L0#Q +X [P#. .T Y0#L /< ZP#_ .L _P#K /\ [ #_ .P _P#L /\
M_P .!O\ "P3_  D#_P * ?\ %P#_ "4 _P T /\ 0 #_ $P _0!7 /H 8 #Y
M &D ]P!P /0 =@#R 'P \ "! .\ A@#N (L [0"0 .L E@#J )T Z0"D .@
MK0#F +D Y #) .( X #A /, X #_ .  _P#@ /\ X0#_ .$ _P#A /\ _P +
M!O\ !@3_  ,#_P * ?\ %0#_ "$ _  O /D / #V $@ ] !3 /$ 7 #O &4
M[ !L .D <P#G 'D Y0!^ .0 @P#C (@ X0"- .  DP#? )D W0"A -P J@#9
M +0 U@#$ -4 V0#3 .T TP#] -( _P#2 /\ T0#_ -  _P#0 /\ _P $!?\
M  3_   "_P ( ?\ $ #Y !T \P J .\ -P#L $, Z0!. .8 6 #B &$ WP!H
M -P ;P#; '4 V0!Z -< ?P#5 (0 U "* -( CP#1 )8 SP"= ,P I@#* +
MR "_ ,< T@#% .@ Q0#Y ,0 _P#! /\ P #_ ,  _P#  /\ _P  !?\   /_
M   !_P $ /\ "@#O !8 Z0 E .0 ,@#@ #X W !* -@ 5 #4 %T T0!D ,\
M:P#- '$ RP!V ,H ? #( ($ QP"& ,4 C ## )( P0": +\ HP"] *T NP"[
M +H S "Y ., MP#T +4 _P"S /\ LP#_ +( _P"R /\ _P  !/\   +_
M_P   /8  P#F !  W@ > -@ *P#2 #D S0!% ,H 3P#' %@ Q !@ ,( 9P#
M &T O@!S +T > "[ 'T N@"# +@ B0"V )  M0"7 +, H "Q *L KP"W *X
MR0"L -\ J@#O *D ^P"H /\ J #_ *< _P"G /\ _P   O\   'Z    [
M .0   #<  @ TP 7 ,P )0#& #( P@ _ +X 20"[ %, N !; +8 8@"T &D
MLP!O +$ =0"P 'H KP"  *T A@"L (T J@"5 *D G@"G *D I0"V *,!QP"B
M ML H /M )\$^P">!?\ G07_ )P%_P"<!?\ _P   ?L#  #K"P  X1   -@+
M  #0 @  R0 . ,( '0"] "L N  X +0#1 "Q!4X K@=7 *P)7@"K"F4 J0IK
M *@+<0"F#'< I0Q^ *0-A "B#HP H0Z4 )\0G0">$*@ G!&V )H1QP"9$=T
MEA/Q )43_P"3$_\ DQ/_ )(3_P"2$_\ _P0  .\1  #B'   UR$  ,L?  ##
M%P  O@T" +H'%0"T#20 KQ(R *L4/P"G%DD I1A2 *,96@"A&F$ GQMH )X<
M;@"=''0 FQUZ )H=@0"9'8D EQZ1 )8>FP"4'J8 DAZS )$>Q "/'MH C1_O
M (L?_0&*'O\!B1[_ H@>_P*('O\"^0P  .D>  #;*0  SB\  ,$L  "Y)P
MM!\  +$7#0"K'!\ IA\M *(B.@">)$4 G"5. )HF5@"8)ET EB=D 94G:@&4
M*'$!DBAW 9$I?@&0*84!CBF. 8PIF &+*:,!B2FP H@IP0*&*=8"A"GL X(H
M_ . */\$@"?_!'\G_P1_)_\$\A<  .,I  #4-   Q3D  +DV  "P,@  JRT
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M#F8Y_PYF.?\.Y3$  -1!  #%2P  M$L  *A*  "?2   F40  )1!  "/00L
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M&5A#]1=80O\66$+_%5A!_Q180?\4WCT  ,Q,  "]4P  K5,  *!2  "740
MD$X  (I+  "%300 @$X6 'U0) %X3RX%=$XW"G!,/P]L2T43:4I,%F=*4AED
M25D:8DE@&V%)9QQ?27 =74EZ'5M)A1U92)$=5TB?'55(KQU31\,=4D;>'5%&
M\QM11O\9447_&%%%_Q=11?\7VT(  ,E1  "Y5@  J58  )U5  "35   C%(
M (90  " 4@  ?%,2 'A4(0!T5"P#<%,U"&M2/ YG4$,39$])%V!.3QM>354=
M6TU<'UE-9"!73&TA54QW(51,@B%23(XA4$R<(4Y+K2%,2\$@2TK<($I*\AY+
M2?\<2TG_&DM(_QI+2/\:UT<  ,95  "V60  IED  )I9  "06   B%8  (%4
M  !\5@  =U@. '-9'@!O62D":UDS!V=7.@QB5D$17E1&%EM33!M74E(?5%%9
M(E)182-04&HD3E!T)$Q0?R1+4(PC25":(T=0JR)&3[\A1$_:(41.\1]$3O\=
M1$W_'$5,_QM%3/\;TTP  ,-9  "R7   HUP  )=<  "-6P  A5H  'U9  !W
M6P  <ET* &Y>&@!J7R8!9EXP!6)=. I>7#\/6EI$%5992AI25U >3E96(DM6
M7B1)56<E1U5Q)495?21%58HC0U69(D)5J2% 5;X@/U79'SY4\!X^4_\=/E+_
M'3Y1_QP^4?\<SU(  ,!=  "N7P  GU\  )-?  ")7P  @5X  'A>  !Q8
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M> \Q<X8.,'.5#2]SI@PN<[H++7+4"BQP[@LJ;OT-*6W_#BAL_P\H;/\/OF@
M *YN  "=;@  D&X  (1N  ![;P  <7   &5S  !<=@  4WD  $M[  !%?0L
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M !&.G0 /CK$ #8W*  V+YP .BOH #HG_ 0Z(_P$.B/\!K7T  )Q]  ".?
M@WP  'E]  !N?P  8H(  %>&  !,B@  08T  #>0   MDP  (Y4  !F7 @ 1
MF0T #YD9  V9(P ,F2P "YDV  F90  (F4L !IE7  2990 "F7,  )B#  "8
ME0  EZ@  );   "5VP  E.\  )/[  "3_P  D_\ IH,  ):"  "*@@  @((
M '2$  !HAP  7(L  %&.  !&D@  .I4  #"8   FFP  &YT  !*@   'H@(
M *,,  "C%P  HR$  *0J  "D-   I#\  *1,  "D60  I&@  *1Y  "CBP
MHI\  *&V  "?TP  GNP  )[V  ">_0  GOT GXD  )*(  "'B   >XH  &Z-
M  !BD   5I0  $N8   _G   ,Y\  "BB   >I0  %*<   JI   !JP   *P"
M  "M"P  KA4  *X?  "O*   KS,  *\^  "P2P  L%L  +!L  "P?@  KY(
M *^I  "MQ   K.,  *KT  "J_0  JOT FH\  (^.  ""D   =9,  &B7  !<
MFP  4)\  $2C   XIP  +:H  "*M   7L   #+(   .T    M0   +<   "X
M    N08  +D0  "[&@  O"0  +TO  "^.P  OTH  ,!<  # ;P  P(0  ,":
M  "_L@  O\X  +[F  "]]   O?0 EY8  (J7  !]F@  <)\  &.C  !7J
M2ZP  #^P   RM   )K8  !FX   .N@   [T   "^    OP   ,$   ##
MQ    ,8   #("0  RA0  ,T>  #/*@  T3@  -5)  #87   V'(  -B)  #7
MH0  U[<  -;/  #6XP  UN, DI\  (6B  !YIP  ;*P  %^Q  !2M0  1+<
M #6Z   HO0  &[\   W"   #Q0   ,@   #*    RP   ,P   #.    T0
M -,   #7    V@$  -X,  #B&0  Y28  .@T  #L1P  [EP  .]T  #PBP
M\*$  /"S  #PQ   \,0 CZH  (*O  !TLP  9;8  %:Y  !'O0  -\   "G$
M   <QP  #LH   +-    T0   -4   #8    V    -H   #=    WP   .(
M  #E    Z0   .T   #P!   \Q(  /8A  #Z,0  _D4  /]<  #_<P  _X@
M /^9  #_I@  _Z8 _P .!/\ "@/_  @!_P ( /\ & #_ "8 _P T /\ 00#_
M $P _P!7 /\ 8 #^ &@ ^P!P /D =@#X 'L ]P"  /8 A0#U (H ] "/ /,
ME0#R )P \0"C .\ K #M +@ ZP#( .D WP#I /, Z #_ .@ _P#H /\ Y0#_
M .0 _P#C /\ _P *!/\ !P/_  0!_P ( /\ % #_ ", _P P /\ /0#^ $D
M^P!3 /@ 70#T &4 \0!L /  <P#N '@ [0!] .P @@#K (< Z@", .D D@#H
M )@ Y@"? .0 J #A +0 WP## -T V #= .\ W #_ -H _P#6 /\ U0#_ -0
M_P#4 /\ _P &!/\  0+_   !_P $ /\ $0#] !X ^0 L /8 .0#T $0 \0!/
M .P 60#I &( YP!I .4 ;P#C '4 X@!Z .  ?@#? (, W@"( -P C@#: )4
MV "< -4 I0#3 *\ T0"] ,\ T0#. .D RP#Z ,@ _P#& /\ Q@#_ ,< _P#'
M /\ _P  !/\   +_   !_P   /P "@#T !H [P F .P - #G $  XP!+ .
M50#< %T V@!D -@ :P#5 '$ U !V -( >P#0 (  SP"% ,P BP#* )$ R "8
M ,< H0#% *L P@"X ,$ RP"^ .( N@#U +H _P"Z /\ N@#_ +H _P"Z /\
M_P   _\   '_    _P   /$ !0#J !0 Y  A -T +@#8 #L U !& -$ 3P#.
M %@ RP!@ ,D 9@#& &P Q !R ,, =P#! 'P P "! +X AP"] (T NP"5 +D
MG0"W *< M0"T +( Q0"P -L KP#P *X _@"N /\ K0#_ *T _P"M /\ _P
M O\   #_    ]0   .<   #>  T U0 ; ,\ *0#* #4 Q@!  ,, 2@#  %,
MO0!; +L 8@"Y &@ MP!N +8 <P"T '@ LP!^ +( A "P (H KP"2 *T F@"J
M *0 J "P *8 OP"E -4 I #K *, ^0"B /\ H@#_ *$ _P"A /\ _P   ?\
M  #P    Y0   -P   #2  8 R0 5 ,, (@"^ "\ N@ [ +< 10"T $X L0!6
M *\ 70"M &0 K !J *L ;P"I '4 J !Z *< @0"E (< HP"/ *$ F "@ *(
MG@"M )T O "; -$ F@#E )@ ]0"7 /\ EP#_ )8 _P"6 /\ _P   /(   #F
M"   V@H  ,X%  #%    OP , +H &@"U "< L0 T *T /P"J $D IP!1 *4
M60"D &  H@%F *$"; "? W( G@-W )T$?@";!(4 F@6- )@%E@"7!J  E0:L
M ),&NP"2!\\ D CE (X)]@"-"O\ C K_ (P*_P","O\ ^    .H0  #=&@
MS1T  ,(8  "Z$0  M@@! +( $@"L R  J <N *0*.@"A#$0 GPY- )P050";
M$5P F1)B )@2: "7$VX E1-U )04>P"2%(( D16+ (\5E ".%9\ C!6K (H5
MNP")%<\ AQ;G (47^ "$%_\ @Q?_ ((7_P""%_\ \@L  .,=  #5)P  Q"D
M +@E  "P(0  JQH  *D1" "D$QH GQ<H )L9-0"8&S\ EAQ) )0=40"2'E@
MD!Y> (\?9 ".'VL C"!Q (L@> ")(8  B"&( (<AD0"%(9P @R&I ((AN "
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M!VHP\P=I+_\':"__!V@N_P=H+O\'Y"H  -$Z  # /P  L#\  *0^  "</
MEC@  )$U  ".,@H B30; (4V* &"-C,#?S8\!7PV1 9[-TP'>3=2"'<W60AV
M-U\(=#=F"7,W;0EQ-W8);S=^"6TWB IL-Y0*:C>A"F@WL IF-L,+9#;<"V(U
M\0MA-?\+833_"F T_PI@,_\*WS$  ,U!  "[1   JT0  )]$  "700  D3X
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M$TP__Q-,/_\3U$,  ,-/  "O3P  H$\  )5/  ",3@  A4P  ']*  !Y2P
M=4P+ '%.&P!M3B<!:4XP!65-. IA2SX.7DI%$EM*2Q5825$75DA8&51(7QI2
M2&@:4$AR&T](?1M-2(D:2T>7&DE'IAI'1[D:14;2&45&[!A%1?P7143_%D5$
M_Q5%0_\5T$@  +]2  "L4@  G5(  ))2  "(4@  @5   'I.  !T4   <%$(
M &Q3& !H4R0!95,N!&%2-@A=43P-65!"$55/2!523DX84$U5&TU,7!Q+3&4=
M24QO'4A,>AU&3(<<1$R5'$-,I1M!2[<:/TO0&3]*ZAD^2?L8/TG_%S](_Q8_
M2/\6S$T  +M5  "H50  FE4  (Y5  "%50  ?50  '92  !O50  :E8$ &98
M% !C6"$ 8%@K EQ8,P985SH+5%5 #U!41A1-4TP82E)2&T=16AU%46(>0U%M
M'D%1>!U 484</U&3&SU1HQH\4;89.E'/%SE0Z1<X3_L7.$[_%SA-_Q<X3?\7
MR5(  +=8  "E6   EUD  (M8  ""6   >E@  '!7  !J6@  9%L  &!=$ !=
M7AT 6EXH 5==,01373@(3UL^#4M:1!)'64H61%A0&4%86!L_6&$;/5=K&SQ8
M=QH[6(09.EB2&#A8HQ8W5[45-E?.%#16Z10S5/H5,U/_%3)2_Q4R4O\5Q58
M +-;  "A7   DUP  (A<  !^7   =EP  &I=  !D7P  7F$  %IB"@!78QD
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M!RENGP8H;K(&)VW+!29LY@4D:OD'(VC_"2)G_PHB9_\*N&<  *1G  "49P
MAV<  'UG  !S:   :FH  %YM  !6;P  3G(  $5T   \=P4 .'@2 #9X'0 U
M>"< ,G@O 3!X-P(N>#\$+'A'!2IX4 4H>%D%)WAD!"9X< 0D=WX#(W>- R%W
MG0(@=K !'G7( 1YTY0$=<_@#'''_!!MP_P8;</\&L6L  )YL  "/:P  @VL
M 'EL  !P;0  96\  %IR  !1=0  2'@  #][   U?0  +8 ) "J %0 H@!\
M)H$H "6!,0 C@3D (8%" 2"!2P$>@54!'8%@ 1N!;  :@'H &(") !9_F@ 4
M?ZT $G[% !)]X@ 3>_8 $WK_ 1-Y_P(2>?\"JG   )EP  "+<   ?W   '5P
M  !K<@  8'0  %9X  !+?   0GX  #B!   NA   )8<  !R)"  8BA0 %XH>
M !6*)P 4BC  $XHY !&*0P 0BDT #8I9  N*90 )BG, !XF#  6)E  $B*8
M H:]  *%V  "A>T  X/[  2"_P $@O\ HW8  )-U  "&=0  ?'4  ')V  !F
M>   6WL  %!_  !%@P  .X8  #&)   GC   'HX  !21   *DP@ !)03  *3
M'0 !DR8  ),O  "3.0  DT0  )-0  "370  DVL  )-[  "2C   D9X  )"T
M  "/T   CN@  (WU  "-_0  C?X G'L  (Y[  "">@  >'L  &Q]  !@@
M580  $J(   _BP  ,X\  "J2   @E   %I<   R9   "FP   )P*  "<%
MG1T  )TF  ">+P  GCH  )Y%  ">4P  GF(  )YQ  "=@P  G98  )RK  ":
MQ0  F>,  )CU  "7_@  E_\ EH$  (F   !_@   <X(  &>&  !:B0  3XX
M $.2   XE0  +9D  "*<   8G@  #:    2C    I0   *8   "G"   IQ(
M *@:  "I(P  JBT  *HX  "J10  JU0  *MD  "J=P  J8L  *FA  "HN0
MI]@  *;N  "E^@  I?P D8<  (>'  !ZB0  ;8P  &&0  !5E   29@  #R=
M   QH   )J0  !JG   0J0  !:L   "M    KP   +$   "R    LP,  +,,
M  "T%@  MA\  +<J  "X-@  N40  +I5  "[:   NWP  +J1  "YJ@  M\8
M +;C  "U\P  M?8 CXX  (*/  !UDP  :)<  %N;  !/H   0Z4  #:I   K
MK0  '[   !.S   (M0   +@   "Y    N@   +P   "]    O@   ,    #"
M!0  Q \  ,<9  #))0  RS(  ,Y#  #/5@  T6P  -&"  #1F   T*\  -#&
M  #/W0  S^( BI<  'V:  !PGP  8Z0  %>I  !+K@  /K(  #&V   DN0
M%[L   F^    P    ,,   #$    Q0   ,<   #(    RP   ,T   #0
MTP   -@(  #<%   X"   .,O  #G00  ZE<  .IN  #KA@  ZYP  .NO  #K
MP   Z\4 AJ(  'FG  !MK0  8;(  %.V  !$N0  -+T  "7    8PP  "L8
M  #)    S0   -    #1    T@   -,   #5    V    -L   #?    XP
M .<   #K 0  \ T  /,<  #W+   ^T   /U6  #_;@  _X4  /^7  #_I@
M_ZH _P ) _\ !P'_  , _P & /\ %0#_ ", _P Q /\ /0#_ $D _P!4 /T
M7@#[ &8 ^0!L /< <@#V '@ ]0!] /0 @@#S (8 \@"+ /$ D0#O )@ [0"?
M .L J #J +, Z ## .< V@#E /  Y #_ .  _P#= /\ W #_ -L _P#9 /\
M_P & O\  0'_    _P $ /\ $@#_ "  _P M /\ .0#Z $8 ]P!0 /0 6@#R
M &( \ !I .X ;P#L '0 ZP!Z .H ?@#H (, YP"( .4 C0#C )0 X0"; -\
MI #= *\ VP"] -D T@#7 .H T@#] ,\ _P#/ /\ SP#_ ,\ _P#/ /\ _P
M O\   '_    _P   /\ #0#[ !L ^  H /( -@#O $$ [0!, .D 50#F %T
MY !E .$ :P#? '$ W0!V -L >P#9 (  V "% -4 B@#4 )  T@"8 -  H #.
M *H S "X ,D R@#$ .0 P@#X ,( _P#" /\ P@#_ ,( _P#" /\ _P   O\
M  '_    _P   /< !P#Q !8 Z@ C .4 ,0#B #P WP!' -L 4 #6 %D TP!@
M -$ 9P#/ &T S0!R ,L =P#* 'P R "! ,< A@#% (T PP"4 ,$ G "_ *8
MO "S +@ Q "W -P M@#R +4 _P"U /\ M0#_ +4 _P"U /\ _P   ?\   #_
M    ]0   .P  P#D !$ VP ? -8 *P#2 #< S@!" ,H 2P#' %0 Q !; ,(
M8@#  &@ O@!M +T <P"[ '@ N@!] +@ @@"V (D M "0 +( F "P *( K@"N
M *P O0"K -, J@#K *D _ "H /\ J #_ *@ _P"H /\ _P   ?\   #V
MZ@   .    #4  L S0 9 ,@ )0#" #$ OP \ +P 1@"Y $X M@!6 +0 70"R
M &, L !I *X ;@"M '0 JP!Y *H ?P"I (4 J ", *8 E0"D )X HP"J *$
MN "@ ,P G@#D )T ]@"= /\ G #_ )P _P"; /\ _P   /8   #K    W0
M -$   #(  0 P0 2 +L 'P"V "L LP V +  0 "M $D J@!1 *@ 6 "F %\
MI !E *, :@"B &\ H0!U *  >P"? ($ G0") )P D0": )L F "F )< M "5
M ,8 E #> ), \0"1 /T D #_ )  _P"0 /\ ^P   .T   #@!0  SP4  ,0
M  "]    MP * +$ & "M "0 J@ P *8 .P"C $0 H !, )X 5 "= %H FP!@
M )H 9@"9 &P F !Q )8 > "5 'X E "& )( CP"0 )D CP"D (T L@"+ ,0
MB@#: (@ [@"' ?H A@+_ (4"_P"% O\ \P   .4.  #4%P  Q!4  +D2  "Q
M#   K0,! *D $ "E !T H0 J )T!-0": S\ F 5( )8&3P"4!U8 DPA< )$(
M8@"0"6@ CPEN (T*=0","GP BPN$ (D+C0"'"Y@ A@ND (0+L@""#,0 @0S<
M '\.\ !^#OX ?0[_ 'P._P!\#O\ [0P  -T<  #*(@  NR(  *\?  "H&P
MHQ4  *$,!@"="18 F0TD )40+P"2$CH D!-# (T52P",%5( BA99 (D77P"'
M%V4 AAAK (48<@"#&7D @AF" ( 9BP!_&98 ?1FB 'L9L !Z&<, >!G; '8:
M\ !U&O\ =!K_ ',9_P%S&?\!YQ@  -8H  #"*P  LRL  *@I  "@)@  FR(
M )@;  "6%A  D1H? (T<*P"*'C8 AQ\_ (4@1P"$(4\ @B%5 ($B6P!_(F(
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M!UHN_P=:+O\'V3(  ,0\  "Q/0  HCX  )@]  "/.P  B3@  (0V  "!,P$
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M>!5(0X051D.1%$1#H!1"0K(40$+)$S]!Y!,_0/<2/T#_$3\__Q% /O\1R4@
M +1+  "C3   E4P  (I,  "!3   >DH  '-'  !M20  :$L" &1,$@!A31\
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M$3-4G1 R4Z\.,5/%#3!2X0TN4?4/+4__$"U._Q M3O\1OE0  *E4  "850
MBU4  (!6  !W5@  ;E8  &)7  !<60  5UL  %)<! !/71, 3%X> $I>* %'
M7C #0UTW!D!</0D\6T,,.5M*#S=;4A U6UL0-%ME$#);<0\Q6WX.,%N,#"];
MG LN6JX*+%K$"2M9X DI5_4+*%;_#"A4_PTG5/\.N5<  *18  "46   AUD
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M !1OVP 5;?( %6S_ 11K_P(4:O\#IV0  )5D  "'9   >V4  '%E  !H9@
M7F@  %-L  !+;@  0G$  #ET   P=@  )WD" "![#0 >>Q@ ''LA !M[*@ 9
M>S( &'P[ !=[1  5>TX %'M9 !)[90 0>W, #7N"  MZD@ )>:0 !WBY  9W
MTP '=NL "'3[  ES_P )<_\ H&D  )!I  "":0  =VD  &YJ  !D:P  66X
M $]Q  !%=0  /'@  #)Z   I?0  ((   !># @ .A0T "X48  J$(0 (A"H
M!X0R  :$/  $A$<  X12  &$7@  A&P  (1[  "#BP  @IT  (&R  !_S0
M?N4  'WT  !]_   ?/\ F6\  (IN  !^;@  =&X  &IO  !?<@  5'4  $EY
M   ^?   -7\  "N"   BA0  &(<   ^*   %C 4  (T/  "-&   C2$  (XI
M  ".,@  CCT  (Y)  ".50  CF,  (YS  "-A   C)8  (NJ  "*PP  B.(
M (?T  "&^@  AOX DW0  (5S  ![<P  <70  &5V  !9>0  3GT  $.!   W
MA0  +8@  ".+   :C@  $)    >2    E0   )8'  "6$   EA@  )<@  "8
M*0  F#,  )@^  "82P  F5D  )EI  "9>P  F(X  )>B  "6N0  E-@  )/O
M  "2^P  DO\ C7H  ()Y  !X>0  :WL  %]_  !3@P  2(<  #R+   PCP
M)I(  !N5   2EP  !YH   "<    G@   )\   "@!@  H X  *$7  "B'P
MHR@  *0S  "D/P  I4X  *5?  "E<0  I8,  *28  "CKP  HLL  *'G  "@
M]0  H/L B8   ']_  !S@0  9H4  %F)  !-C@  09(  #66   IF@  'IT
M !.@   (H@   *4   "G    J0   *L   "L    K0   *T(  "N$0  L!H
M +(D  "S,   M#X  +5/  "V80  M'<  +.,  "SHP  LKP  +':  "Q[0
ML/4 AX8  'J(  !MBP  8)   %25  !'F0  .IX  "ZB   BIP  %ZH   NL
M    KP   +$   "R    M    +8   "X    N0   +H   "\ @  O@L  , 5
M  #"(0  Q2T  ,<]  #)4   RV4  ,M[  #+D0  R*H  ,;$  #%W   Q>@
M@H\  '63  !HEP  6YP  $^A  !"IP  -:P  "FP   =LP  $;8   2Z
MO    +X   "_    P    ,(   ##    Q@   ,@   #*    S0   -$#  #6
M#@  VAP  -TJ  #A/   Y%(  .5I  #F@   YY8  .:J  #FN@  YL8 ?IH
M '&?  !DI0  6*H  $RP   _M0  ,;D  "&\   4OP  !<(   #%    R
M ,L   #+    S0   ,X   #/    T@   -4   #:    W@   .(   #F
M[ @  / 7  #S)@  ^#L  /I2  #[:P  ^X(  /R5  #\I   _*P _P & ?\
M @#_    _P % /\ $@#_ "  _P M /\ .P#_ $8 _P!1 /T 6@#[ &( ^0!I
M /8 < #T '4 \P!Z /$ ?P#P (0 [@") .T C@#L )0 Z@"< .@ I #G *\
MY0"^ .0 U #? .T V@#_ -@ _P#9 /\ V@#_ -4 _P#1 /\ _P   ?\   #_
M    _P   /\ #@#_ !P _0 J /H -P#Y $( ]P!, /, 5@#O %X [ !F .H
M; #H '( YP!W .4 ? #D (  X@"% .$ BP#? )$ W@"8 -L H0#9 *L UP"X
M -( S0#- .< RP#Z ,L _P#+ /\ S #_ ,L _P#( /\ _P   ?\   #_
M_P   /X "@#X !@ \@ F .\ ,@#M #T Z0!( .4 40#A %H W@!A -P : #:
M &T V !S -8 > #5 'T TP"" -$ AP#/ (T S0"4 ,H G0#' *< Q "S ,$
MQ@"_ -X O@#T +X _P"^ /\ O0#_ +T _P"] /\ _P   ?\   #_    ^@
M /, !0#J !0 Y0 @ .  +0#< #D V0!# -4 3 #1 %4 S@!< ,L 8P#( &D
MQ0!N ,, <P#! '@ OP!^ +X @P"\ (D NP"0 +D F0"X *( M@"N +0 O@"R
M -0 L0#N +  _P"P /\ KP#_ +  _P"P /\ _P   /\   #^    [P   .0
M 0#<  X U0 < ,X )P#+ #, R  ] ,4 1@#  $\ O !7 +D 70"W &, M0!I
M +0 ;@"S ', L@!Y +$ ?@"O (0 K@"+ *T E "K )T J0"I *@ MP"F ,L
MI0#F *0 ^0"C /\ HP#_ *, _P"C /\ _P   /P   #O    XP   -4   #-
M  D Q0 6 ,  (@"\ "T N  X +0 00"Q $D KP!1 *T 6 "K %X J0!D *@
M:0"G &\ I@!T *4 >@"D (  H@"' *$ CP"? )D G@"D )P L0": ,0 F0#=
M )@ \P"8 /\ EP#_ )< _P"7 /\ _P   /(   #D    T@   ,@   "_  (
MN0 0 +0 ' "O "< JP R *D / "F $0 I !, *( 4P"@ %D GP!? )T 9 "<
M &H FP!O )H =0"9 'P EP"# )8 BP"4 )4 DP"@ )$ K0"/ +X C@#5 (T
M[0", /L BP#_ (H _P") /\ ]@   .@   #5    Q@   +L   "T    K@ (
M *D %0"E "$ H@ L )\ -@"< #\ F@!' )@ 3@"6 %4 E0!; ), 8 "2 &8
MD0!L )  <@"/ '@ C0"  (P B "* )( B0"= (< J@"% +H A #0 (, Z "!
M /< @ #_ '\ _P!_ /\ [@   -X,  #*$   NP\  + +  "I!P  I0   *$
M#0"= !H F@ F )< , "4 #H D0!" (\ 2@"- %  C !7 (L 7 ") &( B %H
M (<!;P"% G8 A -] (,#A@"! Y  ?P.< 'X#J0!\ [D >@/. 'D%Y0!W!O8
M=@;_ '8&_P!V!O\ Z P  -0:  #!'   LAL  *<:  "@%@  FQ$  )D'! "7
M 1( D@0@ (X&*P","#4 B0H^ (<+1@"&#$T A U3 (,.60"!#E\ @ ]F '\0
M; !]$'0 ?!%\ 'H1A0!Y$8\ =Q&; '41J0!S$;H <1'1 ' 2Z0!N$OD ;1+_
M &T2_P!M$O\ X1D  ,LC  "X)0  JB4  * C  "8(   DQT  ) 7  "/$ H
MBQ$9 (<4)@"$%C  @1<Z '\80@!^&4D ?!I0 'L:5@!Y&EP >!MB '8;:0!U
M''$ <QQY '(<@@!P'(T ;AR9 &P<IP!K'+@ :1O. &<<YP!E'/D 91O_ 60;
M_P%D&_\!W",  ,4J  "R+   I"T  )DK  "2*0  C"8  (@B  "'' 0 @QP5
M '\>(0!]("P >B$V '@B/@!V(T8 ="-, ',C4P!Q)%D <"1? &\D9@!M)6X
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M>P98,H8&5C&2!E0QH0=2,;$'4##'!T\OX0=.+_4'32[_!TTM_P=-+/\'RS<
M +4Y  "D.P  ECL  (P[  "#.@  ?3<  '@V  !T-   <30' &TU%@!J-B(
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M#SX^F@\]/JP..S[!#CD]W TY//(-.3O_#3DZ_PTZ.O\-OT(  *I$  ":10
MC44  ()&  !Y10  <D0  &Q"  !F0P  844  %U&"P!:1Q@ 5T<C %1'*P-1
M1S(&3D8Y"4M%/PM(1$4.141,$$-$4Q%!1%P1/T1E$3U$<!$\1'P0.D2*$#A$
MF0\W0ZH.-4._#31"V@TS0?$-,T#_#C,__PXS/O\.NT4  *='  "72   BDD
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M!215V 0C4^\&(E'^"")0_PDA3_\*KE   )M1  ",4@  @%,  '53  !K4P
M8U0  %E6  !26   2UH  $1<   _7@8 .UX3 #E?'0 W7R8 -5\N 3)>-0,P
M7CP$+EY#!BQ>2P8J7E0&*5Y>!B=>:@4F7G<$)%Z%!"->E ,A7:8"(%R[ AY<
MU@$>6NX#'%C]!!Q7_P8;5O\'J%0  )95  "(50  ?%8  '%7  !G5P  7U@
M %5;  !.70  1U\  #]A   W9   ,F4, "]F%P N9B$ +&8I "IF,0$H9C@!
M)F9  B1F20(C9E("(69< B!F9P$>9G0!'&6# 1MED@ 99*0 %V.Y !5BU  6
M8>T %E_\ 15>_P(47?\#HU@  ))9  "#6@  >%H  &U;  !D7   6UT  %)?
M  !)8@  0F0  #EG   Q:0  *6P$ "1M$  B;AH (&XB !]N*P =;C, '&X[
M !IN1  9;DX %VY8 !5N8P 3;7$ $6U_  YMCP ,;*  "VNU  EJS@ *:.@
M"V;Z  MF_P ,9?\!G5T  (Q=  !_7@  <UX  &E?  !A8   5V(  $YE  !$
M:   /&H  #-M   K<   (G(  !EU!@ 4=A$ $W8; !%V(P /=BL #78T  QV
M/0 *=D< "'92  =V7@ %=FL  G5Z  !UB0  =)L  '.N  !QQP  <.$  &_R
M  !N_0  ;?\ EF(  (=B  !Z8P  ;V,  &9C  !=90  4V<  $EK   ^;@
M-7$  "UT   D=@  &WD  !)\   (?@D  G\3  !_'   ?R0  '\M  !_-@
M?D   'Y+  !^5P  ?F0  'YS  !]@P  ?94  'RH  !ZP   >=X  'CP  !W
M^0  =O\ D&<  ()G  !V9P  ;&@  &)H  !7:P  36\  $-R   X=@  +WD
M "9[   <?@  $X$   F#    A@0  (<,  "'%0  AQT  (@D  "(+   B38
M (A"  "(3@  B5P  (EK  "(?   AX\  (:B  "$N0  @]8  (+O  "!^P
M@/\ BFT  'UL  !S;   :6T  %UO  !2<P  1W<  #Q[   Q?@  )X(  !V$
M   4AP  "HH   &,    CP   (\$  "0#   D!4  )$<  "2(P  DRP  ),W
M  "31   E%(  )1A  "4<P  DX8  )*:  "1L   C\P  ([I  ",^   B_\
MA'(  'IR  !P<@  9'4  %=X  !,?   0($  #2$   IB   'HP  !6/   *
MD0   I0   "6    F    )D   ": @  FPH  )P2  "=&@  GB(  )\L  "@
M.   H$<  *%7  "A:0  H7P  *"1  "?IP  GL   )W>  "<\0  F_L @7@
M 'AX  !K>@  7GX  %*"  !%AP  .(P  "V0   BE   %I<   N:   !G
M )\   "A    HP   *0   "E    I@   *<'  "H#@  J1<  *L@  "M+
MKCD  *Y*  "O70  KW$  *^%  "NG   KK0  *W0  "MYP  K/0 ?WX  '*
M  !EA   6(D  $R.   _DP  ,I@  ":<   ;H   #J,   .F    J    *L
M  "M    KP   +    "R    LP   +0   "V    N <  +H1  "]&P  OR@
M ,$W  ##2@  Q5\  ,-W  #"C@  P:4  ,&]  # U0  P.@ >H@  &V+  !@
MD   4Y4  $:;   YH   +*4  ""J   4K0  ![    "S    M@   +@   "Y
M    NP   +T   "_    P0   ,,   #%    QP   ,H   #/"@  TA@  -8F
M  #;-P  WDP  .%C  #A>@  XI$  -^G  #=NP  W-  =9,  &F7  !<G0
M3Z,  $*I   UK@  *+,  !RW   .NP   ;X   #!    Q    ,8   #&
MR    ,D   #+    S@   -$   #4    V    -T   #A    YP0  .L3  #O
M(P  \S<  /9.  #X9@  ^7X  /F2  #ZH0  ^:X _P ! /\   #_    _P "
M /\ #@#_ !T _P K /\ -P#_ $( _@!. /L 5P#X %\ ]@!F /0 ;0#S ',
M\0!X /  ?0#O (( [0"' .P C #I ), YP": .0 HP#A *X WP"\ -P T #7
M .L U@#^ -4 _P#5 /\ U #_ ,\ _P#+ /\ _P   /\   #_    _P   /\
M"P#_ !H _  G /D ,P#V #X ] !) /  4@#M %H Z@!B .< : #C &\ X !T
M -X >0#< 'X V0"$ -< B0#5 (\ U "6 -( GP#1 *D S@"V ,P R #) .(
MR #X ,< _P#' /\ R #_ ,4 _P#" /\ _P   /\   #_    _P   /D !P#T
M !8 [P B .L +P#I #H YP!# .( 30#; %4 U0!= -( 8P#/ &D S0!O ,P
M= #+ 'D R@!_ ,@ A #' (H Q@"1 ,0 F0#" *, P "P +X P "\ -D N@#Q
M +D _P"Y /\ N0#_ +D _P"W /\ _P   /\   #_    ]P   .P  P#F !$
MW@ > -H *0#8 #0 T0 ^ ,P 1P#( %  Q0!7 ,, 7@#! &0 OP!I +T ;P"\
M '0 NP!Y +H ?P"X (4 MP", +8 E "T )T L@"J +  N "N ,X K #I *P
M_0"K /\ JP#_ *L _P"K /\ _P   /\   #T    Z    -X   #4  L S0 9
M ,@ ) #" "X OP Y +T 0@"Z $H MP!2 +4 6 "S %X L0!D +  :0"N &\
MK0!T *P >@"K (  J0"' *@ CP"G )@ I0"D *, L0"A ,4 H #? )\ ]P"?
M /\ G@#_ )X _P"> /\ _P   /4   #H    V0   ,T   #$  8 O@ 3 +<
M'P"S "D L0 S *\ / "M $4 J@!, *@ 4P"F %D I0!> *, 9 "B &D H0!O
M )\ =0"> 'L G0"" )P B@": ), F0"? )< K "5 +T E #6 )( [P"1 /\
MD0#_ )$ _P"1 /\ ^@   .P   #9    R@   +\   "W    L  , *L &0"H
M "0 I0 M *, -P"A #\ GP!' )T 3@"; %0 F0!9 )@ 7P"6 &0 E0!J )0
M< "2 '8 D0!] (\ A0". (\ C ": (L IP") +< B #. (< Z "& /H A@#_
M (8 _P"& /\ \0   -\   #,    O0   +,   "L    I@ & *( $P"> !X
MFP H )D ,0"6 #H E !" )( 20"0 $\ CP!5 (T 6P", &  B@!F (D ; "(
M '( A@!Z (4 @@"$ (P @@"7 ($ I "  +, ?@#' 'T X@!\ /4 >P#_ 'H
M_P!Z /\ Z0   -,'  # "0  L@@  *@'  "A @  G0   )D "P"6 !< DP B
M )  + "- #4 BP ] (@ 1 "' $L A0!1 (0 5P"# %P @0!B (  : !_ &\
M?@!W 'P ?P![ (D >0"5 '< H0!V +$ = #$ ', W0!Q /  < #\ '  _P!P
M /\ X@P  ,H3  "W%0  J18  )\4  "8$0  DPL  )$$ P"/ !  BP < (@
M)P"% #  @@(Y ($#0 !_!$< ?05- 'P&4P![!ED >0=? '@'9@!W!VT =0AU
M '0(?@!R"(@ < B4 &X(H0!M"+  :PC$ &D(W !H"O  9PK] &8*_P!F"O\
MV1@  ,$<  "P'@  HA\  )@>  "0&P  BQ@  (@3  "'"P< A D5 ($+(0!^
M#2L >PXT 'D0/ !X$4, =A)* '034 !S$U8 <1-= ' 48P!N%&L ;11S &L5
M? !I%8< 9Q63 &84H !D%+  8A3% & 4W@!?%?, 7A7_ %X5_P!=%/\ T2
M +HC  "I)@  G"8  )$E  "*(P  A"$  ($=  !_&   ?14/ 'D7' !V&"<
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M!$XLF@1,*ZL$2BN^!$@JV01'*? $1RC_!4<H_P5')_\%P2\  *PR  ";-
MCC4  (0U  !\-   =C(  '$P  !M+P  :2X" &8N$0!C,!P 8# F 5TQ+@);
M,38#63$]!%<Q0P15,4H%5#%0!5(Q5P90,5\&3S%H!DTQ<@9+,7X&23&*!D<Q
MF 9%,*D&0S"\!D$OU@9 +NX'0"W^!T L_P= +/\'O#,  *@V  "8.   BSD
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M0   :C\  &0^  !>/0  6CX  %4_!0!20!, 4$$= $U")@%*02T#1T$T!45
M.@A"0$$*0#]'"ST_3PP[/U<,.3]@##@_:PPV/W<,-#^%"S,_DPHQ/Z0),#ZX
M"2X^T0@M/>L)+3O["BTZ_PHM.O\*L#X  )Y   ".00  @D(  '=#  !N0P
M9T,  &!"  !90@  5$0  %!% 0!,1@X 2D<: $A'(P!%1RL"0D<Q!#]&. <\
M1CX).45%"C=%30LU154,,T5?##)%:0LP178*+T6#"2Y%D@@L1:,'*T2W!RE$
MT 8H0NH')T'[""= _PDG/_\*K4$  )I#  "+10  ?T8  '1&  !K1@  8T8
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M 192_P(44O\#GDT  (Y.  " 3P  =%   &E1  !@40  6%(  %!3  !(5@
M05@  #E;   R70  *E\& "9@$0 D81H (V$B "%A*P @83( 'F$Z !UA0P ;
M84P &6%6 !=A80 686X %&!\ !%@BP /7YT #5ZP  M=R  +7.0 #5KW  U9
M_P -6/\!F5$  (E2  !\4P  <%0  &55  !=50  558  $Q8  !#6P  /%X
M #1@   L8P  )&4  !QH"0 9:!, %V@< !5H)  4:2P $VDU !%I/0 .:4<
M#&A1  IH70 (:&D !F=W  1GAP "9I<  6:K  !DP@  8]T  6'P  )@_  #
M7_\ DU8  (17  !W6   :U@  &)9  !:60  45L  $A=   ^80  -F0  "YF
M   F:0  '6P  !5N   +<0H "'$5  9Q'0 $<28  W N  )P-P  <$$  '!+
M  !P5P  <&,  &]R  !O@0  ;I(  &ZE  !MO   :]H  &GM  !H^   9_\
MC5L  ']<  !R7   9UT  %]=  !67@  3&$  $-D   X9P  ,&H  "=M   >
M<   %G(   UU   $> 8  '@/  !X%P  >1\  'DG  !Y+P  >3D  'E$  !Y
M4   >5T  'EK  !X>P  =XT  '>@  !VM@  =-,  '/M  !R^0  <?X AV
M 'IA  !N80  9&$  %MB  !190  1V@  #QK   R;P  *'(  "!U   7>
M#GH   5]    ?P(  ( *  " $@  @1D  ((@  "")P  @S   (,[  "#2
M@U4  (-D  "#=   @H<  (&:  " L   ?\P  '[H  !\^   ?/\ @68  '5F
M  !K9@  868  %9I  !+;0  0'   #5T   K>   (7L  !=^   -@   !8,
M  "&    B    (D"  "*"0  BA$  (L8  ",'P  C2<  (XP  "./@  CDP
M (];  "/;   CG\  (V4  ",J@  B\,  (GC  "(]   B/X ?&P  ')K  !H
M:P  7&X  %!R  !$=@  .7H  "U^   B@@  &(4   V(   #BP   (X   "0
M    D@   )0   "5    E@8  )8-  "7%0  F1T  )LE  "<,0  G#\  )Q/
M  "=8   G70  )R)  ";H   FK@  )G4  "7[0  E?H >7$  '!Q  !C=
M5G@  $I\   ]@0  ,84  "6*   :C@  #I$   24    E@   )D   ";
MG0   )\   "@    H0   *("  "C"0  I1(  *<:  "I)0  JC(  *I#  "K
M50  K&D  *M_  "KE0  JJT  *G'  "HX0  J/$ =W<  &IZ  !=?@  48(
M $2(   VC@  *I(  !Z6   2F@  !IT   "@    H@   *4   "G    J0
M *L   "L    K0   *X   "P    L@0  +0-  "W&   N20  +HS  "\1P
MO5P  +UR  "]B   O9\  +RW  "\T   N^4 <H   &6$  !8B0  2X\  #Z5
M   PFP  ))\  !>D   *IP   *H   "M    L    +(   "T    M@   +<
M  "Y    NP   +T   "_    P0   ,0   #)!@  S!,  - @  #4,0  V$<
M -Q=  #:=P  UY   ->F  #6N@  ULT ;8L  &&0  !4E@  1YP  #BB   K
MJ   'JT  !*R   %M0   +@   "[    O@   ,$   #"    PP   ,4   #&
M    R0   ,P   #/    T@   -8   #<    X@   .8.  #J'P  [S(  /))
M  #U8@  ]GD  /:.  #UH   ]*\ _P   /\   #_    _P   /\ "P#_ !H
M_P H /\ - #_ #\ _P!) /H 4P#T %L [P!C .P :0#K &\ Z0!U .@ >@#G
M (  Y@"% .0 BP#C )$ X@"8 .  H0#> *L W0"Y -H SP#7 .@ U #] -(
M_P#2 /\ SP#_ ,D _P#% /\ _P   /\   #_    _P   /\ "0#^ !8 ^0 D
M /< +P#V #H [P!$ .D 3@#F %8 XP!= .  9 #> &H W !P -H =0#9 'H
MV "  -8 A@#4 (P TP"3 -$ G #/ *8 S0"R ,L Q@#( .  Q@#W ,0 _P##
M /\ PP#_ +X _P"\ /\ _P   /\   #_    _0   /< ! #O !, ZP ? .<
M*@#@ #4 W@ _ -L 2 #7 %$ TP!8 -$ 7@#. &0 S !J ,H ;P#( '4 Q@!Z
M ,4 @ #$ (8 P@". ,$ E@"_ *  O0"K +L O "Y -4 MP#O +4 _P"T /\
MM #_ +0 _P"R /\ _P   /\   #\    \    .@   #@  T V0 ; -$ )0#.
M #  S  Z ,H 0P#& $L PP!2 ,  60"^ %\ O !D +H :@"Y &\ MP!T +4
M>P"T ($ LP"( +$ D "P )H K@"E *T M "K ,D J0#F *@ ^P"G /\ IP#_
M *< _P"G /\ _P   /L   #N    X0   -8   #.  @ Q  5 ,  (0"] "H
MNP T +D /0"V $4 LP!, +$ 4P"O %D K0!> *P 9 "J &D J0!O *< =0"E
M 'L I "" *( B@"A )0 GP"> )T K "< +\ FP#; )H \P"9 /\ F #_ )@
M_P"8 /\ _@   /    #>    T    ,4   "\  , M0 0 +$ &P"N "4 K  N
M *H . "H $  I@!' *, 30"A %, GP!9 )T 7@"; &0 F@!I )D ;P"7 '8
ME@!] )4 A0"3 (X D@"9 )  IP"/ +< C@#0 (T ZP", /X C #_ (P _P",
M /\ ]@   .(   #0    P0   +<   "N    J0 * *4 %0"B "  GP I )T
M,@"; #H F !" )8 2 "4 $X DP!4 )$ 60"0 %\ CP!D (T :@", '$ BP!X
M (D @0"( (H AP"4 (4 H@"$ +$ @P#& (( XP"! /< @0#_ ($ _P"  /\
M[    -8   ##    M    *H   "D    GP $ )H $ "7 !H E  D )$ +0"/
M #4 C0 ] (L 1 "* $H B !/ (< 50"& %H A !@ (, 9@"" &T @0!T '\
M?0!^ (8 ? "1 'L G@!Y *T > #  '< VP!V /( =@#_ '8 _P!U /\ X
M ,D   "X @  J@,  * "  "9    E@   )$ "0". !0 BP > (@ * "& #$
MA  X (( /P"! $8 ?P!+ 'X 40!\ %< >P!< 'H 8@!X &D =P!Q '8 >0!T
M (, <P". '$ FP!O *D ;@"\ &T U0!L .T :P#Z &H _P!J /\ U@@  , ,
M  "M$   H1   )<.  "0"P  BP<  (D  0"&  T @P 8 ($ (@!^ "P ?  T
M 'H .P!X $( =P!( '4 30!T %, <@!9 '$ 7P!P &8 ;@!N &T =P!K 8$
M:0&, &@ F0!F *@ 9 "Z &, T@!A >D 80+W & "_P!@ O\ SA$  +@5  "F
M&   FAD  ) 8  "(%P  @Q0  ( .  !_!P4 ?0(2 'H#'0!W!2< = 8O '('
M-P!Q"#X ;PE$ &X*2@!L"E  :PM7 &D,70!H#&4 9@QM &0,=@!C#($ 80R,
M %\,F0!=#*D 6PR[ %D,TP!8#>H 5PWY %<-_P!7#/\ QAD  +$<  "@'P
MDR   (D@  ""'P  ?1P  'D9  !W%   =@X* ',.%P!P$2( ;1(K &L3,P!I
M%#H 9Q5! &851P!D%DX 8Q94 &$76P!@%V( 7A=K %P7= !:%W\ 61>+ %<7
MF !5%Z@ 4Q>Z %$6TP!0%^P 3Q;\ $\6_P!/%O\ P!\  *LC  ";)   CB4
M (0F  !\)0  =R,  ',@  !P'0  ;AD% &P8$P!I&AX 9ALG &0<, !B'3<
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M!#HJS00Y*>@$.2CZ!#DG_P0Y)_\$LBP  )\P  "0,0  @S,  'DS  !P,@
M:C(  &0P  !@+@  72X  %DN!P!6+Q0 4S > %$P)@%/,2T"3#$T THQ.P1)
M,4$$1S%(!44Q3P5#,5<&03%@!C\Q:@8],78&.S&#!CDQD08W,*$%-2^T!3,O
MS 4R+N8%,BWY!C(L_P8S+/\&KC   )PS  ",-0  @#8  '8V  !M-@  9C8
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M!2 [_P8@.O\'HSL  )$]  "#/P  =S\  &Q   !C0   7$$  %5!  !-00
M1T,  $-%   _1@0 .T<0 #E'&@ W1R( -$<I 3)', (P1S<$+D<^!2Q'1@4J
M1T\%*$=8!2='8P0E1V\$(T=] R)'C (@1IP"'D:O 1U%QP$<1.(!&T+V QI!
M_P0:0/\%GSX  (Y   " 0@  <T,  &E#  !@1   6$0  %%%  !)1@  0D@
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M6P +6V< "5MU  =:A  %6I0  UFG  )8O0 "5M@  U7M  14^P %4_\ D$L
M (%,  !S30  9TX  %Y.  !63P  3T\  $=1   ^5   -E<  "]9   G7
M'UX  !=A P 08PP #6,6  MC'@ )8R8 "&,N  9C-P %8T   V-+  %B5@
M8F(  &)P  !A?P  88\  &"B  !?MP  7M0  %SJ  !;]P  6OX BT\  'Q1
M  !O4@  8U(  %I2  !34P  2U0  $)7   Y6@  ,%T  "A?   @8@  &&4
M !!G   ':@<  6L0  !K&   :R   &LH  !K,0  :SH  &I%  !J4   :EP
M &IJ  !I>@  :8H  &B=  !GL@  9LX  &7J  !C]@  8OT A50  '96  !J
M5@  8%8  %A6  !/5P  1EH  #Q=   S8   *F0  "%F   9:0  $6P   AO
M    <00  '(+  !R$P  <QH  ',A  !T*0  =#(  '0]  !T20  <U8  '-D
M  !S=   <H4  '&8  !QK0  <,@  &[F  !M]P  ;/\ ?UH  '%;  !F6P
M75L  %5;  !*7@  0&$  #9E   L:   (FP  !EO   0<@  "'0   !W
M>0   'H&  !Z#0  >Q0  'P;  !](@  ?BH  '\T  !^00  ?DX  'Y<  !^
M;0  ?7\  'R2  ![J   >\$  'GA  !X]   =_X >5\  &U@  !C8   6F
M $]B  !$9@  .6H  "]N   D<@  &G4  !%X   '>P   'T   "     @@
M (,   "$!@  A0T  (84  "'&@  B"(  (HJ  "*-P  BD4  (I4  "*9
MBG<  (F+  "(H@  A[H  (;9  "$\0  @_P =&4  &EE  !A90  56@  $EK
M   ]<   ,G0  "=X   <?   $7\   >"    A0   (<   "*    C    (X
M  "/    D 0  )$*  "2$0  E!@  )4@  "7*P  ESH  )=*  "86P  F6T
M )>#  "7FP  E;,  )/1  "2Z@  D?< <&L  &AJ  !;;0  3W$  $)V   V
M>P  *H   !Z$   3AP  !XH   "-    D0   )0   "6    F    )H   ";
M    G    )T   "?!0  H0P  *,5  "E'0  IRH  *<[  "H30  J6   *EV
M  "HC@  IJ8  *7!  "DW   I.T ;W   &)S  !5=P  27P  #N"   NAP
M(8P  !61   )E    )<   ":    G0   *    "B    I    *8   "G
MJ0   *H   "K    K0   *\(  "R$@  M1X  +@M  "X0   N50  +IK  "Y
M@@  N9H  +BQ  "WRP  M^$ :GD  %U^  !0@P  0XD  #2/   HE   &YH
M  Z>   !H0   *0   "G    J@   *P   "N    L0   +,   "U    MP
M +D   "Y    O    +\   ## @  R T  ,P;  #.+   T$,  -%<  #1=
MT8L  -*B  #1M@  T<H 980  %B*  !+D   /98  #"=   BH@  %:<   BK
M    KP   +(   "V    N    +H   "\    O@   ,    #"    Q    ,<
M  #*    S    -    #4    W    .$*  #F&@  ZBT  .Y$  #R70  \'<
M .^/  #MI   [K, _P   /\   #_    _P   /\ " #_ !@ _P D /\ , #\
M #L ^@!% /< 3@#T %< \0!> .\ 9 #M &L ZP!P .D =@#G 'L Y@"! .0
MAP#C (X X0"6 .  GP#> *D W "W -H RP#8 .< U #] -( _P#/ /\ R@#_
M ,0 _P#  /\ _P   /\   #_    _P   /\ !@#[ !0 ]P @ /$ *P#O #8
M[@!  .L 20#G %$ Y !9 .$ 7P#? &4 W !K -L < #9 '8 U@![ -0 @0#2
M (@ T0"0 ,\ F0#- *, RP"P ,D P0#' -L Q0#W ,, _P#  /\ OP#_ +D
M_P"V /\ _P   /\   #_    ^P   /(  @#M !  XP ; .$ )@#? #$ W0 [
M -H 1 #6 $P T@!3 -  60#- %\ RP!E ,D :@#' '  Q0!U ,, >P#  ((
MO@"* +P DP"Z )T N "I +8 N "U ,X M #N +, _P"R /\ L #_ *\ _P"L
M /\ _P   /\   #U    [    .,   #6  H T0 7 ,T (0#+ "L R0 U ,@
M/@#$ $8 P0!- +T 4P"Y %D MP!? +0 9 "R &H L0!O *\ =0"N 'P K "$
M *L C0"I )8 J "B *8 L "D ,0 HP#C *( ^@"A /\ H0#_ *$ _P"@ /\
M_P   /8   #G    V@   ,\   #$  4 OP 2 +L '0"Y "8 MP O +0 . "P
M $  K0!( *H 3@"I %0 IP!9 *4 7@"D &0 HP!I *$ ;P"@ '8 G@!^ )T
MA@"< )  F@"< )D J0"7 +H E@#8 )4 \@"4 /\ DP#_ ), _P"3 /\ ^0
M .8   #6    R    +P   "U    KP , *P %P"I "$ I0 J *, ,P"B #L
MGP!" )T 20"; $X F@!4 )@ 60"7 %X E0!D )0 :@"2 '  D !X (\ @ ".
M (H C "6 (L HP"* +, B #+ (@ Z0"' /T AP#_ (< _P"' /\ [P   -H
M  #'    N    *\   "H    HP ' )X $@": !P F  E )8 +@"5 #8 DP ]
M )  1 ". $H C0!/ (L 5 "* %D B0!? (< 90"& &L A0!S (, >P"" (4
M@0"0 (  G0!^ *T ?0#! 'P WP!\ /8 >P#_ 'L _P![ /\ X@   ,P   "Z
M    K    *,   "=    EP ! )( # "/ !< C0 @ (L *0") #$ AP X (4
M/P"$ $4 @@!* ($ 4 "  %4 ?@!: 'T 8 !\ &< >@!N 'D =P!X ($ =@",
M '4 F0!S *@ <@"Z '$ U !P .\ < #_ '  _P!P /\ U@   ,    "N
MH@   )@   "1    C0   (D !@"& !$ A  ; ($ ) !_ "P ?@ S 'P .@!Z
M $$ >0!& '< 3 !V %$ = !7 ', 70!R &, < !K &\ <P!M 'T ; "( &H
ME0!I *0 9P"T &8 S0!F .@ 90#Z &4 _P!D /\ S $  +8&  "F"   F0H
M (\*  "(!P  A ,  ($   !^  H ?  5 'D 'P!W "< =0 O ', -@!Q #P
M< !" &X 2 !M $X :P!3 &H 60!H &  9P!H &8 <0!D 'L 8P"& &$ D@!?
M *$ 7@"R %P R !< .0 6P#T %H _@!: /\ PPH  *X0  ">$@  D10  (<4
M  " $@  ? X  '@*  !W! 0 =0 . ', &0!P "( ;0 J &L ,@!I 3D : (_
M &8#10!E TL 8P11 &($5P!@!5X 7P5F %T%;P!<!7D 6@6% %@%D0!6!:
M5 6Q %,$QP!2!>  407Q %$%_0!1!?\ O!(  *@6  "8&0  BQL  ($;  !Z
M&@  =!@  '$4  !O$   ;@D' &P'$P!I"1T 9@HF &0++@!B##4 80T[ %\-
M0@!>#D@ 7 ]. %L050!9$%P 5Q!E %80;@!4$7D 4A&% % 1D@!.$*$ 3!"S
M $H/R@!)#^, 20_U $@._P!(#O\ MA@  *(<  "3'@  AB$  'PA  !T(
M;A\  &H<  !H&0  9A4  &42#0!B$QD 7Q4B %T5*@!;%C$ 61<X %@7/P!6
M&$4 51A+ %,84@!1&5H 4!EB $X9; !,&7< 2AF# $@9D !&&:  1!BQ $(8
MR !!%^, 01?V $$7_P!!%O\ L!T  )XA  ".(P  @B4  '@F  !P)0  :20
M &4B  !B'P  7QT  %X;"0!;&Q4 6!P? %8=)P!4'BX 4A\U %$?/ !/'T(
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M RPG_P0L)O\$I"D  ),L  "$+@  >#   &XP  !E,0  7C$  %@P  !4+P
M4"T  $PN  !)+PD 1B\5 $0P'@!","4 0#$L 3TQ,P([,3D#.3% !#@Q2 0V
M,5 %-#%9!3(Q8P0P,6\$+C%[!"PQB@,J,)H#*#"L R<OP@(E+MT")2WS R4L
M_P0F*_\$H2T  ) O  "!,@  =3,  &LT  !B-   6S0  %0T  !/,P  2S(
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M7@(>0FH!'$)W 1I"A@ 8098 %D&I !5 OP 3/]H %#[Q !0\_P$4._\"EC<
M (4Z  !X/   :ST  &$]  !8/@  43X  $H_  !$0   .T(  #9$   Q10
M+4<% "E(#P G2!@ )4@@ "-))P A22\ ($DV !Y)/@$<24< &TE1 !E)7  7
M26@ %4EU !-(A  11Y0 #D>G  Q&O  +1=8 #$3O  U"_0 -0?\!DCL  ($^
M  !T/P  :$   %U!  !500  34(  $="  ! 1   .$8  #-(   M2@  )DP
M "%."@ >3Q0 '$\< !I/(P 83RL %T\R !5/.P 43T0 $D]. !!/60 -3V4
M"D]R  A.@0 &3I$ !4VC  -,MP "2]$  TKI  5)^0 %2/\ C4   'U"  !P
M0P  9$0  %I%  !110  2D4  $1&   ]2   -$L  "Y-   H3P  (5$  !E4
M!  35@T $586  Y6'@ -5B8 "U8N  I6-@ (5C\ !E9)  165  "56   %5M
M  !5?   5(P  %.>  !2LP  4<X  %#F  !/]0  3_T B$0  'E&  !K1P
M8$@  %9(  !.2   2$D  $%*   X30  ,%   "E2   B5   &E<  !-:   *
M70@ !%T1  )=&0  72$  %TI  !=,0  73H  %U$  !=3P  75L  %QI  !<
M>   6X@  %N:  !:K@  6<D  %CF  !6]   5?P @DD  '-+  !F3   7$P
M %-,  !,3   1$T  #Q0   S4P  *U8  "-8   ;6P  %%X   M@   #8P4
M &0-  !E%   91L  &4C  !E*P  930  &4^  !E20  954  &5C  !D<@
M8X,  &.5  !BJ@  8<0  &#B  !?]0  7OT ?$X  &Y0  !B4   6%   %%0
M  !)40  /U,  #96   M6@  )%T  !M@   38P  "V4   -H    :@(  &L)
M  !L$   ;!8  &T=  !N)   ;RT  &\W  !N0@  ;D\  &Y=  !N;0  ;7X
M &R0  !KI0  :[X  &K>  !I\P  9_X =E0  &E5  !>50  5E0  $Y5  !$
M5P  .5L  #!>   F8@  '&4  !-H   *:P   VX   !P    <P   '0#  !U
M"0  =A   '<6  !X'0  >24  'HN  !Z.@  >4<  'E6  !Y90  >'<  '>+
M  !VH   =;@  '76  !S\0  <_P <%D  &1:  !<60  4UD  $E<   ]7P
M,F,  "AH   >:P  %&\   ER   "=0   '<   !Z    ?    'T   !_ @
M@ @  ($.  ""%0  A!P  (4E  "'+P  ACT  (5-  "%70  A6\  (2#  "#
MF@  @K$  ('/  "!ZP  ?_H :U\  &)>  !97@  3F$  $)E   V:0  *VX
M !]R   5=@  "7H   !]    ?P   ((   "$    A@   (@   ")    BP
M (P&  "-#   CQ0  )$;  "3)   E#(  )-#  "35   E&8  )-[  "2D@
MD:L  (_'  ".Y0  CO4 :&0  &!D  !49P  2&L  #MP   N=0  (GH  !9^
M   *@@   (4   "(    BP   (T   "0    D@   )0   "6    EP   )@
M  ": @  G D  )X1  "A&0  HR0  *0U  "C20  I%L  *5O  "DAP  HZ$
M *&\  "?W0  G?  9VH  %IM  !.<0  078  #1\   F@0  &H8   R*   !
MC@   )$   "5    F    )L   ">    H    *(   "C    I0   *<   "H
M    J@   *P#  "O#   LQ8  +8E  "V.   MDP  +AA  "W>@  MI,  +2L
M  "SQ@  L]\ 8G,  %5W  !(?0  .H,  "V)   ?C@  $I0   29    G
M )\   "B    I0   *@   "J    K    *X   "P    L@   +,   "T
MMP   +D   "]    P@D  ,88  #**0  RCX  ,Q5  #-;@  S88  ,V=  #-
MLP  S,@ 77X  %"#  !"B@  -)$  ":7   9G0  "Z(   "F    J0   *P
M  "O    L@   +4   "X    N@   +P   "_    P0   ,0   #&    R
M ,P   #0    V    -T%  #A%0  Y2@  .E   #J7   Z'<  .F-  #JH@
MZK( _P   /\   #_    _P   /\ " #_ !0 _P @ /\ + #^ #< _ !! /D
M2@#V %( ] !9 /( 8 #P &8 [@!K .P <0#J '8 Z !\ .8 @P#C (H X "2
M -T G #; *< V "V -4 R@#4 .< TP#\ -, _P#/ /\ Q0#_ +\ _P"[ /\
M_P   /\   #_    _P   /\  P#U !$ \P ; /( )P#P #( \  \ .P 10#I
M $T Y0!4 .$ 6@#< &  V0!F -4 :P#2 '$ T !V ,X ?0#, (0 R@", ,@
ME0#& *$ Q "N ,( P0#  -P O@#U +P _P"\ /\ N #_ +0 _P"Q /\ _P
M /\   #_    ]P   .X   #F  P XP 8 .  (@#> "P W0 V -< /P#/ $<
MS !. ,D 5 #& %H Q !@ ,( 90#  &L OP!P +T =P"[ 'T N0"% +< C@"U
M )D M "G +( MP"P -  K@#M *T _P"L /\ J@#_ *8 _P"D /\ _P   /P
M  #R    Z    -D   #3  < S@ 3 ,L '@#& "< P0 Q ,  .@"] $( N@!)
M +< 3P"U %4 LP!: +$ 7P"O &4 K0!J *L < "J '< J !_ *8 B "D )(
MHP"? *( KP"@ ,0 GP#B )X ^P"= /\ G0#_ )L _P"9 /\ _P   .X   #@
M    T@   ,<   "_  ( N@ - +0 &0"Q ", KP K *X - "L #P J0!# *8
M2@"D $\ H@!5 *$ 6@"? %\ G@!D )P :@"; '$ F0!Y )< @0"6 (L E "7
M )0 IP"2 +D D0#5 (\ \P"/ /\ C@#_ (X _P". /\ \0   .    #.
MOP   +8   "O    J  ( *0 % "A !T GP F )T +P"< #< F@ ^ )@ 1 "6
M $H E !/ ), 5 "1 %H D !? (X 90"- &L BP!S (D >P"( (4 A@"0 (8
MH "% +$ A #) (, Z0"" /X @@#_ (( _P"" /\ YP   -    "]    L
M *@   "A    F@ # )< #@"4 !@ D0 A )  *@". #$ C0 Y (L /P") $4
MB !+ (8 4 "% %4 @P!: (( 8 "  &8 ?P!N 'T =@!\ (  >P"+ 'H F0!Y
M *D > "^ '< W0!V /8 =@#_ '8 _P!V /\ V0   ,,   "Q    I    )L
M  "4    CP   (L "0"( !, A@ < (0 )0"# "P @@ T (  .@!^ $  ?0!&
M 'L 2P!Z %  > !6 '< 6P!U &( = !I '( <0!P 'L < "' &\ E !M *,
M; "V &L T0!J .T :@#_ &H _P!J /\ S    +8   "F    F@   )    ")
M    A@   (( ! !_  T ?  7 'H ( !Y "@ =P O '8 -0!T #P <@!! '$
M1P!O $P ;@!1 &T 5P!K %X :0!E &< ;0!F '< 90"# &0 D !B )\ 80"P
M &  QP!? .0 7P#Y %\ _P!? /\ P@   *T   ">!   D 8  (<%  "  P
M?    'H   !V  @ =  2 '( &P!O ", ;@ J &P ,0!J #< :0 ] &< 0P!F
M $@ 9 !. &, 5 !A %H 8 !B %X :@!= '0 6P"  %H C !8 )L 5P"K %4
MP !5 -T 50#T %4 _P!4 /\ N00  *8)  "6#   B0\  '\/  !X#0  = H
M ' %  !O  , ;  , &H %0!H !X 9@ F &0 +0!B #, 8  Y %\ /P!> $4
M7 !+ %L 40!9 %@ 6 !? %8 : !5 '( 4P!^ %$ B@!/ )D 30"I $P O0!,
M -D 2P#N $H ^@!* /\ L0L  )\1  "/%   @Q8  'D6  !R%@  ;!0  &D0
M  !F"P  9@8& &0"$ !A AD 7P,A %T$*0!;!2\ 608V %@&/ !6!T( 50A(
M %,(3P!2"%8 4 E> $X)9P!-"7$ 2PE] $D)B@!'"9D 10BI $0'O0!"!M8
M00?K $$'^0!!!_\ K!(  )H6  "*&@  ?AL  '0<  !L'   9AH  &(8  !?
M%0  7A$  %T+" !;"Q0 6 T= %8.)0!4#RP 4Q S %$1.0!/$3\ 3A)& $P2
M30!+$E0 21-< $<39@!%$W$ 0Q-] $$3B@ _$YD /1*K #L1P  Y$-H .1#O
M #D0_  Y$/\ IQ<  )4:  "&'@  >B   ' A  !G(0  82   %P>  !9&P
M5QD  %86 P!4%0\ 4189 $\7(0!-%RD 3!@O $H9-@!(&3P 1QE# $4:2@!$
M&E( 0AI: $ :9  ^&F\ .QI[ #D:B0 W&I@ -1FI #,9O@ Q&-D ,1CP #(7
M_@ R%O\ HQL  )$>  "#(@  =R0  &PE  !D)0  720  %@C  !4(0  4AX
M % <  !-' L 2QT6 $D>'@!''B8 11\L $,?,P!"(#D 0"!  #\@2  ](4\
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M7@(I+&D")RQV B4LA $C*Y0!(2NF 1\JNP >*=4 'BGM 1XH_0(>)_\"F"8
M (<I  !Y*P  ;2T  &(N  !:+P  4B\  $TN  !(+@  0RT  #\N   [+P
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M !(]@  0/)  ##NA  H[M0 ).LX "CGH  LX^0 ,-_\ C3$  'TT  !O-0
M8S<  %DW  !0.   23@  $,Y   ].0  -CL  # ]   K/@  )D   "%""0 >
M0A( '$,: !M#(0 90RD %T,P !9$.  41$$ $D-+ !!#5@ -0V$ "T-N  E#
M?0 '0HP !$&>  ) L0 !/\L  C[D  0]]0 %//\ B34  'DX  !L.0  8#H
M %4[  !-.P  1CP  $ \   Z/0  ,S\  "U!   G0P  (44  !I'!  620T
M$TH6 !%*'0 /2B4 #4HL  M*-  )2CT "$I'  9)4@ $25T  4EJ  !)>0
M2(D  $>:  !&K@  1<<  $3B  !#\@  0_L A#H  '4\  !G/0  7#X  %(^
M  !*/P  0S\  #T_   W00  +T,  "A&   B2   '$H  !5-   -3P@ "% 1
M  50&0 #42$  E H  !0,   4#D  %!"  !030  4%D  %!F  !/=0  3X4
M $Z7  !-JP  3,,  $OA  !*\@  2?L ?SX  '!   !C00  6$(  $]"  !'
M0@  04(  #I#   R1@  *T@  "-+   <30  %E    Y2   &508  %<-  !7
M%0  6!P  %@C  !8*P  5S,  %<]  !72   5U0  %=A  !7<   5H$  %:3
M  !5J   4\   %+>  !1\P  4?T >D,  &M%  !>1@  5$8  $Q&  !%10
M/D8  #5)   M3   )4\  !U1   65   #E8   =9    7 0  %T*  !>$0
M7A<  %\>  !@)0  8"X  & W  !@0@  7T\  %]<  !?:P  7GP  %Z/  !=
MI   7+L  %K;  !:\@  6?X =$@  &9*  !:2@  44H  $I)  !"2@  .4T
M #!0   G4P  'E8  !99   .6P  !EX   !A    8P   &0&  !E#   9A(
M &<9  !H(   :2<  &DQ  !I/   :4D  &E7  !H9@  :'< _^)]$$E#0U]0
M4D]&24Q%  \5 &>*  !FGP  9;8  &35  !C\   8OT ;4X  &%.  !73@
M3TX  $=.   ]40  ,U0  "I7   @6P  %EX   QB   %9    &<   !J
M;    &T   !O!@  < L  '$2  !R&   ="   '4H  !U,P  =4   '1/  !T
M7@  <W   '*$  !QF0  <+$  &_/  !OZP  ;OL :%,  %U3  !44P  35(
M $)5   V60  +%T  "%A   790  #&D   -L    ;P   '$   !T    =@
M '<   !Y    >@0  'P*  !]$0  ?Q@  ( @  ""*@  @C<  (%&  "!5P
M@&@  (!]  !^D@  ?*H  'O&  ![Y@  >_< 8UD  %I8  !36   1UH  #M?
M   O8P  )&@  !AL   ,<    G0   !W    >@   'T   !_    @0   (,
M  "%    A@   (@!  "*!P  BPT  (X6  "0'P  DBH  )$Z  "03   D%\
M (]S  ".B@  C*(  (N^  "*W@  B?, 8%X  %E=  !-8   0&4  #-J   G
M;P  &G0   YX   "?0   (    "#    A@   (D   "+    C0   (\   "1
M    DP   )0   "6    F 0  )H+  "=%0  H!X  *(M  "@00  H%0  *!I
M  "@?P  GID  )VT  ";TP  FNT 8&,  %-F  !&:P  .7   "QV   ??
M$H$   6%    B0   (P   "/    D@   )4   "8    FP   )T   "?
MH0   *,   "D    I@   *D   "L!P  L!   +0>  "T,0  LT<  +1;  "V
M<0  M(L  +.E  "QP0  K]T 6FP  $UQ  ! =P  ,GT  "2#   7B0  "(X
M  "2    E@   )H   ">    H0   *0   "F    J    *L   "M    KP
M +$   "R    M    +<   "[    OP0  ,40  #*(0  R38  ,M-  #-9
MS'X  ,J7  #(L   Q\8 57<  $=]   ZA   *XL  !V1   .EP   9T   "A
M    I0   *@   "K    K@   +    "S    M0   +<   "Z    O    +X
M  #!    P@   ,8   #*    SP   -<#  #<%   WR8  .$_  #C60  Y7(
M .6)  #FGP  YK$ _P   /\   #_    _P   /\ ! #_ !$ _P < /\ * #_
M #, _P ] /D 1@#R $T \ !4 .T 6P#K &$ Z0!F .< ; #E '( XP!X .$
M?@#? (4 W0". -H F #7 *0 U "S -, S #0 .L S@#_ ,L _P#$ /\ N@#_
M +4 _P"S /\ _P   /\   #_    _P   /H   #W  T ]  9 /, (P#O "T
MZ@ X .< 00#C $D WP!0 -P 5@#: %P UP!A -0 9@#1 &P SP!R ,P > #*
M '\ QP"' ,4 D0#" )P OP"K +X OP"] .  NP#Z +H _P"W /\ KP#_ *L
M_P"H /\ _P   /\   #]    \@   .H   #E  @ X@ 4 -H 'P#6 "@ U0 R
M -, / #. $0 R0!+ ,8 40## %8 P !< +X 80"] &8 NP!L +@ <@"W 'D
MM0"! +( B@"P )4 K@"B *P LP"M -$ JP#Q *D _P"H /\ HP#_ *  _P">
M /\ _P   /H   #N    WP   -8   #/  , Q@ / ,( &@#  "0 O0 M +L
M-@"X #X M0!% +, 2P"P %$ KP!6 *T 6P"K &$ J@!F *@ ; "F ', I ![
M *( @P"@ (X G@": )P J@"= ,( G #E )H _P"9 /\ EP#_ )0 _P"2 /\
M]P   .D   #:    RP   ,$   "X    L@ * *\ %0"K !\ J@ H *D , "G
M #@ I0!  *( 1@"@ $P G@!1 )T 5@"; %L F@!A )@ 9P"6 &T E !U )(
M?0"1 (< CP"3 (T H0"- +8 C #6 (L ]@"+ /\ B@#_ (D _P"' /\ ZP
M -@   #$    N    *\   "F    H@ % )X $ "; !D F@ B )@ *P"7 #,
ME0 Z ), 0 "1 $8 D !+ (X 4 "- %8 BP!; (H 80"( &< AP!O (4 =P"#
M ($ @0", '\ F@!_ *T ?P#' 'X ZP!] /\ ?0#_ 'T _P!\ /\ W    ,8
M  "U    J0   *    "9    DP   )  "@"- !0 BP = (H )0") "T B  T
M (8 .@"$ $$ @P!& ($ 2P"  %  ?@!6 'T 7 ![ &( >@!J '@ <@!V 'P
M= "' '( DP!S *8 <@"\ '$ W0!P /D < #_ '  _P!P /\ T    +D   "I
M    G    ),   "-    B    (0 !0"!  \ ?P 8 'X ( !] "@ ?  O 'H
M-@!X #L =P!! '4 1@!T $L <@!1 '$ 5P!P %T ;@!D &P ;0!J '< : ""
M &< C@!F )\ 90"S &4 T !D .\ 8P#_ &, _P!D /\ P@   *X   "?
MD0   (@   ""    ?@   'H  0!W  H =0 3 ', &P!R ", <  J &\ , !M
M #8 ;  \ &H 00!I $< : !, &8 4@!E %@ 8P!@ &$ :0!@ '( 7@!] %P
MB@!< )H 6@"L %D Q !8 .0 6 #Y %@ _P!9 /\ MP   *4   "4    B $
M '\   !Y    =    '$   !N  4 ;  . &H %P!H !X 9@ E &4 + !D #(
M8@ W &  /0!? $( 70!( %P 3@!; %4 60!< %< 90!6 &X 5 !Y %, AP!2
M )4 4 "G $\ O !. -D 3@#S $X _P!. /\ KP   )T#  "-"   @0D  '@)
M  !P"   :P4  &@!  !F  $ 9  ) &( $@!@ !H 7@ A %P * !; "X 60 T
M %@ .0!6 #\ 50!% %0 2P!2 %$ 40!9 $\ 8@!- &P 3 !W $H A !) ),
M1P"C $8 M@!% -( 10#L $4 _ !% /\ J08  )8+  "'#@  >Q$  '$2  !I
M$0  9 X  & +  !>"   70,$ %L # !9 !4 5P = %4 ) !3 "H 4@ P %
M-@!/ #P 3@%" $P!2 !+ D\ 20)7 $<"8 !% FH 1 )V $("@P!  I$ /@&A
M #T M  \ ,P / #G #L ]@ [ /\ HPL  ) 2  ""%   =A8  &P7  !D%P
M7A8  %H4  !7$0  50T  %0)!@!3!@\ 4088 $X'( !-""< 2P@M $H),P!(
M"CD 1PH_ $4+1@!#"TX 0@M6 $ +7P ^"VH / MV #D+@P W"Y( -0NB #0)
MM0 S",P ,0CD #$)]  Q"/T GQ   (P6  !^&0  <AL  &@<  !?'   61H
M %09  !1&   3Q4  $X2  !-#PD 2P\3 $@0' !&$2, 11(J $,2, !!$S8
M0!,] #X41  \%$P .A14 #@47@ V%&D -!1U #(4@P O%)( +1.C "L2MP I
M$M  *1+I "D1]P J$?\ FA0  (@:  !['0  ;A\  &0@  !;(   51\  % >
M  !,'0  21L  $@8  !&%P4 1!<0 $(7& ! &"  /ADG #P9+0 Z&C0 .!HZ
M #<:0@ U&TH ,QM2 #$;7  O&V< +1MT "L;@0 H&Y  )AJB "09M0 B&<\
M(ACI "(8^@ C%_\ EA@  (4=  !W(   :R(  & C  !8(P  42,  $PB  !(
M(0  1"   $,=  ! '0$ /1X+ #L>%0 Y'QT -Q\D #4?*@ S(#$ ,B X # @
M/P O(4@ +2%0 "LA6@ I(64 )B%R "0A@  B((\ (""A !X?M  <'LT '![H
M !P=^0 <'?\ DQL  ((@  !T(P  :"4  %TF  !4)@  3B8  $@F  !$)0
M0"0  #TC   Y(P  -R0( #0D$@ R)1H ,24A "\E*  M)BX *R8U "HF/0$H
M)D4!)B9. 20F6 $B)F0 ("9P !XF?P <)HX &26? !<DLP 6),P %B/G !8B
M^0 7(O\ CQ\  '\C  !Q)@  92@  %HI  !1*0  2RD  $4I  ! *0  .RD
M #<H   T*0  ,2H$ "XJ#@ L*Q< *BL> "DK)0 G+"P )2PS ",L.P$A+$,!
M("Q, !XL5P <+&( &BQO !<L?0 5*XT $RN> !$JL@ .*<L #BCF ! H^  1
M)_\ BR,  'PF  !N*0  8BL  %<L  !.+   1RP  $(L   \+0  -RT  #(M
M   N+P  *R\! "@P"@ E,10 (S$; "(Q(@ @,BD 'C(P !TR.  ;,D$ &3)*
M !<R50 5,F  $S)M !$R?  -,8L "S"<  DOKP '+\8 ""[@  DM]  *+/\
MB"<  'DI  !K+   7BX  %0O  !++P  1#   #XP   Y,   -#   "XR   I
M-   )#4  "$V!P >-Q  '#<8 !HW'P 9-R8 %S@M !4X-0 4.#X $CA( ! X
M4@ -.%X "C=J  @W>  &-X@ !#:8  $UK   -,,  3/=  (R\  #,OP A"H
M '4M  !H+P  6S$  %$R  !(,@  03,  #LS   V,P  ,30  "HV   E-P
M(#D  !L[ P 7/0L %#T4 !(^&P 0/B, #CXJ  P^,@ */CH "#Y$  8]3@ $
M/5H  CUF   ]=0  /80  #R6   [J0  .L   #G=   X[P  -_D @"\  '$Q
M  !D,P  6#0  $TU  !%-@  /C8  #DV   S-@  +C<  "<Z   A/   &SX
M !9    /0P< "D00  =$&  %1!\ !$0F  )$+@ !1#8  $1   !$2@  0U8
M $-C  !#<0  0X$  $*3  !!I@  0+T  #_;   ^\0  /?H ?#,  &TU  !?
M-P  5#@  $HY  !".0  /#D  #8Y   P.@  *CP  "(^   <00  %T,  !%%
M   )2 8  DH,  !*%   2QL  $LB  !+*@  2S(  $L[  !*1@  2E(  $I?
M  !*;0  2GX  $F0  !(I   1KL  $79  !$\0  1/P =S@  &@Z  !;.P
M4#P  $<\  ! /   .CP  #,]   L/P  )4$  !U$   71@  $4D   I+   "
M3@0  $\*  !0$0  41<  %(>  !3)0  4RT  %(V  !200  4DT  %%;  !1
M:0  47H  %&,  !1H0  3[D  $W6  !,\   2_T <3T  &,_  !60   3$
M $1    ^/P  -T   "]"   G10  'T@  !=+   130  "4\   -2    50(
M %8'  !7#0  6!,  %H9  !;(   6R@  %LQ  !;/   6D@  %I6  !:90
M678  %F(  !9G0  5[8  %75  !4[P  4_T :T(  %Y#  !21   240  $-#
M   [0P  ,D8  "I)   A3   &$\  !!2   )50   E<   !:    7    %X#
M  !?"   8 T  &(4  !C&@  9"(  &4K  !D-0  9$$  &1/  !C7P  8W
M &*#  !BF   8;   %_0  !>[0  7?P 94@  %E(  !/2   2$<  $!'   V
M2@  +4T  "-1   :5   $%@   A:    70   &    !C    90   &<   !H
M P  :@@  &L-  !M%   ;AL  ' C  !P+@  <#H  &](  !O6   ;FH  &U]
M  !LDP  :ZL  &K(  !IZ0  :/L 7TT  %5-  !-3   1DP  #M/   P4P
M)E8  !M:   17@  !F(   !E    :    &L   !N    <    '(   !T
M=0   '<&  !Y"P  >A,  'P;  !^)   ?C   'X^  !]3P  ?&$  'QU  ![
MBP  >*,  '>_  !VX@  =?< 6U,  %-2  !,40  0%0  #18   I70  '6$
M !%F   %:@   &X   !Q    =    '<   !Z    ?    'X   !_    @0
M (,   "% P  APD  (D2  "+&P  CB8  (TT  "-10  BU@  (MM  "*@P
MAYP  (:V  "$V   @_$ 65<  %)6  !&6@  .5X  "QC   ?:0  $VX   9S
M    =P   'L   !^    @0   (0   "&    B0   (L   "-    CP   )$
M  "3    E0   )@&  ";#@  GAD  *$E  "@.   GDP  )UA  "=>   FY
M )FK  "7R@  END 6%T  $Q@   _90  ,6H  "1P   6=@  "'L   "
MA0   (@   "+    C@   )$   "3    E@   )@   ":    G    )\   "@
M    HP   *8   "I!   K T  +$8  "S*@  L$   *]6  "P;0  L(4  *V@
M  "LO   J]T 4F8  $9K   X<0  *G@  !Q^   -A    (D   "-    D0
M )4   "8    FP   )\   "B    I0   *@   "J    K0   *\   "Q
MLP   +8   "Z    OP   ,<&  #,&   S"T  ,I%  #-7   SW0  ,N.  #)
MIP  Q\  37$  #]X   Q?@  (X4  !6,   %D0   )8   ";    H    *0
M  "H    JP   *T   "P    L@   +4   "W    N@   +P   "_    P0
M ,4   #)    SP   -@   #>"P  Y!X  .(W  #D3P  YVD  .2#  #BFP
MXK  _P   /\   #_    _P   /\  @#_  T _P 9 /X ) #] "\ _0 Y /D
M0P#U $L \0!2 .T 6 #J %X Z !C .8 : #D &X X@!S -\ >@#= (( V@"*
M -< E #4 *  T0"O ,X Q@#+ .D S #_ ,8 _P"Z /\ M #_ *\ _P"K /\
M_P   /\   #_    _P   /L   #X  D [P 5 .T ( #L "H Z@ T .4 /@#A
M $8 W0!- -H 4P#7 %D U !> -( 8P#0 &D S0!N ,L =0#( 'L Q0"$ ,(
MC0#  )D O0"G +H N@"X -H MP#[ +@ _P"N /\ J #_ *, _P"A /\ _P
M /X   #Y    \    .D   #@  0 V@ 1 -8 ' #2 "8 T0 O -  . #+ $
MQP!( ,0 3@#! %0 OP!9 +P 7P"Z &0 N0!I +< < "U '8 L@!^ +  AP"M
M )( JP"@ *@ L "F ,H I #M *< _P"B /\ G0#_ )D _P"6 /\ _    /4
M  #F    W    -(   #&    P0 + +T %@"[ "  N0 J +@ ,P"V #L LP!"
M +  2 "N $X K !3 *H 6 "H %T IP!C *4 :0"C '  H0!X )\ @0"= (L
MF@"8 )@ IP"6 +T E #> )8 _P"5 /\ D0#_ (X _P"+ /\ \P   .4   #1
M    Q0   +@   "Q    K  & *D $0"G !L I0 D *4 +0"D #0 H0 [ )\
M0@"= $@ FP!- )D 4P"7 %@ E@!= )0 8P"2 &H D0!R (\ >P"- (4 B@"2
M (@ H "& +( A0#- (< ^ "' /\ A0#_ (( _P"  /\ Y    ,T   "^
ML@   *<   "@    FP ! )@ "P"6 !4 E  > ), )P"2 "\ D0 V (\ / "-
M $$ BP!' (H 3 "( %$ AP!7 (8 70"$ &, @@!K ($ = !_ 'X ?0"+ 'L
MF !Y *D =P#  '@ ZP!X /\ > #_ '8 _P!U /\ U    +X   "N    H
M )@   "1    C0   (D !@"' !  A0 9 (0 (0"$ "D @P P ($ -@!_ #L
M?@!  'P 10![ $L >0!1 '< 5@!V %T = !D '( ;0!Q '< ;P"$ &T D0!L
M *( :@"V &L W0!J /L :@#_ &H _P!J /\ Q0   +$   "@    E    (L
M  "%    @0   'T  @![  L >0 4 '@ ' !W ", =0 J ', , !Q #8 <  [
M &\ 0 !M $4 ; !+ &L 40!I %@ 9P!? &8 : !D '( 8@!^ &  BP!? )L
M7@"N %X S0!> /  70#_ %T _P!= /\ N0   *8   "5    B0   ($   ![
M    =@   '(   !P  < ;0 / &L %P!J !X :0 E &@ *P!F #$ 90 W &,
M/ !B $$ 80!& %\ 30!> %, 7 !: %L 8P!9 &T 5P!Y %8 A@!4 )4 5 "I
M %, P0!2 .4 4@#] %$ _P!1 /\ KP   )L   ",    @0   '@   !Q
M;    &D   !F  ( 8P * &$ $P!@ !H 7P A %X )P!< "T 6P R %D -P!8
M #T 5P!" %4 2 !4 $\ 4@!6 %$ 7P!/ &D 30!U $P @@!* )  2@"C $D
MN0!( -D 2 #T $< _P!( /\ IP   )0   "% P  >04  ' %  !H!   8P(
M %\   !=    6P & %D #0!7 !4 5@ < %4 (P!3 "D 4@ N %$ - !/ #D
M3@ ^ $T 10!+ $P 2@!3 $@ 7 !& &8 1 !Q $( ?@!" (T 00"> $  L@ _
M ,T /@#K #X _@ ^ /\ H    (X&  !_"0  <PL  &D,  !A"P  6PH  %<(
M  !5!0  5 $! %( "0!0 !$ 3P 8 $T 'P!, "4 2@ K $D , !( #8 1@ [
M $4 0@!# $D 0@!0 $  60 ^ &, .P!O #H ?  Y (L . "; #8 K@ U ,4
M-0#D #4 ]P U /\ F@8  (D+  ![#P  ;A$  &02  !<$@  5A$  %$0  !.
M#0  3 H  $P&! !* PL 20$4 $<!&P!% B$ 0P(G $(#+0!  S, /P0Y #T$
M0  \!4< .@5/ #@%6  V!6( - 5N #(%>P Q!8H +P29 "T$JP L L( + #?
M "P \@ L /T E0P  (01  !V%   :A8  %\6  !7%@  418  $P5  !(%
M1A(  $4.  !$"P8 0PD. $$)%P _"AX /0HD #L+*@ Z"S$ . PW #8,/@ U
M#48 ,PU. #$-6  N#6, + UO "H-?0 H#8L )0V; "0,K0 C"L, (0K= " *
M[P @"OH D1   ($5  !S&   9AH  %P:  !3&@  31H  $<:  !#&0  0!<
M #\5   ^$@$ /!$) #H1$P X$AH -A,A #03*  S%"X ,10U "\4/  N%40
M+!5- "H55P G%6$ )15N ",5?  @%8L 'A2< !P3KP :$\8 &1+A !H2\@ :
M$OT C10  'T8  !O&P  8AT  %@=  !0'@  21X  $0=   _'0  .QP  #D:
M   W&   -1@% #,8#@ Q&1< +QD> "X:)0 L&BL *AHR "@;.@ G&T( )1M+
M ",;50 A&V  'AML !P;>@ :&XD %QJ: !49K@ 3&<4 $QC@ !,8]0 4%_\
MBA<  'H;  !L'@  7R   %4A  !-(0  1B$  $ A   [(0  -R   #0?   R
M'@  +QX" "T>"P K'Q0 *1\; "<@(@ E("@ )" P "(A-P @(4  'B%) !PA
M4P :(5X &"%K !4A>0 3((@ $2"9  X?K  ,'L( "Q[=  P=\@ -'/\ AQH
M '<>  !I(0  7",  %(D  !))   0B0  #PD   W)   ,R,  # C   L(P
M*20  "8D"  D)1$ (B48 " F'P ?)B8 '28M !LF-0 :)CT &"9' !8F40 4
M)EP $29I  XF=P +)H8 "266  @DJ0 &([\ !2/9  8B[@ '(?P A!T  '0A
M  !F)   624  $\F  !&)P  /R<  #DG   T)P  ,"<  "PG   G*   (RD
M " J!  =*PT &RL5 !HL'  8+", %BPJ !4L,@ 3+3L $2Q$  XL3P ,+%H
M"2QF  <L<P $+(,  BN3   JI@  *;L  "C8   G[  !)_@ @"   '$E  !B
M)P  5B@  $PI  !#*@  /"H  #8J   Q*@  +2H  "DJ   B+0  'BX  !HO
M 0 7, D %#$2 !(R&0 0,B  #C(G  PR+P *,S< "#)   8R2P $,E8  C%B
M   Q<   ,8   #"1   OHP  +KD  "W6   M[   +/@ ?20  &TH  !?*@
M4RP  $DL  ! +0  .2T  #0M   O+0  *RT  "8N   ?,   &S(  !8T   1
M-@8 "S@.  DX%@ '.!T !3@D  ,X*P ".#,  #@]   X1P  -U(  #=?   W
M;0  -WT  #>.   UH@  -+<  #/4   R[0  ,OD >"@  &DK  !;+@  3R\
M $4P   ],   -S   #$P   M+P  *#   "(R   <-   %S8  !(X   +.P4
M!#T,   ^$P  /AH  #XA   ^*   /C   #\Y   ^0P  /D\  #U<   ]:@
M/7H  #V,   \H   .K8  #G3   X[0  ./L ="T  &4O  !7,@  3#,  $(S
M   Z,P  -#,  # R   J,P  )#4  !TW   7.0  $CP   L^   %0 0  $(*
M  !#$   1!8  $4=  !&)   1BL  $8T  !&/@  14L  $18  !$9@  1'<
M $2)  !#G0  0K0  $#2   _[@  /OP ;S(  & T  !3-0  2#8  #\V   X
M-@  ,S4  "TV   F.   'SH  !@]   2/P  "T(   5$    1P(  $@'  !*
M#   2Q,  $P9  !.'P  3B<  $XP  !..@  348  $Q3  !,8P  2W,  $N%
M  !+F@  2[(  $C1  !&[@  1?T :3<  %LY  !..@  1#H  #TZ   W.0
M,#D  "@[   @/@  &$$  !)#   +1@  !4D   !+    3@   $\$  !1"0
M4@X  %04  !6&P  5R(  %<K  !7-0  5D   %5.  !57@  5&\  %2!  !3
ME@  4Z\  %'/  !0[@  3?X 8SP  %4]  !*/@  0CX  #L]   T/0  +#\
M "-"   :10  $D@   M+   $3@   %$   !3    5@   %<   !9!0  6PD
M %T/  !?%0  8!P  &$E  !A+P  8#H  &!(  !?6   7FH  %Y]  !=D@
M7*H  %S*  !9[0  6/X 74(  %%"  !'0@  0$$  #E!   O0P  )D<  !Q*
M   33@  "E$   -4    5P   %H   !<    7P   &$   !B    9 0  &8)
M  !H$   :A8  &P>  !M*   ;#0  &M!  !J40  :F0  &EW  !HC   9Z4
M &;"  !FYP  8_P 5T<  $U'  !&1@  /T4  #1(   I3   'U   !14   )
M6    5L   !>    80   &4   !G    :@   &P   !M    ;P   '$"  !S
M!P  =0T  '<6  !Z'P  >BL  'DX  !X2   =UL  '9O  !UA0  =)X  '*Z
M  !QWP  </@ 4TP  $Q+  !%2@  .4T  "U2   B5@  %EL   I?    9
M &<   !K    ;@   '$   !T    =@   '@   !Z    ?    'X   "
M@P4  (4,  "(%@  BB   (HN  "*/@  B5   (AE  "&>P  A90  (*O  "!
MT0  ?^\ 4E$  $M0   ^4P  ,E@  "5>   88@  "V@   !L    <0   '4
M  !Y    ?    '\   "!    A    (8   "(    BP   (T   "/    D0
M )0"  "7"@  FA4  )XB  "=,@  FT4  )E;  "8<@  EXH  )6E  "2P@
MD>0 458  $59   W7@  *F0  !QJ   .<    '8   ![    @    (,   "'
M    B@   (T   "0    D@   )4   "7    F@   )P   "?    H0   *0
M  "H    K <  + 4  "T(@  LC<  *].  "N90  K7X  *R7  "IL@  I](
M2V   #YE   P:P  (G(  !-Y   $?@   (4   "*    C@   )$   "5
MF    )L   "=    H    *,   "E    J    *H   "M    KP   +(   "V
M    NP   ,$'  #(%   RBD  ,9"  #%6@  QG(  ,>*  #"I0  P,$ 16L
M #=R   I>0  &H    J'    C0   )(   "7    F@   )X   "B    I@
M *L   "N    L    +,   "V    N0   +P   "_    P@   ,8   #+
MT0   -@   #C 0  Z14  .<N  #G1P  Z6   .IY  #GD@  Y:@ _P   /\
M  #_    _P   /\  0#_  D _P 6 /\ (0#] "P _  V /D 0 #U $@ \@!/
M .\ 5@#L %P Z@!B .@ 9P#E &T XP!S .$ >0#> (  VP"( -@ D@#4 )\
MT "O ,P Q@#( .@ Q0#_ +T _P"T /\ K #_ *< _P"D /\ _P   /\   #[
M    ^@   /H   #R  4 [@ 2 .L '0#J "@ Z0 Q .8 .P#B $, W@!+ -L
M40#8 %< U0!< -( 80#0 &< S0!L ,L <P#( 'H Q@"" ,, C #  )@ O "G
M +@ N@"U -L LP#Z +  _P"G /\ H0#_ )T _P": /\ _0   /<   #S
M[P   .$   #<    U  , -( & #0 "( SP L ,\ -0#* #T Q@!$ ,, 2P#
M %$ O0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L !] *X A@"L )( J0"@ *4
MLP"C ,T H0#P )\ _P"; /\ E@#_ )( _P"/ /\ ]0   .T   #D    U0
M ,@   #     O  ' +D $P"W !T M@ F +4 +P"S #< L  ^ *T 1 "K $H
MJ0!/ *@ 50"F %H I !@ *, 9@"A &T GP!T )T ?@"; (D F "7 )8 J "3
M ,  D #D (X _P", /\ B@#_ (< _P"% /\ Z@   -P   #,    NP   +(
M  "K    IP ! *0 # "B !< H0 @ *$ * "A #  G@ W )P /0"9 $, EP!(
M )4 3 "3 %( D0!8 (\ 7@"- &4 C !M (H =@"( ($ A@". (4 G0"# +,
M@@#3 (  ]@!_ /\ ?0#_ 'L _P!Z /\ VP   ,<   "W    J0   *    ":
M    E@   )( !P"0 !$ CP : (\ (@"- "H BP Q (D -P"' #T A@!" (0
M1@"# $L @@!0 (  5@!_ %X ?0!F 'L ;P!Z 'H > "& '8 E0!T *D <@##
M '$ Z@!Q /\ <0#_ &\ _P!N /\ R@   +<   "E    F0   )$   "+
MAP   (,  P"!  L ?P 4 'X ' !] "0 ?0 K 'L ,0!Y #< >  \ '8 00!U
M $8 <P!+ '( 4 !P %< ;@!? &T :0!K ', :0!_ &< C0!E *  9 "V &,
MV@!C /T 9 #_ &, _P!C /\ O    *<   "8    C0   (0   !_    >@
M '8   !S  < <0 / '  %P!O !X ;@ E &T + !K #$ :0 W &@ / !G $$
M9@!& &0 3 !C %( 8@!9 &  9 !> &X 7 !Y %H AP!8 )D 5P"M %8 RP!7
M /, 5P#_ %@ _P!7 /\ L    )P   "-    @@   'H   !S    ;@   &H
M  !G  ( 90 * &0 $P!B !H 8@ @ &$ )P!? "P 7@ R %T -P!; #P 6@!!
M %D 1P!8 $T 5@!4 %4 7@!3 &D 40!T $\ @0!- )( 3 "E $L OP!, .@
M3 #_ $T _P!, /\ I@   ),   "%    >0   '    !I    8P   &    !=
M    6P & %D #@!8 !4 5P < %< (@!5 "@ 5  M %, ,P!2 #@ 40 ] $\
M0P!. $D 30!0 $L 6@!) &0 1P!P $4 ?0!# (T 00"? $( N !" -L 0@#X
M $( _P!" /\ G0   (L   !]    <@   &@   !@    6@   %<   !4
M4@ # %$ "@!/ !$ 3@ 8 $X '@!- "0 2P I $H +P!) #0 1P Y $8 /P!%
M $4 0P!- $$ 5@ _ &  /0!L #L >0 Y (D -P": #D L  Y ,X . #N #@
M_P X /\ E@   (4!  !W!   :P<  &$'  !9!P  4P8  $\$  !, @  2P
M $D !@!(  T 1P 4 $8 &@!% "  0P E $$ *P!  #  /P V #T /  \ $(
M.@!* #@ 4P V %T - !I #( =@ Q (8 ,0"7 #  J@ O ,, +P#C "\ ^0 O
M /\ D0$  ($&  !R"0  9@L  %P,  !4#0  30P  $D+  !%"0  0P8  $(#
M @!!  D 0  0 #X %@ ] !P .P B #H )P X "T -P S #4 .0 T $  ,@!(
M #  40 N %L +0!G "L =0 J (, * "3 "< I@ F +P )0#9 "8 \P F /\
MC08  'P+  !N#@  81   %<1  !/$@  21(  $,1  ! #P  /0T  #L+   Z
M" 0 .@4+ #@$$@ V!!D - 0? #,%)  Q!2H , 8P "X&-P M!CX *P=' "D'
M4  G!UL )0=F ",'=  A!X( 'P>2 !T&I  <!+D ' +4 !P [@ = /L B H
M 'D/  !J$P  7A0  %,5  !+%@  1!8  #\5   Z%   -Q,  #42   T#P
M,PP& #(+#0 P"Q4 +@P; "T,(@ K#2@ *0TO "@.-@ F#CX ) Y' "(.40 ?
M#EP '0]H !L/=@ 8#H4 %@Z5 !0-I@ 3#+H $PO3 !(*Z0 2"O8 A0X  '43
M  !G%@  6A<  % 8  !(&0  01D  #L9   V&   ,Q<  # 6   N%0  +1,!
M "L3"  J$Q$ *!08 "84'P D%24 (A4L "$5-  ?%3P '15% !L63P 9%EH
M%A9F !06=  1%80 #A64  P4I@ *$[H "1/4  D2ZP *$?D @A(  '(6  !C
M&0  5QH  $T;  !$'   /1T  #<<   S'   +QL  "P:   I&@  )QD  "49
M!0 C&0T (1H5 !\:'  =&R( '!LJ !H;,0 8&SH %AM# !0;30 2&U@ #QME
M  P;<@ )&X  !QN0  4:H@ $&;<  AC1  ,7Z  $%_8 ?Q4  &\9  !@'
M5!T  $H>  !!'P  .A\  #0?   P'P  +!X  "@>   E'@  (1X  !\> @ =
M'PH &B 2 !@@&0 7("  %2$G !,A+P 1(3< $"%!  TA2P *(54 ""%A  4A
M;@ #(7T  2".   ?H   'K4  !W/   <Z   '/4 >Q@  &L<  !='P  42
M $<A   ^(@  -R(  #$B   M(0  *2$  "4A   A(0  '2(  !DD   6) <
M$R8. !$F%@ /)AT #2<D  LG*P ))S0 !R<]  8F1P $)E(  29>   F;
M)GL  ":,   DG@  ([,  "+-   AZ0  (/8 >!P  &@?  !:(0  3B,  $0D
M   [)0  -"4  "\D   J)   )B0  "(D   ?)   &B8  !4H   1*@4 #"L,
M  DL%  '+!H !2PA  ,L*  !+#   "TY   L0P  +$X  "M;   K:0  *W@
M "N*   KG0  *+(  "?,   FZ   )?@ =!\  &0C  !6)0  2R8  $$G   X
M*   ,2<  "PG   H)@  )"8  " F   ;*   %BH  !(L   ,+@0 !C$*  (Q
M$0  ,A<  #(>   R)0  ,BT  #,U   S/P  ,DL  #%8   Q9@  ,78  #"'
M   PFP  +K$  "W,   KZ@  *_D <",  & F  !2*   1RH  #TJ   U*@
M+RH  "HI   F*0  (BD  !TJ   7+   $B\   PQ   ',P0  34)   V#@
M-Q4  #@;   Y(@  .2D  #DR   Y.P  .4<  #A4   W8P  -W,  #>%   V
MF0  -K   #3-   RZ@  ,?L :R<  %PJ  !.+   0RT  #HN   S+0  +2P
M "DK   D+   'BT  !@O   3,@  ##0   <V   !.0(  #L'   \#   /A(
M #\7  ! '@  0"4  $ N  !!.   04,  #]1   ^8   /7   #V#   ]EP
M/:\  #O-   Y[   ./P 9BL  %<O  !*,   0#$  #<Q   Q,   +"\  "8O
M   ?,0  &3,  !,U   ,.   !SH   $]    /P$  $$%  !#"0  1 X  $84
M  !(&@  22$  $DJ  !),P  23X  $A,  !'6P  16T  $5_  !%E   1*P
M $3,  !![0  /_X 8#$  %(S  !&-   /30  #4T   P,@  *C(  "(T   :
M-P  %#D   P\   &/P   $(   !$    1P   $D"  !*!@  3 H  $X0  !0
M%@  4AP  %,E  !3+@  4SD  %)&  !15@  3V@  $Y[  !.D   3:D  $W(
M  !,[0  2?\ 6C8  $TX  !".   .C@  #0V   N-@  )3@  !P[   4/@
M#$$   5$    1P   $H   !-    3P   %(   !4 0  5@4  %@*  !:$
M718  %\>  !>*   7C,  %U   !;4   6F(  %EW  !8C   5Z0  %?#  !6
MZ@  5?\ 5#P  $D\   _/   .3L  #(Z   H/0  'D   !5$   ,1P  !4L
M  !.    40   %0   !6    60   %L   !=    7P   &(%  !D"@  9Q$
M &D8  !K(@  :BT  &DZ  !H20  9EL  &5P  !DA@  8YX  &*[  !AY
M8?T 3T$  $5!   ^0   .#\  "U"   B10  %TH   Q.   $40   %4   !8
M    6P   %X   !A    9    &8   !H    :P   &T   !O P  <@D  '41
M  !W&@  >"4  '<R  !U00  =%0  '-I  !Q@   <)@  &^S  !MVP  ;?@
M2T8  $1%   ^1   ,D<  "9+   :4   #E4   ):    70   &$   !D
M9P   &L   !N    <0   ',   !U    =P   'D   !\    ?@   (('  "$
M$   AQL  (<H  "&-P  A$D  (->  ""=@  @(X  'ZI  !\S   >^\ 2DH
M $1)   W30  *U(  !Y7   27   !&$   !F    :@   &\   !R    =@
M 'D   !\    ?P   ($   "$    A@   (@   "*    C0   )    "3!@
MEQ$  )L=  ":*P  F3X  )A2  "6:@  E((  )*=  "1NP  C>  2D\  #U3
M   P6   (U\  !5D   &:@   '    !V    >@   '\   ""    A0   (D
M  ",    C@   )$   "4    E@   )@   ";    G@   *$   "E    J00
M *T0  "R'@  L#$  *Y&  "L7@  JG<  *B0  "GJP  H\H 1%D  #9?   I
M90  &FP   IS    >@   (    "%    B@   (X   "2    E0   )@   ";
M    G@   *$   "D    I@   *D   "L    KP   +(   "W    O    ,,!
M  #+#0  T"   ,LX  #&4@  Q&H  ,.#  ##G   O;< /64  "]L   A<P
M$7L   &"    B0   (\   "4    F    )P   "?    HP   *8   "H
MJP   *X   "Q    M    +<   "[    O@   ,(   #'    S@   -4   #@
M    YQ(  .<J  #A1P  XU\  .1W  #ECP  X:D _P   /\   #\    ^@
M /L   #^  @ _P 3 /\ 'P#^ "H _@ T /P /0#X $4 ]0!- /( 5 #O %H
M[0!@ .H 90#H &L Y0!Q ., > #@ '\ W0"( -H DP#6 *  T@"Q ,X S #(
M /$ Q #_ +8 _P"K /\ HP#_ *  _P"< /\ _@   /@   #T    \P   /0
M  #P  $ [0 - .L &@#J "0 Z@ N .@ . #C $  WP!' -P 30#9 %, U@!9
M -, 7@#1 &0 S@!J ,P < #) '@ QP"  ,0 B@#  )8 O0"G +H O0"V .(
ML0#_ *< _P"> /\ F #_ )8 _P"3 /\ ]@   .\   #K    YP   -T   #6
M    T@ ( -  % #. !\ S0 I ,T ,0#) #D Q@!  ,, 1@#  $L O !0 +D
M50"W %H M !A +( : "O '  K0!X *H @@"H (T I@"< *0 KP"B ,X H0#W
M )L _P"2 /\ C #_ (H _P"( /\ [    .0   #>    S@   ,(   "\
MN  " +4 #@"T !D M  B +( *@"N #( JP Y *@ 0 "F $4 I0!* *, 3P"B
M %0 H !9 )\ 7P"= &8 FP!O )D >@"6 (8 E "3 )( I "/ +T C0#E (L
M_P"& /\ @0#_ 'X _P!] /\ X    -8   #!    M0   *P   "F    H@
M *  " "= !( FP ; )L ) "; "P F  S )8 .0"4 #\ D@!$ )  20". $X
MC0!3 (L 60") %\ B !G (8 < "$ 'X @@"+ (  FP!_ +  ?0#2 'L _ !X
M /\ = #_ ', _P!R /\ T0   ,    "N    H@   )H   "4    D    (P
M P")  P B0 5 (@ '@"' "4 A@ L (0 ,P"" #D @0 ^ '\ 0P!^ $@ ?0!-
M 'L 4P!Z %D > !@ '< :0!U '0 <P"$ '  DP!N *8 ; #! &L [P!J /\
M9P#_ &< _P!F /\ PP   *P   "=    DP   (L   "%    @    'P   !Z
M  < >  0 '< & !W !\ =P F '4 +0!S #, <@ X '$ /0!P $( ;P!( &T
M30!L %0 :@!; &D 8P!G &T 90![ &( C !@ )T 7@"T %P WP!< /\ 6P#_
M %P _P!; /\ LP   )\   "1    A@   'T   !W    <0   &X   !K  (
M:@ * &D $P!I !H :0 A &@ * !G "X 90 S &, . !B #T 80!" %\ 2 !>
M $X 7 !5 %L 7@!: &< 6 !S %8 A0!4 )8 40"K $\ S@!/ /8 3P#_ %$
M_P!1 /\ I@   )0   "&    >P   '(   !J    90   &$   !?    7@ &
M %T #@!= !8 7  < %P (@!: "@ 6  M %< ,@!6 #@ 5  ] %, 0P!2 $D
M4 !0 $\ 60!- &( 3 !N $H ?P!( (\ 1@"B $0 P !# .H 1@#_ $< _P!'
M /\ G    (L   !^    <@   &<   !@    6@   %<   !5    4P # %(
M"@!2 !$ 40 7 %  '0!/ ", 3@ H $P +0!+ #, 20 X $@ /@!' $4 10!,
M $0 5 !" %X 00!I #\ >@ ] (H .@"= #D M@ X -T / #^ #P _P ] /\
ME    (0   !V    :@   %\   !7    4@   $X   !,    2@   $D !@!(
M  P 1P 3 $8 &0!& !\ 1  D $( *0!! "X /P T #X .@ \ $$ .P!( #D
M4  X %H -@!F #0 =0 R (4 ,0"8 #  KP Q -$ ,@#T #, _P S /\ C@
M 'X   !P    8P(  %D#  !1 P  2P(  $<   !$    0@   $   P _  D
M/@ / #T %0 \ !H .P @ #D )0 X "H -@ O #4 -@ S #T ,@!$ #  30 O
M %< +0!D "L <0 J ($ *0"3 "@ J0 I ,0 *0#I "D _P I /\ B    'D!
M  !J!0  7@<  %0(  !+"   10@  $ '   \!0  .@,  #@!   W  8 -@ +
M #4 $0 T !< ,P < #$ (0 O "8 +@ L "T ,@ K #H *@!! "@ 2@ G %0
M)0!A ", ;P B 'X (0"0 "  HP @ +L 'P#= !\ ]@ ? /\ A $  '0&  !F
M"   60L  $\,  !'#0  0 P  #H,   V"P  ,PD  #$(   P!@, , ,( "X!
M#0 M 1, *P$9 "H '@ H "0 )P$I "8 ,  D 3< (P$_ "$ 2  @ 5, '@%?
M !P ;0 ; 'P &0", !@ GP 7 +0 %@#1 !4 [0 6 /\ @ 4  ' )  !B#
M5@X  $L1  !#$0  /!$  #81   R$   +@\  "P-   J#   *0H$ "D("0 G
M!Q  )086 "0'&P B!R$ (0@G " (+@ >"#8 ' @^ !L(2  9"5( %@A> !0(
M;  2"'L $ B+  X&G0 -!;$ #0/+  T!Z  . /D ?0D  &T-  !>$   4A(
M $@4   _%0  .!4  #(4   N%   *A,  "<3   E$@  (Q$" "(.!0 A#@L
M( T2 !X.&0 <#A\ &PXF !D.+@ 7#C8 %0\_ !,020 0$%0 #1!@  H0;  )
M$'L !Q"+  8.G0 $#;   PS)  (+XP #"?, >@P  &D1  !;$P  3Q4  $47
M   \&   -1<  "\7   J%P  )A8  ",6   A%0  'Q4  !T4 @ ;% < &10.
M !<5%@ 6%1T %!4D !(5*P 0%C0 #18]  L61@ )%E  !A9<  06:0 "%G@
M !:(   5FP  $ZX  !+'   1XP  $?, =Q   &84  !8%@  3!@  $(:   Y
M&@  ,AH  "P:   G&@  (QD  " 9   =&   &Q@  !@9 0 5&00 $QH+ ! ;
M$P .&QH #!LA  H;*  (&R\ !ALX  0<0@ "&TT  1M9   ;9@  &W8  !N&
M   :F0  &:X  !?&   6XP  %?4 <Q,  &,7  !5&0  21L  #X=   V'0
M+QT  "D<   E'   (1P  !X;   ;&P  &!L  !4<   0'@, #!\)  D@$0 &
M(!< !2 >  ,A)  !(2P  "$U   A/@  (4D  "!6   @9   ('0  !^%   ?
MF   'JT  !S'   :Y0  &O8 ;Q8  %\:  !1'   1AX  #L?   S'P  +!\
M "<?   B'@  'QX  !P=   9'0  %1X  !$@   ,(@, !R0(  ,E#@  )14
M "8;   F(@  )BD  "8R   G.P  )T8  "94   E8@  )7(  "2$   DEP
M)*T  "'(   ?Y0  'O@ :QH  %L=  !.'P  0B$  #@B   P(@  *B$  "0A
M   A(   '1\  !H?   6(   $B(   PD   ()@,  R@(   J#   *Q,  "P8
M   L'P  +"8  "PO   M.   +4,  "U/   K7P  *G   "J"   IE@  *:P
M "C)   FZ   )/D 9QX  %<A  !*(P  /R4  #4E   M)   )R0  ",C   @
M(@  '"(  !<C   2)0  #2<   @I   #*P,  "T'   O"@  ,1   #,6   S
M'   ,R,  #0K   T-0  -$   #1,   R7   ,6T  #!_   PE   +ZL  "_)
M   LZP  *OP 8B(  %,E  !&)P  .R@  #(H   K)P  )B8  "(E   >)
M&"8  !,G   -*@  ""P   ,O    ,@$  #0$   V"   . P  #H2   [&
M.Q\  #LG   [,0  /#P  #Q(   [5P  .6D  #=]   WD@  -JH  #;)   U
M[   ,O\ 72<  $XI  !"*P  -RL  "\K   I*0  )2@  " H   :*0  %"L
M  TN   ',0   C,    V    .    #L"   ]!0  /PD  $$.  !#%   1!L
M $0C  !$+0  1#@  $1$  !$4@  064  #]Y   _C@  /J<  #W&   ][
M._\ 5RP  $HN   ^+P  -"\  "TM   I*P  (RL  !PM   5+P  #C(   <U
M   !.    #L    ]    0    $(   !% @  1P8  $D*  !+$   3A8  $X>
M  !.*   3C,  $X_  !.30  2V   $EU  !'BP  1Z0  $;$  !%ZP  1?\
M43$  $4R   Z,P  ,C(  "TP   G+P  'C$  !8T   .-P  !SH    ^
M00   $,   !&    20   $L   !.    4 (  %(&  !5"P  5Q(  %H9  !:
M(@  6BT  %DZ  !92   6%D  %5O  !2A@  4IX  %&\  !0Y@  4/\ 3#8
M $ W   X-@  ,C0  "LS   A-@  %SD   \]   '0    $0   !'    2@
M $T   !0    4P   %8   !8    6@   %T!  !@!0  8@L  &83  !H&P
M:"8  &@R  !G00  95$  &)H  !@@   7I@  %VU  !<WP  6_P 1SL  #T[
M   W.0  ,#@  "4[   :/P  #D,   9'    2P   $\   !3    5@   %D
M  !<    7P   &(   !D    9P   &D   !L    ;P0  '(+  !V%   =Q\
M '8K  !U.@  <TH  '!@  !N>   ;)(  &NL  !ITP  :/8 0T   #T_   V
M/0  *T   !Y%   22@  !4\   !3    6    %P   !?    8@   &4   !I
M    ;    &X   !Q    <P   '8   !Y    ?    '\#  "#"P  AA8  (<B
M  "%,0  @T(  (%7  !_;P  ?(H  'ND  !YQ@  =^T 0T0  #Q#   P1P
M)$L  !=1   )5P   %P   !@    90   &D   !L    <    ',   !W
M>@   'P   !_    @@   (0   "'    B@   (X   "1 0  E0H  )@7  "8
M)0  EC<  )1+  "28P  D'T  (Z7  ",M0  BMP 0TD  #9-   I4@  &U@
M  U>    9    &H   !O    =    '@   !\    @    (0   "'    B@
M (T   "0    D@   )4   "8    FP   )\   "C    IP   *P*  "R&
ML2D  *\^  "L50  J6\  *:)  "CI0  H<0 /%,  "]9   A8   $F8   )M
M    =    'H   "     A0   (H   "-    D0   )0   "8    FP   )X
M  "A    I    *<   "J    K0   +$   "V    O    ,,   #,"@  U!D
M - O  #+2   QF(  ,1[  #!E0  OJ\ -5\  "=F   8;@  !W8   !]
MA    (L   "1    E0   )H   "=    H0   *0   "G    JP   *X   "Q
M    M0   +@   "\    P0   ,4   #+    T@   -L   #D    [@@  / @
M  #K.P  Y5<  .1P  #DB   XZ  _@   /D   #U    ]    /4   #X  4
M_  1 /\ ' #_ "< _P Q /X .@#[ $( ^ !) /8 3P#S %0 \ !: .T 7P#I
M &0 Y@!J ., <@#? 'H W "$ -@ CP#4 )P T "L ,T QP#+ /  Q #_ +
M_P"C /\ FP#_ )4 _P"3 /\ ]P   /$   #L    ZP   .T   #O    [0 )
M .L %@#K "$ [  J .D - #A #P VP!# -@ 20#4 $X T@!4 -  60#. %X
MRP!C ,D :@#' '  Q !Y ,$ A0"^ )0 N@"D +< N0"S .  L #_ *( _P"8
M /\ D0#_ (P _P") /\ [@   .<   #B    X    -H   #4    SP $ ,X
M$ #+ !H QP D ,@ +0#% #4 P0 \ +X 0P"\ $@ N !- +8 4P"S %@ L0!=
M *\ 8P"L &H J@!R *@ >P"F (8 I "9 *$ K@"? ,T G0#W )4 _P"* /\
MA0#_ (( _P!_ /\ XP   -H   #4    R    +X   "X    M    *X "0"N
M !0 K@ > *T )@"J "\ IP V *0 / "B $( H0!' )\ 3 "> %( G !7 )L
M70"9 &0 EP!K )4 =0"3 '\ D0", (\ H@", +X B0#H (8 _P!_ /\ >0#_
M '8 _P!T /\ U0   ,H   "[    L    *@   "B    FP   )D  P"7  T
ME0 7 )8 ( "6 "@ E  O )$ -@"0 #P CP!! (X 1P"- $P BP!1 (H 5P"(
M %X AP!E (4 ;@"# 'D @0"% (  E !\ +, >0#7 '8 _@!Q /\ ; #_ &H
M_P!H /\ Q@   +4   "G    G0   )0   "-    B0   (4   "$  @ @P 1
M (0 &@"% ", A  J (( , "  #8 ?@ [ 'T 0 ![ $4 >0!+ '@ 4 !V %<
M=0!> ', 9P!Q '( ;P!^ &X C0!M *$ :@#% &8 \@!C /\ 7P#_ %T _P!=
M /\ MP   *4   "7    C    (0   !]    >    '4   !T  , =0 , '0
M%0!T !P =  C '( *0!P "X ;@ T &P .0!K #X :0!$ &@ 2@!F %$ 9 !8
M &( 80!A &L 7P!W %X A@!= )< 6P"W %D X@!6 /\ 4P#_ %( _P!2 /\
MJ0   )@   "*    ?P   '4   !N    :0   &<   !F    90 ' &0 #@!D
M !8 9  = &, (P!A "@ 7P M %T ,P!< #@ 6@ ] %D 0P!7 $D 5@!2 %0
M6P!2 &4 40!Q %  ?P!/ )  30"L $L T !) /D 1P#_ $< _P!' /\ G0
M (T   !_    <P   &D   !A    70   %L   !9    5P " %< "0!6 !$
M5@ 7 %8 '0!4 "( 4@ H %  + !. #$ 3  W $H / !) $, 2 !* $< 5 !&
M &  1 !K $, >@!" (D 0 "D #\ P@ ] .X / #_ #P _P _ /\ E    (0
M  !V    :0   %\   !7    4P   $\   !-    3    $L !0!*  L 20 2
M $@ & !& !T 1  B $, )P!! "P 0  R #X .  ] #X .P!% #H 3@ X %H
M-P!F #< =  V (0 - "< #, MP R .0 ,@#_ #( _P V /\ C    'T   !N
M    80   %<   !0    2@   $8   !#    00   $   @ ^  < /  - #P
M$P \ !@ .@ > #@ (P W "@ -@ M #0 ,P S #H ,@!! #  2@ O %8 +@!B
M "P <  K (  *@"6 "D K@ I -8 *0#[ "L _P M /\ A@   '8   !H
M6P   %$   !)    0@   #T    Z    -P   #4    T  0 ,P ) #, #@ S
M !0 ,0 : #  'P N "0 +0 I "P ,  K #8 *0 ^ "@ 1@ G %( )0!> "0
M;  C 'X (0"1 "$ J  A ,D (0#R "( _P D /\ @0   '$   !B    5@(
M $P#  !#!   / 0  #<#   S @  +P(  "T    L  ( +  & "L "P K !$
M*@ 6 "@ &P G "  )@ F "0 +  C #, (@ [ "$ 0P ? $\ '@!; !T :0 ;
M 'H &@", !H HP 9 +\ &0#E !D _P : /\ ?    &P   !>!   408  $<(
M   ^"   -P@  #$(   M"   *0<  "<&   F!   )0($ "0 "  C  P (P 3
M "$ &  @ !T 'P C !X *0 < #  &P X !H 00 9 $T %P!9 !8 9P 4 '<
M$@") !$ G0 1 +0 $0#6 !$ ]0 0 /\ >    &@$  !:"   30H  $,+   Z
M#   ,PP  "T,   H#   )0L  "(*   @"0  'P@# !X&!@ =!0H ' 0/ !L$
M%0 :!!H & 0@ !<$)@ 6!"X %00V !0#0  2 DL $0)7  X#9  + W0 "0*%
M  @!F  ( *X " #+  @ [  ( /\ =00  &4'  !6"P  2@T  #\/   V$
M+Q   "D0   E$   (0X  !X.   <#0  &@P" !@+!0 7"@< %PD, !4)$@ 4
M"1@ $PD> !$))  0"2P #@DU  P)/P *"4H " I6  4+8P ""G,   J#   )
ME@  !ZH   7#   #X@   /@ <0<  &$*  !3#0  1Q$  #P2   S$P  +!,
M "83   B$@  'A(  !L1   8$0  %A " !00!  2#P< $0X)  X.#@ -#Q4
M"Q <  H0(P ($"H !Q S  40/0 $$$@  A%4   180  $'$  !""   .E0
M#:H   O"   *WP  "?, ;@H  %T-  !0$0  1!0  #D5   P%0  *14  ",5
M   ?%0  &Q0  !@4   5$P  $Q,# !$2!0 /$@< "Q,(  D4#  '%1, !A49
M  05(  "%B<  18O   6.@  %D4  !91   57P  %6\  !6!   4E   $ZH
M !'$   /X@  #?8 :@T  %H1  !-%   0!<  #87   M&   )A@  "$7   =
M%P  &18  !86   4%0( $A0$  \5!0 +%@4 "!<'  09"@ !&A   !H6   ;
M'0  &R0  !LM   ;-@  &T(  !M.   ;7   &FT  !F    9E   &*H  !?%
M   5Y0  $_@ 9A$  %<4  !)%P  /1H  #,:   K&@  )!H  !\9   ;&
M%Q@  !47   3%@, $!<#  P8 P (&00 !!L&   ="0  'PT  " 4   @&P
M("(  "$J   A,P  (3\  "!,   @6@  'VP  !Y_   =DP  ':H  !S&   ;
MZ   &?L 8A4  %,8  !&&@  .AP  # =   H'   (AP  !T;   9&@  %QD
M !08 0 0&0  #!H   @< 0 $'@(  " $   B!P  )0L  "82   F&   )Q\
M "<G   G,0  )SL  "=)   G5P  )F@  "-]   CD0  (JD  "''   AZP
M'OX 7A@  $\;  !"'@  -A\  "T?   E'P  (!X  !P=   9&P  %AL  !$<
M   ,'0  "!\   ,A    (P   "8#   H!0  *PD  "T.   M%0  +AP  "XD
M   N+@  +C@  "Y&   N5   +60  "IZ   HD0  **@  "?'   G[   )_\
M61P  $L?   ^(@  ,R(  "HB   C(0  'R   !L>   7'@  $Q\   T@   (
M(@   R4    G    *0   "P!   O P  ,0<  #0+   V$@  -AD  #8A   V
M*@  -C4  #9"   V4   -F   #)W   PC@  +Z8  "[&   N[0  +O\ 5"$
M $8D   Y)@  +R4  "@D   B(P  'B$  !HA   4(@  #20   @F   "*0
M "P    N    ,0   #,    V 0  .04  #L)   ^#P  /Q8  #\>   _)P
M/S$  #\^   _3   /UP  #UP   YB@  -J0  #;#   U[0  -?\ 3R8  $$H
M   U*0  +2D  "8G   B)0  '20  !8F   .*   ""L   (M    ,0   #,
M   V    .0   #P    _    00(  $0&  !'"@  2A$  $H9  !+(0  2BP
M $HY  !*1P  25<  $AJ  !#A0  0*   $"^   _Z@  /O\ 22L  #PM   R
M+0  *RL  "8I   @*   &"H  !$L   (,    3,    W    .@   #T   !
M    0P   $8   !)    2P   $X!  !1!0  5 L  %<3  !7'   5B8  %8S
M  !600  55$  %1D  !/?P  3)H  $JW  !)Y0  2/\ 0S$  #@R   P,
M*BX  "0M   ;+P  $C(   DV   !.@   #X   !!    1    $@   !+
M3@   %$   !3    5@   %D   !< 0  7P8  &(,  !E%@  92   &0L  !D
M.P  8TL  &%=  !=>   69,  %:Q  !6VP  5?T /S8  #4U   P,P  *3$
M !XT   4.   "CP   !!    10   $D   !-    4    %,   !7    6@
M %T   !?    8@   &4   !G    :P   &X'  !R#P  =!D  '0F  !S-
M<T,  '%5  !M;P  :8D  &:H  !ES   9/4 .SH  #4X   O-P  (SH  !8_
M   *1    $@   !-    4@   %8   !:    7@   &$   !E    :    &L
M  !N    <0   '0   !W    >@   'X   ""!0  AP\  (D<  "'*@  A3L
M ().  !]9@  >H   '>>  !UO0  =.D .SX  #4\   I0   &T4   Q+
M4@   %8   !;    8    &0   !H    :P   &\   !S    =@   'D   !\
M    ?P   ((   "%    B0   (P   "1    E@8  )H2  ":(   ES$  )1$
M  "17   CG8  (N3  "(L   AMD .T(  "]&   A3   $U(   19    7P
M &4   !J    ;P   ',   !W    >@   'X   ""    A@   (D   ",
MCP   )$   "5    F    )P   "A    I@   *H%  "O%   KB0  *HX  "H
M3P  I6D  **%  "?H   G+\ -4T  "A3   960  "6$   !G    ;@   '0
M  !Z    ?P   (0   "(    C    )$   "5    F    )L   "?    H@
M *4   "H    K    +$   "W    O0   ,4   #-!   UA4  -$H  #,0
MQUH  ,%V  "]D   N:H +ED  "!A   0:    '    !W    ?P   (8   ",
M    D0   )8   ":    G@   *(   "F    J@   *X   "R    M0   +D
M  "^    PP   ,D   #0    V@   .,   #L    ] 0  /D7  #T,   [TP
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M_/[______________________________________________________P
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M______________________________________\
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M_VUF=#$      P0A   !                     0
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M^;Y'._/+34_LUE)EY>%5?-SF69'-WUVCP-=@L;+08KRFRF3&F\9FSX[!:->
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M\(^"H.N'B:OG@9"TY'R8N>-ZG[SB>JB^X7JRO]-TL\'$;++"P&JRP\!JLL/
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MY'R8N>-ZG[SB>JB^X7JRO]-TL\'$;++"P&JRP\!JLL/ :K+#P&JRP\!JLL/
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M$O^D-1S_KSTD^[I$,O/&2D/MTT]7YM]4;N'I5H33Y5N8Q-Q?J+;48[6ISF;
MG,AIRI#$;-*#P'#8?+]]VGF_DMEVNJ/7=;2DUG6TI-9UM*36=;2DUG6TI-9U
MM*36=;2DUG6TI-9UM*36=;2DUG6TI-9UM*36=;2DUO^B%P+_HR((_Z(K$O^G
M-1K_LCTC][Y$,._,2D'GW$Y5X.E0;-GN5(+(YUJ6N=Y=I:O67[*=SV&]C\IB
MR(+%8]!WPFC5<\%UUG'"A]5OPYS3<<2DTG'$I-)QQ*32<<2DTG'$I-)QQ*32
M<<2DTG'$I-)QQ*32<<2DTG'$I-)QQ*32<<2DTO^C%P+_I"((_Z,K$?^J-1G]
MMCT@\L1$+>C323W?Y4M3V>].:\[R4H"]Z%B3KN!;H:#97:Z3TE^XALU?P7O)
M8<EQQF7-;<9QSFO&@,UJQY+,:<>7S&G'E\QIQY?,:<>7S&G'E\QIQY?,:<>7
MS&G'E\QIQY?,:<>7S&G'E\QIQY?,:<>7S/^D%@+_I2('_Z0K$?^N-!;XNSP=
MZ\M#*>#=1SG6ZDI3S?5-:L+T4'ZRZU:.H^-9G9;<6ZB*UERQ?M)=N73.7\!L
MS&3$:,MMQ6?,>L1FS(G#9<R.PV7,CL-ES([#9<R.PV7,CL-ES([#9<R.PV7,
MCL-ES([#9<R.PV7,CL-ES([#9<R.P_^E%@+_IB$'_Z8K$/^S-!/QPCP9X]1"
M(M;F1#K+\DA2P?Q+:+;V3GJG[E.)F>97EHS@6:&!VUJJ=M=;L6W47;9GTF*Y
M9-%JNF+2=;IATH*Y8=*&N&'2AKAATH:X8=*&N&'2AKAATH:X8=*&N&'2AKAA
MTH:X8=*&N&'2AKAATH:X8=*&N/^G%0'_J"$&_ZHK#?>Z,P_GS#L3V.$](LSN
M0SO ^D91M/](9*KY2W6;\5&#CNI4CX/E5IEXX%>A;]U9IFC;6ZICV6"M7]EF
MKE[9<*Y=V7NM7-E_K5S9?ZU<V7^M7-E_K5S9?ZU<V7^M7-E_K5S9?ZU<V7^M
M7-E_K5S9?ZU<V7^M7-E_K?^I% '_JB$%_[(J">[$,@G:VS$.S>L\)<#X03NS
M_T).I_]%7YS]2&Z0]DU[A/!1AGKK4XYPYU65:>17FF/B6IU?X5Z?7.%CH%O@
M:Z!9X72@6>%WH%GA=Z!9X7>@6>%WH%GA=Z!9X7>@6>%WH%GA=Z!9X7>@6>%W
MH%GA=Z!9X7>@6>%WH/^K$P#_K2 $];LG!-_2*0+.YS(2P?8Z)K/_/3FF_S]*
MFO]!68__16>%^TER>O9->W'Q4()I[E*(8^Q5C%_K6(Y<ZER06NE@D5CI9Y%7
MZ6Z15^EQD5?I<9%7Z7&15^EQD5?I<9%7Z7&15^EQD5?I<9%7Z7&15^EQD5?I
M<9%7Z7&15^EQD?^N$0#^LQX"YLH; -#D(P7"]#$5M/\U)J;_.#:9_SI$C?\]
M4H/_05YY_T1H</Q(<&CY3'9B]D]Z7O52?5OT57Y9\UF 5_-=@%;R8H%4\FB!
M5/-J@53S:H%4\VJ!5/-J@53S:H%4\VJ!5/-J@53S:H%4\VJ!5/-J@53S:H%4
M\VJ!5/-J@?NR#0#OP0\ T]\) ,3Q)@FU_RT6IO\O))C_,C*,_S4^@?\X2G?_
M/%1M_S]=9?]#9%__1VA;_TMK6/U.;E;]4F]4_%5P4_Q8<%+\77%1_&)Q4?QC
M<5'\8W%1_&-Q4?QC<5'\8W%1_&-Q4?QC<5'\8W%1_&-Q4?QC<5'\8W%1_&-Q
M4?QC<>RW!P#2S08 Q>\5 ;?^(PNH_R86F?\H(8S_*RV _R\X=?\S0FO_-TMC
M_SI27/\^5U?_05M4_T5=4?])7U#_3&!/_T]A3O]284W_5F%,_UIB2_]<8DO_
M7&)+_UQB2_]<8DO_7&)+_UQB2_]<8DO_7&)+_UQB2_]<8DO_7&)+_UQB2_]<
M8M+# @#'UP0 N?L7 ZK_' N;_QX4C?\A'H#_)"AT_RDR:?\M.V#_,4)9_S5'
M5/\X2U#_/$Y-_S]02_]"44K_15))_T=22/]*4T?_3E-&_U)41O]35$;_4U1&
M_U-41O]35$;_4U1&_U-41O]35$;_4U1&_U-41O]35$;_4U1&_U-41O]35/^7
M%03_EB *_Y,I%/^.,R'_D3TL_Y=&./^:4$;_F5M7_Y9F:/^1<'C\BGJ&]H.#
MD_%\BY[N=Y2D['2=J.MTI:KK=*VKZG2UK.ASO:W=;K^NT6G K\EEO[#)9;^P
MR66_L,EEO[#)9;^PR66_L,EEO[#)9;^PR66_L,EEO[#)9;^PR66_L/^7%03_
MEB *_Y,I%/^.,R'_D3TL_Y=&./^:4$;_F5M7_Y9F:/^1<'C\BGJ&]H.#D_%\
MBY[N=Y2D['2=J.MTI:KK=*VKZG2UK.ASO:W=;K^NT6G K\EEO[#)9;^PR66_
ML,EEO[#)9;^PR66_L,EEO[#)9;^PR66_L,EEO[#)9;^PR66_L/^7%03_EB *
M_Y,I%/^.,R'_D3TL_Y=&./^:4$;_F5M7_Y9F:/^1<'C\BGJ&]H.#D_%\BY[N
M=Y2D['2=J.MTI:KK=*VKZG2UK.ASO:W=;K^NT6G K\EEO[#)9;^PR66_L,EE
MO[#)9;^PR66_L,EEO[#)9;^PR66_L,EEO[#)9;^PR66_L/^7%03_EB *_Y,I
M%/^.,R'_D3TL_Y=&./^:4$;_F5M7_Y9F:/^1<'C\BGJ&]H.#D_%\BY[N=Y2D
M['2=J.MTI:KK=*VKZG2UK.ASO:W=;K^NT6G K\EEO[#)9;^PR66_L,EEO[#)
M9;^PR66_L,EEO[#)9;^PR66_L,EEO[#)9;^PR66_L/^7%03_EB *_Y,I%/^.
M,R'_D3TL_Y=&./^:4$;_F5M7_Y9F:/^1<'C\BGJ&]H.#D_%\BY[N=Y2D['2=
MJ.MTI:KK=*VKZG2UK.ASO:W=;K^NT6G K\EEO[#)9;^PR66_L,EEO[#)9;^P
MR66_L,EEO[#)9;^PR66_L,EEO[#)9;^PR66_L/^7%03_EB *_Y,I%/^.,R'_
MD3TL_Y=&./^:4$;_F5M7_Y9F:/^1<'C\BGJ&]H.#D_%\BY[N=Y2D['2=J.MT
MI:KK=*VKZG2UK.ASO:W=;K^NT6G K\EEO[#)9;^PR66_L,EEO[#)9;^PR66_
ML,EEO[#)9;^PR66_L,EEO[#)9;^PR66_L/^7%03_EB *_Y,I%/^.,R'_D3TL
M_Y=&./^:4$;_F5M7_Y9F:/^1<'C\BGJ&]H.#D_%\BY[N=Y2D['2=J.MTI:KK
M=*VKZG2UK.ASO:W=;K^NT6G K\EEO[#)9;^PR66_L,EEO[#)9;^PR66_L,EE
MO[#)9;^PR66_L,EEO[#)9;^PR66_L/^7%03_EB *_Y,I%/^.,R'_D3TL_Y=&
M./^:4$;_F5M7_Y9F:/^1<'C\BGJ&]H.#D_%\BY[N=Y2D['2=J.MTI:KK=*VK
MZG2UK.ASO:W=;K^NT6G K\EEO[#)9;^PR66_L,EEO[#)9;^PR66_L,EEO[#)
M9;^PR66_L,EEO[#)9;^PR66_L/^8%03_ER *_Y0I%/^/,R'_DSTK_YI&-_^=
M4$7_G5I6_YIE9_^6;WC\D'B']8B!E?"!B:'L>I&IZG>:K>AVH[#H=:NQYW6T
ML^%SNK35;KRUR&>[ML%FN[7!9KNUP6:[M<%FN[7!9KNUP6:[M<%FN[7!9KNU
MP6:[M<%FN[7!9KNUP6:[M?^8%03_F!\*_Y4I$_^0,R#_ECPJ_YU%-O^B3T3_
MHEE5_Z!C9_^=;7C[EW:(])!^E^Z)AJ3I@8VNYGN6M>1YG[GC>*F[XWBRO-9S
MM;[(;+2_O&BUOKAJN+JX:KBZN&JXNKAJN+JX:KBZN&JXNKAJN+JX:KBZN&JX
MNKAJN+JX:KBZN&JXNO^9%03_F!\*_Y8I$_^1,R#_F3PH_Z!%-/^F34/_IE=4
M_Z5A9_ZC:WC[GW2)\YA\F>V1@Z?GB8JRXX&2O.!\F\'?>Z;$VWFOQLIQK\>Z
M:*W)LVRRPK!NM;ZP;K6^L&ZUOK!NM;ZP;K6^L&ZUOK!NM;ZP;K6^L&ZUOK!N
MM;ZP;K6^L&ZUOO^9%0/_F1\)_Y8I$_^2,Q__FSPG_Z-$,_^I3$+_JE94_ZI?
M9ONH:'GXI7&*\Z!ZF^R9@:GFD8>VX(>.P=V E\G9?:+-T'NKS<!TJ\VR;JO,
MJW"PQJERL\&I<K/!J7*SP:ERL\&I<K/!J7*SP:ERL\&I<K/!J7*SP:ERL\&I
M<K/!J7*SP?^:%0/_F1\)_Y<I$_^3,Q__G3PF_Z5$,O^K2T'_KE13_:Y=9OFM
M9GGUJFZ+\:9VG.NA?JODF82YVHR)Q="#D,W+@9S0R8.IT+AZJ<^K<ZG/I'2M
MR:)UL<2B=;'$HG6QQ*)UL<2B=;'$HG6QQ*)UL<2B=;'$HG6QQ*)UL<2B=;'$
MHG6QQ/^:%0/_F1\)_Y<H$O^5,A[_GSPF_Z=$,O^M2T#_L5-2^[)<9O>Q9'GS
MKVR+[:QSG>:H>JW=GH"ZTI2&Q<>*C,W A9;1OH:CTK& I]*D>*?2G7>KS)MX
MK\>;>*_'FWBOQYMXK\>;>*_'FWBOQYMXK\>;>*_'FWBOQYMXK\>;>*_'FWBO
MQ_^:%0/_FA\)_Y@H$O^6,AW_H#LE_ZA#,?^O2D#^M%-2^;5;9?6U8GGPM&J,
MZK)PGN&L=J[7I7VYRYN$Q,"1B<VWBI'3LXJ=U*N&IM2=?:;4EGJISY5[K<J5
M>ZW*E7NMRI5[K<J5>ZW*E7NMRI5[K<J5>ZW*E7NMRI5[K<J5>ZW*E7NMRO^;
M%0/_FA\)_Y@H$O^7,AS_HCLD_ZI#,/^Q2C_\MU)1^+E:9?.Z87GNNF>,YKEM
MG]VR=*W1JGNYQ:&!P[J7ALROCXW3J8R7UJ2,I-:7@:36D'VHT8]^J\R/?JO,
MCWZKS(]^J\R/?JO,CWZKS(]^J\R/?JO,CWZKS(]^J\R/?JO,CWZKS/^;%0/_
MFQ\)_Y@H$O^9,AS_HSLC_ZQ#+_^S2C[[NE%0]KU89/&_7WCKP&6-X[]KG]BX
M<JS,L'BXOZ=^PK.>@\RHE8G4GY"1V)R1H=B/AZ/8B8&FU(B!J<^(@:G/B(&I
MSXB!J<^(@:G/B(&ISXB!J<^(@:G/B(&ISXB!J<^(@:G/B(&IS_^;%0/_FQ\)
M_YDH$O^:,AO_I3LB_ZU"+O^U23WZO5!/]<)79._%77CHR&.-W\5IGM.^<*O&
MM7:WN:Q[PJVD@,NAG(73E92+V9"4F=J(C:':@8:DUH&%J-&!A:C1@86HT8&%
MJ-&!A:C1@86HT8&%J-&!A:C1@86HT8&%J-&!A:C1@86HT?^<%0/_FQ\(_YDH
M$?^<,AK_ICHA_Z]"+?VX23SXP4].\L=68^S,6WCET&",VLQGG<W$;:O NW.V
ML[)XP:>K?<J:HX'3C)N&V8::D]R!EZ';>HVCUWJ*I]-ZBJ?3>HJGTWJ*I]-Z
MBJ?3>HJGTWJ*I]-ZBJ?3>HJGTWJ*I]-ZBJ?3>HJGT_^<% /_G!\(_YHH$?^=
M,AG_J#H@_[)"+/J[2#OTQDY-[LY48>C567?@V%Z+U--DG,;*:JJYPF^UK+ET
MP*"R><F2JWW2A:2!V'^DC]I]I*+9=9>DUG63I])UDZ?2=9.GTG63I])UDZ?2
M=9.GTG63I])UDZ?2=9.GTG63I])UDZ?2=9.GTO^<% /_G!\(_YLH$?^?,AC_
MJSH?_K1!*O>_2#GPRTU+ZM928./A5G79X%N*S=IAF[_19ZFRR6RTI<)POY>Z
M=,B*M'?0?Z]^UGNQCM9ZM*75<Z6FTW*>J=!RGJG0<IZIT'*>J=!RGJG0<IZI
MT'*>J=!RGJG0<IZIT'*>J=!RGJG0<IZIT/^=% +_G1\(_YLH$?^B,1?_K3H=
M^[A!*/+$1S?KT4Q(Y.%07=WH4W31YUF(Q.!>FK?:8Z>ITF>SG,MKO8[$;L>!
MOW+.>;U[TG? C-)VQ*/1;[2ISV^LJ\QOK*O,;ZRKS&^LJ\QOK*O,;ZRKS&^L
MJ\QOK*O,;ZRKS&^LJ\QOK*O,;ZRKS/^>% +_GA\'_YPH$/^E,17_L3D;]KU!
M)>W*1S/DVDM$W>E-7-7N47/([%:&N>5:F*O=7J:=UF&QD-!CO(/+9L5WQVK+
M<<9US6['A,UMQY?,:\BLRFN]K\=KO:_':[VOQVN]K\=KO:_':[VOQVN]K\=K
MO:_':[VOQVN]K\=KO:_':[VOQ_^>% +_GQ\'_YTH$/^I,1/\M3D9\<- (N;2
M1B_;XTA#T^U,6\KS3W&]\5.$KN=8E)_@6Z*2V5RNA--=N'?.7L!LRV/&:,IM
MQV;*>\9ERXO%9,R>Q&7-K,)ES:S"9<VLPF7-K,)ES:S"9<VLPF7-K,)ES:S"
M9<VLPF7-K,)ES:S"9<VLPO^@$P+_H!X'_Y\H#_^M,!'VNS@5Z<L_'-S>0BO2
MZD=#R/1*6K[X36ZQ\U& H^I6CY7C6)R(W5JG?-A;L'#37+=HT6*[9-!JO&/0
M=KQBT8.[8=&4NF#2G[E@TI^Y8-*?N6#2G[E@TI^Y8-*?N6#2G[E@TI^Y8-*?
MN6#2G[E@TI^Y8-*?N?^A$P'_HAX&_Z0G#/ZS, WOPS<0W]8]%=+F02S'\D5#
MO/Q(6+'\2FNF]DY[F.Y3B8OG5I5_XE>>=-U9IFK:6ZQCV&"O8-=GL%[8<;!>
MV'VO7=B+KUS9E:Y<V96N7-F5KES9E:Y<V96N7-F5KES9E:Y<V96N7-F5KES9
ME:Y<V96N7-F5KO^C$@'_I!X%_ZHG"?:[+@GDSC0)U.(X&,CP0"Z\^T-#L/]%
M5:7_1V::^4MTC?)0@8+L4XQWYU64;>-7FV7A6J!@WUZB7=]DHUO?;*1:WW:C
M6=^"HEG@BJ)9X(JB6>"*HEG@BJ)9X(JB6>"*HEG@BJ)9X(JB6>"*HEG@BJ)9
MX(JB6>"*HO^E$0'_IAT$_K(E!>K&*0/6WBD(R>TX&[SZ/2^O_S]!H_]!49C_
M1&"._D=M@_=,>'CR3X%O[E*)9^M5CF'I6))=Z%R46N=BE5GG:)57YW"55^=Z
ME%;H@916Z(&45NB!E%;H@916Z(&45NB!E%;H@916Z(&45NB!E%;H@916Z(&4
M5NB!E/^G#P#_J1P#\KT> =K9$P#*ZBP,O?DU':__."ZB_SL]EO\]2XO_0%F"
M_T-D>/U(;F_Y2W9G]4][8?-2@%WR5H):\5J$6/!>A5;P9(55\&N%5/!SA53Q
M>814\7F$5/%YA%3Q>814\7F$5/%YA%3Q>814\7F$5/%YA%3Q>814\7F$5/%Y
MA/^J# #[M!0 V,X' ,SH&P*^]RP/L/\P':+_,RN5_S8YBO\X17__/%%V_S];
M;?]"8V7_1VE?_4MN6_Q/<5CZ4W-6^E9T5/E:=5/Y7W52^61U4?EK=5#Y<'50
M^7!U4/EP=5#Y<'50^7!U4/EP=5#Y<'50^7!U4/EP=5#Y<'50^7!U4/EP=?>N
M" #7P@0 S=<& +_U'P6Q_R<0H_\I&Y7_+">)_S S?O\S/G/_-DAJ_SI08O\]
M5UO_05Q7_T5@5/])8E+_3610_U%E3_]594[_669-_UUF3/]C9DS_9F5,_V9E
M3/]F94S_9F5,_V9E3/]F94S_9F5,_V9E3/]F94S_9F5,_V9E3/]F9=BX  #,
MRP0 P/(, ++_' >D_R 0EO\B&8G_)21]_RDN<O\L.&C_,4!?_S1'6?\X3%3_
M/%!0_S]23?]#5$O_1E5*_TI62?]-5DC_4%='_U171O]95T;_7%=&_UQ71O]<
M5T;_7%=&_UQ71O]<5T;_7%=&_UQ71O]<5T;_7%=&_UQ71O]<5\W" @#!U0(
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M>%#X@GA0^()X4/B">%#X@GA0^()X4/B">%#X@GA0^()X4/B">/ZF"0#FM@8
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M2EU-_U!>2_]57TK_6U])_V%?2?]G7TC_;EY(_W=>1_^ 74?_@%U'_X!=1_^
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M7=V#U5S@@M%=XW[17>-^T5WC?M%=XW[17>-^T5WC?M%=XW[17>-^T5WC?O^
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M?4_UQWU/]<=]3_7'?4_UQWU/]<=]3_7'??^4"0'_H0P VK0" -#%!0#(V <
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M0?^+44'_BU%!_XM10?^+4=.N  #(O@  O<X  +#<  "D_PX#E_\5"(O_&A"
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MD5BVU9%8MM616+;5D5BVU9%8MM616+;5D?^%" 3_BA(%_YP6 O^K%@#JO X
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MDZQQSI.F;M23HF_9C)]OW8><;^& G&_A@)QOX8"<;^& G&_A@)QOX8"<;^&
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M,!]^]S4L=/<Y-VGV/$)?]C]+5_9$4U'V2EA-]U)<2O=;74GX9EU(^7)<1_F
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M*R+_82H@_VLI(/]K*2#_:RD@_VLI(/]K*2#_:RD@_VLI(/]K*;C!  "KS
MG=4  ([=  " Y   =/4  FG_  5?_P *5O\!#TW_!11&_PD8/_\-'#G_$AXT
M_Q8A,?\;(B[_'R,K_R0D*?\H)2?_+"4E_S$E(_\V)2#_.R4>_T D'?]&)!O_
M3",9_U,B&?]3(AG_4R(9_U,B&?]3(AG_4R(9_U,B&?]3(O]9$P__3QL6_T4G
M'?]&+2'_23,E_TD\*_]'2#+_154X_T-C//]#<CW_1( ]_T2,/?]%ESW_1J$]
M_T>I//](LCS_2+D\_TG"//])S3O_2M@[_TKC._]+[3O_2_4Z_TS\.OY,_SK]
M3?\Z^4W_.OE-_SKY3?\Z^4W_.OE-_SKY3?\Z^4W_.O]9$P[_4!L5_T4G'?](
M+"#_2S(E_TL[*_]*1C+_1U,X_T5A/?]%<#__17X__T:*/_]'EC__2)\__TFH
M/_])L#[_2K@^_TK!/O]+RS[_2]8]_TSB/?],[#W_3?4]_DW\/?_B?1!)0T-?
M4%)/1DE,10 1%?Q._SWZ3O\]]D[_/?9._SWV3O\]]D[_/?9._SWV3O\]]D[_
M/?]:$P[_41L5_T8F'?],*A__4# C_U$Z*O]/1#'_3%$Y_TE>/O](;4+_2'M#
M_TF'0_]*DT/_2YQ#_TRE0_],KD/_3;5#_TV^0O].R4+_3M-"_T_@0OY/ZT+\
M4/1"^E#\0OA0_T+S4/]"\%'_0?!1_T'P4?]!\%'_0?!1_T'P4?]!\%'_0?];
M$@[_4AH5_T@F'/]0*![_52XB_U<X*/]50S#_44XY_TY<0/]+:D3_3'A&_TR$
M1_]-D$?_3II(_TZC1_]/JT?_3[-'_U"\1_]0QD?^4=%'_%'>2/I2ZDCW4O1(
M]5+\2/%2_TCM4O]&ZE/_1.I3_T3J4_]$ZE/_1.I3_T3J4_]$ZE/_1/]<$@W_
M4QH4_TPD&_]5)QS_6BT@_UPW)O];02__5DPX_U-90/]09T?_3W1*_T^!3/]0
MC$W_4)9-_E&@3?U1J$W\4K!-^U*Y3?I3PTWY4\].]U3<3O54Z4[R5/-/[U3[
M3^I4_4[F5?]+XU7_2>-5_TGC5?])XU7_2>-5_TGC5?])XU7_2?]>$0W_5!H4
M_U B&O]9)1O_8"P>_V,V)/]B0"W_7THV_UI60/]68TG_4W!._5-]4?M3B%/Y
M4Y)3^%2<5/=4I53V5*U4]56V5?15P%7S5<Q6\5;:5N]6Z%?L5O-7YE;X5^)7
M^U/=6/Y0VEC_3MI8_T[:6/].VEC_3MI8_T[:6/].VEC_3O]?$0W_5AD4_U4@
M&/]?(AG_9RL<_VHT(?]J/BK_9T@T_V)3/_U=7TGZ66Q2]U=X5_56@UKS5HY;
M\5:87/!6H5SO5ZE=[E>R7NU7O%[K5\A?ZEC88.=8YV'B5_%AW5GV7=A:^5K3
M6OU6SUO_4\];_U//6_]3SUO_4\];_U//6_]3SUO_4_]@$ S_5QD3_UD>%O]D
M(1;_;2H9_W$S'_]Q/"?_;T8Q_6Q0/?AF7$GS8&A4\%MS7.U9?F'K6(ECZ5B3
M9>=8G&;F6*5GY%BN:.-8N&GB6,1JX%C4:]U8Y6S86N]HTEOT9,Q<^&#(7?M<
MQ5[]6<5>_5G%7OU9Q5[]6<5>_5G%7OU9Q5[]6?]A$ S_6!D3_UX<%/]J(!3_
M<RD7_W<R'/]X.R/^>$0N^'5..O)O64?M:&14Z6)N8.5=>6?A6X-LWUJ-;MU9
MEW#;6:!QV5JJ<=A;M''67,%QU5W1<=)=XG'-7>UOQU_Q:L)@]&:^8/=BNV'Y
M7[MA^5^[8?E?NV'Y7[MA^5^[8?E?NV'Y7_]B#PS_6A@2_V(:$_]O(!+_>"@4
M_WTQ&?]_.B#Z?T,J\WY+-NUY5T3G<F%2X6IK8=MB<VS677UTTUV'=M%=D7?/
M7IMWS5^D=\Q?KG?*8+IWR6')=\=AVW?"8>EVO6+L<;AC\&RT8_-GLF3U9+)D
M]62R9/5DLF3U9+)D]62R9/5DLF3U9/]C#@O_6Q@2_V<8$?]T'Q#_?2<2_X(P
M%OZ%.1SVAD$F[H9*,NB!54#A>U]0VG-G8-)J;VW-9'AVR6*!>L9ABWS$8I5\
MPF.??,%CJ7R_9+1\OF7"?+QFU'RX9>1\LV7H=Z]F['*K9N]MJ6?Q::EG\6FI
M9_%IJ6?Q::EG\6FI9_%IJ6?Q:?]D#@O_71@2_VH7#_]X'P[_@280_X<O$_N+
M-QGRC$ BZHU)+N.)5#S;@UU,TWME7<MS;6S$;'1VOVA\?;QFA8"Y9H^!N&>9
M@;9HHX&T:*Z!LVF[@;)JS(&O:N&!JFGD?*9IZ'>C:NMRH6KN;J%J[FZA:NYN
MH6KN;J%J[FZA:NYNH6KN;O]E#@O_7A@1_VX7#O]['PW_A28-_XLN$/>0-A;N
MDC\>YI-'*MZ14SC5BEQ*S8)C6\5[:FF]='%UMVYX?K-K@(.P:XJ%KFN4A:QL
MGH6J;*F%J6VVA:AMQH6F;MJ&H6W@@IYMY'R;;>AWF6SK<YELZW.9;.MSF6SK
M<YELZW.9;.MSF6SK<_]F#0K_81<0_W$7#?]_'@O_B"4,_X\M#O24-1/KEST:
MXYI&)=J74C70D%I'QXEB6+^":&>W>V]TL'5U?JMQ?(6G;X6(I6^/B:-OF8JA
M<*2*H'&PBIYQP(J=<M2*F7#=AY9PX8&4;^5[DF_H=Y)OZ'>2;^AWDF_H=Y)O
MZ'>2;^AWDF_H=_]G#0K_9!4/_W06"_^"'0K_BR0*_),K#/&8-!#HG#P6WY]%
M(-6<4#/,E5E%PHY@5KJ(9V6R@FURJGQR?:1W>86?=("+G'.*C9ISE(Z8<Z".
MEW2LCI5TNXZ4=<Z.D'/9C(YSWH6,<N)_BW'E>XMQY7N+<>5[BW'E>XMQY7N+
M<>5[BW'E>_]G#0K_9A0._W<6"O^$'0C_CR,(^I8J">Z<,@WEH3H2VZ1#'=&@
M3C#'FEA#OI1?5+6.96.MB&MPI8)P>YY]=H68>7R,E'>%D)%VCY*/=IN2CG>G
MDHQWMI*+=\B2B';5D(9UVXJ%=-^$A'3B?X1TXG^$=.)_A'3B?X1TXG^$=.)_
MA'3B?_]H# K_:1,-_WH5"?^'' ?_D2(&]YHI!^NA, KAIS<.V*A!&\VD3"[#
MGE9!NIA>4K&39&&HC6ENH(AN>IB#<X21?GF-C'J DXAYBI6&>9:6A'FCEH-Z
ML9:!>L.6?WG2E7YXV(Y^=]R(?7;?@WUVWX-]=M^#?7;?@WUVWX-]=M^#?7;?
M@_]I# K_:Q(,_WP5"/^*&P;_E"$%])TG!>BE+0?>K#0*TZP_&<FH2RR_HU0_
MMIU<3ZV88U^DDVALG(YM>).(<8.+@W:-A']\E']]A9A]?)"9>WV>F7E]K)EW
M?KV9=7W/F75\U))V>]F+=7G=AW5YW8=U>=V'=7G=AW5YW8=U>=V'=7G=A_]J
M# G_;A +_W\4!_^-&@3_F" #\:$D ^6I*03;L2X'S[ ]%\6L22J[IU(\L:):
M3:B=85V@F6=JEY1K=HZ/;X&&BG.,?85XE7:"@)IR@8N<<(&9G&^"J)QM@KF;
M;(/.FVR!TI5M?]>.;7[;BFU^VXIM?MN*;7[;BFU^VXIM?MN*;7[;BO]J"PG_
M<0X)_X(4!?^0&0/\FQT"[:4@ >&N(@'6MBH%R[0[%<"P1RBVK% ZK:=82Z2C
M7UJ;GV1HDIII=(F5;7^ D7&*=HQUE&V(?)MIAX>=9XB5G6:)I9QEB;:;9(K,
MFF6'TI5EA=:/9H/:BV:#VHMF@]J+9H/:BV:#VHMF@]J+9H/:B_]K"PG_= P(
M_X83!/^3%P+XGQD!Z:H8 -RU%0#1NB<$QK@Y$[NU126QL4XWJ*U62)ZI7%>6
MI6)EC:%F<82<:GUZF&^'<)1SD6>1>IABD(6:89&4FF&2I)A@D[677Y/+E5^1
MU))@C=F-8(O;B6"+VXE@B]N)8(O;B6"+VXE@B]N)8(O;B?]M"@C_> L&_XH1
M O^7% #THQ( WJ\) -6[" #+OR0"P+XV$+:[0B*LMTLTHK1319FP6520K%YB
MAZAC;GZD9WISH6N$:9YPCF&;>)->FX2479R3DUV=HY)<GK207)[*CUN<V8Q<
ME]R(6Y3>A5N4WH5;E-Z%6Y3>A5N4WH5;E-Z%6Y3>A?]N"@C_?0H$_XX. ?B<
M#0#:J04 T[0& ,V_!0#$Q1\!NL4R#;#"/QZFOT@QG+M009*W55")M%I>@+!?
M:W:M8G9LJF> 8JALB%RG=HQ:IX.-6:B2C%FHHHI8J;.)6*K*AU>HWH58H^&!
M6)_C?EB?XWY8G^-^6)_C?EB?XWY8G^-^6)_C?O]P"0?_@PD"_Y,) -^A @#4
MK0, S+@$ ,7$ @"\S!D L\TM"JG+.QJ?R$4LE<1,/8O!44R"O59:>+I:9VZW
M77)CM6)[6[-I@E>S=(16LX&$5;21@E6UH8%4MK)_4[;)?E.VY'Q4L.9Y5*SH
M=U2LZ'=4K.AW5*SH=U2LZ'=4K.AW5*SH=_]U!@7_B08!ZYD" -6G  #-L@(
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M?EV'Y'U=A^1]78?D?5V'Y'U=A^1]78?D??]E"@G_> <$_X@) .^5!P#9H ,
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M8DVV]V)-MO=B3;;W8O]^  '@CP  TYT  ,FI  # M   M[T  *W' @"BT 8
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M'!;_8!P4_VH;$O]V&A'_>1H1_WD:$?]Y&A'_>1H1_WD:$?]Y&K&_  "DR
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M=&]T[6]O=.UO;W3M;V]T[6]O=.UO;W3M;_]:"PO_; 4%_WL) OR'"@#KD D
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M;5>-[VU7C>]M5XWO;?]I  3_?   X(H  -66  #-GP  Q*@  +RN  "RLPX
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M*C/ZK"@S^[\G,OO8)C+\["4R_.PE,OSL)3+\["4R_.PE,OSL)<:D  "\L
MLKH  *;#  "9R@  C-   (#6  !TW0  ;/,$ 63_#@9<_Q8+5/\<$4W_(1=&
M_R8</_\K(#K_,2,V_S@E,_\_)C#_1R8N_U$F+?];)2O_9R0J_W8C*/^%(2C_
ME2 G_Z0?)_^T'B;_QATF_\8=)O_&'2;_QATF_\8=)O_&';ZN  "UN   J<$
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M7H1J_%J$:OU8A&K]6(1J_5B$:OU8A&K]6/]1"PO_80,&_W ( O]["@#U@PP
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M9V5U\V=E=?-G977S9_]= P;_;@ "]7P  -R'  #4CP  S94! ,:: 0"]GA@
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M0T3!RT)$P.=!0[[W0$.]_S]#O/\_0[S_/T.\_S]#O/\_0[S_/]R&  #-E0
MPZ$  +JK  "QLP  IKD  )J_  ".Q0  @LL# 'G2# !TU" #;M,M"V;2-A5>
MT3P@5M!"*D_/2#-)ST\X1<]8.T3/8SQ#T&\[0M%].D'1C3A!TIXW0-*Q-C_3
MRC0_TN<S/M#V,SW._S,]SO\S/<[_,SW._S,]SO\S/<[_,]./  #&G0  O:D
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M%2'_SQ0A_]@4(?_8%"'_V!0A_]@4(?_8%+NM  "QMP  IK\  )C%  "*RP
M?=$  '#7  !EW0  6N,  %/U  ),_P0%1?\+"3[_$0TX_Q<1,O\<$R[_(A4K
M_R@7)_\N%R3_-1@@_ST7'O]&%QO_4189_UT5%_]K$Q3_>Q(3_XH1$O^8$!+_
MJ \2_ZT/$O^M#Q+_K0\2_ZT/$O^M#[2U  "HO@  F\4  (S+  !^T0  <=@
M &3>  !9XP  3N@  $?X  ) _P %.?\ "#3_!0LN_PH.*?\0$"7_%1$B_QL2
M'_\A$QO_)A,7_RT3$_\T$@__/1(+_T<1"/]3$ 7_7P\"_VP. /]Y#0#_APP
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M4GII_U)Z:?]2>FG_4O]3 P?_8P "_'$  .)Z  #8@0  T88" ,R(! ##BQP
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M64Z5PU=-E=U63I3Q4TZ3_5%.DO]03I+_4$Z2_U!.DO]03I+_4/=O  #<?P
MSXL  ,65  "\G0  LZ,  *FG  ";JP  E*T1 (^N)@*(K34)@JL_%'NI1A]S
MJ$PK:Z91-F.D5D!;HEM(5:!A3U"?:51.GW1539^ 5$R?CE),H)Y12Z"N3TJ@
MPTY*H-Y,2I[Q2DJ=_4E*G/](2IS_2$J<_TA*G/](2IS_2.9V  #6A0  RI$
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M*#G'_BDYQO\I.<;_*3G&_RDYQO\I.<;_*<V/  #"G0  N:<  +"O  "FM@
MF;L  (V_  " Q   =<H  &G0 @!?V @ 6]L9 5;;)@=0VR\.2MHV%43:/AL_
MVD8@/-M/(3O;6B(ZW&8A.=UT(#G=@A\XWI,=-]ZE'#;?NQLUX-@:--WO&S+;
M^APQVO\=,=K_'3':_QTQVO\=,=K_'<69  "[I0  LZ\  *FV  "=O   D,$
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M"0G_N0D)_[D)"?^Y";&T  "EO   E\(  (G(  ![S@  ;=,  &':  !5WP
M2^0  $'I   Z]@ "-/\ !"[_  8I_P0))?\)"B#_$ P<_Q4,&?\;#17_(0T1
M_R<-#/\O#0C_.0P$_T0+ /]0"@#_7@D _VT) /][" #_B0< _Y0' /^4!P#_
ME < _Y0' /^4!ZB[  ":P@  C,@  'W.  !OU   8=L  %7A  !)Y@  /^H
M #7N  $O^@ "*?\ !"/_  8?_P '&O\ "1;_ 0D3_P8*#O\+"PO_$0L'_Q<+
M O\="@#_) H _RT) /\X"0#_1 @ _U ' /];!P#_9@8 _W & /]P!@#_< 8
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M.XQ>_SN,7O\[C%[_._]* @C_6  #_V0  .YL  #=<0  V'0# --T!P#*=Q\
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M8E9UO&%5=M5@5G;L6UAV^E=8=?]36'7_4UAU_U-8=?]36'7_4_]?  'D;@
MUWL  ,R$  ##BP  NY   +*2  "HDP0 H94> )J5+P24DSP.C9!%&8:.3"1_
MBU$O>8A6.G&%6T-J@U]-8H!D55Q]:EQ7?'-@57Q^851\BF!3?9E?4GVI75%]
MNUQ1?M1;4GWL5U)]^E13??]14WS_4%-\_U!3?/]04WS_4/]D  #@<P  TW\
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M0$>8^C]'E_\^1Y?_/D>7_SY'E_\^1Y?_/N!V  #0A   Q(\  +N9  "SH
MJJ4  )^H  "2JP  A*T  'ZO%@!ZKR@"=*XT"6ZM/1)GK$0;8*I*)5FI3RY2
MJ%0V3:=;.TFF9#Y'IF\^1J9[/D:GB#Q%IY<[1:>H.42GNSA#I]4V0Z7M-D*D
M^C5"HO\U0J+_-4*B_S5"HO\U0J+_-=E]  #*BP  OY8  +>?  "NI@  I*L
M )FN  ",L0  ?K0  '2W"@!PN!\ :[@M!66X-@Q>MSX56+5$'E&T229+M% L
M1[-7,42S8#-"LVPS0;-X,D&TAC! M)4O/[2F+3^TNBP^M-4J/;+M*CRQ^RH[
MK_\K.Z__*SNO_RL[K_\K.Z__*]"&  #$DP  NIX  +*F  "IK   GK$  )&T
M  "%MP  >+L  &O   !CQ!  8,0A 5O$+0=5Q#4.3\,\%4G"0QQ$PDHA0,)2
M)#["7"4\PF@E/,-U)#O#@R,ZPY,A.<.D(#G$N1\XQ-0>-\'M'C; ^Q\UOO\@
M-+[_(#2^_R TOO\@-+[_(,B/  "^G   M:4  *VM  "BLP  EK<  (FZ  !\
MO@  <,(  &3(  !9S@, 4=,/ $[3'P)*TRD'1-,R##_3.A([TT(6.--,%S;4
M5A@UU&(7-=5O%C35?A4SUHX4,M:@$S'7MA(PV-(1+]7K$2[3^!,LT?\4+-'_
M%2S1_Q4LT?\5+-'_%<&9  "XI   L*T  *:S  "9N   C+P  '_   !SQ0
M9\D  %O/  !1U0  1]P% $3C$P$_Y!T%.>0E"33D+@TQY38/+N5 $"SF2A K
MYU40*N=B#RGH< XIZ( -*.F2#";JI@LFZKT*).O;"B/I\0DAYO\*(>;_"B'F
M_PHAYO\*(>;_"KJC  "SK   J;0  )RZ  "/O@  @<(  '3'  !HS   7-$
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M Z6Z  "7P   B<8  'K,  !LT0  7M@  %'>  !&XP  .^<  #'K   H[@
M(?<  1S_  ,8_P $%/\ !1'_  8,_P &"/\$!@3_"@< _Q$' /\8!@#_'P8
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M4FECO5)G8M13:&3L36ED^TEJ9?]&:F7_1&IE_T1J9?]$:F7_1/]2  'M80
MW&T  -%V  #(>P  OW\  +=_  "O?PP J($C *& ,@:9?CX0DWM&&XQX32:&
M=%(P@7%8.7MN7$%U:V)(<&AH3FUG;U)J9GA49V:"569FC59D9II68F:I5F!F
MNE9?9M%68&?J46%H^4QB:/])8VC_1V-H_T=C:/]'8VC_1_]6  'F90  V7$
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M34]Y]DI/>?](4'C_1E!X_T90>/]&4'C_1NQB  #;<@  S7T  ,.&  "ZC
ML9   *B2  ";D@  DY,1 (Z4)0&(DS,&@I$]#WR/11EUC4LC;XM0+&B)539A
MAEH^6H1?1E2"94Q0@6Y/3H%Y4$V!A4]-@I--3(*C2TR"M$I+@LM(2X+E1TN!
M]D1+@?]#2X#_0DN _T)+@/]"2X#_0N9H  #6=P  R8(  +^+  "VD0  KI4
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M*SZ=_RL^G?\K/IW_*])]  #%B@  NY4  +.=  "KHP  H*<  )2J  "(K
M>JX  &VQ 0!GLA8 9+(F 5^R,0=9L3H-4[! %4VO1QQ(KDTB1*Y5)D&N72@_
MKF@H/JYT)SVN@28]KI D/*ZA(SNNLR$ZKLL@.JWF'SBK]R WJO\A-ZG_(3>I
M_R$WJ?\A-ZG_(<N&  "_D@  MYP  *^D  "EJ0  FJT  (VP  " L@  =+4
M &:X  !;O < 5[T: %2])P)/O3$'2KPY#46\0!- NT<8/+M0&SJ[61PYO&0;
M.+QP&C>\?ADVO(T8-KV>%S6]LA8TO,H4,[OF%#&Y]Q8PN/\7+[?_%R^W_Q<O
MM_\7+[?_%\./  "ZFP  LJ0  *JK  "?KP  DK,  (6V  !XN   ;+P  %_
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M!;>B  "PJP  IK(  )FW  ",NP  ?KX  ''"  !DQ@  6,L  $W/  !#U
M.=H  "_?   L[@@!*.X3 B7O&P0A[R,%'N\L!ASP-@89\4 &%_%,!13Q6 41
M\F@$$/-Y P_TC ,-]*("#/2Z @KUV0$)]? !"//Y 0CS^0$(\_D!"//Y ;*K
M  "IL@  G+@  (^\  "!P   <\4  &7)  !9S@  3M,  $/8   YW   +^$
M "?E   C]  !(/T& AS^#@,9_A8$%?X=!!'^)04-_RX$"?\X! 7_1 0!_U$#
M /]A @#_= ( _X@! /^< 0#_L $ _\4  /_9  #_V0  _]D  /_9 *NR  "?
MN   DKT  (/"  !TQP  9\P  %K1  !.U@  0]L  #C@   NY   )><  ![L
M   :^0 !%O\  A/_  ,/_P8#"_\-! ;_% 0"_QP$ /\D P#_+@, _SH" /](
M @#_60$ _VP! /]^ 0#_CP  _Y\  /^I  #_J0  _ZD  /^I **X  "5O@
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M!/\ FP/_ *$#_P"G O\ K0+_ +0"_P"] ?\ R0'^ -@!_0#F /L \0#X /P
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M4@  XUP  -ED  #0:   _^)]$$E#0U]04D]&24Q% !(5R6H  ,-G  "Z9Q4
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M  #A9   TV\  ,AV  "_>P  MGX  *U^  "C?0( G'X9 )9^*@*/?3<)B7I
M$H-W1QQ]=4TE>')2+G)O5S=L;%P^9FIA16)H:$I>9W!-7&=Z3EIGA4Y89Y).
M5V>A3E9GL4U49\9,5&?@2E5H]$96:/]#5VC_0%=H_T!7:/] 5VC_0.]8  #=
M:   SW(  ,5Z  "\?P  LX(  *F#  "?@@  EX(5 )&#)P&+@C0'A7\^$']]
M11EY>TLB<WA0*VUV531G<UH\87%?0UMN94E7;6U-56QW3U-M@TY2;9!.46V?
M3%!MKTM/;L1*3V[?2%!N\T50;?Y"46W_0%%M_T!1;?] 46W_0.E=  #:;
MS'8  ,%^  "XA   L(<  *:(  "9AP  DH<0 (R((P"'AS$%@84[#7N#0Q9U
M@4D?;W]/*&A]4S%B>E@Y7'A=0%9V8T92=&M*3W1U2TYT@4M-=8])376>2$QU
MKD9+=<-%2W7>0TMU\D%+=/X_3'3_/4QT_SU,=/\]3'3_/>5B  #5<   R'L
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M*S^0\BL_C_XK/H[_*SZ._RL^CO\K/H[_*]1U  #&@@  NXP  +.4  "KF@
MHIX  ):@  ")H0  >:(  &^B!@!JHQH 9J,I 6*B,P9<H3P-5J!#%%&?21M+
MGD\A1YU6)D.=7BE!G&@J0)US*3^=?R@_G8TF/IV=)3V=KB,\G<0B/)S?(3N:
M\R$ZF?XB.9C_(CF8_R(YF/\B.9C_(LU]  # B0  MY,  *^;  "GH   G:0
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M"!_ _P@?P/\('\#_"+F8  "RH@  JJD  )^O  "3L@  A;4  'BX  !KN@
M7KT  %+!  !'Q0  /,D  #'. 0 HU 8 )-82 "/6'@ AURD!']<T 1[80 $=
MV$L!'-E8 1O99@$9VG8 &-J( !;;G  4V[, $MO2 !'9[0 1U_H!$=7_ A'5
M_P(1U?\"$=7_ K2B  "MJ@  H[   ):T  ")N   >[L  &Z^  !AP0  5<4
M $G)   ^S0  ,](  "K6   BVP  &^0% !GH$  7Z!H %.DD 1+I+@$0ZCD!
M#>I& 0KK4P (ZV, !NQT  3MB  ![)T  .NU  #KUP  ZO   .G_  #I_P
MZ?\  .G_ *^J  "FL0  F;8  (RZ  !^O0  <,$  &+%  !6R0  2LX  #[2
M   TU@  *ML  "+?   :XP  %.L  !'X P -^0L "OD4 0;Y' $"^28! /HQ
M 0#Z/@  ^DP  /E=  #Y<   ^(0  />9  #VKP  ]L<  /?D  #WY   ]^0
M /?D *FQ  "=M@  C[L  (&_  !RQ   9,@  %?-  !*T@  /M8  #/;   I
MWP  (.,  !CF   1Z@  "_$   ?[   $_P   ?\$ 0#_"@$ _Q,! /\< 0#_
M)P  _S4  /]$  #_5@  _VD  /]]  #_D   _Z$  /^R  #_LP  _[,  /^S
M *"W  "2O   A,$  '3&  !FRP  6-$  $O6   ^W   ,N   "CD   >YP
M%>H   [N   &\    O<   #_    _P   /\  0#_  $ _P ! /\( 0#_$@
M_QT  /\J  #_.@  _TP  /]?  #_<0  _X   /^/  #_CP  _X\  /^/ /\#
M(@[_!!\._P$?#O\ (@W_ "@,_P S"O\ 00C_ % &_P!=!?\ :03_ '4#_P!^
M O\ A0'_ (P!_P"3 ?\ F0#_ )\ _P"E /\ JP#_ +( _P"[ /X Q@#\ -0
M^P#C /L \ #[ /H ^P#_ /L _P#Z /\ ^@#_ /H _P#Z /\ ^@#_ /\''P[_
M"!P._P8<#O\ '@W_ "0,_P Q"_\ /@G_ $T'_P!:!O\ 9@3_ '(#_P![ O\
M@P+_ (H!_P"0 ?\ E@'_ )P _P"B /X J0#\ +  ^@"X /D PP#W -$ ]@#@
M /4 [0#U /@ ]0#_ /0 _P#T /\ ] #_ /, _P#S /\ \P#_ /\+&P__#!<.
M_PH7#O\%&0W_ "(-_P N"_\ .PK_ $D(_P!6!O\ 8@7_ &X$_P!X _\ @ +_
M (<!_P"- ?T E '[ )H ^@"@ /@ I@#V *T ]0"U /, P #Q ,T [P#= .\
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M%I5#_Q650_\5E4/_%?\W  3_0  !]$D  .)-  #;4   U4\! -%(!P#(3!T
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M/V%;L#]?6\1 7EO=/U];\CI?7/\W8%S_-6!<_S1@7/\T8%S_-.].  #>7@
MT6D  ,5P  "\=0  M'8  *MU  "A<@  F7,7 )-S* &-<C0'AV\]$(%M1!A\
M:DLA=V=0*7%E53!L8EHV:&%@.V5@9SYB7W!!8%]Y0EY?A$)<7Y!"6U^>0EE?
MK4)77\%"5E_:0E=?\#U87_TZ65__.%E?_S=97_\W65__-^M3  #;8@  S6T
M ,)T  "Y>   L7H  *=Z  "<=P  E7<3 (]X)0&)=S$&@W0[#7YR0Q5X<$D>
M<FU.)FUK4RYG:%@U8F9>.UYD9$!:8VQ#6&-V1%9C@4558XU$5&.;1%)CJT-1
M8[]#4&/80E%D[SY29/P[4F3_.5-D_SA39/\X4V3_..A8  #89@  RG   +]X
M  "W?   KGX  *1^  "8>P  D'L. (I\(0"%>R\$?WHY"WIX01-T=D<;;G--
M(VAQ42QB;U8S76U;.EAK8C]4:6I#4FES1%!I?T1/:8M$3FF:0DUJJD%,:KU
M2VK6/TQJ[CQ,:?PZ3&G_.$UI_SA-:?\X36G_..1=  #4:P  QG0  +Q[  "T
M@0  JX,  *&$  "3@   BX$) (6!'0" @2P">X V"'5^/Q!O?$48:7I+(&1X
M4"A>=E0P6'19-U-R8#Q/<6A 37!R04MP?4%*<8H_2G&9/DEQJ3U(<KP[1W+6
M.D=Q[3A'</LW1W#_-4=O_S5';_\U1V__->!B  #/;P  PWD  +F   "QA@
MJ(@  )V)  "-A@  A88# '^'%P![AR<!=H8S!G"%/ UJ@T,49(%)'%Y_3B19
M?E,L4WQ8,DY[7C=+>F<Z27EQ.TAY?#I'>HHY1GJ8-T9ZJ39%>KPT1'K5,T-Y
M[3)#>/LQ0W?_,$-W_S!#=_\P0W?_,-MH  #+=   OWX  +:&  "MBP  I8X
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M&C23_QHTD_\:-)/_&L=]  "\B   M)$  *R8  "DG0  F:   (VB  " HP
M<:,  &*D  !7I@8 4Z87 %"G)0!,IB\#2*8X"$2E/PT_I481/*1.%#FD5Q4W
MI& 6-J1K%36D>!0UI(83-*25$C.DIA RI+L/,:/5#C"A[0\NG_L1+9[_$BV=
M_Q(MG?\2+9W_$L&%  "WD   L)D  *B?  "?I   DZ8  (:H  !YJ0  :ZH
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M +&A  "KJ   H*X  ).R  "&M0  >+@  &JZ  !=O0  4<   $7#   YQP
M+LL  "7/   <TP  %-8   O; @ %W0H  ]T7  +=(P  WB\  -\\  #@2P
MX%L  .%M  #A@   X90  .&J  #AQ   X>$  .'R  #A^   X?@  .'X *VI
M  "CKP  E[,  (FW  ![N@  ;;T  %_!  !3Q   1L@  #K,   OT   )-0
M !S9   4W   #-\   3B    ZP   .L&  #J$   Z1H  .DF  #K-   [44
M .]6  #O:0  \'T  /"2  #QIP  \;P  /'3  #RWP  \M\  /+? *:O  ":
MM0  C+D  'Z]  !OP   8<0  %3)  !'S0  .M$  "_5   DV@  &MX  !/B
M   *Y0   ^<   #I    \0   /<   #V    ]@8  /41  #U'   ]BL  /D]
M  #\4   _60  /UX  #^C   _IT  /^M  #_M   _[0  /^T )VU  "/N@
M@;X  ''#  !CR   5<T  $C2   [V   +MP  "3@   9XP  $.<   CJ   !
M[0   .\   #P    ]@   /X   #_    _P   /\   #_!0  _Q(  /\A  #_
M,P  _T<  /]<  #_;P  _X   /^-  #_E   _Y0  /^4 /\ 'PS_ !T,_P =
M"_\ 'PK_ "0(_P R!_\ 0 7_ $X#_P!; O\ 9@'_ '$ _P!Z /\ @@#_ (D
M_P"0 /\ E@#_ )P _P"A /X IP#] *T _0"U /P OP#[ ,L ^P#; /H [ #Z
M /@ ^@#_ /D _P#W /\ ]@#_ /8 _P#V /\ ]@#_ /\"' W_ 1D,_P 9"_\
M&PK_ "$)_P O!_\ /07_ $L$_P!8 O\ 8P'_ &X!_P!W /\ ?P#_ (< _@"-
M /P DP#Z )D ^0"> /@ I #W *L ]@"R /8 NP#U ,< ] #8 /0 Z #S /4
M\P#^ /$ _P#P /\ [P#_ .X _P#N /\ [@#_ /\&& W_!10,_P$4"_\ %@K_
M !\)_P K"/\ .0;_ $<$_P!4 _\ 8 '_ &L!_P!T /T ? #Z (0 ]P"* /4
MD #S )8 \@"; /$ H0#P *@ [P"O .X N #M ,0 [ #3 .L Y #K /$ Z@#[
M .@ _P#G /\ Y0#_ .4 _P#E /\ Y0#_ /\+% S_"A +_P<."O\"$@K_ QP)
M_P H"/\ -0;_ $,$_P!0 _\ 7 +\ &<!^ !P /4 >0#R (  [P"' .T C0#J
M ), Z0"8 .@ G@#G *4 Y@"L .0 M0#C ,  X@#/ .$ WP#@ .X WP#Z -P
M_P#: /\ V0#_ -D _P#9 /\ V0#_ /\1#PS_$0D*_PT'"?\.#0G_$!D(_PPC
M"/\', ?_ SX%^@!+ _4 5P+Q &(![@!L .L =0#I 'T Y@"# ., B0#A (\
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M*'5.LRES3L<I<DW?*7%.\R9P3O\D<$[_(W!._R)P3O\B<$[_(O9!  #C40
MU5P  ,EB  # 9@  N&8  +!B  "G7@8 H%\; )I?*P.3738*C5L_$HA81AF$
M54T?@%13)'U26B9[4F H>5%G*G=1;RIU47<K=%& +')1B2QP494M;U&A+6U1
ML"YK4<,O:5#;+VE1\2MI4?XI:5'_)VE1_R9I4?\F:5'_)N]%  #?50  T6
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M.5-;ZS936_HS5%O_,51;_R]46_\O5%O_+^93  #580  R&L  +UQ  "T=0
MJW8  *)U  "5<   C7 , (AQ'@""<"P#?6\V"7AM/A!R:D48;6A*'VAF3R9C
M9%0M7F):,UIA8#=78&@Z5%]R.U-??#Q17XD[4&"6.T]@ICI-8+@Z3&#0.4Q@
MZ39-8/DT3E__,DY?_S!.7_\P3E__,.)8  #290  Q6\  +MU  "R>0  J7L
M )]Z  "1=0  B74' (-U&@!^=2D!>70T!W1R/ UN<$,5:6Y)'&-L3B1>:E,K
M66A8,51G7C919F8Z3F5O.TUE>CM,98<Z2V:5.4IFI3A)9K<W2&;.-D=FZ#1(
M9?DR2&7_,4AD_S!(9/\P2&3_,-Y=  #.:@  P7,  +AY  "O?0  IG\  )M_
M  ",>@  A'H" 'UZ%@!Y>R4 ='HQ!6]X.@MJ=T$29'5'&5]S3"!9<5$G5'!6
M+D]N7#-,;60V2FUN-TAM>3=';88V1FV4-49NI#-%;K8R1&[.,$-MYR]#;/@N
M0VO_+4-K_RU#:_\M0VO_+=IB  #*;@  OG<  +5^  "L@@  HX4  )F%  ")
M@0  ?H   '> $0!S@2$ ;X N VI_-PAD?C\.7WQ%%5I[2AQ4>4\C3WA4*4MV
M6RY(=F,Q1G5M,41U>#%$=H4O0W:3+D)VHRQ!=K4K0';-*4!UYR@_=/@H/G/_
M*#YR_R@^<O\H/G+_*-1H  #%<P  NWP  +*#  "IB   H(H  ):+  "&B
M>H<  '"'"0!LAQL :(<I 6.',P5>ACL+681"$52#1QA/@DT>2H!3(T9_6B=#
M?V(I0G]L*4%_>"A ?X4G/W^3)3Y_HR0]?[4B/7_-(3Q^YR$[??@A.GS_(CE[
M_R(Y>_\B.7O_(L]N  #!>0  MX(  *Z)  "FC0  G9   ).1  "%D   =H\
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M#+V%  "TCP  K)<  *6=  ";H0  CZ,  (*D  !UI0  9Z4  %FG  !,J
M/ZH  #BK$0 VJQX -*PH #*K,@(OJSH$+:M#!2NK308IJU<&**MB!2>K;@4F
MJWP$):N+!".KG ,BJ[ "(*K( A^IY0(=I_<$'*7_!1RD_P8<I/\&'*3_!K>.
M  "PEP  J9X  *"C  "5I@  B*D  'NJ  !MJP  7ZP  %*N  !%L   .;(
M "ZU   EMPL ([@9 "*X)  @N"X 'K@X !VX0@$<N$T &KA8 !FY90 7N70
M%KB$ !2XE@ 2N*H $+C#  ZVX@ .M/8 #K/_ 0ZR_P$.LO\!#K+_ ;.7  "L
MGP  I*4  )FI  ",K   ?ZX  '*P  !DL@  5[,  $JV   ^N   ,;L  ">^
M   =P@  %,4#  S'#0 *QQH "<<E  ?',0 &QSP !<=)  3'5@ #QV4  <=W
M  #'B0  QIT  ,:S  #%SP  Q.D  ,/W  ##_P  P_\  ,/_ *Z@  "HIP
MG:L  )"O  "#L@  =;0  &>V  !:N   3;L  $&^   TP0  *<0  !_(   6
MS   #<X   31    TP@  -,3  #4'@  U2H  -8V  #71   V5,  -ED  #9
M=P  V8L  -F@  #8N   U]4  -;K  #6]P  UO<  -;W *NG  "@K0  E+$
M (:T  !XN   :KH  %R]  !/P   0L,  #;&   JR@  '\X  !?2   .U0
M!M@   #;    W0   -\   #@"@  X18  .,A  #E+P  YSX  .I.  #K80
MZW4  .R*  #LH   [+8  .O-  #KX@  Z^(  .OB *.N  "7L@  B;8  'NZ
M  !LO0  7L$  %'%  !$R0  -LP  "O0   @U   %MD   S=   %X    .$
M  #D    Y@   .@   #I    ZP   .T*  #P%P  \B8  /4V  #X2   ^EP
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M )< _@"< /X H@#] *@ _ "O /L N #[ ,0 ^@#3 /@ Y #V /0 ]0#_ /4
M_P#U /\ ]0#_ /8 _P#V /\ ]@#_ /\ &0O_ !8*_P 5"?\ %@?_ !\&_P M
M!/\ .P+_ $@!_P!5 /\ 80#_ &L _P!U /T ? #[ (, ^@") /D CP#Y )0
M^ "9 /< GP#V *4 ]0"L /0 M0#S ,  \@#. /  X #N /$ [0#] .T _P#M
M /\ [0#_ .T _P#M /\ [0#_ /\!% O_ !(*_P 1"?\ $ C_ !P&_P I!/\
M. +_ $4!_P!1 /\ 70#\ &@ ^ !Q /4 >0#T (  \P"& /( BP#P )$ [P"6
M .X G #M *( [ "I .L L0#J +L Z #) .8 W #D .T XP#Y ., _P#B /\
MX@#_ .( _P#B /\ X@#_ /\%$ K_ PL)_P )"/\ #P?_ !D&_P E!/\ ,P/_
M $ !_@!- /@ 60#S &0 [P!M .T =0#K 'P Z0"" .@ B #G (T Y@"3 .0
MF #C )X X@"F .  K@#> +< W #% -H UP#8 .@ V #T -8 _@#5 /\ U #_
M -0 _P#3 /\ TP#_ /\*"0K_" 0(_P(!!_\&"@;_!A8%_P$A!/\ +@/\ #L!
M]0!( .X 5 #H %\ Y0!I ., <0#A '@ WP!^ -T A #; (H V@"/ -@ E0#6
M )L U0"C -, JP#1 +4 SP#" ,T T@#, .0 R@#R ,D _@#' /\ Q0#_ ,0
M_P#$ /\ Q #_ /\1 PC_#P &_Q  !?\4!@3_$Q$$_P\= _D(* +Q!#4!Z@%#
M ., 3P#= %H V@!D -<!; #4 G0 T@)Z -$#@ #/ X8 S0., ,P$D@#*!)D
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M$(H]N1")/<P1ASWC$84]]1&#/?\0@SW_$((]_Q""//\0@CS_$/\P  #I/0
MW$@  -%.  #'40  P$X  +E'  "R1 X JT8A :1&+P:>1#H+F4-$#I9#31&3
M0E42D4)=$H]"9!.-0FH3C$)Q$XI">!.)0G\4AT*'%(9"D!2$0IH5@T*F%8%"
MM!: 0L<6?D+>%WQ"\A9[0O\5>T+_%'I!_Q1Z0?\4>D'_%/<T  #E1   UT\
M ,Q5  #"6   NE8  +-0  "K3 H I$T= )Y-+ 282S<*DTE #XY(21.+1U$6
MB498%X=&7QB%1F48@T9L&()&<QF 1GL9?T:#&7U&C!I\1I8:>D:C&WE&L1MW
M1L,<=4;:'71&\!MS1OX:<D;_&7)%_QAR1?\8<D7_&/ Y  #A2@  TU4  ,=;
M  "^70  MEP  *Y7  "F4@4 GU,: )A3* .24C0(C4\]#XA-112$3$P8@DM3
M&G]*6AQ]2F$=?$EG'7I);QYX278>=TE_'W5*B!]T2I,@<DJ?('!)K2%N2;\A
M;4G6(FQ)[2!K2?P>:DG_'6I)_QQJ2?\<:DG_'.Q   #=3P  SUH  ,1@  "[
M8@  LF$  *E=  "@6 $ F5@6 )-9)@&-5S$'B%4Z#8-30A1_44D9>T]0''A.
M5A]V35P@=$UC(G)-:B)P37(C;TU[)&U-A"1K38\E:DV<)6A-JB9F3;LG9$S2
M)V-,ZR5C3?HC8TW_(6-,_R!C3/\@8TS_(.E%  #:5   S%X  ,%D  "W9@
MKV8  *9B  ";70  E%P2 (Y=(@")7"\%@UHX"WY80!)Z5488=5-,'7)24B%O
M45@C;%!?)6I09B=H4&XH9U!W*&50@2EC4(PJ8E"9*F!0IRM>4+@K7%#/+%Q0
MZ"I<4/DG7%#_)5Q0_R-<4/\C7%#_(^9*  #66   R6(  +YG  "U:@  K&H
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M*TE;_RI)6_\I25O_*=Q8  #,9   P&T  +9R  "M=@  I'<  )EV  "+;P
M@F\  'MN% !W;R, <FXN!&UM-PEH:SX/8VI$%EYH2AU99D\C5614*5!C6BU-
M8F(Q2V%K,DEA=C)(8H(Q1V*0,$9BGR]%8K N1&+&+4-BX2Q#8?4J0V'_*4-@
M_RE#8/\H0V#_*-A<  #(:0  O7$  +-V  "J>@  H7P  )=[  "'=0  ?70
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M&\EN  "\>   LX   *J&  "BB@  F8T  (^-  "!C   <HH  &2)  !;B0P
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M!2>9F04FF:P$))G" R.8W@,BEO,%(93_!B"3_P<@D_\'()/_![F$  "PC0
MJ94  **:  "8G0  C)\  '^@  !QH   8Z   %6A  !(HP  .Z0  #"F"  L
MIA8 *Z8A "FF*P GIC0!):8] B.F1P(BIE$"(*9< A^F: $>IG8!'*:% 1NE
ME0 9I:@ %Z2^ !6DVP 6HO$!%J#^ 12>_P(4GO\"%)[_ K2-  "LE0  IIP
M )VA  "2HP  A:4  '>F  !IIP  7*@  $ZI  !!JP  -*T  "FO   ?L0,
M&;(0 !>R'  6LB8 %+(P !.R.P 1LD4 $+)1  VR70 +LFP ";)\  BQC0 &
ML:  !+"U  .OSP #KND !*WX  2L_P $K/\ !*S_ *^6  "IG@  HJ,  ):G
M  ")J0  ?*L  &ZL  !@K0  4Z\  $:Q   YLP  +;4  "*X   8N@  #KP
M  6^"@ !OA8  +\A  "_*P  OS<  +]#  "_3P  OUX  +]N  "_@   OI,
M +VH  "]P   O-T  +OO  "Z^0  NOL  +K[ *R?  "EI0  FJD  (VL  "
MKP  <K$  &2R  !6M   2;<  #RY   PNP  )+X  !K!   1Q   !\8   #)
M    R@8  ,L0  #,&P  S24  ,XQ  #./@  STP  -!<  #0<   T(0  -"9
M  #/KP  SLD  ,[C  #-\@  S?0  ,WT *BF  "=JP  D:X  (.Q  !UM
M9K<  %FY  !,O   /K\  #+!   FQ   &\@  !++   (SP   -    #3
MU0   -<   #9!P  VQ(  -T=  #?*0  X3<  .1'  #E60  Y6\  .6&  #E
MG0  Y;(  .7*  #DWP  Y.,  .3C *"L  "4L   A[0  'BW  !IN@  6[X
M $[!  ! Q0  ,\@  "?+   ;S@  $=,   ?8    VP   -P   #>    X
M .(   #D    Y@   .D'  #L%   [R$  /(Q  #U0@  ]U4  /AK  #X@P
M]YH  />N  #WP   ]\0  /?$ )>R  "*M@  ?+H  &R^  !>P@  4,8  $+*
M   TS@  )](  !O6   /VP  !N    #C    Y0   .8   #H    Z0   .L
M  #M    \    /(   #U    ^0D  /P8  #_*0  _SP  /]0  #_90  _WH
M /^,  #_G0  _Z   /^@ /\ & G_ !4(_P 4!O\ %P7_ " #_P N ?\ .P#_
M $D _P!6 /\ 8@#_ &P _P!T /\ ? #_ (( _P"( /\ C0#_ )( _@"7 /X
MG0#] *, _ "J /D L@#W +P ]@#, /4 WP#T .\ ] #] /0 _P#T /\ \P#_
M /( _P#R /\ \@#_ /\ %0G_ !$(_P /!_\ $@7_ !T#_P K O\ . #_ $8
M_P!3 /\ 7@#^ &@ _0!Q /P > #Z '\ ^0"% /@ B@#X (\ ]P"4 /8 F@#U
M *  \P"F /  K@#N +@ [0#' .P V0#K .L ZP#Z .H _P#I /\ Z #_ .@
M_P#H /\ Z #_ /\ $0G_  T(_P +!O\ #@7_ !H#_P G O\ - #_ $( _0!/
M /D 6@#W &0 ]0!M /, =0#R 'L \0"! .\ AP#N (P [0"1 .P E@#J )P
MZ "C .8 JP#D +4 XP#" .$ T@#@ .< WP#V -X _P#= /\ W #_ -P _P#<
M /\ W #_ /\ "PG_  8'_P #!O\ # 7_ !<#_P C O\ , #[ #X ] !* /$
M5@#N &  ZP!I .D <0#H '< Y@!] .4 @P#C (@ X@"- .  DP#= )D VP"?
M -D IP#8 +$ U@"] -0 S0#3 .( T0#R -  _ #/ /\ S@#_ ,T _P#- /\
MS0#_ /\$! C_   &_P  !?\ !P3_ !0#_P ? ?T *@#R #@ Z@!% .< 40#C
M %L X !D -X ; #< ', V@!Y -@ ?P#5 (0 TP"* -$ CP#/ )4 S0"< ,P
MI #* *T R "Y ,< R0#% -P Q #L ,( ^ #! /\ P #_ +\ _P"_ /\ OP#_
M /\)  ;_!0 $_P@  _\* @+_!PT!_@$9 ?0 ) #F #$ X  _ -L 2P#8 %8
MU !? -$ : #. &\ S !U ,H >P#( ($ Q@"& ,0 C ## )( P0"9 +\ H0"^
M *H O "V +H Q0"Y -@ MP#I +4"^ "S!/\ L@3_ + &_P"O!O\ KP;_ /\0
M  7_#  "_Q0  ?T5  #X$04 \PH1 .@"' #; "H U0 Y - !1@#+ U$ QP1:
M ,0%8P#"!VH OPAQ +X(=P"\"7T N@J# +D*B0"W"X\ M@N7 +0,GP"S#*D
ML0VU *\.Q "N#M@ JQ'K *D3^P"F%/\ I13_ *04_P&D%/\!I!3_ ?\5  /_
M&  !^!T  .@<  #B&0  WA $ -H&$ #2"2$ R@TQ ,02/P"_%4L NQ95 +@7
M7@"V&&8 M!EM +(:<P"P&GD KQM_ *T;A0"L'(P JAR3 *@<G "G':4 I1VQ
M *0>P "B'M, H!_G )T?]P&<'_\"FQ__ IH?_P*9'_\"F1__ O\9  '\(0
MZ2<  . L  #8*P  TB0  ,\9" #'&AL OQXL +DA.@"T(T8 L"11 *TE60&K
M)F$!J29H :<G;P&E)W4!I"A[ :(H@0&A*(@!GRB/ 9XIF &<*:$!FBFM IDI
MNP*7*<T"E2GC Y,I]021*?\$D"G_!8\H_P6/*/\%CRC_!?\>  #N*   XC,
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M$7<][!%V/?P0=3S_$'4\_Q!T//\/=#S_#^\S  #?0P  T4T  ,53  "\5
MM%$  *Q+  "E100 GD88 )A&)P*213('C40\"XE"10Z&0DT0A$%4$8)!6A&
M06$2?T%G$GU!;A)\0782>D%^$WE!AQ-W09$4=4&=%'1!JQ5R0;L5<$'1%F]!
MZ15M0?H5;4'_%&Q _Q-L0/\3;$#_$^LZ  #;20  S5,  ,%8  "X60  L%@
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M'U=+_QY72_\=5TO_'>%*  #05P  PV   +AD  "O9P  IF8  )QC  "170
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M(M)<  ##9P  N&\  *YT  "F=P  G'@  ))W  "#<0  >&\  &YN" !I;A@
M96XE &%N+P1=;3<(66L^#E1J1!-0:$D92V=/'D=F52)$95TD0F5F)4%E<25
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M%35WF!0U=ZD2-':]$3-VV! Q=>\2,'/]$R]R_Q0O<?\4+W'_%,-M  "X=@
MKWX  *>$  ">B   E8D  (N*  !]B   ;H8  &&$  !3@P4 3H,5 $R#(0!)
M@RP!1H,T!$*".P@^@4(+.X%)#CB 4! V@%D1-(!C$3. ;A R@'H/,8"(#C"
MEPPO@*@++G^]"BU_V HL?>\+*WS\#2I[_PXI>O\/*7K_#[YS  "T?0  JX0
M *2*  "<C@  DY   (>0  !ZCP  :8T  %R,  !/C   1(P+ $&,&0 _C"4
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M  F=S0 *G.@ "YKY  N9_P +F?\ "YG_ +",  "IE   HYH  )J>  ".H
M@:(  '2B  !FHP  6*,  $JD   \I@  ,*<  "6I   :JP  $*P(  RL%  *
MK!\ ":PI  >L-  &K#X !*Q*  *L5@  K&0  *MS  "KA   JI8  *FJ  "H
MP@  I]T  *?O  "F^0  IOX  *;^ *R5  "FG   GZ$  ).D  "&I@  >*@
M &JH  !=J0  3ZL  $*L   UK@  *+   !ZR   4M   ";4   "W!P  MQ(
M +@<  "X)@  N#$  +@\  "X2   N%8  +AF  "X>   N(H  +>?  "VM0
MM=$  +/J  "S]@  L_L  +/[ *F=  "CHP  EZ<  (JJ  !]K   ;JT  &"O
M  !3L   1;(  #BT   LMP  (+D  !:[   +O@   [\   #!    P@0  ,,-
M  #$&   Q2(  ,8M  #&.0  QT8  ,E5  #)9P  R7L  ,F0  #(I@  Q[\
M ,;;  #%[0  Q?4  ,7U *:E  ";J0  CJP  (&O  !RL0  8[,  %6U  !(
MN   .KH  "Z]   BOP  %\(   S%   #R    ,D   #,    S@   ,\   #1
M!0  TQ   -4;  #7)P  V30  -M#  #>5   WV@  -]^  #?E   WZH  -_!
M  #?V   WN0  -[D )ZK  "2K@  A+$  '6U  !FMP  6+H  $J]   \P
M+\,  "/&   7R0  #,T   +1    U0   -4   #8    V@   -P   #?
MX0   .0$  #H$0  ZAX  .PM  #O/@  \5(  /)G  #S?P  ])4  /2I  #T
MN0  ],4  /3% )6P  "'LP  >;<  &J[  !;O@  3<(  #[&   PR@  ),T
M !?1   *U0   =H   #>    X0   .$   #C    Y0   .<   #I    [
M .\   #R    ]@8  /H5  #])0  _S<  /]-  #_9   _WP  /^0  #_GP
M_Z<  /^G /\ $P?_ !$&_P 1!/\ $P/_ !X!_P K /\ .0#_ $@ _P!4 /\
M7@#_ &@ _P!Q /\ > #_ 'X _P"# /\ B0#_ (X _0"3 /L F #Y )X ]P"E
M /8 K0#U +< ] #$ /0 V #S .P \@#[ /  _P#O /\ [P#_ .\ _P#P /\
M\ #_ /\ $ ?_  P&_P +!/\ # /_ !L!_P G /\ -@#_ $0 _P!0 /\ 6P#^
M &4 _ !M /L = #Y 'L ^ "  /< A0#U (L ] "0 /( E0#P )L [P"B .T
MJ@#L +, ZP"_ .H T@#I .8 YP#V .4 _P#E /\ Y0#_ .0 _P#D /\ Y #_
M /\ # ?_  <&_P &!/\ # /_ !<!_P D /\ ,@#\ #\ ^@!, /@ 5P#U &$
M\P!I /$ <0#P '< [@!] .P @@#J (< Z ", .8 D@#E )< Y "> .( I@#A
M *\ WP"[ -X RP#; .  V0#R -@ _P#8 /\ U@#_ -8 _P#7 /\ UP#_ /\
M!0?_   %_P  !/\ "0+_ !4!_P ? /D +0#S #L \ !' .X 4@#K %P Z !E
M .8 ; #D ', X0!Y -\ ?@#= (, VP") -H C@#8 )0 U@": -0 H@#2 *H
MT0"V ,X Q0#, -D RP#M ,D ^P#( /\ R #_ ,@ _P#( /\ R #_ /\   ;_
M   $_P   _\ !0+_ !$!_  : .X )P#I #4 Y@!" .( 30#? %< W !@ -D
M: #5 &\ T@!U -  >@#/ '\ S0"% ,L B@#* )  R "7 ,8 G@#$ *< P@"R
M ,  OP"^ -, O0#H +P ]@"[ /\ N@#_ +D _P"X /\ N #_ /\!  3_   #
M_P   ?\   #_  H \P 2 .0 ( #? "X V@ \ -4 2 #1 %( S0!; ,H 8P#'
M &H Q0!Q ,, =@#" 'P P "! +X A@"] (P NP"3 +D FP"W *0 M0"N +,
MO "R ,X L #A *\ \0"N /P JP#_ *H _P"J /\ J@#_ /\&  /_!@ !_0H
M /((  #L @  Y@ ) -L & #4 "< S@ U ,D 0@#$ $T P !6 +T 7@"[ &8
MN0!L +< <@"U '@ M !] +( @P"P (D KP&0 *T"F "K J$ J@.L *@$N0"G
M!,H I0;? *,(\0"A"OX H K_ )\*_P">"O\ G@K_ /\*  '^$0  ZQ4  .,8
M  #=%   V H! -( #@#+ 1X PP0N +X'/ "Y"4< M0M1 +(,60"P#F$ K@YH
M *P0;@"J$'0 J1%Z *<1@ "F$H8 I!*- *,3E0"A$Y\ GQ2J )X5N "<%<D
MFA;? )@7\@"6%_\ E1C_ )07_P&4%_\!E!?_ ?\1  #O&@  Y"0  -HH  #1
M)@  RQ\  ,<4! # $!< N14G +,8-0"N&D( JAM, *<<5 "E'5P HQYC *$>
M:0"@'V\ GA]U )P@? ";((( FB"* )@@D@"7()L E2&F ),AM "2(<4 D"':
M (XB[P&,(OX"BR+_ HHB_P.)(?\#B2'_ _H8  #I)P  W3$  -$U  #(-0
MP3   +LF  "V'A$ KR(B *DE, "D)CT H2=' 9TH4 &;*5<!F2E> 9<I90&6
M*6L!E"IQ 9,J=P&1*GX!D"J% 8XJC@*-*I<"BRNB HDKKP*(*\ "ARO6 X0K
M[ 2"*_P$@2O_!8 J_P6 *O\%@"K_!?(B  #D,0  UCL  ,I   #!0   N3L
M +,T  "L*PH IBT< * O*P&;,#<"ES!" Y0Q2P22,5($D#%9!(XQ8 2,,68$
MBS%L!(DQ<P2(,GH%AC*!!84RB@6#,I,%@C*?!8 RK 9_,KP&?3+1!WLRZ0=Y
M,OD(>#'_"'@Q_PAW,?\(=S'_".TJ  #>.@  T$0  ,1(  "[20  LT4  *P_
M  "E-@0 GC87 )@X)@&3-S($CS<]!HPW10>)-TT'AS=4"(4W6PB#-V$(@C=G
M"( W;@A_-W4(?3=]"7PXA@EZ.(\)>3B;"G<XJ IV.+@+=#?-"W(WY0QQ-_<,
M;S?_#&\W_PQO-O\,;S;_#.DS  #90@  RTL  ,!/  "V4   KDT  *9'  ">
M0   EST3 )$_(@&,/BX$B#XX!X0]00F!/$D+?SQ0"WT\5@Q[/%P,>CQC#'@\
M:@UV/'$-=3QY#7,\@@YR/(P.<#R7#F\\I0]M/+0/:SS)$&D\XA!H//409SS_
M$&<[_P]F._\/9CO_#^4Z  #52   QU$  +Q5  "S5@  JE,  *%.  "91P
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M&]=.  #'6@  NV$  +%E  "H9P  GV<  )5C  ")70  ?ED  '=8#P!R6!X
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M'SY;E1X]6Z4=/%NX'#I;TALY6NL;.5G[&SA8_QLX6/\;.%C_&\M<  "^9@
MLVP  *IQ  "A=   F'4  (YS  " ;@  =6L  &=H 0!A:!( 76@? %IH*0%6
M9S(%4F8Y"4YE/PY*9$421F-+%T-B41I 85D</F%B'3QA;!P[87@<.F*%&CEB
ME!DY8J48.&*X%S9BT18U8>H6-%_Z%S->_Q@S7O\8,U[_&,=A  "[:@  L'$
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M!2=ZS@4F>>D%)7CY!R1V_PDC=?\*(W7_"KIR  "P>P  J((  *&(  "9BP
MD(T  (2,  !VBP  9HD  %B(  !+AP  /88$ #>&$@ UAQX -(<G #&', $O
MAC@"+89 !"N&204IAE$%)X9;!":&9@0EAG,#)(6  R*%CP(AA: "'X2T 1Z$
MS $=@N@!'('Y QR _P0;?_\%&W__!;5Z  "M@P  I8H  )Z/  "6D@  BY,
M '^3  !QD0  89   %.0  !&D   .)   "R0!P HD!0 )I > "21*  CD3$
M(9$Z ""10P$>D$P!'9!6 !N08@ :D&X &)!\ !:/C  4CYT $HZQ !"-R0 0
MC.4 $8OW !&*_P$0B?\!$(G_ ;&"  "IB@  HY$  )R6  "2F   A9D  'B9
M  !JF   6Y<  $R8   _F   ,YD  ">9   ;FP8 %IL2 !6;'0 3FR8 $ILP
M !&;.0 .FT, #)M.  J;6@ (FV< !YIU  6:A0 #F98  )BJ  "7P0  EML
M )7N  "4^@ !D_\  9/_ *V+  "GD@  H)@  )B<  "+G@  ?I\  '"?  !B
MG@  5)\  $:@   XH0  +*(  ""C   6I   "Z8$  .F#P  IQH  *<D  "G
M+@  IS@  *9#  "F3P  IET  *9K  "E?   I8T  *2A  "BMP  H-,  )_K
M  "?]0  G_P  )_\ *J4  "DF@  G)\  )"B  "#HP  =:0  &>E  !9I0
M2Z8  #VH   PJ0  )*L  !FL   /K@  !:\   "P!   L0X  +$8  "R(@
MLBP  +(V  "R0@  LD\  +-?  "R<   LH(  +&6  "PJP  K\4  *WC  "L
M\P  J_T  *O] *><  "@H@  E:4  (BG  !ZJ0  :ZH  %VK  !/K   0:X
M #2P   GL@  '+0  !&V   'MP   +D   "Z    NP$  +P)  "]%   OAX
M +\H  # ,P  P3\  ,).  ##8   PW,  ,*(  #"G@  P;4  ,#1  "_YP
MOO4  +[U *.C  "8IP  C*H  'ZL  !OK@  8+   %*R  !$M   -K8  "FX
M   =NP  $KT   ?     P@   ,,   #$    Q@   ,@   #*!   S T  ,X8
M  #0(P  TB\  -0\  #830  V6   -IV  #:C0  V:0  -B[  #8T@  V.<
M -CG )NI  "/K   @:\  '*R  !CM   5;<  $>Y   XO   *[\  !["   2
MQ0  !\@   #+    S@   ,X   #0    TP   -4   #8    VP   -X$  #A
M$0  Y!T  .8J  #J.0  [4P  .]A  #P>   \8\  /&C  #PM0  \,<  /#'
M )*N  "%L0  =K4  &>X  !8NP  2;\  #K"   LQ@  '\D  !/,   %T
M -0   #8    W    -P   #>    X    .(   #E    Z    .P   #O
M\P4  /45  #X)   ^S8  /Y*  #_8   _W<  /^,  #_G   _ZD  /^I /\
M#P;_  P$_P + _\ #@'_ !H _P I /\ . #_ $4 _P!1 /\ 6P#_ &4 _P!M
M /\ = #_ 'H _@"  /P A0#[ (H ^0"/ /@ E #W )H ]P"A /8 J0#T +,
M\P"_ /( T0#O .< [@#Y .T _P#M /\ [0#_ .T _P#M /\ [0#_ /\ # ;_
M  D$_P ( _\ "@'_ !< _P E /\ - #_ $$ _P!- /\ 6 #] &$ ^P!I /D
M<0#W '< ]0!] /, @@#Q (< \ ", .\ D0#N )< [0"= .P I0#J *X Z0"Z
M .8 R@#D .$ XP#T .$ _P#A /\ X0#_ .$ _P#? /\ W@#_ /\ !@7_  ,$
M_P ! O\ "@'_ !0 _P A /T +P#Z #P ^ !) /8 4P#S %T \0!E .X ;0#K
M ', Z0!Y .< ?@#F (, Y0"( .0 C0#B ), X0"9 -\ H0#= *H V@"U -<
MQ #6 -H U #N -, _0#2 /\ T #_ ,T _P#, /\ RP#_ /\   7_   #_P
M O\ !P'_ !  ^0 < /, *@#P #@ [0!$ .L 3P#H %D Y !A .$ :0#> &\
MW !U -H >@#9 '\ UP"$ -4 B0#4 (\ T@"5 ,\ G0#- *8 R@"P ,@ O@#'
M -( Q0#G ,0 ^0#  /\ O@#_ +T _P"] /\ O0#_ /\   3_   "_P   ?\
M @#^  D [P 6 .D ) #E #( X0 _ -X 2@#: %0 U0!= -( 9 #/ &L S0!Q
M ,L =@#* 'L R "  ,8 A0#$ (L P@"1 ,  F0"^ *$ O "L +H N0"X ,H
MM@#A +, \P"Q /\ L0#_ +  _P"P /\ L #_ /\   /_   !_P   /P   #S
M  ( Y0 / -\ '@#9 "L U  Y ,\ 1 #+ $\ QP!8 ,0 7P#" &8 OP!L +X
M<@"\ '< N@!\ +@ @@"V (< M0". +, E0"Q )X KP"H *T M "J ,4 J #;
M *< [@"F /H I0#_ *4 _P"D /\ I #_ /\   '_    \0   .D   #A
MVP ' -0 %@#- "4 QP R ,( /P"^ $D N@!2 +< 6@"U &$ LP!G +$ ;0"O
M ', K@!X *P ?@"J (0 J0"* *< D@"E )L HP"E *$ L0"@ ,$ G@#5 )T
MZ0"; /< F@'_ )D!_P"9 ?\ F '_ /\   #Q"   YA(  -T4  #5#@  SP4
M ,D #0#" !P O0 J +< . "S $, KP%- *P#50"J!%P J 5C *8%:0"D!FX
MHP9T *$'>@"@!X  G@B' )P)CP";"9@ F0JC )<*KP"6"K\ E O4 )(-Z@"1
M#OH CP__ (\/_P".#_\ C@__ /D)  #J&   WB$  -,D  #*(@  PQL  +X.
M  "Y!A0 L@HC *T.,0"H$3T I1)' *(33P"?%%< G15> )L59 ":%FH F!9P
M )<6=@"5%WT E!>$ )(7C "1&)4 CQB@ (T8K ",&+P BAG1 (@:Z "'&_D
MA1O_ 84;_P&$&O\!A!K_ ?(6  #D)0  UBX  ,HR  #!,0  NBL  +0A  "N
M%@L J!D= *,<*P">'C< FQ]" )@@2P"5(%( DR%9 )$A7P"0(64 CB%L (TB
M<@"+(GD BB*  (@CB "'(Y$ A2.< (0CJ0""([@ @23- 7\DY %])/<"?"3_
M GLD_P-[(_\#>R/_ ^TA  #>+P  SS@  ,,\  "[/   LS<  *PP  "F)04
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M83;_"]\Y  #.1@  P4X  +91  "M4@  I5   )Q*  "30P  BCT( (4]&0"
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M&4I'E!E)1Z091T>V&45'SAE%1N@914;Z&$5%_Q=%1?\61D7_%M!.  #!6
MMEX  *QC  "C9   FF,  )!@  "$6@  >54  '!2" !K4A@ 9U(D 6)1+0->
M4#0'6DXZ"U9-0 ]33$824$M,%4U+4AA+2EH:2DIB&TA+;!M'2W@;14N$&T1+
MDAM"2Z(:04NT&C]+S!H_2^<9/TKY&#]*_Q@_2?\8/TG_%\U2  "_7   M&(
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M$#)>R0\Q7>0/+USW$2Y:_Q(N6O\3+EG_$\)@  "V:0  K&\  *1T  ";=@
MDG<  (AV  !Z<@  ;V\  &%L  !4:04 3F@4 $QI'P!):2D!1F@Q T)G. 8_
M9SX*/&9%#3EF3 \V9500-&5=$#-E9Q R9G,/,6: #C!FC@TO9IX,+F:Q"RUE
MR HL9>0**V/V#"IB_PXI8?\/*6#_#[YE  "S;@  JG0  *)Y  "9?   D'T
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M !1[_P$4>O\"%'K_ K%Y  "I@0  HH@  )N-  "4CP  B)   'R/  !MC@
M7HP  %"+  !"BP  -8L  "B*   ?BPL '(L7 !J+(  9BRD %XLR !:+.P 5
MBT4 $XM/ !&+6@ /BV< #8MU  J*A  (B90 !HBG  2'O0 $AM8 !(;L  6$
M^@ &@_\ !H/_ *V!  "FB0  H(\  )F3  "/E0  @Y8  '65  !FE   6),
M $F3   [DP  +Y0  ".4   8E0  #)8*  F6%@ 'E2  !I8I  66,@ #E3P
M I5'  "54P  E6   )5N  "4?0  DXX  ).@  "1M0  D-   (_G  "/]
MCOL  ([^ *J*  "DD0  GI8  )69  ")FP  >YL  &V;  !>FP  4)L  $&;
M   TG   *)T  !R>   2GP  !J !  "@"P  H!8  * ?  "@*   H3(  *$]
M  "@20  H%8  *!E  "@=0  GX8  )Z8  "=K0  G,<  )KD  "9]   F?L
M )G] *>3  "AF0  F9T  (Z?  "!H0  <J$  &2A  !5H@  1Z(  #FD   L
MI0  (*8  !6G   *J    *D   "J 0  JPH  *L4  "K'0  K"8  *PP  "M
M/   K4D  *U8  "M:   K7H  *R.  "JI   J;P  *C:  "G[P  IOH  *;]
M *2;  "=H   DJ,  (6E  !WI@  :*<  %JH  !+J0  /:H  #"L   CK0
M%Z\   NP   "L0   +,   "T    M0   +8%  "W$   N!D  +DB  "Z+0
MNSH  +Q(  "]60  O6P  +V   "\E0  NZP  +G(  "WY   MO0  +;X *&B
M  "6I0  B:@  'NJ  !LJP  7:T  $^N  ! L   ,K(  "6T   8M@  #+@
M  *Z    O    +T   "^    P    ,$   ##    Q0@  ,<3  #*'0  S"D
M ,XV  #11P  TEH  -)P  #3A@  TIP  -*S  #1R@  T>   -'F )FH  "-
MJ@  ?ZT  &^P  !@L0  4K,  $.V   TN   )[L  !J]   ,P    L,   #&
M    QP   ,@   #)    RP   ,X   #0    TP   -8!  #:#   WA@  .(E
M  #E,P  Z48  .M;  #L<@  [(H  .R@  #LLP  [,0  .S+ )"L  ""KP
M<[,  &2U  !5N   1KL  #>_   HP@  &\4   W(   !RP   ,\   #2
MU    -0   #6    V0   -L   #>    X0   .4   #I    [04  /$2  #T
M(   ^#   /Q%  #^6P  _W(  /^(  #_F@  _Z@  /^M /\ "P3_  D"_P '
M ?\ " #_ !@ _P G /\ -0#_ $( _P!- /\ 6 #_ &$ _P!J /\ <0#\ '<
M^P!] /H @@#Y (8 ^ "+ /< D0#V )< ]0"= /0 I0#S *X \0"Z .X RP#L
M .( ZP#V .L _P#J /\ Z #_ .4 _P#B /\ W@#_ /\ !P3_  0"_P # ?\
M" #_ !0 _P C /\ ,0#_ #X _P!* /X 5 #[ %X ^ !F /4 ;@#S '0 \@!Y
M /  ?@#O (, [@"( .T C0#L ), ZP"9 .D H0#G *H Y "U .( Q0#@ -H
MWP#Q -X _P#: /\ U@#_ -0 _P#4 /\ U #_ /\  03_   "_P   ?\  P#_
M !$ _@ > /L + #X #D ]@!% /0 4 #P %H [ !B .D :@#H '  Y@!U .4
M>P#C '\ X@"$ .  B0#? (\ W0"5 -H G0#8 *4 U0"P -, O@#1 -( SP#K
M ,L _ #' /\ Q@#_ ,8 _P#& /\ Q@#_ /\   /_   "_P   /\   #[  H
M]  9 /  )P#M #0 Z@!  .< 2P#B %8 WP!> -P 90#: &P V !Q -8 =@#4
M 'L T@"  -$ A0#. (L S "1 ,H F #( *$ Q0"K ,, N #! ,L O0#C +H
M]@"Y /\ N0#_ +D _P"Y /\ N #_ /\   +_   !_P   /\   #P  4 Z@ 3
M .4 (@#A "\ W  [ -< 1P#3 %  T !9 ,T 8 #* &< R !M ,8 <@#$ '<
MP@!\ ,  @0"_ (< O0"- +L E "Y )T MP"G +, LP"P ,0 KP#: *X \ "M
M /\ K #_ *P _P"K /\ JP#_ /\   '_    ^P   .\   #F    WP , -D
M&P#2 "@ S0 V ,D 00#% $L P@!4 +\ 6P"\ &( N@!H +@ ;0"V ', M !X
M +, ?0"Q (, KP") *T D "K )D J "B *8 K@"E +T HP#2 *( Z0"A /D
MH #_ )\ _P"> /\ G@#_ /\   #V    [    .,   #;    TP % ,P % #%
M "( P  O +P .P"X $4 M0!. +$ 5@"O %T K0!C *L :0"J &X J !S *8
M>0"E '\ HP"% *$ C "? )4 G0"> )P J@": +@ F #, )< XP"5 /, E #^
M ), _P"3 /\ D@#_ /H   #L!@  X0X  -<0  #."0  QP   ,$ "P"[ !H
MM0 G +$ ,P"M #\ J0!( *8 4 "D %< H@!> *  9 "> &D G0!O )L =0":
M 'L F "! )8 B0"5 )$ DP"; )$!IP"/ ;4 C@+( (P#W@"+!?$ B0;^ (@'
M_P"'!_\ AP?_ /((  #E%P  V!\  ,PB  ##'@  O18  +<*  "Q !$ JP ?
M *8$+0"B!S@ GPA" )P)2P"9"E( EPM9 )8,7P"4#&4 D@QJ )$,< "0#7<
MC@U^ (P.A@"+#H\ B0Z: (@/I@"&$+4 A!#( (,1X "!$_0 @!3_ '\4_P!^
M%/\ ?A/_ .T6  #>(P  T"P  ,0O  "[+   M"<  *T=  "H$08 H@\8 )P3
M)@"8%3( E18] )(710"0&$T C1A4 (P96@"*&6  B!EF (<:; "&&G, A!IZ
M (,;@@"!&XL @!N6 'X;H@!]&[$ >QS$ 'D<W !X'?$ =AW_ 78=_P%U'?\!
M=1S_ ><A  #8+@  R#8  +XY  "U.   K3,  *8K  "?(0  F1L2 ),>(0"/
M("T C"$X (DB00"'(DD A2-0 (,C5@"!(UP ?R-B 'XC: !])&\ >R1V 'HD
M?P!X)(@ =R63 '4EGP%T):X!<B7  7 EV %N)>\";27^ VPE_P-L)/\#;"3_
M ^(J  #1-P  PS\  +E"  "P00  J#T  * V  "8+@  D24, (LG' "'*2@
M@RHS 8$J/ %^*D0!?"I+ 7HK4@%Y*U@"=RM> G4K9 )T*VL"<BMR G$K>P)O
M+(4";BR0 VPLG -K+*L#:2R]!&<LU 1E+.P%9"S\!6,K_P9C*_\&8RO_!MTR
M  #,/P  OT8  +5)  "L20  HT4  )L_  "2.   BB\' (0O%P" ,"0 ?# N
M GDQ-P-V,4 #=#%'!'(Q301P,5,$;S%9!&TQ8 5K,6<%:C%O!6@Q=P5G,8$%
M93*,!F0RF09B,J@'8#*Z!UXRT0A=,NH(7#'["%LQ_PA;,/\(6S#_"-@Y  #(
M10  O$L  +%.  "H3P  GTP  )=&  ".0   A#@" 'XV$P!Z-R  =3<J G(V
M,P1O-CL%;#9"!FHV20=H-4\'9C55!V4U7 AC-6,(8C9K"& V= E?-GX)73:)
M"5LVE@I:-J4*6#:W"U8VS@M5-N@,5#7Z"U0U_PM4-?\+5#3_"]0_  #%2@
MN5   *]4  "F5   G%$  )-,  "*1@  @#\  '@[#@!T/!P ;SPG 6L\, 1H
M.S<&93H^"&(Z10E@.DL*7CE1"ETY6 M;.E\+6CIG#%@Z< Q7.GL-53J&#50[
MDPY2.Z,.4#JT#T\ZRP]-.N8/33GX#TTY_PY-./\.33C_#M!$  #"3@  ME4
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M%#I'Q!,Y1^ 3.4;U$SE&_Q,Y1?\3.47_$\=1  "Z6@  KV   *9D  "=90
ME&0  (IA  !^7   <E<  &52  !=4 T 6E$: %91) %34"P#3T\S!DQ..0E(
M33\-14Q%$$-,3!) 3%,4/DQ<%3U,9A4[3'$5.DQ^%#E-BQ,X39L3-TVM$C5-
MPQ$T3=\1,TST$C-+_Q(S2O\3,TK_$\15  "W7@  K60  *1H  ";:@  DFD
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M!R1=_PDC7/\*(US_"[ED  "O;   IG(  )YW  "6>0  C7H  (-Y  !V=@
M:7,  %MP  !-;0  /VL& #IJ$P X:AX -FHG #1J+P$Q:C8#+VH]!"UJ104K
M:DT&*6I6!BAJ8 4G:FP%)FIY!"1JAP,C:9<#(FFI B!IOP(?:-L!'F?Q QUE
M_@4=9/\&'&/_![5J  "L<@  I'@  )Q]  "4?P  BX   (*   !T?0  97H
M %=X  !)=@  .W0  #%R#  N<A< +'(A "IS*0 H<S( )W,Y 25S00(C<TH"
M(G-3 B!S7@$?<VH!'7)W 1QRA0 :<I4 &'&G !=QO0 5<-D %F[P !9M_@$5
M;/\"%6S_ [%Q  "I>   H7\  )J$  "3A@  BH<  'Z&  !PA   8($  %*
M  !$?@  -GP  "I[ P B>Q  ('L: !Y[(P =?"L &WPT !I\/ #_XGT024-#
M7U!23T9)3$4 $Q48?$4 %WQ/ !5\6@ 4?&8 $GQS !![@@ ->Y( "WJD  EY
MN0 (>-( "'?K  IU^@ *=?\ "G3_ *YX  "F@   GX8  )B*  "1C0  AHT
M 'F,  !JB@  6X@  $R'   _A@  ,88  "6%   9A00 $880 !"&&0 -AB,
M#(8K  J&-  )ACX "(5(  :%4P $AF   H5M  "%?   A(P  (.>  ""L@
M@,T  '_D  !_\P  ?OL  'W_ *J   "DB   G8T  )>1  ",DP  @),  '*2
M  !CD0  5)   $6/   XCP  *X\  !^/   4CP  ") &  "0$0  D!H  ) C
M  "0+   D#8  )!   "03   D%@  )!F  "/=0  CX8  (Z8  ",K   B\0
M (GB  "(\@  B/D  (?^ *>)  "AD   FY4  )*7  "&F   >)@  &J8  !;
MEP  3)<  #V7   PF   ))@  !B8   ,F0   IH   ":"   FA(  )H;  ":
M)   FRP  )LW  ";0@  FT\  )M=  ";;0  FGX  )F0  "8I   E[P  );9
M  "4\   D_H  )/_ *21  "?EP  EYL  (N=  !^G@  ;YX  &">  !2G@
M0Y\  #6@   HH   '*$  !"B   %HP   *0   "E    I08  *40  "F&
MIB$  *<K  "G-@  IT(  *=1  "H8@  IW0  *>'  "FFP  I;(  *3.  "B
MZ0  HO8  *'] **:  ";G@  D*$  (.B  !THP  9:0  %:D  !(I0  .:<
M "NH   >J0  $JH   :L    K    *X   "O    KP   + "  "Q"P  LA4
M +,>  "T*   M30  +9!  "W4@  MV4  +=Y  "UC@  M*8  +/   "SW0
MLN\  +'W )^A  "3I   AJ8  'BH  !IJ0  6JH  $NK   \K0  +JX  ""P
M   4L@  ![0   "U    M@   +@   "Y    N@   +P   "]    OP0  , .
M  ##&   Q20  ,<Q  #)00  RU0  ,UI  #-?@  S94  ,RL  #)Q@  R-X
M ,?L ):F  "*J0  ?*L  &VM  !>K@  3[   $"R   PM0  ([<  !:Y   '
MO    +X   #!    P0   ,,   #$    Q@   ,@   #*    S0   -    #3
M!P  V1,  -P?  #?+0  XT   .55  #F;   YX0  .B:  #GK@  Y[\  .?,
M (VK  " K0  <;   &&R  !2M0  0[@  #.[   DO@  %\$   G#    QP
M ,H   #-    S@   ,\   #0    T0   -0   #8    W    .    #D
MZ    .T,  #Q&P  ]"H  /@_  #[5@  _&X  /R%  #\F0  _*<  /RQ /\
M!P+_  4!_P ! /\ !@#_ !4 _P D /\ ,@#_ #X _P!* /\ 50#_ %\ _@!G
M /P ;@#[ '0 ^@!Z /D ?P#X (, ]P"( /8 C0#U ), ] "9 /( H0#O *H
M[0"V .P QP#J -X Z0#S .< _P#B /\ W@#_ -X _P#9 /\ U@#_ /\  @+_
M   !_P   /\  P#_ !( _P @ /\ +0#_ #H _P!& /L 40#W %L ] !C /(
M:@#Q '  \ !V .X >P#M (  [ "$ .L B0#I (\ YP"6 .4 G0#C *8 X0"Q
M -\ P #= -4 V@#L -0 _P#1 /\ T #_ -  _P#0 /\ S0#_ /\   +_   !
M_P   /\   #_  P ^P ; /@ *0#V #8 \P!" .\ 30#K %< Z0!? .< 9@#E
M &P XP!R .$ =P#@ 'P W@"! -P A@#: (L V "2 -4 F0#3 *$ T0"L ,\
MN0#+ ,T Q@#F ,0 ^@## /\ P@#_ ,( _P#" /\ P@#_ /\   '_    _P
M /X   #V  < \0 6 .T (P#I #$ Y  ] .$ 2 #> %( VP!: -@ 8@#5 &@
MTP!M -$ <P#/ '@ S0!] ,L @@#) (< QP"- ,4 E0## )T P0"G +T M "Y
M ,4 MP#> +8 \P"U /\ M #_ +0 _P"T /\ M #_ /\   '_    _P   /,
M  #K  ( Y0 0 .  '@#9 "L U  X -$ 0P#. $T RP!5 ,@ 7 #% &, P@!I
M ,  ;@"_ ', O0!X +L ?0"Z (, N ") +8 D "S )@ L "B *X K@"L +T
MJ@#4 *D ZP"H /P IP#_ *< _P"G /\ I@#_ /\   #_    \    .@   #@
M    V  * -  & #+ "8 Q@ R ,( /0"_ $< O !0 +D 5P"V %X M !D +(
M:0"Q &X KP!T *T >0"L 'X J0"% *< C "F )0 I "= *( J "@ +< G@#*
M )T XP"< /8 FP#_ )H _P": /\ F0#_ /\   #Q    YP   -T   #3
MRP # ,0 $@"_ !\ N@ K +4 -P"R $$ KP!* *P 4@"J %@ IP!? *8 9 "D
M &H H@!O *$ = "? 'H G@"  )P AP": (\ F "9 )8 I "4 +$ DP## )$
MW "0 /  CP#] (T _P", /\ C #_ /4   #H!   W L  - +  #'!@  P
M +H "0"T !< K@ D *H +P"G #H HP!$ *$ 3 "> %, G !9 )H 7P"9 &4
MEP!J )8 ;P"4 '4 DP!\ )$ @P"/ (L C0"5 (L H "* *X B "_ (8 U0"$
M .L @P#Y (( _P"" /\ @0#_ .T'  #@%0  T1T  ,8>  "]&@  MA$  + %
M  "J  X I0 < *  * "< #, F0 ] )8 1@"4 4T D@)4 ) #6@". U\ C01E
M (L$:P"*!'$ B 5X (8%@ "%!H@ @P:2 ($&G@" !JP ?@:\ 'T'TP![">H
M>@OZ 'D+_P!X"_\ > O_ .<5  #8(@  R2H  +XK  "V*   KB,  *<9  "A
M# 0 FP44 )8)(@"2"RT CPPW (P.0 "*#T@ B!!/ (8050"$$5L @Q%A ($2
M9P" $FT ?A)T 'T3? ![$X8 >A.0 '@3G !V$ZH =12\ ',4TP!Q%NL <!;\
M &\6_P!O%O\ ;Q;_ .$A  #0+0  PS0  +@V  "O-   J"\  * G  "9'0
MDA,, (T5' ")%R@ A1DR (,:.P"!&D, ?QM* 'T;4 ![&U8 >AQ< '@<8@!W
M'&D =1QQ ',=>0!R'8( <!V- &\=F0!M'J< ;!ZY &H>SP!H'^@ 9Q_Z 68?
M_P%F'O\"91[_ MLI  #*-@  OCP  +,^  "J/0  HCD  )HS  "2*@  BB '
M (4?%@"!(2, ?2(M 'LC-P!X(S\ =B-& '0D3 !S)%( <218 &\D7P!N)&4
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M",T_  "_2   M$X  *I1  "A40  F$X  (Y(  "%0P  >SP  '(U" !L-18
M:38A &4V*@)A-3(#7S4Y!5PU0 9:-$8&6#1,!U<T4P=5-%H(5#5B"%,U:PA1
M-78)4#6!"4XVC@E,-IT*2S:N"DDUPPM(-=X+1S7T"T<T_PM'-/\+1S/_"LI$
M  "\3   L5(  *A5  "?5@  EE,  (Q.  ""20  >$,  &T[! !G.A, 8SL>
M %\[)P%;.B\#6#DV!58Y/ =3.$((43A("5 X3PI..%<*33E?"TLY: M*.7,,
M2#I_#$<ZC Q%.IL-0SJL#4(ZP0U .=P-0#GS#4 X_PU ./\-03?_#,=(  "Z
M40  KU8  *99  "=6@  E%@  (E3  !_3@  =4D  &E"  !A/PX 74 ; %I
M) %6/RP#4SXS!4\].0=-/3\)2SU%"TD]3 Q'/50-1CU<#D0]90Y#/G .03Y\
M#D ^B@X^/ID./#ZJ#CL^OPXZ/MH..3[Q#CD]_PXZ//\..CS_#L1,  "W5
MK5H  *1=  ";7@  DET  (A9  !\4P  <4X  &5(  !<10H 5T47 %1%(0!1
M12D"340P!$I#-@='0CP)14)#"T-"20U!0E$./T)9#SU"8P\\0FX/.D-Z#SE#
MB \X0Y</-D.H#C5#O0XT0]D-,T+P#C-"_P\S0?\/-$#_#\%0  "U6   JUX
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M!B=6N@4E5M4$)%3N!B-3_0@B4O\)(E'_"KA>  "N9@  I6L  )QO  "4<0
MBW$  (%O  !T:P  :6D  %QF  !.8@  0%X& #I=$@ X71P -ETE #-=+0$Q
M730"+UT[!"U=0@4K74H%*5U3!BA=704G76D%)5UU!"1=@P,C79,#(EVD B!=
MN0(?7-0!'EOM QU9_ 4=6/\&'%C_![5C  "K:P  HW$  )MU  "3=P  BG<
M (!V  !S<P  9G   %AM  !*:@  /&<  #)E#  O91< +64@ "ME*  I93 !
M)V4X 25E0 (D94@"(F51 B%E6P(?968!'F5S 1UE@@$;99$ &F2C !ADMP 7
M8]( %V+L !=@^P(68/\#%5__!+%I  "H<0  H'8  )E[  "1?0  B7X  ']]
M  !Q>@  8G<  %1T  !&<@  .&\  "MN!0 D;1$ (FT: "%M(P ?;2L 'FTS
M !QM.P ;;40 &6U- !AM6  6;6, %&UP !)M?P 0;8X #FR@  QKM  *:LT
M"VGH  QH^0 -9_\ #6;_ :YP  "F=P  GGT  )>!  "0A   AX4  'N#  !L
M@   77X  $]\  !!>@  ,W@  "=W   ;=@@ %G83 !1V'  2=B0 $78L  ]V
M-0 -=CX #'9(  IV4P (=EX !G9L  1V>@ "=8H  '6;  !TK@  <L<  ''A
M  !P\@  ;_P  6[_ *IW  "C?@  G(0  ):(  ".BP  @XH  ':)  !GAP
M5X4  $F$   [@@  +H$  "&    6@   "8 )  2 %  "@!T  8 F  " +@
M@#<  (!"  " 30  @%D  (!F  !_=0  ?X4  'Z6  !]J0  >\$  'K>  !Y
M[P  >/D  'C^ *=_  "AA@  FXP  )2/  "*D   ?9   &^/  !@C0  48P
M $*+   TBP  )XH  !N*   0B@  !(L#  "+#   BQ8  (L>  "+)P  BR\
M (LZ  "*10  BE$  (M?  "*;@  BGX  (F0  "'HP  AKL  (38  "#[P
M@OL  (+_ *2(  "?C@  F9,  )"5  "#E@  =I4  &>4  !8E   29,  #J3
M   MDP  (),  !24   (E    )4   "5!0  E0T  )46  "5'@  E2<  )8P
M  "6.P  E4@  )96  "690  E78  )6(  "4G   D[(  )'.  "0Z0  CO@
M (W_ **0  "=E@  E9D  (F:  ![FP  ;)L  %V:  !/F@  /YL  #&<   D
MG   %YT   J=    G@   )\   "@    H ,  * ,  "@%0  H1T  *$F  "A
M,   HCT  *)+  "B6P  HFP  *)_  "ADP  H*D  )_#  ">X0  G?(  )W\
M *"8  "9G   C9X  ("@  !QH0  8J$  %.A  !$H@  -:,  ">D   :I0
M#:8   &G    J    *D   "J    JP   *L   "K!P  K!   *T9  "O(@
ML"T  + [  "Q30  L6   +!T  "PB   L)X  *^V  "NTP  KND  *WV )R?
M  "1H@  A*0  '6E  !FI@  5Z<  $BH   YJ0  *JL  !VL   .K@   J\
M  "Q    L0   +,   "T    M0   +8   "W    N $  +H*  "]%   OQ\
M ,$K  ##.P  Q4T  ,=B  #&>   Q)   ,*H  #"P0  P=D  ,'K )2D  "(
MIP  >JD  &NJ  !;K   3*T  #RO   ML0  '[,  !&U   #MP   +H   "\
M    O    +X   "_    P0   ,,   #%    QP   ,H   #- P  T@T  -0;
M  #8*0  W#L  -]0  #B9@  XGT  ..3  #AJ   X+P  -_1 (NI  !^K
M;JX  %^P  !0L@  0+4  #"W   @N@  $[T   2_    P@   ,4   #(
MR    ,H   #+    S    ,\   #2    U@   -H   #>    XP   .D'  #M
M%@  \"4  /0Z  #V4@  ^&H  /F!  #YE0  ^J0  /FQ /\  @'_    _P
M /\ ! #_ !( _P @ /\ +@#_ #L _P!' /\ 4@#^ %P _ !D /L :P#Z '$
M^ !V /< >P#V (  ]0"% /0 B@#R (\ \ "6 .X G@#M *< ZP"R .H P0#H
M -D Y #Q -X _P#; /\ W #_ -D _P#3 /\ T #_ /\   '_    _P   /\
M  #_  X _P < /\ *@#] #< ^@!# /< 3@#T %@ \@!@ /  9P#O &T [0!S
M .P > #J 'P Z0"! .< A@#E (P XP"2 .$ F@#@ *( W@"M -L NP#7 -$
MT0#J ,X _0#- /\ S0#_ ,T _P#) /\ Q@#_ /\   '_    _P   /\   #]
M  D ^0 7 /4 )0#Q #, [0 _ .L 20#H %, Y0!; ., 8@#A &D WP!N -T
M= #; '@ V0!] -8 @@#5 (@ TP". -$ E0#/ )X S0"H ,@ M0## ,D P0#B
M +\ ]P"_ /\ O@#_ +X _P"^ /\ O #_ /\   #_    _P   /D   #R  0
M[0 3 .@ ( #B "X W@ Z -P 1 #9 $X U0!6 -( 7@#0 &0 S0!J ,L ;P#)
M '0 R !Y ,8 ?@#$ (, PP") ,$ D0"^ )D N@"C +< KP"U ,  LP#7 +(
M\ "Q /\ L #_ *\ _P"O /\ KP#_ /\   #_    ]P   .X   #F    X  -
M -@ ' #2 "@ S@ T ,L /@#( $@ Q0!1 ,$ 60"_ %\ O0!E +L :@"Z &\
MN !T +8 >0"U '\ L@"% +  C "N )0 K "> *H J0"H +@ I@#, *4 YP"C
M /H H@#_ *( _P"B /\ H@#_ /\   #V    [    .,   #:    T  ( ,D
M%@#$ "( P  N +P .0"X $( M@!+ +, 4P"Q %H KP!@ *T 90"K &H J0!P
M *< =0"F 'H I "  *, AP"A (\ GP"8 )T I "; +$ F0## )@ W0"7 /,
ME@#_ )4 _P"4 /\ E #_ /D   #L    X0   -8   #,    Q  ! +X #P"X
M !P LP H *\ ,P"L #P J0!% *8 30"D %0 H@!: *  8 "> &4 G0!J )P
M< ": '4 F0![ )< @@"5 (H DP"3 )$ GP"/ *L C0"\ (P TP"* .P B0#\
M (D _P"( /\ AP#_ /    #B @  U0@  ,D(  #! 0  N@   +, !P"M !4
MJ  A *0 + "@ #8 G0 _ )L 1P"9 $X EP!4 )4 6@"3 &  D@!E )  :P"/
M '  C0!W (L ?@"* (8 B "/ (8 F@"$ *< @@"W ($ S0"  .8 ?@#V 'T
M_P!\ /\ ? #_ .@'  #:%   RQL  , :  "X%@  L P  *H!  "D  P G@ 9
M )H )0"6 "\ DP Y )  00". $@ C !/ (H 50") %L AP!@ (8 9@"$ &P
M@@!R ($ >@!_ (( ?0", 'P EP!Z *0 > "T '< R !U >$ = +S ',#_P!R
M _\ <@/_ .$5  #0(0  PR<  +DH  "P)0  J1\  *(5  ";" ( E0 1 )
M'@", BD B0,S (8%.P"$!D, @@=) ( (4 !_"%8 ?0A; 'P)80!Z"6@ > EO
M '<*=@!U"G\ <PJ* '(*E0!P"Z, ;PNS &T+R !K#>( :@[U &D._P!I#O\
M: [_ -L@  #*+   OC$  +,S  "J,0  HBL  )LD  "3&0  C T' (<,%P"#
M#B( ?Q M 'T1-0![$CT >1-$ '<42P!U%%$ <Q17 '(470!P%6, ;Q5K &T5
M<P!L%7P :A:' &@6DP!G%J$ 91:Q &,7QP!B&.$ 81CU & 8_P!?&/\ 7QC_
M =0J  #%-   N3H  *X\  "F.@  G34  )4O  "-)@  A1P! 'X7$0!Z&1T
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M U LBP-.+)D$3"RJ!$LLO@1)+-D%2"OP!4@K_P9(*O\&2"K_!L<^  "Z1@
MKTP  *9.  "<3@  E$L  (I%  "!0   =SD  &PQ @!E+A$ 82\< %XO)0!;
M+RT!6"\T E8O.P-4+T$$4B]'!%$O3@1/+U4%3B]=!4TP9@5+,' %2C!\!D@Q
MB09',9<&13&H!T,QO =!,-8'03#O"$$O_@A!+_\(02[_",1"  "W2P  K5
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M"3 _MPDN/] (+C[K"2T]^PHM//\++CS_"[Q/  "Q5P  IUP  )Y?  "58
MC%X  ();  !V5@  :U$  %]-  !31P  2D0- $=$& !$1"$ 040H 3Y$+P,\
M0S4%.4,\!S=#0P@U0TH),T-3"C)#7 HQ1&<*+T1T"2Y$@0DM19$(+$6B!RM%
MM@<I1<\&*$3J!RA#^PDG0?\*)T'_"[E3  "N6P  I6   )QC  "49   BV,
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M !=5^0$65/\#%5/_!+!B  "G:0  GV\  )=R  "0=   AW0  'US  !Q<
M8VT  %9J  !(9@  .F,  "U@!0 E7Q$ (U\: ")?(@ @7RH 'V Q !U@.0 <
M8$( &F!+ !E@50 78&  %6!M !1@>P 28(L $%^<  Y?L  ,7L@ #%WD  Y;
M]P .6O\!#EK_ :UH  "E;P  G74  )9X  ".>@  AGL  'QZ  !N=P  7W0
M %%Q  !$;@  -6P  "AJ   <: D &6@3 !=H'  5:"0 %&@L !)H-  1:#T
M#FA'  UH40 +:%P "6AI  =H=P %9X<  V>7  )FJ@ !9<(  F3=  )C\  #
M8OT !&'_ *IO  "B=@  FWL  )1_  "-@0  A8(  'B   !J?0  6GH  $QX
M   ^=@  ,'0  "-S   8<@  #'$+  EQ%0 '<1X !G$F  1Q+P #<3@  7%"
M  !Q3   <5@  '%D  !P<P  <((  &^3  !OI@  ;KP  &S9  !J[0  :?@
M &G^ *=V  "@?0  FH,  ).&  ",B   @8@  '.&  !DA   5($  $:    W
M?@  *GT  !Y\   2>P  !GL'  ![$   >QD  'LA  ![*0  >S$  'L[  !Z
M1P  >U(  'M?  !Z;@  >GX  'F.  !XH0  =[<  '73  !T[0  <_@  '+]
M *1^  ">A0  F(H  )*-  "'C@  >HT  &R,  !=B@  3HD  #^(   QAP
M)(8  !>&   +A@   (8!  "&"0  AA(  (4:  "%(@  ABD  (8S  "%/P
MA4L  (58  "%9P  A'@  (.)  ""G   @;$  (#,  !_Z0  ??@  'W_ **'
M  "<C0  EY$  (V3  "!DP  <Y,  &21  !5D   1I   #:0   ICP  '(\
M !"/   $D    )    "0 @  D D  ) 2  "0&@  D"$  )$J  "1-0  D$(
M )%/  "17@  D6\  )"!  "/E0  C:H  (S$  "*XP  B?0  (G] *"/  ";
ME   DY<  (:8  !XF0  :9@  %J7  !+EP  /)@  "V8   @F   $Y@   :9
M    F@   )L   ";    FP   )L(  ";$   FQ@  )P@  "=*@  G38  )U$
M  ">5   GF4  )YX  "=C   G*(  )NY  ":U@  F.X  )?Y )Z7  "7FP
MBYP  'Z>  !OG@  7YX  %">  !!G@  ,:   ".A   6H0  "*(   "C
MI    *4   "F    I@   *8   "G P  IPL  *@4  "I'0  JBD  *HW  "K
M1P  K%D  *QL  "L@0  K)<  *NN  "JR0  J>,  *GQ )J>  "/H   @J(
M '.C  !DHP  5*0  $6E   UI@  )Z@  !FI   *J@   *L   "M    K0
M *X   "P    L0   +$   "R    LP   +4%  "W#P  N1D  +LE  "]-
MOD@  +]>  "^=   OHH  +ZA  "]N0  O=,  +SE )*C  "%I0  =Z<  &BH
M  !8J0  2:H  #BL   IK@  &[    RQ    LP   +4   "W    MP   +D
M  "Z    O    +T   "_    P0   ,,   #&    RPD  ,X6  #2(P  U30
M -E*  #<8   W'@  -F1  #8J   UKT  -;0 (FG  ![J@  :ZP  %RN  !-
MKP  /+$  "RT   =MP  #;D   "[    O@   ,$   ##    PP   ,4   #&
M    R    ,H   #-    T    -0   #9    W0   .,#  #G$@  ZR(  .\U
M  #S3   ]60  /9\  #VD0  ]Z(  /6O /\   #_    _P   /\  0#_  X
M_P = /\ *P#_ #@ _P!$ /X 3P#\ %@ ^@!@ /D 9P#W &T ]@!S /4 > #S
M 'T \@"" /  AP#O (P [0"3 .P F@#J *0 Z0"N .< O0#C -0 W0#O -H
M_P#9 /\ V0#_ -, _P#. /\ R@#_ /\   #_    _P   /\   #_  L _P 9
M /T )P#X #0 ]@!  /0 2@#Q %0 [P!< .T 8P#K &D Z0!O .< = #E 'D
MY !^ .( @P#A (D X "/ -X E@#< )\ V@"I -0 MP#/ ,P S #G ,L ^P#*
M /\ R0#_ ,@ _P## /\ P #_ /\   #_    _P   /\   #Z  8 ]@ 4 /
M(@#K "\ Z0 [ .< 10#C $\ X0!7 -T 7P#; &4 V0!K -8 < #5 '4 TP!Z
M -( ?P#0 (0 SP"* ,T D@#* )H Q0"E ,( L0#  ,, O@#= +P ] "Z /\
MN@#_ +H _P"X /\ M0#_ /\   #_    _0   /4   #N  $ Z  0 .$ '0#=
M "H V0 V -8 0 #3 $H SP!2 ,L 6@#) &  QP!F ,4 :P#$ '  P@!U ,$
M>P"_ (  O0"& +H C0"W )8 M0"? +, JP"Q +H KP#1 *T [ "L /\ K #_
M *L _P"K /\ JP#_ /\   #\    \@   .D   #A    V  * -$ &0#, "0
MR  P ,4 .@#! $0 O@!- +L 5 "Y %L MP!A +4 9@"T &L L@!Q +  =@"N
M 'L K0"! *L B "I )  J "9 *8 I "D +, H@#& *  X0"? /@ G@#_ )T
M_P"= /\ G #_ /X   #Q    Y@   -T   #2    R@ & ,, $P"^ !\ N0 J
M +8 -0"S #X L !& *T 3@"K %4 J !; *8 80"E &8 I !K *, < "A '8
MH !\ )X @P"= (H FP"4 )D GP"7 *P E0"] ), U@"1 /  D #_ (\ _P"/
M /\ CP#_ /0   #G    VP   ,X   #%    O@   +< # "R !D K0 D *D
M+@"F #@ HP!  *  2 "> $\ G !5 )L 6P"9 &  F !F )< :P"5 '$ E !W
M )( ?@"0 (4 C@"/ (P F0"* *8 B "V (8 S0"% .@ A #[ (0 _P"# /\
M@P#_ .L   #= 0  S@8  ,0$  "[    LP   *T !0"G !( H@ > )X * ":
M #$ F  Z )4 0@"3 $D D0!/ (\ 50". %L C !@ (L 9@") &L B !R (8
M>0"$ ($ @@"* ($ E0!_ *( ?0"Q 'P Q0!Z .  >0#U 'D _P!W /\ =P#_
M .,&  #2$P  Q1@  +L7  "R$@  JP@  *0   ">  H F0 7 )0 (0"0 "L
MC0 T (H / "( $, A@!* (4 4 "# %4 @@!; (  80!_ &< ?0!M 'L =0!Z
M 'T > "& '8 D0!T )X <@"M '$ P !P -H ;@#O &T _ !L /\ ; #_ -L5
M  #*(   OB0  +0E  "K(0  HQL  )P1  "5!0  CP . (H &@"& "4 @P N
M (  -@!^ #X ? !$ 'L 2@!Y %  > !6 '8!7 !T 6( <@)I '$"<0!O GD
M;0.# &P#CP!J YP : .K &<#O@!E!-8 9 ;L &,'^P!B!_\ 8@?_ -,A  #$
M*@  N"\  *XP  "F+0  GB@  )8@  ".%@  APH% ($$$P!]!1X >@<H '<(
M,0!T"3@ <@H_ '$*10!O"TL ;0Q1 &P,5P!J#%X : UE &<-;0!E#7< 8PZ!
M &(.C0!@#IL 7@^K %T0OP!;$-D 6A'O %D2_0!9$O\ 61'_ ,TI  "_,@
MM#<  *HY  "A-P  F3(  ) K  "((P  @!D  '@0"P!T$1@ <!(B &T3*P!K
M%#, :10Z &<500!E%4< 9!9- &(64P!@%EH 7Q=A %T7:@!<%W, 6AA^ %D8
MB@!7&)@ 5AFH %09O !2&=4 4AKN %$:_@!1&?\!4!G_ <DQ  "[.@  L#\
M *=   ">/P  E3H  (PT  "#+0  >R0  '$<!0!L&1, :!H> &4;)P!C'"\
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M!#TLM00[*\X$.BOI!3HK^P4Z*O\%.BG_!;]!  "S20  J4X  )]0  "63P
MC4T  (1(  !Z0P  ;ST  &4U  !9+P8 5"T2 %$N' !.+B0 2RXK 4DN,0)'
M+C@#12X^ T,N101"+DT$0"]5!#\O7@4]+V@%/#!T!3HP@04Y,) %-S"@!C4P
MLP8T,,P&,S#G!C,O^0<S+_\'-"[_![Q%  "Q30  IU(  )U4  "55   C%(
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M R$^]P4A/?\&(3S_![52  "J60  H5X  )EA  "080  AV   'U>  !Q6
M9E4  %M2  !/30  04<" #A%#0 U1!< ,T4@ #%%)P O12X!+44T BM%/ ,I
M140$)T5,!"9%5@0E1F$$)$9M R)&>P,A1HH"($:; A]&K@$=1L8!'47B 1Q$
M]@,;0_\%&T+_!K)7  "H7@  H&,  )=F  "/9@  AF8  'QD  !P7P  95T
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M *IG  "B;@  FG,  )-V  "+>   @W@  'IX  !K=   77$  $]N  !!:P
M,V@  "9F   99 ( $&,,  QC%@ *8QX "6,F  =C+@ &8S< !&-   )C2P
M8U8  &-B  !B<   8G\  &*0  !AH@  8+<  %_4  !=Z@  7/<  %S^ *=N
M  "?=   F'H  ))]  "*?P  @H   '9]  !G>@  5W<  $EU   [<P  +7$
M "!O   5;0  "&T'  %L$   ;!D  &PA  !L*0  ;#$  &P[  !L1@  ;%$
M &Q>  !K;   :WL  &J+  !IG@  :+,  &?.  !FZ0  9/8  &3] *1U  "=
M?   EX$  )&$  ")A@  ?H4  '"#  !A@0  47X  $-\   T>P  )WD  !IX
M   .=P   G<#  !W#   =A0  '8<  !V(P  =BL  '8U  !V0   =4P  '59
M  !U9P  ='8  '2'  !SF0  <JX  ''(  !OY@  ;O<  &[_ *)]  ";@P
MEH@  )"+  "%C   >(L  &F)  !:AP  2X4  #N$   N@P  (((  !2!   '
M@0   ($   "!!P  @0X  ($6  " '0  @"0  ($M  " .   @$4  (!2  "
M8   @'$  '^"  !^E0  ?:D  'S"  !ZX0  >?0  'C^ )^&  ":BP  E8\
M (N1  !_D0  <)   &&.  !2C0  0HT  #.,   FC   &(L   N+    BP
M (P   ",    C 8  (L.  "+%0  BQT  (PD  ",+@  C#L  (Q)  ",6
MC&@  (M[  "*CP  B:0  (>[  "&V0  A?$  (3[ )Z.  "9DP  D)4  (26
M  !VE@  9Y4  %>4  !(E   .)0  "J4   <E   #Y0   *5    E0   )8
M  "7    EP   )8$  "6"P  EQ,  )<;  "8)   F"\  )@^  "930  FEX
M )EQ  "9A0  F)H  ):S  "4T0  D^H  )+X )R6  "5F0  B9H  'N;  !L
MFP  7)L  $V;   ]FP  +IP  !^=   2G0  !)X   ">    GP   *    "A
M    H0   *(   "A    H@@  *,1  "D&0  I2,  *8P  "F00  IU(  *AE
M  "H>@  J)   *>G  "FP@  I=T  *3N )B<  ",G@  ?Z   '"A  !AH0
M4:$  $&B   QHP  (Z0  !6E   &I@   *<   "I    J0   *H   "L
MK    *T   "N    K@   + !  "Q"@  M!0  +4A  "V,   MT0  +A8  "Y
M;@  N80  +F;  "XL@  N,T  +CB )"A  "#HP  =:4  &6F  !6I@  1J<
M #6I   EJP  %ZT   BN    KP   +$   "S    LP   +4   "V    MP
M +D   "Z    NP   +T   #     Q 0  ,@0  #+'@  SRX  -)$  #370
MT78  -*-  #2HP  T;@  -', (>F  !YJ   ::H  %JK  !*K0  .:\  "FQ
M   :LP  ";8   "X    N@   +P   "_    O@   ,    #"    PP   ,8
M  #(    RP   ,X   #1    U@   -T   #B#0  YAT  .LP  #N1P  \E\
M /)X  #PD   [J4  .ZT /\   #_    _P   /\   #_  H _P : /\ * #_
M #4 _P!  /P 2P#Z %0 ^ !< /8 8P#T &H \@!O /  =0#N 'H [0!^ .P
MA #K (D Z@"/ .D EP#G *  Y@"K .$ N@#< -  V0#K -@ _P#6 /\ U0#_
M ,\ _P#( /\ Q #_ /\   #_    _P   /\   #_  < _@ 6 /@ ) #U #
M\P \ /$ 1@#N %  ZP!8 .@ 7P#E &8 XP!K .( <0#@ '4 WP!Z -X @ #<
M (4 VP"+ -D D@#6 )L T0"F ,T M #+ ,< R@#B ,@ ^0#& /\ Q0#_ ,,
M_P"] /\ N@#_ /\   #_    _P   /T   #W  , \  1 .L 'P#G "P Y0 V
M .( 00#> $L V@!3 -8 6P#4 &$ T@!G -  ; #/ '$ S0!V ,P >P#+ ($
MR0"' ,4 C@#" )< P "A +X K0"\ +T N@#6 +@ \0"V /\ M0#_ +4 _P"S
M /\ L #_ /\   #_    ^0   /$   #J    X0 - -P &@#7 "8 TP R ,\
M/ #+ $4 R !. ,4 50## %P P0!B +\ 9P"^ &P O !Q +H =P"X 'P M0""
M +0 B0"S )$ L0"; *\ IP"N +4 JP#+ *H Z "H /T IP#_ *< _P"G /\
MI #_ /\   #W    [0   .0   #:    T0 ' ,L %0#& "  P@ L +X -@"[
M #\ N !( +4 4 "S %8 L0!< *X 8@"M &< JP!L *H <0"I '< J !] *<
MA "E (L HP"5 *$ H "@ *T G@#! )P W ": /4 F #_ )< _P"7 /\ EP#_
M /H   #M    X0   -4   #+    Q  # +T #P"X !P LP F +  , "M #H
MJ@!" *< 2@"D %  HP!6 *$ 7 "@ &$ GP!F )T ; "< '$ FP!W )D ?@"8
M (8 E@"/ )0 F@"2 *< D "X (T T ", .P BP#_ (H _P"* /\ B@#_ .\
M  #B    U    ,@   "_    N    +$ "0"L !8 IP A *, *@"@ #, G0 \
M )L 0P"9 $H EP!0 )4 5@"4 %L D@!A )$ 9@"0 &P C@!R (T >0"+ ($
MB0"* (< E "% *$ @P"Q (( Q0"  ., ?P#X '\ _P!^ /\ ?@#_ .4   #5
M    R ,  +X!  "V    K@   *<  P"B  \ G0 : )@ )0"5 "T D@ V )
M/0"- $0 BP!* (H 4 "( %8 AP!; (4 80"$ &< @P!M ($ = !_ 'P ?0"%
M 'P D !Z )P > "K '8 O@!U -H = #R ', _P!S /\ <@#_ -P'  #,$0
MP!4  +84  "M#@  I@4  )\   "8  @ DP 4 (X '@"+ "< AP O (4 -P"#
M #X @0!% '\ 2P!^ %  ? !6 'L 6P!Y &$ > !H '8 ;P!T '@ <@"! '
MC !N )@ ;0"G &L N0!J -( :0#L &@ _ !G /\ 9@#_ -,5  #%'0  N2$
M *\B  "F'@  GA<  )<-  "0 @  B@ , (4 %P"! "$ ?@ J 'L ,0!Y #D
M=P _ '4 10!S $L <0!1 '  5P!N %T ;0!C &L :P!I '0 9P!^ &4 B0!D
M )4 8@"D &  M0!? ,X 7@#F %T ]@!< /\ 7 #_ ,T@  "_*   LRP  *HM
M  "A*@  F20  )$<  ")$P  @0@" 'P #P!W !H =  D '$ + !N 3, ; (Z
M &H"0 !I T8 9P1, &4%4@!D!5@ 8@9? & &9P!?!G  709[ %L'A@!:!Y,
M6 >C %8(M0!5",L 5 GE %,*]@!3"O\ 4@K_ ,<H  "Z,   KS4  *8V  "=
M-   E"X  (PG  "#(   >Q<  ',,!P!N"!0 :@D> &<*)@!D"RX 8@PU & ,
M.P!?#4$ 70Y( %P.3@!:#U0 6!!< %<09 !5$&X 5!%Y %(1A0!0$I( 3Q*B
M $T2M0!,$LT 2Q/G $H3^0!*$_\ 2A/_ ,,P  "V.   K#P  *(]  "9/
MD3<  (@Q  !_*@  =B(  &T9  !E$@T 81,8 %X4(0!<%2D 6A4P %@6-P!6
M%CT 51=$ %,72@!1%U$ 4!A8 $X880!-&&L 2QEV $H9@@!(&I  1QJ@ $4:
ML@!$&LH 0QKE $(:^0!"&O\!0AK_ ;\V  "S/@  J4(  *!$  "70@  CCX
M (4Y  ![,@  <BL  &@C  !>&P@ 6AH4 %<;'0!4'"4 4APM % =,P!.'3D
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M RPJ]00M*O\$+2G_!;=$  "L2P  HU   )I2  "140  B$\  'Y+  !T1@
M:4   %XZ  !2,P  2"X( $,M$@! +1L /2TB #HM* $X+"\!-BTU C4M/0,T
M+D0#,RY- S$O5@,P+V$$+C!M!"TP>@,L,(D#*C&9 RDQK ,G,,(#)C#> R8O
M] 0F+_\%)R[_!;5(  "J3P  H50  )A6  "05@  AE0  'Q0  !R2P  9T8
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M2P  0$4  #) !P M/Q$ *S\9 "D_(0 G/R@ )3\O 2- -@$B0#X!($!' 1]
M40$>0%L!'$%H 1M!=0 :080 &$&5 !=!J  50;X %$#: !4_\0$5/O\"%#W_
M ZY6  "E7   G&$  )1C  ",9   @V,  'EA  !M70  8EH  %A7  !+4@
M/4T  #!( P F10T (T46 "%&'@ @1B4 'D8L !Q&-  ;1CP &D=% !A'3@ 7
M1UD %4=E !-'<P 21X, $$>3  Y'I@ ,1KP "T;6  U%\  .1/X #D/_ :M;
M  "C80  FF8  )-H  "+:0  @FD  'AG  !L9   8F(  %5>  !'60  .54
M "Q1   ?30@ &TT2 !E-&@ 732$ %DTI !1-,  333@ $4U"  ].3  -3E<
M"TYC  E.<0 (3H  !DZ0  5-H@ #3;<  TS1  1+Z0 %2OH !DK_ *E@  "@
M9@  F6L  )%N  "*;P  @6\  'AN  !L:P  7V@  %%D  !#8   -5T  "A9
M   ;5@, $E4,  Y5%0 ,51T "U4E  E5+0 (534 !E4^  1520 "550  55@
M  !5;0  57P  %6,  !4G@  4[,  %+.  !1Y@  4?4  %#^ *9F  ">;
MEW$  )!T  ")=@  @78  '=U  !I<@  6FX  $QK   ^:   ,&4  "-B   7
M8   "UX'  1>$  !7AD  %XA  !>*0  7C$  %XZ  !>10  7E   %U<  !=
M:@  77D  %R)  !<FP  6Z\  %K)  !9Y0  5_0  %?\ *1M  "<<P  EG@
M (][  "(?0  @'T  '-[  !D>   574  $=R   X;P  *FT  !UK   2:0
M!6@$  !H#   :!4  &<<  !G)   9RP  &<U  !G0   9TL  &98  !F90
M974  &6%  !DEP  9*L  &+$  !AX@  8/4  %_] *%T  ";>@  E7\  (Z"
M  "'A   ?(,  &Z   !>?@  3WL  $!Y   Q=P  )'4  !=T   +<P   ',
M  !R"   <A   '(7  !Q'@  <28  '$N  !Q.@  <$8  '!2  !P8   <'
M &^!  !NDP  ;:<  &R_  !KW@  :?,  &C^ )]\  "9@@  E(8  (V)  "#
MB@  =H@  &>&  !7A   2((  #B    J?P  '7X  !!]   #?0   'T   !]
M!   ? H  'P2  !\&0  ?"   'PG  !\,@  >S\  'M,  ![6@  >VH  'I[
M  !YC@  >*(  '>Y  !VV   =?   '3\ )V$  "8B@  DXX  (F/  !\CP
M;HT  %Z,  !/B@  /XD  #")   BB   %8<   >'    AP   (@   "(
MAP,  (<*  "'$0  AQ@  (<?  "'*   AS4  (=$  "'4@  AV(  (=U  "&
MB   A)T  (.T  ""T   @>L  (#Z )N-  "7D@  CI0  (*4  !TE   9),
M %62  !%D0  -9$  ":1   9D0  "I    "1    D0   )(   "2    D@
M )(   "2!P  D@X  ),6  "4'@  E"D  ),X  "41P  E5@  )5J  "4?P
MDY8  )&N  "0R0  C^8  ([U )J5  "2EP  AI@  'F9  !IF0  6I@  $J8
M   ZF   *YD  !R9   -F0   )H   ":    FP   )P   "=    G0   )T
M  "=    G0,  )X+  "@$P  H1T  *(J  "A.@  HTP  *1?  "D<P  I(H
M *.A  "BN@  H-L  )[O ):;  "*G   ?9X  &Z>  !>G@  3IX  #Z?   N
MH   'Z$  !&B   "HP   *0   "E    I@   *<   "H    J0   *D   "J
M    J@   *L   "L!P  KA$  *\=  "Q*P  LCX  +12  "U9P  M7X  +65
M  "TK0  M,<  +/@ (Z?  "!H0  <J,  &.C  !3I   0Z4  #*F   AJ
M$ZH   .K    K    *T   "O    KP   +$   "R    LP   +0   "V
MM@   +@   "[    O@   ,(*  #%&0  QBL  ,A"  #*60  S'   ,V'  #-
MG@  S;0  ,S* (2D  !VI@  9Z<  %>I  !'J@  -JP  "6N   6L   !K(
M  "T    M@   +@   "Z    N@   +P   "]    OP   ,$   ##    Q0
M ,<   #+    SP   -<   #<!P  X1<  .4J  #I0@  ZUT  .EX  #ICP
MZJ,  .JT /\   #_    _P   /\   #_  < _P 7 /\ )0#^ #$ _0 \ /H
M1P#W %  ] !9 /$ 8 #O &8 [0!L .P <0#K '8 Z@![ .@ @ #G (8 Y@",
M .4 DP#B )P W0"G -D M@#7 ,H U0#F -0 _0#3 /\ T@#_ ,H _P## /\
MOP#_ /\   #_    _P   /\   #_  0 ^0 3 /4 (0#R "T \  W .T 0@#I
M $P Y0!4 .( 7 #@ &( W@!H -P ;0#; '( V@!W -@ ? #6 ($ U0"( -$
MCP#- )@ R@"B ,D KP#' ,$ Q@#; ,0 ]@#" /\ P0#_ +X _P"X /\ M0#_
M /\   #_    _P   /H   #R    ZP . .8 ' #C "@ X  R -P /0#7 $<
MTP!/ -  5P#. %T S !C ,H : #) &T QP!R ,4 > #" 'T P "# +X B@"]
M )( NP"< +D J "X +@ M@#/ +0 [0"R /\ L0#_ +$ _P"M /\ J@#_ /\
M  #^    ]0   .T   #C    W  * -8 %@#1 "( S  N ,D -P#% $$ P@!*
M +\ 40"] %@ NP!> +@ 8P"V &@ M !M +, <P"R '@ L !^ *\ A0"N (T
MK0"6 *L H@"I +  IP#$ *4 X@"D /L HP#_ *$ _P"@ /\ G0#_ /X   #S
M    Z    -X   #3    S  $ ,4 $@#  !T NP H +@ ,@"U #L L@!# *\
M2P"L %( J@!8 *D 70"G &, I@!H *4 ;0"D '( HP!X *( ?P"@ (< GP"0
M )T FP"; *@ F0"Z )< U0"4 /( DP#_ ), _P"2 /\ D@#_ /4   #G
MV@   ,X   #%    O@   +< # "R !@ K@ B *H + "G #4 I  ] *$ 10"?
M $P G@!2 )P 5P"; %P F0!B )@ 9P"7 &T E0!S )0 >0"3 ($ D0"* (\
ME0", *( B@"R (D R0"' .@ A@#^ (8 _P"% /\ A0#_ .H   #;    S0
M ,(   "Z    L@   *P !P"F !, H0 = )X )@"; "\ F  W )8 /@"3 $4
MD@!+ )  40". %8 C0!< (P 80"* &< B0!M (< = "% 'P A "% (( D "
M )P ?@"K 'T P ![ -T >@#W 'D _P!Y /\ >0#_ -\   #/    PP   +D
M  "P    J    *(   "<  P EP 7 ), (0"/ "D C  Q (H .0"( #\ A@!%
M (0 2P"# %$ @0!6 (  7 !_ &$ ?0!H 'P ;P!Z '< > "  '8 BP!T )<
M<@"F '$ N !O -, ;@#O &T _P!M /\ ;0#_ -4'  #'#@  NQ(  + 1  "H
M"@  H0$  )D   "3  4 C@ 1 (D &P"% "0 @@ K '\ ,P!] #H >P!  'H
M1@!X $L =@!1 '4 5@!S %P <0!C '  :@!N '( ; !\ &H AP!I ), 9P"B
M &4 L@!D ,L 8P#G &( ^P!A /\ 80#_ ,T4  "_&P  M!\  *H>  "B&@
MFA0  )()  "+    A0 ) (  % !\ !X >  F '4 +0!S #0 <0 [ &\ 00!M
M $8 :P!, &H 40!H %< 9@!> &4 9@!C &X 80!X %\ @P!> )  7 "> %H
MKP!9 ,4 6 #B %< ]0!6 /\ 5@#_ ,<>  "Z)@  KRH  *4J  "=)@  E"
M (P9  "$$   ?04  '< # !R !< ;@ @ &L * !H "\ 9@ U &0 .P!C $$
M80!' %\ 30!> %, 7 !: %H 80!8 &L 5P!U %4 @ !3 (T 4@"< % !K0!/
M <( 3@'< $T"\ !, OL 3 +_ ,(G  "U+@  JS(  *$S  "9,0  D"L  (<D
M  !_'0  =A0  &X)!0!H A  9 (9 &$#(@!>!"D 7 0P %H%-@!9!CP 5P9"
M %4'2 !4!T\ 4@A6 % (7@!/"6< 30ER $P*?@!*"HP 2 J; $<+K !%"L(
M1 O< $,+\0!#"_X 0PO_ +XN  "R-@  ISH  )X[  "5.0  C#0  (0N  !Z
M)P  <1\  &@6  !?# @ 6PL4 %@,' !5#20 4PTK %$.,0!/#C< 3@\^ $P0
M1 !+$4L 21%3 $<16P!&$F4 1!-P $,3? !!$XH /Q2: #X4K  \%,( .Q3=
M #L4\P [%/\ .Q/_ +HU  "O/   I4   )M!  "3/P  BCL  ($V  !W+P
M;2@  &,@  !:& ( 4Q0- $\4& !-%2  2Q4G $D6+0!'%C, 11<Z $070 !"
M&$@ 01A/ #\96  ^&6( /!IM #L:>@ Y&X@ -QN8 #8;J@ T&\  ,QO; #,;
M\@ S&O\!,QG_ ;@Z  "L00  HT4  )E&  "110  B$(  'X\  !U-P  :R\
M & I  !5(0  3!L) $@;% !&&QP 0QPC $$<*0 _'#  /1TV #P=/0 ['D0
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M [%'  "F3@  G5(  )53  ",4P  @U$  'E.  !N2   8T,  %@^  !-.0
M0C,  #8N!P Q+!$ +RP9 "TM(  K+2< *2TM "<N- $F+CP!)2Y% 20O3P$B
M+UD!(3!E 2 P<P$>,8$!'3&2 !LQI  :,+D &##4 !DP[@$9+_T"&2[_ ZY,
M  "E4@  G%8  )-7  "+6   @E8  'A3  !L3@  8DH  %=%  !,00  0#L
M #,V!  K,PT *#,6 "<S'0 E,R0 (S,K "$T,@ @-#H!'S1# 1XU30$<-5@
M&S5C !DV<0 8-H  %C:0 !4VHP 3-K@ $C73 !,U[  4-/T!$S/_ JQ0  "C
M5@  FEH  ))<  "*7   @5L  '=8  !K5   85$  %9-  !+20  /T,  #$^
M   E.@H (CD3 " Y&P >.2( '3HI !LZ,  :.C@ &#M! !<[2P 5.U4 %#MB
M !(\;P 1/'X #CR/  P\H0 *.[4 "3O/  LZZ0 ,.?L #3C_ :I4  "A6@
MF5\  )%A  ")80  @&$  '9>  !J6@  8%@  %95  !)4   .TL  "Y&   A
M0@8 &D 0 !E %P 70!\ %4 F !1!+0 2034 $4$^  Y!2  ,05, "T)?  E"
M;0 '0GP !D*,  1!G@ "0;(  D'+  - Y  %/_8 !C[_ *A9  "?7P  EV0
M )!F  "(9P  ?V<  '5E  !I80  8%\  %-;  !%5@  -U(  "I.   =2@$
M%$<* !!'$P -2!L "T@C  I(*@ (2#( !T@[  5(10 #2%   DE<  !):@
M27D  $F)  !(FP  1ZX  $?'  !&X@  1?(  $3\ *5?  "=90  EFD  (YL
M  "';0  ?VT  '5L  !I:0  768  $]A  !!70  ,UH  "56   94P  #5 &
M  90$  #4!@  5 ?  !0)P  4"\  % X  !00@  4$X  %!9  !09P  4'8
M %"&  !/F   3JP  $W$  !,X0  2_$  $O[ *-E  ";:P  E&\  (UR  "&
M=   ?G0  '5S  !F;P  6&P  $IH   \9   +F$  "!?   47   "%H$  !:
M#   614  %D<  !9(P  62L  %DT  !9/P  64H  %A6  !88P  6'(  %B"
M  !7E   5J@  %7   !3W@  4O,  %+[ *%L  "9<@  DW8  (UY  "&>@
M?GL  '%X  !B=0  4W(  $1O   U;   *&D  !IG   .9@   F0!  !D"0
M8Q$  &,8  !C'P  8B<  &(O  !B.@  8D8  &)2  !A7P  86X  &!_  !?
MD   7J0  %V\  !<V@  6_(  %K] )YS  "8>0  DGT  (R   "%@@  >H
M &M^  !<>P  3'@  #UV   O=   (7(  !1P   ';P   &\   !N!0  ;@P
M &T3  !M&@  ;2$  &TH  !L,P  ;$   &M-  !K6@  :VH  &IZ  !IC
M:*   &>W  !FU0  9>\  &3\ )Q[  "7@0  D84  (N(  "!AP  <X4  &2#
M  !5@0  17\  #5]   G>P  &7H   MY    >0   'D   !Y    > <  '@-
M  !W%   =QL  '<B  !W*P  =S@  '9&  !V5   =F0  '5U  !TB   <YP
M '*R  !QS@  <.P  &_[ )N#  "6B   D8P  (>-  !ZC   :XL  %R)  !,
MB   /(8  "V%   ?A   $8,   .#    @P   (,   "#    @P   (,&  ""
M#   @A,  ((:  "#(@  @R\  ((^  ""30  @EP  ()N  "!@@  @)<  'ZM
M  !]R   ?>8  'SW )F,  "5D   C)(  ("2  !QD0  8I   %*/  !"C@
M,HX  "..   5C0  !XT   "-    C0   (X   ".    C@   (X   ". P
MC@D  (X1  "/&   CR,  (\Q  "/0@  D%(  )%D  "/>@  CI   (VG  "+
MP0  BN   (KS )F4  "0E@  A)<  ':7  !GE@  5Y4  $>5   VE0  )Y4
M !B6   )E@   )8   "7    EP   )@   "9    F0   )D   "9    F0
M )H&  ";#@  G!<  )TC  "=-   GD8  )]8  "@;0  H(,  )^<  "<N
MF]D  )GO )29  "(FP  >YP  &R<  !<FP  2YL  #J<   JG0  &YX   R>
M    GP   *    "A    H@   *,   "D    I    *4   "E    I0   *8
M  "G @  J@H  *L7  "M)0  K3@  *]+  "Q8   L7<  +&/  "QJ   K\$
M *_= (R>  !_GP  <*$  &"A  !0H0  /Z(  "ZD   >I0  #J<   "H
MJ0   *H   "K    K    *T   "N    L    +$   "R    L@   +,   "V
M    N    +L'  "]%@  OR<  ,$\  #%4@  QVH  ,B"  #(F0  R+$  ,?'
M (*C  !TI   9:4  %6F  !$IP  ,JD  "*L   2K0   J\   "Q    L@
M +0   "V    M@   +@   "Y    NP   +T   "^    P0   ,(   #%
MR0   -    #5 @  VQ(  -XF  #@0   XEL  .1S  #EB@  YJ   .:R /\
M  #_    _P   /\   #_  0 _P 4 /X (0#[ "T ^@ X /< 0P#S $T [P!5
M .T 70#K &, Z0!H .@ ;@#F ', Y0!W .0 ?0#C (( X0"( -T D #9 )D
MU@"C -0 L #3 ,0 T0#@ -  ^0#. /\ S0#_ ,4 _P"^ /\ N@#_ /\   #_
M    _P   /\   #[  ( ]0 0 /$ '0#N "D [  S .@ /@#C $@ X !0 -T
M6 #: %X V !D -8 :0#5 &X TP!S -$ > #. 'X RP"$ ,@ C #' )0 Q@"=
M ,0 J@## +L P0#4 +\ \0"^ /\ O0#_ +D _P"T /\ L #_ /\   #_
M_0   /8   #L    YP + .( & #> "0 V0 O -4 .0#1 $, S0!+ ,H 4@#(
M %D Q@!? ,, 9 #! &D O@!O +P = "[ 'D N@!_ +D A@"X (X M@"7 +4
MHP"S +( L0#( *\ YP"N /\ K0#_ *P _P"G /\ HP#_ /\   #Z    \0
M .8   #=    U@ ' -  $P#* !\ Q@ J ,, ,P#  #P O !% +D 30"V %,
MLP!9 +$ 7P"P &0 KP!I *X ;@"M '0 K !Z *H @ "I (@ J "1 *8 G "D
M *L H@"] *$ V@"> /< G #_ )L _P": /\ F #_ /H   #N    XP   -8
M  #-    Q@ ! +\ #@"Z !D M@ D +( +@"O #8 K  _ *D 1@"G $T I0!3
M *0 60"B %X H0!C *  : "? &X G@!T )P >P"; (( F0"+ )@ E@"6 *,
MDP"T )$ S0"/ .X C@#_ (T _P"- /\ C #_ /$   #B    TP   ,@   #
M    N    +$ "0"L !4 J  > *0 * "A #$ GP X )P 0 ": $< F0!- )<
M4@"6 %@ E != ), 8@"1 &@ D !N (\ =0"- 'T BP"% (D D "' )T A0"M
M (0 P@"" ., @0#[ (  _P"  /\ @ #_ .0   #4    R    +T   "T
MK0   *< ! "A  \ G  : )@ (@"5 "L DP S )  .@". $  C !& (L 3 ")
M %$ B !7 (8 7 "% &( @P!H (( ;P"  '< ?P"  'T BP![ )< >0"F '<
MN@!V -8 = #R '0 _P!S /\ <P#_ -@   #)    O@   +,   "K    HP
M )T   "7  D D@ 4 (X '0"* "4 AP M (4 - "# #L @0!  '\ 1@!^ $P
M? !1 'L 5P!Y %P =P!C '8 :@!T '( <@![ '  A@!N )( ;0"A &L LP!I
M ,L : #K &< _@!G /\ 9P#_ ,\%  #!#   M@\  *P-  "C!P  G    )0
M  ".  ( B0 - (0 %P"  "  ?0 G 'H +@!X #4 =@ [ '0 00!R $8 <0!,
M &\ 40!M %< ; != &H 90!H &T 9@!W &0 @@!B (X 80"< %\ K0!= ,,
M7 #B %P ]P!; /\ 6P#_ ,<3  "Z&0  KQP  *8;  "=%P  E1   (T&  "&
M    @  & 'L $0!V !H <P B &\ *0!M "\ :P V &D / !G $$ 90!' &0
M3 !B %( 8 !9 %X 8 != &D 6P!S %D ?@!7 (H 5@"8 %0 J0!3 +X 40#:
M %$ \P!1 /\ 4 #_ ,(=  "U)   JB<  *$G  "8(P  D!T  (<6  !_#
M> (  '$ "@!L !0 :  < &4 ) !B "H 8  P %X -@!= #P 6P!" %D 2 !7
M $X 5@!5 %0 7 !2 &4 40!O $\ >@!- (< 2P"5 $H I@!( +H 2 #4 $<
M[0!& /H 1@#_ +TF  "P+0  IC   )TP  "4+0  C"@  (,A  !Z&@  <A$
M &D& @!C  P 7P 6 %L '@!8 "4 5@ K %0 ,0!3 #< 40 ] $\ 0P!. $D
M3 %0 $H!6 !( F$ 1P)L $4#> !# X4 0024 $ $I  _ [@ /0/1 #P#Z  \
M!/< / 3_ +DM  "M-   HS<  )HX  "1-@  B#$  '\K  !V)   ;1P  &04
M  !;"@4 504. %(%& !/!1\ 308F $L'+ !)!S( 1P@X $8(/P!$"44 0@E-
M $$*50 _"E\ /0MJ #L+=@ Z#(0 . R3 #8,I  U#+@ ,PS1 #(,Z@ S#/D
M,PS_ +8T  "J.@  H3X  )@^  "//   AC@  'TS  !S+   :24  %\>  !6
M%@  30X( $D-$@!&#1H 1 XA $$.)P! #RX /A T #P0.@ [$4( .1)) #<2
M4@ V$UP -!-G #,4=  Q%(( +Q62 "X5HP L%+@ *A32 "H5[  K%/L +!3_
M +,Y  "H/P  GT,  )9$  "-0@  A#\  'HZ  !Q-   9RT  %PF  !2'P
M2!@# $$5#0 ^%18 .Q4= #D6)  W%BH -A8P #07-P S%SX ,1A' # 84  O
M&5H +1EE "P:<@ J&X  *!N0 "8;H@ E&K8 (QK0 ",;Z@ D&OP )!G_ ;$^
M  "F0P  G4<  )1(  "+1P  @T4  'A   !O.@  9#0  %HN  !/)P  1"
M #L<"0 V&Q( -!L9 #(;(  P&R8 +APM "T<-  L'3P *AY$ "D>30 H'U@
M)A]C "4@<  C('\ (2". " @H  >(+4 '"#. !T@Z0 =(/L!'A__ :Y"  "D
M2   FTL  )--  "*3   @4H  '=%  !M0   8CL  %@U  !,+P  02D  #8C
M!0 P(0T +2$6 "LA'  H(2, )R$J "8B,0 E(CD (R-" "(D2P A)%8 ("5A
M !XE;@ <)GT &R:- !DEGP 8);, %B7- !<EZ  8)/H!%R3_ :Q&  "C3
MFE   )%1  ")40  @$X  '9+  !K1@  8$$  %8\  !+-@  0#$  #0L 0 J
M)PH )B83 "0G&@ B)R  (2<G !\H+P >*#8 '2D_ !PI20 ;*E0 &2I? !<K
M;0 6*WL %"N+ !,KG0 1*[( #RK+ ! JYP 1*OD $BG_ :I*  "A4   F%0
M )!5  "(50  ?U0  '50  !I2P  7T<  %5#  !*/P  /SH  #,U   F+P<
M("T0 !XM%P <+1X &RXE !DN+  8+C0 %R\] !4O1P 4+U( $C!= ! P:P .
M,7H ##&*  HPFP ),*\ !S#'  @OX@ *+_< "R[_ *A.  "?5   EU@  (]:
M  "'6@  ?ED  '16  !H40  7DX  %1+  !)1P  /4(  # \   C-P0 &C0,
M !<S%  5-!L %#0B !(T*@ 1-3$ #S4Z  TU1  +-4\ "C9;  @V:  &-W<
M!3>'  ,VF0 !-JP  #;$  $UWP #-/( !#/_ *93  ">60  E5T  (Y?  "&
M7P  ?5X  '-<  !G6   7E8  %12  !(3@  .D@  "U#   ?/P  %#L( ! Z
M$0 -.QD "SL@  D[)P (/"\ !CPX  4\0@ #/$T  3Q9   ]9@  /74  #V%
M   \E@  /*H  #O!   [W0  .N\  #GZ *18  "<7@  E&(  (UD  "%90
M?&0  '-B  !G7P  7ET  %%9  !$5   -D\  "A+   ;1P  $$0%  ="#0 $
M0Q8  D,=  !#)0  0RT  $0U  !#/P  0TH  $-6  !$8P  1'(  $2"  !#
ME   0J<  $&^  !!W   0.\  #_Y *)>  ":8P  DV<  (QJ  "$:P  ?&L
M ')I  !G9P  6V,  $U?   _6P  ,5<  "-3   74   "TT#  %,"P  2Q0
M $P;  !,(@  2RH  $LR  !+/   2T@  $M3  !+8   2V\  $M_  !*D0
M2:4  $B\  !'V0  1O   $7Z *!D  "8:@  DFT  (MP  "$<@  ?'(  '-Q
M  !D;0  5FD  $AE   Y8@  *UX  !Y;   26   !58!  !6"0  51$  %47
M  !5'@  5"8  %0N  !4.0  5$0  %-0  !370  4VP  %-\  !2C@  4:(
M %"Y  !.U@  3>\  $W\ )YJ  "7<   D70  (IW  "#>   ?'D  &]V  !?
M<P  4&\  $)L   S:0  )68  !=D   +8@   &$   !@!@  7PT  %\4  !>
M&@  7B$  %XI  !=-   74   %U,  !<6@  7&@  %MY  !;B@  6IX  %BU
M  !7TP  5NX  %3\ )QR  "5=P  D'L  (I^  "#@   =WX  &E[  !9>
M274  #IS   L<   'FX  !%M   $:P   &L   !J @  :@@  &D/  !I%0
M:!P  &@C  !H+0  9SH  &='  !F50  9F0  &5T  !DA@  8YH  &*P  !A
MS0  7^L  %[[ )IZ  "5?P  CX,  (F&  !_A0  <8,  &*!  !2?@  0GP
M #)Z   D>   %G<   AV    =0   '4   !U    = ,  '0)  !S$   <Q8
M ',=  !S)0  <C(  '%   !Q3@  <5X  '!O  !O@@  ;I8  &VL  !LQP
M:^8  &KY )B"  "4AP  CXL  (6+  !XB@  :8@  %F&  !)A0  .(,  "F"
M   ;@0  #8    !_    ?P   '\   !_    ?P   'X"  !^"   ?@X  'X6
M  !^'   ?B@  'TW  !]1P  ?E8  'UH  !\>P  >Y   'FF  !XP   >.
M '?U )>+  "3CP  BI   'V0  !OCP  7XT  $^,   _BP  +XL  ""*   1
MB@   XD   ")    B@   (H   "*    B@   (H   ")    B@4  (H,  "+
M$P  BQT  (LK  "*/   BTT  (M?  "+<P  BHD  (B@  "'N0  AMH  (7Q
M )>2  ".E   @I4  '25  !DE   5),  $22   SDP  ))(  !62   %D@
M ),   "3    E    )4   "5    E0   )4   "5    E0   )8!  "6"0
MF!$  )D=  "9+@  F4   )M2  "<9@  FWX  )F8  "7L0  EM   )7L )*8
M  "&F0  >9H  &F9  !9F0  29D  #>9   GF@  &)L   B;    FP   )P
M  "=    G@   )\   "@    H    *$   "A    H0   *(   "C    I04
M *<1  "H'P  J#(  *I%  "L6@  K7$  *V)  "MH@  J[X  *G@ (J<  !]
MG@  ;9\  %Z?  !.GP  /)\  "NA   ;H@  "J0   "E    I0   *8   "G
M    J    *H   "K    K    *T   "M    K0   *X   "P    L@   +4#
M  "X$0  NR$  +PV  "_3   PF0  ,-\  ##E   PZP  ,+$ ("A  !RHP
M8J,  %*D  !!I0  +Z<  !ZI   .JP   *P   "N    KP   +$   "R
MLP   +0   "V    MP   +D   "Z    O    +T   #     Q    ,H   #.
M    TA   -,D  #8/   W54  .!M  #AA0  X9P  .&P /\   #_    _P
M /\   #_  $ _@ 1 /L '@#Y "D ]@ T /( 0 #N $D ZP!1 .@ 60#F %\
MY !E ., :@#A &\ X !T -X >0#; '\ V "% -0 C0#2 )4 T0"? -  JP#.
M +T S0#: ,L ]@#* /\ R0#_ ,$ _P"Z /\ M0#_ /\   #_    _P   /X
M  #V    \0 + .T &0#J "4 Y@ O .( .@#> $0 V@!, -< 5 #4 %H T@!@
M -  90#- &H R@!P ,@ =0#% 'H Q "! ,, AP#" (\ P0"9 ,  I0"^ +0
MO #- +H [ "Y /\ N #_ +4 _P"O /\ J@#_ /\   #_    ^@   /    #H
M    X@ ( -T % #6 "  T@ K ,\ - #+ #X QP!' ,0 3@#! %4 O@!; +L
M8 "Y &4 N !J +< ;P"V '4 M0![ +0 @@"S (H L0"3 +  G@"N *P K #!
M *L X0"I /L IP#_ *8 _P"A /\ G@#_ /\   #V    [    .    #8
MT  # ,D $ #$ !L P  E +T +P"Z #@ M0!  +( 2 "O $\ K@!5 *P 6@"K
M %\ J@!E *D :@"H &\ IP!U *4 ? "D (0 HP"- *$ F "? *4 G@"W )L
MT@"8 /( EP#_ )< _P"5 /\ DP#_ /4   #I    W    -    #(    P
M +D "P"T !8 L  @ *P *0"I #( I@ Z *0 0@"B $@ H0!. )\ 5 "> %D
MG !> )L 9 ": &D F0!O )< =@"6 'X E "' )( D0"0 )X C@"O (P Q@"*
M .@ B0#_ (@ _P"( /\ AP#_ .L   #;    S0   ,,   "Z    L@   *P
M!@"G !( H@ ; )\ ) "< "P F@ T )< .P"5 $( DP!( )( 30"0 %, CP!8
M (X 70", &, BP!I (D < "( '@ A@"! (0 BP"" )@ @ "H '\ O !] -P
M? #X 'L _P!Z /\ >P#_ -T   #.    P@   +<   "O    J    *$  0"<
M  L EP 6 ), '@"0 "8 C0 N (L -0") #P AP!! (8 1P"$ $T @P!2 ($
M5P"  %T ?@!C 'T :@![ '( >0![ '< A@!U )( <P"B '( M !P -  ;P#O
M &X _P!M /\ ;0#_ -(   #$    N    *\   "F    GP   )@   "2  8
MC0 1 (D &@"% "$ @@ H '\ +P!] #8 ?  \ 'H 00!X $< =P!, '4 4@!S
M %< <@!> '  90!N &T ; !V &H @0!H (T 9P"< &4 K@!C ,4 8@#E &$
M_ !A /\ 8 #_ ,D$  "\"@  L0P  *<*  "?!   EP   )    ")    A  *
M '\ % ![ !P >  D '4 *0!R #  <  V &X / !L $$ :P!' &D 3 !G %(
M9@!8 &0 8 !B &@ 8 !Q %X ? !< (D 6P"7 %D J !7 +T 5@#; %4 ]0!5
M /\ 50#_ ,(1  "U&   JQH  *(8  "9%   D0P  (D#  "!    >P $ '8
M#0!Q !8 ;0 > &H )0!G "H 90 Q &, -P!A #P 7P!" %X 2 !< $T 6@!4
M %@ 6P!6 &, 50!M %, > !1 (4 3P"3 $X HP!, +< 2P#3 $H [@!* /\
M2@#_ +P<  "P(@  IB4  )TD  "4(   BQH  (,3  !["@  <P   &P !P!G
M !$ 8P 8 %\ ( != "8 6@ L %@ ,0!7 #< 50 ] %, 0P!2 $D 4 !/ $X
M5P!, %\ 2@!I $D =0!' ($ 10"0 $, H !" +, 00#, $  Z0!  /H 0 #_
M +@D  "L*P  HBX  )DN  "0*@  B"4  '\?  !V%P  ;0T  &4#  !>  H
M60 3 %8 &@!3 "$ 4  G $X + !- #( 2P X $D /@!( $0 1@!+ $0 4P!"
M %P 0 !F #X <@ ] '\ .P"- #D G0 X +  -P#( #8 XP U /0 -0#^ +0L
M  "I,@  GS4  )8U  ".,P  A2X  'LH  !R(0  :1D  %\1  !7" , 4 $+
M $P % !) !L 1P A $4 )P!# "T 00$S #\!.0 ^ D  / -' #H#3P X!%D
M-@5C #0%<  S!7T ,06, "\&G  N!:\ +03& "P%X  K!O( *P7] +$S  "F
M.   G3L  )0\  "+.@  @C4  'DP  !O*0  92(  %L;  !2%   20P% $('
M#0! !A4 /0<< #L((P Y""D -P@O #8)-0 T"3P ,@I$ # +3  O"U8 +0QA
M "L,;@ I#7P )PZ+ "4.G  D#;  (@W( "$.X@ B#O0 (PW_ *XX  "D/0
MFT$  ))!  "*0   @3P  '<W  !M,0  8RH  %DD  !.'0  118  #L0!P V
M#1  - X7 #$.'@ P$"0 +A J "P0,0 K$3@ *1)! "@22@ F$U0 )1-? ",4
M;  A%7H 'Q6* !X5FP <%*\ &A3' !H4XP ;%?8 &Q3_ *P\  "B0@  F44
M )%&  "(10  ?T(  '4]  !K.   83$  %8K  !+)0  01X  #<9 @ P%0L
M+!43 "H5&@ H%B  )A8G "06+@ C%S4 (A@^ "$81P ?&5( 'AE= !P::@ :
M&GD &1N( !<:F@ 5&JT %!K& !,:X@ 5&O8 %1K_ *I   "A1@  F$D  (]*
M  "'2@  ?D<  '1#  !I/@  7S@  %4R  !)+0  /R<  #0B   J'0< )1L/
M "(;%@ @&QP 'QPC !X<*P <'3, &QT[ !H>10 9'E  %Q]; !4?:  4('<
M$B"' ! @F  .(*P #!_#  P?WP .'_4 $![_ *A%  "?2@  EDX  (Y/  "%
M3@  ?4P  '-(  !H0P  73\  %,Z  !(-   /3   #,K   H)0, 'R$+ !PA
M$P :(1H &"$A !<B*  6(C  %2,Y !,C0P 2(TX $"19  XE9P ,)74 "B:%
M  DEE@ '):D !27   8DVP ')/$ "2/_ *=)  "=3@  E5(  (U3  "%4P
M?%$  ').  !F20  7$4  %)!  !(/0  /3@  #(S   F+@  &B@) !8G$0 4
M)Q@ $B@? ! H)@ .*2X #2DV  LI0  **DL ""I7  8K9  %*W,  RR#  $K
ME   *Z<  "J]   JV   *>T  BG\ *5-  "<4@  E%8  (Q7  "$6   >U8
M '%3  !E3P  7$P  %))  !(10  /$   "\Z   B-0  %C %  XN#0 ,+A8
M"B\=  @O)  ',"P !3 T  0P/@ ",$D  3%5   Q8@  ,G$  #*    QD@
M,:4  #"[   PUP  +^P  "[X *-2  ":5P  DEH  (M<  "#70  >EP  '!:
M  !E5@  6U,  %)0  !&3   .$8  "M!   >/0  $C@#  @U"P $-A0  C8;
M   W(@  -RH  #<R   W/   -T<  #=3   W8   .&X  #A^   XD   -Z,
M #:Y   UU0  -.P  #3X *%7  "97   D6   (IB  ""8P  >F(  '!@  !E
M70  7%L  %!7  !"4@  -$T  "=(   91   #4$"  ,^"@  /A(  #X8   ^
M'P  /R<  #\P   _.0  /D0  #Y0   ^70  /VP  #]\   ^C@  /:$  #RW
M   [TP  .^T  #KX )]<  "78@  D&4  (EH  "":0  >6D  '!G  !E90
M66$  $M=   ]6   +U0  "%0   53   "$D   !("   1P\  $<6  !''0
M1R0  $<L  !&-@  1D(  $9.  !&6P  1FD  $9Y  !&BP  19\  $.T  !"
MT0  0>P  $#Z )UC  "6:   CVP  (AN  "!<   >7   '!O  !B:P  5&<
M $9C   W7P  *5L  !M8   .50   U,   !2!@  40P  %$3  !0&@  4"$
M $\I  !/,P  3SX  $]+  !.6   3F8  $YV  !.B   39P  $NR  !)SP
M2.L  $?[ )MI  "4;P  CG(  (AU  "!=P  >G<  &QT  !=<   3FT  #]I
M   Q9@  (F,  !5A   (7@   %T   !< P  6PD  %L0  !:%@  61T  %DD
M  !9+@  6#H  %A&  !85   5V,  %=S  !6A0  59D  %2O  !2RP  4.H
M $_[ )EQ  "3=@  C7H  (=\  "!?@  =7P  &9Y  !7=@  1W,  #AP   I
M;0  &VL   UI   !:    &<   !F    9@4  &4*  !D$0  9!@  &,?  !C
M*   8S0  &)!  !B3P  85X  &!O  !@@0  7I4  %VK  !<Q@  6^8  %GZ
M )=Y  "2?@  C8$  (B$  !]@P  ;X$  %]^  !/?   /WD  "]W   A=0
M$W,   5R    <@   '$   !Q    <    ' %  !O"@  ;Q$  &X8  !N'P
M;BP  &TZ  !M20  ;5@  &QI  !J?   :9   &BF  !GP   9N$  &7W ):!
M  "2A@  C8D  (.)  !VB   9H8  %:$  !&@@  -8   "9_   8?0  "7P
M  ![    >P   'P   ![    >P   'L   !Z!   >@H  'H1  !Z%P  >B(
M 'DQ  !Y00  >5$  'EB  !X=0  =HH  '6@  !SN0  <ML  ''S ):)  "2
MC@  B(X  'N.  !MC0  78L  $V*   \B0  +(@  !R'   -A@   (8   "%
M    A@   (8   "&    A@   (8   "%    A0$  (4'  "&#@  AQ<  (8E
M  "%-P  AD<  (99  "&;0  A8,  (2:  ""LP  @=(  (#O ):1  "-DP
M@),  '*3  !BD@  4I   $&0   PD   ()   !&/   "CP   (\   "/
MD    )$   "1    D0   )$   "1    D0   )$   "2!   E H  )47  "5
M)P  E#L  )9-  "780  E7D  )22  "3JP  D<@  )#H )"6  "$EP  =I@
M &>7  !7E@  1I8  #27   DF   %)@   28    F    )D   "9    F@
M )L   "<    G0   )T   "=    G0   )X   "?    H    *,*  "D&
MI"P  *5   "H5   J6L  *F#  "GGP  I;X  */= (B;  ![G   :YP  %N<
M  !+G   .9T  "B>   8GP  !Z    "A    H@   *,   "C    I0   *8
M  "G    J    *D   "I    J0   *H   "K    K0   +$   "S"@  MAL
M +8P  "Y1@  O5X  +YV  "^CP  OJ@  +[" 'Z?  !OH0  8*$  %"B   ^
MHP  +*0  !NG   *J    *D   "J    K    *T   "N    KP   +$   "R
M    M    +4   "V    N    +@   "[    O0   ,$   #&    R@L  ,T>
M  #1-@  UD\  -MH  #<@   W)@  -RN /\   #_    _P   /\   #_
M^P , /@ &@#U "4 \0 P .T / #I $4 Y@!- .0 50#A %L WP!A -T 9@#;
M &L V !Q -0 =@#1 'P T "" ,X B0#- )$ S "; ,L IP#* +< R #2 ,8
M\0#% /\ Q #_ +T _P"U /\ L0#_ /\   #_    _P   /D   #S    [0 '
M .D %0#D "$ X  K -T -@#8 $  U !( -$ 3P#. %8 R@!< ,< 8@#$ &<
MP@!L ,$ <0#  '8 OP!\ +X @P"] (L O "5 +H H "Y *X MP#% +8 YP"T
M /\ LP#_ *\ _P"H /\ I #_ /\   #_    ]0   .L   #D    W0 % -4
M$0#0 !P S  G ,D , #% #H P0!" +P 2@"Y %  MP!6 +4 7 "T &$ LP!F
M +( :P"Q '$ L !W *\ ?@"N (4 K "/ *L F@"I *< J "Z *8 V0"C /<
MH0#_ *  _P"< /\ F0#_ /_B?1!)0T-?4%)/1DE,10 4%?P   #R    Y0
M -L   #2    R@   ,, # "^ !< N@ A +< *P"S #, KP \ *T 0P"K $H
MJ0!0 *@ 50"F %L I0!@ *0 90"C &L H@!Q *  > "? '\ G@"( )P DP":
M *  F "P )4 RP"3 .X D@#_ )( _P"0 /\ C@#_ /    #B    U0   ,L
M  #"    N@   +0 " "O !, J@ < *8 )0"D "T H@ U )\ /0"= $0 G !*
M )H 3P"9 %0 EP!9 )8 7P"5 &4 DP!K )( <@"1 'D CP"" (P C0"* )D
MB0"I (< P "% .( A #] (, _P"# /\ @0#_ .0   #4    QP   +T   "T
M    K0   *<  @"A  T G0 7 )H ( "7 "@ E  O )( -@"0 #T C@!# (T
M20"+ $X B@!3 (D 6 "' %X A@!E (0 :P"" ', @0!\ '\ AP!] ), >P"B
M 'D MP!X -4 =@#U '4 _P!U /\ =0#_ -8   #)    O0   +(   "J
MHP   )P   "7  @ D@ 3 (X &P"+ "( B  I (8 , "$ #< @@ ] (  0@!_
M $@ ?0!- 'P 4@!Z %@ >0!> '< 9@!U &T <P!W '$ @0!P (X ;@"= &P
MKP!J ,D :0#K &@ _P!G /\ 9P#_ ,P   "_    LP   *H   "A    F@
M ),   "-  , B  , (0 %@"  !X ?0 D 'H *@!X #$ =@ W '0 /0!S $(
M<0!' &\ 30!N %( ; !9 &H 8 !H &@ 9@!Q &0 ? !B (D 80"7 %\ J0!=
M ,  7 #@ %L ^0!: /\ 6@#_ ,0"  "W"   K D  *,'  ": 0  D@   (L
M  "$    ?P ' 'H $0!V !D <@ @ &\ )0!L "L :@ R &@ -P!G #T 90!"
M &, 2 !B $T 8 !4 %X 6P!< &, 6@!L %@ =P!6 (0 50"2 %, HP!1 +@
M4 #5 $\ \@!. /\ 3@#_ +T0  "Q%@  IQ<  )T5  "5$0  C D  (0!  !]
M    =@ ! '$ "@!L !, :  : &0 (0!A "8 7P L %T ,@!; #@ 6@ ] %@
M0P!6 $D 5 !/ %( 5@!1 %X 3P!G $T <P!+ '\ 20". $< G@!& +$ 1 #+
M $0 ZP!# /T 0P#_ +<:  "L(   HB(  )DA  "0'0  AQ<  '\0  !W!P
M;@   &@ !0!B  T 7@ 5 %H &P!7 "( 5  G %( + !1 #( 3P X $T /@!,
M $0 2@!* $@ 4@!& %H 1 !D $( ;P!  'P /P"* #T F@ [ *T .@#% #D
MXP Y /@ .0#_ +,C  "H*0  GRL  )8K  "-)P  A"$  'L<  !R%   :0H
M &    !9  < 5  / %  %@!- !P 2@ B $@ * !& "T 10 S $, .0!! #\
M/P!& #T 30 [ %8 .0!@ #< ;  V 'D -0"( #, F  Q *D ,0#  #  W0 P
M /, +P#_ *\K  "E,   G#,  ),S  "*,   @2L  '<E  !N'@  91<  %L.
M  !3!0  3  ( $< $ !$ !< 00 = #X (P ] "D .P N #D -  W #L -0!"
M #, 2@ Q %, +P!> "X :@ L '< *P"% "D E@ G *@ )@"] "8 V0 E .X
M) #Z *TQ  "C-P  F3D  )$Y  "(-P  ?S,  '4M  !L)@  8B   %<9  !.
M$0  10H" #X$"0 Z 1( -P 8 #4!'@ S 20 ,0(J "\",  N S< + ,^ "H$
M1P H!5  )@5; "0&9P C!W4 (0>$ !\(E0 =!Z< ' :] !H&U@ 9!^P &0CY
M *HW  "A/   ES\  (\_  "&/0  ?3H  ',T  !I+@  7R@  %4A  !+&@
M010  #@-!  P" H +0<2 "L(&0 I"1\ )PDE "4)*P D"C, (@H[ " +1  ?
M#$X '0Q9 !L-9@ 9#G0 %PZ$ !4.E0 4#J@ $@V^ !$-V0 2#NX $PW[ *@[
M  "?0   ED,  (U$  "%0@  ?$   '(Z  !H-0  7B\  %,I  !((P  /AP
M #07   K$@4 )! , "$/%  ?#QH 'A @ !P0*  ;$2\ &A$X !@200 7$TP
M%1-7 !,49  1%'( $!6"  T5DP +%:8 "16\  D4U@ *%.\ #!3] *8_  "=
M1   E$<  (Q(  "$1P  >T4  '%   !F.P  7#8  %(P  !'*P  /"4  #(@
M   I&P  'Q<( !H5$  8%18 %Q8= !46)0 4%RP $Q<U !(8/P 0&$D #1E5
M  L:8@ )&W  "!N   8;D0 %&Z0  QJY  ,:TP $&>H !AG[ *5#  ";2
MDTL  (M,  ""3   >4H  '!&  !E00  6SP  % W  !&,@  .RX  #$I   G
M)   '1\% !0;#  2&Q0 $!P;  X<(@ ,'2H "QXS  H>/0 ('T< !Q]3  4@
M8  #(&X  2%^   @CP  (*(  !^W   ?T0  '^D  ![W *-'  ":30  DE
M (I1  ""4   >$\  &],  !D1P  6D,  % _  !&.P  .S8  #$R   E+
M&28"  XB"@ *(A( "",9  <C(  %)"@ !"0Q  (E.P !)44  "51   E7@
M)FP  "=\   GC0  )J   "6U   DT   (^@  "/V *%,  "840  D50  (E5
M  "!5@  >%0  &Y1  !C30  64H  %!'  !&0P  /#\  "XY   A,P  %2X
M  HJ"0 $*1   2H8   J'P  *R8  "LO   L.   *T,  "M/   L7   +&H
M "UZ   LBP  +)X  "NS   JS@  *>@  "CV )]0  "750  CU@  (A:  "
M6P  =UH  &Y7  !B5   65$  %!.  !%2@  -T4  "H_   <.@  $38   4R
M"   ,@X  #(6   R'   ,B0  #(M   S-@  ,D$  #)-   R6@  ,V@  #-X
M   SB@  ,IT  #&Q   PS   +^@  "[W )U5  "56P  CEX  (=@  !_8
M=V   &U>  !C6P  6ED  $Y5  ! 4   ,DL  "5&   70@  "SX    [!P
M.@T  #H4   Z&@  .B(  #HJ   Z,P  .CX  #E*   Y5P  .F8  #IV   Z
MB   .9L  #>P   VRP  ->@  #7X )Q;  "48   C60  (9F  !_9P  =V8
M &UE  !C8P  5U\  $E:   [5@  +5(  !]-   220  !D8   !$!@  0PL
M $,2  !#&   0A\  $(G  !",   0CP  $%(  !!50  06,  $%S  !!A0
M0)D  #ZN   ]R0  /.<  #OY )IA  "39@  C&H  (9L  !_;@  =VX  &YL
M  !@:   4F4  $1@   U7   )UD  !E5   ,4@   $\   !. P  30D  $P/
M  !,%0  2QP  $LD  !*+0  2C@  $I%  !)4@  26   $EQ  !)@P  2)8
M $>L  !%QP  0^<  $+Y )AH  "2;0  C'$  (9S  !_=0  >'4  &IR  !;
M;@  3&H  #UF   N8P  (&   !)=   %6P   %D   !8    5P4  %8+  !6
M$0  51@  %0?  !4*   5#0  %-!  !33@  4ET  %)M  !1?P  49,  %"J
M  !-Q0  3.4  $KY )9P  "1=   BW@  (5[  !_?   <WH  &1W  !4<P
M17   #5M   G:@  &&@   EF    9    &,   !B    8@$  &$'  !@#
M8!,  %\:  !>(@  7BX  %X[  !=20  75@  %QI  !;>P  6H\  %FE  !8
MP   5N(  %3X )5W  "0?   BX   (:"  ![@0  ;'\  %U\  !->0  /'<
M "UT   ><@  $'    %O    ;@   &X   !M    ;    &P!  !K!@  :@P
M &H4  !J&@  :28  &DT  !H0P  :%,  &=D  !F=@  98H  &2@  !BN@
M8=P  &#U )2   "0A   BX@  (&(  !SA@  9(,  %2!  !$?P  ,GT  "-\
M   4>@  !7D   !X    >    '@   !X    =P   '<   !V    =@4  '4+
M  !U$P  =AP  '4J  !T.P  =$L  '1<  !S<   <H0  '";  !NM   ;=0
M &WQ )2(  "0C   AHT  'F,  !JB@  6HD  $J'   YA@  *84  !F$   )
M@P   ((   ""    @@   (,   "#    @@   ((   "!    @0   ($#  "!
M"@  @A$  ((?  "!,   @4(  ()3  ""9P  @'T  '^4  !]K0  ?,L  'OK
M )20  "+D0  ?I$  '"0  !@CP  3XX  #Z-   MC0  '8T   V,    C
M (P   ",    C0   (T   ".    C@   (X   ".    C0   (T   ".
MD 4  ) 1  "0(0  CS8  )!)  "170  D7,  )"+  ".I0  C<$  (SD (Z5
M  ""E@  =)8  &65  !4E   0Y0  #*4   AE0  $)4   "5    E0   )4
M  "6    EP   )@   "9    F0   )D   "9    F0   )H   ";    G
M )\$  "@$@  H"4  *$Z  "C3P  I64  *.   "AFP  H+<  )_8 (:9  !X
MF@  :9H  %F:  !(F@  -IH  "6<   4G    YT   ">    G@   )\   "@
M    H0   *(   "D    I    *4   "E    I@   *8   "G    J0   *T
M  "O!   L14  +$J  "T00  N%@  +EP  "YB0  N:,  +C" 'R>  !MGP
M7I\  $Z?   [H   *:(  !>D   &I0   *8   "G    J0   *H   "K
MK    *X   "O    L    +$   "R    LP   +,   "U    MP   +H   #
M    Q 4  ,@9  #*,   STD  -5B  #6>P  UI,  -:K /\   #_    _P
M /\   #\    ^  ( /4 %@#P "( [0 L .D -P#E $$ X0!) -X 40#< %<
MV != -, 8P#1 &@ S@!M ,P <@#, '@ R@!^ ,D A0#( (T QP"7 ,8 H@#$
M +$ PP#) ,$ [ #  /\ OP#_ +D _P"Q /\ JP#_ /\   #_    _@   /4
M  #O    Z0 $ ., $@#> !X VP G -8 ,0#2 #L S@!$ ,D 2P#% %( P@!8
M ,  70"^ &( O0!G +P ;0"[ '( N@!X +D ?P"X (< MP"0 +4 G "T *H
ML@"] +$ X "O /T K0#_ *D _P"C /\ GP#_ /\   #[    [P   .8   #?
M    U@ " ,\ # #* !@ Q@ C ,, *P"^ #4 N0 ^ +8 10"T $P L@!2 +$
M5P"O %P K@!A *T 9P"L &P JP!R *H >0"H ($ IP"* *8 E0"D *( HP"S
M *  T0"= /, G #_ )P _P"7 /\ E #_ /@   #L    WP   -4   #,
MQ    +T "0"X !, M  = +  )@"M "X J@ W *@ /P"F $4 I !+ *, 40"B
M %8 H !; )\ 80"> &8 G0!L )L <P": 'L F "$ )< C@"4 )L D@"K )
MQ ". .D C0#_ (P _P"+ /\ B #_ .L   #;    SP   ,4   "\    M0
M *X ! "I !  I0 8 *( (0"? "D G0 Q )H . "8 #\ EP!% )4 2@"4 %
MD@!5 )$ 6@"0 &  C@!F (T ;0"+ '4 B0!^ (< B "% )4 A "D (( N0"
M -P ?P#Z 'X _P!] /\ ? #_ -X   #/    P@   +@   "P    J0   *(
M  "=  H F  4 )4 &P"2 ", CP K (T ,@"+ #@ B0 ^ (@ 1 "& $D A0!.
M (0 5 "" %D @ !@ '\ 9P!] &\ ? !X 'H @@!X (\ =@"> '0 L0!R ,\
M<0#R '  _P!O /\ ;P#_ -$   ##    N    *T   "E    G@   )@   "2
M  4 C0 . (D & "& !X @P E ($ *P!_ #( ?0 X 'L /0!Z $, > !( '<
M3@!U %, <P!: '$ 80!P &D ;@!R &P ?0!J (D : "8 &8 J@!D ,, 8P#G
M &( _P!A /\ 80#_ ,<   "Z    KP   *8   "=    E0   (X   "(
M@P ) '\ $@![ !H >  ? '4 )@!R "P <  R &\ . !M #T :P!" &H 2 !H
M $X 9@!4 &0 6P!B &, 8 !L %X =P!= (0 6P"2 %D I !7 +H 5@#; %4
M]P!4 /\ 5 #_ +\!  "R!@  J 8  )\$  "6    C@   (8   "     >@ $
M '4 # !Q !4 ;0 < &D (0!G "< 9  M &, ,P!A #@ 7P ^ %X 0P!< $D
M6@!/ %@ 5@!6 %X 5 !G %( <@!0 '\ 3P"- $T G@!+ +( 20#/ $@ [P!(
M /\ 2 #_ +@.  "L%   HQ4  )D3  "0#0  B 8  (    !X    <0   &L
M!P!G  \ 8@ 6 %\ '0!< ", 60 G %< +0!6 #, 5  X %( /@!0 $0 3P!*
M $T 40!+ %D 20!B $< ;0!% 'H 0P") $$ F0!  *P /@#& #T Y@ ] /P
M/0#_ +,9  "H'@  GB   )4>  ",&@  @Q0  'L-  !R!   :@   &,  @!=
M  H 6  1 %4 %P!1 !T 3@ C $T * !+ "T 20 S $< . !& #\ 1 !% $(
M30!  %4 /0!> #L :@ Z '< . "% #8 E0 U *@ ,P"^ #, WP R /8 ,@#_
M *XB  "D)P  FRD  )(H  "))   @!X  '<9  !N$0  90@  %P   !5  4
M4  + $L $@!( !@ 1  = $( (P!  "@ /P M #T ,P [ #H .0!! #< 2  U
M %$ ,P!; #$ 9@ O '0 +@"" "T D@ K *0 *@"Y "H U@ I /  *0#_ *LI
M  "A+@  F#$  (\P  "&+0  ?2@  '0A  !J'   810  %<+  !/ P  1P &
M $, #  ^ !, .P 9 #@ '@ V "0 -0 I #, +P Q #4 +P ] "T 1  K $X
M*0!8 "< 9  F '$ ) "  "( D  A *( 'P"V !\ T0 ? .P 'P#Z *DP  "?
M-0  EC<  (TW  "$-   >S   '(J  !H)   7AT  %07  !*#@  00@  #H!
M!P U  T ,@ 4 "\ &0 M !\ *P E "D *P G #$ )0 Y ", 00 A $L 'P!5
M !X 8@ < &\ &@%^ !@!C@ 7 :  %@"T !4 S@ 4 .@ $P#W *8U  "=.@
ME#P  (P\  "#.P  >C<  ' Q  !F*P  7"8  %(?  !'&   /A(  #0+ 0 L
M!@@ * ,. "4"%  C AH (0,@ !\#)@ =!"T ' 0U !H%/@ 8!4@ %P93 !0'
M7P 3!VT $0A]  X(C0 -!Z  "P>T  H&S  )!^4 "0?T *0Y  ";/@  DT$
M (I!  ""0   >#T  &XX  !E,@  6RP  % G  !%(0  .QL  #(6   I$0(
M( P( !L)#@ 9"!4 %PD; !8)(@ 4"BH $PHR !$+.P /#$8 # U1  H.7@ (
M#VP !Q![  40C  $$)\  Q"S  $.RP !#>0  @WV *,]  "90@  D44  (E&
M  "!10  =T,  &T^  !C.0  630  $\N  !$*0  .B0  # ?   G&@  '18#
M !01"  .#@X #1 7  P1'P +$2< "1(O  @3.0 '%$, !11/  ,57  !%FH
M !9Y   6B@  %IP  !6Q   5R0  %.,  !/S *%"  "81P  D$D  (A*  !_
M20  =D@  &U$  !B/P  6#H  $XU  !$,   .2P  # H   G(P  '1\  !$9
M!@ )%@T !A<5  48'0 #&"4  ADM  $:-P  &D$  !I-   ;6@  &V@  !QX
M   <B0  &YL  !NO   :R   &>(  !CS )]&  "72P  CTT  (=/  !_3@
M=DT  &Q)  !A10  5T$  $X]  !$.0  .C4  #$Q   E+   &24   P@!@ $
M'@P  !X4   >&P  'R,  !\K   @-0  ($   "!+   @6   (68  "%V   B
MAP  (9H  !^N   >Q@  'N,  !WS )Y*  "53P  CE(  (93  !^4P  =5(
M &M/  !@2P  5T@  $Y%  !%00  .ST  "TW   @,@  %"P   @G!@  )@P
M "43   F&0  )B$  "8I   G,@  )ST  "9)   G5@  )V0  "=T   HA0
M)Y@  "6L   DQ0  (^,  "/U )Q/  "45   C58  (58  !]60  =5@  &M5
M  !@4@  5T\  $]-  !$2   -D,  "D]   ;.   #C,   ,O!0  +@L  "T1
M   M%P  +1\  "XG   N,   +CL  "U'   M5   +F(  "YR   NA   +9<
M "RK   JQ   *>(  "GV )I4  "360  C%P  (1>  !]7@  =%X  &M<  !@
M60  6%<  $U3   _3@  ,4D  "-$   6/P  "3L    X!0  -@H  #80   U
M%0  -1T  #4E   V+0  -3D  #5%   T4@  -&   #5P   U@@  -)4  #*J
M   QPP  ,.(  "_V )A:  "27@  BV(  (1D  !]90  =60  &MC  !A80
M55T  $A8   Y4P  *T\  !U+   01@  !$,   !  P  /P@  #\-   ^$P
M/1H  #TB   ]*@  /38  #Q"   \3P  /%T  #QN   \@   /),  #JI   X
MP@  -^(  #;V )=@  "090  BF@  (-J  !];   =6P  &QK  !>9@  4&(
M $)>   S6@  )58  !=2   )3@   $P   !*    204  $@*  !($0  1Q<
M $8>  !&)P  13(  $4_  !%3   1%L  $1K  !$?0  1)$  $*G  ! P0
M/N$  #WW )5G  "/;   B6\  (-Q  !]<P  =G,  &AP  !9;   2F@  #MD
M   L8   '5T   Y:   #6    %4   !4    4P(  %('  !2#   41,  % 9
M  !/(@  3RX  $\[  !.20  3E<  $UH  !->@  38X  $ND  !*O@  1^
M $7W )1N  "/<P  B78  (-Y  !]>@  <7@  &)U  !2<0  0FX  #-J   D
M9P  %F4   9C    80   &    !?    7@   %T#  !<"   6PT  %H5  !:
M'0  62@  %DU  !81   6%,  %=D  !6=@  5HH  %6@  !3N@  4=X  %#W
M )-V  ".>P  B7X  (2!  !Y?P  :GP  %IY  !*=P  .70  "IQ   ;;P
M#&T   !L    :P   &H   !I    :0   &@   !G @  9@@  &8.  !E%@
M92   &0N  !D/0  8TT  &->  !A<0  8(4  %^;  !>M   7=<  %OT ))_
M  ".@P  BH8  '^&  !QA   8H$  %)_  !!?0  ,'H  "!Y   1=P   G8
M  !U    =0   '0   !T    <P   ',   !R    <@$  '$'  !Q#@  <18
M '$D  !P-0  <$4  &]7  !O:@  ;7\  &N5  !JK@  :<X  &CO )*'  ".
MBP  A8L  '>*  !HB   6(8  $>%   V@P  )8(  !:!   &?P   '\   !^
M    ?P   '\   !_    ?P   'X   !^    ?0   'T   !]!0  ?@H  'X8
M  !]*0  ?3P  'U.  !]80  ?'<  'J.  !YIP  =\0  ';H )*/  ")D
M?)   &Z.  !=C0  38P  #N+   JBP  &HH   F)    B    (@   ")
MB0   (H   "*    B@   (H   "*    B0   (H   "*    BP$  (P*  ",
M&P  BC$  (M$  ",5P  C6T  (N&  "*GP  B+L  (?> (V4  " E   <I0
M &*3  !2D@  09(  "^2   >D@  #)(   "2    D@   )(   "3    E
M )4   "5    E@   )8   "6    E0   )8   "7    F    )H   "<"P
MG!\  )PU  ">2@  GV$  )Y[  "=E0  F[   )K2 (28  !VF   9Y@  %>8
M  !&EP  ,Y@  "&9   1F@   )H   ";    FP   )P   "=    G@   )\
M  "@    H0   *$   "B    H@   *(   "C    I0   *@   "K    K0X
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M_O______________________________________________________
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M\O/T]?;W^/GZ^_S]_O]M9G0Q      ,!(0   0                    $
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M________[WT6       >CO______________________________UD<
M   %B/______________________________JCX)        @/__________
M____________________RH-$$P      </W_________________________
M_____]"=:#PT,TAGBO+________________________________]S*:>H[?4
M^?__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________]JTH):W___________________________________R
MJVM!+B-=U?________________________________^J8AT    RH_______
M_________________________\ES*0     2?NS_____________________
M_________YM#        8<______________________________T6L*
M    2;G_____________________________J3          -*?_________
M____________________?0          'I;_________________________
M___L-@          !XC___________________________^V
M 'K___________________________]=(            &;]____________
M______________^^<S           $WM____________________________
MX:%>*@4      "[9_______________________________-E6=33EYUD*W5
M__________________________________KK[?O_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^[5Q+>KRO______
M___________________________DH6]10#(C8.7_____________________
M_________]>+1@H     -[7_____________________________]I1'
M    %X______________________________OU\)         ''O________
M____________________DRD          %G8________________________
M___N:            $7$___________________________")
M #&S__________________________^0             !NA____________
M______________\]              20_________________________^$
M              "!_________________________U\               !K
M_________________________R(#              !1_O______________
M________JYYK*P             SY__________________________YOW(W
M$@        $6S/____________________________6[C&M95%UK>8B5VO__
M_______________________________Z^?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________#ATO'________________________________ILH]V
M9%5$,WC______________________________\5Z.Q$      $+/________
M____________________S'0G         !BA________________________
M___VB34           *%__________________________^_5
M  !N_O________________________^2'             !9Z___________
M______________AF              !'VO_______________________]8B
M               TR?_______________________Z\                ?
MN/_______________________U4                (I?______________
M_________P                  D_______________________E@
M            @/______________________                    8___
M___________________)                    0O__________________
M____'T8J!0              +>______________________]/_=HF,Y&0
M     0X<+N?____________________________1JXQ_?H:1G:JXQ?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________Z,NTH(]^;6+)________________________
M_____\2$5#0<!0    R3____________________________LV 7
M  !D^O_________________________*9A$            YR___________
M______________^()P             1HO_______________________\I/
M                ?________________________Y<8
M7________________________V,                 4/G_____________
M________X2,                 0.O_____________________J0
M            +=O_____________________5                   %\G_
M____________________                     +7_________________
M__^@                     )_____________________0
M         (/_____________________                     'K_____
M________________*0                   ''_____________________
M@ D.                 &O_____________________]\R_GG=7/288%!LD
M+SM'5'/_____________________________[=3,S-+;Y.WY____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________^N;4
MP:W!_____________________________^>TD'-;13$;!@!E^?__________
M________________KF(G           UR?________________________^M
M4              &F________________________])A @
M</_______________________XPB                1^W_____________
M________X$\                 (<K_____________________J!D
M             *K_____________________;                    (O_
M____________________)@                   &S_________________
M___&                     $[___________________^)
M         #+___________________^J                     "#R____
M_______________4                     !?G____________________
M                     !7C____________________)P
M     !'<____________________:0                    O2________
M____________Q@                    ;+_____________________SP)
M!@                '(_____________________^S3OZB->&EA8&=P>H2/
MFJ78________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____YLJRG(=T7T=!T/__________________________RHI;.!L        $
MF_________________________^F3@0             :O______________
M_________[-+                /.3_____________________YF(
M            $+G_____________________GB,                  )#_
M____________________7                    &S_________________
M___E'P                   $G___________________^?
M         ";Q__________________]Z                      31____
M______________^5                      "S__________________^U
M                      "7___________________:
M      ""____________________                      !X________
M____________+0                    !V____________________9@
M                  !S____________________J0
M  !O_____________________QP                   !J____________
M_________X4                   !E______________________\Z)24;
M#0$    '$!DC+3==___________________________LV<O&R=#:X^KS_?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________?BS;>@PO______________
M_____________]BOC7!6/R@0    <?________________________^\;3(%
M            .^/______________________ZA&                "+'_
M____________________SDT                  (/_________________
M____>                    %?____________________F+
M         "[S__________________^3                      G0____
M______________]M                      "M__________________^)
M                      "+__________________^H
M      !I___________________&                      !)________
M___________G                       M____________________"@
M                   ;____________________-0
M   4^___________________9P                     3]?__________
M________H0                     3]?__________________Y0P
M               ,[____________________UT                    $
MZ?___________________\8$                    X?______________
M______^&                    U/______________________CW!K8U]<
M7V5O>(")D9JDU/______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________]=B^IY%[94TS1?'_
M_______________________YL'U3,1(         #;G_________________
M_____[U>$P               (3_____________________RDD
M         %'_____________________8                    "#B____
M______________^W#0                    "V__________________]?
M                      "/__________________]U
M      !I__________________^7                      !&________
M__________^U                       C___________________3
M                    [?_________________R
M    S/__________________&P                      L?__________
M________0@                      GO__________________;0
M                E?__________________G@
MD?__________________VP4                     D/______________
M_____TH                     CO___________________YP
M            A_____________________]#                    >___
M___________________''0                  :/__________________
M____R28        ##!0<)"TU4?_________________________Y]_'M[?#U
M^___________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________WX<FQE\___________________________^&UDG19
M02H2     (K_______________________^>5R(              %3_____
M________________X%\$                 ![@____________________
M70                    "M__________________^;
M      !]__________________]1                      !2________
M__________]Z                       I__________________^B
M                   #Z/_________________$
M    Q?_________________C                        H___________
M________"0                      @?__________________*@
M                8O__________________3P
M2/__________________>                       ./______________
M____I@                      ,/__________________V@4
M            +?___________________T                      +/__
M_________________X<                     *___________________
M_]@B                    '_____________________^"
M        #?______________________5@                   /______
M_________________V4                  -______________________
M__^X9FEM<GB!B(V4GZ6MM=C_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________^K/MI^';U4[(5;_____________________
M____N(%4+Q           "#D_____________________YY"
M      "N____________________> ,                   !Y________
M__________^8                      !'__________________]%
M                   6]O________________]Y
M    S/________________^G                        I/__________
M_______/                        ?O_________________S
M                6O__________________(
M-___________________00                      %?______________
M____8P                       /__________________A@
M             .__________________K@                       -W_
M________________W@T                      -/_________________
M_T(                      ,W__________________WX
M         ,K__________________\(-                     ,?_____
M______________]@                     +_____________________
M)0                   *S_____________________FQ$
M     (_______________________Z8F                 &7_________
M_______________]?!0    "#!0<)BTS/$W_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___DR:W___________________________'$GGU@12L2      "N________
M______________F84AT               !V____________________N#D
M                  !"__________________^R$0
M   /[?________________\Z                        N___________
M______]T                        C?________________^H
M                8O_________________6
M.O__________________#                       $_______________
M____,@                       /C_________________5P
M             -?_________________>@                       +?_
M________________G0                       )O_________________
MP@                       (;_________________ZA@
M         ';__________________T<                      &W_____
M_____________WX                      &C__________________[P&
M                     &3___________________],
M     %____________________^= 0                   %7_________
M____________8P                   #S_____________________WTX
M                 !?______________________^UC
M  #_________________________P5,   ,3'RP\4FR'J=3_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________\25;UI024$Z,BHA
M%PXT_____________________X\O                   "Y?__________
M_______U1                       L?________________\U
M                ?_________________]I
M4/________________^H                        (O______________
M___<                         /K_________________%@
M             -+_________________0@                       *W_
M________________:@                       (G_________________
MCP                       &?_________________LP
M         $G_________________V 8                      ##_____
M_____________RT                      !S__________________U<
M                      ___________________X4
M      ;__________________[D$                      #_________
M__________A#                      #___________________^+
M                  #____________________;/P
M  #_____________________H!@                   #Y____________
M_________XX5                  #2______________________^O.@
M            $C2__________________________YA=<7^/H;+$V?3_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________P
MY-G2R\;!O;>RJZ:G\/__________________^YEO43DG& H
M:O________________^,(0                      ._______________
M__]2                        #?________________^A
M             .'________________@                         +;_
M________________'0                       (O_________________
M3P                       &/_________________>@
M         #W_________________HP                       !G_____
M____________R0                        #_________________[QT
M                      #__________________T(
M      #W_________________VH                       #D________
M_________Y4                       #6_________________\,-
M                  #,__________________A"
M  #%__________________]_                      "_____________
M_______'*P                    "U____________________?0
M              "B____________________X5(                   "!
M_____________________]13                  !.________________
M_______V?QP   D8)S='7'.+J,[__________________________^[2YO3_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________W6NJ21AGUU
M;FAB75=234A%1__________________%?THA"                    ,/_
M______________^/                         )C________________=
M                         &[_________________'
M         $3_________________5P                       !O_____
M____________B0                        #_________________M0
M                      #Z________________W@P
M      #9_________________S,                       "Z________
M_________UD                       "@_________________W\
M                  ")_________________Z<
M  !W_________________]$;                      !K____________
M______]*                      !B__________________^
M              !;__________________^\'P                    !3
M____________________9@                    !&________________
M____NC(                    K_____________________Y4<
M            ______________________^8*@            LA.5A[____
M____________________R6)=;'N*FZ["V//_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^(X($E#
M0U]04D]&24Q% !45____________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________\\.CAV];0S,C&P\/"Q>__________
M________V:6#:U=&."\G(!H3#08      $?________________4/P\
M                 ![_________________$@
M  #_________________5                         #X____________
M____DP                        #2________________QP
M              "L________________\Q\                       "(
M_________________TD                       !G________________
M_W                        !*_________________Y<
M           P_________________[P%                       :____
M_____________^,L                       +__________________]7
M                        __________________^&
M        __________________^](                       ________
M___________X70                      ____________________H!D
M                    ____________________^6P
M    _____________________]E;                   :ZO__________
M___________A:@D #1DF-D=;<(BCP>7__________________________\C'
MVNKY________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________?QK:GFY")A'YY='!L:VIL;WC_____________
M____E&1"*!4$                  #/________________30
M              "G________________EP                        "!
M________________U                         !<________________
M_RT                        X_________________UL
M           5_________________X8                         ____
M_____________ZX                         _________________]0>
M                        __________________I$
M        __________________]J                        ^/______
M__________^4                        [/_________________#)0
M                    X__________________Y7
M    V/__________________F1(                     RO__________
M________WU<                     L____________________ZDS
M                B?____________________^?,          ,(3A0;(RN
MXO______________________M5MG=X>5I;C-Y/[_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________^.WEXM_<VMC6U=;:X^O_
M________________[;J9?VYA5DU%/SHU,2PH)B4E)RE>________________
MG3 .                       I________________W
M           &_________________S4                         ____
M_____________VH                         _________________YD
M                        _/_______________\,,
M        X/_______________^PU                        Q/______
M__________]=                        K/________________^#
M                    F/________________^J"P
M    BO_________________3-0                      ?___________
M________8P                      =/__________________F!$
M                9O__________________U$\
M4?___________________Y4@                    +O______________
M______!S"@             2*TAFD?_____________________D< \:*CE(
M6&A[DJS(Y____________________________<'-WO#_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________KUL:ZKZ>AFY:3CXN)AXF-EJ&N____
M____________]X%B2SDK'Q4.!P$             _________________S<
M                        Y?_______________W<
M        P________________ZP                         I/______
M_________]HA                        A_________________],
M                    :O________________]U
M    4/________________^<                        ./__________
M_______#)                       )__________________J2P
M                &O__________________=0
M#O__________________HQH                      /______________
M____U4\                      /___________________XL7
M             /___________________]9=                 !@S5___
M__________________^Y2      +&BL^5&Z*J<KP____________________
M____MVAZC)ZOPM/F____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________[X\^_KY^7C
MYNGP^O___________________]6RFXM]<6EB7EE54DY+2DQ05E]JN?______
M_________XHV'@X                     9/_______________\
M                    1?________________,R
M    *O________________]B                        #?__________
M______^-                         /________________^V%P
M                 /_________________</@
M /__________________9                        /______________
M____BP(                      /__________________M2P
M             /__________________XUH                      /__
M_________________XX8                     /K_________________
M_\E4                   2,OC___________________^=,P         4
M*D->?)R\W/_____________________]CB\]3V!P@92JPM[_____________
M_________________\W:[/______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________Z=G.Q;VVL:VJJ*:EIJFO
MN<74WO_______________^>!;%Q/13TU+BDD'QP:&1D:'2(J-___________
M______\^                         /________________]T
M                 /________________^D @
M /_________________/+P                       /______________
M___W6                        .G_________________?@
M             -7_________________I!H                      ,3_
M________________S$,                      +3_________________
M]FT                      *?__________________YHD
M         )/__________________\I7                   %(Y7_____
M______________^2*@          #"1 7GV=O.S____________________A
M=!4.(#! 469]EK'0\___________________________U8R8J[_1Y/G_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__[\^OC[_/_________________________3MZ:;DXN%?GEU<F]P<'-X?XR>
MK/________________^62C@J(1H2"P0              ,G_____________
M___ $P                       +#________________M1@
M             )G_________________<@                       (3_
M________________F@\                      &[_________________
MP3<                      %K_________________YUT
M         $K__________________X4.                     #K_____
M_____________ZXW                     ";__________________]ED
M                   )*4O___________________^5+@           !$N
M36R.LMG____________________6:PT  ! @,49==I&QT_;_____________
M____________NF%G>HV?LLCB_?_______________________________^OP
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________'EW-;1S,?#
MP<# Q<G/U^7Z___________________UE(%R:6)<5U)-2DA'1TE,4UYOAJ;_
M________________71\0!0                   "?_________________
MC                        !3_________________MRP
M          #_________________WU0                       #_____
M_____________WP$                      #__________________Z,K
M                      #__________________\A1
M      #___________________!X$                  <06+_________
M__________^C/0            TK2VZ3N]?____________________8;Q(
M   .'S-*8W^@P^?_________________________L$U#5VM^DJC!W/K_____
M_________________________[Z[TN?\____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Y\F[L:JDGYR:F)B8
MFJ"EL+W3[/__________________O6-63$4^.34P+"HH)R@L,CE*:(O_____
M____________W$8                       #__________________W0
M                      #__________________YPC
M      #__________________\-*                      #_________
M_________^EP!P                    #[__________________^6+
M              XT7'____________________^\4P           !4T57ND
MS>W____________________D?1\    &%RQ#77V>PNC_________________
M________LU(N0E9J?Y6NR^K_____________________________^*64K,+9
M[___________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M]_#LZ.7EX^+EZNWU_________________________[:;D8J%@7Y]>GEZ>X"(
ME*.XVO3__________________YM".3$J)2(?&A42$! 2%!DH2'+D________
M_________[U                       "F_________________^1K
M                  "5__________________^2)P
M!BZD__________________^W30              !BU3>Y_?____________
M_______<<1(          B)&;).ZYO_____________________^EC@    '
M&B]'8H2HSO;_________________________P6$B-TQB=HVHQ>;_________
M____________________^9Y\E:O#V_3_____________________________
M______WI____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________BUL_)
MQ\7%Q<C&S-3;X_+_______________________J8?'1N:FAG9VEG:W%X@Y*D
MPM_U__________________^-+R$:%!$."P8!       1,EZ.____________
M______^T20                 #,5V#___________________;<!
M        )U)ZH\WK___________________^E#4         %#A?B;3:____
M____________________ME8    /)#Q6<I"YX?______________________
M____VGLG-DMB>I.PS>[______________________________ZMTB:&ZU.[_
M__________________________________;3Y_______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________XP+6OK*JM
MK;&WP,70V>/[_______________________OB6!95E1765UC96UU?I&HP^SY
M____________________ES4-"04"       =3'FBS/?_________________
M____O%P#       -,%>"K=C_________________________W'\G  8<-$]L
MC:[6_____________________________)]#.U)KAJ' X_______________
M_________________\)]A:"ZUO;_________________________________
M__[.U//_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______/O[N[O]?S_________________________________\Z^;FIN>I:ZZ
MO,34YO__________________________]Y=43$]46V5N@)? Y___________
M_________________ZY4 !LV4G",J\OV____________________________
M_\IK/V-_G;S>_/_______________________________^>9@ZS(Y_______
M_______________________________;S/+_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________\
M
M
M                 /__________________________________________
M____________________________________________________________
M____________________________________________________________
M________    _^X #D%D;V)E &2      /_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,#
M P,# __  !0( &8#Q 0!$0 "$0 #$0 $$0#_Q !D  $  @(# 0$! 0
M    "0H'" 4&"P0# @$0   & P ! P,!! 0)"P0#   " P0%!@$'" D1$A,A
M% H5,4$B%C(C%[=1,R2V=Q@X>#EA0E(TUEB8N!EY.F(E-393<RC_V@ .! $
M @ #  0  #\ O\"_P+_ O\
M
M
M
M
M
M
M
M
M
M
M
M
M        "OEY<_R!-!^-B1?Z4H%?0Z ZO_36KQU06DR6,HFKD)1#*T:\VM96
M17C]&97:J)O&]>9(_?N6AB*.%X])=LNM AY7_/-HKQTR#[3=#@4-\=2YCFKQ
MS16LN6-H^LT9-'YHYWM&QLRNWR,PNV43=MX!DE]\X:F(=PNP27;+*@%,+=/Y
M'GERW',2#UMTFVT] O%LJM:9I;7M(J</#X^<CC",?8)>&LVR%T<92(3T>3KO
M/QXR7U]#J>^GEN/\ASRN[=EW[QMT4WU)!NU?E;4_3E!I=6B(G'SD7PDPGI:'
MLFQ%DL92*7T=SCK/LQDOKZ'4]X!RVC/R3O+5IB:CWDQOV(WE7&BK<SJF;JU[
M3YR.DD43^ITG%FJ\74-AHF63SDN3)3)/KZ9SC.<#E-)?D6>573TRP=R^]HG=
M=>:JH&=4_<E!J4W'R*21_4Z2]CK,94[^B99/.2Y,E,$_=G.,YP "ZYXEO/#S
MEY.L$UC)1']@W4\?&KOW6G)Z=0F8J^,8QHN\EY[4=I,TBU+*A',6IW;Z+<-6
MTI'H8.?!7;5!5X+E?BJ\XO/7DHP36LC%?V&]/,(Y=\YU%.3:,O%WEE&M%WDM
M.:HLQFL8I8T8]DU.Z>QCALWDV"&#GP5TV05>  G8$WH
M
M
M
M
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MF9.Q62PS+Q:0EYR=F7BTA*RTF^<G4</'\@^<'565.;)CJ'SG.?7( .!'!@
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M_JEHD$DO:J?Y5&4)+/G)$_8@?/NR7&/0AL_NR  ,H
M
M                                   #BYB<A:\R-)3\Q%P<>51-$S^8
MD&D8R*JKG.$DC.GJR"&%%,X]"E]WKG]P  XN$N]+LKI1C7+?5[ ^2;G=JLX2
M?B95TDU3421.Y4;L':ZQ&Y%ER$R?.,%P8Y<>OKG   [0          .'G+#
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M\L#_ ()71O\ I YW_OOI   U_P#PV_\ A(67_? W)_F/I\  6O@    $+'Y
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M;?9O:#"OZ?OMNMM)ME6J4C97KU]5[A3I_7DFM RK(S5RX;HLD97]03RZ^Y
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MCI!1,TJ]:K/<O%7&6Y5<  71P !6/_*Y[%L7.GC&LVD=<8EG&SNP))]K-PG
M-GSJ4@M#U1JUM._[>X*R(H5"L_H1HVLRJRQ<HIM;5ZFR7/H<H '=OQ:NWL]@
M>*G6-.LDM^H;0Y$E''-EO*X<G5?.:E6&+24TY-91756<$C\ZTDV4,10Q\E6>
M03K)<%+CV%  L=  #RKZKI'4_1_Y:6TM)[RHL'LO5-][TZEC[C1K(DLM"6!E
M'US:TXR;OTFZ[98Z;>6BVZY?:<O\:1?W?0  7T\^ [Q )MGJ$7PQJZKK/VN6
M:TO1YK8]!LJ3<RR*YB1]JI5V@;+%&,JW)G)VKM$^?;Z>OI]  !#-Y'=.>0SP
M057_ %Z/'9T_NCH#BZDSD0CT%Q#UI=9_?U<UU5;%+-H1K8]872U2*VR:_0VL
ML\8MUTF+_$M$NEOOG+E_''>HMP + OB^\DNDO*9RC4NFM-X6@7BSI>I[5U?*
M/VS^R:EV=$MVR\Y3I=TV302DV*K9X@_B9$B2)9&)=MUC)-U\K-4  -._.GYJ
MM?\ B$T'$.X6(A=D=6;C1F&.A]52KA?]#9)11$4IC:.S"1KQC+-]>UAT\12(
MU;K-WL]('PT;*HID>O6( &N/ 7ASENE*%2.RO-O/VCMGJ_:D7&;#B=%;G>/5
M.=N68*QLOU.(UU6>?V2S'6AK@S821L3AG,8HQ:NU#M6[;Y$7#]^ !(AN?PB^
M*?=E44K4CPWSWJ^01^->#V#SOKBL<Z[2JLDT;E;Q<K7]@Z:C*98TG$1A(AD$
M'"SEAGX\%5;J)^I,@ 5\J5Y,.KO MY#*YX[/)/N2U=.<%;?1C9OFCLK:2CB0
MV[K*ESDBM",#;'N!4U#7J%H]B0/'6EN].O)1C4S>69*I,%$(M4 "VYU8LDXY
M3Z27053707Y[W"LBLB<JB2R2FN+$=-5)0F3$434(;&2FQG.,XSZX  'FO_B6
M\1<G]N=$=;5;J_1='WG7J1I>DV"IQ-W:O736"F9"\*QSV18E9/61BN'+$N$S
M9-DV/;^X  7+^H?Q^N,Y_1UU:\05FY<.=+P%5G9#16V^:]Q;7U6K!7]H@YF*
MVPL4/$75.M2E5F[.BV+)F,U3D"(?UC9VW6(13  $6_XJGFQZ*[LE=M<5=>6M
MQM7:&I];DW%J[<DLBU2N-EUW&V>NTJW578#QHBU0L,Q6YBX0ZT?)G(:0>-W3
MG#Q18R":A@ +GH               .'GK# 56)=SUHG(>MP<>G\S^9GI-E#Q
M+%+'[57<C(+MV;9/'_2.<N  !\=4N50O<0G8*/:JW<H%90R*,W5)R,L,0JJ0
MB:IDDY*(=/&9U"IK$-DN#YS@I\9_9G   ^R>L,!58EW/6B<AZW!QZ?S/YF>D
MV4/$L4L?M5=R,@NW9MD\?](YRX  'QU2Y5"]Q"=@H]JK=R@5E#(HS=4G(RPQ
M"JI")JF23DHAT\9G4*FL0V2X/G."GQG]F<  #L@  UMZOZQTGQ;IN7WCOBPO
MH:IL9:#JT%#U^%D+5>MA7VUO2Q=.UOK:EPR3B<NE^M\H?"#".:)F.;T.JIE)
MNBLLF !GI_8(2(A%;'-2C.!@FS--^\E+ L6!:1S10I#85E%)C[+]+]GR8P<K
MCXS)FS[38P;Z  #Y:M;ZG>8="PTFT5VX5]T8Q&TY5IN-L$.X.3!<G*A)Q+EV
MR6,3!\>N"GSG'KC_  @ # O/O7^B>F;1OJA:NL[Q78?,NV+!IS=FO+-"2=4N
MU)LT0^>HPTN[KTR@V>/*/L&(:8E:W-M\*QTQ&J8.DI\R;A%$ #9P  ?.1VU4
M<KLTW+=1XU3;K.FI%DSN6R3O*V&JJZ!39513<Y;J?&8V,8/\9O3U]N?0 #Z
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ML4;6%1D;]M'9NP;A>Z_"4G6VM:5%Y(ZLMVN$VX(V9-S*-VY39,JX70;IJK$
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M8Z&](     *X/Y8'_!*Z-_T@<[_WWT@  :__ (;?_"0LO^^!N3_,?3X  M?
M    (3',/&=R^8"Y1ECBX^T<\^+[0;RA+Q,DW2>0MH["[7JJ1[@11,R2\?,-
M]8<J-DXURDH;Y6CJ\JDQ[,_*4X %(KQKS<OX-/R2[%R[<9)Y%:BM^U+%RC,O
M)5<Z:<KJ3>3R$M'-UUD5G&?M4E"2KJG2#UT;W8;-5'J?R8P8Y@ !ZE   \NO
MSKV& J/Y1])M=KG(>L5:L;H\>EALMEL,FRA8"O0$+$Z9DIF<G)F27;1T3#Q,
M<V4<.7+A1-%!%,QSF*4N<X  O]V#S >*2LQ;F8D?)+PTY:-2Y,JC7^I-+VR4
M-C!3'SAM!U6Y3,V\-Z$SZ81;GSG/ICT]<XQD "F_UYQWM;\F_P M5)Z!T!0;
MQ3/&EJ*AZ[T-*]<WVNRFO8K:M%H=UO&Q+M+:<K]J;,+3:YBTRNQY&,A#I,<H
M-$TF[F4RRR?*   O7]2,F<9R7T7&Q[9%FPC^==NLF+-NF5)NU9M-:6%!LV02
M+C!4T4$4RE*7'TP7&,  #S\?PHK/6JQU%VRO9+#!UY!UH/7Z+9:<EF$2DX5)
ML-8YTD%'[AN190I/KDI<YSC'U  %W/OWRG<B<!: O^W-B[HUC(W6+J,R^U7I
MR*ND',;&V]>/M5VU3J-2IL/(.;')(35CR@V=/DT,,HU YW#I9%%,YR@ 58_Q
M$_$;T;H#8&SO(3TMKZT:@C[AJ-WI[0E!O$8O 6^SQ%ML]7M5NVA*5E]AM.UN
M';H4IG'PQ7R*1Y1*0=N2I? 1HNL !?!  $ 5'TQ2/*-VEY.]B;2;%L?.6K-2
MV;Q%Z<3(DR<-S3$S%M[EW#?H4CYL\3:6ICL2:@*JSDF^<?$>I+%_IX.4H %1
M[\93=EX\:GF>WCXZ-WO2P;3=<M>><K4W6RJRAL[\T+,V>3UA86RKX[?*\;9V
M*$_$Q!BIGS(*61D9//L/@V0 /3>  'F!\T?_ #)+'_[@'67^8^Y0 !Z?@  Q
M#T#J& Z!T/NG1%J:M7E:W-JG8.K)UL]P;+56*OU4EJL]^;*9%%2%(A*&-[R8
MR<F<8,7^+&  !YT_X4W0%EJO<73/->73H]&W%SC_ &FK,<'^1NWOFF;Y6(B"
M>81/]&Q7-6VE-)K*IYP90Z3<IRGP4AD@ ,8]N6YYY$/RR*%JG8CA.7UIK3L3
M2G/41593[C,4AK30,S&SE^J:9,H96RWNMMC;(Y4^GM,O,&P4^$\%.4 #U!
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M6%O-A@+7:JG<+5M.1K4B1";J,.9*D,F$+EXD@YE6KYVY(EAGEJNZ  O:@
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M"O>.GM$D>95NTN.E^@G#E32E\MZ1,F:J?V#;>BRND7A4COU&\K]G[C(>TJ8
M$B?;'*N[>L(S7M+UMV[O#C;7D?(6!7<A><X:G1NW=J1$@E"IP$35]T6-E,36
MF5*\9H^.9Y$,5W+PSTGO,0K<I5  (>O!;HBH<R]]><[1=#E[U8:MK_=O'C!A
M8-FW.:V'?YYQ*:%L5@EYJVW.PKN):?FI::EW#A553)2%RI[$B)I$(F4 "S2
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M1_,VGE#P^O=W: AM=/;"^VK8-5IR2=<BWG/TQA*3Q,Q[1JY-AX?YSKX)E(X
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MX7>7-8+L7E_:5-B]B:*JULGUW#M]/RU1B5'K,KM=3!L-2HMB)HIMB)$  G=
M $ 'Y(7^PGI[_?\ ^)?[X6   G_  %2-KL6?M/2OY7_7.@)J2,TU+R-2M$:R
MOU5^=X62Z$YXXYV_); 9UJ4CE"*I6;5&P46#!9LAA5;[I9,^#DS[2F  Y#Q-
M5_S?4CQM\7Q?*%(\,Q-"2F@J#<J*XO6P.SF>Q9,E\B$;E/2^SF]0U>\K"6SI
M.RSCQ6PD8+N&B<N9P1%51,I3Y  V3Y3\1O4,SISR]:B[PM'.--K_ )/[DM?V
M5;XNL>TK#3]5WNX4B1KNS[XRCMPT.D/$IZQ61A"3"B657Z4@NU4(N=-/V%R
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MP=/:)MW7-PUC:6&=@=S."&KMTKS^MR6$&SS4+AEE9!E(&,C[TS$*H4N?3Z
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M0.[    K@_E@?\$KHW_2!SO_ 'WT@  :_P#X;?\ PD++_O@;D_S'T^  +7P
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M5.V,)%77^UTX5@DVBHF:GUZY*LIEFP238H/V'W"*35!Z@T1  L8
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M ":VY0:MGJ%JK:"Z;5>PUN<@T7*Q3'2;JRT8Z8)KJD)_&9-$[C!C8Q]<XQ]
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M]EYT[AU9YK?&XGSG9&T5K1+/\FE)V8A+)8E(C#QWG+I9K&H_)Z9+[<  27@
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MU=,;/8XR>YRVF8F,-V;9G<)AA7%T7RQ4D6T'9'"Q_C)DWH !ZF@
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MRJYRF5Z=J9!ODRB629  V&[>\<NTML]*ZJ[VXIZ B^8>U]5Z_D],2TY<:/\
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MDV*-PW=O[9CAH^V)LF<:QR9&D:64<,D&S%F4RYV<:T;I+.'2Y572P &]H
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M.)&G["JL%=*M(.(UVD_CEWM?LC"2B72S!\@19$RB)C)*D*<N<&QC(  UU_\
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M$\D4^V,5$5HVS1F@];&GHE=N8QTG$++/*\Y?0SC!C>N5&JB)S>F/=G/M+Z
M;]@ #XY&.CY>/?1,LQ9RD7*,W,=)1LBV1>Q\C'O43MGC%\S<D5;NV;MNJ9-5
M)0IB*$-DIL9QG.  !A_5?-/.6BY"5EM): TGIV4G6:,=.26J]5477LA,Q[9;
M+ENQE7E2@8AQ(LT'&?D(DL8Y"G_BQC&?J  ,V  #7O8?)'*>W+4K>MK\R<][
M.NR[=DT7N.P]+ZXNEJ6:QJ>$8YLK8;)6Y*64;QZ.,%0)E;)4BX]"XQ@  ;"
M                            -5^P^.-*]Q:>6TWNQA8$&+"R05^U]?Z'
M.JU#:^FMIU)95S3-M:AO+5!P]I>Q*DY74,S>IIJIG255;N$EVJZZ"@ &T3='
M#9N@W*HLKA!%)'"KA4Z[A7"1"DPHNNIG)UECX+ZF,;/J8V<YR  /V  &JO/W
M&^E>;]@]"[=I+2S6#;G46RG^R-P[2V'9'=RO,W@BSE&DZ\CII^1,\'JG4M>7
M)#U>";$3;1L<B7WY7<G7<J@ ;5
M
M
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M^7#W^6JH1XDFHL7*RKJ07135<*9PFW1;@$U@E
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
I                                                   !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>sny-20231231_g3.jpg
<TEXT>
begin 644 sny-20231231_g3.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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MS@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M]M8  0    #3+4A0("
M                     !%C<')T   !4    #-D97-C   !A    &QW='!T
M   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B
M6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3
M (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $
M,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N
M>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S
M4D="($E%0S8Q.38V+3(N,0
M                            6%E:(        /-1  $    !%LQ865H@
M                     %A96B        !OH@  ./4   .06%E:(
M &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:
M          !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M            9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M 5A96B       $P)5@!0    5Q_G;65A<P         !
M         H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \
M%  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "!
M (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /
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M_]H # ,!  (1 Q$ /P#OXH% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MUY#&F!$($L=*V?R0K$E; E%HDTB='(+K,TY11("RB!$S):O",L(;6+,L(/\
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M'GZ)R=J1/L:E#*Z1V0LCD2%2W/#&]H3VUV:EZ<?VAZ)P0*3"307^P( [VO\
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M2.X3 AU#?YZMRF_W ] /VK-BOX55 _SU;E-_N!Z ?M6;%?PJJ"*N[GJE]_\
M??5K+FHV9,,Z9L6-<S-3&T2=XQYCO-39-&\F/2V/S1N4Q]PE6PDQ8$BT#S&D
M_2-0VJK6+ZW5L$?5&$);^BF<5I7)[L,TEJ3 MJW0W(CBK1VO;L3UK7L'K.F;
MU([='3<Q*0[J0A^S^8<*@^G=0*!0*#Y/&S_^<T?A+;#^SK\>Q[/O;GEKR)Y*
M_#_\F^3?/T@\L>4O O\ Q)Y9\$[#N'<_Z%[KV?9?I?5H-&?_ -TU_P#C_O\
M^8I0/_[IK_\ '_?_ ,Q2@?\ ]TU_^/\ O_YBE!T2>F3_ !UGXPB=?C#OQH_L
M,_!9R+X-^&?^%C[)_:1[1L/> ^&>W#_R/\[^ >*]S[+^C^Y][[/]+[:@[UJ!
M0*!0<M'K!OXGMQ_?,X0_]I3*@^;OI%^,;\Y3/\6_^&S[0?+*;VA_@1>W7SEY
M-\5([GYS]A'_ ([\L^-]EV7?OZ%[UU>K^F=%!8LZM7JAWUL<61[;N>]X9GA
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M#CSAJD@?1_PQZB7TZ.N^+H5A7!^U$;QCBO';&ECL-A$3U6W ;F9E:TMKWZH
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MB4;6RLC2G2-K6W)"0V 4004646&W0$-K4'OJ!0*!0*"C3G X7_QRV/,"P/\
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M*!0*!0*!0*!0*!01VV<P/(-A\=$0>,Y_S;KB[(Y CD*>=X)?V>/2=6)&WNB
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M))&^242<22)Q9 $XPH*AUE$D4)4"8OK6ZYI]NF]K=-[5"]575[OCK4ZP]T\
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M$-L>5?.6/U6:L0:+X1QQCQ8VWD4"@NP>;Y.AS=D:-W2FG-RI#'XK"@L$.=9
M 19R=(^JD79 M<-S#0&%*!;LWOU4=E?@?B"W@OB[CG?>\N(;,SH=5JMU;MR;
MMVZ3.YT1?;=FY^IZ74696-M]^FLS.=./-MNMNRXS#5<,=6FYM=&Z-Z[YUFHU
M\7<W,S--I[)T^5?7&)NOS.=F1;C$W9<75Y(F)M97Q8<KD#Y*HO.$A<$6XJR[
MB\#*IF4*->021C<&1_&M3MDFBC_W!I5*T0EK::4K2J$I9R$P95NN<$T)E?*[
M4G94W[V;=Z:'-NU]F]>$=Z3F6Z?4QE]#FV9F5S9OR<_*YV9;;=S;[;LN^V^;
M<V(OGFV3;-KK=9/5GK>K[4Y-TYT:G=>IYT9>9S>9=%UM)FR^VMT1-)B;9B9B
MZ*X12BVFHG-8%!S,9:Y8\L;@\@$2XX=$Y^R85CCM)9S$IYM0NBS=/I(M5X[B
M,IE\T*Q5'G0P<<2-13?#UJ!&Y*0''KEAI9Y T9)83C[+N$^RCPIU0=0.K[1G
M7IN_/WUO'*TVFS]+N2W/OTN3;;J\_(T^GG79MD=-=?-^HR\W,R;)MMRLNV[+
MS+<Z^Z;+)#;KZL=V<*\#YO'_ !GD7ZS46Y>7?EZ.+YR[(C-OLLR^FNCY>9K?
M;==9$Q%ML3;=%\S2)09MXM=ED6/9--,"\HG(.KV#:&12\QYNR+FU,Z8>E4A;
MT0U%F W',=C4;01])(%!78$&=LM+1",",92BP;V%K'@GM1=6N=Q!IMR\>=5_
M5]9U?YV?&7FWZ3=LV;PR,J^Z(Z6-9G9V==FW943SKHYN7.9$3%M^76)C'-S]
M9'#U^NR]'OOAS<4;BNOBVZ<K3S&?9;,TYW2W7WS=-L8S%+9NI2)M:$X+.7#)
MNZKA,=;=DU#8]YE@L/'/8EDA WH&([(,-;W5I8GY!)&=L2HF,J6QY<^HC"SD
M)1 7!$<8(:<!B0X]1GG;E[)?#/4MI]'UC]6]N;D<':[6=RY^CNONS8TFHOLS
M,W*OR<R^Z[-G(S;<K,B;<R;IRLRVV(S)MS;,O+^WUS=5^[N$+,KB#A^+K-TY
MV;T=^5,S=T69,776S9=,S=S+HMNB8NF>;=$4NF+HMMZ0JKC:!*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!04E^H+S*+$W&GDQE2*PHW;-<R@.'VTRW3<X9+B[&3:1D%!M]
MCH6Q&#."<RXK=%BSK]'0*X;U-;XO[@Z.+.TGNS69MG/TFY='JMX7Q\BMF7&F
MR9GYW4:G*OBGR;8^15M_J-W3Z9]86GSKHKE:/*S<^?[EO1V3_<OS+9_9CD5(
M\'FOG)$PZIR#+>I4YU,A$)S7/78Y7?.$/R4_S1R-Q\)1$25*)9%PD- 8^D<@
MKP)R[]L*RCM[BO;IZEI:=MWK [..OZU-/PEULZ'BS7;[W+H,N+?2W4:/*TUD
M:NFHF+K<^N9TMUG13?/RL<SF4[RL[0ZXM^\ 9W$UFZ^)\C>>=K-'D6T[GS,J
MW+CI:7TF+ZW<Z8YM9PPYM.58M/N(#:3=:4QQWY)-['#(F/(JX$N[/@;7R"HL
M<P8ERNE*+4*+O;A;^B#@]90FLL5LRQV[HH,L0M26,N7:.VX.UYU7=2VZ]3I.
MSAP+E[NXAU67.7F;TWKJKM7J9LYTS$=%9WD?,7]'EZC+R.?9;-^3FS;%TX%H
MNM3AOA#39F5U?[EMR-?FV\V[4ZG,G-S*5PCFQWD=Y/-MS+;.=$<ZRZE5UV"L
M"XBUHQE'L/8/@[/C['L8*-"V,+0 X7:J5(NT7.KJXJS5+F]O;D=]NI6JSCE)
MXOLC'?HMT0LXYX\XNZRN)M1QAQOKL[>'$.JF.?FYE,+8PMLR[+8BS+R[(PLR
M\NVVRV.\MC%J+?6^]Z<0[QS-Z[YSK\_79G>W7<D=Y;;$4BVV/D6VQ$1\B'&[
MM!&V?D$]10QX6?FL,JQE!)K#\?R%G/$;9$NA.#X,?D/)K&['$G!NF;765)7I
MO'U#"AC"I" %PGF6JXKJQWEK.S_\7AG\9Z#-[EXFUVBU&JRLR*<ZW4[RU,:3
M19N7$Q\M?9D7:;-BL71$V3=,39;*5_#FHS>!NH:_>^1=T6\<[)S,VVZ.]C,U
M&9T63=;RS;9.7=WDTI,S\K#MJ1(F**,:9O;DC3&XU'FPM,C1(DZ-G8V-F:TU
M@%$)DQ $Z!L;&Y&3:P0A" HDH'1:U@VJE+.S]=O777:C47YNIWEJ,V9NNNF[
M,S<W,OFLS,S6Z^^^Z<9F9NNF?DS*(%]^=J<Z;\R;LS49EU9F9FZZZZ9[V9QF
M9F?[LRXL>"1A)V0Y9MK]KVEL*;X2QE9NR,TED( )R6YYSSDM47$V8E*(L%FL
MH416/0@V#U1@LD[*P;A$*X;G^W3K[^KCLG\*=5.KS9S-]9\[MTF9,W5F_+W7
MH[9S\R;J_+SW1;IHFN$\_G5K$5ESUT9\[@ZL=V<,YMTW:R^=/E75FLS;ILJ.
M?=7_ +7R\9?T5>]HN@Y[]VI%J+IO:*XX>C6++&QSVNQK'7A$>),[QR%)&RZ[
M),G9C@# <0Y$-RM&U$GE]!J4UY"H+$$TH%ZAGV#.I3=_6WUQ>FO$>3&?PIPY
MD6ZS-R[HKEYVINOYNCR<R)PFR;[<S/NMGY6^W3SEW1-M]T-2=2?!^1Q3Q9W3
MK[.?NS=]D9MULQ6V_,F:95EW+$S%U\Q.%T9<VS6)EZWT_NGL>UWT>B67W!G2
MVROL\2#),B>S4I=W%) ##U!.,8PD6B*+/\%%'0A>K@_,NL=S;7N,)95[=GM^
M=;^\.L/KOU?"&GSKO8IPQ=W'DY<73S+M5$1.MS[K:S'2=-73Q/\ %Y%N%LW7
MQ/)UX<59^_N,<W=67?/I9NZ>BMMKA.;ATU\QWG.YW_A_.V1WDS+..?C,9.).
M,S,3>!04G><QOT$PXP7-N"]C3GZ0$R>1IP%# +MC3H%#G<(>BX;EW_3+7^TZ
M+_#[!'!U_%O:6W/J)MF[1[GR-5O#-I\B,K*G)R9K\B(U6HT\SWM?F?DUCI=2
M.Z9WIUAZ3,F)G*TEF9GW?WMO,LGZ9F6?L]Y\EB/IX<+>RGC=A<I5M_<7G.N0
M)]E=<(ZW2L-;@N!&/HW<8A L(M$H88(2L3E6$(%@K+FVZ!&CM7U_C"N,_95V
MC];NO*S.?H]Q;OTNAMI\S%_,G5YU,<;HS=5=EWW4B:Y<6XQ9:[?7MO?TSX_S
MM-;=SLG19&7DQR5I.;?_ '8NS)MF>]^5IWD0K_\ 5$XYRHI9=2<WQ]J<'7&.
M-';(C#*%Q) W!IB<OE:N!+XHM?T @&I2D4D+C1Z4M0:&Y-SDX4YE[#/) 9OW
MXL'B+A;+UO%O!.\,W+RN)MY9.DS<BV9BS,S]/D6ZJS/MRKJQ=-V3.=;?-EL\
M[FWSF6Q,67S;F_9QU^[;<[>FY\^ZVW>.HMRKK(K2Z^RR,R+XMGO:V<^)F(QI
M/.C"V9B<>G//]I)LVSQZ%YM=@:Y96>T1#._,6220"Q*].ZD@!"\##D?I5,:*
M/KKFBL$,CLT"#TB)O<[H"8;I#KA[ O77U9ZS4;YX)RIXCX5R+YS,K-T<_P#]
M_+RXF9MZ71_*YMV;;2*SI.GB<+XYF-MF'<5]2'&'#N;F:O<]O=^[+)YUMV5X
M?;;$X<[*PNFZ/_*Y_+AC$6F:X:A:M:N%R]QUIQ!"<9%905-KW*5\0"J.+D84
M85I[*$E4K7N 4[$@"[J!HD:,12 BR@=R2@]>_3%SK&ZW>M'K0NTFFZR=[ZW>
M=^Z[;\O(MU'-B<GG<V,RMMMME<V[H[(S,S,B[-NYD1?=-(:VW_Q3Q)Q).5E\
M0ZK.U$Z:)MLB^GRE:1=A$16Z>;'.NNK=-(K.#DUP9(P<P7-^^3W(AX7_ %LU
MH*EDVA\7=#TA\4*QAB)_0,,% J*,-,:32IWD!Z1/[P2*ZD*I.:H3W$8D*#<N
MU[CC=T]D+L29&X>'K>Y^LCB6<C3:C/LBZ,^=;K\J[-U7-F(C,B=+I,O,TNGN
MCF39=;EYD1;FWS%TG-\Z?WJ^IVS1:".9Q!O'F9>9?$3%_39]LW9E/^U_X>5;
M=E63AS9BV["Z<>@/?+ECUYU>@$CC6,9RPYOVCD+4N9,489Q.L1Y%D?G)R0GE
MLCI+4<<$[$,3(T*1 5GIU-PK5I(.HF(-N/I# /J([*/6%UG[_P!-O+B;0Y^Y
M.J_3YMN9KMXZZV[29/<]ET3F69%V=T<YN9F6UR[;[*Y>7=/.S+[:4G1_!75E
MOWB/79>HWCDWZ/AO+NB[.S\Z)RK.CB8YUMDW\V;KKH^5B8^5MG&Z8HA/Z?7C
MAS-J#"\J9RV#8EL#GF;6^+L47QFXC+ _QB$L"AQ=3G29H06,NTR"1N*\GLF\
MP853>G2WLI  XX1)&ZOC .T9P;UN[ZW5P/U?Y]FOW#N3,S\W/UED3T6=J<V+
M+(LT]TTZ3*R;++N=FQ$V9M]__AS-ED7WY?UY<?[IXIU>FW-N*^,_1:.Z^Z_.
MCYF_,NB+:9<_]JVV(FMT873/RLS$5GH\JN9H(H*4]'N#K7+1S8U;LA$,A9)G
MTD0M\I:X"R3&S !MA266 5-[BK$L;6XEQ?GHN.*C&\M08,@'9'GC&4(9@+E3
M2Z[NV]UB]>'5U9U<;WW?NW0;NOS,B_59FGZ7GZF[(YM]EO-OOFS*RYSK8S9L
MB+IYUMD1=$6SSMO<8]<>_P#C+<%O#^JR-/D:>;K)S;LOG5S)LI,129I;;SXB
MZ8BN,6Q$Q$363'(]R'X=T%P=*91)I6R'9E>XT\D87Q86K)4R>72TQ*8F:7 ]
MH+ I4((<S.)I9[DXJ"PI2R@7) (Q2:209K7LY]GKC#K[XXTNZ]V:3/MX-R-3
MESO'73;,9.GR(NB[,LC,FD7:C,LB;<G)LF;YNGGS%N7;??;CO ' F]>-]\Y6
MFT^5?&Z;,RWNC.I2RRRM;HYV$3F716++(GG3,UFEL3='/]Z:'23*+%/)[NO/
M(\YQ: ...5^,,3!>4JMM53E5)'N-OS],F=,>44-9%6AOCH$9"O[*98H6F6)N
M,28=P3[^,JZZ^%]=N+0=2NXM1E:K?^7O&W6Z_H[K;[=-;DY>=E96GS+HF>;G
MYE^=.9=E_-Y=F7;SZ1FVQ.\.T)QANW.T61PAHLRW,UUNHC.S^;,3&7%EM]MN
M7=,=Y?=-W.FWO;8MBM.=%>Q6J?$4R@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4''5ZI[,O
M;/NJ.O:)0 /A[3.LRR5)VO6,,\86(81"%'8VO;L0$^!R$/6%87:7,Z ]7J"Z
MUP?Q6W!W,T/%?6!G6S_XF;IMWY-U,(Z.V[4ZF*_)F>ETDTBE*8UYT4E9V;=T
MTR=Y[]OCYJ[+R+)^=B<S,C_"ROV*;8ITC\=F&+Z^Z-:LXE.3B2N<:PU$%LC3
M" $%T\PEJ&TSFA/0'[%PE2R0K;6%?[(K6Z;_ &;WJN'M#\91U@=>'%/%EEW/
MTVIWSJ+<F[ET^1=W/IY_NY&5EX?([R,&@./-[>GG&6\MZ1-<O,U=\63RV63T
M>7_@6VIG5IIB3T4HD;5#HS(I<_*.ZL<68G>1O*KH#?NS4R-ZAS<5'0(0 W[%
M&E&+[-[6^Q^;:N]NO=VJWQO+3[IT%O/UVJS\O)R[>6_,OBRR/[MUT0YM-I\W
M5ZC+TN3%<[,OMLMCENNF(B/VY<:GITH\Z[!;[[B;ARA,>>N11^1.:LXTZYUD
MTZV+R,NE)RD9][!,5*K-,2=RKWO]K>QXA"MUK@O:X[XQ'>&EZO\ J&X/ZG]U
MW6VY%^HR;+8B*5TVZ-';D1%.\MMZ3/T]W+\K$1-*I9=?6?E;CX)W5PKIIB+)
MOMB,.]R]+E192GR(YU]D_P!S]ET:<LV<!:^<=NU$_2JC4CRNQHNQU&ST]KW5
MD2#+"M'C5M7)+V$"P%#0.4"6V'>_0"R:XN@71U;UU]D_@B.L#M#<+;@S;8OT
M=F\K=7G1/S,Y6AMNUE]MVS,Z",NGR>?2L5K&@^K'<_I[QYNW0W1$Y-NHC-OB
M>\FW)B<V8G9=S.;MK16#Z8K#B>(:<Y7S(<$GQC,V9E#46,JP!#O%,7,21L9@
M*3+6L8$X$DDKY>Q=_M0EB *WV1WJ3GQFO&.9O?KAW5P=9SNX]S;FB^:UIT^M
MS;K\R8CO*=#DZ;'O9F)B?F8;&[1.]KM5Q7I=TQ7HM)I(N_O\ZZ9NI_>69>/+
M6/D(?^JL:'Z[SI2_" J,C 6S.S0298PT:)&_#58J6* "*^R2F5.3>65<(OL"
M/ DO;[-B?L;>^*OU>@[CXTT$3;&\YS=V9DQ2(NNRHMUUL8][=;9?-U8[RV;X
M_?XY5V:LW(Z'>^1AW3SM-=MFVF=$;9B)K^QSMKIGT4=H^^:3ZB.<5/0J(^?K
M/@XILNVV) D3D(\:1I$)  @BUBT9K8<G$G-3] 1)C2A%""$0+AM6CUYZ3>&A
MZZN+M-O2W,MWA;Q+O.;^?7G3-VLSKN=6<;HOB8OMOQB^VZ+HF8F)1XXSRL_)
MXOWIEZF+HSXWAJ*U[V9G-OFM9[VM:Q/R8FOR7,EZI+8%G<W;6G69A?V]<XQH
M<PRSD9C1N!"E4SKG1$S1[' 75&G/&8W+3FD]\/ !0 )@TRDHP'VAG2*S'XKS
M@#6:;2<2]9>OT^99I]3&GT&DS;K)MMS+;+LS-UG,NF*7VQF1IK9FR9B+[+K;
MOEK:1(CLW[CS<O*WAQ#GV71EYG1Y.5=,3$71$W79O-F8QCG='&$TK$Q.,.JK
M6G$:+ >O.$,)MY)1)&*\502"F]E< [*%\<C;<VNJ\PPO[0Y0Y.9!R@TRWV##
M31"_U:JPZRN+<_CWK"WWQKJ+INOWKO75:F*_(MSLZ^^RV(G&(LLFVRV/D1;$
M?(1JXAWI?OO?NLWQ?,S.IU.9F?L1??,VQ^Q$3$1'R(A%W%'(QI!MGG#*6G,0
MF**<SR,I9<RRB(2F&K;PV<-\:6#8INVL2Q\0F,$Q1-Q@A!4$7M<*I+8PXD)Z
M<!A@=G\5]G;KMZI^"-U]<.]]'?H=PZF[3YF1J,C46]T::_.MZ737YMN5=&;I
M[KXI-EW>V7\VR^;,RZVV<CWGP%QCPQN;3<5ZK*G)T69-EUE]F9'29<WQSLN;
MHMGG9<S\B?\ LS2)I=,1-17+WPK:=M&M>:=H\#1@G .0\4Q57/%T=BJH2;%D
MR;VM2$]X:38<L$<CB[LK0'"+;KLPT*2RD!98TIG:7$&7'9%[:'7!J^LG<O5?
MQWJKM_\ #V]=5;I;<[/MKKM/??;3+S(U%M+L[+MNB)SNZ(S;^9-UT9MO-I.T
MNJSK=XKS>(-)PWOK,G7:#4YL9<77Q7.RYF/E;NDC&^V)QNZ3G74K,712B2/
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M<ZCASIN(YB/ELS-FW*F8B(B<SHIMZ:(C"E]D3,1$5CY'D[U^GGQ3L2VXX>,
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M8U H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MRT$EF44CR\Y,!84B?)"T-*LU(8:<26J+3+UB<X:89R<P%AV#<-Q %;IZ;7Z
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MEKLSQVS@C:;O3@C:E1YR9N\2<"".U%:P>U-"'\V]J"7] H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M8FV*'%E>U02W T;>I2K5"T]2BN6'5AO?R@:0<;$4:)/MYG%CQVME!*TZ%0-
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M<WB%R1*A<E#"L.L$)3FA[XVB-'8GO%C["*"%B% H% H% H% H% H% H% H%
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M+L^.N6<C1=0:ADT6U^AKEDXEA<DZBZ52TKYJ6<SXVN](CRS *41+T:J1F%"
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M((;7O8+[9IMQKW"=6Y)NBIR0RR76N,8N<,RJLGP$1D[9G/'38V&.ZF01X,8
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MV5Q9DV&*5SRK;W ].:UENS%#%S#($H2Q*!JTS<9?JV1F!,#JD]#'_P#!1/\
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MXTR:Q3Z6QM<XP)8<N4.# W*E$20.B4@D^P4#@8?9-8DBQ!186U>HZV&D&V'
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M*&'#>.'K7?&605\.C*M\4,EI;()'D)M=W1"F>W5U\)+6(V%(#NJ2Y*,%RNL
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MN86 VP?8:H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M7LMQ\:^O6D\-&W0R2E8X95#(R)8?F2,.R]4IF&.4,*4A8(8U'E(VI4F2-I*
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MQWO03CH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MHM^]WSI_6YAH+NO7$_\ )-QX?WQ-B?[&L2T%W7I<?XBC1G_V)G_GA[!4%_U
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M)*3)4J8H!"=,G( $H@@@@H(2B222@V"  ;6"$-K6M;HH/T& !@!%F!",L81
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MDDGIB7R*8^B4=>"DZH'9J2"G-H:$:TLE07]J8"P[!&'[%[7M0;3H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A
M_:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:U
MWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^
M^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0
M/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O
M4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?
M7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A
M _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:
MUWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR
M^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O
M0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#
MO4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D
M?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'
MA _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _
M:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UW
MR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^
MO0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/
M#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4
MD?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7
M'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A
M_:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:U
MWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^
M^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0
M/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O
M4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?
M7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A
M _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:
MUWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR
M^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O
M0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#
MO4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D
M?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'
MA _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _
M:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UW
MR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^
MO0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/
M#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4
MD?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7
M'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A _:UWR^^O0/#O4D?7'A
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M<.E$)G,69SW$#8C=UJ!];26IS:EJDTNP%+:M7$!$:$LP0#K#+"%F5 H% H%
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M@=8-?>I-P3IKFS43"=MW]NWO3;%D:V/:KQS(3'A2;YT423(#QC+)-FV&'1B
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M-<ON:]8U,$2<XGE/'P9:YH;J^U;H1(<E0.'Q6<KS0(33""6=<M,5%!L838P
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M9M?"LG9"2)'!>& N,=R'C";N;>TIDZQU<(]$LNPZ!R"3H&U(I"8H.;DZHHD
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M$6-[:2G4.3NRX_RU%H),I"QMQ2H%U"Y A4HR+BZ!F!O:]K!2IRU?Z1+P$_\
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M8\*B<'F);;LCD1Q+3*((ZR%6L$?#F,1*U 2688F,_H90%Z= H% H% H% H%
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MVFY*97'GS#')EE[4C';)B8Z"RK6V/MF3G+#^:Y"1)7N3I'C(X8/G_&* I,Y
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M.=&DEU3]Y*+.&(@9G4'U1V$&P=!/K2O\%;3#]\#-OW.3*"P;CXV_U6P)Z??
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MC<D9X_&XVPH2&ME8F1I0E$(FUJ:FY*60G(* $LHH 0AM:UK6H,BH% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MK- WA;TR!&G6K3J#KLH% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M_'(I%#'5*6H$D;T))JD9)%UAZL:<D8 T]FO@%TYSOR/,W*!+LE;+MV?6/+>
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MB?PM-L,83G64,A-V0\B*,F29^RDNBJEQ"^&,#-&"$+(FB<6C"1O9R&A@3WN
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MVO:]^FU[7KR,Z^8G79TQWG2W^"E5KGXYU_ST]^]GWA/^KD^^@]U74<1WA/\
MJY/OH/=4#O"?]7)]]![J@=X3_JY/OH/=4#O"?]7)]]![J@=X3_JY/OH/=4#O
M"?\ 5R??0>ZH'>$_ZN3[Z#W5!S1:X^GC3Z_<OTAY6OPR"9;X]GG:C-WL&]@8
M&'NGX3#)E]F\L^U'VWO7;^2O:MVG??+H/$NX=7L$O;]8D.EWO"?]7)]]![J@
M=X3_ *N3[Z#W5 [PG_5R??0>ZH'>$_ZN3[Z#W5 [PG_5R??0>ZH'>$_ZN3[Z
M#W5 [PG_ %<GWT'NJ!WA/^KD^^@]U0.\)_U<GWT'NJ!WA/\ JY/OH/=4#O"?
M]7)]]![J@=X3_JY/OH/=4#O"?]7)]]![J@=X3_JY/OH/=4#O"?\ 5R??0>ZH
M'>$_ZN3[Z#W5 [PG_5R??0>ZH'>$_P"KD^^@]U0.\)_U<GWT'NJ!WA/^KD^^
M@]U0.\)_U<GWT'NJ!WA/^KD^^@]U0.\)_P!7)]]![J@=X3_JY/OH/=4#O"?]
M7)]]![J@=X3_ *N3[Z#W5 [PG_5R??0>ZH'>$_ZN3[Z#W5 [PG_5R??0>ZH'
M>$_ZN3[Z#W5 [PG_ %<GWT'NJ!WA/^KD^^@]U0.\)_U<GWT'NJ!WA/\ JY/O
MH/=4#O"?]7)]]![J@=X3_JY/OH/=4#O"?]7)]]![J@=X3_JY/OH/=4#O"?\
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M?''-L+FS!DCU5TDSONML0]8(R7.L;.LD=$\>[_C?%\B<H%(XVXJE:\QH94J
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MXQ*G22(3&0Y*8!6$U,"Z818K&=6X;] 29H% H% H% H% H% H% H% H% H%
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M?HL$*^X?M1ZCWF&1.FRW&M)]:./725=)),SX&>,^M$>D^2\V1B*O[C'#YD^
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M >$Y,SY@F^?/2@R3+F2G93()_,^,UG5R^1+3.V<)(_MT7:F5QDCF;U06-=9
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MZVQ$X;#JS&\'2>,0%D0=Z6 Q#@-P8FA[3-Q"0)!80PO&Y*AW/$$N_62-1H0
MN,0;4&[-/>>;BGG>E6),N2C<W7O#;A'\31-)/L/9 R#'XIEN%R>-1MM;9/%F
MS$JQ6"?R\ML=4QI* YC;7%.YD! 8D$: 5J" 7IGUKEL5L1S1<D4>C+Y$\";F
M;<L:/!A+JV&,8Y.R8U>,POSE)UC>,0RU+F:W95:@JS2!FD$.XW)/8TPPLVP
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MTYV6]P,],=Q;2-,@5K6R"AXWI9)3$A7:B0,@-5)&P!5F=-P%@":\OZ-,"XQ
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M:HID6B+5NAR4@84AUPCO8H?5"8//MC+)&8^(/=G&F(<?3?*F1Y7 X6CBV/\
M&\4?IQ-I(K2Y=QXY*DK!%(P@='UX4IFY$<H, G(,$ @D8[VL$ KV"4G&5$Y5
M N-OCY@LZC4@A<VA>D&J$3F,.EC,XQR51.51S T!9Y#&I+'GA,C=V*0,3NC.
M2K42HDI2E4E#*- $81!L'*!I]%=Z-->)KG3-B>HFUUMB,W[JYMCVO,$;==,N
MK<A2EES2VQB !S!!XJ5$_&7R(1%@='%X)>B$ZAK[=N""XS+BL4,+M^,WA#T6
MP?H1JOCG8G1;4K*>>V[$D>?<RS/+VM>)<@Y 59+FUCIO,F1ZE<\ACM*7$F'/
MDA.9D0%)H;)T* DDLHDL "@!7MS/<<J?3_,'&UR-<6NBS<BGVK6SJ5OS?AW2
M#7!K127)&'9HC)6/;J]8^PO$D"U]3-S-''6/&K>S[0DJ66"8/LK6&2&/\LZ?
MD%QISL:3[PZ0Z&Y7W":<9Z'O$>>D88U+H/C_ *TIEVP"5]BSSE!U9D\?AF1D
M$:EJ98G9EW7=1#.*!W P1@0W"/>S6PG-ESZPU-H&P\5^4^,_7&>RB KMG,W[
M(J,A)U88%'925*@(XLMR-B; QK\3=VCZ0XUG86A[<E2I.G*4J$+>H4F4':IB
M?&<4PKBS&F&X&D,;X-B7'\-QG#$!PRC#D44@<<;8M'4AHR"4Q S$S.U$@%<!
M98+W#]@(;?8L&P*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!04M>H&F>QK!Q:["0'5'#.8LW9LV'3-.NK)'<*XXFF3)$Q17
M)PU27)\G>FF#-+LYLT=*Q@WO#?XF?8A&E<G%&$PWK& +,#WFHG"1QU8.U<U_
MQ%D_173'+.3L?XD@L<R5DR?ZRX3GDNG61$4?1>>).\2R30AU?'<3M*1JS2;G
MJ#;E)Q%E!OU !M8*GN2_0E1H3R/\57(GQM:3JT$-AF2GW!FW6*=)=;Q]D/$<
MXL)(NR&^8QP7#@IW Y-")3*2CW5<CL#OR%E)&H"("7J!(+<KECY@=/=CLP0,
MGA'R)N;K;YF5MN#<F:[R":+GF50U4B2'HG&=M&/H!LJ:W*+7*6IU!2UL8KC%
M<J]RBK"" X(<\8^JFX6VW,1%.6?(W' T<2V"<98"DF,R\-F#+C^0\_3B2LLP
MC=GR<PTN%XQ?5*ML0RXL]4YN\89;7)8VA,3=>808:E#43O*.4;A Y1>2_*&'
M>,#,G(=K?R'9/19TB+_@Q-/'%1&WTIXF,J 6ZO>-,69G71@YF<\IO+4O:'MF
M0F. D296WJK)K#NI"7>]D,W:VIV(]-!G_(6IV2HY/H;L=,<A[51;'&/IO,8A
MK3XS(< J"D^2)(UIY&AAS0E0L:BUG!U6)TZD2-08"X0@$ L+F.9Z SK*7%7O
M=CS&4+EN1I_+]>9HR1.#02./$OF,H>51::R5ICL9CZ-P>GMS4W#?LTZ8@TT?
M1]@-Z"L;V!YU_P U7_!X]BV6?;_^+S\E>PWV<S#VP^<N[]7RE[,_!O.OF;K?
M8[AW+O73_P"RZ"U;B$@\UQIQ=Z$X_P CQ"48_GD.U;Q%'Y="9M'W:*2Z+/[;
M%$"9Q9)'&WU(@>6-W;U +EGIE1)1Q0[7"(-KVZ*"KCT[6!LY82G7+^LS-AG*
M^(TF3.1O)\XQPJR=CN7P%/D"%.#Q*34$OA!\J9VDJ5Q=:4H+$2X(+J$A@1AN
M$R]A6Z0; X&SD\^J@T<V%9\,Y7=L!1+CDEL'E6<6W'<O78?C,U4OFX!R>(2#
M):5G-A;-*%!4F;1 ;U*TM6,+@FO8N]CRNN%-.)(YR%<'^Z.YYBSA-DW)^EV+
MV0EF;\-;:8D8) ]S-O8WB3'2)K3N$[C&%=A7B"=BL>0*%+4Z%L:HA\+5J2E*
M],$E3<)9X4;N5W9KU _'=N-NEH*ZZQ8U8-=]A8W'T\!1S7*4>Q3$'/'>>TL=
M:]B,SMR)7C1AR;*9._6[DW=HT*NYK$19R$I2;U1AVBT"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4%4W)Q_ZB/\ ZY/_ * UK/K%_P!3_E?YI#+M=?F]]?\ V&JGK62&10*!034T
M0_Y9'G^]Z]?U^B]9OP#_ %U?_1[O!6)*=ECX1M1ZT9WU?3+=:W$L&*!056;;
M<)O&'NY+7?(N?]4X>ZY-?E!2U[R5"'J88KFKZX%$EI0N4F=<;2&+ES!PNC*"
M3<YX*7C[,(+=/267< 16QGZ8OALQK*"I7?69XR J2+%*QM:,F9<R?*8NA$?<
MJQ2<V,@D[<SOR-$6 8"BG4I>"_:B$98P82AEA8MM/QK:1[HXEQQ@;8K!+7+,
M,XC>$S]C?&<4E^1</0^).:%C6QIN-;&;"\PQZENG:F%R4)4B<VQB=(4>98D
M.N+I#;^K.J.OVE.%XYKUK%CM+B[$,472!S9(HG?I5*32G&4OBZ1/JY=)9P^R
M:6O2I:ZN)E[#6KU B2+%IRK@3DE% #56ZO')IAR(L4#C>XV%4N8FG&3L\O<%
M .;Y+@2V/.,B1HD#X-.[XPF<*=U*5T3-J:QR90>:F&-.4/L^N6 5@TY-N&CC
M=R/JYB72Z;Z\+)#K1@N6/4WQ1C99FW84OR?)) ?)5+JK2S%+EA//G!&>=+W&
MX$2UU4H4_>;V*)!8!=@!+;5?4_ &E&&(_KWK) ?9GB"+.$@=6*(^:9K,NXKY
M2\K) ^G^/Y D<KDZKOSNO-.ZIRTP!77ZA=@ L$-@@CL+P.<3NU&9)CL!G'4A
MKE.7,@."=WF4K9<MY]QT!^>$R1,B\951[&F58?%BWA44E -4K*0EJ%A_6./&
M8<,8Q!:[&V!OBD=8(LTF.QS5&F5J8&PY_D#_ "Q]-;V9"0W(S'J52IS>I1)G
M8:9,&ZEP<EBM>M.N(Y0<:<,8Q! O=/BET%Y#Y+")?N'@7VOR+'+&Y1N&./M1
MS/C_ ,&97=>4Z.*+NF+LBPE"X=X7$A'VBHH\T'1U0B"'IM03B@4&BV,(+"\:
MP9K\#A6/(G'(-#V7OKBY>$1:),Z-@C[7XB[JW!V</#VEO)*[=4>>H-ZG6,,&
M.XA7#+*"L#4'AGXV=#,L'YQU0UP]E645,3>(,=*/;!GJ<]>+/ZQJ7NS7X+DG
M*,PCH>]JV1*/M[)+*"^RZ &!L(=A!E.[7$YH%R'NS3)]LM?F?(LXC\;20^/Y
M"026:PB<LT90.KP^(6)/(H1(H^K6,Z-WD"]04D6=Y2@.6'"L7UAWO05[07TM
M7#?"I*BDBO T[G@4"H"Q/'IUFK)#A&A&E=I<D"UM97M@,<TH#!A$(A4:<0;V
M=@F@&"XP#"^_'^/8'B>%QO&^+X9%\>8_AS60R1.$PIB;(S%8VT)NMV#:R,+.
MF1MC:C+$,0K%DE@#<0KBO]F][W"F'8[TXG$=LO.7+)$EUK%CJ8/JY0Y2%;A.
M;2G&#,^K51IZA2I5PIE<!P5$J4JE(S3CT+8D//,OTFC'0;MTNX1.-'0B7ILE
M8 UR:0960AN%LRGD:02/)\V8;C3G)##XFJF3FZ-,)7'I5)Q1RIE1MZH\DX91
MA@R[V!8-_P"Z_&]I=R)M6/V3<;#/MA:\6N$@=8(E]HF5L?>!+Y2F:DC\?VV+
M9U"%#GW].R)0]58-0 KLNDNP+B'<05^_YLGP@?XDO_OR6W/W_*"8VF'$AQ[\
M>TZE62M0-?O9%-9M$[P:3O7M6S=/O$XM=X;7^[7X=D_),U:47_C9H3F]NG(*
M4?I?5[3J"$$0:VW7X/\ C4W\FJC*.P&O:.^6UQ:0EVRGCB323&LRD)*%-9&F
M\V&15R1,<Q6$(RR2"UCJA6KBDZ<HDLX!)=BZ#V6D7"IQO\?$OODK7'7U"@RO
M9"H;4^59])9-DF<-*)8G&C7%Q=;+W1R:X4<X(SC2%1[*D;U"I.<,@XPPD79T
M%JM H% H% H% H% H% H% H% H% H% H%!DD6_IF+_P4W_7E4&Q*!0*"*.R>
MD&KVWLGP#,MB,8^T*2:NY1;,SX+<?.F0XGY&R6S.#*ZMLD[G!Y9&4$F[LOCR
M,SN;P4X(!]CU1$"",=A!*Z@KUC_%7H9$<[[![*1#!AT1R]M9%Y;#=AW>)Y7S
M9&8KE5AG39X5+"Y)BYCR.@Q79S>0",4C<$S*0X@<SSG L\"X\Y0,(.,_IA^#
MAA=FM\:=(>Z.K*XHG9M5?A*;>G]V<&Y24L1J.P4Y^.3G=BI)"+J& & 71T"M
M>W3:@L_V3T@U>V]D^ 9EL1C'VA235W*+9F?!;CYTR'$_(V2V9P975MDG<X/+
M(R@DW=E\>1F=S>"G! /L>J(@01CL()74$6=P=*]9M^,/&8#VSQI[5\2G29CF
M)D3\Y3^"]:1QNRP+*X^.XUE4.DMNY6<#OTFRRQ!G7_3 "Z ] 259VEO86EK8
MVE/W1J96Y$TMJ7M3S^[-[<F*1HT_;J3#E!W8IB0AZY@QC%T=(KWOTWH(6Q3C
M<TN@>X4NWW@F&A0?:O(+8K9Y_D>&9'RS%&B>('!"B0N!<UQ8P3MOQ!+#G 38
MF5J#G!@4'GNB<IP&,2XL"@(1;V9X"N);<7.,\V1V.U/]HN:<FJ617-YG[=ME
MHCXVHCL998>S&>78)F2,11M[G'(\C3]"1"G"9V/:#L(T8QB#+]/N$;C!T'S"
M7GS4S63V49:)C+Y#BY9[9]A)UU8Y)+HQ/3=X%DK+$QC5^^W;R?TZZ.YY?4_2
MQAZ1=(6L4$6=?]*]9M6\A;&94P3C3R+/=M,D&9=V"?O.4_DWG_(9JZ0N1DA\
M+F,JD+-%>LME:\?=&1.VH;=XZ+$]4!=@ U_TKUFU;R%L9E3!.-/(L]VTR09E
MW8)^\Y3^3>?\AFKI"Y&2'PN8RJ0LT5ZRV5KQ]T9$[:AMWCHL3U0%V 'AY;T:
MU:SIL3@';#*F+_-.?]7O&_87/O.V1&3R/YC"(+S_ .2T<ES1"I-WP(K_ -.&
MUP[/_L.K0>9)]*]9IEMKC?>B28T\2VGQ'C=WQ%CW*/G*?H_+^/'T<K,=8]Y)
M02I+CIV[T.;NE^]KFA2N!WK[0X/9D]F'F[;Z=ZY;UX7=M>MJ<=>U/#[X],$A
M=(AYNG<([T\1=>!T8E?C^.9/$)01W%<"P^S+6@*-Z.J8$8?L4'IME-&M6MOM
M=D^I^Q.+_:'@!+Y,[" ^=LB1+L_9Z)**(?\ E3!I=&9J+P@2,O\ FG*_>.K^
MG]ITWZ0\C:#276+<W (M7=E,9>TC!0U,25B@WG/(,/Z5$&.(418SS- I7%IA
M;PLY,"_1XAU3^KT'6,M>]KA7X[^G0X5'O(R;*:S0/%Q,F2+25Y38T2G+3!CD
M9Y S# %J</,60VW$:U$(1M^NF.8S$Y@;6L, K!#:P6N2K"N*YEA>3:[O,(92
M,)R[&3YAMYQS' 'PV/AQA(HNJA;I#60$//8E46:KQ9:8B3^%FHS415P]W&4(
M !!#T6N&N.&=1\)0'737N&^S[#>+VY>TP:'>895*_ V]S>W.1+D_F&;ODEE3
MGV[R\J3NNL7*!A[3J!O8 0A"%<Q' 'P^(\_)=FV[1[';/EU!+RYXW+F.6978
MX(V2T@=STKPUX9:,@(L,MIB)9T*DY1$?+(3K  4E@"> )E@E9N;QP:/\A#"R
M1[<77.#9K)C(3RHP^.HW^,3J,)EBI(M7H(SDB"/,6R#'FQS5("1JTJ-S(3J[
MEAL< =K=%!C>F'%EQ^\>IKRMT^UA@>'WZ0HA-CS,@+)7.\A+F@Q8)P,9#,CY
M,D4SG8&$U;U3!H0.(4@Q$E7N7?L2NH&V9/I7K-,MM<;[T23&GB6T^(\;N^(L
M>Y1\Y3]'Y?QX^CE9CK'O)*"5)<=.W>AS=TOWM<T*5P.]?:'![,GLPE-0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*"*>XFD>L6_>*4&$-M,;'96Q6VS5CR&1$ SO)$!2'RN-HGA RK71=C*7PQ
MV>D",A]4W\/6*#VXPZY9IA C22!EA*9,F3HTY"-&02E2)22DR5*F* 0G3)R
M!*((((*"$HDDDH-@@ &U@A#:UK6Z*"(VW>A6IV][3C)EVIQ3[3$N&L@(\I8P
M5(YSDG'3Y#9VA3&)$SZU27%DQA,B^U+&$0DIJHQ&8<22:,H1I!(P![4C276)
M-M\LWS)QEU-KU^*@X25Y5\YY!%VN, +4KB&,^1ARL6-B^A8B*'WT+.%P^UZ.
MWZM[VN'Y[5Z0:O;MMV*VK9[&/M-083RBR9GQB1YTR'#/+.2XX0I3,TD[7'TL
MB9SSW,E88'N;@)6@,ZW280*]K7L&[LL8M@F<<69+PIE)B\T8RS!C^98MR+&O
M$WAD\Q03($<<HG+F+QF.N#1(&CQ>/NZA/WI"K2K$_:=<DTLP(1V##M<]=,+:
MAX0@>O&OT0#CO"^+&QP;(3$1R.4RD# VN+RZ21P*%(YP^R24.(37=X4GW&M7
M*!@L9U0BL6$(0AS.\.+0T\C_ "W\C?,V:SMQN(H0]%Z3:;NQ#6F+2R9DA;0Q
MMDWRPE<"[!/7N+M$VMNNG5C&?>R.5JT76 !(66 .M$8 & $68$(RQA$ 8!AL
M( P"M<(@B"*UPB"(-^B]K_8O:@I<GOIW.%_)645&895H;C?SHL>@R!83&IAE
MZ"058Z6<3G4PU9B>"Y%CF*E:94M/%=0G,91)E)=^R-+&5:P+!;ECO', Q%"(
MSC3%<)BF.,=PMJ3L41@T'8&N+Q.,LR7K=W;&-@94J-K;$18AB%8LDH ;B%<5
M_LWO>X5?9\X'.)#9S.3GLAFO2N RG,#\^)I-)I$URW*L$9Y?(B%_B9[[-('C
MV?17'LS=WI?>YCJI=&I6<\"&/OPE%ABM<)=K=$=4E^SF(=QU&)R;;&X&Q(HP
M3B7(":8Y!1)X?BA41)DQL1(@Z*6)\>.A/=Y@X@ J7M*I>6%1:P#P]F5V82YH
M*;\T^GXX=-@LK..:\H:-8[79$>743Z^.,1EV6L6L$@?#G,]Y7/,A@F+,A0N!
M/[J\.:HPYP4+&P\YQ$,5E(C;7O:@M&Q!AO%&O^.8OB+"&.H=BG&,+06;8O!8
M&P-T;C;,EN8,X^Z5L;"""!*URHT9ZI0.PU"M28,XX8S1C'<.(_T[W$+QP\A7
M'%+IUM[JY$LL3EBW*SBR-\X3R?(V-YI=C:F2#'-K$XRS$\S@L@>F-">_*S"D
M:Q2H3 ,-Z]@=8 +A#LCU5TXU>TAQF3A_5#",&P?CX*L#BN:(<W&A7R)X C3M
MUG^92=T4.,KG$DNWHR4XG)X7+EXB"0%B-N  ;6#UF(M)=8L$9^V$VBQ3C+RK
MG7:E3&E>>ISYSR"^>>U$/)5)XZ9Y9DDK>(?%_#B5IMNAF;VX)W6Z3;#O:U[!
M^>P6D&KVT^3=;,Q9XQCY[R/J'D [*6N\C\Z9#C'L]G:ASB3P:^^$0V61YBEG
M7<8*U&=U?$KFCMW7JV*L$TX)@>1GC2O6;9K*.MV:,WXT\[9+U&F[ED?7F2^<
MI_&_9],W=1&53@\^#Q&5,#!+.\'PYM%W=\2N20'=N@)0;&&V&&8[$ZQZ][;8
MX68BV7P] <V8W6KT;L**9!CZ-];TCPW]K9"]M)IX++6-\1EGF%EK41I"H!1I
M@+&6 8,(@KBP'Z?7ASUGR"SY3Q+HUCU/.8ZO0.T?=L@S'+N;$K"\-1]U;4]L
MK#FS(F0HZU/C6ML$],M(2%JDZ@LLTLP)A98@A<E00WW8X_\ 4;D5QO&<1;CX
ME]L./(?-TF1XY'_/F3,?>'3-"PO\92O/BV+)G"'Q7V3')UQ'=SU)J07;]>Y5
MS %C %9/^:X\%'^(S_[\SN'_  @J";)_$%QNK=/XMH6[:K0R0ZJ05UDS_!L;
M2J0Y!E;E"9#,7B0/TBD4.R;))@Z9:BTB7N4J<;A7H'U.L()5C(),+(Z"[!IF
M"^G^X><;8QR7B*':/X_;8CEYFM')XO5S++C]D5QCWB[.^FL+1F*0Y#=<NP]E
M5NK C-4)69\;R%/8V :$8!""(+"W+5?7E]UL;M/Y+B>*2_6EKQE%</),1S9.
MJFL;%CR#M+2RQ!C6FRM4\.[FICB1A1&)'!2I.<R5B0I791WH 3K!$#3?ADXS
M^/\ R4Z9BU)U=9<59-=V51'5,R/R)F+(CNF8UES!+VIF'E/(DW(CR)RN9;O0
M$ $UE79$]KU^Q)Z@-N>%_B_WJF1V1MH-/L=SW(BPQ :[3]A=IWB:<2(QL1J6
M] *5R[#DM@$@EO=D*GL0V<U"NW9$D!OTV3)[%!LC3;B[T X_3E[AJ#JYC?#<
MC=6%5%72=HBWR79-<HNN>4TA6QEPRED%YEF15L=6/:!(I-0F.@DIAJ%)<0+]
MT3=D&T=?]*]9M6\A;&94P3C3R+/=M,D&9=V"?O.4_DWG_(9JZ0N1DA\+F,JD
M+-%>LME:\?=&1.VH;=XZ+$]4!=@!E.RVK.O&XV*7?"&SV(X=FC%KTK2N*F*3
M) -22C>$ %!2!_87-&<C?(O)&\E8>6G<FU2D7D%'F@ :$)@[""NW&'I^.';#
MD7R+$8#H[C]"VY4B$F@<P='V9Y>G$TO%)BUELLE:HKD6<Y$DF0,>>*M1=R!G
MQYS:U("S3; ,#VQW7"3N0>,G1_*>FT1X_9YA+QW46"(HBWQ7$OM)RZU^%(X(
MN\2BA/GQFGS=DU=X4M^WZREZ.$?^8=<P/V*";,<CS/$H\PQ2/)/#V",LK7'F
M-!WA4K[DSLJ$AM;$G>EQZE:I[LB3 !VAQAAH^KTC$(5[WN'Z/K$QRAE=HW)F
M9JD4=?FY8SOK ^MR-W97II<4YB1P:W9J<"5"%Q;ER4T19Q!Q8RC2Q7"(-[7O
M:@I@REZ<GA0S!(C)3+-!<:M#F8)6(27%LRS%@Z.VNM5FK3K%P_"F2,?Q(H(#
MCKA*L%#:Q!-@E%6 4$(+!.33[CMTCT%8W1AU!UMQOA(#ZF1HI%(&!O6O$^DZ
M%O"79O;Y5DR6KY#D23MR$PNYI*=>Z*22E!AIP0V-.-&,,[VDTZU=W8QW;%.U
MN#L?YR@I*T3FV-,W9@JUD==QIC$0WN(2)&8BDT,?A(CC"+KFI8C5W(,&7VG4
M&(-PA%K)P/<2.GV1FG+F!-*L?Q_),>=6A^C$NF<JRGF9TB+^PC5G,S_#;YKG
MN0T\/?FY2L$<4M;"TJH)Y9)O7[1.0(L)@8DT:U:P7L3G[;#%>+_*V?\ :'P3
MVZ3[SMD1[\\>7 A"S?\ DM(Y<[PJ,]S"&W])VUO[3_L^M08IN-QNZ,\@#6U-
MNX&M6.\U',*(YLC\F>"':.Y CK6H476*6J.Y+A+I&<AL+4I5W[8Q*C="2##?
MMQ N+[-!HC53A$XJ=*)T@R=KCIEC>(Y&9EHG*/3J5O$_S%+(HY"**(\2AK_F
MF89"<X:X@(*Z@3VLQ(: )AM@BM8XWKA*HC276)-M\LWS)QEU-KU^*@X25Y5\
MYY!%VN, +4KB&,^1ARL6-B^A8B*'WT+.%P^UZ.WZM[VN$J!@ 8 19@0C+&$0
M!@&&P@# *UPB"((K7"((@WZ+VO\ 8O:@I<GOIW.%_)645&895H;C?SHL>@R!
M83&IAEZ"058Z6<3G4PU9B>"Y%CF*E:94M/%=0G,91)E)=^R-+&5:P+!9_P#@
MYX ]B/X-'L3Q5^#OY4\C>PWR#%_9/Y._-\L^0/#/+'@O7^W[#NW9]I]OT=?[
M:@J:-]-;PAG3:T_'H7#+/MG$ETL@*RGL 1">\D%@+ 5?&I&6B\<B;A!+M<:.
M[5W0P72(98A"O>X63Y>TIU8SEJX[Z4Y"PQ%QZKO4?C$44X5A)KSBB)(HU#9"
MR2J,,<?OBETA;K%6QG?HZC/+);%*0%[$]F*PBAC (/QR=H]J1FO7Z#:L9CP#
MCO*^ L9MT*;8!CK([0*;((@#'4=%$88XL3M)#W*1H)$R18XYN"Z@66<SD2I2
M2:>86J4!-"OK$OIT.%G"<[;<D071" J)0SG%*6WVA3_-F8XTF5$+TCDG5A@N
M7\FSJ#&*TZM"7<LT;<(PL'6 &]BS!A$%UH  + $LL(0%@"$   #8(  #:P0A
M"$-K!"$(;=%K6^Q:U!_5 H% H% H% H% H%!%?>F//\ +M)-Q8I%&-XD\ID^
MJ^PD>C4:CS8M>G^0O[UB27-K,QL;,VD*7%V>'9Q4EITR9.68<><8$  B$*UK
M[2ZC=X:#='79P?O7>N?DZ7=>EXIW3FYV=FWVY>5E967K]/?F9N;F7S%F7EY=
MD3=??=,6VVQ-UTQ$3+)>#,_(TO&&Z=3J;[,O39>\M+=??=,6VVVVY]DW7773
M2+;;8B9F9F(B(K.#YM/XO7?K_$>W _R:,T?VE5Z0?U@^H3]-^$/OSN[T2L ]
MG7!'JSNKS7I_'#\7KOU_B/;@?Y-&:/[2J?K!]0GZ;\(??G=WHD]G7!'JSNKS
M7I_'#\7KOU_B/;@?Y-&:/[2J?K!]0GZ;\(??G=WHD]G7!'JSNKS7I_'#\7KO
MU_B/;@?Y-&:/[2J?K!]0GZ;\(??G=WHD]G7!'JSNKS7I_'#\7KOU_B/;@?Y-
M&:/[2J?K!]0GZ;\(??G=WHD]G7!'JSNKS7I_''TMF=P1$M#64:J(+-*;D)9A
M8S A$ 8$Q01@%:]^FP@BMT7M_P!6O+MKKK;M;G76S6V<V^8G9SI5OYV.=?,=
MYSI[]['Q1N^[4WOH?SZZKCI)XHW?=J;WT/Y]"DGBC=]VIO?0_GT*2>*-WW:F
M]]#^?0I)XHW?=J;WT/Y]"DGBC=]VIO?0_GT*2>*-WW:F]]#^?0I)XHW?=J;W
MT/Y]"DGBC=]VIO?0_GT*2>*-WW:F]]#^?0I)XHW?=J;WT/Y]"DGBC=]VIO?0
M_GT*2>*-WW:F]]#^?0I)XHW?=J;WT/Y]"DGBC=]VIO?0_GT*2>*-WW:F]]#^
M?0I)XHW?=J;WT/Y]"DGBC=]VIO?0_GT*2>*-WW:F]]#^?0I)XHW?=J;WT/Y]
M"DGBC=]VIO?0_GT*2>*-WW:F]]#^?0I)XHW?=J;WT/Y]"DGBC=]VIO?0_GT*
M2>*-WW:F]]#^?0I)XHW?=J;WT/Y]"DGBC=]VIO?0_GT*2>*-WW:F]]#^?0I)
MXHW?=J;WT/Y]"DGBC=]VIO?0_GT*2>*-WW:F]]#^?0I)XHW?=J;WT/Y]"DGB
MC=]VIO?0_GT*2>*-WW:F]]#^?0I)XHW?=J;WT/Y]"DGBC=]VIO?0_GT*2>*-
MWW:F]]#^?0I)XHW?=J;WT/Y]"DGBC=]VIO?0_GT*2>*-WW:F]]#^?0I)XHW?
M=J;WT/Y]"DGBC=]VIO?0_GT*2>*-WW:F]]#^?0I)XHW?=J;WT/Y]"DGBC=]V
MIO?0_GT*2>*-WW:F]]#^?0I)XHW?=J;WT/Y]"DGBC=]VIO?0_GT*2>*-WW:F
M]]#^?0I)XHW?=J;WT/Y]"DGBC=]VIO?0_GT*2>*-WW:F]]#^?0I)XHW?=J;W
MT/Y]"DGBC=]VIO?0_GT*2>*-WW:F]]#^?0I)XHW?=J;WT/Y]"DGBC=]VIO?0
M_GT*2VL7*8Y8 +7>VVU[ #TV[V5_U+?_ %5"DOZ\TQOY[;/C9/NJ%)/-,;^>
MVSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_
MGML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQ
MOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-
M,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23
MS3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4
MD\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ
M%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[
MJA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D
M^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C
M9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VS
MXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GM
ML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY
M[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;
M^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3
M&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\
MTQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)
M/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA
M23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-4;^>VSXV5[JA23S3&_GML^-D^Z
MH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/
MNJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV
M3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^
M-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;
M/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>
MVSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_
MGML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQ
MOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-
M,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23
MS3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4
MD\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ
M%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[
MJA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D
M^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C
M9/NJ%)/-,;^>VSXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VS
MXV3[JA23S3&_GML^-D^ZH4D\TQOY[;/C9/NJ%)/-,;^>VSXV3[JA27ZDR-A4
MG%D$.[><<<,)911:DH0S!BOT!  -A=(A"O\ F6H4E[FU[7Z;6OT]%^B__P *
M_1:_1?\ ^)>C\?[0*!0*"M/D0DZ.-^R#O<-B<M[Y[0.S\T$OQOA_=_)/7[CX
M(_L?5[WV]NU[7M>GLP=7J_;=;7G'FILT_<G/R<K-KTOS?.PIT?><VZWO:XUK
MWD=XB;VH=\9&ZO2/I]!HM=TG=M.Z(SIYG-[DKS.BSLGYJORW.YWS-M*8UK3]
MIS-_<<Q-\3G?]OU:]],<GRII?VLWQU$WV7Z#U!W)]#K/1A[3F;^XYB;XG._[
M?J>F.3Y4TO[6;XZ>R_0>H.Y/H=9Z,/:<S?W',3?$YW_;]3TQR?*FE_:S?'3V
M7Z#U!W)]#K/1A[3F;^XYB;XG._[?J>F.3Y4TO[6;XZ>R_0>H.Y/H=9Z,2MT\
MEB*3Y0=FY%!X7#S00EU57=8J1(RG(T!;S'B[HC!/<E?$G=#;G6&*P20F=8L/
M0.UNM868<$ZO+S][WV6Y&3E3T%TULY]?FK,/EK[HI_<KM2 [-V_]+O/CW/T^
M3NS=VCOC=>;=S\B-1%\Q&=IXYL]+J,VWFS6LTMB:Q'RT16)LN\./^=%_Z(GX
M*MJIRGAQ_P Z+_T1/P5 \./^=%_Z(GX*@>''_.B_]$3\%0/#C_G1?^B)^"H'
MAQ_SHO\ T1/P5 \./^=%_P"B)^"H'AQ_SHO_ $1/P5 \./\ G1?^B)^"H'AQ
M_P Z+_T1/P5 \./^=%_Z(GX*@>''_.B_]$3\%0/#C_G1?^B)^"H'AQ_SHO\
MT1/P5 \./^=%_P"B)^"H'AQ_SHO_ $1/P5 \./\ G1?^B)^"H'AQ_P Z+_T1
M/P5 \./^=%_Z(GX*@>''_.B_]$3\%0/#C_G1?^B)^"H'AQ_SHO\ T1/P5 \.
M/^=%_P"B)^"H'AQ_SHO_ $1/P5 \./\ G1?^B)^"H'AQ_P Z+_T1/P5 \./^
M=%_Z(GX*@>''_.B_]$3\%0/#C_G1?^B)^"H'AQ_SHO\ T1/P5 \./^=%_P"B
M)^"H'AQ_SHO_ $1/P5 \./\ G1?^B)^"H'AQ_P Z+_T1/P5 \./^=%_Z(GX*
M@>''_.B_]$3\%0/#C_G1?^B)^"H'AQ_SHO\ T1/P5 \./^=%_P"B)^"H'AQ_
MSHO_ $1/P5 \./\ G1?^B)^"H'AQ_P Z+_T1/P5 \./^=%_Z(GX*@>''_.B_
M]$3\%0/#C_G1?^B)^"H'AQ_SHO\ T1/P5 \./^=%_P"B)^"H/>1]G5'KQ  ^
M.B:_=S!=H0)/8=[6$7;J_;D"MU;]/_4_U*%6;>6UWUK?_?$?R2A4\MKOK4_^
M^(_DE"IY;7?6I_\ ?$?R2A4\MKOK4_\ OB/Y)0J>6UWUJ?\ WQ'\DH5/+:[Z
MU/\ [XC^24*GEM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_?$?R2A4\MKO
MK4_^^(_DE"IY;7?6I_\ ?$?R2A4\MKOK4_\ OB/Y)0J>6UWUJ?\ WQ'\DH5/
M+:[ZU/\ [XC^24*GEM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_?$?R2A4
M\MKOK4_^^(_DE"IY;7?6I_\ ?$?R2A4\MKOK4_\ OB/Y)0J>6UWUJ?\ WQ'\
MDH5/+:[ZU/\ [XC^24*GEM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_?$?
MR2A4\MKOK4_^^(_DE"IY;7?6I_\ ?$?R2A4\MKOK4_\ OB/Y)0J>6UWUJ?\
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M/Y)0J>6UWUJ?_?$?R2A4\MKOK4_^^(_DE"IY;7?6I_\ ?$?R2A4\MKOK4_\
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M/Y)0J>6UWUJ?_?$?R2A4\MKOK4_^^(_DE"IY;7?6I_\ ?$?R2A4\MKOK4_\
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MQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_?$?R2A4\MKOK4_^^(_DE"IY;7?6I_\
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M>YH'=T_Z@3[T#W- [NG_ % GWH'N:!W=/^H$^] ]S0.[I_U GWH'N:!W=/\
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MC7'D.T=V\DS["]9]I\+9GF,;1C<W>)PJ:M:^3$M)1P4Q[TE8C3$[HZ,:908
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ME%_#/,N1<I3*.8_@D=\;>&^.LWCLNECDT1]H\7D#ND0I>\*"^\+%11(.L88
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M0]B:(M$HDQM,9BT9C[<D9V".1UA0)VID8F1I0%$(6MH:&Q*4G3)B2P$D$EA
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M++>.)'(/:[G?(/B,,7,P9,J9O"<IY/F[&D[5\C"$_O!"8I6'L.I8VQ8S #"
MWIKY]),4^G@C.48;CM\R]+\;(-R)]%<3QD2\,DRA)(=/<DR%CQW'Q-3')G0+
MY-71N*;4ETS:X'V/4@[-,>/H*&&E_P#..^4W_P#-C]__ *1V*_@ T'KN>?NG
MX\;T[OGW_DY]N[CX%XGV7@GM!]L.%>Z]AVWZ5XCX[Y:Z_3_J]W_U>B@[#J#C
MU]2?V/XQWT[GD?M/;9^&RK\ \)ZOB7ECVQ:G]OXQW;^B_"O$_P#8>V_H?L>_
M]'VO;T%_W*\;J25QV;9?ARB3VUE-Q,]E3X/00)\&O&-/>#!@@5%A!%DP,^"V
M"C-[6Z0OH4HOL6M>]@XR?2]]UCG(7&V#D*19/1[8'Z)XO-XNC,UJB#&9+J.Y
MM\M=W!#BE,J :(EW7X]47$RB3F!$1'B)"EZH+6/+H.EGU!_*)*>,S4"-JL7'
MHHSFK9J=VPAC;+DB1*W2%8&"L;A+Y=F62,C2SR>0213"X_<1S:W(FIP&:M$$
MX9"D">Z%6'.[.N1#@CUPX1=KM#M4-R%>9MC,W8;FBJ<SY_U^VGC\VV5V+F:=
M&.1S>62J=8?1M38)V6E7*0%.3M8AO0%%EF*#3NV4'!:=Q!<@NJ&P?"LLU#P=
MEPR7;,ZS\;4Y]KV/28%DU@.A*TB"2=C*[*62B%LL%DA@7M824'PES7]-Q=;^
M8M<5@V=Z1D"0/#+C82<(0G&9QST-?<(16N-7:8!+ (=Q6Z!"LA 2'IM]CHM:
MWYMKT$;=S.M_GB7%7Y;[3Q;\!6=>:^Q['N7@WE+D"Z/$.P_3>^]S^Z/M?^\^
MI]GJT&R,1?Z8!M+_ -%Y'O[(-<Z#JYH%!QW^J$P6GV=V[X)M=ULUE&.4&:ME
M\WXU<IS"3P)I=&6R6K-;&AS=(XH-O8DAW*0*3+$#,L,L(Q6N, P](!!'GFD]
M.=QFZ8\4V;MA-9<=Y @6P.N;=CR6LN7'7,&2)6]3:Q^3H?%WQ',8X[2$>/TI
MBUED9YJ<]B9V0U*O(3F!O<H)Q)P25X]?37<;VS6D&$-GMPD>=]I]E-R==\29
M^G6:<DY[R<@E</EN9L6,TR.M#P1.2,B%[,C8Y*2 I3+2Y.8K/0 ,-MV!@TE!
MMGTE\JF35I%M3KC+)4ME,>U'WJS3A_'3@YC#:S3""FB)/JEI3"Z"[$MPIDL=
MW2P1!MV9KH9:U[ L$( JIX\N:7C19>6;E*Y&=U-FPX]D62'QBUPU!:[8MS;D
MI.7K-!EX4:R1HEF*<7SAD9B9F3 (NL 0(],?WH2\T83N\W.N&[N K>/5YMYL
MN2S635+*Z#).IF["];M=KR\%Q:>01.VY49@VE^3,?LT/R+&(9(VH137.WPN]
MQH;D&-L.2")'U+WM<,^Y@=.(-OOZD70[5W)\VR9!\:Y"X\Y@;/5.)I*7$I5)
M8O&YCLW(G&"J'HY"YE%1F9V; H'8JZ<RY[>::6"Y8Q!- &(<UW 1HIH3H1*M
M[./>*SS5[9?3>18PRA'YNP9ERQ+#I<'VC0F)JS74O(LNF9#"_,5WJ[PWJ60M
MK"):GN0< :<T(20Z[M-,S.6QVG^J>PSTE"A>,\:V8,S,[(0 *+ C<LH8PB\W
M7I0ED6L0 *=4^#!:P/M+6M]C[%!).@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4$1.0/_ +W<_>B;)_N-32@X:>%;6SU)V0
M^.3!LLX\^0/43!.ICDZY:!C?&.587%7><Q]:AR].$$Y.=W!STCS(M.+>9VF<
MEJ:PY"MZJ906&P2+6L06&O>6O!G.=BB:\;[IRN;EZV;,XP=-Z,5H,71S",7C
MS"\QR>%NS6H7O;T>S:IZ^G'MAT> <0$ UZ\-C16OV ;_ *98+Z_4W_\ G9PK
M_P#2J81_KDT4'H_442+*^T^T/&9PVP/(TDQ+C3>:?2J5;)2J+J24[N^XNQP:
MVKBXH0$[J$KTA"!N>G,2)2(:-6YI&VYI1@2;@N&I.3STVG$9K;QG[4YBQ!K_
M "^-YDP)KW.\AQ7)RG.F9WYZ>Y/#8FXJD2F51Q^F[CCE4F<%X0*%1*%D;P7,
M+"$JQ)5QEB##,\?Z%:Q_O5=<O^=1B^@D9H3Z:'C,RKJCK_F[<.,Y=W+S=F;!
M&$9](<@Y8SQFB+^6TSUC2/+6>"P=FQ5D"$!;81$6-4E:VY,Y*'8Y,D0% ).*
M*M8D(8SS1/7I?HSM4\23DNC1F6=PW)EA[),HUC&=[6N,MC49:XZ$45%-&/#.
M38IC6&&$L8DMRTBH29Z5D+2%-DYQ Q* A0AQP;-\=;9ST:&NO#=!ML-:L19?
M%.<0[*8<SJ]-SA$Y.WN$/?E;)Y646S%FJ5O;0I7(2G120^N@NY.S8C/1A+Z1
MA %P.3M:VWGGYZ]ML!;7RV>&:/<7L0@S!%<"Q:4K(N@G629V@;!/+L^+VDU(
MYMQ<C=TKQ=<X(!%.PFUK;49:M.#KWN$6^='AJX]>.=YXW,S:;88=\/2B=;^X
M/QC*$%\J95R"P.3!94[2H2L*7*<RF[BB=S'%I3 N80J*)[$FUK%6$(P8PE_Z
MLC>!JQ=)-']+,I3'.,%U(SLYS3)NY1NN9<<,S%D/%D,7L++&\8Q0,LD$6C1R
M!Y=EB\UP)<EO<1& 1J#"5/=+)C@YM=C-C_2X2/7R51W5#37DGU\VB98N)PPU
MGVTH:GD]+E2.M)QT/<IXUR/=:;Q@B-O$J(3'/)K&PI'!,5UQMG=QA 7<+D>4
M[87(V['IB.*K-.2)6ZJ,I9&VSP)$9;/[C'YA<Y= F?9O$3A/E)Y)J89DB>5\
M/NZ'FEB*ZZPX0P]2U[= 6?YG]*IQ81S4/.YKA'LS3_90K&619R7MG/LVY&<\
MFJLFI(^LDPY6ZQ1O?VW$CRF=9*A,-6$+H^K4GD+#PB57/[)24&&<5.99[FCT
MHF;EV1'M;)'C'NG?(#B5I>G)0)4XGPV"PC+"2%MRHX=K7$7&8TI3-*7\V]D2
M FPKW%:][AZ76G7'#.RWI$X='\V0WSJT8QT[VASQ!TGF&51SP3*V)%^P\EQ[
M*NWB3XPJG+R^]EV.[BL&H;5?1U%*<XO[6@PCT_W!WQ<[ \;NC^Z.7=8/-NR[
MFMF4\79)]M6P[#V\KQML-D-IA;KY.C.6F6 E^#-\0;B^P U!3*>[]8\LT1AM
MQA*;3_\ TKGEH_>1:Y?V':M4%&6XL1TUQ1S'[]9!]1#KEM)D[#>4YBQ(]%\R
M1EQR^3@-CQ.D'(%D<BA"_$LPA+\L<T<,L@*LA;%RTM"Z(W<2QN"H/[S0=$7"
M;KOP0M>6LJ;-<.N4"W1V?\;FXVR/BI/D?)SH9&HLKE,97HGUUQCL,COGF+]Y
MDD#,$A<%AQ;<LLN56+L<5W3NP=(5!SW<M/"ED/<[8#$6^VDNT;GIQOQ@V+^3
M(]/KMZM;"IY%$YD@,;6:4&LUC'>/KTH96X)3UW<GQ(X-*@2!6W'%=F82%?4Z
MV%]6/Q\0N0Y,SAB;2KD,Q#C!E4/N2Y+C$)3%/3(>R(#GU^EK$T1@K CT8I0I
MS+IE 4<(=AE%I1&A;;E6&K$$J=ON0'&?)OZ;#<#;C%\?>H6WS/7O(+%*8#(5
M)3@[P*=Q*3-[-)XP>\)4R-"_HBE!(%2%>24398WJB#3"4QXC4Q(6F<.O\4_Q
MN_O(M9OW(8G04S^G7_P]/4=_]*'/_P!V7:"@JQX4^&?3/DER+R/9AW)1Y3RK
M',4\B6Q,%B6"$>4Y; </=_=3DSLZ3YU1X_7QJ:G350%>E3!/2/2(@29O)+4%
M* 6"$ 231Z=8VX._4(\?43TF63.&ZQ\BT(R?C;*F!G::R.6LR!XBJ-V&UK6]
MWE#DZ/C@U,,@>8^XM]W0]Q<D@T[D4!9V*^Y988SDSC@PAR9^IVY(L.;'27*J
M;#T)UJUHR7),>8VFRF#MF5US7C+7!I9(WD-<A3G.*Z*-2UW\1+)2&)%87!,0
M86I*Z@K##"N:WC#U=X-&_4#E.XU8_-=>ICAK:C'L*R-CUKRID6:QW(<&E#1+
MGYX),5Y0D\UD1)SRBB9K"XM]G #2X-+N=VA%AE6$8%G'(M_I,'!3_>JVW_<I
MRI029]4=_$4;S?\ L,W_ #P]?:",W+%_HHSG^\BT"_LQUDH,0T)]-#QF95U1
MU_S=N'&<N[EYNS-@C",^D.0<L9XS1%_+:9ZQI'EK/!8.S8JR!" ML(B+&J2M
M;<F<E#L<F2("@$G%%6L2$-$<NLB]*5#-P,KR/?*!NN;-RY&I:#\SMN'I]MJ\
M.K4ZQR(,L886J3E8VR]#,.Q61$QV/(D8VL@Y.N(&6$U<04(VYPPJRX1]B=&P
M^H&PNQ<3$:VDP/JEL+@K+\9S?@S81U:%I(YC"<?9-R.R#C)S7E3+J][B[4=%
MV@Y <]NBAW0K#'  #KIE5P4$K,F\3N@&8O5'Y!UCR/@/S%@[*>J,KVIGD(]J
M>:FCQW/4XDJ^1RB=^96+([7+VOQ1Y=#SO"T;@G9B.OU"4A980AL$P_4'Z*ZK
M<>W /FO!VH&+?9%BYYV=PSD=RB_G?(T^[S,WZ311A=7GQK)\OFLB)[TTQ5 5
MW<M6%(#L.L H(QF"&$SN?;4&2[*\04:RSBD*M'L%HXT8OV]PZ^M!1HW]#?&$
M90K,@)6H1!:@P9P(0)2ZD$=D;8]R9D8;AMT6$$,BVOYCF%O]/T'D?@CB%LR;
ML#@)B@&,6QB-N:N9-HLF)E>-'MG9;IS@&'*\43M&^.'180##$S .]@]>]@7#
M;VBVB>N&@G"$P:M[DBB\3Q0Z:\RM_P!XG&72=P@S.:\YN9E#AF9G?IDQNK ^
M(0L9,@M%D*Q"J2N)B5M2!3W"HN"U!R([&Y:]%Y'F&117&FKFW<U=7$Q:PMN1
MM>)#L6!YC@K$W&1,6%%M7LC#XLM3!-!V91;BS+A"$+I&CZGV]@Z-?2*9;F>4
M>)I0SRJ62*7LN&MG<LX@Q@JE)XCW9HQ@UQ;&4SCL=O82MP[FB:%DY6!3) *#
MB$1 @IR!=@46$(=0U H% H% H% H% H% H% H% H% H% H% H*IN3C_U$?\
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MMY)X1&95%9,TH'Z-R:-OTQP^U/D?D#&ZIU;6],;TUJS4RM(I*,(4D&#+, (
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M#XN(=+]C]CB<]LLZ.V/!BF7P".8DQ01%WEBFEE#M.V**9"0Q IXEB!S>U"I
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MO@-SWK+/LIQ1[A9^8]DGG(J2"PQAEJ6\7=GQ$?E/ VMT.!(FI(\"4)+J7A<
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MH+J"MUK](;+1HTC>D2H$"5,A0(4Q"-$B1D%)DB-(F*"2F2I4Q(0$ITR<D 0
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MC0/ ;D [ET)K=UZ@>RZO1:@_3*&"<(9O@%\3YHPWBK+V+;F-)U\:Y0QY$9_
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MUN_QH^2[_+^S[^O] _$7ZW?XT?)=_E_9]_7^@?B+];O\:/DN_P O[/OZ_P!
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M>U![B@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@W*7_L9?\
MV@?];:@_N@4"@4"@4"@4"@4"@4"@4&JI1G;"$'R/ <.S7,F*HAEW*I;F=B_%
MDHR'$8_D?)!+(28I>38#!W9W22:8%M"<D9BH3<E463@!<1G5M:]Z#:M H-9Y
M<S5AO $+5Y(SQEK&6$\=H%K>VKI[ER>1;&\+1.+LHLD:T"N4S)U9F-,M<E0K
M%)RAGA&<9?J@M>_V*#8B-8D<$B5>@5)ER!<F(6(EJ,\I2D6)%)03DRI*I)$,
ME0F4$C", P"N$8;VO:][7H/(H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MQ^/CRK+>*5.CPL<C0.B.7FL6P,>C]FJQ9AZ]>/)+G&U\34HUJ<D8TYX4Q99
M0W$+MK6O0=0/$)R@QKEHU=?]D([B)\PF=$<NOV&9)"7J6()N6"2QZ$8\G"QP
M8Y.A98T)T8S4.14Q)1BAN0J+FIS+B)"'JWN%?O-WZ@E/Q+Y?P]@Z$8*C^?)Y
M/<?NF2YJE><CK(.5!HX>_#CL( 66VQ24FN*R3+61Y&8$VZ:Z<E$4*UC+'](
ME3PE<OC3R[X-RKD!=C5KPUDK#N24L/EN.6J7*9HG!&9%'TKU")H4[JV&.GEI
MY&K2O"*Q B+W <SFBZUPC#:P?US=<K\BXC\!XES/&\+,N;E62\OVQ@>PODU7
M0A.T)[PR32KQ<E>@CDD,5G=HP!)[&Y18>J;<76Z;=%PYPDGK)MAW!G-D2#C1
M9%L?()5J#WU)F.<*6<E.@L9=<>:YDX@&B+)16*'<T5QV"7U;]:]NB]!=)Q#^
MH_U^Y0\IVUSDN)'[6O8EP97E^A<27S%+DB%9(11I K=Y$CBDS3QJ&N*:3-3
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MR.:0<>\>9I)N+L; \*$23M11EB=;/DFGLH3IE*=&N7QC&<$9Y3D61M36I6%
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MBO%^EF )/,).Z7,$4C0)</PP!*5$C( :M=GIV6FE)$"%,6:K7K3RDY!8S3
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MCRF')9Q^[@9?W(UEX_LVY[*NWY2Q^M6.NO.?)/CM)'YK,T#OXR:^8_:$(25
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MR <B>Q.C&J6X7"9JA!L\*]@'-R?)- ]L5L+A;W#,9)D[ZVHG0]*DVAQ5'02
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M4F=XQ9))[6\%SWOLX><Q8&E3:R>#XRR;-'Y-WEAA;F?WDY*6C!W;J#-"884
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MQ';;8UQEYDU\UA9<ZI,Y9 \YX^9_)"B91EZ;XV7Y4?Y6U3:2^)+%98.EG;7
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MM_8HO+87C9@  ,7C2Y%)]B-;I(F)"@<+)B4"M3+@M!;=9$E<+("4MS@O/XL
M\Q3P5F^>\LP]<8J.8AQF;@7"F +)E!N*+IS,C.F4TTS=4@9(0XB7!D,;;6^X
M9;);6"Q*!=8L1@E3@%N% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH%!2IS!_^\[_ /KM_P#NLJS_ (&_UK^3_G&(\5?Y#^__ .XI3K/V(E H%!/O
MCE?62/9U?U[^\-3&@OC%^3V6O#@D;$ESS))#Q%DV4K3B";G&!+%<(>MTWL&_
M1;[%8EQG_5-OB]O@;V0\,_UA=XE/@K5V_M5Q?_=(@7[,(]^N-:N9V>U7%_\
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MH/LJKCZ_8S%^H.?ET23N"2*K,UPG#&5%<92.QB0YU2Q]1.FQ^.9D[F<@(&H
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M7*QMD2$.ZAG<$SLT'ND3EX7AA<#FMU1DJ4PS4XQ$*"@& N$80WL&%.^+="I
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MRH'M9Q7_ '2\?_LRCGZY4#VLXK_NEX__ &91S]<J![6<5_W2\?\ [,HY^N5
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MH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\
M+J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_
M "ZA0\TC^K$K^C$_RZA0\TC^K$K^C$_RZA0\TC^K$K^C$_RZA0\TC^K$K^C$
M_P NH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\NH4/-(_JQ*_H
MQ/\ +J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_+J%#S2/ZL2O
MZ,3_ "ZA0\TC^K$K^C$_RZA0\TC^K$K^C$_RZA0\TC^K$K^C$_RZA0\TC^K$
MK^C$_P NH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\NH4/-(_J
MQ*_HQ/\ +J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_+J%#S2/
MZL2OZ,3_ "ZA0\TC^K$K^C$_RZA0\TC^K$K^C$_RZA0\TC^K$K^C$_RZA0\T
MC^K$K^C$_P NH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\NH4/
M-(_JQ*_HQ/\ +J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_+J%
M#S2/ZL2OZ,3_ "ZA14%REZ ;([]BQ8X:[<B&Y_'B]8X22- Z P*;,P17(B>1
M*VA3WF:QN#9PPTK='=B"TW+;E!C@8%,6J/MV8NT^P*(#ZD>G=18\V0Q9M7R
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MH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\NH4/-(_JQ*_HQ/\
M+J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_+J%#S2/ZL2OZ,3_
M "ZA0\TC^K$K^C$_RZA0\TC^K$K^C$_RZA0\TC^K$K^C$_RZA1^R:1C4J"2+
MQZ2I['&!+[=2WD%IRNM?H[0X85@[@+#^;>]K7Z+4*,DM?IN*W1>W1?HZ;V^Q
M?[%K](?^K;[/1_\ IM1^/]H% H%!3QRQ9.R#CGV!^1)@_1/QGVI^*^"+SD/?
M_#O9QW'O797MVO=>_'=3I_F>T%_U:T!UY[]WSN3TK]*-3G:;I>Z>?T=TV\[F
M]S\VM.]ISKJ?LRG3V+."^$^+_9+[*-W:37]S^E_1=/EVYG1])W=S^;SHPYW,
MLYU.]YL<BGC\)O8/^[!//IY7[JM ^SOC+U3UGTV[]U.CWENJ;]'MT^9\O]P_
M";V#_NP3SZ>5^ZI[.^,O5/6?3;OW3WENJ;]'MT^9\O\ </PF]@_[L$\^GE?N
MJ>SOC+U3UGTV[]T]Y;JF_1[=/F?+_</PF]@_[L$\^GE?NJ>SOC+U3UGTV[]T
M]Y;JF_1[=/F?+_<;YUYQ]#]_)D[8.W,9B]BL2((JLGR. Y)5N#M'TTR87AB:
MV:1E)B5:487-N;I M)+'UOL 4CMT?9K;?4QQ-Q!OCBO-TN]-9J-1IHT.9=%M
M]\W1%T9F5$32?DQ$S%=LHL=KWJ\X&X5ZK]-O+AO=6AT.ONWUD9<YF3E6V739
M=D:JZ;9FV(F;9FVV9CO*VQ/R$POQ$/$#_B"8&^B7O]?*E$K5/Q$/$#_B"8&^
MB7O]?*!^(AX@?\03 WT2]_KY0/Q$/$#_ (@F!OHE[_7R@?B(>('_ !!,#?1+
MW^OE _$0\0/^()@;Z)>_U\H'XB'B!_Q!,#?1+W^OE _$0\0/^()@;Z)>_P!?
M*!^(AX@?\03 WT2]_KY0/Q$/$#_B"8&^B7O]?*!^(AX@?\03 WT2]_KY0/Q$
M/$#_ (@F!OHE[_7R@?B(>('_ !!,#?1+W^OE _$0\0/^()@;Z)>_U\H'XB'B
M!_Q!,#?1+W^OE _$0\0/^()@;Z)>_P!?*!^(AX@?\03 WT2]_KY0/Q$/$#_B
M"8&^B7O]?*!^(AX@?\03 WT2]_KY0/Q$/$#_ (@F!OHE[_7R@?B(>('_ !!,
M#?1+W^OE _$0\0/^()@;Z)>_U\H'XB'B!_Q!,#?1+W^OE _$0\0/^()@;Z)>
M_P!?*!^(AX@?\03 WT2]_KY0/Q$/$#_B"8&^B7O]?*!^(AX@?\03 WT2]_KY
M0/Q$/$#_ (@F!OHE[_7R@?B(>('_ !!,#?1+W^OE _$0\0/^()@;Z)>_U\H'
MXB'B!_Q!,#?1+W^OE _$0\0/^()@;Z)>_P!?*!^(AX@?\03 WT2]_KY0/Q$/
M$#_B"8&^B7O]?*!^(AX@?\03 WT2]_KY0/Q$/$#_ (@F!OHE[_7R@?B(>('_
M !!,#?1+W^OE _$0\0/^()@;Z)>_U\H'XB'B!_Q!,#?1+W^OE _$0\0/^()@
M;Z)>_P!?*!^(AX@?\03 WT2]_KY0/Q$/$#_B"8&^B7O]?*!^(AX@?\03 WT2
M]_KY0/Q$/$#_ (@F!OHE[_7R@?B(>('_ !!,#?1+W^OE _$0\0/^()@;Z)>_
MU\H'XB'B!_Q!,#?1+W^OE![V/<#'#TJ7B*4<?^!#2^[F"ZHFA\Z.M89=K7^P
M^V^S:UZ#-_Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^
M_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/
MQ _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;
M^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!
M]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ
M_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0
M/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D
M]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1
M#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU
M _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\
M-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/;
M 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^
M_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/
MQ _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;
M^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!
M]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ
M_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0
M/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D
M]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1
M#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU
M _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\
M-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/;
M 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^
M_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/
MQ _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;
M^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!
M]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ
M_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0
M/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D
M]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1
M#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU
M _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\
M-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/;
M 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^
M_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/
MQ _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;
M^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!
M]$/OZ_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ
M_4#\0/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0
M/PV_D]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D
M]L ?1#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1
M#[^OU _$#\-OY/; 'T0^_K]0/Q _#;^3VP!]$/OZ_4#\0/PV_D]L ?1#[^OU
M!8G@[7'!VM6+8'A/!&-8WC'%.,%D@<(!!HR2H(9(LME3K)WR1*&LI2I4G%F.
MSM,W0\WK#%TC6F='1:]K6#=E H(?\A7^ +O#^\_V7_<7FM;>[/GP]\$>Z_<W
MX1TS*N!?;ON;UUTGGC+?+!KU)K)2@4"@4'U@F/\ I(S_ /!;?_N0FO(SO#R?
MG^+7^"E5KG^'W_/SW[VE=1Q% H%!$G8/?32_4^2LD.V6V>PM@V521C\S,$?R
M9.V2*.KO'[KU;7XP@1NBD@U2W^(H#B.U#:X>T*$'\VUZ#.\E;2ZY8<PZS[!Y
M4S7CG'^#Y EBZUDRK*I0VL\'=$<V2DK8BI12!6<6@/)D:1068C$$?0> =KAZ
M>F@]Y@[/^$]EX$FREK]E*$YBQRM<G)G237'S^ADD<4.K.<%.ZMY+HW&G)C%3
M>>*P#06%T@%?HO0;?H% H%!#_8'D"TCU2F39CS9/:?"&#YR\QE'-&J)Y*GS%
M%7UPB;BZO3&AD*1O<U1"@YI5O$=7IBSK6Z@CDAH;7Z07H)@4"@4"@4"@4&J,
MU9UPWKACYTRQGK)D-Q'C1D5-:%WG,^?44<C+:L>W!.TM"96ZN!I*4DYR<E19
M!(;BZ1F#L&WV;T&,Z^;4:X;81I[F6M.;<;YRBL;?+QE_D&,Y2V2MJ:)!9 D=
M;L[@L:SSRDSAX<O)/[,5["[,T(OS+T&_:!01;V(W<U$U(6Q9MV<V.Q!@E?-T
MKJNB"/)\V9HFHD:-C-0D/"EH*=%! EI+:<Y)PG"!TV (X-K_ )MJ#)Y#M1KA
M$L )]JI-FW&[%K<J8XQ)DV;G.4MB7&Q\?FKLTL42>"Y2:>%L$WR)Y?D25(98
M?5..5%@#TW%:@\K7[9O7O:V&N>0];,R8]SA!F:3+(6ZRS&LE;I4Q-\L;FIE?
M%T>5N#8<>G)=DC/(D"DPF]^N$E64*]N@=J#>= H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H%!N4O\ V,O_ +0/^MM0?W0*#UCV]LT:9G:1R-V;
M&"/,#8O>WU]>UZ5J9F5F:DIJYT=G9T7&D(6UL;4) SE"@X8"B2@"&,5@VO>@
M@G^-BXLOREF@'^61KK]\:@EWB[+V)LX1))/\*Y0QWE^"+S.Q0S7%TUC60(DM
M.[LE6=DDD<3<W9G4F=S6DF]4!PK]F< 7\R,-[A$3\;%Q9?E+- /\LC77[XU
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M!-(/(/*$(HXDXH5A &&]PB#>U[7Z*#]J!04@_C*\Z_CY?Q77E3$WL _! _"
M\W^!3#VP^<NV[/PSS!Y[\E>6>K_[)\O]ZZ?_ (XH+OJ!0:?V%9LRR/ 6<(]K
MI+(_ M@WW#^2V;!,ZEB8A9%87F5TA;TAQA+)*D51J:)E4?CDV/0K%I9C.[%C
M3$C")&JM>Y PU!H5#=R<?ZG8IB/(%EC'^<=NFCSS[6LI8M;4+1!)1W_),Q<X
M'X$WMN-,/HD_@F,EK*W*NI'&[KK$AHK]X%>ZHX)?T"@4"@4"@4"@4"@4"@4"
M@YV_42;U;4Z*XLT@DFJV4O9:]9?W9@.(LBK/)&.9OYAQX]QR1KW./=WR-$)>
MD:>\JT!0^]H2TRX'4Z '!M<5KAT24'.WK[O5M3./4F[S:!RC*7BFI.'=)HCE
MW'&)_)&.47EW(;HFT\,72'SVW1!)DMW[<>4WZ_=%[RJ0A[_]J3;L$_8AT24"
M@4"@4"@4$/N0R322%:!;QS*&R!\B4OB6GVS$FBLJC+LO89)&9(PX6FKJQR"/
MOC4H2.C*^,KHD*4I%:8TL],>6 PL81AM>P0?]/-E/)V:N'/2[)^9,C3S+62I
M2PY=.D^0\FR^03R<R,YMV$RVRMQK]+)4X.K^[F-[,VITA E"@RY29.64'H
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M"\J@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&Y2_]C+_[0/\
MK;4']T"@C-NI_@;[:?O9L\?N62J@Y N '@@XI=VN*O7;9'9W5?VFYIG3UFQ)
M*IG[<-CX9XJGB.<<B0^/%^7<?9?BD40^'QQB2I^E,A)$;V7:&W&:(8Q![7AW
MUEA>IGJ)=U,(<=4OE4JT A&N;9;-Q0)BHR#C>(96?B(2[1?'I<U$)4WR&9Q>
M4&N);:,U0I>D2 +NB.4&73K>L%E6?/3,<(<*P5FF91G2?PR21+$V1I-'W'\)
M#;A9X>]L,/>75I6]S<,]JT"ONB](69V9Y1A)G5ZHP"#>]KA4;Z=G@VXM=Z^,
M?'NPNU.KWM3S ^9-R]'G27^VO8F$=Z9XO+E#6Q)/ ,<Y;B$7([BA!8':%H@&
MF]'6,$,7V:#>_/'K/A'3H/I\];M<83[.L+8RY&6A)"(9YDETN\$3R+*F.Y@\
ME^8IV_2>5N7?)'(5BCI5KE B^V[,%PE   (6.\L?(MG:<9E:>'_BU-3R3?'-
M<=-/S3F-"M.\I:-X4<^Z)GW($S?FM*OO'\@+69R")"&W]'M):M(H)*&X+F<H
M\+-.-CCDP/QC:V1[7_"R,3P['"+D.7LO/2%.1.LVY,5D_P#CV=R]2 Y8H $Y
M0,9;8W74J"FEOL!. PT5C3S@L!H*1=%9;QQR/E*Y0F#6O .5<?;J0!;C=#N1
MEZ7/KTM@&6#I2!6Y1@6/6E7FB;M;>6WB:;W4W)C$9O875M:QUKWZ PS-_J0^
M-+6K-FV. L]2/*N,I]J2_12+O:=VA3(]%YBD,M;E#JG;L'-D/F4DE<A+9$1(
M1.BQZ;8^WM]U!%C3[7.+ZP?CQR^I"XY^3'-J;73$8LV8FS&]H'=P@\.V!A</
MBQF10Q]K.?'Q%#7B!9%R8P*7=M94BA8)$L5(E9J9(>8268$H5[!7OS89MQ1K
MASP<)F<LY3ECQKB;&L!VAD4WF\B-.+:F)J+B3XE ::!*2J7+%:Q<J*3)4J8H
MY4L5'%D$%F&F  (-XPOU>O$-,LV-^(1N&QD1CCH_)&%%GV:8ICS-A/K+CDJ=
M,[.!Y.1%^4V)A[=5T&JG"*I0)0%#-/L44'M+A8'SD3W02!\?$LF?([AC)&Q&
MJR;(&+[N^/L.O3@TRYRD[D_@2PIY;W)FRYA10-N;G!3VIUK/Y0!E7_V([[ :
M"NOU2*6,(N!=W10EM4L\-22_59+$FA8<>I5M483R!E*86U4H4K7)2>I0M0"B
MAC,4J!B$&]Q&#O>XKAZJ5>K3XEM?%L"PT4Y[ 9O-C\9AT;D^2,'XUC#YB]@=
M$C.T('8-WN<Y&Q\^R5$SGB-[54QMCJF/"0.Z4:CI+[0+I)CM-IAMMQGYOV;3
M.:G8326>ZLYX?<CH(,:ZLLFFN(6O'DQ19@Q^D3G/4#D<6GAC$@=&@Q*<X,B]
M Y=(1*$@P6. %,>9]S^/G5KTT#EDG5?"&;L7Z=["85S_ *_Z]8I6B22W(<'F
M6R"S.S#9SGJZ;YJF:D$9,RBN=')<<3)7Q4E0J0!2IQV"!*4%77!AZD_1G5?2
M_2;CNR%BG;!XS6S21UQBJE$-@V('#%IC_E_/LQ?(TK(>WO.L>E@FA"DGJ,*X
MP3($XHPLZQ11P0@$8'35R7<YF@/%4N98EL9-9?*LOR%J3R)IP5A6-H9ME 48
M4K.XER5X*>G^(PF(M1QP1W3>,O;<H<0$G71%*>Q-Z@8-QN^H,XZ.3Z>"Q!A&
M5Y"QMFP] XNK'AW/L49H5,Y>V,Y:M4[J(<NB\KGD&DBML;48EIR!,\#<P(>N
MH[MV1"D1(;WW6Y>M0>/S8K7K779QPF,(5[%Q?(<Q8\MFIH4FPS 6+&C:J<GL
M[),B?)TR2=N5N7=K)FQ.U,SP>N6G$IP [4T ;A&+1?U%&@O(KM\KTXUF8MAG
MN5@B\KF+5E*58[BL1Q)(6.'HV]8YG-1KED2^44QQWB%BR"W"+(1",+'UNH#J
M#&%\5 H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MP=@]EUVLF=(C-)9G>?P*3QZ8*)=CA6WOC^L1D8T33_OX2FPJR2RN3KQ$%VL
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M3X\G1L?;5YIB]J++1+G8!)1HA*DUK %>]S2[?;V#]/PR/62?DG= /VQH-_\
M1+*"*O"E-=ULA^IHWNEG(9B''>"=LW+CK(!DC&.*G- [P:/HD,LT=008YH<&
MS*&9$1QCS!$S:M4V!(5O54J# W"1>UR"PC!R2;XZL<A?)7MYK'R.\EF6]&=
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M6XWM+=_G+>)SV]PDWYH,PPGUM3XY2.\LGL?;6'VE7S[>7GFM\,E,;2O*AP#
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M\J9GE5)L6P]VR(PF1IHC49-E $60F]2G<VID97$!C,6A6G+D2NQ)0=H>TO\
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MF)CB[,V1V-,S5'8^RHB&UF8F)N1M+,TMR4NQ25 V-B E.B0(DQ0;!+**
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M42 Z%WG6-<3K'>-RUI5S4\"E"S(TP ,9"&X3KH0C $]-B]#>5?1OE>V/Y/\
MCPP;KWO7$-LHRR-4ZPWE67,F/\S8K<6&)QYC/40.;S)_AK0B:C5<? (@:%S6
M#6-2@]L4--C$Z!QH)6:$<O,$V:WR#JIN%QQ3'CZY%%&,'N58X]IB&,SM;D;&
MJ5*:M?T4)S)>#0&6J$BMHBQZJQ"=$H9E);&M)NM$I0=B((X^GV_C,_4F?O\
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M86@JF2*XK#/ BIGX4HETF=YA(3/,60>/:5RM=XA(WU4HZ%*XX)7:]F58!00
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M9."R725;.8:UO4E9&5$^#7=+)=L=7AM\*3E)@KU2I*K$$(->JC_IMPX_])#
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MLA3NC$M9%C:ZJ6^PDJM $\L 6K<O^RV5(YOSZ>1)@_-N481BK8W::4%Y"CT
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MNLXZ1RG?'+YH'\=2>ZH4CE.^.7S0/XZD]U0I'*=\<OF@?QU)[JA2.4[XY?-
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MHG%&N+$8$Q.$2>]^@RP;VO09EIMN?@#?;"3=L-K1)W27XM=9!((PB>GB,/\
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M<SWBK/,4:EI;8^.>,9FR2D<;=#@&')VJ5-S<J-=8JZJ4Q=SBDKB0F/-3W":
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M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H(?\ (5_@"[P_O/\
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MACR/[G[;[H!=<XKG+85*3E.&1F'3E>N61H?D64)U,/DTMF+(8G>%[BZH5IB
M2DI(W]V+(-,5!;_G7@+XELZ#8706F6),*3*(N; ]P^>:SQEHP _1UYC;P)Z;
M7+PC'*!G@<H.[P8,!H'YF=B3BK@L(%Q$)A$A1YR^;H8=X_O4@Z-[19T(FKA
MX/QR3ML\OXXC(I=/)9)9?+-G8O$XG$V,:UJ;U+Y(7]T(3$"6K4*( Q]8Y04"
MUQ4&X&#U5#U!<OXP9]W>*/;?1W6C,TB*CV.]FLMJ)0D0. ' ]J$V2)=$)IA/
M&+$HC*-F=0.+N>R2=\4-R+JF$D+ CM>@N/Y@.4-NXG-98!LHX8@+S:T338"
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M1MGR>G@#3)&7)JBP6J4M<[20K)"4]N"A,+4D=FWFEJRC W":"U["N%G[.O\
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MD0G,.&&D\)<U&=]L87NR7L-PI;%8,U;Q5H?L3L<@E^TB:8H<:[-L$)8&._L
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M%2E<KCZH1%U+*K*#M0Q5E7'.<<;PK+^(IDPY"QED:.MLLA,TC*T#@R2)@=B
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M7Z=+#&G.QC?NGLALOFSD$W"9"7&\9RYG4]:0RQ5Y<[.)"B8,\7>97D.3.,Q
MW.J@DA6]21W)2&*#%28@E9V2@D+],IPGVEXQR-CGQ/P7S_ Y?"?&>Y>)>$^:
MH^X,7B?AW>T'?^X=_P"U['MR>UZG5[0'3UK! CB0XZOQ6>E\3U#]L/MU\KS.
M?R[VA>S[V8]^\\OYKYX?Y3\[Y"[MX7VO9=KXF9V_1UNH7_,T&"<GW%I^,@G&
MB\R]NGL:_ MV19M@_#?9C[1/:5X0[Q!U\H]\]H4&\G=X\J=GW_LG7J=OUN["
MZG0,+-,FXSQ_F?'DTQ-E6(L<]QOD2-NT0F\-DB(MP8Y)&WQ(:A=&IQ2F='7)
M4IC;VL(-PF%BZ!@$$80BL%4W%+Q53SBJ/S7BZ$;=.^8M-IQ,7N;86UWGF*34
MDPUZ<GAV,5G(&+-).57--*6-R;3>HZ)1Q5O L<"2UY-TAQBX*T+DJ"JO47C+
M_!7W\Y"-Y?;9Y[_#P<<:K_9?[-_*_LK]GB)T2=EYV\^R+SQXQXEUNMX0S]WZ
MG1T&=/38&HO&7^"OOYR$;R^VSSW^'@XXU7^R_P!F_E?V5^SQ$Z).R\[>?9%Y
MX\8\2ZW6\(9^[]3HZ#.GIL'C<@O&'^'9LUQL[%^V_P!EGXO38!9G3R=[-?._
MM>[W)L2R+RMYA\_Q#R!V?LM['OW<7OI[]U^[V['JFAY.T/&7^$ER.:$\@/ML
M\F?@0-V3D'LE]F_F+VG>T=E<6CM?/GGUB\E^#=_[3J^"NW>.IU>DKIZU@W-R
M9Z3_ (Q;1W.^F7M,]COML;H4@]I'DSV@^6?)^2X7D3M?)_FN$>,^(^4.Y]7Q
M1)V/>.UZ1]GV0PB9NMQ#?AA<3^*>,#\(7V=^S&!ZU0GVX>R;S;XW^#PQ1ME\
M3]FGM+C'AOG#R_VO8^8%'A_;=7M%/4ZP@V;R@<9?XR+0,S1KVV>QGM''$R_V
MH>S?VB='LN6H%?9>2?/L%Z?'.Y=7K>+_ -#=;IZ#>CHN%*4G]++G5]0^QU/S
MF[]BTU5IALKQK+)UDPDZ%RB:M4J5ND<\0!G=DQ6!,O.4W'>QL#4)NUN,8TYE
MQ] 0OSA_&S@K#'')/N-K7(L[$^+I=@+,.%&^6.*3SM(TSSF2(R:/R+*,N )=
M&QS:4*7B3FN:HJREN).N$*1/=$E 060'GZ'Z%1S3GCYQ7H!,)BFSS$H'CN<8
MTE,I61$V I,@QR?2.8/#VD51(B62X]C3'MDO-0C !V4C&$%S+#!<?5 %"6(/
M2PS' &4FM#ASEPVWA^E+9EYIRN?IB0U/Q<=DQK&ZM;^A9IN^LF:F#&<J,5.S
M$B"N7'X_L<K0I[$W" WJ* !.7DTX <7;V9Z:MR,#;*YBT%W5;VIL8W//V#;K
MS_."%F*;F]G<):P,4PQQ)3)6R,#<!N2.;7(VHT20!):L*L"5,$H,(T!].M!-
M8=GV3=W<#</._)'MG"D1:'&^2\]">"6>#B2DN"%K>DS++<@9=ECU(HZUKQ$M
M1BZ1'(6PT9BE.C+5=W.3!.K:'C+_  DN1S0GD!]MGDS\"!NR<@]DOLW\Q>T[
MVCLKBT=KY\\^L7DOP;O_ &G5\%=N\=3J])73UK!:I0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0<N.U?I
M=L'SG/<DVCT VWV XQ<WS-2O6R97@8]S78_NO=W)*XOBZ,1R,S?$TXAWCYME
M U2!%* LH3A$"3(4P"1E* Q+%7I=O,>1X+DKD2Y2]V^0A;C"4-<K@\8F<GD\
M3BB9=&U1"^+)WD.0,G9_E)R1H<%KL<*S6ZLPSKKPA"(H %(5H6WY.XT_:/RU
M:X<I'MI\&_!]UNEVOGL,]G/B/F[S2?E8[S=[3?/B'P'N'M.Z.X>7EO:]Q_[Y
M!VWZ4'NN6_CJ_&F:7RS4/VP^PKS1,X!+O:%[/O:=W'R,_E/GA_E/SOCWO/BG
M9=EVOB9?8=/6ZAG\S0:RY*.*3\89ISKKJ9[>O9#[ LO8.RKY_P#9=Y_\V>QF
M#RF&> ^5?:+"O O,GF7O/>O$EG<^P[/L3^OUPA;_ $',SNWZ;F,9MV?FFY.C
M&\FP7&9G[+*]0YYD=\%6D"V*SIW<KKCI%)$K3#,GX7E<;DDN7++*'81;\>UJ
MU%C#^X 4J5!YH2(XN>![#7'=EN<;5Y'SKE?=?=C(S8I9I-LOG P\3LB0.B=
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MNA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\
MII9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G
M%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\
MH(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[
MNA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\
MII9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G
M%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\
MH(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[
MNA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\
MII9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G
M%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\
MH(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[
MNA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\
MII9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G
M%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\
MH(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[
MNA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\
MII9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G
M%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(/G%_\ II;[NA4\
MH(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[
MNA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\
MII9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G
M%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\
MH(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[
MNA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\
MII9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G
M%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\
MH(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[
MNA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\
MII9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G
M%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\
MH(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[
MNA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\ II9[NA4\H(?G%_\
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M>"<Y8MV8P]CO/F$I1YUQ+E>,H)C )9X)(HWX_''.PA(7'P*6M##)6OM[ O\
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M6Z(1DW()*]MDCZKFZ*8HY(<+&Z[L24K"L2BL:1UE .L9V03YH% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H*A]DN>GB
M)U*GR[%V<-W,<M,^:%[DTOL;@<:R?FU9&G=H[E9R9Y4=A""9%115W2&+P%B2
MN)J91VP#B[ N80>$L-\ZE<J/'AO2XD,&JFV^(LL2]4U&OJ?'B9Y5Q+*1K,F
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M,\FJCFQ<HO!\AP]%RBAV)RRB6Y'5(L9CA@\SIF"9#R$[!0K8,KQ?9O<&@IS
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M#WU9GE&2X+;YT\^2Y%%7?'E_'$DR<@=WNTW2)>\]*<HH195P!5K#)MZMK>_
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M.&W6&-0<F3J H,;/55Y"QN\QJ6;L\-F[>HFKTP7H4L?V.?$\UD+8H1O:I%X
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M\[O))*90>0%H>SG^EI\</_1O9<_W;M;09GZM[^)?RQ_?FP%_9\EH(G^I^;W
MS@IU!D:9 K6MD%SKIW+)*8D*[42!D!A3(C %69TW 6 )KR_HTP+C$ -S5  ]
M-KWM0=%F!^330#:&70+'VN^W&#LT9!R/#G*>Q^!8VG#5,)FWQAF;FYS=EDYC
M3$:N=L9JVXAU( :DD936KLI$)/8JYX!EA"=%!Q"[I9.>>";U"+MR'90BDD<M
M!^2+&K=CC*$WBK&J?@XRG[0QPI&]V,1I0]Z4R1GD>-$$E$DM>Y[E'GQTLW%J
MU2 Q.6'2$AYI>)-P@A.12.1S3DN/GH+N(&]=GF -D["GLH$E[,[%SD\I,FIE
M_:!Z>ZF- 55R^@SL^SO85!L+3#DNU#W[QKFG-6MV0U+_ (8P3D1\QO,,JRUD
M6X]AZMPC,&B^0)%(V@V969W8F&,S%*R;'.+DD;@=<@\80B3A >8',IRK[TZ2
M9$YLN"S*V/\ <75>=8NQ'+<W*<KY)AVPF))- <8IW8,0\+/R',627+H["R7+
MNQG=QN2E,$[LQ=2]^K?H#KF@FT6M.7\4R_->(L[8AS5AZ$%R4$PR%AN>QC,$
M09SHFQ$2.3M*QUQRXRA*:]-,?6DJCV\%QK>Q4%7L5?M2^L''N^Z3>G9R!))9
MLAH/S5AXS)M.%X7=0VX$WIA&"HP0[W3JE"I<+$&3'>'9<:";I9&N+2H$+NUM
M;?WY0F2)BBK"3 "P[TTFZVSVTL(WDQ5G;/AFX>.=2]C",4Z^[CJF QC<,ZPM
M3YM[PH6C.*[\Y]T:V%H>R37!0X.A2>3@(.6*2BDYE!TZT'+1Z?\ _C!_49?]
M)"X?V<["T#T__P#&#^HR_P"DA</[.=A:##.6K_2)> G_ ->W_P!H'T&9[.?Z
M6GQP_P#1O9<_W;M;09GZM[^)?RQ_?FP%_9\EH(S>I/\ XG/CJ_?=Z._N'Y3H
M-K^KQ<T#)QRZZ/+HH"D;&CD2UY<W%6,)@P)4"#'V<U2M0(!0##1A)3E"%>P0
MB%>UOL6O>@LVROSM<2F*<+/^:S-\]:)XWM,?6O+7 ,:9:ALYR])UQ2%6J;HX
MU8JCSJNGB-W>%*:R8%U[>D3)C30"5&D%WN.P46<-V%9]B[TR7(OD>>,!T6MM
MG!N0_:&%,"DOLCT4!E6M*?',>46+%8L^Z!Y%BT]>A-,*)[RWJB#P!N4:6,03
M#XU&%VE/I2F^,,*(YR?)'QZ[K,+*W)@#-4+W9WML&WMR(@L 1#,.5+%   #:
MU[W$*UK6H-7^G4Y0N/O%O#_J-AS)NVV$\?YEQ^^9#QH_8:E,W:&_+RF63;8:
M=.\.2QC%X5!TZFB"2-DZ:S4RQH0+4MNW& PPLU,J 2&@>._:[!/%9S4\TVMF
M\T]CNO0MPMB&W:7!&7LJ*R8ACF61:9S'*DV0L:V>.8[1MI1$MF6RRD2U8K3M
MP%30Z)CC2595D]P]5SF;E:X\G.S_ !9\=&BF4(9LWED&[..,YS[(&"GMKR'"
M<70*,(%:-S6"RC%E;G%EIB*-/;F_.I#8H7&-B6/=998@X28HX)F;.?Z6GQP_
M]&]ES_=NUM!U+T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@@1RBZEN.
M]''SMAJFQ'HDTJRYB9W;X*:Y" 4V^T6-+&^;8Z*<E S20(VX^<QEO+/47O?N
MY0A&=4?4ZMPYYN _G!UDQ=J_"^.?D(R/']-MK]-0N6#E2#8 \.,(9)X="7):
MWQD IQ)CD\2B\MA;.!.S.3<[K4)BL24M8A[P4<<!(%Q.=.?+B7P9X$W"W.Q#
MFN8RQUCK%$(%K1*67/TAD3U)W<UF:VZSGCIQ>(/&3+*"!C/,?7AJ3IRNSN88
M$2A*$\*6,C;!8SXM/5'[!YVW#=PXQP!R%:?8_CV+,XR)"K#"(O)\?QW"41<&
M-Y?DI2XMO;#7G"*@MP$*Q?<%#NUGJ@E)#K*;A^?J6>3#3G9_1YKX_-/LSXLW
M'V<VUS!A>/P"&ZX2^+YK+8BV#)+-( +W*609W>(M'I ^O;,D943<:L\45 =1
M&!3]T"<H+#*.9F"K\7[E>E4QHZK_ !1TQWM=%X*Y.?:C/\17Q*0::,"Q?VY@
M"S#N^*&\1G7$$-Q=;IO:U_L4'D\N>3XEHAZAWBGY"-AA+8_JR]:YY/UE?LF'
M-:YX8,<3?J9S*"\J[-R96>UF#MGAI$L-ZO:F,I*TPH)MDAP0AFOJ'^6KC9FW
M%;L[@+&&Y^ LSY?SA%X7'\=PG!V0&/,RQ>O1Y.ALE7B?7+&BF3L4+2(&*.JS
MS#7E4@"*Y8"@=<\X@HP+S>)W^*RXT_W@&F__ #=<<T$HM@,U0S6[!>8M@LBJ
M^Y03">,IOE.6'!&$)XF*"QQQDC@F1AO85SW%:0W7)3%!"(PY08 L 1#%8-PX
M,>+OA.Y"]]<'R?DUC7+GL)Q^S7?O)N1LPSB 82BV3B3YDD39*G:>.RB62*%;
M/X9&\)CU[B[*&1*J;C@H&M:$1!O54C#8/YV@T6VGX#=Y./#E+S[R'Y;W]A[Q
MGU!K3GK(F88[-6>58_Q--X^\I5#0ID$SSGG!QE$?,ACA*71$C-/;DK>Z-!(@
M=<:GKDA89N3F_&O'GZHG!^U.U;V@@>N6SFB:_%$)S0]D&F0R%S1F<UB1R(>'
M,!2@;6%*L9F].L5% N0C32M*<H&6G$H,+#TOJ@^4GCQS!QB9)UHPKN!@K.6:
M,E3'#;U%XI@^=L^84EVJ)Y.:)$_+'R68X/DL.C D+6P'C[NXN"54;<15BRA6
M-+N(/7<Y#F+ K!Z;K?B9L[FZZ_ZA9HQ<=FM0W-RMWNP()O&]<Y@T2*[:D3*A
M'KVAHPN\FH.D-A#7V)(+$$PX%!:IR&\TG%.#0#9HQEWTULG#QE;6C,$.@,*Q
MID=FR7D=[E60L9OL>B3$KQQ!37^;Q96X/3XF(/&\(&].V]89BXQ,42>86%2F
MI?\ H4<J_>S;J?\ .^SQ02F;XQ()AZ0(ECB[0M?'@7&:8[ ;6\KMUAK?&T(Y
M&]J"2;7L,[N#(TJ% @!Z1B"5>P;"%T6N&U^)CF>XQ\=<1>GI^7MT]?<6RC!6
MN./<5Y'QA*\A,R7,C5(,4,C= G*S9AE.>KRI*R74;4!8B,:&A>!6E/L85<00
M&=0(P>EMRY"\_P"R'/#GC&ZM:OQWFS?<>7($N<F]0TN*V%Y(GFQ<RBRM>UJ[
M!5-JU2QO) S4YMK&$C%< OLVO0:4]/[N[J)I9E;F5PIMQL9B+6O([7R!Y<G!
M;!FZ;L6-!/K B?93'%_E-3+U;2FEKTA=6$T!C8W"4N5@&DCL1<)Q=[A)??\
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MP3'_ $D9_P#@MO\ ]R$UY&=X>3\_Q:_P4JM<_P /O^?GOWM*ZCB*#G:]4_\
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M,80W"FG9[T[7#[MO)'_(,\U'C<0R#+%=W5UG6$)7-,/*%[@L7EN;H\*8M!9
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M=00 8K7L(0 B^Q8+8>>EN0.G#IR&)G)&F7)RM<Y2XEDJB@'% 7LZQK=VI8$
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M0W4]PN65?H)L(PVXP@+.O3=<).1)@=.'_0B M[T><6>-%!<B9SQ?#PC*5&K
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M%[]E.4R#)N28PAE\(>&-\[LW2V8JTH7!M6IQJ+$]J698([4%BV$<"8DUTPM
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M=P/^2PPI]_J@?@6\S_Y;N!_R6&%/O]4#\"WF?_+=P/\ DL,*??ZH'X%O,_\
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MA3[_ %0/P+>9_P#+=P/^2PPI]_J@?@6\S_Y;N!_R6&%/O]4#\"WF?_+=P/\
MDL,*??ZH'X%O,_\ ENX'_)884^_U0/P+>9_\MW _Y+#"GW^J!^!;S/\ Y;N!
M_P EAA3[_5 _ MYG_P MW _Y+#"GW^J!^!;S/_ENX'_)884^_P!4#\"WF?\
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M!_)/8._A 4#\"+FU_+IP#^2>P=_" H'X$7-K^73@'\D]@[^$!0/P(N;7\NG
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M"@?@1<VOY=. ?R3V#OX0% _ BYM?RZ< _DGL'?P@*!^!%S:_ETX!_)/8._A
M4#\"+FU_+IP#^2>P=_" H'X$7-K^73@'\D]@[^$!0/P(N;7\NG /Y)[!W\("
M@?@1<VOY=. ?R3V#OX0% _ BYM?RZ< _DGL'?P@*!^!%S:_ETX!_)/8._A 4
M#\"+FU_+IP#^2>P=_" H'X$7-K^73@'\D]@[^$!0/P(N;7\NG /Y)[!W\("@
M?@1<VOY=. ?R3V#OX0% _ BYM?RZ< _DGL'?P@*!^!%S:_ETX!_)/8._A 4#
M\"+FU_+IP#^2>P=_" H'X$7-K^73@'\D]@[^$!0/P(N;7\NG /Y)[!W\("@?
M@1<VOY=. ?R3V#OX0% _ BYM?RZ< _DGL'?P@*!^!%S:_ETX!_)/8._A 4#\
M"+FU_+IP#^2>P=_" H'X$7-K^73@'\D]@[^$!0/P(N;7\NG /Y)[!W\("@?@
M1<VOY=. ?R3V#OX0% _ BYM?RZ< _DGL'?P@*!^!%S:_ETX!_)/8._A 4#\"
M+FU_+IP#^2>P=_" H'X$7-K^73@'\D]@[^$!0/P(N;7\NG /Y)[!W\("@?@1
M<VOY=. ?R3V#OX0% _ BYM?RZ< _DGL'?P@*!^!%S:_ETX!_)/8._A 4#\"+
MFU_+IP#^2>P=_" H'X$7-K^73@'\D]@[^$!0/P(N;7\NG /Y)[!W\("@?@1<
MVOY=. ?R3V#OX0% _ BYM?RZ< _DGL'?P@*!^!%S:_ETX!_)/8._A 4#\"+F
MU_+IP#^2>P=_" H'X$7-K^73@'\D]@[^$!0/P(N;7\NG /Y)[!W\("@?@1<V
MOY=. ?R3V#OX0% _ BYM?RZ< _DGL'?P@*!^!%S:_ETX!_)/8._A 4#\"+FU
M_+IP#^2>P=_" H'X$7-K^73@'\D]@[^$!0/P(N;7\NG /Y)[!W\("@?@1<VO
MY=. ?R3V#OX0% _ BYM?RZ< _DGL'?P@*!^!%S:_ETX!_)/8._A 4#\"+FU_
M+IP#^2>P=_" H'X$7-K^73@'\D]@[^$!0/P(N;7\NG /Y)[!W\("@?@1<VOY
M=. ?R3V#OX0% _ BYM?RZ< _DGL'?P@*!^!%S:_ETX!_)/8._A 4#\"+FU_+
MIP#^2>P=_" H'X$7-K^73@'\D]@[^$!0/P(N;7\NG /Y)[!W\("@M!U[@.>\
M?8?QS$-@=@VW8K+T=724_(F9&S#D?PNBR2A<WB6K(T@2XTCTDDS/"!1AG=FE
M$,Y,N5"7B:!'#L6)88$L-_4"@BQO07'S=)=Q"I:J>4,5,U8V#+DRV.H$3K($
M<?'B67!>53$UN;DS-KD\IVVY@TI"A8E(./L$!AQ0;W&':74;=O"WKKX/NW3;
MDW[UCBG=4Y-N===9E79O=^GZ.W-OLLS+[,N;Z1?=9EWW6VUFVRZ8BV<DX,G/
MCC#=4Z6++M3Z9:7F1?,VVS=T]G-BZ8BZ8MF:5F+;IB*S$3.#YMW@?'Y_=0W&
M_:'PI_"-KT>]W=H#U+X.^^F\OR0G_P!-QSY6W3YIU'H4\#X_/[J&XW[0^%/X
M1M.[NT!ZE\'??3>7Y(.FXY\K;I\TZCT*>!\?G]U#<;]H?"G\(VG=W: ]2^#O
MOIO+\D'3<<^5MT^:=1Z%/ ^/S^ZAN-^T/A3^$;3N[M >I?!WWTWE^2#IN.?*
MVZ?-.H]"G@?'Y_=0W&_:'PI_"-IW=V@/4O@[[Z;R_)!TW'/E;=/FG4>A7TJV
MD;G9J;+$$)!$6;T5B1&G&!,$59,7V8C A+N&P[@Z.FUOL=->7G6\_NS.Y].?
MTMU:=Y7G36BN'.\.OYW>\Z>_>P[1Y^YD'Q@[X.NLX\#M'G[F0?&#O@Z&!VCS
M]S(/C!WP=# [1Y^YD'Q@[X.A@=H\_<R#XP=\'0P.T>?N9!\8.^#H8'://W,@
M^,'?!T,#M'G[F0?&#O@Z&!VCS]S(/C!WP=# [1Y^YD'Q@[X.A@=H\_<R#XP=
M\'0P.T>?N9!\8.^#H8'://W,@^,'?!T,#M'G[F0?&#O@Z&!VCS]S(/C!WP=#
M [1Y^YD'Q@[X.A@=H\_<R#XP=\'0P.T>?N9!\8.^#H8'://W,@^,'?!T,#M'
MG[F0?&#O@Z&!VCS]S(/C!WP=# [1Y^YD'Q@[X.A@=H\_<R#XP=\'0P.T>?N9
M!\8.^#H8'://W,@^,'?!T,#M'G[F0?&#O@Z&!VCS]S(/C!WP=# [1Y^YD'Q@
M[X.A@=H\_<R#XP=\'0P.T>?N9!\8.^#H8'://W,@^,'?!T,#M'G[F0?&#O@Z
M&!VCS]S(/C!WP=# [1Y^YD'Q@[X.A@=H\_<R#XP=\'0P.T>?N9!\8.^#H8':
M//W,@^,'?!T,#M'G[F0?&#O@Z&!VCS]S(/C!WP=# [1Y^YD'Q@[X.A@=H\_<
MR#XP=\'0P.T>?N9!\8.^#H8'://W,@^,'?!T,#M'G[F0?&#O@Z&!VCS]S(/C
M!WP=# [1Y^YD'Q@[X.A@=H\_<R#XP=\'0P.T>?N9!\8.^#H8'://W,@^,'?!
MT,#M'G[F0?&#O@Z&!VCS]S(/C!WP=# [1Y^YD'Q@[X.A@=H\_<R#XP=\'0P.
MT>?N9!\8.^#H8'://W,@^,'?!T,#M'G[F0?&#O@Z&!VCS]S(/C!WP=#!L\"B
M9]0'0VL'1U0]'2X+/S.BW1T_T-^;0P?WWB:?-K!](+/DM##:=XFGS:P?2"SY
M+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL
M'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IW
MB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/D
MM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P
M?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>
M)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2
MT,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!
M](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=X
MFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+
M0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'
MT@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB
M:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM
M##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?
M2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)
MI\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T
M,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!]
M(+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XF
MGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0
MPVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0P.\33YM8/I!
M9\EH8;3O$T^;6#Z06?):&&T[Q-/FU@^D%GR6AAM.\33YM8/I!9\EH8;6*3N'
MJ,FP>98VGL1B<G@N0HI(8/-(TY+W&[=(8G+&A8PR-C7V))).NB=F=><G-L 8
M1=0R_1>U_LT,-JM[4?A9X[=%LH'YJU>TSQ;C[*HTQR5!.7B>9<RB^1HI42N2
MK10@[+DPGA4!4N")R/3*3F0" Y2E,N0:(9-K L,-JTSO$T^;6#Z06?):&&T[
MQ-/FU@^D%GR6AAM:JS=A>-[(XLF&$<YXT@V2L43Y$C;IC!Y"N=1LT@1('5 ]
MHTR\*.R12(LAU:TYX>J8'[<JW3]CIM<8;52.-?3@</V*)BSSJ*\?6*'!]8U)
M2I FR)EO8;,$4&<0>2I+NYP'+>3)O!'LNQI >DM:VJ"Q ZP+VN$0@W&&U=TC
M+E+>D2H$#'%T*!"F(1HD2-2H3)$:1,4$E,E2IB48"4Z9.2 (   &P0!M:UK6
MM:AAM>3WB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?
M-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##
M:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"
MSY+0PVG>)I\VL'T@L^2T,-J)F8=(L'9^V!U]VCS#AU@G.;]5U+TNP%*7/(N4
M4S/CMRD(B!N[LAQ\UR1!CAX>E1J-,99:YM"U44:C3#+, -,G$6,-J6?>)I\V
ML'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-I
MWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/
MDM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:
MP?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG
M>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^
M2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K
M!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=
MXFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY
M+0PVG>)I\VL'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL
M'T@L^2T,-IWB:?-K!](+/DM##:=XFGS:P?2"SY+0PVG>)I\VL'T@L^2T,-IW
MB:?-K!](+/DM##:=XFGS:P?2"SY+0PVOV3'RP2@FRM REIKF!L>,A:J&<$J]
M_MQ%@&G"$0[6_,M>]K7H8,DMT]-^GHZ.G[7H_P!6W1;\W_J7ZW31^/\ :!0*
M!00!WF_]2[_V]O\ T1JG7XV7\P/NY^)TM>RW]O?K+[+0!JG5+8H% H)):M?\
MHKE_Q2<OZZL=6-_%?_VA]?[E-9Y\W<CYVD_:#D>NF5]1U"P*K^4%R@4$-<\\
MA^C&KLX*QIL5MA@K"V0#F-!)BH?D7(3!&) 9'W50N2MKP%M<E1*B[>M4-J@!
M9G1U1B)':WYEZ#2WXYSB@_*%ZG?MR1']<*#W&P?+'H;K5J]CO<V>9S:Y!K7E
M?(M\5X^REBMH>LJL,FF9:?()RIO;Q09"\G#3H#L6OB=0HZMB25:$1(Q6,N$-
MPDEJ?M1AC=? $!V;U[D#A*<09,\T^47UUC[S%EZ[R;-9'C]_[=BD"- [H>ZR
M>*+20]L4#M0%V,!T@&$5PD30*!0*!0*!0*!0*!0*!00KB'([H9/\S%Z[0G;G
M DISJ=)G^%E8G9,C1]?.C)9%;.=Y''@1XA6)>)V9+,JOO)-@]<KNYG3;[6]!
M)+*V6<9X+Q])<L9CG49QIC2&I4RZ5SF9.R5CC,?1K'!&U)5+LZK1EI49*AR7
MD$!$,5K7--"'\V]J#66N^X&K>VZ*4N6L>?,6YV00A4U(9>LQA+VJ6)XXL?"5
MI[.F=S&L\\*(YR);5 B0CZ+C"2.]OS+T$95W,=Q5MBU8VN'(%JHC7MZI0A7(
MU&88F4H2+$APR%*8\L2^PBSB#BQ!$&_V;"M>U!NW"'(!HWLJ] C& =O-<,O2
MPP1MBH? \QP.03(T))=SC#RHBB?#)(:EL6$5['!2W*%8 N@5^J+H"7E H% H
M% H% H% H% H% H% H% H% H% H,DBW],Q?^"F_Z\J@V)0*!05M;N\O''AQR
M3*&8_P!S-A/8Y+L@QE3,8@T^R?.&0O%XXC=3V12X]_Q7C2<-B#LW-,,KL51Q
M!]^KUK N"]A7#-]'>3'2/DB:<B/FEV:_;,U8H<8ZTS]5[-\MX[\!<)8F=ED?
M3]AE>!050Z=_3,2H771 4@*[+H,N"X@6$$[J!0*!0*!0:FB6?,%3_(L_Q!!,
MTXFFN6L4=Q]J6+HED:'R3(N-?$[6NV^?X2S/*R2P[Q"U[=AXBF3=KT_:]-!I
MW:_?#5+1_P!D/X4.5/9A[><B(\48H_\ (?)$T\U3]P[OW-@_]QY#Y;X'VW>R
M_P"BG+N:(/6^V.MT7Z EW0*!0*# \FY3QCA6#/V3\R9&@>)<:Q8M$=)\AY-E
M\?@<&CA+DYHF5N-?I9*G!J8&@MP>7).D($H4%V-4J"R@](QA#<,@C,FC<UC<
M?F4-D#'+8A+6-IDT5E49=D#]&Y-&WY G=6.01]\:E"MK>F-Z:U92E(K3&F$*
M2# &%C$ 5KW#WE H%!7UN?R28-T8RYI3AG+45RO(I1O?GEGUXQ$OQTQQ!V8(
MY-7N30.*I73(ZJ2SJ(N+1%RW'(:(9A[8E>%=B2C[V3"$$L!@6"T$-]V.0#4;
MCJQO&<N[CY:]CV/)A-TF.(Y(/(>3,@^(S-<PO\F2LWA.+(9-WQ)VK'&%Q_>#
MTQ20/8=2YMC!E@&$=]-^:[C)Y ,N'X(U&V7]K654L0>9X?%?8UL! ^I%(\L:
M6]W=?',FXIAD<%W16^I0=A99=29VO2 L00CN$+4*!007Y ^1C5CC+P=[>MJI
MFOCT:<'PF+0^,1EI%))_D.5GI%+@&.PR. 4(RUBLEN1&J%"E6H1MR0H%KJ%)
M5QEV&%6&#_4]Z!9^U>W(VQAN*]N6V Z0-F%W?+,;DN/\0(YV_(,ZSQ5CN'FX
M^0M>>'B,.PD+ZC,&X!<79J$2FMURK'BO8%!?)@S+L;V PGA[/,-1/C9$,VXL
MQ]EV*MLF3($<D;XWDF)-$R8T4@1M3D\M:1\2-;R46K+3+%9!9X1A+.-!:PQ!
MM.@4"@4"@4"@4"@4"@4"@4"@4"@4"@B)E[?#5+ VQN!-2\KY4\J;!;/>(>PV
M >1\D/GGCPHXQ.O_ /*J-P]XA,:[ XD5O_'#DW];HZ0]-NB]!+N@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4&,S68QS'<-EN0)BX^#Q&"QE^F,J=NZ+W#P
MN.1AJ5O;XX]P:TJYS7=Q;$)IO8IB3CS>KU2P#'>P;A12#U1?!2,80!WF#80Q
M!#:X]:=P"P6N*]K6N(PS7X)8 ]-_LW%>UK6^S>_107':^[*8!VMQTBRUK;F#
M'^;,<+EJML*EV.Y(W2-J(=D%P67,[D)"<,]H>D5C0"-1JP$J2P& $(%@C#>X
M;NH% H*^LI<DF#<1\AFLW&I)(KE=;G7:K',XR=CV6,C'$%.)F9@@$<R;)WE)
M,WU?.FV8-SNI08I<0)BT+"XDC..36&:6$9HR0V5^'AJE^&/^ ![5/_FN/9W[
M5_9-Y'R1_P"8'=N]^/\ GSR?[,_^]_MNZ^,]]_U.QZ?L4$NZ!0:FEN?,%0#(
ML Q!.\TXFA66LK]^]EN+I;D:'QO(N2O#+7NY>0(2\O*.2S'P^UK]OX<F4]ET
M?;=%!MF@4$1/P\-4OPQ_P /:I_\ -<>SOVK^R;R/DC_S [MWOQ_SYY/]F?\
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MH-G#'PE8&Y<[PYQ-$OCKP-&G<;,$RC#HG;I7!Y)9O6$J!-KPA0KPD' ,$58
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MGP]\$>Z_<WX1TS*N!?;ON;UUTGGC+?+!KU)K)2@4"@4'U@F/^DC/_P %M_\
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M'=O+!9$-OFK2 CLB1V$E46,,N&_=C.V/]%Q'O]D.&'4#5K^>,%8E/L9B'_\
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M@"#R7Y8[K_0_@/EWN_=>I]KV/5H.5/U.)L.MMQP($9XLF_!,,W=D1N>Q/I)
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MYKG$X@OJE&+5;B[*CAF7M<8C%!@NGI&+I#W/ I_&Y>I>_?=X0_LQW)H&V_\
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M@%Y7Q<A6"N0O=?=SCY69*.VEUADLBF@LBR_&+Y/Y/ Y5CN.PJ(06,-6K.-H
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MQO;C(N0(=DQ3$UL:9S&]%CUEC\AC0'%F3K5$6AQZ]O>5;T4H*!9 G*3&EG!
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M4H\TD0@EJ2A!"90;IW$]-E+>07>@K;C<#D#=,A8]3RAI)0:\Q/7(<&;V#"S
M['+VO#<6GQNP,G&Q%JDQP[.3T%E-5KEBE2KL42::"Q(2"Y<O3PZ_<G*?"#Q
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M6DA.3JP.!AK@ ]:%2790%*0%_/$5POZ]<1\#F"+'\E?,MYGR>6TD9.S7*VA
MP+79M8QJ#6J+P^*H5;J5"H<G5JC%1B2Z]P5*U0K#4JS@DI0)PN+H% H% H%
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M)>6Y4I6"3S0_(&<,]O<@BAZHPHX36UGL #S"A 5FJDIQR88=85 H% H% H%
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MXJ'[@=/B)GY]"AXJ'[@=/B)GY]"AXJ'[@=/B)GY]"CWD??0IEXC+M3X?TIS
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M9\EH8;3O$T^;6#Z06?):&&U_ SIF, @";F*P1A$&]P.:\L=K"M>U[A,+3A,
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M;MK)@\0K'DIR*TXK9G5DA\FFJM1,WN-2Z6MS>8U15M='!.G-8X.XF74#+L2
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ML11%YR!E>?0K&,#CJ0Y?()MD.5,4+B+$A3$FJ5"QYDDD7MK,V)"$Y(S!F'G
M $ !"O>UK7O0:LPIM[J;LJI<T6N>T&N^?EC(7<YY284S7C7*BEH)M<BUS7,B
M"R5^-0%VNJ*^V-L"WZ8'^>MTAD6:-C=>M;V1!)=B,\89P+''52:C:Y!FC*$(
MQ:R.2L@28!R5 ZSA\8D"Q22):380"S!"#<X'3;[8/2&)-V;,&[-X/R(_Z^[.
M8HE42<H5,&H&;\.9/B$_CL"4*6M]:+RX,IA,KNV)#HHO0J%'7LXI!%'(#+=L
M4(L0@!%'B@@J?"&D#*@?N20GDX94$HR1)U&Z#O/@3%K=F8MU.$O8#IHLS-G%
M)=LQV)O/2G"%(S"DMRS B*(Z@@T$G5>\>E*#$;5G]=N!JVBP._.:UD8\V*]@
M<3)\1O+RVN-V=Q:6K)!TM!#7%S0.]NZG)R5HS2E/Z4(-A_:T&XL7Y;Q3F^'-
M^0\+9-Q[EZ .XC -4YQ?-(W/X<YC)L"YP6^311R=F5:(JQ@>M8L\5P]:W3^;
M:@]9E_.V$->XH.=Y\S)BK!\'+4IT9DRR_D.(XTBA:M4H3HTJ4<AFCNRM 5*E
M6K**+!<[K#,, &UKB%:UP\;#>P6!=BHX=,-?<W8ASK$DRBZ-1*<-Y)AF3HX0
MK":I($E.>X2]/;84H">C.!< C;"L,H=NCI"+H#;U H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H*Q^7G6/8K:;1S*<0U%
MSGF3 .SL,)+R;A6489RW/,0N<HEL13+#C,9R=U@C\PF/4;R"S*53<!*X#-0)
MW0U&M&&UTH16#5W#/R>Q[D.T$8LZY)7MD(S5A$ESQEN"P/8B(W:#90QPT%'R
MF7.;:NND,C<7E[,6%]*L>$!+?<U4AN8,QO/%8(%<369MD^5C?C9?DZ79=S?!
M..[%;BZZV:/Z\-4^FT2QAF93'K+D,QSUD[&2)T;HS+'$LMT,/2#<D*LTAP=2
MT?;6'&RKC#H)S;M%K-K0A:7/8_8G!6O[:_J^X,3AFW+D Q2A>EUR5*CN;2KG
M<@84[BK[NB.'V9(ACZA(Q='0$5[!F^-,JXNS1$6[(&'<D0'+$#> V&T3;&DP
MCT[B+J 1)*D(FZ219Q=69<$2=269:Y1PK7 8$7Y@K7N',)Z?;^,S]29^_P#V
M?]TO;6@>GV_C,_4F?O\ ]G_=+VUH.DO-NS.M^M#4T/NQVP6$-?V1_6F-K"\9
MMRO \5-3VXDE7/-0-#A.WYA2.2THBUQB*)&,806Z;VZ*#+,89;Q3FZ(H<@88
MR;CW+L#<Q7 VS;&$TC<^B+@.Q)"FX4,DBCD[,RL5DZHHSH+.%?J&!%^8*U[A
MZK&>><&YI73MLPYF;%&67+%LH50?)K?C/(D0GB['4U0G*4ZZ(3M)%GAU41&4
M(U"(X!K>X!3JRQDC"(NUPBM8/(:,VX8D&4Y9@QARYC![S; F-KDTYPZT3Z*.
M64X9&WLI <RR"68^1NQTMCK&[DNJ4:56L2$D* J2KEC%8P'2'\NV<,*L&5HK
M@A]R_BYESA.F%QE,(PT[3^)MN5IC&&<#D:[2.*X[6.Q,OD+"UELRP2E8D1G)
MR I#KC&&Q0^J&T:#CF]2/N)&,I;!:-<5$7WE@.L..<W93DI^_N1&7+\(CCSB
M#'[*SPEVAD3RR>=+6<<%;)>P29Q="$$A.;T3N:6VFW"H)#<-!9AP>\;/&SHN
MQ[ SGC=V]DVV\,S ZP6)Y'?C\_8%SU#8K)\8HY"\-C0UNF!X+$6ICDQ[5DJQ
MR].O.5*!)1HQ@ 4"_6-"S97OQHL@R:9A1=NEJ8BS*4X@9S<2*]C,/)LFENQB
M$+F!K,@1TQ!*@.(VT=E%B+I+&W(O8SJ]6_30;8S-G_!&N,703C87->),#PMU
MD"*)M<OS-DB'8OB[E*G)$Y.3?&D#_-WEC:5D@7MS,L4$HBSA*32$APP@N$H=
MPAMN@U1!<\X-RC,LDXYQGF;%&1,A89<T+)F""07(D0ETRQ2\NAKJ2V-.28Q'
MWAP>X*YN)S&M 0G="$IIPD9]@!O<HSJAK3+F\&EF )81 L\;?:NX3G2DM.<F
MA>7,_P"*,;RQ02K+3')32(Y,I:S/!I:DE:2,L02;V&$T%[=-A!Z0DBT/#3(&
MIN?6%T;GMD=T29R:7AH6IG)J=&Y84$](O;G!$:<D6HE1 PC+-*&( P7M<-[V
MO01U3[KZ:*\3N>>DFVVLBK!C+)%4->,T)\]8K/Q.TR]"06J6Q5SR*7*Q0]!)
M$:8T)AJ$U8!466*PA M:]KT&V\6Y8Q9G&",64L*9+Q_F#&4H\3\M9%Q;,HYD
M""2+P1X<(Z\^!2Z)N3O'W?PB0-"M"J[NH,[NL2FDCZIA8PV#8% H% H% H%
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M2KL!%GK1O4A2F"LG76L6';+C+%V(M"]1V'&.)XKX)A[6##*TB/1Q"('?U;)
MHZM>7%6M6#!<3A)I.J2J%K@N.L(Y:Y*SE!MQ&&#O</F!8'Y!N&S8&7Y:VAYN
ML.[\[K[>YAFLC<#&O'KRSQO 6)X!9T";!8?C0R/[383R"83'VOM$X$ROJ-"%
M*:%.G2",*$L/"U3@3W-TXC_."APCQ;-.TF*](-NL'3_S]KOLHJ85Q$,SEC*/
MRS([/*( J9,H977N#&@A\2LWI5;RZ'O%O$UQ)YIY5D@B@N-]/M_&9^I,_?\
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M)KA,5T0!$MW("8ZL9+ZM,LD6R%(N=5P"0'J[V,--*L'1CZ2C;"#S:=\B&I>
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M4WYT/S%%]3-D\;[ 1 F/MJN"2Z/N,2E<?>'TV..^.-%<:.2U6YM3($%D*QR
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M,DQ9(Y+9W,$YC@N/5F-H5"<Y8X=V2=L6GLJ5!'[TA^IFU.M62MX5^QFL^P.
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M\;+^8'W<_$Z6O9;^WOUE]EH U3JEL4"@4$DM6O\ E%<O^*3E_75CJQOXK_\
MM#Z_W*:SSYNY'SM)^T'(]=,KZCJ%@57\H+E H% H% H% H% H% H% H% H%
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M'0P.T>?N9!\8.^#H8'://W,@^,'?!T,#M'G[F0?&#O@Z&!VCS]S(/C!WP=#
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M)\P:(D5)5+ 6WG/9+,)U4$67F-13LE$?8'3V=E!?3T=:U!NN%32)Y'AL2R'
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M_**Y?\4G+^NK'5C?Q7_]H?7^Y36>?-W(^=I/V@Y'KIE?4=0L"J_E!<H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MH]J<,0;47,,Z=E,FQX3D601263)C>\C8BD[/(0IHT]%/L49XNO:4,J)3]];
MJ2++25"(\TLX1(R0E!])+0O,\M=N-;4_/VT,D)8Y4KU$Q/E#,TWF)X&<)-_9
M>SR.1S>7*5IW9MRI:WA$YN0S+E6+.,-O<LKH[, <)/*'L+L5SV*]NM@\2*7S
M'G&1QIP*22>&*WMO<24N6LF!+*;6]W/:KJ$B=7D":IEXE"<!U[BBD3N&QI85
MC@,I8%D?HI/^2KD!_O@Z_?V.95H+V>;OEPB/%IK8)5%_#9?MIF<EQBVM^,3
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M%^J.<]TI."3,4<088UUCSS*9ZM)?4SF:"2"11Z.2QP)C+4H1% 6J@(CK$%J
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M,!8(W,XD,2Y=TEP_M!-MFMCI+!\,YER.5"S95J/*F*0X25#R3C$,GQ3/W?S
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M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!00!WF_\
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M"=Z^:\F,T5F&9,G.YI):U[FT]>FE\:SH0V1$Q$E)9G!K?$9ZBYQH24AEKFJ
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M%:>198A_H$=R;A#]L$5!S%>M;_Y5>/[^]]L#_9'BJ@[%^*_^+#XXOWANH/\
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M)P0V,/[ N]P@ZU[]4-^BW1:@PK86S(Y^KXT+OB8Y(=)8]HGD^^TP(Z85UDC
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MN4ANQV3A(M)4\+:R,B!<[)K6!YK!D4MUL]W'^G7>;*KF])O7H*-.&+RA^/\
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MA2L A7JAJ5I)9"4[].&2'+XC]7MO+'DK!EW(7&]#0ZYRAV+;8](T;GE^))9
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M>3LF8IRQ$8Q&L691R!$8,Y)\7(Y*ZXIE_M/+,DQII*UR9UC,D[G]LG66-#U
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M#F6?XOR;&72(3>'R!+94UOC"[IQ)U28T/2$U.I*O<)J=22(M0D4EEGDC+-+
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M\L&1B\K@#-+(-$X%%S\?Y"LI3.+&VN2"2Q,/=FYSL%.[-1Y/8A-M9042$_\
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M2BGO[O\ )Z&&TZTY_4HI[^[_ ">AAM.M.?U**>_N_P GH8;3K3G]2BGO[O\
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M,V$/\GB#MD=^8XVR9 RBR/<WC#O%L8)W>2H2SEY!"]:;V_\ 0J-3U#.H%C=
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M^5,CB+1"I-WP(K?TG<G#L_\ L^K02RH% H% H% H% H% H% H% H% H% H%
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M<ZF;0EIP[&ZTX*SB<C+ 4WN&4L60N:O#667<5P!:'M^9EKPT=%AB#TICRKW
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M+<P/$E,19"B:] \RA(ECLA5KU)"<@MX>0="*YH%IP#0]4.ZN@@7R@[>H=#]
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M"@4"@4"@4"@4"@4"@4"@4"@4&21;^F8O_!3?]>50;$H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MAVDT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&Y2_P#8R_\
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MI5)G&42"-J%SNE,!B-S4.V9LZ.+:=%$X +[)#7DH18'<(^Z%6,L,T++-2/\
M2Y>4W]X!AK^L&E5!U<T"@Y)/3G?QD/J5O^DA=_W>-SZ#8GK!OXGMQ_?,X0_]
MI3*@L%YU^/QRY"- <@Q#'!"M-LM@Y>CV(U:D#*,Q))D67\:IU3BFC3&Y) @<
M$RO(# )8SIK -***=5"%69?I2 O8.:CB,WW(Y(>?+5[9%R %'DR_$PY8VSLS
M!2]QLT9MQW-I"R3NY2*W2!$@DAUB'Q$180Q)T#J04._: ':P3"V>PKAO/_JW
ML*8WSQB7&6;,=K^.M0Y+H%ER!Q;)$+6N+25F-6UKU<6F34\L:E:VJ@V-3FC(
M$,DRW6!>U_LT'2A">-7CGQI+HYD#'&@>E&/YY#G=%((C-H3JM@N*2Z+/[:<%
M2W/<<DC%!$#RQN[>H!8PA2E.*.*':P@BM>W30<TW--K/A'<7U#?$!K=L="?:
M+A;)NO\ G5)-X9YDET1\;3QUAS5,&8OS%!'Z,2MM[G(X\C4=*1<G$9V/9CN(
MH8P"#4F^G&!"> C97!?,'QTZ]H)AK+B(2>#[<:T/RE]RN^P:%2A4%J<LV8FF
M^5'.;32).8B#RDYS@6Y6-9'"Q A"&RKW5,4'8UK7L9B';?!6,=C\#2Q)-<3Y
M;BZ&5Q%^36[(ZZ53UR5K2\(1"$>SR2/.A!Z!S0'=50@<$QR<VUC"Q6L'-OZB
MC_#T].)_TH< _=EU?H.KF@4'.SO3Q(8>W*WB>-I-..1.6Z+\CT B3!CK++QA
M*01?(KBNCB)DA[XUH\PX333B&2PA>JQQ(F*UBE3FD;E34H9U1R(\-DYAP0_U
MWW<Y6M">5S5KC&W[V1P-OW ]LH_)%,3R5CZ%,L$SMA\V-0ER<6B\UCL38X@W
MV:%"V,B.4B=R'=<O;UAKB6Z==*-"(,^XB_X_GU"/_&+6K^LTHH-8>F5F4'Q_
ML1S,:W9'=VB/;;@Y!<E3*31>0.)".:S.#E/$N0(7=C3KC25DM:&*0I'A6>H1
M@. 04[D'F""6L($,/SY7,M8LGGJ&."2$0?(\&F,QQ?/LUM^2HO%I6QR!^Q^X
MO%V IK;)HUM2Y6LC+FN&PK+%IEH"3Q=V,OU>@-!N39S_ $M/CA_Z-[+G^[=K
M:#,?5O@ +A@RJ(00B$7FC 0R[B#:]P#O.TY=Q O>W2$5RQB#TV^ST7O;\R]!
MA7+WR2;4Z8:[\4>L^F,HQ5B7/&_7E#&++L+FHIG/Q[A9GBL7PNQJWES#)6>1
MQ= 8N?,LMIIJ]Q:WDA(V(5EBV]0H,)$4%5_*;Q9\C.%=(,YYQW8]1+DA^$Q8
M=G:<G62Y<CQQC+84IL+4&)<5%$BV,@3%-GJ;&NY"$X!T-=E0A*B4W9*@6)!<
M)5;&?Z%M'OWHFK7_ #DL0T$B.3/_ $1IJ_> <<_]?]6Z#(N6+_11G/\ >1:!
M?V8ZR4%[G'Y_@%Z1_O1-;/W&H70<E_#1%9C,M O4OPG&A"L4_E6<=Z(KC],U
M O9<*8OF%LA-$4(;BR[=-E=WI40$FP;?S?1:U!:IZ6?,."Y;PRZZQ''<DB1,
MJPT=EIESE&4SHV D$0F+EE[(,ML\3))94-8B)E$8=DCDC5*>@L: P  7#8@1
M901!THREC7+WJXN0R58IR!#,EQ9)QM-$7/DT"DS/+HZ&21>8Z4LTG8@/C L7
MM9SK&WI,<A<" &B,1+B#4YU@'%&%A#KUH.6CGA_C1O3>?OW<C_U_UEH'/#_&
MC>F\_?NY'_K_ *RT%F'.X  ^'GD/",(1AMK1.!VL(-A6L,L*,PL5K7M>W6 8
M&PK7_-M>UKV^S042[&?Z%M'OWHFK7_.2Q#0=0W'Y_@%Z1_O1-;/W&H70<]WI
M7@ +!R_%EA" L')AE(   #8(  #9:$(0A#:P0A"&W1:UOL6M09KZ0[^*YR-^
M_=V _K!B^@]'Z0:31M5QLY5BB60,:F4M.YV=75TC1#L@.?VUL<&/&9:!Q<&8
MM0)Q1H%QA(PDG&%A+-$"]@WO>UZ# )_.X%M7ZMC3=XUND;'DA#IUI)EE'L_,
MH*X)GR/,0WV-9_C;'#7B0L1JMN7+X_)LW1VYY!IERTBUQ["][*B3"BPV5Q%_
MQ_/J$?\ C%K5_6:44&!\5LCC\=]2=SIPA^>VIGF$P:L2OD4C+BO2HWN2-#,V
M1UQ=W!C;3S0*G-,V-\C0GGW)"/LB518Q= ;]-!BO-EEO&6+>7_@=W3R-,HRY
MZ>QS(&<,</&5$,A3/N-8+DA,\ML;5N\A?6XU9'6#RY(G!*>L4#."85:-+NVZ
MMFTWJ!>7RW;-ZV88XR-MYUF6=P,Z 9*UBS%"X0TJI&TF@S,^Y$QJ^1R)PJ"
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MM>]Z"6#0SM,?:FYB86MN9&1H1)FUI9VA$F;6IK;D902$B!N;T11*1$B2D "
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MCT3;&EH($!*F+*M<!-KV++"'\P-K6#8U H% H% H% H% H% H% H% H% H%
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M9)D:TPT2A*Q.32D)[<?="DU^I< 2[U$X%= ]%-J89MGJ^RY*QM+(7@I?@<F
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M$:'[:#\<6$..MNV&;,)RG*LH(V6V EVQTZ'E-\B+V<TSB:$(T[HU1(42@T(
M@BA $(+IR%@5ZP%[WZZD?V+6!O3QQ80Y!7'6!SS-*<JQD_4W8"+;'8Z!C%\B
M+,2]3B(GIE#:U34,J@TT&XQ0\:4-CR$(FU8*U[]52#[%[!G>].B.M_(QK\]Z
MU;11%;*L=.KTT2EN4,KNICTJB$Q8 K"V27Q%^2A,&U/S>F<52?K#+.3GI%9Z
M<\HT@XPL05P\=_IWM&.-!_S3*\%339.72C.F&Y3@B5/N6YY 'U0U8_F"UB<G
M=+&D,-Q1 F5*YV<8XF.*4JTJT8!6$&]KEBZE!*C7?B2U-UZX\W7C%*MDW+6K
M\A13]MDJ3*4R3$3Q_;<C2I=,'Q"LEV*&+%ET1:9W7WLE&A3)#BRBPA&,R_6$
M(*;S?1H\2QDVM*@37<PABLXDK;XU*S#CB\)$F*+  ;/=>?A$[(WAR@0+C&*T
M@LKL(5^H>$/1:P=*NM>L^"]/\+PG7K6['+'BO$&/4!J",1!B$N4%D75*35SB
MYNCL[*W%]D4@>7!08I7.3@J5+URDP1IYQ@Q7%0;UH% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H(1;D/J9E]G/>(U'I#WGS?U/'BW8SN?8^5^MW7
MPMW:NCO':VZ_7[3^8#U>K]GIJH^,WXMT/"WL([MW%N7?73^G'-[OMUEW0\ST
MJKT7<NLTE.DY\=)TG2?,6<WF?+<Z3W9PW5G;S].>AUNLT?,[DKT$Y4<^O=/S
M72Y6;\S3Y7F\WYJ:UPI"+STV_P!S;'OQ:5_VVU53[[6XOT&X,^E[W_+"3WL6
MUOJUO?Z+2^A#STV_W-L>_%I7_;;3WVMQ?H-P9]+WO^6#V+:WU:WO]%I?0AYZ
M;?[FV/?BTK_MMI[[6XOT&X,^E[W_ "P>Q;6^K6]_HM+Z$//3;_<VQ[\6E?\
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M#F)6X-" 04"3JC5KEZQ"V(K&E!/4EC/( 8'-@P>M(U853 ""3Z99]98$)0E
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MGSX>^"/=?N;\(Z9E7 OMWW-ZZZ3SQEOE@UZDUDI0*!0*#ZP3'_21G_X+;_\
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M<\?\+?/ _'/ ^Z]\[DL[MVO:=@;U>S$&D>.#<C\8)I-@/<7V<^R3VX1U^?\
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M6=:X0NO;5Q+HW('-.$P!#BB2KB '6"$X)*L@M06$T(!F "8$!EK"M80K6O\
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ME>$\OP?8+#N+,ZXS<1.V/<QX]A^384XF6( H4QB;L""1LHEA290K)3+P('$
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M?8FR3IYQ-%H))V*/M[X$,AA"5$1CU&(Z/N%@*6I88<58I.5V2<D.8OTKTJT
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MD(: ]ET-D2@T?;XS'D-[DE$%"$E:6PH%Q! "PKVO?HMT]%!RS;7?Z8EQF?\
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MR)BB<6CN,,R1#+TK=)#)7!$U,C;Y2Q8XS&3(C%S@X%%==0D)*+&*_7$'JBZ
MJ1T__P!*YY:/WD6N7]AVK5 T_P#]*YY:/WD6N7]AVK5!AGJGO_@/_P#TF6+/
M_D&@K^]4'J]@"0\I_'UGK?E^SC >/S)N#ENL^1<O8- T#?\ %F1XC,,M3Z/N
MBH3S#,D).X.0LDH%"],6RJ'!4RM*\Q !0>DN4$-0N/!_Z4UJB!<W4\SDM-9C
M4#4XA1-V[NDKQ+[)W@:,M(69CYHUY73TE>2)<#O24;:%4A"$P2DLJQ1MP!VU
M<?N.<'XGTAU3@6LTVE>2==V?!&-U6#\@3@98Y9,\5R"-(9)!9*^6*BL&L4M>
M(X[IS[EB9VPPH([ &F*&$0+!+^@4"@4"@4"@4"@4"@4"@4"@4"@4"@C-NI_@
M;[:?O9L\?N62J@Y=^ KBST W6X(\. S[J?@:49"RVDV5BC_GD&)<>$;!MG8Y
MYRE'H^_Q[,PHT;/6R01!O0I0-AW?1@(*2%$" --81(@V!Q'[9YHXP-K1\#7(
M=(3ES6@$:IXU-G9#>[;'\R8H6K1D1'#AB]8<804[EA 8E8$8CSAM[FG4QP)A
M@0,@#PN)S5S6<<>M&UDPTWV4SXBP%F&)LL.D12C)S"]-..Y,RS5A2OS>N9<C
MMR5VBC9W(I78A22]J&A1VX!W)+.)MVMPKWY8MQ/3TY3U+S\ZYXS'H!L;+GK'
M<Q(AH,3RK#6;=A%&2#8DI:H4L@;QBQ9)<B1.36<2D:4AY$I0(DA%NJK4EHK&
MVH,^]++ ,SX\X:=?$.9$,@: R2491G6*6:2"5 7(,.R^7*WB)*4J!8,1S:QR
M9><O>6\%@EEJ$3D4J+#<M0$8@I@R9M23Z?SE-YDHR>%.PXAW2U9=]W]5VA06
M%&PKMG!FOB1DBS:4?<Q$V(GC*LGEB522D_,0MR -B.@!!00OR].7J.OU)XI,
M E2PE3[5=D/%MLLM+EX1A<W"49O+;W>-7=>WN-7XJVXL01Y$L[45QW6)SA7L
M'K=0(7GT'(OZF&=1K".X? +L=DI:9'L-85WJ>'W)TT$C5K$,3903#7&2J'%<
M4B)/4FEI8]#718(LD!B@PE";V19@K=6X2QYB<WZZ\G?%?R#:PZ,[#XHV@S%'
M,'0+.+E&->IHQY?,*C&,LTPC)YS48[01>\, 9))$.-5R1*S]\N[GC%;LTIG6
M#80?IQ2<X'&+*../6(N?;?:\X#GF$]=<98SR?B?+>3(KC:9,,EQ1!$$/>"XG
M%I4O:76=-#OY6$L:KL)+D,Y,J3D7"%6(2<(5-<># ^\INQ'J6=RM=&*2-N"]
MN->9?J#KO(U;6IAY&2YROPD]0=/(6M"YV)/0NX$K$T.ZGOMDRI'YJ([P44<,
MXHD)8>G2Y8- ,5<5^'];M@MEL(:N9QU66Y6@N4<99WG4:PP_C5J\LY"FZ!WC
M#7/5[ IF"EP:G\ 7$AN I7)GH"@@\D!ERKFAJ;C*VMP+N?ZJC?K.>M4\3Y-Q
M*Y<<1<39IP@:GQH:GUT@N0-,8M)#6<F0MK2Y+&I,_-J@@A98BR9: KMTPS4X
MRC1A_/&KM5K]QG\TG.)KINYDV':Y/.TFQS3LQA3)F97MM@T"F4*D3_E_(I#,
MIR7(SVZ)MI*-@RVALS@5+"B3#R'!($=E9%R!AKGF9Y#]+=P.4'@1Q-JWL+C_
M #]*<.\DN'9%D5=BMQ,E\(86^79XUZ:8X!-D5I(/@LC6N2J-K;]BU."X:<HD
M(S[%!.3W-"7_ "U?Z1+P$_\ KV_^T#Z"K;U">H^JKMSDX*R#R833.N(M&-F]
M:&6%QS/V$PL:/R%FG&[H]MID;E[C)8#E%/:-I42Q"J<;I&@9Y )"D4=8"=,M
M,"'I9+PB>E*B<6\X.G,W,533<E(?W2-;L:5S24]1878TD/D>':ZOLUL< -^@
MTOP_M"!?:FA *U[4%D_*1#(%CC;7TG6/,5OK]*<80/-S?#,<2:4B"*3R*!1=
MBU'8X>^R,0&:. $_.\>0IU"R]FY!:Z@P?0G(_P!B"'8-0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"'_ "%?X N\
M/[S_ &7_ '%YK6WNSY\/?!'NOW-^$=,RK@7V[[F]==)YXRWRP:]2:R4H% H%
M!]8)C_I(S_\ !;?_ +D)KR,[P\GY_BU_@I5:Y_A]_P _/?O:5U'$4'-5ZL7^
M)]GO]_'!O]DRF@BQP1(ECGZ:/8=M;TQRQ>X0G?9$A1IRQ&J%2Q7"I*0F3$%!
MM<1AQYQ@0A#;[-Q7M:@I/](ALS@#7[:O:)FSGE_'F'S,DX0C9$)<<ERQCA#"
M_N$2F(G)Z9T;_)%S:T7>BFQPLJ+27.L>>G(/& (K$CZ CIS(YHQ)GSU"C)D/
M"6287EF G98TW8$LVQ[(FR61->[1E+C5D?DC9(650L:73PMV1FIS#$YQI7:E
MBM85^B]!/[UIW^$II)_>.R3_ &>MM!T1\PP #].=F8(PA&&VI^M@[6$&PK6&
M7*L+&%BM:]KVZP# V%:_YMKVM>WV:"D7TN*_!;=Q7\K)FSSKX)KFL>')ESD[
M=U>EO<<4R'!K@PSH[NL<;7A]-_\ )QR46_H1*>?;IZ0@%>W101%;_3?;71]<
M[;&</O)C@[,&*QHS7&.S^ 9YE.%\LHF \?B*)F>)+BXM_A=UC;=&8!6:J>V3
M^B$EQB1IQV&20&1\+G*=R:;$9GV%XU,RYA>MB2<I:R;6Q.$ODY>&J937'V78
M=BN7>7W1DRVB&K62N.O;PBL@-\07.2,P9Z=2D/*M8RRD*=>&'$TARGM#.\#I
M^4'*/$Q/9#$ST;9,HX=+XL1D^2QA^*+68AECHR9RP.)CD"(*@]8W)')2I I4
M)3TX %J[DEGA>1O3P%XB86^V>N03U':>8+8[&R(VU3#.V+'W,N1S8RWKW=Y1
MQ&$M;IN9-<D2-&E<W=P5D-#,E57L>I4&@(ZQAHKAB?K)V<V/9OT"8#UYCJ>Q
MZY3-G.=#BQ%&N1K9+F5$8O-*&>J&68L&1<P0;FF7M<71<0OS;A4]M5KGN'Q7
M[:Z-[S[;-D5VE'EEMP[LTW.<E(6O\"D[E&$<:6NN!W]8Y-P4"%^QQ& -21$!
M(G$VMZ(2 : D2=/8@ =YW)/L[B?<O@ VIV9PB]^.XWRUJL[R-E--" IR:5?B
MC<A?HL_I0#,"ADD2?DBEM<"+"&$M8E,L 0P=48@J@]%K_@K;G_O@83^YR705
M.>G@_P!(BSC_ .QI_P!FI]!Z?UDB1(FY0<*')TJ=.<X:*XN5KS222RC%JL&>
M-ET %2L8 A$I4 0HB2;#'<0K%$@!T]4 ;6#II]60249P_P X&8468-/G7!QQ
M Q@"(1!HI N(N:2(5KW+,N0>,%Q!Z+]08K?F7O04P<;G^B3<C/\ QPV"_K%A
M2@PCT^6/YAE7@[YN<<P *XZ:3*&Y'8HTWMMS++GQU6:V2 *:,I^R.3W$*4WM
MX=>UQ=0055[#L(%Q!N$=/2>;U:@Z:YKVV9=I\G0O"Z[,&/L7^SC(N0%IK)&0
M!Q^]3=7,8>?(S;^#M"R0ERAM6$A67+"INTW+*,L;U2C@TQS+[.8$VRYY\-Y/
MUQR='<O8[0RK4B%#FD2NN41Q7(XW-FVSTC:'54C2)7U*C$M+MWQ$)0B-%>]B
MS17"*U@^I#0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0;
ME+_V,O\ [0/^MM0?W0*"&_(5M6S:0:1[/;6O)R(L6%L0RJ31M.X"+"C>,@JD
MMF'&,;.N;>P/_*K(KNUMH;7Z>D2NUK6O?[%PXJ>*_C1]3+CS5",9;TPWET[U
M[QKN&H2[9.T6RQ&VR596>W[+$>8U2653IUE6D>85J5Q?XR@0*@(4S\H1)PGW
M,"64H.4]8-GZ Q'?OB5Y^82R<E>4L-Y3D'+WC66L[YE?"";PK'+_ )@B*XE5
M"QN;2'$.#FYLGQ3TPIVHXIM8N['BFI"@PTU0<H$4%D[)_I>TO_Z*M-_9M%Z#
MU7K#R23>,[ @S"BS!I^0/!)R<8P!&(@X6+L^IQ&DB%:]RC+D'C!<0>B_4&*W
MYE[VH/1^J\=&V+17BAG$C7)&.'Q'DCQHZ2B2N9Y:-F86U(W&.ZI<ZKSA (1I
M$S6SJE S!WL$)2<8KWZ WH.DC8*=P=PPKF.,()E%%TD?=;LJ3MDCR.0M"E\>
M8.3$U3>;,FII)6#7N$4*7O*,@3B26-&$Y42"YG6-!80<_?IK\11O8#T\$9P-
M,EKXV1#-J#<C$4J<HRI0(Y(WQO),]R3#7Q;'UCJVO+6D?$C6\FF)#%*-606>
M$ C"306N 0:7_P RIXLO[OF__P"VGKK_  5:"YCG:_B>^1#][-.__:26@]=P
M(_Q./'I^]WCG]<7>@J\]-C_A-\_'_2AY-_= S10=2<UBC=.X;+8.[G+4S3,H
MR_11T4-IA!+B0W2)J5M"TY :J3K$Q2TI,L$(H1A)H CM:X@"MTAN')1_F5/%
ME_=\W_\ VT]=?X*M!UH0&&MF.H+"\?,AZ]4S02)1R&M"EU-3GN:ELC#.C9$!
M[B<D2H4AR\Y(A (X11))8C+WN$ += ;!RYRC_3 ,<?\ 1>+O[()Y0=2\NE\3
MQ_%I%.9Y*(["83$&5QD<LF$N>VV-Q:+QYG2&KW=^D4@>5*)I9&5J0D#.4JE)
MQ1!!0!#&((;7O01@S9KYH3N%$&[(>PF&]3]E85$V.4D,.1\JP;$V5F:&L*@=
MBY@;&I[)6Y[*B*0*AH#=<>A6)NR.2!$,01DAN$.7GTZDJAL;Y8>7W7W2>5JY
M+QEQ%6R3#%K<R/SE*\5Q3)SA)&UI#;'#PY."\H+0^E%R9,G4I3#@/#4QHC1'
MG%ITY@@E/J'U.1SU$NXVXBC_ ,;X+XK\;I-*, *K]W,;E>=Y6.2I<Q2EM,+[
M5,:M8!K)BTJ#2KB-.0.#48(T( A(L'5!0<DFUW^F)<9G_1O3W_<7()0=0V;L
MWXJUPQ;+,UYNF;=CS%<$3-ZV8S5X(<3VF.(71Y;F!*X.GA:)P5IVX+F[$!/4
M7*[%*4(1QPBR0&&!"',MU=XJ.2QG-R:_X<THW(3.J1J+]K[&P8ERE(A(2QE*
MFQ,DRY% N$I0I#0M]@]D2Z%@.)+$4((B^N"X<GB[7G5O0+U+^@F*^)*3J6%'
ME9FE2#<S N-,DO63(-"X[W.7*I*VRL#F\RQ4QEGQ9 8_&,+DL&%B4MR!:D)1
M!-2= 62Y=_TP#5K_ *+R0_V0;&4'5S0<,/+CQ_X;Y,_4R:]ZHYXDN38ECN2\
M<2&5KGG$;S%F&:%.,+F^Q#TUDI'&90R>L9:)0J+L%0$;<8,9?V #!?[:@N+T
M1],AQ>:$988,Y1"-99SOE6%O1<BQ]*MDII&YB5 'U-="8VO,;BT%@F-(48],
M:M%=2WKG!M7K$*HT1Q!H#"TXB0Z$Z"F?U"W\2_R!?WF4?]GT-H-=XYTHA'(=
MZ>#4W4F<=R1@REQFZ@DPV2K".V\CY-8]><:/V-IL5<LDY6 N.S%N2'*P$=4U
M6W]X2];J'CM<.3W4[<O(6QO)#P!:[[#I75HVWX],N[2ZA[!,[_<T;V>;CYH8
M6> 25Q/-,/,6+5T=9C&E:I,-&<L=F-8IO]H>7<077;X[B\FVZ?,)D_A\T#VD
MQ5HE&\!X9B>3LAY7E#4VNV4,N/#Y#<?9,$S8Z[^QOKN:6T),BM!9B!F\)/ A
M;WA6M<%"?LVX84M<K.B6QNF^?^/E7LSS59(Y"I]-M^\&J#]8,B+'UB'B\U8_
M(7Q7E6/XV=]D<II6!E3A6$M1(T4:9TI*=W* 6:468!.8%_W/#_&C>F\_?NY'
M_K_K+068<[@ #X>>0\(PA&&VM$X':P@V%:PRPHS"Q6M>U[=8!@;"M?\ -M>U
MKV^S0<M'(]%),]^DIXNI8UM2][A6)IKJ9D7,;2B[SV+AC/RUEF"F(W*Y !$A
M0*IS.&,OI47 2$\1=^GKV!:X=LL&V^U:FFM"#;6+YNQ<7K/:$(INIRNHET>:
MX-%8R-K1. RI0ZG+BF^*.+,G6E$+&]6(E4B4W[N:6 VW4H.._A]$&;\5'J3-
MAH2UKV;7S/4YW]DV"4*M L;DHXX7@3(CX:J;"7$A(N,2$L4O9T(QB*!8"A 8
M2+H-*-  +R?3=S6&J>$S2^Z>6QD^T(Q_D$F:7)?FHVT0.3Y=R8YGE2BX%8K,
M!A#;?O PJ^RN$C],OT!^S05[\:LLB&S?J=.6':?7EV;IMKU#M4<:8"EF2HF>
M!?")9F4T_7I E.:WIL$>RR#NA>#I*A(6A,'VY3<,Q.(Q..Q@@]5Z2#)<!QWK
M]N!I%D22,K!N9B;=W,+UEN!R%R)03Z7!/CL-B1\Q0MKL-,_2!.VOV.W5$ON6
M48-O&F -18KO15S _/D=R5CW8OU*7#7AC7R0LLRS%K$9F24;(N$-6E/WL^B1
MS4.2%PB=+4%S6V.O2!AB;S<]$H. L(\PI F%!&K3!.#V/!_,H+B?FL]0#@;+
MKVRQ[9'*FU2')^+FZ4JT[;*IYA@Z69IFK8V0U*X# I<$45AF0HZM-*3=(U+>
MM3J.J,E/<90>N]07F/$LIY-O3WXFC&3()(\GP3DNQ<^3G'S#*V1XF,*:'G.>
MM[8S.$NCK<M4ND:3O+@T+"4EUI1'>C$9]BNOV)O4"97J;M5)CE[0EHVSPF)6
MU;*\;^2F+;3%4G:+7L^ML:BJQN/RBF1&=B=U$C8U-:&4'!MU!&&14D/6Z+B
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MU[WO>_3>][W"G>>^G+X:<GSJ:9*G.G/CDUR'+)'.9@]?A";4-OB\IEKPL?Y
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M'[2@J F'HQ]&W.0G+X3M%M'$XV>JN?://(<6RY8D(,N4,:)$_%0J-7L25?M
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ML;C$CF,G0+52&<82R*\#?#E\V5@., O 0(DLJP20"",9@5V_YE3Q9?W?-_\
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M<Y.,Y%/I;($32?8 K"L0K&+_ +&]!6!Z8K0ZVE'%UC&12=D+:<O;:*0;)Y"
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M&RV#NYRU,TS*,OT4=%#:802XD-TB:E;0M.0&JDZQ,4M*3+!"*$82: ([6N(
MK=(;A#GCGX^,,<8VLS/JK@639/EN/626RV9)'G+KU%'Z9F.<R7EN+H0H<89"
MX"QC0$'%VLG"%N 8$/V!C'?[-!.R@4"@4"@4"@4"@4"@@7R.<>>).3K7.^KN
M<I]F2!XR63Z)3V0WPG(HA&G^6#AEW%0TQ60+IG \@H#8D8\+"' XI.E3++K6
MY*,"DL # &A-V/L#+%&!DBT;;4C-'8TT-K PLZ JQ*%J96=$2W-;:C)M]@I(
MA0IBRBPV_F0 M:@KYY!>,+ O(VKUJ?LLS',6,YWJ7F)%F["N2<&R&&1J<1Z6
M(S6E9=$:OF\ R(VC853Q'&I>:62D(4W6-2403P@",!@5\;U>F$XS-]\W3/8B
M?#V(Q/EK)+]:39%D>%LK-:5/,GNZ(* U:O8\L0C+;$S]N023UBVE.W$V$0&X
M0!ZQG:!*CC4X.= >*QP?);K=!Y;(<N25C%%WO.&8Y.GFV33XN-42N/CS6:UL
MT6AD3;%RQ.68LLS,S<:X7**LJ&<$@@)81JY"/3.<;G(UGQYV6R4=GG#F69>2
MC]HCOKY.87&FO(SHW-R%G02*4,&1,9Y1:$L@(:&P@@Q0TE-EEEP7.5!/4B&<
M()52+AFU,?!<:1+>_9HB;/Q4R13)=:H_'YA&5#:]&J5<)6>&9852F#25]E#8
M09 T=@>'+&93U33NL<*X@7+"<.V6M4%W&UMS-JYDUVEK% ,Y09VQ_+'B"+V=
MLF+<S/(2PJE,=<) PR=E2.9=B[=F-2WJRK?ZI8J"//XM3!7XMS\5UYKRS[ /
M89^#_P";_'8?[8?)O9]GXGY@\B>2O,W5_P#9WE_NO3_\;T$D]7->(5J3KIA;
M63'#I*'J!X)QS%\8Q%WFRUI<I<XL$3;26IN5R->Q,D;9E;N<G(M<\Q*@1DB'
M>]PE M]B@CGHIQMX-X^'G:1\PS*LKR97MOGF1;#Y'+R<^1!Z3LDUDRIR6+VN
M$ BL%A9K;%RC70RQ)"\;DK"&P>LI%>U[W!-^-O!L]Y(,/<H+Q*LKIL^X2P,Y
MZ\16(-KY$"</N$*=EF4EJATD# J@JR:*Y0 W+CE8!Z:0)$E@D)NE->X#;G!6
M;NSZ6WB^WASY)]CY21GG"60<@/CA*LF)=?9]#HU$\B2UV.3*'65/T;G^-<EI
M6A\=CR!G+3&,306M5*3U2@!JLX9]PWIK'Z>[CJTVV>UVVMUKCN3<83K7&$3Z
M&,T=0S%H?8EDE1DEBF<=D<TRXLE43?<BR>7EM4V/*1"1R!M;4):5,42C"06(
MHP+PZ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*"$6Y#ZF9?9SWB-1Z0]Y\W]3QXMV,[GV/E?K=U
M\+=VKH[QVMNOU^T_F ]7J_9Z:J/C-^+=#PM[".[=Q;EWUT_IQS>[[=9=T/,]
M*J]%W+K-)3I.?'2=)TGS%G-YGRW.D]V<-U9V\_3GH=;K-'S.Y*]!.5'/KW3\
MUTN5F_,T^5YO-^:FM<*0B\]-O]S;'OQ:5_VVU53[[6XOT&X,^E[W_+"3WL6U
MOJUO?Z+2^A#STV_W-L>_%I7_ &VT]]K<7Z#<&?2][_E@]BVM]6M[_1:7T(>>
MFW^YMCWXM*_[;:>^UN+]!N#/I>]_RP>Q;6^K6]_HM+Z$//3;_<VQ[\6E?]MM
M/?:W%^@W!GTO>_Y8/8MK?5K>_P!%I?0C>>OK^F?ILO1)8O&HR8&-KE%W"/%/
M):X8 .+0"Z48G1[=4_=C+F6$+H+L/K #T"M;IM>>WQ=''6[.).O77;OTG#7#
MVZ,V.&=5?T^ALU]N=,1J]!'1S.JU^JR^CNYT774RXOYUMM+XCG1=HWM ;DU&
M[N"<G/S=XZ_5VSO'*CF9TY,V17*SYYT='D95W.BE(K=,4F<*TF)E>''_ #HO
M_1$_!5=NAL>''_.B_P#1$_!4#PX_YT7_ *(GX*@>''_.B_\ 1$_!4#PX_P"=
M%_Z(GX*@>''_ #HO_1$_!4#PX_YT7_HB?@J!X<?\Z+_T1/P5 \./^=%_Z(GX
M*@>''_.B_P#1$_!4#PX_YT7_ *(GX*@>''_.B_\ 1$_!4#PX_P"=%_Z(GX*@
M>''_ #HO_1$_!4#PX_YT7_HB?@J!X<?\Z+_T1/P5 \./^=%_Z(GX*@>''_.B
M_P#1$_!4#PX_YT7_ *(GX*@>''_.B_\ 1$_!4#PX_P"=%_Z(GX*@>''_ #HO
M_1$_!4#PX_YT7_HB?@J!X<?\Z+_T1/P5 \./^=%_Z(GX*@>''_.B_P#1$_!4
M#PX_YT7_ *(GX*@>''_.B_\ 1$_!4#PX_P"=%_Z(GX*@>''_ #HO_1$_!4#P
MX_YT7_HB?@J!X<?\Z+_T1/P5 \./^=%_Z(GX*@>''_.B_P#1$_!4#PX_YT7_
M *(GX*@>''_.B_\ 1$_!4#PX_P"=%_Z(GX*@>''_ #HO_1$_!4#PX_YT7_HB
M?@J!X<?\Z+_T1/P5 \./^=%_Z(GX*@>''_.B_P#1$_!4#PX_YT7_ *(GX*@>
M''_.B_\ 1$_!4#PX_P"=%_Z(GX*@>''_ #HO_1$_!4#PX_YT7_HB?@J#WD?9
MU1Z\0 /CHFOW<P7:$"3V'>UA%VZOVY K=6_3_P!3_4H59MY;7?6M_P#?$?R2
MA4\MKOK4_P#OB/Y)0J>6UWUJ?_?$?R2A4\MKOK4_^^(_DE"IY;7?6I_]\1_)
M*%3RVN^M3_[XC^24*GEM=]:G_P!\1_)*%3RVN^M3_P"^(_DE"IY;7?6I_P#?
M$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ?_?$?R2A4\MKOK4_^^(_DE"IY;7?6I_]
M\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\1_)*%3RVN^M3_P"^(_DE"IY;7?6I
M_P#?$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ?_?$?R2A4\MKOK4_^^(_DE"IY;7?
M6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\1_)*%3RVN^M3_P"^(_DE"IY;
M7?6I_P#?$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ?_?$?R2A4\MKOK4_^^(_DE"I
MY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\1_)*%3RVN^M3_P"^(_DE
M"IY;7?6I_P#?$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ?_?$?R2A4\MKOK4_^^(_
MDE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\1_)*%3RVN^M3_P"^
M(_DE"IY;7?6I_P#?$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ?_?$?R2A4\MKOK4_
M^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\1_)*%3RVN^M3
M_P"^(_DE"IY;7?6I_P#?$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ?_?$?R2A4\MK
MOK4_^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\1_)*%3RV
MN^M3_P"^(_DE"IY;7?6I_P#?$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ?_?$?R2A
M4\MKOK4_^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\1_)*
M%3RVN^M3_P"^(_DE"IY;7?6I_P#?$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ?_?$
M?R2A4\MKOK4_^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\
M1_)*%3RVN^M3_P"^(_DE"IY;7_6M_P#T:+Y)0J>6UWUJ?_?$?R2A4\MKOK4_
M^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\1_)*%3RVN^M3
M_P"^(_DE"IY;7?6I_P#?$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ?_?$?R2A4\MK
MOK4_^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\1_)*%3RV
MN^M3_P"^(_DE"IY;7?6I_P#?$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ?_?$?R2A
M4\MKOK4_^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\1_)*
M%3RVN^M3_P"^(_DE"IY;7?6I_P#?$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ?_?$
M?R2A4\MKOK4_^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_P!\
M1_)*%3RVN^M3_P"^(_DE"IY;7?6I_P#?$?R2A4\MKOK4_P#OB/Y)0J>6UWUJ
M?_?$?R2A4\MKOK4_^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G
M_P!\1_)*%3RVN^M3_P"^(_DE"IY;7?6I_P#?$?R2A4\MKOK4_P#OB/Y)0J>6
MUWUJ?_?$?R2A4\MKOK4_^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM
M=]:G_P!\1_)*%3RVN^M3_P"^(_DE"IY;7?6I_P#?$?R2A4\MKOK4_P#OB/Y)
M0J>6UWUJ?_?$?R2A4\MKOK4_^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24
M*GEM=]:G_P!\1_)*%3RVN^M3_P"^(_DE"IY;7?6I_P#?$?R2A4\MKOK4_P#O
MB/Y)0J>6UWUJ?_?$?R2A4\MKOK4_^^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[X
MC^24*GEM=]:G_P!\1_)*%3RVN^M3_P"^(_DE"IY;7?6I_P#?$?R2A4\MKOK4
M_P#OB/Y)0J]^B2F)$Q"<Q8I6C)N9<2E3<%SS[#$8*UC;E@ #H+L9:UNBUOL!
MM1^/,H%!%?>D]@3:2;BJ96V/#U%D^J^PA\E9H\^(HP_NS 5B27&/+8QR5RCT
MN;H\\+VX)A29<H:70E(<,)HTBD(+DCVEU&V:_-Z[.#\O=6;DY.]+N*=TQDYF
M;E79V5EYLZ_3QEWYN39FZ>_-R[;Z77Y5N?DW9EL3;;FY<S%\9+P9&?=QANFW
M3766:F=Y:7F776S?;;=T]G-FZR+K)NMB:3-L7V3=&$76S-8^;3YUT%_Q:-P/
M\N'"_P#]#UKT@^DO7W^DO"'_ "UO'_Y6L [CXW]4-U?>_4?E,\ZZ"_XM&X'^
M7#A?_P"AZT])>OO])>$/^6MX_P#RL[CXW]4-U?>_4?E,\ZZ"_P"+1N!_EPX7
M_P#H>M/27K[_ $EX0_Y:WC_\K.X^-_5#=7WOU'Y3/.N@O^+1N!_EPX7_ /H>
MM/27K[_27A#_ ):WC_\ *SN/C?U0W5][]1^4SSKH+_BT;@?Y<.%__H>M/27K
M[_27A#_EK>/_ ,K.X^-_5#=7WOU'Y3?2Q:27(34V")6$%DB;T5RBQINT&65=
M,7<L A]H'KB"'HM>_1;IO7EUUL71K,Z+YK?TMU9[RL\Z:X*W\[PZ^O>\Z>_>
MP[!V^[TWQ/\ [K76<>!V#M]WIOB?_=:&!V#M]WIOB?\ W6A@=@[?=Z;XG_W6
MA@=@[?=Z;XG_ -UH8'8.WW>F^)_]UH8'8.WW>F^)_P#=:&!V#M]WIOB?_=:&
M!V#M]WIOB?\ W6A@=@[?=Z;XG_W6A@=@[?=Z;XG_ -UH8'8.WW>F^)_]UH8'
M8.WW>F^)_P#=:&!V#M]WIOB?_=:&!V#M]WIOB?\ W6A@=@[?=Z;XG_W6A@=@
M[?=Z;XG_ -UH8'8.WW>F^)_]UH8'8.WW>F^)_P#=:&!V#M]WIOB?_=:&!V#M
M]WIOB?\ W6A@=@[?=Z;XG_W6A@A]-^.O1C)CVHDN2-*M-<@2-68::JD$WU;P
MM*WM2:>*PSC5#J_0]>O.,.':UQ"$9>XKVZ;T,&\\5X+Q?@I@%%,(XRQ1AR+#
M$G&.-8KQK%<>L A)"+)DHA,\1;FAN$),FM8LN]R^D +=6W1;[%#!L[L';[O3
M?$_^ZT,#L';[O3?$_P#NM# [!V^[TWQ/_NM# [!V^[TWQ/\ [K0P.P=ON]-\
M3_[K0P.P=ON]-\3_ .ZT,#L';[O3?$_^ZT,#L';[O3?$_P#NM# [!V^[TWQ/
M_NM# [!V^[TWQ/\ [K0P.P=ON]-\3_[K0P.P=ON]-\3_ .ZT,#L';[O3?$_^
MZT,#L';[O3?$_P#NM# [!V^[TWQ/_NM# [!V^[TWQ/\ [K0P.P=ON]-\3_[K
M0P.P=ON]-\3_ .ZT,#L';[O3?$_^ZT,#L';[O3?$_P#NM# [!V^[TWQ/_NM#
M [!V^[TWQ/\ [K0P.P=ON]-\3_[K0P.P=ON]-\3_ .ZT,#L';[O3?$_^ZT,#
ML';[O3?$_P#NM# [!V^[TWQ/_NM# [!V^[TWQ/\ [K0P.P=ON]-\3_[K0P.P
M=ON]-\3_ .ZT,#L';[O3?$_^ZT,#L';[O3?$_P#NM# [!V^[TWQ/_NM#!L\"
M"7=0'1(&VUNJ'H_\3=/1;HM]C_OO_4H8/[[A+_K V_0W^^Z%8Y#N$O\ K V_
M0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_P"L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0
M[A+_ *P-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O\ K V_0W^^Z%8Y#N$O^L#;
M]#?[[H5CD.X2_P"L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_ *P-OT-_ONA6
M.0[A+_K V_0W^^Z%8Y#N$O\ K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_P"L
M#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_ *P-OT-_ONA6.0[A+_K V_0W^^Z%
M8Y#N$O\ K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_P"L#;]#?[[H5CD.X2_Z
MP-OT-_ONA6.0[A+_ *P-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O\ K V_0W^^
MZ%8Y#N$O^L#;]#?[[H5CD.X2_P"L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_
M *P-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O\ K V_0W^^Z%8Y#N$O^L#;]#?[
M[H5CD.X2_P"L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_ *P-OT-_ONA6.0[A
M+_K V_0W^^Z%8Y#N$O\ K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_P"L#;]#
M?[[H5CD.X2_ZP-OT-_ONA6.0[A+_ *P-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N
M$O\ K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_P"L#;]#?[[H5CD.X2_ZP-OT
M-_ONA6.0[A+_ *P-OT-_ONA6.1J[+^ ()L)#3<=9\@&',X8^/<4+P?!<OXFB
M>2X:<[-8C!MCH;&)FD>F0QQ;AFBN0?<BYI-Q7N 5NF]"L<C9"-DDC>D2H$#L
MRH4"%,0C1(D<?*3)$:1,4$E,E2IB5("4Z9.2 (   &P0!M:UK6M:A6.1Y/<)
M?]8&WZ&_WW0K'(=PE_U@;?H;_?="L<AW"7_6!M^AO]]T*QR'<)?]8&WZ&_WW
M0K'(=PE_U@;?H;_?="L<AW"7_6!M^AO]]T*QR'<)?]8&WZ&_WW0K'(=PE_U@
M;?H;_?="L<AW"7_6!M^AO]]T*QR'<)?]8&WZ&_WW0K'(=PE_U@;?H;_?="L<
MAW"7_6!M^AO]]T*QR'<)?]8&WZ&_WW0K'(=PE_U@;?H;_?="L<AW"7_6!M^A
MO]]T*QR'<)?]8&WZ&_WW0K'(=PE_U@;?H;_?="L<AW"7_6!M^AO]]T*QR'<)
M?]8&WZ&_WW0K'(=PE_U@;?H;_?="L<AW"7_6!M^AO]]T,#N$O^L#;]#?[[H5
MCD.X2_ZP-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-O
MT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[
MA+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_K V_0W^
M^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^
ML#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5
MCD.X2_ZP-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-O
MT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[
MA+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_K V_0W^
M^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^
ML#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5
MCD.X2_ZP-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-O
MT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[
MA+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_K V_0W^
M^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^
ML#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5
MCD.X2_ZP-OT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-O
MT-_ONA6.0[A+_K V_0W^^Z%8Y#N$O^L#;]#?[[H5CD.X2_ZP-OT-_ONA6.0[
MA+_K V_0W^^Z%8Y'[)D4H H)&J>T!Z<)@;GDEM79#,+M?[< #>\B[,0K?F7Z
M+]%#!DENGIOTWZ;=/V/L?F6Z+?8O_P!7[/31^/\ :!0*!00!WF_]2[_V]O\
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M2QH*?'FXRRDI#L%INJ6CLE37/.&2$T+*>0WDFU<XQ\,)\S[-R9V2I7UR4,,
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MRU(W9.QQ,<5R!5%'-1(H<>:6\IVEVO=,H*7A*$DN>J$F$;960H)*"UG&>R^
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M[VN'/ISDXLY3WGU .CZ;#FR>%8G)LDK7P?&VXO[$SJ4>OZ)J@4=0Y5)RZ _
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ML_2[V_3+W_,#>M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MOKTTVW&-LUYVY]MWCAJ83BN>Y9PYL2\>.A$-3"XHL9=EIQ(2':Z<L?>#(NC
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M% H% H% H% H% H% H% H% H% H% H% H%!&;=3_  -]M/WLV>/W+)50<N_
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M[,8"U,P=G9EV&RWL!)WB/LX<-7*E40AB5DA[Y,53[-II<Y''DR50F8QIB$J
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M@F%E+)@Z8<F< 4S-R+('8H*IU$L4V)+*+L/LRB@@"46K&EFJFDD*68^U3P5
M,)1AU.0J7XJ(-8[/<I5MA)R9M6S&6NI[E+9BN;TZDT!![HN5FE!-'8 K6&+I
M"3] H% H% H% H% H% H% H% H% H% H% H% H% H% H% H-RE_[&7_V@?\
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M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$ =YO_4N_P#;V_\
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M;DJE9Y9Q8>J=8T(AV$%\V,<6XVPK XUB[$,$B>,\<PYO U1:$0=A;8U&&)
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M O9EA:"J9(KBL,\TS29^%*)=)G>82$SS%D&1RN5KO$)&^JE'0I7'!*[7LRK
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MX_F+=XQ$9U&7Z'2II[VO;_%(Y)VI6R/C=W]K5(7-#WYL7&E=LF.)/*ZW6+&
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M]281D?(X4R%(KGS1(\BXKF3VF:TQJ)M(E$FP_,X"\RTMO1&]B19S.5]D264
M/0$DJP DWJEI9JIHYCP6+-3<%P'!T*4')%;LAAS899VD[@A2!0)'>:2QU4.4
MNG#X0B!8H*YX7+EG4^QVG1>]!^$/TKUF@.UV6MWXGC3PG:'.<(CF.,IY.\Y3
M]=YHAD21Q9OCS-Y+<I4LQXR>'I(4V [PW-*16;W;I,-&(PVY@2FH% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H*N
M-N.%7BXWHG1N3]G=/<?SK(ZONUW:>1Y]R%B.72,:,I0G2G2Z0X:F6/G68*2$
MRCL@FNAJPSLBR0=;JD$V+#>6G''1I%Q^L#Q'M/=<<?X2)D9:0B3/K*4[/\[E
M"5O,--;D,HR3-'22Y"DK<VG*#3$R9<YJ"$YAI@RP!$8.X@R?8+2#5[:?)NMF
M8L\8Q\]Y'U#R =E+7>1^=,AQCV>SM0YQ)X-??"(;+(\Q2SKN,%:C.ZOB5S1V
M[KU;%6":<$P-IYQP)A79C&K_ (=V"Q9!LQXNDX2/&X-D..-LGCRP]&;90WN
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MX/$\FP>98VGK&BD\%R%%)#!YI&G*QEVZ0Q.6-"QAD;&OL282==$[,Z\Y.;8
MPBZAE^B]K_9H(\::Z,ZJ\?>)EF#M0<2HL.XP<9>[3UQCJ:43F9J7&7/B%I;'
M-[<))D63R^5+E)S:Q(TX FKAE$DIP *" -NB@V=GG7G!>T6.'7$.Q6)8#FG&
M3T<F5N$+R+&FR3L8G!%VGA[ND3.1!UVQ\;+G#$E7)A$K$HA7$48"]^F@JE@7
MIO.$K'$S3SR/:$8_<7M,I$J+0SW(.<,J0P1HU9*VX5&.<GY0F&/5::QQ 0V)
M-:QDA)N(JP;%#$"X77M34V,38W,C(W(&=F9T"-J:&AJ1IV]L:FQO3EI$#<W(
M$A9*1"@0I"0%$DE "646&P0VM:UK4'GT%9NW'#?QC[U2<^<;0:?8SR!/5IB(
MUTR"RJ9=BO(+Z)N(,2HK22=X@DT"ETE+3)1]D$"]8I!8L!8>CJEEV"'YZJ\-
M'%[I2_-\NUOTPQ##)JS+?$6&?2-/(,LY#CB_MNW"LC60,POT^F4;4EF?S T*
MY/< ?M0] ?L4&^]P-"M/=^80VX]V^P'",WQMC4KE<<'(2W1JDT54N:6R-S/B
M,ZBCDP3B)&.*< +*+MKBE[:Y)0A]8115P!IO33B)XWN/R0.$PU(U1@.+9NY$
MK4AL_6N<UR7D1&WN1*=.Y-#+D#+4IG<RCS&XE)064(4"Y,C/N'I&6*][WN&[
M<MZ-:M9TV)P#MAE3%_FG/^KWC?L+GWG;(C)Y'\QA$%Y_\EHY+FB%2;O@17_I
MPVN'9_\ 8=6@\C*.DNL69]CL";;9*QEYDV#UA32=)@W('G/(+/Y(3S)$I;Y(
M7Y48)6U0F2^)(U9@.EX;7 1/6Z2K@%:U[!_6W6D>J>^.,R\/[<83B6;( E<_
M&VMLD0G=L=8Z]]S4MPGJ)RZ+N;%,(B[C0*S2!*FQ>D/$49<%QW#?HH(V8;X:
MN-37[7[/.K>']8FJ%X0V=94<>SQ%$N1\RN;KD9F;@O 6U [3Y]R*Z9%1%MH)
M M"F$B=DHTX5 [%W#;HM8)$J]%-0W75J(Z423 <#FVK<#BD;A<1Q!D1(MR,Q
M,C##TH4<6LG<IVND,D->F D%NZNAJTQT),_3 J+&?;4%><+]-YPE0*=)LBL>
MA&/UT@2.)[H4WS3(.<,CP42E0HNI,*4XNR'E"4XS6-P3+] $9S08D*+_ $L!
M80?:T%V:! A:T*-L;$:1N;6Y(G0-[>@3DHT*!"C) G2(T:1. M.E2)4Y80%E
M@"$  !L$-K6M:U!Y= H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M\Z+_ -$3\%0/#C_G1?\ HB?@J!X<?\Z+_P!$3\%0/#C_ )T7_HB?@J!X<?\
M.B_]$3\%0/#C_G1?^B)^"H'AQ_SHO_1$_!4#PX_YT7_HB?@J!X<?\Z+_ -$3
M\%0/#C_G1?\ HB?@J!X<?\Z+_P!$3\%0/#C_ )T7_HB?@J!X<?\ .B_]$3\%
M0/#C_G1?^B)^"H'AQ_SHO_1$_!4#PX_YT7_HB?@J!X<?\Z+_ -$3\%0/#C_G
M1?\ HB?@J!X<?\Z+_P!$3\%0/#C_ )T7_HB?@J!X<?\ .B_]$3\%0/#C_G1?
M^B)^"H'AQ_SHO_1$_!4#PX_YT7_HB?@J!X<?\Z+_ -$3\%0/#C_G1?\ HB?@
MJ!X<?\Z+_P!$3\%0/#C_ )T7_HB?@J!X<?\ .B_]$3\%0/#C_G1?^B)^"H'A
MQ_SHO_1$_!4#PX_YT7_HB?@J!X<?\Z+_ -$3\%0/#C_G1?\ HB?@J!X<?\Z+
M_P!$3\%0/#C_ )T7_HB?@J!X<?\ .B_]$3\%0/#C_G1?^B)^"H'AQ_SHO_1$
M_!4#PX_YT7_HB?@J!X<?\Z+_ -$3\%0/#C_G1?\ HB?@J!X<?\Z+_P!$3\%0
M/#C_ )T7_HB?@J!X<?\ .B_]$3\%0/#C_G1?^B)^"H/>1]G5'KQ  ^.B:_=S
M!=H0)/8=[6$7;J_;D"MU;]/_ %/]2A5FWEM=]:W_ -\1_)*%3RVN^M3_ .^(
M_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_WQ'\DH5/+:[ZU/_OB/
MY)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_ +XC^24*GEM=]:G_ -\1_)*%3RVN^M3_
M .^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_WQ'\DH5/+:[ZU/
M_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_ +XC^24*GEM=]:G_ -\1_)*%3RVN
M^M3_ .^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_WQ'\DH5/+:
M[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_ +XC^24*GEM=]:G_ -\1_)*%
M3RVN^M3_ .^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_WQ'\DH
M5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_ +XC^24*GEM=]:G_ -\1
M_)*%3RVN^M3_ .^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:G_WQ
M'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_ +XC^24*GEM=]:G_
M -\1_)*%3RVN^M3_ .^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:
MG_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_ +XC^24*GEM=
M]:G_ -\1_)*%3RVN^M3_ .^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GE
MM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_ +XC^24*
MGEM=]:G_ -\1_)*%3RVN^M3_ .^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^2
M4*GEM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_ +XC
M^24*GEM=]:G_ -\1_)*%3RVN^M3_ .^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[
MXC^24*GEM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_
M +XC^24*GEM?]:W_ /1HODE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GEM=]:
MG_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_ +XC^24*GEM=
M]:G_ -\1_)*%3RVN^M3_ .^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^24*GE
MM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_ +XC^24*
MGEM=]:G_ -\1_)*%3RVN^M3_ .^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[XC^2
M4*GEM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_ +XC
M^24*GEM=]:G_ -\1_)*%3RVN^M3_ .^(_DE"IY;7?6I_]\1_)*%3RVN^M3_[
MXC^24*GEM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[ZU/_
M +XC^24*GEM=]:G_ -\1_)*%3RVN^M3_ .^(_DE"IY;7?6I_]\1_)*%3RVN^
MM3_[XC^24*GEM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5/+:[
MZU/_ +XC^24*GEM=]:G_ -\1_)*%3RVN^M3_ .^(_DE"IY;7?6I_]\1_)*%3
MRVN^M3_[XC^24*GEM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'\DH5
M/+:[ZU/_ +XC^24*GEM=]:G_ -\1_)*%3RVN^M3_ .^(_DE"IY;7?6I_]\1_
M)*%3RVN^M3_[XC^24*GEM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_ 'Q'
M\DH5/+:[ZU/_ +XC^24*GEM=]:G_ -\1_)*%3RVN^M3_ .^(_DE"IY;7?6I_
M]\1_)*%3RVN^M3_[XC^24*GEM=]:G_WQ'\DH5/+:[ZU/_OB/Y)0J>6UWUJ?_
M 'Q'\DH5/+:[ZU/_ +XC^24*GEM=]:G_ -\1_)*%3RVN^M3_ .^(_DE"KWZ)
M*8D3$)S%BE:,FYEQ*5-P7//L,1@K6-N6  .@NQEK6Z+6^P&U'X\R@4$5]Z7-
M$RZ2;BO+E'F>7-S3JOL(YKXI(3W],P2=$@Q)+E2J//BF*/D8E*=G>B"A)E(V
MUR;G !)HKIU)!U@&@VEU&Z;.UO79P?H]-J,[2:C-XIW39;GY495V;DW7:_3V
MVYN5&?E9V1.9ES,7V1G9.;E3=$1F96996V<EX,R[\[C#=.5EYE^5F7;RTL1?
M;S9NLF<^R(NMB^V^R;K9QCGV76UCY:VZ*Q/S:?PE\+_D]=/_ -FN_7\.&O2#
M[VO&?_[!XO\ ,W"W_P :6 >Q[>_J[O7Z7NW\GGX2^%_R>NG_ .S7?K^'#3WM
M>,__ -@\7^9N%O\ XT>Q[>_J[O7Z7NW\GGX2^%_R>NG_ .S7?K^'#3WM>,__
M -@\7^9N%O\ XT>Q[>_J[O7Z7NW\GGX2^%_R>NG_ .S7?K^'#3WM>,__ -@\
M7^9N%O\ XT>Q[>_J[O7Z7NW\GGX2^%_R>NG_ .S7?K^'#3WM>,__ -@\7^9N
M%O\ XT>Q[>_J[O7Z7NW\GOI8M"-48U-A@'$\D V]$,!("B1!*"),6()81##<
M5P@M?HM>]^GHM7EUUL3;K<ZVZ:W1FWX\ORTX_P!U6_G89U\3C/.GOWL.XK?G
M93[RG]Q76<9W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_
MN*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[
M*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!
MW%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>
M4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;
M\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N
M*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*
M?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W
M%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4
M_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\
M[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*
M!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?>4_N*!W%;\[*?
M>4_N*!W%;\[*?>4_N*#9X&%ZN %[2URMTA#]CN3=]BW1;HM_L'^I0K'(_OP%
M[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?
M@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[
M^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@
M*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^
MMSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*
M%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^M
MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%
M8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MS
ME\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8
MY#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE
M\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y
M#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\
M2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#
MP%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2
M;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P
M%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;
M?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%
M[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?
M@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[
M^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%Z^MSE\2;O@
M*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^
MMSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*
M%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^M
MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%
M8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MS
ME\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8
MY#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE
M\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y
M#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\
M2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#
MP%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2
M;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P
M%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;
M?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%
M[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?
M@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[
M^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@
M*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y#P%[^MSE\2;?@*%8Y'[)F9
MV)4$FG2=>J*+,",Q.8D0  <$-^FY8Q%DV&$(K?8O>U^FA6&26M>U[_9Z>F_3
M:W_4MT6MT6_^+;I_^+1^/]H% H%! '>;_P!2[_V]O_1&J=?C9?S ^[GXG2U[
M+?V]^LOLM &J=4MB@4"@DEJU_P HKE_Q2<OZZL=6-_%?_P!H?7^Y36>?-W(^
M=I/V@Y'KIE?4=0L"J_E!<H%!SY\OOJ%M;^*Z2I\*((,\;#[/K6-ND:K%[%(4
ML0BT"8GLE0:R.&2)V:UR(YJ='8D %21H1MJQ:>B&$\\2,D]*:>%'9OJK.3>/
MQ\>59;Q2IT>%CD:!T1R\UBV!CT?LU6+,/7KQY)<XVOB:E&M3DC&G/"F++("&
MXA=M:UZ"][6#G)9]L>*':WDLA>O+E"775L.5&AYPW*,@I7QOD$MQEB^"9-/(
M;)\TQ=L4CCKDDGR9,!4:S)U(3"#;W3]7J=(4#,7K,<^R@:DN,\;4<D1B,)8U
M8&+-4T=QI0'7&$D2D+?B)0(@)HBQ6#<7185PWZ/S+T$Y-"/5U8#V.S%#,(;2
MZ].FK;C/) CB4>RDTY&*R/C9/)'EPLA9$LY3+X?"7Z!M:I4>4D&OM=V2D'BL
M<J$E2]J80%R'+SS!X.XC\0168SV,NF5,M926/;;A_"[ \)8ZKE)D<3(SY!(9
M')U2!W+B<+8#'5$0I6 0KU0U*TDLA*=^G#)#E\1^KVWECR5@R[D+C>AH=<Y0
M[%ML>D:-SR_$DL@4)1=#JUL&87MA?H*\.P0HU75 0TC$3</VX!]F/K!V+<=_
M(!@WDJUEBVS."%#DE9G-<MB\TA<@"07*<;9#94Z%1((1(PI##49ZI&G<TRI,
MI($(E:WJTZ@/4[2Y8 Y+\J>KBVIE<YR%&-1^.%')67'CPXL[B^R>09&RNN"4
MV.BM&)Y?&;&<4B:2,)W A"9V9!B]58NX;B[<RUK@L$O.+#U5D-W,V'@>K&T&
M 4N!L@9:D3?"L79 @DJ52: /$]=Q]T9(=*F*1(FZ0Q)5(W6P$+:I(4NX#W!4
M2G-+3AO=1060<W?-4EX?8W@.R+7Y9GN;;&&963Q)(9/2X%&XQ[*P8X"Y+'Y4
M5%Y8[.YBX[)B3NR-,01VMDYMAJ";W!>X<Z+SZN/D/QVJ02S*W'! 8UC%U5)R
MVL3RESA U3D \)2LM*@GDD3N$?6*E+> T18BVH5KV$$RP!!!<(PZP^*'E3PK
MRQZ^.F9\6QJ08ZE,'DA4*ROBJ4K43LYPJ3GM:9X1&-L@;R4B:41-[1*!7;W+
MNJ$T\2<\!J4@PH0*"@G>/U8JN$;(R;5[CUU4#L](HK*W6!AR+(7*4N+=/)FQ
M*%B%Z;<7XNQ\U&2F5L*%:B,L0Z7=$]W$)1AA"3NW9*3@]_Q]>JQ!E_9:+ZH;
M]:QEZN3::2AK@+1D!B=9(F8(W/WH:- S1O)N/)XV)Y5!V]Y=5 20.?B"P*0Q
M2394G*36.6EAV-4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&21
M;^F8O_!3?]>50;$H% H.=GU"'+#MCQ:0K4M?J/C+#>5)SL7E>58U41O+<1R'
M,1JE;>TQXZ-((>W8\R5C=?=\=WA[[#JFF*['7$ ( !%TWN%JW'CN3#=_]+]?
M-M86)N()RYC]J=94P-JD2DB&9(;;#9,EP<0S1C5?^24X;EZ(H9W08>G*+.Z.
MJ:&]PYQ]U_49;&8FYB,7:#ZTXJP=+-;?PE]==4<SY?R'$,G/$I'ES(\TCJ/+
M$?QW(X_DV%1) O@$;E9"&Q"QH=!IGE&><=<Y*<G*N'810*"IKG,V8S=IUQ5[
M9[(ZXS;V=9IQDS8O5PB9^6XC+O!%$BSCC&'O)GEV=L,GBCEWR.2%8GZ%:%0$
MOMNT!8)H #"&(9-Y'IGJ7PB8TY*LCPS\(3(;-J1J1E:>1?S$U8G]H<SS0AP\
MPRAS\:8H-)&.)==\R$>Y]BC81)+=EW<DD@L01%A9+K-F3\(O6_7W8/RYY.]N
MV$,49D\H^+^8?*WM/@;#-O+GC_A;'XYX'XYW7OG<D?>>R[3L"NMV80B?I3DO
MDNG&?=ZH]O#KUA_#FOD"S 2S:$SK'#TU.DJS9AH4TR^A/EF3DC?G#*BEID (
M2S0U98M2SQ$SO+LK#W.]P"(1A8_0*!0*!0*!0*!0*!0*!0*!0*!0*"J+D%Y/
M/P$]FN-G73V(>U/\87L LP7YQ]I7DCV0]TDV)8[YI\O>0)?Y_P"T]J7;=Q[\
MR='<>IWB_;=8H+7:!0*!0*!0*!0*!05P<7^2^2[*F I?(>5'7K#^M>P:/,#^
MS0Z"X4>FI]BKMAI/"\?KH]+'!6SYPSZF+D"Z;.,A1FEB>$QEDR @5T9=A!/4
M!8_0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0:?V%R \X
MFP%G#*D<3-BV0XTP_DO(#$C>R52EF5O,-A;U(VM,[)T*UM7'MAZYM !0 E00
M:(JXK , *]A6#G(]/=SU9GY3);EK#VW6/<.XFS W0AGS-@8O$C!.XG'<KX?3
M2F08YR*YI4&0L@Y$7.+C!<@LQ*89Z-:$H\*DX'8 $A.,&$X^=3E.F?%QJW$9
M=@V%Q+*&T>:,C(H)A+',U9I3(HTK;X^B,EV5)G(F2'2"(ORZ/P^&(;E&"(=4
M7=EKFD/-$-,4>&X;@X5MY,L\CO')@W;[-\>QW%LE9,=<M(7YCQ4TR5C@R0F!
MY>G$ 9Q-#;+I;.7\@Q2S1D@U3<YS46&I&8(%BP7"6 +5*!0*!05SZXY)Y)Y+
MNGMS"-E=?<0X^TAA_@_X'F88@]-2W(V5NV4D!>O/S8DS=.'!N[HE$,1?;Q:-
M](@VZ.O^9<+&*!0*!003Y&)]OQC;69XE'&QA+&&P6T!,MB2-FQQEUV;66&*X
M@L7F%S!U4+G7+F$4@5[4WV"-.&[\4(0K_8)._F:#1G)CR0R_C#X]4^YF0<$H
M,L3UE.P[')OB)JR*#&[8EE^0CVYIDI;=,BHSEHLI!&WE0=8D 2%P5!9=K64W
MM?M;A99CB7>T#'D#GGA_A'G:&1>7>%=[[_X9YD8T+SX?W[NR+OO<N^]GVO8E
M=IU>MU ]/5L$&N/G)/)/D7\([\8GK[B' WEK,SFR:U>RAZ:GCV@X4*[YX7+Y
M?X7F[,_<I$IZA'7*-\#,MU[_ -!!_P"Q"QB@4"@XVLA\PO/OE_?[?34[C>TJ
MTMV$A6EV5R(4\.<[.=(=,6Z/2!0^)X:MD3G-]R\.L$A<W<<7<;&":$ 2RN[]
M)A15AE]</<XYYZ.5+4C:W7G7OFKX\L:Z_0G:.<M>/<>9FP*]JE<>CSR]N\=8
MDR]R-19?V'B4R2,#D^D">D21];75"@6 5 3'7)L0J#L,H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H(?\ (5_@"[P_
MO/\ 9?\ <7FM;>[/GP]\$>Z_<WX1TS*N!?;ON;UUTGGC+?+!KU)K)2@4"@4'
MU@F/^DC/_P %M_\ N0FO(SO#R?G^+7^"E5KG^'W_ #\]^]I74<10*!0<X7,]
MN;S0:U9TQ7%N-+5'V_8K?L3VD$]D?L+FV5/!<@><)&W79/%XQ*6)(W?^3B)$
M?W8PL9GZ;U^MT"M:P;;Y6.0K:W17B-Q_N#%XY"639I:AUN19!BV08>[*XXPR
MS(S0VBR.S'10J0-+HVJFA\-4$%$F+1#2B+Z@[CO:_2&ON/KDAW<W,X4<N[KM
M4(A,UW%9T.?46*8)CZ!/IT<D\L@%Q$09F)A )*X/3PJ<55P@-)*7@&H%?H#U
M*#W_  H[<\N^S4JV!;^3C6+\'Q@B,?Q\LQ$M]BTQQ1YG=W=RE1,O2]YE,E?R
MWKPQ$@0#ZA(2A$=MTBO>P[= = E H% H% H(P;NY?EFO>E^W>?($!I-G.#]8
M,^Y?A93^C.<6(R68TQ3+)G' /3>G5H%"YI&\,I-E)(#R1FD]8(3 7O85@H@]
M-[R^;8<K'X9?X3Z'$Z+V#?@[^1_9?#W>)]I[4?;GYE\<\5E4F[_U/9TW]V[/
ML.RZ3>MU^O;J!T_4"@4"@4%+7,CS(Q?B"B^!Y-)L#OV<B\Y/T\8DB1BGC?!A
MQT<&;XPX'*5)SA&),%Q"XADP0A"$)-R[DWO>XNM:U@L6T_V(1;;ZMX#V<;8L
MJA"#.V+8AD]'$%SJ2^+(XGEC40Z%M"EX(1-I+D<B"?U!'!3DA'>W38%OS*"1
M] H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H-RE_[&7_V
M@?\ 6VH/[H%!XB]>A:T*QS<UB1N;6Y(H7N#@O4$HT*!"C)&H5K%BM0,M.E2)
M4Y8AF&#$$  !N(5[6M>]!R)Y!]0YO#N3G+).#N"3CY2;>1W%"\QED>T.9G!>
MQ86='DE?:_\ XM3G3'#L:86-W:VQ:-D->9JA=7L)ME!;826D&6J#SX[S(<\6
MJLHBWXSGAO92\2261,K6]Y?U,DZAXC^+662NB-C;I%.3XWDS:2*HT34Y$*;K
M+NCW'2^R5)?MRA7*LM#KHH% H% H% H%!SZ</&[^T.T^\W-SAW/&3O/>.-0]
MOVW%NN\<\EX\C'L]@BB<;#LYK%XO#8G'GV6==N@K47WI\5.:RW=>M8VPC3A&
M!T%T"@4"@4"@4"@4"@JBX>>3S\;#K+.MB_8A[ _)6P$\P7Y.]I7M3\3\DQF!
MR+S3YA\@8Y[GXGYV['N/<3>Q[KU^\&=IU2PM=H-,[#[ XEU5PEDK8?.LN10;
M$V)HRKE<TDRX!IP43>G,)2IDB)&G 8K<WIY<U1"%O1$!&H6KE))!01&&!#<.
M3F+\Z?.!R"FO&0.(KB3AC_K@VO+PWL&5]KI,2V6R$@:EEFT:QB5.6;M;X00Z
MD+>D*Q T/$JLB-",D2@0BC!6"9VCO+ARCK]O,-:7<H/%F[ZZ2#-QTM98GL?B
M-V<W;!();#X7,IVH9%1UW;*,0."\M,2,*)LCG*Q:2;U#.['$GV&2&[^67U!>
MEO&.W9=Q$ME3G.MVXWCT#UCS J7'&0E3&?)9?&U+CC9WG,\-;XU B8#=P,3'
M/ &Z0&O1:'M D)[J.J&P6"\96SL]W/T'U8VFRBT1!AR#G#%33.98SP% \M<-
M;W9>K7D')X\WR%_E+VD;@@2AN$"EQ5FVO>_29?['0$ZJ!0*"N#=;)?)=!\^Z
M*Q[1[7K#^8]?)[F YFWVG61WIJ:Y5A/#09IB!"1+,8I'#.&*U+M(!PEYF2RY
M:9GEQG>6E('N=KC"0L"Q^@4%37.9LQF[3KBKVSV1UQFWLZS3C)FQ>KA$S\MQ
M&7>"*)%G'&,/>3/+L[89/%'+OD<D*Q/T*T*@)?;=H"P30 &$)LZ>3R5Y3U(U
M:R=/'7QV<9&USPC/)F]]Q;6SQF5R_&<8D$B=?#69&W-#=XB[N)QW8)$Y"8GK
M]0HL +!#8)&4%<_'SDGDGR+^$=^,3U]Q#@;RUF9S9-:O90]-3Q[0<*%=\\+E
M\O\ "\W9G[E(E/4(ZY1O@9ENO?\ H(/_ &(0F].5NILSOCH7-,T;79+]JN2V
MG:;,&.&^2^38!!N[PR+-$#5,+-X/C>*P]@-[B>]*1=X&E$K-[7H,-'8(+!"_
M&@K@QIDODN=.2[87&&3]>L/QSC"CF'V5YUTV+9GIJ/S+/<RGM6#SGR)RQC)S
M@^NR./HW9]G919AL$92[ELJ.]E@[# ->& XCY//:GRY[3\5_L0\"_!HU_AN=
M/;M[2O$_.OFYOPJN\K>S#R W>7/#_;!U>_>85_:^'=/=P=XZ"0M=H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H.8[GAYJ=IN/++>%-=M%\0X=S;
MFN180S5L]FMIRTP3B3HH!@7%3.YNI4I1-\$R7C16D[TDA,I4GG*E1X;ELX2B
M21G'!Z NXT)VJ8=X-,];=L(^6@2I\X8HC$Q>&IL-N<@CTT$ENUY!BB<P2I:8
M(,1G;:Y-E^N:,RPDE[#OU[7H)<T"@J:Y3^4/\6A^!_\ ^X-]M?X5VS,5UT_Y
M3/9QY"\S=A_Y8_\ )_//-/<NV_I?_P"+NTZ/^^04%LM!4II3FSE%D^CVQ.2^
M3# V']6]HH8YY;48RBF%'-@E$548RCN(HH_PR<.%TN:MAVDV0&Y#4/R8U.>Z
M%6$F;R.N@" =CE(:Y]/;MSL+O%Q<X:V+VCR#[4,R2N9YE:7^8^5(1"N_M\4R
MA)HZP)_+V.XU$HJE[@S-Y)/7)0EC-ZG7,N,=Q"N%V- H% H.?3U .[^T.DD-
MT"==8<G>S)?FS?+%N&,G'^2\>3/S-C21M3XI>8WV608G+"6;OAR,L7?&\*1>
M7U>@L\-KWM<.@N@4"@4'(-GSU%6PFL_.#+-%,IXOP8FT*A.9L(8<F>;R(ODI
M%E&"+<^X8CLJAK]*YP/)#CCI*W(Y^\*#3PBC)':,+>H"$8#R[JJ#JHS=F.!:
M\X<RGGC*3MX%CC#F/Y;DN;NH0!./1QB%L:V0/ D:81A/?7$Q&@$!,G"*PU"@
M0"@=(AVM0<SO =SH;A<J6T>R&(-C<+X.Q!#,;X;BV9,<H,>QC)33.C62?2!@
M4PSS8]3/)<J9W] Y0"3(UI2I"TM85ES@*"P@),"58.K.@4"@Y]/4 [O[0Z20
MW0)UUAR=[,E^;-\L6X8R<?Y+QY,_,V-)&U/BEYC?99!B<L)9N^'(RQ=\;PI%
MY?5Z"SPVO>UPG9NMDODN@^?=%8]H]KUA_,>OD]S <S;[3K([TU-<JPGAH,TQ
M A(EF,4CAG#%:EVD X2\S)9<M,SRXSO+2D#W.UQA(6!8_0*"IKE/Y0_Q:'X'
M_P#[@WVU_A7;,Q773_E,]G'D+S-V'_EC_P G\\\T]R[;^E__ (N[3H_[Y!06
MRT"@4"@Y]'[=_:%%ZD"%:$ILG=EJ<[Z&J\SN&*?)>/!]XR64\2U*"2>>C(F/
M))75(;" ]S \!07ZG3V'2(5[AT%T%$O/QR7;-<8>MF \G:HP/#>1,G9FVDB&
M @1[-C-+'B-F(I9 LBR!()L#$LDXN/0/AT@BJ(@"A6X"1ED&F]H7:]PF%A57
M/>47U5&L,4>LY;0<1&J;O@?'K8Z2+)16')BG=)L@C+4U+G)R>R3(/N)L \,[
M0QI48E:]<.+."9.E*'<VY5KV,"'27QR[ZXGY*M1L8;;8?0.\?8IV2YMDBA<A
M&0<_0&>1A<:SR^'.2M*$"5S"V.9%QHUI8"@KVXY.I[(FYMR2PG'0*"M/+63N
M3MGY)]=\98@UTPW*N,F28L4NVQ^Q#\^-*?,4 RN$K,UTT9B3(?G6..RUC,-9
M(3:YA4%>P=#PK_HNW4'=$%EE H% H*HL1\GGM3Y<]I^*_P!B'@7X-&O\-SI[
M=O:5XGYU\W-^%5WE;V8>0&[RYX?[8.KW[S"O[7P[I[N#O'02&?<H&2^2[%>
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MDQ)@J6.T'Q>4Q2]FB,X+FL=*6G.*HUP;FRZI0Y  E+,2E$+504[^C:A$9?\
MD0SS,GAL3N#[ =3I&9$E*DHD[P1=)LGXS9G5U07,*$:E=#&3MT(3BQ!O9(M4
M%WZ0FWZ ]+ZP_'#1"N3'$>1H^42VN64M5((\R0Y)89*Y;+(9D3)D3(?3U .K
M?MO*;8SHRKVOUP!;[?9Z.KT!]$G5J<N63]9-<\EO!ZI4[Y#P1B*<NJI<(H:U
M2Y2W'\>?UQZP9 "R!*CE3@(1EP!""X[WZ+6M0;WH% H% H% H% H% H% H%
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M-*&$0;WM>UZ#VM H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M5)'B*:W*7>01+':UW/B$<?'50^KC%*M&C)//&L/$,8KFF7$'-S N*3<O+?J
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MPL^R_*\M0FDNKRI7NDIL<O7&]10F 66E*#LVH% H% H% H% H% H% H% H%
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M7 &81@V>#Q..0]J&=:UC1-L99T;*A$;8/VMC!)40;BZ/L=-!EE H% H% H%
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M\V+#()A#)L6C&)H\F.1.,CFN3'3)\:A*])'8V@27$H/:T;F0$9I=C#2B[C-
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M_P#W(37D9WAY/S_%K_!2JUS_  ^_Y^>_>TKJ.(H.:KU8O\3[/?[^.#?[)E-
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MNY'_ *_ZRT#GA_C1O3>?OW<C_P!?]9:"S+G:_B>^1#][-.__ &DEH*(]C/\
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M<5?=T1(.T.",?4) 'IZ AM8-ZT&L,NX2PQL%#%&.,]8CQAF['JM>@=5<#R[
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M:%(,;.NBFF[GCIKD2Z7MD!<-8L)K84W2QS)-3N4H0153"#&)'(G @\8#UI9
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M%:X>6#!.$"LOG;!EX;Q47GQ1%+011F\&/(B#+Y\'">4I##3LE!:+3,V*64D
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M<8*):F<A0O,&/(CDR)B<41@3D:\4<FC0]L]UJ0X%AE&]CURQ6M<-[7M0:U_
MBTOM!X7C*VHFL'LVQO,4^1,=X]]@6*?(\"R E("F2SF%Q/RGX#%IBF3!L66Y
MH4Y"T +6#8RUOL4&6;-Y9D&"-><T9CB.-9OF27XXQO+)7#\3XWBDAF\XR/+F
MMH4FQ>%QV,15"XOSDMD;]W=+>Y!(N[E&B.'<)98QA"GWT[>F65M:=+93G/:%
M@DS+N9OCF*<;2[)$SIJ<V*=-#G*WMS\G1*3LCRE0.K&XH6H]0\JD"P@"Q Z2
M!:G-O^EA  +]:!0:LCF#,)P_)D[S3$L/8LBV8\HI&A!DW+,<Q]$F3)F14,?2
M)$#"CG<\;&A+*9<D9$* @E(6X*E $Q1)8"[!" -K!M.@U)&, 8(A63YSFZ&X
M4Q)$LT9.2(T&2LNQC&\.8<GY#0MP$1;>CG,^:F9)*Y8D0EMJ8)):]6H 59.7
M8-K6 'H#S\KX5PWGF*G07.6)<99FA"DRQRB'97@<6R)%5!P;= 33H]+VIX:#
M3+6^Q80B;WZ*#!<*:BZH:UGN2G7/6+7G *EX",#NHPIA;&^*SW4!O=;&A<C8
M+&F(Q<$RR$GK6-N*U^Q!T_S >@,QS!@G"&PL3% L_8;Q5G&"B6IG(4+S!CR(
MY,B8G%$8$Y&O%')HT/;/=:D.!891O8]<L5K7#>U[4&M?P(M+[0>%XRMJ)K![
M-L;S%/D3'>/?8%BGR/ L@)2 IDLYA<3\I^ Q:8IDP;%EN:%.0M "U@V,M;[%
M!LR>8,PGE.4XWG&3\/8LR/-<-OBF38@F$\Q]$I?*<52188V&K)!C>02%H<7:
M#/BHUD1",5M9R4\8DA-Q#O<H'5#S<J8>Q'G6'+<>9NQ;CG,< <CB%+C!LJ0B
M,Y"AR]0FL99,>MC,N;'=E5')[&BZ@QD"$#K7Z+VZ;T&G4>BVDC?BEYP.WZ=:
MKH<'2)>VNL@PTCU[Q(FQ2^N;,Z&O;0XO..R8B"(.:]J>CQK$QQZ,9A"H8C07
M"9>XJ#?SM!(._0Y1CM\AL4>L?JV4J.*H*[1YH<8<ICQ!!:4AA41A8C.9#F4E
M*2 L"41%R E@L&P>BUK4&H\):BZH:T*'99KAK%KSK^K?R>[/JK"6%L;XI4/2
M>XTQO8.Q\$C3":XD]JB)%U#KC#UB07Z.D(>@/QS5IYJ1LFM;7/8O5K7//KDS
M%W):'#-6$<9Y46M1-[7M<IM5SJ,/IZ$N]A7MU2A!M]F@V-B[#V(\'15-!,*X
MMQSA^$(A!&CAN+H1&<?Q5(,"<A( 2:/1-L:6@@0$J8LJUP$VO8LL(?S VM8-
M;YCTZU%V)D+%+M@=6-<<Z2N+DW31F3YCP?C+)TACJ>YY*JY#$]36,/;DT$W4
MIBS.HG-+#VA81='2&U[!E#?KEKTTY-9<U->!\,MN9(U"$N,H[EIOQ?"$>36#
M&Z$L9*+'S+/$[&7*6J$(RC1!*:2%9: L(KV"5:U[T&YJ#5&6L#8-SZV1UDSM
MAG%&:F:(2A!.(FT9:QW$,CMD7FK4G6)&N7QU!,6=Y2,DH;4C@H*3N"8!2LDL
M\P(#+6&*UPVO0:,4:P:TJLVIMEU6O&#%.QR)%9M1[ *,2P$[-J1N"R'1H*!-
ME4R/BG9"*T<4&-]B@+[ [D,1'1V0KAN'BYLU1U;V6 V%[&ZV8"S^6RB*&S S
M9AS'>50-(R++PD"; SJ./P4 B0NJJP+E=2X;*3>C_9!](0UV_=)'QGZ@.\^X
MV^/J!Y5>HC,X8:ZZL:[XW08W53" *GQ8;-S8BT8DB:@U+)FQ&XJ%:4TIC>A=
MN:9T(5 S;VN%&W'S">1/DQYI8+RQ;;:1SGC_ ,+:M:XR?"&)\798\R()_*GZ
M5),BLXPB1S6#8\ETA)!;*CXN5.1C$T-Q!1*!.GLH,N<8(.N.<0&"Y.C#I"<D
MPN)9"ACX3=,]1&<1QGED8>$]_P TAT8'Y&O:G F_\X:4,/\ \*@T-B#1G2;7
MN1CF& M/-6<'RTPNQ(Y3B#7W$N-)&,FQ2DBQ0WN%Q%E<Q%V(6G ZMS>CJ'#M
M^8(72$BI)&8W,F-QC$OC['*HT\$V3.T>DC2@?&-T3A-+."0XM+HG5(%I(3B@
MCL TL0;"#:_1TVM01SQ!HMI)KW);S3 >G6J^#YC<D2:\LQ!KWB3&DENG$6<2
M(B[[#(BRNER1%*3 W!VO5N$P5NCH%?I#/,VZTZX[+M#/']C\ 83V 8(ZO/=8
M^R9MQ5!,K-#$YJ20IE+BSML[87Y$V+U"<%BQG$  8,%K!O>]K=%!Z-YU"U-D
M>,(GA&0ZOZ[ON&($],\C@N(GG"F-73&$+D,=1*6V/OT3@*V-'Q2./3$W+3DZ
M-4C2$GI2#1@+$$(A6N$A#B25!)J=046>0>6,D\@X 323B30W 84:6.P@&%F
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M_?8H'^;S\=/\]MS_ )<^V/WV*!_F\_'3_/;<_P"7/MC]]B@?YO/QT_SVW/\
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MGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\
MY=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3
MM_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\
M>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'
M^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:?
M?:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#E
MU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W
M_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX
M?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?Y
MO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]
MJ@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77
MMI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_
M .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]
MT[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]
M_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ
M!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>V
MGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\
MY=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3
MM_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\
M>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'
M^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:?
M?:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#E
MU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W
M_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX
M?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]J@?Y
MO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77MI]]
MJ@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_ .77
MMI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]T[?_
M .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]_'A]
MT[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ!_F]
M_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>VGWVJ
M!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\ Y=>V
MGWVJ!_F]_'A]T[?_ .77MI]]J@?YO?QX?=.W_P#EU[:??:H'^;W\>'W3M_\
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M1QANG(NF^VV_>6EMF;;IMNBN?9%;;K9B;;HK6+HF)B<8FKYM7X9\T_N*:?\
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M8_Z2,_\ P6W_ .Y":\C.\/)^?XM?X*56N?X??\_/?O:5U'$4$4-UMU,!<?\
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M$8+M24::PURQ*28$C=%GC=B3:XP>6;_M6"HIL9+$EI!(\=Z_1F9L4/QHWN(
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M% H% H% H% H%!4U^-#_ /PPGXI_V&_^\S?A%^WSVF?_ %WL_)WLL]G_ /\
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M4W&"OTJT[?WDL/=CDYIP==% H% H% H% H% H% H% H% H% H% H% H% H%
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MVHNJ&S*AE6;(:Q:\[!*XX2:FCRK-V%L;Y74,*<X9AIQ#*?/(T_&M9)IIHA"
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M]J",D(T*T9QE')W#L;Z8:GX^B.4H^KB>38M"-=,01..9%BJ\)85\:G;&PPY
MV2Z/K0D@L<B<"E"8RP+=8%^BU!L9?K9KHZX5+UL=,!85<M="FIM8BL!+\605
M9A4MC9G5*^M#,7BM0Q&04#4U/:$A8F3V0=B0K) < (3 !%8-IQ^/L$28&2*Q
M5D:(S%XRT-L?C<;C[:B9F"/L#,B);6=D9&=M)3-S2T-+<F+(3)B"RR2"2P@
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M?%F3WA)VJ5"A-[JYS>*OBTCM$36F)%U!VZ2DY0+_ &I8+6#;N-L68QPU$FV
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MO< NK:@M$H%!6#R/DDJ95H$G4%%*$ZC>K"I)Y!Q8#23B37(P!I1I0[" 848
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MZUPW_EC7B%9BGN$<B29TE"%ZP)+7"90]*Q+6E*UN3HXDMY!Y$E(<&1S5K$
M-I=P!2GHS+7N+I'?IMT!F^6,;,68L:3G%<F5NR&/9 C+K%7E8Q'HTKRF;WA*
M-(I.;%#@@=$)*T!9E[EB-3G L+\T K?8H-*RS3_&DQPCAW CF^3DB'X2=<:N
M\5<D#FP%25P4XM0W;X^"0K%$95-:LA82+I663(T@C!?9+$5;[%!L787!<2V4
MP_+\*3IQD;3%9IX!XHX1-6V(9 G\N2AEEB'P]4\-#ZW%=JXL1(#>T2&]8@0[
M!ZHKA&$/<3/$\=G.'9'A%V6O2>*2?'J_&R]P;E*$F0DL3BPCCIZM&K4MJMM+
M=@HC+B 8-(838W[-RKA^UH--S72_#.0<"8ZU\DX92ICV)FJ+(,=S1$]$-628
MJXP]J*9F>3-<B;6U*A)?K(ROTW^@KHS3+V%=/T@+Z@:+D_%UA*?1V[1DO*^S
M>4GTA>VJV:?Y*S"9-)A&DK>M$N-:([9[8%44;FYT-O:RH7A0E0@6ZH#@6$/K
M!*[+&O$*S%/<(Y$DSI*$+U@26N$RAZ5B6M*5K<G1Q);R#R)*0X,CFK6(  ;2
M[@"E/1F6O<72._3;H#?-!4CJ?&HSL!O-M)N,W,B$J+PM<DP'C1X(*,$&4/\
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M*6PS#F4XWEV,!C*UI1@722+F#,;T3]9U8WD2IC.$._;%I[I3Q6_F3@4'E.^
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M';=-^O37@S,DX*QD_/L)@;]$W]@DLS0K&3';H!Z=L@/+8E:_:"J;"' 1Y%P
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M9X^CV,,*$16>;H902IG^+1*1IU#Q%\9XX2N!A;ID7(32UN36Y*0O@FY2WL:
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MV:8L@X_SL^((]$L4XR@^-9O'Y>GE6=%T#)=F>%2-XBSBYD19O:$"0;F]&GB
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M% H% H% H% H% H% H%!N4O_ &,O_M _ZVU!_= H%!R2>GL_C8/4S_OW<?\
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MH,JY/3+U9!0B33BU1Y03B[B"(L*M84P\%NX4/8=@N63G.W*R1NU/6A'+IH3
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MDF!\BF%82_9 A"+&C5BK8)LBS>>\/$$4Q-X=UT-R,N:4))SF=%7EID(VQ>K
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M<^N%>4O*N"LJY4U"R/J!["I;,<6M21>MATK)=I"WKFHLY\5L<3O)B!!9%29
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MT"LMHX]D^&<N1)JGV*)#C')T%?B0J6.:8]=HK-(D\IQ!",)[5(XVH<F=Q)$
M8;V&2<,-[7M?I^S0K+-?+L?^8F;Z,1? 4*R>78_\Q,WT8B^ H5D\NQ_YB9OH
MQ%\!0K)Y=C_S$S?1B+X"A63R['_F)F^C$7P%"LGEV/\ S$S?1B+X"A63R['_
M )B9OHQ%\!0K)Y=C_P Q,WT8B^ H5D\NQ_YB9OHQ%\!0K)Y=C_S$S?1B+X"A
M63R['_F)F^C$7P%"LGEV/_,3-]&(O@*%9/+L?^8F;Z,1? 4*R>78_P#,3-]&
M(O@*%9/+L?\ F)F^C$7P%"LGEV/_ #$S?1B+X"A63R['_F)F^C$7P%"LGEV/
M_,3-]&(O@*%9/+L?^8F;Z,1? 4*R>78_\Q,WT8B^ H5D\NQ_YB9OHQ%\!0K)
MY=C_ ,Q,WT8B^ H5D\NQ_P"8F;Z,1? 4*R>78_\ ,3-]&(O@*%9/+L?^8F;Z
M,1? 4*R>78_\Q,WT8B^ H5D\NQ_YB9OHQ%\!0K)Y=C_S$S?1B+X"A63R['_F
M)F^C$7P%"LGEV/\ S$S?1B+X"A63R['_ )B9OHQ%\!0K)Y=C_P Q,WT8B^ H
M5D\NQ_YB9OHQ%\!0K)Y=C_S$S?1B+X"A63R['_F)F^C$7P%"LGEV/_,3-]&(
MO@*%9/+L?^8F;Z,1? 4*R>78_P#,3-]&(O@*%9/+L?\ F)F^C$7P%"LGEV/_
M #$S?1B+X"A63R['_F)F^C$7P%"LGEV/_,3-]&(O@*%9/+L?^8F;Z,1? 4*R
M>78_\Q,WT8B^ H5D\NQ_YB9OHQ%\!0K)Y=C_ ,Q,WT8B^ H5D\NQ_P"8F;Z,
M1? 4*R>78_\ ,3-]&(O@*%9/+L?^8F;Z,1? 4*R>78_\Q,WT8B^ H5D\NQ_Y
MB9OHQ%\!0K)Y=C_S$S?1B+X"A63R['_F)F^C$7P%"LGEV/\ S$S?1B+X"A63
MR['_ )B9OHQ%\!0K)Y=C_P Q,WT8B^ H5D\NQ_YB9OHQ%\!0K)Y=C_S$S?1B
M+X"A63R['_F)F^C$7P%"LGEV/_,3-]&(O@*%9/+L?^8F;Z,1? 4*R>78_P#,
M3-]&(O@*%9/+L?\ F)F^C$7P%"LGEV/_ #$S?1B+X"A63R['_F)F^C$7P%"L
MGEV/_,3-]&(O@*%9/+L?^8F;Z,1? 4*R>78_\Q,WT8B^ H5D\NQ_YB9OHQ%\
M!0K)Y=C_ ,Q,WT8B^ H5D\NQ_P"8F;Z,1? 4*R>78_\ ,3-]&(O@*%9/+L?^
M8F;Z,1? 4*R>78_\Q,WT8B^ H5D\NQ_YB9OHQ%\!0K)Y=C_S$S?1B+X"A63R
M['_F)F^C$7P%"LGEV/\ S$S?1B+X"A63R['_ )B9OHQ%\!0K+]"F)D(, <0S
M-1)Q0K#+-*;TA9A8PWZ0C ,!-A $&_YE[7Z;4?E9>TZ+6Z>BUK=-^F__ ,._
M1:W3?_JWZ+4'^T"@4"@Y /5;_P#O!?\ [%'_ /.ZU;Q\55^?GW$_&Z5'9G^W
M?UG]E.0"K>4IR@4"@ZS_ $JO_G_N=_Q/PK_7K)%5/?&G?U!P9_3-X_4]&C%V
ME?(.Z?%=1X'*=E]4WHFE H.''-/"MZE/*.^$-Y 2-_M#;9[PBW3J!:\3YR1N
M"1QQ_B25BR4V$Q1?"F_1$_'4A6VC&5'A,:J=$+JL -9<8%0ADIS"PNIY:>-?
M;;D9X_\ 4K7ENR3A7\(O%&;];<SYPG4[=91&(!,'O&F-IE'<I+X@*#8L=U=E
MLBF,INK;4PF)H1]UN+K62=4!%PMPVBQB_P";=9MB<,Q56T-\HRY@K+F,8VOD
M"A:D8$3_ #V 2"*LZM[5-K>[.*9H3.+L6-280E4G )"*X"C!6L"X0UX9]*LI
M\=O&SKAIUFM_Q_*,FX?]L'F5]Q:ZR-[@B[V@9ZRCE)F\"<Y9%83(%/=H_-DA
M*KO#6EZBPLT .T+" TP-%:%<;><M6^3;E-W/R!*L4/&+MWY!C%UQ0PPY\E[A
M/H^GA89#9T!D-K>X+'HZTG*/%B^[V;75V"/JBZ]P=%ND/+X8N.+-_'6Q[OMF
M;)3BJ4'[+;JY-V.@H\6/DN>R6F#S1&U)VMJEHI;!H0-!*R!H1W4$(PKT8+7M
MU%(_LVL'B//&WG)QYX(GR@D2K% <!,.FJG7A9$#7R7AS 9-3G22K0NB9@!!1
MPL<7L4\E6N>*0 5]8(OZ&Z+6N('.WQMYRY/M9M?\,X#E6*(C*,5;E8JV'D*_
M+[Y+V!@60J#0#+T5=FME50R"S]Q42A0XS]&-,0>E3I!DE'7&I+$$ # _KFRX
MF'WE$Q3A)SP]F$O .UNJ.3+Y9URRJM3KS69K?58V)0[,SNM9"CI#'BU;K%&9
MR3.B I4H0KF@@7=CPB%:P4X9EX/N?;>? N3,=\@'+=CN7"311>CQ1A/"B5;C
M_#F09844E,C*S8:8PK7K%+DYQ1J<A''*4)D0DZE2(D@92E.;:PR@M.SAQ8[!
M9+]/ZR\4[%,<-I-AFW777K$1\R=I!-B,,#DF)I_C252-:5(4>/5\X$QK6Z&J
M@(C+QT)YAQA5C220B&, 6_:NXQ?\):S:[89E2MH<)1B/!6(\8R1?'U"U6P+7
M^!0"/Q5X5LBIR;VEQ4M"EQ:3!IC#TJ8X9(@W&46*]P6"J7ATXO<P:#M/((P[
M%/>&<@,FWFUV0<TQAIQZZ2N3MQ>.)JF6HAQN?I)K 8604]*$BP12I(E"XHA
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M4362,\4V14M$@EN.T3N1$)&^-2AB0F)E:Q&<>0-&0( PW*+N$((\Y).XN?\
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M=2L2+3B3TJ=068: (!AO<-&!Y,..$<NO  <@.D@YY:0#B=X2':S!(I=:5%N
MFDR-7C=IY=Y\P = W371=CWFRBUR[@Z_V*":J92G6)R%B,\E4D5$E*4JI,:
M].I3G@":0>0>4(11Q)Q0K" ,-[A$&]KVOT4'[4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@K(Y&N+?$/)3['/:KD')$$]B_M"\!]GPXP#Q7VC>1_%/%_,; ^=
M/<?(B;N_8]E_LQG7ZWVO5DSV=>U#Q=V;?3CV*[OW;K_3KN3I>ZXSOE.Y.Z>9
MT?0YN5\UW5?S^=SOF;:4QKL3@'K(WKU?=U^EF1I\[NOHN=TO/^5Z+I*<WF76
M][TDUK7O(I\E6/\ YKAJ'_C![(>_8Q_M!J3/_5"ZW/T?X<_:UOHIL3]8_BGR
MCN__ #WCA_FN&H?^,'LA[]C'^T&G_5"ZW/T?X<_:UOHH_6/XI\H[O_SWCA_F
MN&H?^,'LA[]C'^T&G_5"ZW/T?X<_:UOHH_6/XI\H[O\ \]XX?YKAJ'_C![(>
M_8Q_M!I_U0NMS]'^'/VM;Z*/UC^*?*.[_P#/>.+)..KBCPWQN/65'O%>1<FS
MI1EAKBC4\E9 '%ADMI,25OJM$8V>7(\R#L:I&_F6-[6YEN@ >K:WV>F-_:([
M5?&/:/T6ZM%Q3N[=FAR]TYN??ESI8SZWSGVY5MT7]-FYD4B,J.;S:=[-:X-?
M\>=9F]NL#)TV3O+3Z?)MTMU]UO1<_'GQ;$UY]UW><V*4HM+J+K6Y0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!00_Y"O\ 7>']Y_LO^XO-:V]V?/A[X
M(]U^YOPCIF5<"^W?<WKKI//&6^6#7J362E H% H/K!,?])&?_@MO_P!R$UY&
M=X>3\_Q:_P %*K7/\/O^?GOWM*ZCB*"F[G'XO7#E7TP'A:%RUIA.8L<SMMRY
MA]YDEUH8FY2II89#'%L/EQ[>0M6M[#*&22'E]](3J#D2PI.=V1I8#23 X)8]
M@#U''#WYJ9\4PO<'%F/D#PH>7L_#C5?/F 52HOL0><U;7'$62\:-WBJ1.0$Q
M8X(D:L9=BTZJP1@[$(7I\(/J<-A=C]G<9:8[V,,'DKAF!T.B&.L\Q!B(@<B2
M9!&B//8X[D*(M74B#FCEBU)= E4M2-I,2+SR0F$'EF"&0$1/6+[CCR+L[@71
MN*NI(V' D1]J624X%"<@@>5<MDD%19J=S%5BPICHGC1"G7$F]H FY,I,[3IN
M"UP! KG-Q?H%$-?^-%1I=LI@+,T_PI@)'K1GM%B&>,,@=W-WC99>0&G)JIM9
M5(CNS?I_*9@-6M&"P@B5(B>M<(2PA#O*XQ]R ;V\1.+<^N#F%SGAV Y7CW+@
MAG6-7 ROC!@=(3,USB7VIPTQTK5M 'T@L8KC[DZD"O\ S5!\S7B&W*V;T7VM
M<,VZFX!#LCE$W$LRABG'PXAD":@3Q)[=HJO>9*)GQJH32$L+4I94I=SQ"[L7
M91T#^R(%!,B99\VO]3%R*8#Q)EZ=8"UV4E,[C#X$T!)=V"'12.D+2G^=6C*)
M\=7Z49#RS(D:01Z9L.<4Q;@8@+(*$B*",=!V:\P.][/P1\9^!\!ZY,[DX91?
M<>M^M.N,A=B4JAOA3;BZ$1]FD&6):.X0D.TF:FQ8F4)$MB[EK7I8$XZUTY)Y
M9@<RV$)_Q6:V<.^\0';<:&9OY0-W,*/8\AJ3V'*+J_-;C)7UODY.'F&5OL(3
MH52X3ETKY*Z&K.H[OEKWN<:G2I!T$D/2";F:R8"5;(8$R_EAGA.7=D\LX$8,
M(0I>U29:NR \)VV?M!R%M6M#(XM" PMQ?$A5[K5"4'2=:_3T6%>P8%RN<D>)
M>5/DR8](\\;!_@@\9>I^4),FRK)7A))5,GS#/\:NRV+S)V;F6,L$C,+D#FL$
MI8(B!8G-3,S<:N>E%C3CO# A69ZBK/FD>>-LM;0<?DLATHUSPQH[BS!K$F@K
M%)H_'HBY0[+F>GGRB0CEC,RNRA0ACLI;5)JD0#KJ!*^N8<8=<V]@^EMH+N9K
M+N?@MHE.L66&?+3!CI%%\=S1R9FJ3-13#,T$/8G%6Q*"Y,R,9YZ@A$O),N,D
M!I-[#M:P[WZ;6"(',WS"8:XK< .JTYW:95M+D-A=46 \.)STZUR/=C23D:?(
MLX0A.L<RXTBZZ]C#CC;!&Z*"NY);"'<\Q.'-EZ3/C$R^KRV^\IF;6UVC<,'&
M)E$=?$[RF$C>,GR2<&>'3O*8"5*<)GDAJ9Q+6Q&H!8(71P7'C*'8I"*R@(5\
M_>EFWVC/+2IY),88\DDYQ7*<RXOV8QGDQNBSC*(G#,J8X40]\5P7)7@A8[,!
MB67Q:RI#98)*6ZM)UK$&F')UEB0\[ESYX,I<H''2D@"SCLF^%\?6ROC)YD>Q
M;M.GF78V;IV@129;'HK"5:G$T1;E;U,V8AS/* -T$K(;TZFP25!81J !T0^D
M,97MKXG71<Z];N,DVKS$]1KK)RR;69"(QC&.G]0PLXP2L/F-A</TP82Q6OT@
MZMP@"(02S]0=R>%<;6C;^=!'Q.BV7V&\7Q7@9*6<&SFP".0%VGN6"B+VN+N^
M-F%Q+NF,Z! L^N#:$81%#,Z H;](CQEFFBF/*)F1@[PH5F2/&&K%GDH1RD8Q
M&*F;+^84@CK"OVAYMSXJW*;#[2_0]A&#H$08(*@/4A7<G/GQR<WR!*C4,P%&
MIK:R)S!76%+(ZIQ1B]0M*<$JBYI!?:ORUP+$38-BQDV"*X;W&*]P[<_4G)H\
MHX4=W+R6_41IF?"RE <$LTPPJ0@V/P\"-6+N02>:5WE],3D#%:U@]D:.PQ!+
MN,5@IF]%::]"U^WF(/)"&.EYCQ,:U*+!+ZYKT="9*!_)$*P[G7"0A3MHK6$&
MP;7,OU;WO<5K!VRT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4&Y2_P#8R_\ M _ZVU!_= H/42!_98HP/<IDCDD9H[&FAR?WYX7FV)0M3*SH
MCG%T<EAU_L%)$*%,8:8*_P#,@!>]!P'\./-?QD8XVDY/N0+>/9D[&&P&Y.PU
MF;%\0<L0[!Y"<HGJYC]*$>-TEGK&>*9G'4H5S<O;V<U*<NNL "))Q7((+&"Y
MX29],#N#KRS[O<GN@^N.2TF0=8)7E-_V]TV>P,<QAA0X8Y.K=')Y%B(M.H[%
M7Q&O8&!XBB*Y9C<WB,$QK%!91J<8!EACN]NA>.^1WU03WK?EZ?Y3A&*#^/6$
MSG(C7B:2AB;QDZ.Q.6H1!QA(G<:5>$$*D#NX)5+B78@PX84(.P$G46*5$!J3
MG:XF=.^'7'^E'(+QRPR5Z]9BQ?NIB2&N29)E?*,V:9<WNT>G<R+=%XLDRN:K
MT+B6OQ\6WJ4J,U*UN#4Z+"5*<VW4#<)&>K%U UVF66.,S.,DQYXEE',6UV*=
M5LCRCS;.4?F/ H'=V?@P3P5!)DL=:.AVESB;XH@2)7G^B.KWOJ%E! %X>->'
M'C@XZH%L]EW3C7/V/9#F&L66\<2.0>UW.^0?$88N9@R94S>$Y3R?-V-)VKY&
M$)_>"$Q2L/8=2QMBQF &$!O37SZ28I]/!&<HPW';YEZ7XV0;D3Z*XGC(EX9)
ME"20Z>Y)D+'CN/B:F.3.@7R:NC<4VI+IFUP/L>I!V:8\?04,-+_YQWRF_P#Y
ML?O_ /2.Q7\ &@Z_:#DDX@?](<Y^_P#A'%7]<#J"7?JJ/XCK;;_C%K?_ ,Y?
M$M!"WF+P9D3#FKO&AS2:SLXE6P7&S!L&K,EMJ*XB#\DZIR^+,#9.HH\J"@J%
M9K0P*Y K).L45_0K')7I6(5NP!<(?E/\YX[V:]23P?["8F> OV-\R\<F9\B0
MYRZ @/,991CG9US3I7!.$0[H7=MN>),M3#OVB56282.UA@%:P1IYZ8AMY//4
M'\7$3T-RG \*[9N^K,_!B')V36]$ZP:++4I^QB^5'/S>XXYRTB4%N4$2NB(B
MPX\Y=52I+%8)5[6/*":V'M2?5MLV7,6O&9N4'1>6X?:<C0ARRO%8_C^%IG^3
M8U0R9L53J/LB@CCOC)Z=W>8N4J3)A@<F\8#C WLI(O;M0!MGG:7>GL:)OC&3
M<O;<DGN;F6#7:L58]B,WV0+R;?'SI)U1YZ\R&8#G<5:6N/FO-EIQ3I(KI"U5
MT:@A(><<59/<./.7;3\/L(Y - ,E\(N,=O\ 5W*L)VWQO$,C*)Z_+5F'LIXH
MDTS;8Z]'LRF:YSR_E<M1*D"T;:J;5Y#6WK6-><%2E+4 L$0?0%YPMT3M#N,3
M:+.#$Z^%Y*<X9?$F&1$W%XD+*V7#@PF-N3. /0$YQAJ5S5R'J"OU1$LYGV!7
MZ "#&^,O2E_X_P#AZQCKDRMJMMS4V:\R^=SP#>2,I[OL!DR.N\WDB  S.@Y2
MOBTH>2V1&8((!"3-:?I #HZM@K"]&OY4_%+RWP#N7CGX7^7O//=^R[UY@\BX
MA\.[_P!3],[3RAX;V?7_ /9?1T?8H.K5X\)\)=/'_#O O#EOC7C'=O"?">[&
M^(^*=]_H/P[N?7[?M?TKLNMUOM>F@Y%_1F^(_B^=H_#O%?9A^'5D/V9^+=OV
MGAWLFPWW_N_>/L]GV'<^UZGVG>^V_P#9G:4$'/5/)P+MW<'BX_K93%R1LFI^
MP;GLV?@,RQ"E!I4&!2 M>;E)2VC*5 D@HTID &T 1>)";#B V#=09';"#ILX
M*UFHR[BNU%.TK3A1X?!CE&0\HUXFT<U2Y=),$#,)63C&PLHH[(5Y_9:-:;8
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M1MQS,E.(",OP5,T*1CO=<"X@Z)5Z/0%TX#M36GDX=HRUZ>KM*M)3\A%2>6Y
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MBWV18N>=G<,Y'<HOYWR-/N\S-^DT4875Y\:R?+YK(B>]-,50%=W+5A2 [#K
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M_8*GK9G&=9L+R^ZR:4Q<Z.%6=(WKSBR08BP[+W_(TJ,L<B:T*!/,3;&K"^T
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MG4*2>+MGW83_ -<7YU"DGB[9]V$_]<7YU"DGB[9]V$_]<7YU"DGB[9]V$_\
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M 0AZ06MTWO0I+W]KVOTVM?\ F;]%_P#X5^BU^C_K7M1^/]H% H%!PH>M7_\
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M0%E@"$  !L$-K6M:U!Y= H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M(\=Y5@T3R1 I#X8Z,_CT+G+ WR>+//A+\@:WQK\48W0@_NZU,G5D=IU#BBS
MB!8,X[,O]3!^A#^=0.S+_4P?H0_G4#LR_P!3!^A#^=0.S+_4P?H0_G4#LR_U
M,'Z$/YU [,O]3!^A#^=0.S+_ %,'Z$/YU [,O]3!^A#^=0.S+_4P?H0_G4#L
MR_U,'Z$/YU [,O\ 4P?H0_G4#LR_U,'Z$/YU [,O]3!^A#^=0.S+_4P?H0_G
M4#LR_P!3!^A#^=0.S+_4P?H0_G4#LR_U,'Z$/YU [,O]3!^A#^=0.S+_ %,'
MZ$/YU [,O]3!^A#^=0.S+_4P?H0_G4#LR_U,'Z$/YU [,O\ 4P?H0_G4#LR_
MU,'Z$/YU [,O]3!^A#^=0.S+_4P?H0_G4#LR_P!3!^A#^=0.S+_4P?H0_G4#
MLR_U,'Z$/YU!N(M.G[,'Z03_ # ?_90/YVW_ -30?WW=/^H$^] ]S0.[I_U
MGWH'N:!W=/\ J!/O0/<T#NZ?]0)]Z![F@=W3_J!/O0/<T#NZ?]0)]Z![F@=W
M3_J!/O0/<T#NZ?\ 4"?>@>YH'=T_Z@3[T#W- [NG_4"?>@>YH'=T_P"H$^]
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M>YH'=T_Z@3[T#W- [NG_ % GWH'N:!W=/^H$^] ]S0.[I_U GWH'N:!W=/\
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M',E4L4;QM@S-.Y&=Y"A'<26,RI9"I%#\&7>0&IE1%O"G^R5,=;L^D2.:!Z#
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MJ#7N4KFI")R<&N%0YD2.TRG+TE0A[02)G;URN]A!M8N]QAM<(ZZ;<Q?&EO\
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M88(V&SGER'8;PVH0,*\J<927C@2(7F=*6L8&L3=*26M\+DCH29^EM(DMG3M
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M?8QWPUKB8IY#]RT90SCFI0BB0C&?$,+>B2RQEE&+S#C4"L!EOMT,X(&686(
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MH"PAL%JG+/JIJ]K!PZ\FJ?6K6[ FO)$TUJDITQ(P;A['F)298<P$'@8C9*7
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MSVG5IB;D2R3,2I58Q."XNL06:&W1T7O:_P!B@U%LGBOE8W94QK"V4,08SQC
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MCB*"@'G\T'W>W<Q+K>^Z#35MA.<M;LOO.3FY>#);QB::FEN44.84U\?S%N3
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MYMED77WW4C"VRVZZZ<+8F9B'S:?P'LT?773_ /E"M!?X2]>D'W[^#/*7%_\
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M7N&4+ER)L1+')R6)6YN;DJA<X."Y04D1(420H:A4L6*E RR$R5,06(9A@Q!
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MP3TQYI0KAO:POL7H,OH% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MS%&[LR=6MGBYT3<\4F2.41BT?C*Y7,43PLR%9? U@[I%2!$V]B83?O\ UA#
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M3K6I]BTG0$)%#M#YG&G9.C>8Q*&DM<2,U*I*#VA!Q2@@1J8\@XP.)'@ZYR-
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M:RE8H[$H)*&R4P,3U4REM1Z;SE6/PUEJ+8DFR5S=H#$\Q#9&"/RHZ8X8G:E
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MN!U!+OU5'\1UMM_QBUO_ .<OB6@N'TK_ ,#?4O\ >S8'_<LBM!)F@Y1MV_\
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M$0;W#8A6QF%U>'E^?6F<HY%B1K;U3JY2Z)M;_+BT*%O-L2YG*F:,-3M(B1-
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M&7R91FPY Y1MB20A;#ED;)#DA#VQRI^1J@W*/ZJ<?5+[4+1<\80QMLKA?*&
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M9 S_ "9J6L;K-W6;9'E\\2HP-2^02<]$T0=IDZ>/-P+*@E>'-1%RDZ,JX$9
M2UH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!2
MIS!_^\[_ /KM_P#NLJS_ (&_UK^3_G&(\5?Y#^__ .XI3K/V(E H%!<CQ!_^
M<><_^!()_N^45@G''A6G^>O[ZUE?"WAF=^Q;W\KQJUXS$H%!\]3#O#%J]R_\
MT'.4V;*SS/<'(P%L)"UT.'@V48\C1SD=DIPR8G?0R44^Q;DP"PM("#)+I+)0
MH[EW,.[2YO6!8L-B3C53)_IO^4?BX@^G&V.<\H:F;_9N0X+G^L^9)(V/MP 4
M9#Q?!Y(^'-D69HO"W5Q*,S@0Z,#DWL#8YMSDB.3'*#TJX\LX.V/9O:S7C33%
MRO-6SV5([AW%R)U1,2B828#F:W^-.2=:I;6DDAG;W-Q5.+B4W'6()*)&8<,'
M4!:XQ!#<*Q\7>H_X4,Q35EQ]#-[H4ED<@5ID+6/(&,\\XAC1BM8L2H$Q*N<9
M:Q5"(2V"-4K 6_HIQ)M8'6'>]@ &((6A[+;-X.T_P7.=E=BIP''N$\;)&-=-
M)L".RR8 9TDDDK+$&0X,?@;#*)4Z!72&1(T]NYH5%P6.[0=@E!&,(0 SUST<
M1VLPX2FS+NG!H^YY A43R''X_'X9EO)$J21*<L"*51)PF$2QGCV82;'2M\CC
MDG6DH9"D:U_=SRQ")#88>D)8;B<@VF&@,4:9GN!L+ \)-4@,5E1MO?375[F,
MINWE=LXF13'L/;)'/I0F;0B %2:WMBDI.8<4 P01G%!&&M]+N6+COY#'5\CV
MG^T<(RW+(XB.=':#FM,UQWD MF3&IDZM^20#*D7@\S=8ZC4K2"CW%(A/1$FG
ME@&:$1@+7"Q"@Y(/6#Q1NG>F6CL'=SEJ9IF7([B**.BAM,()<2&Z18JS2T+3
MD!JI.L3%+2DRP0BA&$F@".UKB *W2&X8@Y^C*TABB>\AUTW,WNPWEUN+76BN
M1'.98CDZ=@.7M:]K4CNTP;$V'),>6I3KA%'A32!#<Y*,TFXK6-ZP0RKBJW8W
MXTEY'5G"-RGY,,V ?9G W3).EVU3DN=7J2Y*C;8CD;\!EE<HD/5D$B1/L?AK
M]V:EY-4N[7(F12UW5N2=2A/)"R(C$''0IYZ%F6B<]9>'R8H-1 E*]>?"EP<.
M%8$'W6/AF_C(\*A;#)%<]:4'L SD1_6%UNX=2U^@)C[G\I&@/'J-F2[A;.0/
M#KY(FX+RR0X])*9OD)S9#'$+06^I<<8VC\QG@V$QRZY(5WAUDHA$']!E[)S[
MEAZC33EFXZN01Y<(QJ+M1 <LS%L;%KVK@8T$PQ_D2S&VJDZ)Q?4^/<H1J%35
M<QH%2LD!RPA 8F*N>5UAVL:7<0>5N?RL<>O'LM9FC;_:*!XCDL@1!<VJ$V02
M[(&0E#08I"D(>S<=XOC<VG"%A5*NN62N/;RDAPB3K ,%V)W4#.-->1'2GD&B
M[U+M.]AH1FUMC)B4N4-C.!]CLSBMG :HML/E..YNSQB?QI$[#0GV1J%S8G(5
MW(,[$8^S'T!&S:[G+XJ=(LINV$MF=NHW ,L1\XI/(X(U8\S-DM^C1ZAD8)(B
M+DR?%..)N7'1.3%)T2I)WT9'>RC17)Z_9'6+"0FF7))HWR$,SV]:=['0;-5H
MR20JDS V%2"+SJ-(E:U6WHG&18YGC+%9^Q-C@L0F@3J5;82G47#TEC%:X;W#
MT>Y_*1H#QZC9DNX6SD#PZ^2)N"\LD./22F;Y"<V0QQ"T%OJ7'&-H_,9X-A,<
MNN2%=X=9*(1!_09>R<^Y8>HTTY9N.KD$>7",:B[40'+,Q;&Q:]JX&-!,,?Y$
MLQMJI.B<7U/CW*$:A4U7,:!4K) <L(0&)BKGE=8=K&EW$'E;G\K''KQ[+69H
MV_VB@>(Y+($07-JA-D$NR!D)0T&*0I"'LW'>+XW-IPA852KKEDKCV\I(<(DZ
MP#!=B=U SC37D1TIY!HN]2[3O8:$9M;8R8E+E#8S@?8[,XK9P&J+;#Y3CN;L
M\8G\:1.PT)]D:A<V)R%=R#.Q&/LQ] :5W!YF>,;0N;>S3:G;F!XZR.66W'.&
M/V=AR#E2;,)+NB-<FLV4Q3#\.GS[$BW!N*LH)$YD)+&$'$CMTA4$7,#=&G/(
MII+R ,+W(-/=BX#FY/&"6Q3*&=B,>&.:15*]74A:%<IQ],6J.3N-I'0Q$>!.
M:N;2"SC"# !O<98[!":5 H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!ZUY_I.Z_P#!J[_<
MIM!0'QL:? S-JG'IF9L]M_C M?)YJW#AN'\U6A4$( A>#4HE*:.BC+H$I8X!
MMUU([FBL:9>]^BWYE!)365MD>F>X M($$FOD+#V3,;O>=84\/[.RH<B1:0&/
MCRC>$TMD;&WM]IP-UM'C^NL5D@,M:Z8LGL2R1E&!:2;CK'QTU3Y*.@L.-R*D
M:Q,B6?FQAD,FJ9F%8^PFA/*A(;OI+6*RDRUTX3[%7[07VOVU^D,QH*Z^6+_
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MQ9YFW?\ E-,?W]^$_*F]/I>1Z(/9SK_^4 TT^/[)?P;:?KU]67J%Q9YFW?\
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M"P%]^F@?C7=D?R+W)=]!8"^_30/QKNR/Y%[DN^@L!??IH'XUW9'\B]R7?06
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MQ_7S[]U _&X[,?D2.3_]C^OGW[J!^-QV8_(D<G_[']?/OW4#\;CLQ^1(Y/\
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MS[]U _&X[,?D2.3_ /8_KY]^Z@?C<=F/R)')_P#L?U\^_=0/QN.S'Y$CD_\
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M3R6B@\1<!PO(\_7/<E+9W!^.1IX]BZ'S:1E)$K6V&C.6&I"T1 Q%%&'!-/(
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M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$$^4?^++Y%?WB>W/\
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MOUP$W^UL'5\BVRP*LYWWC3'\"7$)>P35IF5FO\.WHA@\QJ(F8[M;![(>I[*
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MODS?",494S*1-W/'SI+70ZR1"AE"J?X0P0Z,+4I<#"DUUZ!.\D)##PF+>ZI
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MD_6S>G6K:?4&+;RXVGR1OUWD4&?Y\YRR;W2Q8R!-<,&ZIY^AR"4H6*$4=<X
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MY/J%,"PRAE&"46O8 5=<:N.\BXE]3ECW&V7\@H\L96ANW6PC)DK)R! %K3Y
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M/+YPS-#N@1.K2Z\H^&VUT:W)*0N;G)N7+&M*M0+T2HLU,L1+$QHBS2C B 8
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MMM=A)9"SD%N*8\DI,H(!08KZ8+_EOYT/^DAF7]EV7J#K;H% H% H% H% H%
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M[IQ,;Q!7%?L&YQEQC1I( GHEV'%F;Q01>G&(%@71&K[IQ M:]Q_]C076Z=<
MVDVIFE&>],C"Y5E-)M7'2V'8G+;\<B89U,;-Z94&*ABY364H;H4TX_<UISBQ
M)+=_NG7FC-5&K+BO:@I4PUZ3?9O7_*DJ*PERVY7PG@N;B[A,[X:8<@8URI-(
M:4>H,30V5)XEEMGA[T("-6:G[\K&I2A&8,^S;U1W34$M]0/2XQ#37D2QYO!
M=R9!(H9C'(,MF$<PI+,*B<92L;))%)-%R&J1YL%F<7C#XG\QW5JG2T8("M/
M+JI$X3+6+#JZH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M0+)>,>Y:[PB,PZ-XM;(@YG,TIQ&;CMDM'X+)<?2966ZJ4,FC;5UB;'K0+B7
MDX\EP*5D*5!1H4#-WIA-O8F0CQMCKU >_<(UB0)BH\BP0W7R<00C@2HFQ,CA
MZ-P8MI8YCY*F>;*5E@=2'V1% 4]4U(HZH[FA<6HX8]89+Q>H>*[*DLR[F#$Z
M$N6/!&7Y[(V1?G5)DN7Y.E^8E&46^5)HZF:29,R3J;KKH;*$"HLQKO9$X=_
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M]/5H*87'TKF2\.2F6E<=',MNOH=AB7OBF1J\,Q4^?R- C<SS#!)RBI%CG87
M/BZ!G3'"2HS'5 XNEDH06/7*#>N:8%G^/>"S7J.<:V>>-C).9<\YVB.QDQ79
M*R!FG)LA977+*/(Y:+'2*(2:+.0F<TA"3!@XE8!(4JZ[EVEDQI)QHTIW=RPB
M_P ;OI_LTZ';(87R_/.5G9':/#VN3=.6G!VKTRCTLC^+(*W3+'\KQN20B;7G
M/61XN@\ C\GM=/9H8V<%SD]N@ "Q]F ,(V@],TAD^R&3=F^.WD,V1XOYAG%U
M.?LQQG!@)6MA4E>ERYR=W90Q)(%F+!D@CC<Z/CB)==M/<7)L1J33[(TZ8DPL
MDD)Q<4W![@'B_D&0LSWR9DC:+;C,+4!FR?LSF,X Y*O:SU3>Z/;+$6BZY[6Q
MQEDK\U)ER^Z]U>W16<F(":N&426 (;EP_P :?LHY7=M.3SVT^/\ X4>$<<X;
M]B'LY\+\C>S]FQ8T^8_:5Y\<?,WBWLT[3N?@#?V'?>KVYG8])H6F4'%QPV:K
MX0VEYX^53E$Q/%"4> <,9@EV'<'N7>2%K7+=C)HQHFK8'*48-)1$]5 L3)W9
MQ*".X>A)/D]P7-N$5RP[1Z!05:<;O&G^+XG&]\R]M/M<_#8VSG6T7AOLY\@^
MS/SJ[OCKY&[YY\FGG/PSQKL_$^R:>V[/K=T+ZW0$+2Z"I+C!XM/Q;\XWHF7M
MT]LOX:6R+SL'X;[,?9W[-?%W>7NOE'OGM"G/G'N_FOL^_P#9-77[#K=V#U^@
M 9%QN\:?XOB<;WS+VT^US\-C;.=;1>&^SGR#[,_.KN^.OD;OGGR:><_#/&NS
M\3[)I[;L^MW0OK= 0M+H*DN,'BT_%OSC>B9>W3VR_AI;(O.P?AOLQ]G?LU\7
M=Y>Z^4>^>T*<^<>[^:^S[_V35U^PZW=@]?H %MM H% H% H% H% H% H% H%
M H% H% H% H*/N9?_P!YP_\ 7?\ _=75&OM#?:?Z[^QEB'8)_.O[F?C!1]4:
MEB!0*!072\.'_G+GG_@. _[OE52+[/?DS>GB61X+-0 [>7]4\-_TG6^ TZ]V
MI/*WB@4'SU,.\,6KW+_S0<Y39LK/,]P<C 6PD+70X>#91CR-'.1V2G#)B=]#
M)13[%N3 +"T@(,DNDLE"CN7<P[M+F]8%BPV).-5,G^F_Y1^+B#Z<;8YSRAJ9
MO]FY#@N?ZSYDDC8^W !1D/%\'DCX<V19FB\+=7$HS.!#HP.3>P-CFW.2(Y,<
MH/2KCRS@[8]F]K->--,7*\U;/94CN'<7(G5$Q*)A)@.9K?XTY)UJEM:22&=O
M<W%4XN)3<=8@DHD9APP=0%KC$$-PK'Q=ZC_A0S%-67'T,WNA261R!6F0M8\@
M8SSSB&-&*UBQ*@3$JYQEK%4(A+8(U2L!;^BG$FU@=8=[V  8@A:'LMLW@[3_
M  7.=E=BIP''N$\;)&-=-)L".RR8 9TDDDK+$&0X,?@;#*)4Z!72&1(T]NYH
M5%P6.[0=@E!&,(0 SUST<1VLPX2FS+NG!H^YY A43R''X_'X9EO)$J21*<L"
M*51)PF$2QGCV82;'2M\CCDG6DH9"D:U_=SRQ")#88>D)8;B<@VF&@,4:9GN!
ML+ \)-4@,5E1MO?375[F,INWE=LXF13'L/;)'/I0F;0B %2:WMBDI.8<4 P0
M1G%!&&M]+N6+COY#'5\CVG^T<(RW+(XB.=':#FM,UQWD MF3&IDZM^20#*D7
M@\S=8ZC4K2"CW%(A/1$FGE@&:$1@+7"Q"@Y(/6#Q1NG>F6CL'=SEJ9IF7([B
M**.BAM,()<2&Z18JS2T+3D!JI.L3%+2DRP0BA&$F@".UKB *W2&X:JR5Z-7C
M\@4!ETZP[MYNKBG)\*87"70C),XGV%WJ(PA]C1(GI+)']!$L(8RDHFYKLB$8
M,U$_-BA-T6.";^E]403Z]+)LULQM-Q5,,QV?E4JR!(83F_)&+,<Y%FZI6[2N
M;XJBK/"5K.XO,D<!FN,J4L<K?'ED"O4F&J!EM02C3!C*$*X: ]'G_%F9U_?_
M .=_W-,#T%L.V7-_Q5:/Y'/Q!LKN- X9D]!U@OD%B\8R;F&1Q-0$E*J"@G#=
MA:#Y#.@KJ>D6DGE(WCN*HX@P)I98B[V%039ULVJURW#QJDS!K!F6!YMQRK6J
M&R\E@KT2YE-KNDL6-4R/[<*Q#Q&7Y.2<6:-"XITJL))I9ER^H8 0@T+NCRBZ
M!\>86,K</9J#8==Y*D"XL,0.1RJ<9!=&D2R[>%\2XXQK'IE/11^ZX(RO$+MM
MD7:%&6[7I*,ZH>ZTTY)-&>0=F>'G3S9& YJ%'20*Y''&SQR+Y CB U::WIG2
M18SGC/%<B,+0M6D"+3K%;62E4BM^E&#Z;=(9?MUO1J-H; D>2]N\\P;!\3=3
MEZ5@')U*Y;(I8L:DQ2QT0PJ$1Q ]S:;+VY,>6,\AI;EAQ5C2^L&W: ZP<>?.
MIRH\?_(K!>-=NTWV4BN8WR$\FV#G2414,?GD FC4S&-S\@L_#A.48G"9:JCM
MEZLE.)Q(1&H@*#BRQ&V&,(;AW>4%;W,5_%/\D7[R+9G]R&64'(WQ>^E2T WC
MX\-:-J\D9JW$BN4LWXW72A];H1.,*IX SO@)%(F1)X2POV WR17:BBVLDPP@
MYY,.,%<=K'@L(/5#<$R?>1'TPVPF#Y+ES:W(6]/$7GO)Z'&,N595/D#UD; 3
MV^C<WY2H94;P\28R/R!N9B')[2%LR\#-+PM[F6J;FY:)*J"%[7*+ASCAS#N-
MP^R_<'8'+.,<[X^V0<Y;H5$,7H5#I#<X9433C7>:K8]D=Q1X7RBB1QD#S"(N
M66<:\Q0LQ*XJNHL$+H-2A9AM3N;JQI#CP&5-L,YP'!T(4JSVYJ<IFZ"*<9(Z
M)DAC@>S0^,MI#A*9F^%(21G71-*)8K[(-Q=GT?9H(4:Q\\'$GN%DEGQ!@'=*
M!R3)<D=6QAB\0E\0RMAUTECZ]!7B:F.(^V> 8^32MZ7#;1E%I&XQ2HN>823U
M.U4IP&A+G;[?/3[0B#H,A[>Y]@V$(T\G+4T>!(SW)SD\K4-A!:ER(AT$B[<_
M3F8G-I)Q8E &MN5B([4NP[!N8"P@TSIIR[<;W('('"'ZD;70'*4W;25JLV +
M6R:XTR(L;VTE.H<G=EQ_EJ+0292%C;BE0+J%R!"I1D7%T#,#>U[6#<F:-\=3
M-=\\88UHS3F!NQ_F;8)EFDBQ/&7B,S@YID##CMI6OLU>'2>-L878]A3='F=N
M/4'FOKJV@N44*X+BH-#:[<Q_&GMKL:X:GZV;41?,F<FYH?'\V/0J'91<(LL9
M8VE1K'IR9<KF08C$<A2(B%Y7VR!]4]H.X@ ZPP#"$,(V:YV.)C3W*;AA3/\
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M'X;O-K^0L@'\K#@[^#_0/PW>;7\A9 /Y6'!W\'^@?AN\VOY"R ?RL.#OX/\
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M'X;O-K^0L@'\K#@[^#_0/PW>;7\A9 /Y6'!W\'^@?AN\VOY"R ?RL.#OX/\
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M'X;O-K^0L@'\K#@[^#_0/PW>;7\A9 /Y6'!W\'^@?AN\VOY"R ?RL.#OX/\
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M'X;O-K^0L@'\K#@[^#_0/PW>;7\A9 /Y6'!W\'^@?AN\VOY"R ?RL.#OX/\
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M 0M4;7^LHD15V$OC*T&@8WD1;;::IY]CY8;%++# $"D%DBKD&F9"D+2$=SQ
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M3HM='J2LYDDR!B)N/:A/LF=7)O/;)4SJ4R=::VJ4:LE(B-&&1:B\:_+%N]R
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M!G:QXZAV17APG;<@GZ69+DB%.QP$Q,I$Y/;6)7.H*$YT3J@E!  )BP5PBO\
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M8M6NB]Q5&E(T;<C1E"--/,&$HLH-Q"%8-KWH(P8XWUT9S%-Q8SQ'N?J?E/)
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M&8'T$8RRH8Y&X_'FP\Y2VL+&TLK>I4F$G*%"%K0)T*0\\Y.40G-.-3D!$,0
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M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$ =YO_4N_P#;V_\
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M30V<N=SK,D3R2S(F)P?Q$ ---)9G!G>)%'5:VQ!5S I>_!5& Z;@+%U1]4+
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MXB,!8R.R+&,<R)S5E*X(Y31V+:8X_3)MF4\$V1!P5CN(_P#\=-]U(2;$%G'
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M[98K<I$GV-@>'V)IG4V8FV?%8?BN1,BRD]GD D]FU9%U),2@$;C3,@L%.0>
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M7*DBS8_*2-PG2ALOVCBUXGQMV4DDZXH@1)R8*@)X"UB4:@(B;F-8[7#>UKB
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M#2BK43/!7&C)4:B+J+9S?<UF;7K,:E$F*'0"DUX;U HD6@( )39]#%T055T
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M3"+;FZ=-1ACOB^-SAA1OB=[ M<0V:VZ%.DI>)<2?X<D"=V!HCCNK>X_YGHZ
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ML\B(A[M-8DURU2Q+90FB[C(V=%(E$9;1&@<9$0R*5A3F:Q(!D#L>K"5=.5<
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M H% H% H% H% H% H% H% H% H% H% H(>\@*-T7:6[(IV<LXQ9;&#XI& @
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MB[\BO<-N]-#\URAL<20B$$=@#&E4BL$71?JBZ+_ZE!J7 VT3CJGJ+M#B2?.
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MG2'C+4Q_#T!%9PD$==C0#"$@];+$"M$28&X@^*,U@6O?K!ZX7$HD:1N1I&]
MF(1(4"8A&B1I2@$)DB1*4 A,F3DEV"62002 (0!#:U@AM:UOL4'DT"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@TIL+@2![+8HDV(LB)E V*0DE&IG% ,LIWCSVB'<]HD+,>:6:64XMB
MG[:UAA&4<7<91H1E&#"((9QS&'*#BME2P&&9EU7R]%6A&%L99WFZ/Y4:<F$-
MY STR$"]/#!N#*[*T3?8D7>%JA4>>;:]CAF=%S# R>9:N[(9 UCV$QEDC.[!
ME#*N:$Z,EA6+F!3 \:P!$@5H!IH^T(&0F0K;(!%)1F'+.YW5J#1 L=8P0+G"
M#"(1CKE-B6/X9BINENC<8CL/B<9A+=,&ANS9(YL@9XLU(6=$X ;Y A31-T=U
M"-N!8ZQJ<E.*Y@Q  7?JV"$B=6M3&[7H^<3B43A[S!G/+"Q(XY.RS)4Q"):[
M"1%V B8V%J(,4%,$9;__ &4F":/IL L/2$HE.20&532,;.+MC<526$9$AS/K
M4TL#JGRSCYQ0I#9?)Y"<ED@&E<QK3(*ZJTZ5*K5-@C+ ?&ZUPIS.DL?3>QH2
M4H-*;"X$@>RV*)-B+(B90-BD))1J9Q0#+*=X\]HAW/:)"S'FEFEE.+8I^VM8
M81E'%W&4:$91@PB"&<<QAR@XK94L!AF9=5\O15H1A;&6=YNC^5&G)A#>0,],
MA O3PP;@RNRM$WV)%WA:H5'GFVO8X9G1<PP/=Y U6V3R3J[L#B[(N>([D_*V
M9C&03"L<6!5 L:0% RO3.M*CS0@8D\B761#3-Y@S%?<KJE!PP6.L.X;GB#+-
M@=19'F/7["<)8)BTPO,F 7'&4S@$R$D4NL>3S?'S,G;AIUA8B"%QK XGE]H$
MSL.U 8228(D5@C)$$;MB-4>0;:O"[Y <J9@UMC*JRV/'-,(QFQSQ%#96>UNR
M1::^3N<RAI?Y:A4($X#1)FYK; )#U5B3#3 !+N 02]SCCW;LR1Q"9:SY;QNQ
M>!Q5/'9'BO+C ^.&/I6L(="U0'TQ\CME,C9EI*$XTG^@TY)AP2P!&;U16N2&
MM,7ZR; 2K8J';/;8S;%"R88MC$AC&,H%@MGDZ6&-%Y4@<&A\?79]F][25S6*
MFIR.!9,((B@&&]< PV!U!AC+IK;M_AS.N:LHZG3+7MRBF?GAMELPAFP"#(9
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M*K'#A-;E63JILR/<)MYH:'5RL:8H4DEA"%0KO<1IAA8BRR VO@:"[A)Y\ZY
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M%<6XG=@EHIC%]7X_,SWV<,?2:)8T+93DJUES$0YV-L2H 190F-(!8)A!@1F
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M,5W'SYL*X.49.A>4X!C>*Q]L1K'4R4(W"'H4J9S.>41[,G:4Z(\PB]R!$+5
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M874.$'HO0;>@VG.6I[EF%YRW.R\QY3D.-327+&>)\?,!\=Q#!I&(A*<?(O\
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MG%@&4(030AZ 4'Y5QM14(MF?4=*UE)A-]\QD0S(!^6CBPIC>R>#H<K1&8O\
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M.[HN. F0MK6V(9">M7KUB@P)91)0!F&#%8(;7O>UJ#>U H% H% H% H% H%
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M4/,@>5S^H9RE)#66"SXZN2=F0(250P%I4 $J4(;!MV?0 '5#:U H% H% H%
MH%!K/*>'L<YJ966/9,COF5GCTL8YPSH_%WUF[G*(V,\QE=.\1]S:E2CN0U([
M]@:,:<SK?IA8NBW0&S*!0*!0*!08]+HJQSF+2*%R9,H6QR5LKG'7Y$D<W1F4
M+&=X1FH')(6ZLBUN=T%U*,\8+FICR3@V%]J*U_LT'J\=8[AF)81',<8\8B(U
M"XDWA:X^R)U"Y86@1V--4"")8YJEKDM/.4'C,-.4'&G&F#$,8Q"O>]PS6@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@JFYD.Q_ _([QV7=_;!CCM^VZO8]CVCOVO:]?[3LNIT];I^Q
MT?FT&RB2>)Q2<4G3E<>"A0H-+)(()+UL-...-'8!1110+"&8:8,5K!#:U[WO
M?HM0:7V(:#MB]L\9: L"H^"ZZXVQ&ERKF2-P<8HH7)6!O6I(]$<8IP-%D9+=
M$6TLUK"%,F[,H)2P=P@L8D3B+"9]M'-.[,((W^#+A/P\L@I.%1?'D;N_7+)-
M"< 0Y5=!>3FGW&"UA&B67,&#I"(5PWO:X1AVIP%CO6_CIV5QUBM([-<+&V.4
MD;F-T>5CZ!A->Y%&QJVMJ7N8CW6[26>GN:6%4>I/L8:.XC1=-K6#%\!?BOO8
M3A7SM^ 3YS]DN./-WFK\'KS/YG\G,WC_ )C\7_\ &OCWBO:]\[U_1'>.OVGV
M_308KO;!L4>;N-.$Q&'8\]D+ULFU@0Q&.1Z-^S=VC<K=8PYK@)&!L2>6%[')
M/%35!M@%#(6=Y&8+K]H*]PQSD]PCKMBO$,/?L,8^@&+-D_:;!DV%2L1,#)")
MP^O:Q\*(4D)6>()&X][3EI@B$ TXD825820!,",RP# M5RCAN-9_PZHQ-F)*
MJ7L4G3PQ1,T#.XF-)B];&)!'Y<8A+<$/0H2H%CTP@*.NG$6;=,(=BC"QW"8$
M*MMX\5Z'Q_#$PPYBK'&(CMER+-35C&#X886==G1'-Q+&LQJ&\AAI1TS3(BD2
M^RE2)Z,"0>F^S;M#KDVN%G4'4Y*Q]K3%5LX;5T]R["<)M"R4LR!28K=)AD".
M0@@]U:$JU$B<#5;D^OZ,9 3B4QXC3C>N H=[V!</WUURE,,SXCC619YB62X.
ME#X>^E.&-)<)T&_L(&E_<FA$<L$\QJ(N-PO")"6M*ZZ FW9* ]6XP] Q!NZ@
MH<P9^"+^&!R&?A1?@X=X]L$7\E>WSV9=MV/9S/Q_RO[0_M^RZ_<^^=T^QT]C
MVG_84%A;&5I.PXZS1DC7^":LS,N*8QF!4Z2X=;<2F ?(W=B6ORN"2QUA38YA
M(8Y8%@L$Q,L*.(.L3U[DF]GT4$7,_P [C&3>(:83V&8Y8<1QF48Z9W-IQS&/
M#_ HJ2+*+04:A;KM3'&F\11RDH9XKE(4UKF&BO<-[](KAD+5NQG**8ABLZBV
MC.697@Z)0*,FON17B;Q&%2HYF:6!L\7DT<Q"K3.\P?8V!+UE*56(28M2DMVP
MNQ+L,0 WCF[>J$8PUNQILW#H\=DF#Y+E4-8&XCQ53&EK>@E);L)8X*2D\>E"
ML]TCI[0:0>W%I^T,4!$6$RUPVZP9=BW/V=LESUK(5:CS+'>#GA Y."/+N0<C
M0AEE)129&K.:_%<)$]\F;-=Z4D%EA I/+/3@.L8:6&UKVN&CR=\\H9*<).Z:
MLZA3/83%,0>7)C<<K"R9#\9M,@5LU[6<SL=L\C0+W"=HRNH98H2819AH[ !U
M B,#:P;%)V/@>SVG&=YY"2G=H5-F,<NQ>:0R3)/#I7!9@TPEXLZ1N0H.L,):
MD@)H#"S 7N$PH8>GJ&6,*+"&^I&T6>F#4K##9A32S)6:8]!<?)D,GF3E.(IB
MMM<%J$]R&M!C=J?4KU(,E$)>P&2(Q"E!UE8+D L,75N()%Y>V!A.S/'%G[*D
M& XHD*_$61FAZ8'HBR9\BLG:&D\AZCCR0$0RPK4!HPBL(-[A-),+,MT6'T6#
M)\.9(EN*]!-:Y3!\3RG-,EMA?#[:W06(J"43DL,6PINZ%BEQ4IE:9M:D@RK=
MX/& 5BP"Z;!&+J@$&'KMZ\Q8J>8>/:S3B38$QW,I0V0Y-DQFS%!,Q,C"].X[
MDHC)8CB;>WGL+3<T0;W/,,$,183+E%FC+[,0;UV0VK)P?(\?XQAF-)-FS.&5
M;/!T$QC&7!O8 J&]B3B/<GN22MX :V1EB3B#<(E!A9W5L P=PV 4,5@QS'FQ
M6S;\]/$9R7I#,,9/=HC(I#$5B++L$R%"Y \-#><I:8F\S2/HDC?#7*1K4XDY
M)BHLTLF]P#';JC#05HZ"9DVNBZ+9$G'.F7M22/NU62GN9K?PB<;PCR'+W IA
M ]PCNSZUJ#91Y?**+'XDDN!*K[7H+#:X;T'01055[J.\LSKLK@K1%AD[G#X)
M/(P[99SVYQ]:8WR![QRT*W1$AAR->6 5TB-_6,"HA0&W:=H(\@1@;DE#+."5
M+?HQIRV1LB*IM9L+&MB=$) 6J<("P.\D$0.X[W,/F+LC6R]2MM<=^A28N&H#
M]CH';HMT!KR01W%W&YK9FS(&(X0YNL6:WTO(H\<+9DL3-Q+F_*HK$53='WQQ
M;)&O9&FP"RU-BC"UO0;U[!N$(K6 #&FUV;\PNV.W6 :=S86&I<<R@?LMS7(\
M0@(F-&M*1F.S_'<<OZ($YF<9;^\#$C5]W;A.A1=C"2[!';H#T\OW:G+SDV=8
MMU8UGDNS+EBMRLPY*E!>18IB>"1Z2@[4"V,-\IEB->D?I TJ"^R5IBPE"*,"
M/HZP0=:X;"P?MZUYRB.6 M./I)$<WX7)<TLXP-,U(&V1H7XEN7+6!,G>4B%<
M2L8)0H17(3N)248@WM<=T]P7)N<'J8?NO%I/I,JW.5QD3.U(89+)"J@WF "Y
M0"01E\=HPGB=I#=F1V[5[D+<4G(4B0 Z *@&7*N'[%P_..;L1N0Z4N^XMHI=
M&4QQ"4/+GCLR0WNJ12V-.BY@O"E<B-84QB8Y<_)BB0JA-G2$I0 VQ [7"$05
MZ[B9HSE*LN\;LZ;-;>U6.2YMR5"X]?+T:3#E,WE[&P.+KBL]<ZL389&E,50V
M1B-=UJ8*-28K$ LNUR17N$A-OY]FR?\ 'SM$NS=@#\'UY0-\:2,S%[58EE?Q
MYL'+HD<:[^*1%&B2M?9*A")[N;:Y@NKU[7Z+T'DH]W,T0_#$;R'$-),IS#!<
M(@;$=)LEO\VBF/'X3%'V1K*>Y9&<4NJ1TF[_ !@E*$U4G6&%HRE",OO%[EDV
M&86%D>,\B1C+>/H;DV&*CED6G,>;)*R'*2>[*[(71,!060M3=<SNR]((5RCR
M^L+LS@"#TWZ.F@BUR0_X#VQ?_$@C^R)DH(W8"_%?>PG"OG;\ GSG[)<<>;O-
M7X/7F?S/Y.9O'_,?B_\ XU\>\5[7OG>OZ([QU^T^WZ:"7F0YXOP-CK'C7JQK
M03F!GDJ@X,1A^(U\2QWCME;G@TM^L_J7\AL.B+"P/REX-4A5 +N6H.-$;>]P
MB,-"&J(?NSD-IRSCS$6S^KTFUP=,NK%;1C63%9)B.7(:^2%. (B8^YOL21MY
M#&[.)M^Q((O8\T1II-Q! 49<T ;:V6VPCFO*F$0]OATGRQF3*2Q6BQKB2% *
ML]R&[=8!CFZ.3DH":DCT?;B17$:K, ;>U@C$$NY91YA(:?:-OME$\B(@>0]$
M)U"9Y*F&7+L7IF[,./YE Y=(XM&G"3E1&09+;42)A@;D]HVA2!-=2!2.XP!%
MV=RNU,*"#O&?EW:&/8AO&X+J#[18"Y9OF9K]DGV_X\B/EM2Z/#:7)$ODYX;3
MWIX\JDWN9UR3 A7='5*Z+T%AN8]QWF+9;5X P%@V2[)YD8F-%(YLPLTL8<?Q
M.!-;F A0UDRJ=R1.M:VUY<V]0!0G2B*_32C"^@?6'U0A[O7O;PG+D^EN$LEX
MPDF \_PIK3R!TQE*'9LDB1XC2@9)%Y%"IFS%)VF6-*14> LXTHHL/Z8$1?:A
M";<H-/(]^YQ*\E9SP]BK5:;92R'A^?NL.2)F2:L['$'9J:.] -DDNG\L8V2,
MP Y>H3]FB;+&NRQ6()EP6ZI?2()W8QD$WE,$CK_DC'WLKFSDF4&O^/\ S6T3
MCRTI+7*DY"7S6PDIVEX[RB**4=<D 0@[;J7^V!>]!6GR5LC-)<O<>,>D;0UO
M[ ][0-;4],;V@2.K.[M:Y?$TRYM=&Q<4>B7H%B<P19I)H!EF %<(K7M>]J#5
MG)[A'7;%>(8>_88Q] ,6;)^TV#)L*E8B8&2$3A]>UCX40I(2L\02-Q[VG+3!
M$(!IQ(PDJPD@"8$9E@&!:AE7-44U[PXMRMF1RNWH(VSM7C9;822K<7:1K0)D
MA;''6\)Q!;@Z.CL;<L@NPP%V#TF#&62 9@0A<X[\9M@S*CR?F31G)>-< 'J&
M_P 0R5;(\1E,KC34ZK"4:-\E>(FYL2RI@0%".ZRGMC>N3:X;6L8,P 1!)+8+
M;C'F!HOC]V+;G[)TJS"N1MN'<?X^3E.DAR*I6DH%):IJ&,8$A#,0F=$QARH=
M[V"%078 #!"L&@UA!-ML\>T*$P;/FEL]PJAR*[)V*,39DR3#,O11*[*4C@K*
M2S!PCB1F+B=U%D'4)";<X\X8NBQ5NBW2'XS;=>9.63)IBG5O6Z3[-O\ C!P*
M:,EOZ>?Q3%>/HP^#+/NHC2:9RI.X(GJ3MIQ5BU2,LLNY0K#M88A%##8-D8"V
MR:,VL62TCI!9#B_+^%[]VRGAV6*DQKO'5BAL4NK0I;WI(2%,^1M]3)1]U7@3
ME7,L"XKDV (H1H1@QER&YOSMB]AR%@W1:?S\XX#X.5@6Y4BL)AC28TO+LWEH
M(A-)3'T2S)#F-"B3GJ"D#04!,<H$FL,TX@RU!F$KVQ'L#H]G3(F(\7OCO+V:
M/S['.1<42F0L\*DV/'(AE4()NI=5CH4<E5^4V->-S*3A 6>X@*[N$)*FXRRP
MU'QO98V9]AVND#_!+_\ <+^!GH/;U[>(!_2;Q%[4^/>RWPWS7_3#^ANZ]MVO
M_LSIZOV*#<SOO3D::3"<1W4[5.5[*Q_&;ZYQ2:9#'DJ)8GAEY2SV3W<F6'N,
MF0.UYD<ANHM8WL;$COTA,* :084<,-\X$VLAFP$$G4F86*1Q288M<GN.Y+Q;
M-$Y;5+X5*60I888TNP"KJB+IE_<C.[JB^N$74, , #BCB0!%+$_(5F?8+&;!
M-\#:13?(+LH4NI$M2K\KQ* P&/"0NSDWI4+#DB;L3.&=OAJ1,F5*DZ%J 0A"
MKL6-0(TL8*"T=$:I/1I#EB7N*LY,0:J1=N6I[FI,* ,]+WDJUBE'=S;W!UPV
ML$?1TV^Q>@CCF36/7G*TQ8\OYRBK'++XTC#BF;BINK(% 6)J LN^NSV]LZP1
M+,X!*+3?IPG.ZA$6G+O>Y8?MAW"MPR'X6DF^NL\DT+8HFE;H:5-+[)S7"*!"
MCPH"%JFEILR1ET=(J3[/W.3N01J@V2HNNJ[8],<=;K$@-3A=U0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*#T\@CT?EC*Y1N5,;/)HZ])3$+PP2!L1/+
M*[(3NCM4;DU.)"E"N2F]'VQ9I8P"_P!6U!41QJXNQDAS1O0^(L=01&]8]VWR
M=%X"\)8C'T[I!XSXI)6OR[$' IO KC3%X8*Z;NB(9"?L+W+ZG4^Q02<RINC(
MFS+[Y@77# $FV9R?"4"!RR04VS2.8W@\$*=D]U38UNT\DB=Q;+R14G#<=D0B
MRK7^R !HSBSBB@8"W+F&6]A)5KI/M>)#A*7PO%I>0WT4BG#+)AB6WD3*PC:F
M<N/M-VMX8#K/%CDSN6NM938J]NZAM>PZ"+>$L?LW(5GK.F<<[DFS/"N%<H/F
M&<$8E7JEH80!9&"4XG^</S$$XDEV=WA$O1G]518PNXU8RAV&6E3A $U)_P ?
M^FF1F)0PNVNN+F$LX@XHET@$5:L<OJ(TT1!@%:=WA*9C5F'ICDP! "?<XF]N
ML 8!%&&@&&:9AR]"M2<(MSP]">9*)A;X] ,?Q<LX"V;9,F(D9+-%(JV 3).N
MX2!^/3!$>:4F%8HNQI_9=4%PT%2D4Q5DJ%\DVEF1<XOPGK-N;63/LSG3:E5&
M'1R HD^)I@DBF,8J4(PPH#5"FHT1)AH;C[=88</M#0]4T8709TR')\48GF60
MH9C9^R_)HRA1JFG&\8$X ?92<I=6]O-2-PFIAD[A8U*F6#4B[) HOV9(ND-K
M=(@AD&+Y8\SO'$$FLCA[GCY_ED28)$]05[NK$\0]T=VQ,N71IT$N;&1;=>RJ
M#Q)S>U1I3.N7?K% OTAL&9JDJ9:F4(UB<A6C5D&I5:1446>F5)CRQ%'IU!!H
M1E'$'%#N$8!6N$0;WM>W104S:Z86PX@Y0-QV5#B;&:-GQQ%L#R#'K2E@<63M
MD#?CX/"'4][AB EJ EB[N<Z'#4C4H0$'"4#N9<77O>]!)S,F\[MB[9,[6J.:
M^3K+DH68L;L@1H^!O*,Q:Y.K@_B:O!GQL<6I*W12-(4"8]2I?3W(PLHP)9/=
MKW.L,(:WOR/S.%3E1B+.NG>6\?YE>&4AYQC 8%)(YF@&1P*E%D9:9%)8\E9&
MELNF4!-&K._HE.C3)CA'#";8!!@;%@FZV0R<V0+">R&L$BUU=,O)WF^)) /)
MD3RDRREQ8";JW)G=SXJ@1$1EQ D,)ZI0C51ECE!8# E@& T0>-D7>R3178W(
M.LT%UJG>8)W%X[$7F-&PZ2-B-M>#I.TIG4\R;.+XU(67&<9:!*RTXG,]8OL<
M>:6&Q >M>X0P5OY():TS5[PMD_3[+\5V)*2M;G#\1PA]CV5"9BR.=E'6?BYR
MUIV-@:F5JNF'=:K$$Y*0$ [=H(PLPL ;0Q)N;.7S.S)KKL+KB]ZYY&FL9>)3
MCD(\D1?*D>F*./ISUKRA)?XLW-R-"[)&]$I4=C;M[6*3"[018A%!,#;,&V2\
MZ;29PUJ\F>&^QF+0.2^=/,7?/,GG9G;'7N7ESP)+X/X9XCV?:=_5=MU.MU2^
MGHL"3;)>7=L\;ZN^3.^>T'&,AR/YY\Q=W\(\!5.Z;P;RSX$?W_O?A76[QX@1
MV?:='9"ZO3<-".V^LJ'G+.VO>/M8I[E3(&)E\30QRT4D[4DCTE!(H\J>UCI.
M91(FEGCV)VEL4V3)"1G*74Y>8H$(HJUB3+4&Q]<MNW7+^2Y[@K*N&7W .<L?
ML2*7.$%=)6S3IL=X>O5)$14@C\N8T;<@=DZ94XI2S^S)N2 :D 0&F""98 8=
M+]VIR\Y-G6+=6-9Y+LRY8K<K,.2I07D6*8G@D>DH.U MC#?*98C7I'Z0-*@O
MLE:8L)0BC CZ.L$'6N&W]9MJHSL:3-6,R+23&&5\7/!;%D[$LT 4&1158IL<
M)N7)U2>P$STP.H4YG=U982[CN7>XBP@$2,T-!%;WY*R5(92'5?4J8;#8VA$@
M71F095ODR&XP8'-S:KD^*!@"25)%1LY*2A$/HN2:0(=[%] ; . .X9UKQM@J
MVEA.QUU^+';%"_$4HEV-5S$_2%.]OAZUL9UEU8WA*D:&Y*PNB10 1!Z,L]>
MLT K!4#M:U[A'SCLRO",'<84(RMD5U\'A\-MD]Q=58"^W4FB-RS*T3>VMZ;K
M [VZO#FJ)2)2NL'M5!P W$&U[WL&4K.0#-D:BQ&8I[HGE.*:ZFE(7(_(Y618
M6]3AJC;B(GL)&]X;(1I9&T-Y9)ES3AG*@E%%=48C.J.UZ#T')OD&*/VJ^#<H
M1QSM(X6Y;"8,FC2ZLI!ZP3NP&$OKNG4-Z/LRU9JA2C_F"! "=VE^H((1]-K!
MF$UWVS!C1(3DC(NC^689KD)S1)W#*3M-X>=.XZT."VR!.^RG"+80ODD<3A4"
M#8P"M<5U.N"W6N,PL PWWG7:YKP^LUALR1@C(#+LQER"8S:'U+);L:9C:YV:
MW]PF"<J[ \7?R"TCB X"3KHNU#T6[8'3TV#WFW^QWX*6"I)FKR;Y]\O.<;;O
M+7F'RMWSS"^HF7MO&? Y'W?N??.UZO=!]IU>KTAZ>M8(H;NJ.][+<9ZOJ=GW
MK-\C4=GUNOU.V:8B9U.MU0];J];HZ>BW3_U*#?";*T#,WV<,*API$2\AI]>0
M9$,ST&S-YS4,(I4A8;0$=K10+YX0$TX*CKW>1$]8%@]VZ?M[!JI+OS.Y5D?-
MV(,4:HSS*F0<0Y#>X826RS-D88.XM3*$T-I#+<B2QG9HY!%SJI*$6B:K"=%:
MBQ9H@BZ 6ZP;FUCVP/SO),GXPGF*WW!V;\/+6LN<8U>WYOEA)36_$C4,;XPR
MMK1MR%^;EI  CN840$KJ'$C*&<4< RX3"H*<8U"T/(%MWGM3F4T^0Z[:HRZV
M+X#B4MR<$<;DF2D8ER.3R^6)T1J0;R:VJFX\)0!W"6,H\@K[<DM0%2$UYIH;
MIO.V-2P.NMV(FI,I :&RZ%PEC@+XF&84(NQR9]AB-C=2QE=;K!M<T1?6M:]P
MWH,MEDPQGIKKPA6O[J[F0G%$18HE'B5ZD#M+Y4I;$*=DB\;0=0I+=[E3\<04
M2"P2P!N.XC3.H4 P80I_D^/,KE;CZ%; 9]4*4.7<ZY2G*@W'A2TY0PX=QW&8
M\P&03&[<4:6583RWE2!4I>5%@ L<XJ3/M.N$PPX.@J@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@JHYC0 ,U"3%F "869F/&X!@&&P@# (YW"( PBM<(@B#?
MHO:_V+VH)I$ZC:HICBE"?6+7I.H3FEG$'DX6QN4<2<4.PRC2C01H(RS2QAM<
M(K7M>U[=-J"!&<Y(EU+Y&H3L=/AB;\); XCOA&1S4Q,>)K@\V:W1O=6L;^>2
M$PM(A7$L*"P#S+@L$@Q89</9I!CH):9VUATXV8+9<NYM88U-6YBCX&AGG7M.
ME<<C2:/C=5)Y8 N<2FC#'U) W=>9:QYEQCN8/J=?[ 0V"H[!H""^%K9 "6X;
MI@2>? 3W .Y@+D!DL,L3<!EQ"N8'L[6Z!=-^FWV>F@M&UMU4U>?==L"/;WK=
M@1X>GC"V+75W=W7#V/'!T=71P@S$K7N3DO5QTY6N7KE9PS3CC1B,-,%<0KWO
M>]Z"-/)ICR%2R;<>V*WJ/HAX^?MA&N#N,6;1*&%O\IK11)E.8T%V$YM4M"(+
M4/L"NYF$"(!:UB[@ZMN@,$S-JU#N.[)\'W(UYQ>C><1Q=/Y6SCCE:)QF<@B4
M=>5J=./*6.7N7JWU^;'9 $WLEEP+"[%E6L"]PHU*P9 6S*<^8:0X[B>6G#(T
M8;L:38UC)CLW<' ".-JC9&$?A(%CJ?8"1G[<TL10Q+!$!(4!N4;<!GVM!"KD
M%QUJHFUTRYFB11[&D=R4JBBR2XWRW'$C"P9+>\EH6H ,>G,DX8K(I._W.=;(
MBC !4GE70](AA[,NP@A*#5R72]=JMAN;YI<1-TI,Q.P2*</<G,(:C2BBF8*T
MY^DAZH9)#>>:T%@5K3#KE=F,0Q&6+O800ANZ(S.'Y 8$<K@<KC4VB[B)4!OD
MD1?6N2,"\:%4<A6@1O#,J6MRH21:F,)-L P5RS2Q %T"#>U@R6@ICU.PYB+*
MVWO) 9E'%>.,DF,>8X6!E'/H/&)B-G XDSP3@!K%(FMQ$WA7"1$W.L5U+&W*
M!UNGJAZ GOD_$V*\5:Z[$I\7XSQ_C=.\X?R,<\$0*&1R'DNQR*#2(",UR*CS
M:W 7&I *#+%"-L.Y=C!6#T=:_2%;#K_$9E?WHV;]UM#065#REC2$ZDMF0Y?)
MHV&!H,,M_?' ]T0'-CL(F(!2&L2$T)II3HZ."I.8C*2$]H><H_2@@$/[6@I8
M>8A)87Q-:B-TH2J$"UTV4A$I0-ZH-P')6"53?(#\P&7#>]^J6ZM2XI<"WV+V
M JMTVL+IM0=!66&5YDF+<E1V.WN&0/\  )DRL0@C++N%Y=8ZXH6R]AFC+*!>
MRT\'V1""&W^K>UJ""G%I.X,=I3 XZG<FQC?,2VFK)E%@<5*=L<X6]IYE*'A>
MIE"-6,@]H+7HU'?;FJ+ #8(AV%>PBS A"..N:Y)-8IRV9>A][GXGR(]Y%+@C
MJ0 X#5(5\=Q].?-<D:;C  I0E?#WI(?VP?LF=:UA= @]%@F5H),8BTZ(X,D#
MI*(\W,46QPF*DSRM>FY,UQXU":><M)>UYRD"5J.2%'@$8 \0! L,-[VMUK=(
M5\X80GK..[D<R2@1G-\"R_D39.>8R(,3C2E+(<I:TK<E=TB<P!0R4IZE 8D"
M$0 "L)#?IMT=6@V-+\YY2Q?IMQS8YQ3+VC%KQG^/8@QVY9A?6M"\M^/FHR$Q
MP)R@E$Z!NUW=7$;C:Y(S[A"$M.;8(BAW">4&C.2+ 1>(\*('>=;EY\RMD=[G
M,)+08SGF3&-)!WY 4Y]B>]MN(&YL(%8QD3)>M=82<(L"CI&/[<?1<+(]K<'X
MMS7E?%P4&?G/7[:6%,#ZYXHD<=<D!;ZOC\@$I8UZ:\<=5#>"7-85_7 <D1JB
M%%RCS2S16*46H-38MS%M!A_<B"ZGYMRW!=D&7)<-E<H0S)CA35 IY !1MJ='
M=$.81V,CLR(6A[);+)R.TLH./.4%B"<&P!!.#]^,(].B/W;BRE007(F;=3+:
MUS9Q&!"X(T+C9J1MZX]*+H/+2+U+.J 29<-@F"(':U_M;T%J%!4;M\Z?@U[R
MZX[@R=(I]CCS!737[)LB2)%BHJ#GKG%]=H]('<*0H\=D*I5( WOU0#$(EN."
M&US;E!$$M\T:]:A[;,D4R+EIJC.2XS&6M>**S%!DF2LL;2M3X:@.7'%O$)E[
M&T+DZLU&1>QAPS>K>UK!N'K7M<*4<6H&%JXON1=KBW=_+#;L3(T$<[HM,<DG
M@*-VQ$G:.ZN!JA4:O3^'EE]0X1I@C0] KC%>_3<.A;!G_(GAW^]9C[^Q)HH*
M\N*YT:XO&]C,(R-0F:\RPK9/);Q-HZN,)3O[F@=PL*5MF)22X^V6LSA= (DM
M27UR;V+ *PNH:4(8?WKN]M&3.3/;')..5B=ZQ['</P+&LFDS09=2P/N2"%;"
M< "9>182)Q5,;:P*T(QA&*X+D7L&]P"L*X0UA+:J.RK*>-411@F(6]3AEET1
M6*$$HG71E9$69$K"N*N4%*6B=79"U@*&*W5,/4WZ@;_:= ?IGAM61?)F;N/)
M.!2CC^T^TV"\H0<H@LTH";&^2G4Z3YD5H1""(*-LBLPQ\66243?J7M<WJV#T
M"+H)I[Y7;(UG_C>=E9J%CC+'GQR:#5B@92%J;+N#;&4K0E&>/J)4A1G<Q +L
M(0;6L'_J6OT!N'DV_P !38;_ (M1_P#LYBU!MI]  S3QY+, $PLS6IQ , PV
M$ 8!8N."( PBM<(@B#?HO:_V+VH-;\;W^ ]KI_Q(/_LB>Z!R0_X#VQ?_ !((
M_LB9*#U.MNJFKS[KM@1[>];L"/#T\86Q:ZN[NZX>QXX.CJZ.$&8E:]R<EZN.
MG*UR]<K.&:<<:,1AI@KB%>][WO0:QVNR1E)+L+K1IQAK(+7KC%LDQE\=7/(#
M9'&-4NLU10A0G:L<P!$XDEL[,ONE:.S+L38LP'>4X2[]4%R#PB#L=AMJP_LW
MHN@<=JLV9SR([[/P!?(85E7*+5)6V-I37QE/M)([CQO;41D)3."E18DF_6$1
M<F_9E]-@_8"2^5'IHQ?RP8@G&3')&RP[(>LSMCG'LC>SRT+*BG**7NB]:Q!7
MJ! 3)EZE&O"$-QB!8P;J47:]Q"L&@LQ=\E0)AF<3QT[RUC13N=>*BB<0,6EC
MD+T0R-2YZ=EJ9K*N8K+;6]N;C1&*C @3!'8)?7[4PL @KMXDU20O7>?QVZM,
M)\C.P>5D+^U!.!=>TJ3ES>:06O27O8]-W@L-[EW&$-AV"+H^R$70'J-0'1K@
M6]6_N.)NH3,V1,@S>%9"A!3H82E5S2 ";9&K2>71&#MXL1&TSP2$X)-Q"+N8
M.U[6$2=8L/[E+VT9'Y9<.)\>K$[RJPE@G(*?,SFT&74I6<#[XZ@C\0>E::PR
M .B!Y>TZJZ4P727=3^98P PA#W>@O^$!R.?OG#/]9(*"T*@J#Y1H;&\B9'T%
M@4Q;?&(G,MD4L9DC5WQ>W^),;VIBS>YH>_-:I"Y(^\HU P=JG.*.!T](!A%:
MU[!K?,VK4.X[LGP?<C7G%Z-YQ'%T_E;...5HG&9R")1UY6ITX\I8Y>Y>K?7Y
ML=D 3>R67 L+L65:P+W"C4K!D!L?D\? 9-U?P%E_&4U)!C1KS[B?(CSD-G9T
MLN;XY$E25]:V^=+(RM$4ED"6-/KLFL<UJ>K8U2.Q!X0WL/J!^L]P+L=D3"TA
M63WE5A+M@R<15>C?9&KUEP4V0YUBSJE.3K32Y>BF2 I(2,BP^JI3JRC21AZP
M!A&&U[!K%Z2Q3 ^T'%]+91-4DCPPWZXK\30[+[HB$P1U1)+P,]"P2)84O6KA
M1FTO:'YO+(+4GW[$LX729<)!PP!<5(\H8\B3W$(S(IBPM<CGSD2TPQ@.7E&/
M4D6G$J5 ?"FM/<Y<I2%D)#!F*; [L2$/2,P/3;I"C'2S'>Q[FYY]QA!-WF_7
MJ?1C/F1UDTPVXZ_XMR%)G!:X*4IP<A$/DJ>$CX]M$@1D@" PH TY04UKA%U!
M@$,)?X-PLH@.<-DII.=O([LAFF1X9*8ITPLF-(MCYQC"!@N-"RK9*DA4G=V9
M(X +0W2%)U"1*L& (A](@A%09!Q32!A1\?>'3U;VT)2(V5E,^1'*')&04PD^
MUW(CEVST8:<$#65X<8$_K'W+MV(K#_F;]-!H+5\F\^@/*?E6&IC%..LO3;+I
M>-UY!-P(Y4<UPV7$.\@:"PVL8I2/:YZ('8ZP/TPWK!Z;F '8(2MXX5Z9_P!"
M\()X\\(QK4\*?&(:M(>6HNSOJ9]?B#"%8"A"$0L0'F &(L5K#Z+VOT= K7N&
MG^(^11UDUA<\2NJM QY/Q!D3)+7E:+."LA,_,KE:2*U/BCLC.& \" *,8$O>
MKVN1<Q(8#K]8L5K!B^KCDWY#VLY,,OX^/)68D=TD$A3>]MIG:L,FFD1@"M!)
MEK4J(ZR)SLC7DJ% CP"%81;H48"X@'=:@V[Q'_X!6'/^$LG?NI3&@LFH-8OV
M1L2'S,_!\IE,/%,Y#$2'D>.9&I0!62:'2-<]1OKIFAUL%-)&]<L:%:52G)L?
M<%NBQP A.+ZX56["1S%^"MU-,&+55EC6.\J33(X&;,F/\4)$,?9GG"QOA(WE
MPGL*CUDS$1X8R'+UC>><E+-'V9Q]KC$G+&6%T% H% H% H% H% H% H% H%
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M<N6$6^+R9CD*R(Z\9 8I00S.25R$PO0U$F<;-#K=(::!&YA0JRC1$#O8T #
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M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&JLQ82QAGZ(
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M3TGN<E-&G-">E4DF%B*4HER0\%ADJ"#"SR1VL( PW^S015;>-G2)IA\B@J#
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M8L>5R@<><KLLLC+^V*&*6Q!XZ3^S;I$RJNL)*:>%..Y9A0SB#+@&$)EQEFA
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MY1EOM+AK?75BSI&\1QIGV1F<:R!F%*>^BD\KB*5.B8'$A0_N2A@ C3I8I"2
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M3J8T:3B.*8H)B"0B;H;+V\HB,N;H-\*7C/)N$Q69<TFQ'1:XNN*]!+_97/\
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MNQ/L>U\8,/-THC3\RLT9;UR-F?LGR4Y5+PRAW;R1%J+($I2/OE[!(-+*%8T
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MT "B0W6J$B8!IQPBP!O<HSH#Q,JZJX_VUY%-EX'D5RDR%L;=>,>.;+>/NIJ
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M">G++,$'IL=:_9WSUQ_;18J&/)0X^]9,<7_5%#FHTY-D1S@$2D3-)F)M>PO
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ML]86>6:<6X-W9)CB[ +N:7UKC"5VNNHC?BN"9<;LJR4.8LB[&.3R[9XF2QK
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M):N[*DMAD!+"8C<$M@WN44"U@N]H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M9*OLAR2_QG#^"B$^=$T&@T!CA@F]FD@O9<SV3*Y<_=J=WHT2WK](1"&#H,
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M^"X@XU=4-@<FZQ0,J#29^;XHV ,.D,QEQ1DA7/EHG''D14SD4@*(%&0R]4L
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MH,\H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H-&Z]X AVM>/AXW@KE)G5C')I'*KJI8L:ESMXA*' 3DO)L>SLS$C[D2>+
MH)#V'7"#[ ACO]F@WE0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#%WV<0J+.D:8Y
M-+XO'7J9KS6J'L[[(&EH=)6Z$!*&>VQIO<%:=6^KR0'EW&2E :8&PPWO;[-J
M#QLA05BR;!Y3CZ3=_P#+\P95S"[W:UQS8Y60N!5R3Q(7%/T'HE00WZ0&@^V
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M0>VH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M-03UK=<%NFU!D] H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M*7$ R[D=X"G 9<\L-A=<=@T&Q\\;D8NP-*V7'2MAR9E3*L@:AOS;BC"<*4Y
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M,6*9?$HADO#^S>NQD[>D\;B,BV P\H@,3>Y K$$M,T)WLA[>RR5 S3"PB&<
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MB:V\]N<36,)Z!J.*90')>HD ),GN!,$ >S!T=6P6-YORBTX3Q!DC++U<H2&
MP]\DEDYHA!"XKT*(T32T $&]KV/>781"0O[-K=H<'IO:WV;!1GI9&)IJCL'K
M),Y^XN2I+R 8JE2J<JG !(2467E$C7Y$C S"R>@:,];&WUJ1!*';K"7."H71
M8-K@("_F:RIO@D.ELW=R5JEIAL9?I4YIVTL@YP/;X\U*G=:2@*4J$:8U::F1
MB"4$PTH AWM80PVZ16#6^NN>X?LUB.-9G@;;)6F+RH]]3MZ"7(VM _DCCS^Y
M1U;=8E9GA_;BPFK6HP1745&7$4(-Q=45[AL&>9#Q]$,JPF28ZGS1X]#9<V&L
M\A9^_N;7X@W'" ,U/X@RK6YU2=81=K]<@\HRW1]@5!1+R":#ZF80A. W?%^*
M/+#C-=IL68XDRCSUDIZ\3ADC:9HJ>6;LI#,78A'WP]I3B[PG"4K+[/H+-#80
MK7"T+$?'WJ)@F>LV3\58D\K3F/E.A+0^>?<FOG="WEJ6,KD'PV1S1W:#^\MC
M@<5TFIQW!U^L'JCL$5@VCKCL/"MG\:E92@+7*&B/G/[]'0HY>B:4#S9;'EG<
MEIHD[*]R!%9*:;]DH7>+C$'^:"&_V*#P<:;+03*;]GN.Q]IEJ-;KM+5L-FQK
MR@9TZ5T<T*9P5&GQ8:)^<35J 1;:.P1*P(3+WN'I!:U[WL$36'E7P9,XBCEN
M.<2;0Y/ZJ-Q7RI@QYAX,G=L=)&]<Y)+'SI>DDP8DV!6)6\*TNR=S5W"C4DC-
ML4*XP #)D_)SKM)6ED5XCCN;\_O[JU^,.,$PGB9\F$SB"'O1B&YDQ0*#FAL9
MC.]D&!"#OAHC  L:"PB3"3# DUKUL?C/9F!FS['"IV)3-KLLCTHC<H;? Y;"
MY*W%DG+X]*&FYZHE&XI25 !7$2>H3BL+[0T5PBL$(QO/)GA AV?BX5CC8O,,
M)B:\;=+,P8DQ$LEF)HX<F/&2YGN$J,=FPXY U%E".,4)4J@@XBW73B/M>W2$
ME5.S.)C->GG9V-/*B<XK9X<[382R)D$'NZUM9"3C'-N3MCRJ9;)']&<G,(.1
MK3$AA"@ BS>S$&_0&A(GR(8LR,= 0XLQ/LGE5!-?+)3O(L>XA52&)XP<),!L
M- TY)EA;R3'FUP827/K.EFU2Z%(+ISP&#[0NX+A/N@@A+.0_!L1R;E3#2F/9
M<?LHXP<(^U)X/#($*92/)2]_8E<AL5CAJCKJX+5Q#.B3E@7J'4#0F3G*B 6,
M%VEKV#8NO&W^,MCGJ90]A8<CXZR-  I%$MQ?F"(BA$^9V]>*P43H>SV<'5.)
M"?<8.GJJ+FE=J5V@ =J7U@Q7+6]>*L89!<L4,$*S5GG)<?(2*Y;"]?,<*LCN
M\-2+B!'I3I,;9P9VQ (P'4Z20*#5!?:@ZY8;"Z:#;&O^R>+]DXLYR7'JQW2*
MXVY#8YK#9<TG1N<01]  1@F>6,"D9MT*FY8!7"84:>E,N 80&B$68$ 1N>N2
MG#!;[(FW'F--C,[QV'N VN69)P=B-5.,:QY8G"$Q<%=)Q/#58XA 3UC!G)B3
MR3"B[C)&:"X;B#-9AO\ :^0[$^$\WJETG<L9YUF:.$QF2(F9*W$Q]<<I=$3F
MZS-/*76.J6AACJMD5@6J" JQ6L1<PD!Q5PC$&28JW B.7Y@Y,,>Q3L$PPM%'
MG&4(<XS[%#E!<*/[.VV1C,4,LND:U"X#NH*5",)LI;TUAEISA]-@!L(0:16\
MH.# !=WU@QGLK-\4L"Q8D>\]0W#+D[88;+-R@:9P5JI4<Z(EUD*(T(>N8%"*
MU[&!N'K=/V EI(=CL*1G"=]B'.?LU\/C8TC^CF",1ZQ,Y)%YH$R!(W(B"1.*
MEY5KS+);(;%65@5]8DPL!@!A"$8F3D:Q\Y.3&!ZU]V_@D2DCDWMC)DZ;X&<6
MK'+@)W4 *:5A3XB>W-8%O<DP[J2C1)0VLF (8[!Z.B@SF8NFO!6]&(F>00.4
M+ME5>'9*O@F0DRY:"),L!1JI22[,CD@!,D:(YT5&JU]RQB9%8N@\/]$ ZH;
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M8*B<:R P2"9+6M PQO++ V,+N3-$N+U94M0RAS37;BCD]EII#458\?4+/"8
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MG\/C\K2DA'8RZ.[RVIUJAN.%;\Q2V*31IS;7^R$TH5K_ &;4&Q:!05:<K?\
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MB0V;K$V*[V*/(1/=U?8_8\8$^W4W7]?].NNN=VOZ9UZ"$^>[1DKD#XV5$2\
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M;HM:UK?8M:UJ"-D U9Q]CG8'+FR#(\3%5.,S-S8V2AJ=7!D/BB!.TE-12<;
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M-Q$9+'"3,X<+9/C&6(F1%%;.WIU4@B8A";&UZ*<F-XL<P#L+H-)3=U/N&UK
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M5%W"4$5P]85K!N$4DO(PF6IDZQ'I%R&JT:L@I4D5I=:RSTRI,>6$TA0G/*G
MRCB#BAV$ 8;W"(-[7M?HH)TX\F7M!A,;FOE69PCS&V%.7E+(;'Y:FS#VHAA[
MA)&'O2WPMS+ZG2(KM3.BU[?9^S09E0*#QEJQ,WHU:]89V*1"F/6*C>H89V29
M,4,X\SLR@C-'U"@7OT!#<5^CHM:]Z#7^(\O8[SM F;)^*I#YI@T@,="6A\\)
M?&/O9C,ZK&5R#X;(VQH=R.[.;><5TFIP6'U.L'K N$5PV30*!0*"(NRVY$&U
MBDN,8=(L>9CR3*<N>90PZ/X=B3/,7E6=%K,PG%,-J72A@<3U)I;V6,D"4I3<
M0"S+BZE@VZP:\AO(OA][GT:QMD3'&P>NDFFJQ(W0D.P^*C\>MTM<5IQJ4E$T
M.)#P^IRS;JP )ZZONQ(CCBRP#$,5[6"?M H% H% H%!B<[G$7QI#9-D";.G@
ML1AS,ND$C=^Y.+EX<T-I E"U7W!I2+W-7V)(+W[,@DTT71T!#>_V*#]85,HW
MD2'QB>PYR\8B<R86J31MU[FO;_$F-[1$N#8N[BZ)4+DC[RC4 'V2@DHX'3T#
M $5KVL&3T"@4"@]#*)1'(5'GB62Y[;8Y&F!"<Y/3X\*R4+:VH2+=)JA4J/$$
MLL-KWM:UNGK#%>P0VN*]K7#6^OF<XCLGB&)9J@B"0MD5F=Y!9J12M&W('XFT
M<E#W$EHER1I=GQ 58YQ83C">HJ,N(@0+BZ@[B $-S4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%7NDW^&+R7_WTL2_V/S>@
M\7E)#83+IP$5K""+=S#(1!%:U["M=))[7M>U_L7M>U!^&L0KZG;:Y7T[<;W1
MXORY=QSWK0(V]P(D-UMS+Y%QLW7%^E@NSG)!J$B0O_8D:(9YGVZJW2&(:4?X
M%>Y']]S;+^L!5!JS0;<_V6ZCX>@?X)^ZF1?+Z&6%^<\68*\W0)[[]/I4Z=I'
MY%YI;_$BD??N['W[$'9JB32_L]3IN%FDKD^8\R8";);@P]=KQ-Y&*RT7X04'
MLAD<)8D:IS1NPWZ%F#>$J5YN!*!0E">:)/V(@&F7N&]RQ!6QE/9C.VHSI%94
M_P"^F#=NFD$TC;%D/"MH1B7'>1T$9?1@L8_19)CN1.3VI6D)5%C>LK !,3^D
MF" <6(8:"V[.C1EY^Q/,FC LI883EU:A1EPJ4R=.0K8FA>!U;SEASBG4QR7$
M&E&M!:@H-A-RJUC# WZH;_;A#(,7H)\U8X@C9E1[;)+DM!$F!'/I"R%%D,[W
M+T[8F*D+JUD$M# 44@7.@33"@A0HPV *UK$E_P Q8,ZH*M-T_P##AXQ/^.^?
M/['<;T$\<^R9\A6"<U3*,KO#))$L2Y'DT><N[)%OA[XPPYY=6E=W-P3JT"ON
MB](69V1Y1I)G5ZHP"#>]KA@6F^09?E75[">19\[^/3*70= \2%X[@V-?B#B<
M>I :H\/943<U).L$NUNH0047;H^P&@A#AS9_.<JX[]C,Z/\ .._Y4@:[-Q,4
ME/EJ'I?"BX@02..A\$11]/'%WAXAWOTJ49US?_9O7H/6QS\95D76V,;#$;-8
MQ@CA;#T>R*R8W:<-QB1)\AMX8@WR(*^=S)[)L**R"7HRA*#T[(W@0HS5ER2K
M%! $18>PPO)N03<S#D:S=%L]XJUF9'QF5 B<=BF)4&35LN<V-0X,3NZ2YRGZ
MA6"((U\G;#PD$MY*T2=)8-Q6.':XC0S[%N^CG;0>4[39:CJ$,VQF?(H;)H^S
M"-;VZ13YGD*2*L)":P^^#:R']T=D/>[EV/ DN,\98;@!8NP8REC_ ">.&,P9
M^)V&Q@3)U,7M/T>K8,(LAT,-1G,-G=/"C<C"<;3X#Z(HSL^K91<OO]K NM["
M]QV#P,\;Q3*1<:Z?;3"+G[.INZK(F@/+NA893>-/09XFB4P9PII*SN38M3".
M(/LF..2!-&E-*.L$L0K= 2;QI!=T'V:Q')N4=AH1&(:,NRM]US@&)&5Z95"!
M0W*[($:O,4B7DS ;XG/5D&K%"-&F1F&IKA)) 49>@FG0<]*G!#SFZ6\F:R!"
M.1YEQ#LA!<OX:=D00^))YM"T$L<2FM&*_189D@0EFI2RQW['O@DY@[7L5:@V
M]M!G=FV4U9T$R^T!)3GR7=? !<C:2A"O=@F#6VY";I2R#"9T'!+0O*<VQ AV
M"(U,(HWHZH[4$P=G,[9B]L>.=3M:1QEGRW/XJZ9%EF1)@@\99,78T:EYK66]
MIF$(Q >GUZ>$AJ5.6>6-. 5@6$"]CNU3AJU3D+:W4G+^#F'/^;([LEA[/D\2
M8G!*[8LCN))=CS(+Z7_Y)!"@B:A2R.T?=3R1!.$>9<X(;&CMU+% ":'LI=F;
M9/8[8O*6ONL$WC.$85@4EB1Y3S>]PI!D61+)H_EC6(XK#HA(#$K :G2@0*B%
M9BBU[VN08,)I?2GL<&<LOX:6((+L(+,F3X)E9EBF&Y=+L5Y=880SPN7VES2T
MR%=W*6PM,:?%R[("TZ8].$A(J3&!#<)QPQ=8 @TGK0?O[L[A#%.5''9R$X:;
M7)N3*R[,6%HCDB69(1IW%<G<W>8GO'E:+PLY:<GN4E1,J =BDX0#-.$;<5KA
M[^^5]I-M<V9I@FM^6(QKMB+7V76QV^9*5XX9LIS.>Y"1%+BY&VMK#*#RHZAC
MK(O3=EUPB*4"#<H\)IH3A$$!GNN&?,TLV?I[I_LRNC<NR)%8(VY.QYE>)LP8
MPERE CCD;4O.=8L6+N+7*D+N<*Q@$5BTQERE 2RK%IPGJ CC@+*&X6\[1)\I
M8ZVYQ_K@V))*_,K+@YCPS",I2=D;654%.E59 <9HXE/K8ZN #B1&#3EB2F!-
ML,LLKIL38-U;B96V;URT/>IZXS^)D[ 1^0L;>OG$(BS<=&E;>[Y+\/;C$4:F
MK6\HDRE3"U24I8 PDT)2WM;DCN&P!W#]=N-DLJ1;*6N^NN,YW!L+/&<6:0/;
MWG7(;6@>FN+I&%L$<%LCK&[&)(VOD[DJ!>Q):X=DYAQB<BUK7.ZU@W7A?&NX
M<$G)!F5]FX=L!C-8TKKK@K,.,.+)DUO(PA\,$R>2U*UE<&LNY-KFW5#L8*QX
M^K:W9@ZP3"H*)F#/7L(Y*]Y'+V,9\S+Y@:,.HNX8&QU[0W)C[E XP?WN0I?&
M&?PU"K[;J$&=8?:&!%;HMT4%HV!=D/;PLDJ/V"[)X9\MIFU3WK/6+?9VC?O$
MC5A7=XT?XZ\>**4'<^LI!T%]D TN_3?K?8"#,W#N-CQ*:]9)Y/\ 6S&DT*&F
M.)Q5(<8XA88&J<RT29P+C9DUF#JUSPEO=B.D0S[(^]A)-[0JP+7#U V?B_?P
METX_56XV0XXE3O<::W9L>XVRFG)&Q^FZ"2 B#*F:##_$%3:W2=X6(Q#Z]E D
M #S.FYH2>N(,=C4(Y.<@PAOR\'9O%N.I3)&DN3LNO \*1UW@K:E=$MES/'9!
MDU0<X3A(M+3*0!5#(+6V).!T!--#UKW",FSD+V8E6\.B1BO-K9BS),YQ],#V
M0IEQ?%):SX.F37BQ&=E-(TDN[TM+R&V2MW"J*(\15#\.*&&Y)IO5L(02XS%E
MK834G$$,@[QE!MV=V7SQF%!CC#\B?,;L.+8\RWD:=J1EFR&.PM6I1+&B*J@#
M.$?VH3SCG$NQ@>P('>@P++3[OSI_# [!SC/4+V:@$:<6=1EK%-L01K&:M@C#
MJY)&U<LQ]+8Z:8Z/*AJ5N0 @,<B@6 0"QYI1EK&@H,_WBV3RK 89J5+M='Q"
M$W-><<:L($+FC81MLVBDS:C7-NCK@YN[)(38XA?1&IP'+T( JTQ8[C+'TVZ+
MA('#^.-KV:=J)KF[92*S2-.;,K*'A2$888XM$XP^J!H;IE;%D1<\.,_>4+:6
MF.#8"\-A*!*+B%8%@ #8)64%0TW#N-CQ*:]9)Y/];,:30H:8XG%4AQCB%A@:
MIS+1)G N-F368.K7/"6]V(Z1#/LC[V$DWM"K M</4#V2C8IVVEXI<OY=D;0A
M990XX>RFQR9&U6."T&/<<)<FM2X-1:@Y0H3H7,HDM0$DPPP1 C!%=<=@6&(,
M?R5F3)&!.)'#&2\3R/RI-FC$>NJ-N>O!V%][NF=T\3;7$OPV2M;PTF]X1*1@
MZ1D"$#K=(;A%:U[!G67VGDGA4$E6?TF?L2%+H.Q.,V<]9V+$"%SA*R/L"%2\
M.[(5E)V4CR$[OI;82,(>P+0%K%!(;%"(L9T4&KMX\P^W#1K6',\29RK+IQG/
M!$D;XZM6]@G(D=[R$M5'E#G8D?43)9 F,274]G?I 'M.I_V-!ENQ#QR&Z]XR
M==GWC8'%<G10A0R/4XUNCV'4"&"^7U[XG:G) P93=%:O(SJ8V@<B1W.. W"&
M4689;H$"Q)X3!S*?F[)6,\>RC F8X=@)LD"!KD\OG$UBK9,%K1%GQN;'!!9E
M:'TLN.F.A/>A6,NM.))%:_4M>PA6&6$$63:#,.#=BL(XSENXN%=T(?F&>6Q?
M)VZ+1O&\)R7BV4.2@EM9EYS)C9]=B M!;H:6%0-PZ1W_ $XFQ8#.R-L%SU H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!5
M[G/^-)T>_O6YX_L0DU!*;=7_  0=G?[P^4_[#'B@J9QB&^IS7HAN(W6NCQ?E
MS#>-<";+A*M<")#=:S(K8ZR2XV#^E@NSG) )U:LS_8D:(!!?VZJ_2$TH"*PN
M5G.H@WL((M3X"((@WM>PK7EK/>U[7M]B]KVH(F8,V,]@VX'(83["=C\S^:,P
M1<SM<!XP]HI,=\'+F8>SE _'&?PDUT\2Z4=N@SM[)SOYGJ?9"P\C/WMXP-L,
ML]BFP.&?+>-9>F[KGK&_L[6/WB4-D9O>(T1XR\>*)D'<^JI'TE]D,TNW1?K?
M8"N_1GD9U(P/IOBG'<\R*Z!R/#VR6@<X,RP*>.KL>K<I]*7EM;V]U+CI404*
MEK<YD#!<3F H-Q]48PBL(-@F3QJX8G^+<7Y0EF18LIQZ[YRS/+\LM>-5H2RG
M&#QI\"D)96MW2E!++;W<PE.(0TW9EF)R+$@- 6;8PHL(G<ONK6"&K">1-ET$
M%[#-KU+L?(W.:^9YB;WE,,UMC0B_+ATA,B1/2R-Y)'26@ +[3K]/:7$*X7F4
M$:V>,;.$[/RN5/61(<KU75P1,@B6-4Z%(&:M<^"&-64O:Y>&"I5AC68)*YWL
M 3^H#_1!?]#VZ+=D$E*!05>\4W_)%L#^_"S9_N2&T&RLQ9JR9%=]=/\ "S#)
M>X8TRE%LS.4[C7@T?5>.K8I!I&\,!WC*UJ4/[9W!R0%&=5&J3@-ZG5,L,-Q!
MN#>7-63,.N>IJ?'$E\NDY,VFQOCB;@\&C[OXW#']0<!V9NL^M3H)M[V$-K=X
M273JR_\ L#0T&O-E,N[6I-S\58!UXE<%9FV;X1?)6\)LB,*9SCK2L0R=U1+9
M?8UM0!EJ]W;FE($I"WEKB4!RH0!* 7+L9TAIW(F2>036?.&(<-JLUXNV1.V9
M22EAQZ_Y Q>V8H1P"6143,I=7%T;L;"5*W1G1-CV298 SU!BH5Q "$JY?2:&
M93&>;F:G9;UU7YBS[&,_XMSQEQCQ!)HXEP]&L;FX\?9F(0&55&'A@4*W9[;V
MT\1@^NO,$:<E17 (KM3>U+#:N>LXYSG.R;1IYK$_QS'DG;\?BRAES,DFC94O
MM!XVK7$-3.T1:+N%P-#Q)5)ZY.>(*OI(&4H+L$0>S/N$,78LN;-ZQ;#8BPQL
MMD:.9^QML&H<HY ,OML#9L7RF,Y#;2TZ@N.R2+QU0HCQS2["7$IDHBQ"4&C-
ML988>Q-*&'I9%EG;V;[T9QURQ!D&$Q6#1S'>.Y 4^3.)M<@%C@AY:V4]Y>XP
MQM[>UNLXDSJX+NH2F=G@IL3%",%<-[V+!8)]83AN5X-#3&3,F9O;M+A/*Y:7
M-O9W&\8=FT'D(P(F3RW%E2ML'W XDXSO-Q]J;V_5%;H &@@WRX?X+L=_O\8F
M_KBXT'K<7?\ S(.]4TPH?_0&%-Q/$\M8DZWZ4V1[,S44#VB1!+T]4DCQ])8*
MH ?M2RP]P3%!N(0J#PM'I@R8]!R83V2GC31V$[D[%RU^4%!"8:2SQWMW=R,)
M+&84 PX*-&.X W$&PA=%NFW30?WC4SD)VEA*'/L9V!@FM44F2<<@Q=ATC#T;
MR5XC%1&&WCZB?321F>+M:B0IB"SC#&TLZUDZGM $DCL$@(>:T<A[DP:8Y S?
MD2&H#,T8FR(\X$D\$93E9;,^9E:7%$VI@MH[@4KD;&N3.):\X%^L,L))Y!0Q
MC""X@]H5C3E''&TV2 [.8CM.U"$#P?KFMPK'2<;HE!B 0[Q4.44JT^<'*23N
MJ&YMQV*[U<5N]7(M88@]=G/-NVR';W!&"L1O$'95&1, .4HE3!,VU"JB#%+$
MZ]Y)>)2-8VMSE+W4R.)4(K(FQ*ZITBQ0 NQQO9W,&(/=Y>RCL)I1A>2RG(V9
MD&U&4,FSV'XZP/'E.)HSB1F9)A)+/'50.)41>5BM]9^ZIQ*174*2SKB1EI['
MEW47. &%Y,MR-:VXZ>MAY%L+CC.S?"4-Y1D3 E\.L4+8DD5)7)E$C\D9&9+E
M2M:KCS/8T9)SB2 -DX###"E)H %&!D6S6Z4I(C&HK?@J0Q#'0]Q+#6-N8LEI
M"7!@QBR%LT:=;$GMIQX&A1+UBF3%)22EMS$H3R#"A@Z1V-)#=F(,9;GP^>1=
MVGFVD)V#Q.X@6G2A X82C&,Y&G2&QYYNPJX4Z0-8X-KE91(3V\Q3WT5@"1 ,
MN4*P^BQ@8'AS87);KLYR 1"6O*B30' "#&SKCR))&:/HE;82YPR0OS^A2N;<
MTI7AW4/"IM+L"Z\]5<H718OJAO>UPT)KW,-UMS,?@SK!=SL7XB*=%ST-#@B,
M84A.1D\73MCTZ(6EIGLHDCB7,VEP>0H.DT8";V$C$!2G#TF=2P6MXY33Y'!X
MTDRBY1UYR F;2R)4[1)(L01US<RAF $O;$*^UE2,I62$ QE"^P68(00](;6O
M00.Y</\  *S'_P )8Q_=2AU!ZB#<@/AD)AS;^!+R#.'A\6CZ+O[9K;WMM6]T
M:4A'>V]5YS+[RA4]GURC.J'KEBM?HMTT$I-A6W/$GB,8/PEF"):^E#4!73N:
M3R(-DI<V1@4%(AD%M;"_6\O!>$YPQA."M4%%?^R["L(5C"PKZ9-H,PX-V*PC
MC.6[BX5W0A^89Y;%\G;HM&\;PG)>+90Y*"6UF7G,F-GUV("T%NAI85 W#I'?
M].)L6 SLC;!OC+6;]@LO[,R#4W5R2QC%ML81ACE.;,XR*-))POC:F3IDZR/Q
M.'0YU$6R.KFH;7 E28-3>Y8OTPOM$XB+V4!YH,<[[LS)EF"SC9""S*)NV*G9
MPAF=4.'8NQS^*S=N>F@Y4PO&-4[B5#7%C?HD>XD%GANI,+&4$P0R# !"I")_
M%MBC9=UUWP;.HWMEY5PTGE<F7+<$^PB /GB#.U9*?RY*Q^T]>XERI)YL/2J#
M.\@)N:@[UU2K7L6'I#?U\K[2;:YLS3!-;\L1C7;$6OLNMCM\R4KQPS93F<]R
M$B*7%R-M;6&4'E1U#'61>F[+KA$4H$&Y1X330G"((#/];<]9I:=@9WIYLRX1
MF5Y$B\&;,F8\RS%F@,7190@1ZA&T+SWB,%B[BTRAO=SQ6- BL6F'<I2$LJQ:
M<)Z@(\Z]Y!WPVB.V(8XYGF$8NBV.]C,C0=IR8OQ9&)U/DC<PJFT3-!6&&!2Q
M>&^!MB 775.SJ->Y*1+K +N&Y%QB"V:"-$H8(;&62;3#V@2YK9D**1S;R^W1
M3S2[IR @6O?EMI-.;&/Q ZUS.[$#$45T]4-[VM05+\BV1X9B+<#CUR1D-Y\O
M0N).^97*0//ASJ[>'HA-\)2!.\.8T+D[*NE0I 'JD$&#^VZ>CHM>]@Q+9[-F
M.N2 >)]>-4+O&25K3E2)Y,R!E <4D<6BF)(FPA>&Y6K7+YDRL+F-]<RW,=TA
M*4F_>0E#+ ,1E^I8+ MQMB)1@>&PIHQE'6^69IS1/F;%F)V1Y&<!@)D3U<0C
MY#)+IS2%-V%A3!L,X)8PB$88780@E]H,(14RR[;]:DPH[8N=;"PG8F$118UK
M,I88+PW&<>E-<9>7EO;'!1 )JQG>8'1;'Q.-N[C<K% [ %S3RSQ6N7<-H;!;
M.92D.3\.:TZI&QE%DC,,"#EMYR9,D(G-FQGB@RYG<'Y.P7L).]/[T<D.*)(.
M[4LH5BPC*ZJBQY 9KB^![SXWRG$R<C[ 038S##R5(29PYN6*H[B6=PI42P+E
MD<6,"&(N F=X:U+ZB(3*1GF'GE@5BZ$]PV[=.&AL?S[<7=T<JRA@_.,9U?P"
MW2A_BF,%0<31G+4UR8GC2\;:MEK\5+EA;6Q-:Y8$P) $AEC"Q$W*$69U>\&A
MF6)=F<QN>--R<<Y5/CR38G4U@D8E4OBC>42P2E"Z09_E..ITC8'5.<F2JE(6
MFYBA*,D:6_07>X V-N4$-8X,*Y'-E, 8[RPDVDQMB!4\1 EPC[:W87C$W<\@
M'V&N+"[Y'>'=*B9H:<YJDX>H1'VHTI.C,#<0!GA&$08;.<Y94VHXV=A'-TD#
M?BS*N'%F1,?YV;FF+HGYKF%H&S'BD,:;DSX>$Z+II@B=$HAKB!&*$*D@X!-N
MK?H"&V='X#L-",*8'RU/-NK/V!&K!K')C\*"P-!&8++%A8Z[RSME\F-:\^7+
MK0T(R3N\7([=P[IU3 V[45!Z7$DHWLW-B*C8#'.>XCK'C!^=Y"#$F-QX=C.3
M'B2Q]@=EC*0OR%(I*H J8SW)S:32Q";+&A[(0S"R^BQ76#9V%]KLEY#U\VB3
M3QM:(;LAJZWY(BLU,CH"5T<5R2.Q=]<HO-V% ZEK"[-KL>U#$$A0 T@T:80P
MA[$T)( UIK0?O[L[A#%.5''9R$X:;7)N3*R[,6%HCDB69(1IW%<G<W>8GO'E
M:+PLY:<GN4E1,J =BDX0#-.$;<5KA;501'VUU:P1L-#U#_F&"^;W;&\1G"R%
MJ_,\Q8/!E+BUD+5AG81>0LB9Q[92Q)1="L!X0]ET!M:PAV$&H^)W_  P'_ZZ
M?[M61J"Q2@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@J]TF_PQ>2_P#OI8E_L?F]!XW*/_2;3?\ ?NX8_P!RR>@V;R&XBDLO
MQ.RYHQ<7<O-VL$A)S#CM004,Q2Y(&7L5,UB)@"?Z(6(']B1=J-(#[*PY&41?
M[4P72$5N/20^;N/K9V5]U[CYGF^RLA[EVO;]S\:AB!R[KV_4*[;N_>>IU^J'
MK='3T6_,H)2\67^ 5K]_P;.OW4IQ0:MY4VE[<8/@U4_MDS>M;6C,+6X;.-<%
M\2N[#@184]TJUT S#+<[QI#>RNZFX+A"!0)/>PP'6)&$*[=S)GHC)M<"T>H&
M$F]<)!/80-TS1&\%NL59XJ4:^FV,CSMDJ<1Y@DZMU?!@L E$G$J ,JPNM< 2
M[VL'09G3,D8U]Q/,LQ3- _.<9@Z%&O=D,82MZU]4$K75O9R@MR5U=&5O--"I
M<0"%8U43:Q=A7M>][6#<,@Q?D%FRSCB"90CB9S1,&0HDP3)E1O9*1,\)6N1M
MB9U0D.B="M<D1*\I.J"$T)2@\L([7L$8K=%[AG5!5ING_AP\8G_'?/G]CN-Z
M"?N;8BYY PSER!LMRK/$VQC/HBTW.& LFSG)(J[,R"YHS!EE@*[TM!UKB$&U
MK?FWM^;059:>[S8JQ5K[CO7B4QG+)^R^,&93"G7 #)BR:N$]<'9K<5 40DAW
MA!490HW!(K(-$:N<$EDX1W$98(+!$(-0ZWG&J.(K;$\],-&>>KV,..2&C ,Q
M*:8A2C,3&#*N(L8R!BN&]PWN&][?8^Q067X8_B]\4?O-8+^XDUT&#\67^ 5K
M]_P;.OW4IQ00-Q!@Z0[$\8VQ^,8>6$^8+<]91?XJC&:62%S>8C.6"2E,H3#C
M"4Y9[ZG;#41(S1@*+// ,8K!#>]!(ELY2L5M>*$45/B>40;8-T5)CUM<A8PF
MXIF?D1"Q6+LG ,##=INPF.!-U'6[:RVR'I'W7KV[.@BWG3!,HUUX9 XZG!'<
MIK>1Q*42EKL<0HLS.<IRFA=RF01J89I U+2V'IR%-P&&%W5%FW ,0+AO07^L
MW])VK_@U#_N4J@]E05>Z*_X47)-_?XBO];I705T;BP&2Z[;48VQ0RHKAP9GS
M;O"^S$* &]P(XMD%F<W*'Y-CK>5:W4M9S43!$M$&W5+3I;)"B[?:CO02MY!-
M?8,+9O'.R&;,-2[-^NRK&8\8Y);8.=*[/^-7]M?W%XC605"2%OS ^KV$\EY&
MC/#8P2<D(#!#L(\:4L0:QQDV<2CQES%"/6#!F0\O9##DJ"'(GJ'BV6)8,9GE
MR-*L)G,U53E^;TA#-'"F\U<(%T:P@^R:X#K )[4TL-UM>1$>@.V6T#WG)EE#
M9@+9)_CN38=F=EB[[)HU'9(42O(D,7EX(ZC=W)M5*7=\$2E"$H8Q!)*,L7U%
M-[DAOI5MU"-G,0[0IL41>=KL;QG F0E*7+S]%WN+Q"7O*J-2A$>R1 #VW(UK
ME=L3I.U4F&V3FE"&$%R.B_7H,XXWO\![73_B0?\ V1/=!#G%^6(SQUYLV;@N
MQB.3Q'$N8\PO.:<29B21.22>&.7G HQ0YPUR51EK>'-+(V4*8E/V5R!C&(@T
MT82B3"##@SK7U>^[0[KR_=!DA\I8L'07!*?#>(W>3LZJ.N.55JQZ/EBR2,S4
MN)[^9&B[/"TLI1<'5-[9-U;]J!002$5<CY XILNG.,BRUB?*& -EG$\*A3#6
M&!Y6AN74T[&J(,"H9$$00"QV\2-T?2;@3+'0DI2I/%<T\!!XQ7"'^YQ1YO0<
M,G=]@/,@9T&21 2,F:#/',TL/'D]N%$DTJ[YTKBW8MHN#H+4WNI)37*+.L$T
M(@!"=>Y.3M7&-/ \?;?X9?Y1BAXB 'E#EL$+?Y%%H.]*SRH\N:U;_%4X93$G
M94E4)S"SVPT:DSM"[=0 @E"$$2-/&O'8=RXPMT%6Y8.U'+A$L,SEY@O/RL1W
MDBE"Z!B**&EY'(2/:B4II!W7MA&V-/ G*.[,=RA'W$%[U!5%K/\ QGO(-_Q:
MPA_87'J"P//:?(2O".7$N)3S4V3E&.)F3 3TY@259<L,CZ\+&)O/,N$HAS[_
M '!W8PR]BP*.H(?VMKT%'6J4GX[XSC.-1&8:^/>6-O -!A&2L82K!$MR;E%Z
MGJA<1XT=UIM'U,(9$RES-*N4<>M062)S;=N((QFW&'GZUX/D6Q'#?)\90XJR
MF8K91+'^+(A'%$6<WF)Y!0R0IFL:H-(3%G/:9M-1E"-& HLX\ Q7L$-Z"7L-
MY2\#,6/F2/Y)9,K1?8)D8DC.^:_7Q7-CL@+I4TH2TJQ$Q7NRIXX-.XJTQ@TU
MU:Y&8$JWZ:66*UPT&&;=3-;"\U<>FY$_A4OBV-XHUS@O+B<#&[O3GB17DZ!M
M"=O32Q&A:PN)5F=<Z*25-^[!.N-", 2>V$ H0?MM).F;92!Z_P"XFJWBN:V3
M5C/A4BD\>9XO*V5]D$93E,2F<)XVT2EE9'1S<VQ*4CZ+E)C"NS..&$=Q)C"[
MACNSF[F.MM,+OVMNJ+7-<IYES(!MAKC'QP65QM+BYO5.2$^0N>0G:0L[>S-Y
M:!(E4)A&)E*E.0<$9IAMBR[7,#WN\4,#CF&\9V/0*>^@@FT>N4, L^S_ $6&
M+M29D"I^R$%_T^R'K?9M:_V?S+4%PM!J7/:?(2O".7$N)3S4V3E&.)F3 3TY
M@259<L,CZ\+&)O/,N$HAS[_<'=C#+V+ HZ@A_:VO04=:I2?COC.,XU$9AKX]
MY8V\ T&$9*QA*L$2W)N47J>J%Q'C1W6FT?4PAD3*7,TJY1QZU!9(G-MVX@C&
M;<89+J[_ !*N:/\ BCGW_P!KKZ#)=JOXE;%?]ZS6/_VM#*#?&<.1G"\ZQI/<
M1X0;\D9%V%G,7>H.PX@*Q5D!DD[&\2IK/9@.4J\PQUL:4#6Q!<@*%-P*3KW#
MU;?8 (1@ U'LKB%TP+H+IOB1\/(/?H=G_ :9_$E'8U*6_N3M)7M\2I3[#,"I
M3(G5S.)+-M>UC0%V':P;7ZM@FYR0_P" ]L7_ ,2"/[(F2@KXVK1Q\AUX_P"3
M;)-4K>-*&7$3-Y\LR))$XQEHR69#T'EQQR WQ4!SJJ:3>E$!.#J"$: *HLL)
M@1'E&!KK*$JU-E.;-"%&I^%4\9B2/:/':59F)FPL;C2-R^]G-D&3&$4E?V2/
MRZ9.+=<=SU5SB#"2;]05S1B,#>@Z*:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"KW.?\:3H]_>MSQ_8A)J"4VZO^"#L[
M_>'RG_88\4&EL#8BC6>>-S$N(9<783).M>8DS&*+% ..:U]V1(I9GU& S[2Z
M]A>$Y"PCI^QVQ >G['300(XSI#DMRW4R]$<P)1$Y%P[KJU86D2P9IYPGKV<S
MUF9VE[N:H  Y1X@Q]VOWB]Q]\M;O-K]!UK6"4^B'^%WR:_WY<?\ _M#(M!8%
MG/\ Y$\Q?WK,@_V).]!7]HWAV"Y\XOL4XHR,UV=(M+(Y/D2GL^R O;%@,I3@
MUM?692:4<%$],JX %"4VX!A":7:PPC!<0!!YVF^:)MB+(3GH9LH\'+,CPE(:
MNP3D9QO<M-F7$I5S_!0 4GFF7-E#"@3#+$5US#!$IC21B&<C--/"//+[M+@A
MUPGD36A!.NWS:RR['RQSA7EB8E=V3 -;9*(SS&='BXD=T,C@2?T%KQB^WZG1
MVEA!L%I>!=I<$;.HY*OP=.O.Z2(*6U'(C?+$QC7AZEX*6'-Q?9R^/,!JOO!2
M Z_20$T(.IT"N&]P](>L9]I<?/>S\KU-2,\Q+R+#X(FR$YO2AO9 0H]E5!C0
MRTJ%Q+D)KZ:Z6M*4_2 QM**^T,Z#+] >N$E*!05>\4W_ "1; _OPLV?[DAM!
MZ+>9P486VLTTVTD;.^N&'\8VRK#\DO4?9E[V;"P3>)+F-H?79*W%'J0M(Q/)
MPQ#""_1=)<%NL8:4 81[V_VJQULA+])?8^U3R10)JW(Q K%EMSA3_$<?NSQ=
MU FM%XVJEJ)E>GUY2@,.,6=DBL0D"2&PC+W.+M<):3S^-;P3^]0GO]ESQ0>C
MW3_PX>,3_COGS^QW&]![/DM_]XA_?X8)_P#2*@PS,KRLT^WL<]J)M'Y$Z:]Y
MLQ"V8\FTUC+$XR$>+IC%EC68A<Y0W-12QP*C2EE8R^@XHNXC!GF]0 AI^J<&
M,R3*#5R![/ZP%X ;)(_X.USG(\R9"S.YQM^BT67/[:!$.-0^-VD[6TNC@Z6<
MD BE)5R #$$X1@+=BG&;<-GX@_C5]M_[P^(O]QQ6@M"H*O>7#_!=CO\ ?XQ-
M_7%QH-W;YX(><W8*6K($(Y'F7$+PWY?PT[(@A\23S:%CNXE-:,5^BPS) A+-
M2EECOV/?!)S!VO8JU!7QQYHU^UVL?("G463QEXV&R_F)3U;7-/1QYZR;#$RT
MFPNFP#U")I<G@/6M]J,PLN]OL7O01MQK!N,7%L);8+O!@B:X<V!B".S)+B7]
M3L<L:\B.38"Y9DOA;AC^1.494MKV58D\5P!1) '*.A/UD_4,H)-R77Z%9@T+
MR4@TRP'/\3%1C.[=E&"0S(OG"S]E5R@C7&TCG)VA%-W]Z<$Z!X:CU25N3%J3
M *E#78NX"5)Q@"0DL3RMZ]&QU*A!&\NJ\\G(BR3];D&+YL;DDB3W0W4C8^V-
M8B8^8GL;:PK'@5".NE&$WN_6Z2K!Z:8+E3IRF:L.2UN.:%KCJ?,URMI4"$-0
MV*E:J4J%#<>,9*<8CD1IERQ7N67>X@WZ0A_,L&R>2+$D^R'B"!3G%S JE\YU
M]S)",VM\.0 &<YRULBHUI;PRM*8L!@U3G8M86K+*  PXX"491)9AQ@ ""/F>
MN0S%>?L&SS!FO,>R3D+8++\-?,:WQ+;'DI:GN"#F":\3DBV<.;FVIHVV)8ZD
M=C;&GD+%*<I1U.V,)*ZYI89GE .!]:-==:]>=M<0O63L6H\>IVF4Y,;84YS.
M(XWG,5;F M4L<UC.C"_QA.^#=W'N*UO,NX73IC"NR,+&<, 1:UV:\-CW"PTX
M<:RO*X\(@\X#V8LJ#DTG""%OLP-A+(A+,R@G*=U<U7*0V,[(8CS0F72#3W"2
M _L@DSK<[JF#=WE*?4+.MD*YD2X6=T; VA,&XOBIM@$I6)V=  DA4<):Y'$V
M)*L HP5QCMT!%?[%PAAEB7<5.2VR1R!)CG*F%]ICFY6>QP&"PG*L)RFCG2I$
M>Z-A2-ACJ15BOQ%4XNECKJ3K%G'$ M>XK Z@;A<OI<DS(AU=PXEV ,=C<M%1
MD^TH%(#33Y"$@3TZCC)4B.4#,5F2$B)"0 7W/%=1=6$SMK]IUZ"//+A_@%9C
M_P"$L8_NI0Z@G?C/_DWQ]_Q(BG]84%!5+R/(X^1L#K#)MDFJ5O&E#*EE'GRS
M(DD3C&6C)9@%'EQQR WQ4!SJJ:3>E$!.#J"$: *HLL)@1'E&!&?*$JU-E.;-
M"%&I^%4\9B2/:/':59F)FPL;C2-R^]G-D&3&$4E?V2/RZ9.+=<=SU5SB#"2;
M]05S1B,#>@E1*I4+1O>/-F;,FQJ6CUTV;C,$.493CL==90T8WFL(:RV@YLF2
M=D2KW1$C<0V4J2A@)$,P*@ 22SNQ47)"5^(]O\;[6R>70/"S+.)'!4F/7AP7
M9J<(C(8QC\U_5KT#$AAS.9(FEO<G![&0M5JCNU)3V*+17L6$_I,$2$*.-_9[
M$F$L5X\TUS Y2/'NQ+%D*6PLK'[Y!)T:>\.,IG+L[LBQ"[-D<7L29J66>[%6
M4*U*8L/8C-%>Q%P&B#]L7Y8C/'7FS9N"[&(Y/$<2YCS"\YIQ)F))$Y))X8Y>
M<"C%#G#7)5&6MX<TLC90IB4_97(&,8B#31A*),(,.#8.NBIZVHW@D^Y31%9/
M&L%0O""+"V)G^5,ZF.KLG*W!]-E*^4M+4X%@6F1A,!Z6A+47#8)MC4W0+M *
M"20]OQ<?TFW(_?NYG_W+&*"TN@JBW._P^>-+_C+F?^L\0H,GW6PG.X'+FS>G
M6Q(,69<8-04V480F","'-N)$5BC'EF=$R8 C5K\R-J4(DX[!&H&G3@L582A(
MC!0:6W!213>G7?7793%\*=LWP''<_!)LD8:9U2Y#.G6&.!"9OR'%$X8\Z)'=
M/-XV:@*L%,E-N8>6/O! C";EW."+ZU/PL'(.Y0W .6,@Y/&(Q(5A2-)]H_:.
M4[%6. :UKB'&7(H\2>D5EA*4=BO4C+$.W5 9T7M8);YF1/&KNS^!MP4^,)HN
MP:HUV;L$Y0:HJW.<J?L/)DB@+LPNSPC.#=Z4LZ((TB,\\P !A$B-[07>#R23
M0D]CG?#"&Q>1H_BC!B*>93:)$ADOG;)#9")=&X+CMO;XZX+22GUTE3 TJQ.[
MVOLF1I2@D!(ZRJPKG]>P"30IXQU@C0S6\J0XFY"<-RR,3^,25]*C.:C#<]GP
M#,415.:E1&7-@OBU_6-R%U);.L6:FLB*"46GM8XRZJQQ80G#@1LU3!@C==YU
M.P9D/&D'585<$AV1)F+(X&7+ _(>1EZ8R%)L@OSX==JC*58 9IX.['FB<P=J
M2$ 2##0Q[4WD2UKPQJ?A;'\U<IZFR:P0)N;VK'J7&$\5/<Y4C,&)N'"G(IA%
M%G5&\'J>Q3'&.!(!F %^9;JW$&6X8UPRT/1#;\4LBB]@S!M6OSMEM-CE2686
M\,"J9LIEHO#ER<18!EO2U0BN,0!%E&E76@)-++,+&&P>[U"V8P)F'7O'FEAT
MI?HUG4>!UV(Y1C][@4Z1.K"NC<#6QZ0JUCH;'R(P046A1&*R@&.)1@@C 5>P
M5 NSL&O=6=R<>::88:=8MLD<OQAEG#RJ2QQF1E0672-HRLU&O[J\L+ECUWC[
M*X-S@!60Z$I0C5&)"3#+EF=I:Q@[%!D. H5D!7@OD*V8R%$';'BC:%IR+*XC
M") 7W:0M./HS 9BCBBQ]07  U XN1#R;T@'8(C2R0GA#8LTNX@E;QO?X#VNG
M_$@_^R)[H)NT$1]M=I<$:\P]0P9AG7E!VR1$9PCA:3RQ,7_QE2W-9")87V\7
MCSVF;NQ4OJ4/2K&0$7:](;WL$=PA"+B6VEP0IU[PAK$1.NOG%O3906+(1Y8F
M(>Q3#R#/)H$SS*./!B!G3&5Q2GH"X"%]MV?1VMK@L%RM H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!#O>_7R
M9[0:V2[#L <XPT29_=XDO1KI@M=6]B+)89(W/"P*E4RLL@< &F)D@@E6"E':
MYE[6%<-ND5@F)0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!08!EB*N$[Q;DJ$-!R
M),[3* 3**MBAR,/);R'"0QUQ:$1R\U,G6*2D12E8$1HBRC1A!:]P@%?H#<,
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M>XV7P[CW.7)C@2#Y08O,\0#K9)G]7'CER]$W.RQBFKRL;"'@#>I2FN#80NL
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24"@4"@4"@4"@4"@4"@4"@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>sny-20231231_g4.jpg
<TEXT>
begin 644 sny-20231231_g4.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8
M,0  86-S<$U31E0     245#('-21T(                  /;6  $
MTRU(4" @
M           18W!R=    5     S9&5S8P   80   !L=W1P=    ?     4
M8FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D
M   49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P
M ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E12
M0P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M        $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V
M,3DV-BTR+C$
M                 %A96B        #S40 !     1;,6%E:(
M          !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4
M !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO
M+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M
M9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ
M  !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@
M  !,"58 4    %<?YVUE87,          0                        */
M     G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ",
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M P,# P,# P,# P,# P,# P,# P,#_\  $0@%2PQS P$1  (1 0,1 ?_$ 1X
M 0 " P$! 0$! 0         ("08'"@4+! ," 0$!  ,! 0$! 0$!
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MR RV;#[.I?8#LX7-%U1=<L'1;I"?- H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M<C5(2;B4FMI:(E2J(#;OI?.<++&O.P^*N/'8:;N<RU:SC($..L,J)2Y'KUN
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M BCR#R#0B*.).*%<(P"M<(@WO:]NB@^$!EAK0,FRV2V7$'^"VC.<R:\7>#C
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M4I2JDQH#TZE.> )I!Y!Y0A%'$G%"L( PWN$0;VO:_10?VH% H% H% H% H%
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MVHAL>?HE&<[XWCN1&F,2<;>:^L)+XE[0YJ<#VI2K;U1B)4 8 G%CM8XNP1W
M7<5RPA(AR<FYF;E[N[KT34TM2)4Y.CHY*B$+<VMR$@Q4M7KUJHPI,C1(TQ0C
M#33!! 6 -Q"O:UKWH.(?DZ]8UCC#DMD&'N-S&44V ?(^M6-3SL;E50^DX8\3
M0*34:M/CB#1Q8P2C);4,5KW)?3GAE;Q#*ZR5.Y)#BU-!S82_U5G.%)7U2[LV
MV$9Q\WGEI@%1>(:X:W+6)$(@@LDTY,HGN*IO)AF+3 7--L<XG L8.]BPE@ZH
M+!-W4OUE7(;BR0,:':W'V'=I\? +;DDC7-L=)POEPVR?J$JGEID$*!?&UEJD
MH8SCTAL5"0><$ "341?7ZP?0@T$Y =:N2?7F/[(ZPRTY^B+DK.8Y/&7PA*US
M[&<T0D)U#K!,B1U,M<0L<D;R%9)P>S/4(UJ,\E6C/4)3R3AA->@4"@4"@H)6
M>E\X,%ZM4N5Z.]JJ6J#U:DW\)?< OM%"DT1QQG4*V  6#KF#O?H#:P;=/P6M
M:@XH?5.\;VE_'#G75*&Z8X:]S<;R5B:=2::MWO$RMD/QI[9I@A:FU;WS*LZG
M*]N[L@.$7V:0T@D?3UA $+HO0=7OH^?YGMN_E,YO_P""AM!U+T"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4'"/ZXG_ *)N/#^$38G]S6):#(O0_P#^;UOI_#-A[]Q$KH.X5W>&F/M3
MB^OSHW,C(T(E+D[/#NM3-K4UMR,H1ZM>XN"TTE(B1)2 "&8::,(  M>XKVM:
M@YDN;OU%FJ^DF ,C8MU;S/!,Y[IS=E=85"VC%<E;9K'\(KG0@UN=,C9)ED9<
M%#(Q/4-2FF'-C)92:[*G>R6QR4M#WA24'$IZ<CC#GW(7R 8SGCS%W$_6?6";
MQ?,&<9HN3'>7W1VB[D5)(-B@I:9<!;F_9 D3:396E+'VI+&4L4"N&]BK&!]>
MF@4'-#ZFO57C*S+IX7EC>G+*#7#*^.$CXWZWYFCC2GD^5'^1*$PG([$C7C8I
M<V.&88N]JP%GGMO>$=F8P5UP7!M)&M-.#YDFIFSFX&D$Z#M'J)/\HXI5Q=Y2
M15SR%'6I0=!78US*6+VV#Y):G!*]8\DZ=Y2(350&1Y+6DC&G[<HNYA 3@!<Y
MQN:^/WJ.MX));D=Y)Y,RY09V5&Z1B#.+,W'9#RQ$RE#@ME$0P"0H)8\+XG11
M<0K+CFUM:%@NJ><I)9C2BUBD@/J":B:?:[Z*X+BFN>L&.6K&N+XGVZHMN1".
M6/$BD"\! 7B83*0K1G.\KE[Y=,7WE>L-,-N44407V:8@@DL.!SGJYZN6'2[E
MAVLUHUHVL]VN$L:^XSR5"O<9K;,?!?..MN'9_(__ %1S_#LJEKCXC+94O5_W
M6O/['M^R*ZA("RP!W4<;N5\D9WX^M),VYA?#)-E3+^JN!LFY"DIK,S1T4BEL
MYQG&Y,^/UF..-;)'VHMX7.8U("$*-,C  RUB2P%]6U@]GD#_ ,PO=S^2)LG_
M !-32@^1/P2_SPG'?_*9@G_"JJ#[2= H%!RV>K_QHT3?A]>Y>N1)SG/#FQ&%
M)TR+1WZBE$<^K7S%JX*<8;=8PM4@R$.QA5[]F+JA'>UQ% O8.9'T7V37"+\G
M&8,;]Z$%CRGJ-.!'H;?V!\C@V1\7OC&M%^N!MUD3*K=R[? *_0IO^A\-Z#Z@
M- H% H.&GUP'^;UH7_#-F']Q$4H'H?\ _-ZWT_AFP]^XB5T'<M042\W?-;K_
M ,7>O&06-JG\7E&Z4QB3FR82PBRNR%VE4=D+^U]BS9/R4S(CS5</@,8"N Y$
MB<+)3'\Q/W1#<=[GG)@^:WP@Z*S/D5Y*\ XP*;G5V@41F[/G'8*2W)$N):,4
MX]D+8_R3Q=<JN864MG;MW6/I#3;'"[^[EF"+," RU!]GZ@^)1NI_.];:?Z2'
M/'_6<E5!]M>@YO?5A_S)NP_\(FO'\=4-H."7@"XC89RZ;7R_&N4LFOV.<288
M@:7)V0DT,1)#)U.&Y5(4,;01*+O+J2M9HH8I6KK'*7)0C<+E$%7+*3",-L<2
M'U.=/N-?1C0R-MT>U6UIQAB]6A))+4SA,P)WW*;\<4@4MMU<DRG(_%9\]G&)
M%ZD-@'N B"@JSP%%EEFC!</S;U\;FGO(MBR0XRV=PW$I<J<V-2UQG)R=F;$.
M6L;K^R57:GZ Y +2>/LJMG7*Q* I;FF-JR_6*5IE"<PTH8?(%FK%L%PX\F#T
MS,[X)OSEI%L-8UAD2.RAO;9BWQIS*<&)U&D$(2@<*RYCY>28>B/M?O#,\#3G
M@O89@*#[2N#\MQ7/N%\1YT@Q_>H5F;&4$RK$E'7L8(V-Y!B[7+&00QV""US/
M#78OK?,AO873TVM?X*#Y\?K&.3J6S#-\=XQ,92)6UXTQ0T1')>QZ=N4B3BFV
M4I2WII7CV%OG=U N^1N!PQ>W/8$QM@EGNKL6:87<QO2&A"?OIT?3CZ_1?7[&
M>\V^&+X[FC,&:(ZSY$Q!AK(K4DD&-L2XVD"1.[0N02:%.1)[/+<D2UG/*<[@
M=2E*5E2J4Y($Q3@4>:$.TYOB$3:8R"%-47CK9#2VY0S@B3>R-J.,@:5@#BU;
M6!A3)BVH+<J+4&!,(L5V0[#%80;]-^D.._U,' _K1/M2<M[W:KXBAV&=A-?V
MA;E#*;7C9B0Q.(YCQ2T6NKR,OD$49"4<>23F',]SW\#T0G*5+TZ-4G674C-3
M&I0JO]%SN[)XALGG30F2/2]5CK,4!7YOQLT*#NU01[*^.CFAMEP&M/U.LF%.
ML>N%CEH^O<%Q1E-:P;"&(5P^D%0?$HW4_G>MM/\ 20YX_P"LY*J#[:]!SO\
MJJ/YCK;;_G%K?_UE\2T'+1Z);_/TVR_DB#_CEQI0?2WH/E@>L@_G<F'^2)AG
M]V.6J"TOT^GIGM2\X:V86W\W6<5N?!9=:ELNQQKRA5.D9Q5&6=#(75G;E^25
MS<<WRG(<B./9 J+-Y:AO8B &#3JB'4 K# '=EC'$F*<)1-' L,XRQ[B.#-X@
M#00O&,+C<!B:$9:-(W@$CCD5;6EG3" @;R"+7 2&]B2"P?V( VL'%?ZNSBMU
MQ:=367D#PAB>$8HRSC+)$/AV95F/HRUQ-LR9CO(!MXLRN\M:V(A"V+Y?$)C=
MJ3(W,1'?#FY<:G4&FEIT0$X19]$7L7)D^3MT]25KLH40UW@<0V+C;&;<8DC/
M)HY(&_&<V=D0>TL62HDC5*8^2JOU!7-"U)_A#V?0(/H;#& L C#!! 6 (AC&
M,5@@  -KB$(0A7L$(0AMTWO?X+6H/CR\L>[&;N<#E,*C&)QN,MA;CE5)K5I3
MC@E9W9F*C+Q+TL799284-0<VMKUE5XL4^/;@8.]DZ89))AUTC>1V8?1&XJ^
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MY1,)NT(#U=@#-2(CSSB@W- "@^MQJ_I%J+I9$44)U7UWQ5A!D1(CD!JF%11
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M&&Z>R)EETW0,+4DELJCL84PIAD<B3HB2G=[9X@LDLR51AN<UP!G%(#'9Q$E
M.Q=U!O5Z]PK/Y.N'#2SE<A;<T;%0Y>QY-BB!2BQYGS')K>P98AI!USCP,XW9
M4WN+?+8==:>(X;,[)U:0!AAAJ;NJ@RZBP<9>;O1'[=,[\>'7#<?7'(D7,7FW
M3'9N8LFX:?DK8)*F-)">F@D:SPWN"\A:8<G%<)R8LTHH"BUBQ&B3$A[NO_HC
M-DW5X1';3[G8.@C 0[B$XMNO\8GN67AT8"0-Q@2D3WD5FPLB8'=R,&K)N8-O
M<B402R3NHJN8,@H.S7C<XA](N*^&.4?U=QRKM-I.@3M^0,X9"<")9F7("9.:
M0>6A>9.! UMS''[*$I)O@[$A:682@D*@242GK'""?64L6XZS=CJ9XCRY#(_D
M/&F0X^X1::PJ4MY+HPR)A=";DK&]P1G6N$01!O819@;A-)-"$PL0# !%8.)*
M<>B7B@<P/^0L!<D$OPC%"9N=+<51=3K<HF\SQ<F3N@7:-MZ;*;?LG 7!\=8J
MH++LD=0MR!7TDEF"_7K7,$'6-%M8\\/&B,UU)V0V=:L[Y4FN$,CX0==EV_"E
M\:KG=OFL*=H4U3"4XS+RI,D+S+VE*Z=NX&I7AM3NYQ?2$I&(8A4''1_48_\
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M<RD<OF![6VLALA>W:1.*VQ2B[0SIB IT)2-"4 KI 0$8C!#"<- H% H% H%
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MLC%&UNGTUCUR3!&NF0U>:<8/(%%E1X"2BV*-XKRZA-),0A*,$9=Q (!HQ%V
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M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@X4/453AXSSR/XHUOB-P+5T
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M-R7%65GUNV5:=8I&E=CU;],''!L=SHH>&D;<I2IVA RRJ61EG91D+SP*A*1
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MC3U(2D"5::J,$G((&,=K O<  "O?HM:]!F- H% H% H% H% H% H% H% H%
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MV2'E64+B$WAB$1H.]J2 WZU@\S2OU)W%CO/FMAU[QKDV>8\RG-'6S#CIDS;
MC8*WY%?31! A8HM)$3M(XZ!^>#!6+;T#BJ;UC@HN%.F*-4#+*&%]M H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MS0R0_">#D>ON5&N-/N3,5MB+.F-\[9]\\)@-'>6 A]$F:WEK+LZD%FD*BP!
M T5B>@(=:/$1S]\=N6,-<>6CP,X9 D^W:_7O7G"LB:'W&&45 77,T0PU&VF=
M%N>0G9B$R.1@Y"PKQ&.9BP92P=NUL:/M+"N%*G(SJKP%RWEWS)^$)O7N# MO
MI?L- %4HQ7"\0!>,>M.0I0EA"J+,+7)Q8A>"#FA<0X-]S3Q.)EBKG#L(P/5O
MU0[YLHY3QOA''LMRQE^<Q?&N-((T'OTQG,T>4,?C,=:4X@%C6.CLXG$)4X3#
MS0%%!N+KG'F *+"(P80W#F[GWJ\^'2&2M=&V25;"9/;41EB@S: X16$11:+M
M3"C+H09"D,"E1I974ZUQB:P &$5K@N/X>@+@=#.432#DJBSS)-1,VM&0%\5)
M1GS:!.;<ZQ')<(+<#CTZ(^20>2(VYY*;%:A,,LEP3 4MAY@;@*4#%:]K!H3>
M/G1XX>.K-*;7_:K+,MA63U4*8L@DLS)B;(TU1BB\C7/3<TK+O$5CSHV!./5,
M"D(B;F]J"P+7%:UA6Z0CSM/ZFWB1U2>VB*ON:Y-EZ7.+*VOCE&\"0PR?GQ).
M[I$:Y$WRU[6.<=B+5(K)U?\ =+4%Q-<D RA@5$$#N (PL6T'Y)=/N2_&#OE3
M4;*1,[:XJYI&2=QAT:7*+3['SPX$*%+8BF$1>B$[BWDO"=&<-"M*[PVK^[GA
M3*#1)SPEA.R@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@H!YSN#'\]'^"[_ /+1
M?@V?@V>^S_\ $G[XO.GOB]T?_P#=S%GEWR[[K/\ ^/[YW_\ \!V'Z\'RXN.#
M3?\ .";LX#TZ]XWND]^$B?F#WB^4//OECP2%2:8=[\H^:(7XUWGRYW?L_%$G
M4[;M.L+J=00?56UF@.!/3E<5;%$=E]@G/(.(\)S5]/?<Q-&&WYC7K5^;,IJU
M;$WE8TC4FRB[DA1.\H*1B. N4!&$-SA6*#>X0AY3-ZDWA[>L%3?84K:,+?"X
M1)"H==B>X#.67),OE2AH+>B6> XX<6-/+)6&R0\JRA<0F\,0B-!WM20&_6L'
MF:5^I.XL=Y\UL.O>-<FSS'F4YHZV8<=,F;8$;!6_(KZ:(($+%%I(B=I''0/S
MP8*Q;>@<53>L<%%PITQ1J@990PNKROEC&F"L<3++^8IQ&\;8QQ\QJI'-)Q+G
M-.SQZ/,R/JV,5KURD006$:<8 D@H'6.4J# $E &:8  @YU?ZW'PT>\3R/[R,
MW^ >(]P]['N+E'N[[+O/=_$^Z]X]Y7AW5_7>GRYVW9_^#ZWS-!Q'\9DRC&1?
M4LXHR#"7=-((;.^0S-,RB3^C">!(]QB3RG)SVPNZ4"DHA2!,Y-2XHX%C  '8
M([=8-K]-J#HF]0SKYP=3#D+42KD&W3VLP1GY\PGC,\,$P]BB\SAP8.A/DK-'
M'@+P7BN8=5S<5+8KL>2)9T@[,-^H&PK=(=G>N[5C_&.KV#&2*2=2LQ7CW F,
MFJ-S.7B2LRM5C^)X\9$C/)Y0,TEM1-2D^.-Y:M;<1:<H@5Q](0!#T6"D?83U
M4W#I@"8N\&3YJG.=7E@7B;'A9@'&SG,XH0L+N/MK-LY?UL/ADI2$]4/2J9U[
M@D'<=K -%<([ "6_'YSH<<?);,QXMUJRW(+YB*CZN4FXCR)C^50F8^ MQ1!C
MHX(EJA"MA3V%I$?8*DMO=U9I/1U[A[,0!B" F0/5V\-,-<!(H[/L\Y836.&5
M9VQ_@>2MK>( .MU5(2\IK,:.O8F]6W5M=+8SYJW2&WP] 2*U!]2MQ,[F9*BN
M'81FV38RR?.G%&R0N*9R@#Q "I+('%7W)OCK?+TYC_ "WYR4B++2)5#L0:M.
M.+)3V-.%V=@I^]8=R'P:!8/Q-I5BG,61H!MFU9QQ9L$_M4(%.H?8>"UV,]B(
M6-2;D!C\.9EH5$T6-]AM7?!'BN6 ^Y75*L((0Z].IZ@'3+2;2;*.*N0#9#+R
MK,D@VFFV08T8^1/+V958<9.N)<(QQF 7)T+=)2D":TIBCS>R"YX!%"N(WL[6
M/L(06&>H]QUP[9]EFEF6N0G;/9' !DLPS*UV#$N%<8G3!)+X2Y.45DKF[R0L
MW'$T5,KBF%(T(2R31)A7":*UP7N 5[!T$<1$$U[QKQNZG0_5*?S7*6NZ''J]
MRQ1D#(K."/S63QJ2S&32>R^0,H&:/6;E87!Y/*"7=$G%8HL'6#UNF]P@7M7Z
MH#B)U2R"[XN<\T2_-\SC3JI9)6FUX@BC(#!&W-'<P"I*?.G1SBD"?3$QY?8F
MV9G-SN0?TEF=08#+ #<VA_J"N,+D-GK;B+"^:76'YE?3#"HQBC-<468YE<N-
M*(4*C$L07FJ'6&2=U"F2&&>'HG8YQN6&X[)[A"*]@F#OOR0ZG<:..H;E7;J;
MOD%A<]FML?1EP8H1+)TH62B[$[2.R,YOB+4[+$9/A+*H'VQH E=8-@]/6%:U
MP@/+O4K<0,/U\C6Q:K912ZQZ:O3XQPW'K+!)6?F>1*(VXV:WEP!C-8WH'M@C
MJ=58RQ;J\>'-JD10RR#S#;6+N&RN/'GMXXN3+("G#^ON2Y1'LS!;')[:L3Y@
MB!L#E\I9V8DY4\+8>>4X/D6E!S4WD#5J42-R-<B419BD2>Q!)QA87-4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M^8)ZU;^=-P'_ " ,6?\ 6*VJH/*Y^^)X['FI6AG*5@Z.&$PW)&JNI\(VI0LY
M0K$QG)ON7@S5 ,MFE$WOW)NGR-.2S.1]@E$%O25$8*XU+J*]PI-Y%N1^=<C,
M:TN><O6<7#-&N.M_X/>1ILM[(0,E"CF0I:^P^=#,"I/4F/SE#'U$G>3#K $I
M>$JE4&P0* @ 'TDWE?H<1Z;;3IIY)Y.='=29!H7Q[E3E&V.\A:9/,WN*8VPG
MDF%0>(6A][2YSD$@E,'2V[JVW >-(6>,9I!!9R@H.6:4\J7IY5J1?A;5W@ >
ML^H3DPV)C42,;5#,DOZ?LBV].L12N-J<W9<1*5KAW<LI79PNY=!_:"ZIXKDB
M"I[@G?CXWSOZ>J8(PR;$+:NV1FD>20)Q?G!TD4.A\ACT\95F-Y(^JFQ@7/ZE
MLCZT34X'*$*0:P18QF)RA"N6$)U>L@_G<F'^2)AG]V.6J"Y[<?TX?&/ASA+R
M9L9C?&T^2[*X]U/:-@T.;9#E^?NKX[2!MB#1-WQF=X62Z),1B8W@@:E)8"6-
MI5!01@N \ PW'<**/2_<8VIW)IL3L%&=P(Y,9_ ,)8UC$VCV.V2>R*"1I^?Y
M3)36!8IE"V'*6:8&A2($ >PLW.K<+K7OVMS0V $(1?\ 47:$8#XX^25YPCJ^
MQNL-Q#(<18VRS&H>X2B0RXR'+)*HD;(ZL[=(I4M=92L;@N<3,5$77+ERDNRC
MJW/%:P0A"]CU<>WN7U6L_&+K*&4/)<2R]A5%L1F<ZS@>69DF6M4=@;1#"I!9
M.82%<B8G1S>7(P@\)A!R]4E/L$)J0H5@KIT Y;.$S5+3N)Z^YMXBDFRV5G*/
MN!>;LU3^-X/E\CFTE?%1RI=Y8D4Q;G"5PV-L)8B$[.0W*$(T=TA:L/57",/$
M$.^#3/:3$?.MK#*=>$TDA6*<K;)R#$3-"GAU$K<PX.S0YO449(?,E-U3B4^J
MXXTNK:K,$8<HL)T:R5 3+F%@-L'V&J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*#@#]<Y_\"[_][9_^Q'H+NO2>?S)NO'\(FP_\=4RH*B_7"GP/
MW1\?B999 +)U\C9W/CM[V*NYE0.T9QT7,[!OT]N! ?(!,/3TVZ@C"[='PAO0
M07TKV=SSJ;Z17;::PM\=8W(\C;D2K"^)Y8UKUR%SB..,G(L),&0'%D6%&)U+
M>XJ5*:7I$IZ,TL:18M"I *QI8K4%.G#?OSQJ:%WRI,-TM"#-U\I2IQ9$..54
MG:L8RR"8UB38F,4.)C7$LEHW-K\YOST?:YKEW89Z9(D*+3F%6-4V,"*O(SM+
MJOG+<HO9;CXU]>M)X:-NADE*QPRJ&1D2P_,D8=EZI3,,<H84I"P0QJ/*1M2I
M,D;24!"1P*.&40#IL(073^JN3[*Y=R=Q][@3UDDBG!6:] L$.,2?TA"HZ QO
M+DE(?9[E&("$G2$-+)+5Y4C;5UP7M8:]OL1V0AA1F%)@_IJ'RT>G[;\%XXPC
MN#PH-")X9(,T0B=9>Q*&*Y,E,L=D+8E1N$^$_2^08MR>QKY&Z!.6* DR!:M;
M0&=FG4*;! &@N_V'S9IQHWZ;/:'(7#)EF8NF&M@,V!B4?>W=\>3)K@>19N/Q
M[%<NP$"A\;F>=,#XP0)G/3H!N!JAV1'.Y*XE<I*LF/&%1OI1N'_5??MPV-V1
MV[A:3+L-PB^0['6.\2NK@ZHXFXR^3-#L_P CELT1M*IM/?"61I*0$-B(P\:(
MPY6I-4$C$2FO8.ODOTZ_'7 -NM:]SM9($KU@R;KWD)OF*R,X\5N#EC#)C2D9
MW1H-97R%R!T5D1EWZJ\ R7-F.1VZ0#NJ2K!F6&6'S\N=&%CR1ZAG9S'A;TKC
M9D]V3P-"P2) 7<Y<PCE./\.L87I&2%0D$:K:Q+NW+#8TJXAEVMUP_HV#LEUI
M](1HMK-F?7?86.;(;9R/*>O>;\4YO;0/;IAXF 25VQ1,6:<MC(NC"#%)4B0-
MSH],1(#S"WTPT*40P Z#+A-"'(GH#_M1<5_TF6P_[OLL4'3KZVG_ #"]3?Y7
M8/XFLET$<_36\)G&AN7QN-^QNTNN*?-.5IGE7*,25O4BR%D]E0L\=B3FE:FE
MNC[)"9E%FIN,N6(1IJL11JX1H[]!P06  (<P>P6.+<2/.TZPC7Q_? -.K&XV
M.'S&:I8X#/>?([PY1&:ML,?7(9)?C 10R578G,PPOJ.!-SNT!<)H@W":/JU=
M7,":L<G4-9L 8Y;,;MF8=8(]GS)*1K<7YQ!*LO9!V"V02S&;+!O[L[FI5[XG
MCR()A*81*0%B+=F2"]Q=(=I/#[PZ\:L5U1XV]SX]JM$FO9U5JGJ[FM1EHB5Y
M+$]&Y1F6#8<_2>6B:SIL9&N]O#L^*SC"+(;)+=N((2@@Z V#AXT!_P!J+BO^
MDRV'_=]EB@F9ZS/9?)$YY",9:PJW=:EQ'@G!D5E['%R5A]FURR%E)>^KY),U
MZ0(P)SG$,=;&QL37&$8DQ28ZY8@V5&AN'4-J5Z</B\=^-K#F)LEZX0B798R1
MKW$'R?;&V+<PY;*RE/(4B?7:9PV6W6D.;"W1R2.UQL[4'JMUD:4DE60IL)1<
MX.+KTQ^PN0-4^:+%&'&R2*/(>>G7(NO.6&5.-4%HE%FZ.2UU@;MW&P%  .+'
MD6.H34R@9?:DI%*LGM"RU!PJ#7_.1!FG)_J(=E,:OZAQ2,60]F< P9Z5LYR9
M.[)6F6P/#; XJ&L]:D<$9#B0C<!B(&:0>4$VP;B+&&UPW#I&YQO3F<9VHG%-
MG#835S$\O@6=-?$6-I"FGKOF+)<N-R U.>3H5"9<BFL>E<A>H228=&I,K6IQ
M,C4S""XIB V$$BYI8@P+T-4E?E4;Y+X>H=%9T88GS4>2M#*,=KH6]^E:#9)K
MD;HG+Z.D"MX;X8U%'"Z;]8"$JWP='PAWP4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4'QP<O?[2#E#_3=37_KWN=!]?K+W_1-E#^#N:_N:<Z#Y OI\=#\
M \B_)#"]>-ET,K>,4%XWR-D-UC\2DIT24R)?#4+>:VLKJ]H4QCTF851B\5U%
MF\]"M%U ]FI+MUK""S;U47$'IMQJK-/L@Z78]=<413-?OBBF08,MR%/,@-!3
MYC\K&[G%G]@69)?I?*TJEV12UR*<0#=!I;=U2W((+$(X0PV!MGM[E^">D9XR
M,7,TH>23-E,LYFQ5/GXMP/3K%>&\+9WV%$SX[[1(8G-\*47CL=2B!>XBAMC6
M-,8$8#A= 3!]+?P@Z.[2:>2;=';S$[1L#*YGE.88^QS#9@X/?D6"P^#)FQO<
M70R.-3BV(GV6R61+EEC#G"RLI&C2)>Z )-&H&8'/=R!X Q!JYZ@:38&P)"D6
M.L1X]W$UM1PR%-S@].:!@2/(,0R9Q2HUD@<G=V$F->GI2< !B@82;&=F78!0
M  "%['KB?^EGCP_@[V)_=+B6@G9F#:3).IOH^,#S3$;POC,^R#K[B3"#9+6I
M48B=(JT93G"IBFCJU*TXRE:)W/@P7)$C5)S"U"%6K+4E#L82&@IX]*-P_P"J
M^_;AL;LCMW"TF78;A%\AV.L=XE=7!U1Q-QE\F:'9_D<MFB-I5-I[X2R-)2 A
ML1&'C1&'*U)J@D8B4U[!U\E^G7XZX!MUK7N=K) E>L&3=>\A-\Q61G'BMP<L
M89,:4C.Z-!K*^0N0.BLB,N_57@&2YLQR.W2 =U258,RPRPI>Y<=O?3>:Q[Z9
M]R-L3JU)-]]ZI6KA#9EQB:!GRW&&.76"P&)X_:8F\DS.;1[%C0^-\7A:"S@4
MWM+^XIUHADJA)QB/)+#E"Y7=H](MKXEC2>:?\3+GH*D;Y0M;G',C-+'"T RF
MSJ&8]2@AE\?M&/F''2*2)"0IW0MQ0N1BVY CBC2U!0BCRPZ9N/K7S#^UOI)L
MT+]AH<7E)5JGC_D4R[KT:_O4C(MBW(<%QQE&21*0Q\MI>&THWP1]>U:HI(J"
MH0W-4#N,D5K]%!1QZ6+2C5S?#D%S#B';;$3+FC'$<TWR#DAEBSX[2AF2()LT
M9LUZC#:_EJHF^Q]Q,4I6*8.2>Q8SA$7"J%>X+B" 00ZU?40:F:\:5^GVSY@[
M5_&;9B3%*#,&$I(CAK0ZR-X0)GJ0YPA"AY7%*I2\OKH$2\\H(Q [?L["Z;A#
M;IOTA!GT;TT'C?C]Y(LB%H0N9D"R4FF@&T9MR . XMA18^!0B/"$8B0JQ(>S
MN.UKW#873T4'-OPM8 ;.8;F?C0]TW1;E!FG;KEK9'.R!S<G9,HR8L8&M<^(H
MG=<C5!6MT=5R]R;2CTI1Q00,28U&0(KI*N .@3U7?$/HSK#IEB?:_5C!,&UZ
MG4?SK&<2RYJQHVG1Z*SF%S>(S1S3&ND;3*+LI4DC;[$4XDZXD@D\],L4@4C.
MZJ;L@KIQGM'.LZ>D=VYQ'D!]6R%1JSMO@[',"5N!RA2J;<3R>?8HF<7C8E)Y
M8KG)F"1KWLA('M1]V;^[I@@+*)*L(-F>ELX:]"^2#%FS.8=RL<2O+B[&.2(S
MCR)0TG)<WQ]#$J!VB=Y K>E=\9/$-F*U^NK-L6&YCQ=$$D ;=VZ_6&(*5.:K
M4N%<8W+!FS"FLBR012 XP?,0Y0PJ:N?U;_)89>3X^@^2$R0+ZXEB7JA1*;+U
M9+<:J,4JKHDR<2@XXZY@Q!]FN@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'Q]/3784QML?RH0/ V8(X
MGEN,,N8(VD@<WCRD0BK.+!(<#3A LLF5%7L>@<4UC;')%15PGI5)99Q8@F "
M*P>NV+ME/3-\S)A"KQ=_8L:20"9R* 66D;]E-/\ (3B RRE*"YQ+9=S>X^AL
M83?M!D,LR9^H/KW0F $&3^FO>T<E]0CJ=(VZQP6^02W;Q[0A4@"4HLC==5-C
MEZ6QY8!F!+.L0>'KAL(5K"Z;=-_T:#KAYXMA. ' VVT3RCR'88E>X.Y,9P9&
M\?1C!<)4N[\TPS'B:43::19?D&/K)Q!<8-BU^<\AN)X/%SG1SNW]DH);^IW<
MPX.1/DTW<XW=P->%QFG/"VMU->8S)HX>CVKB$F\NQEA;#G.R1;&IC!H+CT./
MY+YO,[RB3#7.Y2M&J(*,3FCZ#4H@Z-_1WR![6<;/(K&E3JO4,#'E-T=&9G.4
MFF-[6X2#!A!+VK0IA"N4F.=2F)'8^X+6[3NX.GX;4'+%Z?'0_ /(OR0PO7C9
M=#*WC%!>-\C9#=8_$I*=$E,B7PU"WFMK*ZO:%,8])F%48O%=19O/0K1=0/9J
M2[=:P@G'ZI7BTU%XT<ZZNVTZ@;GBZ!YPQK/%DA@2N=3B?MS?)L>2"/(AO34[
M9&?97*TX7MOEA-CB#7-00$U-UBBR;"O807@\>?IS.,_9'AP@&R.3<>Y$E>SF
M<=;I+E(.9'7,F0D"Z"3@YLD![.*,1.-NS-CY6PM*MO(Z"'IF>3S2K"L8:8*]
MA6"C[T>K^]-'+^E;&QR5HF^4ZR9K9I$C(-N AX:TBF%R-*B6E_#8TDA\8D:H
M-OT;&IPW_P"S:X5\;H;EQ+87FAR]LMO'%YKFC"$6VDEK.]8<C\A"WN2O!^)I
M<],$!PZQN"]60C9&,QJ94B=T&E$ENH$I7JR^HJ4B'<)F<J7*EQ![N:L6Q;K'
MQ7-&HV>8F^1=QQGEV"1/#,"3(&A(\I@RR+2\O%J*/+Y2QO$;4K;IREX%X$SF
M(!Y82QC--H.D#T3N;)G+].ML\&OKFM<8GA;.<2D\%(6*!*"V)-F"*.ALA8VL
M!EKB1-5WR!#<>P#?LN^.*DVP;#-,$,.U:@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@Y O6K?S66 _Y?\ BS_JZ[54&N_1+?YA>V7\KL?\36-*"17K
M'#X&7Q(M!,KL@%)U&UF'K8QLHL5=:"5E1S(YCP<W6%>QH1!@%G@!H@6O:Q9G
M0+^RM04"^F[V#S!J=Q,<[VQT+-$7;&&/<:/6'5!O:&I6;,HX%F9J7R$24ZW<
ME 60QXBJPXH-[#4%I;%CN&UP7H*(^*W<C235S8[(.PO(9JO(-[ECLQJQ0F)R
MD^)2V-AR!)'HQREN1LBL^3/$FV=2 U-80$@EY:P 5*U0J,#=2!.:6'L<PVYV
M@6\66<;Y8T=TL_ L6I8[(&;,L7:&^#QV&SER"N:U4/D[/$\=]RBS._$D&N13
MJ>4@3&K[B3F'#/,L(00MCYJGO;/:CA2X-MI7X$UFV(XIB3)D"S/)$YC@[H6O
M*,?>(QB_'LXR282GZGB<VC6/G M*ZK!F=*T2HH8RSE@>]!'WC9Y3.%_ ^O$'
MP;N_PZQ3,\T83'9-,MC8MY.R3/9^0\N;BK$]G1S*)\561EU:6U00C)1H)*!!
MTD7/([E<=R[!U":?9MXN]6^+?E?WOX4'V8L*Q1B1+*Y5@W(:QV7.FN>9F*+3
MUEQHL-C\T&^/I;0K<)8-R[.[X_,ZZS482B5 L6>46'+OZ:7C8Q#RH[VY7?=O
MC'G)F-<*P,[,,SB;G)'XMSR_DF8S%*VLA<XD25:1(G!A&H.<W1U&!:4J7K"B
M"C1F$'J0B#N'V"],SQ<Y2=<9SG"V("=3,LXEGT)G<7FN&3G*S&\"A\L:Y,*/
MSG'KT[J(U(6QT A,)[RG\/=2!# (*L11=TY@<$/.C"QY(]0SLYCPMZ5QLR>[
M)X&A8)$@+N<N81RG'^'6,+TC)"H2"-5M8EW;EAL:5<0R[6ZX?T;!V2ZT^D(T
M6UFS/KOL+'-D-LY'E/7O-^*<WMH'MTP\3 )*[8HF+-.6QD71A!BDJ1(&YT>F
M(D!YA;Z8:%*(8 =!EPFA#D3Y@?\ :9,L?RS-6?W/8-H.G7UM/^87J;_*[!_$
MUDN@CGZ:WA,XT-R^-QOV-VEUQ3YIRM,\JY1B2MZD60LGLJ%GCL2<TK4TMT?9
M(3,HLU-QERQ"--5B*-7"-'?H.""P !#F#V"QQ;B1YVG6$:^/[X!IU8W&QP^8
MS5+' 9[SY'>'*(S5MACZY#)+\8"*&2J[$YF&%]1P)N=V@+A-$&X31]6KJY@3
M5CDZAK-@#'+9C=LS#K!'L^9)2-;B_.()5E[(.P6R"68S98-_=G<U*O?$\>1!
M,)3")2 L1;LR07N+I#M)X?>'7C5BNJ/&WN?'M5HDU[.JM4]7<UJ,M$2O)8GH
MW*,RP;#GZ3RT36=-C(UWMX=GQ6<819#9);MQ!"4$'0&P</',#_M,F6/Y9FK/
M[GL&T%Y?K;ME\D-"33+4EC=UK1C"8HL@YNR WHUAY)4RD,:<F.)P)&[$E#+
MH;HF!8ZJ@$F=H48J6E&W#8Q,4*P3EX%>"GCBR%Q38&RKLEK1C?8#+&SL4?<C
M36<3A,[+79C9)!(7I!$8K W A>@<8(6P1!$CL>I:S$RPYU&I/L?<%R E!Q_:
M[/[UQ(^H3;X-AF6O)<)PSONY:XNAJI2H$JENODFRZ#'D@CDH+3DF =%JB .(
M3!"N0: #NE)5%%]H25T!,CUD'\[DP_R1,,_NQRU07XYB],GQ<1SB%R-EJ"XO
MR 7LS&M*I%GZ,YQ?LSY"5OJS(\?PTIR:@;WR(IW9-B"\4=GU%9$K+(C!2@M
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M :2Y;P?K- M@KJB=@LDOR5P:9SEHV SAM#C.(IVI@2,2T3)'>^KG!0F<UYQ
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MOY1$&_BU*H.;WU8?\]EL/_!WKQ_$K#:#ZVU H% H% H% H% H% H% H% H%
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MH90;A-$9<8;AM>U_@M0;=H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M[(LAL'NZ\^^\OPGR%-7F'][\W>2\?]^\5\([QV?A9/8=IV?6,ZO7$%D- H%
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M@N(S!!^$8 7^"@G90*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!05L\J/\
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ME$GY&UR:*O'=3@F!)7)";G%W[0JXR[V'<)4T"@4"@4"@4"@4"@4"@4'NQO\
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M/.HRS%<<7JGUQBD0R P3W*1D+3K[G79&<4#W>E#S)):!IO8KO+=$%5S3[7.
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MZ97D6,&9Q96&-$J54AE3##<B0N;Y!AC*@1V$L=7.:8ZCCLTDHB0C-6F++$
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M*52,.=W[)J[';5*H]C6)07#,JEB)?([H97+<@2),2WQ2-"6+AC<%%A# ,18
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M(ER?S#-\,QJ*MG8,S,I.ZZQ<G +L^H&]QB"$08/R<;%\ZN+LK1^(<6^@&O\
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MX =>WTX(#0!,#8Y.[LBA.;8([7M8P@\H(P"_1",-KVZ+VM>@HXS'R5;!\?/
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M;WN98P(3XS]&YQ\1>4%/61\\;0Y284BQ2>GAP7G'L';%Z85RK(T,@=62$*Y
MK+(+[2YHV]4U&&F7+N&Y80# :%N^VG"AIOM=J)B31<E3E76S6?#4P3SB-8^U
MF?H7$27A[1MCXW)#)DNR!C[)ZN3]F?)%JXTX\7?%CF?=6J./." 80D_Q^:$X
M0XV=:H[JY@%9-GB#L$BELL427)+HPO4[DT@F+R<Z+W*2.47C$-CZ@Y"D[LW)
M>[-B6P$"$@([&&V,.,"/W*%P\:K<M#/B!LV/?LOP]=A)RERZ&R;"T@A,<D1B
M2<)6)/(F)X4S?'F14*QE5'1E"H"66F(.+/3VO8SJB&$0:*S'P!:E9VT0UPX]
ML@YGVP78<U<F3K,<:RY--\1%97/NY F!":-R5_4X.5Q9QC+"BFJA,@*3LJ12
M2G3IRQ'C"7?KA8!H'HSB7CFUEA^J>$9#D64X\A3Q,'MJ><J.T:>YFH5S63.4
MJ=2W!QB41@[&:G3N#H8!/8MN*$ FP;#$8*UQW"HS8#TN?';G;9F6[5M,_P!K
M=>\ARR<(\F6:-=,AXL@\/BV0DRM*['2^$HY!A*92"+O"Z2)KNH[IW*Q1#@8(
MQ, @/5 $.B>-M2QACK QN,B>I>X,S*U-2Z6R0MB*D4H6-R$A&ID3^5%V2-1D
MIZ>SR1*506YM;T 3S163IB"NH4$*A.3W@[U.Y8IOBV?;%9"V'ACQB.*O<0C:
M;"LLQM'6U:VO[N0]+#WLF<XER,J4KBU2>P2A$')B[%WO80!7^:H+4\1XU8L,
M8HQCAZ+JW9?&<48]A>-8ZN?ST:I]6L4%C;;%VA6]*6Y UMZAV4-[66-280E3
M$C.N*X"BPWL"P;"H*(>.+T].E_&#L(JV3P'D[9^73E9CV28U-:LOS3%+_$PL
M4H<8^YN"L"&&85@#Q9V)41PBQ)EU]R0@&9810[W#<(7O4%2G*3PU:P\M_N,_
M"/G>>85^#][S?)ON1D^/8WXG[UO=[YB\S>>\7Y)[[W+W;(>Y=U[EV?:G]KVW
M6+[()8P;2G#4)T?;N/P9LQE>!$FNSEJ^X&25\2%3F08P>8.NQZ[A=9%%6F,)
M") X1QQ.")6@1HK%G"ZY19=[6M8.;'(?HS]$7U\4N..-E-G\?-"DX9UH\\&X
MUG:= $=K7LE;7$R&QIR"E*%T]7O1BL[J_ (P5_AH+'N.GTZ/'UQTY":,V19O
MGV<\[1X2DV*9*S:\,SJ5 U*H!R8U=!(9&6*.19H=KHC+  X+"')S3"ZXDJE.
M$P0*#=_*!PIZC<KYT&?-@'C+L.G>,H^\1R#37%,L9VA4WMKRO)=E*-U8I3&9
M;''E&-R3@$/^YB55R[B 6H*O>P@A2[&_1B:2(9(4NE.U6S\ABI2JYPH\UI<6
MQQU4IPJ0&%)%,D,B#Z5U1)@W+-&4@*&.XNL"Y71T4'3UI_IAK=H=AAJP)JYC
M9MQKCMN7'O:Y,G4KG5[E,I6HT"%TF$PD3LH6.\CDSHF;$Y9JE0:*Q9!!1!(2
MDY)))85,<C'IN-!N0_*;WGMV4Y'U_P W2@(#IC+L,+(PEC\^=RR1D@D<WA,D
MCCRVKY$:'J=Y7-YS6I77+ZZD9QM[F4&OM#O2[<>NE64(SFZ1.62MG,H0AZ3R
M&#FY?4QM-CZ(OK8H*5L<B;L?1ED0$.DB9E1=CB#G9:Y)B5 2SR4Q)Y19E@Z2
MZ!0*!0*!0*!0*!0*!0*!0*#)XG_A$[_S(S_ATU!L&@4"@@-N7QTX3WCR7IGE
M3+,HRG'I#HWL-&-E<3(\=O<2:6:0SJ*/\5D;<TY$3R6$2U<[1(Y=$$P#B&U0
MT+!%#-L%4 0@" $[')M;GEN7M#N@1.K2ZHE3:Z-;DE(7-SDW+B#$JU O1*BS
M4RQ$L3&B+-*,"(!@!7"*U[7O:@I_XS^#W4#BDRCG?*6L,ISJX*\_(&UH?HGE
M"6P>21"(,S-(7:1-+5!28[C6'R)(D;S7<28 G1R=3A)2B[#,$;89HPU/R*>G
M'XV.2G*:K.>58[E'#^:7OP\,TR5KM+H["WC(0&I(:A0F35BF4)R+!W1U+2B+
M+,="FE.\*"DQ!1RLPHD +!(CC5X7M$>*E'(EFL4$D3ADB8M2=@EV;<K2 B9Y
M6?8\G-1J[1T+HA:8[&HVPJG-"6L5)&5J;"%JHLH:@)O=TUB0V\EXXL().1QR
MY/2Y3E46?'37\O7%1$1OD1OB $'+=$#N%U)8 P8,S#*[J6X ;GBD D?4N*W=
MNF]KV#^/)+QMX-Y1\&1/7[/\JRO$(;#LP1+-;8YX=?(A'Y,?*H:QRU@;&]>L
MFL%R"U&Q\]',E0CRBT12D1I95P'@"$81A8+0*#FAV#]*5QB[,9.V/S3DF2;4
M6RMLIF239J?9K'\JPMJ58_>YC)UTJDD:QRQ&XI6Q$$2<EK@85U9 W2!S)3]%
MBEH#+=I039XSN#'0+BH6O<LUTALQEV7Y$V*X^[9WS9)&Z:Y2O%U:^[@.+LQK
M%'H="(BT",L6!1=F9&]4XED$V7'*KDEW"&_>0'BXTIY-X3'X=MQB-/,U<,4J
M54"G[ ZKXCDR"#<#$PW=+&YDRF$KPLKV%(79:V*PJVQ2,LLX:>Z@A.<4%*6+
M/1Q<1>/I23():\;;YS:2BP '!LIYGB;1%E(@JTRBYQRO"6*L.S8)AA) B+V+
M>"P=D<.]@V-L686%R7)9Q3ZC<K>+8MC':AAEMC,?N[L^XWR)CB1)XMD?'SE(
M$*9N?Q1YU<FB1,*E ^)D"6ZM$Y-K@A/-1IC1$W,(*&$(LZ?^GHX[-/=;=G-4
MFADRGG'$>WJ2'HLWH<^S-E?G9Z(Q^HD:V%&,2['</QDGB3G%W&3'*T+@W$)W
M!,M(3J"SPG$ ,H(>8A](1Q#XLRF5DIY1;'9H:D;N)Y;,29>RM'%N+$!Q;D%R
M0(34,"QQC^9R!H;NH%/9([O;@0K36N!8%3UAW$%Q?'!QO8(XO,(S' 6O#]DI
M_@TTS),,VK1Y0=(<ZNS5))HRQ-A7L;"*#P;'[.AB3<@AJ2R-,-&:>3<1G6/&
M&X @"P&@Y5<Y^D&XUM@,V9ASS,LW[QMDOS;E/(.794VQG)6!$<;;Y)DF6N\R
M?$4?1NNM#RZ)&-(Z/)I:0M2L5GED! $PXT=KC$%LN7.)37',_&5&N*>437-B
M#7F+0;$./V^9,$C@B7,YS-A:31>5192LD+CC=T@YCFO<8DF X#!'2RC21F6)
M+(%<(P!2/_4J>++]_P W_P#NIZZ_^RJT%Z/%WQ8Z^\2V$YS@;7*8YDFL0G^4
MW#+KRY9LD$)D<D321RB41AIZ)L607'N-VLEC UPQ*8 LU&<?8\PT5SK@$
MLLH.:C=?TL7'UOAM'EW;;+V8=R(YD?-#TTODI9<;Y!PFT0E K9HNQ1-*6P-L
MGUZF#ZE3&-T?)&990Y*A7/$.]A!#<( A%G^I4\67[_F__P!U/77_ -E5H.O!
MM0DM;<@;$XC!D-R)*A(&=<(CA$I""TY8C1  6 1@@%VN*]@AM>_Z%K?H4&D]
MF=8L$[C84FFNNRF/D&4<-9");")="G%TD+&2Y^"O""0,Z@EZBCNPR1H7M3VU
MIU292B6)U!)Y(!@':]J#FFFGHRN)N4/ZEX8\@[JXX;CRR %12%Y?Q8N8$8BB
M[ ,.3*,AX'GLH$8I%\T.QSD:"PO[ ( _!078\>?$WHWQ?QB0,FIF)?+DCF9:
M<F>Y3ESVX37*<V3HSQ'H6]WE3N.X6MA1"ZEP-30G;&JYQ=E DPE0C#QA4YZI
M^;-T^U"P#QVPZ+,<YV3Y"-G\4XWP@TN85(U,,##9A'7>3Y22C0"&K;R6E6[-
MC&K4")-*+;) L,';JEBZ Z!]5M=8+J/K?A'67&I 2H3@_&L4QRR']WLE/=K1
MUJ(1N$B<";'*>AWE#J$]Q6BN89<:M48*XA7O>]PCZEXXL().1QRY/2Y3E46?
M'37\O7%1$1OD1OB $'+=$#N%U)8 P8,S#*[J6X ;GBD D?4N*W=NF]KV#^/)
M+QMX-Y1\&1/7[/\ *LKQ"&P[,$2S6V.>'7R(1^3'RJ&L<M8&QO7K)K!<@M1L
M?/1S)4(\HM$4I$:65<!X A&$8;!WIT1UOY&-?GO6K:*(K95CIU>FB4MRAE=U
M,>E40F+ %86R2^(OR4)@VI^;TSBJ3]899R<](K/3GE&D'&%B"N'CO].]HQQH
M/^:97@J:;)RZ49TPW*<$2I]RW/( ^J&K'\P6L3D[I8TAAN*($RI7.SC'$QQ2
ME6E6C *P@WM<L74H+">/;0W$/&OJY#-2<&2/)$KQQ!GJ9/C2]98>(P^S90KG
M$H<Y8[%N+E#X?!&(U,G<74P">Q3:2(! 0V&(P5KCN&)XZXV\&XRY%L^\FS#*
MLKJ\\[%X?C.%)M$G=\B!^(FN*Q5'B]$WN$584<%03)#(#BL3-USC5;^N3"$<
MIZI +#*L2$4.2CT_W'ARCSA+EK.D7R%CK-1;8W,CKF/ DH8X5-I8SLX$B=G1
M3)-*(C.X7)SFAM261)EJMH,<B4'53A46))3 )#)^-3@FX^N+!Y<ISKQ"9C+\
MQN[0LCJS.6;),AFV2B(XN5"5*F-B\%8(A!XBD56ZA2@UG9$"M:04 M4<>$/1
M024G?'3A/(/(?A3DO>I1E-+G; ^$Y%@:(1-K>XD3B5QB$F-R"<O<I(Q*X0MF
M*R2$BR0N[$Y*_(TH;%$=9./JF=J$ILYXBC>P&$\PX&F2U\;(AFW%F0<12IRC
M*E CDC?&\DQ)WAKXMCZQU;7EK2/B1K>33$ABE&K(+/" 1A)H+7 ((LX;XZ<)
MX/X\#.-")RC*;A@DW">5\#"EDA>XDKRU:(9A*FA,F<K/K;"&F'>9$(9TK[@=
MX#W4JY9/:ISNJ/M VGI1J-C?0_5S$6I.(7N;R/'&%V5V8XL]9(<F%WFR](\R
MA]EBHQ_<HQ&H>Q*E);C(#@%W3MJ4-B @M<(A6$,0:9UWXU,%:S[G;>;S025Y
M9=LM;I>5O>E'I:^P]?CI@\HA !M\@-+-!&&2M?;V!;M_$7=UZW^]ZE!890*!
M0*"/.V6M4%W&UMS-JYDUVEK% ,Y09VQ_+'B"+V=LF+<S/(2PJE,=<) PR=E2
M.9=B[=F-2WJRK?[I8J#]NKFO$*U)UTPMK)CATE#U \$XYB^,8B[S9:TN4N<6
M")MI+4W*Y&O8F2-LRMW.3D6N>8E0(R1#O>X2@6^"@CGHIQMX-X^'G:1\PS*L
MKR97MOGF1;#Y'+R<^1!Z3LDUDRIR6+VN$ BL%A9K;%RC70RQ)"\;DK"&P>LI
M%>U[W!-^-O!L]Y(,/<H+Q*LKIL^X2P,YZ\16(-KY$"</N$*=EF4EJATD# J@
MJR:*Y0 W+CE8!Z:0)$E@D)NE->X#;G!'_DOX,= N55Q8Y?L9#9C%,NQQH)CC
M5G'"LD;H5DZ\9(7 7DQUZ.>H]+X;+FQ*;V@4OC#,X'MX%!]D9B?MC+B#".-W
MT^?'1Q@SP67\(Q3(62<V$('%J8\Q9]E;--9G$&QX+5I7=/#D,7BD#@T;5N;:
ML$B.7IF<#F-#UT_>>R/4A."6&Q'&I@K9C<[4/>:=RO++3EK2WS3[K8]$GV'H
M,=/_ )N",#EY_:7F"/TE=.PL._8>'.[5U?\ ?=>@S'>KCLU"Y(<6(\2;<XD;
M,CL+&O4.\-?R%KA&YYC]Z5E$$JW2$39B4(G]B$X 2$66I0FC;W(*<H*Q.H 4
M (0H=@7HV^(^'S-/*)#)-O\ *C(2I$>9CF>YEA#=#%90E9*FR-0NQAB#'&0@
MI@$EB3VN4_%'=B8*]QW-L$P(7M;;<<.G6[^N;'JQL;B%!-<2P](Q$X^(+>'U
MKEV.%L8:0,<?>H1.D;B"5-#NWM1=DYI@E1Q;BGN,A<!408:4,*/,3^CSXD<9
MY"13M[==L,Q-S>K+6I<=Y-S'$T4( I(=43FE&,_$^+,73PX*8",24(!O@@#3
MGF=I89W9FEA9IR?<)NCW+.5"G+9=ER!&LC8\;C6&(YCPU)VF)9(;HHI=;/*N
M(K#I+&)M$'^.FN(CC2BG)G6&(3%2D:,Q.-0<(80 :_25<3K%B.+XT84^PC3*
MXWEV(9=4[ %Y"@[CG*2&0MID3:V8[='9\Q8ZP!FQFO4R,2]Q0,4=9U;@O1(C
M3U0PI"@!"V7?OC4P5R,?@W^^V5Y9BWX+V<V#8" >ZM]A[)XO,HYV7<6R8>;8
M)./$(R;V-NU)1>'JA?#U5 :"0&U6I.NN[>&)%K_M%BR.Y<Q5)3$ZQ5'GX*M,
MJ:WE$!04VR6*R%I4M\BB$K:RU9P$SFV*DJTDLXTNQG9FF@&'."5Z-'B6+FUY
M4.:[F'L5W$Y;;&IN8<<6A(4QI8P 9[+R,(DY&\.3B'88!7D%U=Q!MUSQ!Z;7
M#IJP#@;%6K^&<=:^X/C H9B7$\;2Q*!Q8;Y(9(-D840S32$8GV5NKY(G,033
MQBN:K5GFWN+HZW1:UK!N"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@@-
MR1<=.$^436T[5S/THRG$( ?.8KD ;QAY[B3!,;/,0"YA;4P7":0C(#+9L/LZ
MF=N"[?<T75#U# =%^D*U./;TS>B'&OM'#-ML&99VWE>1X,RS)C:67+$[PX^P
ME0DG$7<XF[&.+;#\"P1]-4IVYU,&GN4Y$A >$-QA,#:X+A97C?CIPGB[D%V'
MY)&"49369RV7Q9"L13N*O#W$E&*&F-P1L@+4T+8DQHH0WR] ^*4^.D(E)BQ]
M7D#&:?<!)=A%V*#S-^^-3!7(Q^#?[[97EF+?@O9S8-@(![JWV'LGB\RCG9=Q
M;)AYM@DX\0C)O8V[4E%X>J%\/54!H/[[G\;>#=Y\N:4YFRU*LKQV4:(9Y9]A
M\1(,=/D0:6"1S5DDT#E25KR.EDL%ESB[Q<QQQXB 80V*F=7<DT^UE(1"+&6&
MTMYM.,8\@.JN6M0<R/L\C6-<R(HNAD[YC)SC[-.4!,3G,8G[<)A<I5%YFP)3
M#GF*)RC[J&Q58289@0V .X3 !AF1..K5W,>C,4X\\RQ%QRIKS#L38QQ&T%RI
MT"FG!:'$,=8X]!IF5*XLCC@FG(#8&/IU0ES<0B),/N:7=/W0XU,(*7<(>D.X
MC,.3<^:O2/8K.X0B..9XAF_)D1=80PJAD.!2=20QP#&..C9 %$:M+- F?#W9
M&:-(58\DTNYX#@M0U?XHM=]3./?('&QCF9YH>L&9(B6<(:^2N:R*#N.6$K9G
MUI>V>8GM3ZQ8ZC</(7MJ9^.$V".8CRR3 @N>!1:P@B"26E&HV-]#]7,1:DXA
M>YO(\<87979CBSUDAR87>;+TCS*'V6*C']RC$:A[$J4EN,@. 7=.VI0V(""U
MPB%80Q!J#4?C;P;IEL7O'LWB^597?IYO[D:*Y.S&T3U\B#I$8T_Q%RR6ZMJ3
M&:"/06+/+,T'J,J.%CRW1>\G" 2GL$T%P&W.!G?C;P;L+N[J7OO-)5E=LS!I
MLV3-JQC&XN^1!%C5]3SEO=FUV'/&=V@KU*',Y.0\&W3W;WEK" 80W'8RUKV$
M'[,;\=.$\7<@NP_)(P2C*:S.6R^+(5B*=Q5X>XDHQ0TQN"-D!:FA;$F-%"&^
M7H'Q2GQTA$I,6/J\@8S3[@)+L(NQ0?CW/XV\&[SY<TIS-EJ597CLHT0SRS[#
MXB08Z?(@TL$CFK))H'*DK7D=+)8++G%WBYCCCQ$ PAL5,ZNY)I]K*0B$6,L-
M\[<ZQ0+<_6K,FK.47>7L./LX0Q;!I8\0%>S-<R;VE>>F/.41YPD+!*61(XA&
ME#8(U+<K*M:]^DN_P= 15GG$=IEEOC]Q7QM9DBDFROK]AB(06+X]>)7("$.5
M6%QQRTFLL5G:":0UJBB=MFZ9O4'DGGHT*9$L3JE"8]*8D/.(&%5>%?2&\1^'
MSI4M=R-C,X.;_&9!'F-=FK)$(>"<?JY PN;#>616/P?%4 B3I)F8#G=6WBD3
M>_(4J\@D^R:XB[4%V.IV@N!]1=(XEQ_Q6TKR=K]%X9D;'RI)F19'I'(IC$,J
M228R29,DR4Q>,0N/N2)Q%.5R+J$-J4-T-P '88[",&%/^ _2F\8>MFU6.ML<
M9/VTB>2XER5&<K8ZQH]96B+MBR,RF'/C;(HX$LLS%Q62G=L;G-K +L7"2JQ'
M!&()HQVZO5"4O)1Z?[CPY1YPERUG2+Y"QUFHML;F1US'@24,<*FTL9V<"1.S
MHIDFE$1G<+DYS0VI+(DRU6T&.1*#JIPJ+$DI@$AD_&IP3<?7%@\N4YUXA,QE
M^8W=H61U9G+-DF0S;)1$<7*A*E3&Q>"L$0@\12*K=0I0:SLB!6M(* 6J./"'
MHH)')>.+""3D<<N3TN4Y5%GQTU_+UQ41$;Y$;X@!!RW1 [A=26 ,&#,PRNZE
MN &YXI )'U+BMW;IO:]@G_0<?V#L68TY+/4][%[:QZ'L)F'N+'&40P>KF21*
MH.)RMMD1:8L"1R<C+J!M:UQQ:)SD:$)Y8KF)3(HSCN5^O , '8#0*" &NG'%
MA#6/;W<;=.!2G*KOE+=U;!UV5F"7/D17P"/G0%,O2LX<>M3-!F"1-):DMQ'=
M39R=7:XQ6#U+EVM>UP:Z<<6$-8]O=QMTX%*<JN^4MW5L'7968)<^1%? (^=
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M?=>?N-W?M1_F7W/C[K'>N<YU6F@90*!0="/'I_FR1K_G%+_\=J*J?FWW:O\
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MM=\"2C*<NA3[E.89=5NF7GN)/\I+DDV1L*)U1)EL,A$ :0,:<J.D73EB0C/
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MCJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K'
M\)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]C
MJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \
M)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ
M3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)
ME7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3
MXY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E
M7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3X
MY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \*E7M:3]CJ3XY0Z#PF5>U
MI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"
ML<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI
M/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L
M<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/
MV.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<
M#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V
M.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<&
MI<3ZW8UP(DE"#!<#Q!A=!-Y,LFLT18GPO!,=))?,G$HHEPELH30]&SDO\F7$
MD  <O5A-5&A &PC+VM:A6.#;7A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A
M,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2
M?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,
MJ]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?
M'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J
M]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'
M*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]
MK2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*
M%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K
M2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%8X'A,J]K2?L=2?'*%
M8X,IM877%>XND%PAL$'5_L16N.XA=;IZ;]>U[6Z/]SJ__#H_C_5 H% H%!7W
MR4KHRWZ]-RB6Q]QDK1;),; )K:Y ",JA*!,\F[ ^SH-F?@A 3>U^L#N]^OT_
MV0:DW*=N:[<YC!=%E_@;NF;>M'DV^56.^\/F"[';H8G+;-UGA(Z(FGE3Y=)[
MRA?S7@C]YN;?=F3_ 'KZLCP.Y>?X_O7_ *B%^%T7G-_WS_D/->"/WFYM]V9/
M]Z^G@=R\_P ?WK_U#PNB\YO^^?\ (>:\$?O-S;[LR?[U]/ [EY_C^]?^H>%T
M7G-_WS_D/->"/WFYM]V9/]Z^G@=R\_Q_>O\ U#PNB\YO^^?\B[G2(]I=-?H\
MJAK>MB3'=[DX"6=S<RI4L+/ \J+*#S'CPUAL:$\R_2$%DP+%AZ+=(K](KUCS
M/;FMW>^,UT7Y.I;TQ;U8\CA6>^G.Q78KMNMG%;-MG6NZ)FOE\:1WDM^ZNGU5
M!\GE?3JC[V*QP.ZNGU5!\GE?3J%8X'=73ZJ@^3ROIU"L<#NKI]50?)Y7TZA6
M.!W5T^JH/D\KZ=0K' [JZ?54'R>5].H5C@=U=/JJ#Y/*^G4*QP.ZNGU5!\GE
M?3J%8X'=73ZJ@^3ROIU"L<#NKI]50?)Y7TZA6.!W5T^JH/D\KZ=0K' [JZ?5
M4'R>5].H5C@=U=/JJ#Y/*^G4*QP.ZNGU5!\GE?3J%8X'=73ZJ@^3ROIU"L<#
MNKI]50?)Y7TZA6.!W5T^JH/D\KZ=0K' [JZ?54'R>5].H5C@=U=/JJ#Y/*^G
M4*QP.ZNGU5!\GE?3J%8X'=73ZJ@^3ROIU"L<#NKI]50?)Y7TZA6.!W5T^JH/
MD\KZ=0K' [JZ?54'R>5].H5C@=U=/JJ#Y/*^G4*QP.ZNGU5!\GE?3J%8X'=7
M3ZJ@^3ROIU"L<#NKI]50?)Y7TZA6.!W5T^JH/D\KZ=0K' [JZ?54'R>5].H5
MC@=U=/JJ#Y/*^G4*QP.ZNGU5!\GE?3J%8X'=73ZJ@^3ROIU"L<#NKI]50?)Y
M7TZA6.!W5T^JH/D\KZ=0K' [JZ?54'R>5].H5C@=U=/JJ#Y/*^G4*QP.ZNGU
M5!\GE?3J%8X'=73ZJ@^3ROIU"L<'K,:)Z,<20IWPM.;<)O5-NU$'6#:Q0KBM
MV8E ;7ZUO@_1^"AT,[\)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]
MCJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K'
M\)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]C
MJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \
M)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ
M3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)
ME7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3
MXY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E
M7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3X
MY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7
MM:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY
M0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M
M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0
MK' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:
M3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K
M' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3
M]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K'
M \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]
MCJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K'
M\)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]C
MJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \
M)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ
M3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)
ME7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3
MXY0K' \)E7M:3]CJ3XY0K' \)E7M:3]CJ3XY0K' \*E7M:3]CJ3XY0Z#PF5>
MUI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE
M"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>U
MI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"
ML<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI
M/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L
M<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/
MV.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<
M#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V
M.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#
MPF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.
MI/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#P
MF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I
M/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF
M5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/
MCE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5
M>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/CE"L<#PF5>UI/V.I/C
ME"L<#PF5>UI/V.I/CE"L<'IMB-X3&&B<GH#H 0+6*+ V$H.R':_3<=QE'FW,
MZ;?!T7Z.B@]BC^%!6_R]_P VCN/_  /N/^-FBM&^*+\I3D[WXL^PR)_V6_Q"
MVGV7'>N?,AK],CH@4"@4'0)Z;G_/TG?\F'('\8V(*YX?.9?)^T'[4Z3\3W!0
M_C$?$7![Y8O0L[N2K@ZQ04"@J@Y*>9S2/BU0,[?L%+)!),K2AKL]Q/!>+&I#
M)<FNS$8<M1$R9Q3.CLP1R*1<UR0&IP+'1P2B5&%&V2%*1$'! %!J#UIFLACP
M<0YZ4YW1Q\(D5D[F@R%C]Q>#0&7_ .4A',:A*UHB!)+?]XL%Q,LH_P!]<F@Z
M7>.GD:UYY/\  CAL1K:5/D4.9)\Z8PD3-DN-(XO+(_-V6,1"7N3.M1M3W)61
M8%.R3EN'WE"X+$HQF" $RX@"Z A_RM<Z>L?$O-<28ZR_C_*F49IEF+R":I63
M%H(<(V+1=F=DK$WNLC'+)/'K@+DSMWTE#9.$^PKM:GM+E] +#"0/%MRF8(Y7
ML)S+,^$8[-(,#'^15>.)9!LB^72Y<UK@,3+(FM[N3&GM]0F1]_0O%P)#^U#<
M:A$J+ZMKDWO<//Y4N5+$'$[B#'68\QXZR1DADR1DBV,VMKQG:,7=4#K>,/LI
M\0</-+ZPI/#^Z,)A?ZV8,SM!A^9ZO3>P45_USS1C\5;;']3A_P"^/07&<:W.
M;HERBOKO <%OTY@>8F-G/D*K#6:6!GBLW<V!$<%.XOD541Z2R^)RMO;S!@$>
M6C<AKTQ!@33TQ(+WN$+BZ#F<W=]4OH;I?L=.M;;0/,>>W_&9Q#+-YCB#R IA
M#5-0=K=\A25TD4P9CG9VBHK%IW$P@H2=.O[5+U[G)S;!#H;PWDQJS3B#%68V
M) X-3'EG&\&R8S-;MW;Q5M:IY&&N4MR!S[F<I2>((TCJ L[LC#"^T#?JB$'H
MO<-2;F;A80T0UUR'LUL!) L$!@#;<TM$F$F-DDSDRP)A<<@<*;%*A+9YE\I7
MAL0E(ZX"BP]=0H,)2D'GE!4SQD^HAUFY1=CUFM.),(9UQ[*D>-Y/DP;_ )%#
M +1\;5%G..-:QO#>,R]\<?$%!LD*$7TD]GU2Q]85K]'2'030<Z'(;ZF#1WCW
MV*>M97N'96SO/H:VHS<B+<-^1E<;@<F6B-,O WASDLL8KJ9>V(+%'KR$H#BD
M(E $YI@50%!!(79:K[!QK;#7#"6RT-9'R-Q7.6-XMDR/L$FL@M(&AJE;80Z(
MV]XLU*U[=X@F*/L$SL#C2^M;YD5[4'+_ "7UD.D$8D;_ !M7JYM6H51Y[=6-
M2>G#B+NYZAI7'H#CB.UR( SL3#$]Q!ZP;"ZM[=-K7H,NPUZO'2W-.7\58<8M
M9MH6E[RSDB#8S9G1V#BCPIM=9Y)VN+-[@Y]SR"I5^'HU;J P[LBS#.S#?JA$
M+HM<+C.5+E2Q!Q.X@QUF/,>.LD9(9,D9(MC-K:\9VC%W5 ZWC#[*?$'#S2^L
M*3P_NC"87^MF#,[08?F>KTWL%%?]<\T8_%6VQ_4X?^^/073<4',%A/EPCF:9
M)AC&&4L:)<(O<*8W\C)]HE90[*)NAD:] <T>5)"_E]BD+C9H3NV$4+K& ZMA
M6Z>@*X][?5;:+:C96E.%,60/(.U\T@KHO89C(8$\1R*8H;9"VJ"TK@PM,\=K
MO"V4+&Q2$\I2H0-)S;8TJP251_2.Y8;8XV/4P:1<A65H]K\XQB>ZV9QF:@EO
M@4:R0I9'R&3Y[&A$J'&HOD!B-))!)##B#2TJ1T0-EW 79%I1&J3K)@AT:T"@
M4"@4"@4"@4"@4"@4"@4&3Q/_  B=_P"9&?\ #IJ#8- H% H.8C5KU+>.=F^3
MD.@J;6)WAN*95F#.^$,.;=*<M&/48RM.<'MRAS.2-T"#B9I1-I,K3EI[I^SD
MRXU-XHW=J#^ZPV '3O0*!05YZ[\E>"MF-SMO-&8)%,LM.6M+?*WO2D,M8H>@
MQT_^;@@&V^0'9FG;])73L+#MV_B+0U=7_>]>@_'R#;HYZT\_!Q]QNC67MUO?
M5F9LQG/O=0=,R?<7$UW<^\93E_E#$65^O'4'>1]>RWP=-^M7Z58?AZ L8H%!
M1_RC\]6H?&#,(KA*0,60MBMIYN%D4,&NF#D+>[2IK;Y JL2RN$Y=ERHI'&12
M  1V:VY.2Y/B\P9 PH0HS[+ !5X+U1&TF*B+3;<+@/WYUMP<E""[QE80,B/1
M#:/YE<<&R7*&M.!8@8$N.I%ZVUS9$GN+NE@WL$H1AY 6:;K<XV,=:N+3&/*?
MAG#3]L!C#+DF@S)$(')YA[D)!X=,ELF;C7)W<[0S*04"UE71@XL24*,X!_6Z
MP#[!M:X@K$-]33OU$T9<NR]Z=#?+'&*D/=%,IR$:XYH5(V%I6FDIDKB7:3Z7
M0:.*N\JU1)105#PA*,$:&UC>M<(1!=QQ@<Q.FG+%!WU_UPDKXQY A!*0[(V#
M<E(VQ@RI#$RL8$Z=]$V-CN]-4DARQ8+L279L5JDX3! *4V3*!V(H-"<FW-$_
MZ%YTC&K>%>/O;#>[8*58?8\T(8Y@J/+5$-0QN2RK)$696MXD43C64)LCD QX
MC?EIY0(N:06A3EF%G&]*@*4(/:Y>I_;G/8_&VM7(IQT[+\9DFS0[H(]BN3Y@
M,E3S&71X=W%M:&@4H(G6',%RB/1]>[N $@G1&W.Z)&>:2)6-.G&:H3A=QR-\
MCVMO%[KJX[&[*.[T%D,>DL1@T'B"!.[3W)DY<$:YP11.(MJU:V-ME-FUL4JU
M2M<J2(4:5.,1AMAW*+-#G<4>JRS1C\ELROL/PA;OX4T\='Q*F3;++E<N5)%$
M=>%QA4;=T+5--?L9XS7N[VW%W. @+G/8W.L(HE6>&W:W#JQUUV#Q)M;@_&>Q
M>"):DG.),N1=%+H3)4A*A+=8VJAFIU"1>WK"R5S0^,KFF/0N*%266I0KTQR<
MX #2QAL&Z*!0*!0*#F*:?4L8Z<^5]/QTBUB=2,-.&S,@U':-T 9=N?&G3-T>
M84J55&$V-_=04UF&>]9P21T5@3 PT"162Y]2X1V24'1KEB5N,$Q9DN<-!*)2
M[0W'\RE;6G<BSSFX]QCL<<G=$2O*2J$:DU$:I1A":$LXH8@7O8(PWZ!6"M;A
M%WRR]R4<>&*MMLYQS&\4R/.97E1C=F7$[/)V*$ITD'R$_P 3:3&YMF$PG;Z4
MI4-S46-1<UR.",\0K@"6&]@6"VF@4% ?-ESAN_$!(M;(VQZB+]J5^PD?S=)!
M%-N9CL5*H<VX11P=T>E-T:?#N5C'](>S2U0L4&]*(*!.W#&+M CN(H+9=.-J
M<9;N:P84VJQ N"K@>:8,U2U ENH I6QQV'8Q!*X4\FEEDEWD$%E:):SN'5#8
M'?$1G4Z0=45PB5H=R6?AM;1\D.MGN6]V7YOG-T<PWYT]XWG/WN>8%^34/F/R
MYY#BGD'NGNYZW<^_O7:=\Z.W#V72:%IE H% H*^L=<DF#<F\BV?>,EABN5TF
M>==,/QG-<VEKNQQ C$3I%94CQ>M;V^*OR.=+YDND!)666ZQQ2M@0I@B)4]4\
M=@%7."P6@4'.9OKZD?6+5//+AJ!K=A/-'(/MXUKU[ [XCUS;AK&&.S1$%4EO
MC]\F"!IES^OFI+UW9,L1Q^.O]FWM#RU0RER>Z$P(7F^J;SOAH09%O)P8;\ZI
MXLN&QHI\:FF+\*R=,K1D/)X4.7L"ZXQT06TIP(O;_ENP1FGEECN3881W#J5U
MLV#QQM=@7%&R&(5;JNQGF:&-,[A2I]:CF-Y,8WDJYB7Q-I4"&:@6EW"()A=Q
M"M85O@$*W1>X;NH% H% H% H% H(F;S;CXQX_M5<M;?9D8IY)<:X;11==)V/
M&39'WF<KR99.8Q &X+"VRJ40Q@5&$O,K3FGV4.:6P4P#!!N,=@EC#<&#,NQO
M8#">'L\PU$^-D0S;BS'V78JVR9,@1R1OC>28DT3)C12!&U.3RUI'Q(UO)1:L
MM,L5D%GA&$LXT%K#$$,]*=UL^[09]WJQ%EW17,&J$)U0S 3CC#.9LCG30V*[
M?Q4V:9?C \G8Q!)\08X:"H^4T8X:G6]FIUDZ;NTG2?W78%B3E86/T"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@@-R1;<YLTGUM.S
M;@'33*>]L_*G,5B@,$8>-EI,Q-9G\+G=REX1PO%F8'KPR.W0EV/M9GN5_= >
MN<5\'6"GCB1]0QG?E2S^PXX;^*O+>'<$J5>0&"8[7H\J3'*N)<>SJ#0BTR+@
M$E>2-8H'#D$M>0KFX@*%5($BPFSFF,L29VI0# Z@*!05&\QG*)?B^U^@4OA6
M)5N?]B,_99CF#-=,*(EJUN!,)[(@F&F+756VH'%S,:F<@)90$:,H2UR<UJ)&
M6(@!YJM,%1<HY1O4):Q:/;M[:[YZ(Z?8)+PIBS$<HU^4-"Y1)F66SB;YVQOC
MV1QW(L0ANX^1YL0D20:9*EB>W:, TS@G $XPWYI/<.ES3_+LDV U+U=SS,D3
M&V2_-NNN$LNRIMC*9>CC;?),DXTC,R?$4?1NKD\NB1C2.CR:6D+4K%9Y9 0!
M,.-':XQ!(J@4"@4"@4"@4"@4$>=LME8+ISK;F;:/)K3+7V 8-@SMD"6,\$0,
M[G,7%F9@EB5)HZWR!^C#*K<S+&6[,"EP2%7_ -TP- U-V5@NXVMN&=H\9-,M
M8H!G*#-.0(FSSM SMDQ;F9Y"8)*FD3?'WZ3LJ1S+L7?M )G!65;_ '#!4$AJ
M!0*!0*!0*"N?7'='/6:MT]N=8I]HUE[!>(]=?!_==M9+SIF/'.R_B2D@A7Y!
M*>L11",E^%EFW,,\.D;_ /,@OT]2WPV"QB@4"@J6YNM\LO<:_'AE7;;!D<QO
M*\CP:5XK8VEERPSR=]A*A).,A,$3=C'%MA\P@CZ:I3MSJ8-/<IR)" \(;C"8
M&UP7!NSR$;(:JZ0Z\[/8/T.RCOWE#+KKB5IE>$, 7GB%VB#3/L1RO(3[D<)<
M0Q3GB0E1!@D,=2-%@*4(2@FO*>QBZQM@%J MIH% H%!7GOWR5X*XY_P;_?;%
M,LRG\*'.;!K_  #W5L4/>_")E(^R[BYS#S;.X/X?&2NVMVIR+Q!4'X>JG%03
M?GTA<XC!9I*V2-KYF\QB)2.0M$/:KJ+.<K<V5G6.2"-MUTB!U5V7OJM,!*3V
M2529VAMNJ49?H!<(@<<^V&9]T=9F?.6>M/LGZ-9"<I;+8\KP'ETV5G3-K;(Z
MO+2-<D4#F>,<1/ET$E)'<Y/UF8LOJV^8--M\U03LH% H% H% H% H% H% H%
M H% H% H% H% H% H*V>5'_-E0?PH17_ !1**E?)ONO/W&[OVH_S+[GQ]UCO
M7.<ZK30,H% H.A'CT_S9(U_SBE_^.U%5/S;[M7^8L[RP>7O<RWS5W?3>J,O;
M*!0<S6\?JH>/+4')DAPW!FC).U,]A[HK9)>X8B#&D.+V!Z;C+D.+);(LC=TX
M)&Z(E/ZV8-F0.3>$8#"Q*PFEB+H(F8G]9GI1)79L;LP:P;%XK1+1 )6OT8<(
M#E%L9S3#A@LH6)QNT$>E#:43U1F#3)#U-KWN$"<SHM<0=?$2D[/-XK&9G'CS
M%3!+H^S2=C4G$')35#._MR9U;#S4J@ #TQAR)6 0BQAL,%[]%[6O:]!RFY#]
M8)H) <L3;&P,&;*RIGA>09#"+Y%CJ7&!\9D*&.R%6PF3*/IE&0"'93'W0E'=
M:C"824I-2C!UBP&7N"P=7S&]M$F96>1Q]R1O+#(&MO>V1W;CRU3>ZM#JD)7M
MKDA4E7$4H1KD1X#2C WN$8!6O;X+T'.YR)>I1U9XX-J)IJ?E# V?YW,80R0M
M\7R2!!QU>,JT\WBS9*T!*/S#,V9T[9(C= %G==.$/:AOU;B#T7N$,V7UFN@"
MIT1IW[6C;UG:3C! 6.:!HPX]*D8;EC[(X#89EEILJ+L?U;&6L>$82[B$$(Q!
ML6(.ES3G='7+?7"3-L#K!D%+D#';JN5LJPVZ):SO\7D[:4E.=HE+XZYDIW./
MR)L*6DF#)-!U#4YY2@@9J<XDX8;?S#E_&N <73O-&8I@SP'&&-(VY2R:RY^4
M=W;65D:R;FGFBL$(U"M8I,N$A*E( :J6*C2R""S#C  $'/'I9ZH74+>/;/%&
MI.-,";%QR3Y@D;['XU+YDGQNFC27P2-2"4]^=B&B<NKP02L;X^,(0%D&C"88
M&PK=%KWL%@?*AS#ZR\2<8Q8[Y_C.5YM(,VBGQ.,XEBM@87-4YFXX+AUY,H?7
MB3R:,,\?;49D]; ]?M%"DRQP[E)S>S':P4!M7K4-<SI'W5[T?S6WQ+M@A\;:
MLH05XD?=[FDV&;Y65LK$V=L$@1@K%^,=6XPA#U[6%<0 ZA]"^0+6?DAP8FS]
MK!+'!]BQ3P?&)5'9*U"CTYQ_+TB)"Y*XI,V&ZA:0C="4#FG. <D4K6]44;8:
M92<'IO8*?N1+U0>C6BF6)+@2(Q2=;29<@KDO8\@I,;.#"P8\A$D;B^HLB;MD
M)Z&LLYR=O7BLG7$-3<X$MYQ9Y"@XM60-+0>/Q^>J9T:W7RW$<"SN$9#U;RAD
M-[;8S #)\O895C64RAX,[JU18N?,@F]2R/SPXB F1!<FI&C5*#2R0J.W, 4(
M.F^@J6Y3^9'5?B;C&/EV;B)5/I_D]R4%1'$&,KQY7/3HRW%G6>)XZ$2!Z9&Y
MFB#>O"6B >>>$U:M.N6F+-L0K$G#)N*WE2Q!RQ8@R+F/#F.LD8W9,;Y(OC-T
M:\F6C%G5>ZVC#%*?$&_RL^OR3P_NC\67^N& ,[0 OF>KT7N%:V[WJB=2M%MJ
M,P:GY!U[V+F$QPT]-#&^22&AQIY9=5#Q%F&5DG-/C<X:W3L2D;^66+MB"Q=H
M 71:X>B]PBI_7/-&/Q5ML?U.'_OCT'34_;G8(@.GS)N_E^5I\18,<</0G,SF
M[S$8+KF)CGL>9GYB83431=Q.>98M.?4[>F;VZRI0O<3 $)0FC,!80<N<]]9_
MJ:S3=6T8\U#SO.H&E<E20N:O<PA$&=W%"GN LEV;H:$B4V[%<.PQ%E*G)(<$
MGJ"," P0RBPZ$>-CE:U*Y3L<2&<:V2!^1R&"'-"3)F*)^V)6'(^/U3ZG4'-!
M[JW(7%W:71A>!(5($;DW+%:,XQ,:7<8#BS"@!910*!0*!0*!0*!0*!0*!0>[
M&_\ "R?_ -H/_P"!'0;+H% H%!S$9V]2WCG"7*5^;V'K$[R;$S%GW#FM>2-Q
M"<M&-T6@.4LNMA1Y32LQZ5B9V3*PQEXLL1J0FR=&>:%H<3P%]1+<(PZ=Z!0*
M"O/\Y7@K\Y'^:Z\J99]__N,_" \W^!0_W/>3>T[/PSS!Y[\Z^9NM_P"!\O\
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MZROWLLJ\4\@-BK3R:H&[PP%[6/["+QKK='P]K0=!6]NU?*SQ]Z[\,\$S%L_
MY)M1G#?**8/W R3C+'>,7J#99Q]+LC.JEOC["CE6#H:GBY9./W)M0GK&>/L#
M@%2G,$ X8K]X-#HVSEM7J]K 3&E&RNR.!->2)H8[$PX_.68<>8E)EAS %N&^
ME1HR?2*/@?3&4#PDNK"EN;=-943<SJ]H#K!C>%-W=+]E)4X0773;O6#/TV:8
M^JECI#L*9]Q3E25-L50N+4SKI*X1Z"RQ]=T<?1N[ZA2FK3"0IBU*P@H0[#.+
M"(.5OTMF-H[MGF_DJY;LQMY,RV'R+MA-<60=]D9"1S68LC!K,WS:1(88<>4:
M<QB<X]/&A@"(@8>[,C,!$1<"<U06:':'0<HWJVXA$X'PNFQ:#Q>.PR,-VSN'
MSF^.11D;8ZPH3G59/7=S-1M#0F1MZ4QQ=EYZH\0"PW.4'&&#Z1C$*X=2\0_]
M:<7_ .;K)_BU-0<:_+-BF&<='/9P];NZX,B+&[INUF9VUWV4B<&1)(^R3\+O
M-L6P&03)[:4_4:G5^ED>SB$U?UB2@G.,;1+A"[^,:J@[!,PY.8,)8CREF:5)
M'=PB^(\<S?)TD01].B5OZU@@49<Y4\)&1*Y.#2W*7=2W-)@$Q9ZI,2,X0;#-
M+#>X[!PJ;&;_ ."?5![*:>:7890L>K.#L19U:\WS?*&TV1L20;8C)PVMDLS'
MX:UYQ!&)S*W5]DDC1/"X=^YN:TLRZ1.M."19 (@X+A_4^ZRO^1=6]?\ ;^*Y
M%PW%7_CUSRS[ )X'GR5M<-QQF9/WIA,#CTMV?W!#'5DU=WF-(4S6VK+EA=2E
M2I(6<4:: )H0PVH]2SA[*6CF1M?\QZ5[&:S[<[389=L00K$^T\19\<Z_N#EF
MF'$Q_P!XIV<<F.,&:%6%8FV3-*[J7)S;&<T]*81U2@$GV5@#H%X<M.#=".-?
M5?6%9.6/)+M#H4ZRJ03.*.A;U#7B1Y9E\BRT_>1W@DE,4\0I Z38U,U+;%EW
M7(22U(@V$:*U!9I0</T*W^]1%MSO3RB:;Z+O>$7*#X-VWR1CB/[&YXA^.6&-
MZH8\:)GD6+PJ)1\J-PDQ=/Y$[)VLM590]L,\76+:+7,3V :<,X-?CY1/4F:(
M[C%<9.>8'K?R"[8[)X_2335*9,B.-P2(H07O)3763770N(Z\LLCA$7:<?2(Q
MX;']!'7-&:B"M\2"@L I:&6[+[D^I5X@5&(-T.07,NJ^R>G\TRO&X3EG!>'H
MA"RW7%C=,QA?#&E.]H<*X>F*:2-[&V.+>R+RI-+&@+B0$+C=2 U,:<'5KR%;
M@1[2O0W9+;\U4D4%8MPV^2J# 4#(*2O\\?49+)BAF%=<'J6)DD\?&M*+K%F#
M"6?>]BC!6[,0<:.0N+2;0KTM>/=A4:9Q2;D03*+-RX.\RL269,A+9@X)QKEK
M@O4%'JRC&#79>U2!>G4V%U79C%V@ #M>U@Z]\0[1QW=;BT9=JXR)(%%G#3Z1
M35S0(A"$0P2]3C=Y13V)]88AW$=#YPB<6HV]A##<U&+H$*W0*X<:/"2B]0KF
MWC2Q'BGC5>]5=1-=8#)LN+6W9;.:EHELQS/+'C*;RZR5@C\44XRSV"-,T44K
MAH>LLB:4*DQ.>86Y#%<M.2%\7#KR5[XR+<787B@Y76.#?AAX*QZU9<@67\?M
M[.RQW->-C#(TE=EQR6.HV6(.#F,N7MKD@4L[:U!-2B7)E3>C5-AP1ATQ4'*O
MS4M#5(.:WT\;"^MR)W9'O(FV;0\-+DF*6-SHU.3#A]$X-R](>$9"I$M2'#*-
M+&&X!@%<-[7M>@Q3A^7./%'R=[9\(L]<W$O!F5E+GN)QQO$A6'J._0B0DJ3Y
MWBQN<%X['N;BS-C$H"()1910G"(O:R]NLN!U@S;@G4IT?)[ZDI8L/)2I$NZ^
M/5*I4I- 0G3)R'O9PT\\\\T02B222@W$,8KV"$-KWO?HH-%)-V>>OF0D.1,F
M<0<@USTFT8@F0)%!\79[V#;&>0SG8I5"EQ[&^NJ1K?</Y]LU,+F>L+5DDD19
MO+0B372#>%*DM2102]XR>0'D<@&]4AXG^7QFQA(=@W+#:G.VNFRN'"&QNAN<
MH1'7 YBDJ5:U,S+%6VSFJ&T.+@E, PQM0F"V+"E3<78Q$,88W".03<SCRY;5
MFD7)KF8O+VH.Y1AJ_C\VLD4 Q5C<V+2Q.O3DD8.R0LQ1"<?Q94ZG*GDME5+%
M:4Q3XC=G6!LG1.YP489WK[O)N!RE<E4M_ KRTHPYQ0Z5/2Z 9ARXTX_Q?+UV
M[F=TBI.I<H'CJ4Y$A4R,8\;Q\LD 3G6.F)%0FHVZKO/7>&DQ '-G L"\],@]
M0#O[ ]?]U]9(/O@U8&CTCRIFF4Q2.*\9R77)RO@51CB LC4IU)F#<1+6".O$
M0(5G B3>:,UJ57$XJ;C$8L#NEX[('OCC?6./1;DAS5C+/^TB:32]5(\D8C:F
MYFA:^+K'<PZ'-J1"U8EPFC M:6>X2E K,!-Q&6Z;FG7^;N'\N3K/LHU<X\=S
M]@8,:8FG.+-<\I26$+BK $)KF8(NO0Q-XN$8P!&6S2!8G5#MT]-P$WM:U[]%
MKA4AZ633;%V">,7%NR:5E0/&P.X@I7E++V5'%/9;,7AL#.Y(S0Z'CD*PQ4Z"
MC[.T,Y:TQ/VH2SG=<K4C#<PSIL%NDUY+>-.'2&6XZR+O_HS%99%7I^A4[@DU
MVJP&QR&.2%C7*V*3Q*6QA]GB5R9WIG<DIZ->@6$%GISRS"C2PB"(-@B[O]R4
MX&XXM X1G;6>&X[SDFRS)H=AG2C%F"7&-"QEEC).2QNRF(I8HXX\"L8C8000
MW+G%08T!'98(FR4DPL]66:$*=G2 ^LELS*]D2\^:)IA%-@I;;1-KC4#5//20
ME[H+'Z1_58-7%GN9]R[KK=.7QV$:+LPK[6Z$M@F^#EZG^S_I_<_<D6#R/<-L
M;CO#.3TCXT!:V66$8MSUB]>4T/P6]HG+.^LSJRK+C)=&],ZHU8BD#@22I",\
MLR]!6?KKF'U7_(_JGA7-F \AZE:@0HW&L7<&7(N6&> .N6]L%)4?L%TR>*-I
M\$YCQ_!6.<O(AJ&YO!'X<!,6$OJ&'I!!5'A:_P "/)QL'O1B7:3%F[K!&8CM
MYH?FYTPIGE>P)6YA8W8"<V1(4KX[-J!4:Q,DB:Y'!I VN=D%P-9EFTM218L)
MPRB@KO2;L\]?,A(<B9,X@Y!KGI-HQ!,@2*#XNSWL&V,\AG.Q2J%+CV-]=4C6
M^X?S[9J87,]86K))(BS>6A$FND&\*5):DB@E[QD\@/(Y -ZI#Q/\OC-C"0[!
MN6&U.=M=-E<.$-C=#<Y0B.N!S%)4JUJ9F6*MMG-4-H<7!*8!AC:A,%L6%*FX
MNQB(8PKOQUR*\_NU.['*AI?I*BQ),6O"VXTQQY#MF<]LN/8GC;3O$C!/,C1Q
MAAZ!JB./R7S*LQE1+.G&!6[)9FO1H6DT0V\X2JZHD+;\=8-]1#&= )Y!)IN1
MI7D/D4<]B#'N"9G?(N8BPK'=9U,#B;8.(*VJ%ZJP;M\B()XD=W%,:=$UQ0B5
M103EIA=K)2@J0V">/5M\<N)I=N+F?;K23<'#V%$!<NREB*,0:%H5QD%;%B57
M(Y"I&WZL:SR$QL:FT@RRKPN1W<"TQHS"4QHP6$6&S/4"YHV3WAX!,9;C:W3"
M)8EULR7C7%>6]NL/S$MN>YG+8I/)?B0J!P2$OHL<2$R[GC[,JDD]8K3.<6NK
M0I!"$,\([HA!E?#OKIZBQI9^/S(N6M]=3Y/QT^YO"\@M@5CAT83Y8]P#EAUL
M.QM!_&"=,(\Z>:(^T*VDI8=YT[49B4VXG!3>]QFA/WA_W4V9VDW%YI<5YVR7
MYZ@6I>[*S$6OK#Y-@$9\@8\*E>9&TN/>*0Z*QYYE75111 #O;VH<EU^[]-SN
ML,RXPK1D?(/S><NNQNQ,'X7WW FJNHVK&47;$+CM-G%E9'Y?F#(,< J ](T9
M<HQCG E,S.)(B%R! V1&RQ"@/2*')R*$O+1$AO\ X^^3+DJU_P"0R*\3W,S'
M\923)^9X8]2[5W;#$#:B9X?EQ1%VQX<'-G="V5CA\7.3/:&)N0DHPL4:=6]S
M**2JFX9;FB,)#1NT')!S6F<V6ZW'WQ\1K&^;HY&\*X8>,>Q_,+/ (YC/60N4
MXUP])IOF:0RIL:8MD*;K53Q*%:5N;7&0."0I:Y@$!M6E$!24&!IMXN>WB>W7
MTXA'+'F+7/;/5;=C++%A,F98:B4492\129\?T;"6H;G5APOKS)DSJSF29"YJ
MR7=L?D"]D2GEHS@+@'7 ':=0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0<DGHV/YM[:3_ $D.;OXA]7Z#"-H.2#FM,YLMUN/OCXC6-\W1
MR-X5PP\8]C^86> 1S&>LA<IQKAZ33?,TAE38TQ;(4W6JGB4*TK<VN,@<$A2U
MS (#:M*("DH,#3;Q<]O$]NOIQ".6/,6N>V>JV[&66+"9,RPU$HHREXBDSX_H
MV$M0W.K#A?7F3)G5G,DR%S5DN[8_(%[(E/+1G 7 .N -$>IEQ_R2J>3CB]=<
M8[ 8BCV/LA[.XQAO'ZQ/+$S*W3!NT1L@PXRO^2,I&*L(OPG:&+9TZL:THI2L
MF!9:9&=U&LOI[ \)(\BV)>6K$_ 1REHN6'9_!FS<U>#-<%6'W?!\?96!NBL7
M2[!8H*DS:_E,VO&O9:A:XNQB<TD0TKE<("Q6L:5;Y@07KZYM>R;UPNZE->G\
MCQG$=E5>@FI8,1R/,A#LIQ@UR0.'<8FG'3(AB89.[F-1C0!27T)T"DSM1@O8
M-O[((4<Y*PQZQG"$6F6;#-[]%<ZMD :GR9JL&0V!P$ESEC6VI%2Y5'V$Z1:8
M8B-.,1(PB&G =+F]2=<D(+J#3!=0P+3=:^4><[J<%N6N12',R##N=(WJOM5(
M%"%F3HY%'X=G#!4*R 6GD,9;Y60^I'"-JI!&DKPA;W8M?8I.H"D5W5]F88<%
M&VENQ'JNN3[4O%65, Y5U5UJ@J5J=#$&QV8XACLC(6T3DU2&2-CJN2PUJPCF
M"%1EA1JQ@0)N[0V,$F":+#LN4W&>(T/&U.Y7/4C[N+\P\>V%L-:S1[;74W(C
MWC#:W=G(A;,UQG''6>G^'QQ2O@+>D<X HF9LGACV<4N88](V]Y;4EAIH^460
M<J4!-313>[F$U'Y7,5<7O+]D+#.QB;:[&4LR!@?.^((O%F%$UO<6C,AD=F8E
M7$<;X2 JCH@8^>6U:D=HH!V*=U*,\E6)N':XPP+:SD7YOEW-SN)Q\<=C=C#+
M43C&),)/T18LR1B ,^.];FZ28UP_*9MEMXF+<W1B>RA6X2"3J$B5"Y.[T0 Q
MSO9.V*.R)+*",&9>1GU)G#UL1@?%VZ[CK=R/D;F^,8XUXC^-V2-PI$HS.!QC
MT:8(\SR6"X0P%(TDB+E<\81*6]Y9U:%Y;U(R$*U(H"<K2!G>U^;_ %9VE&&7
MKD<SEEO2HW"V/5K!)LI:40J)PF0*83%GAS)BYR1\=2<86E+BPMKFO2GJS6#+
M3NY$=X :$9B8I2 H.F269AVDW&XW<<; \<3YB'&&P.PF)L%Y@Q2JV1)?7#'$
M4:9YY-E\RC\S#$HS+G50ZH(8O<6\@:9 >5=S"6*X@E=)E@YU,S17U@.F.,)O
MM#--V-(-J(-A.+R+(<ZPU&L?00#D_0R+,3D]R5Q[$G4771Y<"6%I0&J[I6R5
M(G-0(H):<M0(5RA!N+E(V<VDY*/3>,6Y>KDC@V!8_D+'+S/=PH!++)9"*487
MBC?D+'V6\58X=%^.9FIL[J<M,R)2V*[&1U7=M2"Z[@0(0R#@CSPAZ[>HF480
MXZ,DQ_?+5%#QMA18ADI^OZJ'Q@>7!ZV)I E527'P7H6F2QUM+W",%*TQ)WG:
MQH3C0WLY%7MVH D)GGD1YAN2?=[9C3SA35X5U_PUI=*C\:9KW'SDT,[XA?\
M+S0N<6][B3"1(8!E]N U"?8VYMJ$ELB3TH.)1W<E2Y"G6HBPA[FH_)-RPZ/[
M_P" ..3FJ0X?RHV;=A>VG6K<3##8UL35(L@-RP9948>2(]%<=1YU0*W)<W,_
M=0Q1@>6Q4[-JA2%2F6=L /)WXY+N6S&?-S(-$]"H=&]A&:5:<Q>4P;"DZ;L<
MQC'6,9_('L 'O8;(F0AL#/DAUB4+:D8RC62TH1)5:E:2$D!A_9ISPQG8"+^J
M/U?TJW5V9S#OUKK*)EBF+Q7,N*8-KGB'$LK,9XG%I&XKLY1-]0Y'TYBO;QMF
MQ<Z&N:53XB[.W;QTLOO5@G*##PZ(--=ZL9;2<?>(=]EKJV1:!2O!1F5\DJC5
M !-D <H6T.%LQMBM0 P[H20.3QMW2F#O?K7+1]:]K7OT4%?G CMAN5O]B39/
M=[8^=+S<$YJV*G35I)AE1",;QLG&.!H(_O;8%<=(HG#&:6S)S<WA8)E4*7IV
M=+]O&C#2;%=X'<87WT% /'1NUL[G?E[YC=7<K9-\U8*U6>L'I,"P;R9CYC\B
M)Y@V/RB1%^9HW%&>82CQ$Y$5?I>7!Q$3U>@JX+7O:X5<2#D8YW\O\KO);H=H
M<AQ#DZ*XMF>/VR%3S.S+CZ+XUTYA*J.B6N3TN51B,LT[R8_3YY6@(0EN1TI/
M1V0FC+;#B;G&I@R+!6]?-[QQ\ENG>G'+[E+!&T&&M]GEW@.*\MXAC$1CWE>?
MIC&-F0(V-;%L0X$6K#&N7REB1O")X830W2/Q:A$K&(FY(@GWS&\J.U6"L_Z\
M<:W&;BV,Y7W^V;954Y"Z30"1?#,,8H1GOJ2\K=FY2YMC7XJN%&'59=2Z'6;V
MQN:C##$RTU6F+"'.AS68G]1QB7C9R];D>V<TYV?U@E,DQ*&8#QJP-4?R;C9^
M09)B2J&C9+1G7O7AN7!>I,82G6=I9_* E+/O:Q NR-$%]_,#NILSHIQ/<?N5
M-5LE^ZV>S+,6FF(I(_>38!-_$L>2_"DR<I%'O"\C167LR/Q!;&T0^]ITY2XK
ML>@HX 1F6$$V^:7E/5\7FO$'?L;8T#FS:+8?(S;AG6/$:DIU-9Y+/'$:3O;M
M)"V0](\KF-B+7)RPMZ$XE<Z.2Y&D+-3@.-5I@J$C6)/64&I&O-SCM)H6 :T(
M'=1J%)8WCXM6VV<!7:O+;I(HOKCV'690J+.@A)<G'7O8GJ=Y/%>Z086G;IPK
MGCS5@'5$[1G+VG>H><WC$+4Z;DI<NMBR2F17,;BRXU=U<<PL(G%^S\,41UAD
M)$G:U9B\QR"-&<G&E5*#+!5@"DW*6Y_J+>&*980S)R;96U=W?TWREF*%8DR$
MZXCCT5C<BQL?* OA@!LRV.8+US>D3\:UM:E>2:N:GYF4"0 1C.1'*@CN&!>K
M9@N]:_83CRD<!S/C5DUT?LV8HA>!H$Z-3<;+(5NA:1RA29EN3+#,4.ZI7CT4
M:7,:>R8QZ=R.V1G7\%Z17-/"XO27$WJ =?5&R>1^33>/638;%C/K!DQ7BB.8
M3AL3;))%\WM0V9]CDR<^Z:A8)*7,;?'6IU(&G4.*].8>I*ZZ(RUNU*#VN%[D
M=R7EKA21<@^^643IV_P)LV8GF5\@)89!HJM/@V&9?-C"R&Z(X\C\,BQKFCBT
M="F3$IT9)RU18 1"&:9UKA5)B'83U1O+3"EVY6E>1=5= M6)*ZR&^",8Y188
ME)9IE"'-+BM;$SZ)XEFON>W1<HNX,IR,3@J%#4"]0,1Z-)="(I18+5.&+E0V
M4VGRKM)H/R%XHC.'M_=-%+2MFZ>$EC20[)V.WLY*G;YLRM8G5\*1*4=G5I4&
MJ4JH;4[(']O6(0E%FF$%!3+J-O\ ^I$Y Y5NQ@K4-^P$6QXGVUS+!"MU=A(Y
MC>.,V'(NR./A$(PG"H5!<9KP2J2-R-*-U4.[K%9B:(I226K&F_6;JPG#QH<@
MG*S@[E-4\2'+[)L49EGV3\)N^;< 9WQ8P1B.IG]*QAD3F:F3EQ&#8J:W>'.K
M-"I(0$:R-MCPA<V&X!A/)4=J .L2@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@K
M9Y4?\V5!_"A%?\42BI7R;[KS]QN[]J/\R^Y\?=8[USG.JTT#*!0*#H1X]/\
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MZE+F@PG&)SI!'=0M(L<Q1 7%)ALQD(HM_(R_E2/W3 EX83&97 \['QYCL(L
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MF<7K7C8Y2(ZWA!AI1P$<23JBEUC$Z56FN2IL%FG#GR-;<9VRQM/Q^\D>.HA
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MCXS-42PP$#*HB\D<" &!A)%K'1\-Q*@W,"8Y!=]0<DGJM?\ !/$G_I(<<_\
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ME1((RQ9AR*V8LU!LLL>BLX9AE<2.QO+,APL(QDFGIX[=Q3*QK ?W,:IB*@@
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M-WOE.U&6(-@"%9ST7Q3'\<3_ "Q)&J"P!U>T$6UF67;E\TD:INCK$):5C)]
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M89ZI[_X#_P#Z3+%G_N#0=95 H% H% H% H% H% H% H% H% H% H% H% H%
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MU,3E\\GC 8X+'_4]?/>X2S)+W(I<Z]2?JG()O;K#@$'V&25U"RP@"$S.,O\
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M[A,FM68L3?\ JVR)#?*F1V3L_#)%_P"P_ET4\=[MV0?[D<N^(!]'S9 J"65
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M8X@(;$FM8R0DW$58-BAB!<+!=A]$=3]JT^ T6=<0H)<@U?R-&,L8&;6J3SF
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M43]*H'AQ_P!5%_ZHGZ50/#C_ *J+_P!43]*H'AQ_U47_ *HGZ50/#C_JHO\
MU1/TJ@>''_51?^J)^E4#PX_ZJ+_U1/TJ@>''_51?^J)^E4#PX_ZJ+_U1/TJ@
M>''_ %47_JB?I5 \./\ JHO_ %1/TJ@>''_51?\ JB?I5 \./^JB_P#5$_2J
M!X<?]5%_ZHGZ50/#C_JHO_5$_2J!X<?]5%_ZHGZ50/#C_JHO_5$_2J!X<?\
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M)^E4#PX_ZJ+_ -43]*H'AQ_U47_JB?I5 \./^JB_]43]*H'AQ_U47_JB?I5
M\./^JB_]43]*H'AQ_P!5%_ZHGZ50/#C_ *J+_P!43]*H'AQ_U47_ *HGZ50/
M#C_JHO\ U1/TJ@>''_51?^J)^E4#PX_ZJ+_U1/TJ@>''_51?^J)^E4#PX_ZJ
M+_U1/TJ@>''_ %47_JB?I5 \./\ JHO_ %1/TJ@>''_51?\ JB?I5 \./^JB
M_P#5$_2J!X<?]5%_ZHGZ50/#C_JHO_5$_2J!X<?]5%_ZHGZ50/#C_JHO_5$_
M2J!X<?\ 51?^J)^E4#PX_P"JB_\ 5$_2J!X<?]5%_P"J)^E4#PX_ZJ+_ -43
M]*H'AQ_U47_JB?I5 \./^JB_]43]*H'AQ_U47_JB?I5 \./^JB_]43]*H/78
MVE2>Y$E@>G-.*X3;]J2)/8P/04*_1;K$BM\/1T7^"A5G?EM=[5/_ -$1_%*%
M3RVN]JG_ .B(_BE"IY;7>U3_ /1$?Q2A4\MKO:I_^B(_BE"IY;7>U3_]$1_%
M*%3RVN]JG_Z(C^*4*GEM=[5/_P!$1_%*%3RVN]JG_P"B(_BE"IY;7>U3_P#1
M$?Q2A4\MKO:I_P#HB/XI0J>6UWM4_P#T1'\4H5/+:[VJ?_HB/XI0J>6UWM4_
M_1$?Q2A4\MKO:I_^B(_BE"IY;7>U3_\ 1$?Q2A4\MKO:I_\ HB/XI0J>6UWM
M4_\ T1'\4H5/+:[VJ?\ Z(C^*4*GEM=[5/\ ]$1_%*%3RVN]JG_Z(C^*4*GE
MM=[5/_T1'\4H5/+:[VJ?_HB/XI0J>6UWM4__ $1'\4H5/+:[VJ?_ *(C^*4*
MGEM=[5/_ -$1_%*%3RVN]JG_ .B(_BE"IY;7>U3_ /1$?Q2A4\MKO:I_^B(_
MBE"IY;7>U3_]$1_%*%3RVN]JG_Z(C^*4*GEM=[5/_P!$1_%*%3RVN]JG_P"B
M(_BE"IY;7>U3_P#1$?Q2A4\MKO:I_P#HB/XI0J>6UWM4_P#T1'\4H5/+:[VJ
M?_HB/XI0J>6UWM4__1$?Q2A4\MKO:I_^B(_BE"IY;7>U3_\ 1$?Q2A4\MKO:
MI_\ HB/XI0J>6UWM4_\ T1'\4H5/+:[VJ?\ Z(C^*4*GEM=[5/\ ]$1_%*%3
MRVN]JG_Z(C^*4*GEM=[5/_T1'\4H5/+:[VJ?_HB/XI0J>6UWM4__ $1'\4H5
M/+:[VJ?_ *(C^*4*GEM=[5/_ -$1_%*%3RVN]JG_ .B(_BE"IY;7>U3_ /1$
M?Q2A4\MKO:I_^B(_BE"IY;7>U3_]$1_%*%3RVN]JG_Z(C^*4*GEM=[5/_P!$
M1_%*%3RVN]JG_P"B(_BE"IY;7>U3_P#1$?Q2A4\MKO:I_P#HB/XI0J>6UWM4
M_P#T1'\4H5/+:[VJ?_HB/XI0J>6UWM4__1$?Q2A4\MKO:I_^B(_BE"IY;7>U
M3_\ 1$?Q2A4\MKO:I_\ HB/XI0J>6UWM4_\ T1'\4H5/+:[VJ?\ Z(C^*4*G
MEM=[5/\ ]$1_%*%3RVN]JG_Z(C^*4*GEM=[5/_T1'\4H5/+:[VJ?_HB/XI0J
M>6UWM4__ $1'\4H5/+:[VJ?_ *(C^*4*GEM=[5/_ -$1_%*%3RVN]JG_ .B(
M_BE"IY;7>U3_ /1$?Q2A4\MKO:I_^B(_BE"IY;7>U3_]$1_%*%3RVN]JG_Z(
MC^*4*GEM=[5/_P!$1_%*%3RVN]JG_P"B(_BE"IY;7>U3_P#1$?Q2A4\MKO:I
M_P#HB/XI0J>6UWM4_P#T1'\4H5/+:[VJ?_HB/XI0J>6UWM4__1$?Q2A4\MKO
M:I_^B(_BE"IY;7>U3_\ 1$?Q2A4\MKO:I_\ HB/XI0J>6UWM4_\ T1'\4H5/
M+:[VJ?\ Z(C^*4*GEM=[5/\ ]$1_%*%3RVN]JG_Z(C^*4*GEM=[5/_T1'\4H
M5/+:[VJ?_HB/XI0J>6UWM4__ $1'\4H5/+:[VJ?_ *(C^*4*GEM=[5/_ -$1
M_%*%3RVN]JG_ .B(_BE"IY;7>U3_ /1$?Q2A4\MKO:I_^B(_BE"IY;7>U3_]
M$1_%*%3RVN]JG_Z(C^*4*GEM=[5/_P!$1_%*%3RVN]JG_P"B(_BE"IY;7>U3
M_P#1$?Q2A4\MKO:I_P#HB/XI0J>6UWM4_P#T1'\4H5/+:[VJ?_HB/XI0J>6U
MWM4__1$?Q2A4\MKO:I_^B(_BE"IY;7>U3_\ 1$?Q2A4\MKO:I_\ HB/XI0J>
M6UWM4_\ T1'\4H5/+:[VJ?\ Z(C^*4*GEM=[5/\ ]$1_%*%3RVN]JG_Z(C^*
M4*GEM=[5/_T1'\4H5/+:[VJ?_HB/XI0J>6UWM4__ $1'\4H5/+:[VJ?_ *(C
M^*4*GEM=[5/_ -$1_%*%3RVN]JG_ .B(_BE"IY;7>U3_ /1$?Q2A4\MKO:I_
M^B(_BE"IY;7>U3_]$1_%*%3RVN]JG_Z(C^*4*GEM=[5/_P!$1_%*%3RVN]JG
M_P"B(_BE"IY;7>U3_P#1$?Q2A4\MKO:I_P#HB/XI0J>6UWM4_P#T1'\4H5/+
M:[VJ?_HB/XI0J>6UWM4__1$?Q2A4\MKO:I_^B(_BE"IY;7>U3_\ 1$?Q2A4\
MMKO:I_\ HB/XI0J>6UWM4_\ T1'\4H5/+:[VJ?\ Z(C^*4*GEM=[5/\ ]$1_
M%*%3RVN]JG_Z(C^*4*GEM=[5/_T1'\4H5/+:[VJ?_HB/XI0J>6UWM4__ $1'
M\4H5/+:[VJ?_ *(C^*4*GEM=[5/_ -$1_%*%7IMC6H;QFC.>')SL8 (0@7"(
M$$J]K]/7+[(DJ_6O^A?IZ?@H/8H_A05O\O?\VCN/_ ^X_P"-FBM&^*+\I3D[
MWXL^PR)_V6_Q"VGV7'>N?,AK],CH@4"@4'0)Z;G_ #])W_)AR!_&-B"N>'SF
M7R?M!^U.D_$]P4/XQ'Q%P>^6+T+.[DJX.L4% H.?/E]]0MK?Q725/A1!!GC8
M?9]:QMTC58O8I"EB$6@3$]DJ#61PR1.S6N1'-3H[$@ J2-"-M6+3T0PGGB1D
MGI33PH[-]59R;Q^/CRK+>*5.CPL<C0.B.7FL6P,>C]FJQ9AZ]>/)+G&U\34H
MUJ<D8TYX4Q99 0W$+MK6O0=0/$)R@QKEHU=?]D([B)\PF=$<NOV&9)"7J6()
MN6"2QZ$8\G"QP8Y.A98T)T8S4.14Q)1BAN0J+FIS+B)"'JWN%?O-WZ@E/Q+Y
M?P]@Z$8*C^?)Y/<?NF2YJE><CK(.5!HX>_#CL( 66VQ24FN*R3+61Y&8$VZ:
MZ<E$4*UC+']( E3PE<OC3R[X-RKD!=C5KPUDK#N24L/EN.6J7*9HG!&9%'TK
MU")H4[JV&.GEIY&K2O"*Q B+W <SFBZUPC#:P?ZYNN5^1<1^ \2YGC>%F7-R
MK)>7[8P/87R:KH0G:$]X9)I5XN2O01R2&*SNT8 D]C<HL/5-N+K=-NBX<X23
MUDVP[@SFR)!QHLBV/D$JU![ZDS'.%+.2G06,NN/-<R<0#1%DHK%#N:*X[!+Z
MM^M>W1>@NDXA_4?Z_<H>4[:YR7$C]K7L2X,KR_0N)+YBER1"LD(HT@5N\B1Q
M29IXU#7%-)FI@0'.9K:M:20=Q(.$2J47('0='HQ@+ (PP00  $0QC&*P0  &
MUQ"$(0KVL$(;6Z;WO\%K4'%EO-ZOR%8"V6R#AO5_7"-;(8TQVL#&#\R.V57*
M'-DOE[<8>5*#(<VMT(D(%\.;%UK(TCB,^UG$P@U02&Z4P@PP.O'7S)ZC-N!,
M(9G5M!,>59<Q#C7)ZE@3K!N"=C43Z&,LK.:"%YJ=(8N);3':Y(3A%%"-""PK
M@#>_18(I\FO(WA7C#U=E6Q&7%!;N\W[6.XCQ>D7EHI#EK):M&>>S11J,$2I$
MWM9 21*W=R$4:4V-I)AO4..N0F/"F'AJ]1M..5';M?K'(=5HIAI CQ!-,GAE
M[+E5WF:P:B*/,2:RVB[.N@\>)"2M#)1#$=WCK N3:U@WZU[V"0/.5SE2WB"E
MNNT9C.NT<SD#.4<R*^JU;[D5S@PXZ.#.<2;R4R8EOB4ELXA<;240A"$(FY=R
M;6M876O>P4L)_6%;1+$Y"M)Q<DJDJHDI0F4I\IY#/3J$YX FDGD'%8:$6<2<
M6*P@B#>X1!O:]K]%!U!\0?(-.N2[4]=L9D/!OX/C^DRQ,,<@@?C;P_\ :M\9
M:(JY)W[OSY'(NMMXB9(3"^SLFN /8=-ABO>]K!5KRF>J$U[T:RK)=:==<7+-
ML-@X>\'Q:=G)I.&+8GQ]+B3+)5,2/?VYJDC[.YJRN/2F<6MO3)2$:FPDQC@%
M64>F*#0NC'J$.1S/NW^OV"=BN-SW(8GS]D5)#V_)BV(9VAH8^WN#2Y+D2DIY
MG+69&Y*L.4%I0@N"R(!H3.@(;7,!<(=26Q^TFOFH6/2LK[+95B^'<='R!OBA
M4NEQRLAI,D3JC<E[:T!,1I%AO?%J1G4C+#U.@797M:_6O:UPY?P>JU@>2>23
M$FG&L^"67+F!,M;%X(P(P;'NTTE$)='(&4Y?#85)Y@SXZ=8)WP;;''B1*K(
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MQ8@L]T^V?F,>RMC#6[*.6%>QF+=E<%6V3X_=N7*.)HU*LSXA:FN*.THQAFY
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M_E#_ #:'X'__ + WWU_A7;,Q773_ *3/=QY"\S=A_P"K'_H_GGFGN7;?X/\
M^3NTZ/\ RD%!;+0*!0*!0*!0*!05P:4Y+Y+IQGW>J/;PZ]8?PYKY LP$LVA,
MZQP]-3I*LV8:%-,OH3Y9DY(WYPRHI:9 "$LT-66+4L\1,[R[*P]SO< B$86/
MT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%;_+W_ #:.X_\
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M_@K/V_F?W(?^IWSCY=[AU^]_W;W+N_3^M=G03!H% H% H% H% H% H/=C?\
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M@6O:UK7$G#.O4D/3MM3DGC1X=((L5^-[M[-L.0\TA9[#,<V/7C#QAJB1N2H
M#+C @"2K='XL5B[WN9#Q_KA80BL,+HMQ^2#03BSC&'&C;3+Z; 47GR)\C&'V
M]'C++^04B]!C!OBZ9W:TI&*(#/#65-'VZ2-@ =^LFL<$ZUB;F7+,Z@89I5S,
M<;/(EE-_PIIUL?[X,FQ?'[KE)]C7N?SUC_N,$9)'%8FYOOC.4L70F/J>[2";
M-:?NI*LQ8/O77 4(LLT98<J<#P!R*[-<Z/-SB+1#:^(:81A^R!@TW9+-YT:7
M2K+C;#D\?4ABK/AEM2@2! ]+UYZ\Y<;9VCZBQ28H!3D389A9P;Q4*>4OT_\
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MNR;?9_X=<[:U9'CO/]AGF?U<RSFJ)8CV-PP_YZC&2,T8_8IV<8D49-A<?4[
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M-P'$C)A,95(U6.HR!B5[6(IO(<;0!<:".8Q99(BAB%0N1M"!&6=W(GM0FB*
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M:UV*P<DA+:ER-:"-\?5YZZDS3N0)"!#WTM6Q!)LE";W4SK6* $?FKT:N0&)
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MZ?C?#DCTCY%T\YQ+B//FR<IVMUJV+3P*63N(2^&392N+2!=4<!8'V3+#ET<
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M'<NXA%/]C;)]MA8V8(6J*D*)='9Q;865LK,US.?O2,A0ALWQ0"<VZ%4%.<G
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MA#K$Y4^,S8K+7IV=<];$[:Y3[9;3+'.M637>%L8U;^\2.1XDQ,Z8XR+#8S=
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M_BC"U!?]R9_S;W()_(BVN_B'GM!6]Z7'^8HT9_\ >F?^N'L%07_4'+1Z?_\
MG!_49?Z2%P_=SL+01Q]4]JFT+LH:"<@>6M<YCMCIUKD[SC'>Z>(H2_2>-/[9
MBN8JF5UC\X2/D'=H[)F9 UK0.8CUHG)O;RW).UI5*D@A<:98*]T\F]#6?"RY
M2;CN8HWP;9W\6-E"WE&%-"573T>"&+DDY58ZNYVM\/7 _C1]'_AZ":7,Z3J:
M7Z6F#*-%X)(L::F.\WPS),*0N6.,E=9"TQJ4YQ?)(M.<ELPET[DPS'B1.JU<
M "QU5&DE*0E]!5@6)+":K7ZK7AN@&M#(_MV;L@3/)L2QNUI$V"&K!F86N<OT
MC8VLEK*8$\J?H4WXB0^(*4EC0JCI'8@M,980KW.M<B@BCQ>Z\9H@?!?S&[:9
MYAKCC.9<B$(WKVICV-G(@],JCF-93@:<J(DY*$Z]*B="?-+@Y.2U%<\L%E+(
M)O5 #:RB]!_+6&8[)0#T;#7,=23I6DSHQ8(R\I872#"4%3%AAQNYL\2YBDT9
M5(1 <6YZB^&5$@<2%:005J,Q-8Y.()Y9=[!3#I^F](DR:OXVF>U\BV*V(VXD
MT!C#GF+'DN3;BHYR?FEX4W/G3=$5F$DN.\2KDA\A<3@MHU4G7".:2$USU!CD
M-0(X+0_3A8/B^QG'OSIZVXHCL@P["L[YHV*P?C6)9$3N:>58LB^3\)2&!PZ.
MSE*N=9$\D2"$-+XF3.99RY<J"I2F6&><.US!!^OA8YV]4N-_5=#QG<HBC(&H
M6PVF,FR! 5!LDQ+DB;,DK9'B>/<U9TX2\416;OK<_-A4M,) :>WEM+DTD)%Z
M5>INKN$(2EY$]G<'^HEXN]_<+<:0\FY>G6K;K@W)J QPQ^YPIJRTZ)9G,'@<
M0QVU2?ND[>GY=C['SPM2)%#.W'J%RUJ2E]<\]40F"EO5J:>CBF.((M?;G6>>
M:I[$L#4WQ[+^+YS*>2J7B0Y$9R+MLQ$PO&(IU,FX;+XZC.$4!>2T.!0# EFH
MB3 #  +H-0E?#:]\6G-1(.'C$\WQ[! ZLYLBF9)%+7?-:]%.9!'M;\S.4-.C
MB'..1YO)V]$T-4G6B,$%&T=KWX%C &C+M8D++O3@_P R;H/_  =SO^.K)M!
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MX1BR;JU I>_S(,*8Y>*>A:2L6 @RL3DG7&#\<NZD)1B#="(\/97#;?$7_/\
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M3M[6TM;>G+(3)B"RR2"2P@ $(0VM8/6H(P8@TBTOU[E@Y[@/436#!\Y-:5C
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MCJT38)"P.:![8GUDU&U_:GEE>6I44N:W9I=$./B%S:YMJX@!R=02,!I)H C
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MIF:8Y'&EL8(\P-B!D8F)D0)6IF969J2E(6MI:6M"40A;6QM0D )3IR0 *)*
M$  V#:UJ#6[U@#!$DR_#]A)%A3$C_GS'K&NC,!S@]8WASKE^#QMS32!$Y1^'
MY+7,Q\SC3&X(Y8ZDGI$2T@@TIS5A$"X5!UA@48 P0LS$@V(5X4Q(JV :XV.&
MMF=%&-X<?F)NB!@5@3(J@R::S"FJ.-C"XJ+70EK@I;V/,Z0?-BZ0VW0:DPU@
M#!&N<;=8;KWA3$F"(@^21=,GN*X:QO#L81MXE[F@:VIRE3JQPAF8VMPDC@UL
M:),>N.*&J-(1D%B'<!1=@AMN@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4&K,PX,PGL-#A8\S]A[%F<H -S0O8X-F''T2R9#AO+98
MZS:["C,T:'ME$YM]E)G8*+D=J5V@NH*W6OTAIO$^@6B&!)LW9+P9I1J1A?([
M0F<4;3D#$^M^',=39K2.Z(YM=DK=*X?#6=]1)G1N4F)U "CPA/(,$ =A!%>U
MPW(SX,PG'LKRW/+!A[%C'G*?,;;&9WF9GQ]$FS*\UC;.2U)FB/RW(B)H(E\C
M8VI.Q(2TR18L.(( C("  ;%%V"'\<J8#P5G3R?[[<+8FS%[O),EFL ]ZF.8?
MD+R/,D/5[C+8?YM9G?RS)D?5MV2]%V"HOHMU3+4'^LBX&P;F!_QQ*LM89Q1E
M&48<E"><8BDF1<=Q";/^*YJD6M;DEE^.'B2L[FXP>4)G%C1'EN#88E5@.1D#
ML9811=PA[>3<68QS5!G[&&9,<P/+6-926B)D^/,FQ"/SR#2,EM<T3TW%/T3E
M3>ZL#N6WO+:G5D!4)S+%*4Y9H>@8 BL'J-4'A3%"F[&S)$(NSXZ9XNC@[1 6
MJ/M+?"FJ%-[26PH(@W19(D)8D,70L1($1+>40%(4D#8D)=B[6#0:&Q?H_I9A
M%]>91A?4'5W$,FD:96CD,BQ?@#%$ ?7Y(O(<$JY*\N\4B32X.B98E=E19H#S
M!A,+4FA%:]C!VN&<PK6_7?&N)W7 N.<"X7@&#'Y!)6I\PO"L6P>*XG>6R:$*
M4LQ;G7'3$Q((>XH)8F6'%N9)R,9:\LT83[#L(5KAF.-\98WPY"6#&F(<?0C%
M>.(HF/1Q;'^-XHPP>$QM(J6JG)4E8(I&$#6Q,Z92XK3E!@$Y!81GG#'>UQ#%
M>X8_ L#8-Q5+LF9 Q?AG%&-YYFEW0R#,<V@6.XA#Y=EE_;#GE2VO>3))'F=N
M>9V[MZB1N!A"ET.5'%#7J!!%:YYMQ E&!L&S?)4#S--,,XHE^8,6$N*;&.5Y
M1CN(/^2L<IW@H\AV(@<Z=F=7*(@2Z$*C0* -ZI.$\!@K#L*PK](?T9\&83CV
M5Y;GE@P]BQCSE/F-MC,[S,SX^B39E>:QMG):DS1'Y;D1$T$2^1L;4G8D):9(
ML6'$$ 1D!  -BB[!#^>1<#8-S _XXE66L,XHRC*,.2A/.,123(N.XA-G_%<U
M2+6MR2R_'#Q)6=S<8/*$SBQHCRW!L,2JP'(R!V,L(HNX0RB?8^@65H;(<=91
MA$0R3CZ7-QC/+(+/HTS3"&R=I.$ 9S7(8Q(43BR/3<:,L-Q$*2#2A7#:]P_!
M:@_ RXJQ=&\<-^'8]C> L.(VB-DPUJQ8RP^/->.&R()TMD*>*M\'0MQ$911L
MA%;L0(2TH4H2OF+ L'X*#2^-=&=)L,(9>UX>T\U9Q.V9!85\6GS=C77W$L$0
MS>,.J-0W.<<EZ2+Q%J3R5A<F]6:0>C6A.3G$FC ,%PBO:X;JQEBS&.%8,PXP
MPWCF!XEQK%BUI,8QYC*(1^!P:.$N3FM>G$IAB<5;VI@:"W!Y<E"L\*=.78U2
MH,-%TC&(5PTNRZ.:4QO*9F<H[I_JVP9L-<_&S<PLNOV)FO*9CSVI!_BQF04,
M2(EHW/MDI0^\75]KUBPWZW2&W0&PLS:[Z_[&L"2*;"X,P[GB+H%(EB&-YFQE
M"LH,")6(Q,:)4D9YNR/C<G4B-1DBN,!=A7$4"_3TA#T!Z.(\'X5U_B94"P/B
M#%V$X*0I/6$0O$< B>-XF2K5&#.4JBHY#6EF9RU*@XP0S!V)L(8A7O>][WO0
M?S!@G"!67SM@R\-XJ+SXHBEH(HS>#'D1!E\^#A/*4AAIV2@M%IF;%+*2 &6;
MA+;H^N (NSZ;6O0;5H.9?CYP7G;;'FFWOY/]F\+9>Q) \$,J72_06-9IQ_-,
M;N+GCYO4N5YSF*)QZ;L[*['L,I+[VK0+BPC1GVFKB1U>V2_K0=-% H-51'!.
M$,?S_(66(%AO%4(REEPQL.RMDJ(X\B,:G^3CF4!I;.;D*9,S0BD4T,:2SQA3
M"<E*FY 1BL#JVO>@1'!.$,?S_(66(%AO%4(REEPQL.RMDJ(X\B,:G^3CF4!I
M;.;D*9,S0BD4T,:2SQA3"<E*FY 1BL#JVO>@_P Y!P-@W+4FQK-<JX9Q1DV9
M89D Y9A^6Y!QW$)G)L4RHQ2T+3)+C5^D;.Y.L%D UC @.NM:S4JFYJ).*X^L
M27<(9%D3&N.LO0Y[QYEB PK)\ DJ0:"1P;(D58IK#I A,MT#1O<9DJ!S975(
M.U_A+/(,!?\ [%!H1NT*T99\7R/"#1IAJ>U87F+FTO<NQ"W:Z8@0XOE+RP++
MN+$[2. )H<5%'QS97"_;I%"I(::F.^;+$$7PT&SLCZ[Z_P"8H7&L;9=P9AW*
M>.X8ZL+[#X%D?&4*G$+B;Y%D"IJC#S&HM)F1T8V)UCC6N.3(%"4@HY&G.&64
M( !BM<-P#  P BS A&6,(@# ,-A & 5KA$$016N$01!OT7M?X+VH(@-O'GH$
MRS\.5V?1S3YIRD!>K=09*;=9\+(9^%S<$IZ%>XAF*6%%2(*]:B5&DG'64]H8
M48( KW"*]KANS,&"<(;"Q,4"S]AO%6<8*):F<A0O,&/(CDR)B<41@3D:\4<F
MC0]L]UJ0X%AE&]CURQ6M<-[7M0:R-T?TL.Q6@P6=J#JZ;A)KD2.7MF'3< 8H
M,Q6W2QO"K WRA!CT42O$DDB0@<#[$K2T85)5CS+!';KBZ0D))XM&)O'W>)32
M.,,NBK^B-;7Z,R=H;W^/O;<?T6.0.[,ZIU;:Y(CK6MUBCBQ@%_NVH-%8DTTT
M_P  )Y*CP1JGK9A1)-&Q4R3%+B3!F,,;IY8S+@$E+FF2D0Z+LQ3ZV+"DY834
MZJQI1@0!L(-[!MT!LO$^&\0X$A+=C3!F*L;X7QPT*7%8TX_Q/!HQCJ$M:MW6
MG.3LJ;HI#VMG8D2ET<5)BA0,H@(CSS!#'<0A7O<-49ATBTOV&DJ::9^U$U@S
ME,49($R269AP%BG)DE2IRRTQ)9"9]FD3>W0@DLI$2$( FV#8)0+6MT!#T!(Q
ME9&:-M+>PQYI;&%C:$A*!J965 E:VEL0IP6 G1M[<A*(1HDA += "RP! &WP
M6M:@U[BS!.$,&$RU/A/#>*L/$3Z5KYW.B,68\B./B9K.'4)8'292TN)-#0"1
MRMR 2"RAQ66.6'6#:PS+]%J#_+O@;!L@R[%=@7[#.*'O/,%CZV)PG-KOCN(.
M678=%7(M[*<(U%<DK&<Z91Z/KRI*XA.1)%I*8T+@IL(%['F]8-KT"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4%;/*C_ )LJ#^%"*_XHE%2ODWW7G[C=W[4?YE]S
MX^ZQWKG.=5IH&4"@4'0CQZ?YLD:_YQ2__':BJGYM]VK_ #%G>6#R][F6^:N[
MZ;U1E[90*" N5^*WC:S@[K)%E+1G5Z521Q[2[E)AX;A31)G(9HRS!'.4B86E
MK>G!181=NJ8<>,P%KBL&]K"%:X;;U_TGU U4&M/UMUDP9A!>YDW3.CSC7&42
MBLA=4M[A%W5UDC6UD/SFE"(%KA*/4F%AO;X+6H/SNVB^DC]E4.=GS3K5AZS>
M"5-4[!F1VU[Q(XY5#-V)6C7LDR#D-9$3I<&5,ZYN3G)7&RSO:<T@L99@1 #>
MP2GH(J/>B.C\FR@/-\DTUU4D&:#),VS4>7GO7C$3KE <R9U"18T2T<_7Q!1*
MQ29J5H"#4R^ZOO1!A)8@&!$ -[!_;).C6D^99\=E;+^GNK65<HJ?">\9)R3K
M[B:<SY1X G3I&+MIC)XBZ2(WP5(D**2=93?NQ90 E]6P;6L$F7%N;W=O7-+L
MA1NC4Z(U3<YMCBE(6M[BWK2!IEB%<C4@-3*T:M,:(LTHP(@& %<(K7M>]J")
M>/>/707$DR8<C8IT>T_QED**JC%T8G>/=:,+PN91Q:<E/0FK&&41N%-KVSJC
M42HTD1B<\L8BC! O?JBO:X3 H(P,ND6E\;RV=GZ.ZB:P,&=U$F?YJHS6RX"Q
M2UY;/F4K,<391+3LD(8F1,39-)#7A6)>O$MNJ6"5'7.,'<T?6"3]!J3,N <$
M;&Q=!"-A,*8DSO"VM^2RILB.9<<0[*$7;I0A;W1H121 P3=F?&I&_(VI\6I2
MEA905!:=8>6$=@&F!$'K8KQ!B7!<,;\<81Q=CK#F/&E0X*VJ!8KA,:Q[#&Q6
M[+3G%U5-\7B38T,:)0YN"@P]0,L@(CCAB&.]Q"O>X;%H(Q*=)=,EN7 [ +-1
MM8E>> 21),@9L4X#Q4?EP$O07)NAE8<D&Q0<R#)$5TQ=R5UEO>B[EAZH[=6W
M0$C79I:GYK<&1];&]Z979&H;G5H=D29Q:W-O6%"(5H7! L+.2+4:H@8@&%&
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M6(,$(BR(XT!0#U!#%&T#:V@5*0D@[4WL^T-N&UQBO?X:#8] H% H% H% H%
MH% H%![L;_PLG_\ :#_^!'0;+H% H-69AP9A/8:'"QYG[#V+,Y0 ;FA>QP;,
M./HEDR'#>6RQUFUV%&9HT/;*)S;[*3.P47([4KM!=05NM?I#9Y))*<DI.G*+
M(((+ 2002 )1)))0; +**+!8("RRP!M8(;6M:UK=%J#560L!X*RW*<:3G*V%
ML39-FV%WXV4X=F&0L<P^:2G$\G4*V5>?(\:2"2,SD[01^.71QN.&L:SDJ@1J
M!,.X[B(*N$-LT&GY]KU@+*TUQQDK*.#\/Y)R-AQS&]XBG\^QI"YC-<5O)JQM
M<3';'$JD3*XOL'<S'!F1GB4-AZ4VYR0D=Q=8H%PA_6,8 P1"LGSG-T-PIB2)
M9HR<D1H,E9=C&-X<PY/R&A;@(BV]'.9\U,R25RQ(A+;4P22UZM0 JR<NP;6L
M /0&?R:,QN:QN00V91]CEL0EK&[1F5163-*!^C<FC;\@4-3Y'Y QNJ=6UO3&
M]-:LU,K2*2C"%)!@RS " *]KAC>+<3XLP=!&+%N%,:8_P_C*+^)^6L=8MAL<
MQ_!([XV\.$B>? HC$VUHC[1XO('=6N5=W3E]X6*C3A]8PP8KAL"@U9C_  9A
M/$TAR-+L5X>Q9C25YAD@IEER3X_Q]$H;(<IR\9[BJ'*LC/4<:&URF\D$I=U9
MEUSF:J57,5'"Z_28.X@V><22H)-3J"BSR#RQDGD' ":2<2:&X#"C2QV$ PLP
M KV$&]KVO:_1>@AN5QR<>A$VODHC0_3,G(PG$YX%/RM7\(ES:[LH+&4H=+RH
M$'L^W<3RC1!&?V_:B"*]KBO:]Z"K'U/^$LPY[XD,EXSP'B/)6:,@+,KX07MN
M/\00&49&F*IL9YJE4N2Q#%(8TO#V>@:T8.T/,+3W+(+MUAW"'X:"S2"Z#Z6.
M/NXR[+]+=75^=4$4B"Q9D^2:YXH5991R%+'T9"A4IFKI#AS!.\ISAF@&,:FQ
MX!7%:][7O>@F5)HS&YK&Y!#9E'V.6Q"6L;M&95%9,TH'Z-R:-OR!0U/D?D#&
MZIU;6],;TUJS4RM(I*,(4D&#+, ( KVN&/XRQ9C'"L&8<88;QS \2XUBQ:TF
M,8\QE$(_ X-'"7)S6O3B4PQ.*M[4P-!;@\N2A6>%.G+L:I4&&BZ1C$*X:5BF
MC.DT$R4=F:#Z>:LPW,"E:8Y*,K137W$L=R4>XG*TZ\U>=.FB(HY0:M-7(R3A
M&B57&(TH [WZP0WL&T<8X)PAA,Z:J,,X;Q5B,_)4K73O(I^,<>1&!'3Z<.8A
MC<IE-3(JT-0Y5*W 9@KGN*ZYZPVXKW$9?IO085FS3_4O998U..QNKNNN?W!B
M)$F9%V;,)8TRJL9DXA&#$0U*IU&7X]O)$(T=[@)$ -[BO\'PWH-HXYQ?C3#T
M3;(%B/'D&Q;!F4DA,SPO',28(1$VE.E1I6]*0V1R,M[8SH"4R!$206 HD 0$
MD@!:U@@#:P:,RYHAH]G^3WFV>--=4\V3,1-DPI=ES7C$62)/=.'J]!%W^91!
MY=;DVZMN@':]7X+?!0;J2XDQ2AQPOPZBQECU'B-TC[S$W/%B6%QM/CAQBLC2
MJT,AC2^#DMH(RKC[ZB7GDK41B42944<8 T @C%:X?KQOC+&^'(2P8TQ#CZ$8
MKQQ%$QZ.+8_QO%&&#PF-I%2U4Y*DK!%(P@:V)G3*7%:<H, G(+",\X8[VN(8
MKW#'X%@;!N*I=DS(&+\,XHQO/,TNZ&09CFT"QW$(?+LLO[8<\J6U[R9)(\SM
MSS.W=O42-P,(4NARHXH:]0((K7/-N($HP-@V;Y*@>9IIAG%$OS!BPEQ38QRO
M*,=Q!_R5CE.\%'D.Q$#G3LSJY1$"70A4:!0!O5)PG@,%8=A6%?I#*IQ 8+DZ
M,.D)R3"XED*&/A-TSU$9Q'&>61AX3W_1(=&!^1KVIP)O_P!P:4,/_P *@T-B
M#1G2;7N1CF& M/-6<'RTPNQ(Y3B#7W$N-)&,FQ2DBQ0WN%Q%E<Q%V(6G ZMS
M>CJ'#M^@(72&T91@G"$XR/ <Q37#>*I?EW%1;F3B_*<HQY$9!D?&Y+V28F>2
MH#.'9H5R:'ENZ<X9:H+<J3V4 '<)G6M>]J#V<FXLQCFJ#/V,,R8Y@>6L:RDM
M$3)\>9-B$?GD&D9+:YHGIN*?HG*F]U8'<MO>6U.K("H3F6*4IRS0] P!%8/8
M9(;$(U$&G'T<BL;8("P1M!#6*$,C&UM4098@U-93(UQ5IC2%*0RML;;64@"1
M.A)( E)2@"4 %B[6#0:(Q9I1II@R:+LDX3U)UDP]D5T$M&Y3[%F!<5X^FCB-
MRLKLXB72F)11H?%8E]EY]CKF'BN;8XSK=/7%TA)N@U)BC &",#@EQ>#L*8DP
MR7/Y(IF4[!BC&\.QV";2]9:X5<JEP8@S,X9))%017L8N6=LJ':_S0[T&VZ"(
MS%Q_Z&Q=[C$FC.DVHT=DD)GRS*L,D#%K=AMH>XCE%P-8CU^2(PZM\,3KV"?+
MCHNV#.>$AA3B:)N2W$=>Z<KJ!+F@T_/M>L!96FN.,E91P?A_).1L..8WO$4_
MGV-(7,9KBMY-6-KB8[8XE4B97%]@[F8X,R,\2AL/2FW.2$CN+K% N$,\F,-B
M&1(G)(%D"*QN=0:9,;G&9?"YBQM<GB<KC;VC-;WF/R2./:5<SOK&[H%!A"I(
MJ)-(4$C$ 8!!O>UPP;"VON!=;8HM@FNV$<0X#@[B_*Y2X0W"V-H9BR*+Y.O0
MMC6ND:V.P9E8FA4_+6QE1IC5@R1*#"$A)8AW 4"P0V[0*",TDTKTWF2[)SI+
M]2]9I6Y9L6L[EF9QDF!\6/J[+CC'4K@ACZ_)RMTBJI1/5K$A=E1*,UU$K&E*
M4F@+N$)@[7#-\,:[Z_ZX1]9$M>,&8=P-%7%;XDX1G#&,H5BZ/KG']<MW]8S0
M=D8VU2MZ#1?KHRQ#^:O\/PWH/YYIURUZV28VZ,;%8'PSGR--"T;DTQ[-.+X1
ME-C:W$P)8#%[<TSEC?4"):,!(+7-*+".]@VM>_P6H,0.TQT]40R"8Y4:H:U'
MX]Q;*VZ=XR@9V"L7&PS',X9TA3>T3*"1<<6$R1"5M2 D!"9Q;R$ZP@D 0 ,"
M&UK4&>9>P'@K8./6B.>\+8FS?% ]?JQC+V.8?DJ/![12@6F=#+,V9Z;;==8U
M)3;_ *U\)J8H5_FBP7L&.X3U4U>UI)=4^N.MV!-?R'PP9SV1A/#V/,5$O!Q@
M48##74N"1UA X&# W)[7$=8=[V(+M?\ L ] ;.G$!@N3HPZ0G),+B60H8^$W
M3/41G$<9Y9&'A/?]$AT8'Y&O:G F_P#W!I0P_P#PJ#0V(-&=)M>Y&.88"T\U
M9P?+3"[$CE.(-?<2XTD8R;%*2+%#>X7$65S$78A:<#JW-Z.H<.WZ A=(;@RI
MA[$>=8<MQYF[%N.<QP!R.(4N,&RI"(SD*'+U":QEDQZV,RYL=V54<GL:+J#&
M0(0.M?HO;IO0:7'H;HV;B<O IFF6J)F#2I$3+RL,#UVQ"/$Y4L3V<+$2@O'0
MH?>( D1%G=7U%MD=E(>]&] [=H/K!*Z@\I]7+6QC>7)L:S'MR;VIQ7-[*2=9
M,<[K4B,Y0D:RE%RC[)S%YY82@CN ?4N/IZM^CHH.(F;\D&T+_F]?-CO1R2!9
MM$=)+$,^P$HQB;.5Z&=K#Q)6Z5N6;$VA382XMB5>M[52Z%RU&FL1<P8EY(.N
M:$+E>!713:/62 ;6[1;T)HZP[B\A>>UF?\MP&+";C&S&S22-]/B<.4F-#@\-
M('4APESPK$G2K5I2%&K3)C#S%)2B]!<5FG6G7'9%K0,>Q. ,)Y[96H[O+6SY
MIQ5!,I-;:HO>PNW0-\Y87U(C.ZUK7ZY8 BZ;?HT']L,ZY:]:Y,RN.:]8'PS@
M>/+S G+F'#.+X1B]F6G!.4J FJVN$,;&A4&!4+#AV$,%[V&:,7Z(A7N'HQ'!
M.$,?S_(66(%AO%4(REEPQL.RMDJ(X\B,:G^3CF4!I;.;D*9,S0BD4T,:2SQA
M3"<E*FY 1BL#JVO>@_SD' V#<M2;&LURKAG%&39EAF0#EF'Y;D''<0F<FQ3*
MC%+0M,DN-7Z1L[DZP60#6," ZZUK-2J;FHDXKCZQ)=PAL1Z9&:2-+@PR%I;'
MYC=TAR!U97I E=&ES0J 7 H1N#<N*/1K4AX+] RS " *WP7M>@BG N/;07%<
MS3Y&QAH]J!CC(212)8DGD"UIPO#YFF5C5DN U2>41Z%-SV2I&O3EGW&$^PKG
M "/IZUK7L$OZ!01;9='-*8WE,S.4=T_U;8,V&N?C9N8677[$S7E,QY[4@_Q8
MS(*&)$2T;GVR4H?>+J^UZQ8;];I#;H#9\1P3A#'\_P A98@6&\50C*67#&P[
M*V2HCCR(QJ?Y..90&ELYN0IDS-"*130QI+/&%,)R4J;D!&*P.K:]Z#_.0<#8
M-RU)L:S7*N&<49-F6&9 .68?EN0<=Q"9R;%,J,4M"TR2XU?I&SN3K!9 -8P(
M#KK6LU*IN:B3BN/K$EW"&Q'ID9I(TN##(6EL?F-W2'('5E>D"5T:7-"H!<"A
M&X-RXH]&M2'@OT#+, ( K?!>UZ"*<"X]M!<5S-/D;&&CVH&.,A)%(EB2>0+6
MG"\/F:96-62X#5)Y1'H4W/9*D:].6?<83["N< (^GK6M>P;JR=@G"&;#H4HS
M-AO%67#\:RM#.\='Y.QY$9Z= 9PV" -MF4*,E30ZCBLK;QEAN0XH;D+"KAM<
M)ENBU!M6@C!/-(M+\IY)2YER=J)K!D;+Z(3<-%E:>8"Q3+\DI!M!@SFD26<R
M")N$H3B:SC!"3W JM<@0KW!U;WO0;(9L#8-CF57_ #M'L,XH8<WRN+H(/*,R
M,V.X@UY5DD*:K-%FR(/^0T+.1+GB+MUH^@[!O4+#$A/<D_4+MV)?5#FVXH=#
M4DOW"YZ"]U-,DTHQ+EWD#63O#X-HM=BGO'63XQYZS4ZE3+&P<L0]3&IJP]*A
MM4A<6OO*?YM,98SX2KW#I1Q)A+#& (@1C[ ^(\883@256J7IH1B2 Q3&\03K
MEH^U6K"(U#6EF9BE:LSYHTP)-AF"^$5[WH*S^=++&RN->-[-T;U PSF;->P^
M>TR77F!-&$\=3'(;_#4N44S@VS7(CT&',KP?$&6,P),YV3O2ONJ-(]*$ 1'E
MC,!TA)/C-TR8./S176[4QD D,7XMQZ@+G3JDZ@BI%E.3'J99E&0@/" )AZ1T
MG;VO$D[2XA$H;$$]:X2PT$[*!0*!0*!0*!0*!0*#5&6L#8-SZV1UDSMAG%&:
MF:(2A!.(FT9:QW$,CMD7FK4G6)&N7QU!,6=Y2,DH;4C@H*3N"8!2LDL\P(#+
M6&*UPVO0:SRYA7#>?X6KQOGC$N,LV8[7K6]R70++D#BV2(6M<6E196UKU<6F
M34\L:E:VJ@V-3FC($,DRW6!>U_AH-B(T:1O2)4"!*F0H$*8A&B1(R"DR1&D3
M%!)3)4J8D("4Z9.2 (   &P0!M:UK6M:@UAAW V#=>(ROA6 ,,XHP9#720+Y
M8YQ+#N.XAC*,N,J=4R!$YR5>PPIG9&I7('%&U)23UIA0E)Q28H(QW"6"U@PK
M-6GFI&R:UM<]B]6M<\^N3,7<EH<,U81QGE1:U$WM>URFU7.HP^GH2[V%>W5*
M$&WPT&QL78>Q'@Z*IH)A7%N.</PA$((T<-Q="(SC^*I!@3D) "31Z)MC2T$"
M E3%E6N FU[%EA#^@&UK!^#%F"<(8,)EJ?">&\58>(GTK7SN=$8LQY$<?$S6
M<.H2P.DREI<2:&@$CE;D D%E#BLL<L.L&UAF7Z+4'^7? V#9!EV*[ OV&<4/
M>>8+'UL3A.;7?'<0<LNPZ*N1;V4X1J*Y)6,YTRCT?7E25Q"<B2+24QH7!380
M+V/-ZP5!^H6E&UKAQ_OFL^F.&<O98S1NA,X_K8M=L8P*:2MFQ9BJ:FB+RE-<
ME2.+-#FV0.&.L;#>/*5SF,A.6F>CS^FX$QPBPL^TXUDA&F.K&!=6,= Z8G@W
M&49@21<(/44/[HV(0#DTM7AMT "ZS*3J%CJLZ@0%]Z6&=0  ] ;!GSO@;!L@
MR[%=@7[#.*'O/,%CZV)PG-KOCN(.678=%7(M[*<(U%<DK&<Z91Z/KRI*XA.1
M)%I*8T+@IL(%['F]8/Z/&#,)R'*\2SR_X>Q8^9R@+&Y1F"9F>,?1)SRO"HV\
M$NJ9WC\2R(M:#Y?'&-U3OJXM2D1K"2#P+#PC *QIEA!_3+N$L,;!0Q1CC/6(
M\89NQZK7H'57 \NP&*9)ABES:C;GM;BHB\S:7IC.7MIPKC3G"(N82*_2"]KT
M&0,>/H%&(.WXQC4(B$>QLTQT$0:L>L<:9FF#MD3+0W;"XNWQ- B3L*..@;;W
M3V1%IPIK$7[.P.K\%!&9@XZN/J*S?WFQ?133>-Y(\1<GCW@L&L6$V>;^+//>
M?%W3S6W0A._>(NO?3N\G]X[4_M1]<0NL+I"54GBT8F\?=XE-(XPRZ*OZ(UM?
MHS)VAO?X^]MQ_18Y [LSJG5MKDB.M:W6*.+& 7^[:@TOA+475#6A0[+-<-8M
M>=?U;^3W9]582PMC?%*AZ3W&F-[!V/@D:837$GM41(NH=<8>L2"_1TA#T!^7
M-FF^H6RKFU/6QFJNMV?GEA3'(V-VS9@W&.5'-F2*+EB4)6I?.HN_*FY,>(D%
MQ@)& (K@MTVOT6H-W1.(1. QQJA\%B\=A<284UT;'%HFR-L<CC,DN:8?=*U,
MC.F1MC<FN><,?4)* 'KBO?HZ;WH,.Q_@S">)I#D:78KP]BS&DKS#)!3++DGQ
M_CZ)0V0Y3EXSW%4.59&>HXT-KE-Y()2[JS+KG,U4JN8J.%U^DP=Q!_&6X#P5
M/\BP#+\[PMB::Y:Q1W[W6Y1EN.8?),BXU\3M>SEY FSRS+)+#O$+7OV_ARE-
MVO3\UTT'IY4P]B/.L.6X\S=BW'.8X Y'$*7&#94A$9R%#EZA-8RR8];&9<V.
M[*J.3V-%U!C($('6OT7MTWH-/@T9TF*Q&HU_+T\U9+P.K>D\C583!K[B4&(U
M,A2*SEZ1^48W#$;0TYZ2KE)AQ:H2*YX#3!#L*PA7O<-EY0P!@C-\388%FC"F
M),O0:+/C-)HQ"\H8WAT_B<<DD<1K&^/2!ACDK9G9G:'QB0."@A&K3DEGI23S
M %C"$8K7#;=!JS'^#,)XFD.1I=BO#V+,:2O,,D%,LN2?'^/HE#9#E.7C/<50
MY5D9ZCC0VN4WD@E+NK,NN<S52JYBHX77Z3!W$&N<HZ5Z;YPG+;D_-6I>LV7\
ME,WA_A&0\HX'Q9/YRU>$&$G-7ALMED5=G]#X8:F+$G[)0'L1%AN#JW#;H#-T
M.N^O[7DYJS8V8,PZW9F8H0FQDR9<0XRA23)S-C='T]SQ\U3U.R%RIOA"7K7[
M-I)5@0 Z?F2K4&XJ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"O
MWE3D;A$.//:R4-*=A5N;!C(YV0II1%HQ-XZ>J1/;,>24]P^:-#_$I*VC&"UC
MD3BA5(U .D!I0PWO:]_>*SMVGW?Q@^5=KU=V>S3:C<XQW78,^;39HMNQY(F<
M>HTV3%GPWT_LY,.2S)9/3;=$Q5..S73V:KGK;--EF^,=^IBV9LOOQW1$VW1]
M3?CNMOLGA=9=;='DQ,2^>'^'#FCV*T__ -7KH+_[+17Z%?W(<F>O>;__ )7S
M3_K+=OP.VCS[=?\ N>Y?E9^'#FCV*T__ -7KH+_[+13]R')GKWF__P"5\T_Z
MR? [://MU_[GN7Y6?APYH]BM/_\ 5ZZ"_P#LM%/W(<F>O>;_ /Y7S3_K)\#M
MH\^W7_N>Y?E9^'#FCV*T_P#]7KH+_P"RT4_<AR9Z]YO_ /E?-/\ K)\#MH\^
MW7_N>Y?E:[C@.V)R!F3=":126Q_!3.V)M=YL]E*\5ZMZQX-D8EB2>XM2%$J)
M?A7$, E:UH&2O,N:WGK3$!QH2C3"1&D$#+PC\X9V<<O\I=AVBW/:M3OV74W<
MR:7'-NMWS>MRQ=6[2:ZZ9C!N.OU6"V^ML4RVXXRVV]:VV^++[[;J6[=^7]#M
M?)N'4Z;)K;LD[ACMIFUFKU%M)Q9IZ+-1GRV1=T12Z+8NB*Q$TF8GL)\((_9"
M_P#;AWZ=<6F1*GA!'[(7_MP[].A4\((_9"_]N'?IT*GA!'[(7_MP[].A4\((
M_9"_]N'?IT*GA!'[(7_MP[].A4\((_9"_P#;AWZ="IX01^R%_P"W#OTZ%3P@
MC]D+_P!N'?IT*GA!'[(7_MP[].A4\((_9"_]N'?IT*GA!'[(7_MP[].A4\((
M_9"_]N'?IT*GA!'[(7_MP[].A4\((_9"_P#;AWZ="IX01^R%_P"W#OTZ%3P@
MC]D+_P!N'?IT*GA!'[(7_MP[].A4\((_9"_]N'?IT*GA!'[(7_MP[].A4\((
M_9"_]N'?IT*GA!'[(7_MP[].A4\((_9"_P#;AWZ="IX01^R%_P"W#OTZ%3P@
MC]D+_P!N'?IT*GA!'[(7_MP[].A4\((_9"_]N'?IT*GA!'[(7_MP[].A4\((
M_9"_]N'?IT*GA!'[(7_MP[].A4\((_9"_P#;AWZ="IX01^R%_P"W#OTZ%3P@
MC]D+_P!N'?IT*GA!'[(7_MP[].A4\((_9"_]N'?IT*GA!'[(7_MP[].A4\((
M_9"_]N'?IT*GA!'[(7_MP[].A4\((_9"_P#;AWZ="IX01^R%_P"W#OTZ%3P@
MC]D+_P!N'?IT*O?CL?2JEII8UCJ78*48^L0XJ"1WO8X@/1<0!6O</S7Z'_9H
M59GY00_5%_\ EI9\_0J>4$/U1?\ Y:6?/T*GE!#]47_Y:6?/T*GE!#]47_Y:
M6?/T*GE!#]47_P"6EGS]"IY00_5%_P#EI9\_0J>4$/U1?_EI9\_0J>4$/U1?
M_EI9\_0J>4$/U1?_ ):6?/T*GE!#]47_ .6EGS]"IY00_5%_^6EGS]"IY00_
M5%_^6EGS]"IY00_5%_\ EI9\_0J>4$/U1?\ Y:6?/T*GE!#]47_Y:6?/T*GE
M!#]47_Y:6?/T*GE!#]47_P"6EGS]"IY00_5%_P#EI9\_0J>4$/U1?_EI9\_0
MJ>4$/U1?_EI9\_0J>4$/U1?_ ):6?/T*GE!#]47_ .6EGS]"IY00_5%_^6EG
MS]"IY00_5%_^6EGS]"IY00_5%_\ EI9\_0J>4$/U1?\ Y:6?/T*GE!#]47_Y
M:6?/T*GE!#]47_Y:6?/T*GE!#]47_P"6EGS]"IY00_5%_P#EI9\_0J>4$/U1
M?_EI9\_0J>4$/U1?_EI9\_0J>4$/U1?_ ):6?/T*GE!#]47_ .6EGS]"IY00
M_5%_^6EGS]"IY00_5%_^6EGS]"IY00_5%_\ EI9\_0J>4$/U1?\ Y:6?/T*G
ME!#]47_Y:6?/T*GE!#]47_Y:6?/T*GE!#]47_P"6EGS]"IY00_5%_P#EI9\_
M0J>4$/U1?_EI9\_0J>4$/U1?_EI9\_0J>4$/U1?_ ):6?/T*GE!#]47_ .6E
MGS]"IY00_5%_^6EGS]"IY00_5%_^6EGS]"IY00_5%_\ EI9\_0J>4$/U1?\
MY:6?/T*GE!#]47_Y:6?/T*GE!#]47_Y:6?/T*GE!#]47_P"6EGS]"IY00_5%
M_P#EI9\_0J>4$/U1?_EI9\_0J>4$/U1?_EI9\_0J>4$/U1?_ ):6?/T*GE!#
M]47_ .6EGS]"IY00_5%_^6EGS]"IY00_5%_^6EGS]"IY00_5%_\ EI9\_0J>
M4$/U1?\ Y:6?/T*GE!#]47_Y:6?/T*GE!#]47_Y:6?/T*GE!#]47_P"6EGS]
M"IY00_5%_P#EI9\_0J>4$/U1?_EI9\_0J>4$/U1?_EI9\_0J>4$/U1?_ ):6
M?/T*GE!#]47_ .6EGS]"IY00_5%_^6EGS]"IY00_5%_^6EGS]"IY00_5%_\
MEI9\_0J>4$/U1?\ Y:6?/T*GE!#]47_Y:6?/T*GE!#]47_Y:6?/T*GE!#]47
M_P"6EGS]"IY00_5%_P#EI9\_0J>4$/U1?_EI9\_0J>4$/U1?_EI9\_0J>4$/
MU1?_ ):6?/T*GE!#]47_ .6EGS]"IY00_5%_^6EGS]"IY00_5%_^6EGS]"IY
M00_5%_\ EI9\_0J>4$/U1?\ Y:6?/T*GE!#]47_Y:6?/T*GE!#]47_Y:6?/T
M*GE!#]47_P"6EGS]"IY00_5%_P#EI9\_0J>4$/U1?_EI9\_0J>4$/U1?_EI9
M\_0J>4$/U1?_ ):6?/T*GE!#]47_ .6EGS]"IY00_5%_^6EGS]"IY00_5%_^
M6EGS]"IY00_5%_\ EI9\_0J>4$/U1?\ Y:6?/T*GE!#]47_Y:6?/T*GE!#]4
M7_Y:6?/T*GE!#]47_P"6EGS]"IY00_5%_P#EI9\_0J>4$/U1?_EI9\_0J>4$
M/U1?_EI9\_0J>4$/U1?_ ):6?/T*GE!#]47_ .6EGS]"IY00_5%_^6EGS]"I
MY00_5%_^6EGS]"IY00_5%_\ EI9\_0J>4$/U1?\ Y:6?/T*GE!#]47_Y:6?/
MT*GE!#]47_Y:6?/T*GE!#]47_P"6EGS]"IY00_5%_P#EI9\_0J>4$/U1?_EI
M9\_0J>4$/U1?_EI9\_0J>4$/U1?_ ):6?/T*GE!#]47_ .6EGS]"IY00_5%_
M^6EGS]"IY00_5%_^6EGS]"IY00_5%_\ EI9\_0J>4$/U1?\ Y:6?/T*GE!#]
M47_Y:6?/T*GE!#]47_Y:6?/T*GE!#]47_P"6EGS]"IY00_5%_P#EI9\_0J>4
M$/U1?_EI9\_0J>4$/U1?_EI9\_0J>4$/U1?_ ):6?/T*GE!#]47_ .6EGS]"
MIY00_5%_^6EGS]"IY00_5%_^6EGS]"IY00_5%_\ EI9\_0J>4$/U1?\ Y:6?
M/T*GE!#]47_Y:6?/T*GE!#]47_Y:6?/T*GE!#]47_P"6EGS]"IY00_5%_P#E
MI9\_0J>4$/U1?_EI9\_0J>4$/U1?_EI9\_0J>4$/U1?_ ):6?/T*GE!#]47_
M .6EGS]"IY00_5%_^6EGS]"IY00_5%_^6EGS]"IY00_5%_\ EI9\_0J>4$/U
M1?\ Y:6?/T*GE!#]47_Y:6?/T*GE!#]47_Y:6?/T*GE!#]47_P"6EGS]"IY0
M0_5%_P#EI9\_0J>4$/U1?_EI9\_0JRFP;6&(?2+I$$(;VZ;]6U@7'>U[!_0L
M*_7^&_\ N]%O^Q1_'^J!0*!0*"*NX0TQ>*$9BIHCCV $P:+A12F,1V7-?7NW
MO(;'7:)0UN[7=06$5[ ,N3V@.F_5O;IO6./'C[7>T7L4[&,/.79AN=^U<RW;
MWIM/.:W%@S3.'+AU-U]DV:C%FQTNNQV37J=:)MBDQTK:[&.4N7>=.;[]GYGT
MUNKVV-%DR19==?;'7MOQQ;=7'=9=6(NF/)IT],*P>_M/[W>%/N"X5^T&N0_^
MXEXY7Z[:C_M^T_D#57\O?8Y^A,/W[4_ASO[3^]WA3[@N%?M!I_N)>.5^NVH_
M[?M/Y ?R]]CGZ$P_?M3^'._M/[W>%/N"X5^T&G^XEXY7Z[:C_M^T_D!_+WV.
M?H3#]^U/X<[^T_O=X4^X+A7[0:?[B7CE?KMJ/^W[3^0'\O?8Y^A,/W[4_AWE
MNO&+A7;$Q+EZ79<VQQ4\+$O@(XCK5L9.-=\6D)V-4J((6H<9XL,CT/0NZZQM
MQ+%124!JLSYLVXA]-[]E?$R[4N>^V+L(T//':1K[MSYJS:W68\FHNQX<4W68
M<]UF.)LP8\6*.K9$6_4V16(K=6ZLSDCM=Y7V+E#G;-LG+FGMTVUV8<5UN.+K
M[HB;[(FZ:WW77=,]/3=/<Z.AY?YB_6[\:/DN_+^S[]?ZU4K(_,7ZW?C1\EWY
M?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7
M]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY
M?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7
M]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY
M?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7
M]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY
M?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7
M]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY
M?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7
M]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY
M?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7
M]GWZ_P! _,7ZW?C1\EWY?V??K_0/S%^MWXT?)=^7]GWZ_P! _,7ZW?C1\EWY
M?V??K_0/S%^MWXT?)=^7]GWZ_P!!_8C@RUQ+- (&TO)@ 5[V#U@<@.P !6L+
MX+] @2$(K?!>@V7^86UG_&MY/_\ 6&;!_;!0/S"VL_XUO)__ *PS8/[8*!^8
M6UG_ !K>3_\ UAFP?VP4#\PMK/\ C6\G_P#K#-@_M@H'YA;6?\:WD_\ ]89L
M']L% _,+:S_C6\G_ /K#-@_M@H'YA;6?\:WD_P#]89L']L% _,+:S_C6\G_^
ML,V#^V"@?F%M9_QK>3__ %AFP?VP4#\PMK/^-;R?_P"L,V#^V"@?F%M9_P :
MWD__ -89L']L% _,+:S_ (UO)_\ ZPS8/[8*!^86UG_&MY/_ /6&;!_;!0/S
M"VL_XUO)_P#ZPS8/[8*!^86UG_&MY/\ _6&;!_;!0/S"VL_XUO)__K#-@_M@
MH'YA;6?\:WD__P!89L']L% _,+:S_C6\G_\ K#-@_M@H'YA;6?\ &MY/_P#6
M&;!_;!0/S"VL_P"-;R?_ .L,V#^V"@?F%M9_QK>3_P#UAFP?VP4#\PMK/^-;
MR?\ ^L,V#^V"@?F%M9_QK>3_ /UAFP?VP4#\PMK/^-;R?_ZPS8/[8*!^86UG
M_&MY/_\ 6&;!_;!0/S"VL_XUO)__ *PS8/[8*!^86UG_ !K>3_\ UAFP?VP4
M#\PMK/\ C6\G_P#K#-@_M@H'YA;6?\:WD_\ ]89L']L% _,+:S_C6\G_ /K#
M-@_M@H'YA;6?\:WD_P#]89L']L% _,+:S_C6\G_^L,V#^V"@?F%M9_QK>3__
M %AFP?VP4#\PMK/^-;R?_P"L,V#^V"@?F%M9_P :WD__ -89L']L% _,+:S_
M (UO)_\ ZPS8/[8*!^86UG_&MY/_ /6&;!_;!0/S"VL_XUO)_P#ZPS8/[8*!
M^86UG_&MY/\ _6&;!_;!0/S"VL_XUO)__K#-@_M@H'YA;6?\:WD__P!89L']
ML% _,+:S_C6\G_\ K#-@_M@H'YA;6?\ &MY/_P#6&;!_;!0/S"VL_P"-;R?_
M .L,V#^V"@?F%M9_QK>3_P#UAFP?VP4#\PMK/^-;R?\ ^L,V#^V"@?F%M9_Q
MK>3_ /UAFP?VP4#\PMK/^-;R?_ZPS8/[8*!^86UG_&MY/_\ 6&;!_;!0/S"V
ML_XUO)__ *PS8/[8*!^86UG_ !K>3_\ UAFP?VP4#\PMK/\ C6\G_P#K#-@_
MM@H'YA;6?\:WD_\ ]89L']L% _,+:S_C6\G_ /K#-@_M@H'YA;6?\:WD_P#]
M89L']L% _,+:S_C6\G_^L,V#^V"@?F%M9_QK>3__ %AFP?VP4#\PMK/^-;R?
M_P"L,V#^V"@?F%M9_P :WD__ -89L']L% _,+:S_ (UO)_\ ZPS8/[8*!^86
MUG_&MY/_ /6&;!_;!0/S"VL_XUO)_P#ZPS8/[8*!^86UG_&MY/\ _6&;!_;!
M0/S"VL_XUO)__K#-@_M@H'YA;6?\:WD__P!89L']L% _,+:S_C6\G_\ K#-@
M_M@H'YA;6?\ &MY/_P#6&;!_;!0/S"VL_P"-;R?_ .L,V#^V"@?F%M9_QK>3
M_P#UAFP?VP4#\PMK/^-;R?\ ^L,V#^V"@?F%M9_QK>3_ /UAFP?VP4#\PMK/
M^-;R?_ZPS8/[8*!^86UG_&MY/_\ 6&;!_;!0/S"VL_XUO)__ *PS8/[8*!^8
M6UG_ !K>3_\ UAFP?VP4#\PMK/\ C6\G_P#K#-@_M@H'YA;6?\:WD_\ ]89L
M']L% _,+:S_C6\G_ /K#-@_M@H'YA;6?\:WD_P#]89L']L% _,+:S_C6\G_^
ML,V#^V"@?F%M9_QK>3__ %AFP?VP4#\PMK/^-;R?_P"L,V#^V"@?F%M9_P :
MWD__ -89L']L% _,+:S_ (UO)_\ ZPS8/[8*!^86UG_&MY/_ /6&;!_;!0/S
M"VL_XUO)_P#ZPS8/[8*!^86UG_&MY/\ _6&;!_;!0/S"VL_XUO)__K#-@_M@
MH'YA;6?\:WD__P!89L']L% _,+:S_C6\G_\ K#-@_M@H'YA;6?\ &MY/_P#6
M&;!_;!0/S"VL_P"-;R?_ .L,V#^V"@?F%M9_QK>3_P#UAFP?VP4#\PMK/^-;
MR?\ ^L,V#^V"@?F%M9_QK>3_ /UAFP?VP4#\PMK/^-;R?_ZPS8/[8*!^86UG
M_&MY/_\ 6&;!_;!0/S"VL_XUO)__ *PS8/[8*!^86UG_ !K>3_\ UAFP?VP4
M#\PMK/\ C6\G_P#K#-@_M@H'YA;6?\:WD_\ ]89L']L% _,+:S_C6\G_ /K#
M-@_M@H'YA;6?\:WD_P#]89L']L% _,+:S_C6\G_^L,V#^V"@?F%M9_QK>3__
M %AFP?VP4#\PMK/^-;R?_P"L,V#^V"@?F%M9_P :WD__ -89L']L% _,+:S_
M (UO)_\ ZPS8/[8*!^86UG_&MY/_ /6&;!_;!0/S"VL_XUO)_P#ZPS8/[8*!
M^86UG_&MY/\ _6&;!_;!0/S"VL_XUO)__K#-@_M@H'YA;6?\:WD__P!89L']
ML% _,+:S_C6\G_\ K#-@_M@H'YA;6?\ &MY/_P#6&;!_;!0/S"VL_P"-;R?_
M .L,V#^V"@?F%M9_QK>3_P#UAFP?VP4#\PMK/^-;R?\ ^L,V#^V"@?F%M9_Q
MK>3_ /UAFP?VP4#\PMK/^-;R?_ZPS8/[8*!^86UG_&MY/_\ 6&;!_;!0/S"V
ML_XUO)__ *PS8/[8*!^86UG_ !K>3_\ UAFP?VP4#\PMK/\ C6\G_P#K#-@_
MM@H'YA;6?\:WD_\ ]89L']L% _,+:S_C6\G_ /K#-@_M@H'YA;6?\:WD_P#]
M89L']L% _,+:S_C6\G_^L,V#^V"@?F%M9_QK>3__ %AFP?VP4#\PMK/^-;R?
M_P"L,V#^V"@?F%M9_P :WD__ -89L']L% _,+:S_ (UO)_\ ZPS8/[8*!^86
MUG_&MY/_ /6&;!_;!0/S"VL_XUO)_P#ZPS8/[8*!^86UG_&MY/\ _6&;!_;!
M0/S"VL_XUO)__K#-@_M@H'YA;6?\:WD__P!89L']L% _,+:S_C6\G_\ K#-@
M_M@H'YA;6?\ &MY/_P#6&;!_;!0/S"VL_P"-;R?_ .L,V#^V"@?F%M9_QK>3
M_P#UAFP?VP4#\PMK/^-;R?\ ^L,V#^V"@?F%M9_QK>3_ /UAFP?VP4#\PMK/
M^-;R?_ZPS8/[8*!^86UG_&MY/_\ 6&;!_;!02HU8XUL<:@/\JDF+MB-SY*OF
M#.B9'4C-^Q\ESZU)D:%;=>2:QM&7D$O;F!P&<+H,4HRR3S2_F!"N'X*"Q>@4
M%;_+W_-H[C_P/N/^-FBM&^*+\I3D[WXL^PR)_P!EO\0MI]EQWKGS(:_3(Z(%
M H%!T">FY_S])W_)AR!_&-B"N>'SF7R?M!^U.D_$]P4/XQ'Q%P>^6+T+.[DJ
MX.L4% H.?/E]]0MK?Q725/A1!!GC8?9]:QMTC58O8I"EB$6@3$]DJ#61PR1.
MS6N1'-3H[$@ J2-"-M6+3T0PGGB1DGI33PH[-]59R;Q^/CRK+>*5.CPL<C0.
MB.7FL6P,>C]FJQ9AZ]>/)+G&U\34HUJ<D8TYX4Q99 0W$+MK6O0=0/$)R@QK
MEHU=?]D([B)\PF=$<NOV&9)"7J6()N6"2QZ$8\G"QP8Y.A98T)T8S4.14Q)1
MBAN0J+FIS+B)"'JWN%?O-WZ@E/Q+Y?P]@Z$8*C^?)Y/<?NF2YJE><CK(.5!H
MX>_#CL( 66VQ24FN*R3+61Y&8$VZ:Z<E$4*UC+']( E3PE<OC3R[X-RKD!=C
M5KPUDK#N24L/EN.6J7*9HG!&9%'TKU")H4[JV&.GEIY&K2O"*Q B+W <SFBZ
MUPC#:P?ZYNN5^1<1^ \2YGC>%F7-RK)>7[8P/87R:KH0G:$]X9)I5XN2O01R
M2&*SNT8 D]C<HL/5-N+K=-NBX<X23UDVP[@SFR)!QHLBV/D$JU![ZDS'.%+.
M2G06,NN/-<R<0#1%DHK%#N:*X[!+ZM^M>W1>@NDXA_4?Z_<H>4[:YR7$C]K7
ML2X,KR_0N)+YBER1"LD(HT@5N\B1Q29IXU#7%-)FI@0'.9K:M:20=Q(.$2J4
M7('0='HQ@+ (PP00  $0QC&*P0  &UQ"$(0KVL$(;6Z;WO\ !:U!Q9;S>K\A
M6 MEL@X;U?UPC6R&-,=K Q@_,CME5RAS9+Y>W&'E2@R'-K=")"!?#FQ=:R-(
MXC/M9Q,(-4$ANE,(,,#KQU\R>HS;@3"&9U;03'E67,0XUR>I8$ZP;@G8U$^A
MC+*SF@A>:G2&+B6TQVN2$X110C0@L*X WOT6"*?)KR-X5XP]795L1EQ06[O-
M^UCN(\7I%Y:*0Y:R6K1GGLT4:C!$J1-[60$D2MW<A%&E-C:28;U#CKD)CPIA
MX:O4;3CE1V[7ZQR'5:*8:0(\033)X9>RY5=YFL&HBCS$FLMHNSKH/'B0DK0R
M40Q'=XZP+DVM8-^M>]@D#SE<Y4MX@I;KM&8SKM',Y SE',BOJM6^Y%<X,..C
M@SG$F\E,F);XE);.(7&TE$(0A")N7<FUK6%UKWL%+"?UA6T2Q.0K2<7)*I*J
M)*4)E*?*>0STZA.> )I)Y!Q6&A%G$G%BL((@WN$0;VO:_10=*?&-R;S#>K1#
M(^YF4<!*,&...Y1E9J58S2/KH]JW)EQE#F*6^)I7&11V*GEJ'H+H:0 (DW9
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M7;3/+<*(?BFF>['0N<.F.6N-Y&@SCM5-,D),?H95''0#@$QNCAJHI%<29Q
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M%[?"AW1B&4[NL?;USD6(3> MO$("T\=KW("$F][?,6L'HH,[H% H% H% H%
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MG.54*!&FD$_P5.(<_K""^S5.27&LY2.3(8NZH @/,3 R.H* ;>XC+EAL"_0
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MCL9M^ND:O)T4TQ9"Y3(V!U?YW.T\I88T6]*'=PC"- B-8+O#*D)/,L>NNL4
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MMTMK&I+U34Z7$6+D[XCCJ-Y, : I$FD+ S3-$$*D5K76K&ZX &&&%!$'6
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M@;"^7XBT3S&.3B=IX;.(@^I^\-C['GO8S+R1<D.M:X#DYP0#[0A02(M0E/
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M_BV/4'G;;_[7+Q9?R ,R_P"(-U:#JYH% H% H% H% H% H% H% H% H% H%
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MWEZ:4#6A9K'ID]ERE>3=,%MV_P!DO3CA\X6A:499RX9$CY5HSF;4[ JH^"9
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M5P%HQ#'<U9!DKOL$HC<W9IF^Y9.Q^FB+7G[)4ID1 4QN.'%:H,&S,QP2%Z0
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M*\X\PQ2G-%<P?6MT7M;H"=&-\98OPW$6S'^(<?0'%4#90B SPG&\3CT&B+2
M=@V$%LC<80-;,@"*P+=-BB06OT6_[%!G?:%_VP'ZH/Z= [0O^V _5!_3H':%
M_P!L!^J#^G0.T+_M@/U0?TZ!VA?]L!^J#^G0.T+_ +8#]4'].@=H7_; ?J@_
MIT#M"_[8#]4'].@=H7_; ?J@_IT#M"_[8#]4'].@=H7_ &P'ZH/Z= [0O^V
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M0.\)_P"WD_10?/4#O"?^WD_10?/4#O"?^WD_10?/4#O"?^WD_10?/4#O"?\
MMY/T4'SU [PG_MY/T4'SU [PG_MY/T4'SU [PG_MY/T4'SU [PG_ +>3]%!\
M]0.\)_[>3]%!\]0.\)_[>3]%!\]0.\)_[>3]%!\]0.\)_P"WD_10?/4#O"?^
MWD_10?/4#O"?^WD_10?/4#O"?^WD_10?/4#O"?\ MY/T4'SU [PG_MY/T4'S
MU [PG_MY/T4'SU [PG_MY/T4'SU [PG_ +>3]%!\]0.\)_[>3]%!\]0.\)_[
M>3]%!\]0.\)_[>3]%!\]0.\)_P"WD_10?/4#O"?^WD_10?/4#O"?^WD_10?/
M4#O"?^WD_10?/4#O"?\ MY/T4'SU [PG_MY/T4'SU [PG_MY/T4'SU [PG_M
MY/T4'SU [PG_ +>3]%!\]0.\)_[>3]%!\]0.\)_[>3]%!\]0.\)_[>3]%!\]
M0.\)_P"WD_10?/4#O"?^WD_10?/4#O"?^WD_10?/4#O"?^WD_10?/4#O"?\
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MJEV3,@8OQ!B+&\\S2[H9!F.;0+'\-A\NRR_MASRI;7O)DDCS2W/,[=V]1(W
MPA2Z'*CBAKU @BM<\VX@2C!V!9ODJ!YFFF(,12_,&+"7%-C'*\HQ_#7_ "5C
ME.\%'D.Q$#G3LTJY1$"70A4:!0!O5)PG@,%8=A6%?I#^C/A3!<>RO+<\L&)<
M3,><I\QML9G>9F>!P]LRO-8VSDM29HC\MR(B:B)?(V-J3L2$M,D6+#B" (R
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M5E\[8,O$6)"\^*(I:"*,W@@,.!E\^#A/*4AAIV2@M-IF;%+*2 &6;A+;H^N
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MZ-O;D)9"-$D(!;H 66 ( V^"UK4&O<681P1@PF6I\)XBQ)AXB?2M?.YT1BR
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M,HY'#(FRO VE<H0$#.37.[$T9)8A!O< ;V#R<D:!Z)9CF[ODW+VE6I.5,D2
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ML1]8F.4,SG'9*S-4BC[TB/;7EB?6Y&[,SLW*B[E*D#FV+R5")>B4E"N$PHT
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MG0K)X0V?L,G_ +0OTZ%9/"&S]AD_]H7Z="LGA#9^PR?^T+].A63PAL_89/\
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MROTJ![JL<>Q<?^3ROTJ![JL<>Q<?^3ROTJ![JL<>Q<?^3ROTJ![JL<>Q<?\
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M_@?<?\;-%:-\47Y2G)WOQ9]AD3_LM_B%M/LN.]<^9#7Z9'1 H% H.@3TW/\
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M?),%))"6!.:ZDW;W5W9'QK(4+4"DLLFZ>P;@Y*6OU!F2=@DV,N,61ZFZ^ZY
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MZ-\<>H&5YSA_9_D&V;B,6OD7%<QD$(R!C3!4!=6QSR1,T$EB*]LDD>2%KW)
M:I-)/!WQE;W5/U#@B,!8-U<QG+2DXF,-X.Q?AW'SOLMN3L$O1XOUFP\].DBE
MCM(%;,%DCQLZR.H;E)TZEH1O#N@1DI2#RG:3O"RY92DKJ*U2<*ND&*O683-I
M3YR%L]H]C Y46U2.VGZ^,XJ/=DX4J9ONHA*A^+UUGJ DQW$ RZH5\GW&4:8;
M8E<G#8FP GWPO\SN2MV\D9NT;WFPTW:T<B6LA9BB=X_;N]HXWD:+MI[8UO4K
MC#8XN#R<SNK(Y.R,:Q&2XN2!:WN21R;51R0XTM(&$8AWYV^TSYEYCQW\B&7_
M 'LZ^;B)AS3C:SP]8^QKCT]N<27!7<W7V5..,H3!X^_28 EO@W>5I9J\]S2-
M1@ EA?R2"@WOS9\C.:]9V?!.ENB $[[R3[RS-!"=?D0FQAD*+%,02.9'G7-L
MQ9Y$UR!B+869&0>0G,=$)S:464O<#[&)VE24,+C<(1/(\$Q!C:'Y@RHOSAE:
M/0YC;<C9<<8S$H6=D&:$HBKR22D1""L<<BL9;%[J(VZ) D2!LE1V*+,,/-"8
M>:')!Z@?GBV>P(MR5A'B^= MSQJ@[PM5NQM4GB$%R!$<426=O(8M!-=&)-D2
M.2V"N60GQS5FJWH/=%"Y !M-3DV :D=;I0ZGTV=63'&H*39?,SV(F/0;7%+F
M_*<B E0D&!:H[C0N=31V)0D6;FTLX29(I- 078@GKWL -@!Z.@.17".TWJ=^
M8*,2[<30S)>L6C>I2F52YIP; LH1F$ODIRFQ1AP4M!IJ9\EN!<^.#NZH71G-
M;UKB:=%6<YU&H+3 [$BXB N!X/N5?.>\1FS6JF\&-HWB#??26:DQ#,<<BA)K
M?')M'5J]U:&V;,S2:YO9")>@=F8Q(Z=Q7*VE390B<$0RTS@6E3!?Y0<UG(UG
M;-\'Y\>%##L*S)E6(8BRJP[$'90Q9%\ARZ/XXR0<R1)^4LQL^@[2[I(S,#&A
M02 Q*)Q2J+IQ@L(OJWM:]!TIT%<'*!C3DNRI@*(1[BNV%P_K7L&CS P/,QG6
M:V5J?8J[8:3PO("&0Q-O2/&#\^IBY NFSC'EA1@6=,99,@/#98780B% 6/T"
M@4"@4"@4"@KGY!L;<D^1?P<?S=FP6(<#>6LS-CWLK[UV5J>/>#A0KN?BD0B'
MBF$<S]RD2GJ']0TKP,RW7M_=H?\ >A"SU#N]F?\ 2C3''K+J<[)(SLIMML5C
MO5K%\U5HTROR"9.D,@='F6H/$43BUDNX2&$IL3'')SQI!NG>RB[F)@B"&F]/
M.(SE7U(0[#Y*?N:S,VUF:,DZB9@QOA['>=F[)3SA+$&T<Q:6ETQEF E?D?+F
M=FA>PXVFK3<CH# 0C6-2LWK(NIUF\T+D-"H;N3C_ %.Q3$>0++&/\X[=-'GG
MWM92Q:VH6B"2CO\ DF8N<#\";VW&F'T2?P3&2UE;E74CC=UUB0T5^\"O=4<$
MOZ!0*#F(Y\]_M\L49IT^T.XMYN3#]O,WQ_->>I<MM!<>Y 4E8>Q#C^5.S5'1
M-.2(1D%D0!GSQ&WFZ=6! 4?9:PE$64%E*#0C"QCA)WN=^1?C8UUV.FCND>LN
MF,:_'&<UB5N;V?O67,;KC(W)GP]H9DC>QM)TV2)TDA[J@((1)P.X2R"B2PA*
M $&MB<YYL9/4\Z"X"9<PY3:,$S+0+*$RE^%6O(,M08EE4O;UFRX4$JDF.$CN
M5#GR2(@L*&Q*Y4C-5%V1$=4=NQ+ZH=(E H% H% H% H% H% H% H% H% H%
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M9OE3(\K@<T62G(&2)6_3B;216ER[D-M2JG^5R=>Z/KPI3-R(E.6-0>8(!!(
M6O8( VL%P=!7/Q\XVY)\=?A'?G$]@L0YY\RYF<WO6KW4,K4S^[["AO?/"XA+
M_"\(X8[[(DW7(ZYIOCAE^I?^[1?[X+&*!0*!04@[Q\E>==9^5?C%T9@D4Q,[
M8EW2]XGO2D,M8I@OR*P>42S1MOD!V9IVPQIK[>X+=OXBT.O6_P![U*"S+;F-
M;)S#6K,D8T\R#$,4[.O4,6HL+9%GR)*XPV(S89Z82%XD*%=",DI%+<20$T(@
MF,3H&]Q6_6!?HV!J-&MDX?K5AN,;AY!B&5MG66&(D6:<BP%$E;H;+IL ]2)<
M\1Y"AA&-DB9N.($4$(2V)K#:X;_K ?T;A(R@4"@4"@4"@4"@4"@4"@KG]VW)
M/^<J]YWX06(?S8WN9\$_!U\%:O?'[Z^Y=3S?XW[D?%O+O?OF^R\]=GU?_C+_
M 'M!8Q0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#G.]
M2ENCNMI7JQK"_P"A^4"\5YIS/N9 <$W=#H9BN:$OC3,\=916HHZ:ER[$)E&F
MDM9*V5M,$M 00>58GHN<$H1H1!,/A+WZ?^0[0?'F4\G&=CL?C)Y?L [3LQS,
MBC:YLSQC"Z1#)%R^.MQ29N95,O9EK>^&)4I"9(E.<C$Y))(2>R '.%S-<Z6_
M.,.2%NPIHEE,O&^K6 ,Q8 U@V%E1&-\.3Y)D'8K+2F03:215$^Y(@DO=&PN(
M0>/'LRI.U&)#D#J@6"4#O<]'U0[JZ!04O>H9RGD["O#GNCD_#>1IYB7)468<
M1'1C(>,I?(('.8X<Y;"8D97$UAED5<&I_:#'!F<E"0\2=07<U,H,*%T@&(-P
MUKG/>[.6F?IY\8[X0TR/Y2SS"-*-)9J-?G,4OF[5-95DM)@F*RY^GRIJE\7F
M4C=W,J;+5IBJ[P4I.<;A..&;:Y@# MAT_P NR38#4O5W/,R1,;9+\VZZX2R[
M*FV,IEZ.-M\DR3C2,S)\11]&ZN3RZ)&-(Z/)I:0M2L5GED! $PXT=KC$$:M*
M<:<ET'S[O5(=X=A</YCU\GN8"7G0F"XX96IKE6$\-!FF7UQ\3R<K;\'XK4NT
M@'"7F&H[&*7B7&=Y:58N^6N,1ZP+'Z!0<SNT&><Y1_U1/&WK\PYFRNR8&G6D
M&6)9-L)-&1)>VXBF,J;63;HUODLJQLC>"8;(9 @-C3<(E:K1'*2A-Z:X1VN0
M5U0Z8J!0*""?(Q =^,DZS/$7XV,VXPU]V@.EL26,V1\NM+:]0Q)$$:\PR8-2
MA"ZXCS<D$O=6^X0)Q7831!%;X#B?[*@E_ 4<O;X+"T&075 ^SU#$HXCF[VU%
M@);'B7IF=&3)75N**;F<LI X/(#CB0A2)0A+':UB2K?,!#+:!0<+V \9<K?J
M#\F;:;50'ECS9QV:L8EV;R1KSK]BO 1&0DYZUFA"2+N/?)0W8[S!@,YW5GQY
M^;52AU>5SLK-=U2TE*0A1@+)"';9C6,O<+QU 8=)I<OG\DB<*BL9D$\=2#4K
MG-GMA8D#6ZRYQ3'N#L<G7R1>E,6'%C5*1 ,.O:YIE[=>X9K0*!04@Z.<E>==
MF.5?DZT9G<4Q,TXETM]W?NMD,28I@@R*_P#FXLH;EY_=GF=OT:=.PN._8>'-
M#5U?]]UZ"4W(-C;DGR+^#C^;LV"Q#@;RUF9L>]E?>NRM3Q[P<*%=S\4B$0\4
MPCF?N4B4]0_J&E>!F6Z]O[M#_O0L8H% H% H% H% H%!S'<86?,ZS_GAYM\0
M3O-.69KB7%'N@]UN+I;D:823'6-?$R2;N7D"$O+RLC4.\0O>_;^')DW:]/S7
M30=.-!S.\J^><Y8[YLN"S%./\S97@N+LN2W-R;*^-H=D27QF Y.3M(8AX61D
M.',CPACLT);>\F=W Y)E(2>T%U+6ZU^D.F*@4"@4"@4"@4',[ZKS/.<M=.+M
MER!KYF;*^"9X;M)B:/FS;#>1)?C"7&,#E%,G*7%D,DD)>&-Y&T+U#>08<FN=
M<DT9!8A!O< ;V#IBH%!6/S/3Z=8MXJ][LAXRFDMQS/XAKS-'N)SF"2-XB$QB
M[RE+372NT=DT?6-[TR.::XK]FH3'E&@Z?@%:@A!@G=/.N"_3<8[WF\?]\6?\
M>:,H,M^8<[.LPR%YXF2$@0^^Y$=O-31-9-WP0OU\SQ<A49T6_7K4%G'&OLK.
MMQM#-5=H\FM,28I_G+#\:R!+&>"('ALAS<\O(#A*DT=;Y _2=Z2-A=R[=F!2
MX*S;?[I@J";] H% H%!6_P O?\VCN/\ P/N/^-FBM&^*+\I3D[WXL^PR)_V6
M_P 0MI]EQWKGS(:_3(Z(% H%!T">FY_S])W_ "8<@?QC8@KGA\YE\G[0?M3I
M/Q/<%#^,1\1<'OEB]"SNY*N#K%!0*#YU'J,^(3>>*[\SSD5U<QYD++V-,C+H
M#DI2]X>;'"39&P;DG'T;B<=//=8LP$*)3=E[[%27I ](DJA*B ,TM6-/=. T
M\- 80]6QREX+=D,4V'@^&L]IX_W=MDZ.?8^=,2Y3/$FZES.U>((K88ZS/!Y-
M[6&-1&%(/AL+LNGIO<.WOBVY.M7^1?6"<[3XLC"?":AAE#L;LG#Y)X"G=(?.
M6.(,AR^32:4-*9 EF+.J@K2A[D_GE$G'-R )!I2<:,2<D.$W09+$^:7U!D[V
M&SVG95>!QS+(NP,G8)VO)0-IF)L<H44!P% 7(UV7@(/5)S3HFD5I@&6[=.E5
MB*+  -[%AZ/#_D<_B2]0%(-7WN5A68GGF5YQIR\OUG%*K;I)'IE(B%&O,Z,-
M26$VB.=Y,FC1PE'ZW9(B=55KB &Y@;A?+ZSS_,8U6_E8A_B?R/04I<77J:&+
MC5T&B.HZ'4=VRS.(0YY.>V><JLNHXG%%CE.Y@^2IL"Y,!,"?'<*%G&[ +/ 4
MKL8IL5>P!D]>P@!M_P!,UQUY]VHWH(Y:LEH8_$\)0;(.9)@SFM2M$G%DK-L\
M;9@Q.T>B\90+UKE'(E 54S.7J3%XB+"$!&F3A5%FJ3" G5SP<D+_ +O[1L?"
M7JIF"'X7AZR8%L.Z^Q&1I<U8Z@C6!E$!RD&.3Y!('-B*5Q.#HDXE+XG)4!/D
M+N EG3V$ !X504>^H?PYIAK8@X\]<]),BXPR9C[%.",A))=*\>3>%SITDL^>
M9HTJWZ:9#=(8Y.*8,NEQZ>Y]PFW!8I*64G3A"F3DE@#NFQ#R,ZDZO\1^*MDY
M1EZ%S>(:Z:E:XM^0&+%\LC,XEB2=.6,8DP1?&A[4RNRGP2:2J4 LW)D[D-&
MDZQ@U RB2#C"PYMN*D6+N3?>*7<S?*GL9K=#"(C* LNG.KL]SACEI)A]H2Z*
M1QI]41242)N7-D&Q2N,-$S /2$*9#+3%CZH 5V18G$*J/2FY4QAA_D_>9;EO
M(\#Q;%1ZO98:02;(LOCT(CXW59*L9'(VP+S)G%L;A."HI(:(LFQG:#"4.X;7
ML&_0&>^KLR2_S/E(CL65._?HCCS6+%2*&(TJFYS661+':8S%V=TX"S!I3%CP
MJ=P ,4 ^:.3)4P;WN$H'0$U]RLT>J8X\L(0_/LG68LU\U:Q(TPR"H<6Z_1#6
MB<8ZP;&C_"(5#(G*V1S8)[+E##812%I3N W1W2(U)Q("UB<]07<P+Y^*/GKA
M&U/&WG7;[;DEGQM+],S/#=B3X2U+CF:2-ZUL(6P.70R-C6N"U,Z9#4C,:BVN
MZBX/&TYG9B*3&E!+"C?1N38QYJN0^2\G?)9GO V*-9\ RFT<U.U%RMFG&[)=
M><R*@.S$2\1.32%M.4Q..G#(=']<:C"7*I":!.&XFY$:E %;7!_E?%L!]0>Z
MY*G628!"L<F3K=!07/Y;,8['(4-.^L>2P,9X)4\.*-B$2\C5%62"L?U5%S V
M+N+K6Z0^H>W*([)T3#*6D]ED+>J0DO,7D;<:A=D2EM>D(#$[JPNZ82@@Y"[-
MB@(@'IS+EGD#M>PA %;I#DW]5KR8X5Q%I],^/=@=F>9;$[&%P<Z5QA(86OOB
M/&#!,8_/RY1*NI8PAOD$L6Q=,E9T)MPJKICS5_5 66G$>&T_2EZ#Y8U T>G6
M7LTLZZ(2[;V7Q?(4;@KJE-2/+%BF*1]6@@+R_ICAA,;W:9F2%Q<2T@BPF%-A
MB,9E[&FC)(#I#R9DO%.O&+ICE7*$HB^+<3XW8W*4R^5/1J=FCL=:$XQJ5JPZ
MQ1=NNH6+#^J40268I6*S@E$@,/-  0?,<%'YMZA?GKD>2L$PETCN%G').-Y%
M+I<L;3"+0;7/"B"(PT,XF!@!E6)F,\:8H"S<W".[43HY$H[#L0G,/*#ZE] H
M% H% H% H% H% H% H%!D\3_ ,(G?^9&?\.FH-@T"@4%!WJ6=R!:><2NP)K$
M\EM&1]CRT&KF.[]Y)3*AG99(7ILAJTQHQA.2F-N'VV0FE*B^K=,L[ 77 *X1
M6"C3DHCG&VR^GJPIJIK_ ,@>CTLV7T&8<0YSQ@DQYM7@!ZG$HS5&EREQSK>"
MM\7R"L>UCK+54^D[L@0(@+3EKD2C+M8XZQ9X0Z@==-LVG>?B6C.UK68G[SF+
M4"6/LL2)#$QA#/D9M@+_ !W)S 4))U2>S8,A,SFC!\P4*X";7N67>]P!#CQX
M0^"I9RD\:F+YAMEO9LZQZIDRO*+1AK4K 3O&H1&(NYLN3I ;+)K-G*7QN>QB
M8/TBF99RE/8R/W6(4Y100N @7+3)0LJX*8;E;0WE2Y+>%-VS5.\TZU8FPS",
MXX3<)NN H<X6V29OQ68:W,B8(S&]A4N<>S@D1NI"5.0W*'&/A5ITR>QXPFA3
M'HYZ=32;9CE7Y.M&9WE':9IQ+I;[N_=;(8E-L2H,BO\ YN+*&Y>?W9YPB_1I
MT["X[]AX<T-75_WW7H+8.8G3C&/']@+T_NH.&WV>27&N&^4?'*&,/F37./O,
MY7DRS):^?N(GYRBL7AC J,)>96H*(NG;$M@I@%A%88[",&%]/*OS.ZO<0#=@
M]SV5@>>YP1GU;D)##@8-B^/)*<VG8U(ABA]%)0S[*6,P(RU8)RDLDNE$LN9<
ML[M+%=4%S TGQ?\ J%M+^67/LOUTUTQCL_"YM"\/O^:W1TS7"\4QR*J(K')I
MC^"KF]O707-61W<V0&N^1T)A11B$I,),4>(1X1A++-"L;T>K8V2;"'(OGF2$
M)E6<LG;RR-LR3(%*>P)"O;&B(LLR:2'$XZUUH4WF_(\B/"6._18\TV]^D730
M=B]!RT>L&_F>W'^4SA#_ (*94'3K$/\ UIQ?_FZR?XM34'(GZAEK10'EW].Q
MFJ I4R+-$IVN%B5V<4Y5SG&1XV19KUP3)(\N!8817:D <N2,H/5N"]K/:B_6
MM>UKA#L,&,!8!&&"" L 1#&,8K!   ;7$(0A"O8(0A#;IO>_P6M0<<VTDC#Z
M@_E!UQUUUN3%R/CRXS,Q$9BVEVC1EG'PW*&9FM4WFM^%<4/'9W;Y,68G9O#1
M+DIERC4KBXN18AI4K:-R"8WJ:HCK+.M7M?(MD%ZS W[FN^PT<1\;[7KXD:GK
M+[]LRL-;F]M2I8\_/D;9%6/4RQ:V&OJT]P;S&\^R 2939680F5!71O!G?U*6
MO>A4TQ1N!A'"N6L03#'9,*V$W6TW;A9&S_BK"\@C2<O,3V]8652G%D>=<@)8
MDN<TI\A:FMKBC08D4*#%!)=TCB,.D#A]+TV2\;VJ[5H-(U<LUA98":UPQ\>4
MH6^8+Y"2_.YV2560VP*1 %LR,MR.H=5#X2 DM/9P--$FZR41(Q!4'HF$SD7]
M05OAO>OL6[X0XWH@GT*UG6W-"K;5&4EIK^DS++(^I+L:C4*&XTV4IC5)-R['
MM,H;[!&< '6L&E\\I$F2?6+:C,>1.JYLV)-)'618H97, A-A,A!"L]/-G1$B
M/O=*I<T3F_+UI:@(;F%GMY(K7ZZ4NX [$*#CSW1*(QMZO3C$?L=""CD^:-0I
M0UY=9T!75O(F!)'-M&9*_/=[=(E(BVB(I; O\ 2[1LB_^]OTA8+ZE_!>N^3^
M+?+>4\TSHO$4_P!9%*#,NLN6F]2<AE[#GAN/*11"%QA4@/2O!YF4EAI;082F
M,MW8X:=TO:PVPLPL*P?3"OQ>[&Q.ZV_^Z$Y<9WR;Q8R#8%7X_FL6%$'' ^!4
M\090-;_#HBM[#P53D]^:5J1S&G2)A(1MI]K=3QE792%GG.[RC/&F\0Q+J#@?
M(./<4;>[O*W.&P'-N9Y@RXQPOK+C, P-,]V G&1Y4M;8^V.\8(6W"P)>N>:-
MP!<_L%!A"=O<0H(Y;R^+76'T_P#*=-M,=T]6=B\L.F9L.9%RB]P78O#N3\X9
M]R@LF:!PR3E^7-41FLAE#LH4"(MT=:RD#4U$$)[FB 3V@@NMY%MG<$YQ]/'M
MXHURSWAW-:B":>8XAF0!8<RA"\E"A3D\-\':W*/2_P D/KR*-NI[7WP(DJWL
M3;@+,Z07L$70$W>!%O0-O#CQZ)VT!9:<S7>..!@2NIU;KW9Q=W1U'?J6L'M#
M718<(?\ N]>]^GX>F@ITTR$*->L+Y5(U&K]1@DFD4"DTI:4Q1B9&C?[PS0UR
ML['A%>X5BT]>_'FW-#T!L)W-#T=:UZ#L!H.,;G^Q%EC/?-1PS8=PAGA^UBR=
MD&![&1^/9YBS/=]D^-DQ[8K.DCS'&X+LPFB?E,6(6I$9Q2Y&<E4*0'E'E&%A
M&$(^<A/IRD/&]K1E/DJT>WPW02[DZV1U-F*937)D^B3J5DEJCBQD69"L0OBT
M(BLH;.T;TI[C9"].$G0N)*0#<L : T2D(;=YT=EU^Y' IQ:[0O+>G:9%FW:[
M2V<RUL0DC(;4$U<<4YE*FJ5I*,,--"RDRM.L"BN,5QB2V+N+X;WM02S]5+GS
M/&'L(Z80^,Y6S%KOJ3FG95/"=V=A<&(7A1/(#C8'EH;0S)E+">B=;(I"U+9
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MX<M>$>0KKYXL!=6J7K6WL2R;=PZP1C,"W+4GT_&FG$LS;8YYURR9LW-9?/\
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MZ6.*%Q"4N?5K"\Q$3:[C;$:X*)RLW/[4< %Q%I% +] 6YZF^L4S+9U00/?\
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M<=')LMRKM<5GE.BQ#LZ"))9SB$&([SV,2!+*4#0)A-P6?,KQ YP:2P')[/\
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M]0EN5^UP8?-H\_8:?DD..86HZQ6*<N)HFOB\YC(E-U1O46MSL?=04(L"U.
MP6"L[EI]0/B7EJUQ!JIB7CR>+YBFCQ"E$:RC*7!CR#DO'ZN,R5'*G9GQ T1*
M&*)(N629$W'MB@^RQ*$36N6!$C$(P(BPS5BQ-G7A/]/OM,MSFB68LV:Y1,DQ
M3#L+Q2YW4I)G \1%Q5Z)E*^7(2!7.99(\P!9(R52(SLC&L+JW 5#"L,,1E!J
M+AZ]-$3R9:>H]L<B[)23!""5Y$FL8QY'6/%R";%2.(PDY"P+I<>ZN<PB_=S#
MYRF>&VR<HDXL%FSKW-N(P19015YM.$Q[X:776^<0+.,ES'$,KK)84EG"B%D8
M_=8%D;'JF/.[<@#=KDTB!<QW;'BRQO.L:4;8QN4_!^MAO07!^H0VY;MZN"WB
M^VC2J4YSQDW,C*9/2$W=0EMF4XUB')L2RDU )1@))(3HI^Q.(4]NR)ZZ7LAV
M+!8=@V":7#]QRX(Y(?3E0G F4(\QMTBD\QSZYP'*I#(C.EN.LCLF69L"'3!"
MXEA3N*M.VFF73+4=SPEKFL]0E%<(3>L$*!>+;>[/OI[^0S)FJFW#,]-N#GZ;
M(H3L7#B+*W1+&E0.H3#=C,;E% O=Y0ELBTA89=*5<;[&S^I8L2LE'8D.JC.W
MI>>-3=[,.1=PG;/^VJY?LU*''-QJ_%N4\#'8V<2\C#M)TSC!#UNOLI5*(FX)
M7 !R T;DNN8F& 7;F6O85PY O4(\3.N?$[ES7: ZZS3-<S9\N8XETODBG-4C
M@LB<D3DP29(RHR&0Z#8XQRE3(3$JBXC0GDJ3+F6M<(PV^9H.NO1_T].E[QQ:
M+L(*<G;/EQ3?B ZD; YA<")IBD,AC<RAT<;\AMC9C569A4UM9XR>]20\H\ET
M2/*H24!80*0&6$8(-<?U-7C#_?VWR^Z?KY_[*]0<<7!)QU83Y/MW''6S/DHR
MG$8,CPA/,E%.N('N),$L$^Q=]A38WI!KIG")^SW:3D\C/N<79!8X0P%W":"U
MA6$'01ZL'BGR^OE.)M\,#PV39%QW$L.1?!^=D+$B$^2*$6Q\K<;07)3NVM:2
MRU3'7QD>KMKDM))LE;3VU.(VQ8%0;V",V^_J;D^_/&JJTCC^M<Z0[)9K8<8P
M?+4R-<F9YABM=&I%%Y%(G7&S(R%BDKH[3U]C("TZ!2C3A;25Q@0FJC"BQC"V
MS@RX/93?B;VDPCN^BR7AHWD'D4*=7B$QPUHC.6X#B_&:I ZP58XVEC!+&N-2
MZ4/EUBD]O7-)QZ1K&0$\):HPPI*&POZFKQA_O[;Y?=/U\_\ 97J#CMXR^./"
M&YW+6OT,RA*<JL.($LHV/9"Y' 7R(M>2;I</MDT6QHP;Q(8/*8Q=0N-CA%EU
M[,]@FA&/L@DWN&X0[<>>+D6REPM:,ZO81U,;B5,TGD9-P/ <OSXYL?W?&D2P
ME"(4RVDXHT6Q(XY*Y\\-CDGL2<>20UI%)9APD)X+@("'!'I!O9@O NRKYMEN
M=JE)^1#+Y\BO,8Z+)VQ(8=#RIHI.,5+IMD&/N^%<LK\IR8E7U#&_OZ\AM1BL
M(9B)0<%,:F#Z"_##Z@?\[OG3*F%OP2?P>_=EB:^4/,OOZ]['C?1,(Y%/ _!O
M<QC3PW_UP=X[SWI1_P!YZG9?-]<(<.?,7S/[-<EN:'V%SI4LQSJYCB>N*2%:
M[0M^$2VJ/ '(YL%*IS)#&NUYI/5I"<RZ=6K1"0-%C;A1HP7$H&I"R30KU,FL
M'&]A)!@[6/B3"P-(Q)E\TFSWNBE=<D92DA!1A=Y1D25$ZAH1O3E:QYEDZ<HI
M.W-Q1@B429.3^MT'T3,"90]]^"\+YI\#\L>][$V.<H>6O$_&O+WG^'L\K\#\
M9\/:?%O"?%N[]Y[JF[?L^OV1?6ZE@VQ0*!0*!0*!0*!0*!0*!0*#)XG_ (1.
M_P#,C/\ ATU!L&@4"@Y .37',*Y=N>[4GC&GK0KF>KFD^!IYL[MK&FZ02&-W
M=I'DIH:"(O$G)VB;HR/S:(M,M@]R5*9<E6 129=V-P7MUQA8#_5<>"C\1G_W
MYG</_P!F"H*PN"V5/6K,1YJ.&O(;LK/?=+91G'(V$0NXK^(O^",BQAZ;O$FX
MH(06*:"S$K#(!=H&P[GS;IM<5ND)83Y])Y_,FZ\?PB;#_P =4RH-$:D?[7+R
MF_R ,-?X@TJH*_LN;R%<"?/+R)Y^VRU[SK,]9][(EC-\Q;E/$,?8W4:EU98\
MPK1-36&:R""0YY.;WPEZ;W1+=\3N*"Z(A0%.>G4@'<-J\OFV:?>?7KT_NUB+
M&$QPVW9=Y3H&XM..L@7!>8LC-',JNL+9E;\ E(D((5R1KC9+H$HJQA1):T(
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M,-F,ZQR>1%OF)F*HD9/9EC:*8\A#FW.I3:Y&]^5GJ;W,&H+6(1&M*D-H:O\
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M>Y'99JC0.K A)D+2):4X%IERLOQ XL240"B;7#)/3?Z/;*;?<GQ_*+D''[M
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MYV+BR_I+- /RR-=?OC4#\[%Q9?TEF@'Y9&NOWQJ!^=BXLOZ2S0#\LC77[XU
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MJ#;WFV*^TT?^66[XS0/-D5]IH_\ ++=\9H'FR*^TT?\ EEN^,T#S9%?::/\
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MN^,T#S9%?::/_++=\9H'FR*^TT?^66[XS0/-D5]IH_\ ++=\9H'FR*^TT?\
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MRW?&:!YLBOM-'_EEN^,T#S9%?::/_++=\9H'FR*^TT?^66[XS0/-D5]IH_\
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M _ #T1_$IU)_)PPY]IM _ #T1_$IU)_)PPY]IM _ #T1_$IU)_)PPY]IM _
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M\6H'E.*^S,?^1F[XM0/*<5]F8_\ (S=\6H'E.*^S,?\ D9N^+4#RG%?9F/\
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MN^+4#RG%?9F/_(S=\6H'E.*^S,?^1F[XM0/*<5]F8_\ (S=\6H'E.*^S,?\
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M,W?%J!Y3BOLS'_D9N^+4#RG%?9F/_(S=\6H'E.*^S,?^1F[XM0/*<5]F8_\
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M<>V^GV.V:3/;5&6A6AAC3AC ,E;F(M-%61A;QITKY+7%188R1'7$J%:X[A"
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MO^2&QRGB>6,,4DS(QR4Z,M#B_$N)3L4I -!!528!5P*;C$';UJ/L3%=M]7\
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M:9*,3.6?$^W.L1^"F:3'PIWS23GS%1N)FJ9)2RCE,2<LC E8H>ADR<E06,:
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M[(:FXL;(;RP%\5*!PSO!9.R;2QG) 8@CRBD78_R6U-.%6J3M6>\!$OB><G2
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MVS2B&%>R1K($8D*9DC!+;#8XN4*41<<+;B@1X;@"XU#@H7GKSPFOZI_^9CV
M_A!U_P#XY(A01.]&K_-AYV_EY9/_ .KYJ]02+WBTKRQR>\M4!Q]*Y3N1JYJY
MHAK8JG\(V,P(-[PT^3':G-4D9"EK7B+-$@ACW%G4F,XM;TH'-4T66K&]64I0
MB$G$>=>P:6SKQAY?X\]K]!M^L#;"<F/( ]0C8-KP1GZ);!9$>-MYE%]8,W,K
M_'9M+(6SQ7&K1(FV.PI<>%Q<2Q".2V5"2*;6*$0(RX=6E H% H% H% H% H%
M H%!D\3_ ,(G?^9&?\.FH-@T"@4'-KZJC<@.K/%#DG'[&^>$9#V^D3/KC'>P
M.. K+ACX$Z09C7FDD!$::RJL<,BQC5WM:]K"?B;7L+K6#<*)^1[D X+\L<%L
M:XZM=]RT\BR[K)C_  T_Z^!_!]VI8!2;,V(2DZ>1.7C\HP0PLK,\Y2:7J3$]
M\4*FU*G6O?:&#)(",%!U.Z-;C%;Z<,$+V94KR5\OF&I4\8<HB*.,-$5ES'\,
MD<$R8(T!]N\I@N4PCRI<06;<8[)%10NT-L*Q@PYE_3P<"6AN]''SC3:S=)NR
MOL0YR*095AT$Q,]9>R%!L3XACT4R5)6Q4&$MV,9%#I2%SE;X6I='$1KK= 8H
M/M<",!MCCU 2]X7,#L/']SR\L7&7AAZDQVI8=>\9YXBT'DDA<7LR/O+JW826
M$)"UBL5U0E#:WYU=&FZ[M1+5S<@0"5FG'$A$6$&>._A6XS<Z<SG+SJ?E36KS
M3@#5[W6^XN ^^3/[)Y'\QE$B>?\ U4QS*K1-9-WP0K_X8<G#L_\ >=6@GOSJ
MZSX1TZQUP-ZW:XPGW=86QERF8L20B&>9)=+O!$\BG I@\E^8IV_2>5N7?)'(
M5BCI5KE B^V[,%PE   (76\J_(IM#Q_MV#UFM7&CGOD8/RFMR$EF*'!JC(9!
MV)"8<1##6)5)?(.!,Y#$7-AR96!)WH#9:UVH[L[G_-V)#2?%_P LNZ&]^?9?
MB+8OAYV?X^H3',/O^1VO,V:U65CXK)I4T33'\80XQ;P3K6#"K1:0/+1+USJ5
M<MU4*>[,I_52#!VAQ 0"W2_VOCB#_D19N_BTW]H-B>L&_F>W'^4SA#_@IE0=
M.L0_]:<7_P";K)_BU-09%0<DFEO^U\<OG\B+"/\ %IH%0=;=!1'S <IDAUR(
M:-%=((\MSQRA[/LJV-86Q5#!)G!3AAG?&]24JSOE!2(\#?$VJ+-?;N+4!Q&4
M0H-2][4]1M3JC:"2?#GQML?%AHU -9"7]),,A+G=VRIG2:MY1I37*\S35$SI
MI.I9;*"4ZPZ/Q]J86YD;E"DLI4K0-1)YQ91I@R@!:30<,N_''YB[DL]4"YZW
M9MF>2(IB8O0"!9(G35C%]3QQWR*UPB8(3D>/'MW4HG(":*.[VX)52VX"!J?[
MA!W<:=18I40$;.?;A9TWX\U7'WEKCY0Y*U'FN6MJ&/6J5/4%S#EJ2.!:')#,
MO &<,SS.YO(I6PR1I;TRQ&,IN=$2%8D6C+-(O?YN@L!WW]+YQ;Z^<7^V&0<=
MP?)BW8G 6M67,WL^P\OS#/G682>2XC@3WD16GDD,2NZ/#QC=*[QXU*>6FC:<
MXL"CI+/ 8&QM!9[QJ;Q'XZ]/9@;=_/K^KDAV&=/I9(Y(Z/"GI=I7[DU<OA,5
M:3UM@B.7R"4@A[>WEG&==0K6J0C,$(TP0KASL<)W*APZX,X_ME(;R ;:]UV;
MY#<H["Y W"8S\';*S-P-;,JW?(*".*9+#L*2V&.1;Q&%*U]Z4ZQPL4HDAY9X
M[F!$02%DGI!MMX_D'4?8+2--/4F0+Z8YQD8\52LE,^LY<PU]RX^2!]BDA;H_
M)T:!];$A\Z:) L$0>2G/1D.J4D].0;:_:!!?C_XCM5>3CE!YQ7_;U3E6;XZP
M9R*3V['@B.Y)D4"Q=*Y)+L@YJ[>7S8N(*&J6+7YF:V82) <WN;:82F6J0C&9
M8P-BPV?LCHSAC@GYE.(O+W'Z1,<4X=WJS09J%G+!)L^ELUBZI'*I+BV#HW),
MXY!=Y/*W-L6+LEE/1Z=P<U=D+JPISD796,N4 .XN@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4$.=^M)<2\B.I^6=1\TFN[?#,HMC<$J1QP20N20Z41QY02
M6)2Y@&N3J4EU[%(&H@T9)@+E*TW:IS/ULX=!S48[T,]49QVQ5GQ9J;NMJ?N?
MKSCY(WQC&&/\[L1C!.6B*LB>UVQ".\CBQ#JR,9#:U$-29M!DMS3("3P@3%D%
M@N>6$X>*_FEV+V&V\R/QI\DFIR#4K>K'D*4Y"0IX.Y*7;%F0X^WD,JIS3,91
MTAG?ABL+4\!<F]:CD<@9W5"4IL!60>G 4J"J71'1/#WJ!=[.2/=WD9-GF7L5
M8%V5EFJ&M.N14^EL"A,,@\*&O$C-=5F/I"PRI.M0L)S2IN2TN+:C7/RIS6K0
MK!*  )#]^?=*<<\ '+IQ?9DT)=YSCS6G??-A6I>Q6OCM-I)-(H7:226'1J/N
MZ1;*W5YECZV-M\D>,) +E2U:U.,?Z2E)A3@:EL$O?_HPG_YV;_[E4&1,G^U[
M2_\ T5:;]VT7H(FY.UK;>>?GKVVP%M?+9X9H]Q>Q"#,$5P+%I2LBZ"=9)G:!
ML$\NSXO:34CFW%R-W2O%US@@$4[";6MM1EJTX.O>X1;YT>&KCUXYWGC<S-IM
MAAWP]*)UO[@_&,H07RIE7(+ Y,%E3M*A*PI<IS*;N*)W,<6E,"YA"HHGL2;6
ML580C!C#O^H*+/4=ZXX9S[Q*;32#+4-\V.^O$#D.>,.J_,,J8O)^5H]'G>-,
M\J["-/C,ED'=&25+R>XN@%K:9V_7&G$8 L0 @AP<\('%Z]::<=>]KEK%WG:L
MF"8MSP7E/WT["D]7*S"Z D#3*O(Z?+)6.+]T=VXD[N-V>[:9U.J-.(%Q!N&5
M\-W\^'ZC#^%75K_%69*#'>>O^=R]-#_*[S?^['3:@C9ZA?5E@W9YEN'#5:63
MN<XVB>:H#L3%)9+\:KD3;-T<5 A/=Y(V,*]R2.+:E.DS(V'M9HU*56FLG6F=
MJG4%]8D81OY_^!KCQX^..$W;;2^ 3[!V><!Y/PV:FG[=F?*\F=I@"0R]HB5U
MKL1+Y:^M<=D#2[N*=W1KHZG8S$ZU/T!MV5PEA"Q# _I7N,K)6HS/),RH,T9O
MV<SKBQLR"][/3[-61DTW9\C9$BR>1&OS7'(Y(&Z".21K>G6PP ?VQ_5* %_W
M2>>,0A7""O&IR%YNUS])7L;L"QRIS/R)K1*,A8"PK)%99+BXPDG)&1,60Z"N
M" 2H70I#CQ\SN-4W!4]L4F*1$DV+&G) 102[X[?3"\;&5-(L,YDW&A&1MC-G
M-FL217.F2<NO^<<N1]UCTQS3%R)VK)C*.%S*/LCRKCY\F!VJ^0IWT]T<2#%1
M]Q%'W3!#)/3VG9)TSWCY1N&B0Y*DV4\,:D2*#95UI<9>>%6^Q&!9*((>'"-F
MJ"!&("DR]DF4;4FI4@4:(MX+<51*4D2XTLL*M/3M\(NH7(EJK--@]UW/+N;H
MA$-F<UP'&NMMLHS?'^$X6I+:84ND\Z CQ_((]+%,WE:IR2V4*4CFW$C3MB8I
M02JL6"X0VOSD:,X=TZR[QB0>6ZN;%37@1UIB67U&3\-:]3#*$N-Q[E::S/)4
M_EDQGLE?9FY3-,T+EDQ;UI*UQ?D!UFTEW0MB]+T]C<-X<=V"_2A[&[.:]330
M26NN%=J\29$BV3,>XZ?\G;'Q.4RZ61J0)Y$T1P+)M Y3.'9(,&DBBD*EOB2U
M0N+;5QHS!DG]V.3AVMT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4$4-R?^B1-_P \&;_B+Q7/#YS;Y..#]I=%Z!K%^^+A
M_$&_WNS?9X565?GZ;N*!0*"Q[7#_ **VK_TB]?XP-K]%7S<WR7=L]\]P_&;F
M /&"_B5J/8V#T.&]JW4I,H,)R7C^/99QQD#%DN+5&Q3)<)E>/Y.4A/"E6F1Z
M9,2^./1:-2(HX*=4-M<C;%F7 .P!WM?JWZ.B@^8QG#@<YIN+O/3SE32]MRWD
MZ/QU4[)8!GW4A^5@R*Z1%P,",+-*L5QYUMDI(N6H E =6TMO=F0X\ @%J598
M0CN&9Z]>IMY>=)LGMV/MTF99G&.,2@E-,,6[ XO(P]FMJ9C1"ZXF:7L\6B4B
M1O@#BQ"+/D;<^EF!ZY5P!_6S" D5ZN7,T(V+:>*3/N-5ISAC_-&N^3\GPY2J
M*LG77CLX'AN1-9+FDL,P2!V2)7 )2M,*_:)E(!E#M80+VL&E\<>J.R1C;CD@
MW'UB739I33R.:Z-^M3)F]WS,KEP5)BB(FP8R7-F&T>(&>XWX\"SMT"$V0+$Y
M2JP FV5E]8L83E]-)Q4;-Z_QK:/D(S?CZ1XG6OVKF0\8ZTPF;D+(W)I09)TR
M64ON27J.'&-S]'6%->'MZ!HNM[ 3B4X*U0"@EDHU)H5P^D,3IS^6-S-.().,
M1ZJ9B4)##2@&#2J!2;&201Z<8PW$0<)*J-*N(/0*Y9@@]/0*]KA-CUJ29F#G
M_1=61?\ ]4)^'LN)G2W9BMT,R6:Q<UAOVW8A"/I7+''YFQ@KAZ.FX0]:UQAV
M-\1RA]5<6O':?(R^S<A:6ZV@+_L.DQG)Q+%28XI'<LPVPC%<>+2FB%>_7$(=
M[BM85[VL%!OJ>>9/$^&L Y)XX\*/3;/MC,YL)<1S&-G/*<VG">,W8XDQ[9GY
M2E/$7[RYTWE=R3-/0,Y"VJ35BJQ(AH J0W?Z7#BXR9HCK!D//>?F9PA^:=NC
M(2ZD8U>4HT;[C?%$&+DAL*2R=(=8)[5,)FJEJMS7(#+=JA1A0$GA)6!5)R@M
MYY3$/(4Y:F/23C$>6U@VK,FT*$RN;L5B4Y"3# +SAS(!I>:FIZ@]Q'(+ "'K
MIQJK"O;LKAOTWL'SD=T$>V^&^1/"T_\ 468VS?GQG5M+:X)&2#9.Q)'FR48U
M9)*J5'-<,/QLQN>/K1%$^+U-W6--1D3<S;K+WNM0#/+/&'0GZM')T,RYQA\>
M^2,)K&MPP-DS,$8GL%6-:0QG2&1QZP+)G''043#T(PM*<N,NRH DIB8!J$0;
M$7L5>PP7"TCTK:=.1PS8(-)()),69'S\H5F%% +&J4!RY*$@3U P!L(\X*5*
M4580ND5BRPAZ>@-K6#CSX?NT:O4UPI+CL';M96UN[+<V%W+"4$<(]W^Q*=Q-
M$0>%'8'=HE8TX(;@ , R[7"#KVL&@^IO0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0>[&_\+)__ &@__@1T&RZ!0*#EH]8-_,]N/\IG"'_!3*@T%S5Y&G7"QR-X
M[YDL/P4Z7XNVHP=.=3=J84@3W+;WO-,5A"Q^UNF+ZL,4I4J56\'Q-H1GJ+"N
M>4QQ)<42$9RSH$%;?*_IK*]/?3.8O-S#90MVCV?WAQ]MQM<_N9"<I\<\W9SB
MN5)0ZM;O8A,1V"V(,(T#4I)#<9%G%*J-*Z GWM037]4SO U8N3\>^EF4ICG&
M"ZD9V0/63=RC=<RXX9F+(>+(8"+LL;QC% RR01:-'('EV6+S7 ER6]Q$8!&H
M,)4]TLF.#G7V,V/]+A(]?)5'=4-->2?7S:)EBXG##6?;2AJ>3TN5(ZTG'0]R
MGC7(]UIO&"(V\2HA,<\FL;"D<$Q77&V=W&$!=PO<Y+MEY]M_Z0W FP.4WA7(
M\D3!?@9CF\F<+]9SE4EQIFM\Q8[2MV,M8(3G>4*X4)>K,#8(3%*@8K!#:]K6
M"Q+&7I4.+:9ZY)AYC;<YYLV)RA TC^_[5S_.&2!9,13>5,1"\<C:XRPR1FQH
MN3LB]5;N:5Z:'@T:8H!:M0J,ZYP@USZ:O*N0<A\"&=(A/WY7(;:_S';'!T+4
MK%AZ\U#"6C&,=GC>RD*U80JA-C.[Y"7$(2AWO9,A 2078!1998 SGTY7^SCH
M/^;NZ_[L\G4%77IX.!+0W>CCYQIM9NDW97V(<Y%(,JPZ"8F>LO9"@V)\0QZ*
M9*DK8J#"6[&,BATI"YRM\+4NCB(UUN@,4'VN!& VQQZ@)B\*&$FGCOY\.5CC
M9P:^R:^JJ' F+-@X9#)(_+G\R-2%8CP@Y(B"U#AVAIJAJ1YR<VJZP0QK%[<W
MH+K#3SB0B &C=*=&L9>H4W]Y$MT^0]PGF3L%:V;$274_6;7!#/))"XBP16&*
MG$ZXW=QA+K'I6VED,QC:O-):EC=9Q?'-<I5&G6"$N@Q;9;BXTRXT>?+A,3:;
M8Z?,71W-^1LD.\NB:_($WR S(U\$9F!I:C6!;D-\E$I1A5A?51ZH)[BI",XW
M];L46$!80D5N-@A+S6^H6R%Q[[(36>(=)^.O6Z%Y==\/PV0J8LDR;EC(L?QA
M(BG%R7(S3592E:T9L2HSG$JQ2Q(VLIJ1$-(8O4*AAI7FMX<];^(/ L*Y5.*M
M+,]4,U:F95QBJD# @R;DK(D,GT5F\R10LTIZ)RA-I5)0F'OLB;D:]"0X7:'1
MC-5I5*$5S>\%A)?G+S'E??S*_#YQAXOR#*,)8=Y+4%LR[%O484$E/;SBA&Q1
M>6H(6G4G"2W7)&EC _+3V]67=$XN936(XL=DXBA!,AU])UPG.&/R8:DU[R,Q
M2(I 0C'EAJV&S.=D!2H*+$ QU.;7N8/.+ KU(A6$,)<:+2V%:W4) 'IM<*Y-
MD=763ERYY'7B_P \3O)!6B/%QJ1BV9&8HC\E%'#LJ9'D<*Q,K;7>0NC462+Q
M5RC^8$:56YI2$JA*@9CDB#N0W ]2,-=\UO#GK?Q!X%A7*IQ5I9GJAFK4S*N,
M54@8$&3<E9$AD^BLWF2*%FE/1.4)M*I*$P]]D3<C7H2'"[0Z,9JM*I0BN;W@
ML-V\N4MGG+)R$<4W$ZWY$F.'=6]GM;&K>[8HJ%+RVU]E\07L^27V/1%0XJBS
M@.0FE'BE<E0IE*(Y 0ZO!#BI3*1(2+)PGQ(_2B<*[M$VMBC> LD8YE#66BN7
ME*(;!YA<)PI7H6T]&!V5-F0I7.L9=].<3"W$8"XZ6E[X0  20I+F)C K:R3K
M63ST<\^X>O\ MI-<@7T9XQ(S!F.&8!BDE/BB.8Y%FS2TDNKP^KVE2%:G\R/R
M5^/5.:/L7;PM$V( *$X F7$%R6'?3C\4NN&Q6%-H-<,+SG".3L%R@4LC?EO-
M>49E'7YP&VN32--*VG,4ER88H0#1.A@;A;SFXVU[!O8RU[7Z0J3Y=9%Z4J&;
M@97D>^4#=<V;ER-2T'YG;</3[;5X=6IUCD098PPM4G*QMEZ&8=BLB)CL>1(Q
MM9!R=<0,L)JX@H1MSAA5EPC[$Z-A]0-A=BXF(UM)@?5+87!67XSF_!FPCJT+
M21S&$X^R;D=D'&3FO*F75[W%VHZ+M!R Y[=%#NA6&.  '73*K@H+T=2/]KEY
M3?Y &&O\0:54'5S0<PG/>QD96WN]/UKU([!58]GF^DDR9+&=0?U6]Z58038N
M>&EM7)1WL2I)<$$H<4@NF]C.R5# #X3+T'3W0<,&^?)7I(3ZEW$[IN?G$O&V
MM?%QA&0DPP8H9E+(S3)=O,B-[4X/)"9FQ5"9P](UK URYK-//-3IDA3E!@%&
MGB&("<T-8N7+)H&;ZE#4[<32?81)DW%^YN+&G4+;LDS'F8<8>#3-T7HH;BN4
MN!F4<>0,#H@4N37!PW,*+7A2)X\JL<:G"<0( =]M!6]S%?S3_)%_(BV9_BAE
ME!R1<6FKGJ@IQQ\:P2;2[D<TUQ%JT^8]4J,-XXR!"HHNF\2BUY-("#FY^<E>
MB.3%YJ\3P6J.",4@<AV 8'H.MT6  -]\5&1MIN(3DU!H_P F^%L833-7)Q*'
MN6QOD3@<^D\_F>8YFRJ'@MDC$X=IBJ(4B@P7((&QJ;$;%$U+,I<$9BE J)5=
MX3!W!T''CR<]T_K4O"KY\_Z/?<A(?+7B?9>#^\SOVRGA/<>V^8\9\S^5^CH^
M;[7NW5^:Z*#L.H% H.4+E*#^"!Z@WAIW?3EEM\0V7;IMH?E==:_=VTY:]K5;
M+CPU_/L6$!*DY[S@F5$GB%\T5&[!-N$DGX0_S@+ S7R<<@OJ*\A28"15"SL8
M(^(W%2\\JYA+*9&\?N1><RPN(TXAIE;)F!O:G4NY-A#(/-"*]NL24,85'YHW
M%GN2_2D:PZN-IQB;8;)&S, XO'N('JQ!?4SIAW)CI(62-?K8CE*(L, @D5;E
M]AV"666Y73_"6:788=ZV!,11_7_!F&<$1,!8(OA;%6/<41T)1/=R_!,>1-IB
M38()'6,[+KHVD KVN(5[7O\ #>]_AH-LT'$%ZH;$F5M#LMXLY:M*\C^Y3+6Q
MS<]<?&Q(6E, !D\(R9C"9*H+.QF=D=V4BC\5@"A-==8/>$2MC85"?H,2C[0.
MHOC1T,QMQLZ9X>U/QP6B6#A3+9TR+,4R42=3DC+,@ 2NR!/G"YUQK!^,/%KE
M(2CAC$A:$R1$"_9)BPV# >9G&K)EKB>Y$H>_DDG(R-0LY3=$%18KL"Y'BV"N
M^4(BI,$=^ME!22N'HC>TO\)?4Z]OAM:@Q+@QGSWDOB$X]I1(5REQ=2]:H-$S
M5JNP>\GI<>%JL?-ESQA,-$H,"UQ@D-SABN8=T=H/YL0K4%E61YHDQOCR>9#7
MHU+B@@4,E$T6MZ,91:M<DBS&N?%*-*,Z]B0*51*$0 7'>P;"%;I^"@X@^&3B
M4P=S68QR1RP\L*B;[0Y3V-RSD!HA$ 'DF>X^Q_ (+ G<V-)4;7;&THBTM3)F
MU\(6(6IK Y$-;:U(4X0IS##3#;A8EMUHUJIZ?'0CDBWIX[8]/L19*F&$X+C!
MK9%\]>\CQ2%/\URM&\:0R:14&03GZ7$OD4?<GV7A$M>5R6]TP.NG,ZMPB#4/
M';Z87C8RII%AG,FXT(R-L9LYLUB2*YTR3EU_SCER/NL>F.:8N1.U9,91PN91
M]D>5<?/DP.U7R%.^GNCB08J/N(H^Z8(9)Z>T[).F>\?*-PT2')4FRGAC4B10
M;*NM+C+SPJWV(P+)1!#PX1LU00(Q 4F7LDRC:DU*D"C1%O!;BJ)2DB7&EEA5
M;Z=O@VTMY$-79MLINE?*^;6J+;)YIQMC[ @\I36!X?AQ29MAKE()4E3X_>XW
M,12B4KW5*-48E=4*8P+8F"<2HZO303;XY-<(1Q=>I>V"T@U:6R9@U6SMI4GS
M$+$[])7>4((C(F]TC[DQ!0/+\H7R!Y\K*D[RF;5#BJ5+@-KV:4H/4& ";<,$
MY<>/33_3SF&X/LUZYXA]W>3=L^2YWGFP,E\_Y0EWG^5VS=KY++.O@TZFLGC\
M5_\ 5!/W=1V#(D;4W]U]3L^S*) 6$\N</^>$]-7_ "F=GO\ A=4:"R'GN_F<
M>0O^3O(_\8M%!1#MSN#F#43TJ.@!>!'USB.6=GL6:I:H16:L2\QI?XD3D?&T
MCE4G<&%X+&4-C=W6'X\<&DEP ,H] )Q[RG,*4E$F@":V%O23<1D.P9'H'F3%
ML\S3F:["FM-<]+,UY>B3\MEBE&E$]+HO$H?+X_CIK82'4)UVY.N97!26G,L%
M4>J,MVE!I/TA2&*PCC+W/;7EQ2-4(B/(EL4A=7>0.:=N0ML58-?]:4ZYQ>WD
MXQ"E0)$;0D$:I5"$264 (AWN"UNFP4^;#S_T4N(%$MC$5UISCG-X9CC6.SKK
MQ/=O'-.8O-&:@5.<2D69=E<=P9_)83K7."JN8I;5@0A&G[Z4*UAA.3TK \.;
M4X'Y>=+DAN69_P >ZK)#"S8AQ?FE\,8Y\U85V,9\T,DKBD@78WE RXL_/T9B
M:'Q,R.NI!-W.ZA8F&4<>,=PCEP$\*W&;NO\ G(/PF]:O>7[A-YI]AW$W_L9,
M_P -\J8X9.]^&1W_ -A_E6*>.]V[(/\ =;EWQ>/H^;/%0?A]0AM-JUBW>S5'
MC(V=OL_&N+#4[6#'#X[X'U4<F5SG.3YV4B7Q_%+!)WO*60HS9RA4$@\8:B2E
MRYR<'@DWOHR;]Z6]]3!3QM]M_P"G^;L>LV2.)G6[D*T>WGQ+,8O.\*Y46RA(
M]P4]Y:I$S&N*.=&S+;_-[\TI$T>+6F(#V1 4:)P$66L"H1C-*L'U,M5\LK,^
M:PZXYU<4I*)PS3@;$&65R), 12=(LR-CV/3!4E(+&(8BR4Y[R(  WO>]@VM;
MIO01&YA=(D_(3QT;,:SI4*97.GZ$'S#$!Q]AA$CS#CTT$OQ\$H\J_:)"WQZ:
M@M*HP-AWLA<3[=45KW#<*]>,_EPCCAP'%;OYI6G+9WIAA^8XJSHSN0@DOKOE
M[!+<EC$397, NZF)Y1EI$LC2@0#0)^HX/MP7ZM@]:@\+@:U<C6$^)?)NR.ZK
MFT-\KY%19=W'V^G$Y>S(DC+Q?EUL>536*2S 3@TK&./J,7+CI&>I$I3'-ZN2
M+;A.M<(3*#G)V&RCZ*S')4HC,&U=V3S"Y$JS(VGE6O,PVK$:C.5-IXCY9%UF
MQ.RF.XHZ)(\X![ (U2180I4V"82F6(A7.N%C_IJ]RG;%'$%RBSZ/O\[GV&-&
MIGL9E+6YDRJ)"IEK-BV-8269;9H<\H65R-:&PQ>K8A+ES>W+.X%.KDMNG,L$
MSKW#\'#1P9:N\F6L*'DZY30Y"V]V%W,DF1IT)OD.6<BP:+PF/->1'V),O< 8
MHE$)?#G-5:+'FD)1.-V5J:%29 E;T]TG6N$F^1#6+!WIU>,'?W.'&>3DC$.0
M-HW7!.,4%G*=KYPU8G<C9M,FJTLQ^YRH*V<-3TW0'(CRC1J53NY&IUR1K5 Z
MIY*HY4&7Z7^E4XO2-9L:O&VN,9OLIL;D*$,4YRKE229OS+$SB)[-&<E_D:6,
M-&,\@1)C.:FAW=!EIU#H4Z+5ER;'*#C+F"!011YZ]$\&\<W#OJGK-KJ*9AQ:
MT<J&'IBSHYU($\G>6Q9-HWG%X=&TAX):FD]0U)58[V364A/4A!?H,.,OT7H)
M:^K];5#UQM:_,Z-S5LBMVY"L -J5Y0"&!<T*%V.LZI2'-&,HY.:%6@--L:7<
M)@!6&"W0*U_AL'Y,S^E4XL(YJ'G<UPCV9I_LH5C+(LY+VSGV;<C.>35634D?
M628<K=8HWO[;B1Y3.LE0F&K"%T?5J3R%AX1*KG]DI*"-6BW([G+7_P!))*]K
M"9(I=<O:_P 4GV"<53%W!9X<&4;YGMMPIB)W-)4@$F6F8O39';RD!9X#4]T[
M.G">$T':!&'.1K?M!Z9)JQ&T*=X=5^3C;_;*8-A<CSGG622QN:O%,J/Q)KA,
M5T0!$MW("8ZL9+ZM,LD6R%(N=5P"0'J[V,--*L'1CZ2C;"#S:=\B&I> 'S-C
MKIEC&6P+,NHL?V!-819.QG$,BKY@WSR%/I47?91&TQ)CV@;U!);<MNE-4!5+
M1%@4KE%@AVJ4"@4"@4'+1ZJ/_H0XR/\ 2RZT_N1RK00QY<\O9BX+.2G*&]&N
MT!<Y;C7E3ULE^)WN*1]J"X(V'?+&<>NAPK/E;58X05XE:MW0*S&\JQ1SP2LD
M(RBSE5K"L$7>6;1\?'SQ,\,^OS^8%PRR=R'8YR=L))1++N2N4Y\R=&9?*<E.
M*QV%T"> L[FK S)%0K6&<W-:80^D?6O<-W^JEWEQM'-Q-+]#-HY3L-']%5N-
M3=G=I8EJX3&KY5S5XG+9Y"L600XV9S"%QDR+M$CQ>J.4EGK+@(\0NML0H6HV
MX2<.?;:W:#TV;C@YR5<?&J'([J?N;!O!I7@G.0YBF6MB7(T77M[BSJIN-_W+
MR<8R-RE0C$9=?'&E*Y-ZL0#TUKA*[ 8="?.CG"7;B^G7XM<XRIU4M.0\X[ :
M6O4PD38"R50GR"\8/S*V2N3-1242/N?:RHM2M2EEB!V(1 #8?S/6H)JYG]*I
MQ81S4/.YKA'LS3_90K&619R7MG/LVY&<\FJLFI(^LDPY6ZQ1O?VW$CRF=9*A
M,-6$+H^K4GD+#PB57/[)24&&<5.99[FCTHF;EV1'M;)'C'NG?(#B5I>G)0)4
MXGPV"PC+"2%MRHX=K7$7&8TI3-*7]&]D2 FPKW%:][AM7CT_V2Q9_HWMZ?\
MB6Q5! O@T]/+QY;<<>6M^V>YS'E?9^<Y7@TB31^*2_,N385 ,01*.Y-F3,S1
M/'C;BV5PN0$("3VY6L, L<U*(2IS4#+2DB%UJ#?OITH"9IER3\T7&[C^4R9^
MUPP?D#&D[Q0RRMR"Y+XJI?Q/R578*DM.F+5.+G&7%J0N"GJ [W=C3F]0(A#Z
M0BGQ0<=F$O4'3[;7E@Y*S)SFZ/2G8J<8:UWP$7D::06#X^Q7#&AD>F)&-3 '
MN-3!*@CZ"9HT+<A1N3<6-:A7.#@6N4. C:#U6OC>U.XU_5-\6&.]080^8Z@&
M3L!;*9(>HDZS>63Q$VR.V -MXR+P1VG#J_R@E 8V,B?I*4KU5^T#<5A6ZU[4
M$_63_:]I?_HJTW[MHO05DY-XG= ,Q>J/R#K'D? ?F+!V4]497M3/(1[T\U-'
MCN>IQ)5\CE$[\RL61VN7M?BCRZ'G>%HW!.S$=?J$I"RPA#8)A^H/T5U6X]N
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MJ,7)2P+;V#O'H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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ME1($")*6:I6+5BDT)91181#,&*P0VO>]K4'+_P 1.M^Q&-?3+;+8%R-@7-$
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M]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ
MK^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"
M?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBO
MU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGG
MB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*
M2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OX
MO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@
M*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@
MGZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K
M]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)Y
MXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"
MDGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^
M+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H
M"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8
M)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*
M_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>
M>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0
MI)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_
MB]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ
M K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6
M"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H*OXO0I)YXB
MOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DG
MGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T
M*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"O
MXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^
M@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5
M@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(
MK]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)
MYXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]
M"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K
M^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?
MH"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU
M8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB
M*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2
M>>(K]6"?H"OXO0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO
M0I)YXBOU8)^@*_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I)YXBOU8)^@*
M_B]"DGGB*_5@GZ K^+T*2>>(K]6"?H"OXO0I+*;##<8B[7^;"$(Q!_[ 1W'8
M-_\ L?#<N_\ VJ/X_P!4"@4"@4%;?*=LO@W5+6ANR;L%D!OQM!5648M%")"Y
M-K\Z)AR!U9I2N;VWN\=:7A> Q2E:5 [#$58JW9]%Q6O<-KXI\?3LUYX[5NQ'
M!RKV?;?EW/?_ ,_:7-X''=CLGP6/!JHOOF[+?CLB+9NMCINK,S$1$KC[#N8M
MEY7YROW/?M1;IM#Z1RV=>Z+ICK77XJ12V+IK-)\KRG.O^>SXM_QN8A]AV5/M
M#KC=_(_XU/ZGZSVQH?RIKC]\_9C^EL/WO/\ @C\]GQ;_ (W,0^P[*GVAT_D?
M\:G]3]9[8T/Y4?OG[,?TMA^]Y_P1^>SXM_QN8A]AV5/M#I_(_P"-3^I^L]L:
M'\J/WS]F/Z6P_>\_X(_/9\6_XW,0^P[*GVAT_D?\:G]3]9[8T/Y4?OG[,?TM
MA^]Y_P $F_@_U G#U%L>MS._[N0=N<B5SH::E,@F9#1@+/6&&E"N-/C<XJ]A
M@%:_P"KMAXD?9[SEV7]@.@Y1Y\T.3;N8\6NUN2_!??CONMLRY[K[)ZV*_)9]
M5;-8I=6/+B&..V7?]HYEYZS[KL>>W4;?=@PVQ?$71$S;9$712Z+9Z)[C;O\
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MA;()=-IM(&F*1&+,#:2)2XO<CDCZK0,S&T-Z<%S#U*HXHDH%KB$*UK=-!_"
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M(E+DH(1H//T#S3B&-*U:EU0,J9*3.LMXSA$&&I4+W(KJ \1ZPR>N?:UR2C3
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MN'NT!@[584,<0%C?'5M$>:0$LJPQG$!,"65 H% H% H% H% H% H% H% H%
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MCG"\6=V;::58B9L^18G +3.@17!#9"'M1#I 2\Q>6@.>K1]$G6"$I&!6:%:
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M",KQ"[;9%VA1ENUZ2C.J'M::<DFC/(.S/#SIYLC <U"CI(%<CCC9XY%\@1Q
M:M-;TSI(L9SQGBN1&%H6K2!%IUBMK)2J16_6C!]-ND(.$8@XZ%//0LRT3GK+
MP^3%!J($I7KSX4N#APK @^ZQ\,W\9'A4+89(KGK2@]@&<B/ZPNMW#J6OT!8E
MMUO1J-H; D>2]N\\P;!\3=3EZ5@')U*Y;(I8L:DQ2QT0PJ$1Q ]S:;+VY,>6
M,\AI;EAQ5C2^L&W: ZP<>?.IRH\?_(K!>-=NTWV4BN8WR$\FV#G2414,?GD
MFC4S&-S\@L_#A.48G"9:JCMEZLE.)Q(1&H@*#BRQ&V&,(;AW>4%;W,5_-/\
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M98P(>6MV)CE.28@9'CO%S8WK1@!"ZI8A$4*X=P'!;%SW&2V(SJB."8AB#><
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MW=M47 M[W<TUP#9;<8"@XYLE;-2W*W-!R?9PRGPMYJYH5>$,]O.KV*XXV$Y
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M5A:&R9%X9)(EB;',9D#=WE(L\/>V&'LS4[(N^-ZA6@5]T7I#"^T(-,),ZO6
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M:;LK,NZ^OWG* 2;S_CPV5YD<BY#X7#I5(7F*]9%*T ^Z/:=M76[QT7)ZP#+
M#&>1#1K:7.G,YQ#;88KQ?YIP!J][TO?I/O.V.V3R/YC*."S?^I:1RYHFLF[X
M(5O\#MKAV?\ O^K0:NY6N,#?$O=B"<M7$9.H0S[>1O&1V(\R83R8J;D,0SQ
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M8\FY>D+I$/-T$F_=6>42Y0Z,2OQ_',GE\7/[\A'8?9EK1FE=/5," 7P4%Y=
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M?.4*'F]#]3G_ .15GSE"AYO0_4Y_^15GSE"AYO0_4Y_^15GSE"AYO0_4Y_\
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M;'!.6K0.+<O2&')%R!<D. :2<4,19I8K"#>]KVO0?OH(18DY(='\WQ'8;(D
MV(AE\;:I9(>\2; 9/FZ22XHQ?CJ?1Q46C>FA7DG*S%"X.^(D*A03:[DUKUS6
M,*I.("@05! C _M">2KCGR7+HYC_ !QOYI1D">3%W11^(PF$[4X+E<NE+^Y'
M!3-S)'(VQ3M>\OCNX*!V+(3)233C1WL$(;WOT4$@)%GG!L0RE",'2S,V*(QF
MO)J!R=<;X?D61(@RY2R"V,R=P6.[C",?N3PFEDL0-21H5FJ3D"10606E-$.X
M0ECN$-KT"@4&M\L9DQ#@2$N.2\YY5QOA?'#0I;D;MD#+$YC&.H2UJW=:2VM*
M5QE<P=&=B1*71Q4EITX#3PB//," %A"%:UPV1011R_OEHWKW,C<=9\W-U1P?
MD$AN0O!\%R_L3B'&DR):70)@VQT-C$SF#*]EMSB H5R#[D6*.L&]P"OT7H,%
MC_*#QH2U_9(K%>1#1>32B3.[;'XW&X_MM@)Y?Y _O*TEM9V1D9VW("EQ=G=V
M<5)9"9,068<><8$  B$*UKA.B@_BI4IT:<]8L/)2I$I)JE4J4F@(3IDY !&G
MGGGFB"42224&XAC%>P0AM>][]%!4?COGDXE,N;(1G4S%NY40R'G.:2]/!(@P
M0R YDD<1D\H5IA*DJ!AR\U8X58==4RDL-P@6$OXT0S;=E8VYGS%!;M0*!0*#
M46*-@L"YY\W^XW-V(<S^[Z1'1"?>ZC),,R+Y(EB;M.\1>7^4'IX\M2(CL1]=
M$M[!2'JWZ06Z+T&W:!0*!0*!0*!0*!0*!0*!0*#46*-@L"YY\W^XW-V(<S^[
MZ1'1"?>ZC),,R+Y(EB;M.\1>7^4'IX\M2(CL1]=$M[!2'JWZ06Z+T&W:!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!01&RGR
M :&X,EBB!9LW9U&P].4A/>5<+RGLCAO'TL3)^^+&_MU$<ELS:'@DGO[<H(ZX
MB;![8@P'3U@"M8)$07(F/\HQY-+L9SF'9%BBP5@))/!9,RRZ/*AW((56"F>H
M^M<&T\5TRHHSH";>_9F!%^@*U[AF- H(F_ARZM?AA?@#>]#_ .6S]V7OB]U'
MDG(G_1QUNIYB\]>4?=K_ &7P=T\9[_\ _$*#:OX06!??'^#K[[L0_A!>7?-_
MN*]Y,,]\?E/L^V\T>['QKSMY=['YOOO<>[=7X>OT4&W:"*.U>[^KVDC=BMUV
M>R=[LD&;,HLF&,8G^2\AS/S-DN1D*5+-&^RQ]$Y8<S=\)1F"[XX!2("^KT&'
MAO>UKA*Z@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@J=YTOYHO?7^ EU_QVQU+N0OCCM_LB.]+Z]!ZLQ^
M:?("K929E H%!U!^DI_G,<D?R.LH?QK8*JI>V7XJXO9V/T/*\C>?4D>;CO2^
MCI6848*!0?,M]2UOSL!G_DMG6AS]F!UP[J=AF48I@IT=3K'E/#%SG*8K$I3*
M,QY29V*UU\R,8Q3,ZR-,,*@M(UH072D@4GJ3#@LD@7I)] \]XC3O>N/)I(LI
M2U4PDK4F18:GP[DG%JM6H3FV3.-X?#7T+TC:5"JX/UF\E,-+"$0.T$/X0A?_
M ,$>@FR/&SJIEW6C9&=->1UC=M#,I/B"6,,E=WYA7X3<L4X69HR!G;'VX7*#
MIT\FCKT$UC$6 M(K[8PJYQ1P%!P<='J5\R9&Y$>7^$Z0X :7"?+<!-;)@>#Q
M9JZ1A?<SSX*.:Y17H^U':Q/AQ1C6S+AB  )8XX:/YH%@C$$[/1H[E#0N^SF@
MLK<PE%N(4VR>)T"P^Y1H75"!F@.7FA*4<5>YIRE 7'%I:<!@;EA1K#;%BZQH
MP!,/UGG^8QJM_*Q#_$_D>@I>XJO3+1+DLT3A.VI^W<CQ#)YT[Y.844-)P\V3
M1A:EL'E[[$FU8J=1Y"C3@N2KC&H!YY0"B1A",0 CZ;6%08%Z<'9[9W5/EQAV
MB;;D9VEV%<ASO->(<G8U1OC@]X[->L<Q;(C\1DJ"H#PJT;&Y-T@AG>C%Z0D@
M2]I,/*4"ZHPF%!] WD4W^PEQLZP3;93-;@$TAH)&S8]@B-441),J9(<$JDR,
MP.-@&$T03G$Y.(U:KN684VMQ)ZLVUP$W"(/E(<FJG=3-$WQQOINK<2.0[SLL
MFR3B./*35:<YAPW$7=)&X>F98X>2$J+P 291U&$GM!*5Z0H3B?88EME*D/K3
M:$_YC&E_\D[73^)^'4'-ASG\AN;=KL\L/!CQHJQ2+-V8E5HUMEDQC6FD,F-X
M6L3!52+&2Z3-Y2LUG;6^-C,<)\N(",:)KL!F*LI6JUR(@*!/2$?SK[Y_).S#
M^Z[%5!/+UK?_ $J\?W\'VP/[H\54&I-9_31:&;$XVPG(6_E_QVGR9EC&V/I@
MNQ*Q-N&I!*H_)9A%V=Z<X<6SD9P*D"MP871S$B$ :,I1<POH&4 =[AL'57JM
MHW(.%/BMVJQS@C(+EL)D''T,V6V0QPXO\)21H]WR*FQ"!?$XB9&T#[(2EJ4U
M_@Z4'3WBPC^\W!U;=%KW#@$XM,,ZW\LV\^03N5G=V<05\E;&=*8_(GZ?Q:+2
M?,^05S^4&T)0Y%R0TR"(15&@2JAC2,R=&48I)%9*V63]G:U@V+E[!D[XB.<B
M%8 XV,[Y)R>_M61<&-T83-[@WKY?(2<F&1IV<<&Y43PTEHBD\3K$#D6%>"[>
MB1FHU11HTR<TNX@!W&\R/!K$N7V48'DTFV)D>#3,&L,\8DB1BQTV3D$B!.7"
M,.!RE2<X2V,B;A-PHR$(0A"=8RQU[WN'JVM<.1'EU]/!K9Q4:H+L^R/>*;S^
M?R"3-$%P_BDW#$>83)]+5YO?76RIV)R.Z*6AAC,72*UZQ8%*<$(BR4]K=JI*
MZ0L,]'CI[DE1CK=+9V1@\NXKS-&VW72 *CT:D3E(WAB$YN\YD[<6?9,F/C\;
M&^(D)1I8S *W"ZLGK%"1&6&&>_U*3%7](#D'\GZ.??5H.1#..C4='R-N.@&D
MV2'C9Q69EUFP3$LB.L83Q!#*,A=Y3LTT7%H61TEI:2!0V066@/=^U-*$W-QR
M_JV3]6]!]CK%<--QUC#'&/CUY;J?!(%#X:<YDD"2E.)L8CS<R&+RDHS3AIBU
M@T-S EW&.X+"Z+BOT=-!GE H% H% H% H% H% H% H,GB?\ A$[_ ,R,_P"'
M34&P:!0*#1&T.?HAJKKCG/9.>FE@B.#,53G*#T0-2!*8YDPZ/+WHAB0F&6%U
MW60K$I:%&6$(C#E:@LL 1#$$-P^<5B'#F5] \9<6GJ+,B.#NLGVQN^F7)CN*
M>4:XC+!@K9QT=&EF6W;BU@P)$CO"6"9.R<RX5!0U,G;"CQ]H445</I>RF;,<
M4@4CR.H,,=HW&X@[S8\UB&C7G.;&SLRA],,9AC5ID"TQ:@37NGO<\LDRX@])
M@0WZU@YJ'SU=W$>Q8.A&83%6Q#I)IPI? $Z],>.80ZYQC#>QR97&;O$W+394
MOB.+IG82(:]"E42WQ-2V"+462VL:7886B\;_ "]Z:\IF+9_DO6%_F):[$XD
M<GXLR/'D$7RE!P/"%Q<&!6ZL[:_2..KVR0%,RTM(L;G5:C,/1G%"-"86(-@X
MA='/45Z3:S\J_)UO-.\7;3.V)=TO=W[K8]$H3B5?D5@\HEE <O/[2\YN88TU
M]O<%^P\.=W7K?[[J4'2=MEOIQ*[N:S<5&U>T>LFR.3\>;.[;H8MIXS64D0N9
MXLSBAG[MCA',<IMV/=D(DQWC)+Y$QF]F6XR@ DEP"$AN8(900Z;:!0<*&E7&
M'HWR2\TW/>AW3PA[YTN(-@,:J\=%>\K+V.O+JB<N>72929U\43^"F.WBA<3;
M[="ZZH)'=_UFQ=QF=<,8VLTIQAP+<R_$I...23Y @,$WNSF+!.;-;'&<R&<L
M"F"K,CX@@;L2@\P*763OS"M:LQ&J6\M]6.9[:^LI"M,HN/K6)"0G(KIWKEO7
MZIC7#7K:G'7O3P^^<:HI"Z1#S=.X1WIXB\OV)=&)7X_CF3Q"4$=Q7 L/LRUH
M"C>CJF!&'X*"7>SGI'N+G)$)67U69LFZ8YG9DX7+'N1H1E?*&2F1MF#>88K9
M'.4QG+<TF+LO;DZ[LA#"S.S$M!<D R5)8K"[0,Y].UOELWEYMVVX[M\'E7*-
MP>.;)1..GO(3LM$N=\I8U5.<BC;,\.#FH**6RYSC+U$#@BD!H0#>6=V:%!ES
ME(U*D\*6_4^:U\TI>(=F<ZYCW/P^_P#&4S9DBI^/-9(4Y.L8R&3&I5-X\SX\
M:I\UQS7R&-.0!1:2G)E]P/LO>@(SB J2!F*"RZ#N+U:_S9-<_P" C$7\7\>H
M(B<P^Z9>@''#M'LJB<"T$XCV/U,1Q+TF""H.R[D=01!L>GI2@?KJKP%_?"W9
M0 '1?N3>>*X@A#<5@BCQ6<4^)L=\+.*='-FX 9+4&P>/[93VIB2N02F,NLAG
MV7US7D)V87N10UYCDF0.L(1$-$?,/0+2!C"QA_73+"&,P*#> 7C#T;?^63F'
M.=L(=[,XX-U<:I-,!>\K+Q'N:3H<I[3H4I?0FGY(<A]DEQBQAZ979]$+N/3>
M][G*+FA8SR&?[4;PB?P$;'_Q=["4'5S0*!0?-]]3=K/S517&&0<Z;B;IX?R?
MHBMVL7L."M?<:.KQ'I%&8_*WK(L@PR7/HHQZ]XNBDK=X5!T%T:E>YOS\O)5=
M%RSU/3<^P?2"H."OD5P]Q]9R]4 _0;DQ=\6,FLP]%XB['K<PYS<]>8=:>-Z&
MUHF4+(;3D'&:L#F8$]5V"+Q.P570+I*,ZGS(7/ZK<'?ISI[(HOG/3O$V&<NN
MN(YO%9@P3O"^[>>LRLD4FT7>P/T75KQQ_9*6QDQ2D>F'M0I5Y9I!]TXP&%&
ML,-!T:T'.#ZG_D"C.F7&UD;$IJ;(A62]UHI-\$XQD,,0LIS#'[#3Q\61//3D
MNEL>>FAJ>\=O*]$G,;DCH:8H.L TD!5Q#H*LO3N;C<'^6)%J%IIA+CZ7MN\4
M"PVAF<GVARMK=K@Y.2O,6/8*B><IS6-YNMD::9G;@NLG+6F,-BD"*R9,8678
MI&&UPA#J2XW>1;"?*)K:3M'@&+Y3B$ /G,JQ^!GS"R1)@F-GF(!;!.2D3?"Y
MOD!ELV'V=2^P'9PN:+JBZY8.BW2'XT'))@UQY('OB^(BN5PY]8<#%;#K)>:Q
MQ .'S(4<L:406M,_@G0YH.46->2KW(%'P).J$7]T]-K6$$(N1/U&W&SQK947
MX*RQ(LIY:S6P!:S)GC+7R&,<P>8$6](0N;:"7OTSF6.H(WN9S>:4>-M*=SW0
M@E028:F  TL0@VSQB<Y6C7+(]RZ&:U*<MQO)<%B5YU*,:9AQZ7&)$W1.TE#%
M;O 7R*/TZQVM#XBK1#[ A\-5=BX%7[+K 5!3AAW"S+>..:MV\CGQY8!RK@@A
MBW$G<(V2!E-]>GH[(&=HV06HD$SB07;-&8P(8HM \7LG 2)D#>][]* OH#>@
MU1OOZFKC%X_,Q/N IN]Y@SGEB&.9C'D6,ZWPR*S!/CE^3A.[['Y5)IWD#&<2
M'(&LXJQ"Y"W+W!6WJA7(5%DG%G%EA./CCY;M).4Z(/\ (M4\BN*Z30M,U*<A
M8DGS&.'96@1;R#I0GO<=&J<6QV:C#["3W<V5>ZM-E0+D]ZN9;JT$<=E?4&<=
M.GFS^QNJ6RTHR-BF<:V0&#3EZDKK$&I\B.2U.18_#9'&8+A]#$)3(LDRN:F-
M\W375@51UM;$ $ZD]2M*2D]X$&G=#/4Y\:/(%L"R:SX_]_.'LGS-79KQJ3GV
M!1"-Q_)C]V2]3Y=BS] ,D9+2('PQ(WW&02]V:.^#-+(3".4CL10=#U!$S>;<
M?&/']JKEK;[,C%/)+C7#:*+KI.QXR;(^\SE>3+)S&( W!86V52B&,"HPEYE:
M<T^RAS2V"F 8(-QCL$L8459E]7AQ'8C70]L:U6Q6:5TDC<>D$@!AK&T+>4.-
ME4@9&A\M%I@_3'*4'CKM)&0IV[LX!C"R1(TJU*H([R(POH$%X&M^^NLFW.JI
MFX^NL[]YN&DT=E+VYF-2$Q!+&)TA328[2F$2*,/@VM6P3=G) $(D:P1)9H3B
M5!1IB-00I,"E*0^K;XEHYK]C_.2IQSVX2'(JF1!;-<V*"P%\S_'VV-2Q5$E#
MW.FYNRN?BN$HG0Y&->W)W&6$.*]LZJ@E**P@AN$]LC\X^@N&-%<$;_YDF<OQ
MCB[9:.A?\+8VD,<;W/.TW&'YI:S-D"A\@D[:-:S$B+,<%=G2[.WA4)[*%I8U
M! 3 ACIYZJ[BGW!RXP86(=\XZZ2Z9.[5'80NV4@D/BT/EDC>3C$Z!C33#'62
M<I,,;5GJ0@* :_'-"0TXXHHLX9@[ H*X/69;CXQBF"M:=*W%BG9V4Y+F:!;5
MH7]$V1\R %8\Q\WY6QZ\LRMU/E">1%S-2]2=.:E3@:C$(TH#!&*RS+!+&%M'
M&[ZD#1[E$V2)U<P#BO:R(3\^#2K( 'C,,'Q$P0ZS-$!-@7),)PA><L@/5G,^
M[J7V +-]RA=477,!T6Z0Q;=[U1?%GH[E^08,?7_,6P>1(4ZJX]D!%K1#(A,F
M."29N/5)76,ODMGF1<919Q?F14E[!>G:5;G="J%=,?<M22H*)"QOCIY3-..4
MG&CYD;5"?KWE1#5;:WY&QO,V<44RAC=P>$YRIH)E<9&J7I1H'8I,=9(YMJMQ
M:%1J8\DE4,Y.H+*"*_"S+>..:MV\CGQY8!RK@@ABW$G<(V2!E-]>GH[(&=HV
M06HD$SB07;-&8P(8HM \7LG 2)D#>][]* OH#>@C9+_57<5&/XQF9TG#IG6-
MS?#F:)W@\6%3L?Q-WRSD1^Q[V1;U*X,UQO([W%F_'JQ<9=(A=).[QOO:HHTL
M)=KDF]0)<\8/.OHCRQO\S@NN;EDV%Y5@S"*7.V),WQ5AB4Y6PPIS2LRJ7,%X
ME,)]$WUF;W1Q2$JK)W4:M()81<XDL)H;W"Y2@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@HG]2-L;GO5WB+V-R7KH]O4/G2]QQO
MCYTR!&Q*4\B@,)R%.6:+RF0,3FE$$YB=5R1>%I)< 7L>A$Y]LG&4I 2<6%=?
M&MZ<7@\SIIC@K,\@AKCN?*<G8_BLSFN97#8?,;((^<R)A;WN81P+!AK),#8X
MX9'7QQ-2F-S@G/>40BNS6G&*+&"$%F7''P1ZN<6.S65,]ZJ3W+R2(Y>Q"CQI
M),+Y!?$$P8&MV;)-'7]NET;DY:%G?2^S*9U19B-S"ZFV/<SQIU2<CJI*#]')
M/S_\=W%S-DV)\ZRO(&1,V";FQY=,,8%BS--9S%F5Z+3J6APF"J3RN"0B+F.;
M<I"L3H5CR4YG(1 4@3").(&:&2\:G.SQ]<I[RY0;7B;3&(9C:&A9(EF#<V1E
M#"<E'QQ"J$E5/C%X*_R^#RY(EMU#5!3.]KU:(@T!BHD@(NF@K"_^C"?_ )V;
M_P"Y5!8@EEO'&KYXW* %X!RJ'DS:].RYNHV(&^O5L0#P28L01T,,)8@YH$S"
ME=KN(.D8H,$74L(7?^M:UKAO7DHYA]'N*F.QM?M+/'PR;3= Y.D#PSC-B)F6
M69>UM0A$*G9&QJ'-C8H^QC7!NE(<'QS:D"E4$PHDX8R3K%AQX\L_.QI'RV,G
M'= M;T&;(;D3&_(_@Z:/T%S7 F6-NQ\.$4Z,(Y(UO$'F61H6H2%/+NF($G,=
M27"]S>N%/<L(QA#Z*=!SZ>ILVYQOJYQ09QBN0&2;O#AMBB==8L='0YM87!&R
MSV5P^43!N=YJ8]26/GMT0);(0K <H0EN2T)YA(0I1@$,985-<(?J1]&X]A#C
MHXR5N*MKC<\J$6(=8@2U+!L0CQ':>R>0)8L@=Q/QN=")E:($N#L6,Y19@NM"
M2$5PI1BM8%PZ=]:>1;">U&U.Z6H6/8OE-GR5HK((#&\MO<R9(DWP>1+LBIY,
MI9#<<N3)-Y"_NZ1*"*J+*A.;8T#!<9?9A-Z17 'X]N.23!NF6Q>CFLF4(KE=
M^GF_N1I5C'#CO F.(.D1C3_$7+&C4Y*\F+Y#.HL\LS0>HRHWW(,:T#R<(!*B
MXB@7 58X-4;Z<RVF?&QG/ V$-KEN1(8'/L4G\S:<K-<:97S%L&8\=)#5+L*>
M&DRHG(5W%U. !*V(V&//JI<L/*) 789@;4%9N-O5\<1>1,R-6)E:C9'&[(\O
M29D19OR3BV)L^&RSUJE*D2+G5<RY-D60H^RF'*NDU8X1U*G2%%C-4C)*#U[A
MZ&>O5T<1&$<F*,<,3QL!L&G0.(VMVR1@7&<9>,9MZDDU.0J-3ON1LC8S=9*W
M)S#C.A8RH'-(I 0,:<PX B1&A?UKAM-@K;#7F![3X/GC=*,(9$C*N5L4R5 /
M82$K<TJE[?(2) E>BT2F/N,6=6E6D<B502[I%"4T([] >M<.??-GJ]>(S#^5
MW'%[*HV.SJW-#G9H<LM83QA$7/%!2TEQ-;7(;<[9 R?CJ525L;!DB-[^TLZ]
M N3]4U <K ,%Q!?)IQNIK5OSA!CV%U7R6V9,QJ\JU#0J5IDZUJ?8M)T!"10[
M0^9QIV3HWF,2AI+7$C-2J2@]H0<4H($:F/(.,"C]R]6;Q-LN!09L>'/.Z"0J
ML@2R!->NH(- W;8)Q!#BFT3A-SX^P94=H!&((XJ7,*=M6/DD:U#DH(4A3IS+
M)CQ%A(:3>HVXV8'HO@3?3(LBRG X5LV+*)>$\*/,,8W78F9&8@R%*L:3$889
M#9E*(>SMA,AB9ERW)=(4S78M8D <I*4G=W"&F=+?50<8V[>=X)KI$FG9O$>1
M\HRV/07'!69<4QDIEE\LDYBU,U,Z1UQ)DG+EF<0W!.0F&>ZEMZ4!BTD5S>R"
MH,(#I(H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MVA>L@N4$DI+87(F/#F9'):CS##C&^-N;HS'EM,>F#P6SE // "R=&,5K& Z
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M(*="71CQYA/&JB105)-LH+92<RH$T(<<@M2UDC"5D@:VZ\].<D)5.*L)J0@
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M4_/&X_HK7_7Z+\L/#9/.LGT;/MW11Z9'!N,<7<@N0)'!]RM;=CGD_57(C49
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MD<,(RA.&.)*).7';M@7XUD3NJL@YP)9Q/22R@98;A*$I+L*]KC#:X9E@;8W
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M66\F,*A9J@A+YF&(.".92ELA4:7, \/-,\<I,@<Y.\)TMCVY.J)+$.XS! +
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M;[;%C@BU1QL4<X%68BI3%"7B99WE;F--<\I'Y=D_BZ-<9UQ"[C'"KC[,0;@
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M@[@XGT[WMXU]D>-V7;#.K7',!2+-#E)E"*:R-[=5;$QH7QBR%AC!;XQ-T@D
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MTM>LF%LAX[T]UOCX'R2H8W)(A##6+$>*(Y%8LWIEJ2"L+R!,B(0LZ0BR)O\
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M5Y^FE^*LBQ*$O>7HYD\:Q*8]K\FJU^E.:'XQSDC5W)8W#72!6.[0-,$L))8
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M#W<^%^1O=^S8L:?,?O*\^./F;Q;W:=IW/P!O[#OO5[<SL>DT/&Y3^+S\Y?\
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M,D=6IL?6QQ9'MN0/#,\(%C4[M#JC3N#8ZMC@G,2+VYQ0*RSDBY N2'#*.)-
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M7)5MKO[F]KA4EQ_%U>8WA\30-AC\J&B"YG^7)UD#-4L/?"$C:22F/)D25.4
M1W63F=<%B@A7E'TNKTW["Y<RGHURF;6:!XBSY,5,QRW@+#Y,O\,>#WAP4+I
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M_O2A2.)W^7^S[;\L_P!Z4*1Q._R_V?;?EG^]*%(XG?Y?[/MORS_>E"D<3O\
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M_O2A2.)W^7^S[;\L_P!Z4*1Q._R_V?;?EG^]*%(XG?Y?[/MORS_>E"D<3O\
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M2$0=S7]HV*0&]LE)/(MUNK<=AVN&P39H(@:X;ZZG;;Y3V<PIKWE;W@9-TWR
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M["DBV)VFR6@Q1AZ*KV!J>98M9)3)S@N<G>$C$QMS;&(0QR:7/R]:XK0_K*!
MI,*("8>98!!)I@ _MJKM=@'=K!T1V1UBGOO-PM.E,D2169^5II#/%5$1DSO#
MY"7Y=R#'(I*T/A\C8E2?I4H20F]EVA5QE" ,02(H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!
M@61,IXVQ(Q"DV3YU%("PV'<D#I*WQO9$RE18/6LD177'DC7K16_L22;&&B_W
M WH-00O='4_(3T1'8AL'BQU?58@%H6H<K;FQ<XG&"ZH$S60[F(!N:P71>_8I
M^T-ZMKWZO1;IH).4"@CKGW;' &K_ )3]^D^\C^>/'?*W_J6FLF\4\L^#>-_^
ML^.2#N7<O,"/_P H['M.V_6^MU1]4/\ >8MKL!8"B4/G66I[Y3BL^&4").GE
M::/OBPCFPMX*MW&-1QY<4/6;C0F?W223T=/5O\U\S0;EA\LC\]B46G43</%H
MK-(XR2R-.G=5J'Q*/R-L2O#,X=Q<DR-Q1]\;EA9G9*"2CR^MU1@"*UPV#(J#
M3&=-A</ZUQ)NG6:Y?Y+BKM(TD3;W3P"42/O$@7-CN\)6_N,397UQ*[5N8E9G
M:C)"0'LNK<=A" $09KCS(,0RK"8WD6 N_CT-ES84\1YX[@YM?B#<<(8"E'A[
MTB;G5)UA%WMU#R"C+='PAH,RH% H% H%!B$MR# 8"6B.G<WB$*)<QGE-ILMD
MK+'"W Q,$L:DM$-X6HPJQIPG N.Q=Q7!8=NGHZ;4'K*9"R)(\HEACDF-CB9F
M-D(WA$*[BC,9"4(G(3DD&@"INN3#0![4NY%C+F@O;J6%TVZ0T=@+;' &T'FS
MW%S[SQY'\"\T_P#J6FL9\+\S>,^"?^O".1_OO??+ZS_R?MNS[']<ZO6!U@D5
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"IWG2_FB]]?X"77_';'4NY"^..W^R([
MTOKT'JS'YI\@*ME)F4"@4'4'Z2G^<QR1_(ZRA_&M@JJE[9?BKB]G8_0\KR-Y
M]21YN.]+Z.E9A1@H%!\L+U*^?<BY=YD<CX;V!E\V9=?L$/6((9#8NR$&*BX?
MC63P2!S&;3>*QE<I1,[U,Y,9)URZRLVX!JP@2HQG=W3$V+"[7"7%5Z5;;>",
MT%P+M<83D:0,Z=.R/KQLVK@6<UKFI),()4>ZW+[0QLBQ\ I-"(U&GBP2^L"U
MK%! +YH.A?ANXPE'$Y@#-6N964B<NQ>9;/S'-<!E!C&.//Z6&R;%^'86B8)>
MVA/5-WF9K=,>K.U/1&B2JB#"3@@(&,:8D.(KG)F&3.7GG50Z8:^J$;[;%C@B
MU1QL4<X%68BI3%"7B99WE;F--<\I'Y=D_BZ-<9UQ"[C'"KC[,0;@ $P?1X[;
MNN+]B-EN/O(1ZQD!DMK/RU!(V\DJ4:IIRUBNX8UDR/ 1'&%C2/C["1D*%99A
M/7"7%NBX@7!U1A8=ZSS_ #&-5OY6(?XG\CT%?_#/Z>CC]WZXT(/M=L%,,[P[
M(<G<\SM[_((;DB'QJ'QQM@TUDT=;7X+=)8$_)4P6II:@*%(U2D:<0BQ"'8(+
MW#8*S?3FRS(^%><?&^(,#Y!733%TODV=\9Y#<(^<HO#,J8BA4(R.],DS=429
M99 )"F<8VWO;4H&8*Y*H199=S+'C*.#OLY@.4[%W%3JV[99D0$,HS)-@N<5U
M[Q28HZA\WG@401W=7@LDTI4E@$*"I*6O:H%P"[(124H=E2M/:X?,9Y-M8=M<
M5K<%[3[NREV=]A-_([-=A)!&Y&D5$2J(1X#VUM$23R?O1UK-;DYLQH#$[(4G
M(*8&HM&CZ # -.G#ZR6A/^8QI?\ R3M=/XGX=0<IO*WMIFSFHW4:^%'CPDYB
M/!D0? NF\6PS1<];$S4D0>D )*U&*&]0F [8ZQ>ZB*(NFNH*#+)J-,B*$2E1
MEK%84S^D(_G7WS^2=F']UV*J">7K6_\ I5X_OX/M@?W1XJH-2:SZ)^E<R=C;
M":;)6_.1(EFN4XVQ\MR4T/N53<?16/Y)<XNSGS5I,DDQP6AB3*WM<G4*20B/
M=1$EEE]/;##:X[AVX<<>BNM_'QKBFPIJJ_RJ48BDDN=\LMC_ "V7LTY5.JZ:
M-,?2FKFJ1L#.RM:UA5-[$E,37**&&]A"%8P5A6Z ^61H3C7CZRKOAEF,<E>6
MI-AC70"++SHDF$37.3>Z&9&23AK*C+/<]JA4]572K6U2XC&'N-@WN2'I-!T6
ML(.O?0;AP].EG?+D#R'I?M]D;,.3\/S*,Y59(.7GF*II66MQW)FQ_0NKKC*0
MXJC$\5Q4EW;R *5!:4M.(!E@V.#<P KAT)<IN#-[MA-94<"X[L_1?6[/Y63(
MN^JLARZ226+-)N/T+1)T<DCP7.*X_P DN=UCDO<4!I9=VZQ=^[W%<XL0 6$'
MS5H'AK8?7WU"&L&(-L,HI<T[$0_D=TO!E+***7R^>)9@_/>6<.R1.XDRV>,L
M=ECP$EG>$R?K+$2<15R>R+#V0 7N'URZ#D9YXN2#,^<<O1CA$XU#U$IV?S\H
M+C&QTXC;B:E28N@CLW&+W?&QD@;PGF,2A;$^U=)JY6MU&2, NEL$]2N/ A#E
MMX@<*&ZU>HUP[KF?("Y:?@';;9/"ATJ);Q-!4F-Q7&LTP4R0%-0U:\;86\C8
M;J0I[GG7)L9U+F#Z.M<.N[EIU]_"AYIN)G#'OOV%UV\RX*W26>]C5O)7NDS2
MP>7X>C?NZQF=>"R#PI&]^']R<0=U,[R@/.)Z0]?K6#6^P^KDOX7MFM,=S,7[
MF;1;<N^Q>S.%]#<M0#>B9Q+8C*$DQ1F5W>URX6&<IGQ"+3R$K(HZ,*1>%J;K
MV2N*PH@2X9J<NR88=:5 H% H% H% H% H% H%!D\3_PB=_YD9_PZ:@V#0*!0
M0QR!QP\>669G(<CY4T-TQR7D*6K[NLKGF0-7<'S*9R=S$440)QD,HD<&<GQZ
M7B)) "YRD\TRX0!MT]%K4'*=P*:.:4YAW]]07#<N:?ZMY2B&%]_76&X=BN1M
M?L33>-XGB!>:=M6HN*XT8Y-$G-K@D; UQMN360M925+8A F+L#J$%6"%W'(K
MM3K'Z?\ U/CF;L!Z/809X7E397'N*IE \*-T(U=8RE4LB$X=C<FOAN/L1R=-
M)W&.-4#[O9,:W!//).M8*HNQ5@#"*^+_ %$N1MG=F</X^TVXG=TL]Z@9/SC
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MGF;P3M>U[C_=7=>MUOUOIH-*\SNNG&-MQEO0K W")%M47C?-ZS^R/[G)^/\
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M,2WG2G(ZB-1*2GJ%\%4KY6K@F-S5:^20TQ"Z&D>$D61B6]AUSNS[4827E_\
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M+;DW#VAO6-"90:RYVWALD+/IT_LJPIP9WQMS.\-*\GKV)7-CFEPLM0+"K&!
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M*W8Y[9V\R*M<HCZY@E#(SJG[PJ2-$DD<J$I2NK>@-L0H(.)L$P9-^J849<P
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M H% H% H% H% H% H*G>=+^:+WU_@)=?\=L=2[D+XX[?[(CO2^O0>K,?FGR
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M%*=9QL<>ZE(>2J3':0:HC)4)S0'D&@O@B!VL(LTH0BQAZ;?HVO>U!27Z?_\
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M1N',8\RSX+NH.DTOU/S6L1DM5I6K$WI0&.XA,S/8X*DM*49(F).)O- 8YM"
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M6^\I29.J]1IP(E*B"5)06/9-2$L\H!P J$<4?5B,\(# B#8Y*K( :6/^R 8
M(@WL*UKT%C7J#''%C?PW[Z@RVLCJ5D<L*KVZ+%R,U&64NRF8[M*C%"-G+5WM
M=3(O>"E;S40"K7."<588>BP+WL%64/XG,J\BO#-PNRF*9WD&K^Y&F>+,49DU
MRR@\L5I2V-!"]EBCK&6J0,7>25*=()AB$66-JFUE/<BT 2#D2@LXPL(8UG+D
MLY^>("+Q_+O)=@C2_;W4E#*XW#I]FG5N4OT'RBSN$K&RIFM>!!*2X@UK2PB
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MTC+"XP9PB&/L:GQ-=#US4D4QE9%SVCC4$TG1U2RFD#1#2WNG$F$"Y?S'5H)
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M2V2EC%8L183O@OU+=4/H6QSR]Y>8?*/@OE/P5K\L>7.X^7O+W<2/!? ?#/\
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ML7(-6<W,$U=F6;()9#CWV"R221U08B/ET?5MRU"4WFNXD@!FW$Z$FC._7+)
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M1\ON[TZXI3X\;!-F1HC!XDO@KC#U<[R8D>D!22'#N<H-5@+5EK+E"3 L"XC
MJ&FGI8'[&F19O).-'E?V_P"./'.17Y=(I-AW':F>R..$JSK)O#6]F>8'GO!#
MR:S,5K'E)0O=WU<%,,HNZJ]RA#."S#6/@_PQA?2O:33;->?]AMMDNYH5A^>L
MKY?E24Z<J'8QB3,;.ZP!4I3/R^-G1@Y G<T%G5;(+A=BNU,$:3?NU@A!HAZ<
M;+VEV?L)3=VY:=G<UZRZZ3-?.,2:<O<>D\>Q:T.PANH&7Q1"ISQ+\?G>&)WY
M:::8V1)H-/<3;*2Q)[6,)-"T?C_XT_P%]@^1G._OI]Z/X?VR*C8/RK[N?)/N
MF[=\R&]>4?'//DN\^=3SYV7?^YLW3W3K=V_7>J6%<N[?IN8QFW9^:;DZ,;R;
M!<9F?LLKU#GF1WP5:0+8K.G=RNN.D4D2M,,R?A>5QN22Y<LLH=A%OQ[6K46,
M/[@!2I4'FA(CBYX'L-<=V6YQM7D?.N5]U]V,C-BEFDVR^<##Q.R) Z)T!,@-
MB[*Z2":OB-\DUD "5KHZ/SRY70 "D)/)(&J"J"26'^-/W4<KNVG)Y[Z?'_PH
M\(XYPW[D/=SX7Y&]W[-BQI\Q^\KSXX^9O%O=IVG<_ &_L.^]7MS.QZ30\;E/
MXO/SE_X'_P#['+W*?@H[,Q78O_HS]X_GWRSV'_J._P"D"!^5N^]C_A#_ )1[
M/I_\F'0:JY8N$W'W)E,,-9\AFP.4=-]Q, (E#)B_9C$!2E9($$9.<5;RD8WE
MM;)/!)$=Y<>G-<K:%37(&=4B-<UMA#. ?8)855Y2])]*-A\+R&,[2\NVW^SV
M>KF1XO&F7,X)YID/'6+$+9)CG1Z&SX5EN?GUX=7I\C:I0U%GG3$"1%WU4I D
M&:86$D+?N3_B5_.0Z1X)TW]__N9]RF3<-Y%]XWNJ]XGF;W2X^ET$\'\H>\B"
M^#>8/-7>N\>**^Z=AV79'=?M !<A01[VMU@Q%NAKKEK5S.[(I?\ %.98H?%I
M2C0*@(79%<"M([L4CCZ\U.K);Y-$9(V(W5L4&$GE$."(D8RC0!N6(.97&OI<
MLV0VR#$[_P X7("YZ7- 2FIIU8@SW-L<MJ2'IGI*ZIXGXQ;.DKQJ2@M8L[K]
MU@J0KO)@5!918B[@&%LO#]Q%1?B+B&RV/H1F [*4+SIG5;EF(-"F!JH<HQ;%
M[-8&1@QZ>ZK<A3Y9/#F1I(**&\'7;C58B[C&F"(5Z#/>(;C3_-5:N2/6SWT^
M_CS!F[(&9/.GNY]U_=//2"+H?+GESSYD3M_"_+?6[YW\';]MT=@7U.D0>-^:
M\_\ MPGYV#WY?_,S?@Z>X/W9_P#Q7M/./O3]X'_U/#_+G_US01$Y/^ 5%O7M
M+$=X-;]U\U<?NV3-$$4!D^5,1MKP]WE<9:T3BV-JE,&+9+PY,HO*_!7+PQ4L
M3/XT2QJ3D$#16&$9Q@>+E/@"?,L<<&%M#I9O;D293;&^W;%M_.MG\J8V69+F
MN5IDC03,F0,KBQ.67VUV;4SPNF AI5JR0O*I$F3 ),[V*_;6#HZH%!RN[B^G
M1V.S[OWLCOAK?R\9LT<D.R 8*DD,4PCBZ=M3RG9H1CZ$0DEC>LB0/:O%*Z6M
MBM="PN023VX@H@TZP+ &(JQHPU4S>E6F67Y?%%/)#R_[I;^XKASXA?FS$DL6
M3R+-ZE0E M[VA5R+(6?,^KFU \7.*)4&LQ#2Y!1]X+)5DFG%J$X=/TNU?U\G
M>NBS4B68EASQK:MQRVXD,P\:W73P\C'C*VHFEBC;<E1&IE+22P(VU-X>>E-)
M5(#DQ1R<TLXH!@0Y>5WI3YOA>2R07')S%[MZ)8QE;NL>W?&,>53&3$75*2T5
MDJ<M_P 79RUTNX)&JY)I1!CHC<EXDG=RS51II)AZ@+ ^.'@%Q9HML,3N7E/:
M_9O=+;\,7>8H/+6;)6;9D3(96WF@F*ANC"U=+I6<K?WIT<E72[29W G"K#8
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MF,O,IA[.->G0DM2@U.C$ *@!UR%"8+*OS7G_ -N$_.P>_+_YF;\'3W!^[/\
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M,9R@PPT8QW'1W6U>K.?[;%/H#O\ &*'1W3JSG^VQ3Z [_&*'1W3JSG^VQ3Z
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MDB58G[3J'%%F!$"P; H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH%!5GO*A3;";!:J:8#"<LC#Y(7#/6:T)"@U* S'<!3K4C&T+CTHN\V02MV$N
M2"M:X+@/"0,(K#L$98>EQAO[O&8%E[5>6JS%,LU2RW)(*G,/-L8>O@#\XN+U
M"GKH$$LX*5R.+<.[6N (;)"R;!Z/A  )39YS=D'$LIPFPPK TQS&VY0G:>)R
M^0Q<;V!#B=E.<6!$.822S3#I00)K)(=SS[V5'MI741C_ %^UNL( 24H(1<D/
M^8]L7_S((_=$R4$/H&?Q5I=4\>J,GE:<G2 K!D%%.RF@G$Y^73)#Y)9[2 !1
M4:M?(HIN)WN;8WL>APLKZUQWL*P[V#)-3#I1A7BO6R?.L%)R&U,4$GD[;,73
M@].H3O.,S#%#S%XP]7=VR0HDS<ZH+=X(*,1'EITBDH-R+7#<L(2?,VNQ3A[3
M_$V>'*$VAD=FD+Q];'F&8 D1+UQ\@FK$0Y1W&<)0H6Y@0*SDY-S @N6E2%!3
M)C#+%!Z+%W#5*S??*6,3XW(-H=/)Q@+#\J>D#&DRJ5DF)9+3QPYW'U6Q7D*+
M1MN1/,(1#[0NQW>!&'%F7&6 LTP'4$&Y=H]PVS61]P6W*,>R#)+;FE^D+*2;
M!U"ASDJ+P9K;%[?:,11N974V;N4@4.I:=,F J0@L*]A7.ZE[W"&J%>]F3X!.
M<<MVPNHDTP=BS*\M;8/#\I+<F0F;&)I*_%%F,"&:Q"+)S3H9==80[F!4KQGE
M )-$$LSL3K%AO39O:UCUW%"8JU0J2Y<S+E-<N;<8XCAHTY+S(CFPD"AR<W9R
M4 4%1R--Q0[=NM$0HN'YH5BA%E*#"0K5V4RYG3(&;]"&;-FK[[K\N;MLX&YM
M*T6383E2-/R8YT:T@DA3[$0I+H'L@P AC2FI_@(L$?7^:M:@O9H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H%!4[SI?S1>^O\!+K_ ([8ZEW(7QQV_P!D
M1WI?7H/5F/S3Y 5;*3,H% H.H/TE/\YCDC^1UE#^-;!55+VR_%7%[.Q^AY7D
M;SZDCS<=Z7T=*S"C!0*"'.X_(!I]H%"44\VTSE$\2M3P8H(C3.NLYO\ -I<I
M2EW&H)B4!BR![F4A+2WN *A0F0C2)!&E]X-*L,-[A3,@]6;Q!+'@YL42_/;6
MB*$B""0K\'O!C.HLKOT'C)(;'5QD 0MGZ)_:(2[B_P# V-H+QM3]Q]9]Y<6"
MS5JEEECS%C0J0*XFLD3*@D+,8U2E TLC\MCCXPRMG8)(POB1FDB!2:E6HR#P
M%*RQ7#;K6H(Z[Y\LVC?&LZXX8=M<I.D)?,K-\C=X:SQ^"3*=N"IIBREJ1NKD
MXDQ!F=O!D=UCR44G$JN5WH8#K$V'V!O4#;>D&^^L'(EB5WS9JE/%4]@3!-W3
M';XK<HS(8@ZM,M9VEC?5;8M8I.W-;J4$3/)$2@HZQ5R30'?,BN(([!#Q]Z^1
M+5?C@Q[#\H;831ZA$.G4RM 8VO8X7*9NH5R:[(Z2'NAR"*-CHL2$^%LQX^V,
M $OK!L'IZPK6H*NOZT_PQ_C 9!_)_P R?:A06?Z8\E6CW(.V/B_478.)Y:61
M=.0KE$5+0R2'SV.(U"BZ,IQ=X!/62+S%,SF+0W) OLB$@--Z EG#ZP>D)S4%
M.>W//3QB:0YM?M>,]YY<&[*\4;VA=*X]#L=3S(!,8.?$OB"!F?7:),+HUH)!
M=K,)5&HA&]N20J)$8$-QVM06M8YGL9RKCV"90A:PYPAV2(;&)[$UZA&I;U"Z
M,S!D0R%A6'H%I9*Q"<I:W$H8B30!-*$*X16L*U[4&.9PS;BW6_$>0,ZYKF#7
M <5XOC:Z5S26/ QV2-;2AL$-@$D$ -6.3HXJS2DJ%$F+-5KUIY2=.68<:6 0
M5UZ4<W7'AR#YD48%U>RI*YEDM+#7N?'-#UBO(4-1VC,>6L[>ZJ[.\G8&UM$<
M2J?4U@DV,[0=AWN&U[!OT!9SD#(4#Q/"Y)DC*$SB^/,?PYK/>Y9-IJ^MD9BL
M;:$W5[=R>WYX4HVQM1EB&$-S#C !N(5@V^&]K7#GPR3ZJ_A^Q_)U,::LGY;R
MD6B=O"54DQMAN1J(P"Y9@RE3BF<)F?"E+JTI#2[V[=&0HLH#T#3V.+%8=PN8
MU>W*P1MYJY$]QL02%R%@F8M,Z?&V1RUE619<D:L;RR50R8+'=H7VNJ;R6M[A
MCA;K"Z;&$E6,#>X1!O04U96]5;P^XU>E+*Q92RQF42106F/=,4X:DQC+VEPJ
M>\"3..13,=%N"=(80$ CDUCBC;F@$2(T'7& )CZ-\YG&SR#S)-B_ V<Q-V7U
MR4Q8UXERI&G?&\U?RB$IBU63%+O15XS,W)"E3G&GHF=R7+24Z<P\95B ]K06
M%;"[&X.U0Q/)\Y;%Y,C.)<50\DHQ]E\I4G%)"SE1G8H6QM0(B%CQ('YT47L4
MC;F].J7K#;V+(),'>P:"A$OU9'#^.8>613C.I++W@)/O#,P=(;P^Y8E8$]U?
M<B5QL_[N D5S[V\#[7L@WM8%S>@NX7_8,SQAW9C%D3S9@/(L9RIBN<(1.$8F
MD3767-;@44<8E6)30# 2M;'9L6DF)UJ%640M0JBQDJ"BS0#!8*L=V?4"\9&A
MV1'C#V5\QO4VR[&3C$LMQUA:(K<A/$/7E]WZS3*'H*AHA3,_ L??M6XUULO3
M=F*QY)5[@L,,^T.YO>.GD6E/NYU^S,H0Y;&C,<$F(<HQU?CZ?/"-,W"<W$V,
M)G$2AAF!C0E(/$L):'!<>F+3F'& "GZIH@MKH% H% H% H% H% H% H% H,G
MB?\ A$[_ ,R,_P"'34&P:!0*"NW>'DRP1H)DO3C%>8HGEN22'=[-B' V*%F-
M&&'/#-'Y>O?X-'"7+(2B4SV&KFF-A73]&,1S:G=E5BBCKV3W$$ 3 L2H*[=>
M>3+!&RVZVV^B$%B>6VG+NF1,>/RA(Y:PPY!CA^!);H[(+0)W9YZ_2=T$5WT'
M;>(L[78/1?J];X.D*FMLO5@<=FG.R69M7,FX9W2?9_@V<NV/Y8\03'>#7.'.
M+RS"+"J4QUPD&QD8>E;89<RW9C4MZ0V_^Z6&@U_A[UA'&AFW+F+<,Q7!V]#?
M*,N9&A&,8VOD&-,!)&!$_P ]DS9%6=6]JFW9IV<4S0F<78L:DPA*I. 2$5P%
M&"M8%PF9R;>HDTIXI=A&+6S8?%^TDRG,@Q9',NHG7#$*Q-(HF5&Y/(YC&$")
M4NG&;<=/ 'PE?"58SBP(!D!),*N$X8A# 6&C-3_5A<3NU.4X_B,YVSKKA()<
M^-$;BCULE 8=&80]OCV:<F0HCYCCG)>4F2*D]\ 42-6^F-2$ U!?2=U>T$6'
M0;FS,^--=,1Y&SOF22>3L58EB#W/,@RKP=_D/E^*1U&8X/#KX'%FI\D;KW-(
M4(?8(D:E29T= "Q"Z+4',,\^LNXEFR9%1A%"MS)$R&+6I*/(K-A['!$-((<0
MI1+'(U#(,W,60;HF&Z@8580,0U [D#[L4HM<NY@=&>H^W^O&\^#HOL5K!D9L
MR9BR5"4I$[LB(6-SDROK?8GQB*RI@=$Z1XC4H91J 64HE9)9E@&%F@ZY)I1H
MPDO0<FN1_6.\9&,,ASS&K_@O>Y6^X\F<H@STK9\9:_*&E4[1)\7,#BH:SUNS
MS>L/;CUC>,1 S2"#1%7#<18!7N&P89_75N++]X/?_P"Y9KK_ .S54'0QQV<@
M&&^3/6./;78'C638ECN2R:7Q1"S9<9HLPS0IQA;N8RNARMNALSGK&6B4*B[B
M3B XF#&7\(P O\S03EH*WN07EGT3XQ62.K]M<RIHK)YF793"<6Q5F<YOE.5M
MX%8T:E[0P]@(4*&J,I#$Y]A.SJ8WM8SDXTQ2@Q7<"<84PXV]9+Q(3F4)6"3Q
MC<'#32H"6(V<9)PW!72+HKC6HTH@*DF(,PY6F@Q%$*AJ1=BSG6N0F,L&XCKE
M%&ATW85S5BS8O%<(S=A*:-61,59'902&$S1DLK"UR!G,//2V5I2UZ9$N)ZBI
M*84,LXDLTLPL01!L*U[4&T:"LWEOY%?S6>E\LV\]SWOU\KS. 1'W>^\'W8]^
M\\OY3'XAYL\D9"[MX7VO:]EX89V_1U>N7_94&&<E'*'^;SX[&_?GW&^][OWN
M8_\ 84>\SR!V7O=&V _]?7N_FO7\O>(]/^!K=[ZG_@>GX LRQQ+O>!CR!SSP
M_P (\[0R+R[PKO??_#/,C&A>?#^_=V1=][EWWL^U[$KM.KUNH'IZM@S.@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&*SJ=0S&,,E.1,B2EAA$#A#
M"Z2B7R^4.B1ECL:CK*D-7NST].R\TE&WMS>C)&8::8,(0A#0<O&6_6+\1^-)
MHX1.+LVV>=6Q!VH?/^),10A)"UIY*]<B&0WVS!ES$LO4=8M&!2 WP@*<:=25
M<)ES.T++"UOCHYG]!^4AQE48U4R-*''(D%C:683'&<]Q]*(5+&&+JUR%J+>A
M+%2)7"WE(6\N!:0VS8[K32#KAN8 )9A)A@6K4"@J:_.A_P#VX3\T_P"XW_YF
M;\(OW^>\S_XKV?D[W6>[_P#^KXAYC_\ K:@V;^<YP+^<J_-9>4<O?A!>YGWY
M></ 89[G/*?<N_\ AWF#S]YV\Q=C\'8^7N[=;_XXZ/AH+&*"J/E6Y//S9,>U
M6?O<A[[?PF=HH1K;W3WE>[;R3YR0N:WSGV_D"?>9/#O#NKX=U$';=?I[T#HZ
M+A:Y0:FSMG+%NL^'LB9\S;*/)6)<41E?,9_+/!)%)/ (XV6")<X^!1)H?I*Z
M=A8=OUE$C4GBZ?F07H&"<Y8MV8P]CO/F$I1YUQ+E>,H)C )9X)(HWX_''.PA
M(7'P*6M##)6OM[ O^LK4:8\/1\T"U!MF@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'/?ZEW^;K9/
MY2&-/W*Y(KH'\VM\HC/^SFL]'T:\_%[^/E_O?E^SQ.!&N]S;A0*!0='_ *7W
M_/ZR[_(_GW\=& *YR?.=_P !-H_:_2_^W;JH'QC/B1I??7%^+ZEW?UPI8N*!
M0<5OJ)M6M9$');P+.*'7/!")PV7Y$$3/L<O28BQ^F6; -*[-.I#6M:\VJB8\
M _*K<L;)$X)S2'T2\HPA>H+$&X#C+"#HMWKV+QOQ#<<V6-@L0ZY0A;CC6AFB
M)D6UWQN>PX%A(DDZRS%8:J0,!L8@LD8H:F3N,\.=# IV,\*D\ PW" 1PC@A0
M@]^K$F,W@Y&4=0>'S<;:/%,4BZ9TSCEQO52Z,XKQC(2&%N=I,TM\UB.!<N(7
MN/QE7=Q(-=7L$4,,+064=S 6;>Q(9VH]6M@7+$/Q^TZ):*[C;K[.2V+F224Z
MY06&NK<IQD-L6FIGULDDPA\6RN[/PB$:8;@C6,,==6\U",JZL] IN<F("PSB
M0YO(9R<SC-NOT]UOR5ICM[KXDL]Y(UTRFZFO+NGBXGZT>4NK6X.T1QQ+ KXR
MYK6XA]0ND;:C6Y0[) %B5!,N8$(6[$^I_A.O&Z&U6C!VC>;\QYNPS/(ICK L
M7P1)3,ARG8Z0/+ 9)9&<LB9..V]=C1NBK7V5K!0FR]P7&J ]FD"46H.)#4<$
M]7%BK'<TF^-^2?C]VHX]Y_'X4*;1*&R!%(<A2><)S+%^$,OEJ:8OP#)8PYRH
M85%FM6L178C>ZC[=Q3?!TAYRCU7\JQY*X'*MF>(+<K6S3W(TD:V.,;33TZ4)
M"%Z%W"2:0\H(A(,(1*&/X4Z/MU9J5JF;@I$D3W&0$\5^SL%V'(7RB-6C$AX_
M&MBQ,BSHR;Z;18WUT9Y0VY/*AK=!VK(ZZ/)V_)2#L(-.")ZB*22 "@I  ]K
MJ &W0L!8?6L$W=L<Z?@OZL;+;+^5O/'X.^O^9,Z>2O&_+/G#W28ZD<_\K>8_
M")!Y?\P>7^Z=^[@N[IVW:]W.ZO9B"N^&\M7FWAD6<NON \/[IA"=YD_!\]ZO
M>^T\E3.0Q'RY[U_=NFZOB?@/>.^>6K]CVO9]@9U>N(*C47JMY-F+&L5F&D_$
M=N)N.^-T48'78/W;AG1F*L(RUPCI3[(H*GRC$L Y&=9>MAYB@LE2M71R-HU
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MCXP[L:1W4N#:0[,CXHCT-='5.V/C2H;W0A8RM:YL5V)">18*@@0PNIH% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MX[.,C2^-0.&,GX.FV+9XS*Y>\HH_'6KQ)YP2W-#=XB[N))/;JU!"8GK]<TP
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M=E3E!FA$F5 ZZV[8"PBK!M?U*^><<;1>GK#L5B%U.>L99IE&KN186X*TW<G
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M(F/D>]2"Q-"8MN94'(&A-0-*2URFY );D_;,U39$C#?L$A8[@"&P"PA $
M#:P !#8/V\"G\[EZE[^5WA#]V.Y- VW_ -KEXLOY &9?\0;JT&;[]\J/)3.^
M1B>\4W$3@S#+_F3"6*HME?83..?G0L##"FR2L\-F#8VQ1E4R!A:NS.:IY'D)
MJHXE^5JE#X: IO2%(C7, 4/\L&%><Z Y,XXY]RF;6:JYJQ(]<BF$DV)\=:^Q
MAN:7C&T^<WP#N._C-]:,220^,HHVW*$?5521Z&8>$@9@3C !4@"ZOE4:FQY]
M1=P(HG=N0.J*S1L8OLD<D:=<ELN:8V\NS4LLG5%FE65MCHB)4IS.CKDJ"0&
MO880WL&ZO5EH4:OA2SPH5)B3SVO)^O:YN--+",:)89ER,M@U*85[7N4<-O<3
MR;BM\-RSA!_0O>@NVU8BD9!I_KU#2&!H2Q-1KKBYE-CB)O3(66[2X8Y9"%K>
M!N1ED)24BDI08$8 !#:_7O\ ]F@Y!N!90>?Z6GD9*-,$,M'%^15.F"+] D@6
MKS4K$6#_ + ;J51@_P#Z8[T%XOILF=I:>$_1<;4UMS8-WAF07AV&WHDR,3F[
M*,RY%3J'1P$F*+NM<3R$I0!GF=8T0"PVN*]@VM8*]> F,QU!R^^I27HF)H2K
MV_;7%Z9 N);D@%J%+*LC;>/DF2(U82N\)4D@>6U,J6%%B"6I4)BAF6$(H%PA
MZG)DD3(/4R\%K\C(+3O+EC?/[&O<2PVLI5-".*Y3[JWG#OT]9,1YB7=6W^YW
MHS_LT'H;7\IW*WLER#;"<>G#OA'! #-0$4:%L'GK8IQ)ZEY%(4:58F:XFR*Y
M"U)$#"!6I-;^MX8]KERA&:>"Z),$ CPJ%VZPIS/XPY0N#V2\K>TVLVP[)(>0
MB&(L%->OT7:V-3CL\S)V&E<\0.;B1K5@M[5L+L@-:B4Q:MP>QB[G>YG4'TF&
MA;=MZ<2F]7)Q5"4&EIPJ]",S(T@CAA*"J5VCFZIMTJ>X[AL<IL5;K=0/2+J_
M#T=%!.'U,W\QUO?_ ,W<*_\ 67PQ04\>H \;_JW_ !M]EXC[O_,7'K[ZO#>K
MV_NO_!KE/;=;_P +_P"OCP/LNS^;[QV?^YTT'8_!#<7*,30T_'HH@/"QV.X\
M;!Q,5FX,"%BXR-(QQH3,$JP6D,0%$Q$73V#:R:R+J]'S%!R!>G.\!_!-YT_<
M_P!W_!8_"[V9_![\*['R]X#[M7?L_!/#_P#D3N_NZ\I=7NGS'8=ET?K?94$\
M/28M38@X5L%K4+<@1K7O)^P*]Y5I$:=.J=UR?+<F:4ZQS4$E@-7JR&MN3I@&
M&W&,*<@LNU[  &U@T5ILW(F?U<'*^G:DQ;>F=]%<//KDE26N0E6/)T>TM">Y
MG)@7L1=:?<TP8S+!L(9AI@Q=(S#!"#K&H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H/RKD1#BB6-ZKMKIEZ50B4V3J5*)1<A42,@[L%B(Y.L2'=F._5-*
M, :6+H$$5A6M>P:_Q'B#'&"8&T8RQ1&2(E"6(UR/;68E>[.HRCW=Q5.S@>H=
M7Y>Z/+@>H7+!BZZA0:( .J6&X2P  $/PY6P?B[-R>(ILG1CS&&!S!JGT0/)>
MI#'US%+64)P6QW1N49=F9PN)/VXKW)&:-.8*P1#+%< +A#\F4< 8DS0]XWD>
M2XGYD><1R<J98]6>/29G\OR0A6UKBG+N[ \M25VZJIE3#[%<!2GOV71<'0(=
MA!N.@PC)&.(9EV#R/&^0V;S#"Y:A"VR!F\1=6GQ!$%00K"3XBQKFUV2]"A,
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M.6XY,B[+NW!1-D?:3[!\,6%L+8@<4)Q*A,78HT-!?;Q'\0S[H3O=L!GW*G+
MY\@N?,BX&)Q?D.(9!8%*?,;,WMLNQ\X1V93&0R39/-<X6H(XW10#,D3K4:<H
MDE: (#P!+"28&O?2'?S7.1OY;NP'^(,7T&%!  /K"AB"$(1&<9]AF7"&UKC'
M8\)=A#O:W2(5BP!#TW^'HM:WZ%J#%..F90?#OJ;N9;'N<7=HB>8LXQ?#KO@%
M1+7$AN4S>" 9H:[JXS"'!Q-(3OB]:S.C 8!N2B-4B S'A "_<5'9A_/U4.6L
M6+U'%_AE!D>#+LNLW(_A*8O.+T4K8U>0&:)^&+D@)(\1!.N,?FIC.4OZ(!2I
M0062:)27U!"ZUJ#=',YOKO@+D1T\X@M!\S8JU.GFTV*EV4IMLYD]$U."IO87
M)YR9'6Z"X_L^,LB1HI>K1XI=NZ%HT)CRY.[@V$(UC5U3E=PH%YXN./=/5K2Z
M5Y8W(YY\D;02V0NN*2+Z0R8R00F%Y%6J90UM%G>'0==L>L8WY-! MA[QWM-
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MZ;?#T7O;]"]!>3K 22HU>UX3J"BSR#\"8E)/(. $TDXDW'D? 84:6.P@&%F
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M7$X0;(NLEFIC#86?'O)<(<LT15"QR8F2C;85<S%(<2QXM\[L6WKU((F-Q.;
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M7I([*5:Q3 \'Y5AP(*0K6J!*3S6QOR[BO+CTSI@F#%8I(D7DH4Y=[%DD@+"
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M'DB*8XG+U#7QV>L3O$88ILG5P>4-DL:2VYRF$/G;$4F4.+46!18UM.$,@0K
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MCR!;J89W':T07:/YBDDXBP(NXS(@B[HH$I!BF#8YRE$D4@EB9.?9>1)'94U
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MR-9G_P *:,H1&%2%>@;GA.<D$L*2"2#5$'% -$82:$ 27H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M)D$DE"<8H1$E3.+M4C+*1GG +-/2E@<K6+&((1"!:U[VM>_10;*H% H% H%
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MED6[<YL L2N)@NM>Q93BTI[+RABN*UR7& $7"6+K7-L'590<DGHQ/YI_)O\
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M2;+GE\:F]6D"X-Q[IF,0G6_7#=RO'FI&J">C*$30:O\ 5B<>VBNOO&W%<RX
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MMR7DY97"6X\"8<?>QQJ)TA($[^ -PAL4J?U-K7';]<&'070<DGHQ/YI_)O\
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M/EK8>RP4])W("Y'"6X-[.G7&-*,X11@=$'/#_.C>F\_ENY'_ ,?ZRT%F'.X
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M [,0Q@#0IN7(CS+\_>BQ^.U(9/JQQS:E13=IZ/ J)<&@[.&P\:AD\Q>W&&6
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M]-OAZ+WM^A>@O)U@))4:O:\)U!19Y!^!,2DGD' ":2<2;CR/@,*-+'80#"S
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M]8@R9LP2B:A3:4MRM<&\C8#!D1X1?97*.,)<@K>B>A7/EPKY%S-CKB%ANO\
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M9&KQ+'LA2_"DEL1@L7C[.CO*D)@A#2+'92[7;S@EJ$84ZHH"BP=$= H% H%
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M/H'C61_8./\ V>F_:?0/&LC^P<?^STW[3Z!XUD?V#C_V>F_:?0/&LC^P<?\
ML]-^T^@>-9']@X_]GIOVGT#QK(_L''_L]-^T^@>-9']@X_\ 9Z;]I] \:R/[
M!Q_[/3?M/H'C61_8./\ V>F_:?0/&LC^P<?^STW[3Z!XUD?V#C_V>F_:?0/&
MLC^P<?\ L]-^T^@>-9']@X_]GIOVGT#QK(_L''_L]-^T^@>-9']@X_\ 9Z;]
MI] \:R/[!Q_[/3?M/H'C61_8./\ V>F_:?0/&LC^P<?^STW[3Z!XUD?V#C_V
M>F_:?0/&LC^P<?\ L]-^T^@>-9']@X_]GIOVGT#QK(_L''_L]-^T^@>-9']@
MX_\ 9Z;]I] \:R/[!Q_[/3?M/H'C61_8./\ V>F_:?0/&LC^P<?^STW[3Z!X
MUD?V#C_V>F_:?0/&LC^P<?\ L]-^T^@>-9']@X_]GIOVGT#QK(_L''_L]-^T
M^@>-9']@X_\ 9Z;]I] \:R/[!Q_[/3?M/H'C61_8./\ V>F_:?0/&LC^P<?^
MSTW[3Z!XUD?V#C_V>F_:?0/&LC^P<?\ L]-^T^@>-9']@X_]GIOVGT#QK(_L
M''_L]-^T^@>-9']@X_\ 9Z;]I] \:R/[!Q_[/3?M/H'C61_8./\ V>F_:?0/
M&LC^P<?^STW[3Z!XUD?V#C_V>F_:?0/&LC^P<?\ L]-^T^@>-9']@X_]GIOV
MGT#QK(_L''_L]-^T^@>-9']@X_\ 9Z;]I] \:R/[!Q_[/3?M/H'C61_8./\
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M?0/&LC^P<?\ L]-^T^@>-9']@X_]GIOVGT#QK(_L''_L]-^T^@>-9']@X_\
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MBXITX;@)O81YY8+?-##:X;NS#G/">O,.%D//V8<68-@ '-"R#G.8<@Q+&<.
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M*$BQ&K3C,3JDBI.8$99@!" , K"#>]KVO0?KH% H% H% H% H% H% H% H%
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M]I_O.M02RH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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ME-=80 M:2>0<(HDP9!P.T**-L,H 25H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MI6:SMK?&QF.$^7$!&-$UV S%64K5:Y$0% GI"/YU]\_DG9A_==BJ@GEZUO\
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M0V%Z/G^9[;OY3.;_ /@H;08[%_\ ; ,C_P"B\0_N@@=! ;-6GNP>\?J7^3?
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M8WMT5QDA9CAD\I1B -P_=+X\>V/*I,D3ED.*!:*ZDZQ5U9@?2 Y:.,+$?+#
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M5*)87'\F9 A#Q+WB?QUR4-*0*Y.Y)CC%!/>+6,+-4B."%_U H% H% H% H%
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M5W2.N./V\ULE=VU"E5J5CLWG61L:45EB<#<4:0&!J<B^JN5X9/UT/X.>+$6
ME,;-AYV%P+L1$XO%%CAB-,80P<GD:+CA39=0*YMB@)PA"=^N6Z!_-4&CY+J?
MN+I/Z2/?+7C=/&/N@GD4R\UN^/H*7/H+D1&UXIF&QVMLJ0#;WK'TWR SI$1\
M]=I#<*4YPNM"*PC30?KH3# ZKN)C7G!NO7'WJ2VX1Q1!L8D3;6S \WFQ\1CZ
M!K=)M,9%C"//KU*9F]EE7>99(%[H[J31*W ]2>&QMP!%8%K!L%C] H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H%!!+D0_Z T?\ "#'?\62"
MH5SY[AQ]WL[US.7C1?PUQ^^>#T/,H[JFW/(H% H+ N-[_IQE7\%+Y^Z^#5.N
MS_W9R^Q;OL\;37BI_P 0]9[RYOQG2+KZM]T *!0<M&!_]KMW4_T345_C,U+H
M/S>IBUNR-!H3@?E]UC0=78;C]>3VW)!*4L=C)_JKD<Q9&YQ'7P1%S%BMFC*R
M4*@'ED@#=,QR1[5"&&Y(!!"&?#UILX\@/I4\FZBL;BW-,HRY)LYAA*]X&>4S
ME9!@N:&C)>/@.ZA,*QZ5J4S6&H"E)P;&=B0,0^S-L'LQ!!;!O)'QF:"XJA>L
M/,5Z?>,X]VEQ"PM>-72?Q31346:(,Z#@[>E:UF2%SOE0[&_?WYW;C&U4O<&A
MSE#8]*E@W$A620J((L'2SP@;*:E[7+-CLC:B\30N.W&#&@Q.CBN8%^N6-,#K
M-GV:8J\EN@4[6/&4*;8\]H,?,\=9W!44FD+^4G.E!-OUL'8*5H<YG%]RU%^G
MGBV=N+;?+5+::1Y(C6R$WDF GC#L*B;LFRBT3%)'(^T%($\RG4,NY,,G=V$E
MP:71CN]]Z*>>PNG"<GL$X)-\:>R><=M_4YS'/.>-79;J ^37CD>3H3AK(#M=
MRGZ7%Z.58]2PV4S5*<UL2^.R"5DEG*C&Q2@2')"A%VZII=P*#@G[I_\ [5SR
MT?R(M<OW':M4$SO4-:"97Y"^..38[P"E"ZY\POD^#;)8<CO>R6]1*I=CI#)F
M)PCC6O5J$R!+('*$S5VLV=YOW<YR"028(H)G;E!4&P^K^B<:QP5B'*_'CN&G
MY&6B.I(\OP(CB#&S0F0Y43LJ,P^ZI2[/2;-$-:GI58]=9O!!W5:B2W 4$:CX
M5%@V9Q]Z2[&ZN\'G+QG/<./&0O9[?+%V[^S^1($K1G-[U!6N2X%G9C"PRAN5
MJ%RYJDRYV7N[N>A//,4MR=T(2*0EK2%0+!Z/'QIRZ[_>DIQUJ1'5K<@EN6<,
MYD\B*7@XU*S^\6![?9'R9CM.[K"!6-0M2R<0QO)4J+!,[ @P1ERS;!N6((KZ
MJ>IR2<>>O>+]%.1G13<:);AZYX]CF#V)HAL0A1[-EHG'R,Z!0%Z.',YI"WEN
M#($S$A2&.+&CE+>Z'6.7H3#2S2DU!-?@TU-V;V'R/R7\G^\N)WK7N0\F29NQ
M]C+#+H6YH9M#<"(6)Q90N;B&0(D;V0F<(\)B;F@Y8C;CUH6,YP[D4D6(@V"K
MCCSY?%OIT8!.^+[DPU3V5/%BS,637? >7L*1&(.[#E:#RAZ0/(E[*ER%/,=L
M[VPK')S.=$[DUNZ\TD#J4WK$:56E-N(-MZ([<9/WD]3MC?87(VJN3]14\BX[
M92EQ[C?+QA_GY^Q@A<7WR]DQZ;#V)@/CZ28.B]99$G&28 Q&22H*//)4%&""
MS_U0&O<O7ZA8DY#,(B$V;'\8V;(?L%"7Q/< %(\?N$GB[?D!H-MVB8:E D>&
MMA>E)=S+A&A9U1-BQW/O:@_?Z:#7V>BUJS7R4[!)^WV5Y1<Q2/8"1*U*819[
M)B1*^R!/BV.-=U*A8H31U>8Y.;PWE@& OP9P;BK@_N8%Z#I7H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MD0E+ <\&A3R:5D]@X)6P8EA_4ZZ8.K%,F3HTY"-&02E2)22DR5*F* 0G3)R
M!*((((*"$HDDDH-@@ &U@A#:UK6Z*"BW9/C&V ?>:/3KE.UDEV'8Y'X3C)WP
M=N!!Y^_35@D.1\<+;R!L;G6$I(M 98TR65MC++A'%DNK@RI[+(VT N<(JYPB
M@SK5'CIS9@OE\Y)M_P"6RC%CCAS<6%8-C>,HU''N6J\F,2[&4)A4;?C9VS.<
M(:(LV)%:Z.'C2";WET&84,NY@2A7$$(7/4%&VGW&;G?7[F,Y&^0F92S$CGA?
M;V%0.-XUC$8?IBMR>QKHN@QZE<#9RRNL"98HVI#C(FIN2) ].8Q6&7U@@O<5
M@!#[97CU]1I'L^YJR!H/R\8J08AROE6=3J,XHV4A);M;$$4ETD<Y8TX_B+A+
M\([36-:H<>^&M23NO@Y'AJ-/8LA.4$M$F#W>.S@NV*A&YZ3DPY7MOT^Z6Y<9
M9E;)BMEBK<L2X?Q&)>C<$I[S'S'%@A)*CPXF0.1;.T-D8C;*SG+%"VQ"A8>4
M-&&'X8#?D@]25G?-AY87O7SAQP^3KWCDT18#V17M=E:S\BR$[%EFFF)U+Y%D
MYTF:5E@V$)$IC[4=<!)MRS!AU.T%&W/QQFYWY4M2\,8&U[EF)(=+\=;:XZSR
M]N697Z8QZ-JHA$<:9DAKDVM2R$0+(;H?)#W3(:(P@DY&0E$04>(2@ PE@,"\
MF@Y9MR>#O>&#[I98W\X6-UXOIYEW8\5W#8C$N5&PYQPW-Y@H6!5.TY)(OCK,
M3$N7OBY6M=#4KO%7$U(]+%BA&M3%KS"20R+0;@]VU1[HP[DAY?=SFS<O:3%+
M0Y-6$H- 6U4APQBM<ML\(P21M$JB>-FQ2)&A>CU"%J;8BPHD+N<):,:M0608
M6%;V_>$]S,[^IPED8T,VB;-2MB8_QTPV;Q[(K_$T4QC#^V,$O;BW#'\I;7%I
MDB,B/R!2O3GGG&-#N7?N02AHS0&BN$)38]X).3_<S/\ A?)O.IR 8YV>PYKS
M+4\XA6MN!&2S1 )Y(F[LU#:.>)T&%]?8F@2&*[B(<C0QYV=E[1<U 4N1EJAC
M+"TWF!X@VWDP9<+9*Q?FA^U;W-U;DPY9KOL3&$RQ2>R&*5[4Z.$8DJ=I<69Y
M.:CG%F3JV]:E5 5LR\ CB@'DGJTJD*;I%P<\[>^::(8-Y8^5O&$LT[CL@C[W
M),?:VL5B)IDA+'CB5*9IE:M-KUK\W.ZL"AL2G)%\B42LMO<+]_"C-5$AN:'4
MED?#<\@>FLOP%HTY0[!^1X9KRYXHU1=9 D+6P3%<GCD"'%</K'A&XQB?%K(W
M$5J- (\![.\=H01?KIE-[W+&''Q-^%?U0>1ML\,[RS/D3T >=I=?8A)H'B'*
M'AJIO\HQ28-$S89&U>26K0!#CM_\1:<A/!7;N;0M4D]\ZQ1@!E$"+#K&X[('
MOCC?6./1;DAS5C+/^TB:32]5(\D8C:FYFA:^+K'<PZ'-J1"U8EPFC M:6>X2
ME K,!-Q&6Z;FG7^;N$TGL;R6S.QD<3MBR0@;%XV)(]K%3<S*GD*4T36G=G!"
M@=%R!L/76 %0<2E4FE%7$(!1@K6!<*9>$/C2S!QTX6V"5[037'>3ML-J]E9[
ML'F_(.,'B5OT3<SY"(F["TM[K-8E")&K[JM4NCF?=2@L,*YX4!L:: (!4$TN
M2#3]MWXT9V9U&7J6AN79GQ@[LD/>G\HTYDCF2F<Y+*<72=V F2+EOAD<R(Q-
MBU3=.4-3V! ^RMVG5H*/]GN''?[:#@8UZXRYEDW6(>TF$I-C9N59$43_ "XI
MPZ^8RQ$MEC1!"B9 ;A4Z>E29%CQ<T-YQ!C#=,-2B-,"H"6,  AHXOC_]75*D
M".#3?E[TYBD!5A;V]V>,:0EE0SEH:VXP@]...KF#1+&;Z)6$Q&6 82Y W7/)
MN,LPT18Q@&%G_$OP<XFXU)#/-@)_EF:[=[P9B2'I\G[095[X>]A1N9Z=>^,D
M+2/+S*'U"2_."4DQT<W)T<79U$G+ZYI!']S6#T^8/A+Q+RJ(,:Y':LER;6C;
M_ W0/"FRD$2FJ7AK1IW2\A0166H4#K'7AT86J27$XM*I$Y(7-A<CCE*0VX%"
MM,J"K%LXYO5D(""L66YEM:/<XG./:"IRIB)#SFX<;LJ-4D.I[JZZ@F3$^2&"
MN'KA,G8S"P7N79<(L-K7"]3BTT!R#Q]85R%"\P;99/W0S%F'+;CF;)>:\IE.
M)#LL?W&&PN%DL#.0]2F;/A<?9FR%DV([TZ'BO<P74+(+L D 6:4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@UWES$V.
ML[XPGN&<N1-JG.,LG11ZA4YB+V3<YM?HX_HC4#DA.Z@@'$&").N(D\H99Z<X
M(#2A@,  =@Y%VG@(Y?\ CUDDN:N%WE68<=Z_S"1*G])@W:EG$\,\$$YV4V<!
M-Q:G$6PF/I'(AV2(P&/*2+1E:N(ZH%/6NC+,4!*_5CB*Y<YIL=A'9;E0Y8UN
M94V#,@,.4&;637^/'L6#I3-(PJ,(CRZ3EHHOA&&GIFEO:T2D'_J%,667+%=R
M5*<=C5+@'H<@_")M>][F2+DBXAMQ6K3#;')+"VL&;XE.$"M3AK+IC:-@3IY$
M[611'(Z!*H/0,"<QR;'&*O[<ZN"4A7:R-2)2<H#!M2N#'>7)NYV'M\^:W=Z+
M[@9.UJ5IWG7_  UB=G,;,,Q&8MRXE<QS4\D&/,-1YN5L[DTMSJ-*TQ% >YO"
M%&<O7J2D(25 3RSEQMYRR;SGZ7\FS#*L4),#:Z:P3_"DVB3N^2\C+KI*I4V;
M"HF]PBK"C@J^&KH^2;EENN<:K?T*D(25/5('<!5C@U-RR\+N2MO<[8OWUT.V
M85Z9\@V'(NJA;9D;L7+R1D^'62O0&N-SHUB3.#FSJT8GQ0D,<O#7PA6SGC0K
M&Y466E$F"!,<X&^4W>C,F'I5SI\AN.=D,$8(EJ::QW6W7U@"S0C(KP@$$Q*5
M.B6K#&N\50!6 5*D2U?=A>7H;.<<A2K48%8S"0MBY*N.?-6XNY/$GL)BV38J
MCT&T)V(E>6LMM$Y>98TR:01A[<L/*T+?C1!'8/)V=V>22,?+ F%.:UG3AN81
M8)PK"'<L+D'AH:I TNC"^MR)W9'MN6M#PTN28I8W.C4Y)C43@W+TAX1D*D2U
M(<,HTL8;@& 5PWM>UZ#D-6\$'+)H7-LAAX0.36+X1U[R7+5\KMK;LZR!D\1Q
MFI?AB4/((<K>,/;#QES5D&MC>E3.((XS/)S8$*=:M5#2]NL"S3C$TJY></9O
ME.P/)WR3,.T!C[B9_P >-&N^*8=Y>PY&I2\2['KHBR>D7-<5PU'U#\RQ?'@F
M\DJT))-ZTA<# JB[W4"< K^V!X'.0+7C;'-&VW![OG$M2CMDI KEN7]>\QLI
MSAB $N=5CFX/;\P%"QQFV*.B YP>U:EK;G&'W41\U2>!$XA3'%ITP3XXUM&N
M6#'F2LC9=Y6N0Z.[8 G>(9'BI)KMBR,G1["4?52.11(U3.RS6B(858%S\&'P
MDM 6$,,3GD">W*Y:NUS5!B\*?,1<#/.GI*IG>M^@?*CB;&FA,UR([3 EGE;<
M^)\VQQM>50.\I8_T8/G:F*/PFIO2$*UD;FL=*<55C5=R$Y@Q $$M=S>%KDJA
MF^6:-_\ AMWGQSK1/-IDC"3L'C7.[(-XAZMU9&NR(V01]<OQ+GUF>B7)2E)4
MDMSA'2#FE6I6&)'&Q!Q:,D-5+^"SEERKM)QU[=;><DT.VMG^M&TD&S+E>!/J
M9XQ;B" P"(R2!2!:U:[P6 XL#&91D:1&Q]8!:Z.#="R%)!*$DP%^H,X 6>[Q
M\:F==F.5?C%WF@DKQ,TXETM]XGO2CTM?9@@R*_\ FXLT#;Y :6:"/T:=.PN.
MW;^(N[5U?][UZ"[Z@@!R:<=N&^4/4J:ZJ9F5N,>1N[BU3#'^06-*F7R#%^3H
MT!:7&IPSMZTPE&Y]@C=%C>O1F#)[\T.*M. Y.8:!04'/+$>+KU36,61IP# .
M9C7V^N$=0(XJPS*31 ;YG='$DR$@LN]ETFUAE\TLYMQH.[I@BR,88!*6"X51
M=OUD(2(W0X*]TYXIT8VJU(Y"5;%R=:7X7*P>[[)9K:'D<<V CUW&6O8W:6)#
MRLSGQU6!TR%("U"%<V2I ZMSK9*H $"8NXPAUM5P5\^._.L,R@^Z/+%B;)N0
M>^PTV"8)B#,KQ5K"[G,TT\2<'[+<FQAKY!WN7+6B/7&H:49D(47L]73C,6@*
M0E","VWDMXN-@-R8/Q5QK&$PPZQ+]&]E<$9DRR;/)!-6M)(8QB]HCZ!_0X[,
MCV/I0<[/RPYI,NC*<BVA.8$0>T/*O>]K!:_N!B*2; :E[18&AJUC;)?FW77-
MN(HJY292O1QMODF2<:2:&L:V0+&IM>71(QI'1Y*,5F)D:L\L@(Q%DFCM8 @@
M-Q\<9)N$^'S'7&'N*''^32@8SS)C#+UL;/$C<86]LN4<FY'EQ1D4?Y+%X9)D
M[BVLLQ3#)6#;4:A$Z)^T(O?LBSA!29!.%CU">@R%RPAQ@<M>%TVJ"=W<W2"1
M#9N'I%DI@R%>XK7$F/M39(-;=F6!K)+&X&C6G,BQC0N2VXU=VU.,VY986=%\
M*DXV4XULDZ0<GVX4YW"RID',"C-T;V)3M9[*]8.ES3$HW#H$BQJTR!U?&PQC
MCZ%E<!KDX4K8G<RY*ZEW()4J!N!@5XL?&9ZJ7"J1OP_@WF:UWE6"F M(QL<N
MS+!4SOF0$;"42WFFJ1S35K.<E$XM[85:Z4HR=J+V-#:UE)-[W-H+ <[\6&[>
M9.%3/O'QDG<ACVBVWS4OCKX/8#-A$M@T(1&HLP8SR&?$3;,2?*3^BC<;8X6I
M1MYR-L+"K4& ,&B2=J:((7*:NXQ?\):S:[89E2MH<)1B/!6(\8R1?'U"U6P+
M7^!0"/Q5X5LBIR;VEQ4M"EQ:3!IC#TJ8X9(@W&46*]P6#>M H% H% H% H%
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MSF0/L!E7ULH'O%;O9S('V RKZV4#WBMWLYD#[ 95];*![Q6[V<R!]@,J^ME
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M%;O9S('V RKZV4#WBMWLYD#[ 95];*![Q6[V<R!]@,J^ME!GMAVN8(OJCZ0
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M=3=EC)%V2+:1;3R8NFODS_=>AMN]6[CGG!;CFR8LFZM:^1,13R(XI]5&GME
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M5D)GYE<K216I\4=D9PP'@0!1C E[U>UR+F)# =?K%BM8/Y:5N+;D7=OD&R[
M#B%V(GEYQ1"4+RWC[9@E$SB44NWR=6UJ";"0N@4BXE0>(\ A!$4Z%& N(!W6
MH(<2K(LCU"9-S-%(J4JM*<H3R.CU-0IS0 ,5QG9-4!@D#:UG   Y$7"4X322
M3  Z?$NT%:X+=4P06.YW?G/0'C_5WQ*UIW5YQ%"8?$&-8L2W4H"'A\?&B.ND
MV=4MK! ?<+H]*'*Y8@]B:K&$ [6+$+H"(N=\"R$.HV0,T9PY",VRAR>,+2M]
M8&B*3V*8KP[.9+((@ZN**"FQ-K:S$TV8)0ZJ"&TI 6-.8>F&,DL!5C;%E!8'
MQ_\ ^9;K9_!9'_\ VPV@F#0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!05.\Z7\T7OK_ 2
MZ_X[8ZEW(7QQV_V1'>E]>@]68_-/D!5LI,R@4"@Z@_24_P YCDC^1UE#^-;!
M55+VR_%7%[.Q^AY7D;SZDCS<=Z7T=*S"C!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#)XG_A$[_S(S_ATU!L&@4"@T9G#
M9_6G61N8'?9+8?!FO;3*EJQMB[IG#+4!Q.W21Q;B"E3@@8%L]D# F>%J%,>
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MQ508V!=[I/$ MXQ)[&]B*X+AKG:_4!ZVLY;^0V#X;5MD'V%POH?HEGS3V7@
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MEOU@'$7C#*2G&[)?9G,[.A<2VQ=EW$F*8FIQ:2?9U4M:\],JR!D_'LY>VYM
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MS&SLJR2>YK.L8987/7F.MRLQ,X/$7,C4KG$-E!;<78M0I3('=0N3)3@G&D
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M$M!</I7_ )F^I?\ )FP/_%9%:#E.]0GBF&:&\B'%7RJ:[,B+'.:)7M4W8DV
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MMLH.^Z^8(EE#-FR+G%&[,.)UK<^OR)MQ)![RW:W C]#X,EC)X"+E(FT9:@!
M4AJDP*(M.G">#-K=ZAG:?E/X[MTML^,[5G78[7#-3*5E#-^NF1\,,DRD6$I<
MI9HI/T63+*MQLOR?(+5$H!=R+:DB)$-:22O5D$A-"H[*P=T= H% H% H% H%
M H% H% H% H% H-3>_S!7OA_!X]].)O?_P"6?.ON-]XT/]\/DWIZOFWW9^,^
M=?+/6^#O_<NZ]/\ X2@VS0*#5&5L\X-P0GBJS.&9L48:23N4(8/"%65LB1#'
MB>935S ::VQ"*GRYX9RI#*' H@8B&])<Y6:$ KA+O:UZ#:] H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MEQ+,I$OF<FBP']X/O@MSBVRV=&MQE<C;^T6DGFEN)(A%(U@A+ 6,&$C./O\
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M&[S<Q7'KQUO**'[.9Z;V+)+BWIG9'BF&L,@R#D6S4M":-$YNS!%&]Q!%6]>
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MESWA>;/)_P#TJ0&#^+^+^1W3_P @[UW?NOZ_V?:$]H'!OZ-7^<\SM_(-R?\
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MX)P7(F9W$ZG, H,&&!BETS<,-CPR 2SKW#;NW1>][!^3GHXV\Y<H^G^-M?L
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M/QTYLQ=S:;P\DC_*,6+,&[+ZZXGQ%!(JSO<M497:9)!&###4[K9:QK80WQ!
MQJ5&.EPDQB-]7GC :1<9)=Q&6*#R>5GC;SEO/LSQ-9FQ+*L41V+Z(;E1?8?+
MJ#(KY+VE_D<*9)_AN5*FO'"6-067-SO*#&['BT!9#FJ9TESC2+74A"(P983*
MY-=8I[N?H/M/JSBYWB##D'.&*G:#1-XGR]Y:X:WNR]6@/)42%PCS!*7M(W!
ME%80TS<K-M>]N@N_P] 0@DO#-#]CN&/ G%SM:_M!,PQ#AO%#"VY8Q:-;($,
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M25N;3E!IB9,N<U!"<PTP98 B,'<035H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MT+(AR(]Y#Q1(6J8EXTQ4ZR-M&H;HQ%GQ)9UD;B<_);. DY ;)E)O0%:/#1Q
M<BFJ/,SE7:_/NO/D+ ,D_">\%GOO:P;*>^^\24'.,._]2T+R9(YHG\81BL/]
M=;B^[_H']F+X*#)/4V\2'(1R$[6X R5J!K][W85"=>@P:3O7O6PC ?#)3;)$
MU?[M?AV3\DPIV6_\DNZ<WMTY!J?]<ZO:=<(@A#TN?+CPY@]SL?Z2Z\:KXI=I
M[KOB[7B J\OPE!F+ D!:K;$LB0^.GVD)<YR=$7"8"C,;2$A;S2.^M28:H\9
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M3S4IRP+HJ( $ MP]&?4K<C#AJ!EK;K&^NK'&L1[<XEG(-.L!2?%;%[MF"/\
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M\1>*YX?.;?)QP?M+HO0-8OWQ</X@W^]V;[/"JRK\_3=Q0*!02^TJ_P"E-_\
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M"'W-CAGO5R)J,L.<28%F1;0^88<RM*I1#29HI0&R0B(/\D3%+E;8%39$H5E
M-,+$8 (K!U,X>T0T>UYF(<AX!TUU3P;/P-BYD!.</:\8BQG,0,SG<F[DTADT
M+B#(]!;'"Z8OMT]C^R-[,/7#?JVZ Y<O3W9<D>O_ *>;D$SQ#P=K+<)SO?\
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MG,2U"&&N+D \!(RW%ZQ;&V!:>7V9?8FJ!%W#>X+B$%^U H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MF2I4Q,> 2G3)R0!    V" -K6M:UK4'Z/S_'#;_2$X ^5WWZPT#\_P <-O\
M2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^
M5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7?
M?K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L
M- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#
M\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <
M-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2
M$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@
M#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E
M=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WW
MZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\
M_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'
M#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O
M](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA
M. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X
M^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZ
MPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0
M/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/
M\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QP
MV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\
M2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^
M5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7?
M?K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L
M- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#
M\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <
M-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2
M$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@
M#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E
M=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WW
MZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\
M_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'
M#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O
M](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA
M. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X
M^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZ
MPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#0
M/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/
M\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\ 2$X ^5WWZPT#\_QP
MV_TA. /E=]^L- _/\<-O](3@#Y7??K#0/S_'#;_2$X ^5WWZPT#\_P <-O\
M2$X ^5WWZPT#\_QPV_TA. /E=]^L- _/\<-O](3@#Y7??K#06VE/#8>\+F I
M82-Y;&UJ>%[>&]^\)6Q\5/*)I6&VZ.K8E>JCRT!=[7O>XDP^GHZ+=(>E0*!0
M*!010W)_Z)$W_/!F_P"(O%<\/G-ODXX/VET7H&L7[XN'\0;_ 'NS?9X565?G
MZ;N*!0*"7VE7_2F__P '[K^Z**UTH^:U^4#O'[':O_W+:6=_&8^(FD]]\7XO
MJEGU=[&'"@4$;-Q-98;N9JSGO5>?J!-\6SMC"4X\6/12$IS4QE>]-Q@&"7H&
M\Y0D)6N</D):5T2EB-*"-0D!:XPV^&P55\*W!VT\1*G/,H?MDG/:O)V;6S%4
M0*GKSC(_&1T*QIB%B6L<7@;6VJ<H93-6( )U"<NP[*TY92-L1)BR0@3VO<)A
M<HO&!@;E7UZ18+S2ZRN$NT1E[?D3%&68 <A3SC&DZ;4RI"%R;+N*92B<V5V;
MEAB9Q;SK! I*N PHQ.K3I51 4AL7I>,LSZ'R: ;L<T&]&X4 '%W5MQ_B^1O>
M3(YB:.RD4>7M44D,PA,IV)RN;,VB'NQR1>2V-RZ-B/NB"0-58D8[4%OVLO$K
MAK$_%/$>*'8![2;.XC:H=.(=+I,IB1^,S943+<JRO*S8]-3 DETR6PZ00UZD
M*8QN5D.Z@\E<W%*RQ%BO8L 4J-'I7]@,7A/QEKCSI[W80U-4.*H)NO+0":A"
M;&'H[LI6RGO$$V%QEC4YQD30(:<U7>#]WN,77.2'@Z2;A<;)>%#4G)'&?$>,
M',KOE/+F,(6<^R9BS%+9&T&9Z:<L22932?NF7FF7%1[PE/,;27(3O8'>6]8G
M4-RL:1>!< U0(X*>H[Z73:%E3MN+S.>W?8&J+3U6YMU[CM\AQU.W1A ,2^/L
M3:Y"V6=<;H/!WXI.LL,N%63B$3?LTY)EPG%A;#,>'"-.FV7%5L5"\[O4:AW%
MKAU?A6)XRD< 1S"0Y;C5L=%8W8G!^R2W2Z&-\6>FYK2E'JAD1M:2L/L+J%I@
MBM8(;1VAXR_PDN1S0GD!]]GDS\"!NR<@]TONW\Q>\[WCLKBT=KY\\^L7DOP;
MO_:=7P5V[QU.KTE=/6L&YN3/2?\ .+:.YWTR]YGN=]]C="D'O(\F>\'RSY/R
M7"\B=KY/\UPCQGQ'RAW/J^*).Q[QVO2/L^R&'D2/C?P)EWCOQQQR;*-I.:L5
MPG V'\,.,@"B/A;TO>,.PR.QA@R?%+(W9Y7024$.<= XI E+E@4_:"2G&*TP
MS@'!0&W^EZVGQGV,!UKY\M^\&ZVMYA:1FPDWF9%.\+CP^HG<&<EV@6R^*H&
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MQ_\ 8;'/K;0/=-BO][3'_P!AL<^MM ]TV*_WM,?_ &&QSZVT#W38K_>TQ_\
M8;'/K;0/=-BO][3'_P!AL<^MM ]TV*_WM,?_ &&QSZVT#W38K_>TQ_\ 8;'/
MK;0/=-BO][3'_P!AL<^MM ]TV*_WM,?_ &&QSZVT#W38K_>TQ_\ 8;'/K;0/
M=-BO][3'_P!AL<^MM ]TV*_WM,?_ &&QSZVT&J,.R#3K8>,KYK@![UHSG#6N
M0+XFYRW#KEBW)L9;I4U)D"USC2]^A1SVU)) W(W5*<>B,-"I)*4E"&"P3 7N
M&U_=-BO][3'_ -AL<^MM ]TV*_WM,?\ V&QSZVT#W38K_>TQ_P#8;'/K;0/=
M-BO][3'_ -AL<^MM ]TV*_WM,?\ V&QSZVT#W38K_>TQ_P#8;'/K;0:JCK[I
MY+\GSG"42>=:I1F?&")K<LEXBCKABY[R?CQN?$J):R+YS 6TY3*XDB>$3FF.
M2FKTB<"@I06,NX@F!O<-J^Z;%?[VF/\ [#8Y];:![IL5_O:8_P#L-CGUMH'N
MFQ7^]IC_ .PV.?6V@>Z;%?[VF/\ [#8Y];:![IL5_O:8_P#L-CGUMH'NFQ7^
M]IC_ .PV.?6V@>Z;%?[VF/\ [#8Y];:![IL5_O:8_P#L-CGUMH'NFQ7^]IC_
M .PV.?6V@>Z;%?[VF/\ [#8Y];:![IL5_O:8_P#L-CGUMH'NFQ7^]IC_ .PV
M.?6V@>Z;%?[VF/\ [#8Y];:![IL5_O:8_P#L-CGUMH'NFQ7^]IC_ .PV.?6V
M@>Z;%?[VF/\ [#8Y];:![IL5_O:8_P#L-CGUMH'NFQ7^]IC_ .PV.?6V@U9C
M]ZT_RS(<C1'%;MK9DN5X>D@H;ER,8_7XOF4AQ9+P'N*4<5R,RQPUR<H1) J6
MA67="YE)55C$IP>ITECL$-I^Z;%?[VF/_L-CGUMH'NFQ7^]IC_[#8Y];:![I
ML5_O:8_^PV.?6V@>Z;%?[VF/_L-CGUMH'NFQ7^]IC_[#8Y];:![IL5_O:8_^
MPV.?6V@>Z;%?[VF/_L-CGUMH'NFQ7^]IC_[#8Y];:![IL5_O:8_^PV.?6V@>
MZ;%?[VF/_L-CGUMH'NFQ7^]IC_[#8Y];:![IL5_O:8_^PV.?6V@>Z;%?[VF/
M_L-CGUMH'NFQ7^]IC_[#8Y];:![IL5_O:8_^PV.?6V@>Z;%?[VF/_L-CGUMH
M'NFQ7^]IC_[#8Y];:![IL5_O:8_^PV.?6V@>Z;%?[VF/_L-CGUMH'NFQ7^]I
MC_[#8Y];:![IL5_O:8_^PV.?6V@>Z;%?[VF/_L-CGUMH'NFQ7^]IC_[#8Y];
M:![IL5_O:8_^PV.?6V@>Z;%?[VF/_L-CGUMH'NFQ7^]IC_[#8Y];:![IL5_O
M:8_^PV.?6V@>Z;%?[VF/_L-CGUMH'NFQ7^]IC_[#8Y];:![IL5_O:8_^PV.?
M6V@>Z;%?[VF/_L-CGUMH'NFQ7^]IC_[#8Y];:![IL5_O:8_^PV.?6V@>Z;%?
M[VF/_L-CGUMH'NFQ7^]IC_[#8Y];:![IL5_O:8_^PV.?6V@>Z;%?[VF/_L-C
MGUMH'NFQ7^]IC_[#8Y];:![IL5_O:8_^PV.?6V@>Z;%?[VF/_L-CGUMH'NFQ
M7^]IC_[#8Y];:![IL5_O:8_^PV.?6V@>Z;%?[VF/_L-CGUMH'NFQ7^]IC_[#
M8Y];:![IL5_O:8_^PV.?6V@>Z;%?[VF/_L-CGUMH'NFQ7^]IC_[#8Y];:![I
ML5_O:8_^PV.?6V@>Z;%?[VF/_L-CGUMH-69 >M/\32'',1RH[:V8TE>89(&&
MXCC&0%^+X;(<IR\9[<E!%<<LLC-;7*;R02EW2%V0MA2I5<Q42'J=)@+"#:?N
MFQ7^]IC_ .PV.?6V@>Z;%?[VF/\ [#8Y];:![IL5_O:8_P#L-CGUMH'NFQ7^
M]IC_ .PV.?6V@>Z;%?[VF/\ [#8Y];:![IL5_O:8_P#L-CGUMH'NFQ7^]IC_
M .PV.?6V@>Z;%?[VF/\ [#8Y];:![IL5_O:8_P#L-CGUMH'NFQ7^]IC_ .PV
M.?6V@>Z;%?[VF/\ [#8Y];:#2:B?:/(\UH-:E<TU32[&.C8-[;, J)'B(C-;
MBS%LZR0F.R#%9JP,Z6-@&!N4+KJ"T BK(R##KB[, A6#=GNFQ7^]IC_[#8Y]
M;:![IL5_O:8_^PV.?6V@>Z;%?[VF/_L-CGUMH'NFQ7^]IC_[#8Y];:#5!L@T
MZ(S FUZ/>]:"<^K(N*<(\'&N6+2\P*H4$P\D4O38T&=::'Q<)J4T-W **Z2P
MBQ6[3I#?H#:_NFQ7^]IC_P"PV.?6V@>Z;%?[VF/_ +#8Y];:![IL5_O:8_\
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MGR*UB.GR4@:V0J,H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M(K6OT!Q^:.>HEU!A7*OR=91V/W^RRLTFR5[N_P #ELEK#M?/\=-WAY95I7Y
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M=,';'P,TLR(YRQ5!<HL999USQH$LTCC>^#9U0Q%DF <610L&C5%C 684I(&
M8 C"(-@Y.>*_=75/1G<'U&65]M,Z0/!\(-Y)7U,U+9<X'C>90O;Y9L0XK&>$
M0]F2NLRG;\0A!<V[>S-Z];<'1>Q5^FU!T::4\JG'WR)JI.V:<[,P[,$@AR0+
MC(XA=FF^/IV@9Q'E)+OY<"RG%H1,W"-DK%!1!KDF0G("CSBBAFA,-+"(+!:!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M04S^H6_F7^0+^!E'^[Z&T'.MHYZ3/2;8W1;4_:ICV<W,Q+L/F77?#&;DLC89
M=B5P@T#R1,X9'Y@>N8(PCQ%&IP)F9W9</N1(96G7E!""]UHAAN,06%>G5W:V
M)2M_)EHUO'F0[+CIQ49;5P\G823KU[P\.N,VMWR[%I"0_OBLU>^/#1$5>%%+
MD@/<#%3L6B=KI#3!!2$EEA-US]3'P=M,I-AZK>^-FNQ+F0TC5MF&-E'J+75*
M#"BBS2IPS897PH]L"(ZUQK0. D90;"$,T(0BO8+D,/9DQ3L#C6)9BPCD*)94
MQ=.VP+O$IU"'I$_QQ\0]J:F.NE<$)II8%:!:0:F5IC.HI1JR3"#RRSBQ@"%;
M*KG=XE6_ )6SCIN?!F?#RN?2G&+4Z/</RPRS*0S6$I6E9+6N*XC=8 CR_+$D
M>(?D5U2]M8E;<4)44"Y_7&$-PI8Y7-H\$[H[(^F4V7UHG/O*PEDKDA=O)4U\
MLS&'>->3LU8:@$C_ /4Y/X]%9:W>'2V*KTG]UH".V[#M2NN2,LP8=0&V6XNL
M^C&'G//>U^6X_AS%34YMC(9(WI(^/*QQ?'DX13:Q1N*Q-I?YA+7Q2 HT[N;6
MWK%($B<]0, 2"#C !4QRI-'%]M]".-?(>Y.?-@,)1F3;.P*5Z=7BF,\BPJ0Y
M/S#(?#+PZ)9"A<[UTFTTAC"]%E$#_P"66^+W"4;88E98!!%06H;1;P:N:7G8
M:(V8RD7C(>P.46?#&)!'0^?RHF59)?Q% :H\:H@\5DQ$;+47.#UESL)"W%6O
MTF* 6M>]@@S-O4'\-&/<MWPE)M]L3!G0'$+2H4L+/DB8XZ0N%U"E(8G<\S0Z
M#OV'6KNJA(,*@:E^* FZ+7-N"P@WN%M3C.X.SPE9DMWF44:\<MT9-FKA/W&0
MM"&$H8:0V7>CY:LE2E84Q)HR2S!NK&O&>%*%+;M;F=3YJ@ID4>I*X1TT[OCH
MS?6#"D 5Y;==P3XUSPK@G>#4X%03+912XJ.QD)!8L=K"56=[I0&=)8C+&6N&
MP6V>_K!_N9!L8+,&,B\ &0PK(H<V&SB-$XJ\@G(@N)4S%/C7($7!&1H1V-LM
MNJLGZE^GK4%6,%]1-PN9&R<3B*,[Z8U!,5#N8Q)E,HB.78% E+D6X%-80)LM
M3O'<;Q2I2*%9P>P4@>A)E!5^U*,&5:X[!:5G'/&)];\,3_83,TM+B.'L7Q17
M-YQ,B6B02@EFBR$!9JEV*9H>TR"1/!8"S0B"6A1J3C+7^9 *@K5RKS^</N%8
MCC.:Y$W>Q^V-678A')["6IEA^6YM.C(C+VFS[&7N58S@V/9)D?':9Y:!!/(#
M(FIJ-$ P'S-KC!806+:Z[*X&VVQ1'LXZVY3B68<4R@2LEGF4/7B5H!K6XZZ=
MR:G!*H*2NC&^-A]NHI0+B$RQ.*]K&%!Z;=(45<2NGF2IWR)\FG+5M!B[(&.L
MA9>S5)-<=4XAEV(O$0E\<UFQ8"/QE-D5+&Y(UH%S6BR@UQ1D3-J@!1)ETK6N
M&$1Z=QL<:$K,[>H4X;=;\AO.*\J;RP$F;QQ6K;G]MQ]!\R9J;F5T;E9S>Y,S
MI)L+8WR!%D+XV+DQA*E$8M"K3F@N$PL-[=%!9/KOLSK]MKC9+E_6G+\#S9C1
M6ZN;""7X_?DCZUIWUF$4%T8W+NXN\M+TB I)-&D5%DJ+$'DG=3LCBAC#>=!6
M?N1S%\:&@,P2X\VQVR@V,\A*24*HW'[6Q3_*,[:$;HB&XM:Z30[$$0GLDB:!
MT0!L<F/<TJ0E06, BQ"L8#K!SY8*VMUUW.]5-B/.>KN6HKF;%;SQDO+6FE<4
M/5V D>6][F1[@POK0ZI&U_C,B0$+B##VYR2)%I)9Y8AE!"8"]PM[(Q!QT*>>
MA9EHG/67A\F*#40)2O7GPI<'#A6!!]UCX9OXR/"H6PR17/6E![ ,Y$?UA=;N
M'4M?H"8^Y_*1H#QZC9DNX6SD#PZ^2)N"\LD./22F;Y"<V0QQ"T%OJ7'&-H_,
M9X-A,<NN2%=X=9*(1!_09>R<^Y8>1IIRS<=7((\N$8U%VH@.69BV-BU[5P,:
M"88_R)9C;52=$XOJ?'N4(U"IJN8T"I62 Y80@,3%7/*ZP[6-+N(/U;G\K''K
MQ[+69HV_VB@>(Y+($07-JA-D$NR!D)0T&*0I"'LW'>+XW-IPA852KKEDKCV\
MI(<(DZP#!=B=U SC37D1TIY!HN]2[3O8:$9M;8R8E+E#8S@?8[,XK9P&J+;#
MY3CN;L\8G\:1.PT)]D:A<V)R%=R#.Q&/LQ] 1LVNYR^*G2+*;MA+9G;J-P#+
M$?.*3R."-6/,S9+?HT>H9&"2(BY,GQ3CB;EQT3DQ2=$J2=]&1WLHT5R>OV1U
MBPD)IER2:-\A#,]O6G>QT&S5:,DD*I,P-A4@B\ZC2)6M5MZ)QD6.9XRQ6?L3
M8X+$)H$ZE6V$IU%P])8Q6N&]P\/<_E(T!X]1LR7<+9R!X=?)$W!>62''I)3-
M\A.;(8XA:"WU+CC&T?F,\&PF.77)"N\.LE$(@_H,O9.?<L/(TTY9N.KD$>7"
M,:B[40'+,Q;&Q:]JX&-!,,?Y$LQMJI.B<7U/CW*$:A4U7,:!4K) <L(0&)BK
MGE=8=K&EW$'ZMS^5CCUX]EK,T;?[10/$<ED"(+FU0FR"79 R$H:#%(4A#V;C
MO%\;FTX0L*I5URR5Q[>4D.$2=8!@NQ.Z@9QIKR(Z4\@T7>I=IWL-",VML9,2
MERAL9P/L=F<5LX#5%MA\IQW-V>,3^-(G8:$^R-0N;$Y"NY!G8C'V8^@)H4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$?=J_\W?+/_-11_QI+7A\S>X.J^Y3
MWX5EVR_PNWOV%=]E:YT*H)RR*!0*":FB'_3(\_P>O7^/HO4WY!]VK_8]WV5C
M2GBL?Q&U'O1F]'TRW6KB=!B@4'(#SD>FT?.0G.$GW(T[RA XIG"3-;0TY<Q=
MD4]>@A<]D$-9FJ-M<@8)A'F]\/A\PO%FI,B5H5J Q$N.().&H1#$H,.#EWR?
MKEZ@GA:CB;)#E(MF,%8<BJYI:4\OQGFY'DG J2R]P @8DTEBL9ETMAS.VN#N
M:!,E3R-G2 -4G%EA+N(XNPP[(>$SG"?]PN//9S8/<,+&@R!HTWN[UF&919J3
M1UJG\!30AXFT?E!#& 93.V35T+C+D@4H4-BDARL@DQ.2192%.6'&-Q0;TZX,
MG+](N1KD:R Y1U.6[9GS>UB;(=,,A^*YNR2J5,["RIFJ.M;PK;F&'LTQ<EC<
M8;8LE"-I1%%6MT L$/-TYW/P#H[SKM.QFM<N,4Z9OFR,ICI#@J8G:'I6_6O.
MSFH:W- YQY[0('5,GQ&@DY2DHLPDGMU,=*,#T &&]PZF?6>?YC&JW\K$/\3^
M1Z#F:UOWTYSM)^,>,R[7E0Z8YX_5$MFL.C&86K&F()0<RRZ82Z0%R0/F-T;'
M^;QM0=+^]I4J]:G(((6"**3'!-&GL(+BO2.:2Z[97R!D+D(F&;CLF;48F>I+
M&46'5J960[8M5Y):WQK<<Q2M[=E2IPGSED>-N3@C;U1%BTJ(8W$*@2A7<NZ4
M(I<V_)7 =P.5PG5'<MUR7C?CMTIS'((Q+H+AYO(DL^RS+H<(]!*),L+4/D90
MI'*7*RQLK:HNIOY=9#CE!(#%B@\)@04Y\>133+?N6:AH=(H;-H!BC6_"CUBA
M/$I;"&6"(6%#XXW'QQIB[4R221D#:6]G06+O<0RA!%:WP"O>XJ#JTQAZ@7#,
M6X3,@9QUAA$TE64M&\+ZIZ]O+3E"/H8[$_>_/8RT8U8'\@;5)71=)87''IC5
M+U)5KH%*XD@L@(B+GW.)"@_A3Y6>-S2^;YDW6WL=MD<[\AN>))*#'B?(<91N
M4LN.XH]N(SW>T9=W.>,9A\PR$H#VKFN*1IBT+4%.U(0$$67=]"NC@+Y \#\:
MN\[EL5L4FGBO'ZO!60,=%%8ZCS?)I!Y@DS]!W)M$)M<GV/)[-]D\>4=H9WBX
M@BN"U@7Z;WL$JO5?2(V5<JI#Z ;@)F<]6L".,:+< "+$0Q.R63O!11!=Q&%E
ME^(.*@9@2Q"!90(WX;WZ:";W,'Z;>4ZHZG9&W\;=[LF[*9+Q1Y/D&4C,OQ\U
M*_2]M?9>R18<EATSM-I,[-CA'W*0IE8$"XU98U( ZY2P)P"BCPNF])UO=G3;
M?3W,F*<]2]^R0^ZN3^)1V&9 E;FK>I2OQW/F!T7L45?7IQ4*G)Z.A[E%EQ:5
M2H&(P+>I3IK7N!,&@]KU>_\ -0,?\K'#W[D<JT&P/2=?S/L"_AQSE^Z9-029
MYR^*:?\ +7@S"&%H)EB'X?MCK-H<ER.2RUD>I'VS+:#2J+71LC,S&(^_.G?'
MXLSJGJTA79@%^N=;HM<.4K=[TR>VO'WJ_D/:#"G(2HR0T:]PM5D>21!'&9Q@
M1];&1E-&KDZF!KVC*F0&Q4L9D!@UH FC:S%00&A!T'=F T+(/3>[OYRY3M3M
M[>/C<S(,JRJB9L. A+!ER1+3WO(ZG%F?8K/\9S"-2J4++]]DKE&;I2E38X.!
MZAR4V7GEGGC+3D]4*;M;M0.>'@>W+G,CUOU EFQS7(T:O%JY[A^+9MFG!V8H
M$J>4CXQ2%3?&SDAD\ <$Y[.6H3GN*AK5-)QAB=2$P@\9:@*^>;K-6^6U&\<,
M<MZ,(X_PIL:7A;&D$C>$,7=JH6QN$O<JFLLQ^TS%*=-IZO)R*_GSHY8:G4+"
M5($BU( :5-?]:"'=7O?K[O\ XVW=XOML]2]/S-V$^H>NV;,69'BQNQV&L!FJ
M7_(D&8X&@4FR[**PI2K,ZEU*\1B-D5EG7([,=T]S0WL'X<JX2Y;>6X+%@3<;
M7C%G&UH<IE\:D.P&/F'8-@V0V2SY'X:Z-4E08S9IMC%.W8_B4(D\A:@7<%!A
M:5Q3E!+$$*H)0TZD.CUK;&YD;6YF:$*5L:6A"D;&MM0D%ID3>W($Y:5$A1IB
M@A*3I4B8H)98 VL$  VM:W1:@_=0*!0*!0*!0*!0*!0*#)XG_A$[_P R,_X=
M-0;!H% H.5OU=>Y!.NW&-; ;,ZF()UN=D1GQH6!(,(' C%<#5-N0,INB:PCB
MKFICS43*QJB_T#$[^(-[AM?IH*#M_N>OB#V=XAEO&5B'!&ZL35X]Q5B>+Z\R
M66XNP0UQZ.3C"7E_RF^254Q[+R5W3)I0D9U2%Y5EHW)9<AW5'6+.47L*X=7?
M%ON7?>C@QAF9G9T"ZY 8M8,DX<RT<+J66CR5A^$/4(>G5S++,,+*7S!N;$;_
M '"'J [-V!<("PWL6$*A_2[<3W'AEOC9@FUF;]4<0Y\S7E:9Y699"^YWB35E
MY@;62"Y#D,4C[9%8'/$SW!HUV:!NL8>K3-P7%4>:+M5 RP$%DAGW%=A#'.H/
MJ7N6O4W $=08_P!<WG4_%65R,2LY9A42:)$XIM=W[NS<UC.,1$M#8ZYEDUD"
M4)824")SNE)" D'0(-1\86C.DT_YX>;?$$[T\U9FN)<4>Z#W6XNENON)9)CK
M&OB9)-W+R!"7F(K(U#O$+WOV_AR9-VO3\UTT$C/418LQCA5'P<XPPWCF!XEQ
MK%N5##Q,8QYC*(1^!P:.$N4E2/3B4PQ.*M[4P-!;@\N2A6>%.G+L:I4&&BZ1
MC$*X6Y<J^8>87$K=@\SB6U4P)L^Y/JW(0,ZI\Y2)CCY,+1-Q$,%CDZ-">MD=
M>;*C'\]:]A5V+&[=2R,GK!3=:USPTGQ?Y]Y]\J9]E\>Y4=(M8-:]?$>'W]YA
MTZPI+(V^RIVS*GFF/T,>B;@D9]N\^J2X^NA+C(5AI@F=,792@(#=87<02% 1
MYW,]-S$LM[0S7=31+=W83C7V/RDZK7_*CSALQW>H3-'YV5C<9$]V88Y/\42M
MF<9DXFC/>"?'E3,L/%<VS< 8S[GA7%L[G/U#W [&(=LML=M%A#DFTO*G<<B&
M1XX]QI%$\F1U1*SU=KFWD)4&CDP:2W,X%DK2X6>Y,B2KNR"I:BR!=!P3P]1M
MB%XSGH%KCRF:R@7I,W:"S'&6Y&*G890$SX9AV5G0U^FK>M*1JKV %FLB8)$N
M!94(L*%B6% [01UND-'\S^^(N0K1GC7TXU$>^Y9"YK97BL:TE"J,<5^-<$LR
MR-ON70R?PX))I!<3G"@AO=^D90%2!A>R0A,"6;8 ;,]3?AZ#:^>G\-P5C)J+
M9,>X?DVJN-H8UEA+#=+'(;(F=@:K'B* 6$]::E0A,4&WMUSCQ#,%>XA7O<)Z
MX"X%>(Y@U)C&(+Z.8.D:6:8P:P2/)4WB#7-\YJ'641Y.I=Y*U9IE"9TR%%7R
MZ]:8H2W:%R!*WCZH$A!!( %!"J3TS\AD3CP"[<1%[>%#LVXJRCNEC^( /N98
MIKCM\.1";J42,@9QX4B=3+)HZ+KE@OU;'+!W^$0A"N$^?2JC +@[U,"$01"+
MDFQX#+!%:]P#OLIE@RP1VM?I"*Y8PBZ+_#T7M?\ 0O01HTD_VLOF7_DB:T_Q
M0Z94$2N%S3[7WE5W:Y6.03?2 Q+9N?0_<:6X)Q)C#+Q*?(./,70"+*7$YE2>
M0) G41Q_0-T7$ULC1=Q2'D)R6E28 JR@\TV@ZB<3<9O'_@'-K;L5@743!F"\
MP-49>H<DE&%X.VXI1BCDA+2%O+<MB,!#'X4Z=]"A*O<Y4W''@$"P@#"+IO<.
M9#TY68)!KUP \E>?8F4$^58/S)OCF"-$#3DJP'2#&FL&,IHS%"2*0&)U(3'%
ME+M<LP(@#M?H%:]KWM04><9N<5N/=?T.097Z7K-G*IDG,T@F^09YNWE6)Y&S
MHSYG?)%,WA6O>8<DDFDF:H<P)$"HD214:VNBQ2L<B59ZE2(TXPLL+@>!9%L>
MQ<QF>LBQ?B4V=XM]/=C=9EJ:8X>G4%S,#"+/FK'\BC#G&I7&I=-,,8>C,>6N
M[>J=TZ%B)26)2^)+>ZV[(82B G_Z?_\ G!_49?Z2%P_=SL+009XF>-O2W<WE
MCYULS;4X,BN>)%@[D#F[#C>.Y(*,D6.6LN7Y/S*[OB]XQZK'>+3!:I-C*4H(
M'A.O2%D]<(2;7&(5PS;;C5W 6BGJ4>'23Z?XH@VN2/82+Y9BN5(/AZ-MF/L<
M2)&VQ:4Q02JT!BQ#7%&]6XLK\"RJR9(22>K0)EA@!*P".&$]/4RY8F\AUBUZ
MXW<)N1B;._*%LA M?F8E-;I/;\3,4AC[[E&3J>R/*4EL+:ZKXZC=K])1%V9Q
M67.- 6$5A!T!80Q!"M?<-8IP3C=O\+@&',=PW&,-07L38U/&X/'T$<9[*1$%
M$%'+3$3< 9YE@!N:<(0[VZ17H.77B9_VCOGI_P#1V)O_ &]@H,!V->D&(_6&
MZ:R7*(Q-L:S)IBK@^))"YC,"S$RIRBV>8XB8TJU9V25.YNTE;E+<6E3",,$K
M>TO6#:ZOIH+^N4#)?)=BO 40D/%=KUA_938-9F!@9IC!<UO34Q15IPTHA>0%
MTAEC>K>,X8"3&2!#-FZ/(RBPO"DRZ9>>*R,RP1'IPIGXW>6SEZR9RJ$\<')C
MK#JGKR]"UYE6<3VO#Q+\]S$"5(8V%Q-0&6M.SN<H!=L<^U5=NF[.ZP/9AZ;E
M=/S05+.VANQV^_J+^7B#ZW\A.;./&0P9CQ;*Y#/<(D3L]YG[,JA.(6@F(/08
M'FS"*X+8D7* K0W/6+2NU+MT$A%T#L%_G'MPS;WZ<[1PS/.<^;_;?=C'$999
MDV.VO66$>8R83*5<FB[FPM+JXF3#;;+#%93%G%<6X)^U9% KGIP]09(N@P(7
MP9>_Z)LH?P=S7]S3G0<YWI%/YFC'_P##OGC]U"6@C1ZL%IRN_2_AH8\#29CA
M6<GK?!&TX9F4F3DJXW$LKN+IBY'CN32!*IC\M3J6-AEYR-4K+,:G, R"AV$D
M4VO<D850<H40YR\0N.MV%N;7D1\1XW-E,FH<?9QS+I7 (,4RPQ((\A9:,Y0+
M8]?-=9 <F=PI *RREJ=Z;>X)EBHA&Y*48FXX._+5W"V%M===L,X2US0MB#!N
M.<>QQ@QA9H=2G]"XQ0* M6@D%I$2:>7)%<GNJ$Y*7+M#+N*E48IN(5S;WN&^
M:#BD+T*U8WQ]55R(L6U^,467XAAS6+7?)T4@[ZXN:>(KIA?%6N,73+)4T-BI
M%:3MR)M?%%P(%0QH3316N>2;8-@T&FO4/\66A\<W5X38IBS7'&6!(QM;N(R:
MV9V8-?XA'<.LTUQW(LI8$9>V$S0=K:6-LE;4US1W)3NJ=*!8,*VUCQFV3IK%
M!8YS6\/'&AASAPVJ6X6TRP)B>88(Q<FGN-LH0^ M*7,#:\162-BNQ3YEX\)^
M39LB>6Y8J1+"7QV<BCB3PB$$1A"<10;@.W]?=3/3)8BW$D<G5GY60\>N$XM
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M3:_S2,RF(R%5'I0])S];\&X^Q67'92B:E P$%!1+EJ!$8((#@CNH#Z"U H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M.$UDV<G52A!<ZZPZYH3 ZO\ @]XIDW$_J6KQ=)9.TSK.>5)7[Q<VRZ/67@C
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M/B4.;\I8AR]*(@P B\ECC QMJU8Z))7E;!"U620]1P;@UK&>2#'T/)Z98B&
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M(].:Q$@ M&D3MX4QX=7M H% H% H% H% H% H% H% H% H% H% H% H% H%
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M2P]$-N9@]1Y_5I83!K,\<8'LN,P7/#V:Y+4D62@* $_&*42A,F$(XD*T83#
MGIZ>+0[='1B-\@#?NNP$D3G-NY4IRM&L@IGG&"I/F9D<4 R%^5"(SB^42)!
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M3;3[TM _K"''A^QMO_R%-M/O2T#^L(<>'[&V_P#R%-M/O2T#^L(<>'[&V_\
MR%-M/O2T#^L(<>'[&V__ "%-M/O2T#^L(<>'[&V__(4VT^]+0:,V;YP=+<UZ
M\YHP]C#)FW^#I[E'&\L@$;R^#CGVWG*K'"R6-"EC-ES9%00V&>+/3.C6FFH;
M7<TH2EEBC17&$%RQAH+C1Y'N+;C4TPP[I_ W?<&:)\;('A7*,A'\>VV<96Y$
MG4J?'"22R8JV&V/I&)F"XN;C<I*C$X+KH4!"=-8\T)-A7">']80X\/V-M_\
MD*;:?>EH']80X\/V-M_^0IMI]Z6@?UA#CP_8VW_Y"FVGWI:!_6$./#]C;?\
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M5E*<$QP#"!*2BK&@%80>FU[7H,LH% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M7&8EVI*?)W*U$CS#-D6.8E#9?,G1V=7B8.4;R1DXJ3. 41ART1Z>Y(4=@FG
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M)SU+]C].YUC.-R;*C4SM^7L8YE;)&IQM,7./DW1,TL(7PT(Y"T/*-$:9>X"
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MRB!A%8D=[7^8%T!GU H%!K">9NPOBQ<A;,G9=QACER<THES:WSR?12(+G!"
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M$;%5B,'9H4EPJ'$A0685<%ND-@]703*^R[KB[7""R34WRKAI/B"*(46=O?O
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MB.[$D0@7/ *P2;2B4C3)Q+"B"%@B"A*R$J@Q6F)4W+#<\I.K-2HC51!9M[V
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MMPBL1U1A*:^B&FHHMY/OK1AWPGNH4?>[0II#*>Q"=8^P_/(2;3;O77MT7/\
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MO[A+<6CQ;CQNPS)\B;.Y3B*:3I=?H?(V-2;%.HWA,>3)CD(PN[ TQAI>RST
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MH.D8;=40PDI04P[D^Y_\Y)J-[^/=K[K_ '/Y.\P>]SROY"[;PZ:>#>,^<O\
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M$N&UY"U3VIMK&&]NI+$+K"M80NGIO\-![7): %QZ/F7 &Y@-[L& "9<-KC"
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MMC6VZ!"QQ>"O<*7H9 HS^LD"UNEI#E>2#>U;6D+9%#RO4/2D9YA!/=KG#O<
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MT+4'X,NJDC/RM:LKG56F;DK[KYD:/-!RPX"8MP>RULG5>%I3#;@+.7&$J07
M4&]QBN*UK6Z;VM</\\F7^&=$OY;N'_\ C1]!^=I=F:&\M\Y!.#D[4LR7J_&&
MW$KB[&@)3NPV^2-?CD<9#S[6 )S5JV=4?V !6$(*8?P7N,-A!Y&XDKC#KO\
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M=<SH#T!H9MXKM"&I>E<4NOZ$U0D-L:46Y9 RN\H!CM:]NA4UO$\7-BTKHO\
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MTP9B&@;$42>T%/H&9J6 :S1E=[0)TJOI,&/M>N,8A!G^/,?1#%4)C>.H"T>
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MP1 :^,_1MGC<EB:' ##9IEQ2$AZ.5R:?.3]<AN=&UY3$-4L<I8KE4=($XM)
MS@-RU*%0 -RS;#+&, @DMDR1J\0X<EDAAD-?IDXP6%*KP^"QEI>9,]OSDVM]
MD4;8$;<V 6O2X*E;8@HXP-AF%D=<T=^@(A4$;N/'!+K@W6Y@M,6L37E'*3JZ
MY:R@0H;BVI<DDTR-"K3,BIN"66-K,CS$!(E-27L$)"L!_0 NXA!L$YJ#",D8
MXAF78/(\;Y#9O,,+EJ$+;(&;Q%U:?$$05!"L)/B+&N;79+T*$P!=8@\L?S/1
MT]%[VN$,&WBNT(:EZ5Q2Z_H35"0VQI1;ED#*[R@&.UKVZ%36\3Q<V+2NB_\
M8'$F O?_ '/@H)R1.(16!Q]MB<)CC)$HRSD63-3!'6M&SM" FU[BN!*@0$D)
MBNN.]Q"O8/2,5[B%>][WO08C ,,8UQ?(,CRF"QOP-^RW)[S+(2[QA_<_,$DO
M91:[EW5X=7!&U? J,_64):8CYK^P^"W0'X\S8'Q#L)%00O,D%:)U'25@7!(E
M<1KD:QM7A*,([\T/+0K;GMF6"3FB+$:E4$C$6*X;WN&][4&EH[H!I[$V^(-T
M;P@P,X(-.V;)4<<$;S+@2 J91TXT]B<W:3BD0I')DK2<>,1"%S5+&\OKBZ".
M@5^D-9;Y(L;O8("PY=TORGM-!C_%U1LAPVSN+Y.,?NA1B*Z9"E1QQSC4H*;Y
M%8OK*!D.J9-<*:P3@&7[.UPC#KGKBS3/9#!^2<5ZES'5' .OC9D-Z(%EIM-C
MN6LI9!GK,GBX$SLSN+Y)Y8)FBI38!0E/<%YH!!N/L^@*CJ4%V%!X,GBT:FS
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M&IB")GF2;7Z-.40Q([J91,%BB+1]XC@8DY(C@JW\\B2FJH^&Q%U#L!>IM?\
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M<"9V9W%\D\L$S14IL H2GN"\T @W'V?0%1U*"TG-&N^$]AV1+'\SXYC\\;T
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M!TC;%*TCJJ=6-2-,.Y:D!MK]7J]H66._4L&0J-VY.Y8,V8F(<'SO#^7M>,?
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MK(LQ0+'RU/+43LO;RF:4B=;."E*4SO;"I Z$V0@[$8S1E!Z;]8L?P= 3)H%
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MO\(C:2/]QE<F>?=+&,M^$X26>5\E/Z?PI? _+ZCO#+(O#>NZ$=[MWLQ0=?K
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MORP\*EM@JE9JAR06N"]TY74" LT(2JX[,QY"S3K4TO.57 MZGT/E\RQO(9"
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MN8LB9HXH=A'C*SF6^SV(0O-F.'^0A)((,?S8@2I2I'-4%, H@Q:)">44::$
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M#)*^%+D@@WO8-S[$B_L@AN$/-@PK:[\G>28*.XDD&W,QT@R;&2^W#W(K*L
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M>=T]0 2RPA9,<,11)I@"Q'#++,&$D'189H@!N()8+W^#K#O;HMT_[MZ"JCB
M2E.^MDORLYW[]/<NYJR#*IZ^*+=HYN#J6K3IB4RM0( 3KD)KB-4%EWO<(#5A
MHK=%S!6H+6Z"F'*.=2,^;.YBP_+]Q$VGV#<$&LD7':+Y2A>*LJY:GJTJZ]Z7
M-\LDB@#BTQ^**4UTAI:4HTHWI#8RPKG"L2&4ZN9J/@>V%]8&'9\&W.'IWC9T
MG\$G+OD"-9/G\ E;"XGA>H=*9I'%"B[PD7LY-U15U5BKEWN4$@HL/:]H&":B
M?YL7)_\ P\;;?Q?)*":?&]_F/:Z?\R#_ -T3W030<G%"SMR]V<U1*%M:T2IQ
M<%J@743HT*(@Q2K5'CO\ "4Z<H0Q7_W VO04AX;P,HW!U2W8S(]MUSIAN!,9
M1(,:W6)CBU2*.XA6GIL+MH!G&]LG+(?V<Q*8(N]K&);!L+KA^9H)H:O;3MLF
MT)8MA9/=2X+L98JD=\BH[#ZKJID>(FA<D?P&]8)O8N$C R 6EVO:_0%<7TVM
M?I#8-!8"P-GW:?'<>V6R[MYL-CB59+2AF,%Q[@V7HH5C&$1=2>I41%O=HJI9
MG1%-+F(.[GGB4V*-/)'V*@T\?6/N&OM&TBIOT(WE0+G$]X6HLF[7I%;LJ*)(
M4NBI-C1D)4.*@E, M.2>M-!<T82PA $0KV#:UNB@_;J3JCE7,NH^'7Q^W!SS
MC5*9C]&'&,5P0[(<;1R(MQ8' A!>:&)DRV0Y*7GKKV5*KC7-H.J*Z<JP A ;
M8/[1+>O*T+XWW;,4Q4-,DSA&)Z\8&:GYWNC1M+Q+4\BLS-4J?K_W,B'9G9#1
M*5-Q=D6L-17$9<%C1CL&OY64S1+'+OEB.\OBR5;)1N/*I@"-&;%XG<,'RJ3M
M#28M-AS;ADE7X<% ]&I^Y)K=8T-S1V.NFN,74L&T=C]QLDO&HVIN5XY(5V$X
M[GZ60QDS9EB.,1\A58G9%@!IY*K82#2U(TI2ES1*KISQ!&ILG3]0KI.,#>@V
MWKIBF$+9I&9G@OD>S9G)O9S27.:0&=YKBN<&U[93B+ +;UC(!,V/$&/O96*X
MS1EW4 -N5U@VN7T"#T-9\A2]TW9Y"X]*)K)W6%P%5A4Z+Q]ZD+NXQR')5\2?
MUKV*.LRQ6>W,)2\Q.$U39*45VP@6$/K7M:@TE@2)YDY"XW)=BIELSG_!\ >Y
MC+F/"^,\ R\C')+/$V%>!K2NLS=DS>O4RUW5+DIX3P&]%P&EC$2<448%.2&Y
M=6<SY<L_[9ZO9JEHIMD36[NRR,9. A)9'J90":1Y>^Q5Q>TS98"--(VA")((
MTTJX1""K+#<1IA)B@T(Z:583SSM5J?C2>Y0W7V2C[>X6FP8D@Q?,+QB5EGM.
M0)JRGN>1<D.I,AF,_&:L(, G1C4)4B1O(2E%VZY?7H)<<=.5<F9#Q7DZ)Y=D
M9TSFV",\Y#PBJFBHLHM?*F^'V:#D+JZ=C\R8XV&Y&D"'>XQF%$EC&888(8KA
M/%Y_P.Z_^C5W_%3:#FGUF3J,&:OZ=[QLA!UD.+<A9%Q9G8"-,<>:Y8/R+DEW
M0"<%9:<H9BBT*DBNRI*7U@6$K5@Z>FP>B@]G:9,9FC5/;S=EX3GV)RSD/'>,
M\)!5EC+&WX&QOD=F;4*]*6:E2G)_/<K1J'%26*YMK#(+N$71>]!9KN+F;*#*
M[ZPZT82DA<&R)LI(%3:OR)9N2NZV"8_B#6V+Y:YLS<LL),-_6(U]^ZF#MT
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M\>D$'790RWFIXD$=CCVCC0718SQZ%0=XDZIO;FR3/;DUFC,,+.LK"F$$PO\
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M,SL[&*+V& *H29.'G:=02<1C+G(6Y26&RJ/-TUSRX/$-7OD>=VE%+6@:.0A
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M'6PFF6%I,7E;#N78)+G&,Q)[R9D%[FD, Y70OK"BC[Q()0H.N,:LD9XDI(3
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M^9?V+S%@#'<X4'NV),0ZY29'C]U9HB2J<$C4ZS"<!:G)QD*IZ3"L=8DPNX!
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ME44P,5G[87$F/E>L1,X4(,)Y4>($,Z0M\OEJ4*TQ*$IS9##5::Q99Y@D=SS
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M\S:UK![/$B&X=7Y($5KA$'/.6@B"*U[7#>SDW6O:]K_#:]KT'_,0?SJ^V_\
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M,MXDX+"T.C&+)"DBD>(?9Q?)=YB\%M""SG* I,I39@2E/JVY%U#FG3LK4G3
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M DJ6<:0Q&6"X"!@*-(M<DP(R1"!<*]$^RF;<N9=S8R:6Z\8C5)X),S<>9%V
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M1&<\S'&\5Q:XN"V88P8@/8H_EI.L4MYQ"&2B;YBQ-P241:,PL'>F]R#T'BZ
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M,ZR$D:0C  Q W9:<75!(6TT"(L)28P@@L"6]ND!=P_,4$L=<M;\=:QXS)QG
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MRIM9ES9SSGW_ -Z<#B,)\D>7>Z^!>526HGQ/S+XZI\3[_P"&=/8]P3]EU_\
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MEAR@\N,GFV/A8WBF5H;YG=;%^(/,-;Y(XM%X6>MN"XC+I[FFV^9 4840442
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M, @WN$01!OTVO;X+VH/]4'\CB25))J=044H3J"C"3R#BP&DG$F@N THTH=A
M,*, *]A!O:]KVOT7H/"B</B4"C[?$X+%HY"XJT]Z\+C439&R.1]M[\M4N2[P
M]F9TJ-N1]\<5AR@WLRP]H>:,8ND0A7N&14$/LQ[\:F8 G"S&^7,K^4IH@0MS
MDK9O(N2G[LD3LGLK;SO$8S#GEI,[PG%875">(8/T!6M?X*#-<';;ZY;(FN";
M"V56&9N+41WM>R62O4>D1"+MKD77^7)6UL3Z:W@.Z "4 3B) (8+7%;K@ZP2
M,H% H% H% H,6DTYA,*&PES*8Q:)&2E\1QF,%R:0M+".1R1QO<+?'V$+JK2"
M=WQ<*U[$I$_:'FWM\R"]!E- H% H%!"W)7(CI?B.2KX?.,\QM+(VI:L;79MC
MS-,)T)J<FX8"7!M=%,%CDD1-KBA4#N4<G/, <6< PL0;&%&!"$FL=9+@&7(J
MAF^,Y<Q3:)N(SR4CY'UQ2Y$-0E,[)4D-N"_:)5J4SX#230@-+O>W6#;IM09Q
M0*!0*!0*!0*!0*!0*!0*!0*#P95)F.%1B1S*3+O#(W$F%XDTA<N[*UOA[&PM
MZAU=EW<V].K7J^Z($AAG9$%&G&=7J@ (5[6N$0,;\C>F>79Q',;X\S'YAFDM
M7";8^S>[W*C3X@M"G/5B)\1?(.VM*7H3IABZQYY8/F>CIZ;VM<)19%R?CO$<
M:/F&3II&X)&4YQ:8;S)G5*U(S%9UAW(1)1*3 #6KS[%BN602$9P[!OU0WZ+T
M$/VGE$T.>G8+*CV#9B5@Q'@L<[0_)# TVNG",1EQ/S[#&YB $5@7Z@A*;!-O
MT6!<5[VZ0D3DG93!N)<8-^:)OD5G38L=U38C:9O'T[K.65U.>;'W;!MIL&;Y
M(<O2J[)3.J>4 9%NK\([=-ND(N_G8M /W_/_ )%F:OO<T$\H?+(_/8E%IU$W
M#Q:*S2.,DLC3IW5:A\2C\C;$KPS.'<7),C<4??&Y869V2@DH\OK=48 BM<-@
MQG%F7<=9LC)TRQ?)297&2'UZC8W=.@=F].)XCRP3>[IB /*!N4*24RH%PA/+
M -.<'H$4,8+V%0:HSON7K9K,]L<<S=D?R2\R-J->V9'Y/GLD[XV$JS$)JGO$
M1BS\E3]544('4-&69?HZ;!Z/AH//PQO'JEL'(;Q+$N9&&22@11QR>/+VN3Q!
MX<0)BPG*+M#?-6*.JGH1!(KF#"D"<()81BO:P0#N$)7T"@_"YN2)G;7!W<CN
M[-S4A5N2]1V9IW8(D)!BI4=V1!9IYO9$%"%U0!$,71T6M>_P4$((5R8:29$F
M$8@4.S7XQ+)D_-49C;5[N,MM_B3X]K26]L0]^=($A;4?>5B@ .U4'%$@Z>D8
MPAM>]@G;08FU0*#,4ED4T9(9$V:8R\*($LEC5'6=ODLH V$A3MH)$^I$9+H]
MA;R V 192:;8H%K6#T6^"@]9]86*4LSG'),RM,CCSTB/;7EB?6Y&[LSLWJ@7
M*4H'-K<"5"%>B4%BN$PHT P##?HO:]J#^K.SM$>:&M@8&MN8V)C;D+.R,C.A
M3-C0SM#8F*1-K6UMJ(HA&WMS>C( 4004 !110 A"&P;6M0>C0:]RQDEBP[C2
M<Y4DR1V71['\9=94\HV(A&J>5+>SI1JU)+8G<%[6A.6C++O8L)J@D%Q?HC#;
MX:#5KGMIA.,X4Q?GV<O[G!<?Y=)AGE(Q[CSPZO'B,\9#G^/LSHVPM+*[HEYC
M>F-[4=AF(RAEWM<^_2&X@DI0*!0:JR)FW&&*'[&\9G\F\ >\NRQ/!\>(O!9"
MZ>890J-1D$-?>65I<4C3US5Y5NW7&)D]NOTW,M:PN@-JT&HX;G;%60,B9'Q/
M$93XO/\ $9K63D)@\#D:#R^8] -,; ^*N;0B977O("!7Z4*E38'1\WU>FU!Y
M.O\ G^&['PMUG4';),U-#1-)/!5*>5HVI"XC=XHJ+2.*@@EH>7Q,)N.,-M<D
M8C@FB#_9%@O\%!O*@4"@4$/LK;^:?84D"F*9%SG&&R2(%)J)R961ODTX<&A:
M1:USD;RG@K%)!LRLKIZ!%*NQ&$7P7MT_!09KAG;G6S8-39OQ!F&(S!YNC,<+
M1L"A6QRRZ$@PPI0LM$I*D9I+=,E$7^NCLEZI01EB'>UC"[B"1E H% H%!^)R
M<F]G;U[N[KT34TM2)4Y.;FY*B$+>W-Z$@:E:O7K5(RDR-$C3%",--,$$!8 W
M$*]K6O>@_!&Y-&YDQMTGB$@8Y5&G@BZIHD,;=D#XQNB:Q@R;J&YV:U"I N(L
M<4(/7*,$'K!O;IZ;7H-38&V#AFP[;D9TA39)VM/C'+4OPV_ E")J1'*Y/"T[
M.H=%[0%I>GL"AA4 >RK)S3A)U [A'UR =%KB#>M H(-Y Y)-+<6S62X\G>9O
M IC$'50R2)G]W>5W/PYS2WM8]-X@SP5P:U?9W%;YL@\TN_\ N"O09Q@O=W6#
M926N,%PID[SI*FF.*Y8X-?DO(4<[O'T+FT,ZIP[]+(FQ-QO9.+ZD+[(!PCQ=
MKUK N$(Q!"5E H%!BZF<0I%+6V K)?%TDZ>6M0]L\+4R!I(EKJS(QG%JW=MC
MAJL#PN:THTY@3%!1(B@7 *UQ6ZM^@,HH% H% H-;S3+N.L>2;'4-F,E)9I-E
ME]6QO'K0) [+E$B>&Y&%P7IBAMJ!8G;R4B4P AGJQITX1# 'K]<80W#9%!_,
MXXM.2:H.%U"B"S#C1] A=4LH-QC%U0V$(75"&]^BUKWO05W_ )V+0#]_S_Y%
MF:OO<T$WL>Y(@.6(NBFN-9>P3>*.!AY*5]CCBG<T U"4?9JDAAI Q73K4IGS
M)I)E@&EW^ 0;4&;4"@4"@4"@4&+HYQ"G"5N\#02^+KIQ'T"-U?H:CD#2IE;(
MUN 2A(')WCI*L;NVH%P3P7)..) 6;88>K>_3:@RB@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%;/+A_F%9C_ /26,?XTH=0>1!N5
M#0UGA,.:'+.W=G%JBT?;5Z?W89D.[!:A:4B543VI&/#2#>R/*$'K $( NCIM
M>]OAH-;\:$^B64MAN1#(<$=O'8=+\H8W>XZ\=P<FSQ%L5)\CW(4^'O"-O=$G
M:6#?Y@\@HRW^Z&U!'[C[WCU;UOQQF"!9GRAY-EB[9'*,F2M7DK(DB[5C<$T9
M;T:[OT4B3ZV@[98T* =D(ZQP>SZ1 L$0;B"US#^X6N>S9,V:,'Y$\[N,5C]W
M)_3^49U&^X(G$*M*C.[671A@(5=L>0,/5)$8,/1TBM:U[7H*[^+C8;7/'6D[
M/&,IYGP_$W-/(<CJ7>(3"=Q%O?C6E8ZJ3K!-B;DY!>%Y+DBO?LB0IC!*@BZH
M CZUK7#;?%U&#2A[691BD=<8E@;+^<ETDP2S+6Q2P)%<62FO0%,E8X^IL6)M
M8G<A<C(3]4  6"B[(-K!)L$(6,1;%^+<:(Y6=%H;$XHFE+K(97.'%.W(DYTB
M='Y:L=Y \RIV4A$J=A*#E1MQ#5FF )3V"4#J$E@ $*VN,<EN=<@;R9 QTWA;
M, 33/"8.)2$"42*.+E+&&2ES!]BZ4!9*,MF=K.#;<D)  EE%EA)M8/9=0(38
M72?9PO:!GBJ''4..U7.@AJ]YR4:N26FJ2?6 Z7*9$Z"\Z*6":Q#*26N.S :'
M]=%_=%NB_4"2E!4'RC3*-X[R/H+/9BY>#Q.&[(I9-)'7N:]P\-8V13%G!S7=
MQ:TJYR6=V1IQC[).2:</HZ  $*]K7#;;GRN:"*&UP3DYZZYIZ)624#W6YH#U
MC#2#  #UA8Z"$/6$*UNF][6M0:*XVIDZ8YXO)1D)D(0*GJ"->?YDT)74I0>U
MJ72,$/3V@(<B4BI"K.0'*T( G!*/),$7>]@C!?H%8+&-6,JR'.&O.)<M2Q&S
M-\CGL11O[PBCR=<D9$RQ0<H+&4VIG)Q=EY*:UBK= 35)P^GI^:O00>C>]>7'
MC0?-6TRF.XY!D''$TDD<8V<AHDP8:J0L\OC; F-=6\R7FO9ZH:-X-$8(EP(!
M<T(;V"$-KA$'\97LER,-N(%>R*/!.ND<Q='8@"<OV.Y1+)N[YC=(@W-Y;P\R
MAO5L)Z6$1Y.J8^NM+0*35BY 46(!EE!H;!&'I(=F=]<R8VMGC V"\$1#$_EY
M1*&5CS-,)5(,FY%94B2ZLY7%TD!,;8]'!J!)%!*<IV/",ZXBC/@!?HN$G,2[
M$RK8'4N/9^P_!VYQGDJC:L]HQ^^OA:!I#+V5_51E_9U;^;W2Y32F=&M4,E2(
M ##4H2QV+ZP[%W"+V1LZ<DFOT#<,U9>QMJ-,\;14E ZS6(XL?\J-&1VEC4J4
MX%RDITEIJZ)G',P#NH?V 5?6'?KE!,+"*]!N;;+;>08>UYQ/G7$4?:Y<5DZ<
M8H;F]GD;:O4*W"(Y':UCR6!M1MT@8N[2A0D 2!-VRDQ,6<.]C #M\-@TYF/9
MC?K!</,V#G^#]?46#65>R'S3&+1-9?(,]1>.O+P4SV4K),06AQBK7HE"U-8Z
MR I>6"YO3\)5C320L_87MODK$RR-I-N>U/[2W/;8>(/4N<WNJ,E<B-N#IOU;
MF)CPWZ/]SIH*[^7#_,*S'_Z2QC_&E#J#R(-RH:&L\)AS0Y9V[LXM46C[:O3^
M[#,AW8+4+2D2JB>U(QX:0;V1Y0@]8 A %T=-KWM\-![6Q&]:J+8WUBRMK4TL
MF9(OGS.3#C9*C<FB1,KO)6=4X/#0X-\0+?5L--8)4L>F8Q$C4NQ!B(LV]C#"
M1E7L*X89E39[>O7%J2YKSIAK7]3KZ4],Z*9Q[&$KFKQES'#0_.B!F2.SR]O9
M:"&R.Z5P6@+N6W([A/--+!<9 .L=8-_Y_P!F9-C;*>F\3@J6)/D2V0GJ^/O[
ML[HW=6N(CH&U@<6UQBJA"]-25(J5%.XA7&K(6%W#U>@NU[7Z0\W8W:#)$8RU
M#=9M:X+&<AY\E\;63AT43=S7-^.\905*I,;RY--!LQA3PKLL<0=F6D3F$G7#
M<'1UAGD%F!!G+2W:4W=SCI0[.,F#TB]'-LQ'19]P:[354QO0%C#$+/2-R:)V
ME)>&E4S 3(>H98TXI3WD=P]7L[VH)NYNV;R\9FL.L>J<!ATWRVU1E#,\BR_)
MSF\MF+L6L+L8$IE3OY<?L6_O+V[@/*4 3HS+& 3#"( #NDWNX?BQ!LGG=DSX
MU:R[:PG&;#/)Q$W>8XKGN&'*1J\=S=/'0G*9''/#9@(<E:GYF;2A*!".O8!H
M"1WZ@ B)$:&K(IM=N)EW+6R^'\-XHPTK48=RFZQ!GR5D!TE,=@3"Q(>_ ;TD
MM;F1VD4OF,P?#4M[@LUI&U"F**$(X=KF M8/VYAVGV\PSD+5/#HL88;RKE?-
M3!E0R:1Z#.$K8&$<@BJ0Y7'E$,E$N=B1LD;:T!Q2YY$YH%AYJ=*H GN4(18[
M!B4^V^WCUMG..V//>"L(Y):LU."N+8S;\ 2R5L[VEGQE@>!1"3.N1Q'-IZER
M4+$Y(STZ4E, ':G%F&B!W>X>_,=HMU]>'_%TNV9QIKR'"62\@L&.%Z?$K].U
MV1L;NTML,3.MDSE)# 15Y2H I%'>+-Z>Y1PBNJ$\FXBNU"7^PCSM<A.AC3J]
M#L0/2EWM(!S"5YG>G]%&8C9 =';,) &:)J29*]'/Y*QQZ1)PB ENC#<S^S
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M[AA3/KQK_'6N0,D?P9AUB99:B$VRIH9\90IL:Y,WC,*.&@D"!$R$)'E$,T@
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M5(FY.[MH[FMSH0A=TJQ,4XH#!7$2>$-C2A7Z0BM>@_)-L=8^R6U 8LCP6&Y
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M(#!,D,PHYD2%1*>QX:@E6)AFD<9Y2S"5IA7$G5":WQ&N0W4)Q7Z0#[/K O\
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M+'4$QTW.2@"MQ002(Q^(HEZLHNY12I:EC[>WD*E!95[A",P(A6#?HM?HH/\
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MSTTQR/,J(]R>7U]<4;0S-+>E!<U2O<W1P.3H4").6&XC#31@  -NF][6H/\
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MF02"2Q)AF,6>Y5#!-X)A&6B0M+E((H-V),4-0)*S(E9SBQ"<TY(QI[*BRKG
M#<0.FUKWH,IH% H/#DDFC<-8W&3R^0,<5C3.194[R&2.R!C8VM-<P!-E#B[.
MBA*@0D7.-"'KFF!#UA6MT]-[4'I(5R%T0HW-L6)7%M<4J=<WN"%02K0KD*LD
M"A(L1JTXS"%25408$99@!" , K7M>]KVO0?JH% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M!*4MSBVK"!ISTI@+'@4!N7U;CO:UPAT+E'P>6F!*#\4;2)\0G'W+3Y].P:\
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M5<P!A=A@$&X^,)\QF1C.6P(#&]139V-R)2=M(U3Y6)?DR0Y .4J>O,W-U5
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MW(/DK+2C-+KLGN&S3<IVDKE%E4:S$T-Q6.DLJ,6^*1W'!ZF"KW>(QFZ-P-2
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MIZ0">.$H&9L4I&ZY:B][@4G+#>M:WZY:WP7#>5 H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M%T%V"F"*P?[(0K_#08^\ZHX\<-CV+:5E>YK",G-S#>,2,N'N+$BC&26'JV*
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M%6 =8TJW;=>P+&@*, $66CC/PV8[1I;E+*NR^Q++#U1"^-P7/68%$U@;4O2
M 6E4E1U R1\HT!0"@!$G-&-(<4"Q1I1A5Q $%B8  +  LL 2RRPA    V"
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M*<R4LSFXQ'&;>J($64H1V1KE?0,NP[&B,\/##EN4=HMJ\SY?@.M>3HSKWB/
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M]OS4V*UT-' ']3+7!P1@4&"[09 $Q*,)RD91O8]G8)9;P[!9DQTP:DN^ 7%
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MFPK#T#:D*0F5Q5R**:K.BA_6%05F5*"5)I*NX+#>7*UK&A^9!T6L )*4%/\
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M*[%VZ0EE6"4$+GB<Q09QPV?G=@7+9'CNT 7Y+;U[:W*D;@\1= R*'_M4#7(
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MA/1,B," $DB4<:@)$ABD@@M.G%<0 7MT L -[V"6= H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H,:F?_K/EG_-I]_Q6JH((<3O^8!@/_P!VG_'5D:@Q'BF_Z(M@?Y86;/\
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MXJP0SRU/"K2=\;1-1LNDC].#@2)<O;DP0C3);%B* ?T""8 %C"SPL,H% H%
MH% H% H% H% H% H% H% H-);)XV?<Q8"R_BN,JVE#(<@0"215F6/IZQ*S)G
M!X;SDB8YS4-Z!T7$H@&&6N8(I.<.P?T "O\ !0>O@>"N^+\'8:QH_J&Y8^X[
MQ3CN"O:MG.4J&A4[Q*(,[ Y*&L]:D;UA[<>L;QB(&:00:(JX;B+ *]PV#:U
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M'S?:=;J=3X>GHH-2,>Q>ODGD'E.-9VPW(95W@Q)Y98\GPEVD'>B5 4AJ;P9
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M%DY%CW%^:82K Q16.F#@\YCC4M>V@:**L,?1GJ(H[OB)*I,$4:*RP9X F"*
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MRW)<@XSCF2W*%YXR7B2)%9*2!GK/&X-&3FAV;VQDCTH\38&T\QRD*HX]02F
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M$U!UKG6FF.\AS_#T+R!+\@$Y"2OKS.6DB5')$33DF:1I CC);U963$RR$#6
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M?(D.EN)W]_0*,!QB/(4B9\A,>+7/YB]#)U!$%C)RM4>A4-X W,<'>]A$#_7
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MC=61YPK*(!"I!C<O)Z:6.<P=&,4?;7R>G2!$!A1M1R,TTU;9L0B,[P.URB[
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MOUSP?!TAIV>:Q[,X]V0R1L7J-,L* 49L9XR@R; <]()O>/@=8DWV;6U_CSM
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M@EKCKTQRJ(.#L81<\5BFB\L8F9(ZJ3TR>YP"$YIJCLO[(L(K""$-X9<SKA_
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M4"@\E^?6>+L;Q)9"XI6=AC[6O>GIV7&V)1-C4V)35K@O5FB^ M.D2DC&._\
MN!#>@X\,D[A8QV"WF09YV :IP\X'A3N F&8^C#8S.[LLB\6/4*8FT."%^D4:
M:TJ:1O0O$GJUSSA7L<:E#88+@,+#;>JV>(E.>7!IRW!T;ZTPK+L[G):=NDQ"
M5$^@\Z01[)L4XIVUUD*(DZ\L&6;8)2HTNX+6M:Y=K]  EGR/ZI;*OFUC%L]
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MQ2!&$"1"6UINJ0$DH-BRK ZH;6M:U![U H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H*V>7#_,*S'_Z2QC_&E#J#_>[.(I++
M]=L<YHQ<7<O-VL!<<S#CM004,Q2Y(&5K;U,UB)@"?[H6(']B1=J-(#X5AR,H
MB_S)@ND-2\8>4F3-N5-W\LQTH],T3^>8FD:9&JM>REO-70UZNM;%%[A"$P]L
M7A-3C&'I ,1=Q O<-[7N$0M7=%8SLGBS9/([;*Y)$LZQS:#)";#<Q2O;@D:X
M$^P]4VR% <2@1BZ $29T>PEN2BP3%!8$J<PBUADW":%I>EFUSOFA'*,/YH;"
MH1M+A<_P3*<,/+*17?DZ;NY"3(<:3 L%.I87RR@H9O=>L00:>6,OH2J48C E
M\XY$Q\SR]CQ\[SJ'-4^DZ4]=&H0XR=D0R^0H4H%AJE8QQI2N*>G9*G+;E C#
M$Y)@ !(,O>]K %T!F-!5[RX?YKL=_AXQ-_C%QH,BY$H#)6>-8]V[Q>BN?E34
MZ0BFIJ4B]RS)3BA=8"3)D56& MTW179>LI&,5A7(2 5V*MVAO301FT?SDG:\
M(<D^Q\$:3I.B)V"SWF*(-*DD\@3NB-C_ )O8BG$HJ]E29.:G,*$JZGZX65U^
MKTBM:U![^),;S[/^ XULML/R'9FA;!*F*\Q<DN%YI$,$PR "," D$?<7U(U*
MBU-V%(2(A64H 3<2SI$*XS B-.#5.J")4X<+N:$J,D9Y]X7L,>$HL(AF"+1A
M=59]P@!80A7"00*_1:W^Y06BZ,NC:[Z=:SJ6M<E<$Y&%L?-9YR,\L\LIR98X
MA:79"8,L0K 5-SFB.3G O\T6:6(-[6O:]!%'B6?V1FU/DK(\.S:U.F.\O9/0
MSA&XKTB,V+GW=0+K7>^V.!9O($G%>]C3;A+%V8^B]^H+H#%=$Y+'YE,>3&51
M1X;Y!&W[-+VYLCXTJ2UC8ZMREEE0TR]O6$W$2J1J2_FBS 7N 8;VN&][7M>@
MV[Q'_P"85AS_ -)9._C2F-!JQO?\[;@[2[,XH3;'RG7?&V '=IB*&"XP1,3?
MDF7IW8E00X34^6N:50ZMJ%2%&9W4U. P":ZI,((2S 7&I#7VGT5B\*Y-,VQF
M)YKGF?$+5K$B(6SK)&1464924[7G,$&NCJN4H$B-/<IEN(( I>IUTPA""+YK
MIM8-\:"_YP'(Y_*<,_\ ;)!06A4'.]A/2. [69"Y%'F0/\G89_&]K\O,^)Y&
MV.ZU.AQS)_/*^16EZ%I2FD 5.3DM;4298,0K&W0)^J0(D[J' "Q+2O9^8RMP
MD.L.RI1$;VIP^4%$]%'" 2ERO%4Q8+-V1HN9V9!+B)8B$4:ML0$(1]J%2666
M P9*<,,Q!_.K[;_P#XB_XG%:#2.HG^;%R?\ \/&VW\7R2@T_DMAD+UPL805,
M=E7<(RH@DGEQB1N(>1I(FVSM\)7N1K*I&62[I6I<L2JC2!W[,19-Q&7"6$8@
MA*11B+9K)&(W62J.5R%OF&93%UJ%YD8M6L$(XFHC+\@\/7IE[V&5(RFH!Z-P
M[$RPS2#B1#ZM^H/X+!H_.D.CF/\  ?%I#(A/TV4HQ'MML0(&/(*)K-94,J;P
MOSP:0Y(6TUQ=[IT-[&=0FX51Y9A0 C+'< @T%[E H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H/->?\#NO_HU=_P 5-H.?[C>TT:<YZH1Z4ONP^UL/
M9G64S%M<\98XS%>*8N7(F]\&0>2?%@QY:/\ Y9 "_?1!4A&:(5Q!N"_1>P67
MY=%C'0#2S(ZK%#$AAC/!HBY$Q%*0,U0M<L@RD9+!'G5V7*1G.+VZJI&XI35)
MYHQF63$WM:X"2@V $/M:\%<DF(=?(MBV)M6BXX>ZLSB\.:')AVP"Z;KS9\)0
M]O:2<FLA"9G.>2[.PD:@*8-R0 )L (AV#UQ!FG&.YRK'F/L^Z>9(4-=Y[K--
M'<@@IH5KE32?"Y\D52-K5,9KFD1."II-?+KU11AI99O8+B+&%ECO\T&"<4FO
M. <BZ=163Y!P;AZ=251,)VE42&98SA<G?#TR-^-)2)SG9[9%R\TA*3;JE@$9
M<( _ &UK4'N3+%V,L6<JFG;9C''4$QRVN>),OKG)O@<1C\00N"X$4GZ<"Q<D
MC[>WD*U0" 6!8PP(AV!:UNGHMT4%K\HR)CZ#KHVV36=0Z'N4R= ,D0;Y1)V2
M/KI4]&')4X&B-I'9<D/?'09ZX@%DZ4)IMQG MU>D8;7#,:"MGEP_S"LQ_P#I
M+&/\:4.H/!A'&[C"913'[AEG-VUN;(SX#%WT.,LJYN6O^-P+;H6UP( !@;F1
ME5@1HQ [(HJROJ6)^9%UNBU[ Y"6] TR'CO:FI"C;&MLWDP0WMK:WIB42!O0
M(EUDR-"A1I@%ITB-(G+"6446$("P!L$-K6M:U![G+D  ]"\P"$ (A%.F,AEB
M$&U[ECOD^(%W&"][7N 5RS!!Z;?#U17M^A>]!'?>)LFK;M_I?+VS-"375G<L
M>S:$1K-#W!HQD&.Q2=+$)QREJ7M$N6(F)M4R]G7D(259Y@+AO>]P7Z &B 'O
M9WUFS$^L,$*V8Y,8PZ08G($.EL79G/6W%D15R64LSDG\#)BSA%9FW2-Q<E-W
M2Q18$/>+W"IM>Y8P]%!MEB_G?9G_ "$$O\<L4H/^;1 !;D0XWC+ #8P8=EP"
M,L&UAB 7CA (L A='6N$ C17M:_P6N*_1^C>@Q+>1;?5W8W7G>=$D6>4"S%6
M!M@@M:(2P]1!)-90X1MX/2D&@..$QN)1YUAVM:YBE*B(N*_6 6(-B\;</>W>
M 9&VIG202;(6V\^<\DG)SA6,-9,=(%:]MQK&RC.BXA(4+48<H3"ZU[B1JB+"
MM88+T&@=+,@N.)]?N1_)[0R^8G7'VS6RTQ;F2_:]DY+8]&&9T3)E5T][* (1
M&IK74"+_ %P)-A7#TWM:U!_;$F-Y]G_ <:V6V'Y#LS0M@E3%>8N27"\TB&"8
M9 !&! 2"/N+ZD:E1:F["D)$0K*4 )N)9TB%<9@1&G!I_5W^95S1_S1S[_P .
MOH-F2_.>4L7Z;<<V.<4R]HQ:\9_CV(,=N687UK0O+?CYJ,A,<"<H)1.@;M=W
M5Q&XVN2,^X0A+3FV"(H=PGE!HSDBP$7B/"B!WG6Y>?,K9'>YS"2T&,YYDQC2
M0=^0%.?8GO;;B!N;"!6,9$R7K76$G"+ HZ1C^;'T7">6ZG^=9QO_ ,,N1/W*
ML=!_CE8  6NT$$( 1"+V,PP,NX@VO<L=WA>7<8+WMTA%<LP0>FWP] KV_0O0
M>-L[_.3<=?\ Z,V$_<"HH/<PW_.?[C?P-8,_Q0WT'^,H !;E1UB,L -C!:YY
M5 (=@VZX@%K'@0 "%T=:X0",%>UOT+7%?_LWH(;Z[P/819LAN;C*%;F(=;LA
MJ-B)O.%6.77!N-\F/D^B\D-&\QJ?,CO,W9 [J&H;">7:Z%*6,A 3<LP74$HN
M&P3"P#@EZA>Y3YD'*>Y\=V#S<;@ATASE!&S%,0QN^M4'2S2++TKY($T(E3@A
M3DH7DT)!%EJ M2KNHOV9H@);A %G%!3'J=AS$65MO>2 S*.*\<9),8\QPL#*
M.?0>,3$;.!Q)G@G #6*1-;B)O"N$B)N=8KJ6-N4#K=/5#T!Y7)-@K".+F+59
M[QGAS%>.GI=MYBEJ6N\%Q[$HBZ+&LQ')%9C:J7Q]H;U:A -6C*-N2,=R[F%
M%>W2$-[!)/DTQ[(G#"D>SYCPF_O2U3FS1F:+J"BA&''Q]L4)@3AI-L'IZS2:
MU$E."P'P=J2U]2_385PB#66E\A!N%LYEW=LU N30"(1UFP-@A Z!. >D % C
MDF1GFZ<SJ%@5C<76Q)9P VL,E::4+YHJ@]C3]T:8QO-R#0>5G)VO(LLFT F4
M82N8PE.4GQ^6Q/1J,]C$=U3'! QIW-/VH2NFQ5E ;?#U!]0/$52^*2[F'AUH
MM)&.1^6M/G6,R 3&Z(W0#-(4\^E[HH9'(:(XX"1U3MSNE.,('>Q@ '@N*UNM
M:@R/4;^<"Y*/_2>O_P"X^0T'F;0.;9CCD>TJRGD(].T8U<(3D[';7*G89*=@
MCF07)K?BTMG!Q.%8AM4/A#^E2$B-N (^L,5KW"4<( .5Y]9I!C##^$F%:F7Y
MFR3G7&JK&L>0&]O($MV]>O)53 I,FL8K2-2&RJZ42KHL'K*;V#>]@F7"&=<F
M3Q#Y+AMIUV#%2LB9KSM(F]DPC#DJGNKJS2AM-[P=E Q>7:Y[&QP5",TQ4J^9
M :6:(@R]DQBD98:\XSG=NQ@JS#JKDYI Q;30Z9O4VR-(G!T<WMPSHRO:LLUH
MRBWO[[>[J[I"4*Y.0,L75L6$TM3< #U2D!88[N1+;Z3[<8ZW+*;5RK&V6('(
M<-YJ;VPD0Q+)+'F=0^8W<C+]08;.KH)M3) &7_[VB:30_,]H*X@D3QPXQ?XI
M@4[*\_!<S*NS,H=<[SM2;VW;%@F9EUL5:@V/$(XA*BCII1X2!?"G.6&E_H!M
M00PUFRR_8*U:Y)LM19J)>9%"=KLYNC*A4EF'(PN)P(>WIEZ\@H19A[<T&++*
MU(+"!<9! P]8/3UK!D2C#<OGFK9&PVP7(?FLDB4XP5S1.GQG/(CAC&-G221Y
M0Z%PU22WM!A,G3AN66W71BLG-&>6>$LHL1HBPA_37B!X-RCQ08,QUL!+28)#
MI@O>VAFEACNF8C66;>]J>K8RH2.S@4<TI%0U",98;++=W/",1-[V&8"@_EFF
M7[@Z$QV$9%.VKCVT.+G.8,4:18RR'!F1HR3(69^7&B+#$YHQN"Y^G$@3-II=
M[K%"D)-KBL;=,(NUB1!BS[%<R%\F.R4?BVTZ'5V3Y4B>)7O':Q[Q-!,G RQ&
M&N,(F$]BC1DY<FXMI71U^;SR[HT?7/<!@-,$"]D]A7#?K)KO.F?;G76<; ;Z
M1W+F2H1;(I&.\7!PA \;2M^;)# GPJ3V".$2ZZ^S.A;B+*S%"U"I3 $38D B
MS%5NN%K5 H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M8I#'7)I;7@X\ZZAN-"I3BLH, $0".J18)(ZO:/.^(%N493G7-4FV7G&68J3
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M"\XO,9[YE+'C,\1^'RCQJ0I_!VA_3."-W2>")78B.N'>TSJ>'M%20\TOM.D
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M?$IS)75O4(U3TD(QLC5/#LSM#,@0F&77JC[%J>U+N6&P;&""$M\A0>:K>3G
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MNJ22'O(CS"K=B*X:FR#)\Y[$[A:)9&_!8S/C+%$ EV3SBI!.F(5I(46_,$6
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MI=6,QXXQ+!<N+W03Y.V,89H59>C9?$G2;P^.^.DXTCB(M*6!.>ZK0&*S;F]
M !*OTA[N?< *<4[63K9!RU09]P,-9H8(HGG4820F(9"R=BV7PYK+9@OL'B,K
M0*#'MKD+*A!<].C-*,4*[]!IA024P30SO +M$9=G"#JL4<9)^ (DT"DJB49L
MRGA''.%YK&!@B;D2WH86P-R6[^M-?79Q3HSEB988&R0P\%R+AN:8G#86E,*F
M,5RWO8Y2B)2:-MTOV9=WZ)KW]A=6=%*&(U&:$MZCJIQ2IR'II,%?H"I3"-)O
M?] 5!Y\-C$SCW(CLYDQ7!IF;"E>N^/DK'(2(VZW9I,\,HD"E;'HX\FIBVEW?
M@6($"Z4DX1H1_ *UJ""&%,TSV^P$VVGV<TVWFF&53A*XMAN-P_7!V=X3AO&M
MQ'B)1LJU_>(TM62MQ N.*5J^XE=%AGC",7?# %!O_;TJ>[58OP#F>-ZWYH=H
M5A[.=Y'E+6;*T,!$,C3N*MY"(D;JA@IKBZER-,G)$H(3)PC.,5A6&6[$103;
M4&JMSYYE?8W6VV/L):,["P2&-\[A+J[&33':&$R-.H1OAQ]DL5Q%%C9)(GM"
M:+]>6.743)$A=K]?K"&"X@O>H/X*DR=:F4(U9)2E(K(-3*DYP F$J$YY8BCB
M32Q6N$91I8[A%:_P7M?HH.>?$.N>>/?[CC3R6XWFH-6]>=F,C9Y8LA.L8DI<
M$D\92HTSUB^,)GQ8E!'74\M\<E=U1 5!XA#<U0+V%8@SK!87R78<R/F#"L(!
MCV+J<C$8^S'"LB3C$Z14%(HR7"6(MT(=X\1UC2;+SPW7 ,LDO>]S06$,L(U!
M9(!!$#;/)61L\:=9*Q'@3078;'K&N%"!R B5XP;,<JV^[+.X(Z$$0#&D:&]R
M:?J33&X@HTPA&D3I&XD\\9G0FN5024V@P?F%<UZA;%85B1<NRMJ^40J<\9."
MXN/.,QA\EB[(V2]C1J7"Q0$\A;BFP0"2#+A'<*@_J ./"4G-#.(SN1F/)LO@
M<.@.E6Q<1NX2N.I<FS#.D42XYAT+B EQ-Y8ZQM><\'"G+BE;B5 4995THA#N
M6;V1M[A3F!HV+@S'H3F[8$TK7_*>===L\Y%<\O1E[P2S)IO.85+Y#UC'^-/,
M$[\VK+MECS"RR57:%D@3$%""8<8(XH@-B9$R/G79+5G<$MPUKR)BYA6XK7,F
M&(U*6\:G+V0E[BPOXW\UR@32:N<V%04:)N(1H+$FFC,&;>QQU[W+(#469\7Y
M+=./[1N&-F/)RXS")3#5-5*HH@B3^LDL931V/#(D"B0L2=O,=&4AB.OU%@U)
M184HO@,N&]!-'?V,R29:=9ZC$0C[Y*I*\0\E*T1Z-M*]\?'139^9SKIVYI:T
MZI>N/L24(74*+$+JAO?HZ+7H(N;+:QS:>XOTZRS%L5QS+,VUPC#0&48%R*A:
MRV_(40D<)CK;+XT>WREO5MA,L8U+, Q$4K)M<D^Y@[ ,4%$DC#6#A*,:25*&
M.8HX97XS)*@):47O;UCQ)C;&+2M&<F1*5@IZL1J$3\WMZI1<P  ]PNM(+Z]C
M2 7$86%V(  +  LL 2RRPA    V"   VL$( !#:P0A"&W1:UO@M:@_U0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*"..PF'\L93)B2O$&Q,GU[D<54N9PW%GBK3.F
M*1DN1K,99-)8@^N+>TNH6^S4+NPC+WN5=09;X0#,+,#4N,-.I6@RI&,V[';"
MRK93(N/DSNEQMWV%Q?&4%A0GY$)N=W9#!8L-:A4R)4@ZI5E@SPV#T=>Y8C0$
MC*"=% H% H% H% H% H% H% H% H% H% H% H% H-$;-X3_"-P5D/"OF;R=Y
M];&]N\R^#>8?"NXOK4]=MX-XLQ]^[7PSLNKWLGJ]?K=-^CJW#:\38O*\5C,9
M[UW[R['V9B[[V'=N^>$-R9O[UW;ME'=^\=WZ_4[0?4Z>CK"Z.FX9!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!05OK=&\LP6?Y'ENJ^V[_KQ&\KRE7.ICCU;B"%9>CMIFY=6
M[J\QRTM<T%H\6Y#MUC2BRABO:P"^T[$DDLL+'"0F )* <;VYH"RPFG=0)7;&
M!#:PS>S#TA+[05KWZMO@MT]%!_2@4"@4"@4$-]D]2U6:9IC[,.-<M2# V=\9
M)ES/&\D,C V3! LC#J=<YQCDHAKRJ0-\A;[#./$G -0646-2;<TL^UP! &[L
M+0_*<'A06/,.8??E,;.J]6*<^[Z.XSZS8HL1W%H\LQ=2K:P^'W+'_='7[0WM
M/FK6ZMJ#;5 H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H
M% H% H% H% H% H% H% H% H% H*_N4*9S#'^E&5Y7 Y7)83*&YPQV!ODD1?
M72-OZ "[)$40K0(WAF5(G%*%6B4F$FV 8&QA1@@"Z0BO:X1_F6I.4(+@-RSC
MC3>;<<G(<3Q@KR<E09.RZ'(>.W ]MARF0N#,Y11>P)2#4JVP1%$G*!+ I;]4
MRY)P@VH-W,&X,Q#QQ)]O'6-H'&>IL6JWH]F+*4)F9=*D3\HAI3N<E3W[P0Q*
MG0D+B<06,-PI1"+ 8"W098-7XFU-RMG[$\)S)E'>K:M'.<G0YHFQ:3"&2D>-
M\8L":5MP'YH:F^)M+$:2NLSDN0"CSP')AJ;EW#:Q=K!O8-Q.> -GFW7'8C&K
MMLQ,\C3!U;W!YP1D)H*%CO)$>5-R2SZV19V=X@8A6*A+I"A D-6!6&=X1J#
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M&+3@&7>PC[N-B;?!TC^&W2&EN5M4F6Z[8F6(U!"M&KV5PNJ2*TII9Z94F/\
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M<[C>@DKOC''F6:<[%L; G/5NIV,7Y<0E3!ZZA22R@*>ER<DOHN(TTY WFAL
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M6C-CFWO3:WO#0M3.34[(4CFV.*(X"A&O;UY!:I$M2*"KB+/3*DQH1EC#>X1
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MPW6U15O20MNA#L6E?FM-%T<5<B5R(H2%Z;R6DMH6%K&X\:HD25Q3A%8P@8C
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MX+W[P RR\RPR[] :">T:CS3$8XP11@2%H&*,,C5'F5"4$(2D;2RH2&UN2%A
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M%&3QF4  YQ:'QV I[2[M4:$XA0<>K'<DH2FQ-A&=G8TX-Z:Z[FJ)GBG.TDV
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M(6UK;$)1") @1IRPEE$E  66 -@AM:UK6H-=.V!,%O\ *@SI]POB9ZFP3@*
MS%VQS#W&5!4%W&(!X9"L9SG>QP!&BO87;=:UQ7^'X;T&=2>+1B;,3C%IG'&&
M71EW*+)=HY)VAO?F)T)*/*5%%.+0ZIU;>M**4D ,"$TL5@F "*WPVM>@]1"A
M0M:%&V-B-*W-K<E3H6]O0IR4B%"A2$@3I$:-(G 60E2I2"P@++ $(  #:UK6
MM:UJ#PV"%0Z*K9$Y1>)1F-N,O=AOTL7L#"U,ZV4/IH;A,>I$J;DJ<]Z=C WZ
M!*5(C3KV_1%0?X;X-"6B4R"<M4.BS9-980W)95,&^/-**4R9,SIB432GD$@3
M)"G9Y(:T:<LE.!2<8$@H 0@L$(;6L'^O),,\X>\+RC&//W@/E7SQX U></+'
M??$O+GF7NGC7@/B/]T=S[?N_;?-]3K?#0?PCN/X'#TS\BB4)B,61RIW<9!*$
MD=C;,R)I(_.Y993L]OQ#8B3%/#NYE%!"H4J+&''!#:PQ"M:U!^R)P^)0*/M\
M3@L6CD+BK3WKPN-1-D;(Y'VWORU2Y+O#V9G2HVY'WQQ6'*#>S+#VAYHQBZ1"
M%>X8T?#D,#BN0C\-PB#,$PD 91+R$:-B;X^SRS)C@W&C2O4Q$R :3G18\NA"
M<"]::;94:5;X3;7M:]@JU61';23AE#/%^-S6O!N39NVR*+NNS <B8D7D-J21
M@4-KI(B&>)1@[)*HX]$?8XL)QYXQ&EV$<2+_ +U8++]?<0MV!,*8TP\V+;N:
M> 11N8SW2Y 4WBSH$(E3V[!2A$/NI;H\J3U 2KB'<L)E@W$.]KBN&XJ# YQB
MS&.3DQ"+)..8'D)&E%8:9).(A'Y8F3C#>X@C((?F]P*)$$0KWM<-K7M>]!_>
M$8VQUC-O-:<<0&%8_:CQ!&>V0B*L44;SA@,4'!&:C84"!,8()JLT5KW#>]A&
MCO\ HBOTA^U'!X4WRMWGB"(1=#.) @1M3],D<?:4TK>VMO"4% VN\B)2 =W)
M A"0"Q))QPRRK #U;6Z+4'OK$2-Q2*4#@D3+T*T@U*L1+""E216F/!<LY.I3
M'@&2>0<6*X1 $&X16OT7MT4&NH-A/#.,%JYRQKB/&./'%S*+)<E\&@45B2UP
M)*$8,HI<J8&EO/5E%C.'<(3!"M:X[WM^C>@RJ6PZ(3]@712=Q6-S6+.=THG*
M-2UC;)&P.%T*PAP177,SPE6-RNZ->E*/*[0L79G%A&'H$&U[!^Q7'H^X1]5$
MU[&SK8LM9SH\LC2ML1*8^KCZE$)M4,:IF.(&W*&=0W#NG&F&7<@9%[@N&X;]
M%!_R/1R/1%D;8U$V%FC$<9DP43/'X\UH65D:D8+B$!(VM3:0F0(4P+BO>Q91
M806O>_P4&"OV#,)RJ6I)])\/8LD<[;SVY4@FK]CZ)/$M1*6<X*EH4))&X-"A
MX3'M:@ 3$PP'!$0.UA N&]NF@RQGA,,CS[)Y2P1&,,<FFQK8=,Y&SL#4V/LN
M.92#TK.;)W=$D(<'XUI3*C2TPE1AMR"S!!!U;"O:X/),,\X>\+RC&//W@/E7
MSQX U></+'??$O+GF7NGC7@/B/\ ='<^W[OVWS?4ZWPT&3T&*)H)!T<P<,A)
M(;%$L^=FDEA=9PFCS01,'-B3F)C2&5PDQ2,+TM:2341(@)C#Q$A$4"]@VN$/
M0&5T&KPX0PL":CR2'$&+PY%-5V<#)\& 1.TU,7VN"]EHY39IL^#5VN6']<N?
MU_F;?#\%J#*(I!X5 T;@WP>(1>&('9X72)U0Q2/M,=1N<@<[$A<GUP3-"1&2
MM>' *8NQZHP(CS;%AZPK]6W0&&O^ \%2N3%32485Q+))B0:0>3+'_'$.>),2
M<E/&I2G%/SBS*70LU,I,$86*QMK@&*XK=%[]-!GDABT8EK"NBTKCC#)HPYIK
M(G*.2%H;WIA<$=NKT)%S0Y)U+>K36ZEOULPL0?@M\%!XL&QCC7&#8L9,:8]@
M^/&9Q6B<G!H@T38(DV+W :<E(->L0,#>WI%2T:1,65<T8!#N66$/3T!M:P>#
M',$8.A\F/FL2PUBF+3)5=4)3+8YCN(,DF4W7&A/77/?FQG2NIUUAX+#-ZQM^
MT':UQ=-[4&6R:#0F:C83)E#HM+3(L^(Y-&#)-'FE^'')(W7N)OD#")U2*Q-#
MXA%>]R5:?LSRKW^9':@RF@4&CG#6/6QV0HFQTU[P<Y-K:>N5-S>X8G@2Q"@4
MNB@2QS4(DBA@,3I3W%6,1IXP!"(XR]Q#O<5^F@W0C1(VY(F0-Z1,@0HB"DJ-
M$C(*2I$B8@%BR4Z9,0 !)!!)8;!" (;!#:W1:W10:QFV!L&Y+<P/61L,8HG[
MP458DMVFV.HA*G,LFP"B[% 7OK.O5 *L62 /5L/HZ !M_N6H-C-C.T,C<G9V
M9K;FAH2%C*2M;8A3(&Y,48,9IA:="E**3$EF&&"$*P0VM<0KWO\ #>]!KZ)X
M.PI I&MF$&P_BV%RYR)6IW&4Q/'\3CDC7IW)24M<2%KVSM"-S5$KUA #3@F&
MB":: (A6N*UKT'^@X0PL":CR2'$&+PY%-5V<#)\& 1.TU,7VN"]EHY39IL^#
M5VN6']<N?U_F;?#\%J#*(I!X5 T;@WP>(1>&('9X72)U0Q2/M,=1N<@<[$A<
MGUP3-"1&2M>' *8NQZHP(CS;%AZPK]6W0&44"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4&+/4&A,E?(Q)Y%#HL_R6$'N"J&2%ZCS2ZOD1
M4NQ:8ET41AV7)#U[ >Y$HB0J!I#"A'!*!8=[V"'H#*:#4[M@3!;_ "H,Z?<+
MXF>IL$X"@,Q=L<P]QE05!=QB >&0K&<YWL< 1HKV%VW6M<5_A^&]!J3>G&4W
MS'J?F7&F-V3S'-I6QLZ-@9?$FAH[^I2RM@<CR_$GY>UM*7LT2(T?2<>6&_5Z
M+7N*]K7#,,>:\8B84D$EKGA;%B3*['&HR4MF=H'##IHC?FYC1H59P)>F;#70
M:LDXL8.W+5"ZUO[$5[7Z:"00@V%:X16L((K7"((K6O85KVZ+VO:_P7M>U!JJ
M.8(P=#Y,?-8EAK%,6F2JZH2F6QS'<09),INN-">NN>_-C.E=3KK#P6&;UC;]
MH.UKBZ;VH,QET,A^0&!9%)Y%(U-HNXB2C<(W+F)KDC O&A5$KD0UC.\I5K<J
M$D6IBSBKC+%<LTL(P] @VO8-/DZC:HICBE"?6+7I.H3FEG$'DX6QN4<2<4.P
MRC2C01H(RS2QAM<(K7M>U[=-J#=[ZPL4I9G..29E:9''GI$>VO+$^MR-W9G9
MO5 N4I0.;6X$J$*]$H+%<)A1H!@&&_1>U[4'\8W&8W#6-NC$0C['%8TSD72M
M$>C;2@8V-K37,&==.W-+6G2H$)%SC1"ZA180]85[]'3>]![E!B\A@\*ERR.N
M$LB$7DZ^'O!$BB2Z0Q]I>ED7D":X!)GV.J7)(I.9'A.(L-P*DPBCP7#;H%;H
MH,HH-52;!.$)I)4TSF.&\52R8(Q(QI)7)L>1%^DJ4;<;8]O&F?71H5.A D)P
M;#)N$VURA6Z0]%Z##]K8))<CZS9OQW!6D+O*I;C&4QR,,H%;:U@7.C@U')4"
M$"UU5M[4A"88*P;#/.**!;^R%:U!A. M7L8QO$F #,B8-Q7[Y('AW%<;?I Y
MP>"/LM9I/&84SM;LF)F*="XGJ#D#J4H!8],L,*'>XAEC$$76N$NZ#4[=@3!;
M/++SUIPOB9KG-U%U=YFW8YAZ*6757N"]U-Y$F9RGBZB]R@_-]MUOF;?#\%J#
M,);!X5/F]*TSJ(1>:-2%T1O:)LEL?:9&WHWEN[2[>[I43PD6)D[HAN</L5
MV-*ZU^J*W3>@\^<8QQMDY$0VY)Q[!\A-R4RYJ5!.(FPRQ$F-$(L0C"$K\WKR
M"3+B*#>]PAM?I#;_ +%J#]<,@,%QPS CN/(5$H''RSCE &*&1QGB[,!0H,&:
M>>!L8T:%$$XXT8A#%8'6$*][WO>]Z#'YWA3#64E2);DW$F,LC+6TDQ.W*YW
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6% H% H% H% H% H% H% H% H%!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>sny-20231231_g5.gif
<TEXT>
begin 644 sny-20231231_g5.gif
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@A^X8@O!(@?)XC=QHCP/'6_F8<]?%C_\(D %Y 04  #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>sny-20231231_g6.gif
<TEXT>
begin 644 sny-20231231_g6.gif
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>B]"8B])H M38B]98B4BGC1E1C-T(CN$HCD!8   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>sny-20231231_g7.gif
<TEXT>
begin 644 sny-20231231_g7.gif
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MJ:_F4ZR'K-55\SIX1%*UC6<(YF _[%K&IO50G?ULIU *UY>6JUO'BUJ75KO
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<27EF&8=H699.R9;%.(%O>9+.*)=U:9=U60  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>sny-20231231_g8.gif
<TEXT>
begin 644 sny-20231231_g8.gif
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MV\ZU>+@=4VSK3]NK-O:=3YU5<R\:W<QF-[D[[>T<@EL[REYVN=4-Z7D/F]'
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-BVB)F:B)F_@"!0  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>sny-20231231_g9.gif
<TEXT>
begin 644 sny-20231231_g9.gif
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MZSR:2"_U3&&>DJ,Z]"9-34JIFTHQISRM:4D92LR?[G1 +^TF46.Z V1>RVU
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;V9/>V7(R(IY460GE28QSB9[KR9[MB0 %   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534549776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sanofi<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">I0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">46,&#160;avenue de la Grande Arm&#233;e<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Paris<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">FR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">1,264,799,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001121404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Roy Papatheodorou<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">46,&#160;avenue de la Grande Arm&#233;e<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Paris<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">FR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1 53 77 40 00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember', window );">American&#160;Depositary&#160;Shares,&#160;each&#160;representing one half of one ordinary share, par value &#8364;2&#160;per&#160;share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American&#160;Depositary&#160;Shares,&#160;each&#160;representing one half of one ordinary share, par value &#8364;2&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SNY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=sny_OrdinarySharesNASDAQGlobalSelectMarketMember', window );">Ordinary shares, par value &#8364;2&#160;per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value &#8364;2&#160;per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=sny_OrdinarySharesNASDAQGlobalSelectMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=sny_OrdinarySharesNASDAQGlobalSelectMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534524080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLineItems', window );"><strong>Auditor [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers Audit<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Neuilly-sur-Seine<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_ErnstYoungEtAutresMember', window );">Ernst &amp; Young et Autres</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLineItems', window );"><strong>Auditor [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young et Autres<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Paris-La D&#233;fense<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sny_ErnstYoungEtAutresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sny_ErnstYoungEtAutresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533465056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated balance sheets - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">&#8364; 10,160<span></span>
</td>
<td class="nump">&#8364; 9,869<span></span>
</td>
<td class="nump">&#8364; 10,028<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">1,948<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">49,404<span></span>
</td>
<td class="nump">49,892<span></span>
</td>
<td class="nump">48,056<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">24,319<span></span>
</td>
<td class="nump">21,640<span></span>
</td>
<td class="nump">21,407<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">677<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">3,218<span></span>
</td>
<td class="nump">3,095<span></span>
</td>
<td class="nump">3,127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsNoncurrent', window );">Non-current income tax assets</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">6,427<span></span>
</td>
<td class="nump">5,381<span></span>
</td>
<td class="nump">4,598<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">95,794<span></span>
</td>
<td class="nump">92,611<span></span>
</td>
<td class="nump">89,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">9,666<span></span>
</td>
<td class="nump">8,960<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">8,433<span></span>
</td>
<td class="nump">8,424<span></span>
</td>
<td class="nump">7,568<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">3,455<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">3,571<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Current income tax assets</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">8,710<span></span>
</td>
<td class="nump">12,736<span></span>
</td>
<td class="nump">10,098<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Current assets</a></td>
<td class="nump">30,655<span></span>
</td>
<td class="nump">34,026<span></span>
</td>
<td class="nump">30,564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets held for sale or exchange</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">126,464<span></span>
</td>
<td class="nump">126,722<span></span>
</td>
<td class="nump">120,242<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilitiesAbstract', window );"><strong>Equity and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to equity holders of Sanofi</a></td>
<td class="nump">74,040<span></span>
</td>
<td class="nump">74,784<span></span>
</td>
<td class="nump">68,681<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Equity attributable to non-controlling interests</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">74,353<span></span>
</td>
<td class="nump">75,152<span></span>
</td>
<td class="nump">69,031<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">14,347<span></span>
</td>
<td class="nump">14,857<span></span>
</td>
<td class="nump">17,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current lease liabilities</a></td>
<td class="nump">1,755<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Non-current liabilities related to business combinations and to non-controlling interests</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Non-current provisions and other non-current liabilities</a></td>
<td class="nump">7,602<span></span>
</td>
<td class="nump">6,341<span></span>
</td>
<td class="nump">6,721<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent', window );">Non-current income tax liabilities</a></td>
<td class="nump">1,842<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
<td class="nump">2,039<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="nump">1,841<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">27,904<span></span>
</td>
<td class="nump">27,596<span></span>
</td>
<td class="nump">29,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Accounts payable</a></td>
<td class="nump">7,328<span></span>
</td>
<td class="nump">6,813<span></span>
</td>
<td class="nump">6,180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Current liabilities related to business combinations and to non-controlling interests</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentProvisionsAndOtherCurrentLiabilities', window );">Current provisions and other current liabilities</a></td>
<td class="nump">13,741<span></span>
</td>
<td class="nump">12,021<span></span>
</td>
<td class="nump">11,217<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Current income tax liabilities</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current lease liabilities</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">4,174<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Current liabilities</a></td>
<td class="nump">24,194<span></span>
</td>
<td class="nump">23,964<span></span>
</td>
<td class="nump">21,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Liabilities related to assets held for sale or exchange</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 126,464<span></span>
</td>
<td class="nump">&#8364; 126,722<span></span>
</td>
<td class="nump">&#8364; 120,242<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes the impacts of the IFRIC final agenda decisions of March&#160;2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April&#160;2021 on the attribution of benefits to periods of service, as described in Note&#160;A.2.1. to the consolidated financial statements for the year ended December&#160;31, 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Current assets; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale; Non-current assets or disposal groups classified as held for distribution to owners]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities other than liabilities included in disposal groups classified as held for sale. [Refer: Current liabilities; Disposal groups classified as held for sale [member]; Liabilities included in disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph p<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_p&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentProvisionsAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentProvisionsAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348535018944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated income statements - EUR (&#8364;)<br> &#8364; in Millions, shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Profit (loss) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 43,070<span></span>
</td>
<td class="nump">&#8364; 42,997<span></span>
</td>
<td class="nump">&#8364; 37,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">3,374<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(14,236)<span></span>
</td>
<td class="num">(13,695)<span></span>
</td>
<td class="num">(12,255)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">32,208<span></span>
</td>
<td class="nump">31,694<span></span>
</td>
<td class="nump">26,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(6,728)<span></span>
</td>
<td class="num">(6,706)<span></span>
</td>
<td class="num">(5,692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(10,692)<span></span>
</td>
<td class="num">(10,492)<span></span>
</td>
<td class="num">(9,555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">1,969<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(3,516)<span></span>
</td>
<td class="num">(2,531)<span></span>
</td>
<td class="num">(1,805)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization of intangible assets</a></td>
<td class="num">(2,172)<span></span>
</td>
<td class="num">(2,053)<span></span>
</td>
<td class="num">(1,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="num">(896)<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="num">(93)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="num">(1,490)<span></span>
</td>
<td class="num">(1,336)<span></span>
</td>
<td class="num">(820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">7,875<span></span>
</td>
<td class="nump">10,656<span></span>
</td>
<td class="nump">8,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(1,313)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
<td class="num">(368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="nump">7,153<span></span>
</td>
<td class="nump">10,422<span></span>
</td>
<td class="nump">7,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="num">(1,602)<span></span>
</td>
<td class="num">(2,006)<span></span>
</td>
<td class="num">(1,558)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="num">(115)<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">5,436<span></span>
</td>
<td class="nump">8,484<span></span>
</td>
<td class="nump">6,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Net income attributable to equity holders of Sanofi</a></td>
<td class="nump">&#8364; 5,400<span></span>
</td>
<td class="nump">&#8364; 8,371<span></span>
</td>
<td class="nump">&#8364; 6,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Average number of shares outstanding (in shares)</a></td>
<td class="nump">1,251.7<span></span>
</td>
<td class="nump">1,251.9<span></span>
</td>
<td class="nump">1,252.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Average number of shares after dilution (in shares)</a></td>
<td class="nump">1,256.4<span></span>
</td>
<td class="nump">1,256.9<span></span>
</td>
<td class="nump">1,257.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent', window );">Basic earnings per share (in euros per share)</a></td>
<td class="nump">&#8364; 4.31<span></span>
</td>
<td class="nump">&#8364; 6.69<span></span>
</td>
<td class="nump">&#8364; 4.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent', window );">Diluted earnings per share (in euros per share)</a></td>
<td class="nump">&#8364; 4.30<span></span>
</td>
<td class="nump">&#8364; 6.66<span></span>
</td>
<td class="nump">&#8364; 4.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a contingent consideration asset (liability) relating to a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BasicEarningsLossPerShareAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BasicEarningsLossPerShareAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348522478864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of comprehensive income - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">&#8364; 5,436<span></span>
</td>
<td class="nump">&#8364; 8,484<span></span>
</td>
<td class="nump">&#8364; 6,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Attributable to equity holders of Sanofi</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">8,371<span></span>
</td>
<td class="nump">6,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses)</a></td>
<td class="num">(171)<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments', window );">Change in fair value of equity instruments included in&#160;financial assets and financial liabilities</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss', window );">Tax effects</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="num">(77)<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax', window );">Change in fair value of debt instruments included in financial assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax', window );">Change in currency translation differences</a></td>
<td class="num">(1,540)<span></span>
</td>
<td class="nump">2,278<span></span>
</td>
<td class="nump">2,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss', window );">Tax effects</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="num">(1,526)<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
<td class="nump">2,510<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for the period, net of taxes</a></td>
<td class="num">(1,603)<span></span>
</td>
<td class="nump">2,764<span></span>
</td>
<td class="nump">3,307<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="nump">3,833<span></span>
</td>
<td class="nump">11,248<span></span>
</td>
<td class="nump">9,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Attributable to equity holders of Sanofi</a></td>
<td class="nump">3,810<span></span>
</td>
<td class="nump">11,130<span></span>
</td>
<td class="nump">9,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="nump">&#8364; 23<span></span>
</td>
<td class="nump">&#8364; 118<span></span>
</td>
<td class="nump">&#8364; 67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in other comprehensive income on the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income that will be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income that will not be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) On Remeasuring Debt Instruments, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519728336">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated statements of changes in equity - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Attributable to&#160;equity holders of Sanofi&#160;</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><div>Reserves and retained earnings</div></th>
<th class="th"><div>Stock options&#160;and other&#160;share- based payments</div></th>
<th class="th"><div>Other comprehensive income</div></th>
<th class="th"><div>Attributable to&#160;non- controlling interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 63,252<span></span>
</td>
<td class="nump">&#8364; 63,106<span></span>
</td>
<td class="nump">&#8364; 2,518<span></span>
</td>
<td class="nump">&#8364; 362<span></span>
</td>
<td class="num">&#8364; (705)<span></span>
</td>
<td class="nump">&#8364; 60,149<span></span>
</td>
<td class="nump">&#8364; 4,138<span></span>
</td>
<td class="num">&#8364; (3,356)<span></span>
</td>
<td class="nump">&#8364; 146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for&#160;the&#160;period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,307<span></span>
</td>
<td class="nump">3,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,279<span></span>
</td>
<td class="nump">6,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,586<span></span>
</td>
<td class="nump">9,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent', window );">Dividend paid out of earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,008)<span></span>
</td>
<td class="num">(4,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(382)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(382)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Issuance of restricted shares and vesting of existing restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans', window );">Employee share ownership plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">168<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">244<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions', window );">Tax effects on share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment', window );">Other changes in non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">186<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">69,031<span></span>
</td>
<td class="nump">68,681<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="num">(939)<span></span>
</td>
<td class="nump">63,013<span></span>
</td>
<td class="nump">4,405<span></span>
</td>
<td class="num">(857)<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for&#160;the&#160;period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,764<span></span>
</td>
<td class="nump">2,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,484<span></span>
</td>
<td class="nump">8,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,248<span></span>
</td>
<td class="nump">11,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent', window );">Dividend paid out of earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,168)<span></span>
</td>
<td class="num">(4,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent', window );">Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(793)<span></span>
</td>
<td class="num">(793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(497)<span></span>
</td>
<td class="num">(497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction in share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">35<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Issuance of restricted shares and vesting of existing restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans', window );">Employee share ownership plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">153<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">245<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions', window );">Tax effects on share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75,152<span></span>
</td>
<td class="nump">74,784<span></span>
</td>
<td class="nump">2,522<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="num">(706)<span></span>
</td>
<td class="nump">66,734<span></span>
</td>
<td class="nump">4,658<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income for&#160;the&#160;period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,603)<span></span>
</td>
<td class="num">(1,590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,513)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,436<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,833<span></span>
</td>
<td class="nump">3,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,513)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent', window );">Dividend paid out of earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,454)<span></span>
</td>
<td class="num">(4,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests', window );">Payment of dividends to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(59)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Share repurchase program</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(593)<span></span>
</td>
<td class="num">(593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedPaymentPlansAbstract', window );"><strong>Share-based payment plans:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">37<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares', window );">Issuance of restricted shares and vesting of existing restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans', window );">Employee share ownership plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">159<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees', window );">Value of services obtained from employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">283<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions', window );">Tax effects on share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity', window );">Other changes arising from issuance of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment', window );">Other changes in non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 74,353<span></span>
</td>
<td class="nump">&#8364; 74,040<span></span>
</td>
<td class="nump">&#8364; 2,530<span></span>
</td>
<td class="nump">&#8364; 313<span></span>
</td>
<td class="num">&#8364; (1,184)<span></span>
</td>
<td class="nump">&#8364; 67,499<span></span>
</td>
<td class="nump">&#8364; 4,944<span></span>
</td>
<td class="num">&#8364; (62)<span></span>
</td>
<td class="nump">&#8364; 313<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes the impacts of the IFRIC final agenda decisions of March&#160;2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April&#160;2021 on the attribution of benefits to periods of service, as described in Note&#160;A.2.1. to the consolidated financial statements for the year ended December&#160;31, 2021.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">See Notes&#160;D.15.1., D.15.3., D.15.4. and D.15.5.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">This line includes the use of existing shares to fulfill vested rights under restricted share plans.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">This line mainly comprises changes in non-controlling interests arising from divestments and acquisitions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">This amount includes the valuation of the shares distributed as a dividend in kind, at a price of &#8364;14.58 per share, as of May&#160;10, 2022 (see note&#160;D.2.1.).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">This line comprises the impact of the issuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control of EUROAPI.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners of the parent. [Refer: Parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReductionOfIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReductionOfIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through changes in non-controlling interests arising from divestment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through issuance of restricted shares, equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee share ownership plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax effects of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of services obtained from employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareBasedPaymentPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareBasedPaymentPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526681968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of changes in equity (Parenthetical) - &#8364; / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Dividends paid, ordinary shares per share (in EUR per share)</a></td>
<td class="nump">&#8364; 3.56<span></span>
</td>
<td class="nump">&#8364; 3.33<span></span>
</td>
<td class="nump">&#8364; 3.20<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidOrdinarySharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends paid per ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 34<br> -IssueDate 2023-01-01<br> -Paragraph 16A<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=34&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16A_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidOrdinarySharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518840112">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of cash flows - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from (used in) operating activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity', window );">Net income attributable to equity holders of Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 5,400<span></span>
</td>
<td class="nump">&#8364; 8,371<span></span>
</td>
<td class="nump">&#8364; 6,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod', window );">Share of undistributed earnings from investments accounted for using the&#160;equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">295<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset', window );">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,792<span></span>
</td>
<td class="nump">3,420<span></span>
</td>
<td class="nump">3,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Gains and losses on disposals of non-current assets, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(509)<span></span>
</td>
<td class="num">(711)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxExpense', window );">Net change in deferred taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(970)<span></span>
</td>
<td class="num">(578)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Net change in non-current provisions and other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(136)<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Cost of employee benefits (stock options and other share-based payments)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">283<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue', window );">Impact of the workdown of acquired inventories remeasured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss', window );">Other profit or loss items with no cash effect on cash flows generated by operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">283<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Operating cash flow before changes in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,494<span></span>
</td>
<td class="nump">11,233<span></span>
</td>
<td class="nump">9,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile profit (loss) [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">(Increase)/decrease in inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(840)<span></span>
</td>
<td class="num">(927)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">(Increase)/decrease in accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(397)<span></span>
</td>
<td class="num">(777)<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Increase/(decrease) in accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">402<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities', window );">Net change in other current assets and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,599<span></span>
</td>
<td class="nump">545<span></span>
</td>
<td class="nump">1,130<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash provided by/(used in) operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">10,258<span></span>
</td>
<td class="nump">10,526<span></span>
</td>
<td class="nump">10,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from (used in) investing activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets', window );">Acquisitions of property, plant and equipment and intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,024)<span></span>
</td>
<td class="num">(2,201)<span></span>
</td>
<td class="num">(2,043)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Acquisitions of consolidated undertakings and investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(3,870)<span></span>
</td>
<td class="num">(992)<span></span>
</td>
<td class="num">(5,594)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Acquisitions of other equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(134)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets', window );">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">1,488<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">42<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetChangeInOtherNonCurrentAssets', window );">Net change in other non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,200)<span></span>
</td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(7,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from (used in) financing activities [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Issuance of Sanofi shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">195<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DividendsPaidAbstract', window );"><strong>Dividends paid:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities', window );">to shareholders of Sanofi</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,454)<span></span>
</td>
<td class="num">(4,168)<span></span>
</td>
<td class="num">(4,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities', window );">to non-controlling interests, excluding BMS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries', window );">Payments received/(made) on changes of ownership interest in a subsidiary without loss of control</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Additional long-term debt contracted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,684)<span></span>
</td>
<td class="num">(2,718)<span></span>
</td>
<td class="num">(2,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayments of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(265)<span></span>
</td>
<td class="num">(291)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">765<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="num">(414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Acquisitions of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(593)<span></span>
</td>
<td class="num">(497)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,052)<span></span>
</td>
<td class="num">(5,821)<span></span>
</td>
<td class="num">(7,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Impact of exchange rates on cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net change in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,026)<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,736<span></span>
</td>
<td class="nump">10,098<span></span>
</td>
<td class="nump">13,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 8,710<span></span>
</td>
<td class="nump">&#8364; 12,736<span></span>
</td>
<td class="nump">&#8364; 10,098<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes non-current financial assets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">This line item includes contributions paid to pension funds (see Note&#160;D.19.1.).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Including:<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:56.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Income tax paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,623)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,452)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,280)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest paid</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(380)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest received</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Dividends received from non-consolidated entities</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2023, it includes the net cash outflow on the acquisitions of Provention Bio and QRIB (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note&#160;D.2.1.). For 2021, it includes the net cash outflows on the acquisitions of Kymab, Kiadis, Tidal, Translate Bio, Kadmon and Origimm (see Note&#160;D.2.2.).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For 2023, 2022 and 2021, this line item mainly comprises disposals of assets and activities related to portfolio streamlining and disposals of equity and debt instruments.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">For 2022, this line item includes the net cash inflows (before taxes) of &#8364;101&#160;million on the divestment of EUROAPI (see Note&#160;D.2.1.).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">For 2023, this line item includes &#8364;946&#160;million related to the US commercial paper program. For 2023, 2022 and 2021, it also includes realized foreign exchange differences on (i)&#160;cash and cash equivalents in non-functional currencies (primarily the US dollar) and (ii)&#160;derivative instruments used to manage such cash and cash equivalents.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for undistributed profits of investments accounted for using the equity method to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to equity holders of the parent, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to non-controlling interests, classified as financing activities. [Refer: Non-controlling interests; Dividends paid to non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsToReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 42A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_42A&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 42B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_42B&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for noncurrent provisions and other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DividendsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends Paid [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DividendsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetChangeInOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net change in other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetChangeInOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534512544">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of cash flows (Parenthetical) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income tax paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (2,623)<span></span>
</td>
<td class="num">&#8364; (2,452)<span></span>
</td>
<td class="num">&#8364; (1,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(559)<span></span>
</td>
<td class="num">(380)<span></span>
</td>
<td class="num">(334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">547<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities', window );">Dividends received from non-consolidated entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">765<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="num">&#8364; (414)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember', window );">Commercial paper program in USA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">For 2022, this line item includes the net cash inflows (before taxes) of &#8364;101&#160;million on the divestment of EUROAPI (see Note&#160;D.2.1.).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">For 2023, this line item includes &#8364;946&#160;million related to the US commercial paper program. For 2023, 2022 and 2021, it also includes realized foreign exchange differences on (i)&#160;cash and cash equivalents in non-functional currencies (primarily the US dollar) and (ii)&#160;derivative instruments used to manage such cash and cash equivalents.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends received from non-consolidated entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedCashFlowStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedCashFlowStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523645040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Introduction<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GeneralInformationAboutFinancialStatementsAbstract', window );"><strong>General Information About Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Introduction</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Introduction</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi, together with its subsidiaries (collectively &#8220;Sanofi&#8221;, &#8220;the Group&#8221; or &#8220;the Company&#8221;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements for the year ended December 31, 2023, and the notes thereto, were signed off by the Sanofi Board of Directors on</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> January&#160;31,&#160;2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GeneralInformationAboutFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General Information About Financial Statements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GeneralInformationAboutFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534445152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text">Basis of preparation<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.1. International financial reporting standards (IFRS)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements cover the twelve-month periods ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with Regulation No.&#160;1606/2002 of the European Parliament and Council of July&#160;19, 2002 on the application of&#160;international accounting standards, Sanofi has presented its consolidated financial statements in accordance with IFRS since&#160;January&#160;1, 2005. The term &#8220;IFRS&#8221; refers collectively to international accounting and financial reporting standards (IASs&#160;and&#160;IFRSs) and to interpretations of the interpretations committees (SIC and IFRIC) with mandatory application as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements of Sanofi as of December 31, 2023 have been prepared in compliance with IFRS as&#160;issued&#160;by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS as endorsed by the European Union as of December 31, 2023 are available under the heading &#8220;IFRS Financial Statements&#8221; via the following web&#160;link:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality, and aggregation.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.2. New standards, amendments and interpretations</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.1. New standards applicable from January 1, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following amendments are applicable from January&#160;1, 2023, and have had no material impact: &#8220;Disclosure of Accounting Policies&#8221; (amendment to IAS&#160;1); &#8220;Definition of Accounting Estimates&#8221; (amendment to IAS&#160;8); and &#8220;Deferred Tax Assets and Liabilities Arising from a Single Transaction&#8221; (amendment to IAS&#160;12).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;23, 2023, the IASB issued &#8220;International Tax Reform&#8212;Pillar Two Model Rules&#8221;, an immediately applicable amendment to&#160;IAS&#160;12 that was endorsed on November&#160;9, 2023. The amendment relates to the effects of the global minimum corporate income tax rate of 15% that will come into force in 2024, in accordance with the model framework of OECD Pillar Two.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The French Finance Bill for 2024 imposes a global minimum corporate income tax rate of 15% and introduces (i)&#160;a supplementary multinational tax and (ii)&#160;a supplementary national tax for annual accounting periods commencing on or after December&#160;31, 2023. Given that the legislation had not come into force as of December&#160;31, 2023, Sanofi is not liable for any current taxes in that&#160;respect. In addition, Sanofi has not recognized any deferred taxes associated with the minimum tax, in accordance with the&#160;temporary exemption available under the May&#160;2023 amendment to IAS&#160;12. At this stage, a material impact is expected in respect&#160;of Sanofi's operations in France and Singapore, because Sanofi&#8217;s average effective tax rate in those countries was less than 15% at the end of 2023. Other things being equal, applying the Pillar 2 rules in 2023 would have led to an increase of approximately 1.5&#160;percentage points in the effective tax rate based on the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS&#160;17 (Insurance Contracts), issued on May&#160;18, 2017 and applicable on or after January&#160;1, 2023, does not apply to the Sanofi consolidated financial statements because the insurance activities carried on by Sanofi&#8217;s captive insurance companies are internal within the Sanofi group (the sole policyholders being subsidiaries of Sanofi), and hence are eliminated on consolidation.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.2. New pronouncements issued by the IASB and applicable from 2024 or later</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This note describes standards, amendments and interpretations issued by the IASB that will have mandatory application in 2024 or subsequent years, and Sanofi&#8217;s position regarding future application.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;22, 2022, the IASB issued an amendment to IFRS&#160;16 (Leases), relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable at the earliest from January&#160;1, 2024;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> it will not have a material impact on the Sanofi financial statements, and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has not early adopted it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January&#160;23, 2020, the IASB issued &#8220;Classification of Liabilities as Current or Non-current&#8221;, an amendment to IAS&#160;1, and then on&#160;October&#160;31, 2022 issued &#8220;Non-current Liabilities with Covenants&#8221;, a further amendment to IAS&#160;1. The amendments are applicable at the earliest from January&#160;1, 2024; they will not have a material impact on the Sanofi financial statements, and Sanofi has not early adopted them.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS&#160;7 and IFRS&#160;7, which is applicable at the earliest from January&#160;1, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union) and which relates to disclosures of information about such arrangements. The amendment does not </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August&#160;15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS&#160;21 (The Effect of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable at the earliest from January&#160;1, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union); it</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.3. Use of estimates and judgments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date of the finalization of the financial statements. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions (see&#160;Notes&#160;B.13. and&#160;D.23.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment of property, plant and equipment and intangible assets (see Notes&#160;B.6. and D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the valuation of goodwill and the valuation and estimated useful life of acquired intangible assets (see Notes&#160;B.3.2., B.4., D.4. and&#160;D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of contingent consideration receivable in connection with asset divestments (see Notes&#160;B.8.5. and&#160;D.12.) and of contingent consideration payable (see Notes&#160;B.3. and&#160;D.18.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of financial assets and liabilities at amortized cost (see Note&#160;B.8.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of post-employment benefit obligations (see Notes&#160;B.23. and&#160;D.19.1.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks (see Notes&#160;B.12., B.19., B.20., D.19. and&#160;D.22.); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences (see Notes&#160;B.22. and&#160;D.14.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, Sanofi has also taken account of risks related to the effects of climate change and energy transition.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its Planet Care program, Sanofi has committed to move towards carbon neutrality by 2030 and net zero emissions by&#160;2045 for its Scope&#160;1, 2 and&#160;3 emissions. That involves:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">aiming for a 55% reduction in greenhouse gas (GHG) emissions from Sanofi&#8217;s own activities (Scopes&#160;1 &amp;&#160;2) and a 30% reduction in Scope&#160;3 GHG emissions by 2030 (versus a 2019 baseline), and a 90% reduction in GHG emissions (all scopes) by&#160;2045. These objectives have been validated by the Science Based Target initiative (STBi);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">supplying all our sites with 100% renewably-sourced electricity by 2030;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">promoting an eco-friendly vehicle fleet by 2030; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">engaging the Sanofi supply chain in reducing Scope&#160;3 emissions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The analysis of climate-related physical and transition risks facing Sanofi was updated in 2023 on the basis of three global warming scenarios out to 2030 and 2050. A number of assumptions &#8211; on issues such as carbon costs, natural disasters, water stress, raw material scarcity and logistics disruption &#8211; were built into this analysis, which also takes account of certain capital expenditures on mitigations derived from the Planet Care roadmap.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, that analysis was taken into account as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the value of intangible assets and property, plant and equipment was subject to impairment testing conducted at CGU level, as described in Note&#160;D.5. Certain climate-related assumptions, such as the evolution of energy costs, transitioning to sustainable agriculture, and waste management, are already built into the forecast used for impairment testing purposes. For those assumptions not yet built into budgets, sensitivity analyses can be performed as needed;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the periodic reviews conducted on the useful lives of property, plant and equipment take account of environmental regulatory constraints, including not only GHG emissions but also physical risks;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">environmental risks are covered by provisions on the basis described in Note&#160;D.19.3.; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the credit facilities available to Sanofi as of December&#160;31, 2023 incorporate performance objectives, including objectives related to cutting Sanofi&#8217;s carbon footprint, which could reduce the cost of debt if they are attained (see Note&#160;D.17.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is important to bear in mind that estimating climate change related risks involves an element of unpredictability. Uncertainties may arise from factors such as changes in government policy, rapid technological change, and varied responses from stakeholders. That high level of uncertainty adds complexity to assessment of the potential impacts on our operations, and to how those impacts are reflected in our budgets. Actual impacts on Sanofi&#8217;s profits and financial position could therefore differ from initial estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, in line with its environmental protection objectives, Sanofi has initiated projects to build eco-design into its products so as to limit their environmental impacts over their entire life cycle. Those projects will require Sanofi to redefine all of its production methods, and as such have also been built into definitions of the useful lives of Sanofi production facilities.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.4. Hyperinflation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi continued to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July&#160;1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100% based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January&#160;1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.5. Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;18, 2020, Sanofi and the US Department of Health and Human Services extended their research and development partnership to leverage Sanofi&#8217;s previous development work on a SARS vaccine to attempt to unlock a fast path forward for developing a COVID-19 vaccine. Under the terms of the collaboration, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services, is helping to fund the research and development undertaken by Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April&#160;14, 2020, Sanofi and GlaxoSmithKline (GSK) entered into a collaboration agreement to develop a recombinant COVID-19 vaccine candidate, with Sanofi contributing its S&#8209;protein COVID-19 antigen (based on recombinant DNA technology) and GSK contributing its pandemic adjuvant technology. Sanofi is leading clinical development and the registration process for the vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;31, 2020, the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK was selected by the US&#160;government&#8217;s Operation Warp Speed (OWS) program. Under the OWS, the US government is providing funds to support further development of the vaccine, including clinical trials and scaling-up of manufacturing capacity. Initially, the agreement also provided for the supply of 100&#160;million doses of the vaccine. In light of the evolving context of the pandemic (including variants of the virus) and the availability of vaccines on the market, the parties decided to review the initial supply contract. At the end of 2023, the agreement was amended in respect of the supply clause, confirming that Sanofi had fulfilled its contractual obligations and setting the amount of compensation paid to Sanofi. On the basis of that signed amendment, Sanofi recognized an amount of &#8364;411&#160;million within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; that amount was paid to Sanofi in December&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has recognized the funding received from the US government as a deduction from the development expenses incurred, in accordance with IAS&#160;20 (Accounting for Government Grants and Disclosure of Government Assistance).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of government aid received from the US federal government and BARDA and recognized </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a deduction from development expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and other operating expenses was &#8364;59&#160;million in 2023, compared with &#8364;265&#160;million in 2022 and &#8364;147&#160;million in 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2020, Sanofi and GSK signed pre-order contracts with the Canadian and UK governments and with the European Union for doses of the vaccine candidate. During 2021, Sanofi and GSK contractualized with the Canadian and UK governments and with the European Union on the number of doses ordered.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;15, 2021, Sanofi and GSK announced positive preliminary data on their COVID-19 booster vaccine candidate and indicated that their Phase&#160;3 trial was to continue, based on recommendations from an independent monitoring board.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November&#160;10, 2022, in line with the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, the European Commission approved VIDPREVTYN Beta vaccine as booster for the prevention of COVID-19 in adults aged 18&#160;years and older. Designed to provide broad protection against multiple variants, this protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK&#8217;s pandemic adjuvant. VIDPREVTYN</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Beta is indicated as a booster for active immunization against SARS-CoV-2 in adults who have previously received an mRNA or adenoviral COVID-19 vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;21, 2022, following the European Commission approval, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved VIDPREVTYN Beta vaccine for the prevention of COVID-19 in adults aged&#160;18 and over within the UK.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;15 (see Note&#160;B.13.1.), Sanofi recognizes revenue when control over the product is transferred to the customer (for vaccines, transfer of control is determined by reference to the terms of release and acceptance of batches of vaccine). Payments received subsequent to signature of vaccine pre-order contracts relating to doses not yet delivered are customer contract liabilities (i.e. an obligation for the entity to supply goods to a customer, for which consideration has been received from the customer). They are presented within &#8220;Customer contract liabilities&#8221; in the balance sheet (see Note&#160;D.19.5.), and within &#8220;Net change in other current assets and other current liabilities&#8221; in the statement of cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The pre-order contracts for Canada, the United Kingdom and the European Union expired in 2023. The customer contract liabilities, which amounted to &#8364;269&#160;million as of December&#160;31, 2022 and &#8364;319&#160;million as of&#160;December&#160;31,&#160;2021 (see Note&#160;D.19.5., &#8220;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Current provisions and other current liabilities&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) were released to profit or loss in 2023, including an amount of &#8364;94&#160;million classified in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other revenue</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in respect of doses which there was no longer an obligation to deliver as of December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534425008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policiesBasis of consolidation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;10 (Consolidated Financial Statements), the consolidated financial statements of Sanofi include the financial statements of entities that Sanofi controls directly or indirectly, regardless of the level of the equity interest in those entities. An entity is controlled when Sanofi has power over the entity, exposure or rights to variable returns from its involvement with the entity, and the ability to affect those returns through its power over the entity. In determining whether control exists, potential voting rights must be taken into account if those rights are substantive, in other words they can be exercised on a timely basis when decisions about the relevant activities of the entity are to be taken.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Entities consolidated by Sanofi are referred to as &#8220;subsidiaries&#8221;. Entities that Sanofi controls by means other than voting rights are referred to as &#8220;consolidated structured entities&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;11 (Joint Arrangements), Sanofi classifies its joint arrangements (i.e. arrangements in which Sanofi exercises joint control with one or more other parties) either as a joint operation (in which case, Sanofi recognizes the assets and liabilities of the operation in proportion to its rights and obligations relating to those assets and liabilities) or as a joint venture.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi exercises joint control over a joint arrangement when decisions relating to the relevant activities of the arrangement require the unanimous consent of Sanofi and the other parties with whom control is shared.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi exercises significant influence over an entity when it has the power to participate in the financial and operating policy decisions of that entity, but does not have the power to exercise control or joint control over those policies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), the equity method is used to account for joint ventures (i.e.&#160;entities over which Sanofi exercises joint control) and for associates (i.e. entities over which Sanofi exercises significant influence).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the equity method, the investment is initially recognized at cost, and subsequently adjusted to reflect changes in the net assets of the associate or joint venture. IAS&#160;28 does not specify the treatment to be adopted on first-time application of the equity method to an investee following a step acquisition. Consequently, by reference to paragraph&#160;10 of IAS&#160;28, Sanofi has opted to apply the cost method, whereby the carrying amount of the investment represents the sum of the historical cost amounts for each step in the acquisition. As of the date on which the equity method is first applied, goodwill (which is included in the carrying amount of the investment) is determined for each acquisition step. The same applies to subsequent increases in the percentage interest in the equity-accounted investment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the criteria of IFRS&#160;5 are met, Sanofi recognizes the equity interest within the balance sheet line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The equity method is not applied to equity interests that are classified as held-for-sale assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transactions between consolidated companies are eliminated, as are intragroup profits.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A list of the principal companies included in the consolidation in 2023 is presented in Note&#160;F.</span></div>Foreign currency translation<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.1. Accounting for foreign currency transactions in the financial statements of consolidated entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets (other than receivables) and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate prevailing at the acquisition date.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the end of the reporting period. The gains and losses resulting from foreign currency translation are recorded in the income statement. However, foreign exchange gains and losses arising from the translation of advances between consolidated subsidiaries for which settlement is neither planned nor likely to occur in the foreseeable future are recognized in equity, in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Change in currency translation differences.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.2. Foreign currency translation of the financial statements of foreign entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi presents its consolidated financial statements in euros (&#8364;). In accordance with IAS&#160;21 (The Effects of Changes in Foreign Exchange Rates), each subsidiary accounts for its transactions in the currency that is most representative of its economic environment (the functional currency).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All assets and liabilities are translated into euros using the exchange rate of the subsidiary&#8217;s functional currency prevailing at the end of the reporting period. Income statements are translated using a weighted average exchange rate for the period, except in the case of foreign subsidiaries in a hyperinflationary economy. The resulting currency translation difference is recognized as a separate component of equity in the consolidated statement of comprehensive income, and is recognized in the income statement only when the subsidiary is sold or is wholly or partially liquidated.</span></div>Business combinations and transactions with non-controlling interests<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.1. Accounting for business combinations, transactions with non-controlling interests and loss of control</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for in accordance with IFRS&#160;3 (Business Combinations) and IFRS&#160;10 (Consolidated Financial Statements).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method. Under this method, the acquiree&#8217;s identifiable assets and liabilities that satisfy the recognition criteria of IFRS&#160;3 (Business Combinations) are measured initially at their fair values at the date of acquisition, except for (i)&#160;non-current assets classified as held for sale (which are measured at fair value less costs to sell) and (ii)&#160;assets and liabilities that fall within the scope of IAS&#160;12 (Income Taxes) and IAS&#160;19 (Employee Benefits). Restructuring liabilities are recognized as a liability of the acquiree only if the acquiree has an obligation as of the acquisition date to carry out the restructuring.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal accounting rules applicable to business combinations and transactions with non-controlling interests include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">acquisition-related costs are recognized as an expense, as a component of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration is recognized in equity if the contingent payment is settled by delivery of a fixed number of&#160;the&#160;acquirer&#8217;s equity instruments; otherwise, it is recognized in liabilities related to business combinations. Contingent&#160;consideration is recognized at fair value at the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a financial liability, subsequent adjustments to the liability are recognized in profit&#160;or loss in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, unless the adjustment is made within&#160;the 12&#160;months following the acquisition date and relates to facts and circumstances existing as of that date;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">goodwill may be calculated on the basis of either (i)&#160;the entire fair value of the acquiree, or (ii)&#160;a share of the fair value of the acquiree proportionate to the interest acquired. This option is elected for each acquisition individually.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Purchase price allocations are performed under the responsibility of management, with assistance from an independent valuer in the case of major acquisitions. IFRS&#160;3 does not specify an accounting treatment for contingent consideration arising from a business combination made by an entity prior to the acquisition of control in that entity and carried as a liability in the acquired entity&#8217;s balance sheet. The accounting treatment applied by Sanofi to such a liability is to measure it at fair value as of the acquisition date and to report it in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, with subsequent remeasurements recognized in profit or loss. This treatment is consistent with the accounting applied to contingent consideration in the books of the&#160;acquirer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, management may where it deems fit elect to apply the optional test to identify concentration of fair value permitted under IFRS&#160;3 in order to determine whether a transaction is a business combination within the meaning of IFRS&#160;3, or merely the acquisition of an asset or of a group of similar assets.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.2. Goodwill</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The excess of the cost of an acquisition over Sanofi&#8217;s interest in the fair value of the identifiable assets and liabilities of the acquiree is recognized as goodwill at the date of the business combination. Goodwill arising on the acquisition of subsidiaries is shown in a separate balance sheet line item, whereas goodwill arising on the acquisition of investments accounted for using the equity method is recorded in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Investments accounted for using the equity method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill arising on foreign operations is expressed in the functional currency of the country concerned and translated into euros using the exchange rate prevailing at the end of the reporting period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;36 (Impairment of Assets), goodwill is carried at cost less accumulated impairment (see Note&#160;B.6.).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill is tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Such events or circumstances include significant changes more likely than not to have an other-than-temporary impact on the substance of the original investment.</span></div>Other intangible assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets are initially measured at acquisition cost or production cost, including any directly attributable costs of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. Intangible assets are amortized on a straight line basis over their useful&#160;lives.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The useful lives of other intangible assets are reviewed at the end of each reporting period. The effect of any adjustment to useful lives is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of other intangible assets is recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> except for amortization charged against (i)&#160;acquired or internally-developed software and (ii)&#160;other rights of an industrial or operational nature, which is recognized in the relevant classification of expense by function.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi does not own any intangible assets with an indefinite useful life, other than goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Intangible assets (other than goodwill) are carried at cost less accumulated amortization and accumulated impairment, if any, in accordance with IAS&#160;36 (see Note&#160;B.6.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.1. Research and development not acquired in a business combination</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internally generated research and development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS&#160;38, research expenses are recognized in profit or loss when incurred.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated development expenses are recognized as an intangible asset if, and only if, all the following six criteria can be demonstrated: (a)&#160;the technical feasibility of completing the development project; (b)&#160;Sanofi&#8217;s intention to complete the project; (c)&#160;Sanofi&#8217;s ability to use the project; (d)&#160;the probability that the project will generate future economic benefits; (e)&#160;the availability of adequate technical, financial and other resources to complete the project; and (f)&#160;the ability to measure the development expenditure reliably.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Due to the risks and uncertainties relating to regulatory approval and to the research and development process, the six criteria for capitalization are usually considered not to have been met until the product has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some industrial development expenses (such as those incurred in developing a second-generation synthesis process) are incurred after marketing approval has been obtained, in order to improve the industrial process for an active ingredient. To the extent that the six IAS&#160;38 criteria are considered as having been met, such expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as incurred. Similarly, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS&#160;38, in which case the related expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separately acquired research and development</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments for separately acquired research and development are capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that they meet the definition of an intangible asset: a resource that is (i)&#160;controlled by Sanofi, (ii)&#160;expected to provide future economic benefits for Sanofi, and (iii)&#160;identifiable (i.e.&#160;it is either separable or arises from contractual or legal rights). Under paragraph&#160;25 of&#160;IAS&#160;38, the first condition for capitalization (the probability that the expected future economic benefits from the asset will flow to the entity) is considered to be satisfied for separately acquired research and development. Consequently, upfront and milestone payments to third parties related to pharmaceutical products for which marketing approval has not yet been obtained are recognized as intangible assets, and amortized on a straight line basis over their useful lives beginning when marketing approval is&#160;obtained.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments under research and development arrangements relating to access to technology or to databases, and payments made to purchase generics dossiers, are also capitalized, and amortized over the useful life of the intangible asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subcontracting arrangements, payments for research and development services, and continuous payments under research and development collaborations which are unrelated to the outcome of that collaboration, are expensed over the service term.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.2. Other intangible assets not acquired in a business combination</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Licenses other than those related to pharmaceutical products and research projects, in particular software licenses, are capitalized at acquisition cost, including any directly attributable cost of preparing the software for its intended use. Software licenses are amortized on a straight line basis over their useful lives for Sanofi (<span style="-sec-ix-hidden:f-646">three</span> to five years).</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated costs incurred to develop or upgrade software are capitalized if the IAS&#160;38 recognition criteria are satisfied, and amortized on a straight line basis over the useful life of the software from the date on which the software is ready for use.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.3. Other intangible assets acquired in a business combination</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets acquired in a business combination (in-process research and development, technology platforms, and currently marketed products) that are reliably measurable are identified separately from goodwill, measured at fair value, and capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IFRS&#160;3 (Business Combinations) and IAS&#160;38 (Intangible Assets). The related deferred tax liability is also recognized if a deductible or taxable temporary difference exists.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In-process research and development acquired in a business combination is amortized on a straight line basis over its useful life from the date of receipt of marketing approval.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Rights to technology platforms and to products currently marketed by Sanofi are amortized on a straight line basis over their useful lives, determined (in particular for marketed products) on the basis of cash flow forecasts which take into account the patent protection period of the marketed product.</span></div>Property, plant and equipment owned and leased<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.1. Property, plant and equipment owned</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in&#160;the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent costs are not recognized as assets unless (i)&#160;it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii)&#160;the costs can be measured reliably.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the&#160;item.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they&#160;relate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The customary useful lives of property, plant and equipment are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;to&#160;40 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 to 15 years</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.2. Property, plant and equipment leased</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective from January&#160;1, 2019 leases contracted by Sanofi have been accounted for in accordance with IFRS&#160;16 (Leases). Sanofi recognizes a right-of-use asset and a lease liability for all of its lease contracts, except for (i)&#160;leases relating to low-value assets and&#160;(ii)&#160;short-term leases (12&#160;months or less). Payments made in respect of leases not recognized on the balance sheet are recognized as an operating expense on a straight line basis over the lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On commencement of a lease, the liability for future lease payments is discounted at the incremental borrowing rate, which is a risk-free rate adjusted to reflect the specific risk profile of each Sanofi entity. Because lease payments are spread over the lease term, Sanofi applies a discount rate based on the duration of those payments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The payments used to determine the liability for future lease payments exclude non-lease components, but include fixed payments that Sanofi expects to make to the lessor over the estimated lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After commencement of the lease, the liability for future lease payments is reduced by the amount of the lease payments made, and increased to reflect interest on the liability. In the event of a reassessment or modification of future lease payments, the lease liability is remeasured. The right-of-use asset &#8211;&#160;which is initially measured at cost including direct costs of the lessee, prepayments made at or prior to the commencement date, less lease incentives received and restoration costs&#160;&#8211; is depreciated on a straight line basis over the lease term, and tested for impairment as required.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi recognizes deferred taxes in respect of right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leasehold improvements are depreciated over their economic life, which is capped at the lease term as determined under&#160;IFRS&#160;16.</span></div>Impairment of property, plant and equipment, intangible assets, and&#160;investments accounted for using the equity method<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.1. Impairment of property, plant and equipment and intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;36 (Impairment of Assets), assets that generate separate cash flows and assets included in cash-generating units&#160;(CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. A&#160;CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS&#160;36, each CGU or group of CGUs to which goodwill is allocated must (i)&#160;represent the lowest level within the entity at which the goodwill is monitored for internal management purposes, and (ii)&#160;not be larger than an operating segment determined in accordance with IFRS&#160;8 (Operating Segments), before application of the IFRS&#160;8 aggregation criteria (see Note&#160;B.26.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Quantitative and qualitative indications of impairment (primarily relating to the status of the research and development portfolio, pharmacovigilance, patent litigation, and the launch of competing products) are reviewed at the end of each reporting period. If there is any internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset or CGU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets not yet available for use (such as capitalized in-process research and development), and CGUs or groups of CGUs that include goodwill, are tested for impairment annually whether or not there is any indication of impairment, and more frequently if any event or circumstance indicates that they might be impaired. Such assets are not amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When there is an internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. To determine value in use, Sanofi uses estimates of future cash flows generated by the asset or CGU, prepared using the same methods as those used in the initial measurement of the asset or CGU on the basis of medium-term strategic plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of goodwill, estimates of future cash flows are based on a six-year strategic plan and a terminal value. In the case of other intrangible assets, the period used is based on the economic life of the asset.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Estimated cash flows are discounted at long-term market interest rates that reflect the best estimate by Sanofi of the time value of money, the risks specific to the asset or CGU, and economic conditions in the geographical regions in which the business activity associated with the asset or CGU is located.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Certain assets and liabilities that are not directly attributable to a specific CGU are allocated between CGUs on a basis that is reasonable, and consistent with the allocation of the corresponding goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on property, plant and equipment, software and certain rights, are recognized within the appropriate income statement line item according to the origin of the impairment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on other intangible assets (products, trademarks, technology platforms, acquired R&amp;D) are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.2. Impairment of investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), Sanofi determines whether investments accounted for using the equity method may be impaired based on indicators such as default in contractual payments, significant financial difficulties, probability of bankruptcy, or a prolonged or significant decline in quoted market price. If an investment is impaired, the amount of the impairment loss is determined by applying IAS&#160;36 (see Note&#160;B.6.1.) and recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.3. Reversals of impairment losses charged against property, plant and equipment, intangible assets, and investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the end of each reporting period, Sanofi assesses whether events or changes in circumstances indicate that an impairment loss recognized in a prior period in respect of an asset (other than goodwill) or an investment accounted for using the equity method can be reversed. If this is the case, and the recoverable amount as determined based on the revised estimates exceeds the carrying amount of the asset, Sanofi reverses the impairment loss only to the extent of the carrying amount that would have been determined had no impairment loss been recognized for the asset.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reversals of impairment losses in respect of other intangible assets are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, while reversals of impairment losses in respect of investments accounted for using the equity method are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Impairment losses taken against goodwill are never reversed, unless the goodwill is part of the carrying amount of an investment accounted for using the equity method.</span></div>Assets held for sale or exchange and liabilities related to assets held for sale or exchange<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;5 (Non-Current Assets Held for Sale and Discontinued Operations), non-current assets and groups of assets are classified as held for sale in the balance sheet if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Within the meaning of IFRS&#160;5, the term &#8220;sale&#8221; also includes exchanges for other assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets or asset groups held for sale must be available for immediate sale in their present condition, subject only to terms that are usual and customary for sales of such assets, and a sale must be highly probable. Criteria used to determine whether a sale is highly probable include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the appropriate level of management must be committed to a plan to sell;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an active program to locate a buyer and complete the plan must have been initiated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">completion of the sale should be foreseeable within the 12&#160;months following the date of reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Before initial reclassification of the non-current asset (or asset group) to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent to reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held-for-sale assets or liabilities within the balance sheet line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Liabilities related to assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, provided that the disposal satisfies the IFRS&#160;5 classification criteria.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The profit or loss generated by a held-for-sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">represents a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is a subsidiary acquired exclusively with a view to resale.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;10, transactions between companies that are held for sale or treated as discontinued operations and other consolidated companies are eliminated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Events or circumstances beyond Sanofi&#8217;s control may extend the period to complete the sale or exchange beyond one year without precluding classification of the asset (or disposal group) in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that there is sufficient evidence that Sanofi remains committed to the planned sale or exchange. Finally, in the event of changes to a plan of sale that requires an asset no longer to be classified as held for sale, IFRS&#160;5 specifies the following treatment:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each asset is measured at the lower of (a)&#160;its carrying amount before the asset was reclassified as held for sale, adjusted for any depreciation, amortization or revaluation that would have been recognized if the asset had not been reclassified as held for sale, or&#160;(b)&#160;its recoverable amount at the date of reclassification;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the backlog of depreciation, amortization and impairment not recognized while non-current assets were classified as held for sale must be reported in the same income statement line item that was used to report impairment losses arising on initial reclassification of assets as held for sale and gains or losses arising on the sale of such assets. In the consolidated income statement, those impacts are reported within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the net income of a business previously classified as discontinued or as held for sale or exchange and reported on a separate line in the income statement must be reclassified and included in net income from continuing operations, for all periods presented;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in addition, segment information relating to the income statement and the statement of cash flows (acquisitions of non-current assets) must be disclosed in the notes to the financial statements in accordance with IFRS&#160;8 (Operating Segments), and must also be restated for all prior periods presented.</span></div>Financial instruments<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.1. Non-derivative financial assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;9 (Financial Instruments) and IAS&#160;32 (Financial Instruments: Presentation), Sanofi has adopted the classification of non-derivative financial assets described below. The classification used depends on (i)&#160;the characteristics of the contractual cash flows (i.e.&#160;whether they represent interest or principal) and (ii)&#160;the business model for managing the asset applied at the time of initial recognition.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through other comprehensive income</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments that Sanofi does not hold for trading purposes and that management has designated at &#8220;fair value through other comprehensive income&#8221; on initial recognition. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such instruments are derecognized, the previously-recognized changes in fair value remain within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as does the gain or loss on divestment. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through profit or loss</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration already carried in the books of an acquired entity or granted in connection with a business combination;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments whose contractual cash flows represent payments of interest and repayments of principal, which are managed with a view to selling the asset;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments that management has designated at &#8220;fair value through profit or loss&#8221; on initial recognition; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments: equity instruments that are not held for trading and which management did not designate at &#8220;fair value through other comprehensive income&#8221; on initial recognition, and instruments that do not meet the IFRS definition of &#8220;equity instruments&#8221;.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gains and losses arising from changes in fair value are recognized in profit or loss within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of equity investments in unquoted entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On initial recognition of an equity investment in an entity not quoted in an active market, the fair value of the investment is the acquisition cost. Cost ceases to be a representative measure of the fair value of an unquoted equity investment when Sanofi identifies significant changes in the investee, or in the environment in which it operates. In such cases, an internal valuation is carried out, based mainly on growth forecasts or by reference to similar transactions contracted with third parties.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets at amortized cost comprise instruments whose contractual cash flows represent payments of interest and repayments of principal and which are managed with a view to collecting cash flows. The main assets in this category are loans and receivables. They are presented within the line items</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Accounts receivable </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Cash and cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Loans with a maturity of more than 12&#160;months are presented in &#8220;Long-term loans and advances&#8221; within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. These financial assets are measured at amortized cost using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main assets involved are accounts receivable. Accounts receivable are initially recognized at the amount invoiced to the customer. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.2. Derivative instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that do not qualify for hedge accounting are initially and subsequently measured at fair value, with changes in fair value recognized in the income statement in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, depending on the nature of the underlying economic item which is hedged.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that qualify for hedge accounting are measured using the policies described in Note&#160;B.8.3. below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS&#160;13 (Fair Value Measurement) requires counterparty credit risk to be taken into account when measuring the fair value of financial instruments. That risk is estimated on the basis of observable, publicly-available statistical data.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy on offsetting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order for a financial asset and a financial liability to be presented as a net amount in the balance sheet under IAS&#160;32, there must be:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(a) a legally enforceable right to offset; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(b) the intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.3. Hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its overall market risk management policy, Sanofi enters into various hedging transactions involving derivative or non-derivative instruments; these may include forward contracts, currency swaps or options, interest rate swaps or options, cross-currency swaps, and debt placings or issues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such financial instruments are designated as hedging instruments and recognized using the hedge accounting principles of&#160;IFRS&#160;9 when (a)&#160;there is formal designation and documentation of the hedging relationship, of how the effectiveness of the hedging relationship will be assessed, and of the underlying market risk management objective and strategy; (b)&#160;the hedged item and the hedging instrument are eligible for hedge accounting; and (c)&#160;there is an economic relationship between the hedged item and the hedging instrument, defined on the basis of a hedge ratio that is consistent with the underlying market risk management strategy, and the residual credit risk does not dominate the value changes that result from that economic relationship.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A fair value hedge is a hedge of the exposure to changes in fair value of an asset, liability or firm commitment that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument and changes in fair value of the hedged item attributable to the hedged risk components are generally recognized in the income statement, within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, or within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flow hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A cash flow hedge is a hedge of the exposure to variability in cash flows from an asset, liability or highly probable forecast transaction that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for hedges related to operating activities, and within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cumulative changes in fair value of the hedging instrument previously recognized in equity are reclassified to the income statement when the hedged transaction affects profit or loss. Those reclassified gains and losses are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When a forecast transaction results in the recognition of a non-financial asset or liability, cumulative changes in the fair value of the hedging instrument previously recognized in equity are incorporated in the initial carrying amount of that asset or liability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss previously recognized in equity remains separately recognized in equity and is not reclassified to the income statement, or recognized as an adjustment to the initial cost of the related non-financial asset or liability, until the forecast transaction occurs. However, if Sanofi no longer expects the forecast transaction to occur, the cumulative gain or loss previously recognized in equity is recognized immediately in profit or loss.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedge of a net investment in a foreign operation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a hedge of a net investment in a foreign operation, changes in the fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. When the investment in the foreign operation is sold, the changes in the fair value of the hedging instrument previously recognized in equity are reclassified to the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its market risk management policy, Sanofi may designate currency options or interest rate options as hedging instruments, the effectiveness of which is measured on the basis of changes in intrinsic value. In such cases, the time value of the option is treated as a hedging cost and accounted for as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the option includes a component that is not aligned on the critical features of the hedged item, the corresponding change in the time value is taken to profit or loss;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">otherwise, the change in the time value is taken to equity within the statement of comprehensive income, and then:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a financial asset or liability, the change in the time value is reclassified to profit or loss symmetrically with the hedged item, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a non-financial asset or liability, the change in the time value is incorporated in the initial carrying amount of that asset or liability, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a period of time, the change in time value is reclassified to profit or loss on a straight line basis over the life of the hedging relationship.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of forward contracts and foreign exchange swaps, and of cross-currency swaps that qualify for hedge accounting on the basis of changes in spot rates, Sanofi may elect for each transaction to use the option whereby the premium/discount or foreign currency basis spread are treated in the same way as the time value of an option.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinuation of hedge accounting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Hedge accounting is discontinued when the eligibility criteria are no longer met (in particular, when the hedging instrument expires or is sold, terminated or exercised), or if there is a change in the market risk management objective of the hedging relationship.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.4. Non-derivative financial liabilities</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings and debt</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement over the term of the debt using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These line items record the fair value of (i)&#160;contingent consideration payable in connection with business combinations and (ii)&#160;commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adjustments to the fair value of commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests, are recognized in equity.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other non-derivative financial liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-derivative financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.5. Fair value of financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS&#160;13 (Fair Value Measurement) and IFRS&#160;7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt">level&#160;1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">level&#160;2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt">level&#160;3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS&#160;7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type&#160;of financial&#160;instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in<br/>fair&#160;value<br/>hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>technique</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>model</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest<br/>rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market&#160;price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost/Approach based on comparables</span></div></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the&#160;end of the reporting period using the method described in&#160;Note&#160;D.7.3.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value held&#160;to meet obligations under <br/>post-employment benefit plans</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than three&#160;months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the&#160;consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1., D.19.</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The liability for future lease payments is discounted using the&#160;incremental borrowing rate.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160; year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&gt;&#160;1&#160;year:&#160;</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160;year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid&#160;Money&#160;Market  and LIFFE interest rate futures</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&gt;&#160;1&#160;year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid&#160;Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present&#160;value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160; year:<br/>Mid&#160;Money Market and LIFFE interest rate futures<br/>&gt;&#160;1&#160;year: <br/>Mid Zero Coupon</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (CVRs)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (other than CVRs)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Under IAS&#160;32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note&#160;B.8.4.</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.6. Derecognition of financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets are derecognized when the contractual rights to cash flows from the asset have ended or have been transferred and when Sanofi has transferred substantially all the risks and rewards of ownership of the asset. If Sanofi has neither transferred nor retained substantially all the risks and rewards of ownership of a financial asset, it is derecognized if Sanofi does not retain control of the asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A financial liability is derecognized when Sanofi&#8217;s contractual obligations in respect of the liability are discharged, cancelled or extinguished.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.7. Risks relating to financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Market risks in respect of non-current financial assets, cash equivalents, derivative instruments and debt are described in the discussions of risk factors presented in Item&#160;3.D. and Item&#160;11. of Sanofi&#8217;s annual report on Form&#160;20-F for 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Credit risk is the risk that customers may fail to pay their debts. For a description of credit risk, refer to &#8220;We are subject to the risk of non-payment by our customers&#8221; within Item&#160;3.D. and Item&#160;11. of Sanofi&#8217;s annual report on Form&#160;20-F for 2023.</span></div>Inventories<div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories are measured at the lower of cost or net realizable value. Cost is calculated using the weighted average cost method or the first-in, first-out method, depending on the nature of the inventory.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cost of finished goods inventories includes costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the launch phase of a new product, any inventories of that product are written down to zero pending regulatory approval, other than in specific circumstances which make it possible to estimate that there is a high probability at the end of the reporting period that the carrying amount of the inventories will be recoverable. The write-down is reversed once it becomes highly probable that marketing approval will be obtained.</span></div>Cash and cash equivalents<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash and cash equivalents as shown in the consolidated balance sheet and statement of cash flows comprise cash, plus liquid short-term investments that are&#160;readily convertible into cash and are&#160;subject to an insignificant risk of changes in value in the event of movements in interest rates.</span></div>Treasury shares<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;32, Sanofi treasury shares are deducted from equity, irrespective of the purpose for which they are held. No gain or loss is recognized in the income statement on the purchase, sale, impairment or cancellation of treasury shares.</span></div>Provisions for risks<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;37 (Provisions, Contingent Liabilities and Contingent Assets), Sanofi records a provision when it has a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If the obligation is expected to be settled more than 12&#160;months after the end of the reporting period, or has no definite settlement date, the provision is recorded within Non-current provisions and other non-current liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions relating to the insurance programs in which Sanofi&#8217;s captive insurance company participates are based on risk exposure estimates calculated by management, with assistance from independent actuaries, using IBNR (Incurred But Not Reported) techniques. Those techniques use past claims experience, within Sanofi and in the market, to estimate future trends in the cost of&#160;claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow of economic resources is&#160;remote.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi estimates provisions on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management&#8217;s knowledge at the date of preparation of the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reimbursements offsetting the probable outflow of resources are recognized as assets only if it is virtually certain that they will be received. Contingent assets are not recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring provisions are recognized if Sanofi has a detailed, formal restructuring plan at the end of the reporting period and has announced its intention to implement this plan to those affected by it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No provisions are recorded for future operating losses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi records non-current provisions for certain obligations, such as legal or constructive obligations, where an outflow of resources is probable and the amount of the outflow can be reliably estimated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of environmental risks, including at sites where operations are ongoing, Sanofi recognizes a provision where there is a violation of integrity in respect of human health or the environment resulting from past contamination at a site that requires remediation. The amount of the provision is a best estimate of the future expenditures to be incurred on the remediation plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Where the effect of the time value of money is material, those provisions are measured at the present value of the expenditures expected to be required to settle the obligation, calculated using a discount rate that reflects an estimate of the time value of money and the risks specific to the obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Increases in provisions to reflect the effects of the passage of time are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>Revenue recognition<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.1. Net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenue arising from the sale of goods is presented in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Net sales comprise revenue from sales of pharmaceutical products, consumer healthcare products, active ingredients and vaccines, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. Analyses of net sales are provided in Note&#160;D.35.1. &#8220;Segment Information&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;15 (Revenue from Contracts with Customers), such revenue is recognized when Sanofi transfers control over the product to the customer; control of an asset refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from that asset. For the vast majority of contracts, revenue is recognized when the product is physically transferred, in accordance with the delivery and acceptance terms agreed with the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For contracts entered into by Sanofi Pasteur, transfer of control is usually determined by reference to the terms of release (immediate or deferred) and acceptance of batches of vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of contracts with distributors, Sanofi does not recognize revenue when the product is physically transferred to the distributor if the products are sold on consignment, or if the distributor acts as agent. In such cases, revenue is recognized when control is transferred to the end customer, and the distributor&#8217;s commission is presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects the various types of price reductions or rights of return offered by Sanofi to its customers on certain products. Such price reductions and rights of return qualify as variable consideration under IFRS&#160;15.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In particular, products sold in the United States are covered by various Government and State programs (such as Medicare and Medicaid) under which products are sold at a discount. Rebates are granted to healthcare authorities, and under contractual arrangements with certain customers. Some wholesalers are entitled to chargeback incentives based on the selling price to the end customer, under specific contractual arrangements. Cash discounts may also be granted for prompt payment. Returns, discounts, incentives and rebates, as described above, are recognized in the period in which the underlying sales are recognized as a reduction of gross sales.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These amounts are calculated as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of chargeback incentives is estimated on the basis of the relevant subsidiary&#8217;s standard sales terms and conditions, and in certain cases on the basis of specific contractual arrangements with the customer;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of rebates based on attainment of sales targets is estimated and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of price reductions under Government and State programs, largely in the United States, is estimated on the basis of the specific terms of the relevant regulations or agreements, and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of sales returns is calculated on the basis of management&#8217;s best estimate of the amount of product that will ultimately be returned by customers. In countries where product returns are possible, Sanofi operates a returns policy that allows the customer to return products within a certain period either side of the expiry date (usually 12&#160;months after the expiry date). The amount recognized for returns is estimated on the basis of past experience of sales returns. Sanofi also takes into account factors such as levels of inventory in its various distribution channels, product expiry dates, information about potential discontinuation of products, the entry of competing generics into the market, and the launch of over-the-counter medicines. Most product return clauses relate solely to date-expired products, which cannot be resold and are destroyed. Sanofi does not recognize a right of return asset in the balance sheet for contracts that allow for the return of time-expired products, since those products have no value.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The estimated amounts described above are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a reduction of gross sales, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the balance sheet. They are subject to regular review and adjustment as appropriate based on the most recent data available to management. Sanofi believes that it has the ability to measure each of the above amounts reliably, using the following factors in developing its estimates:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the nature and patient profile of the underlying product;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the applicable regulations or the specific terms and conditions of contracts with governmental authorities, wholesalers and other customers;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">historical data relating to similar contracts, in the case of qualitative and quantitative rebates and chargeback incentives;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">past experience and sales growth trends for the same or similar products;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actual inventory levels in distribution channels, monitored by Sanofi using internal sales data and externally provided data;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the shelf life of Sanofi products; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market trends including competition, pricing and demand.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of provisions for discounts, rebates and sales returns is provided in Note&#160;D.23.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.2. Other revenues</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is used to recognize all revenue that falls within the scope of IFRS&#160;15 but does not relate to sales of Sanofi products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It mainly comprises (i)&#160;royalties received from licensing intellectual property rights to third parties; (ii)&#160;VaxServe sales of products sourced from third-party manufacturers; and (iii)&#160;revenue received under agreements for Sanofi to provide manufacturing services to third parties.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Royalties received under licensing arrangements are recognized over the period during which the underlying sales are recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VaxServe is a Vaccines segment entity whose operations include the distribution within the United States of vaccines and other&#160;products manufactured by third parties. VaxServe sales of products sourced from third-party manufacturers are presented within&#160;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>Cost of sales<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> consists primarily of the industrial cost of goods sold, payments made under licensing agreements, and distribution costs. The industrial cost of goods sold includes the cost of materials, depreciation of property, plant and equipment, amortization of software, personnel costs, and other expenses attributable to production.</span></div>Research and development<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note&#160;B.4.1. &#8220;Research and development not acquired in a business combination&#8221; and Note&#160;B.4.3. &#8220;Other intangible assets acquired in a business combination&#8221; describe the principles applied to the recognition of research and development costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contributions or reimbursements received from alliance partners are recorded as a reduction of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>Other operating income and expenses<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16.1. Other operating income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the share of profits that Sanofi is entitled to receive from alliance partners in respect of product marketing agreements. It also includes revenues generated under certain agreements, which may include partnership, co-promotion arrangements and licenses not included in Other revenues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item also includes realized and unrealized foreign exchange gains and losses on operating activities (see Note&#160;B.8.3.), and operating gains on disposals not regarded as major disposals (see Note&#160;B.20.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16.2. Other operating expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise the share of profits that alliance partners are entitled to receive from Sanofi under product marketing agreements.</span></div>Amortization and impairment of intangible assets<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.1. Amortization of intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The expenses recorded in this line item comprise amortization charged against intangible assets (products, trademarks and technology platforms, see Note&#160;D.4.) whose contribution to Sanofi&#8217;s commercial, industrial and development functions cannot be separately identified.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of software, and of other rights of an industrial or operational nature, is recognized as an expense in the income statement, in the relevant line items of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.2. Impairment of intangible assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item records impairment losses taken against intangible assets (products, trademarks, technology platforms and acquired research), and any reversals of such impairment losses.</span></div>Fair value remeasurement of contingent consideration<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in the fair value of contingent consideration that was (i)&#160;already carried in the books of an acquired entity, or (ii)&#160;granted in connection with a business combination and initially recognized as a liability in accordance with IFRS&#160;3, are reported in profit or loss. Such adjustments are reported separately in the income statement, in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item also includes changes in the fair value of contingent consideration receivable in connection with a divestment and classified as a financial asset at fair value through profit or loss.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, it includes the effect of the unwinding of discount, and of exchange rate movements where the asset or liability is expressed in a currency other than the functional currency of the reporting entity.</span></div>Restructuring costs and similar items<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring costs are expenses incurred in connection with the transformation or reorganization of Sanofi&#8217;s operations or support functions. Such costs include collective redundancy plans, compensation to third parties for early termination of contracts, and commitments made in connection with transformation or reorganization decisions. They also include accelerated depreciation charges arising from site closures (including closures of leased sites), and losses on asset disposals resulting from such decisions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, this line item includes expenses incurred in connection with programs implemented as part of the transformation strategy announced in December&#160;2019 (and previously in November&#160;2015), and intended primarily (i)&#160;to deliver a global information systems solution, further supported by the implementation from 2021 of Sanofi&#8217;s new digital strategy; and (ii)&#160;to create a standalone CHC entity and proceed to the proposed separation of the CHC business as announced when the new chapter in the Play to Win strategy was presented in October&#160;2023.</span></div>Other gains and losses, and litigation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the impact of material transactions of an unusual nature or amount which Sanofi believes it necessary to report separately in the income statement in order to improve the relevance of the financial statements, such as:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gains and losses on major disposals of property, plant and equipment, of intangible assets, of assets (or groups of assets and liabilities) held for sale, or of a business within the meaning of IFRS&#160;3, other than those considered to be restructuring costs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment losses and reversals of impairment losses on assets (or groups of assets and liabilities) held for sale, other than those considered to be restructuring costs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gains on bargain purchases;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">costs relating to major litigation; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">pre-tax separation costs associated with the process of disinvesting from operations in the event of a major divestment.</span></div>Financial expenses and income<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.1. Financial expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise interest charges on debt financing; negative changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange losses on financing and investing activities; impairment losses on financial instruments; and any reversals of impairment losses on financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> also include expenses arising from the unwinding of discount on long-term provisions, and the net interest cost related to employee benefits. This line item does not include commercial cash discounts, which are deducted from net sales.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.2. Financial income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes interest and dividend income; positive changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange gains on financing and investing activities; and gains on disposals of financial assets at fair value through profit or loss.</span></div>Income tax expense<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">includes all current and deferred taxes of consolidated companies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi accounts for deferred taxes in accordance with IAS&#160;12 (Income Taxes), using the methods described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are recognized on taxable and deductible temporary differences, and on tax loss carry-forwards. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">French business taxes include a value added based component: &#8220;CVAE&#8221; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cotisation sur la Valeur Ajout&#233;e des Entreprises)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Given that CVAE is (i)&#160;calculated as the amount by which certain revenues exceed certain expenses and (ii)&#160;borne primarily by companies that own intellectual property rights on income derived from those rights (royalties, and margin on sales to third parties and to Sanofi entities), it is regarded as meeting the definition of income taxes specified in IAS&#160;12, paragraph&#160;2 (&#8220;taxes which are based on taxable profits&#8221;);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are calculated using the tax rate expected to apply in the period when the corresponding temporary differences are expected to reverse, based on tax rates enacted or substantively enacted at the end of the reporting period;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets are recognized in respect of deductible temporary differences, tax losses available for carry-forward and unused tax credits to the extent that future recovery is regarded as probable. The recoverability of deferred tax assets is assessed on a case-by-case basis, taking into account the profit forecasts contained in Sanofi&#8217;s medium-term business plan;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a deferred tax liability is recognized for temporary differences relating to interests in subsidiaries, associates and joint ventures, except in cases where Sanofi is able to control the timing of the reversal of the temporary differences. This applies in particular when Sanofi is able to control dividend policy and it is probable that the temporary differences will not reverse in the foreseeable future;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">no deferred tax is recognized on eliminations of intragroup transfers of interests in subsidiaries, associates or joint ventures;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each tax entity calculates its own net deferred tax position. All net deferred tax asset and liability positions are then aggregated and shown in separate line items on the relevant side of the consolidated balance sheet. Deferred tax assets and liabilities are offset only if (i)&#160;Sanofi has a legally enforceable right to offset current tax assets and current tax liabilities, and (ii)&#160;the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred taxes are not discounted, except implicitly in the case of deferred taxes on assets and liabilities which are already impacted by discounting. In addition, Sanofi has elected not to discount current taxes payable or receivable where the amounts in question are payable or receivable in the long term;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">withholding taxes on intragroup royalties and dividends, and on royalties and dividends collected from third parties, are accounted for as current income taxes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accounting for business combinations, Sanofi complies with IFRS&#160;3 as regards the recognition of deferred tax assets after the initial accounting period. Consequently, any deferred tax assets recognized by the acquiree after the end of that period in respect of temporary differences or tax loss carry-forwards existing at the acquisition date are recognized in profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The positions adopted by Sanofi in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, Sanofi assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of Sanofi&#8217;s best estimate and recognized as a liability; uncertain tax assets are not recognized. The amount of the liability includes any penalties and late payment interest. The line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Income tax expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the effects of tax reassessments and tax disputes, and any penalties and late payment interest arising from such disputes that have the characteristics of income taxes within the meaning of paragraph&#160;2 of IAS&#160;12 (&#8220;taxes which are based on taxable profits&#8221;). Tax exposures relating to corporate income taxes are presented separately within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current income tax liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (see Note&#160;D.19.4.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No deferred taxation is recognized on temporary differences that are liable to be subject to US global intangible low taxed&#160;income (GILTI) provisions. The related tax expense is recognized in the year in which it is declared in the tax return to the extent that it arises from the existence of non-US profits that exceed the theoretical return on investment specified in the GILTI&#160;provisions and are taxed at a rate lower than the applicable US tax rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;1 (Presentation of Financial Statements), current income tax assets and liabilities are presented as separate line items in the consolidated balance sheet.</span></div>Employee benefit obligations<div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi offers retirement benefits to employees and retirees. Such benefits are accounted for in accordance with IAS&#160;19 (Employee Benefits).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Benefits are provided in the form of either defined contribution plans or defined benefit plans. In the case of defined contribution plans, the cost is recognized immediately in the period in which it is incurred, and equates to the amount of the contributions paid by Sanofi. For defined benefit plans, Sanofi generally recognizes its obligations to pay pensions and similar benefits to employees as a liability, based on an actuarial estimate of the rights vested or currently vesting in employees and retirees, using the projected unit credit method. Estimates are performed at least once a year, and rely on financial assumptions (such as discount </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">rates) and demographic assumptions (such as life expectancy, retirement age, employee turnover, and the rate of salary increases).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Obligations relating to other post-employment benefits (healthcare and life insurance) offered by Sanofi companies to employees are also recognized as a liability based on an actuarial estimate of the rights vested or currently vesting in employees and retirees at the end of the reporting period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such liabilities are recognized net of the fair value of plan assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of multi-employer defined benefit plans where plan assets cannot be allocated to each participating employer with sufficient reliability, the plan is accounted for as a defined contribution plan, in accordance with paragraph&#160;34 of IAS&#160;19.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The benefit cost for the period consists primarily of current service cost, past service cost, net interest cost, gains or losses arising from plan settlements not specified in the terms of the plan, and actuarial gains or losses arising from plan curtailments. Net interest cost for the period is determined by applying the discount rate specified in IAS&#160;19 to the net liability (i.e. the amount of the obligation, net of plan assets) recognized in respect of defined benefit plans. Past service cost is recognized immediately in profit or loss in the period in which it is incurred, regardless of whether or not the rights have vested at the time of adoption (in&#160;the case of a new plan) or of amendment (in&#160;the case of an existing&#160;plan).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses on defined benefit plans (pensions and other post-employment benefits), also referred to as&#160;&#8220;Remeasurements of the net defined benefit liability (asset)&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> arise as a result of changes in financial and demographic assumptions, experience adjustments, and the difference between the actual return and interest cost on plan assets. The impacts of those remeasurements are recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net of deferred taxes; they are not subsequently reclassifiable to profit or&#160;loss.</span></div>Share-based payment<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Share-based payment expense is recognized as a component of operating income, in the relevant classification of expense by function. In measuring the expense, the level of attainment of any performance conditions is taken into account.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.1. Stock option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has granted a number of equity-settled share-based payment plans (stock option plans) to some of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;2 (Share-Based Payment), services received from employees as consideration for stock options are recognized as an expense in the income statement, with the opposite entry recognized in equity. The expense corresponds to the fair value of the stock option plans, and is charged to income on a straight-line basis over the four-year vesting period of the plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of stock option plans is measured at the date of grant using the Black-Scholes valuation model, taking into account the expected life of the options. The resulting expense also takes into account the expected cancellation rate of the options. The expense is adjusted over the vesting period to reflect actual cancellation rates resulting from option-holders ceasing to be employed by Sanofi.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.2. Employee share ownership plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may offer its employees the opportunity to subscribe to reserved share issues at a discount to the reference market price. Shares awarded to employees under such plans fall within the scope of IFRS&#160;2. Consequently, an expense is recognized at the subscription date, based on the value of the discount offered to employees.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.3. Restricted share plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may award restricted share plans to certain of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;2, an expense equivalent to the fair value of such plans is recognized in profit or loss on a straight line basis over the vesting period of the plan, with the opposite entry recognized in equity. The vesting period is three years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of restricted share plans is based on the quoted market price of Sanofi shares at the date of grant, adjusted for expected dividends during the vesting period; it also takes account of any vesting conditions contingent on stock market performance, measured using the Monte-Carlo valuation model. Other vesting conditions are taken into account in the estimate of the number of shares awarded during the vesting period; that number is then definitively adjusted based on the actual number of shares awarded on the vesting date.</span></div>Earnings per share<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares outstanding during the reporting period, adjusted on a time-weighted basis from the acquisition date to reflect the number of own shares held by Sanofi. Diluted earnings per share is calculated on the basis of the weighted average number of ordinary shares, computed using the treasury stock method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This method assumes that (i)&#160;all outstanding dilutive options and warrants are exercised, and (ii)&#160;Sanofi acquires its own shares at the quoted market price for an amount equivalent to the cash received as consideration for the exercise of the options or warrants, plus the expense arising on unamortized stock options.</span></div>Segment information<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Sanofi Business Services,&#160;etc.), which are mainly managed centrally at group-wide level, were presented within the &#8220;Other&#8221; category. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in&#160;order to reflect (i)&#160;progress on the &#8220;Play to Win&#8221; strategy leading to the creation of the standalone Consumer Healthcare Global&#160;Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its&#160;own&#160;dedicated global support functions (including Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Global Business Services,&#160;etc.); and (ii)&#160;organizational changes to Sanofi&#8217;s Manufacturing &amp; Supply global function (previously known as Industrial Affairs). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, with effect from January&#160;1, 2023, Sanofi reports two operating segments: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#8217;s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment&#8217;s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Information about operating segments for the years ended December 31, 2023, 2022 and 2021 is presented in Note&#160;D.35</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">., </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Segment information&#8221;.</span></div>Management of capital<div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to maintain or adjust the capital structure, Sanofi can adjust the amount of dividends paid to shareholders, repurchase its own shares, issue new shares, or issue securities giving access to its capital.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following objectives are defined under the terms of Sanofi&#8217;s share repurchase programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the implementation of any stock option plan giving entitlement to purchase shares in the Sanofi parent company;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the allotment or sale of shares to employees under statutory profit sharing schemes and employee savings plans;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the consideration-free allotment of shares (i.e. restricted share plans);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the cancellation of some or all of the repurchased shares;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market-making in the secondary market by an investment services provider under a liquidity contract in compliance with the ethical code recognized by the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Autorit&#233; des march&#233;s financiers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (AMF);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares on the exercise of rights attached to securities giving access to the capital by redemption, conversion, exchange, presentation of a warrant or any other means;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares (in exchange, as payment, or otherwise) in connection with mergers and acquisitions;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the execution by an investment services provider of purchases, sales or transfers by any means, in particular via off-market trading; or</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.1pt">any other purpose that is or may in the future be authorized under the applicable laws and regulations.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is not subject to any constraints on equity capital imposed by third parties.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total equity includes </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Equity attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Equity attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as shown in the consolidated balance sheet.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi defines &#8220;Net debt&#8221; as (i)&#160;the sum of short-term debt, long-term debt and interest rate derivatives and currency derivatives used to hedge debt, minus (ii)&#160;the sum of cash and cash equivalents and interest rate derivatives and currency derivatives used to hedge cash and cash equivalents.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523952368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal alliances<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesTextBlock', window );">Principal alliances</a></td>
<td class="text">Principal alliances<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.1. Alliance arrangements with Regeneron Pharmaceuticals,&#160;Inc. (Regeneron)</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Collaboration agreements on human therapeutic antibodies</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In November&#160;2007, Sanofi and Regeneron signed two agreements (amended in November&#160;2009) relating to human therapeutic antibodies: (i)&#160;the Discovery and Preclinical Development Agreement, and (ii)&#160;the License and Collaboration Agreement, relating to clinical development and commercialization. Under the License and Collaboration Agreement, Sanofi had an option to develop and commercialize antibodies discovered by Regeneron under the Discovery and Preclinical Development Agreement.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discovery and development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because Sanofi decided not to exercise its option to extend the Discovery and Preclinical Development Agreement, that agreement expired on December&#160;31, 2017.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a result of Sanofi&#8217;s exercise of an option with respect to an antibody under the Discovery and Preclinical Development Agreement, such antibody became a &#8220;Licensed Product&#8221; under the License and Collaboration Agreement, pursuant to which Sanofi and Regeneron co-develop the antibody with Sanofi initially being wholly responsible for funding the development program. On receipt of the first positive Phase 3 trial results for any antibody being developed under the License and Collaboration Agreement, the subsequent development costs for that antibody are split 80% Sanofi, 20% Regeneron. Amounts received from Regeneron under the License and Collaboration Agreement are recognized by Sanofi as a reduction in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Co-development with Regeneron of the antibodies DUPIXENT, KEVZARA and REGN3500 (SAR440340 - itepekimab) is ongoing under the License and Collaboration Agreement as of December&#160;31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Once a product begins to be commercialized, and provided that the share of quarterly results under the agreement represents a profit, Sanofi is entitled to an additional portion of Regeneron&#8217;s profit-share (capped at 20% of Regeneron&#8217;s share of quarterly profits since April&#160;1, 2022, and at 10% until March&#160;31, 2022) until Regeneron has paid 50% of the cumulative development costs incurred by the parties in the collaboration (see Note&#160;D.21.1.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On the later of (i)&#160;24 months before the scheduled launch date or (ii)&#160;the first positive Phase&#160;3 trial results, Sanofi and Regeneron share the commercial expenses of the antibodies co-developed under the License and Collaboration Agreement.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is the lead party with respect to the commercialization of all co-developed antibodies, and Regeneron has certain option rights to co-promote the antibodies. Regeneron has exercised its co-promotion rights in the United States and in certain other countries. Sanofi recognizes all sales of the antibodies. Profits and losses arising from commercial operations in the United States are split 50/50. Outside the United States, Sanofi is entitled to between 55% and 65% of profits depending on sales of the antibodies, and bears 55% of any losses. The share of profits and losses due to or from Regeneron under the agreement is recognized within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, which are components of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, Regeneron is entitled to receive payments contingent on the attainment of specified levels of aggregate sales on all antibodies outside the United States, on a rolling twelve-month basis. A liability for those payments is recognized on the balance sheet when it is probable that the specified level of aggregate sales will be met. The opposite entry for that liability is capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> on the balance sheet. Two payments of $50&#160;million each were made in 2022, following attainment first of $2.0&#160;billion and then of $2.5&#160;billion in sales of all antibodies outside the United States on a rolling twelve-month basis. The final milestone payment of $50&#160;million, payable to Regeneron in the event that $3.0&#160;billion in sales on a rolling twelve-month basis is attained, was made in 2023.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendments to the collaboration agreements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January&#160;2018, Sanofi and Regeneron signed a set of amendments to their collaboration agreements, including an amendment that allowed for the funding of additional programs on DUPIXENT and REGN3500 (SAR440340 &#8211; itepekimab) with an intended focus on extending the current range of indications, finding new indications, and improving co-morbidity between multiple pathologies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective April&#160;1, 2020, Sanofi and Regeneron signed a Cross License and Commercialization Agreement for PRALUENT, whereby Sanofi obtained sole ex-US rights to PRALUENT, and Regeneron obtained sole US rights to PRALUENT along with a right to 5% royalties on Sanofi&#8217;s sales of PRALUENT outside the United States. Each party is solely responsible for funding the development, manufacturing and commercialization of PRALUENT in their respective territories. Although each party has sole responsibility for supplying PRALUENT in its respective territory, Sanofi and Regeneron entered into agreements to support manufacturing needs for each other.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective September&#160;30, 2021, Sanofi and Regeneron signed an amendment to their collaboration agreement in order to specify allocations of responsibilities and associated resources between the two parties in connection with the co-promotion of&#160;DUPIXENT in certain countries. The terms of the collaboration relating to REGN3500 (SAR440340 &#8211; itepekimab) are unchanged.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective July&#160;1, 2022, Sanofi and Regeneron signed an amendment to their collaboration agreement in order to increase the additional portion of Regeneron&#8217;s quarterly profit-share attributable to Sanofi from 10% to 20% with retroactive impact as of April&#160;1, 2022.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Immuno-oncology (IO) collaboration agreements</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;1, 2015, Sanofi and Regeneron signed two agreements &#8211;&#160;the IO Discovery and Development Agreement and the IO License and Collaboration Agreement (IO LCA)&#160;&#8211; relating to new antibody cancer treatments in the field of immuno-oncology.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Amended IO Discovery Agreement, effective from December&#160;31, 2018, was terminated through a Letter Amendment dated March&#160;16,&#160;2021 in which Sanofi formalized its opt-out from the BCMAxCD3 and MUC16xCD3 programs. </span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIBTAYO</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(cemiplimab)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the 2015 IO LCA as amended in January&#160;2018, Sanofi and Regeneron committed funding of no more than $1,640 million, split on a&#160;50/50 basis ($820 million per company), for the development of REGN2810 (cemiplimab, trademark LIBTAYO), a PD-1 inhibitor antibody. The funding was raised to $1,840&#160;million by way of amendment effective on September&#160;30, 2021. Regeneron was responsible for the commercialization of LIBTAYO in the United States, and Sanofi in all other territories. Sanofi has exercised its option to co-promote LIBTAYO in the United States. In 2021, Regeneron exercised its option to co-promote LIBTAYO in certain other countries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The IO LCA also provided for a one-time milestone payment of $375 million by Sanofi to Regeneron in the event that sales of a PD-1 product were to exceed, in the aggregate, $2 billion in any consecutive 12-month period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the IO LCA Sanofi and Regeneron shared equally in profits and losses generated by the commercialization of collaboration products, except that Sanofi was entitled to an additional portion of Regeneron&#8217;s profit-share (capped at 10% of Regeneron&#8217;s share of quarterly profits) until Regeneron had paid 50% of the cumulative development costs incurred by the parties under the IO Discovery Agreement, as amended.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">LIBTAYO is approved in the United States and Europe for the treatment of two types of locally advanced or metastatic skin cancer (cutaneous squamous cell carcinoma and basal cell carcinoma) and non-small cell lung cancer (NSCLC). It is also approved in Brazil and Canada as a second line treatment for recurring or metastatic cervical cancer. In the fourth quarter of 2022, it was approved in the United States in association with chemotherapy for the treatment of NSCLC, and in Europe and Japan as a second line treatment for recurring or metastatic cervical cancer. LIBTAYO is currently approved in more than 30&#160;countries.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2022, Sanofi and Regeneron restructured their IO LCA. Under the terms of the Amended and Restated IO LCA, Regeneron holds exclusive worldwide licensing rights to LIBTAYO with effect from July&#160;1, 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July&#160;2022, Sanofi received as consideration an upfront payment of $900&#160;million (&#8364;856&#160;million), which was recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> on the date of receipt. The same line item also includes a regulatory milestone payment of $100&#160;million (&#8364;96&#160;million) following the US FDA approval in November&#160;2022 of LIBTAYO in combination with chemotherapy as a first line treatment for NSCLC. In addition, Sanofi is entitled to royalties of 11% and to milestone payments (&#8364;116&#160;million in 2023, &#8364;111&#160;million in 2022) linked to global net sales of LIBTAYO; those royalties are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in line with the pattern of sales. All of the cash inflows relating to the above items (&#8364;196&#160;million in 2023, &#8364;952&#160;million in 2022) are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net cash provided by/(used in) operating activities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amendment to the terms of the IO LCA resulted in Sanofi recognizing an accelerated amortization charge of &#8364;226&#160;million in&#160;2022; this was allocated to the LIBTAYO product rights included within the residual carrying amount of the intangible asset recognized in July&#160;2015 to reflect rights to an antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) under the Sanofi/Regeneron alliance.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The transaction also includes a time-limited transitional services agreement with Regeneron which includes manufacturing, distribution (for which Sanofi acts as agent), and promotion.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investor agreement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2014 and 2020, Sanofi and Regeneron amended the investor agreement entered into by the two companies in 2007. Under the terms of the amendments, Sanofi accepted various restrictions, including &#8220;standstill&#8221; provisions that contractually prohibit Sanofi from seeking to directly or indirectly exert control of Regeneron or acquiring more than 30% of Regeneron&#8217;s capital stock (consisting of the outstanding shares of common stock and the shares of Class A stock). This prohibition remains in place until the earlier of (i)&#160;the later of the fifth anniversaries of the expiration or earlier termination of the ZALTRAP collaboration agreement with Regeneron (related to the development and commercialization of ZALTRAP) or the collaboration agreement with Regeneron on monoclonal antibodies (see &#8220;Collaboration agreements on human therapeutic antibodies&#8221; above), each as amended or (ii)&#160;other specified events.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Starting in 2018 Sanofi began to sell shares of Regeneron stock and announced on May&#160;29,&#160;2020 the closing of its sale of 13&#160;million shares of Regeneron common stock in a registered offering and a private sale to Regeneron (see Note&#160;D.2.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Pursuant to subsequent sales in 2022, Sanofi no longer holds any shares of Regeneron stock, as of December 31, 2023.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.2. Agreements on the commercialization of BEYFORTUS (nirsevimab, previously MEDI8897) in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March 1, 2017, Sanofi and AstraZeneca entered into an agreement to develop and commercialize a monoclonal antibody (MEDI8897, nirsevimab) for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the agreement, Sanofi made an upfront payment of &#8364;120&#160;million in March 2017, a development milestone payment of &#8364;30&#160;million in the third quarter of 2019, a regulatory milestone payment of &#8364;25&#160;million associated with the approval of BEYFORTUS (nirsevimab) by the EMA in Europe in November 2022, and a regulatory milestone payment of &#8364;65&#160;million associated with the approval of BEYFORTUS (nirsevimab) by the US FDA in July 2023. In addition, Sanofi could pay up to &#8364;375&#160;million if sales objectives are met. Those amounts are recognized as a component of the value of the intangible asset when payment becomes probable. During 2023, an amount of &#8364;25&#160;million was recognized as an accrued expense further to a contractual threshold being passed.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The agreement also specifies that AstraZeneca is responsible for development and manufacturing, and Sanofi for commercialization. Sanofi recognizes the sales and cost of sales (purchases of finished products from AstraZeneca) and shares the Alliance&#8217;s commercial profits (i) 50/50 in major territories and (ii) based on 25% of net sales in other territories. The share of commercial profits and losses due to or from AstraZeneca is recognized as a component of operating income, within the line items</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. In addition, Sanofi and AstraZeneca share development costs 50/50, with Sanofi&#8217;s portion recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">s.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 9, 2023, Sanofi and AstraZeneca simplified their contractual agreements for the development and commercialization of BEYFORTUS (nirsevimab) in the US. Sanofi thereby obtained control of all commercial rights to BEYFORTUS (nirsevimab) in the US, and ended the sharing of commercial profits between the two partners in that territory. In line with the terms of the revised agreements and in accordance with IAS 38, Sanofi recognized an intangible asset of &#8364;1.6&#160;billion for the fair value of the additional US rights. On the same date, AstraZeneca and Sobi ended their participation agreement, signed in 2018, which transferred the economic rights for the US territory to Sobi. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi simultaneously entered into an agreement with Sobi relating to direct royalties on US net sales of BEYFORTUS (nirsevimab). In line with the terms of that agreement, on April 9, 2023 Sanofi recognized a financial liability amounting to  &#8364;1.6&#160;billion. That liability is classified as a financial liability at amortized cost under IFRS 9. Other than royalty payments, subsequent movements in the liability comprise (i) the unwinding of discount and (ii) changes in estimates of future cash outflows for royalty payments. Those movements will be recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net financial income/(expenses)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with paragraph B.5.4.6 of IFRS 9. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023 the liability was remeasured by an amount of &#8364;541&#160;million, reflecting the strong success of the US launch of BEYFORTUS (nirsevimab), which led to sales forecasts being revised upward from the initial estimate. The resulting adjustment was recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For territories other than the US (except for China, which is now considered a &#8220;major market,&#8221; with profits/losses shared 50/50 with AstraZeneca), the existing agreement between AstraZeneca and Sanofi continues to govern the principal terms of the collaboration: Sanofi recognizes the sales and cost of sales and shares the Alliance&#8217;s commercial profits with AstraZeneca.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May 2023, data from the HARMONIE Phase 3b study confirmed that nirsevimab prevents infant hospitalizations due to RSV with consistent and high efficacy.</span></div>BEYFORTUS (nirsevimab) was approved in Europe in November 2022, and in the United States on July 17, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfPrincipalAlliancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for principal alliances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfPrincipalAlliancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534167264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal changes in the scope of consolidation in 2023<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock', window );">Principal changes in the scope of consolidation in 2023</a></td>
<td class="text">Presentation of the financial statementsPrincipal changes in the scope of consolidation in 2023<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Provention Bio, Inc.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March&#160;13, 2023, Sanofi entered into a merger agreement with Provention Bio, Inc. (Provention), a US-based publicly traded biopharmaceutical company developing therapies to prevent and intercept immune-mediated diseases including type&#160;1 diabetes. Under the terms of the agreement, Sanofi acquired the outstanding shares of Provention common stock for $25.00 per share in an all-cash transaction valued at approximately $2.8&#160;billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of Provention was completed on April&#160;27, 2023, with Sanofi holding all of the shares of Provention on expiration of the tender offer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph B7A of IFRS&#160;3. The transaction was accounted for as an acquisition of a group of assets, given that the principal asset (teplizumab-mzwv, commercialized in the United States under the name TZIELD) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of a share purchase agreement entered into by Sanofi and Provention in February&#160;2023, Sanofi already held an equity interest in Provention, representing approximately 3% of Provention&#8217;s share capital. On the date Sanofi obtained control of Provention, that equity interest was remeasured at a price of $25.00 per share, representing a total amount of $68&#160;million. The impact of the remeasurement was recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition price for the shares not already held was $2,806&#160;million. Out of the total price (including the fair value of the shares already held), $2,810&#160;million was allocated to TZIELD and recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction, after taking account of the previously-held shares and acquisition-related costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of $2,722&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of QRIB Intermediate Holdings, LLC</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;28, 2023, Sanofi announced that it had acquired QRIB Intermediate Holdings, LLC (QRIB), the owner of QUNOL, a market-leading US-based health &amp; wellness brand. The acquisition strengthened Sanofi's Consumer Healthcare (CHC) operations in the Vitamin, Mineral and Supplements (VMS) category.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of QRIB by Sanofi was completed on September&#160;29, 2023, at a purchase price of $1,419&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation led to the recognition of goodwill of &#8364;475&#160;million, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:66.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">774</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of QRIB Intermediate Holdings, LLC</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">867</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,342</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The other acquired intangible assets identified consist of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">QUNOL brand.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill mainly represents the expected future profits attributable to the development of the VMS platform in the United States as a result of the integration of QRIB into the Sanofi group.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The entire amount of goodwill is deductible for tax purposes over a period of 15 years.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since the acquisition date, QRIB has generated net sales of &#8364;71&#160;million, and has made an immaterial impact on consolidated net income.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition-related costs were recognized in profit or loss during 2023 within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; the amount involved was immaterial</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition is reflected in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for&#160;using the equity method</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows, and represents a net cash outflow of $1,410&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.2. Principal changes in the scope of consolidation in 2022 and 2021</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.2.1. Principal changes in the scope of consolidation in 2022</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Amunix Pharmaceuticals, Inc.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;8, 2022, Sanofi acquired the entire share capital of the immuno-oncology company Amunix Pharmaceuticals, Inc. (Amunix), thereby gaining access to Amunix&#8217;s innovative PRO-XTEN technology and a promising pipeline of immunotherapies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition price of Amunix comprises a fixed cash payment of &#8364;970&#160;million, plus contingent consideration in the form of milestone payments based on attainment of certain future development objectives of up to $225&#160;million, the fair value of which as of the acquisition date was &#8364;156&#160;million. In accordance with IFRS&#160;3, this contingent purchase consideration was recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and non-controlling interests </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see Note&#160;D.18.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation led to the recognition of &#8364;609&#160;million of goodwill, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Amunix</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,126</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Other intangible assets&#8221; comprise PRO-XTEN, an innovative universal protease-releasable masking technology platform for the discovery and development of transformative cytokine therapies and T-cell engager (TCE) immunotherapies for patients with cancer. In 2023, an impairment loss was taken against the PRO-XTEN platform, in line with a strategic decision to de-prioritize  certain R&amp;D programs (see Note&#160;D.5., "Impairment of intangible assets and property, plant and equipment&#8217;).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill mainly represents the value of Amunix&#8217;s upstream research and development pipeline of immuno-oncology therapies based on next-generation conditionally activated biologics, especially when combined with Sanofi&#8217;s existing oncology portfolio.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The goodwill generated on this acquisition does not give rise to any deduction for income tax purposes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amunix has no commercial operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a cash outflow of &#8364;852&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">EUROAPI - Loss of control and accounting implications</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March&#160;17, 2022, the Sanofi Board of Directors approved a decision to put to a shareholder vote the proposed distribution in&#160;kind of approximately 58% of the share capital of EUROAPI, thereby confirming Sanofi&#8217;s commitment (announced in February&#160;2020) to discontinue its active pharmaceutical ingredient operations. As part of the same corporate action and on the same date, Sanofi entered into an investment agreement with EPIC Bpifrance, which undertook to acquire from Sanofi &#8211; via the French Tech Souverainet&#233; fund &#8211; a 12% equity interest in EUROAPI at a price not exceeding &#8364;150&#160;million and to be determined on the basis of the volume weighted average price (VWAP) of EUROAPI shares on the Euronext Paris regulated market over the&#160;thirty-day period starting from the date of initial listing, i.e. May&#160;6, 2022. On completion of those transactions, Sanofi holds an equity interest of 30.1% in EUROAPI, which it has undertaken to retain for at least two years from the date of the distribution, subject to the customary exceptions. With effect from that date, Sanofi exercises significant influence over EUROAPI as a result of (i)&#160;its equity interest, and (ii)&#160;having one representative on the EUROAPI Board of Directors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;3, 2022, the General Meeting of Sanofi shareholders approved the decision of the Board of Directors to distribute approximately 58% of the share capital of EUROAPI in the form of an exceptional dividend in kind.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;10, 2022, the payment date of the dividend in kind in the days following the admission to listing of EUROAPI shares, those Sanofi shareholders who had retained their Sanofi shares received 1&#160;EUROAPI share per 23&#160;Sanofi shares, representing in total&#160;57.88% of the share capital of EUROAPI. As of that date, Sanofi lost control over the EUROAPI entities, based on an assessment of the criteria specified in IFRS&#160;10 (Consolidated financial statements). The assets and liabilities of EUROAPI, which since March&#160;17, 2022 had been presented as assets and liabilities held for sale within the Sanofi statement of financial position in accordance with IFRS&#160;5 (Non-Current Assets Held for Sale), were deconsolidated. In addition, because EUROAPI operations do not constitute a discontinued operation under IFRS&#160;5, the contribution from EUROAPI has not been presented within separate line items in the income statement and statement of cash flows or in information for prior comparative periods. The contribution of EUROAPI operations to the consolidated net sales of Sanofi in the year ended December&#160;31, 2021 was &#8364;486&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal consequences of the deconsolidation of EUROAPI are described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the derecognition of the carrying amount of all the assets and liabilities of EUROAPI, representing a net amount of&#160;&#8364;1,227&#160;million as of May&#160;10, 2022. This includes goodwill of &#8364;164&#160;million, determined in accordance with IAS&#160;36 (&#8220;Impairment of Assets&#8221;), which was historically allocated to the Pharmaceuticals cash generating unit (CGU), and which for the purposes of the deconsolidation was allocated using an alternative method based on the relative values of goodwill as of the date of consolidation (the &#8220;notional goodwill method&#8221;). That method was considered more appropriate to the capital-intensive nature of EUROAPI operations than the method based on the relative values of EUROAPI operations and the retained portion of the&#160;CGU;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a reduction in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Equity attributable to equity holders </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reflecting the distribution in kind, measured at &#8364;793&#160;million based on the weighted average price of &#8364;14.58 per share as of the date of delivery of the EUROAPI shares to Sanofi shareholders and corresponding to the fair value of the distribution in accordance with IFRIC&#160;17 (Distribution of Non-Cash Assets to Owners);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a cash inflow of &#8364;150&#160;million from the divestment of 12% of the share capital of EUROAPI to EPIC Bpifrance as of the settlement date of the shares, i.e. June&#160;17, 2022;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the recognition in the statement of financial position, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, of the retained 30.1% equity interest in EUROAPI at an amount of &#8364;413&#160;million, determined on the basis of the weighted average price of &#8364;14.58 per share and representing the fair value of the equity interest in accordance with IFRS&#160;10;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the reclassification within the net gain/loss on deconsolidation of unrealized foreign exchange losses amounting to&#160;&#8364;35&#160;million arising on EUROAPI subsidiaries, in accordance with IAS&#160;21 (The Effects of Changes in Foreign Exchange Rates);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the recognition of transaction-related costs and of the effects of undertakings made under agreements entered into with&#160;EUROAPI setting out the principles and terms of the legal reorganization carried out ahead of the date of deconsolidation. The principal undertakings made to EUROAPI relate to compensation for:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">environmental remediation obligations on non-operational chemical sites in France transferred to EUROAPI, amounting to&#160;&#8364;14 million, and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">regulatory compliance costs relating to certain state-of-the-art active pharmaceutical ingredients of EUROAPI, capped at&#160;&#8364;15 million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These elements collectively resulted in a pre-tax loss on deconsolidation of &#8364;3&#160;million, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement. The tax effect of the deconsolidation was a net gain of &#8364;111&#160;million, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cash impact of the deconsolidation of EUROAPI, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Disposals of consolidated undertakings and investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the statement of cash flows, was a net cash inflow of &#8364;101&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has entered into an agreement with EUROAPI for the manufacture and supply of active pharmaceutical ingredients, intermediates and other substances, which took effect on October&#160;1, 2021 and expires five years after the loss of control. Under the terms of the agreement, Sanofi committed to target annual net sales of approximately &#8364;300&#160;million for a list of specified active ingredients until the agreement expires in 2026. As of December&#160;31, 2022, that commitment amounted to &#8364;1.1&#160;billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of the date of deconsolidation, the 30.1% equity interest in EUROAPI is accounted for using the equity method in accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), and the share of EUROAPI profits or losses arising from application of the equity method is excluded from &#8220;Business operating income&#8221;, the non-IFRS financial indicator used internally by&#160;Sanofi to measure the performance of its operating segments.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.2.2. Principal changes in the scope of consolidation in 2021</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Kymab</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April&#160;8, 2021, Sanofi acquired the entire share capital of Kymab for an upfront payment of $1.1 billion (&#8364;973 million) and up to&#160;$350 million contingent upon reaching certain development milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the KY1005 project, currently in Phase&#160;2 clinical development, and relating to the human monoclonal antibody OX40L, an essential regulator of the immune system) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;965 million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;932 million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Kiadis</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November&#160;2, 2020, Sanofi and Kiadis, a biopharmaceutical company developing novel "off-the-shelf" natural killer (NK) cell therapies for patients with life-threatening diseases, entered into a definitive agreement whereby Sanofi was to make a public offer to acquire the entire share capital of Kiadis, i.e. 61&#160;million shares, at a cash price of &#8364;5.45 per share.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition was approved unanimously by the Boards of Directors of Sanofi and Kiadis, and 95.03% of the share capital of Kiadis had been tendered into the offer as of April&#160;16, 2021. As of the end of the post-closing acceptance period on April&#160;29, 2021, Sanofi held&#160;97.39% of the share capital of Kiadis, and proceeded to buy out the remaining non-controlling shareholders. As of&#160;December&#160;31, 2022, Sanofi held 100.00% of the share capital of Kiadis.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the K-NK technology platform) concentrates substantially all of the fair value of the acquired set of activities and assets. In 2023, an impairment loss was recognized against the K-NK technology platform to reflect the impact of the strategic decision to de-prioritize certain R&amp;D programs (see Note&#160;D.5., "Impairment of intangible assets and property, plant and equipment").</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;339 million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;326 million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Tidal</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April&#160;9, 2021, Sanofi acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a unique mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofi&#8217;s research capabilities in immuno-oncology and inflammatory diseases, and may have applicability to other disease areas as well.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Tidal Therapeutics was acquired for an upfront payment of $160&#160;million (&#8364;136&#160;million), and up to $310&#160;million contingent upon reaching certain development milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the unique mRNA-based in vivo reprogramming technology) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;130&#160;million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;135&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Translate Bio</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August&#160;3, 2021, Sanofi entered into a definitive agreement with Translate Bio, a clinical-stage mRNA therapeutics company, under which Sanofi was to acquire all outstanding shares of Translate Bio for $38 per share. The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of Translate Bio by Sanofi was completed on September&#160;14, 2021, with Sanofi holding the entire share capital of Translate&#160;Bio upon expiration of the squeeze-out procedure.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation, as presented in the table below, led to the recognition of goodwill of &#8364;2,118&#160;million:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shire contingent consideration liability (see Note&#160;D.18.)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(323)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Translate Bio</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">462</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,118</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,580</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The other intangible assets mainly comprise a messenger RNA technological platform applied to the development of vaccines and therapeutic agents.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill mainly represents the effects of expected future synergies and other benefits to be derived from the integration of Translate Bio into the Sanofi group, in particular by accelerating the delivery of development programs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The goodwill generated on this acquisition did not give rise to any deduction for income tax purposes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Translate Bio has no commercial operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;2,333&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the collaboration agreement between Sanofi and Translate Bio as announced on June&#160;23, 2020, Sanofi held an equity interest of approximately 5% in Translate Bio. As of the date when Sanofi obtained control of Translate Bio, that interest was remeasured at the purchase price of $38 per share. The change in fair value was recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, in accordance</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">with paragraph&#160;42 of IFRS&#160;3 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see Note&#160;D.7.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Kadmon</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;8, 2021, Sanofi entered into a definitive merger agreement with Kadmon, a biopharmaceutical company that discovers, develops and markets transformative therapies for disease areas with significant unmet medical needs. Shareholders of Kadmon common stock received $9.50 per share in cash, representing a transaction valued at $1.9&#160;billion on a fully-diluted basis. The Sanofi and Kadmon Boards of Directors unanimously approved the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of Kadmon by Sanofi was completed on November&#160;9, 2021, with Sanofi holding the entire share capital of Kadmon upon expiration of the squeeze-out procedure.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was therefore accounted for as an asset acquisition given that the principal asset (belumosudil, commercialized in the United States under the brand name REZUROCK) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;1,739&#160;million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the consolidated statement of cash flows is a net cash outflow of &#8364;1,575&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Origimm</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;3, 2021, Sanofi acquired the entire share capital of Origimm Biotechnology GmbH, a privately owned Austrian biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria that cause skin diseases such as acne, for an upfront payment of &#8364;55&#160;million and up to &#8364;95&#160;million contingent upon reaching certain development and regulatory milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was therefore accounted for as an asset acquisition given that the principal asset (the group of Propionibacterium acnes antigens) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Nearly &#8364;55&#160;million of the acquisition price paid was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the consolidated statement of cash flows for the year ended December&#160;31, 2021 is a net cash outflow of&#160;&#8364;50&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519621328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal changes in the scope of consolidation in 2022 and 2021<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock', window );">Principal changes in the scope of consolidation in 2022 and 2021</a></td>
<td class="text">Presentation of the financial statementsPrincipal changes in the scope of consolidation in 2023<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Provention Bio, Inc.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March&#160;13, 2023, Sanofi entered into a merger agreement with Provention Bio, Inc. (Provention), a US-based publicly traded biopharmaceutical company developing therapies to prevent and intercept immune-mediated diseases including type&#160;1 diabetes. Under the terms of the agreement, Sanofi acquired the outstanding shares of Provention common stock for $25.00 per share in an all-cash transaction valued at approximately $2.8&#160;billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of Provention was completed on April&#160;27, 2023, with Sanofi holding all of the shares of Provention on expiration of the tender offer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph B7A of IFRS&#160;3. The transaction was accounted for as an acquisition of a group of assets, given that the principal asset (teplizumab-mzwv, commercialized in the United States under the name TZIELD) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of a share purchase agreement entered into by Sanofi and Provention in February&#160;2023, Sanofi already held an equity interest in Provention, representing approximately 3% of Provention&#8217;s share capital. On the date Sanofi obtained control of Provention, that equity interest was remeasured at a price of $25.00 per share, representing a total amount of $68&#160;million. The impact of the remeasurement was recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition price for the shares not already held was $2,806&#160;million. Out of the total price (including the fair value of the shares already held), $2,810&#160;million was allocated to TZIELD and recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction, after taking account of the previously-held shares and acquisition-related costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of $2,722&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of QRIB Intermediate Holdings, LLC</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;28, 2023, Sanofi announced that it had acquired QRIB Intermediate Holdings, LLC (QRIB), the owner of QUNOL, a market-leading US-based health &amp; wellness brand. The acquisition strengthened Sanofi's Consumer Healthcare (CHC) operations in the Vitamin, Mineral and Supplements (VMS) category.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of QRIB by Sanofi was completed on September&#160;29, 2023, at a purchase price of $1,419&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation led to the recognition of goodwill of &#8364;475&#160;million, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:66.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">774</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of QRIB Intermediate Holdings, LLC</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">867</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,342</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The other acquired intangible assets identified consist of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">QUNOL brand.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill mainly represents the expected future profits attributable to the development of the VMS platform in the United States as a result of the integration of QRIB into the Sanofi group.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The entire amount of goodwill is deductible for tax purposes over a period of 15 years.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since the acquisition date, QRIB has generated net sales of &#8364;71&#160;million, and has made an immaterial impact on consolidated net income.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition-related costs were recognized in profit or loss during 2023 within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; the amount involved was immaterial</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition is reflected in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for&#160;using the equity method</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows, and represents a net cash outflow of $1,410&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.2. Principal changes in the scope of consolidation in 2022 and 2021</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.2.1. Principal changes in the scope of consolidation in 2022</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Amunix Pharmaceuticals, Inc.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;8, 2022, Sanofi acquired the entire share capital of the immuno-oncology company Amunix Pharmaceuticals, Inc. (Amunix), thereby gaining access to Amunix&#8217;s innovative PRO-XTEN technology and a promising pipeline of immunotherapies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition price of Amunix comprises a fixed cash payment of &#8364;970&#160;million, plus contingent consideration in the form of milestone payments based on attainment of certain future development objectives of up to $225&#160;million, the fair value of which as of the acquisition date was &#8364;156&#160;million. In accordance with IFRS&#160;3, this contingent purchase consideration was recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and non-controlling interests </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see Note&#160;D.18.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation led to the recognition of &#8364;609&#160;million of goodwill, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Amunix</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,126</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Other intangible assets&#8221; comprise PRO-XTEN, an innovative universal protease-releasable masking technology platform for the discovery and development of transformative cytokine therapies and T-cell engager (TCE) immunotherapies for patients with cancer. In 2023, an impairment loss was taken against the PRO-XTEN platform, in line with a strategic decision to de-prioritize  certain R&amp;D programs (see Note&#160;D.5., "Impairment of intangible assets and property, plant and equipment&#8217;).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill mainly represents the value of Amunix&#8217;s upstream research and development pipeline of immuno-oncology therapies based on next-generation conditionally activated biologics, especially when combined with Sanofi&#8217;s existing oncology portfolio.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The goodwill generated on this acquisition does not give rise to any deduction for income tax purposes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amunix has no commercial operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a cash outflow of &#8364;852&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">EUROAPI - Loss of control and accounting implications</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March&#160;17, 2022, the Sanofi Board of Directors approved a decision to put to a shareholder vote the proposed distribution in&#160;kind of approximately 58% of the share capital of EUROAPI, thereby confirming Sanofi&#8217;s commitment (announced in February&#160;2020) to discontinue its active pharmaceutical ingredient operations. As part of the same corporate action and on the same date, Sanofi entered into an investment agreement with EPIC Bpifrance, which undertook to acquire from Sanofi &#8211; via the French Tech Souverainet&#233; fund &#8211; a 12% equity interest in EUROAPI at a price not exceeding &#8364;150&#160;million and to be determined on the basis of the volume weighted average price (VWAP) of EUROAPI shares on the Euronext Paris regulated market over the&#160;thirty-day period starting from the date of initial listing, i.e. May&#160;6, 2022. On completion of those transactions, Sanofi holds an equity interest of 30.1% in EUROAPI, which it has undertaken to retain for at least two years from the date of the distribution, subject to the customary exceptions. With effect from that date, Sanofi exercises significant influence over EUROAPI as a result of (i)&#160;its equity interest, and (ii)&#160;having one representative on the EUROAPI Board of Directors.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;3, 2022, the General Meeting of Sanofi shareholders approved the decision of the Board of Directors to distribute approximately 58% of the share capital of EUROAPI in the form of an exceptional dividend in kind.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;10, 2022, the payment date of the dividend in kind in the days following the admission to listing of EUROAPI shares, those Sanofi shareholders who had retained their Sanofi shares received 1&#160;EUROAPI share per 23&#160;Sanofi shares, representing in total&#160;57.88% of the share capital of EUROAPI. As of that date, Sanofi lost control over the EUROAPI entities, based on an assessment of the criteria specified in IFRS&#160;10 (Consolidated financial statements). The assets and liabilities of EUROAPI, which since March&#160;17, 2022 had been presented as assets and liabilities held for sale within the Sanofi statement of financial position in accordance with IFRS&#160;5 (Non-Current Assets Held for Sale), were deconsolidated. In addition, because EUROAPI operations do not constitute a discontinued operation under IFRS&#160;5, the contribution from EUROAPI has not been presented within separate line items in the income statement and statement of cash flows or in information for prior comparative periods. The contribution of EUROAPI operations to the consolidated net sales of Sanofi in the year ended December&#160;31, 2021 was &#8364;486&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal consequences of the deconsolidation of EUROAPI are described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the derecognition of the carrying amount of all the assets and liabilities of EUROAPI, representing a net amount of&#160;&#8364;1,227&#160;million as of May&#160;10, 2022. This includes goodwill of &#8364;164&#160;million, determined in accordance with IAS&#160;36 (&#8220;Impairment of Assets&#8221;), which was historically allocated to the Pharmaceuticals cash generating unit (CGU), and which for the purposes of the deconsolidation was allocated using an alternative method based on the relative values of goodwill as of the date of consolidation (the &#8220;notional goodwill method&#8221;). That method was considered more appropriate to the capital-intensive nature of EUROAPI operations than the method based on the relative values of EUROAPI operations and the retained portion of the&#160;CGU;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a reduction in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Equity attributable to equity holders </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> reflecting the distribution in kind, measured at &#8364;793&#160;million based on the weighted average price of &#8364;14.58 per share as of the date of delivery of the EUROAPI shares to Sanofi shareholders and corresponding to the fair value of the distribution in accordance with IFRIC&#160;17 (Distribution of Non-Cash Assets to Owners);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a cash inflow of &#8364;150&#160;million from the divestment of 12% of the share capital of EUROAPI to EPIC Bpifrance as of the settlement date of the shares, i.e. June&#160;17, 2022;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the recognition in the statement of financial position, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, of the retained 30.1% equity interest in EUROAPI at an amount of &#8364;413&#160;million, determined on the basis of the weighted average price of &#8364;14.58 per share and representing the fair value of the equity interest in accordance with IFRS&#160;10;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the reclassification within the net gain/loss on deconsolidation of unrealized foreign exchange losses amounting to&#160;&#8364;35&#160;million arising on EUROAPI subsidiaries, in accordance with IAS&#160;21 (The Effects of Changes in Foreign Exchange Rates);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the recognition of transaction-related costs and of the effects of undertakings made under agreements entered into with&#160;EUROAPI setting out the principles and terms of the legal reorganization carried out ahead of the date of deconsolidation. The principal undertakings made to EUROAPI relate to compensation for:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">environmental remediation obligations on non-operational chemical sites in France transferred to EUROAPI, amounting to&#160;&#8364;14 million, and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">regulatory compliance costs relating to certain state-of-the-art active pharmaceutical ingredients of EUROAPI, capped at&#160;&#8364;15 million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These elements collectively resulted in a pre-tax loss on deconsolidation of &#8364;3&#160;million, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement. The tax effect of the deconsolidation was a net gain of &#8364;111&#160;million, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cash impact of the deconsolidation of EUROAPI, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Disposals of consolidated undertakings and investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the statement of cash flows, was a net cash inflow of &#8364;101&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has entered into an agreement with EUROAPI for the manufacture and supply of active pharmaceutical ingredients, intermediates and other substances, which took effect on October&#160;1, 2021 and expires five years after the loss of control. Under the terms of the agreement, Sanofi committed to target annual net sales of approximately &#8364;300&#160;million for a list of specified active ingredients until the agreement expires in 2026. As of December&#160;31, 2022, that commitment amounted to &#8364;1.1&#160;billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of the date of deconsolidation, the 30.1% equity interest in EUROAPI is accounted for using the equity method in accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), and the share of EUROAPI profits or losses arising from application of the equity method is excluded from &#8220;Business operating income&#8221;, the non-IFRS financial indicator used internally by&#160;Sanofi to measure the performance of its operating segments.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.2.2. Principal changes in the scope of consolidation in 2021</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Kymab</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April&#160;8, 2021, Sanofi acquired the entire share capital of Kymab for an upfront payment of $1.1 billion (&#8364;973 million) and up to&#160;$350 million contingent upon reaching certain development milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the KY1005 project, currently in Phase&#160;2 clinical development, and relating to the human monoclonal antibody OX40L, an essential regulator of the immune system) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;965 million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;932 million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Kiadis</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November&#160;2, 2020, Sanofi and Kiadis, a biopharmaceutical company developing novel "off-the-shelf" natural killer (NK) cell therapies for patients with life-threatening diseases, entered into a definitive agreement whereby Sanofi was to make a public offer to acquire the entire share capital of Kiadis, i.e. 61&#160;million shares, at a cash price of &#8364;5.45 per share.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition was approved unanimously by the Boards of Directors of Sanofi and Kiadis, and 95.03% of the share capital of Kiadis had been tendered into the offer as of April&#160;16, 2021. As of the end of the post-closing acceptance period on April&#160;29, 2021, Sanofi held&#160;97.39% of the share capital of Kiadis, and proceeded to buy out the remaining non-controlling shareholders. As of&#160;December&#160;31, 2022, Sanofi held 100.00% of the share capital of Kiadis.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the K-NK technology platform) concentrates substantially all of the fair value of the acquired set of activities and assets. In 2023, an impairment loss was recognized against the K-NK technology platform to reflect the impact of the strategic decision to de-prioritize certain R&amp;D programs (see Note&#160;D.5., "Impairment of intangible assets and property, plant and equipment").</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;339 million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;326 million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Tidal</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April&#160;9, 2021, Sanofi acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a unique mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofi&#8217;s research capabilities in immuno-oncology and inflammatory diseases, and may have applicability to other disease areas as well.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Tidal Therapeutics was acquired for an upfront payment of $160&#160;million (&#8364;136&#160;million), and up to $310&#160;million contingent upon reaching certain development milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the unique mRNA-based in vivo reprogramming technology) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;130&#160;million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;135&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Translate Bio</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August&#160;3, 2021, Sanofi entered into a definitive agreement with Translate Bio, a clinical-stage mRNA therapeutics company, under which Sanofi was to acquire all outstanding shares of Translate Bio for $38 per share. The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of Translate Bio by Sanofi was completed on September&#160;14, 2021, with Sanofi holding the entire share capital of Translate&#160;Bio upon expiration of the squeeze-out procedure.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation, as presented in the table below, led to the recognition of goodwill of &#8364;2,118&#160;million:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shire contingent consideration liability (see Note&#160;D.18.)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(323)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Translate Bio</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">462</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,118</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,580</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The other intangible assets mainly comprise a messenger RNA technological platform applied to the development of vaccines and therapeutic agents.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill mainly represents the effects of expected future synergies and other benefits to be derived from the integration of Translate Bio into the Sanofi group, in particular by accelerating the delivery of development programs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The goodwill generated on this acquisition did not give rise to any deduction for income tax purposes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Translate Bio has no commercial operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the consolidated statement of cash flows is a net cash outflow of &#8364;2,333&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the terms of the collaboration agreement between Sanofi and Translate Bio as announced on June&#160;23, 2020, Sanofi held an equity interest of approximately 5% in Translate Bio. As of the date when Sanofi obtained control of Translate Bio, that interest was remeasured at the purchase price of $38 per share. The change in fair value was recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, in accordance</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">with paragraph&#160;42 of IFRS&#160;3 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see Note&#160;D.7.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Kadmon</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;8, 2021, Sanofi entered into a definitive merger agreement with Kadmon, a biopharmaceutical company that discovers, develops and markets transformative therapies for disease areas with significant unmet medical needs. Shareholders of Kadmon common stock received $9.50 per share in cash, representing a transaction valued at $1.9&#160;billion on a fully-diluted basis. The Sanofi and Kadmon Boards of Directors unanimously approved the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The acquisition of Kadmon by Sanofi was completed on November&#160;9, 2021, with Sanofi holding the entire share capital of Kadmon upon expiration of the squeeze-out procedure.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was therefore accounted for as an asset acquisition given that the principal asset (belumosudil, commercialized in the United States under the brand name REZUROCK) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Of the total acquisition price paid, &#8364;1,739&#160;million was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the consolidated statement of cash flows is a net cash outflow of &#8364;1,575&#160;million.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Origimm</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;3, 2021, Sanofi acquired the entire share capital of Origimm Biotechnology GmbH, a privately owned Austrian biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria that cause skin diseases such as acne, for an upfront payment of &#8364;55&#160;million and up to &#8364;95&#160;million contingent upon reaching certain development and regulatory milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was therefore accounted for as an asset acquisition given that the principal asset (the group of Propionibacterium acnes antigens) concentrates substantially all of the fair value of the acquired set of activities and assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Nearly &#8364;55&#160;million of the acquisition price paid was allocated to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of this acquisition as reflected within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions of consolidated undertakings and investments accounted for using the equity method </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the consolidated statement of cash flows for the year ended December&#160;31, 2021 is a net cash outflow of&#160;&#8364;50&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523597504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text">Property, plant and equipment<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.1. Property, plant and equipment owned</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment owned by Sanofi is comprised of the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Buildings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Machinery<br/>and<br/>equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fixtures,<br/>fittings&#160;and<br/>other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property,&#160;plant<br/>and&#160;equipment<br/>in process</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">236</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,828</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,127</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,524</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,454</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23,169</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,504&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(839)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">240</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,170</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,648</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,655</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,097</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,810</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(294)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,480)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(163)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(150)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,104)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(240)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(559)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,626)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(318)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">237</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,328</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,848</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,515</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,996</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23,924</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(340)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,071)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">228</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,681</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,500</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,449</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,770</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(10)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,898)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,792)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,981)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(123)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(13,804)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(306)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(592)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(167)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(99)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(208)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(9)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,190)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,340)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,115)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(128)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,782)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(356)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(622)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,142)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(186)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(10)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,225)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,637)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,015)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(168)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,055)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,080)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,500)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,873)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,037)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(192)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,610)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,980&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,308&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,969&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,028&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,869&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">220</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,181</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,039</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">463</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,257</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,160</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line includes in particular property, plant and equipment in process brought into service during the period, but also the effect of the reclassification of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:57.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,693</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,748</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,504</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biopharma</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vaccines</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consumer Healthcare</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take into account of the two new operating segments, Biopharma and Consumer Healthcare, effective January&#160;1,&#160;2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments relating to property, plant and equipment as of December 31, 2023, 2022 and 2021 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Firm orders of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment pledged as security for liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the net impairment losses recognized in each of the last three financial periods:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net impairment losses on property, plant and equipment</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">130</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">186</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">39</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts mainly comprise impairment losses recognized as a result of decisions taken during the periods presented, relating primarily to shutdowns or changes in use of industrial sites.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.2. Property, plant and equipment leased &#8211; right-of-use assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Right-of-use assets relating to property, plant and equipment leased by Sanofi are analyzed in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:82.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Right-of-use assets</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,711</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(91)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,745</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,872</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,672</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(513)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(797)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(341)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,057)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,018)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,948</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,815</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,654</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line also includes the effect of the reclassification of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In December&#160;2018, Sanofi signed two leases on real estate assets in the United States (at Cambridge, Massachusetts) for an initial lease term of 15 years. The first lease, relating to office space, began in April&#160;2021; Sanofi recognized a right-of-use asset of &#8364;320 million, as well as the lease liability. The second lease, relating to laboratory facilities, began on July&#160;1, 2021; Sanofi recognized a right-of-use asset of &#8364;424 million, as well as the lease liability.</span></div><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leased assets comprised offices and industrial premises (90%) and the vehicle fleet (10%) as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Annual lease costs on short term leases and low value asset leases amounted to &#8364;19 million in the year ended December 31, 2023, &#8364;26 million in the year ended December 31, 2022, and &#8364;25 million in the year ended December 31, 2021. Variable lease payments, sub-leasing activities, and sale-and-leaseback transactions were immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total cash outflows on leases (excluding annual lease costs on short term leases and low value asset leases) were &#8364;315 million in&#160;the year ended December 31, 2023, &#8364;389 million in the year ended December 31, 2022, and &#8364;302 million in the year ended&#160;December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A maturity analysis of the lease liability is disclosed in Note&#160;D.17.2.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Commitments related to short-term leases and low value asset leases, including future payments for lease contracts committed but not yet commenced, are disclosed in Note&#160;D.21.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534418368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory', window );">Goodwill and other intangible assets</a></td>
<td class="text">Goodwill and other intangible assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in goodwill comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:82.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44,364</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(89)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">48,056</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(258)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49,892</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(873)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49,404</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph&#160;86 of IAS&#160;36, and in 2022 the loss of control of EUROAPI (see note&#160;D.2.1.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><br/>In accordance with IAS&#160;36, goodwill is allocated to groups of Cash Generating Units (CGUs) at a level corresponding to the Biopharma and Consumer Healthcare segments. When testing goodwill annually for impairment, the recoverable amount is determined for each of the two segments (Biopharma and Consumer Healthcare) on the basis of value in use, as derived from discounted estimates of the future cash flows in accordance with the policies described in Note&#160;B.6.1.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The allocation of goodwill by segment as of December 31, 2023 is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.361%"><tr><td style="width:1.0%"></td><td style="width:55.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.078%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></div></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,324</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,080</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49,404</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of QRIB Intermediate Holdings, LLC (2023)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation for QRIB Intermediate Holdings, LLC resulted in the recognition of intangible assets (other than goodwill) o</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">f &#8364;774 million as of the acquisition d</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ate (September&#160;29, 2023), a</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">nd of goodwill provisionally measured at&#160;&#8364;475 million as of the acquisition date (see Note&#160;D.1.).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Amunix Pharmaceuticals,&#160;Inc. (2022)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation for Amunix Pharmaceuticals, Inc. resulted in the recognition of intangible assets (other than goodwill) o</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">f&#160;&#8364;493&#160;million as of the acquisition date (February&#160;8, 2022), and of goodwill measured at &#8364;609&#160;million as of the acquisition date (see Note&#160;D.2.1.).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Translate Bio (2021)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation for Translate&#160;Bio resulted in the recognition of intangible a</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ssets (other than goodwill) of&#160;&#8364;396&#160;million as of the acquisition date (September&#160;14, 2021), and of goodwill measured at &#8364;2,118&#160;million as of the</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> acquisition date (see Note&#160;D.2.2.).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets comprise:</span></div><div style="margin-bottom:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:53.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Products,<br/>trademarks and<br/>other rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other<br/>intangible assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,600</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">61,074</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,633</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72,307</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,821&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,626&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(313)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(173)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(502)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(784)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,207</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">65,906</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,752</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78,865</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(423)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(543)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,576)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(174)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,354</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69,579</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,783</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81,716</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,401&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,062&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,970&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,584)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,253)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,772</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">73,733</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,808</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85,313</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at January 1, 2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,508)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(49,345)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,113)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(53,966)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(119)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,740)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(192)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,869)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,022)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at December 31, 2021</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,477)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(52,744)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,237)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(57,458)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,099)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(97)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,196)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,567)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(214)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at December 31, 2022</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,128)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(54,652)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,296)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(60,076)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,225)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,345)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(842)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(932)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,734)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(55,908)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,352)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(60,994)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,730&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,162&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,407&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,927&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,640&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,038</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,825</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,319</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes the impact of the IFRIC agenda decision of March&#160;2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement (see Note&#160;A.2.1. to our 2021 consolidated financial statements, included in our annual report on Form&#160;20-F for that year).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The &#8220;Transfers&#8221; line mainly comprises (i)&#160;acquired R&amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets as </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The &#8220;Changes in scope of consolidation&#8221; line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Notes&#160;D.1. and&#160;D.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;See Note&#160;D.5.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of &#8364;226&#160;million in&#160;2022 (see&#160;Note C.1.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)  This line mainly comprises:</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April&#160;2023 in respect of the agreements on BEYFORTUS (nirsevimab) (see Note&#160;C.2.);</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">an upfront payment of $500&#160;million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co-commercialization of TEV&#8217;574; and</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">an upfront payment of $175&#160;million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Products, trademarks and other rights&#8221; mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">&#8220;marketed products&#8221;, with a carrying amount of &#8364;16.6 billion as of December 31, 2023 (versus &#8364;12.7 billion as of            December 31, 2022 and &#8364;11.7 billion as of December 31, 2021) and a weighted average amortization period of approximately 11&#160;years; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">&#8220;technology platforms&#8221;, with a carrying amount of &#8364;1.2 billion as of December 31, 2023 (versus &#8364;2.2&#160;billion as of           December 31, 2022 and &#8364;1.2&#160;billion as of December 31, 2021) and a weighted average amortization period of approximately 18&#160;years.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides information about the principal &#8220;marketed products&#8221;, which were recognized in connection with major acquisitions made by Sanofi and represented 96% of the carrying amount of that item as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:20.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>amortization&#160;&amp;<br/>impairment</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortization</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">period</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(years)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Residual</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">amortization</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">period</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(years)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,279&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,071)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Boehringer Ingelheim </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consumer Healthcare</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,698)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,213&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33,043&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33,000)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(818)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Protein Sciences</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ablynx</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(746)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,357&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,798&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,646)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,152&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,836&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,065&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">REZUROCK</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,907&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TZIELD</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,546&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,405&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BEYFORTUS</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QUNOL</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total: principal marketed products</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66,880</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(50,953)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,927</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,863</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,752</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Weighted averages. The amortization periods for these products vary between 1&#160;and 25&#160;years.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Weighted averages.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Commercialized products derived from the acquisition of these companies.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal intangible assets brought into service during 2023 were:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ALTUVIIIO (efanesoctocog alfa), which extends protection from bleeds and treats acute hemorrhages in people with hemophilia&#160;A. The asset came into service on the date of marketing approval (February 23, 2023), and has a gross value of&#160;&#8364;1,110&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During 2022, some of the acquired research and development came into commercial use, and started being amortized from the date of marketing approval; the main item involved was ENJAYMO (sutimlimab-jome), a treatment for cold agglutinin disease.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main asset brought into service during 2021 was the Translate Bio mRNA technology platform.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of other intangible assets is recognized in the income statement within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, except for amortization of software and other rights of an industrial or operational nature which is recognized in the relevant classification of expense by function. An analysis of amortization of software is shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">120</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">97</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">119</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533371248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of intangible assets and property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentOfAssetsAbstract', window );"><strong>Impairment Of Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock', window );">Impairment of intangible assets and property, plant and equipment</a></td>
<td class="text">Impairment of intangible assets and property, plant and equipment<div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When testing goodwill annually for impairment, the recoverable amount is determined for each of the two segments (Biopharma and Consumer Healthcare) on the basis of value in use, as derived from discounted estimates of the future cash flows in accordance with the policies described in Note&#160;B.6.1.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The value in use of each segment was determined by applying an after-tax discount rate to estimated future after-tax cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A separate discount rate is used for each segment to reflect the specific economic conditions of that segment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The rates used for impairment testing in 2023 were 7.00% for the Consumer Healthcare segment and 7.25% for the Biopharma segment; an identical value in use for Sanofi as a whole would be obtained by applying a uniform 7.2% rate to two segments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The pre-tax discount rates applied to estimated pre-tax cash flows are calculated by iteration from the previously-determined value in use. Those pre-tax discount rates were 9.3% for the Consumer Healthcare segment and 10.0% for the Biopharma segment, and equate to a uniform rate of 9.9% for Sanofi as a whole.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The assumptions used in testing goodwill for impairment are reviewed annually. Apart from the discount rate, the principal assumptions used in 2023 were as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the perpetual growth rates applied to future cash flows were zero for the Biopharma segment, and 1% for the Consumer Healthcare segment;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Sanofi also applies assumptions on the probability of success of current research and development projects, and more generally on its ability to renew the product portfolio in the longer term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Value in use (determined as described above) is compared with the carrying amount, and this comparison is then subjected to sensitivity analyses by reference to the principal parameters, including:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">changes in the discount rate;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">changes in the perpetual growth rate; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">fluctuations in operating margin.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No impairment of goodwill would need to be recognized in the event of a reasonably possible change in the assumptions used in&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A value in use calculation for each of the segments would not result in an impairment loss using:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a discount rate up to 2.8&#160;percentage points above the rates actually used; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a perpetual growth rate up to 4.9&#160;percentage points below the rates actually used; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an operating margin up to 7.2&#160;percentage points below the rates actually used.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No impairment losses were recognized against goodwill in the years ended December 31, 2023, 2022 or 2021.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When there is evidence that an asset may have become impaired, the asset&#8217;s value in use is calculated by applying an after-tax discount rate to the estimated future after-tax cash flows from that asset. For the purposes of impairment testing, the tax cash flows relating to the asset are determined using a notional tax rate incorporating the notional tax benefit that would result from amortizing the asset if its value in use were regarded as its depreciable amount for tax purposes. Applying after-tax discount rates&#160;to after-tax cash flows gives the same values in use as would be obtained by applying pre-tax discount rates to pre-tax cash&#160;flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The after-tax discount rates used in 2023 for impairment testing of other intangible assets in the Biopharma and Consumer Healthcare segments were obtained by adjusting Sanofi&#8217;s weighted average cost of capital to reflect specific country and business risks, giving after-tax discount rates in a range from 7.25% to 8.25%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In most instances, there are no market data that would enable fair value less costs to sell to be determined other than by means of developing a similar estimate based on future cash flows. Consequently, recoverable amount is in substance equal to value in use. The estimates used to determine value in use are sensitive to assumptions specific to the nature of the asset and to Sanofi's activities. Apart from the discount rate, the principal assumptions used in 2023 were as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">mid-term and long-term forecasts;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">perpetual growth or attrition rates, when applicable; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">probability of success of current research and development projects.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The assumptions used in testing intangible assets for impairment are reviewed at least annually.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, 2022 and 2021, impairment testing of other intangible assets (excluding software) resulted in the recognition of net impairment losses as shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impairment of other intangible assets, net of reversals (excluding software)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">932</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(454)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">192</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,561)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Biopharma</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1,526)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Consumer Healthcare</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development projects and technology platforms</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)(b)(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Others</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;For 2023, this amount mainly comprises an impairment loss of &#8364;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN  technology platforms.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;For 2022, this amount mainly comprises a reversal of &#8364;2,154&#160;million of impairment losses taken against ELOCTATE and BIVV001 (assets belonging to the ELOCTATE franchise), consisting of &#8364;1,554&#160;million for marketed products and &#8364;600&#160;million for research and development projects respectively. In 2019, the launch of competing products for ELOCTATE led Sanofi to update its sales forecasts for products belonging to the franchise, as a result of which impairment losses of &#8364;2.8&#160;billion were recognized against the assets in question. The reversal reflects the approval by the FDA on February&#160;22, 2023 of  ALTUVIIIO (the commercial name of efanesoctocog alpha, corresponding to the BIVV001 project), which was submitted in 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;For 2022, this amount mainly comprises:</span></div><div style="margin-top:1pt;padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.93pt">an impairment loss of &#8364;1,586&#160;million taken against the development project for SAR444245 (non-alpha interleukin-2), recognized following revised cash flow projections reflecting unfavorable developments in the launch schedule;</span></div><div style="margin-top:1pt;padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.93pt">the &#8364;600&#160;million reversal relating to the BIVV001 project (see above).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For 2021, this line relates to the discontinuation of the development of sutimlimab in the treatment of Immune Thrombocytopenic Purpura (ITP), and to the termination of various research projects in Vaccines.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, plant and equipment</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses taken against property, plant and equipment are disclosed in Note&#160;D.3.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks and opportunities related to climate change</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has identified specific plausible scenarios to assess climate risks and opportunities liable to impact its activities in the medium and longer term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an Aggressive Mitigation scenario, based on global collaboration to start reducing emissions immediately to meet Paris Agreement goals (limit temperature increase to 1.5&#176;C above pre-industrial levels), generating risks related to transitioning to a lower carbon economy and entailing extensive policy, legal, technology, and market changes to address mitigation and adaptation requirements;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a No Climate Action scenario (leading to global warming of 4&#176;C above pre-industrial levels by 2100), with event-driven physical risks resulting from climate change or longer term shifts in climate patterns leading to potential financial implications such as direct damage to assets and indirect impacts from supply chain disruption; changes in water availability, and in the sourcing or quality of resources; food security; and extreme temperature changes affecting premises, operations, supply chain, transport needs, and employee safety; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a Most Likely scenario, encompassing fragmented regional efforts to start reducing emissions but not at a sufficient level to meet Paris Agreement goals (emissions continue to increase but at a slowed rate, leading to a 2.8&#176;C temperature increase).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The importance and likelihood of such risks have been assessed and have not led Sanofi to identify any material impact that could generate a risk of impairment of the assets of Sanofi&#8217;s CGUs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for impairment of intangible assets and property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpairmentOfAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpairmentOfAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534448384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments accounted for using the equity method<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Investments accounted for using the equity method</a></td>
<td class="text">Investments accounted for using the equity method<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method comprise associates and joint ventures (see Note&#160;B.1.), and are set forth below.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%&#160;interest</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH&#160;&amp; Co. H&#246;chst KG</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">424</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">677</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Following the distribution in kind and the acquisition of an equity interest by EPIC Bpifrance, Sanofi holds an equity interest in EUROAPI accounted for using the equity method in accordance with IAS&#160;28 (see Note&#160;D.2.). As of December&#160;31, 2023, an impairment loss of &#8364;231&#160;million was recognized on the equity-accounted investment in EUROAPI in view of the fall in the share price since March&#160;2023. The amount of the loss was determined on the basis of the share price as of December&#160;31, 2023 (&#8364;5.73).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Joint venture.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi&#8217;s overall share of (i)&#160;profit or loss and (ii)&#160;other comprehensive income from investments accounted for using the equity method, showing the split between associates and joint ventures in accordance with IFRS&#160;12 (the amounts for each individual associate or joint venture are not material):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:28.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.425%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint&#160;ventures</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint&#160;ventures</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint&#160;ventures</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of other comprehensive income from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">94</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(208)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;An impairment loss of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8364;231&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> was recognized on the equity-accounted interest in EUROAPI as of December&#160;31, 2023, to reflect the fall in the share price since March&#160;2023. The amount of the loss was determined on the basis of the quoted market price as of December&#160;31, 2023 (&#8364;5.73).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include arm&#8217;s length transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.999%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases and other expenses (including research expenses)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and other payables</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In 2022, these items include Sanofi's transactions with EUROAPI from May&#160;10, 2022 (see Note&#160;D.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Includes loans to joint ventures and associates.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">There were no funding commitments to associates and joint ventures as of December 31, 2023, December 31, 2022 or     December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For off balance sheet commitments of an operational nature involving joint ventures, see Note&#160;D.21.1.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523066720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other non-current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory', window );">Other non-current assets</a></td>
<td class="text">Other non-current assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income (D.7.1.)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income (D.7.2.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss (D.7.3.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations (Note&#160;D.19.1.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivative financial instruments (Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,218</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,095</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,127</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;As of December 31, 2023, this line includes:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- the renewal of a loan of &#8364;157&#160;million to the BioAtrium joint venture which matures on December&#160;1, 2031, of which &#8364;156&#160;million was recognized in "Other current assets" as of December&#160;31, 2022; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- a receivable under a sub-lease amounting to &#8364;132&#160;million (&#8364;170&#160;million before discounting), versus &#8364;164&#160;million (or &#8364;201&#160;million before discounting) as of December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.7.1. Equity instruments at fair value through other comprehensive income</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quoted equity investments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line &#8220;Equity instruments at fair value through other comprehensive income&#8221; includes equity investments quoted in an active market with a carrying amount of &#8364;470 million as of December 31, 2023, &#8364;387 million as of December 31, 2022 and &#8364;396 million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">There were no material movements in quoted equity investments during the year ended December 31, 2023.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main changes during previous years in quoted equity investments included in the &#8220;Equity instruments at fair value through other comprehensive income&#8221; category are described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in 2022:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">the sale in June&#160;2022 of the residual equity interest in Regeneron (see Note&#160;C.1.) for $174 million, the entire loss on which was recorded within Other comprehensive income, and </span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">the acquisition of an equity interest in Innovent Biologics, in connection with a strategic collaboration agreement to intensify&#160;development in oncology medicines signed in August&#160;2022, which had a fair value of &#8364;250 million as of that date and &#8364;228 million as of December&#160;31, 2022;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in 2021:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">following completion of the acquisition of Translate Bio on September&#160;14, 2021 (see Note&#160;D.2.2), the equity interest of approximately 5% in Translate Bio previously held by Sanofi ceased to be accounted for in the &#8220;Equity instruments at fair value through other comprehensive income&#8221; category.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A 10% decline in stock prices of the quoted equity investments included within &#8220;Equity instruments at fair value through&#160;other&#160;comprehensive income&#8221; would have had a pre-tax impact of &#8364;47 million on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as of&#160;December 31, 2023.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unquoted equity investments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item &#8220;Equity instruments at fair value through other comprehensive income&#8221; also includes equity investments not quoted in an active market with a carrying amount of &#8364;618 million as of December 31, 2023, &#8364;549 million as of December 31, 2022 and&#160;&#8364;427 million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The change in unquoted equity investments included in the &#8220;Equity instruments at fair value through other comprehensive income&#8221; category during the year ended December 31, 2023 was mainly due to various equity stakes acquired through the Sanofi Ventures fund.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, commitments relating to equity investments classified in this asset category amount to &#8364;65 million as of December 31, 2023 (compared to &#8364;60 million as of December 31, 2022).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.7.2. Debt instruments at fair value through other comprehensive income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Debt instruments at fair value through other comprehensive income&#8221; category includes quoted euro-denominated senior bonds amounting to &#8364;346 million as of December 31, 2023, including &#8364;107 million of securities obtained in exchange for financial assets held to meet obligations to employees under post-employment benefit plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi held &#8364;329 million of quoted senior bonds as of December 31, 2022 and &#8364;447 million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards debt instruments held to meet obligations to employees under post-employment benefit plans, an increase of 10&#160;basis points in market interest rates as of December 31, 2023 would have had a pre-tax impact of &#8364;1 million on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards other quoted debt instruments, an increase of 10&#160;basis points in market interest rates as of December 31, 2023 would have had a pre-tax impact of &#8364;1 million on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other comprehensive income recognized in respect of &#8220;Equity instruments at fair value through other comprehensive income&#8221; and &#8220;Debt instruments at fair value through other comprehensive income&#8221; represented unrealized after-tax gains of &#8364;349 million for the year ended December 31, 2023, versus unrealized after-tax gains of &#8364;256 million for the year ended December 31, 2022 and of &#8364;322 million for the year ended December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of the change in gains and losses recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, and of items reclassified to profit or loss, is presented in Note&#160;D.15.7.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.7.3. Other financial assets at fair value through profit or loss</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other financial assets at fair value through profit or loss&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">category includes:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration receivable by Sanofi following the dissolution of the Sanofi Pasteur MSD (SPMSD) joint venture, based on a percentage of MSD&#8217;s future sales during the 2017-2024 period of specified products previously distributed by&#160;SPMSD (see Note&#160;D.12.).</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of the MSD contingent consideration was determined by applying the royalty percentage stipulated in the contract to discounted sales projections. A reduction of one percentage point in the discount rate would increase the fair value of the&#160;MSD&#160;contingent consideration by approximately 1%.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in the fair value of this contingent consideration are recognized in the income statement within the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Fair value remeasurement of contingent consideration </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see Note&#160;B.18.). As of December 31, 2023, the contingent consideration asset amounted to &#8364;214 million (including a non-current portion of &#8364;104 million), versus &#8364;303 million (non-current portion: &#8364;196 million) as of December 31, 2022 and &#8364;378 million (non current portion: &#8364;275 million) as of December 31, 2021;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a portfolio of financial investments (amounting to &#8364;572 million as of December 31, 2023) held to fund a deferred compensation plan provided to certain employees (versus &#8364;512 million as of December 31, 2022 and &#8364;549 million as of&#160;December 31, 2021);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">unquoted securities not meeting the definition of equity instruments amounting to &#8364;132 million as of December 31, 2023 (versus &#8364;115 million as of December 31, 2022 and &#8364;78 million as of December 31, 2021). In addition, commitments relating to unquoted securities classified in this asset category amount to &#8364;159 million as of December 31, 2023 (compared to &#8364;192 million as of December 31, 2022).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other non-current assets. [Refer: Other non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523711520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets held for sale or exchange and liabilities related to assets held for sale or exchange<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory', window );">Assets held for sale or exchange and liabilities related to assets held for sale or exchange</a></td>
<td class="text">Assets held for sale or exchange and liabilities related to&#160;assets held for sale or&#160;exchange<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets held for sale or exchange, and liabilities related to assets held for sale or exchange, comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:52.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.216%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets held for sale or exchange</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities related to assets held for sale or exchange</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523711520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,550&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(139)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,869&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,316&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,663&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(678)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,985&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(554)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,025&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,045&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(247)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(284)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,590</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(924)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,666</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,024</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,064)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,960</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,619</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(904)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,715</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Allowances include write-downs of products on hand pending marketing approval, except in specific circumstances where it is possible to estimate that recovery of the value of inventories as of the end of the reporting period is highly probable.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No inventories were pledged as security for liabilities as of December 31, 2023 (versus &#8364;3 million as of December 31, 2022 and&#160;&#8364;20 million as of December 31, 2021).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348527182752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfTradeReceivablesTextBlock', window );">Accounts receivable</a></td>
<td class="text">Accounts receivable<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:52.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.216%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,528&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,537&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(113)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,433</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,424</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,568</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impact of allowances against accounts receivable in 2023 was a net expense of &#8364;8 million (versus a net amount of less than&#160;&#8364;1 million in 2022 and a net expense of &#8364;12 million in 2021).</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The gross value of overdue receivables was &#8364;689 million as of December 31, 2023, versus &#8364;452 million as of December 31, 2022 and &#8364;455 million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:17.123%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;accounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">gross value</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&lt;1 month</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to&#160;3&#160;months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to&#160;6&#160;months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6&#160;to&#160;12&#160;months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&gt;&#160;12&#160;months</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">689</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">154</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">123</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">62</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amounts overdue by more than one month relate mainly to public-sector customers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables&#160;derecognized was &#8364;761 million as of December 31, 2023 (&#8364;131 million as of December 31, 2022 and &#8364;3 million as of&#160;December 31, 2021). The residual guarantees relating to such transfers were immaterial as of December 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfTradeReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfTradeReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534413728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory', window );">Other current assets</a></td>
<td class="text">Other current assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax receivables, other than corporate income taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate derivatives measured at fair value (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency derivatives measured at fair value (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current financial assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,455</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,532</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,571</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line mainly comprises advance payments to suppliers, and receivables relating to Sanofi's activities as agent under a transitional services agreement.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This item mainly comprises bank loans and receivables maturing in less than one year with high-grade counterparties. For 2021, this item also includes debt instruments derived from the acquisitions of Translate Bio and Kadmon (carried out in 2021) with maturities of more than three months at inception and less than 12&#160;months at December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets. [Refer: Other current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526555328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities measured at fair value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueMeasurementAbstract', window );"><strong>Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock', window );">Financial assets and liabilities measured at fair value</a></td>
<td class="text">Financial assets and liabilities measured at fair value<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS&#160;7 (Financial Instruments: Disclosures), fair value measurements must be classified using a fair value hierarchy with the following levels:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">level&#160;1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">level&#160;2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">level&#160;3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The valuation techniques used are described in Note&#160;B.8.5.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the balance sheet amounts of assets and liabilities measured at fair value.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:32.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in the fair value</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">hierarchy</span></div></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in the fair value<br/>hierarchy</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in the fair value<br/>hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial assets measured at fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted equity investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unquoted equity investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted debt securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.2.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unquoted debt securities not meeting the definition of equity instruments</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.3.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration relating to divestments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.3.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.3. &amp; D.11.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.11.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mutual fund investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.13.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,349&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total financial assets measured at fair value</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,737</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">201</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">964</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,765</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">967</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,449</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">298</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">883</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial liabilities measured at fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bayer contingent purchase consideration arising from the acquisition of Genzyme</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSD contingent consideration (European vaccines business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shire contingent consideration arising from the acquisition of Translate Bio</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration arising from acquisition of Amunix</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other contingent consideration arising from business combinations and acquisitions</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.20.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.19.5</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total financial liabilities measured at fair value</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">291</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">709</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">326</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">779</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">714</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No transfers between the different levels of the fair value hierarchy occurred during 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities at fair value explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348527182752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text">Cash and cash equivalents<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,249&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,740&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,710</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,736</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,098</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;As of December 31, 2023, cash equivalents mainly comprised the following: (i)&#160;&#8364;5,349 million invested in euro and US dollar denominated money-market mutual funds (December 31, 2022: &#8364;9,537 million; December 31, 2021: &#8364;5,057 million); (ii)&#160;&#8364;1,191 million of term deposits (December 31, 2022: &#8364;1,167 million; December 31, 2021: &#8364;2,768 million) and (iii)&#160;zero commercial paper (December 31, 2022: zero; December 31, 2021: &#8364;179 million). Cash equivalents also include &#8364;476 million held by captive insurance and reinsurance companies in accordance with insurance regulations (December 31, 2022: &#8364;439 million; December 31, 2021: &#8364;427 million).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348527170000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net deferred tax position<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory', window );">Net deferred tax position</a></td>
<td class="text">Net deferred tax position<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of the net deferred tax position is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred taxes on:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consolidation adjustments (intragroup margin in inventory)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision for pensions and other employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of other acquired intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,904)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,079)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Recognition of acquired property, plant and equipment at fair value</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity interests in subsidiaries and investments in other entities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,023)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(617)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(590)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax losses available for carry-forward</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock options and other share-based payments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accrued expenses and provisions deductible at the time of payment</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,859&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,536&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net deferred tax asset/(liability)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,570</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,540</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,981</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;As of December 31, 2023, includes remeasurements of the acquired intangible assets of Bioverativ (&#8364;1,241 million), Principia (&#8364;610 million), Ablynx      (&#8364;204 million), Genzyme (&#8364;50 million) and Amunix (&#8364;109 million).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately &#8364;60.4 billion) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2023, Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the&#160;European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December&#160;31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October&#160;2023 (see Note&#160;D.30.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes deferred tax assets related to restructuring provisions, amounting to &#8364;286 million as of December 31, 2023, &#8364;256 million as of                 December 31, 2022, and &#8364;226 million as of December 31, 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes deferred taxes arising on the spread tax deduction of R&amp;D expenses, amounting to &#8364;1,331 million as of December 31, 2023 and &#8364;742 million as of December 31, 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The reserves of Sanofi subsidiaries that would be taxable if distributed but for which no distribution is planned, and for which no deferred tax liability has therefore been recognized, totaled &#8364;10.0 billion as of December 31, 2023, compared with &#8364;10.6 billion as of December 31, 2022 and &#8364;10.0 billion as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Most of Sanofi&#8217;s tax loss carry-forwards are available indefinitely. For a description of policies on the recognition of deferred tax assets, refer to Note&#160;B.22. For each tax consolidation, the recognition of deferred tax assets is determined on the basis of profit forecasts that are consistent with Sanofi&#8217;s medium-term strategic plan, and taking into consideration the tax consequences of the strategic opportunities available to Sanofi within the period of availability of tax loss carry-forwards and the specific circumstances of each tax consolidation. Deferred tax assets relating to tax loss carry-forwards as of December 31, 2023 amounted to &#8364;2,729 million, of which &#8364;1,203 million were not recognized (including &#8364;473&#160;million in respect of capital losses). This compares with &#8364;2,650 million as of December 31, 2022 (of which&#160;&#8364;1,144 million were not recognized) and &#8364;2,391 million as of&#160;December 31, 2021 (of which &#8364;875 million were not recognized).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows when tax losses available for carry-forward are due to expire:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:70.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Tax&#160;losses&#160;available for carry-forward</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2029 and later</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,933</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,503</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,644</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Excluding tax loss carry-forwards on asset disposals. Such carry-forwards amounted to &#8364;5 million as of December 31, 2023, &#8364;5 million as of       December 31, 2022 and &#8364;5 million as of December 31, 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Use of tax loss carry-forwards is limited to the entity in which they arose. In jurisdictions where tax consolidations are in place, tax losses can be netted against taxable income generated by entities in the same tax consolidation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deferred tax assets not recognized (primarily because their future recovery was not regarded as probable given the expected results of the entities in question) amounted to &#8364;1,062 million in 2023, &#8364;995 million in 2022 and &#8364;615 million in 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDeferredTaxesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523970144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Consolidated shareholders' equity</a></td>
<td class="text">Consolidated shareholders&#8217; equity<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.1. Share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, the share capital w</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as &#8364;2,529,599,938, consisting of 1,264,799,969&#160;shar</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">es with a par value of &#8364;2. Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of&#160;shares </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%&#160;of&#160;share&#160;capital <br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13.45</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.063</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.650&#160;</span></td><td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.28&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.658&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares are deducted from shareholders&#8217; equity. Gains and losses on disposals of treasury shares are recorded directly in equity and are not recognized in net income for the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in the share capital of the Sanofi parent company over the last three years are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:33.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,258,971,738</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190,076&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,836,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 28, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,562,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,263,560,695</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by exercise of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">490,373&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,499,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 27, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,027,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of December 14, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reduction in share capital by cancellation of </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">treasury shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,742,380)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,260,835,732</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by exercise of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">504,956&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,330,558&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 27, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,128,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,264,799,969</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Shares issued on exercise of Sanofi stock subscription options.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Shares vesting under restricted share plans and issued in the period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the disclosures about the management of capital required under IFRS&#160;7, refer to Note&#160;B.27.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.2. Restricted share plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note&#160;B.24.3. The principal characteristics of those plans are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 25, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 3, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 14, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 27, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Service period</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares awarded </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,838,434&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65,129&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,344,432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109,981&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,484,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,425,047&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000,627&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,335&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,209,901&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;87.69&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;77.42&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;91.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;79.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;77.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,413,387&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64,185&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,343,805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99,646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,274,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;83.74&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;74.50&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;86.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;69.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;71.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;68.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer - additional shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;43.60&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;34.90&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;49.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;54.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;82.17&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;84.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;71.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan at the date of grant </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">326</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">294</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">262</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Weighting between (i)&#160;fair value determined using the Monte Carlo model and (ii)&#160;market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Additional tranche subject to a higher level of market conditions: 121,097&#160;additional shares were awarded in May&#160;2023, and 5,838&#160;additional shares were awarded in December&#160;2023 (versus 114,874&#160;additional shares awarded in May&#160;2022, and 9,066&#160;additional shares awarded in December&#160;2022).</span></div><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023 (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022 (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested as of December 31</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,773,084&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,245,513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,507,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,780,513&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,099,158&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,330,801&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2021 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,893,413&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,097,531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,364,895&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2020 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,817,181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,014,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2019 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,128,458&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Additional tranche subject to a higher level of market conditions: 126,935&#160;additional shares were awarded in 2023, versus 123,940&#160;additional shares awarded in &#160;2022.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.3. Capital increases</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The characteristics of the employee share ownership plans awarded in the form of a capital increase reserved for employees in&#160;2023, 2022 and 2021 are summarized in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 2, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 3, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Subscription price </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79.58&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Subscription period</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 5-23, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 9-29, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 7-25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares subscribed</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,009,306&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,909,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,438,590&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares issued immediately as employer&#8217;s contribution</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119,417&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118,049&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124,112&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subscription price representing 80% of the average of the opening quoted market prices of Sanofi shares during the 20&#160;trading days preceding May&#160;31,&#160;2023, June&#160;6,&#160;2022 and June&#160;3, 2021, respectively.</span></div><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the expense recognized for each plan:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense recognized</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which employer&#8217;s contribution</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.4. Repurchase of Sanofi shares</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Annual General Meetings of Sanofi shareholders held on May 25, 2023, May&#160;3, 2022 and April&#160;30, 2021 each authorized a share repurchase program for a period of 18 months. The following repurchases have been made under those programs:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.185%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:29.25pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in number of shares and &#8364; million)</span></div><div style="padding-right:29.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year of authorization</span></div></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023 program</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,584,540&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022 program</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,000,204&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,510,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021 program</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,976,992&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,765,388&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020 program</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,758,569&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.5. Reductions in share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reductions in share capital for the accounting periods presented are described in the table included at Note&#160;D.15.1. above.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those reductions have no impact on shareholders&#8217; equity.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.6. Currency translation differences</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Currency translation differences comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(865)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(68)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,462</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(907)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The balance as of December 31, 2023 includes an after-tax amount of &#8364;(574) million relating to hedges of net investments in&#160;foreign operations (refer to Note&#160;B.8.3. for a description of the relevant accounting policy), compared with &#8364;(580) million as of&#160;December 31, 2022 and&#160;&#8364;(317) million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The movement in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Currency translation differences</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is mainly attributable to the US dollar.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.7. Other comprehensive income</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Actuarial gains/(losses) excluding investments accounted for using the equity method (see&#160;Note&#160;D.19.1.)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(212)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;padding-right:29.25pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(77)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">451</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">797</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow and fair value hedges:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,551)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,643&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Currency translation differences (investments accounted for using the&#160;equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Hedges of net investments in foreign operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(354)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(254)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,526)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,313</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,510</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: immaterial amount in 2023, immaterial amount in 2022 and &#8364;4 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: &#8364;1 million in 2023, &#8364;2 million in 2022 and &#8364;12 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: &#8364;(56) million in 2023, and &#8364;(40) million in 2022 (including &#8364;(35)&#160;million relating to the deconsolidation of EUROAPI). The amounts reclassified to profit and loss were immaterial in 2021. Currency translation differences arise from the translation into euros of the financial statements of foreign subsidiaries, and are mainly due to the appreciation of the dollar against the euro.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.8. Stock options</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock option plans awarded and measurement of stock option plans</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No stock options were awarded during 2023, 2022 or 2021.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock subscription option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Details of the terms of exercise of stock subscription options granted under the various plans are presented below in Sanofi share equivalents. These plans were awarded to certain corporate officers and employees of Sanofi companies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table shows all Sanofi stock subscription option plans still outstanding or under which options were exercised in the year ended&#160;December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:18.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date of grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>options<br/>granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Start&#160;date&#160;of<br/>exercise<br/>period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options outstanding as of 12/31/2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2013</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">788,725&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/06/2017</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72.19&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2014</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,009,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/06/2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73.48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91,355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/24/2015</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">435,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/25/2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/24/2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337,714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/04/2016</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">402,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/05/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/04/2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/10/2017</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/11/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/10/2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2018</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/03/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">04/30/2019</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">04/30/2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The exercise of all outstanding stock subscription options would increase shareholders&#8217; equity by approximately &#8364;107 million. The&#160;exercise of each option results in the issuance of one share.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of stock option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A summary of stock options outstanding at each balance sheet date, and of movements during the relevant periods, is presented below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise&#160;price</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">per share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,579,270</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">75.61</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">195</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,845,050&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">74.51&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">137&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(190,076)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options cancelled</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)&#160;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(51,216)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,337,968</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">77.13</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">180</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,949,184&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">78.15&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">152&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(490,373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options cancelled</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)&#160;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9,626)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,837,969</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78.64</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">145</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,624,569&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(504,956)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">80.53</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">107</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,333,013&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">80.53&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">107&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Mainly due to the grantees leaving Sanofi.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">residual&#160;life</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price per</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price per</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;60.00 to &#8364;70.00 per share</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.34</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;70.00 to &#8364;80.00 per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">569,505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.12</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">569,505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;80.00 to &#8364;90.00 per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.29</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.9. Number of shares used to compute diluted earnings per share</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.991%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.7&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.9&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,252.5&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,256.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,256.9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,257.9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023 and 2022, all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. In 2021, 0.6 million&#160;stock options were not taken into account in computing diluted earnings per share because they had no dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523941968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling interests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory', window );">Non-controlling interests</a></td>
<td class="text">Non-controlling interestsNon-controlling interests did not represent a material component of Sanofi&#8217;s consolidated financial statements in the years ended December 31, 2023, 2022 and 2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523859872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock', window );">Debt, cash and cash equivalents and lease liabilities</a></td>
<td class="text">Debt, cash and cash equivalents and lease liabilities<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.17.1. Debt, cash and cash equivalents</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in Sanofi's financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.991%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,347&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,857&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,123&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,531</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,218</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,250</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,793</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,437</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,983</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities, which amounted to &#8364;2,030 million as of December 31, 2023, &#8364;2,181</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> million as of December 31, 2022, and&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">2,108&#160;million as of December 31, 2021 </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(see the maturity analysis at Note&#160;D.17.2.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Net debt&#8221; is a non-IFRS financial measure used by management and investors to measure Sanofi&#8217;s overall net indebtedness.</span></div><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Reconciliation of carrying amount to value on redemption</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:25.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustment<br/>to debt<br/>measured&#160;at<br/>fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,347&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,546&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,143&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,176&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion<br/>of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(157)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,531</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,573</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,273</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,314</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,793</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,492</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a) Principal financing transactions during the year</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the movement in total debt during the period:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:14.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash&#160;flows&#160;from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">cash</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">flows </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,857&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(604)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,347&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,672)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,218</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,684)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">48</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">895</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">76</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,531</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts mainly comprise &#8364;946&#160;million related to the US commercial paper program.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;These amounts mainly comprise changes in accrued interest balances, and fair value adjustments.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi did not carry out any bond issues in 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Three bond issues were redeemed in 2023:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt">&#8364;1,750&#160;million issued in March&#160;2018, redeemed at maturity on March&#160;21, 2023;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt">$1,000&#160;million issued in June&#160;2018, redeemed at maturity on June&#160;20, 2023; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.57pt">&#8364;1,000&#160;million issued in November&#160;2013, redeemed at maturity on November&#160;14, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi entered into the following transactions relating to its syndicated credit facilities during 2023:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a new &#8364;4&#160;billion revolving credit facility, linked to sustainable development indicators, was put in place on March&#160;8, 2023. This syndicated facility was initially due to mature in March&#160;2028, and included two extension options of one year each; it replaced an existing &#8364;4&#160;billion facility that was canceled on the same day; and</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the maturity of this credit facility was extended to March&#160;7, 2029, following the exercise of an extension option in December&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, as of December&#160;31, 2023, Sanofi had two&#160;syndicated credit facilities to provide liquidity for the purposes of current operations, each of them linked to environmental and social indicators:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a &#8364;4&#160;billion facility maturing December&#160;6, 2027, with no further extension option available; and</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a &#8364;4&#160;billion facility maturing March&#160;7, 2029, with a one-year extension option.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In line with Sanofi&#8217;s commitment to embed sustainable development in the &#8220;Play to Win&#8221; strategy, those two&#160;revolving credit facilities build in an adjustment mechanism that links the credit spread to the attainment of two&#160;sustainable development performance indicators:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">for the facility maturing in December&#160;2027: (i)&#160;Sanofi&#8217;s contribution to polio eradication, and (ii) the reduction in Sanofi&#8217;s carbon footprint; and</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">for the facility maturing in March&#160;2029: (i)&#160;Sanofi&#8217;s contribution to improving access to essential medicines in low-income and intermediate-income countries via its Sanofi Global Health non-profit unit, and (ii)&#160;the reduction in Sanofi&#8217;s carbon footprint.</span></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the movement in total debt during prior periods:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash&#160;flows&#160;from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>cash<br/>flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,123&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,632)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(228)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,857&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,707)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,718)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,549</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(330)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">442</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,218</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the&#160;Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These amounts include movements in accrued interest and fair value remeasurements.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash&#160;flows&#160;from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>cash<br/>flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,745&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,704)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,123&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,767&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,203)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(615)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(197)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,631</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,241)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(812)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">381</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">291</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These amounts include (i) effects of changes in the scope of consolidation, amounting to &#8364;299&#160;million; (ii) movements in accrued interest; and (iii) fair value remeasurements.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b) Net debt by type, at value on redemption</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:14.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current </span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current </span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,416&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,134&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,044&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,817&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,861&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,118&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,946&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,546</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,027</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,573</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,143</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,130</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,273</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,176</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,138</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,314</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,546</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,711)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,143</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,651)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,492</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,176</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,129)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities (see the maturity schedule in Note&#160;D.17.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bond issues carried out by Sanofi under the Euro Medium Term Note (EMTN) program are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issuer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ISIN code</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issue date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual&#160;interest&#160;rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013143997</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2016</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.625%&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013505104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.000%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0014009KS6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.875%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0012969038</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.500%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013324340</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.000%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0012146801</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.750%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013201639</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.500%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013144003</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.125%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013409844</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.875%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0014009KQ0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.250%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013324357</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2030</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.375%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013505112</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2030</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.500%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013409851</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.250%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013324373</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2018</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2038</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.875%&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bond issues carried out by Sanofi under the public bond issue program (shelf registration statement) registered with the&#160;US&#160;Securities and Exchange Commission (SEC) comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issuer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ISIN code</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issue&#160;date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual&#160;<br/>interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($&#160;million)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US801060AD60</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 2018</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.625&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other borrowings&#8221; line mainly comprises participating shares issued between 1983 and 1987, of which 58,115&#160;remain outstanding, with a nominal amount of &#8364;9 million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to manage its liquidity needs for current operations, as of December&#160;31, 2023 Sanofi had:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a syndicated credit facility of &#8364;4&#160;billion, drawable in euros and in US dollars, maturing December&#160;6,&#160;2027; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a syndicated credit facility of &#8364;4&#160;billion, drawable in euros and in US dollars, maturing March&#160;7, 2029.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi also has two commercial paper programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a &#8364;6&#160;billion Negotiable European Commercial Paper program in France, with an average drawdown of &#8364;0.2&#160;billion and a maximum drawdown of &#8364;0.8&#160;billion during 2023, and an amount of &#8364;40&#160;million drawn down as of December&#160;31, 2023; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a $10&#160;billion Commercial Paper program in the United States, with an average drawdown of $3.7&#160;billion and a maximum drawdown of $7.3&#160;billion during 2023, and an amount of $1.0&#160;billion drawn down as of December&#160;31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financing in place as of December 31, 2023 at the level of the holding company (which manages most of Sanofi&#8217;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking spreads or fees to the credit rating.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c) Debt by maturity, at value on redemption</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,134&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,050&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used <br/>to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,573</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,027</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used <br/>to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,711)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities, which amounted to &#8364;2,030&#160;million as of December&#160;31, 2023; &#8364;2,181&#160;million as of&#160;December&#160;31, 2022; and&#160;&#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">2,108&#160;million as of December&#160;31, 2021</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> (see the maturity analysis at Note&#160;D.17.2.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, the main undrawn confirmed general-purpose credit facilities at holding company level amounted to&#160;&#8364;8 billion, half of which expired in 2027 and the other half of which expires in 2029.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, no single counterparty represented more than 6% of Sanofi&#8217;s undrawn confirmed credit facilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,861&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,817&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,684&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,273</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,130</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">661</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,600</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,160</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,722</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,492</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,651)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">661</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,600</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,160</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,722</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,946&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,629&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,979&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,314</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,138</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,647</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">602</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,751</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,160</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,016</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,129)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,647</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">602</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,751</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,160</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,016</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d) Debt by interest rate, at value on redemption</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below splits net debt between fixed and floating rate, and by maturity, as of December 31, 2023. The figures shown are values on redemption, before the effects of derivative instruments:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,080</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,050&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">14,228</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,852</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% fixed-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">97</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Floating-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">511</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,591</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,045</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4,115)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4,251)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,881</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,665)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi issues debt in two currencies, the euro and the US dollar, and also invests its cash and cash equivalents in those currencies. Sanofi also operates cash pooling arrangements to manage the surplus cash and short-term liquidity needs of foreign subsidiaries located outside the euro zone.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To optimize the cost of debt or reduce the volatility of debt and manage its exposure to financial foreign exchange risk, Sanofi uses derivative instruments (interest rate swaps, currency swaps, foreign exchange swaps and forward contracts) that alter the fixed/floating rate split and the currency split of its net debt:</span></div><div style="margin-bottom:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,382</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,034)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,050&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11,382</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% fixed-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Floating-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,191</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,061&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">113</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,300</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,573</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,027</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,738)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4,642)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2,132)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1,143)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,835</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,711)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the fixed/floating rate split of net debt at value on redemption after taking account of derivative instruments as of&#160;December 31, 2022 and December&#160;31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed-rate debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,386&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,612&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Floating-rate debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,273</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,314</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,781)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,267)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,492</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The weighted average interest rate on debt as of December 31, 2023 was 1.6% before derivative instruments and 2.1% after derivative instruments. Cash and cash equivalents were invested as of December 31, 2023 at an average rate of 3.9% before derivative instruments and 3.7% after derivative instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The projected full-year sensitivity of net debt to interest rate fluctuations for 2024 is as&#160;follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:53.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in short-term interest rates</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact&#160;on&#160;pre-tax&#160;net</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">income&#160;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact&#160;on&#160;pre-tax</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">income/(expense)&#160;recognized</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">directly in equity</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+100&#160;bp</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25&#160;bp</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-25&#160;bp</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-100&#160;bp</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e) Debt by currency, at value on redemption</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows net debt by currency at December 31, 2023, before and after derivative instruments contracted to convert the foreign-currency net debt of exposed entities into their functional currency:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:53.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Before&#160;derivative&#160;instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">After&#160;derivative&#160;instruments</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,113&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,852&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,376)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,143)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pound sterling</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other currencies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,881</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows net debt by currency at December 31, 2022 and 2021, after derivative instruments contracted to convert the foreign currency net debt of exposed entities into their functional currency:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:74.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,489&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,129&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,404)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(669)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other currencies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,593)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,413)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,492</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">f) Market value of net debt</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,086&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,227&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,024&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,835&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,492&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,047&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of debt is determined by reference to quoted market prices at the balance sheet date in the case of quoted instruments (level&#160;1 in the IFRS&#160;7 hierarchy, see Note&#160;D.12.), and by reference to the fair value of interest rate and currency derivatives used to manage net debt (level&#160;2 in the IFRS&#160;7 hierarchy, see Note&#160;D.12.).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">g) Future contractual cash flows relating to debt and related derivatives</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:42.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,710</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,153</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,187</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,285</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,719</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,454</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,468&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,917&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,011&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,079&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash flows related to derivative instruments</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">143</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">47</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,853</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,200</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,944</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,210</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,309</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,735</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,455</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Future contractual cash flows are shown on the basis of the carrying amount in the balance sheet at the reporting date, without reference to any subsequent management decision that might materially alter the structure of Sanofi&#8217;s debt or its hedging policy.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt as of December 31, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:42.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,408</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,206</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">868</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,803</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,184</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,283</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,064</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,932&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,928&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,601&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,011&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,580&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash flows related to derivative instruments</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">209</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">60</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">38</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">25</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,617</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,230</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">928</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,841</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,215</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,314</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,089</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:42.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,728</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,330</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,826</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">791</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,937</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,176</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,668</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,086&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,588&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,011&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,080&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash flows related to derivative instruments</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(51)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(59)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,677</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,271</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,825</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">793</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,939</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,178</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,671</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.17.2. Lease liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A maturity analysis of lease liabilities as of December 31, 2023, 2022 and 2021 is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:41.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.398%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Undiscounted future minimum lease payments</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less than 1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From 1 to 3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From 3 to 5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More than 5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Discounting effect</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total lease liabilities as of December 31, 2023</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,030</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">291</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">360</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">989</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(58)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total lease liabilities as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,181</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">320</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">515</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">436</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,129</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(219)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total lease liabilities as of December 31, 2021</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,108</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">314</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">476</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">362</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,184</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(228)</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Lease liabilities include leases relating to real estate assets located at Cambridge, MA (United States), as described in Note&#160;D.3., which have a lease term of 15 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of debt instruments issued explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523859872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities related to business combinations and to non-controlling interests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock', window );">Liabilities related to business combinations and to non-controlling interests</a></td>
<td class="text">Liabilities related to business combinations and to non-controlling interests<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of the nature of the liabilities reported in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, refer to Note&#160;B.8.5. The principal acquisitions are described in Notes&#160;D.1. and&#160;D.2.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS&#160;7 fair value hierarchy (see Note&#160;D.12.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.734%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bayer</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">contingent</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">consideration</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">arising&#160;from&#160;the</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">acquisition of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Genzyme </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">MSD<br/>contingent<br/>consideration<br/>(European<br/>Vaccines<br/>business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shire</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">contingent</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">consideration</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">arising&#160;from&#160;the</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">acquisition of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Translate Bio</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contingent consideration arising from acquisition of Amunix</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at January 1, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">104</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">312</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">189</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">605</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">New transactions</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(152)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(258)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">354</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">714</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">New transactions</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(79)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(136)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">204</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">380</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">165</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">779</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">New transactions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">127</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">441</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">709</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Portion due after more than one year: &#8364;501 million as of December 31, 2023 (&#8364;674 million as of December 31, 2022 and &#8364;577 million as of December 31, 2021); portion due within less than one year: &#8364;208 million as of December 31, 2023 (&#8364;105 million as of December 31, 2022 and &#8364;137&#160;million as of&#160;December 31, 2021).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Amounts reported within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, and mainly comprising unrealized gains and losses.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Mainly corresponds to the recognition of the Shire Human Genetic Therapies&#160;Inc. (Shire) contingent consideration liability of $382 million resulting from the acquisition of Translate Bio in September&#160;2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column mainly relates to the contingent consideration liability due to True North Therapeutics as a result of Sanofi's acquisition of Bioverativ which was settled in the first half of 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprised:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture, which amounted to &#8364;127 million as of December 31, 2023, &#8364;204 million as of&#160;December 31, 2022 and &#8364;269 million as of December 31, 2021 (see Note&#160;D.12.). The fair value of this contingent consideration is determined by applying the royalty percentage stipulated in the contract to discounted sales projections. If the discount rate were to fall by one percentage point, the fair value of the MSD contingent consideration liability would increase by approximately 1%;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi&#8217;s acquisition of Translate&#160;Bio in September&#160;2021. In a business combination carried out in December 2016 and predating the acquisition of control by Sanofi, Translate Bio (then called Rana Therapeutics, Inc.) acquired from Shire the intellectual property rights relating to the latter&#8217;s Messenger RNA Therapeutics (MRT) program. As of December 31, 2023, Shire was entitled to receive the following potential payments:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">milestone payments contingent on the launch of products based on MRT technology, and on the attainment of a specified level of sales of those products, and</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">a percentage of sales of those products.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of the Shire liability was measured at &#8364;441 million as of December 31, 2023, compared with &#8364;380 million as of&#160;December 31, 2022 and &#8364;354 million as of December 31, 2021; it was determined by applying the contractual terms to development and sales projections which were weighted to reflect the probability of success, and discounted. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately 12%;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the contingent consideration liability arising from the 2022 acquisition of Amunix. The fair value of the liability is determined on&#160;the basis of the nominal value of payments due subject to the attainment of specified</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> development milestones. The liability was measured at &#8364;137&#160;million as of December 31, 2023 </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">compared with &#8364;165 million as of&#160;December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. If the discount rate were to fall by one percentage point, the fair value of the liability would increase by approximately&#160;1%.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Bayer contingent consideration liability arising from Sanofi&#8217;s acquisition of Genzyme in 2011 was extinguished during 2023 in accordance with the contractual terms.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the maximum amount of contingent consideration payable in respect of already-marketed products:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From&#160;1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From&#160;3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commitments relating to contingent consideration&#160;in connection with business combinations</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The nominal amount of contingent consideration was &#8364;604 million as of December 31, 2022 and &#8364;689 million as of            December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to business combination and to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523830416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock', window );">Provisions, income tax liabilities and other liabilities</a></td>
<td class="text">Provisions, income tax liabilities and other liabilities<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,262&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,822&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,340&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,602</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,341</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,721</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes derivative financial instruments: &#8364;164&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">as of December 31, 2023</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, &#8364;232 million as of December 31, 2022, &#8364;6 million as of December 31, 2021.<br/>The figure as of December 31, 2023 includes &#8364;1,960&#160;million for the liability in respect of royalties payable to Sobi on net sales of BEYFORTUS (nirsevimab) in the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;1,112&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;2,860 million.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current income tax liabilities are described in Note&#160;D.19.4., and other current liabilities in Note&#160;D.19.5.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth movements in non-current provisions for the reporting periods presented:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:33.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions&#160;for<br/>pensions and<br/>other&#160;post-employment<br/>benefits<br/>(D.19.1.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions<br/>for other<br/>long-term<br/>benefits</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Restructuring<br/>provisions<br/>(D.19.2.)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>provisions<br/>(D.19.3.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,276</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">879</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">868</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,975</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,998</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(222)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(107)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(459)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(145)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(200)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(370)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(425)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(448)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(448)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,947</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">935</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">524</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,024</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,430</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(96)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(76)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(200)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(275)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(528)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(191)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(288)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(265)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(780)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(780)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,039</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">844</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">761</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,178</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,822</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(758)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(572)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,214</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">718</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">554</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,776</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,262</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Includes the impact of the April&#160;2021 IFRIC agenda decision on the allocation of benefits to service periods, as described in Note&#160;A.2.1. to the consolidated financial statements for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.19.1. Provisions for pensions and other post-employment benefits</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi offers its employees pension plans and other post-employment benefit plans. The specific features of the plans (benefit formulas, fund investment policy and fund assets held) vary depending on the applicable laws and regulations in each country where the employees work. These employee benefits are accounted for in accordance with IAS&#160;19 (see Note&#160;B.23.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi&#8217;s pension obligations in four&#160;major countries represented approximately 89% of the total value of the defined-benefit obligation and approximately 88% of the total value of plan assets as of December 31, 2023. The features of the principal defined-benefit plans in each of those four countries are described below.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">France</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Lump-sum retirement benefit plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All employees working for Sanofi in France are entitled on retirement to a lump-sum payment, the amount of which depends both on their length of service and on the rights guaranteed by collective and internal agreements. The employee&#8217;s final salary is used in calculating the amount of these lump-sum retirement benefits. These plans represent approximately 39% of Sanofi&#8217;s total obligation in France.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Defined-benefit pension plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These plans provide benefits from the date of retirement. Employees must fulfil a number of criteria to be eligible for these benefits. All of these plans are now closed. These plans represent approximately&#160;61% of Sanofi&#8217;s total obligation in France.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Germany</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Top-up defined-benefit pension plan</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The benefits offered under this pension plan are wholly funded by the employer (there are no employee contributions) via a Contractual Trust Agreement (CTA), under which benefits are estimated on the basis of a career average salary. Employees are entitled to receive an annuity under this plan if their salary exceeds the social security ceiling. The amount of the pension is calculated by reference to a range of vesting rates corresponding to salary bands. The plan also includes disability and death benefits. This plan represents approximately 60% of Sanofi&#8217;s total obligation in Germany.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi-Aventis plus (SAV plus)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A top-up pension plan (SAV plus) replaced a previous top-up defined-benefit plan. New entrants joining the plan after April&#160;1,&#160;2015 contribute to a defined-contribution plan that is partially funded via the company&#8217;s CTA.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All employees whose salary exceeds the social security ceiling are automatically covered by the plan. The employer&#8217;s contribution is 14% of the amount by which the employee&#8217;s salary exceeds the social security ceiling.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Multi-employer plan </span><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Pensionskasse)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This is a defined-benefit plan treated as a defined-contribution plan, in accordance with the accounting policies described in&#160;Note&#160;B.23. Currently, contributions cover the level of annuities. Only the portion relating to the future revaluation of&#160;the&#160;annuities is included in the defined-benefit pension obligation. The obligation relating to this revaluation amounted to&#160;&#8364;744 million as of December 31, 2023, versus&#160;&#8364;652 million as of December 31, 2022 and &#8364;877 million as of December 31, 2021. This plan represents approximately 26% of Sanofi&#8217;s total defined-benefit obligation in Germany.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Defined-benefit pension plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the United States, there are two types of defined-benefit plan:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">&#8220;qualified&#8221; plans within the meaning of the Employee Retirement Income Security Act of 1974 (ERISA), which provide guaranteed benefits to eligible employees during retirement, and in the event of death or disability. Employees can elect to receive a reduced annuity, in exchange for an annuity to be paid in the event of their death to a person designated by them. An annuity is also granted under the plan if the employee dies before retirement age. Eligible employees do not pay any contributions. These plans are closed to new entrants, and the vesting of rights for future service periods is partially frozen. These plans represent approximately 59% of Sanofi&#8217;s total obligation in the United States;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">&#8220;non-qualified&#8221; plans within the meaning of ERISA provide top-up retirement benefits to some eligible employees depending on the employee&#8217;s level of responsibility and subject to a salary cap. These plans represent approximately 14% of Sanofi&#8217;s total obligation in the United States.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare cover and life insurance</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi companies provide some eligible employees with healthcare cover and life insurance during the retirement period (the company&#8217;s contributions are capped at a specified level). These plans represent approximately 27% (or &#8364;412 million) of Sanofi&#8217;s total obligation and&#160;3% (or &#8364;23 million) of total plan assets in the United States.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United Kingdom</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">Defined-benefit pension plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi operates a number of pension plans in the United Kingdom that reflect past acquisitions. The most significant arrangements are defined-benefit plans that have been closed since October&#160;1, 2015. With effect from that date, employees can no longer pay into these plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under these defined-benefit plans, an annuity is paid from the retirement date. This annuity is calculated on the basis of the employee&#8217;s length of service as of September&#160;30, 2015, and of the employee&#8217;s final salary (or salary on the date he or she leaves Sanofi).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The rates used for the vesting of rights vary from member to member. For most members, rights vest at the rate of 1.25% or 1.50% of final salary for each qualifying year of service giving entitlement. The notional retirement age varies according to the category to which the member belongs, but in most cases retirement is at age 65. Members may choose to retire before or after the notional retirement age (60&#160;years), in which case the amount of the annual pension is adjusted to reflect the revised estimate of the length of the retirement phase. Pensions are usually indexed to the Retail Price Index (RPI). Members paid a fixed-percentage contribution into their pension plan (the percentage varied according to the employee category), and the employer topped up the contribution to the required amount. These plans represent approximately 100% of Sanofi&#8217;s total obligation in the United Kingdom.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For service periods subsequent to October&#160;1, 2015, employees belong to a new defined-contribution plan.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Actuarial assumptions used to measure Sanofi&#8217;s obligations</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial valuations of Sanofi&#8217;s benefit obligations were computed by management with assistance from external actuaries as of&#160;December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those calculations were based on the following financial and demographic assumptions:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.95% to 3.15%</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.95% to 3.15%</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.75%</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.50%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.55% to 3.75%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.55% to 3.75%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.90%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.75%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.10%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.10%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.10%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.10%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.70%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.90%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">General inflation rate</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.20%</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.20%</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.05%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.50%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.50%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.25%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.95%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.95%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.30%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pension benefit <br/>indexation</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.20%</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.20%</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.90%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.50%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.50%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.00%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.95%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.95%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.15%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Healthcare cost </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">inflation rate</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.00%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.75%</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.29%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.56%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.50% to 4.50%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retirement age</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 67</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 70</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 65</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 67</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 70</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 65</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 67</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 70</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 65</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mortality table</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TGH/<br/>TGF<br/>05</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Heubeck<br/>RT<br/>2018 G</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RP2012 Proj.<br/>MP2021 White Collar</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAPS<br/>S3</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TGH/<br/>TGF<br/>05</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Heubeck<br/>RT<br/>2018 G</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RP2012 Proj.<br/>MP2021 White Collar</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAPS<br/>S3</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TGH/<br/>TGF<br/>05</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Heubeck<br/>RT<br/>2018 G</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RP2012 Proj.<br/>G.&#160;Scale<br/>MP2020 White Collar</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAPS<br/>S3</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The discount rates used were based on market rates for high quality corporate bonds with a duration close to that of the expected benefit payments under the plans. The benchmarks used to determine discount rates were the same for all periods presented.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The rate depends on the duration of the plan (0&#160;to 7&#160;years, 7&#160;to 10&#160;years, or more than 10&#160;years).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Inflation for the euro zone is determined using a multi-criterion method.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;No post-employment healthcare benefits are provided in France since 2020, Germany and UK.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average duration of obligation for pensions and other long-term benefits in principal countries</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the duration of Sanofi&#8217;s obligations in the principal countries:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:25.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted average duration</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sensitivity analysis</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the sensitivity of Sanofi&#8217;s obligations for pensions and other post-employment benefits to changes in key actuarial assumptions:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions and other post-employment benefits, <br/>by principal country</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement of defined-benefit obligation</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in<br/>assumption</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.50&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+56&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+170&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+78&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+42&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">General inflation rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pension benefit indexation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Healthcare cost inflation rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortality table</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+1 year</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+38&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+53&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+19&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below reconciles the net obligation in respect of Sanofi&#8217;s pension and other post-employment benefit plans with the amounts recognized in the consolidated financial statements:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:63.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement of the obligation:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Beginning of period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,651&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,456&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial losses/(gains) due to changes in demographic assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(162)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial losses/(gains) due to changes in financial assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,006)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial losses/(gains) due to experience adjustments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(120)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan amendments, curtailments or settlements not specified in the terms of the plan</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(229)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan settlements specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(463)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(503)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation and transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Obligation at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,930</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,651</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,175</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Beginning of period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,899&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,651&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,358&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between actual return and interest income on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Administration costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan settlements specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan settlements not specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employer&#8217;s contributions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(426)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(458)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation and transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan assets at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,993</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,899</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,651</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net obligation</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,943</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,770</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,539</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts recognized in the balance sheet:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded obligations (see Note D.7.)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(408)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Obligations provided for</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,214&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,039&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount recognized at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,943</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,770</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,539</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit cost for the period:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in&#160;the&#160;terms&#160;of the plan</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest (income)/cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Administration costs and taxes paid during the period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense recognized directly in profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">190</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">168</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">276</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(650)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(685)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">361</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(482)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(409)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts include the impact of applying the April&#160;2021 IFRIC agenda decision on the attribution of benefits to periods of service.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;For 2023, this line includes &#8364;66&#160;million of assets in the United Kingdom (versus &#8364;99&#160;million for 2022 and &#8364;220&#160;million for 2021); those amounts are not subject to any asset ceiling, in accordance with IFRIC&#160;14.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Amounts recognized in Other comprehensive income (see Note&#160;D.15.7.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show Sanofi&#8217;s net liability in respect of pension plans and other post-employment benefits by geographical region:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:25.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Measurement of obligation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,911&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,930&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,401&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,235&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,993&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">647</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">510</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">703</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">144</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,943</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:25.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Measurement of obligation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,324&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,730&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,651&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,317&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">627</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">413</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">686</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(95)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">139</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,770</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:25.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Measurement of obligation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,576&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,099&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,175&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,651&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">819</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">768</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">972</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(215)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">195</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,539</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The adoption in April&#160;2023 of pension reforms in France (including the raising of the retirement age from 62&#160;to 64&#160;years) qualifies as a plan amendment within the meaning of IAS&#160;19, and resulted in the recognition of an immaterial amount in the income statement and the balance sheet for the year ended December&#160;31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the fair value of plan assets relating to Sanofi&#8217;s pension and other post-employment plans, split by asset category:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Securities quoted in an active market</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84.9</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84.4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">86.9</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bonds and similar instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commodities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13.1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance policies</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has a long-term objective of maintaining or increasing the extent to which its pension obligations are covered by assets. To this end, Sanofi uses an asset-liability management strategy, matching plan assets to its pension obligations. This policy aims to ensure the best fit between the assets held on the one hand, and the associated liabilities and expected future payments to plan members on the other. To meet this aim, Sanofi operates a risk monitoring and management strategy (mainly focused on interest rate risk and inflation risk), while investing a growing proportion of assets in high-quality bonds with comparable maturities to those of the underlying obligations and in contracts entered into with leading insurance companies to fund certain post-employment benefit obligations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the service cost for Sanofi&#8217;s pension and other post-employment benefit plans, by geographical region:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Service cost for 2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost/(income) including administration costs and taxes paid during the period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) recognized directly in profit or loss</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">56</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">190</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">55</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">143</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">82</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">39</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">361</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Service cost for 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost/(income) including administration costs and taxes paid during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) recognized directly in profit or loss</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">53</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(13)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">36</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">168</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(156)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(204)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(382)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(650)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(145)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(151)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(301)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">117</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(482)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Service cost for 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost/(income) including administration costs and taxes paid during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) recognized directly in profit or loss</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">80</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">276</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(106)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(113)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(157)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(236)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(73)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(685)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(26)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(61)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(73)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(230)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(19)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(409)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of the &#8220;Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)&#8221; line in the preceding tables is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:19.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.429%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) arising during the period</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(131)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprising:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">on experience adjustments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(120)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(620)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(287)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) <br/>on demographic assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) <br/>on financial assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Experience adjustments are mainly due to the effect on plan assets of trends in the financial markets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The net pre-tax actuarial loss (excluding investments accounted for using the equity method) recognized directly in equity is presented below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net pre-tax actuarial loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,259)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,090)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,738)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The present value of Sanofi&#8217;s obligations in respect of pension and other post-employment benefit plans at the end of each reporting period is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of wholly or partially funded obligations in respect of pension and other post-employment benefit plans</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,463&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,416&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of unfunded obligations</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,930</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,651</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,175</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense for pensions and other post-employment benefits (&#8364;190 million in 2023) is allocated between income statement line items as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating (income)/expenses, net</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">190</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">168</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">276</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The estimated amounts of employer&#8217;s contributions to plan assets in 2024 are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employer&#8217;s contributions in 2024 (estimate):</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the expected timing of benefit payments under pension and other post-employment benefit plans for future years:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated future benefit payments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2029 to 2033</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,213&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows estimates as of December 31, 2023 for the timing of future payments in respect of unfunded pension and other post-employment benefit plans:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than 1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to <br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to <br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated payments</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.19.2. Restructuring provisions</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in restructuring provisions classified in non-current and current liabilities:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,233</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,118</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,499</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in non-current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in provisions recognized in profit or loss for the period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(522)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(571)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discount</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,132</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,233</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,118</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in non-current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Provisions utilized mainly correspond to payments related to employees affected by separation programs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions for employee termination benefits as of December 31, 2023 amounted to &#8364;968 million (compared with &#8364;1,039&#160;million as of December 31, 2022 and &#8364;943 million as of December 31, 2021).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisions apply mainly to France, and relate to various voluntary redundancy programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">agreement under the Job Management and Career Paths (GEPP) scheme affecting several French legal entities, signed on&#160;February&#160;28, 2022 and announced in April&#160;2022 as part of the &#8220;Play to Win&#8221; strategy. The agreement provides internal transfer and outplacement opportunities for employees whose jobs are undergoing transformation, and also includes an end-of-career paid leave program and an external retraining program. Most of the provisions charged in 2022 relate to this plan, which began to be implemented in 2022. The provisions charged in 2023 reflect adjustments to the job profiles deemed to be "sensitive"; the reversals recognized during 2023 are due mainly to the Borne Law, which raises the retirement age to 64 and hence disqualifies some participants eligible under previous legislation (in light of the maximum period for portage workers);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">collectively-agreed separation programs involving a number of legal entities announced at the end of June&#160;2020 as part of the rollout of the &#8220;Play to Win&#8221; strategy; these include an end-of-career paid leave plan and an external retraining program, and were still ongoing during 2023. In addition, Sanofi-Aventis Recherche &amp;&#160;D&#233;veloppement (i)&#160;announced a voluntary redundancy program in&#160;2020 in connection with the reorganization of R&amp;D operations in France, which was implemented in&#160;2021, and (ii)&#160;signed a collectively-agreed termination program in&#160;2021 as part of the rollout of the &#8220;Play to Win&#8221; strategy; these programs, which cover support functions, include an end-of-career paid leave plan and an end-of-career transition plan;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">programs announced in 2019 relating to (i)&#160;R&amp;D (Sanofi-Aventis Recherche &amp;&#160;D&#233;veloppement) and (ii)&#160;sales forces (the&#160;&#8220;SAF&#160;2019&#8221; plan implemented by Sanofi-Aventis France);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">collectively-agreed separation programs announced in 2018 relating to the reorganization of support functions (&#8220;Horizon&#160;2020&#8221; plan).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The remainder of the provision for France comprises termination benefits associated with previously-announced programs (early retirement plans and end-of-career transition plans).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provision includes the present values of:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gross annuities for self-funded plans;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">employer&#8217;s social security charges on early retirement annuities for all plans (outsourced and self-funded); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the levy charged on those annuities under the &#8220;Fillon&#8221;&#160;law (only for plans with termination of employment contracts).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The average residual portage periods under these plans were 2.22&#160;years, 2.60&#160;years and 1.94&#160;years as of December 31, 2023, 2022 and&#160;2021, respectively.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main other countries covered by restructuring provisions are Germany, Japan and the United States.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The timing of future termination benefit payments is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit payments by period</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employee termination benefits</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">France</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other countries</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">968</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">362</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">86</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit payments by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employee termination benefits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">France</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other countries</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,039</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">374</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">215</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit payments by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employee termination benefits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">France</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other countries</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">943</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">476</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">394</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">67</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.19.3. Other provisions</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other provisions</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> include provisions for risks and litigation relating to environmental, tax, commercial and product liability matters.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Environmental risks</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Product liability risks, litigation and other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,776</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,178</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,024</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions for environmental risks relate primarily to contingencies arising from business divestitures, and include remediation costs relating to such environmental risks.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Identified environmental risks are covered by provisions estimated on the basis of the costs Sanofi believes it will be obliged to meet over a period not exceeding (other than in exceptional cases) 30&#160;years. Sanofi expects that &#8364;86 million of those provisions will be utilized in&#160;2024, and &#8364;194 million over the period from 2025 through 2028.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards greenhouse gas emission quotas, which relate to Sanofi production facilities in France and Ireland, in the absence of specific IFRS pronouncements  Sanofi has adopted the "net liability approach". That involves recognizing a liability at the balance sheet date if actual emissions exceed the quotas held, in accordance with IAS&#160;37 and French GAAP (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Plan Comptable G&#233;n&#233;ral,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Article&#160;615-1s). Quotas are managed as a production cost, and as such are recognized in inventory at a zero value (if received free of charge) and at acquisition cost (if bought on the market). As of December&#160;31, 2023, no liability was recognized, and quotas valued at &#8364;3&#160;million were held in inventory.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Product liability risks, litigation and other&#8221; mainly comprises provisions for risks relating to product liability (including IBNR provisions as described in Note&#160;B.12.), government investigations, regulatory or antitrust law claims, contingencies arising from business divestitures (other than environmental risks), and remediation costs related to leases.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main pending legal and arbitral proceedings and government investigations are described in Note&#160;D.22.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A full risk and litigation assessment is performed with the assistance of Sanofi&#8217;s legal advisers, and provisions are recorded as required by circumstances in accordance with the principles described in Note&#160;B.12.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.19.4. Non-current income tax liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current income tax liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amounted to &#8364;1,842 million as of December 31, 2023 (versus &#8364;1,979 million as of          December 31, 2022 and &#8364;2,039 million as of December 31, 2021).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item includes the residual liability due after more than one year arising from </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">the estimated tax charge on deemed repatriation attributable to the accumulated earnings of non-US operations (</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8364;247 million as of December 31, 2023, &#8364;459&#160;million as of December 31, 2022 and &#8364;576 million as of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The expense was initially recognized in 2018 at an amount of&#160;$1,092&#160;million, and payment is being made over eight years through 2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current income tax liabilities include uncertainties over income tax treatments totaling &#8364;1,595 million as of                   December 31, 2023, versus &#8364;1,520 million as of December 31, 2022 and &#8364;1,463 million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A US legal restructuring resulted in a capital loss of &#8364;3&#160;billion&#160;recognized in the 2020 final tax filing. One-third of the capital loss has been used against 2020 capital gains and the remaining balance will be eligible to carry back for three years. Due to management&#8217;s judgement about potential alternative interpretations of the prevailing tax law, no tax benefit has been recognized on this transaction in accordance with IFRIC&#160;23.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.19.5. Current provisions and other current liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Current provisions and other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Taxes payable, other than corporate income taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,106&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring provisions (see Note&#160;D.19.2.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate derivatives (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency derivatives (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity derivatives (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amounts payable for acquisitions of non-current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Customer contract liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,590&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,741</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,021</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,217</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;See Note&#160;A.5.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, &#8220;Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. The year-on-year change in this item between 2022 and 2023 includes revenue of &#8364;269&#160;million  recognized in profit or loss during 2023 previously included in </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Customer contract liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> as of December&#160;31, 2022, compared with revenue of  &#8364;85&#160;million </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">recognized in profit or loss during 2022 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">previously included in  </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Customer contract liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> as of December&#160;31, 2021</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> . No such revenue was recognized in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#8220;Other current liabilities&#8221; mainly comprises provisions and liabilities for customer rebates and returns; provisions for discounts and rebates granted to healthcare authorities and governmental programs (see Note&#160;D.23.); and the liability payable at each reporting date under the Monoclonal Antibody Alliance with Regeneron.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;As of December 31, 2023 includes &#8364;131&#160;million (nominal value: &#8364;137 million) for the current liability relating to royalties payable to Sobi on net sales of BEYFORTUS (nirsevimab) in the United States (see Note&#160;C.2.)</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of provisions and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523627376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative financial instruments and market risks<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory', window );">Derivative financial instruments and market risks</a></td>
<td class="text">Derivative financial instruments and market risks<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the fair value of derivative instruments as of December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">assets</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current<br/>assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current<br/>liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current<br/>liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>liabilities</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2023 (net)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2022 (net)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2021 (net)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency derivatives</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">operating</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">financial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate derivatives</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(165)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity derivatives</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">201</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">201</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(164)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(127)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(291)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(90)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">( 120)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">213</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Objectives of the use of derivative financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi uses derivative instruments to manage operating exposure to movements in exchange rates, and financial exposure to movements in interest rates and exchange rates (where the debt or receivable is not contracted in the functional currency of the borrower or lender entity). On occasion, Sanofi uses equity derivatives in connection with the management of its portfolio of equity investments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi performs periodic reviews of its transactions and contractual agreements in order to identify any embedded derivatives, which are accounted for separately from the host contract in accordance with IFRS&#160;9. Sanofi had no material embedded derivatives as of December 31, 2023, 2022 or 2021.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Counterparty risk</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of counterparty risk, refer to &#8220;Item&#160;11. &#8212; Quantitative and Qualitative Disclosures about Market Risk&#8221;.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">a) Currency derivatives used to manage operating risk exposures</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of Sanofi&#8217;s objectives, policies and procedures for the management of operating foreign exchange risk, refer to &#8220;Item&#160;11. &#8212; Quantitative and Qualitative Disclosures about Market Risk&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2023, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as<br/>cash flow hedges</span></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which&#160;derivatives&#160;not<br/>eligible&#160;for&#160;hedge&#160;accounting</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which<br/>recognized&#160;in&#160;equity</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,112</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,112</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,981&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,981&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,246</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,246</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,358</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,358</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2022, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as<br/>cash flow hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which&#160;derivatives&#160;not<br/>eligible&#160;for&#160;hedge&#160;accounting</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which<br/>recognized&#160;in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,403</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,403</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,732&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">56&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,732&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">56&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,459</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(27)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,459</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(27)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Taiwan dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,862</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,862</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2021, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:20.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives<br/>designated&#160;as&#160;cash&#160;flow&#160;hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which&#160;derivatives&#160;not</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">eligible&#160;for&#160;hedge&#160;accounting </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which<br/>recognized<br/>in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">665&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">665&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Taiwan dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,374</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,374</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">833&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">833&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Russian rouble</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,286</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,286</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">b) Currency and interest rate derivatives used to manage financial exposure</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of Sanofi&#8217;s objectives, policies and procedures for the management of financial foreign exchange risk and interest rate risk, refer to &#8220;Item&#160;11. &#8212; Quantitative and Qualitative Disclosures about Market Risk&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:22.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.187%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,279</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">111</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,559</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,655</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6,628&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">59&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5,384&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,055</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,293</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">197</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,073&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(b) (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,816&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">205&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,334</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">53</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,556</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,948</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">212</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of December 31, 2023, the fair value of these forward contracts represented an asset of &#8364;54 million; the opposite entry was recognized in "Other comprehensive income", with the impact on financial income and expense being immaterial.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2023, the fair value of the contracts was a liability of &#8364;31 million, the opposite entry for &#8364;2.7&#160;million of which was credited to &#8220;Other comprehensive income&#8221; under the cost of hedging accounting treatment.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,044 million expiring in 2024, designated as a fair value hedge of the exposure of an equivalent amount of commercial paper. As of December 31, 2023, the fair value of the swaps was a liability of &#8364;3 million, the opposite entry for &#8364;0.7&#160;million of which was credited to &#8220;Other comprehensive income&#8221; under the cost of hedging accounting treatment.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:17.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2023</span></td><td colspan="3" style="background-color:#e3e3e3;padding:0 1pt"></td><td colspan="6" style="background-color:#e3e3e3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></div></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.03%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.32%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.69%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.92%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 3.43%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">999</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">906</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">650</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,405</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(165)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,405</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(165)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2022:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:17.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028 and later</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.03%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.32%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.69%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.92%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,584</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,434</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(232)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,434</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(232)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:17.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027 and later</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized EONIA/receive 0.06%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay -0.57%/receive capitalized EONIA</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized USD SOFR/receive 1.03%  </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized USD SOFR/receive 1.32%  </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">receive capitalized Eonia/pay 1.48%</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,642</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">880</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,579</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,979</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">600</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These interest rate swaps hedge fixed-rate bonds with a nominal of &#8364;99 million held in a Professional Specialized Investment Fund dedicated to Sanofi and recognized within &#8220;Long-term loans and advances and other non-current receivables&#8221; (see Note D.7.).</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">c) Actual or potential effects of netting arrangements</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below is prepared in accordance with the accounting policies described in Note&#160;B.8.3.:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:31.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.081%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross carrying amounts before offset (a)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(326)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(85)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross amounts offset (in accordance with IAS&#160;32)&#160;(b)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amounts as reported in the balance sheet (a) -&#160;(b) =&#160;(c)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">201</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(291)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(326)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">298</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(85)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effects of other netting arrangements (not fulfilling the IAS&#160;32 criteria for offsetting) (d)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(160)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(67)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of financial collateral</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net exposure (c) + (d)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(120)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(166)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">231</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of derivative financial instruments. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523654560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off balance sheet commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract', window );"><strong>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock', window );">Off balance sheet commitments</a></td>
<td class="text">Off balance sheet commitments<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The off balance sheet commitments presented below are shown at their nominal value.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.21.1. Off balance sheet commitments relating to operating activities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments relating to Sanofi&#8217;s operating activities comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:48.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Irrevocable purchase commitments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">given</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,141&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">received</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(443)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(96)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development license agreements - commitments given</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">commitments related to R&amp;D and other commitments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">contingent milestone payments in connection with development programs in progress</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,886&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total - net commitments given</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,079</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,563</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,878</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,625</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes the variable portion of future lease payments not recognized as lease liabilities as of December 31, 2023; the equivalent amount of these commitments as of December&#160;31, 2022 was &#8364;38&#160;million.<br/>During 2023, Sanofi signed a 15-year lease which will take effect in 2025 and for which Sanofi is committed for a minimum period of 12 years, corresponding to a minimum commitment of $0.2&#160;billion. The lease includes two extension options of five years each.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These comprise irrevocable commitments to suppliers of (i)&#160;property, plant and equipment, net of down-payments (see Note&#160;D.3.) and (ii)&#160;goods and services. As of December 31, 2022, irrevocable commitments amounted to &#8364;6,194 million given and &#8364;574 million received.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Irrevocable purchase commitments given as of December 31, 2023 include &#8364;926 million of commitments to joint ventures, and the commitment to EUROAPI as described in Note D.2. and amounting to &#8364;804&#160;million as of December 31, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Commitments related to R&amp;D, and other commitments, amounted to &#8364;259 million as of December 31, 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;This line includes only contingent milestone payments on development projects in progress. The equivalent amount as of December 31, 2022 was     &#8364;2,919 million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In pursuance of its strategy, Sanofi may acquire technologies and rights to products. Such acquisitions may be made in various contractual forms: acquisitions of shares, loans, license agreements, joint development, and co-marketing. These arrangements generally involve upfront payments on signature of the agreement, development milestone payments, and royalties. Some of these complex agreements include undertakings to fund research programs in future years and payments contingent upon achieving specified development milestones, the granting of approvals or licenses, or the attainment of sales targets once a product is commercialized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Research and development license agreements&#8221; line comprises future service commitments to fund research and development or technology, and contingent milestone payments regarded as reasonably achievable (i.e. all potential milestone payments relating to projects in the development phase, for which the future financial consequences are known or probable and for which there is a sufficiently reliable estimate). This line excludes:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">commitments given relating to (i)&#160;projects in the research phase, amounting to &#8364;16.8 billion as of December&#160;31, 2023 and &#8364;18.0 billion as of December&#160;31, 2022 and (ii)&#160;payments contingent upon the attainment of sales targets once a product is commercialized, amounting to &#8364;17.9 billion as of December&#160;31, 2023 and &#8364;18.5 billion as of December&#160;31, 2022);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">commitments received amounting to &#8364;10.0 billion as of December&#160;31, 2023 (&#8364;8.8 billion as of December&#160;31, 2022), mainly&#160;comprising research, development and commercialization agreements with partners further to the acquisitions of&#160;(i)&#160;Ablynx&#160;(&#8364;0.9 billion as of December 31, 2023, versus &#8364;1.0 billion as of December&#160;31, 2022); (ii)&#160;Kymab (&#8364;0.2 billion&#160;as of&#160;December 31, 2023, versus &#8364;0.2 billion as of December&#160;31, 2022) and (iii)&#160;Provention Bio (&#8364;0.3 billion as of&#160;December&#160;31,&#160;2023), plus contingent consideration receivable based on attainment of regulatory and&#160;sales milestones for commercialized products under the terms of licenses or rights assignment agreements amounting to &#8364;8.5 billion&#160;as of&#160;December&#160;31, 2023 (&#8364;7.6 billion&#160;as of December&#160;31, 2022).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The major agreements entered into by Sanofi in 2023 are described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">on June&#160;19, 2023, Sanofi expanded its collaboration with Scribe Therapeutics signed in September&#160;2022 and entered into an exclusive license agreement on CasX-Editor(XE) genome editing technology associated with guide RNAs for multiple targets including sickle cell disease and other genomic diseases. Under the terms of the agreement, Scribe Therapeutics received an upfront payment of $40&#160;million and may receive more than $1.2&#160;billion based on the achievement of certain milestones;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">on October&#160;3, 2023, Sanofi entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), to develop and commercialize the vaccine candidate against extra intestinal pathogenic strains of E. coli developed by Janssen, currently in&#160;Phase&#160;3. Under the terms of the agreement, both parties will co-fund current and future research and development costs. Sanofi paid $175&#160;million upfront to Janssen and may pay to Janssen milestone payments contingent on the attainment of certain development and commercial objectives;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">on October&#160;4, 2023, Sanofi entered into a collaboration with Teva Pharmaceuticals to co-develop and co-commercialize asset TEV&#8217;574, currently in Phase&#160;2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease. Under the terms of the new collaboration agreement, Teva received an upfront payment of&#160;&#8364;469&#160;million ($500&#160;million) and may receive up to &#8364;940&#160;million ($1&#160;billion) in milestone payments, depending on the achievement of development and commercialization goals.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, by acquiring all of the outstanding shares of Provention Bio, Inc. on April&#160;27, 2023 (see Note&#160;D.1.), Sanofi assumed  commitments amounting to &#8364;946&#160;million made by that company to various partners under collaboration agreements previously entered into.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of commitments as of December&#160;31, 2023 also includes commitments under agreements entered into by Sanofi in prior years, the principal ones of which are described below. For a full description of each agreement, refer to the Annual Report on Form&#160;20-F for the year in which the agreement was entered into.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The major agreements entered into by Sanofi in 2022 are described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">with Exscentia: an innovative license agreement and research collaboration to develop up to 15&#160;novel small molecule candidates across oncology and immunology, leveraging Exscientia&#8217;s end-to-end AI-driven platform utilizing actual patient samples;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">with ABL Bio: a licensing and collaboration agreement for the development of ABL301, a bispecific antibody intended as a treatment for alpha-synucleinopathies;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a collaboration and exclusive license agreement with Adagene Inc., a company specializing in the discovery and development of antibody-based therapies;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a strategic risk-sharing collaboration with Blackstone under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to &#8364;300&#160;million to accelerate the global pivotal studies and clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody SARCLISA, to treat patients with multiple myeloma. That amount will be paid to Sanofi on the basis of development expenses incurred. In addition, Sanofi may pay royalties on future sales of this solution;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an exclusive collaboration agreement with IGM Biosciences, Inc. to create, develop, manufacture and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a collaboration agreement with Skyhawk Therapeutics, Inc. to discover and develop novel small molecules that modulate RNA splicing to address challenging oncology and immunology targets;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a collaboration agreement with Atomwise that will leverage its ATOMNET platform to identify and synthesize up to five drug targets;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a research collaboration with Scribe Therapeutics to leverage its CRISPR by&#160;Design platform and to obtain a non-exclusive license to genome editing CasX-Editor(XE) technology for multiple oncology targets;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a strategic research collaboration with Insilico Medicine to leverage Insilico Medicine&#8217;s AI platform, Pharma.AI, to advance drug development candidates for up to six new therapeutic targets;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7-H3 from Innate&#8217;s ANKET (Antibody-based NK Cell Engager Therapeutics) platform.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal agreements entered into by Sanofi in previous years are listed below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Biond Biologics (2021): license agreement for the development and commercialization of BND-22 (a humanized IgG4 antagonist antibody targeting the Ig-like transcript&#160;2 (ILT2) receptor, in development for the treatment of solid tumors);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Kymera (2020): agreement to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Nurix Therapeutics (2020): collaboration to develop novel targeted protein degradation therapies;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">Denali Therapeutics&#160;Inc. (2018): collaboration agreement on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases. The two lead molecules are DNL747 in multiple sclerosis and amyotrophic lateral sclerosis, and DNL758 in systemic inflammatory diseases such as rheumatoid arthritis and psoriasis;</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and one of its alliance partners have decided to terminate the following agreement (the related commitments are no longer included in Sanofi&#8217;s off balance sheet disclosures as of December 31, 2023):</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">on January&#160;6, 2023, Sanofi and Regulus Therapeutics Inc. terminated their collaboration and license agreement on the discovery, development and commercialization of new micro-RNA derived molecules in fibrosis. The termination took effect on February&#160;5 ,2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, under the collaboration agreement with Regeneron on monoclonal antibodies (see Note&#160;C.1.), Sanofi is entitled to receive an additional share of quarterly profits (capped at 10% of Regeneron&#8217;s share of quarterly profits until March&#160;31, 2022, and thereafter at 20%), until Regeneron has paid 50% of the cumulative development costs incurred by the parties to the alliance. As&#160;of December&#160;31, 2023 this represented total commitments received of &#8364;2.1 billion (versus &#8364;2.7 billion as of December&#160;31, 2022), against cumulative development costs of &#8364;8.6 billion.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi entered into an agreement with Royalty Pharma in December&#160;2014 relating to development programs, under which Royalty Pharma bore a portion of the remaining development costs of the project on a quarterly basis in return for royalties on future sales. The products in development under that agreement have been launched in territories including the United States and Europe, marking the end of the joint development programs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;27, 2017, Sanofi and Lonza announced a strategic partnership in the form of a joint venture (BioAtrium AG) to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. An initial investment of approximately &#8364;0.3 billion to finance construction of the facility, split 50/50 between the two partners, has now been made in full. In addition, Sanofi could pay BioAtrium AG in the region of &#8364;0.6 billion over the 2023-2031 period  as its share of operating expenses and the cost of producing future batches.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February&#160;2014, pursuant to the &#8220;Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits&#8221; (still effective as of December 31, 2023), Sanofi Pasteur and the World Health Organization (WHO) signed a bilateral &#8220;Standard Material Transfer Agreement&#8221; (SMTA&#160;2). This agreement stipulates that Sanofi Pasteur will, during declared pandemic periods, (i)&#160;donate 7.5% of its real-time production of pandemic vaccines against any strain with potential to cause a pandemic, and (ii)&#160;reserve a further 7.5% of such production on affordable terms. The agreement cancels and replaces all preceding commitments to donate pandemic vaccines to the WHO.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.21.2. Off balance sheet commitments relating to financing activities</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit facilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Undrawn credit facilities are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">General-purpose credit facilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, total credit facilities amounted to &#8364;8,000 million (versus &#8364;8,000 million as of December 31, 2022 and&#160;&#8364;8,000 million as of December 31, 2021).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the amount of guarantees given and received:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Guarantees given:</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,936</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,815</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,794</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Guarantees provided to banks in connection with credit facilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other guarantees given</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,869&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,752&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Guarantees received</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,272)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,229)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,149)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.21.3. Off balance sheet commitments relating to asset acquisitions and divestments, and to changes in the scope of consolidation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, Sanofi had received commitments amounting in aggregate to &#8364;0.3&#160;billion in respect of (i)&#160;divestments of assets relating to transactions not yet finalized as of that date and (ii)&#160;contingent consideration arising under past agreements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments of a financing nature with associates and joint ventures are disclosed in N</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ote&#160;D.6.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off-balance sheet commitments relating to securities classified in the categories Equity instruments at fair value through other comprehensive income and Unquoted debt securities not meeting the definition of equity instruments are respectively disclosed in Notes D .7.1. and D.7.3..</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The maximum amount of contingent consideration relating to business combinations is disclosed in Note&#160;D.18.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of off-balance sheet commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523627376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal and arbitral proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract', window );"><strong>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock', window );">Legal and arbitral proceedings</a></td>
<td class="text">Legal and arbitral proceedings<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi&#160;products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures. Provisions related to legal and arbitral proceedings are recorded in accordance with the principles described in Note&#160;B.12.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Most of the issues raised by these claims are highly complex and subject to substantial uncertainties; therefore, the probability of loss and an estimation of damages are difficult to ascertain. Contingent liabilities are cases for which either we are unable to make a reasonable estimate of the expected financial effect that will result from ultimate resolution of the proceeding, or a cash outflow is not probable. In either case, a brief description of the nature of the contingent liability is disclosed and, where practicable, an estimate of its financial effect, an indication of the uncertainties relating to the amount and timing of any outflow, and the possibility of any reimbursement are provided in application of paragraph&#160;86 of IAS&#160;37.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed, we have indicated our losses or the amount of provision accrued that is the estimate of the probable loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a limited number of ongoing cases, while we are able to make a reasonable estimate of the expected loss or range of the possible loss and have accrued a provision for such loss, we believe that publication of this information on a case-by-case basis or by class would seriously prejudice the Company&#8217;s position in the ongoing legal proceedings or in any related settlement discussions. Accordingly, in those cases, we have disclosed information with respect to the nature of the contingency but have not disclosed our estimate of the range of potential loss, in accordance with paragraph&#160;92 of IAS&#160;37.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These assessments can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Our assessments are based on estimates and assumptions that have been deemed reasonable by management. We believe that the aggregate provisions recorded for the above matters are adequate based upon currently available information. However, given the inherent uncertainties related to these cases and involved in estimating contingent liabilities, we could in the future incur judgments that could have a material adverse effect on our net income in any particular period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Long term provisions are disclosed in Note&#160;D.19. They include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">provisions for product liability risks, litigation and other amount to &#8364;1,283 million in 2023. These provisions are mainly related to product liabilities, government investigations, competition law, regulatory claims, warranties in connection with certain contingent liabilities arising from business divestitures other than environmental matters and other claims;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">provisions for environmental risks and remediation amount to &#8364;493 million in 2023, the majority of which are related to contingencies that have arisen from business divestitures.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">a) Products</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi Pasteur Hepatitis&#160;B Vaccine Product Litigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since 1996, more than 180&#160;lawsuits have been filed in various French civil courts against Sanofi Pasteur and/or Sanofi Pasteur&#160;MSD&#160;S.N.C., the former French subsidiary of Sanofi, and the latter a joint venture company with Merck&#160;&amp; Co.,&#160;Inc. now terminated, for which past ongoing litigation is now managed by the originating party. In such lawsuits, the plaintiffs allege that they suffer from a variety of neurological disorders and autoimmune diseases, including multiple sclerosis and Guillain-Barr&#233; syndrome as a result of receiving the hepatitis&#160;B vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January&#160;2018, the Appeal Court of Bordeaux found a causal link between hepatitis&#160;B vaccine and multiple sclerosis. In&#160;July&#160;2019, the French Supreme Court </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cour de cassation)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> cancelled the&#160;judgment&#160;of the Appeal Court of Bordeaux and referred the&#160;case back to the Appeal Court of Toulouse. On March&#160;30, 2022, the Appeal Court of Toulouse dismissed all the plaintiff&#8217;s claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there were six&#160;ongoing lawsuits related to Sanofi Pasteur hepatitis&#160;B vaccine.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TAXOTERE Product Litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, there were approximately 6,770&#160;ingesting plaintiffs cases remaining in courts across the country.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Lawsuits have been filed against affiliates of Sanofi under US state law for personal injuries allegedly sustained in connection with&#160;the use of TAXOTERE. The actions are held in several jurisdictions around the country. In 2021, there were two&#160;bellwether trials as part of a federal multi-district litigation in the Eastern District of Louisiana both resulting in jury verdicts in Sanofi's favor. In 2023, Sanofi settled approximately 100&#160;individual cases.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TAXOTERE &#8211; Mississippi Attorney General Litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In October&#160;2018, the Attorney General for the State of Mississippi filed a civil action in Hinds County, Mississippi, Chancery Court against various Sanofi Defendants related to TAXOTERE. The State asserts one cause of action based on the Mississippi Consumer Protection Act (MCPA) and seeks a permanent injunction prohibiting Defendants&#8217; conduct and civil penalties of up to&#160;$10,000 for each violation. Sanofi filed a motion to dismiss the entire action in Hinds County, Mississippi, Chancery Court, which is currently pending.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZANTAC Litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2019, the US Food and Drug Administration (FDA) announced it was investigating the claims of an online pharmacy&#8217;s Citizen Petition that the medication ZANTAC (the brand name for ranitidine) used for stomach heartburn contains or can generate the chemical N-Nitrosodimethylamine (NDM), an alleged human carcinogen. As a precautionary measure, Sanofi initiated a voluntary recall of branded over-the-counter ZANTAC in October&#160;2019. Concurrent with FDA&#8217;s investigation, multiple personal injury lawsuits and class actions alleging that ZANTAC causes various cancers and seeking damages for either alleged personal injuries or alleged economic injuries were filed. Federal court cases were coordinated into a Multi-District Litigation (MDL) in the Southern District of Florida in February&#160;2020.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;6, 2022, the MDL Court granted Sanofi and other defendants&#8217; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Daubert</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and summary judgment motions. As a result, the Court entered final judgment in all cases involving plaintiffs&#8217; five designated cancers and dismissed the class action cases. Based on the preliminary estimates, more than 12,000&#160;plaintiffs have filed notices to appeal the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Daubert</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> ruling in the Eleventh Circuit. The MDL Court subsequently dismissed all pending cases alleging a non-designated cancer for failure to serve expert reports.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other cases are pending in various state courts. The majority of the state court plaintiffs have cases pending in Delaware, where a hearing on defendants&#8217; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Daubert</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> motions to exclude plaintiffs&#8217; experts was scheduled for January&#160;2024. Trials are scheduled in&#160;2024 in single-plaintiff cases in several states. No ZANTAC case has gone to trial to date.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Overall, there are currently around 3,280&#160;product liability &#8220;complaints&#8221; filed. These complaints encompass&#160;26,984&#160;individual product liability &#8220;plaintiffs&#8221; who have all filed against Sanofi. The vast majority of these plaintiffs participated in the MDL Court&#8217;s census registry program, allege cancers that the plaintiffs&#8217; leadership decided not to designate and pursue in the MDL, and have since filed their complaints in state courts. Additional cases may be filed.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, in November&#160;2019, Sanofi received a Civil Investigative Demand (CID) related to this issue from the Arizona Attorney General. Sanofi provided responses in December&#160;2019 and July&#160;2020 and has not received any follow-up requests.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2020, the New Mexico Attorney General filed a complaint against Sanofi, the previous marketing authorization holders for branded ZANTAC, a dozen generic manufacturers, and several retailers. The complaint brings claims for alleged violations of the New Mexico Unfair Practices Act, violations of the New Mexico False Advertising Act, violations of the New Mexico Public Nuisance Statute, common law public nuisance, and negligence. Trial in the case is scheduled for September&#160;2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2020, Sanofi received a notice from the US Department of Justice Civil Division and US Attorney&#8217;s Office for the Eastern District of Pennsylvania of an investigation into allegations that pharmaceutical manufacturers violated the False Claims Act,&#160;31&#160;U.S.C. &#167;&#160;3729, in relation to the drug ZANTAC and ranitidine hydrochloride through alleged failure to disclose to the federal government information about the potential presence of NDMA. In response to the notice, Sanofi provided information and documents including applications and communications with&#160;FDA, in August&#160;2020. Sanofi has not received any subsequent requests from the federal government.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In November&#160;2020, the Mayor and City Council of Baltimore filed a complaint against Sanofi, the previous marketing authorization holders for branded ZANTAC, generic manufacturers, and several retailers. The complaint alleges violations of the Maryland Consumer Protection statute, public nuisance, and negligence. Trial in the case is scheduled for June&#160;2025.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January&#160;2021, Sanofi was served with the Center for Environmental Health&#8217;s Second Amended Complaint alleging Proposition&#160;65&#160;violations. The case is pending in California Superior Court&#160;in Alameda County, and no trial date has been set.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZANTAC Litigation in Canada</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Between 2019 and 2022, seven&#160;proposed class actions naming some or all of Sanofi Consumer Health&#160;Inc., Sanofi-Aventis Canada Inc., Chattem (Canada)&#160;Inc., Sanofi and Sanofi Pasteur Limited as Defendants, relating to ranitidine were filed in courts in various Canadian provinces. The cases allege that proposed class members suffered personal injury from the ingestion of ranitidine, and seek damages in unspecified amounts, disgorgement of profits, restitution in the amount of the purchase price of ZANTAC and subrogated damages on behalf of provincial health insurers for health care costs related to ranitidine use.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May&#160;2023, in the proceedings pending before the Supreme Court of British Columbia, the Court dismissed the action, ruling that there is no scientific support for plaintiff&#8217;s claims. After this ruling, the Superior Court of Quebec stayed the corresponding proposed ZANTAC class proceedings in Quebec until the result of the US Multi-District Litigation (MDL) appeal is announced or&#160;October&#160;15, 2024&#8239;(whichever comes first).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of the remaining lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GOLD BOND Product Litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Over the last few years, Sanofi affiliates have been named in product liability actions in the United States regarding the alleged presence of asbestos in talc products originating from past acquisitions. A certain number of these claims were also dismissed during that time. As of December&#160;31, 2023,  there were approximately 500&#160;product liability ongoing actions. To date, no cases have proceeded to trial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DEPAKINE Product Litigation in France</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Civil proceedings</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, 79&#160;families brought a civil claim involving 133&#160;people exposed in utero to sodium valproate against a French affiliate of Sanofi seeking indemnification under French law for personal injuries allegedly suffered by children in connection with the use of sodium valproate by their mothers during pregnancy to treat their epilepsy (DEPAKINE). These actions are held in several jurisdictions in&#160;France.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Thirty lawsuits are in progress on the merits, the most advanced was tried at the French Supreme Court level which issued in&#160;November&#160;2019 a ruling sending the case before the Paris Appeal Court to rule on Sanofi&#8217;s argument on the compliance of the&#160;product with mandatory regulations, as well as on the question of defectiveness of the product and the assessment of damages. In January&#160;2023, the Paris Appeal Court ordered a stay in the proceedings until the submission of the second expert opinion report as part of the criminal investigation (see below).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Seven first instance rulings on the merits were handed down in 2022 by the Judicial Tribunal of Nanterre. In three cases, the Court declared the judicial expert report null and void and the Court dismissed one claim in another case.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Concerning three other cases relating to births that occurred between 2005 and 2009, the Court held, on the basis of a non-fault liability, that Sanofi was liable in light of the wording of the patient information leaflet. Provisional compensation amounts were set in the range of &#8364;0.1&#160;million to &#8364;0.5&#160;million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All the judgments have been appealed and are still pending.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the class action lawsuit filed in May&#160;2017 by the APESAC </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Association des Parents d&#8217;Enfants souffrant du Syndrome de l&#8217;Anti-Convulsivant)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> against the French affiliate, the Judicial Tribunal of Paris ruled on January&#160;5, 2022 that a class is admissible, retaining Sanofi&#8217;s liability between 1984 and January&#160;2006 for malformations and between 2001 and January&#160;2006 for neuro-developmental disorders (NDD). This decision is based on the conclusions of a criminal expert report within the frame of ongoing criminal proceeding, for which the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre de l&#8217;Instruction</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of the Appeal Court of Paris had ordered a counter-expertise (see&#160;below). The APESAC, Sanofi and its insurers appealed the Judicial Tribunal of Paris&#8217; ruling related to the class action.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;21, 2021, the Judicial Tribunal of Cr&#233;teil (France) dismissed a claim for damages brought against Sanofi regarding a child born in&#160;1995. The Judicial Tribunal considered that the risk of occurrence of NDD in children born to mother exposed to sodium valproate during pregnancy was not demonstrated by the state of scientific knowledge at the time of her pregnancy. This decision was appealed and the proceeding is now pending before the Appeal Court of Paris, which had ordered a stay in the proceeding until the end of the criminal investigation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July&#160;2020 and December&#160;2022, a collective redress against the French affiliate was filed by</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> 64&#160;f</span><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">amilies which represents 273&#160;claimants including 100&#160;people exposed in utero, seeking indemnification for a</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> prejudice of anxiety</span><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. In September&#160;2023, 27&#160;people exposed to sodium valproate in utero and 56&#160;indirect victims requested the withdrawal of their claims. The trial hearing is set for June&#160;6, 2024.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Criminal investigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A criminal investigation was initiated in May&#160;2015 before the Paris Civil Court. In January&#160;2020, the French affiliate of Sanofi was indicted for aggravated deception and involuntary injuries and in July&#160;2020 for involuntary manslaughter. In July&#160;2020, a judicial supervision of the affiliate was ordered, together with the implementation of financial guarantees. In November&#160;2020, the Health Authority (</span><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ANSM) was similarly indicted for involuntary injuries and involuntary manslaughters.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On March&#160;9, 2022, the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre de l&#8217;Instruction</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of the Appeal Court of Paris </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cour d&#8217;appel)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> ruled that certain complaints for involuntary manslaughter and several others for aggravated deception and involuntary injuries were time-barred. The Public Prosecutor, as well as the civil parties, have brought the matter before the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre Criminelle </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">of the Supreme Court </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cour de cassation)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2022, the investigating judges appointed two&#160;experts for a counter-expertise following the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre de l&#8217;Instruction&#8217;s</span><span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> ruling handed down end of 2021. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since 2022, several individual medical assessments have been ordered by the investigating judge.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June 2023, the </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre Criminelle</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of the French Supreme Court </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Cour de cassation</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> confirmed the Paris Court of Appeal&#8217;s decision </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Chambre de l&#8217;Instruction</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> dated March&#160;2022 which had ruled that certain complaints for involuntary manslaughter and several others for aggravated deception and involuntary injuries were time-barred. In August&#160;2023, Sanofi received the counter expertise report and sent its comments in November&#160;2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Public compensation scheme</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2017, the French government set up a public compensation scheme to indemnify patients for damages suffered in connection with the prescription of sodium valproate and its derivatives. The scheme was further amended through the 2020 Finance Law, with notably the introduction of presumptions of default for lack of information of the mother since 1982 for malformations and since 1984 for NDD. The scheme was amended again through the&#160;2021 Finance Law in order to increase the maximum premium applicable in case of refusal to make an offer (or insufficient offer) which would be deemed unjustified by a court ruling.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The committee of the compensation scheme has issued several final opinions holding the French affiliate liable for damages either in full or in part along with the French State, and, in some cases, healthcare practitioners. The French affiliate disagreed with the committee&#8217;s conclusions and has accordingly not offered indemnification to the claimants who have received compensation from the ONIAM </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Office National d&#8217;Indemnisation des Accidents M&#233;dicaux)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The ONIAM is now seeking reimbursement from Sanofi who has filed legal actions to oppose ONIAM&#8217;s payment orders.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Administrative Actions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July&#160;2020, March and June&#160;2021, the Montreuil Administrative Court had held the French State liable in five&#160;administrative proceedings initiated by families against the State. In March&#160;2021, the Administrative Court did not retain any lack of information of the mother regarding the risk of neurodevelopmental disorders for births in 1999 and in 2002, based on the state of scientific knowledge at the time. However, regarding the risk of malformations, liabilities were retained against the State, the healthcare professionals and Sanofi, notably for discrepancy between the SmPC (Summary of the Product Characteristics) and the patient leaflet. In other cases involving births in 2005-2008, the liability of the State was retained for both malformations and neurodevelopmental disorders, and partially exonerated, taking into account the roles of healthcare practitioners and Sanofi. Given that the French affiliate was not a party to these administrative proceedings, its arguments (i.e. notably several requests from the French affiliate to the Health Authorities to reinforce warnings to healthcare professionals and patients in relation to DEPAKINE) were not considered. All rulings were appealed by the claimants. Sanofi has filed requests for voluntary intervention in these proceedings to present its arguments before the Administrative Court of Appeal. In one proceeding, the claimants decided to withdraw their claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to make a reliable assessment of the outcome of these cases.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DEPAKINE Product Litigation in other EU countries and in the UK</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Switzerland, eleven&#160;families have filed a civil claim for damages concerning seventeen&#160;people exposed in utero. Some of them also involve the claimants&#8217; physicians. In November&#160;2022, one action was declared time-barred by the judge. The claimant appealed this court decision on the merit. The appeal is on-going.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Spain, there are six ongoing actions relating to thirteen&#160;children. In March&#160;2022, in one trial, the Court condemned Sanofi to indemnify four&#160;patients. Sanofi appealed this decision. In January&#160;2023, in another trial filed by one patient, the Appeal Court confirmed the first instance's decision and dismissed the claim. The other actions are still at a preliminary stage.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Belgium, there are two&#160;civil proceedings (currently on hold) and a criminal complaint against&#160;X and against Sanofi.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Ireland, there are two&#160;cases in Pre-Action stage and two&#160;civil claims on-going.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the United Kingdom, there are three&#160;cases in the Pre-Action stage in Great Britain and one&#160;civil claim ongoing in Northern Ireland.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is not possible, at this stage, to assess reliably the outcome of these cases.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DENGVAXIA (Philippines)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Since early 2018 up to present date, several claims were filed in the Philippines by parents of deceased children whose deaths were allegedly due to vaccination with DENGVAXIA. Early March&#160;2019, 2020 and 2022, the Philippine Department of Justice (DOJ) prosecution panel announced it had found probable cause to indict several Sanofi employees/former employees and former Government officials for &#8220;reckless imprudence&#8221; resulting in homicides. Since then, several criminal actions have been filed in court as a result of this finding and are pending at various stages of the legal procedure. Petitions for Review to the DOJ Secretary have been filed and the said petitions remain pending. Meanwhile, the majority of the respondents have challenged the jurisdiction of the lower court where the first&#160;eight&#160;cases had been assigned and this issue is now filed with the Supreme Court. There are several claims that have not yet been filed in any court despite resolutions by the DOJ that there is probable cause.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">b) Patents</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ramipril Canada Patent Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi was involved in a number of legal proceedings involving companies which market generic ALTACE (ramipril) in Canada.&#160;In&#160;2004, Sanofi unsuccessfully brought Notice of Compliance proceedings (NOC proceedings) at the end of which eight&#160;manufacturers obtained marketing authorizations from the Canadian Minister of Health for generic versions of ramipril in Canada. Sanofi filed unsuccessful patent infringement actions against all those companies and ultimately Sanofi was liable for damages under Section&#160;8. Sanofi made payment in complete satisfaction of those awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2011, Apotex commenced an action in the Ontario Superior Court of Justice asserting damages under the Ontario Statute of Monopolies, the UK Statute of Monopolies, and the Trade-marks Act (the &#8220;Ontario Action&#8221;).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the request of the parties, in June&#160;2021, the Court ordered that the action be stayed in view of the lower court&#8217;s decision in March in the Apotex vs. Lilly case. In the Lilly case, the Court dismissed Apotex&#8217;s Statute of Monopolies claim by way of summary judgment. </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April&#160;2023, the Canadian Supreme Court denied Apotex&#8217;s application for leave to appeal in the Lilly case and based on the Supreme Court decision, Apotex&#8217;s claim no longer has any basis. Sanofi is seeking the court&#8217;s assistance to conclude the case and recover appropriate costs.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRALUENT (alirocumab)-related Amgen Patent Litigation in the US</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2014, Amgen filed four separate complaints against Sanofi and Regeneron in the US District Court for the District of Delaware (&#8220;District Court&#8221;) asserting patent infringement relating to Sanofi and Regeneron&#8217;s PRALUENT product. Together these complaints alleged that PRALUENT infringed seven patents for antibodies targeting PCSK9 and sought injunctive relief and unspecified damages.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February&#160;2021, the Federal Circuit affirmed the District Court&#8217;s ruling invalidating the Amgen asserted patent claims. In&#160;November&#160;2021, Amgen filed a petition with the US&#160;Supreme Court, asking it to overturn the Federal Circuit decision.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November&#160;4, 2022, the US Supreme Court granted Amgen&#8217;s petition for review. </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In May&#160;2023, the Supreme Court issued a unanimous decision in favor of Sanofi and Regeneron regarding the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">patent infringement actions filed in 2014 by Amgen relating to Sanofi and Regeneron&#8217;s PRALUENT product. Sanofi is in the process of seeking certain legal costs from Amgen.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRALUENT (alirocumab)-related Amgen Patent Litigation in Europe</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2023, Amgen filed an action for infringement of EP&#160;3&#160;666&#160;797 against Sanofi and Regeneron concerning PRALUENT in the Munich Local Division of the Unified Patent Court. Amgen seeks a permanent injunction and unspecified damages and compensation from March&#160;1, 2023. In June&#160;2023, Sanofi filed a revocation action attacking the validity of EP&#160;3&#160;666&#160;797 in the Munich Central Division of the Unified Patent Court. These cases are underway: a hearing in the revocation action is scheduled in&#160;June&#160;2024 and a hearing in the infringement action is scheduled for October&#160;2024.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JEVTANA (cabazitaxel)-related patent litigation in the US</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">JEVTANA is currently covered by four Orange Book listed patents US&#160;7,241,907, US&#160;8,927,592, US&#160;10,583,110 and US&#160;10,716,777. In&#160;May&#160;to July&#160;2020, Sanofi filed patent infringement suits under Hatch-Waxman against 12&#160;generic filers asserting the &#8216;110&#160;patent and the&#160;&#8216;777&#160;patent in the US District Court for the District of Delaware, adding the '592&#160;patent after its amended claims issued in&#160;August&#160;2021. Sanofi reached settlement agreements with most of the defendants and went to trial against the remaining defendant Sandoz on the &#8216;777&#160;patent in January&#160;2023. In June&#160;2023, the US District Court for the District of Delaware issued a decision in favor of Sanofi in connection with the JEVTANA patent litigation against Sandoz and on August&#160;2, 2023, Sandoz appealed to the Court of Appeals for the Federal Circuit. On October&#160;5, 2023, Sanofi and Sandoz filed a joint stipulation voluntarily dismissing Sandoz&#8217;s Appeal, bringing this matter to final conclusion.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLAVIX Litigation (Commonwealth) in Australia</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In August&#160;2007, GenRX (a subsidiary of Apotex) obtained registration of a generic clopidogrel bisulfate product on the Australian Register of Therapeutic Goods. At the same time, GenRX filed a patent invalidation action with the Federal Court of Australia, seeking revocation of Sanofi&#8217;s Australian enantiomer patent claiming clopidogrel salts (a &#8220;nullity action&#8221;). In September&#160;2007, Sanofi obtained a preliminary injunction from the Federal Court preventing commercial launch of this generic clopidogrel bisulfate product until judgment on the substantive issues of patent validity and infringement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In August&#160;2008, the Australian Federal Court confirmed that the claim in Sanofi&#8217;s Australian enantiomer patent directed to clopidogrel bisulfate (the salt form in PLAVIX) was valid and the patent infringed. On appeal, the Full Federal Court of Australia held in&#160;September&#160;2009 that all claims in the patent are invalid. Sanofi&#8217;s appeal to the Australia High Court was denied in&#160;March&#160;2010. On conclusion of the proceedings in 2010, the Sanofi patent was invalidated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In April&#160;2013, the Australian Department of Health and Ageing (&#8220;Commonwealth&#8221;) filed an application before the Federal Court&#160;of&#160;Australia seeking payment of damages from Sanofi related to the Apotex preliminary injunction.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and BMS settled the patent litigation with Apotex in November&#160;2014. In April&#160;2020, the Commonwealth&#8217;s claim was dismissed. In&#160;May&#160;2020, the Commonwealth filed a Notice of Appeal to the Full Court of the Federal Court. On appeal, the Commonwealth reduced its claim to a range of AUD223.3&#160;million (&#8364;137.8&#160;million) to AUD280.2&#160;million (&#8364;172.9&#160;million) which, inclusive of interest to&#160;December&#160;31,&#160;2023, ranges from AUD360.5&#160;million (&#8364;218.0&#160;million) to AUD487.5&#160;million (&#8364;294.3&#160;million). </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In&#160;June&#160;2023, the Full Court of the Federal Court of Australia unanimously dismissed the Commonwealth&#8217;s appeal following</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> its application seeking payment of damages from Sanofi/BMS related to the preliminary injunction. O</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n July&#160;24, 2023, the&#160;Commonwealth filed an application for special leave to appeal to the High Court of Australia, which was granted on&#160;December&#160;18,&#160;2023.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">c) Other litigation</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLAVIX (clopidogrel) &#8211; Attorney General Action in Hawaii</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In March&#160;2014, the Hawaii Attorney General (AG) filed a complaint that sets forth allegations related to the sale and marketing of and variability of response to PLAVIX. The Hawaii AG specifically alleged that PLAVIX had a diminished effect in patients of certain genetic backgrounds and that Sanofi and BMS had failed to make an earlier disclosure of this information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February&#160;2021, the Court issued its decision, imposing penalties in the total amount of $834,012,000 against both Sanofi and Bristol Myers Squibb (BMS), with $417,006,000 being apportioned to each company. In June&#160;2021, Sanofi and BMS appealed this&#160;judgment. The appeal was transferred directly to the Hawaii Supreme Court. In March&#160;2023, the Hawaii Supreme Court vacated the judgment and ordered a new trial. A second trial was concluded in October&#160;2023 and Sanofi is expecting a decision in Q1&#160;2024. To the extent there is a new judgment entered by the court, this would be split evenly with BMS.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLAVIX (clopidogrel)-related litigation in France</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In France, in the claim concerning allegations that Sanofi&#8217;s communication and promotional practices inhibited the entry on the&#160;market of generics of clopidogrel (the active ingredient of PLAVIX), the French Antitrust Authority issued its decision on&#160;May&#160;14,&#160;2013, imposing on Sanofi a fine of &#8364;40.6&#160;million. This decision was confirmed by the Supreme Court </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cour de cassation)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in 2016. As a consequence of the May&#160;2013 ruling, claims were filed by Sandoz and by Teva in 2014 before the Commercial Court of Paris for compensation of their alleged damages: loss of margin and other ancillary damages. In June&#160;and November&#160;2016 respectively, settlement agreements were entered into with Sandoz and Teva. Consequently, they subsequently withdrew their civil claims, jointly and severally. In September&#160;2017, Sanofi and its French affiliate received a summons before the&#160;Paris Commercial Court from the French</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> Caisse Nationale d&#8217;Assurance Maladie &#8211; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">CNAM</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(French Social Security) claiming&#160;&#8364;115.8&#160;million for their alleged damages. On October&#160;1, 2019, the Paris Commercial Court dismissed the CNAM&#8217;s action as time barred. On February&#160;9, 2022, the Paris Court of Appeals overturned the Paris Commercial Court's ruling, finding the&#160;CNAM&#8217;s action as not time-barred and designated an expert to determine the amount of damages. The expert report is expected to be issued in March&#160;2024.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">340B Drug Pricing Program in the United States</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is currently involved in several matters relating to the 340B&#160;program in the US (a federal program that requires drug manufacturers to supply certain products to certain &#8220;covered entities&#8221; at reduced prices). In 2021, Sanofi filed a lawsuit against the Department of Health and Human Services (HHS), the Health Resources and Services Administration (HRSA), and certain of their administrators in the&#160;US&#160;District Court for the District of New Jersey challenging (i)&#160;HHS&#8217;s December&#160;2020 Advisory Opinion&#160;(AO) stating that drug manufacturers are legally obligated to deliver discounts under the 340B&#160;program to an unlimited number of contract pharmacies; (ii)&#160;HHS&#8217;s December&#160;2020 Administrative Dispute Resolution (ADR) Rule; and (iii)&#160;HRSA&#8217;s May&#160;2021 letter to Sanofi concluding that Sanofi&#8217;s 340B integrity initiative (under which Sanofi collects limited, de-identified, claims data on 340B-priced drugs dispensed by contract pharmacies) violates section&#160;340B and that Sanofi has therefore &#8220;overcharged&#8221; certain covered entities. The court issued its opinion in November&#160;2021, upholding HRSA&#8217;s conclusion in the&#160;May&#160;2021 letter, but did not impose any fines, penalties or refund obligations against Sanofi for any &#8220;overcharges&#8221;. The court also rejected Sanofi&#8217;s challenge to the ADR Rule and dismissed its challenge to the AO as moot. Sanofi appealed the court&#8217;s decision to the Third Circuit Court of Appeals (Third Circuit) and the government filed a cross-appeal.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January&#160;2023, the Third Circuit held that Sanofi&#8217;s restrictions on delivery to contract pharmacies do not violate Section&#160;340B. It also enjoined HHS from enforcing against Sanofi its reading of Section&#160;340B in the AO and the May&#160;2021 violation letter. As to Sanofi&#8217;s challenge to the 340B ADR rule, the Third Circuit held in favor of the Department of Health and Human Services (HHS) and HHS is in the process of revising the ADR rule (HRSA has sent the final rule to the Office of Information and Regulatory Affairs for review). The Third Circuit remanded the case back to the US District Court for the District of New Jersey (District Court) and on May&#160;24, 2023, the District Court issued an injunction and declaratory judgment consistent with the Third Circuit&#8217;s opinion. This ruling concluded the case as to Sanofi; however similar cases brought by other manufacturers remain pending.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">ADR Proceedings</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In January&#160;2021, the National Association of Community Health Centers (NACHC) filed an ADR proceeding before HRSA on behalf of a number of covered entities, seeking to require Sanofi and AstraZeneca to supply contract pharmacies with 340B discounts without conditions. On August&#160;10, 2022, the ADR panel granted the motions to dismiss filed both by Sanofi and AstraZeneca, holding that the Delaware district court&#8217;s decision granting AstraZeneca&#8217;s motion for summary judgment precluded NACHC&#8217;s ADR claims against both AstraZeneca and Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2023, the University of Washington Medical Center and Harborview Medical Center filed a petition for monetary and equitable relief against Sanofi before the ADR Panel. The petition alleges that Sanofi has violated Section&#160;340B of the Public Health Service Act, 42&#160;U.S.C. &#167;&#160;256b, by imposing data reporting requirements on &#8220;Covered Entities&#8221; that are authorized under that statute to receive discounts on certain prescription drugs and that in June&#160;2023, Sanofi further restricted access to 340B discounted drugs. The parties are waiting for a panel to be assigned to the case.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2021, HRSA referred Sanofi (as well as other manufacturers) to the HHS Office of the Inspector General (OIG) in accordance with the 340B Program Ceiling Price and Civil Monetary Penalties Final Rule. The Third Circuit&#8217;s decision and the District Court&#8217;s injunction and declaratory judgment (described above) would preclude action against Sanofi based on the particular program at issue in the Third Circuit case.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February&#160;2021, the Vermont Attorney General issued a Civil Investigative Subpoena seeking certain information about Sanofi&#8217;s participation in the 340B Drug Pricing Program. Sanofi cooperated with this investigation, including producing documents to the Vermont Attorney General&#8217;s office.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Mosaic Health</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In July&#160;2021, Mosaic Health Inc. and Central Virginia Health Services (covered entities) filed a nationwide antitrust class action complaint against Sanofi and three other manufacturers in the United States District Court for the Western District of New York. Plaintiffs allege that Sanofi and the other defendants conspired to eliminate favorable 340B pricing, particularly with&#160;respect to diabetes therapies. On September&#160;2, 2022, the court granted Defendants&#8217; motion to dismiss the complaint. On&#160;October&#160;3, 2022, plaintiff filed a motion for leave to file a second amended complaint. On February&#160;1, 2024, the Court denied plaintiffs&#8217; motion for leave to file an amended complaint and dismissed the case.  An appeal by plaintiffs is expected.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Adventist Health System/West</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In June&#160;2023, Adventist Health System/West sued several drug manufacturing companies, including Sanofi-Aventis US LLC, Sanofi US Services Inc. and Genzyme Corporation, alleging that the companies violated state and federal False Claims Acts through overcharging for 340B Program drugs in violation of federal &#8220;penny pricing&#8221; policy. The manufacturers jointly moved to dismiss.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preliminary investigation by the Parquet National Financier (PNF) in France</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In November&#160;2023, Sanofi learnt through the press of an ongoing preliminary investigation by the French financial prosecutor (</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Parquet National Financier &#8211; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PNF) started in March&#160;2023 relating to allegations regarding Sanofi&#8217;s financial communication on the launch of DUPIXENT at the end of 2017. Sanofi considers these allegations as groundless and is cooperating with the PNF to respond to the potential questions relating to the ongoing investigation.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">d) Contingencies arising from certain mergers &amp; acquisitions transactions</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a result of divestitures, the Company is subject to a number of ongoing contractual and legal obligations regarding the state of the sold businesses, their assets, and their liabilities, some of which may be subject to dispute.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aventis CropScience Retained Liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The sale by Aventis Agriculture SA and Hoechst GmbH (both legacy companies of Sanofi) of their aggregate 76% participation in Aventis CropScience Holding (ACS) to Bayer and Bayer CropScience AG (BCS), the wholly owned subsidiary of Bayer which holds the ACS shares, was effective on June&#160;3, 2002. The Stock Purchase Agreement (SPA) dated October&#160;2, 2001, contained customary representations and warranties with respect to the sold business, as well as a number of indemnifications subject to limitation periods and caps, in particular with respect to environmental liabilities for which some outstanding claims from Bayer remain unresolved.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Infraserv Hoechst Retained Liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">By the Asset Contribution Agreement dated December&#160;19/20, 1996, as amended in 1997, Hoechst contributed all lands, buildings, and related assets of the Hoechst site at Frankfurt Hoechst to Infraserv GmbH &amp; Co. Hoechst KG. Infraserv Hoechst undertook to indemnify Hoechst against environmental liabilities at the Hoechst site and with respect to certain landfills. As consideration for the indemnification undertaking, Hoechst transferred to Infraserv Hoechst approximately &#8364;57&#160;million to fund reserves. In 1997, Hoechst also agreed it would reimburse current and future Infraserv Hoechst environmental expenses up to &#8364;143&#160;million. As a former operator of the land and as a former user of the landfills, Hoechst may ultimately be liable for costs of remedial action in excess of this amount.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Boehringer Ingelheim (BI) Consumer Healthcare Liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi and Boehringer Ingelheim (BI) have agreed upon respective indemnification obligations for liabilities as part of the swap of Sanofi&#8217;s Animal Health (AH) business for BI&#8217;s Consumer Health Care (CHC) business in January&#160;2017 and under a Global Settlement Agreement concluded in September&#160;2019 regarding notably the offset of respective AH and CHC claims notified under the SPAs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In February&#160;2020, BI initiated an arbitration against Sanofi seeking indemnification for losses it could incur as a result of the ZANTAC litigation in the US (see above). In an award rendered on June&#160;19, 2023, the arbitral tribunal irrevocably dismissed BI&#8217;s indemnification claim against Sanofi and confirmed that Sanofi shall not be liable to indemnify BI for any potential losses in relation to the ongoing ZANTAC litigation in the U.S. The case is closed.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLegalAndArbitralProceedingsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Legal And Arbitral Proceedings [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLegalAndArbitralProceedingsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523699264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions for discounts, rebates and sales returns<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract', window );"><strong>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock', window );">Provisions for discounts, rebates and sales returns</a></td>
<td class="text">Provisions for discounts, rebates and sales returns<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adjustments between gross sales and net sales, as described in Note&#160;B.13., are recognized either as provisions or as reductions in accounts receivable, depending on their nature.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in these items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:25.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Government</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">and State</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">programs</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Managed&#160;care</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">and&#160;GPO</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">programs</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chargeback<br/>incentives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rebates<br/>and<br/>discounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sales<br/>returns</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>deductions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,507</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">908</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">333</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,557</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">688</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,039</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,813&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in provision related to prior period sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(136)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(152)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(242)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,561)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,979)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,828)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,291)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(697)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19,461)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,596</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">931</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">303</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,425</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">610</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,899</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,744&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,246&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,244&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,141&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in provision related to prior period sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(120)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(315)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,824)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,208)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,093)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,809)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(599)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(166)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21,699)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,603</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">362</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,805</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">629</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">70</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,490</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,758&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,590&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,861&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in provision related to prior period sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,251)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,446)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,564)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,603)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(511)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(278)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22,653)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(76)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(213)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2023</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,962</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,119</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">637</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,269</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">715</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">60</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,762</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Primarily US government programs: Medicaid (&#8364;1,421 million in 2023, &#8364;1,307 million in 2022, &#8364;1,244 million in 2021) and Medicare (&#8364;1,099 million in 2023, &#8364;775 million in 2022 and &#8364;941 million in 2021).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Mainly rebates and other price reductions granted to healthcare authorities in the United States (including Managed Care: &#8364;1,028 million in 2023,     &#8364;934 million in 2022 and &#8364;896 million in 2021).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Provisions related to US net sales amounted to &#8364;5,124 million as of December 31, 2023, &#8364;4,270 million as of December 31, 2022 and &#8364;4,057 million as of&#160;December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for provisions for discounts rebates and sales returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523762864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EmployeeBenefitsAbstract', window );"><strong>Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory', window );">Personnel costs</a></td>
<td class="text">Personnel costs<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total personnel costs (other than termination benefits, presented in Note&#160;D.27.) include the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Salaries</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,183&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,145&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,625&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Social security charges (including defined-contribution pension plans)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,929&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other employee benefits</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:3.9pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.1pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,814</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,991</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,340</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes expenses related to share-based payments and defined-benefit plans.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total number of registered employees was 87,994 as of December 31, 2023, compared with 91,573 as of December 31, 2022 and&#160;95,442 as of December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EmployeeBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Benefits [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EmployeeBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523762864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">Other operating income</a></td>
<td class="text">Other operating income<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">totaled &#8364;1,292 million in 2023, versus &#8364;1,969 million in 2022 and &#8364;859 million in 2021.</span></div>Other operating income includes (i)&#160;gains from asset divestments, amounting to &#8364;688&#160;million in 2023 (versus &#8364;655 million in 2022 and &#8364;418 million in 2021); and (ii)&#160;income from Sanofi&#8217;s pharmaceutical partners, amounting to &#8364;290 million in 2023 (including&#160;&#8364;227 million from Regeneron, see Note&#160;D.26. below and Note&#160;C.1.), compared with &#8364;1,178 million in 2022 (including&#160;&#8364;1,147 million from Regeneron), and &#8364;245 million in 2021. For 2021, it includes a payment of &#8364;119&#160;million from Daiichi Sankyo relating to the termination of a vaccines collaboration agreement in Japan<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526620944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory', window );">Other operating expenses</a></td>
<td class="text">Other operating expenses<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> totaled &#8364;3,516 million in 2023, compared with &#8364;2,531 million in 2022 and &#8364;1,805 million in 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2023, this line item includes &#8364;3,206 million of expenses related to Regeneron (see Note&#160;C.1.), compared with&#160;&#8364;2,378 million for 2022 and &#8364;1,568 million for 2021 (as shown in the table below):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &amp; expense related to sharing of (profits)/losses under the Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,321)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,325)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,253)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(476)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total - Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,196)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,367)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,429)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immuno-Oncology Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other (mainly ZALTRAP and LIBTAYO)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">217</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,120</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(12)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other operating income/(expenses), net related to Regeneron</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,979)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,231)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,373)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which amount presented in</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> (Note&#160;D.25.)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">195&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Following the restructuring of the Immuno-Oncology agreement between Sanofi and Regeneron, applicable from July&#160;1, 2022 (see Note&#160;C.1.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;As of December 31, 2023, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to &#8364;2.1 billion, compared with &#8364;2.7 billion as of December 31, 2022 (see note D.21.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Charges to provisions for litigation and environmental risks are also recorded within this line item.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523627376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs and similar items<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock', window );">Restructuring costs and similar items</a></td>
<td class="text">Restructuring costs and similar items<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring costs and similar items amounted to &#8364;1,490&#160;million in 2023, &#8364;1,336&#160;million in 2022 and &#8364;820&#160;million in 2021, and were comprised of the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs related to transformation programs</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,490</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,336</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">820</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> were &#8364;154&#160;million higher in 2023 than 2022. For 2023 they include the impact of French pension reform on future annuities under the rules of each severance plan, while for 2022 they mainly comprised severance costs recognized further to the announcements made during that period. Also included in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> are the impacts of ongoing transformational projects, primarily those associated with the creation of the standalone Consumer Healthcare entity and the implementation of Sanofi&#8217;s new digital strategy.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of restructuring costs and similar items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523639472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other gains and losses, and litigation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock', window );">Other gains and losses, and litigation</a></td>
<td class="text">Other gains and losses, and litigation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2023 represent a charge of &#8364;38&#160;million, </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">including costs relating to the settlement of  litigation with Bioverativ former shareholders.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2022, this line item represented a charge of &#8364;370&#160;million, comprising the pre-tax loss arising on the deconsolidation of EUROAPI (see Note&#160;D.2.) and costs related to major litigation.</span></div>For 2021, this line item represented a charge of &#8364;5 million<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of other gains and losses, and litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534174896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial expenses and income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Financial expenses and income</a></td>
<td class="text">Financial expenses and income<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(365)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(313)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(124)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(259)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) on disposals of financial assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(722)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(234)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(328)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,313)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(440)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(368)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">591</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">40</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes net gains/(losses) on interest rate and currency derivatives used to manage debt: &#8364;(67) million in 2023, &#8364;(11) million in 2022, &#8364;14 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Includes net gains on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;(13) million in 2023, &#8364;68 million in 2022,          &#8364;51 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note&#160;D.19.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes a financial expense of &#8364;541 million (zero in 2022 and 2021) in respect of the liability recognized in the balance sheet for estimated future royalties on US sales of BEYFORTUS, which was remeasured as of December 31, 2023 to reflect the very successful US launch of the product (see Note C.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, 2022 and 2021, the impact of the ineffective portion of hedging relationships was not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523878384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax expense</a></td>
<td class="text">Income tax expense<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,560)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,774)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,908)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,602)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,006)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,558)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,153</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,422</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,798</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Probable reversal of temporary differences on investments in Consumer Healthcare subsidiaries</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19.2</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In accordance with IAS&#160;12, a deferred tax liability was recognized in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October&#160;2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In determining the amount of the deferred tax liability for 2023, 2022 and 2021, Sanofi took into account changes in the ownership structure of certain subsidiaries.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the periods presented, the amount of deferred tax assets recognized in profit or loss that were initially subject to impairment losses at the time of a business combination is immaterial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523948368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share of profit/loss from investments accounted for using the equity method<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock', window );">Share of profit/loss from investments accounted for using the equity method</a></td>
<td class="text">Share of profit/loss from investments accounted for using the equity method<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> was a net loss of &#8364;115&#160;million in 2023 (including an impairment loss of &#8364;231&#160;million on the equity-accounted investment in EUROAPI &#8211; see Note D.6.), compared with net income of &#8364;68&#160;million for 2022 and &#8364;39&#160;million for 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share of profit loss of associates and joint ventures accounted for using equity method explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519973440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income attributable to non-controlling interests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock', window );">Net income attributable to non-controlling interests</a></td>
<td class="text">Net income attributable to non-controlling interests<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the reporting periods presented:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of net income attributable to non-controlling interests</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">36</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">113</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">56</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for net income attributable to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534168560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related party transactions</a></td>
<td class="text">Related party transactions<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal related parties are companies over which Sanofi has control or significant influence, joint ventures, key management personnel, and principal shareholders.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has not entered into any material transactions with any key management personnel. Financial relations with Sanofi&#8217;s principal shareholders fall within the ordinary course of business and were immaterial in the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note&#160;F.1. lists the principal companies controlled by Sanofi; those companies are fully consolidated, as described in Note&#160;B.1. Transactions between those companies, and between the parent company and its subsidiaries, are eliminated when preparing the consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transactions with companies over which Sanofi has significant influence, and with joint ventures, are presented in Note&#160;D.6.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Key management personnel include corporate officers and the members of the Executive Committee (an a</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">verage of 10&#160;members</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in 2023, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in 2022 and in 2021).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows, by type, the compensation paid to key management personnel:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term benefits</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Post-employment benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total recognized in profit or loss</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">55</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Compensation, employer&#8217;s social security contributions, directors&#8217; compensation, and any termination benefits (net of reversals of termination benefit obligations).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the aggregate obligation as of December&#160;31 for each period presented for individuals who hold or have held executive positions within Sanofi during that period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523880448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disclosures about major customers and credit risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExplanatory', window );">Disclosures about major customers and credit risk</a></td>
<td class="text">Disclosures about major customers and credit risk<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Credit risk is the risk that customers (wholesalers, distributors, pharmacies, hospitals, clinics or government agencies) may fail to pay their debts; for Sanofi, that risk is mainly concentrated on amounts receivable from wholesalers in the United States. Sanofi manages credit risk by vetting customers in order to set credit limits and risk levels, and asking for guarantees or insurance where necessary; performing controls; and monitoring qualitative and quantitative indicators of accounts receivable balances, such as the period of credit taken and overdue payments.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">27% of net sales in </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The three largest customers respectively accounted for approximately 11%, 9% and 7% of Sanofi's net sales in&#160;2023 (12%, 8% and 7% in 2022; 10%, 7% and 6% in 2021).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCreditRiskExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of credit risk. [Refer: Credit risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Credit risk<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g35A-38_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCreditRiskExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523817984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OperatingSegmentsAbstract', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment information</a></td>
<td class="text">Segment information<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As indicated in Note&#160;B.26., Sanofi has two operating segments with effect from January&#160;1, 2023: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Sanofi Business Services,&#160;etc.), which are mainly managed centrally at group-wide level, were presented within the &#8220;Other&#8221; category. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in order to reflect (i)&#160;progress on the &#8220;Play to Win&#8221; strategy leading to the creation of the standalone Consumer Healthcare Global Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its own dedicated global support functions (including Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Global Business Services,&#160;etc.); and (ii)&#160;organizational changes to Sanofi&#8217;s Manufacturing &amp; Supply global function (previously known as Industrial Affairs). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, with effect from January&#160;1, 2023, Sanofi reports two operating segments: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#8217;s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment&#8217;s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.35.1. Segment results</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.35.1.1. Analysis of net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth Sanofi&#8217;s net sales for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.491%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.5pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="border-right:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" rowspan="2" style="border-left:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:9pt"><td colspan="42" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,265</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,790</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,890</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,498</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,985</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,329</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,812</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,426</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,246</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,621</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33,293</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Specialty Care</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,206</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,917</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,917</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,040</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,016</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,848</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,593</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,457</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,764</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,847</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,141</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,752</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">DUPIXENT</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8,145&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10,715&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,346&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8,293&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,249&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">AUBAGIO</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,955&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">CEREZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">FABRAZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">MYOZYME/<br/>LUMIZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">JEVTANA</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ALPROLIX</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ELOCTATE</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">General Medicines</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,932</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,084</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,360</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,376</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,141</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,846</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,140</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,127</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,437</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,637</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,144</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,218</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,988</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,485</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,797</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,270</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,917</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,653</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,819</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,389</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,868</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,315</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,585</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,768</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">LOVENOX</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">TOUJEO</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">PLAVIX</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Non-Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,396</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">592</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,536</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,524</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,637</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,176</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,305</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,118</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,846</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,281</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,515</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,642</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">LANTUS</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other non-core assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,424&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,687&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Industrial sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">548</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">582</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">587</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">620</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">723</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">808</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,697</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,264</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,513</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,474</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,341</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,291</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,596</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,228</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,225</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,762</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,336</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,323</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Polio/Pertussis/<br/>Hib Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,504&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,285&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,159&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Influenza Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,669&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,977&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer Healthcare</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,557</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,247</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,376</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,180</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,501</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,290</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,394</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,185</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,139</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,996</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,468</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Allergy</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pain Care</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Digestive Wellness</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,392</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,512</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,166</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,999</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,275</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,723</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,759</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,385</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,617</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,761</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective January&#160;1, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.35.1.2. Business operating income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi reports segment results on the basis of &#8220;Business operating income&#8221;. This indicator is used internally by Sanofi&#8217;s chief operating decision maker to measure the performance of each operating segment and to allocate resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Business operating income&#8221; is derived from </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, adjusted as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature), are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3) or business divestments, and presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amounts reported within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">other gains and losses including gains and losses on major divestments, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">other costs and provisions related to litigation, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">upfront payments and regulatory milestone payments recognized within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and related to transactions outside the ordinary activities of Sanofi are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates to&#160;joint ventures and associates with which Sanofi has a strategic alliance; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">net income attributable to non-controlling interests is deducted.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi&#8217;s segment results for the years ended December 31, 2023, December 31, 2022 and December 31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,890</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,180</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,322&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,374&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,282)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,933)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14,216)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,509)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,868)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,692)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,387)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,224)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,247</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,670</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,812</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,185</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11,793)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,903)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13,692)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,503)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(205)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,706)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,736)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,761)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,492)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,679)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,514)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,490</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,522</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,040</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January&#160;1, 2023.</span></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:39.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,970</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,323</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,468</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,761</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,430)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(250)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,251)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,330)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(712)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(497)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,692)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,326)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(805)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,036)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9,555)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,172)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(946)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,409</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,609</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,493</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,797)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,714</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS&#160;8, shows a reconciliation between aggregated &#8220;Business operating income&#8221; for the segments and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:57.552%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.684%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,670</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,040</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,714</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(88)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,068)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,599)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,772)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,490)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(820)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(370)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income from out-licensing</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,875</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,656</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,126</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,313)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(440)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(368)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,153</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,422</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,798</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;For 2023, this amount mainly comprises an impairment loss of &#8364;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN  technology platforms. For 2022, this line includes a reversal of &#8364;2,154&#160;million on ELOCTATE franchise products following FDA approval of ALTUVIIIO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">dated February&#160;22, 2023, partially offset by an impairment loss of &#8364;1,586&#160;million on intangible assets relating to SAR444245 (non-alpha interleukin-2).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For 2022, this line includes an upfront payment of $900&#160;million and a regulatory milestone payment of $100&#160;million related to the out-licensing of LIBTAYO following the restructuring of the Immuno-Oncology Collaboration and License Agreement with Regeneron (see Note&#160;C.1.).</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.35.2. Other segment information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the split by operating segment of (i)&#160;the carrying amount of investments accounted for using the equity method with which Sanofi has entered into a strategic alliance, (ii)&#160;acquisitions of property, plant and equipment, and (iii)&#160;acquisitions of intangible assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal investments accounted for using the equity method in the Biopharma segment are the interests in MSP Vaccine Company, and Infraserv GmbH &amp; Co. H&#246;chst&#160;KG (see Note&#160;D.6.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:48.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,619&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:48.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January&#160;1, 2023.</span></div><div style="margin-top:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:48.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.613%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.35.3. Information by geographical region</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with&#160;IFRS&#160;8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS&#160;16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>United&#160;States</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,392</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,379</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,216</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,512</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,462</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,160&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,659&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,085&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,316&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,185&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,404&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,319&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,566&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,852&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>United&#160;States</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,999</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,296</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,984</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,275</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,014</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,869&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,892&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,640&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,257&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,178&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>United&#160;States</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,761</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,759</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,256</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,075</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,385</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,927</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,028&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,959&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,407&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,059&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As stated in Note&#160;D.5., goodwill is not allocated by geographical region.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Segments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523846864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal accountants' fees and services<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory', window );">Principal accountants' fees and services</a></td>
<td class="text">Principal accountants&#8217; fees and services<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PricewaterhouseCoopers Audit and Ernst&#160;&amp; Young et Autres served as independent auditors of Sanofi for the year ended December 31, 2023 and for all other reporting periods presented. The table below shows fees charged by those firms and member firms of their networks to Sanofi and consolidated subsidiaries in the years ended December 31, 2023 and 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:29.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ernst&#160;&amp;&#160;Young</span></td><td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PricewaterhouseCoopers</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Audit:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> Statutory audit of separate and consolidated financial statements</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Services other than statutory audit</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Audit-related services</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14.6</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst&#160;&amp; Young &#8364;7.9 million in 2023, &#8364;7.3 million in&#160;2022; PricewaterhouseCoopers Audit &#8364;8.3 million in 2023, &#8364;7.7 million in 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Services other than statutory audit provided by Ernst&#160;&amp; Young during 2023 comprised:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- contractual audits, including on the combined financial statements of the Consumer Healthcare business;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- additional procedures to enable reports previously signed by the firm to be incorporated by reference;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- issuance of the Independent Third Party&#8217;s report on the consolidated statement of extra-financial performance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Services other than statutory audit provided by PricewaterhouseCoopers during 2023 comprised:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- contractual audits, including on the combined financial statements of the Consumer Healthcare business;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- additional procedures to enable reports previously signed by the firm to be incorporated by reference; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst&#160;&amp; Young: &#8364;5.2 million in 2023, &#8364;1.4 million in&#160;2022; PricewaterhouseCoopers Audit &#8364;5.3 million in 2023, &#8364;0.3 million in 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes &#8364;0.5&#160;million for services that can only be provided by the statutory auditors, such as comfort letters, attestation services required by regulation (which qualify as audit fees under SEC rules).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of compensation to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAuditorsRemunerationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523884688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>List of principal companies included in the scope of consolidation during&#160;2023<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory', window );">List of principal companies included in the scope of consolidation during&#160;2023</a></td>
<td class="text">List of principal companies included in the scope of&#160;consolidation during&#160;2023<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">F.1. Principal fully consolidated companies</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi&#8217;s principal subsidiaries and their country of incorporation:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hoechst GmbH</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Deutschland GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">A. Nattermann &amp; Cie. GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Austria</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Belgium</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ablynx NV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Flanders BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi A/S</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Denmark</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Spain, SL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Oy</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Finland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis France</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Winthrop Industrie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Recherche &amp; D&#233;veloppement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Groupe</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Chimie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Participations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma S.A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Biotechnology</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Mature IP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur NVL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SECIPE SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Merieux SAS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare International SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare France SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Group SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Polyclonals SAS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis A.E.B.E.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Greece</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Private Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chinoin Private Co. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Hungary Commercial K.F.T</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Hungary K.F.T</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carraig Insurance DAC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Ireland Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Holdings (Ireland) Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Italy SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Global Sarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Luxembourg Sarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Norge AS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Norway</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Foreign Participations BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Sp. z.o.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Poland sp.z.o.o.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Sp. z.o.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Produtos Farmaceuticos Lda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Portugal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis, s.r.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Czech s.r.o</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Romania SRL</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Romania</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Romania SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Romania</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis UK Holdings Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Synthelabo UK Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma Holdings Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare UK Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AO Sanofi Russia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi AB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sweden</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Suisse) SA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Global Sarl Baar Intellectual Property Branch</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Ilac Sanayi ve Ticaret AS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Asi Ticaret AS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare T&#252;ketici Sa&#287;l&#305;&#287;&#305; Anonim &#350;irketi</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Saglik Urunleri Limited Sirketi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Therapeutic Products Limited Partnership</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi US Services Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis U.S. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventisub LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VaxServe, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ U.S. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ Therapeutics Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principia Biopharma Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Research Invest LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Bioverativ Holdings LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RPR US Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Kadmon Corporation, LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amunix</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Synthorx, Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provention Bio</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QRIB Intermediate Holding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QRI</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TargeGen Inc.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem (GB) Holding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Translate Bio, Inc.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:57.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other Countries</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis South Africa (Pty) Ltd</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Africa</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Alg&#233;rie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Algeria</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Arabia Trading Company Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Saudi Arabia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Argentina SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Argentina</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Healthcare Pty Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Australia Pty Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Medley Farmaceutica Ltda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Brazil Ltda.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Canada Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Merieux Canada Holdings ULC (Canada)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (Hangzhou) Pharmaceuticals Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (China) Investment Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (Beijing) Pharmaceuticals Co.Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Biologies Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shenzhen Sanofi pasteur Biological Products Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shanghai Rongheng Pharmaceutical Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Colombia SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Colombia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Korea Co. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella healthcare Korea Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Gulf FZE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Arab Emirates</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Egypt</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Hong-Kong Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hong Kong</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi India Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">India</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Healthcare India Private Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">India</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Isra&#235;l Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi K.K.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SSP Co.,Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Malaysia) SDN. BHD.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Malaysia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Maroc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Morocco</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Mexico SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Azteca Vacunas, SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Panama SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Panama</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Panama SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Panama</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Puerto Rico Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Philippines Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Philippines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Philippines Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Philippines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Singapore Pte. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma (Manufacturing) Pte. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Manufacturing Pte Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Taiwan Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Taiwan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Thailand) Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thailand</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thailand</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Venezuela SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Venezuela</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Vietnam Company Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vietnam</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Vietnam Shareholding Company Limited</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vietnam</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85.0&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">F.2. Principal investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:62.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Haleon US, LP</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH&#160;&amp; Co. H&#246;chst KG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Maphar</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Morocco</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MCM Vaccine BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company (formerly MCM company)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B4<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B4_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523916640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events subsequent to December 31, 2023<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events subsequent to December 31, 2023</a></td>
<td class="text">Event subsequent to December 31, 2023<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January&#160;23, 2024 Sanofi announced the entry into a merger agreement with Inhibrx, Inc. (Inhibrx), a publicly traded, clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases (the Merger Agreement), pursuant to which Sanofi has agreed to acquire Inhibrx following the spin-off of Inhibrx's non-INBRX-101 assets and liabilities into a new publicly traded company ("New Inhibrx"). Under the terms of the Merger Agreement, Sanofi has agreed to: (i)&#160;provide Inhibrx's stockholders with consideration of $30 per share of Inhibrx common stock at the closing of the merger (approximately $1.7&#160;billion), and to additionally issue one non-transferable contingent value right per share of Inhibrx common stock, which will entitle its holder to receive a deferred cash payment of $5, conditioned upon the achievement of a regulatory milestone (approximately $0.3&#160;billion, if the regulatory milestone is achieved); (ii)&#160;pay off Inhibrx&#8217;s outstanding third-party debt (approximately $0.2&#160;billion); and (iii)&#160;provide a capital contribution to New Inhibrx (up to $0.2&#160;billion). At the closing of the merger, Sanofi will acquire 100% of the equity interests in Inhibrx, which will become a 100% wholly owned subsidiary of Sanofi. In addition, Inhibrx will retain a minority stake (approximately 8% equity interest) in New Inhibrx. INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. INBRX-101 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. INBRX-101 acquisition is expected to </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">support Sanofi&#8217;s portfolio growth strategy and complements the Company&#8217;s 30-year heritage in rare diseases and track record in immunology and inflammation. The transaction is subject to various closing conditions, including the receipt of regulatory approvals and completion of the spin-off of New Inhibrx. Assuming satisfaction of those closing conditions, Sanofi currently anticipates that the transaction will close in the second quarter of 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534682016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">International financial reporting standards (IFRS)</a></td>
<td class="text">International financial reporting standards (IFRS)<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements cover the twelve-month periods ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with Regulation No.&#160;1606/2002 of the European Parliament and Council of July&#160;19, 2002 on the application of&#160;international accounting standards, Sanofi has presented its consolidated financial statements in accordance with IFRS since&#160;January&#160;1, 2005. The term &#8220;IFRS&#8221; refers collectively to international accounting and financial reporting standards (IASs&#160;and&#160;IFRSs) and to interpretations of the interpretations committees (SIC and IFRIC) with mandatory application as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements of Sanofi as of December 31, 2023 have been prepared in compliance with IFRS as&#160;issued&#160;by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS as endorsed by the European Union as of December 31, 2023 are available under the heading &#8220;IFRS Financial Statements&#8221; via the following web&#160;link:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality, and aggregation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">New standards, amendments and interpretations</a></td>
<td class="text">New standards, amendments and interpretations<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.1. New standards applicable from January 1, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following amendments are applicable from January&#160;1, 2023, and have had no material impact: &#8220;Disclosure of Accounting Policies&#8221; (amendment to IAS&#160;1); &#8220;Definition of Accounting Estimates&#8221; (amendment to IAS&#160;8); and &#8220;Deferred Tax Assets and Liabilities Arising from a Single Transaction&#8221; (amendment to IAS&#160;12).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;23, 2023, the IASB issued &#8220;International Tax Reform&#8212;Pillar Two Model Rules&#8221;, an immediately applicable amendment to&#160;IAS&#160;12 that was endorsed on November&#160;9, 2023. The amendment relates to the effects of the global minimum corporate income tax rate of 15% that will come into force in 2024, in accordance with the model framework of OECD Pillar Two.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The French Finance Bill for 2024 imposes a global minimum corporate income tax rate of 15% and introduces (i)&#160;a supplementary multinational tax and (ii)&#160;a supplementary national tax for annual accounting periods commencing on or after December&#160;31, 2023. Given that the legislation had not come into force as of December&#160;31, 2023, Sanofi is not liable for any current taxes in that&#160;respect. In addition, Sanofi has not recognized any deferred taxes associated with the minimum tax, in accordance with the&#160;temporary exemption available under the May&#160;2023 amendment to IAS&#160;12. At this stage, a material impact is expected in respect&#160;of Sanofi's operations in France and Singapore, because Sanofi&#8217;s average effective tax rate in those countries was less than 15% at the end of 2023. Other things being equal, applying the Pillar 2 rules in 2023 would have led to an increase of approximately 1.5&#160;percentage points in the effective tax rate based on the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS&#160;17 (Insurance Contracts), issued on May&#160;18, 2017 and applicable on or after January&#160;1, 2023, does not apply to the Sanofi consolidated financial statements because the insurance activities carried on by Sanofi&#8217;s captive insurance companies are internal within the Sanofi group (the sole policyholders being subsidiaries of Sanofi), and hence are eliminated on consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">New pronouncements issued by IASB and applicable from 2024 or later</a></td>
<td class="text">New pronouncements issued by the IASB and applicable from 2024 or later<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This note describes standards, amendments and interpretations issued by the IASB that will have mandatory application in 2024 or subsequent years, and Sanofi&#8217;s position regarding future application.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September&#160;22, 2022, the IASB issued an amendment to IFRS&#160;16 (Leases), relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable at the earliest from January&#160;1, 2024;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> it will not have a material impact on the Sanofi financial statements, and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has not early adopted it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January&#160;23, 2020, the IASB issued &#8220;Classification of Liabilities as Current or Non-current&#8221;, an amendment to IAS&#160;1, and then on&#160;October&#160;31, 2022 issued &#8220;Non-current Liabilities with Covenants&#8221;, a further amendment to IAS&#160;1. The amendments are applicable at the earliest from January&#160;1, 2024; they will not have a material impact on the Sanofi financial statements, and Sanofi has not early adopted them.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May&#160;25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS&#160;7 and IFRS&#160;7, which is applicable at the earliest from January&#160;1, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union) and which relates to disclosures of information about such arrangements. The amendment does not </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August&#160;15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS&#160;21 (The Effect of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable at the earliest from January&#160;1, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union); it</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Use of estimates and judgments</a></td>
<td class="text">Use of estimates and judgments<div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date of the finalization of the financial statements. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions (see&#160;Notes&#160;B.13. and&#160;D.23.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment of property, plant and equipment and intangible assets (see Notes&#160;B.6. and D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the valuation of goodwill and the valuation and estimated useful life of acquired intangible assets (see Notes&#160;B.3.2., B.4., D.4. and&#160;D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of contingent consideration receivable in connection with asset divestments (see Notes&#160;B.8.5. and&#160;D.12.) and of contingent consideration payable (see Notes&#160;B.3. and&#160;D.18.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of financial assets and liabilities at amortized cost (see Note&#160;B.8.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of post-employment benefit obligations (see Notes&#160;B.23. and&#160;D.19.1.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks (see Notes&#160;B.12., B.19., B.20., D.19. and&#160;D.22.); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences (see Notes&#160;B.22. and&#160;D.14.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, Sanofi has also taken account of risks related to the effects of climate change and energy transition.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its Planet Care program, Sanofi has committed to move towards carbon neutrality by 2030 and net zero emissions by&#160;2045 for its Scope&#160;1, 2 and&#160;3 emissions. That involves:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">aiming for a 55% reduction in greenhouse gas (GHG) emissions from Sanofi&#8217;s own activities (Scopes&#160;1 &amp;&#160;2) and a 30% reduction in Scope&#160;3 GHG emissions by 2030 (versus a 2019 baseline), and a 90% reduction in GHG emissions (all scopes) by&#160;2045. These objectives have been validated by the Science Based Target initiative (STBi);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">supplying all our sites with 100% renewably-sourced electricity by 2030;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">promoting an eco-friendly vehicle fleet by 2030; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">engaging the Sanofi supply chain in reducing Scope&#160;3 emissions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The analysis of climate-related physical and transition risks facing Sanofi was updated in 2023 on the basis of three global warming scenarios out to 2030 and 2050. A number of assumptions &#8211; on issues such as carbon costs, natural disasters, water stress, raw material scarcity and logistics disruption &#8211; were built into this analysis, which also takes account of certain capital expenditures on mitigations derived from the Planet Care roadmap.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, that analysis was taken into account as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the value of intangible assets and property, plant and equipment was subject to impairment testing conducted at CGU level, as described in Note&#160;D.5. Certain climate-related assumptions, such as the evolution of energy costs, transitioning to sustainable agriculture, and waste management, are already built into the forecast used for impairment testing purposes. For those assumptions not yet built into budgets, sensitivity analyses can be performed as needed;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the periodic reviews conducted on the useful lives of property, plant and equipment take account of environmental regulatory constraints, including not only GHG emissions but also physical risks;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">environmental risks are covered by provisions on the basis described in Note&#160;D.19.3.; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the credit facilities available to Sanofi as of December&#160;31, 2023 incorporate performance objectives, including objectives related to cutting Sanofi&#8217;s carbon footprint, which could reduce the cost of debt if they are attained (see Note&#160;D.17.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is important to bear in mind that estimating climate change related risks involves an element of unpredictability. Uncertainties may arise from factors such as changes in government policy, rapid technological change, and varied responses from stakeholders. That high level of uncertainty adds complexity to assessment of the potential impacts on our operations, and to how those impacts are reflected in our budgets. Actual impacts on Sanofi&#8217;s profits and financial position could therefore differ from initial estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, in line with its environmental protection objectives, Sanofi has initiated projects to build eco-design into its products so as to limit their environmental impacts over their entire life cycle. Those projects will require Sanofi to redefine all of its production methods, and as such have also been built into definitions of the useful lives of Sanofi production facilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory', window );">Hyperinflation</a></td>
<td class="text">Hyperinflation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi continued to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July&#160;1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100% based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January&#160;1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock', window );">Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK</a></td>
<td class="text">Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;18, 2020, Sanofi and the US Department of Health and Human Services extended their research and development partnership to leverage Sanofi&#8217;s previous development work on a SARS vaccine to attempt to unlock a fast path forward for developing a COVID-19 vaccine. Under the terms of the collaboration, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services, is helping to fund the research and development undertaken by Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April&#160;14, 2020, Sanofi and GlaxoSmithKline (GSK) entered into a collaboration agreement to develop a recombinant COVID-19 vaccine candidate, with Sanofi contributing its S&#8209;protein COVID-19 antigen (based on recombinant DNA technology) and GSK contributing its pandemic adjuvant technology. Sanofi is leading clinical development and the registration process for the vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July&#160;31, 2020, the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK was selected by the US&#160;government&#8217;s Operation Warp Speed (OWS) program. Under the OWS, the US government is providing funds to support further development of the vaccine, including clinical trials and scaling-up of manufacturing capacity. Initially, the agreement also provided for the supply of 100&#160;million doses of the vaccine. In light of the evolving context of the pandemic (including variants of the virus) and the availability of vaccines on the market, the parties decided to review the initial supply contract. At the end of 2023, the agreement was amended in respect of the supply clause, confirming that Sanofi had fulfilled its contractual obligations and setting the amount of compensation paid to Sanofi. On the basis of that signed amendment, Sanofi recognized an amount of &#8364;411&#160;million within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; that amount was paid to Sanofi in December&#160;2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has recognized the funding received from the US government as a deduction from the development expenses incurred, in accordance with IAS&#160;20 (Accounting for Government Grants and Disclosure of Government Assistance).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of government aid received from the US federal government and BARDA and recognized </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a deduction from development expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and other operating expenses was &#8364;59&#160;million in 2023, compared with &#8364;265&#160;million in 2022 and &#8364;147&#160;million in 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September&#160;2020, Sanofi and GSK signed pre-order contracts with the Canadian and UK governments and with the European Union for doses of the vaccine candidate. During 2021, Sanofi and GSK contractualized with the Canadian and UK governments and with the European Union on the number of doses ordered.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;15, 2021, Sanofi and GSK announced positive preliminary data on their COVID-19 booster vaccine candidate and indicated that their Phase&#160;3 trial was to continue, based on recommendations from an independent monitoring board.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November&#160;10, 2022, in line with the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, the European Commission approved VIDPREVTYN Beta vaccine as booster for the prevention of COVID-19 in adults aged 18&#160;years and older. Designed to provide broad protection against multiple variants, this protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK&#8217;s pandemic adjuvant. VIDPREVTYN</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Beta is indicated as a booster for active immunization against SARS-CoV-2 in adults who have previously received an mRNA or adenoviral COVID-19 vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December&#160;21, 2022, following the European Commission approval, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved VIDPREVTYN Beta vaccine for the prevention of COVID-19 in adults aged&#160;18 and over within the UK.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;15 (see Note&#160;B.13.1.), Sanofi recognizes revenue when control over the product is transferred to the customer (for vaccines, transfer of control is determined by reference to the terms of release and acceptance of batches of vaccine). Payments received subsequent to signature of vaccine pre-order contracts relating to doses not yet delivered are customer contract liabilities (i.e. an obligation for the entity to supply goods to a customer, for which consideration has been received from the customer). They are presented within &#8220;Customer contract liabilities&#8221; in the balance sheet (see Note&#160;D.19.5.), and within &#8220;Net change in other current assets and other current liabilities&#8221; in the statement of cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The pre-order contracts for Canada, the United Kingdom and the European Union expired in 2023. The customer contract liabilities, which amounted to &#8364;269&#160;million as of December&#160;31, 2022 and &#8364;319&#160;million as of&#160;December&#160;31,&#160;2021 (see Note&#160;D.19.5., &#8220;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Current provisions and other current liabilities&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) were released to profit or loss in 2023, including an amount of &#8364;94&#160;million classified in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other revenue</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in respect of doses which there was no longer an obligation to deliver as of December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text">Basis of consolidation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;10 (Consolidated Financial Statements), the consolidated financial statements of Sanofi include the financial statements of entities that Sanofi controls directly or indirectly, regardless of the level of the equity interest in those entities. An entity is controlled when Sanofi has power over the entity, exposure or rights to variable returns from its involvement with the entity, and the ability to affect those returns through its power over the entity. In determining whether control exists, potential voting rights must be taken into account if those rights are substantive, in other words they can be exercised on a timely basis when decisions about the relevant activities of the entity are to be taken.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Entities consolidated by Sanofi are referred to as &#8220;subsidiaries&#8221;. Entities that Sanofi controls by means other than voting rights are referred to as &#8220;consolidated structured entities&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;11 (Joint Arrangements), Sanofi classifies its joint arrangements (i.e. arrangements in which Sanofi exercises joint control with one or more other parties) either as a joint operation (in which case, Sanofi recognizes the assets and liabilities of the operation in proportion to its rights and obligations relating to those assets and liabilities) or as a joint venture.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi exercises joint control over a joint arrangement when decisions relating to the relevant activities of the arrangement require the unanimous consent of Sanofi and the other parties with whom control is shared.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi exercises significant influence over an entity when it has the power to participate in the financial and operating policy decisions of that entity, but does not have the power to exercise control or joint control over those policies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), the equity method is used to account for joint ventures (i.e.&#160;entities over which Sanofi exercises joint control) and for associates (i.e. entities over which Sanofi exercises significant influence).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the equity method, the investment is initially recognized at cost, and subsequently adjusted to reflect changes in the net assets of the associate or joint venture. IAS&#160;28 does not specify the treatment to be adopted on first-time application of the equity method to an investee following a step acquisition. Consequently, by reference to paragraph&#160;10 of IAS&#160;28, Sanofi has opted to apply the cost method, whereby the carrying amount of the investment represents the sum of the historical cost amounts for each step in the acquisition. As of the date on which the equity method is first applied, goodwill (which is included in the carrying amount of the investment) is determined for each acquisition step. The same applies to subsequent increases in the percentage interest in the equity-accounted investment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the criteria of IFRS&#160;5 are met, Sanofi recognizes the equity interest within the balance sheet line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The equity method is not applied to equity interests that are classified as held-for-sale assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transactions between consolidated companies are eliminated, as are intragroup profits.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A list of the principal companies included in the consolidation in 2023 is presented in Note&#160;F.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text">Foreign currency translation<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.1. Accounting for foreign currency transactions in the financial statements of consolidated entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets (other than receivables) and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate prevailing at the acquisition date.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the end of the reporting period. The gains and losses resulting from foreign currency translation are recorded in the income statement. However, foreign exchange gains and losses arising from the translation of advances between consolidated subsidiaries for which settlement is neither planned nor likely to occur in the foreseeable future are recognized in equity, in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Change in currency translation differences.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.2. Foreign currency translation of the financial statements of foreign entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi presents its consolidated financial statements in euros (&#8364;). In accordance with IAS&#160;21 (The Effects of Changes in Foreign Exchange Rates), each subsidiary accounts for its transactions in the currency that is most representative of its economic environment (the functional currency).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All assets and liabilities are translated into euros using the exchange rate of the subsidiary&#8217;s functional currency prevailing at the end of the reporting period. Income statements are translated using a weighted average exchange rate for the period, except in the case of foreign subsidiaries in a hyperinflationary economy. The resulting currency translation difference is recognized as a separate component of equity in the consolidated statement of comprehensive income, and is recognized in the income statement only when the subsidiary is sold or is wholly or partially liquidated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory', window );">Business combinations and transactions with non-controlling interests</a></td>
<td class="text">Business combinations and transactions with non-controlling interests<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.1. Accounting for business combinations, transactions with non-controlling interests and loss of control</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for in accordance with IFRS&#160;3 (Business Combinations) and IFRS&#160;10 (Consolidated Financial Statements).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method. Under this method, the acquiree&#8217;s identifiable assets and liabilities that satisfy the recognition criteria of IFRS&#160;3 (Business Combinations) are measured initially at their fair values at the date of acquisition, except for (i)&#160;non-current assets classified as held for sale (which are measured at fair value less costs to sell) and (ii)&#160;assets and liabilities that fall within the scope of IAS&#160;12 (Income Taxes) and IAS&#160;19 (Employee Benefits). Restructuring liabilities are recognized as a liability of the acquiree only if the acquiree has an obligation as of the acquisition date to carry out the restructuring.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal accounting rules applicable to business combinations and transactions with non-controlling interests include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">acquisition-related costs are recognized as an expense, as a component of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration is recognized in equity if the contingent payment is settled by delivery of a fixed number of&#160;the&#160;acquirer&#8217;s equity instruments; otherwise, it is recognized in liabilities related to business combinations. Contingent&#160;consideration is recognized at fair value at the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a financial liability, subsequent adjustments to the liability are recognized in profit&#160;or loss in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, unless the adjustment is made within&#160;the 12&#160;months following the acquisition date and relates to facts and circumstances existing as of that date;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">goodwill may be calculated on the basis of either (i)&#160;the entire fair value of the acquiree, or (ii)&#160;a share of the fair value of the acquiree proportionate to the interest acquired. This option is elected for each acquisition individually.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Purchase price allocations are performed under the responsibility of management, with assistance from an independent valuer in the case of major acquisitions. IFRS&#160;3 does not specify an accounting treatment for contingent consideration arising from a business combination made by an entity prior to the acquisition of control in that entity and carried as a liability in the acquired entity&#8217;s balance sheet. The accounting treatment applied by Sanofi to such a liability is to measure it at fair value as of the acquisition date and to report it in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, with subsequent remeasurements recognized in profit or loss. This treatment is consistent with the accounting applied to contingent consideration in the books of the&#160;acquirer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, management may where it deems fit elect to apply the optional test to identify concentration of fair value permitted under IFRS&#160;3 in order to determine whether a transaction is a business combination within the meaning of IFRS&#160;3, or merely the acquisition of an asset or of a group of similar assets.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.2. Goodwill</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The excess of the cost of an acquisition over Sanofi&#8217;s interest in the fair value of the identifiable assets and liabilities of the acquiree is recognized as goodwill at the date of the business combination. Goodwill arising on the acquisition of subsidiaries is shown in a separate balance sheet line item, whereas goodwill arising on the acquisition of investments accounted for using the equity method is recorded in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Investments accounted for using the equity method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill arising on foreign operations is expressed in the functional currency of the country concerned and translated into euros using the exchange rate prevailing at the end of the reporting period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;36 (Impairment of Assets), goodwill is carried at cost less accumulated impairment (see Note&#160;B.6.).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill is tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Such events or circumstances include significant changes more likely than not to have an other-than-temporary impact on the substance of the original investment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Other intangible assets</a></td>
<td class="text">Other intangible assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets are initially measured at acquisition cost or production cost, including any directly attributable costs of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. Intangible assets are amortized on a straight line basis over their useful&#160;lives.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The useful lives of other intangible assets are reviewed at the end of each reporting period. The effect of any adjustment to useful lives is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of other intangible assets is recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> except for amortization charged against (i)&#160;acquired or internally-developed software and (ii)&#160;other rights of an industrial or operational nature, which is recognized in the relevant classification of expense by function.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi does not own any intangible assets with an indefinite useful life, other than goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Intangible assets (other than goodwill) are carried at cost less accumulated amortization and accumulated impairment, if any, in accordance with IAS&#160;36 (see Note&#160;B.6.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.1. Research and development not acquired in a business combination</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internally generated research and development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS&#160;38, research expenses are recognized in profit or loss when incurred.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated development expenses are recognized as an intangible asset if, and only if, all the following six criteria can be demonstrated: (a)&#160;the technical feasibility of completing the development project; (b)&#160;Sanofi&#8217;s intention to complete the project; (c)&#160;Sanofi&#8217;s ability to use the project; (d)&#160;the probability that the project will generate future economic benefits; (e)&#160;the availability of adequate technical, financial and other resources to complete the project; and (f)&#160;the ability to measure the development expenditure reliably.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Due to the risks and uncertainties relating to regulatory approval and to the research and development process, the six criteria for capitalization are usually considered not to have been met until the product has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some industrial development expenses (such as those incurred in developing a second-generation synthesis process) are incurred after marketing approval has been obtained, in order to improve the industrial process for an active ingredient. To the extent that the six IAS&#160;38 criteria are considered as having been met, such expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as incurred. Similarly, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS&#160;38, in which case the related expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separately acquired research and development</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments for separately acquired research and development are capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that they meet the definition of an intangible asset: a resource that is (i)&#160;controlled by Sanofi, (ii)&#160;expected to provide future economic benefits for Sanofi, and (iii)&#160;identifiable (i.e.&#160;it is either separable or arises from contractual or legal rights). Under paragraph&#160;25 of&#160;IAS&#160;38, the first condition for capitalization (the probability that the expected future economic benefits from the asset will flow to the entity) is considered to be satisfied for separately acquired research and development. Consequently, upfront and milestone payments to third parties related to pharmaceutical products for which marketing approval has not yet been obtained are recognized as intangible assets, and amortized on a straight line basis over their useful lives beginning when marketing approval is&#160;obtained.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments under research and development arrangements relating to access to technology or to databases, and payments made to purchase generics dossiers, are also capitalized, and amortized over the useful life of the intangible asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subcontracting arrangements, payments for research and development services, and continuous payments under research and development collaborations which are unrelated to the outcome of that collaboration, are expensed over the service term.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.2. Other intangible assets not acquired in a business combination</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Licenses other than those related to pharmaceutical products and research projects, in particular software licenses, are capitalized at acquisition cost, including any directly attributable cost of preparing the software for its intended use. Software licenses are amortized on a straight line basis over their useful lives for Sanofi (<span style="-sec-ix-hidden:f-646">three</span> to five years).</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated costs incurred to develop or upgrade software are capitalized if the IAS&#160;38 recognition criteria are satisfied, and amortized on a straight line basis over the useful life of the software from the date on which the software is ready for use.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.3. Other intangible assets acquired in a business combination</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets acquired in a business combination (in-process research and development, technology platforms, and currently marketed products) that are reliably measurable are identified separately from goodwill, measured at fair value, and capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IFRS&#160;3 (Business Combinations) and IAS&#160;38 (Intangible Assets). The related deferred tax liability is also recognized if a deductible or taxable temporary difference exists.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In-process research and development acquired in a business combination is amortized on a straight line basis over its useful life from the date of receipt of marketing approval.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Rights to technology platforms and to products currently marketed by Sanofi are amortized on a straight line basis over their useful lives, determined (in particular for marketed products) on the basis of cash flow forecasts which take into account the patent protection period of the marketed product.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment owned and leased</a></td>
<td class="text">Property, plant and equipment owned and leased<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.1. Property, plant and equipment owned</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in&#160;the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent costs are not recognized as assets unless (i)&#160;it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii)&#160;the costs can be measured reliably.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the&#160;item.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they&#160;relate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The customary useful lives of property, plant and equipment are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;to&#160;40 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 to 15 years</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.2. Property, plant and equipment leased</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective from January&#160;1, 2019 leases contracted by Sanofi have been accounted for in accordance with IFRS&#160;16 (Leases). Sanofi recognizes a right-of-use asset and a lease liability for all of its lease contracts, except for (i)&#160;leases relating to low-value assets and&#160;(ii)&#160;short-term leases (12&#160;months or less). Payments made in respect of leases not recognized on the balance sheet are recognized as an operating expense on a straight line basis over the lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On commencement of a lease, the liability for future lease payments is discounted at the incremental borrowing rate, which is a risk-free rate adjusted to reflect the specific risk profile of each Sanofi entity. Because lease payments are spread over the lease term, Sanofi applies a discount rate based on the duration of those payments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The payments used to determine the liability for future lease payments exclude non-lease components, but include fixed payments that Sanofi expects to make to the lessor over the estimated lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After commencement of the lease, the liability for future lease payments is reduced by the amount of the lease payments made, and increased to reflect interest on the liability. In the event of a reassessment or modification of future lease payments, the lease liability is remeasured. The right-of-use asset &#8211;&#160;which is initially measured at cost including direct costs of the lessee, prepayments made at or prior to the commencement date, less lease incentives received and restoration costs&#160;&#8211; is depreciated on a straight line basis over the lease term, and tested for impairment as required.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi recognizes deferred taxes in respect of right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leasehold improvements are depreciated over their economic life, which is capped at the lease term as determined under&#160;IFRS&#160;16.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method</a></td>
<td class="text">Impairment of property, plant and equipment, intangible assets, and&#160;investments accounted for using the equity method<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.1. Impairment of property, plant and equipment and intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;36 (Impairment of Assets), assets that generate separate cash flows and assets included in cash-generating units&#160;(CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. A&#160;CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS&#160;36, each CGU or group of CGUs to which goodwill is allocated must (i)&#160;represent the lowest level within the entity at which the goodwill is monitored for internal management purposes, and (ii)&#160;not be larger than an operating segment determined in accordance with IFRS&#160;8 (Operating Segments), before application of the IFRS&#160;8 aggregation criteria (see Note&#160;B.26.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Quantitative and qualitative indications of impairment (primarily relating to the status of the research and development portfolio, pharmacovigilance, patent litigation, and the launch of competing products) are reviewed at the end of each reporting period. If there is any internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset or CGU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets not yet available for use (such as capitalized in-process research and development), and CGUs or groups of CGUs that include goodwill, are tested for impairment annually whether or not there is any indication of impairment, and more frequently if any event or circumstance indicates that they might be impaired. Such assets are not amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When there is an internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. To determine value in use, Sanofi uses estimates of future cash flows generated by the asset or CGU, prepared using the same methods as those used in the initial measurement of the asset or CGU on the basis of medium-term strategic plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of goodwill, estimates of future cash flows are based on a six-year strategic plan and a terminal value. In the case of other intrangible assets, the period used is based on the economic life of the asset.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Estimated cash flows are discounted at long-term market interest rates that reflect the best estimate by Sanofi of the time value of money, the risks specific to the asset or CGU, and economic conditions in the geographical regions in which the business activity associated with the asset or CGU is located.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Certain assets and liabilities that are not directly attributable to a specific CGU are allocated between CGUs on a basis that is reasonable, and consistent with the allocation of the corresponding goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on property, plant and equipment, software and certain rights, are recognized within the appropriate income statement line item according to the origin of the impairment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on other intangible assets (products, trademarks, technology platforms, acquired R&amp;D) are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.2. Impairment of investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), Sanofi determines whether investments accounted for using the equity method may be impaired based on indicators such as default in contractual payments, significant financial difficulties, probability of bankruptcy, or a prolonged or significant decline in quoted market price. If an investment is impaired, the amount of the impairment loss is determined by applying IAS&#160;36 (see Note&#160;B.6.1.) and recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.3. Reversals of impairment losses charged against property, plant and equipment, intangible assets, and investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the end of each reporting period, Sanofi assesses whether events or changes in circumstances indicate that an impairment loss recognized in a prior period in respect of an asset (other than goodwill) or an investment accounted for using the equity method can be reversed. If this is the case, and the recoverable amount as determined based on the revised estimates exceeds the carrying amount of the asset, Sanofi reverses the impairment loss only to the extent of the carrying amount that would have been determined had no impairment loss been recognized for the asset.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reversals of impairment losses in respect of other intangible assets are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, while reversals of impairment losses in respect of investments accounted for using the equity method are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Impairment losses taken against goodwill are never reversed, unless the goodwill is part of the carrying amount of an investment accounted for using the equity method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory', window );">Assets held for sale or exchange and liabilities related to assets held for sale or exchange</a></td>
<td class="text">Assets held for sale or exchange and liabilities related to assets held for sale or exchange<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;5 (Non-Current Assets Held for Sale and Discontinued Operations), non-current assets and groups of assets are classified as held for sale in the balance sheet if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Within the meaning of IFRS&#160;5, the term &#8220;sale&#8221; also includes exchanges for other assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets or asset groups held for sale must be available for immediate sale in their present condition, subject only to terms that are usual and customary for sales of such assets, and a sale must be highly probable. Criteria used to determine whether a sale is highly probable include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the appropriate level of management must be committed to a plan to sell;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an active program to locate a buyer and complete the plan must have been initiated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">completion of the sale should be foreseeable within the 12&#160;months following the date of reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Before initial reclassification of the non-current asset (or asset group) to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent to reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held-for-sale assets or liabilities within the balance sheet line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Liabilities related to assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, provided that the disposal satisfies the IFRS&#160;5 classification criteria.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The profit or loss generated by a held-for-sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">represents a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is a subsidiary acquired exclusively with a view to resale.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;10, transactions between companies that are held for sale or treated as discontinued operations and other consolidated companies are eliminated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Events or circumstances beyond Sanofi&#8217;s control may extend the period to complete the sale or exchange beyond one year without precluding classification of the asset (or disposal group) in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that there is sufficient evidence that Sanofi remains committed to the planned sale or exchange. Finally, in the event of changes to a plan of sale that requires an asset no longer to be classified as held for sale, IFRS&#160;5 specifies the following treatment:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each asset is measured at the lower of (a)&#160;its carrying amount before the asset was reclassified as held for sale, adjusted for any depreciation, amortization or revaluation that would have been recognized if the asset had not been reclassified as held for sale, or&#160;(b)&#160;its recoverable amount at the date of reclassification;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the backlog of depreciation, amortization and impairment not recognized while non-current assets were classified as held for sale must be reported in the same income statement line item that was used to report impairment losses arising on initial reclassification of assets as held for sale and gains or losses arising on the sale of such assets. In the consolidated income statement, those impacts are reported within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the net income of a business previously classified as discontinued or as held for sale or exchange and reported on a separate line in the income statement must be reclassified and included in net income from continuing operations, for all periods presented;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in addition, segment information relating to the income statement and the statement of cash flows (acquisitions of non-current assets) must be disclosed in the notes to the financial statements in accordance with IFRS&#160;8 (Operating Segments), and must also be restated for all prior periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text">Financial instruments<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.1. Non-derivative financial assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;9 (Financial Instruments) and IAS&#160;32 (Financial Instruments: Presentation), Sanofi has adopted the classification of non-derivative financial assets described below. The classification used depends on (i)&#160;the characteristics of the contractual cash flows (i.e.&#160;whether they represent interest or principal) and (ii)&#160;the business model for managing the asset applied at the time of initial recognition.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through other comprehensive income</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments that Sanofi does not hold for trading purposes and that management has designated at &#8220;fair value through other comprehensive income&#8221; on initial recognition. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such instruments are derecognized, the previously-recognized changes in fair value remain within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as does the gain or loss on divestment. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through profit or loss</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration already carried in the books of an acquired entity or granted in connection with a business combination;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments whose contractual cash flows represent payments of interest and repayments of principal, which are managed with a view to selling the asset;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments that management has designated at &#8220;fair value through profit or loss&#8221; on initial recognition; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments: equity instruments that are not held for trading and which management did not designate at &#8220;fair value through other comprehensive income&#8221; on initial recognition, and instruments that do not meet the IFRS definition of &#8220;equity instruments&#8221;.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gains and losses arising from changes in fair value are recognized in profit or loss within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of equity investments in unquoted entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On initial recognition of an equity investment in an entity not quoted in an active market, the fair value of the investment is the acquisition cost. Cost ceases to be a representative measure of the fair value of an unquoted equity investment when Sanofi identifies significant changes in the investee, or in the environment in which it operates. In such cases, an internal valuation is carried out, based mainly on growth forecasts or by reference to similar transactions contracted with third parties.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets at amortized cost comprise instruments whose contractual cash flows represent payments of interest and repayments of principal and which are managed with a view to collecting cash flows. The main assets in this category are loans and receivables. They are presented within the line items</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Accounts receivable </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Cash and cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Loans with a maturity of more than 12&#160;months are presented in &#8220;Long-term loans and advances&#8221; within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. These financial assets are measured at amortized cost using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main assets involved are accounts receivable. Accounts receivable are initially recognized at the amount invoiced to the customer. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.2. Derivative instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that do not qualify for hedge accounting are initially and subsequently measured at fair value, with changes in fair value recognized in the income statement in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, depending on the nature of the underlying economic item which is hedged.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that qualify for hedge accounting are measured using the policies described in Note&#160;B.8.3. below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS&#160;13 (Fair Value Measurement) requires counterparty credit risk to be taken into account when measuring the fair value of financial instruments. That risk is estimated on the basis of observable, publicly-available statistical data.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy on offsetting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order for a financial asset and a financial liability to be presented as a net amount in the balance sheet under IAS&#160;32, there must be:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(a) a legally enforceable right to offset; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(b) the intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.3. Hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its overall market risk management policy, Sanofi enters into various hedging transactions involving derivative or non-derivative instruments; these may include forward contracts, currency swaps or options, interest rate swaps or options, cross-currency swaps, and debt placings or issues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such financial instruments are designated as hedging instruments and recognized using the hedge accounting principles of&#160;IFRS&#160;9 when (a)&#160;there is formal designation and documentation of the hedging relationship, of how the effectiveness of the hedging relationship will be assessed, and of the underlying market risk management objective and strategy; (b)&#160;the hedged item and the hedging instrument are eligible for hedge accounting; and (c)&#160;there is an economic relationship between the hedged item and the hedging instrument, defined on the basis of a hedge ratio that is consistent with the underlying market risk management strategy, and the residual credit risk does not dominate the value changes that result from that economic relationship.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A fair value hedge is a hedge of the exposure to changes in fair value of an asset, liability or firm commitment that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument and changes in fair value of the hedged item attributable to the hedged risk components are generally recognized in the income statement, within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, or within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flow hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A cash flow hedge is a hedge of the exposure to variability in cash flows from an asset, liability or highly probable forecast transaction that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for hedges related to operating activities, and within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cumulative changes in fair value of the hedging instrument previously recognized in equity are reclassified to the income statement when the hedged transaction affects profit or loss. Those reclassified gains and losses are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When a forecast transaction results in the recognition of a non-financial asset or liability, cumulative changes in the fair value of the hedging instrument previously recognized in equity are incorporated in the initial carrying amount of that asset or liability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss previously recognized in equity remains separately recognized in equity and is not reclassified to the income statement, or recognized as an adjustment to the initial cost of the related non-financial asset or liability, until the forecast transaction occurs. However, if Sanofi no longer expects the forecast transaction to occur, the cumulative gain or loss previously recognized in equity is recognized immediately in profit or loss.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedge of a net investment in a foreign operation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a hedge of a net investment in a foreign operation, changes in the fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. When the investment in the foreign operation is sold, the changes in the fair value of the hedging instrument previously recognized in equity are reclassified to the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its market risk management policy, Sanofi may designate currency options or interest rate options as hedging instruments, the effectiveness of which is measured on the basis of changes in intrinsic value. In such cases, the time value of the option is treated as a hedging cost and accounted for as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the option includes a component that is not aligned on the critical features of the hedged item, the corresponding change in the time value is taken to profit or loss;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">otherwise, the change in the time value is taken to equity within the statement of comprehensive income, and then:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a financial asset or liability, the change in the time value is reclassified to profit or loss symmetrically with the hedged item, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a non-financial asset or liability, the change in the time value is incorporated in the initial carrying amount of that asset or liability, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a period of time, the change in time value is reclassified to profit or loss on a straight line basis over the life of the hedging relationship.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of forward contracts and foreign exchange swaps, and of cross-currency swaps that qualify for hedge accounting on the basis of changes in spot rates, Sanofi may elect for each transaction to use the option whereby the premium/discount or foreign currency basis spread are treated in the same way as the time value of an option.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinuation of hedge accounting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Hedge accounting is discontinued when the eligibility criteria are no longer met (in particular, when the hedging instrument expires or is sold, terminated or exercised), or if there is a change in the market risk management objective of the hedging relationship.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.4. Non-derivative financial liabilities</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings and debt</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement over the term of the debt using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These line items record the fair value of (i)&#160;contingent consideration payable in connection with business combinations and (ii)&#160;commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adjustments to the fair value of commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests, are recognized in equity.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other non-derivative financial liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-derivative financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.5. Fair value of financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS&#160;13 (Fair Value Measurement) and IFRS&#160;7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt">level&#160;1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">level&#160;2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt">level&#160;3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS&#160;7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type&#160;of financial&#160;instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in<br/>fair&#160;value<br/>hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>technique</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>model</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest<br/>rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market&#160;price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost/Approach based on comparables</span></div></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the&#160;end of the reporting period using the method described in&#160;Note&#160;D.7.3.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value held&#160;to meet obligations under <br/>post-employment benefit plans</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than three&#160;months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the&#160;consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1., D.19.</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The liability for future lease payments is discounted using the&#160;incremental borrowing rate.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160; year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&gt;&#160;1&#160;year:&#160;</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160;year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid&#160;Money&#160;Market  and LIFFE interest rate futures</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&gt;&#160;1&#160;year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid&#160;Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present&#160;value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160; year:<br/>Mid&#160;Money Market and LIFFE interest rate futures<br/>&gt;&#160;1&#160;year: <br/>Mid Zero Coupon</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (CVRs)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (other than CVRs)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Under IAS&#160;32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note&#160;B.8.4.</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.6. Derecognition of financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets are derecognized when the contractual rights to cash flows from the asset have ended or have been transferred and when Sanofi has transferred substantially all the risks and rewards of ownership of the asset. If Sanofi has neither transferred nor retained substantially all the risks and rewards of ownership of a financial asset, it is derecognized if Sanofi does not retain control of the asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A financial liability is derecognized when Sanofi&#8217;s contractual obligations in respect of the liability are discharged, cancelled or extinguished.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.7. Risks relating to financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Market risks in respect of non-current financial assets, cash equivalents, derivative instruments and debt are described in the discussions of risk factors presented in Item&#160;3.D. and Item&#160;11. of Sanofi&#8217;s annual report on Form&#160;20-F for 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Credit risk is the risk that customers may fail to pay their debts. For a description of credit risk, refer to &#8220;We are subject to the risk of non-payment by our customers&#8221; within Item&#160;3.D. and Item&#160;11. of Sanofi&#8217;s annual report on Form&#160;20-F for 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories are measured at the lower of cost or net realizable value. Cost is calculated using the weighted average cost method or the first-in, first-out method, depending on the nature of the inventory.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cost of finished goods inventories includes costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the launch phase of a new product, any inventories of that product are written down to zero pending regulatory approval, other than in specific circumstances which make it possible to estimate that there is a high probability at the end of the reporting period that the carrying amount of the inventories will be recoverable. The write-down is reversed once it becomes highly probable that marketing approval will be obtained.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">Cash and cash equivalents<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash and cash equivalents as shown in the consolidated balance sheet and statement of cash flows comprise cash, plus liquid short-term investments that are&#160;readily convertible into cash and are&#160;subject to an insignificant risk of changes in value in the event of movements in interest rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory', window );">Treasury shares</a></td>
<td class="text">Treasury shares<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;32, Sanofi treasury shares are deducted from equity, irrespective of the purpose for which they are held. No gain or loss is recognized in the income statement on the purchase, sale, impairment or cancellation of treasury shares.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions for risks</a></td>
<td class="text">Provisions for risks<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;37 (Provisions, Contingent Liabilities and Contingent Assets), Sanofi records a provision when it has a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If the obligation is expected to be settled more than 12&#160;months after the end of the reporting period, or has no definite settlement date, the provision is recorded within Non-current provisions and other non-current liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions relating to the insurance programs in which Sanofi&#8217;s captive insurance company participates are based on risk exposure estimates calculated by management, with assistance from independent actuaries, using IBNR (Incurred But Not Reported) techniques. Those techniques use past claims experience, within Sanofi and in the market, to estimate future trends in the cost of&#160;claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow of economic resources is&#160;remote.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi estimates provisions on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management&#8217;s knowledge at the date of preparation of the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reimbursements offsetting the probable outflow of resources are recognized as assets only if it is virtually certain that they will be received. Contingent assets are not recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring provisions are recognized if Sanofi has a detailed, formal restructuring plan at the end of the reporting period and has announced its intention to implement this plan to those affected by it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No provisions are recorded for future operating losses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi records non-current provisions for certain obligations, such as legal or constructive obligations, where an outflow of resources is probable and the amount of the outflow can be reliably estimated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of environmental risks, including at sites where operations are ongoing, Sanofi recognizes a provision where there is a violation of integrity in respect of human health or the environment resulting from past contamination at a site that requires remediation. The amount of the provision is a best estimate of the future expenditures to be incurred on the remediation plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Where the effect of the time value of money is material, those provisions are measured at the present value of the expenditures expected to be required to settle the obligation, calculated using a discount rate that reflects an estimate of the time value of money and the risks specific to the obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Increases in provisions to reflect the effects of the passage of time are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text">Revenue recognition<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.1. Net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenue arising from the sale of goods is presented in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Net sales comprise revenue from sales of pharmaceutical products, consumer healthcare products, active ingredients and vaccines, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. Analyses of net sales are provided in Note&#160;D.35.1. &#8220;Segment Information&#8221;.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;15 (Revenue from Contracts with Customers), such revenue is recognized when Sanofi transfers control over the product to the customer; control of an asset refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from that asset. For the vast majority of contracts, revenue is recognized when the product is physically transferred, in accordance with the delivery and acceptance terms agreed with the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For contracts entered into by Sanofi Pasteur, transfer of control is usually determined by reference to the terms of release (immediate or deferred) and acceptance of batches of vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of contracts with distributors, Sanofi does not recognize revenue when the product is physically transferred to the distributor if the products are sold on consignment, or if the distributor acts as agent. In such cases, revenue is recognized when control is transferred to the end customer, and the distributor&#8217;s commission is presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects the various types of price reductions or rights of return offered by Sanofi to its customers on certain products. Such price reductions and rights of return qualify as variable consideration under IFRS&#160;15.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In particular, products sold in the United States are covered by various Government and State programs (such as Medicare and Medicaid) under which products are sold at a discount. Rebates are granted to healthcare authorities, and under contractual arrangements with certain customers. Some wholesalers are entitled to chargeback incentives based on the selling price to the end customer, under specific contractual arrangements. Cash discounts may also be granted for prompt payment. Returns, discounts, incentives and rebates, as described above, are recognized in the period in which the underlying sales are recognized as a reduction of gross sales.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These amounts are calculated as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of chargeback incentives is estimated on the basis of the relevant subsidiary&#8217;s standard sales terms and conditions, and in certain cases on the basis of specific contractual arrangements with the customer;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of rebates based on attainment of sales targets is estimated and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of price reductions under Government and State programs, largely in the United States, is estimated on the basis of the specific terms of the relevant regulations or agreements, and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of sales returns is calculated on the basis of management&#8217;s best estimate of the amount of product that will ultimately be returned by customers. In countries where product returns are possible, Sanofi operates a returns policy that allows the customer to return products within a certain period either side of the expiry date (usually 12&#160;months after the expiry date). The amount recognized for returns is estimated on the basis of past experience of sales returns. Sanofi also takes into account factors such as levels of inventory in its various distribution channels, product expiry dates, information about potential discontinuation of products, the entry of competing generics into the market, and the launch of over-the-counter medicines. Most product return clauses relate solely to date-expired products, which cannot be resold and are destroyed. Sanofi does not recognize a right of return asset in the balance sheet for contracts that allow for the return of time-expired products, since those products have no value.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The estimated amounts described above are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a reduction of gross sales, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the balance sheet. They are subject to regular review and adjustment as appropriate based on the most recent data available to management. Sanofi believes that it has the ability to measure each of the above amounts reliably, using the following factors in developing its estimates:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the nature and patient profile of the underlying product;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the applicable regulations or the specific terms and conditions of contracts with governmental authorities, wholesalers and other customers;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">historical data relating to similar contracts, in the case of qualitative and quantitative rebates and chargeback incentives;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">past experience and sales growth trends for the same or similar products;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actual inventory levels in distribution channels, monitored by Sanofi using internal sales data and externally provided data;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the shelf life of Sanofi products; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market trends including competition, pricing and demand.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of provisions for discounts, rebates and sales returns is provided in Note&#160;D.23.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.2. Other revenues</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is used to recognize all revenue that falls within the scope of IFRS&#160;15 but does not relate to sales of Sanofi products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It mainly comprises (i)&#160;royalties received from licensing intellectual property rights to third parties; (ii)&#160;VaxServe sales of products sourced from third-party manufacturers; and (iii)&#160;revenue received under agreements for Sanofi to provide manufacturing services to third parties.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Royalties received under licensing arrangements are recognized over the period during which the underlying sales are recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VaxServe is a Vaccines segment entity whose operations include the distribution within the United States of vaccines and other&#160;products manufactured by third parties. VaxServe sales of products sourced from third-party manufacturers are presented within&#160;</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory', window );">Cost of sales</a></td>
<td class="text">Cost of sales<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> consists primarily of the industrial cost of goods sold, payments made under licensing agreements, and distribution costs. The industrial cost of goods sold includes the cost of materials, depreciation of property, plant and equipment, amortization of software, personnel costs, and other expenses attributable to production.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development</a></td>
<td class="text">Research and development<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note&#160;B.4.1. &#8220;Research and development not acquired in a business combination&#8221; and Note&#160;B.4.3. &#8220;Other intangible assets acquired in a business combination&#8221; describe the principles applied to the recognition of research and development costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contributions or reimbursements received from alliance partners are recorded as a reduction of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock', window );">Other operating income and expenses</a></td>
<td class="text">Other operating income and expenses<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16.1. Other operating income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the share of profits that Sanofi is entitled to receive from alliance partners in respect of product marketing agreements. It also includes revenues generated under certain agreements, which may include partnership, co-promotion arrangements and licenses not included in Other revenues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item also includes realized and unrealized foreign exchange gains and losses on operating activities (see Note&#160;B.8.3.), and operating gains on disposals not regarded as major disposals (see Note&#160;B.20.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16.2. Other operating expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise the share of profits that alliance partners are entitled to receive from Sanofi under product marketing agreements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Amortization and impairment of intangible assets</a></td>
<td class="text">Amortization and impairment of intangible assets<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.1. Amortization of intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The expenses recorded in this line item comprise amortization charged against intangible assets (products, trademarks and technology platforms, see Note&#160;D.4.) whose contribution to Sanofi&#8217;s commercial, industrial and development functions cannot be separately identified.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of software, and of other rights of an industrial or operational nature, is recognized as an expense in the income statement, in the relevant line items of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.2. Impairment of intangible assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item records impairment losses taken against intangible assets (products, trademarks, technology platforms and acquired research), and any reversals of such impairment losses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="text">Fair value remeasurement of contingent consideration<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in the fair value of contingent consideration that was (i)&#160;already carried in the books of an acquired entity, or (ii)&#160;granted in connection with a business combination and initially recognized as a liability in accordance with IFRS&#160;3, are reported in profit or loss. Such adjustments are reported separately in the income statement, in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item also includes changes in the fair value of contingent consideration receivable in connection with a divestment and classified as a financial asset at fair value through profit or loss.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, it includes the effect of the unwinding of discount, and of exchange rate movements where the asset or liability is expressed in a currency other than the functional currency of the reporting entity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock', window );">Restructuring costs and similar items</a></td>
<td class="text">Restructuring costs and similar items<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring costs are expenses incurred in connection with the transformation or reorganization of Sanofi&#8217;s operations or support functions. Such costs include collective redundancy plans, compensation to third parties for early termination of contracts, and commitments made in connection with transformation or reorganization decisions. They also include accelerated depreciation charges arising from site closures (including closures of leased sites), and losses on asset disposals resulting from such decisions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, this line item includes expenses incurred in connection with programs implemented as part of the transformation strategy announced in December&#160;2019 (and previously in November&#160;2015), and intended primarily (i)&#160;to deliver a global information systems solution, further supported by the implementation from 2021 of Sanofi&#8217;s new digital strategy; and (ii)&#160;to create a standalone CHC entity and proceed to the proposed separation of the CHC business as announced when the new chapter in the Play to Win strategy was presented in October&#160;2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock', window );">Other gains and losses, and litigation</a></td>
<td class="text">Other gains and losses, and litigation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the impact of material transactions of an unusual nature or amount which Sanofi believes it necessary to report separately in the income statement in order to improve the relevance of the financial statements, such as:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gains and losses on major disposals of property, plant and equipment, of intangible assets, of assets (or groups of assets and liabilities) held for sale, or of a business within the meaning of IFRS&#160;3, other than those considered to be restructuring costs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment losses and reversals of impairment losses on assets (or groups of assets and liabilities) held for sale, other than those considered to be restructuring costs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gains on bargain purchases;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">costs relating to major litigation; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">pre-tax separation costs associated with the process of disinvesting from operations in the event of a major divestment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory', window );">Financial expenses and income</a></td>
<td class="text">Financial expenses and income<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.1. Financial expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise interest charges on debt financing; negative changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange losses on financing and investing activities; impairment losses on financial instruments; and any reversals of impairment losses on financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> also include expenses arising from the unwinding of discount on long-term provisions, and the net interest cost related to employee benefits. This line item does not include commercial cash discounts, which are deducted from net sales.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.2. Financial income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes interest and dividend income; positive changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange gains on financing and investing activities; and gains on disposals of financial assets at fair value through profit or loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income tax expense</a></td>
<td class="text">Income tax expense<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">includes all current and deferred taxes of consolidated companies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi accounts for deferred taxes in accordance with IAS&#160;12 (Income Taxes), using the methods described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are recognized on taxable and deductible temporary differences, and on tax loss carry-forwards. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">French business taxes include a value added based component: &#8220;CVAE&#8221; </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cotisation sur la Valeur Ajout&#233;e des Entreprises)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Given that CVAE is (i)&#160;calculated as the amount by which certain revenues exceed certain expenses and (ii)&#160;borne primarily by companies that own intellectual property rights on income derived from those rights (royalties, and margin on sales to third parties and to Sanofi entities), it is regarded as meeting the definition of income taxes specified in IAS&#160;12, paragraph&#160;2 (&#8220;taxes which are based on taxable profits&#8221;);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are calculated using the tax rate expected to apply in the period when the corresponding temporary differences are expected to reverse, based on tax rates enacted or substantively enacted at the end of the reporting period;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets are recognized in respect of deductible temporary differences, tax losses available for carry-forward and unused tax credits to the extent that future recovery is regarded as probable. The recoverability of deferred tax assets is assessed on a case-by-case basis, taking into account the profit forecasts contained in Sanofi&#8217;s medium-term business plan;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a deferred tax liability is recognized for temporary differences relating to interests in subsidiaries, associates and joint ventures, except in cases where Sanofi is able to control the timing of the reversal of the temporary differences. This applies in particular when Sanofi is able to control dividend policy and it is probable that the temporary differences will not reverse in the foreseeable future;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">no deferred tax is recognized on eliminations of intragroup transfers of interests in subsidiaries, associates or joint ventures;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each tax entity calculates its own net deferred tax position. All net deferred tax asset and liability positions are then aggregated and shown in separate line items on the relevant side of the consolidated balance sheet. Deferred tax assets and liabilities are offset only if (i)&#160;Sanofi has a legally enforceable right to offset current tax assets and current tax liabilities, and (ii)&#160;the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred taxes are not discounted, except implicitly in the case of deferred taxes on assets and liabilities which are already impacted by discounting. In addition, Sanofi has elected not to discount current taxes payable or receivable where the amounts in question are payable or receivable in the long term;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">withholding taxes on intragroup royalties and dividends, and on royalties and dividends collected from third parties, are accounted for as current income taxes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accounting for business combinations, Sanofi complies with IFRS&#160;3 as regards the recognition of deferred tax assets after the initial accounting period. Consequently, any deferred tax assets recognized by the acquiree after the end of that period in respect of temporary differences or tax loss carry-forwards existing at the acquisition date are recognized in profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The positions adopted by Sanofi in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, Sanofi assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of Sanofi&#8217;s best estimate and recognized as a liability; uncertain tax assets are not recognized. The amount of the liability includes any penalties and late payment interest. The line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Income tax expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the effects of tax reassessments and tax disputes, and any penalties and late payment interest arising from such disputes that have the characteristics of income taxes within the meaning of paragraph&#160;2 of IAS&#160;12 (&#8220;taxes which are based on taxable profits&#8221;). Tax exposures relating to corporate income taxes are presented separately within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current income tax liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (see Note&#160;D.19.4.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No deferred taxation is recognized on temporary differences that are liable to be subject to US global intangible low taxed&#160;income (GILTI) provisions. The related tax expense is recognized in the year in which it is declared in the tax return to the extent that it arises from the existence of non-US profits that exceed the theoretical return on investment specified in the GILTI&#160;provisions and are taxed at a rate lower than the applicable US tax rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS&#160;1 (Presentation of Financial Statements), current income tax assets and liabilities are presented as separate line items in the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefit obligations</a></td>
<td class="text">Employee benefit obligations<div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi offers retirement benefits to employees and retirees. Such benefits are accounted for in accordance with IAS&#160;19 (Employee Benefits).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Benefits are provided in the form of either defined contribution plans or defined benefit plans. In the case of defined contribution plans, the cost is recognized immediately in the period in which it is incurred, and equates to the amount of the contributions paid by Sanofi. For defined benefit plans, Sanofi generally recognizes its obligations to pay pensions and similar benefits to employees as a liability, based on an actuarial estimate of the rights vested or currently vesting in employees and retirees, using the projected unit credit method. Estimates are performed at least once a year, and rely on financial assumptions (such as discount </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">rates) and demographic assumptions (such as life expectancy, retirement age, employee turnover, and the rate of salary increases).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Obligations relating to other post-employment benefits (healthcare and life insurance) offered by Sanofi companies to employees are also recognized as a liability based on an actuarial estimate of the rights vested or currently vesting in employees and retirees at the end of the reporting period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such liabilities are recognized net of the fair value of plan assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of multi-employer defined benefit plans where plan assets cannot be allocated to each participating employer with sufficient reliability, the plan is accounted for as a defined contribution plan, in accordance with paragraph&#160;34 of IAS&#160;19.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The benefit cost for the period consists primarily of current service cost, past service cost, net interest cost, gains or losses arising from plan settlements not specified in the terms of the plan, and actuarial gains or losses arising from plan curtailments. Net interest cost for the period is determined by applying the discount rate specified in IAS&#160;19 to the net liability (i.e. the amount of the obligation, net of plan assets) recognized in respect of defined benefit plans. Past service cost is recognized immediately in profit or loss in the period in which it is incurred, regardless of whether or not the rights have vested at the time of adoption (in&#160;the case of a new plan) or of amendment (in&#160;the case of an existing&#160;plan).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses on defined benefit plans (pensions and other post-employment benefits), also referred to as&#160;&#8220;Remeasurements of the net defined benefit liability (asset)&#8221;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> arise as a result of changes in financial and demographic assumptions, experience adjustments, and the difference between the actual return and interest cost on plan assets. The impacts of those remeasurements are recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net of deferred taxes; they are not subsequently reclassifiable to profit or&#160;loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payment</a></td>
<td class="text">Share-based payment<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Share-based payment expense is recognized as a component of operating income, in the relevant classification of expense by function. In measuring the expense, the level of attainment of any performance conditions is taken into account.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.1. Stock option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has granted a number of equity-settled share-based payment plans (stock option plans) to some of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;2 (Share-Based Payment), services received from employees as consideration for stock options are recognized as an expense in the income statement, with the opposite entry recognized in equity. The expense corresponds to the fair value of the stock option plans, and is charged to income on a straight-line basis over the four-year vesting period of the plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of stock option plans is measured at the date of grant using the Black-Scholes valuation model, taking into account the expected life of the options. The resulting expense also takes into account the expected cancellation rate of the options. The expense is adjusted over the vesting period to reflect actual cancellation rates resulting from option-holders ceasing to be employed by Sanofi.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.2. Employee share ownership plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may offer its employees the opportunity to subscribe to reserved share issues at a discount to the reference market price. Shares awarded to employees under such plans fall within the scope of IFRS&#160;2. Consequently, an expense is recognized at the subscription date, based on the value of the discount offered to employees.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.3. Restricted share plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may award restricted share plans to certain of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;2, an expense equivalent to the fair value of such plans is recognized in profit or loss on a straight line basis over the vesting period of the plan, with the opposite entry recognized in equity. The vesting period is three years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of restricted share plans is based on the quoted market price of Sanofi shares at the date of grant, adjusted for expected dividends during the vesting period; it also takes account of any vesting conditions contingent on stock market performance, measured using the Monte-Carlo valuation model. Other vesting conditions are taken into account in the estimate of the number of shares awarded during the vesting period; that number is then definitively adjusted based on the actual number of shares awarded on the vesting date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text">Earnings per share<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares outstanding during the reporting period, adjusted on a time-weighted basis from the acquisition date to reflect the number of own shares held by Sanofi. Diluted earnings per share is calculated on the basis of the weighted average number of ordinary shares, computed using the treasury stock method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This method assumes that (i)&#160;all outstanding dilutive options and warrants are exercised, and (ii)&#160;Sanofi acquires its own shares at the quoted market price for an amount equivalent to the cash received as consideration for the exercise of the options or warrants, plus the expense arising on unamortized stock options.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment information</a></td>
<td class="text">Segment information<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS&#160;8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Sanofi Business Services,&#160;etc.), which are mainly managed centrally at group-wide level, were presented within the &#8220;Other&#8221; category. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in&#160;order to reflect (i)&#160;progress on the &#8220;Play to Win&#8221; strategy leading to the creation of the standalone Consumer Healthcare Global&#160;Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its&#160;own&#160;dedicated global support functions (including Finance, People &amp; Culture, Legal, Ethics, Business Integrity &amp; Global Security, Information Solutions &amp; Technology, Global Business Services,&#160;etc.); and (ii)&#160;organizational changes to Sanofi&#8217;s Manufacturing &amp; Supply global function (previously known as Industrial Affairs). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, with effect from January&#160;1, 2023, Sanofi reports two operating segments: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#8217;s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment&#8217;s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The &#8220;Other&#8221; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Information about operating segments for the years ended December 31, 2023, 2022 and 2021 is presented in Note&#160;D.35</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">., </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8220;Segment information&#8221;.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Management of capital</a></td>
<td class="text">Management of capital<div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to maintain or adjust the capital structure, Sanofi can adjust the amount of dividends paid to shareholders, repurchase its own shares, issue new shares, or issue securities giving access to its capital.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following objectives are defined under the terms of Sanofi&#8217;s share repurchase programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the implementation of any stock option plan giving entitlement to purchase shares in the Sanofi parent company;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the allotment or sale of shares to employees under statutory profit sharing schemes and employee savings plans;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the consideration-free allotment of shares (i.e. restricted share plans);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the cancellation of some or all of the repurchased shares;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market-making in the secondary market by an investment services provider under a liquidity contract in compliance with the ethical code recognized by the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Autorit&#233; des march&#233;s financiers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (AMF);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares on the exercise of rights attached to securities giving access to the capital by redemption, conversion, exchange, presentation of a warrant or any other means;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares (in exchange, as payment, or otherwise) in connection with mergers and acquisitions;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the execution by an investment services provider of purchases, sales or transfers by any means, in particular via off-market trading; or</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.1pt">any other purpose that is or may in the future be authorized under the applicable laws and regulations.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is not subject to any constraints on equity capital imposed by third parties.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total equity includes </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Equity attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Equity attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as shown in the consolidated balance sheet.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi defines &#8220;Net debt&#8221; as (i)&#160;the sum of short-term debt, long-term debt and interest rate derivatives and currency derivatives used to hedge debt, minus (ii)&#160;the sum of cash and cash equivalents and interest rate derivatives and currency derivatives used to hedge cash and cash equivalents.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for business combinations and goodwill. [Refer: Business combinations [member]; Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 46<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about financial reporting in hyperinflationary economies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 29<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=29&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS29_g39-40_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An explicit and unreserved statement of compliance with all the requirements of IFRSs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreements Relating To The Recombinant Covid-19 Vaccine Candidate Developed By Sanofi In Collaboration With GSK</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for basis of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for cost of sales explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for fair value remeasurement of contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for other gains and losses, and litigation explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for other operating income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for restructuring costs and similar items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534435872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock', window );">Summary of Useful Lives of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The customary useful lives of property, plant and equipment are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;to&#160;40 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 to 15 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Disclosure of Detailed Information about Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS&#160;7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type&#160;of financial&#160;instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in<br/>fair&#160;value<br/>hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>technique</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>model</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest<br/>rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market&#160;price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost/Approach based on comparables</span></div></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the&#160;end of the reporting period using the method described in&#160;Note&#160;D.7.3.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value held&#160;to meet obligations under <br/>post-employment benefit plans</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than three&#160;months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the&#160;consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1., D.19.</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The liability for future lease payments is discounted using the&#160;incremental borrowing rate.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160; year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&gt;&#160;1&#160;year:&#160;</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160;year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid&#160;Money&#160;Market  and LIFFE interest rate futures</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&gt;&#160;1&#160;year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid&#160;Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present&#160;value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&lt;&#160;1&#160; year:<br/>Mid&#160;Money Market and LIFFE interest rate futures<br/>&gt;&#160;1&#160;year: <br/>Mid Zero Coupon</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (CVRs)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (other than CVRs)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Under IAS&#160;32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note&#160;B.8.4.</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of estimated useful lives of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523913376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal changes in the scope of consolidation in 2023 (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Summary of Provisional Purchase Price Allocation</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation led to the recognition of goodwill of &#8364;475&#160;million, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:66.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">774</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of QRIB Intermediate Holdings, LLC</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">867</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,342</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation led to the recognition of &#8364;609&#160;million of goodwill, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Amunix</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,126</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation, as presented in the table below, led to the recognition of goodwill of &#8364;2,118&#160;million:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shire contingent consideration liability (see Note&#160;D.18.)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(323)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Translate Bio</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">462</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,118</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,580</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Section Disclosures application of paragraphs 59 and 61<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;doctype=Appendix&amp;subtype=B&amp;dita_xref=IFRS03_gB64-B67_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523848192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal changes in the scope of consolidation in 2022 and 2021 (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Summary of Final Purchase Price Allocation</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation led to the recognition of goodwill of &#8364;475&#160;million, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:66.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">774</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of QRIB Intermediate Holdings, LLC</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">867</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,342</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation led to the recognition of &#8364;609&#160;million of goodwill, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Amunix</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,126</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation, as presented in the table below, led to the recognition of goodwill of &#8364;2,118&#160;million:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shire contingent consideration liability (see Note&#160;D.18.)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(323)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Translate Bio</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">462</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,118</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,580</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Section Disclosures application of paragraphs 59 and 61<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;doctype=Appendix&amp;subtype=B&amp;dita_xref=IFRS03_gB64-B67_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526971728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment owned by Sanofi is comprised of the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Buildings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Machinery<br/>and<br/>equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fixtures,<br/>fittings&#160;and<br/>other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property,&#160;plant<br/>and&#160;equipment<br/>in process</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">236</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,828</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,127</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,524</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,454</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23,169</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,504&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(839)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">240</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,170</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,648</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,655</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,097</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,810</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(294)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,480)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(163)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(150)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,104)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(240)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(559)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,626)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(318)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">237</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,328</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,848</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,515</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,996</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23,924</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(340)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,071)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">228</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,681</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,500</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,449</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,770</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(10)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,898)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,792)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,981)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(123)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(13,804)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(306)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(592)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(167)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(99)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(208)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(9)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,190)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,340)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,115)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(128)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,782)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(356)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(622)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,142)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(186)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(10)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,225)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,637)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,015)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(168)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,055)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,080)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,500)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,873)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,037)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(192)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,610)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,980&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,308&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,969&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,028&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,869&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">220</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,181</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,039</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">463</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,257</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,160</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line includes in particular property, plant and equipment in process brought into service during the period, but also the effect of the reclassification of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock', window );">Summary of Acquisitions and Capitalized Interest by Operating Segment</a></td>
<td class="text"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:57.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,693</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,748</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,504</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biopharma</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vaccines</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consumer Healthcare</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">of which Manufacturing &amp; Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take into account of the two new operating segments, Biopharma and Consumer Healthcare, effective January&#160;1,&#160;2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock', window );">Summary of Off Balance Sheet Commitments Relating to Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments relating to property, plant and equipment as of December 31, 2023, 2022 and 2021 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Firm orders of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment pledged as security for liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock', window );">Summary of Impairment Losses Recognised in Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the net impairment losses recognized in each of the last three financial periods:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net impairment losses on property, plant and equipment</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">130</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">186</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">39</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts mainly comprise impairment losses recognized as a result of decisions taken during the periods presented, relating primarily to shutdowns or changes in use of industrial sites.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Summary of Property, Plant and Equipment Leased</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Right-of-use assets relating to property, plant and equipment leased by Sanofi are analyzed in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:82.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Right-of-use assets</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,711</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(91)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,745</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,872</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,672</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(513)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(797)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(341)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,057)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation &amp; impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,018)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,948</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,815</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,654</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line also includes the effect of the reclassification of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In December&#160;2018, Sanofi signed two leases on real estate assets in the United States (at Cambridge, Massachusetts) for an initial lease term of 15 years. The first lease, relating to office space, began in April&#160;2021; Sanofi recognized a right-of-use asset of &#8364;320 million, as well as the lease liability. The second lease, relating to laboratory facilities, began on July&#160;1, 2021; Sanofi recognized a right-of-use asset of &#8364;424 million, as well as the lease liability.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of changes in property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Impairment Losses of Property, Plant and Equipment [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Off-Balance Sheet Commitments of Property Plant and Equipment [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523052800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract', window );"><strong>Intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory', window );">Schedule of Movements in Goodwill</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in goodwill comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:82.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44,364</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(89)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">48,056</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(258)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49,892</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(873)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49,404</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph&#160;86 of IAS&#160;36, and in 2022 the loss of control of EUROAPI (see note&#160;D.2.1.).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock', window );">Schedule of Allocation of Goodwill</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The allocation of goodwill by segment as of December 31, 2023 is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.361%"><tr><td style="width:1.0%"></td><td style="width:55.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.078%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></div></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,324</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,080</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49,404</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock', window );">Schedule of Movements in Other Intangible Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets comprise:</span></div><div style="margin-bottom:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:53.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquired R&amp;D</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Products,<br/>trademarks and<br/>other rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other<br/>intangible assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,600</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">61,074</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,633</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72,307</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,821&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,626&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(313)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(173)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(502)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(784)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,207</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">65,906</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,752</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78,865</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(423)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(543)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,576)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(174)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,354</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69,579</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,783</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81,716</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,287&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,401&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,062&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,970&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,584)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,253)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,772</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">73,733</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,808</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85,313</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at January 1, 2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,508)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(49,345)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,113)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(53,966)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(119)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,740)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(192)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,869)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,022)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at December 31, 2021</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,477)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(52,744)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,237)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(57,458)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,099)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(97)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,196)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,567)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(214)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at December 31, 2022</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,128)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(54,652)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,296)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(60,076)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,225)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,345)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(842)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(932)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization &amp; impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,734)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(55,908)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,352)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(60,994)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,730&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,162&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,407&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,927&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,640&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,038</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,825</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,319</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes the impact of the IFRIC agenda decision of March&#160;2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement (see Note&#160;A.2.1. to our 2021 consolidated financial statements, included in our annual report on Form&#160;20-F for that year).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The &#8220;Transfers&#8221; line mainly comprises (i)&#160;acquired R&amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets as </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The &#8220;Changes in scope of consolidation&#8221; line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Notes&#160;D.1. and&#160;D.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;See Note&#160;D.5.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of &#8364;226&#160;million in&#160;2022 (see&#160;Note C.1.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f)  This line mainly comprises:</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April&#160;2023 in respect of the agreements on BEYFORTUS (nirsevimab) (see Note&#160;C.2.);</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">an upfront payment of $500&#160;million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co-commercialization of TEV&#8217;574; and</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">an upfront payment of $175&#160;million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock', window );">Detailed Information for Principal Marketed Products</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides information about the principal &#8220;marketed products&#8221;, which were recognized in connection with major acquisitions made by Sanofi and represented 96% of the carrying amount of that item as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:20.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>amortization&#160;&amp;<br/>impairment</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortization</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">period</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(years)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Residual</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">amortization</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">period</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(years)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,279&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,071)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Boehringer Ingelheim </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consumer Healthcare</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,504&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,698)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,213&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33,043&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33,000)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(818)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Protein Sciences</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ablynx</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(746)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,357&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,798&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,646)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,152&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,836&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,065&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">REZUROCK</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,907&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TZIELD</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,546&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,405&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BEYFORTUS</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QUNOL</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total: principal marketed products</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66,880</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(50,953)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,927</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,863</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,752</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Weighted averages. The amortization periods for these products vary between 1&#160;and 25&#160;years.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Weighted averages.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Commercialized products derived from the acquisition of these companies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock', window );">Amortization of Softwares Recognized in Income Statement</a></td>
<td class="text">An analysis of amortization of software is shown in the table below:<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">120</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">97</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">119</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of amortization of software and other rights by income statement line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of goodwill by operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfPrincipalMarketedProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of principal marketed products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfPrincipalMarketedProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of changes in other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523858528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of intangible assets and property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentOfAssetsAbstract', window );"><strong>Impairment Of Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock', window );">Summary of Net Impairment Losses of Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, 2022 and 2021, impairment testing of other intangible assets (excluding software) resulted in the recognition of net impairment losses as shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impairment of other intangible assets, net of reversals (excluding software)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">932</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(454)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">192</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,561)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Biopharma</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1,526)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Consumer Healthcare</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development projects and technology platforms</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)(b)(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Others</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;For 2023, this amount mainly comprises an impairment loss of &#8364;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN  technology platforms.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;For 2022, this amount mainly comprises a reversal of &#8364;2,154&#160;million of impairment losses taken against ELOCTATE and BIVV001 (assets belonging to the ELOCTATE franchise), consisting of &#8364;1,554&#160;million for marketed products and &#8364;600&#160;million for research and development projects respectively. In 2019, the launch of competing products for ELOCTATE led Sanofi to update its sales forecasts for products belonging to the franchise, as a result of which impairment losses of &#8364;2.8&#160;billion were recognized against the assets in question. The reversal reflects the approval by the FDA on February&#160;22, 2023 of  ALTUVIIIO (the commercial name of efanesoctocog alpha, corresponding to the BIVV001 project), which was submitted in 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;For 2022, this amount mainly comprises:</span></div><div style="margin-top:1pt;padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.93pt">an impairment loss of &#8364;1,586&#160;million taken against the development project for SAR444245 (non-alpha interleukin-2), recognized following revised cash flow projections reflecting unfavorable developments in the launch schedule;</span></div><div style="margin-top:1pt;padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.93pt">the &#8364;600&#160;million reversal relating to the BIVV001 project (see above).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For 2021, this line relates to the discontinuation of the development of sutimlimab in the treatment of Immune Thrombocytopenic Purpura (ITP), and to the termination of various research projects in Vaccines.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Impairment Losses Of Other Intangible Assets [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpairmentOfAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpairmentOfAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523664048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments accounted for using the equity method (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock', window );">Summary of Investments in Associates and Joint Ventures</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%&#160;interest</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH&#160;&amp; Co. H&#246;chst KG</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">424</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">677</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Following the distribution in kind and the acquisition of an equity interest by EPIC Bpifrance, Sanofi holds an equity interest in EUROAPI accounted for using the equity method in accordance with IAS&#160;28 (see Note&#160;D.2.). As of December&#160;31, 2023, an impairment loss of &#8364;231&#160;million was recognized on the equity-accounted investment in EUROAPI in view of the fall in the share price since March&#160;2023. The amount of the loss was determined on the basis of the share price as of December&#160;31, 2023 (&#8364;5.73).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Joint venture.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock', window );">Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures</a></td>
<td class="text"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi&#8217;s overall share of (i)&#160;profit or loss and (ii)&#160;other comprehensive income from investments accounted for using the equity method, showing the split between associates and joint ventures in accordance with IFRS&#160;12 (the amounts for each individual associate or joint venture are not material):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:28.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.425%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint&#160;ventures</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint&#160;ventures</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint&#160;ventures</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of other comprehensive income from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">94</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(208)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;An impairment loss of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8364;231&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> was recognized on the equity-accounted interest in EUROAPI as of December&#160;31, 2023, to reflect the fall in the share price since March&#160;2023. The amount of the loss was determined on the basis of the quoted market price as of December&#160;31, 2023 (&#8364;5.73).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Summary of Principal Transactions and Balances with Related Parties</a></td>
<td class="text">The principal transactions and balances with related parties are summarized below:<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.999%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases and other expenses (including research expenses)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and other payables</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In 2022, these items include Sanofi's transactions with EUROAPI from May&#160;10, 2022 (see Note&#160;D.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Includes loans to joint ventures and associates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of investments in associates and joint ventures explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of profit or loss and other comprehensive income of associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523943344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other non-current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock', window );">Summary of Other Non-current Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income (D.7.1.)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income (D.7.2.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss (D.7.3.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations (Note&#160;D.19.1.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivative financial instruments (Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,218</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,095</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,127</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;As of December 31, 2023, this line includes:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- the renewal of a loan of &#8364;157&#160;million to the BioAtrium joint venture which matures on December&#160;1, 2031, of which &#8364;156&#160;million was recognized in "Other current assets" as of December&#160;31, 2022; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- a receivable under a sub-lease amounting to &#8364;132&#160;million (&#8364;170&#160;million before discounting), versus &#8364;164&#160;million (or &#8364;201&#160;million before discounting) as of December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of components of other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526617936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets held for sale or exchange and liabilities related to assets held for sale or exchange (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock', window );">Summary of Assets Held for Sale or Exchange, and Liabilities Related to Assets Held for Sale or Exchange</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets held for sale or exchange, and liabilities related to assets held for sale or exchange, comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:52.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.216%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets held for sale or exchange</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities related to assets held for sale or exchange</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of assets held for sale or exchange and related liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348532557408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,550&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(139)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,869&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,316&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,663&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(678)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,985&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(554)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,025&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,045&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(247)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(284)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,590</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(924)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,666</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,024</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,064)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,960</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,619</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(904)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,715</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526519872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock', window );">Summary of Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts receivable break down as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:52.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.216%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,528&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,537&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Allowances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(113)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(137)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,433</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,424</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,568</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock', window );">Summary of Gross Value of Overdue Receivables</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:17.123%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;accounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Overdue&#160;by</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">gross value</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&lt;1 month</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to&#160;3&#160;months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to&#160;6&#160;months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6&#160;to&#160;12&#160;months</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&gt;&#160;12&#160;months</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">689</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">154</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">123</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">62</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfCurrentTradeReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of current trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfCurrentTradeReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of overdue receivables gross value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523793760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax receivables, other than corporate income taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate derivatives measured at fair value (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency derivatives measured at fair value (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current financial assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,455</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,532</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,571</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line mainly comprises advance payments to suppliers, and receivables relating to Sanofi's activities as agent under a transitional services agreement.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This item mainly comprises bank loans and receivables maturing in less than one year with high-grade counterparties. For 2021, this item also includes debt instruments derived from the acquisitions of Translate Bio and Kadmon (carried out in 2021) with maturities of more than three months at inception and less than 12&#160;months at December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519908256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities measured at fair value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueMeasurementAbstract', window );"><strong>Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the balance sheet amounts of assets and liabilities measured at fair value.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:32.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in the fair value</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">hierarchy</span></div></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in the fair value<br/>hierarchy</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in the fair value<br/>hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial assets measured at fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted equity investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unquoted equity investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.1.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Quoted debt securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.2.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unquoted debt securities not meeting the definition of equity instruments</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.3.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration relating to divestments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.3.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial assets held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.3. &amp; D.11.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.7.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.11.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mutual fund investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.13.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,349&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total financial assets measured at fair value</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,737</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">201</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">964</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,765</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">967</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,449</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">298</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">883</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial liabilities measured at fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bayer contingent purchase consideration arising from the acquisition of Genzyme</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSD contingent consideration (European vaccines business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shire contingent consideration arising from the acquisition of Translate Bio</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration arising from acquisition of Amunix</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other contingent consideration arising from business combinations and acquisitions</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.18.</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.20.</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current derivatives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">D.19.5</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total financial liabilities measured at fair value</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">291</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">709</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">326</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">779</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">714</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value of financial assets and liabilities explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523986288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock', window );">Summary of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,249&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,740&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,710</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,736</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,098</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;As of December 31, 2023, cash equivalents mainly comprised the following: (i)&#160;&#8364;5,349 million invested in euro and US dollar denominated money-market mutual funds (December 31, 2022: &#8364;9,537 million; December 31, 2021: &#8364;5,057 million); (ii)&#160;&#8364;1,191 million of term deposits (December 31, 2022: &#8364;1,167 million; December 31, 2021: &#8364;2,768 million) and (iii)&#160;zero commercial paper (December 31, 2022: zero; December 31, 2021: &#8364;179 million). Cash equivalents also include &#8364;476 million held by captive insurance and reinsurance companies in accordance with insurance regulations (December 31, 2022: &#8364;439 million; December 31, 2021: &#8364;427 million).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348527182752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net deferred tax position (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Summary of Net Deferred Tax Position</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of the net deferred tax position is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred taxes on:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consolidation adjustments (intragroup margin in inventory)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision for pensions and other employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of other acquired intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,904)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,079)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Recognition of acquired property, plant and equipment at fair value</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity interests in subsidiaries and investments in other entities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,023)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(617)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(590)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax losses available for carry-forward</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock options and other share-based payments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accrued expenses and provisions deductible at the time of payment</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,859&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,536&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net deferred tax asset/(liability)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,570</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,540</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,981</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;As of December 31, 2023, includes remeasurements of the acquired intangible assets of Bioverativ (&#8364;1,241 million), Principia (&#8364;610 million), Ablynx      (&#8364;204 million), Genzyme (&#8364;50 million) and Amunix (&#8364;109 million).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately &#8364;60.4 billion) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2023, Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the&#160;European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December&#160;31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October&#160;2023 (see Note&#160;D.30.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes deferred tax assets related to restructuring provisions, amounting to &#8364;286 million as of December 31, 2023, &#8364;256 million as of                 December 31, 2022, and &#8364;226 million as of December 31, 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes deferred taxes arising on the spread tax deduction of R&amp;D expenses, amounting to &#8364;1,331 million as of December 31, 2023 and &#8364;742 million as of December 31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock', window );">Summary of Tax Losses Available for Carry-forward</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows when tax losses available for carry-forward are due to expire:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:70.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Tax&#160;losses&#160;available for carry-forward</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2029 and later</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,933</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,503</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,644</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Excluding tax loss carry-forwards on asset disposals. Such carry-forwards amounted to &#8364;5 million as of December 31, 2023, &#8364;5 million as of       December 31, 2022 and &#8364;5 million as of December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of availability of tax losses carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534391872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Summary of Treasury Shares Held</a></td>
<td class="text">Treasury shares held by Sanofi are as follows:<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of&#160;shares </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%&#160;of&#160;share&#160;capital <br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13.45</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.063</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.650&#160;</span></td><td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.28&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.658&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock', window );">Summary of Movements Share Capital</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in the share capital of the Sanofi parent company over the last three years are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:33.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,258,971,738</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190,076&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,836,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 28, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,562,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,263,560,695</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by exercise of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">490,373&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,499,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 27, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,027,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of December 14, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reduction in share capital by cancellation of </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">treasury shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,742,380)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,260,835,732</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by exercise of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">504,956&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,330,558&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 27, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,128,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,264,799,969</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Shares issued on exercise of Sanofi stock subscription options.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Shares vesting under restricted share plans and issued in the period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory', window );">Principal Characteristics of Restricted Share Plans</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note&#160;B.24.3. The principal characteristics of those plans are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 25, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 3, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 14, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 27, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Service period</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares awarded </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,838,434&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65,129&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,344,432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109,981&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,484,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,425,047&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000,627&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,335&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,209,901&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;87.69&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;77.42&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;91.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;79.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;77.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,413,387&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64,185&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,343,805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99,646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,274,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;83.74&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;74.50&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;86.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;69.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;71.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;68.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer - additional shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;43.60&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;34.90&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;49.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;54.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;82.17&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;84.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8364;71.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan at the date of grant </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">326</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">294</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">262</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Weighting between (i)&#160;fair value determined using the Monte Carlo model and (ii)&#160;market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Additional tranche subject to a higher level of market conditions: 121,097&#160;additional shares were awarded in May&#160;2023, and 5,838&#160;additional shares were awarded in December&#160;2023 (versus 114,874&#160;additional shares awarded in May&#160;2022, and 9,066&#160;additional shares awarded in December&#160;2022).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock', window );">Summary of Number of Restricted Shares Not Yet Fully Vested</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023 (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022 (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested as of December 31</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,773,084&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,245,513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,507,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,780,513&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,099,158&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,330,801&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2021 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,893,413&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,097,531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,364,895&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2020 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,817,181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,014,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2019 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,128,458&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Additional tranche subject to a higher level of market conditions: 126,935&#160;additional shares were awarded in 2023, versus 123,940&#160;additional shares awarded in &#160;2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock', window );">Summary of Characteristics of Employee Share Ownership Plans Awarded</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The characteristics of the employee share ownership plans awarded in the form of a capital increase reserved for employees in&#160;2023, 2022 and 2021 are summarized in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 2, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 3, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Subscription price </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79.58&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Subscription period</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 5-23, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 9-29, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 7-25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares subscribed</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,009,306&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,909,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,438,590&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares issued immediately as employer&#8217;s contribution</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119,417&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118,049&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124,112&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subscription price representing 80% of the average of the opening quoted market prices of Sanofi shares during the 20&#160;trading days preceding May&#160;31,&#160;2023, June&#160;6,&#160;2022 and June&#160;3, 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements', window );">Summary of Expenses</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the expense recognized for each plan:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense recognized</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which employer&#8217;s contribution</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock', window );">Summary of Repurchases program</a></td>
<td class="text">The following repurchases have been made under those programs:<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.185%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:29.25pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in number of shares and &#8364; million)</span></div><div style="padding-right:29.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year of authorization</span></div></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023 program</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,584,540&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022 program</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,000,204&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,510,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021 program</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,976,992&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,765,388&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020 program</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,758,569&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock', window );">Summary of Currency Translation Differences</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Currency translation differences comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(865)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(68)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,462</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(907)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock', window );">Summary of Movements within Other Comprehensive Income</a></td>
<td class="text"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Actuarial gains/(losses) excluding investments accounted for using the equity method (see&#160;Note&#160;D.19.1.)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(212)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;padding-right:29.25pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(77)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">451</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">797</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow and fair value hedges:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,551)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,643&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Currency translation differences (investments accounted for using the&#160;equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Hedges of net investments in foreign operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(354)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(254)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,526)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,313</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,510</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: immaterial amount in 2023, immaterial amount in 2022 and &#8364;4 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: &#8364;1 million in 2023, &#8364;2 million in 2022 and &#8364;12 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: &#8364;(56) million in 2023, and &#8364;(40) million in 2022 (including &#8364;(35)&#160;million relating to the deconsolidation of EUROAPI). The amounts reclassified to profit and loss were immaterial in 2021. Currency translation differences arise from the translation into euros of the financial statements of foreign subsidiaries, and are mainly due to the appreciation of the dollar against the euro.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock', window );">Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table shows all Sanofi stock subscription option plans still outstanding or under which options were exercised in the year ended&#160;December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:18.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date of grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>options<br/>granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Start&#160;date&#160;of<br/>exercise<br/>period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options outstanding as of 12/31/2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2013</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">788,725&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/06/2017</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72.19&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2014</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,009,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/06/2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73.48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91,355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/24/2015</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">435,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/25/2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/24/2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337,714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/04/2016</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">402,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/05/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/04/2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/10/2017</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/11/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/10/2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2018</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/03/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">04/30/2019</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">04/30/2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock', window );">Summary of Stock Options Outstanding at Each Balance Sheet Date</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A summary of stock options outstanding at each balance sheet date, and of movements during the relevant periods, is presented below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise&#160;price</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">per share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,579,270</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">75.61</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">195</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,845,050&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">74.51&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">137&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(190,076)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options cancelled</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)&#160;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(51,216)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,337,968</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">77.13</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">180</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,949,184&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">78.15&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">152&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(490,373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options cancelled</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)&#160;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9,626)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,837,969</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78.64</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">145</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,624,569&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(504,956)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">80.53</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">107</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,333,013&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">80.53&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">107&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Mainly due to the grantees leaving Sanofi.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock', window );">Summary of Options Outstanding and Exercisable</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">residual&#160;life</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price per</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price per</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;60.00 to &#8364;70.00 per share</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.34</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;70.00 to &#8364;80.00 per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">569,505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.12</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">569,505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From &#8364;80.00 to &#8364;90.00 per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.29</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock', window );">Summary of Number of Shares Used to Compute Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.991%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.7&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.9&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,252.5&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,256.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,256.9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,257.9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional information about share-based payment arrangements necessary to satisfy the disclosure requirements of IFRS 2. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information of accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of number of restricted share plans Not yet fully vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of reserve of exchange differences on translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of share based compensation shares authorized under stock option plans by exercise price range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share repurchase program explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of shares used to compute diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of statement of changes in equity of parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of stock options outstanding at each balance sheet date and of changes during the relevant periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of stock subscription option plans under which options were exercised in the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519450640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfChangesInFinancialPositionTableTextBlock', window );">Summary of Changes in Financial Position</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in Sanofi's financial position during the period were as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.991%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,347&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,857&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,123&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,531</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,218</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,250</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,793</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,437</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,983</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities, which amounted to &#8364;2,030 million as of December 31, 2023, &#8364;2,181</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> million as of December 31, 2022, and&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">2,108&#160;million as of December 31, 2021 </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(see the maturity analysis at Note&#160;D.17.2.).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock', window );">Summary of Reconciliation of Carrying Amount to Value on Redemption</a></td>
<td class="text"><div style="margin-bottom:4pt"><span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Reconciliation of carrying amount to value on redemption</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:25.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value on redemption</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustment<br/>to debt<br/>measured&#160;at<br/>fair value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,347&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,546&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,143&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,176&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion<br/>of long-term debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(157)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,531</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,573</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,273</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,314</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,793</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,492</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Disclosure of Movement In Total Debt</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the movement in total debt during the period:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:14.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash&#160;flows&#160;from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">cash</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">flows </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,857&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(604)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,347&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,672)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,218</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,684)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">48</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">895</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">76</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,531</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts mainly comprise &#8364;946&#160;million related to the US commercial paper program.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;These amounts mainly comprise changes in accrued interest balances, and fair value adjustments.</span></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the movement in total debt during prior periods:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash&#160;flows&#160;from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>cash<br/>flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,123&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,632)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(228)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,857&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,707)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,718)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,549</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(330)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">442</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,218</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the&#160;Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These amounts include movements in accrued interest and fair value remeasurements.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash&#160;flows&#160;from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>cash<br/>flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,745&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,704)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,123&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,767&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,203)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(615)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,704&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(197)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,631</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,241)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(812)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">381</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">291</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These amounts include (i) effects of changes in the scope of consolidation, amounting to &#8364;299&#160;million; (ii) movements in accrued interest; and (iii) fair value remeasurements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock', window );">Summary of Debt by Type Valuation of Redemption</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:14.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">current </span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current </span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,416&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,134&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,044&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,817&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,861&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,118&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,946&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,546</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,027</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,573</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,143</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,130</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,273</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,176</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,138</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,314</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,546</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,711)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,143</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,651)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,492</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,176</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,129)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities (see the maturity schedule in Note&#160;D.17.2.).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock', window );">Summary of Bond Issues</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bond issues carried out by Sanofi under the Euro Medium Term Note (EMTN) program are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issuer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ISIN code</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issue date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual&#160;interest&#160;rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013143997</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2016</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.625%&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013505104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.000%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0014009KS6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.875%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0012969038</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.500%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013324340</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.000%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0012146801</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.750%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013201639</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.500%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013144003</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.125%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013409844</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.875%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0014009KQ0</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.250%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013324357</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2030</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.375%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013505112</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 2030</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.500%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013409851</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2034</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.250%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FR0013324373</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2018</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 2038</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.875%&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bond issues carried out by Sanofi under the public bond issue program (shelf registration statement) registered with the&#160;US&#160;Securities and Exchange Commission (SEC) comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issuer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ISIN code</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issue&#160;date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual&#160;<br/>interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($&#160;million)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US801060AD60</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 2018</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.625&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock', window );">Summary of Debt by Maturity at Value on Redemption</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,134&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,050&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used <br/>to manage debt</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,573</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,027</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used <br/>to manage cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,711)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities, which amounted to &#8364;2,030&#160;million as of December&#160;31, 2023; &#8364;2,181&#160;million as of&#160;December&#160;31, 2022; and&#160;&#8364;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">2,108&#160;million as of December&#160;31, 2021</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> (see the maturity analysis at Note&#160;D.17.2.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, the main undrawn confirmed general-purpose credit facilities at holding company level amounted to&#160;&#8364;8 billion, half of which expired in 2027 and the other half of which expires in 2029.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, no single counterparty represented more than 6% of Sanofi&#8217;s undrawn confirmed credit facilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,861&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,817&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,684&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,273</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,130</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">661</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,600</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,160</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,722</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,736)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,492</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,651)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">661</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,600</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,160</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,722</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bond issues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,946&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,629&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,979&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other bank borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other borrowings</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bank credit balances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,314</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,138</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,647</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">602</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,751</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,160</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,016</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8211;</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,129)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,647</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">602</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,751</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,160</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,016</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock', window );">Summary of Debt by Interest Rate</a></td>
<td class="text"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below splits net debt between fixed and floating rate, and by maturity, as of December 31, 2023. The figures shown are values on redemption, before the effects of derivative instruments:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,080</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,050&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">14,228</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,852</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% fixed-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">97</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Floating-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">511</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,591</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,045</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,710)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4,115)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4,251)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,881</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,665)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To optimize the cost of debt or reduce the volatility of debt and manage its exposure to financial foreign exchange risk, Sanofi uses derivative instruments (interest rate swaps, currency swaps, foreign exchange swaps and forward contracts) that alter the fixed/floating rate split and the currency split of its net debt:</span></div><div style="margin-bottom:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,382</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,034)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,050&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11,382</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% fixed-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Floating-rate debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,191</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,061&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">113</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,300</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,573</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,027</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,738)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which euro</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4,642)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2,132)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1,143)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% floating-rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,835</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,711)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,698</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,011</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,151</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,607</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,079</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock', window );">Summary of Interest Rate of Net Debt at Value on Redemption</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the fixed/floating rate split of net debt at value on redemption after taking account of derivative instruments as of&#160;December 31, 2022 and December&#160;31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed-rate debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,386&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,612&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Floating-rate debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,273</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,314</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,781)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,267)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,492</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock', window );">Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The projected full-year sensitivity of net debt to interest rate fluctuations for 2024 is as&#160;follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:53.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in short-term interest rates</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact&#160;on&#160;pre-tax&#160;net</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">income&#160;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364;&#160;million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact&#160;on&#160;pre-tax</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">income/(expense)&#160;recognized</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">directly in equity</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+100&#160;bp</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25&#160;bp</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-25&#160;bp</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-100&#160;bp</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock', window );">Summary of Debt by Currency Before and After Derivative Instrument</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows net debt by currency at December 31, 2023, before and after derivative instruments contracted to convert the foreign-currency net debt of exposed entities into their functional currency:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:53.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Before&#160;derivative&#160;instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">After&#160;derivative&#160;instruments</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,113&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,852&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,376)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,143)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pound sterling</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chinese yuan renminbi</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other currencies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,881</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock', window );">Summary of Debt by Currency After Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows net debt by currency at December 31, 2022 and 2021, after derivative instruments contracted to convert the foreign currency net debt of exposed entities into their functional currency:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:74.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,489&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,129&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">US dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,404)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(669)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other currencies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,593)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,413)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,492</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,047</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock', window );">Summary of Market Value of Net Debt</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The market value of Sanofi&#8217;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,086&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,227&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,024&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value on redemption</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,835&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,492&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,047&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock', window );">Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:42.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,710</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,153</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,187</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,285</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,719</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,454</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,468&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,917&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,011&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,079&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash flows related to derivative instruments</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">143</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">47</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,853</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,200</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,944</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,210</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,309</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,735</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,455</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt as of December 31, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:42.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,408</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,206</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">868</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,803</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,184</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,283</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,064</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,932&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,928&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,601&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,011&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,580&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash flows related to derivative instruments</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">209</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">60</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">38</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">25</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,617</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,230</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">928</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,841</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,215</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,314</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,089</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:42.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027 and later</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,728</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,330</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,826</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">791</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,937</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,176</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,668</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,086&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,588&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,011&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,080&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash flows related to derivative instruments</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(51)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(59)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,677</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,271</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,825</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">793</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,939</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,178</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,671</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock', window );">Disclosure of Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A maturity analysis of lease liabilities as of December 31, 2023, 2022 and 2021 is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:41.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.398%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Undiscounted future minimum lease payments</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less than 1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From 1 to 3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From 3 to 5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More than 5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Discounting effect</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total lease liabilities as of December 31, 2023</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,030</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">291</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">360</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">989</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(58)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total lease liabilities as of December 31, 2022</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,181</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">320</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">515</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">436</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,129</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(219)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total lease liabilities as of December 31, 2021</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,108</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">314</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">476</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">362</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,184</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(228)</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Lease liabilities include leases relating to real estate assets located at Cambridge, MA (United States), as described in Note&#160;D.3., which have a lease term of 15 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfChangesInFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of changes in financial position [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfChangesInFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt by currency at value of redemption after derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt by currency at value of redemption before and after derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt by interest rate at value of redemption after taking account of derivative instruments N1 N2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt by interest rate at value of redemption and by maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt by maturity at value of redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt net of cash and cash equivalents by type at value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detail Of Bonds Issued Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfMarketValueOfNetDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of market value of net debt [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfMarketValueOfNetDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of maturity analysis of future undiscounted cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Maturity Analysis Of Lease Payments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of sensitivity analysis on long-term borrowings and debt securities assuming a 1% increase and decrease in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526519872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities related to business combinations and to non-controlling interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock', window );">Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in liabilities related to business combinations and to non-controlling interests are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:34.734%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bayer</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">contingent</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">consideration</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">arising&#160;from&#160;the</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">acquisition of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Genzyme </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">MSD<br/>contingent<br/>consideration<br/>(European<br/>Vaccines<br/>business)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shire</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">contingent</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">consideration</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">arising&#160;from&#160;the</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">acquisition of</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Translate Bio</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contingent consideration arising from acquisition of Amunix</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at January 1, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">104</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">312</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">189</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">605</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">New transactions</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(152)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(258)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">354</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">714</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">New transactions</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(79)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(136)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">204</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">380</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">165</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">779</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">New transactions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">127</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">441</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">709</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Portion due after more than one year: &#8364;501 million as of December 31, 2023 (&#8364;674 million as of December 31, 2022 and &#8364;577 million as of December 31, 2021); portion due within less than one year: &#8364;208 million as of December 31, 2023 (&#8364;105 million as of December 31, 2022 and &#8364;137&#160;million as of&#160;December 31, 2021).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Amounts reported within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, and mainly comprising unrealized gains and losses.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Mainly corresponds to the recognition of the Shire Human Genetic Therapies&#160;Inc. (Shire) contingent consideration liability of $382 million resulting from the acquisition of Translate Bio in September&#160;2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The &#8220;Other&#8221; column mainly relates to the contingent consideration liability due to True North Therapeutics as a result of Sanofi's acquisition of Bioverativ which was settled in the first half of 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock', window );">Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the maximum amount of contingent consideration payable in respect of already-marketed products:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From&#160;1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">From&#160;3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commitments relating to contingent consideration&#160;in connection with business combinations</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes in liabilities related to business combinations and to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518687568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock', window );">Summary of Non Current Provisions and Other Non-current Liabilities</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non current provisions and other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprises the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,262&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,822&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,340&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,602</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,341</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,721</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes derivative financial instruments: &#8364;164&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">as of December 31, 2023</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, &#8364;232 million as of December 31, 2022, &#8364;6 million as of December 31, 2021.<br/>The figure as of December 31, 2023 includes &#8364;1,960&#160;million for the liability in respect of royalties payable to Sobi on net sales of BEYFORTUS (nirsevimab) in the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#8364;1,112&#160;million; the nominal value of payments estimated to be due after more than five years is &#8364;2,860 million.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsTableTextBlock', window );">Summary of Movements in Non-current Provisions</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth movements in non-current provisions for the reporting periods presented:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:33.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions&#160;for<br/>pensions and<br/>other&#160;post-employment<br/>benefits<br/>(D.19.1.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Provisions<br/>for other<br/>long-term<br/>benefits</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Restructuring<br/>provisions<br/>(D.19.2.)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>provisions<br/>(D.19.3.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,276</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">879</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">868</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,975</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,998</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(222)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(107)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(459)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(145)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(200)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(370)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(425)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(448)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(448)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,947</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">935</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">524</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,024</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,430</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(96)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(76)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(200)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(275)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(528)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(191)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(288)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(265)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(780)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(780)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,039</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">844</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">761</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,178</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,822</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increases in provisions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reversals of unutilized provisions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(758)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(572)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest related to employee benefits, and unwinding of discount</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains and losses on defined-benefit plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,214</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">718</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">554</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,776</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,262</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the case of &#8220;Provisions for pensions and other post-employment benefits&#8221;, the &#8220;Increases in provisions&#8221; line corresponds to rights vesting in employees during the period, and past service cost; the &#8220;Provisions utilized&#8221; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#8220;Reversals of unutilized provisions&#8221; line corresponds to plan curtailments, settlements and amendments.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Includes the impact of the April&#160;2021 IFRIC agenda decision on the allocation of benefits to service periods, as described in Note&#160;A.2.1. to the consolidated financial statements for the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfActuarialAssumptionsTableTextBlock', window );">Summary of Financial and Demographic Assumptions</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those calculations were based on the following financial and demographic assumptions:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Discount rate</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.95% to 3.15%</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.95% to 3.15%</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.75%</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.50%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.55% to 3.75%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.55% to 3.75%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.90%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.75%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.10%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.10%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.10%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.10%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.70%</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.90%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">General inflation rate</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.20%</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.20%</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.05%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.50%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.50%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.25%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.95%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.95%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.30%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pension benefit <br/>indexation</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.20%</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.20%</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.90%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.50%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.50%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.00%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.95%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.95%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.15%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Healthcare cost </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">inflation rate</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.00%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9.75%</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.29%</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.56%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.50% to 4.50%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retirement age</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 67</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 70</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 65</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 67</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 70</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 65</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 67</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 70</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">to 65</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mortality table</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TGH/<br/>TGF<br/>05</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Heubeck<br/>RT<br/>2018 G</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RP2012 Proj.<br/>MP2021 White Collar</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAPS<br/>S3</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TGH/<br/>TGF<br/>05</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Heubeck<br/>RT<br/>2018 G</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RP2012 Proj.<br/>MP2021 White Collar</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAPS<br/>S3</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TGH/<br/>TGF<br/>05</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Heubeck<br/>RT<br/>2018 G</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RP2012 Proj.<br/>G.&#160;Scale<br/>MP2020 White Collar</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SAPS<br/>S3</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The discount rates used were based on market rates for high quality corporate bonds with a duration close to that of the expected benefit payments under the plans. The benchmarks used to determine discount rates were the same for all periods presented.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The rate depends on the duration of the plan (0&#160;to 7&#160;years, 7&#160;to 10&#160;years, or more than 10&#160;years).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Inflation for the euro zone is determined using a multi-criterion method.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;No post-employment healthcare benefits are provided in France since 2020, Germany and UK.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock', window );">Summary of Weighted Average Duration of Obligation for Pensions and Other Long-term Benefits in Principal Countries</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the duration of Sanofi&#8217;s obligations in the principal countries:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:25.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted average duration</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory', window );">Summary of Sensitivity for Pensions and Other Post-employment Benefits to Changes in Key Actuarial Assumptions</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the sensitivity of Sanofi&#8217;s obligations for pensions and other post-employment benefits to changes in key actuarial assumptions:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions and other post-employment benefits, <br/>by principal country</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement of defined-benefit obligation</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in<br/>assumption</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.50&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+56&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+170&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+78&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+42&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">General inflation rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pension benefit indexation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Healthcare cost inflation rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortality table</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+1 year</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+38&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+53&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+19&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock', window );">Reconciliation of Net Obligation in Respect of Sanofi's Pension and Other Post-Employment Benefit Plans</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below reconciles the net obligation in respect of Sanofi&#8217;s pension and other post-employment benefit plans with the amounts recognized in the consolidated financial statements:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:63.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement of the obligation:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Beginning of period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,651&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,456&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial losses/(gains) due to changes in demographic assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(162)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial losses/(gains) due to changes in financial assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,006)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(210)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial losses/(gains) due to experience adjustments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(120)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan amendments, curtailments or settlements not specified in the terms of the plan</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(229)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan settlements specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(463)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(503)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation and transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Obligation at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,930</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,651</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,175</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Beginning of period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,899&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,651&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,358&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between actual return and interest income on plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Administration costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan settlements specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan settlements not specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employer&#8217;s contributions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(426)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(458)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation and transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan assets at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,993</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,899</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,651</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net obligation</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,943</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,770</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,539</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amounts recognized in the balance sheet:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded obligations (see Note D.7.)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(408)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Obligations provided for</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,214&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,039&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount recognized at end of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,943</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,770</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,539</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit cost for the period:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in&#160;the&#160;terms&#160;of the plan</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest (income)/cost</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Administration costs and taxes paid during the period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense recognized directly in profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">190</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">168</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">276</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(650)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(685)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">361</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(482)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(409)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These amounts include the impact of applying the April&#160;2021 IFRIC agenda decision on the attribution of benefits to periods of service.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;For 2023, this line includes &#8364;66&#160;million of assets in the United Kingdom (versus &#8364;99&#160;million for 2022 and &#8364;220&#160;million for 2021); those amounts are not subject to any asset ceiling, in accordance with IFRIC&#160;14.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Amounts recognized in Other comprehensive income (see Note&#160;D.15.7.).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock', window );">Net Liability in Respect of Pension Plans and Other Post-employment Benefits by Geographical Region</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show Sanofi&#8217;s net liability in respect of pension plans and other post-employment benefits by geographical region:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:25.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Measurement of obligation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,911&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,930&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,401&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,235&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,993&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">647</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">510</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">703</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">144</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,943</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:25.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Measurement of obligation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,324&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,730&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,651&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,317&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">627</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">413</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">686</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(95)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">139</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,770</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:25.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Measurement of obligation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,576&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,099&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,175&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,651&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of asset ceiling</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amount shown in the balance sheet at end of period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">819</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">768</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">972</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(215)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">195</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,539</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory', window );">Fair Value of Plans Assets relating to Pension Plans and Other Post-employment Plans</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the fair value of plan assets relating to Sanofi&#8217;s pension and other post-employment plans, split by asset category:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Securities quoted in an active market</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84.9</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84.4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">86.9</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bonds and similar instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commodities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13.1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance policies</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock', window );">Service Cost for Pension and Other post-employment Benefit Plans, by Geographical Region</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the service cost for Sanofi&#8217;s pension and other post-employment benefit plans, by geographical region:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Service cost for 2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost/(income) including administration costs and taxes paid during the period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) recognized directly in profit or loss</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">56</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">190</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">55</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">143</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">82</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">39</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">361</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Service cost for 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost/(income) including administration costs and taxes paid during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) recognized directly in profit or loss</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">53</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(13)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">36</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">168</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(156)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(204)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(382)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(650)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(145)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(151)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(301)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">117</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(482)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Service cost for 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current service cost</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost/(income) including administration costs and taxes paid during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contributions from plan members</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) recognized directly in profit or loss</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">80</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">276</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(106)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(113)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(157)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(236)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(73)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(685)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expense/(gain) for the period</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(26)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(61)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(73)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(230)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(19)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(409)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock', window );">Remeasurement of Net Defined-benefit (Asset)/Liability (Actuarial Gains and Losses)</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of the &#8220;Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)&#8221; line in the preceding tables is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:19.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.429%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses) arising during the period</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(131)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Comprising:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">on experience adjustments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(120)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(620)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(287)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) <br/>on demographic assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) <br/>on financial assumptions</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Experience adjustments are mainly due to the effect on plan assets of trends in the financial markets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock', window );">Summary of Net Pre-tax Actuarial Loss</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The net pre-tax actuarial loss (excluding investments accounted for using the equity method) recognized directly in equity is presented below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net pre-tax actuarial loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,259)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,090)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,738)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock', window );">Summary of Present Value of Pension and Other Post Employement Benefits</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The present value of Sanofi&#8217;s obligations in respect of pension and other post-employment benefit plans at the end of each reporting period is shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of wholly or partially funded obligations in respect of pension and other post-employment benefit plans</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,463&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,416&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Present value of unfunded obligations</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,930</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,651</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,175</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock', window );">Total Expense for Pensions and Other Post-employment Benefits Allocated between Income Statement Line Items</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense for pensions and other post-employment benefits (&#8364;190 million in 2023) is allocated between income statement line items as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating (income)/expenses, net</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">190</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">168</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">276</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock', window );">Estimated Amounts of Employer's Contributions to Plan Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The estimated amounts of employer&#8217;s contributions to plan assets in 2024 are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employer&#8217;s contributions in 2024 (estimate):</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock', window );">Expected Timing of Benefit Payments under Pension and Other Post-employment Benefit Plans</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the expected timing of benefit payments under pension and other post-employment benefit plans for future years:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated future benefit payments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2029 to 2033</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,213&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock', window );">Timing of Future Payments in Respect of Unfunded Pension and Other Post-employment Benefit Plans</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows estimates as of December 31, 2023 for the timing of future payments in respect of unfunded pension and other post-employment benefit plans:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than 1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to <br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to <br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated payments</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringProvisionsTableTextBlock', window );">Movements in Restructuring Provisions Classified in Non-current and Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in restructuring provisions classified in non-current and current liabilities:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,233</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,118</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,499</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in non-current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in provisions recognized in profit or loss for the period</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provisions utilized</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(522)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(571)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discount</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,132</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,233</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,118</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in non-current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Classified in current liabilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Provisions utilized mainly correspond to payments related to employees affected by separation programs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock', window );">Timing of Future Termination Benefit Payments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The timing of future termination benefit payments is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit payments by period</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employee termination benefits</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">France</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other countries</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">968</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">362</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">86</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit payments by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employee termination benefits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">France</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other countries</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,039</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">374</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">215</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Benefit payments by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Employee termination benefits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">France</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other countries</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">943</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">476</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">394</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">67</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock', window );">Summary of Other Provisions</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other provisions</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> include provisions for risks and litigation relating to environmental, tax, commercial and product liability matters.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Environmental risks</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Product liability risks, litigation and other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,776</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,178</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,024</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock', window );">Current Provisions and Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Current provisions and other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Taxes payable, other than corporate income taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,106&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring provisions (see Note&#160;D.19.2.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate derivatives (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency derivatives (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity derivatives (see Note&#160;D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amounts payable for acquisitions of non-current assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Customer contract liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,590&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,741</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,021</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,217</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;See Note&#160;A.5.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, &#8220;Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. The year-on-year change in this item between 2022 and 2023 includes revenue of &#8364;269&#160;million  recognized in profit or loss during 2023 previously included in </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Customer contract liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> as of December&#160;31, 2022, compared with revenue of  &#8364;85&#160;million </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">recognized in profit or loss during 2022 </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">previously included in  </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Customer contract liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> as of December&#160;31, 2021</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> . No such revenue was recognized in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#8220;Other current liabilities&#8221; mainly comprises provisions and liabilities for customer rebates and returns; provisions for discounts and rebates granted to healthcare authorities and governmental programs (see Note&#160;D.23.); and the liability payable at each reporting date under the Monoclonal Antibody Alliance with Regeneron.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;As of December 31, 2023 includes &#8364;131&#160;million (nominal value: &#8364;137 million) for the current liability relating to royalties payable to Sobi on net sales of BEYFORTUS (nirsevimab) in the United States (see Note&#160;C.2.)</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of defined benefit plan assets. [Refer: Plan assets [member]; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 142<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_142&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 145<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_145&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfActuarialAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Actuarial Assumptions [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfActuarialAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of current provisions and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of estimated amounts of employer's contributions to plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expected timing of payments in respect of unfunded pension and other post employment benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expected timing of payments under pension and other post employment benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expense for pensions and other post employment benefits by income statement line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of future benefit payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of net defined benefit liability assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of net liability in respect of pension plans and other post-employment benefits by geographical region.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNonCurrentProvisionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of noncurrent provisions explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNonCurrentProvisionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherLongTermProvisionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other long term provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherLongTermProvisionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of pension and other post employment benefit expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Pre Tax Actuarial Loss Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of provisions and other non current liabilities explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of remeasuresment of net defined benefit liability asset by country.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRestructuringProvisionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of restructuring provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRestructuringProvisionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of service costs of net defined benefits by country.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of weighted average duration of defined benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534216640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative financial instruments and market risks (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock', window );">Summary of Fair Value of Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the fair value of derivative instruments as of December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">assets</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current<br/>assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current<br/>liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current<br/>liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>liabilities</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2023 (net)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2022 (net)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2021 (net)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency derivatives</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">operating</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">financial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate derivatives</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(165)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity derivatives</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">201</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">201</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(164)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(127)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(291)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(90)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">( 120)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">213</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock', window );">Summary of Operating Currency Hedging Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2023, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as<br/>cash flow hedges</span></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which&#160;derivatives&#160;not<br/>eligible&#160;for&#160;hedge&#160;accounting</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which<br/>recognized&#160;in&#160;equity</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,112</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,112</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,981&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,981&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,246</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,246</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,358</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,358</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2022, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as<br/>cash flow hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which&#160;derivatives&#160;not<br/>eligible&#160;for&#160;hedge&#160;accounting</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which<br/>recognized&#160;in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,403</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,403</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,732&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">56&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,732&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">56&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,459</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(27)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,459</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(27)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Taiwan dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,862</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,862</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2021, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:20.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives<br/>designated&#160;as&#160;cash&#160;flow&#160;hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which&#160;derivatives&#160;not</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">eligible&#160;for&#160;hedge&#160;accounting </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of&#160;which<br/>recognized<br/>in&#160;equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">665&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">665&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">199&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Taiwan dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,374</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,374</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">833&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">833&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Russian rouble</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8211;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,286</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8211;</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,286</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock', window );">Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:22.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.187%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,279</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">111</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,559</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,655</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6,628&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">59&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5,384&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,055</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,293</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">197</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,073&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(b) (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,816&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">205&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,334</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">53</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,556</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,948</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">212</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi&#8217;s net investment in Bioverativ. As of December 31, 2023, the fair value of these forward contracts represented an asset of &#8364;54 million; the opposite entry was recognized in "Other comprehensive income", with the impact on financial income and expense being immaterial.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2023, the fair value of the contracts was a liability of &#8364;31 million, the opposite entry for &#8364;2.7&#160;million of which was credited to &#8220;Other comprehensive income&#8221; under the cost of hedging accounting treatment.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,044 million expiring in 2024, designated as a fair value hedge of the exposure of an equivalent amount of commercial paper. As of December 31, 2023, the fair value of the swaps was a liability of &#8364;3 million, the opposite entry for &#8364;0.7&#160;million of which was credited to &#8220;Other comprehensive income&#8221; under the cost of hedging accounting treatment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock', window );">Disclosure of Instruments</a></td>
<td class="text"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:17.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2023</span></td><td colspan="3" style="background-color:#e3e3e3;padding:0 1pt"></td><td colspan="6" style="background-color:#e3e3e3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></div></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.03%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.32%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.69%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.92%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 3.43%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">999</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">906</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">650</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,405</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(165)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,405</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(165)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2022:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:17.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028 and later</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.03%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.32%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.69%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.92%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,584</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,434</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(232)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,434</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(232)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:17.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027 and later</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized EONIA/receive 0.06%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay -0.57%/receive capitalized EONIA</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized USD SOFR/receive 1.03%  </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized USD SOFR/receive 1.32%  </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">receive capitalized Eonia/pay 1.48%</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,642</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">880</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,579</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,979</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">600</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;These interest rate swaps hedge fixed-rate bonds with a nominal of &#8364;99 million held in a Professional Specialized Investment Fund dedicated to Sanofi and recognized within &#8220;Long-term loans and advances and other non-current receivables&#8221; (see Note D.7.).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock', window );">Disclosure of Actual or Potential Effects of Netting Arrangements</a></td>
<td class="text"><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below is prepared in accordance with the accounting policies described in Note&#160;B.8.3.:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:31.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.081%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross carrying amounts before offset (a)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(326)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(85)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross amounts offset (in accordance with IAS&#160;32)&#160;(b)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amounts as reported in the balance sheet (a) -&#160;(b) =&#160;(c)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">201</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(291)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(326)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">298</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(85)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effects of other netting arrangements (not fulfilling the IAS&#160;32 criteria for offsetting) (d)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(160)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(67)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of financial collateral</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net exposure (c) + (d)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(120)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(166)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">231</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of actual or potential effects of netting arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of fair value of derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interest rates hedging instruments with notional amount by expiry date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533560032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off balance sheet commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract', window );"><strong>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock', window );">Summary of Off Balance Sheet Commitments Relating to Operating Activities</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments relating to Sanofi&#8217;s operating activities comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:48.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Irrevocable purchase commitments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">given</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,141&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">received</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(443)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(96)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development license agreements - commitments given</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">commitments related to R&amp;D and other commitments</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">contingent milestone payments in connection with development programs in progress</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,886&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total - net commitments given</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,079</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,563</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,878</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,625</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes the variable portion of future lease payments not recognized as lease liabilities as of December 31, 2023; the equivalent amount of these commitments as of December&#160;31, 2022 was &#8364;38&#160;million.<br/>During 2023, Sanofi signed a 15-year lease which will take effect in 2025 and for which Sanofi is committed for a minimum period of 12 years, corresponding to a minimum commitment of $0.2&#160;billion. The lease includes two extension options of five years each.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;These comprise irrevocable commitments to suppliers of (i)&#160;property, plant and equipment, net of down-payments (see Note&#160;D.3.) and (ii)&#160;goods and services. As of December 31, 2022, irrevocable commitments amounted to &#8364;6,194 million given and &#8364;574 million received.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Irrevocable purchase commitments given as of December 31, 2023 include &#8364;926 million of commitments to joint ventures, and the commitment to EUROAPI as described in Note D.2. and amounting to &#8364;804&#160;million as of December 31, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Commitments related to R&amp;D, and other commitments, amounted to &#8364;259 million as of December 31, 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;This line includes only contingent milestone payments on development projects in progress. The equivalent amount as of December 31, 2022 was     &#8364;2,919 million.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock', window );">Summary of Undrawn Credit Facilities</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Undrawn credit facilities are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;year</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1&#160;to<br/>3&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3&#160;to<br/>5&#160;years</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">General-purpose credit facilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock', window );">Summary of Amount of Guarantees Given and Received</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the amount of guarantees given and received:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Guarantees given:</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,936</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,815</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,794</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Guarantees provided to banks in connection with credit facilities</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Other guarantees given</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,869&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,752&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Guarantees received</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,272)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,229)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,149)</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of guarantees given and received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of off balance sheet commitments relating to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of undrawn borrowing facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523821360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions for discounts, rebates and sales returns (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract', window );"><strong>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock', window );">Summary of Movement in Provisions for Discounts, Rebates and Sales Returns</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows movements in these items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:25.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Government</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">and State</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">programs</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Managed&#160;care</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">and&#160;GPO</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">programs</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Chargeback<br/>incentives</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rebates<br/>and<br/>discounts</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sales<br/>returns</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>deductions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,507</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">908</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">333</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,557</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">688</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,039</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,813&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,714&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in provision related to prior period sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(136)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(152)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(242)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,561)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,979)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,828)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,291)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(697)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19,461)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,596</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">931</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">303</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,425</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">610</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,899</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,744&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,246&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,244&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,141&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in provision related to prior period sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(120)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(315)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,824)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,208)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,093)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,809)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(599)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(166)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21,699)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,603</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">362</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,805</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">629</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">70</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,490</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision related to current period sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,758&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,590&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,861&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in provision related to prior period sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments made</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,251)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,446)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,564)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,603)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(511)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(278)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22,653)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(76)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(213)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance&#160;at December 31, 2023</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,962</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,119</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">637</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,269</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">715</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">60</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,762</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Primarily US government programs: Medicaid (&#8364;1,421 million in 2023, &#8364;1,307 million in 2022, &#8364;1,244 million in 2021) and Medicare (&#8364;1,099 million in 2023, &#8364;775 million in 2022 and &#8364;941 million in 2021).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Mainly rebates and other price reductions granted to healthcare authorities in the United States (including Managed Care: &#8364;1,028 million in 2023,     &#8364;934 million in 2022 and &#8364;896 million in 2021).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Provisions related to US net sales amounted to &#8364;5,124 million as of December 31, 2023, &#8364;4,270 million as of December 31, 2022 and &#8364;4,057 million as of&#160;December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes in provisions for discounts rebates and sales returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523880448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EmployeeBenefitsAbstract', window );"><strong>Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock', window );">Summary of Personal Costs</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total personnel costs (other than termination benefits, presented in Note&#160;D.27.) include the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Salaries</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,183&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,145&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,625&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Social security charges (including defined-contribution pension plans)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,929&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other employee benefits</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:3.9pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.1pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,814</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,991</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,340</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes expenses related to share-based payments and defined-benefit plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfPersonnelCostsDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of personnel costs details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfPersonnelCostsDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EmployeeBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Benefits [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EmployeeBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518843168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherOperatingExpensesTableTextBlock', window );">Schedule Other Operating Expenses</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2023, this line item includes &#8364;3,206 million of expenses related to Regeneron (see Note&#160;C.1.), compared with&#160;&#8364;2,378 million for 2022 and &#8364;1,568 million for 2021 (as shown in the table below):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income &amp; expense related to sharing of (profits)/losses under the Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,321)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,325)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,253)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(476)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total - Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,196)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,367)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,429)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immuno-Oncology Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other (mainly ZALTRAP and LIBTAYO)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">217</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,120</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(12)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other operating income/(expenses), net related to Regeneron</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,979)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,231)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,373)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which amount presented in</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> (Note&#160;D.25.)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">195&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Following the restructuring of the Immuno-Oncology agreement between Sanofi and Regeneron, applicable from July&#160;1, 2022 (see Note&#160;C.1.).</span></div>(b)&#160;&#160;&#160;&#160;As of December 31, 2023, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to &#8364;2.1 billion, compared with &#8364;2.7 billion as of December 31, 2022 (see note D.21.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherOperatingExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Expenses [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherOperatingExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534328896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs and similar items (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock', window );">Summary of Restructuring Costs and Similar Items</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring costs and similar items amounted to &#8364;1,490&#160;million in 2023, &#8364;1,336&#160;million in 2022 and &#8364;820&#160;million in 2021, and were comprised of the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charges, gains or losses on assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Costs related to transformation programs</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,490</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,336</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">820</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRestructuringCostsDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of restructuring costs details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRestructuringCostsDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519107808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial expenses and income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock', window );">Summary of Analysis of Financial Income and Expenses</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(365)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(313)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(124)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(259)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) on disposals of financial assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(722)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(234)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(328)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,313)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(440)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(368)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">591</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">40</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes net gains/(losses) on interest rate and currency derivatives used to manage debt: &#8364;(67) million in 2023, &#8364;(11) million in 2022, &#8364;14 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Includes net gains on interest rate and currency derivatives used to manage cash and cash equivalents: &#8364;(13) million in 2023, &#8364;68 million in 2022,          &#8364;51 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note&#160;D.19.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes a financial expense of &#8364;541 million (zero in 2022 and 2021) in respect of the liability recognized in the balance sheet for estimated future royalties on US sales of BEYFORTUS, which was remeasured as of December 31, 2023 to reflect the very successful US launch of the product (see Note C.2.).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519389808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock', window );">Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,560)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,774)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,908)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,602)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,006)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,558)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,153</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,422</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,798</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock', window );">Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Probable reversal of temporary differences on investments in Consumer Healthcare subsidiaries</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19.2</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In accordance with IAS&#160;12, a deferred tax liability was recognized in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October&#160;2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In determining the amount of the deferred tax liability for 2023, 2022 and 2021, Sanofi took into account changes in the ownership structure of certain subsidiaries.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of allocation of income tax between current and deferred taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of average effective tax rate and applicable tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523914720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income attributable to non-controlling interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock', window );">Summary of Trends in Net Income Attributable to Non-Controlling Interests</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for the reporting periods presented:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of net income attributable to non-controlling interests</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">36</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">113</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">56</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Information About The Amounts Attributable To Non Controlling Interests Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533872224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock', window );">Schedule of Compensation Paid to Key Management Personnel</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows, by type, the compensation paid to key management personnel:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term benefits</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Post-employment benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total recognized in profit or loss</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">55</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Compensation, employer&#8217;s social security contributions, directors&#8217; compensation, and any termination benefits (net of reversals of termination benefit obligations).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory', window );">Summary of Aggregate Amounts Payable to Key Management Personnel</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the aggregate obligation as of December&#160;31 for each period presented for individuals who hold or have held executive positions within Sanofi during that period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of compensation paid to key management personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526908912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OperatingSegmentsAbstract', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock', window );">Summary of Net Sales by Segment and Geographical Area</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth Sanofi&#8217;s net sales for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.491%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.5pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="border-right:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" rowspan="2" style="border-left:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:9pt"><td colspan="42" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,265</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,790</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,890</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,498</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,985</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,329</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,812</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,426</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,246</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,621</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33,293</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Specialty Care</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,206</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,917</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,917</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,040</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,016</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,848</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,593</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,457</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,764</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,847</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,141</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,752</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">DUPIXENT</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8,145&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10,715&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,346&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8,293&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,249&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">AUBAGIO</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,955&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">CEREZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">FABRAZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">MYOZYME/<br/>LUMIZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">JEVTANA</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ALPROLIX</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ELOCTATE</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">General Medicines</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,932</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,084</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,360</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,376</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,141</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,846</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,140</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,127</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,437</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,637</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,144</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,218</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,988</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,485</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,797</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,270</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,917</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,653</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,819</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,389</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,868</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,315</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,585</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,768</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">LOVENOX</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">TOUJEO</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">PLAVIX</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Non-Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,396</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">592</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,536</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,524</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,637</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,176</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,305</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,118</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,846</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,281</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,515</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,642</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">LANTUS</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other non-core assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,424&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,687&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Industrial sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">548</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">582</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">587</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">620</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">723</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">808</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,697</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,264</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,513</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,474</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,341</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,291</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,596</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,228</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,225</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,762</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,336</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,323</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Polio/Pertussis/<br/>Hib Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,504&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,285&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,159&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Influenza Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,669&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,977&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer Healthcare</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,557</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,247</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,376</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,180</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,501</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,290</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,394</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,185</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,139</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,996</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,468</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Allergy</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pain Care</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Digestive Wellness</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,392</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,512</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,166</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,999</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,275</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,723</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,759</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,385</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,617</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,761</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective January&#160;1, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Schedule of Segment Results</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi&#8217;s segment results for the years ended December 31, 2023, December 31, 2022 and December 31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,890</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,180</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,322&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,374&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,282)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,933)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14,216)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,509)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,868)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,692)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,387)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,224)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,247</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,670</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,812</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,185</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11,793)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,903)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13,692)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,503)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(205)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,706)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,736)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,761)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,492)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,679)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,514)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,490</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,522</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,040</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January&#160;1, 2023.</span></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:39.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,970</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,323</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,468</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,761</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,430)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(250)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,251)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,330)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(712)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(497)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,692)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,326)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(805)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,036)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9,555)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,172)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(946)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,409</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,609</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,493</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,797)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,714</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This caption reconciles segment financial information to total consolidated financial information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock', window );">Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS&#160;8, shows a reconciliation between aggregated &#8220;Business operating income&#8221; for the segments and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:57.552%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.684%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,670</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,040</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,714</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(88)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,068)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,599)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,772)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,490)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(820)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(370)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income from out-licensing</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,875</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,656</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,126</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,313)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(440)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(368)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,153</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,422</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,798</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;For 2023, this amount mainly comprises an impairment loss of &#8364;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;D programs, in particular those related to the NK Cell and PRO-XTEN  technology platforms. For 2022, this line includes a reversal of &#8364;2,154&#160;million on ELOCTATE franchise products following FDA approval of ALTUVIIIO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">dated February&#160;22, 2023, partially offset by an impairment loss of &#8364;1,586&#160;million on intangible assets relating to SAR444245 (non-alpha interleukin-2).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For 2022, this line includes an upfront payment of $900&#160;million and a regulatory milestone payment of $100&#160;million related to the out-licensing of LIBTAYO following the restructuring of the Immuno-Oncology Collaboration and License Agreement with Regeneron (see Note&#160;C.1.).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock', window );">Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:48.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,619&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:48.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January&#160;1, 2023.</span></div><div style="margin-top:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:48.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.613%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory', window );">Summary of Geographical Information on Net Sales and Non-Current Assets</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with&#160;IFRS&#160;8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS&#160;16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>United&#160;States</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,392</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,379</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,216</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,512</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,462</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,160&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,659&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,085&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,316&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,185&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,404&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9642;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,319&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,566&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,852&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>United&#160;States</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,999</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,296</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,984</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,275</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,014</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,869&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,892&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,640&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,257&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,178&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of&#160;which<br/>United&#160;States</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,761</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,759</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,256</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,075</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,385</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,927</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,028&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,959&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,407&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,059&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of geographical information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of net sales by segment and geographical area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments reconciling items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Segments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523889904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal accountants' fees and services (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AuditorsRemunerationTableTextBlock', window );">Disclosure of Accountants' Fees and Services</a></td>
<td class="text">The table below shows fees charged by those firms and member firms of their networks to Sanofi and consolidated subsidiaries in the years ended December 31, 2023 and 2022.<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:29.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ernst&#160;&amp;&#160;Young</span></td><td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PricewaterhouseCoopers</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(&#8364; million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Audit:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> Statutory audit of separate and consolidated financial statements</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Services other than statutory audit</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Audit-related services</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14.6</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst&#160;&amp; Young &#8364;7.9 million in 2023, &#8364;7.3 million in&#160;2022; PricewaterhouseCoopers Audit &#8364;8.3 million in 2023, &#8364;7.7 million in 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Services other than statutory audit provided by Ernst&#160;&amp; Young during 2023 comprised:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- contractual audits, including on the combined financial statements of the Consumer Healthcare business;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- additional procedures to enable reports previously signed by the firm to be incorporated by reference;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- issuance of the Independent Third Party&#8217;s report on the consolidated statement of extra-financial performance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Services other than statutory audit provided by PricewaterhouseCoopers during 2023 comprised:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- contractual audits, including on the combined financial statements of the Consumer Healthcare business;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- additional procedures to enable reports previously signed by the firm to be incorporated by reference; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst&#160;&amp; Young: &#8364;5.2 million in 2023, &#8364;1.4 million in&#160;2022; PricewaterhouseCoopers Audit &#8364;5.3 million in 2023, &#8364;0.3 million in 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Includes &#8364;0.5&#160;million for services that can only be provided by the statutory auditors, such as comfort letters, attestation services required by regulation (which qualify as audit fees under SEC rules).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AuditorsRemunerationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditors remuneration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AuditorsRemunerationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348522353296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>List of principal companies included in the scope of consolidation during&#160;2023 (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory', window );">Summary of Principal Companies and their Country of Incorporation</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi&#8217;s principal subsidiaries and their country of incorporation:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hoechst GmbH</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Deutschland GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">A. Nattermann &amp; Cie. GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Austria</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Belgium</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ablynx NV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Flanders BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi A/S</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Denmark</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Spain, SL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Oy</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Finland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis France</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Winthrop Industrie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Recherche &amp; D&#233;veloppement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Groupe</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Chimie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Participations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma S.A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Biotechnology</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Mature IP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur NVL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SECIPE SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Merieux SAS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare International SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare France SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Group SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Polyclonals SAS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis A.E.B.E.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Greece</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Private Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chinoin Private Co. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Hungary Commercial K.F.T</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Hungary K.F.T</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carraig Insurance DAC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Ireland Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Holdings (Ireland) Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Italy SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Global Sarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Luxembourg Sarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Norge AS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Norway</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Foreign Participations BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Sp. z.o.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Poland sp.z.o.o.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Sp. z.o.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Produtos Farmaceuticos Lda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Portugal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis, s.r.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Czech s.r.o</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Romania SRL</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Romania</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Romania SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Romania</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis UK Holdings Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Synthelabo UK Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma Holdings Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare UK Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AO Sanofi Russia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi AB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sweden</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Suisse) SA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Global Sarl Baar Intellectual Property Branch</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Ilac Sanayi ve Ticaret AS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Asi Ticaret AS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare T&#252;ketici Sa&#287;l&#305;&#287;&#305; Anonim &#350;irketi</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Saglik Urunleri Limited Sirketi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Therapeutic Products Limited Partnership</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi US Services Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis U.S. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventisub LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VaxServe, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ U.S. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ Therapeutics Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principia Biopharma Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Research Invest LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Bioverativ Holdings LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RPR US Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Kadmon Corporation, LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United&#160;States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amunix</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Synthorx, Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provention Bio</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QRIB Intermediate Holding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QRI</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TargeGen Inc.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem (GB) Holding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Translate Bio, Inc.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:57.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other Countries</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis South Africa (Pty) Ltd</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Africa</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Alg&#233;rie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Algeria</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Arabia Trading Company Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Saudi Arabia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Argentina SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Argentina</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Healthcare Pty Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Australia Pty Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Medley Farmaceutica Ltda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Brazil Ltda.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Canada Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Merieux Canada Holdings ULC (Canada)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (Hangzhou) Pharmaceuticals Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (China) Investment Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (Beijing) Pharmaceuticals Co.Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Biologies Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shenzhen Sanofi pasteur Biological Products Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shanghai Rongheng Pharmaceutical Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Colombia SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Colombia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Korea Co. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella healthcare Korea Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Gulf FZE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Arab Emirates</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Egypt</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Hong-Kong Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hong Kong</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi India Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">India</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Healthcare India Private Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">India</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Isra&#235;l Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi K.K.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SSP Co.,Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Malaysia) SDN. BHD.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Malaysia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Maroc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Morocco</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Mexico SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Azteca Vacunas, SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Panama SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Panama</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Panama SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Panama</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Puerto Rico Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Philippines Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Philippines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Philippines Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Philippines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Singapore Pte. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma (Manufacturing) Pte. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Manufacturing Pte Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Taiwan Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Taiwan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Thailand) Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thailand</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thailand</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Venezuela SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Venezuela</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Vietnam Company Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vietnam</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Vietnam Shareholding Company Limited</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vietnam</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85.0&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock', window );">Summary of Principal Investments Accounted for Using the Equity Method</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:62.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Haleon US, LP</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH&#160;&amp; Co. H&#246;chst KG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Maphar</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Morocco</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MCM Vaccine BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company (formerly MCM company)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 2<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_2_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Investments In Subsidiaries Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534696368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation (Details)<br> &#8364; in Millions, vaccine_dose in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>vaccine_dose</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>scenario </div>
<div>emission</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Average effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.40%<span></span>
</td>
<td class="nump">19.20%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInEffectiveTaxRate', window );">Increase in effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanetCareProgramObjectivesNetEmissionsBy2045', window );">Planet Care Program, net emissions by 2045 | emission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030', window );">Planet Care Program, percentage of reduction in scope 1 and 2 greenhouse gas by 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030', window );">Planet Care Program, percentage of reduction in scope 3 greenhouse gas by 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030', window );">Planet Care Program, percentage of reduction in all scopes greenhouse gas by 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030', window );">Planet Care Program, percentage of renewably-sourced energy in all sites by 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios', window );">Planet Care Program, number of global warming scenarios | scenario</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,374<span></span>
</td>
<td class="nump">&#8364; 2,392<span></span>
</td>
<td class="nump">&#8364; 1,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Current contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Average effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TypesOfAgreementAxis=sny_CollaborationAgreementWithGSKMember', window );">Collaboration agreement with GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 269<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Current contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherRevenuePerformanceObligationNoLongerRequired', window );">Other revenue, doses no longer an obligation to be delivered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TypesOfAgreementAxis=sny_CollaborationAgreementWithGSKMember', window );">Collaboration agreement with GSK | US Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfVaccineDosesToBeSupplied', window );">Number of vaccine doses to be supplied | vaccine_dose</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses', window );">Government grant recognised as deduction from development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 59<span></span>
</td>
<td class="nump">&#8364; 265<span></span>
</td>
<td class="nump">&#8364; 147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_AR', window );">Argentina</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears', window );">Cumulative inflation rate over three years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_TR', window );">Turkey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears', window );">Cumulative inflation rate over three years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CumulativeConsumerPriceInflationOverTheLastThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative consumer price inflation rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CumulativeConsumerPriceInflationOverTheLastThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Grant Recognised As Deduction From Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Effective Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfVaccineDosesToBeSupplied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Vaccine Doses To Be Supplied</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfVaccineDosesToBeSupplied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherRevenuePerformanceObligationNoLongerRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Revenue, Performance Obligation No Longer Required</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherRevenuePerformanceObligationNoLongerRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PlanetCareProgramObjectivesNetEmissionsBy2045">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Planet Care Program Objectives, Net Emissions By 2045</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PlanetCareProgramObjectivesNetEmissionsBy2045</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Planet Care Program Objectives, Number Of Global Warming Scenarios</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Planet Care Program Objectives, Percentage Of Reduction In All Scopes Greenhouse Gas By 2030</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Planet Care Program Objectives, Percentage Of Reduction In Scope 1 And 2 Greenhouse Gas By 2030</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Planet Care Program Objectives, Percentage Of Reduction In Scope 3 Greenhouse Gas By 2030</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Planet Care Program Objectives, Percentage Of Renewably-Sourced Energy In All Sites By 2030</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_CollaborationAgreementWithGSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_CollaborationAgreementWithGSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_USGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_USGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_AR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_AR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_TR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_TR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534106208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Other Intangible Assets not Acquired in Business Combination (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519837104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Summary of Useful Lives of Property Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful lives or depreciation rates, property, plant and equipment (in years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful lives or depreciation rates, property, plant and equipment (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful lives or depreciation rates, property, plant and equipment (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful lives or depreciation rates, property, plant and equipment (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful lives or depreciation rates, property, plant and equipment (in years)</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful lives or depreciation rates, property, plant and equipment (in years)</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful lives or depreciation rates, property, plant and equipment (in years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful lives or depreciation rates, property, plant and equipment (in years)</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_MachineryAndEquipment1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_MachineryAndEquipment1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533687920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Treasury Shares (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainLossOnPurchaseOfTreasuryShares', window );">Gain (loss) recognized on purchase of treasury shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainLossOnSaleOfTreasuryShares', window );">Gain (loss) recognized on sale of treasury shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainLossOnImpairmentOfTreasuryShares', window );">Gain (loss) recognized on impairment of treasury shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainLossOnCancellationOfTreasuryShares', window );">Gain (loss) recognized on cancellation of treasury shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainLossOnCancellationOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on cancellation of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainLossOnCancellationOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainLossOnImpairmentOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on impairment of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainLossOnImpairmentOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainLossOnPurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on purchase of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainLossOnPurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainLossOnSaleOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on sale of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainLossOnSaleOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523872400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Provision for Risks (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsRecordedForFutureOperatingLosses', window );">Provisions recorded for future operating losses</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ProvisionsRecordedForFutureOperatingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provisions recorded for future operating losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ProvisionsRecordedForFutureOperatingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526547040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Income Tax Expense (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense</a></td>
<td class="num">&#8364; (958,000,000)<span></span>
</td>
<td class="num">&#8364; (768,000,000)<span></span>
</td>
<td class="num">&#8364; (350,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember', window );">Temporary differences subject to GILTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems', window );"><strong>Disclosure Of Detailed Information About Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523597504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Share-Based Payment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_StockOptionPlansMember', window );">Stock option plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems', window );"><strong>Disclosure Of Detailed Information About Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OptionVestingPeriod', window );">Option vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlansMember', window );">Restricted share plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems', window );"><strong>Disclosure Of Detailed Information About Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Share-Based Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OptionVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OptionVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_StockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_StockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523970144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Segment Information (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments1', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516458304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal alliances - Collaboration agreements on human therapeutic antibodies (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2020</div></th>
<th class="th">
<div>Jul. 01, 2015 </div>
<div>agreement</div>
</th>
<th class="th">
<div>Nov. 30, 2007 </div>
<div>agreement</div>
</th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Rate</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>Rate</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Rate</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>bond</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>bond</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 43,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 42,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 37,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfAgreementsSigned', window );">Number of agreements signed | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfSecondPartOfDevelopmentCostsFunded', window );">Phase III costs, responsibility percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty', window );">Phase III costs, responsibility percentage for Regeneron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfProfitShareOnCounterpartiesProfit', window );">Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfCumulativeDevelopmentCostsReimbursed', window );">Percentage of cumulative development costs reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared', window );">Period before scheduled launch date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPayments', window );">Number of payments | bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, first achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PaymentRelatedToAttainmentOfGoal', window );">Payment related to attainment of goal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, first achievement | Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, second achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PaymentRelatedToAttainmentOfGoal', window );">Payment related to attainment of goal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, second achievement | Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Prior agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfProfitShareOnCounterpartiesProfit', window );">Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | New agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfProfitShareOnCounterpartiesProfit', window );">Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales Of Antibodies, Third Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PaymentRelatedToAttainmentOfGoal', window );">Payment related to attainment of goal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales Of Antibodies, Third Achievement | Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations', window );">Percentage of profits and losses arising from commercial operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfLossesArisingFromCommercialOperations', window );">Percentage of losses arising from commercial operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RoyaltyExpensePercentage', window );">Royalty expense, percentage (percentage)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfProfitsArisingFromCommercialOperations', window );">Percentage of profits arising from commercial operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfProfitsArisingFromCommercialOperations', window );">Percentage of profits arising from commercial operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfAgreementsSigned', window );">Number of agreements signed | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfProfitShareOnCounterpartiesProfit', window );">Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfCumulativeDevelopmentCostsReimbursed', window );">Percentage of cumulative development costs reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about Principal Alliances [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfAgreementsSigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Agreements Signed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfAgreementsSigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PaymentRelatedToAttainmentOfGoal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Related To Attainment Of Goal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PaymentRelatedToAttainmentOfGoal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfCumulativeDevelopmentCostsReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative development costs reimbursed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfCumulativeDevelopmentCostsReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfLossesArisingFromCommercialOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Losses Arising From Commercial Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfLossesArisingFromCommercialOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfProfitShareOnCounterpartiesProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of profit share on counter parties profit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfProfitShareOnCounterpartiesProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of profits and losses arising from commercial operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfProfitsArisingFromCommercialOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Profits Arising From Commercial Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfProfitsArisingFromCommercialOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfSecondPartOfDevelopmentCostsFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Second Part Of Development Costs Funded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfSecondPartOfDevelopmentCostsFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of second part of development costs funded by other party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period Before Launch Date During Which Commercial Expenses Of Antibodies Co-Developed Under License Agreement Are Shared</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RoyaltyExpensePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Expense, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RoyaltyExpensePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesFirstAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesFirstAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sny_AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sny_AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesSecondAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesSecondAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_PriorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_PriorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_NewAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_NewAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesThirdAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesThirdAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OutsideUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OutsideUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533753024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal alliances - Immuno-Oncology Agreement with Regeneron Pharmaceuticals, Inc. (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2015 </div>
<div>agreement</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating income/(expenses), net related to Regeneron | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (2,979)<span></span>
</td>
<td class="num">&#8364; (1,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets held for sale or exchange | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets held for sale or exchange | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfAgreementsSigned', window );">Number of agreements signed | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfProfitShareOnCounterpartiesProfit', window );">Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfCumulativeDevelopmentCostsReimbursed', window );">Percentage of cumulative development costs reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements', window );">Upfront payments for projects under collaboration agreements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements', window );">Regular milestone payments for projects under collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 96<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Major Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements', window );">Upfront payments for projects under collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 856<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RoyaltyIncomePercentage', window );">Royalty income percentage (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating income/(expenses), net related to Regeneron | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProceedsFromCollaborationAgreements', window );">Proceeds from collaboration agreements | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 196<span></span>
</td>
<td class="nump">&#8364; 952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Development of cemiplimab (REGN2810)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PriorDevelopmentBudget', window );">Prior development budget in total | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1', window );">Contractual agreement for anti-programmed cell death protein</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5000.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany', window );">Maximum additional funding for PD1 - part of each company | $</a></td>
<td class="nump">$ 1,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment', window );">PD1 sales milestone payment from Sanofi | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment', window );">Minimum sales of PD1 in 12-month period to be achieved for milestone payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Anti programmed cell death protein 1 sales milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ContractualAgreementForAntiProgrammedCellDeathProtein1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Agreement For Anti-programmed Cell Death Protein1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ContractualAgreementForAntiProgrammedCellDeathProtein1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfPrincipalAlliancesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Principal Alliances [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfPrincipalAlliancesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum additional funding for anti programmed cell death protein 1 part of each company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum sales of anti programmed cell death protein 1 in twelve month period to be achieved for milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfAgreementsSigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Agreements Signed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfAgreementsSigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfCumulativeDevelopmentCostsReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative development costs reimbursed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfCumulativeDevelopmentCostsReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfProfitShareOnCounterpartiesProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of profit share on counter parties profit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfProfitShareOnCounterpartiesProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PriorDevelopmentBudget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prior development budget.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PriorDevelopmentBudget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ProceedsFromCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ProceedsFromCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regular Milestone Payments For Projects Under Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RoyaltyIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Income, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RoyaltyIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payments For Projects Under Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sny_MajorCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sny_MajorCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_DevelopmentOfCemiplimabREGN2810Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_DevelopmentOfCemiplimabREGN2810Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518803856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal alliances - Investor Agreement with Regeneron Pharmaceuticals, Inc. (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 29, 2020</div></th>
<th class="th"><div>Jan. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SaleOfStockAxis=sny_PublicOfferingMember', window );">Public offering | Regeneron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember', window );">Regeneron Pharmaceuticals, INC | 2014 Amended Investment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems', window );"><strong>Disclosure of detailed information about Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MaximumOwnershipPercentageAllowedToAcquire', window );">Maximum ownership percentage allowed to acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about Principal Alliances [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MaximumOwnershipPercentageAllowedToAcquire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum ownership percentage allowed to acquire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MaximumOwnershipPercentageAllowedToAcquire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Issued In Transaction, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SaleOfStockAxis=sny_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SaleOfStockAxis=sny_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_TwoThousandFourteenAmendedInvestmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_TwoThousandFourteenAmendedInvestmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518701600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal alliances - Agreements on the commercialization of Beyfortus&#8482; (nirsevimab, previously MEDI8897) in the US (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 09, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,340<span></span>
</td>
<td class="nump">&#8364; 2,340<span></span>
</td>
<td class="nump">&#8364; 519<span></span>
</td>
<td class="nump">&#8364; 291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CollaborationAgreementsUpfrontPayment', window );">Collaboration agreements, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CollaborationAgreementsDevelopmentMilestonePayment', window );">Collaboration agreements, development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CollaborationAgreementsRegulatoryMilestonePayment', window );">Collaboration agreements, regulatory milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 65<span></span>
</td>
<td class="nump">&#8364; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement', window );">Commitments related to milestone payments for projects under collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Accruals', window );">Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">&#8364; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations', window );">Percentage of development costs arising from commercial operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | AstraZeneca | Other intangible assets excluding software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">&#8364; 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | AstraZeneca | Major territories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfProfitsArisingFromCommercialOperations', window );">Percentage of profits arising from commercial operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | AstraZeneca | Other territories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfNetSalesArisingFromCommercialOperations', window );">Percentage of net sales arising from commercial operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | AstraZeneca | China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfProfitsArisingFromCommercialOperations', window );">Percentage of profits arising from commercial operations</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfPrincipalAlliancesLineItems', window );"><strong>Disclosure of Principal Alliances [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">&#8364; 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
<td class="nump">&#8364; 1,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities', window );">Increase through remeasurement of financial liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Accruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Accruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CollaborationAgreementsDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Development Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CollaborationAgreementsDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CollaborationAgreementsRegulatoryMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Regulatory Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CollaborationAgreementsRegulatoryMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CollaborationAgreementsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CollaborationAgreementsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Related To Milestone Payments For Projects Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfPrincipalAlliancesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Principal Alliances [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfPrincipalAlliancesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Development Costs Arising From Commercial Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfNetSalesArisingFromCommercialOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Net Sales Arising From Commercial Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfNetSalesArisingFromCommercialOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfProfitsArisingFromCommercialOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Profits Arising From Commercial Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfProfitsArisingFromCommercialOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_MajorTerritoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_MajorTerritoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherTerritoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherTerritoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517807600">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Principal changes in the scope of consolidation in 2023 - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 29, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 29, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 27, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 13, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,870,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 992,000,000<span></span>
</td>
<td class="nump">&#8364; 5,594,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GoodwillTaxDeductiblePeriod', window );">Goodwill, tax deductible period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sny_ProventionBioIncMember', window );">Provention Bio, Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage', window );">Investments, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ProventionBioIncMember', window );">Provention Bio, Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationPurchasePricePerShare', window );">Purchase price per share (in euro/usd per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate', window );">Equity interest in acquiree held before acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_QRIBIntermediateHoldingsLLCMember', window );">QRIB Intermediate Holding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,342,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 774,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationPurchasePrice', window );">Business combination, purchase price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueOfAcquiree', window );">Contributions from acquiree to net sales | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 71,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossOfAcquiree', window );">Contributions from acquiree to net income | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Acquisition-related costs | &#8364;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2023, it includes the net cash outflow on the acquisitions of Provention Bio and QRIB (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note&#160;D.2.1.). For 2021, it includes the net cash outflows on the acquisitions of Kymab, Kiadis, Tidal, Translate Bio, Kadmon and Origimm (see Note&#160;D.2.2.).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph p<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_p_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) of the acquiree, since the acquisition date, included in the consolidated statement of comprehensive income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_q_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_q_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GoodwillTaxDeductiblePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Tax Deductible, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GoodwillTaxDeductiblePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sny_ProventionBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sny_ProventionBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ProventionBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ProventionBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_QRIBIntermediateHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_QRIBIntermediateHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518833888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Principal changes in the scope of consolidation in 2023 - Summary of Provisional Purchase Price Allocation (Details) - QRIB Intermediate Holding<br> &#8364; in Millions</strong></div></th>
<th class="th">
<div>Sep. 29, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate', window );">Other current and non-current assets and liabilities</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred taxes, net</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net assets</a></td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Purchase price</a></td>
<td class="nump">&#8364; 1,342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets and liabilities as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_QRIBIntermediateHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_QRIBIntermediateHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348508199072">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Principal changes in the scope of consolidation in 2022 and 2021 - Additional Information (Details)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 17, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 10, 2022 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 03, 2022</div></th>
<th class="th">
<div>Mar. 17, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 03, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 09, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 29, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 08, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 08, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 09, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 14, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 14, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 03, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 09, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 09, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 08, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 02, 2020 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,870<span></span>
</td>
<td class="nump">&#8364; 992<span></span>
</td>
<td class="nump">&#8364; 5,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,070<span></span>
</td>
<td class="nump">42,997<span></span>
</td>
<td class="nump">37,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent', window );">Exceptional supplementary dividends recognised as distributions to owners of parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 677<span></span>
</td>
<td class="nump">&#8364; 677<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">677<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains, (losses) and litigation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax expense (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,602)<span></span>
</td>
<td class="num">(2,006)<span></span>
</td>
<td class="num">(1,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 42<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember', window );">Provision for decommissioning, restoration and rehabilitation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_RegulatoryComplianceCostsMember', window );">Regulatory compliance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod', window );">Ownership interest in subsidiary, minimum holding period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 413<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital', window );">Exceptional supplementary dividend proposed, percentage of share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58000000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital', window );">Exceptional supplementary dividend, percentage of share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares', window );">Number of shares received (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SpecialDistributionNumberOfSharesConverted', window );">Special distribution, number of shares converted (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SpecialDistributionPercentageOfShareCapitalDistributed', window );">Special distribution, percentage of share capital distributed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets', window );">Decrease through loss of control of subsidiary, net assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill', window );">Decrease through loss of control of subsidiary, intangible assets and goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Weighted average share price (in EUR per share) | &#8364; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Net foreign exchange loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains, (losses) and litigation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax expense (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_EuroapiMember', window );">EUROAPI | Manufacture and supply collaboration agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CollaborationAgreementPeriodAfterLossOfControl', window );">Collaboration agreement, period after loss of control</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CollaborationAgreementAnnualNetSalesTarget', window );">Collaboration agreement, annual net sales target</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CollaborationAgreementCommitmentAmount', window );">Collaboration agreement, commitment amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,100<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_EuroapiMember', window );">EUROAPI | EPIC BPIFrance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfVotingEquityInterestsDivested', window );">Percentage of voting equity interests divested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12000000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12000000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ConsiderationTransferredMaximumAmount', window );">Consideration transferred, maximum amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ConsiderationTransferredValuationPeriod', window );">Consideration transferred, valuation period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember', window );">Attributable to&#160;equity holders of Sanofi&#160;</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent', window );">Exceptional supplementary dividends recognised as distributions to owners of parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_AmunixPharmaceuticalsIncMember', window );">Amunix Pharmaceuticals, Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations', window );">Commitments related to milestone payments, business combinations | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration recognised as of acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_KymabMember', window );">Kymab</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 973<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement', window );">Commitments related to milestone payments for projects under collaboration agreements | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_KiadisMember', window );">Kiadis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering', window );">Number of shares included in public offer (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationPurchasePricePerShare', window );">Purchase price per share (in euro/usd per share) | &#8364; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering', window );">Proportion of issued and outstanding share capital tendered into the public offer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired', window );">Percentage of share capital owned (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0000<span></span>
</td>
<td class="nump">1.0000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_TidalTherapeuticsMember', window );">Tidal Therapeutics</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 136<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement', window );">Commitments related to milestone payments for projects under collaboration agreements | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember', window );">Translate Bio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationPurchasePricePerShare', window );">Purchase price per share (in euro/usd per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage', window );">Investments, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_KadmonMember', window );">Kadmon</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationPurchasePricePerShare', window );">Purchase price per share (in euro/usd per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis', window );">Estimated purchase price on a fully-diluted basis | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_OrigimmBiotechnologyGmbHMember', window );">Origimm Biotechnology GmbH</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Net cash flow on acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement', window );">Commitments related to milestone payments for projects under collaboration agreements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="27"></td></tr>
<tr><td colspan="27"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2023, it includes the net cash outflow on the acquisitions of Provention Bio and QRIB (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note&#160;D.2.1.). For 2021, it includes the net cash outflows on the acquisitions of Kymab, Kiadis, Tidal, Translate Bio, Kadmon and Origimm (see Note&#160;D.2.2.).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">This amount includes the valuation of the shares distributed as a dividend in kind, at a price of &#8364;14.58 per share, as of May&#160;10, 2022 (see note&#160;D.2.1.).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">For 2022, this line item includes the net cash inflows (before taxes) of &#8364;101&#160;million on the divestment of EUROAPI (see Note&#160;D.2.1.).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets and goodwill resulting from the loss of control of a subsidiary. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisitions, Percentage Of Voting Interests Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Estimated Purchase Price On A Fully-Diluted Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Number Of Shares Included In Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Proportion Of Issued And Outstanding Share Capital Tendered Into The Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CollaborationAgreementAnnualNetSalesTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Annual Net Sales Target</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CollaborationAgreementAnnualNetSalesTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CollaborationAgreementCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Commitment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CollaborationAgreementCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CollaborationAgreementPeriodAfterLossOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Period After Loss Of Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CollaborationAgreementPeriodAfterLossOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Related To Milestone Payments, Business Combinations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Related To Milestone Payments For Projects Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ConsiderationTransferredMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration Transferred, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ConsiderationTransferredMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ConsiderationTransferredValuationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration Transferred, Valuation Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ConsiderationTransferredValuationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease Through Loss Of Control Of Subsidiary, Net Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExceptionalSupplementaryDividendPercentageOfShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exceptional Supplementary Dividend, Percentage Of Share Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExceptionalSupplementaryDividendPercentageOfShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exceptional Supplementary Dividend Proposed, Percentage Of Share Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership Interest In Subsidiary, Minimum Holding Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfVotingEquityInterestsDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Voting Equity Interests Divested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfVotingEquityInterestsDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SpecialDistributionNumberOfSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Distribution, Number Of Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SpecialDistributionNumberOfSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SpecialDistributionPercentageOfShareCapitalDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Distribution, Percentage Of Share Capital Distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SpecialDistributionPercentageOfShareCapitalDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SpecialDistributionSharesReceivedPerConversionOfParentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Distribution, Shares Received Per Conversion Of Parent Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SpecialDistributionSharesReceivedPerConversionOfParentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_RegulatoryComplianceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_RegulatoryComplianceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_ManufactureAndSupplyCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_ManufactureAndSupplyCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_EPICBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_EPICBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_EquityAttributableToOwnersOfParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_AmunixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_AmunixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_KymabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_KymabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_KiadisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_KiadisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_TidalTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_TidalTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_KadmonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_KadmonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_OrigimmBiotechnologyGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_OrigimmBiotechnologyGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516448368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Principal changes in the scope of consolidation in 2022 and 2021 - Summary of Purchase Price Allocation (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Feb. 08, 2022</div></th>
<th class="th"><div>Sep. 14, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_AmunixPharmaceuticalsIncMember', window );">Amunix Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate', window );">Other current and non-current assets and liabilities</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred taxes, net</a></td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net assets</a></td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="nump">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Purchase price</a></td>
<td class="nump">&#8364; 1,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember', window );">Translate Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate', window );">Other current and non-current assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets and liabilities as of acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_AmunixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_AmunixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517445968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">&#8364; 9,869<span></span>
</td>
<td class="nump">&#8364; 10,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions and other increases</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
<td class="nump">&#8364; 1,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">10,160<span></span>
</td>
<td class="nump">9,869<span></span>
</td>
<td class="nump">10,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">23,924<span></span>
</td>
<td class="nump">24,810<span></span>
</td>
<td class="nump">23,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(2,104)<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions and other increases</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
<td class="nump">1,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="num">(502)<span></span>
</td>
<td class="num">(559)<span></span>
</td>
<td class="num">(314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="num">(245)<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">24,770<span></span>
</td>
<td class="nump">23,924<span></span>
</td>
<td class="nump">24,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation &amp; impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(14,055)<span></span>
</td>
<td class="num">(14,782)<span></span>
</td>
<td class="num">(13,804)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="num">(1,080)<span></span>
</td>
<td class="num">(1,142)<span></span>
</td>
<td class="num">(1,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment', window );">Impairment losses, net of reversals</a></td>
<td class="num">(130)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="nump">112<span></span>
</td>
<td class="num">(138)<span></span>
</td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">(14,610)<span></span>
</td>
<td class="num">(14,055)<span></span>
</td>
<td class="num">(14,782)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions and other increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land | Accumulated depreciation &amp; impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment', window );">Impairment losses, net of reversals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">3,103<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">3,181<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">7,328<span></span>
</td>
<td class="nump">7,170<span></span>
</td>
<td class="nump">6,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions and other increases</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="num">(94)<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">7,681<span></span>
</td>
<td class="nump">7,328<span></span>
</td>
<td class="nump">7,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Accumulated depreciation &amp; impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(4,225)<span></span>
</td>
<td class="num">(4,190)<span></span>
</td>
<td class="num">(3,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="num">(321)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment', window );">Impairment losses, net of reversals</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">(4,500)<span></span>
</td>
<td class="num">(4,225)<span></span>
</td>
<td class="num">(4,190)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_MachineryAndEquipment1Member', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">3,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">3,039<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">3,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_MachineryAndEquipment1Member', window );">Machinery and equipment | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">10,848<span></span>
</td>
<td class="nump">11,648<span></span>
</td>
<td class="nump">11,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(1,480)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions and other increases</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="num">(340)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="num">(71)<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">10,912<span></span>
</td>
<td class="nump">10,848<span></span>
</td>
<td class="nump">11,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_MachineryAndEquipment1Member', window );">Machinery and equipment | Accumulated depreciation &amp; impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(7,637)<span></span>
</td>
<td class="num">(8,340)<span></span>
</td>
<td class="num">(7,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="num">(620)<span></span>
</td>
<td class="num">(622)<span></span>
</td>
<td class="num">(592)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment', window );">Impairment losses, net of reversals</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="nump">44<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">(7,873)<span></span>
</td>
<td class="num">(7,637)<span></span>
</td>
<td class="num">(8,340)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Fixtures, fittings&#160;and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Fixtures, fittings&#160;and other | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">2,515<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
<td class="nump">2,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions and other increases</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,515<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Fixtures, fittings&#160;and other | Accumulated depreciation &amp; impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(2,015)<span></span>
</td>
<td class="num">(2,115)<span></span>
</td>
<td class="num">(1,981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment', window );">Impairment losses, net of reversals</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="nump">21<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">(2,037)<span></span>
</td>
<td class="num">(2,015)<span></span>
</td>
<td class="num">(2,115)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_PropertyPlantAndEquipmentInProcessMember', window );">Property,&#160;plant and&#160;equipment in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">2,828<span></span>
</td>
<td class="nump">2,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">3,257<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
<td class="nump">2,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_PropertyPlantAndEquipmentInProcessMember', window );">Property,&#160;plant and&#160;equipment in process | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">3,097<span></span>
</td>
<td class="nump">2,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions and other increases</a></td>
<td class="nump">1,583<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(1,626)<span></span>
</td>
<td class="num">(839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">3,449<span></span>
</td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">3,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_PropertyPlantAndEquipmentInProcessMember', window );">Property,&#160;plant and&#160;equipment in process | Accumulated depreciation &amp; impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(168)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment', window );">Impairment losses, net of reversals</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and other decreases</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">&#8364; (192)<span></span>
</td>
<td class="num">&#8364; (168)<span></span>
</td>
<td class="num">&#8364; (128)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals and retirements. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised resulting from the write-down of property, plant and equipment to its recoverable amount or reversals of those write-downs. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Scope Of Consolidation Through Business Combinations, Property, Plant And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_MachineryAndEquipment1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_MachineryAndEquipment1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_PropertyPlantAndEquipmentInProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_PropertyPlantAndEquipmentInProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517739104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems', window );"><strong>Disclosure of acquisitions of property plant and equipment by operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">&#8364; 1,693<span></span>
</td>
<td class="nump">&#8364; 1,748<span></span>
</td>
<td class="nump">&#8364; 1,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestCostsCapitalised', window );">Capitalized interest</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems', window );"><strong>Disclosure of acquisitions of property plant and equipment by operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">1,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Manufacturing &amp; Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems', window );"><strong>Disclosure of acquisitions of property plant and equipment by operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_PharmaceuticalsSegmentMember', window );">Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems', window );"><strong>Disclosure of acquisitions of property plant and equipment by operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_VaccinesSegmentMember', window );">Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems', window );"><strong>Disclosure of acquisitions of property plant and equipment by operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems', window );"><strong>Disclosure of acquisitions of property plant and equipment by operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">&#8364; 73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare | Manufacturing &amp; Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems', window );"><strong>Disclosure of acquisitions of property plant and equipment by operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="nump">&#8364; 90<span></span>
</td>
<td class="nump">&#8364; 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of acquisitions of property plant and equipment by operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_ManufacturingAndSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_ManufacturingAndSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_PharmaceuticalsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_PharmaceuticalsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_VaccinesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_VaccinesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523718256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Summary of Off Balance Sheet Commitments Relating to Property, Plant and Equipment (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FirmOrdersOfPropertyPlantAndEquipment', window );">Firm orders of property, plant and equipment</a></td>
<td class="nump">&#8364; 638<span></span>
</td>
<td class="nump">&#8364; 861<span></span>
</td>
<td class="nump">&#8364; 769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity', window );">Property, plant and equipment pledged as security for liabilities</a></td>
<td class="nump">&#8364; 16<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment pledged as security for liabilities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 74<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_74_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FirmOrdersOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Firm orders of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FirmOrdersOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526604848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Summary of Impairment Losses Recognised in Property, Plant and Equipment (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Net impairment losses on property, plant and equipment</a></td>
<td class="nump">&#8364; 130<span></span>
</td>
<td class="nump">&#8364; 186<span></span>
</td>
<td class="nump">&#8364; 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533811360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Summary of Property, Plant and Equipment Leased (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,815<span></span>
</td>
<td class="nump">&#8364; 1,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">&#8364; 1,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">1,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,030<span></span>
</td>
<td class="nump">2,181<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_CambridgeMassachusettsMember', window );">Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfLeaseAgreementsSigned', window );">Number of lease agreements signed | lease</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InitialLeaseTerm', window );">Initial lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_OfficeSpaceCambridgeMassachusettsMember', window );">Office space, Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_LaboratoryFacilitiesCambridgeMassachusettsMember', window );">Laboratory facilities, Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,872<span></span>
</td>
<td class="nump">2,745<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets', window );">Changes in scope of consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets', window );">Acquisitions and other increases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets', window );">Disposals and other decreases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets', window );">Currency translation differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">2,872<span></span>
</td>
<td class="nump">2,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">2,872<span></span>
</td>
<td class="nump">2,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation &amp; impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,057)<span></span>
</td>
<td class="num">(797)<span></span>
</td>
<td class="num">(513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets', window );">Changes in scope of consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation and impairment charged in the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(341)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets', window );">Disposals and other decreases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets', window );">Currency translation differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,018)<span></span>
</td>
<td class="num">(1,057)<span></span>
</td>
<td class="num">(797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1,018)<span></span>
</td>
<td class="num">&#8364; (1,057)<span></span>
</td>
<td class="num">&#8364; (797)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition Through Business Combinations, Property, Plant and Equipment, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions Other Than Through Business Combinations, Property, Plant and Equipment, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals And Retirements, Property, Plant And Equipment, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Net Exchange Differences, Property, Plant and Equipment, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Transfers, Property, Plant and Equipment, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InitialLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InitialLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfLeaseAgreementsSigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Lease Agreements Signed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfLeaseAgreementsSigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_OfficeSpaceCambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_OfficeSpaceCambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_LaboratoryFacilitiesCambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_LaboratoryFacilitiesCambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348527154224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to short-term leases and low value assets</a></td>
<td class="nump">&#8364; 19<span></span>
</td>
<td class="nump">&#8364; 26<span></span>
</td>
<td class="nump">&#8364; 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash outflow for leases, excluding short-term leases</a></td>
<td class="nump">&#8364; 315<span></span>
</td>
<td class="nump">&#8364; 389<span></span>
</td>
<td class="nump">&#8364; 302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember', window );">Office and industrial premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LeasedAssetsPercentage', window );">Leased assets, percentage</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicle fleet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LeasedAssetsPercentage', window );">Leased assets, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense Relating To Short-term Leases And Low Value Assets For Which Recognition Exemption Has Been Used</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LeasedAssetsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leased Assets, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LeasedAssetsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348525936416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Schedule of Movements in Goodwill (Details) - Goodwill - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="nump">&#8364; 49,892<span></span>
</td>
<td class="nump">&#8364; 48,056<span></span>
</td>
<td class="nump">&#8364; 44,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Acquisitions during the period</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill', window );">Other movements during the period</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(258)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation differences</a></td>
<td class="num">(873)<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="nump">&#8364; 49,404<span></span>
</td>
<td class="nump">&#8364; 49,892<span></span>
</td>
<td class="nump">&#8364; 48,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518837776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Schedule of Allocation of Goodwill (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#8364; 49,404<span></span>
</td>
<td class="nump">&#8364; 49,892<span></span>
</td>
<td class="nump">&#8364; 48,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">42,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#8364; 7,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519761632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 29, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 08, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 14, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments1', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#8364; 49,404<span></span>
</td>
<td class="nump">&#8364; 49,892<span></span>
</td>
<td class="nump">&#8364; 48,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">24,319<span></span>
</td>
<td class="nump">21,640<span></span>
</td>
<td class="nump">21,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">3,112<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember', window );">Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">&#8364; 16,600<span></span>
</td>
<td class="nump">12,700<span></span>
</td>
<td class="nump">11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember', window );">Technological platforms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">&#8364; 1,200<span></span>
</td>
<td class="nump">&#8364; 2,200<span></span>
</td>
<td class="nump">&#8364; 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ALTUVIIIOMember', window );">ALTUVIIIO | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">&#8364; 1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_QRIBIntermediateHoldingsLLCMember', window );">QRIB Intermediate Holding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_AmunixMember', window );">Amunix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember', window );">Translate Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_TechnologicalPlatformsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ALTUVIIIOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ALTUVIIIOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_QRIBIntermediateHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_QRIBIntermediateHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_AmunixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_AmunixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518377472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="nump">&#8364; 21,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="num">(2,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,053)<span></span>
</td>
<td class="num">&#8364; (1,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="nump">24,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,640<span></span>
</td>
<td class="nump">21,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="nump">81,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,865<span></span>
</td>
<td class="nump">72,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Changes in scope of consolidation</a></td>
<td class="nump">3,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">3,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">3,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="num">(683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(543)<span></span>
</td>
<td class="num">(502)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="num">(1,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">2,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="num">(396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="nump">85,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,716<span></span>
</td>
<td class="nump">78,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="num">(60,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,458)<span></span>
</td>
<td class="num">(53,966)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Changes in scope of consolidation</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="num">(2,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,196)<span></span>
</td>
<td class="num">(1,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="num">(932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,591)<span></span>
</td>
<td class="num">(2,022)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="num">(60,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,076)<span></span>
</td>
<td class="num">(57,458)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredRDMember', window );">Acquired R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="nump">6,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="nump">6,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,226<span></span>
</td>
<td class="nump">7,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredRDMember', window );">Acquired R&amp;D | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="nump">10,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,207<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Changes in scope of consolidation</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">1,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="num">(262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="num">(242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="num">(1,253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,576)<span></span>
</td>
<td class="num">(784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="nump">9,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,354<span></span>
</td>
<td class="nump">11,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredRDMember', window );">Acquired R&amp;D | Accumulated amortization&#160;&amp; impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="num">(4,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,477)<span></span>
</td>
<td class="num">(3,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,107)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="num">(3,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
<td class="num">(3,477)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="nump">14,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="nump">17,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,927<span></span>
</td>
<td class="nump">13,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="nump">69,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,906<span></span>
</td>
<td class="nump">61,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Changes in scope of consolidation</a></td>
<td class="nump">3,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="nump">1,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">1,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="num">(380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="num">(1,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
<td class="nump">2,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="nump">73,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,579<span></span>
</td>
<td class="nump">65,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights | Gross value | Antibodies Collaboration agreement | Teva Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights | Gross value | Antibodies Collaboration agreement | Janssen Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights | Accumulated amortization&#160;&amp; impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="num">(54,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,744)<span></span>
</td>
<td class="num">(49,345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Changes in scope of consolidation</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="num">(2,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,099)<span></span>
</td>
<td class="num">(1,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="num">(842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,567)<span></span>
</td>
<td class="num">(1,869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="num">(55,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,652)<span></span>
</td>
<td class="num">(52,744)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsTrademarksAndOtherRightsMember', window );">Products, trademarks and other rights | Accumulated amortization&#160;&amp; impairment | IO License and Collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="nump">456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="nump">1,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,752<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Changes in scope of consolidation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions and other increases</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="nump">1,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="nump">1,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Accumulated amortization&#160;&amp; impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, beginning balance</a></td>
<td class="num">(1,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,237)<span></span>
</td>
<td class="num">(1,113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill', window );">Impairment losses, net of reversals</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill', window );">Disposals and other decreases</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation differences</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIntangibleAssets', window );">Other intangible assets, ending balance</a></td>
<td class="num">&#8364; (1,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1,296)<span></span>
</td>
<td class="num">&#8364; (1,237)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals and retirements. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 119<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Scope Of Consolidation Through Business Combination, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredRDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_AcquiredRDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsTrademarksAndOtherRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsTrademarksAndOtherRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_TevaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_TevaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_IOLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_IOLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516125568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 24,319<span></span>
</td>
<td class="nump">&#8364; 21,640<span></span>
</td>
<td class="nump">&#8364; 21,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember', window );">Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ConcentrationRiskThresholdPercentage', window );">Concentration risk percentage</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 16,600<span></span>
</td>
<td class="nump">12,700<span></span>
</td>
<td class="nump">11,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsMember', window );">Total: principal marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 15,927<span></span>
</td>
<td class="nump">11,863<span></span>
</td>
<td class="nump">10,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsGenzymeMember', window );">Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 208<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period of intangible assets material to entity</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember', window );">Boehringer Ingelheim Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 1,806<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
<td class="nump">2,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period of intangible assets material to entity</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAventisMember', window );">Aventis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 43<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period of intangible assets material to entity</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsChattemMember', window );">Chattem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 501<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period of intangible assets material to entity</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsProteinSciencesMember', window );">Protein Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 420<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period of intangible assets material to entity</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAblynxMember', window );">Ablynx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 1,220<span></span>
</td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period of intangible assets material to entity</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 5,152<span></span>
</td>
<td class="nump">4,836<span></span>
</td>
<td class="nump">3,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period of intangible assets material to entity</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsRezurockMember', window );">REZUROCK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 1,580<span></span>
</td>
<td class="nump">1,702<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period of intangible assets material to entity</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsTZIELDMember', window );">TZIELD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 2,405<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period of intangible assets material to entity</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBeyfortusMember', window );">BEYFORTUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 1,870<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period of intangible assets material to entity</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsQunolMember', window );">QUNOL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 722<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period of intangible assets material to entity</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | Total: principal marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 66,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">10,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | Boehringer Ingelheim Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">3,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | Aventis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">33,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | Chattem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">1,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | Protein Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | Ablynx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">1,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">8,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | REZUROCK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">1,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | TZIELD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">2,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | BEYFORTUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">1,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value | QUNOL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | Total: principal marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">(50,953)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">(10,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | Boehringer Ingelheim Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">(1,698)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | Aventis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | Chattem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">(818)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | Protein Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">(411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | Ablynx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">(746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">(3,646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | REZUROCK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">(327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | TZIELD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">(141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | BEYFORTUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated amortization&#160;&amp; impairment | QUNOL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="num">&#8364; (19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life, intangible assets other than goodwill (in years)</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining amortisation period of individual intangible assets that are material to the entity&#8217;s financial statements. [Refer: Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 122<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_122_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ConcentrationRiskThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration risk threshold percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ConcentrationRiskThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsGenzymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsGenzymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAventisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAventisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsChattemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsChattemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsProteinSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsProteinSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAblynxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAblynxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsRezurockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsRezurockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsTZIELDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsTZIELDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBeyfortusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBeyfortusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsQunolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsQunolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518723056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and other intangible assets - Amortization of Softwares Recognized in Income Statement (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">&#8364; 14,236<span></span>
</td>
<td class="nump">&#8364; 13,695<span></span>
</td>
<td class="nump">&#8364; 12,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">6,728<span></span>
</td>
<td class="nump">6,706<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="nump">10,692<span></span>
</td>
<td class="nump">10,492<span></span>
</td>
<td class="nump">9,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="nump">3,516<span></span>
</td>
<td class="nump">2,531<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="nump">2,172<span></span>
</td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseCategoriesAxis=sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember', window );">Amortization of computer software and other rights of an industrial or operational nature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization expense</a></td>
<td class="nump">&#8364; 120<span></span>
</td>
<td class="nump">&#8364; 97<span></span>
</td>
<td class="nump">&#8364; 119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseCategoriesAxis=sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseCategoriesAxis=sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518714640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of intangible assets and property, plant and equipment - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments1', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss', window );">Discount rate</a></td>
<td class="nump">280.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss', window );">Perpetual growth rate</a></td>
<td class="nump">490.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss', window );">Operating margin rate</a></td>
<td class="nump">720.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill', window );">Impairment of goodwill recognized | &#8364;</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AfterTaxDiscountRates', window );">After tax discount rates</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AfterTaxDiscountRates', window );">After tax discount rates</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember', window );">Cash-generating units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UniformImpairmentTestingPercentage', window );">Uniform impairment testing percentage</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UniformPreTaxDiscountRates', window );">Uniform pre-tax discount rates</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare | Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Perpetual growth rates applied to future cash flows</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare | Cash-generating units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentTestingPercentage', window );">Rate used for Impairment of goodwill</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PretaxDiscountRateAppliedForGoodwill', window );">Pre-tax discount rates</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Perpetual growth rates applied to future cash flows</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Cash-generating units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentTestingPercentage', window );">Rate used for Impairment of goodwill</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PretaxDiscountRateAppliedForGoodwill', window );">Pre-tax discount rates</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph d<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_d_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_e_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AfterTaxDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After tax discount rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AfterTaxDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpairmentTestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Testing Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpairmentTestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount rate above rate actually used would not cause impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of operating margin rate below rates actually used would not cause impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of perpetuity growth rate below the rates actually used would not cause impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PretaxDiscountRateAppliedForGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-tax discount rate applied for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PretaxDiscountRateAppliedForGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UniformImpairmentTestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uniform impairment testing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UniformImpairmentTestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UniformPreTaxDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uniform pre-tax discount rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UniformPreTaxDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516050704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment of intangible assets and property, plant and equipment - Summary of Net Impairment Losses of Other Intangible Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">&#8364; 896<span></span>
</td>
<td class="num">&#8364; (454)<span></span>
</td>
<td class="nump">&#8364; 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sny_EloctateMember', window );">ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount', window );">Reversal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_MarketedProductsMember', window );">Marketed products | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount', window );">Reversal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember', window );">Research and development projects and technology platforms | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount', window );">Reversal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill', window );">Impairment of other intangible assets, net of reversals (excluding software)</a></td>
<td class="nump">932<span></span>
</td>
<td class="num">(454)<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | SAR444245</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill', window );">Impairment of other intangible assets, net of reversals (excluding software)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | NK Cell and ProXTen technology platforms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill', window );">Impairment of other intangible assets, net of reversals (excluding software)</a></td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill', window );">Impairment of other intangible assets, net of reversals (excluding software)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,561)<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | Research and development projects and technology platforms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill', window );">Impairment of other intangible assets, net of reversals (excluding software)</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill', window );">Impairment of other intangible assets, net of reversals (excluding software)</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Other intangible assets | Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill', window );">Impairment of other intangible assets, net of reversals (excluding software)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,526)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare | Other intangible assets | Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems', window );"><strong>Disclosure of impairment loss and reversal of impairment loss [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill', window );">Impairment of other intangible assets, net of reversals (excluding software)</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="num">&#8364; (35)<span></span>
</td>
<td class="nump">&#8364; 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment loss on intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Loss Recognised In Profit Or Loss, Intangible Assets Other Than Goodwill, Reversal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sny_EloctateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sny_EloctateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_MarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_MarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sny_SAR444245Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sny_SAR444245Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sny_NKCellAndProXTenTechnologyPlatformsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sny_NKCellAndProXTenTechnologyPlatformsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_OtherProductAndServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_OtherProductAndServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517748464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Investments in subsidiaries, joint ventures and associates</a></td>
<td class="nump">&#8364; 677<span></span>
</td>
<td class="nump">&#8364; 424<span></span>
</td>
<td class="nump">&#8364; 250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockPrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember', window );">Infraserv GmbH&#160;&amp; Co. H&#246;chst KG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVentures', window );">Investments in joint ventures</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">&#8364; 90<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember', window );">MSP Vaccine Company (formerly MCM company)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVentures', window );">Investments in joint ventures</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">&#8364; 96<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember', window );">Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVentures', window );">Investments in joint ventures</a></td>
<td class="nump">&#8364; 84<span></span>
</td>
<td class="nump">&#8364; 76<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate (in percent)</a></td>
<td class="nump">30.10%<span></span>
</td>
<td class="nump">29.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVentures', window );">Investments in joint ventures</a></td>
<td class="nump">&#8364; 392<span></span>
</td>
<td class="nump">&#8364; 162<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss recognised in profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_MCMVaccineBVMember', window );">MCM Vaccine BV | MSP Vaccine Company (formerly MCM company)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture', window );">Proportion of ownership interest in joint venture (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in joint ventures in an entity's separate financial statements. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_StockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_StockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=sny_InfraservGmbhAndCoHochstKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=sny_MSPVaccineCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_MCMVaccineBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_MCMVaccineBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_MSPVaccineCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_MSPVaccineCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533940960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments accounted for using the equity method - Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockPrice', window );">Stock price</a></td>
<td class="nump">&#8364; 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember', window );">Joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">&#8364; 101<span></span>
</td>
<td class="nump">&#8364; 74<span></span>
</td>
<td class="nump">&#8364; 26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax', window );">Share of other comprehensive income from investments accounted for using the equity method</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures', window );">Total</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember', window );">Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="num">(216)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax', window );">Share of other comprehensive income from investments accounted for using the equity method</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures', window );">Total</a></td>
<td class="num">(208)<span></span>
</td>
<td class="num">&#8364; (9)<span></span>
</td>
<td class="nump">&#8364; 13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss recognised in profit or loss</a></td>
<td class="nump">&#8364; 231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the other comprehensive income of associates and joint ventures accounted for using the equity method, before tax. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of joint ventures accounted for using the equity method. [Refer: Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_StockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_StockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348522476400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details) - Associates and joint ventures - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions', window );">Sales</a></td>
<td class="nump">&#8364; 157<span></span>
</td>
<td class="nump">&#8364; 131<span></span>
</td>
<td class="nump">&#8364; 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions', window );">Royalties and other income</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Accounts receivable and other receivables</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions', window );">Purchases and other expenses (including research expenses)</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Accounts payable and other payables</a></td>
<td class="nump">&#8364; 71<span></span>
</td>
<td class="nump">&#8364; 132<span></span>
</td>
<td class="nump">&#8364; 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsReceivableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsReceivableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchasesOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchasesOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods in related party transactions. [Refer: Revenue; Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties and other income, related party transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526688288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments accounted for using the equity method - Additional Information (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember', window );">Associates and joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsMadeToJointVenturesAndAssociates', window );">Funding commitments to associates and joint ventures</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsMadeToJointVenturesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments made to joint ventures and associates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsMadeToJointVenturesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_AssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526651840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other non-current assets - Summary of Other Non-current Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Other financial assets at fair value through profit or loss</a></td>
<td class="nump">&#8364; 808<span></span>
</td>
<td class="nump">&#8364; 823<span></span>
</td>
<td class="nump">&#8364; 902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PreFundedPensionObligations', window );">Pre-funded pension obligations</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LongTermPrepaidExpenses', window );">Long-term prepaid expenses</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLoansAndReceivables', window );">Long-term loans and advances and other non-current receivables</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialAssets', window );">Derivative financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">3,218<span></span>
</td>
<td class="nump">3,095<span></span>
</td>
<td class="nump">3,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinanceLeaseReceivables', window );">Non-current finance lease receivables</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">3,455<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">3,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentFinanceLeaseReceivablesGross', window );">Non-current finance lease receivables, gross</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_BioAtriumMember', window );">BioAtrium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLoansAndReceivables', window );">Long-term loans and advances and other non-current receivables</a></td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember', window );">Trading equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Fair value through other comprehensive income</a></td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="nump">823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Fair value through other comprehensive income</a></td>
<td class="nump">&#8364; 346<span></span>
</td>
<td class="nump">&#8364; 329<span></span>
</td>
<td class="nump">&#8364; 447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial assets. [Refer: Derivative financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinanceLeaseReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current finance lease receivables. [Refer: Finance lease receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinanceLeaseReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets measured at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLoansAndReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current loans and receivables. [Refer: Loans and receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_c&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLoansAndReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherNonCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LongTermPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LongTermPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentFinanceLeaseReceivablesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Current Finance Lease Receivables, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentFinanceLeaseReceivablesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PreFundedPensionObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded pension obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PreFundedPensionObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_BioAtriumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_BioAtriumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516287392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other non-current assets - Additional Information (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Sep. 14, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount', window );">Pre-tax impact on other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=sny_QuotedEuroDenominatedSeniorBondsMember', window );">Quoted euro denominated senior bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Debt instruments at fair value through other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=sny_SeniorBondMember', window );">Senior bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HeldtomaturityInvestments', window );">Financial assets held for investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 329<span></span>
</td>
<td class="nump">&#8364; 447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember', window );">Financial instruments held to fund deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInvestments', window );">Financial investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">512<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember', window );">Trading equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Fair value through other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember', window );">Trading equity securities | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Fair value through other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_UnquotedEquityInvestmentsMember', window );">Unquoted equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Investments in equity instruments designated at fair value through OCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_UnquotedEquityInvestmentsMember', window );">Unquoted equity investments | Quoted euro denominated senior bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts', window );">Exchange for financial assets held to meet obligations to employees under post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember', window );">Commitments related to unquoted debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Investments in equity instruments designated at fair value through OCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss', window );">Financial assets at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_QuotedEquitySecuritiesMember', window );">Quoted equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity', window );">Unrealized after-tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_SPMSDContingentConsiderationAssetMember', window );">SPMSD contingent consideration asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueOfTheContingentConsideration', window );">Fair value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentAssetsMember', window );">Non-current assets | Fair value of SPMSD contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueOfTheContingentConsideration', window );">Fair value of the contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_UnquotedDebtSecuritiesMember', window );">Unquoted debt securities not meeting the definition of equity instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss', window );">Financial assets at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">&#8364; 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember', window );">Increase of ten percent basis point in market interest rate | Debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTax', window );">Other comprehensive income before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember', window );">Increase of ten percent basis point in market interest rate | Quoted debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTax', window );">Other comprehensive income before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=sny_RegeneronMember', window );">Regeneron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod', window );">Proceeds from sales of investments accounted for using equity method | $</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=sny_InnoventBiologicsMember', window );">Innovent Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount', window );">Investments in equity instruments designated at fair value through other comprehensive income, transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=sny_TranslateBioMember', window );">Translate Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems', window );"><strong>Disclosure Of Other Non Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage', window );">Investments, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 11A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_11A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that are measured at fair value and for which gains (losses) are recognised in profit or loss. A financial asset shall be measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income. A gain (loss) on a financial asset measured at fair value shall be recognised in profit or loss unless it is part of a hedging relationship, it is an investment in an equity instrument for which the entity has elected to present gains and losses in other comprehensive income or it is a financial asset measured at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-derivative financial assets with fixed or determinable payments and fixed maturity that an entity has the positive intention and ability to hold to maturity other than: (a) those that the entity upon initial recognition designates as at fair value through profit or loss; (b) those that the entity designates as available for sale; and (c) those that meet the definition of loans and receivables. An entity shall not classify any financial assets as held to maturity if the entity has, during the current financial year or during the two preceding financial years, sold or reclassified more than an insignificant amount of held-to-maturity investments before maturity (more than insignificant in relation to the total amount of held-to-maturity investments) other than sales or reclassifications that: (i) are so close to maturity or the financial asset&#8217;s call date (for example, less than three months before maturity) that changes in the market rate of interest would not have a significant effect on the financial asset&#8217;s fair value; (ii) occur after the entity has collected substantially all of the financial asset&#8217;s original principal through scheduled payments or prepayments; or (iii) are attributable to an isolated event that is beyond the entity&#8217;s control, is non-recurring and could not have been reasonably anticipated by the entity. [Refer: Derivative financial assets; Held-to-maturity investments; Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Financial instruments, class [member]; Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, before tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherNonCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherNonCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Instruments At Fair Value Through Other Comprehensive Income (Loss), 10% Decline In Credit Prices, Pre-tax Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValueOfTheContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValueOfTheContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that are classified as financial assets available-for-sale, held-to-maturity investments or loans and receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Transaction Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity instruments at fair value through other comprehensive income and Debt instruments at fair value through other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=sny_QuotedEuroDenominatedSeniorBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=sny_QuotedEuroDenominatedSeniorBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=sny_SeniorBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=sny_SeniorBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradingEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_UnquotedEquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_UnquotedEquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_QuotedEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_QuotedEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_SPMSDContingentConsiderationAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_SPMSDContingentConsiderationAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis=sny_FairValueOfSPMSDContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis=sny_FairValueOfSPMSDContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_UnquotedDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_UnquotedDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_DebtInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_DebtInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_QuotedDebtInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_QuotedDebtInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=sny_RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=sny_RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=sny_InnoventBiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=sny_InnoventBiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=sny_TranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=sny_TranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533374880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets held for sale or exchange and liabilities related to assets held for sale or exchange - Summary of Assets Held for Sale or Exchange, and Liabilities Related to Assets Held for Sale or Exchange (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale', window );">Assets held for sale or exchange</a></td>
<td class="nump">&#8364; 15<span></span>
</td>
<td class="nump">&#8364; 85<span></span>
</td>
<td class="nump">&#8364; 89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale', window );">Liabilities related to assets held for sale or exchange</a></td>
<td class="nump">&#8364; 13<span></span>
</td>
<td class="nump">&#8364; 10<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph p<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_p&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 38<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_38&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526067008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of Inventories (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInventoriesLineItems', window );"><strong>Disclosure of inventories [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterials', window );">Raw materials</a></td>
<td class="nump">&#8364; 1,550<span></span>
</td>
<td class="nump">&#8364; 1,474<span></span>
</td>
<td class="nump">&#8364; 1,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Work in process</a></td>
<td class="nump">5,316<span></span>
</td>
<td class="nump">4,985<span></span>
</td>
<td class="nump">5,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">2,501<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total</a></td>
<td class="nump">9,666<span></span>
</td>
<td class="nump">8,960<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInventoriesLineItems', window );"><strong>Disclosure of inventories [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterials', window );">Raw materials</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,613<span></span>
</td>
<td class="nump">1,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Work in process</a></td>
<td class="nump">5,869<span></span>
</td>
<td class="nump">5,663<span></span>
</td>
<td class="nump">5,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">3,045<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total</a></td>
<td class="nump">10,590<span></span>
</td>
<td class="nump">10,024<span></span>
</td>
<td class="nump">9,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sny_WriteDownMember', window );">Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInventoriesLineItems', window );"><strong>Disclosure of inventories [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterials', window );">Raw materials</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Work in process</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">678<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total</a></td>
<td class="nump">&#8364; 924<span></span>
</td>
<td class="nump">&#8364; 1,064<span></span>
</td>
<td class="nump">&#8364; 904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WorkInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WorkInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInventoriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInventoriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sny_WriteDownMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=sny_WriteDownMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518635856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoriesPledgedAsSecurityForLiabilities', window );">Inventories pledged as security for liabilities</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 3<span></span>
</td>
<td class="nump">&#8364; 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoriesPledgedAsSecurityForLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventories pledged as security for liabilities. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoriesPledgedAsSecurityForLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516344896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts receivable - Summary of Accounts Receivable (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of accounts receivable [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">&#8364; 8,433<span></span>
</td>
<td class="nump">&#8364; 8,424<span></span>
</td>
<td class="nump">&#8364; 7,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of accounts receivable [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">8,528<span></span>
</td>
<td class="nump">8,537<span></span>
</td>
<td class="nump">7,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember', window );">Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAccountsReceivableLineItems', window );"><strong>Disclosure of accounts receivable [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Accounts receivable</a></td>
<td class="nump">&#8364; 95<span></span>
</td>
<td class="nump">&#8364; 113<span></span>
</td>
<td class="nump">&#8364; 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAccountsReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Accounts Receivable [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAccountsReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AllowanceForCreditLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526622256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables', window );">Impairment loss recognised in profit or loss, trade receivables</a></td>
<td class="nump">&#8364; 8<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Gross value of overdue receivables</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerecognizedReceivables', window );">Derecognized receivables</a></td>
<td class="nump">&#8364; 761<span></span>
</td>
<td class="nump">&#8364; 131<span></span>
</td>
<td class="nump">&#8364; 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for trade receivables. [Refer: Impairment loss recognised in profit or loss; Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerecognizedReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognized receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerecognizedReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OverdueReceivablesGrossValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Overdue receivables gross value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OverdueReceivablesGrossValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526652256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts receivable - Summary of Gross Value of Overdue Receivables (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of financial assets that are either past due or impaired [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">&#8364; 689<span></span>
</td>
<td class="nump">&#8364; 452<span></span>
</td>
<td class="nump">&#8364; 455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Less than 1 month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of financial assets that are either past due or impaired [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">1&#160;to&#160;3&#160;months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of financial assets that are either past due or impaired [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember', window );">3&#160;to&#160;6&#160;months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of financial assets that are either past due or impaired [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember', window );">6&#160;to&#160;12&#160;months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of financial assets that are either past due or impaired [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Later than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems', window );"><strong>Disclosure of financial assets that are either past due or impaired [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OverdueReceivablesGrossValue', window );">Overdue receivables gross value</a></td>
<td class="nump">&#8364; 81<span></span>
</td>
<td class="nump">&#8364; 51<span></span>
</td>
<td class="nump">&#8364; 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OverdueReceivablesGrossValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Overdue receivables gross value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OverdueReceivablesGrossValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516345056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax', window );">Tax receivables, other than corporate income taxes</a></td>
<td class="nump">&#8364; 768<span></span>
</td>
<td class="nump">&#8364; 658<span></span>
</td>
<td class="nump">&#8364; 802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateDerivativesMeasuredAtFairValue', window );">Interest rate derivatives measured at fair value (see Note&#160;D.20.)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyDerivativesMeasuredAtFairValue', window );">Currency derivatives measured at fair value (see Note&#160;D.20.)</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other current financial assets</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Total</a></td>
<td class="nump">&#8364; 3,455<span></span>
</td>
<td class="nump">&#8364; 3,532<span></span>
</td>
<td class="nump">&#8364; 3,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrencyDerivativesMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency derivatives measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrencyDerivativesMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateDerivativesMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate derivatives measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateDerivativesMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517055984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial assets and liabilities measured at fair value - Summary of Assets and Liabilities Measured at Fair Value (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">&#8364; 6,737<span></span>
</td>
<td class="nump">&#8364; 10,765<span></span>
</td>
<td class="nump">&#8364; 6,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Bayer contingent purchase consideration arising from the acquisition of Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | MSD contingent consideration (European vaccines business)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Shire contingent consideration arising from the acquisition of Translate Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Contingent consideration arising from acquisition of Amunix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Other contingent consideration arising from business combinations and acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Non-current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Quoted equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Unquoted equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Quoted debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Unquoted debt securities not meeting the definition of equity instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Contingent consideration relating to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Financial assets held to meet obligations under deferred compensation plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">512<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Non-current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level&#160;1 | Mutual fund investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">5,349<span></span>
</td>
<td class="nump">9,537<span></span>
</td>
<td class="nump">5,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Bayer contingent purchase consideration arising from the acquisition of Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | MSD contingent consideration (European vaccines business)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Shire contingent consideration arising from the acquisition of Translate Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Contingent consideration arising from acquisition of Amunix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Other contingent consideration arising from business combinations and acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Non-current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Quoted equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Unquoted equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Quoted debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Unquoted debt securities not meeting the definition of equity instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Contingent consideration relating to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Financial assets held to meet obligations under deferred compensation plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Non-current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level&#160;2 | Mutual fund investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">964<span></span>
</td>
<td class="nump">967<span></span>
</td>
<td class="nump">883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">779<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Bayer contingent purchase consideration arising from the acquisition of Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | MSD contingent consideration (European vaccines business)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Shire contingent consideration arising from the acquisition of Translate Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">441<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Contingent consideration arising from acquisition of Amunix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Other contingent consideration arising from business combinations and acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Non-current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Quoted equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Unquoted equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Quoted debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Unquoted debt securities not meeting the definition of equity instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Contingent consideration relating to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Financial assets held to meet obligations under deferred compensation plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Non-current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Current derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level&#160;3 | Mutual fund investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationOnIncomeStatementLineItems', window );"><strong>Disclosure of information on income statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets measured at fair value</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInformationOnIncomeStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information on income statement line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInformationOnIncomeStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=sny_ContingentConsiderationTranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=sny_ContingentConsiderationTranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=sny_NonCurrentDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=sny_NonCurrentDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=sny_CurrentDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=sny_CurrentDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_QuotedEquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_QuotedEquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_UnquotedEquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_UnquotedEquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_QuotedDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_QuotedDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_UnquotedDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_UnquotedDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_ContingentConsiderationRelatingToDivestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_ContingentConsiderationRelatingToDivestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_CurrentDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_CurrentDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_MutualFundInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_MutualFundInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348527164000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and cash equivalents (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">&#8364; 1,461,000,000<span></span>
</td>
<td class="nump">&#8364; 1,385,000,000<span></span>
</td>
<td class="nump">&#8364; 1,358,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">7,249,000,000<span></span>
</td>
<td class="nump">11,351,000,000<span></span>
</td>
<td class="nump">8,740,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">8,710,000,000<span></span>
</td>
<td class="nump">12,736,000,000<span></span>
</td>
<td class="nump">10,098,000,000<span></span>
</td>
<td class="nump">&#8364; 13,915,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashEquivalentsMoneyMarketMutualFunds', window );">Cash equivalents, money market mutual funds</a></td>
<td class="nump">5,349,000,000<span></span>
</td>
<td class="nump">9,537,000,000<span></span>
</td>
<td class="nump">5,057,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Cash equivalents, term deposits</a></td>
<td class="nump">1,191,000,000<span></span>
</td>
<td class="nump">1,167,000,000<span></span>
</td>
<td class="nump">2,768,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashEquivalentsCommercialPaper', window );">Cash equivalents, commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">179,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies', window );">Cash equivalents, captive insurance and reinsurance companies</a></td>
<td class="nump">&#8364; 476,000,000<span></span>
</td>
<td class="nump">&#8364; 439,000,000<span></span>
</td>
<td class="nump">&#8364; 427,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents captive insurance and reinsurance companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashEquivalentsCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalent commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashEquivalentsCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashEquivalentsMoneyMarketMutualFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalent money market mutual funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashEquivalentsMoneyMarketMutualFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348507849104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net deferred tax position - Summary of Net Deferred Tax Position (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax asset/(liability)</a></td>
<td class="nump">&#8364; 4,570<span></span>
</td>
<td class="nump">&#8364; 3,540<span></span>
</td>
<td class="nump">&#8364; 2,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="nump">1,841<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture', window );">Reserves likely to be distributed in the foreseeable future</a></td>
<td class="nump">60,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">6,427<span></span>
</td>
<td class="nump">5,381<span></span>
</td>
<td class="nump">4,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember', window );">Consolidation adjustments (intragroup margin in inventory)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax asset/(liability)</a></td>
<td class="nump">1,525<span></span>
</td>
<td class="nump">1,388<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember', window );">Provision for pensions and other employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax asset/(liability)</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember', window );">Remeasurement of other acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax asset/(liability)</a></td>
<td class="num">(2,904)<span></span>
</td>
<td class="num">(3,269)<span></span>
</td>
<td class="num">(3,079)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember', window );">Remeasurement of other acquired intangible assets | Bioverativ(c)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember', window );">Remeasurement of other acquired intangible assets | Principia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember', window );">Remeasurement of other acquired intangible assets | Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember', window );">Remeasurement of other acquired intangible assets | Ablynx NV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember', window );">Remeasurement of other acquired intangible assets | Amunix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember', window );">Recognition of acquired property, plant and equipment at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax asset/(liability)</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember', window );">Equity interests in subsidiaries and investments in other entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax asset/(liability)</a></td>
<td class="num">(1,023)<span></span>
</td>
<td class="num">(617)<span></span>
</td>
<td class="num">(590)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Tax losses available for carry-forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax asset/(liability)</a></td>
<td class="nump">1,526<span></span>
</td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_StockOptionsAndShareBasedPaymentsMember', window );">Stock options and other share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax asset/(liability)</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember', window );">Accrued expenses and provisions deductible at time of payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax asset/(liability)</a></td>
<td class="nump">1,994<span></span>
</td>
<td class="nump">1,859<span></span>
</td>
<td class="nump">1,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax asset/(liability)</a></td>
<td class="nump">2,536<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_DeferredTaxRelatingToRestructuringProvisionsMember', window );">Deferred tax relating to restructuring provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">&#8364; 226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember', window );">Deferred tax relating to capitalisation of R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">&#8364; 1,331<span></span>
</td>
<td class="nump">&#8364; 742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ReservesLikelyToBeDistributedInTheForeseeableFuture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserves likely to be distributed in the foreseeable future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ReservesLikelyToBeDistributedInTheForeseeableFuture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_PrincipiaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_PrincipiaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AblynxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AblynxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AmunixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AmunixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_StockOptionsAndShareBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_StockOptionsAndShareBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_DeferredTaxRelatingToRestructuringProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_DeferredTaxRelatingToRestructuringProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533437152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net deferred tax position - Additional information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures', window );">Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised</a></td>
<td class="nump">&#8364; 10,000<span></span>
</td>
<td class="nump">&#8364; 10,600<span></span>
</td>
<td class="nump">&#8364; 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards', window );">Total deferred tax assets for tax loss carryforwards</a></td>
<td class="nump">2,729<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
<td class="nump">2,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses for which no deferred tax asset recognised</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused capital losses for which no deferred tax asset recognised</a></td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable', window );">Deferred tax assets not recognized as future recovery not probable</a></td>
<td class="nump">&#8364; 1,062<span></span>
</td>
<td class="nump">&#8364; 995<span></span>
</td>
<td class="nump">&#8364; 615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Associates [member]; Subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets not recognized as future recovery not probable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TotalDeferredTaxAssetsForTaxLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total deferred tax assets for tax loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TotalDeferredTaxAssetsForTaxLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unused Capital Losses For Which No Deferred Tax Asset Recognised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533810704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net deferred tax position - Summary of Tax Losses Available for Carry-forward (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems', window );"><strong>Disclosure of tax losses available for carryforward [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxLossesCarryforwards', window );">Tax losses available for carry-forward</a></td>
<td class="nump">&#8364; 8,933<span></span>
</td>
<td class="nump">&#8364; 8,503<span></span>
</td>
<td class="nump">&#8364; 7,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxLossCarryforwardsOnAssetDisposals', window );">Tax loss carry-forwards on asset disposals</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">&#8364; 5<span></span>
</td>
<td class="nump">&#8364; 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Year 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems', window );"><strong>Disclosure of tax losses available for carryforward [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxLossesCarryforwards', window );">Tax losses available for carry-forward</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Year 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems', window );"><strong>Disclosure of tax losses available for carryforward [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxLossesCarryforwards', window );">Tax losses available for carry-forward</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Year 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems', window );"><strong>Disclosure of tax losses available for carryforward [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxLossesCarryforwards', window );">Tax losses available for carry-forward</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Year 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems', window );"><strong>Disclosure of tax losses available for carryforward [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxLossesCarryforwards', window );">Tax losses available for carry-forward</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Year 5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems', window );"><strong>Disclosure of tax losses available for carryforward [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxLossesCarryforwards', window );">Tax losses available for carry-forward</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Year 5 and later</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems', window );"><strong>Disclosure of tax losses available for carryforward [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxLossesCarryforwards', window );">Tax losses available for carry-forward</a></td>
<td class="nump">&#8364; 8,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of tax losses available for carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TaxLossCarryforwardsOnAssetDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax loss carryforwards on asset disposals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TaxLossCarryforwardsOnAssetDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TaxLossesCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax losses carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TaxLossesCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526633632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Additional Information (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">&#8364; 2,529,599,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares (in shares)</a></td>
<td class="nump">1,264,799,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in euros per share)</a></td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax', window );">Hedges of net investments in foreign operations</a></td>
<td class="num">&#8364; (574,000,000)<span></span>
</td>
<td class="num">&#8364; (580,000,000)<span></span>
</td>
<td class="num">&#8364; (317,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockOptionsWithNoDilutiveEffect', window );">Number of stock option not taken for computing diluted earning per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AwardsDateAxis=sny_May252023Member', window );">May 25, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PeriodOfShareRepurchaseProgram', window );">Period of share repurchase program</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AwardsDateAxis=sny_May32022Member', window );">May 3, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PeriodOfShareRepurchaseProgram', window );">Period of share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AwardsDateAxis=sny_April302021Member', window );">April 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PeriodOfShareRepurchaseProgram', window );">Period of share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_StockSubscriptionOptionPlanMember', window );">Stock subscription option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions', window );">Increase in shareholders equity due to exercise of stock purchase option</a></td>
<td class="nump">&#8364; 107,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesIssuedByExerciceOfEachOption', window );">Number of shares issued by exercice of each option (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Hedges of net investments in foreign operations after tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesIssuedByExerciceOfEachOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued By Exercice Of Each Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesIssuedByExerciceOfEachOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PeriodOfShareRepurchaseProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of share repurchase program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PeriodOfShareRepurchaseProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholder's equity increase due to the exercise of all stock subscription options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_StockOptionsWithNoDilutiveEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock options with no dilutive effect.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_StockOptionsWithNoDilutiveEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AwardsDateAxis=sny_May252023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AwardsDateAxis=sny_May252023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AwardsDateAxis=sny_May32022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AwardsDateAxis=sny_May32022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AwardsDateAxis=sny_April302021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AwardsDateAxis=sny_April302021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_StockSubscriptionOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_StockSubscriptionOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533406208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Summary of Treasury Shares Held (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesHeld', window );">Number of shares (in shares)</a></td>
<td class="nump">13,450<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
<td class="nump">11,020<span></span>
</td>
<td class="nump">8,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfShareCapitalForThePeriod', window );">%&#160;of&#160;share&#160;capital for the period</a></td>
<td class="nump">1.063%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.872%<span></span>
</td>
<td class="nump">0.658%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfShareCapitalForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of share capital for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfShareCapitalForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519957824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Summary of Movements Share Capital (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2023</div></th>
<th class="th"><div>Dec. 14, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Jul. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,264,799,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,835,732<span></span>
</td>
<td class="nump">1,263,560,695<span></span>
</td>
<td class="nump">1,258,971,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions', window );">Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,956<span></span>
</td>
<td class="nump">490,373<span></span>
</td>
<td class="nump">190,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease', window );">Capital increase by issuance of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,330,558<span></span>
</td>
<td class="nump">1,499,987<span></span>
</td>
<td class="nump">1,836,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees', window );">Capital increase reserved for employees (in shares)</a></td>
<td class="nump">2,128,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,027,057<span></span>
</td>
<td class="nump">2,562,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ReductionOfSharesByCancellationOfTreasuryShares', window );">Reduction in share capital by cancellation of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,742,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,264,799,969<span></span>
</td>
<td class="nump">1,260,835,732<span></span>
</td>
<td class="nump">1,263,560,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted shares issued in regards of capital increase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Issues In Regards To Capital increase Reserved For Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in regards of capital increase by exercise of stock subscription options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ReductionOfSharesByCancellationOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction Of Shares By Cancellation Of Treasury Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ReductionOfSharesByCancellationOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sny_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sny_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348515810320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Principal Characteristics of Restricted Share Plans (Details)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PerformanceSharePlanOneMember', window );">Performance share plan one | With market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,935<span></span>
</td>
<td class="nump">123,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Restricted share plan 2023 | Performance share plan one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfYearsServicePeriod', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,838,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueOfPlanAtDateOfGrant', window );">Fair value of plan at the date of grant | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Restricted share plan 2023 | Performance share plan one | Without market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,425,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 87.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Restricted share plan 2023 | Performance share plan one | With market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 83.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares', window );">Fair value per share awarded for three year service period, additional shares (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer', window );">Fair value per share awarded for three year service period, to chief executive officer (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 82.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Restricted share plan 2023 | Performance share plan two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfYearsServicePeriod', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueOfPlanAtDateOfGrant', window );">Fair value of plan at the date of grant | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Restricted share plan 2023 | Performance share plan two | Without market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 77.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Restricted share plan 2023 | Performance share plan two | With market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 74.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares', window );">Fair value per share awarded for three year service period, additional shares (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer', window );">Fair value per share awarded for three year service period, to chief executive officer (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Restricted share plan 2022 | Performance share plan one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfYearsServicePeriod', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,344,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueOfPlanAtDateOfGrant', window );">Fair value of plan at the date of grant | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Restricted share plan 2022 | Performance share plan one | Without market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 91.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Restricted share plan 2022 | Performance share plan one | With market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,343,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 86.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares', window );">Fair value per share awarded for three year service period, additional shares (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer', window );">Fair value per share awarded for three year service period, to chief executive officer (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 84.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Restricted share plan 2022 | Performance share plan two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfYearsServicePeriod', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueOfPlanAtDateOfGrant', window );">Fair value of plan at the date of grant | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Restricted share plan 2022 | Performance share plan two | Without market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 79.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Restricted share plan 2022 | Performance share plan two | With market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 69.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares', window );">Fair value per share awarded for three year service period, additional shares (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer', window );">Fair value per share awarded for three year service period, to chief executive officer (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member', window );">Restricted share plan 2021 | Performance share plan one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfYearsServicePeriod', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,484,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueOfPlanAtDateOfGrant', window );">Fair value of plan at the date of grant | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member', window );">Restricted share plan 2021 | Performance share plan one | Without market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,209,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 77.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member', window );">Restricted share plan 2021 | Performance share plan one | With market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,274,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 71.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares', window );">Fair value per share awarded for three year service period, additional shares (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer', window );">Fair value per share awarded for three year service period, to chief executive officer (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 71.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member', window );">Restricted share plan 2021 | Performance share plan two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfYearsServicePeriod', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValueOfPlanAtDateOfGrant', window );">Fair value of plan at the date of grant | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member', window );">Restricted share plan 2021 | Performance share plan two | Without market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member', window );">Restricted share plan 2021 | Performance share plan two | With market condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Total number of shares awarded (in shares) | shares</a></td>
<td class="nump">5,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod', window );">Fair value per share awarded (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 68.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares', window );">Fair value per share awarded for three year service period, additional shares (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer', window );">Fair value per share awarded for three year service period, to chief executive officer (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValueOfPlanAtDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of plan at the date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValueOfPlanAtDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValuePerShareAwardedForThreeYearServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value per share awarded to a three year service period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValuePerShareAwardedForThreeYearServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Per Share Awarded For Three Year Service Period, Additional Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Per Share Awarded For Three Year Service Period, To Chief Executive Officer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfYearsServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Years, Service Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfYearsServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_PerformanceSharePlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_PerformanceSharePlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MarketConditionAxis=sny_WithMarketConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MarketConditionAxis=sny_WithMarketConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MarketConditionAxis=sny_WithoutMarketConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MarketConditionAxis=sny_WithoutMarketConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_PerformanceSharePlanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_PerformanceSharePlanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R137.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348508104896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MarketConditionAxis=sny_WithMarketConditionMember', window );">With market condition | Performance share plan one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,935<span></span>
</td>
<td class="nump">123,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember', window );">Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Total expense for restricted share plans | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 231<span></span>
</td>
<td class="nump">&#8364; 206<span></span>
</td>
<td class="nump">&#8364; 193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,773,084<span></span>
</td>
<td class="nump">9,245,513<span></span>
</td>
<td class="nump">9,507,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Restricted share plan 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,780,513<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Restricted share plan 2023 | Performance share plan one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,838,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member', window );">Restricted share plan 2023 | With market condition | Performance share plan one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Restricted share plan 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,099,158<span></span>
</td>
<td class="nump">3,330,801<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Restricted share plan 2022 | Performance share plan one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,344,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member', window );">Restricted share plan 2022 | With market condition | Performance share plan one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,343,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member', window );">Restricted share plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,893,413<span></span>
</td>
<td class="nump">3,097,531<span></span>
</td>
<td class="nump">3,364,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member', window );">Restricted share plan 2021 | Performance share plan one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,484,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member', window );">Restricted share plan 2021 | With market condition | Performance share plan one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="nump">121,097<span></span>
</td>
<td class="nump">114,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,274,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2020Member', window );">Restricted share plan 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,817,181<span></span>
</td>
<td class="nump">3,014,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2019Member', window );">Restricted share plan 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfRestrictedSharesNotYetFullyVested', window );">Number of shares not yet fully vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,128,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfRestrictedSharesNotYetFullyVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted shares not yet fully vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfRestrictedSharesNotYetFullyVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MarketConditionAxis=sny_WithMarketConditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MarketConditionAxis=sny_WithMarketConditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_PerformanceSharePlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_PerformanceSharePlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_RestrictedSharePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R138.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516865328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Summary of Characteristics of Employee Share Ownership Plans Awarded (Details) - &#8364; / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Feb. 03, 2022</div></th>
<th class="th"><div>Feb. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfAverageOfQuotedMarketPricesOfShares', window );">Subscription price (as a percent)</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfTradingDaysPrecedingPlanApproval', window );">Number of trading days preceding plan approval</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeesShareOwnershipPlanMember', window );">Employees share ownership plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_SubscriptionPricePerShare', window );">Subscription price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 79.58<span></span>
</td>
<td class="nump">&#8364; 80.21<span></span>
</td>
<td class="nump">&#8364; 69.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfShareSubscribed', window );">Number of shares subscribed (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,009,306<span></span>
</td>
<td class="nump">1,909,008<span></span>
</td>
<td class="nump">2,438,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IssuanceOfFurtherSharesAsAnEmployersContribution', window );">Number of shares issued immediately as employer's contribution (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,417<span></span>
</td>
<td class="nump">118,049<span></span>
</td>
<td class="nump">124,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IssuanceOfFurtherSharesAsAnEmployersContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Further shares as an employers contribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IssuanceOfFurtherSharesAsAnEmployersContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfShareSubscribed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares subscribed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfShareSubscribed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfTradingDaysPrecedingPlanApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Trading Days Preceding Plan Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfTradingDaysPrecedingPlanApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfAverageOfQuotedMarketPricesOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of average of quoted market prices of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfAverageOfQuotedMarketPricesOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_SubscriptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_SubscriptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeesShareOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeesShareOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R139.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534547232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Summary of Expenses (Details) - Employees share ownership plan - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense recognized</a></td>
<td class="nump">&#8364; 52<span></span>
</td>
<td class="nump">&#8364; 39<span></span>
</td>
<td class="nump">&#8364; 51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution', window );">Expense recognized of which employers' contribution</a></td>
<td class="nump">&#8364; 12<span></span>
</td>
<td class="nump">&#8364; 11<span></span>
</td>
<td class="nump">&#8364; 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense recognized in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeesShareOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_EmployeesShareOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R140.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533956624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Summary of Repurchases Program (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AwardsDateAxis=sny_ShareRepurchase2023ProgramMember', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesRepurchased', window );">Number of shares (in shares)</a></td>
<td class="nump">2,584,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmountOfSharesRepurchased', window );">Value</a></td>
<td class="nump">&#8364; 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AwardsDateAxis=sny_ShareRepurchase2022ProgramMember', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesRepurchased', window );">Number of shares (in shares)</a></td>
<td class="nump">4,000,204<span></span>
</td>
<td class="nump">1,510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmountOfSharesRepurchased', window );">Value</a></td>
<td class="nump">&#8364; 363<span></span>
</td>
<td class="nump">&#8364; 137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AwardsDateAxis=sny_ShareRepurchase2021ProgramMember', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesRepurchased', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,976,992<span></span>
</td>
<td class="nump">2,765,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmountOfSharesRepurchased', window );">Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 360<span></span>
</td>
<td class="nump">&#8364; 242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AwardsDateAxis=sny_ShareRepurchase2020ProgramMember', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSharesRepurchased', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,758,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmountOfSharesRepurchased', window );">Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AmountOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AmountOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AwardsDateAxis=sny_ShareRepurchase2023ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AwardsDateAxis=sny_ShareRepurchase2023ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AwardsDateAxis=sny_ShareRepurchase2022ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AwardsDateAxis=sny_ShareRepurchase2022ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AwardsDateAxis=sny_ShareRepurchase2021ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AwardsDateAxis=sny_ShareRepurchase2021ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AwardsDateAxis=sny_ShareRepurchase2020ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AwardsDateAxis=sny_ShareRepurchase2020ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R141.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519222480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Summary of Currency Translation Differences (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Attributable to equity holders of Sanofi</a></td>
<td class="nump">&#8364; 74,040<span></span>
</td>
<td class="nump">&#8364; 74,784<span></span>
</td>
<td class="nump">&#8364; 68,681<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">74,353<span></span>
</td>
<td class="nump">75,152<span></span>
</td>
<td class="nump">69,031<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">&#8364; 63,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember', window );">Reserve of exchange differences on translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Attributable to equity holders of Sanofi</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="num">(865)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Attributable to non-controlling interests</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="num">&#8364; (68)<span></span>
</td>
<td class="nump">&#8364; 1,462<span></span>
</td>
<td class="num">&#8364; (907)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes the impacts of the IFRIC final agenda decisions of March&#160;2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April&#160;2021 on the attribution of benefits to periods of service, as described in Note&#160;A.2.1. to the consolidated financial statements for the year ended December&#160;31, 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R142.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348508105632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Summary of Movements within Other Comprehensive Income (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="num">&#8364; (77,000,000)<span></span>
</td>
<td class="nump">&#8364; 451,000,000<span></span>
</td>
<td class="nump">&#8364; 797,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="num">(1,526,000,000)<span></span>
</td>
<td class="nump">2,313,000,000<span></span>
</td>
<td class="nump">2,510,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures', window );">Actuarial gains/(losses) excluding investments accounted for using the equity method (see&#160;Note&#160;D.19.1.)</a></td>
<td class="num">(171,000,000)<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
<td class="nump">685,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures', window );">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures', window );">Tax effects</a></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="num">(212,000,000)<span></span>
</td>
<td class="num">(36,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items not subsequently reclassifiable to profit or loss | Equity instruments included in financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="nump">97,000,000<span></span>
</td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="nump">154,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax', window );">Change in fair value (investments accounted for using the equity method, net of taxes)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges', window );">Equity risk hedging instruments designated as fair value hedges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,000,000<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod', window );">Tax effects</a></td>
<td class="num">(21,000,000)<span></span>
</td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="num">(18,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items not subsequently reclassifiable to profit or loss</a></td>
<td class="num">(77,000,000)<span></span>
</td>
<td class="nump">451,000,000<span></span>
</td>
<td class="nump">797,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="num">(6,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures', window );">Change in fair value (investments accounted for using the equity method, net of taxes)</a></td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome', window );">Tax effects</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures', window );">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</a></td>
<td class="num">(1,551,000,000)<span></span>
</td>
<td class="nump">2,643,000,000<span></span>
</td>
<td class="nump">2,719,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures', window );">Currency translation differences (investments accounted for using the equity method)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="num">(11,000,000)<span></span>
</td>
<td class="num">(6,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations', window );">Hedges of net investments in foreign operations</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="num">(354,000,000)<span></span>
</td>
<td class="num">(254,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInCurrencyTranslationOnTaxEffects', window );">Tax effects</a></td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="nump">91,000,000<span></span>
</td>
<td class="nump">71,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="num">(1,526,000,000)<span></span>
</td>
<td class="nump">2,313,000,000<span></span>
</td>
<td class="nump">2,510,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures', window );">Change in fair value (excluding investments accounted for using the equity method)</a></td>
<td class="nump">21,000,000<span></span>
</td>
<td class="num">(77,000,000)<span></span>
</td>
<td class="num">(21,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures', window );">Tax effects</a></td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Cash Flow And Fair Value Hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="num">&#8364; (56,000,000)<span></span>
</td>
<td class="num">(40,000,000)<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income | Items subsequently reclassifiable to profit or loss | EUROAPI | Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems', window );"><strong>Disclosure of analysis of other comprehensive income by item [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items subsequently reclassifiable to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (35,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation before tax excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation on hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInCurrencyTranslationOnTaxEffects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in currency translation on tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInCurrencyTranslationOnTaxEffects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value on cash flow hedges excluding associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value on cash flow hedges net of tax on associates and joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Risk Hedging Instruments Designated At Fair Value Hedges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Associates And Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassifiedItemsAxis=sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassifiedItemsAxis=sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_EquityInstrumentsIncludedInFinancialAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_EquityInstrumentsIncludedInFinancialAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassifiedItemsAxis=sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_DebtInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_DebtInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_CashFlowAndFairValueHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_CashFlowAndFairValueHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=sny_ForeignCurrencyTranslationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R143.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517824432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 02, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 10, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 04, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 24, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 05, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 05, 2013 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanMember', window );">Stock subscription option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems', window );"><strong>Disclosure of stock subscription option plan outstanding and option exercised [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,333,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanFourMember', window );">Stock subscription option plan four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems', window );"><strong>Disclosure of stock subscription option plan outstanding and option exercised [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockBasedCompensationStockOptionsExercisedPricePerShare', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 72.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanFiveMember', window );">Stock subscription option plan five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems', window );"><strong>Disclosure of stock subscription option plan outstanding and option exercised [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockBasedCompensationStockOptionsExercisedPricePerShare', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 73.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanSixMember', window );">Stock subscription option plan six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems', window );"><strong>Disclosure of stock subscription option plan outstanding and option exercised [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockBasedCompensationStockOptionsExercisedPricePerShare', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 89.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanSevenMember', window );">Stock subscription option plan seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems', window );"><strong>Disclosure of stock subscription option plan outstanding and option exercised [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockBasedCompensationStockOptionsExercisedPricePerShare', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanEightMember', window );">Stock subscription option plan eight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems', window );"><strong>Disclosure of stock subscription option plan outstanding and option exercised [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockBasedCompensationStockOptionsExercisedPricePerShare', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 88.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanNineMember', window );">Stock subscription option plan nine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems', window );"><strong>Disclosure of stock subscription option plan outstanding and option exercised [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockBasedCompensationStockOptionsExercisedPricePerShare', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 65.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanTenMember', window );">Stock subscription option plan ten</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems', window );"><strong>Disclosure of stock subscription option plan outstanding and option exercised [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_StockBasedCompensationStockOptionsExercisedPricePerShare', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 76.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments granted in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of stock subscription option plan outstanding and option exercised [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_StockBasedCompensationStockOptionsExercisedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation stock options exercised price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_StockBasedCompensationStockOptionsExercisedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockSubscriptionOptionPlanTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R144.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517470592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Summary of Stock Options Outstanding at Each Balance Sheet Date (Details) - Total stock option plans<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement', window );">Number of options, beginning balance (in shares) | shares</a></td>
<td class="nump">1,837,969<span></span>
</td>
<td class="nump">2,337,968<span></span>
</td>
<td class="nump">2,579,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options, options exercisable (in shares) | shares</a></td>
<td class="nump">1,333,013<span></span>
</td>
<td class="nump">1,624,569<span></span>
</td>
<td class="nump">1,949,184<span></span>
</td>
<td class="nump">1,845,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options, options exercised (in shares) | shares</a></td>
<td class="num">(504,956)<span></span>
</td>
<td class="num">(490,373)<span></span>
</td>
<td class="num">(190,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement', window );">Number of options, options cancelled (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,626)<span></span>
</td>
<td class="num">(51,216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of options, options forfeited (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement', window );">Number of options, ending balance (in shares) | shares</a></td>
<td class="nump">1,333,013<span></span>
</td>
<td class="nump">1,837,969<span></span>
</td>
<td class="nump">2,337,968<span></span>
</td>
<td class="nump">2,579,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Average exercise&#160;price per share, beginning balance (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 78.64<span></span>
</td>
<td class="nump">&#8364; 77.13<span></span>
</td>
<td class="nump">&#8364; 75.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Average exercise&#160;price per share, options exercisable (in euros per share) | &#8364; / shares</a></td>
<td class="nump">80.53<span></span>
</td>
<td class="nump">78.89<span></span>
</td>
<td class="nump">78.15<span></span>
</td>
<td class="nump">&#8364; 74.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Average exercise&#160;price per share, options exercised (in euros per share) | &#8364; / shares</a></td>
<td class="nump">73.65<span></span>
</td>
<td class="nump">71.39<span></span>
</td>
<td class="nump">59.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement', window );">Average exercise&#160;price per share, options cancelled (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.56<span></span>
</td>
<td class="nump">65.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Average exercise&#160;price per share, options forfeited (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Average exercise&#160;price per share, ending balance (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 80.53<span></span>
</td>
<td class="nump">&#8364; 78.64<span></span>
</td>
<td class="nump">&#8364; 77.13<span></span>
</td>
<td class="nump">&#8364; 75.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement', window );">Total, beginning balance | &#8364;</a></td>
<td class="nump">&#8364; 145<span></span>
</td>
<td class="nump">&#8364; 180<span></span>
</td>
<td class="nump">&#8364; 195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement', window );">Total, options exercisable | &#8364;</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">&#8364; 137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement', window );">Total, options exercised | &#8364;</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement', window );">Total, options cancelled | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement', window );">Total, options forfeited | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement', window );">Total, ending balance | &#8364;</a></td>
<td class="nump">&#8364; 107<span></span>
</td>
<td class="nump">&#8364; 145<span></span>
</td>
<td class="nump">&#8364; 180<span></span>
</td>
<td class="nump">&#8364; 195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Cancelled In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfShareOutstandingInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share outstanding in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfShareOutstandingInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value Of Share Options Cancelled In Share Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of share options exercisable in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of share options exercised in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of share options forfeited in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of share options outstanding in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Share Options Cancelled In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_TotalStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=sny_TotalStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R145.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519055056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Summary of Options Outstanding and Exercisable (Details) - Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, Number&#160;of options (in shares) | shares</a></td>
<td class="nump">1,333,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">1,333,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember', window );">Exercise price range two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, Number&#160;of options (in shares) | shares</a></td>
<td class="nump">168,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual&#160;life (years)</a></td>
<td class="text">4 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</a></td>
<td class="nump">&#8364; 65.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">168,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, Options exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 65.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember', window );">Exercise price range three</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, Number&#160;of options (in shares) | shares</a></td>
<td class="nump">569,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual&#160;life (years)</a></td>
<td class="text">3 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</a></td>
<td class="nump">&#8364; 75.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">569,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, Options exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 75.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember', window );">Exercise price range four</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, Number&#160;of options (in shares) | shares</a></td>
<td class="nump">594,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average residual&#160;life (years)</a></td>
<td class="text">2 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)</a></td>
<td class="nump">&#8364; 89.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable, number of options (in shares) | shares</a></td>
<td class="nump">594,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise&#160;price per share, Options exercisable (in euros per share)</a></td>
<td class="nump">&#8364; 89.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | Exercise price range two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">60.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | Exercise price range three</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | Exercise price range four</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">80.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | Exercise price range two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | Exercise price range three</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">80.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | Exercise price range four</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding options (in euros per share)</a></td>
<td class="nump">&#8364; 90.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=sny_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=sny_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=sny_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R146.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534293568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated shareholders&#8217; equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Average number of shares outstanding (in shares)</a></td>
<td class="nump">1,251.7<span></span>
</td>
<td class="nump">1,251.9<span></span>
</td>
<td class="nump">1,252.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Adjustment for stock options with dilutive effect (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares', window );">Adjustment for restricted shares (in shares)</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Average number of shares used to compute diluted earnings per share (in shares)</a></td>
<td class="nump">1,256.4<span></span>
</td>
<td class="nump">1,256.9<span></span>
</td>
<td class="nump">1,257.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dilutive effect of share options on number of restricted shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R147.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519863040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Summary of Changes in Financial Position (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">&#8364; 14,347<span></span>
</td>
<td class="nump">&#8364; 14,857<span></span>
</td>
<td class="nump">&#8364; 17,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">4,174<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">16,531<span></span>
</td>
<td class="nump">19,218<span></span>
</td>
<td class="nump">20,250<span></span>
</td>
<td class="nump">&#8364; 22,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">(12,736)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="num">&#8364; (13,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">7,793<span></span>
</td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">9,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">&#8364; 2,030<span></span>
</td>
<td class="nump">&#8364; 2,181<span></span>
</td>
<td class="nump">&#8364; 2,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R148.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518328288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">&#8364; 14,347<span></span>
</td>
<td class="nump">&#8364; 14,857<span></span>
</td>
<td class="nump">&#8364; 17,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">4,174<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">16,531<span></span>
</td>
<td class="nump">19,218<span></span>
</td>
<td class="nump">20,250<span></span>
</td>
<td class="nump">&#8364; 22,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">(12,736)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="num">&#8364; (13,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">7,793<span></span>
</td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">9,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AmortizedCostMember', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember', window );">Adjustment to debt measured&#160;at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Long-term debt</a></td>
<td class="nump">14,546<span></span>
</td>
<td class="nump">15,143<span></span>
</td>
<td class="nump">17,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">4,178<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">16,573<span></span>
</td>
<td class="nump">19,273<span></span>
</td>
<td class="nump">20,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">(12,736)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">&#8364; 7,835<span></span>
</td>
<td class="nump">&#8364; 6,492<span></span>
</td>
<td class="nump">&#8364; 10,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AmortizedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AmortizedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AdjustmentToDebtMeasuredAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R149.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517393680">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Disclosure of Movement In Total Debt (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 19,218<span></span>
</td>
<td class="nump">&#8364; 20,250<span></span>
</td>
<td class="nump">&#8364; 22,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,684)<span></span>
</td>
<td class="num">(2,718)<span></span>
</td>
<td class="num">(2,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">New borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Other cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">895<span></span>
</td>
<td class="num">(330)<span></span>
</td>
<td class="num">(812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ForeignCurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ReclassificationFromNonCurrentToCurrent', window );">Reclassification from non-current to current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,531<span></span>
</td>
<td class="nump">19,218<span></span>
</td>
<td class="nump">20,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">765<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="num">(414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings', window );">Net change in borrowings through change in scope of consolidation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember', window );">Commercial paper program in USA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments', window );">Net change in short-term debt and other financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LongtermBorrowingsMember', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,857<span></span>
</td>
<td class="nump">17,123<span></span>
</td>
<td class="nump">19,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">New borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Other cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ForeignCurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ReclassificationFromNonCurrentToCurrent', window );">Reclassification from non-current to current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(604)<span></span>
</td>
<td class="num">(3,632)<span></span>
</td>
<td class="num">(2,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">88<span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,347<span></span>
</td>
<td class="nump">14,857<span></span>
</td>
<td class="nump">17,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember', window );">Short-term debt and current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,174<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
<td class="nump">2,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,672)<span></span>
</td>
<td class="num">(2,707)<span></span>
</td>
<td class="num">(2,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">New borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Other cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">903<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="num">(615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ForeignCurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ReclassificationFromNonCurrentToCurrent', window );">Reclassification from non-current to current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">604<span></span>
</td>
<td class="nump">3,632<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">4,174<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtLineItems', window );"><strong>Disclosure of debt [line items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">187<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">New borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Other cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ForeignCurrencyTranslationDifferences', window );">Currency translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ReclassificationFromNonCurrentToCurrent', window );">Reclassification from non-current to current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(69)<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 139<span></span>
</td>
<td class="nump">&#8364; 187<span></span>
</td>
<td class="num">&#8364; (56)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">For 2023, this line item includes &#8364;946&#160;million related to the US commercial paper program. For 2023, 2022 and 2021, it also includes realized foreign exchange differences on (i)&#160;cash and cash equivalents in non-functional currencies (primarily the US dollar) and (ii)&#160;derivative instruments used to manage such cash and cash equivalents.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ForeignCurrencyTranslationDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Translation Differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ForeignCurrencyTranslationDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Change In Scope Of Consolidation, Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ReclassificationFromNonCurrentToCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification from non current to current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ReclassificationFromNonCurrentToCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LongtermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_LongtermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R150.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516994672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Additional Information (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 08, 2023 </div>
<div>EUR (&#8364;) </div>
<div>extension</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>program </div>
<div>credit_facility </div>
<div>bond </div>
<div>currency </div>
<div>performance_indicator </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>bond</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>program </div>
<div>credit_facility </div>
<div>currency </div>
<div>performance_indicator </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2013 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfBondIssuesRedeemed', window );">Number of bond issues redeemed | bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCreditFacilities', window );">Number of credit facilities | credit_facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfSustainableDevelopmentPerformanceIndicators', window );">Number of sustainable development performance indicators | performance_indicator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCommercialPaperPrograms', window );">Number of commercial paper programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCurrenciesDebtIsIssuedIn', window );">Number of currencies debt is issued in | currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | Weighted average interest rate before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashAndCashEquivalentsInvestedRate', window );">Cash and cash equivalents, invested rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | Weighted average interest rate after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CashAndCashEquivalentsInvestedRate', window );">Cash and cash equivalents, invested rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member', window );">&#8364;1,750 million bonds maturing March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Credit facilities, amount drawable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_OneBillionBondsMaturingJune2023Member', window );">$1,000 million bonds maturing June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Credit facilities, amount drawable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_OneBillionBondsMaturingNovember2023Member', window );">&#8364;1,000 million bonds maturing November 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Credit facilities, amount drawable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingMarch2029Member', window );">&#8364;4 billion facility maturing March 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Credit facilities, amount drawable</a></td>
<td class="nump">&#8364; 4,000<span></span>
</td>
<td class="nump">&#8364; 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CreditFacilitiesExtensionOptionNumber', window );">Credit facilities, extension option, number | extension</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CreditFacilitiesExtensionOptionPeriod', window );">Credit facilities, extension option, period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingMarch2029Member', window );">&#8364;4 billion facility maturing March 2029 | Sanofi Euro Medium Term Notes (EMTN) bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Credit facilities, amount drawable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_SyndicatedCreditFacilityCanceledMember', window );">Syndicated credit facility canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Credit facilities, amount drawable</a></td>
<td class="nump">&#8364; 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingDecember2027Member', window );">&#8364;4 billion facility maturing December 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Credit facilities, amount drawable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingDecember2027Member', window );">&#8364;4 billion facility maturing December 2027 | Sanofi Euro Medium Term Notes (EMTN) bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Credit facilities, amount drawable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_ParticipatingSharesMember', window );">1983 to 1987 participating shares issued | Sanofi Euro Medium Term Notes (EMTN) bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ParticipatingSharesNumberOutstanding', window );">Number of participating shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ParticipatingSharesCarryingAmount', window );">Participating shares carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember', window );">Commercial paper program in France | Sanofi Euro Medium Term Notes (EMTN) bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingAverageDrawdown', window );">Borrowing, average drawdown</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingMaximumDrawdown', window );">Borrowing, maximum drawdown</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingDrawdown', window );">Borrowing, drawdown</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember', window );">Commercial paper program in USA | Sanofi Euro Medium Term Notes (EMTN) bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial paper programs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingAverageDrawdown', window );">Borrowing, average drawdown | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingMaximumDrawdown', window );">Borrowing, maximum drawdown | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BorrowingDrawdown', window );">Borrowing, drawdown | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommercialPapersIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of commercial paper issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommercialPapersIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BorrowingAverageDrawdown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Average Drawdown</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BorrowingAverageDrawdown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BorrowingDrawdown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Drawdown</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BorrowingDrawdown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BorrowingMaximumDrawdown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum drawdown.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BorrowingMaximumDrawdown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CashAndCashEquivalentsInvestedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents invested rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CashAndCashEquivalentsInvestedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CreditFacilitiesExtensionOptionNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit Facilities, Extension Option, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CreditFacilitiesExtensionOptionNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CreditFacilitiesExtensionOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit Facilities, Extension Option, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CreditFacilitiesExtensionOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfBondIssuesRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Bond Issues Redeemed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfBondIssuesRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCommercialPaperPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Commercial Paper Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCommercialPaperPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCreditFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Credit Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCreditFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCurrenciesDebtIsIssuedIn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Currencies Debt Is Issued In</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCurrenciesDebtIsIssuedIn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfSustainableDevelopmentPerformanceIndicators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Sustainable Development Performance Indicators</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfSustainableDevelopmentPerformanceIndicators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ParticipatingSharesCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Participating shares carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ParticipatingSharesCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ParticipatingSharesNumberOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Participating shares number outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ParticipatingSharesNumberOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_OneBillionBondsMaturingJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_OneBillionBondsMaturingJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_OneBillionBondsMaturingNovember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_OneBillionBondsMaturingNovember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingMarch2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingMarch2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_SyndicatedCreditFacilityCanceledMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_SyndicatedCreditFacilityCanceledMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingDecember2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_FourBillionFacilityMaturingDecember2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_ParticipatingSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_ParticipatingSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_CommercialPaperProgramInUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R151.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348515509120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Summary of Net Debt by Type Valuation of Redemption (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">&#8364; 139<span></span>
</td>
<td class="nump">&#8364; 187<span></span>
</td>
<td class="num">&#8364; (56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">16,531<span></span>
</td>
<td class="nump">19,218<span></span>
</td>
<td class="nump">20,250<span></span>
</td>
<td class="nump">&#8364; 22,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">(12,736)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="num">&#8364; (13,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">7,793<span></span>
</td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">9,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">15,134<span></span>
</td>
<td class="nump">18,861<span></span>
</td>
<td class="nump">19,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">16,573<span></span>
</td>
<td class="nump">19,273<span></span>
</td>
<td class="nump">20,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">(12,736)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">7,835<span></span>
</td>
<td class="nump">6,492<span></span>
</td>
<td class="nump">10,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">3,817<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">2,027<span></span>
</td>
<td class="nump">4,130<span></span>
</td>
<td class="nump">3,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">(12,736)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(6,711)<span></span>
</td>
<td class="num">(8,651)<span></span>
</td>
<td class="num">(7,129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | 1&#160;to&#160;2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">3,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">2,698<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">2,698<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | 2 to 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">3,011<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">3,011<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | 3 to 4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | 4 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">6,050<span></span>
</td>
<td class="nump">7,684<span></span>
</td>
<td class="nump">6,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">6,079<span></span>
</td>
<td class="nump">7,722<span></span>
</td>
<td class="nump">7,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">6,079<span></span>
</td>
<td class="nump">7,722<span></span>
</td>
<td class="nump">7,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">14,546<span></span>
</td>
<td class="nump">15,143<span></span>
</td>
<td class="nump">17,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">(12,736)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(6,711)<span></span>
</td>
<td class="num">(8,651)<span></span>
</td>
<td class="num">(7,129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">14,416<span></span>
</td>
<td class="nump">15,044<span></span>
</td>
<td class="nump">17,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">14,546<span></span>
</td>
<td class="nump">15,143<span></span>
</td>
<td class="nump">17,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems', window );"><strong>Disclosure of reconciliation of carrying amount to value on redemption [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">3,817<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">&#8364; 2,027<span></span>
</td>
<td class="nump">&#8364; 4,130<span></span>
</td>
<td class="nump">&#8364; 3,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankOverdraftsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of carrying amount to value on redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherBankBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other bank borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherBankBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=sny_NonCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=sny_NonCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=sny_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=sny_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R152.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517704128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Summary of Bond Issues (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | April 2016 EMTN ISIN FR0013143997</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | March 2020 EMTN ISIN FR0013505104</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | April 2022 EMTN ISIN FR0014009KS6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="nump">0.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="nump">&#8364; 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | September 2015 EMTN ISIN FR0012969038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | March 2018 EMTN ISIN FR0013324340</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | September 2014 EMTN ISIN FR0012146801</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | September 2016 EMTN ISIN FR0013201639</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | April 2016 EMTN ISIN FR0013144003</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | March 2019 EMTN ISIN FR0013409844</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | April 2022 EMTN ISIN FR0014009KQ0</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="nump">&#8364; 650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | March 2018 EMTN ISIN FR0013324357</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | March 2020 EMTN ISIN FR0013505112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | March 2019 EMTN ISIN FR0013409851</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | March 2018 EMTN ISIN FR0013324373</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_ShelfRegistrationStatementProgramMember', window );">Shelf registration statement program | June 2018 SNF ISIN US801060AD60</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Annual&#160;interest&#160;rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_April2016EMTNISINFR0013143997Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_April2016EMTNISINFR0013143997Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_March2020EMTNISINFR0013505104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_March2020EMTNISINFR0013505104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_April2022EMTNISINFR0014009KS6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_April2022EMTNISINFR0014009KS6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_September2015EMTNISINFR0012969038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_September2015EMTNISINFR0012969038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_March2018EMTNISINFR0013324340Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_March2018EMTNISINFR0013324340Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_September2014EMTNISINFR0012146801Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_September2014EMTNISINFR0012146801Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_September2016EMTNISINFR0013201639Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_September2016EMTNISINFR0013201639Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_April2016EMTNISINFR0013144003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_April2016EMTNISINFR0013144003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_March2019EMTNISINFR0013409844Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_March2019EMTNISINFR0013409844Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_April2022EMTNISINFR0014009KQ0Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_April2022EMTNISINFR0014009KQ0Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_March2018EMTNISINFR0013324357Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_March2018EMTNISINFR0013324357Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_March2020EMTNISINFR0013505112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_March2020EMTNISINFR0013505112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_March2019EMTNISINFR0013409851Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_March2019EMTNISINFR0013409851Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_March2018EMTNISINFR0013324373Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_March2018EMTNISINFR0013324373Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtInstrument1Axis=sny_ShelfRegistrationStatementProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtInstrument1Axis=sny_ShelfRegistrationStatementProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_June2018SNFISINUS801060AD60Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_June2018SNFISINUS801060AD60Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R153.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348507761232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Maturity at Value on Redemption (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">&#8364; 139<span></span>
</td>
<td class="nump">&#8364; 187<span></span>
</td>
<td class="num">&#8364; (56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">16,531<span></span>
</td>
<td class="nump">19,218<span></span>
</td>
<td class="nump">20,250<span></span>
</td>
<td class="nump">&#8364; 22,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">(12,736)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="num">&#8364; (13,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">7,793<span></span>
</td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">9,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">2,030<span></span>
</td>
<td class="nump">2,181<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember', window );">Sanofi Euro Medium Term Notes (EMTN) bonds | Main undrawn confirmed general purpose credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Credit facilities, amount drawable</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">989<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">15,134<span></span>
</td>
<td class="nump">18,861<span></span>
</td>
<td class="nump">19,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">16,573<span></span>
</td>
<td class="nump">19,273<span></span>
</td>
<td class="nump">20,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">(12,736)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">7,835<span></span>
</td>
<td class="nump">6,492<span></span>
</td>
<td class="nump">10,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">3,817<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">2,027<span></span>
</td>
<td class="nump">4,130<span></span>
</td>
<td class="nump">3,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">(12,736)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(6,711)<span></span>
</td>
<td class="num">(8,651)<span></span>
</td>
<td class="num">(7,129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | 1&#160;to&#160;2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">3,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">2,698<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">2,698<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | 2 to 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">3,011<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">3,011<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | 3 to 4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | 4 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Bond issues</a></td>
<td class="nump">6,050<span></span>
</td>
<td class="nump">7,684<span></span>
</td>
<td class="nump">6,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherBankBorrowings', window );">Other bank borrowings</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank credit balances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt', window );">Interest rate and currency derivatives used to manage debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">6,079<span></span>
</td>
<td class="nump">7,722<span></span>
</td>
<td class="nump">7,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent', window );">Interest rate and currency derivatives used to manage cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">&#8364; 6,079<span></span>
</td>
<td class="nump">&#8364; 7,722<span></span>
</td>
<td class="nump">&#8364; 7,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankOverdraftsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage cash and cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateAndCurrencyDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate and currency derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateAndCurrencyDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherBankBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other bank borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherBankBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtInstrument1Axis=sny_SanofiEuroMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R154.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348505907968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Interest Rate (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">&#8364; (8,710)<span></span>
</td>
<td class="num">&#8364; (12,736)<span></span>
</td>
<td class="num">&#8364; (10,098)<span></span>
</td>
<td class="num">&#8364; (13,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">7,793<span></span>
</td>
<td class="nump">&#8364; 6,437<span></span>
</td>
<td class="nump">&#8364; 9,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember', window );">Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">&#8364; 16,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtPercent', window );">Debt, percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">&#8364; 7,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember', window );">Value on redemption before derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">&#8364; 16,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtPercent', window );">Debt, percent</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember', window );">Value on redemption before derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">&#8364; 511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtPercent', window );">Debt, percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">&#8364; (8,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember', window );">Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">16,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtPercent', window );">Debt, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,738)<span></span>
</td>
<td class="num">&#8364; (12,781)<span></span>
</td>
<td class="num">&#8364; (10,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">7,835<span></span>
</td>
<td class="nump">&#8364; 6,492<span></span>
</td>
<td class="nump">&#8364; 10,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember', window );">Value on redemption after derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">&#8364; 11,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtPercent', window );">Debt, percent</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember', window );">Value on redemption after derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">&#8364; 5,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtPercent', window );">Debt, percent</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Year 1 | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">&#8364; 2,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(6,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Year 1 | Value on redemption before derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Year 1 | Value on redemption before derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Year 1 | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">2,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(6,711)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Year 1 | Value on redemption after derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="num">(3,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Year 1 | Value on redemption after derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">5,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Year 2 | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">2,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">2,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Year 2 | Value on redemption before derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Year 2 | Value on redemption before derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Year 2 | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">2,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">2,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Year 2 | Value on redemption after derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Year 2 | Value on redemption after derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Year 3 | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">3,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">3,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Year 3 | Value on redemption before derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">3,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Year 3 | Value on redemption before derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Year 3 | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">3,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">3,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Year 3 | Value on redemption after derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">3,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Year 3 | Value on redemption after derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Year 4 | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Year 4 | Value on redemption before derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Year 4 | Value on redemption before derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Year 4 | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Year 4 | Value on redemption after derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Year 4 | Value on redemption after derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Year 5 | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Year 5 | Value on redemption before derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Year 5 | Value on redemption before derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Year 5 | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Year 5 | Value on redemption after derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Year 5 | Value on redemption after derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Year 5 and later | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">6,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">6,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Year 5 and later | Value on redemption before derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">6,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Year 5 and later | Value on redemption before derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Year 5 and later | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">6,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">6,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Year 5 and later | Value on redemption after derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">6,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Year 5 and later | Value on redemption after derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">10,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Value on redemption before derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">14,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Value on redemption before derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(4,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">6,852<span></span>
</td>
<td class="nump">&#8364; 10,489<span></span>
</td>
<td class="nump">&#8364; 13,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Value on redemption after derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">11,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Value on redemption after derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(4,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">US dollar | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(2,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">US dollar | Value on redemption before derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">1,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">US dollar | Value on redemption before derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(4,251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">US dollar | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="num">&#8364; (2,404)<span></span>
</td>
<td class="num">&#8364; (669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">US dollar | Value on redemption after derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">US dollar | Value on redemption after derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfBorrowings', window );">Debt</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(2,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_SGD', window );">Singapore dollar | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_SGD', window );">Singapore dollar | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(1,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_SGD', window );">Singapore dollar | Value on redemption after derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">&#8364; (1,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Of Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_SGD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_SGD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R155.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533503888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate of Net Debt at Value on Redemption (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems', window );"><strong>Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">&#8364; 16,531<span></span>
</td>
<td class="nump">&#8364; 19,218<span></span>
</td>
<td class="nump">&#8364; 20,250<span></span>
</td>
<td class="nump">&#8364; 22,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,710)<span></span>
</td>
<td class="num">(12,736)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="num">&#8364; (13,915)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">7,793<span></span>
</td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">9,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember', window );">Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems', window );"><strong>Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,273<span></span>
</td>
<td class="nump">20,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(8,738)<span></span>
</td>
<td class="num">(12,781)<span></span>
</td>
<td class="num">(10,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">&#8364; 7,835<span></span>
</td>
<td class="nump">&#8364; 6,492<span></span>
</td>
<td class="nump">&#8364; 10,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtPercent', window );">Debt, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember', window );">Value on redemption after derivative instruments | Fixed-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems', window );"><strong>Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,386<span></span>
</td>
<td class="nump">&#8364; 17,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtPercent', window );">Debt, percent</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember', window );">Value on redemption after derivative instruments | Floating-rate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems', window );"><strong>Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,886<span></span>
</td>
<td class="nump">&#8364; 2,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtPercent', window );">Debt, percent</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of interest rate of debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R156.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348525936544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents (Details) - Change in Euro and US dollar short-term interest rates<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=sny_PlusHundredBasisPointsMember', window );">+100&#160;bp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems', window );"><strong>Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfChangeInInterestRateOnPreTaxIncome', window );">Impact on pre-tax net income</a></td>
<td class="nump">&#8364; 48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfPreTaxIncomeRecognisedInEquity', window );">Impact on pre-tax income/(expense) recognized directly in equity</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=sny_PlusTwentyFiveBasisPointsMember', window );">+25&#160;bp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems', window );"><strong>Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfChangeInInterestRateOnPreTaxIncome', window );">Impact on pre-tax net income</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfPreTaxIncomeRecognisedInEquity', window );">Impact on pre-tax income/(expense) recognized directly in equity</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=sny_MinusTwentyFiveBasisPointsMember', window );">-25&#160;bp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems', window );"><strong>Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfChangeInInterestRateOnPreTaxIncome', window );">Impact on pre-tax net income</a></td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfPreTaxIncomeRecognisedInEquity', window );">Impact on pre-tax income/(expense) recognized directly in equity</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=sny_MinusHundredBasisPointsMember', window );">-100&#160;bp</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems', window );"><strong>Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfChangeInInterestRateOnPreTaxIncome', window );">Impact on pre-tax net income</a></td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpactOfPreTaxIncomeRecognisedInEquity', window );">Impact on pre-tax income/(expense) recognized directly in equity</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of interest rate of debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpactOfChangeInInterestRateOnPreTaxIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of change in interest rate on pre tax income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpactOfChangeInInterestRateOnPreTaxIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpactOfPreTaxIncomeRecognisedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of pre tax income recognised in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpactOfPreTaxIncomeRecognisedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=sny_PlusHundredBasisPointsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=sny_PlusHundredBasisPointsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=sny_PlusTwentyFiveBasisPointsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=sny_PlusTwentyFiveBasisPointsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=sny_MinusTwentyFiveBasisPointsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=sny_MinusTwentyFiveBasisPointsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=sny_MinusHundredBasisPointsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=sny_MinusHundredBasisPointsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R157.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519053360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Currency (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">&#8364; 7,793<span></span>
</td>
<td class="nump">&#8364; 6,437<span></span>
</td>
<td class="nump">&#8364; 9,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember', window );">Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">7,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember', window );">Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">7,835<span></span>
</td>
<td class="nump">6,492<span></span>
</td>
<td class="nump">10,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">10,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">6,852<span></span>
</td>
<td class="nump">10,489<span></span>
</td>
<td class="nump">13,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">US dollar | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(2,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">US dollar | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="num">(2,404)<span></span>
</td>
<td class="num">(669)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_SGD', window );">Singapore dollar | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_SGD', window );">Singapore dollar | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(1,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">Pound sterling | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">Pound sterling | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CNY', window );">Chinese yuan renminbi | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CNY', window );">Chinese yuan renminbi | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=sny_OtherCurrenciesMember', window );">Other currencies | Value on redemption before derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=sny_OtherCurrenciesMember', window );">Other currencies | Value on redemption after derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDebtByCurrencyLineItems', window );"><strong>Disclosure Of Debt By Currency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DebtNetOfCashAndCashEquivalents', window );">Net debt</a></td>
<td class="nump">&#8364; 259<span></span>
</td>
<td class="num">&#8364; (1,593)<span></span>
</td>
<td class="num">&#8364; (2,413)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDebtByCurrencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Debt By Currency [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDebtByCurrencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionAfterDerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_SGD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_SGD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CNY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CNY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=sny_OtherCurrenciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=sny_OtherCurrenciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R158.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348508073184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Summary of Market Value of Net Debt (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">&#8364; 16,531<span></span>
</td>
<td class="nump">&#8364; 19,218<span></span>
</td>
<td class="nump">&#8364; 20,250<span></span>
</td>
<td class="nump">&#8364; 22,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtMarketValueMember', window );">Market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">7,086<span></span>
</td>
<td class="nump">5,227<span></span>
</td>
<td class="nump">11,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember', window );">Value on redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">16,573<span></span>
</td>
<td class="nump">19,273<span></span>
</td>
<td class="nump">20,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RedemptionOfDebtInstrumentIssued', window );">Total debt at redemption</a></td>
<td class="nump">&#8364; 7,835<span></span>
</td>
<td class="nump">&#8364; 6,492<span></span>
</td>
<td class="nump">&#8364; 10,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RedemptionOfDebtInstrumentIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of debt instrument issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RedemptionOfDebtInstrumentIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtMarketValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtMarketValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOnRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R159.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517404960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Debt</a></td>
<td class="nump">&#8364; 17,710<span></span>
</td>
<td class="nump">&#8364; 20,408<span></span>
</td>
<td class="nump">&#8364; 21,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalUndiscountedCashFlow', window );">Principal</a></td>
<td class="nump">16,468<span></span>
</td>
<td class="nump">18,932<span></span>
</td>
<td class="nump">20,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestUndiscountedCashFlow', window );">Interest</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Net cash flows related to derivative instruments</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalUndiscountedCashFlow', window );">Total</a></td>
<td class="nump">17,853<span></span>
</td>
<td class="nump">20,617<span></span>
</td>
<td class="nump">21,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Year 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Debt</a></td>
<td class="nump">2,153<span></span>
</td>
<td class="nump">4,206<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalUndiscountedCashFlow', window );">Principal</a></td>
<td class="nump">1,917<span></span>
</td>
<td class="nump">3,928<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestUndiscountedCashFlow', window );">Interest</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Net cash flows related to derivative instruments</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalUndiscountedCashFlow', window );">Total</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
<td class="nump">3,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Year 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Debt</a></td>
<td class="nump">2,912<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalUndiscountedCashFlow', window );">Principal</a></td>
<td class="nump">2,703<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">3,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestUndiscountedCashFlow', window );">Interest</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Net cash flows related to derivative instruments</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalUndiscountedCashFlow', window );">Total</a></td>
<td class="nump">2,944<span></span>
</td>
<td class="nump">928<span></span>
</td>
<td class="nump">3,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Year 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Debt</a></td>
<td class="nump">3,187<span></span>
</td>
<td class="nump">2,803<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalUndiscountedCashFlow', window );">Principal</a></td>
<td class="nump">3,011<span></span>
</td>
<td class="nump">2,601<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestUndiscountedCashFlow', window );">Interest</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Net cash flows related to derivative instruments</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalUndiscountedCashFlow', window );">Total</a></td>
<td class="nump">3,210<span></span>
</td>
<td class="nump">2,841<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Year 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Debt</a></td>
<td class="nump">1,285<span></span>
</td>
<td class="nump">3,184<span></span>
</td>
<td class="nump">1,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalUndiscountedCashFlow', window );">Principal</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">3,011<span></span>
</td>
<td class="nump">1,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestUndiscountedCashFlow', window );">Interest</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Net cash flows related to derivative instruments</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalUndiscountedCashFlow', window );">Total</a></td>
<td class="nump">1,309<span></span>
</td>
<td class="nump">3,215<span></span>
</td>
<td class="nump">1,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Year 5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Debt</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">3,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalUndiscountedCashFlow', window );">Principal</a></td>
<td class="nump">1,607<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">3,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestUndiscountedCashFlow', window );">Interest</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Net cash flows related to derivative instruments</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalUndiscountedCashFlow', window );">Total</a></td>
<td class="nump">1,735<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Year 5 and later</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Debt</a></td>
<td class="nump">6,454<span></span>
</td>
<td class="nump">8,064<span></span>
</td>
<td class="nump">8,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalUndiscountedCashFlow', window );">Principal</a></td>
<td class="nump">6,079<span></span>
</td>
<td class="nump">7,580<span></span>
</td>
<td class="nump">8,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestUndiscountedCashFlow', window );">Interest</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Net cash flows related to derivative instruments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalUndiscountedCashFlow', window );">Total</a></td>
<td class="nump">&#8364; 6,455<span></span>
</td>
<td class="nump">&#8364; 8,089<span></span>
</td>
<td class="nump">&#8364; 8,671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestUndiscountedCashFlow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest undiscounted cash flow.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestUndiscountedCashFlow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalUndiscountedCashFlow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal undiscounted cash flow.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalUndiscountedCashFlow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TotalUndiscountedCashFlow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total undiscounted cash flow.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TotalUndiscountedCashFlow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R160.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519322032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt, cash and cash equivalents and lease liabilities - Lease Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems', window );"><strong>Disclosure of maturity analysis of finance lease payments receivable [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,030<span></span>
</td>
<td class="nump">&#8364; 2,181<span></span>
</td>
<td class="nump">&#8364; 2,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LeaseLiabilitiesEffectOfDiscounting', window );">Discounting effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (58)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_CambridgeMassachusettsMember', window );">Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems', window );"><strong>Disclosure of maturity analysis of finance lease payments receivable [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InitialLeaseTerm', window );">Initial lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems', window );"><strong>Disclosure of maturity analysis of finance lease payments receivable [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 291<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">From&#160;1&#160;to 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems', window );"><strong>Disclosure of maturity analysis of finance lease payments receivable [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">From&#160;3&#160;to 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems', window );"><strong>Disclosure of maturity analysis of finance lease payments receivable [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems', window );"><strong>Disclosure of maturity analysis of finance lease payments receivable [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 989<span></span>
</td>
<td class="nump">&#8364; 1,129<span></span>
</td>
<td class="nump">&#8364; 1,184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InitialLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InitialLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LeaseLiabilitiesEffectOfDiscounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liabilities, Effect Of Discounting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LeaseLiabilitiesEffectOfDiscounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=sny_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R161.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519089248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">&#8364; 779<span></span>
</td>
<td class="nump">&#8364; 714<span></span>
</td>
<td class="nump">&#8364; 605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">New transactions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests', window );">Other movements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests', window );">Currency translation differences</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">779<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Non-current liabilities related to business combinations and to non-controlling interests</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests', window );">Current liabilities related to business combinations and to non-controlling interests</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember', window );">Bayer contingent purchase consideration arising from the acquisition of Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">New transactions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests', window );">Other movements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests', window );">Currency translation differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember', window );">MSD contingent consideration (European vaccines business)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">New transactions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests', window );">Other movements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests', window );">Currency translation differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember', window );">Shire contingent consideration arising&#160;from&#160;the acquisition of Translate Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">New transactions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests', window );">Other movements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests', window );">Currency translation differences</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">441<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_AmunixMember', window );">Amunix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">New transactions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="num">(69)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests', window );">Other movements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests', window );">Currency translation differences</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Beginning balance</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">New transactions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination', window );">Payments made</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests', window );">Other movements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests', window );">Currency translation differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Ending balance</a></td>
<td class="nump">&#8364; 4<span></span>
</td>
<td class="nump">&#8364; 4<span></span>
</td>
<td class="nump">&#8364; 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember', window );">Translate Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ContingentConsiderationLiabilities', window );">Contingent consideration liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised for new contingent liabilities recognised in a business combination. [Refer: Contingent liabilities recognised in business combination]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination that were settled. [Refer: Contingent liabilities recognised in business combination]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ContingentConsiderationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ContingentConsiderationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through net exchange differences business combinations and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Other Movements, Business Combinations And Non-Controlling Interests</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_AmunixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_AmunixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilities1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R162.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534714032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liabilities related to business combinations and to non-controlling interests - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="nump">&#8364; 709<span></span>
</td>
<td class="nump">&#8364; 779<span></span>
</td>
<td class="nump">&#8364; 714<span></span>
</td>
<td class="nump">&#8364; 605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations', window );">Commitments relating to contingent consideration&#160;in connection with business combinations</a></td>
<td class="nump">&#8364; 133<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember', window );">MSD contingent consideration (European vaccines business)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageIncreaseInFairValueLiabilities', window );">Increase in fair value of liability</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="nump">&#8364; 127<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember', window );">Shire contingent consideration arising&#160;from&#160;the acquisition of Translate Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="nump">&#8364; 441<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ShireHumanGeneticTherapiesIncMember', window );">Shire contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageIncreaseInFairValueLiabilities', window );">Increase in fair value of liability</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_AmunixMember', window );">Amunix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems', window );"><strong>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageIncreaseInFairValueLiabilities', window );">Increase in fair value of liability</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Fair value of contingent consideration payable</a></td>
<td class="nump">&#8364; 137<span></span>
</td>
<td class="nump">&#8364; 165<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Relating To Contingent Consideration In Connection With Business Combinations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageIncreaseInFairValueLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in fair value liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageIncreaseInFairValueLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ShireHumanGeneticTherapiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ShireHumanGeneticTherapiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_AmunixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_AmunixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R163.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526877344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liabilities related to business combinations and to non-controlling interests - Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems', window );"><strong>Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations', window );">Commitments relating to contingent consideration&#160;in connection with business combinations</a></td>
<td class="nump">&#8364; 133<span></span>
</td>
<td class="nump">&#8364; 604<span></span>
</td>
<td class="nump">&#8364; 689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems', window );"><strong>Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations', window );">Commitments relating to contingent consideration&#160;in connection with business combinations</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">From&#160;1&#160;to 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems', window );"><strong>Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations', window );">Commitments relating to contingent consideration&#160;in connection with business combinations</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">From&#160;3&#160;to 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems', window );"><strong>Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations', window );">Commitments relating to contingent consideration&#160;in connection with business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems', window );"><strong>Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations', window );">Commitments relating to contingent consideration&#160;in connection with business combinations</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Relating To Contingent Consideration In Connection With Business Combinations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R164.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516637072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Summary of Non Current Provisions and Other Non-current Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 09, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions</a></td>
<td class="nump">&#8364; 5,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,822<span></span>
</td>
<td class="nump">&#8364; 6,430<span></span>
</td>
<td class="nump">&#8364; 6,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">2,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Total</a></td>
<td class="nump">7,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,341<span></span>
</td>
<td class="nump">6,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 232<span></span>
</td>
<td class="nump">&#8364; 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">1,960<span></span>
</td>
<td class="nump">&#8364; 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB | Later than one year and not later than five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNonCurrentProvisionsLineItems', window );"><strong>Disclosure Of Non-current Provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">&#8364; 2,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNonCurrentProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Non-current Provisions [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNonCurrentProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R165.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517495584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Summary of Movements in Non-current Provisions (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">&#8364; 5,822<span></span>
</td>
<td class="nump">&#8364; 6,430<span></span>
</td>
<td class="nump">&#8364; 6,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
<td class="nump">731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(408)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Reversals of unutilized provisions</a></td>
<td class="num">(758)<span></span>
</td>
<td class="num">(288)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(572)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
<td class="num">(425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans', window );">Actuarial gains and losses on defined-benefit plans</a></td>
<td class="nump">171<span></span>
</td>
<td class="num">(780)<span></span>
</td>
<td class="num">(448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">5,262<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember', window );">Provisions for pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">2,039<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">3,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(162)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Reversals of unutilized provisions</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans', window );">Actuarial gains and losses on defined-benefit plans</a></td>
<td class="nump">171<span></span>
</td>
<td class="num">(780)<span></span>
</td>
<td class="num">(448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">2,214<span></span>
</td>
<td class="nump">2,039<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember', window );">Provisions for other long-term benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">935<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Reversals of unutilized provisions</a></td>
<td class="num">(190)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans', window );">Actuarial gains and losses on defined-benefit plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">844<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember', window );">Restructuring provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Reversals of unutilized provisions</a></td>
<td class="num">(159)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(361)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans', window );">Actuarial gains and losses on defined-benefit plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember', window );">Other provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract', window );"><strong>Reconciliation of changes in other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Beginning balance</a></td>
<td class="nump">2,178<span></span>
</td>
<td class="nump">2,024<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Increases in provisions</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions', window );">Reversals of unutilized provisions</a></td>
<td class="num">(388)<span></span>
</td>
<td class="num">(191)<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount', window );">Net interest related to employee benefits, and unwinding of discount</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans', window );">Actuarial gains and losses on defined-benefit plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Ending balance</a></td>
<td class="nump">&#8364; 1,776<span></span>
</td>
<td class="nump">&#8364; 2,178<span></span>
</td>
<td class="nump">&#8364; 2,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ActuarialGainsAndLossesOnDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains and losses on defined-benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ActuarialGainsAndLossesOnDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease of unused provision reversed, other provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Changes In Scope Of Consolidation, Other Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net interest related to employees benefits and unwinding of discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForOtherLongTermBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_NonCurrentRestructuringProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_MiscellaneousOtherProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R166.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517047840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Additional Information (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>Country </div>
<div>age </div>
<div>plan</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCountriesIncludedInPensionPlans', window );">Number of major countries included in pension obligations | Country</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PensionObligationPercentageToDefinedBenefitLiability', window );">Pension obligation, percentage to defined benefit liability</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PensionObligationPercentageToPlanAssets', window );">Pension obligations, percentage to plan assets</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">&#8364; 968<span></span>
</td>
<td class="nump">&#8364; 1,039<span></span>
</td>
<td class="nump">&#8364; 943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans', window );">Average residual holding periods</a></td>
<td class="text">2 years 2 months 19 days<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InventoryTotalQuotasHeld', window );">Quotas held in inventory</a></td>
<td class="nump">&#8364; 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent', window );">Non-current income tax liabilities</a></td>
<td class="nump">1,842<span></span>
</td>
<td class="nump">&#8364; 1,979<span></span>
</td>
<td class="nump">&#8364; 2,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">&#8364; 2,340<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LiabilityRecognizedRepresentingEstimatedCost', window );">Liability recognized representing the estimated cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod', window );">Tax charge on deemed repatriation attributable to accumulated earnings payable period</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused capital losses for which no deferred tax asset recognised</a></td>
<td class="nump">&#8364; 473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_USLegalRestructuringMember', window );">US legal restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused capital losses for which no deferred tax asset recognised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CapitalLossesCarryBackPeriod', window );">Capital losses, carry back period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CapitalLossesUsedAgainstCapitalGainsPercentage', window );">Percentage of capital losses used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Later than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">&#8364; 247<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_OtherEnvironmentRelatedProvisionMember', window );">Other environment related provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod', window );">Identified environmental risks provisions estimated obligation period</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths', window );">Other provisions, expected utilized amount in 2022</a></td>
<td class="nump">&#8364; 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive', window );">Other provisions, expected utilized amount in 2023 through 2026</a></td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=sny_UncertaintiesOverIncomeTaxTreatmentsMember', window );">Uncertainties over income tax treatments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent', window );">Non-current income tax liabilities</a></td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
<td class="nump">1,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">&#8364; 611<span></span>
</td>
<td class="nump">804<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfDefinedBenefitPlans', window );">Number of types of defined-benefit plan | plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RetirementAge', window );">Retirement age | age</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NotionalRetirementAge', window );">Notional retirement age | age</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DefinedBenefitPlansVestingRightsPercentage', window );">Vesting right percentage</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DefinedBenefitPlansVestingRightsPercentage', window );">Vesting right percentage</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_LumpSumRetirementBenefitPlansMember', window );">Lump-sum retirement benefit plans | France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PensionObligationPercentageToDefinedBenefitLiability', window );">Pension obligation, percentage to defined benefit liability</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_DefinedBenefitPensionPlansMember', window );">Defined benefit pension plans | France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PensionObligationPercentageToDefinedBenefitLiability', window );">Pension obligation, percentage to defined benefit liability</a></td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_DefinedBenefitPensionPlansMember', window );">Defined benefit pension plans | US | Qualified defined benefit pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PensionObligationPercentageToDefinedBenefitLiability', window );">Pension obligation, percentage to defined benefit liability</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_DefinedBenefitPensionPlansMember', window );">Defined benefit pension plans | US | Non qualified defined benefit pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PensionObligationPercentageToDefinedBenefitLiability', window );">Pension obligation, percentage to defined benefit liability</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_DefinedBenefitPensionPlansMember', window );">Defined benefit pension plans | UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PensionObligationPercentageToDefinedBenefitLiability', window );">Pension obligation, percentage to defined benefit liability</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_TopUpDefinedBenefitPensionPlanMember', window );">Top-up defined-benefit pension plan | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PensionObligationPercentageToDefinedBenefitLiability', window );">Pension obligation, percentage to defined benefit liability</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_SanofiaventisPlusPensionPlanMember', window );">Sanofi-Aventis Plus | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling', window );">Employer's contribution percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_MultiemployerDefinedBenefitPlansMember', window );">Multi-employer plan (Pensionskasses) | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PensionObligationPercentageToDefinedBenefitLiability', window );">Pension obligation, percentage to defined benefit liability</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">&#8364; 744<span></span>
</td>
<td class="nump">&#8364; 652<span></span>
</td>
<td class="nump">&#8364; 877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_HealthcareCoverAndLifeInsuranceMember', window );">Healthcare Cover And Life Insurance | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PensionObligationPercentageToDefinedBenefitLiability', window );">Pension obligation, percentage to defined benefit liability</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">&#8364; 412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_HealthcareCoverAndLifeInsuranceMember', window );">Healthcare Cover And Life Insurance | US | Plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PensionObligationPercentageToPlanAssets', window );">Pension obligations, percentage to plan assets</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net amount shown in the balance sheet at end of period</a></td>
<td class="nump">&#8364; 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average residual holding periods under various early retirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CapitalLossesCarryBackPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Losses, Carry Back Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CapitalLossesCarryBackPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CapitalLossesUsedAgainstCapitalGainsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Losses Used Against Capital Gains, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CapitalLossesUsedAgainstCapitalGainsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DefinedBenefitPlansVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plans vesting rights percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DefinedBenefitPlansVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employer contribute percentage on amounts exceeding the social security ceiling.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identified environmental risks provisions estimated obligation period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identified environmental risks provisions expected utilized amount next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identified environmental risks provisions expected utilized amount year two to five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InventoryTotalQuotasHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Total Quotas Held</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InventoryTotalQuotasHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LiabilityRecognizedRepresentingEstimatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recognized representing estimated cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LiabilityRecognizedRepresentingEstimatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NotionalRetirementAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notional retirement age.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NotionalRetirementAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCountriesIncludedInPensionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of countries included in pension plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCountriesIncludedInPensionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PensionObligationPercentageToDefinedBenefitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pension obligation percentage to defined benefit liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PensionObligationPercentageToDefinedBenefitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PensionObligationPercentageToPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pension obligation percentage to plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PensionObligationPercentageToPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provisions and other current and non-current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RetirementAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retirement age.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RetirementAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax charge on deemed repatriation attributable to accumulated earnings payable period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unused Capital Losses For Which No Deferred Tax Asset Recognised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_USLegalRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=sny_USLegalRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_OtherEnvironmentRelatedProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_OtherEnvironmentRelatedProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=sny_UncertaintiesOverIncomeTaxTreatmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=sny_UncertaintiesOverIncomeTaxTreatmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_LumpSumRetirementBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_LumpSumRetirementBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_DefinedBenefitPensionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_DefinedBenefitPensionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=sny_QualifiedDefinedBenefitPensionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=sny_QualifiedDefinedBenefitPensionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=sny_NonQualifiedDefinedBenefitPensionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=sny_NonQualifiedDefinedBenefitPensionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_TopUpDefinedBenefitPensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_TopUpDefinedBenefitPensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_SanofiaventisPlusPensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_SanofiaventisPlusPensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrs-full_MultiemployerDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrs-full_MultiemployerDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_HealthcareCoverAndLifeInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_HealthcareCoverAndLifeInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>R167.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518285952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Summary of Financial and Demographic Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined benefit obligation</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=sny_MinimumPlan1Member', window );">Minimum Plan 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined benefit obligation</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=sny_MaximumPlan1Member', window );">Maximum Plan 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined benefit obligation</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=sny_MinimumPlan2Member', window );">Minimum plan 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined benefit obligation</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=sny_MaximumPlan2Member', window );">Maximum plan 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined benefit obligation</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation', window );">General inflation rate</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases', window );">Pension benefit indexation</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined benefit obligation</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases', window );">Pension benefit indexation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019', window );">Retirement age</a></td>
<td class="text">62 years<span></span>
</td>
<td class="text">62 years<span></span>
</td>
<td class="text">62 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019', window );">Retirement age</a></td>
<td class="text">67 years<span></span>
</td>
<td class="text">67 years<span></span>
</td>
<td class="text">67 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation', window );">General inflation rate</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases', window );">Pension benefit indexation</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019', window );">Retirement age</a></td>
<td class="text">63 years<span></span>
</td>
<td class="text">63 years<span></span>
</td>
<td class="text">62 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined benefit obligation</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined benefit obligation</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates', window );">Healthcare cost inflation rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.29%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019', window );">Retirement age</a></td>
<td class="text">55 years<span></span>
</td>
<td class="text">55 years<span></span>
</td>
<td class="text">55 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates', window );">Healthcare cost inflation rate</a></td>
<td class="nump">9.75%<span></span>
</td>
<td class="nump">6.56%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019', window );">Retirement age</a></td>
<td class="text">70 years<span></span>
</td>
<td class="text">70 years<span></span>
</td>
<td class="text">70 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation', window );">General inflation rate</a></td>
<td class="nump">3.05%<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases', window );">Pension benefit indexation</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration of defined benefit obligation</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019', window );">Retirement age</a></td>
<td class="text">60 years<span></span>
</td>
<td class="text">60 years<span></span>
</td>
<td class="text">60 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019', window );">Retirement age</a></td>
<td class="text">65 years<span></span>
</td>
<td class="text">65 years<span></span>
</td>
<td class="text">65 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of inflation that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of increases in pension that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical cost trend rate used as significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfRetirementAge2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 147<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_147_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=sny_MinimumPlan1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=sny_MinimumPlan1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=sny_MaximumPlan1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=sny_MaximumPlan1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=sny_MinimumPlan2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=sny_MinimumPlan2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=sny_MaximumPlan2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=sny_MaximumPlan2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>214
<FILENAME>R168.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533808064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Summary of Weighted Average Duration of Obligation for Pensions and Other Long-term Benefits in Principal Countries (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration in main countries</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration in main countries</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration in main countries</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration in main countries</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Weighted average duration in main countries</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">17 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 147<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_147_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>215
<FILENAME>R169.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516042720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Summary of Sensitivity for Pensions and Other Post-Employment Benefits to Changes in Key Actuarial Assumptions (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption', window );">Possible decrease in actuarial assumption</a></td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember', window );">General inflation rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Possible increase in actuarial assumption</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember', window );">Pension benefit indexation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Possible increase in actuarial assumption</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember', window );">Healthcare cost inflation rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption', window );">Possible increase in actuarial assumption</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=sny_ActuarialAssumptionOfMortalityTableMember', window );">Mortality table</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PossibleIncreaseInMortalityTableInYears', window );">Possible increase in mortality table (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_FR', window );">France | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">&#8364; 56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_FR', window );">France | General inflation rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_FR', window );">France | Pension benefit indexation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_FR', window );">France | Healthcare cost inflation rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_FR', window );">France | Mortality table</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_DE', window );">Germany | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_DE', window );">Germany | General inflation rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_DE', window );">Germany | Pension benefit indexation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_DE', window );">Germany | Healthcare cost inflation rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_DE', window );">Germany | Mortality table</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_US', window );">US | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_US', window );">US | General inflation rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_US', window );">US | Pension benefit indexation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_US', window );">US | Healthcare cost inflation rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_US', window );">US | Mortality table</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_GB', window );">UK | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_GB', window );">UK | General inflation rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_GB', window );">UK | Pension benefit indexation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_GB', window );">UK | Healthcare cost inflation rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=country_GB', window );">UK | Mortality table</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Measurement of defined-benefit obligation</a></td>
<td class="nump">&#8364; 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PossibleIncreaseInMortalityTableInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Possible increase in mortality table in years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PossibleIncreaseInMortalityTableInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=sny_ActuarialAssumptionOfMortalityTableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=sny_ActuarialAssumptionOfMortalityTableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>216
<FILENAME>R170.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348515253312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Reconciliation of Net Amount Recognized in Respect of Pension and Other Post-employment Benefit Plans (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Actuarial losses/(gains) due to changes in financial assumptions</a></td>
<td class="num">&#8364; (171)<span></span>
</td>
<td class="nump">&#8364; 654<span></span>
</td>
<td class="nump">&#8364; 686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PreFundedPensionObligations', window );">Pre-funded pension obligations</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Obligations provided for</a></td>
<td class="nump">5,262<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
<td class="nump">&#8364; 6,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Actuarial losses/(gains) due to changes in demographic assumptions</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Actuarial losses/(gains) due to changes in financial assumptions</a></td>
<td class="nump">43<span></span>
</td>
<td class="num">(1,143)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Beginning of period</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">2,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest (income)/cost</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan', window );">Plan amendments, curtailments or settlements not specified in the terms of the plan</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod', window );">Administration costs and taxes paid during the period</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions from plan members</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan', window );">Net obligation</a></td>
<td class="nump">1,937<span></span>
</td>
<td class="nump">1,752<span></span>
</td>
<td class="nump">2,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PreFundedPensionObligations', window );">Pre-funded pension obligations</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss', window );">Expense recognized directly in profit or loss</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">End of period</a></td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">2,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="nump">171<span></span>
</td>
<td class="num">(650)<span></span>
</td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EmployeeBenefitsExpenseGain', window );">Expense/(gain) for the period</a></td>
<td class="nump">361<span></span>
</td>
<td class="num">(482)<span></span>
</td>
<td class="num">(409)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits | UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Beginning of period</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions from plan members</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PreFundedPensionObligations', window );">Pre-funded pension obligations</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss', window );">Expense recognized directly in profit or loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">End of period</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits | Present value of defined benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Beginning of period</a></td>
<td class="nump">8,651<span></span>
</td>
<td class="nump">12,175<span></span>
</td>
<td class="nump">12,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest (income)/cost</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Actuarial losses/(gains) due to changes in demographic assumptions</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Actuarial losses/(gains) due to changes in financial assumptions</a></td>
<td class="nump">157<span></span>
</td>
<td class="num">(3,006)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Actuarial losses/(gains) due to experience adjustments</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan', window );">Plan amendments, curtailments or settlements not specified in the terms of the plan</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset', window );">Plan settlements specified in the terms of the plan</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BenefitsPaidOrPayable', window );">Benefits paid</a></td>
<td class="num">(483)<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="num">(503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset', window );">Changes in scope of consolidation and transfers</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Currency translation differences</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">End of period</a></td>
<td class="nump">8,930<span></span>
</td>
<td class="nump">8,651<span></span>
</td>
<td class="nump">12,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits | Plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Beginning of period</a></td>
<td class="num">(6,899)<span></span>
</td>
<td class="num">(9,651)<span></span>
</td>
<td class="num">(9,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interest (income)/cost</a></td>
<td class="num">(276)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan', window );">Plan amendments, curtailments or settlements not specified in the terms of the plan</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset', window );">Plan settlements specified in the terms of the plan</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset', window );">Changes in scope of consolidation and transfers</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Currency translation differences</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="num">(344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Difference between actual return and interest income on plan assets</a></td>
<td class="nump">197<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod', window );">Administration costs and taxes paid during the period</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions from plan members</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Employer&#8217;s contributions</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefits paid</a></td>
<td class="num">(446)<span></span>
</td>
<td class="num">(426)<span></span>
</td>
<td class="num">(458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">End of period</a></td>
<td class="num">(6,993)<span></span>
</td>
<td class="num">(6,899)<span></span>
</td>
<td class="num">(9,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits | Effect of asset ceiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Beginning of period</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">End of period</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember', window );">Provisions for pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Obligations provided for</a></td>
<td class="nump">2,214<span></span>
</td>
<td class="nump">2,039<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">&#8364; 3,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember', window );">Provisions for pensions and other post-employment benefits | Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Obligations provided for</a></td>
<td class="nump">&#8364; 2,214<span></span>
</td>
<td class="nump">&#8364; 2,039<span></span>
</td>
<td class="nump">&#8364; 2,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BenefitsPaidOrPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of benefits paid or payable for retirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BenefitsPaidOrPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from business combinations and disposals. [Refer: Business combinations [member]; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from changes in foreign exchange rates. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit in a defined benefit plan. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Administration Costs And Taxes Paid During The Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Payments In Respect Of Settlements Specified In The Terms Of The Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Plan Amendments, Curtailments Or Settlements Not Specified In The Terms Of The Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EmployeeBenefitsExpenseGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Benefits Expense / (Gain)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EmployeeBenefitsExpenseGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PreFundedPensionObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded pension obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PreFundedPensionObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total expense for pensions and other post-employment benefits recognized directly in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PlanAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_EffectOfAssetCeilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_EffectOfAssetCeilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>217
<FILENAME>R171.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348515824160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Net Liability in Respect of Pension Plans and Other Post-employment Benefits by Geographical Region (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Measurement of obligation</a></td>
<td class="nump">&#8364; 968<span></span>
</td>
<td class="nump">&#8364; 1,039<span></span>
</td>
<td class="nump">&#8364; 943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Measurement of obligation</a></td>
<td class="nump">8,930<span></span>
</td>
<td class="nump">8,651<span></span>
</td>
<td class="nump">12,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets</a></td>
<td class="nump">6,993<span></span>
</td>
<td class="nump">6,899<span></span>
</td>
<td class="nump">9,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanAssetsEffectOfAssetCeiling', window );">Effect of asset ceiling</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net amount shown in the balance sheet at end of period</a></td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">2,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Measurement of obligation</a></td>
<td class="nump">611<span></span>
</td>
<td class="nump">804<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Measurement of obligation</a></td>
<td class="nump">1,322<span></span>
</td>
<td class="nump">1,324<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">697<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanAssetsEffectOfAssetCeiling', window );">Effect of asset ceiling</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net amount shown in the balance sheet at end of period</a></td>
<td class="nump">647<span></span>
</td>
<td class="nump">627<span></span>
</td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Measurement of obligation</a></td>
<td class="nump">2,911<span></span>
</td>
<td class="nump">2,730<span></span>
</td>
<td class="nump">3,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets</a></td>
<td class="nump">2,401<span></span>
</td>
<td class="nump">2,317<span></span>
</td>
<td class="nump">2,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanAssetsEffectOfAssetCeiling', window );">Effect of asset ceiling</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net amount shown in the balance sheet at end of period</a></td>
<td class="nump">510<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Measurement of obligation</a></td>
<td class="nump">1,528<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanAssetsEffectOfAssetCeiling', window );">Effect of asset ceiling</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net amount shown in the balance sheet at end of period</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="nump">972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK | Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Measurement of obligation</a></td>
<td class="nump">2,174<span></span>
</td>
<td class="nump">2,080<span></span>
</td>
<td class="nump">3,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets</a></td>
<td class="nump">2,235<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
<td class="nump">3,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanAssetsEffectOfAssetCeiling', window );">Effect of asset ceiling</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net amount shown in the balance sheet at end of period</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Measurement of obligation</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other | Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Measurement of obligation</a></td>
<td class="nump">995<span></span>
</td>
<td class="nump">971<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PlanAssetsEffectOfAssetCeiling', window );">Effect of asset ceiling</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net amount shown in the balance sheet at end of period</a></td>
<td class="nump">&#8364; 144<span></span>
</td>
<td class="nump">&#8364; 139<span></span>
</td>
<td class="nump">&#8364; 195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PlanAssetsEffectOfAssetCeiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Plan Assets, Effect Of Asset Ceiling</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PlanAssetsEffectOfAssetCeiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>218
<FILENAME>R172.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519769280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Fair Value of Plans Assets relating to Pension Plans and Other Post-employment Plans (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket', window );">Securities quoted in an active market</a></td>
<td class="nump">84.90%<span></span>
</td>
<td class="nump">84.40%<span></span>
</td>
<td class="nump">86.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities', window );">Other securities</a></td>
<td class="nump">15.10%<span></span>
</td>
<td class="nump">15.60%<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssets', window );">Total</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_CashAndCashEquivalents1Member', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket', window );">Securities quoted in an active market</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_EquityInstrumentsMember', window );">Equity instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket', window );">Securities quoted in an active market</a></td>
<td class="nump">22.30%<span></span>
</td>
<td class="nump">21.70%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_BondsAndSimilarInstrumentsMember', window );">Bonds and similar instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket', window );">Securities quoted in an active market</a></td>
<td class="nump">54.30%<span></span>
</td>
<td class="nump">52.40%<span></span>
</td>
<td class="nump">53.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_RealEstate1Member', window );">Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket', window );">Securities quoted in an active market</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DerivativesMember', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket', window );">Securities quoted in an active market</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_CommoditiesMember', window );">Commodities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket', window );">Securities quoted in an active market</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket', window );">Securities quoted in an active market</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_HedgeFunds1Member', window );">Hedge funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities', window );">Other securities</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=sny_InsurancePoliciesMember', window );">Insurance policies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities', window );">Other securities</a></td>
<td class="nump">15.10%<span></span>
</td>
<td class="nump">15.60%<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageContributedToFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage contributed to fair value of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageContributedToFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Contributed To Fair Value Of Plan Assets, Other Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Contributed To Fair Value Of Plan Assets, Securities Quoted In An Active Market</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_CashAndCashEquivalents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_CashAndCashEquivalents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_EquityInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_EquityInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_BondsAndSimilarInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_BondsAndSimilarInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_RealEstate1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_RealEstate1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_CommoditiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_CommoditiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_HedgeFunds1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_HedgeFunds1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=sny_InsurancePoliciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=sny_InsurancePoliciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>219
<FILENAME>R173.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517617696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Service Cost for Pension and Other post-employment Benefit Plans, by Geographical Region (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="num">&#8364; (3)<span></span>
</td>
<td class="nump">&#8364; 156<span></span>
</td>
<td class="nump">&#8364; 106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="num">(98)<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement', window );">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset', window );">Net interest cost/(income) including administration costs and taxes paid during the period</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions from plan members</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss', window );">Expense/(gain) recognized directly in profit or loss</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="nump">171<span></span>
</td>
<td class="num">(650)<span></span>
</td>
<td class="num">(685)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset', window );">Expense/(gain) for the period</a></td>
<td class="nump">361<span></span>
</td>
<td class="num">(482)<span></span>
</td>
<td class="num">(409)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits | France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement', window );">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset', window );">Net interest cost/(income) including administration costs and taxes paid during the period</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions from plan members</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss', window );">Expense/(gain) recognized directly in profit or loss</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(156)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset', window );">Expense/(gain) for the period</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement', window );">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset', window );">Net interest cost/(income) including administration costs and taxes paid during the period</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions from plan members</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss', window );">Expense/(gain) recognized directly in profit or loss</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="nump">98<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset', window );">Expense/(gain) for the period</a></td>
<td class="nump">143<span></span>
</td>
<td class="num">(151)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement', window );">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset', window );">Net interest cost/(income) including administration costs and taxes paid during the period</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions from plan members</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss', window );">Expense/(gain) recognized directly in profit or loss</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="nump">26<span></span>
</td>
<td class="num">(382)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset', window );">Expense/(gain) for the period</a></td>
<td class="nump">82<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits | UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement', window );">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset', window );">Net interest cost/(income) including administration costs and taxes paid during the period</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions from plan members</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss', window );">Expense/(gain) recognized directly in profit or loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset', window );">Expense/(gain) for the period</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement', window );">(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset', window );">Net interest cost/(income) including administration costs and taxes paid during the period</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions from plan members</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss', window );">Expense/(gain) recognized directly in profit or loss</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset', window );">Expense/(gain) for the period</a></td>
<td class="nump">&#8364; 42<span></span>
</td>
<td class="num">&#8364; (2)<span></span>
</td>
<td class="num">&#8364; (19)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense/(gain) for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>(Gains) Losses Related To Plan Amendments, Curtailments Or Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense (Income) Including Administration Costs And Taxes Paid, Net Defined Benefit Liability (Asset)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total expense for pensions and other post-employment benefits recognized directly in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>220
<FILENAME>R174.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348507878480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Remeasurement of Net Defined-benefit (Asset)/Liability (Actuarial Gains and Losses) (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gains/(losses) on financial assumptions</a></td>
<td class="nump">&#8364; 171<span></span>
</td>
<td class="num">&#8364; (654)<span></span>
</td>
<td class="num">&#8364; (686)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) arising during the period</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments', window );">Gains/(losses) on experience adjustments</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gains/(losses) on demographic assumptions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gains/(losses) on financial assumptions</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) arising during the period</a></td>
<td class="num">(98)<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments', window );">Gains/(losses) on experience adjustments</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(620)<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gains/(losses) on demographic assumptions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gains/(losses) on financial assumptions</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) arising during the period</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments', window );">Gains/(losses) on experience adjustments</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gains/(losses) on demographic assumptions</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gains/(losses) on financial assumptions</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains/(losses) arising during the period</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments', window );">Gains/(losses) on experience adjustments</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(1,328)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gains/(losses) on demographic assumptions</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gains/(losses) on financial assumptions</a></td>
<td class="num">&#8364; (43)<span></span>
</td>
<td class="nump">&#8364; 1,143<span></span>
</td>
<td class="nump">&#8364; 77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actuarial gains/(losses) on experience adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>221
<FILENAME>R175.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523871632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Summary of Net Pre-tax Actuarial Loss (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity', window );">Net pre-tax actuarial loss</a></td>
<td class="num">&#8364; (2,259)<span></span>
</td>
<td class="num">&#8364; (2,090)<span></span>
</td>
<td class="num">&#8364; (2,738)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net pretax actuarial loss excluding associates and joint ventures recognized directly in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>222
<FILENAME>R176.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518279024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Summary of Present Value of Pension and Other Post Employment Benefits (Details) - Pensions and other post-employment benefits - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability (asset)</a></td>
<td class="nump">&#8364; 1,943<span></span>
</td>
<td class="nump">&#8364; 1,770<span></span>
</td>
<td class="nump">&#8364; 2,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember', window );">Present value of defined benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability (asset)</a></td>
<td class="nump">8,930<span></span>
</td>
<td class="nump">8,651<span></span>
</td>
<td class="nump">12,175<span></span>
</td>
<td class="nump">&#8364; 12,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis=ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember', window );">Wholly or partly funded defined benefit plans | Present value of defined benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability (asset)</a></td>
<td class="nump">7,693<span></span>
</td>
<td class="nump">7,463<span></span>
</td>
<td class="nump">10,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis=ifrs-full_WhollyUnfundedDefinedBenefitPlansMember', window );">Wholly unfunded defined benefit plans | Present value of defined benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability (asset)</a></td>
<td class="nump">&#8364; 1,237<span></span>
</td>
<td class="nump">&#8364; 1,188<span></span>
</td>
<td class="nump">&#8364; 1,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrs-full_PresentValueOfDefinedBenefitObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis=ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis=ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis=ifrs-full_WhollyUnfundedDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis=ifrs-full_WhollyUnfundedDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>223
<FILENAME>R177.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518812672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Total Expense for Pensions and Other Post-employment Benefits Allocated between Income Statement (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">&#8364; 14,236<span></span>
</td>
<td class="nump">&#8364; 13,695<span></span>
</td>
<td class="nump">&#8364; 12,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">6,728<span></span>
</td>
<td class="nump">6,706<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="nump">10,692<span></span>
</td>
<td class="nump">10,492<span></span>
</td>
<td class="nump">9,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating (income)/expenses, net</a></td>
<td class="nump">2,979<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember', window );">Pensions and other post-employment benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating (income)/expenses, net</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RestructuringCostsReversedAndSimilarItems', window );">Restructuring costs</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss', window );">Total</a></td>
<td class="nump">&#8364; 190<span></span>
</td>
<td class="nump">&#8364; 168<span></span>
</td>
<td class="nump">&#8364; 276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RestructuringCostsReversedAndSimilarItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Costs (Reversed) And Similar Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RestructuringCostsReversedAndSimilarItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense recognized directly in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=sny_PensionsAndOtherPostEmploymentBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>224
<FILENAME>R178.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517951408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Estimated Amounts of Employer's Contributions to Plan Assets (Details) - Year 1<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Estimate of contributions expected to be paid to plan for next annual reporting period</a></td>
<td class="nump">&#8364; 86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Estimate of contributions expected to be paid to plan for next annual reporting period</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Estimate of contributions expected to be paid to plan for next annual reporting period</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Estimate of contributions expected to be paid to plan for next annual reporting period</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">UK</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Estimate of contributions expected to be paid to plan for next annual reporting period</a></td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems', window );"><strong>Disclosure of fair value of plan assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan', window );">Estimate of contributions expected to be paid to plan for next annual reporting period</a></td>
<td class="nump">&#8364; 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimate of the expected contributions to be made to a defined benefit plan for the next annual reporting period. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 147<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_147_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 148<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_148_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>225
<FILENAME>R179.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348508112320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Expected Timing of Benefit Payments under Pension and Other Post-employment Benefit Plans (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Year 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">&#8364; 579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Year 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Year 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Year 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Year 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember', window );">2029 to 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">3,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | Year 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | Year 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | Year 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | Year 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | Year 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | 2029 to 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | Year 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | Year 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | Year 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | Year 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | Year 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | 2029 to 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Year 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Year 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Year 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Year 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Year 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | 2029 to 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK | Year 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK | Year 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK | Year 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK | Year 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK | Year 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GB', window );">UK | 2029 to 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other | Year 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other | Year 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other | Year 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other | Year 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other | Year 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other | 2029 to 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans', window );">Estimated future benefit payments under pension and other post-employment benefit plans</a></td>
<td class="nump">&#8364; 343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated future benefit payments under pension and other post-employment benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>226
<FILENAME>R180.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348522381536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Timing of Future Payments in Respect of Unfunded Pension and Other Post-employment Benefit Plans (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans', window );">Estimated payments</a></td>
<td class="nump">&#8364; 1,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans', window );">Estimated payments</a></td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">From&#160;1&#160;to 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans', window );">Estimated payments</a></td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">From&#160;3&#160;to 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans', window );">Estimated payments</a></td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans', window );">Estimated payments</a></td>
<td class="nump">&#8364; 891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected timing of payments in respect of unfunded pension and other post-employment benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>227
<FILENAME>R181.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348522906320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Movements in Restructuring Provisions Classified in Non-current and Current Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringProvisionsLineItems', window );"><strong>Disclosure of Restructuring Provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Balance, beginning of period</a></td>
<td class="nump">&#8364; 6,341<span></span>
</td>
<td class="nump">&#8364; 6,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RestructuringProvisionAbstract', window );"><strong>Of which:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermRestructuringProvision', window );">Classified in current liabilities</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="nump">&#8364; 594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(408)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(572)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
<td class="num">(425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Balance, end of period</a></td>
<td class="nump">7,602<span></span>
</td>
<td class="nump">6,341<span></span>
</td>
<td class="nump">6,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember', window );">Restructuring Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfRestructuringProvisionsLineItems', window );"><strong>Disclosure of Restructuring Provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Balance, beginning of period</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RestructuringProvisionAbstract', window );"><strong>Of which:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermRestructuringProvision', window );">Classified in non-current liabilities</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="nump">&#8364; 868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermRestructuringProvision', window );">Classified in current liabilities</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="nump">594<span></span>
</td>
<td class="nump">&#8364; 631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod', window );">Change in provisions recognized in profit or loss for the period</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provisions utilized</a></td>
<td class="num">(561)<span></span>
</td>
<td class="num">(522)<span></span>
</td>
<td class="num">(571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UnwindingOfDiscount', window );">Unwinding of discount</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation differences</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities', window );">Balance, end of period</a></td>
<td class="nump">&#8364; 1,132<span></span>
</td>
<td class="nump">&#8364; 1,233<span></span>
</td>
<td class="nump">&#8364; 1,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermRestructuringProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provision for restructuring. [Refer: Restructuring provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermRestructuringProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RestructuringProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RestructuringProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermRestructuringProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for restructuring. [Refer: Restructuring provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermRestructuringProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in provisions recognized in profit or loss for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfRestructuringProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of restructuring provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfRestructuringProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UnwindingOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unwinding Of Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UnwindingOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>228
<FILENAME>R182.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348525288112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Timing of Future Termination Benefit Payments (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">&#8364; 968<span></span>
</td>
<td class="nump">&#8364; 1,039<span></span>
</td>
<td class="nump">&#8364; 943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">From&#160;1&#160;to 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">From&#160;3&#160;to 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">611<span></span>
</td>
<td class="nump">804<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | From&#160;1&#160;to 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | From&#160;3&#160;to 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other | From&#160;1&#160;to 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other | From&#160;3&#160;to 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Employee termination benefits</a></td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>229
<FILENAME>R183.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533374880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Summary of Other Provisions (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsAbstract', window );"><strong>Disclosure of other provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionForEnvironmentRisks', window );">Environmental risks</a></td>
<td class="nump">&#8364; 493<span></span>
</td>
<td class="nump">&#8364; 526<span></span>
</td>
<td class="nump">&#8364; 650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther', window );">Product liability risks, litigation and other</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
<td class="nump">1,374<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLongtermProvisions', window );">Total</a></td>
<td class="nump">&#8364; 1,776<span></span>
</td>
<td class="nump">&#8364; 2,178<span></span>
</td>
<td class="nump">&#8364; 2,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLongtermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLongtermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionForEnvironmentRisks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Environment risks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionForEnvironmentRisks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product liability risks litigation and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>230
<FILENAME>R184.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533813792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions, income tax liabilities and other liabilities - Current Provisions and Other Current Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Taxes payable, other than corporate income taxes</a></td>
<td class="nump">&#8364; 395<span></span>
</td>
<td class="nump">&#8364; 420<span></span>
</td>
<td class="nump">&#8364; 428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Employee-related liabilities</a></td>
<td class="nump">2,106<span></span>
</td>
<td class="nump">2,158<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermRestructuringProvision', window );">Restructuring provisions (see Note&#160;D.19.2.)</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentInterestRateDerivativesPayable', window );">Interest rate derivatives (see Note&#160;D.20.)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentCurrencyDerivativesPayable', window );">Currency derivatives (see Note&#160;D.20.)</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentEquityDerivativesPayable', window );">Equity derivatives (see Note&#160;D.20.)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmountsPayableForAcquisitionOfNonCurrentAssets', window );">Amounts payable for acquisitions of non-current assets</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Customer contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">9,590<span></span>
</td>
<td class="nump">7,894<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrentProvisionsAndOtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">13,741<span></span>
</td>
<td class="nump">12,021<span></span>
</td>
<td class="nump">11,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">3,374<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TypesOfAgreementAxis=sny_CollaborationAgreementWithGSKMember', window );">Collaboration agreement with GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Customer contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">&#8364; 85<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TypesOfAgreementAxis=sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember', window );">Direct royalty agreement with SOBI on sales of BeyfortusTM in the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RoyaltiesPayable', window );">Royalties, payable</a></td>
<td class="nump">&#8364; 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermRestructuringProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for restructuring. [Refer: Restructuring provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermRestructuringProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AmountsPayableForAcquisitionOfNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for acquisitions of non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AmountsPayableForAcquisitionOfNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentCurrencyDerivativesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentCurrencyDerivativesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentEquityDerivativesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Equity Derivatives Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentEquityDerivativesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentInterestRateDerivativesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current interest rate derivatives payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentInterestRateDerivativesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrentProvisionsAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrentProvisionsAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provisions and other current and non-current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_CollaborationAgreementWithGSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_CollaborationAgreementWithGSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TypesOfAgreementAxis=sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TypesOfAgreementAxis=sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>231
<FILENAME>R185.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348525077616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative financial instruments and market risks - Summary of Fair Value of Derivative Instruments (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of Credit Risk Exposure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialAssets', window );">Non-current assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialAssets', window );">Current assets</a></td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Total assets</a></td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Non-current liabilities</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Current liabilities</a></td>
<td class="num">(127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Total liabilities</a></td>
<td class="num">(291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Market value</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_CurrencyDerivativesMember', window );">Currency derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of Credit Risk Exposure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialAssets', window );">Non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialAssets', window );">Current assets</a></td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Total assets</a></td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Current liabilities</a></td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Total liabilities</a></td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Market value</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_CurrencyDerivativesOperatingMember', window );">operating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of Credit Risk Exposure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialAssets', window );">Non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialAssets', window );">Current assets</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Total assets</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Current liabilities</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Total liabilities</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Market value</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_CurrencyDerivativesFinancialMember', window );">financial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of Credit Risk Exposure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialAssets', window );">Non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialAssets', window );">Current assets</a></td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Total assets</a></td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Current liabilities</a></td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Total liabilities</a></td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Market value</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateDerivativesMember', window );">Interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of Credit Risk Exposure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialAssets', window );">Non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialAssets', window );">Current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Non-current liabilities</a></td>
<td class="num">(164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Current liabilities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Total liabilities</a></td>
<td class="num">(165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Market value</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_EquityDerivativesMember', window );">Equity derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of Credit Risk Exposure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialAssets', window );">Non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialAssets', window );">Current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue', window );">Market value</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="num">&#8364; (16)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial assets. [Refer: Derivative financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCreditRiskExposureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial instruments designated as hedging instruments. Hedging instruments are designated derivatives or (for a hedge of the risk of changes in foreign currency exchange rates only) designated non-derivative financial assets or non-derivative financial liabilities whose fair value or cash flows are expected to offset changes in the fair value or cash flows of a designated hedged item. [Refer: At fair value [member]; Derivatives [member]; Derivative financial assets; Derivative financial liabilities; Financial instruments, class [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 22<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_22_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial assets. [Refer: Derivative financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CurrencyDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CurrencyDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CurrencyDerivativesOperatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CurrencyDerivativesOperatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_CurrencyDerivativesFinancialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_CurrencyDerivativesFinancialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_EquityDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_EquityDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>232
<FILENAME>R186.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348503113072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative financial instruments and market risks - Summary of Operating Currency Hedging Instruments (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">&#8364; 10,358<span></span>
</td>
<td class="nump">&#8364; 8,862<span></span>
</td>
<td class="nump">&#8364; 6,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">6,112<span></span>
</td>
<td class="nump">5,403<span></span>
</td>
<td class="nump">3,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2,981<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">788<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Sales In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales in Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">3,459<span></span>
</td>
<td class="nump">2,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">2,047<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Purchased In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases In Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward Currency Purchased In Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases in Hungarian Forint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases In Russian Rouble</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward Currency Sales In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency sales in Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward Currency Purchased In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases In Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward Currency Purchased In Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases in Hungarian Forint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges | Forward currency purchases In Russian Rouble</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">10,358<span></span>
</td>
<td class="nump">8,862<span></span>
</td>
<td class="nump">6,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">6,112<span></span>
</td>
<td class="nump">5,403<span></span>
</td>
<td class="nump">3,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2,981<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">788<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward Currency Sales In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency sales in Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">3,459<span></span>
</td>
<td class="nump">2,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">2,047<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward Currency Purchased In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases In Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward Currency Purchased In Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases in Hungarian Forint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Not eligible for hedge accounting | Forward currency purchases In Russian Rouble</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Sales In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales in Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Purchased In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases In Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward Currency Purchased In Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases in Hungarian Forint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases In Russian Rouble</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward Currency Sales In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency sales in Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward Currency Purchased In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases In Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward Currency Purchased In Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases in Hungarian Forint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges | Forward currency purchases In Russian Rouble</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward Currency Sales In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency sales in Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward Currency Purchased In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases In Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward Currency Purchased In Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases in Hungarian Forint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Not eligible for hedge accounting | Forward currency purchases In Russian Rouble</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency sales in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency sales in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency sales in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency sales in Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward Currency Sales In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency sales in Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency purchases in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency purchases in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency purchases in Chinese Yuan Renminbi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward Currency Purchased In Korean Won</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency purchases In Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward Currency Purchased In Taiwan Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency purchases in Hungarian Forint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges | Forward currency purchases In Russian Rouble</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems', window );"><strong>Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Operating currency hedging instruments in place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instrument</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanRenminbiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInJapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInJapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInKoreanWonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInKoreanWonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInTaiwanDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInTaiwanDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInKoreanWonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInKoreanWonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInJapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInJapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInTaiwanDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInTaiwanDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInHungarianForintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInHungarianForintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInRussianRoubleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInRussianRoubleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=sny_NotEligibleForHedgeAccountingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=sny_NotEligibleForHedgeAccountingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>233
<FILENAME>R187.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517829696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative financial instruments and market risks - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Derivative financial assets</a></td>
<td class="nump">&#8364; 201.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">291.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">&#8364; 7.0<span></span>
</td>
<td class="num">&#8364; (6.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember', window );">Forward currency sales in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount of forward sales | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Derivative financial assets</a></td>
<td class="nump">54.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInUSDollarUSBondMember', window );">Forward currency purchases in US dollar, US bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount of forward sales | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">31.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember', window );">Forward currency purchases in US dollar, commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount of forward sales | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative financial liabilities</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax', window );">Change in fair value of cash flow hedges</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">17,334.0<span></span>
</td>
<td class="nump">12,556.0<span></span>
</td>
<td class="nump">16,948.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">10,279.0<span></span>
</td>
<td class="nump">7,559.0<span></span>
</td>
<td class="nump">7,655.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">7,055.0<span></span>
</td>
<td class="nump">4,997.0<span></span>
</td>
<td class="nump">9,293.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Less&#160;than 1&#160;year | Forward currency sales in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">6,628.0<span></span>
</td>
<td class="nump">6,114.0<span></span>
</td>
<td class="nump">5,384.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Less&#160;than 1&#160;year | Forward currency sales in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">1,556.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Less&#160;than 1&#160;year | Forward Currency Sales In Chinese Yuan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">513.0<span></span>
</td>
<td class="nump">203.0<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Less&#160;than 1&#160;year | Forward currency purchases in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">3,073.0<span></span>
</td>
<td class="nump">2,011.0<span></span>
</td>
<td class="nump">4,816.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Less&#160;than 1&#160;year | Forward currency purchases in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">2,696.0<span></span>
</td>
<td class="nump">2,154.0<span></span>
</td>
<td class="nump">2,910.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Less&#160;than 1&#160;year | Forward currency purchases In Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">341.0<span></span>
</td>
<td class="nump">205.0<span></span>
</td>
<td class="nump">235.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">53.0<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="nump">212.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">111.0<span></span>
</td>
<td class="nump">66.0<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Forward currency purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="num">(58.0)<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="nump">197.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Less&#160;than 1&#160;year | Forward currency sales in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">101.0<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Less&#160;than 1&#160;year | Forward currency sales in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Less&#160;than 1&#160;year | Forward Currency Sales In Chinese Yuan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Less&#160;than 1&#160;year | Forward currency purchases in US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="num">(52.0)<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">128.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Less&#160;than 1&#160;year | Forward currency purchases in Singapore Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="num">(10.0)<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Less&#160;than 1&#160;year | Forward currency purchases In Japanese yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems', window );"><strong>Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure', window );">Financial currency hedging instruments in place</a></td>
<td class="nump">&#8364; 3.0<span></span>
</td>
<td class="nump">&#8364; 4.0<span></span>
</td>
<td class="num">&#8364; (2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeFinancialInstrumentsToManageFinancialExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instruments to manage financial exposure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeFinancialInstrumentsToManageFinancialExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInUSDollarUSBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInUSDollarUSBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencySalesInChineseYuanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInSingaporeDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInSingaporeDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInJapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_ForwardCurrencyPurchasedInJapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>234
<FILENAME>R188.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348504176736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative financial instruments and market risks - Disclosure of Instruments (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 3,405<span></span>
</td>
<td class="nump">&#8364; 2,434<span></span>
</td>
<td class="nump">&#8364; 3,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Nominal value of interest rate swaps hedge fixed-rate bonds</a></td>
<td class="nump">10,358<span></span>
</td>
<td class="nump">8,862<span></span>
</td>
<td class="nump">6,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">3,405<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
<td class="nump">2,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Nominal value of interest rate swaps hedge fixed-rate bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 1&#160;to&#160;2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2 to 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 2 to 3 years | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 3 to 4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | 4 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">906<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember', window );">Notional amount | More&#160;than 5&#160;years | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Nominal value of interest rate swaps hedge fixed-rate bonds</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Nominal value of interest rate swaps hedge fixed-rate bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember', window );">Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Nominal value of interest rate swaps hedge fixed-rate bonds</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="nump">1.03%<span></span>
</td>
<td class="nump">1.03%<span></span>
</td>
<td class="nump">1.03%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 453<span></span>
</td>
<td class="nump">&#8364; 467<span></span>
</td>
<td class="nump">&#8364; 440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | 1&#160;to&#160;2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | 2 to 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | 3 to 4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | 4 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Notional amount | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Fair value | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% | Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="nump">1.32%<span></span>
</td>
<td class="nump">1.32%<span></span>
</td>
<td class="nump">1.32%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 453<span></span>
</td>
<td class="nump">&#8364; 467<span></span>
</td>
<td class="nump">&#8364; 440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | 1&#160;to&#160;2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | 2 to 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | 3 to 4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | 4 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Notional amount | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Fair value | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% | Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="nump">0.69%<span></span>
</td>
<td class="nump">0.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 850<span></span>
</td>
<td class="nump">&#8364; 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | 1&#160;to&#160;2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | 2 to 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | 3 to 4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | 4 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Notional amount | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Fair value | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member', window );">Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% | Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="nump">0.92%<span></span>
</td>
<td class="nump">0.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 650<span></span>
</td>
<td class="nump">&#8364; 650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | 1&#160;to&#160;2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | 2 to 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | 3 to 4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | 4 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Notional amount | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Fair value | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92% | Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="nump">3.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Notional amount | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Notional amount | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Notional amount | 1&#160;to&#160;2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Notional amount | 2 to 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Notional amount | 3 to 4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Notional amount | 4 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Notional amount | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Fair value | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member', window );">Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43% | Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.06%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | 1&#160;to&#160;2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | 2 to 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | 3 to 4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | 4 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Notional amount | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Fair value | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member', window );">Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% | Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.57%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | 1&#160;to&#160;2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | 2 to 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | 3 to 4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | 4 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Notional amount | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Fair value | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember', window );">Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia | Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestRateSwapsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.48%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialInstruments', window );">Nominal value of interest rate swaps hedge fixed-rate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | 1&#160;to&#160;2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | 2 to 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | 3 to 4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | 4 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Notional amount | More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Fair value | Derivatives designated as fair value hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Fair value | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember', window );">Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent | Of&#160;which recognized&#160;in&#160;equity | Cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents', window );">Currency and interest rate derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial instrument</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestRateSwapsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Rate Swaps, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestRateSwapsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_AtNotionalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_FairValueHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_FairValueHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfHedgesAxis=ifrs-full_CashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=sny_ValueOfHedgeRecognizedInEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive069Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive092Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEsterReceive343Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>235
<FILENAME>R189.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517165920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative financial instruments and market risks - Disclosure of Actual or Potential Effects of Netting Arrangements (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sny_DerivativeFinancialAssetsMember', window );">Derivative financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of Offsetting of Financial Assets and Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset', window );">Gross carrying amounts before offset</a></td>
<td class="nump">&#8364; 201<span></span>
</td>
<td class="nump">&#8364; 206<span></span>
</td>
<td class="nump">&#8364; 298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32', window );">Gross amounts offset (in accordance with IAS 32)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetAmountsAsReportedInTheBalanceSheet', window );">Net amounts as reported in the balance sheet</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetExposure', window );">Net exposure</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sny_DerivativeFinancialAssetsMember', window );">Derivative financial assets | Effects of other netting arrangements not fulfilling the IAS 32 criteria for offsetting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of Offsetting of Financial Assets and Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral', window );">Fair value of financial collateral</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments', window );">Financial instruments</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sny_DerivativeFinancialLiabilitiesMember', window );">Derivative financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of Offsetting of Financial Assets and Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset', window );">Gross carrying amounts before offset</a></td>
<td class="num">(291)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32', window );">Gross amounts offset (in accordance with IAS 32)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetAmountsAsReportedInTheBalanceSheet', window );">Net amounts as reported in the balance sheet</a></td>
<td class="num">(291)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetExposure', window );">Net exposure</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sny_DerivativeFinancialLiabilitiesMember', window );">Derivative financial liabilities | Effects of other netting arrangements not fulfilling the IAS 32 criteria for offsetting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of Offsetting of Financial Assets and Liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral', window );">Fair value of financial collateral</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments', window );">Financial instruments</a></td>
<td class="nump">&#8364; 171<span></span>
</td>
<td class="nump">&#8364; 160<span></span>
</td>
<td class="nump">&#8364; 67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial assets and liabilities gross amounts offset in accordance with IAS 32.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial assets and liabilities gross carrying amounts before offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of offsetting of financial assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effects of other netting arrangements not fulfilling the IAS32 criteria for offsetting fair value of financial collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effects of other netting arrangements not fulfilling the IAS32 criteria for offsetting financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetAmountsAsReportedInTheBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amounts as reported in the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetAmountsAsReportedInTheBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net exposure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sny_DerivativeFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=sny_DerivativeFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DerivativeInstrumentAxis=sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DerivativeInstrumentAxis=sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=sny_DerivativeFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=sny_DerivativeFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>236
<FILENAME>R190.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348518242304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off balance sheet commitments - Summary of Off Balance Sheet Commitments Relating to Operating Activities (Details)<br> &#8364; in Millions, $ in Billions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>extension</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet', window );">Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 221<span></span>
</td>
<td class="nump">&#8364; 38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsGiven', window );">Irrevocable purchase commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsReceived', window );">Irrevocable purchase commitments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments', window );">Research and development license agreements - commitments related to R&amp;D and other commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress', window );">Research and development license agreements - contingent milestone payments in connection with development programs in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,886<span></span>
</td>
<td class="nump">2,919<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalOffBalanceSheetCommitments', window );">Total - net commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LeaseTerm', window );">Lease, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LeaseCosts', window );">Lease, cost | $</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LeaseExtensionOptionsNumber', window );">Lease, extension options, number | extension</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LeaseExtensionOptionsTerm', window );">Lease, extension options, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsGiven', window );">Irrevocable purchase commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LeaseTerm', window );">Lease, term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet', window );">Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsGiven', window );">Irrevocable purchase commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsReceived', window );">Irrevocable purchase commitments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments', window );">Research and development license agreements - commitments related to R&amp;D and other commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress', window );">Research and development license agreements - contingent milestone payments in connection with development programs in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalOffBalanceSheetCommitments', window );">Total - net commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">From&#160;1&#160;to 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet', window );">Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsGiven', window );">Irrevocable purchase commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsReceived', window );">Irrevocable purchase commitments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments', window );">Research and development license agreements - commitments related to R&amp;D and other commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress', window );">Research and development license agreements - contingent milestone payments in connection with development programs in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalOffBalanceSheetCommitments', window );">Total - net commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">From&#160;3&#160;to 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet', window );">Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsGiven', window );">Irrevocable purchase commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsReceived', window );">Irrevocable purchase commitments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments', window );">Research and development license agreements - commitments related to R&amp;D and other commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress', window );">Research and development license agreements - contingent milestone payments in connection with development programs in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalOffBalanceSheetCommitments', window );">Total - net commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet', window );">Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsGiven', window );">Irrevocable purchase commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsReceived', window );">Irrevocable purchase commitments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments', window );">Research and development license agreements - commitments related to R&amp;D and other commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress', window );">Research and development license agreements - contingent milestone payments in connection with development programs in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TotalOffBalanceSheetCommitments', window );">Total - net commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_SuppliersMember', window );">Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsGiven', window );">Irrevocable purchase commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsReceived', window );">Irrevocable purchase commitments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (574)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember', window );">Joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems', window );"><strong>Disclosure Of Off Balance Sheet Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IrrevocablePurchaseCommitmentsGiven', window );">Irrevocable purchase commitments given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Related To Research And Development License Agreements, Contingent Milestone Payments In Connection With Development Programs In Progress</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments related to R&amp; D licence agreements and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOffBalanceSheetCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOffBalanceSheetCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IrrevocablePurchaseCommitmentsGiven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Irrevocable purchase commitments given.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IrrevocablePurchaseCommitmentsGiven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IrrevocablePurchaseCommitmentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Irrevocable purchase commitments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IrrevocablePurchaseCommitmentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LeaseExtensionOptionsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Extension Options, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LeaseExtensionOptionsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LeaseExtensionOptionsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Extension Options, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LeaseExtensionOptionsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short Term Leases, Low Value Asset Leases And Lease Contracts Committed But Not Started Yet</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TotalOffBalanceSheetCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TotalOffBalanceSheetCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_SuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_SuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>237
<FILENAME>R191.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348508667120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Off balance sheet commitments - Additional Information (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 04, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 04, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 19, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 15, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 27, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 04, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 27, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 08, 2022 </div>
<div>target</div>
</th>
<th class="th">
<div>Aug. 17, 2022 </div>
<div>target</div>
</th>
<th class="th">
<div>Mar. 29, 2022 </div>
<div>target</div>
</th>
<th class="th">
<div>Jan. 07, 2022 </div>
<div>molecule</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase', window );">Commitments related to research and development relating to projects in research phase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18,000<span></span>
</td>
<td class="nump">&#8364; 16,800<span></span>
</td>
<td class="nump">&#8364; 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets', window );">Commitments related to research and development payments contingent upon attainment of sales targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">17,900<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements', window );">Commitments related to collaboration, discovery, development and commercialization agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts', window );">Commitments related to attainment of regulatory and sales milestones for commercialized products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CumulativeDevelopmentCostsIncurred', window );">Cumulative development costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">Total credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,000<span></span>
</td>
<td class="nump">&#8364; 8,000<span></span>
</td>
<td class="nump">&#8364; 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments', window );">Commitments received in respect of disposals proceeds receivable and contingent consideration on divestments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_WorldHealthOrganizationMember', window );">World Health Organization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TransferPercentageOfPandemicVaccines', window );">Percentage of pandemic vaccines agreed to transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ReservePercentageOfPandemicVaccines', window );">Percentage of pandemic vaccines agreed to reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember', window );">Joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty', window );">Percentage of future development expense funded by other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_ScribeTherapeuticsMember', window );">Scribe Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UpfrontPayments', window );">Upfront payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_ScribeTherapeuticsMember', window );">Scribe Therapeutics | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement', window );">Commitments related to milestone payments for projects under collaboration agreements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UpfrontPayments', window );">Upfront payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_TevaPharmaceuticalsMember', window );">Teva Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">&#8364; 469<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_TevaPharmaceuticalsMember', window );">Teva Pharmaceuticals | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement', window );">Commitments related to milestone payments for projects under collaboration agreements</a></td>
<td class="nump">&#8364; 940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_ProventionBioIncMember', window );">Provention Bio, Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement', window );">Commitments related to milestone payments for projects under collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_ExscientiaMember', window );">Exscientia | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement', window );">Number of novel small molecule candidates developed | molecule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_IGMBiosciencesIncMember', window );">IGM Biosciences, Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOncologyTargetsUnderCollaborationAgreement', window );">Number of oncology targets under collaboration agreement | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement', window );">Number of immunology or inflammation targets under collaboration agreement | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_AtomwiseMember', window );">Atomwise | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfDrugTargetsUnderCollaborationAgreement', window );">Number of drug targets under collaboration agreement | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_InsilicoMedicineMember', window );">Insilico Medicine | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement', window );">Number of therapeutic targets under collaboration agreement | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=sny_LonzaMember', window );">Lonza | Joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVentures', window );">Investments in joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany', window );">Percentage of future development expense funded by company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmountsPayablePartnersInCollaborationAgreements', window );">Amounts payable partners in collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | Blackstone Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement', window );">Commitments related to maximum payments for projects under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | Regeneron Pharmaceuticals, INC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfProfitShareOnCounterpartiesProfit', window );">Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfCumulativeDevelopmentCostsReimbursed', window );">Percentage of cumulative development costs reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsReceivedForDevelopmentCosts', window );">Commitments received for development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,700<span></span>
</td>
<td class="nump">&#8364; 2,100<span></span>
</td>
<td class="nump">&#8364; 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_AblynxMember', window );">Ablynx NV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements', window );">Commitments related to collaboration, discovery, development and commercialization agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_KymabMember', window );">Kymab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements', window );">Commitments related to collaboration, discovery, development and commercialization agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement', window );">Commitments related to milestone payments for projects under collaboration agreements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_ProventionBioMember', window );">Provention Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems', window );"><strong>Provisions And Other Current And Non-Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements', window );">Commitments related to collaboration, discovery, development and commercialization agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in joint ventures in an entity's separate financial statements. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UndrawnBorrowingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UndrawnBorrowingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AmountsPayablePartnersInCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable partners in collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AmountsPayablePartnersInCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsReceivedForDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Received For Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsReceivedForDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Related To Attainment Of Regulatory And Sales Milestones For Commercialized Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Related To Collaboration, Discovery, Development And Commercialization Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Related To Maximum Payments For Projects Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Related To Milestone Payments For Projects Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments related to r and d payments contingent upon attainment of sales targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Related To Research And Development Relating To Projects In Research Phase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CumulativeDevelopmentCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative Development Costs Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CumulativeDevelopmentCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfDrugTargetsUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Drug Targets Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfDrugTargetsUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Immunology Or Inflammation Targets Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Novel Small Molecule Candidates To Be Developed Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOncologyTargetsUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Oncology Targets Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOncologyTargetsUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Therapeutic Targets Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Off-Balance Sheet Commitments Received In Respect Of Disposals Proceeds Receivable And Contingent Consideration On Divestments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfCumulativeDevelopmentCostsReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative development costs reimbursed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfCumulativeDevelopmentCostsReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfFutureDevelopmentExpenseFundedByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development expense funded by company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfFutureDevelopmentExpenseFundedByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development expense funded by other party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfProfitShareOnCounterpartiesProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of profit share on counter parties profit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfProfitShareOnCounterpartiesProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provisions and other current and non-current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ReservePercentageOfPandemicVaccines">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserve percentage of pandemic vaccines.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ReservePercentageOfPandemicVaccines</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TransferPercentageOfPandemicVaccines">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer percentage of pandemic vaccines.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TransferPercentageOfPandemicVaccines</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_WorldHealthOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_WorldHealthOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_ScribeTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_ScribeTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_TevaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_TevaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_ProventionBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_ProventionBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_ExscientiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_ExscientiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_IGMBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_IGMBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_AtomwiseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_AtomwiseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_InsilicoMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_InsilicoMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_LonzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_LonzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_BlackstoneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_BlackstoneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_AblynxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_AblynxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_KymabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_KymabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>238
<FILENAME>R192.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348527086288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Off balance sheet commitments - Summary of Undrawn Credit Facilities (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLineOfCreditFacilityLineItems', window );"><strong>Disclosure Of Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">General-purpose credit facilities</a></td>
<td class="nump">&#8364; 8,000<span></span>
</td>
<td class="nump">&#8364; 8,000<span></span>
</td>
<td class="nump">&#8364; 8,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less&#160;than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLineOfCreditFacilityLineItems', window );"><strong>Disclosure Of Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">General-purpose credit facilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">From&#160;1&#160;to 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLineOfCreditFacilityLineItems', window );"><strong>Disclosure Of Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">General-purpose credit facilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">From&#160;3&#160;to 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLineOfCreditFacilityLineItems', window );"><strong>Disclosure Of Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">General-purpose credit facilities</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More&#160;than 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLineOfCreditFacilityLineItems', window );"><strong>Disclosure Of Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">General-purpose credit facilities</a></td>
<td class="nump">&#8364; 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UndrawnBorrowingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UndrawnBorrowingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of line of credit facility table line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>239
<FILENAME>R193.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348527285488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Off balance sheet commitments - Summary of Amount of Guarantees Given and Received (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_GuaranteesReceivedMember', window );">Guarantees received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfGuaranteesLineItems', window );"><strong>Disclosure of Guarantees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities', window );">Estimated financial effect of contingent liabilities</a></td>
<td class="nump">&#8364; 1,272<span></span>
</td>
<td class="nump">&#8364; 1,229<span></span>
</td>
<td class="nump">&#8364; 1,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_GuaranteesGivenMember', window );">Guarantees given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfGuaranteesLineItems', window );"><strong>Disclosure of Guarantees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities', window );">Estimated financial effect of contingent liabilities</a></td>
<td class="nump">3,936<span></span>
</td>
<td class="nump">3,815<span></span>
</td>
<td class="nump">3,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember', window );">Guarantees provided to banks in connection with credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfGuaranteesLineItems', window );"><strong>Disclosure of Guarantees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities', window );">Estimated financial effect of contingent liabilities</a></td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_OtherGuaranteesGivenMember', window );">Other guarantees given</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfGuaranteesLineItems', window );"><strong>Disclosure of Guarantees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities', window );">Estimated financial effect of contingent liabilities</a></td>
<td class="nump">&#8364; 2,869<span></span>
</td>
<td class="nump">&#8364; 2,808<span></span>
</td>
<td class="nump">&#8364; 2,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 86<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_86_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EstimatedFinancialEffectOfContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfGuaranteesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfGuaranteesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_GuaranteesReceivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_GuaranteesReceivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_GuaranteesGivenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_GuaranteesGivenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_OtherGuaranteesGivenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_OtherGuaranteesGivenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>240
<FILENAME>R194.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348505993808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal and arbitral proceedings (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
<th class="th" colspan="1">72 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 03, 2022</div></th>
<th class="th">
<div>May 14, 2013 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>expert</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>manufacturer</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>case </div>
<div>person </div>
<div>manufacturer </div>
<div>lawsuit </div>
<div>complaint </div>
<div>plaintiff </div>
<div>action </div>
<div>trial </div>
<div>children </div>
<div>family </div>
<div>claim </div>
<div>patent</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>trial</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>proceeding</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>person </div>
<div>manufacturer </div>
<div>lawsuit </div>
<div>complaint </div>
<div>plaintiff </div>
<div>action </div>
<div>trial </div>
<div>children </div>
<div>family </div>
<div>case </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>person </div>
<div>manufacturer </div>
<div>lawsuit </div>
<div>complaint </div>
<div>plaintiff </div>
<div>action </div>
<div>trial </div>
<div>children </div>
<div>family </div>
<div>case </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>AUD ($) </div>
<div>person </div>
<div>manufacturer </div>
<div>lawsuit </div>
<div>complaint </div>
<div>plaintiff </div>
<div>action </div>
<div>trial </div>
<div>children </div>
<div>family </div>
<div>case </div>
<div>claim</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>claimant</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>case </div>
<div>claimant </div>
<div>family</div>
</th>
<th class="th">
<div>Dec. 06, 2022 </div>
<div>plaintiff </div>
<div>cancer</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>person</div>
</th>
<th class="th">
<div>Aug. 20, 2022 </div>
<div>ruling</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>complaint</div>
</th>
<th class="th">
<div>Nov. 18, 2014 </div>
<div>patent</div>
</th>
<th class="th">
<div>Dec. 31, 1997 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther', window );">Provisions for product liability risks, litigation and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,283.0<span></span>
</td>
<td class="nump">&#8364; 1,374.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,283.0<span></span>
</td>
<td class="nump">&#8364; 1,283.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,652.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonCurrentProvisionForEnvironmentRisks', window );">Environmental risks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 493.0<span></span>
</td>
<td class="nump">&#8364; 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 493.0<span></span>
</td>
<td class="nump">&#8364; 493.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 526.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DefendantAxis=sny_ActionForWhichWeAreDefendantMember', window );">Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfFirstInstanceRulings', window );">Number of first instance rulings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DefendantAxis=sny_ActionForWhichWeAreDefendantMember', window );">Action for which we are defendant | Product liabilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LitigationAmountPayable', window );">Litigation amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DefendantAxis=sny_ActionForWhichWeAreDefendantMember', window );">Action for which we are defendant | Product liabilities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LitigationAmountPayable', window );">Litigation amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_SanofiPasteurHepatitisBVaccineMember', window );">Sanofi Pasteur Hepatitis B Vaccine product litigation | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCivilIndividualActions', window );">Number of civil individual actions | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOngoingLawsuits', window );">Number of ongoing lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_TaxotereProductLitigationInTheUSMember', window );">Taxotere product litigation in the US | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,770<span></span>
</td>
<td class="nump">6,770<span></span>
</td>
<td class="nump">6,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfBellweatherTrialsHeld', window );">Number of bellweather trial held | trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfIndividualCasesSettled', window );">Number of individual cases settled | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember', window );">Taxotere mississippi attorney general litigation in the US | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation', window );">Maximum penalty amount sought by plaintiffs for each violation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_ZantacLitigationInTheUSMember', window );">Zantac litigation in the US | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,984<span></span>
</td>
<td class="nump">26,984<span></span>
</td>
<td class="nump">26,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCancersAssociatedWithDismissedCases', window );">Number of cancers associated with dismissed cases | cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal', window );">Number of plaintiffs who filed notices to appeal | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfComplaintsFiled', window );">Number of complaints filed | complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,280<span></span>
</td>
<td class="nump">3,280<span></span>
</td>
<td class="nump">3,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_ZantacLitigationInCanadaMember', window );">Zantac litigation in Canada | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfClassActionLawsuits', window );">Number of class actions | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_GoldBondProductLitigationInTheUSMember', window );">Gold Bond Product litigation in the US | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfClassActionLawsuits', window );">Number of class actions | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOngoingTrials', window );">Number of ongoing trials | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInFranceMember', window );">Depakine product litigation in France | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCivilIndividualActions', window );">Number of civil individual actions | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPeopleExposed', window );">Number of people exposed | person</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfLawsuitsRuledOnMerit', window );">Number of lawsuits ruled on merits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfFamiliesWhoFiledACivilClaim', window );">Number of families who filed a civil claim | family</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfClaimant', window );">Number of claimant | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfClaimantExposed', window );">Number of claimant exposed | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim', window );">Number of claimant exposed who withdrawed their claim | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim', window );">Number of indirect victim who withdrawed their claim | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCounterExpertiseExperts', window );">Number of experts | expert</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfAdministrativeProceedings', window );">Number of administrative proceedings | proceeding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInSwitzerlandMember', window );">Depakine product litigation in Switzerland | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPeopleExposed', window );">Number of people exposed | person</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfFamiliesWhoFiledACivilClaim', window );">Number of families who filed a civil claim | family</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfActionDeclaredTimeBarred', window );">Number of action declared time-barred | person</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInSpainMember', window );">Depakine product litigation in Spain | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOngoingTrials', window );">Number of ongoing trials | trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPeopleExposed', window );">Number of people exposed | children</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPatientsToIndemnify', window );">Number of patients to indemnify | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInBelgiumMember', window );">Depakine product litigation in Belgium | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCivilIndividualActions', window );">Number of civil individual actions | complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInIrelandMember', window );">Depakine product litigation in Ireland | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPreActionProtocolCases', window );">Number of pre-action protocol cases | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCivilClaimsOnGoing', window );">Number of civil claims on-going | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInGreatBritainMember', window );">Depakine product litigation in Great Britain | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPreActionProtocolCases', window );">Number of pre-action protocol cases | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInNorthernIrelandMember', window );">Depakine product litigation in Northern Ireland | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCivilClaimsOnGoing', window );">Number of civil claims on-going | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_DengvaxiaProductLitigationInThePhilippinesMember', window );">Dengvaxia product litigation in the Philippines | Action for which we are defendant | Product liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfCases', window );">Number of cases | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_RamiprilCanadaPatentLitigationMember', window );">Ramipril Canada Patent Litigation | Action for which we are a plaintiff | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug', window );">Number of manufacturers with marketing authorization for generic version of drug | manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember', window );">Praluent (Alirocumab)-related amgen patent litigation in the US | Action for which we are defendant | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPatentActionsInitiallyFiled', window );">Number of patent actions initially filed | complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPatentsAllegedlyInfringed', window );">Number of patents allegedly infringed | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_JevtanaRelatedPatentLitigationInTheUSMember', window );">Jevtana related patent litigation in the US | Action for which we are a plaintiff | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPatentsAllegedlyInfringed', window );">Number of patents allegedly infringed | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfPatentsCoveringProduct', window );">Number of patents covering product | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_PlavixLitigationCommonwealthInAustraliaMember', window );">Plavix litigation (Commonwealth) in Australia | Action for which we are defendant | Minimum | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs', window );">Reduced amount of compensation claimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 137.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 137.8<span></span>
</td>
<td class="nump">&#8364; 137.8<span></span>
</td>
<td class="nump">$ 223.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded', window );">Reduced amount of compensation claimed, interest included</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218.0<span></span>
</td>
<td class="nump">218.0<span></span>
</td>
<td class="nump">360.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_PlavixLitigationCommonwealthInAustraliaMember', window );">Plavix litigation (Commonwealth) in Australia | Action for which we are defendant | Maximum | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs', window );">Reduced amount of compensation claimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172.9<span></span>
</td>
<td class="nump">172.9<span></span>
</td>
<td class="nump">280.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded', window );">Reduced amount of compensation claimed, interest included</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 294.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 294.3<span></span>
</td>
<td class="nump">&#8364; 294.3<span></span>
</td>
<td class="nump">$ 487.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_PlavixAttorneyGeneralActionInHawaiiMember', window );">Plavix Attorney General Action in Hawaii | Action for which we are defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GlobalPenaltyFeeIncurredByDefendants', window );">Total penalty fee incurred by defendants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 834,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PenaltyFeeIncurred', window );">Penalty fee incurred by Sanofi | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_PlavixRelatedLitigationInFranceMember', window );">Plavix related litigation in France | Action for which we are defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PenaltyFeeIncurred', window );">Penalty fee incurred by Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PaymentOfDamagesClaimedByCounterparty', window );">Payment of damages claimed by the French CNAM (French Social Security)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 115.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_A340BDrugPricingProgramInTheUnitedStatesMember', window );">340B Drug Pricing Program in the United States | Action for which we are defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOtherManufacturersInvolvedInProceedings', window );">Number of other manufacturers involved in proceedings | manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_AventisCropScienceRetainedLiabilitiesMember', window );">Aventis Crop Science retained liabilities | Contingencies arising from certain business divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EquityInvestmentSoldPercentage', window );">Aggregate participation percentage of legacy companies in ACS</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LegalAndArbitralProceedingsAxis=sny_InfraservHoechstRetainedLiabilitiesMember', window );">Infraserv Hoechst retained liabilities | Contingencies arising from certain business divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems', window );"><strong>Disclosure of Legal and Arbitral Proceedings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking', window );">Fund reserves transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 57.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense', window );">Maximum amount to be reimbursed for current and future environmental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 143.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration Transferred To Fund Reserve For Indemnification Undertaking</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfLegalAndArbitralProceedingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of legal and arbitral proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfLegalAndArbitralProceedingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EquityInvestmentSoldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity investment sold percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EquityInvestmentSoldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GlobalPenaltyFeeIncurredByDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Global Penalty Fee Incurred By Defendants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GlobalPenaltyFeeIncurredByDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LitigationAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Amount Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LitigationAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount To Be Reimbursed For Current And Future Environmental Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum penalty amount sought by plaintiffs for each violation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionForEnvironmentRisks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Environment risks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionForEnvironmentRisks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product liability risks litigation and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfActionDeclaredTimeBarred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Action Declared Time-Barred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfActionDeclaredTimeBarred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfAdministrativeProceedings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Administrative Proceedings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfAdministrativeProceedings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfBellweatherTrialsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Bellweather Trials Held</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfBellweatherTrialsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCancersAssociatedWithDismissedCases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Cancers Associated With Dismissed Cases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCancersAssociatedWithDismissedCases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Cases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCivilClaimsOnGoing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Civil Claims On-Going</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCivilClaimsOnGoing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCivilIndividualActions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Civil Individual Actions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCivilIndividualActions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Claimant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfClaimantExposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Claimant Exposed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfClaimantExposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfClaimantExposedWhoWithdrawedTheClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Claimant Exposed Who Withdrawed The Claim</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfClaimantExposedWhoWithdrawedTheClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfComplaintsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Complaints Filed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfComplaintsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfCounterExpertiseExperts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Counter-Expertise Experts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfCounterExpertiseExperts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfFamiliesWhoFiledACivilClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Families Who Filed A Civil Claim</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfFamiliesWhoFiledACivilClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfFirstInstanceRulings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of First Instance Rulings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfFirstInstanceRulings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfIndirectVictimWhoWithdrawedTheClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Indirect Victim Who Withdrawed The Claim</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfIndirectVictimWhoWithdrawedTheClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfIndividualCasesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Individual Cases Settled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfIndividualCasesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfLawsuitsRuledOnMerit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Lawsuits Ruled On Merit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfLawsuitsRuledOnMerit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Manufacturers With Marketing Authorization For Generic Version Of Drug</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOngoingLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ongoing Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOngoingLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOngoingTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ongoing Trials</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOngoingTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOtherManufacturersInvolvedInProceedings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Manufacturers Involved In Proceedings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOtherManufacturersInvolvedInProceedings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfPatentActionsInitiallyFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patent actions initially filed .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfPatentActionsInitiallyFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfPatentsAllegedlyInfringed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patents allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfPatentsAllegedlyInfringed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfPatentsCoveringProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Patents Covering Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfPatentsCoveringProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfPatientsToIndemnify">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Patients To Indemnify</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfPatientsToIndemnify</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfPeopleExposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of People Exposed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfPeopleExposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Plaintiffs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Plaintiffs Who Filed Notices To Appeal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfPreActionProtocolCases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Pre-Action Protocol Cases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfPreActionProtocolCases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PaymentOfDamagesClaimedByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Damages Claimed By Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PaymentOfDamagesClaimedByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PenaltyFeeIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Penalty Fee Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PenaltyFeeIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduced Amount Of Compensation Claimed By Filled Plaintiffs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduced Amount Of Compensation Claimed By Filled Plaintiffs, Interest Included</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DefendantAxis=sny_ActionForWhichWeAreDefendantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DefendantAxis=sny_ActionForWhichWeAreDefendantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_ProductLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=sny_ProductLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_SanofiPasteurHepatitisBVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_SanofiPasteurHepatitisBVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_TaxotereProductLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_TaxotereProductLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_ZantacLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_ZantacLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_ZantacLitigationInCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_ZantacLitigationInCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_GoldBondProductLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_GoldBondProductLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInSpainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInSpainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInBelgiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInBelgiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInGreatBritainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInGreatBritainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInNorthernIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_DepakineProductLitigationInNorthernIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_DengvaxiaProductLitigationInThePhilippinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_DengvaxiaProductLitigationInThePhilippinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_RamiprilCanadaPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_RamiprilCanadaPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DefendantAxis=sny_ActionForWhichWeArePlaintiffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DefendantAxis=sny_ActionForWhichWeArePlaintiffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=sny_Patents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=sny_Patents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_JevtanaRelatedPatentLitigationInTheUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_JevtanaRelatedPatentLitigationInTheUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_PlavixLitigationCommonwealthInAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_PlavixLitigationCommonwealthInAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_PlavixAttorneyGeneralActionInHawaiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_PlavixAttorneyGeneralActionInHawaiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_PlavixRelatedLitigationInFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_PlavixRelatedLitigationInFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_A340BDrugPricingProgramInTheUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_A340BDrugPricingProgramInTheUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_AventisCropScienceRetainedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_AventisCropScienceRetainedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_ContingenciesArisingFromCertainBusinessDivestituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_ContingenciesArisingFromCertainBusinessDivestituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LegalAndArbitralProceedingsAxis=sny_InfraservHoechstRetainedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LegalAndArbitralProceedingsAxis=sny_InfraservHoechstRetainedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>241
<FILENAME>R195.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348505700256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions for discounts, rebates and sales returns - Summary of Movement in Provisions for Discounts, Rebates and Sales Returns (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, beginning balance</a></td>
<td class="nump">&#8364; 6,490<span></span>
</td>
<td class="nump">&#8364; 5,899<span></span>
</td>
<td class="nump">&#8364; 6,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns', window );">Changes in scope of consolidation</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales', window );">Provision related to current period sales</a></td>
<td class="nump">24,296<span></span>
</td>
<td class="nump">22,141<span></span>
</td>
<td class="nump">19,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales', window );">Net change in provision related to prior period sales</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns', window );">Payments made</a></td>
<td class="num">(22,653)<span></span>
</td>
<td class="num">(21,699)<span></span>
</td>
<td class="num">(19,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns', window );">Currency translation differences</a></td>
<td class="num">(213)<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, ending balance</a></td>
<td class="nump">7,762<span></span>
</td>
<td class="nump">6,490<span></span>
</td>
<td class="nump">5,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_GovernmentAndStateProgramsMember', window );">Government and State Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, beginning balance</a></td>
<td class="nump">2,603<span></span>
</td>
<td class="nump">2,596<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns', window );">Changes in scope of consolidation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales', window );">Provision related to current period sales</a></td>
<td class="nump">7,758<span></span>
</td>
<td class="nump">6,744<span></span>
</td>
<td class="nump">5,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales', window );">Net change in provision related to prior period sales</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns', window );">Payments made</a></td>
<td class="num">(7,251)<span></span>
</td>
<td class="num">(6,824)<span></span>
</td>
<td class="num">(5,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns', window );">Currency translation differences</a></td>
<td class="num">(76)<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, ending balance</a></td>
<td class="nump">2,962<span></span>
</td>
<td class="nump">2,603<span></span>
</td>
<td class="nump">2,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ManagedCareAndGPOProgramsMember', window );">Managed care and GPO Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, beginning balance</a></td>
<td class="nump">1,021<span></span>
</td>
<td class="nump">931<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns', window );">Changes in scope of consolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales', window );">Provision related to current period sales</a></td>
<td class="nump">3,590<span></span>
</td>
<td class="nump">3,246<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales', window );">Net change in provision related to prior period sales</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns', window );">Payments made</a></td>
<td class="num">(3,446)<span></span>
</td>
<td class="num">(3,208)<span></span>
</td>
<td class="num">(2,979)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns', window );">Currency translation differences</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, ending balance</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_ChargebackIncentivesMember', window );">Chargeback incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, beginning balance</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns', window );">Changes in scope of consolidation</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales', window );">Provision related to current period sales</a></td>
<td class="nump">3,861<span></span>
</td>
<td class="nump">4,147<span></span>
</td>
<td class="nump">3,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales', window );">Net change in provision related to prior period sales</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns', window );">Payments made</a></td>
<td class="num">(3,564)<span></span>
</td>
<td class="num">(4,093)<span></span>
</td>
<td class="num">(3,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns', window );">Currency translation differences</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, ending balance</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_RebatesAndDiscountsMember', window );">Rebates and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, beginning balance</a></td>
<td class="nump">1,805<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns', window );">Changes in scope of consolidation</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales', window );">Provision related to current period sales</a></td>
<td class="nump">8,177<span></span>
</td>
<td class="nump">7,244<span></span>
</td>
<td class="nump">6,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales', window );">Net change in provision related to prior period sales</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns', window );">Payments made</a></td>
<td class="num">(7,603)<span></span>
</td>
<td class="num">(6,809)<span></span>
</td>
<td class="num">(6,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns', window );">Currency translation differences</a></td>
<td class="num">(46)<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, ending balance</a></td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_SalesReturnMember', window );">Sales returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, beginning balance</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns', window );">Changes in scope of consolidation</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales', window );">Provision related to current period sales</a></td>
<td class="nump">654<span></span>
</td>
<td class="nump">578<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales', window );">Net change in provision related to prior period sales</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns', window );">Payments made</a></td>
<td class="num">(511)<span></span>
</td>
<td class="num">(599)<span></span>
</td>
<td class="num">(697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns', window );">Currency translation differences</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, ending balance</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=sny_OtherDeductionsMember', window );">Other deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, beginning balance</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns', window );">Changes in scope of consolidation</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales', window );">Provision related to current period sales</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales', window );">Net change in provision related to prior period sales</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns', window );">Payments made</a></td>
<td class="num">(278)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns', window );">Currency translation differences</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, ending balance</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, beginning balance</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">4,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, ending balance</a></td>
<td class="nump">5,124<span></span>
</td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">4,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Managed care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, beginning balance</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, ending balance</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_MedicaidMember', window );">Medicaid | US | Government and State Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, beginning balance</a></td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">1,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, ending balance</a></td>
<td class="nump">1,421<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">1,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_MedicareMember', window );">Medicare | US | Government and State Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, beginning balance</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns', window );">Provisions for discounts, rebates and sales returns, ending balance</a></td>
<td class="nump">&#8364; 1,099<span></span>
</td>
<td class="nump">&#8364; 775<span></span>
</td>
<td class="nump">&#8364; 941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments made for discounts, rebates and sales returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net change in provisions related to prior period sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in scope of consolidation in provision for discounts rebates and sales returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency translation differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision related to current period sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ProvisionsForDiscountsRebatesAndSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provisions for discounts, rebates and sales returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ProvisionsForDiscountsRebatesAndSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_GovernmentAndStateProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_GovernmentAndStateProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ManagedCareAndGPOProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ManagedCareAndGPOProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ChargebackIncentivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ChargebackIncentivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_RebatesAndDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_RebatesAndDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_SalesReturnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_SalesReturnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_OtherDeductionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_OtherDeductionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=sny_ManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=sny_ManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sny_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sny_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sny_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sny_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>242
<FILENAME>R196.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348522441328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Personnel costs - Summary of Personal Costs (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EmployeeBenefitsAbstract', window );"><strong>Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Salaries</a></td>
<td class="nump">&#8364; 7,183<span></span>
</td>
<td class="nump">&#8364; 7,145<span></span>
</td>
<td class="nump">&#8364; 6,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security charges (including defined-contribution pension plans)</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,098<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Other employee expense</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">748<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total</a></td>
<td class="nump">&#8364; 9,814<span></span>
</td>
<td class="nump">&#8364; 9,991<span></span>
</td>
<td class="nump">&#8364; 9,340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEmployeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employee expenses that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEmployeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EmployeeBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Benefits [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EmployeeBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>243
<FILENAME>R197.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523900704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Personnel costs - Additional Information (Details) - employee<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_EmployeeBenefitsAbstract', window );"><strong>Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="nump">87,994<span></span>
</td>
<td class="nump">91,573<span></span>
</td>
<td class="nump">95,442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_EmployeeBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Benefits [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_EmployeeBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>244
<FILENAME>R198.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348507887888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeLineItems', window );"><strong>Disclosure Of Other Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">&#8364; 1,292<span></span>
</td>
<td class="nump">&#8364; 1,969<span></span>
</td>
<td class="nump">&#8364; 859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeStatementLocation1Axis=sny_OtherOperatingIncomeExpense1Member', window );">Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeLineItems', window );"><strong>Disclosure Of Other Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsOnDivestmentOfProducts', window );">Gains on divestment of some mature products</a></td>
<td class="nump">688<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember', window );">Regeneron | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeLineItems', window );"><strong>Disclosure Of Other Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeLineItems', window );"><strong>Disclosure Of Other Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">&#8364; 290<span></span>
</td>
<td class="nump">&#8364; 1,178<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_DaiichiSankyoMember', window );">Daiichi Sankyo | Other operating income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeLineItems', window );"><strong>Disclosure Of Other Operating Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherOperatingIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Other Operating Income [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherOperatingIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainsOnDivestmentOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains on divestment of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainsOnDivestmentOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeStatementLocation1Axis=sny_OtherOperatingIncomeExpense1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeStatementLocation1Axis=sny_OtherOperatingIncomeExpense1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=sny_DaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=sny_DaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>245
<FILENAME>R199.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533572464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating expenses - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expense</a></td>
<td class="nump">&#8364; 3,516<span></span>
</td>
<td class="nump">&#8364; 2,531<span></span>
</td>
<td class="nump">&#8364; 1,805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>246
<FILENAME>R200.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516078256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other operating expenses - Other Income and Expense (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">&#8364; (3,516)<span></span>
</td>
<td class="num">&#8364; (2,531)<span></span>
</td>
<td class="num">&#8364; (1,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">1,969<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating income/(expenses), net related to Regeneron</a></td>
<td class="num">(2,979)<span></span>
</td>
<td class="num">(1,231)<span></span>
</td>
<td class="num">(1,373)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember', window );">Antibodies Collaboration agreement | Regeneron Pharmaceuticals, INC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CommitmentsReceivedForDevelopmentCosts', window );">Commitments received for development costs</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember', window );">Regeneron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(3,206)<span></span>
</td>
<td class="num">(2,378)<span></span>
</td>
<td class="num">(1,568)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeStatementLocation1Axis=sny_OtherOperatingIncomeExpense1Member', window );">Other operating income (expense) | Regeneron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibody Alliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(3,196)<span></span>
</td>
<td class="num">(2,367)<span></span>
</td>
<td class="num">(1,429)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibody Alliance | Share of profit or loss from commercialization of monoclonal antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(3,321)<span></span>
</td>
<td class="num">(2,325)<span></span>
</td>
<td class="num">(1,253)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibody Alliance | Share of profit or loss from commercialization of Zaltrap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember', window );">Monoclonal Antibody Alliance | Commercialization related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(543)<span></span>
</td>
<td class="num">(476)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_ImmunooncologyAllianceMember', window );">Immuno-Oncology Alliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sny_OthersCounterpartyMember', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems', window );"><strong>Disclosure Of Other Operating Income Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="nump">&#8364; 217<span></span>
</td>
<td class="nump">&#8364; 1,120<span></span>
</td>
<td class="num">&#8364; (12)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CommitmentsReceivedForDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Received For Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CommitmentsReceivedForDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfOtherOperatingIncomeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other operating income (expenses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfOtherOperatingIncomeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MiscellaneousOtherOperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other operating income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MiscellaneousOtherOperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeStatementLocation1Axis=sny_OtherOperatingIncomeExpense1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeStatementLocation1Axis=sny_OtherOperatingIncomeExpense1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeStatementLocation1Axis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeStatementLocation1Axis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeStatementLocation1Axis=sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeStatementLocation1Axis=sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeStatementLocation1Axis=sny_CommercializationRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeStatementLocation1Axis=sny_CommercializationRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sny_ImmunooncologyAllianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sny_ImmunooncologyAllianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sny_OthersCounterpartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sny_OthersCounterpartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>247
<FILENAME>R201.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526102784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses', window );">Employee-related expenses</a></td>
<td class="nump">&#8364; 489<span></span>
</td>
<td class="nump">&#8364; 507<span></span>
</td>
<td class="nump">&#8364; 193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories', window );">Charges, gains or losses on assets</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts', window );">Costs related to transformation programs</a></td>
<td class="nump">676<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherRestructuringCost', window );">Other</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Total</a></td>
<td class="nump">&#8364; 1,490<span></span>
</td>
<td class="nump">&#8364; 1,336<span></span>
</td>
<td class="nump">&#8364; 820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense of restructuring activities related to property plant and equipment to inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense Of Restructuring Activities, Transformation Programs Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherRestructuringCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherRestructuringCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>248
<FILENAME>R202.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523853712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs and similar items - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncreaseDecreaseInExpenseOfRestructuringActivities', window );">Increase in restructuring costs</a></td>
<td class="nump">&#8364; 154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncreaseDecreaseInExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Expense Of Restructuring Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncreaseDecreaseInExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>249
<FILENAME>R203.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348523936368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other gains and losses, and litigation (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains, (losses) and litigation</a></td>
<td class="nump">&#8364; 38<span></span>
</td>
<td class="nump">&#8364; 370<span></span>
</td>
<td class="nump">&#8364; 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>250
<FILENAME>R204.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348512248656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial expenses and income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems', window );"><strong>Disclosure of detailed information about finance income expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Cost of debt</a></td>
<td class="num">&#8364; (555)<span></span>
</td>
<td class="num">&#8364; (365)<span></span>
</td>
<td class="num">&#8364; (313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InterestIncome', window );">Interest income</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_CostOfDebtNet', window );">Cost of net debt</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NonOperatingForeignExchangeGainsLosses', window );">Non-operating foreign exchange gains/(losses)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions', window );">Unwinding of discounting of provisions</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NetInterestCostRelatedToEmployeeBenefits', window );">Net interest cost related to employee benefits</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets', window );">Gains/(losses) on disposals of financial assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Net interest expense on lease liabilities</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other</a></td>
<td class="num">(526)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial income/(expenses)</a></td>
<td class="num">(722)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(1,313)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
<td class="num">(368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_LiabilityRecognisedForEstimatedFutureRoyalties', window );">Liability recognised for estimated future royalties</a></td>
<td class="num">(541)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember', window );">Interest rate and currency derivatives used to hedge debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems', window );"><strong>Disclosure of detailed information about finance income expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesOnDerivativesUsedToManageDebt', window );">Gain on derivatives used to manage debt</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents', window );">Gain on derivatives used to manage cash and cash equivalents</a></td>
<td class="num">&#8364; (13)<span></span>
</td>
<td class="nump">&#8364; 68<span></span>
</td>
<td class="nump">&#8364; 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised due to the unwinding of the discount on provisions other than provisions for employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on available-for-sale financial assets. [Refer: Financial assets available-for-sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_20_a_ii&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_CostOfDebtNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of debt net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_CostOfDebtNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent detailed information about finance income expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on derivatives used to manage cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_GainsLossesOnDerivativesUsedToManageDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain derivatives used to manage debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_GainsLossesOnDerivativesUsedToManageDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_LiabilityRecognisedForEstimatedFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Recognised For Estimated Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_LiabilityRecognisedForEstimatedFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NetInterestCostRelatedToEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net interest cost related to employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NetInterestCostRelatedToEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NonOperatingForeignExchangeGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-operating foreign exchange gains/(losses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NonOperatingForeignExchangeGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgedItemsAxis=sny_InterestRateAndCurrencyDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>251
<FILENAME>R205.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533687792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current taxes</a></td>
<td class="num">&#8364; (2,560)<span></span>
</td>
<td class="num">&#8364; (2,774)<span></span>
</td>
<td class="num">&#8364; (1,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred taxes</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total</a></td>
<td class="num">(1,602)<span></span>
</td>
<td class="num">(2,006)<span></span>
</td>
<td class="num">(1,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="nump">&#8364; 7,153<span></span>
</td>
<td class="nump">&#8364; 10,422<span></span>
</td>
<td class="nump">&#8364; 7,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>252
<FILENAME>R206.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519314400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Standard tax rate applicable in France</a></td>
<td class="nump">25.80%<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
<td class="nump">28.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfForeignTaxRates', window );">Difference between the standard French tax rate and the rates applicable to the Sanofi</a></td>
<td class="num">(13.60%)<span></span>
</td>
<td class="num">(6.50%)<span></span>
</td>
<td class="num">(9.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes', window );">Revisions to tax exposures and settlements of tax disputes</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments', window );">Probable reversal of temporary differences on investments in Consumer Healthcare subsidiaries</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other items</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">22.40%<span></span>
</td>
<td class="nump">19.20%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Rate Effect Of Reversal Of Temporary Difference On Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Rate Effect Of Revisions To Tax Exposures And Settlements Of Tax Disputes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>253
<FILENAME>R207.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533626752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share of profit/loss from investments accounted for using the equity method (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="num">&#8364; (115)<span></span>
</td>
<td class="nump">&#8364; 68<span></span>
</td>
<td class="nump">&#8364; 39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss recognised in profit or loss</a></td>
<td class="nump">&#8364; 231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>254
<FILENAME>R208.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526850496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income attributable to non-controlling interests (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems', window );"><strong>Disclosure of net income attributable to non-controlling interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">&#8364; 36<span></span>
</td>
<td class="nump">&#8364; 113<span></span>
</td>
<td class="nump">&#8364; 56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember', window );">Share of net income attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems', window );"><strong>Disclosure of net income attributable to non-controlling interests [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">&#8364; 36<span></span>
</td>
<td class="nump">&#8364; 113<span></span>
</td>
<td class="nump">&#8364; 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of net income attributable to noncontrolling interests [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>255
<FILENAME>R209.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516446672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions - Additional Information (Details) - executives<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfExecutiveCommitteeMembers', window );">Average number of members of executive committee</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfExecutiveCommitteeMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of executive committee members.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfExecutiveCommitteeMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>256
<FILENAME>R210.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348534633616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions - Schedule of Compensation Paid to Key Management Personnel (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of compensation paid to key management personnel [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term benefits</a></td>
<td class="nump">&#8364; 36<span></span>
</td>
<td class="nump">&#8364; 31<span></span>
</td>
<td class="nump">&#8364; 33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payment</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total recognized in profit or loss</a></td>
<td class="nump">&#8364; 46<span></span>
</td>
<td class="nump">&#8364; 52<span></span>
</td>
<td class="nump">&#8364; 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>257
<FILENAME>R211.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348517961632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions - Summary of aggregate amounts Payable to Key Management Personnel (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee', window );">Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members</a></td>
<td class="nump">&#8364; 10<span></span>
</td>
<td class="nump">&#8364; 10<span></span>
</td>
<td class="nump">&#8364; 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits', window );">Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel</a></td>
<td class="nump">&#8364; 6<span></span>
</td>
<td class="nump">&#8364; 5<span></span>
</td>
<td class="nump">&#8364; 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate pension obligation in favor of certain corporate officers and of members of the executive committee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key management personnel compensation, termination benefits and lump sum retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>258
<FILENAME>R212.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348527086576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disclosures about major customers and credit risk (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_LargestCustomersMember', window );">Largest customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue (in percent)</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerOneMember', window );">Customer one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue (in percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember', window );">Customer two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue (in percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember', window );">Customer three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems', window );"><strong>Disclosure of information about major customers and credit risk [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue (in percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about major customers and credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_LargestCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_LargestCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=sny_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>259
<FILENAME>R213.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348532799312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Additional Information (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OperatingSegmentsAbstract', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments1', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Segments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>260
<FILENAME>R214.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348505342848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Summary of Net Sales by Segment and Geographical Area (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 43,070<span></span>
</td>
<td class="nump">&#8364; 42,997<span></span>
</td>
<td class="nump">&#8364; 37,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments1', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 37,890<span></span>
</td>
<td class="nump">&#8364; 37,812<span></span>
</td>
<td class="nump">33,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Specialty Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">18,040<span></span>
</td>
<td class="nump">16,457<span></span>
</td>
<td class="nump">12,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | DUPIXENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">10,715<span></span>
</td>
<td class="nump">8,293<span></span>
</td>
<td class="nump">5,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | AUBAGIO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">955<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | CEREZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">707<span></span>
</td>
<td class="nump">683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | FABRAZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | MYOZYME/ LUMIZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">783<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | JEVTANA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | General Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">12,376<span></span>
</td>
<td class="nump">14,127<span></span>
</td>
<td class="nump">14,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Core Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">6,270<span></span>
</td>
<td class="nump">6,389<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | LOVENOX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | TOUJEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,123<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | PLAVIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">948<span></span>
</td>
<td class="nump">983<span></span>
</td>
<td class="nump">929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Non-Core Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">5,524<span></span>
</td>
<td class="nump">7,118<span></span>
</td>
<td class="nump">7,642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | LANTUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">2,259<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Other non-core assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">3,687<span></span>
</td>
<td class="nump">4,381<span></span>
</td>
<td class="nump">4,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Industrial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">620<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">7,474<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
<td class="nump">6,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Polio/Pertussis/ Hib Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,165<span></span>
</td>
<td class="nump">2,285<span></span>
</td>
<td class="nump">2,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma | Influenza Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,669<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
<td class="nump">2,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">5,185<span></span>
</td>
<td class="nump">4,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare | Allergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">769<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare | Pain Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">1,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare | Digestive Wellness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,502<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">10,392<span></span>
</td>
<td class="nump">9,999<span></span>
</td>
<td class="nump">9,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">8,835<span></span>
</td>
<td class="nump">8,498<span></span>
</td>
<td class="nump">8,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | Specialty Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">3,206<span></span>
</td>
<td class="nump">3,016<span></span>
</td>
<td class="nump">2,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | DUPIXENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,224<span></span>
</td>
<td class="nump">940<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | AUBAGIO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | CEREZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | FABRAZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | MYOZYME/ LUMIZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | JEVTANA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | General Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">3,932<span></span>
</td>
<td class="nump">4,141<span></span>
</td>
<td class="nump">4,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | Core Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">1,917<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | LOVENOX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | TOUJEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">441<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | PLAVIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | Non-Core Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">1,637<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | LANTUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | Other non-core assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">961<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | Industrial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | Polio/Pertussis/ Hib Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Biopharma | Influenza Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">1,501<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Consumer Healthcare | Allergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Consumer Healthcare | Pain Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">502<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe | Consumer Healthcare | Digestive Wellness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">18,512<span></span>
</td>
<td class="nump">18,275<span></span>
</td>
<td class="nump">14,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">17,265<span></span>
</td>
<td class="nump">16,985<span></span>
</td>
<td class="nump">13,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | Specialty Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">11,917<span></span>
</td>
<td class="nump">10,848<span></span>
</td>
<td class="nump">7,847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | DUPIXENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">8,145<span></span>
</td>
<td class="nump">6,346<span></span>
</td>
<td class="nump">3,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | AUBAGIO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | CEREZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | FABRAZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | MYOZYME/ LUMIZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | JEVTANA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | General Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,084<span></span>
</td>
<td class="nump">2,846<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | Core Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">1,653<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | LOVENOX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | TOUJEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | PLAVIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | Non-Core Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">592<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | LANTUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | Other non-core assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | Industrial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">3,264<span></span>
</td>
<td class="nump">3,291<span></span>
</td>
<td class="nump">2,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | Polio/Pertussis/ Hib Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Biopharma | Influenza Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Consumer Healthcare | Allergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Consumer Healthcare | Pain Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States | Consumer Healthcare | Digestive Wellness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">14,166<span></span>
</td>
<td class="nump">14,723<span></span>
</td>
<td class="nump">13,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">11,790<span></span>
</td>
<td class="nump">12,329<span></span>
</td>
<td class="nump">11,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | Specialty Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,917<span></span>
</td>
<td class="nump">2,593<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | DUPIXENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,346<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | AUBAGIO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | CEREZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | FABRAZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | MYOZYME/ LUMIZYME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | JEVTANA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | General Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">6,360<span></span>
</td>
<td class="nump">7,140<span></span>
</td>
<td class="nump">7,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | Core Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,797<span></span>
</td>
<td class="nump">2,819<span></span>
</td>
<td class="nump">2,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | LOVENOX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">635<span></span>
</td>
<td class="nump">754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | TOUJEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | PLAVIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | Non-Core Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">3,536<span></span>
</td>
<td class="nump">4,305<span></span>
</td>
<td class="nump">4,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | LANTUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">782<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | Other non-core assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,424<span></span>
</td>
<td class="nump">2,840<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | Industrial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,513<span></span>
</td>
<td class="nump">2,596<span></span>
</td>
<td class="nump">2,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | Polio/Pertussis/ Hib Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">1,504<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Biopharma | Influenza Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,376<span></span>
</td>
<td class="nump">2,394<span></span>
</td>
<td class="nump">1,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Consumer Healthcare | Allergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Consumer Healthcare | Pain Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember', window );">Other countries | Consumer Healthcare | Digestive Wellness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 844<span></span>
</td>
<td class="nump">&#8364; 822<span></span>
</td>
<td class="nump">&#8364; 618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_SpecialtyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_SpecialtyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_DupixentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_DupixentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_AubagioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_AubagioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_CerezymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_CerezymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_FabrazymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_FabrazymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_MyozymeOrLumizymeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_MyozymeOrLumizymeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_JevtanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_JevtanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_AlprolixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_AlprolixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_EloctateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_EloctateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_GeneralMedecinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_GeneralMedecinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_CoreAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_CoreAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_LovenoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_LovenoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_ToujeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_ToujeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_PlavixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_PlavixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_NonCoreAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_NonCoreAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_LantusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_LantusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_OtherNonCoreAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_OtherNonCoreAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_VaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_VaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_InfluenzaVaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_InfluenzaVaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_AllergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_AllergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_PainCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_PainCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_DigestiveWellnessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_DigestiveWellnessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>261
<FILENAME>R215.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348533722624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Schedule of Segment Results (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 43,070<span></span>
</td>
<td class="nump">&#8364; 42,997<span></span>
</td>
<td class="nump">&#8364; 37,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">3,374<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(14,236)<span></span>
</td>
<td class="num">(13,695)<span></span>
</td>
<td class="num">(12,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(6,728)<span></span>
</td>
<td class="num">(6,706)<span></span>
</td>
<td class="num">(5,692)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(10,692)<span></span>
</td>
<td class="num">(10,492)<span></span>
</td>
<td class="num">(9,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="num">(115)<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">&#8364; 36<span></span>
</td>
<td class="nump">&#8364; 113<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_NumberOfOperatingSegments1', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember', window );">Total Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 43,070<span></span>
</td>
<td class="nump">&#8364; 42,997<span></span>
</td>
<td class="nump">37,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">3,374<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(14,216)<span></span>
</td>
<td class="num">(13,692)<span></span>
</td>
<td class="num">(12,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(6,728)<span></span>
</td>
<td class="num">(6,706)<span></span>
</td>
<td class="num">(5,692)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(10,692)<span></span>
</td>
<td class="num">(10,492)<span></span>
</td>
<td class="num">(9,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="num">(2,224)<span></span>
</td>
<td class="num">(1,514)<span></span>
</td>
<td class="num">(946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="nump">12,670<span></span>
</td>
<td class="nump">13,040<span></span>
</td>
<td class="nump">10,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">37,890<span></span>
</td>
<td class="nump">37,812<span></span>
</td>
<td class="nump">33,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">3,322<span></span>
</td>
<td class="nump">2,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(12,282)<span></span>
</td>
<td class="num">(11,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(6,509)<span></span>
</td>
<td class="num">(6,503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(8,868)<span></span>
</td>
<td class="num">(8,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="num">(2,387)<span></span>
</td>
<td class="num">(1,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="nump">11,247<span></span>
</td>
<td class="nump">11,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_PharmaceuticalsSegmentMember', window );">Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_VaccinesSegmentMember', window );">Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,430)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(805)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">5,185<span></span>
</td>
<td class="nump">4,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(1,933)<span></span>
</td>
<td class="num">(1,903)<span></span>
</td>
<td class="num">(1,606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(219)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="num">(1,828)<span></span>
</td>
<td class="num">(1,761)<span></span>
</td>
<td class="num">(1,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling and general expenses</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(2,036)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_MiscellaneousOtherOperatingIncomeExpenses', window );">Other operating income and expenses</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="num">&#8364; (15)<span></span>
</td>
<td class="nump">&#8364; 28<span></span>
</td>
<td class="num">&#8364; (2,797)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_MiscellaneousOtherOperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other operating income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_MiscellaneousOtherOperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_NumberOfOperatingSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_NumberOfOperatingSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_PharmaceuticalsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_PharmaceuticalsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_VaccinesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_VaccinesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>262
<FILENAME>R216.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348516998048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (115)<span></span>
</td>
<td class="nump">&#8364; 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,490)<span></span>
</td>
<td class="num">(1,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,875<span></span>
</td>
<td class="nump">10,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,313)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments', window );">Income before tax and investments accounted for using the equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,153<span></span>
</td>
<td class="nump">10,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember', window );">Immuno-oncology collaboration agreement | Regeneron Pharmaceuticals, INC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements', window );">Upfront payments for projects under collaboration agreements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements', window );">Regular milestone payments for projects under collaboration agreements</a></td>
<td class="nump">&#8364; 96<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill', window );">Impairment of other intangible assets, net of reversals (excluding software)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">932<span></span>
</td>
<td class="num">(454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | NK Cell and ProXTen technology platforms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill', window );">Impairment of other intangible assets, net of reversals (excluding software)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | SAR444245</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill', window );">Impairment of other intangible assets, net of reversals (excluding software)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sny_EloctateMember', window );">ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount', window );">Reversal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessOperatingIncome', window );">Business operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,670<span></span>
</td>
<td class="nump">13,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember', window );">Material reconciling items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Share of profit/(loss) from investments accounted for using the equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Net income attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill', window );">Amortization and impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,068)<span></span>
</td>
<td class="num">(1,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories', window );">Expenses arising from the impact of acquisitions on inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseOfRestructuringActivities', window );">Restructuring costs and similar items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,490)<span></span>
</td>
<td class="num">(1,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_OtherGainsLossesAndLitigation', window );">Other gains and losses, and litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_IncomeResultingFromOutLicensing', window );">Income from out-licensing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseOfRestructuringActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseOfRestructuringActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a contingent consideration asset (liability) relating to a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and impairment of intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses arising from the impact of acquisitions on inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment loss on intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Loss Recognised In Profit Or Loss, Intangible Assets Other Than Goodwill, Reversal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before tax and investments accounted for equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_IncomeResultingFromOutLicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Resulting From Out-Licensing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_IncomeResultingFromOutLicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_OtherGainsLossesAndLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_OtherGainsLossesAndLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regular Milestone Payments For Projects Under Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payments For Projects Under Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_NKCellAndProXTenTechnologyPlatformsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_NKCellAndProXTenTechnologyPlatformsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=sny_SAR444245Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=sny_SAR444245Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sny_EloctateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sny_EloctateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>263
<FILENAME>R217.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348526008656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember', window );">Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InvestmentsInAssociatesAndJointVentures', window );">Investments accounted for using the equity method</a></td>
<td class="nump">&#8364; 262<span></span>
</td>
<td class="nump">&#8364; 285<span></span>
</td>
<td class="nump">&#8364; 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of other intangible assets</a></td>
<td class="nump">1,305<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_PharmaceuticalsSegmentMember', window );">Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InvestmentsInAssociatesAndJointVentures', window );">Investments accounted for using the equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_VaccinesSegmentMember', window );">Vaccines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InvestmentsInAssociatesAndJointVentures', window );">Investments accounted for using the equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember', window );">Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InvestmentsInAssociatesAndJointVentures', window );">Investments accounted for using the equity method</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="nump">1,619<span></span>
</td>
<td class="nump">1,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of other intangible assets</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember', window );">Consumer Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_InvestmentsInAssociatesAndJointVentures', window );">Investments accounted for using the equity method</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of other intangible assets</a></td>
<td class="nump">&#8364; 18<span></span>
</td>
<td class="nump">&#8364; 21<span></span>
</td>
<td class="nump">&#8364; 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_InvestmentsInAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments, joint ventures and associates in an entity's separate financial statements. Long term equity interest, significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_InvestmentsInAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_PharmaceuticalsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_PharmaceuticalsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_VaccinesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_VaccinesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>264
<FILENAME>R218.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519102368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">&#8364; 43,070<span></span>
</td>
<td class="nump">&#8364; 42,997<span></span>
</td>
<td class="nump">&#8364; 37,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment owned</a></td>
<td class="nump">10,160<span></span>
</td>
<td class="nump">9,869<span></span>
</td>
<td class="nump">10,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">49,404<span></span>
</td>
<td class="nump">49,892<span></span>
</td>
<td class="nump">48,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">24,319<span></span>
</td>
<td class="nump">21,640<span></span>
</td>
<td class="nump">21,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_ReportableGeographicalZonesMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">43,070<span></span>
</td>
<td class="nump">42,997<span></span>
</td>
<td class="nump">37,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment owned</a></td>
<td class="nump">10,160<span></span>
</td>
<td class="nump">9,869<span></span>
</td>
<td class="nump">10,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">49,404<span></span>
</td>
<td class="nump">49,892<span></span>
</td>
<td class="nump">48,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">24,319<span></span>
</td>
<td class="nump">21,640<span></span>
</td>
<td class="nump">21,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">10,392<span></span>
</td>
<td class="nump">9,999<span></span>
</td>
<td class="nump">9,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment owned</a></td>
<td class="nump">5,659<span></span>
</td>
<td class="nump">5,365<span></span>
</td>
<td class="nump">5,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">5,566<span></span>
</td>
<td class="nump">6,257<span></span>
</td>
<td class="nump">7,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">2,296<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment owned</a></td>
<td class="nump">3,085<span></span>
</td>
<td class="nump">2,875<span></span>
</td>
<td class="nump">3,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember', window );">North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">19,216<span></span>
</td>
<td class="nump">18,984<span></span>
</td>
<td class="nump">15,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment owned</a></td>
<td class="nump">3,316<span></span>
</td>
<td class="nump">3,284<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">17,852<span></span>
</td>
<td class="nump">14,178<span></span>
</td>
<td class="nump">13,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">18,512<span></span>
</td>
<td class="nump">18,275<span></span>
</td>
<td class="nump">14,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment owned</a></td>
<td class="nump">2,322<span></span>
</td>
<td class="nump">2,457<span></span>
</td>
<td class="nump">2,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember', window );">Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">13,462<span></span>
</td>
<td class="nump">14,014<span></span>
</td>
<td class="nump">12,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment owned</a></td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="nump">&#8364; 901<span></span>
</td>
<td class="nump">&#8364; 1,205<span></span>
</td>
<td class="nump">&#8364; 1,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_ReportableGeographicalZonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_ReportableGeographicalZonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>265
<FILENAME>R219.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348519088032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal accountants' fees and services (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAuditFeesAndOtherServicesLineItems', window );"><strong>Disclosure of audit fees and other services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices', window );">Auditor's remuneration for comfort letters and attestation services</a></td>
<td class="nump">&#8364; 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AuditorsNameAxis=sny_ErnstAndYoungMember', window );">Ernst&#160;&amp;&#160;Young</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAuditFeesAndOtherServicesLineItems', window );"><strong>Disclosure of audit fees and other services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">Statutory audit of separate and consolidated financial statements</a></td>
<td class="nump">15.1<span></span>
</td>
<td class="nump">&#8364; 14.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ServicesOtherThanStatutoryAudit', window );">Services other than statutory audit</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AuditorsRemunerationForAuditRelatedServices', window );">Audit-related services</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForTaxServices', window );">Tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForOtherServices', window );">Other</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Total</a></td>
<td class="nump">&#8364; 20.5<span></span>
</td>
<td class="nump">&#8364; 16.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfAuditorRemunerationForStatutoryAudit', window );">Statutory audit of separate and consolidated financial statements, percentage</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements', window );">Services other than statutory audit, percentage</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfAuditorsRemuneration', window );">Total, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries', window );">Audit of the financial statements of the parent company and its French subsidiaries</a></td>
<td class="nump">&#8364; 7.9<span></span>
</td>
<td class="nump">&#8364; 7.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries', window );">Audit-related services charged to the parent company and its French subsidiaries</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AuditorsNameAxis=sny_PricewaterhousecoopersMember', window );">PricewaterhouseCoopers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_DisclosureOfAuditFeesAndOtherServicesLineItems', window );"><strong>Disclosure of audit fees and other services [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">Statutory audit of separate and consolidated financial statements</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_ServicesOtherThanStatutoryAudit', window );">Services other than statutory audit</a></td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AuditorsRemunerationForAuditRelatedServices', window );">Audit-related services</a></td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForTaxServices', window );">Tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForOtherServices', window );">Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Total</a></td>
<td class="nump">&#8364; 20.5<span></span>
</td>
<td class="nump">&#8364; 14.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfAuditorRemunerationForStatutoryAudit', window );">Statutory audit of separate and consolidated financial statements, percentage</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements', window );">Services other than statutory audit, percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_PercentageOfAuditorsRemuneration', window );">Total, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries', window );">Audit of the financial statements of the parent company and its French subsidiaries</a></td>
<td class="nump">&#8364; 8.3<span></span>
</td>
<td class="nump">&#8364; 7.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries', window );">Audit-related services charged to the parent company and its French subsidiaries</a></td>
<td class="nump">&#8364; 5.3<span></span>
</td>
<td class="nump">&#8364; 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForAuditServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for auditing services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForAuditServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForOtherServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for services that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForOtherServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForTaxServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for tax services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForTaxServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit of the financial statements of the parent company and its French subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit-related services charged to the parent company and its French subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AuditorsRemunerationForAuditRelatedServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor's remuneration for audit related services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AuditorsRemunerationForAuditRelatedServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor's Remuneration For Audit Related Services, Comfort Letters And Attestation Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_DisclosureOfAuditFeesAndOtherServicesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of audit fees and other services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_DisclosureOfAuditFeesAndOtherServicesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfAuditorRemunerationForStatutoryAudit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of auditor remuneration for statutory audit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfAuditorRemunerationForStatutoryAudit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfAuditorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor's remuneration, Total Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfAuditorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Services other than audit of financial statements, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_ServicesOtherThanStatutoryAudit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Services other than statutory audit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_ServicesOtherThanStatutoryAudit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AuditorsNameAxis=sny_ErnstAndYoungMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AuditorsNameAxis=sny_ErnstAndYoungMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_AuditorsNameAxis=sny_PricewaterhousecoopersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_AuditorsNameAxis=sny_PricewaterhousecoopersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>266
<FILENAME>R220.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348508397904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>List of principal companies included in the scope of consolidation during&#160;2023 - Summary of Principal Companies and their Country of Incorporation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_HoechstGmbHMember', window );">Hoechst GmbH | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeutschlandGmbHMember', window );">Sanofi-Aventis Deutschland GmbH | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_A.NattermannCie.GmbHMember', window );">A. Nattermann &amp; Cie. GmbH | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGmbHMember', window );">Sanofi-Aventis GmbH | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBelgiumMember', window );">Sanofi Belgium | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AblynxMember', window );">Ablynx NV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeFlandersBVBAMember', window );">Genzyme Flanders BV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiASMember', window );">Sanofi A/S | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSAMember', window );">Sanofi-Aventis SA | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareSpainSLMember', window );">Opella Healthcare Spain, SL | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiOyMember', window );">Sanofi Oy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMember', window );">Sanofi | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisFranceMember', window );">Sanofi-Aventis France | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiWinthropIndustriesMember', window );">Sanofi Winthrop Industrie | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisRechercheEtDeveloppementMember', window );">Sanofi-Aventis Recherche &amp; D&#233;veloppement | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGroupeMember', window );">Sanofi-Aventis Groupe | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiChimieMember', window );">Sanofi Chimie | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisParticipationsSASMember', window );">Sanofi-Aventis Participations | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurFranceSAMember', window );">Sanofi Pasteur | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaSAFranceMember', window );">Aventis Pharma S.A. | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBiotechnologyMember', window );">Sanofi Biotechnology | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMatureIPMember', window );">Sanofi Mature IP | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurNVLMember', window );">Sanofi Pasteur NVL | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurEuropeMember', window );">Sanofi Pasteur Europe | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SECIPESASMember', window );">SECIPE SAS | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurMerieuxSASMember', window );">Sanofi Pasteur Merieux SAS | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareInternationalSASMember', window );">Opella Healthcare International SAS | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareFranceSASMember', window );">Opella Healthcare France SAS | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareGroupSASMember', window );">Opella Healthcare Group SAS | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymePolyclonalsSASMember', window );">Genzyme Polyclonals SAS | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiaventisAEBEMember', window );">Sanofi-Aventis A.E.B.E. | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPrivateCoLtdMember', window );">Sanofi-Aventis Private Co, Ltd | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">99.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChinoinPrivateCoLtdMember', window );">Chinoin Private Co. Ltd | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">99.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareHungaryCommercialKFTMember', window );">Opella Healthcare Hungary Commercial K.F.T | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">99.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareHungaryKFTMember', window );">Opella Healthcare Hungary K.F.T | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">99.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_CarraigInsuranceDACMember', window );">Carraig Insurance DAC | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeIrelandLimitedMember', window );">Genzyme Ireland Limited | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisHoldingsIrelandLtdMember', window );">Sanofi-Aventis Holdings (Ireland) Ltd | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSRLMember', window );">Sanofi SRL | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareItalySRLMember', window );">Opella Healthcare Italy SRL | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeGlobalSarlMember', window );">Genzyme Global Sarl | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeLuxembourgSarlMember', window );">Genzyme Luxembourg Sarl | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisNorgeASMember', window );">Sanofi-Aventis Norge AS | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBVMember', window );">Sanofi BV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiForeignParticipationsB.V.Member', window );">Sanofi Foreign Participations BV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiaventisSpZooMember', window );">Sanofi-Aventis Sp. z.o.o. | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePolandSpZOOMember', window );">Opella Healthcare Poland sp.z.o.o. | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurSpZooMember', window );">Sanofi Pasteur Sp. z.o.o. | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiProdutosFarmaceuticosLdaMember', window );">Sanofi Produtos Farmaceuticos Lda | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSROMember', window );">Sanofi-Aventis, s.r.o. | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareCzechSroMember', window );">Opella Healthcare Czech s.r.o | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisRomaniaSRLMember', window );">Sanofi Romania SRL | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareRomaniaSRLMember', window );">Opella Healthcare Romania SRL | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisUkHoldingsLimitedMember', window );">Sanofi-Aventis UK Holdings Limited | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaLimitedMember', window );">Aventis Pharma Limited | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSynthelaboUKLtdMember', window );">Sanofi-Synthelabo UK Ltd | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaHoldingsLtdMember', window );">Aventis Pharma Holdings Ltd | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareUKLimitedMember', window );">Opella Healthcare UK Limited | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AOSanofiRussiaMember', window );">AO Sanofi Russia | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareLLCMember', window );">Opella Healthcare LLC | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiABMember', window );">Sanofi AB | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSuisseSAMember', window );">Sanofi-Aventis (Suisse) SA | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember', window );">Genzyme Global Sarl Baar Intellectual Property Branch | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiIlacSanayiVeTicaretASMember', window );">Sanofi Ilac Sanayi ve Ticaret AS | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurAsiTicaretASMember', window );">Sanofi Pasteur Asi Ticaret AS | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareTuketiciSalAnonimSirketiMember', window );">Opella Healthcare T&#252;ketici Sa&#287;l&#305;&#287;&#305; Anonim &#350;irketi | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSaglikUrunleriLimitedSirketiMember', window );">Sanofi Saglik Urunleri Limited Sirketi | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeTherapeuticProductsLimitedPartnershipMember', window );">Genzyme Therapeutic Products Limited Partnership | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisIncMember', window );">Aventis Inc. | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiUSServicesIncMember', window );">Sanofi US Services Inc. | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisUSLLCMember', window );">Sanofi-Aventis U.S. LLC | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChattemIncMember', window );">Chattem, Inc. | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisubLLCMember', window );">Aventisub LLC | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeCorporationMember', window );">Genzyme Corporation | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurIncMember', window );">Sanofi Pasteur Inc. | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_VaxServeIncMember', window );">VaxServe, Inc. | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativIncMember', window );">Bioverativ Inc. | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativUSLLCMember', window );">Bioverativ U.S. LLC | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativTherapeuticsIncMember', window );">Bioverativ Therapeutics Inc. | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_PrincipiaBiopharmaIncMember', window );">Principia Biopharma Inc. | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiResearchInvestLLCMember', window );">Sanofi Research Invest LLC | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBioverativHoldingsLLCMember', window );">Sanofi Bioverativ Holdings LLC | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_RPRUSLtdMember', window );">RPR US Ltd. | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_KadmonCorporationLLCMember', window );">Kadmon Corporation, LLC | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AmunixMember', window );">Amunix | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SynthorxIncMember', window );">Synthorx, Inc | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ProventionBioMember', window );">Provention Bio | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_QRIBIntermediateHoldingsLLCMember', window );">QRIB Intermediate Holding | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_QRIMember', window );">QRI | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_TargeGenIncMember', window );">TargeGen Inc. | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChattemGBHoldingMember', window );">Chattem (GB) Holding | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_TranslateBioIncMember', window );">Translate Bio, Inc. | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSouthAfricaPtyLtdMember', window );">Sanofi-Aventis South Africa (Pty) Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisAlgerieMember', window );">Sanofi-Aventis Alg&#233;rie | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiArabiaTradingCompanyLimitedMember', window );">Sanofi Arabia Trading Company Limited | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisArgentinaSAMember', window );">Sanofi-Aventis Argentina SA | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisHealthcarePtyLtdMember', window );">Sanofi-Aventis Healthcare Pty Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisAustraliaPtyLtdMember', window );">Sanofi-Aventis Australia Pty Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMedleyFarmaceuticaLtdaMember', window );">Sanofi Medley Farmaceutica Ltda | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareBrazilLtdaMember', window );">Opella Healthcare Brazil Ltda. | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisCanadaIncMember', window );">Sanofi-Aventis Canada Inc. | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurLimitedMember', window );">Sanofi Pasteur Limited | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_MerieuxCanadaHoldingsULCCanadaMember', window );">Merieux Canada Holdings ULC (Canada) | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHangzhouPharmaceuticalsCoLtdMember', window );">Sanofi (Hangzhou) Pharmaceuticals Co., Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiChinaInvestmentCoLtdMember', window );">Sanofi (China) Investment Co., Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBeijingPharmaceuticalsCoLtdMember', window );">Sanofi (Beijing) Pharmaceuticals Co.Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurBiologiesCo.LtdMember', window );">Sanofi Pasteur Biologies Co., Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember', window );">Shenzhen Sanofi pasteur Biological Products Co, Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ShanghaiRonghengPharmaceuticalCoLtdMember', window );">Shanghai Rongheng Pharmaceutical Co, Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeColombiaSAMember', window );">Sanofi-Aventis de Colombia SA | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisKoreaCoLtdMember', window );">Sanofi-Aventis Korea Co. Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurLtdMember', window );">Sanofi Pasteur Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareKoreaIncMember', window );">Opella healthcare Korea Inc. | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGulfFZEMember', window );">Sanofi-Aventis Gulf FZE | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiEgyptSAEMember', window );">Sanofi Egypt | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">99.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHongKongLimitedMember', window );">Sanofi Hong-Kong Limited | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiIndiaLimitedMember', window );">Sanofi India Limited | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">60.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHealthcareIndiaPrivateLimitedMember', window );">Sanofi Healthcare India Private Limited | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">99.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisIsraelLtdMember', window );">Sanofi-Aventis Isra&#235;l Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiKKMember', window );">Sanofi K.K. | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SspCoLtdMember', window );">SSP Co.,Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisMalaysiaSDNBHDMember', window );">Sanofi-Aventis (Malaysia) SDN. BHD. | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisMarocMember', window );">Sanofi-Aventis Maroc | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeMexicoSADeCVMember', window );">Sanofi-Aventis de Mexico SA de CV | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurS.A.deC.V.Member', window );">Sanofi Pasteur SA de CV | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AztecaVacunasSADeCVMember', window );">Azteca Vacunas, SA de CV | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDePanamaSAMember', window );">Sanofi-Aventis de Panama SA | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePanamaSAMember', window );">Opella Healthcare Panama SA | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPuertoRicoIncMember', window );">Sanofi-Aventis Puerto Rico Inc | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPhilippinesIncMember', window );">Sanofi-Aventis Philippines Inc. | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePhilippinesIncMember', window );">Opella Healthcare Philippines Inc. | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSingaporePteLtdMember', window );">Sanofi-Aventis Singapore Pte. Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaManufacturingPTELTDMember', window );">Aventis Pharma (Manufacturing) Pte. Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiManufacturingPteLtdMember', window );">Sanofi Manufacturing Pte Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiTaiwanCoLtdMember', window );">Sanofi Taiwan Co., Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisThailandLtdMember', window );">Sanofi-Aventis (Thailand) Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurThailandLtdMember', window );">Sanofi Pasteur Ltd | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeVenezuelaSAMember', window );">Sanofi-Aventis de Venezuela SA | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisVietnamCompanyLimitedMember', window );">Sanofi-Aventis Vietnam Company Limited | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiVietnamShareholdingCompanyLimitedMember', window );">Sanofi Vietnam Shareholding Company Limited | Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Financial interest in principal fully consolidated companies</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_HoechstGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_HoechstGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeutschlandGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeutschlandGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_A.NattermannCie.GmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_A.NattermannCie.GmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBelgiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBelgiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AblynxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AblynxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeFlandersBVBAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeFlandersBVBAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareSpainSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareSpainSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiOyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiOyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiWinthropIndustriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiWinthropIndustriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisRechercheEtDeveloppementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisRechercheEtDeveloppementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGroupeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGroupeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiChimieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiChimieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisParticipationsSASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisParticipationsSASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurFranceSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurFranceSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaSAFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaSAFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBiotechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBiotechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMatureIPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMatureIPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurNVLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurNVLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SECIPESASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SECIPESASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurMerieuxSASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurMerieuxSASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareInternationalSASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareInternationalSASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareFranceSASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareFranceSASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareGroupSASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareGroupSASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymePolyclonalsSASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymePolyclonalsSASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiaventisAEBEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiaventisAEBEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPrivateCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPrivateCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChinoinPrivateCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChinoinPrivateCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareHungaryCommercialKFTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareHungaryCommercialKFTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareHungaryKFTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareHungaryKFTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_CarraigInsuranceDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_CarraigInsuranceDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeIrelandLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeIrelandLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisHoldingsIrelandLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisHoldingsIrelandLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareItalySRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareItalySRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeGlobalSarlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeGlobalSarlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeLuxembourgSarlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeLuxembourgSarlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisNorgeASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisNorgeASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiForeignParticipationsB.V.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiForeignParticipationsB.V.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiaventisSpZooMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiaventisSpZooMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePolandSpZOOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePolandSpZOOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurSpZooMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurSpZooMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiProdutosFarmaceuticosLdaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiProdutosFarmaceuticosLdaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSROMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSROMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareCzechSroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareCzechSroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisRomaniaSRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisRomaniaSRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareRomaniaSRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareRomaniaSRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisUkHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisUkHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSynthelaboUKLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSynthelaboUKLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaHoldingsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaHoldingsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AOSanofiRussiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AOSanofiRussiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSuisseSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSuisseSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiIlacSanayiVeTicaretASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiIlacSanayiVeTicaretASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurAsiTicaretASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurAsiTicaretASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareTuketiciSalAnonimSirketiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareTuketiciSalAnonimSirketiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSaglikUrunleriLimitedSirketiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiSaglikUrunleriLimitedSirketiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeTherapeuticProductsLimitedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeTherapeuticProductsLimitedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiUSServicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiUSServicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisUSLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisUSLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChattemIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChattemIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_GenzymeCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_VaxServeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_VaxServeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativUSLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativUSLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_BioverativTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_PrincipiaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_PrincipiaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiResearchInvestLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiResearchInvestLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBioverativHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBioverativHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_RPRUSLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_RPRUSLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_KadmonCorporationLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_KadmonCorporationLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AmunixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AmunixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SynthorxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SynthorxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_QRIBIntermediateHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_QRIBIntermediateHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_QRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_QRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_TargeGenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_TargeGenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChattemGBHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ChattemGBHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_TranslateBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_TranslateBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSouthAfricaPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSouthAfricaPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=sny_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisAlgerieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisAlgerieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiArabiaTradingCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiArabiaTradingCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisArgentinaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisArgentinaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisHealthcarePtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisHealthcarePtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisAustraliaPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisAustraliaPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMedleyFarmaceuticaLtdaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiMedleyFarmaceuticaLtdaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareBrazilLtdaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareBrazilLtdaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisCanadaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisCanadaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_MerieuxCanadaHoldingsULCCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_MerieuxCanadaHoldingsULCCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHangzhouPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHangzhouPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiChinaInvestmentCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiChinaInvestmentCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBeijingPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiBeijingPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurBiologiesCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurBiologiesCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ShanghaiRonghengPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_ShanghaiRonghengPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeColombiaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeColombiaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisKoreaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisKoreaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareKoreaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcareKoreaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGulfFZEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisGulfFZEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiEgyptSAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiEgyptSAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHongKongLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHongKongLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiIndiaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiIndiaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHealthcareIndiaPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiHealthcareIndiaPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisIsraelLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisIsraelLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiKKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiKKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SspCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SspCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisMalaysiaSDNBHDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisMalaysiaSDNBHDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisMarocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisMarocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeMexicoSADeCVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeMexicoSADeCVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurS.A.deC.V.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurS.A.deC.V.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AztecaVacunasSADeCVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AztecaVacunasSADeCVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDePanamaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDePanamaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePanamaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePanamaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPuertoRicoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPuertoRicoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPhilippinesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisPhilippinesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePhilippinesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaHealthcarePhilippinesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSingaporePteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisSingaporePteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaManufacturingPTELTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_AventisPharmaManufacturingPTELTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiManufacturingPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiManufacturingPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiTaiwanCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiTaiwanCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisThailandLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisThailandLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurThailandLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiPasteurThailandLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeVenezuelaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisDeVenezuelaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisVietnamCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiAventisVietnamCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiVietnamShareholdingCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_SanofiVietnamShareholdingCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>267
<FILENAME>R221.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348525670336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>List of principal companies included in the scope of consolidation during&#160;2023 - Summary of Principal Investments Accounted for Using the Equity Method (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointOperationsAxis=sny_HaleonUSLPMember', window );">Haleon US, LP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointOperationsLineItems', window );"><strong>Disclosure of joint operations [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointOperation', window );">Financial interest in principal investments accounted for using the equity method</a></td>
<td class="nump">11.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointOperationsAxis=sny_InfraservGmbhAndCoHochstKGMember', window );">Infraserv GmbH&#160;&amp; Co. H&#246;chst KG</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointOperationsLineItems', window );"><strong>Disclosure of joint operations [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointOperation', window );">Financial interest in principal investments accounted for using the equity method</a></td>
<td class="nump">31.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointOperationsAxis=sny_MapharMember', window );">Maphar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointOperationsLineItems', window );"><strong>Disclosure of joint operations [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointOperation', window );">Financial interest in principal investments accounted for using the equity method</a></td>
<td class="nump">48.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointOperationsAxis=sny_MCMVaccineBVMember', window );">MCM Vaccine BV</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointOperationsLineItems', window );"><strong>Disclosure of joint operations [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointOperation', window );">Financial interest in principal investments accounted for using the equity method</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointOperationsAxis=sny_MSPVaccineCompanyMember', window );">MSP Vaccine Company (formerly MCM company)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointOperationsLineItems', window );"><strong>Disclosure of joint operations [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointOperation', window );">Financial interest in principal investments accounted for using the equity method</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointOperationsAxis=sny_EuroapiMember', window );">EUROAPI</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointOperationsLineItems', window );"><strong>Disclosure of joint operations [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInJointOperation', window );">Financial interest in principal investments accounted for using the equity method</a></td>
<td class="nump">29.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfJointOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfJointOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInJointOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a joint operation attributable to the entity. [Refer: Joint operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInJointOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointOperationsAxis=sny_HaleonUSLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointOperationsAxis=sny_HaleonUSLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointOperationsAxis=sny_InfraservGmbhAndCoHochstKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointOperationsAxis=sny_InfraservGmbhAndCoHochstKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointOperationsAxis=sny_MapharMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointOperationsAxis=sny_MapharMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointOperationsAxis=sny_MCMVaccineBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointOperationsAxis=sny_MCMVaccineBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointOperationsAxis=sny_MSPVaccineCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointOperationsAxis=sny_MSPVaccineCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointOperationsAxis=sny_EuroapiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointOperationsAxis=sny_EuroapiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>268
<FILENAME>R222.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140348525177120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Events subsequent to December 31, 2023 (Details) - Inhibrx, Inc - Major business combination<br> $ / shares in Units, $ in Billions</strong></div></th>
<th class="th">
<div>Jan. 23, 2024 </div>
<div>USD ($) </div>
<div>rightPerShare </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationPurchasePricePerShare', window );">Purchase price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash transferred</a></td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred', window );">Outstanding third-party debt liabilities incurred</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_InhibrxIncMember', window );">INBRX-101 business (Remain Co.)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_InhibrxIncMember', window );">Non-INBRX-101 business (Spin Co.)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_InhibrxIncMember', window );">Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare', window );">Number of non-transferable contingent value right issued | rightPerShare</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight', window );">Cash payment per non-transferable contingent value right (in USD per share) | $ / shares</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=sny_InhibrxIncMember', window );">Top of range | Non-INBRX-101 business (Spin Co.)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sny_BusinessCombinationCapitalContribution', window );">Capital contribution</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in a subsidiary held by the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Cash Payment Per Non-Transferable Contingent Value Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Number Of Non-Transferable Contingent Value Right Issued Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Outstanding Third-Party Liabilities Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sny_BusinessCombinationPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sny_BusinessCombinationPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sny_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=sny_InhibrxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=sny_InhibrxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_INBRX101BusinessRemainCo.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_INBRX101BusinessRemainCo.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sny_NonINBRX101BusinessSpinCo.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sny_NonINBRX101BusinessSpinCo.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>270
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M$2QX67UA4)UHL;:[^M=":U'8PY31A$ES _Q_*83>G)@';+_S&/\#4$L#!!0
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M/T$R;M+6J]P6DP!*IPN:VGP 6!1Y(]@@ 7!8 TPOKS$W,],H=1<9 (LCXO"
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M[Y@TB?; JAJFT-K'IY\-T\AAX(-(F!.'@ _"$8[@_B?'_B>C_;\12B.Q&8Y
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M_=MLL77,V5 V.##8CX;AVZ CBJ?!]WH(3PNB9K+\_%2Q10W4B5@\;1@)K!W
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M\C)*S50W\Z(J"NVIFN09R83QFHJ^(X1OARM\H&A0GKHC(/!FEI<04$CMN(&
M>"<"'7AIMO?2[&C<B#?0UT*O\R"^!#@DT0X0:)_/W#;,0CL*(J @M&<& N)]
M08)ZK=+QWL"GV\4P$QZEEK[UH,@A%A0'@%1&2YF:=1;K_",5/S"T]YM2AP'
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M$GFG,G]1/#6MN">N%$_,XXI@H$D+P/<%ASPK7K2!LE\\^0]02P,$%     @
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MYR\VJ<CV4 42=*/6J0?@P+<20W^2.LGN\=H4Q%Q:AHY@IE-$ANBO9T4U =W
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M!J*UK!^X^QCY>E%MQ/&:TDSA_JI)86=ZC]J-.[J?#$=W+YS2)W:PLHZ7([.
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M:J T_)'><#<UW8#KU'0-?] &\==PGO\?4$L#!!0    ( .%95U@(V!"3^B0
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MBM(T/EZ)KLW=(ONCBMD?V06.B@8H#"YKQKM@ H5)/5CPO>#P4)!>8N/W9>[
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M:7J#)J:^-PO5S125= C_QR3\0UJ=Z =ADO=Z>JD>"TN/AK'#B >]WO/RAW'
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M>G@4R U(+!J=XQG\"!H+1?V'7G!9K+GS9CT5$$@%IU8'Z.:.IU?X$(04R::
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ME31D ?.%*R3 =K5)XY,FQ^'A!E@J%*0#[.K#P@/]!7J88H7K]@U:33>B.[[
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M.4"OSSO</8]Z!FLQGW,+':[O,5P%#N?SP*)OC4U$N#?OW5N,D<"OO-M=9E;
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MA$#>8A?D'!\?.@"N 3TLOF1@K?[?%CPZF'$Z$N>HZOA[TGFT'9B?SN5$/%>
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MZ</M_(\J+^ACZ;.\JO(U_8@-YJK$!^#OBQR U?X#)_!?SW_ZOU!+ P04
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MS3]6Z4UD<T\TF6^"]$$\Z478OMCQRY4UK'9M;P'J674O XI'&P>0@:^B@,@
M:B-=]$B8!]VGY"BFQS8=:)V7PO;8@;!A<Q024%6,<JJ8M%VY[ XHDMWE9-HX
MM=(4A50C9VRZDZF$OY .]3LJH *[Z/.?4=Q' CYOJG'/[6*>N<6\P]KUWG;M
M<_EG$PIW*K;<9()(T,UTK6P;%8H-H_-I$=U.GI@DB=LC& YMNVZU-&8VR]UJ
M=,W$ BR@%*I<\%Q^LCE4(!](Y7$ OA0\W02UUFEU&=+FZM'.[>K,]O$W2/O
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M&I:"PRUKT"VV4KE*,I($7D>9J73-+OYQ,'I-G0R@ZH(NJ33\I]4#!J>_UN"
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M<(L0F=7(\\Q-XL.V'H#(0U!,(E@>+47HV@NA#X>-8UB:[\10"WE?PI+0@7,
MB6RU7)6F9$,]U[3%7Y8]$RQ8L:Q%T=A2:7<L&/E.Z)*9H*[Q@]"PZ!FO"WTG
MC<#=9$A6?JUEA3C?&S)61]R(ZZ5F;QP N\O-L53U2<2J2II*LY$WP(+P'^6T
M/C1(\_& 8(J[I]5$@GN$1 3_X0>HQ_.M>I*(F#3\<L=4!<_"[V%  'I!'!-8
M')('5L&^^2)V M-K/"LN])\>Q9K=R(_D "Q(D9)(:6Q$\LB:#@??\=R8_"2,
M-G$\@*L^C3Y*M@#,(9"'/#P _-AZ1F0^NYO4N^\9?I*09@ A,@OBQ-]2#(=-
M.1ZWT<^)0JM]3NB,(A=I+WJN8F!M@\NG70*9AQM'XJ[1BG&K@[5"?> HV7*)
MU-_K$@A<S$<"#CP6\72_5E)*_%X2,(K(%%JWM0'L0!(9(0!%]^\IPR<OB7UR
MCI 29V*4X1NE0!E(.5"&:)H[ZHJ[GG2GL\6@XL+Q'0_"AEZ(3(5L$!^RF;,(
M2HFH[DMYS ((C,U1X!ZRV<=FUP<8,2H>&'\8H:Q ]$U- $5?4*[RKJ4F)+*V
MKP\OWUU=GC,QEU4N2%>F%:(?/PB4RU8H98O@3.FV[XYGQ=R."% ZVZDD-A*'
M=5T675FM^])OI6TE+3;5( I4W,GFADKQT;40UV,&*<G<C8XV5>K$5/O4ZZM5
M8_G9N #H4G%?905J2]WB"U/'.I1F26)S+.T3%=)*"3NN81DD$(UP0>W%.U/]
MHVQOV9T4#:IALBWJ&LBTN7NZ-CIS[YT^,JP8%6-;:P_+8$,V$TM)];2BU6CB
M#:^ 9,>0A;QF5( 2^HT2=7<QZ[ TL/=S2<TF]FHAR]RP#Y>3I GY-3,1@QV;
MP#"08F\D>5HZXG$&_^D*@)UM9-<C_65!!_&J&[2;"8P8ED-+D>\2?ZUT;7IH
M \=;VZ)0V+G>-"[AL<DQ9@ #C>?&9H P$:-1Q+K]N?S(WL/$*/81M7-5EF*J
M[*2(3>:-M.:VI]]#3[<54H!R,Y>#[H[\MN^]^GG2QH3/;;M*!=_CXZZ7-I9"
M!88!>GB@-Q9E_,5RV8NFX<CEVD+@PA F9U/9WDI9L6M1J5EAA)[0Y/HW"74(
M8FZ"\\IN!$7/470M-^% ])!H<I*SBU_??;SZ_.6:C:JBT?*F6 JJ$ >203NG
M:\Z!TZJ>-0J(UN+.( NZ_PC1R?7H-)(B/>E=[11T5>6FC1ZP8@WHL[P1]R<>
MF\CT(D>&*E5M SR$QE<;=^OU1D."BY\-M_%I& >G9ND>[KW!_,?&BF=PC7(6
MWE$].JK9@"'@6UE&EB'F, W=PINAMQ=P-*E;.\$0[4(A4A<9(Y46-BQ<O(!5
M%\>]IV]:;RS)Y5(T?PS3L>6\]_9[1FAMD$>G/3':+<DOZHYJM]'IG!K!;3LU
M;5S"BXXC-MV:1^S(NE16K/1Z#S^.]^SAO<K,>F_O>A1QM$&P6_,\CEP)9R+?
M;7MT%X'(UVO(^A6&WDH@@R*2TH+>6,H G59FBTJ5:G[':BB2GH@^!Z!C_EQ\
M^-XMV_#L7?YWT4DL.G84W@K*!E-ZKFNGJKE)./9!L>%AJE:M#?@(_5E1PZ;W
M&]JB0!URBZ)P3X99BM_AG0_SS/1N& Q1 =#SK(K.2J-_]G%OAYI,\BY043RF
MG9W/LDR;/*Q%'RIUL@/:D<%Q;*JU*ZF+G*J573I8+YP>5)'RP\K6[V3U%R*>
M'66X#D=S,_*H"8&!<'3RJ*]1GM)T"54F9V=*+BAY@\0E_I<+62QW/J0@>M2\
M!Z8)3Q,[ET.-&Y-GH3/T8QJ"T9#@!CI!;C0[?,<-J"3'IXM6 ]<TC6-APF*?
MFJ*6M&*G?*;$33Q0#EU0](E51'86ICY-(5L)2[G.BJ[/PY;$I[$&C3\"3I4Z
M0ZF=)BR$6)-I>5=][0BG482^,##3)$XK;1_BAS&-E]";G!7JQCQSNK%TG1AD
MT$9$M"=TO)#;/8$#&P$*;A2RJXO?OEQ]//\7T4=7,/*Y;6X3T*<I%(V>7&ZF
M=B[[_-OEQ?NW-.@*P(I'LQZ.9B(T2_F#?GR3K$&<=MA)6!*[Y*>$.$[I%__T
MY<>/[UF,5FQ$0Y'8S,# ['VB9FK[<N"O#QR519&3@/(H1)]$<R,O-/V+1Z,,
M4H>90))=_W(OQG1A8X>5ZS[1FFE]=\X-C87Z\L8SSHQ.IXL_Y X[Z)-BS@=E
MP)!O9.SBAAJ(1BT?C,IM6-#2I$91%3VS&R >%L#31JW @*WU==?;=%6N<7P*
M8B_9Y/WG+S]?7J(R'<F9J*166:L0V)@H9V+<!SPD?]2UFMAMNRAG&,5Y,K<)
MO45?;8J0%2JQA02,S4)T17XM55UV#S_IIWI1E(5 ,V4A)X8'C4G/;%=.F><$
M0,#JNFOK$- A]>89#_<WS]3 S,)4J//!E'"0Z1S/6U> Q^SM&A+NH$E<RJUG
M%51.480V[2=1'E9VC_52E@<T@$UK:N NWI%=#37\N&"VZJ9RR(;\HKI1)5G'
M+>2Z^/&'R:\?H"^-\FU94A'\XG?P;1XG&BT8YLAF,X663,SG)596!<TS- T_
M+.R&O,5^CZUXYEQB:?NYU/+JQPG;478<;R<5B/C88YSB?J-F1@)51FI8-]#&
M;KK?3+-B,+E_Q$/B#G6@LK90B'O+U^. ^\5HUV$55;Y"64L:Q>[U\WS<5J)=
M89]UC)T"H)!&>T &LM4V$^5^](4R8+:JC"<!+>@!E.]T84]_C%7\K!?JMNK/
M&90XN[*_\7*3=8T.SY4VE02UYQIQT03XA/+[;NON6-7,IZ<(Z'=!EFR47D1"
M^]8 BO42#SU5PAE2CGUWH\,+R]=+. NVXSBR!F(\A>:4[7KSZ&3PVAB<:VY>
MCJ,G?Z@;[!MDZV_7[]]-[&MGF^7VY;T/:)"I/RGE#%O=XS@\LMKN;UI5FY?0
MIJIMU=)<+B3*M886X/>90MSK;NB ]5N);_X+4$L#!!0    ( .%95UC5?/]0
MR T  !@E   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;+5::V\;-Q;]
M*X2+9FU EB59=NPX">"\6F.;QG#==('%?J!F.!(WG.&4Y%A1?OV>>\D9C2S9
M3H'M%UL/\O(^SSV\HY=+Z[[XA5)!?"U-Y5_M+4*H7QP=^6RA2NF'ME85OBFL
M*V7 6S<_\K53,N=-I3F:C$:G1Z74U=[KE_S9M7O]TC;!Z$I=.^&;LI1N]489
MNWRU-]YK/[C1\T6@#XY>OZSE7/VFPN_UM<.[HTY*KDM5>6TKX53Q:N]R_.+-
ME-;S@L]:+7WOM2!+9M9^H3=7^:N]$2FDC,H"29#X=Z?>*F-($-3X,\G<ZXZD
MC?W7K?0/;#MLF4FOWEKSA\[#XM7>V9[(52$;$V[L\F>5[#DA>9DUGO^*95Q[
M>KHGLL8'6Z;-T*#45?POOR8_]#:<C1[8,$D;)JQW/(BU?">#?/W2V:5PM!K2
MZ 6;RKNAG*XH*+\%AV\U]H775V4MM8.7@["%T%60U5S/C!+2>Q6\D%4N:H<<
M<&$U$+616$B?J3\;7=.VET<!:I"PHRP=^28>.7G@R/%$?+156'CQOLI5OBG@
M"/IW1DQ:(]Y,'I7X3F5#<3P>B,EH<OR(O./.*<<L[_AIIWPJQ&7TQ+\O9SXX
M9-%_=ID<!4YW"Z3*>N%KF:E7>R@=K]R=VGO][(?QZ>CB$76GG;K3QZ3_/3'\
MFX\4/UF;+[4QXH^%JD10/NAJ+N;MI[*J&FG,2@!WA.Y.&XBP4 "#S-XI)_G
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MEDAPY=O]3&HJ2(QSCA8F^ZYCP@ ^9D#)9JT!P2D9VJ^ORK*!Z-L%J-+,9JM
M3T$!L=>XR30.W>CJ]OI@T'(MWLYDKCOR3CJ:KJZ1H*M\'/=99AGQ[*&X?O09
MR=43Z/?X$Q:^-<(9V-I[EO!N>#P4-T3O>;FM::[65$P0^\B?F4B0T] FP<R"
M+GL\$2]H2-GQ49S?Q"&/S\#>8;M/W)6)>Y+E'CC6Q%MCL&UKXV%@QUO;")4J
MU\V:77:S/^"(5VF,IE[T!R67\SD"X(E)?X2H>0Q/J^)@S?[G!G32H%Z-0:JE
M63G=- (19H>4SBA%5:F]C\.SDK2!48;'E24]/[^F(2'.=$IQ .:6J1",ISNW
M*GEJ0WP=JM)\C"T>#T^>_3!^?GKQ-DV8Z$*JJQPW/$<@9BAO/7(M3DNY4J(?
M^VT:".Z9^Z5"DO 0X)B&FC-8$A^WQ#L>38? F\F:KX$N&G?IV1/2R.!.;P:]
MYIZFM?&:ULX;27Z>DV-1S9U7::',91WB6T>)Z-@1/>(O:=[T-J7#9;81#GA*
MR1:-4T! ',O4F:??X2;J%Y/Q:$3 37-='D@>YO2H#CQGL?+\(*=U'W4Y$L[W
MH7OY#ISIY1A8LRYB[;;K:MQ7E$,F])2N46 H#1Q1  HJ;D+(:+K I/M;0YS
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MIEJ=@HPF=RYH(>3"T7_S=:QAU$ET$<)1XL<N'G6(V%06[&N!J%$4D#ND4_;
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MPP!TWTI[PZK6MZ]<66J&?EK3UP>UVT#KE5)V8[@#QN]9]A-02P,$%     @
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M?6M7TS3_5WSZ$[\*LY>4;(4[4@TO%ID'9OIGIH/3W3C;M]K13S&2-7W-:%B
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MT>?:40UTVYK>:6@\ _U?:^WVA%<POOQ6_P%02P,$%     @ X5E76(3@828
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MF8#?%P*W^_7  &S_+9G] U!+ P04    " #A65=8#]RK$F@#   G"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R=5MMNVS@0_96!"A0UH+6NEB^Q
M#23I+K8/!8(&W7TH]H&6QA81BE1)*F[VZSND;-G=)$:[+S1)S3ES9DC.>+E7
M^L'4B!:^-4*:55!;VRZBR)0U-LR,58N2OFR5;IBEI=Y%IM7(*@]J1)3&<1$U
MC,M@O?1[=WJ]5)T57.*=!M,U#=-/-RC4?A4DP7'C$]_5UFU$ZV7+=GB/]G-[
MIVD5#2P5;U :KB1HW*Z"ZV1QDSM[;_ 7Q[TYFX.+9*/4@UM\J%9![ 2AP-(Z
M!D8_CWB+0C@BDO'UP!D,+AWP?'YD_\/'3K%LF,%;)?[FE:U7P2R "K>L$_:3
MVO^)AW@FCJ]4PO@1]KUM4010=L:JY@ F!0V7_2_[=LC#&6 6OP)(#X#4Z^X=
M>97OF67KI59[T,Z:V-S$A^K1)(Y+=RCW5M-73CB[OF6F!B8K*-T$OW;\D0F4
MUBPC2_3.*"H/5#<]5?H*59+"1R5M;>!W66'U(T%$N@9QZ5'<37J1\3V68\B2
M$-(XS2[P94.PF>?+7N&[[S:E8,;P+2^9NQ0&U!9H ZT)07"VX8);CL9GQ"7#
M+[ZPC;&:[L\_+R6E=YF_[-*]J85I68FK@!Z-0?V(P?KMFZ2(KRX$E \!Y9?8
M?^WT_B<5O'O[9I85^15=/R$H:2-_'&Y(W9" AR9A7B0T9K.)&R>S?OL'(C:"
M:9CF<TB<10*S<)K'\+IG^I[$D*3A-"L@B<-X/O,DU_[<Z'9@LT$]W)#P.8,K
M2^()2M6TFANLP-8(6R6H%G&Y6\ [/H)#>),P(V6'&('+1S26 %P"=EIY@9_O
MH2(LT_3NI:+7R)Q%HR0^_48E[8%J:-/9C@G8=K*B@/\K,5T<O<W#238]>KMZ
M%DNR.,F*)X/AZ(H4GR0G83)/!LF4$HNZ(6VM,MQ>=$_(XJ?<4^Z+V>GD719(
M 4GX%RDIE-<&=<DIXI:UA'_)I;.\Y"*9#FD?C9_?&B:,HE,H15?A$9)/BR'L
M&D4%&SICUKH"3Z:FTTR6Z,5J/*W=+6#2O6CNVD&I=.7W]]S69S"-NTX<RL.%
M%.;9_&<2F*>GTQN_].2CL^)-R=SY%F5(;"=M7\>'W:$+7O?%_V3>M]"/3.\H
M#A"X)6@\GDX"T'U;ZA=6M;X5;)2EQN*G-75RU,Z OF^5LL>%<S#\-UA_!U!+
M P04    " #A65=8OAI;.!\)  "5%P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R-RYX;6R=6&MOVS@6_2N$!R@20+4E^=TF 9(^9KI 9XJDW?VPV ^T1-N<
M2J2&I.)X?OV>2TKR(W&272"1+)&\O(]SS[W4Q4:;GW8MA&,/9:'L96_M7/5N
M,+#96I3<]G4E%$:6VI3<X=&L!K8R@N=^45D,TCB>#$HN5>_JPK_[9JXN=.T*
MJ<0WPVQ=EMQL;T2A-Y>]I->^N)6KM:,7@ZN+BJ_$G7 _JF\&3X-.2BY+H:S4
MBAFQO.Q=)^]N1C3?3_BG%!N[]YN1)0NM?]+#E_RR%Y-"HA"9(PD<MWOQ010%
M"8(:?S4R>]V6M'#_=RO]L[<=MBRX%1]T\2^9N_5E;]9CN5CRNG"W>O.;:.P9
MD[Q,%]9?V2;,32<]EM76Z;)9# U*J<*=/S1^V%LPBT\L2)L%J=<[;.2U_,@=
MO[HP>L,,S88T^N%-]:NAG%04E#MG,"JQSEW]CKC#"&&,R)GC#ZS25I*_+@8.
MXFG2(&M$W011Z0E12<J^:N76EGU2N<@/!0R@5Z=<VBIWDSXK\:/(^FR81"R-
MT^$S\H:=L4,O;WA"WA>5Z5*P[_Q!6/;OZX5U!JCXSU.F!D&CIP51IKRS%<_$
M90^I8(6Y%[VK-[\DD_C],VJ..C5'STG_WV+R?XIBU\@(Q8NME9;I)7-KP=3)
MR9AC,0@.<&NVH$Q^Q\[>_#(;3D;O@<JBP*1S'R6ZI'1)V,<]4?"W5N_8!ZVL
M+F3.0T;F?P+@R'!GV9E4",;*Z+H"O,U*8E/ZN\>H-MMSED3C=(SK<#;#-9VG
M[)O1]]*3 _1B52 *"ZMRIF&.8:*L"KT5 AHKL938938>XC^&@"29LEM1"FYK
M(T@%<D)8QK._:DEZ0R6N5G)1",8M[(>6:32/1^?LC.-_&*63N;_'4]QO1:97
M*O@+LCHIE0&#&K>-6%5P[$/Z"8Q5?E<.KW)IV#TO:@'Y"02FM$,Z.6>?,,UM
M20\!E&%_N,36"RMSR8T4P5;R4>M%C#>F*P=-,.-L 5E)A,C@/DFFN([G\3GE
M "LTK(*0>RX+3E:2'S-NS/8M?FVXR;W7)W2-_369L#NGLY],5^[(V7;-C7A+
M! F3^3;H,QLQ! H1N\XR4V-$/%"<&LVK-H 6L,MK\+-WM?-@=*!^\F,CBYUE
MA('Y?(3K;#PG;69C]H??^RP'^*+QD'2<C@DE\73&'F'?!W%P5DB^D 4<>\Y&
MT7@:LV$T'L40,)\E/K+7/B- /J)<0'I+0!'<FQ5U#NW-/G*Z_'D&.)AQ(_6]
M,$#^?9<ZP/$HZ?(G J*Q@ZPD[V9,DGAO_'I1;-5#-YC&H[W!7X7Z&Z[J1L>[
ME=[;UV6MY&YQ$L^[\;Z'R1> B^@QTS5R$>")V!U7>BDI_<EI#4(VTJW7NLBE
M6C6IO4,!N3D#$E9XNUD+Q7)Y+W.A<DPR D^@7+FHG<C[G@R0"/!@L>VV,B&+
M_B:IA]'KP@8F\>YNB-<[][,1*EM[1: B2O%1HISQ"FA[D"CCHMBRUKMQ?\06
MK9,V:PD1TD'P"MB' F3V3YKO-#AD7WO*--*!-K-"!-_4#HCHDQ]S@8Q%M?8N
M(F24Y-,6)R?,XJ=@U[C&H;4A:&D S<>(/*W(TXTR>J.$L6M9,>B)=((V)#$#
M^_ CYHB\JVB16"[1(/FMC\1!.]ZRV2Z,&/QLN,I$!.,+5(+61E,7]+.Q\8.N
MC3?X'Z!XF8GV_:>:Z) K]D/YPA*VNH.[@/H,[-$I!L>BLR*1'%F6ATR#\326
MQLF8?9:*] "WN/[IG'5KCUXE=ME[$EAPC:4-ET:7S*%\:(-&%<;#1P0P7\6.
M"?< 9P%#3<"([,BU&R ,YB#[+6F!!%.J:4HIE[Q%5"4T<:<5%3>=WX,K%5IF
M&/6;X(5;9Y1(BQJ*"DMQI/13@$,64/E'YC1YP!?C,V"3_:Z=8!_[P[A/B9Y1
MHC>.>,R.1&T%)X##TU1S H[(*3NVCAH\^\CK-IG2V:0EE--0;N>.7YJ;!H2V
M\].7YB=]7P6>-(U"WD2VH8YP@/%F-Y4GN/OV#2^K]Q^[,O6TI6A"ALE+MNZK
M/QVE+YG;9]^/**T!T0&\W!K5<:/K(B<^H@0EXI'+ VK"-?"TQZ+2N\&FE:,^
M1(D\:NER;^;3>;'FM#52@.@..PNUXVF(<=KQ0G36)G$_;EGU-!+0B0/H6.53
M8+=T\L+2=-^QK]@*P/BJK=MY%$O39/K>!AO1 AVV/*%0[7HBB;/,$DQ.=://
M<!+T]&$S(ZL6-15:VDP&<@C,== )/I%E$9UGJ5SJD)TW?4( "1<<D?!5=+]5
MCEXIEZ+;UAX,-/J@*0M-/E(8;; O6J!:U^")[*7=@!)JM'P\CEQ5BES6Y5L2
M3+4%!+&2F<=14TCX3TH17YR\J%PT'-84$O_6%_M,=/W23I*N0+6N5J%GW3D?
MXIHT(*V:8H%N6NK<]]AA8M,5+$]'M"DI%GPLE]@ODR:K2^MXJ\[3;N\?G&$.
M&+)AA),[GB(%3R>!7EMNBZ9IUXI%M"RDXZY'C(<=>VR0A$A4MY=_='0BTB.-
MFC6CZ6Z%I%PEPWT*9+R22-:F]3\GU@$TFERT![F81I-="WDR&<\>ZYN,1L_I
M>WY [-%P_A*5)H\WF4W'SVX1V-1Y#/GC*HXG>M.TI.YU1Q_?K]8>@R@'Z.N?
M.O*^\AA%IPI8,F(3NHW9E&X3-AS1'0_^V(QS;>K'Y]Y#5(8-FT73X91])X8]
M":I9-!\.GYV#,QB.<,_/2=@TFB!TI.NGAQ91IP#NHT7?!%!<T+CPPO;978T(
M'2?"8\"/7]TFO#3SH!:\-!F%X(<5S]&$;Q1+V6CKFV,Z1M,!O($?WE&7B$;-
MM_E_HC.RN<S"67A#%?(QB82" A&@2^J:]^"7H0]>^.\NM"=?H4M'I>K*>OA:
MM1**R)0*^W9WKF^XT*(W?BUO'=-&97 <,A+'FP7*00W?0*(TS3G&3T7+NF4;
MWJZE8Q$I:JF2++R2*WDO@BJAV\5P:-P[EM]7&07 NG B?8P+G-HGZ3YO'6!A
M/A\?C1U$?Y(<#R?]IS[%#?8^E:*G7OD/PC:<><-7T^YM]\WY.GQJW4T/'ZR_
M^L]4P(Q88FG<GXY[S(2/P.'!Z<I_>%UHYW3I?Z[1=@I#$S"^U*C]S0-MT'V)
MO_HO4$L#!!0    ( .%95UA9_&2MFA(  /DX   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;+U;66_;2+;^*P4/9JX$,#3WQ5D 9YM) ^D$<?<,!A?W
M@2)+%B<4J>9BQ_/KYSNGBHNHQ<ZD^S[8$HM5I\Z^5>G%?55_;392MN+;MBB;
MEQ>;MMU=75XVZ49ND\:L=K+$FW55;Y,6C_7M9;.K99+QHFUQZ5A6<+E-\O+B
MU0L>^UR_>E%U;9&7\G,MFFZ[3>J'U[*H[E]>V!?]P)?\=M/2P.6K%[OD5M[(
M]M?=YQI/EP.4+-_*LLFK4M1R_?+BVKYZ[=%\GO#W7-XWD^^"*%E5U5=Z^)"]
MO+ ((5G(M"4("3[NY!M9% 0(:/RF85X,6]+"Z?<>^GNF';2LDD:^J8I_Y%F[
M>7D178A,KI.N:+]4]W^3FAZ?X*55T?!_<:_F!M@Q[9JVVNK%>-[FI?I,OFD^
M3!9$UHD%CE[@,-YJ(\;R;=(FKU[4U;VH:3:@T1<FE5<#N;PDH=RT-=[F6->^
M>E.5357D6=+*3#2;I):;JLADW?SE3Y%CA\^%_*W+VX<7ERTVHR67J0;\6@%V
M3@"V'?&Q*MM-(]Z5F<SV 5P"RP%5IT?UM7,6XEN9FL*U#>%8CGL&GCN0[C(\
M]P2\&Z)6O$EV>9L4AO@B&UG?R49<EYGXU&YD+=XQ[>)#V<I:-JWXW^M5T]90
MI/\[Q@^UFW=\-S*NJV:7I/+E!:R'M[IX]9<_V8'U_ PMWD"+=P[Z:3'^SQD!
M_I<@]S5#O#5MW[1-H=B9*G:*ZT94:P&1R>T*G.S%9@@P5D$;IMZ+I!$ Z@;>
M<\?PG=CPX]B(W<@0*7#(FS8O;PF:;3B!9X3T,H@9B("X[O-V(Q*QP]-=4G22
M9O;03/$+/%73U0]JST9L9)&)U8.X2<IJG0O" [NOJP+>J;D2/W>,+D#H^8MM
M7A1P'TOQYV%TP/R /&&[IN<+V[0"%POF[QT1F8XE+#/PK2.O;6%CI8/W4>C@
M_4])V<%1BOXM%D>\.,++.6&$%^RL2TE<Z[K:GI&9*?X*=XTUT/2B:AHLAX/,
M\F97-4G!DFN/@*]E6M78 S/QM2T>1%[V6D"@:$Y9M3SOMLS_C9F84"*RY&5:
M;2787+/\=[+.J\R$@[B3</!M0_,.%8/0P* 6%02,J5")[2XI'P26*F!% LML
M-[64XD$FM4*UP:;8#9JQHKAS)> <)7B6E$VBPL&!I.?2L$C?_,B(0]L(W4B\
M[6K20Y:$=AI$%_%)DD;);[).\X;U#VX[_8I MVK2.M_Q?A5_0*&2I;!CR[#"
MX%&0>=-T29DR2') =9X.Q@A(*T RH.B&'<;B=974F=@B#FAK^:F#@)S(. %>
M^Z",A2*WNZ)ZD  * PP<(X06'M%.V)^+]Y81Q/X$>>='^>&!'V[H/@KR*?SP
MR#U$X2E^A,8)\"?Y86&-Y1\!.##(]C30+VQ_1!WT>5^7@7U*J!=%HL@_-+%%
M8(2>8[B1M3SB.8CY%J3M0QF=":?<'V6^;WE&[ >/@GP*\UW7,GRXI[/,/P+^
M)/-M*'"(%4<\[5XP($)N%":$)R"!RBD3M!,YS0N32= PD 8PYAU2E_J 6K$K
M$NT]]6;:??5^[;WV<_"H*?QKQPYTA9281[=)B727_!XAUBM(38ZT!BRUYX?W
M7VX$^(4<E?Q<)7ZNX,!>FTYHJHB+V/;E.%XGACG4I6G5E:UF=%[R0)VQ6#F.
M,A6(^FD.E#-)7%HI^OK]/=-%5*5I4)<TWP'U%+O JX)X<"U5X6-3-7L;3V(L
MBX]UFKW*+P\[EA!-%I]ES84&(?0CW]G= ^B^(B:[75W=T3>FDS;\F$ O?:U3
MHT6[>H1>N]H"#^W]&CPH!'1>4?(I;2MZK_7<%C=0ZCSM]4*X.D ]]?.7BA2C
MG >JY#[A*.S"&T2&YWHB\&$H,09<S\, G(5%3M#&B!=AA&(9'#>AN!;WFSS=
M*&F7%92Q_BHIJI99SN;@8+IO6%XH8L\C]V?!W3LA0,*Z?0PX!-NR!:<4SG/Q
M/LG[S MT:I7K<22[U,E8%)HP5/T0AJ;G] ^Q;=KCF]BTP\DT)QQVVD?^ '/X
M?E#IPO?#,=B13_[( Y,L7\!+!%Y /B/T#!^;:7:<Q;WB&J#=0$M@?Z0Q;S:Y
M7(MWWV3:42T)A-80;\V>HZ?2-4-O0-\SD>CU;P)D;OU#$)O!\":T37=X""+*
M('\GQ)Z))%/<@2+UGCH=D/7<"1:N9\;#@Q>;UO#@>V9H#5)XDMR_@V&.EG</
MG <]$^*:#0YLFF_?.X]$^==,V_XMLKU6+/1J,23RKA,(*'+LB4@X 8R%M?2C
M4B=8=+H7,+3-'0%M@+G_0H6NO6F6W^69++,&<6<GV?UF*J32RCZB]"&"./ /
M;AG0Z$JV]U*68I$OQ7HD+)-PJBCZ*2HT/22JJJELK0M8;Y7)@@/1(L?2[?\S
M#="DZU&_4!F7*27QW>I?6$LZD(@-2(3 "WDG.:&?6RWB@>W8AA6'1U3U7DY4
M*M?.FJM((MDG__>$58/?9H^^0-W0= U*+<^(8*J'ZP\W=-2&L6$%P?D%T[V<
MI0J4+;MQ8FC9R&EQ1!Q/BN)$?J'V)+Z/$> P[Z)ZZX&*G:Y AD42DIFA2J!-
M=5_VF4F;K K9UT**#]!Y#F+ZBZW#38\G(7<B\3DT*<>U 0,.-G8/"ZMC*%)"
ML-\? '?#T#6LR,,WQ_/AIEU\\ZW0B+Q8_,I9$6.ND'"-,+)XTMPQ#5.=8:J%
M & C+W4Y0XTFT6N8;.O)CA'%+D427A8:ODMA%.1BW!^G6WIZ#P?+[!!1AR9;
M4"TO#H;)B#?[D_M/E_-;#XB1$'X74PJ,&%'Z<:-09M3; K['GG5>M8FA.O=$
M!CA/X1M6]:.9H!PR>JU%T$OLN\EW?8(X;D*S*8FCE<F0&S]6)PSTL-#);%B@
M; 7<;.Y[$<=-8<Q%GYPVOI>KFGLSCDX4AX$>BV' ZY/!:=&A7'1O2$N6/S(?
M:$)DF9B,_ "^;7^)2B)_ZDHI_&=.GZ'R<_S,B?6^_!P^TSFM?6B.NOBAM)ZR
MN]APR7"1TL&]61'E?\@J?:0"!RO[8F>[E5D.3L&:8<9:#+5N,36DD/ :JTXE
M978,8T+Z:$=(*I%X.<C-;.5UCG"DEMP<+9GOD?7G7H,2:"J*IOZ1SB1HQF]=
M1<YD&O>:P\ W"6&P6]A61H]9\M!@"3P0/W*F/W0IF8O!1*%X0/'<IJJLH?"(
ME*9XT$Y^U"IJ/C6Z^\3:?]SSRP29+"G3U3&'.M5+"QG4 0C?$6XL?)O(55GQ
M(X) HD,-1F7!'E6/NZZ&P39'4@6BZ+HL.]C>7R6,%9\?E3$<L%<W&%5CM=HO
MJ(R]^HG8.*N8F =)AVI1F6BB/40]X@;30Z:R5<&R-P)J!D?(?NA\0?%?59<D
MR'$MD(+>0"C(K+9))G5IK6M3!1=.<T%-RH,B"\@>2.6?*,O8,VF,52MGYD.T
MV?R=,[C3#RJ4:>(<PT>=YL,%.^YAICW_5*%-+_6X0G,L3[@!=45\%&H80843
M'EMH#PL/@U$<(GK$T"L4!8X1HJIT(S@$3ROAJ87S3]L(?7@0%'LV"&)U\\VQ
M-]8<-L?.O>M[QKIU,>:?;+SD*F2FF]^3;L7HZ!$[BHZB"])?[F'TYQ7)JKJ3
MI#P5&]:  >L,*N-\NT,H(Y4^UTAG: 'B85?7LDP?.'0WNLF7Y>NUI&$HU*,3
MJ+%=4[>JG:KSH\[!%M>MLG(F%YF"[LCWACG:Z\*U=8=4+*+ 7QZL+*OR&3L-
M[$Z,SO7!%U(^-USJ?YZSU*GB(H@8'FJH16SA'1GB*BFX W.0X.EXI>5!%B:2
M-> _:Y-O(MF2<"='-PL_])8]R1 /,8Q\> 5'D]TJ+Z].%BBA' X1H"THJJBI
M!Z>E>YSS%EI$^8MR)TIG=D-'=D.:@ 2+"L>IPE%'[&%IJ,,':M)Q!V) E3JV
M/:K'Z7:F#@5R"!];8"NWMM4G)$3;HQJ4-X*.X2DLSP1+A/UZ(S+(-:FUTH:F
M/N5DQ9,;.FB_D_U1S7@T0Z1B]^KTW+':T%G5XRJ;MLB-<NC0+1U$72[4*=3R
MBIV($SP_.0/1E/1':><H^OW&YE@L:UO82CAL%,D-<M#>"<1P E!G.X11T'E<
M$/F/[PY)??>V!BLJJ5?R38Y%@"?L8;]?8 (2@DP!$X%M@0ED;L&R/X(&$FW=
M]6JN/1KI>U["V@C1I.&T@]1L'"SR9)47R.EE<W76;Q,2;S9)>2L9ZMB"6/P
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M"5,\2^8BM,+8%8'EN:&(K1BLH:=MDW6!F?*BAOQ7V6&MQIIDB=MMNL+4N^(
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M54G]H2[V_$N.RZ*NBQV_W:H$CH :X'NZ]]Q\H G:G_9\\7]02P,$%     @
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M8F11^K"HK.@\#UN36>J2A[>&@U"I;G[QIT(@B(_>3?4@IBGU5D*[1%CP-"4
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MFI"@JM%L4)\__9.@.^>UPX;J#0R;#I8Y/+!?#WMVBJDT@^!4$;.;VNR0[F6
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MD'(=S=8,XAST[Z^.<5AE'9IS^ES8Q.U6(,"XSTSP0S7X(_JJ8 :91]1B"-0
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MN*JC*RZ*47*)AT>I_"3T>R)?QO0T,*,>OI O#@$=TKZDB6?A(W'L.A!&+>I
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M1;90MW/!IR(G (S/,D1(^84(U#^B.?L_4$L#!!0    ( .%95UBMRYZFIA4
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MGI;E)>!R0E(EHC/$!H)M&4/K^X2@-29A[0731;PU5L$HJ$8B$RZ7.M38#(R
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M^#JXW%/*<2 ^U:*";7V.IHTH^-XD_\@Z+JUA<1_]UWKKFQU<*5!?HWEM372
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M6!!IK'N#_L(V%>IDY&6^@CW:(_#/Q3CF'S8Z@AYU<*92;1FX&,0YTO7"ZPA
M_)*?-%-@\VS1TE'@ONDSU*P&71JXII4U=SG\607Q(VH!%-.:)!V@]@,<+08
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MZ!KXQSA<<4IV*89^[;'?P!.CMUCIR(".FRK(%(>!89<MT:1 EX@B:JA]X5'
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M&6Y;2EO68G0C&8*;;,%CTC@(H42-.+3@B"BUTN1_/]QQ:4H#X+V47('7TNS
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MJZ[5^L1A_D7==ZZ]3:(-*;=6-OFTFE.,!J>$$T@?+V__P<%(QSI'Y^Y0Q+O
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M+EY'U9AB5F90"@8BII@E/(6,Q2 2XJ\L_P??690G"3+-,=Y)Q)(<<GQ'G+P
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MO)Y,/.O/2F 9.GM7)(AG=9/;9E=0[N/K,-&-9B%S&;-;QB3<4HDUX4/2B1@
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M%E^$XBH77#)XP$1;L(RK@@F5ZQJ.(X<F2##*>[BS#BYY RY.V%>M7&799U5
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MI7CN[(ZG2EM/2%M(BJ,0E KI%<U.% 2XU6+HR;Y5OAM-[N792E? [<4]Q$E
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M/1HVH.]KK=UVP0Z&/PRK?P%02P,$%     @ X5E76"5Y2?"W @  L 8  !D
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M[5M0.J OO$51:]P"Z'=/#5MGM&9U0$(7(S:N@OW*J ("T[%);3Q!DRVH MI
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M;"]W;W)K<VAE971S+W-H965T-#<N>&ULK59+;^,V$/XK Q5I=P'#LN2\&C^
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MRS&Y3 R7,49Y-D'@@SO/HN-10Z!!%(,KFWQ&CO 6&(^ +_NX.L2H7NYK8G<
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M6T..I^>=R_[)U5#TH\(OFA=^0R;)9&+M%WGYF)]W>A(0EYP%05!XW/,UEZ4
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M?7CHN&LP8Q)WZ@2+75@C.4F1PAX]?48:)FR9#02CEB!>LA/CO?Y[+W^^"I;
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M7]GT%U(OPSL9614#4XMO&&\A1>I(%ZD;^#*03CNX0>1RH4LX">VPQQU[_BB
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M34W$O\84!]X!<9F=9D5)/Y-"SF]:6@9ZZU2_R-'#-58*Z2:D$^+E^,-H)?F
M"?.(^30N5G<?Q9!SA<4A),D+2WSEE%3\,'?4D>%PYH=VA>YB/M[J(86/0UF3
M=.Y'T3P*2G  7EJN,12$A"3JR2!.%9T)'QG8-VNO$W>W.?D(1@OSV',8XMR2
MJLP+-+Y)RRI[XI)L5B-'0CF.WUR4&\,F\-R?3L6\1YQ7Y#9'?8W*&C%=+2XP
MC#ZE4PZ'T*9.A8];H?/2MPJ]=M\@+$ H#H')7RGF!),)7[G?F")4),80 V4(
M1/M<C8B6]/:9\&/KZHB[Q\YLLF[#S!XP6/)D3WW<(5K-3+S=NB=L<8OO/_(A
M]I00Q[(LF$!4!O@/$"KJ0:>D*Y]D1LZKPI1S)7Q=7#;<NKF>E%$%IZ2P[X8"
M]1HF [F@Q;QH!I5MUY^AZ!F"PXW/4+$L<-E%!(($S+K8<'635CO$N01#XQ)+
M"&_:?(,I[H182+./<@ZDWKA1P A-+M0CN$<%59Q35'?"<$RJ!P].J"W$]NHD
MH+#6AVY!]C<MY^SA^%KCAM14Y$ MM#8YDVB)5X/RNSJHSF/JIXW6Y(=9J" [
ML3IGT0N7^JV#BSH=6/ V8S=+FCU;3EVNAUQ(=,Q,<L4G,=ISD"2QNJ@K.PO(
M(F%"\^SOMX5,7C.E&H&C?$QR?UTDXB-=4CMU7I78Y T1$H&ANBTJ7CP6'>+5
ML$)C7OCH+!2&I&0"&WQ9%!MR*P33*>?O8''3&7V'K^;<PUNA+Z"_+XHZUK1B
MK)&  D+)YP(_@M<!TU@DBQ*+%*JR"V$]!H C&M7!1O02635:,5%&N(V2@/S=
M7LO,P;*>[S6HM!3<:KC)RS2=[_<[AL/B,,1J&X2/5LE7]#3V%-_&9J#3,3UD
MA-5F.ETVE%)*"!7)OT8.0A495M\YG)H>OZY)4QHD&K<0;"M;B,/JB<KFT3V9
MEQ7QA7[(DS(.M?P$6BCE@DPHC.BH522:HV9Z_&0DQ,L:G*)N<A$ 7T;R-$LM
M#%40#FH+TR<J1,"F ZHH@>RE0M*.=I[] 'K0G7CM:"R;].CCN4>L8U$9OH;E
M09RO,W&QHUS,X"+$R+)DGB.S$;T?JQF02]?HR2D_"()ILX"%&J$V>%,++J<4
M7!E9L2@4F !(W&JF[P1N^,(<?,F]<T67<[I-%_-L[XW;4T!.=;JZN7IQ+)]8
MY.S1(+'%MFW@DHGGZG1:$8U@*;IC<2E8B.M1[53_[*P<,L4SPHY0/60'%EWG
MM C.WI0L;<YP+!<^.9P1HQ(7&ZM:J^G:Y@2'X.V9NH*6(:'KLTA1BJL\\,*^
M'MRM"<:09_<$+(YB4@'9HDE:;(7&G5$2ZZ8/B@[#3BA%1=>*0(XFLTJ9IP06
M<H#R\2"'(?Z.\2P8$@P8I]05J4XP=N_%WF]XJ2UNL43J3GD1J_OQIR:8%=<B
MW:O6Y*@4#=$&]!JD48K!5>SO(S.2[(RJA#G2E/9*\XL@S2_VNT?Q,-%WZ!*)
MNU"HJ1>$KF.-0E+<@Y30IKI34NS_ =\EB(&Q?G"=&GOVH(%56OC(V<24VV(
MN#>%@'V9G=@0+]P0IP$!Z3CO\_SHJ03^X?4%UHF#H8N,SIFXHL\4QE-*S#$
MA3@?5&=Z'L9943"13LQ/N09<!C2T"_9L16O8$$MG7EO6!,$@4]5H-T2$<4LT
M9H.;@ BD]5B_&ZOYP9P0^RR:3-Z[CS.B)-5YDE555.*.8!#3/7NTPDH?9^90
MW;E:P^<7Z'4A;O$>P1^$-/ O3[.35X1A46#R "%8("6\]2@3(ZDR9'OZ]YTY
M%^2LF265@U]2YGX4_@G@,T,%E+)7T'C-@M/:34W#A&K1./Q6AM)T&$]4J?4Y
MV,,8RB9,VBI[^1 3NU5K0A>;;+&H^,7\=L+=0]7H)$;*2#BHO-$D<GMOPZ%T
MD@>D5Y+G7@)O='@Y*%8?4;&T9"=W<JU=79-H>!3$/9ZQ-_2^Q'65_7A2GH9<
MC6CR1,CC<\QBX\LS8<-D92MQ2=&S)//AVA&M[ QH*:--B[^/04RPSVZXI'!T
M$X)::G=BYITC[*IC]4<,MG!YQOKY.%X;J^G?A<4CZ,UQ #XS+%9@Y-K"38@4
MTWP9I?4#XUAS%Y,XNV:TQ9SO:)!W*RX"1;2ILEULUYQFV7%PC+2\X(?&]P.5
MFR\+BVBO49^K%MM*<4Y[GS$KMA#R88U8P08Z>A@PHUE&7)O1H-$O;U;)Y"LN
M]"&\B!4O<2NIB3YGR-%FHR2JR>I)+QI&6>_*Y18):)Z]V;8+2MECS"KX9;-P
M@C<4Q0<49:G]+0/Y^O)^A6&2W-9D8A\MMAWJS.O\'Y3395/MYBI71Z[@O/:\
M-CB%M9@Q27EYC.F>NOM,@M<[%P6!C6E:W7N_D3[]J/9!#:8\ ?$=2"CO?+5X
M8#!T(O>@I 6GUJDNOQ#Y)"\H'K7_6!=5R_5#AC4M]J2RFLTH8JC#N__C QBJ
M#C<MTX1N'*N*&,J0F\>,2>@_[ X'_+DSA(O&^Z8JP64Z+=CDPC?-AVXHBEQ5
MMP,&1*9!OGS<L651K-%7WO-UC-W_?%>Q, ,O,H8U61O=<>.+6NM?FI4_L VZ
MQPE'B6^CW Z,RU.64@13J9D!N5<N"'<R3?F.[V+4FW 55+$EWK6&A<GT!]<
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M4)P!G[O&7_W1WFB9VZ#+B,2[HHU%]]2U7A?:#K>@69B;M*M(;T)G>& 4K&&
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M>4%9G/][BQ"=@N2!"_@G=A^0GX72%'S/%QN = +;LZQV(\A"M%FV)N2FT]M
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M3N"3A]DFBYK8X"[;$=T0;5T;#Z5<  'HHXI#;K&3\] >&P<F[O+B^3%9&?F
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M6)]I8_&!"S(QS9>(4?7ZW:90W.<%/B[@HU3M(+%Q&@Y9+]HO1+^!=*VSL48
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M;M.33X5^]:;**4[V]](=! KV*)WYET7?\%;O1V>X"(72%_N+F]E6&UJ80L9
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M8?R$ WLQDE$NMGR8E2@/P659 BSE(7N>(M*-$^C@#49YM()13#O4)J!242^
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M1-+2I<[^IA*7GO;>]D1",UEE[EXO?Z7:'@\PUIGUOV(9UKY^W1-Q99W.Z\U
MD*LB_)>/-0^=#6]'.S9,Z@T3CSLH\BBOI)-G)T8OA>'5D,87WE2_&^!4P4YY
M< 9O%?:YLX?@#*%GPJIYH68JEH4#6;&N"J>*N2AUIF)%5AQ\E%%&]N7)T$$Q
M;Q_&M9*+H&2R0\EX(FYUX5(KWA4))9L"AD#<PIXTL"\F>R5>43P0TW%?3$:3
MZ1YYTY:&J9<WW2'O4IM2&^E(J")$N@^9(A'6X2FBT#%%-]?W#R+6>9DI6<0D
M_B$CZPPBZY_;2 DJ#[>KY&P[MJ6,Z;2'=+)D%M0[>_&7\>O1+WL,.FP-.MPG
MO>O73Y9F52;>(_HMW]\9I+1QJ[ZXR[RO8>6[KY4JV<IM=NS7]#&E.E!97Q64
M98VRLE56MLJH42:D(2&MF.D,Q<$>BXM*90F"SHKQD7!:'([$BJ2QXEH]N@HL
MB?&(GT^:Y[<R3H$'BC<%^]V0$5;]YE(R8MI]MH?BHY;BH[V&7RD;9]H"%AMZ
M14ZJC!)QTPV@"'40X M$BY(9WB%<*D9HMQ&]7Q\3[3@%1<2U5-@4G F8)I(6
MB46A! D&."JDF@D1^P9/,^FS&13PCIPD+_=<E48!78G4%K)$9&,O5LU:T&H-
M>B ^:.3(QU7I;=ZV1MQV1+^G!?%+\5EF5:#DEERJ$XX3KR8A1P9UC<1,*B,6
M6$?=U=)\06=*4-K$N\<XE<6<A,_3FP(;R3IQ-7@SZ% LK25G&P,3(5U7\L'7
M"@:$2'&KKFDOQ?5ZV;A1'&Y_#YOR\ Q\(?4_#,]_3'5"D?MS%5?%\ZR>BDMM
MW?"\1-(BKWRW2P2\P!5/&E_]Q<T,MZ ]AC+<PH41<A@!YHM8@6J)U&^@^"!I
M%?21I% .OQ4 O6B=K*R(I3$<>$B7?JV7)XIL]43]X#M-C[5O8AR+N+0**1%T
M&HI)+5CF$PKN$;)%1:\""-EPP<G7$:R9A?\HFBUK SP1$:I4\@=*I4]$+IN[
M1, *?D^H:=#$E^!7F]"/R2B?0(V4/&140C8V*H(>Y)M/4Z9J^IV,I93YO,QY
M(-11IN8>D:W+R<\*58#%M"'=]^K'O$6&47-,8#0,='%KL3^*[;TNYJ_81R+3
M+(8;B4P6W-_#C?;=H]#%J[B";CAK[6$KSG/VR[\\)*0%B^4_CA>Y^0J>S/X[
M7<\("T1<H1U,A1;PC01*U R<L:B9T3GO DUKQCD^QHB2FP(=V_FBP &45ZZ"
MNV:@?1^S'W#E7=K<>U99W@>::Z=\%CRM>'WV7D[&!T0I@;SO7]>#)UF.CU);
MY0(IGK#VR0["+RB6:"ILGZ6N-I'*!5<H4%(9+G_L!];AT$WP8P@IY*?3_E./
M*6ZG<VD2#E/&XN&5H0G[TO"HZDZ_4>AX<=V30SJRJ^"64"_KS+>8JQ.? >LV
MV@Z;OM"-WPS&@SY?_!6W3.(3VP_DR];^FZ E1MEB,)[SI7+IGV]YB,D?-QRG
MK9WP@9*VP?^9")Y4;5(^)U&\#?E$0O& J*_?UI1G)6@S!FPT8>WE<\@TIR[>
M.ZMXYF67IF+& _*Z(^N(#PS>&WEG1'J._G8:Z"((K*_9P/DF4IER?.YKE2ZD
M"0E=RE5@RE9HC4RX7LF,%V]X8I-''7P!:<J?#!IK.>0:"_FX\$<XKS<9,$&%
MYE%C ]*>HMLL6^%481H*,R^AA:UL5_NZDV(.#H,K&(BTP7F W_"XR6 F(\_2
M$EDA0G6.5[Z%\P%PHTA.<,;RP]!Z6OC6E[<J$2\R]PM**I](COT#')-IU938
M%_,G;_].1F-&JTIP&?"T4["?B>U2ED^ [!AG?@H^KLWO;ZZOWX6AKH419-GG
MX+\TVMI7+9M;#/@1I B<MPB;3L#X\T\X<43L;ZZ":$(1 CZ,%[[/Z-!YV:4X
MD;+O&\.L.+C\?/_=L_K_!$B8$7P1_ ;3SOGU4S@-GC^(Z:2_>_!$BH3!%05_
M*T#.';FE4*P&6T9D7QZZ>?O_G8<O!F\'AP/?-;=UR^Y,RD:FE,QY-]I"X&-C
M3$WFOC;X<S6PIJKLUR*-6?$K=%34EZ8%;72=2&;^\U'X[(JJDU50+L+QUH]?
MW7[F',RH0NNM>U@-S2C[Y0#%>]O'C&'GFR!FK;G_\LFN!*CP>;!]VGY</0_?
M%-?+PY=9A#F,M:BB,VP=#=X<]:#:?^T,-TZ7_@MCI)W3N;],2<)[O #O9QKT
MUS>LH/WD?/9O4$L#!!0    ( .%95UB2J7"9QP,  +$)   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4T+GAM;+56;6_;-A#^*P<5*!S LZP7OZ6V@3A9UP!M
MYR79]F'8!UHZ6T0I4B6I./WW.U*RZF2)L07;%YLO=\_=/<]1Y'RO]!=3(%IX
M*(4TBZ"PMCH/0Y,56#(S4!5*VMDJ73)+4[T+3:61Y=ZI%&$\'([#DG$9+.=^
M;:V7<U5;P26N-9BZ+)G^MD*A]HL@"@X+-WQ76+<0+N<5V^$MVE^KM:99V*'D
MO$1IN)*@<;L(+J+S5>KLO<%O'/?F: RNDHU27]SD.E\$0Y<0"LRL0V#T=X^7
M*(0#HC2^MIA!%](Y'H\/Z.]][53+AAF\5.)WGMMB$4P#R''+:F%OU/X#MO6,
M'%ZFA/&_L&]LQZ, LMI85;;.E$')9?//'EH>CARFPQ<<XM8A]GDW@7R65\RR
MY5RK/6AG36ANX$OUWI0<ETZ46ZMIEY.?7:XUEQFOF("L8'*'!K@$6R"8C(0'
MM85,2:,$SYEGD7;C89Q [XYM!)JS>6@I"X<59FW$51,Q?B%B%,,G)6UAX$>9
M8_X8(*3TNQKB0PVK^"3B%68#2**^S^P$7M)QDGB\Y 6\56UHQ1BX5.6&RZ;P
M/RXVQFIJHC^?*[D!3)\'= ?KW%0LPT5 )\>@OL=@^?9--!Z^.Y%NVJ6;GD)?
MWC;GR6FUUNJ>N_-">JYK39(:I$6>(5P(H3)?RG/YGXSP?/YWU"354;SJ$*_R
M\5@7#P3F8)7O*HV9VDGNERG?G5+YG@OAQF_?3)-Q^BZ=C*C/A2"+/ATOBYJZ
MG@"8@:TBS+TYAUYK>S \@_>,:[AGHJ; EH[ZUYK2\E&H;Q%^IMB:>M=2BW/J
M6T(S: U,)FF[E]5:HR17F8-4\H=NWABZ9<'9A@M"I4,R&\(E,X5?S]P *2+%
M)Q<#4[C"+9(_E<T>T/1!TM>U-SJ#S]@A4L6_W%ROX%JZ$C'G+L\/2N1<[LCC
MX\=+F(XG\-.!(<?+^C'%43])8W Z;/EK%6B9' ]G!S*/=?G_%4AGR>L4Z$7)
MV0D-HN@%%:;14QDNREKR!QA%1VP[/O[&=A2/_PG;?<>4/R<D;7[XGEKWO82-
MNP7[_^Y$Q'U73$OT?TA],AL_HN@QO3.B]U7"Q,GHA"YQ.H';@FMT]XJE7G=(
M[HKA.>JV65NP;] SB/!940U7@V@Z.(->$B=/Y;O33!KA"EUQ!>DX_JYBP]P3
M'>/^:#J$Y[Z[X=$U6J+>^<>"H>QJ:9L;M5OMWB,7S37\W;QYS'QB>L>E(:&W
MY#H<3.CZU\T#H9E85?E+>:,L7?%^6-";"K4SH/VMHK+;B0O0O=*6?P%02P,$
M%     @ X5E76#D*.I_- P  M D  !D   !X;"]W;W)K<VAE971S+W-H965T
M-34N>&ULM59M;]LV$/XK!Q4H',"+K!>_)+4-Q,FR!F@[-\FV#\,^T-+9(DJ1
M*DG%Z;_?D9)5)W6,+=B^V'RY>^[N>8XBIUNEOY@"T<)C*:29!86UU7D8FJS
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M_[98L!N)Y(9\=>>FCK>FJO2@D]]5*0<IGS[;&.7A]%"&N)D/W/0ST/R F^:
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M(BP9X/O*&+]]H0#-[Z#I?U!+ P04    " #A65=8KJ5*?^P%  "(#P  &0
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MW&8P]&#8AX$'=],)/&*S(CK<D.8\VT S;,&9U\8E ?A>#P:#LGYR)R.5ZWX
M US"X$%9GD"/]2#H]X&=>0[N.Y6@5E7='TDLNYPMG8A@3I\D9I*R29,\1&X8
MZ>8P_3RKR%*G9;:!MY/;&[C.)<:;A>(4ICQ3<PFQ2B)S: LZJ;+W,DK*S"W4
M$=E' ;$QW(ZGP ;0-$+ ;\H*>--F[58;.X)P(F]$.L/L5-PY)1P24RDUI0H2
M9=S"LN"LZU<UAS4WJ,:A6F3R;\2%(UM /V_Q;O.^&P\^KDBJT33MFO,DH3%Z
M-C'7 G(M,02,$W_ON YC!Z\-#Y3LE&Q7>QU$ A,)S!M*XQ8,RK0TU;I=N_QP
M]% U]EF[W\4D4<L57%D57&F[_GHV=*@-U3HSV'_>:_)S=W-7+[A^;!]A^EG-
M]+.7,GWJPL*'B<9FPJQH^)4R0IU9=#YATB*F#^A*(-U"E;H-WRT*QS%192Q]
M$F!&GWC,MUJ;LL<=X?H7F/65T%1K4Z%NRA;6I$*>5,B;$L>5@Q_NP9<%_+E6
MZ1ZE7T204P>JFC)Y@EYGPJZ%0.+L9^.OW1J;@\QZ=S\%_)0U;=V2QCD7'+L5
MQ4&N9+1$6:DM4X1[=H&2D"F+'W)L7<F3UOES^?RWU'[<1[93Q1^9J=NG*$*G
M225H_6!^G6KZ'J)F?M""?@^:^,=0B;M;1_]Y5:'9;P%*'&M!L]MR+BN!+W1]
MB#B8-T! 6*TA O(($&$=_^=B=T"ZOZ6T5M%IEHZE_YL&?EDJ@HG:\83G_._1
MPB.B%=2B%;Q4M"8:@Y(YUN8!OX6&NY-Y0;QKGA#'3$&R>Y%P0CSAF@Y?AU3I
MN%/*55Y[L\^]S?:\Z=);7GAS]"QN*:[J3M?.#U!RRUEWRB'>3CF>C<$_ZV.K
M^=#WX%YM>%)81;^J/).XM@^Z,/ A"&!<-))K-2%73DRWJ[>#QGV96&\(W:Z'
M_!K"9(GM@:>H7>OB*][8:*B)?I)E1.2A0Z?KI&JR!4&/00]//7Y_L 60\\TS
M[^6(@;Z/(3%WJ,!@\7Q,@9]2>QDDLA4IJ27Y$Z7X_V3V\^Y27;'#4?Z.;U V
M3LL4/C^J4*RWA46#G8Z6B#K/!)J ;B7\8+MV=FY'J= +=P<TX"(N+DKU:'W-
M'!>WJ^WRXHZ*;%Q(Q)&(.6[UVGW\-.KBWE>\6)6[N]9,6;RYN<<8K\I"TP*<
MGRL,L'PA!_7E>_0/4$L#!!0    ( .%95UCM=P$?_P,  .P(   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;*U6WV_;-A#^5PXJ4"2 ;4F4_"NQ#21-
MAPY8NZ#IMH=A#Y1\MKA2I$M2=KJ_?D=*5ES,\=->*)&Z^^[[CG>D%@=MOMH*
MT<%S+95=1I5SNYLXMF6%-;<CO4-%7S;:U-S1U&QCNS/(U\&IEC%+DDE<<Z&B
MU2*L/9K50C=."H6/!FQ3U]Q\OT>I#\LHC8X+G\6V<GXA7BUV?(M/Z'[;/1J:
MQ3W*6M2HK- *#&Z6T5UZ<Y][^V#PN\"#/7D'KZ30^JN?_+Q>1HDGA!)+YQ$X
M/?;X#J7T0$3C6X<9]2&]X^G[$?VGH)VT%-SB.RW_$&M7+:-9!&O<\$:ZS_KP
M 3L]8X]7:FG#"(?6=C*)H&RLTW7G3 QJH=HG?^[R<.(P2UYQ8)T#"[S;0('E
M W=\M3#Z ,9;$YI_"5*#-Y$3RF_*DS/T59"?6_WJ*C2@M!J6C3&H''!KT5FX
M^L(+B?9Z$3L*XXWCLH.\;R'9*Y I@X]:N<K">[7&]8\ ,?'K2;(CR7MV$?$!
MRQ%DZ0!8PK(+>%DO.@MXV2MX3TU12M(I-J+DOC@LZ$TG? !2\$)(X01:X&H-
M^*UI)W_RPCI#=?37N:2T(?/S(7UOW=@=+W$94?-8-'N,5F_?I)/D]H*@O!>4
M7T(G0:&EO(IV0S^=;.A=T'6.\F705TNCU/7."(LW</7VS2R;Y+=4F5)2'J_#
M#OF!^2&%]SYWWT$H2EQ#O4S>W,&&"P-[+AL$5QG=;"O0(5A QLKW_![)B^8(
M5P^CZ2@=74,Z2&8SF&<3F%&0!RS<_P#,"#C+)Y"Q.>3YM,O?1BBN2L'E4?-Y
M\)W1&^% &Y#:VA8P(\!9,@L<YPF#1X/#3>,[ 7;=8:8+*;9=X5U]T@[A893.
M@T8V38%-B HA_*+5=NC0U!0'=UQ0*3Y[""K%-,V!S28PGI]82<U56[)\O2?Z
M7?WJ_^RCP1+%/O0W7/%K0DDA'S/(9V-*JZ%/_J@\2<)IFH^$64)T:?]9RF[[
M9P9?M".';,#2&8W)?$QCRJ8ASEWH,^IFK NB=.SH >536/#UY[=&-FNT-S"D
M522J"@\$Z/LS"/1O7=6EX^FQ\,#I8'XO])TSHJGA;RU(Z9XH-P;A4(FRHG/3
M3XB$>B$1.'@FA-M:]>B3'OW K4^:WBKQ#^VC4!"U=?)C9T3T/*>0$N,W8D@2
M7E(/OB8,+=FF&$JDFP5XK1OEA-IZ.4<:&>MI'-LMG2;]6H%T,R.LA2T[Y^L!
MR3:VL3W$)'^!H%KMEEF27D)Y3<OHW'D5G]Q -9IMN&?]24%@[674K_97^5U[
M@[V8M_\!'[G94KV!Q VY)J/I. +3WJWMQ.E=N,\*[>AV#*\5_8Z@\0;T?:.I
M0+N)#]#_X*S^!5!+ P04    " #A65=8VK56SY8"  "3!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V,2YX;6RE56U/VS 0_BNG("&0*O)6&"MM) I,3!H2
MHGOY,.V#DUP:"R<.MDN[?[^SDX8B2KMI4E7[SK[']]Q;QDNI'G6):&!5B5I/
MO-*89N3[.BNQ8OI$-EC322%5Q0R):N[K1B'+G5$E_"@(SOR*\=I+QDYWKY*Q
M7!C!:[Q7H!=5Q=3O*0JYG'BAMU8\\'EIK,)/Q@V;XPS-M^9>D>3W*#FOL-9<
MUJ"PF'B7X6@ZM/?=A>\<EWIC#Y9)*N6C%3[G$R^P#J' S%@$1LLS7J$0%HC<
M>.HPO?Y):[BY7Z-_<MR)2\HT7DGQ@^>FG'CG'N18L(4P#W)YBQV?4XN72:'=
M/RR[NX$'V4(;677&Y$'%ZW9EJRX.?V,0=0:1\[M]R'EYS0Q+QDHN0=G;A&8W
MCJJS)N=X;9,R,XI..=F9Y%)K-!I*%#E0BD$S@4 KKK*2U7,$5N<@.$NYX(:C
MID0(9C '(X'MLSWZRE*!^GCL&W+5/NAGG5O3UJWH';?"".YD;4H--W6.^6L
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M6M,!3^%?:YR#FQ @^X:8[J2UORCV?ZT\R#T]?(]62>T@C44I8))R,:5Q4;"
MI!DA61V0O,S)9GD.$S&X\+*"+]0@0/6PM8:H'11Q)6J8%$4VI7&6"K)"$(DH
MJRGD<5T5A!3EX),''\8+>*=Z1077PMJ8UD$6L[R "<^+*?"X8HQLF5<!*0-2
ML)2LJ$DMK_* Y%0NGXR7&E(6%S6#2<UIH::]18 8)]5IS 2!55P+%I92$E&S
M 2G3 LZ]H.2D#71HUT.S"_>WZ_W8$8[HL9_>C&WDC_O8C#]*NU94(QI7%,JN
MRB(".S:X<>+-=F@J2^.I10W##?T3T 8'6E\9XY\G88/C7V;Q&U!+ P04
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M?+3R"!U.\!3229XO>,U^2AAB#I^4(PZ!@W!338:%?5NPT!+:WE -R*Q0&'A
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MT,YTYKL.@,M= BD1HVR?FL>\(F[F3SQ_J)FG>G.WX+Y.JK1@62.)%]#]U%-
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MH"6SK;@YT84P=7G<040'(.DG]M91,L46?*TC"F9;\&4=^'K.#CK"Y= ;^<<
M9[<$F@A"5922PN.Q&T7B';G(Z6QQKI(C_K,.TO8=8D3G1U#A*IT]T_]EWU=N
M8$.KN,*'"FEVY+0PLET_UDFQ=5)9K@,E1\GET.D_1(+.?O XU>6ITT6H3+4Y
M]<%IK4)]Z#VT 5 VNVL.5[+KHGR_H4&WAE4Z]A8-OA3[= R#H<#QV/>"L*8
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M,BYX;6S-&FMSV[CQKV!TS8TT9202?-NQ9YS8;MPV%T_L7#]T^@&B((L3BE0
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M=:\'E7F]?E^+ IY=?RN JE8*+=?UL&?F4"7_&%+1P(J]2'704*U7>9*MH9;
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MQHP/Z:$P7*0<C=I<<=(X<KWDXDX=+ >K05WHT]?FK3F[?J:/;&_!]<'W3TQ
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M7 23  K<LKVP]^KP 5L]0X>7*V&\A4/CFTP#R/?&JJH-)@85E\TO>VKOX47
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M@_$P -W,IV9C5>UGPD99FC!^6=)(1^T<Z/M64;W;C4O0_4DL_P!02P,$%
M  @ X5E76'"W>QT2!   E@@  !D   !X;"]W;W)K<VAE971S+W-H965T-S8N
M>&ULA59M;^,V#/XKA \H'" 7Q[*3]"4)D/;NL YW:]%V&[9A'Q2;B8V3)9\D
MU^V_'R4G7MJEW1?;LLF'ST-2HN>MTM]-@6CAJ1+2+(+"VOH\BDQ68,7-2-4H
MZ<M&Z8I;6NIM9&J-//=.E8C8>#R-*E[*8#GW[V[U<JX:*TJ)MQI,4U5</U^B
M4.TBB(/]B[MR6UCW(EK.:[[%>[2_UK>:5E&/DI<52E,J"1HWBV 5GU^FSMX;
M_%9B:PZ>P2E9*_7=+:[S13!VA%!@9AT"I]LC7J$0#HAH_-AA!GU(YWCXO$?_
MXK63EC4W>*7$[V5NBT5P&D".&]X(>Z?:GW"G9^+P,B6,OT+;V:8L@*PQ5E4[
M9V)0E;*[\Z=='@X<3L=O.+"= _.\NT">Y2=N^7*N50O:61.:>_!2O3>1*Z4K
MRKW5]+4D/[N\L05JH!IK;DNY!7RB<ALT$#[PM4 SF$>6PCCC*-M!7G:0[ W(
MF,$W)6UAX+/,,7\)$!&_GB3;D[QD[R)^PFP$23P$-F;).WA)+SKQ>,D;>"O)
MQ;,I#:@-E#)3%0*7^5X[_,77QFKJE[^/B>^@T^/0;@^=FYIGN AHDQC4CQ@L
M3S[$T_'%.\33GGCZ'OKRGO9DW@B$KFPW?=D^[\IVC/#[D-3;/JU#L 5EQ'V&
MTF+E$B.:G#KAY,-I,DTODB$;3ZD%A7"[B3+7MXI&P2WF8!7<X18E:C((#2+\
MHBS"U2@>#89 ::ZY)K.VM,4>E V3V6D/NNFX,%^-G44\G$S_8Q%#R V80K62
M>!)S!.O:%=;NE!F<0[CSWCL.O,8.W/M?=V4_X55]T1?^0(@IN':))9UAK=6F
MM&80"66<WH;:6ON@U.<J$XK:"5;2EFN5/\.* G*9(83),&'Q $(2R29TCX=L
MD@Q@E>>E.Y'(R45!%Z,+ 34O<U@_'Z31JI;KW-!!\TC2:CH.+6726-J@ZP%,
M*35IDD+,9N135NM&&_0V+VI! >@<%"_V-Y6WT:X<X20E4F$ZF](U&=/S@[+$
M[>/_JHO/IIVZZ<RK2]G9 *ZKJI'JXPWE5ZCM@0-5A,7L N(I$.NN@4,W-L0S
M_+GZ^G"WNO5U_WI]^;#ZXX80.54MGD$\C-F8\-D 7I]6W>:-PKTJ:C-)@^QX
M0[+AV>RL*T,2^WLR([64G+8HLP)XI1K*G-^VTKE39QT/"*%O[$\C-AD11^8Y
MIG0]FWC67Y2@-G3VKDD(S^HFL\V^H=S+UVGB6XU=Y=9H6T0)]UQ23_B4]"*&
MP.M:E)GO]8U6%?S<4/JZDY&]WG.C8R=.=# K*M1;/Q$-]11I[\9&_[8?NJMN
MUOQKWDWL;UQO2TEG!F[(=3R:30+0W13L%E;5?O*LE:4YYA\+^G% [0SH^T81
MU]W"!>A_19;_ %!+ P04    " #A65=8]=F)KEX#  !(!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970W-RYX;6R-54UO&SD,_2O$%"@2(,U\QG%2VT"2=M$>
MB@9Q=GM8[$&>H3U"I=&L),?)_OHEI;'K%H[1BSV2R,?'1XJ:;(S][EI$#\]:
M=6Z:M-[WUVGJZA:U<.>FQXY.EL9JX6EI5ZGK+8HF.&F5%EDV2K6073*;A+U[
M.YN8M5>RPWL+;JVUL"^WJ,QFFN3)=N-!KEK/&^ELTHL5SM'_V=];6J4[E$9J
M[)PT'5A<3I.;_/JV8OM@\)?$C=O[!LYD8<QW7GQNIDG&A%!A[1E!T-\3WJ%2
M#$0T_ATPDUU(=MS_WJ+_$7*G7!;"X9U1WV3CVVDR3J#!I5@K_V VGW#(YX+Q
M:J-<^(5-M*VN$JC7SAL].!,#+;OX+YX''?8<QMDK#L7@4 3>,5!@^4%X,9M8
MLP'+UH3&'R'5X$WD9,=%F7M+IY+\_.P!G;?KVJ^M[%90&^<=B*X!)[54PH+T
MJ!V</(J%0G<Z23W%9,^T'O!O(W[Q"GY>P!?3^=;!QZ[!YF> E,CN&!=;QK?%
M4<0/6)]#F9]!D17E$;QRIT 9\,I7\&XZH5Z<=&"6(+O:: P"X#/UO4/X6RQ(
M(6J>?PXE'Z&KP]!\H:Y=+VJ<)G1C'-HG3&9OW^2C[/T1XM6.>'4,?3:/]XAY
M_US%NUT5YT,5/W,5#_$_'N'WFD-HL^X\-N -O'TS+D?5^_RLNLJH797BFR>[
M4*NS'Z=E.?KEM C @\&X^-69RLWG&[1(/'1OI:. E+EO$99&T6QABH'0-9P,
M.%N0TQ _AF$P^*A[95X0WUE4@JD/U790C:_@(KN$_*J$NU;8%;HS6-%PH_ZP
MH(QC(YXF]$%JG C")M-BE$.>9X/T6U02A%JG<W%V<C:]-2LK2+31Y0@NJDNH
M1B5\I20LE,0MISUX-%XHB!)&J5@/CO384IMRD4@#&HL<BIM6]T):&I1^RX^E
M$G5-H\\&'@U2^]4R4JAC5OLD'>D&-3FOJ4OAA&Z!6C>LIT+!.O.Y.XTE.*!%
M0W/5>280^ S2"*H18RRMT12,W@W1R?\BAX;8\%AW-,H:A,4+S$5GEO+\T+5(
M]Z:;1N+.,]R1!-1U<=#M=G?/Q$V<CC_,XQOSA5)G^@J7Y)J=7UXD8./<C@MO
M^C K%\;3Y V?+3UU:-F SI?&^.V" ^P>S]G_4$L#!!0    ( .%95UAC>$8C
MM00  )0*   9    >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;)U6;6_B.!#^
M*U966@6))20!VE) ZMON[8?=K=KMG4ZG^V"2@5AU;-9VH.ROOQDG!-K2?K@/
MF#B>>>:9-V<F&VT>;0'@V%,IE9T&A7.K<139K("2VYY>@<*3A38E=[@UR\BN
M#/#<*Y4R2OK]451RH8+9Q+^[-;.)KIP4"FX-LU59<K.]!*DWTR .=B_NQ+)P
M]"*:359\"??@'E:W!G=1BY*+$I056C$#BVEP$8\O!R3O!?X4L+$'SXP\F6O]
M2)NO^33H$R&0D#E"X/BWABN0DH"0QJ\&,VA-DN+A\P[]L_<=?9ES"U=:_B5R
M5TR#TX#EL."5='=Z\P<T_@P)+]/2^I5M:MEA&K"LLDZ7C3(R*(6J__E3$X<#
MA=/^&PI)HY!XWK4AS_*:.SZ;&+UAAJ01C1Z\JUX;R0E%2;EW!D\%ZKG99Z&X
MR@27#)XPT18LXRIG0F6Z!!;^Y',)MC.)'-HBC2AK<"]KW.0-W#AAW[1RA64W
M*H?\.4"$)%NFR8[I9?(NXC5D/9;&79;TD_0=O+3U//5XZ1MX%XK+K166Z<7.
M7?*\"0/[A\^M,U@T_QYSOH8>'(>F1AK;%<]@&F"G6#!K"&8?/\2C_OD[Q <M
M\<%[Z+/[NG^(]Z$/^TQ^W7MSTR3UF _O6[G CCF*_JQ.]J^;$**TQ:L$;PM7
ML#GU_)B%'S^<IJ/!.=:OE-B*'9]"6A):8G:EK2,C.<P="WF'A</A$-=TY-<X
M[:!/#C"4KJW,>8<-4P09Q&PX:!$4VJY1D@15XV2 :S(\Z[#O6GW"J\QP)]22
M^&&_*G0F*[A: EOB_66C4&J+KI$._E W80]J(U1..D10V$Q7RC7;E=%K0=>3
M96%&K,](LT^&8[0(Q+:AG1%! Y([R)G3#,J5U%L C)&"A7"(<)*2S1-:T/*7
MYX3P D/C*VVY]/E8M('G*$#J:#%FZ7.KNV)&;0EX=S$I^%Q(X03F+TR)[H#H
MIACG'ZX P\*<_$A&'89)2^+DG,4CC[EXD>DHW!4"*ISX:"<I13M-3COH;KDR
M&!JU'!\KG3#N^JRBI][\"%5>E=+P+,;R&+%!W]<$5K6L<E2F'"]?1:?U&3-<
MUWY6&0,JVV)!&+'F=/M;5MDZ_B46-Z:=:F7,FOH,1QC\ID81SU=IMSVDE#X_
M3-K#>/#B*.[Y"GW-^?]3S;@M:F%Z@%\5"DI0SN[Y4TC?XC\Z?9/],#["'NOY
MU@B\:(3<$NF#6L?F8:#6PFB%GV>'&<-4/]HN(Z=,E;G*4(/L-;J>]PL$W.8H
M^VG7%!Z#A19[XKO&N%SWXK->I^<KLHTC/ZC#MK@7K2.#O2?A;S!ZYZJW3XYU
MZ W27.%00(I8\VU/;/$@TTLE?@-] /W9G$NT!JP>D+SCUF%4B/"B0D>!&;WE
MTC<46GVX9]BAX%OT\N;OSS_N?C[<=]FF$%G!-MRBB1(;$?5R;%R2PL\:E'/L
MO-VGC5*.DPF-+9["&O"NMU66@;6+2I()R2N%> W_)I 'H;OJ)1BY8Y^:Z&!2
M*,$L_3QDF;_4ZJ&A?=N.7!?UI+$7K^>U;]PLJ: E+%"UWSL9!IA#/P/5&Z=7
M?NZ8:X=3C'\L<&P$0P)XOM#(M=F0@780G?T'4$L#!!0    ( .%95UA>.,Q8
M%@4   0,   9    >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;(U6VV[;.!#]
ME8&++1+ D"4YOB1-#.2*YJ%HD&1W'Q;[0$ECBZA$JB05I?OU.T-=[#2NT1=*
MI(;#<V8.1W/>://-YH@.7LM"V8M1[EQU-IG8-,=2V$!7J.C+6IM2.)J:S<16
M!D7F-Y7%) [#^:044HU6YW[MP:S.=>T*J?#!@*W+4I@?5UCHYF(4C?J%1[G)
M'2],5N>5V. 3NC^K!T.SR> EDR4J*[4"@^N+T65T=C5C>V_PE\3&[KP#,TFT
M_L:3^^QB%#(@+#!U[$'0XP6OL2C8$<'XWOD<#4?RQMWWWON=YTY<$F'Q6A=_
MR\SE%Z/E"#)<B[IPC[KYC!T?#S#5A?4C-)UM.(*TMDZ7W69"4$K5/L5K%X??
MV1!W&V*/NSW(H[P13JS.C6[ L#5YXQ=/U>\F<%)Q4IZ<H:^2]KG5O4IUB>#$
M*^ K9=HB'#V+I$![?#YQ= ";3=+.V57K+/Z%LRB&+UJYW,*MRC![ZV!"R 9X
M<0_O*C[H\0;3 *;1&.(PGA[P-QWH3KV_Z6&ZS^(5+?QSF5AG2!?_[J/:.CK9
M[XCORIFM1(H7([H,%LT+CE8?/T3S\-,!F"<#S)-#WE=/[14!O8;+HM"I\ JF
MV18_W';IND+7("JXKHU!Y4"H#&YPC33+6J+[V!T\?S^[YYQU0M* A.\RV%PW
M%ARMBC<8Y7M))1W&= =CUF-TC/$,CCY^6$[G)Y](Y45!KHY]SGF(>8@&@MX>
MCN+Q;!X>\W.Q.*%G-#X-E\=;ZJW9Z6P)B_D2IK,0GK43!1O.P]AOI,+E-\YF
MM+$+;8)4Z5KTC%*J%[2.JI"S5$%272M'OLD$:BO5QM/'[[5T/Z!$E^L,%N-H
M-H4H')\0\,5X<;J$ XJ8#8J8_:XB;N2:**)*M[F_I15?WKPR'H5##_[)T2A,
M!M?:5-KP\HZ V&R?- X#815D6P1]9GT<!A0</=.CX$^V1Y(.2'9DTII652%3
MKR^IX,X(=B\M:ZB@GPM%75@*/$FM8;7\\4X? ]O#+N-9L.R&97"R&\U=+@/@
M._Z6OV?$$[M[@M/P))1>2S@2K*IIP.*:!S,:3WE\Q!?)_S++IMWMT+8V[(:<
M6G2NP%9IE&4VR*2M:CXF#A9P% :DTB@(X<'HQ!]I\ 6-)4VS/98<6)+(-COD
M2+U1,$7AF@#4)1KXC*)P>2I([+9.K,RD,)(O5G(,LR "NHYQ%'\:GG="&G@1
M1<WGEB@8.7OEPU.J^G0;>$:OY M-6PY"<D3 Z;KU;KY2\ Q(@DM'I93$8$I6
MI][R]KV XIAR%)T&G&.BSJ$]H,"]R>HF/R>+K[G<J+?DJ27@?J$M:VOZ-="+
M<'UB<U(@M4,M-Q_-4J@?X*L";Q]#J:T/2)-+PI$+HD)Z)<);%.2PUV+@@WVO
M?&4QF9=G(UT.]Y=/$,5C$&^J)!12)++@6M,(QIKJC9+_(5>I]C+H-@S[M4 ,
M?<EZKXDW(6BA=XRY@',X&JK)G=S\7:(LJZZO\H#YU,IHTC.RDBMAAM\!?]HG
MNH0+*%H*FN +H"B(:4OE:^IT0L9,*? BH1!EZ-!0 ]0775%RU/L#?A$FKM/L
M9=R6"98#EXIQ3\]1MT@GDAJZV@XI96>#/BKL5S>**.>RHH)@ZM21YKW>T3CQ
M4^""?55^LM.9$?^-[S]MJYBV21M6AQ;WLNWLMN9M?_Q%F(TDU16XIJUAL* Z
M;=J>LYTX7?D^+]&.ND;_FE.;CH8-Z/M::]=/^("A\5_]#U!+ P04    " #A
M65=8PFRPB),"  #\!0  &0   'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6R=
M5%%/VS 0_BNG3$(@;:1)2D'01FIATW@ (=IM#],>W.3:6#AV9E\I_/N=G3;K
MIM('7AR????=]_ER-UP;^^0J1(*76FDWBBJBYC*.75%A+=RI:5#SS<+86A";
M=AF[QJ(H0U"MXK37&\2UD#K*A^'LP>9#LR(E-3Y8<*NZ%O9U@LJL1U$2;0\>
MY;(B?Q#GPT8L<8KTK7FP;,4=2BEKU$X:#187HVB<7$[ZWC\X?)>X=CM[\$KF
MQCQYX[8<13U/"!46Y!$$?Y[Q&I7R0$SC]P8SZE+ZP-W]%OU+T,Y:YL+AM5$_
M9$G5*+J(H,2%6"EZ-.NON-%SYO$*HUQ88=WZGO<C*%:.3+T)9@:UU.U7O&S>
M82?@HO=&0+H)2 /O-E%@>2-(Y$-KUF"]-Z/Y39 :HIF<U+XH4[)\*SF.\GNN
MN]2%J1$$D97S%8FY0B #VNA/A=%DC>*H);L16G3DX'CF?=S),":FX('B8I-N
MTJ9+WTB7I'#'D)6#S[K$\E^ F+EW M*M@$EZ$/$&BU/(DH^0]M+L %[6/4@6
M\+(W\,9:J%<G'9A%]S"Z!'SA-G (/\7<D>5_Z=<^\2UT?S^T[Z]+UX@"1Q$W
MD$/[C%%^]"$9]*X.$.]WQ/N'T/-IVU:>]\RB+AW3!U_>VU;%^+_RWG-YKW?*
M>[LM[SYA!U/O%S:K.$U(-O>M#ZXR:P?O^M]X]@ QG,7&6/)W#5II6&)(QW[E
M)1P??;C(!OTK[A*.-_HD_!%^2?V2P+02%OWSZ/=PR :0)!F<#6!F2*@=>U_M
MXIV.K-$NP]QQ4)B5IK8YN]-NM(W;CO[KWL[%.V&74CM0N.#0WNGY602VG36M
M0:8)_3TWQ-,B;"L>SVB] ]\OC*&MX1-T S__ U!+ P04    " #A65=8J6QK
MS.0#  #W"   &0   'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6R55FUOXC@0
M_BNCK+3:2D @O)1K 8EV]W2G4R54NG<?3O?!22:)5<?.V0Z4^_4[=D*@$F5U
M*@VQ,_/,,^-G,BSV2K^: M'"6RFD60:%M=5=&)JDP)*9@:I0TI-,Z9)96NH\
M-)5&EGJG4H31<#@+2\9EL%KXO8U>+51M!9>XT6#JLF3Z\(!"[9?!*#AN//.\
ML&XC7"TJEN,6[?=JHVD5=B@I+U$:KB1HS);!>G3W,'7VWN!/CGMS=@\NDUBI
M5[?X/5T&0T<(!2;6(3#ZVN$C"N& B,:_+6;0A72.Y_=']%]][I1+S P^*O$7
M3VVQ#.8!I)BQ6MAGM?\-VWP\P40)XZ^P;VQGTP"2VEA5ML[$H.2R^69O;1W.
M'.;##QRBUB'RO)M GN579MEJH=4>M+,F-'?C4_7>1(Y+=RA;J^DI)S^[>D;!
M+*90,6T/8#63AOEZ&?CRPF*!YF816@KDS,.D!7UH0*,/0$<1/"EI"P/?9(KI
M>X"0&'8THR/-A^@JXE=,!C >]2 :1N,K>.,N[;''&_\D[8U/^^]U;"CUQ/YS
M*=<&:7(9R37-G:E8@LN NL*@WF&P^OQI-!O>7^$YZ7A.KJ&OMM2$:2T05 :/
MJJ16-,RK><-X"E;!'WB )R:I?ZA3+&Q0&R4EBDN)7 _U4B!8=^(0NU8%4ZB]
MZ4%,JCA4V -+SY-S"E5+X94HE"<*U9'"'7SY_&D^GDWN2;A"D,N-/SYWB=QE
M!-M":=NWJ$L**C'CEF3';F \H\.&\1@VRM@^EI50!P_>647^;ULPC7W7E4[!
MC<D<1K\0.KPHRP2]-Q*52_X?&7"BK!5Y@](@E#$PF<$T@NG4QSPO;P^:F*@I
M@VAT>V_ J(03GL&DUIPTDY# -8]KWRL]2#E%LDJ;UN%=J7K 9$K_5$I*E<NF
M?J>,);U\Z8 U[JAV3!BWN& )*A8\]UOF9G!%7=-.7=/KZFK>Q"[<.L\U$C;"
MNE2U)%8;=O!J^)\BNQKQ<K=<5)[7&^M8G5('YNM#;P0L8]1.*#2; %E2..UQ
M15)PT-+UMWO"9<IW/*U=8?>%@D*)U$F@8#N$ FF!;W2J;CI I0QOWGY[;@M2
MS)9)D@RD=.@R)T[,MD$&/U?WJ:965?VZ@JH=9F?)4(B,[8@-I92@MC1&23JZ
M4MIGG66<=HW7#UE\ZXB26DMN+2*4O@P&1D/WB>;G82^IS4&)NJSZ-(=)<I:$
M^[ZUSBE]U-M G0.W<$F#X=DP*E'G?N0:2HI4U<RE;K>;ZNMFF)W,FY\$3TSG
MG,Y"8$:NP\$MB4LW8[994%W]:(N5I4'I;POZ98+:&=#S3"E[7+@ W6^=U0]0
M2P,$%     @ X5E76"L=6"Z3$   ;R\  !D   !X;"]W;W)K<VAE971S+W-H
M965T.#(N>&ULY5IK;]M(EOTK!<^B80.,31:+K[P .7%FW)O8ANUDNG>Q'VBI
M+'%#D1J2BN/Y]7/.+8J2'<5M9X+!  ,D%LFJNG4?YS[J\?*F;CZW,VL[]75>
M5NVKG5G7+9X?'+3CF9WG[7Z]L!5:KNMFGG=X;:8'[:*Q^40&S<L#[?OQP3PO
MJIW7+^7;6?/Z9;WLRJ*R9XUJE_-YWMP>VK*^>;43[*P^G!?36<</!Z]?+O*I
MO;#=Q\59@[>#@<JDF-NJ+>I*-?;ZU<XH>'Z8LK]T^%38FW;C65&2J[K^S)?C
MR:L=GPS9THX[4LCQ\\6^L65)0F#C;SW-G6%*#MQ\7E%_)[)#EJN\M6_J\J_%
MI)N]VDEWU,1>Y\NR.Z]O_F)[>2+2&]=E*W_53=_7WU'C9=O5\WXP.)@7E?O-
MO_9Z>,P W0_0PK>;2+A\FW?YZY=-?:,:]@8U/HBH,AK,%16-<M$U:"TPKGM]
M8:=0<:>*RAF8FMJ]S*]*V^Z]/.@P _L=C'MJAXZ:_@ZU0*L/==7-6G543>SD
M+H$#L#;PIU?\'>H'*;ZUXWT5!I[2O@X?H!<.\H9"+_P.O=.%;2!E-56]Y*WZ
MW]%5VS6 Q_]M$]B1,]O)T66>MXM\;%_MP"=:VWRQ.Z]_^5,0^R\>8-8,S)J'
MJ+^^<)ZBZFMU O^\R&$5=76[8EWEU43]V=;3)E_,BG%>JA'\<IL0#T]S.;.J
MH\G5%9U4M19: 1RZ&::LZNOBES^E.DA>M*H"%ZUP@6;58=RMS9M665I;P59V
M?F6;P5[R5PN;> B>JUU0"F/S D@N2T!M3QTM&P08];$J.E"XZ/(.Q$]!N1$*
M]]J'!JUV\_N#A\9 [5[MJ<.B7LQR8%JE7AI&*D@\'>,G\)+,5V'BI?A)/9.E
M*HB]+$63]D*=21. C"8=JR#TM(DY*@;=$&]9J"X6=ESD97>KWN2-5?CH2Y<L
M2)26OT'J^0:S>'Z %M]+38J6"&,QEXG8+8F-PDR&SX$).'L2:=KZ!L:<J;<?
MSXY_.SJY5(&GM0$[@0&+7FB$8!)$*L,,L?O@^7Z"+F0N-A#!RY) Q1 F ON9
M&GT\'/WY^%29,%$F]E64JBR*5!1@6HCI@Z(/-OPPP#?-6?@W9"O[O3DZ/_J?
MWS\<*0V*09HI'6<J3L%YB/?,*)U %G"@C8&>0[3': _5N]'A^<B-A(21CQ;(
MFV4!**7*@$=2R$(H![8.LPB_L4I!Y</OIQQWH$(,U!'(IJE*0-+X*?"% :&&
M#" 2T)@@3"F@AE#]>O3I<G0R@D+1R<<@%:(M1)<D4BFG@5QLC$(%"!@(.'I_
M=G[Z_O@W)4C7+Y0Q3B<1?H=O,#+ $OEF^!2"B52#!Z..WI^^N1Q='JW;:%/,
M3RD'$I$OWZ)T@RQU&AH5Q2&<N4)X*M4'.RG&\-*6EL0<,$UJ:&O8CBA-8F4$
M-!H B@&C@/SBDX9]/5I9>S'^LL&P04-C;VI@==2*=\.NT"=L#]@#=UD"XCJA
M!@6]7@S=@':0<5(8//#2.!5<L'^$41$ G*[1^O[TT]')Z6_ G%;@(2,F QVI
M&"8"Q3@4[,)6"4&0J80FQ?2QNCS]^.L1H$EI M@WSF0HGN!PFA;'5WP!E9!0
MBP!O.%6&?F?O1Y]@-$R6"F@R>%G@!RI3*1"186Q -U&IC[^8]*2NGMW50HBQ
M4::AYBC$DQ=ILD7584;1<HBQ4&- Z5-Q-9T&^!X%_!Z;#8]]/SJY_'BA0KHW
M^B2I[KV+@22)2-,'3>U1!@.726-Z6( WC3AD^@A6@<LQN<P=EQEZA3Y!8,!=
MZ-'QJ"'0((K!E4\^TT!XBYQ'P)<-OB;H=5Q-4$<T"%A][(Z@)K"8 (8:_Q,:
M"!J-P6E"O4,\\ 8_^Y2/'0JA$D $<0XQ"^:'01*/ C <!?Q.CT9X(Q3IV0Q9
M JR8#(90+6 $TH.JSFJ$_X,SVW3+MBW: T""YA5()@Q% 4)U"!HFHLKI<UJ$
M"^&$1H :IH0HE7=<79=+6_T]7S,<9P(O=(YB:C>6@$4-);!M)!K/$C@(G0]N
MA7X,$ CR]),*)2H,\1>+&#\;,\2#!;&?EG!-_XN\(/6%-=%[1J:)3WX7K(>"
M6@9(+\N()+/I+Z.RM,WT%N[@K @K). 1L<A@B,8$"9N8C4 ?"(W1ZPQ%MDLY
M$?# ^8W@-:"<&(IXLOH"3!"A 68.!8<^4L/;8FI;5L'JKRB#H2=@@6$S=.Y#
M84  \891(]4"7[+   "RL3@!T\)EW0%-ZVH "2G,R)$GZ0.!"!HU "%DR" ^
MLX;'\!L0DG1M?$0B0,;+^"VDRH!L^G@"U 22WB7/7Q?3)2HK-<N_L#ZQ*.0G
M_P\\(^%W-<J6S_"3\;A>HAR"<EF2=#<U6+M1]5#JM7VIYVT4!2Q*MEC:4_;Z
MVLI20?V:5TN67WTULR]EQ=NEY<2Y*O/Q9TZ9?\F+4JJG"0IPH4LNQO5\4=JO
M/;>NTNQF>8=5RK*<0!(L:?ZV+!K(L;O(FZX8+\N\*6^ELJJ7#9H7*,'(?E>C
MR-_SA*R4-W=T4M6=TPN^L'P2O6!IPW6/&L_R"C97>5.T)'7=U'.A+@IJIGE5
M_%V*?@:'KEF..Q#>?Z!TC8;2-7JX=,7J<;*$4J"A5;EZ;ENLE=IM!>K#Q+XI
M4&?U37N_-NV-3#5PEL=6J/<_N7+U_E?4KE*.?EO KA$UH,F%<2+8^<G)X"=]
MU>EBQU  .#]QHQK[Q59+2?PA>$%!.-03"#L&D[0"=$=O-V!4U'MX0)T0\I?_
MF>_C/>H;LB/84*()")?U0E1DOV)-WW)\#)?/,$0'^+N:"5\3G>[!;I 1H.'P
M:5^9K(>F+ EDYI2=#9Y\I DPXR19NU]1P1FLD%D/1[1,DSW$!?AZ0#J:92XF
MG3&^0<)% ^MV![MEW;9[#KA%]<6N?*EW>AB5AEX*NFEN.A4*\[GM9O5$J@&]
MKK\"J)366''4(2U>+1VTX#4N\U9=4SO!"]"G5Y%=GZ+&&TH*\7+(>1E&OQ$V
M<+D" 13!=3>(]EBWQ3"SP&)6M&J<+SJWLX$IQP7-N8+P=5'E%5<8=Y;E#'>"
M)_1OD3\GXNQ;^^ZOUTA/0>S5=L0BI+NLMBY9)7S?0RP3/18D:\1J20KW$<OU
M5^@0ZX<.-Z'#S2/QRL':AT:U(-6/_QBI"8V%&9%9]E0D2#6/1BJ*GP3>$1BI
M9/$:!3\=I\CWP5IQ*,U_#*5!\@U*PS] J<FDBM&L09B#N6S]=TB^HLBM&?A?
MXSW!=[SG3"08VV7''9=V77(^PIETC*+3[VMA5Q .T=V5/?==*C92ND4L#(<@
MYG&]><^M0#F&2^R&"#@2JKR8CK&K(WGCFB-XE(<9>C&&)(&DE8C>9C+B*G)>
M^K"O19"-\Z9TT%U6Z2ZV^^*!&<KHZ-%N%R2:81.P#)@DR$EFXI^>(A"EN2&P
M-D7V@]YGLCX!1ZO?!U-$AO6)K$U\KA$,ZO-=68KON?T=(P#\3R@W_T5>_4!5
M&P]5;?SHJO:\Y[%PG!S:[H9J&>R]WFD^=O9>%:3#QC-MU[<=VFNN^"_SK_W7
M-8I'=U#\<4#QD4/Q!T'QMIKZ85'NU=2>DOUKF0>+3(%3 25:=5-T,W7\[OQ"
MI5Y?>>>#@7KAKWKA\^FTL5.Q ;U)^R^^"W]I#UX,6FFW:.7*::7KM?)TW]ZV
MXRQUO&0W ?<#R=$5;'U.['WRY\8>23$H2ADP&2=#1) ?BSWPH##F)F<4J]&<
MGNP<S2ENOLB+1MP(G&,4O+0@S7Z':7<LF</OZ_DHRURUQ/C[#B/5E[Q<,H+,
M;=XN^>,HD1?PP3?Z7S$1#?($B16>1K&$0NEH%='O! 7J@FR-A5 ^AEK:@F-A
MB$HT675U4S 13/;Z\EM2D22Q/G20VKAN>]"T!6R<-ZKH[%SR!TH;EX,D]Z2D
MX3+/-"\J-X;6LRA-Y!GS3WO^0[%&XKM@OG)@%\VZ9V4QYK$D9M^UZUHKVUBL
MG=X'$\IH;G]@A00#I5Z@8_5NB%*;22^4/&>,"$R#O-L(9D(JXF8;M\'\G^8G
MB8=$3^X,MV^1A%*!YJ\UL*)H"HG_I W$U&"&IS02&-QNEEN*(T%PH4U,D@E)
M6SQ9Z^RT&*N\= '%A?NCK^-R.:'(Q9ZDDFT6W2W06(O)-O/:H]UB7Y#]KF[Z
MM7['')//I5[E@372'P,=<"G2;?H)@4%D]N$CA6?U$<1;9;N5*M<PEC@V"#RQ
MXZ+MD]3$/L,T #3\$LG:-AVW\LY_R>>+%V\92Z9-/@<.\7&=G4&O;NEVY2K/
M<H*3_U8\Q!8%G9V?/OOM\NA$=78\J^JRGMZJ!7HSZ4'Z7G+=2\X40! YQ>=2
M9C:H'S?DY(:J64E*3QR.-:X;& ]4++F=P%C<82F1.:B&=V]'*E^@X8NC-GI_
M^?'3\?'QJ7()^9V]:J20)R_.%B(F,,'3S6M$(9YK/F@"Q*4TWF3MVS@FFG(E
MC+H8G1MCM,%JC_C(2RP]'#)*N_Q<5,_TWK[$ELM!-4QJS:3=8E3>+)C4-]40
MJQS"UT%J"(WP$-0JZYB)-Q+8"'"BDGV)' _;IU++!4(.-+'(;U<A][\RWQ^4
M( Z)N:= "QBY90-P7X/,YI!@8\@],-V-9NC\_OCP<O3[Z89MV>VN@_9*.9[/
MEU7][!0Q2(#W!D/RJ[I9YYWW0MFJ$:H"ES0D9IQ;63<PSK86@*X[J][L!_M[
M#Y5HR5"B)8\NT48;6L?K\1HP[@#(4V<\0&ZZ6SR5>7^BSL)J,9RO/[D4VSB@
MWU:5/<S]Z$XBW):KR=-BX'HQ<&T'K@%BV&M15V+E.ZD5ON5XGSA+DGE0*NK)
M_A/V-]VR]OC)64:'AIL,.M;JOIP/2X3%;)#)>2R*$CS='^U2Q+>ZXGD8S^)Y
M'.-'3]P3^V$I3:IX )M&3Y8RXL&H'+\BO3]6R"@QW.*,LNC?>=]F6QGNMEC^
M>$/E1RW!L\%LO:[7D?]DB_@\<4U1$X5R,OEXZ)DH &!3Q0/(Z#]F)?] _$Z'
M^)T^]L[3G:M-QQNK?OQ;WX>BWN1@?XFP!Z.YT+XM]#XX\?:K7%PE3S?9*.ZR
ML3X"9?%3\(S)'5$AG?.RX(2=NOM$RGJ<KY*2F%SN^=EF'U(*MIO)MTMO=I1*
MMY=SJ'EH[6%>Z^IJU? VXK/Z^MFRW5H>E2A7J+P6I2EJHCF4,5'+"BLX-V$0
M>T]?1WB].WS+IG?G6[^0D?5*W^PV)*]M0URO&[Z;EEQ,Z"^ #:?J)W)I;7AU
MJ[WU_FM_TM:?5O,<G]>7>%@V'%V'GD%Z.OE&@.=N0R-^\0<A T6BY;&3%_":
M%59[O(SE\^*"QULK6D[U@N$TA02G=3VY@5S*<$=P?;GHCW^SV.#W>R%(&TS)
M&V!1'*\WC[$0W5BG9CP?8\;X,7VNCO%YPJ\]G8D>L]1L'/?[@?FGU9EY*>]&
M>&',2R5<2(?([+P28MRM#.UOU6::Z2=HTXW_KC:1E>6^G<:4@S:-%R3IQLZ\
M1IGQG5SW0QKNCP7<10ENXD/#$4 <#;<F8 *=_ S ^BC-(B\3P&JY_I5EO+3(
MJHT7EX(M*DX]/XI_IHJ-STMK/I@8=!K"638T#L<*U+8\<[!Q"1JQ="I7O5LE
M8<O=AQZ^#K?)1^X2];J[NXK^(6^FW"$J[36&^OM)M.,"ZNJEJQ=RI?JJ[A"X
MY7%F<P1/=D#[=8TU3?_""88[]J__ 5!+ P04    " #A65=8@\=^=#H%  #6
M#0  &0   'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6SE5]MNXS80_96!%]TF
M0"+;LAUG<S&0[ 6[#XL&F[1%4?2!EL86L1*I):DX_ON>H2S'FQO: D4?^F)1
M).?,S)G#,76VLNZK+Y@#W56E\>>](H3ZI-_W6<&5\HFMV6!E85VE E[=LN]K
MQRJ/1E793P>#HWZEM.G-SN+<E9N=V2:4VO"5(]]4E7+K2R[MZKPW['437_2R
M"#+1GYW5:LG7''ZNKQS>^EN47%=LO+:&'"_.>Q?#D\NQ[(\;?M&\\CMCDDSF
MUGZ5ET_Y>6\@ 7')61 $A<<MO^6R%""$\6V#V=NZ%,/=<8?^(>:.7.;*\UM;
M_JKS4)SWCGN4\T(U9?AB5Q]YD\]$\#);^OA+JW;O9-"CK/'!5AMC1%!ITS[5
MW8:''8/CYPS2C4$:XVX=Q2C?J:!F9\ZNR,ENH,D@IAJM$9PV4I3KX+"J81=F
M5TZ;3->J!#^9;4Q0)O@?:<'L29F</+M;G>%E[T;-2_;[9_T MV+<SS8N+EL7
MZ3,NABE]MB84GMZ;G//O ?J(=QMTV@5]F;Z(^(ZSA$;# TH'Z>@%O-&6A%'$
M&SV#=V%4N?;:DUT0Z+ 5Q]SY#M+W3+^KN0\.^OGCJ>1;Z/'3T'*F3GRM,C[O
MX= (F]R;O7XU/!J<OA#X>!OX^"7TV3OML]+ZQK&$?K%;P0]=!:\W%7PJ]I?1
M;PJF(%6GN1Q>\H5=^58:6:'<DG.:KRD4%APMM*M:?Q57<W:;"405"M:.#(?8
M:"A8NE;&+G3<G%GC;:ES%0#FF[G7N59.PX,V8DEK5LX3BW (96^QN])'" S2
MA-X[XP.]5E5]2K^!A25!V1FO .P*V\BQ12,#5+03FYW1WNM7QZ.C\2D.6%FB
M5^S3125,T@\O#II<AQ.Z#BHTP;HU*9F0E#W7RL'SXQ07VBB<-QPW#S-&=PLX
M6FJ?AI-D2-,Q8(?C)*7C-^UH2M.T'0WIS12CKIIDP8X#1<I$J-T(]N;[-$G&
ME!Z):7),PR$&$PS28PP&R81&7?R'CLN6_.U!S_;W<@$8P782S<3B1MWA.2!0
ME0[3T^_&/\58!HAQ *MNMGO>V(!\4P$9#@82TA%LV^'N[#@YV@R%D$\F*YL<
M\6P#JYV]U7DG.H9"<JY%&:A&3-RZ3G $_F4:1[E69AWK\ $S6?&=R$Z>D,U&
M"M/D3:<&D:)HY>!^;?1@#5D^([=(<F=X_,AP%W3Z$#2)E?PK%=^EYG%*>8,F
MOVSU+HPX[3D_H4.19NQKC;1_ ?('TO_ N^RW[0F$Q1R-X1GM;OA^"Y$W%<+[
MR*H,10;Z:=YXV'E_"D\J!SI2@S%BS1@A<>P%;&*#<5Q;%Z3&?*O!7[DFKY?F
MOMC23F3_G&.'=M@>98ME_(VSU):C(X]NB# 9R$O<*F*4!Z26CCD_;&HD=1_
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M#@M\>+&3#5A?6!NZ%W&P_92;_0E02P,$%     @ X5E76$PVH1Z;"0  &!\
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MTOJ@\L8=KG.:#WWCI.UJ0",&4+2F'+5Q)&[C^-REU+CV+_?HHS#Y3[(55@E
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M,UMT51^+U@,C2W\4>>L_#?QE#C0#Y2;8YTLIS</ !6@/IV<_ %!+ P04
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MM>2,,M1P#NN2*#Q?VB!DL"(O]FX,G%VC(8SK=[/86#X.-:8[W\O@.SGANY_
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MK9'ZW"\;FL1@G .=5UKC?N,N&&9[_AM02P,$%     @ X5E76(N4:V24#@
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MFR%TQ5JZVD-CC<1T)&8@,1.)64C,7F.C$BOV#9\FQ]KYV?E%_VDSKQU+J=I
M;2_E(COF=:UR<#9HK]('K;*5L&&=L*$T85=YSGA.%BR:$K'C37(:B;$R(^PE
M6-!DSN0QDMJ'Q@B)Z4C,0&(F$K.0F+W&AAOO5G6XE:'WBXRW%G&17?*&[P(T
MWHJU#UI?*SVC.CTC:7ID>ZO?;KH2(_4.30P2TY&8@<1,)&8A,1N).4C,16(>
M$O-!6"NO9W5>SSYX?_ ,F5\DIB,Q XF92,Q"8C82<Y"8B\0\).:#L%9^QW5^
MQQ\X6Y7:AV87B>E(S$!B)A*SD)B-Q)SQNWFMIHVV)K;(%7I(S =AK4B>UY$\
M_XDIL AD=<(G?3OA(_Z+Z&-:'-$I3I5*3D5<2]=\:&"1F([$#"1F(C$+B=E(
MS$%B+A+SD)@/PEK)5I7F!*[RP=/E:@6@"$,U':H94,V$:A94LZ&: ]5<J.9!
M-1^EM<.\48VA2@?J;ZOXL3B9,FO&W)SDX3QA4S%*2\=AN7QPBM7WDZWV5$N'
MKM" :B94LZ":#=4<J.9"-0^J^2BM'4VMB:8FC>8M?0GC54SH=!H6LV(QQ"ZS
M=!;RXUS,J=F7HJAIR;) Q)/.R[&XGG7_*R=_KVC&61:]5HW(4;-X5RW&M;PW
M!\<9J>E0S8!J)E2SH)H-U1RHYD(U#ZKYE5:,S?5HI)PT)X7;B6[JCE1I6<3D
MKI768!6O(EK4!),I>V)1NBP+'H,T%T-PQL+X<97EG?6&U_+U')Q5: 425#.@
MF@G5+*AF0S4'JKE0S8-J?J5M976X(ZM-C9$J+S+ZOIR)@923)7U=3XJ+(\MB
M*/V3!>+.*IF*6?..@U:YF#E_ZHPMM, (JNE0S8!J)E2SH)H-U1RHYE::JFY$
MXUQ1VKM5'G2=/DIKQ[8I7%+EE4MB"BP&U8S$8<1RGB;L'P6X,[S0LB:HIJOO
M*V+.MTY4&-4RK3>#NOUF,*']LJ":#=4<J.;N]>QZT'7Z**T=M:;*2?V9,J?]
MS_&()6_IGR*<-ZV_7TF//4$KIJ":#M4,J&9"-0NJV5#-@6HN5/.@FH_2VA\#
M3?&4^M'54RJT? JJZ5#-@&HF5+.@F@W5'*CF0C4/JODHK1WFII)*E9=2_<Q>
M;V>TH=554$V':@94,RNM5>(^W)K16]5"\MT[&]HQ!ZJY4,V#:CY*:R>Q*:!2
M?U!!E;[2B+]67V[;/-%SU-SN/I$#+9"":CI4,Z":66G;!_W5[=3MM9@-[9L#
MU5RHYD$U'Z6U?U>A*6[2I/46'_?=4OEZ#TTE5-.AF@'53*AF036[TEK?C5.W
M1FFG<Z'M[Y="^^5!-1^EM1/95"AI\@JENRP-&)N*J6B6QK)3+K+P04N5H)H.
MU0RH9D(U"ZK9E;8Y15:W#WH['0N=#[7M\$%KD*":C]+:X6MJD#1Y#1+P&*^^
M4>-05#^P.%Q&84P?R=&]87W3QJK2.9V5]_#@[$+KDJ": =5,J&9!-1NJ.5#-
MA6H>5/-16OO3H*E?TC[ZAY,T:.$25-.AF@'53*AF034;JCE0S85J'E3S45H[
MS$V!DR8O<!+Q3;-6Y>'C:CH7^[9A(G9KN8CUCBHFN7MPAJ%53%#-@&HF5+.@
MF@W5'*CF0C4/JOE:1X65.CI5NJL/M::,29.7,=VD"<]HP%?%[Z36D^CB9 Q-
M>'B\S-)Y1N.83<4\.HI$BBE?%.=I. N3SLQ"BY>@F@[5#*AF0C4+JME0S8%J
M+E3SH)I?::T#^,-=B6VJH31Y-53'MW5FJV1:'$,N8GNGJ^28+&E6[OPR&BS$
MKG*\I,GKSF%VU/'1,C[=.KUW(^_6P5F$UBY!-1.J65#-AFH.5'.AF@?5_*XW
M^5C;%<:F)DF3EDE,BK05OP*3OZ\#7A]&?J!).@MW1@]:D 35=*AF0#43JEE0
MS89J#E1SH9H'U?Q*VSQ]-3C;\>T:K:DSTN1U1K=A4HZ6ZY 6!Y-$8L6.IZH=
MQ\5/Y1?U#F%:GE]]9$2,EJ'83UW_NM/[1.]*,;3V"*KI4,V :B94LZ":#=4<
MJ.9"-0^J^5I'J9BF*-L#;7_CNAXQR^;EU6IR,5-=)7S]^_KUH_45<:[*ZX)L
M/:ZK7RVUXW%;_>JOKW?3\.O+[]S2;!XF.8G83*Q*.3D3GSC9^HHVZSL\7997
M%7E,.4_C\N:"T2G+B@7$WV>IV/NM[A0KJ*\K-/D_4$L#!!0    ( .%95UA#
MA71A- ,  %D*   9    >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;,56;6O;
M,!#^*\*#T4(7O^6EZY) FFZL8QFA9=N'L0^*<XE%9<F3Y+B%_?B=9,=-1F+H
M""P?8DN^>^Z>Q[KS#4NI'G0*8,ACQH4>>:DQ^97OZR2%C.J.S$'@DY54&36X
M5&M?YPKHTCEEW(^"H.]GE EO/'1[<S4>RL)P)F"NB"ZRC*JG:^"R''FAM]VX
M8^O4V U_/,SI&N[!?,WG"E=^@[)D&0C-I" *5B-O$EY-+ZV],_C&H-0[]\0R
M64CY8!>WRY$7V(2 0V(L L7+!J; N07"-'[5F%X3TCKNWF_1/SCNR&5!-4PE
M_\Z6)AUYEQY9PHH6W-S)\B/4?'H6+Y%<NW]2UK:!1Y)"&YG5SIA!QD1UI8^U
M#CL.87S$(:H=HK\=>D<<XMHA=D2KS!RM&VKH>*AD292U1C1[X[1QWLB&"?L6
M[XW"IPS]S'BNF$A83CFAG#,J$M#D#;D5&\#0BDS6"@!?FL&T3$KN8 T"%,H_
M3RF*F$!A6$*YOD"7I$/.;L!0QO4Y8FBT #WT#69I8_E)G=&TRB@ZDE%(9E*8
M5)/W8@G+?7\?V344HRW%ZZ@5<$:?2/3V@D1!%!Q*I]W[$Q4=$H?6/>RV9!,W
M@L<.KWM,\&+!64+D:@4H_9K\?A;U0'+7K6"VQ*]TCJ]AY&$-:U ;\,:O7X7]
MX-TAIB<"V^/=;7AW'7I\A/<-TPF7NE" W+'0[#F!)6&BZD2NI!?89LCSB9PT
M)_+'9T0CMP8R_?.02MU3JG0BL#V5>HU*O=;3<4^YTP>++WFX(*+(%J#<AJLF
MPK0NG&K$*"HTK7KA&:XK@_-#ZE0A>RZD[>J;<1@'[C?T-[O,6W/[1^;]AGF_
ME7E;:_DRQ3*Q]4<FV(NP*]0-RC6FID4=HMX:\Z4'XT1@>_(,&GD&_Z]\!J=4
MZ41@>RI=-BI=MAZB&7UD69$16>)1TBG+20XJP;.! XG]P,D2-3,2AX=?!5-P
M2(O6 "_5H@(+@YW2"SIQ4W451W_GZYV!6KNA1I-$%L)4'_)FMYF;)FY<\)_-
MJZ%K1M6:"4TXK- UZ RPHE4UR%0+(W,W"RRDP<G"W:8X^X&R!OA\):79+FR
M9IH<_P%02P,$%     @ X5E76-44\$E+"   ,U@  !D   !X;"]W;W)K<VAE
M971S+W-H965T.38N>&ULM9QM;^,V%H7_"N$"Q0PPC2WY?28)D$3O:+;!#*8%
M=K$?&)FVV4JB2]')9+$_?BE9L2Q;8>SLR9=$DGD?4M8])*5C\?Q1R+_R)6.*
M_$B3++_H+)5:?>YV\WC)4IJ?B17+]"=S(5.J]*Y<=/.59'16!J5)U^[U1MV4
M\JQS>5X>NY.7YV*M$IZQ.TGR=9I2^73-$O%XT;$ZSP>^\L52%0>ZE^<KNF#?
MF/J^NI-ZK[NES'C*LIR+C$@VO^A<69\C>U($E"5^Y^PQW]DFQ:G<"_%7L1/.
M+CJ]HD4L8;$J$%3_>V W+$D*DF['WQ6TLZVS"-S=?J9[Y<GKD[FG.;L1R1]\
MII87G4F'S-B<KA/U53P&K#JA8<&+19*7?\EC5;;7(?$Z5R*M@G4+4IYM_M,?
MU1>Q$V -7@BPJP![/V#X0D"_"N@?6\.@"A@<&S"L H;'-FE4!8R.#1A7 >/]
M@-$+ 9,J8'+L.4RK@.FQ 5;O^<KUR@S:7/(R7QRJZ.6Y%(]$%N4UK]@HDZZ,
MUVG"LT(?WY34GW(=IR[O),]BOJ()H4G":1:SG/Q"KA:2,:T"E1.=PVK)2"S2
ME,F8TX3_AY:9+>;DFCUIA:IU_O-/D\'$_D(^9%SF[(&G]/X3T7I]X&*=)T_D
MUG7"R60Z_DCX!O?]&_G@,$5YDG_4];G?OY(/&M(?#;Y\)-5&4?:6ZU:)+#_O
M*GVR19.[<75B-YL3LU\X,8O<BDPM<^)F,S9KB??,\?W7XGUS_/2U^."5]ML&
M0%=?Y>VEMI\O];5M)%ZMY!GI33\1NV?WV[Y0<WBT3LY(WWHQW#&'_T,\Z/!>
M&6ZWA+OF\%LJGVNWQFU7TQS^C:V>:[>F;1?3'.ZPV'CNP?\7'AX?WO;51<>'
M6X8\ZF^[C'[)Z[_$XWF<B'PM6=$'U!W(U;8#^=>O.H2$BJ7YOUO:>[WA#]KY
MQ8S@<[ZB,;OHZ"XD9_*!=2Y__LD:];ZT92T2YB!A+A+F(6$^$A8@82$2%H%@
M#94,MBH9F.B7O^EA3I),9+_$:RGU4$JT.NYYPA5G;</9M1%WJBB0, <)<Y$P
M#PGS-[!1"2MN*QXN[?Z@=]Y]V$WV8PJ%AX6&Q:BS6R9J 4VM;9E&R@VW*3<T
MIMQ5IOB]F.G\(OIV(:'W0FZF:O1Y.D?^2ZYR)>D_6<9BVI:%QAI.S4(DS$'"
M7"3,0\)\)"Q PD(D+ +!&CH9;74R>N<)S BI$B3,0<)<),Q#PGPD+$#"0B0L
M L$:*AEO53(VCB8O#"'Y)[)>S:6^-24K^E0<:1.($7VJ0) P!PESQP>#N&7O
M308\9(4^$A8@82$2%H%@C;R?;/-^\L:\G[$'EHA5.9%*><)R)?0H85"!L:)3
M58"$.4B8BX1YDP-)]?<4Y2/K"Y"P$ F+0+"&"*9;$4S?* +)%NN$*B&?CM.
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MTG)SR>B,R:* _GPNA'K>*2K8KA-\^3]02P,$%     @ X5E76,8>H '3"
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M*+L YS=2FO>.+?+U$QW] 5!+ P04    " #A65=8+%P&EKHJ  #J$P, &0
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MF:@V0#4+U6Q4<U#-134/U7Q4&Z+:"-4"5!./3,7UD\,I*A\;9>=CX^I'GL]
MNR%1K8-J75234*V':C*J]5%-0345U314TU'-0#43U0:H9J&:C6H.JKFHYJ&:
MCVI#5!NA6H!JHLAR-Q2W&S[*PLI&=6.EN4P6R7*=)/+PL7E:U$.\R--'%N7C
M9?D+(4S39!R'V;K34EA$RW$TSP[V6E8/5CMLH,V6J-9%-0G5>J@FHUH?U114
M4[?:]9,S;6?O6F=[CUC4T$'U@X,VK_?KIM%!350;H)J%:C:J.:CFHIJ':CZJ
M#5%MA&H!JHE'YMOZ\> 4Q9C-LABS65T_:1P,!.GJ-HTG<;C\]E:8Q?-XMIH)
M#\ET4A1@YO$@/OQ(J.JAZH:#(QO>%+Y%X?+0Y1D==#NZJ":A6@_59%3KHYJ"
M:BJJ::BFHYJ!:B:J#5#-0C4;U1Q4<U'-0S4?U8:H-D*U -7$(_-T[5A!<;NQ
MHBS';%:78R*/F*P>HW:>0*LP4:V+:A*J]5!-1K4^JBFHIFZUG9[IQMY#FK7M
M0NVJA71TNXS7#&FB0PY0S4(U&]4<5'-1S4,U']6&J#9"M0#5Q",S9_V)_A1]
ME,UF.=%75DY57159O6;MZ1LMDT2U+JI)J-9#-1G5^JBFH)J*:AJJZ:AFH)J)
M:@-4LU#-1C4'U5Q4\U#-1[4AJHU0+4 U\<A47#\YG*),LEF6238WG50_YJK(
M)EI#B6H=5.NBFH1J/5234:V/:@JJJ:BFH9J.:@:JF:@V0#4+U6Q4<U#-134/
MU7Q4&Z+:"-4"5!-%EKNAN-WP4196YB\K#UM\'4>+(DB$4R%=+1;3J#A7$2Z_
M"9/X<SR)YI.B F*1I-'D[>,%D>'].JFD#V$>6<;A(L["Z<'H43ET[>A!:AU4
MZVZUXD%LWX\EMZ_.\O_M'DZ6T&%[J":C6A_5%%1344U#-1W5#%0S46V :A:J
MV:CFH)J+:AZJ^:@V1+41J@6H)AZ9INNG"HC;315E<66SLIOJ%:FB?IA VRJW
MVLZ$??:NO7<M>N=UBW71;9-0K8=J,JKU44U!-175-%334<U -1/5!JAFH9J-
M:@ZJN:CFH9J/:D-4&Z%:@&KBD4FW?D8X1;]DL^R7;%;W2^JKV6VT_#[WI\(R
M&D?QYVBROO=R\]XOPG^WKPY& K1]<JL]O1RLL1\'T/))5)-0K8=J,JKU44U!
M-175-%334<U -1/5!JAFH9J-:@ZJN:CFH9J/:D-4&Z%:@&KBD6FX?FHX1?ED
MLRR?;%:73]J+:!R'4V$2I]DROET5!QG>"O/]+#%.YI^C958G3*#5E5OM:9AH
MMO;3!%I(B6H2JO5034:U/JHIJ*:BFH9J.JH9J&:BV@#5+%2S4<U!-1?5/%3S
M46V(:B-4"U!-/#(]UT\3IRBD;):%E,W*SJD7TD3%F8ERR>CPG9IH!^56VVW,
M:5]>/3M-@;9+HIJ$:CU4DU&MCVH*JJFHIJ&:CFH&JIFH-D U"]5L5'-0S44U
M#]5\5!NBV@C5 E03CTS-]9/$*=HEFV6[9+.Z75*/,B$-IR\<6T#+(E&M@VI=
M5)-0K8=J,JKU44U!-175-%334<U -7.K[?1+7%WL1O<!.J2%:C:J.:CFHIJ'
M:CZJ#5%MA&H!JHE'YMCZD> 4C9*MLE&R55W,^"D:+Z,PC83L89FL[A^$:9*F
MQ1&%<3+/ELET?7#A2;_D/(\089I&V<$,43U8W0RQU78>M=EL7NX=5T#'[**:
MA&H]5)-1K8]J"JJIJ*:AFHYJ!JJ9J#9 -0O5;%1S4,U%-0_5?%0;HMH(U0)4
M$X_,RK5#!,7MAHBR/[)5W1]9-T3$\RR<W\>WTVB;)81P/A'NDV3R)9X>O+&B
M>@-J!XOG97^-B_/]7(%V1J*:A&H]5)-1K8]J"JJIJ*:AFHYJ!JJ9J#9 -0O5
M;%1S4,U%-0_5?%0;HMH(U0)4$X],U/5SQ2GJ*EO-,E=4UU7Z47S_4%P?&7Z.
MEL65#IO+'!;+>+QY^%7'M8H+(3;O%Y=._O2/J];%^6_"^XJ+**L'K9TE-MK5
MTRQQ_OPF3730+JI)J-9#-1G5^JBFH)J*:AJJZ:AFH)J):@-4LU#-1C4'U5Q4
M\U#-1[4AJHU0+4 U\<CT7#]-G*+"LE566+8J6ZK65S_<)<L\4\R%Z.OX(9SG
MB:(X4G$P)*"-E%OMZ0&'5GL_(: ]DZ@FH5H/U614ZZ.:@FHJJFFHIJ.:@6HF
MJ@U0S4(U&]4<5'-1S4,U']6&J#9"M0#5Q"-3;OV$<(J>R5;9,YF_K$H(1O80
M+87[,)ZG;X6?BVA0W)!9G)N8QEE\O^ZR/A@6*MG:8>'\V259^W=EH@-V44U"
MM1ZJR:C61S4%U514TU!-1S4#U4Q4&Z":A6HVJCFHYJ*:AVH^J@U1;81J :J)
M1R;?^ED!XG:S0MD>V:INCW3"KT+T=1'-T_6IB'$RBWXYF W02LBMMM/_U-AO
M@$*'[**:A&H]5)-1K8]J"JJIJ*:AFHYJ!JJ9J#9 -0O5;%1S4,U%-0_5?%0;
MHMH(U0)4$X],M_73P2EZ(UME;V2KNC?R4YPNDC2<;B^"3)-I/ F+*QE6\TFT
MS,*_XOG]YJK'N.ZSMS?W8.1N%GX]&#C0PLFMMG.IY-FSP(%63J*:A&H]5)-1
MK8]J"JJIJ*:AFHYJ1NM 0^O^+XR)#CE -0O5;%1S4,U%-0_5?%0;HMH(U0)4
M$X],S/5SQ"F:)%MEDV2KNDER^\!NX;^"%LY7=^$X*Y[ 6>2&]1,KON7A8CH-
M;Y/E]A&<]\MH_12+@\$ +8]$M0ZJ=5%-0K4>JLFHUD<U!=545--034<U ]5,
M5!N@FH5J-JHYJ.:BFH=J/JH-46V$:@&JB4?F[OI1XQ0UDZVR9K*U*9_Z,4_X
M;J&=DZC60;4NJDFHUD,U&=7ZJ*:@FHIJ&JKIJ&:@FHEJ U2S4,U&-0?57%3S
M4,U'M2&JC5 M0#519+D;BML-'V4S9:NZF?+CX<,8ZYKK.)D(X5T6+?=K)0[F
M#+3%$M4ZJ-9%-0G5>J@F'_G9:0O?HG!YZ"Z>/KH="JJIJ*:AFHYJ!JJ9J#9
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MG&AS*!]"M9) ,A>4LS".HEZ8$\J#R<B=F\G)2!2:40XSB521YT3^N@$FUN,
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MHMS:*2I.8VY0&T<P"+I,SZB&)5%D^N4LW<BFYHK?N)O?A!ZXJB^;:M7 YN2
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MOP444N;NL4<?0).#X<,L)3O3D"PG78^ UK+"LL\]UT[_<Z/;**#) 5VEIE]
MP\U3P82[=&/;6>%<[L:Y0X?+<P!G*=D+C%7$932T:6O(0C%<X6:XD</E!1C0
MC,VV1*+$['^0R'9,6*%(KO!,<@58&!B1TQ#!ND RE0-$++8L!R@4QA7^,:X
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MB1>?J,JVQY#IF4<&4H^,HCZ4((1D(P(BLCQ<8)6-TO54(P.Y1MS8Q]#V7.(
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MFG MH#[?,"8?;_0+ZF/DY?]02P,$%     @ X5E76.$V)$+2 @  ^@<  !H
M  !X;"]W;W)K<VAE971S+W-H965T,3 S+GAM;*U576_:,!3]*U>95+52UWQ!
MREJ(5*#5]E -@;H]3'LPR06L.G9J&VC__6PGI!0HJJ:^)+9SS\D]Q_:]W;60
MCVJ!J.&Y8%SUO(76Y97OJVR!!5$7HD1NOLR$+(@V4SGW52F1Y Y4,#\*@L0O
M".5>VG5K(YEVQ5(SRG$D02V+@LB7/C*Q[GFAMUD8T_E"VP4_[99DCA/4#^5(
MFIG?L.2T0*ZHX"!QUO-NPJMAV\:[@%\4UVIK#%;)5(A'._F1][S )H0,,VT9
MB'FM<(",62*3QE/-Z36_M,#M\8;]SFDW6J9$X4"PWS37BY[7\2#'&5DR/1;K
M[UCK<0EF@BGWA'4=&WB0+94610TV&1245V_R7/NP!0B3=P!1#8AV :UW '$-
MB#\*:-6 EG.FDN)\&!)-TJX4:Y VVK#9@3/3H8U\RNVV3[0T7ZG!Z70DS0F2
M^N4<2D:X!L)SP*<E+<W6:O@*D^HX@)C!S]D,^L1$90@3=R0'HBBHMI$*QLB(
MIGP.6L KZ:@AO6U(3X>H"67JS-#?/HSA].1+)TY:UV=0#X!RN*>,F7.ANKXV
M*FVN?E8KZE>*HG<4A1'<"ZX7"FYYCOE; M_8TW@4;3SJ1T<9AYA=0!R>0Q1$
M\8&$!A^'1P?@PX_#PR-JXF;'8\<7_]>._R%3I:6YC7\/.5\QMPXSVPIUI4J2
M8<\S)4BA7*&7GGP)D^#ZD&N?23;\)+(WCK8:1UO'V-,[*@L0,D>I[#TICQE\
MR-6*/7'LMDROTB3N=/W5MEG[,9TD?!LSW(^Y3+XU,6^DM1MI[:/2CA^6DF$^
MQQR( H794E+] J83 :-D2AG5% _>W_9>GF&R(W<_)-@1NQ^Q*]7?JHH%RKGK
M+@HRL>2ZNOS-:M/ ;ES=WEGOF\96]:%7FJHKWA,YIUP!PYFA#"XN35:RZC35
M1(O2U=ZIT*:2N^'"-&>4-L!\GPFA-Q/[@Z;=I_\ 4$L#!!0    ( .%95UB0
MW>^@F0(   X'   :    >&PO=V]R:W-H965T<R]S:&5E=#$P-"YX;6RM55U/
MVS 4_2M704(@,?)5.@9I)$J8AC2FJHCM8=J#F]PV%HX=;+>%?S_;24-AH4(3
M+XE]?<^Q[[%]G*R%O%<EHH;'BG$U\DJMZS/?5WF)%5''HD9N1N9"5D2;KESX
MJI9("@>JF!\%P="O".5>FKC81*:)6&I&.4XDJ&55$?DT1B;6(R_T-H$I793:
M!OPTJ<D";U'?U1-I>G['4M *N:*"@\3YR+L(S[*!S7<)/RFNU58;;"4S(>YM
MY[H8>8%=$#+,M64@YK?"2V3,$IEE/+2<7C>E!6ZW-^Q?7>VFEAE1>"G8+UKH
M<N2=>E#@G"R9GHKU-VSK.;%\N6#*?6'=Y@8>Y$NE1=6"S0HJRIL_>6QUV *$
MPS< 40N(7@,&;P#B%A"_%S!H 4YJORG%Z9 13=)$BC5(FVW8;,.)Z="F?,KM
MMM]J:4:IP>ET(LT)DOKI"&I&N ;""\"'):W-UFKX!+?-<0 QA^NJ)E2Z^'>A
M%"J88BX6G"HL@')XIIIT5%<=U4&&FE"F#@WIU=T4#O;W3N/AX/P0VH:EN*&,
MF=.@$E^;VNP*_;RM8]S4$;U11QC!C>"Z5'#%"RQ>$OA&E$Z9:*/,.-K)F&%^
M#'%X!%$0Q3T+NGP_/.J!9^^'ASNJB;M]CAU?_%_[_)O,E);F#O[I4[YA'O0S
M6U\Z4S7)<>09XU$H5^BE^WOA,#CO4^TCR;(/(GNAZ*!3=+"+/?UA/)D^7PG6
M7 EC9?4NJ?OT;>89NGFL3:_2, X2?[4M6T_.Z?!E3O9O3ORE2VEJ]+><HD*Y
M<(ZK(!=+KINKT44[4[]P7O8J/C9FWWCS,TWS4MP0N:!< <.YH0R./Y]X(!OW
M;3I:U,Z/9D(;=W/-TCQ8*&V"&9\+H3<=.T'W!*9_ 5!+ P04    " #A65=8
M=BZ .L@'  #Y/0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,#4N>&ULS9M=
M;]LV%(;_"N$!Q0;4M4G)7VUBH+&TK<"Z!>VZ70R[8&3:)J8/3Z23!=B/'R6K
MIB52K-F= +E)+/GP$?6>8Y*O+5X]%.5?8L>81/]D:2ZN!SLI]Z]'(Y'L6$;%
MJV+/<O7.IB@S*M5AN1V)?<GHNFZ4I2,R'D]'&>7Y8'E5G[LMEU?%0:8\9[<E
M$H<LH^7C#4N+A^L!'GP^\8%O=[(Z,5I>[>F6?63RT_ZV5$>C$V7-,Y8+7N2H
M9)OKP5O\.@Z#JD$=\1MG#^+L-:INY:XH_JH.WJVO!^.J1RQEB:P05/V[9RN6
MIA5)]>/O!CHX7;-J>/[Z,_W[^N;5S=Q1P59%^CM?R]WU8#Y :[:AAU1^*!Y^
M9,T-32I>4J2B_HL>FMCQ "4'(8NL::QZD/'\^)_^TPAQUH#T-2!- ])M0'H:
M!$V#X-(&8=,@O+3!I&E0W_KH>.^U<!&5='E5%@^HK*(5K7I1JU^W5GKQO"J4
MC[)4[W+53BYO2U5SI7Q\B?8IS26B^1JQOP]\KXI!HB'Z>"P@5&R0#KT]A<:G
MT)^82M<:?1LQ27DJOD,OOID'T_ -XCEZS]-4586X&DG5Y>K"HZ3IWLVQ>Z2G
M>QB]+W*Y$RC.UVQM:;_Z0GOB (R45B?!R&?!;HB3&+'D%0KP2T3&>([2ZJYM
MW;H80@(4?_J OFWD^LX"BRZ'D2_"XLMAV 5KB1><JBVHZ4$?G8LD+<2A9%5!
MK>M2447#\^.(5X\<=VHX0WMG6?Y1<1&7+!-_VFKJV(G0WHEJZ'TM]C1AUP,U
MM@I6WK/!\L4W>#I^8\LD)"R"A,5 L%8FPU,F0Q=]6<\HPV(S/ B&J!!,"D0E
MNF-;GN<\WU;Y51GDA>U#>^-D^R;H")O6L&I>O%_B.9Y<C>[/A;<$+<)Y.R@&
MZE9+T,E)T,G7",I4X3NE=%)]I3S")N<J32=A1TI+D*%W/''KW9)H>I)HZBN1
M31$GQ%>1Z26*6(),12Q!O8K,3HK,G(K4DRY*.;WC*9><6?5P(GSUF!EY)>-@
MW-%C9MPJ48)T]+ %C7OTF)_TF#OU6-'LKN3K+7N)WJL"H<E.E8JTEXF3Y"L+
M)"R"A,5 L%8Z%J=T+)[#=+^ S"0D+(*$Q4"P5B;Q6/N$L?.C]?,ANV-EE<=Z
MS8OHMF2L2H] @F]SE=9_>U?#-PV[]6%O#P<K]^5]A0>EQ5"TMO1G%@T[I7^7
MJ[&=IHWPDI6956,W!$_0(Z.E;2A<?7W3R-W46V@@6EMHHH4FSAO]9;/A"4/U
M)5XBG\G$#?8=@T!I$2@MAJ*U4Z0-)'X6#A*#6DA06@1*BZ%H[7QJ&XF?TD>Z
MX=YI@J1%#>U\S@M(9Z4<0UVRK;[VG/AI3*<;ZZT[)"T"I<78=+OG66SKKHTL
M!G&R;HJWS)"T")068],=]\NLW3$&L,=NAK?(D+0(E!9CTW+WBZPM-W9[[I_4
M?%M2692/:$.31FC/U1.H%P>E1:"T&(K6SI7VX_A9&'(,ZLA!:1$H+8:BM7^*
MTJ:<N$WY_UL]N>&^:0*E1<3\QB DG>]=8ZA+MM77OIRX??'7KI[<6&_=(6D1
M*"UN:'U9;.NN;3IQV_0+5T]NBK?,H)X<E!8WM,MDUE:;.*W?9:LG-\-;9%"C
M#$J+&]IE(FO_2]S^]X>R$ +=T_1@_>+4W=I;7E"#"TJ+H6CM/&@G3";/865$
M0(TS*"T"I<50M'8^M<,FW@[;9V4$:KP;6NM'T_FL\P-(1$P+3&9A]U=D2Q2>
M8=PS#&FG3-Q.>;6C^9:)ZF$MD:@"K^1)BEP4*5_7U6]5"=0Y@](B8GK=(9EV
MQ32#%D&/E-H/$[<??INHT4#P2C11CPZ%W+%2*9N4U81JGT5!#7!#:U52..N6
MFR5H0;H"F4&+:9]"VH42IRNJQMI](6AZ+L^:N>0!]9,-K54: >X^TV&+(H$A
MD"5JT?-I#+2M"]RV;G4H2Y8GCTB6-!?I<?I9\\V&5:?M&KF1W@^]F?9K..D\
M+A59@O"X^YB')6@V[1%(.Z_ [;Q^K711:MB5 +57@6EAAK/NTV6VH.[#9590
MCQ#:"@7>5N@B"^K&>FMD^@\R-28X6Y0Q#<:VJ/-IL"W4V8.G;C-SH6=T4[QU
M,2V#31=+E$472U2_+MI_!&[_\39)#ME!#3%JL;MFZJ82?AQN7M!L_P;Q;$]Y
M62UMK6J!NA-06@1*BZ%H[2QI=Q(\"W<2@+H34%H$2HNA:.U\:G<2/*4[<<.]
MTV0ZBB$>3[KK15O8;#'KCE*6J GN63$&VIX$3V!/W$QOF4#M26 ZC^X*-(:Z
M8EMS[6,"MX^)SF>#:AS1<P%*=K3<U@,04JMW5ZF"&IO M"-#P[1$MJ@@--:E
MMBC<-Y]J;Q, >QLWSULATX^0V;0KD!DT-Y8;9DS8\U-QJ'U-".]KW$COO2*6
M!U$[E1%98H:X.]!9@WJJ)]2^)OP?OL;=UEL)TXX$70]LB>G6B26DQ]V%VM2$
M3V-JW%AO@4PCHN9%W#7!]K#N]!G;PLZGS[94VM:$(+;&3?%6)C"^S[0J8PTS
ME;&$F<J,SK:X9DQ-/M7>8J$6 8=<'C=OGLZ>]B^_K7?M=LZO\.OXN M98XZ;
MHM^K.8WG J5LHY#C5S.5K/*XS_AX((M]O9'VKI"RR.J7.T;7K*P"U/N;HI"?
M#ZH+G'9[+_\#4$L#!!0    ( .%95U@3!PP-GP,  *8/   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$P-BYX;6S-5TUOVS@0_2N$"A0MD$9?MN.DMH DRF(+
M;+!!BG8/BSTPTL@B2HDJ2=GIO]\AI2B6(PL)H$,O-DG-/,Y[0PXXJYV0/U0.
MH,ECP4NU=G*MJPO754D.!56GHH(2OV1"%E3C5&Y<54F@J74JN!MXWL(M*"N=
M:&77[F2T$K7FK(0[251=%%3^N@(N=FO'=YX6[MDFUV;!C585W<!7T-^J.XDS
MMT-)60&E8J(D$K*U<^E?Q+YUL!;?&>S4WI@8*@]"_#"3+^G:\4Q$P"'1!H+B
MWQ:N@7.#A''\;$&=;D_CN#]^0O_#DD<R#U3!M>#_L%3G:V?ID!0R6G-]+W9_
M0DMH;O 2P97]);O6UG-(4BLMBM89(RA8V?S3QU:(/0=_<<0A:!V"0X?9$8>P
M=0A?ZS!K'696F8:*U2&FFD8K*79$&FM$,P,KIO5&^JPT>?^J)7YEZ*>C.XE'
M2.I?)Z3BM-2$EBF!GS6K,+>:?"*7:<I,@B@G7\KFF)ET?8A!4\;51S2Y^79/
M/KQ_MPP7L\\?23L@K"2WC',T5BM78Z1F/S=IH[IJH@J.1.4'Y%:4.E?DIDPA
M[0.X2+'C&3SQO I&$6-(3DGHGY# "\*!@*Y?[QX,N,>O=_='V(1=UD*+%Q[#
M8RKA0M42B,CPF)M<0(J:/V>(/N M)]5H>O\UN(1I*-1_0TEJ@I@-!V$JTH6J
M: )K!TN. KD%)WK_SE]XGX<$GA(LG@BL)_ZL$W\VAA[=/&+158!5CZ/4Y89H
M050NI/ZD01:$ Y8A997&HDJVE-= J%*@!R]"L]?"[F6*]#;RSU?N=E^YER;!
MHF\2#YC,.Y,>RWG'<C[*\IJJG. 1R@P)/%8MKQ,"CPFO4\/[!>DA?O,7D87^
M_(#@@,WR0(1XP,8+ABDN.HJ+48I_9QE+P&:*E2G66LFPS.&)*=@1,J-X;[T0
M4X+%$X'U=#SK=#S[':K1V93B3PD63P36$W_9B;\</<1_F9N7M@4&A069H)CX
M9!N2L('RO;U;Y)T>EIO1_=XJS41@/6G..VG.1Z7Y#CE+.)",X^MH2(Y1][>>
MJ"G!XHG >K+YWO.;T/L=+G0;Q43Z3XH63X76S\#>J]R?[E:W6 ?7VC^XUN,[
MOEF?B= :?=R]!J8 N;&-H"*)J$O=O/&[U:[9O+0MUL'ZE6E";6/T#--TL+=4
M;EBI\*62(:1W>H8/"MDTA<U$B\JV20]"8]-EASDVTB"- 7[/A-!/$[-!UYI'
M_P-02P,$%     @ X5E76!1-AV54 P  )PH  !H   !X;"]W;W)K<VAE971S
M+W-H965T,3 W+GAM;*U636_;.!#]*X0*%"W01)^6Y=06$$=M=P_!!@G:/10]
M,-+8(DJ1+DG9[;]?DI)56Z:].?1BD\-YC_-FQ"'G.RZ^RQI H9\-97+AU4IM
M;GQ?EC4T6%[S#3"]LN*BP4I/Q=J7&P&XLJ"&^E$0I'Z#"?/RN;4]B'S.6T4)
M@P>!9-LT6/Q: N6[A1=Z>\,C6=?*&/Q\OL%K> +U>?,@],P?6"K2 ).$,R1@
MM?!NPYLB,_[6X0N!G3P8(Z/DF?/O9O)WM? "$Q!0*)5AP/IO"W= J2'28?SH
M.;UA2P,\'._9/UKM6LLSEG#'Z;^D4O7"RSQ4P0JW5#WRW5_0ZYD8OI)3:7_1
MKO<-/%2V4O&F!^L(&L*Z?_RSS\,!($S/ *(>$(T!R1E W /BEP*2'I#8S'12
M;!X*K' ^%WR'A/'6;&9@DVG16CYAINQ/2NA5HG$J_\1YM2.4(LPJQ%4- A&F
M,%N39PH(2PE*HBOTI#^WJM46OD+W? NZ\-I.&!KP;PI0F%#Y5GL/QBOTX?,C
M>O/Z51:GR?NWJ!\8X+U>UX67<U]I&288O^Q#7G8A1V="#B,= E.U1!]8!=4Q
M@:_U#TF(]DE81A<9"RBO41R^0U$0Q8Z [EX.CQSPXN7P\(*:>"AI;/GB<WQ$
MEI3+5MAJ"2@Y*PDEV)XS;2EK75ZPU5OO"_75D""BH)'?7!7I=DS<.YK6=",W
MN(2%IWN/!+$%+W_]*DR#]ZYL_DFRX@^1'64Z&3*=7&+/E[ FC!&VUJV'8E:"
M*W4=16HI3!/>YLDLF^GO9'N8$X=7%DS28Z_"X97H S5X':F8#"HF%U7<EC]:
M(HGY/"2J6F'TZ$: -B (KUR2.K[)81C3R4C0J4\:S$9R3GVB<#ISJTD'->E%
M-?_8'M8,/>I%@M*30*YFP4B0PR>:9"-%#J?LC*#I(&AZ4=!=*P2P\A=2 C-)
MNV-<D=4*C!F<#73J"&,:CP2=.H5)-BICX7!*@\BM*!L491<5Z;;]/V<F<YR9
M)$A& EQ>)R>K<'@=G:Q.@G]PA38@UO8I(E')6Z:ZBV2P#J^=6WO)C^Q+_0KJ
M'BV_:;HGU#T6NEU(1&&E*8/KJ<ZJZ)XEW43QC;VHG[G2U[X=UOHE!\(XZ/45
MYVH_,1L,;\/\/U!+ P04    " #A65=8_\CJOP #  "4#0  &@   'AL+W=O
M<FMS:&5E=',O<VAE970Q,#@N>&ULO9?1;ILP%(9?Q:)2U4I;(4 2TB9(;=C6
M752J6G6[F';AP$FP:C"SG="]_6P@5NAHE%2H-V";\_\<?\;&GI:,/XL40**7
MC.9B9J52%I>V+>(4,BPN6 &Y>K)D/,-25?G*%@4'G%2BC-JNXXSL#)/<"J=5
MVST/IVPM*<GAGB.QSC+,_]X 9>7,&EC;A@>R2J5NL,-I@5?P"/*IN.>J9AN7
MA&20"\)RQ&$YLZX'E]%$QU<!/PB48J>,=$\6C#WKRO=D9CDZ(: 02^V U6T#
M<Z!4&ZDT_C2>EGFE%NZ6M^Y?J[ZKOBRP@#FC/TDBTYD56"B!)5Y3^<#*6VCZ
M,]1^,:.BNJ*RB74L%*^%9%DC5AED)*_O^*7AL",8^&\(W$;@'BKP&H%WJ,!O
M!'Y%INY*Q2'"$H=3SDK$=;1RTX4*9J56W2>Y'O9'R=53HG0R_,984A)*$<X3
MQ&0*')%<XGQ%%A00%@*D0)_1H_K<DK5J84MT32F+<35JJF8,SB*0F%!QKL*_
M/#V@L].3P!OY5^>H*2AC=*<BE5!,;:F2URG8<9/H39VH^T:B$<07R!M\0J[C
M>AWR^>%RMT,>'2X?M.6V(FZPNP:[6_EY;_D1$5,FUKPBRB%F>4PH,53C5 T!
M"(ULM07\2YL@(B$3O[OXU6_TN]^HEX]+4> 89I9:'P3P#5CAZ<E@Y%QUT>S3
M+.K)K$7:,Z2]?>[F ^\B5BM'E5*OCYO0G_B./[4WNRBZHH*)VXZ*.J("9S@R
M4:WD?9.\OS?Y&\**%*OEK2O[O=)CQ[M/LZ@GLQ:RH4$V_/"9->R3=)]F44]F
M+=(C0WKT[IE5*X>[L\'UW-<S:Z__L2AZ,FNA&!L4X[THYNJ7ML[4O_,6,)5I
MC#ET4=EK<NQWU*=9U)-9"UY@X 4?/F.#/DGW:1;U9-8B/3&D)^^>L9/__E]C
M)W!>3=B]]L>2Z,FL)F'O;('U>>4.\Q7)!:*P5/;.Q5BM1;P^ ]05R8IJ5[Q@
M4NVQJV*JCDW =8!ZOF1,;BMZHVT.8N$_4$L#!!0    ( .%95UA?-0GX-P<
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M0[+.TG 3Y.T&@I9QZKD-I=E0F@.EN5":AZ*I2MGSK.B+KQE5ERAA(6DVE.9
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M0[9O\G1=/K#B+LWS=%6^7'(_Y%G10'X^3]/\\4W1P>ZY+>/_ %!+ P04
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M3]VMD\*Y91TW]<['M8R<!TD!A9@8F3%/-:>F.*<>,V.>NNMDC#D3YKBQ=T3
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M(@U.D\:+CZO/F]\&#8*"!E1-H-1,TQ1H\-E @T-! ZHF4&IF7K "C1 &&N'
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M*2:U#_=0=^I*@V>O-&R7N>),JV39D7O/==!%!: T"D4S@[.Q(^"D6P)@]P3
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M._3?$^>E,X^(XRL:_$F6PC_O37I@B5=H$XA;NOV*,X>&"L^C 4_^@FTF:_>
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MA#W&+3$:S&C:$M/%N#53&F*\2HS7*^8S2S87$GBLQ@1VA(8('C)5H!7B=3J
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M69Q?;H&$P#. ^G[-F'R\R<[#JQ],%O\#4$L#!!0    ( .%95UB3(GJ>10L
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M35(HC4%I'$6S965<6-_MPE[(U2JILUTNTBJW:<UL'I+BK%SOZ+XSY&[A8'E
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M[\Z'*+77D L$(VL-.4!1'+O7$ Q.XTWPTN[;*)PUS0SEE@<7"B';A N5I/F
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M]&ZN/:*:$=4X1E;NT2ZDP1'@S!5.=5 V /<+*<W6L7.@^Y](/@!02P,$%
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M9SO$=;2BZ48M9IVMRJ>5?NX/DJN[5.7)^8<L8YM*"O4,,Z!;\E@ >H<>FEF
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M?Y!<W26*)Y-O<@5<)>(<2HFP$" %.D]!8D+%!7J//OZX1^?OSF(_"JXO4+M
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MF^;P?^_YA%U=>.M]TU;;T^#N#K;E[OAG_N?)$]( %DX,\$\#_+D#@M. 8.Z
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M;6=0T2UHVP_=1.HBL^VGT'A\0C<DH&P<Q::Z5>@,/W49GU ! 67C*#;5T4)
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M&>LY!MU;0+&I#T)HE-!E]E,(%2Y0-HYB4QTME4LL72\Q3%F*$E\/YQ$0\_6
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MFX8Q:L1P&J/9)ZD!NO'TH$+)XKP";+MM+!V'T6F>E11(Y#1-BF[P;>]MK,)
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ML"$!H9\%](YA]#_TF?$U%6K+O;[(W*I[^^SM2Y!H& K-MK?A*^'XC&(:E-"
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M%";)2.UQT.5\-BTV'<2FYX@M:,/LWKZ(X/0HS60^UGLRJ_][!+T0V8&!\\'
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MG3BU#;3__<YVRH"%BH>^X+-SW^>[[^PS@Y60CZH T.2YY)4:>H76];GOJZR
MDJJ.J*'"+W,A2ZIQ*A]\54N@N065W(^"H.>7E%5>.K!KMS(=B(7FK();2=2B
M+*E\N0(N5D,O]%X7[MA#H<V"GPYJ^@!3T#_J6XDS?\V2LQ(JQ41%),R'WF5X
M/DF,OW7XR6"E-FQB,ID)\6@F-_G0"TQ P"'3AH'BL(01<&Z(,(RGAM-;;VF
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M<T*3DK=(X[SZESPV9;T166SS(ETWP:8%ZRBI_X:?FX[8"V!] :P)8*<&\":
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M#LNK\ISIZ=WTX6Z,4LJ 1KPD+,%P8X^I?E(H=;Y@$:\J!_6]IFQV (NYK&Q
M3J9T60B=DUS45U. PQ2OUQF-JUN@Y*G:Z$)<2+A0PBT/H_E6A*6> 14T)NAB
MCO'\$F$A=)_-"5,(LT2O=+,6-#OT!-<'1:\"6@O"2$K!-S@S:R(H3ZHN4)G_
MH!<#)F* 5'[\Q16IC-YTG:[=U;AJ@SL78$T/BRE0)!4(M%<2I;!=K?E,L$!
M'.C!'8[D"R(J@]N[8-<4V=[.W3PG8ED^NTA8MF"J#F\CKMYV)G9T6SZ!M.13
M)YHY)KD;S5R3W(MFGDGN1S/?) ^B66"2A]$L-,G[T:QOD@^BV< DMZUH!L?F
M\,N-K9^S3'N&I-\^=/5>V*N>R2!CEQ22-R,I,&EU0ZA?HGIYJB:*K\N'CP57
MD*OE<$4P-!^M -]3#CE13_0"S?O?Z%]02P,$%     @ X5E76&D3TU&$!P
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M:T.0.*>RV"E:X JM/CI&%N,]RF+L5!8[10M<H=5_J#>RF/P?9#%IBMB6AP6
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M*2YGC$8LRPWT]Q,AU/.'O('5NSNC_P!02P,$%     @ X5E76(.,97MR"
M*W(  !H   !X;"]W;W)K<VAE971S+W-H965T,30S+GAM;,W=[6_:2 (&\'_%
M8J75KG0']HS!T":1VGC>3NIMM=7>?3C=!P<FP2K8K&V25MH__OP6C(,]C2\/
M4?*A0&!^8\@S8/.DX>(A3KZF:ZTSZ]MV$Z67HW66[=Y-)NERK;=!.HYW.LJO
MN8V3;9#E%Y.[2;I+=+ J!VTW$V+;L\DV"*/1U47YO<_)U46\SS9AI#\G5KK?
M;H/D^T>]B1\N1\[H\1N_AW?KK/C&Y.IB%]SI+SK[8_<YR2]-#LHJW.HH#>/(
M2O3MY>B#\TZY=C&@O,6_0OV0'IVWBKMR$\=?BPMJ=3FRBRW2&[W,"B+(3^[U
MM=YL"BG?CC]K='28LQAX?/Y1Y^6=S^_,39#JZWCS[W"5K2]'\Y&UTK?!?I/]
M'C](7=^A:>$MXTU:_FL]U+>U1]9RGV;QMAZ<;\$VC*K3X%O]0!P-($[/ %(/
M($\'],U ZP'TN0/<>H#[W '3>L#TN?=A5@^8/7> 5P_PGCM@7@^8/QE 2<^
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M;6RUF=UOVS80P/\5P@6*%F@L4=]*'0-UY&%[Z%HTZ_8P[(&6:%NH)+HDG:3
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M@/A^2PA_N2D-M.?DR_\ 4$L#!!0    ( .%95UC62RWC;P4  #XC   :
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M$RB1J ]8]43Q776"6'(%YY%JN(5#*14: /?7G*O'B3Z4M,?<Z3]02P,$%
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M!H%B-91:OT$=5A,[5MNHC3S.PW;UP<Z"\C"46M_9CH>)G8<_Z\MZH\F0H+H
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MYO>5E/KI2]W!X?S^]?\!4$L#!!0    ( .%95UCVX/[,!@P  &^2   :
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M>"K>JEFNJ^:A+OM.J,MEM5UVO7?LEF51UY]7VP]>L:D>MJW75E[7Y0^=NA\
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M;C]Z-U7=;=[MRK@Y 6R.B,QS$*(2F7FRQD)ED>D+F;>M+QI7 K*&?O*%MD3
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MH3J$R>@FV%JD"4+0!/$,3"8@/$ FPT2 R3 19#*ZQ;:.:@H1-(503';8=-2
M) W,&\68+$MB\PHU)DL# ?RX1*$?ZD(_I"_:XU1VP+"VVO\OO![(T-V'#G]N
M!>\TFG0:3;F*-NXH7<&'P4L@LM!187[H3Y?1I--HRE6T<7]J! EI!&&(+(2T
M(!+?/-TA*B"2B"A,P#A$IVMKQ^"QITGDP1-9",'!/&LO$ VX@8AHS,I3T3G;
M>J())*0)9 J-A9 9P$["2B0O472NMEYH[@AI[IA*8R'D . '*Y&\1-'YVOJA
M62*\Q%-1)Y\3A+P 7&,EDI<HNE6VKFGD"&GDH DLA% @$CBX(,] P=$%BL($
M7)&GL[5U0]-%2-/%60 6PNH>["*L1/(212=M:XH&A) &A&= KA"2 ;"2E4A>
MHNBFVCZ3J]DBHMF"8JT(/K^#'&N("AYKB @YUNA<;;W0Y7M$7X#'.4OTNU!X
MFJ[HH.=6XTZC2:?1E*MHX^[1U7CT(EZ@B)R^0>$TFG0:3;F*-NY/C1,1\TP5
M35<1<O?!!Q<3$15D,(FH@$C1Z=K:,7@]8A))\'05(;<@3%=XG$ DPC3D$C@1
M:9R(:)R8@E81CQ*\1/(21>=JZX5&B8A&B:EH%?&0P$LD+U%TOK9^:$B(+O$@
MU,E"!Y( <(V52%ZBZ%;9NJ9A(J)A@GD%"];]W8 +AA:HP@9<Y*$H'XPOEZ"(
M2%-$1%/$66@5\3S 2R0O4732EJ;$F@=BF@>> :UBR +@G3=6(GF)HIMJ:Z7&
MB9C&"0JM8N0Y'7BL(2KD6$-4\%BC<[7U0M?N,7TE'4>KL-^%HM-H10<]MQ1W
M&DTZC:9<11MWCR[%X_ EH%7LJ,(^]*?+:-)I-.4JVK@_-4O$S'-1-%K%"$$$
MY@O2"T05=1F:HP\2*P4O6]/YVOHQ>"M[$DKP;!4C+U28MO \P4=1=,*VAFB>
MB&F>F,)6,<\2O$3R$D7G:NN%9HF89HFI;!7SE,!+)"]1=+ZV?FA*B"_Q0-/)
M2H>_)\%+)"]1=*ML7=,T$=,T0;-5# O_;L0%0PM482,N$BLU8RDZ74L[$LT1
M"<T19\%5PA,!+Y&\1-%)VYJBB2"AB> YILF , "L9"62ERBZJ;96:J!(:*"@
MX"K!7@@ !QNB0@XV+!8\V.AD;<W0Y7M"7TG'Z2KJ]Z'X-%W10<^MQIU&DTZC
M*5?1QMVCJ_$D>@ETE3BJL0_]Z3*:=!I-N8HV[D]-$PGSG!--5PE2_2>^^?X-
MH@)C#Y3 $4K1R=J:,9CY:1))\&B50!  0S*/$[Q$T0G;&J)Q(J%Q8@I:)3Q*
M\!+)2Q2=JZT7&B42&B6FHE7"0P(OD;Q$T?G:^J$A(;G$@TLGZQS^G@0OD;Q$
MT:VRG0]-LT1*LP2-5BDRRU#BF^]D(2K3"$2"#+=TKK9>:(1(:80XBZM2'@9X
MB>0EBD[:UA0- RD- \_ 52GD & E*Y&\1-%-M;52HT1*HP0Y^R V;Q$\TJ *
MV  EV)%VB:H]U55[2E]#QZ'J;567@[DP8CT7!K[;.*W)G4:33J,I5]'&O:5K
M\C1^"8R5.BJV#_WI,IIT&DVYBC;N3XT5*?/ $\U8*<2 Q =WL!!5FICS[$DL
M5IZ:[U[1^=KZ,9@4=A)5\)B5(B](F--)(QKSQ7.):,  ?0FX2#5<I#1<3 &M
ME <+7B(1B3FAKJ*3M35#DT5*D\54TDIY9N EDI<H.E_;R8,U,V27>([I5.63
M\3<H>(GD)8INE:UKFBXRFBYHTLJP!XW,@7*!J-)4F/.A82H_,*>&I=.UM4-S
M149SQ5FPE?&$P$LD+U%TTK:F:$+(+K'ZP5FPE;$(L> EDI<HNJFV5FK$R&C$
MH& K@\_58 <;5&$'&Z)"#K9+5/"9KN S^JHZSEL_5MM7^_T+=\EI/>XTFG0:
M3;F*-NX=78]GR4O@J\Q1E7WH3Y?1I--HRE6T<7]JGL@<3NR4\;<K>(GD)8I.
MVM:4P9(3?_E43AD/)+Q$\A)%-]762LTCF?T<3AGR %,4F^L"+#!9'$3FY-:8
M+ U2<':[!(_DFD=RFSF<%J?/;'2\L]?#<#IID]-HRE6T<<]HYLE?Q*1-N=/7
MQ)U&DTZC*5?1QOVIH2UW"&TYQ"ULRD),ADU9B.J0*0OI)MA:I!$N_\L1+H?P
M!:<LQ$1@RD),!*<LI%MLZZ@FN=R>Y')(7]B4A9@,F;(0DR%3%M+YVOJA82Z_
M ,S1,<\>(IW"G--HRE6T<>]HF,M?!,SE3F'.:33I-)IR%6W<GQKF<N8-%OIF
M60[!*X@B\_K/ I/%?F3>+L-D*9AO7=$IVUJB42Z?='.(OU^6(PMSF',U+Q!1
MGIN^("_&F\^)TTG;FC)8R(^&LBEWS'+^!A$OD8@$W#&CD[4THZNVCF[TGUW<
M,WN*0WDR02,G:!23L[4K@^7P_$N\I')R#1V??P9M@D9.T"BF9=;>B8%W-'LP
MBWKYR,LDR(4/5(=<^4!UR*4/)FMK7P:KY_DV+Z@05S^8@.?6#F[#2;?AE+-P
M1O\,UO'S7\0;*D]I..M5I\_#N0VGG(4S>G6PPJ#_I]Y3>=I\=%L0+KB(J) E
MA3 9LJ80D[*U*8-%!GU'[ZL\!1J_1HCX@\C PD*H"JPLQ.1N[<Y@?4'_S[^\
M\A1C=&L:N,)J)*:!CEQD>4!_L#Z@[^85EJ<XHP, +OV*J)"U7S$57/R5SMS:
MF\%J@?YSOL[R]&WC*WWP>$-4< 585 66@*7;9^O@<#EN9CUNIF \;)V,]BFP
MWA F0Q8<PF3(BD-,RN>:,F_NRK*515M<7]UWW?^VJ#^LMHVW+M]WX?UO^^>,
MZ]6'N^,/;77?>3CK!J&VK3:[CW=ET>U/O:#[^_NJ:I]^F'?Q'ZOZX^X[KO\/
M4$L#!!0    ( .%95UA2)7!U. P  )#!   :    >&PO=V]R:W-H965T<R]S
M:&5E=#$U,BYX;6R]W6U/XU8:QO&O8M&J:J7NX,>0M S2='P>5S/J#IW=%ZM]
MX0$#5O- ;3-TI?WPZR0>S$DR)H[^35]T"'!^Q\"YB0^7;^?\<5'^7MWE>>W]
M.9O.J]<G=W5]_]/I:75UE\^RZM7B/I\W'[E9E+.L;AZ6MZ?5?9EGUZM!L^EI
MZ/NCTUE6S$\NSE?O^[6\.%\\U--BGO]:>M7#;):5__TEGRX>7Y\$)U_>\:&X
MO:N7[SB].+_/;O/+O/YX_VO9/#I]4JZ+63ZOBL7<*_.;UR=O@I_L:#5@]1G_
M+/+'ZMG;WO)+^;18_+Y\8*Y?G_C+(\JG^56])++FG\_YVWPZ74K-<?S1HB=/
M<RX'/G_[BRY77WSSQ7S*JOSM8OJOXKJ^>WTR/O&N\YOL85I_6#SJO/V"DJ5W
MM9A6J_][C^WG^B?>U4-5+V;MX.8(9L5\_6_V9_N->#8@#+\R(&P'A/L.B-H!
MT;X#XG9 O.^ I!V0[#M@U X8[3O@K!UPMN^ <3M@O.^ 23M@LN^ P/_RD_-7
M*VC](U^MES2KLXOS<O'HE<O/;[SE&ZM%MQK?+)-BOJR/R[IL/EHTX^J+-/]4
M_^A=9=6=E\VOUV_D?SP4G[-I/J^KU3NG>;, O6F1?2JF15WDE?<W[W)=3][B
MQOMET7R.J:J'Y@/?IWF=%=/J!^^[;\;1*/[9*^;>NV(Z;6JA^M'[]OG#\].Z
M^0*6AW%ZU1[L+^N##;]RL&_NRU=>Y/_HA7X8>N+C!^_[=IH?=F!O^[%WV1(+
M5IC_(I;NC063%S'1C]F'^9<O,QA['R]3[_MO=S%R_V,:OWA,JA^[S.^?CFGT
M(J;W_CGN@9G]CRQY$;/[8W$?=MK4V5.QA4_%%J[T^&MZ-E_<%)YX*!?>N_RZ
M>)AYO^7ES'N_J)>U(][]]OX'[U-33I7W/Z_Y)A73]CO4?, SE^:])S_X?A %
M<329G.VJG][YE\^U/U7WV57^^J1Y,JWR\G-^<O'=-\'(_WE7_9!82F*"Q"2)
M*1+3)&9(S$*84T714Q5%*SWZVE-645U-%]5#F2^??:Y73SCY=?/,LCY;7)UU
M?6I.!9M**ANZF-]6WK^7B%?4^:SZSZZZB<BZ(;&4Q 2)21)3)*9)S)"8A3"G
M;N*GNHE[GWW>S.</V73-%?,Z;V:HUX_*K,YW546O-[0J2"PE,4%BDL04B>DU
M%JQ_K2[WS9\O_%?--CI,SD\_/U_QY*P6PIP5GSRM^*1_Q<\6#_-ZU\KN'3=T
M99-82F*"Q"2)*1+3:VST;&&/?']C49,36@AS%O7H:5&/N$U$LP>\NFMWN!N;
MB,1/ C_>51R]\P\M#A)+24R0F"0Q16*:Q R)60ASJNCLJ8K.CKZ)."/KAL12
M$A,D)DE,D9@F,4-B%L*<NAD_U<T8WD3T>D.K8HTM_PC^_!PV<)_K4W)*06*2
MQ!2):1(S)&8AS%GNDZ?E/CEP!]$[;NBRGFR=P ;^YAEL2LXH2$R2F"(Q36*&
MQ"R$.:LZ\+O4S^>3B&7FYFXB8M^?_/URM#/)ZSV H06":BFJ"523J*903:.:
M035+:6Y!/8O1@Z/O)]HIJ1(BM135!*I)5%.HIE'-H)JE-+>$NG \Z$_'AV\M
M6G#K3]KCL\1_]M_&]N!M_W$,K@0TV48UB6H*U32J&52SE.960A=P![TY8,^N
MHQWX?*<P3OS-]8T&T*@F4$VBFD(UC6H&U2REN>N["Z*#_B1ZT.[C,K]OSI ^
MY65[@9>[ PDGHXD?C7?6"AI?HUJ*:@+5)*HI5-.H9E#-4II;5%W6'23'WX&@
M.3FJI:@F4$VBFD(UC6H&U2REN274)>M!?[1^P X$S<I1+44U@6H2U12J:50S
MK3;92*PVKKFRU*3NRN_2\* W-.S;<:"I-JJEJ"903:*:0C6-:J;5GN])SS;W
MI)::TEW?76H=],?6!UTTM>R:V;AH*@KC*/9WU@F:<Z-:BFH"U22J*533J&90
MS5*:6U!=+AY,CK_;0#-U5$M13:":1#6%:AK5#*I92G-[ ;L,/NS/X(?O-OK!
MH06":BFJ"523K?;"96,*G52CFD$U2VGNRN_"\K W2>S9;?0/'+S"T<@;U02J
MR59SKB!+-J\@4^B<&M4,JEE*<Q=X%V6'8*.W$W#$6P%'$(_&RU]5.XJ%[?9F
MV[W9?F^VX9OM^&9;OMF>;[;I^Z](Q<,N%0^/W_<=HHW?J):BFD UB6H*U32J
M&52SE.:64!>\A_W!^P%;#C1$1[44U02J2513J*91S:":;;7-N.2LRTO<I=_%
MX^&AO>#] P<O<33D1C6!:A+5%*II5#.H9L/M=O4@"?RO+/ NO [!OG!GS[%]
M@ZGE.Z/)SF)! V]42U%-H)I$-85J&M4,JEE*<XNJR\7#X[>)AVBBCFHIJ@E4
MDZBF4$VCFD$U2VEN"771>TAWC/>#@PL$C=)13:":1#75:AMGXO[&A4L:G=2@
MFJ4T=^5W&7EX:/-X_\#!*QQ-NE%-H)I$-17N:+L/-J]<TNB<!M4LI;GWX>P2
M[.@OZ"+?>3_;V/>C7872?P!#"P754E03J"913:&:1C6#:I;2W(+J@O'H^%WD
M$1JIHUJ*:@+5)*HI5-.H9E#-4II;0EWT'M%=Y/W@X )!8W14$Z@F44VAFHYV
MWQD@"+9N=HO.:RG-7?S/[HQ^:.-X_\#!BYR]Q3E[CW/V)N?L7<[9VYQOWPS@
M;.N^M^B4EM+<]=WEUU%_?GU8&\=D:\,1^Y-QO//>M_T',+A.T+P;U02J2513
MJ*91S:":I32WH+I4/#I^TWB$YNFHEJ*:0#6):@K5-*H95+.4YI90E[M'=--X
M/SBX0- ,O=4&WE)+H <A44VAFD8U@VJ6TMQ*Z,+RZ- F\OZ!@U<\&GE'V^W+
MH\T00*!32E13J*91S:":I31W?7=)=@0VD;]PT]Q_[&PB[S^ P76")M^H)E!-
MHII"-8UJ!M4LI;D%U07DT?&;R",T6D>U%-4$JDE44ZBF4<V@FJ4T]R7]N@@^
MIIO(6W#S"OO-/XR_[9]XZ-)'-8%J$M44JFE4,ZAF*<U=^EU8'A_:11YO=T-O
MG=*_[=<'KV\TR48UB6H*U32J&52SE.:N[R[)CL$F\A?N697L?+7P_@,8>JZ$
M:BFJ"523J*903:.:035+:6Y!=>EX?/P&\AC-U5$M136!:A+5%*II5#.H9BG-
M+:%G+R'>'\ ?L-U  W542U%-H)ILM:TKF**SC8V:0N?5J&90S5*:N_B[L#P^
MM(6\?^#@18Y&WJ@F4$W&VZW0X=8+'RIT3HUJ!M4LI;D+O(NRX^.]M'@0[BP4
M-/I&M135!*I)5%.HIE'-H)JE-+>@ND0\/G[[>(QFZ:B6HII -8EJ"M4TJAE4
MLY3FEE 7NL=T^W@_.+A =K9!;[Y^0XI.*E!-HII"-8UJ!M4LI;DKOTO'XT/;
MQ_L'#E[A>[WZ.#JG0#6):@K5-*H95+.4YBSPI,NN$[!]_(5NCF3G'7+[#V!H
MH:!:BFH"U22J*533J&90S5*:6U!=(IX<OWT\0=O'42U%-8%J$M44JFE4,ZAF
M*<TMH2YT3^CV\7YP<(&@(7JKO72MET!GE:BF4$VCFD$U2VGNTN_B\>30YO'^
M@8.7.!IR)]M-T%LO?"'0*26J*533J&90S5*:N[Z[[#KISZ[)ZZG.=MZMJO\
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M@&$R#,!0'0)@=!=L+5*X$-*X< $ "R$I0 ##1 # ,!$$,+K'MHXJY AIY*
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M=8&B, 'GVNEL;=U0*!'1*'$2;46PE >'B%'"S!).)VUKBJ*!B*:!"_!5!#$
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M"G_NT.G!D46+9XKF1M84S_'IXEF=GO7VP=_QY+1]'7",4&?E1LT4QC%X!_7
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M+WHV0>C>\='IX=%E!0"%\Z)K"8""% !%GP#(T^YLPPH %"<8S@UZ:0F 4A<
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M8"3*NC00[Z\)X4\7\@%6\TAT]C]02P,$%     @ X5E76)HS1':3 P  W0X
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MFDB+]I B2+;=PV(/M#2VB5"B2])V]]\O22FJ)2M:)Q5ZL4EJWN/,/'K,T?S
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MH.ZO&)-/%\4/-"?ZLW\!4$L#!!0    ( .%95UC4K>\'M D  '1/   :
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M[4:5WS7?,+O)JRK?-3^W7.2Y10T0QS=Y7CUNU"<X?&AO\3]02P,$%     @
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MCP6(Q)GXUZ12,;'0/#'=\Z[$"B5X[*BF)C#?8&?R\0/L>Y]-FMD$BVR"Q9;
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M%6=5W:6.^:N1@;0LS)H$3/<$B/!"]P2).EVPYRD\>PJ=GOY=QGFUD;:@JH=
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MS-EWE;S!H+%JX*@\38FU%^38?9*IH>UKJ766W9/K</;--AM#6B93*(U":>Q
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MFC*+;?<H3S6(<G.>"I38#GZTF6P!"(R)8#NY[JZTDZO.@=+* =Q,KM*/K=:
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MG,UY7AK(WQ=9)EZ^E /LWFDW_1]02P,$%     @ X5E76.\PFQS& P  2Q8
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M0DI#'O*LT">CA3'+=^.QGBYD+O2!6LK"OC-792Z,W2QOQGI92C%S@_)L3(.
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M[/M<BF(JR3_DI^4I+M0WJT#$\&A Q_A * 6$4A1CDW/K$CLQMZRRD[-K4GO
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MBRPIJO]:3PUV/+ 6NZ+,-DUA48--G-;_1L\-$0<%;/^5 JPIP/0"[BL%G*:
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MKZ^O'\IL6]W/?I^59;:I/C[P:,ES"1!_7V59^?(@?V#_/Q&X^3]02P,$%
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M>WW&[I6-^F)3PSUXS.[S.;NI*1&,B)Z;%E00ZT7(@L)D;.,72XF*W1)U4FO
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MT)F.UWA)[HG\>SWC:J]3H\QI1G)!60XX64R"3]$UBJ%.*"*^4;(3>]M E_+
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MG_,=/A(/MXS_%BL B>Y3FHF1M9(RO[)M,5M!BL4ERR%35Q:,IUBJ*5_:(N>
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MI&2%>5QA-,=< ]3[!6-R/] +-!=0TW\ 4$L#!!0    ( .%95UB^].]OA0,
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MRAB^\(E!VDI(^DOA%_?UW!FMU^[8M+9ECHQ/HX[7J(JD+8NDMV*=4AV3;SY
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M\\:D3<[M"YKGKXJBWMYII]CMIA">_0]02P,$%     @ X5E76 // =]7 P
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MH@4)F1-V9=0>PV=A4_?=Z!M= 5]!6,!3E(7%J"\M;$@];0'[ B3TX9'(&]$
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M/YTXTOGYZ=A,GY87I+TJI+TJI,:CI_#B8I/(HB*UI+=<QN7[6W33<'I(HJQ
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M<6"=\,4(83Z"Z>"KL3_LC;JK[82U;0+B[=I$-IM!9;-#KU?1ZSGI?4X7"=\
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M^4U5B>>#]OG9PP/6B_\!4$L#!!0    ( .%95UBG)5Q&BA\  /?S 0 :
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M/ \E9Y>C(5S7Y.01;; D")4S,#E6+$*"37J/:.-Y93A_<Y OB+]:."+$QD@
MJA&X1-^V/T3OOPEW13[=L(=P*#E6"L)Y34ZFT08+@U Y Y-CQ2(PV*0WC3:N
M(?1=[>P-GJ#*V1S<('5J;R ,U0B\H)*]07PE3K@C\LF&/3E#R;%"$-!K<K*%
M-E@"A,H9F!PK%B' )KTMM/&\;%P[.X,GJ."O)8WT]NQ\$,AJ!';/MSUAQ+V?
MX;[(YR;V[ PEQVI!:+#)R?O98%D1*F=@<G:Q6L**;7KO9[@)<8JA<F:0F\0T
M+>&V5F#^/&O'"5^<$VY>GE3LF1Q*CJ6?(&6;D_.SQ4(G5,[ Y%BQ"'2VZ9V?
MK>NM?-?RIQ5?4-GPIQ5/5'UJ0R"PU@ILFF_;$.*GJ.&^R"<<]F .)<=J0:"R
MS<FRV6+!$RIG8'*L6 0\V_26S=8U1;XK'+.5+ZITO@3U1IW:'PBRM4B')>:*
MG7"7Y#,/>S2'DF,E(=38YF3);+%8"94S,#E6+(*5;7I+9AM]@_F5+^:=^PCA
M!C4GMHB.P%B7VI!YYJ4[X7Z)IQY4SL#D6%T(ZW4YN34[+!E"Y0Q,CA6+D&&7
MWJW9N1Y+]T#5$^3\CFHPA@V1\%27R*QYUC4\X<[(YQOVD XEQXI!N*_+R;'9
M8<$0*F=@<JQ8! R[]([-SO59.J3AB7$.3<)=/3L9!+RZU-9.V;T\X>[(YR;V
M3 \EQ\I! +'+R=798=$1*F=@<JQ8!!V[]*[.SG5CN@\96(I#R;&\$8KK$EE%
MS[VH)]P?^3S&GO^AY*QZJ/F(G,<_9[/I#)T%%0LK9V!RK%@%*59RKVBD"7F*
MXU>/PIID>2M)WE+[3\4W]T2Z),\S]$@0)L=*HDA),O*A#IV%%0N*N# Y5BQ-
MBI7<AQII0IYB*)@.<A.^IU'SBN0MD;?UW*M\(AV29QEZU B38P6I24$R\K@.
MG845"\K#,#E6K(84*[G'-=*$/,50BAWDIEC3U+PEB8NPZ:?G-C_?K:[O9KOE
M]?9VL_K?Y<WSOZXVS_]=_O-Q=?C9<Z68/Y'0PTFLG(')L91W).49>5Z'SL**
M!65>F)Q=K((P;Y'<\SHT$3I)GA!CPC%LA 04BP@HOFT'$%WU$^F+>+9!Y0Q,
MCM6"P&>1D5-UZ"RL6%@L1<FQ8A$L+9([58<FPEM#_(WSX1@V0L)R183E$FT-
M4<]JI&/RJ8<E0)0<*PR!Q2(CS^K065BQL"")DF/%(B!9)/>L#DV$]XGX*^G#
M,6R$A+Z*"'TEW"<F&],BG91/0RR_H>18D0CI%1D96(?.PHJ%9424'"L68<0B
MN8%U:"*\9T1C3#C&'F%)P*J,@%7"/6.*WSW2/_$,A,H9F!RK#\'",B,?Z]!9
M6+&PW(B28\4BW%@F][$.302WBWB,"<>P$1+8*B.PE7"[B-T3%.F;?/9AC_Q0
M<JPV!!/+C%RM0V=AQ<*B(TJ.%8N@8YG<U3HT$=XJXJ^C#\>P$1+>*B.\!=LJ
MI-<&17HFGWO84SJ4'*L,X<0R(]?JT%E8L;"\B))CQ2*\6"9WK0Y-A#>*^&OJ
M(UT].QF$Q\H(CR5\_(CZ4B.=D\]4[!D=2LXNCB(HJ7+RI2HL5T+E#$R.%8MP
MI4KO2PTW(4\QE@95R.;*\D803T40#[\#!2\5BO1'GF3LZ1]*CM6# *G*R92J
ML(0*E3,P.58L0J@JO2E5A6R?0]ZB,28<PT9(L$Y%L"[A]A _K@UW3C[]L">
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MY3?- X>5S]_:K^GV <H"LWV>\\<HKUQ9D(0O*J3U*JS2>KY]1/+V39FMFV<
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M^_77?UN>[J@XZ-VN'[;'_Y]]/96=7\UN/V]WZ\?3A_<U>%P]/?^Y^.WD!/E
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M&6%T0I_LH6H.I>9_G]H]V^=)G^USZ+,]5,VAU'SGNV?[/-:S?1Y^MA\HTAO
M3J[@N0:0[_)57^:S<7SY]VSRY=5]#[L6$&,Q(._ )$^Z')!#N06JYE!JOO,=
MM^2QU@1D8;6I4"0YJ4V Y[SCC#RTRL"G!W.8'NSXKWE94.T04LVAU'PS.[;)
MRZ0#'HH_4#6'4O.=[_ G%Q_R+QGP5?C7?+"($XOX]]2!12Z#17]HVL/0+(2A
M*0JJ.PA2S:'4?#,[G,F;I$,3RCY0-8=2\R,1'?L8\0G_@J%Y$O:^R9J7;' .
M%.*#4RSBWU7'%4;FBO[@_&&]69(OG8ON2^?AFP-AP<D%I)I#J?G>=LAB\J0Q
M&BBQ0-4<2LUWGN27Y*64"\:JZ:]A];[+&BB4%35?JI;K>*X''3L8F1U4(_MR
M?I9KH^Z-4.! J?DMT;&)*9+. U"0@:HYE)KO? <R1EZDN6 >@#(*5,V=U/QT
MV]B30(<>1D:/[UY&^: ?T(43J)I#J?G&=7QCZJ3#&PI#4#6'4O.=[V#(R&L[
M%PSOIC>$7F4E3Z0-E<H-CY$.E!I9M;(=;%@9-L"A%]LGAYS=QLV$,FZ@3#8R
M\=@.0:R,(-W$<_E3B'PI[6"!JCF4FF]S1R,V*8U8*(U U1Q*S7>^HQ$;BT9L
M'S0&IJFA4OUI:J#42-;=DBT+,F-X0W=*:%;64_<2*"6@U'PO.TJP22G!0BD!
MJN90:K[S'2786)1@^T_B_+N"<!$W4"0;&9G=T[R5G^;1#Q#AU85P$2<6\6^T
M>_JV\NK"/SX\]X2O]ZO;^]EF>;O^^+3ZG^7=\[^NGI[_7/[S\VKW^]1)"OK$
M#55S*#7?[>Z)VR9=?K#0Y0>HFD.I^9OH.B(H8BT_%,&5A9MP$2<6\>^I>_(O
M0HL/V*V!SU<KI1L-%G%B$?]&NV?O0@XO?=_>U_O##?QTO*\?%[_O9Z-/J]WB
MX3!?S7[^R<U^^L=W[V?7L_?+V^5APWCV>F[^.'BGT(=MJ)I#J?E6=P_;1=*P
M4@$-*T'5'$K-=[Z#@4*&@>_IX!WT[OGS#1U9K^?9W/!!.JV<"Y?S[X3L6);#
M1)<,U_TSQH3W#L@54'<CZ-,X2LTWOWL:+Y*&CPKH%_M0-8=2\YWOF*&(%3XZ
M"=/?F;;H#>N!0F7%Q_1 (3OV^[>#A$*&!.R OOQK2KFZZDX()0R4FM]4'6$4
M20FC@!(&5,VAU/P75W2$4<8BC++/!OWA/U2H-_R'"HT-_[+CC%+F#/CPG_(M
M@EPG]9L[H$L1*#6_/3H<*I,N1910.H*J.92:[WQ'1V6LI8BROWS X3I<Q(E%
M_'OJN*.<R!VHT:W;=B_73MW;H$L:*#6_93J.*I,N:910B(*J.92:[SQY"U6L
M)8TRO*01+N+$(OX]=7A2RG@"'^?3-^S+-5/W-&CZ":7FMTJ'5F72]%,))26H
MFD.I^<YWI%3&2C^5_<12;XP'BSBQB/]6MXY!*IE!X&,\M-E?KH_Z56_0+><H
M-;\M.FJJLI0CNX+R$53-H=1\YSL^JN3EHO-'=A5^NU6XB!.+^/?4D4<EDP=\
M9(?V]\KU4?<OZ$H-2LUOBXZ8*IMT9$.)"*KF4&J^\QT15;%>AU4%WW1U$R[B
MQ"+^/76L4<FL 1_9H>W!<GW4_0NZA(-2\]N"O!8W[7MQL2_&Q;X9-P8'51T'
M5;%>GU7U7WO5__9\H%!O;$M%_+OJ&*.2&0,^MI6[B^7JJ3L<=+D&I>:_B[E#
MI3KIN[AJ*!A!U1Q*S7>^ Z,ZUKNXZO"[N :*])?)A@J-+9/5'7;4\5)J^Z$M
M;R"4KZWN3]!%&92:[WN'1G72R%H-!2&HFD.I^<YW(%3+2T<7C&3;&X&O+'\[
M[5"AWBD40X6*D:'<<48=-<&&W)(GUU3=_:"K-"@UOY4Z<JJ31MUJ*"=!U1Q*
MS7>^XZ0Z5M2M[N]A&1CX X7Z W^@T-C )T=T1$VZJ3?TR=51]S'H^@Q*S6^*
MCIWJI$FV&HI&4#6'4O./<^G0J(F59&O">V7"19Q8Q+^G#CJ:J!FV"-ODY IK
M.R!4S:'4_,;J2*I)&G!KH"P%57,H-=_YCJ6:6 &WD["T>RQ<Q(E%_'OJ**6)
M%' S^>#N,?ERZNX#79]!J?E6=]S4)$VL-5 6@JHYE)KO?,="S<15I+'=8Z?/
M\]U>_#T7-Q/+N7 Y_TXZMF@BY=3VPW7:[C&Y NIN!%V&0:GYYG?\TR2-HS50
MW(&J.92:[SPY1#%6'.TD+.\>&RK4^UY\J-#8]^+9G!YI&"F6-CBD+_].+5!?
M;3_$RCF8'&LO<A#B/&ETK;T\S'XH^\#DF/TYL3]6?JU5EA?#!TOU)H/!4N.S
M 3FG<1XIRC8V&TRA[4"E]'T.>[XC2HXU"CGA<9XTT]9>'F8_E)I@<LQ^<LSC
M/-HYC_-PLFU"&2>783=&CGF<1TJWC0UVY:&N<O7T_0Y[6"1*CC4/.2YRGO:\
MR#GVP$BHG(/),?O)F9'S:(=&SH.)MIL)99Q<AMT8.35R'BGX-C;L%:?#RE73
M]SGL"90H.7;(.8&QQ ?,@T^8!Q\Q'^F,>7K(?+Q3YJ<<,S_EG'FI#+LQ0BV!
M@^;A0SYXT*Q<(7U/@R[DP.18@Q#.RI+FXC+H$?<W6#D'DV/V$Z*2CX:_:*#W
M,VW]@1XLX^0R[,8(JP3.I(</]-!6M$"%]#T-NO #DV,-0A@K2YJ#RU!GVK?V
M8QD*)<?L)PPEGRQ_T4 /OQ=Z0ADGEV$W1N@D<*0]?*"'=J8%*J3O:= %(I@<
M:Q!"55G22%Q[>9C]6')"R?GVYX2<Y$/J+QGH^917O V5Z@UUL0R[-4(E\O'S
M^*&NW*@6J)^ZZT'E'$R.M0^!JSQI(JZ]/,Q^+$JAY)C]!*7D@^HO&OGA%[\-
ME1E8CQLJ-;H>EQ-0D8^?OW3LR_O6 A?7]RSLP@]*CIE/8"I/FIAK+P^S'XM.
M*#EF/T$G^4#ZBP9V_QUMKVS_5_I J:+L#>U^J9&WL&<Y 9,\:I(.N8LM4%5]
M/\0N!*'D6%,1U,J3YN[:R\/LQX(52H[93\ JCQ6^:Y5#T\! J8%IH%]J;!HP
M!%M,U/2=>D];H#[JS@:5<S YUAZ$M4S:=)W!HA14SL'DF/T$I4RT=)T)OQYN
M0ADGEV$W1B#%1,W51=CB%JBQOBMBEXA0<JS%"'F9M*$[@V4OJ)R#R3'["7N9
M:*&[D[*TVVU"&2>783=&J,9<'KK[VW9?ADP#\]=E,[C=+7 Q?2_"+O^@Y)C9
MA+),V@B=P9(35,[!Y)C]A)S,Q$6JL8UOK0#;J38O^5LGIA9T@2J=?=.$5\SE
M\;K! 3YM@US@\OH^AUT(0LGY]EM"5#9MA,YB 0HJYV!RS'X"4#9:A,[V3R>M
MB]YO[BFE7*"69_M 2,9>GKB;. L ON&3*ZOOM-@E))0<:RQ"9S9M&L]B40LJ
MYV!RS'Z"6C9:&L_V4W1#<\:$4BY0R[-](,QC+P_O39\S)GT)(-=(WS.Q2U H
M.=8B!-9LVO2>Q>(;5,[!Y)C]!-]LM/2>G9#>"Y=Q@1J>[0%A*'MYT&_ZI*#<
MH2?73=\_L4M3*#G6-@3U;-K,G\6B'E3.P>1\^PN">D6TS%\1?AG>A#(N4,.S
M/2"\55P>#IP^/2AV\LGU4O=-J)R#R;%V(?Q7I T%%EBB@\HYF!RSGQ!=$2T4
M6/2C? -(,5"J/SE$ :N"@%5Q>7IP^N00W/,GUT;?)[%+6B@YUAH$[XJT<<("
MRW)0.0>38_83EBNBQ0F+\,&Q0V4&OF.0ZWBV"P2IBLMSA].GA.#N0+DV^CZ)
M72!#R;'6('!7I(T6%EA^@\HYF!RSG_!;$2U:6(3/F9U0Q@5J>*X')8&H\O($
MXO0)(;B+4*Z-ND="Y1Q,CK4&P;DR;?ZPQ%(;5,[!Y)C]A-K*:/G#<D+^,%S&
M!6IXM@<$G<K+HXK3)P3M7D.Y<OH.BETJ0\FQQB%$5Z9-)998A(/*.9@<LY\@
M7!DME5A.>!5@N(P+U/!L#PA'E9$"C.']B/*5];T/NQR&DF/.$W8KTZ892RRL
M0>4<3([93V"MC/9"P++_(K]7>=T;_@.E^'8E%ZCEV3X0:BKC!1RA^Q;E>NK[
M*W9Y#"7GMU-%R*Y*FX2LL"@'E7,P.68_0;DJ6A*RZK\$<&"Z&"K5GR[D6I[M
M V&J*EX24K^_4:Z,OE-BU\50<JPQ"-Q5:9..%1;?H'(.)L?L)_A614LZ5OT,
M8X\?PF5<H(9G>T 8JHJ7<HRQ#U*NKK[+8I?-4'*LN0CN56DCD!66^:!R#B;'
M["?,5T6+0)Z4Q7V0X3(N4,.S/2#@545YU^'\=3-\2&#@>OH^AUT60\DQOPG@
M56ECC166VZ!R#B;GVU\3;JLGKLB-[IH\"?#-D T_+W!J01>HTMDW36BICO*2
MP^,8G[AQ4JZ!NMM!Y1Q,CK4 X;0Z;6*QQI(95,[!Y)C]A,SJ:(G%NG\P;]E/
M+$XIY0*U/-L'@DCUY9G%Z1,!X%M&N;[Z?HM=$D/)L?8B.%>G33766#R#RCF8
M'+.?X%D=+=58]Q.+0]/&A%(N4,NS?2"<5$=YG^+XM#'INP.Y4OK.B5TQ0\FQ
M1B'@5J>--]98CH/*.9@<LY]P7!TMWEA/B#>&R[A #<_UH"$PU41YP>+XO*#<
M02E73]U%H7(.)L>:AV!?DS;OV&"9#RKG8'+,?L)\3;2\8S,A[Q@NXP(U/-L#
M EY-E%<SCL\0BDV4<M7TW1.[7(:28TU#6+!)FW9LL&@'E7,P.68_0;LF6MJQ
MF9!V#)=Q@1J>[0'AJR;*&<GCLT-P%Z5<(7VGQ"Z(H>18@Q#0:]*&(!LLTD'E
M'$R.V4^0KHD6@FPFG(H<+N,"-3S; \)5390#E,?GA. V2KE"^DZ)73%#R7D-
MDL\[R#O\G'!.:"\/LA\KYV!RS/Z,V!\KZ=@J2W/"A#(N4,.S/<B)!U%.6!Z?
M$T([*0,5TG=*Z'H:3(XUB"$-DC3IV%X>9C\4W6!RS'Y+[(^5=&R5Y3DAG'0,
MU/!L#PKB093#F,?G!.5FRD#]]'T4NG8&DV/M4Y+V21IM;"\/LQ]*<C Y9G]%
M[(\5;6R5Y:7+2:5<H)9G^U 3'^+%&X-[*@,7UW="Z!H93(Z9WQ#SDV8=V\O#
M[(>2&TS.MS\CY);%>H5CJ^QO?[)\#A@J565\#I!K>;8/!*&RJ/%'Y+;*0%75
M718JYV!RK*D(Z65)<Y+MY6'V8[D.)<?L)UR7Q<I)MLJA&6.@U,",$06P,@)8
M6=2<I'IG9: ^^GX)72R#R;'V(+"7)<U!MI>'V8]E.90<LY^P7!8K!]DJB]\W
MA,NX0 W/]H  518U QEA<V6@QOI>"UU-@\FQ%B/HER4-2+:7A]F/A3^4'+.?
MP%\6*R#9*DN;*R>4<8$:GNM!3@@LCQ*0-*^M&=Q<&;B>NL]!Y1Q,COE-2"]/
MFGAL+P^S'TMO*#EF/Z&W?.(ZW=CFRE: [9DTO7/C U?26Q.%K')"5GF4(.1Q
M)IBV!3-0 WWGQ"Z:H>18"Q"FRY/F'=O+P^S'(AQ*CME/$"Z/E7=LE>FO^J;A
MA]@&KJ\W+ ITY02Z\BCAR)$9 _#5I5Q??0?'KKBAY%A[$4#,DV8GV\O#[,?2
M'DJ.V4]H+X^5G6R5B\#\@N4SE!PSC/!9'B5H.3Z_3/K.0JZ4OA=CE^Q0<GZC
M& *,)FW8TF#Y$2KG8'+,?L*/)EK8TDP(6\I7U]L5A?<,X3T3)9<Y/H7H]G\&
MJJ?OS5CF1,FQYB',:=*F- T6.*%R#B;'["? ::*E-$T_@3GP1")?7V]8%$0T
M!!%-E$CG^'0R?;-HH&KZOHR%490<:QH"HR9MFM-@V1(JYV!RS'["EB9:FM.$
MS^H.7%UO5Q06-(0%3930Y_A$$MI7&JB0OO]B61,EQQJ$L*9)&P0U6*J$RCF8
MG&^_)51IHP5!;?@L[\#5U7:AY)A=A )ME+SH^/01VH(:J)"Z_T+E'$R.-0CA
M3)LV%6JQ' F5<S Y9C_A2!LM%6J#)WG?!*ZNMRL*]UG"?39*>'1\^@CN5I4K
MI.^_6*Y$R;$&(5QITZ9'+98=H7(.)L?L)^QHHZ5'[83TJ'QUO5U16,\2UK-1
M@J;CTX=V8ZM</WUWQL(E2HZU#X%+FS96:K$H"95S,#EF/T%)&RU6:L/OW0Q<
M76]7%/0K"/H5\1*HX?VO\L75?14JYV!RS'P"DD7:.&J!Q4:HG(/),?L)-A:Q
M7L#9*GO[U#(^5\B7U_L5A?,*PGE%U(PJ=)^L7%5]U\8R)DJ.-15AS")MF+7
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MB_]O1M1O=):KJ/<="Y H.;^)2@*095J ++$ "95S,#EF/P'(,AI RLIZ9[$
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M\M->9T61+;8/[Y)XEN35 N7[-UE6/#VI5O CRW_??IS+_P-02P,$%     @
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MA&92$ 7ETGL?7F9A; %UQ!\,#KK7)C:5.RGO;>=+L?0".R/@D!M+0?%O#U?
MN67">?S3DGK=F!;8;S^P_U8GC\G<40U7DO_)"K-9>C./%%#2'3<W\O 9VH0F
MEB^77->_Y-#&!A[)=]K(J@7C#"HFFG_ZHQ6B!PB3)P!1"XC.!<0M(#X7D+2
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MAU7S6:+I&+FM7]3OI,'7_KJY 5J L@%XOY32/'3LNW_W<6CU'U!+ P04
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MR*&:B&H2JLFHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVK>6MO\'6+K359]=,
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M!P,S>T@?92 1U4=72&1!6*P0#X],VXUQ#P9XBU"]&=:@#(>Q'@,@PZO(,DV
M%;YA-[Y-X1X,3;/I4 J(C&DLT,B"/5BA'!Z9BYL'>[#): BAE1XVH#)Z7@&H
M^CWO,'#%>WAD_NXI*1]EB)LO\M+;R),S>[$TH-/GXC'9IYOPY39<SE+D2,)9
M%[2\<J17-^'+;9A9Q9'$/2$Y'^UT%0]&,N-^!!(9MR.0B%B&"J(XC[@Y;Q+L
M$).[KG2 <]=[\?EAUFBA'=);'CYS?F\*[1 3OTC,C228*HH,!@"]D*UI%<T1
M-\UYHQUBTMB5/K9 &F-H@426-3RBH(Z,S->-P0Z!$(OIBSQK2$;#E7$90FXQ
MMMQU$,5LQ,UL4V"'@)-K>ES "JO.VZ"19<PGBM_(R/3;/+!#3#+C)-*C-D5&
MORL@46B[[A3C$3?C]3<$G6(& W'Z7#P@^W03OMR&.52X2%:SHHY7B/3J)GRY
M#;?O*(BD,ZPZG[>!QUPL1G&H;X. 5!3K^R @%6.6"0"J.(^Z.6\2[5 3O*[T
M.V5WO9>>(E"-EEM/JDB/GCFC-P5WJ,E?,8KT3A=01=A8UP)4G! +SE&%<]2-
M<]YPAYHX=F4LX4$B1/29$5#%;$W9VX,W,D\WACP4 *W(7&&&9#P.C?UTD RO
M+'Q %;G1D3UU$Y"'0I1F7(VF*-8Y#C)"M@Y&41P]<\.<7^2AT"XYKC,XH#([
M8 &I^AWP,'(%>]0->_?]F, 8G.4O'9.]N@E?;L/<*6*D\9RT0[URI%<WX<MM
MF%G%D72&9>;S:,=<'99]HGY% B*D;WZ 1+'E?I(ISF-NSINV8=G$KBO]?M)=
M[\5;E@'0LX2N*(^=.9LWA728R5Z<Z7,%@(A%^N /B6++V,\4QC$WQGG#' 9,
MXND<OH9$1IRFAEEV23!%<VQD<FX,<1A$:4B?@ -5QEH/I.(K"PPPA6EL9 _=
M!+YA &L1?1$5$%&C5: ).0MDL]Y3$&=NCO/+-PS8-J?OC5\#(J/'%9 (V<)6
M6,?<6/='.R1OT^US^T@?W').BTM'8:]NPI?;,'V*#5DT)]\PK^3HU4WX<AMF
M5I$CFV$]^2R^8>8R<&3T0Z9&7VL7@(;:1@>%=6QT-7D"W "/>N@!>9WI RJT
M]$1<81T_<_INTA-9)FQA9CR0!4WCZ3/G@,@V7G+%;=S-;=[0AIODA?6Y#T"C
M;Y@0@,:V.8<K@.,C\W!C9,,A,-/I<@VI$-<7=D!5:+G9YXK.^,@6N0EDP\&Y
M,#TJ4V0\"@CY6 )2J,9G>*QUG&NX"6%<[T0!C=[1"D!#+ NG7+$<=[/<IWOP
MD)V%+AULO;H)7V[#A/4>AN5S8@SW"HA>W80OMV%F%2#R&5:*S\(8;B[Q4FR
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MOS\41?WM2U/!Z46HM_\#4$L#!!0    ( .%95UB$'O_W%0,   \)   :
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M-*YF"GPA&YQ#XN@*EB .X*1OW_@S[].84Z\IEKV2V)F+X>!B^#_U]-N^WH)
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MIEB#@Q9>H.FX$\?"8 710;>9K/ 8F^,=5_&.K?%>IRIZXLM()[%>U6+ZQ+/
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M!D1QZJZX4'R;GT-[XDKQ)/^Y873)1&:@GZ\X5_N+[ 75V<?Y?U!+ P04
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MG$I[18LFUG-05DG%RP:L,R@)J^_XI?%A!>!'.P!! PC> GH[ &$#" \%]!I
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M0!#]E9$K(9 *3IP+"!)+":%J52%%(-J'J@\;>YRLV(N[NTG@[SN[=DP(X?+
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M965T<R]S:&5E=#(Q,RYX;6RM5$V/TS 0_2M6D!!(T#1)6U!I(_4#Q!X6JJV
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M3AKL5[>M<**"L@YX7TAIC@?[0#^CT]]02P,$%     @ X5E76,$9N?K:'@
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MD.'=">:/3MJS$?JDHX2='?O_\8X2JMK<:+$;M&ZG:]VO';5_WU+7:.L@DT\
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M[T@1RNHY_V:@6!:(A9M=!-'61LZH)4N/V4UO/,?T@P*=IL/@&,=$^KO"'IF
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MH@Y6\DE9AN_;TZC:O^!N_Z4I-[M7OCV635.N=Q^7,EO(JA6HOS^59?/VI3W
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MRK^PW1^T+<BM^!8L+>O_P:[%.A.PV):<96VPR"!+\N9W_*-MQ%X ]$8"4!N
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M%LTNS^:$LTV][_&><<ZR^G!-XR4M*H#X_($Q_G12W:#;:SO_'U!+ P04
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MU@5D]0A;/@*+*0.$TP6=TP7'C2D#^Y@RZ$PML(DI&SU4=;(L92$@VKF@<[8
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MIA#FC6;,&RV#:0 :<4A-&=Y&&_ VC4;LU !I]QC?1H>X<!1"N=&,<J-E% U
M#0[A* /:: /0YE-<3I,W26Z?B,H#]BTM8]OH$2X1A>!M-,/;:)E!<WA=C!P2
M44:RT0:2S69AH/?XS?D3)Q.1Q^U=8>:!(UP6"J';:$:WT3*"!B /ARR4@6RT
M 63SJ8SS*FLO,)H+4(<%'?*PO0O,W&^$"T AG!O-.#=:AM$ U.$0@#*DC38@
M;?8?Z%$LZYEW=ENFD]A[?%7?;Q]2^E<]2\IFBLN\+G\Y14A3R+@W>HP+1R$
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MC9=;VXR A2#-!'R^$4*_=,P"U3\HIO\"4$L#!!0    ( .%95UAH2_B?,@0
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MWP>W[D?>ZC[EM7_2#_\"4$L#!!0    ( .%95UB7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ X5E76"D5X8.8#
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MH8RE*D"AF-BA",]OHFPK:@H*4Q$4.Q8!@8:F+T"AF-C!"+!$9:.'R0B*'8V
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M7G*]%T"]EUSO!5#OQ?Y9":CWDNN] .J]Y'HO@'HON=X+H-Y+KO<"J'?-]:Z
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M\\O/KF^___7AKR?]M7G-]?;]C-.G?P!02P,$%     @ X5E76(.@L>;2 P
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M_.%SU=5-_S(_VF_JKWX"4$L! A0#%     @ X5E76 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #A
M65=8!>TVPN\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #A65=8F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .%95UBFUE>^
MU 8  /,A   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #A65=8[5-"-Z4"  #."   &
M@($8#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ X5E7
M6+?,)1%^"   ^R8  !@              ("!\Q$  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( .%95U@\H<P8I08  ,L;   8
M      " @:<:  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #A65=8(OCC#28%  #R%   &               @(&"(0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ X5E76#_G4<U<#P  2H,  !@
M             ("!WB8  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( .%95UACP2H730(  'X%   8              " @7 V  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #A65=8V<+14%@+  #]
M,@  &               @('S.   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ X5E76&@/UF)M!0  .Q8  !@              ("!@40
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( .%95UCM-H@N
M*0,  *$&   9              " @21*  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ X5E76-'2M0O8&   &4<  !D
M ("!A$T  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #A
M65=8"-@0D_HD   !A@  &0              @(&39@  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( .%95UB,9SOC'A4  +!    9
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M970Q-RYX;6Q02P$"% ,4    " #A65=8U7S_4,@-   8)0  &0
M    @(%8[P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M .%95UB(:B2(- 8  "D0   9              " @5?]  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ X5E76-]JHB?S"0  ="$  !D
M             ("!P@,! 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #A65=8HI9L378"  #;!@  &0              @('L#0$ >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .%95U@NYC,9O0,
M /@'   9              " @9D0 0!X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ X5E76 N$73\/!   !0H  !D              ("!
MC10! 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #A65=8
MA.!A)@ $  "/"   &0              @('3& $ >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( .%95U@NVM.DN@4  #D1   9
M      " @0H= 0!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ X5E76 _<JQ)H P  )P@  !D              ("!^R(! 'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #A65=8OAI;.!\)  "5%P
M&0              @(&:)@$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( .%95UA9_&2MFA(  /DX   9              " @? O 0!X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ X5E76(;BH?1>
M @  : 4  !D              ("!P4(! 'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #A65=83YB64@H8  #F4P  &0
M@(%610$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .%9
M5UAY &(G&0D  $@=   9              " @9== 0!X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ X5E76#E?]&:Z*   SH<  !D
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M=#,V+GAM;%!+ 0(4 Q0    ( .%95UA^]UIM+@,  ,L&   9
M  " @<GF 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
MX5E76,G\V1(^ @  .P4  !D              ("!+NH! 'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " #A65=8DM?0VJ($  "2"@  &0
M            @(&C[ $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( .%95UAD:5EP2@0  *0)   9              " @7SQ 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ X5E76+3V"'?$ @
M8P8  !D              ("!_?4! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " #A65=8;&N$7] $  #["@  &0              @('X
M^ $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( .%95UC3
M=(-8; 4  #P,   9              " @?_] 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ X5E76"5Y2?"W @  L 8  !D
M     ("!H@," 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .%95U@YJ;DC704  +(.   9              "
M@2 H @!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ X5E7
M6#IQGW.;"0  #1\  !D              ("!M"T" 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " #A65=8=&ZO2'<&  !M#@  &0
M        @(&&-P( >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( .%95UA$ 0-\TFT  '2E 0 9              " @30^ @!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ X5E76!^$*@AU!P  ?A8
M !D              ("!/:P" 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " #A65=8DJEPF<<#  "Q"0  &0              @('ILP(
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( .%95U@Y"CJ?
MS0,  +0)   9              " @>>W @!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ X5E76/8TJ-_M"@  F2(  !D
M ("!Z[L" 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #A
M65=89\W+!B,,  "V(   &0              @($/QP( >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( .%95UCX)%59P04  !,-   9
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M970V,BYX;6Q02P$"% ,4    " #A65=8QBCO$A8#  "'!P  &0
M    @('/Z0( >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M .%95UB-@6S?$P0  (\(   9              " @1SM @!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ X5E76'VE9]+#!   4PX  !D
M             ("!9O$" 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    " #A65=8[S:+<7D#   A"   &0              @(%@]@( >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( .%95UCC=($4_08
M /80   9              " @1#Z @!X;"]W;W)K<VAE971S+W-H965T-C<N
M>&UL4$L! A0#%     @ X5E76%=][Y<J$0  )C<  !D              ("!
M1 $# 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " #A65=8
M-%)IR&$3   %20  &0              @(&E$@, >&PO=V]R:W-H965T<R]S
M:&5E=#8Y+GAM;%!+ 0(4 Q0    ( .%95UB>_PS<&P8  *\1   9
M      " @3TF P!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%
M  @ X5E76%&<L1FO&0  V%T  !D              ("!CRP# 'AL+W=O<FMS
M:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " #A65=8-Z_ @<4+  #=+P
M&0              @(%U1@, >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+
M 0(4 Q0    ( .%95U@CCV;"& 8  &D/   9              " @7%2 P!X
M;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ X5E76)8X$:N+
M!0  7 T  !D              ("!P%@# 'AL+W=O<FMS:&5E=',O<VAE970W
M-"YX;6Q02P$"% ,4    " #A65=8,/N R?D"   P!@  &0
M@(&"7@, >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( .%9
M5UAPMWL=$@0  )8(   9              " @;)A P!X;"]W;W)K<VAE971S
M+W-H965T-S8N>&UL4$L! A0#%     @ X5E76/79B:Y> P  2 <  !D
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M=#@Q+GAM;%!+ 0(4 Q0    ( .%95U@K'5@NDQ   &\O   9
M  " @:YZ P!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @
MX5E76(/'?G0Z!0  U@T  !D              ("!>(L# 'AL+W=O<FMS:&5E
M=',O<VAE970X,RYX;6Q02P$"% ,4    " #A65=83#:A'IL)   8'P  &0
M            @('ID , >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4
M Q0    ( .%95UAC-%CK#P<  .<R   9              " @;N: P!X;"]W
M;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ X5E76-]$US<- P
MF0P  !D              ("! :(# 'AL+W=O<FMS:&5E=',O<VAE970X-BYX
M;6Q02P$"% ,4    " #A65=8 4E] , #  "H%@  &0              @(%%
MI0, >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( .%95U@D
M@RTPIP(  -D&   9              " @3RI P!X;"]W;W)K<VAE971S+W-H
M965T.#@N>&UL4$L! A0#%     @ X5E76-#(MU9H @  !P4  !D
M     ("!&JP# 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .%95UB\L7HRH0D  &-H   9              "
M@3;& P!X;"]W;W)K<VAE971S+W-H965T.30N>&UL4$L! A0#%     @ X5E7
M6$.%=&$T P  60H  !D              ("!#M # 'AL+W=O<FMS:&5E=',O
M<VAE970Y-2YX;6Q02P$"% ,4    " #A65=8U13P24L(   S6   &0
M        @(%YTP, >&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0
M   ( .%95UC&'J !TP@  &Y1   9              " @?O; P!X;"]W;W)K
M<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ X5E76!?P7:T& P  K@<
M !D              ("!!>4# 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q0
M2P$"% ,4    " #A65=8+%P&EKHJ  #J$P, &0              @(%"Z ,
M>&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0    ( .%95UC(ZM6&
M1@0  /\3   :              " @3,3! !X;"]W;W)K<VAE971S+W-H965T
M,3 P+GAM;%!+ 0(4 Q0    ( .%95UC(U?;[,Q   &^/   :
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M,3 U+GAM;%!+ 0(4 Q0    ( .%95U@3!PP-GP,  *8/   :
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M,3$P+GAM;%!+ 0(4 Q0    ( .%95UB8']YE00\  "V\   :
M  " @3A<! !X;"]W;W)K<VAE971S+W-H965T,3$Q+GAM;%!+ 0(4 Q0    (
M .%95UAU#/)E-00  !<1   :              " @;%K! !X;"]W;W)K<VAE
M971S+W-H965T,3$R+GAM;%!+ 0(4 Q0    ( .%95UASA*3PT04  %HJ   :
M              " @1YP! !X;"]W;W)K<VAE971S+W-H965T,3$S+GAM;%!+
M 0(4 Q0    ( .%95UB"%R5; @<  !A"   :              " @2=V! !X
M;"]W;W)K<VAE971S+W-H965T,3$T+GAM;%!+ 0(4 Q0    ( .%95UANRR=(
MIP4  & C   :              " @6%]! !X;"]W;W)K<VAE971S+W-H965T
M,3$U+GAM;%!+ 0(4 Q0    ( .%95UAWY(P)A 0  %X7   :
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M,3(P+GAM;%!+ 0(4 Q0    ( .%95UA." I%G (  *L'   :
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M,3(U+GAM;%!+ 0(4 Q0    ( .%95UCS2NL]^P,  # 8   :
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M,3,P+GAM;%!+ 0(4 Q0    ( .%95UB-^& R:0,  +,*   :
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M,3,U+GAM;%!+ 0(4 Q0    ( .%95UA#!'"(M@\  &[S   :
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M,30P+GAM;%!+ 0(4 Q0    ( .%95UA!Y_V4!04   L4   :
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M,30U+GAM;%!+ 0(4 Q0    ( .%95UC53CRK7@,  /0)   :
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M,34P+GAM;%!+ 0(4 Q0    ( .%95U@\V-7;8 X  ,Z+   :
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M,34U+GAM;%!+ 0(4 Q0    ( .%95UB:,T1VDP,  -T.   :
M  " @=24!0!X;"]W;W)K<VAE971S+W-H965T,34V+GAM;%!+ 0(4 Q0    (
M .%95UC8TCYI5@8  (HZ   :              " @9^8!0!X;"]W;W)K<VAE
M971S+W-H965T,34W+GAM;%!+ 0(4 Q0    ( .%95UC%8E,4M0,  (T1   :
M              " @2V?!0!X;"]W;W)K<VAE971S+W-H965T,34X+GAM;%!+
M 0(4 Q0    ( .%95UBJ%7 2E <  /(P   :              " @1JC!0!X
M;"]W;W)K<VAE971S+W-H965T,34Y+GAM;%!+ 0(4 Q0    ( .%95U@5"2IW
MPP0  -T?   :              " @>:J!0!X;"]W;W)K<VAE971S+W-H965T
M,38P+GAM;%!+ 0(4 Q0    ( .%95UC4K>\'M D  '1/   :
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M,38U+GAM;%!+ 0(4 Q0    ( .%95UB1?^1/X@T  *N6   :
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M,3<P+GAM;%!+ 0(4 Q0    ( .%95U@QAOF;%@<  !LR   :
M  " @3__!0!X;"]W;W)K<VAE971S+W-H965T,3<Q+GAM;%!+ 0(4 Q0    (
M .%95UB'4F.0604  #HG   :              " @8T&!@!X;"]W;W)K<VAE
M971S+W-H965T,3<R+GAM;%!+ 0(4 Q0    ( .%95UA(<P.GQ@D  )I*   :
M              " @1X,!@!X;"]W;W)K<VAE971S+W-H965T,3<S+GAM;%!+
M 0(4 Q0    ( .%95UB\TO=V9P4  #<?   :              " @1P6!@!X
M;"]W;W)K<VAE971S+W-H965T,3<T+GAM;%!+ 0(4 Q0    ( .%95UC))3Q5
ML@(   H'   :              " @;L;!@!X;"]W;W)K<VAE971S+W-H965T
M,3<U+GAM;%!+ 0(4 Q0    ( .%95UA"V/=*W@,  ((5   :
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M,3@P+GAM;%!+ 0(4 Q0    ( .%95UC#6IH,: 4  -L=   :
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M,3@U+GAM;%!+ 0(4 Q0    ( .%95UBG)5Q&BA\  /?S 0 :
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M,3DP+GAM;%!+ 0(4 Q0    ( .%95UAECZLGJ1@  .O* 0 :
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M,3DU+GAM;%!+ 0(4 Q0    ( .%95UB$'O_W%0,   \)   :
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M,C P+GAM;%!+ 0(4 Q0    ( .%95UBC=86 1 ,  /()   :
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M,C U+GAM;%!+ 0(4 Q0    ( .%95UBR0])8Z@,  +L,   :
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M,C$P+GAM;%!+ 0(4 Q0    ( .%95UC.W2_]#0,  #4(   :
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M,C$U+GAM;%!+ 0(4 Q0    ( .%95UBM-\,?_PD  '!5   :
M  " @:-J!P!X;"]W;W)K<VAE971S+W-H965T,C$V+GAM;%!+ 0(4 Q0    (
M .%95UCUF,JI+ 4  '8A   :              " @=IT!P!X;"]W;W)K<VAE
M971S+W-H965T,C$W+GAM;%!+ 0(4 Q0    ( .%95U@M$[54GP8  '<K   :
M              " @3YZ!P!X;"]W;W)K<VAE971S+W-H965T,C$X+GAM;%!+
M 0(4 Q0    ( .%95U@#>!G@6 4  !T:   :              " @16!!P!X
M;"]W;W)K<VAE971S+W-H965T,C$Y+GAM;%!+ 0(4 Q0    ( .%95UA-^Q4I
MP1H  "8M 0 :              " @:6&!P!X;"]W;W)K<VAE971S+W-H965T
M,C(P+GAM;%!+ 0(4 Q0    ( .%95UCB @!!P@,  *P0   :
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .%95UB_"7Y1I04  ,F!   :
M          "  5.[!P!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( .%95UB#H+'FT@,  (=Z   3              "  3#!!P!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    #F .8 _#\  #/%!P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>271
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>272
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>274
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2717</ContextCount>
  <ElementCount>917</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>632</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>46</UnitCount>
  <MyReports>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedbalancesheets</Role>
      <ShortName>Consolidated balance sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated income statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedincomestatements</Role>
      <ShortName>Consolidated income statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated statements of comprehensive income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome</Role>
      <ShortName>Consolidated statements of comprehensive income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated statements of changes in equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity</Role>
      <ShortName>Consolidated statements of changes in equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated statements of changes in equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical</Role>
      <ShortName>Consolidated statements of changes in equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated statements of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedstatementsofcashflows</Role>
      <ShortName>Consolidated statements of cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated statements of cash flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical</Role>
      <ShortName>Consolidated statements of cash flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Introduction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Introduction</Role>
      <ShortName>Introduction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Basis of preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Basisofpreparation</Role>
      <ShortName>Basis of preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Principal alliances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Principalalliances</Role>
      <ShortName>Principal alliances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Principal changes in the scope of consolidation in 2023</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023</Role>
      <ShortName>Principal changes in the scope of consolidation in 2023</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021</Role>
      <ShortName>Principal changes in the scope of consolidation in 2022 and 2021</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Propertyplantandequipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Goodwill and other intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Goodwillandotherintangibleassets</Role>
      <ShortName>Goodwill and other intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Impairment of intangible assets and property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Impairmentofintangibleassetsandpropertyplantandequipment</Role>
      <ShortName>Impairment of intangible assets and property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Investments accounted for using the equity method</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod</Role>
      <ShortName>Investments accounted for using the equity method</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Other non-current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Othernoncurrentassets</Role>
      <ShortName>Other non-current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Assets held for sale or exchange and liabilities related to assets held for sale or exchange</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Assetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchange</Role>
      <ShortName>Assets held for sale or exchange and liabilities related to assets held for sale or exchange</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Accounts receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Accountsreceivable</Role>
      <ShortName>Accounts receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Othercurrentassets</Role>
      <ShortName>Other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Financial assets and liabilities measured at fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Financialassetsandliabilitiesmeasuredatfairvalue</Role>
      <ShortName>Financial assets and liabilities measured at fair value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Cashandcashequivalents</Role>
      <ShortName>Cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Net deferred tax position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Netdeferredtaxposition</Role>
      <ShortName>Net deferred tax position</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Consolidated shareholders??? equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Consolidatedshareholdersequity</Role>
      <ShortName>Consolidated shareholders??? equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Non-controlling interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Noncontrollinginterests</Role>
      <ShortName>Non-controlling interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Debt, cash and cash equivalents and lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Debtcashandcashequivalentsandleaseliabilities</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Liabilities related to business combinations and to non-controlling interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests</Role>
      <ShortName>Liabilities related to business combinations and to non-controlling interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Provisions, income tax liabilities and other liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Provisionsincometaxliabilitiesandotherliabilities</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Derivative financial instruments and market risks</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Derivativefinancialinstrumentsandmarketrisks</Role>
      <ShortName>Derivative financial instruments and market risks</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Off balance sheet commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Offbalancesheetcommitments</Role>
      <ShortName>Off balance sheet commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Legal and arbitral proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Legalandarbitralproceedings</Role>
      <ShortName>Legal and arbitral proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Provisions for discounts, rebates and sales returns</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Provisionsfordiscountsrebatesandsalesreturns</Role>
      <ShortName>Provisions for discounts, rebates and sales returns</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Personnel costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Personnelcosts</Role>
      <ShortName>Personnel costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Other operating income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Otheroperatingincome</Role>
      <ShortName>Other operating income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Other operating expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Otheroperatingexpenses</Role>
      <ShortName>Other operating expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Restructuring costs and similar items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Restructuringcostsandsimilaritems</Role>
      <ShortName>Restructuring costs and similar items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Other gains and losses, and litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Othergainsandlossesandlitigation</Role>
      <ShortName>Other gains and losses, and litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Financial expenses and income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Financialexpensesandincome</Role>
      <ShortName>Financial expenses and income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Income tax expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Incometaxexpense</Role>
      <ShortName>Income tax expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Share of profit/loss from investments accounted for using the equity method</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Shareofprofitlossfrominvestmentsaccountedforusingtheequitymethod</Role>
      <ShortName>Share of profit/loss from investments accounted for using the equity method</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Net income attributable to non-controlling interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Netincomeattributabletononcontrollinginterests</Role>
      <ShortName>Net income attributable to non-controlling interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Relatedpartytransactions</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Disclosures about major customers and credit risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Disclosuresaboutmajorcustomersandcreditrisk</Role>
      <ShortName>Disclosures about major customers and credit risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Segment information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Segmentinformation</Role>
      <ShortName>Segment information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Principal accountants' fees and services</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Principalaccountantsfeesandservices</Role>
      <ShortName>Principal accountants' fees and services</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - List of principal companies included in the scope of consolidation during??2023</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023</Role>
      <ShortName>List of principal companies included in the scope of consolidation during??2023</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Events subsequent to December 31, 2023</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/EventssubsequenttoDecember312023</Role>
      <ShortName>Events subsequent to December 31, 2023</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTables</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Summaryofsignificantaccountingpolicies</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Principal changes in the scope of consolidation in 2023 (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023Tables</Role>
      <ShortName>Principal changes in the scope of consolidation in 2023 (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021 (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021Tables</Role>
      <ShortName>Principal changes in the scope of consolidation in 2022 and 2021 (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyplantandequipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Propertyplantandequipment</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Goodwill and other intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables</Role>
      <ShortName>Goodwill and other intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Goodwillandotherintangibleassets</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Impairment of intangible assets and property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentTables</Role>
      <ShortName>Impairment of intangible assets and property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Impairmentofintangibleassetsandpropertyplantandequipment</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Investments accounted for using the equity method (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables</Role>
      <ShortName>Investments accounted for using the equity method (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Other non-current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OthernoncurrentassetsTables</Role>
      <ShortName>Other non-current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Othernoncurrentassets</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Assets held for sale or exchange and liabilities related to assets held for sale or exchange (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeTables</Role>
      <ShortName>Assets held for sale or exchange and liabilities related to assets held for sale or exchange (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Assetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchange</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Inventories</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Accounts receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsreceivableTables</Role>
      <ShortName>Accounts receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Accountsreceivable</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Other current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OthercurrentassetsTables</Role>
      <ShortName>Other current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Othercurrentassets</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Financial assets and liabilities measured at fair value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueTables</Role>
      <ShortName>Financial assets and liabilities measured at fair value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Financialassetsandliabilitiesmeasuredatfairvalue</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/CashandcashequivalentsTables</Role>
      <ShortName>Cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Cashandcashequivalents</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Net deferred tax position (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NetdeferredtaxpositionTables</Role>
      <ShortName>Net deferred tax position (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Netdeferredtaxposition</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Consolidated shareholders??? equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequityTables</Role>
      <ShortName>Consolidated shareholders??? equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Consolidatedshareholdersequity</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Debt, cash and cash equivalents and lease liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Debtcashandcashequivalentsandleaseliabilities</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Liabilities related to business combinations and to non-controlling interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables</Role>
      <ShortName>Liabilities related to business combinations and to non-controlling interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Provisions, income tax liabilities and other liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Provisionsincometaxliabilitiesandotherliabilities</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Derivative financial instruments and market risks (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksTables</Role>
      <ShortName>Derivative financial instruments and market risks (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Derivativefinancialinstrumentsandmarketrisks</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Off balance sheet commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OffbalancesheetcommitmentsTables</Role>
      <ShortName>Off balance sheet commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Offbalancesheetcommitments</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Provisions for discounts, rebates and sales returns (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsTables</Role>
      <ShortName>Provisions for discounts, rebates and sales returns (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Provisionsfordiscountsrebatesandsalesreturns</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Personnel costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PersonnelcostsTables</Role>
      <ShortName>Personnel costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Personnelcosts</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Other operating expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtheroperatingexpensesTables</Role>
      <ShortName>Other operating expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Otheroperatingexpenses</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Restructuring costs and similar items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables</Role>
      <ShortName>Restructuring costs and similar items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Restructuringcostsandsimilaritems</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Financial expenses and income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialexpensesandincomeTables</Role>
      <ShortName>Financial expenses and income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Financialexpensesandincome</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Income tax expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncometaxexpenseTables</Role>
      <ShortName>Income tax expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Incometaxexpense</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Net income attributable to non-controlling interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsTables</Role>
      <ShortName>Net income attributable to non-controlling interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Netincomeattributabletononcontrollinginterests</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Related party transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RelatedpartytransactionsTables</Role>
      <ShortName>Related party transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Relatedpartytransactions</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Segment information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationTables</Role>
      <ShortName>Segment information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Segmentinformation</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Principal accountants' fees and services (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesTables</Role>
      <ShortName>Principal accountants' fees and services (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Principalaccountantsfeesandservices</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - List of principal companies included in the scope of consolidation during??2023 (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023Tables</Role>
      <ShortName>List of principal companies included in the scope of consolidation during??2023 (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Basis of preparation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/BasisofpreparationDetails</Role>
      <ShortName>Basis of preparation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Basisofpreparation</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Summary of significant accounting policies - Other Intangible Assets not Acquired in Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails</Role>
      <ShortName>Summary of significant accounting policies - Other Intangible Assets not Acquired in Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Summary of significant accounting policies - Summary of Useful Lives of Property Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Summary of significant accounting policies - Summary of Useful Lives of Property Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Summary of significant accounting policies - Treasury Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTreasurySharesDetails</Role>
      <ShortName>Summary of significant accounting policies - Treasury Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Summary of significant accounting policies - Provision for Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesProvisionforRisksDetails</Role>
      <ShortName>Summary of significant accounting policies - Provision for Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Summary of significant accounting policies - Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails</Role>
      <ShortName>Summary of significant accounting policies - Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Summary of significant accounting policies - Share-Based Payment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails</Role>
      <ShortName>Summary of significant accounting policies - Share-Based Payment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Summary of significant accounting policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of significant accounting policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Principal alliances - Collaboration agreements on human therapeutic antibodies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails</Role>
      <ShortName>Principal alliances - Collaboration agreements on human therapeutic antibodies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Principal alliances - Immuno-Oncology Agreement with Regeneron Pharmaceuticals, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails</Role>
      <ShortName>Principal alliances - Immuno-Oncology Agreement with Regeneron Pharmaceuticals, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Principal alliances - Investor Agreement with Regeneron Pharmaceuticals, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails</Role>
      <ShortName>Principal alliances - Investor Agreement with Regeneron Pharmaceuticals, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Principal alliances - Agreements on the commercialization of Beyfortus??? (nirsevimab, previously MEDI8897) in the US (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails</Role>
      <ShortName>Principal alliances - Agreements on the commercialization of Beyfortus??? (nirsevimab, previously MEDI8897) in the US (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Principal changes in the scope of consolidation in 2023 - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails</Role>
      <ShortName>Principal changes in the scope of consolidation in 2023 - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Principal changes in the scope of consolidation in 2023 - Summary of Provisional Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails</Role>
      <ShortName>Principal changes in the scope of consolidation in 2023 - Summary of Provisional Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021 - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails</Role>
      <ShortName>Principal changes in the scope of consolidation in 2022 and 2021 - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021 - Summary of Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails</Role>
      <ShortName>Principal changes in the scope of consolidation in 2022 and 2021 - Summary of Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails</Role>
      <ShortName>Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Property, plant and equipment - Summary of Off Balance Sheet Commitments Relating to Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyplantandequipmentSummaryofOffBalanceSheetCommitmentsRelatingtoPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, plant and equipment - Summary of Off Balance Sheet Commitments Relating to Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Property, plant and equipment - Summary of Impairment Losses Recognised in Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyplantandequipmentSummaryofImpairmentLossesRecognisedinPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, plant and equipment - Summary of Impairment Losses Recognised in Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Property, plant and equipment - Summary of Property, Plant and Equipment Leased (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails</Role>
      <ShortName>Property, plant and equipment - Summary of Property, Plant and Equipment Leased (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Property, plant and equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails</Role>
      <ShortName>Property, plant and equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Goodwill and other intangible assets - Schedule of Movements in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails</Role>
      <ShortName>Goodwill and other intangible assets - Schedule of Movements in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Goodwill and other intangible assets - Schedule of Allocation of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails</Role>
      <ShortName>Goodwill and other intangible assets - Schedule of Allocation of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Goodwill and other intangible assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and other intangible assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails</Role>
      <ShortName>Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Goodwill and other intangible assets - Amortization of Softwares Recognized in Income Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails</Role>
      <ShortName>Goodwill and other intangible assets - Amortization of Softwares Recognized in Income Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Impairment of intangible assets and property, plant and equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails</Role>
      <ShortName>Impairment of intangible assets and property, plant and equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Impairment of intangible assets and property, plant and equipment - Summary of Net Impairment Losses of Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails</Role>
      <ShortName>Impairment of intangible assets and property, plant and equipment - Summary of Net Impairment Losses of Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails</Role>
      <ShortName>Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Investments accounted for using the equity method - Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails</Role>
      <ShortName>Investments accounted for using the equity method - Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails</Role>
      <ShortName>Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Investments accounted for using the equity method - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails</Role>
      <ShortName>Investments accounted for using the equity method - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - Other non-current assets - Summary of Other Non-current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails</Role>
      <ShortName>Other non-current assets - Summary of Other Non-current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - Other non-current assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails</Role>
      <ShortName>Other non-current assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>9954540 - Disclosure - Assets held for sale or exchange and liabilities related to assets held for sale or exchange - Summary of Assets Held for Sale or Exchange, and Liabilities Related to Assets Held for Sale or Exchange (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeSummaryofAssetsHeldforSaleorExchangeandLiabilitiesRelatedtoAssetsHeldforSaleorExchangeDetails</Role>
      <ShortName>Assets held for sale or exchange and liabilities related to assets held for sale or exchange - Summary of Assets Held for Sale or Exchange, and Liabilities Related to Assets Held for Sale or Exchange (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - Inventories - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/InventoriesAdditionalInformationDetails</Role>
      <ShortName>Inventories - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>9954543 - Disclosure - Accounts receivable - Summary of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails</Role>
      <ShortName>Accounts receivable - Summary of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>9954544 - Disclosure - Accounts receivable - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails</Role>
      <ShortName>Accounts receivable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>9954545 - Disclosure - Accounts receivable - Summary of Gross Value of Overdue Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails</Role>
      <ShortName>Accounts receivable - Summary of Gross Value of Overdue Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>9954546 - Disclosure - Other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OthercurrentassetsDetails</Role>
      <ShortName>Other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/OthercurrentassetsTables</ParentRole>
      <Position>127</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>9954547 - Disclosure - Financial assets and liabilities measured at fair value - Summary of Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Financial assets and liabilities measured at fair value - Summary of Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>128</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>9954548 - Disclosure - Cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/CashandcashequivalentsDetails</Role>
      <ShortName>Cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/CashandcashequivalentsTables</ParentRole>
      <Position>129</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>9954549 - Disclosure - Net deferred tax position - Summary of Net Deferred Tax Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails</Role>
      <ShortName>Net deferred tax position - Summary of Net Deferred Tax Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>9954550 - Disclosure - Net deferred tax position - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NetdeferredtaxpositionAdditionalinformationDetails</Role>
      <ShortName>Net deferred tax position - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>131</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>9954551 - Disclosure - Net deferred tax position - Summary of Tax Losses Available for Carry-forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails</Role>
      <ShortName>Net deferred tax position - Summary of Tax Losses Available for Carry-forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>132</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>9954552 - Disclosure - Consolidated shareholders??? equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>133</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>9954553 - Disclosure - Consolidated shareholders??? equity - Summary of Treasury Shares Held (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Summary of Treasury Shares Held (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>134</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>9954554 - Disclosure - Consolidated shareholders??? equity - Summary of Movements Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Summary of Movements Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>135</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>9954555 - Disclosure - Consolidated shareholders??? equity - Principal Characteristics of Restricted Share Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Principal Characteristics of Restricted Share Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>136</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R137.htm</HtmlFileName>
      <LongName>9954556 - Disclosure - Consolidated shareholders??? equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>137</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R138.htm</HtmlFileName>
      <LongName>9954557 - Disclosure - Consolidated shareholders??? equity - Summary of Characteristics of Employee Share Ownership Plans Awarded (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Summary of Characteristics of Employee Share Ownership Plans Awarded (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>138</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R139.htm</HtmlFileName>
      <LongName>9954558 - Disclosure - Consolidated shareholders??? equity - Summary of Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Summary of Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>139</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R140.htm</HtmlFileName>
      <LongName>9954559 - Disclosure - Consolidated shareholders??? equity - Summary of Repurchases Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Summary of Repurchases Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>140</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R141.htm</HtmlFileName>
      <LongName>9954560 - Disclosure - Consolidated shareholders??? equity - Summary of Currency Translation Differences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Summary of Currency Translation Differences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>141</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R142.htm</HtmlFileName>
      <LongName>9954561 - Disclosure - Consolidated shareholders??? equity - Summary of Movements within Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Summary of Movements within Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>142</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R143.htm</HtmlFileName>
      <LongName>9954562 - Disclosure - Consolidated shareholders??? equity - Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>143</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R144.htm</HtmlFileName>
      <LongName>9954563 - Disclosure - Consolidated shareholders??? equity - Summary of Stock Options Outstanding at Each Balance Sheet Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Summary of Stock Options Outstanding at Each Balance Sheet Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>144</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R145.htm</HtmlFileName>
      <LongName>9954564 - Disclosure - Consolidated shareholders??? equity - Summary of Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Summary of Options Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>145</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R146.htm</HtmlFileName>
      <LongName>9954565 - Disclosure - Consolidated shareholders??? equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails</Role>
      <ShortName>Consolidated shareholders??? equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>146</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R147.htm</HtmlFileName>
      <LongName>9954566 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Changes in Financial Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Summary of Changes in Financial Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>147</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R148.htm</HtmlFileName>
      <LongName>9954567 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>148</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R149.htm</HtmlFileName>
      <LongName>9954568 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Disclosure of Movement In Total Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Disclosure of Movement In Total Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>149</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R150.htm</HtmlFileName>
      <LongName>9954569 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>150</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R151.htm</HtmlFileName>
      <LongName>9954570 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Net Debt by Type Valuation of Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Summary of Net Debt by Type Valuation of Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>151</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R152.htm</HtmlFileName>
      <LongName>9954571 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Bond Issues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Summary of Bond Issues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>152</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R153.htm</HtmlFileName>
      <LongName>9954572 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Maturity at Value on Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Maturity at Value on Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>153</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R154.htm</HtmlFileName>
      <LongName>9954573 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Interest Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Interest Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>154</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R155.htm</HtmlFileName>
      <LongName>9954574 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate of Net Debt at Value on Redemption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate of Net Debt at Value on Redemption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>155</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R156.htm</HtmlFileName>
      <LongName>9954575 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>156</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R157.htm</HtmlFileName>
      <LongName>9954576 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Currency (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Currency (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>157</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R158.htm</HtmlFileName>
      <LongName>9954577 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Market Value of Net Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Summary of Market Value of Net Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>158</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R159.htm</HtmlFileName>
      <LongName>9954578 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>159</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R160.htm</HtmlFileName>
      <LongName>9954579 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails</Role>
      <ShortName>Debt, cash and cash equivalents and lease liabilities - Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>160</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R161.htm</HtmlFileName>
      <LongName>9954580 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails</Role>
      <ShortName>Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>161</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R162.htm</HtmlFileName>
      <LongName>9954581 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails</Role>
      <ShortName>Liabilities related to business combinations and to non-controlling interests - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>162</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R163.htm</HtmlFileName>
      <LongName>9954582 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails</Role>
      <ShortName>Liabilities related to business combinations and to non-controlling interests - Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>163</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R164.htm</HtmlFileName>
      <LongName>9954583 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Non Current Provisions and Other Non-current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Summary of Non Current Provisions and Other Non-current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>164</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R165.htm</HtmlFileName>
      <LongName>9954584 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Movements in Non-current Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Summary of Movements in Non-current Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>165</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R166.htm</HtmlFileName>
      <LongName>9954585 - Disclosure - Provisions, income tax liabilities and other liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>166</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R167.htm</HtmlFileName>
      <LongName>9954586 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Financial and Demographic Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Summary of Financial and Demographic Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>167</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R168.htm</HtmlFileName>
      <LongName>9954587 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Weighted Average Duration of Obligation for Pensions and Other Long-term Benefits in Principal Countries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Summary of Weighted Average Duration of Obligation for Pensions and Other Long-term Benefits in Principal Countries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>168</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R169.htm</HtmlFileName>
      <LongName>9954588 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Sensitivity for Pensions and Other Post-Employment Benefits to Changes in Key Actuarial Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Summary of Sensitivity for Pensions and Other Post-Employment Benefits to Changes in Key Actuarial Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>169</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R170.htm</HtmlFileName>
      <LongName>9954589 - Disclosure - Provisions, income tax liabilities and other liabilities - Reconciliation of Net Amount Recognized in Respect of Pension and Other Post-employment Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Reconciliation of Net Amount Recognized in Respect of Pension and Other Post-employment Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>170</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R171.htm</HtmlFileName>
      <LongName>9954590 - Disclosure - Provisions, income tax liabilities and other liabilities - Net Liability in Respect of Pension Plans and Other Post-employment Benefits by Geographical Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Net Liability in Respect of Pension Plans and Other Post-employment Benefits by Geographical Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>171</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R172.htm</HtmlFileName>
      <LongName>9954591 - Disclosure - Provisions, income tax liabilities and other liabilities - Fair Value of Plans Assets relating to Pension Plans and Other Post-employment Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Fair Value of Plans Assets relating to Pension Plans and Other Post-employment Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>172</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R173.htm</HtmlFileName>
      <LongName>9954592 - Disclosure - Provisions, income tax liabilities and other liabilities - Service Cost for Pension and Other post-employment Benefit Plans, by Geographical Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Service Cost for Pension and Other post-employment Benefit Plans, by Geographical Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>173</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R174.htm</HtmlFileName>
      <LongName>9954593 - Disclosure - Provisions, income tax liabilities and other liabilities - Remeasurement of Net Defined-benefit (Asset)/Liability (Actuarial Gains and Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Remeasurement of Net Defined-benefit (Asset)/Liability (Actuarial Gains and Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>174</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R175.htm</HtmlFileName>
      <LongName>9954594 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Net Pre-tax Actuarial Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNetPretaxActuarialLossDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Summary of Net Pre-tax Actuarial Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>175</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R176.htm</HtmlFileName>
      <LongName>9954595 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Present Value of Pension and Other Post Employment Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Summary of Present Value of Pension and Other Post Employment Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>176</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R177.htm</HtmlFileName>
      <LongName>9954596 - Disclosure - Provisions, income tax liabilities and other liabilities - Total Expense for Pensions and Other Post-employment Benefits Allocated between Income Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Total Expense for Pensions and Other Post-employment Benefits Allocated between Income Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>177</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R178.htm</HtmlFileName>
      <LongName>9954597 - Disclosure - Provisions, income tax liabilities and other liabilities - Estimated Amounts of Employer's Contributions to Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Estimated Amounts of Employer's Contributions to Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>178</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R179.htm</HtmlFileName>
      <LongName>9954598 - Disclosure - Provisions, income tax liabilities and other liabilities - Expected Timing of Benefit Payments under Pension and Other Post-employment Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Expected Timing of Benefit Payments under Pension and Other Post-employment Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>179</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R180.htm</HtmlFileName>
      <LongName>9954599 - Disclosure - Provisions, income tax liabilities and other liabilities - Timing of Future Payments in Respect of Unfunded Pension and Other Post-employment Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Timing of Future Payments in Respect of Unfunded Pension and Other Post-employment Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>180</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R181.htm</HtmlFileName>
      <LongName>9954600 - Disclosure - Provisions, income tax liabilities and other liabilities - Movements in Restructuring Provisions Classified in Non-current and Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Movements in Restructuring Provisions Classified in Non-current and Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>181</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R182.htm</HtmlFileName>
      <LongName>9954601 - Disclosure - Provisions, income tax liabilities and other liabilities - Timing of Future Termination Benefit Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Timing of Future Termination Benefit Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>182</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R183.htm</HtmlFileName>
      <LongName>9954602 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Other Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Summary of Other Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>183</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R184.htm</HtmlFileName>
      <LongName>9954603 - Disclosure - Provisions, income tax liabilities and other liabilities - Current Provisions and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Provisions, income tax liabilities and other liabilities - Current Provisions and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>184</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R185.htm</HtmlFileName>
      <LongName>9954604 - Disclosure - Derivative financial instruments and market risks - Summary of Fair Value of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails</Role>
      <ShortName>Derivative financial instruments and market risks - Summary of Fair Value of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>185</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R186.htm</HtmlFileName>
      <LongName>9954605 - Disclosure - Derivative financial instruments and market risks - Summary of Operating Currency Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails</Role>
      <ShortName>Derivative financial instruments and market risks - Summary of Operating Currency Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>186</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R187.htm</HtmlFileName>
      <LongName>9954606 - Disclosure - Derivative financial instruments and market risks - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails</Role>
      <ShortName>Derivative financial instruments and market risks - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>187</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R188.htm</HtmlFileName>
      <LongName>9954607 - Disclosure - Derivative financial instruments and market risks - Disclosure of Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails</Role>
      <ShortName>Derivative financial instruments and market risks - Disclosure of Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>188</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R189.htm</HtmlFileName>
      <LongName>9954608 - Disclosure - Derivative financial instruments and market risks - Disclosure of Actual or Potential Effects of Netting Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails</Role>
      <ShortName>Derivative financial instruments and market risks - Disclosure of Actual or Potential Effects of Netting Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>189</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R190.htm</HtmlFileName>
      <LongName>9954609 - Disclosure - Off balance sheet commitments - Summary of Off Balance Sheet Commitments Relating to Operating Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails</Role>
      <ShortName>Off balance sheet commitments - Summary of Off Balance Sheet Commitments Relating to Operating Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>190</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R191.htm</HtmlFileName>
      <LongName>9954610 - Disclosure - Off balance sheet commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails</Role>
      <ShortName>Off balance sheet commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>191</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R192.htm</HtmlFileName>
      <LongName>9954611 - Disclosure - Off balance sheet commitments - Summary of Undrawn Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails</Role>
      <ShortName>Off balance sheet commitments - Summary of Undrawn Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>192</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R193.htm</HtmlFileName>
      <LongName>9954612 - Disclosure - Off balance sheet commitments - Summary of Amount of Guarantees Given and Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails</Role>
      <ShortName>Off balance sheet commitments - Summary of Amount of Guarantees Given and Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>193</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R194.htm</HtmlFileName>
      <LongName>9954613 - Disclosure - Legal and arbitral proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/LegalandarbitralproceedingsDetails</Role>
      <ShortName>Legal and arbitral proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Legalandarbitralproceedings</ParentRole>
      <Position>194</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R195.htm</HtmlFileName>
      <LongName>9954614 - Disclosure - Provisions for discounts, rebates and sales returns - Summary of Movement in Provisions for Discounts, Rebates and Sales Returns (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails</Role>
      <ShortName>Provisions for discounts, rebates and sales returns - Summary of Movement in Provisions for Discounts, Rebates and Sales Returns (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>195</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R196.htm</HtmlFileName>
      <LongName>9954615 - Disclosure - Personnel costs - Summary of Personal Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails</Role>
      <ShortName>Personnel costs - Summary of Personal Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>196</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R197.htm</HtmlFileName>
      <LongName>9954616 - Disclosure - Personnel costs - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PersonnelcostsAdditionalInformationDetails</Role>
      <ShortName>Personnel costs - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>197</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R198.htm</HtmlFileName>
      <LongName>9954617 - Disclosure - Other operating income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtheroperatingincomeDetails</Role>
      <ShortName>Other operating income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Otheroperatingincome</ParentRole>
      <Position>198</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R199.htm</HtmlFileName>
      <LongName>9954618 - Disclosure - Other operating expenses - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtheroperatingexpensesAdditionalInformationDetails</Role>
      <ShortName>Other operating expenses - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>199</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R200.htm</HtmlFileName>
      <LongName>9954619 - Disclosure - Other operating expenses - Other Income and Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails</Role>
      <ShortName>Other operating expenses - Other Income and Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>200</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R201.htm</HtmlFileName>
      <LongName>9954620 - Disclosure - Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails</Role>
      <ShortName>Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>201</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R202.htm</HtmlFileName>
      <LongName>9954621 - Disclosure - Restructuring costs and similar items - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RestructuringcostsandsimilaritemsAdditionalInformationDetails</Role>
      <ShortName>Restructuring costs and similar items - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>202</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R203.htm</HtmlFileName>
      <LongName>9954622 - Disclosure - Other gains and losses, and litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails</Role>
      <ShortName>Other gains and losses, and litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Othergainsandlossesandlitigation</ParentRole>
      <Position>203</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R204.htm</HtmlFileName>
      <LongName>9954623 - Disclosure - Financial expenses and income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/FinancialexpensesandincomeDetails</Role>
      <ShortName>Financial expenses and income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/FinancialexpensesandincomeTables</ParentRole>
      <Position>204</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R205.htm</HtmlFileName>
      <LongName>9954624 - Disclosure - Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails</Role>
      <ShortName>Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>205</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R206.htm</HtmlFileName>
      <LongName>9954625 - Disclosure - Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails</Role>
      <ShortName>Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>206</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R207.htm</HtmlFileName>
      <LongName>9954626 - Disclosure - Share of profit/loss from investments accounted for using the equity method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails</Role>
      <ShortName>Share of profit/loss from investments accounted for using the equity method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Shareofprofitlossfrominvestmentsaccountedforusingtheequitymethod</ParentRole>
      <Position>207</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R208.htm</HtmlFileName>
      <LongName>9954627 - Disclosure - Net income attributable to non-controlling interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails</Role>
      <ShortName>Net income attributable to non-controlling interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsTables</ParentRole>
      <Position>208</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R209.htm</HtmlFileName>
      <LongName>9954628 - Disclosure - Related party transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RelatedpartytransactionsAdditionalInformationDetails</Role>
      <ShortName>Related party transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>209</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R210.htm</HtmlFileName>
      <LongName>9954629 - Disclosure - Related party transactions - Schedule of Compensation Paid to Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails</Role>
      <ShortName>Related party transactions - Schedule of Compensation Paid to Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>210</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R211.htm</HtmlFileName>
      <LongName>9954630 - Disclosure - Related party transactions - Summary of aggregate amounts Payable to Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/RelatedpartytransactionsSummaryofaggregateamountsPayabletoKeyManagementPersonnelDetails</Role>
      <ShortName>Related party transactions - Summary of aggregate amounts Payable to Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>211</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R212.htm</HtmlFileName>
      <LongName>9954631 - Disclosure - Disclosures about major customers and credit risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails</Role>
      <ShortName>Disclosures about major customers and credit risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/Disclosuresaboutmajorcustomersandcreditrisk</ParentRole>
      <Position>212</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R213.htm</HtmlFileName>
      <LongName>9954632 - Disclosure - Segment information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails</Role>
      <ShortName>Segment information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>213</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R214.htm</HtmlFileName>
      <LongName>9954633 - Disclosure - Segment information - Summary of Net Sales by Segment and Geographical Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails</Role>
      <ShortName>Segment information - Summary of Net Sales by Segment and Geographical Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>214</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R215.htm</HtmlFileName>
      <LongName>9954634 - Disclosure - Segment information - Schedule of Segment Results (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails</Role>
      <ShortName>Segment information - Schedule of Segment Results (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>215</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R216.htm</HtmlFileName>
      <LongName>9954635 - Disclosure - Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails</Role>
      <ShortName>Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>216</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R217.htm</HtmlFileName>
      <LongName>9954636 - Disclosure - Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails</Role>
      <ShortName>Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>217</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R218.htm</HtmlFileName>
      <LongName>9954637 - Disclosure - Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails</Role>
      <ShortName>Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>218</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R219.htm</HtmlFileName>
      <LongName>9954638 - Disclosure - Principal accountants' fees and services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails</Role>
      <ShortName>Principal accountants' fees and services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesTables</ParentRole>
      <Position>219</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R220.htm</HtmlFileName>
      <LongName>9954639 - Disclosure - List of principal companies included in the scope of consolidation during??2023 - Summary of Principal Companies and their Country of Incorporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails</Role>
      <ShortName>List of principal companies included in the scope of consolidation during??2023 - Summary of Principal Companies and their Country of Incorporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>220</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R221.htm</HtmlFileName>
      <LongName>9954640 - Disclosure - List of principal companies included in the scope of consolidation during??2023 - Summary of Principal Investments Accounted for Using the Equity Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails</Role>
      <ShortName>List of principal companies included in the scope of consolidation during??2023 - Summary of Principal Investments Accounted for Using the Equity Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>221</Position>
    </Report>
    <Report instance="sny-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R222.htm</HtmlFileName>
      <LongName>9954641 - Disclosure - Events subsequent to December 31, 2023 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sanofi.com/role/EventssubsequenttoDecember312023Details</Role>
      <ShortName>Events subsequent to December 31, 2023 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sanofi.com/role/EventssubsequenttoDecember312023</ParentRole>
      <Position>222</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" original="sny-20231231.htm">sny-20231231.htm</File>
    <File>sny-20231231.xsd</File>
    <File>sny-20231231_cal.xml</File>
    <File>sny-20231231_def.xml</File>
    <File>sny-20231231_lab.xml</File>
    <File>sny-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sny-20231231_g1.jpg</File>
    <File>sny-20231231_g10.gif</File>
    <File>sny-20231231_g11.gif</File>
    <File>sny-20231231_g12.jpg</File>
    <File>sny-20231231_g13.jpg</File>
    <File>sny-20231231_g14.jpg</File>
    <File>sny-20231231_g15.jpg</File>
    <File>sny-20231231_g16.jpg</File>
    <File>sny-20231231_g17.jpg</File>
    <File>sny-20231231_g18.jpg</File>
    <File>sny-20231231_g19.jpg</File>
    <File>sny-20231231_g2.jpg</File>
    <File>sny-20231231_g20.jpg</File>
    <File>sny-20231231_g21.jpg</File>
    <File>sny-20231231_g22.jpg</File>
    <File>sny-20231231_g23.jpg</File>
    <File>sny-20231231_g24.jpg</File>
    <File>sny-20231231_g25.jpg</File>
    <File>sny-20231231_g26.jpg</File>
    <File>sny-20231231_g27.jpg</File>
    <File>sny-20231231_g28.jpg</File>
    <File>sny-20231231_g29.jpg</File>
    <File>sny-20231231_g3.jpg</File>
    <File>sny-20231231_g4.jpg</File>
    <File>sny-20231231_g5.gif</File>
    <File>sny-20231231_g6.gif</File>
    <File>sny-20231231_g7.gif</File>
    <File>sny-20231231_g8.gif</File>
    <File>sny-20231231_g9.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="47">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="3630">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>277
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sny-20231231.htm": {
   "nsprefix": "sny",
   "nsuri": "http://www.sanofi.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "sny-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "sny-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sny-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sny-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sny-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sny-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 411,
   "keyCustom": 506,
   "axisStandard": 53,
   "axisCustom": 12,
   "memberStandard": 94,
   "memberCustom": 504,
   "hidden": {
    "total": 7,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 1,
    "http://www.sanofi.com/20231231": 2,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 2717,
   "entityCount": 1,
   "segmentCount": 632,
   "elementCount": 1826,
   "unitCount": 46,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 3630,
    "http://xbrl.sec.gov/dei/2023": 47
   },
   "report": {
    "R1": {
     "role": "http://www.sanofi.com/role/Coverpage",
     "longName": "0000001 - Document - Cover page",
     "shortName": "Cover page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.sanofi.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.sanofi.com/role/Consolidatedbalancesheets",
     "longName": "0000003 - Statement - Consolidated balance sheets",
     "shortName": "Consolidated balance sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CurrentTaxAssetsNoncurrent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.sanofi.com/role/Consolidatedincomestatements",
     "longName": "0000004 - Statement - Consolidated income statements",
     "shortName": "Consolidated income statements",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GrossProfit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome",
     "longName": "0000005 - Statement - Consolidated statements of comprehensive income",
     "shortName": "Consolidated statements of comprehensive income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
     "longName": "0000006 - Statement - Consolidated statements of changes in equity",
     "shortName": "Consolidated statements of changes in equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-17",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical",
     "longName": "0000007 - Statement - Consolidated statements of changes in equity (Parenthetical)",
     "shortName": "Consolidated statements of changes in equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DividendsPaidOrdinarySharesPerShare",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DividendsPaidOrdinarySharesPerShare",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.sanofi.com/role/Consolidatedstatementsofcashflows",
     "longName": "0000008 - Statement - Consolidated statements of cash flows",
     "shortName": "Consolidated statements of cash flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
     "longName": "0000009 - Statement - Consolidated statements of cash flows (Parenthetical)",
     "shortName": "Consolidated statements of cash flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.sanofi.com/role/Introduction",
     "longName": "0000010 - Disclosure - Introduction",
     "shortName": "Introduction",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.sanofi.com/role/Basisofpreparation",
     "longName": "0000011 - Disclosure - Basis of preparation",
     "shortName": "Basis of preparation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.sanofi.com/role/Summaryofsignificantaccountingpolicies",
     "longName": "0000012 - Disclosure - Summary of significant accounting policies",
     "shortName": "Summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.sanofi.com/role/Principalalliances",
     "longName": "0000013 - Disclosure - Principal alliances",
     "shortName": "Principal alliances",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfPrincipalAlliancesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfPrincipalAlliancesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023",
     "longName": "0000014 - Disclosure - Principal changes in the scope of consolidation in 2023",
     "shortName": "Principal changes in the scope of consolidation in 2023",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R15": {
     "role": "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021",
     "longName": "0000015 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021",
     "shortName": "Principal changes in the scope of consolidation in 2022 and 2021",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R16": {
     "role": "http://www.sanofi.com/role/Propertyplantandequipment",
     "longName": "0000016 - Disclosure - Property, plant and equipment",
     "shortName": "Property, plant and equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.sanofi.com/role/Goodwillandotherintangibleassets",
     "longName": "0000017 - Disclosure - Goodwill and other intangible assets",
     "shortName": "Goodwill and other intangible assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.sanofi.com/role/Impairmentofintangibleassetsandpropertyplantandequipment",
     "longName": "0000018 - Disclosure - Impairment of intangible assets and property, plant and equipment",
     "shortName": "Impairment of intangible assets and property, plant and equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod",
     "longName": "0000019 - Disclosure - Investments accounted for using the equity method",
     "shortName": "Investments accounted for using the equity method",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.sanofi.com/role/Othernoncurrentassets",
     "longName": "0000020 - Disclosure - Other non-current assets",
     "shortName": "Other non-current assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.sanofi.com/role/Assetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchange",
     "longName": "0000021 - Disclosure - Assets held for sale or exchange and liabilities related to assets held for sale or exchange",
     "shortName": "Assets held for sale or exchange and liabilities related to assets held for sale or exchange",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.sanofi.com/role/Inventories",
     "longName": "0000022 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.sanofi.com/role/Accountsreceivable",
     "longName": "0000023 - Disclosure - Accounts receivable",
     "shortName": "Accounts receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfTradeReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfTradeReceivablesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.sanofi.com/role/Othercurrentassets",
     "longName": "0000024 - Disclosure - Other current assets",
     "shortName": "Other current assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.sanofi.com/role/Financialassetsandliabilitiesmeasuredatfairvalue",
     "longName": "0000025 - Disclosure - Financial assets and liabilities measured at fair value",
     "shortName": "Financial assets and liabilities measured at fair value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.sanofi.com/role/Cashandcashequivalents",
     "longName": "0000026 - Disclosure - Cash and cash equivalents",
     "shortName": "Cash and cash equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.sanofi.com/role/Netdeferredtaxposition",
     "longName": "0000027 - Disclosure - Net deferred tax position",
     "shortName": "Net deferred tax position",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.sanofi.com/role/Consolidatedshareholdersequity",
     "longName": "0000028 - Disclosure - Consolidated shareholders\u2019 equity",
     "shortName": "Consolidated shareholders\u2019 equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.sanofi.com/role/Noncontrollinginterests",
     "longName": "0000029 - Disclosure - Non-controlling interests",
     "shortName": "Non-controlling interests",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.sanofi.com/role/Debtcashandcashequivalentsandleaseliabilities",
     "longName": "0000030 - Disclosure - Debt, cash and cash equivalents and lease liabilities",
     "shortName": "Debt, cash and cash equivalents and lease liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests",
     "longName": "0000031 - Disclosure - Liabilities related to business combinations and to non-controlling interests",
     "shortName": "Liabilities related to business combinations and to non-controlling interests",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.sanofi.com/role/Provisionsincometaxliabilitiesandotherliabilities",
     "longName": "0000032 - Disclosure - Provisions, income tax liabilities and other liabilities",
     "shortName": "Provisions, income tax liabilities and other liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.sanofi.com/role/Derivativefinancialinstrumentsandmarketrisks",
     "longName": "0000033 - Disclosure - Derivative financial instruments and market risks",
     "shortName": "Derivative financial instruments and market risks",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.sanofi.com/role/Offbalancesheetcommitments",
     "longName": "0000034 - Disclosure - Off balance sheet commitments",
     "shortName": "Off balance sheet commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.sanofi.com/role/Legalandarbitralproceedings",
     "longName": "0000035 - Disclosure - Legal and arbitral proceedings",
     "shortName": "Legal and arbitral proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfLegalAndArbitralProceedingsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.sanofi.com/role/Provisionsfordiscountsrebatesandsalesreturns",
     "longName": "0000036 - Disclosure - Provisions for discounts, rebates and sales returns",
     "shortName": "Provisions for discounts, rebates and sales returns",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.sanofi.com/role/Personnelcosts",
     "longName": "0000037 - Disclosure - Personnel costs",
     "shortName": "Personnel costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.sanofi.com/role/Otheroperatingincome",
     "longName": "0000038 - Disclosure - Other operating income",
     "shortName": "Other operating income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.sanofi.com/role/Otheroperatingexpenses",
     "longName": "0000039 - Disclosure - Other operating expenses",
     "shortName": "Other operating expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.sanofi.com/role/Restructuringcostsandsimilaritems",
     "longName": "0000040 - Disclosure - Restructuring costs and similar items",
     "shortName": "Restructuring costs and similar items",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.sanofi.com/role/Othergainsandlossesandlitigation",
     "longName": "0000041 - Disclosure - Other gains and losses, and litigation",
     "shortName": "Other gains and losses, and litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.sanofi.com/role/Financialexpensesandincome",
     "longName": "0000042 - Disclosure - Financial expenses and income",
     "shortName": "Financial expenses and income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.sanofi.com/role/Incometaxexpense",
     "longName": "0000043 - Disclosure - Income tax expense",
     "shortName": "Income tax expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.sanofi.com/role/Shareofprofitlossfrominvestmentsaccountedforusingtheequitymethod",
     "longName": "0000044 - Disclosure - Share of profit/loss from investments accounted for using the equity method",
     "shortName": "Share of profit/loss from investments accounted for using the equity method",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.sanofi.com/role/Netincomeattributabletononcontrollinginterests",
     "longName": "0000045 - Disclosure - Net income attributable to non-controlling interests",
     "shortName": "Net income attributable to non-controlling interests",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.sanofi.com/role/Relatedpartytransactions",
     "longName": "0000046 - Disclosure - Related party transactions",
     "shortName": "Related party transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.sanofi.com/role/Disclosuresaboutmajorcustomersandcreditrisk",
     "longName": "0000047 - Disclosure - Disclosures about major customers and credit risk",
     "shortName": "Disclosures about major customers and credit risk",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCreditRiskExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCreditRiskExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.sanofi.com/role/Segmentinformation",
     "longName": "0000048 - Disclosure - Segment information",
     "shortName": "Segment information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.sanofi.com/role/Principalaccountantsfeesandservices",
     "longName": "0000049 - Disclosure - Principal accountants' fees and services",
     "shortName": "Principal accountants' fees and services",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023",
     "longName": "0000050 - Disclosure - List of principal companies included in the scope of consolidation during\u00a02023",
     "shortName": "List of principal companies included in the scope of consolidation during\u00a02023",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.sanofi.com/role/EventssubsequenttoDecember312023",
     "longName": "0000051 - Disclosure - Events subsequent to December 31, 2023",
     "shortName": "Events subsequent to December 31, 2023",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of significant accounting policies (Policies)",
     "shortName": "Summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTables",
     "longName": "9954472 - Disclosure - Summary of significant accounting policies (Tables)",
     "shortName": "Summary of significant accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023Tables",
     "longName": "9954473 - Disclosure - Principal changes in the scope of consolidation in 2023 (Tables)",
     "shortName": "Principal changes in the scope of consolidation in 2023 (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021Tables",
     "longName": "9954474 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021 (Tables)",
     "shortName": "Principal changes in the scope of consolidation in 2022 and 2021 (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://www.sanofi.com/role/PropertyplantandequipmentTables",
     "longName": "9954475 - Disclosure - Property, plant and equipment (Tables)",
     "shortName": "Property, plant and equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables",
     "longName": "9954476 - Disclosure - Goodwill and other intangible assets (Tables)",
     "shortName": "Goodwill and other intangible assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentTables",
     "longName": "9954477 - Disclosure - Impairment of intangible assets and property, plant and equipment (Tables)",
     "shortName": "Impairment of intangible assets and property, plant and equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables",
     "longName": "9954478 - Disclosure - Investments accounted for using the equity method (Tables)",
     "shortName": "Investments accounted for using the equity method (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.sanofi.com/role/OthernoncurrentassetsTables",
     "longName": "9954479 - Disclosure - Other non-current assets (Tables)",
     "shortName": "Other non-current assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeTables",
     "longName": "9954480 - Disclosure - Assets held for sale or exchange and liabilities related to assets held for sale or exchange (Tables)",
     "shortName": "Assets held for sale or exchange and liabilities related to assets held for sale or exchange (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.sanofi.com/role/InventoriesTables",
     "longName": "9954481 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDetailedInformationAboutInventoriesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDetailedInformationAboutInventoriesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.sanofi.com/role/AccountsreceivableTables",
     "longName": "9954482 - Disclosure - Accounts receivable (Tables)",
     "shortName": "Accounts receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.sanofi.com/role/OthercurrentassetsTables",
     "longName": "9954483 - Disclosure - Other current assets (Tables)",
     "shortName": "Other current assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueTables",
     "longName": "9954484 - Disclosure - Financial assets and liabilities measured at fair value (Tables)",
     "shortName": "Financial assets and liabilities measured at fair value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.sanofi.com/role/CashandcashequivalentsTables",
     "longName": "9954485 - Disclosure - Cash and cash equivalents (Tables)",
     "shortName": "Cash and cash equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.sanofi.com/role/NetdeferredtaxpositionTables",
     "longName": "9954486 - Disclosure - Net deferred tax position (Tables)",
     "shortName": "Net deferred tax position (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables",
     "longName": "9954487 - Disclosure - Consolidated shareholders\u2019 equity (Tables)",
     "shortName": "Consolidated shareholders\u2019 equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables",
     "longName": "9954488 - Disclosure - Debt, cash and cash equivalents and lease liabilities (Tables)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables",
     "longName": "9954489 - Disclosure - Liabilities related to business combinations and to non-controlling interests (Tables)",
     "shortName": "Liabilities related to business combinations and to non-controlling interests (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables",
     "longName": "9954490 - Disclosure - Provisions, income tax liabilities and other liabilities (Tables)",
     "shortName": "Provisions, income tax liabilities and other liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksTables",
     "longName": "9954491 - Disclosure - Derivative financial instruments and market risks (Tables)",
     "shortName": "Derivative financial instruments and market risks (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.sanofi.com/role/OffbalancesheetcommitmentsTables",
     "longName": "9954492 - Disclosure - Off balance sheet commitments (Tables)",
     "shortName": "Off balance sheet commitments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsTables",
     "longName": "9954493 - Disclosure - Provisions for discounts, rebates and sales returns (Tables)",
     "shortName": "Provisions for discounts, rebates and sales returns (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.sanofi.com/role/PersonnelcostsTables",
     "longName": "9954494 - Disclosure - Personnel costs (Tables)",
     "shortName": "Personnel costs (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfPersonnelCostsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfPersonnelCostsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.sanofi.com/role/OtheroperatingexpensesTables",
     "longName": "9954495 - Disclosure - Other operating expenses (Tables)",
     "shortName": "Other operating expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherOperatingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherOperatingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables",
     "longName": "9954496 - Disclosure - Restructuring costs and similar items (Tables)",
     "shortName": "Restructuring costs and similar items (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.sanofi.com/role/FinancialexpensesandincomeTables",
     "longName": "9954497 - Disclosure - Financial expenses and income (Tables)",
     "shortName": "Financial expenses and income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.sanofi.com/role/IncometaxexpenseTables",
     "longName": "9954498 - Disclosure - Income tax expense (Tables)",
     "shortName": "Income tax expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsTables",
     "longName": "9954499 - Disclosure - Net income attributable to non-controlling interests (Tables)",
     "shortName": "Net income attributable to non-controlling interests (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.sanofi.com/role/RelatedpartytransactionsTables",
     "longName": "9954500 - Disclosure - Related party transactions (Tables)",
     "shortName": "Related party transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.sanofi.com/role/SegmentinformationTables",
     "longName": "9954501 - Disclosure - Segment information (Tables)",
     "shortName": "Segment information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesTables",
     "longName": "9954502 - Disclosure - Principal accountants' fees and services (Tables)",
     "shortName": "Principal accountants' fees and services (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:AuditorsRemunerationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:AuditorsRemunerationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023Tables",
     "longName": "9954503 - Disclosure - List of principal companies included in the scope of consolidation during\u00a02023 (Tables)",
     "shortName": "List of principal companies included in the scope of consolidation during\u00a02023 (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.sanofi.com/role/BasisofpreparationDetails",
     "longName": "9954504 - Disclosure - Basis of preparation (Details)",
     "shortName": "Basis of preparation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AverageEffectiveTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:IncreaseDecreaseInEffectiveTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails",
     "longName": "9954505 - Disclosure - Summary of significant accounting policies - Other Intangible Assets not Acquired in Business Combination (Details)",
     "shortName": "Summary of significant accounting policies - Other Intangible Assets not Acquired in Business Combination (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-436",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfPrincipalMarketedProductsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-82",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails",
     "longName": "9954506 - Disclosure - Summary of significant accounting policies - Summary of Useful Lives of Property Plant and Equipment (Details)",
     "shortName": "Summary of significant accounting policies - Summary of Useful Lives of Property Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-83",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-83",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTreasurySharesDetails",
     "longName": "9954507 - Disclosure - Summary of significant accounting policies - Treasury Shares (Details)",
     "shortName": "Summary of significant accounting policies - Treasury Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:GainLossOnPurchaseOfTreasuryShares",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "sny:GainLossOnImpairmentOfTreasuryShares",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:GainLossOnPurchaseOfTreasuryShares",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "sny:GainLossOnImpairmentOfTreasuryShares",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesProvisionforRisksDetails",
     "longName": "9954508 - Disclosure - Summary of significant accounting policies - Provision for Risks (Details)",
     "shortName": "Summary of significant accounting policies - Provision for Risks (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:ProvisionsRecordedForFutureOperatingLosses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:ProvisionsRecordedForFutureOperatingLosses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails",
     "longName": "9954509 - Disclosure - Summary of significant accounting policies - Income Tax Expense (Details)",
     "shortName": "Summary of significant accounting policies - Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DeferredTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-91",
      "name": "ifrs-full:DeferredTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails",
     "longName": "9954510 - Disclosure - Summary of significant accounting policies - Share-Based Payment (Details)",
     "shortName": "Summary of significant accounting policies - Share-Based Payment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-92",
      "name": "sny:OptionVestingPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "sny:OptionVestingPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSegmentInformationDetails",
     "longName": "9954511 - Disclosure - Summary of significant accounting policies - Segment Information (Details)",
     "shortName": "Summary of significant accounting policies - Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfOperatingSegments1",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R93": {
     "role": "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
     "longName": "9954512 - Disclosure - Principal alliances - Collaboration agreements on human therapeutic antibodies (Details)",
     "shortName": "Principal alliances - Collaboration agreements on human therapeutic antibodies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-94",
      "name": "sny:NumberOfAgreementsSigned",
      "unitRef": "agreement",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
     "longName": "9954513 - Disclosure - Principal alliances - Immuno-Oncology Agreement with Regeneron Pharmaceuticals, Inc. (Details)",
     "shortName": "Principal alliances - Immuno-Oncology Agreement with Regeneron Pharmaceuticals, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherOperatingIncomeExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:OtherOperatingExpensesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-120",
      "name": "ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails",
     "longName": "9954514 - Disclosure - Principal alliances - Investor Agreement with Regeneron Pharmaceuticals, Inc. (Details)",
     "shortName": "Principal alliances - Investor Agreement with Regeneron Pharmaceuticals, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-122",
      "name": "sny:SaleOfStockNumberOfSharesIssuedInTransactionTotal",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "sny:SaleOfStockNumberOfSharesIssuedInTransactionTotal",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
     "longName": "9954515 - Disclosure - Principal alliances - Agreements on the commercialization of Beyfortus\u2122 (nirsevimab, previously MEDI8897) in the US (Details)",
     "shortName": "Principal alliances - Agreements on the commercialization of Beyfortus\u2122 (nirsevimab, previously MEDI8897) in the US (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:OtherNoncurrentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-123",
      "name": "sny:CollaborationAgreementsUpfrontPayment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails",
     "longName": "9954516 - Disclosure - Principal changes in the scope of consolidation in 2023 - Additional Information (Details)",
     "shortName": "Principal changes in the scope of consolidation in 2023 - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-136",
      "name": "sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails",
     "longName": "9954517 - Disclosure - Principal changes in the scope of consolidation in 2023 - Summary of Provisional Purchase Price Allocation (Details)",
     "shortName": "Principal changes in the scope of consolidation in 2023 - Summary of Provisional Purchase Price Allocation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-139",
      "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "sny:OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
     "longName": "9954518 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021 - Additional Information (Details)",
     "shortName": "Principal changes in the scope of consolidation in 2022 and 2021 - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-155",
      "name": "ifrs-full:OtherProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
     "longName": "9954519 - Disclosure - Principal changes in the scope of consolidation in 2022 and 2021 - Summary of Purchase Price Allocation (Details)",
     "shortName": "Principal changes in the scope of consolidation in 2022 and 2021 - Summary of Purchase Price Allocation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-142",
      "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-142",
      "name": "sny:OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
     "longName": "9954520 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)",
     "shortName": "Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
     "longName": "9954521 - Disclosure - Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)",
     "shortName": "Property, plant and equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestCostsCapitalised",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofOffBalanceSheetCommitmentsRelatingtoPropertyPlantandEquipmentDetails",
     "longName": "9954522 - Disclosure - Property, plant and equipment - Summary of Off Balance Sheet Commitments Relating to Property, Plant and Equipment (Details)",
     "shortName": "Property, plant and equipment - Summary of Off Balance Sheet Commitments Relating to Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:FirmOrdersOfPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:FirmOrdersOfPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofImpairmentLossesRecognisedinPropertyPlantandEquipmentDetails",
     "longName": "9954523 - Disclosure - Property, plant and equipment - Summary of Impairment Losses Recognised in Property, Plant and Equipment (Details)",
     "shortName": "Property, plant and equipment - Summary of Impairment Losses Recognised in Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails",
     "longName": "9954524 - Disclosure - Property, plant and equipment - Summary of Property, Plant and Equipment Leased (Details)",
     "shortName": "Property, plant and equipment - Summary of Property, Plant and Equipment Leased (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-288",
      "name": "sny:NumberOfLeaseAgreementsSigned",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails",
     "longName": "9954525 - Disclosure - Property, plant and equipment - Additional Information (Details)",
     "shortName": "Property, plant and equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails",
     "longName": "9954526 - Disclosure - Goodwill and other intangible assets - Schedule of Movements in Goodwill (Details)",
     "shortName": "Goodwill and other intangible assets - Schedule of Movements in Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-293",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails",
     "longName": "9954527 - Disclosure - Goodwill and other intangible assets - Schedule of Allocation of Goodwill (Details)",
     "shortName": "Goodwill and other intangible assets - Schedule of Allocation of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:Goodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-300",
      "name": "ifrs-full:Goodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
     "longName": "9954528 - Disclosure - Goodwill and other intangible assets - Additional Information (Details)",
     "shortName": "Goodwill and other intangible assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfOperatingSegments1",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-361",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
     "longName": "9954529 - Disclosure - Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)",
     "shortName": "Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:OtherIntangibleAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:OtherIntangibleAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
     "longName": "9954530 - Disclosure - Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details)",
     "shortName": "Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-360",
      "name": "sny:ConcentrationRiskThresholdPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfPrincipalMarketedProductsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails",
     "longName": "9954531 - Disclosure - Goodwill and other intangible assets - Amortization of Softwares Recognized in Income Statement (Details)",
     "shortName": "Goodwill and other intangible assets - Amortization of Softwares Recognized in Income Statement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-439",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
     "longName": "9954532 - Disclosure - Impairment of intangible assets and property, plant and equipment - Additional Information (Details)",
     "shortName": "Impairment of intangible assets and property, plant and equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfOperatingSegments1",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
     "longName": "9954533 - Disclosure - Impairment of intangible assets and property, plant and equipment - Summary of Net Impairment Losses of Other Intangible Assets (Details)",
     "shortName": "Impairment of intangible assets and property, plant and equipment - Summary of Net Impairment Losses of Other Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-467",
      "name": "sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
     "longName": "9954534 - Disclosure - Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details)",
     "shortName": "Investments accounted for using the equity method - Summary of Investments in Associates and Joint Ventures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R116": {
     "role": "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails",
     "longName": "9954535 - Disclosure - Investments accounted for using the equity method - Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures (Details)",
     "shortName": "Investments accounted for using the equity method - Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "c-486",
      "name": "sny:StockPrice",
      "unitRef": "eurPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-488",
      "name": "ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R117": {
     "role": "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
     "longName": "9954536 - Disclosure - Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details)",
     "shortName": "Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "117",
     "firstAnchor": {
      "contextRef": "c-494",
      "name": "ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-494",
      "name": "ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R118": {
     "role": "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
     "longName": "9954537 - Disclosure - Investments accounted for using the equity method - Additional Information (Details)",
     "shortName": "Investments accounted for using the equity method - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "118",
     "firstAnchor": {
      "contextRef": "c-497",
      "name": "sny:CommitmentsMadeToJointVenturesAndAssociates",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "sny:CommitmentsMadeToJointVenturesAndAssociates",
       "sny:CommitmentsMadeToJointVenturesAndAssociates",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-497",
      "name": "sny:CommitmentsMadeToJointVenturesAndAssociates",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "sny:CommitmentsMadeToJointVenturesAndAssociates",
       "sny:CommitmentsMadeToJointVenturesAndAssociates",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R119": {
     "role": "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails",
     "longName": "9954538 - Disclosure - Other non-current assets - Summary of Other Non-current Assets (Details)",
     "shortName": "Other non-current assets - Summary of Other Non-current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "119",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R120": {
     "role": "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails",
     "longName": "9954539 - Disclosure - Other non-current assets - Additional Information (Details)",
     "shortName": "Other non-current assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "120",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R121": {
     "role": "http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeSummaryofAssetsHeldforSaleorExchangeandLiabilitiesRelatedtoAssetsHeldforSaleorExchangeDetails",
     "longName": "9954540 - Disclosure - Assets held for sale or exchange and liabilities related to assets held for sale or exchange - Summary of Assets Held for Sale or Exchange, and Liabilities Related to Assets Held for Sale or Exchange (Details)",
     "shortName": "Assets held for sale or exchange and liabilities related to assets held for sale or exchange - Summary of Assets Held for Sale or Exchange, and Liabilities Related to Assets Held for Sale or Exchange (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "121",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R122": {
     "role": "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails",
     "longName": "9954541 - Disclosure - Inventories - Schedule of Inventories (Details)",
     "shortName": "Inventories - Schedule of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "122",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:RawMaterials",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDetailedInformationAboutInventoriesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:RawMaterials",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDetailedInformationAboutInventoriesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R123": {
     "role": "http://www.sanofi.com/role/InventoriesAdditionalInformationDetails",
     "longName": "9954542 - Disclosure - Inventories - Additional Information (Details)",
     "shortName": "Inventories - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "123",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:InventoriesPledgedAsSecurityForLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:InventoriesPledgedAsSecurityForLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R124": {
     "role": "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails",
     "longName": "9954543 - Disclosure - Accounts receivable - Summary of Accounts Receivable (Details)",
     "shortName": "Accounts receivable - Summary of Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "124",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-219",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfCurrentTradeReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R125": {
     "role": "http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails",
     "longName": "9954544 - Disclosure - Accounts receivable - Additional Information (Details)",
     "shortName": "Accounts receivable - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "125",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R126": {
     "role": "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails",
     "longName": "9954545 - Disclosure - Accounts receivable - Summary of Gross Value of Overdue Receivables (Details)",
     "shortName": "Accounts receivable - Summary of Gross Value of Overdue Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "126",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sny:OverdueReceivablesGrossValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-548",
      "name": "sny:OverdueReceivablesGrossValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R127": {
     "role": "http://www.sanofi.com/role/OthercurrentassetsDetails",
     "longName": "9954546 - Disclosure - Other current assets (Details)",
     "shortName": "Other current assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "127",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R128": {
     "role": "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
     "longName": "9954547 - Disclosure - Financial assets and liabilities measured at fair value - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "shortName": "Financial assets and liabilities measured at fair value - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "128",
     "firstAnchor": {
      "contextRef": "c-644",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-644",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R129": {
     "role": "http://www.sanofi.com/role/CashandcashequivalentsDetails",
     "longName": "9954548 - Disclosure - Cash and cash equivalents (Details)",
     "shortName": "Cash and cash equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "129",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:Cash",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:Cash",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R130": {
     "role": "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails",
     "longName": "9954549 - Disclosure - Net deferred tax position - Summary of Net Deferred Tax Position (Details)",
     "shortName": "Net deferred tax position - Summary of Net Deferred Tax Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "130",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DeferredTaxLiabilityAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DeferredTaxLiabilityAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R131": {
     "role": "http://www.sanofi.com/role/NetdeferredtaxpositionAdditionalinformationDetails",
     "longName": "9954550 - Disclosure - Net deferred tax position - Additional information (Details)",
     "shortName": "Net deferred tax position - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "131",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R132": {
     "role": "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails",
     "longName": "9954551 - Disclosure - Net deferred tax position - Summary of Tax Losses Available for Carry-forward (Details)",
     "shortName": "Net deferred tax position - Summary of Tax Losses Available for Carry-forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "132",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:TaxLossesCarryforwards",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:TaxLossesCarryforwards",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R133": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
     "longName": "9954552 - Disclosure - Consolidated shareholders\u2019 equity - Additional Information (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "133",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R134": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails",
     "longName": "9954553 - Disclosure - Consolidated shareholders\u2019 equity - Summary of Treasury Shares Held (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Summary of Treasury Shares Held (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "134",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sny:NumberOfSharesHeld",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "sny:NumberOfSharesHeld",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R135": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails",
     "longName": "9954554 - Disclosure - Consolidated shareholders\u2019 equity - Summary of Movements Share Capital (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Summary of Movements Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "135",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-759",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R136": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
     "longName": "9954555 - Disclosure - Consolidated shareholders\u2019 equity - Principal Characteristics of Restricted Share Plans (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Principal Characteristics of Restricted Share Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "136",
     "firstAnchor": {
      "contextRef": "c-813",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-770",
      "name": "sny:NumberOfYearsServicePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R137": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
     "longName": "9954556 - Disclosure - Consolidated shareholders\u2019 equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "137",
     "firstAnchor": {
      "contextRef": "c-813",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-792",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R138": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails",
     "longName": "9954557 - Disclosure - Consolidated shareholders\u2019 equity - Summary of Characteristics of Employee Share Ownership Plans Awarded (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Summary of Characteristics of Employee Share Ownership Plans Awarded (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "138",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:PercentageOfAverageOfQuotedMarketPricesOfShares",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "sny:PercentageOfAverageOfQuotedMarketPricesOfShares",
       "span",
       "div",
       "sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:PercentageOfAverageOfQuotedMarketPricesOfShares",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "sny:PercentageOfAverageOfQuotedMarketPricesOfShares",
       "span",
       "div",
       "sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R139": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails",
     "longName": "9954558 - Disclosure - Consolidated shareholders\u2019 equity - Summary of Expenses (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Summary of Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "139",
     "firstAnchor": {
      "contextRef": "c-818",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:AdditionalInformationAboutSharebasedPaymentArrangements",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-818",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:AdditionalInformationAboutSharebasedPaymentArrangements",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R140": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails",
     "longName": "9954559 - Disclosure - Consolidated shareholders\u2019 equity - Summary of Repurchases Program (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Summary of Repurchases Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "140",
     "firstAnchor": {
      "contextRef": "c-824",
      "name": "sny:NumberOfSharesRepurchased",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-824",
      "name": "sny:NumberOfSharesRepurchased",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R141": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails",
     "longName": "9954560 - Disclosure - Consolidated shareholders\u2019 equity - Summary of Currency Translation Differences (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Summary of Currency Translation Differences (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "141",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:EquityAttributableToOwnersOfParent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-836",
      "name": "ifrs-full:EquityAttributableToOwnersOfParent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R142": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
     "longName": "9954561 - Disclosure - Consolidated shareholders\u2019 equity - Summary of Movements within Other Comprehensive Income (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Summary of Movements within Other Comprehensive Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "142",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-839",
      "name": "sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R143": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails",
     "longName": "9954562 - Disclosure - Consolidated shareholders\u2019 equity - Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "143",
     "firstAnchor": {
      "contextRef": "c-879",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-879",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R144": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails",
     "longName": "9954563 - Disclosure - Consolidated shareholders\u2019 equity - Summary of Stock Options Outstanding at Each Balance Sheet Date (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Summary of Stock Options Outstanding at Each Balance Sheet Date (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "144",
     "firstAnchor": {
      "contextRef": "c-886",
      "name": "sny:NumberOfShareOutstandingInShareBasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-888",
      "name": "ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R145": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
     "longName": "9954564 - Disclosure - Consolidated shareholders\u2019 equity - Summary of Options Outstanding and Exercisable (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Summary of Options Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "145",
     "firstAnchor": {
      "contextRef": "c-901",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-901",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R146": {
     "role": "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails",
     "longName": "9954565 - Disclosure - Consolidated shareholders\u2019 equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)",
     "shortName": "Consolidated shareholders\u2019 equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "146",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R147": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails",
     "longName": "9954566 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Changes in Financial Position (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Summary of Changes in Financial Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "147",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R148": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
     "longName": "9954567 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "148",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-902",
      "name": "ifrs-full:LongtermBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R149": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails",
     "longName": "9954568 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Disclosure of Movement In Total Debt (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Disclosure of Movement In Total Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "149",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:Borrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R150": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
     "longName": "9954569 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Additional Information (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "150",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfBondIssuesRedeemed",
      "unitRef": "bond",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-916",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R151": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
     "longName": "9954570 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Net Debt by Type Valuation of Redemption (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Summary of Net Debt by Type Valuation of Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "151",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sny:InterestRateAndCurrencyDerivativesUsedToManageDebt",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-943",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R152": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails",
     "longName": "9954571 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Bond Issues (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Summary of Bond Issues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "152",
     "firstAnchor": {
      "contextRef": "c-949",
      "name": "ifrs-full:BorrowingsInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-949",
      "name": "ifrs-full:BorrowingsInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R153": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
     "longName": "9954572 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Maturity at Value on Redemption (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Maturity at Value on Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "153",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sny:InterestRateAndCurrencyDerivativesUsedToManageDebt",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-977",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-9",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R154": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
     "longName": "9954573 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Interest Rate (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Interest Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "154",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1010",
      "name": "sny:IncreaseDecreaseOfBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R155": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails",
     "longName": "9954574 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate of Net Debt at Value on Redemption (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate of Net Debt at Value on Redemption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "155",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:Borrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1074",
      "name": "ifrs-full:Borrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R156": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails",
     "longName": "9954575 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "156",
     "firstAnchor": {
      "contextRef": "c-1078",
      "name": "sny:ImpactOfChangeInInterestRateOnPreTaxIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1078",
      "name": "sny:ImpactOfChangeInInterestRateOnPreTaxIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R157": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails",
     "longName": "9954576 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Currency (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Summary of Debt by Currency (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "157",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sny:DebtNetOfCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1088",
      "name": "sny:DebtNetOfCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R158": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails",
     "longName": "9954577 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Summary of Market Value of Net Debt (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Summary of Market Value of Net Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "158",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:Borrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1100",
      "name": "ifrs-full:Borrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfMarketValueOfNetDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R159": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails",
     "longName": "9954578 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "159",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R160": {
     "role": "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
     "longName": "9954579 - Disclosure - Debt, cash and cash equivalents and lease liabilities - Lease Liabilities (Details)",
     "shortName": "Debt, cash and cash equivalents and lease liabilities - Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "160",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfChangesInFinancialPositionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "sny:LeaseLiabilitiesEffectOfDiscounting",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R161": {
     "role": "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
     "longName": "9954580 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)",
     "shortName": "Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "161",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R162": {
     "role": "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
     "longName": "9954581 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Additional Information (Details)",
     "shortName": "Liabilities related to business combinations and to non-controlling interests - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "162",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-529",
      "name": "sny:PercentageIncreaseInFairValueLiabilities",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R163": {
     "role": "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails",
     "longName": "9954582 - Disclosure - Liabilities related to business combinations and to non-controlling interests - Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests (Details)",
     "shortName": "Liabilities related to business combinations and to non-controlling interests - Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "163",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1106",
      "name": "sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R164": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails",
     "longName": "9954583 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Non Current Provisions and Other Non-current Liabilities (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Summary of Non Current Provisions and Other Non-current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "164",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NoncurrentProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1168",
      "name": "ifrs-full:OtherNoncurrentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R165": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails",
     "longName": "9954584 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Movements in Non-current Provisions (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Summary of Movements in Non-current Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "165",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:NoncurrentProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNonCurrentProvisionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNonCurrentProvisionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R166": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
     "longName": "9954585 - Disclosure - Provisions, income tax liabilities and other liabilities - Additional Information (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "166",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfCountriesIncludedInPensionPlans",
      "unitRef": "country",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfCountriesIncludedInPensionPlans",
      "unitRef": "country",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R167": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
     "longName": "9954586 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Financial and Demographic Assumptions (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Summary of Financial and Demographic Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "167",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfActuarialAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1263",
      "name": "ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfActuarialAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R168": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails",
     "longName": "9954587 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Weighted Average Duration of Obligation for Pensions and Other Long-term Benefits in Principal Countries (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Summary of Weighted Average Duration of Obligation for Pensions and Other Long-term Benefits in Principal Countries (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "168",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfActuarialAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R169": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails",
     "longName": "9954588 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Sensitivity for Pensions and Other Post-Employment Benefits to Changes in Key Actuarial Assumptions (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Summary of Sensitivity for Pensions and Other Post-Employment Benefits to Changes in Key Actuarial Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "169",
     "firstAnchor": {
      "contextRef": "c-1274",
      "name": "ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1274",
      "name": "ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R170": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
     "longName": "9954589 - Disclosure - Provisions, income tax liabilities and other liabilities - Reconciliation of Net Amount Recognized in Respect of Pension and Other Post-employment Benefit Plans (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Reconciliation of Net Amount Recognized in Respect of Pension and Other Post-employment Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "170",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1321",
      "name": "ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R171": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
     "longName": "9954590 - Disclosure - Provisions, income tax liabilities and other liabilities - Net Liability in Respect of Pension Plans and Other Post-employment Benefits by Geographical Region (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Net Liability in Respect of Pension Plans and Other Post-employment Benefits by Geographical Region (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "171",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1312",
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R172": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails",
     "longName": "9954591 - Disclosure - Provisions, income tax liabilities and other liabilities - Fair Value of Plans Assets relating to Pension Plans and Other Post-employment Plans (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Fair Value of Plans Assets relating to Pension Plans and Other Post-employment Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "172",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R173": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
     "longName": "9954592 - Disclosure - Provisions, income tax liabilities and other liabilities - Service Cost for Pension and Other post-employment Benefit Plans, by Geographical Region (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Service Cost for Pension and Other post-employment Benefit Plans, by Geographical Region (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "173",
     "firstAnchor": {
      "contextRef": "c-1267",
      "name": "ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1321",
      "name": "sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R174": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails",
     "longName": "9954593 - Disclosure - Provisions, income tax liabilities and other liabilities - Remeasurement of Net Defined-benefit (Asset)/Liability (Actuarial Gains and Losses) (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Remeasurement of Net Defined-benefit (Asset)/Liability (Actuarial Gains and Losses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "174",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1267",
      "name": "sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R175": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNetPretaxActuarialLossDetails",
     "longName": "9954594 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Net Pre-tax Actuarial Loss (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Summary of Net Pre-tax Actuarial Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "175",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R176": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails",
     "longName": "9954595 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Present Value of Pension and Other Post Employment Benefits (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Summary of Present Value of Pension and Other Post Employment Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "176",
     "firstAnchor": {
      "contextRef": "c-1312",
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1381",
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R177": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails",
     "longName": "9954596 - Disclosure - Provisions, income tax liabilities and other liabilities - Total Expense for Pensions and Other Post-employment Benefits Allocated between Income Statement (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Total Expense for Pensions and Other Post-employment Benefits Allocated between Income Statement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "177",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1321",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R178": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
     "longName": "9954597 - Disclosure - Provisions, income tax liabilities and other liabilities - Estimated Amounts of Employer's Contributions to Plan Assets (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Estimated Amounts of Employer's Contributions to Plan Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "178",
     "firstAnchor": {
      "contextRef": "c-753",
      "name": "ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-753",
      "name": "ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R179": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
     "longName": "9954598 - Disclosure - Provisions, income tax liabilities and other liabilities - Expected Timing of Benefit Payments under Pension and Other Post-employment Benefit Plans (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Expected Timing of Benefit Payments under Pension and Other Post-employment Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "179",
     "firstAnchor": {
      "contextRef": "c-1106",
      "name": "sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1106",
      "name": "sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R180": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails",
     "longName": "9954599 - Disclosure - Provisions, income tax liabilities and other liabilities - Timing of Future Payments in Respect of Unfunded Pension and Other Post-employment Benefit Plans (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Timing of Future Payments in Respect of Unfunded Pension and Other Post-employment Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "180",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R181": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails",
     "longName": "9954600 - Disclosure - Provisions, income tax liabilities and other liabilities - Movements in Restructuring Provisions Classified in Non-current and Current Liabilities (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Movements in Restructuring Provisions Classified in Non-current and Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "181",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1427",
      "name": "sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfRestructuringProvisionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R182": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails",
     "longName": "9954601 - Disclosure - Provisions, income tax liabilities and other liabilities - Timing of Future Termination Benefit Payments (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Timing of Future Termination Benefit Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "182",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1106",
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R183": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails",
     "longName": "9954602 - Disclosure - Provisions, income tax liabilities and other liabilities - Summary of Other Provisions (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Summary of Other Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "183",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sny:NonCurrentProvisionForEnvironmentRisks",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOtherLongTermProvisionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:OtherLongtermProvisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOtherLongTermProvisionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R184": {
     "role": "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails",
     "longName": "9954603 - Disclosure - Provisions, income tax liabilities and other liabilities - Current Provisions and Other Current Liabilities (Details)",
     "shortName": "Provisions, income tax liabilities and other liabilities - Current Provisions and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "184",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R185": {
     "role": "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails",
     "longName": "9954604 - Disclosure - Derivative financial instruments and market risks - Summary of Fair Value of Derivative Instruments (Details)",
     "shortName": "Derivative financial instruments and market risks - Summary of Fair Value of Derivative Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "185",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NoncurrentDerivativeFinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:CurrentDerivativeFinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R186": {
     "role": "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails",
     "longName": "9954605 - Disclosure - Derivative financial instruments and market risks - Summary of Operating Currency Hedging Instruments (Details)",
     "shortName": "Derivative financial instruments and market risks - Summary of Operating Currency Hedging Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "186",
     "firstAnchor": {
      "contextRef": "c-1567",
      "name": "sny:DerivativeFinancialInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1483",
      "name": "sny:DerivativeFinancialInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R187": {
     "role": "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
     "longName": "9954606 - Disclosure - Derivative financial instruments and market risks - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)",
     "shortName": "Derivative financial instruments and market risks - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "187",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:DerivativeFinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1792",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R188": {
     "role": "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
     "longName": "9954607 - Disclosure - Derivative financial instruments and market risks - Disclosure of Instruments (Details)",
     "shortName": "Derivative financial instruments and market risks - Disclosure of Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "188",
     "firstAnchor": {
      "contextRef": "c-1567",
      "name": "sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1567",
      "name": "sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R189": {
     "role": "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails",
     "longName": "9954608 - Disclosure - Derivative financial instruments and market risks - Disclosure of Actual or Potential Effects of Netting Arrangements (Details)",
     "shortName": "Derivative financial instruments and market risks - Disclosure of Actual or Potential Effects of Netting Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "189",
     "firstAnchor": {
      "contextRef": "c-2017",
      "name": "sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2017",
      "name": "sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R190": {
     "role": "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
     "longName": "9954609 - Disclosure - Off balance sheet commitments - Summary of Off Balance Sheet Commitments Relating to Operating Activities (Details)",
     "shortName": "Off balance sheet commitments - Summary of Off Balance Sheet Commitments Relating to Operating Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "190",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R191": {
     "role": "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
     "longName": "9954610 - Disclosure - Off balance sheet commitments - Additional Information (Details)",
     "shortName": "Off balance sheet commitments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "191",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "sny:CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "sny:CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R192": {
     "role": "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails",
     "longName": "9954611 - Disclosure - Off balance sheet commitments - Summary of Undrawn Credit Facilities (Details)",
     "shortName": "Off balance sheet commitments - Summary of Undrawn Credit Facilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "192",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:UndrawnBorrowingFacilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1106",
      "name": "ifrs-full:UndrawnBorrowingFacilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R193": {
     "role": "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails",
     "longName": "9954612 - Disclosure - Off balance sheet commitments - Summary of Amount of Guarantees Given and Received (Details)",
     "shortName": "Off balance sheet commitments - Summary of Amount of Guarantees Given and Received (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "193",
     "firstAnchor": {
      "contextRef": "c-2067",
      "name": "ifrs-full:EstimatedFinancialEffectOfContingentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2067",
      "name": "ifrs-full:EstimatedFinancialEffectOfContingentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R194": {
     "role": "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails",
     "longName": "9954613 - Disclosure - Legal and arbitral proceedings (Details)",
     "shortName": "Legal and arbitral proceedings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "194",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2082",
      "name": "sny:NumberOfFirstInstanceRulings",
      "unitRef": "case",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R195": {
     "role": "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails",
     "longName": "9954614 - Disclosure - Provisions for discounts, rebates and sales returns - Summary of Movement in Provisions for Discounts, Rebates and Sales Returns (Details)",
     "shortName": "Provisions for discounts, rebates and sales returns - Summary of Movement in Provisions for Discounts, Rebates and Sales Returns (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "195",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "sny:ProvisionsForDiscountsRebatesAndSalesReturns",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "sny:ProvisionsForDiscountsRebatesAndSalesReturns",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R196": {
     "role": "http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails",
     "longName": "9954615 - Disclosure - Personnel costs - Summary of Personal Costs (Details)",
     "shortName": "Personnel costs - Summary of Personal Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "196",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfPersonnelCostsDetailsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfPersonnelCostsDetailsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R197": {
     "role": "http://www.sanofi.com/role/PersonnelcostsAdditionalInformationDetails",
     "longName": "9954616 - Disclosure - Personnel costs - Additional Information (Details)",
     "shortName": "Personnel costs - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "197",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NumberOfEmployees",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:NumberOfEmployees",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R198": {
     "role": "http://www.sanofi.com/role/OtheroperatingincomeDetails",
     "longName": "9954617 - Disclosure - Other operating income (Details)",
     "shortName": "Other operating income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "198",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:MiscellaneousOtherOperatingIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2162",
      "name": "sny:GainsOnDivestmentOfProducts",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R199": {
     "role": "http://www.sanofi.com/role/OtheroperatingexpensesAdditionalInformationDetails",
     "longName": "9954618 - Disclosure - Other operating expenses - Additional Information (Details)",
     "shortName": "Other operating expenses - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "199",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:MiscellaneousOtherOperatingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R200": {
     "role": "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
     "longName": "9954619 - Disclosure - Other operating expenses - Other Income and Expense (Details)",
     "shortName": "Other operating expenses - Other Income and Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "200",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:MiscellaneousOtherOperatingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2171",
      "name": "ifrs-full:MiscellaneousOtherOperatingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:OtherOperatingExpensesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R201": {
     "role": "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails",
     "longName": "9954620 - Disclosure - Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details)",
     "shortName": "Restructuring costs and similar items - Summary of Restructuring Costs and Similar Items (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "201",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfRestructuringCostsDetailsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R202": {
     "role": "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsAdditionalInformationDetails",
     "longName": "9954621 - Disclosure - Restructuring costs and similar items - Additional Information (Details)",
     "shortName": "Restructuring costs and similar items - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "202",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:IncreaseDecreaseInExpenseOfRestructuringActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:IncreaseDecreaseInExpenseOfRestructuringActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R203": {
     "role": "http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails",
     "longName": "9954622 - Disclosure - Other gains and losses, and litigation (Details)",
     "shortName": "Other gains and losses, and litigation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "203",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:OtherGainsLossesAndLitigation",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R204": {
     "role": "http://www.sanofi.com/role/FinancialexpensesandincomeDetails",
     "longName": "9954623 - Disclosure - Financial expenses and income (Details)",
     "shortName": "Financial expenses and income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "204",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R205": {
     "role": "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
     "longName": "9954624 - Disclosure - Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)",
     "shortName": "Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "205",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R206": {
     "role": "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails",
     "longName": "9954625 - Disclosure - Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)",
     "shortName": "Income tax expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "206",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R207": {
     "role": "http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails",
     "longName": "9954626 - Disclosure - Share of profit/loss from investments accounted for using the equity method (Details)",
     "shortName": "Share of profit/loss from investments accounted for using the equity method (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "207",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R208": {
     "role": "http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails",
     "longName": "9954627 - Disclosure - Net income attributable to non-controlling interests (Details)",
     "shortName": "Net income attributable to non-controlling interests (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "208",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToNoncontrollingInterests",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2196",
      "name": "ifrs-full:ProfitLossAttributableToNoncontrollingInterests",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "sny:DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R209": {
     "role": "http://www.sanofi.com/role/RelatedpartytransactionsAdditionalInformationDetails",
     "longName": "9954628 - Disclosure - Related party transactions - Additional Information (Details)",
     "shortName": "Related party transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "209",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfExecutiveCommitteeMembers",
      "unitRef": "executives",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfExecutiveCommitteeMembers",
      "unitRef": "executives",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R210": {
     "role": "http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails",
     "longName": "9954629 - Disclosure - Related party transactions - Schedule of Compensation Paid to Key Management Personnel (Details)",
     "shortName": "Related party transactions - Schedule of Compensation Paid to Key Management Personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "210",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R211": {
     "role": "http://www.sanofi.com/role/RelatedpartytransactionsSummaryofaggregateamountsPayabletoKeyManagementPersonnelDetails",
     "longName": "9954630 - Disclosure - Related party transactions - Summary of aggregate amounts Payable to Key Management Personnel (Details)",
     "shortName": "Related party transactions - Summary of aggregate amounts Payable to Key Management Personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "211",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R212": {
     "role": "http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails",
     "longName": "9954631 - Disclosure - Disclosures about major customers and credit risk (Details)",
     "shortName": "Disclosures about major customers and credit risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "212",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:PercentageOfEntitysRevenue",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:PercentageOfEntitysRevenue",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R213": {
     "role": "http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails",
     "longName": "9954632 - Disclosure - Segment information - Additional Information (Details)",
     "shortName": "Segment information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "213",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:NumberOfOperatingSegments1",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R214": {
     "role": "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails",
     "longName": "9954633 - Disclosure - Segment information - Summary of Net Sales by Segment and Geographical Area (Details)",
     "shortName": "Segment information - Summary of Net Sales by Segment and Geographical Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "214",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2221",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R215": {
     "role": "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
     "longName": "9954634 - Disclosure - Segment information - Schedule of Segment Results (Details)",
     "shortName": "Segment information - Schedule of Segment Results (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "215",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2522",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R216": {
     "role": "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
     "longName": "9954635 - Disclosure - Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)",
     "shortName": "Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "216",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2533",
      "name": "sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R217": {
     "role": "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
     "longName": "9954636 - Disclosure - Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)",
     "shortName": "Segment information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "217",
     "firstAnchor": {
      "contextRef": "c-2536",
      "name": "sny:InvestmentsInAssociatesAndJointVentures",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2536",
      "name": "sny:InvestmentsInAssociatesAndJointVentures",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R218": {
     "role": "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
     "longName": "9954637 - Disclosure - Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)",
     "shortName": "Segment information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "218",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2544",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "unique": true
     }
    },
    "R219": {
     "role": "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails",
     "longName": "9954638 - Disclosure - Principal accountants' fees and services (Details)",
     "shortName": "Principal accountants' fees and services (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "219",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sny:AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sny:AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R220": {
     "role": "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
     "longName": "9954639 - Disclosure - List of principal companies included in the scope of consolidation during\u00a02023 - Summary of Principal Companies and their Country of Incorporation (Details)",
     "shortName": "List of principal companies included in the scope of consolidation during\u00a02023 - Summary of Principal Companies and their Country of Incorporation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "220",
     "firstAnchor": {
      "contextRef": "c-2566",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2566",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R221": {
     "role": "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails",
     "longName": "9954640 - Disclosure - List of principal companies included in the scope of consolidation during\u00a02023 - Summary of Principal Investments Accounted for Using the Equity Method (Details)",
     "shortName": "List of principal companies included in the scope of consolidation during\u00a02023 - Summary of Principal Investments Accounted for Using the Equity Method (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "221",
     "firstAnchor": {
      "contextRef": "c-2706",
      "name": "ifrs-full:ProportionOfOwnershipInterestInJointOperation",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2706",
      "name": "ifrs-full:ProportionOfOwnershipInterestInJointOperation",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sny:DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R222": {
     "role": "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
     "longName": "9954641 - Disclosure - Events subsequent to December 31, 2023 (Details)",
     "shortName": "Events subsequent to December 31, 2023 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "222",
     "firstAnchor": {
      "contextRef": "c-2712",
      "name": "sny:BusinessCombinationPurchasePricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2712",
      "name": "sny:BusinessCombinationPurchasePricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sny-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "sny_A.NattermannCie.GmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "A.NattermannCie.GmbHMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A. Nattermann &amp; Cie. GmbH",
        "label": "A. Nattermann &amp; Cie. GmbH [Member]",
        "documentation": "A. Nattermann &amp; Cie. GmbH [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_A340BDrugPricingProgramInTheUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "A340BDrugPricingProgramInTheUnitedStatesMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "340B Drug Pricing Program in the United States",
        "label": "340B Drug Pricing Program In The United States [Member]",
        "documentation": "340B Drug Pricing Program In The United States"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ALTUVIIIOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ALTUVIIIOMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALTUVIIIO",
        "label": "ALTUVIIIO [Member]",
        "documentation": "ALTUVIIIO"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AOSanofiRussiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AOSanofiRussiaMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AO Sanofi Russia",
        "label": "AO Sanofi Russia [member]",
        "documentation": "AO Sanofi Russia."
       }
      }
     },
     "auth_ref": []
    },
    "country_AR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "AR",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Argentina",
        "label": "ARGENTINA"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AblynxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AblynxMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Ablynx NV",
        "label": "Ablynx [member]",
        "documentation": "Ablynx."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Accruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Accruals",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals",
        "label": "Accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "sny_AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and provisions deductible at time of payments",
        "label": "Accrued Expenses And Provisions Deductible At Time Of Payments [member]",
        "documentation": "Accrued expenses and provisions deductible at time of payments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation &amp; impairment",
        "verboseLabel": "Accumulated amortization\u00a0&amp; impairment",
        "label": "Accumulated depreciation, amortisation and impairment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r73",
      "r143",
      "r157",
      "r160"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "verboseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated other comprehensive income [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "sny_AcquiredRDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AcquiredRDMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired R&amp;D",
        "label": "Acquired R&amp;D [Member]",
        "documentation": "Acquired R&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in scope of consolidation",
        "label": "Acquisition Through Business Combinations, Property, Plant and Equipment, Right Of Use Assets",
        "documentation": "Acquisition Through Business Combinations, Property, Plant and Equipment, Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest in acquiree held before acquisition date",
        "label": "Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Consideration transferred, acquisition-date fair value",
        "terseLabel": "Purchase price",
        "label": "Consideration transferred, acquisition-date fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition-related costs",
        "label": "Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions during the period",
        "label": "Acquisitions through business combinations, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "sny_ActionForWhichWeAreDefendantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ActionForWhichWeAreDefendantMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Action for which we are defendant",
        "label": "Action For Which We Are Defendant [member]",
        "documentation": "Action for which we are defendant."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ActionForWhichWeArePlaintiffMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ActionForWhichWeArePlaintiffMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Action for which we are a plaintiff",
        "label": "Action For Which We Are a Plaintiff [member]",
        "documentation": "Action For Which We Are a Plaintiff."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfDiscountRates",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Actuarial assumption of discount rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfDiscountRatesMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Actuarial assumption of discount rates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflation": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfExpectedRatesOfInflation",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General inflation rate",
        "label": "Actuarial assumption of expected rates of inflation"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected rate of inflation that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfInflationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfExpectedRatesOfInflationMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General inflation rate",
        "label": "Actuarial assumption of expected rates of inflation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the expected rates of inflation used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfExpectedRatesOfPensionIncreases",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension benefit indexation",
        "label": "Actuarial assumption of expected rates of pension increases"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected rate of increases in pension that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension benefit indexation",
        "label": "Actuarial assumption of expected rates of pension increases [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the expected rates of pension increases used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfMedicalCostTrendRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfMedicalCostTrendRates",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Healthcare cost inflation rate",
        "label": "Actuarial assumption of medical cost trend rates"
       }
      },
      "en": {
       "role": {
        "documentation": "Medical cost trend rate used as significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "ifrs-full_ActuarialAssumptionOfMedicalCostTrendRatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfMedicalCostTrendRatesMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Healthcare cost inflation rate",
        "label": "Actuarial assumption of medical cost trend rates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the medical cost trend rates used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "sny_ActuarialAssumptionOfMortalityTableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ActuarialAssumptionOfMortalityTableMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortality table",
        "label": "Actuarial Assumption Of Mortality Table [Member]",
        "documentation": "Actuarial assumption of mortality table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ActuarialAssumptionOfRetirementAge2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionOfRetirementAge2019",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement age",
        "label": "Actuarial assumption of retirement age"
       }
      },
      "en": {
       "role": {
        "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "ifrs-full_ActuarialAssumptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumptions [axis]",
        "label": "Actuarial assumptions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ifrs-full_ActuarialAssumptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialAssumptionsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumptions [member]",
        "label": "Actuarial assumptions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "sny_ActuarialGainsAndLossesOnDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ActuarialGainsAndLossesOnDefinedBenefitPlans",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains and losses on defined-benefit plans",
        "label": "Actuarial Gains And Losses On Defined Benefit Plans",
        "documentation": "Actuarial gains and losses on defined-benefit plans."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Actuarial losses/(gains) due to changes in demographic assumptions",
        "verboseLabel": "Gains/(losses) on demographic assumptions",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Actuarial gains/(losses)",
        "negatedLabel": "Actuarial losses/(gains) due to changes in financial assumptions",
        "verboseLabel": "Gains/(losses) on financial assumptions",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains/(losses) excluding investments accounted for using the equity method (see\u00a0Note\u00a0D.19.1.)",
        "label": "Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Excluding Associates And Joint Ventures",
        "documentation": "Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes",
        "label": "Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures",
        "documentation": "Actuarial gains (losses) arising from changes in financial assumptions net defined benefit liability asset net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Actuarial losses/(gains) due to experience adjustments",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "ifrs-full_AdditionalInformationAboutSharebasedPaymentArrangements": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalInformationAboutSharebasedPaymentArrangements",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Expenses",
        "label": "Additional information about share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "Additional information about share-based payment arrangements necessary to satisfy the disclosure requirements of IFRS 2. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrs-full_AdditionalPaidinCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalPaidinCapitalMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional paid-in capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and other increases",
        "label": "Additions other than through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and other increases",
        "verboseLabel": "Acquisitions",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "sny_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and other increases",
        "label": "Additions Other Than Through Business Combinations, Property, Plant and Equipment, Right Of Use Assets",
        "documentation": "Additions Other Than Through Business Combinations, Property, Plant and Equipment, Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Address Type [Domain]",
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average number of shares after dilution (in shares)",
        "totalLabel": "Average number of shares used to compute diluted earnings per share (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "sny_AdjustmentToDebtMeasuredAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AdjustmentToDebtMeasuredAtFairValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to debt measured\u00a0at fair value",
        "label": "Adjustment To Debt Measured At Fair Value [Member]",
        "documentation": "Adjustment to debt measured at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase)/decrease in inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase)/decrease in accounts receivable",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "ifrs-full_AdjustmentsForDeferredTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDeferredTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in deferred taxes",
        "label": "Adjustments for deferred tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "sny_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets",
        "label": "Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right-of Use Assets And Intangible Asset",
        "documentation": "Depreciation, amortization and impairment of property, plant and equipment, right-of use assets and intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in accounts payable",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains and losses on disposals of non-current assets, net of tax",
        "label": "Adjustments for losses (gains) on disposal of non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "sny_AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in non-current provisions and other non-current liabilities",
        "label": "Adjustments For Non-Current Provisions And Other Non-Current Liabilities",
        "documentation": "Adjustments for noncurrent provisions and other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile profit (loss) [abstract]",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of employee benefits (stock options and other share-based payments)",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ifrs-full_AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share of undistributed earnings from investments accounted for using the\u00a0equity method",
        "label": "Adjustments for undistributed profits of investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for undistributed profits of investments accounted for using the equity method to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "sny_AfterTaxDiscountRates": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AfterTaxDiscountRates",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After tax discount rates",
        "label": "After Tax Discount Rates",
        "documentation": "After tax discount rates."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/RelatedpartytransactionsSummaryofaggregateamountsPayabletoKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members",
        "label": "Aggregate Pension Obligation In Favor Of Certain Corporate Officers And Of Members Of The Executive Committee",
        "documentation": "Aggregate pension obligation in favor of certain corporate officers and of members of the executive committee."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedIndividuallyImmaterialAssociatesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "verboseLabel": "Share of net income attributable to non-controlling interests",
        "label": "Aggregated individually immaterial associates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the aggregation of associates that are individually immaterial. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedMeasurementMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated measurement",
        "label": "Aggregated measurement [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r159",
      "r199"
     ]
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated time bands",
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r208",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r251",
      "r313",
      "r353",
      "r361"
     ]
    },
    "sny_AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK",
        "label": "Agreements Relating To The Recombinant Covid-19 Vaccine Candidate Developed By Sanofi In Collaboration With GSK [Policy Text Block]",
        "documentation": "Agreements Relating To The Recombinant Covid-19 Vaccine Candidate Developed By Sanofi In Collaboration With GSK"
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All levels of fair value hierarchy [member]",
        "label": "All levels of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r200"
     ]
    },
    "ifrs-full_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "All other segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for business activities and operating segments that are not reportable."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r274"
     ]
    },
    "sny_AllergyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AllergyMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allergy",
        "label": "Allergy [Member]",
        "documentation": "Allergy, Cough And Cold [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllowanceForCreditLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllowanceForCreditLossesMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowances",
        "label": "Allowance for credit losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an allowance account used to record impairments to financial assets due to credit losses."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "sny_AlprolixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AlprolixMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ALPROLIX",
        "label": "Alprolix [Member]",
        "documentation": "Alprolix"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmericanDepositorySharesNASDAQGlobalSelectMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AmericanDepositorySharesNASDAQGlobalSelectMarketMember",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American\u00a0Depositary\u00a0Shares,\u00a0each\u00a0representing one half of one ordinary share, par value \u20ac2\u00a0per\u00a0share",
        "label": "American Depository Shares, NASDAQ Global Select Market [Member]",
        "documentation": "American Depository Shares, NASDAQ Global Select Market [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of intangible assets",
        "negatedTerseLabel": "Amortization expense",
        "terseLabel": "Amortization expense",
        "label": "Amortisation, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization and impairment of intangible assets",
        "label": "Amortization And Impairment Of Intangible Assets Other Than Goodwill",
        "documentation": "Amortization and impairment of intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of computer software and other rights of an industrial or operational nature",
        "label": "Amortization Of Computer Software And Other Rights Of An Industrial Or Operational Nature [member]",
        "documentation": "Amortization of computer software and other rights of an industrial or operational nature."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmortizedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AmortizedCostMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost",
        "label": "Amortized Cost Member [member]",
        "documentation": "Amortized cost."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmountOfSharesRepurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AmountOfSharesRepurchased",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value",
        "label": "Amount Of Shares Repurchased",
        "documentation": "Amount of shares repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmountsPayableForAcquisitionOfNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AmountsPayableForAcquisitionOfNonCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sny_CurrentProvisionsAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts payable for acquisitions of non-current assets",
        "label": "Amounts Payable For Acquisition Of Non-Current Assets",
        "documentation": "Amounts payable for acquisitions of non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmountsPayablePartnersInCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AmountsPayablePartnersInCollaborationAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts payable partners in collaboration agreements",
        "label": "Amounts Payable Partners In Collaboration Agreements",
        "documentation": "Amounts payable partners in collaboration agreements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountsPayableRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and other payables",
        "label": "Amounts payable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r113"
     ]
    },
    "ifrs-full_AmountsReceivableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountsReceivableRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable and other receivables",
        "label": "Amounts receivable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r113"
     ]
    },
    "sny_AmunixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AmunixMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amunix",
        "label": "Amunix [Member]",
        "documentation": "Amunix"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AmunixPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AmunixPharmaceuticalsIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amunix Pharmaceuticals, Inc",
        "label": "Amunix Pharmaceuticals, Inc [Member]",
        "documentation": "Amunix Pharmaceuticals, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analysis of income and expense [abstract]",
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AntiProgrammedCellDeathProtein1SalesMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PD1 sales milestone payment from Sanofi",
        "label": "Anti Programmed Cell Death Protein 1 Sales Milestone Payment",
        "documentation": "Anti programmed cell death protein 1 sales milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AntibodiesAllianceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AntibodiesAllianceMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monoclonal Antibody Alliance",
        "label": "Antibodies Alliance [Member]",
        "documentation": "Antibodies Alliance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AntibodiesCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AntibodiesCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antibodies Collaboration agreement",
        "label": "Antibodies Collaboration Agreement [Member]",
        "documentation": "Antibodies collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AntibodiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AntibodiesMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antibodies",
        "label": "Antibodies [Member]",
        "documentation": "Antibodies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ApplicableTaxRate",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard tax rate applicable in France",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "sny_April2016EMTNISINFR0013143997Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "April2016EMTNISINFR0013143997Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2016 EMTN ISIN FR0013143997",
        "label": "April 2016 EMTNISINFR0013143997 [Member]",
        "documentation": "April 2016 EMTN ISIN FR0013143997."
       }
      }
     },
     "auth_ref": []
    },
    "sny_April2016EMTNISINFR0013144003Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "April2016EMTNISINFR0013144003Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2016 EMTN ISIN FR0013144003",
        "label": "April 2016 EMTNISINFR0013144003 [Member]",
        "documentation": "April 2016 EMTN ISIN FR0013144003."
       }
      }
     },
     "auth_ref": []
    },
    "sny_April2022EMTNISINFR0014009KQ0Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "April2022EMTNISINFR0014009KQ0Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2022 EMTN ISIN FR0014009KQ0",
        "label": "April 2022 EMTN ISIN FR0014009KQ0 [Member]",
        "documentation": "April 2022 EMTN ISIN FR0014009KQ0"
       }
      }
     },
     "auth_ref": []
    },
    "sny_April2022EMTNISINFR0014009KS6Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "April2022EMTNISINFR0014009KS6Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "April 2022 EMTN ISIN FR0014009KS6",
        "label": "April 2022 EMTN ISIN FR0014009KS6 [Member]",
        "documentation": "September 2014 EMTN ISIN FR0012146777."
       }
      }
     },
     "auth_ref": []
    },
    "sny_April302021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "April302021Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 30, 2021",
        "label": "April 30, 2021 [Member]",
        "documentation": "April 30, 2021"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r199",
      "r200",
      "r203",
      "r277",
      "r280"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AssociatesAndJointVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AssociatesAndJointVenturesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associates and joint ventures",
        "label": "Associates And Joint Ventures [Member]",
        "documentation": "Associates and Joint Ventures."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssociatesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associates",
        "label": "Associates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entities over which the investor has significant influence."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r119",
      "r121",
      "r198"
     ]
    },
    "sny_AstraZenecaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AstraZenecaMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AstraZeneca",
        "label": "AstraZeneca [Member]",
        "documentation": "AstraZeneca"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "At fair value [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r159",
      "r199"
     ]
    },
    "sny_AtMarketValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AtMarketValueMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market value",
        "label": "At Market Value [member]",
        "documentation": "At market value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AtNotionalAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AtNotionalAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount",
        "label": "At Notional Amount [member]",
        "documentation": "At notional amount."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AtomwiseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AtomwiseMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Atomwise",
        "label": "Atomwise [Member]",
        "documentation": "Atomwise"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AubagioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AubagioMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AUBAGIO",
        "label": "Aubagio [Member]",
        "documentation": "Aubagio."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audit of the financial statements of the parent company and its French subsidiaries",
        "label": "Audit Of The Financial Statements Of The Parent Company And Its French Subsidiaries",
        "documentation": "Audit of the financial statements of the parent company and its French subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audit-related services charged to the parent company and its French subsidiaries",
        "label": "Audit Related Services Charged To The Parent Company And Its French Subsidiaries",
        "documentation": "Audit-related services charged to the parent company and its French subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.sanofi.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ]
    },
    "sny_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLineItems",
     "presentation": [
      "http://www.sanofi.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor [Line Items]",
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.sanofi.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.sanofi.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorTable",
     "presentation": [
      "http://www.sanofi.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor [Table]",
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AuditorsNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AuditorsNameAxis",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditors Name [Axis]",
        "label": "Auditors Name [Axis]",
        "documentation": "Auditors Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AuditorsNameMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AuditorsNameMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditors Name [Member]",
        "label": "Auditors Name [Member]",
        "documentation": "Auditors Name [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AuditorsRemuneration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AuditorsRemuneration",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Auditor's remuneration"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_AuditorsRemunerationForAuditRelatedServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AuditorsRemunerationForAuditRelatedServices",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails": {
       "parentTag": "sny_ServicesOtherThanStatutoryAudit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audit-related services",
        "label": "Auditor's Remuneration For Audit Related Services",
        "documentation": "Auditor's remuneration for audit related services."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor's remuneration for comfort letters and attestation services",
        "label": "Auditor's Remuneration For Audit Related Services, Comfort Letters And Attestation Services",
        "documentation": "Auditor's Remuneration For Audit Related Services, Comfort Letters And Attestation Services"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AuditorsRemunerationForAuditServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AuditorsRemunerationForAuditServices",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails": {
       "parentTag": "ifrs-full_AuditorsRemuneration",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory audit of separate and consolidated financial statements",
        "label": "Auditor's remuneration for audit services"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for auditing services."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "ifrs-full_AuditorsRemunerationForOtherServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AuditorsRemunerationForOtherServices",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails": {
       "parentTag": "sny_ServicesOtherThanStatutoryAudit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Auditor's remuneration for other services"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for services that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "ifrs-full_AuditorsRemunerationForTaxServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AuditorsRemunerationForTaxServices",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails": {
       "parentTag": "sny_ServicesOtherThanStatutoryAudit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax",
        "label": "Auditor's remuneration for tax services"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for tax services."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_AuditorsRemunerationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AuditorsRemunerationTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Accountants' Fees and Services",
        "label": "Auditors Remuneration [Table Text Block]",
        "documentation": "Auditors remuneration."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AventisCropScienceRetainedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AventisCropScienceRetainedLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aventis Crop Science retained liabilities",
        "label": "Aventis Crop Science Retained Liabilities [member]",
        "documentation": "Aventis crop science retained liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AventisIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AventisIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aventis Inc.",
        "label": "Aventis Inc [member]",
        "documentation": "Aventis Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AventisPharmaHoldingsLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AventisPharmaHoldingsLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aventis Pharma Holdings Ltd",
        "label": "Aventis Pharma Holdings Ltd [Member]",
        "documentation": "Aventis Pharma Holdings Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AventisPharmaLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AventisPharmaLimitedMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aventis Pharma Limited",
        "label": "Aventis Pharma Limited [member]",
        "documentation": "Aventis Pharma Limited."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AventisPharmaManufacturingPTELTDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AventisPharmaManufacturingPTELTDMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aventis Pharma (Manufacturing) Pte. Ltd",
        "label": "Aventis Pharma Manufacturing PTE LTD [Member]",
        "documentation": "Aventis Pharma (Manufacturing) PTE LTD."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AventisPharmaSAFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AventisPharmaSAFranceMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aventis Pharma S.A.",
        "label": "Aventis Pharma S.A. France [member]",
        "documentation": "Aventis Pharma S.A. France."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AventisubLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AventisubLLCMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aventisub LLC",
        "label": "Aventisub LLC [Member]",
        "documentation": "Aventisub LLC."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageEffectiveTaxRate",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average effective tax rate",
        "totalLabel": "Effective tax rate",
        "label": "Average effective tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "sny_AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average residual holding periods",
        "label": "Average Residual Holding Periods Under Various Early Retirement Plans",
        "documentation": "Average residual holding periods under various early retirement plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_AwardsDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AwardsDateAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Date [Axis]",
        "label": "Awards Date [Axis]",
        "documentation": "Awards Date 1 [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AwardsDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AwardsDateDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Date [Domain]",
        "label": "Awards Date [Domain]",
        "documentation": "Awards Date [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_AztecaVacunasSADeCVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "AztecaVacunasSADeCVMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Azteca Vacunas, SA de CV",
        "label": "Azteca Vacunas, S.A. De C.V [Member]",
        "documentation": "Azteca Vacunas, S.A. De C.V"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BankOverdraftsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BankOverdraftsClassifiedAsCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank credit balances",
        "label": "Bank overdrafts"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "sny_BasicEarningsLossPerShareAttributableToOwnersOfParent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BasicEarningsLossPerShareAttributableToOwnersOfParent",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings per share (in euros per share)",
        "label": "Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent",
        "documentation": "Basic Earnings (Loss) Per Share, Attributable To Owners Of Parent"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bayer contingent purchase consideration arising from the acquisition of Genzyme",
        "label": "Bayer Contingent Consideration Arising From The Acquisition Of Genzyme [Member]",
        "documentation": "Bayer contingent purchase consideration arising from the acquisition of Genzyme."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BenefitsPaidOrPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BenefitsPaidOrPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefits paid",
        "label": "Benefits paid or payable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of benefits paid or payable for retirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "sny_BioAtriumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BioAtriumMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioAtrium",
        "label": "BioAtrium [Member]",
        "documentation": "BioAtrium"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BiopharmaSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BiopharmaSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biopharma",
        "label": "Biopharma Segment [Member]",
        "documentation": "Biopharma Segment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BioverativIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BioverativIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bioverativ Inc.",
        "label": "Bioverativ Inc. [member]",
        "documentation": "Bioverativ Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_BioverativMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BioverativMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bioverativ(c)",
        "label": "Bioverativ [member]",
        "documentation": "Bioverativ."
       }
      }
     },
     "auth_ref": []
    },
    "sny_BioverativTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BioverativTherapeuticsIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bioverativ Therapeutics Inc.",
        "label": "Bioverativ Therapeutics Inc. [member]",
        "documentation": "Bioverativ Therapeutics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_BioverativUSLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BioverativUSLLCMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bioverativ U.S. LLC",
        "label": "Bioverativ US LLC [member]",
        "documentation": "Bioverativ US LLC."
       }
      }
     },
     "auth_ref": []
    },
    "sny_BlackstoneLifeSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BlackstoneLifeSciencesMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Blackstone Life Sciences",
        "label": "Blackstone Life Sciences [Member]",
        "documentation": "Blackstone Life Sciences"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BondsAndSimilarInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BondsAndSimilarInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonds and similar instruments",
        "label": "Bonds And Similar Instruments [member]",
        "documentation": "Bonds and similar instruments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BondsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BondsIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bond issues",
        "label": "Bonds issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of bonds issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_BorrowingAverageDrawdown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BorrowingAverageDrawdown",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, average drawdown",
        "label": "Borrowing, Average Drawdown",
        "documentation": "Borrowing, Average Drawdown"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BorrowingDrawdown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BorrowingDrawdown",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, drawdown",
        "label": "Borrowing, Drawdown",
        "documentation": "Borrowing, Drawdown"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BorrowingMaximumDrawdown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BorrowingMaximumDrawdown",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, maximum drawdown",
        "label": "Borrowing, Maximum Drawdown",
        "documentation": "Maximum drawdown."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total debt",
        "periodStartLabel": "Borrowings at beginning of period",
        "periodEndLabel": "Borrowings at end of period",
        "terseLabel": "Total debt",
        "verboseLabel": "Total debt",
        "label": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [axis]",
        "label": "Borrowings by name [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "ifrs-full_BorrowingsByNameMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [member]",
        "label": "Borrowings by name [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual\u00a0interest\u00a0rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r220",
      "r230",
      "r334",
      "r336",
      "r417"
     ]
    },
    "ifrs-full_BuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BuildingsMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Buildings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "sny_BusinessAcquisitionsPercentageOfVotingInterestsAcquired": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessAcquisitionsPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of share capital owned (in percent)",
        "label": "Business Acquisitions, Percentage Of Voting Interests Acquired",
        "documentation": "Business Acquisitions, Percentage Of Voting Interests Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessCombinationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations 1 [Abstract]",
        "label": "Business Combination [Abstract]",
        "documentation": "Business Combination [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationCapitalContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessCombinationCapitalContribution",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital contribution",
        "label": "Business Combination, Capital Contribution",
        "documentation": "Business Combination, Capital Contribution"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationCashPaymentPerNonTransferableContingentValueRight": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessCombinationCashPaymentPerNonTransferableContingentValueRight",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment per non-transferable contingent value right (in USD per share)",
        "label": "Business Combination, Cash Payment Per Non-Transferable Contingent Value Right",
        "documentation": "Business Combination, Cash Payment Per Non-Transferable Contingent Value Right"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated purchase price on a fully-diluted basis",
        "label": "Business Combination, Estimated Purchase Price On A Fully-Diluted Basis",
        "documentation": "Business Combination, Estimated Purchase Price On A Fully-Diluted Basis"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of non-transferable contingent value right issued",
        "label": "Business Combination, Number Of Non-Transferable Contingent Value Right Issued Per Share",
        "documentation": "Business Combination, Number Of Non-Transferable Contingent Value Right Issued Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationNumberOfSharesIncludedInPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessCombinationNumberOfSharesIncludedInPublicOffering",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares included in public offer (in shares)",
        "label": "Business Combination, Number Of Shares Included In Public Offering",
        "documentation": "Business Combination, Number Of Shares Included In Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding third-party debt liabilities incurred",
        "label": "Business Combination, Outstanding Third-Party Liabilities Incurred",
        "documentation": "Business Combination, Outstanding Third-Party Liabilities Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of issued and outstanding share capital tendered into the public offer",
        "label": "Business Combination, Proportion Of Issued And Outstanding Share Capital Tendered Into The Offering",
        "documentation": "Business Combination, Proportion Of Issued And Outstanding Share Capital Tendered Into The Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessCombinationPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, purchase price",
        "label": "Business Combination, Purchase Price",
        "documentation": "Business Combination, Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "sny_BusinessCombinationPurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessCombinationPurchasePricePerShare",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in euro/usd per share)",
        "verboseLabel": "Purchase price (in USD per share)",
        "label": "Business Combination, Purchase Price Per Share",
        "documentation": "Business Combination, Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combinations [axis]",
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372"
     ]
    },
    "sny_BusinessOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "BusinessOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Business operating income",
        "terseLabel": "Business operating income",
        "label": "Business Operating Income",
        "documentation": "Business operating income."
       }
      }
     },
     "auth_ref": []
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CN",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CNY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "CNY",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chinese yuan renminbi",
        "label": "China, Yuan Renminbi"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CambridgeMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CambridgeMassachusettsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cambridge, Massachusetts",
        "label": "Cambridge, Massachusetts [Member]",
        "documentation": "Cambridge, Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CapitalLossesCarryBackPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CapitalLossesCarryBackPeriod",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital losses, carry back period",
        "label": "Capital Losses, Carry Back Period",
        "documentation": "Capital Losses, Carry Back Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CapitalLossesUsedAgainstCapitalGainsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CapitalLossesUsedAgainstCapitalGainsPercentage",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of capital losses used",
        "label": "Capital Losses Used Against Capital Gains, Percentage",
        "documentation": "Capital Losses Used Against Capital Gains, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CarraigInsuranceDACMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CarraigInsuranceDACMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carraig Insurance DAC",
        "label": "Carraig Insurance DAC [member]",
        "documentation": "Carraig Insurance DAC."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r70",
      "r143",
      "r149",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r245",
      "r258",
      "r259"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount",
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r70",
      "r149",
      "r156",
      "r158",
      "r159",
      "r245",
      "r258",
      "r259"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/CashandcashequivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/CashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.sanofi.com/role/CashandcashequivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/CashandcashequivalentsDetails",
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "totalLabel": "Cash and cash equivalents",
        "negatedLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r172",
      "r192"
     ]
    },
    "sny_CashAndCashEquivalents1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CashAndCashEquivalents1Member",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash And Cash Equivalents1 [Member]",
        "documentation": "Cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CashAndCashEquivalentsInvestedRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CashAndCashEquivalentsInvestedRate",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents, invested rate",
        "label": "Cash And Cash Equivalents, Invested Rate",
        "documentation": "Cash and cash equivalents invested rate."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ifrs-full_CashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/CashandcashequivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/CashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "sny_CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/CashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents, captive insurance and reinsurance companies",
        "label": "Cash Equivalents, Captive Insurance And Reinsurance Companies",
        "documentation": "Cash equivalents captive insurance and reinsurance companies."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CashEquivalentsCommercialPaper": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CashEquivalentsCommercialPaper",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/CashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents, commercial paper",
        "label": "Cash Equivalents, Commercial Paper",
        "documentation": "Cash equivalent commercial paper."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CashEquivalentsMoneyMarketMutualFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CashEquivalentsMoneyMarketMutualFunds",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/CashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents, money market mutual funds",
        "label": "Cash Equivalents, Money Market Mutual Funds",
        "documentation": "Cash equivalent money market mutual funds."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CashFlowAndFairValueHedgeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CashFlowAndFairValueHedgeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow And Fair Value Hedge",
        "label": "Cash Flow And Fair Value Hedge [Member]",
        "documentation": "Cash Flow And Fair Value Hedge"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowHedgesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow hedges",
        "label": "Cash flow hedges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the exposure to variability in cash flows that (a) are attributable to a particular risk associated with a recognised asset or liability (such as all or some future interest payments on variable rate debt) or a highly probable forecast transaction; and (b) could affect profit or loss. [Refer: Hedges [member]]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r252",
      "r253",
      "r254"
     ]
    },
    "ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows",
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax",
        "label": "Cash flows from losing control of subsidiaries or other businesses, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r174"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) financing activities [abstract]",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows",
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in short-term debt and other financial instruments",
        "label": "Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments",
        "documentation": "Cash Flows From (Used In) Increase (Decrease) In Current Borrowings And Other Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r174"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) investing activities [abstract]",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r161",
      "r174"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from (used in) operating activities [abstract]",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating cash flow before changes in working capital",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r412"
     ]
    },
    "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions of consolidated undertakings and investments accounted for using the equity method",
        "terseLabel": "Net cash flow on acquisition",
        "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash outflow for leases, excluding short-term leases",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_CashTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash transferred",
        "label": "Cash transferred"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial assets [axis]",
        "label": "Categories of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of Related Parties [Axis]",
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "sny_CerezymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CerezymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEREZYME",
        "label": "Cerezyme [Member]",
        "documentation": "Cerezyme."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)",
        "label": "Change In Currency Translation Before Tax Excluding Associates And Joint Ventures",
        "documentation": "Change in currency translation before tax excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences (investments accounted for using the equity method)",
        "label": "Change In Currency Translation Net Of Tax On Associates And Joint Ventures",
        "documentation": "Change in currency translation net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedges of net investments in foreign operations",
        "label": "Change In Currency Translation On Hedges Of Net Investments In Foreign Operations",
        "documentation": "Change in currency translation on hedges of net investments in foreign operations."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInCurrencyTranslationOnTaxEffects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInCurrencyTranslationOnTaxEffects",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax effects",
        "label": "Change In Currency Translation On Tax Effects",
        "documentation": "Change in currency translation on tax effects."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInEuroAndUSDollarShortTermInterestRatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInEuroAndUSDollarShortTermInterestRatesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Euro and US dollar short-term interest rates",
        "label": "Change In Euro And US Dollar Short-term Interest Rates [Member]",
        "documentation": "Change in Euro and US dollar short-term interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Cash Flow Hedges Excluding Associates And Joint Ventures",
        "documentation": "Change in fair value on cash flow hedges excluding associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (investments accounted for using the equity method, net of taxes)",
        "label": "Change In Fair Value On Cash Flow Hedges Net Of Tax On Associates And Joint Ventures",
        "documentation": "Change in fair value on cash flow hedges net of tax on associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures",
        "documentation": "Change In Fair Value On Debt Instrument Excluding Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (excluding investments accounted for using the equity method)",
        "label": "Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures",
        "documentation": "Change In Fair Value On Equity Instruments Excluding Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value (investments accounted for using the equity method, net of taxes)",
        "label": "Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax",
        "documentation": "Change In Fair Value On Equity Instruments For Investments Accounted For Using The Equity Method Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInProvisionsRecognizedInProfitOrLossForThePeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInProvisionsRecognizedInProfitOrLossForThePeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in provisions recognized in profit or loss for the period",
        "label": "Change In Provisions Recognized In Profit Or Loss For The Period",
        "documentation": "Change in provisions recognized in profit or loss for the period."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in scope of consolidation",
        "label": "Change In Scope Of Consolidation Through Business Combination, Intangible Assets",
        "documentation": "Change In Scope Of Consolidation Through Business Combination, Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in scope of consolidation",
        "label": "Change In Scope Of Consolidation Through Business Combinations, Property, Plant And Equipment",
        "documentation": "Change In Scope Of Consolidation Through Business Combinations, Property, Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ChangesInOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases in provisions",
        "label": "Increase (decrease) in other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "sny_ChargebackIncentivesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChargebackIncentivesMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chargeback incentives",
        "label": "Chargeback Incentives [Member]",
        "documentation": "Chargeback incentives."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChattemGBHoldingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChattemGBHoldingMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chattem (GB) Holding",
        "label": "Chattem (GB) Holding [Member]",
        "documentation": "Chattem (GB) Holding"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChattemIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChattemIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chattem, Inc.",
        "label": "Chattem Inc [member]",
        "documentation": "Chattem, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ChinoinPrivateCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ChinoinPrivateCoLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chinoin Private Co. Ltd",
        "label": "Chinoin Private Co. Ltd [member]",
        "documentation": "Chinoin Private Co. Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [axis]",
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r129",
      "r204",
      "r215"
     ]
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets [member]",
        "label": "Assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r204",
      "r215"
     ]
    },
    "ifrs-full_ClassesOfContingentLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfContingentLiabilitiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of contingent liabilities [axis]",
        "label": "Classes of contingent liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r243"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial assets [axis]",
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r266",
      "r267",
      "r288",
      "r289"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial instruments [axis]",
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r260",
      "r261",
      "r262"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments, class [member]",
        "label": "Financial instruments, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r258",
      "r260",
      "r261",
      "r262"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets and goodwill [axis]",
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [axis]",
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities [axis]",
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of other provisions [axis]",
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "sny_CollaborationAgreementAnnualNetSalesTarget": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CollaborationAgreementAnnualNetSalesTarget",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, annual net sales target",
        "label": "Collaboration Agreement, Annual Net Sales Target",
        "documentation": "Collaboration Agreement, Annual Net Sales Target"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CollaborationAgreementCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, commitment amount",
        "label": "Collaboration Agreement, Commitment Amount",
        "documentation": "Collaboration Agreement, Commitment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementPeriodAfterLossOfControl": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CollaborationAgreementPeriodAfterLossOfControl",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, period after loss of control",
        "label": "Collaboration Agreement, Period After Loss Of Control",
        "documentation": "Collaboration Agreement, Period After Loss Of Control"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementWithGSKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CollaborationAgreementWithGSKMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement with GSK",
        "label": "Collaboration Agreement With GSK [Member]",
        "documentation": "Collaboration Agreement With GSK"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementsDevelopmentMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CollaborationAgreementsDevelopmentMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreements, development milestone payment",
        "label": "Collaboration Agreements, Development Milestone Payment",
        "documentation": "Collaboration Agreements, Development Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementsRegulatoryMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CollaborationAgreementsRegulatoryMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreements, regulatory milestone payment",
        "label": "Collaboration Agreements, Regulatory Milestone Payment",
        "documentation": "Collaboration Agreements, Regulatory Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CollaborationAgreementsUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CollaborationAgreementsUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreements, upfront payment",
        "label": "Collaboration Agreements, Upfront Payment",
        "documentation": "Collaboration Agreements, Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommercialPaperProgramInFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommercialPaperProgramInFranceMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper program in France",
        "label": "Commercial Paper Program In France [Member]",
        "documentation": "Commercial paper program In France."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommercialPaperProgramInUSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommercialPaperProgramInUSAMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper program in USA",
        "label": "Commercial Paper Program In USA [Member]",
        "documentation": "Commercial paper program in USA."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommercialPapersIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CommercialPapersIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper programs",
        "label": "Commercial papers issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of commercial paper issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_CommercializationRelatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommercializationRelatedExpensesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercialization related expenses",
        "label": "Commercialization Related Expenses [Member]",
        "documentation": "Commercialization related expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsMadeToJointVenturesAndAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsMadeToJointVenturesAndAssociates",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding commitments to associates and joint ventures",
        "label": "Commitments Made To Joint Ventures And Associates",
        "documentation": "Commitments made to joint ventures and associates."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsReceivedForDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsReceivedForDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments received for development costs",
        "label": "Commitments Received For Development Costs",
        "documentation": "Commitments Received For Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to attainment of regulatory and sales milestones for commercialized products",
        "label": "Commitments Related To Attainment Of Regulatory And Sales Milestones For Commercialized Products",
        "documentation": "Commitments Related To Attainment Of Regulatory And Sales Milestones For Commercialized Products"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to collaboration, discovery, development and commercialization agreements",
        "label": "Commitments Related To Collaboration, Discovery, Development And Commercialization Agreements",
        "documentation": "Commitments Related To Collaboration, Discovery, Development And Commercialization Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to maximum payments for projects under collaboration agreement",
        "label": "Commitments Related To Maximum Payments For Projects Under Collaboration Agreement",
        "documentation": "Commitments Related To Maximum Payments For Projects Under Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToMilestonePaymentsBusinessCombinations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsRelatedToMilestonePaymentsBusinessCombinations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to milestone payments, business combinations",
        "label": "Commitments Related To Milestone Payments, Business Combinations",
        "documentation": "Commitments Related To Milestone Payments, Business Combinations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to milestone payments for projects under collaboration agreements",
        "label": "Commitments Related To Milestone Payments For Projects Under Collaboration Agreement",
        "documentation": "Commitments Related To Milestone Payments For Projects Under Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails": {
       "parentTag": "sny_TotalOffBalanceSheetCommitments",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development license agreements - contingent milestone payments in connection with development programs in progress",
        "label": "Commitments Related To Research And Development License Agreements, Contingent Milestone Payments In Connection With Development Programs In Progress",
        "documentation": "Commitments Related To Research And Development License Agreements, Contingent Milestone Payments In Connection With Development Programs In Progress"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails": {
       "parentTag": "sny_TotalOffBalanceSheetCommitments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development license agreements - commitments related to R&amp;D and other commitments",
        "label": "Commitments Related To Research And Development License Agreements, Other Commitments",
        "documentation": "Commitments related to R&amp; D licence agreements and other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to research and development payments contingent upon attainment of sales targets",
        "label": "Commitments Related To Research And Development Payments Contingent Upon Attainment Of Sales Targets",
        "documentation": "Commitments related to r and d payments contingent upon attainment of sales targets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to research and development relating to projects in research phase",
        "label": "Commitments Related To Research And Development Relating To Projects In Research Phase",
        "documentation": "Commitments Related To Research And Development Relating To Projects In Research Phase"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatedToUnquotedDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsRelatedToUnquotedDebtSecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to unquoted debt securities",
        "label": "Commitments Related To Unquoted Debt Securities [Member]",
        "documentation": "Commitments Related To Unquoted Debt Securities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments relating to contingent consideration\u00a0in connection with business combinations",
        "label": "Commitments Relating To Contingent Consideration In Connection With Business Combinations",
        "documentation": "Commitments Relating To Contingent Consideration In Connection With Business Combinations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CommoditiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CommoditiesMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commodities",
        "label": "Commodities [Member]",
        "documentation": "Commodities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r38",
      "r178",
      "r180",
      "r190",
      "r332"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to non-controlling interests",
        "label": "Comprehensive income, attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r41"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome_1": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to equity holders of Sanofi",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r42"
     ]
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer software [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "sny_ConcentrationRiskThresholdPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ConcentrationRiskThresholdPercentage",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "label": "Concentration Risk Threshold Percentage",
        "documentation": "Concentration risk threshold percentage."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedCashFlowStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedCashFlowStatementTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Cash Flow Statement [Table]",
        "label": "Condensed Cash Flow Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedCashFlowStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedCashFlowStatementsCaptionsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Cash Flow Statements, Captions [Line Items]",
        "label": "Condensed Cash Flow Statements, Captions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ConsiderationTransferredMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ConsiderationTransferredMaximumAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred, maximum amount",
        "label": "Consideration Transferred, Maximum Amount",
        "documentation": "Consideration Transferred, Maximum Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ConsiderationTransferredToFundReserveForIndemnificationUndertaking": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ConsiderationTransferredToFundReserveForIndemnificationUndertaking",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fund reserves transferred",
        "label": "Consideration Transferred To Fund Reserve For Indemnification Undertaking",
        "documentation": "Consideration Transferred To Fund Reserve For Indemnification Undertaking"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ConsiderationTransferredValuationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ConsiderationTransferredValuationPeriod",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred, valuation period",
        "label": "Consideration Transferred, Valuation Period",
        "documentation": "Consideration Transferred, Valuation Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ConsolidationAdjustmentsIntragroupMarginInInventoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ConsolidationAdjustmentsIntragroupMarginInInventoryMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation adjustments (intragroup margin in inventory)",
        "label": "Consolidation Adjustments Intragroup Margin In Inventory [Member]",
        "documentation": "Consolidation adjustments intragroup margin In Inventory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ConsumerHealthcareSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ConsumerHealthcareSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consumer Healthcare",
        "label": "Consumer Healthcare Segment [Member]",
        "documentation": "Consumer Healthcare segment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ContingenciesArisingFromCertainBusinessDivestituresMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ContingenciesArisingFromCertainBusinessDivestituresMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies arising from certain business divestitures",
        "label": "Contingencies Arising From Certain Business Divestitures [Member]",
        "documentation": "Contingencies Arising From Certain Business Divestitures [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration arising from acquisition of Amunix",
        "label": "Contingent Consideration Arising From The Acquisition Of Amunix [Member]",
        "documentation": "Contingent Consideration Arising From The Acquisition Of Amunix"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ContingentConsiderationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ContingentConsiderationLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liabilities",
        "label": "Contingent Consideration Liabilities",
        "documentation": "Contingent consideration liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentConsiderationRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration recognised as of acquisition date",
        "verboseLabel": "Contingent consideration",
        "label": "Contingent consideration recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "sny_ContingentConsiderationRelatingToDivestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ContingentConsiderationRelatingToDivestmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration relating to divestments",
        "label": "Contingent Consideration Relating To Divestments [Member]",
        "documentation": "Contingent consideration relating to divestments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ContingentConsiderationTranslateBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ContingentConsiderationTranslateBioMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shire contingent consideration arising from the acquisition of Translate Bio",
        "label": "Contingent Consideration Translate Bio [Member]",
        "documentation": "Contingent Consideration Translate Bio"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContingentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities [member]",
        "label": "Contingent liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r243"
     ]
    },
    "ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contingent consideration liability",
        "label": "Contingent liabilities recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r345",
      "r347"
     ]
    },
    "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Fair value of contingent consideration payable",
        "label": "Contingent liabilities recognised in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "sny_ContractualAgreementForAntiProgrammedCellDeathProtein1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ContractualAgreementForAntiProgrammedCellDeathProtein1",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual agreement for anti-programmed cell death protein",
        "label": "Contractual Agreement For Anti-programmed Cell Death Protein1",
        "documentation": "Contractual Agreement For Anti-programmed Cell Death Protein1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer\u2019s contributions",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from resulting from contributions to plan by employer"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions from plan members",
        "negatedLabel": "Contributions from plan members",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from contributions to plan by plan participants"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "sny_CoreAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CoreAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Core Assets",
        "label": "Core Assets [Member]",
        "documentation": "Core Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "label": "Corporate information and statement of IFRS compliance [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CostOfDebtNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CostOfDebtNet",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Cost of net debt",
        "label": "Cost Of Debt Net",
        "documentation": "Cost of debt net."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails": {
       "parentTag": "sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of sales",
        "terseLabel": "Cost of sales",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r52"
     ]
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [axis]",
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "ifrs-full_CounterpartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [member]",
        "label": "Counterparties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.sanofi.com/role/AuditInformation",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CreditFacilitiesExtensionOptionNumber": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CreditFacilitiesExtensionOptionNumber",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facilities, extension option, number",
        "label": "Credit Facilities, Extension Option, Number",
        "documentation": "Credit Facilities, Extension Option, Number"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CreditFacilitiesExtensionOptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CreditFacilitiesExtensionOptionPeriod",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facilities, extension option, period",
        "label": "Credit Facilities, Extension Option, Period",
        "documentation": "Credit Facilities, Extension Option, Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CumulativeConsumerPriceInflationOverTheLastThreeYears": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CumulativeConsumerPriceInflationOverTheLastThreeYears",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative inflation rate over three years",
        "label": "Cumulative Consumer Price Inflation Over The Last Three Years",
        "documentation": "Cumulative consumer price inflation rate."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CumulativeDevelopmentCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CumulativeDevelopmentCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative development costs incurred",
        "label": "Cumulative Development Costs Incurred",
        "documentation": "Cumulative Development Costs Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CumulativeEffectAtDateOfInitialApplicationAxis",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative effect at date of initial application [axis]",
        "label": "Cumulative effect at date of initial application [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "sny_CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency and interest rate derivatives",
        "label": "Currency And Interest Rate Derivatives Used To Manage Debt Net Of Cash And Cash Equivalents",
        "documentation": "Currency and interest rate derivatives used to manage debt, net of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrencyDerivativesFinancialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrencyDerivativesFinancialMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "financial",
        "label": "Currency Derivatives Financial [Member]",
        "documentation": "Currency derivatives, financial."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrencyDerivativesMeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrencyDerivativesMeasuredAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthercurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency derivatives measured at fair value (see Note\u00a0D.20.)",
        "label": "Currency Derivatives Measured At Fair Value",
        "documentation": "Currency derivatives measured at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrencyDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrencyDerivativesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency derivatives",
        "label": "Currency Derivatives [member]",
        "documentation": "Currency derivatives."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrencyDerivativesOperatingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrencyDerivativesOperatingMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "operating",
        "label": "Currency Derivatives Operating [Member]",
        "documentation": "Currency derivatives, operating."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrentAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current Assets [Member]",
        "documentation": "Current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current assets",
        "label": "Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Current assets; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale; Non-current assets or disposal groups classified as held for distribution to owners]"
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term debt and current portion of long-term debt",
        "label": "Current borrowings and current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sny_CurrentProvisionsAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current contract liabilities",
        "verboseLabel": "Customer contract liabilities",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "sny_CurrentCurrencyDerivativesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrentCurrencyDerivativesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sny_CurrentProvisionsAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency derivatives (see Note\u00a0D.20.)",
        "label": "Current Currency Derivatives Payable",
        "documentation": "Currency derivatives."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentDerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentDerivativeFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails": {
       "parentTag": "ifrs-full_DerivativeFinancialAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current derivative financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial assets. [Refer: Derivative financial assets]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails": {
       "parentTag": "ifrs-full_DerivativeFinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Current liabilities",
        "label": "Current derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "sny_CurrentDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrentDerivativesMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current derivatives",
        "verboseLabel": "Current derivatives",
        "label": "Current Derivatives [Member]",
        "documentation": "Current derivatives."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentEquityDerivativesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrentEquityDerivativesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sny_CurrentProvisionsAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity derivatives (see Note\u00a0D.20.)",
        "label": "Current Equity Derivatives Payable",
        "documentation": "Current Equity Derivatives Payable"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CurrentInterestRateDerivativesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrentInterestRateDerivativesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sny_CurrentProvisionsAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate derivatives (see Note\u00a0D.20.)",
        "label": "Current Interest Rate Derivatives Payable",
        "documentation": "Current interest rate derivatives payable."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current lease liabilities",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "sny_CurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrentLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current Liabilities [Member]",
        "documentation": "Current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current liabilities",
        "label": "Current liabilities other than liabilities included in disposal groups classified as held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities other than liabilities included in disposal groups classified as held for sale. [Refer: Current liabilities; Disposal groups classified as held for sale [member]; Liabilities included in disposal groups classified as held for sale]"
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities related to business combinations and to non-controlling interests",
        "label": "Current Liabilities Related To Business Combinations And To Non-Controlling Interests",
        "documentation": "This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sny_CurrentProvisionsAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payable, other than corporate income taxes",
        "label": "Current payables on social security and taxes other than income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]"
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthercurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_CurrentProvisionsAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CurrentProvisionsAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current provisions and other current liabilities",
        "totalLabel": "Total",
        "label": "Current Provisions And Other Current Liabilities",
        "documentation": "The amount of current provisions and current other liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthercurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax receivables, other than corporate income taxes",
        "label": "Current receivables from taxes other than income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]"
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current service cost",
        "label": "Increase in net defined benefit liability (asset) resulting from current service cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax assets",
        "label": "Current tax assets, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentTaxAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current income tax assets",
        "label": "Current tax assets, non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current taxes",
        "label": "Current tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax liabilities",
        "label": "Current tax liabilities, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentTaxLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current income tax liabilities",
        "label": "Current tax liabilities, non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r298",
      "r300"
     ]
    },
    "sny_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer one",
        "label": "Customer One [member]",
        "documentation": "Customer one."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer three",
        "label": "Customer Three [member]",
        "documentation": "Customer three."
       }
      }
     },
     "auth_ref": []
    },
    "sny_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer two",
        "label": "Customer Two [member]",
        "documentation": "Customer two."
       }
      }
     },
     "auth_ref": []
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "DE",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Germany",
        "label": "GERMANY"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DaiichiSankyoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DaiichiSankyoMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Daiichi Sankyo",
        "label": "Daiichi Sankyo [Member]",
        "documentation": "Daiichi Sankyo"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrument1Axis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DebtInstrument1Axis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument1 [Axis]",
        "documentation": "Debt instrument1."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DebtInstrumentDomain",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Domain]",
        "label": "Debt Instrument [Domain]",
        "documentation": "Debt Instrument [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DebtInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instruments",
        "label": "Debt Instruments [Member]",
        "documentation": "Debt Instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtNetOfCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DebtNetOfCashAndCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net debt",
        "terseLabel": "Net debt",
        "label": "Debt, Net Of Cash And Cash Equivalents",
        "documentation": "Debt net of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DebtPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DebtPercent",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, percent",
        "label": "Debt, Percent",
        "documentation": "Debt percent."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Debt securities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for instruments held by the entity that represent indebtedness."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r335"
     ]
    },
    "sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains/(losses) on experience adjustments",
        "label": "Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Actuarial Gains (Losses) On Experience Adjustments",
        "documentation": "Actuarial gains/(losses) on experience adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administration costs and taxes paid during the period",
        "label": "Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Administration Costs And Taxes Paid During The Period",
        "documentation": "Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Administration Costs And Taxes Paid During The Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Plan settlements specified in the terms of the plan",
        "label": "Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Payments In Respect Of Settlements Specified In The Terms Of The Plan Net Defined Benefit Liability (Asset)",
        "documentation": "Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Payments In Respect Of Settlements Specified In The Terms Of The Plan"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Plan amendments, curtailments or settlements not specified in the terms of the plan",
        "label": "Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Plan Amendments, Curtailments Or Settlements Not Specified In The Terms Of The Plan",
        "documentation": "Decrease (Increase) In Net Defined Benefit Liability (Asset) Resulting From Plan Amendments, Curtailments Or Settlements Not Specified In The Terms Of The Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease through loss of control of subsidiary, intangible assets and goodwill",
        "label": "Decrease through loss of control of subsidiary, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets and goodwill resulting from the loss of control of a subsidiary. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "sny_DecreaseThroughLossOfControlOfSubsidiaryNetAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DecreaseThroughLossOfControlOfSubsidiaryNetAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease through loss of control of subsidiary, net assets",
        "label": "Decrease Through Loss Of Control Of Subsidiary, Net Assets",
        "documentation": "Decrease Through Loss Of Control Of Subsidiary, Net Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments made",
        "label": "Decrease Through Payments Made Provisions For Discounts Rebates And Sales Returns",
        "documentation": "Payments made for discounts, rebates and sales returns."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DefendantAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DefendantAxis",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defendant [Axis]",
        "label": "Defendant [Axis]",
        "documentation": "Defendant [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DefendantDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DefendantDomain",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defendant [Domain]",
        "label": "Defendant [Domain]",
        "documentation": "Defendant [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DefendantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DefendantsMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defendants [Member]",
        "label": "Defendants [Member]",
        "documentation": "Defendant."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r25",
      "r61"
     ]
    },
    "sny_DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets not recognized as future recovery not probable",
        "label": "Deferred Tax Assets Not Recognized As Future Recovery Not Probable",
        "documentation": "Deferred tax assets not recognized as future recovery not probable."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax expense",
        "negatedLabel": "Deferred taxes",
        "label": "Deferred tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r25",
      "r61"
     ]
    },
    "ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred taxes, net",
        "negatedTerseLabel": "Deferred taxes, net",
        "label": "Deferred tax liabilities recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net deferred tax asset/(liability)",
        "label": "Deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "sny_DeferredTaxRelatingToCapitalisationOfRDExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DeferredTaxRelatingToCapitalisationOfRDExpensesMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax relating to capitalisation of R&amp;D expenses",
        "label": "Deferred Tax Relating To Capitalisation Of R&amp;D Expenses [Member]",
        "documentation": "Deferred Tax Relating To Capitalisation Of R&amp;D Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DeferredTaxRelatingToRestructuringProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DeferredTaxRelatingToRestructuringProvisionsMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax relating to restructuring provisions",
        "label": "Deferred Tax Relating To Restructuring Provisions [member]",
        "documentation": "Deferred tax relating to restructuring provisions."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DefinedBenefitObligationAtPresentValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefinedBenefitObligationAtPresentValue",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails": {
       "parentTag": "ifrs-full_LiabilityAssetOfDefinedBenefitPlans",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee termination benefits",
        "verboseLabel": "Measurement of obligation",
        "label": "Defined benefit obligation, at present value"
       }
      },
      "en": {
       "role": {
        "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]"
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "sny_DefinedBenefitPensionPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DefinedBenefitPensionPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit pension plans",
        "label": "Defined Benefit Pension Plans [Member]",
        "documentation": "Defined benefit pension plans."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefinedBenefitPlansAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit plans [axis]",
        "label": "Defined benefit plans [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_DefinedBenefitPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefinedBenefitPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit plans [member]",
        "label": "Defined benefit plans [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "sny_DefinedBenefitPlansVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DefinedBenefitPlansVestingRightsPercentage",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting right percentage",
        "label": "Defined Benefit Plans Vesting Rights Percentage",
        "documentation": "Defined benefit plans vesting rights percentage."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DengvaxiaProductLitigationInThePhilippinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DengvaxiaProductLitigationInThePhilippinesMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dengvaxia product litigation in the Philippines",
        "label": "Dengvaxia Product Litigation In The Philippines [Member]",
        "documentation": "Dengvaxia Product Litigation In The Philippines"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DepakineProductLitigationInBelgiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DepakineProductLitigationInBelgiumMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depakine product litigation in Belgium",
        "label": "Depakine Product Litigation In Belgium [Member]",
        "documentation": "Depakine Product Litigation In Belgium"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DepakineProductLitigationInFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DepakineProductLitigationInFranceMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depakine product litigation in France",
        "label": "Depakine Product Litigation In France [Member]",
        "documentation": "Depakine Product Litigation In France"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DepakineProductLitigationInGreatBritainMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DepakineProductLitigationInGreatBritainMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depakine product litigation in Great Britain",
        "label": "Depakine Product Litigation In Great Britain [Member]",
        "documentation": "Depakine Product Litigation In Great Britain"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DepakineProductLitigationInIrelandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DepakineProductLitigationInIrelandMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depakine product litigation in Ireland",
        "label": "Depakine Product Litigation In Ireland [Member]",
        "documentation": "Depakine Product Litigation In Ireland"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DepakineProductLitigationInNorthernIrelandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DepakineProductLitigationInNorthernIrelandMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depakine product litigation in Northern Ireland",
        "label": "Depakine Product Litigation In Northern Ireland [Member]",
        "documentation": "Depakine Product Litigation In Northern Ireland"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DepakineProductLitigationInSpainMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DepakineProductLitigationInSpainMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depakine product litigation in Spain",
        "label": "Depakine Product Litigation In Spain [Member]",
        "documentation": "Depakine Product Litigation In Spain"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DepakineProductLitigationInSwitzerlandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DepakineProductLitigationInSwitzerlandMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depakine product litigation in Switzerland",
        "label": "Depakine Product Litigation In Switzerland [Member]",
        "documentation": "Depakine Product Litigation In Switzerland"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation expense",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation and impairment charged in the period",
        "label": "Depreciation, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "sny_DerecognizedReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DerecognizedReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognized receivables",
        "label": "Derecognized Receivables",
        "documentation": "Derecognized receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativeFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails": {
       "parentTag": "ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Derivative financial assets",
        "label": "Derivative financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "sny_DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails": {
       "parentTag": "sny_NetAmountsAsReportedInTheBalanceSheet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross amounts offset (in accordance with IAS 32)",
        "label": "Derivative Financial Assets And Liabilities, Gross Amounts Offset In Accordance With IAS 32",
        "documentation": "Derivative financial assets and liabilities gross amounts offset in accordance with IAS 32."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails": {
       "parentTag": "sny_NetAmountsAsReportedInTheBalanceSheet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross carrying amounts before offset",
        "label": "Derivative Financial Assets And Liabilities, Gross Carrying Amounts Before Offset",
        "documentation": "Derivative financial assets and liabilities gross carrying amounts before offset."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DerivativeFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DerivativeFinancialAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial assets",
        "label": "Derivative Financial Assets [member]",
        "documentation": "Derivative financial assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DerivativeFinancialInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DerivativeFinancialInstruments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating currency hedging instruments in place",
        "verboseLabel": "Nominal value of interest rate swaps hedge fixed-rate bonds",
        "label": "Derivative Financial Instruments",
        "documentation": "Derivative financial instrument"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DerivativeFinancialInstrumentsToManageFinancialExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DerivativeFinancialInstrumentsToManageFinancialExposure",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial currency hedging instruments in place",
        "label": "Derivative Financial Instruments To Manage Financial Exposure",
        "documentation": "Derivative financial instruments to manage financial exposure."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails": {
       "parentTag": "ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total liabilities",
        "terseLabel": "Derivative financial liabilities",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "sny_DerivativeFinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DerivativeFinancialLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial liabilities",
        "label": "Derivative Financial Liabilities [Member]",
        "documentation": "Derivative financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativeFinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails": {
       "parentTag": "sny_TotalUndiscountedCashFlow",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash flows related to derivative instruments",
        "label": "Derivative financial liabilities, undiscounted cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "sny_DerivativeInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DerivativeInstrumentAxis",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Derivative instrument."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DerivativeInstrumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DerivativeInstrumentDomain",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Domain]",
        "label": "Derivative Instrument [Domain]",
        "documentation": "Type of derivative instrument."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativesMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives",
        "label": "Derivatives [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r333",
      "r335",
      "r349",
      "r363"
     ]
    },
    "sny_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of consolidation",
        "label": "Description Of Accounting Policy For Basis Of Consolidation [Policy Text Block]",
        "documentation": "The description of the entity's accounting policy for basis of consolidation."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combinations and transactions with non-controlling interests",
        "label": "Description of accounting policy for business combinations and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for business combinations and goodwill. [Refer: Business combinations [member]; Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "sny_DescriptionOfAccountingPolicyForCostOfSalesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForCostOfSalesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Description Of Accounting Policy For Cost Of Sales [Policy Text Block]",
        "documentation": "Description of accounting policy for cost of sales explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefit obligations",
        "label": "Description of accounting policy for employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "sny_DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurement of contingent consideration",
        "label": "Description Of Accounting Policy For Fair Value Remeasurement Of Contingent Consideration Liabilities Explanatory [Policy Text Block]",
        "documentation": "The description of the entity's accounting policy for fair value remeasurement of contingent consideration liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial expenses and income",
        "label": "Description of accounting policy for finance income and costs [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for finance income and costs. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method",
        "label": "Description of accounting policy for impairment of assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of assets."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "label": "Description of accounting policy for income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization and impairment of intangible assets",
        "label": "Description of accounting policy for intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management of capital",
        "label": "Description of accounting policy for issued capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Description of accounting policy for measuring inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale or exchange and liabilities related to assets held for sale or exchange",
        "label": "Description of accounting policy for non-current assets or disposal groups classified as held for sale and discontinued operations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Non-current assets or disposal groups classified as held for sale]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "sny_DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other gains and losses, and litigation",
        "label": "Description Of Accounting Policy For Other Gains And Losses And Litigation Explanatory [Policy Text Block]",
        "documentation": "Description of accounting policy for other gains and losses, and litigation explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income and expenses",
        "label": "Description Of Accounting Policy For Other Operating Income And Expenses Explanatory [Policy Text Block]",
        "documentation": "The description of the entity's accounting policy for other operating income and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment owned and leased",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for risks",
        "label": "Description of accounting policy for provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Description of accounting policy for recognition of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "sny_DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring costs and similar items",
        "label": "Description Of Accounting Policy For Restructuring Costs And Similar Items [Policy Text Block]",
        "documentation": "The description of the entity's accounting policy for restructuring costs and similar items."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Description of accounting policy for segment reporting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTreasurySharesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares",
        "label": "Description of accounting policy for treasury shares [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New pronouncements issued by IASB and applicable from 2024 or later",
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Perpetual growth rates applied to future cash flows",
        "label": "Growth rate used to extrapolate cash flow projections"
       }
      },
      "en": {
       "role": {
        "documentation": "The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132"
     ]
    },
    "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New standards, amendments and interpretations",
        "label": "Disclosure of initial application of standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "sny_DevelopmentOfCemiplimabREGN2810Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DevelopmentOfCemiplimabREGN2810Member",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development of cemiplimab (REGN2810)",
        "label": "Development Of Cemiplimab (REGN2810) [Member]",
        "documentation": "Development of cemiplimab (REGN2810)."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DigestiveWellnessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DigestiveWellnessMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Digestive Wellness",
        "label": "Digestive Wellness [Member]",
        "documentation": "Digestive [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DilutedEarningsLossPerShareAttributableToOwnersOfParent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DilutedEarningsLossPerShareAttributableToOwnersOfParent",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per share (in euros per share)",
        "label": "Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent",
        "documentation": "Diluted Earnings (Loss) Per Share, Attributable To Owners Of Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for stock options with dilutive effect (in shares)",
        "label": "Dilutive effect of share options on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "sny_DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for restricted shares (in shares)",
        "label": "Dilutive Effect Of Share Options On Number Of Restricted Shares",
        "documentation": "Dilutive effect of share options on number of restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates and judgments",
        "label": "Disclosure of accounting judgements and estimates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sny_DisclosureOfAccountsReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAccountsReceivableLineItems",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of accounts receivable [line items]",
        "label": "Disclosure Of Accounts Receivable [line items]",
        "documentation": "Disclosure Of Accounts Receivable [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAccountsReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAccountsReceivableTable",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of accounts receivable [Table]",
        "label": "Disclosure Of Accounts Receivable [Table]",
        "documentation": "Disclosure of Accounts receivable Table."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements within Other Comprehensive Income",
        "label": "Disclosure Of Accumulated Other Comprehensive Income Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information of accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment",
        "label": "Disclosure Of Acquisitions Of Property Plant And Equipment And Other Intangible Assets And Carrying Amount Of Investments In Associates And Joint Ventures By Operating Segment [Table Text Block]",
        "documentation": "The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Acquisitions and Capitalized Interest by Operating Segment",
        "label": "Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments Explanatory [Table Text Block]",
        "documentation": "Disclosure of acquisitions of property plant and equipment by operating segments explanatory [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of acquisitions of property plant and equipment by operating segments [line items]",
        "label": "Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments [Line Items]",
        "documentation": "Disclosure of acquisitions of property plant and equipment by operating segments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsTable",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of acquisitions of property plant and equipment by operating segments [table]",
        "label": "Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments [Table]",
        "documentation": "Disclosure Of Acquisitions Of Property Plant And Equipment By Operating Segments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Actual or Potential Effects of Netting Arrangements",
        "label": "Disclosure Of Actual Or Potential Effects Of Netting Arrangements [Table Text Block]",
        "documentation": "The disclosure of actual or potential effects of netting arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfActuarialAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfActuarialAssumptionsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Financial and Demographic Assumptions",
        "label": "Disclosure Of Actuarial Assumptions [Table Text Block]",
        "documentation": "Disclosure Of Actuarial Assumptions [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes",
        "label": "Disclosure Of Allocation Of Income Tax Between Current And Deferred Taxes [Table Text Block]",
        "documentation": "The disclosure of allocation of income tax between current and deferred taxes."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of Softwares Recognized in Income Statement",
        "label": "Disclosure Of Amortization Of Software And Other Rights By Income Statement Line [Table Text Block]",
        "documentation": "The disclosure of amortization of software and other rights by income statement line."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/RelatedpartytransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Aggregate Amounts Payable to Key Management Personnel",
        "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of analysis of other comprehensive income by item [line items]",
        "label": "Disclosure of analysis of other comprehensive income by item [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAnalysisOfOtherComprehensiveIncomeByItemTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of analysis of other comprehensive income by item [table]",
        "label": "Disclosure of analysis of other comprehensive income by item [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the analysis of other comprehensive income by item."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "sny_DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assets Held for Sale or Exchange, and Liabilities Related to Assets Held for Sale or Exchange",
        "label": "Disclosure Of Assets Held For Sale Or Exchange And Related Liabilities [Table Text Block]",
        "documentation": "The disclosure of assets held for sale or exchange and related liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAuditFeesAndOtherServicesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAuditFeesAndOtherServicesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of audit fees and other services [line items]",
        "label": "Disclosure Of Audit Fees And Other Services [Line Items]",
        "documentation": "Disclosure of audit fees and other services."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfAuditFeesAndOtherServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAuditFeesAndOtherServicesTable",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of audit fees and other services [Table]",
        "label": "Disclosure Of Audit Fees And Other Services [Table]",
        "documentation": "Disclosure of audit fees and other services [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAuditorsRemunerationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAuditorsRemunerationExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Principalaccountantsfeesandservices"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal accountants' fees and services",
        "label": "Disclosure of auditors' remuneration [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of compensation to the entity's auditors."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sny_DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Tax Losses Available for Carry-forward",
        "label": "Disclosure Of Availability Of Tax Losses Carry Forwards [Table Text Block]",
        "documentation": "The disclosure of availability of tax losses carry forwards."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Basisofpreparation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of preparation",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [line items]",
        "label": "Disclosure of detailed information about business combination [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsTable",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [table]",
        "label": "Disclosure of detailed information about business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "sny_DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/CashandcashequivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash and Cash Equivalents",
        "label": "Disclosure Of Cash And Cash Equivalents Details [Table Text Block]",
        "documentation": "The disclosure of cash and cash equivalents details."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Cashandcashequivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sny_DisclosureOfChangesInFinancialPositionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfChangesInFinancialPositionTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in Financial Position",
        "label": "Disclosure Of Changes In Financial Position [Table Text Block]",
        "documentation": "Disclosure of changes in financial position [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests",
        "label": "Disclosure Of Changes In Liabilities Related To Business Combinations And To Non-Controlling Interests [Table Text Block]",
        "documentation": "The disclosure of changes in liabilities related to business combinations and to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Disclosure Of Changes In Property, Plant And Equipment [Table Text Block]",
        "documentation": "Disclosure of changes in property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movement in Provisions for Discounts, Rebates and Sales Returns",
        "label": "Disclosure Of Changes In Provisions For Discounts Rebates And Sales Returns [Table Text Block]",
        "documentation": "The disclosure of changes in provisions for discounts rebates and sales returns."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Treasury Shares Held",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [line items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "sny_DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/RelatedpartytransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Compensation Paid to Key Management Personnel",
        "label": "Disclosure Of Compensation Paid To Key Management Personnel [Table Text Block]",
        "documentation": "The disclosure of compensation paid to key management personnel."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Non-current Assets",
        "label": "Disclosure Of Components Of Other Non-Current Assets [Table Text Block]",
        "documentation": "The disclosure of components of other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCreditRiskExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCreditRiskExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Disclosuresaboutmajorcustomersandcreditrisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosures about major customers and credit risk",
        "label": "Disclosure of credit risk [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of credit risk. [Refer: Credit risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r377"
     ]
    },
    "ifrs-full_DisclosureOfCreditRiskExposureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCreditRiskExposureLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Credit Risk Exposure [Line Items]",
        "label": "Disclosure of credit risk exposure [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCreditRiskExposureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCreditRiskExposureTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Credit Risk Exposure [Table]",
        "label": "Disclosure of credit risk exposure [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the credit risk exposure."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "sny_DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Provisions and Other Current Liabilities",
        "label": "Disclosure Of Current Provisions And Other Current Liabilities [Table Text Block]",
        "documentation": "The disclosure of current provisions and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfCurrentTradeReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfCurrentTradeReceivablesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accounts Receivable",
        "label": "Disclosure Of Current Trade Receivables [Table Text Block]",
        "documentation": "The disclosure of current trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Debt by Currency After Derivative Instruments",
        "label": "Disclosure Of Debt By Currency At Value Of Redemption After Derivative Instruments [Table Text Block]",
        "documentation": "The disclosure of debt by currency at value of redemption after derivative instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Debt by Currency Before and After Derivative Instrument",
        "label": "Disclosure Of Debt By Currency At Value Of Redemption Before And After Derivative Instruments [Table Text Block]",
        "documentation": "The disclosure of debt by currency at value of redemption before and after derivative instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtByCurrencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDebtByCurrencyLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Debt By Currency [Line Items]",
        "label": "Disclosure Of Debt By Currency [Line Items]",
        "documentation": "Disclosure Of Debt By Currency [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtByCurrencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDebtByCurrencyTable",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Debt By Currency [Table]",
        "label": "Disclosure Of Debt By Currency [Table]",
        "documentation": "Disclosure Of Debt By Currency [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Interest Rate of Net Debt at Value on Redemption",
        "label": "Disclosure Of Debt By Interest Rate At Value Of Redemption After Taking Account Of Derivative Instruments N1N2 [Table Text Block]",
        "documentation": "The disclosure of debt by interest rate at value of redemption after taking account of derivative instruments N1 N2."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Debt by Interest Rate",
        "label": "Disclosure Of Debt By Interest Rate At Value Of Redemption And By Maturity Explanatory [Table Text Block]",
        "documentation": "The disclosure of debt by interest rate at value of redemption and by maturity."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Debt by Maturity at Value on Redemption",
        "label": "Disclosure Of Debt By Maturity At Value Of Redemption Explanatory [Table Text Block]",
        "documentation": "The disclosure of debt by maturity at value of redemption."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Debtcashandcashequivalentsandleaseliabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, cash and cash equivalents and lease liabilities",
        "label": "Disclosure Of Debt Instruments Issued Explanatory [Text Block]",
        "documentation": "Disclosure of debt instruments issued explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDebtLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of debt [line items]",
        "label": "Disclosure Of Debt [Line Items]",
        "documentation": "Disclosure Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Debt by Type Valuation of Redemption",
        "label": "Disclosure Of Debt Net Of Cash And Cash Equivalents By Type At Value On Redemption Explanatory [Table Text Block]",
        "documentation": "The disclosure of debt net of cash and cash equivalents by type at value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDebtTable",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Debt [Table]",
        "label": "Disclosure Of Debt [Table]",
        "documentation": "Disclosure of debt [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDeferredTaxesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDeferredTaxesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Netdeferredtaxposition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net deferred tax position",
        "label": "Disclosure of deferred taxes [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of defined benefit plans [line items]",
        "label": "Disclosure of defined benefit plans [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansTable",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of defined benefit plans [table]",
        "label": "Disclosure of defined benefit plans [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to defined benefit plans."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Derivativefinancialinstrumentsandmarketrisks"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial instruments and market risks",
        "label": "Disclosure of derivative financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sny_DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Bond Issues",
        "label": "Disclosure Of Detail Of Bonds Issued Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detail Of Bonds Issued Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Movement In Total Debt",
        "label": "Disclosure of detailed information about borrowings [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [line items]",
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about borrowings [table]",
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021Tables",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Provisional Purchase Price Allocation",
        "verboseLabel": "Summary of Final Purchase Price Allocation",
        "label": "Disclosure of detailed information about business combination [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeExpenseLineItems",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about finance income expense [Line Items]",
        "label": "Disclosure Of Detailed Information About Finance Income Expense [Line Items]",
        "documentation": "Line items represent detailed information about finance income expense."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeExpenseTable",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Finance Income Expense [table]",
        "label": "Disclosure Of Detailed Information About Finance Income Expense [table]",
        "documentation": "Schedule disclosing information related to details of finance income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Detailed Information about Financial Instruments",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r260",
      "r268"
     ]
    },
    "sny_DisclosureOfDetailedInformationAboutIncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutIncomeTaxesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Income Taxes [Line Items]",
        "label": "Disclosure Of Detailed Information About Income Taxes [Line Items]",
        "documentation": "Disclosure Of Detailed Information About Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDetailedInformationAboutIncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutIncomeTaxesTable",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Income Taxes [Table]",
        "label": "Disclosure Of Detailed Information About Income Taxes [Table]",
        "documentation": "Disclosure Of Detailed Information About Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDetailedInformationAboutInventoriesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutInventoriesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventories",
        "label": "Disclosure Of Detailed Information About Inventories [Table Text Block]",
        "documentation": "The disclosure of detailed information about inventories."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about Principal Alliances [Line Items]",
        "label": "Disclosure Of Detailed Information About Principal Alliances [Line Items]",
        "documentation": "Disclosure of detailed information about Principal Alliances [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Share-Based Payment [Line Items]",
        "label": "Disclosure Of Detailed Information About Share-Based Payment [Line Items]",
        "documentation": "Disclosure Of Detailed Information About Share-Based Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDetailedInformationAboutShareBasedPaymentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentTable",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Share-Based Payment [Table]",
        "label": "Disclosure Of Detailed Information About Share-Based Payment [Table]",
        "documentation": "Disclosure Of Detailed Information About Share-Based Payment"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OthercurrentassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Assets",
        "label": "Disclosure Of Detailed Information Of Other Current Assets [Table Text Block]",
        "documentation": "The disclosure of detailed information of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Characteristics of Employee Share Ownership Plans Awarded",
        "label": "Disclosure Of Employee Stock Ownership Plan Awarded In Capital Increase Reserved Explanatory [Table Text Block]",
        "documentation": "Disclosure of employee stock ownership plan awarded in capital increase reserved explanatory [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Segmentinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "sny_DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Amounts of Employer's Contributions to Plan Assets",
        "label": "Disclosure Of Estimated Amounts Of Employer's Contributions To Plan Assets [Table Text Block]",
        "documentation": "Disclosure of estimated amounts of employer's contributions to plan assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Useful Lives of Property, Plant and Equipment",
        "label": "Disclosure Of Estimated Useful Lives Of Property Plant And Equipment Explanatory [Table Text Block]",
        "documentation": "The disclosure of estimated useful lives of property plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Events subsequent to December 31, 2023",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "sny_DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Future Payments in Respect of Unfunded Pension and Other Post-employment Benefit Plans",
        "label": "Disclosure Of Expected Timing Of Payments In Respect Of Unfunded Pension And Other Post Employment Benefit Plans Explanatory [Table Text Block]",
        "documentation": "The disclosure of expected timing of payments in respect of unfunded pension and other post employment benefit plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Timing of Benefit Payments under Pension and Other Post-employment Benefit Plans",
        "label": "Disclosure Of Expected Timing Of Payments Under Pension And Other Post Employment Benefit Plans [Table Text Block]",
        "documentation": "The disclosure of expected timing of payments under pension and other post employment benefit plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Expense for Pensions and Other Post-employment Benefits Allocated between Income Statement Line Items",
        "label": "Disclosure Of Expense For Pensions And Other Post Employment Benefits By Income Statement Line Explanatory [Table Text Block]",
        "documentation": "The disclosure of expense for pensions and other post employment benefits by income statement line."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Fair Value Measurement of Assets and Liabilities [Table]",
        "label": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Table]",
        "documentation": "Disclosure of fair value measurement of assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value of Derivative Instruments",
        "label": "Disclosure Of Fair Value Of Derivative Instruments [Table Text Block]",
        "documentation": "Disclosure of fair value of derivative instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value",
        "label": "Disclosure Of Fair Value Of Financial Assets And Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure of fair value of financial assets and liabilities explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueOfPlanAssetsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Plans Assets relating to Pension Plans and Other Post-employment Plans",
        "label": "Disclosure of fair value of plan assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of defined benefit plan assets. [Refer: Plan assets [member]; Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ifrs-full_DisclosureOfFairValueOfPlanAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueOfPlanAssetsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of fair value of plan assets [line items]",
        "label": "Disclosure of fair value of plan assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueOfPlanAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueOfPlanAssetsTable",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of fair value of plan assets [table]",
        "label": "Disclosure of fair value of plan assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value of defined benefit plan assets."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Financialexpensesandincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial expenses and income",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Financialassetsandliabilitiesmeasuredatfairvalue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets and liabilities measured at fair value",
        "label": "Disclosure Of Financial Assets And Liabilities At Fair Value Explanatory [Text Block]",
        "documentation": "Disclosure of financial assets and liabilities at fair value explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedLineItems",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial assets that are either past due or impaired [line items]",
        "label": "Disclosure of financial assets that are either past due or impaired [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsThatAreEitherPastDueOrImpairedTable",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial assets that are either past due or impaired [table]",
        "label": "Disclosure of financial assets that are either past due or impaired [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets that are either past due or impaired."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "sny_DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated",
        "label": "Disclosure Of Financial Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate Explanatory [Table Text Block]",
        "documentation": "The disclosure of financial currency hedging instruments with notional amount translated in to euros at closing exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Analysis of Financial Income and Expenses",
        "label": "Disclosure Of Financial Income And Expenses Explanatory [Table Text Block]",
        "documentation": "The entire disclosure for financial income and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial instruments by type of interest rate [line items]",
        "label": "Disclosure of financial instruments by type of interest rate [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial instruments by type of interest rate [table]",
        "label": "Disclosure of financial instruments by type of interest rate [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial instruments, by type of interest rate."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r260",
      "r268"
     ]
    },
    "sny_DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Future Termination Benefit Payments",
        "label": "Disclosure Of Future Benefit Payments Explanatory [Table Text Block]",
        "documentation": "The disclosure of future benefit payments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Introduction"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Introduction",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Geographical Information on Net Sales and Non-Current Assets",
        "label": "Disclosure of geographical areas [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of geographical information."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [line items]",
        "label": "Disclosure of geographical areas [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasTable",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [table]",
        "label": "Disclosure of geographical areas [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to geographical areas."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "sny_DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Allocation of Goodwill",
        "label": "Disclosure Of Goodwill By Operating Segments Explanatory [Table Text Block]",
        "documentation": "The disclosure of goodwill by operating segments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Amount of Guarantees Given and Received",
        "label": "Disclosure Of Guarantees Given And Received Explanatory [Table Text Block]",
        "documentation": "The disclosure of guarantees given and received."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfGuaranteesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfGuaranteesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Guarantees [Line Items]",
        "label": "Disclosure Of Guarantees [Line Items]",
        "documentation": "Disclosure of guarantees."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfGuaranteesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfGuaranteesTable",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Guarantees [Table]",
        "label": "Disclosure Of Guarantees [Table]",
        "documentation": "Disclosure Of Guarantees [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfHyperinflationaryReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfHyperinflationaryReportingExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hyperinflation",
        "label": "Disclosure of information about hyperinflationary reporting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about financial reporting in hyperinflationary economies."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "sny_DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal changes in the scope of consolidation in 2023",
        "verboseLabel": "Principal changes in the scope of consolidation in 2022 and 2021",
        "label": "Disclosure Of Impact Of Changes In The Scope Of Consolidation Due To Acquisitions And Divestments Explanatory [Text Block]",
        "documentation": "The entire disclosure for impact of changes in the scope of consolidation due to acquisitions and divestments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of impairment loss and reversal of impairment loss [line items]",
        "label": "Disclosure of impairment loss and reversal of impairment loss [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfImpairmentLossAndReversalOfImpairmentLossTable",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of impairment loss and reversal of impairment loss [table]",
        "label": "Disclosure of impairment loss and reversal of impairment loss [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to impairment loss and the reversal of impairment loss."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "sny_DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Impairment Losses of Other Intangible Assets",
        "label": "Disclosure Of Impairment Losses Of Other Intangible Assets [Table Text Block]",
        "documentation": "Disclosure Of Impairment Losses Of Other Intangible Assets [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Impairment Losses Recognised in Property, Plant and Equipment",
        "label": "Disclosure Of Impairment Losses of Property, Plant and Equipment [Table Text Block]",
        "documentation": "Disclosure of Impairment Losses of Property, Plant and Equipment [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Impairmentofintangibleassetsandpropertyplantandequipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets and property, plant and equipment",
        "label": "Disclosure Of Impairment Of Intangible Assets And Property Plant And Equipment Explanatory [Text Block]",
        "documentation": "The entire disclosure for impairment of intangible assets and property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Incometaxexpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]",
        "label": "Disclosure of information about credit exposures designated as measured at fair value through profit or loss [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutCreditExposuresDesignatedAsMeasuredAtFairValueThroughProfitOrLossTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Table]",
        "label": "Disclosure of information about credit exposures designated as measured at fair value through profit or loss [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to credit exposures designated as measured at fair value through profit or loss."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutEmployeesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Personnelcosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel costs",
        "label": "Disclosure of information about employees [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about employees."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of information about major customers and credit risk [line items]",
        "label": "Disclosure Of Information About Major Customers And Credit Risk [Line Items]",
        "documentation": "Disclosure of information about major customers and credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfInformationAboutMajorCustomersAndCreditRiskTable",
     "presentation": [
      "http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information About Major Customers and Credit Risk [Table]",
        "label": "Disclosure Of Information About Major Customers And Credit Risk [Table]",
        "documentation": "Disclosure of information about major customers and credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]",
        "label": "Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutTermsAndConditionsOfHedgingInstrumentsAndHowTheyAffectFutureCashFlowsTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Table]",
        "label": "Disclosure of information about terms and conditions of hedging instruments and how they affect future cash flows [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the terms and conditions of hedging instruments and how they affect future cash flows."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "sny_DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Trends in Net Income Attributable to Non-Controlling Interests",
        "label": "Disclosure Of Information About The Amounts Attributable To Non-Controlling Interests Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Information About The Amounts Attributable To Non Controlling Interests Explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfInformationOnIncomeStatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfInformationOnIncomeStatementLineItems",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of information on income statement [line items]",
        "label": "Disclosure Of Information On Income Statement [Line Items]",
        "documentation": "Disclosure of information on income statement line items."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of initial application of standards or interpretations [line items]",
        "label": "Disclosure of initial application of standards or interpretations [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of initial application of standards or interpretations [table]",
        "label": "Disclosure of initial application of standards or interpretations [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the initial application of standards or interpretations."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Goodwillandotherintangibleassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and other intangible assets",
        "label": "Disclosure of intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]",
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [table]",
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "sny_DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfInterestRateOfDebtNetOfCashAndCashEquivalentLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Interest Rate of Debt Net of Cash and Cash Equivalent [Line Items]",
        "label": "Disclosure Of Interest Rate Of Debt Net of Cash And Cash Equivalent [Line Items]",
        "documentation": "Disclosure of interest rate of debt net of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfInterestRateOfDebtNetofCashAndCashEquivalentTable",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Interest Rate Of Debt Net Of Cash And Cash Equivalent [Table]",
        "label": "Disclosure Of Interest Rate Of Debt NetOf Cash And Cash Equivalent [Table]",
        "documentation": "Disclosure of interest rate of debt net of cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Instruments",
        "label": "Disclosure Of Interest Rates Hedging Instruments With Notional Amount By Expiry Date Explanatory [Table Text Block]",
        "documentation": "The disclosure of interest rates hedging instruments with notional amount by expiry date."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInterestsInSubsidiariesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Principal Companies and their Country of Incorporation",
        "label": "Disclosure of interests in subsidiaries [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "sny_DisclosureOfInventoriesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfInventoriesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of inventories [line items]",
        "label": "Disclosure Of Inventories [Line Items]",
        "documentation": "Disclosure of inventories."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfInventoriesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfInventoriesTable",
     "presentation": [
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of inventories [table]",
        "label": "Disclosure Of Inventories [Table]",
        "documentation": "Disclosure of inventories."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Investmentsaccountedforusingtheequitymethod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "label": "Disclosure of investments accounted for using equity method [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sny_DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Investments in Associates and Joint Ventures",
        "label": "Disclosure Of Investments In Associates And Joint Ventures [Table Text Block]",
        "documentation": "The entire disclosure of investments in associates and joint ventures explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Principal Investments Accounted for Using the Equity Method",
        "label": "Disclosure Of Investments In Subsidiaries Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Investments In Subsidiaries Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfJointOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfJointOperationsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of joint operations [line Items]",
        "label": "Disclosure of joint operations [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfJointOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfJointOperationsTable",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Joint Operations [Table]",
        "label": "Disclosure of joint operations [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to joint operations."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfLegalAndArbitralProceedingsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Legal and Arbitral Proceedings [Line Items]",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Line Items]",
        "documentation": "Disclosure of legal and arbitral proceedings."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfLegalAndArbitralProceedingsTable",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Legal and Arbitral Proceedings [Table]",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Table]",
        "documentation": "Disclosure of legal and arbitral proceedings."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLegalAndArbitralProceedingsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfLegalAndArbitralProceedingsTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Legalandarbitralproceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal and arbitral proceedings",
        "label": "Disclosure Of Legal And Arbitral Proceedings [Text Block]",
        "documentation": "Disclosure Of Legal And Arbitral Proceedings [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Liabilitiesrelatedtobusinesscombinationsandtononcontrollinginterests"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities related to business combinations and to non-controlling interests",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Non-Controlling Interests Explanatory [Text Block]",
        "documentation": "The entire disclosure for liabilities related to business combination and to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Non-Controlling Interests [Line Items]",
        "documentation": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTable",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Table]",
        "label": "Disclosure Of Liabilities Related To Business Combinations And To Non-Controlling Interests [Table]",
        "documentation": "Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests Table"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfLineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Line of Credit Facility [Line Items]",
        "label": "Disclosure Of Line Of Credit Facility [Line Items]",
        "documentation": "Disclosure of line of credit facility table line items."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfLineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfLineOfCreditFacilityTable",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Line of Credit Facility [Table]",
        "label": "Disclosure Of Line Of Credit Facility [Table]",
        "documentation": "Disclosure of line of credit facility table."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfMarketValueOfNetDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfMarketValueOfNetDebtTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Market Value of Net Debt",
        "label": "Disclosure Of Market Value Of Net Debt [Table Text Block]",
        "documentation": "Disclosure of market value of net debt [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant accounting policies",
        "label": "Disclosure of material accounting policy information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [line items]",
        "label": "Disclosure of maturity analysis for derivative financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [table]",
        "label": "Disclosure of maturity analysis for derivative financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis of finance lease payments receivable [line items]",
        "label": "Disclosure of maturity analysis of finance lease payments receivable [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfFinanceLeasePaymentsReceivableTable",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis of finance lease payments receivable [table]",
        "label": "Disclosure of maturity analysis of finance lease payments receivable [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis of finance lease payments receivable."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "sny_DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of Future Undiscounted Contractual Cash Flows Relating to Debt and Derivative Instruments Designated as Hedges of Debt",
        "label": "Disclosure Of Maturity Analysis Of Future Undiscounted Cash Flows Explanatory [Table Text Block]",
        "documentation": "The disclosure of maturity analysis of future undiscounted cash flows."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Lease Liabilities",
        "label": "Disclosure Of Maturity Analysis Of Lease Payments [Table Text Block]",
        "documentation": "Disclosure Of Maturity Analysis Of Lease Payments [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests",
        "label": "Disclosure Of Maximum Amount Of Contingent Consideration Payable And Firm Commitments To Buy Out Non-Controlling Interests Explanatory [Table Text Block]",
        "documentation": "Disclosure of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]",
        "label": "Disclosure Of Maximum Amount Of Contingent Consideration Payable And Firm Commitments To Buy Out Non-Controlling Interests [Line Items]",
        "documentation": "Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsTable",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests [Table]",
        "label": "Disclosure Of Maximum Amount Of Contingent Consideration Payable And Firm Commitments To Buy Out Non-Controlling Interests [Table]",
        "documentation": "Disclosure Of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests Table"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net defined benefit liability (asset) [line items]",
        "label": "Disclosure of net defined benefit liability (asset) [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTable",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net defined benefit liability (asset) [table]",
        "label": "Disclosure of net defined benefit liability (asset) [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the net defined benefit liability (asset)."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "sny_DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Net Obligation in Respect of Sanofi's Pension and Other Post-Employment Benefit Plans",
        "label": "Disclosure Of Net Defined Benefit Liability Assets Explanatory [Table Text Block]",
        "documentation": "The disclosure of net defined benefit liability assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfNetIncomeAttributableToNonControllingInterestsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net income attributable to non-controlling interests [line items]",
        "label": "Disclosure Of Net Income Attributable To Non-Controlling Interests [Line Items]",
        "documentation": "Disclosure of net income attributable to noncontrolling interests [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNetIncomeAttributableToNonControllingInterestsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfNetIncomeAttributableToNonControllingInterestsTable",
     "presentation": [
      "http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net income attributable to Non-controlling Interests [Table]",
        "label": "Disclosure Of Net Income Attributable To Non-Controlling Interests [Table]",
        "documentation": "Disclosure of net income attributable to Non-controlling Interests [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Liability in Respect of Pension Plans and Other Post-employment Benefits by Geographical Region",
        "label": "Disclosure Of Net Liability In Respect Of Pension Plans And Other Post-employment Benefits By Geographical Region [Table Text Block]",
        "documentation": "Disclosure of net liability in respect of pension plans and other post-employment benefits by geographical region."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Sales by Segment and Geographical Area",
        "label": "Disclosure Of Net Sales By Segment And Geographical Area [Table Text Block]",
        "documentation": "Disclosure of net sales by segment and geographical area."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNonCurrentProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfNonCurrentProvisionsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Non-current Provisions [line items]",
        "label": "Disclosure Of Non-Current Provisions [Line Items]",
        "documentation": "Disclosure Of Non-current Provisions [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNonCurrentProvisionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfNonCurrentProvisionsTable",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Noncurrent Provisions [Table]",
        "label": "Disclosure Of Non-Current Provisions [Table]",
        "documentation": "Disclosure Of Noncurrent Provisions [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfNonCurrentProvisionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfNonCurrentProvisionsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in Non-current Provisions",
        "label": "Disclosure Of Non-Current Provisions [Table Text Block]",
        "documentation": "Disclosure of noncurrent provisions explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [text block]",
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]",
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]",
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNoncontrollingInterestsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Noncontrollinginterests"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Disclosure of non-controlling interests [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of non-controlling interests. [Refer: Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "ifrs-full_DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Assetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchange"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale or exchange and liabilities related to assets held for sale or exchange",
        "label": "Disclosure of non-current assets or disposal groups classified as held for sale [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sny_DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Number of Restricted Shares Not Yet Fully Vested",
        "label": "Disclosure Of Number Of Restricted Share Plans Not Yet Fully Vested [Table Text Block]",
        "documentation": "Disclosure of number of restricted share plans Not yet fully vested."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Offbalancesheetcommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off balance sheet commitments",
        "label": "Disclosure Of Off-Balance Sheet Commitments Explanatory [Text Block]",
        "documentation": "Disclosure of off-balance sheet commitments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Off Balance Sheet Commitments [Line Items]",
        "label": "Disclosure Of Off-Balance Sheet Commitments [Line Items]",
        "documentation": "[Line Items] for Disclosure Of Off Balance Sheet Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Off Balance Sheet Commitments Relating to Property, Plant and Equipment",
        "label": "Disclosure Of Off-Balance Sheet Commitments Of Property Plant And Equipment [Table Text Block]",
        "documentation": "Disclosure of Off-Balance Sheet Commitments of Property Plant and Equipment [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Off Balance Sheet Commitments Relating to Operating Activities",
        "label": "Disclosure Of Off-Balance Sheet Commitments Relating To Operating Activities [Table Text Block]",
        "documentation": "Disclosure of off balance sheet commitments relating to operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffBalanceSheetCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOffBalanceSheetCommitmentsTable",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Off Balance Sheet Commitments [Table]",
        "label": "Disclosure Of Off-Balance Sheet Commitments [Table]",
        "documentation": "Disclosure Of Off Balance Sheet Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Offsetting of Financial Assets and Liabilities [line items]",
        "label": "Disclosure Of Off Setting Of Financial Assets And Liabilities [Line Items]",
        "documentation": "Disclosure of offsetting of financial assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOffSettingOfFinancialAssetsAndLiabilitiesTable",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Off Setting Of Financial Assets And Liabilities [table]",
        "label": "Disclosure Of Off Setting Of Financial Assets And Liabilities [table]",
        "documentation": "Disclosure Of Off Setting Of Financial Assets And Liabilities [table]."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Operating Currency Hedging Instruments",
        "label": "Disclosure Of Operating Currency Hedging Instruments With Notional Amount Translated In To Euros At Closing Exchange Rate [Table Text Block]",
        "documentation": "The disclosure of operating currency hedging instruments with notional amount translated in to euros at closing exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Results",
        "label": "Disclosure of operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [line items]",
        "label": "Disclosure of operating segments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method",
        "label": "Disclosure Of Operating Segments Reconciling Items [Table Text Block]",
        "documentation": "The disclosure of operating segments reconciling items."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [table]",
        "label": "Disclosure of operating segments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherCurrentAssetsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Othercurrentassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Disclosure of other current assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other current assets. [Refer: Other current assets]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOtherGainsAndLossesAndLitigationTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Othergainsandlossesandlitigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other gains and losses, and litigation",
        "label": "Disclosure Of Other Gains And Losses, And Litigation [Text Block]",
        "documentation": "The entire disclosure of other gains and losses, and litigation."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherLongTermProvisionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOtherLongTermProvisionsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Provisions",
        "label": "Disclosure Of Other Long Term Provisions [Table Text Block]",
        "documentation": "The disclosure of other long term provisions."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherNonCurrentAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOtherNonCurrentAssetsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Non Current Assets [Line Items]",
        "label": "Disclosure Of Other Non-Current Assets [Line Items]",
        "documentation": "Disclosure of other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherNonCurrentAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOtherNonCurrentAssetsTable",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Non-current Assets [Table]",
        "label": "Disclosure Of Other Non-Current Assets [Table]",
        "documentation": "Schedule disclosing information related to other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Othernoncurrentassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Disclosure of other non-current assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Otheroperatingexpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating expenses",
        "label": "Disclosure of other operating expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sny_DisclosureOfOtherOperatingIncomeExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOtherOperatingIncomeExpensesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Operating Income Expenses [Line Items]",
        "label": "Disclosure Of Other Operating Income Expenses [Line Items]",
        "documentation": "Disclosure of other operating income (expenses)."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherOperatingIncomeExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOtherOperatingIncomeExpensesTable",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Other Operating Income Expenses [Table]",
        "label": "Disclosure Of Other Operating Income Expenses [Table]",
        "documentation": "Disclosure of other operating income expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Otheroperatingincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income",
        "label": "Disclosure of other operating income [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "sny_DisclosureOfOtherOperatingIncomeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOtherOperatingIncomeLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Operating Income [Line Items]",
        "label": "Disclosure Of Other Operating Income [Line Items]",
        "documentation": "Disclosure Of Other Operating Income [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfOtherOperatingIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOtherOperatingIncomeTable",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Operating Income [Table]",
        "label": "Disclosure Of Other Operating Income [Table]",
        "documentation": "Disclosure Of Other Operating Income [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of other provisions [abstract]",
        "label": "Disclosure of other provisions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of other provisions [line items]",
        "label": "Disclosure of other provisions [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherProvisionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsTable",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of other provisions [table]",
        "label": "Disclosure of other provisions [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to other provisions."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "sny_DisclosureOfOverdueReceivablesGrossValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfOverdueReceivablesGrossValueTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Gross Value of Overdue Receivables",
        "label": "Disclosure Of Overdue Receivables Gross Value [Table Text Block]",
        "documentation": "The disclosure of overdue receivables gross value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Present Value of Pension and Other Post Employement Benefits",
        "label": "Disclosure Of Pension And Other Post Employment Benefit Expense [Table Text Block]",
        "documentation": "Disclosure of pension and other post employment benefit expense."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfPersonnelCostsDetailsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfPersonnelCostsDetailsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/PersonnelcostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Personal Costs",
        "label": "Disclosure Of Personnel Costs Details [Table Text Block]",
        "documentation": "The disclosure of personnel costs details."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Pre-tax Actuarial Loss",
        "label": "Disclosure Of Pre Tax Actuarial Loss Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Pre Tax Actuarial Loss Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfPrincipalAlliancesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfPrincipalAlliancesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Principal Alliances [Line Items]",
        "label": "Disclosure Of Principal Alliances [Line Items]",
        "documentation": "Disclosure of Principal Alliances [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfPrincipalAlliancesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfPrincipalAlliancesTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Principalalliances"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal alliances",
        "label": "Disclosure Of Principal Alliances [Text Block]",
        "documentation": "The entire disclosure for principal alliances."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfPrincipalMarketedProductsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfPrincipalMarketedProductsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Detailed Information for Principal Marketed Products",
        "label": "Disclosure Of Principal Marketed Products [Table Text Block]",
        "documentation": "The disclosure of principal marketed products."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Netincomeattributabletononcontrollinginterests"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income attributable to non-controlling interests",
        "label": "Disclosure Of Profit (Loss) Attributable To Non-Controlling Interests [Text Block]",
        "documentation": "The entire disclosure for net income attributable to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share of Profit or Loss and Other Comprehensive Income of Associates and Joint Ventures",
        "label": "Disclosure Of Profit Or Loss And Other Comprehensive Income Of Associates And Joint Ventures [Table Text Block]",
        "documentation": "The disclosure of profit or loss and other comprehensive income of associates and joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Propertyplantandequipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "sny_DisclosureOfProvisionsAndOtherLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfProvisionsAndOtherLiabilitiesTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Provisionsincometaxliabilitiesandotherliabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions, income tax liabilities and other liabilities",
        "label": "Disclosure Of Provisions And Other Liabilities [Text Block]",
        "documentation": "The entire disclosure of provisions and other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Non Current Provisions and Other Non-current Liabilities",
        "label": "Disclosure Of Provisions And Other Non-Current Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure of provisions and other non current liabilities explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Provisionsfordiscountsrebatesandsalesreturns"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for discounts, rebates and sales returns",
        "label": "Disclosure Of Provisions For Discounts Rebates And Sales Returns [Text Block]",
        "documentation": "The entire disclosure for provisions for discounts rebates and sales returns."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property, Plant and Equipment Leased",
        "label": "Disclosure of quantitative information about right-of-use assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "sny_DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate",
        "label": "Disclosure Of Reconciliation Of Average Effective Tax Rate And Applicable Tax Rate Explanatory [Table Text Block]",
        "documentation": "Disclosure of reconciliation of average effective tax rate and applicable tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionLineItems",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of carrying amount to value on redemption [line items]",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Line Items]",
        "documentation": "Disclosure of reconciliation of carrying amount to value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTable",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of carrying amount to value on redemption [table]",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table]",
        "documentation": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of Carrying Amount to Value on Redemption",
        "label": "Disclosure Of Reconciliation Of Carrying Amount To Value On Redemption [Table Text Block]",
        "documentation": "Disclosure of reconciliation of carrying amount to value on redemption [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movements in Goodwill",
        "label": "Disclosure of reconciliation of changes in goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillLineItems",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [line items]",
        "label": "Disclosure of reconciliation of changes in goodwill [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillTable",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [table]",
        "label": "Disclosure of reconciliation of changes in goodwill [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in goodwill."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "sny_DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movements in Other Intangible Assets",
        "label": "Disclosure Of Reconciliation Of Changes In Other Intangible Assets [Table Text Block]",
        "documentation": "Disclosure of reconciliation of changes in other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Relatedpartytransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transactions",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "sny_DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of Net Defined-benefit (Asset)/Liability (Actuarial Gains and Losses)",
        "label": "Disclosure Of Remeasurement Of Net Defined Benefit Liability Asset By Country [Table Text Block]",
        "documentation": "The disclosure of remeasuresment of net defined benefit liability asset by country."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Currency Translation Differences",
        "label": "Disclosure Of Reserve Of Exchange Differences On Translation [Table Text Block]",
        "documentation": "The disclosure of reserve of exchange differences on translation."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringCostsAndSimilarItemsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfRestructuringCostsAndSimilarItemsTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Restructuringcostsandsimilaritems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring costs and similar items",
        "label": "Disclosure Of Restructuring Costs And Similar Items [Text Block]",
        "documentation": "The entire disclosure of restructuring costs and similar items."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringCostsDetailsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfRestructuringCostsDetailsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restructuring Costs and Similar Items",
        "label": "Disclosure Of Restructuring Costs Details [Table Text Block]",
        "documentation": "The disclosure of restructuring costs details."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfRestructuringProvisionsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Restructuring Provisions [line items]",
        "label": "Disclosure Of Restructuring Provisions [Line Items]",
        "documentation": "Disclosure of restructuring provisions."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringProvisionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfRestructuringProvisionsTable",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Restructuring provisions [Table]",
        "label": "Disclosure Of Restructuring Provisions [Table]",
        "documentation": "Disclosure of Restructuring provisions [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfRestructuringProvisionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfRestructuringProvisionsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movements in Restructuring Provisions Classified in Non-current and Current Liabilities",
        "label": "Disclosure Of Restructuring Provisions [Table Text Block]",
        "documentation": "The disclosure of restructuring provisions."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Sensitivity for Pensions and Other Post-employment Benefits to Changes in Key Actuarial Assumptions",
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]"
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of sensitivity analysis for actuarial assumptions [line items]",
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of sensitivity analysis for actuarial assumptions [table]",
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the sensitivity analysis for actuarial assumptions."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "sny_DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Interest Rate Fluctuations of Debt Net of Cash and Cash Equivalents",
        "label": "Disclosure Of sensitivity Analysis On Long-term Borrowings And Debt Securities Assuming A 1% Increase And Decrease In Interest Rates [Table Text Block]",
        "documentation": "Disclosure of sensitivity analysis on long-term borrowings and debt securities assuming a 1% increase and decrease in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Cost for Pension and Other post-employment Benefit Plans, by Geographical Region",
        "label": "Disclosure Of Service Costs Of Net Defined Benefits By Country [Table Text Block]",
        "documentation": "The disclosure of service costs of net defined benefits by country."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Options Outstanding and Exercisable",
        "label": "Disclosure Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table Text Block]",
        "documentation": "The disclosure of share based compensation shares authorized under stock option plans by exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedshareholdersequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated shareholders' equity",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "sny_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Shareofprofitlossfrominvestmentsaccountedforusingtheequitymethod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit/loss from investments accounted for using the equity method",
        "label": "Disclosure Of Share Of Profit (Loss) Of Associates And Joint Ventures Accounted For Using Equity Method [Text Block]",
        "documentation": "Disclosure of share of profit loss of associates and joint ventures accounted for using equity method explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Repurchases program",
        "label": "Disclosure Of Share Repurchase Program Explanatory [Table Text Block]",
        "documentation": "Disclosure of share repurchase program explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Number of Shares Used to Compute Diluted Earnings Per Share",
        "label": "Disclosure Of Shares Used To Compute Diluted Earnings Per Share [Table Text Block]",
        "documentation": "The disclosure of shares used to compute diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of associates [line items]",
        "label": "Disclosure of associates [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable",
     "presentation": [
      "http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of associates [table]",
        "label": "Disclosure of associates [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to associates."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r198"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "List of principal companies included in the scope of consolidation during\u00a02023",
        "label": "Disclosure of subsidiaries [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r195"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of subsidiaries [line items]",
        "label": "Disclosure of subsidiaries [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Subsidiaries [Table]",
        "label": "Disclosure of subsidiaries [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r195"
     ]
    },
    "sny_DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements Share Capital",
        "label": "Disclosure Of Statement Of Changes In Equity Of Parent [Table Text Block]",
        "documentation": "The disclosure of statement of changes in equity of parent."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Options Outstanding at Each Balance Sheet Date",
        "label": "Disclosure Of Stock Options Outstanding At Each Balance Sheet Date And Of Changes During The Relevant Periods [Table Text Block]",
        "documentation": "The disclosure of stock options outstanding at each balance sheet date and of changes during the relevant periods."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of stock subscription option plan outstanding and option exercised [line items]",
        "label": "Disclosure Of Stock Subscription Option Plan Outstanding And Option Exercised [Line Items]",
        "documentation": "Disclosure of stock subscription option plan outstanding and option exercised [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfStockSubscriptionOptionPlanOutstandingAndOptionExercisedTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of stock subscription option plan outstanding and option exercised [Table]",
        "label": "Disclosure Of Stock Subscription Option Plan Outstanding And Option Exercised [Table]",
        "documentation": "Disclosure of stock subscription option plan outstanding and option exercised [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Stock Subscription Option Plan Outstanding and Option Exercised",
        "label": "Disclosure Of Stock Subscription Option Plans Under Which Options Were Exercised In The Year [Table Text Block]",
        "documentation": "The disclosure of stock subscription option plans under which options were exercised in the year."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfTaxLossesAvailableForCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfTaxLossesAvailableForCarryforwardLineItems",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of tax losses available for carryforward [line items]",
        "label": "Disclosure Of Tax Losses Available For Carryforward [Line Items]",
        "documentation": "Disclosure of tax losses available for carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfTaxLossesAvailableForCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfTaxLossesAvailableForCarryforwardTable",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Tax Losses Available For Carryforward [Table]",
        "label": "Disclosure Of Tax Losses Available For Carryforward [Table]",
        "documentation": "Disclosure Of Tax Losses Available For Carryforward [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Deferred Tax Position",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Characteristics of Restricted Share Plans",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "sny_DisclosureOfTradeReceivablesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfTradeReceivablesTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/Accountsreceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Disclosure Of Trade Receivables [Text Block]",
        "documentation": "The disclosure of trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of compensation paid to key management personnel [abstract]",
        "label": "Disclosure of transactions between related parties [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Principal Transactions and Balances with Related Parties",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [line items]",
        "label": "Disclosure of transactions between related parties [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [table]",
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "sny_DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Undrawn Credit Facilities",
        "label": "Disclosure Of Undrawn Borrowing Facilities [Table Text Block]",
        "documentation": "Disclosure of undrawn borrowing facilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Weighted Average Duration of Obligation for Pensions and Other Long-term Benefits in Principal Countries",
        "label": "Disclosure Of Weighted Average Duration Of Defined Benefit Obligation [Table Text Block]",
        "documentation": "The disclosure of weighted average duration of defined benefit obligation."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Disposals and other decreases",
        "label": "Disposals and retirements, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals and retirements. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsAndRetirementsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals and other decreases",
        "label": "Disposals and retirements, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals and retirements. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "sny_DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Disposals and other decreases",
        "label": "Disposals And Retirements, Property, Plant And Equipment, Right Of Use Assets",
        "documentation": "Disposals And Retirements, Property, Plant And Equipment, Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sny_DividendsPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DividendsPaidAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends paid:",
        "label": "Dividends Paid [Abstract]",
        "documentation": "Dividends Paid [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DividendsPaidOrdinarySharesPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsPaidOrdinarySharesPerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends paid, ordinary shares per share (in EUR per share)",
        "label": "Dividends paid, ordinary shares per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends paid per ordinary share."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "to shareholders of Sanofi",
        "label": "Dividends paid to equity holders of parent, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to equity holders of the parent, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "ifrs-full_DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "to non-controlling interests, excluding BMS",
        "label": "Dividends paid to non-controlling interests, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to non-controlling interests, classified as financing activities. [Refer: Non-controlling interests; Dividends paid to non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "sny_DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dividends received from non-consolidated entities",
        "label": "Dividends Received from Non-Consolidated Entities Classified As Operating Activities",
        "documentation": "Dividends received from non-consolidated entities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DividendsRecognisedAsDistributionsToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsRecognisedAsDistributionsToNoncontrollingInterests",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of dividends to non-controlling interests",
        "label": "Dividends recognised as distributions to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to non-controlling interests. [Refer: Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsRecognisedAsDistributionsToOwnersOfParent",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividend paid out of earnings",
        "label": "Dividends recognised as distributions to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to owners of the parent. [Refer: Parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r374"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "sny_DupixentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "DupixentMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DUPIXENT",
        "label": "Dupixent [Member]",
        "documentation": "Dupixent [member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EPICBPIFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EPICBPIFranceMember",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EPIC BPIFrance",
        "label": "EPIC BPIFrance [Member]",
        "documentation": "EPIC BPIFrance"
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "EUR",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Euro",
        "label": "Euro Member Countries, Euro"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfAssetCeilingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfAssetCeilingMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of asset ceiling",
        "label": "Effect of asset ceiling [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the effect of asset ceiling in a defined benefit plan. Asset ceiling is the present value of any economic benefits available in the form of refunds from the defined benefit plan or reductions in future contributions to the defined benefit plan. [Refer: Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of exchange rates on cash and cash equivalents",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166"
     ]
    },
    "sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails": {
       "parentTag": "sny_NetExposure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of financial collateral",
        "label": "Effects Of Other Netting Arrangements Not Fulfilling The IAS 32 Criteria For Offsetting Fair Value Of Financial Collateral",
        "documentation": "Effects of other netting arrangements not fulfilling the IAS32 criteria for offsetting fair value of financial collateral."
       }
      }
     },
     "auth_ref": []
    },
    "sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails": {
       "parentTag": "sny_NetExposure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial instruments",
        "label": "Effects Of Other Netting Arrangements Not Fulfilling The IAS 32 Criteria For Offsetting Financial Instruments",
        "documentation": "Effects of other netting arrangements not fulfilling the IAS32 criteria for offsetting financial instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of other netting arrangements not fulfilling the IAS 32 criteria for offsetting",
        "label": "Effects Of Other Netting Arrangements Not Fulfilling The IAS 32 Criteria For Offsetting [Member]",
        "documentation": "Effects of other netting arrangements not fulfilling the IAS 32 criteria for offsetting."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EliminationOfIntersegmentAmountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EliminationOfIntersegmentAmountsMember",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elimination of inter-segment amounts",
        "label": "Elimination of intersegment amounts [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the elimination of intersegment amounts in the reconciliations of total segment amounts to amounts recognised in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365"
     ]
    },
    "sny_EloctateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EloctateMember",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ELOCTATE",
        "label": "Eloctate [Member]",
        "documentation": "Eloctate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EmployeeBenefitsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EmployeeBenefitsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefits [Abstract]",
        "label": "Employee Benefits [Abstract]",
        "documentation": "Employee Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r52",
      "r295"
     ]
    },
    "sny_EmployeeBenefitsExpenseGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EmployeeBenefitsExpenseGain",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense/(gain) for the period",
        "label": "Employee Benefits Expense / (Gain)",
        "documentation": "Employee Benefits Expense / (Gain)"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EmployeesShareOwnershipPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EmployeesShareOwnershipPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees share ownership plan",
        "label": "Employees Share Ownership Plan [member]",
        "documentation": "Employees share ownership plan."
       }
      }
     },
     "auth_ref": []
    },
    "sny_EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer's contribution percentage",
        "label": "Employer Contribute Percentage On Amounts Exceeding The Social Security Ceiling",
        "documentation": "Employer contribute percentage on amounts exceeding the social security ceiling."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Addresses, Address Type [Axis]",
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Listings, Exchange [Axis]",
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "ifrs-full_EntitysTotalForAssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForAssociatesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for associates",
        "label": "Entity's total for associates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r198"
     ]
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for business combinations [member]",
        "label": "Entity's total for business combinations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r246"
     ]
    },
    "ifrs-full_EntitysTotalForCashgeneratingUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForCashgeneratingUnitsMember",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for cash-generating units [member]",
        "label": "Entity's total for cash-generating units [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Cash-generating units' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r135"
     ]
    },
    "ifrs-full_EntitysTotalForJointOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForJointOperationsMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's Total for Joint Operations [Member]",
        "label": "Entity's total for joint operations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Joint operations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_EntitysTotalForJointVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForJointVenturesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for joint ventures",
        "label": "Entity's total for joint ventures [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Joint ventures' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r196"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for related parties",
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrs-full_EntitysTotalForSegmentConsolidationItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForSegmentConsolidationItemsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for segment consolidation items [member]",
        "label": "Entity's total for segment consolidation items [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Segment consolidation items' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForSubsidiariesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical",
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for subsidiaries",
        "label": "Entity's total for subsidiaries [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r195"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r32",
      "r177",
      "r179",
      "r199",
      "r200",
      "r203"
     ]
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity and liabilities",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity and liabilities",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity attributable to equity holders of Sanofi",
        "terseLabel": "Attributable to equity holders of Sanofi",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParentMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to\u00a0equity holders of Sanofi",
        "label": "Equity attributable to owners of parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "sny_EquityDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EquityDerivativesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity derivatives",
        "label": "Equity Derivatives [Member]",
        "documentation": "Equity Derivatives [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-tax impact on other comprehensive income",
        "label": "Equity Instruments At Fair Value Through Other Comprehensive Income (Loss), 10% Decline In Credit Prices, Pre-tax Amount",
        "documentation": "Equity Instruments At Fair Value Through Other Comprehensive Income (Loss), 10% Decline In Credit Prices, Pre-tax Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityInstrumentsIncludedInFinancialAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EquityInstrumentsIncludedInFinancialAssetMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity instruments included in financial assets",
        "label": "Equity Instruments Included In Financial Asset [Member]",
        "documentation": "Equity Instruments Included In Financial Asset"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EquityInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity instruments",
        "label": "Equity Instruments [Member]",
        "documentation": "Equity instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interests in subsidiaries and investments in other entities",
        "label": "Equity Interests In Subsidiaries And Investments In Other Entities [member]",
        "documentation": "Equity interests in subsidiaries and investments in other entities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityInvestmentSoldPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EquityInvestmentSoldPercentage",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate participation percentage of legacy companies in ACS",
        "label": "Equity Investment Sold Percentage",
        "documentation": "Equity investment sold percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity risk hedging instruments designated as fair value hedges",
        "label": "Equity Risk Hedging Instruments Designated At Fair Value Hedges",
        "documentation": "Equity Risk Hedging Instruments Designated At Fair Value Hedges"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ErnstAndYoungMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ErnstAndYoungMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ernst\u00a0&amp;\u00a0Young",
        "label": "Ernst And Young [Member]",
        "documentation": "Ernst And Young."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ErnstYoungEtAutresMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ErnstYoungEtAutresMember",
     "presentation": [
      "http://www.sanofi.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ernst &amp; Young et Autres",
        "label": "Ernst &amp; Young Et Autres [Member]",
        "documentation": "Ernst &amp; Young Et Autres"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EstimateOfContributionsExpectedToBePaidToPlan",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of contributions expected to be paid to plan for next annual reporting period",
        "label": "Estimate of contributions expected to be paid to plan for next annual reporting period"
       }
      },
      "en": {
       "role": {
        "documentation": "The estimate of the expected contributions to be made to a defined benefit plan for the next annual reporting period. [Refer: Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95"
     ]
    },
    "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EstimatedFinancialEffectOfContingentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated financial effect of contingent liabilities",
        "label": "Estimated financial effect of contingent liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "sny_EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated future benefit payments under pension and other post-employment benefit plans",
        "label": "Estimated Future Benefit Payments Under Pension And Other Postemployment Benefit Plans",
        "documentation": "Estimated future benefit payments under pension and other post-employment benefit plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_EuroapiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EuroapiMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EUROAPI",
        "label": "Euroapi [Member]",
        "documentation": "Euroapi"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_EvotecMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "EvotecMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Evotec",
        "label": "Evotec [Member]",
        "documentation": "Evotec."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExceptionalSupplementaryDividendPercentageOfShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExceptionalSupplementaryDividendPercentageOfShareCapital",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceptional supplementary dividend, percentage of share capital",
        "label": "Exceptional Supplementary Dividend, Percentage Of Share Capital",
        "documentation": "Exceptional Supplementary Dividend, Percentage Of Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExceptionalSupplementaryDividendProposedPercentageOfShareCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExceptionalSupplementaryDividendProposedPercentageOfShareCapital",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceptional supplementary dividend proposed, percentage of share capital",
        "label": "Exceptional Supplementary Dividend Proposed, Percentage Of Share Capital",
        "documentation": "Exceptional Supplementary Dividend Proposed, Percentage Of Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi",
        "terseLabel": "Exceptional supplementary dividends recognised as distributions to owners of parent",
        "label": "Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent",
        "documentation": "Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange [Domain]",
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of outstanding options (in euros per share)",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "sny_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price range four",
        "label": "Exercise Price Range Four [Member]",
        "documentation": "Exercise Price Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price range three",
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price range two",
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated payments",
        "label": "Expected Timing Of Payments In Respect Of Unfunded Pension And Other Post-employment Benefit Plans",
        "documentation": "Expected timing of payments in respect of unfunded pension and other post-employment benefit plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExpenseArisingFromTheImpactOfAcquisitionsOnInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expenses arising from the impact of acquisitions on inventories",
        "label": "Expense Arising From The Impact Of Acquisitions On Inventories",
        "documentation": "Expenses arising from the impact of acquisitions on inventories."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseCategoriesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExpenseCategoriesAxis",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense Categories [Axis]",
        "label": "Expense Categories [Axis]",
        "documentation": "Expense Categories [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseCategoriesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExpenseCategoriesDomain",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense Categories [Domain]",
        "label": "Expense Categories [Domain]",
        "documentation": "Expense Categories [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseDueToUnwindingOfDiscountOnProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unwinding of discounting of provisions",
        "label": "Expense arising from passage of time on other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised due to the unwinding of the discount on provisions other than provisions for employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense recognized of which employers' contribution",
        "label": "Expense From Equity-Settled Share-Based Payment Transactions Of Which Goods Or Services Received Did Not Qualify For Recognition As Assets Employer Contribution",
        "documentation": "Expense recognized in equity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Total expense for restricted share plans",
        "terseLabel": "Expense recognized",
        "label": "Expense from equity-settled share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Expense/(gain) for the period",
        "label": "Expense Gain For The Period Net Defined Benefit Liability Asset",
        "documentation": "Expense/(gain) for the period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseOfRestructuringActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseOfRestructuringActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      },
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restructuring costs and similar items",
        "totalLabel": "Total",
        "label": "Expense of restructuring activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "sny_ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee-related expenses",
        "label": "Expense Of Restructuring Activities, Employee Related Expenses",
        "documentation": "Employee related expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charges, gains or losses on assets",
        "label": "Expense Of Restructuring Activities, Related To Property Plant And Equipment And To Inventories",
        "documentation": "Expense of restructuring activities related to property plant and equipment to inventories."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseOfRestructuringActivitiesTransformationProgramsCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExpenseOfRestructuringActivitiesTransformationProgramsCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs related to transformation programs",
        "label": "Expense Of Restructuring Activities, Transformation Programs Costs",
        "documentation": "Expense Of Restructuring Activities, Transformation Programs Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense relating to short-term leases and low value assets",
        "label": "Expense Relating To Short-term Leases And Low Value Assets For Which Recognition Exemption Has Been Used",
        "documentation": "Expense Relating To Short-term Leases And Low Value Assets For Which Recognition Exemption Has Been Used"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ExscientiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ExscientiaMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exscientia",
        "label": "Exscientia [Member]",
        "documentation": "Exscientia"
       }
      }
     },
     "auth_ref": []
    },
    "country_FR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "FR",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "France",
        "label": "FRANCE"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FabrazymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FabrazymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FABRAZYME",
        "label": "Fabrazyme [Member]",
        "documentation": "Fabrazyme [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FairValueHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FairValueHedgesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives designated as fair value hedges",
        "label": "Fair value hedges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the exposure to changes in fair value of a recognised asset or liability or an unrecognised firm commitment, or an identified portion of such an asset, liability or firm commitment, that is attributable to a particular risk and could affect profit or loss. [Refer: Hedges [member]]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r252",
      "r253",
      "r254"
     ]
    },
    "sny_FairValueMeasurementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FairValueMeasurementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Abstract]",
        "label": "Fair Value Measurement [Abstract]",
        "documentation": "Fair Value Measurement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in equity instruments designated at fair value through OCI",
        "label": "Investments in equity instruments designated at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r270"
     ]
    },
    "sny_FairValueOfPlanAtDateOfGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FairValueOfPlanAtDateOfGrant",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of plan at the date of grant",
        "label": "Fair Value Of Plan At Date Of Grant",
        "documentation": "Fair value of plan at the date of grant."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FairValueOfSPMSDContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FairValueOfSPMSDContingentConsiderationMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of SPMSD contingent consideration",
        "label": "Fair Value Of SPMSD Contingent Consideration [Member]",
        "documentation": "Fair value of SPMSD contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FairValueOfTheContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FairValueOfTheContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of the contingent consideration",
        "label": "Fair Value Of The Contingent Consideration",
        "documentation": "Fair value of the contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FairValuePerShareAwardedForThreeYearServicePeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FairValuePerShareAwardedForThreeYearServicePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per share awarded (in euros per share)",
        "label": "Fair Value Per Share Awarded For Three Year Service Period",
        "documentation": "Fair value per share awarded to a three year service period."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per share awarded for three year service period, additional shares (in euros per share)",
        "label": "Fair Value Per Share Awarded For Three Year Service Period, Additional Shares",
        "documentation": "Fair Value Per Share Awarded For Three Year Service Period, Additional Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per share awarded for three year service period, to chief executive officer (in euros per share)",
        "label": "Fair Value Per Share Awarded For Three Year Service Period, To Chief Executive Officer",
        "documentation": "Fair Value Per Share Awarded For Three Year Service Period, To Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails": {
       "parentTag": "sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Financial expenses",
        "terseLabel": "Financial expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net financial income/(expenses)",
        "label": "Finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial assets measured at fair value",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r258",
      "r259",
      "r261",
      "r348"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instruments at fair value through other comprehensive income",
        "label": "Financial assets at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets at fair value through profit or loss",
        "label": "Financial assets at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets that are measured at fair value and for which gains (losses) are recognised in profit or loss. A financial asset shall be measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income. A gain (loss) on a financial asset measured at fair value shall be recognised in profit or loss unless it is part of a hedging relationship, it is an investment in an equity instrument for which the entity has elected to present gains and losses in other comprehensive income or it is a financial asset measured at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsCategoryMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, category [member]",
        "label": "Financial assets, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "sny_FinancialAssetsHeldToFundDeferredCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FinancialAssetsHeldToFundDeferredCompensationPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments held to fund deferred compensation plan",
        "label": "Financial Assets Held To Fund Deferred Compensation Plan [Member]",
        "documentation": "Financial Assets Held To Fund Deferred Compensation Plan"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets held to meet obligations under deferred compensation plans",
        "label": "Financial Assets Held To Meet Obligations Under Deferred Compensation Plans [Member]",
        "documentation": "Financial assets held to meet obligations under deferred compensation plans."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, class",
        "label": "Financial assets, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r266",
      "r267",
      "r288",
      "r289"
     ]
    },
    "sny_FinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]",
        "documentation": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Market value",
        "label": "Financial instruments designated as hedging instruments, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial instruments designated as hedging instruments. Hedging instruments are designated derivatives or (for a hedge of the risk of changes in foreign currency exchange rates only) designated non-derivative financial assets or non-derivative financial liabilities whose fair value or cash flows are expected to offset changes in the fair value or cash flows of a designated hedged item. [Refer: At fair value [member]; Derivatives [member]; Derivative financial assets; Derivative financial liabilities; Financial instruments, class [member]; Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [axis]",
        "label": "Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "ifrs-full_FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [member]",
        "label": "Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments measured at fair value through profit or loss, because a credit derivative is used to manage the credit risk of these instruments. It also represents the standard value for the 'Financial instruments measured at fair value through profit or loss because credit derivative is used to manage credit risk' axis if no other member is used. [Refer: Financial instruments, class [member]; Credit risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "sny_FinancialInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FinancialInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial investments",
        "label": "Financial Investments",
        "documentation": "The amount of financial assets that are classified as financial assets available-for-sale, held-to-maturity investments or loans and receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial liabilities measured at fair value",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Current finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r301",
      "r397"
     ]
    },
    "sny_FirmOrdersOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FirmOrdersOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofOffBalanceSheetCommitmentsRelatingtoPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Firm orders of property, plant and equipment",
        "label": "Firm Orders Of Property Plant And Equipment",
        "documentation": "Firm orders of property plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FixedInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FixedInterestRateMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed-rate debt",
        "label": "Fixed interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "ifrs-full_FixturesAndFittingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FixturesAndFittingsMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixtures",
        "terseLabel": "Fixtures, fittings\u00a0and other",
        "label": "Fixtures and fittings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "ifrs-full_FloatingInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FloatingInterestRateMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floating-rate debt",
        "label": "Floating interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a non-fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "sny_ForeignCurrencyTranslationDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForeignCurrencyTranslationDifferences",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Foreign Currency Translation Differences",
        "documentation": "Foreign Currency Translation Differences"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForeignCurrencyTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForeignCurrencyTranslationMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation",
        "label": "Foreign Currency Translation [Member]",
        "documentation": "Foreign Currency Translation"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasedInChineseYuanRenminbiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencyPurchasedInChineseYuanRenminbiMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Chinese Yuan Renminbi",
        "label": "Forward Currency Purchased In Chinese Yuan Renminbi [member]",
        "documentation": "Forward currency purchases in Chinese Yuan Renminbi."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasedInHungarianForintMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencyPurchasedInHungarianForintMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Hungarian Forint",
        "label": "Forward Currency Purchased In Hungarian Forint [Member]",
        "documentation": "Forward currency purchases in Hungarian Forint."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasedInJapaneseYenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencyPurchasedInJapaneseYenMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases In Japanese yen",
        "label": "Forward Currency Purchased In Japanese Yen [Member]",
        "documentation": "Forward Currency Purchased In Japanese Yen"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasedInKoreanWonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencyPurchasedInKoreanWonMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Purchased In Korean Won",
        "label": "Forward Currency Purchased In Korean Won [Member]",
        "documentation": "Forward Currency Purchased In Korean Won"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasedInRussianRoubleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencyPurchasedInRussianRoubleMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases In Russian Rouble",
        "label": "Forward Currency Purchased In Russian Rouble [Member]",
        "documentation": "Forward Currency Purchased In Russian Rouble [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasedInSingaporeDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencyPurchasedInSingaporeDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in Singapore Dollar",
        "label": "Forward Currency Purchased In Singapore Dollar [member]",
        "documentation": "Forward currency purchases in Singapore Dollar."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasedInTaiwanDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencyPurchasedInTaiwanDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Purchased In Taiwan Dollar",
        "label": "Forward Currency Purchased In Taiwan Dollar [Member]",
        "documentation": "Forward Currency Purchased In Taiwan Dollar"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasedInUSDollarCommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencyPurchasedInUSDollarCommercialPaperMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in US dollar, commercial paper",
        "label": "Forward Currency Purchased In US Dollar, Commercial Paper [Member]",
        "documentation": "Forward Currency Purchased In US Dollar, Commercial Paper"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasedInUSDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencyPurchasedInUSDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in US Dollar",
        "label": "Forward Currency Purchased In US Dollar [Member]",
        "documentation": "Forward currency purchases in USD."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasedInUSDollarUSBondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencyPurchasedInUSDollarUSBondMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases in US dollar, US bond",
        "label": "Forward Currency Purchased In US Dollar, US Bond [Member]",
        "documentation": "Forward Currency Purchased In US Dollar, US Bond"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencyPurchasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencyPurchasesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency purchases",
        "label": "Forward Currency Purchases [Member]",
        "documentation": "Forward currency purchases."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInChineseYuanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencySalesInChineseYuanMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Sales In Chinese Yuan",
        "label": "Forward Currency Sales In Chinese Yuan [Member]",
        "documentation": "Forward Currency Sales In Chinese Yuan"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInChineseYuanRenminbiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencySalesInChineseYuanRenminbiMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Chinese Yuan Renminbi",
        "label": "Forward Currency Sales In Chinese Yuan Renminbi [member]",
        "documentation": "Forward currency sales in Chinese Yuan Renminbi."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInJapaneseYenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencySalesInJapaneseYenMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Japanese Yen",
        "label": "Forward Currency Sales In Japanese Yen [Member]",
        "documentation": "Forward currency sales in Japanese Yen."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInKoreanWonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencySalesInKoreanWonMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Currency Sales In Korean Won",
        "label": "Forward Currency Sales In Korean Won [Member]",
        "documentation": "Forward Currency Sales In Korean Won"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInSingaporeDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencySalesInSingaporeDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Singapore Dollar",
        "label": "Forward Currency Sales In Singapore Dollar [member]",
        "documentation": "Forward currency sales in Singapore Dollar."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInTaiwanDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencySalesInTaiwanDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in Taiwan Dollar",
        "label": "Forward Currency Sales In Taiwan Dollar [Member]",
        "documentation": "Forward Currency Sales In Taiwan Dollar"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesInUSDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencySalesInUSDollarMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales in US Dollar",
        "label": "Forward Currency Sales In US Dollar [Member]",
        "documentation": "Forward currency sales in USD."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ForwardCurrencySalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ForwardCurrencySalesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward currency sales",
        "label": "Forward Currency Sales [Member]",
        "documentation": "Forward currency sales."
       }
      }
     },
     "auth_ref": []
    },
    "sny_FourBillionFacilityMaturingDecember2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FourBillionFacilityMaturingDecember2027Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u20ac4 billion facility maturing December 2027",
        "label": "Four Billion Facility Maturing December 2027 [Member]",
        "documentation": "Four Billion Facility Maturing December 2027"
       }
      }
     },
     "auth_ref": []
    },
    "sny_FourBillionFacilityMaturingMarch2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "FourBillionFacilityMaturingMarch2029Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u20ac4 billion facility maturing March 2029",
        "label": "Four Billion Facility Maturing March 2029 [Member]",
        "documentation": "Four Billion Facility Maturing March 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FundingArrangementsOfDefinedBenefitPlansAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FundingArrangementsOfDefinedBenefitPlansAxis",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding arrangements of defined benefit plans [axis]",
        "label": "Funding arrangements of defined benefit plans [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_FundingArrangementsOfDefinedBenefitPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FundingArrangementsOfDefinedBenefitPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding arrangements of defined benefit plans [member]",
        "label": "Funding arrangements of defined benefit plans [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all defined benefit plans when disaggregated by funding arrangements of defined benefits plans. It also represents the standard value for the 'Funding arrangements of defined benefits plans' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "GB",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UK",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "currency_GBP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "GBP",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pound sterling",
        "label": "United Kingdom, Pounds"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainLossOnCancellationOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GainLossOnCancellationOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) recognized on cancellation of treasury shares",
        "label": "Gain (Loss) On Cancellation Of Treasury Shares",
        "documentation": "Gain (loss) on cancellation of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainLossOnImpairmentOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GainLossOnImpairmentOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) recognized on impairment of treasury shares",
        "label": "Gain (Loss) On Impairment Of Treasury Shares",
        "documentation": "Gain (loss) on impairment of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainLossOnPurchaseOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GainLossOnPurchaseOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) recognized on purchase of treasury shares",
        "label": "Gain (Loss) On Purchase Of Treasury Shares",
        "documentation": "Gain (loss) on purchase of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails": {
       "parentTag": "sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)",
        "verboseLabel": "Actuarial gains/(losses) arising during the period",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "sny_GainLossOnSaleOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GainLossOnSaleOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesTreasurySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) recognized on sale of treasury shares",
        "label": "Gain (Loss) On Sale Of Treasury Shares",
        "documentation": "Gain (loss) on sale of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnAvailableforsaleFinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains/(losses) on disposals of financial assets",
        "label": "Gains (losses) on available-for-sale financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on available-for-sale financial assets. [Refer: Financial assets available-for-sale]"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ifrs-full_GainsLossesOnCashFlowHedgesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnCashFlowHedgesBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of cash flow hedges",
        "label": "Gains (losses) on cash flow hedges, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on cash flow hedges, before tax, before reclassification adjustments. [Refer: Cash flow hedges [member]]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "sny_GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivatives used to manage cash and cash equivalents",
        "label": "Gains (Losses) On Derivatives Used To Manage Cash And Cash Equivalents",
        "documentation": "Gain on derivatives used to manage cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainsLossesOnDerivativesUsedToManageDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GainsLossesOnDerivativesUsedToManageDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivatives used to manage debt",
        "label": "Gains (Losses) On Derivatives Used To Manage Debt",
        "documentation": "Gain derivatives used to manage debt."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in currency translation differences",
        "label": "Gains (losses) on exchange differences on translation of foreign operations, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "sny_GainsLossesOnRemeasuringDebtInstrumentsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GainsLossesOnRemeasuringDebtInstrumentsBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of debt instruments included in financial assets",
        "label": "Gains (Losses) On Remeasuring Debt Instruments, Before Tax",
        "documentation": "Gains (Losses) On Remeasuring Debt Instruments, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of equity instruments included in\u00a0financial assets and financial liabilities",
        "label": "Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, entity's own equity instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in other comprehensive income on the fair value measurement of the entity's own equity instruments. [Refer: At fair value [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)",
        "label": "Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "sny_GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan",
        "label": "(Gains) Losses Related To Plan Amendments, Curtailments Or Settlement",
        "documentation": "(Gains) Losses Related To Plan Amendments, Curtailments Or Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GainsOnDivestmentOfProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GainsOnDivestmentOfProducts",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains on divestment of some mature products",
        "label": "Gains On Divestment Of Products",
        "documentation": "Gains on divestment of products."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GeneralInformationAboutFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GeneralInformationAboutFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Information About Financial Statements [Abstract]",
        "label": "General Information About Financial Statements [Abstract]",
        "documentation": "General Information About Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GeneralMedecinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GeneralMedecinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Medicines",
        "label": "General Medecines [Member]",
        "documentation": "General Medecines"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GenzymeCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GenzymeCorporationMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genzyme Corporation",
        "label": "Genzyme Corporation [Member]",
        "documentation": "Genzyme Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GenzymeFlandersBVBAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GenzymeFlandersBVBAMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genzyme Flanders BV",
        "label": "Genzyme Flanders BVBA [member]",
        "documentation": "Genzyme Flanders BVBA."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GenzymeGlobalSarlBaarIntellectualPropertyBranchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GenzymeGlobalSarlBaarIntellectualPropertyBranchMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genzyme Global Sarl Baar Intellectual Property Branch",
        "label": "Genzyme Global Sarl Baar Intellectual Property Branch [Member]",
        "documentation": "Genzyme Global Sarl Baar Intellectual Property Branch"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GenzymeGlobalSarlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GenzymeGlobalSarlMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genzyme Global Sarl",
        "label": "Genzyme Global Sarl [member]",
        "documentation": "Genzyme Global Sarl."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GenzymeIrelandLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GenzymeIrelandLimitedMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genzyme Ireland Limited",
        "label": "Genzyme Ireland Limited [member]",
        "documentation": "Genzyme Ireland Limited."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GenzymeLuxembourgSarlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GenzymeLuxembourgSarlMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genzyme Luxembourg Sarl",
        "label": "Genzyme Luxembourg Sarl [Member]",
        "documentation": "Genzyme Luxembourg Sarl"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GenzymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GenzymeMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genzyme",
        "label": "Genzyme [Member]",
        "documentation": "Genzyme."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GenzymePolyclonalsSASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GenzymePolyclonalsSASMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genzyme Polyclonals SAS",
        "label": "Genzyme Polyclonals SAS [Member]",
        "documentation": "Genzyme Polyclonals SAS"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GenzymeTherapeuticProductsLimitedPartnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GenzymeTherapeuticProductsLimitedPartnershipMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genzyme Therapeutic Products Limited Partnership",
        "label": "Genzyme Therapeutic Products Limited Partnership [Member]",
        "documentation": "Genzyme Therapeutic Products Limited Partnership [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [axis]",
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r310",
      "r338",
      "r341"
     ]
    },
    "ifrs-full_GeographicalAreasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [member]",
        "label": "Geographical areas [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r310",
      "r338",
      "r341"
     ]
    },
    "sny_GlobalPenaltyFeeIncurredByDefendants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GlobalPenaltyFeeIncurredByDefendants",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total penalty fee incurred by defendants",
        "label": "Global Penalty Fee Incurred By Defendants",
        "documentation": "Global Penalty Fee Incurred By Defendants"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GoldBondProductLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GoldBondProductLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gold Bond Product litigation in the US",
        "label": "Gold Bond Product Litigation In The US [Member]",
        "documentation": "Gold Bond Product Litigation In The US"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r130",
      "r134",
      "r245"
     ]
    },
    "ifrs-full_GoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodwillMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodwillRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "sny_GoodwillTaxDeductiblePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GoodwillTaxDeductiblePeriod",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, tax deductible period",
        "label": "Goodwill, Tax Deductible, Period",
        "documentation": "Goodwill, Tax Deductible, Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_GovernmentAndStateProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GovernmentAndStateProgramsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government and State Programs",
        "label": "Government And State Programs [Member]",
        "documentation": "Government and state programs."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grant recognised as deduction from development expenses",
        "label": "Government Grant Recognised As Deduction From Development Expenses",
        "documentation": "Government Grant Recognised As Deduction From Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofAccountsReceivableDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross value",
        "label": "Gross carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r143",
      "r157",
      "r160",
      "r245",
      "r259",
      "r261",
      "r348"
     ]
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "sny_GuaranteesGivenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GuaranteesGivenMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantees given",
        "label": "Guarantees Given [member]",
        "documentation": "Guarantees given."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantees provided to banks in connection with credit facilities",
        "label": "Guarantees Provided To Banks In Connection With Credit Facilities [Member]",
        "documentation": "Guarantees provided to banks in connection with credit facilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_GuaranteesReceivedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "GuaranteesReceivedMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantees received",
        "label": "Guarantees Received [Member]",
        "documentation": "Guarantees received."
       }
      }
     },
     "auth_ref": []
    },
    "sny_HaleonUSLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "HaleonUSLPMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Haleon US, LP",
        "label": "Haleon US, LP [Member]",
        "documentation": "Haleon US, LP"
       }
      }
     },
     "auth_ref": []
    },
    "sny_HealthcareCoverAndLifeInsuranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "HealthcareCoverAndLifeInsuranceMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Healthcare Cover And Life Insurance",
        "label": "Healthcare Cover And Life Insurance [Member]",
        "documentation": "Healthcare Cover And Life Insurance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_HedgeFunds1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "HedgeFunds1Member",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedge funds",
        "label": "Hedge Funds1 [Member]",
        "documentation": "Hedge Funds1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_HedgedItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgedItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedged items [axis]",
        "label": "Hedged items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "ifrs-full_HedgedItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgedItemsMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedged items [member]",
        "label": "Hedged items [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedged items. A hedged item can be a recognised asset or liability, an unrecognised firm commitment, a forecast transaction or a net investment in a foreign operation. The hedged item can be: (a) a single item; or (b) a group of items (subject to paragraphs 6.6.1\u20136.6.6 and B6.6.1\u2013B6.6.16 of IFRS 9). A hedged item can also be a component of such an item or group of items (see paragraphs 6.3.7 and B6.3.7\u2013B6.3.25 of IFRS 9). This member also represents the standard value for the 'Hedged items' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "sny_HedgesOfNetInvestmentsInForeignOperationsAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "HedgesOfNetInvestmentsInForeignOperationsAfterTax",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Hedges of net investments in foreign operations",
        "label": "Hedges Of Net Investments In Foreign Operations After Tax",
        "documentation": "Hedges of net investments in foreign operations after tax."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_HedgingInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgingInstrumentsAxis",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging instruments [axis]",
        "label": "Hedging instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r252"
     ]
    },
    "ifrs-full_HedgingInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgingInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging instruments [member]",
        "label": "Hedging instruments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r252"
     ]
    },
    "ifrs-full_HeldtomaturityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HeldtomaturityInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets held for investments",
        "label": "Held-to-maturity investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-derivative financial assets with fixed or determinable payments and fixed maturity that an entity has the positive intention and ability to hold to maturity other than: (a) those that the entity upon initial recognition designates as at fair value through profit or loss; (b) those that the entity designates as available for sale; and (c) those that meet the definition of loans and receivables. An entity shall not classify any financial assets as held to maturity if the entity has, during the current financial year or during the two preceding financial years, sold or reclassified more than an insignificant amount of held-to-maturity investments before maturity (more than insignificant in relation to the total amount of held-to-maturity investments) other than sales or reclassifications that: (i) are so close to maturity or the financial asset\u2019s call date (for example, less than three months before maturity) that changes in the market rate of interest would not have a significant effect on the financial asset\u2019s fair value; (ii) occur after the entity has collected substantially all of the financial asset\u2019s original principal through scheduled payments or prepayments; or (iii) are attributable to an isolated event that is beyond the entity\u2019s control, is non-recurring and could not have been reasonably anticipated by the entity. [Refer: Derivative financial assets; Held-to-maturity investments; Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "sny_HoechstGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "HoechstGmbHMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hoechst GmbH",
        "label": "Hoechst Gmbh [member]",
        "documentation": "Hoechst GmbH."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IGMBiosciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IGMBiosciencesIncMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IGM Biosciences, Inc",
        "label": "IGM Biosciences, Inc [Member]",
        "documentation": "IGM Biosciences, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "sny_INBRX101BusinessRemainCo.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "INBRX101BusinessRemainCo.Member",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INBRX-101 business (Remain Co.)",
        "label": "INBRX-101 Business (Remain Co.) [Member]",
        "documentation": "INBRX-101 Business (Remain Co.)"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IOLicenseAndCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IOLicenseAndCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IO License and Collaboration agreement",
        "label": "IO License And Collaboration Agreement [Member]",
        "documentation": "IO License And Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ]
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets",
        "label": "Identifiable assets acquired (liabilities assumed)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r345",
      "r347"
     ]
    },
    "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Identifiable intangible assets recognised as of acquisition date",
        "terseLabel": "Other intangible assets",
        "label": "Identifiable intangible assets recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r345",
      "r347"
     ]
    },
    "sny_IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Identified environmental risks provisions estimated obligation period",
        "label": "Identified Environmental Risks Provisions Estimated Obligation Period",
        "documentation": "Identified environmental risks provisions estimated obligation period."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions, expected utilized amount in 2022",
        "label": "Identified Environmental Risks Provisions Expected Utilized Amount Next Twelve Months",
        "documentation": "Identified environmental risks provisions expected utilized amount next twelve months."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions, expected utilized amount in 2023 through 2026",
        "label": "Identified Environmental Risks Provisions Expected Utilized Amount Year Two To Five",
        "documentation": "Identified environmental risks provisions expected utilized amount year two to five."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImmunoOncologyCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ImmunoOncologyCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immuno-oncology collaboration agreement",
        "label": "Immuno Oncology Collaboration Agreement [Member]",
        "documentation": "Immuno oncology collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImmunooncologyAllianceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ImmunooncologyAllianceMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immuno-Oncology Alliance",
        "label": "Immuno-oncology Alliance [Member]",
        "documentation": "Immuno-oncology Alliance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImpactOfChangeInInterestRateOnPreTaxIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ImpactOfChangeInInterestRateOnPreTaxIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact on pre-tax net income",
        "label": "Impact Of Change In Interest Rate On Pre Tax Income",
        "documentation": "Impact of change in interest rate on pre tax income."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImpactOfPreTaxIncomeRecognisedInEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ImpactOfPreTaxIncomeRecognisedInEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact on pre-tax income/(expense) recognized directly in equity",
        "label": "Impact Of Pre Tax Income Recognised In Equity",
        "documentation": "Impact of pre tax income recognised in equity."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impact of the workdown of acquired inventories remeasured at fair value",
        "label": "Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value",
        "documentation": "Impact of the workdown of acquired inventories remeasured at fair value arising from business combination in accordance with IFRS 3."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ImpairmentLossOnIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of other intangible assets, net of reversals (excluding software)",
        "label": "Impairment Loss On Intangible Assets Other Than Goodwill",
        "documentation": "Impairment loss on intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment losses, net of reversals",
        "label": "Impairment loss recognised in other comprehensive income, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in other comprehensive income for intangible assets other than goodwill. [Refer: Impairment loss recognised in other comprehensive income; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss recognised in profit or loss",
        "label": "Impairment loss recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r128"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of goodwill recognized",
        "label": "Impairment loss recognised in profit or loss, goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment of intangible assets",
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal amount",
        "label": "Impairment Loss Recognised In Profit Or Loss, Intangible Assets Other Than Goodwill, Reversal Amount",
        "documentation": "Impairment Loss Recognised In Profit Or Loss, Intangible Assets Other Than Goodwill, Reversal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofImpairmentLossesRecognisedinPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net impairment losses on property, plant and equipment",
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r50",
      "r68"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossTradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss recognised in profit or loss, trade receivables",
        "label": "Impairment loss recognised in profit or loss, trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for trade receivables. [Refer: Impairment loss recognised in profit or loss; Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_ImpairmentOfAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ImpairmentOfAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment Of Assets [Abstract]",
        "label": "Impairment Of Assets [Abstract]",
        "documentation": "Impairment Of Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ImpairmentTestingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ImpairmentTestingPercentage",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate used for Impairment of goodwill",
        "label": "Impairment Testing Percentage",
        "documentation": "Impairment Testing Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements_1": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before tax and investments accounted for using the equity method",
        "terseLabel": "Income before tax and investments accounted for using the equity method",
        "label": "Income Before Tax And Investments Accounted For Equity Method Investments",
        "documentation": "Income before tax and investments accounted for equity method investments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeResultingFromOutLicensing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncomeResultingFromOutLicensing",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from out-licensing",
        "label": "Income Resulting From Out-Licensing",
        "documentation": "Income Resulting From Out-Licensing"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeStatementLocation1Axis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncomeStatementLocation1Axis",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location1 [Axis]",
        "documentation": "Income Statement Location1"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeStatementLocation1Domain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncomeStatementLocation1Domain",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location1 [Domain]",
        "documentation": "Income Statement Location1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements_1": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofAllocationofIncomeTaxExpenseBetweenCurrentandDeferredTaxesDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "negatedTerseLabel": "Tax expense (income)",
        "negatedTotalLabel": "Total",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r55",
      "r57",
      "r58",
      "r116",
      "r193",
      "r276"
     ]
    },
    "sny_IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures",
        "documentation": "Income Tax Relating To Actuarial Gains (Losses) Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset Net Of Tax On Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income tax relating to cash flow hedges included in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r56"
     ]
    },
    "sny_IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Associates And Joint Ventures",
        "documentation": "Income Tax Relating To Change In Fair Value Of Debt Instrument Excluding Associates And Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax effects",
        "label": "Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method",
        "documentation": "Income Tax Relating To Change In Fair Value Of Equity Instruments Excluding Equity Method"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax effects",
        "label": "Income tax relating to components of other comprehensive income that will be reclassified to profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax effects",
        "label": "Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will not be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "sny_IncomeTaxesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncomeTaxesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Abstract]",
        "label": "Income Taxes [Abstract]",
        "documentation": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax paid",
        "label": "Income taxes paid (refund), classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r321"
     ]
    },
    "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of applying IFRIC agenda decision on IAS 19",
        "label": "Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial effect of changes in accounting policy for cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInContingentConsiderationAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fair value remeasurement of contingent consideration",
        "negatedTerseLabel": "Fair value remeasurement of contingent consideration",
        "label": "Increase (decrease) in contingent consideration asset (liability)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a contingent consideration asset (liability) relating to a business combination."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement of defined-benefit obligation",
        "label": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "sny_IncreaseDecreaseInEffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseInEffectiveTaxRate",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in effective tax rate",
        "label": "Increase (Decrease) In Effective Tax Rate",
        "documentation": "Increase (Decrease) In Effective Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInExpenseOfRestructuringActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseInExpenseOfRestructuringActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in restructuring costs",
        "label": "Increase (Decrease) In Expense Of Restructuring Activities",
        "documentation": "Increase (Decrease) In Expense Of Restructuring Activities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in provision related to prior period sales",
        "label": "Increase (Decrease) In Provisions Related To Prior Period Sales",
        "documentation": "Net change in provisions related to prior period sales."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate and currency derivatives used to manage debt",
        "label": "Increase (Decrease) Interest Rate And Currency Derivatives Used To Manage Debt [Member]",
        "documentation": "Interest rate and currency derivatives used to manage debt."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseOfBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseOfBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Increase (Decrease) Of Borrowings",
        "documentation": "Increase (Decrease) Of Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reversals of unutilized provisions",
        "label": "Increase (Decrease) Of Unused Provision Reversed, Other Provisions",
        "documentation": "Increase decrease of unused provision reversed, other provisions."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in scope of consolidation and transfers",
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from business combinations and disposals"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from business combinations and disposals. [Refer: Business combinations [member]; Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "sny_IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in borrowings through change in scope of consolidation",
        "label": "Increase (Decrease) Through Change In Scope Of Consolidation, Borrowings",
        "documentation": "Increase (Decrease) Through Change In Scope Of Consolidation, Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from changes in foreign exchange rates, net defined benefit liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes in foreign exchange rates. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "sny_IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other changes in non-controlling interests",
        "label": "Increase (Decrease) Through Changes In Non-Controlling Interests Arising From Divestment",
        "documentation": "Increase decrease through changes in non-controlling interests arising from divestment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in scope of consolidation",
        "label": "Increase (Decrease) Through Changes In Scope Of Consolidation In Provision For Discounts Rebates And Sales Returns",
        "documentation": "Change in scope of consolidation in provision for discounts rebates and sales returns."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in scope of consolidation",
        "label": "Increase (Decrease) Through Changes In Scope Of Consolidation, Other Provisions",
        "documentation": "Increase (Decrease) Through Changes In Scope Of Consolidation, Other Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "sny_IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other changes arising from issuance of restricted shares",
        "label": "Increase (Decrease) Through Issuance Of Restricted Shares, Equity",
        "documentation": "Increase (decrease) through issuance of restricted shares, equity."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (Decrease) Through Net Exchange Differences, Business Combinations And Non-Controlling Interests",
        "documentation": "Increase decrease through net exchange differences business combinations and noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (decrease) through net exchange differences, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "sny_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (Decrease) Through Net Exchange Differences, Property, Plant and Equipment, Right Of Use Assets",
        "documentation": "Increase (Decrease) Through Net Exchange Differences, Property, Plant and Equipment, Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation differences",
        "label": "Increase (Decrease) Through Net Exchange Differences Provisions For Discounts Rebates And Sales Returns",
        "documentation": "Currency translation differences."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other movements during the period",
        "label": "Increase (decrease) through other changes, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "sny_IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other movements",
        "label": "Increase (Decrease) Through Other Movements, Business Combinations And Non-Controlling Interests",
        "documentation": "Increase (Decrease) Through Other Movements, Business Combinations And Non-Controlling Interests"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase through remeasurement of financial liability",
        "label": "Increase (Decrease) Through Remeasurement, Other Current Liabilities",
        "documentation": "Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee share ownership plan",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Employee Share Ownership Plans",
        "documentation": "Employee share ownership plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted shares and vesting of existing restricted shares",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares",
        "documentation": "Increase (decrease) through share-based payment plans issuance of restricted shares and vesting of existing restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effects on share-based payments",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Tax Effects Of The Exercise Of Stock Options",
        "documentation": "Tax effects of the exercise of stock options."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of services obtained from employees",
        "label": "Increase (Decrease) Through Share-Based Payment Plans Value Of Services Obtained From Employees",
        "documentation": "Value of services obtained from employees."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other movements",
        "label": "Increase (decrease) through other changes, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers",
        "label": "Increase (decrease) through transfers and other changes, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers",
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers",
        "label": "Increase (decrease) through transfers, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "sny_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers",
        "label": "Increase (Decrease) Through Transfers, Property, Plant and Equipment, Right Of Use Assets",
        "documentation": "Increase (Decrease) Through Transfers, Property, Plant and Equipment, Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseOfTenPercentBasisPointInMarketInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseOfTenPercentBasisPointInMarketInterestRateMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase of ten percent basis point in market interest rate",
        "label": "Increase Of Ten Percent Basis Point In Market Interest Rate [Member]",
        "documentation": "Reduction of ten percent basis point in market interest rate."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IncreaseThroughNewProvisionRelatedToCurrentPeriodSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IncreaseThroughNewProvisionRelatedToCurrentPeriodSales",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision related to current period sales",
        "label": "Increase Through New Provision Related To Current Period Sales",
        "documentation": "Provision related to current period sales."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash-generating units [axis]",
        "label": "Cash-generating units [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash-generating units",
        "label": "Cash-generating units [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "sny_IndustrialSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IndustrialSalesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industrial sales",
        "label": "Industrial Sales [Member]",
        "documentation": "Industrial Sales"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InfluenzaVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InfluenzaVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Influenza Vaccines",
        "label": "Influenza Vaccines [Member]",
        "documentation": "Influenza Vaccines."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InfraservGmbhAndCoHochstKGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InfraservGmbhAndCoHochstKGMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Infraserv GmbH\u00a0&amp; Co. H\u00f6chst KG",
        "label": "Infraserv Gmbh And Co Hochst KG [member]",
        "documentation": "Infraserv GmbH and Co. Hochst KG."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InfraservHoechstRetainedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InfraservHoechstRetainedLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Infraserv Hoechst retained liabilities",
        "label": "Infraserv Hoechst Retained Liabilities [member]",
        "documentation": "Infraserv Hoechst retained liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InhibrxIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InhibrxIncMember",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inhibrx, Inc",
        "label": "Inhibrx, Inc [Member]",
        "documentation": "Inhibrx, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InitialLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InitialLeaseTerm",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial lease term",
        "label": "Initial Lease Term",
        "documentation": "Initial Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InnoventBiologicsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InnoventBiologicsMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Innovent Biologics",
        "label": "Innovent Biologics [Member]",
        "documentation": "Innovent Biologics"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InsilicoMedicineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InsilicoMedicineMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insilico Medicine",
        "label": "Insilico Medicine [Member]",
        "documentation": "Insilico Medicine"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InsurancePoliciesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InsurancePoliciesMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance policies",
        "label": "Insurance Policies [Member]",
        "documentation": "Insurance policies."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets and goodwill [abstract]",
        "label": "Intangible assets and goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsAndGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinGoodwillDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets and goodwill [member]",
        "label": "Intangible assets and goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other intangible assets",
        "terseLabel": "Intangible assets other than goodwill",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r149"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets other than goodwill",
        "label": "Intangible assets other than goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r316",
      "r339"
     ]
    },
    "ifrs-full_InterestCostsCapitalised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestCostsCapitalised",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized interest",
        "label": "Interest costs capitalised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net interest cost/(income) including administration costs and taxes paid during the period",
        "label": "Interest Expense (Income) Including Administration Costs And Taxes Paid, Net Defined Benefit Liability (Asset)",
        "documentation": "Interest Expense (Income) Including Administration Costs And Taxes Paid, Net Defined Benefit Liability (Asset)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest (income)/cost",
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": "sny_CostOfDebtNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of debt",
        "label": "Interest expense on borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net interest expense on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "sny_InterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails": {
       "parentTag": "sny_CostOfDebtNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income",
        "documentation": "Interest Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "sny_InterestRateAndCurrencyDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateAndCurrencyDerivativesMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate and currency derivatives used to hedge debt",
        "label": "Interest Rate And Currency Derivatives [Member]",
        "documentation": "Interest rate and currency derivatives used to hedge debt."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "sny_DebtNetOfCashAndCashEquivalents",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest rate and currency derivatives used to manage cash and cash equivalents",
        "label": "Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent",
        "documentation": "Interest rate and currency derivatives used to manage cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateAndCurrencyDerivativesUsedToManageDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateAndCurrencyDerivativesUsedToManageDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest rate and currency derivatives used to manage debt",
        "label": "Interest Rate And Currency Derivatives Used To Manage Debt",
        "documentation": "Interest rate and currency derivatives used to manage debt."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateDerivativesMeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateDerivativesMeasuredAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthercurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate derivatives measured at fair value (see Note\u00a0D.20.)",
        "label": "Interest Rate Derivatives Measured At Fair Value",
        "documentation": "Interest rate derivatives measured at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateDerivativesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate derivatives",
        "label": "Interest Rate Derivatives [Member]",
        "documentation": "Interest rate derivatives."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateSwapsInterestRate",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Interest Rate Swaps, Interest Rate",
        "documentation": "Interest Rate Swaps, Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPay057ReceiveCapitalizedEoniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateSwapsPay057ReceiveCapitalizedEoniaMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia",
        "label": "Interest Rate Swaps Pay -0.57% / Receive Capitalized Eonia [Member]",
        "documentation": "Interest rate swaps pay -0.57% / receivecapitalized Eonia"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEoniaReceive006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateSwapsPayCapitalizedEoniaReceive006Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06%",
        "label": "Interest Rate Swaps Pay Capitalized Eonia / Receive 0.06% [Member]",
        "documentation": "Interest rate swaps pay capitalized Eonia / receive 0.06%."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive069Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive069Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.69%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.69% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.69%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive092Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive092Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 0.92%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.92% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 0.92%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedEsterReceive343Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateSwapsPayCapitalizedEsterReceive343Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 3.43%",
        "label": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.43% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized Ester / Receive 3.43%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03%",
        "label": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.03%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32%",
        "label": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32% [Member]",
        "documentation": "Interest Rate Swaps Pay Capitalized USD SOFR / Receive 1.32%"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent",
        "label": "Interest Rate Swaps Receive Capitalized Eonia / Pay 1.48 Percent [Member]",
        "documentation": "Interest rate swaps receive capitalized Eonia / pay 1.48%."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestRateTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRateTypesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate types [member]",
        "label": "Interest rate types [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "label": "Interest received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "sny_InterestUndiscountedCashFlow": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestUndiscountedCashFlow",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails": {
       "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Undiscounted Cash Flow",
        "documentation": "Interest undiscounted cash flow."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InterestsInOtherEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InterestsInOtherEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interests In Other Entities [Abstract]",
        "label": "Interests In Other Entities [Abstract]",
        "documentation": "Interests In Other Entities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "totalLabel": "Total",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r99",
      "r298"
     ]
    },
    "ifrs-full_InventoriesPledgedAsSecurityForLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InventoriesPledgedAsSecurityForLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InventoriesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories pledged as security for liabilities",
        "label": "Inventories pledged as security for liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of inventories pledged as security for liabilities. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "sny_InventoryTotalQuotasHeld": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InventoryTotalQuotasHeld",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quotas held in inventory",
        "label": "Inventory, Total Quotas Held",
        "documentation": "Inventory, Total Quotas Held"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "label": "Investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r194",
      "r278"
     ]
    },
    "sny_InvestmentsInAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InvestmentsInAssociatesAndJointVentures",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments accounted for using the equity method",
        "label": "Investments In Associates And Joint Ventures",
        "documentation": "The amount of investments, joint ventures and associates in an entity's separate financial statements. Long term equity interest, significant influence."
       }
      }
     },
     "auth_ref": []
    },
    "sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, ownership percentage",
        "label": "Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage",
        "documentation": "Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in equity instruments designated at fair value through other comprehensive income, transaction amount",
        "label": "Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Transaction Amount",
        "documentation": "Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income, Transaction Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in equity instruments designated at fair value through other comprehensive income [axis]",
        "label": "Investments in equity instruments designated at fair value through other comprehensive income [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in equity instruments designated at fair value through other comprehensive income [member]",
        "label": "Investments in equity instruments designated at fair value through other comprehensive income [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for investments in equity instruments that the entity has designated at fair value through other comprehensive income. It also represents the standard value for the 'Investments in equity instruments designated at fair value through other comprehensive income' axis if no other member is used. [Refer: At fair value [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r270"
     ]
    },
    "ifrs-full_InvestmentsInJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentsInJointVentures",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in joint ventures",
        "label": "Investments in joint ventures reported in separate financial statements"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in joint ventures in an entity's separate financial statements. [Refer: Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentsInSubsidiariesJointVenturesAndAssociates",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in subsidiaries, joint ventures and associates",
        "label": "Investments in subsidiaries, joint ventures and associates reported in separate financial statements"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "sny_IrrevocablePurchaseCommitmentsGiven": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IrrevocablePurchaseCommitmentsGiven",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails": {
       "parentTag": "sny_TotalOffBalanceSheetCommitments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Irrevocable purchase commitments given",
        "label": "Irrevocable Purchase Commitments Given",
        "documentation": "Irrevocable purchase commitments given."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IrrevocablePurchaseCommitmentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IrrevocablePurchaseCommitmentsReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails": {
       "parentTag": "sny_TotalOffBalanceSheetCommitments",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Irrevocable purchase commitments received",
        "label": "Irrevocable Purchase Commitments Received",
        "documentation": "Irrevocable purchase commitments received."
       }
      }
     },
     "auth_ref": []
    },
    "sny_IssuanceOfFurtherSharesAsAnEmployersContribution": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "IssuanceOfFurtherSharesAsAnEmployersContribution",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued immediately as employer's contribution (in shares)",
        "label": "Issuance Of Further Shares As An Employers Contribution",
        "documentation": "Further shares as an employers contribution."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "sny_ItemsNotSubsequentlyReclassifiableToProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ItemsNotSubsequentlyReclassifiableToProfitOrLossMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items not subsequently reclassifiable to profit or loss",
        "label": "Items Not Subsequently Reclassifiable To Profit Or Loss [Member]",
        "documentation": "Items not subsequently reclassifiable to profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ItemsSubsequentlyReclassifiableToProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ItemsSubsequentlyReclassifiableToProfitOrLossMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items subsequently reclassifiable to profit or loss",
        "label": "Items Subsequently Reclassifiable To Profit Or Loss [Member]",
        "documentation": "Items subsequently reclassifiable to profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "sny_JanssenPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "JanssenPharmaceuticalsIncMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen Pharmaceuticals, Inc",
        "label": "Janssen Pharmaceuticals, Inc [Member]",
        "documentation": "Janssen Pharmaceuticals, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "sny_JevtanaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "JevtanaMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JEVTANA",
        "label": "Jevtana [Member]",
        "documentation": "Jevtana."
       }
      }
     },
     "auth_ref": []
    },
    "sny_JevtanaRelatedPatentLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "JevtanaRelatedPatentLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jevtana related patent litigation in the US",
        "label": "Jevtana Related Patent Litigation In The US [Member]",
        "documentation": "Jevtana Related Patent Litigation In The US"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_JointOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "JointOperationsAxis",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint Operations [Axis]",
        "label": "Joint operations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_JointVenturesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "JointVenturesAxis",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint ventures [axis]",
        "label": "Joint ventures [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r196"
     ]
    },
    "ifrs-full_JointVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "JointVenturesMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint ventures",
        "label": "Joint ventures [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for joint arrangements whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r196"
     ]
    },
    "sny_June2018SNFISINUS801060AC87Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "June2018SNFISINUS801060AC87Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2018 SNF ISIN US801060AC87",
        "label": "June 2018 SNFISINUS801060AC87 [member]",
        "documentation": "June 2018SNFISINUS801060AC87."
       }
      }
     },
     "auth_ref": []
    },
    "sny_June2018SNFISINUS801060AD60Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "June2018SNFISINUS801060AD60Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2018 SNF ISIN US801060AD60",
        "label": "June 2018 SNFISINUS801060AD60 [member]",
        "documentation": "June 2018SNFISINUS801060AD60."
       }
      }
     },
     "auth_ref": []
    },
    "sny_KadmonCorporationLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "KadmonCorporationLLCMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kadmon Corporation, LLC",
        "label": "Kadmon Corporation, LLC [Member]",
        "documentation": "Kadmon Corporation, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "sny_KadmonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "KadmonMember",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kadmon",
        "label": "Kadmon [Member]",
        "documentation": "Kadmon"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total recognized in profit or loss",
        "label": "Key management personnel compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-employment benefits",
        "label": "Key management personnel compensation, post-employment benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RelatedpartytransactionsScheduleofCompensationPaidtoKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "sny_KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/RelatedpartytransactionsSummaryofaggregateamountsPayabletoKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel",
        "label": "Key Management Personnel Compensation Termination Benefits And LumpSum Retirement Benefits",
        "documentation": "Key management personnel compensation, termination benefits and lump sum retirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_KiadisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "KiadisMember",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kiadis",
        "label": "Kiadis [Member]",
        "documentation": "Kiadis"
       }
      }
     },
     "auth_ref": []
    },
    "sny_KymabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "KymabMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kymab",
        "label": "Kymab [Member]",
        "documentation": "Kymab"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LaboratoryFacilitiesCambridgeMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LaboratoryFacilitiesCambridgeMassachusettsMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory facilities, Cambridge, Massachusetts",
        "label": "Laboratory Facilities, Cambridge, Massachusetts [Member]",
        "documentation": "Laboratory Facilities, Cambridge, Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LandAndBuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LandAndBuildingsMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office and industrial premises",
        "label": "Land and buildings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ifrs-full_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LandMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "sny_LantusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LantusMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LANTUS",
        "label": "Lantus [Member]",
        "documentation": "Lantus."
       }
      }
     },
     "auth_ref": []
    },
    "sny_LargestCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LargestCustomersMember",
     "presentation": [
      "http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Largest customers",
        "label": "Largest Customers [Member]",
        "documentation": "Largest Customers"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFiveYearsAndNotLaterThanTenYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029 to 2033",
        "label": "Later than five years and not later than ten years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years and not later than ten years."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r362",
      "r381"
     ]
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Year 5 and later",
        "terseLabel": "More\u00a0than 5\u00a0years",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r221",
      "r353",
      "r360",
      "r362"
     ]
    },
    "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Year 5",
        "terseLabel": "4 to 5 years",
        "label": "Later than four years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than four years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r221",
      "r353",
      "r362",
      "r381"
     ]
    },
    "ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneMonthAndNotLaterThanThreeMonthsMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1\u00a0to\u00a03\u00a0months",
        "label": "Later than one month and not later than three months [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one month and not later than three months."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r355",
      "r362"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Later than one year and not later than five years",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r362"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From\u00a01\u00a0to 3\u00a0years",
        "label": "Later than one year and not later than three years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than three years."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r358",
      "r362"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Year 2",
        "terseLabel": "1\u00a0to\u00a02 years",
        "label": "Later than one year and not later than two years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r221",
      "r353",
      "r362",
      "r381"
     ]
    },
    "ifrs-full_LaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Later than 12 months",
        "label": "Later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6\u00a0to\u00a012\u00a0months",
        "label": "Later than six months and not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than six months and not later than one year."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r357",
      "r362"
     ]
    },
    "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3\u00a0to\u00a06\u00a0months",
        "label": "Later than three months and not later than six months [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three months and not later than six months."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r356",
      "r362"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From\u00a03\u00a0to 5\u00a0years",
        "label": "Later than three years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r359",
      "r362"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Year 4",
        "terseLabel": "3 to 4 years",
        "label": "Later than three years and not later than four years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than four years."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r221",
      "r353",
      "r362",
      "r381"
     ]
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Year 3",
        "terseLabel": "2 to 3 years",
        "label": "Later than two years and not later than three years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than three years."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r221",
      "r353",
      "r362",
      "r381"
     ]
    },
    "sny_LeaseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LeaseCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, cost",
        "label": "Lease, Costs",
        "documentation": "Lease, Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LeaseExtensionOptionsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LeaseExtensionOptionsNumber",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, extension options, number",
        "label": "Lease, Extension Options, Number",
        "documentation": "Lease, Extension Options, Number"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LeaseExtensionOptionsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LeaseExtensionOptionsTerm",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, extension options, term",
        "label": "Lease, Extension Options, Term",
        "documentation": "Lease, Extension Options, Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "sny_LeaseLiabilitiesEffectOfDiscounting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LeaseLiabilitiesEffectOfDiscounting",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Discounting effect",
        "label": "Lease Liabilities, Effect Of Discounting",
        "documentation": "Lease Liabilities, Effect Of Discounting"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LeaseTerm",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, term",
        "label": "Lease, Term",
        "documentation": "Lease, Term"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LeasedAssetsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LeasedAssetsPercentage",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased assets, percentage",
        "label": "Leased Assets, Percentage",
        "documentation": "Leased Assets, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LegalAndArbitralProceedingsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LegalAndArbitralProceedingsAxis",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal And Arbitral Proceedings [Axis]",
        "label": "Legal And Arbitral Proceedings [Axis]",
        "documentation": "Legal And Arbitral Proceedings [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LegalAndArbitralProceedingsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LegalAndArbitralProceedingsDomain",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal And Arbitral Proceedings [Domain]",
        "label": "Legal And Arbitral Proceedings [Domain]",
        "documentation": "[Domain] for Legal And Arbitral Proceedings [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a01",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r200"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a02",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a03",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Levels of fair value hierarchy [axis]",
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r200"
     ]
    },
    "ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeSummaryofAssetsHeldforSaleorExchangeandLiabilitiesRelatedtoAssetsHeldforSaleorExchangeDetails",
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities related to assets held for sale or exchange",
        "label": "Liabilities included in disposal groups classified as held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r248"
     ]
    },
    "ifrs-full_LiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities [member]",
        "label": "Liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilityAssetOfDefinedBenefitPlans",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net amount shown in the balance sheet at end of period",
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "totalLabel": "Net amount shown in the balance sheet at end of period",
        "verboseLabel": "Net defined benefit liability (asset)",
        "label": "Net defined benefit liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "sny_LiabilityRecognisedForEstimatedFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LiabilityRecognisedForEstimatedFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Liability recognised for estimated future royalties",
        "label": "Liability Recognised For Estimated Future Royalties",
        "documentation": "Liability Recognised For Estimated Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "sny_LiabilityRecognizedRepresentingEstimatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LiabilityRecognizedRepresentingEstimatedCost",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability recognized representing the estimated cost",
        "label": "Liability Recognized Representing Estimated Cost",
        "documentation": "Liability recognized representing estimated cost."
       }
      }
     },
     "auth_ref": []
    },
    "sny_LitigationAmountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LitigationAmountPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation amount payable",
        "label": "Litigation Amount Payable",
        "documentation": "Litigation Amount Payable."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "sny_LongTermPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LongTermPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term prepaid expenses",
        "label": "Long Term Prepaid Expenses",
        "documentation": "Long term prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofChangesinFinancialPositionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Non-current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ifrs-full_LongtermBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LongtermBorrowingsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-term borrowings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r328",
      "r331"
     ]
    },
    "ifrs-full_LongtermRestructuringProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LongtermRestructuringProvision",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classified in non-current liabilities",
        "label": "Non-current restructuring provision"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provision for restructuring. [Refer: Restructuring provision]"
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "sny_LonzaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LonzaMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lonza",
        "label": "Lonza [member]",
        "documentation": "Lonza."
       }
      }
     },
     "auth_ref": []
    },
    "sny_LovenoxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LovenoxMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOVENOX",
        "label": "Lovenox [Member]",
        "documentation": "Lovenox."
       }
      }
     },
     "auth_ref": []
    },
    "sny_LumpSumRetirementBenefitPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "LumpSumRetirementBenefitPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lump-sum retirement benefit plans",
        "label": "Lump-sum Retirement Benefit Plans [Member]",
        "documentation": "Lump-sum retirement benefit plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MCMVaccineBVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MCMVaccineBVMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MCM Vaccine BV",
        "label": "MCM Vaccine BV [Member]",
        "documentation": "MCM Vaccine BV."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MSDContingentConsiderationEuropeanVaccinesBusinessMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MSD contingent consideration (European vaccines business)",
        "label": "MSD Contingent Consideration (European Vaccines Business) [Member]",
        "documentation": "MSD contingent consideration European vaccines business."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MSPVaccineCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MSPVaccineCompanyMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MSP Vaccine Company (formerly MCM company)",
        "label": "MSP Vaccine Company [Member]",
        "documentation": "MSP Vaccine Company"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MachineryAndEquipment1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MachineryAndEquipment1Member",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Machinery And Equipment1 [Member]",
        "documentation": "Machinery And Equipment1"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Main undrawn confirmed general purpose credit facilities",
        "label": "Main Undrawn Confirmed General Purpose Credit Facilities [member]",
        "documentation": "Main undrawn confirmed general purpose credit facilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorBusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorBusinessCombinationMember",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major business combination",
        "label": "Major business combination [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for major business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "sny_MajorCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MajorCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Collaboration Agreement",
        "label": "Major Collaboration Agreement [Member]",
        "documentation": "Major Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major customers [axis]",
        "label": "Major customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_MajorCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersMember",
     "presentation": [
      "http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customers [member]",
        "label": "Customers [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "sny_MajorTerritoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MajorTerritoriesMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major territories",
        "label": "Major Territories [Member]",
        "documentation": "Major Territories"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ManagedCareAndGPOProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ManagedCareAndGPOProgramsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Managed care and GPO Programs",
        "label": "Managed Care And GPO Programs [Member]",
        "documentation": "Managed Care And GPO Programs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ManagedCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ManagedCareMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Managed care",
        "label": "Managed Care [Member]",
        "documentation": "Managed care [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ManufactureAndSupplyCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ManufactureAndSupplyCollaborationAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacture and supply collaboration agreement",
        "label": "Manufacture And Supply Collaboration Agreement [Member]",
        "documentation": "Manufacture And Supply Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ManufacturingAndSupplyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ManufacturingAndSupplyMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing &amp; Supply",
        "label": "Manufacturing And Supply [Member]",
        "documentation": "Manufacturing And Supply"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MapharMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MapharMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maphar",
        "label": "Maphar [Member]",
        "documentation": "Maphar."
       }
      }
     },
     "auth_ref": []
    },
    "sny_March2018EMTNISINFR0013324340Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "March2018EMTNISINFR0013324340Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2018 EMTN ISIN FR0013324340",
        "label": "March 2018 EMTN ISIN FR0013324340 [Member]",
        "documentation": "March 2018 EMTN ISIN FR 0013324340."
       }
      }
     },
     "auth_ref": []
    },
    "sny_March2018EMTNISINFR0013324357Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "March2018EMTNISINFR0013324357Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2018 EMTN ISIN FR0013324357",
        "label": "March 2018 EMTN ISIN FR0013324357 [Member]",
        "documentation": "March 2018 EMTN ISIN FR 0013324357."
       }
      }
     },
     "auth_ref": []
    },
    "sny_March2018EMTNISINFR0013324373Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "March2018EMTNISINFR0013324373Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2018 EMTN ISIN FR0013324373",
        "label": "March 2018 EMTN ISIN FR0013324373 [Member]",
        "documentation": "March 2018 EMTN ISIN FR 0013324373."
       }
      }
     },
     "auth_ref": []
    },
    "sny_March2019EMTNISINFR0013409844Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "March2019EMTNISINFR0013409844Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2019 EMTN ISIN FR0013409844",
        "label": "March 2019 EMTN ISIN FR0013409844 [Member]",
        "documentation": "March 2019 EMTN ISIN FR0013409844 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_March2019EMTNISINFR0013409851Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "March2019EMTNISINFR0013409851Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2019 EMTN ISIN FR0013409851",
        "label": "March 2019 EMTN ISIN FR0013409851 [Member]",
        "documentation": "March 2019 EMTN ISIN FR0013409851 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_March2020EMTNISINFR0013505104Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "March2020EMTNISINFR0013505104Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2020 EMTN ISIN FR0013505104",
        "label": "March 2020 EMTNISINFR0013505104 [Member]",
        "documentation": "March 2020 EMTNISINFR0013505104"
       }
      }
     },
     "auth_ref": []
    },
    "sny_March2020EMTNISINFR0013505112Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "March2020EMTNISINFR0013505112Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2020 EMTN ISIN FR0013505112",
        "label": "March 2020 EMTNISINFR0013505112 [Member]",
        "documentation": "March 2020 EMTNISINFR0013505112"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketConditionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MarketConditionAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition [Axis]",
        "label": "Market Condition [Axis]",
        "documentation": "Market Condition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketConditionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MarketConditionDomain",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Condition [Domain]",
        "label": "Market Condition [Domain]",
        "documentation": "Market Condition [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MarketedProductsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketed products",
        "label": "Marketed Products [Member]",
        "documentation": "Marketed products."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MarketedProductsTrademarksAndOtherRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MarketedProductsTrademarksAndOtherRightsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products, trademarks and other rights",
        "label": "Marketed Products Trademarks And Other Rights [Member]",
        "documentation": "Marketed products trademarks and other rights."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material reconciling items",
        "label": "Material reconciling items [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for material adjustments used to reconcile items in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [axis]",
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r208",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r251",
      "r265",
      "r313",
      "r353"
     ]
    },
    "sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum additional funding for PD1 - part of each company",
        "label": "Maximum Additional Funding For Anti Programmed Cell Death Protein 1 Part Of Each Company",
        "documentation": "Maximum additional funding for anti programmed cell death protein 1 part of each company."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount to be reimbursed for current and future environmental expense",
        "label": "Maximum Amount To Be Reimbursed For Current And Future Environmental Expense",
        "documentation": "Maximum Amount To Be Reimbursed For Current And Future Environmental Expense"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MaximumOwnershipPercentageAllowedToAcquire": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MaximumOwnershipPercentageAllowedToAcquire",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum ownership percentage allowed to acquire",
        "label": "Maximum Ownership Percentage Allowed To Acquire",
        "documentation": "Maximum ownership percentage allowed to acquire."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum penalty amount sought by plaintiffs for each violation",
        "label": "Maximum Penalty Amount Sought By Plaintiffs For Each Violation",
        "documentation": "Maximum penalty amount sought by plaintiffs for each violation"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MaximumPlan1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MaximumPlan1Member",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum Plan 1",
        "label": "Maximum Plan 1 [Member]",
        "documentation": "Maximum Plan 1"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MaximumPlan2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MaximumPlan2Member",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum plan 2",
        "label": "Maximum Plan 2 [Member]",
        "documentation": "Maximum Plan 2"
       }
      }
     },
     "auth_ref": []
    },
    "sny_May252023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "May252023Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 25, 2023",
        "label": "May 25, 2023 [Member]",
        "documentation": "May 25, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_May32022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "May32022Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "May 3, 2022",
        "label": "May 3, 2022 [Member]",
        "documentation": "May 2, 2018 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement [axis]",
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r159",
      "r199"
     ]
    },
    "sny_MedicaidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MedicaidMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicaid",
        "label": "Medicaid [Member]",
        "documentation": "Medicaid [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MedicareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MedicareMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare",
        "label": "Medicare [Member]",
        "documentation": "Medicare [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MerieuxCanadaHoldingsULCCanadaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MerieuxCanadaHoldingsULCCanadaMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merieux Canada Holdings ULC (Canada)",
        "label": "Merieux Canada Holdings ULC (Canada) [Member]",
        "documentation": "Merieux Canada Holdings ULC (Canada)"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MilestoneTypesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MilestoneTypesAxis",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Types [Axis]",
        "label": "Milestone Types [Axis]",
        "documentation": "Milestone Types"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MilestoneTypesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MilestoneTypesDomain",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Types [Domain]",
        "label": "Milestone Types [Domain]",
        "documentation": "Milestone Types [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MinimumPlan1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MinimumPlan1Member",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum Plan 1",
        "label": "Minimum Plan 1 [Member]",
        "documentation": "Minimum Plan 1"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MinimumPlan2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MinimumPlan2Member",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum plan 2",
        "label": "Minimum Plan 2 [Member]",
        "documentation": "Minimum Plan 2"
       }
      }
     },
     "auth_ref": []
    },
    "sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum sales of PD1 in 12-month period to be achieved for milestone payment",
        "label": "Minimum Sales Of Anti Programmed Cell Death Protein 1 In Twelve Month Period To Be Achieved For Milestone Payment",
        "documentation": "Minimum sales of anti programmed cell death protein 1 in twelve month period to be achieved for milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MinusHundredBasisPointsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MinusHundredBasisPointsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "-100\u00a0bp",
        "label": "Minus Hundred Basis Points [Member]",
        "documentation": "Minus hundred basis points."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MinusTwentyFiveBasisPointsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MinusTwentyFiveBasisPointsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "-25\u00a0bp",
        "label": "Minus Twenty Five Basis Points [Member]",
        "documentation": "Minus twenty five basis points."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating expenses",
        "verboseLabel": "Other operating expenses",
        "terseLabel": "Other operating expense",
        "label": "Miscellaneous other operating expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income",
        "label": "Miscellaneous other operating income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_MiscellaneousOtherOperatingIncomeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MiscellaneousOtherOperatingIncomeExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income and expenses",
        "label": "Miscellaneous Other Operating Income (Expenses)",
        "documentation": "Other operating income and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherProvisionsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions",
        "label": "Miscellaneous other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for miscellaneous other provisions. [Refer: Other provisions [member]]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_MultiemployerDefinedBenefitPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MultiemployerDefinedBenefitPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multi-employer plan (Pensionskasses)",
        "label": "Multi-employer defined benefit plans [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for defined benefit plans (other than state plans) that: (a) pool the assets contributed by various entities that are not under common control; and (b) use those assets to provide benefits to employees of more than one entity, on the basis that contribution and benefit levels are determined without regard to the identity of the entity that employs the employees. [Refer: Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97"
     ]
    },
    "sny_MutualFundInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MutualFundInvestmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual fund investments",
        "label": "Mutual Fund Investments [Member]",
        "documentation": "Mutual fund investments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_MyozymeOrLumizymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "MyozymeOrLumizymeMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MYOZYME/ LUMIZYME",
        "label": "Myozyme Or Lumizyme [Member]",
        "documentation": "Myozyme or Lumizyme [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NKCellAndProXTenTechnologyPlatformsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NKCellAndProXTenTechnologyPlatformsMember",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NK Cell and ProXTen technology platforms",
        "label": "NK Cell And ProXTen Technology Platforms [Member]",
        "documentation": "NK Cell And ProXTen Technology Platforms"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetAmountsAsReportedInTheBalanceSheet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NetAmountsAsReportedInTheBalanceSheet",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails": {
       "parentTag": "sny_NetExposure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net amounts as reported in the balance sheet",
        "label": "Net Amounts As Reported In The Balance Sheet",
        "documentation": "Net amounts as reported in the balance sheet."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in other current assets and other current liabilities",
        "label": "Net Change In Other Current Assets And Other Current Liabilities",
        "documentation": "Adjustments for decrease (increase) in other current assets and increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetChangeInOtherNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NetChangeInOtherNonCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net change in other non-current assets",
        "label": "Net Change In Other Non-Current Assets",
        "documentation": "Net change in other non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetDefinedBenefitLiabilityAssetAxis",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability (asset) [axis]",
        "label": "Net defined benefit liability (asset) [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetDefinedBenefitLiabilityAssetMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net defined benefit liability (asset) [member]",
        "label": "Net defined benefit liability (asset) [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "sny_NetExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NetExposure",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofActualorPotentialEffectsofNettingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net exposure",
        "label": "Net Exposure",
        "documentation": "Net exposure"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetForeignExchangeLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net foreign exchange loss",
        "label": "Net foreign exchange loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r383",
      "r398"
     ]
    },
    "sny_NetInterestCostRelatedToEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NetInterestCostRelatedToEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net interest cost related to employee benefits",
        "label": "Net Interest Cost Related To Employee Benefits",
        "documentation": "Net interest cost related to employee benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net interest related to employee benefits, and unwinding of discount",
        "label": "Net Interest Related To Employees Benefits And Unwinding Of Discount",
        "documentation": "Net interest related to employees benefits and unwinding of discount."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNetPretaxActuarialLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net pre-tax actuarial loss",
        "label": "Net Pretax Actuarial Loss Excluding Associates And Joint Ventures Recognized Directly In Equity",
        "documentation": "Net pretax actuarial loss excluding associates and joint ventures recognized directly in equity."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NewAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NewAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New agreement",
        "label": "New Agreement [Member]",
        "documentation": "New Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NewBusinessModelRolloutInVariousGeographiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NewBusinessModelRolloutInVariousGeographiesMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New business model, rollout in various geographies",
        "label": "New Business Model, Rollout In Various Geographies [Member]",
        "documentation": "New Business Model, Rollout In Various Geographies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New transactions",
        "label": "New liabilities, contingent liabilities recognised in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised for new contingent liabilities recognised in a business combination. [Refer: Contingent liabilities recognised in business combination]"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "sny_NonCoreAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonCoreAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Core Assets",
        "label": "Non-Core Assets [Member]",
        "documentation": "Non-Core Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonCurrentAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current assets",
        "terseLabel": "Non-current",
        "label": "Non-Current Assets [Member]",
        "documentation": "Non-current assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonCurrentDerivativesMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current derivatives",
        "verboseLabel": "Non-current derivatives",
        "label": "Non-Current Derivatives [Member]",
        "documentation": "Non-current derivatives."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentFinanceLeaseReceivablesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonCurrentFinanceLeaseReceivablesGross",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current finance lease receivables, gross",
        "label": "Non-Current Finance Lease Receivables, Gross",
        "documentation": "Non-Current Finance Lease Receivables, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonCurrentLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current",
        "label": "Non-Current Liabilities [Member]",
        "documentation": "Non-current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities related to business combinations and to non-controlling interests",
        "label": "Non-Current Liabilities Related To Business Combinations And To Non-Controlling Interests",
        "documentation": "This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentProvisionForEnvironmentRisks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonCurrentProvisionForEnvironmentRisks",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails": {
       "parentTag": "ifrs-full_OtherLongtermProvisions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Environmental risks",
        "label": "Non-Current Provision For Environment Risks",
        "documentation": "Environment risks."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentProvisionForProductLiabilityRisksLitigationAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonCurrentProvisionForProductLiabilityRisksLitigationAndOther",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails": {
       "parentTag": "ifrs-full_OtherLongtermProvisions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product liability risks, litigation and other",
        "verboseLabel": "Provisions for product liability risks, litigation and other",
        "label": "Non-Current Provision For Product Liability Risks Litigation And Other",
        "documentation": "Product liability risks litigation and other."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonCurrentProvisionsAndOtherNonCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current provisions and other non-current liabilities",
        "totalLabel": "Total",
        "periodStartLabel": "Balance, beginning of period",
        "periodEndLabel": "Balance, end of period",
        "label": "Non-Current Provisions And Other Non-Current Liabilities",
        "documentation": "The amount of non-current provisions and non-current other liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonCurrentRestructuringProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonCurrentRestructuringProvisionMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring provisions",
        "label": "Non-Current Restructuring Provision [Member]",
        "documentation": "Restructuring provisions."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonINBRX101BusinessSpinCo.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonINBRX101BusinessSpinCo.Member",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-INBRX-101 business (Spin Co.)",
        "label": "Non-INBRX-101 Business (Spin Co.) [Member]",
        "documentation": "Non-INBRX-101 Business (Spin Co.)"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonOperatingForeignExchangeGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonOperatingForeignExchangeGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-operating foreign exchange gains/(losses)",
        "label": "Non-Operating Foreign Exchange Gains (Losses)",
        "documentation": "Non-operating foreign exchange gains/(losses)."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NonQualifiedDefinedBenefitPensionPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NonQualifiedDefinedBenefitPensionPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non qualified defined benefit pension plans",
        "label": "Non Qualified Defined Benefit Pension Plans [member]",
        "documentation": "Non qualified defined benefit pension plans."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_NonadjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsMember",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [member]",
        "label": "Non-adjusting events after reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity attributable to non-controlling interests",
        "terseLabel": "Attributable to non-controlling interests",
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r181",
      "r183"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to\u00a0non- controlling interests",
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r29",
      "r188",
      "r332"
     ]
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/AssetsheldforsaleorexchangeandliabilitiesrelatedtoassetsheldforsaleorexchangeSummaryofAssetsHeldforSaleorExchangeandLiabilitiesRelatedtoAssetsHeldforSaleorExchangeDetails",
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for sale or exchange",
        "label": "Non-current assets or disposal groups classified as held for sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange for financial assets held to meet obligations to employees under post-employment benefit plans",
        "label": "Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Financial instruments, class [member]; Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ifrs-full_NoncurrentDerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentDerivativeFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails": {
       "parentTag": "ifrs-full_DerivativeFinancialAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative financial instruments",
        "verboseLabel": "Non-current assets",
        "label": "Non-current derivative financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial assets. [Refer: Derivative financial assets]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ifrs-full_NoncurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails": {
       "parentTag": "ifrs-full_DerivativeFinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofFairValueofDerivativeInstrumentsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "negatedTerseLabel": "Non-current liabilities",
        "label": "Non-current derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ifrs-full_NoncurrentFinanceLeaseReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentFinanceLeaseReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current finance lease receivables",
        "label": "Non-current finance lease receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current finance lease receivables. [Refer: Finance lease receivables]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value through other comprehensive income",
        "label": "Non-current financial assets at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets at fair value through profit or loss",
        "label": "Non-current financial assets at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets measured at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current lease liabilities",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r189",
      "r332"
     ]
    },
    "ifrs-full_NoncurrentLoansAndReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLoansAndReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term loans and advances and other non-current receivables",
        "label": "Non-current loans and receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current loans and receivables. [Refer: Loans and receivables]"
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ifrs-full_NoncurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails": {
       "parentTag": "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "verboseLabel": "Obligations provided for",
        "label": "Non-current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails": {
       "parentTag": "sny_TotalUndiscountedCashFlow",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt",
        "label": "Non-derivative financial liabilities, undiscounted cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "North America",
        "label": "North America [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NotEligibleForHedgeAccountingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NotEligibleForHedgeAccountingMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not eligible for hedge accounting",
        "label": "Not Eligible For Hedge Accounting [Member]",
        "documentation": "Not eligible for hedge accounting."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneMonthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneMonthMember",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 1 month",
        "label": "Not later than one month [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one month."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r354",
      "r362"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMaximumAmountofContingentConsiderationPayableandFirmCommitmentstoBuyOutNonControllingInterestsDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFuturePaymentsinRespectofUnfundedPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Year 1",
        "terseLabel": "Less\u00a0than 1\u00a0year",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r216",
      "r217",
      "r221",
      "r353",
      "r362"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofFinancialCurrencyHedgingInstrumentsinPlacewithNotionalAmountTranslatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facilities, amount drawable",
        "verboseLabel": "Amount",
        "netLabel": "Notional amount of forward sales",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_NotionalRetirementAge": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NotionalRetirementAge",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional retirement age",
        "label": "Notional Retirement Age",
        "documentation": "Notional retirement age."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfActionDeclaredTimeBarred": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfActionDeclaredTimeBarred",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of action declared time-barred",
        "label": "Number Of Action Declared Time-Barred",
        "documentation": "Number Of Action Declared Time-Barred"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfAdministrativeProceedings": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfAdministrativeProceedings",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of administrative proceedings",
        "label": "Number Of Administrative Proceedings",
        "documentation": "Number Of Administrative Proceedings"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfAgreementsSigned": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfAgreementsSigned",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of agreements signed",
        "label": "Number Of Agreements Signed",
        "documentation": "Number Of Agreements Signed"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfBellweatherTrialsHeld": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfBellweatherTrialsHeld",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of bellweather trial held",
        "label": "Number Of Bellweather Trials Held",
        "documentation": "Number Of Bellweather Trials Held"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfBondIssuesRedeemed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfBondIssuesRedeemed",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of bond issues redeemed",
        "label": "Number Of Bond Issues Redeemed",
        "documentation": "Number Of Bond Issues Redeemed"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCancersAssociatedWithDismissedCases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfCancersAssociatedWithDismissedCases",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of cancers associated with dismissed cases",
        "label": "Number Of Cancers Associated With Dismissed Cases",
        "documentation": "Number Of Cancers Associated With Dismissed Cases"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfCases",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of cases",
        "label": "Number Of Cases",
        "documentation": "Number Of Cases"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCivilClaimsOnGoing": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfCivilClaimsOnGoing",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of civil claims on-going",
        "label": "Number Of Civil Claims On-Going",
        "documentation": "Number Of Civil Claims On-Going"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCivilIndividualActions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfCivilIndividualActions",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of civil individual actions",
        "label": "Number Of Civil Individual Actions",
        "documentation": "Number Of Civil Individual Actions"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfClaimant": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfClaimant",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of claimant",
        "label": "Number Of Claimant",
        "documentation": "Number Of Claimant"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfClaimantExposed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfClaimantExposed",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of claimant exposed",
        "label": "Number Of Claimant Exposed",
        "documentation": "Number Of Claimant Exposed"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfClaimantExposedWhoWithdrawedTheClaim": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfClaimantExposedWhoWithdrawedTheClaim",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of claimant exposed who withdrawed their claim",
        "label": "Number Of Claimant Exposed Who Withdrawed The Claim",
        "documentation": "Number Of Claimant Exposed Who Withdrawed The Claim"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfClassActionLawsuits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfClassActionLawsuits",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of class actions",
        "label": "Number Of Class Action Lawsuits",
        "documentation": "Number Of Class Action Lawsuits"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCommercialPaperPrograms": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfCommercialPaperPrograms",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of commercial paper programs",
        "label": "Number Of Commercial Paper Programs",
        "documentation": "Number Of Commercial Paper Programs"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfComplaintsFiled": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfComplaintsFiled",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of complaints filed",
        "label": "Number Of Complaints Filed",
        "documentation": "Number Of Complaints Filed"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCounterExpertiseExperts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfCounterExpertiseExperts",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of experts",
        "label": "Number Of Counter-Expertise Experts",
        "documentation": "Number Of Counter-Expertise Experts"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCountriesIncludedInPensionPlans": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfCountriesIncludedInPensionPlans",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of major countries included in pension obligations",
        "label": "Number Of Countries Included In Pension Plans",
        "documentation": "Number of countries included in pension plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCreditFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfCreditFacilities",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of credit facilities",
        "label": "Number Of Credit Facilities",
        "documentation": "Number Of Credit Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfCurrenciesDebtIsIssuedIn": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfCurrenciesDebtIsIssuedIn",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of currencies debt is issued in",
        "label": "Number Of Currencies Debt Is Issued In",
        "documentation": "Number Of Currencies Debt Is Issued In"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfDefinedBenefitPlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfDefinedBenefitPlans",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of types of defined-benefit plan",
        "label": "Number Of Defined Benefit Plans",
        "documentation": "Number of defined benefit plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfDrugTargetsUnderCollaborationAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfDrugTargetsUnderCollaborationAgreement",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of drug targets under collaboration agreement",
        "label": "Number Of Drug Targets Under Collaboration Agreement",
        "documentation": "Number Of Drug Targets Under Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfEmployees",
     "presentation": [
      "http://www.sanofi.com/role/PersonnelcostsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Number of employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of personnel employed by the entity at a date."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_NumberOfExecutiveCommitteeMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfExecutiveCommitteeMembers",
     "presentation": [
      "http://www.sanofi.com/role/RelatedpartytransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average number of members of executive committee",
        "label": "Number Of Executive Committee Members",
        "documentation": "Number of executive committee members."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfFamiliesWhoFiledACivilClaim": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfFamiliesWhoFiledACivilClaim",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of families who filed a civil claim",
        "label": "Number Of Families Who Filed A Civil Claim",
        "documentation": "Number Of Families Who Filed A Civil Claim"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfFirstInstanceRulings": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfFirstInstanceRulings",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of first instance rulings",
        "label": "Number Of First Instance Rulings",
        "documentation": "Number Of First Instance Rulings"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of immunology or inflammation targets under collaboration agreement",
        "label": "Number Of Immunology Or Inflammation Targets Under Collaboration Agreement",
        "documentation": "Number Of Immunology Or Inflammation Targets Under Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfIndirectVictimWhoWithdrawedTheClaim": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfIndirectVictimWhoWithdrawedTheClaim",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of indirect victim who withdrawed their claim",
        "label": "Number Of Indirect Victim Who Withdrawed The Claim",
        "documentation": "Number Of Indirect Victim Who Withdrawed The Claim"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfIndividualCasesSettled": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfIndividualCasesSettled",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of individual cases settled",
        "label": "Number Of Individual Cases Settled",
        "documentation": "Number Of Individual Cases Settled"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options granted (in shares)",
        "label": "Number of instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of instruments granted in share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "sny_NumberOfLawsuitsRuledOnMerit": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfLawsuitsRuledOnMerit",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of lawsuits ruled on merits",
        "label": "Number Of Lawsuits Ruled On Merit",
        "documentation": "Number Of Lawsuits Ruled On Merit"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfLeaseAgreementsSigned": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfLeaseAgreementsSigned",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of lease agreements signed",
        "label": "Number Of Lease Agreements Signed",
        "documentation": "Number Of Lease Agreements Signed"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of manufacturers with marketing authorization for generic version of drug",
        "label": "Number Of Manufacturers With Marketing Authorization For Generic Version Of Drug",
        "documentation": "Number Of Manufacturers With Marketing Authorization For Generic Version Of Drug"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of novel small molecule candidates developed",
        "label": "Number Of Novel Small Molecule Candidates To Be Developed Under Collaboration Agreement",
        "documentation": "Number Of Novel Small Molecule Candidates To Be Developed Under Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfOncologyTargetsUnderCollaborationAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfOncologyTargetsUnderCollaborationAgreement",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of oncology targets under collaboration agreement",
        "label": "Number Of Oncology Targets Under Collaboration Agreement",
        "documentation": "Number Of Oncology Targets Under Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfOngoingLawsuits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfOngoingLawsuits",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ongoing lawsuits",
        "label": "Number Of Ongoing Lawsuits",
        "documentation": "Number Of Ongoing Lawsuits"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfOngoingTrials": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfOngoingTrials",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ongoing trials",
        "label": "Number Of Ongoing Trials",
        "documentation": "Number Of Ongoing Trials"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfOperatingSegments1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfOperatingSegments1",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/SegmentinformationAdditionalInformationDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number Of Operating Segments1",
        "documentation": "Number of operating segments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfOtherManufacturersInvolvedInProceedings": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfOtherManufacturersInvolvedInProceedings",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other manufacturers involved in proceedings",
        "label": "Number Of Other Manufacturers Involved In Proceedings",
        "documentation": "Number Of Other Manufacturers Involved In Proceedings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options outstanding (in shares)",
        "verboseLabel": "Outstanding, Number\u00a0of options (in shares)",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r227",
      "r230"
     ]
    },
    "sny_NumberOfPatentActionsInitiallyFiled": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfPatentActionsInitiallyFiled",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of patent actions initially filed",
        "label": "Number Of Patent Actions Initially Filed",
        "documentation": "Number of patent actions initially filed ."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfPatentsAllegedlyInfringed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfPatentsAllegedlyInfringed",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of patents allegedly infringed",
        "label": "Number Of Patents Allegedly Infringed",
        "documentation": "Number of patents allegedly infringed."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfPatentsCoveringProduct": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfPatentsCoveringProduct",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of patents covering product",
        "label": "Number Of Patents Covering Product",
        "documentation": "Number Of Patents Covering Product"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfPatientsToIndemnify": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfPatientsToIndemnify",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of patients to indemnify",
        "label": "Number Of Patients To Indemnify",
        "documentation": "Number Of Patients To Indemnify"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfPayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfPayments",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of payments",
        "label": "Number Of Payments",
        "documentation": "Number Of Payments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfPeopleExposed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfPeopleExposed",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of people exposed",
        "label": "Number Of People Exposed",
        "documentation": "Number Of People Exposed"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfPlaintiffs": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfPlaintiffs",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of plaintiffs",
        "label": "Number Of Plaintiffs",
        "documentation": "Number Of Plaintiffs."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfPlaintiffsWhoFiledNoticesToAppeal": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfPlaintiffsWhoFiledNoticesToAppeal",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of plaintiffs who filed notices to appeal",
        "label": "Number Of Plaintiffs Who Filed Notices To Appeal",
        "documentation": "Number Of Plaintiffs Who Filed Notices To Appeal"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfPreActionProtocolCases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfPreActionProtocolCases",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of pre-action protocol cases",
        "label": "Number Of Pre-Action Protocol Cases",
        "documentation": "Number Of Pre-Action Protocol Cases"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital increase by issuance of restricted shares (in shares)",
        "label": "Number Of Restricted Shares Issued In Regards Of Capital Increase",
        "documentation": "Number of restricted shares issued in regards of capital increase."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfRestrictedSharesNotYetFullyVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfRestrictedSharesNotYetFullyVested",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares not yet fully vested (in shares)",
        "label": "Number Of Restricted Shares Not Yet Fully Vested",
        "documentation": "Number of restricted shares not yet fully vested."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital increase reserved for employees (in shares)",
        "label": "Number Of Share Issues In Regards To Capital increase Reserved For Employees",
        "documentation": "Number Of Share Issues In Regards To Capital increase Reserved For Employees"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfShareOptionsCancelledInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfShareOptionsCancelledInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, options cancelled (in shares)",
        "label": "Number Of Share Options Cancelled In Share-Based Payment Arrangement",
        "documentation": "Number Of Share Options Cancelled In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of options, options exercisable (in shares)",
        "terseLabel": "Exercisable, number of options (in shares)",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, options exercised (in shares)",
        "label": "Number of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, options forfeited (in shares)",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Total number of shares awarded (in shares)",
        "terseLabel": "Number of options granted (in shares)",
        "label": "Number of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "sny_NumberOfShareOutstandingInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfShareOutstandingInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, beginning balance (in shares)",
        "periodEndLabel": "Number of options, ending balance (in shares)",
        "label": "Number Of Share Outstanding In Share Based Payment Arrangement",
        "documentation": "Number of share outstanding in share based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfShareSubscribed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfShareSubscribed",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares subscribed (in shares)",
        "label": "Number Of Share Subscribed",
        "documentation": "Number of shares subscribed."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfSharesHeld": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfSharesHeld",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "label": "Number Of Shares Held",
        "documentation": "Number of shares held."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "sny_NumberOfSharesIssuedByExerciceOfEachOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfSharesIssuedByExerciceOfEachOption",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued by exercice of each option (in shares)",
        "label": "Number Of Shares Issued By Exercice Of Each Option",
        "documentation": "Number Of Shares Issued By Exercice Of Each Option"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital\u00a0increase\u00a0by\u00a0exercise\u00a0of stock subscription options (in shares)",
        "label": "Number Of Shares Issued In Regards Of Capital Increase By Exercise Of Stock Subscription Options",
        "documentation": "Number of shares issued in regards of capital increase by exercise of stock subscription options."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfSharesRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfSharesRepurchased",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "label": "Number Of Shares Repurchased",
        "documentation": "Number of shares repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfSustainableDevelopmentPerformanceIndicators": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfSustainableDevelopmentPerformanceIndicators",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of sustainable development performance indicators",
        "label": "Number Of Sustainable Development Performance Indicators",
        "documentation": "Number Of Sustainable Development Performance Indicators"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfTherapeuticTargetsUnderCollaborationAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfTherapeuticTargetsUnderCollaborationAgreement",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of therapeutic targets under collaboration agreement",
        "label": "Number Of Therapeutic Targets Under Collaboration Agreement",
        "documentation": "Number Of Therapeutic Targets Under Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfTradingDaysPrecedingPlanApproval": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfTradingDaysPrecedingPlanApproval",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of trading days preceding plan approval",
        "label": "Number Of Trading Days Preceding Plan Approval",
        "documentation": "Number Of Trading Days Preceding Plan Approval"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfVaccineDosesToBeSupplied": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfVaccineDosesToBeSupplied",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of vaccine doses to be supplied",
        "label": "Number Of Vaccine Doses To Be Supplied",
        "documentation": "Number Of Vaccine Doses To Be Supplied"
       }
      }
     },
     "auth_ref": []
    },
    "sny_NumberOfYearsServicePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "NumberOfYearsServicePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service period",
        "label": "Number Of Years, Service Period",
        "documentation": "Number Of Years, Service Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments received in respect of disposals proceeds receivable and contingent consideration on divestments",
        "label": "Off-Balance Sheet Commitments Received In Respect Of Disposals Proceeds Receivable And Contingent Consideration On Divestments",
        "documentation": "Off-Balance Sheet Commitments Received In Respect Of Disposals Proceeds Receivable And Contingent Consideration On Divestments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OfficeSpaceCambridgeMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OfficeSpaceCambridgeMassachusettsMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office space, Cambridge, Massachusetts",
        "label": "Office Space, Cambridge, Massachusetts [Member]",
        "documentation": "Office Space, Cambridge, Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OneBillionBondsMaturingJune2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OneBillionBondsMaturingJune2023Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,000 million bonds maturing June 2023",
        "label": "One Billion Bonds Maturing June 2023 [Member]",
        "documentation": "One Billion Bonds Maturing June 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OneBillionBondsMaturingNovember2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OneBillionBondsMaturingNovember2023Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u20ac1,000 million bonds maturing November 2023",
        "label": "One Billion Bonds Maturing November 2023 [Member]",
        "documentation": "One Billion Bonds Maturing November 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u20ac1,750 million bonds maturing March 2023",
        "label": "One Billion Seven Hundred Fifty Million Bonds Maturing March 2023 [Member]",
        "documentation": "One Billion Seven Hundred Fifty Million Bonds Maturing March 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareBrazilLtdaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareBrazilLtdaMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare Brazil Ltda.",
        "label": "Opella Healthcare Brazil Ltda. [Member]",
        "documentation": "Opella Healthcare Brazil Ltda."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareCzechSroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareCzechSroMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare Czech s.r.o",
        "label": "Opella Healthcare Czech s.r.o [Member]",
        "documentation": "Opella Healthcare Czech s.r.o"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareFranceSASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareFranceSASMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare France SAS",
        "label": "Opella Healthcare France SAS [Member]",
        "documentation": "Opella Healthcare France SAS"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareGroupSASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareGroupSASMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare Group SAS",
        "label": "Opella Healthcare Group SAS [Member]",
        "documentation": "Opella Healthcare Group SAS"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareHungaryCommercialKFTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareHungaryCommercialKFTMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare Hungary Commercial K.F.T",
        "label": "Opella Healthcare Hungary Commercial K.F.T [Member]",
        "documentation": "Opella Healthcare Hungary Commercial K.F.T"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareHungaryKFTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareHungaryKFTMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare Hungary K.F.T",
        "label": "Opella Healthcare Hungary K.F.T [Member]",
        "documentation": "Opella Healthcare Hungary K.F.T"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareInternationalSASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareInternationalSASMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare International SAS",
        "label": "Opella Healthcare International SAS [Member]",
        "documentation": "Opella Healthcare International SAS"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareItalySRLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareItalySRLMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare Italy SRL",
        "label": "Opella Healthcare Italy S.R.L. [Member]",
        "documentation": "Opella Healthcare Italy S.R.L."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareKoreaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareKoreaIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella healthcare Korea Inc.",
        "label": "Opella Healthcare Korea Inc. [Member]",
        "documentation": "Opella Healthcare Korea Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareLLCMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare LLC",
        "label": "Opella Healthcare LLC [Member]",
        "documentation": "Opella Healthcare LLC"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcarePanamaSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcarePanamaSAMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare Panama SA",
        "label": "Opella Healthcare Panama S.A. [Member]",
        "documentation": "Opella Healthcare Panama S.A."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcarePhilippinesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcarePhilippinesIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare Philippines Inc.",
        "label": "Opella Healthcare Philippines Inc. [Member]",
        "documentation": "Opella Healthcare Philippines Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcarePolandSpZOOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcarePolandSpZOOMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare Poland sp.z.o.o.",
        "label": "Opella Healthcare Poland sp.Z.O.O [Member]",
        "documentation": "Opella Healthcare Poland sp.Z.O.O"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareRomaniaSRLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareRomaniaSRLMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare Romania SRL",
        "label": "Opella Healthcare Romania S.R.L. [Member]",
        "documentation": "Opella Healthcare Romania S.R.L."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareSpainSLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareSpainSLMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare Spain, SL",
        "label": "Opella Healthcare Spain, S.L. [Member]",
        "documentation": "Opella Healthcare Spain, S.L."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareTuketiciSalAnonimSirketiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareTuketiciSalAnonimSirketiMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare T\u00fcketici Sa\u011fl\u0131\u011f\u0131 Anonim \u015eirketi",
        "label": "Opella Healthcare T\u00fcketici Sa\u011fl\u0131\u011f\u0131 Anonim \u015eirketi [Member]",
        "documentation": "Opella Healthcare T\u00fcketici Sa\u011fl\u0131\u011f\u0131 Anonim \u015eirketi"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OpellaHealthcareUKLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OpellaHealthcareUKLimitedMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opella Healthcare UK Limited",
        "label": "Opella Healthcare UK Limited [Member]",
        "documentation": "Opella Healthcare UK Limited"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opening balance before adjustment, cumulative effect at date of initial application [member]",
        "label": "Opening balance before adjustment, cumulative effect at date of initial application [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member indicates the opening balance before the cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. It also represents the standard value for the \u2018Cumulative effect at date of initial application\u2019 axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "sny_OperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments [Abstract]",
        "label": "Operating Segments [Abstract]",
        "documentation": "Operating Segments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating segments",
        "label": "Operating segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for operating segments. An operating segment is a component of an entity: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity); (b) whose operating results are regularly reviewed by the entity\u2019s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and (c) for which discrete financial information is available. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "sny_OptionVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OptionVestingPeriod",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option vesting period (in years)",
        "label": "Option Vesting Period",
        "documentation": "Option vesting period."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OrdinarySharesNASDAQGlobalSelectMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OrdinarySharesNASDAQGlobalSelectMarketMember",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value \u20ac2\u00a0per share",
        "label": "Ordinary Shares, NASDAQ Global Select Market [Member]",
        "documentation": "Ordinary Shares, NASDAQ Global Select Market [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OrigimmBiotechnologyGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OrigimmBiotechnologyGmbHMember",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Origimm Biotechnology GmbH",
        "label": "Origimm Biotechnology GmbH [Member]",
        "documentation": "Origimm Biotechnology GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAdjustmentsForNoncashItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAdjustmentsForNoncashItems",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other items",
        "label": "Other adjustments for non-cash items"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAdjustmentsToReconcileProfitLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other profit or loss items with no cash effect on cash flows generated by operating activities",
        "label": "Other adjustments to reconcile profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "sny_OtherBankBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherBankBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other bank borrowings",
        "label": "Other Bank Borrowings",
        "documentation": "Other bank borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other borrowings",
        "label": "Other borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income for the period, net of taxes",
        "terseLabel": "Other comprehensive income for\u00a0the\u00a0period",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r37",
      "r47",
      "r191"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income:",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income before tax",
        "label": "Other comprehensive income, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, before tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Items subsequently reclassifiable to profit or loss",
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Items not subsequently reclassifiable to profit or loss",
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304"
     ]
    },
    "sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherContingentConsiderationArisingFromBusinessCombinationsMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other contingent consideration arising from business combinations and acquisitions",
        "label": "Other Contingent Consideration Arising From Business Combinations [Member]",
        "documentation": "Other contingent consideration arising from business combinations."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherCountriesInSegmentResultsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherCountriesInSegmentResultsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other countries",
        "label": "Other Countries In Segment Results [Member]",
        "documentation": "Other countries in segement results."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherCountriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherCountriesMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTimingofFutureTerminationBenefitPaymentsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "verboseLabel": "Other countries",
        "label": "Other Countries [member]",
        "documentation": "Other countries."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherCurrenciesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherCurrenciesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other currencies",
        "label": "Other Currencies [Member]",
        "documentation": "Other Currencies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/OthercurrentassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/OthercurrentassetsDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "totalLabel": "Total",
        "label": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "sny_OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current and non-current assets and liabilities",
        "label": "Other Current Assets And Current Liabilities As Of Acquisition Date",
        "documentation": "Other assets and liabilities as of acquisition date."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthercurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current financial assets",
        "label": "Other current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sny_CurrentProvisionsAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OthercurrentassetsDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OthercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "sny_OtherDeductionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherDeductionsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other deductions",
        "label": "Other Deductions [Member]",
        "documentation": "Other deductions."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherEmployeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherEmployeeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other employee expense",
        "label": "Other employee expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "ifrs-full_OtherEnvironmentRelatedProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherEnvironmentRelatedProvisionMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other environment related provision",
        "label": "Other environment related provision [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an environment-related provision that the entity does not separately disclose in the same statement or note. [Refer: Other provisions [member]]"
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "ifrs-full_OtherFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails_1": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/FinancialexpensesandincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "sny_OtherGainsLossesAndLitigation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherGainsLossesAndLitigation",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/OthergainsandlossesandlitigationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other gains and losses, and litigation",
        "terseLabel": "Other gains, (losses) and litigation",
        "negatedTerseLabel": "Other gains, (losses) and litigation",
        "label": "Other Gains, (Losses) And Litigation",
        "documentation": "The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherGuaranteesGivenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherGuaranteesGivenMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofAmountofGuaranteesGivenandReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other guarantees given",
        "label": "Other Guarantees Given [Member]",
        "documentation": "Other Guarantees Given"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other cash flows",
        "label": "Other inflows (outflows) of cash, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_OtherIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Other intangible assets, beginning balance",
        "periodEndLabel": "Other intangible assets, ending balance",
        "label": "Other intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "sny_OtherIntangibleAssetsExcludingSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherIntangibleAssetsExcludingSoftwareMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets excluding software",
        "label": "Other Intangible Assets Excluding Software [Member]",
        "documentation": "Other Intangible Assets Excluding Software"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "label": "Other intangible assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "sny_OtherLiabilities1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherLiabilities1Member",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities1 [Member]",
        "documentation": "Other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherLongtermProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherLongtermProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofOtherProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Other non-current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "sny_OtherNonCoreAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherNonCoreAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-core assets",
        "label": "Other Non-Core Assets [Member]",
        "documentation": "Other Non-Core Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails": {
       "parentTag": "sny_NonCurrentProvisionsAndOtherNonCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "sny_OtherOperatingExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherOperatingExpensesTableTextBlock",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Other Operating Expenses",
        "label": "Other Operating Expenses [Table Text Block]",
        "documentation": "Other Operating Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherOperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails": {
       "parentTag": "sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income/(expenses), net related to Regeneron",
        "negatedLabel": "Other operating (income)/expenses, net",
        "label": "Other operating income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "sny_OtherOperatingIncomeExpense1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherOperatingIncomeExpense1Member",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income (expense)",
        "label": "Other Operating Income (Expense)1 [Member]",
        "documentation": "Other Operating Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OtherProductAndServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherProductAndServicesMember",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Product And Services [Member]",
        "documentation": "Other Product And Services"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "ifrs-full_OtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions",
        "label": "Other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r31",
      "r136"
     ]
    },
    "sny_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]",
        "label": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]",
        "documentation": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisionsMember",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions [member]",
        "label": "Other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_OtherRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherRelatedPartiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other related parties",
        "label": "Other related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "sny_OtherRestructuringCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherRestructuringCost",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails": {
       "parentTag": "ifrs-full_ExpenseOfRestructuringActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/RestructuringcostsandsimilaritemsSummaryofRestructuringCostsandSimilarItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Restructuring Cost",
        "documentation": "Other restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "sny_OtherRevenuePerformanceObligationNoLongerRequired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherRevenuePerformanceObligationNoLongerRequired",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue, doses no longer an obligation to be delivered",
        "label": "Other Revenue, Performance Obligation No Longer Required",
        "documentation": "Other Revenue, Performance Obligation No Longer Required"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other items",
        "label": "Other tax rate effects for reconciliation between accounting profit and tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_OtherTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherTemporaryDifferencesMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other temporary differences [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences that the entity does not separately disclose in the same statement or note. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "sny_OtherTerritoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OtherTerritoriesMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other territories",
        "label": "Other Territories [Member]",
        "documentation": "Other Territories"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OthersCounterpartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OthersCounterpartyMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Others Counterparty [Member]",
        "documentation": "Others Counterparty [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_OutsideUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OutsideUnitedStatesMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outside the United States",
        "label": "Outside United States [member]",
        "documentation": "Outside United States."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OverdueReceivablesGrossValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OverdueReceivablesGrossValue",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/AccountsreceivableAdditionalInformationDetails",
      "http://www.sanofi.com/role/AccountsreceivableSummaryofGrossValueofOverdueReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross value of overdue receivables",
        "verboseLabel": "Overdue receivables gross value",
        "label": "Overdue Receivables Gross Value",
        "documentation": "Overdue receivables gross value."
       }
      }
     },
     "auth_ref": []
    },
    "sny_OwnershipInterestInSubsidiaryMinimumHoldingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "OwnershipInterestInSubsidiaryMinimumHoldingPeriod",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest in subsidiary, minimum holding period",
        "label": "Ownership Interest In Subsidiary, Minimum Holding Period",
        "documentation": "Ownership Interest In Subsidiary, Minimum Holding Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PainCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PainCareMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pain Care",
        "label": "Pain Care [Member]",
        "documentation": "Pain Care [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value per share (in euros per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "sny_ParticipatingSharesCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ParticipatingSharesCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Participating shares carrying amount",
        "label": "Participating Shares Carrying Amount",
        "documentation": "Participating shares carrying amount."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ParticipatingSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ParticipatingSharesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1983 to 1987 participating shares issued",
        "label": "Participating Shares [Member]",
        "documentation": "Participating shares."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ParticipatingSharesNumberOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ParticipatingSharesNumberOutstanding",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of participating shares outstanding (in shares)",
        "label": "Participating Shares Number Outstanding",
        "documentation": "Participating shares number outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sny_Patents1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "Patents1Member",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents1 [Member]",
        "documentation": "Patents."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PaymentOfDamagesClaimedByCounterparty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PaymentOfDamagesClaimedByCounterparty",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of damages claimed by the French CNAM (French Social Security)",
        "label": "Payment Of Damages Claimed By Counterparty",
        "documentation": "Payment Of Damages Claimed By Counterparty"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PaymentRelatedToAttainmentOfGoal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PaymentRelatedToAttainmentOfGoal",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment related to attainment of goal",
        "label": "Payment Related To Attainment Of Goal",
        "documentation": "Payment Related To Attainment Of Goal"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsFromChangesInOwnershipInterestsInSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments received/(made) on changes of ownership interest in a subsidiary without loss of control",
        "label": "Payments from changes in ownership interests in subsidiaries that do not result in loss of control"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171"
     ]
    },
    "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits paid",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of lease liabilities",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsToAcquireOrRedeemEntitysShares",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions of treasury shares",
        "label": "Payments to acquire or redeem entity's shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire or redeem entity's shares."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "sny_PenaltyFeeIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PenaltyFeeIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penalty fee incurred by Sanofi",
        "label": "Penalty Fee Incurred",
        "documentation": "Penalty Fee Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PensionObligationPercentageToDefinedBenefitLiability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PensionObligationPercentageToDefinedBenefitLiability",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension obligation, percentage to defined benefit liability",
        "label": "Pension Obligation, Percentage To Defined Benefit Liability",
        "documentation": "Pension obligation percentage to defined benefit liability."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PensionObligationPercentageToPlanAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PensionObligationPercentageToPlanAssets",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension obligations, percentage to plan assets",
        "label": "Pension Obligation, Percentage To Plan Assets",
        "documentation": "Pension obligation percentage to plan assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PensionsAndOtherPostEmploymentBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PensionsAndOtherPostEmploymentBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pensions and other post-employment benefits",
        "label": "Pensions And Other Post-Employment Benefits [Member]",
        "documentation": "Pensions and other post-employment benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageContributedToFairValueOfPlanAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageContributedToFairValueOfPlanAssets",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Percentage Contributed To Fair Value Of Plan Assets",
        "documentation": "Percentage contributed to fair value of plan assets."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageContributedToFairValueOfPlanAssetsOtherSecurities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageContributedToFairValueOfPlanAssetsOtherSecurities",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails": {
       "parentTag": "sny_PercentageContributedToFairValueOfPlanAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other securities",
        "label": "Percentage Contributed To Fair Value Of Plan Assets, Other Securities",
        "documentation": "Percentage Contributed To Fair Value Of Plan Assets, Other Securities"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails": {
       "parentTag": "sny_PercentageContributedToFairValueOfPlanAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities quoted in an active market",
        "label": "Percentage Contributed To Fair Value Of Plan Assets, Securities Quoted In An Active Market",
        "documentation": "Percentage Contributed To Fair Value Of Plan Assets, Securities Quoted In An Active Market"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageIncreaseInFairValueLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageIncreaseInFairValueLiabilities",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in fair value of liability",
        "label": "Percentage Increase In Fair Value Liabilities",
        "documentation": "Percentage increase in fair value liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfAuditorRemunerationForStatutoryAudit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfAuditorRemunerationForStatutoryAudit",
     "calculation": {
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails": {
       "parentTag": "sny_PercentageOfAuditorsRemuneration",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory audit of separate and consolidated financial statements, percentage",
        "label": "Percentage Of Auditor Remuneration For Statutory Audit",
        "documentation": "Percentage of auditor remuneration for statutory audit."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfAuditorsRemuneration": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfAuditorsRemuneration",
     "calculation": {
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, percentage",
        "label": "Percentage Of Auditors Remuneration",
        "documentation": "Auditor's remuneration, Total Percentage."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements",
     "calculation": {
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails": {
       "parentTag": "sny_PercentageOfAuditorsRemuneration",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services other than statutory audit, percentage",
        "label": "Percentage Of Auditors Remuneration For Services Other Than Audit Of Financial Statements",
        "documentation": "Services other than audit of financial statements, percentage."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfAverageOfQuotedMarketPricesOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfAverageOfQuotedMarketPricesOfShares",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Subscription price (as a percent)",
        "label": "Percentage Of Average Of Quoted Market Prices Of Shares",
        "documentation": "Percentage of average of quoted market prices of shares."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfCumulativeDevelopmentCostsReimbursed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfCumulativeDevelopmentCostsReimbursed",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of cumulative development costs reimbursed",
        "label": "Percentage Of Cumulative Development Costs Reimbursed",
        "documentation": "Percentage of cumulative development costs reimbursed."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfDevelopmentCostsArisingFromCommercialOperations",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of development costs arising from commercial operations",
        "label": "Percentage Of Development Costs Arising From Commercial Operations",
        "documentation": "Percentage Of Development Costs Arising From Commercial Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Percentage Of Discount Rate Above Rate Actually Used Would Not Cause Impairment Loss",
        "documentation": "Percentage of discount rate above rate actually used would not cause impairment loss."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfEntitysRevenue",
     "presentation": [
      "http://www.sanofi.com/role/DisclosuresaboutmajorcustomersandcreditriskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of entity's revenue (in percent)",
        "label": "Percentage of entity's revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of the entity's revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "sny_PercentageOfFutureDevelopmentExpenseFundedByCompany": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfFutureDevelopmentExpenseFundedByCompany",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of future development expense funded by company",
        "label": "Percentage Of Future Development Expense Funded By Company",
        "documentation": "Percentage of future development expense funded by company."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfFutureDevelopmentExpenseFundedByOtherParty",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of future development expense funded by other party",
        "label": "Percentage Of Future Development Expense Funded By Other Party",
        "documentation": "Percentage of future development expense funded by other party."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfLossesArisingFromCommercialOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfLossesArisingFromCommercialOperations",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of losses arising from commercial operations",
        "label": "Percentage Of Losses Arising From Commercial Operations",
        "documentation": "Percentage Of Losses Arising From Commercial Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfNetSalesArisingFromCommercialOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfNetSalesArisingFromCommercialOperations",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net sales arising from commercial operations",
        "label": "Percentage Of Net Sales Arising From Commercial Operations",
        "documentation": "Percentage Of Net Sales Arising From Commercial Operations"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating margin rate",
        "label": "Percentage Of Operating Margin Rate Below Rates Actually Used Would Not Cause Impairment Loss",
        "documentation": "Percentage of operating margin rate below rates actually used would not cause impairment loss."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Perpetual growth rate",
        "label": "Percentage Of Perpetuity Growth Rate Below The Rates Actually Used Would Not Cause Impairment Loss",
        "documentation": "Percentage of perpetuity growth rate below the rates actually used would not cause impairment loss."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfProfitShareOnCounterpartiesProfit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfProfitShareOnCounterpartiesProfit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)",
        "label": "Percentage Of Profit Share On Counterparties Profit",
        "documentation": "Percentage of profit share on counter parties profit."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfProfitsAndLossesArisingFromCommercialOperations",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of profits and losses arising from commercial operations",
        "label": "Percentage Of Profits And Losses Arising From Commercial Operations",
        "documentation": "Percentage of profits and losses arising from commercial operations."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfProfitsArisingFromCommercialOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfProfitsArisingFromCommercialOperations",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of profits arising from commercial operations",
        "label": "Percentage Of Profits Arising From Commercial Operations",
        "documentation": "Percentage Of Profits Arising From Commercial Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleDecreaseInActuarialAssumption",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Possible decrease in actuarial assumption",
        "label": "Percentage of reasonably possible decrease in actuarial assumption"
       }
      },
      "en": {
       "role": {
        "documentation": "The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInActuarialAssumption",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Possible increase in actuarial assumption",
        "label": "Percentage of reasonably possible increase in actuarial assumption"
       }
      },
      "en": {
       "role": {
        "documentation": "The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "sny_PercentageOfSecondPartOfDevelopmentCostsFunded": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfSecondPartOfDevelopmentCostsFunded",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase III costs, responsibility percentage",
        "label": "Percentage Of Second Part Of Development Costs Funded",
        "documentation": "Percentage Of Second Part Of Development Costs Funded"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase III costs, responsibility percentage for Regeneron",
        "label": "Percentage Of Second Part Of Development Costs Funded By Other Party",
        "documentation": "Percentage of second part of development costs funded by other party."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PercentageOfShareCapitalForThePeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfShareCapitalForThePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofTreasurySharesHeldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "%\u00a0of\u00a0share\u00a0capital for the period",
        "label": "Percentage Of Share Capital For The Period",
        "documentation": "Percentage of share capital for the period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of voting equity interests acquired",
        "label": "Percentage of voting equity interests acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "sny_PercentageOfVotingEquityInterestsDivested": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PercentageOfVotingEquityInterestsDivested",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of voting equity interests divested",
        "label": "Percentage Of Voting Equity Interests Divested",
        "documentation": "Percentage Of Voting Equity Interests Divested"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PerformanceSharePlanOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PerformanceSharePlanOneMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance share plan one",
        "label": "Performance Share Plan One [member]",
        "documentation": "Performance Share Plan One."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PerformanceSharePlanTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PerformanceSharePlanTwoMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance share plan two",
        "label": "Performance Share Plan Two [member]",
        "documentation": "Performance share plan two."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period before scheduled launch date",
        "label": "Period Before Launch Date During Which Commercial Expenses Of Antibodies Co-Developed Under License Agreement Are Shared",
        "documentation": "Period Before Launch Date During Which Commercial Expenses Of Antibodies Co-Developed Under License Agreement Are Shared"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PeriodOfShareRepurchaseProgram": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PeriodOfShareRepurchaseProgram",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of share repurchase program",
        "label": "Period Of Share Repurchase Program",
        "documentation": "Period of share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PharmaceuticalsSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PharmaceuticalsSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmaceuticals",
        "label": "Pharmaceuticals Segment [member]",
        "documentation": "Pharmaceuticals segment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PlanAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PlanAssetsAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails": {
       "parentTag": "ifrs-full_LiabilityAssetOfDefinedBenefitPlans",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of plan assets",
        "label": "Plan assets, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "sny_PlanAssetsEffectOfAssetCeiling": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlanAssetsEffectOfAssetCeiling",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails": {
       "parentTag": "ifrs-full_LiabilityAssetOfDefinedBenefitPlans",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of asset ceiling",
        "label": "Plan Assets, Effect Of Asset Ceiling",
        "documentation": "Plan Assets, Effect Of Asset Ceiling"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PlanAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PlanAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets",
        "label": "Plan assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for defined benefit plan assets. Plan assets comprise: (a) assets held by a long-term employee benefit fund; and (b) qualifying insurance policies."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "sny_PlanetCareProgramObjectivesNetEmissionsBy2045": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlanetCareProgramObjectivesNetEmissionsBy2045",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planet Care Program, net emissions by 2045",
        "label": "Planet Care Program Objectives, Net Emissions By 2045",
        "documentation": "Planet Care Program Objectives, Net Emissions By 2045"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planet Care Program, number of global warming scenarios",
        "label": "Planet Care Program Objectives, Number Of Global Warming Scenarios",
        "documentation": "Planet Care Program Objectives, Number Of Global Warming Scenarios"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planet Care Program, percentage of reduction in all scopes greenhouse gas by 2030",
        "label": "Planet Care Program Objectives, Percentage Of Reduction In All Scopes Greenhouse Gas By 2030",
        "documentation": "Planet Care Program Objectives, Percentage Of Reduction In All Scopes Greenhouse Gas By 2030"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planet Care Program, percentage of reduction in scope 1 and 2 greenhouse gas by 2030",
        "label": "Planet Care Program Objectives, Percentage Of Reduction In Scope 1 And 2 Greenhouse Gas By 2030",
        "documentation": "Planet Care Program Objectives, Percentage Of Reduction In Scope 1 And 2 Greenhouse Gas By 2030"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planet Care Program, percentage of reduction in scope 3 greenhouse gas by 2030",
        "label": "Planet Care Program Objectives, Percentage Of Reduction In Scope 3 Greenhouse Gas By 2030",
        "documentation": "Planet Care Program Objectives, Percentage Of Reduction In Scope 3 Greenhouse Gas By 2030"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planet Care Program, percentage of renewably-sourced energy in all sites by 2030",
        "label": "Planet Care Program Objectives, Percentage Of Renewably-Sourced Energy In All Sites By 2030",
        "documentation": "Planet Care Program Objectives, Percentage Of Renewably-Sourced Energy In All Sites By 2030"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlavixAttorneyGeneralActionInHawaiiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlavixAttorneyGeneralActionInHawaiiMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plavix Attorney General Action in Hawaii",
        "label": "Plavix Attorney General Action In Hawaii [Member]",
        "documentation": "Plavix Attorney General Action In Hawaii"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlavixLitigationCommonwealthInAustraliaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlavixLitigationCommonwealthInAustraliaMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plavix litigation (Commonwealth) in Australia",
        "label": "Plavix Litigation (Commonwealth) In Australia [Member]",
        "documentation": "Plavix litigation (commonwealth) In Australia."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlavixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlavixMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PLAVIX",
        "label": "Plavix [Member]",
        "documentation": "Plavix [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlavixRelatedLitigationInFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlavixRelatedLitigationInFranceMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plavix related litigation in France",
        "label": "Plavix Related Litigation In France [Member]",
        "documentation": "Plavix Related Litigation In France"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlusHundredBasisPointsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlusHundredBasisPointsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "+100\u00a0bp",
        "label": "Plus Hundred Basis Points [Member]",
        "documentation": "Plus hundred basis points."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PlusTwentyFiveBasisPointsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PlusTwentyFiveBasisPointsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "+25\u00a0bp",
        "label": "Plus Twenty Five Basis Points [Member]",
        "documentation": "Plus twenty five basis points."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PolioPertussisHibVaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PolioPertussisHibVaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Polio/Pertussis/ Hib Vaccines",
        "label": "Polio Pertussis Hib Vaccines [Member]",
        "documentation": "Polio Pertussis Hib Vaccines."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PossibleIncreaseInMortalityTableInYears": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PossibleIncreaseInMortalityTableInYears",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Possible increase in mortality table (in years)",
        "label": "Possible Increase In Mortality Table In Years",
        "documentation": "Possible increase in mortality table in years."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Praluent (Alirocumab)-related amgen patent litigation in the US",
        "label": "Praluent (Alirocumab)-Related Amgen Patent Litigation In The US [Member]",
        "documentation": "Praluent (Alirocumab)-Related Amgen Patent Litigation In The US"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PreFundedPensionObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PreFundedPensionObligations",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded pension obligations",
        "verboseLabel": "Pre-funded pension obligations",
        "label": "Pre-Funded Pension Obligations",
        "documentation": "Pre-funded pension obligations."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentValueOfDefinedBenefitObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PresentValueOfDefinedBenefitObligationMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of defined benefit obligation",
        "label": "Present value of defined benefit obligation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the present value of a defined benefit obligation. The present value of a defined benefit obligation is the present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "sny_PretaxDiscountRateAppliedForGoodwill": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PretaxDiscountRateAppliedForGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-tax discount rates",
        "label": "Pretax Discount Rate Applied For Goodwill",
        "documentation": "Pre-tax discount rate applied for goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PricewaterhousecoopersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PricewaterhousecoopersMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PricewaterhouseCoopers",
        "label": "PricewaterhouseCoopers [Member]",
        "documentation": "PricewaterhouseCoopers."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalAlliancesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalAlliancesAxis",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Alliances [Axis]",
        "label": "Principal Alliances [Axis]",
        "documentation": "Principal Alliances"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalAlliancesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalAlliancesDomain",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Alliances [Domain]",
        "label": "Principal Alliances [Domain]",
        "documentation": "Principal Alliances"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsAblynxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsAblynxMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ablynx",
        "label": "Principal Marketed Products Ablynx [Member]",
        "documentation": "Principal Marketed Products Ablynx [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsAventisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsAventisMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aventis",
        "label": "Principal Marketed Products Aventis [member]",
        "documentation": "Principal marketed products aventis."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsBeyfortusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsBeyfortusMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BEYFORTUS",
        "label": "Principal Marketed Products Beyfortus [Member]",
        "documentation": "Principal Marketed Products Beyfortus"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsBioverativMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsBioverativMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bioverativ",
        "label": "Principal Marketed Products Bioverativ [Member]",
        "documentation": "Principal Marketed Products Bioverativ"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Boehringer Ingelheim Consumer Healthcare",
        "label": "Principal Marketed Products Boehringer Ingelheim Consumer Healthcare [member]",
        "documentation": "Principal marketed products Boehringer Ingelheim Consumer Healthcare."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsChattemMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsChattemMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chattem",
        "label": "Principal Marketed Products Chattem [member]",
        "documentation": "Principal marketed products chattem."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsGenzymeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsGenzymeMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genzyme",
        "label": "Principal Marketed Products Genzyme [member]",
        "documentation": "Principal marketed products genzyme."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total: principal marketed products",
        "label": "Principal Marketed Products [member]",
        "documentation": "Principal marketed products."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsProteinSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsProteinSciencesMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Protein Sciences",
        "label": "Principal Marketed Products Protein Sciences [member]",
        "documentation": "Principal marketed products Protein Sciences."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsQunolMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsQunolMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "QUNOL",
        "label": "Principal Marketed Products Qunol [Member]",
        "documentation": "Principal Marketed Products Qunol"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsRezurockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsRezurockMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REZUROCK",
        "label": "Principal Marketed Products Rezurock [Member]",
        "documentation": "Principal Marketed Products Rezurock"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalMarketedProductsTZIELDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalMarketedProductsTZIELDMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TZIELD",
        "label": "Principal Marketed Products TZIELD [Member]",
        "documentation": "Principal Marketed Products TZIELD"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipalUndiscountedCashFlow": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipalUndiscountedCashFlow",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails": {
       "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal",
        "label": "Principal Undiscounted Cash Flow",
        "documentation": "Principal undiscounted cash flow."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PrincipiaBiopharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PrincipiaBiopharmaIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principia",
        "verboseLabel": "Principia Biopharma Inc.",
        "label": "Principia Biopharma Inc. [Member]",
        "documentation": "Principia Biopharma Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PriorAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PriorAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior agreement",
        "label": "Prior Agreement [Member]",
        "documentation": "Prior Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PriorDevelopmentBudget": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PriorDevelopmentBudget",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior development budget in total",
        "label": "Prior Development Budget",
        "documentation": "Prior development budget."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New borrowings",
        "label": "Proceeds from borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "sny_ProceedsFromCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ProceedsFromCollaborationAgreements",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from collaboration agreements",
        "label": "Proceeds From Collaboration Agreements",
        "documentation": "Proceeds From Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax",
        "label": "Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the disposal of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Sanofi shares",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_ProceedsFromNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromNoncurrentBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional long-term debt contracted",
        "label": "Proceeds from non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sales of investments accounted for using equity method",
        "label": "Proceeds from sales of investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "sny_ProductLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ProductLiabilitiesMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product liabilities",
        "label": "Product Liabilities [Member]",
        "documentation": "Product Liabilities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [axis]",
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r337"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesMember",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [member]",
        "label": "Products and services [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r337"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "verboseLabel": "Net income for the period",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r36",
      "r162",
      "r178",
      "r180",
      "r277",
      "r279",
      "r332",
      "r340"
     ]
    },
    "ifrs-full_ProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit (loss) [abstract]",
        "label": "Profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome",
      "http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income attributable to non-controlling interests",
        "terseLabel": "Attributable to non-controlling interests",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r182"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income attributable to equity holders of Sanofi",
        "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/Consolidatedstatementsofcomprehensiveincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income attributable to equity holders of Sanofi",
        "terseLabel": "Attributable to equity holders of Sanofi",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r387"
     ]
    },
    "ifrs-full_ProfitLossOfAcquiree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossOfAcquiree",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions from acquiree to net income",
        "label": "Profit (loss) of acquiree since acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) of the acquiree, since the acquisition date, included in the consolidated statement of comprehensive income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "periodStartLabel": "Property, plant and equipment, beginning balance",
        "periodEndLabel": "Property, plant and equipment, ending balance",
        "verboseLabel": "Property, plant and equipment owned",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r70"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment [abstract]",
        "label": "Property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_PropertyPlantAndEquipmentInProcessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PropertyPlantAndEquipmentInProcessMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property,\u00a0plant and\u00a0equipment in process",
        "label": "Property, Plant And Equipment In Process [Member]",
        "documentation": "Property, plant and equipment in process."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesLeaseLiabilitiesDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment [member]",
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r316",
      "r339"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentPledgedAsSecurity",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofOffBalanceSheetCommitmentsRelatingtoPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment pledged as security for liabilities",
        "label": "Property, plant and equipment, pledged as security"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property, plant and equipment pledged as security for liabilities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in associate (in percent)",
        "verboseLabel": "Proportion of ownership interest in associate (in percent)",
        "label": "Proportion of ownership interest in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r120",
      "r186"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInJointOperation": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInJointOperation",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial interest in principal investments accounted for using the equity method",
        "label": "Proportion of ownership interest in joint operation"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a joint operation attributable to the entity. [Refer: Joint operations [member]]"
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInJointVenture": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInJointVenture",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of ownership interest in joint venture (in percent)",
        "label": "Proportion of ownership interest in joint venture"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a joint venture attributable to the entity. [Refer: Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r120",
      "r186"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial interest in principal fully consolidated companies",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r120",
      "r184"
     ]
    },
    "ifrs-full_ProportionOfVotingPowerHeldInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfVotingPowerHeldInSubsidiary",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of voting rights held in subsidiary",
        "label": "Proportion of voting rights held in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of the voting rights in a subsidiary held by the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r120",
      "r184"
     ]
    },
    "sny_ProventionBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ProventionBioIncMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention Bio, Inc",
        "label": "Provention Bio, Inc [Member]",
        "documentation": "Provention Bio, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ProventionBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ProventionBioMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention Bio",
        "label": "Provention Bio [Member]",
        "documentation": "Provention Bio"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProvisionForDecommissioningRestorationAndRehabilitationCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProvisionForDecommissioningRestorationAndRehabilitationCostsMember",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for decommissioning, restoration and rehabilitation costs",
        "label": "Provision for decommissioning, restoration and rehabilitation costs [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a provision relating to decommissioning, restoration and rehabilitation costs. [Refer: Other provisions [member]]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319"
     ]
    },
    "sny_ProvisionForPensionsAndOtherEmployeeBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ProvisionForPensionsAndOtherEmployeeBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for pensions and other employee benefits",
        "label": "Provision For Pensions And Other Employee Benefits [member]",
        "documentation": "Provision for pensions and other employee benefits."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProvisionUsedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Provisions utilized",
        "label": "Provision used, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesLineItems",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions And Other Current And Non-Current Liabilities [Line Items]",
        "label": "Provisions And Other Current And Non-Current Liabilities [Line Items]",
        "documentation": "Provisions and other current and non-current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ProvisionsAndOtherCurrentAndNonCurrentLiabilitiesTable",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions And Other Current And Non-Current Liabilities [Table]",
        "label": "Provisions And Other Current And Non-Current Liabilities [Table]",
        "documentation": "Provisions and other current and noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ProvisionsForDiscountsRebatesAndSalesReturns": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ProvisionsForDiscountsRebatesAndSalesReturns",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Provisions for discounts, rebates and sales returns, beginning balance",
        "periodEndLabel": "Provisions for discounts, rebates and sales returns, ending balance",
        "label": "Provisions For Discounts Rebates And Sales Returns",
        "documentation": "Provisions for discounts, rebates and sales returns."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ProvisionsForOtherLongTermBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ProvisionsForOtherLongTermBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for other long-term benefits",
        "label": "Provisions For Other Long Term Benefits [member]",
        "documentation": "Provisions for other long term benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for pensions and other post-employment benefits",
        "label": "Provisions For Pensions And Other Post-Employment Benefits [Member]",
        "documentation": "Provisions for pensions and other post-employment benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ProvisionsRecordedForFutureOperatingLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ProvisionsRecordedForFutureOperatingLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesProvisionforRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions recorded for future operating losses",
        "label": "Provisions Recorded For Future Operating Losses",
        "documentation": "Provisions recorded for future operating losses."
       }
      }
     },
     "auth_ref": []
    },
    "sny_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering",
        "label": "Public Offering [Member]",
        "documentation": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions of other equity investments",
        "label": "Purchase of financial instruments, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions of other intangible assets",
        "label": "Purchase of intangible assets, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions of property, plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions of property, plant and equipment and intangible assets",
        "label": "Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfTreasuryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share repurchase program",
        "label": "Purchase of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "ifrs-full_PurchasesOfGoodsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchasesOfGoodsRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases and other expenses (including research expenses)",
        "label": "Purchases of goods, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "sny_QRIBIntermediateHoldingsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "QRIBIntermediateHoldingsLLCMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023SummaryofProvisionalPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "QRIB Intermediate Holding",
        "label": "QRIB Intermediate Holdings, LLC [Member]",
        "documentation": "QRIB Intermediate Holdings, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "sny_QRIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "QRIMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "QRI",
        "label": "QRI [Member]",
        "documentation": "QRI"
       }
      }
     },
     "auth_ref": []
    },
    "sny_QualifiedDefinedBenefitPensionPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "QualifiedDefinedBenefitPensionPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qualified defined benefit pension plans",
        "label": "Qualified Defined Benefit Pension Plans [member]",
        "documentation": "Qualified defined benefit pension plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_QuotedDebtInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "QuotedDebtInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted debt instruments",
        "label": "Quoted Debt Instruments [Member]",
        "documentation": "Quoted equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_QuotedDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "QuotedDebtSecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted debt securities",
        "label": "Quoted Debt Securities [Member]",
        "documentation": "Quoted debt securities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_QuotedEquityInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "QuotedEquityInvestmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted equity investments",
        "label": "Quoted Equity Investments [Member]",
        "documentation": "Quoted equity investments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_QuotedEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "QuotedEquitySecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted equity securities",
        "label": "Quoted Equity Securities [member]",
        "documentation": "Quoted equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_QuotedEuroDenominatedSeniorBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "QuotedEuroDenominatedSeniorBondsMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted euro denominated senior bonds",
        "label": "Quoted Euro Denominated Senior Bonds [Member]",
        "documentation": "Quoted euro denominated senior bonds."
       }
      }
     },
     "auth_ref": []
    },
    "sny_RPRUSLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RPRUSLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RPR US Ltd.",
        "label": "RPR US Ltd [Member]",
        "documentation": "RPR US Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RamiprilCanadaPatentLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RamiprilCanadaPatentLitigationMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ramipril Canada Patent Litigation",
        "label": "Ramipril Canada Patent Litigation [Member]",
        "documentation": "Ramipril canada patent litigation."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r220",
      "r230",
      "r334",
      "r336",
      "r417"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges [member]",
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r220",
      "r230",
      "r334",
      "r336",
      "r417"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options [axis]",
        "label": "Ranges of exercise prices for outstanding share options [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options [member]",
        "label": "Ranges of exercise prices for outstanding share options [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]"
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "ifrs-full_RawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Current raw materials"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r301",
      "r397"
     ]
    },
    "sny_RealEstate1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RealEstate1Member",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesFairValueofPlansAssetsrelatingtoPensionPlansandOtherPostemploymentPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real estate",
        "label": "Real Estate1 [Member]",
        "documentation": "Real Estate1"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RebatesAndDiscountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RebatesAndDiscountsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rebates and discounts",
        "label": "Rebates And Discounts [Member]",
        "documentation": "Rebates and discounts."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ReclassificationFromNonCurrentToCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ReclassificationFromNonCurrentToCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification from non-current to current",
        "label": "Reclassification From Non-Current To Current",
        "documentation": "Reclassification from non current to current."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReclassifiedItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReclassifiedItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassified items [axis]",
        "label": "Reclassified items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrs-full_ReclassifiedItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReclassifiedItemsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassified items",
        "label": "Reclassified items [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for items that have been reclassified when the entity changes their presentation or classification in its financial statements. It also represents the standard value for the 'Reclassified items' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RecognisedLiabilitiesDefinedBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net obligation",
        "label": "Net defined benefit liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deficit in a defined benefit plan. [Refer: Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "sny_RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of acquired property, plant and equipment at fair value",
        "label": "Recognition Of Acquired Property Plant And Equipment At Fair Value [member]",
        "documentation": "Recognition of acquired property plant and equipment at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInOtherProvisionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReconciliationOfChangesInOtherProvisionsAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofMovementsinNoncurrentProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in other provisions [abstract]",
        "label": "Reconciliation of changes in other provisions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RedemptionOfDebtInstrumentIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RedemptionOfDebtInstrumentIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total debt at redemption",
        "label": "Redemption Of Debt Instrument Issued",
        "documentation": "Redemption of debt instrument issued."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ReducedAmountOfCompensationClaimedByFilledPlaintiffs",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduced amount of compensation claimed",
        "label": "Reduced Amount Of Compensation Claimed By Filled Plaintiffs",
        "documentation": "Reduced Amount Of Compensation Claimed By Filled Plaintiffs"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduced amount of compensation claimed, interest included",
        "label": "Reduced Amount Of Compensation Claimed By Filled Plaintiffs, Interest Included",
        "documentation": "Reduced Amount Of Compensation Claimed By Filled Plaintiffs, Interest Included"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReductionOfIssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReductionOfIssuedCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reduction in share capital",
        "label": "Reduction of issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "sny_ReductionOfSharesByCancellationOfTreasuryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ReductionOfSharesByCancellationOfTreasuryShares",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reduction in share capital by cancellation of treasury shares (in shares)",
        "label": "Reduction Of Shares By Cancellation Of Treasury Shares",
        "documentation": "Reduction Of Shares By Cancellation Of Treasury Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RegeneronMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RegeneronMember",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeDetails",
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regeneron",
        "label": "Regeneron [Member]",
        "documentation": "Regeneron"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RegeneronPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RegeneronPharmaceuticalsIncMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regeneron Pharmaceuticals, INC",
        "label": "Regeneron Pharmaceuticals, INC [Member]",
        "documentation": "Regeneron Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RegularMilestonePaymentsForProjectsUnderCollaborationAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regular milestone payments for projects under collaboration agreements",
        "label": "Regular Milestone Payments For Projects Under Collaboration Agreements",
        "documentation": "Regular Milestone Payments For Projects Under Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RegulatoryComplianceCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RegulatoryComplianceCostsMember",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory compliance costs",
        "label": "Regulatory Compliance Costs [Member]",
        "documentation": "Regulatory Compliance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RelatedPartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Abstract]",
        "label": "Related Party [Abstract]",
        "documentation": "Related Party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining amortisation period of intangible assets material to entity",
        "label": "Remaining amortisation period of intangible assets material to entity"
       }
      },
      "en": {
       "role": {
        "documentation": "The remaining amortisation period of individual intangible assets that are material to the entity\u2019s financial statements. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "sny_RemeasurementOfOtherAcquiredIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RemeasurementOfOtherAcquiredIntangibleAssetsMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of other acquired intangible assets",
        "label": "Remeasurement Of Other Acquired Intangible Assets [Member]",
        "documentation": "Remeasurement of other acquired intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments",
        "label": "Repayments of borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_RepaymentsOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofcashflows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of long-term debt",
        "label": "Repayments of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "sny_ReportableGeographicalZonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ReportableGeographicalZonesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Reportable Geographical Zones [Member]",
        "documentation": "Reportable geographical zones."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReportableSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReportableSegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total Sanofi",
        "terseLabel": "Reportable segments",
        "label": "Reportable segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for operating segments for which IFRS 8 requires information to be disclosed. The entity shall report separately information about an operating segment that meets any of the following quantitative thresholds: (a) reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 per cent or more of the combined revenue, internal and external, of all operating segments; (b) the absolute amount of its reported profit or loss is 10 per cent or more of the greater, in absolute amount, of (i) the combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all operating segments that reported a loss; or (c) assets are 10 per cent or more of the combined assets of all operating segments. Additionally operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed, if management believes that information about the segment would be useful to users of the financial statements. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r277",
      "r311",
      "r342"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.sanofi.com/role/AuditInformation",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails": {
       "parentTag": "sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "terseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development projects and technology platforms",
        "label": "Research And Development Projects And Technology Platforms [Member]",
        "documentation": "Research and development."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCurrencyTranslationDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve of exchange differences on translation",
        "label": "Reserve of exchange differences on translation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r297"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options\u00a0and other\u00a0share- based payments",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "sny_ReservePercentageOfPandemicVaccines": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ReservePercentageOfPandemicVaccines",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of pandemic vaccines agreed to reserve",
        "label": "Reserve Percentage of Pandemic Vaccines",
        "documentation": "Reserve percentage of pandemic vaccines."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ReservesLikelyToBeDistributedInTheForeseeableFuture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ReservesLikelyToBeDistributedInTheForeseeableFuture",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves likely to be distributed in the foreseeable future",
        "label": "Reserves Likely To Be Distributed In The Foreseeable Future",
        "documentation": "Reserves likely to be distributed in the foreseeable future."
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RestrictedSharePlan2019Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2019",
        "label": "Restricted Share Plan 2019 [Member]",
        "documentation": "Restricted Share Plan 2019 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RestrictedSharePlan2020Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2020",
        "label": "Restricted Share Plan 2020 [Member]",
        "documentation": "Restricted Share Plan 2020"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RestrictedSharePlan2021Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2021",
        "label": "Restricted Share Plan 2021 [Member]",
        "documentation": "Restricted Share Plan 2021"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RestrictedSharePlan2022Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2022",
        "label": "Restricted Share Plan 2022 [Member]",
        "documentation": "Restricted Share Plan 2022"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlan2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RestrictedSharePlan2023Member",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plan 2023",
        "label": "Restricted Share Plan 2023 [Member]",
        "documentation": "Restricted Share Plan 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RestrictedSharePlansMember",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share plans",
        "label": "Restricted Share Plans [Member]",
        "documentation": "Restricted Share Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RestrictedSharesMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted shares",
        "label": "Restricted Shares [Member]",
        "documentation": "Restricted shares."
       }
      }
     },
     "auth_ref": []
    },
    "sny_RestructuringCostsReversedAndSimilarItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RestructuringCostsReversedAndSimilarItems",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails": {
       "parentTag": "sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring costs",
        "label": "Restructuring Costs (Reversed) And Similar Items",
        "documentation": "Restructuring Costs (Reversed) And Similar Items"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RestructuringProvisionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RestructuringProvisionAbstract",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Of which:",
        "label": "Restructuring provision [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RestructuringProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RestructuringProvisionMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Provision",
        "label": "Restructuring provision [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Other provisions [member]]"
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves and retained earnings",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r297"
     ]
    },
    "sny_RetirementAge": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RetirementAge",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement age",
        "label": "Retirement Age",
        "documentation": "Retirement age."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Difference between actual return and interest income on plan assets",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales",
        "label": "Revenue from sale of goods"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromSaleOfGoodsRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales",
        "label": "Revenue from sale of goods, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods in related party transactions. [Refer: Revenue; Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "ifrs-full_RevenueOfAcquiree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueOfAcquiree",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions from acquiree to net sales",
        "label": "Revenue of acquiree since acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofPropertyPlantandEquipmentLeasedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "periodStartLabel": "Right-of-use assets at beginning of period",
        "periodEndLabel": "Right-of-use assets at end of period",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r214"
     ]
    },
    "sny_RoyaltiesAndOtherIncomeRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RoyaltiesAndOtherIncomeRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofPrincipalTransactionsandBalanceswithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties and other income",
        "label": "Royalties And Other Income, Related Party Transactions",
        "documentation": "Royalties and other income, related party transactions."
       }
      }
     },
     "auth_ref": []
    },
    "sny_RoyaltiesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RoyaltiesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties, payable",
        "label": "Royalties, Payable",
        "documentation": "Royalties, Payable"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct royalty agreement with SOBI on sales of BeyfortusTM in the United States",
        "label": "Royalty Agreement With SOBI On Sales Of Beyfortus In The US [Member]",
        "documentation": "Royalty Agreement With SOBI On Sales Of Beyfortus In The US"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RoyaltyExpensePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RoyaltyExpensePercentage",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty expense, percentage (percentage)",
        "label": "Royalty Expense, Percentage",
        "documentation": "Royalty Expense, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_RoyaltyIncomePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "RoyaltyIncomePercentage",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty income percentage (percentage)",
        "label": "Royalty Income, Percentage",
        "documentation": "Royalty Income, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SAR444245Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SAR444245Member",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SAR444245",
        "label": "SAR444245 [Member]",
        "documentation": "SAR444245"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SECIPESASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SECIPESASMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SECIPE SAS",
        "label": "SECIPE SAS [Member]",
        "documentation": "SECIPE SAS"
       }
      }
     },
     "auth_ref": []
    },
    "currency_SGD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "SGD",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Singapore dollar",
        "label": "Singapore, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SPMSDContingentConsiderationAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SPMSDContingentConsiderationAssetMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPMSD contingent consideration asset",
        "label": "SPMSD Contingent Consideration Asset [Member]",
        "documentation": "SPMSD contingent consideration asset."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SaleOfStockAxis",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Axis]",
        "documentation": "Sale Of Stock"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SaleOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SaleOfStockDomain",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Domain]",
        "label": "Sale Of Stock [Domain]",
        "documentation": "Sale Of Stock"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransactionTotal",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale Of Stock, Number Of Shares Issued In Transaction, Total",
        "documentation": "Sale Of Stock, Number Of Shares Issued In Transaction, Total"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SalesOfAntibodiesFirstAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SalesOfAntibodiesFirstAchievementMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of antibodies, first achievement",
        "label": "Sales Of Antibodies, First Achievement [Member]",
        "documentation": "Sales Of Antibodies, First Achievement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SalesOfAntibodiesSecondAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SalesOfAntibodiesSecondAchievementMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of antibodies, second achievement",
        "label": "Sales Of Antibodies, Second Achievement [Member]",
        "documentation": "Sales Of Antibodies, Second Achievement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SalesOfAntibodiesThirdAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SalesOfAntibodiesThirdAchievementMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Of Antibodies, Third Achievement",
        "label": "Sales Of Antibodies, Third Achievement [Member]",
        "documentation": "Sales Of Antibodies, Third Achievement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SalesReturnMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SalesReturnMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales returns",
        "label": "Sales Return [Member]",
        "documentation": "Sales return."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiABMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi AB",
        "label": "Sanofi AB [member]",
        "documentation": "Sanofi AB."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiASMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi A/S",
        "label": "Sanofi A/S [Member]",
        "documentation": "Sanofi A/S [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiArabiaTradingCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiArabiaTradingCompanyLimitedMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Arabia Trading Company Limited",
        "label": "Sanofi Arabia Trading Company Limited [Member]",
        "documentation": "Sanofi Arabia Trading Company Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisAlgerieMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisAlgerieMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Alg\u00e9rie",
        "label": "Sanofi Aventis Algerie [member]",
        "documentation": "Sanofi-Aventis Algerie."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisArgentinaSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisArgentinaSAMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Argentina SA",
        "label": "Sanofi Aventis Argentina S A [member]",
        "documentation": "Sanofi-Aventis Argentina S.A."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisAustraliaPtyLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisAustraliaPtyLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Australia Pty Ltd",
        "label": "Sanofi Aventis Australia Pty Ltd [member]",
        "documentation": "Sanofi-Aventis Australia Pty Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisCanadaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisCanadaIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Canada Inc.",
        "label": "Sanofi Aventis Canada Inc [Member]",
        "documentation": "Sanofi-Aventis Canada Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisDeColombiaSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisDeColombiaSAMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis de Colombia SA",
        "label": "Sanofi Aventis De Colombia S A [Member]",
        "documentation": "Sanofi-Aventis de Colombia S.A."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisDeMexicoSADeCVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisDeMexicoSADeCVMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis de Mexico SA de CV",
        "label": "Sanofi-Aventis De Mexico S.A. De C.V. [Member]",
        "documentation": "Sanofi-Aventis de Mexico S.A. de C.V. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisDePanamaSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisDePanamaSAMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis de Panama SA",
        "label": "Sanofi Aventis De Panama S A [Member]",
        "documentation": "Sanofi-Aventis de Panama S.A."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisDeVenezuelaSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisDeVenezuelaSAMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis de Venezuela SA",
        "label": "Sanofi Aventis De Venezuela SA [Member]",
        "documentation": "Sanofi-Aventis de Venezuela SA."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisDeutschlandGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisDeutschlandGmbHMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Deutschland GmbH",
        "label": "Sanofi Aventis Deutschland Gmbh [member]",
        "documentation": "Sanofi Aventis Deutschland GmbH."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisFranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisFranceMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis France",
        "label": "Sanofi Aventis France [member]",
        "documentation": "Sanofi-Aventis France."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisGmbHMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis GmbH",
        "label": "Sanofi Aventis GmbH [member]",
        "documentation": "Sanofi Aventis GmbH."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisGroupeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisGroupeMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Groupe",
        "label": "Sanofi Aventis Groupe [member]",
        "documentation": "Sanofi-Aventis Groupe."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisGulfFZEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisGulfFZEMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Gulf FZE",
        "label": "Sanofi Aventis Gulf FZE [Member]",
        "documentation": "Sanofi-Aventis Gulf FZE."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisHealthcarePtyLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisHealthcarePtyLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Healthcare Pty Ltd",
        "label": "Sanofi Aventis Healthcare Pty Ltd [member]",
        "documentation": "Sanofi-Aventis Healthcare Pty Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisHoldingsIrelandLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisHoldingsIrelandLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Holdings (Ireland) Ltd",
        "label": "Sanofi Aventis Holdings (Ireland) Ltd [Member]",
        "documentation": "Sanofi Aventis Holdings (Ireland) Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisIsraelLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisIsraelLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Isra\u00ebl Ltd",
        "label": "Sanofi Aventis Israel Ltd [Member]",
        "documentation": "Sanofi-Aventis Israel Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisKoreaCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisKoreaCoLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Korea Co. Ltd",
        "label": "Sanofi Aventis Korea Co Ltd [Member]",
        "documentation": "Sanofi-Aventis Korea Co. Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisMalaysiaSDNBHDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisMalaysiaSDNBHDMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis (Malaysia) SDN. BHD.",
        "label": "Sanofi Aventis Malaysia SDN. BHD [Member]",
        "documentation": "Sanofi-Aventis (Malaysia) SDN. BHD."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisMarocMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisMarocMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Maroc",
        "label": "Sanofi Aventis Maroc [Member]",
        "documentation": "Sanofi-Aventis Maroc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisNorgeASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisNorgeASMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Norge AS",
        "label": "Sanofi-Aventis Norge AS [Member]",
        "documentation": "Sanofi-Aventis Norge AS"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisParticipationsSASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisParticipationsSASMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Participations",
        "label": "Sanofi Aventis Participations SAS [member]",
        "documentation": "Sanofi-Aventis Participations SAS."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisPhilippinesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisPhilippinesIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Philippines Inc.",
        "label": "Sanofi Aventis Philippines Inc [Member]",
        "documentation": "Sanofi-Aventis Philippines Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisPrivateCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisPrivateCoLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Private Co, Ltd",
        "label": "Sanofi-Aventis Private Co, Ltd [member]",
        "documentation": "Sanofi-Aventis Private Co, Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisPuertoRicoIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisPuertoRicoIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Puerto Rico Inc",
        "label": "Sanofi-Aventis Puerto Rico Inc [Member]",
        "documentation": "Sanofi-Aventis Puerto Rico Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisRechercheEtDeveloppementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisRechercheEtDeveloppementMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Recherche &amp; D\u00e9veloppement",
        "label": "Sanofi Aventis Recherche Et Developpement [Member]",
        "documentation": "Sanofi aventis Recherche et Developpement."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisRomaniaSRLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisRomaniaSRLMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Romania SRL",
        "label": "Sanofi-Aventis Romania SRL [member]",
        "documentation": "Sanofi-Aventis Romania SRL."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisSAMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis SA",
        "label": "Sanofi Aventis SA [member]",
        "documentation": "Sanofi-Aventis SA."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisSROMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisSROMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis, s.r.o.",
        "label": "Sanofi-Aventis, S.R.O. [Member]",
        "documentation": "Sanofi-Aventis, s.r.o."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisSingaporePteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisSingaporePteLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Singapore Pte. Ltd",
        "label": "Sanofi Aventis Singapore Pte Ltd [Member]",
        "documentation": "Sanofi-Aventis Singapore Pte Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisSouthAfricaPtyLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisSouthAfricaPtyLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis South Africa (Pty) Ltd",
        "label": "Sanofi-Aventis South Africa (Pty) Ltd [Member]",
        "documentation": "Sanofi-Aventis South Africa (Pty) Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisSuisseSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisSuisseSAMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis (Suisse) SA",
        "label": "Sanofi-Aventis (Suisse) SA [member]",
        "documentation": "Sanofi-Aventis (Suisse) SA."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisThailandLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisThailandLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis (Thailand) Ltd",
        "label": "Sanofi Aventis Thailand Ltd [Member]",
        "documentation": "Sanofi-Aventis Thailand Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisUSLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisUSLLCMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis U.S. LLC",
        "label": "Sanofi-Aventis US LLC [member]",
        "documentation": "Sanofi-Aventis US LLC."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisUkHoldingsLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisUkHoldingsLimitedMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis UK Holdings Limited",
        "label": "Sanofi-Aventis UK Holdings Limited [member]",
        "documentation": "Sanofi-Aventis UK Holdings Limited."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiAventisVietnamCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiAventisVietnamCompanyLimitedMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Vietnam Company Limited",
        "label": "Sanofi-Aventis Vietnam Company Limited [Member]",
        "documentation": "Sanofi-Aventis Vietnam Company Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiBVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiBVMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi BV",
        "label": "Sanofi BV [Member]",
        "documentation": "Sanofi BV."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiBeijingPharmaceuticalsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiBeijingPharmaceuticalsCoLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi (Beijing) Pharmaceuticals Co.Ltd",
        "label": "Sanofi Beijing Pharmaceuticals Co Ltd [Member]",
        "documentation": "Sanofi Beijing Pharmaceuticals Co.Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiBelgiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiBelgiumMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Belgium",
        "label": "Sanofi Belgium [member]",
        "documentation": "Sanofi Belgium."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiBiotechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiBiotechnologyMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Biotechnology",
        "label": "Sanofi Biotechnology [Member]",
        "documentation": "Sanofi Biotechnology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiBioverativHoldingsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiBioverativHoldingsLLCMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Bioverativ Holdings LLC",
        "label": "Sanofi Bioverativ Holdings LLC [Member]",
        "documentation": "Sanofi Bioverativ Holdings LLC"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiChimieMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiChimieMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Chimie",
        "label": "Sanofi Chimie [member]",
        "documentation": "Sanofi Chimie."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiChinaInvestmentCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiChinaInvestmentCoLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi (China) Investment Co., Ltd",
        "label": "Sanofi China Investment Co Ltd [Member]",
        "documentation": "Sanofi (China) Investment Co., Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiEgyptSAEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiEgyptSAEMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Egypt",
        "label": "Sanofi Egypt S.A.E [Member]",
        "documentation": "Sanofi Egypt S.A.E."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiEuroMediumTermNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiEuroMediumTermNotesMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Euro Medium Term Notes (EMTN) bonds",
        "label": "Sanofi Euro Medium Term Notes [Member]",
        "documentation": "Sanofi Euro Medium Term Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiForeignParticipationsB.V.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiForeignParticipationsB.V.Member",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Foreign Participations BV",
        "label": "Sanofi Foreign Participations B.V. [Member]",
        "documentation": "Sanofi Foreign Participations B.V. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiHangzhouPharmaceuticalsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiHangzhouPharmaceuticalsCoLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi (Hangzhou) Pharmaceuticals Co., Ltd",
        "label": "Sanofi Hangzhou Pharmaceuticals Co Ltd [Member]",
        "documentation": "Sanofi (Hangzhou) Pharmaceuticals Co., Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiHealthcareIndiaPrivateLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiHealthcareIndiaPrivateLimitedMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Healthcare India Private Limited",
        "label": "Sanofi Healthcare India Private Limited [Member]",
        "documentation": "Sanofi Healthcare India Private Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiHongKongLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiHongKongLimitedMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Hong-Kong Limited",
        "label": "Sanofi Hong-Kong Limited [Member]",
        "documentation": "Sanofi Hong-Kong Limited."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiIlacSanayiVeTicaretASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiIlacSanayiVeTicaretASMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Ilac Sanayi ve Ticaret AS",
        "label": "Sanofi Ilac Sanayi ve Ticaret A.S. [member]",
        "documentation": "Sanofi Ilac Sanayi ve Ticaret A.S."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiIndiaLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiIndiaLimitedMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi India Limited",
        "label": "Sanofi India Limited [Member]",
        "documentation": "Sanofi India Limited."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiKKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiKKMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi K.K.",
        "label": "Sanofi K.K [Member]",
        "documentation": "Sanofi K.K."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiManufacturingPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiManufacturingPteLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Manufacturing Pte Ltd",
        "label": "Sanofi Manufacturing Pte Ltd [Member]",
        "documentation": "Sanofi Manufacturing Pte Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiMatureIPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiMatureIPMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Mature IP",
        "label": "Sanofi Mature IP [Member]",
        "documentation": "Sanofi Mature IP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiMedleyFarmaceuticaLtdaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiMedleyFarmaceuticaLtdaMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Medley Farmaceutica Ltda",
        "label": "Sanofi Medley Farmaceutica Ltda [Member]",
        "documentation": "Sanofi Medley Farmaceutica Ltda [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementsShareCapitalDetails",
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sanofi",
        "terseLabel": "Sanofi",
        "label": "Sanofi [member]",
        "documentation": "Sanofi."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiOyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiOyMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Oy",
        "label": "Sanofi Oy [member]",
        "documentation": "Sanofi Oy."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurAsiTicaretASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurAsiTicaretASMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur Asi Ticaret AS",
        "label": "Sanofi Pasteur Asi Ticaret A.S [member]",
        "documentation": "Sanofi Pasteur Asi Ticaret A.S."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurBiologiesCo.LtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurBiologiesCo.LtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur Biologies Co., Ltd",
        "label": "Sanofi Pasteur Biologies Co., Ltd [Member]",
        "documentation": "Sanofi Pasteur Biologies Co., Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurEuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurEuropeMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur Europe",
        "label": "Sanofi Pasteur Europe [Member]",
        "documentation": "Sanofi Pasteur Europe [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurFranceSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurFranceSAMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur",
        "label": "Sanofi Pasteur (France) SA [member]",
        "documentation": "Sanofi Pasteur (France) SA."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurHepatitisBVaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurHepatitisBVaccineMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur Hepatitis B Vaccine product litigation",
        "label": "Sanofi Pasteur Hepatitis B Vaccine [Member]",
        "documentation": "Sanofi Pasteur Hepatitis B Vaccine"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur Inc.",
        "label": "Sanofi Pasteur Inc [member]",
        "documentation": "Sanofi Pasteur Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurLimitedMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur Limited",
        "label": "Sanofi Pasteur Limited [Member]",
        "documentation": "Sanofi Pasteur Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur Ltd",
        "label": "Sanofi Pasteur Ltd [Member]",
        "documentation": "Sanofi Pasteur Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurMerieuxSASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurMerieuxSASMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur Merieux SAS",
        "label": "Sanofi Pasteur Merieux S.A.S [Member]",
        "documentation": "Sanofi Pasteur Merieux S.A.S"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurNVLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurNVLMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur NVL",
        "label": "Sanofi Pasteur NVL [Member]",
        "documentation": "Sanofi Pasteur NVL [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurS.A.deC.V.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurS.A.deC.V.Member",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur SA de CV",
        "label": "Sanofi Pasteur S.A. de C.V. [Member]",
        "documentation": "Sanofi Pasteur S.A. de C.V. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurSpZooMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurSpZooMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur Sp. z.o.o.",
        "label": "Sanofi Pasteur Sp z.o.o. [Member]",
        "documentation": "Sanofi Pasteur Sp z.o.o."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiPasteurThailandLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiPasteurThailandLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Pasteur Ltd",
        "label": "Sanofi Pasteur Thailand Ltd [Member]",
        "documentation": "Sanofi Pasteur Thailand Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiProdutosFarmaceuticosLdaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiProdutosFarmaceuticosLdaMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Produtos Farmaceuticos Lda",
        "label": "Sanofi Produtos Farmaceuticos Lda [member]",
        "documentation": "Sanofi Produtos Farmaceuticos Lda."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiResearchInvestLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiResearchInvestLLCMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Research Invest LLC",
        "label": "Sanofi Research Invest LLC [Member]",
        "documentation": "Sanofi Research Invest LLC"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiSRLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiSRLMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi SRL",
        "label": "Sanofi SRL [Member]",
        "documentation": "Sanofi Spa."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiSaglikUrunleriLimitedSirketiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiSaglikUrunleriLimitedSirketiMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Saglik Urunleri Limited Sirketi",
        "label": "Sanofi Saglik Urunleri Limited Sirketi [Member]",
        "documentation": "Sanofi Saglik Urunleri Limited Sirketi [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiSynthelaboUKLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiSynthelaboUKLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Synthelabo UK Ltd",
        "label": "Sanofi-Synthelabo UK Ltd [Member]",
        "documentation": "Sanofi-Synthelabo UK Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiTaiwanCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiTaiwanCoLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Taiwan Co., Ltd",
        "label": "Sanofi Taiwan Co Ltd [Member]",
        "documentation": "Sanofi Taiwan Co Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiUSServicesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiUSServicesIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi US Services Inc.",
        "label": "Sanofi US Services Inc [member]",
        "documentation": "Sanofi US Services Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiVietnamShareholdingCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiVietnamShareholdingCompanyLimitedMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Vietnam Shareholding Company Limited",
        "label": "Sanofi Vietnam Shareholding Company Limited [Member]",
        "documentation": "Sanofi Vietnam Shareholding Company Limited"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiWinthropIndustriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiWinthropIndustriesMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi Winthrop Industrie",
        "label": "Sanofi Winthrop Industries [member]",
        "documentation": "Sanofi Winthrop Industries."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiaventisAEBEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiaventisAEBEMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis A.E.B.E.",
        "label": "Sanofi-Aventis A.E.B.E. [member]",
        "documentation": "Sanofi-Aventis A.E.B.E."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiaventisPlusPensionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiaventisPlusPensionPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Plus",
        "label": "Sanofi-Aventis plus [member]",
        "documentation": "Sanofi-Aventis Plus."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SanofiaventisSpZooMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SanofiaventisSpZooMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi-Aventis Sp. z.o.o.",
        "label": "Sanofi-Aventis Sp. zoo [member]",
        "documentation": "Sanofi-Aventis Sp. z.o.o."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2023AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ScribeTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ScribeTherapeuticsMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scribe Therapeutics",
        "label": "Scribe Therapeutics [Member]",
        "documentation": "Scribe Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "ifrs-full_SegmentConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentConsolidationItemsAxis",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment consolidation items [axis]",
        "label": "Segment consolidation items [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [axis]",
        "label": "Segments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r207",
      "r277",
      "r311",
      "r342"
     ]
    },
    "ifrs-full_SegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofAllocationofGoodwillDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentSummaryofNetImpairmentLossesofOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [member]",
        "label": "Segments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r207",
      "r282",
      "r311",
      "r342"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails": {
       "parentTag": "sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAmortizationofSoftwaresRecognizedinIncomeStatementDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Selling and general expenses",
        "terseLabel": "Selling and general expenses",
        "label": "Selling, general and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "sny_SeniorBondMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SeniorBondMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior bond",
        "label": "Senior Bond [Member]",
        "documentation": "Senior bond."
       }
      }
     },
     "auth_ref": []
    },
    "sny_September2014EMTNISINFR0012146801Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "September2014EMTNISINFR0012146801Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "September 2014 EMTN ISIN FR0012146801",
        "label": "September 2014 EMTNISINFR0012146801 [Member]",
        "documentation": "September 2014 EMTN ISIN FR0012146801."
       }
      }
     },
     "auth_ref": []
    },
    "sny_September2015EMTNISINFR0012969038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "September2015EMTNISINFR0012969038Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "September 2015 EMTN ISIN FR0012969038",
        "label": "September 2015 EMTNISINFR0012969038 [Member]",
        "documentation": "September 2015 EMTN ISIN FR0012969038."
       }
      }
     },
     "auth_ref": []
    },
    "sny_September2016EMTNISINFR0013201639Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "September2016EMTNISINFR0013201639Member",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "September 2016 EMTN ISIN FR0013201639",
        "label": "September 2016 EMTNISINFR0013201639 [Member]",
        "documentation": "September 2016 EMTN ISIN FR 0013201639."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ServicesOtherThanStatutoryAudit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ServicesOtherThanStatutoryAudit",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails": {
       "parentTag": "ifrs-full_AuditorsRemuneration",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PrincipalaccountantsfeesandservicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Services other than statutory audit",
        "label": "Services Other Than Statutory Audit",
        "documentation": "Services other than statutory audit."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments made",
        "label": "Settled liabilities, contingent liabilities recognised in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised in a business combination that were settled. [Refer: Contingent liabilities recognised in business combination]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "sny_ShanghaiRonghengPharmaceuticalCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShanghaiRonghengPharmaceuticalCoLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shanghai Rongheng Pharmaceutical Co, Ltd",
        "label": "Shanghai Rongheng Pharmaceutical Co. Ltd [Member]",
        "documentation": "Shanghai Rongheng Pharmaceutical Co. Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period (in years)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareBasedPaymentPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShareBasedPaymentPlansAbstract",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment plans:",
        "label": "Share Based Payment Plans [abstract]",
        "documentation": "Share based payment plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareCapitalReservesAndOtherEquityInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShareCapitalReservesAndOtherEquityInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital, Reserves And Other Equity Interest [Abstract]",
        "label": "Share Capital, Reserves And Other Equity Interest [Abstract]",
        "documentation": "Share Capital, Reserves And Other Equity Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails": {
       "parentTag": "sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of other comprehensive income from investments accounted for using the equity method",
        "label": "Share of other comprehensive income of associates and joint ventures accounted for using equity method, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the other comprehensive income of associates and joint ventures accounted for using the equity method, before tax. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedincomestatements_1": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit/(loss) from investments accounted for using the equity method",
        "label": "Share of profit (loss) of associates accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails": {
       "parentTag": "sny_BusinessOperatingIncome",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails",
      "http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit/(loss) from investments accounted for using the equity method",
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r275",
      "r281"
     ]
    },
    "ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails": {
       "parentTag": "sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit/(loss) from investments accounted for using the equity method",
        "label": "Share of profit (loss) of joint ventures accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of joint ventures accounted for using the equity method. [Refer: Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit or loss from commercialization of monoclonal antibodies",
        "label": "Share Of Profit Or Loss From Commercialization Of Monoclonal Antibodies [Member]",
        "documentation": "Share of profit or loss from commercialization of monoclonal antibodies member."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShareOfProfitOrLossFromCommercializationOfZaltrapMember",
     "presentation": [
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of profit or loss from commercialization of Zaltrap",
        "label": "Share Of Profit Or Loss From Commercialization Of Zaltrap [Member]",
        "documentation": "Share of profit or loss from commercialization of Zaltrap."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2020ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShareRepurchase2020ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020",
        "label": "Share Repurchase 2020 Program [Member]",
        "documentation": "Share Repurchase 2020 Program"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2021ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShareRepurchase2021ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021",
        "label": "Share Repurchase 2021 Program [Member]",
        "documentation": "Share Repurchase 2021 Program"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2022ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShareRepurchase2022ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022",
        "label": "Share Repurchase 2022 Program [Member]",
        "documentation": "Share Repurchase 2022 Program"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShareRepurchase2023ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShareRepurchase2023ProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofRepurchasesProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Share Repurchase 2023 Program [Member]",
        "documentation": "Share Repurchase 2023 Program"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and other share-based payment [Member]",
        "label": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "sny_ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in shareholders equity due to exercise of stock purchase option",
        "label": "Shareholder's Equity Increase Due To The Exercise Of All Stock Subscription Options",
        "documentation": "Shareholder's equity increase due to the exercise of all stock subscription options."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShelfRegistrationStatementProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShelfRegistrationStatementProgramMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofBondIssuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf registration statement program",
        "label": "Shelf Registration Statement Program [Member]",
        "documentation": "Shelf registration statement program."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShenzhenSanofiPasteurBiologicalProductsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShenzhenSanofiPasteurBiologicalProductsCoLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shenzhen Sanofi pasteur Biological Products Co, Ltd",
        "label": "Shenzhen Sanofi Pasteur Biological Products Co Ltd [Member]",
        "documentation": "Shenzhen Sanofi Pasteur Biological Products Co, Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shire contingent consideration arising\u00a0from\u00a0the acquisition of Translate Bio",
        "label": "Shire Contingent Consideration Arising From The Acquisition Of Translate Bio [Member]",
        "documentation": "Shire Contingent Consideration Arising From The Acquisition Of Translate Bio"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShireHumanGeneticTherapiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShireHumanGeneticTherapiesIncMember",
     "presentation": [
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shire contingent consideration",
        "label": "Shire Human Genetic Therapies Inc. [Member]",
        "documentation": "Shire Human Genetic Therapies Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShortTermDebtAndCurrentPortionOfLongTermDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShortTermDebtAndCurrentPortionOfLongTermDebtMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesDisclosureofMovementInTotalDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt and current portion of long-term debt",
        "label": "Short-Term Debt And Current Portion Of Long-Term Debt [Member]",
        "documentation": "Short term debt and current portion of long term debt."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails": {
       "parentTag": "sny_TotalOffBalanceSheetCommitments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced",
        "label": "Short Term Leases, Low Value Asset Leases And Lease Contracts Committed But Not Started Yet",
        "documentation": "Short Term Leases, Low Value Asset Leases And Lease Contracts Committed But Not Started Yet"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/CashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents, term deposits",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sny_CurrentProvisionsAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee-related liabilities",
        "label": "Short-term employee benefits accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "ifrs-full_ShorttermRestructuringProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermRestructuringProvision",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails": {
       "parentTag": "sny_CurrentProvisionsAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Classified in current liabilities",
        "terseLabel": "Restructuring provisions (see Note\u00a0D.19.2.)",
        "label": "Current restructuring provision"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provision for restructuring. [Refer: Restructuring provision]"
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofMovementswithinOtherComprehensiveIncomeDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodAdditionalInformationDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/NetincomeattributabletononcontrollinginterestsDetails",
      "http://www.sanofi.com/role/OtheroperatingexpensesOtherIncomeandExpenseDetails",
      "http://www.sanofi.com/role/OtheroperatingincomeDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/ShareofprofitlossfrominvestmentsaccountedforusingtheequitymethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associates [axis]",
        "label": "Associates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r198"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofcashflowsParenthetical",
      "http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical",
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [axis]",
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r195"
     ]
    },
    "ifrs-full_SocialSecurityContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SocialSecurityContributions",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Social security charges (including defined-contribution pension plans)",
        "label": "Social security contributions"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "sny_SpecialDistributionNumberOfSharesConverted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SpecialDistributionNumberOfSharesConverted",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Special distribution, number of shares converted (in shares)",
        "label": "Special Distribution, Number Of Shares Converted",
        "documentation": "Special Distribution, Number Of Shares Converted"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SpecialDistributionPercentageOfShareCapitalDistributed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SpecialDistributionPercentageOfShareCapitalDistributed",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Special distribution, percentage of share capital distributed",
        "label": "Special Distribution, Percentage Of Share Capital Distributed",
        "documentation": "Special Distribution, Percentage Of Share Capital Distributed"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SpecialDistributionSharesReceivedPerConversionOfParentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SpecialDistributionSharesReceivedPerConversionOfParentShares",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares received (in shares)",
        "label": "Special Distribution, Shares Received Per Conversion Of Parent Shares",
        "documentation": "Special Distribution, Shares Received Per Conversion Of Parent Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SpecialtyCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SpecialtyCareMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Specialty Care",
        "label": "Specialty Care [Member]",
        "documentation": "Specialty Care"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SspCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SspCoLtdMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SSP Co.,Ltd",
        "label": "SSP Co Ltd [member]",
        "documentation": "SSP Co., Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of cash flows [abstract]",
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [abstract]",
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
      "http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity",
      "http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of comprehensive income [abstract]",
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of financial position [abstract]",
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfIFRSCompliance",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International financial reporting standards (IFRS)",
        "label": "Statement of IFRS compliance [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "sny_StockBasedCompensationStockOptionsExercisedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockBasedCompensationStockOptionsExercisedPricePerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in euros per share)",
        "label": "Stock Based Compensation Stock Options Exercised Price Per Share",
        "documentation": "Stock based compensation stock options exercised price per share."
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockOptionPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Plan",
        "label": "Stock Option Plan [member]",
        "documentation": "Stock Option Plan [member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockOptionPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockOptionPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option plans",
        "label": "Stock Option Plans [Member]",
        "documentation": "Stock Option Plans"
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockOptionsAndShareBasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockOptionsAndShareBasedPaymentsMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and other share-based payments",
        "label": "Stock Options And Share Based Payments [Member]",
        "documentation": "Stock options and share based payments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockOptionsWithNoDilutiveEffect": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockOptionsWithNoDilutiveEffect",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stock option not taken for computing diluted earning per share (in shares)",
        "label": "Stock Options With No Dilutive Effect",
        "documentation": "Stock options with no dilutive effect."
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockPrice",
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofInvestmentsinAssociatesandJointVenturesDetails",
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price",
        "label": "Stock Price",
        "documentation": "Stock Price"
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockSubscriptionOptionPlanEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockSubscriptionOptionPlanEightMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subscription option plan eight",
        "label": "Stock Subscription Option Plan Eight [Member]",
        "documentation": "Stock subscription option plan eight."
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockSubscriptionOptionPlanFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockSubscriptionOptionPlanFiveMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subscription option plan five",
        "label": "Stock Subscription Option Plan Five [Member]",
        "documentation": "Stock subscription option plan five."
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockSubscriptionOptionPlanFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockSubscriptionOptionPlanFourMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subscription option plan four",
        "label": "Stock Subscription Option Plan Four [Member]",
        "documentation": "Stock subscription option plan four."
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockSubscriptionOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockSubscriptionOptionPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subscription option plan",
        "label": "Stock Subscription Option Plan [Member]",
        "documentation": "Stock subscription option plan."
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockSubscriptionOptionPlanNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockSubscriptionOptionPlanNineMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subscription option plan nine",
        "label": "Stock Subscription Option Plan Nine [Member]",
        "documentation": "Stock subscription option plan nine."
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockSubscriptionOptionPlanSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockSubscriptionOptionPlanSevenMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subscription option plan seven",
        "label": "Stock Subscription Option Plan Seven [Member]",
        "documentation": "Stock subscription option plan seven."
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockSubscriptionOptionPlanSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockSubscriptionOptionPlanSixMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subscription option plan six",
        "label": "Stock Subscription Option Plan Six [Member]",
        "documentation": "Stock subscription option plan six."
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockSubscriptionOptionPlanTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockSubscriptionOptionPlanTenMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subscription option plan ten",
        "label": "Stock Subscription Option Plan Ten [Member]",
        "documentation": "Stock subscription option plan ten."
       }
      }
     },
     "auth_ref": []
    },
    "sny_StockSubscriptionOptionPlanThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "StockSubscriptionOptionPlanThreeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityDisclosureofStockSubscriptionOptionPlanOutstandingandOptionExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock subscription option plan three",
        "label": "Stock Subscription Option Plan Three [Member]",
        "documentation": "Stock subscription option plan three."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subclassifications of assets, liabilities and equities [abstract]",
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SubscriptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SubscriptionPricePerShare",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription price (in euros per share)",
        "label": "Subscription Price Per Share",
        "documentation": "Subscription price per share."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SuppliersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SuppliersMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suppliers",
        "label": "Suppliers [Member]",
        "documentation": "Suppliers."
       }
      }
     },
     "auth_ref": []
    },
    "sny_SwedishOrphanBiovitrumABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SwedishOrphanBiovitrumABMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesAgreementsonthecommercializationofBeyfortusnirsevimabpreviouslyMEDI8897intheUSDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofNonCurrentProvisionsandOtherNoncurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swedish Orphan Biovitrum AB",
        "label": "Swedish Orphan Biovitrum AB [Member]",
        "documentation": "Swedish Orphan Biovitrum AB"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SyndicatedCreditFacilityCanceledMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SyndicatedCreditFacilityCanceledMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Syndicated credit facility canceled",
        "label": "Syndicated Credit Facility Canceled [Member]",
        "documentation": "Syndicated Credit Facility Canceled"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SynthorxIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SynthorxIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Synthorx, Inc",
        "label": "Synthorx, Inc [Member]",
        "documentation": "Synthorx, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "sny_SynthorxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "SynthorxMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Synthorx",
        "label": "Synthorx [Member]",
        "documentation": "Synthorx [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_TR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "TR",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Turkey",
        "label": "T\u00dcRKIYE"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TargeGenIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TargeGenIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TargeGen Inc.",
        "label": "TargeGen Inc. [Member]",
        "documentation": "TargeGen Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax charge on deemed repatriation attributable to accumulated earnings payable period",
        "label": "Tax Charge On Deemed Repatriation Attributable To Accumulated Earnings Payable, Period",
        "documentation": "Tax charge on deemed repatriation attributable to accumulated earnings payable period."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxLossCarryforwardsOnAssetDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TaxLossCarryforwardsOnAssetDisposals",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax loss carry-forwards on asset disposals",
        "label": "Tax Loss Carryforwards On Asset Disposals",
        "documentation": "Tax loss carryforwards on asset disposals."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxLossesCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TaxLossesCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofTaxLossesAvailableforCarryforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax losses available for carry-forward",
        "label": "Tax Losses Carryforwards",
        "documentation": "Tax losses carryforwards."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurement of contingent consideration",
        "label": "Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations",
        "documentation": "Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxRateEffectOfForeignTaxRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxRateEffectOfForeignTaxRates",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Difference between the standard French tax rate and the rates applicable to the Sanofi",
        "label": "Tax rate effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "sny_TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probable reversal of temporary differences on investments in Consumer Healthcare subsidiaries",
        "label": "Tax Rate Effect Of Reversal Of Temporary Difference On Investments",
        "documentation": "Tax Rate Effect Of Reversal Of Temporary Difference On Investments"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes",
     "calculation": {
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails": {
       "parentTag": "ifrs-full_AverageEffectiveTaxRate",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/IncometaxexpenseSummaryofDifferenceBetweenEffectiveTaxRateandStandardCorporateIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revisions to tax exposures and settlements of tax disputes",
        "label": "Tax Rate Effect Of Revisions To Tax Exposures And Settlements Of Tax Disputes",
        "documentation": "Tax Rate Effect Of Revisions To Tax Exposures And Settlements Of Tax Disputes"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxotereMississippiAttorneyGeneralLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TaxotereMississippiAttorneyGeneralLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxotere mississippi attorney general litigation in the US",
        "label": "Taxotere Mississippi Attorney General Litigation In The US [Member]",
        "documentation": "Taxotere mississippi attorney general litigation in the US."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TaxotereProductLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TaxotereProductLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxotere product litigation in the US",
        "label": "Taxotere Product Litigation In The US [Member]",
        "documentation": "Taxotere product litigation in the US."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TechnologicalPlatformsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TechnologicalPlatformsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technological platforms",
        "label": "Technological Platforms [Member]",
        "documentation": "Technological Platforms"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]",
        "label": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised",
        "label": "Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Associates [member]; Subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "sny_TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary differences subject to GILTI",
        "label": "Temporary Differences Subject To US Global Intangible Low Taxed Income [Member]",
        "documentation": "Temporary Differences Subject To US Global Intangible Low Taxed Income [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TevaPharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TevaPharmaceuticalsMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsScheduleofMovementsinOtherIntangibleAssetsDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Teva Pharmaceuticals",
        "label": "Teva Pharmaceuticals [Member]",
        "documentation": "Teva Pharmaceuticals"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TidalTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TidalTherapeuticsMember",
     "presentation": [
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tidal Therapeutics",
        "label": "Tidal Therapeutics [Member]",
        "documentation": "Tidal Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/EventssubsequenttoDecember312023Details",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r220",
      "r230",
      "r334",
      "r336",
      "r417"
     ]
    },
    "sny_TopUpDefinedBenefitPensionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TopUpDefinedBenefitPensionPlanMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top-up defined-benefit pension plan",
        "label": "Top-Up Defined-Benefit Pension Plan [Member]",
        "documentation": "Top-up defined-benefit pension plan."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TotalDeferredTaxAssetsForTaxLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TotalDeferredTaxAssetsForTaxLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total deferred tax assets for tax loss carryforwards",
        "label": "Total Deferred Tax Assets For Tax Loss Carryforwards",
        "documentation": "Total deferred tax assets for tax loss carryforwards."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesTotalExpenseforPensionsandOtherPostemploymentBenefitsAllocatedbetweenIncomeStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Total Expense For Pension And Other Post-employment Benefits Recognized Directly In Profit Or Loss",
        "documentation": "Expense recognized directly in profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails": {
       "parentTag": "sny_ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesReconciliationofNetAmountRecognizedinRespectofPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense recognized directly in profit or loss",
        "verboseLabel": "Expense/(gain) recognized directly in profit or loss",
        "label": "Total Expense For Pensions And Other Post-employment Benefits Recognized Directly In Profit Or Loss",
        "documentation": "Total expense for pensions and other post-employment benefits recognized directly in profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TotalOffBalanceSheetCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TotalOffBalanceSheetCommitments",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofOffBalanceSheetCommitmentsRelatingtoOperatingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total - net commitments given",
        "label": "Total Off-Balance Sheet Commitments",
        "documentation": "Total."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InvestmentsaccountedforusingtheequitymethodSummaryofShareofProfitorLossandOtherComprehensiveIncomeofAssociatesandJointVenturesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Total Share Of Profit And Comprehensive Income Of Associates And Joint Ventures",
        "documentation": "Total."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TotalStockOptionPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TotalStockOptionPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock option plans",
        "label": "Total Stock Option Plans [Member]",
        "documentation": "Total stock option plans."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TotalUndiscountedCashFlow": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TotalUndiscountedCashFlow",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAmountofFutureUndiscountedContractualCashFlowsRelatingtoDebtandDerivativeInstrumentsDesignatedasHedgesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Total Undiscounted Cash Flow",
        "documentation": "Total undiscounted cash flow."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ToujeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ToujeoMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TOUJEO",
        "label": "Toujeo [Member]",
        "documentation": "Toujeo."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.sanofi.com/role/Consolidatedbalancesheets": {
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedbalancesheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r299",
      "r386"
     ]
    },
    "ifrs-full_TradingEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradingEquitySecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsSummaryofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading equity securities",
        "label": "Trading equity securities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that (a) are acquired or incurred principally for the purpose of selling or repurchasing it in the near term; or (b) on initial recognition are part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent actual pattern of short-term profit-taking."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r335"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.sanofi.com/role/Coverpage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TransferPercentageOfPandemicVaccines": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TransferPercentageOfPandemicVaccines",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of pandemic vaccines agreed to transfer",
        "label": "Transfer Percentage Of Pandemic Vaccines",
        "documentation": "Transfer percentage of pandemic vaccines."
       }
      }
     },
     "auth_ref": []
    },
    "sny_TranslateBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TranslateBioIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translate Bio, Inc.",
        "label": "Translate Bio, Inc [Member]",
        "documentation": "Translate Bio, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TranslateBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TranslateBioMember",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/LiabilitiesrelatedtobusinesscombinationsandtononcontrollinginterestsSummaryofMovementsinLiabilitiesRelatedtoBusinessCombinationsandtoNonControllingInterestsDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021SummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translate Bio",
        "label": "Translate Bio [Member]",
        "documentation": "Translate Bio."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedstatementsofchangesinequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares",
        "label": "Treasury shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "sny_TwoThousandFourteenAmendedInvestmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TwoThousandFourteenAmendedInvestmentAgreementMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesInvestorAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Amended Investment Agreement",
        "label": "2014 Amended Investment Agreement [member]",
        "documentation": "Two thousand fourteen amended investment agreement,"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TypesOfAgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TypesOfAgreementAxis",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types Of Agreement [Axis]",
        "label": "Types Of Agreement [Axis]",
        "documentation": "Types Of Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_TypesOfAgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "TypesOfAgreementDomain",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesCurrentProvisionsandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types Of Agreement [Domain]",
        "label": "Types Of Agreement [Domain]",
        "documentation": "Types Of Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfHedgesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfHedgesAxis",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of Hedges [Axis]",
        "label": "Types of hedges [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254"
     ]
    },
    "ifrs-full_TypesOfHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfHedgesMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedges [member]",
        "label": "Hedges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of hedges. It also represents the standard value for the 'Types of hedges' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254"
     ]
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateFluctuationsofDebtNetofCashandCashEquivalentsDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of interest rates [axis]",
        "label": "Types of interest rates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityAdditionalInformationDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofCharacteristicsofEmployeeShareOwnershipPlansAwardedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofExpensesDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails",
      "http://www.sanofi.com/role/PrincipalalliancesCollaborationagreementsonhumantherapeuticantibodiesDetails",
      "http://www.sanofi.com/role/ProvisionsfordiscountsrebatesandsalesreturnsSummaryofMovementinProvisionsforDiscountsRebatesandSalesReturnsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesEstimatedAmountsofEmployersContributionstoPlanAssetsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesExpectedTimingofBenefitPaymentsunderPensionandOtherPostemploymentBenefitPlansDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesNetLiabilityinRespectofPensionPlansandOtherPostemploymentBenefitsbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesRemeasurementofNetDefinedbenefitAssetLiabilityActuarialGainsandLossesDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesServiceCostforPensionandOtherpostemploymentBenefitPlansbyGeographicalRegionDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofSensitivityforPensionsandOtherPostEmploymentBenefitstoChangesinKeyActuarialAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofGeographicalInformationonNetSalesandNonCurrentAssetsDetails",
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US",
        "verboseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "USD",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US dollar",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "sny_USFDAApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "USFDAApprovalMember",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US FDA Approval",
        "label": "US FDA Approval [Member]",
        "documentation": "US FDA Approval"
       }
      }
     },
     "auth_ref": []
    },
    "sny_USGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "USGovernmentMember",
     "presentation": [
      "http://www.sanofi.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Government",
        "label": "US Government [Member]",
        "documentation": "US Government"
       }
      }
     },
     "auth_ref": []
    },
    "sny_USLegalRestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "USLegalRestructuringMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US legal restructuring",
        "label": "US Legal Restructuring [Member]",
        "documentation": "US Legal Restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "sny_UncertaintiesOverIncomeTaxTreatmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "UncertaintiesOverIncomeTaxTreatmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertainties over income tax treatments",
        "label": "Uncertainties Over Income Tax Treatments [Member]",
        "documentation": "Uncertainties Over Income Tax Treatments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UndrawnBorrowingFacilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UndrawnBorrowingFacilities",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails",
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsSummaryofUndrawnCreditFacilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total credit facilities",
        "terseLabel": "General-purpose credit facilities",
        "label": "Undrawn borrowing facilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "sny_UniformImpairmentTestingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "UniformImpairmentTestingPercentage",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uniform impairment testing percentage",
        "label": "Uniform Impairment Testing Percentage",
        "documentation": "Uniform impairment testing percentage."
       }
      }
     },
     "auth_ref": []
    },
    "sny_UniformPreTaxDiscountRates": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "UniformPreTaxDiscountRates",
     "presentation": [
      "http://www.sanofi.com/role/ImpairmentofintangibleassetsandpropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uniform pre-tax discount rates",
        "label": "Uniform Pre-Tax Discount Rates",
        "documentation": "Uniform pre-tax discount rates."
       }
      }
     },
     "auth_ref": []
    },
    "sny_UnquotedDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "UnquotedDebtSecuritiesMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unquoted debt securities not meeting the definition of equity instruments",
        "label": "Unquoted Debt Securities [Member]",
        "documentation": "Unquoted debt securities."
       }
      }
     },
     "auth_ref": []
    },
    "sny_UnquotedEquityInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "UnquotedEquityInvestmentsMember",
     "presentation": [
      "http://www.sanofi.com/role/FinancialassetsandliabilitiesmeasuredatfairvalueSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unquoted equity investments",
        "label": "Unquoted Equity Investments [Member]",
        "documentation": "Unquoted equity investments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OthernoncurrentassetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized after-tax losses",
        "label": "Unrealized Gains (Losses) On Securities Measured At Fair Value Through Other Comprehensive Income That Will Be Reclassified To Profit And Loss Recognized In Equity",
        "documentation": "Equity instruments at fair value through other comprehensive income and Debt instruments at fair value through other comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "sny_UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionAdditionalinformationDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused capital losses for which no deferred tax asset recognised",
        "label": "Unused Capital Losses For Which No Deferred Tax Asset Recognised",
        "documentation": "Unused Capital Losses For Which No Deferred Tax Asset Recognised"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused tax losses for which no deferred tax asset recognised",
        "label": "Unused tax losses for which no deferred tax asset recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxLossesMember",
     "presentation": [
      "http://www.sanofi.com/role/NetdeferredtaxpositionSummaryofNetDeferredTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax losses available for carry-forward",
        "label": "Unused tax losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "sny_UnwindingOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "UnwindingOfDiscount",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesMovementsinRestructuringProvisionsClassifiedinNoncurrentandCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unwinding of discount",
        "label": "Unwinding Of Discount",
        "documentation": "Unwinding Of Discount"
       }
      }
     },
     "auth_ref": []
    },
    "sny_UpfrontPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "UpfrontPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Upfront Payments",
        "documentation": "Upfront payments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "UpfrontPaymentsForProjectsUnderCollaborationAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/PrincipalalliancesImmunoOncologyAgreementwithRegeneronPharmaceuticalsIncDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofReconciliationBetweenBusinessOperatingIncomefortheSegmentsandIncomeBeforeTaxandInvestmentsAccountedforUsingtheEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payments for projects under collaboration agreements",
        "label": "Upfront Payments For Projects Under Collaboration Agreements",
        "documentation": "Upfront Payments For Projects Under Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsAdditionalInformationDetails",
      "http://www.sanofi.com/role/GoodwillandotherintangibleassetsDetailedInformationforPrincipalMarketedProductsDetails",
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesOtherIntangibleAssetsnotAcquiredinBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life, intangible assets other than goodwill (in years)",
        "label": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "presentation": [
      "http://www.sanofi.com/role/SummaryofsignificantaccountingpoliciesSummaryofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful lives or depreciation rates, property, plant and equipment (in years)",
        "label": "Useful life measured as period of time, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "sny_VaccinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "VaccinesMember",
     "presentation": [
      "http://www.sanofi.com/role/SegmentinformationSummaryofNetSalesbySegmentandGeographicalAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vaccines",
        "label": "Vaccines [Member]",
        "documentation": "Vaccines."
       }
      }
     },
     "auth_ref": []
    },
    "sny_VaccinesSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "VaccinesSegmentMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentSummaryofAcquisitionsandCapitalizedInterestbyOperatingSegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofAcquisitionofIntangibleAssetsPropertyPlantandEquipmentandInvestmentsAccountedforUsingtheEquityMethodbySegmentDetails",
      "http://www.sanofi.com/role/SegmentinformationScheduleofSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vaccines",
        "label": "Vaccines Segment [member]",
        "documentation": "Vaccines segment."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOfHedgeRecognizedInEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ValueOfHedgeRecognizedInEquityMember",
     "presentation": [
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksDisclosureofInstrumentsDetails",
      "http://www.sanofi.com/role/DerivativefinancialinstrumentsandmarketrisksSummaryofOperatingCurrencyHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Of\u00a0which recognized\u00a0in\u00a0equity",
        "label": "Value Of Hedge Recognized In Equity [Member]",
        "documentation": "Value Of Hedge Recognized In Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOfShareOptionsCancelledInShareBasedPaymentArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ValueOfShareOptionsCancelledInShareBasedPaymentArrangement",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total, options cancelled",
        "label": "Value Of Share Options Cancelled In Share Based Payment Arrangement",
        "documentation": "Value Of Share Options Cancelled In Share Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOfShareOptionsExercisableInShareBasedPaymentArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ValueOfShareOptionsExercisableInShareBasedPaymentArrangement",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total, options exercisable",
        "label": "Value Of Share Options Exercisable In Share Based Payment Arrangement",
        "documentation": "Value of share options exercisable in share based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOfShareOptionsExercisedInShareBasedPaymentArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ValueOfShareOptionsExercisedInShareBasedPaymentArrangement",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total, options exercised",
        "label": "Value Of Share Options Exercised In Share Based Payment Arrangement",
        "documentation": "Value of share options exercised in share based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total, options forfeited",
        "label": "Value Of Share Options Forfeited In Share Based Payment Arrangement",
        "documentation": "Value of share options forfeited in share based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement",
     "crdr": "credit",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Total, beginning balance",
        "periodEndLabel": "Total, ending balance",
        "label": "Value Of Share Options Outstanding In Share Based Payment Arrangement",
        "documentation": "Value of share options outstanding in share based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOnRedemptionAfterDerivativeInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ValueOnRedemptionAfterDerivativeInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofInterestRateofNetDebtatValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value on redemption after derivative instruments",
        "label": "Value On Redemption After Derivative Instruments [Member]",
        "documentation": "Value on redemption after derivative instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOnRedemptionBeforeDerivativeInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ValueOnRedemptionBeforeDerivativeInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyCurrencyDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyInterestRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value on redemption before derivative instruments",
        "label": "Value On Redemption Before Derivative Instruments [Member]",
        "documentation": "Value on redemption before derivative instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_ValueOnRedemptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ValueOnRedemptionMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofDebtbyMaturityatValueonRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofMarketValueofNetDebtDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofNetDebtbyTypeValuationofRedemptionDetails",
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesSummaryofReconciliationofCarryingAmounttoValueonRedemptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value on redemption",
        "label": "Value On Redemption [Member]",
        "documentation": "Value on redemption."
       }
      }
     },
     "auth_ref": []
    },
    "sny_VaxServeIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "VaxServeIncMember",
     "presentation": [
      "http://www.sanofi.com/role/Listofprincipalcompaniesincludedinthescopeofconsolidationduring2023SummaryofPrincipalCompaniesandtheirCountryofIncorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VaxServe, Inc.",
        "label": "VaxServe Inc [member]",
        "documentation": "VaxServe, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vehicle fleet",
        "label": "Vehicles [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/PersonnelcostsSummaryofPersonalCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries",
        "label": "Wages and salaries"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageDurationOfDefinedBenefitObligation2019",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofFinancialandDemographicAssumptionsDetails",
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofWeightedAverageDurationofObligationforPensionsandOtherLongtermBenefitsinPrincipalCountriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average duration of defined benefit obligation",
        "verboseLabel": "Weighted average duration in main countries",
        "label": "Weighted average duration of defined benefit obligation"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "sny_WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average exercise\u00a0price per share, options cancelled (in euros per share)",
        "label": "Weighted Average Exercise Price Of Share Options Cancelled In Share-Based Payment Arrangement",
        "documentation": "Weighted Average Exercise Price Of Share Options Cancelled In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Average exercise\u00a0price per share, options exercisable (in euros per share)",
        "terseLabel": "Weighted average exercise\u00a0price per share, Options exercisable (in euros per share)",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average exercise\u00a0price per share, options exercised (in euros per share)",
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average exercise\u00a0price per share, options forfeited (in euros per share)",
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofStockOptionsOutstandingatEachBalanceSheetDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Average exercise\u00a0price per share, beginning balance (in euros per share)",
        "periodEndLabel": "Average exercise\u00a0price per share, ending balance (in euros per share)",
        "terseLabel": "Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r227"
     ]
    },
    "sny_WeightedAverageInterestRateAfterDerivativeInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "WeightedAverageInterestRateAfterDerivativeInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average interest rate after derivative instruments",
        "label": "Weighted Average Interest Rate After Derivative Instruments [Member]",
        "documentation": "Weighted average interest rate after derivative instruments."
       }
      }
     },
     "auth_ref": []
    },
    "sny_WeightedAverageInterestRateBeforeDerivativeInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "WeightedAverageInterestRateBeforeDerivativeInstrumentsMember",
     "presentation": [
      "http://www.sanofi.com/role/DebtcashandcashequivalentsandleaseliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average interest rate before derivative instruments",
        "label": "Weighted Average Interest Rate Before Derivative Instruments [Member]",
        "documentation": "Weighted average interest rate before derivative instruments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofOptionsOutstandingandExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average residual\u00a0life (years)",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "ifrs-full_WeightedAverageSharePrice2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePrice2019",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedstatementsofchangesinequityParenthetical",
      "http://www.sanofi.com/role/Principalchangesinthescopeofconsolidationin2022and2021AdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average share price (in EUR per share)",
        "label": "Weighted average share price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "calculation": {
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails": {
       "parentTag": "ifrs-full_AdjustedWeightedAverageShares",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/Consolidatedincomestatements",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofSharesUsedtoComputeDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average number of shares outstanding (in shares)",
        "verboseLabel": "Average number of shares outstanding (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_WhollyOrPartlyFundedDefinedBenefitPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WhollyOrPartlyFundedDefinedBenefitPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wholly or partly funded defined benefit plans",
        "label": "Wholly or partly funded defined benefit plans [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for wholly funded or partly funded defined benefit plans. [Refer: Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_WhollyUnfundedDefinedBenefitPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WhollyUnfundedDefinedBenefitPlansMember",
     "presentation": [
      "http://www.sanofi.com/role/ProvisionsincometaxliabilitiesandotherliabilitiesSummaryofPresentValueofPensionandOtherPostEmploymentBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wholly unfunded defined benefit plans",
        "label": "Wholly unfunded defined benefit plans [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for wholly unfunded defined benefit plans. [Refer: Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "sny_WithMarketConditionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "WithMarketConditionMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails",
      "http://www.sanofi.com/role/ConsolidatedshareholdersequitySummaryofNumberofRestrictedSharesNotYetFullyVestedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "With market condition",
        "label": "With Market Condition [Member]",
        "documentation": "With Market Condition"
       }
      }
     },
     "auth_ref": []
    },
    "sny_WithoutMarketConditionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "WithoutMarketConditionMember",
     "presentation": [
      "http://www.sanofi.com/role/ConsolidatedshareholdersequityPrincipalCharacteristicsofRestrictedSharePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Without market condition",
        "label": "Without Market Condition [Member]",
        "documentation": "Without Market Condition"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WorkInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WorkInProgress",
     "crdr": "debit",
     "calculation": {
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Current work in progress"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]"
       }
      }
     },
     "auth_ref": [
      "r301",
      "r397"
     ]
    },
    "sny_WorldHealthOrganizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "WorldHealthOrganizationMember",
     "presentation": [
      "http://www.sanofi.com/role/OffbalancesheetcommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "World Health Organization",
        "label": "World Health Organization [member]",
        "documentation": "World Health Organization."
       }
      }
     },
     "auth_ref": []
    },
    "sny_WriteDownMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "WriteDownMember",
     "presentation": [
      "http://www.sanofi.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowances",
        "label": "Write-down [member]",
        "documentation": "Write down."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WritedownsReversalsOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WritedownsReversalsOfPropertyPlantAndEquipment",
     "presentation": [
      "http://www.sanofi.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment losses, net of reversals",
        "label": "Write-downs (reversals of write-downs) of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised resulting from the write-down of property, plant and equipment to its recoverable amount or reversals of those write-downs. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "sny_ZantacLitigationInCanadaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ZantacLitigationInCanadaMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zantac litigation in Canada",
        "label": "Zantac Litigation In Canada [Member]",
        "documentation": "Zantac Litigation In Canada"
       }
      }
     },
     "auth_ref": []
    },
    "sny_ZantacLitigationInTheUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sanofi.com/20231231",
     "localname": "ZantacLitigationInTheUSMember",
     "presentation": [
      "http://www.sanofi.com/role/LegalandarbitralproceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zantac litigation in the US",
        "label": "Zantac Litigation In the US [Member]",
        "documentation": "Zantac Litigation In the US"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "41",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_41&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "p",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_p&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "90",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_90&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "98",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "ab",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_ab&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "74",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_74_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "145",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "148",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_148_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_34_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "29",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=29&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS29_g39-40_TI",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "34",
   "IssueDate": "2023-01-01",
   "Paragraph": "16A",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=34&code=ifrs-tx-2023-en-r&anchor=para_16A_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "d",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_d_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_e_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "135",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "86",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_86_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "86",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "88",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "122",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "39",
   "IssueDate": "2023-01-01",
   "Paragraph": "86",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2023-en-r&anchor=para_86_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "39",
   "IssueDate": "2023-01-01",
   "Paragraph": "86",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2023-en-r&anchor=para_86_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "46",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "2",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_2_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2023-03-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_52&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "p",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_p_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "q",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_q_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures application of paragraphs 59 and 61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI",
   "URIDate": "2023-03-23"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "38",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_38&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "11A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_11A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24G",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24G&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Credit risk",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g35A-38_TI",
   "URIDate": "2023-03-23"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2023-03-23"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_20_a_ii&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_22_b&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_b&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_21_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "87",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_87&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Section": "D Examples: disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_D_TI",
   "URIDate": "2023-03-23"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2023-03-23"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG4",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_IG4&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "144",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_144&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "57",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_57_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>278
<FILENAME>0001121404-24-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001121404-24-000009-xbrl.zip
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M0D#E)IB.C^E"6)\'O2R!]"VLESE^]A4"\(^  %P4ONFEY2K^6Q0+GP-$Z=R
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MUHN;SS_KRH19)>)M 93K.)RM@4!NAQ5RH$%]H'XIHN/1W0<ETB^<[54VNQ7
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M=#$R+FAT;>U]67/<1K;F^_P*C!SCEB:*M*C%LB2W(]BRY%;$=<LCZ;8?)U!
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M&[O,FB7282Q1VPC9%/Z-6;,8LR00[HI37;+9^$M$=B[3<Z9U5.>Z:DVQ\=[
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M@FC4U?XI#U!OZS/^S.(D_+SC3U!+ P04    " #C65=8$LE=\5@'  ""(@
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M4=G=)GM?/-MG\T/!J?^!XB]02P,$%     @ XUE76#J B[.L!   91$  !0
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MAU7^\R.@&>M'VZE[+/X#4$L#!!0    ( .-95U@\2I;,_0(  *P*   4
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MFMNG7>[/'2?/)>?>6DV+Q^64^AU02P,$%     @ XUE76!A#AW3E @  %0H
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M7%&@9Q/)984XE 6N9KM<9X_XY(SE4-T??W_Z\A7_4[W;X!V#J_TM"=][7P#
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ML:Q<LU$F$G/%6ODJ;'/!U5J[(-Y#E9=<@R-;-!CK")N0* 93L&[?5B3O Z>
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MPB7D09U4]@16FGW<'#E;.SZXH!U]&487ZO<T&1]13._P4/3@:#%*]GXV%>P
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M[[FC*<<I/67:)&#$1$69U=,<DY#*MAE6-/7#QXD;K\R.3LH67U<2RL)>X@A
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MM# 3JVJ8$F_X!Q<EYU"U ]=W5'-6\UKI*=\&;;8F#3&I208QQ8ID)$H7S&D
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M9_Z0T!:$G!WK(6T3L. _82:057(]6',S@%(+MJ>7N^W#U'! '@U' ;S]J%5
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M(J2(@,YZ!;I#FRD;B!E_VQ YDLLF@THABKRHJB.&ZP42@3P.C@=<?H&&3>6
MXY+LK['O3A+!QK7558R5XIIP*5IB5).#4A/(+YI<EZ#@]LIA7^'MX%A$" FC
MG%(^=68]<:$'8NR"F@\JS#,[S4F(/#J*:#8)*P*W,-=1]&2=]M7&$9^U436/
MSU\Y@G^NGUM$B#I^\XVUG_3%NPJF!TE?$+2AH'"V=ESH*(Q:X9#""_G)VF4B
MS1("Q/"UR7+?%\I!*<D%TQ8.)CD]( B.H&Q=Q;BO9^G@+[?!&AXVKWYRD5!/
M%C!!;M3B0$P(9L/>RH9\XR-AOQBVEACML[Y%GE9+@JX0(A;LTQ&TRL/OXTK"
MHB)Q-K=3^[[BUG75P"(37.D&H7JI%%=Z.&_J6DV3X^!PQ@'O\E#[C>3OH_'I
M^&#\='A&:=4MC,'^ZY'T$(U@)#U(DMWR#"]/IR'+CV5A&R7/\6W(Z*#LO?[Q
M^WTB0-)N@&).P>6._1GWGM;JSO[X^Z/CXU<PM.8QEW@_>5>.*.YP,#YZ>2S4
MH!J92([.A2%8?3JF 7AB:PD6.:[FR:N&%_5Q%W3=$BX[7K3(-.+6X08*BRFQ
M#0.6U2+D*/@S%5U&]^(4M.__VH*_&?]-X7Z9NMBL\]/N(ZBYPHJ;BKMGR!\)
M]542B!K>S<0W<DD@+QA^*5-B'Z*%\ZTNN&8@M]>&*OEQ#B4U&0\ZOLCCI=A)
MWNE[LSJS.F@+(;W/E1C,K5:M_%MNFGN3\%5HNL-O$5;/[40=J1#N8#R"X>?A
MZ*?[9,3AZKW]16_/MV\OW 0Q!5S6=:^O1]1V(B?<?"6 ?:R6AS]2/3NV8:ZY
MD\"\T]P"7=7-(Y0PZE<8'%G!X="$,!__'H^2.[4*YG3S3MX0A]]MOOU0]Z T
MP=%1U&!J:NNLE'B+:="FNK2-*Q1V>TYMS[AP=\5E%U;:9"-#)"SNE.B.T0)"
MYN,X#+6DUD4Q"WSGEB*N24^"\196LERLM'N X].+62FQ'@>;;J<!,@ ><'R<
MC(F:]/@/.#TB0!@,W/;ZH5!STDM3S90^3X\S*P24'^PQ3IU6DASL-W)&,$^/
M";8%&8\3'[_'-KN#CR!942*_K)JV"T3E88T)%V13YP5L)SLWS(A/BL3L G9?
M'[B%A1M.!^+)6+G#@+M7:.!T%VMZM'W@)L$K OSDJ&9FVCEB5TC[ %L3EE9+
M-9IOV$'7F+*5Q/NW#=&8-<2_J)V[%V&M[4#1A),"0<=\ 3;4)RP81:AV9?_9
MSC#IQSR-L*XS.[<%M1?CZP)[!E)U8[9TY8X4$M?^6WB[S0E"FH>)@FKP-1(F
M8[<$[W7Y@\0F5LD>#SSFZI!+G^ZU&VO@<L*N"*W)#[#PX;(L9U*=9*=7!:S[
M)9$5_? QJ5<U=O=,P91:+1O\9$7M%! +L&RXA&!FB1HT32[-8I*3N=64GV%,
MV 6T(=.9?H$V&?QIGVS5WIJZ:E!4##4E<(GF?%X9Y"Z?PLO ].&A8E6E$I(&
M\T6N-1S?#7;423F0B4D;R=S52X.&K2S8E46&2_@6:J&H@W<*%W>UP)@U\J72
MVZA(& <^W=<L<VVQG003"]AKFY=+;H,QN.9(<4OYCW"!PZ%/LM)]!#.8KI#-
M6[84K%00'Q$0E*H<.0[(2*_*"3:GQ6YE!$>XQL+7HD7#@_8&)FT7F3"_4LO9
M?Z%'UBXZ.\TKISN4QL,$>[K,K]GV!K/I8(K<=X7^1I9)BEV75V53PDKVQ2E<
M#F;%4TL2C$A[0_%C?N0^2<QFX=Q>=43-F; N&"U-='"&[&_7F3#3@M\[V..*
M[$$*!.7H<"X"I0PI*(]L4]G2^12:\Z%WL2[2'MCSK.)<$I$:.=8CU$%R3-#5
MDI)Z 44$[KT0PA).)B!/\0?H2SDB<&ZS;!]<,M=/A1@9715J=V#H^F;9\!SF
M;47LE_:S62@WKVP8V#&S4?)#(=Q_#0Z$';;;A\@[2I0ER(.- PT6EG.\)Z=K
M]XPHOZ/=< /!Q+#$ +"JG@]<C3> ]4F86P8G Z#M(>IY3T6/(!=0T8X4+=H=
MZ8>CG3 K.\?Z:L>Z%G\95E&:BX$7VI <37J8B!H.J&F$G0-F9!L9+OG;C?F$
M'F5BL@4S9H.L-L(;(E-TU[2[GFDXIA./4MOG-\D=\>JYE"DN(N;0V1N,GG9E
MKND20 H?MP9W$1KR6=F 7A.!@G5SIY';BE.$P:N73EN_/2?W,"C7&Y3XI6'Q
MFY8'7-'#>8V5G<I^7J+=DW:.#P6G.R=,>XIW!\OS4?J%.6&WX.K$@X8'%NQ5
MO"6(44.]=5"U4Q%%3UINUU<D?GNE .-=*<"W70KP4)+&]_\4>;T:HJL1*@UM
M<8E0R-/S5UX?-3>9-*;R".T!+88:(U1,0306WM6B5=U6!:%ME;O+?(Y#HLZY
M1=T1*">E=8B0G<D>@\?E-V2.*@QTZ(L%193!)H*A[&^O87JA/?#FB.? ZOA/
MVLT:KMFIG>&MC*@A!P=A0B0-QG, 7-J UZ& X(;Z>+MVPA;TD- LQ^F"3BN<
M+28LP(OR-35Y"#K8U.C2UNQ1>FQH3"84=1L"VYI/9Y (\P )#O58#]8)3MCF
MF#M=]I1EZ6]DRB9:YVUZJE+&%D:-)S0S* :-/_VU3_MP+B,&R]Z^',F>0C/X
M +\7;L7QZ='!F...X9^.N3]:[YMCU^'RQ^_W1\D_KH1R,3 =6:SK2+V,CT[3
MT\-#*A*7^6>V@\33N0\T?^$0$+[G+Z8 PPW;PLIB*-73L#<7,CXYG)5F+F21
M^]E86NP6B=)\(*E81:2T%V\^@(1]#^>\91!A2&Y?<SSMEBUQ]KVWWT!(YQC!
M0)A8+?%BI-:LLKHL7(]1,?!(MCJ=D>V_Z#* M>I>+$)B"?8W* \R;,G6YI&1
MP]$G]1.)X97]NXK!V>E!* 7:3)E?(W."A<-*9 38PGSFQ/\EV<.LS&/^3,QQ
M8YL4&#@G.[?A AF&O;VFWH22::5$..7YD@N8]P$VJ,<K? MFOU:1HXJML'<.
M:_-:\>.;X&Z,-?!R2RX]D6'B-XF^DA/<R%5>"3X</3:M@$FFO667=*IR)1'+
MGWM+N<30'$+2]4 '=)IPY"S84]AW+6A?A'> 9KZY=44K\4>)'=*PXC?2_TA:
MMYT@:H,(%$"K<("%_-]?O6!8MW;C:#\9^S?'91%6!Z[*HB0M@7RFTH%)](H*
M8X)!G,6R4:)P1^."(Z<PD)A$)A1AM8JT_[#S_$U(<T:PPFTX[,/B_M.&+1+@
MIF98Z';Q^XL(8/;Y68 O#5*KT[<<DH!DO"2QQ!M#5E3ER=/!$@Q 0#J(M:6K
M*=B#\J;@0X(RV!C..10MX9@<-G=[-^F#U8">2C:G7#S+<R%Y&:8NVF"@,=Y%
MC@-=WD>OD@CH_,$!G=]Y(_1GAE?)D=D*._[6RT]LZ8P+Y+=@QNN%ZQWH.#:<
MWHS&IZ/Q"*1(&!I;;CM7YAGC!X->@\B03E*E-B@'&G^ OXH5=CZ*(P"N])/(
MPL%7P(Z;1X<'WY.[I*55&7J=U'P.S2_E[7W6Q_ONP%&I6V;+E&[1R+5[SHMP
M6^EQQ- L::9UM9I]G%G/J/>64<A:J@X+%[=A*K]AVF;PZ,"O .FN5MH.;/"'
MV"B:>BE&;EM%R6DDJ7>&!XSP+Z6I")GX1L$S'%*/:%1QX$I>JYRL_1\F-FNN
M;-0P!U$$3P;P3)LHX/&<_^=2S A.3O+?&K3>'I/785^-Q"4A"Y_) B[+]KK,
MJL==. P@F*I:48FI(&GIK/6T%).\#@@QRKJF9KW,$W<Y;8>(_^NKS,Z3MY_!
M0B3#\2?$W5##\S0,*&WXJL>QR3FG$B%\D;ZV?G)[SRV$L:W()>]_P?]3F?9S
MTI&,EO^W?E2)>-97\MTOX+5W#3OX%!+;@88?HC":T>G.!=HU6GJ@I>?3X( 6
M(:N+\_5WF_$PFT%DCAP-*> MT]S4%+G!F#U8A#ZJLL-I/T3#(T8'.S> 2UQ,
MTQAL:$A9+Q_FNLRN&>\[I9QIV<_<?2,W:GR;3E;)D'+WZ]:];INKBEK>2TT8
M00 FBO*3@(-SSW8W\]>_'ER"F+> VPW55[O+X%&6'BX$V]2^80=#PC]EF"O?
M;<C7+JEBU<2=P#B87&*KL-W2?^VEGU!A^+6M:KD&%!";\_UB$:H]X0[ 54N!
MZ]VF/,2F\#4?0+*753G/,&V Y3D5=OHI*\?,:!=9N]C9K@_1M]A'TJY-1=!Q
M5WE!.9VD1G307%O>SO7\4!;>]003M,#VFJYO7#MP6"D7\^RC[E3W4SE.3^A5
MUE,5?P:OG;QXU15^CE#[9X78B'GEB/IO3(4U"$IM&%:02.U<8[FI MX_9!D$
MS=84:9?\?90<'1\?'!]UBB4Z*9=]185]E6Q*2O5$6)#O".O^U9858L:PBL#\
MD],=$58PZ.:*L6!]VX:W8 V)<T."X!UC@WTLNQ?D<(T[>07:PA39 L^+FW<(
MPY27.[[&\$UWD8NN/(R2"^20H*"YSTKK/+[FMO1WA4DOJMMWA_"OB./P:X^9
MY@[RX+_H,8K$P:=UOO#?)4;JWTO9%CWU0P ,X3X6[O<$,MYUI?BMI2A'NU*4
M72G*@Z#/NNU">SU&'0>M6BC8*3)O!7?-J3RI1B?D=3_E&"?,PQN\G]=9=^MJ
MK]CJ?M&\*%D)^A=1AT@'!!_#@QK4RMI:[.6+Q#7()*@R?H=N..8IUHX^X?2)
M7TAP$K%JWZ32?9_<7[-F W/,L,"/R:SJ,D&P7S;/*$IGFEWP[2$X7!R^_O*R
MXI1Z9+WT;08"WTI4->2-)K3,$CFBETS]Q.'LA<D*+$; XDU3KQ?=G3O]K'9[
MLG(T)>@AX!'>*P5D9%P@O5DM;7"JP3P./(>3\?C@*$4FL/&+LU=W9\7<=V#K
MOK3U1>SHY' G8L]2Q#@^7=AIHP0)= ^JN'U-$4OVN$.XO Y32Q42ULPP,)NW
M-4@<5VP9IB:&#SRBW)5#[@3UR0KJD"N,%00!=U-DPWG+#39]022HG#AW_0^)
MWJ&6]C]4VRJ" 3\8KRFU-,P=05D6*5/1$KYAXTKM,4<;@N85AJ>E[,$-,R6A
MIC_J/%PJE&K2T*FG,@PMRCX^_ -H\"HY.?S#/I:R:0UA0&])93^9U"TR0X3)
MM242'@8P.5=@T]'127(NOU$R>(P_N<H_>M/XD/^QQ5"PN"=2$K<V#3N8*C\;
M$Y_[-IF>OL7,YUF>D>WMRTM%5/\*GL?2BR W9T"1EC9)U./V\.6P%&[QZC-Q
MR?=V4K6HYXFQV 4-UT"E\6C-^-B&P&JJ!5V#+'6(X#J!VPKN"7Q9#'CM77L:
MNN.P5*!1UN[G*'D++N J4#GMA)J\,* \Z,- Y\R%':<VNR;]$E4 (?R'Q0#K
MIPI]JL>^-N7R  ;A$L'D7?[%KDIA>F$JHN8&Q,OWD*=R/KS:BI)+77/I&%,2
MYE?1N[X?PHU9!6ITX]N3/;MY_O%8W,3GN-$]X-\]IKTON'M^G71Y8Z6&4RV7
MMDAF7 KYGRVL,HK9]AZJ-ZTC31I8D30Y/D['QT==#5: H@>+Z?0LH0NG$NJO
MH$F1Z^0(XG"4'AZ^3(\/S[0Z#XX:OK&VZ3@=OSA)3X^/HWY\P:.N,Y-\__KG
MMQ+>K:6Y'*M<.-@9]SI<V[AXCH1$.!X_ RG(D)LP+&7E5./QR\-T?':J(W(C
MD+9V7!3W!0:@I7G]$>!E?W)RDIX=GNLH'*_ 9!4\Z>:JY!6S($J9$GA0$&AC
M)V<D[*#?D5&N.\@DU=@^,E=&:RGOG%'UIR_1;6LIN[WC FSO^;GP8CX>OTQ/
MQB\B21:PP?U48W ^DK/#].CL.'H8:-^!$\&2<_0B/1^?N*]$(NME"RR78W!/
M0JZ*G4P]'9GZ[X@C/0*0QC;F@!B0KZ(\M;. YHA51[B-O-5$SM,6F4\>X^*R
MK,PKSO?CWLE@HJ?+ _D'(L]UNT2>U[J$NWV"]MANGP;.(K<3P"#YE]HK-,AD
M)$SF%6_28K=U,00Y[,[ UD]G\EK(S(8E\=3XH)#SQ2CS&\4.F/D6J^=YPV&L
MYI+LYNU=SI^*Y&)997ER?$@N\7@H?8?2[G)X7S!WUP_$@' 3)R<Q3 <$%.@E
M:=0#*45<ZT\<;+1_"L;Q)"DE>X=UVN4W#3-Y'9(SD@0/F C*A&VU8#GQ**M=
M?NQ!>AQT"6RO80G58_&QK>-S;JPID;>XQ8I$B<GF&YW^NF"@"_FM#0Y*JK=L
M @X4L>'J/GKFX@9^7WO2CJ^+@XF6]W"T1AX?&TE 6^>B=>/C,%HWL-Y(=.P)
MDP^"LQS)#)*AHW))CM.7A\?IZ=EQH$C.T^.3E\G$%I;(WZL.9_R&L-/^*+EH
MA'P3GX["DG(]M+ML! /QF3J>@Y$ *[^.]0^[$B%SX+Q%:V*6Y22(U*MU>Z^A
M#QD&^"EJ(Q?1$86O4\%%++,J*@QBFFB]?@20S,7GF,2Z,C,FG7.TX\YNBL%]
M:P2J*,'Q*2[A<<C?OOD"$^2LM\767FCELE$ :GQM#5Y76[S95BQHT83(-9.<
MC?SZI\D'6^ &_^@L,-((;]V*J?)\.V*MZ=F/_OC[XY-7SWKM[LDX\,8^%,W,
MMX>A[!-&[3"4.PSEU_%JNY2H?,TYIKZ-N'YNO#FS'OW>AT4*L#N NP_<B)HL
MFKE>S)M YY+""^B0NN0:E9VU4XP',N_1Q URD(: G+*V07+ F6<C2)A(BAZE
M/_/^?/_[/)Q-WU@_NKCB+QX (S<=-2_Y@+A=>>Y,$!W WV0U,;A P0JM[]?W
M2TN9AMC:9QRD &M/:PWP-T8+#D(.17-9D<& X[W)ZBWFM,03(;G"5&%%4VQC
MB54?&!F@]CC@C4L_\NY6X-+6K<)HP:1PM-Q=F>]B:U$XXG8UW6>W2^%G%825
M[UKJB.S7F(/"(8VG]>CD@!Q5\5U'R5U",1'N=TWB'#WBHS/Q@@5 U<*QSB/[
M^GC?<QW@P_@L#.@-JG>A^2NS+#8@V7:V3LFNLMMY8UW6@Y>"-G![EF"81?/G
M+E9N"V:Z)A5(5V\0Q5QWRV9SE 4&>@VS7' OVZ7)9DP_6E^E#DP4G61JUT0L
MTWU,(H\".QC[!U-< "YN8=_$'G\<$\#;KAYZBBMTHP=>9M?B-I,3BQ>/(D*&
MQB==@_A)8A0(_;[F.ER;[I4XW?#+FC,6F$A1)("N:0CCH^,3+)H"3S=$ACL\
MVJ"5%M84VA4:UAD6?:4=Q;"M5W, GC0#7>%#+'J%2?5DFI(KU =@#B8-6O:S
MC;B*J'6BD6:35$RG>%C=$ >[7[DF2SDVEJ*@XMNV*@L0_^1G4VUS7*>_WCV6
M<R2D[J^BFF@WAK!#VJ]N/L^(+OG:LG6J)I6>*NEXDC0WY0'<M!)8#4!^O\Z^
M74.$2.FBEIJ<4S-JBE.TH!;HP\JZ3G642O3X36XR6G/W,Z31E2.@9@YWS&.H
MLS)V@_?,_19H1?K'?:@''7V5V=W7H6C5$HU;IVGY+(L\CE5 /3 /F, H+-\,
M1!PN2! U4CC2@A"Y6^'TN6'#GS(V( :0V'>4#&[O  I$=.'TJBRWV1)>PS4[
MS1@]O%%TO>KG.&I(\^;2>Q1NCG2@NR><>=A3YX1;#&#.G(=1K+7/QV#/PNW=
MF_Z9Z^%+UY<>('AG:$?2&.LM;CL=*=_.R],3^%=%F'+8PREFJS!CF16N1'ZC
MN"04=$FH=V&M22XC2DJ5\!I%Z'N&-;X7S/"2A,4EY.LB_/RWEIG$O6.HX,1W
MC[E#I8EJPJ!<X.A.3EU?NC>)\./8\LC1GKK;D1K\RGGW48FG,8U[1K^)?/[7
M3>')*9--;3RT$;#K[1M'L@BO!&=!(UEPGI@MA'A(*GM)+4T9X+M(Y!&<CY(C
M(GU(20,]$8F^IRC\3:1[2Z1A("0<70MYA+N96<PL5UG$2A+>ST,1+P_+#)RA
ML%AE@HBJ\A-:S167N8 8F9E;8BI.(HNUP;#G/ZRK,M;^.S0'Z@J&$T"W!Z3;
M5-I3;<^PW,G,Z#.Z#E?PHH5KHDV>96"U4K-#&"^;A]D2&73VV03)76$!]5.)
M!%^?ATW$9@OI\\O3_&79V.O,D!7MXXXWP81J"V_#!*W,R"'Y"K.P+M(;!FOE
M,#JP+A*?FTYG(G>E2)O@-*(O&/HBO![&G#$A(%[N%A'HJU'RMOM^7?KZJKRI
MHZ'B?^N7I(RDVXB'5,I(UX5C'D0M)1X8YB2>%O7Z'C:0HEYX!$V3!0.1=2Z\
M+>@F;^S^8S*ND]UGJ$VCD\YHV^H B!I\1\1MC4S@3J<$Y>;04;Q3W-FK26;E
ME$GS$FP02\8:NL/;:Z +:)>L. F_:'O:,#(C 'U8XN#J'"GD5V_7\%K%%:6_
MXP$*=JE<OTL3>V7R.;4_+-SA#&@9V$ /SK=OTQ.>=->5TWV/B4GTB:!B>GHV
M?@N7H_:5Q^VOUN=PJR^\G3H:PZFOC"$;KI4J.04R0A%TZ2$>MA!3C:5=B:2U
MZER2:?7Z_<#=I&8QZ@0Y$L];)I4)[K>[9EM_)A3CON2V8(13]WIB ?=JSD?"
MR9 D3;L:26^5SJ+2\Z;4(DHD'V.XS/:\*"OMY$K]=*B[JQ8$8AU92<.C&YC@
M[T'83FY*KF?KBG)F_4WG8G_!BR[@P,N]OG)/0FT0M@5]:A<;[Q"L'"R;R1_Y
M]@I-,MI&XADY$CAM0$[8[5],E;Q9/<U+"?"KW%"@CZ9(,@-6*=BK@=5$.0?^
M5QJ\LD1<#<9X2?::;JJUK/3OT2A !/1E*.BLGS3@KU%0E0P0N!T:RJ&A3G9H
MJ!T:ZB$DK=,5$T/(U/P<M8,S*++"G5;X: Z6G W;:::<89V@:[RLN/)^0!V@
MM;2);)1, Y^K9:=3\HSSA%*AMIAQ\H(N5$9:9 TAAUTS/,8.J4[IS(_+6ECY
M9$/>/GBETD]5-)>9<J8FSPDEGFJV!C^3:]K-FII>JW\-ZID&+JYI?SG$L?83
M0^Q3":/IUEDP!@89#MB/( :1+V8S/96K]^-OBY(^N9-UAT[!6,]L!*,4$<UT
M0TY!!)E%8'L ,<.+][[CKX?94Z2LEY!,&?DE$XML 4*NJ$L6.(HQ$F# ?70J
M28QH4$BI1 ;AD602R2ABR_RW^9BWC@/MJ#!JP? -,&DH1.:% PL@F&.3*?NG
MK@:"=6)NK[%HYM81;:]8721S:[D&9*%IMXRN&:7%QI6:5.4GU-C4X]W[7K3.
M7.N-3/R7IIH1A!3.]LV5;;39:/ U;L!>:YZ?",4;;#ZB?F_"<BX%-[.VP<X+
M"A+*5VY@WC/,"&P /GR##"R6KUJDI.(0@")FGUBK1KQ$'[<7)_5(QFJRR,_N
M[4@/&1'D?\+DS9?F\'^<5.5;-(ZFUDRR'%UQ!'"!_L@3,(WH3]ESOX/_P2$-
M#Y;0F:U<:/*)G12T$:3S+_\/G.NR "OXL7L 7YJ":OM\I398RW0H^.1P#?"B
MK!N-36AU'7TP<P &.$IXWO3<X9-^*7!S^&1]:#C!%26'#(%B&BSN@[L*$1)!
MTVAIWP0G'!E4&@8[\#OFP>,3>?*7OMSZOO63$?\+CATCR2/13JN_DN'.P!\Y
MN:<1NUUM_5>OK2^3<D(6_S];L$!GF5@)8- BDD\:CB!$[)</<D[(^1T\1_"4
M7SX(+ ]]S9K\=GF^)9]R:N.[CL*XZI_"T?I?2T8)MZ9V6&.VG]WKHR?@5V4\
M:8?? T[II6""'241YX(HW"LN\Y5A [6)\FW\2'Y!@HG%29[55PMYO4$JB JA
MGJM0WPR F)HK#'@:,7RSPOWGLG)\26)NQS?=:J#^2U=W;F?<]\,G3U#U[0AK
M'^"X6+906-@YIE+#X9E=2F9U(KX6AG9:2JM)$O82,V?-O4_5;E,?8%,G%2/C
M8&LRN#J1!V2J ;I._"P0@< HQ7(,-$66<I9A7]<<TOL(0EEUY !%8R<+CW#
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M,\\B4B8TU'OVNIXV3Z_@ -78U]!Q+&BH0[O9JHX/ A._8#XGP$4AH&)N*=H
M/[H41A1,N12U_ -U=V,^\XO9H,%?@P#+3T2_@O($+;%8^B_#6Z>??$&@^SN_
ML!E8&05A<_H0VU6 $XZ7_&#,**0AJ<-5E(+KH(9;EUS-+8<@$0J4P1]S\WK1
M3<]90N]Y.G^:*/)F,$BVQ73PH;O=M!6E*X/S2))S^RWVQ ^9GH6]\7X7Z.:[
MX@5%Q.  P]:8QK-Q!PQR>T?[0?C21T^#)''P?#4(E(?2Q5*-5U+*EN=?U*?*
MJ[+Z4[B(FR<:?!:/[)L]X7$;Y.<\\;N?9ZU"[XJ*\L$'$:>.O@LE.- &4;"
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M*DWP:2_3"/[1A5%(%6BUB:K9I=.I!023.S9);@VZH3<EQ7.(T9'9EV$EW(G
M<H;<=F@CP6S5<ZB9W!B\(*E?.Z,4+B;4\4BL2Z>+[>X[+(:,F<QR1IB4@:&
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M;QBGRW,XB;K#]CA>"]9[PPO)=BEE[>A&<+V,# =+7 R-KPAT(;%[KVE\(=-
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M2@ZI=+Y#*NV02@\A:;&:[+$HQ FWZ"+TD2+3Z%&N ]<-"7E"\U;L7NY)5P;
MC(A:!U&E-T(D5&7V6K+>7FF0/A+6Z_@3REII%<%>-K*CE'7K!)-'0O7!5 LW
M=H(Z.S0\8M4T___;N]H>QXDD_%<B(:%;R3O'WA[H8"6D%0+I$">A6R0^>Y+.
MC)F,'?PR$'[]=3U5U5W=MC,S!_.6]2=0)NO8W>7J>GGJ>? SN ,NY9;\W74O
M?\*O0"F^V5=!AD;AO7*95R><Z<^6D6*:OT7=D0\] BH?H(P6#.@65F5I^B&9
M# ++0RV94R*N#*F*MOG]0$@K;V()=541)UH!"QH,:PYTYXD5V0Z]3D0/E\Y
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M"2S-K6&%\9@^C?&6U7G# ]"U8T/,EJU/:I$3PTV%:GB;B\2UUDO$3T870 B
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M/F^X.*7Y7%+17&9 HK=_LWC[Q_#V?S]O-@?_G\O^>O?U_P!02P,$%     @
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M*2I;1;RQ> =5>Z4Z0QDK=&^FK%7Y9%A"FM0Q8;,,M$USKN>RJ$?/(9[P"UG
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MD2[4RVL*66Q&UPLOS[U8:HH9_ 9I@%!B4\CFF),F J4VA6R..NF*WE53R*8
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MI6Z<=',>:+U><5Q-R85^G_A?KU<<=^-;L6*W ZC7*P[+\1WI<C^F(U,VN L
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MK(MP.]%R\0"=I:<%S G>U6%MP#>DN%'?J0D!# _>%6(UW!LRF(GR3RDT'1&
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M4Z >10H(Y@#:'*@'S %Y%2C% < DD$H,H,V">A19()@#:-.@'C -Y%6@% <
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MD 5((Z-.C2PX!+( Z?U6G1HP-21C =JP*""+#($L0)L4!61Y(9 %2&]ZZ@3
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MN."'U.'9Y*EM/WEJ-B</,"3 %\W1]M N,"R %*V@<^>[P!P 4@>$2P6ZP/
M4K2";J+1!08#D#I Y-K A !2M*+*5<JH8.N"=(</O<XESC_PN]0#E<@KK08R
M.8OU99;FXSQ4T7CNC,6'KU\7M_Z*^=O<?HLM?['-"[Z.XC2-IY>C^8-D3-<#
M9B0O#O-M/-MNC-G=H(X#1CMLA#*- ,R6V BHV6H/&&Y9%7"BI1=+G"=Y$C">
M [8=P10.R'/ *!+8<UY: 1APLA6 LR5@($L^Q][BD(:*)DO 1)E@1H)K;R#+
M,3QG)^1.Z-6 B38[ 353ZM4J@:6!IBDP_;V0(LGTO+O\--#]::Q3]1\Y/(X3
M,A<,]FK N/3E81[^*UN<>7H;YW=%>WS2L)^NCK^G,_C T/#%P9\/[V5T+8=R
M.BOF*,ZBAAJ8E0$,M<5-7KT:,(L"&&J+FU%[-61\LSSA=_U@WZ>'/\?1.)5Z
M>A1K'7\S*2:978R]&C"^ !AUB&P=N=QW+U%!BVR 7%J_-.KS FEB\O9;,^!Y
M-MF/AHL#Q].K/)N/H\M1KL?R83(A*D"N5C&50 A; 7#1"RI;4:$,N"Y^58GS
M:*!-@BM/Y.*_S\U/TC))KXTA5\(,'D[,0-R+5-W+Y&LBA[?QA8C$6-(*<,"E
M,RE](,(><'%.2LRB@B%P1?^4)A\]?!%3^230922/5!B:Y\\/J/PUBX9:#L_4
M*'VX6/S]*(Z&R85(,VU>?R'T8)(/7)&RY.>'-:S) ES];R/+L^'_6Q;),D:_
MO7;(T6&C#TP!=A[]+_']_.T*5\"$I<": L!%_NL*Y"W21PG.Q$"%YGMOAJ!>
MP2M#?K>0[GX29)%:C+_YV^)7KS28+MCJ_$>N'EV^S?+!Y;_S]WE%UCHP14"3
M=3-[6Q?V[>SMV5,/RM[JP*SA=;UN'J*A&N2WWSLV68%*EZ(=BV@@0SDD, 4'
M\R_^?Z/';_[B1-QXSC[3$9A)[#4=3<*^7.LZ9%+P.C"/0 N*14D C!S0)'!"
M%5:!T3QM%.MI'LG_3RW"?*Q?#(\O/G.?($F-8#CK-]EL?]>!N03 J .<O-2K
M S,*_(Z&U<D"S"M E8"80,"0@RH;MSFM&L"T@I0^").M 8PR !**8@X1[C6
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M$D>+.Z&FUS*_#^D@#]C1>/540A( TY17)5A;*E4RD&9EBF2<)8O M'HN(1&
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M;R+,Y.7H^2LO[T(U+GXGE-5[&_6 ^1K[Y""?V+S93J,&S/S8)P?YI&;5)\"
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MR*LX?Q-*%4V;8NU8[GC;C204*\ARQ]MN/ &N(ZN[&1WBI*4V<.%;W9WK&-8
MKM&KN\T=PQK .*&ZY\I 6*,#3#[X<@DDHP"#&TY*G1XDV0$F39R4NK4&,!KC
MI-2M-8 I'B>E;JT!#!PY*44R"I-2=&NX.B>[PZ04/2EU9@TFI1PU7K$&DU*V
MQLO6Z#(I9:-L911@4@J5>>3[O%0T[FLMHK',/R.Y'+WZ#9]>]_LD#L.'2WUE
M! T?\G>1PQ=>9N^+[GHO=2T3\V-^$V$F-W_0Y5VHQB(U'T!GOU67^2X;VK&A
MK6YHZP)3:39T-0QM=<=@%YBE'^:AK]&H>/= S3EZ5K:;; "S?[:R[U:VFV8
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M]R;>W5.Z:J@-S 20!MUJB=D!KOJ1!MUJ$=D!KNMW'/1+\\O-_RJX4K0:9SK
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MY/\F9F+.IZ17=Q*RJS@P",</,]L[#$ER8 9-A YP9-G"9L#$&:-:XW!FQ6?
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MBB<.;1;=!LS$,=R&OP^!JO6\8_(%+7!,#6RZ#AC-^[?2,3-8V@Z8T'LVPUO
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MVZ;DN0J>&VK7AW[B;G<^Y)T0>UO13_#NT(J\#V)O+P*W $AZD7=![&U%X+8
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MR>8%8.,C&9%@DX!/$-A>WX R<2^K2^Z;YL!,V]$Q@=QE+LQLP!@;JLOLF^[
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M 2/LP;=Z_58;CL,<,OAYC]U\]O V/A+1'Z;R,:^,Y"!?"7Y7Z>18RZ%*S\2
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M/>[F0(3I>. L"+KSZVJWF06+I]K:FMN!([A;&^E_C6O%P+I9_%PN+ "C6OO
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M%B6F2340]@D$B?E2)8&@D-N5%2-74H^IU6Z7NFB3F/_5;M>!85%B+EH#89]
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MSK2<;MCWK8%%O%0U_E>7FF,_^#+I?]W=FHRL]^#*;+Q*'.Z_#!9=XKA#J_Z
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M$,D-7[I8"]3"0VL<1HP16V-E%UC)#8>ZB)6('-,@V1XDN:%/%T'"4G0:([O
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M90V_8#^WB14OLFE^#1M>K+*?VQ *M4R:7V8-9P/XK+P-ZU0\S:3]E2*VO,+
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MEG@_C+9#W[^L@4I8^%*A5KW8C=];*5R42IO,%<]YE*7I3[3NJZ;F!3%,K,'
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M\$1^$5\CM/(I% 9T_ RX2'PL]F#8H+UIBV!,^($Z/A?5.YZ^0(O#6_(>]WD
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M3.^!QY4ZM>'UQX;+-GH$W3/=C5PP8^DY GW39+ ZCSE-:!4+0P-F_1!G;)]
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M3'WZ,?KET\#RIS:9?;0<!E%VTZ?E-RP,'?9"_G4DBHO">?4"I2$,HGBQ^+8
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M^(R-GGT&12^];*4AK;T1["[23_@K] -K.%N-N^K%:8F>IZ'PA;KP. (P6$!
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M7K4:HEKZ:[UGW'>:WYMW/0C/NO=-_H4V3ZII74KSE-E(?MY\_5K($-\:SD_
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M&V[D@N/J2_OFRKALWUUQ^Q@PWQ-QW$>O#5P[/_2@=33VTAXM<'&99VB:8$K
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M,7[TJ3T\85UC/ I/K)GH/+,(RK63GK:-##HF])D!FE 4.7D@ELW^Q@!X@C6
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MU*\RDM'F1F2P1/>$J753&:"7Z+\ OR6 @]-L]E'.]2DY ?O9N[W9F^>E>&O
M&\2>EH@,!(4+Q5I!F&%=KU4.8S^!MS:!X@U%TX3.8/>](^S(N:<[0.L0> 7V
MF^XVYXQ"#DI8T;:CS"*PJJVP93 "2^<I<8=CJ4+;ZO+NY^[VYHXE)H@X0[W2
MW'89F+ZMY,-[RJ1+ROV=YPQ!,OOEN[/#_33>WC1JO*&89I!)J%]*6"?JQ_T7
M]Z]2XS3.PP/U9[_1(LPWLS)KVR-R?YG#9C^IMSBIJ#L<:<O:K YU2 @3#+=J
MZCME?6'#S[56+8J@D0NZ;I6&1"F)4?1I5'W[P1W(9+?/2D&@'KPX^^&E* H^
M??/#RV='QX_T4VWRHJRG+CXZXU/\P'W@[!^'7M[K4K+P3_+7^??]3V<$L^>K
MFM*=YL'?NGDX6Q'&VOWP'2MQO6DNLDJ/CX.W9]^]V2_06UR@[;)8="(KQLT\
MZ*)*G,L]SR$4Z<X,+]]FDEU6JDU[VV;UT9I:6MVR7'$U66I:/Q4K]Z"-T2<+
M.CKHJJS8%UST[&OHY_8KXQ:C:&H0S"XN*!F-N:D;FE1GQJP#N HB$S[]:?2"
MVRY?KW/-JVQ2H1LCTT>+PTI9)\[_!'MY:FXE32)ND1U2-M6MQ:)JF68*8!SN
MDMJH%$$KST.BQ6^?O!*5XOTBNKU@OJ"P DP'4&]T<U;5U5'(J791^LVZ-J3<
M.?,5>$OF8S]EH\Q4^*B3:4;KI1#^ -8X6.50I1KTU4&.NW)W>;POI?S^I93M
M'*W(=9J.^HRH/UIV=K\[/SMDLD2H=WIZNNV*G*^![DLJMWR"T/8DA8LNR:FQ
M4!$.W$$<%5UXGV-'-NP.>+I[EMD4-X3JHY*91UHW*X^NZF;NKY_J*LK=B52O
MW*9?U7-"=E07.$0,YY=;4+8H[JZ6%:VBB*99(]KG:#>D"&RS=TAN;SGU%0$@
M:FE26SK+3YV%G%ND<MO18+GL3_[;G*V(<-2?TFY3TYX+$!56F#6X3,^'J* ]
M49;8']"W<$ 'PH.?)XU.0V\YAW"4W,C=%%)?WWXCWMI&K-PX"3DUME74FE\K
M)PLW.N.@\_ONGTS#X OB&:V%_0EXBU4:+SW69I=D>;A$&G:IV9G.H4Z'JFE9
M(HD9LL/_?O+P'O?S3 OG'!%M"S)_Y<;G<T[NG-RC7>V\*[-,7O[]AY=GR<O*
MS5W7=_G^H+W=18%6 B:D]RT<I9N2=I:M<^%Y! E63,/-?!.";M<6AO?,\/'A
M,,ZN0-2;)ALY6[CI\HWG'Y+7M#IFB>$=>P&>-X[VOVTH.7RXJ^CSER.]'9J(
MIXW1@^>(/-#3NY,[?U' :45$;6#YX'84H6E]^>X,I*RF5^6LOW#O:*2PP6!+
MY#"<1 .\O\D)W6HK?)(DO10OZL#7 $TU(4W>9HU<^AGQCX"TCK/S_O.%+P>N
MW5.5% 4=LE,6M,88%ZNZ!S Y]*C63-SGYZ87M$U 19N4Q4>"OBJ;>^;QL*;E
MPD-Q1',RN6CJ*_<($')G>I>@CS!)?EP6U/YJG,;0.T()(^ZA46B(= 5P)AI8
M+>""QT>,F#"\\IA79PW2YX&[S8^^;H62E1D9,ZQZ]K-L+O40^11:==R?GWUX
M^_(?SU^?"Q4FR.M/[MP]WHN=W:"U>"]VMJ<C^(/2$?R!5]F]76)?V(N=[<7.
M]F)GM]_QJ<H>IOUMM$WJ D";KCXBU_O@Q?GK0\T]L<,J[5;H&I4)13QT8<1Z
MB5:UAH2S41IR,9&4$U!Y!M2%$R6&59%==- 6M-U655J+TO20_5J%1ACA$\ P
M7+).7KQ]XSSP@V*23WB^S]H9(#W_[8: P[-5T6;-H?,<K[@$ABL15_[#>XA
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MG#>,!9(F?(!!1:A*$'HXGO ]VE00LX+/Z?YE_%2XP-R-*8!2=[YG5]YNFP[
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M3=?A9O@\ZW0E6(0:BTL%2,!TH[EAO<?V0%7UR&LJ%Q,_WH*TQMQ; MW(LG7
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MXKB._/+;=^_9(C] "<;'=^Z:%,RTBHEX.'DP29-GD^,[$ZS@SXMO4N56N6F
M<_U*_S,OQ9,_\U*T*_$V%MZ>E'U/RKX'U__1P?5_X%7V:)=Z"?:D['M2]C\)
M*?O=KRQU^,%D?<>2P\@PL*"DZ/$&\M&%\^4 ^[09.X2WI5'=Y11^&K%_]$2R
M"T4IU2@+."1^O+Q"2ZKT:%.ZATG 65<O8-&09RPZW\ZJ[ GT<9.M\?*BHRW^
M  /2#%/F#%%ZR 2,D"1$"/+S9>Y[RKDD6:RF!*%0V.I0$'0K7<F)GY!P1>J
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M)8-N:"Z"K6&T%G3Z2 ?1-F<QB1H$BS87;(7PK$0C:D=/BH. )5T10]*%LF3
MA%'UA?<CZK?.-5O6Y1S4>M_55SG:>1A0@')/<M%G[E9=+LTQF -9@5T-<O_L
MFH=20P;P)W<+A8X?W]JA3O0L6\, P)G3?KAQ_YGP*P/7&4MW#2X+N,WH^:BB
M.<6)*R13U[1"T9]L[Y3YMMT"I-O*R=VZB?@1"4P*>D9JX?$N;0[Z#-D6C(>J
M^VY-,)]>]C4(4=KN:%6#?XP<+-!97>5^?$PE(B#[=>#=X/'VY@J DCB:_17G
MJ>&,8@J$UP/TABKI8;AO0"XCS#4WH60)J68W=$CA?X*L<U?-,NU6-<MAA=J
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M8"]XEP513?L.9/PXWJ7TN4#GKP):^Z$R,6)\#+=N_64!27,0Y<=2Y6S#EH1
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MI@C)G!R\>/)!R'@."GVT<<UBNNW[F#DYIN?^CVRU?IR\I_3%1NW@HJ\XJW%
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M/6S05AJ&*<5IAW71=D=LQZ)S;J?HH-\KB35UG:]R=P!_W%$;>1[ 8#=@]"
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M97&[K5R#4;LSN7M,HS%HP? *>PEPF5-/@4=VY#R_S#@??B2Y6DE<'P4B-?=
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MBA?4#S8*+4P_+^/<HXYV_#*[L;N'9+/ E'C)$]ZY;^A^Y>JZ^9[#SJ5FW_7
M/_R\MY5*Q$_YODT#R,?[)30L);; +[4HWEY1%>DJHB79@&/\4%NJ34.834.8
M'] 0YM6F(<RFA&#3$&;3$&;3$.9OVA#FL=G\B V[N!E3AQ3,]-8Z HG'BF&:
M-! GD&L:AB(?XF2R0>C:(6@_7P9KDMDG9J-2F#[(!:/7]LHQ+:5WXIBR6D,J
MWB=TOJ"W^%_6/ VDU'9?OSFC>?M)[CZS3@>&<73PL&&A /]K7(VJ:5[Q 79>
M\0"Z,@"W'5?EE%[.?*$*;(@.7#2JX%[,K:OI!6TE?*1R+HE:?IFOQ6=60M[!
MN?#QY"9T(1!:XM2GP\UK;M2!M,%[T0E;\Q3Q"(!\YA].'R85[.3]',\"'TG\
MGEVE3CB]P#ZRKQ5'8F*#C7R>S.H.* ;,H)<9AXY](VN69D[XRS9^X.G"2_U*
M]W3%R7J81'.0HQ)L +E%LQNKM?<D:A6'5@0#'"A,>F>&=WFV5=<GTK%GZ; F
M:NL:JS@/3P=B-OYXGEG2>.8E$H2$H#!ZU51(Z^STHK>%'9<@_JJZDX@2BVYC
M5.,.QYKC>\I'R. TGWUCNA#&B\#E]KLGC+,2ORAI:]G-!39:  XN%3=GZE"
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M++;"Z)Q8NGYLZXTT&4E"N@+GV6TKE)%KK4700CN7A4,\M1LCML[YR5%TS?(
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M1Y0%[K[5^+.7046**;\#(Z8IO*ERF?*[;36?DWQF/KP-' $>5^)HWM6/]]'
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MI/?S^/<D)?.4MH \[CCLYS+B5K)\VO/H79F.;!*2JPN0T_3$'-Z,L_P=TF%
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M2\7'@B/Y)/BHL:B)]RJ9U"R;T0$:CC\EOF>BI96*6F?O3R1TV]@-83NRJ]M
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MUU?G)^=7U[U+H$.!]LD*_@ 9,2,4G<#9G&GF7/W=(MI['AXZ]LOJYU+Z2S'
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M'ET62=040>B^;+M-;05(2A<[#$,@MN79UFI36F4\6G$@IF8!C9#H/S-)LZ+
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MFN*+,KG+$;WDZ 2-^JK&J.U5P_-9B6AJ%G4?:/$OC))M)GU)$//W1\VSWF*
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M5:(!+RV;6]<5Y'PYEE".ZAVY&LBOJ1HTWWH'!WVK*TGM$4A[U#9BLTL3@:Q
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MJ/A9AF/-Z][1=:_*]A?6UQ<XDL7+JV93R3 ) F82-AIL 6P+84KNS>9H'PP
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MZZ&LTWC\NAC9 469DY/,]V0RC5QK=6])(R"EW1,*,3S\ENT?[WVR:0%6$%*
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MR>\Z<64A6L#!9S7"]&&^,#G0 K1SWM&.FO0BK3EB ! S:?0BO^#NE?$^VD#
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MDC[]+<NCL F]H,%+$H"#CO$.I_[K.R!THV.X!(V-1:-4Q.*.!G5G=.5F%E_
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MU.K15GS;M')0O'PKX Y.:M+@Y/I#2U)O'MAF\8EQ*RRVE&32.%(* /,!K9D
M'4>,CBB!F3'C)G.F\RY*1/UI$QO=3M*<-!ZD$F8,L P*"Y>RL%VL',\3]![N
M[QSX!5EH-U9]QHGY03Q@>. 88D1211?,96(,$:7BC9/?':;ED'%;&->\F]:W
MBB[@7S6N$9>4+T^:]Z;R6X;I6H*</L2; 4<_TM?FLC)!JYE5(]F,E+1B5FSC
M+2>"S1$0 $),,*PG\4QO=Y<!!'/DVG A, Q<S2RK'M8[Z00K#Q .>P@D\:V]
M TD)"4&F1<[A@%:&!LY%?A:+OS?G=QK'M, 35&J\>/1*H[=92F/_&2;#!^!F
M= P24:01'7&*@>765#IR@AI,?/G^ZJQ[78?!X67UK;A()[O*KY S>&P+KF &
M-<WAYU@P'D.,80" O+Y(TSA,N%%=0'<:]#A4ING?39&_,O4$[>3]Y:G4$V#'
M:,>MPV\\"'PJB;W@1#<T#602 ?YG1!:=H*S33-*GM;0/0>-P_V]LB4RR 6KW
M(N@0-I\BI;"(/M,KYSUEV*$Q\, :-.QXH##WN(RV8A&9R@3_Q"WFDRG)?]'D
M;(3)8+049$%.;DP]^\LKB2H4IF#">Q:JID2/O6(/ME!T;O!KDW@HU:P\SKJ1
MB)(606EQK1\CN]?)0^/=^YL/UTT1'J2\%R'?&_73BD;FVGGC=;Y/M,B@5%P#
M4UIB-*VM9U'QG<:WV<QH<%*:='9(51E]AC/0U:K<A:9C6A7U*1G0DX7S=F@3
M61=A_DG0S+KE;)SE)M78G<I,,0"% _JD^PF"P0LS7"6M\&SR.C#0QZ\X^YNE
M.)]T,!GA"D- (47>GK\\N[KYH_WRLNF!/E<@,7W#RH#2^2Y5CUQ)E.A.HPEY
M1?3[P0LKQ#^G( PV2Q#\$Y1C/P_ L3]<%)"3RP_OVR=OSD^:]2Z8<:;9^84[
M3)^5Z:<4W66D4T9<ZJ:GZ&H)V!$:?[E]=T=H_(TMY4=5L=L1&N_P&':$QMNA
M\W:$QCM"XZ\#+=A>ZS':+.L1%04+;L3!+_<%4*R;4$4Q7? :*FD4#M&[Y(N'
M[5BY;%!FM$9R74U?TN'C]RR&FR0;SW4R5G$MU$$\FVS5 P#.2B9LX<@"O2!6
M?5L36DL@GXN^U?F[TP_-59O),8>1[Q;CK&;8N9+5..JH3;I@$D4SC<EHCL$&
MVEUPE!L2+;M@7!B4A+U@2R?W-"ZJ'+!>Z%_?K5#XU8C>HX\PXHBD<R'KZU/W
MUB2$H8N\G+ HH$'4YVSKH.1"5M?#.<WC#/I,(FE+@3)+-FO0 $RP;O,%_&N+
M'K3R<^UUGO<S=F-]SM^VGWBD;:MJ$YH"ATUJBWX_X= I.$/JU)F-L2/5)S'V
M?!R52$<BEI[/QGSF;>W.NZE&E!8!+MT,UBM[VD=,;L'-_'^6MW2RDVZ+!S'S
M'P)LT\W02P,C@]L<'[1!(5TALS+1\1J^["H5GE1!];-/L? 7*0!R2W.J+=/3
M*7J3[EZ0CDU*$#K[;#^,,8!.3Q#]/*T0_20J,E_Q@K9"FM4*!]MG1JQ,5%UP
ME27G*41^533A"VV ZY*@TL@;9Q?=9I53F@EPRQ&)#=]@N<=-,B4.=IJ;WRUK
M+2WQD X=M-QIXEKRHXRA2B]KU6\UZ>UR9Y)(KMD!YEUJJ_Z_=BXW7X?6[R:@
M24]!?H'>X?90(7!KY-DS$XS45"2SCCM "(AHFNZ=NJ!Q_=L?E]>53(!-]VAI
MESG+++DZ,V^AJ*I"N>Z6TI$A<&-G$CY"5AAI:]B(PKZ3T\.V<+^MH,$*^VH<
MTM;5(:A1OJ?M&=R;3VLH  $,GI(FEFD0QQHM@^I33F]#*FRFND,7AKT(U3"-
MF\YIDRF+U;#R,)5M(4YP!QAL:7?/4)2BO9*AXSG7 KA((9Z+<D1*(,'Q4@1"
M@A3V9\X.8ZSYG)0.=]R39^FRM$K;JL<6(SZ!IDG0EWI(ZD=V ,A<Z&!E^XAZ
M-"<>-+7HYBK13%WW\(&T;R7A7-'<0:\(F*D9G2/&*:#)\I2EV*.ZIWF9 SE?
M+)@-YGE$=JHQ4;R;'>!FF[_-[C$K+"\]S9)*):PH=(]I(FO$F(:RK'7SF$9W
M++1FCE8JR =B<R]E4(WCM/'3_ T<5YO0G+6:?VW 7#5:0^<1^@$W'I^1#GS&
M:@> 4@9L'K\>82]]!J:]YCPGM->X,@<\W-D$3>P7371F]X%F8C'9!&A@'&F1
M*2__A-<1$)R .S%SQH,V6J&V-%F*VBQR &D"'.4KV&0KEE/$D7C4 S-5&VI<
MEL=_=45OL/DRN:)=WIO%I<K?A8D35G79N+8"BU=+04[-/-*"]/.LD#/MXL*;
M8(T;E)-=)?!:*H%7L! WSB^NWO^C$@]S@E$C!$OE=SWX)O_,)G&O168"NA8&
M&1,_2WGOYW 2@5,Z$X#(P3WU7BAK99LUC0;+Y#K8LL;9:7G%;,+P0_\M9EJC
MMZ*V+1!3Q!QE;<9\)(5U"T!55R[&;TD##<($8X:Y!=Y)C LB%I'<<5RP&C]=
M/  O+MB *5R)&<>?D'\1ZRLL8D4Q\#H.O,HO-P\_21W/1E;"UI?IG%]U?WM[
MWFWZ[I9&/'RR+5Y=$HPJN")$H.)N _P6ZS>P2%5B 6/I<<!XDC;.@G'(*!C:
MI$-;)HG *Y<QRF-,>P0OIHZA^ O6O7Q1B4'CBPGMKM%*CLF72=C_5,QPZ[<H
M_+Q6L(3'+XO;4%RHLOCZXN)U\.;T%<<1'JK$?3W=\C1XC<Z&VN5DR,SP9RW=
M@:]A1K<HY=: I4:P>NT(7Z#:*F%+Y>"PEJ:.L48TL=5>HP\I!8M9R(T*%VJ5
M7<!,DR(SQ5#B26H^?K'=R%+(6C[.QOG-F^Y)MZF,61HR?K#,ULBI<NI]X:HE
MR40!?YN9]XH)._HL21>/7U8VLO!AV24Q&DUJX7&8>H)AJALFR#5:PH5)U!^'
M:5Q,Q+[JFQ^'=?'=!Z3&^0RFRY:5V!9!L*XH##)PR0O.04WT^]Z]V0=IFQ>@
M]'(+E:DT7O4OGE<M+2[)?#(=9[TDA!4?H)^9N=^0DN'OV>6.!^Z;!HWEM_/3
M:VE](5T_P8BV(:N[HK(3W;+)_"%+X3!16XL9MF(YH^;;GOXB^M&.WT$1W'7Q
MXC>6@Z];H0BVK/82&S8\ABU)T-O: ,1H_1SBE-8]QOK0<MMF!49CJ\_A;T&2
M]JMQ5.^!/OJ)(!J%)-=$$0/,R$'0R,=9V^/-[&=Q$@$4(TXX/]!Y ;E2MF!&
M4B/Q)8$G$6L?-!TCL>(HU&<*5D?\1!27-19[1IT#/]WLT@&J]B330N[4<-86
M"Z0]!M&#Y:8TE[S^^.:T&7#]<3 ,XP0D$!B \=^0W7;^&Y]<-HVHBG5;-9OI
MGESTC=E=SLL1PT[T@&6WB+* V,M=YC<S>[P9NS#B6L*(74MZHG";%:_3J+EZ
M*R%#44$&8G,ZRE<$X1>MK)K>67]//7Y#?2/C8MU4LC1+LN"<.2L*C"4_96WW
M3R%PG_=C"24L!9.5R=UR)6<H?C&Y1Z\E,A?D@TI0S._EMG'>6R<NW-8,3$Q6
MU\%@7I@>YZ!Q\K9["I[W8AJ3J%7&N37:]VM-$@<V^., \FK'N*4 >6S+)!EM
M#7@?093^<SZ)E-Y&$@[&(Q(*0&.Z3\(4JJW]I$T>3T$&_"QRI9#H!38<!P#'
M(.L@#T;)O)\AG=HKXV30+J>232WZ*$]&WE2C:?<,P;>*'N#S7F:3:>3(5]3J
M7P:\#FG/D*\1<Q6<GNDZBK"/JK.$WJ\]2DI2^_& +:+7W>ZZ60/VUBTZYZ;.
MJ[6P$!R3US)7"8!PLBCG3&M(LRJ;]I0V[3U.THZ0?$=(OFN _4O>?X,:8!^Q
ME!T>;T?#[ZZ[=T=(_MA[>S<MG-2MYA.]:@8?+DSJZ>^W=#G 5\2?#7,E73S/
MR$E$>$^1ZD*VQ<76%?(PE/-+27'%1GY\[N%?BS__<!:/_SS_&+PYE?I49&M1
MBTWNTY>XL!.4 !1+%'JNP\+(1H1X+LF,ZX)I\?(/,N[SS!D0<X"6"V!2<A6L
MB5KP.)8>79C2^'#D _CZQ>U!0Z(;-"TI5T;WHR:@&7V>.\G@W$?183H:[\$5
M$ORR1R>;?S6T_]=RS/B<4T'WY(_?VS<W/ODBJ$C14X$.#X7/A =?89.JR/,B
MN8S*I5^+/8Z2J>&500V9XYH1_28L2AYOJB$_7"S)1ZBK'(TK_'-[CCW!;\&L
MV50-1OSTN(!G=]E2RH2.RF9K8?_=0VBY?%.3AO$YAG%3?YQ((S#0H:V.^_W-
M>R9Z8@3#H6FM>\"]PQ[=?:]F*PG(6AUPFVSH$2UI/]9-K,"Q'N\D/^])@(9*
M[T$M [()WF94N?H]@8SF.O(9PTDSW3$])XXNN15BJZ.Z,R@>_,>_Q<^'X=/A
MD^>]H^?[1T?'^]'S_M%A].SHZ*A_L'_8>7+\W\\[__:U!#_/OS$DOF+#+9'\
MU/L%(/DYV NN_D\XF;XX#<X^3R,T-I6YHI!SWU*!_A0_V;3QZF\59[+W=@S2
M2Y8&Z,RDK,GETL()-HYH!=)$AT^.7CQI/3UXIF)-IX0C=#H,&NZ2_2=UEQPP
M3.9DFL<<Q[>7'^\_7[J<(3,MVT$1C61 -$#]V4&G_D>@B2PGM.G?1&$R&W/P
M7W^^!Q#J^C>-_"G)(V0&(GYSCFT"'Y8AA3O'>T_^ADT!O9N2J5:05O7(P0OQ
MTWR$4+SWZG-RD\3B]W@V7C7S+:U(ME"NBVS5F-"/QDPQV\B?R$H+LZ[A8>M9
M9T%2O!5^]NSX?D$[;#U_^BRH^>73@Z-@6?102)J@3F3(50)55M("ZX^+SUG=
M H->4?N%W]Y^[^8!?V5I7ZYM+$Q(TV#EVDF9A"AHU=;KA=GDZ+U'XUJ@2G\&
MOVO/=80/AV&<%_X &&M;Y_I:4<A-Z@D<TI/(V[D'K?V#I_=/*%VR?[1JY\KK
M(,MJD+5A3-(CB\!5YV1\[-89A@\\,(Z^^L#H'*PZ,;X^!M#I?&,0X.7>\9Y"
M\'Y78K@?ZOYR9(MM $:#OHT83)X<U%Y9Q,R+[>MA^GP4P46>CED^D6%5(TB4
M(>1&+!!FFU=*\R%X:5">\HX,3)&UT[U#FCV25&A5DJ4B2YA1=1 ,8V[-$W#N
MF0!)M]3RE":%<_I4.Y:?[8E9PS P*5EF\CDI(1+2A[HJ!QNV*FBC=2#/DL()
M"M(URF>0A^DGM<%ME(;KZ$R97&4^Q=Q'UVM%6^DQQD /C>BSL>N-,FJVI.HB
MA7]*9R69V;0*>!#MH^ELD6+YHGL3-"XR1NCO\D($-T#U:$IODO1?6R8%U<J,
MDWW^GQ_/N\'%^6GW.D@R-["0QC-CN K!RI:PR6V8QZ@]]&W\.:KV^S#)@X*D
MJ<^'LWF?W]*L1[<=@QKV<]P':O?KLROR-%[E\)R$]N;-Q14I<Y(8\I*2NA;,
M!RJRIUMC^1[O=?8\^' VC6(@N?5*2,N6JK/?(RG>L+J+7,-<B[OC=,&N>[HO
M\NL<178$R]SR;$G0[C:,$[;P&'N?\0["M"Y4L D47.O.17>>[:^=;NW^9JPU
M3Y 1MKV@*Q-5.8 A?>%H1,<J?$_G;*PX=[G_SAC;))[*&>C.1SIBW\L6T$W^
MRAZN5]%M'-WQAY>DVV&G%T&%,>_*L6._=_NH<LD?*"@YXT"182H(#CLML3!/
M*DVP]UP*NCMFCO-(EKDL'>8(FG50\0*2X^H!IAF)8)1D/6[5I5GBZ:*7+J6'
M3 ]/L;>C7)HXW+1*D9CS43:O"O1W>@0>LTKA/[1(A2?X2>VN7%/Q7Z>S=\!3
M\2&-(;[73,/T:W 7L7T3I#&67GI:*S80EO!P[_G?-J]8\R=8+ FW\BJ%"OU#
MQGW^Y4U*&U L+@4-RGB'>JM*>_YX[_AOXCP8(2##/F?-)NV9<R,/1WL'?ZO\
M_ 5^MA.('R\0"\%V*QE8/DF(SB)6XK2(?P\Q\!5;ND-;6A9?=CZXX,9T6JV^
M_NAOFY^+6N%V)X E'8T#Z[CXQC=R+G18T;-NT>/4FQL_IX7)+9 WQ*G?S^.I
M1/#S<F0 ,&BX3+<V1D:&SCCIB;!WSW)VI0<1(EO&J>^/<5+FS&(IUV?E+(G@
M=:.D%/$0^J<T5Q<MT^8O)=99/@I3;;02 WJ$<%"JL3*:YQF_$W!VLDGD3&O
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MOM[$!;9*5.T9[LC%$4 Z("^G;+K,HOZ8V^497<4O2F/R% .;7&UN1\$,WDX
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M0Y4U-HUE[1[]LN7]<6)R3NZCTSW_CX .UAX8Z.W+5!_NNMRR<F:#PLB'F"&
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M)"UE"G_6O+LXL#[(L=T'V5VZD&.Z3Z6WS#G//$8T^./]:F( %J3)37#HDV>
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MRU6LF8"7V4\T&AY]C@LA6T40O*W)X@6&$2GJQ<E35&AJ7D;OHK?E9U2H)K'
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M-:'!A^^0W<L_XI>OUQ8'^W7:8L&L_,)ANF6:XNU2%/A7EYA%,L;GJF?"-4"
M/94TX_7ER?_W5T44UB@Z7S4G%USR1W-R]+T$[&N[$]8G/*]MUL1/D?RU$K&^
MMZV']ODUZ)8CE!M51,!X9MN],%;5?8TT/W[CZNWEU?NWY_\5-&AP^?_/WI=V
MM9%D:?^5/#U3<T0?H0*)U7YGSA$8EZG&P!AL=_>7.2%E2(IR*E.5"UCUZ]^[
M162D)%:#)8'>I<M ;A%QX\9=GOM<'2>QZB;(V]A3K]#"^ISI-Z42W..#X?RR
M_7?*LYY?'OU]3E;'_ 2D-#T^*NH0OQ74Y%_[Y<'I,IA'GTN<X'P%:+&F[+WN
MI-A+#W_<L7)U]/=94_3\I^U"F2/9+?:(;2N);?QV@YJ@<=;NL0E7,[*:D<?%
M4UZ6/4>'F6O@N?/:S%E1P'LK:_&)K,7+SU^.CS$8IWLJUEG2S9/%L!<7X;CW
M#OG6KF<\(J/_WX,IS?1:ITG:"@?[R,#>V@Y6$S(Q(7?*R\\R$1<IE'>;#6!=
MMJW6# /@A1UUJYGYJ3/S>DU'_S3;?KP!]:+GZ +I6JWW<2-=TK2FWIVC^3B7
M"3PX^M?[LT^7V \I-FFFK\Q0=?"S1O?Q75_ZP7^_4_\USXT-,DH%%%91<'M6
M2SV@NBDV#EG%'V^:PY49>5?VTU?F6\W@-1I,J]GY";/S>DW*WXOHD>;DD@_\
M%.3&FHD/KUN9#$:^^#SLX=&GHW__Z^-14#-#TX^*+FRZ3+\^2_%<U,XDZNMU
MV3.K6;C?+,P^5UJM5YFJ>/?Y_/B?1Z>702TL1B8JP-U<^0,VYM7:+"$(KWY2
MG.EFTZ2MI@=LJ;DY:PEGY73E-WJC*P?U\0"9UM:MXO@:W=1[(A[ U7B%?MAM
MDU.&/%9S,SDW9]T\$;G97 @/=:%\-(?[W'\N--7B^:539]\CH#++N^*EKO"0
M40N:M9F?[!R=G!U>MB^/$/,S3-+%@?S,.[A>Q'H%$Z\BYP7NO"BE(S4O[K:"
MJS\ KEZ6 :W ZBMH]FI&?N:,O.;T4*Q_%E9]H0;N'U/;#]@>=Z'47ZG!>OI[
M^U\?SX):5N1F&)E5Z#>L9B!;*ZS1K9.SBN7^! E[I5'=PSOQR*\U;+F:F>>:
MF==K4?H8]JV7*C// SI:\L%+=&[FP!]%K]9\H0?X^_;!IS:#K51?19D)529>
M6$?GK[:J<P4Z6LW"CT*O9OO?+R9JX1'EE* 8Z7I!75P4-N5IKDN"I)O$/9-B
MRYGWJH-]6K@%Y$/"@<]:5'9#+X,YLU[]ZG=PN8L!Z[7@@W\_^G+9/FT'M:[J
MJ+],KK[KZ#6A@_=:%<_[2#H%W2"[BR+8]-6/0JPX9-[&JSN!)I9ZYA'T@E8Z
MF%[DQ1S=#[(2KL1SW@OX,/&TOO2MFFCE5_J1K/8IE7N;."O@KT$_HG8+*^+N
M%7?U:O"O)2[[*"]F-?+7-_+5T>D?G6=?CD[/D),Y3KZKD4I-S'9'EH2F&+[6
MD.P=9N;J/'G5@W\]A^GK.$8.GNS<G"=]PAP/D<\?CS&M]^O'?YU)>B]"*H6$
M,WRK^HV5!ET-_J[CXY4B:$^/_OGEF$$!OP;\PSM6(5>+ID06P1QU% $;*]+G
MNZGHFGN"L+5H6A,'![_5@Z.+>O#^4SWX#?[_A\_UX/2D'EP<4TG=Q=%;.Y-4
MNJ7B<9" 19"N(+B52?;+2YHK3H4'L0&/7S1,;C4;SS(;+]_IO G\(^KXI4K(
M3<..$S""7BSZ_(EIKA\:OKVEC_/+.K'/3]I?L.=>-TI&)DSZJ8X$<6NR DSJ
M?)4E73FGJ\$_^HS]>7WAYQ[UO5,\5I/PBB:!]LJON>I$V@-836R=K;W&YCZ\
M<91D!H':;^#X4;FYTF^O39@/Y&W^C7;ZREM4!V:QR*=O@87 MT_,/\Q1I$:9
M?F/_\38TV2A2XS<FIH'236^'!!&RJP5K-37[N#C\9WGS_GYC9V<77RZ!?7FQ
M?%<#ONO7Z=_O-QN[V]LS_[31V)SY^YL>M=W8V+K]27>D'1XH@$,3AI&NKH]W
M2XI+_"@)O:=L[D[*9A.7_J)]>O;^. @<!OG9WC^U-^C][\\^?03C=/W]L[]_
M]OAO&_?NWD93[\Q^+[X,7ORH,3<WFJWG\D064\JV9HUWAL[S_W>0EE/0U^N=
M5*MOZZJ7Z_2-BJ[5.,,MZHUR" K(J=W=QB[8&3?J19G4=9S!-WMXN/"\FCC$
M@J%U^M7?YJ 2]W=;#U:)>XW]C=E_>AY%QM\\6X@>OF7VK #1@]Z8'%[2O<<F
M.F]_N@R.9QF<<R[<NFFCD)3=/:[CRZ./P58C.(Y[23KD@BRQ&[I@;JMX?)?A
M,&4^3(NB-_0_BBPWO?&2"/OF=J.Y]S3G?W.GL;L[^Y9Y/ZKU%+OY.6KN9NR&
MYB99XT]];# Y86PPSW21JUQG/Y%][#G'=%2DR4C#*V%P2?Q"!O6[@O<]VOE_
M\;C0R[//OQ^=N9(*#AFNZBI60;/5X.^#Y7G-R6U7MS8K>[.:DM64#*@YFYN3
MUI.A1VX&R[V:=-\_CT[/!8,+PQ@5)</.:\;/$67XC)9$*^R<-S^.B+NUL8R\
ME LR<;/%:64J3!\"S8VMUL]B65S>Z5A-Q"H_?Q=FJE1 6Z\L3WU_2L;7/1]E
MV< #<O@2(L=3&D==R4!M;C9:6S/#\M6TE%SWC//QP"3,W]D:GOY?.+C?!$R_
M%USJ=!@<V9Z+C>"__F.ON;GY%ANZO DNBM$HTD.X#HL,SM,DUUW*>1RB&/20
MDDZ7MX"167UL.\2)PML;4_0T+WKF:VKMIKF_*#I_P"0&>1)$NJ^BH#M04:1C
M.!TZNI>D&NU,PJ3 WPZ3(OVI<W<#E] #<U5/O I[]TS.L>AEP4!'89"D :P5
M2#4<Q)UQ(.\*DR!.<K3V8=*#+GB,&=K]5R;4@>[U4+JO-/[&"KKJ*Q/#@:,H
MOZ=S PJ'Y'WW;1;T&3J$[RI9&4!#VNZEL'KXK+#HYEDC> ^7Z>]J"#NJCE^!
MCEF6*ZZ_P0SB*-69CKL:;P6E+O1S8D74O0_(@D@5<7< ?[6?(&\E[Z5]<G+T
MVZ<VCA(?BW1!H]3 VT'F^#WT2>+E9/ =]"CX*]HIZW#).CDZ&JT/E1?9&I4+
M??Q\<MG^7_O4H\]WRN6"BLE7#0M?T.KB0%*MX$R$?ZH<?T[QKS',#8+25985
M8+/!DM"?KS5XTR WL%!7RD3!]4#'^$NX#/0AR BO%4Y19'+3Y_PPSIWW]*$:
MX]-1JO#)&5Y]/3!P9ED9U3#S0_CLC&\S.8@M_("".U @GBK(BAXH7X/OZJC,
M9+AV\A$)6 .PU$/4)" +M-ZR+U 1PP=Q;5@^@-M2/4K2O![T2M'$O_&^N*;/
M]04?)6>4X-\4WC+$\Q='B%^F1B.-E!I]_)8>[BZ4;Q&6;J3,,+-;PK^5O^TM
MCDE%.7YY-QW#S$2X;G0E/9T>P#L9GX"?))@Y?.A0Y2BL]EGP$%A!CS*5GH"R
M73YAJ/-!$M).R^P,-8(+K>DT:VZ\/<[UD#5VJQ'\0X\K*7_2 $W1Z.\:_-]/
M)OL6O%==VJ"5*_ O6?")\( \02>D^E$R/#/F(PUCXMZO**'1&%$&I$YD+?%6
MKM7#-4F-IA.: $0D#4ZIB6FDO;\QPC'H@KB <IM45'5ZMNF!D(%,3K]/GG.-
MPA&!RLMU6(?)OH+='2H,E^ :FK1;#*]T3'^D-3<Q2+N!08.2*R)X *@84-,=
MW! P:O@+#!+?HD+493AD10I9APU:DLVW2ZIOVAF2\G:C)..=5TK67H.WJ,'Y
MC0N:'-Z0J%12W(M7273%MV4P&#*Y8--[VJ6;@!))8W>&L ;R3C!X@PKB@NI,
M)L^D>\YH"\;IV1H[CS&U9N.+-C?N-86'UD9BV:8QXM$HXWCT,"JFT*U6Y,.A
M4^70'F@\5K9_N].!P\;0QCK5U\&[M.@';;#*1;=E0:U]^JX]&9!<FLUQ;&V4
MNC-E&$AE8*WIM.-8RKWG 3<$JC7<$-T98H.'7D2/P3-S8F-D0SRXADFDNT6D
M/=NM'0?X^(!V*IYU]KUXGJ@@Q*\9JKCH@?HO4DVF5JJ[&A4OV!J#) 7?U-.]
M:M)PHVT:LX85))DS,^%UH,U+>:_C2T,]A%'GJ1PI8E\$HR)%#:)#T)^3KQBH
MC*[)U)#&-D(G#N:FEJF>SL>>C@?=,8C1S0] I2LP__A&& 6($AY<$U\$$X0V
M :MV'$I:GFI5542S?/OKZCS5RE]<5(9]=HI@8#U\RE@CAPU!3H/W?#U\DXKD
M_(KAW O)?''^%2VX*,C(9+DUA#3>[V;[#(-T.CA(DF^-X-BWH()!$J&I6+H6
MX+.AR9/!66G([(,9&,'W:F=J\XWE-[!1Q'L;+A ",K2R:;*N01<EUW7[42AO
M'96BW=)+DR%G)'"]>]XRP#]P9"*A89':LZ"UP8\'00%/ V8MBI)K^2/_A7R,
ML=B)_*OM=9Q8?P&]Z$I0H\,*/BD@Z[&GZ=O@]8;-$_A\T"APDT)Y$%.JM;%.
MGX#>Q%C.\C7P<"*=@;4A7B]^L([#RK=4!U"7&66A!;,=S)-,YSD'*,CJ0Z,"
M;.!0=XV3>&=.AX$V+&YVL_"$6=O:Q#V<.OX4D0]9O\2[J?H7DUG;!\7N5[@0
M/#>T%+L:0TW+ZB/Y&XI5DVQ*VFXD!&Y508T8,*7=/,(>0*,%Y"%W[JW,%L)3
MBUSCJA>E8Y."*KO2XHPYL3-#;'\P))7-.U?<5O9]6?%:%5?1O>BCB9V=JV_R
M8#3.82 1Q>?9\Z5@*(OO")RR4 V5'!53>WY9U['=[>H(M"9*+"[@>CX>:<YT
M@J+0K%A'"8Y4+'#6NH@UIM,J'O-:D8L7@7*U/J4<C6BI>I-?<:$JALQ!8[O1
MLIY2N<KO4SB,KI/TF^@%4MYR_[IUCF KNS]W0%0: 7A%H'V_X3>&H(50;SCG
MR'HH5Z:?I$F1P:A8S6>:/5OXR*++J5YP3,"1+\C4IG&Q%^WLYCX<X-9)G8X%
MH6"+4!J6_5CC<\$/CO#@ _GE@)),6J_ .4+'ZCYO+X_JQWFGP6V.:? XGS18
MN:,/=4>7T>NX8(--+(*-[5IGK=9<N\'P=F'&)=619YZTT9([(</P5Y0E('HN
M9N]%Z\>5B"SX)LZ 5YZSXDY1>.K@6H$Z+6(T(K/94RS[_KT.*0'P/DE 8G'.
M>1\<)MD0WM@-VFAT7^(Y+,]%[9Q<9Q3*<^^D'^ \##GU3(JHW%A@J^JN$8L:
M3_4D\Q0[&3RIYJ TQA5Q"]@MAO. SR.K%%9-?P>K"/6(\PS0)<(OU$$Y./NI
MAB(B<#W,*3W!&6-NDC@B.FM,K)?EW'>A;(7!%0RV!MG &KD<.X67Z3\+ [?B
M,,22@-7ADV'*DUE2(;[@Y$,$4X=G.9G(UR8;B&Z?<CL[!KZMC]XV?&Z1FPA>
M1J[M+:(+ H/Y4WAJZ3F=?[CP9!&E>?=M:WNS]JU<;1VC.>$[SKP.]AQ1[$A0
MYL.N)WE17J8%_4(.M^.Q7PJ:E0<['/Q8^PB0@QC? SJ]S,X$M0',&KS8_DSP
MN!@V-LPIW@]_&FJ%X8-> ?ZHZ<FG96MXDAC,BK#LDXU$=\/ P%Y>=^FF<C@'
M)^V[!>MGU(_/*#;MXG&8+DEEV59C>V?G24JX]EN-9FMK3I7E/[^T]]G:L\YU
M6*NZ^(6IBU_ .O%;T ZKTG&?:N 5U([/'.=++1Y?1E>3*VZ7U.H^MEB8NF=:
M3R>#$/)!_E-I&>)M9-2*P^<%/C'A)0[9+2D7"<72,_P(/8:\!3K4"#XDUQID
MOR[0$PI2^1D0PO^,LUP/T9[GI6!93&T($#_"2XE8S^R:PB7DG\W(D%#$1U^1
MPR72K3F$)KDP=$^J&0WV4,BRYVO^<ODURK%X460;J!_J:BK<@9RL;U!)2]4G
MG<;,0G'<U.*DE]]1R9?PG*H2<6*O\N<>O8&D0*^YK])P9B#9>30<MVH$I[A
M<!DG0Y"&.<ERD0IPQ_\H4I-1&)' 759T9@8@+2C,9L""+!E./D%3/--.E(32
M:_1<^0$S&D/,E\3Y6GW&VN*D4>R5,#9_P#T5H!R%Z<KI,3WTP3LZ,O!F>'*>
M5<(K=BE#CF[>#8UX)&1A_Y'HT!OTPQ1L8;:9=M#8:33!-4Y5J'%*,@>5?9<,
M,=89JZ$N?WF8C,8D%DNJ#:N!- QT)Z@C4BPI)D&Z3E+X!<>_\G)2++:N"P)J
M1'UTM "[*!:+R2!8?$+BV5!YOX_;#/''^%[O<;"71I22Q$,/)J023F8T7F*S
MTAQDAXF#U5 =$^$NE@!T/TVN\P&E&CCSG.L@UM<4HX?GU,HWUH/06\XZ[([T
MRG2922Y;X[!%%PQ?VA#]*.G @#J@]T*.;,%#<>/'H+$L^E10!YCE*$8X<CXO
M8 M%R8BSG94T3+T,H]&#*;O5P[ 'IM8#,&)S-#G*W%8E)U_Y7OHDV*($+K1O
MA^M!40_O#1A:-,GT=B EO#"'W"TH7N9$*[>3 [IUJ%-*#KA,36]:B&36*/Y=
M@B1Q 5G[P:1W=5TR'W2NP<#3!/YQ93(CLD89!@29RO%F2#/*XO+9/YEQ6]8U
MJ*@\7 686$X[,GZ L)ZJC%/C,A0QFPJJ@\?JM>B),*&M0:%Y3-P2M"[ 1%7,
MJ-XDT'%F<1 *DY>2W*7(,R)D$>M<(,IA5.36$,=/7M;)Q>DP0S=R[0&"Q#[P
M%.0UJI7.T)#$#[2*\D&7<AV><883U*%\W V&F:1'$ >-IB+;'+2Y6+?@D0[F
ML<WJ4>*USMEB# FC[6IBBL9W$\H>D%FL0*FS7<>15;0 TI V[)C'E%S#J_V,
M-9P:O0C-&_A"20;BIDGE(%%7"6$SQ@X"@#<4F4-F)YB*P2DC@6"K;$FEX"SN
M)S@-(>B-W!K0>C@"GP >PQ@N[R0EU=_E?=*UMH=_-N!1D"6]_)J6&B;K6G?
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MMEG/(?E$8K'Y\.="2:'C>V*R8&.TPMU>#PY5K$)5!V,M-/"?C_J[Z28,.!^
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M00QY5$*([N=J0J[GPX^R^I#+=X>3G*XSBZ[B8JBIZ(I;-2WK\A-.T=5+TBR
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MD<8DVN7P[$O[Y/CB!^R+^Z[9 Q4(]H$P.?:!:+U%+X8P#P65& [)TR3R+\1
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MJ;8*%%1>1"F+#+%,$:-)D]@0_EFH+2H0QF!(;7$%$&JBR"]PK@?,A" F9RF
M5 FL">S@.)4<MP/QW7YS?79-:A.:^1(3@V+F.&3.U;K72KCDM_7@K<3]%$X&
MA'5)+/3))3EP:N$G0S3V].PC-X_UH"T [_+P_J11%[E([*&("'8:.VH??BC[
M5]WPKL/*X5\/3A1FU*0>YAS..=47Y=0M'WUX<KX&FR8)>D5$**JRH(3>ZFS7
M <'P^M1G30!\J8Y ,K!DQBF[67+M\';NN\NAM1&&-F8AJAT=?FC?F\E[(;P;
M+J1:4EWL+ZSI)T0'1U%YP^>W #DDZ<.BJZOGJ"3QQ#WR#0&YS*I6@=,+)8JX
M&=UODN\'NT(C*X?JCD')A9;^."H3*[8>BME'3<PWJGR2J FU,L+U1>]Z*:<@
MHP("5OU8;,)X5DF;<-%(1"#KGK6/"FOBTHEB9T:ENG+\$#ZZS*!E(-?L>,7,
MLC/07E9BXJ-X^N1@D==:Y^X(SS2!W93<1LPQ25YDO>J63E3!U9FUR%6[E3K<
MX[FM>YR]EJ%F1@V3',64:"+V(W0?BUCTI+1@M18P=5J<L%FS*;X0;C$\PW 4
MU >O*)QCL(= ^KT\$>$!&8[.;$I43A7+TA%L'IO(A<ZQ079RD)@A@A3LP>Q[
M"B/"PCN#5J-/@=5V(GK><F64U23T#/-%KGM9S/LJKD53 [@0 G=V2S^KJPA(
M'G?;Y#I%:;C)_+R&8$L7L)I9PLK\^/@XJ#ET8:R&KFK*G0),RV,LXB/4>" P
MXL\#388(=27=Y+PT3JVR(57^V3MQ)!DIZ7LNK%.6*@BY133SE0FT"7P3G0V2
MB.,Y(I1"8%(5)7+72D\H [<-"\*RM9GP,YG5"#Q1BTJM1E-*%D;&I_JH<V9+
M05_3V\2\<!JWAF66194WLG11'C W3[Z;+E&216HXI&A0Z8EPS9RU_<I\.Y6Z
M2=JV!.HXGWQ91?Q3-71EK5P)-+"9#[(3^:6Z+E]?\9Q+K(NM2B-82K\ (>%.
M$-,*E4B8"8AFMP#B$#JXU$B@4]9N6$9">^3X7ZRH#)4/.3#5L#VZCSVN@ XL
M#5%9(%6,0B;0/G<4G$@D*@R@2'6%M&<(\8GY:%_GG#>-P:+-+9[;G@26(%NF
MS5Y7]_6DAU3W8C]\1I*V%1;;S#%T^DWB4W?6L5*!(^?^0+Y%$T)IML-T<1GW
MS+9M #P(QWJ.Z$JX)(*#DBI5C?:(+=E,=W11)(."@+3*V[<*?$ >AG3&S@;#
MNSJB_C V.,Y,-UEW#QDIT/48P:+-X@7>PIDV?LV/&997E(%RDLFIV.":BS6-
M;:\+ZB6BG.GDA<&]0R%"AY]3=N4WR%!8>U.%9%6%2ZDS@\TK<ZO]X>)NA.,B
MDG!:Z=N Z]<M]0.I9A?C8SBU PMQJ(+E?+T8N27&BDPCT':FU?=9G.FX]%</
M1M;7;-:Z34'/)/!3D5DP#MED9'(.A*?-.6==5Q,P$;]?6F_]JZXB13T#VR/4
MS,9@D@PG@&YY&2BJ^X'T+"]" BSZQ:OB;-.T>0]VM([E@^N3EJ'/F3RR'4<\
MBCGK2KC^%JAV*S?1=L2]K(;4YX+)(RB2A1_!A-5$@3BE^=V1,\'[KRV4D@\9
M>&:$!?/]01 G)2"?V.@ZMG^<G6","&#L24RCTB@"V;)\!N#,A?<6JH7PWA_.
M?;)H9\J!'B?8F(E<1I!>799:>DTDP#(==E#M% YVI\R0-X1X1M96J<*C)PB.
M72+2*7/IAT.J#(1*QWUX2&SQLG!X&]BHW!*+:W\4ZZ.)@D0V$LH:5Z^$)#/?
M18U/W8,$@?V)&A%\;<F6^ :YVD$I)J@J^PH!@4:JN#A;QB2QH<E<,S4-AR"[
MGV\#*AI\.Y$W*\^9\GO>,D?%6QL&QA*)-'M %[1%DZM+LD8)F6VN_-H>3YO"
M)'=%IS0W-C>LBL)DMF.SL<)(L=-O^#^P1GUV^?00#CSPN_"A.B^\_#2\')M/
MZAP96EW &@ORB;/2BI>/TY16H6-2W?".YD9K@[Z@N;&U7>VO0=VZ"-=9[HH<
MN3AR6P@I;1EF[P7I#,02D",[# 96T.8!6ZI1^7#D?P_Z4=+AY $[<12TXCH[
M:2W%/L'A=*\NB3Z;F.T)&C>Y@KPF!,7N<U!7@.OBCN A$C\ J+YHXD=SX9(:
M(%W[0<_T.6 EA2%4")ZK;[+O)39$=K!*.^!CE%N],PZVMW\):ED7U"$+[";.
MGLCNF@U@:2(')M%!2EP3.=)FS(]2(1L]>CT&59!*<5&!S[>[ &1.&EGZ[ZH'
M3;^=7RNH29M+FU^B'\KOM3U)2@V[5A<&_SSX2Z<)?C#*=:DP.4Z@*9>8:1(M
MB@&06'-U^P L)O(\8'%!4LEXYJIH*VD5 +H6#P73E+FCXR$J*3O[P6 <IJ9+
MBC\#[7TF1$*(>Z'QUZLS:V>IV6*]$,JJA<'AV3-!+K8;V\U[2-P,H#41MS$*
M>Q(5IS)R]?_V/\V?@'6Y=9]49+RU=YN,DS:FY<8]A<$-/,K@MLV]7U9,NBLF
MW3DPZ>ZMF'17./LY,NFN.'$7$XJ^XL1]@6#T18LBGA'%5B3DDN#">5@<:^^:
MTO&EI'6P!R86&>U9I22^H[V2X_V-7Z8<BN:VM(*#FSES@V$'M(##-!F-^"G-
M1NL7RR!9WMFJ^-$6MLU)[83Z)5Q3.BI._++G7]A%P/<>>.&(2A>XW"<^S-B%
M0%)!@QPVXWH)VU%FR#F ;Q9>ZJ7$KZ5C"%G^+BA3Q>BY#H5E]%G8%=W7(#,/
M]?&Q[Y</L\-8TECU>Q,[ C0*98![5CBODD-QU/RB3W7* 052.-_"?OV-S0NG
M2U4]A"TGJ"/3 XD9=R,,K;6G!*M.2^GFVT_/&<9]AZXZ/ZRV\UMGZ*!#9Y(P
M$A#1-K42U"HYY:67@EF<Z6 :;T%V3FJ<U<=&ICJ\-Q9LT9:=2&!B[1HHEBVZ
MG210Y*9,MA_;9G2?$A4.U8B" .>.]S'&\%"'HYQMV%!#TTV3#J:#/FG;)@Q1
M?'Z;,\KATX_MCY^"5)Z+D4V;^"JURGH9+4XU-6*$=:.D=N8!MVPWP5YB8\&<
MN\@-]M0S71^7SDEL+X@H?; 8BF6%R:O"%X8(KO>G3+1][+1HNFRHWSG='YF#
MJV<%X=BY ZL%_'!%#ZJPH4L58J]UK#+ -"!CB 0SOEYR]?I1PG*'EBQ[OIQ[
MLU*I&C]41!1$;-Z6FT;09Y0"3%+4Y^M1DI"V+?EK;$TY?I<'F ^0^*H"A+\9
M(7[/MA'-S;\]-']S,\7](Q,XDU&;V;[&82,X2T%URLD-:W"1IP6EJ1\_^JTG
M'/U/)/@_;&R"H)7D/,&%U\[X 5FY1=*C%OS)T4Q$:!$>1<J&:-]6>)^0ZW%D
M\Z2"=581==1J[FQ8*B[AG1:>*_*VD&K]FC,#2&M!1&A"'./-:*5!] W,6]S\
M61%.0Z>$C+,1_K)1<87[>HJ]BD91AZ_1'L'F>RF)R05?=R_.J[I5NG3.E/4U
MFWO.9%-Q7% 6&0NI'I*]G2DG/]UWW2,Y>9#OV@3IVY@=F'MHP&YSO[&[O?<T
MC]IN;&S<'ON[]Z-V&UM/]56MQN[N_H*4G#<W88:Z3QZUHMC-Q:QM7O5YGS^.
M\9P#?,?PP__727_]'P^BF,0O:(R'TJ[]A0_SW)XCK,PE3?B#PGKK9GPPQ<AS
M#O^].^A<?NO&8VO^7WN5"-<AEDV!+7!3F/IF#2K'*!J:&V@W!73F!_:KGU#!
M_HA)=V>@GF9#&(6E1"#N-NXAM(\?_X-W[?-/P.]%- [ 5-S<W]E[;6/G?A2\
M]MR4XK7-P'DU^'7C\)N/&?Y&L!R3X#@Y)X?_J!6G06\LMM;[Y1G)B^8[LM]T
M_-=XB."U>1E:SS_&T^2*7?PFZ>W]S1<WPD<IYN4:XL,U[TM4K2O=N4 CL[J3
MZV&#@\:7^UC#R[7MSKIY0JISZX6JSE-*N&%>?Z4S5SIS08;T<G7FAT1W!UD>
M_#;L?'AQ^XUB WNH*'>W7MS@I.'DBQO72DFNE.2"C8R?MFZ[M[T#V<RZ ^H,
M^T+U9JP#K-D""W/WQ8UNI3A7BG.AAO1J%"=SY9B1D )=M"]>W"9\KSMI@5C$
MYC;"ES::+V^$1+GQXH:UTIXK[;E@(YO0GA?PX6J$)2GGN0Y.\O#%[<&/:AQL
M;KU0L],MWXL;V4IUKE3G@HU,GG9@$D<2^O(</@>5Q]*SYL9FZ\6-<&5KKA3F
M(@WIQ2O,]V"?P,=,>NHO,I7>'J4F"IK[9&_>!SNZ7,-;)=)7"G3AU,R#%*BM
M:HN36$O!U$)>]0+/@:\F1O:#D6OH]?*,,&<];Q(*=7<5J5V28:V4_VM0_E*T
M8&D/E[U.2YYVCLPLU"?Q(95:CYN$!13JWU5,R;%-!F7=)\C[TJ;@1VJV7LPD
M/+ILZYXS\%*4_(/7?4F/@2KQW?*PJ2!A.V;Y]\LN =Q_),'.+;;?F:5ACXLA
M-]92W3\+DYFR&RWRR64Y=YRH(4W)4%%;.J3MY?8KF>TU8:F*VD)?\L%DU*\(
M'_.NVE1]@@2=N(Z0=6^-6JN,RL9%Q$GG?Q/<;(LIL$D9!DH<+SU8RP>)'F"7
M#8T'65]',"G#H'9PO :OBS,<9?#!-5# )XC>=\_8K6-H_HKZ(5WA!1_+ED3P
M9S@=VIUH''^G>XM8^W^YP*[:28I_XU]//+RY40^DH-\H=]&%'N5D[ON7_6,\
M5)VI$6)5VB6N8H0,#_"=>,7T_9M,(=[&MGW?@PF-5L<3'N^S>!!W6_.ML&65
M7#/2GO3H\Z>S]ODQ3T?E!MN$9'*-SM-$NIWA9]([&W3Q_WXZ/N F[+:!T >F
M^H$/.SDY;# S7K-%A#TESPVW!K(-&YT(>*]ESCWN L<<."6ASKO&9J/5"![$
MI^,Z=8VUPOX#2*QC'3,A=]_DW$:5>0<?7B':04:W][#K[+2MOY='JYR>/<'7
M)U]<>1.\9<>UQ[2&FF-$^'CQ+JA]BY/K&(F*/NJT^\U2S?&1'O!I3O-_J&(5
MJC49$!.G33P8G_=' FYV@$M(_==O70QN)XS,!Z6R^/4!*]-LV&X>CUF46?,%
M*^-/W \NS]FLW<QKO^M6!>?V9N6#8^$&8-3!B!M8F"ZK9&7[3*>:O[&B5W8F
MV>ST=^ZA@M//+W=])-JQ&<+ 6,.YWBA![2.U ERC@1T<N\MGJ41[TZUKCB1=
M_I??OKX_LKJSM]SN#Z_IK0+M'0"D1UGA5X_&B2'SFZKC_K&1WR77>W?/@;")
M/7XBW(%&7:7=R77K3#SWXN/I^"R+;Q<1#U [ 70,PVEL5&C@@+J$[X\FCF#X
MJPIMI]0SL.3-<%B9H;KT_L!O;[JND)YZA%_=<E0WW!E[\\%<G[T*P;L?U*TS
M%Z#UXP?>K4(W,34S+(G[&!+.COCI\NE/#XR8B#LW]QJS6?BFY^J'>?GFY'$<
MQZ[';I>XN8QT\,%&>V,<9Y8,78-"=S9)YUG4)-89J=@>TB4X2KI^KR/JP"N]
MPTL'ASJ)V#:999?N+G(1=H2R@H_98<5OJ?@;229<OI\T]45E<O1WG\^/_WET
M>DFB]X^C+_]N?VHO9!^;]69C'YW=&QO9S+N/#5&<X_RV_P(;XM\PQ5V%,WQP
M]*_W9Y\N/U\PJV:O2*4'NB.IKS-?,>[8<@\?BK,IOJ?C2PO:462H5ZAU,!_+
MIGGO/0R;_Y;=^S/:Z\R!E'-G9_?!#26:C=WM[2?AK-QN;&S=_J3G:Z)C'W$_
MWKD[MM:J#<T/C'^!VM"\8"G;VG]XVYV'<''O.B[N>33K677F^<%$Y9(VYIDU
MS)?:EV<QJ>R;#7;CD-(_\1C^N96E;8NYI-U!O.B@ 1^RPBJ/6H0;O$9C]"Z'
MV$&66.UE&M#XA)_1_;].O+EX@YXP-U<):K^ADP)3]Q&\X"[Z5/7@@MMYYF-N
M38LO_X)MO.&/W!QR1N!O6=NO? 57 I,@]-AZV93$1-CH!GWV3]2/]1W^*1=O
MTEX]@])P5IA]XE?UDM(VJ,&[K]S<VA!!N3R9[J,_T0@^)-<:U RW6I*H"1(%
M][FGB?U(?P/4O4"QM.ZA9@2PI-C^%3_,WJ9[V,H 12K!WB+T2/1U/2\X _VF
MR7'N%1$VII)XLDF#-(DH%R9/XQ;*"I[('9V26(=>&P.086S]C WGW?O!)6//
MF6,XU(S%DW0*_7 .<H -?\ KRQ!LX?H>4TAHS'VI0&_H.*-&O.R)#55<]!1V
M^L!/QD3'^B"YYK!8JD(- OJ-^A+9^(/[B/?8W&9 5_8$/NY_%[X5/UK>J*L?
M7;Y6UZEYC4YQ5X%P2F(4P8<=<,-H4-2W'$5NHG]Z/="&'%EN_0L['63DRBB)
M:+BGH,+#R<8E7M:]>$8RS:A,;F U@A6!9<9K8"9D12=7#@4:L\HP-P,=A;:C
M6@_48W)=-@%!Q7?/B4$#L&+H;6XU-G=GSE;5^I/K[C^%7^$5%'2\]]3--JXI
M2+'S=JZQF8DIVVPT:2J<,GOC]*:\]Z/"S1$<G[O?5*K:D$4AJ#'4<\U><B-5
M#9YDQ'ZRYE+LM0,=]4TQ7+M!4WMY&E3&+A+O782AX/JMX76;:S_)0S\[7ZIP
MOFCB5)@<ULRSX?/%U-_A(/X>:FPT0U_9F,SGRSV2=[%?Z%@J^(LNVI*0F<ZQ
MWTR/O]HAS[9#NM:<&CASZDW0;@2G*L])IF&QC>:^\%.R?CC JX:!)S)G(PW^
MI9^5)2/DXAQDIH&"&M1^5S#^I>V9QVV38!]T4S.RMCZ?FC9\:V!.N(F@G")U
MZAO)9H_^LS C[ET/QW8E $S)[>9;F^#A_YZ[9YR[9QS99]CX,/6%:@1G?'C?
M_$YL447GE)Q9J^-JH38C(IM(-[^94+V"MFH[E7PX,$.CW8_3A26S=J*XJK8%
M'9QPI8/@SK9/< :"M3BPHDD;_]U__4>SU7I+.+@16=8K93T?^9A"1DV*BCUW
MK=4!SDFJ1F0W9'CL<E_6D_.9=@D)1.547ZWS?-99#MDW=YF>J_69S_HP%G%R
M\\$KA[@W5ZLRGU41I^N-TVWO<:/H- L.OART"?*[6IFYK,PQ8@7BL%P9^87=
M,3/<@7LFWUH;R]H(%YNP,GZ#VE/[: Y&5H!O-C"C#,S[_%KKV/6-%1M]23TH
M1-#),T=@EH)78COEILIDFIOH=HKHVXQJ"\+^PE@XY=*KS%YA[^T5<9CQPT+J
M^:XU>%M^$!,VJ_S$ >/R0=C1G7RWR90'(_\F/ECZ>F.O\*[*!L$H22@VK=(4
M8<[D<A6H@(+K@:%H[A@>FHZB(N,;;-"P$KTUF72G#P,L54E5)&W*L>PCXTBS
MLG^B5(N-$#M\=8J-MODA]!'9.$-''0%CD>J"=T#]Z\7]FQB4C9"CJQCV=6:G
M4 +@WOR4+F]EII94+C&S!)XR3 6*A<JGFR:SL,R675K)_<U?;#C@!B'=W797
M^()P\YPMT@S)\[@3#'S!9:H5C&(<'!)\T7JI0>WBZ/)P#>8P0!##>G(=EV5;
M9=?:H&Q\J@5DO-F4[8+S'*EKDC0YU.LH^R%F"NEZ$,I1FEP9;D=?F>,K$$,L
M"// <3J],ET699[Z6\7UOB=/:UD:T+]K!.>WQ84>/P4[RWGX$GSZ[ K%0E\O
MJ;[":-] J_#/0J4YVK@8X\'4G&RG<Q#OK"X1I09,X:W1QBV)-Y[U>K!3@HL1
M'!/5\.*23M-7;8_I*GK;0K83'O HU4.R/G!C(.8>:R?K-A=J8R-1TC<9A5)Z
MJHMY>CJOX6\CN/"[&<);P,+8E?IC!R9W6 A0:Y36YECMY*L'H+4TG.]1>42,
M"*4+%DU7"C+HR'#(<P;R<HD 07'AP])D.*7D;"&& (_YS%K6%6T'!*L+L6K0
M3I1!*PSL&9K F&PJ/'92-* )&PVS5N.#"'9]!C]%<';I01*%:WBP\%D"?Y50
M^B5"I<O7X \J8V0"G'BP^!JWFVH@5KOR&SAU^H3]AQ]XMHM8%>$-/L[#YGL9
M@'U;&XV-_:TG04CO-K9VGPIKW6K-ON.A3VJU&OL[>T\TO)U6\^$(R)WG0$ ^
M9VOQ W^S^AOU 1Q*&SC F[G#EGHF)O748Z;E%?5F/W8HG=?9EWI[_U6WI?XA
M/?&2]L&)M5]>YS9H[KSJ;?"2V#$_B;?U4CD';Y?4I1?%1;'<GG_<9^@_OE I
MW=UZV5+ZDA0FQ^A>+$=K\V5+XL^P8)_X*2]I\YS8$.Y+W3XOG.'X2<R-AU[V
MNFB5S[#JZ]72Q[9>.WGL_';8C8RU/X.!9@;BHDNXAF7)O#2V=W:>)#.QWVHT
M6[?G<)Z/F^:GDX-L;_P,,I05L\Y/'O\",>L\'=-,:W^N3#.WX)Y7Y#./M6B6
ME'UFYCA7]#,_$\/6; 3OI@M1*;'\ "9.;US[3XQ.W+C?2<4/\N@7'C*$A4,G
M943*:<'KHS3I$EEHKVQB@$#5BY)=IPNJFSC(?XN2#HS^P$+4L-"/B4@1VH>X
M;!,7Q'V2!"I4(X9D3Q(/X>\^5GA'N(CSHAB-HG$0:OP\K@:.'<),9"?6UR5"
M;IB$.EI6D-CEO6>AEW2I= !F#_X!8]&IP-QQ<00Z'/Q9**3EX3X#V4#1(V'6
M!$UY86DE_#=>$.K>HBC[21).$,*,$&>/H=RR&T%8[3:AB+Z%/BTBQ@K\T>2"
M@):/6N8U\J67:$S3@GAK</"WK!_50< @&)+'O*B")?>>@9.*?^OA_\S<76\F
M&*>H+':2E,HR4#$!U8?#99UOUPL#"U:R'$:CHB0NB?-9$VE"3WKZJ0*Z%YTF
MH-AZ15[Q8N3%T;EL#N+]@NLKY"6@=OHI/)+[LL#WK*$BXJ*"ANO705C83%BU
M+7L8XZ:^3^PB1E+5/.CS,9RAX[HMHN6RC<__L%AH^LX/1=Q7*;)8$*NOPG*!
M-,N#R&3"0(5?%,/J,9 :?^,:B.Q0/4@3Z7XM<P+Q1!D0*3R_\"'P2U>?'R<!
M3#0V5Z#B&K"S//IS>'V,G%!=@@LS63=6UZ0Z,V%!\X7<T/!MM>9^8R_X969M
MREJ BRAM%OXLD,YIJ/-!\N.HTX57X+8FRA&H19HF4;Y(]OV'BR.::_E1'G,X
M4"9>5M[R2O,5J5 "8^$:"\6(NIRV89%/,%LY0'L>;$O6E[<0UN!L34#75T0@
MS[F&-Q3,[OFK@J*,Y]<$-6+)/K^J-I_#$C6;L]9HRGA8+=-\E\EF0\ME0HWI
MZ4.OB0/H4&OIK:@"YK5>K5G;"FQN;Z&6];A&BP8\-F3*)*[-(J8B\R2R+79<
M^Q4\MS%<F]AR)CC$F6XTK!C?:+9N-63*.DB,FL12NX1QKQ0KX%<'^!S$V".>
M;$ZL#R_[2L',:65 E>":;,Q8DV7UE+YJK%HTFCB*P:CW.'QQ;%ZEJC0.1=W
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M&MO9(.\8FU<GH 6"HC)F3^]%:CA4A +H)& ^61#?C5H VQ%4)<33"R0GV,7
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M;VX-Q@;6K&*M%M<^Z! ()8_F_)1^$HMK$B_9<;C 6Q;L;ZXUNEA"-0D)*W/
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M09Z*5UP]%(T!KOM9:=6^8W8.!7UAF59O>+!']8M_HE$T:HNB43/@C&9B9;Q
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MNARZ+LA.P9-:]+UC=PFO2(Q[H(7A@F*$6$Q$%I1B=,4RJ ,/E%PGF)O^F_+
MK=YR2>^,%0KXWASY![! 9G3I G\[C;(^5V^MU5'&249 M^BG&/3^BI(Z37D#
MDJIN)*)]?"5A<!^N)9HA @@BT+\@E),@<H/,MZH0%Y0!QM["]>ERN?I3DUW
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M!PO[Q:IPZ_P7=#>0XO9AK:!?'F<AEN0B$$",Q:\0()HN YFA5MTU#GI$-53
M2O47LBEZZD4Q_0+Z)P\$XAIT6QV#=39$/"B)V=+@23TQ> U_!3VH9YX,YA*6
MHYC\>PG+4Y?*2M=8M O$0KP1LHGT6O<28]#^$S\6$(<_I2=I&N>9=@0(?$-9
M6I%ON,,R\95*P17U,@7]&",#:W!(%VQV1QR9A,S+5/EQLZ9"6R"*O$+=S$:=
M8-+3/U/7E8NS<2Y5_/Z/W[]=_?WRZUW+^-OECW^>WYPS<;K\^6NGVVX;)PC
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M28$IC3=24<;_E(LQA.F-P)GRA+?!@BZ^H'S@"BZD=U 0/LI6([SA>'44BUU
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MS_X,AHR"/OU^>\9*$F;$]:DA\-_N?/$>-2]6S8^H)I^P<).;GC2$P4AP3U\
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ME9>#S:I,B\$.%0:UMXOJY*R>?_[X_::1>$MV7T^RVA]OJ>Z!J1H1RZF[7FZ
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M\H+0;6M#??\2G$9>WK62 \?>[&QI.=ANQ [J?A_4R6']Z-V3./$>B/$K\?V
MQ-4"F#R(YZHOOP.$:[O-O/TJ2:Q.W35T$]169Z"5UMXC$72*J>IRT+5U"&=_
MBUW+0=7E8.!HSW7OJOE.W07A2*[KQ'MXJX3K["F&%6&Y\!<2  #=BB>+RVN*
M(NCI/.S^WJQM;IZ26'E%4"-B]<S-K=XUI56ME)9E:6]V_U:G8=T'.C5!$FQ]
M?>]?FE-S,[X!<M#IZ:3,WC="W4O4ZI2)_4:B. RH^]K$\N%N5T=Q][_U&FG]
M59)6/6VA5%YG.6T-,;>O'/2;"3%7*SG8K,FT%&P]0-WV71-!<+01N[?+6OLJ
M^CKYK%_#X.PBC,B[ZV1&HL;)>V=SDE#+^PXE> V-U5:26)VVN3E-5U-BU4IK
MG5CM4ZVPM*W>;"G0U?-[WP:.U<PBJ5K)@=76&,,'0$"H>05:(^967X1!O)R3
MR/B%N'XR&[\T#5O)\5+=EC70T\)J0\X_]_0803U&\ !;A<%"FI$T(^V]5:ME
M._UZ<5*3+QBJ%X;UHJ;6"V^D%[I=K1=J0\X_=[1>T'KA %NU6YU^KUZ<U&B]
M8%EFS=1\>17#L\-U-GV*,ZY6N(X][44*L6"[Y9<@I]-J]RL2HBOFIZ-IQ$K2
M\\_=JH3H=J5FF73$RRRE:C)2V[0U(VE&VM\5'[2Z5LU8J=$WC&,.ZD5-K1C>
M1C&T6YVA5@RUH2=5#-KTU(KA (K!:5F]BD3IM&+8J6RD6R]JEE<Q8)#N7>*.
M?"(@*ND_Q'+X#YV!:0WIPQ=A["5>2-F%^"Z,:WC_Z$V2&7^P^L-1F"3A_*=V
M^A-W%(?^,EG_$^6XQB1(2$3_C.M*GQE-2 1'[[N+F/PD_N7]Q(L7OOOTDQ?@
M;O%'[^=N=.\%9WPAW<7*^>/[V)_YFH9#<]COP+)XU)*_F*_8I"M^M_JY8W9[
MO<*_M$VK\/-U3QIV3+OC;'Q4N9!37\J'-B*$2J]@#3)J-;=U>_[U^M.581@;
M--AAWK^BP?#]GZYOOAAV^^S3T=]?O/]-^^8YC<+WPLOHBU^T9[MM=PJ8J4"W
MJ?\$W>--_N</WG#J]J>]X<@9MAVGVR;#L=,A \=QQG:[8_6Z_V>WNW\0OYI%
M*5?>D[-11-S?SMPIU5<_N?ZC^Q2#F"IJ;4Z5D-2_?;-OTQVM4X&<S\^ J:E>
ML4%KB<\BMG_VX8JN9)]XP83^UT]G Y-^J2+J<S@PA^WB/^VO] K-&K;HXHOW
M^1PZ$!R*#_K)2^A+QCOP[+?SFSOCZH@]V4FX6'O!XKF\J*A_G6X CMMAUU=W
MEU^8C=4UC>L%B:@9$=PC;/;4"]Q@[+F^$9$'CSSBAXLHC!=DG!2A:*\5;U7Z
M,FS<H6ODG]#3^:FW>,$9%'.!U=YI^YUWQE>2&+'KD]C )C[KO?'!"Q<S-YJ[
M1DSNYU2 LWM=NYN<(OC7,DZ\Z=/A6S4&.]+VU@O&Q !=W#+"960$E(8K>Z.,
M/5]$7DSW#]^YI<2E)$^>$&^N9?Q, LH3OO&%3/X_>^_:W#:2I O_%43O]KQ2
M# 03('AK[YD(6;ZT9FW+8\G=T_-E P2+)-H@P,%%,N?7OYE95;@1H$B)% D2
M.^>T;0DH5&5EY:TRGW1L^$)(7/";9?-_#.,0_\2WST+&B(1&Z_5UQ&9*1[O4
M=*VCPA;Q+UU[8Q^^C-8G/0>DAA\H(Q99CLM&"L@]V_7#.,"O#/TXHAGY"5.*
M&?,I?/8CQAGWK=8&WHU\>MKV/3!KG9$5L2P'AQ'\@+\,1''C$?S6@AG!#_D@
M>E]3_+$231T<WHN)Z^=^$)UK-=W]:T]LO9<P.%([FK(2)K!FX$4AR8",L#?M
MKOFZW5/[ X%< C-T8==4)9XK+<WX6?$]Q1($@I>&5NCP7>F AD#"7KW[JBEW
M\*D%LX(+W[O /Y,7+O@+L!.@K$.&A!<?[?5S'X0WQBY*&\4:@32%1]D/>VIY
M$Z8 3\"_QF/^6YH^\D@Z?UWM=_J%Z>,4D0!C4+7^ SX/K \<,H?M3L:BV?^R
MYJX;&8N K 3=U/1>*2OD30+Q7($_ECU:X7FN8)S?X=OX_2I5L,PPY88BG<GN
MZZ>;J5M@VP(M=<T@&@&CXJ%60!20"$&Y-@[\F?+VVY?K?[[[?*><_55L>]GT
MGT+5;1]'0P7J[I6V,I@B3L-Y<AI<*_;L*2J L?+YW3]_N[[\UQ^?W@%)E4.G
MZ<K2@3U1]/+CW;??KJ^O;W8TM8[6,=8Z24NQ(32Q+@SP"9:=!Q#(#$< <30,
MT,+?*U63PZQW^XHDKJH\3!U[JLS\@ ';PL3\\3@$W68IH\"?@S816@ZX^/+;
MF\L/US?*V46B#%K=03+4Z_T(]U.7X7I7Z_P,YI[0^MD-DXA1RB78DJ"$'QRP
MQ#R23LL6Z#@ !0"&&LONK][KY@]CL\E[V.14G>"NOGGWQ_N;KW??;E/UW.D9
M^6U:U[Q^N6W:MC2[\F?<\_ Y0V>,&.)]=%MFUI]@FR_;Y>!NCV*R2N%LP#_N
M'?1<A@RLUW4)MW<?.^]2[L";6A4CVF 3-XP72=-SS[I2.1NQ>^"'.? %2$P*
M(@[]@+QL$J/*5S9!$8KV"?V%7./4*4R=+[VE]O1.W@%SI!<)GI\Q6.'Z\=?:
MIM9*'<!KSO#?/ <?O44?/%33SR;&.^@#L#]'<AY]53>KIR$^9&C=G_$KJC+T
M_9"FLD#O'[S F((%$:QX MIFAD:9T"7B./U_,.,YGB:B&:@5HE;X"TS<GSLV
MO$1ABLB!V5IA-)U9X$5;,&]E[KN+.?R4@7'EP6%U@%<4%N*QG8CG*4@6!\[$
M5SSXFFL%3DBD>!>#F<+4[$1@/)HZKBVW)7R1B7(S#'/)$7\QOMO\6N$E^+[=
MT@:" 48!6+=>8?_!-WD YH>-K]Q4VJOLOB8<^Y6%$0\',>5W/W!')T[L@$V(
MZY(3*_BV5(JH;3-OBH'V-[L8&(+=.D^V:V8YGKO 7?N[A:O"S;@"H\\Z_(!;
M^29]SA+CB9=NNU-7PB7:M[8:,]?%/>](^2U%>R9R-^AT"M).\,HH9O@8GDHK
M "Z"@PND)J7FV&&5OGF8,C">Y%.*;<V8-,6 H;[#KL&_/EF!/16A8$,5RF;/
MI_[ MNRBV]/Z?,] P8N],KOY$'%.TPF:TQ4#BR@:03'HAJY(UR&;H-B+B!,9
M2#_@Y5LVC]ALR ).5&3#PQ>'Y>O+B4-<XL&)Q"_(EOO6[",GI&A($M38-UN>
M??KC!N._KSY^^W2-?ZEG''/?)E/B$J41]5?\KV_AK^?* RHE<*KZ4J9*/9C*
M5K#[6_V"=+U-(F9EPS9;]33K-N=^FD;1_.!7QNA5B$>,0A1+^I<%RT/<7I([
M"JZXO&.!94\<3 0B :3,@504'SJS1O<8%<*L&VO"SOD55W,<MW0<D_OF$9R[
MR/K.T*C!G BY 9G3U1!]&T0G&3?R'[Q\&L#9H=XG7NB8O[!O!9PWL ^55KU^
MNWCY&::B3(@[RB?9,SU314F^"??LPD:-[D"-S@,6,DHC:G<H5 R&/X%RY-./
MN-I;,GP;1V=7CLY[:Q@L#L31V;=TC< $B.AN;<\$>7_YYNOE#FV+M2DB'0_2
MUC($-]"+(=Q#541X][QOG<UIE0MO@VU9>I.@\%CZ(1,47=)],V4]C*"#2T#C
MB:W\,G3)(3U@GANDD>5\Q>?>R'K0?-=IK2K4?WF^*\GU3I*[DQ1N2MQ+/ 1K
MY,]YQG;F.MRR S^$W[DN_#A@3 C+L/ZFH;1]#\XV_&#%=J9)X[[#X'MFZTQJ
MX9XI L+P':5A[S]PMF_> %*\???QP^6>*7%>S%,:]%<D2_4U\V>>!97L))<$
M,O _$!D1&3.GV^_E!Z1<J^72!Z<B2R6U+8V.R(Y)%*J,7'<'>=&=-5BSP5!Q
M11Y8\P6O!K3N_8#*5^<!YN%.*)HRMP(0ULS-1%3D;BD@RC'$RC_7E?-)K_F-
M0;$\A]+51.).DF%6%EJ'%79D_D!A@7K7+"Z07T?#.UVM_7-BJF<O6O1^\1U9
M&U%#^]UH8YIU886%Y.A]F_=6F&<VL@;8*&<,@,9,PXC2:]^%); ?Q?ONX\W5
MW>7=WMW_U3FA9D^OD'$4U]<[@M?47'(.V78HO\9I.0P=J203Y![WF854['FH
M!^EX>&W7-4EK,QL(5F7L!"&FYU_8KA6&*B@:F\%K[+N[ "UC1W#N<:ZH 5S+
MIJK=1!-%4PLKEKTQ"T(E!&H[8\>V>*)\A%>MJ#$GEN.!U 9=Q4;<\IZR&4_6
MM93+1.B O@$Q)(K?*O1,/CN'DL3$+3W\)#TY2SF0G:382!Z8NKHP)67$!YG>
M^/'+UYN/U_]LKFZ>?%$K*W3,DJ)O70?3J9AM#2>#/\G/#/^[.#@\Z3)W+2+U
M>C'=HN)[W+RKZ[$Y[&3@V\NO5Q^O;_?M495>/1RJ-=#NZ\M\VNZA%[=G,L(Q
M.52B29_.]T?YNC>LRRA&^7Y)O95.\?:IW18.Y'E%KE7BRBU=7!D](;OH59F;
M+*J">.W!F82?Z!6W>,];.U<,F2"X$R"2_8B?O[_[[>[R\]ZESXHBEK;1*G5[
ME#.L)^W+4I9,@E^^\C6I-D@X#O^6V(]ZM3-4RM['L_57EV\^7O]VO>^0XKZ/
M=37G&4:O,J@HZE-:6&-)MEB&_]+D1NO!"AB",N&HEOWOV DHLA+X,V 3QY9_
MO; 78)PR#WXRCP/X?Y9R9MW=?9'1KR11 F: 2Q"B/'9&9+6&/#T5>?4:$>\\
M*J+$#CR^[;!H@0'$._XEB0[TJP5^6!A1R>C9]>W=KQA2M:D\FK)KN6=(WXHY
M+)!@%W+B4%_@_);R-0L&I:ZOD9R+-6DB='&>* -Q4M-MD;%:4VB03$1M*7B9
MKU&:(/58("N,@,PL$D6YX'1B 6T8NQ193#<NN063&W@\Q_Z?[SY_N6D2:9^1
M6L>#X6428U"T2P4GEK.]]/*,8O8F' $9*)=*4"_<\C:^V"[BP)__?OG'I[U'
MY@I"M%#@(.QX3L4AHP+K)/HU#QQ@ *>*Y9"SR,RNYI^7@+7> _IJM]O;&'W5
MT'J=SE;0JSM:RUP]TN[ J^40.X4X7<O4:^"?#P;^^8BYK#LH6>\C<-<-</4*
MT7EHP-5EK'AJN-4-//5+0V<M8=]M@/EU2!9X<HFX#.;WX<VWC%=3=.6IW7?!
M$N6)!P;F5U7!$/<T7<G"4(V  (&3%"+EKKOZ14N7QB>\&K\<XKB3#/UD"+:<
ME,7+-;.*MS87)"EO;1J;2P$8:^KI)7RV[^3-94KNRZ];YOBN:O2*5Z[\3.$5
M2]F1&L81779A%"P+[HV!!GX?'(A/5 (U?WWWKV]?;Z[^EXZ0P&9#M*[ @<'Q
M\H<_=G?S[>_O;E3E[E=PB3]\O'GS[>/U9U7Y\O7RXS?$G<*WOWR\_.WZGRKF
M'D;@<PH4V.%"P<J'(/7T/][\]N[SS3^5,Q&22[Z: :/!;PX=\!V!$E80\C#(
MIYM_W;RY_IB\Z/H\EOKM%N''W3AT[IUH<:XI6<12R[8%A#K&*CLMK9>I?UP6
M>WR626P7)V5AF);<;).J)_DOC;I&7=XLE GS)X$UGR[4'*FDJ!<\EB*U/9)P
M.4CN\;+!JK^:2"P>QXVF?CR9TKL.$-2.*,5GB5$HI8?@WGD -HQA^I37"C\'
M"Z(:T2&;UI!6M_=PLYMDA1T%R*3HV+<D+=@F;;TH1*U<1EJVNT''E.DL"F_*
MX40R\TSE4)0_G!EP&'"IJ<)*^,!)=NS4NF?*D#&/7\JPD0S'<8D&PA:D=,0\
M>T%M$>ABA!8?,'3J8%2<N[@((O<O1+DV9,3B(+$E$AK9UC&<HL#Y#[^LF/HN
M^'HDTQ(1#D>#@/KD<8!_7\838.(4M(H&IH>4S_)>B(0?_/E%8MI>CL"EA8F+
M>Y&SSY^^7)ZGR)Q#YL8S/XQ'CJN<R8^?)Y4TZ?T4$#A-))[ F_("" N1N-'&
M5T%$LZ= -,=6/@3@:RN_ >WB4/G5!ZGS5M2@G-D??OOU[3FLSN>DMU <6"/V
M[QB;3@0LG(/"(M5@^^@JX6U>X#NC$'.6?<Q55,(%_&R&EVURFK4M8A*H>B$#
M?3U2@ 8!7FP!T;GJ$I]+^.L+[IX7\1-!CN;AB92[?UV_^_AVWP)%Y8SE^?<4
MY"XDQF88'%E^SORY*^Y@H\5<9-[IRLBQAHQTDTB^SFI:U+!C,,C\#/0%7WN)
M75@">Y2Y]R6=^0-]:U+9UHA:Y%BS^058AH4K33AV('/$F50<=')(*M(QA],-
MK\^.Z'*3&ZW[YJ;"K74*C&^T*Q,*P,TUA%[ZP*TPM)>6 %H?*S:2Q3WGN2J
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MO(C!YG>Y-HAI,E)2M!"J.'LW'O%FV]?P4SZ(WN<E-E2*Y\64P(0U*Z)SY3R
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M]B,+5:&C(V=2:RNE2H5CR %%GE=B1;0+5?K/]?JWO:A9-EE+W,[)4\/_Y0L
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MIE4N?EP P.: ^\33FUM>^3!OAL96Q!NUR+P+)#=U;_$Y@BVE-L''0DWY'2U
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MC*'U?\8R:RM*:_Y#Q1A@D7T&3(AJLXM?:[>., 6;=XZ$#9G2XBMY*2DN1)"
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M77:RRE%<MKROIM9YG"4WDS"FN1]#]@D%WYQE+X<^.'@6*LUL]+Z8@S)'-SV
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M0PBSI/S.!,Z*K#WT"LL!49%#IP_C&<>ZIT"+#WJ# *+P%<30\X,H_0'_J$B
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MKR4G];55(-<-(VV3D9Z!*]!?IQ"E?U"UU-9AM4_,$W2@=:EF1SKERLAG'+9
MU'<O5\ZK(@W=FHDF[I$O,_X-M=5NK:HKX;^3U2FRP0U_5>_K:[]JK%W*] BS
M9'AE7Q5+^ZP\H #I<)$I-!#Y[PAAX0=AMHB 3YGZJ?9>ATD] 2]YQ(^R$?96
MK6OMQIU/E>9A2-42@E1H8CGA=Q5K+H!6LKH%23W)FF""WNI*:F,M%19Y<)LM
MJ>40Q186KYWAOP6^EU47!'Z0\;O.DVJL$8?(!<WU\\JS@B.@H;3RJ;:F7'J6
MNQ#5B3SY+DRJW9<JRXA/2BKE@9FBQ9RIP%+8_!W!>JNK*52"W4CZL#@>=G9E
MXHN:WM-T398:Y<J?4M*&$?R X#_4%+[#BI1K^*D ]^AKO) *SX+GQ53L@JF$
M=674WYG"?E E:M*0?1Q'>$*3JJHP4U8E2HE*&]P\@*3%/NUA/!X[MH/'7T*J
MT$O(!;P",#T/5A!@63J'7($=F[N6S1X1\WR6@A!8CHC-W:GU^P+TRSUSB0]0
MZX3Q\$]:F@\/W#/X:(1E41,K( 2=3+,]/"<"<,>G5X%#(LM!L)&%8KM6C)P,
MU/M.[S%&LJP@P^ <C1SB2WBHKOQP657Z";)ERMR1HK>U8JUCL?Q8I;9] 1V>
MD- N1C%!$'$1(W 9D-C '/ \XS@LNM8"V2-&HY'X=T15V7X;+<M7EEJ+UJ2@
MRM0ZW>W44PW:FM$V]]2"^>5[X'8?B8+4<UE- ^F#:2#=-%0^GH;*&X=)CK&C
M<HFJW'X#\U-KM;QU))(/OC\BBWW?&!4I9M$!4$41J.9+S5_V3"59>-UKJSVC
M@-:"4!?HTI\KP+P,7;0T"C;(1\%*L,$2-);(^H[XB[:-@3@TPW.P#!)M")'"
MT$-S7=^V.+!(%D 3'\VACHQBBFM(+ X<=S7*R*%BO3R&?@*KV3./7,+6N)R:
M1B\35SE4BMZR>91Q\(V!=#4%-A9X;NY".0L9RP=R=AC%P5U\[P<S,DW/B7HI
M[,>>MY?B>>!73SQ'%JY:'A=/0(D B>9[H^PY!/6-3\+JOMTJI((I;/'FW1]@
M?M_!S\X\)PA!^<VLX3D_MHCM!$S!.% /,GL"'&1- L:#NB O["D&@UCTP)@G
M0S%(K<LP"JQ_,8_9%LHE8DG.B8?*A07^ND(0U!?B+Y3&*+'C^8,5C)09B$4>
M""-TTKD51,#__GB,.PQ2W9IAR?)_.!Y/U<%^0<HYL[GE!,01H!J""5 A(^W!
MUG+\$4<:PCN!9'' %H_!SNTA>+9U2^(Z"^3-E2IRD1\H<2AI)")A,Q9-_;UO
M9P(W:!3 !A.TVE'6MB@ F:H%%#=N92L9'G%]!/0"(P.8=P+/AE&&!A<IB5($
M=&25=]^^WEQ^N>:19!J90X@%_EQB?/T[]O$]8(WO<%"X?0*G3[XI(!&!Z/#S
M3Q:8,4+?9-SQ0Q-*QW  ;I8ZMQZ&*5URT]S&HKX".UL59G**<*<7#/%CV#1^
MY0MR& V!R/JQVQZ[:\-5ENR9J79Z*[,#*K&4VTM8IJN@NA_E@J4L!7$S6T2U
MS)(5':W (3T@D"+#.0S,29Y>E\!7OO[%FLU?OZ5+.B_$NY4ENZ!B8+IK 9,$
M[ XK6.1073-(^-E^$ZB92W$A84:.+=] R^CJURMEB'IL/U?TVV?[C)2B"^20
MG-?R!M2[;X^X]KE(P@)JMV44M'8X]1'\$95P&=<:7;U<@8]B)CV(@KL1I5>W
MEIN085& ,P[\A>42V\RM!06$\:K4'SK(ZIB'$%HN3PNH<$2$6O\&'V:CBUNT
MML/4#50VLM ?1RFN 7=^S#0:R1Q=>0#Q\GL(:X\2GHU\SK P<N##[H(T2+JJ
M[YMELYT7B@+<!8X-<A)71<<J>7KPF+Y=MT-'IZX=.MH:[(* 7*UIAD$AXP2/
M,?OAA.0Q4,Y)@AZ;5M>2+A-))\CDY:DF7 !P@%IPM!B(#)(_#W[PG8\NX6DI
MTI&X\ I0:LJU, *&4=A#.7,TIM$/=2E986G3,-,T(0EJ,@]# .7Y*CR*A(\B
MS%AF;/[8D"U\^'T88PYD&K#1C0OZG'"CSS7E,N(' W&3\QD9*]!GR6P2(:$$
M1[FGMPJ2/XR'(#+A2<L%!8!Y>""=94I9(#[C>/PM%@=^6!*6:^\P;H+K#_'9
M$N-.VH.];M(A2.205!,F71783\ 6!(8/+FD<$ /QU)3TWSR[R*'V7.3,!R/Z
M.:&@IX^)ED3(H75-_X'#&<1<_V*J(D_><ZT%&REI9RQ@^'OPXE'%R(9+(B_,
MAOG[,\+O?ICZQ APLM/N(F2WXJ_  H"MP.=&\$#@#&-,$ 7C%ISUF6538O#4
M#^F\PE]MF*EC<X$PP5Q1CV>73L">=:1U(%(I4W8"COQ?MLC!6%.REO%:>2N.
MWU=<Y'O>\D3^4H0',D^$RM?,'<<-+/2-U+VY=X!ZF'J623O+$G(5O43*)_#Y
M6Q;AD1<7E2*G#-<-MICGSQP;J3IRHH*!*MJV((.&V#"$HBD!TF9JW2-KAK'+
MHRL\)#>S%I3CYGC<W.,/$']G#$9ABEF8G3O![&UO AR/1]29,1',H>0ZER(S
MN"01R$%+Q69PX%  \V'"S*PTY7;JQ^Y(_%S.7LX(!$1$4Q2B6HE#/LD+!D<X
MQML7G)?XKK1#N8D:LLRGB2 BH9&+4HY);L,^C6/D1Q"S#GP;J :+A*/@\6Q5
M)PQCH8&J")],9;TE4^QO#A*3Y*R<.S4F0Q:C:=%>#3&FCM^*DS :95ER>QQF
MN8!AP&# A-<1R"YN#6),7GQL(=*N4<1*V\^CJ<QFL>?P>SLNO#('UF,3'V:6
M- N0K#IW0:"H/,0KVJ4E.;BX)+1'$^' F<ME$VRUQ=L.*C<P96*-Q&"EK$"2
M BKGKYF\<XP":Y3?/UPPNB040PYPWX$>!94LTI]!S(!T!;DH!0^M@P\>DE]#
M=L0\'@+UE) ASX'N'\'F+.5!RP8J&U01P"[DFGFMKD!(<Y^756EK?56ZN2:M
MJ68JMW^L$8A58FQ'!#&0):6A1T$3.+(Q!H#)VGQ@G#?HALM'$Q(4 \P('EY-
M<9DAJH%?.@JL!SJA8PQMCZ20!B$FO;1LO,I*^P0D)EBKV)NPS+31\*H(TV>=
M$(YIF#%LHH!J (0<(&59J@!U75/^$:-A%_%^/]3& YA!_OLM#.WZ(=''&F(O
MCD\\BHY:3Q-*J:8,4_ S,GY$FL!>[4L4T]:KMB)M@$%2G#8BD0)+N\'_LHLM
M6=?S[=?5\S5!D8S'Q9:4F?*!5U<8[@"E@\+.!Q$_22,BG.[<4D)AP0*;Z^!$
M;M27R<EFN >]Y\?<@*J@@;)J^?FH<?Z$:&3QKAP9GU\Y>H7J(VMYBI4#HEHG
ME#JPK:D*%>W0'WV-&Q9O-6.G13PY-;S)IS9.!!CQ8T[!]<AR7")0EF0\"P,_
MGO9FQ) &7F"*5JSWS/7G_/X=<VN'?B!R V2F1IC(+1;:@3//!G+34;G1+5VI
M'"/8+* JF,1RX^VHN4;%1)TQUZ,YLAG:2#N7E*-MWCKYZFK$%"N&GGY:X=PP
MLK\I L&S=<CQ&+*5':9?HE9F#XG@W6YOXT1P0^MU.ELIB>EH+7/U2+NKB'F1
M;.NFIJ1>-25'S&6]7LEZFQJ:XZFAV12H[!A+:$ZN4L:L#>^;0-!!?SN5M!J0
MNQEIK9&, Y$VS_$2UD-P6O*2-^@]V,+E%3'^]'*0/[U4)QU(GX4O\K)1A/[Y
MW<T.16_3:?, =IT00==9Z).[31S4<C_R%M>61UA1.MUOG,[J=27R:>$BBQI7
M7XV=?W3+;\OE=TYR^9]\">^2'(".LDR#%VT[\UQ$CBTH__>4JB!P;S+1P12,
MB?].UMP*$HJ+9P[6AG]+[CPHF6'*1A.>"!!&09R[[]CR*DM0\\L6^@S4_&>
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M,U8PP"F/@D0:3UC'O-T8DTV(?]S4J@0?C[@RL?E0&@Z9C1GJU@/Y@L(8Y;]
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MI*A99\0S)PSW%MV$:GDE2)> M/FX$) 6C+:">*++"J29!\*CPKX4%W=LD=S
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M?12CMCJP\#>U'1<K@W>-WM1L38&(KH*2H]],:B,<H_]77O.:V2D4?!P[$W"
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M.]8 ->4==<$@_ <<A&S$F= %WV)#A!6"^$<U+IX\!+HGG"3^FQT=7/^1RD%
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M\ZC%;#*!7Z (_P!T :K</]2JQ+#,";XL*!5[A$>+'8QU G+B_?2F/L*F7FP
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M=AZG T9\&PL*^LY@IMKR3.GY31S7F]].]'B%#8;13D1O[,@F0W0/9?@< QS
M,?GW6)>BJ%0<T^>@#9*S$08_L)97C9:%)]QP9L-[P,?<A#7-2LM8XUIB#B Q
M"2)S[7-GRF E?SC\R04Y\&W#M/86K]K.FZAW4O<F:M7CJ^DW>H&9</0NCN'G
M'<+_U3?7-\_(S?,;!FH<13WHWY_V[_-P;E83:W&R3EG]>_W[G$4R7\,GRW*[
ML6]@ U@(AH3]?HC\DJ?6MD_,9IQ:9,I-<"BGUF(-1&XZ:Q]%SAP;GE6'Z1;M
MTJ8$EW*Q\FA*$8PH[/I4?=$KD)+F;8]]9V!BZVN\5](;PT88R8;2L,%7-.0+
MK"HW%"""LB,>.K^EC,OPW/8Z(T<65EB:1[HXP[(<;'OU1*LP!GZV9UV)@%+A
M#+'-0F@QUV V_M5]OR'A:DL0>M%XUCH(/7E=>B&N9=(>(\2U&8.70EPU00K?
M%FH0&/M,#6#:C Q\T8H\Y<[8[(LNJA)P7P:X1$L5)P-&O?'RY$#-KKVS"U2.
MD< K!\$9&!\BGAULO!*9F&X$3@3!14Q7M:Y_P&VI>7=XWJW8:!R4*0_YQ+Y/
M31ZB$"#J'?XISY;\GBSR6,7$QXO#G\2Y, "!],51LX0$X3+V)- -!G#HN"SA
MY!7I$43[&]"I;+\7>)B>+S$F"9PG CM3I6%$^2AL"C8P_0E2&8N0!7%+I.][
MZI03(!Q]W[0& NH/R NGN>G-B+ ?JA^DU6A*Z Q<RY :S'/EQ^H:(I!<GM@,
MO_0<GEN6!="LEJIF!-:4MCSL]7E^#"4CH4C="&B*0#B!ST=< L0B&LJ2Z0O[
M:6[*NG*ON?J(/P('#><<W'K3%DT3<T ><&68[<J3(=QB LE'H=J,!&S,F I$
MF@@TLOC:Q5TLTM=PO_#G(GM)"0@&PJ4.GJGM@<F@N7X$KK^(/+$ Y;5F41RF
M1' E/.[.S'?RZ &Q$&C:R_Z;PN9RL73 ]N+"%/6+G1>$QX$#2R  H2('3C\Q
M;_YA"1ZW\+PQ+.E\WNDC6C=L$9IPW*EH!E*(OX1.X;,I-Q%02*$QR8H(3@7T
MKBRGAP<$3S#&S'C"-^5,GO+L3U^@$3DV%CJ@@(-1A*>LA"^RS">D&N*)X]DL
M#"Q/B_$1Q!A# TIK(7LB$-)@&-F,#=A ^Q]'XHUI/SO6LS(-0H"W5V#<8%^[
MSE#BB F,[W%HX7+'$F5(01Q5Q,-PF .J$Z6)'(Y6H[#^42@<7R!Q3]3I9"I0
M. 7-=5Q0[5\.#^35:K6W1HRME=O-9BH(1\URI;'^3ON#S@YNL5=85@T^O<'Z
M,P0^76 INVAG"VP[MT"&>T7,WG;P<A$!LT\,%SMK@3?PYU7@31E'HOA;1-\2
M\'S!/Z)@KZ'S@WZ>(1)JX!K!/X;F0'IF&,$T7==GN<U,=BUE0M(7*AQ=#&A@
MYI>&%F2 7@MKCUFVJZS:,$P&E(*;^$@DQ IT7AA?#$?;CLW@$PNC9W(LD[*A
MPX!SF&\.'RV!E@5(+[ZM^GX>8?,8G>25';UXD"$T_==Z$0KC.DPC<S;"N",(
MKJJ8WSRNO",6<29J4*Z?J167&1FC#495S4-S.16.W\+1>)A><>.KA/W!/=Q@
M"K8<)XWQ@>!R&)N*C/0SG %6#$1212$<^I2IS1\"Y+O)!)V#I9,)T(;TP_*1
M$$T<#A=[0$6:S68A-+2$+,=A@C,QB4IBMJL5!,+\IV]R 5H^E)/$V)R]GH//
M4DE963=A,1QN)6\9'7$U'R>HW.+Y0K<IK9!(YBY&^\0E$G#'C@T)F*/KY%7[
MW,Y#E26D):XO&!4V9I*C@KCG^"'HEV76S(<JG$ERR;Z=E:1ZA^H+AXJ%X.\E
M,8/,MOUHX#/RA-A,!-]5$7GF4=."#X(A8C:<%F+:FICZ,)\SIC1BCQD<?L)G
M"\CP<L >2$)P^"'$O@IOA.$<M4-6Z9GYMB@3<HUQG3!?(%2UY8A:'S)D+W"2
MJ72L@O*7H>;X(H(UNJ#X<5Z;.4*5B.>#A_0ODZX<P0:TE2\$VV&*@PD5TCWL
MHBG0&_;2F4K&2JS]T(IY)XT=H//LKWF;53*)Y%:%6P+[I)'DH62H]BT%W:^4
MBMR9--SP6^^[#VK0AN*M3*^IRC0<=A=D8(('R*Y!#)#UQ0W$>#RZH';4P#K8
MR#PT'H8.<@6_%>HHO]L7'1-95D2#="03QX'C\V!3*3(B]6J56JTDE1G&#4!)
MOXAI!D*<DC:UT,UAC2#H]'/'/D?5'IWE@+J2Q>3^3/XDV%0K+)EW)7$;>R 9
M-P&5'B1?T)3D9M\/=EW\]DI 1?W#:R>5V,2.P! 2%\P"K#11W"#'=>!@!OJL
M9F)&5D9C0RK4/DD<YR$U"1973":XA=1W,JUBXN1$TYV/MH3WB2THKP+X.&_9
M19P$4=Q1PV?B*2'^4?T0E:LY+4,3)7+&8EWHJF-#CE0%%2B[=4%XJ^D<]0<>
MQI'6OL?=6UK<MC@B94[BX"R%8_O9I MGS)D8 >T:L,=0:_>!0N_R+(7! :7X
M+Y1;E#*8_=S/F265QN9GU@M-.K3F*BSR(C>LSWW0)FH\+&AN6%<CSR[;54 F
MTQ9*0II9?4QE%654V=RTP$ASJ/3%4;"\ZOBYAO@%<+&/FU97?!TAK1OZ#6*R
MMCC2(XJ C)DU4".;I8HYB_\ 3J8 5S.<QDSE:#G3H'/7B"+\A.D^*>S#J R$
M=22J*P4-_\ ?,=W(G4PL0+(&[W1IQA'D1$[^BC,_*ARHSBTJIJ@]J\B$YM,1
M^!141063Y8<RUHH!AN_H,N-L<EU#<[3BS,F4@?MGF.O2*7H&_.N)7#T#?L=*
M@@L] UZ7X1QQ!CSJ'G/PKQ_,SI"VAZU.O]&I-!K-"NL8C3J[:#0:1JU2K[::
M_ZTUVC_HR?$YK(/1D^/UY/B"S+UMEIN=6BIFQD6M7*NLGU:;*(FM-5 ;M>I;
M(4%W&6.W0A@[&QU4-^#NU^KU#P/Y!S<-<N^K?U"R2N*6 7O::P&06TO;-YC!
M\8KI:TY&Q.7&OWYP[=DY'G!5^+__CJJU\O^FHQ\(M;Q__7!U__C?[M7=[=?_
MUNKRXX5WJU2FWW>14?%#(0@IFV:A[EUUZDFG)O$T.YPA51?A4FS4<8:D;W*@
M"/FW;ZE8<+U$JIU6G9R!JAHH959YM[G K$-X6B GP3\[Y68"89=)E'P ')AJ
M7T6 513KO5>XKDEGW!MHLO6YEU'YNC&YZP4A3C9X3^YHD&Q88\YJTF&H']$$
M!,  <]]C,'AE4;HF%Y#K(Q:UB*)/B5GSGJ@[![W^C5:)T&=F^YA+(Q8EGSB8
M7XQT^42>ARR\M-VL5-M23!\0G"#\XH9CBNZX?$BDK#)-]N+L?O4Q8X:GA#NF
M6$"'<>CWI%H"7FYFL^; 6FU6&UO'Q"ZVME97?]ZHIM,F)EZJOKW=VUEC]RI_
M,<56C-U,WLW$]=+G/#;S-#'3MD>?-,G\VS2'O,]]_,?MX^?;K^3Q\S51\;M/
MW^Y_>]@Z0/D*1&%!J'7_VV/O]NIZ$W(=LK=GGTM.K#O#?UPMC0\^CJRL-/;W
M297;<'1#F'(_9$ K97/KM:S?JS2IIY+S>X.I%\_UM<IRVMJB[/8\#J[M:#8O
MH]ILVH:F\"H*W[' #-RN?$W3/4VZ]PP32^R'IK&*PD?2RIJQVS+V"Z.#6#%R
M.+P&^R+I=,0FIFW^I/=/JOO'GV+MO>OPV=R^Z3DV[*='9VHX)6P@#697N^9D
M:L%>@[_^#[4=K,0QGI0=,-MC\GOS-)L@^IGK&*8,8GCR#P2+(]20+0C!,E28
MX]U1F//#+]&Q6&(>EC@OSN'U\,^@%)E491'RB=C9-^AHRWK=WK[T^.(TAK1O
MFXM3) 7FU0-WP.'PB9W@#VPMJX4D=5%/DNCYW ,SS*;DUGYFKK""55H?\_R1
M$R0X*D#%.7SJ<%%8+=N*OOC?X61R?#XB%GTI$:4'KY@A#ZRJ5(2;)TG6S8G;
MC[RM5RS%"2D^8*%U/)XH$C.BV\;TQ@JX>*$>6X<8=8@QXR%&?0!L=0!\=>QL
M.-OY#($F% 5M(WB__+//\:S) /WUUMEVZT2;+]%^ZGZY(ET?U+*#+18_Y<R"
M7F>(['DC#E<Z'UDGFMXZJ9XZ^:RSV*TJN':14G5$I=RNM-.[U0X%QNE[12M-
M@GVZ1-<#WZ AAM&*QL?75=,Z:K V_._%;M306F9;+?.)TX&OJH&OOW;)66:B
MVS_^K5:I?C 0OSPHO&5D\(_N -,CKB>!LXX4TWZGLS-OC*FQ$4+K"<"H+$K<
M@V/-/&:,;?-/?TWA9Y9Q?3?KZ!3!QZ_.L[30-\#\7F[ZR/XB90/6'":L.Q"I
M0-1Y'[G_G5D6<\D7BB3PR"<XC:9O\$RR3P[!\SLZVX3=.5S?Z_5L(I(OGI;$
MYW2S:IDG5R^>AT4DO^+)Q&(<X@AGSBH8C8W/G).4RW]3>U.QS.')M*BJ<B.6
M!Z93I%ZB$ ?S*JB':O,\[R98\M)60<Z+*JS%(J9/\D];-2^#WW<H<^S@#*]T
MSI'KL8A)05DM)SVL,,U.6P@NSE$23D$(3I[5=63U19%8+?QEA<1]8V(W $X:
MU0Q7#*\AP^M%8O@5F_K>C&B^KR91M=,1.KU6)+Y_QL8%X.O(<OK :5>5U ?)
MH %[9I8S%461ZGB__E/,;+I"R&HO^.*TQ:)YCK)1)+'H*J!]C]S)4MB2A"%7
M_PK';@6%L.0CM9^PA'(P%PO3)E\<>X"2Y&5*0(Y!T&KGHHU2TMS8#5Q.HJH<
M<&[6_#OE8BQ> *GJ1@MLXRD_<O:)V0R$@-S:8H:YE"HG.(5PX SH)9P\="=_
M%D[-N#8<VYG,A+I2%R]?]-$?C)C$:).'6?"%O%!*=.0B[,?S;5.FQ5=")>6N
M8F,'9(SJZW"'^E:;WRI1GU6;A2FOOXS -+]>,A)=N!3_ (<9,^K$=2QS0.!\
MV 6K;U=C@'S!Y>RJ^"J1W.1\Z&0PL%U-69&%#P3Y/'5+\6$68W.Z^DJEWW[N
M&@:("$[^6*;Q2J6D1[GK4>X:0WH_J8SL8$@76,HN.IL98CMB9C<K!\',SH8E
MF#7@:ST 7@^ S]-F*#:\=6I.PV;(U@_4M\AG?^!&*@%V!K!NIPU@74\"L*Y6
M-7[U?O&K[T$5@4,DM5.U(3"LVU$,ZV9K"PSKZLE@6'_DX*.Y&X%8%YHH2W#5
M/3;UA(\=@%97.R=/I"]4S..-H*G&8;UK)T^A)>CN5LHD.7835%J$.G'0[OK!
M0;O;E=)%I;ER\$?NDA.[C+*[*%_4UB-D;_YYHYJ./0\O56_M$!/<(\9.NN-J
M]H+=O:^4;U8!8S2\3H[@=0Z\VE6%EBLK3 X&]Y IN)K=G+XP4'!<BVQE><<Q
M&X=W>:ET[,?-D,#G6R($3%ZP?W37]M9=VP$2HB9DJN#$2Z#U29:ZQNS)/E_7
M8?;LYOD7Z'!>#6&504H=(!BN-\%8H]=J]-JC.XS:O<Z1>ZW5<4KJ^&3,CLUC
M H<]A[38']$*R3:K,VZ=9YMX>I^DMD].(2^H868US*S6,@?"^P2?DXD>3--P
M)?CG'07CC(FVRCOF<6?J6*8'K_N;#2XI=TUO5B*__;KI6:09GAF&FU/+F5#D
M.*CR)X8-:)+CHAE\3+F<"'=KPV'A^;*<\RZX4O,\CSS_##N;(UC?E1-T90/[
MPV*O>!MW*>6MGU4DB.0#[@9WPD*5J1C\5=T;#-2!5[@. 6H!>C5W/%T)W]<Z
MWR<'CP+D=7V/+/OJ/(/&-EWR )I[0@WFB]=S?RI%0%434NYYW[TK89T$IUM%
MXG0 P>& ?1TTDZ/UK08<(KC3')V#>J2+FOS_,9L9]"=R9MJ&Y>-"R0-GKHGG
M8BEZ"?FM]R$B(+\CKD;DRJ\.]\:D.X'G&/0#^<:F\!U\([K-YQ.2?Z23Z8=5
M3_CUUQ+Y-P6B1:X0,X<BU_2FU(3O<5WX"N?S"_&CL4(X>N#F!,^Q2\H9'D<X
MO?%7/+2=R9H^DCQ+]$>&\1^"@GW*,MT#@P039.</EN./QB4R%^L _>J31+^Z
MFQNU()=]$]8R$AJQO%0;<[15NQ1Q[>5Z@[>-+?>31;\[/=#4XU_Q+C^!N24N
MER]RWIO9WEC6VUNT[ZPQQDXB4'11OG@E)*-O%7S>*==:.X2O-+I-L=!M0&E:
MWMB 8_3G:<QP!,4Z\ 7JUCR>5R+;@.&4R&WLP^A][AC'D<S*7*#&G[ZIM%[&
M,' 2$OMACW$>=&*CW&RU4M$8G7JY5F\<"1WGX,YQIW((.!:-[7/@]6<(VR=%
MK)OZ0;!N8A'%1KF&6BOXC,OURP^7=&5R+#8/ZG.O,#F":*>.DY-PP*:/2*4!
M=#2 3FX ="['W'1A?R#2+>W[5F(:?<$&?@N,SFJPG$826$Y=8^7L%RMG"=I$
MH.4T8V@Y%QHM)P$M1Q:2GCS*R1)83C Z4&/EA#1:@95#-$R.ALG1,#G'KW=>
M 9-3+0$O3SG'H4%R-$A.3OO2=!=?CKKX#KS:9=P*W0&G6S6S5T ;AP7I^@/3
M6UM*I_NKLL_34/<HKHHWK'SX\H][+FUT:I$;L$Q$'=$?#ASBX@JPS TP34UI
M-3)[X+R(T/ 0+LU99]ZZG,/1FAIS0S2]XS3^2"X+H#3^B/9<BN>Y:'6L\4<T
M_H@6^^+BCV@K/3N;(P4BRWQDQ-O\B7S"^NGWN11.K8?>$G^(!1U^ZY%;VRB3
M,]7@UO.HQ]QW)STD0H/!:# 8K9+V'N;^V"V1S]>7V&[I.)9$_@B*7_/>7[NB
M,\($&7VM4BKO8 ]RY#@VU09@#]2+G3F%@WR0;*UV+BYRQ\CUK</S-N%(J.Z+
MJ!EJ?UBR):-]TM0E49,C#OJB.O+4;'J1\@#1L6D)[V^3._;=-)P/L1NH+C]+
MIL-DZ_Z:FZ+TA3_'^XM,FFM2\D -$Z22_+^H8W9:UDTV>X6S>2O=P:P[F%'#
M;]&2[.[6DUP*].'/7<, <9$ :)>];QEK5CZ"DFNUVEOWU-7*[68Z+ERS7&GL
M4'>82N]N0LHE_<8UW=2[P?HSU-1;8"GK5/?;Q-PZ2!-S;DW#O78B;VO4%+$1
M6?<;YV<SZ'[C%/N-OU%CS, G]ZG]]D[CY6#*1IW&S:1.XVI-MQKOM]7XW[X5
MA#J;V&7<KL2ZC.M;=!EOT766OX;(6)<QQL.8NU%7?J&)LM1FW)URTPHBY[7*
MR1-HJ8VVD3))CIW^TFVT6:]NTVVTNHVVF&VT*ZM@=#6ZKD;/3C7ZP6LU!VS*
MQ&D>[I]C]]1FJ*!;]QQDIL(HUD@K$IFV*XL%PG[:)!6O"UJSS]M8=<G_[?ZT
MNZK5W;"ZSOYT]LKGWL?+O&T6S?<4=.2 &88C"_76\'\A0'%"?=''\$+?V!RM
MG5+ME&;6*=7J.K<MTOETIK5IDG]9SSZKM;^F-\<Q-\<I),YT_ZWNO]5:YB#]
MM_,IZQ@D^,-T#<=V89/?45 !P.L%6(!-CVS-Y:QP^:,HO'2X:MITR8"-.!.]
M2]? :V=B&C+O'>]9>N1T@*,8Q]0>C:FY\&W/\P=@B$2EYTQT<.9^+O*ZONUP
M9@J6656W2'AF>6G19&X0+RPM1(FW\$(+PVQ19TB62@SSNZQD1B>'A4^9X=75
M3?SY6M8*AD=SI47E<W(G3+73:9VOW=$YG&VO.I-_-T&$'SAS3<%OG%#/;,;A
MK+ZV@//<-'Y:@GC"4W_^$]F1?'E]+WY\'9]P[^Y^O@>NI U.[>K(PN)5I^/K
M9A/W()NWTF@,64-CV%'EO1&2H;W?H?+N[O[;VH6U7F_9%$LKO:')/@7*?G0H
M'Y")<'4P*;T]SL76P<M# %<DY&;EY.B<G!2-<K/52D6/=NKE6KUQ)$B+PV,*
MU+9.JN9A61J0(S. '"D"5'0. E 1BQ0VRC746L%G7*Y??KBD*Y-CK'E0GWO%
MMA!$.W5PBX0#-GT8&8UZH5$O<H-Z<4F%EW'#.+82'PWXHI4(?-'6P!?[!;Z(
M0A5HX(L-@2]D)>#)PSHLX5[<T1 O>K/A\84FSQ+J15.C7FC4"XUZD0$#4@!,
MK \N'07UXJ*V0\2K8/U&&O5"-Q@5IL'HX)7X&O5"HU[DH.)S[?AX#7>13Z9^
M=FR'4SZ+%.S@L1WM\'[$*!/YZCQ3<F8[]CF6Z /KJ>LZABE<[(6 @^;"MER(
M%5A=TNF(X00:\CM\XJ,+T.OV2@1I;YDN5EI)-3G+6:.;QB;1BNU@6RJJP>8[
MJH<E'&+PU"6UZ8#BC,K7=Y:F?CK4_^U7,K42Z8T3OAP^A:,(/]343Y'ZGWKD
MLV.)99(OH)*":MU?<?'.Y%TB.S202S8"*QK(1<=9BAIGT7H]I?Y]'1_2]GOA
M9#VT83 <<3FFYLK($WQ\8U.#7%'NS7[2MF.:4;[KL*TA1N]_^S9350-5#$YH
MHN_!7=*BG")5>ZP_<$KD"R,/F(_4I$T1 90;8] 8]WTX[Z@,KIQ-.7O&2=_6
M#+[V0)Q=4JOJ,'&*5+\>J GJC]2RX(PT&=?DW6>"2ZOF?1UXCH6MY(@ ]6#:
MU+>\<U$&EK/LAH;QTZ[1X3>/ML33I6W/[[N>Z?FRX+YK4=/&^M4[R@UF6;Y;
MBJ0S/G+JFA90G9S!7_\R+6W@I"C9#VC7_/478@A1US7)V:U'K9DF\5XR<]?X
M9I3TOI"SWA1D7I,Y30?)\CB\T*UM.\_40#NG5_Y2_BV9U*=5U*T1634BJS88
M]U[D=WU)>L;8<2Q41W=ACW()_NYZC/\C0.\\7.;OX+ .",!'SLD*I(6<@[5=
MCDTV)#?@/=N&"=OT?C@T#18_XX\$I_&&F5!9QOP#<:J?KP5US*$8*0&R1^0>
MU+R*Y48M&0'GB3U\GNSAF[PE2I-Q]E:1O;65[,W7>M8HB&N?.U-ZZ?#IB<)W
MUN#.R.O5R,MOW,H9X34:<P%XYR488RX3YD#/L6>+G;8%V<753J=VCNPM"&=E
M2@+Y^ C\<JD,FO<8?P8&NX1ZY('#WUXHV'1CQW?9I>. (G?)V</+Y;ME[IZ$
MAYE-Q-%LWDKCH&H<U "M4P.;[@'85)[*[.>N8< >\4 <,@EI>@35WFJUMT;>
MJY7;S72"A\URI;'^3OL#+@UNL5=XNXV4GX;^S ST9X&EK+-?J--6[2!0I[DU
MB/>*5[JM*5=$N%*-2IJ?S:!125-$)?UBNDRTE3I'0R1M)R&2:D#2?0.2^B/8
M]5(!U1&1M%6-(I*V:AJ1- &1](K:IJL129<02:/PMHM#M4Z10$N8I V-29I(
M*(U)JC%)-2:IQB35F*0:*Z-@6!D'7JW&)-68I+FH;%UHV8PH]A+YY#QC!@YG
M,*L9M+UO&K T[QR/EB."!^W8[ T5IAH&4_>*%GN[Q!5DSY]BL9CK\!F110NB
M__J9N1YW2/?33^3L$^,3:B_VV6D$0(T F L[77LU.?)JM#K?5IUK!$!MNIRX
MK&>?U;FVZW>6U%_^V>=HDV5 .>F]EN9>.X5$3JU>OFAME[#)V:T:Y4IU/3I"
M<H=#36,:;$H.#6IPT,B&@"X0:?GVAP#  #LOOC%WZMBNV3>QSD;%?H/:@!+Y
MS08OF;OXE3,D'ZDW7AJ)L*G5H:4A,]+PD1IC!D].D(<[RI\8MMJ(K7]M.+8S
M,0U$\G*FS![3$;-#\0A@,LZNF V'SY,6A4*)PC<&E!6H!B@*7>SRLSWR";Y]
M0E"#1>70I7SLNUH8<BP,8;KH$NDY-*414"*W7WO7W2MR)LNY-N9L5OO?5_1S
MF9C\7!KLGMUVA]V+$]9F P^0=<BI8*S&O.@41S"V37!ISF9H05&F!LJ\1+I/
MC)//#C?_PL.\V^L"8[\Z_(7.$F N"L+1U2@F.=RK"X4[ Y64?J VLS"<23[[
ML$M-CW*32I_]BCV#53<576Q=<P"[VN&P5G6>?W6>'?@/?.(^D1NTMZ2WO[7M
M-A>.("*%I\KJXV'QJL+<-,6JECT9?0%25_-\/[OC6$NZO+Y748OY^)UHV9.*
M5GQ5 &V?+*<O()TF4VIXY.RWWE8Z,#\2J6^:DYOF9)_5*A6$!ZLVBJ,ZY@KC
M=Q.LAOE<\<M@NB[&0)3B4%6Q BX.@> \.APBB%CL+.W^W$LX1/=84'1@BE4[
MG0YBQ*UVD7,G! JY*2X!)>3O$QL[U@#LKKD0!/Q6,X)WX_4I:Y%JY^+B'*5H
MCP)T###8N;-U;3^;W+'1\@8[HSL<4I.[J#%0</Z:3=@&(=)32")G%-0OF[?2
M4(,::M!3N$J?&;6\L4$Y^WDZIGQ"#>:+]R.F/0 5P&>1)#T<9-L@$Y;(YNA\
MM[%/DPH#L@32%_PDPER#X0IRHBX;Y6:KE8HRZ=3+M?H.'<^I *L='C^ML76*
M(P_+TN"#F0$?3!&,KWD0,+Y8ZK=1KJ'6"C[C<OWRPR5=F9PTSX/ZW"N.GR#:
MJ0/Y)1RPZ4-F:H0_C?"7&X2_!^IQTW@BOW+'?CO&7WLWC+^+)(R_:D6#_.T7
MY*_'II[PH10T6PN!_IKU*-!?N[(%T%^UR)AM,: _V;FVR7XI-$V6@/[NZ"R
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MY^:\8EQ]%6Q^\@G1RXK'48FJ612V_DZYZ?AN@-?B2"TM5#'NW:&)_0$F_"O
M?7.C93F%YW7C'!E>$%[?1YC+H\/H3.;B88N:.'$3AQ.K^N9HQ+ 2B^)1KWXF
MLW/*GI_$308YPLKU^ZXY,"D7TZN">Q=/7-H=%)?5L-TY]-X"_3#?_F#?"6-0
M%K;<F;8I@##1J%>@F"60"L/R!6PS=3'I\3\P#>$*>>ZK&\A<'F9&N(RVCE3X
M%5O\E<2I.YH@7;+Q_QO(#N/P_X1YT0L5%+ MH:;.KK[=?KM^)S28TE3!>X:B
M/&(V[ 8KK#T$N_*DDX?91./-YJTT1G#6,(*/DM#:#][O(MQO%&'XCG$X7(,)
M"=3XTS>56EYFPE$Q@(^@]%JM]M90E;5RNYE.Q42S7&FLO]/^D'X3:K/3QX/<
M+/6@L7)7/O? 6+D%EK).<[_8P!<'P0;.K:FX5X#?;8V<(N+[:AC?_&P&#>.;
M(HSO'XXU'%%[1+Y0__O;<7R7PRT;X?AV$G%\FQK'=[\XOO^F=J2PJH$HOJV+
M*(IOL[4%BN\6\(WY0Q:-H?C*N=$I0XOFCR9+*+[=*3>ML$RON@F!3@N.MIFR
MS!R[Z24M0F42CK:Y!SYD!8LVR6E>-F64X7& UZR5:NTVN;E\N [>$XW>:JG9
MO" /C \=5+@&6^?L[_/UY#N=<K)"8_=F,RFP$6SO(6;U9@RP0N/UY@O>X^!+
M#OM:0W PS)VO"[-H[(PM3/@P(E#+JNU:U(;M>-7@)A"_&@DU)ZQ= >KS!M=:
MXY7L0 V]&7*W&4X(4O# 'L@;T02U1Z(]DFQZ)%H=IZ&.M=.TC>FQL^#]\L\^
MQ[,F _376R==2R:31JNV]/7^R,3^.(7<BT:9TRAS6LOL6\L\.*YW/G!$8YIH
MU@0_%:RZ(;,LYR7HH!-@".0W&QQ9[IJ>Z,'[RE[(?QS^A-?T/,>>D8_<<9[(
M68 Q4I%M<>H6\1_?P;M.X1$FX^('+8%)H(?MO)69X_)56338\A$8"08QQFPB
MNR8%T-@R([ ZY&GH<X_0";FCIJU9\,9Y1PZ?BA[/L+@Y; 2]1(TU!)WE*2S'
MGB'4I?O@_'Q[T]UC*XNXV48%Z(*J9_,W)=W!1#:TPEO[',N0>HYARNHC3_[A
MZGW[5A!JGSM3!J\A._>NS*GE3"CISP@SG"N:=RRJ]>AQE9R"D*V<BBL:R>$]
M_@K2CV!?FS95D$7J09=C<V+*<9CJ$Q!N;PQR0,)>=+=$+KEC?C\?L/./C,,1
MBY=_PJ2]9<W(F2SM>P-:>1[$H[HWE(-#+\BCP^'24#:9)[B\N3Z__'1)X"6?
MF%<TO H$&CQ?*HW. R>3UP,F%/!MP"PVBH(Y%(=;C;URZQCH(O'RD#_ ;P%[
M#+Q.P[1*"RIYS.C@3Y]RCQUS_-<!]N/^T)>/S^$(6)B-'+6\<8FX=,@\>8B^
M@ 1@KM9P[(&"FSF[_-R[?,S]:;H2\+5ROD];Z\#K48@8+GI0'K@GZ/0^<,?
M;HHK]LPL9RJ;2 ,,H<#-!<=7]()]!M^ET?I@C.&WW4];@%H4*<*:3=";;-Y*
M0_%H*!Y4/%+C#$V#>(@D"F]=4C"U!N7LY^F8\@DUF"_>%]221"J+@>NL@MTI
MDRWTT"' =1)*8PR&+Y\3!=<H-UNM5+9_IUZNU7?HN4D%$.7PN">MK6LJ\K L
M#1J4&="@]$!TVM6#@.C$XK:-<@VU5O 9E^N7'R[IRN2(=Q[4YU[Q=P313AV
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MWT01&E"RYN@TGG#C"3?GH\$.:[##UN'Z5.K]!CBLD3(+2YF;4?M]&YL/*<P
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MR'95I7J@+>R$BAX&;A!+>^0#?>X>6UDS%#SA!WA5?EA+90P<O)A4"=\O# 9
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M],"-Z%SDZ<=+*Z:[D4=_58&]UHSWQNA$OD.VTSE^F[V"BV%#2D/C$@*JEJO
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M*[5AX["B"7G/^*P)_"CZ#4/X/WX%BRU1D5=X(CA/&.2/6M;O6,-X+T>N[6'
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MXU[9,T&[!T?V'+\C!,VI+V$?G<16$4#']?@)D@+.B[PJPBY@2!J80Z1E[-2
M:)3_.(@1'%('V>X4)>IZM,Z?W"=0F;XR\<.2VJE,4B2.!8U$A9-6O2\4QP&Q
MS9T#M@NRF7$<=. 3HY$Q17XBUU%?FU.9UN$IT Z]I?APUQ^K.07(EJDW7M>=
MK.C:&(.%$7%0"5D5ORPY.)P@NR."^&9*;0OKT9A!Z*,#BDB5*BI0N52\0-N9
MT?C!;-%-QPX[L.'Q]^CR!-1H[64?TK:N!)SE4&:U**L]\WAC)^"-PCS3C:7
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M6C0@[0U(>P/27J>D (4-V%C"\ ?X;,$#>HL/''S)VX361#SJUMG4WB2+O<(
M+/,CLL6J&QY(N7,YGC2>/$X+\/)SY' 8.*C*_G/\&_@M7JN0 K6[!E>$"48+
MN(85&*'(/R)2\;M(S>-2:1X%8-GKP\M0T&I#)69/V<(7*+S8/&?-J+#AK8VR
MLL'45A>0DPJ(&]-A 4:]:U&Q=1%V:0D(B(IP0UJ"G:O3_I7^\1!40X-PUNPI
M(!05Y04$"Z4;@9P-%A0U#+\<PS]P;;96?LQIG"7/<K#2AP2WGI/&5$/L4^_7
M&#%^IP,D>,FO@:E%<FVP5S"\@3G:-'I#Z>TX=">,-,R-4[8D-#8+\R.A%KD@
MAU7;%UAELD19VV"Q"==?ZE5:JD&0;I?^D$^43$^4] F1*I)6$B7"FPKC)#ZW
MICVS(R6?4S",_L*.QTF[<]Q?UO$X/&R?')VN)/(""S\^Z>WRK8[!^YR-[K&@
M]])!WT7=QUQVMHB3HV !EO#F>N F]^V5!P ZTWDK:<#I<A[=@J1X#NG2R]0Q
MPV1?!P6M%06>ZUC_T3LD*JP24V"=A#7N(HTO-?8$SBPA ;\ @7>-$FS159AL
MUB")-0P_&UL-A?+&YQ)'<ML77&(X+Q-">OJV+QM(>XZ9.#?F3*283AMN%]^O
MGP(J37F$*>E7NO;35N_HM:Z]V\7T]&M;_)=?S]<8--_LV@JQCQ?66UMW:)^Z
M=ZM.%*[MR*XX4UH' ARV3HX: E0ENG9$CI6'7G=5G"UJ?]5R<2N0U=N[N(4M
MJ%U9W2X)F5DI(376*)<7VM5M;L3/;AH*K]Y4K"+ +@FQZ4D)NWJ2&S%5U\6M
MPDJJFPS*1ID6ECPJSJ9;%.H>8+^U<>P\C4Q>1CH]BPK;>PJ6C++OVO*7#+3O
MVO*7C;6O009LH91<R%++%V_7JI,4W$L>\JT!D:Q((JQ\7  [XOHNGC^IRGH?
M1I)0QX.0H)>R?9 ,D,.I:>&G%9-N1"@[O@(P1J@K_"#04]BXE R(@R*9>^X0
M=P"A!$*!_:;4EF@:_."'>GIBKA".VDD9%K6N7;[O<PV71"C8EAB!ZBW$7P[L
MP!_*D""C=&U>;L.01O>$*&=:=B?"=1CR/%]AF*L]403%/4Z)6*S"T^@@B>3.
M7WX^;EY9)=X4*'YZMQ@[O6V\95TWZIQAG?1$ QY:KXH>$1PB(@Q=PY@CZ1D4
M5"JS= 1C^Q),2<P T@QZ1#N%/=0>[CW!6338J!NHRG6'>L-PKTA&WI9@#TP!
M1E>-\H#O(QX4.)!#+-.E,2$T5@1_8GY/3(#EO&KS"5]%.-* >"-CY>5> QZY
M<1XQASHC95%RNS@<-Y8*8"C3/S-O?DSQVL7[!!0+X8]&L !&8=",HY@J,EQ%
M P40M8=8TW34UU0L9[#' C)/3 &[_YB?/Y-#A)R%3(7TI>''?I 3UB2GXV""
M"$%XM4:QJBOIOJAI,I73!H  LT?\*%HSQM@4>!N\USUU*T29,_)*('^J:5I:
MY5<OQM$@401$PY @!AFK;,ENE$I,&J8AC(7(X['2+M ]Q!-B:)C]%#]7W];,
M2:*G$X!'9CX43H0IO%:>]:R/<A;:4!9+J!+/I:Z'O6K\Q.+,2BVW:KJVP5RI
M:NQD0-88^YP4"F&Q-U1!%)50F-!\*CD)9;Q077U3?@:SC!-(=1W[C,8H?R#H
M9^23J6$6>F$[L[\S3V1N7_>8+'0<S6DVOZ,Q2RI2H/IY^?A6* 6" $,*)V%(
MX' &/F]?3[6.,(PD/;*Q&:]H2O\RZ"?#-/YP?4=-,$(T6:5N3%,PC4XNU_,M
MNE(8C,$H#NP?5C!10-QA">@@<]#J]5FM>K]S6%)54ZD6EAIFHC4%7T\)B8H_
M@[5&X,L01ZE&0T0@0TPN-:1GL2[TPY9B&IM43#J<>ZH[_%KH7Q[I7SJ$.NZG
M(DNS;KJZ. A^J+-17_F ZE(U<[)$5J$XM74*M<]&U>C&2X@/$9G!9DX!AE.-
MO82#%4N&"<.?C@@_E+JR1^Z$[XSXH<4AF0Q+-YU6UMJ%H?C=4$W37-Q?>FL,
MB[*\4*VQ.Y^H I1>S8Y+9!' L]_J2I$_5JO89EJX2#_E+1KQJ-:C?$8U,.L
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M)FKF[$7B(5(!*X7WB)D4N3%(>/4Y\IF-0QU0MM^HXP8?NN.)YPY=NV"0O!(
M])/VT6H*B[9 <&_>E+ZX_59G3T =)C:%S+&Y]._=,*!!IF!=X615G]#H]D))
M@TEM.<Y,B5=.@6M;#MA,P5V2P54M R-$'+3$)UVA,$SP2BRN2F%[#)Q*XR\L
M5;GU6I5"N6&%>N&%39=7HD2ZO15KD1EX&RMJ:-[X"ZSJ.?4IG9VE'',YXI-V
M9VIR.WSVU!$"*WCU&?/97^@=\F/8>;;]F[]=^B-4Q2:U"/+G+J3>&=\"<O/?
M8OR;=?%U3>_>;Q_-S9?1ZT_52S%CGYU.IZ$0@09O\.9OO0U2_,W?+)F1[<-A
MH/!*S\F+:%E65LV W:(>_L$+!J B/DKA@=GSN^_&UMZ'C[]7#PYM>/])O/]I
M+.ZTK?I-3I*8'+C?@/7O K0DP\#S@H1V!JW)%$%R$ H.4S<[LMH=00A$ST6!
M]*MU&8]<.U+;8^*WGWQP#4+PRG^S/)$@MK/:'<1UQG]?!+Z3V/&R5NM&U.C6
MV?NS0K&5=:T93.1NIC"+-E:!(I<4(N2/PTSPY)4L?,DRI+V_[NLQ'<7_7B%(
MNHR%ZQ$.\,PJDT,KE$,9(B3FFU*XV6IXZXD )G,XX4!W@COJ024YP&L%6HR7
ME*)>3Z/7ON%*DKG B2O<TJ7P%9^$M#VO0ND%(;@O_TQ 0ATP#MZZP+>WH2+K
MZ;"VQ/@96'_/'>,)P)POJESU:07__F<!.YHQFY\!] U6+IB74F'*P[7\_6FO
M==11W6O3LQ4*IZT$A;X-ZJIT/%!A)#R_.<X2#M4P(C-J* .?K,&1&?Z44&X#
M:B2,,9[F<67@3_[CM^HL4)[5>E/'N]_NGBQRO/FZ%3#E'_!L?'Y5#<PT,Y;7
M2A,F]W&I4;/YLS(E0WM$/+-Y9G,->.;B ,/6X=$O4TC%/?SL&UE/[],05E?#
M<J-O9YX)GRXZ8*?AEXWRBS[?*?JQM3>-*[V?<A'-+1@1K#O(I^^PZX*%)["1
MHP628$!Q,#E\Z1%\>X^%GB<%OH1UQQ[I!)AO+&R9D$&K)HVX,OK-.A_?21^+
M=N)0_ ^8,S;<S+-;UCOQ"$Q[_@'^%;I1''@'UX\(O7\+&G(P /%HMUO6I>>J
M&2XNCE(G]E1#3/B"#Y[X&=R"@AC]@[B8;OWW8.2CV&4'0?_%/[B6H?U#_?M+
M<"_  H_H+>"/ *?<.&[THV7=#&%#0G4=/O9;8 .]/@8>K?IS[+07E:.U4=E7
M:K !#E2PQ 3<+5M/?RI)EX#N' \D5J+C;[ZG0H-!N<=21$FH#5(.RU@X,R.R
M]@C)VY@"&ZZU5D/Y&/X=QQS\0/>];7T'WF?>2U]W#Z]54R74>^#"O\&/K$]C
M#-!3N$R-@-A'.F0&A0S4G".RV_%.E[XS"4#.6\5[[<D(72J&X\>D&$Y0&($4
M/T!8>TU;3D$@Q9U]/:+KG0IO+73+P*^^81M_>@"W^H$C8]#PB*R'(/'0)R'$
M?)>3:8I@ELO+IU7"?=]:Z#?B16Z<^RY^"-[2@>H>E7^/RVQ;5[.';+1H:E3F
M#2?BD=Z>C"-8"0XVLP,2?11!T^.DP.:"._)<*C_= "+172A%+ E#WD>72N+\
M"4W8L73<=#P7DI5$XL[A]-,PLHP%T&)3$M;-0/QH8TP-ZN"O>/X$*IHNCP:A
MR7+(.BW\V3+="2NT(UZ0=MWV1F59GFIG[:-#),94</DW-28'SP#\B;X%#@O1
M%8W(\'[@'Z#+EOA*!8!2Q"$?P/.Q2]-#X)@&R=VH-"Y-YWOG-[NW39M]TN[3
M,+8;4-W@)V,IZ6_XWP$(OJL@B''H+$@YB?%/'A"(T_0BUF]=-I24XXNE%^HR
MU-UK2^X<M8]Z"ZVS-+G3Y4[Y%T_N+&Q5F/2.=1^!X=T]V]\Y5?$^C722#94)
M@V1G[N0,R=FA&UD5'6.;5#? M=2<2&U'C27Z,6X$MF42J6'-VNQB)13CI%,R
M$#S,JZ6#9S+C9G1<99(8,PGT?9*=#_8@!\",LJ6#4&^R$:PW9OJY(LB;M)[I
MC86MSVKFIG//-.*KSGGP45I93A&I9S-+'5KY>L<@ME;3@-?KMH^.9V,Z+-Q>
MW08YN*K!-=W>:I9W MI\-4V/N+S9+U4^M^;TU<VMN4W&<!0>J6MI$=DV6WHM
M/-[FK!EO\[1ZMF:\S594JVZVBVMN2/Q)Z&([2+%/.K]0,GOO.?#?.SC(Y/"H
MF0JT(U.!-BN<TFD1UMZ[+Y^J9=%.SP7JSSE..WYJ7L6LB9F8X,_ [*C%XM>E
M6NMXV'M/U)VU/^8;P2[?_K->;\#R.=Q<>Z;=%FBI]:^[6/^T.EBI6IS91D5E
M:MN;X4_/4%'+7O9Z1$RVC.*UBA=XR5 <3 D9T<B81L;LF!E<>MQWR_QMYO7L
M@&S^GFF5WW4]=/ESMAYZ?<9N,^ETYQ71K ->;_TSAWEKSZ,O/2^N9,DO-RIN
MU=.]=FXZ%_RW&<_53)EK^+CAXT7Y>"$XCF7JS%^PG'S1AOA<8WUD#7 'L7,L
M3#Q)X%2N'[D.]G&%0I6("^HQ"R)I#3S8=801X#:WJ,5-KS[6AW.S(E9\,U+
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MY)S-.0^!'$&+;H#_>SXG*C-S#JP*\3ZX>L'=P,0S [8P'Y'0^(J)[7,K]/R
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MO5%$!]ZTTUO,<> Y4;C^EHPL6D!C[L//%%1(G^F#;XK!"\=<!/Q-_(^W$SL
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M^L:']EQTNYW:&!./QG,[P.9-F [[-Q.GA=ZAPS.7:^SS&/U^^"9R3=>>>U'
MOM I/!A<EU<W7Y9;6)'PL-^OK[!D3C2'PN=?1G<1K-X29X;&P?;9"J6I;+-'
M1GIQ4LKA+)"*I)\\/>-)"4U?"4W9,HFE4,1 7PE%G)Q-^S-WN6\Z[".?V,JX
MW>]6?0EFE(.EY!2!Q?;A5'4BFV$PTYE[L#F:H4P@9O9\85JA:"N^\&%C9];,
M=!SNWBV?ERNN/)TK5W"7[49 YH7GAU-8O!X+@/0.976C-=-B_(?%^23N$H_F
M"YN@D1LFB0P+WYM$Z)#0N,$<PD]H]0BC5_%K;_RZ_?SKS7_^=LD<,W*M&1'?
MC!<6$AS<BV^??_O;A\]H<%[-;-=<']A?V@#Z';4!W"XX]DNRPT=V9?I<J?^]
M"6Y22Q)@"Z0WN2H2434N'61%\GV1_%>A(T E7/[Z[;??;VYN/L<]B<$K?B,X
M(8EO>> WNT&D5/7^#)XYZ!'N8'""3<S0A%V2!YP"$6#E(!<^1+ZWX##<2\N<
M\/DC-;3F>-@%X[Y[).W^.YJDXN/9A\OWOY^+#1CX=>?C"1DKK=^[ Z7?KWZY
M>J,TS/YM>C(]7# +[S#]0"2W7E!,S,<J05(TBNQ[,]I-_YY?8&0YL$"!L"F8
M>0ZVG%<DWA>)O_B>T*]ST,PHVE<WE[_>W))D?[O\>'/]ZV\L>+!#:[8^>UN%
M6 H8_M%THRDX]I&/#B62\S9:+. ]2G;WYB.F1=EYYQ",/S(>\'CD(QU2W"YE
MV+08R/2,0$&R!CJH&H3^"S HXWMXK&5:O@>KX]:<\O"Q)9-.X!^"F<37*R\(
M6_2OY"Y@6!2$/H)891\_ 2L)Q!0NN \T'**AA&%?PO#A!PB @X&:'$.G#%YQ
MCU$URF0ED9#.K_1]2VLUO=U3:NV]L'R4%MMK9-*WQY&((WKLW>>;?*!@$G'\
M_MYTX!^6S_,I@HK^>[7MITQ:\P1 F-LSQ)9A,KD$+J:8%-%BES?B7\Q<@/8W
MK1DRZQ<.^F5&^H6!B75O@PH(A!5 /L)7O@C>L"1P#-O'!.O8*#==F&+P$#I4
MAW\N?-OS,50GP\]!)KHAXJ-*&O86OLMX=AC,N)CXL&6[; [T"G QXB[B+>A$
M8(&VLSFG/446/O(?W(HH,^:-/$Z S3[F,<G/J$,9^N',#MC"6T2.D*V9>8]V
M8IJ4@?R-7S!^9-=\C 9#MVSZ>@4RJH^)U.D!%65ZRE7D@!%><^BR@OH*D:)=
MA63LUU5!:"U*":\ENX]$OUQ.M"+<+CT7-:/WZK4^U :UIN"1,LY[94&PCX5+
MI\RI)YI37Y,,";!Y[CTG<L$8>F2P(;L$H@??/GA@3*%%*TTHWU-!]'VRX-N,
MQ[G=R(>%O:!&U&2U_IT_LM_)KWP/9BX:H%^)^C,S8&/.<0(^=^_ %G55T/T
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MQ+.X1K";&:DPT7A07("9=F7YVP&J9W:>SIJ=9\N.DD^</2B8]!$0(/O]P<Y
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M!:O4_\[#"S+)26+=B8R</9A!'(KHMP;@\K?QC3EG/Q^*K9J?W=6&W2/[V()
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M]E,0^CRT9C^EO[484.M[FE22GJDN;,<Q_: @(P6(%A?./9:-5]7WG#Q-!:B
M\/8U$MW+Z12!53&J=VE9/ C>8,/?>YLR>> CUMF!!*">$CV=@;NNYUX@,&V$
M3=SQSHD=8&8/:*#0EF5]HG^TG,#/ DOR%VXZX:S5>#X;5>)S5^MWD!A?0$/
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M(_TG/&F/7"_=2@'!<%<"%DDX&4C^T7R4^=F]ETZZ*#N)E@3#?S #=F\Z$0*
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MC]5"KH,JV%72B5MP!,5V$/-0L>=(UD<6UQ7YE)2+QO$WM"+)_ 0]#]25[6M
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M.@AG/YC)9;AY8BTTE/![1#F;<7-B"2LJS-P'_K0K.YD$$>A?^2J1M2:[ B0
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M;Y/TX]=)M#045M0"9'IN6CPBIP+W=N"H_RC>&)0]75];,KW)TUKO9Y3E]Y6
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MB:&7,]^[FM'+>$&^F(GX<K62)N<$T1Y6$TUX4/B]G5-NFXB_5[!7[A_JL@;
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MI/4>K4]T'YUWWO\>]='985N9"2>D;5K-@F,RE#N1'\ZPO?()0E7@A%OM2$-
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M[C^RKSSYL2^]_3ZYW!?L/DC^_5I+REVO](X[0^&Q3PGW56NWM_$/33V:>C;
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M>H#VM&JWUY)AUGXPSO)8//Z,)*#"I-OKI%< 6;O;=#JZC][RRLR6 ?;N!/A
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MCPNQ]>/9[<^K,/O-M@E8M.5W**)-PF LYB+:VBC/KK%-T,'V@6);1KW>E(K
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M<R1(6A5NR(@V7*3102A$'Y@6PC"B!V1OF5@"9L?A0Y\0=^%C^DJ\KKA^O*>
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M+;-=WZ-CMX3=<)B(>)-AK''T/AX@H[5N0PN-H??1W.H-P]Y?')$%_TO,>YZ
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M*$8<WM-G01)',< 6SAH@/),S$1])%FE,/W2"^MS12/1=N,Q[22&/FL"R@&[
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M=I\$NQD,7$>$!N-^'_[WPCZ)<1*_S+LN8D'(1B1CX-<!/?*:^_Q1C  P[+>
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MM:(>;*#' ':*3NF?4_#25V"8C!%?1(KJBZ<@1@59FB\&$S\<+R&5&;_L"5^
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MIT>NX=!NK8GSJUB,IL!R/PV6.P666P++PURPK,*GNE51N\^5(W86-A7-]7I
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MT^TH*J;2] Y;I6E8AMUH&MU7;%?-&C+KTVRV-*B6XZ(-H]VN&XV&'AF]',"
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M9$!B.#\\I.V-0)URQYY:&=R6+]; 1P0]$"9R?'<)*R:-#>[LO11MRQ%W85.
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MPU9JGU'3K3@MXU!W?9W>,+T[)DU$<S(W./9;EHKLBHX+KH(H)E.?#GW8;K-
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M>\3Y.?*'!P=]D+ /1#\N;\O!<2/$\HS7>6LT:Q\,WOYS>=\?'MW30NW>%NE
M,'BZZ^W,^H#P^DDZ&/\ ^KR32_.CAC[Z6'"- >WPI$-1QA\X[K$S&MY9E_9!
MCUX;WIU:YL?4A/N3>R:O>SWX?=>I.ZO4R?F]<_RWYR'J!CO/Z,C?W[\?$6+M
M2V\I(^C\3!W<CW-LU2QMQ(-$#"=.82<5>XY&@_U):\E6M;)3KML* V,L4#E6
MT\W_/:->WBHWS!72R!Q9$H)&'UJP5/ZP[Q^.#G0A#S)G1!FS,&#EV\3WX&$P
M,TPWA$VFF:"IG=4B2JY47B"' =[_*DJOJ/_JU< [7<7?0*0?IN+$TB$TF3<R
MM<0&S D3'U&/:?H"J44ZF.B/>$D/39?$:(!L4$5V0QQ"5:HD:;#^@1MK8]=G
M=:F2G+E!J+WY"\LNH=N#)P[/@W3)QAI*Z?7L317-G>$JNI6TXUL%<WRP58(Y
MW5PP;9_I-<(Y\N$;[B"<CB09.:TWV:X]E"AKL$=XGI?"A5-KSXX/>/O;IY]^
M.W_CY<NT((J0NXKT*D'VXBB81G%4W#BRO#_2P_/;9!E91>3*\>"(Y]?Y''8^
M4.!GF0HC? U\U8O5@O["*Y%.1X:9T]1K-A:'N:3(5$";^]&E>LO4[>SAI7HR
M>02I=AZ*!$V6G6T9+%7V($J8*(\VD>!-!7CXW 7XS_\]S=!,6?_"[25ORE4K
M,].%2A11)05T\MM3$0D&#>V?YF:<9^F"SU$DS@ ;@6F6PF@^AQ]A=>#&J2JN
ME:JP$1J\")ZQF@3-]RY@Y1.FW2+)K5?T5X8@_(8-!DG#4^;0E$6X0>9H5TQO
M6)CX@7((P.!AH^;1K*K96Z8'B<G6?FQ4L4905\ [M.@:@C"DH>+=4:&A.D$:
M*B\ML]L9J'8'WN_(HWG#;%:L/H@[3B@V&_/BV' PA6%D?D+^.AX"\6YVF6?P
M]<!C9=)*=I=W=+.>>GAL$+48+-<R2XGZE%4J"@N*%5G-).@U2K[?SGEM.6^3
MKQ"]_8,[,J#MTJD3@+#G95P@=>&-:U_IG55E7Y-]51V2%Q!U:6')$(,25B$@
MES:^$0L]9[HU<];B=ZM_E7@XP7$"!R8,).<O)CZXKK+JG8$#!$=302?LM?+*
MW&&)1!83^&[+?:LW]\![#0L&\P%+$]_X7@03E"C<YPO,V;V%FY?(\_];@FOS
M*YL)Y[B88,^HC#AA@RGH2U&J^FV6S]$7=CU<;:+5 PD!,9MYY?)2!: V<_*[
M1B,QH)BR%M:PA"7V&Z9W12YR;7G1_2![91QZEP'2V%0DW_IJ.!90P8M<[ ,Q
M+)"+$W;%E,@P'<9,I U.:.JL*/.GY+Z(:8&:$"^<Z8F<J=S:+$C="!:?3 ?,
M,6D8V$H8GGAPC7D_VB!\WOHP#4G8+Q%LFQ W3H=Y5W]'TU/;*<C:E<' _DT$
MPRH T_D&Z24+6*,%+" (^!3/2=!?9;:,RYPI6W&UK9 D2H6YUBP5LE9<>SX\
MY43'?34OB3=:S D0=3I)P81%1;A#[T1FZD54%'Q9G((Z\V)U$>5,M[S+MH0,
MW@X\5+AQZ&1>!$EPH7C3B^31J.$(^*>:.:HYN6#R6#">B>*)3"B9\P@9GV+:
MX@LDK8Z*"DLG.!-1P:8?C!+)NG'WX(SDY1PV7J1-!+T[YE&V0!..+'CP+F;H
M(D3*<F+B0NJ)Y$6B7:]-/=#L929.!5[28A#E^E@:'0U&@]D [ZW\ZF+ +-8;
M'53=%7$TTK(<1L%">0E:?P_5GF/+B3\:JR"D P'/1Y61ZH4E87+<!9P%-WM"
M^ 6R$Y8S?1\>O*A:P9E2.9'@BGOKKE*,?Q(FWTPI?%YQV=D3=J6S;(4<_P.-
M"SC6F+:5S [V5L6]/?:/1D/K"Q-S<_OZ@&42DD%&QP9YN1%8*G_:</K&#6]U
M GM@$V^5K]M\HG^'5^!KOI62C>*OAR_7P-X??YD;#OZ8I@+>'ZN9T$3;)1*C
MD5;1X&HKAG1E"RW PT+".3@"P"$\I7,%; 3ZF2R0J4*28CP?4N3$#@/X0F\:
MY)'5@F+)FG,%AQ#(0\BM0VL#K"0XE;S1\(_:= XN+C)U0<=>\P%V%"_Q/;V
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MREW.^'N>Y$^38:'!+X,;"CZA8@'5>IG&H.*Z2IKZL<R0]:/01'$-)>+K#]1
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M.<(WB>W;<)B!","B!!'G"]ZH*Q6G2TY[?928#;SBK#+(T_D\B#+*'%XC@4/
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MYX^F;YG_TGZ;N ,$UX,;.;W"P/?8C#NJ'QZOGV^O_Y,!2[%5:.> _^708V3
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M#"(.!S)/8:P3YW1N17@^%)_NHW"9. L0$U#4B:1LA0A#5+Y%CHY9'Q:5\=C
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M.RSW/0C-_K^O/[YI#P[,]QH2[=8=ALGY94='P^>;WX^2AB_F+]=QIQ_:W:^
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M\#Y?+7V2&@NQWLE18R$V#5:TU%@(%>JKQEB(?D-%OG:D/_<.B;UY['9_,R.
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M"N)$]!BA&D#N#?O!/AIUW+$*/%[8B2&%> WHB_)(F^EY$&F-BY+E.+R/%:%
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MER/J<<G7;W74S2\*P+&L"=FYF#./,VH36U14(@!%C?X@L%]9]"J.AXK9=_2
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MJ4,5!GY@.A;6 "WG@T)6B(_\8@?T5(99RE;H:R:4/^,2D/1I*$<;8-+;=85
MDU73,GY>[:NV%W7M7_AP8G$!>>9/R:E:<9RCT=;K.6>&G+B76#IVZ>^'79J"
M77*6RBBN.(P2:>R'+5J,+8SZ8AEDB7VE(W*&S%% _VW9DQ#9HO+^T,DY/*>@
MC-;IHFOKGZ%/=5$Q.JG-=%*GGG.^J:K/WKMO4BSA.X+P>R[G/5GZKO<RBB5P
MEQ&XNV\"[\Z=F'O$!7S^BZ[7FRWQ'-NQB!-\N> _S,X9?]'GP3.W"Q/^_6\]
M*EB7N_8K5G#E9>)L>O5^&T[AJ^G;0XV8G@-;U&;4"4(>+9T'1 ^PV6E=YO>
M-DWR'97>(:'WG7BH+E9Z%8:,D8&\<<=9 V+2XA&K8]-<WS1B?0.S-^M-A198
M!G+W=T_N_ME5I]Y1SL,^A;BQ<[(V&R#%_3V/1CZIWBBV[:+S3LHWVM WNH5H
M$+&.TCO*SG%;%DEEY.FC5LY+=3/GL"*TLXX^5DZ V(*(5WC&03'-"C^M0*8Q
MT%/;K.Q5\489O;T"F:.)_MYF":D=,L<Q>82?D1C"7$N^VM3T7FT'\WK PLM=
M-W8Z$!RT1Q^KO+DKA/E)^@?2"SE/MGIUO0\O='T;B/W%(Q,SL-_(Y;MM!6/!
ML](7!:7CKY@#2G#*A$N_(BU\2* FG_Z:57TGF8B>XL2<^>2+^,NE.$3;04'"
M+UWRL^(+H0PWSSOX/O9KOJ9^O][K]F%9G)'XB_F*ZW3%GQ=_3J7!:*7^IE'7
M4W^^[$E]@[Z_L_)1Q<9*I[9E3<CFJ==-_7L#YXU<M(K(6Y9N7\_7CT_W#YJV
MQ6U@4]/!SO7IQQ^:T;BXW_G[T_>_:M_=7L,@G?3WPLOHBS?:L]& *M8%9DK1
MIO)_0?F 6;/[([,[ZO0'K7ZCU6HW2'_8:I)>J]4:&HVFWFG_3QLP#/FWQE[,
ME:_D8N 1\^<%%@I\,2?OYH</<BHK;:J%(MO>K7<-NJ-E.C"AT5MUHRUI>8_M
MG_UP05DFE7ROCE?5?>O/7MTPVGGU)_U6OY'^J]UHO;0HR+RCD>[WY6??7OZK
M>\30VLW3X_/3MX?;ZY>[6^W^X?'Z\>;A^IOV_$)_\,?=X\OS,I;?Z*B*]H*7
M*1%@S0PG<.,ZZ"&:$&OQ _H'PRIT1W1?TYE'QL3QJ0N2AKNS5.Z+M0=Z;Z<[
M6>+]21*YZ.L=PF?J=YNY?:9^O=5L%^(TM>N=9J^0)^G-NMY*_\JA'[7VJ+8/
M-I<-CV+#6*>V4!.WGVJX$?YO1]VP;I )5RQC:K2T35,)+VX_9-OQ=HSCVHZ>
M83L*_V^MG*HV]$.WH>>MC6NV%/Y?9=I%RL*/.\3_:[85_I]BN_WC_S4["O\O
ME>\JX/\<XE9VK<![RD2."H#Z-+O+0'V4RU-=9CH0ZDZSMPQUIRQV0_%,Z6!Q
MFOUEL#AE89I3C?'.>Q/;0 \?:1]0&1V"['";K4:!^+PGU3I21MN=@^[Z!IB[
MBKZ'MK,Y"&SDQ]$]-HNYR_C04S F7FHUP9=M;6&._.*:[Q?[L3T14G5*;=XI
M=3T,0M.SS8GV:MJ.S\:/$O^HX6JZ)P=74^S4\HAG?@.6^88,<^W9,&KPWG.G
M-V/3>27^@W-O.Z8SI)^[]OUP.L/9PX\DN"4CND#K*W$(F"S;'-@3._B@'R)!
MFET"X+64\( :,GJ8<0Y+1\ONF2U:9U>==DZ (\4"Q7B?9>$!&'75.R6?5;DZ
MF[LZC/FHSZV-3-O3WLQ)B(/7><*+\FO@A:SLE_KED] B%OT+XZ61X%?-!%[T
M-=.QM/B'$\ZI-O&5XW1,CE.A?I.D$W^0H?OJV#ZQ'AR\&-[(]\('O!;>4R[]
M+V#2/XCIAQY6I-\Y >55_^G=84.='V*F3=./G;.KO+ ?RGW:;V1N_TP!&'(J
MCE>*Z5?[)WZ/$K^3LS-<>4PGZC&]F+\T,AJ18:#<FJ-R:XJ-!S'E1)GE!T(.
M.*\O+B@O*M=4"3V-EFFSE[$9_&5/)H]N\)50]3>AKK4]LHGUXK)LQI/'ZA\7
MM5C_[&K1@JF T'[X8:U+LW=^:#?.K@Q],0ZPC",4X3=3!&O]F?U37C^[2@D"
M[H/P%2@GWF4Z\SD<T"T$YN2+9@=DZFN.2W<2#GSRKY!2>_*A>1$A13'0#(FI
MN9X&62;M_#I+!^BQ%17ODBC;V?6E4=TMY?:1!$\CJA32Y-<XN^HN1BARF_+3
M* <M2_O*6@]@APP#V&9M-:)3,65^[V2'7-FB:BPETGKB7%DV%TG%@HK/GEED
M$"S+G6GS:;,3'@JZ79"IFITGNTZM 6RJ%$)_<GZ0*4;&Z5G<4KZ48N%?R<CU
MR!+MW8;P@6IF*Q5[;!>2FKO*%,4HG7RW%<4*90A2[8@7NJE*HP2\H%)L1^!6
M#4U_K(TF[KLV)M:K*BM2^;<,<;J$6KNA''1/&>AWY)^5J@R* E0ZK?P%0KF(
MVJ>^BJKR*8/'L34M.XVSJ\-D-Y4O44E?8AAZ'G&&'UK@T5= *I;RL&6/1@1^
MK+P)Y4WD559WOX;(7;<Q$STY+S%W2>HK'Y1'!_K*:^W6(IB0<D!*Z(#LC@\,
M>I^N&=V>\EE*5IF\2Z(W@>BM]@$GSBH/IT(>CBI(5B[,[@N2<]8@=EIY;F?*
M>]FM][+4G=TS4[2I6]LX8*/-Z;! COC+GGD TH4']&?+5GYSZ KEG-7)7U5U
M\E%4)V>KZ<MY<>EBU,(HP.Z?1I5 6:I$MRY=W@DW]> :W$SIRC[Q E+%L 64
M->^$8_O L6U],6I[XAQ[XC[7<I!+8#"-_E:;T0>[5DUS2 "%+H'YBT KV/]1
M[E:UW:V\*J3; !>JTRB@D5M9I$JX4+DY1 <CT^VH"5J*"8MSBW)SH7%VU:PU
M&ZJ[2[DZ,AENUDTX5Q[,7A7".GU0A"IH@BKH-2MR3U?N4AD8<ZV[5 1CMF X
M1\UH+68;2LF9B@%+Y2H5P8'MLZM^K9T"QGSB#%@!+ZF0="X^4DT=+4MV/2<Y
M=NUI%3G\K]M!+RPE]JS<H>IRU29N4J%<U4472F_F92O%/27@GHU\G$+9IX?^
MCYZSDKE"C@A[ZBGX(MO,+,U^6%OZ(QG)<2+BO[7T9Y^3V(74=][!P\40LW #
MHIBH4 \D.Q/U(/FIYZP-5<Q2'F8IP.'(P2WZV54G[QR7O3++&N?B,VY9-.M(
M'5!3TWNU'?1_YCCFGZ$?V*./5>U05_\8>)^ODHU RY^]O-DJ\PL/RZ,&\*BV
M=+O\8ZU>7>_#=EW?!B[YXF&I^QNY?+>M8"Q87?JB8)'X*^: <DH8+'Z%$AV=
MI"2/T>.8F#.??!%_N11,8#NX _S2):<'?QWEQWG6PI-GO^9O[O?KO6X?7L[=
M4_YBOJXZ7=?GQ9_W#?JM=NJO&G4]]>?+'M6J]XW53RJV2W!J6]:$).DS+Y$;
M,>.FT69DNN?KQZ?[!TW35L1RBWE_.M/?/_WX0S,:%_<[?W_Z_E?MN]MK&*23
M_EYX&7WQ1GLV&N!D;M_C6!TNN[]HIVPXQ7[(_X4=@)6T^R.S.^KT!ZU^H]5J
M-TA_V&J27JO5&AJ-IMYI_T];IU:4?VOLQ2?W2BX&'C%_7I@C:H&_F)-W\\,'
MR99-"=5;D:O0K7<-NJ%EZC1A9UIUHRW9'H\1G/U0.O$A >N?-#V].K:\[EOC
M]NH&:+R<&K=7[S?2?[4;/2EW4Q<DEKT-+3((JG;S]/C\].WA]OKE[E:[?WB\
M?KQYN/ZF/;_0'_QQ]_CRO(RS]S+6?D.I!0;,<  WKH..I1D0H#W]@P$! XH=
MF_<:C=%D69Z$Q[I4OI=1=K/-Z+T=[V6)]RG)WJ*ON7_I[M?[W69>Z3;:]4Z_
M7X@_U:XWUOA369_4J7?UU1HG^YI:O58A3^K6FX91T)/ZS6+.J5_O=HM:4\?H
ME6QWE';]K>S.T0>WS__^MUZST[K4Z.LF]'*7H\MBLT/94YU,9\$Z+>D"'IL>
MP4#!T)S!J9W8_J_I0N%23S<.AS S;8NZF"=\("\>HCU_X!'XP!W%YG7*?P(_
M"/WF&V%#S#T2F/03ED9,SP'@H!,[C.? '?Y$7G!G("<^\^[HT; ?0A<!^Q'R
MR@7^=&#ZQ.+R]($>XHF=&C97,"4BA[GQ)]E+X0O+BFT"OI4MX+%CY2PE!);>
M),JPT,#-=.DIPU+C$L)2+W.NO#'C0)RC4!X)K@>-(;@+"B^X4HGR8EREY*C
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M6Y8.HGCF-PQGBHZ6>PQF2JX:3AX"3N'!_BO;_(,SU'!R*]AI]9HT-89-2GF
M9@YQ4BJ[N_#$:B*2X<$;P%\EXL1!&B>J&IA"'8>,LJ7C4U]O@#G53K9**F5P
M" 20TBD#O9G.#DH=E-?/5+NEO/)W!*\.KG2V;K*"%:LF*R6 9=[&(L)B)1;
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M_@X2H^(02I3*)TI%Q2%VE:1!F21)^<*E\X6?C)\:FTS8V <OV.85#G$D(N4
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MV7W.18@+6Y3 5[9Y113VZ)^W/Q?,]AA\>A>0&0W?!P;;XADSD,G8Y\/)O6
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M!+<WD0&:"-Q>]E2ZW)M3.-Y><N]/#13K/9A8!?08]KMGE_U:H[.]-BF"B ?
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M%++@ZTE9Y=J\;=F4"K7-4@^(2:0<,6_[4$_:9H>N#1W?Z0D7X>4@ 5 0X7A
M6PTK0CPN@2O*0!;L:QCR<RF0/5GZ2S>64ZNJXP-^\R-;^!&S'9O%9,M8W'N&
M!<9MV_!,Z&KGOZ+-@L< ;X7 P]?!.BU0PK-(C +M;<T#*^8"MOJ"OL>"&%!X
M+O:0X+UKVNO4PH%JL8B6-/0P]XFP:5GAGG8J[$PIBFXLP9QXK!&#)CT )W:8
MI!UMG$>/;,>L^&!(%! RTUGP[/#&XVGM@:5FXVW7,J-FX^W2_H#CXO??\*&Z
MASYN]Y :CG<Z;3&Y49%47TQVJ:F>6FK:.EOGYE3*H0%K.F:1BDQ4(S,3)8$,
M@L*\6#X/K"O118[.RH]PKG@T%Y41;@ZJV!&X@'\V'/O.:G1>7UE0Y"&QI5!@
M_!HQ@8RP4 =#V).E2]'6C&6LI+(22=OMK7J\[JTP^WFM 0MWF%?8H0O3$9VL
M1.C9(^:2+*";3'==A?Z7=[:&L7JRK%'^^YW>6FF=M7-O.?HW8G7!V[.P$BN]
M)$Y4#M)&1+*U9E!/0'$^*VR$TPSLA..@!!'7UUM-_09AT",[?,6(6R"]$7D#
M=[&L/%!A'7"U?(95"$G+5@._8N@%86P$A(> EENG /2F=HX\RI-3^.-K^BE/
M10I($'D_#=-6JT&AJ?-*PL&PQAO!6DA3R%]0+NH5SRU#@H&\R=0Q"Y8Y8ZN2
MLIO^Z925]W+JGZ\98G3(%1=\-E=;652P$+2U0PHFTO<6UKC]<VF*X^S*-H-Z
MM[2&-SW%)=#U9*[E=YYY9_)>Q"?_AL>(-O==4BAZ:@I%7^]Q]$JFZE$'1IH
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M\?Q58&'.+(J@QR(HMP'IS ?J7# PV9TW'I=A-IM8\-4(=M4(C;BX;.HKPCE
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MQ$D@'$E*Y8=Y"X._)4Z,OZ"WY-JVJFS[A#48/%>#50/^*^/U':&_2RUL-LV
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M*:%9JI?JEL7R^0K6O7O\O,^HBM L5^  B&"5@%H:10Y6L5%U[2ZQA_'G(VB
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M(O*9[DXV89EGL^4$P2M4DOLSL87[:\# 9,7/A&);OZODB)33^]SUJXBC\'M
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M1D44O7QKA.'SZ&J@.*B^)* D9[#@'ZF/+/P%NPS$<"[#('NA#5.'W7G6Q=?
M4_TIGJ"T"!:;KCVWZ7K"?0WDC2M$YDHR,,^0QK$M',V)>S2GBPSI7=/IUKK1
MX;5; =,]GCS &:<>U]C") 4+#6TB&/V_R6?E'B+>M;#2@?,V*#A':X+K/ !\
M)CAXX(OSLR3DGJ1,81:F&?K%+?FOI%#?P,MB"G8J/DT8N6*?@*1B:H0RA5E3
M[;%OXT!WB('+DXPA[RY)AIF>&R5"=$@[P4PV?'E:I&!694'+_ D$$A8YHP2(
M[B?#G\+O"S*H0</V\92J_;%?PDH;;@&Y4$$ !I)/B=%AA7W ?S5UJ3\YI%?=
MD &,;4*BFP4,&R $CK(^DA1$T$^1CZ5(.<.ADUU"VV@_P]J1R30*]!*ZOA4'
MR/2.S\;^GOYW8G3V,C"6FF%NO"6ES_K"+^+!V)N.)0GDP^2()&]8#,#G\N-9
M2=SH"/NY^@*IH(<TS'/P/8;@P.&"_!M!NTH#I,$=ZA<X[9S#A1UL>1:F S8+
MC=)PA/=9F Z*";J+2+GX, YA8+2ZV)H\ 4-2DC]J.W@H^*R 4Y9CF",.K:]]
MF>4Y1?6,6LZJHJUP]@\A^*]]?,@@0=4(X^&4*"Y!<$0+0%2?>*2)D'! @^_#
M]R?P>QP?>,$\PDC&S^@Q>K$LD'Y/TF<O^HF-H+/F&$&=XPU;0=^2MRI9?0T'
M/XG1K_D\N@8/Z"H>XO]Y9_P@8QLY#)NSWGJVT:G;&H'-P+>R^J[X89NRE'K+
M+*4S]]C.YR8)MZ[2YJX9IK&S,9W,I4EH_+VFBZ6[P$3C\%H UXC+85K>-"K@
M&@GA/4-\?)ISF[C0:M=%IQL4)'LU<(L-8>9RX><A(S!4Q(\:RZFO6@X9:4C,
MR*."Q"8CRCNSTN1R*?+L$#63,Z'N?:#;AI4J,&J\IQM6)Y<-4B>=S3M5WU(R
MR6>W8]C0[-U?V-*;+D"C/1R.R-G)>MKCW'U"+\ ZE?>#6/KIYKRKDV4ZX\(]
MHLO=U1DW1,,-=B*I "*E+B&HY'UY>4$EUH7F#_),8Y >U4T^:WEA*B$VC).)
M_0 V/]@N 04TV*2!OW*4%3O$:_E[CW%:7-(B#EGZ@B)]41?'(1A+$S_*_NO%
MS:?W2CJS>/;R=S 5/H"5]#F^F4S],,7#_WE4EL87. PPG4">_\I?CL*_@N$1
MFFLO/! \7/UC(Z22E=KLT+Z(!_0C SM[BH%=<Y3;YV/]^,&=/\7@;N$M/S(H
MT J?$G7LU;A>/^(/WAWF5D"2(Q@7F[HF%Q.+O8RVKGV-QNH<B.^+?A*<%2VD
M^+R!M?QT<LIG[FEOK+-N@VZL[N9OK"_@=804IG?>5I>.V^IRO=O*\0CX<^\8
M*X_5NTE#4JYB4U<6#=(Q].["P<*HG(/M+ H3+L3U[=K5=NX=F&5O>=>)1N3:
MM1MHDEH?75%NZ%#?BGCR,7'KHSO+S^(49)A39MC7$2F3>&SA-\CWCX([3$FF
M9(V#_-"5V6+(*?RLB'(.1DQ],%K)IGTE^=^R\PR+FQ0Y$?MCABG($E S,/A@
MTD^&Y,W#,.-D L>D'\3!"/OR&2\>KNV4JU-@;GG$81PSW%=LEF-^D+L2Z, #
MJ"M\PL0?ZGN^'#5P#6K5&-S.R=*HLBZX#<%?:.=(:4\@ZS>TVGATNG;',H^
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MP0(HJ7!*ACVF) W7@47?)?RA[JFQ-FP$X1]1UX@6YWKY<O>)LA?L1U'(?7[
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M&OJAG@U&I6J&2QE*UJ?*Q)1OL5<#SPJH]-?/$:"J6M8SGI%R8.2X#)#>07J
M($/.]R N5;,WG)K[!/LOW.;)X+LG)B,9/ T%#%DE6'"Y,XK'BPML'DM2\J\"
M+*DC=HVP?K(NI&+N9;45.<1K(1.0/P:5='"&+W/+G:(" 'H.@O\G(#)L(A!E
M Q_MNX IZ.GO)?DKR5X:4B]#;MBE"PP"F5SCZWE*, Q=I-/U#EA]O*&=D?L
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MKRRD22W;&N@@"X)2B6VWT^ZT5V[&O'LJAV])$$:"<VG??''?B]/*!H;)\$V
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M!XXF@ !&./S APN-"+,G/FB84/&L6WS01H%Q<&+]+2J%XHXNZM1=7T%WQ$6
MMN8M3 L7(!EFJZW I5F!LQ>ON^WZ$O",^S)CG[/=\2/F<?:3YG&.\ZC;T>5Y
MA):+L.I]L?RZ(+ZGD!H@A/#P'$FVY7 ^8L'.?Z+X7SC%OR3M+9R**C6R+G4I
M/+\G<B.\B=:<YL5/D@OPZGM+Y=O(Q>*]QDN6SS9F=Q[\S-8 *V>T=B*Z=X5
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M#"(BCN:*9:O2^\.;T_9CZWP S:CZW[?]WE?-_ZI5\[^PE+T_ZG7V/ &_-$_
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MQ AW>5CF6^\9#+8?$H/LCPU%]N8ELV77>SE.]E':?/*O_Y)$4<,S'Y$S#$<
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ML_[Y7< /?[6P7\"-_T[",G1ZJ1<\U-B!%GP:">CIU"GA!SQV;\^H& 0"!R>
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MAW"24E??%$YD,"@Y3+H/DY1L1U,P43A,>@&3E%Q%4S!1!V,EK>NFDSYBKYS
MO5:XW30F9SGQ*"]!#A_P_'= )C?7-:P 74+:@?8 NZ)F!T_72CIX]>C(\X=
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M+I;_#]4$GY CER.W.'(S4R75(1>G :M#P^!*]^*G %U/)IO%9FZOR13@M_(
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MDC:N7N-4_8[H58GQFNKT=V1BC6N.GN[I:P&6:^.!6P"2LN<OON.'P<(#MT&
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MHN#5Y9A1I8XD(X]=Q3Z7?Y'^#;? VZ0IV_CB)*M;^L)Z7=Y)/A'%PHTR78I
M;B@H@H'>52# 0$;#('DA3 ZJ+\O&>/=K<,TD*IY*?!$KXHM@;;P^B@=VA<?
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M:?<W6N+EJQ>5.<ID1Z:B04VZ"Z$Y6[T@V%0Q"(]POL&G\3>N #?Y[DR( +H
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M?];-#WWEHI*&#2Z8H/514NVH"!*29!FWH@BE(_5"D87#>,=^&"+>&#%YG.W
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MH">7 \W2[0P&):&\E/HH1=KO%,[@4:E'AAA+'CL.,-TWQE[:]@]"9/$#C^:
M?B1#LO2SQ J-VT\R)LMI[D?,4'U04+R;4LV9/0@L# M5$I)"8]%[:-C'8H,@
M@N!4&6XBXRS$.(\]%Y2$\]@\9SAG>&EN\NP0SEZ"PS [ __U"D_ GPJ>;$^T
M930/3AK'QDJH6TXM9Z*2%J2PZ(2_Z78ATSX$YKCJ!Q6'[7:3JA]. S[K@L3I
M*I\\11I:7=@"_*T.P9+@E"5&>U@BAXIFRM3YB4XNR=%2VV;+%QBY-51S]L=P
MV3B&6=$BI7HUFA6E-<QA5+A\',%VI")\EB\5/7 V>?LEN6P<0392&V7+EXT^
M1+C1&M.FR,;9))NSG9!+OPC.@$%P5GWI.4\ D1-EFJLN4@ZQ5R>_$N >>=5_
MQRJG"D'?X6<$CF=0<B(B%0GI.-(R: WS@K]S5(22@__(R;!A%D6#4#"S1>%2
M4-<1L%XI&" $/)>"JJ4@<M)KF!2(>9(%7 JJ/=)5R?OLHP &4@,PLXI?G9XU
M[,M%0QDDWOYA_3JEVU9J!#0EIR[%:@/"L',(E_.5P)(O#"N5107K,J/GN^S9
M "X0)9NDI&O 2L6@UQJJT1,<-TGG(H$EGS0KE<4^N$=ND!IDD!+N%BL5 @2(
MN7#H)RZ!:<?=2B5P$'N%>;$2F')\/@)$61.Q9Z[T1/B<FUC8KHHJCXNN_Z10
MQ 9:!A2Q4T$MRHYV%@-%MQ<OSK/AN5.3C+UZD=#^7-JX8#  OXC77$0T.&]E
M0T3;!5FJU,BE("_EP' Z$JK!U+!T"]RM">\'G\NJ2T#$S.4$>_;G:W0#DUAO
MWDSP''@CH[R[1A7P%X:( BZ6J^S!_G-!YG2/H@&,3=UUC:D!OZ<Z9>KXT84.
M7HZX'2$;@L7&>H5Q+%Y#J_S*%OF3/?\'>_S];_"-EN[9SBHD8B(35\-:DLF-
M%_P07[:-7(&$ T4!NBV <%LD01J,=!,!%%R&H+"S,;IU=SD'T: &A )*?(Y"
M@X4E*@GJ@Z[M)* 3-%7."YW0&W2Z8FD@!9HV**&'/^M"I$Y74VM<^C$6I=6'
MB="4.KYC-HV?2G?D7GB'O9J5%Q0CDYPTC3;)4!&EC/>,]P-2$G1IL<W&]$O&
M[;>Z?LF3Y'P%H!H5=0L?IPP: OXL4],NJ:4Q7_8M=2C33_).(+1]<.PY4OMY
M^C?;GKBAP'@5CIOCCO*:U!J*O9QSK)O0OIC7\61<6MJ$G4L7R=1Y.R6(I(P)
MX+Q=VL>0/"Y3I<A4OP:94EI#->?$Z488L[.;&__37NDF2YM8$[]#BO5$'0ZI
M<?ZJDA 18+)U3=@ YI5=O^72$APWE;=[L(Z>DU)/F9=4KIS@KLN2EWYK.,CI
MJ*L1"\[P_;ZT+(:K8"!RMIYS/UF([7XS +V:),8[3>]O/.;FAVY%%]E50VB-
M2H#0.G]U3ATT><.PNW^NY2&7.@]:0TF)UOQQAW^R I,*JG:8P&BMH2SG/$=Q
MCU\IQU.[UP_A>+_;1;"9G":"N_Q"?/^Q=,8S\)#AHS'YO2 6_NB*E7 @+(A#
M7(+50NM?<E=:1C)]3?[\^:5^%YMOE6@C!_>D)RLOJ9GN@^1%:@V5F,'>W)$V
M[NA<$L/Q4D/-B>?2"#_JI\&#R9%G@6&]/EPO]-7.R=K_B7NX2\U'N//4J:SG
MUQ^,ZKDT"J]T2L9RSB[DQ[B[SK"Z;%>-%RV264_(142RAS?7>:/ (XD>%ZHC
M',*+"%4?3N!Y@> :8LZ.U:'6S$:T1PO;;:0V-NFX1# \,M]T9K!U_1]WN_F
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MF/HSFR;D'7S1@OX6'@KQ'[YC)<S)Q!C#/ES!!>8R%WFS? ,>;]2U[0O>3)_
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M%)3T_HSCS\*?2]L#_H$'07\+UI8Z:0P G%^H1Q!6@MP#,3%\"I0+?A;6K:L
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MOG ,ETQ8[9]MFO8'LD.X,M8OH;==)3A]O&?>$?OOMD56WW7G%_&^+[VE;CZ
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MW4X<VEFU(M \&W0YUC5+N=E9:5.\]1P<;#VQ8P6"I&@>K[8YPF?*L'CS-ZC
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MJQ":._-V1<@4^V+?4(3+RXSG5V75+:MGXOYU XE4F6D$&D!V>3[]FR=!*XL
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MF1:E]N 5#$:*-.2U@H%I>F15/2Y:E/+#<^$8$$D<:AP]LV@* 2U*^>$Y ;O
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MXX<MY:M-^1$Y$<Z3-$D><D4K0OLA^5N%JH9,F-QP2S5A(&=%8N6".2L44>=
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M?NN81*Y&'H)A/SE^X*T6I:;K:.)@I$MQ>1M2(VJ@RI#60F&>$G3]_OT%2+)
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MI'Q&/4\9<"2 @*3GG7\H+F5]@5*>BE@OM)GU7>1P944\-0M^D<9R&MW+615
M%>UE:3!*J,I+V\N4D26%<D9M4$6,E,_&R%['<1J0NDKO0CD%I61&;5!%FTO%
MFTNF4K)N*9E1-501([5&&=F:?LBUMX$^.5[3>%>A.DE2>0ODLHT7%$XG'9#E
MA'9"&7,VJZ%-)7,V:6_==H&UQJ&P"@_CAX><$,\WIEBE6*VE W1YK$+\4QG*
M:CRMB8*U=2T$6X/)/!VGRV-2")N22QW!)(5>D]#+T^&Z//1$[%@-DQK\4>3U
M'GEY.FJ71YY$&J8*75'$%'J-"KT<';S+0T\.&WBK'7&N*?0:A5Z.CN'EH:?
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M$Z_L]A(KRSF>X&;I^A9P\=I#-L'&#401KP16DI9Q4AD^@BM@L!I;KA.Z%0J
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M3PRS<==KNW_R <3C^,<W;!U=/=9^_^3U9ZU;U3@!*<GWA9OA&Y=:,S8&Q;0
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M15U-\^ $H5EV#!67@(JZ>MC!<46SWQ@J+@$5I<P+RX(*V<]*4QDJ+@ 5A>=
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M:2+(G+#_L]<RY\(,Q+*FV8B1*[SX31,M/U,SC\^1GS2@K^=5V:J1CYWB9:P
M%(L+0*S(SZET7;R$ZP%4HK=]3 ^P<K8]MLH?:GQ.K8EM^^+;7BJ^[3'T&RX'
MZ?:V;XT?J[$NE7VK](B6@C$MZ,J1@AIL+&,H)O2G[%(ER&78K*VJ,CJ&7SZI
MK;,:H^;#(7T&=;1 C<D6+T>@&AA=&TJ"W O8,X&:7Z JA06JSHHV6R!06Z.7
MM[$#6:==_3DKU-(U]Y)R4W4, 8E#3<]1EE:?X"^G@)<!*X\&4Q:P<%PP/Q35
M<,SIHH'5]YKNGM<-Q GF*NH&= GK!F0C[&?N5=U P8V6=A3T$KTU5COK,CT
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MAEJ^B%U7\WT82$^]BJW!*>9%#J5\&0L]@RDK\ KCUV@+?D7$KRZRL3E,_N;
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MG$A)@6;$EX=/6>P:,W!W[*Q/D1?44[.%6N_^@W\U78]L' [MV!\^9J>FXUB
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MR 8F/AL&DZ;]ZO#RD2:NT?").[77).CL25=$ UAMM'*K)\N[G*=-J-.X"VN
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M[!"J,GYRMO)BM$EYR:WG:SHO$K5,O_^<_A?+^:I&.$J%O/T1RR\'_U52(:=
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MA?\ID1<%[O;FV^U'SGP&(II4%E,NV_[F,!<+>^JG-\+7MTA'QFSAYN,0*\
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ME9E@F,-5',Z$\QAV8F"Y'\JD(\<$AEG)E/A^ ?B_U09VZ1$%<.76/' \!'X
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M/OWJP"4RW-9E[#R+&+GQ\Z60/(%2?9+1?^+J<.S_DE4U*4PBK]:@&&B#2<0
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M,?GS@1%A\N<_LQ"A&VO-+@.ZL=X<6[T;"\ZVHSNR5K9Q.[M>MG&[O-9_YC%
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M,M*Q$B!!!SM)S+RQ<-"FK 06U#0,@R0M-38I_5P5((@+;36@:M3AY-R%=K&
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MIU3/^PIT2CQG,N:KU"1+FE+Z*X+</='<XI"+'143XK.51"X!M%B [FEB4!Q
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M]T"I3+%]GJM^9L.%!\(;=()_+MQ(K"/W!]WT%R@"EO>3!<<$9W8=SLLP-,
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MS?CB.B.?.V-\&ZYO>:1QI#E\)0;^C$ZCV]9(XR 9H&J=$F&H PR5A)#:><N
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M90-@[7"V*/84''K,\I>S36$Q.#0R<*77B3V<2':PGC'I#F"5%H(3+N\Q."9
M4#9:#97TFU+?A:O8/DX,O8I&54H+'X>=1L,LKZ?+N;[P( Z<&SZCT@\\G$?Y
M=@4O!L,)/LSF_$MXFAW/ 7?$VW&?%CR%/>,?9NCL8N%44^8'TA@G7[+@E;%P
M!FITV0F;CB0W?,EU&&P;/O5R'BI\R!W:%HYC6SXSG]H*;[/?<]A/>&.\"/!&
M<XN/VN3WYL\]XX-2_=7%T5[BFS/#V:I\A^!95SODSAFN'XGFV?Y/:>8"1W(]
MW :\7<)&21^0C-,W:>P.87_Y,H"L0 Y8+GXDO!!^VW;&4[Y9_*6/5TC8*<Z!
M_06?Y;>0X$B_\CWWW+GKK:;(AKMD.]($(';-!]<"V0:\+24.J@4 S.:6QP>
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M^K $^"U'AH$%$H2'BN)AAQE9(--0B6E47;O890SFP"RT1E<EY:)Z$-AES.4
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M_#,^$H#P2?C<%\HK#I_M)$V8X$GPW!=R+ Z>'1#OQ#X)G^EBH\7A$T?^Z,1
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M.G@G"D%*HVND-;0)0><0XA.%(!4#/"FK10A!YQ DS(2@E.5HAH;E:'*"ZD0
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MZAN\>,](V8">B)R1R >G6>1"9!.)K"?D]93:K2W&02)_O$"Y-^;_Y6/7]]W
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M6;CPS$):'%MKDO2LB/3,0L%VH]LINN%JS0*@>VEX.[&<%X8R9R/V[[&A^^+
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MSX)5N/=QS4(?5\/'[;3V/"YG+_LWN%7H([<;7;FYCMDG/G)R,'+MP-YT,&
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MQ(-E>_^#IVQSJ1LKW#$Q0E&,V,2(Y&G*RZ4G[8A2T)R)O;SW^(&=V!@;C^R
M3=U7R9^XK^&XSC'L8<BJ\."NRS6W:;EKG.*FYTR^B-$/LM($02!DR$*GJ<O[
MYZG7^4IF$]BYD"OIS98L9MB&N"M5>&S'?G#6K)SO>)TR\]B.$U)>EY=X'X@K
M?CC$QKC%G5RX_*=\5T^9G-Q:O\D<D1K^'P/OC_=+K/_BPB2OLUS:YJ'!!1[3
MU+Q^J[P]^Q6N(9IN?;4?V/0MM*]"]=T*$CPF'\ N/U$(UFK%RL6M6$Y8\05-
MADKJ97=,2O)E3V>1M<[!W/OU6.0$/]*R%OSX\E/%S%I^2M-[*HF/VX/@B(-
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M#BBV;2&<:F)FJ0XVVX"3ICY6GJP>5TD*F/V^%+ 38TDE.5[V/CE>)\N22@I
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M_C(@*&Z+*# JG(KZX# *S'V ![WC2<X$CE00]?VY1'Y/W7 N#?$TV"#P=\B
MW4JJ[BZ4>JOO2W*)#'&K)^/#2'H=NX/QQG.P <\X).C9 :8.@:M-?M"1XX82
M:+(SIHR0M8?-8,X^OFV7X$5:94H__-(;@"HOC5 [6UO\#CG*):8BEY);3B]Y
M3CLD#78I# ([1.OJ%Q+<S@.QE/'^Y:5E,V41]7(9M6 I"CQW*/V'JE'NE9EN
M?TA @%#53FJU^DFMUCBIU79/:K7F05>[AQ)$"50+*2S)\8>2!\=9^,:9_>&
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M"!3V]YPXX>G0@2\Z#B@)M 4)3F@^A;9" ^,D:? ]",G:?MA(B'J*%:FJ6TO
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MI7$O;-<7DD'P[,-S#24GXA_PX/NNQWIWPXOP_4ROX0MZ*_*OF?L""/5CR9D
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MGX_PP.@6QQ07ZH4#72WP0>*[_E\S&DA@FM_00Y4O0D</TZ_7O$#)]$4BX>&
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M:@)S2C-I5GR951^BIN[(:NH^,,INSRRE>!6AJ <\HGK HOW]1#G@E@(U-;]
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M/:EY3.J\J$W'JIT2XF7=N\'B30*<"H ;BS>IIY7:?QWIEOLFJ?^<.];I^X.
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M%./H?,'2JGX2W<^@&\@G"&/')[1P.!/8&]B+S[;#<<H$4N/$X)LF#(]PH4J
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M[/:51KC'.W3$&G!-\^G,1TH=,UX&COLR0=3@S\*5W,+R$N4V'")?[76UE%)
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M%IKU(1IMOL$C'38W3&7I'$0/MC[F^##+[DRHP3H="LAO[DC(*6\""QM=TD,
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M*W![>"[V$BAQ5?'5,WW$[SBSPXETB3O@^KM8BB#7E'LKJK1:H2=+FT:\1-H
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MJ@65#,@?B8$IS!^8$D*:K?*J)7,1GAIO+I*+)=1.Q*9 (1&;A.,/Y-4)WH/
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M Y1,)VY5+W,FD6^[K1TJ*M=K5OJ]YEIQHI[7HA'^D]<NPU3M\DTW+% M#B<
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M0C]+]1:KI-RHY(]UX)_NJI*_0LV\W;"T\8BVHYW6=M3(=C[0Q%LP7G7'6-&
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MEMHW8#=F D<Q>^XF\5MVFXTZNK5>@HR(=<F!Q>/.W6TVMM;YR7]C&C5T]Q*
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MS!T"R,&DU0LM $3^B/$[37=TS-D)=NK!PAW#'M>4 795BBTBZ(^R/5=]S%N
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MV3H=G(J>5E7%OW?HL@A1[LCO2%&)N@TIZSG3LKO5,GHYKZ*'88($GVUE9/9
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M,N?5&#&7/CC&[S[R<2PL^# ]S6!N4KM5L]XXL5I'/D[C^=EASU2_[K,,MF@
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MMF.(BJX<2R9;!6F:VQV:0E,3^%?)>$PETN4F75D>2Q-[VC=U-:,:)LKFIJQ
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M:"&=&ZNWUHTKZPR'+'QZI?*X+:HL=ZY*BLQ0&VUAO<ZH2$8XK6UQ%5&6K.$
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MTJ<)0["XTA 8 &'B_G2](;*?U'/'\08C<KK!\VC(?B4(XW2 ]]VQ]!),ACU
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M#*=0HEJ9VIL348NR58IK5FXK><? $+6+\K^(Y6&GT=;*R\BC#N/487P'[XK
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M[@-+LN>.RB"JF+MQJUT4;S>[#'AY9%9.YL4RFB(@+_PTQ'[%T+'5&EE$1PH
MU$9;3^EP5X&>%T3EW77\5C)C;"A+?>01Z,PC58K[^PB.$>]%J+QI4\44N&,L
MS5D=<T[NZ_*HN*MJVD!% S/?#]C9X72(M;.&V4 M$RR)54/B:)S0TYEM*>JN
M'FYJP1-(]CC,B=GJFOEQMH6+/G*Z/;B_L)K^C6CS3>[F^]O-?27[J=!"Q[AB
M9!I!75G'N##&%GN:(2;8V68X#!/8W.NNI_2AK207$-B/#.SK;*[#H-U!D6\Y
MJRX" OM^AF>^0>*YQAD7<<3@EQ0R2)SWYI5^)LUYN?'ISGKWQC,"7P9>=R E
MSSAP(XE/!.7S!/D(\F@<PI>?O*[D#N/9@CE'=Q_M]JX?W7WUJSN<]& GWWG)
M=\(U59+OO.DW EZJ,3^Q?>>6NZ>V\=VU&P]2&*?4:SBOWH,=?$;A+#V[GC]\
MY5,P0X]WD/#GNR5B40PVCTA&S&7,+=,V:([9/7A[;%]XLRU'P>COV@ZJR:R\
MIA2R_I!UQ],SY%N_##ZE<\;(>*,H&2+?8V>P64'HC8%44A>$+VRB]/T?[O/H
MXA/.MW@*W>>HB=-%1RY*Y@D6^X+JB[ GU9#/"\59]'"#V]^E2S8<<KQ_^WYW
M]M\/5[>2-&;=@0\@>GJ50%"/<>%12TH(J"8$1.*CES;F)IQ1"FH@<H<YR:6;
MYJ[4PJ&Q3SZ@!51Y'+6_"_']K33\GCQBAV,O.T651EN%\]YJR?H"3;&YR=67
MNTL<Y2OU0Q"_L%T,Z=(#*1/!78?#X 4)?OVI([DC^.!GO&V=+P]__'ES<W-7
M0GYZ)L;.F[&^QW#S0L13CV/_FCV&$S=\C:F&@([E$F<6T)BO0(L^ $AZ?!4J
MCO2#BB/>^\^PU_F)Y\"[TI\VEAI<1 72?>>[KNNJ;DCO4.NYP]' C?7=D$U^
M@$93WY^:TNNM57H/,TF)(YS#7I0BY%^"\$<O>/%G39)B2V[6.>.MCR!8@F.I
M_]9@$/Z%%YCKK"0APD]M^]G:[4\3/ZM^L#Y_71QP"9M5*PB643^$BX"$>IWV
MDOP_:X7/).JE"!]CO?#Y([[ZM_CB$3P,:-5_@U$2_0$T#R]QW#0<%..&:T\A
M8\G9.47(8/-$>5UT8RIB^)$&4/T$=@E _!4'!X.M#*?!@A;XG=\J_#J]C8B5
MXNREK2M=LK86:M!PC5]N/CYT_N=NSB3 KRT>2!(I<?/\//&#LSN_&QMF"\_*
MMS0NC&#2[,'CPR(LGOD,""R]BQA8?,&8Q0]YV5):RZ(Z6<[MY!F0W=TRN7Q1
M?.@MQ4H5'XFD:/_S,?S0WB::DLMK<*5Y8:6N$SB6+:O,3.=69$Y@U"4>592<
M3/JII1DMM27%A?L1>^)[[/FQ(EZIU<\^]%VP/-UU6/W# ,-<H.TCZ9$!#*5H
M '_PX\=HZ'$KZ&U4\'39@,K9 1J_VG7#\!6_D)SK>)O[C"&SO,Z-YMQ1?;'+
M()_V!\\^?FWB20:>"QD%;SK"YVI.S_GK?KUB"6U5K16F,9P9_:XWXKDU62D#
M1TE\\Z,7@+4'<)_A (<J<I-FZO# KWZ]_R;]"1=&-78))WO7?XVW^L:'\Q"L
MX:?TV_/C9XF?6.$;+>GS/_ZFZN9%=Q"-8TK\_MNRN/K4,E?$U8*T6HT4OFF
M3U[4!>-]@E.Q%EJ4X8PL#I!O"(^.W[N:@@/^SCE]V12']R\3L,?G2.S4/=O/
M&W_]H*V/K[.L\OMX^Q[X% ]XYH_#H/MC3KN ,F.@=$;P^* *6..(H-;9QD,<
M"1OY$B@9PGZ- I^KS@6NA'-2#-5>K!X1?' E+^CMS9NQ-V_1=]Y%-3N*V/GT
M+Q=3[[7G\[7S'UVLWF'I3,QO&']\\>+UQH-SQVF9IH7!D"3G(KEQ_*G2@KW\
ML/J^;K=4V4[]2&XIJ>^ONY1BM"S'JN2E-B]PQX1'&4,6RU$()UO>X%(0K<MU
M456B:.BU6(C\'%DFZ.[V5YP+G'A=I,2Z7DG*34M:$I.&GZ77Q?36RU&R\O$Q
MT]9;ND84NEV5BCMC[W T%OA1Y#-SA^,!&*[KLXQ/9V<> F##+,*D3J58-P=(
M[JM3E486/SBL<E,^QTZ&=*I#!OM_:^M",\=1I46060.9C5F?^2%C 616,WD(
M,4>/&-70-D63]X",#9 Q,_8&.A1FCNPXL'FD9A:_'E6-;6 -R]K:"6$2=@=N
MQ#8XQRZ';A1Y?8_U.E',3ONU2E!XRW-369U&6*5:M-,%C;TFE4HL:%9QH<J;
MPFR$B@-K677[X.KR98G*FS58E9$E>]?5';6BCG-GUXZ\+J8\KO:<ET6)+P>P
MA/,;SRQ3[8SC$P61M[S#U"GC+8O^SXRW%$AI "G!)W/"4X7PE,ER*%R Z;R[
MD[S:X+*J@-NI8HK"W13N=O;V]J1'-.- ^$%"WJKP2LN4MOUI=\_=MM]-:]M_
M9,ZY,F+U%)(7NBN5BB_O$7FOQP90@%UT@/WD0UQK? ![AKA4;">F9SU\4;_+
M0R# +@8!)DY((P < 0 V=@+*#P">&)'U.$S![$,%LVL/=&N-H#MLG,GF%=5J
MQC@3==[,YX%>4SU?> 0:.SYE5(9$XIQ.X5)HG)'--3Z6W2R[P>[!HL:'&]>9
M-72\=08FQ5FR*$X!<3M-:;0-*VL2]J'B<P2/+$I5!#Q4.%=D;3=/Z#@*?2P"
M'AJ.(\AW[#QTL+6 ECI5;%2SH6\EAN:DOO?$NU8.W)_80IWY2=?$I >*^X--
M_;_3OB9K$9ET&-C8 /SF]GK>Y7$[>7YDX5U_N<P^4A:L/MB-+EI^+]B0B;U-
MF9?GH*@WVN.78 6*DL]>5KMA1,VYS@AX>)]&.Z2W2$=38OT^-OK[F0PD_Y?K
MOS4A4^(>9#MW;JI&0-^QM!P!?=D0%#I76J:2_E&-+J7MDALP_7#&JUR8+)T<
MPN!ETY&R"EZSPJ+,ROYKKEPBA%*K1(@E"*MR&H3K%1+^QA5&ETWXPZQ/B:[=
MPI/>0">T8DI_J$CZP^&\6_ES(';T<YUN&%0OIJ6 9C3:BI&UC(@"X8= 0#$=
M C2ST<X\'Y$ < @ K*DGR 2 ^<A0W_O%>F=_L3!(!8:%HU=L55$O"!U'@(Y-
MDR#V$ _8#<+(6IU,>3*4)U-4/&?K3.!#!-!Y;P=9S1@6I"2*?! HI21_E<I@
M@[<U.V-G'*)Q/AJOZ75?.(V51MM:-]&(2"PV]KJF@=5!1;G.2_UUJ^241\J%
MHERH<HTC =D,<.9HZP9ENQP-/(KL2) "#SY )E^9%<&CVC:7"'@8C7;&C&,"
MQW%8:R+083;:ADF9<@=-0=F6$/=IPD<#N]+0[?[@P_U^NMZ0YVCUW'&<*,9'
M)P7/HR'[M3!?>#QPQ])+,!GVI$<<")9,!7SW-L]U^,ICA\$DA(]'09B,9P3V
M?-_DE\4,D<5\/#\8QSEY.*AG.I<LF3\K 3C])YPV%WH\',ESU/#J/.,M?')]
M[R\^Y<H=2M/Q9,N3!I>GA^&_D5,\?^+&0]+GX)!LHVZW% ?AL))3DB1!Q=PX
M]\,I@-]^XCX"CB?CU9\<("?.MIRL.7&."K\RA*2,Z2U'W7PEL?[A9Z_7&RZ-
M)]JMR\869LV;;,"9\KYS>W=](TE[C)_-JSOB<8YWW[\"_YU=%W[_]/5O6G?V
M@7F[K7EA&,VVIB:U0-GU&>:JI^>S+2K!^3\'X=LF/+&SQY"Y/\[<_IB%Y^[P
MQ7V-D$GGM2:(H)EA8K4L%9YMG61<4*EZ2YT?TAC&M(O?7$E@7-2R?-17^0G%
M=DM%X951>-HM1]Z<;UM>2"P[<]DY[8[;NX>K>^GA3GKX?"5=WMW>WWVY^=1Y
MN/HD7=_<=FXO;SI?I'N<0/[UZO;A/BWQ:CEGV-B0<+G28VPMR)<T_M1BU57E
MS-@TQ:ZR S^U%DXMG([XQ&&83RQX"MW1 #&!4VQ7)G_N-)7P[60P/YOPM[EK
M=T T1%>_,-3)Q^3.F?_6\8X'Q$F4"SLX-T 5AX_[#$XE+@XC'87!3Z_'>LE4
M4B^2,)6XAU\:+U]D&'23*\15)5U89@#[C\3CV79A#R>%\@FCL75^<_W]/OZ;
M'=O+.,R\.PE#/M5R.O8<#>O9$[!??"*SQ$7I6= _FT2I$]*'0#>TI",X$H)L
M!0D.EYC@@&'I[:Z*V<P^A[.9^(%7G[6Y\)[GPZ$"I[K^FGV,IXT>Z[,0SQ%O
M'QS?T,0<12<JG#%T1TQ-AMPRG?2?T*4*OI196)M,Q::QD)5)"2JL".B4I_F=
MYCY<33 R3AO1#OJQU<&'J_,BE.L0#2+:FO8MF'CQEG2XP>[2GJ3 Y0_? ]LT
M?O<>G<<[%6_5?)OX?'B^/=QV#[VE7:E,A]="^6=Z8#NJH:A%[DC&W/2M33:^
MLY_,G[#K,'B^AXV^Z_\6!+T<R5MVHZUK3=E:35@77DF\6XRUDE,3";F[(E?9
MFA(A"KF802XW-6<UO9B02\C-BEQ%-;>.SQ*$7$.&\WA32TF8)> 2<',8"V6)
M7 .'*#I-55E-0B/D$G*SBURY-.1BC8+=-!0R%@BY0F3NUMQ.4<C%J8=:4T^9
M+T_(S5H-=.Q>E94([WD)#K?4X!A=OE:7+R@:N"X-;2&S.W<:]W_!]?":^S$5
M=NQ0S8O\69E[UQ4L9KW;+8=G76WL:R %+S[+T SJ=*?1Z]N'8J\KE,VNJWGY
M5A/48T6FS!,:EM&PO?6].#08C;;1-#/W"B,PE (&1=6V%W>* P..3VO*F>=G
M$1C*D@QKIJ85 @8+P:"EN-$(#!4 @Z(J9:H)FT<#U(Q=<@@,)8%!U[87>8L#
M V^+I51&3="YL'+GPJ<@Z+UXPR$=_D0<_GY+=C,SIYIRHZT[35W..MB*Y'9E
MSGKIQ-_<Y-54\C9Y)<)7YER7B_ J$;[2A-_E#)>+\!H1OM*$W^6\EHOP.A&^
MVH3?X6R6B_!&U0A_R&:7!9[4Q$+G'W\#EE6K<V)S6JJ#N[%WF\XM4=Z3;K*V
M_8BWW%J-%^@\#%P__]G/;+15O:DIHD([!^O21\C:Y_Q8 +(LC!D:IJC(  &K
M<L#:Y7R:$5A;K!E;M#5#J*H<JG8Y_!8@KC!<835M0U3PBI!5.63M<KH6*J\L
MF>15_5&UP]%]!U2EH$=IM!TY:X?]PR%GI_;(U&]KM?%3-=M1U?Y2._7;FGZ8
M=_3\MGY<M1G7KM+L\[D-V;E#53V6NWLCJGJL=Y]^4_78@5QMI>JQ=%'=H^JQ
M&]0D*FN3J-,M-3;6#+(77FILJ8VVKC8=QSJ.4N.3F)I='1PJ9?7'L30XP@,,
MCZ0_#L&PW#9-6[V1HF"H8V&&ZAQ)LQN"8;E:>>O@4%$P-'CK&L=>330G')XZ
M#D$<;@W[B<*AR7&H6JNU283#4\<AR,.M20VB<&@!#O6FK) \I+Y' EQ%VUKL
MT%6$7(4J22N3EUQ$AZ&ZYRN @M/**P.W;/2 V&;&_.)BC)H3(.W6;OL"2>M@
MAJ^6=4XWD39GKFV)I+5Y7V\[Y8!$I"V":TOLRV$KV+%'3?'!$&D+X%JU3*Y5
MD6MU8S7H1:0M(.U3+]&,LK%W<E-5,[9CI*8YM3OJ9&Z:4W=&W.4\D[LLQ-9Y
M;QP[930/R=2#G%_RU&'8>:O@B8Q%G55RD=$D,E;L7)*+C!:1L6)GD%QDS%N,
M2V0LZKR1BXS.@<A8TT8P]3Y][-T YN3+17<YKH@O;W?0H:LT33WK/(=#U1L3
M3G8X"Q6 $Z71-IMJ5A<BP:3*9RVA/0V<W,U#"2,5/L@5($HTGMVF6#;AY#AP
MLLM)4:PLR=V6E#!2X6-H ;+$X.$O.>LPB6KT/,',0D3!^M-F?-FD"\JZ RBU
M1J%+U:DUBH!4;2&RD5_RW!O#[;H[2,MWH+$T4[^0X'9#$$'OUR9PU['-BT)M
M7N8VA-J\U'J]U.:%VKQ0FY<*MWGA.JALEECI];)CT.,D:RG-DFHI'9Q*:S4M
M<[5?Y@G64A(.EW"HE%5;[EA8[V2EC,HF&)XZ#!75*JO5AL-'\:H&=7PA&*9H
MY;+Z7SG85=]HRM1I@W"8)@[+Z;1ARK+,8Y%:RC1JPN&IXQ#D83F-V "'"N!0
M;3HJ]:6DCB_4\>58KD)ED)5+1*:.+YD4W%;WAZA29=!Q*N@XN2FK&?.^J"PD
M'VW-K4VU!=)6PY8O3HIWBTA;1&KO5N^Y0-+JO"^(H1%I2^':K9Y @:0UT!GH
M."20R^':,@6RR?V\&G7S*27W=7MK6(&DQ>ZP3=G*. "06K[4[JQ#+5]R'&AR
MYIH#W]F-MFXWY938&<G4@YQ?LI>6 !4/5=9^FF3<Y:R2AXQ*W@G*1,:BSB6Y
MR*@0&2MV!LE%QKRUOT3&HLX;N<BH4<L7.GU0RY<J'5=$U\P"E^N\Y8LN4R^/
MH\')]K-0 3@Q&FT+CKL98SH$DRJ?M02V:0"$Y.V[21BI\D&N %&"+FNMJ=BD
M<HX$)[N<%,7*DKQ=0PDC53Z&%B!+L'2@J:34\U6OY4ORA+<37B.=U@)FKO/*
M:L,7\2"P<=V;8: B##H1W-0=LQZ<[Z3;8,SBO?W4,EI-:1IVDKQ(\H.QY Z'
M09=_^?%5>F+!4^B.!KA%4LB>@#"MI2,A; H"R?,G;ISA/+<MR5/H=DMQL#-.
M$'GXG?.0#>'+/]G%M!D)!^O<#Z>$??N)^PCTG8S7_R2M<4;IO71LR\G:2T=O
M.:HNI*>+H\+]=^KI(BCL^^SU>D.VH4!["[CS.E(XJ*_/<-#Y1N_$<2[LOG-[
M=WTC25)^'U%>I1%O[-WWKY(JGUT7?O_T]6]:MV7+*C/3[XLW@QOG6K,JJ]JZ
MEC=+2F#N3Y0^J,@\I^]:?=-YU!U9UPV9.5U=8[:NZUU5UA33^%]+U1O37PW"
M-U0^L;/'D+D_SMP^2*QS=_CBOD;(J/.Z!<303*M;+4N%%:T3@@NN/;VE&G/]
MR,)X_?&;*])RT3G*-4OY M1NJ:J158#"KQPY_:/]Q5YFHRX[0NWL':HX9F_O
M'J[NI8<[Z>'SE71Y=WM_]^7F4^?AZI-T?7/;N;V\Z7R1[A_@C:]7MP_W:6T\
MEM2T8FQHY91>+9'&&VO-(FP==C'7+,]9YWW/OH>*F7,3KSY(_UPPZY:MXE4C
M^),7=8=!- G97;\SZ7GC((R^L^>)ST)N 5W]PEH%%]Y^?;-S53FVM\%,8KW.
M>/HF7I^!53Q" R:<@,KY%GI^UQN!N>5V>0\6UQ]'_"AE74A]QB)> P'K_^EU
ML3G)DDVZ(,.63+.YAX'['I']"GO292]@DX:#8!*QRP"3[R*);S[?CJO0C\:Q
M4?L/]WET(?T/[-R3Q,;PG7$(>X;[!1:M&TDHX4:,BSG)3:@G!7TI>68XODAP
MJ)%>F1M*^+6>](EUV?,C"R5-:4JH*/@M\8M@*DMQW"1DHP!$!-P3GLP+>I$T
M@MNB8.VU=@18Y+^>I\'I 3GL 7[P$>SR'W.(4M(0I:PBZ@&6$\OQ1S8,7J1H
M$+Q$,92Z Z![;.F/!T'$I+X7/L<(>X[7'+\!^P/+]$+)9^.7(/P12>-@NF/X
M97@.?OKBQX9H\AAY/<_%YD%XX)AN9[1Q/^$O:BLGG)6<<#Z*5IL.Z$0Q/1^M
MEJ,90JYDMFQ3$W(ENR7;MJ#5R<KFP\\AGDG4CHN\DJQL;MVZH[646GVIY'6I
M*:E&:46J>Y?U2_Q7KF36MP6MY4ZDJ^(L/>(VPL=\VS.W^^,IA!WNG27+8A;\
M9U_DKQ>OUDXN'#F7P6,N8Z<.RU5W62Z1O=YD+ZCPI*CPRN['R8Q=H[4B(5^I
M)BV=9SS&TD:T_WXZ?61WIWD]UKL3:6L.;^)SXO.ZK_?O66R9J>/(#WRVODL1
M?6O=MZK5;%QDMLX:9D+O[_D!*P,:;0D;WD\P=!$[Q]'S&[&1&\*)?]73V_=\
MU^]Z[C!.+\'Z]ZB@Q]=;QM98 :]M6$DQ07R<J2U=7_71/KH1PRN W>Z^WY)+
MH I57W5,(%,-<S&!S%B-G:4%.*Z#D+]]G\2TTM+$5.PV9;2R9HF),31$I1@2
M;O[?AC_!T,\VZ*CS0;%O+$2?AOOT%F]=@L],:/&/9_@Y4^< I#7:5L;V*87!
MYR">C(WT6F^R'K!S;.7$FU:8>-.Q<7%+S94$6_/^P5445EK!PLIHM.U\A5JG
M)I-(IZX35GIAPLKDPBIK\0_98E7#S5KQIA<LWBRPQ;+J.K+%3E4+IXLWHS#Q
M9G/QEJ\@B6RQTH654;"P<AIM)U^A:VUE4G'-(P^TO*D\2+)YQP/^# N>T"/U
M:SX*\&O62HYD<ERB%)EB8U;KND9HS*D036ZTC98H;U/)%G"MJ"W&W;AL0ZQ
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MUPL[\0B_31_Q,%5;EX$?X:!>Z3-SA^-!%QA#>IQ$\+LHNJCQ#N(3(W/"I@#
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M I;P<O%!H,_@-Q, 52C=7UU*X63(HO=+T,4%(E4\?^(FX:B5=U;A'4=TSC7
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M_,YY"+;AV/O)+EZ\WG@P)<S<#Z>K>ON)^PB+FXS7_V1N75V&6P\?\V=?VC
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M&_H<^/$B)7?,-PTE$Y(QV<.$ ]ZY(]B<7_"T8P8$V;CF;6L]LU=%XJ4;#1[
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M%A\^_*?H-N3+5<1F\\0[.SG[E#7+_AK][)]-)S]^_/'3A\_3B?_ATP^??_Q
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M7M>P.?35-NT<S;SE,8TBM1U+>*TP(4)P,:.C!)GMB-)$]QQC"A-J(BF<#2R
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M@!%<.XL5?/C,BK.JRH_XD*U"%+^LKFFFX9+@B<YV_K3<Z91-^^"GBB]Q@WV
M4I\OI4':I2P;93[&^#A]69Y<UW$7V(A47N *Q$B@N8I"4U$>!626K:]P VQY
MDD9)K[@<-Y!TK2P7RK:$HI75O"(M#,E6Z(\'O+U23:-7-J%#^(*%+IV)Q[)1
M+_CZQ_H.)FH4\8KW<!--7\[?PP7H^KTFQLLV?>7;XPF^D4ZO"@CBA\VJG+&0
M^B_R&XO#)K]K\\?3-6'BL)2EB7:MP6]QBD;1WJ9_L#1SK9H;3OZ#FKWW)S'_
M?_N^4&C^5+Q1Q2)DX4:QC'\[2G4W/S)-'B-LGW]2_(Y?RXG=.KA1$G?D'409
MA&E]P*Z%H.',CK+5B;V/<MV9:EFU'%2-;5])\#:8F5$JM^EBU*1235G3=6NM
M%EZ=D>\HMA;"(>"05#V#!N-P]<4_" (^P5"P%YJ\41I*D.D1?#1QI>U6G'<Y
M8Z.8;]/)*9&HU$I:3=AU]HE\19Y:4@;UG2_JN %LQ.DR3M@"OZ.TEQ9E::)8
M1!*REU3X A*.SXI!]S+Q7W5&1@'>IMLRGZBR->L%<Z+_'7NEV0I[!(*"#PZW
MN'UW47A'^R7UQVS!PAF?9B]U(@Z#. U]NOZTWY=#92=3-8KS-GV+V0H\N00!
MKY19%-0J/+&,H^MD)YJ($AR9<IE]<<TC\1Q.\?/[C@C\[N9KE/IM.@\+85>Y
MKKFLEQTHV6J.PK\+X=="AT6]0P3_B( O!:%A0.*831GZI8OH8B U_,K!^#N9
MJD'D?SS9II^P% A=6H,>"EVL8CU>&ND.CS'[VSCFQS1:J/2A-87A:Q[>YED8
MY7.;WKW*D:S-KZJ2'*6NBPU,7L%?.S.D852C5&W5H:;5.I'7]C'MHQ,W&S//
MOO8-W&,B1DG;IG^K->'M>'%FB"<9,LPTRW!@!4(,?*^%@%B*6/R[EJY1Q*PT
M0.AT0D+9X0R, E>#]YA#Y>3S\;0)"1F24_+$G-;R1$HA,0VX.T=!LV3SPU*D
M7H>S#",.,8I$1OE7E+4.DS"*6PUBXT;BEL^M0-%3LSL*7 =>ZX5#\DRO9G8S
M#,>;4*QW>L]E%J(T/6?U=#O6Y'1CJD;AK0&!["Z\Y9(H15I=J_PR$3PXH:+$
MK)<M)(LM+Y9R%/0.TO,U#E'#>$:1JP&-W%3DCN=B/_:):)R 1X\\@8;0ZW(Z
MI1/T"][3!*^@011A+M/7$ZA>,S**7 U\XZ8B)R?JH6L]FZJGYJIBGL05KD_W
M($7S83I]D05S8ZR7.RG0=0IE;#K5B_YJ #P%NF>N%,%WQ\2\KB_AW4_#*(05
MUPH,Z*E)>6)6GC:M-9T0FI;K#NLP13H^:*$]%E,\"EZ)XYN#;/2D;1*1TXHK
MPB0B1\B,+@?-<^A'Y"T<1A2^VA69]#&I;3Z,40HJ!O\.!X4:VY.#>\7H1YFH
M9U8&BW>=$KBI$TKC:] *T*7^1"<4?NSV[-OJB$9)J1CQ.TA*@8U73,03,Q'*
M3S:7@Y2;6SH3N#4D>F%)1()EQ"<4?<ZSCCB.9CI&'E?,YX*HX%%&UM/H'B2_
M"G< W($9GGH<T1>2"#='3 )$TDS2**QBJB%6B];](NO^E'<?8?<GV;VG_^6K
MS<LH3RU)'B)2.)_FMYZ:J) U,55/S;4>_4WBP92(713$GC1B8N*>FOEA2BR-
M8AZ&-)AP':M5_AI!@[I"QG8A:)21:LI%1MT3Y-<R*=08(J'RR,YM/# ZT#,R
MLYI84&'F\1E1J(SH2N;9(UJZI[MI@"T$C+RJV$:E9SLGE_G+CYRA,KEE&X_Y
M[G2-?*P8'-?YF USW'QF%HO?RA0D4!Y45M,66-Q*U\CBJCFOF<7R3RJ+"A6@
M+#7K$)E<"HL5-Q!JPFS! A*QA"X*Y:74<JA:CF3+&VS920AV,*Y)2,XJ!KUR
M3+"\?X5Z+:E[8B)E]:K<99AW41/RQ(R.DE3'T<TOA\V&,,I'Q=1G*Q_'2Z-\
M:<P4]D8@0"OP!R _ZZD,6! S<K9JFA-WP"R'UY#$OY4_Y_0/DH-YQ$AV9<(W
MZ:%YF\D8N58QMA7!+/EUC@P[8#7<^)7_?KHE=@&A(\,V9]A-%OJM/DCAB)!Y
M_@Q!2F6C,7E7FNFYS/P?Y@E6%W1*X6<?FG3TF.UP?*-X5(R=-T6\N9K.FE<D
MGY.,*Q*M8<Q<8U<3RX/-B8".EW/SQ.2.0J8S^8)-X>/0<)*Q5 ;)L%=D-M8C
M1]4Z$3X2?\BC)8?7$\VE 1ML1]BV-P^CT%6LIR:A*^:6BU<^.R%\HFZ[T/G5
M#+U\BKJ,BF:'*'VC.<'@L64$LI"@8C6-^(*%KZ!,RWBSB:JP"YHREA>;@2Z&
M)5*3%<C*G'=S\6YK,*,<50RW8F04&#GV]SBXAZ-[VO!>/K[PP(@9># %3\[!
MDY,X2#&YIXG4 T@BT4.P\EMC ;U.0M&/M%$$*O9@Q%)3NHP^4GMMO$/DM2KB
MNB11LDHPF)Q,D/)63 (]*!LY7;$89U5HQ3B>/M#Q^6_#Z-%D3OTTH%CQ<H&7
MKICG(V%^PG^AJSL2$AF7F[O#MB(%_8<UBDC%XMPJ(ME$9/7+8BH>S@7/"ZQ-
M44Q'\PH>I4AC9Z8_DMDLHC/4$R4@E:H;NEM9VG!PDT1]K#%/MTE4H;'F$_+4
MC/(ZJD?!6DO-R#]O3%YXFBS(/W@T2>,$KO (31X3$:F)20;=$BRZTS6*0\4:
MK0WBB5$\,8R7CR,>)7(DD2=QD"P>T9F,U\HOXLV5C(XTC:RMF*/5 )XVPE&O
M:.>J#K,L(MA>5JH1[ (=#WX04;(AMWN-992"BK6T7@K6L)MEM-[+*F^-F[Z$
M?X^3. J)9%RN_ZF_/=$X#3J^)KN3-;*^8@EM8+VF-68MU%!'!J]QHEP<2UGN
MSE7Y^CP/2]KGH'LRIXH:7L_RU^?X!S0PBM_D-IR!9D)Z5B:D2V&^N>MAKW)Z
M"4;!K5A3S8*[5K4LLZEFZ])RY)3Q% UE:"++%B=../4WN3YA7Y6_+2QM@Y*E
M[3FWM,EU>G>':VEKD[G!!#Y/S#*_#UQH,P8O!PG>^RC"M)(5 CSB58>?<JFN
MO0[2E=^66]LI>YFU<7-43<3&S:$M1+JXLJ4H^.1OO6PUWPJ837G=YROJN0DT
M[>&X'TH*GJY(:3HW#S/-#S[X/<\\H3U0PG<TME$V*[9KH[)9TBGU]P?\7Z&(
MH@ B9F;F@3UHU&]5?5GY?&"WQE,J4XMDD:NN^4K6](SLK\'/SDI%:]3_MX?T
M98B;&N$@.7G+X@1]BNH3 4>6)&18(WD2I#ZF]L&9&D_@8.934&YB'C!?3-D7
MD8)G)V<?M6(L>>EQ104^+W1GD:S1O9+A%M*!W-4PX<)$C;)7L93CK*7C-)/!
M?.)>-G-,7\.+2TP>&Y>F[\GY_^N_G/YX\N^XBO5J,D4=](PP"K58C:J-OLI"
M2O(%'45]6Q*TJ\>3*Y,UB?RGBBG_*XK\\4UD(_>7K_B!XO0EIO],X<>$7] )
M7;S0Z.,I?MU.<FE+S"@W%9N_I.P5I-&EDQ'W/IY^ZPE1^'^<@__Q_7O\,UDN
M45?%W\A_AR&7<Q>_@M_00&4^ W_C</7WXDL^3#4%]F&]*A1,AHJ\C6\\\A(G
M$9DD?_DFB5+ZC1>2!=7=1M:$0A8$Z(++"+V_1 '[&5YRC/NXL+]\ _M94/E&
M<#=AB:B?<QWQ=/F7;V1SS"_XQDM$<_D;F!V:@.#W2.2;[YN6/A(2^DCBA*;1
M.>,!GR&@,/_N-O'OA/ TK=6FY]87YR?1!_PI/OW9YPO"0HL5ILMEP&@4&Y:S
MWLR%N<OC5\/)NU%7P$V81TR+AU3[VCJ3<6'M&)X;^O#:N! =&K?<>C,7YGZ?
MXG=\F)[3('BC!'-(QE@^,_Y" U]?R11^ER_%T&M')P4&G,UH9'M47/&(LEGX
M2**$H1XAP@S.O_OU.YO3PMC9!>:=DYA-+DD4(C +UCM]I)&(X1QHH7MC_O 6
MPFGQ,(7%0.]&IO:DMLL/L50SL&7Y;Z@N1WQY ^HQWBO4=)0:>KG 9#E'F!LC
MMVP!Q*QNN[KV+JQ&&=7D.5^@9&811XW":>QG7AS";Q*46/DG!6/UEV]D>$FG
MDVC!0]!.HY5YO0),:1#Z P6E]%@@*0W>6:-Z9NRV!5[ZR<\^6\B26#>]U3)=
MD;R@+\GYZHY@=FFR&LARO0_3)^K3Q1)'OWQ?PD<G"8]68W&:T/?D/."3WQOY
MOBWRNY3])!O&8C,O*:HPL*J\O"2<LA-\LLQ@*>*P&Y(E2[0VM/D>[DNNPV;I
M<63C^.9/(0N)9P!.F%HR$'JM#U?O->?^&\RQ<>%VG7=\-=FML_!O2 V6WE(2
M4PE_AY.+8;0X;E:U++OW/_]\^K*SXR^WX=P)K&/JPT'FIY,DOJ;A'ZL%;;_*
M;'N[<+%E*K'8<_%-'*?4/U]=OH.8L GLQ4LRF3\LY1P,6K4-B5T]QN70G4[]
M9ESC\?J5WF2!,)+8SG4W7^&N35_H=JX[S2QY$XY@5 8Z5R0+RFYPS?4AZ\CU
MIB]C2.(Y:##X']3:7DE "TCU'I^E$SU'OH<ZIQYYL()UA+"TT6#4?N:U=G'A
MH,NBG&"3OJC*?L@35=0/U ^XL41UC2F-<*Y82AM!D4*IKSVQV;SE#;H5XCM3
M;SH\2(M[6RL7IM(?QKQFG3$(]YACMR+'[B9+L;-0#[8SC*//J)L0R!-$SY+_
M'<-[/9W-AW,L?@#'9,-Z!A%#!]%5Q!<7+#M5&[_E=@?ILE>_YJ>\(^]LD2XP
M].JT_2BJ:^G""71!7VG 1;087 MTP4#S7Y"7I\OK^[//IR?MB[+L[,(ZI:[W
M*T@4UB@60S?*;FW;'2F)62<+66-A)D%G!EFK:>D$#]($]"_Z'*(A37C%#";%
ME@XNK ?FA<Z^F\62L C_,LY%1ID-&D7,IJL3+VY=:RR':L..SPYS!<Y8CK/M
MH99N-H C>FI^EZEI7X)6A8K$0*V_2=C-_?;M-)8&LF0U!*7-8#>O:^K$EAU=
M\U<:A?C+]B74M71A!7=D,@<]-%H-M-!UH_+1UL>%54E'R^#<QAU3M')AY@HJ
M'[YLCI_?OHB6#BZLQ\J8Z*#-L&0"P_-S/1:^4QB/B<*>C^(GZJ<3ZLNR, \E
M](IA0-@";9U7,$7J@Q+(X"*93IN?O?V(.?JX72O48Q#C^L8NB+,LY"Y"D1EJ
M0.5,4H/:;-77A57J#K9!"E+!HR>Z2$,J![[B$6K]*5IIQ9^;?5B="3FG76N1
M@P.$;[A#](9A!MZ UEJQ;YY8_'O?B,0.=/>M:XJ;?D1F ?O].4K#  96$1@C
MAOXK9J,IV/1W8AO R2BO& DE"#*,_QI2AL:Q9J$W='/3C9EYYBXPVA?N%AK"
M#PFNI<4RV]9GWQ%R=R2:S,].3G^ZO!O?WXQN[J^>3DY./WXZ^>GSIT\FQ=RB
MJPL26GZE+RC!'Z7=[YXF9;9DQO.5D,;SE4JHZ64/V,I(CA@&8/I2QXH'\1-=
M\BC!4-SQG.KNVN8M8-?;S3V?)_%G2?LF8TA+AWW?3 DP6UJ(Q?ECN(<:6KNP
MI^]@-)J^#TE(?/*%!R(B[OEV*']A.+BL^KJPRL:XE\%+L K?>P;-E#N[L,[,
MT98YWFY"PW$IGP/*V28JI&/4^376/+@5Y0X>, 80^0S'P\#_1ZKB*)I/[J\W
M@PW\@;L\YN" CA+V1V:]AH=TFM!HQ*?)&X9^A[YXF0G'>@S*6I@%29/@(5(G
M'D8IW&-4IL$"LY.A7)!CD!EI]E=F\)(%)EM7U4W?=F_VH^>HC%7K'3W15WC(
M47]0KGO48N^QIN#H-_B%^ N,'\ASLV]OA^W;I:V'"U(/6Q(F\862()E/8 /_
MPN$(A8/48.@Q]')A9=G3;;W"NO&M5^VP[5"DCN^\]?!Y.%F:(NG.5T@JBZH/
MMQFTO^51'7D;C<D[1_>GTJ]N\QI+XHGS;(CSL^WMPGYH"(P"MEZ^3\1%5528
MB!MBSKH&MNUT3%=CLZYX](;U0<35/ED)/**;\*]D26!U]&\FWX!U=Q>$*M-P
MLMF*L,Y 9:%_H?X,=&DTGY3"H55:9JX--LO/MLB[*BJ53#B;Q.J:YBZ(0C7)
M*]NK(K.GFN@%>[M(!-M&4MF6QG/D9GJ(V(PM%N<,;IC)/$3 @]7UXN6+03,S
M]')!4DI0#MV 'QP#>]!E4(-,Q,1J'>Q1CWXY7U5,C)O)_D[&=60/7-!X$K&E
MM#4HT" ,5N0!FZS@G,='Y,-47)':8EH,1?W(.?(UK@B+U*D&VF61-0$_8;1J
M-H.&Q5OV=M.._U\IG&?^91KQ"QIB(2U,C1C1D/'HG(>^X=ZT[>W"D9(EOL+3
MX@+C8Q*,.S7$C;?VV7O\>/:NOB5O,>@O\5,:(+(26O);O$ZMG?;\(!?.%4SJ
MRT^3W-$RHL;@']O>+DACRUS'&ZQS[-8JUYZGZ - T[9X=,)]D&5OKM 5*LRW
M1E=$!TJNODV*R"8Q?XDZ,.;:-5*$@5B$1]D0<0/1@+\R1-.(02'( V6+V%FA
M'3Q1>$6TO%N[$7$THO&_4A*P*:/^6O"+!!NQ\$%W(.#$*5!Z4&)&,@8ZE&/8
M1-[H.6QP7V6S=HJ(ZT-USU$')202S)+Q$4T+EY)GX E/SE4:^BT8)UW).!$D
M>1UPV&D@KIA0<D71OXQV*/]\E:/ -1\!=IU=/?QU4\KHC2P1HDEAT+ _J/\\
MNA@]7#U) !-Z>O*Q_2#H2\V%4V&T"I,YC]Z-/K&:AB[,'X[95_9>>"80EH.'
M;\)U=Q,.T#</7#!$W70DXL*ZLP?$S6*12C/80P3G;D 6\N =DV@&2L<SG#?P
M[L?Y*@?M8!91VIIBO@W2#KD4KU(,Q<@N9WD!;6B3ZDK2$0.+OH26UXOD[&]S
MEB'YQ+_!\28A?F(5'/DW2J(>'VX'HSKR;:4Y0N$B/=%E&DWFH/& ICR+R*)-
M<6CMMG?KACP:;8Y/ETY'/8H+WB-%.OA#I6R1B%,:STEHQ'/;C*BC(3^5F(;!
M%)29P@>GP1RW"T$/0BY(BJS1ZP]E<-_UXX/:>H;5&KNYL#;\*P8I9M=R&YAG
M?5MG$#PS3SD:N>&#@TJ-BD<T HTT&=-HH:O@!M;U(N4".Y6G$&-Q$AY?$7AB
M3RB,,N'QK2FNW*ZO"ZL4VN4U#8T/DIJ&+LQ??NG+V6J9C :7-EQ9;^O.*@98
M!H/%=W 1K6)&1A?WYU\NK* $VCJZL+[!QT\GYQ=1.GN,V 1]I/+XEG%MUC@Z
M7:FXL/([LOIX=G)F@CI::^7"S#M%VVW%SKW#$5VUC*'U#NUX8_(N$/I JL>\
M%-E>K-,$8M:=D@MB-@B6$0],;Y[U5B[,/#/<#"9(&806U!KX_J!]G1/DA-'B
MT]S1(7M.C9=!X8J44E!ZA=GUHNR(!4+=O(:0[O56+LAMZ>04W_N6PV$!NK@R
ML1E.&OO^+JRV@+_"2P'U [LGI[F?"ZO3/6'23*KYP##K,(RI](*=KP2KT%'6
M'-+6EYP3#K8&]:&<?=\Q[6XCFJXJ'0\@V7Y:*1@@3$K-:**MG=R,\QO-642_
MI L2PL.5PO,;'@H160HT(9/_S::K"R= EN>2Q^/*:GU&..U*>U>E53UN'^=H
M11D-KB(<TZ MMG5Q@6FZ&@0*NTP3'[R".H0SP]AA4 174YF[TRDHI NU/0>#
M#!9I:-3[2VV<8-U&\ "9]_(FA%\O!=C1B":)'",6>*,8XB1,&JA1Q2*\&AUV
MAE%V!&>PP_DZZJ$I5URQ*GFH-]W-RZU7#9;U!(T<EEANSCY/MLXT'7FLZ6LH
MGB\9;(*FM'7['+:D'/D*HDR4+U_5CV9P[Z;F+L35ENS>(YXF\\$T8A/RF*PL
M4\!,?5VX:PR1;I<Q_%G%N9W\9# Q]Z/EQ%<0@5$/H*9B<%1]")1A[1THN+#B
M)[XB 9XAIA*8U8:.1G^7]MQU&DRO_MO*65??PP4>22@6&[@6EV8M(L)$;+B.
MCZS!N\5Y"!@ZV3#M2V@WS>4F>Q-THTAP#M."$-%$&+EX;&&[K[3?L\D^,\$^
M1G1)F*]L=<V&K<;V;EIRU#F0OA@ADNI:NK#SGI?3B(=Y^"J\RD%[_ >\J-HB
M>YOYUY><JU:>#)-#@Z/('QN& ".+GBX(@+S0'E8VUU[1RH69ZT\>>-;G#WG-
M**!G865OH4<>)Y>+9<"%B&:^H?/5-44_RG(.*G?P1&<,0]P[OT2_RCP<>;<-
M;L?/O][<W#P83K[U9@[*CHC*.%\I\P'&<FI,&$24]!.%SF0=X:Q6U38OT)B5
MV.MTLC=C'FUO!%>OC@(35(B!Z1E<V]B%K9*IE@@B(2H]QQC=#6W,VFA=EWWC
MR8OOBYBM"7OA/KQ1KU@4)X/)G-%7BS>[=7<76'<K]PN/5@70XY L7B+FS^@=
MB6,RF:<Q34RA%=WIN+#Z"WA"_,[".MS">Q[A%1S>1'#XA ;#7'<Z+JQ><_]/
MF+$49'UC%]:Q=J5*M_ @D3 +XOIL*A'<R4'9F_2>O95BWLJ$FEVD4JNDH'HH
MI1(3',(W%B*._,,TBTIM W7N3]/5Z_B.A.F4J)A3C)U*E\O \.II[^/"[KCE
MX1^&I(]2$Q?F?$'#V2OH>J0>4/9Q#C?,<HG1(*9SN2L=%U:?%:7Y7"Y*\_'L
MT\=/AH+05EU=6&-C88=SAN&+: WI61FB2L"%]6ZUKGW3BVF;8SCJCL&8M@B8
M#H^%B7G_-[5V02)*V)6E8A+U1200UQ6U#Q'1FX'C],')W-98CE@B&@^")_I'
M&@&)GN?(>G<79&80QWS"5)[07SF\:'^%/P-;3?EGQGXNK"ZS"3Q2O@RHK3]K
MK?6>O5EHOZ4)IGNKH/N'%[1/H6U?#U%_DO"4J(>,)GQ)3X$O9]<1I>&<PS/Y
MFL 6/#OY>-):>G"KX^Q. +K$P<OKQQ (O-[,U??$B"X3L;U (?NAI)"=_?3C
M3R<?/QOL2+;=7=B["L50^*[7W><@>^O ;H,HPJS(5@/P)B1=%0EKK'X!BC$F
M[XU?IP<E5S_*S?4=*.WQ1)09,R<X-#9W81]<L "A/2])%&)%/HQHSP)'RF:C
MAS=031&HG$1MFZ W/3>"5 KL&YPYQMS.0KE_X=J:LN0APM\;47%D?2P2R *<
MS1?#;D9S--Z[FI$JW2FQ\*?XFU:2Z$+0D:> >,FB,0YXEWG_X#Q$3XS2DA;4
M'](@N* DF<.O$LK"TQ8/9#]R+H09-X31/-%9&@@6WK$ +@T0-G5]MGR%SI1<
MO6C62@H]*A U.!^&<R:J"J4D?*+A@H4OAOKFO4BY<$&5RHC<_WK;H>B(UMJ%
ME3Q,IWKIY5*\@(@&][7P&CC;X($(<@W;=$*I'Q?IH%C'K;X*Q$-XP7+5JCF_
M]&O/P\U QW4L\^2")/#S=41:#I?V3JZ>(W)7C)ZL-H_6S(5=\QS^4U0!P5)1
M(SK!(E!&WV]['Q=65<(.Q4BZA+UBPEY(@E7,XH<P!WK@4<3?4)6&[59>#VB#
MZ0*]>*=9QJ%HDB4?EN#>^D":[F%:CNAE^F?8AG="UT0[\6!W@SORI94*EB\.
MWHBP?P36P_2:DV;,4G-'5P]CZ;98+ZG<?%LW-'?TD5=*)@)= 28/__\R4>@F
M2ZMXM XD7#O,FY6K3K$[5F3V'*>#DT+S)@D>"0R:8P0^CP:&/ )S1Q?8JM]4
MI=J= H_&'R2Y,FBT_-N0<%-+KKEM'G,L;S9I7KJYHYL+UA/J?F/)_)X+DR:P
M[7(ZA2=1>WY>:\?](A;\E;X";4-DU5HC%[:A*@(H2NAJG@.KRH%-G5Q8%[Z8
M><!\::?R_Y'F+A%8SPP'NB/1#"B%N(!06*X,QVIO@BY\#P0X8QC9(% OA% +
M-!U\2K2;T2UZ.AH=I+N^I<E?>@]!D4_QZECBR@0"Z[2EYF)'*DY R*DT6/3X
M:ZHMXG2^EI\[C85QQ9LGD^0V9+E=#.6H]BT>"]>PW6(%317Z10AI^Q.CN9>S
M#ZDEA8E]$<6,)B#O$GQL9 (*-79SX3#4N(&E)R0&(D@MFEJT@A/G=,HCVN9V
M[T[(57;K5[JM(;"]CPN,'BPC%B @>2E@YM/)R4^_C'XT!,G9='5AC4]TAG&M
M\ "8%_490$B-D1,6'5U8WQT+198G[()30[A[34L75G 31?253W :V2--,SE<
MPQNF^?:PZNOP6Z^^:M?(A)=HU]<%YJY?>(\<$_M&R_]^,*2Y6W1T87TVE5HU
MY6T[^.DFJH[8UY45=0B:[4@&H#WA6D+J:ZX%*Y@7.Q(NR,/XC8\Q6AAD]8JG
M44)I.( &/O(OLP18PIGU(N7"-Q!/'3;!0BWB/6RZ9^M;N["27\G$(G%FO94+
M,Q?/*N&4BU3DGD7&<FU[%U8SBI=#;D9\7&OEPLQU\\@@A0<*C^#-OTA#%:UR
MQ:,1C5[9A!:AE:+=P_2*A:"%((1%EEC44CM^R\,X8:;) WPPAWX0L5BA%0]I
MA'= 9N27X3[,(K-G X(NR)+)EC2.2!CG2D)6QT*42.]MGVJEZ:@AJ@5@8K2$
M+]T;GJ+4VP6)R-.Z8!S<N&@H].DB9-/FXA^M??:<$":0QDD ZJ^,U@?29?1M
MV,&OL%E;,MVZD-BO3^SR?4+%LPV.7@1"$'\% 8?CA_F@YVDQ^8-87T]LG1"Q
MS2$<W>R:KPDKQ-%EA/P7KZ30E^F[$JQ4G72E&L,R\T$F,&!I=OWWPIU1;Y(7
M>;\/T^=8J4I(LYPGT5SNV-'I.LI=&8Y3H!1\X8$O4GM,^* 6'9TZP -HGK#I
M-/YMSJ_PN7_/$]36QGRP7-*66+0.%/9\N \P.00AV71OCZ:$B=*/F)27*:0B
MF%/&-!C*3, Y%Z3(W^;<[>8=N>=IN>KR*-V:$G4.0_-G)/)!IC),>15E"]HC
M/"^H#V=:CFQD5U"C'^5=19]97MU%/JT.AZTEU9ZOJBFWF (C_N=7?%V$LT<Q
MVV9%9IMC[.A[99ULXMDP_;Q4=.8AA>TRP4#O<-96F:V]GZO;!XN&H.V2AW )
MF2LM5IJZ<#L-TP6FK<%S6*L/*-Y^P):TM?BI35<W_3+KCH<O:0@GTZJ(&_WE
M:MS-==%&P04V/X3T'*:!\H<)K'=$&@'N02HEHL+91\."[0FXL%X9$AFK*K1P
MA^/)HAVL,6A.5VDP92*783RG-X/1Q[-A!,."GH#54$'+DKVTE*Q</Q YH E"
M*36_R[[>#-S<9*+H4+ME2F_BZ.MDR$.T9,J1GUC\^W@.ZL,<GAJ/YKI+=IV=
M,,3JUN7F@_V)LL5+&K7!$'4GY,3Z,:*:IXD$O0*^@=; 3$5AVONX< PV@P)R
M.L?SFXK_">; #@SO3>'V*BZUOH"#76B[\)6D&6S.E@60$@9>,)\1S.87(37*
MN&!0Z'M0VKO:WFA3$B@A$QJ;BXA;]G>!UZ!^#Y*(I8OV156:N3#WM9A*DX^C
MMK$+Z]#-+#01Y3;''(N17] IQ7>#_AI&L3) 3_0EY\*WN*;A'_"NOP[X"Q8R
MB()S0B(\/8* "J25;'N=8QCQW COV8>8"]\A,Q@]A#,.I^,M>8M3UJ(Z-K;?
MLP54#^M"^SX&O8S90B!^9V4Z1&T.5=^FM;2-*'[3(YYL-P,[$G*F+U0A_(XC
MXNOU['M\,DM*#GZ#)F9K("O/X33%H#)KUF^&E?659^0(3X9SDD"CZW.EX!GB
M5!I:NW 6Y^Z2P@WR,+WC$9KL$_GY#2&=]@1<6&\)$ !>,]R0-M#<WH75_$;1
M%TS] ;I%9S2#"!5)T67TT"&:3X*@-R#I#D9R Z7QCOIL0I@A%G&]E0O,5SYQ
M&LR,3YS:IBZLX9XFCQ%-R'M^C*#'UL+1JB)=_J#^!8O@F@E6-Z',S6JKV[+]
ML5SU5Y7T'7@30<>PL%#S4.E \AG51X?J2M.1F_N>OEG&Z]>U=&'+Z%RX!CF&
MYPU5RJL-&DRERQ;6Y"<_SU=H?DU?Q(G;#P/F&7:%"-S%0-4'N&>DLWA,WL<1
M)39(#5THN,;*6SH#'2KT!]$+@Z4%"B-1!#EU0?NQH[-GN)\2/%'CZ6$%;M32
MVQG)SLN/YR7DA,5.80O?-.=#FCLZ9 )ISFQ3F[##*65/RQDFCWF"21<Y<(]X
MRAI2PMJZN'! B;FU8S/I378+_FRIT+<%_+^QY \:;533LH:&"YS*3@J5O';!
M8PP5/:<B3IQ9E))I[KCODK09]&>&^SF> ^'9/(_D%,5=4"/5((NDA2GBKPQ-
M3LVFY:W0=O4-( &+8GA[X^P0O7T"KY:821O-^J79'%';D8RC^$BC.3S>&D"F
MM0#A\9R6UB<RIC#\QACWM\4!7#A1AB2>XROWE01";X8/O9+N_[L4_4OH=6NI
MQV?7V\UPIFW#YG93X+<[X)XU_5J'[1VER<-+H.Y4Z:IJ<N :5*CMT7=ASY6L
MS5J%5B.ZC45'%]:GY6042&F(?8] ".)Y#G<):O[BYX=H1),D:#=,;T+2T3C$
MM2"SP3MK/#AJFV[G2>2SA738;? D$MG&Z(;60 4)IJ>R28:RT,A8N\XNU)NI
M.9TSK1K.YVP=.,M".Q QOB*33[[E']7[I@L&[@:#[-EL(%3H<Q+^7F#_MR,*
MKK=U5<<4QW"I+OIC0LU(%Z9N+IS=S55__DJ61)3]H:;HK2XD7%CSF+PCW+:,
M[T=0A2Q9=TP72QZ)U&OX&ZZ&/H0:.'#SJ=:?H@M52BM19QV#U%QB;EX?-H,2
M.%\IWS7)7F8"X5+FY36SM#.=/6<[5B%^2PFR>5I344:S UJPF903*0#-)]'S
MZ +3;:+G$28_]3W/ZJFX(/4E)VYFYMK&F[./$WF7XSOB<);X3/#T9!+<SP*W
MJZ:U:Y+S,)V.9,*:EJ>6PU%H[+1WY'6DZ(S?1[JD<M!C@<:1W]J#R43@IHM\
M=Q$R<D>3.?=M5(7-";MJF+X;/:H7'%IC2&@H1M#8W(5=,9C-(CJ#(TN%MQ9V
MIYOPBKQB;J?"(QOR"#4\K/$W91-0^S 2=BK7$H.6,,>HNHFH\B%!;Q/:_!S<
M];".FD;T(CBC-[)$KT2&,/$']2_C! M<B<J3'S\9TIS[T7)!YKYP.IG'R?7B
MY4O[$FL:NC!_]=ZU>1,[-&L%L @;I@9C4?Q>8FNI0PK/ZR2^0LUPGB<&MM66
MV!I]1_<NNH2N OX6X]O@6:C)Z^[7F\R76*H)*92B_)MHB6ZMWJ=M#^7H5Q4Q
M) I=#'0!=1W$K5D6M1&M>IGX9O/%;D9S]-O*]PE>J!DH0YA)UA?JP\OEGN*&
M)>\/80^DJBU1=U7)4R@6>FH 2,R4 LV^20B;D'3U,Y7QRO"IHPJLE)'(A*O2
M$O3,1,353_%((Q'M)RI58HT &/0A-$$3M'=R0G$($_;"?3,Z?J6="[/7 &9Q
M3PE+9WP3PEN<!,%*0!/:@-,V]]UW""O-:FFVFAU@N#A6H5 2KN<FQ$=XY*/H
M(3R( /5IMGMM>1@W(V<&W]UCKB/NQW#(Z'?F)TI;#Q?$7[=1K=?HL+%K5?LX
M8[DJ5.'LOP8 S!)NW\!?L! QAL54!=(/FF<Q-/N1,/]"N#'QT=(.H_)U)^&H
MHCE0P$)"P3'LE[JF+FR4.Q:F\?@-?@4'^RLJ8BQ^1%75<.N9^[FPNL;CVQ1(
M;NCFPMJRATCFQ\HB4C'$9!L/G-YTG554\^#O[.&;A4"'?A$/;>L%Z4O-F7MD
M$ 0TFAF,^&N-7)#[+"N:_0,#;LIE 6WJT]AV=V&MF3=5"SV/=>_]KSS1G:FB
M61L@;&]ZN]'VEZE5:M!ZXJ"*2\")RKRR+EF']9W=V958TO/CR=G)F:&09$U#
M%R16H)Z^<)4_D65B%^4@#86\;;L[&DF(AAQ1!R(LZD)81R39=7;U=LV37MDK
M"X8!80M8R#5O@Q5OZ[)G\T)Q*!8OG-SBJUWJ%C%6)@(NQ$++LS#W6]WRB9"@
MT[8@]O8^SD2S_\:!DD0U?8AF)&1_B%$-N+'MG5PX:+$D XDF\P&B*.;0O:"5
M_@-!K?$Y32?SD =\AKB?"5I;S34@>U-TX8OD>32HT]VR!?H7K J;UO9P844-
M>:X5EXGP$&"R )[SJHJ<5LP36*<J42#R&Q,_K;?IFFN[FSFX>KDIWZF(<D33
M%!_->92,:;00 .G2=_,FSG9I*+CBT6]S-IDK)RI.YO*=2J"U+R0^IS1\;L/H
MWMV CMK2=#U=%<D4=L&':<6PB)':J 7V0C[L3=NEP-18S)%&2Q(EA@=\<WL7
M#KC!'PF=D%_)) U)/!I<T.&OAA.[N8,+Z]$EK3 "%::B'@)K0\81V=2GK5L8
M6JKB9;:SM5)X>+X-212M$.%-//FD2T;%R-ZTV!_/5_D+?T1GV+S'1W=X]H[P
M&I^HF J568OUL,R'\%'$/LL70K-FT8&$JXK!F@ICD?K>UL.U(ZS.8*8TD[@3
M.H(EH3VC'F3VB"NR@-<YS6LX#@H#A=&6T=IWW[4?$ZQ&B75HY:ED<EG6MW9!
M2'6;]56*)Z?V8LT"'05\->IS(O#6*AO.FI83Z7 WBT4:<@Z["=_D@R!@>.(9
MPN=;^[C 6X3\"'V\:5N,3VN-G+$VU3^+!VH-S1A$[;WV?"[6I5R<_/!GE66A
M)U_PD)'NZ1MF6B[(I2H.-"(!!9T0H_Y +YQ%9+&@_I &P04ER1Q^E5 6GMZ$
MXS<:O-(['L(OY3SY.1U,YHS*.JIW<#O$"2@:BN6-Y]/.Q_T?8!%0>7-Q4??!
MVNG7V-49EY\^6SW /H\K@$LGHG,\FEZIU)U@68U/B![/G1V,ZL@S99B"K"]H
MA&7]##=C;5,7#IZ;,!2E:<\9WMEL8GA@-#9W82WPJKO2RXIH>%_-"EI;'S<#
M:O/*>YF"%;<I,TVMG=%JLE"P(BX.A J]TO"^27*O9DL98KON;O*R%!:<.^95
MJL:TUO[3XPCN2=F98U;#$C4=LS5-73B:2O618(0% EKD,?VJ[#V:TD/8-2]B
M^%B!UO5E^C:&<44">)P@ /A+<D_;PGM*K1S5/#556R;VC.<L\I4.C2U-$8:6
MW5V0>F7@&((4SD2Z0]M%U=#8F7M*H)IC5O4D8K*F50[0?HEX>@:^6?9V@6WK
MU>T%[=%@9' &&GJYL+(\L?N.O..[]R(B;SY_:ZZVT-S!5:=!"6,ZPX"$ =4"
MC"&25KT=/5MO0KCZ<)A''K"),;FRL;D+HEJ"[QVD.'_0WQ^3E640>GM/YU9X
M08?PHER\,#(:=%A>73<7UO8<IC'UE<51*MU9$,T]SW"G$<%)IJ^)L)JVD)W>
M]-Q\]A1Q!Z5G6VOMK;8N+K <X\BY+^)N#8^4:D,GYJ\+EX@P.">3WPVIFNV=
M=N1:L"]NKW3*<JF%+#2@%(<1:DFYIL"YSN0<O2[7"C(4V)R/9%D6W[8Z#I5N
M;AXY:V;[=)$*4,DF<_1F)9 W&\"15_<=^0>WAZEL:NW"T5;6B((9#&ZPU[?U
M<&%%%[1X2&9>*$PY1$5V!9I!;OA\@G["&BH3?AIJT6@Y(YI<2FH6DK^7R3BR
M2TJN+AK%/ QI("* 9<&Z7BXS&SJ.K+_0RT3P69J!U6?QI+9:77MO%_:<GCBG
M0C$-H1=M/1P)1[L)??;*_)0$0PS]EZ50S.@]3=WV71CN F=%0U]YY*F/2II$
MAU;5VJA_":<.'B[#@,0QFS+J#^(\?! !B5[;L^^V.H:CJF&Y^E2(P-S":'5%
M)@)VI6/YJE8">]X):_JKBG^Y":\B<\";75\7#J]2-MH7'LCJOR93DJF7$RM#
MC%0>Q?<PXS;_0K6=,ZZ%W%4G0T0S:#X90R5KE:GP!!U5DZZC:K8# FYW$#<?
M>;78*+8:2$T7%^2[)J;?#.!@Z.3"NFIPD*R99M?7A54.X?//Z L!53K$P&NS
MH;.MAPLK>B(+AO @0WB8^43".!;5D UB:=77A55>PV6'=5IJRCV/Y_39X NU
M[>W"2K-*8W@IW#S:524KMW5A%7",W]R?/_W?TY/3#(=HM,1*!]\9CW]#/Q=6
M-Z01Q:I9AI-CK94+,V_(\!?ZQ1V7(2MQ0UV?AJH^7=$$-AO+53__'=#&, N#
M57:ME0LBL1XH<I.08#5ZNNT67K+>RX659=81B3CQ1)=9]2^C/:6FQYY+PHUH
MR'AD+GA6;><")_*H9XF,2K.;.#ZGJRF/DM2@A-GW=V*UZ['K1=KAF#< Y[:D
M+/8AY@+0E-1.B'+:7)Y?VB@S-<U=8.F8+Y^7:U#]DC'XEFM?F%U?%U99A+':
M)9@VMW=A-3GD'"9D$Y'?R^$H_VW.$:3=C\@;]4']M\OUMB.RYZ3O CNQ*-)8
MC_1URR8B=")#78PSOWC6OR4D<8MCN&FV^F\8D$ST5Z)\(+=O!E,OE[;$.")H
M.[X@J_@QHA.*_Q!I!\MEQ%])8-P.9@)[#S;2<_WAYR5-L 8CD']+YIB1? YR
M^@9;]TFD.&)YEB!8(6[6;SP-X &2#$D:TW*NCEV9W:T-Y@3R0$DG5C5]5/7D
MWF6"-J*Y*\FB$SCA PN+&U_!JV>EHL\*SC>7GV[LX 2#&Y7KX1SK?BQZJN9K
MO5TX_M8?K<^_6$%'&KNYL#:I/O_RBXV27;1R8>9=0X_=CCN67_B1Q E-HR]T
M23#R(#Y7Y7%MN&/JZ\(J!3*E'ADVG5*,NL4X Q5OUG@<6O5U4S,LEPT25<V0
M_N"%IPG<[BJU<Y#(=$X1(=94#'VSB-;=#>Y('-MS&%$)#B,*YF75\D9TDD;*
MJUC)*M<-S#4AOF.XD'Z#U9W3)SK) X'&7")BJ))\127,FU!6[6Y) G%GBH[&
M+0GQBZA-KGAM4Q>.NBQ0Y8DNTE#%Q%[Q2/Q:O8 5T"PZ,= :>4NQ7!JZ,6 S
MPG837;(V[<6%MSF.JS*A='_I!R)A.B489@H+N0E?>?"*8@WR/J'B4=G\O3K3
MV7LP)%SHO\,]7N.%OH:3)#F'4P,DTA1JT8F("QM(O[<0#D"KV8P8XM37;Z-.
MMV ':HY<:[DY40!/PQT!YWZ0^D)6"YNP6>B-_??]2,XF*I2]P@0X8K/0PO_6
MT&O?._@Y9*AV2;C:3%T5)IT6):&YBQ.O_]&<!M,G.LM+-.95/E3XK.')8MO=
MA9/H.B41/!DHS6/%#7%#C>U=6(U\+0[G;&&7/E5NZ<(*\*RBR1 C(J6P/+Q@
M_1%\TNL&U2>*5YVXXT83OJ0?X::CX9RG,;TF\?GJ[.3C2;-E=IMC[.ZCV6]8
MT G?2.1G0%N/68C"3?@\NL"26M%:&'R[;/0FYX( U9<0&X1A2H)[F@ATGC'&
M;W:M0E9/PM%*9%8E!&PR0UHZ.X.@64%<@O<V#S= ;&KL[X* EVT^&F9^!JS%
MIYC_+8H0Z&G@'8I?=R;JC"CD\+;8++X0G[2YAG%=6Q=8+-$9SBFHB?26I.%D
M?@&\D'6Q!:)(<?YF,/JZ^ ZY<KE37R2-K'O=!Q$5[K1FI?OK36#O/N&[%<>(
MW(?H-ETP<P1O8W,7Y ;>$V@-%"@?4WF)QP\2.! V^)+'P.-&GMMU=M,(7P(#
M^ 6$EEB7 F[LY )#<R/QPW3T>#>Z:,C'-ZASW8BXL.Z2U^LRQ0(\'=QDY0XN
MK ?>62%GX:-P3U(+V6SIX,)ZM#)S"E8G$E[^97V=I,+98<J)VY"L"]^F#!-1
M2=>\7$_75!=H+Q"*WM0=L7W*8RF$E[:J52A5CL*/KYERVT6G#R47I*53?4VX
MHJ5G'+2M\9Q>OJ,*%N.YCMBE*FAJ.Z4\+8=R-?<&;S9@=E1$Z*AZ:B:T $,W
M%T1&/P*TN[U6U'N<*EU).G*4P.D7(U!Z46_[CD=83":1\0PWX=\HB5K"-6W[
M[_W%4CCX9'P';-OUIWTYN*:I_?\ VY5P=5]1FM<ER7S9]@5@#!2<,5UD1RSH
M?!/ZA+&M%E5+#)U<.*[6KQWA@E>6Q#Q= .;/(VEU$-8XZTO,DIJK]U2SJ?U+
M&LY(Q @&?##3O=69C!." 9-]Y1.<1C;A4B:)=*\U2X)E=T=/N3Q695DN^!J?
MFL-;:KKLVP]^Q\(T!F'SX9N!,LGB1RP/94*D;._D@I"NQY:<K[)--DB4EK3^
MYL#@JVE"HVTI9+L8UA&EK1X$YV,?Y)R/KDJ-93'I:NGGN!.$VU:&V3/06^D9
MDL$&R3!87(/R-&P6)MV+KB/;9?0&%U(\?XB6<Q*>,]![<'\/S@VV44,O%S;,
M'5F=_6#>^I5F+LQ=O"J*N*!K.'D-%OFV'BZLZ XS=^$SGUS>C>]O1C?W5T\G
M)Z<??SCYX?3TS,0ABZXNK%&\F-[@O1")B)X)QP/3C#G1TL>%596JP&#IUR?*
M%B]I%(OBKUGQM5 A#%Z&KRSB(5+(';G-A6BW0-I-[Z%^/;14@7I($YP;AHZC
M+4'\/GM_^YWNZBT,LN>;^HJ\1,3L+:\T<V&/C,D[AK9D.69/- MKXFCT1C '
MK&@+7U]B)DN<@JF,U5VF;9&]6Z#L1@"P[AE_)%'",)U7J);&(F-V?5V0@YMP
M&I&81J]?.)W,X^0)4=Q#W&66&)<="+BPWH>0GL,T\,'(0S\6&(&PV?^:AM2L
M>5EV=F&=%^F2O1M=/>NM7)CYPW0*"L9H229T2!8O$?-G]([$,9G,0=U(3.84
MZ^XNK/416@V-Z'CKK5R8N7Z3PR<_ERK*:$YILHZ$ SMDS&M0Y7N\6[<TDB,O
MV75$SR>*W]Z(!6KLYH)\-!OC19!9^)LQ8,N>@ OK+=LJL1(*3K6<C*YRF<D[
M[6;5ZD9OSTIQO6'RI(\U\\0E!FMGS1WQZ9C_%<WTO\*_E3H[B&,^8:U);YUH
M..JR:0J2C[]0?R:P%')[.R+!W7,<G03RQ7R.8#\L6F$@]:9 #[L9VI&K8:UZ
M*(@(_2.%*ZYCU=&:?B[L)?W5+\Q)CS02&[^1]2T]=@OI*0;I&.^8(3]EX(]Q
MQXC&MOZ.R&<6@0 /=YHAKQ;.RYM0@E[IF]3TBNQ+SP5Y'O.$!,VZ:;.IQ-3/
M35.AYCUZ!6ZTK[&^L9L+*P70C^>@=)'0MTRA:.[E@H3>A'/V$KW#-C/MP_5V
M+LR^5)-+U%M,%/JSO!#$9)JU+KO>>P]I;,G(SH)>K@,.&^$W$BW0=0V')('9
MM81S]J>X[U":.M0?2S71IJLCU^APCM&*-V'VRAU')(P#4L2S"),Y(IF@/2-_
M',!+H?1R:!;];=%W-710E/.M3U4WN6B-'5TX^1K2%00?IS2*&T-<GMALGCQ,
MGV.%'-8U(:+/"(X":XUP$\"U_,3A/S2<R3*!$PJC3$A@DR-I3\ %F5'@7C'6
M^ZR7\)8;PZ:OHWS&I%W"T J0BKJ6%X.A(=&EN8,+?)3Y;!+/3+A+9<B^151-
M<R<7UI6EX6H8U\JY+U-,>B%G;T;4U>NM9/'2JC3#0Q@FCYDZJEYSV)PAVAM%
M;KL#.J)QK1G('F&BBZY6M?5.+FPJW30R>B/+&,1\2)8LD4BLE_ XC50ZP,F/
M/YD>@7UHN? 5&JXLK?A&CG>BCH&.^$?MI%P]1N[A$:A> N)^*/",#,JAN:.K
MNH!Z\&A@Z+DAR@9%O;VG"Z*N\KPPN&@U4"MI=J_5M=VSHS 3+ $KA\B=65EZ
M?*[+1TA-$<3UB\CX]-V4O*M[^@ZDY#G$0DN(9#[%B]J_IFCO"![3"(LQK=N]
M3 _BOO1<V V9.2NK$VY,'RL:NFCI:L"WW@9&MK-'-NB1K^Q=S5;';[Z*S!77
M+#N[(*HE=X%5G96V'BZL2*@&>=A5EDED::VUZ^S(ZR&'A<C<SP.,41*Q_R+E
M'-$1U$8S."5Z4-IQ5+2EI[M/3*;[@9BC.8^2,8T6 F$[ON5O@CE""9"_PB(3
M5*17AV*%L734PE8\3Y-[GHS@E(-__*T%4G6[@[CI0BT2<M=AZ"4*?7,Q,&-'
M5S6Q!BBY(B+U@N6>;R/R3F=*+NR>WR(@<,'?#"&=E68NS+UDVQFE##9C)W/0
M>A<7UJ1;\:XY]]^P=$XUYWFS"+Q^A!VYR$LLO(DC0H-N4)F5/B[P/7O<7+[3
M28JFB^SZ4 JP^5G4TG/?[Z12;4P5#_AB6[->;[^;8L2V!>M5^4=C)$ZUG0L2
M9I>,T=OET)6D(Z=)'K'Y'/JJE D5&.%7 7]K\;6V]G(T_KNHM+, CB!2S17F
M)EA4YEEKO^>:X%I6)EQ<8O.JJ1;)Q\VLL^J\WX-&HJ!B.;U05C[4*NP^*!0\
MV%:J#MAX3D<8_1.H,GVK(65!VR?8%GDG<GUEN< B0G7$ __17,#8U,V)M974
MEB<XYT-&1D^W'72=:B<7KJ(6_( K4& ,Z[/K[,(Z+V@QR>E@DI6"?>0!FZRN
M>"3"Y-<<'/*/%G?O-F@[<@FOZ1&(+@!+T;".\L@%+36]4QY>'ZI[=K+=P?2Q
M2'=(>1J73:TR>S SN#8CGMA3<-5 @X$L"$4AB\W)62N4]=BBGJUM=U>77PO\
M52>V&I9\;PU^LP$<.4J$1O=$ERKG&%-1+8O^F?JY<*'(N_TF(!/XB:S8KW3,
M$.4[L4,U:>WHPOK6(IDS3R]FW!8PN7"Y954GXR?ZHJ+>!5#N$TW2J 5"?FOT
M'77$ZN#V..?UR$F#$=NZNPNR<D^3#)*H+0BJ:+.;-YT]<X2;,!:%J%KK>E7;
MN?"Y1ZLPF?/HW2!!:ZV<F'G+@X&GAEJ2EIU=6.<]?<O"HNZX3X,G'@0":N)7
M3 Q+XVN*]]ER;HPGZD'(B?7G\4$)GE6#(* SZ@<KA+E"UYS9T-72<\\F+UU/
MD^%QL8X<;[ZR>GB)MC*.(VHAEM0B2V8H1E!NY(),:YG7V6M%@\JXH#&;A1@W
MI:GG2K<1[SVTW$9TCCFS"*<M,&<P.XR(NL#2TM>27O85QG8S%.(Y?&/"$OPP
MS>2]\3/5MG7U0:D9>A%C>\KD.X_'&,$2P28/9S)_+"N/J2P&;769-J+IA)VU
MDC6A4B3TS D>,@)J\.FGSVJ]'1,QNI!TX>0Y9WPIDB6M"D\UM79A);50<PWQ
M.C<801U2<40A$%%-G+D51M26!G+4D9@%Z!>EML)RW-<V$M\W(^[J 7Q-0\03
MOHFH@!JQB2%N[>+"!BN5<7A%$!5A-5P):&!Y#XBJO H7L(\NVH>L(ZKG$U^1
M(%GE>6BXVT</YS</H:K;?DZQ7G&2@I8UGM-G@R6O-SD7)"6/* A(' _$X7=+
MWF)0+<WQ3;5]]AW95'-LJQL^=ZZ+L1O69MO=T7N@R"G,GXBP&37H_"<6_]["
M6<ONCJY>A5%05:DV-J7R-;??=]D:N%[O:0);C,1SN$KQ/_C>>X4#I2TAR]C/
M4<;=8(EF$HAP?8SI;WD!KS?<.])4?6XS7@+7HU],(>H675VX)6K*X*'AJ4C?
M'O*X+7W4LKN;IH?_A@')1,^#LU *#)U<8*JNS:$+/L1<5*+"5U[A5313=2>
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MWX7-^;R<1G#@9[QOE)Q*.T?CI.1K]H[Z 5U=::D'\)PU8+S:]'2!8S5X!2+
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MQ7*4+HJ$$V7 $IIB^Q5KU=6%:U9E_H&P_C'GZ5JPHS6$MDU_%U8[YO#.K-1
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M#VXK&5AI0V'4W=*W*6=M_YN%( B%!P@15CG72D9A;A6L/^N4FEI3F,D#7[,
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M@VYDM%?:>#,"A8V.J%EFFKX$8IEE:5JB26K;4MC)1W4,VR?2V)S"7,9\QWZ
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M%WL("G+[;AP=<[E*WD!P<L!O=N9![1 =X\-W"@5L);]P.. C>Q?;=)ME4;
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MZP1TXD9,(;4'1L3%NBXSQZKT6>@H7"J9S>0 $#(&Z> WGBAX^V^J**75ZN+
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M<\UI<NWNIW916.W D$H(*4&0C%N02*TD\<YEHKTVW .7DK8+J^\Z,,:A'$_
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M@FUD.MV9((N,7[A:PB=4RM,OL+903K2C7GIZ7:/JH+54L[#6M<';K]L8RLI
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MW)N(_D1CL#Y+\!C\OS'"MIZ4ZU0[P6IS>WS1O8.KQ;+OKHM+^,G/2L./]Y\
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MT-.!>M/\_>9(G_^T6"X77_'D[2;2B9@CHZ4!72FW+11;Y8C0FCE/2\I%NVG
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MP4K<2#D7]KFBKDO56 [IEC!K)<0]0W*;S\L?I5/!?_S+_P]02P,$%     @
MXUE76'5J:$<:# ( D&47 !0   !S;GDM,C R,S$R,S%?9&5F+GAM;.R]:7,;
M29(F_'U^16WOUXVNN(^VF5FCKAI95Y>TDJI[9[_ XO @,0TB.0E Q_OK7P^
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M2(RVKI1@L00M\D""MT))+;B#X:*4&R$>[J;GH'IR1TOWYZN7X- =6)=!^B[
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M?NR.=5NQUJECW38B'Z9CG4B6\G)9( ;FB 2-&QMEC#!AA&+9TZ1_X(YU^VG
M7L*N70!F=1/L>V!Y=3H5T/%D.+TD=5GAT+2Q'#R1EFEG%?61VPY&_:9G'Z-!
M5T6.=WE5-7E='_UV0+3%V?GF488_.=]?^@]0N8?H>GY9+Y%)D8T3DA)'>2C5
M6'#C2)838Z1PH)+'7>6)D?G B?D07&XCL=J73OUDB>C[N=";<3N;G\2S,7R^
M?K07;-:VY&EIS] D4#P3%TI34S0SI=2&:M,E$:+C<,.>LM5@I>E7I+4OM-V&
M^!%B,TUW,0K'!(U"$@6ELE(.I54)1QO#VXCX,].FRQ75KN,=%^\UA%H_T:EI
M;Q_;.P;):LF)LJ;T2LJ:^) 8R<RX@&M9-K%+*LRF9S]K0O<65N44Q-_@RVTT
M4G+JO([HI#"%"F0L6O[ "6?)9J5*59<N>^W=)S]KXO845,6CZXWKPJ>S<;MA
M66!H4D#IO)HI9<6HP'E;F8E0"7R,H$SHPF7'X9XUP7V(M&(<>];.2P^\M(CS
M=^U':#^/XRI6QZB+PO)$@L-]7T81B,LLDM(03W($JME#]6"RGX4E SC ZJ@1
M)O-9^>WJK/&^L8_2TZTAY[N\ZPJ\ES*KEXC6.5M=0'4XQMA2">X"&=@?KL+1
M7<(K";BF??4@.*,HS=$E0C.X4EQ7H'['0+1,3'B9T1EXJ$WY$V7]/L=Y.-*W
MD6MO.:?K],RU@<]4$,Q[$H'SDDZO2,C*$V&"3&AZ^&@>*ZKPT/,'W+KKB7YC
M$NH><JOL$=])C TZ1$&=(A2R18,1 MKY"@U&B%ERE6+V74HM'#!_N&?N=I!3
M+V>&OS53G_YKL2S0\OKSLE1<GD/[ 2Z:]JIHRW+U"4PDAG!QJJED3:/][W1Q
M!TSP4CD!\G9I^!Y/D;KC/D;3K7?^[NJ:Z4/7UF]!!V2#IZC<A_90Z2I],=U!
MI?:@::!%:QVG "=B#@P)7<8I%)"@O2#:.)X=$PR2/U(%>C3GY?#ZLPT[E8W-
MO_G_:MH';U^%8 ' 6")$N<29DR;.28,+,K7!")YRIXOFCPYTB'2'.HPT?8FS
MLC'ZVZ(@N!8NFWT<GTXAC;)2C&HF2CD,7PIGEK)-S!(-3B?JF/:L2Z3^ON<_
MO4J M0M959-N[=H1:)4A$G^*LE@=&[WW[;S(Y3-,FHM5G\C9?/9F42K0C92.
ME@DA2X\<*!J)F#.-1"E(.JFLL^S2H6*[47\,[>B1B=IG>5LA??'M72EU6+[R
M;:036N7.4Q*"04>;H?OF$WIN$1CW/B5%9:>:)#LC^$.7*C)4N]+)-=3OVR:/
M5_58WTUOEO)9_=7(4HY0! I#E;*\JASFV,1)HESBNU$N(W>JD+'-H#^>]M3E
MH?(!YW6@+Q?GBPG*Y3/<5O(/,#X/BW96%DV%^ZDNJ:K6,32M>*D3$-&^DEJ!
MIN#R[=O=C^I,EW%_/+6ISD;-0](55O387@!*!7[UBVD\>^7G\&J!8CG]Q]DX
MGKULSL]Q/F,_N>SX=N/4]V5S.2U(O^,*VOXZCN4[5[EZ+2Q?F31*2:+MKB7N
MR]82&74@H334ID)[IVD"Y[O<"QP*[P^CJ4^/_<J)SW<7\1*,O^S$V8YG.-4W
M2,;53-]=P,H?G8TT1$BQY);BVDTDE!NV&C)1*7/CF'=2=>EDN@>$'T8/!^&H
M9J;!/; ?09O0-LA*)&),R*6P9KG9D0-ZN,8XRD%KUG$9W'+D'U>1*C)2\4CC
M-MINRIY20#F@4R)<2D1RS8FWZ)Y8IK)7V7%&NYQK;SWPCZ<]]?FXJSRV1HCR
MLE7&;,234C%PU%Q?\F*-]20L#P'18Z4"'1!ENFQ6MY_[8U"_ES3O,NOV6A96
M&#X .@Z0/C4G<Y3#M'ST+O_2^,DH>I99Y)9X80.1E.&297#+2Q3=!1^84[K3
M*O#(.#\&\U6EO2' 6.$R[@>TLJ<+**M0R;LMN)HT&V4)SG"52(K&$.E8L8%*
M W>CM/00%1VP1-MFC,>O0E59VJ ^^Q4^;[[YR?S;I>]VM;V-A#$9F(K$:X_^
M&"_-V@)#G?8L94]S\KI+_.>^YQ\_[=6DNX%R/D!_JILU1;][[%_&\[,'2KS7
M;%&U'X(>NE15%$GE1E4/*6^R(AH0N)[PDF=ADR N,468STH'E0/OU+F@XW!#
M-9YR64<0UA+!E,0W:&E2FT R=>B@A0S)#]>JXTDVGJJE$[LVF-J&H2?=8*ID
MWIKH.5'<%Q<.#3WK(B?@0M16,D79<(4HGU^#J:WTH$N#J6WX&*YW4!=4?S28
MVH/);DV$=J%AP 93%AU%G12AVI:8 37$9B-)TCP&2 &-S.$*93WM!E,]Z,8V
MTA^\P904@4F:,N'H5)3"_*[TR8XD> 4J2<$UZY+O\XP:3&W#QE8-IK81Y3 -
MIAA+W!@)!+0"M+? HK]'+4F4&@<V"JVZW%1ZG@VF=C$ *LERJ 9373 =4X.I
MK3CHTHQH%P$.U6#*<A[MLFISCIG(G!EBPSV)":4,EY*[3NW@GWJ#J>J<;B.W
MREQNT1"',ZV8PVTHF9)XHJ4ES@#N& ']8\:TEKK+H=BSZS6T%3N[]1K:1K25
M]^'-)>&,C"4'DU 5/)%H0Q+<?0*A,LF@8E1)=:F4]1R+5.ZZ!^\MQ\IYK/=5
M6NR Z&B*5&XC_0Y%*G<0W3!%*E.0EI=K@<%J1.:C)!X7*\*TD-X+&6+JD@GU
MI(M4UN5R&XE5YO!:\O*[_!+.QQ>3\;D/'U[_\ANWC*ZK5BL731) HJ.4R%2V
M'V-PTX'@,S#)/'2AM--@3Z)ZUE:,-'V*L_(&^[?Q!&;S9@K+B:]:@C/K<$_1
M)":<(0XN<*=GAJ2D@(:0G:"Q [EWGWRLF^N>,JR<Z'\3S:7^=L&SQ<:Z:8SA
MM]5]Y7XOA7L(K?95]$VX8O \*8K;2S9H\J>DB3><$Q-+/_>(+@#O<C5Y.!(?
MV$[[YG ;657F[O>/;UZ=G%Q<M,UG/[E<Z6F@4GG<1Z)#)!*Q$4N](M9* Y"L
MCZ%+??T-CQYVF]Q?UDT]057<$G>J@.'0T\[,)N)S<"6M"%UP\)$X4%$8XXU/
MM_K?_E'KJ/<#YY[XJWAGJ4/)C2[(_JAUU!/3W6O5[$+3L+6.@*:L& O$NA+"
MDUHA5H_KLP-K#;"(V\N1*E#-6D<]Z<\V[ Q>ZRA123FE0%B&4D>4XR8L/)#L
MI -P+*G<)>_P>=4ZVHJ1K6H=;2/.7@R;4H%GG,?13^=OIY_1BEM>@WD[/9G-
MFC@N+4J7JLX-V!27URL3+Q=Y/0D^&^(84X8E[7#_'6S%Z(;YN V:'GBK>$OV
M"N?KZ7P\_S;[U,S]Y$W37L%;GR9U #BX3?,(Z$.9-GUP?D>Q^B"L%^OF,:#"
M1RF<=01LE"5(ZTJ05I"T:A7E1+#JN#7J45OG22C4-CP-GK]G!?.&(SCAH*34
MNTBL*1Q[IUV4R0/O=&'J*>;O525FJU2^;:0Z5(5')[@5+GB<GC:(R7,2)"M%
M2VAFT6C*3)=8W-.K\%C[QD@U*=9/TFS::R=L+Q;I%.:C#)2SA(AHM+AX@<O$
M@F*$:BU53$Q2V24]9//3CXO5"A*LO$"_;*;SUL?Y N>Y5K6R5.'*];YM3EM_
M?@[I)4PFK\#/S_"C.8RG;!1#R(+%0,#1A+J7@83LT'U+%FP QHW)'3C?;?3C
MTHD!&*B<SOLW_W5\OC@_26DI=MS;%M-4BGD\BGI5(_*U7]:_NO#XK&PUC[;<
MVO:"$2FR),$:0;(/N)!E[7BGS(:*D(Y+NP[%5>7\M4>P+INF?3\CNRP\,8+$
MJ:,^$IJ#1O\_H!&D:2FE33VNKX$'VL6TW&7LXU*BWJ5?/25C6I3^6BN]!]"_
MG7[Z I//\#=<A\]6L>=/S0NX[+B7\$6Y,S7%M&")>\(4X-2$2_@B,$Z\"J5T
MNJ"*BBZ+5K\PCTL'GQ*GO1=2?*@:+H],@"]BL][A>R4E00]0$2J\5 8= !&Z
MF%[/I"IQ+U9X;_+NL0QBIWJW(J+'P(4A3L9244FA$DLMB& LIXS:[6DG5^S9
M5!_N6SVJ2[URH</?+U VT_FZN!HN;*BU_P5Q/EO6C=U\,C8;29JUX+0@+FT_
MN+<$A15)S#'1Q&TVMS-H-J=%[33Z<6G+  Q4KF_X 4Y1I^_L@)VAB\R##*I<
M<_.H[E9H8A7+!!3W0?D0;>3=(K;[P#@N+1J2D\I%%2^+=;V=QN;\>JTN)3V/
M/B4B7%D500+:_R&@0<4B,,#_=ZJH>L_CCXS^"C+LIT+BLF_'95W6Z>D*X&5=
MMA$B<Y$[3HPNE3PS&D7.E@8QCCJK;>(0;EU<Z/'\[P&@QZ,K]7FI71@15ZL(
MD&:KPKZ;%RNN9-+6!N*H-:4!3"#!.$MR8-FFA 93IZO#'88Z'N;[D.W]%1+W
MS(F,B[8M5_5F,YC/WK4HEXMFYB>_M,WB8O9RXF>S<1Y#.IG]!TR*,UZ<^I$+
MAE*(AC >*6JM1C]+9$9XS FD\)8&&&PUV7$2QZ-OP_*Y01/%$+4ZERD937N0
M*IT[CMU'?<X:8JA<F7.7<K/&"Y<X!\)T3D0*37$5U)%D8XW$SZ3/70J.[ EC
MJ$J>"JPW5&F2C-9$&H,>I*&)<-"")FUHN)TX\Z-5\NQ;AW:M\+D-<T^ZPJ<3
M:&H*6T3D!9$AZ^)_HJ%ILD*GDSI]V\7[H\+GKGK0I<+G-GP,5[RQ"ZH_*GSN
MP62W*HZ[T#!@&5@NN1"EESDM/JMTI2N$UT18M!P1L?6WJVT?A7+L4N&S!]W8
M1OJ#9PBGJ%GB.I&@4[G&D8%XIG'FT3)MM$>GYMEF"._/QE9IP=N(<I@*GZBP
MTBF9B1$%AT-3RV5\)[7U-"K.0+GCK?"YBP%0299#5?CL@NF8*GQNQ4&7:I"[
M"'"H"I\Z6NF!!\)H:<P,NBQ9$O?4%)C4REO;*0OXJ5?XK,[I-G*K73/N2_/I
MK%G,_#2]:1;M'&!Z<KX,W%S=3[I]A58X&J2 $C640*0.ACAN+=$Z!4X9>*F[
M7-S88>@G4O-S*[Z:X81=>8M>-=?Z.&_B/U>EY)7@V8 BC $K]V>A-,XVQ!N$
MIF2DKE.6R*W''NNFO(_T*F=+7X-RJ<%=P&RQ#=\98/C]=R]Q;Z9M#UE57J7O
M@M(F:!F\(DF5+$27 NY!1A+G58#H#1>F2YN#@8A[8(_MC[=M1%3;0EJ$R3B^
MRQE*@_?+E=SSY27.TO,N*B(9SBPXW$2RPJ4\H,>59:>.U!N>/>R^N*>HFXIR
M.F2%#NV8C@K]9LV]1YPTDE *=.L0F9"X*SA[*VWACPH=O4; >^"MXD64[M?
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MP20$VGH)\H1STHZ5F<4L@'$;!0=5(NW53=N#-ES \:&PG3T'F4CS,RX)NK_
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ML2!1,E=YQBV70FO?[*#?3/97%+P,:-2!ZCR?$7.55.\@Z-Y;#1\1_N :#GO
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M%]M=4[UH@L-A ;6)G7KV@3[A*8YQ.AE?BT('<[;1U%N)5!LPZ)"./"^8'+5
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M#C$))FL_KH[@6>#9L<R-HQ#-":[:%3YMN8@?N-S:I#V?=A^G^.M5O3G[N/0
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MN[>G[CNI]@%G;S%=5#*/EU; Q^DHX>SC%,_"WU<GE)0;U+:.DDF)K(%L%/B
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MV$K0-FFR$S37MHL!MP^&ER)*@_&I8?7N#<463^H&LEUGT25%^T8&J'@ HE
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MY1J=!^^3@T3OA%"V5/7U4&+^JX%64\D_B,P,UO:Q>U=?)I545N>:@T%$=4Q
M9"R "9PSKE"P<A2-<4^YJW,;#:1__C=L_KC+N=RNEQ<O#F5F!;Q0NE:"65BD
MFJFH$KU8L>8R'N%=_D+ZOPUUE_<G,P].L6]8R/86XSR%V5=ZC.I?M5SK1[BH
M7C7ZS@723BY&(8XN:!F<79=Q?<(T&2?Z[F)RZ:2\"=/ISSJS\MOD<CR?3Q:U
M>I/Q)\SX;4&EW0O=!@:X=R'<(0FZ9Z'<W3FEMT%]N /J; GJPQJHF\.G65#*
M"@N%K$]0@;XB48]@+,N&^1*MZM*-HPV:?1RQ>R%8!JN*L);G8D $56K7;@G.
M90L66=2!DQ*7NLR'WQ])WT5I!Y*?=6?PP.PZGE*T/^AFH5TOGIP:!K%"BL)=
MAF*CHW?&28A.EMH& RUJS4GY&DPWN0-NZ,CS(03CGD*Q#X-Z\=J]^O)EBE]J
MO?8:M-7,JP[@!@\^/P+X4+'HO9AZ3T1:<V1XL<E:^%)+-@)&J%8?>$0#RGB4
MLO!L!G1N#2XN3T:L!Y26+1C1.')-E^AT/OI?)(MMMH*#T6%)P8-F!4$)7<!9
MVJB3)@14]..[%8\;-: -'WT(\[09X2?MJ-8XJ?55_K^7L_DBWVI2#9JKC>97
M\W=A-%V\CZM<&:E*C-8!-XO^N,+4K0? 7*=A8DHV=FGNTGG!DV%X+Q1N?);O
M*4)7D$((+'O"($4R-;FB=C]R"#**F(HLCNFGS/I'/OY46-R">KW$MGZ?C+_,
M<?KM]60ZG?Q%BN_L/&9"$$6 F%)-H5:2]A@R:'3*2I^+&G"4Q7U\PXG$@6W8
M9DSJ)9ODS>5T2N?B!E)US"Z_][&^7Y5 ?Q*Y[OY:16YUR@6BY#5?U] KIKR
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M#U>,\A#*0T1 &S"R0PQK!RXT3FWX_'4RG=>J@OJ ;@AG5,RK'U^A99H)BRD
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MOB0B]+OZ6-<C6^,H[\?WXR^;2L,6?+MZS\/%^_%L/KU<,/ \6NN,X60Q&YE
ML:B)61@@A>B\9<HIW<GYU!S9<SXP1\"K^Z?+M0S GGV=3BZ_?'WSM?;0>S_^
MG";?B7)O)N/9Y&*4%\_*VE%4F?1"S+$.]W6@2NV58%AUT 3D.@FG2Y>R]+U
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M'7B]7&-8?WX3PC_(Q#VHUMC;LAF7$CPX0U>3+[XFW=5'0U@@*;7&11>XZ=3
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M6F%T<*E+3N2ZGW_LG#>3[8IPU4Y/(+>@_L!_3L^OSF]!22U]8(FL6EM!*6'
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MU@)=0?A.L;?_]VJ2*[Q/?_Y:T7WYY!AGAKWZQ2TN'%0N$J8"O@)3W&0@#=7
MBW?"DJWAL0O=3RYT!&2W%>8*JG<*NZU#]\8L;$EGF+.QYHJ;BB[Q!,Z7:E72
M'U@C>6)=G.\G%SIBJK<3Y@JJFW0>6FSY?I7=24Q:ZN@XA)HEJ%A-&V,Y 1F.
MT1F998CC]:9:C7$?"K*?4HL&' W2@_;/:=TTGET7\IV@L#QR;4'K.OPUUPIQ
M'13(K KF%(1=[NTP;'_B>]A>CJ[LP,G:U_F]%SK6?RO\6/3_QLMYQ>CT7L7H
MV/6/G0'MJ2QR.X'MOUHR6J^"EA!MHNM0DD.#+G*(RO/DK9(QC-?HZEE52[+:
M+-J)"#X;N@MXM!",SC?3E!&1+3]]'XSDGDNU9 _=;%,MV8?3?5=+WNUT>21\
MD)9KB1IT-B2WR"4X9\FET<E8P6T)([:S7 +WO++\>^G#XX$Y._ R\!24Q\/F
MNX#;X]2<1X#W-C=G%U(W3$5IP\CH:F,CG<+((CE#M3.K1 G!9@=D0T=KBL,X
M8EG1Z.KR] "=T;2E#Q&-DX(?=9-9*+ RR3(7P:@:,;=:@=<^UKXOT2>EO+5=
MWIS6_/C]MLG>D8!I6^D-$FMX,/Q)F%KHYCPH5_,2(S> @@L(RB61G5/.LO%L
MBCV.XMNK0;$M(X.4"Z[O&=\%VL\)?-NSV6.XVC94C#R!+Y08DJ<S4]ABZB0<
M!\XZ YJ</42>D^/CN2L'/8%O*"7IP\#($_B8B"%JJ:#X$FMG> MN_AR;3-3>
M^,#]J!'NYS"!KQ>=/2;P]>'B ";P\5K[*)T#9%F"$LR1028"E%*DPL 2NO'.
ME6<\@6\W=1J.L\.8P)=2REE; S$J0;:_]> 8_3:3GQ<DCQ[U/H:B/<<)?(T4
M;0CF#F0"7PJ\)*\BY#K%6]G@P%M#7XN1UF)2,7FS!V5[EA/X6FG;$-P=Q@0^
MR1AW.0EPV1%B7PAQ+)J4(9CLF;$JC]=)]7E/X&ND;$,P-^X$/F9,5,G*6A?!
MR(41%H*KS;=DBD&DHOARM[$7/X&OE>[LP$3C:M-5+159"BHQ+\'P@J""-P0G
M)9"V",FY\Z)TJ21_]DU>MXD0MI!IX^8!*SOO=<%S%$U>>PG^J?Z@VTAMC":O
M7@A#)Y('J^JY5 ]95\<9D4TM91%9>X4'Q6+/)J]-2>PCK)&;O"9A3(E>0W;.
MDL^M.'G?F@,SP7@3LL^^"X^'W^2U%P<]FKSV$> @<;&5K>5$2$D:TEPI!-WO
M7KK:242#-2H47G+1=KS\M.??\'.WE[N=&1IX -R#XHLNN'XV_-R1SZ[-'+<A
M8\R&GX5ER8.A6[)H<C41(R!/JK:Y#B58IX(9<W;VH3?\'$1'^G#0V+CX@X3P
M99)F^/?DE^FDG,[.<_HM3_(,SSY<S;Y/+_(O,[HT+W_%>),Q?X-9.V]S41:8
M10[*T"^N)$U>K;'9)NVXZ-)V?-OU#ZC6K1=[TY%%/Y"]<C?DO7!=+'T20 @(
MC*[MKU2=["R+8DK+Z-UX(>U[P)Y5_=).B?+;LM&XE>RJN?!)%<F]%U"\HD\C
M,@3'78: :#BB+BF[#H?$BA]][/2VD.@@9L3R*'=O,OE/Y#>A\8E.OY @<!6
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M;MEQ\\4Z;7Z4G*[WY5IK\QS2!_PQSSW[F&,F^.$LW^FOY-)9+LE ]G:>/(^
M.A7@&8-@)I<XXJ-'DRT-F]'U%(SKM VM0U&,/M\@=*I]N1)@)KM3*2;)60X6
MRWAM9G;>SF'D<PVCT_W2N=JS?Z#97+(P)YE0@+%F<1>G(204X)1#DW50>L0<
MB\//YAI +S8G<_7A9^3TG"[0?B9S;<]FCSR=;:@865N,8]*(R"!KQ6K/7@-H
MM(4@8T''2LIJO.?P@T[F&DI)^C P<C*7"CKKZ#R0SV-!U:Y")(((B3-C%"8A
MXGC&Z3-)YNI%9X]DKCY<["69:SE= PO74=0Q\<R5^GY>Z'MQ"5)@6AE7.,/Q
M$M)[@C\FE1J2MX%3NM:F:BP]C2:5:[]E5^<>(ZB,$LCSH/\6DRN!!71N#YF#
M7>$?I;(-PMVP65W+R&K+[6!BA,)-':XM/7B!'&H4.+@DE0V;>M&_Q-2'1LJS
M"Q.#I&+]<H87%_FBSJ*<DM-Z^>/#&4XN2;-KF\3O]UJFF)0\W=&L"$%W="V5
M+^1@IA!\$"I'KMQH&M,-\\OUYP?@=)#S:2V\V]Y+3P,<W=]_ O2^O/XA.'^D
M6$,0-HBA]110%F+24B'$Z EHBN3L1E: *8TH:]\'-]X%N!>->C)"<! *U8>G
MQ@DVO^!YF)VFK_D/D@/&;U<7^?*V1;3CF*0)#CAZ,NA8CN Y<<NCMMXRKS1?
MJ@5;^6R]:8U]F#]-Z9@.(,MAW/^EQ]438X)RWB?0G"Y>I=!#"-&"L!F%+SX2
MJO',XR5TAY;1,-;CV4XL-4[%7,;RMI1<Y[F_N<FY.)U\/=&,,Q]00$;Z8)0.
MFKP_+*"51$W[%MECAR.BPU(O2R.&D'_SW$Q"A6=SE)_S[/S$,Y9B$@&8D[6C
MH)> E@7(619%[AXWRG30A>6?^_*(WTFR:WV8ABE-]Y1R5KLVY70Y#5<7M/$+
M4LWS0/*I"]0<GTNZ&R;US9W^15KGZ^E->NF]!O;3O^9/\?2OW_NY'Q<_]_7-
MS_UE^>?^.9W\<O=S%VFK.V1,/8==[9R0]1PVV3+?:WGVQF.<GU?B)+OP\SJ<
M=U]XD=85+BS(8&NN89'@#*_5$C$F[@-]\UV.O,$ [C2EI3&HZY@/M\&YK.@
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M>EE&+$_=92='JY][(/JQFKJ=&NC$RRN<G>+9;R36^AG]/IV_;4_>5)9RNOG
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MI1$+C?-DOTQBGEV2;*K-__ZO/'LW+]3]C/]\GF6\G,_TN<WA-EHE6^II1KZ
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MCSA?3N+D!]+ZVC8+QCQ)S1$TZ9%\/UT@1,DA6/(GI-$LQW8WVD/,Z.0,^8"
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MM6UGK7TD/XX'\N'-Z('5C@;G*+%I5VG73[D=Y&W^M-YO#H=Z<1_/+G8VP3U
M/09C++ED;IF&8NN;8^&YTH0;4+(P$2)**=LUPSP&(]SZFG^\-M@'RU%L[S^_
MS<[/?WZ8USJD\Y]5^IP>%]<&Y(633X-91E Q2O"NR!ID1LD]J<ZVNW3H)?HA
MKA'&M(4'AC<>D*.0]%V*^^>T;!%4BN(#SQ8T-Q9478B8C =),3NO5QPZ//7,
M.H;%;17ZA=C:L."-LKMM\7M7^SW+R607 D16S*4J?! 1$JT!H41A>+_WW8@6
MUD'@%Q-1# W>*%?\6X2\IGC9+F;S^*&3Z(<*&P8'OZ]Y[8'<(;:R=4P3--,Z
M)_#<T+FNDZ!]O=:RV22L#2YFUBXV.*"!;0T)CL6^^@ VBEW=?@&X[S%\".>3
MKRN*C77_8J$8,HP0=:7YXZ94BL8 +BAAM-%6EG87[7TD/X1+-H(!/#"RT= ;
MQ>E_+.262F-!Y"!+Y6.1EJ*15!A48FDIK$,*PMN]1;SPB]PA0!JI=_FC<48'
MT5[;B P";(^V$+N@TKB-B)7*T;Z'8 PM$D4A, 1.7[R01H02?-'M6+N/[=:T
MM;WT >.0;41<=-Y%8P%CY5R-UH'3R&A[M37]76K;L?WE<VTCT@NH7=N(]-'R
M*,[*W9-UXV7:68X^EV@TV"!I*?A"SAMZ6M[.!N,XSSJVZWG60>!#)],URJ 8
M&KI'[>N0"7*WN;QN>GHN;B=O/6CJN7ASOC+]2DZR_#OGZ26OXN<E_:C^M8:)
M<V.*WSZAKAD8[3EA2F#1IOI49'@ 90(%C$70;AR,8:4DAD\2ZX^7*'8$G##"
M)HVJU#9:M2=2?>4(:#T89IU64=,>T]!_?)Z<,'WL:T=.F#XP'4^"W&/^MTLB
MD2O$(5HE0+%,"F/90+&U48K64A;S>ELRG$%TOB'I TSC0+>+:*\W)(, VR/B
MW065QH8CBE08M "A:JQG?0%O#(=09&"A<(:I'<GT<[DA&<M>^H!QR!L2XQ46
M12 F*2EZR\*"BY@A)*=D9CIX);;$$\_[AJ074+O>D/31\B@W))5W_T/YC.=Y
M<28E]]XZ#CXJ4[TX"4&X @R1CE>OF63MHH1;@AWZQF-$UW=7]8]B"Y_R(M-'
M?B/+_37_E<]G/ZK%7D7$9QQE<M;2*D!3R9&8 ,P,07BK@^-%)-:.R/!)44_8
M7H:#:!0?Y',^IS_\^@^:^1S/2<C;33[^RM=R9IY,X C>I=K$7#E C0C6>8RV
MA"QM.]*Z;C*?L$V- -HH:7JKT_0#!9)8J30N+]K6PK%B?.*61'*U Q9Z#AA4
M :UHUZ3C6C'1CM7G"4%/V(R&@F?@KB>T8R[G%W%Y,2>I5EV&/M'&.5_D1);^
M>?)]<H[SR^FSG&(1WH.DR8*BS92$Q%(SQT+*-I5@L(/'VWG D[.%\=0]2L>1
M2TJ&58.]Q1EJGGUMQ)-MT62AD69.IR4D5*J(8(,5[2[D;DMV<E8R   #=_O8
MW%%GSX8Z&*RD_RLHK.8$.J[ <PHD2^2*"\-Y**'#;C*&;"=G4D<!XE'V$?EM
ML9Q\K\^3;[Y7\L;%K%QJ@7;D.^W,EI<](NM3>TOFE7W$:_] /)@R1WD ?H>3
M^54.\<WP-^N*SM02!3E>9E4C9FT@4Z;M5G+K+2TYXVR[(KSN<@_["+QQK,OG
M),N2497"%!GYJ4KKFA&7.10ALB+_-)7,CT<_!WP('M#.GGX*'@BLXWD,_@.K
M6[S\N7I?4-XH4X0&SARYO]%;0-0!"H_9%UY8P7;Y\K<E.XYGWZ' ?V!A.X,P
M#K_FUZ_S_'75I9DT] L=.NN7@2ZB-7_M?53<0[WV[H[F0R:_0:%H;"W)%J6R
M#,!CX;5<A$$P4@$75G'I@HXJG*J5;'WB;6(D?1 8I[ATMOR=!)M_^8;3#]/\
M7QGGZ_*T3&>O+PY8])6L76=P&3-%6+(P1Z%UT>U<FT?%/$14.A"<#^M&!\%B
ME$>^S5UQ; X<"SJP*!-Y;3F!4SE#"-;SH'U1#5-$CKA+V6ANR?ZPC/+F\EC[
MB"Z"O?8IVQO2SOVG=L&C:9\RY6WBGB/8PC6HK LXYR)$HWU0%!R6H$_34';L
M4S:.G?2!89P^95EF'RQZFE?MOQ8S;9/6:_"ETFUK[3Q[JMSJ.?<IZZ7\AWW*
M^FANG#YE1COI!3G+6!P#E<@S"MXC2/):-$^)ER?YZI]SG[)]L.NIN7'ZE$6/
M,0MGP*B::1@K6X73'JIO(E.F[^UP_0&/JT_9/MCUU-PX?<I\D,HZLAG,"D&Y
M&C1(2[]%X4(LEF*)X?H#'E>?LGVPZZFY@1-/5N^.;U>B3/)Z.C$E&R030#L
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M<;=)IE]7:Z635)N]T,[@7X[4UFT<#HDMT.ZAQ@;K^DHZ'E@H421(3-!I$T4
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M!*86"0F;!%WS-740]="I+X^+?Z@4F&&0WY:9,#!L![:T$@I3N4C(NJ;@<R<
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M\U3GRU9[:=AX\C(;H<F_7/F9GRX YK_@BS#%]VL=<^\UM-Q]^2&BS'L2HW+
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M-JDJ,ZQB66RW5L1=P/W5\[T^GW=JV;T/DP;O^>Z#T-PQ=#UCJ?&/4$YKR$2
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M4S;$@Q5.G-L'DG0#IRNER169 ^DS *4D!U>*/I,D-G)&G'/@L]+,BYWB=#_
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M96X#,B[8Y9ZM8*[,29:<T^CL_6S7'H^";IA/U?3M@6.]U&_>>Y5NX*T+ #H
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MB$<TD%P4)CR6F9?]/+1TQP>WDO 33!;S\E5KHR_]^WMK'L.QK\*&I@(-*X9
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M:ZM^)[@XQ:-7UT,$*UP60D"46 >M:0X^UPB^2.^TSEQ[W@/C>TB,"^-6LNS
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ME\0A"R:!2IH#4@@'C+S!PH1UMO1/J/<@.$;T6\NY2QT:U,1MNZXO%YBG5Y$
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M1\[DQ5O:#SG.*=!8YO1J^7MY%?]S/5EN4'R#J_S9BHS*V%H@C11;H/?@.&-
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MP!O%\F5X!S@ZPWV#H6'H,)&2J6*1H %^5)&WFB/BP.GNGO[R8 Q91-!XB]0
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M(%R6^7!5(JY"81^@&12FC+/,,T0<RI2$ P!3;?X9YDWV[3)-)\/ "!C,'N(
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M19CFUI[29"S:<KM=.8ITZ*7,6LU']A.'TF9<M4^G9Q\B.'=5"-KOY&5O&SI
MP!HKWG%16V\M?FZ< RZ][U>1X>B&8SZT76U1O.(&OTK\/*DI0Y$F-C9_:C-
M?[[_AI-ERSS?AC<FRYTD%\?.NYU<;!6Z09F<A.P+S ;/JT@7NS5C"LTB8QB6
MA2OW+=RP,+^35,FJ"]H4CZ&VY$5N^T;NN+UO35E,'2B)T2?V]W\3@X>6G:\7
MA\^"U]O%B7H(3]J/5JS=M;=:Z+.0VU^PP$!E3IBQ-\Y@X$#(P<'+@A7T8DC1
M&F8,ZL= CZ['94!\7&8)@KRQ7&!7,=)%W2/>D('-RK58[9!>+2XXA*Q6KDSV
M#XRHL#=^?CH_(2UR::9]2U3Y>WOVB2-SA$EALQUD_5';^;5\2(NAZYNKVTR@
MZY9N$49G[OM\V_%->I87Q"0V-6%%?""R79(4?734X:73*?.Y?;Z<@425'2PV
MZL9IN[Q!]KV# MOGKE$7H_-R]JFVW#VVJ<O5NE?VK*WS72LEZBF1ZC+\!J.H
M'O :V-?NLKW>N:QO[8AI7OT7=4 >^3X?[O#I\4$6WFW_Z9)7!-/LTI;05&,E
M[)I]WCH$I!^YQN1E8(E;V] ]6$-W1U5*@:3]I/&]I^F69 7BH#>QL5-6Z&R9
MAORT<^YNZ^,=,DLR/B_O_#YD<2?AN@[=S*/^5-''4Y]I4L8XO/"FLN=K="5Y
M:(9ND.^A^&K??1$+?#+CG-X1SSUP8#R.XF"7>_%7#/K0$<Z-=>5M#MATG$$?
M9\N7O.:[]762FNK"TUL%#[8W=9):<?A#6_L8SWJ%"LMB0V%XU46IX7ZK9UU0
MHE=;^PLD&5=H_'EFS*6TR-CL"VZPM7K)I^_#9J?V5>E?.YCY_+L[B34<4B1+
M>1)W#A5QFU*^:?QM5,_:1UG<105-D#D= ;EP=W)9_)NW["\5S181G=W=1M?=
MCLTKVN9 M2(V#=44;#?>UV<754@V1EL_,-S.:TAXUNV5U)G/V+XR)V:\;>_U
M4;?\PO+]]16CARZ$%PC%0N\8Y^;*5[(30;H;?SQ\N;'"/V@,UXG67CGZ?&]R
ME:]%4\O&@J15)B,Y'@MGE)?57JCAIL2')(Z@,A@=9%GQ2>/FK&V1T?FG#3G2
M&\ VE[A RQ%D%V4"$+1MPS>[E3#R(Z'1VC/WP8T6-Z32+M?#N8L9F^T?N C\
M?CK\L'=!=@>K#C6OVM?FH,-:4_2>@6A5NTU+^;T'(34QIQ+$RU3CG+BFT<T?
M709"DE\)W_)!<8.W4*/Y-96@.++P>[3=]NQOTIU%W=@E5'[SD[K@.L)#2H$T
M+VYAR8<"U!?*IKN]T$&'@#/^YQZ_L+OS_MD7!N>(I#\]\N*:1%G2:/.I,_TK
M[Y-+[FU0?4K3KZ\Z6[TO5M,J#N;&_,*MQW874?(5>,$[ 5[9:6K\I/HRJ'"0
M@Q, ,QFPZ'CRYV%<T;YYCUT;7P[47@-6;1Z?-BA1&Z:FR[=.B[-[Z>!M7[!N
M!"BS^+8;L=_Y\ J3HPU6"W*1QZR#;BV!B.HL/LV>%:NS6/MKW)8:V]/P665O
MS'E6P.8K+8K#7"-J2A;LT^WNOJSMXB)C^XT0AUM#;?,_!X%QM;VC+R8 &VYN
M6O!I)&+)Z[H\<]W/^S$/^]7;S^VHRAS?MGT'X5W?R.W0@+77+K<-D3/G?8?=
MZ7Z7/;9CXV.CUJT%+8^&U8%Y6TZ (1+A=4CJEIM^A_T$#T]R\G)N;X)W;L!,
M /9_("3X*][.#^S<=_\H5$(O/5SH7*'<;I#]T]N,QW.'BR\*![YGWDV>_:02
M/LOOKE=?@;,N/FM$EK_\J9Z(M.=LCVW0<&VO7=.M_**ZG(H@7\L;-@+3RZM6
M9Y!./2C]/OK6BU4E'BSWVZ\)I</0IPJ\K4T%7>F(D<X[D0.\ILZ5>9%Y:?[9
ML[:KK\8=\KI:FW 3\VU&%O]IUDS;A@O1YEFQMK"9#N5R;M\]Y5EZML7%KC29
M:^R&_([!P<TI*TXNJV_9LZU'&5&G[*9>&3MY'2\VV!9F07A_S.;+&W'[T#V[
MGFZ?1@F;3=YXI+Y%9BD<WW0-\=#3Z.:0W;TM\_?.I*_LKC#&-N45G\:;[LA+
MM"23DC/SGN<EK;0\V4GG8DEMZ!4WC^7DY2UUL>1G^P79:$(;]OS1QJZ<Z'QD
M%QWS<,SS<?HP^WI*K'TAZ^$K+/+<KFV?'20]UY/L(9<\@FR7< BAK0D9+%$S
MI_?684K @/\ 8H559Y/M#7,PY&1LV=GZUJ%[F,XJG.]67HT1OLRM<1PU5G'P
M6- SI3DV_9/>YJLV+)^ZF:A'LL+MTV-P!9E!FV?S@QVVRT>?6JK[6"=*A>$I
M3OG"\VN_\01GG!8RBZ&)'H(%'G;B?/G)*\9%:8+FP_WI)]:MA<;>E32_J3MG
M:'2S1NEX"U\H;@^*ZUUT&"5HBXY.W6S9NBV'2W,KZ K;=O59Y+N(HMIGQ,Z@
MV+3W,S+7)RT6?L_V.(RZ>F'(:0)0N?-SDW#XPK6='XY_QG7755'*GJ1F77CE
M=I/[*24?JI2.5XX'OX7NOC+D^B[,\'CI$DY> Y:6^771TJ7U3L']\K#O:(CU
MV9+:JZ^LKKR@5ZF <05BO%U^KMV@UYFNG+V6T>@!$=B:(VLU]N!_?K<D(!#U
M25A8&S<NJ'Y1>*;1XMFF9;B0Z;-4Y-X) +2HS>>YQ/X'_[.[H*4I!?Z;*;T]
M[7GM*F+UP;>8D)2F<XA3/Y'CJ?-?S"S;$\C==NKF!E]>W0)Q;7WK*!3VE$3N
M423T?.G@=74:Y9X.CA3Y H/N]M]8)$+5>)$)N5G?48SV3='=>.'AZ:%.IQ>M
MUX^(&3T,>;LFX8MQ](<4["NLK"IH0_HB[Q:A:X.;V4((:MRL]DMDQ]8U/5VM
MLNFKN82]9ZO(5A_1IQ/.BM@!O$57SID_^<A-!;*#S$"+;EB?$S,R[HV4&+WT
M/5 Q+R?WPXES=N7@OINW B6/#JLSQ)?7\"-/V=4Z%_6>Z=TO>:9[_4%T;?>V
M5VL.^#X(E#G%]2T<.>Q:4;9,91_&,YA=ASY1@VSROMFP@!WS>5$+]Q2VV]B[
MQ/;V6:1LQ]C\4;M]'^$Q44'Y!>L>S.SABH7"V\ 3)0C3C0."]/2V< 6^LR-)
MK3:@7;V;>:2DZDW)P=X\45'%F0_W!ZUO'W=CUX:&^@J79X93&V_G-:<.Y<Y1
M>96,H^I?+?Y\[FT-Q0BR(Z)[P>6'FT )M7L5.'V'U_WK#<N'C^O9^._?TF/K
M-&2X+FTOXVU7Y#BO&V'LQD&2,>N\B@WX66L'*_MFGJ^+3:GB=2BS!!WMXWFK
MOGYX14\]<8^5F$]5X1Q6)M2Y778H<S(B[-UU=\/L1UVPP07TZ/9D-^\-Q,(N
MC'<*V\1?-H]?$+'7GU,J.]Z JU^TQFKH'#DV\5J3-[)!!DR@7>O,]Q;5O!0&
MHEI'\D8V6T:&UGUJ#301%&*&[T1E!)J2C79DN+PEYLR9%['U>78=**$OPGS#
MU5L%XPD>YRFE%.#]]^0]LM6/(<=]BIV/EOB?U''8+0GLU_:Z;M%D$S%8BC%U
M?[V%+K>X=1PHW'-Y>%,O\+@G[>HF<T33(>P"Z[ 45 ^*M(K1<^_!A>0J00UQ
ML[9M6W[&U_R+[G:;S5_Y9MGK[EI7/<0RHI^ZA96,C!3BDVIHS)<,UBU>9,B^
MHE0V9/[8*=O(@S?4%B]NXA9^.'W67/:IQ/(IHL]T1W-8^ U8/J[NNUFS>MW[
M9C4_LTXMG-M3U$'.SBO<$5N'JTR5!W_*[2K>TUZ_\L/Z%5!]:['SH*HK8X 7
M^X1\WC*JSJXJ^UR6.*L FY_@\VDZ1LH--NOM3'2/BSMKUW_**0AE-SHPYL%D
M\B^6.JQ?$K+'L+Z"W?8@F)N2]_%4"SM%TIY@VK%U8P>C-'K0WZ!%>U^1:=B)
MF"V)SH$'H"V8"B*;;U?[+OV,W@4P^?R/*>(5"NJJ]_5IN0_7(Y8BLK+4$P G
M'1]Q#6AM_  YW#Z]LJ%[GM'SZR36AA>#_4,EQ,.)JS@';V@;Z=C%QAXLWMO1
MEWRU\=!5QTA6TPEE?LC10=-[[<OVW7MPI54P.#22C'E(R<^.\5\ F<DV0!?V
M]DVG'<UX]R*#49[^^EE_]IX[.V.VY=_9UM8>NNC')ZBWSX%XQ@K;QX\*+T!?
M*EXY[*2>#-=R/7 B9+RW\&35D9MGR4O&;AVSK&\9"T<X[0E*?B.R,KKX*F7_
MXY*WU (D6=(>B)199B<BFMMB @W?G> VG.LJ+7#*OA7E;XKJ/O,C>=9^L[;_
MSC/*):*T^57C2<&W/QAW;?ZX:^#9R*RFG3T;8K_]- 'X>DM/GKCST=+O/3L[
MF7L^MK\N4^H,>B]]]\%J_&5__U6WI6'/1[H:\QHV5LY^'EMQ_5(O.^Y8+'\+
M>\;UNIF>:$[ AOETV.V4=.+[1WEI2U=6LY)[;Y[PLEIG(==]6[0L[I:L(@Y(
M9I0S[&YUGCF:$S-D=_O$ZM$AQ1Q1WGL$/OA0=JQMP;XT5\ [TB <71ASP_>5
M%:AW]O,Y%17CD/I-PHP7&US[')H'"6$"'@I-^R+)_"GY4F#^F&D-_>3CD?R#
MQZ]<'QCHS5#7/)_> NNJ_,A1&9VW6%3T=,-"/+XQ,I[2. &P26I=.[AG?H/X
MC9E7H]&S0EG>J*7-A=.D(TVXS4N.?M&1N4N_&R8&G^VK!-Z 9ACLZ_,96\]8
M7/]N[,">!D98"'OX<Y:DV#ZJ?.SFBF/J=EW5W</R?;-V/UV8I@J_UMMP-SY1
M62K:*ABZ:?@-0^4;'46T8/CC> 6_8UO(I3=FR++5.\N0A?CFP"6!L\F;<^ZW
M!+YEQYR:W;7Z@_GJRGO8T]VE%-J(@E3WS)>;[<%J7GG_^;4CKRL$*W33^R#/
M9[)/N6RX02OP:C[BFL^)BK_6<$#O8HGH2E@E;2T0V@3>F!/=E0Y=&9WW-)^1
M1#:RRR4S;(X-5%94GSN65"FH>5>L'?R9$LG&6BF=^G%KA'TV]QL"*Z#E@H@H
MLY$7"Q'O'KQ+IYXVD37<.VG5URQ*X6,/I29AH''W5E^&4D,"?KBQ,@]IUS@P
M : X)4CO75@=\/AUI47VET-/65N/8ZR#K]?@-2&QTHA2'FA JCE;6R[?$-HA
M3,F%)>6_M_N672J8 $3J9\[NCR]!MB'2:$[1*9!+9U?/+OQ\,T+H0QNI8,*>
M)JB%9DV=G79?HG16CIHPO-,'T1;FOC9[D.:T01Q\0_V]I[XVT+=WS\=&@&&;
MC3LWCJ)+;RPJOY-71.H16&_,2<*,;;D;[Q/]\3@FW=HT/VM;8]Z%39G]SJD5
M;SCO?BH1[ZTHV_=I,;6P^@36>M9];L?9YG%$.YDS%\,D6;XJ[6,>1)2>]V/7
MY%OF(?VNX2$:A^W\S9H7_:9I&&ST)WS%4++EVS2OQ!6""\B8(>)(6.#5#4L1
M(\#<#WC%! "UKNW&:Z<[B2=<A&Z"3; =->RHPZF[4O9'/,!82N8%)D&,"&\(
M]B;DC(\]-@[&=-VCB&-DJ_B&%NDICN"3U5&+Q2:%%$T42"*EIZ>WXO%*.X=]
M'M=R"LG"HX<] #6!;Q#OSCZN& G9D/B\[).I*/_6/(.6XPM7A1XW>.<<A[8,
M>G8F_-S&BH9YC:<\#K:AFXZ4ROAQ*G[FQA1DJFEEPZ4/Y.22K6'WY=(-'N\[
MSWU)R,M-3\U8\*&RHK6\ZQEJDUG7FY!=C\UG>K<6"+(/99VYJ_&L&;;O+,SW
MK#=:ZK\C0J2>!?>L%2UVJY+,.62![OZZ.Z>A[>'&P377K=31XZF%P?7/GQJ7
MAE_"-"'H\9RE.:<)DMWY0:N>#%W_($R"C.<7%UD=WFICO?'CQB*O,PG-<MIG
M6\-*LC$CS^:H[SFSS\TQP-:B0]!\2OEG/-[\>=:,ZM34/7F7;O6\> N&-G7*
M;+PBKC!3XX+FZ.OHSV[FS^"?/,G733X;$Q6SY3[JGDL@LM7=Y);\1):#_.!L
MEX$DKP9C<EL-?D$'BDPFIUM:\LGD.Y%)9%^"90V^$$6U>^917??D<=FP9]9H
MB$!9<^A-XYYK-];&[&3>^=PR:Q /O1LWQS2,F,SXD-N:>@C?%&T94]UV3O2H
MT0+9HI@=W?3BWGH%XO)GDR1*7Q_9"%]:C^_=EKMP1?KK/-?HA/3A/.N7B^HC
MF^Z?L;(8D@U_,=K1+E0#NZ^?B0U853,BR:QXT4MI*!0^A[6=Z-[*9F \:0M;
MAT^X)M8HN,.'7\53;[J70PQ3,L+W;2HZ=I1;ZVL!U_5J/0$//RD;$*>^B4.+
M/BU<L Z>GMUW?@3?-P<SC,D/CDXBVR5\>OEZ:Y^SM\\A"C#.+B8]/S_0_,7*
M]LZ=!8=?]@9BJL*N]9L'8"G7I+,%1-_\HHSQEL<#8:FGTUN6^HT\V[XO,H6^
M?+G/5NVD/FT(YV5D\/X'&Y\UU3B8VGTD^W\Y-H;:ETW=W;WDBJA[@<"WLOBP
MQ5)R(HK+04: <@K/%)1C;*+QD%MK9D:O,8.\G/\98Y5/J;CY(3%)\9JX]YWV
M8SCMY:E%H[TWAY?8R9R>XX(J\_P"NPJVXT,BULN*M5^NVEN>EEJY[FP.]=#
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M(G=A*=M'Z27WG(GZU_>7?)G5<QZN^I&%4#ED6T1#"VM%8VL\XQH+&7@\\>8
M Y0P,U^_(JGE]HD4HR6QY.Y @XB"-V^_7W(^\-:S<&='([ZQ^OC7:SO?WYX
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MN&)-K#HPJ!/?"%4?#.[A#N:]NQ(^>.WM:Y#4=]\@.3+!^?J7*CX95RHKNL2
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M?VU]B_1:L^.-3O'Z&1TAAU@,^TAOPS.R+0>%N>\3+,?X=N*#YI:IFKI$%]G
M4(*Q/NEW ^&UVC:5,N=9KO/4%?;EKY==F[5!%<J32I8S791V;%!J*J?K<F5I
MT_P4I^%$D*^^2[IQF,02AYAVJ6;Z2UF([6*]<C8&UU6Z6-E';'<M6VK=F8Z.
MJ5)RB'$1FG6IW\,I=.<&H5"(PFSAK+G.R5)Z6@&Z@24B%N%D ( :@^DH(TW%
MM*V0A4'Y'??UN!>,?OS^M_T*M+6+K"LV8F[69M'<J(X#D*]JD"V*(TOUCKUP
MQ)0%6YOTD[;OP5S9]><;J\H%T:OFA'O_&BT4R!#SX Q@?C;E$.<<J_\PB,3O
MPR8CXBW@O44,%;G9X41:+TN7?F2D,("7&"WSO% OZ]L1M]U[M*A:.5K388YQ
M#J$4')O'>%28PW)1-"6>L@)?GFG%[Y,V@#G.^]9?] : FD9L"7B!.;#8HC'&
ME?GW<CV5E#1!Z>8;!@ZGCI5KHSZFL[2*T4J5NS!\3?$**O5<!SI14,]'KN_7
M_D8EQ68BV-C8NG/0'-]:=$BY=UY +$4]*\H$ OAZFHRUYQTFV ,=JB?&N>.8
M!FE:$6'"C *V-6;K)48K/LBJ1F^JZ5JIY!]3;8SE6H+ @%=?%/U4OJ]E6=TR
MMY"XDZ$;ZA,;--\!:S)DXYC(2YQP"5E% ('?QB ^5?_G<*C4C].H_T4:_O]O
M8,2U;K^L5^>_M5-IJ3\XTITUSXV\BK__\?0HXX=7)$QP>)(E.*.FLE#LOCU"
M38#C$.<K._.D89GB"L.^QJ^:_-"_5))C"*DVD^K5[17+<^^&'D'R)[4Y2 2G
M!ITJ1 %["2[*%:MAZSXY)Z!0_3=Y<:0R>:3]G[07CET=X5<,6R?R+ZX8"@\7
M)CY;6_+/7C$TE)\^"F,R#\0@]S7^XQ[2ZX9<_0&/%F#PG6'%OHS?R\W\QE1\
M^/[58+X]D^^[D)V1\#$S5R3%MR]>])%\7[KEOY4T! S2;Y9PWUODXY07UXVY
MGXXIWZAB')B_6=FO8J^!M29P  ""*34QL!%#?U;]1+:F8/'&X)1J;=\FA.!0
MHI'A,T-I@L&=&BNU^=!-?83[V6 VW'3[+CKAB@''O%^IZ/4RYPTTUE<\I>)E
M=B]F_6@1A]:NP=A[)32]C9<6&)?Z]JRRZ5IBQ8S%%4.J0^M>(7JNL[/2:@='
MLX&57=ND0O<50(EJ.$'S#T@MK!EE>E4$ .!KO-02RM4J (8Q)6=)3*GX![[9
M98)Z+@V.>L%&B>5^%V>MC25Y!>@A4?X4+81SABM"G"WQS:<:6^B^QNS#CGWY
M9]\%=%R5D *)L9@N,;^0E,6VYPXBF!6;2K8"P^)I=._J>!D!']EVA"_L!=Y3
MVTC3R$3O)"0 #9M=4)[TPS,8!0OYJ2MIZ([DK.7GYT?=\C<-<N.UP0$ Z;5Q
MV"ALW'3RC6@^6U,9"'NTJ:13)(O&PPB34;TZ88]HV\<<B3YEP>G3M_FA7K,]
MR5 8'E]1#X7"$65WTBYOX.LRV;SQ>2U4H\>7;+%L'GSQ"+^D3+Z/7%[CG+US
M9M-L0)^ M86\-M>T;O#^$9O K RV=#:CGSI9[_''2I?AM&OOC]-6;7M/M0<%
M@W[UL<OR]CL%)&X?V4:)R$%/S2,;_(ZQ;J:6>.R=L7ZD]'5J/TMGM^6:+ +?
M( *1W2],>'*VOU=F^L,<S]9&[GRV@-_$D^?,ZS?9>MN+&#FV@DP(RO*^R3H&
M#W<7IP7L_U+.DP$7>41F6PN>0GX?T4MO_NZAV]B:-"4.;#R<,5)?5SJ:QN:A
M^C9)O66,0#(4*NZOOH^<Y"LZRH:ZX'\4Y6XBV U.4^FHRO3#\J604*8_^V\H
MA(NHI4U'2>U'G+#(IL6XMENK%N,S,1,[RP7B+!6#7 +)DHDL+VY]+=+>/':Y
MF/AZ3!J@)6A'[+Z+T]XJC(43F!? LFRL&R0*N_*=*6R$-J$H0Z-H# $?,;IW
M!G4MGM/H$D 6_=BU5$SM,=\!R=U7$)/4KG'M3>PLS6:1):LE/EZ/#,HI@>L3
M4C[H3$WJ/%G^@ ?:]UOX.^7E.FS!+9>"5 7B[J >3_\[#L65/%:]NL&L, ,=
M@8VP)"U"&VR82Q/'"O-O1>00#1]M6"'QY+-[PJ7^>4.W>/(Y:A/.KA7RRIYF
MJMGV-'F$X0T?CIP?+]PL$9FJ^U/,^IU/8 85:J,S9NSB5V!1QB&'T2Z(GG+E
M9DGK/-^MB&X2-,V\\\4#=;<OG!S$=?D+1+"5U<AW\>.^>$.H;T))/D&@ S=)
MN5T4I77@$M4  1-EG/ ;5PS"=;SL$G^XI<:&&E=?Z]'ZAH)P%^*-/LKBZCTB
MBN0@'TN3+C*^YAG[/3""C$L"EMW#^MJ<NHX?"?1&+8,@0XL3QW2?4ZPA^^:2
M'Z#A@WV29NTWTEAS\L'3 _M)TS[9=-;C.,^- \'\R^2S/F-W5MR"_ARR/43:
MM,'#6 -#&!@R'A<-DG9$HWV@DS7GURF+<)2(C9]EQ=2RW4I)^0ZRMSC:YL%F
MY3ZL&Q>Z-YLT>+]$FCV@O]9_=K\UP.-ZHY="::Q<?8PF>1PSABB.1;)Y4LA0
M2\8;+P*B+'L\UZ6T*B)6U=6AZNH:(R:0T,!TR_@1UJ(0/HA;K/PGO&M55N *
M^P1A5T0U.V7*[[UL;T?EI\>M[Y0"5:**),TF]SX*UUE_<' Z]GS)H_C^J1YL
M$E*OJG"P9I]SML!JEC8+GGZD.<4<#5<@0:$SJ/A^Z!@XCU4K!V\4*A)(-U,=
MY>]W(7.KXW%T0Y=<&YY [ONG _D!8>.$E]^8-(Q"RX^X!X7<*)7CS9[F>$M/
M2V*11$HQ'_TL1L6L2GK_R:E#W[%<8 K;C_.HUQMI*W+:Z[.P*X;KO2>/8Y\(
MR?IW:57NI% RC20)G[ZM$0VA,D4C^0.29JLU%<'#XOV151HX\5J .U7VT=/-
M@8+#.&V>V)]9)>X\;]8UJA=HFTCQ_H:[N\-UW?R%;<IHE_5G;397#.BZ/HWZ
M%%IR!\[=Q*(&$V^1;F3+I%2OFM!#H]''%*<A:?FZ'\PUUT&E,26;T $-3=GB
MZJ#X:4.XANSC3F[1NA0ASK)':-.HDD^LL*3QR#8R,'WD<H.[] \0<4 _0@Y3
MRI+ ?JN;G>8*0\M=!.$1LE'MM6QZQHB]VD!C+"K=D&XI2I^.5!%Q_4/=6#OG
M*6UF:O0FLN?>[3BMMQ4<A*KJ"54-(JBF_C2[,@D'<"*Z$'#I3/P=\0-NNKK>
MA7@<D+Y53?TT1G_;86G[71S<_7W^^:'C6MCM?W@R&F2ZH*^\0R_(;=#O[OC3
M7;1WB:"B$K*V&!2X<V/W08PU#];I1#AM8-\H*U^_^2[V:\ICA/4D2<$V#( &
M=-.M7>JQ9R2-Y'.3T:A5*!02&K!#$K-YFUY'B8*.%5B,XP,>32 N9$?UUCM0
MW<CF*P;$X<'PL:.1>_SQG+- DV_C;P-LX4:.3I]8X:5=+)[WA4']05&>"<9I
MD))$H3>E&>&2S^UZYEI/7KZ? FVQ? &H>Z4#-3BV\GV\4K#M9$WGQ2D#853?
M<&<"1-K[%VVIQH@<?SMD21TNRB^ZOC=&4-]%MG8.B+2 !J\82I4F:_H<EFG4
MF'SM3I:#A)()$1_MF6KO%22T6L"CP6Z6.^J9O/NY2#'^?:>V^I[85T>NUB44
MEE.D9&=[)R<:91N4A\<)CF413>!0:@'4D"7)0*R%_0OF#+44I54)$F/FP.>"
MB;(;0+_1SCL (JU*:P+5S]GQ;[B"'_F??Y:FOW:@.)D?(&-X.5HK]&P?$Z<J
M,>H]T>L*K;IQ29A[<WRK<ZM?*L7L?))<"*O02:@540_[ .K+=**DFR)SQ?!T
MTUV!G[;6N/\A*O!^^G2"@88G[,-1(G[-_I.0'7Y!4=S[5[I*)JF*1DN7J0R[
M0E$<JIH_TEYXR(5##"9?%4ITB_OK2T1\]8N,L/;T@J-=<$KVI.$5W+<@BSGA
M-9&960A*2.6W[>Y(4@3E,LE$N4%1;B]3>[\,G_-FV?<\_^?/49H9>GMB0(_>
M@R'0!^XX8&=2@5.J'L9"A)H:2W0E['']#H8N2OSJ[[*RP:W&6RI=(Q+VSIXS
MVI@I,;,YIL*UP9Y4.%Y!GB?$#R#(O1G&&BX93HZ36?LSB]]SV/)+_BLHQ</Q
M+D;+<]YU];@ZC^$X5R=+N9%FDH^*HX-+@#RX:! 5T]*=:U:;'1J(#E.=WV;'
M\N6*)0?CFZ@YS]3/Y\9_J-E>[TSL?ESS-.;[#2XMUL3LQF C0(,]$0\24!_^
M@O(&N N-VCZ&?*F5;_B/7BV,E %P<2GZ#<"Q^B,PK.H_)F3G!KH=!J?5?R=<
MHNRO&.!^9ZO!?5<,S+PGC\[ 6SYQ^)]G6RW=0(/LW,\_]U94$_#TXV=S/=I6
M63)-AJSK3F,GD7-AW*NA4@K?;2O4;%<_3P4 ,'$-6\[?8B=KDL>1NEK:U592
MHU&6Y5VNUO="1#050NXLS5HXGR)/)3JS._+E5I@V5F-2[9WO'CUR5"^00(_M
M.(WY;O*/^X2G\Z-*#PN%AHG-2;'B;$Y)0\ELU^S"_18N?C@WPH,>7XK8>WS0
MN9XIAN$+1FGVU,0$ L6X*L><F7VV1QNY;BBIOO!3-@@WYY#<,1G?'/%&3=..
M0C0DZ_=T9F;%-YOJW"RJ1G4P,@]7<EIG#(_FVB:\-K<^3F]BUL4D+1/1ST>,
M;"PKA&_^0;NA4XE/4/#^&=DK+W6GIO-'7]64;;KJW6">4.M $3ZX%J3.,D;=
MT_CO[F+*Y7Y@-\50+V=@9,YZP+[A.,PA$K;E,F9 NU#\N4(LWXP;9DVI$#VJ
M!5+T6O?82MND*E:FE:W?XY@#I6FQRS_G7H<HE  #-3?$IQ(8E?,$9!YNO#+-
M,7C/-%/OE;7$U!O4T9I3:ZKY?(N*?I29;;6% U"9^;V)X(G<D&2(DG9Q>+VK
M)-9^76R7'>RN2 F>AO8<%XV^Z_WY;V6-)4A7WGR Y+_N'L6[+<-2ED/@V*"B
M=7+6)5-%,X:1]17,<4"V)$(EP)V^\3*YI[%D6W%5*.ET /QW>8[..\SZD\[7
M@TW)?/7%XD798QV5"WM/N$@%%E''VTVR?(E0]H*JF_7U&*%^X':-EH+EM& U
M*O4#V##XBD'G]@*C$"3TX=&_WJSQ#2*=PXA%BB1S#=E/)4<Q-<]";=16AM B
M=D)>9I8;D;T!/>!VKN.F]NB\KZ%'":\W_0Z(&P[1?N(Z=K,<H?:"K@VA^6ZD
MWJZJD\E-8V<?(_+89Z3'S!9!%INGY(ARH3#[N(XA))(.?QOG2+3\AD3^.7J6
MTW)@C$#=J=80CT$<E,Y^3]MZ+L9JR\:YCA5-^O(S-X&L7;"7H^C^]2*[2*%J
M/]:[J;'^"V:EN=%W;KP,KC*N3D@%$SDB(@\!@,?>":K.[&;LE0HNA'6K?[J7
M5X7_&RC_YY&\]UA[(;03U+($@/[DP'&]:)PI<J:A;,TO)Q03O'U&H!UST@9R
MLU1=<@X>Y09WK#2;KT@$IW;L!5]O:'Y">@SYX&)3,^FP(#>*X<.Z9)HK+X]D
MFN!AR41@,M5D E:+S<W^",MTTZ0A@<7)G_3<=@A7##O55PS?$Z\8JO%R'U:L
MKAAB7IS/7#&TW<MM6S@-.WQQ7B7FW!*]KFU*C+&5Z[H%4BTI5G ?N2Z&6/#Z
MC$D7_-UB4W!U>;IQMWZ,NW3R\M@K0&G];K9R;EV*OEJ\0>RYQ\F>6EG[]Z4,
MNPOXEPH /;Z;[EV6S:Q\"?9<#4!,MXM8? ?4.NX0L'8T!5:#N6!+>,*L57;D
M+#33$E^Y0+X7+?+$61/^Y-FI,]3F:=R-&>8)Y1Z'+NZT]8H $6?0=U8H[IU&
MSSVCC0WWGFU)3%]'1CFX)Z.'&<J,B"J!DE+&['WCIQ$E&N!/L92;&A[]%@!R
M]XK&05@B+&-39&AT&>]H3GKE)?BV*( XEKG[O:OG[()^4>1\,4QW*U'N$_F7
M?FH:08J^5^/+]B:1>YUP37,G6(Y1/R_W49N6P*L.$$C?M=?L_NU6_J;/%:J)
MD;+]FEVCZ!6\2#Q7 W,%5[4&=)@B2WIS%&%]"FTB%)!S,78F.'2%O_<W=8UQ
MQ$<7:9[_.O0[9AY52Z"UW:7-/<;/2B#B4A6W$E\?=S8.5MEJ!%I&IB!BQ'N\
M/F#CP38O_<%0K*W[-.7O++$T6UG%]ZK:LVD]8.1Z%*;O7Y4]L?V&$-_:$D>N
M!N"W8U#6!+Z A=]WJ+0:@J?WXX)91D5EW3@V%.;1W. "8''N%%&&KE.])=N?
M\RD81*6XC(P-1;4$$LB=5PRR_RHGM!@VM 0$4PE2I Q-1=0 A]H(/.7M?KVK
M]7WA8!PQZ8J!H:#UTO"-73"KV+*?5WNZA"+7O1BVV'4;K'/O)A &JW^DF2&8
M0 N?GD)JK\WW#%1PFB +:PA6.X!TJWPWH?JB/@Q0=3IK?WEH+M7_*9EX!)M>
MWDQ%;<1QQ#$SP_S^94?/K1?:3EE5_G9IN&]I"G_LT)+H9_Q4+R-]J"NK/.ON
MC8[1,0F+0P*3/6EFG2^5!O44\<5IUJH!G J,*#Z?#%AJR35U:]L+@QJ56$1>
M]<8(#/?TV4M6L:__0^OE1I%77!JE[R\+BVFNFEEW>(-XW?B"5+-'&TJ^]^?
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MZM'>X$M"$CG/(K1?UO\ZLKW_P=8T:1EG7-"5BRQ-8N]P$Q#*L/@V%LS]M68
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M]NZ^QTX,X\?'?#B9PHO;4(J$.9_@0%RF<(8'YIL7#-SKE+R]7U]'\\YJAB8
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M_;D>.BD+72$M2JY!"/F-O2S[ FNQQ^SAVM6R<:..I?/+@70#G@R(LCB,N5%
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M5SC0. \H-%^]1MTJ/126]:GX53#IWL(@HANV>VSM?'H=;M"*[+*F:H13YWU
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M&UW+T2,:5<$=QQY;8I#/K_]ZYN9]57F-^[;!YT FV<Q(J@$>[ K%HPV<"I+
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MZ[>:D=PR.4G%%14Q5&K-CD5$\*?&\ 593=:U0EA7BZ;&O"NKT8$V63AI>%%
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M>4S7CABM^IX/ZVLM)RL4-?TOD^=_K]AL[!XYIFVEN$]1L*YXS,TWRHU#EL
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MV=9Q;(NY\441A;:ZO9@DB#*,^DQ+0NBX7C.R1+C@TS#40G #[5OU6:ECFSY
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M%+GR[:1"ZMU%@A2375&F&>:BX4-/@JJ3*$-1AL_%#W0?-3[AT[0(0\4)1+<
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M74)$%%8_XN)'Q8KL6>KHBO*GI.(_J+X=J$<>-=__RS?[@:C>98%U=1XHTK+
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MN! Y^L1WIX+34PB4+PF#&!_(]Q6 &*JZ%%=NM2@^UK7VW,QS6,ECE_'M42C
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MD%UCFL0[8.Y2XVN_-D/'1,I8,096E_SIP!-F>?/P4&A8OM&4,.4N/Y?]/EF
M0Y\%R;Y["!/M:MUB;3AZZ<&!%R[_(<:\*3)D!H8:0<=$T3H^7J*W]5YT<7L8
MJ*H2YR80^XY3>7KWY5??7/0XE5L$72YL3Q#8[M?5\PU?&1()-^PM%8,>O.[=
ME7A^EJLJ3+]$^#-,XPI1RK]4ZG'?=OBU'W-C-Y#RKWN5[KO2)2X9 E:'$+:H
MJ%2728'H$FC>MUXW%N+;=3Q706/J#YQRFLTYC@J8+HF![:G!UK/>QIHTPB]V
M%J\,J0#$BRH[W'FCT@P5D'IO:'\77"PZ?V\[!7385Y_7-.256W2S"9GZ1\+7
MJOI@&I;JZ*\E OR%)TOW;%8:OWO&+0S&?PGT%B<HB?_2VU]V:TY?=T\E/RR*
ME7D<S3U?1AN]+I"\?[G;ZMDYC)H=W>/B['8)Z!F5T]+!55E,*3^0LUQTL)KK
M5KM<#N:RU?_K,*.A0UFHFJ@#[%?:,>[4NL/6'!PPQ63<K9?:X"Q4H1H'=O%!
M34=#9E3P^7Z)=!823N)L]GQS2\,:"G9(V<CV7 _1]$T%H;.>YPU'W<+V1YX>
M0QVJ4RSSA7YV=-73Q0GMWO>;8^.2?!VG%$U>ODOT_U*ZU"Q=/,+>*-XIH)G=
M(_)RX&L87:1UO:;=EU?/ZD&U,\[.E$,T;5F^,P:L4ISZPM&-V)"<&8Y<NZ"[
M;-,K+W?HK)KT2&2S0AYT:!UPD/G+3;UX/\K4[K!^KHXN10U$6;%W5".--@Q%
M3:02BP2?. @V)_CAGVL__.J:^&#ZLS%JQP)O=T^*(7.3_#B6Q\SI$;![1V@6
M@4KMC58W5.82-D/[K!>1?^M8:O!>;=1!AR,D?8W"C0:N;L8>D!&4;ZOQ>L_#
MOH6L;.JUU/TY?-\NE+!K(DV0_+3I(]B1YL'!_;O;='#@</_A@.6SF0##<W&Q
M>,: Y;Z#)';.Q\$4GER/=R']VXU_6?D=;/?W;@TU.VW_2'7AGBYP;"M.Y^(R
M^AQY,A2EZ194YY<@5NLE93!I.!A;',];\XK"J+1E<2T(8JQ95$#V4S755ASY
MVM23.F%C)?BO2JM;5Z=40,HP)]-'2-^$AYJ\F!RK:+M;V"2/7.=(J%\6/M&Y
M@<_[9G_X_GA06K!WC(W"7K+,\,L9C[G^DL_NK.WI>V3K+Q%%:53 3QAE$C[I
MY!N6PPHSEMNX&)^W!3*(-KY;9N(L\U5&V7]QQ2:M6HXGW"_9?.@V)Z_9F5-\
MO_/W7_)Q_Y&53&\O2W]>-C\:F#F\TQC_2#5*SV#706X2!D%QC0X4O(:6_5=2
M,GI1G<MRZ/]*2M:*CI:8K%U,JE.>YN103K/=J8 ?0:X^]OK7(C@K2LJ^MO+\
M7ZVNY1U*!=3 CQM2X#'J%@3:67EA@HSCJK-0[)\.6]4X34EZ!U;7\,J_9\".
M)P9%2Q+>4C2*AEC^D85W&F?_M%4IJO$T:GV%CI&&R\8>:2SJ"4*0LR4_RDKZ
MP(=Y-TV# QMM_JD5FAH>D[1^/V9<L4S!^60N1V'))Z^J:D6:_-7GMG-UNWO0
M:#[GZIH!)4\_[OI/7;XIM<K2Z>ZK4P:O_$1>5.E\^#DMTKC \3C4(]L]26.A
ME0L< HI U<6I% _138%A$'T)1-%=H.@?Y9VPVNBM)O01OF_UD-[AF_SK]+R'
M*O=K_LT0Z'@_9V*=;)HG1O-/0]4E\-+,3MM50J.JTN>'A_I'?\6RX&!#C<_=
M8H<VOX?-8=]9S,FRJ4\F"0EF>8F>3+%_^J>?ROAX?5K\?^ZG2CKOI@)VE#[
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M(D^& A]';NUN0(ZU+M)<Y:UK7WTX=TS^%%$&>9?\N9X-%LI4?RIN,C.M>F>
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MU)0U=-[&)]/(@XZ4L0*6RBI:RP&Y0#!?^(F# E$SJ[)NR<D^[:"P],1?;E@
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M2H1*%K@)-4D =;CL,A31(M*-A4O8B#7OU&H[(15=1O.C)D1OEE!KVR"C9AM
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M<(2[8M_P.@+NZ;$N-*,+W&X(LK9]\T#J0'.SE6Z9XR34*$K9>;1!LPX(]-R
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M1]+W"4@ZE&%PR3$$O"$K487-+B;,>(QL(<7A!LTS%HP&WLA(.\EBU1'##U%
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M 2-"#R78XJHI[6%XQ8ONNF9*]P\T0+F"BGO_=QJ@!W:=?W9*ZVKV::'[O#3
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MM4,83]>O2EF)MEE2+NDT\^/>[PD_F7A>#XX^/.3*!\W%Y+"<A!HUR=0AGQP
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M="2SQA,MLXUS$$0;3'9QD4B)M$N81F (TMVD??()%EYMOL$L=S%BP,OP*#=
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MV,R47^#/+QN4Q@U7^JQ^]%TN7WVRP^3MXFMI@'4H)93$[/FECP;HI81NJ=$
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M:"_-D&^3AX(-E($J'8W*WB#"RN<I8EQ?*U[$%].T =R-L?<(+!>(1Y3&C9C
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M_[DK5_/JY?TVR[+8]US]8U)#/";=E_H>:3[D30)1C"T?66KRJOX RU;Z>LY
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M+ @&SE<N\&^]713X*])N9.P)TKY?:, F@Q12AM80>6Z3S(]J R:G#@LO:LP
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MX_X_;[66EH<H!J;T$;L*9)K4O(H_KT]85E^"\>(NJ.Z!^/C!)[:Y9BZ_=XV
MDN;+54[56E]JWL'GI-%@[)KVGO&#C=85Z1II!<BKQ$^ZUEV''_K%)&83U.
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M#@&)4BWI:L[!</&!- .B?C HMBVC/BT?,'!2F\S([;1L:4._I\Z9:RL^6,;
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M_!W0X+6I4?\[PJ<#'.YU3%9&)?!L208N+4W+C%^P(68/UC$4DT,>*V]U)M]
M\I+N2(*EM$\8B\.K;PA7*J+?$F/#TJ0";H;->4ZF,4L+3HL\SF5.-_G5&OX/
MK'<;YLM'YLY,."$WOSAHM/'IP2;X^"V:2H1'L:'KM-FZ,&H.D5:+F+'_3UBF
M)BEV4NY)A7*PIWQ4E3.,TW^=NJW$YS*':'BSV P5H7SQ._W^4C[65]M";%2)
MBU_91O(S:Z13DT*,+Y5'A^^CD6U*TH;W,S1W)$]\6;P,WTC4#0LP' 2.LJ)C
MUX%I<V<W0DU,[/YHK6GLZ01.S-95N56Q3VD..9FPQ@9V"_/7+\]M23+D\5=_
MV,?]G\UD:NK'SMO?3#GTN?XON-/_M/^][8IZUZLLQ#ZLA[:ZXRPA7Z:O>5K+
M/E](&:L_7NL\_%>JE*CI/P5"RTC2]_%ZH-]5=+'ENFOTG;C@VEOC9LTWP=/6
MQ*7MJGAW#>-J[&Z1P5,Z:((A8)PN90&_](27"5D<I>&BVUWRW= H[W/TV *[
M3F@=I??,8/TY]U19N<1*%:,CY%ZY&*_=K-.I?Q4<K.RXUCV8EO;Y/U;3MG-]
MZEPJ!X7#Y-X$(<]%802CQ*6P].>E2%BFK.M+9KP'SK7^EQ,R$IU//BBR2*G;
MHE,5;])7O*V$)=<*ZA=Z9-4T.LVQ@9%S.Z_XM@7 RH:KL?DG80Q[P ,@N^=>
MB726!9730'?D?G? 6\[:=ZI?1J];VI[GK'-[]7\(.TLEH]*X%(9*J-Y;HQ.6
M&#AIO+0^F!Y:=0X-%!\O.4 MC0#'P;RCR"SBP4),2T&5=QVY;DR<5SR*I=(E
M?_!#C<R,WV^X,1W\60BT6%;QRJ%*6QA00<J;SW&R%Y+SG>N3#3$'MN'#Z;0;
MT[=7VDF=GD2TX__$NE8PLO50!R5FU*" EY+2<=!:SFQD3[CU]&S#^U\FC'@.
MG7H7T'L3JX%8%:+U-3W#L@A:=Q6LO:MR< _BRDX9PI.'8=FH<E,=P4I'TR+6
MM<NN7:[ JFQ,#1]ZJ:ZL!3;'"!@C#0).;?P OWCV-^#;$/E]I]AQ'^O^8,0:
M_0'6G:I=I^]YGJ4&0C=D\-?\%<5E30(?]_HP34WOR2@+981\Y0[83AU'TZA\
MFJ*@['"- QS<0]<= 9=]SLG-@M<;/[:$HO *T:?%V\>ZK0\2 I9A8+$*[9N/
M5.-#,)N&440Z,KO25@IIB[L4F>?6<=$:63'#H:987@79KW>I,\K5Q;T0O'TK
M'.AI.!+)Z"\"/FL2RR=<I^0 LQE,>]#FS[,/K /\S:8TP:(^VS_7._#O!]:1
M_"5!R)-B9V#'NP+"U?O.PA<92*VR'BGTJ%ND*G<CL*<FR3TM2%K0J*BO%MW+
M!7YF?AS':F5N?U23ETHOJQ[W85;<Y>NM+:AM%G]5)5SJ@BI_&J9L,%U?L'^0
MHUCQP%(=QC"=/@57;[\2HFX>J3$2"[6'.>?(-;(A,W^<^LBID0_^>GAHG(MA
M.ZU@LJ*%J-VB*T7J5/J^5 S<D7S8 R>FN:W4"%T?)6.!?&^F^O$:&@--G6YF
M+T%R[T/Y@Y=FOTM5]_H6!4R7<\8NM3R4T3LP)K(9)$!4KJ-&\6P.YG9B8#"4
MW3-^>(7<Y(/G6@J;YPP%DCPHN7?KN UB<= X6/R52J:Q)^0O]S'#'>8HW*EL
M1Q^R2/FM6B</+#K8,:FF5US3:7*3:E;1PF2+\Z7)DJ3'-M"9QE" ::L^:[#F
MX^:9U6#NC\O$I1#!? _\7W&KZG%6@CF@E"4ETUI2)KA#_\)07&,,T+0!J%2K
M-KTG) /EU!3SC]PTVT@PL_(QR!3QBDX?V(]08@>'VL6<Z\0K6+%Q32:_SAE0
MW%!(Y B8AN4':ZUE5#=-2"2B-DJ?%:P3A01XTQVWHYF22WM_WH*BH^NJ/__[
M6:&KGWXA1\''ML 2#GGY/'#7BV8>=4DVV)0!:OUMTO<'#^A*^=#TUNSV39%<
MX/$Y3MY1V #B.A:>(L%44_)J*X.F:MY"4.3O10-&L6F0.U5SBD_%'AND @LO
MJ[DCL4.6'?H,&Z2Y3 _!C,436W1S^YY38D11BMZR4.@5PMTH+4C_FSO7CPI/
M?NO:@?(,CT\ON+=8I)+<].]( MG0SS^M/>A[(UV[9!#4+XYME=:6M=;4FNT]
MI-&"I1OTS0$E7EFATYV%@!)&R%U>HY@6L"9MO%6CT:V@+*]'X2$MA4$TG%)>
M#+[II,.0)RI?RBQDBARZ14_BFG?M=86<^1EQ20DQ:P\%Z,52?;FIWP-Z99_9
MZ'W.P2E94M6DG M_?'I+ZAEW+7=LS2X..C)V3?H0R(9+F7S2F:L]XP5+4,_Q
M-U!!V<_YY.PW>R-X)D"7@YGBT!'.F/ADZT]$Z9W/,;=ZUMZ&^+))Y7!E/JJC
MBUCF/O@0###X\JGPJ!<E>'F]HL^@^U$@V4^C6H &)3WKFSI#)6['NOFEL<%$
MHGBCW# -8_E!%$O^-83T,GY@E $X;^N(!_![H9@9!.*I-'D[)TV3G:,ST4O8
MS8Q?CB>E[C-7[^LP3ZTV+"7\>U7\1P#&?GB0(U"81T*]$U+7T++4$%,UK2V7
MOEHK%$1ILYSFG-KJF@EBT7)=.L#_66=BU_4+HBF/I]+K,P"_SJCWR4Z"XI'<
M(1M7N&*QP[NWF]GLF2)6PKU:CC.3"+T(&D/'J]/T-YO-$YLOC4><[N..P!@T
MRK#8\%UK;IP(1L\@+)H(*6--[4RQ?9VWFUJQ=&C-7(8/["9"NL6NDR]I?UEO
MT_#.2D3RQ98!RYM5;6IF((+Q,+I8-2A$6=E6;2-_QN?35=V),5HV4\[1ZJ0"
M&#'#7&W]JG?*]$R3I4_&H>Y1#7Z>;2.V04!'Q/=9OJA1E,M*2>36(%GV< I3
M]J!GW)I,6&>EBPL_FM[7E7T-%__CK UMT(:![HN->@  (&IRG0&LXD2L7KK)
M><TV.[6N@DEQ\;B.GAI H&4FG("7^^D;DV=28[P_1ZO5]9ZO\>&6K93PDOFD
M]*G*!@O%6Y7*7GZ]R29,-^(7QY24Q&\QJ#5;)M2_2_7<9_-(]H-X=]N"\.2#
M)0&0>[2E@<!<#&?"$DW).(Z4(]KUF=E))4%?U6Z+0\'SQR&$,""4-Y]5]XQ\
MWII6.^=Q!@I&-X7B <\Z^>2KE4\B6@RUTGD]?U'!%/F8_C-^!4OM>.V($<N+
M;SM6(+.V9"0;J&9., 4IE/7[S[FE^:A5S*?:P'&_"_"7N&#56V/ZMTTN^\</
M_?-S1:S\D/Q9&YINLUV)<] [$K M+AV)0"=J.J0MY:9T3S Q'%)YZ$PNL)/_
M21&<](]A*NM7>B,F]^("BOAI^V'<E93JI"B,6+ID#7>>3?-1].R%DFUU&U#%
MFGM512N[:_-@"[>D)U/(_>'(,)"^][ISR44N/P]KQQUKAA\3U4Y?&!;=+F&;
MM3+49*Q0_2+T6]$]R.60$J*W(+-]0_#8JYB:XYXRV%J5F$-(M;GWJP(]LM]_
M1,PUQ WK\BR![6FR;:!80AXW\7J)OD0WI<NX+U!SX]'^S:=$W=#T,VUG4*"H
M_;9)ZT;O1ENXEOZW^,9X%RXE#-G$0B=V?18F!F\]?QG%#A.LL>?*'!C(:;?C
MFH>?[#=TR-.0?B^HT%;^>9A@,M;%)OC*&V)[,N>8>E^C(5;=(G\:ORGTZ3PZ
M5_2X]3NQ[UF0_7]O%^??75O<]C?G=G$S8"]:NIZ]:#"TM1?7(M86]+M'Z,=4
M3JH\@[7X*F^L7>#N#2RX>[QCP6I/Y(:FB/2.A+QO2K/L90*#9AVVMGZ_G%C/
M9<P51$V5A.P51\P8>A2H+[\_2&]076'ZOACQD^K0NI$3+S5Y:6'[2#-Q,^Z:
ME['&U='5DC)=%#'&CO[CX-]B_-\-'1#[#;%%FJBFWR"(;W!,,T5<?+)8:#OB
M7._'+"PD[3BE;J(.S%WI][3_\;T:*1Y>9@X<P+Z/Z_%^]W[6S0:A)6$X,0W1
M&)4-G2T#OO'@^/C$^4/OP-I8[N_O>[O'C#E"- ,I)G/+)W256*AP;SQ6WS5[
M0I&=H"???*#_K=()M;+*&[W%N(TT(@J*+K-QJ,29! M ,1,(%5"<+E4_J%HW
MDUXHSOE[&8]ZPD(6<<Q.*,[ZI8"R6#%O1G29?M?I#_F4UG]YFC'3CC)YS7HI
M*&OO9=]H Z!PK28@9\.8E-\ISEIFF?&Q3.)'IS![7.+0X5E0_L+U?'NO9M?O
M. &]A!JKMC#'"#W=EM53NN'#XJK@A;1)I%TKM\&FZRW5HN^_:@TAT4POU3>*
MU<_X8L]HG5@>YY7JFL;XJV?=0"=GGUKCL1'B!_T+_!!&TB9-E*'1Y9&K";U9
MVH6F%4<K$Z,&4UO98&+8F4]0V-+BS_T#N760Q[R<=2R766VWV>)K=%/'9G%[
M>4R9KFGSZQ:'F'1T*M*3VJ-OYXHBH)&9[#58&I-I6WM'@F*[B9A3_J3,0Y6\
M_C%^M #[9%P'9,.KM#QUH^&5U&=6'"_X/C\.<FG0D6*%SH%/VUE8@_;5N4Q!
MAW[!V?UMUVB%!>Z!3W:T%6(QY:;-/=!V!&J:(S%EE'E=WWB_N&)) >HP]\W;
MY=$=25<N<CMV9^S;LGCJ3 Z2.:@P./[HQU&F"\MCIE(]$73;@:'G,3ZY&+')
M?BYYE*E<+!3'EM^V>S:6W)NLFW<AX):\U(/O+$OYDX]>0-K:FO?ZFY>'9P2(
MZQ:9SN_\C%KXW*U\SWU=D_7N2$KWZ$>X$JB<DR&2+;Q8K2<8'9<8O+0@]W#L
M@H/ST2 ;YI:,@WA-72LX;;IKI,.&=<'.S.&?E?()M)82''Y):,H]+G!!=-9\
MLL_C7A+W;%V,]B3.YYUMG7E>L_<RS6=A1'R@/77FKQ"-L_DWO5/I)NC%'DSZ
MG)]7FY9#CR!'C^!F1^YOXXV@V).VH8UK_8HQH\MH,N53.;B#WP.(I'EKMZ;#
MP";J.K!0 C,1;<)4-57.,S%<56@E_A8LU7QI^J%\O\MZWB)YEQ<V$U2V=$A)
MH20LE2TD;7S@TVZ'%VN$2NGN30P>0@WU8^#G"=F+X1I?C^YG]4PI!(RY(3H(
M\4"*=E<BHMC_]\8PJ^4:LGI<[,*GQY[R$5T7"W^./UYE0E((H9$-Y-+,R^5X
M6_M 0"K$?.3%<]=#=(W4=@WO3%5F(T6[,5/+PB43.C!SVP.1U\&'*3#4!$PK
M-YLA-\ FB"L5C8N/^7U%G9^I6"Z,?:Y#OKV/ZHKJU.\^05S_-;'U;S;K4=$O
MFL5.3V+*&15QS/76$3=S">OVYAYA[LFX-AOQ]_AE6^PP:[PW][G%BUNB2G^F
MC%+Y"0PVTJ X.F9@:,NW/G<%7-/>UI<5[QZG!?1'T,Y@JN%TFA[ S2MJ,8J#
M9*7XTUM4C->O%N(E6-7X]6DR7NB24Z<9)VN66W=P:SOCX\MXV?VED6B:)=R&
MY-2'O-XRMQB81K@!A/:]O1$R$N1/<#LIXIM-1D.PVM[/AV4VZ3JT._H65?F_
MMJ(K_Y<Y]/]W[)DRKA%?M!;\X&QL<28K/U0YT6=:1C5;8;E59RIU#V"7K$/^
MS]YZ!;=M'L<B^#$AU9Y,. 7 LW# Y4DK.B"%P^/&1]PW^,*B1J.MCX3&5$H,
MQ!CZ]*"J'.DC,:_GT$X&JN9]['G3^S!092,?]Z.>7\,]W3^S(&+SR8:VK],4
MIA%; +'*= 5D.@4BV@3Q\B!EZ2HV>8I+2DK5O!CX@.WM9"2I1B_U,9AA4)0-
M(!F3&9WAR"S^0(!(R_.Z1!F5V\P&+0]*?0 2R;)?7++7G-D$"1<$=V]VNU]D
MS53I.H.8^L&,'!Y*6[U\+@;-%"H%9[PYFR4(@H+5K"SGQR7^2/ZG13@HVQZ*
MIK(E'1&#\C2(28<BP-2\11H-;[KF_O?,./7DZOGO?]ML[DBR9 ODQH,_&T2%
M9[<,CE /?OU_<)1[D:$1W)=BH5Y)B23_4\CVR?%OK;R!?BI)PWV3>B9XR=E+
M7IOL7RV52GBRU(D9_JIEU?VH2U7!94V&8/L7[%3P:S5Y08'(YWGG/_54V<;;
MO5]M?-.]+GEI8>*KPL]>+Y9F_SBD#</H:E/BU[ O!J*!?*C]Z4;8_,?K2@W\
MR2$^+$Z9,"-:TK/ \.\0WZIER,0_95Q"BHFS:N^3:2)/CNU7!RJ.?:/G=V/$
MT;E<$9B#&W]!;?ZXO%8M1VAZ&$A)-]_+E:R19BTEPUN]2:DZ7;4F3[QK1X1'
M6O]Z\6BDEL C#]@I>Y;XT]&37[)\;=WW =]1R#-S(@:[' "OW1(R7;V45RQS
MM580X7I12*$[IN3/=+W!]322$.&9NB8SD?UDF_C\B(:P&WVCT_;O'<EBPZ\[
MDMFY&,PU\H12H)@LY.D=R1GMAN$UD?'JY<S?*B$[-QP,9@Y@+NE%R8> TK&>
MHL%!)YW6V@%46/Y1LS=_G)4VT!#'?\D)H7WZ ;&J8Y=HOF(^\N&6GK#?;^_W
MWOXB]C1%W/@/44A-?WPQFMU96*'-9,/$E>",\D?JVU/ H_.:.!AOZ-MIJ\N3
MK[,[=71^>YGK]P<RK_U3R!4HJZ87O%R5/A?M=!%B-BSU8_%KKUU,D3FEGCI0
M^4EJMWB.L;-IG03EAXY%C6\.P,'G=R1Y&FMRBY3]Y__$0 &F/\="+?HE.G(.
M+$)70_5BA&Y..;5; P1??,D[GKN8IHSN._W^:> B)$BV?&%P8.W!GN$HCQE/
M9.1A87/"48A1W>V!%'%O+'"]W]7%01-%RES5DM:8UY;O$>)_E"AU,\QR.3-T
M'83$6^@@_'W3SCMXAZ21;<O[EX&+Q8T[-PJ_'X#:24.OP%.>MYA?IG<DJA[/
M=*+"DUOPZ;^J.G+U?'\"A3R;1MT+$(O:JZGB@8.DXNPN)>+5S"P+Y])%2N0Z
M689US&T3%?,W7W--'CD)ZO3:D9.;?5@+AP33['^Q]A(HM'R\6.Q8//XX,N"L
M94F,!LZA,*':HI'*JJ*;5L;C'F=-US_ 6U[L-67_7Y\M*%D8$Z.;!-*8Y2UF
M"#KTE+^4W91>%QL#J?@T-G1..,-:K/(B!9WOA^792XP-QIV=V9^)\-[NW-RG
MU8'<D7QJ!S(+"!U;0>[K\'\\.Y^IJ77*I#N*8%W%'E>\5T&XX!>*PXC1E-P)
M"V?T[V[[78<Y)-/"U!%/2OOS:0%W)&LBR#N2ULSGH3]32Q[A#W^%U'/<6&W(
MV-ML64F^]R;UATB%K]?U,G_M?8<5[C5*.L(JC_NP?QAXG1.A3;V5@+O</_B>
MW[9GT]8T:G]#N"+-U-DJ&O>L<#7 VSO&XURWB6.B?A7R%7MGZ6UAJH*O06(E
M3$;\>&BRL#,*,%/OS3+^0""F>IAK7!Q#H[GL#Y_HE!:F(G[I:],CF%"P 7:X
M+&85?\E<;\A=6"Z^O1VX?TWA'T+@*FFM^+<J2$C&CJ\5.2Z=N8X1O=AJVPNH
ML-T)%(W 61X)ILUK6V^6H 5USB:^RFON\9-L3T0XZ"]DQXI9O/J60 OTL/GI
MF?<N-U@'K.(,!Q;^GVN,0W)/.TZY?RG?5GMPWY%0,!HI"39];(F]1SI0X&?!
MD'FMYI9X&4^4V]US* +6<[C_D-*](RG&%EYU_(GR$M,GZ]N52.X^/GG&LH1:
MH1@]6UGH3EA%*BW]X(M\Y8[4P>B\M?KR03*KL[6-/;S[S;B6!>XT!:?#MDQV
M>/KFI_IE>VNH!HY#2:XIW+1RM,UA7#4D-5]^H%:U2OZ7LBOJ$T"^T@RP5/7+
MB[I3.V[MR:L66]#S:TZ0>YZ//1UYZ*+%%X'BCCN2!\UC!2\]'TAG$5G]><Q!
MJJGV37J%AIU4FSR!@6^L5X370#=YWYON2 8_<LAYAZ0\EVNTD&UO3?PFG6(]
MZ5K!9^^9A(!KAQ$9Q<HL(W86)K;KUHH+=;UE"Y$J8NF1)G,'@)Y>^Q0R$QFP
M^(L4*('#C WQ]1PA,.P=)?7Q.:CDMVQ^<+/6J Q\.*0,^!SLG&]G#!3%R;&*
M1Q*:"%.906>Z:LW<M%HAP\:ZUK,2ODLN?3A^5I8,?6''\H^4 L\%Q=FVP:R*
MNI17A)-_4[?_>M 'WT9KL0\X)BBVS#T>%H55+CCYG&S+>(R92X?8<#'O[>XB
M/XF08?IY#,!5)N&\&DP]0(-!BO2]V957\'>3\Q]?[@EV'9YKKA6>R&F]?!>R
M$_Q 84KG2=T=";U>X7E)0^C*)QN=.Y+R&^GPPJH \9CU#:@L7^).8/L=B:R)
MR(V=!\_P^6,IG;00VM =[=7$FP_KVK<<P.HX"_=[WM2S%X2._3\;<7GD;.&.
M! )=S5NXCYZVJ-,-)1K4WKK""W?6'=!:.9\7=C$W[_-N[TA\YVEODZ,I.@YX
M'DR],_P_%(:2_KLP-._2P4QJL-/V'--PFXXS.%WF.3F%RN=3!=:Z#BO/2>[;
M']'0B ;>;]53I5>K+WV0H3E?":>:P[G&#4B]':('##8[T=8YJ3FQK</-AGHZ
M>G&3#YDC6&2SVQME2XM%>D2?,8 E7XCM' !&I@LBT 5L=N7YYY[3N^ZORS*?
MK8V<,:O,GF1S[1<_?QP6I'>##/ED84Q*OYW^"V+B,\/*LZ"_(U(,S8$N!S3V
M[AII-J*R31#I5_BO:2FBH@I<<].-E[E4&Y95]<7[<X* .74>96FYX&X.XVPP
M$4^$UKM3^::U_$!H_-_*%OZWRN>70N!K(1:G79J4O%N2QP7ZG9W?8S[L-"25
M_; U?A,2ZT%U,:1A]T%L8HNG9A'_9@U@S[R7%;@5_I9K_?9?\(^\::Z%0CZL
M&GNV=VQ)0:_'I/IJSFDEO.+ N7C\GYUK'QS?04X],?_-EA0^L0E1%K3O!?]1
MY/OVN^70 _%V-LGU;@'(3JYZ^(PHTQT)R_=5MGRFBBZZ)-0><^2J%>A>+A=K
M+8'QJ=C8IS,?VR4I]Z.SW 7MC<P88^UF,^O'T299$0VV&:H,:>B>,Q]52H+8
MU?"S.+7KMJ=?\V6:0:L^)LV-,-"F>?-0@;TR@UA(6R;WE(GG9WR6[&HF/8MB
M94H-VN^RW-"J^,$!FUV,4\Y*TL_)@U2>5%)[ND[/.)N.FCSKNFK_Y^V?7?C/
M>W-?X90Y)T4$N!(5)W"J@3+0%BAV!3$#T0H<B0\4H;ZVP4ADUDVWFWL3A##O
M0^3[W!,_2V'L6X)251>F;*!4',]:'$&AU0(P PQATB;Y>%5:VK0_.\4MQV_P
M9V_,UN63=XSTAL/F^P+G->VMCWBZ&0NCO*;-EOBI38:E##EFGFQ,326C-NDV
MQO'#C%[(9-K#03^^K%O;^NZYF.KCRDM1!Y59G#8FI3+W-?(*K[#R*FQE=[5J
MZ"P^;'A8VC/2^^+"MP5GR#P$X%(=].?6-%OB>Q;GD=KK>']"YO$$0".?T]!O
M6W:!N;E:ANS6-O=[32)IMR]O^-#,JBY^_OH$6ERE4X.&E0J4.6SGG6NA3$"H
M&%I'YTK8S<GFZY0E)JS+NG'>>H9)"((-H$0X;@9#-!WBH3ONU^WL;? (.[__
MDN4\V(BS_6]9SMA"2@ITR?^4Y6PO#,MR_"]9SJA?LMH_/61#-P)3"1D@I)S6
M*(6Z4U37(3=P9F&AH26C=;_X$EYA0N$B159J>%&7:IK]U/"'8N#DS>O!S>^R
M&*[<E2@&[\/4<L*Z02E";51<H4?2D0C;J_&H_Q[#I4MN9M?_P;O@CL1^X^QL
M"X0/5,[O$,K&$K="FI'"^[S?<QF:$CA-BJMH\#^F3Q51<I;/ B3$&$(E5I_&
MV.5>SQ'0S0'BUU60R-#B*0#/-/@C:TOA?K1ZX*,7T(D[$ET1/QOPC,J1MU).
MP\?G HN(RLJ8T=:B$_83]S2\'K6&S2S^^5&B8[O2 23X*#/,Y$,*4-J<A1 +
M_0QG[L8<<L:;Q<0DE'!&3'D  #K4U&2IBX'39A]AS'7) HQC#>W*5;4@[-$X
M$V'"5$[[Y\M/+1OA3+>8-9<"86A?GRR&6+:K8K[IUJN$X.M2DAP.$$OPIEX2
M"<[+[S2C]KT/?%,4_RFSKB]O_YC^F#1'0.#-PGR.>UOY,#O7)]#T!'^]!_OL
M!3_H<SK#IH-5C4FO(E$!,9/G+KV6BRFX<'^ZBRA)9^K#Y<*<RJAK]AKERQ$Z
M$L]F!OCO2) 7;? ]TS#G$3N:0F--A,3;%!Y<=FY:$-RD9WI7"&3<7&9O2SOF
M3?7$*JV4A_!^\$L*@O+>8L/^L<O9<3Q:=;#:\V)QKAEZ:M!+Y:P)YRY0D\J-
M$9W80@ 02*,IKT1K"+33S?G=&RN^[C?3^XNJD "&*4W %N:>CACF6S187[&3
MZ>=B/';YK_.SQ03C/9[U$^09-G6D7R8JTU*D;E84#E8[8U'EJA5*Y2]#:>+V
M\[@4WYLULY7VJ5G%1QS]2BH;61;*]N2$ $'S--+]6LDRM7T752R[L?'91FCK
M52^?P](X#^R>2<V4ONZOM#<5%O:,TF(_$I46V7"V.J,&/8CS\4%] X205_&X
MGAK/DT(R%M0=B6/\]*^*.Y+*JX:6.Q+<'4F;NNUH1=#@'<GA_9L(N?V:VX?*
M_J&BTHMW)+;"5"]V#8]%[DAH7:$[AK<-.7H_('93RPFL=R1_18@%KZ.UW]%U
M7(Y-E!6GZ8BF2B+RHDNSGQ7'O'8F%YWD$K;.VP*ZZ?X3T>_B69A*QZ(BA@Y,
MCE,T1(R3BR(0.PK:/&,_8I *T[K=T.[6G7%"@<G?<279,*GG8I0F_O:6Z5I#
M(LH[QU\FQNU=CEL3=.0W).H(;'6S[VQ[NJWLF=O67OC6!I^\Y"KD2EH%?:0G
M\RL@Y79^42RI87!#_>W?S6W$O$(R9U_];$.ZCJ."9"%9.JYIL=L.5^(N+F06
M!W&2;C'JU=X3MWVY:1V;@5?O?.]X3#GF%@Z!IILD9?J&JX;G*K\U9)OV:Z?0
MB#@H#U-Z=KPH($3\$Z-T+ R69T:1UGW?N[_,Y5)WM-C $(2Q#']R.!@"W<*I
MH;%ZF44)3L/E77,M_C8*VH#F86VL?OFY8LY)QZNK=.-&5#J;P!F*M%%<?VXH
MEXQ"!FDIIXO6K[8=\J9QLSV[U\A3*!/99VISL\=(UQ?<<WG04]7H=(1QQ"WP
M@*O-S2QGS51RJ/GW9C.IQQ64)O! D&C%/H\:8++BO$+42$ A\7'8.YN@-^+7
MR>7+)6<.L2??6M[\S-I((BDU)W@D\ETM"][[8#'$>T<2T/3<!Q>R0-^"A7!S
M#&%962:9]\IS]#1^'(@L"[H\0Y;P$O-R9=HOUR\*FS%)P%4))Q]WP4>C ;%=
MF70E+Z58#JB-\GU&GY8Q,@C#-9DMHL0\-K<G''13?3Q+,6=;BAY_R(JWC3;\
M-62DC^>)==XLCWI<5M^?>$@KZW?1<-ZJH^L32LQD_SJEZ#$NBL@KPLA3>6]L
MM#3CM3 ZW@.D&33YKG+-];<I$:E0N'Z,KVY8H/E_FD!6NX]^KK/GC<"%-Q[H
MXE4V.-73:IWIFL<ZKM,[W>4R#U/@-1IJI/PBB@T/HJU2:@95&3UY[7*(&!B@
MOX&C(7[?)P.$2"PN+O8N,&DHY'$9GQR940X:-J[P$*@/3,9; =P XI;4M+KE
M*;\4>51TDR(ZU<P^_"& G]+*!*3>Z*XQ9_4)Q05EL9  D!G(,OWUT0#]TCL2
M(QP[6N%4TKYBQ8+IHJIQ2I*!4_?[4(.2W;=]TLL'Y.\>]G]&&K>%^^S:5Y<+
MS?L&>NAFLB^%ICP3X"<&5<A)6?1];G3IJ?&GU,MXS5!=0^U'/FY<,H\B?PF!
M5H /^AY^SW[@#M+[K9BS$H3CTTP[:9"LF(!(TK!(XIY36D0Y*[F_<8]C7256
MY*W'LY<PE ZF6MD0!VL5&%_IKC5N['W]&7-[M4O9GDO1%C 8Z,Z[D3R,&DL>
MVFH.R03 ARF&+C>\)E V@>E#[6 P E,ZK>4%&ZM$OSSB=2A=&[1Q:FD8F/ZK
M/_;[!1 GXJR_\^C7&RO&]7JM^LNG>4S+U6;?B5_G[D@$LP6/GP9G6[]NP_G,
M&+629=>C8-]]59K5'.](MOU*9XK$T#&9>R619^UV-=T$0/^"F%GAK-5^Q\W#
M)LP=27<B/-43NAYR[!,C<^' 4(#XCX5,E*F<A$53P]Q@8B;V;\Z8!3F[0)%5
MO^P^D83-P&#66P?0X+@EO87OM^9YD04S*TKN1WM&\X'>QXCC<SE%RJ&TA?F?
M/>D-9Q+OP Y;[?:A.9_[0JO^,+X"C^Z@OCG_B2#P.LN$JH=X4L6.*?*"D\RS
MW(RX("^9@"A)3:4'29?WG2*"FR[=4U^(G+],HY0]#..W?82%P(+CYFKU%3![
MC+P6;O60IW7W;'RG'#5JHL[05K5_W!ITL58.=6>*N2-YIZ./YNY.1XRQUS>_
M:,G#<KV'CR--YGB&RCIQ8ZZ4,48;K:F-] > T3]H!19?S[WO^VFM\>&;TZ>7
MA5OWL4,@>]:>TRU!=]+#4FBHP03')QF,2+[/*=11K0]1K__.[[";7.G/$:1G
M.)UBKP;?C,?Q6)39F 2S6(U+A5E63P7DVL-4-;@<]F&8 _%&.,*:*E8</E/*
MK>^:EWH^LM%I="[TZ2R+"'QC9@_Z>J3,L9&;MYU7G5=DK]_2Z\[KI(1P4C;3
M&$CV^C'>")$DIT!^V?HM/'B1P>X:I7R^E9U<,7'.'CJD;_$E__GTY-:#<T^B
M&?GQC3=Z?[I$VI!T8SX6/9@AWV2?Q>6>L$(;GI8]%,5MYV:=UE$=E.@HE]5@
M%?7:Y1'90).>@520-F5#(U%MKV&Z3ZS0KA60T@^KC461&YJ^WY;YN23^8LAM
MQ8V37GK/5H(\F8L 4AD*71 PD18%^96]I/D?Q+UE5!M,%^_+6V\I;7&G+>Y.
ML )/*<&E2 @$:2%H0G""M\]3P:4!@@1K<1("14)PBCL4"1:D6-"@Q5MZG_><
M;W>=N^Y=9ZVS[OXV\VUFS\S^_V;VFFV<JQ RZ0JM2'$2$]Z]G%QTJ^IWZ+YK
M0;K;ZE>V;SR^^B_ ???6O3(.3>_V#8/6V6^<IH4.(9>N7H1)\4P$57^E-53H
MC:ZVB7MN1=Y]"&(6:$1FBYV"8 05G'3>FAW)GPGGR3*F!'X_A8F6&CTM>%5M
M'5#-5B"2X/>Z4%(6RC;3IF^6QETO4YTS"&7K5K=-O#7*/* UAO4M;[YCEO_.
M2E%*9:AA=OO4!8X_J5U<"/;6=!6IK9B248[WQ"K)L+2]3,"$7D/)AITV?NQ9
M"[R4RPUJ<4 KBAU*#F8_WI%1?'WFR0BTD\2\@1?E;1I)11,](6[8\GA,MGGF
M'YHS>$!?I!!.A=SA92*673U\ 4F2^MV^?;VM QU3%' P/TR\M3+Z3(H4_>_^
M@2<Y5<YL[Z?+]7B>*)S%?290#>,'YD1<9IXK>?_H^E469.YV9>KW_D<HW:_Z
MJOO60GP4[DN78T0J?0!#QXVQ"SP"G3-!3+O7LCE&B ..;D/ZOL!(*D)^=0;>
M@Y)'\LM,"?/4&6CV%P;AK<W'K[9P*,;-^+"N=T$&/8)-+Y=/\D>C2]YGP+(#
M)?$CY/6FE/B%[H.AF(5-9K]D;A>GG!0[EB) J/<H?^SAZ[KN9S.+"S\%%WE.
M#O _ZKG(J@/X3!?)6LBWR0X/DI'N6@2@0<OD0D?-'SLQSE[!A80.LBHUD/A0
M/QVE;B"TX(R;,UJ@(VRFA?QYPM__N^#Y?\[^8_^FX"0!:ZM=;E=/!Z2 5+ST
M>/[0K Z6"F]RFSYT_:))7CO,MF0N72])8YS-_P'RM5JS5T)WK,5@C.]G5&&G
M7XSMH>/XUJZ'*Q5&[!P]T&XACI1&4%4V?6PU=:4$:A.(#/5/&VLW]C(XJ@&"
M-D=&H##=56T9IWEKEL7 C-2@KP9-DI:.34.6QF]<975D6AK37+0]Q$IKXK4]
MBE*G-,$W?\XMJ+UL^,"*4+L\@;YLWYH;QRP;_K+_GM9AY2Q15RF6>@=PWFK(
MQZ554W$6^U@4GQRL']0F<[CJ(84Q6OQ5\(L@27=[;1VQN/Q;8&[1R_$D:Q#Y
MJQ^!J]_&M_B,FY96S?IY0LKS]G*^9B^NML0-]V[*SB'P*G:=H<)#V:*-)GC0
MA-'=4O^D*$^1 *DVHZ0 Q[;XF9Q=NC:C6V:K\[F"]SVL3)+^>P-VXEK]AT90
MAU_PK 4D5NP7HO&'1KSK#\U/8?@?&GHG=:[Z/S1-DFI)#(I[DA==!U-HT+#H
MO+)@MWX?\NLXM 2I*R&7GQ)9W[8H+E .=G4T#2Q]B7R18W*/X#W=-?PR;,;)
M.^">&?;-V7SW6HNN8G;])7[_M35$]VLC+3QMO@T@%%-06S7[8F3H?LP<T$8K
MT45;C9G^0"W1LA)D-5_QWAD_O1(<<!XQV69SPS"D=\I$?9R;$YE%*I@@ 8%+
ML+Q1!8&6T:?)>OS#50D/,$Y/IVSN,H,&-7\46=L^2;KC )1+./BJ^2B[_IPV
M+NQ]U^UZGF,_2#P,BV>H,9$%@=PP25C<&L@<PPPC:.4]_J[_%PW-G1/*0OVZ
MQ^P#KSF=M?!71D"06P5S"ND$\1Q83:@>[J1T2.^V'<>Z1M3V:HD\Z1RT$NRL
M+(0E)F>WI0(L^FC'R!\&_XW>  9%2:]\(;N5M+3T]V:J9S)B==PWS/QD #P?
M;]3NH-BND,YH5VONVNG1J/A9VRG15\YWT.)'@MP"$TF&*>ADW2ZH7=6$EWR/
M##=PUK<1AK- R%N43]%>_'.L29'B$X9<DTKC+W3\8<!9+_8.\_"Y57(YT'+;
M;%+()/YV#-?=@H3Z_#LD^7WJ Y(MJS* -B[1*'#[D'R87$\W[:C:V]@'?_L]
M]5;5C$R8/7..WGH"2W7VII\'KU\L7_90*\DQ3P!$-X/Q==D[[+X-D!/D'#ZR
M$8[;9*6;!2MS1!.&53!;..#W&,,KTLI;\"Q)Q1)N%O 4CZ#U" 5EUQ3-!.'R
M%?+,[8W-2ESH)^4=I>*34OQS'EBN^<\W0B7F1'%Y+]C-O,M-%A+[M,427D"S
M3NT"/ORH:N;83I>[)1%6"=8F_["6X*HDN%58+9S3-^KW+JQJJUHN35.H0@T>
M5JDW!9JK4V-.YN<,JNV9/2?@6DMYV+$:H!WMYRRI[>(J-%D& L:0()>"8[6:
MYG15VY^&1<<M!I179>A_[-QKFZM@6180,5G(5G+)9(8>O.?:*+=UO;%!O?C7
M9V'8P4Q V)S"VF!2!XQH=RO8;%FLA#YKS6-=NR":MV=;N\_2<NA+R1G)'"X[
MI)K_U5!ANAR$VJ)4>V'\4-10$<*EXEA)S5C4FJ^JF:CW=&,(J79^W!("#Y&#
MR8R1-9\+WBKS"+YGJ-V.N%4MHFVRH*CF&&S6J<R_<JO_J\JVX'KON+_S.!!H
M+G@[/;.YZ]#E9N;.@=&/'X?0&7U%C=PJYXE43S0W9SI);\G8IVE\;@85[Z?<
M%<_G'P_-*OK4+BE-MM54/@@-:.B8Q1$9="MQV)BH1L1QLC.(6\MBUB(/RUMJ
M_L#)KQ&G0ZOH7Y34>MA0[Y2$H&-VB?X*(K!\DG=J1GH/'[!M4 L(UQ4KQV[*
M"9A[3Z\IFUEDM,/*<G1+?Z?.!0Z,]!7]/KRO?"JQNHVS 8_P,[SPB5IN6O4#
M5@\K< WJ#86JN=0G H%^($!Z#T*FF1M]&+$K9\DP!QEYD*1$ZB?!*3DEE+%2
MBPQ3<WW3(',(+XG!63XA:>MCK3\%/VMN9URIFSQ]<548$O"RYUZ-P-^D,O*3
M&>/">S5].<]=GD^$/.S'8(,YV [T/5XWIU-'Z-9W?A\F)_MU2Z5X*!J-4Z6;
M]"FC1'7AKJ7UBV<5'YUU:UVFX:082K'2'QJ0N1[NP,,F\ PIXA/9];=?99O<
MBL[/[0BJA[(-H5K'E 5M8NW_>,3_X!0WQ&D[(X')+6ER6:C[2Z<>[5Y1H(3*
M%S;VB)_."Y3,_TS)U%[0QW_LUUN-(XN2^&TKDCX-%,:=5@*T%DSZ+%\/L=0!
M?.<_U G>]1.#!JS(L4@@IYFWXN%KT2,U!1*@LBJ CG(<+DEQ[(-W&1Q)#!PE
M.RIQXO$YJT"4E"2_-G;CW_F#'IL?HYE!C$9,D\:Q34.47*E P07!"_*PY,6B
MS7;M[4&1 $HY3A"]0()ZQ@</9.A_9&F5NAR4"('>]$IC,WKAVN28V='C,G6^
M,V>_K"B"V@?.3]Z;TY!W3/]7[L#'O7:9$8@?OH.3/7Z!\B'.F-F*Z5FM[S&9
MP'\A-MA&=*U,<L8[U"GF(GAJ<EW@[<XT:59+IW?U<M@% U*OZD#:2+S)?(6I
MM1',%T-C5J%]&9N;:5$Z6AV=/4\"I0KX'RNK(&9K8/-R7.O*E7'0ZX._Q.YU
M5@[JW^>\]<ZF#+)EV75?1N$5?Y*::1F4;0+DEX6-BHH&F>L_OS%E+CL[DQ#>
M,1</AZ#!HAM:6D:BV(*;TR%??%]@;)),$G[+"J/HH'SF ,2S]%GZ8DM! E->
M3)5"Z<> ;464MT]!0!Q[9-;L@$9*FZ$9D)%?769CDOTPN6&^<]6-F'GD$#5\
M60_^O7CM:PA_<F]4PK_1O=PCJ=DFS]/1( BQ%;/=@Y"?\_;\0W.M?]K&I^FW
M7*I.^(!5FD&:?7L],_. 27-5&5S)"?*%L!\.(-)%8V0;&TO!*BZ[ X"_*E+'
M0I_G)!3D582W;Q?T?WE,ZP0+$\Q/6+(-1)EJ,G(O,S5WCH_710Y)ZG8(!>0\
MG[??0^S?:D8R,GU%BOF7:FF!;5NLN-!:V*H$F.B&;_EX=L)0SM=>KLHEI0>/
M!K3LN'X9/,OB6"B'[</&<L)A#1(#P3SYS1(9[;L<K ([STI68%6CS)=,++^B
M$1X$BUPED&%7OGLUO05>*E^(JZ3JKD'E)X?I)0L;94\/=%Z,/P]%X@VXQ;,X
ME]]%O!21HECPJ4]>=HE!96%A*5YKG67A)I#HA%+@.+4QN$^ .J6*T+.X$"4'
M/'HOVT+W!P9N.4QO*=A.V6 K$[6FOB[6Q4SDX;BFW(!^=J<H0&-!HG0PX]!4
M4P:9[ F*>T.,(UJ(7N3;/O_V%^%=D02E7L] U8EZM_,IHEK]D)5>T&)O052S
MI"K22#XJSUV@^(W?J4 C=]MSM*RE882>G%8M6)'MXTZUX:9G<E:"$M=7\5C$
M=0#9.UX7"L-!)OQR*/5[/8JH5&_#(O)].3I8P_FHVI'^NK+M;^$XN_A"*$/)
MA0=!GI<7BQ4M&TI@5?A?E!F\H7D<NZ2^0'&)RZL:4W:6")IDU4%J;8S)#CXQ
MK=,>U.(1F.&C"')7OH>K,94RF+;PE,W7DTM6>&0>SO%FXPZ?MY:AZX9^++.R
M7V9%TG25<5Z;KU(<K!V)T4)ASY;A:_ZRO/6/AQ3V=&H5IOV0Z$8II'+%_?ZS
MII$N+-D@"M6TS-OH -DJA$R Q<!&2%/+DOE[:(O?X3QUIH0@Z&?J0>/G':@7
M67T#C:>* DP_K(0X^3OI/QK=>37061=Z_R+X/!GDJNS4&%&@\^TI2*;_3;^&
M:NA%W^7/!07TI):>P$"ZT3MRU>9!BT!#6))X12@?"H_^5(6',UC* @.5L)VP
MVJH]186EF6+VZ#.0G:L72[N:J4TMME&_A*3EJR#/B^"5@-44WO7B>@U__;]6
MX@I7N $><?O:WXF)*3D&/E<KK2(+0>?S!:*-R796R-]@RB&5;/)K9;*213%0
M24.F'IGD]:PTR=XP0!>D6@^0^03X?U#XSTU>O7'P6XF:<QAGWVP#*EPF<:ZC
M7L[JRWQ XM\2J3[29B'C+K;V)N-;;AF=(@(K!>Y#OOE]2%D9HXP,J&2"S#3V
MM27E>N%IU_I -P(@.;U%_WKY5_5/^R&^E[EKU$O])D'70KLZT_P&UWN;EC!;
MQ[Z"&$]ZIY6[CC+Y*>1'\1.\5/KKUHH/Q=0%<B.'#RK6Z^WJ!((->N "&5:"
MXXVB!P)]=#J5]L1P/M%#K!'!U^%QBT)7N28WJ^1R[[E5(;.;_9@",IF9_.3F
M^4784:Q% -NR<>%:2[;>CK.K<Y>J>+.QW0!8;H*3\.;Y('=_H@K.>$N_^>]L
MIU)ZGW?\X,&X]U6"6G.,-'36VSHD9.R81E0B,2R.5FSW1XO18[N#2ZMF)$[W
MTOB;#]NNGON 65D*?V;X6YTX#]>Q8J\4DJ\?X#5F*#4L^<.WXD3NFL4NG4EL
M7IH8+HQ<[0,VGLT9ZH<+>08F#"R#>$F<:X:.PPL?@2M&ZKYKBA8.$>J,=U5I
M00P!J[LL1D?H26O0MRO9\!<-O\.>S4622 _R%6EO2]4U(M]0,68 '+;QW6/H
ME,,:DT#""Y#OM7&6'ABX5I[3G4M%4W(\Q1<'LCFW0#[JI^6]_24A<OZ"G-3P
M"KSW6T,].]_*DP,8^MI,Z XJL^3PV@#7AUC9%J>*O8.JLOW:ET&CMLS(A#%3
MYGL@1H#TS3?J3]1= ]Q&68V?^HP7D.Y2<:Z'@F(!([8[S'@U5H*G_(E*UU4I
M_/Y!(ZZ*406;9AUZM#3SN.6KMFB"A>A-O?9;U/:_-?UU=#1B;<(4$*'3V2\%
M_(T^=OJ;W1LM/%_JU8<6 >68<K)9I9L@^3;'/@70K$95L/$C9.F4W76GF/((
M!JMO<!D5_/'Q!F=O-@)[@7Y6Z?M*"\((VZQ60SE$S;!/ITPG]?18"QS?YD_R
M+!Q7[%_V_'189*DH)0N<,-(INP<N57WY4&O^>A-A1- _%;O*DX<Y;RL[%7A
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M]BDW<V$/:X]\JW*RV'&[7'RJJ^P!MN+!U+ $R3:FT2B.G=<LMDPAB"G]@5[
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MYT1PR=Q<I9\[W"YO"Z)=\R$M:]">CHUT7"Z+2:G$$$&S]_<O[PANSC!VH-W
M,/WS/E/85DYF(\X"1!S.(G.H'\;$CIWRU#;!R##A)?'RD/FK:B%09L=;MAB!
M2+9XM+G(:M>P])O!DX>%9J6:?D,C15)RM1H=/A,O/OW2I@RI3!;].\B7G](R
M^G\:?)R3UZ_GD[4S[Z,+9Z@<.2J/=J@8;.1_KPT[=\^4FDED_F5O)79$L%0T
MG8VF1UHT%TJ5>>G#CXWBQQZ61#Z<[NA5..S>V<U<?P6'.[HM,53,A6M.)P?
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MI*>31R*T0%O!ON(---VN,6LF; ?V3-\#< @11[7,ZIG:1D779,WN$,#F)<=
M"U">)>[*[B+<]P]-B>!PZ7SP;V3A%EY(VZ("UN0U9K8G5,""_!$?*Y;)3!CP
M[29\2M%C**A),A9@X54R97&7:<^P&OVF[G0J=#B3LB?].(V6]A=4?9ENIJ[[
M0)=,2U]23CG/1):3,SBP]5^54ZE@CS[57>9H#@FY(NN^]+#4>H"(IXQU4F)]
M=LE$GF6FN)%H-)ZCI!//W'_Q,K-!@N5+62EIZ.U?%=H6FVBVU$\!_3NJ88"$
MF#@GXV6)[T+N"5^&<L9+L!$J.%&H\)<X/[:9'[8=Z3Y-4_'S+H8]?A(4U5"Y
MPAQWL/NA[AH66UY@?(M SS&9IU 2KZ5%8@T,5#PU:6X*+6A ]Z\KSX) 04')
M9H(?OH/'RW(-6W1]<[W'B$2>Y17DO7C"JGUCY?>%6?AQ<#KAR0Z+2*J<=P7B
M\%/ E,S#3U59Y9QKLP9Y#>PO/]K09MX-,3E4/K)KH'Y?C?V]L"?I[CW9RIAT
M0EMK,^3#%"TNW7E6Z%SC.SC#]I6W\A<YG:+AW#^, )RJ;Q_MWDS[VN<=YS[\
MD24 5<7'=5(^#B'!45'K?,FNFCM840F6E/&&+.F_MVJ#$-;7^XA-0:2+BW<?
MGCF1A=TB6;FWPR(JI$&Q;J5]5F+^+?GOC5^6/OVXJ,/8_U5SG5\W<M@7\;#5
M5F>52IQNX6N(.@)(9?@(Z9]EB\?7MB,$,C9.]9C\;'2B^BM)E_2&3?,@>GO*
M*"/SD)SGID!=)HT!.78&W4_RJY58\4O%XG5DJE4P;E-N1]C'8E@-@Y-GU.AR
M^PW '9CE19X6_CJCT&N]83%6_=(%*=YXR/")<OZF57ZGWC/O9;4M86510?\E
M@4?*EJ(EX;G"BP#B8RG%-.M0&;+)V\8R;2>,[I+ET0GQSH3CW%]3]:C>))DR
MIU'E'3"_3W.5@E594M%>]>7AA\3J)FAA&P4YEN]>VS.6Z0&T &)Y^3!8=#Z(
M600X]D91,V!]A1OR6.>OS6R)&F'F0O8V"ZH-9,\(XPHJ)XJ8>8Y)'+OZC$D]
M@)MN9C8D24%S5#VCI9-NB&KQ!BW:C+5>V65.=ZTOW.)+6)DV=FK0,?#QBIR=
MZ]R.3C/(YA/JD,1SJDX99#.-:I^*MNB(D89EFY!V(RNG#[J*&AJ(S4GEH4_C
MJ>#&CR#N&ZC\M(\02EXY&H(M;54)?)?YWM$#$_FT(0+AAIBO+/&\*X*3[Y)Y
M5XGYEZ%/GOA.8SKK8&T&\5T*G$6^C<CI0L]ZF9RCBIO8*+_4P/./?<I0,?O=
MD;7\V[DT VRQEL]>,#:$Z,4NR[@;.X\IC!C G75$Q7V:0520_@NBG%-'Y;/%
M"*OI@7>K.%>(U6!*:B#>4]#K&&0*=LAQLA/Y-EO/&AI,__EX3\B?2M:EWI+D
ML9 \V%3PK[X9,POA?1Y;>^A=_7UX&-.)D+@K/L1Z9[531:?_#4>!*5^VG-_D
MSFE\1J!1CKC<B1FJK+M, *S DVG:VT. IK)#8F(VUN*'H24EJ\!9*.:$T!?U
M.GUH]S_17;$.6]%^C%CT6 )07[G<F,E7-&]_/R\O3^2VK<?2'QJS-QD \@3X
M\79(:]KLK765?KL0.=PXG8F?:8<O.EJ<+K5.>/9>MNLSQQN>1QV!2GT=_J.*
MWOU%9H4;MWZ>SAQ6'KUZ[W":V=O0=6A\L(.8Y["K'3W[B%4(#_C8YY& H3SP
M 1T@=-S%>#89W=G6P-2R0#DGPTO$_?3!-#87.4;FIF7M:EG,"=BQ/%2LD* [
M%X,KBBU6V:WC*0N;KM!U/]J:]_J6;>3RW"H[6D.@[O6I9'?5%'?!.U_I[[(J
M2]< <.XG&6BC =LD"7!4>J_P?A2[F52%+ _?H5>=K?&SG;E73 N2OC6^>LZT
MTC/> \)",&R5=49(HW$HJ_-@$I$NNC<)<!/%MK%S9D&N[T\F,AI$'\3I*Y0A
M=.UN&/E:)O@:%(+D1:7*X^V$21!1K[?WSI2+@A3QI +XK81"#\89Q]/7'M83
M9)?1P#27?Y)U=PWG/NI+7E/:QE/..GV=,E#FJSW6 2S>Q&=>*Y3K:F'?*"D]
M1_"9!YQ>M6158?0\SZ2B!(BSAI#DFJ>8DSWA'_/O68FJ59J)<BDCQ[B0=].B
M1 $L(+YHPG0\;K6<*!E?+)EF*L_+JR![6U*AJ&UNSG4>DVRI!WZZIRK[CP(P
M*KFVSZ 3;$VLX;=R)SD5/'$HDRU)IAP1@TSNRMET@OF?-A;()-AZ^9[C))SL
MME\KCRMV!:B_:J\4+E]UKN9+<E69#YY&Q6&LH*#U3&YD@>< ;!6'XFAEL6FM
M:C_8-C1X!)]WOS&$ZNW440;E5+LE^)GO\<)]3>6WO^L0]3PS,SG_B?;,"&]5
MP^^<TGTJ! #H=AM3JP;E8O"6 \\VC\ &UJ4_3R7F]?L-!?W0\E-/HT;%3V.S
M7-DWO;)&,(:51PR_;@T(V"RGI@NRI$FAB95MG 4Y;YS+_,QH,U-QT 1%7C%T
M3"S?3U$)<X4%]9#*85HX"UO?"N$]PC:)#X)=]\@3]5#;*(DB39;B]5*X +!]
M&NPK6143/_4O@S/E9OLMHKP;"QTU=/6?Z>'P0I*X/^? )G2F*+-/NG5PZK/S
MCY0J=A#GN<KVDO;PLYN9*04RB3OJ*RT^I\SQNY)THUZ3[CO\M>VJLLX!S:1.
MUM2X^"?1@^%9YD9<I;?Z-1!Q,ZBL%7Z0+U^(D+@7IYCMFHOSSMBZ5AF1PFVI
M1DV2-TK%BB/\,%2,94F*!5;5.-IYXB*WY#;?4ROY]?@TRZULEWPFABJW8?5"
MT<GQ:EVGNVF/&E]!PW9J^!Y:^T(S1-AF&Y>%1'/N1\\)3O3SMW*LBZ\=+C;2
MG@N>!Q*Z#N(FDT3;8J&TG/@=%ERUY&/G4>JD-5G+7VZQ$^=9@ZIL<(*O3+&E
M\B5+*]ONY')W=?T&NRQ38GJ;$B(D(A#*"H2QVC([X9@M41TA?A6.W>)?!:C%
M9UKD$*+U<_U7]#/>!^9;$"PCI):TKEVMSY*4K9[O$O4ISED>9"=MH!S+IW68
M:?NH4R@VY_-\X-'U7B0Y+S8P=+/-)\SF4>0#&W:GCQ*[CJU$RCR#?V%]_3MM
MW;-::,;B'BTOU;!<1_7UL+0:=<EP8*CM2(+0U3D4B?$E.E#1*997XPBJ!0A!
M/[!-=0^ U0@VQEV\0*FL#6R;\ <[N*S:=>LW3=+=B4A1,2Z?)+US.,U:4(['
MC>>S4Y!!VS]*6$";42V0E,YVD93?8_LNQ]57.]7/3)<X\7VU&=#K,6MC90F-
M#:TMV4CE6L+17.^N"Y-^,V(9Z*54LA:*)MB!$AVG!8[,%J]UY%<2X"22-7\J
M>"./MWFK46)IVC-F$_N]HD>]P?0(^2ICZH&>3\PM.0<=&R\93FWBD_9M'9QU
M26TMC^?;'WK2T\GHLW5[CZ_:9X,3,%QGBE?*UR]W/+AE+PP.UXZBZ\0DNJ9W
MB:&L#$MIEE9AJ8R5)\3 1W;D5@0:NI.705U_^F8P'E59SY,XXY?L/%!_Z'G@
MFV4-$:=]'/HYS+M!B+=*IU9;PERS>TH4A-/AS;<DY)5_%/A#$X\-<&\R-,TY
M]-MM+73[5)&_8/NT9'^<I;G##\'SS_T:L1Z1.3RFY3]-%ZMM]L\27]$JMB6F
M]B8?JC:9- O^PCA?BFLN^E])]%3?/VBN'9L?8&[AA*UCQRP)"/P>Q5^8D""2
M476AF!W:#-M^%J#HX\XT^$U5<^M@HZ1'EU+%(EJQH#7M5&YYA;--L>/4;S#<
MFW@8;_Z+N&P_.8I63O5&#HBYW85TU -3-=D[J?I#].X.K/(X?ZZR%(_Z9=GI
M?K2"[-P6VG/SE_H287W \UB:.NB5>7OA@=SU76DX>(B+&D_OK%O^)&G^4"O!
M,J]%/AG!@<UT(SG;$"QJG :17,0,B8/05!PU'\PW*E_/<:(<@\?+%\+U-POE
M+3ZH9W,9;=-VLJMV\>96U-!)O@]*B_^4F;* =".7T8)'2U3=0KE!J>E-I;[R
MR5$3NHG)K>U&H+Y/>\Q<2\[F>Q49\X=A25[EXP][#IH,9%]1GJG?KA+>3W\,
METL_AB?11CHBHQ%?$T'(.=%-3CWA"AP;M2+[B&>G6MY[?MXH5&)5P@)F0[!:
M ^;M-+LF.D8UP&:Q[F,-],ZY6<_L5B,%S[0\E;]Y&'F)U(J/;!1-3V7JR\V>
M9,L/U\NBL1:CCXZM5,D4*TB(2 P"(VR>W-<++6F-LGW]"UY'M^O9Z'_Y^]=(
MI_>@&5>F._>B9@W1RDO2T?] HBELE<@P*S,1H6>IQU'2"(OW"!6SW(XK3I<6
MOPY KGXWGE.13\;$9\JJ82D[ K:GVK%;.#1(R9_7'+RZ"6^G-;GI3Q=KOR,"
M\;CJJ/.PAJ/?N<1=P/0?RLQ$??Q0 50,U;#']8E$T.61K+I4-5-B&\T;H%"E
M7OQ10.L.'X4QZ*0^3;PC')'J\;6.^B6&BI*U:_&U=D$-1KA/9WJB\$ ]9E!E
M;4F,41/7C%=F9:K]#,#2&GA-!H_B2,#;KHOFV_X<PT97F#UMXBRV;-_]_:+:
M_SAZH$@Z4R76+5^W5Z;-\$2!5ERUKD)%EC>C72>8+5#)CC>7("><(^WA5#\L
M]]F7Q[.UEWWJ[O 9E%W@BC'*9KXR\3+12L CBUQ:R/$35MF/,>7"ID#8<IBC
M##XL(\^R[L1*- VBZ ,D!U!N+<Z%K(.%?F<#HQ4EK"S$^VBB\>&_NFFK5T];
M#.SD*:VPB6M.@-143WK*6ML9(0M_=2*I7/EH%&_UO8R&SFY&V^8CKI;LO5?K
MR6O$T'I><4[5U2Q7UM8(K8S4<2/F,IGA>+^WKE&S\_ZU!'C5&J+:E HBQR--
M<8T'U VGP8X( )FQ0])3 $;EXZ)T3P0PRQMQGG<:W\QG*,6SI(@_QQVG4!_;
M4%"^LVG9C0YOUPEEJBP_@I L=Q7-BVW$' & 1F[V5WAM[2>EIHY#F8[\\_('
M66<Q[,"'%!?$4- ;#4SHV^MM^[]8Z1(QNA[X^IX.3D>M(C(E+-F$/R9FTPF]
MM8Y#,SJ73!+UEEGWYQ?]&VV"$%\\AP<-9RWS%/O+07[H@/IA"#Z((0IM-QHN
M&Y*_7XP6WGGP;.R8T/>!H?:.[L Q9LU(LK5F?"W)3H.? +*#?*Y]<;WI^2V*
M-4 BICHP79+!US_&66Y[=[\%?F5Z>M1PV[EY;7&Y5I&5+L):_$=M_6;JJ0Q6
MDM3<@:!4ABB -DCHK:EN')'1OF1BP^.5^NZE@O-:57=ACE"K\P"GU95/HC&+
M&MM&*L:]IL9R&R;Y;F26XS:J%.3*M&:$>SF+G[RM>P;"*YOG1DZ!W,*T>4=W
MY,!$:V4;8+6LB2P6IQ1FN;;+>8.77\I3;K7E0(9[JI6-Z+DA?H![QC(3:WV@
M&N7<7)><!0:  9-*/XC3G@.07O2V!5@%".&XS99YW29"T#Z!HNHBM)!!]:\(
M@"58./*Q:^7Q EI H*<<\,*' F<!?37!BN.8$6#&>W47W4L#CW,AE!C?327'
M"J'GVA9=G8B<G#7MS@'GK-88U&LLHGK1VS]N(W H<EARB[C8$.B93WDS3O_^
MD;&[=8R53!7O $O4'HM&Z\T!T_Y$^-.Z")>&5Y: 9EY DTW7-S]UFKI;00DN
M1EMC02C62<]2$7RB_J86?'85[ :3[*MCL5LA'3F"HXWSO+VL?!;(@KWQW)[<
M[_NXO:JWI1^81/0IH>,++&P:4O7:Y- 6GCIW#7ES5Y<LIG:=L)OB8H%_: 24
MH8RV7M)[UUD&I^7-$(ITU6U294(9I37X^%.PZ#0)MT78ZK%1GD5R<\,&7>X+
M(5/E_'&#]LLG,SB+"%5K1[]D(WJGD#QS,PGFF*9[Z-'C.H&Q67PW9QCQ2: :
MJ?O7FEWI7&=62W<:WT>';2D/ZY='.)(9^J#0?EH@;LU_?JA)AJMLWK8@ANY.
M0']KSQ'=44#LGNN-2.0,2UN]G]^)1SQJ1ANOY^HDKYNT!"WPB%!++4-6YE56
MP-0.#2G=E6-#EVUU/=3,]PX^ CEV\1SQT2(UJU[SY*(/,%-FMOD[I2"PJ(#
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M$3:$%:".! A2QT1H$W>AUX]& @-\P@,DJ"OS G-CRGN^VWX+V'7EL"TLMB5
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MC (%47N9L#"HJ'4;>0$R2Z(G'G8Z!!XGM(AAB7B(%M[01.QDO2%)!B>KHE:
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M%#GYZ]=3FHFCXQ"N'5;SF2HNG:9)#]T!Y*E4 M60"VFPC$9._[GZ/<PWDGN
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ME_3;@7?7P=FS1^;_];/ZGS9ZZ?^(QYL>0YN/=G<VUH\V7LWW[83M9*#K=JQ
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ME=9%!&7L!O[C()7NB3'P(X9.=9=6UU1ZI]!/H2VH6G9VO$== M@)^\W?N\=
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M3C?QW7%KG!O>HQ8GF?.O8I0_9#]">2Q?W9!QJX.$QRFD(28NE89I9!+9Q44
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M07P7_B3;(<BWF+!]I4WY34&_+C#2SH5[C;P\#4."]=D@S+JG&/Z=E-4N-9&
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M@:^LEOG2>M/<A;MCD-N'0PXF8OOG6I]1/0'KT+L*:%EG=U?F%P@T/WX=V-S
M7SA& [-BZI>^MC4ZZ>]=@]'B71G'V3>QHK$P&(BF(&BM0^=5V]2B/2Y%.FUJ
M\^H(-NG?#?P(6LEU8+=#%P\HB>G(+\$D@EH/5>,R2GB5*928N"3%8];_-K$^
M"S^A>O>$+[Q?J);+5< ^VABSILD< P<FJIU@@?&V"<P3 #T]/1K:@D2&@CI4
M]==U,0?@GS,P#19I:&@X'(TLH %07-X:-BNRATZ@,;YT&P/V!^?.CZJSLUJF
M-[-D]AZ>;2Q%.-?V#?6TX_XD9Q=U?S&GDWS#7RGPUT=Q7(?IAU+1/WZ'>Z/=
MT?;]>9(Y'X?GER+GPBQ3W=UIYN<D2C$GTXT3$($A9@>$.YNLKON05:16@CX*
M9FM[;'"E)EH%&22 +0!E256[PNER3 L^A76@@EQZ'=T7_T;CU!FY]ZM+]"A0
MDW(BD?61#?VT.Z9X-7'G5'ZF.Z]RWRUC.J6<JS%((XWS\O/W<^-/KLAYU_B$
M?FT(V]6' )VMO3F3M'7@FCR-A"Q_YIV4 BN.XO_V+E>.\J-!8MV].C-SA7V3
MA\V6A#@^&O,=:%FB%!#LE#%;R'\B?#1T)1ER9+/P!6K[XH9L?>H0?%9T0^:S
MR/8[7E@QP_^P_(9LQ?6&[$AMPK,Q N.Y),!D[L[J30)LR7ZK3QU/WH<UF8ZB
M$'>1*^QQCG2!0JA>)7$M4!!U) L[$_\Z=R=B"N,\M^'>&,"T45_=,._ 6X\Y
M"^2T;S@*-/.*K<+1JDP10N\2S2NKL$?PPAYV_N=QML1LYK[RN-=NP>^^Y^;)
M:TRI> OD2A)H:T#>HRY?Q[C"6IM"E]W25@$T+83YXSONU"FU])=:;YRGA0%B
MC'"A?"3MDUF%_$F!1+=AMWF3X,[-,I_.-QUO2*LJ(Z*2=W?J"K+JE-,L,NK\
M V85V=Y5[XR#ZVKK+:'JHGM0L4V&92C1UK%L/&^(PC1.C=A=%T3'TB%V/+VP
M2)D/@78XC']CV\3F8MDU)MB-H@HHFVAR\5[EDXTCZK^F_C !,OAW2>S^#=E@
M]1IN7_=ZITWQDM7>ZG]0HO+_)!IQ0Z8PF%'>H7A9=_^&;-OO:F0P,^2&C.-/
MH9'+VC&?H?AQ\#K&['3GM>+Y2=!8,-\-V5R]^@V9;==:5M#6#=DY4\AOBKGC
M<BV%6U"F'5U'V!Q9&,M\O,1PAU&Z9U7=HPM/@]=/4?3=*=RDBH)%EK)^MP[*
M@X\]R='419TO;%*E*QS*,;II5UNI(F)9]GUQ]5]%[[,\;M>T_=A6I?+[J2/P
M#@9.8,Y@J3C!$L#8&K#JN<@I$E,I"Q04<0>?)(F:GN2_J<5;.!MU3G!Y"]%(
M.''*(43#TI9A4!;KII)$QD-W/1CZ83JWU[CW+8<XM5<Y++E@C6G5A,%0(C+%
M 1S_0]8E5_@3J3IY5!B1D&QWM87V#8GK2*\R>N[]T;:2/<_A_6:7"YZF+^#=
M%(<WE1N08J@EJF9,85N6JOT%NG!^L5KSSH@W$*E:]%#DK]Q?N6-TX?=;[8<4
MD4>72<BRQ!GSFN6P#V$HY<=>P7M"KA+Z8&<J7ZKT;*RIZSJ[2W[,R!U]D-(J
M472^-5FF1V \Z>K"'<;T=>;?]5DF;@>D Y$.1M-&/ :K.*"BF9"!=F $I:K1
M5V0M3E6-$.L0_'MSC1QG2.APK9A9XWGTR]5?$5QN"RCP DB<)U!(<N>-P.)$
M$?^D6'S><CWX.&(.2K#F(>K6NC864?16R6RBM@+Z+FN<.ORPN)6Y&S* X_WU
MNM8V8YEZA<K.%F??'%][SW![[K=$[?L-D,.*'_3>M72U\2J@5%URHSU["CZ=
MA"VG=9K-<9<I8<0XD%/WPU-M%X6YXVG7?,%0P@\( =@3DEWTL4;+O8TW?X[S
MTRO.[Z]N=T?SYBH5)O)QFU-()+Y.XZ,"B='1_V=-M,OA'K!Y+V&+,[HLH0>+
MQ8'!%OQ87 $88IH&QQ*A#6#=GUS/R!BK>RP9//?2COTV.X_R$_U^:94VVPS2
M'K>SM)3A\IZGUH=GV6,$U1+ON+R6AA(A3G5>A3(F,LX8=*"7V=&\Y?*^OZ?K
M_ *^T8V"TH\3JNWJ$5O6)4M>(Y!>@R71ER80#-7SS%?,(T0<,#!!<YGE^ZG6
MK,F!-!1][P"N #_]!AK>E8,A,*T\X/1ER_UAQYG^?GQ#+=)A757)Z.3QP6/>
MOXNCZPT+/4#OM'.T@<__-!(CLM6<\*MT84],7$I?=A]LC8GUFX7UV]E[]U'=
MQ=53TUK5[/P&2O,6EFIC(*>56&9D 76_NV\7>G?1.%?;S%=D2YVIMJ7,\X#]
MG2R 6R9'%PN[Z!,2BS4+*S;$Q1C$OL=#.!B^M:F\T.869>SJK-"\&ZN_A^D<
MN&_N&^>"EB\<0&2Q=58VV8K95"\30S>73AD;$JPD#KLW[!.V\(.!8^:KN>S.
M%O<CHW+^&:>3DJ*K;MG<5>^%'^,PJQ!@[^H?$_B(PG@I*GN%D\U5UF@JWX4'
M_TO0KQ4_FN&0"AQ+BA%(\A$3T\QS4*\00W^H'K>;!]CTX7NV]Z]-4L[;' P[
M0&SD):=2A\@6/.EM?Z\)?&W@ADR@L\P8+WH_6^*- &K 5^QG0:C?]#K1LC)_
M=G[./$85<7)82FPR[TUQ3>SIW^^UF=[N$@#WNT)Q57@$:R264#C>[S6B-5&_
M3U?81>-GNMI^4ERB!;*:(YB$7LI:D^JJYA\P$CU4\_(@,);'MRRARRSU5J*5
MVZ->!KX0F3"^A]JL%\'.IZU?_- 1CDR3;WMC N0%!?.,A< ;!:Q'B-4,1RFU
M+D4)?*Q^)2$.PG\UE2KO(#@Z&D&14%JM6@Y@%+#%>N#! _"BNR.8J*^1!(66
MK8WF-AT5*YJI&=]7$Z5U=<&ZZ0)4Y'?F,6NN:B5UKQJ15 &JN?6=W3O<_93J
MY(J:;2T/7F0'$N-^GE6Q];->G]JGFB4?&-D2";U]9>TB'\=7*SE0/24/YU[)
M_H 2!WSZA&U]4!8@/)>@@-Q:$V6_X(N9KBZ'C Q\[,_I"67_3J I"FP*T!,H
M,JG.&-2'_A8U<06--EQDE_'OO-!]0HFVBOG7#IO/3=7;E1_G]C[?+G5[3W"C
M$^Q!/$PJ1C!/27HKP ;\Z^1M!KO$L[@"HVWV\/;$]$,@A5&C$(3H0Y^!9J(H
MM6$'X%54E%I#HFSH"]KF; RTY=NNJV?+K'+X&ZBZHU1 &LDOU/G.1#K=[-0[
M<IJ.-ZD,/!Z@'AY/4USVS,W39#'SKFITGMPG4)H<\1=YU,);-RS$V)$L-IRJ
ME]A4Z]V(M:<!,W'$#-""C5MHVRH,4%KJ<E+5:,_XO[#W'EY-;^VZJ,ME1U1Z
M!Z5WI!.:2TWH12"AA]X# 4+ORP)"(""]A**A!P@ME!# A?06I"34@)30BX"
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M'1TCV=E*PY(^J8X=R:)S6=,, C.S_'.IUB?F6 S&Q^?V[\%L.1=H7ZE#NEL
M5' W;X,&6B>Q45R1R7$/R]]<!<)& =[_:?ME3,WYE/SBD0F!$H0*>F3__.6;
MF. GDP(P4]?VX0WW".:Y^FLH3X\RR=G\'H%*1O&0.#%P_\M%,[L?PS^:RX<S
M23?CH,[>O8>1YG.>I<Y2K-2L02:,LTF:ZHIK@6!$*1"2?-4+B*RQ0R3AW6US
M/VW,__&]I+6U(#D@5<!<0 E2D0&):-[&[E^;=#<OX/B>^2.G]%! 9TX9NIR1
MU,VN*+#*+U$/, 1(2*6YDCB!3Y40G7*S2*_*14AW[$/O^V06(U-Q1*; CL;P
M?CK?4O#GZK.8[!(D'?I59-J8D+G*_02BZ=!Z>?4)L-BR;Q*N+8M=5X3L-;BV
MOP_)K0_]C%:$V7VKRM\S@)GB$!A/>WY^& 2(%<Z@X(JHVEN1^SXA2;#'Z>2S
M.4[_([E,=[.M^6*^:5H^P(-DQS^4).2W4T&=]/T[;LYID1.VDBQS13JOH=W7
M831COG,_]%TBFO$U^W!H6D?J@A)+<VJZ%H4PKG]Y6)4?@)M#[>9NKL%.TQ2U
MBFO/YQ]0UZ:?"I3Y]&:0@>'*CB:C0 @L%[_GT>15G(6WG@2Y)"$2GO\7C_Z+
M1_\Z'OT3USH0QF]J0F=!/N%AE2WFBX][WJVROIH .T/7'SPS$C:"V+#DO$Y-
M]+P*AJWOWB?VLBCI-+ZJ X\EH87FN,JID?,S([[#;YRM8GY/K2M)D)8*&>?/
M--=9U9$B<PB4$4( S0.I%4B*!F3/FG_IX6WZF8N5V8;U";))TUQK.AJ6[<GD
MFL=B>U)C@I]*+%4P%X!=A&Q;5)&OVWX,'0Y,P]L=D,/%Z:N)EUF;J>A$]>Y0
MX9U4<Q:BW'Y!,?\A_SE@ F[&)DPR%]9/XFKQ?T3K1M%&" GKU</H:OZNSPM*
M*X?0JQF-A-&6A$D "Y]&FR*VCQ \/@:V-D$F@F<;]^'K)!+L^\(3X?FG=&L0
M%Z-PK"R61CDU$4TLJ_HBIKDZ*J#_WQ?^?\=WWA.@=%<HFQ:RJJU^N6XDS6 )
M@"E'^=:Y*:UUM2X/H#8@[WJ[*L&NNDF@150=) U99\4SH(?%^A:(.S4[Y<9G
M.W7\T#D#:&Z#7V#+,#>BB.^9E@BUOR[%KD[Q[47J_I]OXUKN&OIT#6M<=-.K
M$0#$*M@W[=3LT]/*Q+C26A.9N5E526LVM2L053F[=XW>I\/YAL\OM#32SQ+:
M$4^%JT;2;S)=.?=J@IA65>=*& J?Q+^DD0Q[*._<) /&YGL?6ZRL":^7\A1U
M>W(Q,8^['\E0Q68+5X.]/ZJ^'G,?,%W[;0W2E5R[]_7EU%)DD%C'X<4T?\WW
MH-/3W-@*P%P/V;UBMB5JJR/A(HER&5:0I7NY!T)^\UKWA3=:Z-72V5"]WG-3
M,YKV^#Q(P5I*_^KP#]N%F34\;)OM6KA#=53U7N7J>.C$?/VYY3>I'Q,5"B\C
M/SS'X7_6!8?TJ,+]J,I&W!@:R6S/H$<7:%%)PEY,31CBVZ]-!<(VG8>J9*1X
M3FRWOPL?A:3")4MG.-^;6KDZN==(*EVVNP79>]<P54.P+K<T2F$?OTP6KS^7
M=;JMU6^E<JS-WS/NS$HTIC"H@,EVG6*R&^X]=R>S__PJ4[#UQ>7+KN9@DJ;.
MN?#@GM2KYKZY+3?)<TCM1;SYBBU7CQBB4SY)+.5VB9+#KTO60,^K$]ML?364
M'?SF#:_2)Y=9J\QQ6HUQM>95_@8.G^Z_6_THX,;P[.-XO&)R(LII5JX,>4,8
MF/; SS2;O>^A!%.&S->V">V8XZHRY7OB;N)$SBXZA:D$>7T90?UD;9]M+7PI
MTT#B,LU93!['1V/^8>#ZU%WE1^&"RY3KQ)H1HS9,YIWUG\E8"P?QCUNYHGE3
MDN KUMJ?OV_U/Y5] DAS^YP.DC[D4I*6IS[0GT])9^\?D& J\OCG;6)]$K'5
M!2"K)>R%UK.\9UCM07PW>E=732$KFBO--=:SW-CAL)[Z^)+42RGTE$=?J1+I
MBWJ=F%.:,L1[QZ\3;&31XBGZV+24"Y YWO)FZ>Y"!U?>GGZOYMN%$.>(&K"W
M'WKR21.4G4#@EWIPN[38RE)XCQ:+2@OL"D8).>XF,QLNFAQET"T!,<AZYQ.\
M."/63'?SM\GTW/"SH@69\<A*2N:QF8.2E&.WU:T')&3NVWG/B0GF890LRS/O
M7F63.E8=-M&Z@+@]Y)':#15Q,1;;>TUS1%VP" C+U<;_+W1Y_\2_T]WK/X'?
MI<M_<#SRL%_X% FK+OFW >M_X5^%_\!PH9?2G18Z,]'BL"&]41M"5MN^9?G(
MG<Z;Z76.9M4STQG1DRV 9[CVL. :HG[RV-6A')+_?!+7N#&MZD_HTD$1\\CM
MB%S7UY_D9#<SBY<"_"]K]?MY3X@)8GZV>X,-;U6VALAX"A+2(O 0'0P>(5-@
M=\K/?]X!L2^]-ZK!<O(\Z."JYV15X["51KUOF[?%#$1S]67+2*%8W6O9(V?V
MT?S'4UP$;;X'$3BUF7Y/5/ZG1X\('0&/1EQ_\G"=[GZVX;)A-?&:"E&>*!V_
M<!M%?*5VFYOB@4#\@?.]K=D^2Q,8#]ZDIU!OTF?)&K"=^(6K9NBG_,2Y;XD/
MI^GG4RV>I)74(W]6T7SADDROP=L;=U:$;93L5;S/%3(.!)?;<J79O!I*Q"8
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M-3,]J76A)KZ_X)5U7'=#7[/5Q%9)WHC!>@9.S_MS&B'T9M_FHQYB#%V;E7^
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M'A@D#"_)AJQ?=#Y%1(.IMM\G%GXJQL1;6EF6[J9".Q>#%ZRJ3+6-?33PK'M
M%_%T 2C7O* /H@0%S;"M5=BOO5/W5U$R;2?7#:F2!O%&]@NLEDUTI#A;YG'M
M_*,;#9N>AZ2X^E\*86;1G6KT5&*:=8 Q2!3_7#1O26X1[FU6@;!NAB2X0%R
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MW ?JJ/V&N@'3-8-GJ7[5(PW:AFVZ_'D;<ML.)6+'LTGGB<NZ/HUCSP\3T1&
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MEGG[ZU2X2?_GV/8/LA*Y:]@F0:VF:NU2\>2$75VF)YAQNSP6%M:\#:\=HK!
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M==]PHU_-<[CX\*;@A[*WW>*(,\_[^N?+S3()"ZN63139,!"1V)KF/FF^4!M
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MV+]+_9^R,(E=/OCE./G'\V]!/Z]HG?!8<].[; L]LA"Z<N67E$6G]6)/+LT
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M!6?L]T6E6#'?->N2,AFUG"GW1J.Z%"ZH(::--WQA1<\M@UFL-#>GFZ3KGV]
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M.9&YEO6]E;'Z;(C;ZJX-W%S>,\DXW;YY=NN(Z<QE<@B$:WU;=&/#U\UB7 !
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MH**[L!L-+O/%6A:$<I0M(*<'135T%-<8D$SKN3VNA$K(<:28:Z+;G>/A?$$
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M$5>HC_,W'.+\]! CI&L6.J4*_DX5@'\6K \@2OD!)[C$_.',P9.% 0E2>$[
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M'?2\\0$D>9^SRDRKA8N4HCNS5+KXNO9KADF8FJ;,Z.Z?QN&=_+5#CA*4LU.
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M@,'^@0M!RLNC -7$?O<,ZU%-W'SL@K**@*<]M,"_HBR#@_]J,%_'A/3D2D9
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M6>%Y'DM6.[@X#5NHVD, <-N'9M\M;*EY13@I^>E[7[GK3#4<X6ZN"4TVVLF
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M73N>A_ZR2[(-BDL 9H%'^I[L[C.MJV$$,F?X,=U8 FXO"/XTVCVCSM7N?N3
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M-&BZ$KJ7\34L)ZI>46GV!]>3P=?&'"MK2[8F?.%9&MV:#2H7SF$JM0?\4]N
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M?U^)6?. B0:\A05Y0(6X10G_,=L7284241A.]AZ/V'C?+K?M2YZK0.%'$;!
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MM*=-F$^,(*"'MZ"9(>2NT0ES:^[>*SV_D"/.C#URW-&UC(,LDZ3EHU5C&*R
MT7J3AX0QG^/EF(1 /-_T$B=!5M+CQ0DCLN-P^?J?ZPJM-IAUR4R(1?<Z1=U
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M7@,E*C#S0^,=#T)]H\NWV/I#AHI/CDQ_NEG-#ETJ<,WU.WOVFE%GJ;!.]%P
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MCR#W+^A0IMH 50:!-;P[D-F2[R_:5(,175.!U?X%<*Z4 $'Z94AUFYNJ5]6
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M=BXL-)I5\Z$&42Y2 &[,S:0.C,<1C%&#GTA5##@6CE)0FOX(R_"17Z(?95)
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M^4JWFUC7V&PJDW7GFGTSUIMX3\R_)A:)VX-XX%Y$Y[OI3<7:]RW.LX^I22U
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MCF_:EQ8%CM(L\Y<H>U^% ]ZR*@PYX/:Y^"2=3RON8"!DI:PAT5:A;% ]B%?
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MTMU1K:M7IF@[J1?S/:]YB-MGXZ91]N/'KW)H!\'F=P6D5W6NH@S"=<_-U8
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M[Z@E)#(T3EJ0PI+2 [.] ('II:VY$2_M:2I/*FV]:P1#ZZ:-"R#> B 8M^Z
MFW"?93^ -S :J] 15MVXF3! *LFFD0ZF.DH4'J?Y2/O/YG9O(2>5<FJ#HO92
ML5DJUXCIH$GY$8T*1PY3W.NG( 5A0JB7W'33OO7=?2KK\^DAO_2D=1-Q==_H
MV9T]CMHH7+#1[I>H#,&2F9#Y-HV^NK%7]Q?-UE*QTR<VWQ):J_\0/3Q0?@K=
M5O/XAI/MBS]B^8O$H<!9IBXPZ^2<H ^2R?$DT+_N3+@GQ?^;C+_+Z!J>\:DC
MAI@!O]3,Z:&0V3ZWM.6JZ6-*DNDC:D:N5!$:<*=";S><%I[YC+9Z&<846>=?
M3X+P:R]NG!^T=D_).9:X.!XK+50\M36&R%>*VLESCQ4 2QB:3EY%2CN+ECMF
M>S!"'>EH4E[V"W@X]6G84QXE>Q86?D UR6MF?>^%@G='W1P.,X,('[:!;F[B
M=H*3AO-FJXV5!-@%PB2*.F%S0FT68075 ])$.KCT^W'?O&UM27JUAD,ZKFG5
MYSL><M-N<?B5N^FM'BS6;,02 <X\2WZ_XA\2K,(\0Z6<-+*J:008'=">:WT6
MKD/38*/O$5V1T^F'(]V3D(1APC/.WV0"B$6XT/#V_MV'\&W*G(:? Y.SW7!.
M"&9<QJRH-H$>5MQ]R"NZ#4RJ!X%VQ)C_$+MXJYW?9),_FR>=DY1&=81]\#V7
M\U064 W.;]<+;#@'!@0$%!2_\+D_-W0I+P@VR944Q+984*)5WS$RIB@2FUUT
M.M#O=O[Z.LPX!B+6>TAA'Z:_<;YXCC;;LA99\%7,UO?]Y7*<8RC,$CG?O<69
MH/^JXKEG2(=$@S%MH:/2>Q.>H]H-^#SF7IC";S)]Q=]DQGTXGD"H10ZH<N&[
MY\6% ]%VKT*VN-KI0ANUJIW5I DY^[/(#=PJ"19I99JR,4UZ99A=:MWQZ<B2
M!($2?B9VH!"I19/[0?)(M>$[&YT5T*@=W:$]CE4<M#J+/_'J298,;!Q@M!V>
M')M7(0AC,"9NG*L?5/IB6&.C06TK!F:%3@VW$YK%BER;FP:_63'X,9[RTMIT
M5/UZQIEQK&R]& M1$0"$J>0++F"27?7B)$97A*8.$YFM$2;"'Q[E*#F;%(TD
M">TJTP>@]5S4I">:9CP!*:9[CU:;9L!J@WSZ:]L"IHR_1 \^[NN08C)=A6NG
MG08:J1"I315A%9.N2BH%N">U];O6NM0T48%U"*<BYBD#IP*(23)<]3$BK>CZ
MXQ2-\8I-9 9Z&-M7&H4VJ,]WYZE@_F_LO&=0$]SW-<JC8@$5D2X@2N]()U0%
M0@]("3T@'9(0(*$W"[T%*:$7I9.0()T$0>F$*KV#]-ZEB>5]?O_YS[SWWKDS
M]YU[[\?W?#P?]LS9<\[>:ZU9^\@Z%(AVXN<#@Z!9NVIGN$'8'7P8J$&3F^2"
M8N$^OG)L!#JU,2N;:LN>]DD"HQV8F '5P4P-34D?0T.KNP3>_.I=8<[=]4!P
MQ+UP0<%/@1H]73,OW'D84\&.AUKCZF 3$,82?-<X\$QR9D,W9@U:)'LW8=>&
M4CVAPC+DOGWIA]]*MD0EPS'%Y_,S"\H@"U!A51DOOM0R#%Z$PZZ)KBG0Z'VR
M(O1*<_:,P42GA@0>=[;/%6>RR-YI<(^0C$ G<"0GC#I83(9DW'0CQGQ:$Q9[
MN#$18)U4'X1S+29%SHRSE35(UAT6C52+$)QORFN#RZKJM?W<WE@O6V2-7.YI
M+!V"ZFK7"@"[L+P)3=N6'Z:%.0F$/D/K;5<@^B]%%"U&!.^0FN*2$M.YU=_5
M[+@-<,%3"_:FTW(X^L9GLN3"Y55Y5CM('1:AZP\E$J*-60&\XNBL/ZYFS+M3
M]8:?X,;^ >]ME"HU%+)#QA+?XAX1Z9P<X89UEKU[7#9KZ@5XE/M%R]8D<[#6
MI+<4/#8.6-#<.U;L WXT5@ KJ$S%M)1>V37;EMIR$[PW_*OKJK[5:#CQF7G%
M./,Z?:H0)QV[_7%<'ES"PKDR].5[>QTO#&X:"&PHK;PBKGQ)_9S-*W8"P'P2
M]LIEA%EK%I,4(D\\9FLBSJLDLY-H>\];^,^L=(9]A_DQT@O/VW.]<G?=$2G9
MWBA4;**.B .T9ZQ@&(H=*P@)C&ZY\"Q_.7!ZP'LF^OB3UZL,XLLM'4T[$P,^
MNGM6X9DYP*WAUN"/-=34LT;A C5YR]L:K,S=4 MVV*]A\9TME*AQ'S5;0ONK
MJB:2YK 1@"?/O,"T8!NUY$02+*F7\888J*DL)HP1FC]5%12)Q&I.OK7>D*X]
M%JQC.>7ZM1;CJ]%5M"W(CG.&P^Z&&"7I1/DH..2E6MVNL^\L][KDZ>XM+!UB
M CR 3@NS^^F#0?31/B9/)==-37LOSGSZ30.,A69U Q(7!Z<^1$KA\LY#$AP,
M&8Z5>N/1,L0#E/FDH)L"*^MGG6,%:D9Y7:+U?['^OQ2JO'7@;]&QV+)HK$EI
MC#QB:QQ65K>1GIXU>O%':?2,+23WC&>4/-4C72;[:M1T6R.62: ^*>E$7?<6
M78N^=8'&A7GO.7W@8N>92_#EQK5+Q4O[]G.A]/W"] "S*8?O+C(M3>S(2I\_
MG*LCZY(YR<Z6[H219O/X&?A#N'>H8Z>(GU_RTS[39*ZJ\E>FO(.U9N-.F?Z&
M,A@RN_=$*E9\K)YW9<KK9Z(1_'>YL&,?.T'Z=]OA 57^#<'H\0_<O-61DE/P
M3$V 4WB/]:LN\8%W*RR#7O$72TG' X/>@_[Z+VN 5A7&#^MKW:6&$;R.X)^L
M=6#([?\<-L8XY[");]D<T\+!L9CGK)&_060],RE7><X>?&!_PN>,L+IIK5U)
MJ,O913N9Z6'+L^O[<F'TV=VBH,0>SY^4 BUS3,SBQPXN#<RMGSR<OV3>=(H2
M1BC<Z9E"]!LN^U?HK0^[YC)V\6GA8?Z6Y+1)F_ "5VQ!J99'VFD]P&:1.C)!
M>P-J_)?B%AW8-695$^74<RLJZMD;2G8K@VYX*%%0>S<EZ7.@XFK(_4Q>5&JT
M-6QV-':_)3$07).<WE+G+/XE'+ZFN"''&Z2E])<B_1ZI]R]%WZF(1+40 =)T
MIH-CS+_H4\\ZVBM-XLN]TMX)K8]B=]ZT=2#9(+IU)V]K!GZYT!H>$40NU$VV
M5Y!*.J=^)(#TL[[ ==E"+$LI%JE[='K*X Y\+]> 14$WRS!FU34/$6B-W6EI
MD(L'6YGZ2Q!0WVBC]5<5YNC7!OI%NL1 14/&0%]9SU3.G>*AH+0$-/],[*53
MT@":ERN?*ZL+6RHT-36_;*974^U01 S<5+\"_]O1Z71SL-%C0+").O_!)]\B
M%^[ +QT+OD5P=&T%&5EI:>H".U_A8WAJ@H<U\3BG:L'L#3 @?,#V+O9".-99
MV=!QR2=(+YB.3_8+$<8WO]^PF@?_DLH3Q]!I3SX?[93.=73J./]DX%T]BZ.%
M2-*.3C!QNNMT242/FZCO" G+ZU'[(FK;<Z;W6:-TSDA*_.=:DU_<4D=6<;]M
MF#AYP_'4XP''='3^^(!EL8W']@. :!HYJ9,%.ZK=BGOBT96L?36,9MUM *^E
M"SDK.;Z@YF.:H=<NBS_NCZ_S[K8$96W4LP^@FA2")P$@-,IA8HHP,837<0.P
M9J9G;9Q!^MWA>X:^ON60K&V\U"A$*C5V&^SHU*.,1Z9F;MRI*^^&SP,*/IOI
M2[S3^Y M9A5?4]&4DU&,B,K?X)XX<&@*'U66S$]GD0DYN31KVYBO)*?*_6$;
M#Y44I8M9'H-!"1BRXGM.V=/TS-B;HR#K/*"Z_!?.Y[^8?/>:(H20.P'[4KP-
MHB/5,>W;=3$_TJ,%=%13PT6IC%8H_\N;*^ U_2Z=>;=+/-YA]>LA)=BZ#B)8
MR@L;*0GS49_9<6NA1.I/D5MG=71>#E46F.BN(C6;E/55;%E\2UKC4N>>.3E:
MD WBOY,O .)!H'@')9;CI)3,O%#[ZOI["H83[Y<% CC%YDVG-*YZ%7HG23>K
MC(WV#+T%,]$'AZN=DA$1-<E5]0BOX-081I"RDVE!P([JTS]LC^[J^+3HN]/E
MQ.DK9'_X9ID"X M5YE4*GX^X[(MG[=C74TQQ#_.+FY[I9I\[.X^"OI;2Z_;?
M-1988RQHH'%J7EM)!W%P+=(+GX22JUI2+?^,P[["FR\6M&JF[+8*Z!V3Q7+!
MEF.K!6)"F[S&Y8\G1#._#_'L=P2E/:2""<1ZLZ:.M2$,\Z>Z5=_>7<I?S>GR
M)O].C4NO8=E?$LY6BA!%H5DOK<@[>2VOJDNN;5[V.786$#%8#+3=R8IL.--L
M)D%IOS5:&XT!JT-LDS[MCPW4,\9FZVW="TH)<Q:; 3#UE\V$. K^DLNJS5!+
MGL6/\)$'\6*FK6)++G=28Y)59^&:W8.2$?>#<52()11ZG7H&L7 4I-!^^=%Y
MS4*"H!I!KDX@?<D4*M6I7IAW^QJC6X3=P=,991N'RD5FWQ7 %21B%AU8_E*\
M_FGR*4I 1FU I6O@O'8EV%9^Y_>+3WN>?VY*+@=L/\+QGW'(R5"]OIN1HBUZ
M="49WC<#7Y'[>F+E'6!S=Z]9D9@J6A_XF"=AVJH/8CW60%MO6WH&W>:C&I8#
MB:7O6L6LU/L'IZZO$Q/0?W;RH@^JBTV5'YO'HA;,]UBVIC4H&SO=TO?*#<4@
MLES3U_5FGH"<,?% ,-7:;$_CU')1:538.6OSRZXN\>.5R;\4ZW9!Z!?$SUSW
MVS\F>0*J)N2W-:3!%>OX]76N)$,9R^G'IRC?<K..,9#\_<A%DP:]OK3#MO%-
M @D86"!"YX2> GY7!UL6^UM&?,V:WDF<TM'1'%+7ZE85_5W1WC/-6'UOA;V3
M+\(QL\4P"X>IZ;JSP0*F.^//DT2/K#1<[R!_RC%:6&;5S0Y8)C;"V.ELNL4=
MX7$:@.A54$ESZ$[*N TE('?BI&HO81=E\P,(%104+-@V(=3:4(X5B\K;*:NE
M*EE7->)U<K:_U.XW;\['Y:2PF )WW-HG5WJM<3E%6@P5KJ*Q;JM33\U3FW/[
M76KF*[,5 F2UCR'?@]EI6=A+F,)QLY"[L +M?)Q.__MFM)D13K!RP40^6Z4*
M^6>O26)>BMO3"EN:Q-"D^\>WM^#?_FU)ZB,0K?%6<MY(T7+6)]@-4#45"?G1
M4*^7.6'V"9#)DWAHT\:KFK$AZRP>O\'5FE%H40P7^1?YK>H0#?$Z>,$-$=JR
M'$%L=$RQ-UO9Q![@42H6+[5I@/>G GMGR+,>X%@'JCPL^+?"M#SPW^*E9CK:
MMZBEWZ?H??Z6K/_)"=*G9K]=\V<IB-Z MMOLC*[G/&I#H!JQLSJ?*7L#VF>?
M9,=LV?=0M/W)6WL_.>S\/;1-[!24Q#XDG5\197+ SG1KOM=NHH<0Y[QPKV1;
M0]8)5FBDD*UQ>98DITN@N8D&"[*.0:_<MK,'<U&=]R7X=2%<+P,6:/>&W^5!
M#%2AX%\>$[X](=R3W%"\?%FO>&J04]-&^R1H3(@+E][#8  --9?8ISV..CZ/
M]4@,NEWO_T=VH'?6K*2SMY.5XYNP>3>8C/+<XLG2& :4+8SG,J<="P6:<4W/
M[I_S#V4<_:68GI_;)3*3.*JC/X]IQ96Z;Q.0I=L%)3.\;2-CEL9&8"F9XLDL
M)'I19'MF'4=G%MN;T<6F*(Q")LWA=M,! JLEMIEF"%#BX9PHZK5WP*U\5)[X
M9[V-F(WXD%GS%H$ GH[4*_RL'XY5,3XF6[PKYR[,^,U&A=G#QBYQ@2/=.GS'
ML=!D#P9R.\^YF%:Q)_(E<Y+'_YW&(@2;V+A26[3.<ID:_DOA^-K4R-9J<?=?
MBNCZET+>-J#I-_;U^?I?BD)EFE^3?^S^4I!#KQ8H3&PCF]E"!>[G-P6.MOC'
M=:M@094^1:"=.&G<CE]IR/F@21][7B4R,_+D\<#TN?RLBG"U,9?UI9JOFX(!
M^;.$H$FJ2=3U8;/26XN2^Z /OS^J[*6<^ ;M#/WI_;+QER*OWD/B]53B7XIK
M0S_9UQ<O\\\35U1>'SUG)5$4;#S[*7?*,?.:#J19!J1!AX8LW[45:)2L6G1?
MQ,_3,GTWEMJO6=D+<NC_U9HY?32K9)M=_2- /3CG?8GO"3EHS\@ZEM.)HIF9
MXM]((&6TDN;%?X1-]WUO]T' KY'ESL* D[P5RMK0!F_U\W0S659\24ECTF6*
MQ?2)%4/#H(0%BTNKY5/IZ8O%#76UQE)OZN$W_S.37-05$Y]6%PZWDOI"GK;/
M7)N5#-UW#^P#FPH*6)6;V*O@;44PV^LCX('T5Y8"IVE:=>,&ZXGA$X'& &/*
MYT7*)KL4;K?:M4=AJ!\3W]DC8\@AH;/62%9W#X62WA;3.+?B>?:VKY)QE4;\
MGCO3TC]^%Y0<U=O#J'J+LEWV]=X6CPD2.9M_I%QK?T-Q+>^W$ F"6OXR&98#
M 0%J"@S'LWX>HT]5.&SEITFAY]R_@_;;").;MXO9\;X\+39L=<W4=Y=B-Y*A
MHRTNW%WB8=\[^)EN4Q@?YXY,YEFY+ =6GW*M,J:(!$4%=L+^^5$W?M8]6C,
MOVW\0UMJOPJ8<+^YBD]&[TZ^Q9KU3+3?L(CBK>AL(3LZ?I/J&_'!FL'P]5)Q
MDD??T>NPF82%Q69W?&O%\/2SGEUV",&J<SO0F"@2N0_L)XPV&7&NZI6T8B??
M<\G@L-_77FX[-H*X?-^B0UG060I?2DHI/<#W#79^G'YYZG?SO&9Q[S3>LIP)
M^!$KSO!S7C[L8=#]INI9P40Z^9<':]3A-EBL!48"^CU2S/.#>0<%!;AIF6.I
MTFQ^[U,CAOPXS73#B^X7!+]7,N*S?7/&H\)WM8,PC/F0Y[AG83G_? <WH/!
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M2G=;H]VJ&-OZ B\$(TN\4AC MQ%%E\Z7)?U?1*8BKN"[G)W5@[Q)%6>)F&\
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M&+9.G9F9"BW"&L54VE[[99.?PQ/]W3<Q:>RNZ,74,9U?>=/86I^TGG%J4H
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M_Q_4?650G.&RYD1(""00W"&XDV #@R:X^PPV0'!W]P2"NSL$A\%M<$@@#,S
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M.L/US3@KGB130<KY,K_:;+\G<J$\V*QX6/D3/>Y*_5P#<5?V[14$Q67)R2_
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MU-N8XDB%L/?(5N# LY[=^$N_%?@I.9 ")0/4T=]PWW:'\X#D'"/2M.4[U)6
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M-\K\^C+F<-R0;#K-S]"1X,%2I4$%Q/Q><T>F<$;G4?]EC.W78KL9M]_./CU
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M%9^E_?G%KW$YG5FF;?5AO5:<6[-E#Q2S5LL-\E4-X4_RD7=MAV[O_!HSO!G
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M>=5K<.BY&6*9] #PQVU?1J-IU<<#N>^/\O2I=<\@R[7V1H+W+G]\;5693Q\
M>0'/$VXZ[DD2K^Y<KSM_?(N@.>!^ !R.BA\I/P":G "!QG$/ (>(!X"+XY^*
M3QC1/C3G1I=\^^@+R5ND__I]^Y';K6=.0&E F9B=WWAP2NA98/P?ZT,:4>_
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M13BYM<6!70G,M9R?Q)!$K@L-7US2TPR77NY(D %Z!CB%I8+R'*&Y@/!S N5
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M[/C],^5((#UFOI036*:H]/)77_$'Z/V9;RK/6$]"[B@>**AHJ&B%LSSI^8Z
M*MU2U5ZJ+B:MG_M3']\Y',E@EL%V]>VOMWOB!]DPQ20%B&D0+6HNA=7MQ8^B
MQ9)B^@U8_5/?MG:1GA<+,'E=-HV_!%@GXH*)I"QW<)MW7X2Q8XGI,%6LGATV
MPAX&+VMD,3$1/T6F^9S$3B2@FYH 0;KS7H,5/&0BVFST^?RRB7"<-J('8:6>
M:U1./,O9//LU[&R]"H!*4?\"99PXAC1KS3O%56D%A6WZR=\=5"J&F:W7U\<)
MCTM!@FWKL;"U*!3R6[54\U\"\;9I*RFCV:_+\&7:+KH0W2^CD*?5[&:B@GFQ
M>N!:^ 1S^+]JS >*G_G]BC#G7G$&!M@@@U)2ZX%JF&E*4JL(!LY<*^4QOF<)
MWIR6I5-;QGR"!8(&XKB#)P(.WHR?(ON&)K5EXPDEG",2ZW%#NOWX=8D'#4.6
MDJ9MU%TUD+S/2P.:34FY(+%S,DXSIEJC?4\)^&QF&)\:RAQ=N* "!75Z>EOR
M;OI&*D>X JY*0/1]?W*D#N$%5:7*N62#>TYL97Z3-:]*\ZP9P0D+DT&2W[P\
MGG-RYG. <T;DQ47D&E'+??(>*SO?I]+$BS*4#:7"W[[ BB,C(>P#FC(RI6_Q
M_"2TRX _Q^*2ZQ#@J._2!HRV)Q\X@DRDG\[A0Z/9[,7$7/O%HL*Y2O(1_SK-
MOZYC%QK6@6XD>_Q*2/].$:GK/?++(LTM' $D_O33XKQ_N*OCP["/"/OSQ'_B
M8JC$6[5L[(;1W4IK$P&JT1OC P6#7)S*JH^O7K3QI=4NJ!R6G4><:(9:"@)\
MPI.^4=-?I(G%.;*5(L$R,'LKU=QR:BH4+5-E^FU'2Y5ZO2S1YTTPZ[<>GR0@
M-OE&Q@18M.D.D-HSW9^BNI81L)K ^>N53$KE5_K$_3F9JAL^?[\-;]R@A$3X
MR4GA*YM=TRSW0L;CX@[2^W,2&!.?M-O:' =)VGYU ;>$]M,5N!-#^!=9G7U#
M!RWY+44N&_<\3>"'PEIU'O.\<% @#+5DT2BYCC0IX1>B2 TO3^*P.C$&) X[
MY(B@VXR U7U8W(N Y\_(Y!+"*#+C>MTYT*%32J=Q2K/P9/',DENHTJ2&[H-+
M3Z+A<NGI<VMK+H>31W%QQ1;\M,CDLA5XS$.;O#23\P+>9[L")[R/*DR_;7;D
MPW]],3CO2&./#?APSA\*I_#&@8CQZ_DS>5H-M5FVT G3H7*UA;,=E;Y>$;4\
M)?-$/SC2'ZAH:7-3)VC8L]&1%RA%/?#OO1R^)5T+_.]_L#O\!E(9O"ED[-[-
MP]0MC,FJKG$UVO;I&.AH%IJ[M:]_M?_)<X+.*PE2&F:66H#-/VTV4]):TZ.T
MZ!4)AP5E#*[QA?_B;I9@/?XX-!5KLZQR526Q639F]J,&<*!2MKG 4[2$X/"U
MZ(/$#D1^&@FWAW/,.AKAK6/[]K->P8^$?M?;: U*ST*W).RIR*3Z&=!E:#X
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M":W'#1\N1#N<8T1?MSDWXT2?+<+Z\G<<XE1G!Z4?4YA]GL\QO3[VT)A;=B&
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M)6Y;UG PX%@(8"QO;NW.. =1L.K*SV,6?\W8YB7@$WQBYI ?TST_(Q:5.,N
MG.)^O5&1L4CL;)P@7F\3]&K[/)$.EY\BCO>@G.F@/800'3Y3O.P>L<^4AR#%
MV2EBIST\BS]0B>6(=T=A_&F"F<00K8T&N)]-8@#\D:O@Y(AQ#0#&B$!J7[$I
M65V!4985?0ZCEMKI&4)!G+D%&-DFEP,'9<,#X@I7@TXCG6LK>3_K:]=U@#V_
M?K3:Q:4O6DI7+HL;+GY^O#G@W!OPOOF?K;\$32O?Y*8ZI!.5DOPCN$2:G[EY
M4DC)ED%B^CREWM>#ZO/1/DF88_FV.7=VI2L@\^85F6[:3U$UQ9\7#I@E(]98
M)]^.2_NXH3O3^BYT[0#XT\[K&!4O_4L="-W,^_R,@I2:2*]H'?C0.F??5=NW
MZ<"6(;-CN(;UL2!I\N\]#Z2,YG#^U 3Y+L@CX%#R%[0^"IQ50J%?AZ8XC*9.
M.A'CHD591-F34-B4:-<72FX; ('E5GR7]"']I\&SCH!"W:CCW'0R55S1!9/]
MXYG+_<ZOYR0/D:JS[6T-'H NED:A_LRCM'46;F<XP+:?"]@P;"F"=:\""OR^
MM&E-[+\JQ03C;07=PP''['OM;[N;^(F6MS7%G!>"1Q('-U0 0#G!6=W2Z+:O
MHB;2(1.RP?/XF &[Y3,FHRCJG/Q]D;*ZTJ=?:GI)FV8.CJ&9CH&/>P5]"X$8
MS:Q$A?B\OP0I9TXAUW+0]$22$BZ&$+!Y7]B/O9T4!M/# W9'3"R-!N!78[I-
MVF$7@R O- 3@UOE@P[+ F(U-*#/6^)>E5,&MBQ0A?(-(D*=9.$>-K\S90GUB
M-5U10AIKK] H_H;V4B;92UF^-TMBQ?&I2;W@Z^PT2?,CU\SC$%[/Z#[J Q?S
M>;SEB^6"#V'%X5:NX(%9<%C=,QIH?>WTE+^%CQTT<6\W=V;0W9Q4&9SE=B&
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M76N"QNQI4V$DY[]6/^4_4A&"C#242S>^X2+E)'0IW?%P+]U3?<LD:4IG+#G
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M@KSQ4EIQ.K_G[??]7U<2X*^W"?]U#-\:UUKCPAD7;(UU%<HK\@DP+6XW-1T
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M(U]]LS(FYZ?%Y\1$VPEJK@^DY<IIVBW_[ZE2.M*B?Z(^[O^$_]!CD"$G0UL
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MCDT*P&0+@)0@IEH"C7;Y/\\[DTQN[.0W'"<B"G4PGVW!5&GBH8[E8#./HKR
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M]0V/C/-ER28/QY+AZV6-.D'34P,&?6NZ@PVBE#\^IM!^/TS4]+#ND9+6>NQ
MX41#W.P,MBQ^T\!D+*;DH',?DX-N;@$?ST0NTO8!658X! A;F-WF0DHP^+AJ
MZ$=9/";DG9^$5H!'WUGA9\1&_,#?7U"-TY4>PEIF$T0#?M,!3,:!%>[']LG/
M6K8[[MP]ZG^S(Y+9NVV;G;CXXC>==+M$\MI@EDZ%T>1H9AO+<8'G &>!YHBG
M.LPD[ L,!T!D2*E/N2$PK"I++&?C@B#>J,NQH!6=&(!<(X"$4LV0UQ@YFIVP
MAJQKKD^LOF(.V=)325D^KAQ[=,-NH3[B@,?&Z)]9%X4=,$>ZOAI9F '&:JP:
M?HC@CLVHKR9'V$X+-T^=A9IWN+>V6#VQUY_N(*Y9M#:AORZNS4"_JU]DJ%Z(
M_LQN,'9'QH%Z,B6DW-+3)P.,M*@_7?,W=R0G=.D;"Y]M<8=K3![55KT-M1W?
M,BF3C<LR^NPC%^3LG4S=ZSN[.I(B)8B4NACMFLE_9+LV.!#CG&,84"T&/0XM
M-R559# UF6U81]1,3 9.^7Y=' I7FG0K1BW\:.VG_C*A/2.'%87Z\U$/"8*N
M.2PQZ<[!?S<*W*JH!>CAO!2T^^!K^I2X\9T5!MC=(X8"(S>19X[1>L& &3E5
M9:[CE>(VTQ/ANV?RT?#/-(> :2X59;8&5!V?4X76>I$HZ UB7I2+8EF8];<@
M&F>>,,[GE+[VV/9B/^"1E>EA_3U8 1\G;*:2?@'PN&P"E4I+6UC_3<>(A\O-
M*JVE^N:\KU[PXD#@2,@:6MY9%\[6H^:X+GU-C.KM4';^_F!O3;/'4*UB7:$S
MU>6AHK=*UYG75PW&=K'".(=3[A;3AKL\27"[XRI2\X.:5YR!5BJCWS50R?U)
MT^H:->?\O^GNZ.?W-:9_E;4[7)BMKB!%;>Q5EZ5=8"R[[;'>GG*4 E>#YD^V
M7EHVMVIJVPIGKOEB!FV/T'<WJ-JLU_0Z\ #7\AKL,P?%O3V4RG!H^UE[]47'
MV=C(6;AO7BB92"29-R#% ]V)3>.%\]H 0)!;=66T14\FJ?3?;J2'F[[SLH9Q
M7]61U]GM#U+ 13H.0#^R.$=M^3:NB3 YW1-9;5&M][.)',O26K?Y"FE>RM_!
M[LC)W0*PGB\4O"%"$8[>7[.^?K-"?^+.LD-!O=H!O@U_-%/#UG=JJ9G. ZR6
MI*WJA,),6\V/$N%)V4O5C94>2751C@[3QTHIH+Y,I^W8+)2LFT_T4QV )8HH
MT17"$@^EC*B;F, <K"$0R/B'\W/)33WRI5];;0>";^&#^-&-'R54MU .!@FF
M3\7!9C$]8=^29*^]&J>_E+IY7:B@WF<WZ55\\3((+J2;3;B(, TL/#CS<HEQ
M4:]J[/!R,B]L(J9KVVDG8R^=SG^ #X@0!_C:I'AT(0^1:MK(Y#&>[#-8T+O6
MU5@Z!]U)"],WDT>@9ZQ+JGMK(29'KK66$F_E!>VW12)*"JP";#YE>UD7&WYS
M]$BW*(7 U*?5N^N5HT70]!M8ZMSKM-:NYUK1%OZZ)N/"2?892O)B3A5>BLZ<
M8KCT;_Z3*C%PZ1M 3T9;_GCB!!8KA]=#AJ(YR 6-_8D08]9J8E-7)5\5T;YM
MT^4/ U^"68):;^3!K&]DFSTM>2R_:44F^)@3TB[42;,<,U!7MT# PNN_.:_S
M*5OPD4?[+7&-T?G5-?YW7Y^4 <NY1&8.-*P?YS9"/=B\K$_/L;O&WFQ.4?*Y
M5G:J=R(N/4$U60=$=@HAQ&IHN/-OC$AU)0J6F"+(QUTC@A5AUW?MS:09O1*M
MT ;ZU^)J2)SHWJE1,[LY/41A65RYNBF>)8G_!LHMBO&B=['D7'-%)4LOW+49
M:EO7P1U\UQ^4_\KF-UVHOJ8PVP9$%5(PN%55HX-+2]6+/V-Y=]>IUT-@*7!"
M4(O63E4+YYS\G"J]!+Z_-*-H43^KD-;GXEJ!9]$031[780*-IYO;I<AJ* )^
MA8H'N+Q<Y>I[]W3<<]E#P5]T1)>&5 HV(J$P>-@0HO[9!I[11R:OLB6\M)=<
M\]72)6/>TDYZ"51U_/#9/@U9?%VD>J\Q7?2:Z-CD!NM##1-ETVW/,P%5F:3C
M1V&ITO&KA<$*"Q4UM"WN/L6F-7I<<30]V;XA719J[ E*FHDEV9I-C965U<(\
MD>(+)7*^/<K7FSJEKI-$UN;@))I!J1M;K,V=)ZN$%U]RH:?5_7<FUS6^N]^I
MM#.HPNG#^2MVA(E?3!I.7:\_TN46:OYE\<)Y4CE6F4'\?3_C%G]!,3CTU$ X
M5U<PZ*O(W-<%"37G/?E83Y<HNS$;B$<O-XJKWB#=>?"X0/IK7BQC]>?U5AX9
M>**)'MI7$5^WPL[\B'HN+!5FE]S!T#O)!_B^CLM),ODR5/)= XN'Q^LS4)@C
MHA79W+B4U;"1 "&S4@[L^W6' S/W&N6T1?>D1U_R=W"WG"R:/896PMI<-R6P
M2W, %F.)Y\^T8=G4QMYJ9C-A4.5SJF2:^)[SXY;YI7<UM_H;%;]3/&DJ 8-*
MK'S9ZW(!7#,2'%,%H,[<OZU <_!N%"/-V2>:=B)E8PGB"WAO;C< U?$'/J-@
M10I&#6UB6ACPZI8%!5B8<>67)I)/4D_-BNSD$-[+1L(CN.>V98>9HC)N<M(=
M*B[\)HR2T^PNX^!P>]&D?Q4_E6H8QY"3.\_3XK<7FN=P)K-(9DTK'E'4WY)T
MWJY$3C59[''^:-,:4SK,PQ6\/&A2@FV_)+:6D4Q'N?"5P<UA$;=5IHO?I >]
MC6>$#9,R<HOEOIN2X.6?$S5%@F7%^4]]+?[C\.I3#=MWCS.Z[8YQ<?S'Z@?!
M88"Q0G@_15XOGF\=,@YY>6A1^6$G*.WAMS,9?\>[0X+6@\E_"Q&@6?5)6ZKP
M^N8V43<I7<S;1M]5Y3#JQ6 "B>@"CJO4CW!":.$+^.88M+YO)B6S]3=*)]P2
M=.;JZLZ_\S*$TYTD2F%G,K8E;)KF""T4Z[FKCR%62\US6;5MKH7/].1Y^,SB
M'6WO+%<VU[^3$)6[KA/P3WDJ8@TX[I"9:@B./ST3!>OK?<M0),OD9-#/I>?S
M*W?T%#:^XW7V>)NU'VJZH^WR=D4\CUI>+++6YW75L* 1S.B$CJVMQ3/"I&^<
M.,0O%(XSM'ZN)/!!*[SAA8OY4,5$A-OHEJ+LA6-\?M#&CR.0_!CF84$>9LA'
M&0E67+-,P67_;!TK^L6DH7HSM:QQ[^7S[8.$IN'['8\]3ATR,<WGV^<;9W[S
M$D>H$:A5Q)MDY2)4'Q[S ,_(:%/Y*Y9G!]S8;OZ9^6;7%-.VWRN;B76P(AX]
M-WM@O$/ NN%EDRU\M^8^84D?.;:-$SLCWRD/RJ)\2[;6W"C3&?TW%C1Q+/^C
M=!=DU$ND&V7,IZXK.8YXEX*AQOZ7U\^;(NRKPWBG<U>\=<%4]MHY=TR/>.<%
MS 3AYRKQPCU#S8U_6]VW9(S$" -S$]9KWG8WC0 M/_^$L9VQ>OHACMB.@7MN
MOFY3>ORED%T];<F2E;.K;P^N$'*22^M:B\/3@LPS-8ZBQ;6V*U=9DCN=^":T
M2O<FGMHG^\T["&5FFG%W])IAVH8#+);UYK2CX>V/(2%;D-K$EE6<LG5-59?S
MF H+1B\49KX6\IWJ4N$^\R@!^MAP6N3S43>G2,]0 :S_AZ6AL.79'YE3DCVN
MS6(6T1IVJVQ6&QZ+JC_FNR?:J2G/ ;D2*S+XBU4/ ,]?Q^=A'()&'^Z_2ZU-
M\EF^G]4?],3M$;+ETY,,LT%3N3<2PD'SS+<;IF<]2925R:59@&'YZ(O&EP3K
MF]H@)X A=XVF\8O_)?</_^]RG^VXX$+"0$5V3!/_F+B2RZ=M=L;J-2>'H.76
M_=MEO@7>D,LMQEP-6WE0Y&#U^5]&;+J;&RE;=%'6/0#1*Y#"5:I>HGLJ*6G'
MF;T8\20?&>CPZL54AL7B\+*68%TB1\O <DCUEEC_ZBN%Y#[UW(,Z5AAV!L!%
M@3_\*N&0$52SI^/NQA-+/I';AH9@*06X7.LTST@+>*+U VLA#;#J/ZH,81OZ
M[6N)1S&I#1!F&U3E5KY<BI[IJCEMPBV>AFQ$+J@Y,7][OV8FPJK(>SO?[G"2
MYP_+^IIITPO7R1O(E>+ C2HY7O#"N,H2-?WTXVM7CU+JA1;0T$9NTY+P,QG,
MSR<J))=AXW-5G[F0(S/,-';KUX_2.W[,BGH-E#J 46MPD3YY9A/<&R5#&;BJ
M]JHI,2,FY=\D"Q77QLC/>HX&"<<N;(IW9HT=Z,D^2:P]CQ[;BCNP*D;RU*>/
M<]3D[HW<3IP)\Y6"$1Q2^^-R ! ](6Q<'&(.9Q4OFC%K73TZ3Z:Z9Z\6D/[(
MW-Q8"+.V#+:\-UO[?;]0050'LYZT TAQ&.5RC?<&/&!=\4SJI8<[_(2/+:X2
M5@!T@\$F8O*,XH#84;GDPN#-CNX8SI4=:YS%SJ7Q=E!-HUCNDWC+,37W)ZX:
M(%5^N(! =)7_C'-R@Z#[6W,5O^SPUJR14'JR$D[R/,<KE'&@>FU[_IQ9R"DX
MN9E5X>+PT;&BK5X4#NR4+:_:5N@<)^<O$@N!P&GC@8I1[K)=4M?J.BNLH:HT
MD[<L32EIJ&2SEUP3, XS[ EKP/&TCOJ(YL[P$Z0\ZFHE>:M-_8M4I<NJ,_R?
MOJ!38E;:4(JTM+[M@#<&3+S+WNA7'AI;XB 4!7 92<VE.59D-W=V%G>@0)J.
MMV1VO:V&LVX!(;ZJ!C9"_"D*Q^YB[XE:*X@=Q=[$9//N0/_,1X/*I"5_$HTE
M<=9"O&B=(W$<-C:)+73;$C7LC2TV>S:FJRF<R?9_6L[Y_ZM=K,B=?<QO.C,7
MSM]T7_7Q%_2[AE"OIGQMT5B3T\#(\NA7MD-'*S^=9H"NE\N,R()G9^4.A1-!
MP?T8B0$?ECE;M?TI5$NC,-AT$U(.!S57L\ *N[A=.H(P:U'2;&HJC=Y.C_*D
M<C!L@P,X_0+1LD+Y#BN3FL;5)_*5=V::AJ0Y==V5BFJCI#]:L(PXM4 'IK(R
MVX$Z2D8BI4)A+E1I=8E(!X:P6KM)W">M\2_Z<W_VQ>/K483+;SJ-1D#?E.&:
MZ-[R'KE\XKJIO\,R^L.@166-PA3NEG:UJH>90*G']*V%I X"OFB;-Z<D0:5.
MKCP7_3<(%W.HX+7882KO-<+A"?P(%-#./X6>H1&%+:NEVA+_BATTU]2*3^X&
M4= 6E-3.7EWU&0KNX+II71]J=:.AS(-)4!KC.(S%E8N*U#T)]<I9=LVP,K-@
MJ;RR$"&Z: TG]/ED%&GR:"T'(GT)AQKU'N;F:)CA7,-U5B#L1TF[=SR?PO.-
MA0![!AU%WM'/B0,VSA]#^QIZ$W#EL7BUC/]>YL?J1/^PH><I,7AP=&95R5I^
MBA)G552*]ZTS6@E)F34^-/M50WSQYDF:)8WIWL-OI3O]-T74??*6G<C"O1A9
M ZGK O?T6K5_TSE9#IRUE43BD@LW!/4T,WNNGRS(%YMUV35L/^X^B"-!^4(.
MHBT7O"3Y^/D3C5Q(_!5)&YS/$Y(]-JTIB$]I;QS0\!)=@I:P$]<W;*!O\J6C
M=99L"NCM6(C'9N)<R4FW7>N4UDZX3_VF1#)BZ1:XIFE*\KZ+]J8+C( 2M$Q.
M<<W* #KW01V^?4WQ" C(4,F'BD@4H 3_^U\^>&-S<QV';"XMD5>2*VERWM3?
M<5RQ&1H*8'_)8O0L_(?8K7AZ=Y^R^HNC+G1BB^%TO<XYP,S;B/- +_FZ@&7Y
MVC]-<8[G_-8:IX7=U$9)<H3&=K9S:C7-RJ:U97.+>FF(=LY'!-YD5K;.*=2%
M%^N.,36+]4A8-,;J';Y)>2_3HUUD3S 9]]$0!,(>H+$Q(1P=!AV6]FS3HC*&
M8"%V]; ":22#=DZ+>GS$V?C^=)]FQ1*F-NP96^OJL/U)=4[ \3<S0=4J.KI#
M.ZKMN3T@\F1LJ?*'2J'F</ORA6,^_B@OM?.[H/#-?9SLAW#HGL5A%W"_MJTV
M8 5ZF(,6T\M^>:A?0>K^BY,[_J%8NE@'V[2\FU9U_,)V7^*<!L+P<1%!<+=@
M:EC2?OUFA%^P2T[;EE@89J"EL.>L^=MPV!=:L,%NGN:A06]+?LU)NR M*#)Y
M@;F&)O@%HKJA:1O-&B6G_T&I!L?S $]O/Q2>16XUM]2+/;1O%%=V_F2S'7#'
MWU/0[C95UFZG&J^[7<8N!]?,ZHPX9JAN=M/ :)5!8XU<+IG:G"S+=A6%QW3>
MWWI,V-ZYY=^\*.=DZN^X=\#,"/9'G+^DX(GP,R6D".?5V,&2&1DL=A/:CW^W
M.+>ND"TP29F$X#X%VL:=9)B)$N%.&XP]8PJY<SFXEE'\' N+ ,PD@':ENQ<=
M+EPY#^P=?J 4:)WY*F58R\^[T'<JJ\SF "G-)[)I[_Z<^NT?EV6CI0O6E]$;
MJ=TJ$:9;W9L17 .08?V">7Q:PV)17=HYY7)[.Y/W'I6E^<WKG@;A7[ZOH,E<
M+@U9/G&^H"'FP:=]:N->1I$SIL1+K_+\S577G]KCAFOH"8W#[=/3C[8':F&?
M^K3<@VRTW(9. \ND+)\&BS]U+YMD?UP+FR' RQ_]C'W5^\^KJWV/@EUEZG57
M:6FG9PN;?;"#%(GHATDMX=1(#D4K$X> E8@CREQ)PZ6*L'33U F;V\GH#KH?
MTH_:\[1V#JCY9P86AXE*$<]N]J@+DS,&9O9!_$RLU8\@X*OJ_Z^ _/_3,3:$
MZUV>Q.FJ<7CP>(.A3)]EG=_:@"'P1!?G+,N!ZR>*B,[D'0BW^A!-/H>W [.0
M$2-[TBJ02W-VT^65QVL>M+)R=Y<WW?;QG]87X> EP\?8B6KHGQ#CV3ZI%HQ4
M[=CMEO0Q^*FP,\<Z1E3A.>;7MA4P[M<RT&PUJ2O;."FP4N'M$PY_ESU+Y%X.
M"I*6G\E(H8R7P--*^^[I'R)#9X9#R3M@F84^GR2WL[GAV\-/I(.CS $LXW?3
MQ52RW4N&03W2DM="#)X40IABF@QU18,;XNP5A_<'?]/=904_N)@SY+[,&RW[
M>C^=8EK:U4]?Z5P9M87T#+B>+)A@= 9Q?LFR&7R@2G\79KI-;(TV;IUV[%NZ
M-+-+T$T</2=)ATKE'BQ;U/E5*$C<_N&<:+RH-6U.*F8^OM,(A0'<"Y\I] 6*
M1PL,.V#N^X;430X8[/:638Q?3$3F[\C4J^UH>=I]4A(;+Z%Z"3=XUHN7G&:1
MPSS 06<<8?3Z8>L*_4B<WV12:D<D?['/+S:PKMSN" VE.W/('6/^; >GR]0_
M=\]^SU,N'B7'W#]#<TR$^6%K>F,L3FIB Z)\LT%X!U)BLN!8;-VN6E[Y$>>5
MB?KTNPK^7<V+(R^ML58,G@%*O\P HT8PX,*.</.>D_2"<2#76LU?'>?E1E+Z
M$/VN\IS63HS"Y&\ZD>:<^/!?U$YB'G"*8%GOOBMYC(@?]:20DLJ+6\Y'HA;@
M<7$3:#AE%L'B$9O!F77(I1#6VWHSAJAC$-#O6DD_AZZHI*<80QDEOW FX%W,
MMVE>'KXXYW9S?&I:W-7Y3:PV5+9OE#^JOREKI4:B)K89GC!J[C23&'U-KWG,
MD2Q:>'QL>\B]V#(=3F9N$"/@:P?2ZWRL;2!,?'S^K/;D*:=:C6YD;SK2D]D.
M?@I@9&'!\(1E_OH8WF9<?9&+X?-(D6MB# (Z,1^9)\Z68'%F5L]3DO#SZ87[
MO^G>SKVZBX0E(9OK4ETF9)4JT_C6W="2C!*BZ8I^6>L@>+5<W#8F6I]KM8V1
MY;/0215VX\5\]8%#4T5D,.=QA]2M&X[;7']=WH;25IR"&U+&-$:N(G;@JX<:
MO=/].Z+!?4(5B9N9$CM[G"TNLG-ZS&8%EM"^HG!9>8P)RLI6=#XF)GL#-A'G
M&MA)Z0D=;J,HOPN=!ZY^^'BB\]-$M<T)F+(]D84?'2<VA7M!B T27.HZ?9;>
M,W%G9.E(7OCJCO8SKHM[YP.!F(Q#">]/)\&O] #=M+^Y)^J3[ M3A&F3],09
M>'918OHOWYK7N8G<FJ0AW?9PA85B&I_[ZSG%RG1*I5]<FG6&-C&F?T^QK+_Q
M22UZ+"[V5)7/\Q4E*GF%C-T?&Y@SG<B;5G1/VL@0M;P&64#=PE1E*6ES6Z-3
M,FJ[/V=)A#Y"KH6V&QQ\&C":=]D>R@%;#UI\VYO9\?:T@=>%N(^5I<M9WU(W
MP9:,F8;WS"B>DFA\D)FDA>JI5T05;H/SC WCX!#P=R@MZUM;416?=>R[5J0"
M^A@VUK40YZ9KSCZB VTMX.7])XQ]=MM>6,(BN8E[6UX;8FHH_6(+ZW!X,O)P
MO_KQT>'U1+O*IFS=]I>#Z> J',7A[9<>3B0EP0#&(S#N9-:&06I4)_D6>6@L
M6XV0!;ME_ =%3I3&*//C'+A-DF5,BJ$<;(P/VS09$]?$E*6&311A.1K_E9I\
MJ)=-T-(+6MYBP[W*Z'*2TWIOYYKH.^3Q?AWY?4LC2*6(1E6?5+(8\5%S4,CH
MOZL2F='FZ)L[]'J1TM UYPZ4-RYH<O@6"D<7D)CT\'*%V5,%GG*W(G8EBFN'
M ^[%P@"'V^(*5D!1 &M_MON:"63RC5"8 DO?&QK\8P%UK+2RN6*KV<Z"VYB=
M?IQQK$X!I>21Y)-2A%LSR@22)9U-.OVJD(M+H:WKYZ/>[JPO@G4>;<M)@:P7
MYW: ;GX&23<#X"U"/1K8"<M1FY_&;NZD>JHGT^S229I^,'\R^H!D2"BX8,A^
MC+85CFK"(./K57^^-6HP4\M3UO-4G]E7RI8#;3J94X^92[4UMIM_=)ID[.4K
ME*R.\'V10.443*IXE,XK%U=YK%/5@"^>2-B*R_\Z'33M/1^/69*VES03>)CN
MB6@C#PN*P!(;+])&3'Z-Z7$HN_$F&FV\K\+I8E**A\P2\#\FMZ2G;,&QYH6(
M/;X+,TDT'(V5N^6VB;=3'\T>_H@]6E6S7&"V_01^\_H=R%CXN>-@*6Q@G:9<
MOC28%E\,"#@:_4TG/E"<9J&[N@Y&K:AZ#S5&!RD23N37W/+],ZM%,W1$)YML
M=NXX<)8Z)2# "H5ZMQ/Q#D:)ZHJ=C%V24J%G/IQ38AFI*G#J(:%(_9LZE,_X
M)2.C+*_^Y4>FX:;,(\6WDUS^.O)LLS_$C;5E&]0$U]FXU,W$C,>G6E\U3S9(
M\\B*,F6P=@\,<O4I0;+NODS;'Q5N;3I#U$13#:A*87,MU._R9C+S]H0Z= !H
M73"*S5-LE# ^YI(T*[!6EI0X)J*5N+9JLM&2P>G[\&D$;^)EOV;K(8[[XYR^
MNQ67G^U4B%0;H=9,1%RHEO2;3A2L8_/$1RUPVW&^0>OGX7-+LY<6FB).LS4;
M_XHS&ZGO*GL3N%2J&ES337_3W:)_$DKMW1] S5AZKNZ^H^NG.<"D'B,70.H(
MCR)1:6WOL@4K\;=$91<84W:2WT"=!!G%71Q7$+%(Q5C*>NS ?CZ.F8"53L">
M%%S\IH/MO\P7/LMJLF4"X2K=Y,(M3&D >>;T ?]C0^K'[F<97!_'_Q#S 4MF
MY FUQ'0H0QJ;"YZV?A9ZZW J_3#BN+2?,Z$WN6*:+!BIRNMC661Z/)E<=[6Q
M*02X_>^4=5LV5V6H88)[L?DL+681G<Z7R1WM%"8,)@BB#]I?5CBZ)LR%[,FQ
M0 XH1C%QF\ ALP>RH1$13<7^=%14[YUH'LG8ZW#/E6WWM\YRX+3*'KW6.+_+
M+LJR4'W+SG7?+S,'1SD?5X?,O!;Z7:0]4^TZ?BV/')PW0"(/OC9.PI<R'FW+
M<Y(?3L0S=H/"])(KW@[!_(M?.V0<BR?^\I4ZFD4HF<TC*KKCE4%U\*P,PSV5
M6AT<6B^KU)<$8,1F.\0R+F*!%$/_8GAE6LP"H,AN-WY'(5$1NUR'2E'0&^Y)
MG"*QR/=<#<AC](/L[-@S56$UA5::2FZO*"A&Z!Y_\Y6;W*LY.K9&/F_MD8HE
M8@" .H.6QO "45.\29U?/(,'(:U05B)-[M=^F*65;">UJ2'@85J1#M^D;$FE
MH75-X>NG/2';=4HNT)U<$K# K7;RY^:*/QA 6[\E"O\O4HCR\8;'"@/A:-P>
MF!U)+(@6]CE8O](\C_/)JUF[DRIN:.IA_*".-/HI=;!WGFISU0%.\-T#BA ^
MOC%_\J#;LVHR?&/=05%?'?8S&=&F+N*^=[A9C']</F,%L^<:#2DTD>1*[M>?
M9QJH=N;4A-A!?(T?O%&)^,OAP">'BTR623B!>KC,/%FSSF%_@WS-T+>/]6MQ
M8=?$FL%9#!4/#!5@H.PY_33U2H:/H\V;749?)3JB!4\SY.5^TX%!V,J?^G8>
M.TM5<YLJ4G5UF.(;V1PK5M:[]'T'2<KKN,FBDA3U3-N35.R2LY/N&WGD7=2+
MUJR=[8=RCK=K)/Q&S,'/WP(<NZ6LK*P!HV."CE"<GE!,$@RFIQ77<EUA":S?
M5:WCH=*TGJ=PAM2X0 MO?,F/_Y%[UM?LO^MH:FXETB22S^D8%Y.NUE^ JO9@
M+I<K;4MQ+ W.B6/T^7) ,'IJGY-GFB)R[")\#_DDT_1X_V*>5C @Z>3>*%:=
MT!ERRI\B-Y/Z48VIB9H0$C)HP2/0S+6&E02O$]L:QZT6!EF#P%< N0GQW-VK
M6(JOJXT;'C?*:@F#=\'TKYDL21")??+:L"F8[/VG,A7$ :[RHCCM#$%#F(DJ
M5'U<]^VPKL<Z&UEJ+OG;'-O9PV1RW 9764P,&@;[\H=)P&#^O/V]<=0"-YA0
M^Z<%9<CZ/9.;4RPAOQ2'='_^:CCI3B+Z 30D-&ISSHN*G7G'C=9Y#D2.XV]#
M]:V$9R'9CM\YV3L.GCS-EV)?>43[FRJR* :B'I_U/U:^_?F?O#*BM'^4PGHR
MX:3<ZTYGYH^Q&;"CGKC25P7[C"R=?Z3J=DWMM6^S[$0R*#LQ#D,NB5*5)B83
MFY)7@B>',-(>"QCP=UGGT:L8.<0,_Q>/&>)--#]G_5-@,O]S"/!%$:_/J[0&
MLE12Q]E1NH4+>GQX736P$;ZN"(.OBU#@5&L1;!/,#$I *_(.H^8K0["-IEA<
M,<SL+51G\_O$F?"4Z#!)HTU65-7&XI@)F0V0KG]\-RL_N2;=QU@TA9&_1$I7
MSS:C:@TVJ@5W4F-E/ZF1MW[BGS]P\G'EWDQ[!/35D.4F!=2UY,@U9H3%\4!1
M?JX:9&PM0B37*D;%6WSL,%!4V^R.HY_MEOZ$\\A9,R+_F9FAMX26%\-73EG3
MT<6 SZ=?9A=++D-[O<OO&SF;ST!5&VV0Q/S6(EJ/?<CH*Y#\ZI*9P'#$TV7G
M+2*]<*O*DAUG6T>&\Z\'+8[*?EC(PXP1Z0(WTXY;CEF]V; *2ZZAETLR*PVM
M;8R>!1:K&E,_R_'#MC*6<=1#7MAP&D?)P 1?3JA,>DN\24:496.7YR*D N<W
MWZGEH<.9@2=U![>X)V0UP;+ACISU>AC!UZ#IT>U4*5^(S-S6[C#8YW.;99OM
M'GZ0UL%Z+Y_5?<?\.\5*5.R#.W>H3-Y7"Y>F%/.5T,FX']F!P!UY334O5L;7
M E0AZ<6;OUCG@>2X>$U^3W4+.#8[((^@#EN:]=UZMOQWEW$6@[Z_-$+?X"CL
M9_YKS^B8QD;7'38G"R$_$[] 3]&L&@7O-B:I;&?VB^1-!MRT!S_F<?[Q(Y6-
M,R/T7/&9\'[=/Q>QG YQRQ.^P$)#0GXF0B <Z?]>_;BNC.#7K#2QV1)%_23O
M-HL2!P#S5@RN >9NKL]JD/Z@R(1$W6BAZ1V.:L<%4$*6/*10 ]]K\MZ#0G2"
M-/L9@QZ9C/UQKV()J9D$AZH@>=FQ^<%?\=&*A[U45 X.ALHAP6!+L#^V9(S.
M65?I/\'B* ALBTC31/&442=NX&'5_5D8P?M8.+%>:_^L<:\Z!>A#R(C/;."&
M/)?6^9!C0AFS8G",ZF\08>]#S4W#0ZL/*B:17JO986?RV[O\Q&Z?: $1['%1
MLA402 $XQDTNHO6R&QG]8&;EOD 0? &S;^::[)!'C4C#653V3TKG<.B@)[!R
M(0#GNUG:E5TPA'_FY"C@Y^HM^OWW>_L)?6_FB"\Z"MSDD:^<>K8?M/_A8>OU
MBL.:40V3<O%KCRU7N'L(+BUD)-4OU4!F@9^H1<7EG#3"X+AU6VE7M0P:$BDI
MP>,?<**-XD,/H]"P8=@D%E=1,=+U&AHEPF4^70Y<X&3 ;F\:G[!]#@KDNSV/
M9I]^8S(<&6'8(K,NF: _TL>;CZFG@J_C(OO7'[99R$28A^9L2S%]WD@<)_;!
MD/;)QB^Y13F9)!F*A%>-PVA@FN4RBPBVRDB8N3?I:'87WYNXFM(YQK0D&;@Q
M2L[2[B3@IGMO^:L TC_G4H!"S1Q+^I6,C1-*48;T[^][8G[3>1<K@81]7F6P
M<?D<XE]9O."1:<2.W-,H8IJ?@V,%9+4#G3Q1TEB@ & <>G(&XXK#8K'NN=39
M;K?<W94XS-U0GDN_9"E:Y=BZR(5C:I+YH^?_SWF/0^#I".(0K5K&Y3VS[KGR
M[_3IRZ>>]YO>2KOB%9\NA*('5VT,7G-V'3@'W* D> 2B$I3)RNVIK]GN07?"
M@RJW9P%\CA-YI0*P:3D&RG(-,+;Y>WOE'&^6@9J*UBGYD>."1KLN=>3$^\5U
M+SJZ^[S[2F.@2NO[C83^:\R*X;9VQ;2M.F'IL/);>JL/L?E$\=07TWOQW-:.
M&XMZT\AY^;Y0J;E%(4;<GLFV CLAYW'LI*N"Y' VJU1%G86S #G4F.#!_:0,
M8UITUP-S+DBLC7T3^@=-$V3)H7\\I.I6PG]T]QXA&U-N^%Y?CIT(J;?.)$ZR
M<==_&I+>UR ?D#/K>K6_> S_3S-OF\U'GI4WBG[5U(N;>C2:T++XTC[8.E28
M'1D< 7_3^4KH_J93!W^ZGJVI5NG5/J2J'LH:^;U^6#SPZ-=E]V^ZP]]T&,_V
M1T]FZR\-_RQ;MG[325_^D=A#3]#?_@/IV/OMG+8W)4#ZW-I>(-/\)8IS7<E,
M8Y,C30H+A*,=XI5AIY8FI5'CI5N<5]'#4D E>71->B*,-4O9@Y-AJ5%Z_I;J
M#[/OG@5*3]R;F7MQ-^MY0,<)#FP[U2VK=JEOM-Y[<@D O\*W@IB5DFTJG[H)
MQ7(U]A-,PV7/'N0T2VF]!B7\U\WSOT^2J?A*_YON2&,DLG5Q[3>=,4GHKZE_
M[LAO\M:)*LF\S.F;^W-7ZEX6[&/\=2O?WE4?OJ#)_3@T-]=H?+[Q_@!\LUY\
MF@32M64<>,5:S]WZ@4$O[%Y3VQCAT_KPAK(:+]1!?^QG:S/5V/AJ6FW_$'SG
M'<<C,[9^* <]B/WO9@G4:V8FO9JD>4Z5_T)8_J-C6#PWCYS ]$:N,[_C&8?)
M7IF*8.+9M)WX33<"_D/!;7/I9.-7G$CZFGMJ<;)K7FE>5URH/FO.,Z6IS/<6
M8?YR.S?@$O:8AWS.7Q6Y\CO!TG#<_!.78.EU.OWK_UJNBEL5NA@$];+<Z)'R
M_U!0X5[_;P/O@^R&D6GQ2<VU/W&74BQFG)0KG$\KJZZY^'+UTW^/1W[R%GTU
M.3>%%TQ.<)VI",WAREF(>O2B/+>'M+ +QP\&_PX[DSK/[>3_:N2@J\O3DA'T
M!OQ$].HP'=&V>^I"C_/OLY,OO^FVU#[0PTYAO^G*MF*?',6G\)QFS/U[ZS[=
MX]FFE<ANZ\\&ZV8E)S^&Z.A^H.F>1ZZ@D2]QX;+<6=+4?N:<!F3*S&^ZVS%*
M=F0*' 2_[/&'L1?G_*;;[_OO6E](1&25[8W?= O,B?E?*&)7[O*P&&O00H1V
M2>D&;85W,#WUGG>^*H8)7I\["@ 95T4)F^P@CHR..>DEJ0'' 2OLGW@DET#>
M31>LL@?0,H>2$6^OXYTXKVG(WQYN@LZZ^6>W,B32GORF:SFC,[JN-=M4OGW9
M\'BNW:]3/N,0:N7C2PON'U-<:4IR((W]"M_VK&[F.O"4]?_\$/ETG%Z;\2\F
M"#BSW[/?Q+O:^^I>Y+[_UU]Y/>_IT2BOTL#NT0GG=P937 /CL32H/_UD\6PQ
M /-5US.L5B7+-;I*1XO)UM1:F%E_W%+BJ<G@3"?:$J,H?)!GPGO[N63Y6+W!
MSJ7JC]6EB,2OZ'&30/K"%5K;5$93=:GH,7R*NNES\W,*'S-%._X:\GD%FRSD
ML4C?5M19A\^\JD_2X!6-R*B_+WD?!ORFDX/W_*;K5BVD"X'^]W^:*/[?[2_E
MGZD'1R> 6H2NW+)FUJKJ3KJ!V7<E'/_C)@MJF]_."KJZ+HE\VT6]PEZ;N4#M
MP48EJ%GV+ASM$. WU3],%3_I:+D.7W/2DG?Y[UG]:6OGE#UX[EE2R+_KE]B1
MJE7?@H(Z>@,^&"#&>8957.;1<O^OKV97:[V4O8^^Q) I ; @\'?2D@8?6HZ[
MN72*,=O[\)UW6I;FP]#9*5:$QYTY+^N^HOSI8[V75V'IZF-;[)K2C.B#E=O9
M90X1O^F6A+YW?QXV[:O(EP[]C@F?&VCHV>$</?"/9QIAJ-/8EN9D@QG)K8TE
M.J:ZI:NK'X$Q#")$D/':<!9Z)I\C?-ZM.EH]9_YV,6.UO!FN'/ U. RML8D
M"$XJC+#_[._2D'!<*=SB^I)=FHP*-(8PY&X>"AHC?IQJE2<_N&-:F^S@P-:A
M!5_GSLW<?CBTUGT^><:139.U0"(/^,U$LBE(<7&^!I01"6:3C,3K VPX<GDC
M?]-5UMML<&ZIZ@I7_J9351C=S*E[WOKE_"#GS;/_^60=-+(OJ?/4/=%8.LAS
MO+EELU\I.&ZS4%SM8W=)"E@4;OG=I<O!+F)_4XR/95C+D>@BP0AF01@N1 *_
M2IPBSVH6R*[#]_G/F.G6YD]M8JH7%GJQ57.]\1_WJO%^X_5012:A/ RS<&V]
M5>K28"9NMYIEQ\XT#8;83('\JK#<0@!%\W)4<69J[V9&:][L<46NM**"K9;O
MOU_\]1. 7[;I$\I #TX)U:F/HK$4-F4_6Q&'+"$28RKZ-]T5_WS%O?2^?LK#
MG7MY*A?V5KV+GI.[>]H+++O2\[3:I!M3SL*T;["DY:4=+^Q%+.,7JRT'^W=(
M6<3@SX'6VU-@F<3V&W6^]==K0LB3)5%-&M]#*<S/1A%D;SZC<KUBOLYEZ>KM
MP,DVV:TURD8[[IGZS+8G"*/1:"K264U=37[3'51I+!*+E[?Y+Q%8#I9@*#'.
MD&I^0/99^C%R\/GS06O;O>P:L7KPI8C%AY>CBCO:O,3$>$D58JU)G%L>'C6)
MGZU3/W)MMB"L_E/MU'JQE3><7TO&P8SPL>4DDL%FXP#$&N9R_?;D#RK%%&K&
MT("[U^!>ONX\1OK56:V2(M4T&>+HE&<)U0#>O+8(#+[!JEL^[)"IB%3C][4C
M,#YO+3_QZ6B7.>MDZ*G?SY'TA?2?&OT)8@B5?Y*-;I7_DYB0 M/ 2CLW46N@
M/5A%@*,9*1Q!P(VP);!:X!@S;D?^>E,C$  +>%BAKJFL$0ULY5JU5MK,[B]%
M162&'TURVKGC_ZU!U.*G(MQ#9,,&E8W812Y:<[A!S:A&L878S"PSP_2R,W:7
M&>'>ZDE@B=1!B6_8KYL-7/[-36=\G3*J >Z[8MO2U*.Y9?2 !3Y7?&*RKG=]
M9Y1HU<89A(V;0%0S-@LE*O$)+X#N-0M)5LM:\,4-6P (MBW=?DD.(J0O%:;5
M+0]*XEB9OSPVFL@)01QHU#]H+72QD#;#W M<1(MCO#QB.PM,%G4LD>]ZB_*>
MFT^##=]Y./)9I,T ;X#@Z_5=>BN[T8J[$LZ6RZG@<>'9GW7FL (4FV>"%LDC
MX+C")*F\$.%2N(XV1FASU99*K2C&,Y%S$G+[N-^$\+UZ8LJ&^91@[_H33D*1
ML.4&2=4_1')<C&[I&3]_1OX\-%WHCSC8E^LR3OBW6624I=NH01L'+(IG%PY(
M6LFM<(PS%EGJR)!'Q.60CZ=60Z4<Y"-%ZX+( 7D6V^).[5JKN::0[^ #%3!L
M!-N:W%BC,>&+E4O0&DNP!_I-;DM*./:.SB][H98=B@N:#;8S<04X/$?9*G13
MO:3HV7Z;B&%RFVSJ:EQ"* _@'%-30OFK:/3NK]+A-)C!3:(YT/GYFE1S40\2
ME3<8\&[DN)-&:VPVGZ],ATJ#"QH1U$+S"75<!A0(%(#Y\_;Y6? 7N9)\OZN/
M5QH)9O0:T[:(7JV(GZ^F?M3JGA]%QG%<ZMOX5\!#L/)Z;6WEPNFIR@_U/A(+
M48M>-!X^3BYB'RXFK6A4YVH?]/O6+[?_J![-!]P',ZB\77$\+; [%L(ED?P]
M"=;2J%=641@0+5",,=]8<X<OOO_.']((L/,(EW)W<&FJ2#\WU9 Z2W(F87$E
MQ"<Z]I"I(7(,P1=8,DLR;?=GFIO(UF,U'/WP_8<K&U2%/O6NUJFY5FU*4M2;
M&$>UBH\UJ9QL/4A?_WD%\S68D[X_6C%-:B2?36H[\M&Z;H=/ILRU(3)OYN[Z
M7+H%P%:,J&+(?)[HP!$S2>(@RW'$Q Y-!08&H>=HM,6S2@%_.'5L73$2"@2]
M@0(%A-XJA:!ZVV:YW2HX;SUW4/C0YXE\OJU)X'LO[2-^!'E?O]R5->[(\$I;
MHRG<,<9CCAUT(Y4TMWZ-K),TXM7F@O<\R.A-K+,<;C].$N.Y0K17<>>KOJ'$
MHTBD8G&SO1(V%R*$Q)1BO_+QK(6$SA/S 3&#2ZFZX^1B,^C@(K(6MJ3N3@DK
M2Y)(>\ROZ'B&>NZ=KC5U?U(HJ/$T,!CIXB-CN"/ 9\U>F&9#DHF23+;&SGCL
M-R'^L#^5;BUCAZINLL^QN3WKJ?6X5U7?6EV;4X!C+"UQ9Q9!FI.T+TQU(YCB
M675@AGXB:&"V.;_V"U26",(46U!L% _14S*$J;["\C">YSK^8H[;$\OL*?1,
M*-IN5*SO+9I/T1>584:#8&")-"#$V_7T3($]M8XWR;&W\.W!LPR0JMXVST%3
M;3<F'17!]SBE^5KZ)5DA$XOMRE,@<'L?%^#!7[DF^X %0*RT2K&)QGB!/"?W
M9PM[&15XW?#_Q=Q;![6AQ=^#O%=7BE.D%"]>+!1_+2Z!AP0/%+<0($&*MZ50
MG!)(<&AQ @E%@@0K11.L6-! \2+!7?=]=__:G=W?'SNS,WO_N#-WYOYQ9^Z9
M>^;<SYSS0?&XN19-6QP&%M\"L1%W_FCOT!:.N(>#U@$??S6*!;THFINZI@(=
MKOJHIW8]7"J;HLUWL4-&8,2L0.2\&N.;IY:$W\F2:OH2%5F.JE4MK/;WG+\H
MN8:^]19N:PKN1/J_B_[HL#6>7@>M"4H'B,&AAQ'CIG6/C!$N[NP>&!#Y&1^D
M-=,\Q&<\?0/0[Q\W:_;VFFIKPE\3IEF)SL<^ZYPT)1X,KXPIJIO:EJH5D9*U
ME;@%!UKT#5Q8 []4EGKPLXJ:_/7I3(2E4' O#FFH=K!I/_Y)P%K1:0#>[R;#
MN><SG0Z"Z6V!9,*"KZF$A2TEY.6<=&FJB0UJ]<9P)08X"D#&M#^ECW,[P\#S
M5J<.M86&RC$&T;IE,":FLFAK2V[RY-K?LI:@/*W:J#'5T1C,M-J\!?\7 IGC
M%8Q([HP7JCNEOYPEQ2:8D'F[LU5\W$@J5JY_-/SE:1,]RM%06D-!OU./+/G2
MVWN#R5Y-0;>FBT9>K+9F+>3*6^[DWIH]4D3XV[.^#&HPG$P;X'5;E3BF1=9^
MS_?(]AK3XJJIB^:..-H5>BK5GS3"$ZVJ]&C%R=_2B;5<\J9J;=+T/;@D@Z%Y
M5IP'<P50)#X^'Q1OK"'+  ;?F3CYZ&YQJ<=J3*'SVLU5XCH64;\=+1O9@P!7
M\OS&#/)S&KY[@QRP);=W"5=AJK.^(:?SBG3F."43/Y]"%AJ2&G>;?@KSIW[G
M^['EU!CK:B(#T8%,%)I4E W4FK.06C*#J(/<JU:YAF<ZCDLS>.JB!_XDX((*
M/$) ^6GQOM(>W$@:)C"#D6'II!+'B7D4]IY62S((]-1<IJLM YND]A#&^?C3
M+18\'MB;Y<>%@CRA3D0L+A$_B[<Z3#*VKJB$V0?L/V)HSI/FQ_76>NN6I("0
M3HWI#,%E??VTICU16;<>[?72IS>7Q]-!Y5]-;<O7%OB?85UEBL0UC=A6VK2M
M'+K$JS^F%(K*P^R=%=/^4]_!#6QWH[ 6?$@CHXU?GW/_SDRV\'A6*+@=W^#(
MHY23OFS1^*P=4./3MPX\;%*\&/$V:/'$JFL!6[7<^NR=;NWYH840F;<WNYW@
MB<.9,"4WHHW@6F-3JEOUZCN)0',56J47R/%A\WU#96C 4SH&_J 5< ,-3DT;
M^\EZ2%?TFHJZ)SI\OI)B!VEO**K%>#CZ! GB8/E&XR _Y#>WH%6KA!P&N?W2
M0-(@#G+JX!4,0!L=^K5'H_R*:/]=6Z6N98<E6;^^(?CF2Y?D[&G0R<!=B+UB
MSC^.<\N7^Y)Q"Y"J3J],!;[^T:GZAM8J!*#0@&FT*F?=T4(0S:6F5@A(<H'W
MYZS!<7UK]$>[TUWXV5-[8WVTC.;V06CU/[7%]TZ7Q_R]3([\.<W:O.$)TINB
MJ+HB$44ZW]K:4BU9I^I3LWK\?O$C'LA1@44QLL"1,4'C7EYT9JU!@]'/9O84
MF<,]RIXO EJ50^&I[Y_^U9 W!^:1L)B6FX^'2<CRI)>LO(9BP6EO(0.FLFL\
M&"2X,MUVLH)_:^-A,G4;Z"3RU7\:TJ9J1=PZJD;-E$M0'/F+Q(U"-^IIF* >
M+:YR'"8R^RK:Z*Z_4/AIY-8C\GN9.!$@+LEW:"2+_#[A<,&C+R ONGEJX @S
M?%*_59!$^UH*P9]Q3IQ5A\P.>#<.R@XO%MBG)FAO%O49J(].)C";@U86XDO5
M:]%EA=OP)?@L12S>_E6D<A0AQDY_&I_T3DJZ)(,&HW<[STT? P*!3%\V^HV%
M:^CGU&OE\P%)?I21<"0/JS0D'>4U[TB=Q2"5I)DN'I]U9,],8=9]V0N7%*%,
MK0YR)V'<>$$#L"$:N@@0Z+])Q]YBM8&Y Q2(^6]A:O@D>0A8$-GV?H5:A$]G
M-HQ@K6N>V_T*1,>W'-AOJS%<V:#?FOST[E&5:1V&1F5I)SB9=W-S*^'X=#=C
M6L1.EAL.$-*!E"&?VT_%FA3LYW.'N&*V' L,9:^I, -<&Z6XNI(5<V"D8WW+
M<D2X@5&XQX':V1BW&WIG-%$_BCNJ548T9=;6:.$\B6F0:SS3G?#D(G*<.6W_
M@EC=N),LWGK\&_-=P8V8RPN4YLI(73;H[AV>ZW4.42Q]/P?58<VHJ_<C;['7
MX,$>W".%_TQ57#[<UIH:+4.*\H(?Q:J[-\3U#D[UHJ#9YYKN/-+S=A78CJN-
M5%<Z"TKCAX*V@]CEP=G&:.G$+,-0<,W!=M*&2.QBV8)RTKXE5_!0W:MM^_M"
M^SGX) 7'^ OA9-/L7$X-VHLUJ.6>?_!Q2#J33(IX?]F&("_S@'?OL$?FCZP.
M8J.(?N/-+P% YZ9RW/P,@?_EE.TQ""7&!0KQXS]F+WW%@GEY1V@G9&/L_&.@
M076<0OCB(6"HQ]V"F9/!DTFX\;/G\ZIYA=6]N5-2_)T90N45-'.A1/<H;8*5
M&QY#GKU(\:16(I+C5"1L+'^3-BR$D_(M)EV:'JYL;6WHMU0*6:6H&NZG"GR"
MCC!U6J6@CDPL)8FEJAHAQ@C]8J<8O1?[%Z/%G55F7]$,:[V..: L=F@U#;>R
MLC17[1-;ND=/AISW8&*,,CW)3KJ_Y#[+'-^W2FQ]T"[^T).VKNU[FHUW#'B@
MQS8ZVI0@G* N'J_')$N,5]TK-;G+UY"-(E%,_W><N9O*ND3E^()O/M\)_;MM
ML,5T!O\%,K%*.;R-#Q O?V4+1'$2^U^<C.6JF=4:)L4N$>R,^ T,EZ&=RLO.
M>G>-F,2!0<W'K9L:CTZ]9Y83B5M&*!EG"#!I;B4H;0R W%;7>A2C*+7OHXX=
M++O:9H,:&S>A&NT!P,? WB0']SM<"_!\QY9 =_20)4-P1HW+(0W355)75K F
M/7>Q6&=SSD<S">BB'_"^0>C:2X?!9^L5MN]U^-H45.9A!((S,Z'ZXTG 9I?\
M)&66@[@A+DTR;Q30W#9'3)"[,GSRI[T?]BYIP[WXT!B?=947,QX+PF:1S\H*
MV>FC#_.GMO]X%J3I(5*K(,]R@MT1Q"7ST4=Z%E&[$JNR\D:_,/ QOA="<:NR
M OW4M).&BT<*T@^R_.P5PZ-#X;"-JO&^%C><>IEM0U,"I>S'4E-=Y/QZ#A2F
M@0NF&)E[<O5#JC$7/ODV7)HYH=[Q@14"(*44'@CL-/S][<J]^**: N^*%,#&
M(^OO*9(4E4K^[8 ^'G-J#Q- $E^L+G"5$#2"T.;[",QT[(XI#FKG5-[W G3]
M6>DWNSK80SV(!),Q!^_&4@"YN"1#,H<O2V/&8:M#!P@^5UDUY2$[(VBS=UZQ
MM3NC-'6/9]5P!="](59J3MLH%V),*M/FPQE6MS[.:?R"6O+;G3(3S'$J<.T:
M[1S\Z'PO8-7.BK,P_Z6C?)"\#CMV+E3#*2C(.V?&S[YN+''%-QU3?FR3NA>#
M]MFX\![71([TFUOJL&4HMP8QYI9]5C^9\]W@_D%Y>4UU9@[]3_NO='5S759)
MX1Y?C'Q7^#A\+J-M/ML2]VDR92TCDZ YNYW%!>0;)=2@G-0D/YEZ,Q[?JQ?4
M#CW &FUQ/.6,_[#T; O>PMT(.?ZTVL?W:KGU9T5>/<3S' &'EN7#BE(@<5-V
M#8I.% \9DJKLQNV.E39ORV 3,LWP-'$\3[0P;TUM7Q DF&&( _(:X0%KK%W(
M]>2:0\5">FK%8FG29#A.[FT>6KWA=3SBVTTB*":2\W$!A#@,9 /L:F>DJ]DM
M=0KL(A8G;'(4+E/W5XD ZJSOGV5?;L+IVPOKW(=H**9M<*'\0) !!ZV$NK(C
M")!1 W++JU#=5F:LZ?0/\8R:1N_+&/U<X=K0QFT9V\B[E-2@00J?<GWSUKD5
M.]%2@*@1N&P4.<B.830+EQZS+(QM&-< =U@[<IV+)]=437/(P,;"RYWO."6;
M"O'/V#P:%>,+CKZHFI\F]]%M4RNT#3HHL/AULU'K3\[.YO%DS60]_DA.<$A6
MQ_/Z)*FO=P](>STB.:3!'TU7QAEDFH&JAVABT>:N%F+(<C4U6&A5F8%;IJ:_
MWA>%OS#>@\!QF96V<.%B;G_AOP'1 @U5\TO9C/E.NE4&TB[)K]I0\2DI<6!^
M(QWGRF$LJM?QT?RW.*?._<I]CIAM904R=%7$"BY?\0-K<EN-J8R=W/>@DK<C
M4XZ##<:=C_,\\8@O%3)R4S,^]4_/*N[:U7KISK_YVZ]B0KWNC>:1BRE&.D_$
M(+J4!I"LG;Y1EBY0O[9(8/)W68$)3YI\3;R1"DSV*GN0?!X1R)C/_<S^"U'Z
MW2S,@,W1>,_(EJ[$:K7>?E%N8ZEA8O6:2C8.\_B&T$*.3JFA1ZJ0P5%?;88E
M2BF#;5R-M1F$]N &*3JX.I&KR.](G;4))@T.?F.,2#OQ@4 Q)$,)GBDR2XK+
M>;YC3,OVL3;TV-4_5:*& OJ[]2/DG=:31!'2:-/7CBV.;KDOZ5M/R(4[Y_J)
M1'WNJK ,1J\P623LIM"YE,< IX2I!;IVBNSG;IS'.PPRTAMCP;-!0DX6A"P?
M\I;E):;/V3_-3UT;^NEPA;?:K7./]%*0&Z$3RZ-DTMY,#H*Z_>7OJB]5HEMO
M(M'Z3QPXP:M*5+1![2="E3.F(3_FHV*DVGK: /]%BQ)XQVI(>N!\?Y2F/]PV
ME8W$3M\S%C$NSJ4EO11U>7_:HO*[8%XEGSF'<4BC<=U6(O^TC>QI+KV;W-2=
MS9_C1H[6HV4%%CL:WUC;<"!2!\]QL<:]=2O!Q67KHBQ5U]JQ'%&Y()AELA9#
M02$E86BO\"LMHBU8A52ZXN4D3,OOS6W+W4!X61VA"]4]S9XC2;?&+X,717.,
M":AD)3:)29!!TC3.S]#1J2!GU9$WO=>4JZ&2NZ%^(OK]:O X/*.R5!0TL#DQ
M@_F0]<C.9:KX,!=8+-K\8FJHQ)0;>Y[=7'DZ;C!^STA$='[!EZS77+PX\4;)
MQW*DE[97=])12.VU]&AZ2/KQ28R7<5BXE.T#A+UBL7()1V^7,!)Y95T!5]DN
MGPP!\'L#>(Z)70?J/Z/I:09!JM%9O8SS,=M-R0T&O<>633+_S$ATO^@-KNI"
MX/WQCJ9<<)<Y4,GZY>@DL ;;C!OYD9S9MV4^'1AV<#$N04?-JKT',+79( ,M
M]S,B$#\;1>X;W10UE3GI,N$)=VOC)K<0$F=?MR\"U'2/32G/0K;$X&8R?8E]
M* $/1]9Y\J=7R!5N94 F?:5E,097)BW$+M?RJB0EB$O+P<U$TM 1TN"1M9^U
M&<U0S^J$<#;2V*P=MXU>,AW#[.7[(:59XH=N1-]*1>OMK[ZS'=OWACY@B#N[
MZO0T-V](B^(S3%R C'L*)N^"[<9\*I_OLN&5 PS5<7P&1O>:+&^3.90S5RV%
M[>:6!Y]#;">Y;^(^B''6JL8(\/I $ _ :7]F$]WO=VUYO!C+T?# @6\P2  W
MG?2@R^GR]PI>@:M9!Z1SRJR654VZ58>^=VUBI#T$QP1'E<8[9-TF:++LQD!R
M!\)5HT)ZP_*7L0X.G8Z+]O0858>#LXO>8?^DM\A($["SYMN3+I U3[W [B2"
M8_[*?$+)LG%V0#QN ?YSIM/Y$[?P5_@0!Y<^_WG?D+A/LVT"H.M,<+-J'F2!
M*W.%&LX2=4,75OQQ8MQU!4#0<*/>X<SH_*1ZGE@21UF$9*):B!HD<NWXGA49
M%(R/J-^T=!S(-VA4Y:'</D@5==_X*5A.W^ZK&6N*JC=%4!14*V=[/\TD7TAP
MR%U3K;;*O1V?D_!G+E)IG&BM_$FA0*$>#B9HLG0U3TFR:@EZ9;J7H2;%+_ZS
MZC9^!96];F<RO"HS&*&E9?<A+FC15XB+N[;9"5MCG]%M\(ZAK/3?>+'HVR95
MM1T+'=SJ<5JPQ,+--?-50MY,E9Z[I"22$<F7,$-?[U/&:/C=R!FJDBF0I/'
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M;#T+,:S)=E06^I+W[^'E7REA(;KOCL%)+YJ_IE$&Y*-/'< 9[,H$4?@I>\-
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M'C-WY'D8RX-X^5[O)$.>LP_E%/@7\W\+Q1EJ&$7\<(!B@1T[_V>3634:BO4
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MGUYH3AD)!XBXIP(8>G]^]"0V@TS4C-S.8DZ*/=N;U##T_HGMJIKP_,L0P/G
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M>5<VY4MB1EV>&4XT=?U%>W<]M2XA.MY#?9!],3 @^H&U6 I#2TTT-9I"+);
M//6GM5][,)#WK%V4M9VK99 UP\^SF;"WRZ5TI")CU[O!"R>NB;![3.*!M:XL
MD[A$57NV23R=R%1C._^2K(^-->4X9=<,DTOI$@56@- 54=P"671T=%+<W'QW
MR)MGW4E64T%58PY[N6ZI*8@XVBXLD)AS:C_9%*L97>>P,'GE93>CF17,FZ])
M.7@HJ9;:#TUHU,M>5!WCU#HT;-TA+H7,AYN2YU]!,/%V<@[K6[GDMJX4]1?E
M>5GKIX;2,9BJ2BVVG;H"$!V@PCM[=^P9I>R(>OK'+X,7#<C;H$N@!3JQH"Z
M%R9P,P .2SL$HNSWC^>OO+QV+[2LC%CGV\@GUV54B[:);TS1K490>-JP$X73
MHEKK=_OO6._D71K9W_T2IXY[[;2$ C5-;^'K )\S:'WNDH#Q %R8"UR6Y%D\
MG#6P3RXA(T?P5T>/3BK/%7F/DA5IE*D>4J9>>X:!O62&S9R/^J"G:K,YV%D
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M(U<@XNS,9#W4P&B1KN$,I[[-';?_48O-*%_/T!;.%PNQDS#+SG7J;5]KM#)
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M(4_6_6]&>$H V3<E.5;+H?IXR7#5L5\H'S2AV\_WL0.2./H5Q&"1_FNKM]6
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M8%)*R[0W^8UA/CH.1X27N[/U-UQ]888.TKF=,<&]0A28$8;A'=P(_ZR;TZ;
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M9Z'/JJJL- 07=8&J1^D_[D6[BGCKCC4MV,!$O&F. JUA1#5CR)NM*V]$QA%
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M,4Y#;;A"A5]%:"8C4(:9=#;_Z('7]HB+K6)5 E#=C2PT*B#O&*JO%FK&8%P
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M\4(X.'CG-$7F1"MF,*4?A9PC7LLL:2["M&LR3"T%S#!R;E;%3,:(L+)WZC@
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MF,!DFN^@,1- ;3BO?#\-?OO@K-W1D=#]3:=R/8FZ*\T@)<$Q.$V207BVCV>
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M,]"-B5;U-#\OA-!,M?@O9VF"92I36;R1DK%26,?\G'V!YTK=EP-=DISIQY%
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MKHQZ?'+>9<;$3,U;"6E+I 0]:$O$[5^@@]*1"G:&X%VQZ)JGW?H6SL?%:*
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M)VXD;C>*E2#86T'$[OY I5R!@TXC2>Z;]H),Q%V/"]"=[1"=!NW2 S3B@$%
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M5,A_,Y0Q#E#O(L-13#P">OCBI))QFE3MK@K$OQAI_P$U [<%ZF@XTG,? O.
M3NG>)4,Q''01M!+I+%\.+SS.996_-YVWX4XU7*A/)%UZ/G47B. FBBWG2KRD
M--, I:6M')YK"?'Y&XLC+$YN'G-FM,&RJY>9M7(<S9MY]UHL\NCK$G?,KX%
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MW8//;?)'HJ!%!J8 B9P7WD<,%1$":%^GH!WKI(\G6?O2CRWK>1Q96&$O[P&
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M.'/+8=T_+[(\]S3:6^S1%AR8 ^JQNR(V>>X+)Q=?%M3!-;92.@0I(X.<02T
M44Y0V-R[3IR>%+Z=_[Z7+K7C7L^AK[[Q'%NW]90C,)M^A#$S&<G!9ZA5.SC
M?K$8OU&$?3(M.?!IQ Q31'X;"BUW&08DR/AHR4+HW3=P1NX5%003XZ*B'5-3
MV1B$XJ.55(;R2K,HY9UW6XQ3S7'?I,=!!&\]QVI'#B6^M_KQ>FV-@S&/KVNE
M*KR; %HF?!+AH$Z_9"AN*Z+[,"EB)K"*L;72P4]4GA28RQSP6B3 &P'K:C.;
MFKT=MH<I@F*1@ 9UB,FS/NDHQ^$/=4OL+9N?4@8WRGJ\BS#&'?5.7L5#)K"X
M+,EBW8 E@P,N=ZZ*LKW)JQA97!'&?P#M'5S36( >: ]PT#<4R6*YWWJME3'
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M2/ N/TG,;C0_S!Q0R'CE3@C1/5^!Q^;;=A540,GX7W8+3!H<<'R=#2BNYHS
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M%\J>NHX-A.&):U(^3:DA)1S]O4T)XJ-(!(W,K5#6X8?\"T'V?RH<MS-_<%8
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M4,>TO1/*+U1#T$'4FJ6A\H20VZNFSM^H2P&C4U!03=B)P<N)HZ->O.(A@'\
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M-7%#I>V[4B5'?8.-9,8<;F/(ZC)M1.U&AXB48E--Y?T+I!,E 0*C*U/JB1&
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M_"0*SGS("'LIGJU973B::[^3KP_T"GT_E%?;S;B$W#B*KDSZ\J.F^ND^PY,
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MDPQV8V5%LRPP[OMMGR']LNV\'V:W3_H5Q&1LH%LL;K>81;60&II"+'U]+_8
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MW,81G?!7\P%]?7[V4^3G:;#Q]'Q_)XC J"&H<(?DUQ+ISBU2RR2IFLBFHHA
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M72^,R!_N\:4^XD')DYGAO^GY'W)M&QB8UVX0R_L?+J&34A$ LZ!'>W/GUG\
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MGA_H[#H-FWHB!?S*+<XA]K\N6E\Z.5C&.NA9J]<).[*C=" 6^#KZU\;6X4A
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M3F94HX5QC!N14+=6#3%<<HH>Q]9C7P<3\5@"]:;AC//A/@P3Y1TQ!;\P:P[
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MH[[';[T]TR1W!N9!<I=HYLID;OU:*;=/2,+B^U;N%.V@&H\[&VQZE=7Z;2
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MPU$?^]FV?JP7K^7Z_&P[*%)]G<N;589?R@,D5"(YQ\5/\R@#O&8Q- U\;Z^
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M'Y;"1.XTP_D)[L]G^UDDY7:9E%(3>R?UIQ@B_NB3PFUSOS.E%-07&N--1&B
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M)=4W#J8W%+L+[ 0GU!54I_?G%3G^G- 1Q62U-60M?T/"2"$_MN^O,=P+FU"
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MD%,=@W*2@ER^9L@=X^+NKN['&K44NH?#]]B!6FV:E1Z<3P2?_#6K&K^8;ZP
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M3?_O0!=4XM(?"&PNF=IJNBT%YXUSOQUZ[EBWXT%N:E4&^ASMHG3T$WWUB\5
MX.D8+UTB?MYL#5=>O,"GI(8>J8<"TB<F0[N1*4VJB^N&$@,5[G!/)!(+- P&
M.OKSNV>M^V&!NRA#M<KQ8COR\/^D6L[?^E]$L'WD=_O<K"9HB$F;::NMBT?A
MFP8.LD&P]N,_$?)'I]RWQ!M$>Y.*\@?ZKO]$P__/>D0A]UENG^@Z(ZRH"O;T
M7[7R1XK>[9/LNI<'[V1%IG0EPOXS6_BW_JD_F_S-[O#"J,JS3QY-]%Z]K";X
M_C-1#"3QJ5'\K[OWWWN*[FCF-9D=907%2<6/9MEFE!3ZZ>R\[W^XMY_N;5$>
M K0Q"1'LKPR;>?^K=MU=$,F:1^JV)G =V:A3IOS*/;X42% GS]/T$MPT>:)S
M)-$QPJC$5=!0[?\>W0QP(T[)_Z6H/H]5@^R*AR1F-\R<1DW-E3M"9CBSK*1.
MV&N,G@DP7CK9!N*OL=K.78U,JL%->4IJ\4HT7I. ^=MHFPND#W*FH77'_HD+
M\[*R!K-\J-E]B*<E^K8!4KVR?$!V(F?8S&:35&^4WN1 .52N]VTMVK=T2KM#
M([+O/%\V@:!.Z%!)MGQ,QDS\LJ8>3&N\\] 5[$(UUZ3U,1-^6IHBT%6DSQ=/
MN0<*K#SMH2M^U1J^*BUT_$ P/E^C.,J9Y],S7J\Y?>;)5%*!?XQPHA<[9*,X
ME@GMZ$23W*6Q^MDY84!>L99\<[F5TX1W^.SUEQC0*P=\!D>T;H[!L6A)@^\F
M3[_8@9!]:7@P>0>9-/V:(U >]22E\T!'5Z*T)U-Y  H%MTYR^F4UM2++_JAE
M*3L2\XK;'AI00)O!)%&V#5_1PFG6@MMM=/T2^XY-(%F5(JVTQ\VJ^O@%6SCY
MQEBS[3N\3M/]P7D12+T!K6TM$_=(DA,E-ZC!R)G27M+3H$*=W9*WS49X/;EK
MK#UI169#I^,XZ/[OS _KLVK!8#9-PZU9+'$_-CTFI4*I[ZCV8,FX?#]-!@B.
MTH-F.Z%@9@^K056CV@6_YMJ-5OAE(LX*:#@^Y>V5B0/\WW\9 '%^9JB#/X_4
M-;W?]1H/KRQ6)S8B-*1% 6/DT4Z[ UL87XS353=DK=;(4JHMY,$(\B8"K!;V
MQ@$SBZ:%J>+F#"BGZMA9_AIE1Q_*LA^X 1<XF;R#+M#S<6/Z1? MLX.7H/'#
MX/$_6EP*AWQ/JFO=_5]NL@U'$MRX2Y=Q\;!566*(9-$LC)/[)KSY!3-U;^ZK
MX^1<0VR(7DIP)"I/B:;TV<D^][>(,X"FT13Y]'<VF^75M-?6%*%<QH\%O:(Z
MYQB:H(_?I\MF--6$-GRC*#@,(K0I;RD[MM1@"6'7H<^T4B^*>1USG(B>\B[S
M8%(QQ2\7(\P4-KVVGI."$CF15+35U"(GE5[0!F2-RL$N^T^#:@C6J3ET2/>B
M1OOT!HK@S*E&#>JL,LK-EMP @V"7=LSJ'1YFX ZO+>AV_'WQJ$\8E Z8<RND
M18>SL;!J).HA6LWM9T=LJQMM3Q&T_2PS6+KL*Q74V0FV*]\??VH7=LB_W"EN
ML\B\2?U&U"E1XIU10?^WSPZ$9EO$"@[\>CN(MI^K(X-E4!00YH(\O8:KGIGV
M-DC9:.!^N6\,%LVI/8-QC3WY/+/9)QK8W:&1L%64"S/YQY](B_*@MC9X>!3F
M.]Y';]V*/\YW:,G9_Y8Y'VK6GXRSKM]PFO^87)VS.T\&C,!)0J H(L\Z=R^,
M,A+1G0)HMAU:2>IX.@C/M)SP2L)QB]@C5(&3O+.H<@/"P*:<>2C:/!53!N!&
M6=7J2N\4' [MWE\@PY= 5&9-A7\ 6V_\2H33^NBD"@K%/NH:>+RV2.-(]C0%
M>U[92R.IQST(XC(/:/=1EB*(^A685#8B5MD[\6.-S"W5B1C;5,8D"-<I;_S>
M/]M;;WL%&F? UGPB JKVK_F--8FK<$]L\QQZ7L";#M[F#3?SFW*5>6@),Q\E
MY9V555+[1.)3JB$CR ?RH#@>G[ <UJ,5+IXOK.XDR5UBEC6S&F1L(K)N5]LY
M(>/)EENK4U+:GNX34\U\CB6[>@>M6CO/I-YM;]/4.;.%\053%5<:(T6?"4;H
M=FI4E9+O,S,81&<*>LPJ4FDW_^#?*&.,U98@!Z<_P+XLN<^DD46U%VBB_ET=
MO:A75"(RL%@]W"E\#U?\DLI(;7:&S?6RS(M7(#?'K"U%H)9ZLT=+O&_U_D#J
MVWAWC&X!T#[T:-M\Y+*MD%XPY_C66(4K![3G]^!,M%%9SX+.YE*#C7:>2TTF
M+-E=![T9EI&T1S;Y,X:E^DM+]H7">9N*R+SJVTC]4F8K"P_3;!#&Y'1]I$QA
ME@P<N"MGFA2%W*?=>R"/%5+(ALVL1=8*EB_E['ELGP!:#CB]8$^279:EJ=,.
M(#-O/P#U\@R!%>]F?(./RPHK]5MCF?S7V-C65N:\)A=#*T2NO8]I)X@S<$ZD
MT:>M@E'?NDD\\B2=7#YX+<<FV?*EUV9J[92PJFFX8^ 54VH1Z+SD=0K5#__!
MDK6<O:QZJVF.8V7Y2FSU7[)(_D_=B\CNR#X+^3VBJ&<D\?A?-C-8>H?W4'N.
MZER<B7:7Z[\X-/MOHC],95\&=1%.:5]^WE[]3343;/]>-;T\H\,D P^/N,RO
M9=(SFGVI1O3!)]%B0,X4AXNWE,; !93,I,S FD%C=$15?(3H1W5D) 2YDUXK
MT8&?-60G]_S/<'\:;#U3N!#2MFOG0;^1*J0IZ(AXJ*<PW^-F3%?WX?"+IQ?)
MDDKHU-C#,OI3.Q1<?KI*Z-9MW<YW@+5'VK?/LI6R6'R_\+I$):MF^D/;.&<!
MCC7N#>OW-_?[(CCSY(L2N-A-2(43-%*YR#0%J:BYW**LJ7MM'UBYWX.E)"":
M0Q?\YJ53%DX8;:9I [/9H-E WOPT?!$Z<M3R[EL5?B2^3(TQ![UH5+1K8B)A
MFU>"C\ [Y\T'8#9][N]YHRHQE%!^C'3*)I5!F[GA( LH.WC>=R)V\C*6UP\/
M,U:WNSDYMZIV9OI\K"63)6;N5K/<B:TFWM\'^]U#SW+^$?-G,BAP1R7<E-N6
MZ5.*'3WJ\G>!.7U_9BV*M#87D3'+]=,SO&;'8"+MGC7-BX1!%:M-N=HYEZ$S
M+VO,JY^YE"F(%A,+$2SW<A74Y6;), ^[1T7'<GL8U)?#0\J_L<%P+M5]>"GL
M3D$R.Q^S>+@7,5>72$$X=H='K<UTZ)OO:(H9I>"].K%1T-;CIJ63=])L"L!5
MG0\C!I(6;?5- 76WU6%3<'!ZDI6.U"9WOU2BP=OMWAI8K0BI#"N<JU X89_6
MKEF60Q9-Z^/E%W(^CB!1<@L!ZY)_/Z:K!<#:7O@\+H6Q-G-N^*U8N9L[S>*K
M8@8LAC+9P#^'])*ZG2OD;('QVX5Z;X@*^4+'BTMM*W<*NZE=5'>;5G>>3-#1
M9[7/(=H,3%M.?OM4Y\P"^OL46*1GDT"\;P5)R9R7E/HNZ80D[=<:=.[3L]?@
M YWB^_79 :4*[6&'J,;+?1F;'R@]353EEHG^>M' MVLVF<)T:]/O=WA@QLW2
M'[Q!@IHH)'*"]-@'G\J>W<'!K&OQG"@CM4$\G^6LU9PY 3DY7R%U8RER(+[%
MQ]&[DZ*Q4@D:E\PW=PP3L]E@I*:Y@?Y92F$ 9:W5<+/<>.O)GF&>Q/>9M_H8
M&=*?)%&;N,'%]RR)#A!WE7#Z5;F8Y/'[SP/IH;2$?K/^Y4H1JSM_$(V= +F?
M"5T5[U)N%7E9GLJ$G7WZOK[4JW #O[C#>RETR'F')_8M$']'XIHS<IT=F$=&
MUAN09HF3)%0]X(%2-_4,HT^5VF;)$#\PO/.:"@DM0.;R$4="T,D#HZY=Y$Y"
MH$IM7F\=\T"!-85@BCA9'I9;<<@"[\^L; HQ_?V/N26_S#):;-*2K9M]9.Z%
M,S3R  _Y["(F1+FH3A]K>IH)/8AF'>]M*$8T.:]VOC#L$@(\Y2<*?Y:15.A)
M9B-2RI/R88DQ]#=^G:LF3DYCSA@,!\_X+S>\Z=5:$F4]8:_MWZ'2Y1OWCH:6
MJIVR@:?)*BC,.>(1CO*J&M+?>@0O;$*&WZ9%*14:'I(J%H\;V6LI?C\ _9I8
MKA>!-N5;NYK*W..I\\#T3E]SA]?E(%Y]F7DL/8T)2U?@CCH-%N5!.4XG]H0?
M2U [/&MTM"TK\9IQ/GS<I$8P:0JA(%6#WH#.:?@U/&FVS[]&>)2%/D/Q?"^E
M210^WJ>D.M"#&OF2*]BDYN+>'5L^=GSBGL"6M=AS./'-I\= #Q/59!(M;^CT
M<EZY^+43$BAG#J3U::L$E$UO8S$,!W=X\:\-F,'R"G6'Y^I+Q_8;7(GUM0RM
M2S,4I_8<+';9F707=)-2YF">>6L57>YT26!4C!/]YVF@$3=FN<2(H>+L34O'
M7C4?=4.C4K+EU8%)US#-GGMM@]'E"WHF8GR>U&FGJ3<ZY$6CG< &,3$\R<Z#
MQ10_=JC-SC6SG_O./(,?0<,E)N3G:BTA,(;,:EIE:Y:%W/E7DTDS+V<6_J;!
MJ/5QD?Z@;2H;)Q;\.\%@"\P8/4(O9HOS=ID&E!F4()<'4PCB'^[/YRAPU^R6
MET8@.//28-;4LQUJ)G82HQ856GKU&:WZC2+8('\M#\Q6UJ6SH09PM5%Y9",6
M8E6*I758V)!T0!.L4T94/$<^/."=.4&]*D?'!TY5J5ZP"?7J9ZS#]FK'U8&F
MCPWU/#WZQQ#M%79/?,'VWH+3HI*W?M%QTE$S$^$T#K@46"I0YKSQ "E/ 7J,
M6' VRTEQ'I"E*,7:,<Z]*H35AMKY'_DZ3LXKY?()?_^%W'!E1_H+K63]7F?#
MON3Y."XY,/C^Q( D"5NM)6 +X8:+#IPEE;34@S,%HUYO].LQCPQ8IQ;V:,;F
M&H3KYJ&>%J9TWNMLE/4^=D_X;7'Y99@AURUT[E@ @<*FA3 JB"]./2R9.S3^
M(T-O<M(J#1T,<V$+=A!\CUJ9#+3.T3=1%M:1%& SA*K2PL&E 0[VJ:47I>)<
M,WV7)1(EY]5"K\:'TE4!Z@!549V,*$B&>]>4_:W,-2 FH0^I4(2TZ]>,2I'X
M6J'E,W;#/U1;=K7J+J2G\]CVZECL+<RE,"RO%60;73:I!7"B!'+8'!>KEU].
MNM$5S;)I>29_T\*.:&90;Y"S?#^55]H5.UQ56^H*'6L1627$M[;$7MLM>D.3
M7S16?Z84,YHR'D<.]ML]XLY2?_&B=JT&)]O)GE=.[.Y%0WZ2.M1$^KBA[@Y/
M2^9^-I4X51??O60"I?Y=6=E=:F,%8!@$WKT];/FEY^L[)#N7QJ=8EV-=PC3I
MF])UK0,_/RF 02%MF 8B>IP4[P]YL[9NCB>RSUT0-],%%Z\.SD@]:G%?(,^^
M.8ZBWLSQ>\+WE0>+XC5R[7YE1L@^G=V7#,^97QNU<Z?.N\,#;JT ILSM#3C^
M@YCB7DA0,,>E2)!'7"S>?W$UBI@[Z&'0'-VY!*FFQ=KS?]7*/?[B&QHY>_.%
M'_Y.Y07N_Z,P]P>-C"*Z7FS#(;DUL7O$2'B2HHD=$R0F5JI9X607Y!A?DM#K
M",^,F1\93Z[^ICK0FS,@\WARKMXR&Z\7U$. 3&4P/^Y'>-^SCIE=AQY IE??
M%[%$U'!6,Z9+"N)2I+M;W.2(''OO5_><)MN-U,A"YI5JV Q$-,Y9EVS$*_*K
MAZAA"Z/"6U/#(TU1RGO5M%6%M&N .5@3<E]8:4N>4E+BF"4EHV1C]Y&Q<1!T
M%\T"<APLS(/57.V^^A;-7%:3K_U9S2N?,I^[Z_I7007(8XD_G0'&.11)?H>W
M4=#AU[X9Y&4,QSW\41#*L=Y"V<G47>UG_+[8IMRUV4JT7K#<4)"E.#ABT 5Z
M,S\6D2 1L337U*SG,\,.'IS5- X%S0.\W=[UB/33&2@65^RGH,PF\SGKP+X#
M2:=)F*VC+QL__ET7/\\ON^_Z5D9.<98^;<*_5_IA>JD*D+&L,,\3:U FHQ.=
M9%8-$(SWHZ"L):L?Y:L9R'HS\(S#-AW&;Y6C=Z'ZU)?BV,WS>#ZSEIBJ*>HH
M?GQ3>K'[W60W:VM#0\CZ4<&Y1T*_*;E!^BNEN.J?!<A3*]X(7'W#?'-C(KN5
M=YR%>!%5?83*=+%L3>N^;]$"PJK,F($VG1,U!RQ" /4[ _ Q]>P29&YK(;A%
MNC);9\=?])JT\ ?X3O6:*MCX:G7.*RU=^6>EZY!R^3ZE+L.T>)MT(0#0_X<U
MI$<P8FUV](2P_[H4EXP/KS%[_?5=^4NR!L3!#@BZGV?SK9-64'R6KV=4CH>)
M=9P'?$D_=<(9%A9MQ3;A-^-U[Q-X9KE!L^"IUKG*N424HYP-9UA,@.A"1(4G
MJ4E)NBR$UTNZ1?@=GKR=R8C\X?Z#GBL"A&R'=6Y]F[/"U,'ULX+FF<$G= ^_
M:[.]^)'O[$R</C".48[&RIK4ZU I\3PI0 0S1R3]WK]I.W=HCEX]5"9U"<*@
MNVPZJ[JRI@;6Z5@%6\<Q$FS^)&5V*K0H+>C6UIBM<B,2957OY)+XH*,ZPPO2
MG=J?^81.I^>*QP2YIBP!;F*H2?J.U@8CX8K%VUMN[8WWVBY&/?U:]BAY)GQM
MNT5L0ZN@R*:XZE' 98C$38M^=/#VR-DHXN9SPEHE/8V=3,500B03/GGIV*V%
M5 ,.<U"/LGQXB$*]NW2M:@L\&)FE[7N1F.7'$A^')JUR'W*<8F<!70O[&>'0
MANJMY70/.HZVTKX(Q#49B:Y%)RFAO>"D.J6YZ2K9GIP([C#XA(C"YV&#?PXW
M!O )E]0CM09-[(K_'9YM:)D1&T^5:7?2R>2>OWJ]&ZDLG3NII_3Z\PC[<Q5G
M)IG;(3N:/2K_=H?0%>K3Z)"78DK?BEM")(J0'")D:TZ0A#)]S1#N)F0$0GA+
M-E)E&7' 6<%0?:_ 46()ZXADKLAF!JKY>HQL!HEC[-[2,L!FT1C^P8]SHEQG
MS>P?(4$L'-H?/\@SFRFI@=L-0/*=NRU  V?@Q)"51GCV8]0D]Q<]KO3Y6,1H
M2FS*3>DQ+FPE590D>-DHAM2)L-SUN35+(\(F0510HH)48G Q+L:@4G;;< I$
MC7+7Z9\ G7#:\#Q)$SZ;^OY&I)FV6F52T2^S;E+1_?97NF=Q><6T?EZA.H+D
M";'IO^H;_WNI(INJ?>7!+L=-QZ^CV\@]^3IIUN$IK;]"+#R\!P:!?(N6JENR
M61194OH%E-9N&P:]6G"6$"2<*G02,2N^&]/)H_"TV,-=U2C3("^#78.\3"#Q
M7=HP3BRD4,(@NC@)/IB3VI:P\"K\AYQVA:A;_^.Z5=3W),YYKWGCKP,O6>L9
M+LGW_1CL!IBHWVT.&^"S,<_1F"^11<<ZIUBJI:F $+CD[VG/PE1F4LE%+CXV
MBJ$EBSP?CIF2-/CP@QZK3?6&N[<5K[9XO[*;Z^N1C$/(I T^:&8<%U^N-/3C
MX%\(V1>>S1"3M/6CGW^0SUR6634. *.>-KTDN^@O:W#JE0'TR A1;&1Z%Y>.
MG1JYDH>MR-O,^>CL?YJ5S/<8!PPGKUN_/S!0M4H*!IYT:^@F-7:X 4E).1'A
M8YPZKLL=.DMT5]>>1"N[X^Q3,EURW)YSO.EP^1>;O\7ZKE:J8NB\:W'2/DZ\
MA?Z\9X$@2HUN,3L7(B49$GU6EYKO2T\K;I5C&9XWIL@JEPDC9GX]1- V1=JT
M/'JYZ#+;APL0QU'X"7V"H]D=@7,-EX(>=/2%HW[B%!"P@&IFR7?MX)1B3-2D
MC"R:2J#HE.W--'O]"2K<BG\\/5@X>@6-FL/9E7JJ#5LI60^X&82GAZ"L--T!
MI$60Q#CM 8VV9^J-O)J*T/<J(L+Z<!=,;=+<N:ILSN@AU'I17GR5N/^S55*:
MCI252?E1D"AZL.!GHY:&BL",[IA3W8C $D_=1+_09VN:KM'K,O,7%),**1UC
MI>NEK6)>4\-)QU_B%OSS,"T5];)RP\D5.ESDX)1,NDT".K2RZ!<;8ZY+MA'I
ML';^H$96U9W?$+J26!<77JU ?V-ZLS'[6KX8>%<O.%#4AMX:O_-2-ADU"AM?
M]!%:9YLPI0?;'1&L(9,*/6I8'>9GK.A>F0KF^3SF3Z%:I @?(+E1KZ#:2#%:
M3,-)/_?/LRSP]3!(3H: G%]%!/03H:F87*0*X@[$E8?F!DU>)7HU"F7 $84'
M@3I$'Y6T05OCR@Y@RJ4=ZQ%DMD86N?.!D?H8Z0SGKK7N<V[?ZDPX+:.+7O*N
M/Y$L?RN393=L/(I6H!PR%?=V/=ISP;;#A$)ZLPKXC^KK3IU\4?:\VQW>O$W0
MDMP=GH.T[F9+5[/BN8?V+@"R2SP=)U2T8HX;R,U;<-I*<E8[)-O/SL*H#WC5
MQUB"!'LRIB 1E[54QJK>:NO>$F(9QBGXJ_7L77N!2W^0@^$.2-84:=E7-/H'
MR'P)T,1"3G/.6&(LA2UIV,](L":ZM,IQHL4CD<M+%NG8M':3-.G5M)--(S"D
MIW<]_AO2M. K^6^;R3ZK]H T3Y*+EK.'WWKT,W/<-AV7BL:$8#9[[D:W+$XA
M5U[IO!T ?=.'8Z[>]*R0>"H.!TK0HE86@4V$U7=ML*ZFBPPQ /8.[R1Q&_;9
MS.+&4&HB<+<%86BRJUD_%-WF4T0CN%?@P)NS/\=<;,638=%&2$?QZ??3;5XZ
MAD:6*(X,KTV)[H?;R2VTJF3JX0_6O%])?#ZB/9CW?N +;:ZR/TA/ZH]Z#4M,
MTQ.HJ;:;>W?1X\9B'F,/L#9O0,VD>T>2:@,@D').!C$]I%(/9[/7$1!$9=/N
M$0V<(]-Q:,/_R1'=*EDGS?AA59.+=MTM+3$!/;MT*34_,E1/@]3,QGD]"!;=
MQZ9G^2J^DZ=ZH)E/N<YB&Y8S*SS.9X"F39*'J)$CMU2RE^97^#=ZQ0NU1@Q:
MRR?79 ?R^HI<^53;1P<=A)-++(;]+;Z 1.=<S ""C7N]041N&62,' Z<M5/Q
M)BH(@X(J?XOTRQ'T=B5@/#ZB1+DE?HU"B18JS9,T#HXM6X6<*<9KR6<_-)4W
M7>4)X7IB4AQET3/RSBH1X_,/1QF)?F;S_=Z;FM5>E4!R@X1H'AKCVW(%/Z-I
M 5*>1A#?-NNU7:],(,1]QA.!=8X?2CCTXDPW"&?WM^CJ2PM7>D&YP[KJOQ\F
M0YA_SGY46Q(!')8H$WTXGJG3<8P0#\L!LJ%TJ=]>W.0E#5M%QR8>MYDGKI-Q
MCW$#U#AN:*Z0'=YK<M(2;M:*(R8">?J>.LX\1;I9X([ZER1>-L.41=R@'HW)
MJW$!;T!'^*?U.:8$E\7QM\'"R 3AK0"+28ZW).&;$3>:5J7E0#YEJU7V' S
MHL&;TDA4,!+VTH/S$SZIHJ''7*(3;'8Y-NJ,A^D'TBJ>J4]N*OXI?\K;7PH4
M_5_Q\'+O\+KMIW?E2LY59:@(@QG![(O,6.J9F_?CR #'PX @[8_?B)J1D '9
M^#()S?:US;9<HIBA,R\"P6T8!SX+.N4K1?C7_V"-^W?[!'\^#*I;^GY]5'^'
MY[5H&O Q7*+'1P7Z_'8B2.&P9^GWO(_GV4/Z5>E\AT=GZ5=,@:)W> ?S@Y55
MKS9IUNE4(#B!HX<>P6O\,],(*>WCU<W L;FI/D>1AY6G^/U])')@9Q(R2U*J
MS6:EE."*[DMCM)HVPRYF.'%_7S*XUT515XE[C$IE3MY6\1\;HO\7W=/SB1TQ
MX_EUAX<]HDM/,0:UY4Z=3!L->Q-9&!0&-/.QP%)#L[-COSC=J^">)F2.X",R
M#/PQZ,.46*!T>43.KZ%!2U RB=PA*$$,[2///)F\G(C<&M%12R-0:#VG_N_,
M2N<L:$K(98=RVW0^"BC1+C3#LF*7U[)[CQL7Q.Z/K>V2UEKI9\_5T !0ENI/
M$E_\U22B-QO>,N+9$TNF!F>]+S'U6,KV>E/P[L!?;1R")@:>!'?OD>_#Z^00
MZ&#)7>&)[F"4C/$ E7.B[@7#4&DP<9KF YB86K"^)L3I+Z_8GGN^ZGJ[W])T
M?>_92=1QW)R"H&-%NRF#&.V:J\XF)B-,1Y6WFWP>V+H*>!%JY*@<R(5SV8EI
M=4YR_>)O/:CA+W3DIW?DKP%)C5#I7J:0!Y>=<?^NH93L!6:&UAH6SB\O:)P&
M:B8-\>;K47?QI&ZKK"]4^R[TLKM]+LB-S%@5W[^\WZ5=A1>E>3EE6+1$[<,:
M2RJ6PM)F?<S0%4S+Q>!W^J;-N?7\FJM%#ZG+),5-V]2A_#(K+MW1Y0SR4VGQ
MI=6E.ILL(7=K29TIA!L1+D5&^H]W-KGH>1QY .SBN\,;&$U= @7I(*Z4SD](
M-L6&EC(97R_G!XGX;UVV.YYP1*Z;MLFE9Y[[M68Q^OFY/>)[ENOQHJB51K+\
MVO3];HW8X:08[F3GVF/ D001!)8#WWJ?V-!&>EQV;RZ5H9S6&.5&S=F/M5F,
MF]<6.:*SR1HRJ/?K2N^#$R[8F?\Y?&A/FR[=NXE%^MXH'K],;/'Y+H@)<65U
M$DBO]-@-,'QA%1MKRCZZ]$:H%621,5AKM0YCKT$-Y#Z3&-"SHQEY]1P9C@*\
M'44QU,798Z\?:2Y6^^*HG+/J0&)\#'6P- .7[;(O&AXF8N_"?\+HT_JU3%;%
M1]SBGP9^^/\><_YO/104&XCT \HH?#53'HT_FE4UVF:?JEK$_ZGLPN3<N[>M
M16;O?%,(;)$>+&87</\<STILM?F0_Y':30[DW,X\=:$R5%(X86KJ#J]87;],
M)YG7<YRG922!<R:LB6+4D3]83QBW0=^0Y58= H]..*DX9E:,^%4YOI$7P/T%
MY"\AF7$TMQEOW#AO'72(=47NBHL1%,BO16_K$#MCGJ#UQ(^T/D]3V3[0$_]]
MR&$795WW5U!H%B1TLS:?,9HL^(3_#N]S34,;G-10#:<R\V).$V@-M=5?+HAH
M@O-4U2^'Y1^6OTNNO'"3->0XQ]+._<:G*^W<I00R&M*R_KN^><Q[\>$,Z;%(
M\]KI"WV)*E\GNBR^3)@YB\;$H%1ST<2&RI@A[2@1:F%-$D6V=H-6<UGJVQO-
MN<,;].9HIE\J'+&/+\$TL)-(C0W "\[5YNW'I".VS&'H8Q%=A&.ZN[LX#&>;
MLL0=.#*%&S3?E]$)WW9L'],B8_LE@"78=;DWN4=">RD<L]*"PUAUZPC"1]./
MCU",)%VBC_76FTL08*VQ'@UG;P;OZMG$3>KNH%1^-UN'RZB63HM 7,6CT+F9
M0BKL_*SG0MW$>3K;1#YL3+A74Q@@2[2_PA60 0F.- !WTILYCD&\IR). 5?2
M75W$S")Q>)Z#4,G\H$I5?5=/\/I4J6"\\9 !7Y5;LMJOFOOZD?$TG*#D2FMS
M5D "UT^@KNPKJU6YVBC"(L(8:Y K623MX'2* ?40<;G[O#HKF1(R(J(\F4-D
M#PC0+S.)!.@O\\R;FLR.S*=+,%$,4J+\Z%&P &+'O.+)8NY"M5+%2H"^_2GB
M5+3X_A+?"QX*%:.Y?5^&(J"./SHB.,QY1%2FS=!H\X YGG!1U'UV/B/<+<J)
M>D@\8V;*HKFQK<>% <U[_JS-H="35+0@65GBT)/T604,14JF^[2AL:$E<UH,
M)FN<@C(Y;S39? DW60<"K_3WF.=T_L>KOL<P=4I<5#3O7+\34CGMJ8X=;3_Y
MMFU<:)"SCVDG[3#-WN2+X1<H[SH,&".H\"^U\=/O(;H6WZ<1Y<IT3Y;X#%X?
M<J7J.A0\C;T1*3_7&W1U5=HK%KB?(,E9@C6X'4:=&B!B,?[:SYHP,2,;*SZ\
M*]=1'C'N-'E994 @:BQ?GOTS\Q/(Q;_@!/X;BJ>X^_#BHV__'=ZK .F@O.NG
M*!)\(<_$5)[$#WA_*-SA1=#T>Y$8!,;3*KUKTP&^._ZRWBFFJ+GF,XCVX3$K
M&4T:V_5BKD_J&:>#6Z7+8,-T4^38']#(7KWX9P34]WD7.CE 6'B']]BEV4ID
MS_=ZR?+2K&8UV&&6U"=EGMM,Y%M(O8H2C7S)"@JU$E%0N[?)2##(CHV/46A3
MEX ?S*K]C /FD4]M'_VL=&G+S; N.>'P/?Y]SL3;?* &^VU6JF5?;XR8L"L<
MD639@F8ZU;7@YI8[0="0(V\8EXB4H;*T;W1F9G^2E\?3O!EX?QU2+;HBT2NH
MFN$.KU[D#J\Q]!;[(3WM)'Z6);M8C([M2M-?"^$7-IY.JIDZ4&R3,%5Q6 K4
MS\OU#5ML,0RP+Y<8-J8T]K$FLY;QC.8:/TG\=JGP9).=JUE%%9PN^/:3O9O@
M$DW1<;)=KKAYU\#8@G023BH95V?S(N\.+S#>/Z2TLD</.>9"FU<,YU[T\GN'
MS(<TAS ?Y$NY7=HG:0IN*3(?OG .9-ZF]'=<::=_?]%?9N"P#7U1=IJP+21A
M\ 9$"Q5D)  =)I$7'J,+;&AXEX$G,<<[2!NBXW1F)!OITS3A%Z:CD:N!=B"/
MSDJ''K7T$9.DM0<$J.=+#$-/?^%<OF1-)7M84Q<)1"TN&58FWG_I+?%M5LRO
MJG5"E7NL[CBA68<_D_87UT7W^,07R:PWD48^]KA'!LUS::P:.0:4K=6A?HX+
ML]M).AHT)SP/L ,N^H?O;4%"U)E?#E;)!#@GY;ER"8INA!+ZW3G*>_48?6;H
MB]GWAR@[DY%B'O)K1PZNOZ>2,GV&7"CDX/5:Z#<Y94]BI(@^"?DD,,D<'+AK
MR8%V5@RVP2E;?V70!#_OS^X\.+*!92=$_P0U<5 SN?B(%U^^H/CDR52Z?40O
M,7U ?1%L2ORK+$U:6[!#$!'!O7#0_,JJ]..;MCIDF[SB^,IO^7\<$F6T>3HO
M^[*(I-NASDOTW/W$VF16PK/%CH]2M8[<@8&L4@)."LU$F8P</N;Y-+VSNQ]"
MPM"H4=1#6V42TJ_Y^3S0=V^P&*@J(OYKS&6YN6=+RKZ)']$$X"#*J->/K'^'
M@U'H&[Z!1$&F )#AS^3=(VI6FS0]?H^^:P59/$Q=N)SO]0)KIZ2'@IRO#&:M
M.]4HO]9!T5R",S6&96>T_$W),R/;KLX_"SW_/.A;9!=O,^E(+USL98!,P!#<
M)?*T=*H \^=(\CN\"Q$18=RF[<D='L)0GE:I@Q>L511=6Z[?DF?@<FZ1.7?M
M''J0'U5@W1I<WB!+X$R^8<Q0>).P29ZKZ<+FFM1F.:+89T,NH")/WBLQXDS^
MY85;(G6/0&T4>6&/E'O&3>K7<@W]^8KB+K$B\?.RBANU'SV]T0LW7;-1)M]-
MC$\5-KRNBL*@<G!+&U/*,0(?ZL;]'E?RO97E_*CU]\4] X?'./VGC@>):XIJ
M[#5 L_M2[:\9H_P>?6DAP4W, ^<0Q:DW,]/CI*X0^NZ&M*35;JYAL$U(367_
MZV=61,IBU [IM!,G0_%^C+D9ZW6PB((R$GI 5+['[MMP11:F:]*E:W?SZ]2@
M?2-\GVSQ61'EC#L\?&S0YP7%M4>\SCC K9?2UKXGGQM4Y[J( W2Y;-$QWZV/
M9!+'KNW-6@1Z@@O2E"]M:62$7+F."'#N5/B,A!3/T,]1>?J3BS%+Q$_N\("+
MKT"-(EP#:/%E$IIZ9T0;VMSPS6\GVX6!:I.2P;[Y]*'?'KLFK^PV([F/&ES7
M(F]_,Y:VF*<T@$",XP:Y=+J 6WZ&E^<>*^?*1 ]T0)TX]WSTV>ZD8KQJ;/JL
MG'?EEK\I4G^IQ=8.]LCA!1<%(7NCGE#P\*6Z=]+;F?X3X5)%Q1_$/_CG.WPD
M,T;Q&X*X%+PB=]0/7FXI4XAI#H4G@)L"#($G2FYKO\.2NJT_D7?S"WRBHWEI
M*R7UP/;WY!7^A,X?=W@4T[)._BX_" ^XIYU1X[B6[O?C%2J4_(]]PDQ?F"3;
MO*S>?\;%BB&/B:P1A\PUA$9I]?^I(O/M+P_(ZI94 )^$BNO#!W,62$*]OY!<
M4(Q?&RCNJ<"PHD7[GCS]?$U3(":QOFF<F;751.EK;9J=1C,1K+E1AR+I"<#_
MB4"\T+=,0:Z5U+'H9KZ3>$<=@A%_Z36?4<;VC)'-VKJ(5JN\V!>B.+>5DC1K
MI7;<M*?G&?H#-(65)Z30%5ED2\K<N&?XN/KG<.P2T>S_G/Y9H5;_F+?D"N.5
M1-C1E0*,R\X&6?9JI?;CF]JPZMP5V5!?4X8TR4(I@?%("I73I-ICR7DNR\B?
M!/*53_N!"?U#:=,BY*=KE7\^<W+SZS#*^ ^6/F*:6_+L->SO<7EIO(WG_[CR
MW.Y:D(&D_7[V><+Z]/R/Q'2[N) !BH6+U"89CXWMTPX&S<:&T%Y7I$RB[3J:
MS&AX5A9S7G@^:'\BZ>X_5Y K/5J+\1Q_4)\TJKM*=9P$+OJ9I;G 7*@)4/&%
M":"@>J8J$J1D;QI_/Y,D]2A>7U)OXX;QQ-T87GU;2&=GLI5L6@ALD6#2.QD_
MW9^M00H0^"_E[U]AP5+]/-BSZ&M:@=?(][(O?MIHN"-L!9"30,T7I!3XC'J%
MVIVU$^FP;5P[]-/J$GD]@V[7A/5V6O3T"%^9FF_=NB  L6WTG,<X,K[@"T;D
M<P+H"3\ )&.O5R+/JW%>'35<2V?0E++-HI1K$2;19RS-*Y.,%J"RK)BQ6MU\
MSO%CC59=?D1^4!APH]\E7?8@0R Q,M%J622] :!04*/,U>><(CYBQQSP^F&]
M02.\BS!KR:]W((A'?-YI*3Z1TG$O.0[E*F,I5;^Z1UZPEMSX1F:JVBO44#21
M@C47A]!$1D4T_XDVYH%+LP;N<<,+/2)RY\0,61MV>_I*0(L UV&^G!]["81=
MT[;>!A/YCGVEEP;#-4=#$-[H#2_\@H+/7JE'6A&/=.0Y+D$]A,=AR#RGA\(X
M^I-E;T81$4/? Q<=!P+1PO:NFJQI,>]KXJ9;'CN%/@SD,BH&I46QE_X[%3OI
M','?9T\.D0*5AC)]7>6V(EA31%9\U!>>5CP]WL;O)]PSJ\5FX*8C3#891&*_
M1,_ 3<L*TC15VR7&8D/#JEP&B%LK5(=5)?B?.O<_<I2$+2N.:0IQ(R'"I'NF
MCPNXO[3CAWVX+W\HVXI[?K$-=5>:;5F;>E0K$/""BK43_&8O>FN178LUBHB%
M08@OWX&.DI'A1(15)7S,8YGMU3K'8Z_WPR9%2<@S=O0+?=&7X3):%X0CA:,,
MW5HZNWS55EHR(!O[_44U?2\U'17>)F((=LIPJZFB0TL&&7VRRFN_P!ZOE1:;
M ->O>9^/V%<#4) O'OV5U]Z7\,S98'JK1;/5"O397NJN;'490D,S] ]^W>&5
M,LRVRKKHN&M7#]D.G@0I@W9.?M[A'=^XB[89[=O0W-[A+9]+*\3-P'?6M('<
M!11 $4:8C+&$S!1=XJ%(87YI3_727$SZTQ4#J;>3+Q>\FHY6#9]Y\X)H!XYK
MJ:S+7K]PQ%1\+\V<*.:',(F]T6!/BX<F%,9F[IQ>=T6:D4VR%'J?6OQ:OL-[
M-_(\:/G0C*2PW5/V4YZCV)#B7XGU6]>HI:MF\:7;*T_7+3'?"+V R2M5$\_
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M2L86'&G(+U%J*$(6IF7Z@Z>J@JD7<+/)J;P2IV[E%?FM8J]TI3_I,M#)VBF
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MM[_W-519 2EYRB*B1GV]F?^UDT;P^H[/>>H*+2Z!RFLOA)65$C3YM8T,8[*
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MO!/.#D'^R(JVWV!W*37O"FTID?Q[+._>^C)+)@OWMNZX(2L"KC4K4F.A5VO
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MH=J=X_+%;QTNVY'0D'*0FQ+T=P-'OL.)YIMJ?]='@B:[U[]BNNJ)_G]:\J0
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MRO_J&/8+=Z:V* #E/IU7ZEJ766_LJ1XRYC=E2@ 5M%-Y;O93$L6B4\8LH]'
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M_!<L2A_I>"L@<8T7\>&>7\^V\'-A,9"4XB\F_V*IRW!?1O],[E44M'3K0V!
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M]C5!4\IJ.U&*.TG!,]'AV>S_O7O=-['0W>8[I>>Z1W-XY>WK6@-#OCEZVUD
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MK;KQ0D!/@NK=*3N%J6UU*C-D?><4AH\0RHC*P^!4(2WHMH3%YHFGUF!+>33
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M[*+YX FUP-%=R[R5"#\V09CHN&:;L^+TT]BB*;[M\Q2U7_Y@BK1X[&T40%^
M>W [!>^_CFOPP? Z VC:^_B0KPZIIF\H'PQ_30DJ#.TC><*R++?Z0,-[^-U[
MI(#G1R$G_:?>V[I95J;3?RJ6!-A&=/(*F+H%<-8ZU;' \^WW_NK]14RHT=G]
M3(R@- M6=H<']JHO0ZO1J@NZ8)1$JFO<T/)'_Z]94M9TL^CE^,,B;X?@U<Y7
M3JZG"VS'["O/=QJ<K_'_B'R\V+UQY^U5HIX<<#8%=S455/ILT8+K$I,^X..E
M)+3<ALI4^QV[ZV8QG1EDP:[?JY_O?'<R?LHP*>7YKBA6VO,!<*2#Y!$9Q,!O
MC3=K%%OTY/=T:&-52>*\B$'!>WZ5(6CHB6[!6)"V5^KG8"L]OV-1V)C4>&6:
M\PN?R:DU4J&S_2E &-[RN69KL8/S1>GI-L;1(]TA.J7$_OZ1R9LZ22^B .SI
MS$:D 53RC'%![NOR/R+*EI9Z'R_XPOZY0/1U]&*0UD:F%KX]LL(M_+9,/ 3Y
MV+$M>!17#>UINCHNLEVY%*C([^:N(&ZK8Y_T6^%8S&I?;?F^MJ3)7+IPI^+<
MC<K);9^YKEQ:_' P$+S*&RW[< 3RJ:9H&Y#+RJUUZ\<VXUMZ?FL.(]K)I6^]
MX?B=^G=%4'$4]9T,L+()5"C(C(V6D_OEI&+]= ;?W;GZCXB^[@+E%\GBRZ^?
M^&+V[UCM&W2;5KNI^G4H#KU5J9+Q/I\XIVX()#D4_+VWN[;=I97(MIE <%II
MV#;B-)K]^\;%,^7O6TE.>K*UQGO&1[ VU&*OO,=1N[[N^8>G"1$6!9[)MJ0G
M3V9[M9.-.-[Q1X!I7@Z_::K5P0;M'!1E*1*R< 3M[!]JBW3R,;5C;%G+>]C&
M:4(M$Z1^C+F%UU$YD4\;$:SJKAG#_H&AT4]*1Y"^@XL\\HC*![86J3[TNB<D
MN7M']UNC[GXSVJ' G YZO7#<1]'/P90?<#[\^GG>7K;K44WT(DU#WA2PWUQK
MK1TDN4[$0BL8-87RT^]_@)T LDB)02);GT\VC(YP7SVX_KJ7 0VOXP/4/9PB
M=42#*J"8K9HT*4O+GB=S_=9E(@_\^V@>J"!&E1.0]S3/_<Q:8^X5^BQ96P=F
M@*7B$HL/1>/R?X8UCTI-+F;*.$8I^G";?%R0D[=+4A&TU>@D=]+^F6:M8D4%
MMTH1'W  <GRGP/7EQH#.-Z\Q/YMIZ@;\-A[R^0X];89E*76\P_<3:J"<^:P.
M[+R)@)B.M*D+7N"KXR)5F!J%MJN0%LT#B[<'I V//KULBMKD[!9OU_R3RWW%
MK>O.F <^M-8Q!T>Y'KS8:_8QB4@\E' .;Z1CU%@@&*/:ZI+>M8>\%IM8 [#U
M[\_6'<5X\"-&6=$J-NA:BI1Y)$IHBC[5<E846XNLC_7?/F5300]!'%G<SF@$
M!PL1VZ92Q=+F"$9&-7Z&6N^?.W7';M)63_.FRG.:VK8O.C$&%?[2J-V@V. #
M 1U"W5\:W>PIFJ%RSK0@W>Q%R5K#TQB3IBI31X>#2EC&#&+V<AUA&R;20NV
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M4<4Z<KZQFLKJ @OMZ?J1;;UPPW165Q?6JO#/86NZC=#B"3RQG6]B,-I48&)
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MNP?G%]]\"0SZV289XN/W$U)I.=E^M04WD8 'X>E04572=&5Q5,Y5TCB4LV"
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M'$[F:_]83C3]3]W)Q=0 ;MGAH?<E*W,]K#6QI"6+8$+27_ P0!N#/!?+H\"
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MR3>QF:\VW#L73RTV]. &^?3,*M7E9)?G2'\<6"TV=%3$6;,BZ6C)&-ILX'<
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M%8[:K+3,+W?1<\M.?T3-O;03O6PI3YC_/&![^E-_E0R]VA&[F@FXGGL"S,L
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M;)A>E=34$"^>..5A+U7QJ[M@^2ZV9U*I[:&G4G$J)_#"RN?!'VO Q19XJC\
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MJHF@RY&C+Q3%9XIS&&LD@!Y9'JGI0I]]1A](4LN*"$TZ<N!SM;B9F#"6G:=
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M#<*EP@+4BWKCB,.:R(SA= 3&Y2+1"2#-16'-3OM.'ESV3I^+F'V7CV/%ST!
MZ5?7'GX,+5"C>P!&=Y'$S$4<1(5A*H_Y@ KR)G4V(-'G.HC4PP7JH37Y.XJ&
M8V]/@PCK@V&.456YJTXEN_L+F*MYDY3E]%Z28-J3JW ?A@-\S]4@H'8*/1X]
M^O&X+2Q?6Y=;*Q6X@XO6EYX6@I#LU]G(J@G]7-K9 QQ0%)$(&N&G9\H96C6J
MUZ@0Z]J=_N:&DSD4G=_SI <>0&$T>X16W'RQK>&S<HV4T3_;V=OCP5"%5H7
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MQ14VF0QBE-USELBPGL>;O'0J^D*O['[UWZSV1G+%;K!'+=[ 0'[SO+N3/1]
MI<FU13"E_X]QZY]3]?<_+K?>),_(C(AZS3= .Z@A?!.(AED:)RBMT1M;ZL;;
M?GQN"_^%<OAE[+<03L@<\;891<K>+LG=MDOHQMZZ,0E[:-FR9Q.B8<L 5X&'
MC"4QU;JG>JYR+!AF\)U<HJJL04G@U*HV(NQVW(4F:=M!>YL9YZ>=#DN9T)3^
M;I@%)=^8\,*>A_K[22\7PFXS%CUR&RTUI31F"9>)J<LV+PF(CS[QQ2 FV-Q'
M_Z:CPHY[J&]DK4^;%FKFF8^ <=43)0?8[OV6'NNJ7Z 73L>1W09)Y=>T!M,E
MJF[:ZPFO>Z[D^(.J8OSRM/B(MJ39?XKB"RE%W"%FU8# T9/H$03%)6M5<QT%
M?#E88XV/XM9<60YDI2I_P=2 G2$K*6._LGI P+I"T@4-C\R]Y.K%&C3BUK4<
MM'28GC80OP,2R/YFS')^"?/:U\7P[5W58TK?7\16^B T+;M:XBQF823 .^[C
M/RI;."'EV!X&BW-S7$W<<Y^J5<=N4![_R1Z>Y</0F2IS"AL+M;42"UEK9BXC
MX><*7YW2IRP+]VWJO/D)#<AN=:E^'WB'Z!P?N!E (DW":VI RJ2_PU*]^#WM
M<JT.NG&U9G66V QP?-9<_)UQPW_OM?Q4(6(3.NBZH] L*. WV"<X'4[CPWE2
M;'=<=DR&UT=K+I]+K_">NAQIHL.1H)! 2TGPW#H/<N[;C<*7R"1+N71=B+P^
M*F)U05*(>N(OA/#3\#I:Q&/"<N?*8306WFIJWSM*8P85U7#)U[<Q:^+*^H=<
M>DJHO/5@5Z-"!#2V3LB)0HX8!#S!KTIQPMHP*_W;MC-JEH%)B$\G<^S*?0/B
M:%<F_+TZ.BBS<D(GH^&%@P?"S"AOPHPK'.X<L8*?:D";6F.;%)X)9C=ZNE!X
M0+3^P;6%Z;J@:IYPFWWO*/W Q'S'4Q\CA97_I,7F>&%1+'2SKEOY?+"Z!)KG
M&SGE(D.Z5W#6Q9-IU"/XU,OG44R28+H:"VF$)E1G#5:O &*>@2<8ELB 0'KL
MO3;LE&CHN+I?OB+?R56%?"[M[&Z3[.16>5$>'AQJ'?9BZBQX954!3F^-R]L7
M%9W'SBDJV\%QX*Q_>:2DJ#T0/-=_:1'3IZU &ZG=M&]()-2+!"V!A&)MS#.U
M57@21L5Z-YAW0" 8['+<-4O5UX+["3B- N2UE5Q1H #!/C1LLS B$E+]V0#W
MI423H8TTI62UA!]A)Y,1=YMN71:7)P^YQGFV?B0)(5J]!ZQ-YE=I429C+>FK
MI=;-<;Q09$;&SX;:D/Z&72&W<!R8=YXA5QSO 17]68,,\#1G=^N[2L)[P,@D
M,T>*^[B@*:_'LDBN%_;<BF$?"V0H_6IY159W'6-VX3+$TDI\OCRHS7/_7+P,
MQ,45MU'3Z-=O5B$T^.?S1[LN(,^\<3SASP3D,#F_:D;@KN9)-C1.!4?2ECWB
MM2)LG"D1(GS@B-7RO?0"6J[H7VE:I7T/H,TR$6OB<:34 :,M5WUEH6B=V=81
M]H8S0JZ^&AFP'AC6'F0UVB>OZ2'M_W:*##0J:6WOC9OOQ-H] ,NWRPJ3BS3"
M[B@%HH8O26V8ZX@7LIK?YM68BB66Y2!,Z-QADH\+ =\#;AQH[P$M NG0I>#H
MCY,K-C>H)1IF?*M"F;OEF03FG2";FR / SCNZ;8"B&>!P\Q]U.VB/(UX;U"Y
MF&MZ>F%0Y/S2V0)[87$U)5)G>&+J#8XS#[@%SM=6/AR<->.J 6;V2JVW4]S+
M&%BZY>!#K,265-7XQ/A&?J110>AM7+VXVN+J8</Z@22$*,M!O&+Y*QT&,A$N
M 3(A[58>&1'X<'B_4T_"Y@F[RDNNIM0]^K!"I$L ?8K*>2<W-"_E2F.#P[VA
MXS)TL1FM_B;L<0MZJU-\YO$^L&!&5\&?YRS1:MB.NM7N26Y(FDM/Y*E.A-U<
M2N;1(=A,T!(.QL&P<-A#G.7%V,9TE-?9538;!,\4C<$S#-"E0;3=$7,^32>Q
MG:5>[0-,+W^?@F19]\F-ET\M#3#>P">^J^?+2K[9<7==;*#TGCI0Y<(L(%+J
M<(B-A\<7 .FY;@J;V-8L#I)V>?#GGB_3U-5TX<GIFTW]/BHA#OQ=-AX[,U/U
MT><#/4*-GX#@%!0!(K\.2\>AZ"HYCL=?8RV9+%^&]<%K"OI'ZGB%8@IJEY5?
MLF=BV9[W%RWE:O\!>$3:N+%Q A$1^S(L+(PLV%UG'V3&Y.O*_Z(TPJ1]0A?9
M=38?D BGM:[50AQZ, D(!V>,V%C(O+;OAS5\@(D;^8'I%NR)R-H6GLT8DT6W
MV5[/R8*F=*O%3ZLR1SB$6#)DA38G:2$N?(A$-W..P>-(H#M_]_)%908^J_Y6
MHI7U3$&UG $$]!,NDX/ )=_FL\4?BE"H8VXLY<-QLG?SH*2!O/JMX)!Z27#C
MKI:&84RO2PQ[_;B@C2F1]'$#P^OY,@V%!M/7\Q-;](OH1&\F?.LVE*+"(= .
M708,"%K]-=/^2IEI/B5=1NJN@@>WC:&[36ZM;RC29UR]7.P8/NZMSV"J8] %
MWDHVIR!Z$C)"JP!D(?<FE/.W&92#;8'NRN$P(ZCJSKIPFL8.A2ZI"Q,EHNJ4
M_PM*\] 7U[+JY:[K8PRSCCT-<6[G"P&;!F#Z1HT$A_7-Y@:XSSF](I$M;3]&
M?8.@ PE9"%/,15KZ]J;R6FN/RD;1!T0>B4PNZT1T43$L9EKUM'R80]X#F&*>
M<_N^^T>3AO^N^G>M?WK\;9&DY=3=N>7V]_;B3\CIZX+KXM^QM0DJ7SVNDCWI
M;A8-)0H,8NFC]JD(MVF)TMPB?%R6AIA9?$RY"?7U4<X'CC<G5J8*!"9]3P<#
MA6]7SF5UZMHUI)>0%+2K=<P(+>DP>M,BR31\-J9"-8(QM;!?B$O4>?SZ1NQE
M^_K7,??JDXVOBR?:@RI9Y49\OC45QZ)+ZRVBEQR.?4N7<E;G,L1NI=$Q_X.\
MMPR*:XNZ13GQ$,4MA 1W@C30Z GN!&E< HV[NYS@+@V-2W"Z@29TTT"C)[@3
MI!MH: CN'BS8R_=]]U6]'_=6W7?K6=6;/];^MVKOM>:<>]08>XU==@(4OQT)
MBKP%^XS]CI3BXBWV'+HC^EJHQVKZ@0D8-EA55-N:MJK)HO/#:U_:(<#A96N<
M38^.>Y-NIB_8FW30H1_EPVF<Y2_AI.O9> PO9$\9B5_TR!SM<YH>U)$O$@RD
M2PVE:>M].'J+L']LE&R6'9?&@C7:T#TB-O-'24M)]$&$IXPU%.V.O^AW<X4)
M<PFFZE]:$@!7V<(@C^K37$.1:F7;O\UC2->F7,Y=E_5Y.2F,I#DXOPED##K'
M95-PF2#VB&_<!YV=?R#1RHH>ME5.8AF43% =^5[:?J&C484]M>$U(QME=)%W
MA%%&); _^WEQ%,<3F:P-X$A82@2O )BZ5]@]++VIS\6S,(V:XFF<^4GTLN9J
MP>)J:R-Q,\O1J93B@B,IA)O[JB[ :V'8UG+$Y6.)(QD!I!$12O&ZSUQ6Z=P0
MTS3SAH?R5.21H$)_28:'"X>8/&C6!@GRO4>;ZKXJW6O;\_ND9K:)'4)'9HHU
MQOA;U CC@BCP3]>^@ LDS%3,8+WD0TVOXV,<IG806W5SC<X0\."KL-R'0NAL
MH=K+)P$]7P+>>/<5GSH5X[<I?Y=JE*]%E<?: ^L \W2-B*VSP<#&2GD6I#<2
M6=62)?/P:;0="I+HAZK@YS45YLC#,*5#1Q2D7;=8Y6LGP&,QKE4;+&*JVDUM
M5BM0)D53<Y<AC?$(-$L+E_X<G=)9>E:.SD49UVKQ;IL+2O\E)9(OFL:C!)E7
MJMFD>Q)N]2-U&_\):*=>02K<$Q_LKIF0._ISD%)XKEGTO.RLIURL?O9$;.<9
M9<\T14O$'/LC"$2'U-G":&"84P'6Y+/E\4X;*@^5$O#45>?0YJCLSE?&< 4L
M33_ 2 _<6)-IYW?8JYMR^<"[S6;4E*<8!NN\>A[DSE#K;U21:90,*[(.Q. _
M%F>/\L^42YG- .VPNL^*7OQU$1I0>#!:]49GSG@L!4O_4;WAQ^53 &R9J;[[
MX42;J:=ITC0M_F?X+&MF_&UWFI'=A"^5G%BLN/SSKSGRG:) #<\A.N@ Z%V\
M3OFU#+V!/\6$K\K1.?@(EUV&\,PUMYN!";.VP%O\Z^0%XF)@!=ZH&%WV.3J3
M%M=WOM;[>3N(-8F*8PN!W.,P12Z=OT%%9$^#9$TU,7=$LCBCW-+II^K?1)"T
M*\:8U=N;8&4?]8_R<QFTN\_FO*7U41TFN>-;*=]PF8[UKFR^WZ0%&^R:!+@3
MXN32A?)6\HM@I5$3B!)U'WW]Y-CXTIM)<T)SFJ-??F+E_J1ZR>O(5JV+U85"
M89N8#F\V_2_SK0J6Z>IB=T0LI/+Y@C*F]@_=](!N!ALO4KUR4N92.P*UB#$
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M$#*F2VVPM3L?:<228=1K\9O&K2*T*3FA,)3E(+,>'EM-K6KN_?"G!AZ)+G=
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M/=^<%B$H:V"+,99A#!/^Z5ADTX_&2B"6:>,$(KPQ%!BL!G,RF1T.@;W;-A.
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MPGHT)=H1'CH]%5E8Z^'0SPH-PD!GVB*\M2&L;\/8 $U,.KKTW[^3*C"/]9*
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M!U$($<T/%^,U84[,@^ ZCFD'I;IV2<S&P-A-LTDMK$MPM4\H67L=+))TEYF
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MV#93(9*Z]QLNCCQ9R\T]1'X(LI>=LZMG%NA8NB1'OPXTNAU0+S#(Y)U;"EQ
M?%\&FO5J;RI447; OTNO^\#0$"\#[D&O78Y5,\/U=797^^;\-2WK#W]J%$'V
M+6*Y*RCWRX4(@54<SN=1CFNL8D:I"Z WW-PJV)EHZS+B6@Q'S''$[[0W<K,(
M6'P$=FNZV151U+^6+NCOC#BX+ZK0&)D:Y]EZ6Y^"PFI6\FVCM.OL]]S >4LY
M$?AN)X/ ,X80QGBCXH3\Y]R^'"))AKDNYO/3\H%D1"!G^W(L1$EHF>_>H'(W
M='P1<?8KHVMS#Z^N-.NJ76,#?7.5T\%8Z=6O>P%28&_P3E=GD<Y+_7RNRMU$
MZ 9]$GO_W)# TFPX_6U9M7Q"VSG_"*D%*WJ1,_G0FT91;HWD/";\Q'\$&3=E
MU>SCX*Y D/A+?,$A1-7@/UR'*R%8<C-/F;=??[-WU#'"E*()H!%?VF"(53QP
MF'J<SRDE-W^([.!W3LGPJP&2E6'#8J>3CU\?E+]O%AT=<<F-._=F:^1=Z0)W
MOJF[1,^PW,8H<1J0_<J>@>;USJ8]-M5 QGKJ#,?D'-]!BEO6Y?!#MSXI91M:
M?$(^B36%):Q;>=%+D_>;?-G#;KSX2)#\<T$H[[AX.,1(]7]/V(*CJC),>:GD
M'E[5=?ZN=3V.26K<)5K %.>/'<07L$K@A@SJE WRLXS:Z [6(DTR9:20S.EO
MV^4FNUT*WJNQB(_SY+E3>_UTZ@25R6KB]8]9,X]\2>S+!=L."X>D1S7-&O*I
MU(]G&"\H-$1M\+>HT!.AU1Z<R0?,Y9-&$9FE39KAR!BA)JUVDY#G"70/E>:M
M,!60*2U=DWR(4C$ITM2I]98-T/I)(Z,NP1C\QCJ-?O2];1;#*%<ZC*2?\OL7
M-(_K+_FDDG\L]UX?[MZ%E.=02L<L;X8O'#F-ZP8:J4QKRC6=4O4S& S#&,8<
MC#_]C?3ZWPB=2%=_RL*YR:4Q&PF*:F($F7UKHCZ1;#0NHR5V25&-,Z8EH<N+
M'77T-^OY>;H884I_^/SP'9K'/LD,C_B?Z%\V^AR8L@8WZ-Y1L7;?:_&MR+-Y
MW%(DZ6WS4X=S3<JVZLI*52#,FV8J&BD_PS<CA6453%&>YU'@"\HZ$9<1L]$+
M=KN*LT5<YJ3/H=MZ\4&&N_I#^_<S7,\U]^U(9BCR2CV.>&QJU]6-PE7&Z)*5
MP]2+UBSDV_@__K$  '#99SJ*R:D45U[8B=S[]R,%4$*Y]XX$9U9^EVYY.^JE
MM-$)?RNK23<>9L>F+AUZ_54U81)<:Z%G=*W32?^!</A:N-EEN+;,KKW4>R"W
M*6WEP,]RIAD#,A*L6DA<1FL$MINNC[B5[!UJN!KJXN06\/8WGE?$90*1,8O>
M5W)^ )0EZ>$<4CYL\A56=3UDMN?1M%=US"D^SK?[&OKL/DYUW/UU;[^BN9X
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M>EV-^]FKYGR'^-;JFQH!'K4X^Q;/$>4BFY%E8,XOQE3@?>-0>LM-4MQYY%#
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M0!LG$XW,/S3@S+03]+1UE.H1CI__P!TZR84)96E,WKL78/D;&-XP3[NX((>
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M;ETQ-KFTH])&LO\AT%G>.<U^NW8$K,MDHX-99YH@E?#S-XT/*3BEA[)?%/=
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M$UIQ3P+-*TSGE):]OFW'="V4IX'*E%;0=Q(G<&@5XX_UII-$;P$/4$)B3.6
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MXS8_KHZ<$7BGQ@:2[QQE0,<A5Y55L6/R_;%Q"0&%)J9K.TU1ZQ"5!C>J+C,
M[X9@N#"V +>-B(3_4 & R%1 =T%.\H2)D=+L0&(9"AVP_9GAO3?[-9IT<-]"
M;2^GQ$M3O+.GOP%,X:6/MC1FX=H]G"5<<3W+H!)4GXB/35H7LG"G?WE5%E1M
MT9LBZIW+T\SXLYI39N_^0MNCSEW SVDV$ =2QF_56$B:@;=>T!@IXZB8$$?]
MSE;*6!$OI"W[+#[(BD&UH&\"_BX*K@SDK:Y00:2X8VK'UES?3NL43FAEM$A)
M>YB/-M?-OEC0V](R H1L9NWX-&"VM3KI[F4"56LR(G\&Z--T"*>@!R?M*.6@
MU7WG-J9XS=W7E!3UL[-J:\D>H6+F:8T+]]=?->T4Y_"O9TX7*)R M]46WM!S
MK2\*C+6:],J9/,-RQ5FOYZB8@BI_)YU&K&:C<STGTNO,/UF\?AXW["A1W6@Z
MI<KZVM[B J<_%&CH+.%C<FP<'2-Z!4]>GX\>G<QE-OG](D ('*VIM9NSZU"3
MR?(E)N)&<ZP-4#+Z8X.#>8"#2;M9=&.FR]U#D>+>VS5AT8XF5.T\8[GG<M,N
M;M!3@W%,C8GQ2_M?4B=L$CGBW4/S5:I]D]M#[/I"KXUQ_6B7@LSZ6PF\PHP*
M#L$K</9"ZWI;"3@/ +K(EAD)/_8QWW8"?,_4W/&H0.V_PI:(O!B?'YOY?9X3
M2%L%N>ATIE)%*9:+37G"-Z73I6G39058V^[73+V'#FJJO/\U=L]K2&Y)H3L>
MH(:XG#CGGH]WF?=T#.Y:\JUT,'O?(+0C(2BXX?T;JO:B/-I4$ &GV[0.0/D7
MA=G"^C HNG))-]DF[9I0^*4>WQL^=] =CN@$V#:O--TJ.(LM1P5JHCH\Q-#H
MQ4$VLI[W6KKG#XD&09J\)V"0F=ZO&S"HZ#V$PRVM3!$(^-7N:!$FCF!K%'\B
ME=$27\T]_Q6LW*"-OS_UYQ:^U.OYHMSH>;6!A('KUN :8NHQ9D]4]T1(NCOO
M22='@'6#H4W885_:V1>*OZN'J(:[HL R1[[TK_@- $P[YKRK\T6#QG(43+#3
MF:LL\[??UM9=1]$F0K*B%L02B110Q$5%H00(#:U0M?3?$W0&$]N>-J?&9#=M
MS@:\>>@=\R4!0S?T5Z"]PX"(EHH2Z]B#9/V$S>'#@M@LL;]_2BFW/GFLQ*@3
M>#1RN)LD29[Q7FMW40(<=(?ATU9=M>8Y+LJ5\?Y8+SMRTYB'%LHT8!^4H%:U
M75>Z"G:E'\6?.0!:ZM(>J(F,;5:'#%E@9KQ<YD9!)A"D/'<\ %BP.:Z<^:9#
MM?R_%XK\'\(7<7#?*WEMT<1OF,-%AZU&S+AV=*[&VJSBLJIGJ!JB*FGFK&'\
MBS+S:(LLI R-/IYU]';YG$4>J2%Y,/-^[PW[KP(>:\#CNS<NP=::8\ VD/.0
M^^.YI@HL@!5=P?-*AT*%\X 2Z,7&>_7H;M\G=;8;5WJF#&A28H-P5?9)T-?'
M'_X?O>S_?X2OI'O_[&, _@_)JV"YT(++9^BG#T6]D]/YDC^0W*JPJ":,_!:B
MJW=8C-3@*.%N/ D!-JO=U3%NJ.8F\/-%RZIH_XBI5O58@9;G[>2PIC><0S_6
M2O+ =NN36[+;8!79ZTLS\3R/#5$ _?D.63<O%T1)N4Z N!]#*2K_T3JP8S;.
M]B3= EGV>!R+0;1$3TX<[12,#YLX?ITP?'3*(7VO3K "4 V)G)-UU';@G#!0
M!702CO,[8^(21QAR5$0%U]2[8(#>_JKDH#+9&=[H=PM%?TA$^ :RL8U!54G5
M5ZZU_4G+@N#E*'(8-M5GU[6<7D!9U[F,+7LJ>,*+WYNW!^DN?]AWR7^[EZQ6
MUZU]G)?//+\45D4>5Q""!  H ,"8;RE8TX/TC=L-+<&U*X$/&SHK?[ ]E^]Q
M&7I=RL /@T:(\FC;2#CD,U55*OE&T;-K"#U:Z_%(ZSTG._0-!MP _?<L!$1#
M3+H0GN^,3Q*7G6).;4QQ?1C+3&\\73OV!M]8.QVX9T[IQ9AO*YI64"TQG*NZ
M,UEAA98 7T_P4V VR\6GV@JV?Y:O"'MI>MMDT2<E/Z3FYWL6:TV[\7"%L\-O
MP(?C*G?^).3;$9O8RK0T2M1&.O?T1O1Y6T-CLDYP8)057^VOBQ&0'&=R:V/P
M\<[T6&B46$7 M9 G+F12-K(RC\7B"8:^YIVGA*WM@8D*<W\I@UL!WJWUK>FH
MT5D\4+'QT].OW#?&!%+.U5_14JS;XL,Z879#L5D/,P4L$HP5U$]#4WU-;,/<
ML_SP51E02]9!/J%OI5E.^$DS\86!4K2&/K('7^AP%\B7=!#I'C=K+6'Z^*V#
MMJW*[A7^7J&?T^Z3I!B42XK*#P?D4:170D3!EAU$+F-:BV&#/5:BL;&W!"X\
M__?WD?)?AG_QFHVXZ>Y3#+ZWM67F?-8C>BE%^_3H[X%-3NH4J"$Y^:A>L-,Q
M KYAYBZF8<7FGU&:1P"^SW.X$B!_U_E_L/=>44UHW[LH>V^[H'20HMO00Y-.
MJ%NE0\  (90$A%!#Z$WZ3P&1+F!HH6PZ)/0  4*1WH. "1T$*=*E@[3K_YQ[
M'\X8Y]QQQGF]=[VMQS77'-_\OC7GFG,WV<)*Q'EM6@/4&I<:H*OX\&E\(,V]
MZ*/=J3<$SQBK3?NYH5HJ1W5^JOVVF+'HNQ.Q8^B&6;LG>A'0KJ&>UK+3Z1?O
MEDP@@(ZO:<Z<5_@Z_)2C5ON=1WYKCHP% 2D')J3-I=)AZIU:'(0)C(H:QZ9U
M_E)!9%\N!"RM0%1)G!"F2[[023/A"(4V!8>HYN")^TQ";?^ALJ0R:2\WBD<@
MJZ2Z,X82/3*9YSE\[Z;RB7G%<O+U2&4BE1L>OPKZ['!CA+0Y=%8>8^&<:;,(
ML!*A)Z41K0JMHV7,'2O*;T4,IR6@5BTV#\\3&D)&3LQ)M-<TZB6.O7!'G:Z$
MV[QV]C,R2BN!]J^RC!# %_Z&C+OSBC%)ZK@%0!I/QDQQXZLTLDZ00)C#H_[[
M28>P_9]=$C%6:1_*JDY:GFV6 ?:(8'4$)BH.G8A/AEHHVDPAG&I+8C2!8M9-
M=RMXR'3Q+)9VQ_L\XV_-/T1C?CV.*QY?XR$L;IEX;6HF]OWM%RI+>%XH+/CB
M=/[Y6L>DW=T_?<Y5AW_N]M'QA),64I/>9"TDW^+6O1@QBWRC"M0&2-61=+9Y
M$)Q!(Q(<0U&_9A2#>BC2,/LF*.UF\/I#!U/@>('7F-$@H09K&0"S;X,XY7Y_
M2W[]QRF?G<VW?%[^HN6TEYU=-5X\PJ+ O>8@6]M 7OW%[V>W=[ZJX_G!G$5(
M'"Y2B.FI)]*!O<=3!:NH.*2Q(Z+Z,%I[=RVQNI?+Q6LY<=?8V;1'AF4D,+,D
MSAD"A4(86'02>WG'9 7-UP96U#3R@#C<#S4U,!#7E"B3N)[;]._>2%+S?_QZ
MR]4?UJ*EZ%[5M(I>FF][Q!/]F4Q?=OE(4@YBWHM.Q85\ZR>B[)XF*^#*LO5>
M"&26QO\[K]E_=20')O&[J2J.A$U/MGR1RN4]:#VK@8MR,J7-6,:1)4@&B9S>
MR\ZF&\*96&'L=\7F7G=:!HDA\/%6%#1J>!MDIZEJ!&7 LJCA*BMJU1# IKL<
M7&6O__/_&^1_-$BD59T%ZJOY87G])C*L%/IM.NMP.+I?<("5530O..ODX?*R
MB>LPSI3L$3^>P]U(EDA(E6?3X[S1(_58Z,'=U&U7<8^8R'S NSL+(C4@'YG$
M:JXU\70&;Z>OL/KZAN:L>FIBJT5D.0<UKW&@54T-5UH.1ZR^SUTY;RD\DAY;
M/B;A120H1#^S'Z:G <,MRTF&#Q@]P.+96::9DNH$6L$B6^1WXW8NGDSZN>^O
ML0Y!BF$CG'%AM_:^;_%T2V!AY!DMNR BZW"<*<5E8@O[EV5%0%USUW@=- &?
M%%47.F1FQ#RP7;\-C1)HM&GD<<:,V/ Q)AQ!2NK,^0>S,]@,4ETTDB22]8F]
MJ@UQ/<XU"FN^V\M.1)EO:6:Z=S#"2'/]3"5LZC9[@^<Q]E553ZU91S5NC8YB
M&O\L^UZ140>*'[D;/'-!V&T+3 ^>POM-<E;^O#7;>A/C6N8R:A=7YC5-G8-_
M/N$QU/BUC:I&F.1CA@+D@.TU)@Y#K#&AX>9E]1^.["= 3,JV:E U[<<4<ZAT
MGF&=#H4US6+F[GC.'L,US9?D@.!TVO-KFK2V8=5%M\N5\-#'B#9AP@3DFF;0
MXIIFW8  W^C]S.GR_E8I? $X,(D^D/#YP5XK([L+V#>2,O@8%_,Z:H):"H!:
MJGBJ#2:G%?: ]]?8SS3;HR\P%T.OTQ!DF>B5VLC[!&*2?P%<]ZYQO&!:C=:1
M6ALTWY3B.<KBF,%@G*^R[55>]K QNY_S!AH&,G$.ID-!81>6-W2P*^Y$JB.+
M\\WI-=D.HA&N2R6KBCP@&LZNKM;SKY_X8Y!15<\.;[3_EI [,G,N0HP6_?W1
MZM;#O[H/9*6<4ZON^[ONX:>F:.E[,$%)6B74NM(5* )5\@$#-5:#/INQL(B9
M23$WEQB#]RT[FV=0!FK57M3K'X?L;2KWW0V&:*34H%3HG2.'K>80FDA1>Q=(
M@V>UC9>#<;&4TWV[=@U4MJR0'I[[P3L-=YQKJLN"%?6.Y_N=J^<G#K>\AUY-
M(W.>-92YVN5;;:J[\0^(9'$+U0XZVWH9!H9/9:_L:*7]0*;:*Q_/*MZ9T[\S
MI+-7/6=_-FHHC1"U&:=.+FI(EB0$0$:@4^K."+6JG8RQC,Z$0W87AY(-">_I
M<* Z4 0YMNUY.6\$EF-B2@(N[ZZN/7FC/K#++8C;6&/?EK._'^OOGR/W%GN"
M37<8;IS_Y7SAN>C=LKE170=%0R0$^W+M8#:"TU0Y,",.UZ3(TEU-ZWIT^EY
MN+ I8!.AE4F'0CD;O2WY\,%.XGW*^&FCY_\S^X0C#Y^JGXE3XZS_7\P^>5<
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M629-"OR0U?1"J9+-7BS[T*Q,7.6&^?+7VO"5)7585)%&/-J+R7#S^3/8W:8
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MH8"^C^LE,9]" R]IER;UUT)<3[3ZLL0=[3@IZ.K^^S/<E*Q!!N]"R.7C#>;
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MM(,-MB:[+3^:ER^6E+]ZS2$XQ6TFW#(G$'>F 9P&6S<61ZYJ&L4/>TTNX^A
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MD*W:6A!U$N5\6A60[7KU9/U2N-M5P:*PKKLM.=;-B"2%-,EJC&IXCMJ(_LE
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MR;#P8N"KU?]%WEM&M;6%T:*<4R\U)%#\X [%"5).*<&E2 A.<0D>7$\%BM,
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MWA$=%$KC>#3J&%TZ52E[R3*Y)DPR T)YCE-G9(U2HM^]7C4RW&GB>^!1.I8
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M)#"WL/ (=  !<D<+!<FWFC4MN4R0V[WD?Q_C]]K.TY\VM&>I+^\J7BC/?K%
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M[D-?#&6'\Y0&E,E?'>3:3Z $D@C#@_&140>RQ4'LKEO24TN;]OVX\CAY2_M
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M"ZM#CS<(,NN&75_VX9LW_SDK@-\3R#JC?9S<;#$\W67;ON8Q.FUR2;M(R]7
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MW_L9IVM>(PB[!P_,XE/R,-2> /'6A@HY67,K? I55C&A8;70DP )T)*1.L5
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ML(R&0])O/!$9UB4B!Y+/GK2?RA$V>H+QXY0,E30<U4FH2QMF/U9L''(8O,>
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MY*/ELNGHL&W=$X5>N>@')+;%I&@-7E_V-CH*=N"Z?#-"OI\XWBQ^+^2=9S@
M+_ZX]]'?<'OK:_(5*;L5H> I=ORDF#"EHFO,MUXWI_]C>I>P)K,Y3I2QP?>9
MBIEH%U^Z&:G\Q7,1]5<?31G^O;AREVGO]#_4?YII7\A>%B]0.)QQ[S!VV31>
M03649(!CT]UB4-$SY8:Z R;C00LH=1K^5I^9^XEB\4*W7W"WC>NL"=B01X[9
MH^KB8Z784WIB?ZI DQ\&6UH/;%@2$;%Y=FG]<0QQ>_3/J=J];0^0=EH=CD'
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ME]%-B1Q0,J8UM"BPJ.Z#F>6R"'N%YRB4G-OX[OZ')AEPS(J:CW/$L)K1-U"
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M5\V.C!6J)LYXX^DCB(&+;!HJ>^O. CGM*24.S5=[7>9%W<:*D[@0-5NFO7S
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M:=QAD&>1>)6T3G<4, !U,5X):^)^Z.2]'?:I43JL0%R9B*G52%^U*%ZB%,
M3^>H+V#'&([?X84W6&0XVB4=^SC?IG./B!U#$70=)A#R3W0O<LJT2OK<8:[Q
MR.>:3A?"HY"71V3BS2U1ZVP"%CY2FC:.VF4]RFS'_6]&*\=(>KE(WL::[M%8
MM36)#.;_%B8/MFAIO7BA)L$N=U%3]:#=RHE+7XJYVQS2,Q2K@ %MI&T94I7%
MF(0:Z<A.5AN-A.Q59'9AX4T[/1"J5)/RK"J_8J$*K]GR8_)@IA6&9,"4,A^9
M__V7+P#UA$Q45-84=;#PE20]@1?66TX$?Z8U7UAE:+*.>#<TK-#=A],'XDBZ
MYQX.A#=K.#-/>PO6,CAS$*DX<8P*[DPY9-E_2&[*U.;^;+1GK9>M:Y*U70S1
MRZ%"R4, M?PK]'I-*FI'H=B)9:1+SJ@I1RFE+,M']718K^&D"5I-N^'#R%&2
MHW?-7*=]/N7(8&RV],5UQ:+'WM0*BB:(P*&#,OU9]X&#$$)?925/B9#Z<G"H
MYX%]"5R3H8#6+/%-X(L6K[G.U"9(ZQD5L7&ZO:'<XHE1]Z5J-TGQ6Y7WY(_8
MW8-3BO_UZE3CSB_56"]+BEZ^0W.?^U"X$3Q5)UEH4YOB<G\7@EA_R R-S:$E
MQV5;CB$.KND3G>1X@:>_TJ1?A9 SN<#9E87TZQK:%4V&EILMO;P5#_\.# TM
M\/Y=)D;0NG[]Y*T?90):'DUS+Q8%Y;*/B?37[.J5A8_-/:9);VIKX%&IG7PR
M< L>$[R\@>A><OSTW(_8"R$V7M0]&6WJ;T7WS>HUC$4O,^TC;0WB0F ]\MD/
M^>J"WWC%FY"WQ=(C]H*._)O(1]84,_;YU*^-S;4+D'TO?N[.4-D7YDJLYBD+
M_H6*)<( ^;4:5/D:%U5,^4+\&"Q#,"8R#^+7A.IP8+TH6G\E':?TCW+>TPN*
M'/>0;W'ORWU"RCTWE**-',[WB'0Y(26)&T2.(K#\22^3Q#"R724H=5H9\H<C
M83D4C7R:N 23.[PT H66<,[A5L=^FD'#;-=/C@PU6O2UZ\->L>!14AC8J!#I
MN&UGQ&'G2;?"VT2%F[51@"JL6*D!U3V!GBEF#-P]]EW'1!ZC[Q/(U397R_(4
MVQ("#L_X ELU*J@*.%A2"G$!140O<Z#Q'LE*O"%5M?*_-*<]4]\FWP2;@[U'
M\LQ;^@)M^,JX+=-$>3<X=QD4"PHJG9'Q0 ^M(*W#88Z,\A_#NEX-[%_V]?94
M*[?!4X6)U4A1G!D#'ZWN$4?.JB; ?I$YP'T 'O^<+4LY%Z@A-Z86KB5/(OPT
MRSZ9D@_MD2W*_O3]<H/8R$#LLZPIJ?Y>A@J,7606$ AA8$V)9H"."J60KM!&
MDV=]UBU5BJW0!^*WH  :Y='9A[76(<T?.(1<=>74A-R Q+V&';#NDE4:8E&Q
MZ!)>T_%UBI&-*:]&Z]LEZ8]<L^>F0XZ/4"(&H8E.E[O- <1+1'(K!9=#>8H*
M6\6$1M!V*&U<\"]NX-PRJ5&YAW/$ #\R2UO>LL0#*%FVJFM6V&]67<S^7/MU
M([MJ+$DQ-Z]V2G&?S7.09=T_7IV0_. HZ?]VZWBA31WMB^PA$\-.F!A/O3!G
M,(%UNNPVOK^<RR93Z2E^==Q?FV^C=MGM4#Y8JJ$04_Y*A(I4><O:KPE^MHHF
M;\JFEPL=L0>/M0<)FY#J'F:^7C!@.'I.?S)-_G?T&8/8F_"RS2+U%#T$W:E5
MIAFG!64%B0N]!49I5,LJ40<3ESJV>@3/3=L&;_Q.U8V*CWJ^XR*_$V]X- YN
MT39:KV%E$ (Z[Q&YA3K)2092XS@Q65L:9&9<VUI/Z1I'LT3%#A,I;;O%HU?6
M1ZROKP4X7;HX5D;20;'=$?>[N%:Z6:V-JI(4)^>?K>D5Z/F2\E@EHJ+J:TL&
MC;H=J.G]-BV_3B\VR;Q0SS:@J!,3!:U64*WK&.=> <%_=^WD5-X"/LMZ6]E\
M6>QX(_QBH.1;[1V>/ID1@EWQ!0MPWLR%SZ4BE25Q>.@':< NN^%],7'[LUB%
M88SN7%2)!_DW:6-^TOE#D>6TPXG7TO[<$\%+FU0Q"EACI9D]FC,MK3B#Z4I%
M\<@J?XI4CZR8*GY34A:!+,[*K)Z @"O32S>%'D4IH ]1E$K5\P)'70[$W[71
M']8B(V^$J1OP/<34,=](,VR>0\W8)8SG"GE*F*F0(ZOT+Z6M1%P*&F]?O7(#
MW>$]E1*ZM6T*OAWW]G7E[)PZ_7S*(WC81HQ1-)*MH7'Q?KR@XC_: 1L&W):W
MB"QX<_I(I29K^6:ZT)SQ/+*TIHIN#W0'$D?8#AES+[A!MR^[5\<.+,++)RJT
MME$CTSM$^ 4_"ABSR1&VK@NM6BR[8SPN?+$9<R7";B"O;-'> *=?O&J6_!:3
MYP3W'*7VA"  Q9>O:\94&>?**RVU0!7'+*%0>"A0#(6=7#I=3$/&>J;SB\<Y
M:@'1P#]RZ@!]@3CJYS+0$1U#&(9_N6>Y ?\';M >P%3^/#LJ^V5L0Z+>7JW;
M=BISLCNC %'K5M] @)[B)Y)A->I'8G6;IR=@S,C .BJ4DJ"G?M[%-]>RQV79
MJ.ACK53YKF4J('I2GI&+*K*%OV@J&:%=%M5RL,VZM_]6X'F4S,D\VZK3(4L)
M@@@>1[ORCQSE$& 3!WX:&O@:V24?M=C-7"FJF3(HXM,U&!86D>RB')%NF8DF
MQ,N4O6!Y(FG5_%MA>0.;M'D;T+M5I]$F&HRZW1I,2P<=G<KBF-/'B*T'<VD%
M;'S$%9_,\\2WJ2+\)6A6 C[[-*A_+6-9HVN3;_4+SPNOU?V>*G%[2L62=+JC
MF/U$9%^A[TPU]L_J#6$ ]@^Y/_H"V+/>N;N:3&S\0E*%;1KC,9Z9]B)*B_(L
M51N7I\):F2=?3%YU]M6>1>3;'NT#FLV+LC5'+4![1=:9W=29<.OJL>*Z^?*?
M_X"B857&>46T9N>:38+#$B5W>/=O3R\O5RN+*G$$F#/0RNWE1078V?XS&;IC
M?9C0%_I>]D*.X9G8H>( 8./F#N]U2:=O+QY)P.8/RJD/Q:Z,5;-YRPLJTNJS
MKCAR/2,(R:S"ZI\&7DZAQX@6R%Y$M55>#V\1:Q7+MYSWCJ;\RH_(OIG<1P#!
MF<1E5A-JKS0)<JCKDFCB%H5#YD M$T%:-/'M4[9%7O'%%V$!F#L\_M6,.:??
M-;&!GW8V[0?GO <Y$F-SS[6Y)X&:; ?*.4P_7GR1O,/S:W%?*"^I/P\[4Q3W
M*?]IJKZO)SX"=M]V<*BPTB03NU=7WS-F\[6P_E#Z>5WS$F&PL*CP)(7UC!2G
M4PM$J?9YX3)+.?[< Y^;]GR2J2:S.[RP@0F=W=A[7QJLNY;ZMH6TO_TF"^3'
MBL)^((G/$JF)FI%5OMTJ3K&$+YXFEX@8#J]+,+>5E/6;KXG7),)-2P7UN;6U
MZK^^9E#_@GPE1Q#KMUYX^S4?%K#ZJ5Z,O%$O.&N^Q23%(G%4@SS$8:/:Z#9R
M;M&=;3Y$RU1K,=%PDMB;;1,%GU)N?QFC\/W=?N^'[G@]<.#(^&8?5>- O\:'
MMZI?5[ BI,<NZ=-7]E19XX=4-'^5#76_3^X\#-:V^[9W^!M>FP9:A,YHMBWF
M-S^NV-RK7R!>2YKP:U##^/&I]@-/Z)J*'*EP5T\TVK_OK<___%C!EVK@[>%2
MZ%6DYI'IS3?*GHN*%'**FN2KE4OF=E.[=\G5FG7>=1FC4/&A^ !UU 6U/L%M
M&)8BXO3Z(O??%!!DLQ!Q2P<>TJ'W?28H%,F?>"67*3^TH;7:2LV</67Y^B[U
M-BK_)5#G*XZ%/@.$:7MW2)QV$*\N(U?U\P*EJF>/DTM4:PWK'B<3AMEZN8S*
M>C_WY:Q(&\I4X(20R;9$^#C=X'$A_[OOW@^AU1&U'6S_849,3CT]>."1Q"-J
M7U0)LBZ0F8\7+$%]>*_L".6W7I&>U$*.N1NZRBJ+23PJ,46D&P:XDBG?%V$!
M"A.JOC'+P</38UQJ_[J"'MML,USN(_<Y:/-]83='?9H0,ZN7.)%^ ]]#P(4F
M N96[=G7ZBF>G?$]\@^(_Z)<DY,HF-9+MI?-HEGW1I5>F4"X8XE'[9;8_=3E
MT;#IC,+RS=O5V\:#FIFVT)F&--MI__=\VT!CA"%YY2EIK5H,J1RJ*BK$^V!^
MM_^!CC2C3-5F7E+ M\D V_%L?>]=Y\EU,P>O5%H).%Q" 3M9+N,5GMJA1E>E
M%)*7?J0_5$8^!/3T3)9M3D@>2%@8>.HFH]E5WCWH32"N=)!NM(.2BC'9'30;
MN4$@ ,+GE X(.-E@=57RX>O$-*.A(P6!CP*_+W=;J<F=39BR!K@GYI;299*_
M<'Q W#2!BL^#\Q3T4K8ZOI^3G&6=J/Q8^4ZX>IJ_3 3R&SNL1FP+Q?-YB7[!
MQ#I>.52]\[D@#]]K2/,7!B8LL:TS\]*%?,%[\!CL=^.&"7!9P/&88)R]86&R
MXQ+\"[)%HPZ'(HZY[?MF)4,HW0I2AUBU@/JP>#^OSID6/1BQ4T-L;3%[3-+Z
MFU<L4B8ES</ )M.KS):%(F\VW_%F>E2YI:&&@UM%5K;&]^)"RK<&FAU0#(UC
MFO K/B&6UW&Q*8,;;,=*B1\M\HP;4&\,Y'(# ME#^W7'-\JT6=ZGA+X5=X<0
M_XOC'K&K:.])DA2SN\_$6J[TXA&QC]5!]\WFC3T<]>WCK8^G0Y;IJ:PM>>K\
M)9R'W$8RQ<.Z51U.Z/Q4:@CO07#9%BJQ:'"/EX90'C$8,XK&  ^S?,7<D[ZZ
M?/]W99;.;X&<('++#$5GMSGL_D/T#F\(=M/CIT]O?WK*:Z2OY#R77F;1X-F#
M<Y+#VC#1?@3HD)Y)/*/RL*L76(V&GH3ZQY)R,B0C),UY10C\D@)D YZ-0EPD
M#H*^A^HU3P%3#FO/7<=CRK('N3I__@GMAJ&O;,S<+B9QKID?,U#[M#3S5'+J
M=>#OHX]WQQ[8M_V_I,V2+N)Z<<MP>-BWO5)*V>?KF3SRXY[GN;/9DY-['8+T
M(^+'W305VP^KLD6&D3/,%D>@9%W"@^7XZ*<^N3W/+2F:?M(*+-%L/F+&)$3^
M=1(2_U;IJ]F761[3'FT$&11MK B1>*%T:OQ 1V6:CIC]G7 +?X3%9C;B9;;5
MFH4A*2H2H=6Y^148R!B@T*8D+K@EGO^\:?LG=6!WPG@B&K)6[%_/LA?@/#V*
M:.ZUC"(UU)[AJSQ5U[>= +AQ?W-]O2<6+2:H/900 ?_X5^,[Q=0WXXB*CA[C
M1L&]FJE9>^\^-+4.%P$7G\Z+.F3KF&YQ?CG[TVU;I^%QD4?W1QQ,/W'T^5)3
MTC_N*8"2<T=/B@EP'CC=VZCK"N3<AA,=>"BZJ^H2.HW6?W[,DDGY9I?$N-^@
M2 LU1N8?VLQ5MS* -G'6G!]L[S2)\K7$2&3\\N?[PH8[<-N(+[[^L1:?,T5%
MG'"-6IC5+W8_S7>U?%3L&3XWXQ?.X:UF@NQ6+[&0Q=POYC/SJ$XL%8[Y(&T
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MQ:,8YXG3SJ1%M,2$[A![M9R8E(JU<IQ'*5S;&2^>L.G"\-9JAA"6L?2AF_8
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MACQUFED=:$.7^M6VEBL,._UI4&-ZUMH5MIICW6M7IUK5&D9V"M6VNZ"NUZ'
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M-7F=JIF=VKF=2]F=.#F=X6F+RTF>54)7YXF9EZF>[>D/!0  .U!+ P04
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M_("42\F4307IE(=0   [4$L#!!0    ( .-95U@-H!=X+J8) %""#  4
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MG'H ]&O/3(L!GFATB+(&TFI/>3* W>+)]2^!VG34NUG X+/:.TJ ^$'V9#,
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MRICNI2^-?^IWH/8-M2J4Y)J^ K8/\5*G/_(7(; EL^0R;J*^*ST.6U8;'%N
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M81SLL$THH]YN!@>/D %*+<\BHF/UX4T"O!6G7S<>_1K?UGJBY1M@M134T U
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M6Z(&,'RT[^"[L <YNB.M0!-<VVE?X&%@7+<Z4);_KBT4^.6HJ'$65)X0I:@
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M;,2'>T-5GVU"K$ TSCG !8BP41UX-'RIJ1>^!=[."X)]AG-1#;!).+U("FN
M$Y--8 (X.NP!# ^'NVV"E<!+C6)A*?"N)^JPAZ3U5S;"\(1;PV:P"'Q+PWN8
M#:Z!TP!3QUY%[H*^Q.H4'H,^PAPXH@%]C*X/_0N]A]9PA4-G4# C'2@793_O
M _W#+KJ4!.UAI@UF0BOIQ^O#H#%4*=L:NHVB!7\&M2?A"GRA3D2KI#70;?C9
MT.U0?QS-Y2/4'<LRO IYBHE[E L-DJI>%$)7B(Q/]T)F^/L4[1 Q9XK9#B&S
MBF%B");AF;\1PJ2M3[2#*"@6(01(&RG<!0&1$!8,+T+L<3D/)B%-]="9+Y"2
MVO/]%I! 66"=-\10_)V1"-$4+$(+(&K<+R<W0HS9CH>3(,X,?/ 7B!=M@XL[
MQ(22:K@,/D$X>M\;LK/CQS08_*L%WSL(GF@(KGD'%M;MHKN#&;(*2"Z8(1X_
M$0BN%P0=J@=/<+X$EX&GF<O.K\$R^BLC8] T2>_N>?#R(.:\)5C>>[*G")S>
M42'O V]O'J"9@-WJ?<&%8->:\\<+P*%2]B%U<*I0&KP*G,[3=&X!>[$#C3Q!
MN\C0.U#PY)3KV3O@S%%TMSO8]/2R# =:ZB905X(6VA)!0-"]1K\\!>AUW<&#
M1:"?U3U!,M W$=&Y'#3+\S:*!EZD9-_. O,N&T^= ;N=O]5E!7IXIJ$:!>H:
MXE(,036]IX$-(';[N]P?(%'3_@/O076*54%[02*9JW,$J%308I0&+*"<N@4&
M%]R)FWP(7CEWLC,8U':!+^T (28?D_>#"D;B 7]!R7W7<XM R1W0 P30T29(
MD#9H7YV.\V:0DZC>J!!H38'<74UHJ<@Y;XM/K]S2JXV+K+Q=(\!"JZ!T'4P;
M( *2BGX$W')B*WH[</G0<50+:#AH">4&!CO-(.] = W*D+\AMVX;X*-A=\_N
MQ#G"&KM]L>XPB.PQI@AVF I =\/203]1/V&(O(^H7%CMP53D(FPZR!@)@KUW
M\D7:PG4-DI F\)*;5KBU^)^3J5A]W(_.(HP;3JTZ$ W'6E-6HFYC2H%M*'?T
M_=RKR%9TPH$\Y"[4S=WQB-NH;,<N! )E;!"$B$:.78_#[F$\/2/''*1;M\^@
MJZ@%DB[4)/D*283:1"H"E"!1Q*TY8TAM_,_].$0M;GY7+2((^]@Q$+Z(M35P
MAG/1Y^9PF%KA[[$E=#^_K,T%]8BK*O9 ;6$U$G<AT0Q>52#B'4V6/8  4BXF
M="/,R$:[-.#]1,S6>7@BH=@@ '8=.WKE+69=G=IH(MI+-M6B1!V3"(5GD35"
M!OXS4HUWM=(,4<QQSII$J#*[XC_"Y?3TG5"X'S5ZJP V0UXRR(=IX_F7R]%#
MK>;#'U%7&AV:$Y#+BF@!'NDA)^%N(EA2DXJ-B)7"L<SW< Y/'!\-W\9NWZD%
MN\PTW)H"VTM/,N! 4XBNETS1B+[((3$*T=G1I(ODM=KS4Q#7&@:PYQ%>==QR
M%[A,1L^T@WN)S^YK@]T0^ 6*8#E<\ZU;H/=9&0:G(3,D_,4KZ(-C@L%]J)#!
MXH8+R)C>>-XV!+8C!#,&?]8,*@N%1RNO9F3![M2D[5L/*Y=Z!WK!5@I9#HO0
M4UQ#@UN0O:3A"Q*T_<S&@:VH-9-Y]5W(M2/]7#]$U.DUZ ?PFBYY*1B^HC7^
MV"B,U. ;QX=MJ2T(> !MD;YQ&(&:\^,-EL O2;,S=-3/:XNG/9 /9A7*.<3C
M<RF< H3)N ':!IX_J'+J'NQ<C]:Q;; ];;OCW*'S#5<#.-#LFEP'/F1.:+%N
M!9A#NGOQ&L.V_.3@"YIOQ:[&2Q1PY1I^(=FH\A+V$W&PJJ[\""$7@,_TPN\"
M'MD'P&T';0GXC8T#O;7OQ R#I7H$#!PR-O.)-@--&5A+70=-;- FPZ'[N3,D
M>V@,IH(P#RTIT\'+H8T9!C@L]&$<#HN'&08$8VIA\?:[,5HPJ9X8S8-[3=M2
M&W%Z_<F4==@092%)@(%QHHEQZ&GT1H(9.NC47=P;U-5CVM@'J.S85LP+E(:_
M"*..'+)[@,Y&*O1:43/(H^<@E.NTYMY9<@35H>X[\3:YE;5$8)!V(1?PV43]
MD@E<,/YGNAEV%^Y3S"M, O:WOP:Z$FMOAT)=PW3K#:.,T)%3#RC._",] :0F
M[N9:"#&0]87)P']AW$'4X2[15Q0W83NI$4>=,3UD>8PC^B+)Q ^"6B*,VFU'
M[2"HZ"T@H[&;)P^0>V7+7:=)VZ5Z-=J$2Z+M#'\\A ^ E^ .</X6B; [6+*T
M2,Q.1OK>*O1^6H3?"E0AI<SV#U).ANB;(LIQ\V?>DH\V"CK3B0^4.K)SA!,U
M5+H1WK!Z*RP7^T:L4=B)N2I0246A;W$W[WF$>LL"[N B_S(\;"\B-])J],/A
M8X2T<1[9MNMPAQF1W>9:32.8-JVC?L8-*W6@F5A&36C!+*9,*DB91%>)-NV)
M0)%XKW:X(/D<%UL>0LG,UB^ VQ WC"625PSYM=TCIO71I$GXFYTO*==P@-9P
M2 HVJN%9_E.,35UUBBK:1D:.;D/]^SJVGT'Z"3BVZ8A ]BU]&DQ.]!SU)-V;
M2FT=)[J.N4CVXF4#/\BW<,$]9\"56-WV<_EFZ(6FU\F'4 ^5 =%;D:_D;[9G
M(=Y(X+9N\&?<1_I-,!]BZ(@GJ?W2G9:;Q%731N)2?-G$'O)JG,DP"#2*>=#W
M_&0%NKFS\,@E5&V+?=0(LKE><[L9HD%6:ZL%%_.A^N/0Q\3]HQ#^5%E?6QTW
MO)PC%;&^5113PQD?*L,A=^A:5?8%\507P+H4+S(4\"H:0OP.[-OVAU '(FPA
MX>?!:3H+N&7(PG -KP/BV_*$LQ<2*?[",H2DD"<8EI 2,(@6 6G)MZ2 (#^3
M74@WH4%13<1X*'%;!OX'],D6?[P=+'6-,4X-[C!DP.W 5#4?8V>AYT0XYBZT
M)^DD_3!*#@JATE"!)W7(UY!+1T)(/LB:R$5"'S+#]PX^#1FP^0L.C,Q8$X)U
M1SH-\#ESE/XF51:3G"O<R:@B61#]:0+"0Z [Y2'^W@E3LBMN.>D448);&QE*
ML,/N\DW#7</P-_=AGV&*U^1CRE$?3F_FV'!^-G"9RVP-_DOZ G,]805M!=T+
M8$*)IK*.6Y#D%(/$:J(Q210AQLN).WU>XR()5IOAV%#\\)H:=!VFOF^*W2.U
MJO=DDD04'H4.%*CAIJET+K'R#_D6.S[/CN3,]#D\1Y#1W<-_X[=2XWW V"GR
MV<T','*RSIH%U#E<6&\:.T^9HGC#W%[KP#U&WR1;@1V@NHB7*E>32X3K<^.)
MYWA'#UL2_-C3X26X<6:NCR4VGEZ^V15C1)W7-45IX7$])FR?ML&Z;L;WID5.
M(.U&O3.FB?*@%E%A0MXH6Y<#)!:*QP^=P,\+A&%/<1G<T][#F+?LW,VKT'Q&
MBFX8,@>O[/K)-NGWKR4SSG=]8)O0^&W-: 9%VE18;D*ZJRS,YA.WU% /-N/I
MTOMA,3A]$=@[ 4/G4ZROHIU9%-U\Q"/\>.<BZ^O8YQH,0SSDRC*AY?3EH$24
M_$Y1F0^IIE4WZQKA68/\H!H^IBX[= 8[+:-[?<&$B'6L:U!SG*.Z9$0A_E;'
M#]:-Z;]R):-BLI,90=LYFHZ\00D=T"J%D<J[%[,\"1UM7PY \"9-7J%I6)K"
MW:L1HR:];0U!X;D)NDJ$$?YEYZRLMJRL9DERH/P4Z[XPOB(=7<$[4^E9]H=S
MJ,HHNY#Y!Z!R,(I^%? PE$2]">SW_$W9 A);99*CP%1M#+$ FMT14XT%X^55
MXE3P%+-<4 [^BG+A?H68E]YD"R#'LDXR]T(&#A30[:!K0^Y3G: %G@CR*>B\
ME2L)!L-KGR,4PHO;GDOQZ,.R+2(0ZA/#A]^(0B%7<7U1FJ>F62^1_9E0AA()
MW:^@X9#1(8$4&M+.<QWI&M+.2I4XC22L5L63D3M;BR3GR!NDMX4CI$WT-;R/
MQ/7P+QP$_D_)#58 ?D-&/4,+EY#P@;J,I0>W450QSSPZ2,&8 LM;1!L,9[4G
M[ASJ1HN9Q(?U2<(0NC'3J?=YF?1QV&/V>YI.\3UF*X5S["(=2@Y(V$XM('X(
MMB(#"1,>\<0>_"/+/D(E_NSJ,NPB)JUI47Q)U"-.%LP*:)1F[E]>"G2&C> 8
M%3UA!K#TTC_1M1D.\2C*-]KA(#99A=+E_HWH1"ZQE.!G2*VKQ[%:V+G&9G%5
M+46T0U INT*NXRJEJR!WV)M$=D4ZC#M\2KHOK8YKLN\EA<XZ$[21Q&$HW1L)
M/71]2SS>@^JHLQ(3AK-L@(MW-1.%5@+O!A^2A)M<=PO\G'55GE?HSD!+@XY6
MT/:( O=%4+SYV;OE)&_.7??#A&C6HF4^KI6>I..'KL:%U@/%6[J;!;H"M?:[
M1 +7HOD7Z"F+WJ!5$,$(K$M.:Z+^EMV,$Y$7)+#=YL2'0H+;+_P;'M\R K>=
M&:ES'&V(RU*2Q:N&_O#-^'?Z>PA\SION(R!55DK;JWP 8U730.I7ZH"R)TZ-
M+*QYL:N.R*H^[M:$%PB;+>VPMUG/=.@H&0ZJ&!(]F&+Q8OD=8Q?P-SGC@\O
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M9P]N._:*[0W<2MS6YU($%7"[$HL,!%9/7$<^ .P[?%%PP%K!0L\& BBGT (
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M"6_CH1!Y.4U#Z/FI<49K]-$=7GH*AK^U4+,)N\_[F](;MWY5O6P$[[!PN50
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M=;BLXN-D5)NX*FAT5'&B>N]@+'UE#:%G'AQ;:VB[?X -&6R\FA0([3+,#HV
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M%W9=T"3!%'O'U8)@B4NW?$1PQ*\X$@W@@!.]<4 *,&:P!S8" P(Q8 ]T$CX
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M%WX6#J"&39AL%UP?([KQ.B09UUK?"<VHN:;7PC(+6C3]\+3T N4;1&&\E3P
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M)7\#\(1$<>Z22H*S4&[C1%K"_M"WKI4SF*+A(COZ-O'Z43W=510^6MS9V)*
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M5-6#"NK1/ LP$8A.^@#. 88B5C'>T^Q7]##.T;".+QF3M&,SSC(RZ J5#<B
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M&X+](GJSA8.94U,P F#=ZM?H"G$^3?[\)WB/EN>D+((7K+%915R..%T<18I
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MK(CRES^D07,O5#<(*K@U=:4T0\ZW1F]D(J>G^4!M B<'FE2PD&,!/YAL!CY
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MG^=NYE@2ZO2GP!'J&*,0D$%&L*^ *MC:EE0@'J&K3 5B4*6YOX%(C'VR$(C
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MX?&);RV<N<?(3_6^<-2,>*P?_Q/J9,LF?BHFK^H3;R?V>,%Y7A[>*;V&^YJ
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M 9ET*Z9"\(WR,^"N$$T[,W58M(Z19CDJ)G)W (W,':@K#!GK%-8?V\?>CZ^
MT#@*8G6] [>$7%+,Y5E1TS.\>3OHKM$?^&V,@P'G^$=8"5,O"2O8,"MG@"2P
M%KZBVY$ZZ36,)HH[1LL44]=WJEA,^NRZ/#:$,5!TA9/%_)T^SO5FUT6OX5[C
MR ,.\<JY&A=[@0</M**(]")[P3#E)/,(S8^6QWJ)YM+-[+\[AACK.<]KF<R=
MW$M%<:RMO%WI(>Q5?$,TG,,75 =LYKP0?'7)XGT3GK.Z(MP/_."7DYX)'E->
M4!1",0I-_4=DU[Z&GBEBUJQAP$3WYFJ9=* B;16+":R+]F&7BIT#%K/_$)-<
MJ-R?$FOK#*&#Y!S/C9@JLR!?)WV3.2)Y%+/,MNTN]9WT;?4$/49ZL_ 'HU%Z
M(BV7V2W='76=E2[=&=#/&I1>=1GC1D@/6_<(2%(8YS?^G-:7](RX4K,$L9K<
MH@ELBZ.<4JNK\9/3YM=");U-14I]RJ IWT8M8E8H]0$*YK@2YW* 0U?$6-_@
M/Y.-<OQQV\UA)#_"<$\]_"NIUH1J'2.?,;96?: F&1H*PVDR?6OJ(OIB'2F*
MSN!K5P>P&,>UKBZWV5=5]3;>?*[L*+L5>V"XF$C";QC\!]Y-9 Z,M<XB?>N?
M7F6FD'N7%MRAGC?GI&)I7TROHBKHIXV7 ] ,5T.(RT=VB\;7IIP_0_:4M1'S
M>!Q+N(-[-5_5_8RP?W1!RP%2Z<B*J@+RZ:$C!8NHV0-?4S-HN/Z2J&AZ=N_:
M@ ZZT#3/U8;U3JNV8? NR:VXEN"=Y@[24G!E^PQ$",B'+&PE@RVPXU5$L IQ
MJR -K$??3W$ N;BEX9_ @\0@WSW2;'*:4X]T'E5A82==S\EG,P$-Y#2Q!-@%
MN];]"GB"V-)2*G9 5U1BQ,G8*_E0,8K0/(<L7D%:';Y4_)URRO>0I(LVZ'0;
MM&6LLI""6MX8\Z-@#.6%?R+TQ2A@&X5JW.GF'.$]PK4*I2B5=#-OJ<A$N9;\
M7/26MCT<!M0Q:+Y_ FN8SYQGBA>QCUF\E:@$FQ@:7B@Q!K>'=Y@<V+63WTQY
MT@3GWZ"1RT\*FNCO\J8(SC$IR6)A#>M">(3P3XZW[QG13&ZL<R> X=VUK!$O
M$:GHU>Q_&(78)9S=S#70@UP:ZW6CCC>=_:5\&F\+Y^]</K^4.Y'LQ;_'>QGV
M08#B'_>](-@B,#B/B,I$4RTW >?%E;1LEC_?$[. ;<O_!KG(OB_8V;"/LT)8
M5H;EM@NOY;SC68C029MY2T4OP_;R8P&R[T4^&?CJ?$58)?YBY0EX2#Y30QAL
MR1/T&J84S(18LH0@JV$*&PIJ2B]QPL#Q'"[G'K@K"<(U@=?#C#Q_J;7O95ZM
MM&6*O8 II5OA170IG!)!=U%M0EUBS%%I.LN9Q:JR>B8K7?FDM(GMI=3D>++O
M*Y.3O#BCBI=A:&ZDXH#O16Z]XL:41/XN^6*K3<)GTDOD-NIS(Q'E39]I>-6Q
MDI%CJ*Q[STS3"TM>L<)TF[./LFVU7Q-OL8]KR\,*. V:D[ZG.11-Y)1&OJ^R
MW^JMD"G]A]1/^380A:31,ON+.P+IW7TY=0H&M->J9) )Z;F<K6#5F+8E_L'V
M,OX1%L)>8+CG>XR]2?=A"IDWJ$ZTGBGTE/D3'U 21Y\@'E&!>8+VC;0UP]_K
M8NE_##65U#%V#!S.KF/NZB]/5+ 4O:_#G-B.Y@[?@VP_8_04.2]:P[$N%?PI
M2R.'J8\URY%]ZLCVH/8;*C/$4/N7\A=L3?&(4HO8G16@C$+OBY^O^(WCA\Q6
M3B.\]F(IYY$^.DQ3C-$B+"QDEMPGQ!N*40B H"KJ8$#;984-HJGFN7P;ZFW1
M?CD="V02Y1D$V_A@>0@)$OQ9GD$!O(;D"VB%#CBY+;/ PD*ZA+^+()5>1Z+@
MZ=)SZ&NMAZ2[<:$UEM(A0N;<?Z1\4F7&&2F2TAJW0XJFS0T^(54P'+RV2"\P
M50Y;I0LXS9-"M; 5GRCA$F9UATK4I,"66Y)^\I?J.9(1:M_<:LDX/3JC0+*"
M<2BN0W*$E1&\1/*!W>=U%DS@['/X"L+Y,(MJ4"KZAIL!M-(>PZ(!-0/6_ O8
MRMQ9Q0%NL^X7K@<F.#;I1\3^W+ X.W$U+S$8%"OY45Y/Q9L%;HZ9D@)1B<4Z
MR1IQ_^1]4LPE=54+K_)PS<FB4'Y9Y1D1FO^K<)9HOF!+>HOHC! ?NP]P%GD&
M=P/%HOU>$P ,8#J*Q87BYY8NXF>@#R:%_P1X N4)VL2P)H7@D/AP9;K03V)7
ML%*(DE2F?1,NDPS% L)WDH?!):)8,,_;390)GG'<">"DD99P<3[X#EW+4RE:
M(#OYK@I8XQ.^7M%8L8/_21%9D">H4=BDK10LDC^/+15\EE\+CA4FRY]Y^PO3
M%#Z.ST1KY+,M5P&;I3-1PURH;B?$C?M=QVYLXH$ZSXH2WBNM.O\9OTWS.PW#
M/Z!1QOH)?#6^P5Z"1O4#[V!!O7JZTU21G>*%Y2,@4UJ*?,E!]P9WBKBN9GG#
M+>ZBGJ/ESWE33%?SQWD:XX>T1+Z5,2CF,Q]N@ =;\ ?U![UG\_NTXTXQ0K$*
M;N4INB'%(:O9(\/:CI^<NB%B Y?S?#"K?#ZWI?]M/HK[5]_F-#L>KM<<<XUW
MVJR;]8[WC^F)=SCONWZI4Y'07?7!*DNDE<J0?-.KYJ4=RXQOVZ?6+S>\@;26
MH?5/8+3<J[K?"$F*FRX5+8O*T.[ 90;"M/,(R]P;M2])FVV?J]-I'R>KSN>W
M(C#Z]Y#@]EWZ"-C4NJLZ./QFZ2+M&(J?&ZEY@'6?H]9DX!='/E:?(OX*K%:O
MH 2Y&]67J5_LBI2+6%:335X7_(*G:^L0?[2MT^Q'^]2^U81B,25WU"!>EZ-2
M/2?^,<=6U44^&3F@LJ0>#<Q2WJ4/N!]4OF'&V TI4KDNDX) Q.IV5WW!^[=N
M4X%$KUH_E3WI4\DLI8ZR*ON9TH/6GJQ1+&,X1)8J.IC#@1&*;+:=^QM%!J?)
M[I[L;_[=22$"V <+4=RD&EON*11TEQJ((IK!*Q;+3S,/9,/E9+9-<K#<DU,:
MZ2B[S64$^LL.\70>OK)U_ 7V$=+K(K&%!?A&_+4+*K=AGVV9+;O$N5:]0S;,
M/5?T35;+6YOU16;-UR9=DNX4X")N2PW"K$ O*4LTQ:-(VBSZ8<\$KX@?6D2#
M8C  RI8*A&^:*=(.D;PZ0IH$.!?)P-^ )&L8/ I\3C*!:C$M8@N($;\)= /K
M)2(//!@/YMIOEGP'WUJ())?!)L@J<+;,NND$.$V65K54\ET&+?*57)"1LDHD
M*V1@4J.$+QN/,$L0LN.!#I(JN:>'4A(IS[)_)DF3[;4X+"D Y1!G\83&I2E5
M_+?&IFJV^)GZ_MS=X@/JP<Q?XA7JNJ0@L4GM&T$3BU3O GZ)NU2_/(;%N<IO
M#N[B'D6KQ83X&/A'IQCX9(IIW"ZV-YZNW"6V--;-)0(W#!LRCP!G#3Z)WX"3
M^OZ(%F"/?E; 9V!(I_58!O UA0[)8FNEWC)&W V>[K0 I@Y4-%8"V?VD2@10
MW*>:&PWX]?9F#@#^YK6)5X&(GL<1!4! 3TC :]$G(\QC@^BVSM>A%NA7CELV
MBMW )^U+A]C-.^OE S?:@\MC^YLAZ'Q5[R<8+6W8O '!BN/UF-"4T#;3:5R(
M;Z+)1%!.Y1FWDB:L7VA-#,_)JGF"A6WW^H'.UW7G^Z9WW2O3FL_!U^:][EF)
M*DGS,6DQM^-\C2">$!II.$8\[9MKX)+?3CVDE],2;,K5']F!DX*=*+#UJ?D9
M(KSV7<]NU.+2XZ8QS(^\6F,//CAUGL%(+(O=JY]/)H7\K7M)9?J6ZLST6A=+
MK9;99K-0I>+^_>]I#]!;OID6X*IJ9QI-!$BIA\%(JLK=HE]$F9(Z7;>;>C*V
M4_N K@@YILUD1OA6:FZPUKIDJ,]R&#8OE24"T:10(1YKF6$8HB!KT/K%M"DE
M'-TN^F!NHO8)XVW*)JT7JR360U/+'@]9JM[(>>K;H2[F!;IP5#G\C;:9BB#1
MM4G!0;*]&:D[S*JH/JG]Q-87?]%&<C;DG-1@N2M3D.I5O$4Q]U7O^.,AO:IF
MP9 O77E?V.NR3?$78&FKE_N*_YG<%S=!BZ95VFR!=W6:!A2\*U:J3PK7YM#4
MTT5S4X)4.-&]F*W*/8 \1*8,$\?Y*A5KQ.]=7LFW2C[;7I2E@1<GA<V3@KWZ
MC>16U19U!MA>/$.E _?E!"H?@7_/>:0LE.;$F!1+I3TA;(6']*WO@+Q')G#U
MD:V2+;";(F7(:)."&;1H-*C.*(>KLE4^RGM%FY5XE47V1<5AY9LY:Q4)RH<Q
M)/E2Y<L0G-Q+9>V[2*95Q;MF2[<H7>URP*/R1Q;Q8"@8U.BHW*['5IY1>NL[
MB]H4#'U\=H_\E.[2'+&\6 ?&U,I.ZDI#H+)<78CO:ND:;:-K._A4'6"'!N<H
M&BU@DGU@?H-*L;TWHQ*O2#=O+7*5KS('9W?*+7K .6TRE>E=3+K,QP2&-$E[
MC*=\-X)?]3=<Z6"!YHB=4G)0@;=02@A@1^VE<47SBK+F^0WM=OGS1^L@N>F:
MD7Y8=D+ZT&M$>OC>01(Z.K!IH O[8-K]_G\(>4Z^YD=DDU6T?I#9,=GD*N'>
MVH8Q1>=XZ<UYIBY-?OCP,7A=^LRA+.33^.<#FS&"<%/_7+Q38%U?,I'IZ=&[
MG3SF1#$MHVVQZM%^X^1."O' ])JAD6?P_M+PX4244YYA<!"#2EL[$(#KBQ_H
M6TTX&-[>6T5Z'5ADSJ':>&;VK**]<=II6,4\:_5,H^&=F2SJF+BJ^J^AY5AB
MB6S0%:_*G>CO(4K34OIBR=7Q:>:+U.GA?CT:VL/ .). ,>[99KS RG+ZH7O!
MN6.=HBX1.D\*6$EGM=_ 9G)<\8O^&,K'7'7O/EI_ZG4SA6$1]ZDGC$D*^V1\
MS;H3&&NXPRGV5!EF<!<Y%VN;!>[66I4_$#XIS 0MJMA]3QA'BBF]("LV-\8<
MQ6:E]IE><M1QQXV;N O#'AADO/V!V7H*_[[G0=V@T,%Y2/T!"+1^H'233)X/
MX$O0HO)M;P<OO]C>[,RORKEG.B%(36TQ#@G>QRTT$(5;PR[J2T3*P I= H#T
M_*B=*X8XWU8=DNRVB5%$@[LGA?V3@M1L"VPK6F7:*Z;E]!I!B5-J@*%9PHSC
MZ],D+\,.ZV:"S, FK8/4U<M?,T5Z>8J/<KULN@U9#I<E3 HCDT*$Z8$\I*C&
MJ)>OR\DWE"M<4Q[I@Q1SXIITK@ILV&:MC6)+(%3]5NGI5:AZJIP]I4JQ25%F
MLTRV01XR*7!!BXK-QGV:%7,_&#B:Q]D_]#F:WRF;=%Z:YW')6E?-_;"E&G?-
M]T"D:D)K[P57OE)_FL*3WU'-LKDD\Y,73@K022'>L-*4,'=$KS1^S3ZD0QBW
MIFBUF49,G)\FUQ@;-J*N-/H%XE5IACPO@3)(ES1EOCQ)/6;S3;I4WCDIE($6
MQ;TKR<WS<HW+/K6M2^M<,M:Y+?[A(F;7FHC,\5;XDB#B? RJW^?$Z'=LG<NZ
M><T$7WO;_D.4;HL!(Y6U8;+)*Z*#Q='+@$Y8;NZ2*.A$6M#"?[J'X[<N^(F,
MC0@;^X(^'L0?=<9!?7Z,#!"NNOP<>DE&VZ-[)72NQ3_Z<]RB2:$9^%FT:?%1
MN&/.D84'D+FIVQ8<1+/BV6,GL>LC[.==P+\(X@^_)X5.#QBB41I="P;VTE;8
M[^Z1LI26+;HNOF&RJ"<2KZ*(A1*,.J=BP7P<-[5N; <!%A\][RPI-_S:\%.*
M?Q!RR)LZ,3UVP$2_X<KM.\E\Y&!C/,C56Z[0^@I-DX(,M)@[O*"?9)W]<&P'
M>46JT[S;U-RXOX=_THZ%[QT*9U0'8090S%O3F_K.L\FN!\W_<#,<((8(@<;R
MM_HU0)\4YDP* 6.WZ1W90Z..C)4I?XVD,5_$_36$8<\,WSDPSH$$B?H><9=/
M-_7F\WZX>?= !0,.^W0'@'0KB.J.)'KR7?P +0IOC>9Q#-G($357EK)[Z"2/
M$7=BT)K?&KZUOU10&63N'1363]_?\TQ$<H,;OP$W'5VU.HG2:JWR$[A\4C@Q
M*2P?N2A<F9TP'"R"IO0,D@&GN+7]&X!5X6MZ?XL[@N:;6R2ATY^9%H&.;LL,
MJ\ )QPX-73IN]5$Y6_IU4AB?%,C#@^#6K*^#5Z4U*9T#TZ67X[1]7;+T\%'S
M+MF6H"4]?O(:7R=CM_RWVP,]6O[.<5Q-D@]8QRLHLLG=#0HG!=^A-N63K&T#
MRU39*3%][U6J.'QOAFION*YG7.T4M-SDH 9]PPQ5:JV[IZY>17:<O,TILZP1
M\JNRBO^J+M@U&*6/S.+TC^D=4NQZ?^G^B:LS5^J=P\6F'?KTH)7&2'V+;[:>
MK(.YYVCI&I*3G?*^RF2MEW?*T)-""6BQ (1LK/?H60WS:DZ2GH##VJ.95Y @
MY EZ/WIA-[I5@UV//%]V K\/:YE!(P[COT1FD,Z2U-YG*/'D'[;YW%GTV+'8
MUNL=6F-?QTGH<<E[:'_W0T9A]RSD"10:,8HQMF!0$_CBTNO82N*9](WX>DI0
MQ":"F1;BW4^BTS-MA9Q]K-)YEHV+D?WZ=:U.&!=Q74<:CD1[ )U"&$6FPRZ2
MUC;C$!+*YE)KM#VM-]T6F\ HC4C',9G[O&&$YRR![08.F@L=^E+G3$)I?S3N
MIX2+7K0F4<]1MW64T\L1Z=!FQOHF<W<9R[&D"C'!+DVCH;,YZ/ S&"ZWT3L)
MW\/=8WN7XR,(&4RM>LH.TE#K7G BA/U-R[C3*;VMG[A/X06=J;SEC<>[NOB=
MQ>O@:0*+U%](@Z WO =U0FCGG8<C"6/LLME<T8'^]16IP *U<\T <$_0U# L
MGDX&6CS%Q=T=[1(QOM$%<EJL+@Z#'12/IZY%1(LWA N1+/$N;P +BG?8'6(-
M2D+[YI;^K7RC/%.E5TKY>77[E6XD4Q-:,0+K:_VB"&B@=2+E"XLV=S'E8:GH
M[H^R'>$$1+FLW7LS9J=LCGTR\XHTH=>EQ-\4K-A?<<$8R&NJG6WP(!YL>*_[
MT?6B95S[I/Y]1[CF8A$46JT^EYH-^TMU/YP&+U'-\'Z%L5,R[ >9";)WYNE%
M8T-)\H?EJ(%M7'/UQ?Y0HGO]SEY>%[19V'.EWMSN;4HI"H?4&M:G)G5]U)>&
M]W83= $^L6BLIL7^&6.Y M?3/)<T7BB/+\N:G\IY6[5MU)L UFT9O@U]V:09
M7%L_MRVI7U%DV2GH%:4F=L7U+ K? MMNFN:#0SW2'7"(8LQ1*DV["R4KBF2+
M2BN7ZCBDRM.+3A&<:^^,6T--C0?'RNKM6KDC(W,?=)P=\DA-@)KZ3X2?@X7V
M$GR&4'S#6H=N^@WEZ@$6@E7OKF:B&IL#!!!,8+L#>1;V#&0/[!!>TYW6D$_,
M1\XO\B#;8DZFI%.6X;?-9E.WD+*GX>@_R4/6A_DKZ$?Z"J#'.FR5VNY8:!YO
M*X+3W47<A#(CZ[N4F*68P/ITW$K<K;F9A-5$_)Q>$HU\=+8364D].:V!5D^[
M8C.-'\"Z:0YJWXG8)-\(Z47G<8-@&=@_"'#X"/X1%(_\3+*JJ\#D4[P*N3@>
MS2[Y'P*<?CYT-9'';)B62[G.<K7IX"WC_FDJ;XDESI%YM&/('NQ]$ CE CZ]
MZPT-"B'"-?3KM4R4%[.DX$\,GS4_F8T3L2^'-N%[.->GQ9)UW#*;>;Q,08=A
MK#&,:0+'6M:PCK/X[0_8=W%!D)6<HYT C,-=6+,)D<)C%B2A]O)3DUTQE_A/
M0\.PCP7<:94DG&"SS02W7W1*'U?7*YPG:6OJ$D4P.UJOB19@@SHNB5YU+(>>
M!))K[+K7 -S\'<AR8%O2"305>!T:@%&)9TPS$YGB]']WM\19>Z\&+>\7IS5T
MR@$&HOFWO Y3V!XMMVI_"2F3;:UFPLIEV/QJA(4L($F/2I'>"?5$-TK73CM-
M6"R=;_N,8P=^UVRITNCY0$K=$MU9NKP)KYN"EK;NUD:V5W5\T516372YJ>EY
MO[IOJY8E89!!RLEG0%4INST=\"\42^WFLHFR!>H-%1_Z<T35M4E],VB[&WW-
M=U"W6R0]M+93[>=,4ZH60R8,Z_-.P6[I44F=B 1=5F@6DJ9M\JS %ZN;[<RL
MY_+?JOOE&\:<A,8:NWGM-+<&B^$>5'TS=W"\#=9VK7];51O$L_=ZWE*8E=DS
MJ16.-XE#VQ%[C<&><MP^[8#=!99(,:;*+]NQY(+@2[7G(BI573]]W!;YH&G!
MF*G-J<UI7DA58&?+T+$\15?#@#&IJ?O/OOY0.B+&G.&Y$5>GA]M;L\(4^_4S
M<47U[N+S^+W-W@P>,:SM/<:=Q(>HVCGD:[#O59NH\<CVO$#:$HPXX13]%QX^
M"V0\)EYW\V(?(Y=:M8JF,"A:6^3;]F' #?T <H7V$[L3]A:U!X]!7&JK)KJC
MQROWD#;B8+F=E$["YX1LZBURTZPYM(/4-K?9K!":W&JOL)O-4L_L=H0_$D(1
MK2@R58928VXA 8P6[]N:AQ,1BRMN$KK(V)Q5I"PJ/GXO^39];M![RB'&);=D
MQB;F+FMOP4E>M%("T1%\^2]@J<0OE SX5O)N1#?R Q724HZ917M5X8C+8]!S
MK GES+_BRT@V[+B@K:1GG&*W/#J1\\H:+9@K,,E?M/<Q_'@JB([91K:#5;*D
M\!;X;K:F&8N:P9&5-V!P7'8V']?+:XO[0.CB1P3-(^;RK[J1:96":NLS_"'1
M51FS=2;_(+>@ RK $=]"VP0_NS&P]T)FTT($6_BH;!OJH:@NVQD;)-H>MQWW
M%? *&L7? HANVZB-P%F;N;S3XL_2V*9O4C@GO(TDI1(F.H>D1-A@5[.TJO%C
M]X0TH2P.J9)Z9:U%7P=_QBFP.\$W0?-Q:\"W;I\H(#AALX87"!X!/1IG:3ZR
M$UOV:MB$R XG]9.N1Y!GZO3&;M@:57_I042M\G,6$K5%B8A#8A8K'@>MPJY4
M]+O'D4_(3]M:<O6R&DE0_4(SB@5MKNL1X9EM6TR\KJK.E<:RAA==4D-H*1&>
MJ7?,2D1NUEG&M:(W:/V"CF#.:X3N!'*DJM*V@NLJ'Q!7UY&&[S)7-X4.,7!W
M6OL&7D//=XSTYS1HH,K>\=+P[CJS<Y8SXJ:I+ZX.]=18%G0'$VAP=%] 6J'I
MME5S5LOW ?-J^0L;F)Z-"0MR<8B696-!4&+[[I'/#9F0[4.W2][#>@<N9[Y!
M1/:]C:M$S>VM#'J/-IL>N1\CY>B<;7=P6N5WI7T4?KTG^QMU8;,# 4+[H^UB
MUT%Z'Z2EX3&C![:OY!;3A/3,>,]:A(F*F<->AOL[@,II)K9,M>47D@,M'<1S
MF=&2%82"]FA6%?$E!(%[1,;!.% $936BI7X#]0TZN/@Z/1K[*".:029PHG<R
MC:1+ 26L5,K9J6G<5;062Q#@<JR!RQ@9?!IC)4Z)7(:E$3HQ/I!PXAM<9]U2
M,HO04_2=\IJT.UU&@U*.1U?31VFK H(9>8RLJ2A.+E-M^4ITF*<1U2&C<0_H
MK6@IX2JF"KN0M+YS-IY"@=4>)<;2K(H*2#?I8VG?*&SFC*B/U',L88 5C<E>
M.%7/^LW99%4N"A7L%]SO;J69:=Z(E_3GZ%1T(3.J(PE;Q*JJ^89/8"/FSB?:
M<1AI$M)!+CUJ R6*U^D_0;G)#YKZ)_.!P,EJBY F^HL_"OW,?4;YT'V$]P<J
M&5G#[VIO1O/YWVKRL1J!?NY4/" ,2 L@E@O71$E)NT0) 4YDKFB-RS3&,X!I
M'2K8)+['@W?>DR21GW7=E,"037"3!&P;0MZ5F*H78UPD"PM[<3,EFU)/XB<D
MIZ/:B4S)VP!O4ADXRZ61X0[BK96"J6 ?M[K#2T4A_8(FJ+P1O=W6RLVMGQ%4
M969U(&JOXG1A+.:E IFJP=U0.$?E$MKDIP/"B67RW2Y&>J?<QOH&7RJSXZ#:
MAHP&4FKG2<-5^,NNC0;;5@H\5N]6M0W9KXLJ>("^K:U-[<#>T>BB$O!8]8N
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M<[G1PE[]O-1/0KZ^(IXL7*1W"3\MO*+[.I,C?*#;[PT5GM363 T6'59;VD8
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M]?\GY)Y=/%+W/1U<J&R2)KY>8&Y]%?5V[,_.J) 5HW.ZNOUC1OZ":Z8]'_Z
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M37E&A&$_SX)#Q/6N)L4:1+%5;LDX2=M@#IQ+DFHRX9WD;B40X0-E5]7*! O
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M10&DIW:(FBPRU<(1[4-QVNB/ODU5U1-B<=2?&ES\,B!5IA-O B?_HY.SU8E
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MT\[C*S3/ KN(3U9X 8;D3PJ_ <7_^]_!/P49'8E><%Z@W<=&VDW04G#-5CK
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M_*A7(4_>(6[/DMP/J6AT$)7[7*M>*;!PR]!-X]Y93Y)?96NLE@NU>(ZQ+QM
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MG$0F+(#V+ /V%GBX\R!ZC+DHX#]$SPQP28+IS!)+'13,'#[Y7I"!/3U(YYW
M5C1\X0:AT<I8]F=$CIT@NI'IY;OP$IC(;,'"X+FQGU!'2!20ARR!EKHL@7Z#
M"LMZ\!*XYD047RB,[O_"F\0_4<_EL'G^BJEL3\Y)5$U,9>-ED=@E(F'O.70
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MZVEJ1'54(S/?J2*TUCH]3$,V?(AK5;1KCVR?*OFE!'QPX0ZILTL1MUKPU7:
MF,VY8RI&8O&%DO!FR4 F^JH^HIM/Z:@V;FL[4%>QM'$B[;)F2\V[N$#% <.J
MT&[)B,;))U*X2![@$L/=(SI@VXN?XHZ:MB#+<+KPX8!7615\L7M]>0[I9%LD
MR3'W9.,HZ4OJK]HP\OW80L,]RNW@4UH:]9ZWC]*8]FKC3,DIQG2;Q8(*8)V1
MC%/ +!4:]SO2'6&++D]Z.FE]:R%=E;NYX17]2BJK!F)LC)UI6,6H"R9K1@!+
M[]F*=*#=Z5_)/*:_C0W_(?..T2UV"TLLB.T+A8:A[,X]4&(YUE(%3=K?V6 #
M-J7.KCX! CMJ*[+ G& [S7PPV>NF_""8Y/1(G EFV'CRW<$BXV7L2:"<+^G%
MV7^"[1TUA'W9_>:7>,Q^F_HBC)ZBJ%Z!GM[AIQ]%;8,>J?,1KE>3W 3^Y'11
M= '.M@GE54'_&(<0V1#(>]#S09C&^MTQ1S"YS+TYG&?8)ZV[PO5*65Y%XTR)
MN:FW(&X$B577\68OLHR#@4[CHLUHADTZ[T\DR9B''X/W\0)ZR'(M*[E=+.TI
M531=%$_D?*L+%UY(%E5^$,R+R=4I>$E!?JI03KU7D/0W\=&I1]B"A]HPN0?0
M$>.;N"D2Q%7VS-,>9$ZT6ZN#2^<T92C.YI36WI+Y)Z^II(@_Q<S7K18.!?Y4
M7N13O=9(4>YFIT;A!O9L&Q7G)?;59"4F0V=QGG?W51UAFK:=J;A04M(T17LF
M^WEMD:HGJ;IRGOQ.=(NV5;HLL%N9)@K:_$ZZC$]Q4@M&.4,V+9PRPL@D$C-"
MNSA>W04-0\"!-D;MSN*CC2V5-[*WUR[1>R49&9K5-Z*W: ,48&":XC^IR>9#
MDC;AL!,FB.-EVASDS&<[FC#0@Y@_&^RV;^MCC+5Y-!TOMFG,J!O+&J\Y6E6U
MN\&P4]\6=5_S6GTT<)6B0GYZLT@2*[[@5,K_S7]F,\X^R#$QJ4&SL2'B;-?K
MGA:&;>NOCME%C8UKFS.SHFN@NK'=089%59NB1)I:W?"VAXHXU?K->9*YTBJG
M;/Z <(/-278)Y[G).&J%KT;^/>Q5+J(8!E'2UOR4WFFDSQF.[=?)=?&A34<H
M8'A';2NU?.L"0Q6MS$.G4=(9#FPYA\&U/"42 [(U'&XMLP\I''6BCU#L#TKH
MSP[\UV/&6)A^K>T'PW/7]\:W#$EX7LU]8(K_O8IK .S!4I]A+G1@RT:8E99O
MA!,LZS77.==98_"]0[[04W+50"N$' "Z@R"K=%J;/7AZ5W>C-:@/=ZQ9#>+^
MG14K0-0C6[T(%#@0LFF@VFJ><!ZH-UK!,0%[X)21/<0-LFG_%6+&@=E=Y?C&
M=)O6;"QI5WY#-MH6]JTZ%5WD3^CW(BR/:%4._-6!D*;#)5:V@CSHJ]$.-A,2
M0$^'!P072'7]UGP@3]IYC&>;-MHRP+FPZZ_Z ;8AK+>J@V#YQ^L&\2P/3^4X
M%NW EQQ"MUE%\H\A(48ZXAJ<"9&'764ZDG-?A>1$GE&GF^A56G"+D7!V7%?]
M*O[NL*RJ!=Q1?TO=*HZEA[G2@A XR"5&^&0K.M\8)8S>$[:($_AEJ$_C57ZT
MSUSY(O=@QZ"<O>=QLUIJ$I=0)Q:]"S.O1 57_+YJ1;R#'O,5&DZE@UXL)>16
M-3P15F?LCBN1O\$#0X&&P^4AO3VZ+[DA'<&:-7O(S<9*A[A)=4MDC.WW*Z>+
M'_J=UBX2^KE_5QCQZAQJQ,LY*ZTF>$OP%N,2?#5*9ST=?%UG6S;1&U/U<_^9
M]GL5O7MF-#5K@W=6UNI5R[;+#0+99S^M1B,^[_Y,WB!H=&@257-E5@^YM83!
MN![KQB:Q=@]*FNO+@GJ^U;_=G]@.U1BG5C4%&5QWAM5Z:('M.PVVREM^Q1I7
MV3KW:_*M(H9#N\B/]]SJ"S>876)\ 4O&\IAW!C=W6I?>[6EM:=__1_NF!J_4
MJ,:OU5=WSJQY5J'9;EYQ75/D%ZW^6['%_;CLHV2Q0Y?P7\$TZYG<21PSX_?8
M2FR"^L>)(K)5@>LX2-Z_US L(U](C.KKI.R-2NFX374)/-[TDV;N[5-K35_M
M_*4BA+'&;KDJ UAE+I7 S"FKA;S3S$^4*\<+&=\*9H\1C(-[R4-5#$WBAMYQ
M1F>4?_M'8%)@>]-J(-?;L280>.O\19_#9-C9*T'6#/,3XCI6Z>J_N>]9;RF<
M8_EP6_[081'T8>_&P6XH(7%>SSWP2]3Z]J7@\<"*1C^PTWMM=3'8[_R?3@N>
MM-NB& "OFG\2/03/K+'G.H(7*6X39'9@?OZHG##/^._@"&Z4\*G[)[8MRJS-
M$U4%JAIRT#^\K:KJ$)KS3^T]9))=I&(ZC%JL$6V$9ZS)XQ"0EOSZ:*?@0K[-
MH>-\CXR!@5?<X831[@V<G,BOK05LWT!ZO8ZP]UY9^0BW=)FL-<.L['+DD>@Z
MBV@A@+BO&6%?A]/)QX[.E:T\\/Z0F6161O& KVA)0D$731 0V=<RP&L(C*Q[
MPC7UGEJYCEWE,D-S@%AGQY9IL2$+H> T&F?T%]L",2+G'8'47@=:1J2*K@SW
M_C:9;X)]YP/QETAZRTKADT#;N@#^"Z\/!A[W7Y?9ZDN<:7:ULLF$F<51@2,6
M:Y1)<)##Y,5'IE3X'L@8F:\-2/_:;Z9*B?^G<[M<&QG8#$N7!DZO[135>/U=
M\4W@ZK)([<^]8#<N+6.3+3[RFW OHWIB%AI*.CF.UY@<6#7,,YQ*[^Q3Z>CQ
M]1U#:K_(14T?%5NW/:FUD"9YW:PH$)6Z&*F&^5*[AY)/G E+([X3L<3H'JY'
MQTFT\<4-W_*N#J^LM4TOZC.OS(C/[?#6=47\W52N]MIVLJ99_M#KHOZ;A.6R
M5A4L7&OW4X)S7UKZ\<X39XQGX]LP"Y+36'/K4)YJZ&!C2/J6WJ,UG^,WM]\T
MG(\8;5JL?;:MJR9$M=+KE%XC"W)Q4KX2@?:+)(Z\>Y8I/"8[W7@]/@DK?CF9
M3"G]X]I#\N^R64>Z*+3R/SKV4]Z4W]294]-(-XC[U!OD5V4D6B+E:?HTVM_4
MBQ%Z>@ZM;[,__2&=M-:-D<Q(>/:XO Y8=^4A*1&P&CM-G@X8M\G)!F"IAD)Q
M!;SQ Y0S +W4E;H/:-CSGC8'.!D^3FL"_O;LH6\&WJZ=3;\ _'K24V9#++@T
M6CX5GS-ZLOPLMJSE(JD<=5>])%LC FPA^1;\7\E,BA".3_V7&@AUAOVD_H"F
M>3K3ZL 8F\?T*!;G<4?)$S%^X7SI#6'5R*>R7O[E9K/R IZ-,IODSNG^?]K3
MV>%%_Y OX"]3YU 4&!@61DU"%VT:IQG#E39CM ?@KX>'2Z9H9Y[[6?)9%3/L
M5WI#WM,H*--+/>0_R\M$GV&(M$,P5OB ;,^3I+A2)G/V;.^B7".L-^50Z]#W
M-L.T(KCDP>KBC%KRV8R2'97_#0Z4NNKY#49EDS7;9)UE#Y7NT)[R8S+G@M>D
M1K%;<CF9+7#;;D_)XMIOLJ9N(9QL+M+F( _OZ8K.M?UW^EOQ6%/3P?22AKH#
M=?=+R5514G%9LKX S"P/5LL+5I%<Y4>2+I--Q*]#AR@S!/,]WE"><,)L'E%[
ML+5WG8LR!DI.Z8ICNW</+"_9U!936U<ZNS%+4E[ZH::'55#VP# U/[K\O"8^
M:3-I1%X?NHO<('KE,4(1\Z)LWE/WX>&W[Q0YC-T^&5"\='ANWT3QN[[@FJR2
MP0ZE>&>IKGDELZ2,J%4<(,J+#?-VMY.2U&6A4\G!THL>$HJ?8*O-+^HZ(N)6
M8]$?I[U.+"MZ='2XMZ*X[Y!7=50)N?^8**$TOK,,4);Y-*_(NUMN65.WVYTT
M2[\F9)3T68%Z%))_BZ:O_9/RA;WN9FWAE2O:XVN*>L^F]G06X\>,J@I*MAZZ
M(>27FO8W,9Z53>O(RHLJ>]+P(_%&^;'*\A",U*UZZQ%+/B%FKUU(.<=^>+<8
MN%)\_705H"^==+ 1()4MJR\$]I?/E[D >TF6T"0@G;R]0 B0*<G)<P$-=6]H
M%3!(R_*(!L[1@ZP1X!DCXK8+PXV>=Y+%V$!7];<R'.@3M?4,=_I'204CC.'+
M,C"R&/K\/0PYXVW2 L9YP"/D 3 -8+C? 38 K=:%0"+PXF8P[1AZ^[B8]A!=
MW7N1/@G)J?Y--X=/BFWH47 X,X$.0X\.A-)/0D6[US&6@[]"G!A[0,2]F%')
M^FF=PKC'VG>=H$X(WDT\I+[CI_4XTY9S'U91:6X<DO 4K82]";"E#1.S\X+I
MB[%[B0GT0K0]6$$_@Y2[+V.8P*[6$8Q\\.)5->6A:LE12ZJQ?+"K@AHCS3?\
MII:+MPA*J(>$7O3?M"7\H-P(&HF;D""C/6+G!,^A!^$'W$[3&]!\ZYWT7_"F
M*U,I)E4+Q^64(OV73B-*K^9UA8SR4/F=OY[J*'?_/Q%X$F#_7NHWX=GXA[1<
M_K(@">TF)]9-1-^,JZSSZ4)$?8E+KFE>/;:1_*K>J_T"95UUKGXW);FBF[>$
MTJ.UH;ZA+E=6[U-3.3++^ #:-%%UD"V-Q%_NEDJ[S]9:PW1']-I%!W)(C_GH
M(S+8CK8)R >;/ND<R._K*-SIE) J&^H42KON:LXMJI4*W]5'K9$Y!9ZEK1)>
M<G.F$5S<6DY[B+T[_X8\963I(2W9H?]2:S@YM4NJG4Y6MZ:SOY$_-H135E)B
MJQURC"@G]3-WK:<&**\$DJB')&*WV30/_A[K.IH.?WYNE'3\V!\CY:1_#B]O
M<2?_-;A>,Y6\HV<;>Q&YN2V+'$69V5"23:>0JW+C!BD?M6&!CM0#<E/7E]1/
MPMG67;2]Q.#93I+TW#_#+%+WB?#F.-+=L1:U,WGET'0BCIS?$T-J(Y]J!;*^
M4SSJB+@D2F<%9=M7JKTRV_4<]9"(;#U,<V=G7WB*5A4=/>R&C)7,:M\!?R_U
MT)O"R66!W,_0A?)\ZFTHF-2XKPA\1+ZXZRW(H7P(%((;:0M==[&NT)=87F65
M,K:>&T,LJ4\/.< ':)M;BZ!3-*[V .1/N\(I!<_2MU#X8!)].&<7.)?AN&L.
MZPRC:MM+%@;,=_G)\@2R+&\Q7P"7S_X)W87O#I=#/G!\\PFP![JN?@[Z0_'L
M%:S'T QR&HL CV<GL+:#:-P6EA&X=5LL\Q_6#Y<69@>KVO(^,Y<5?#H"/,]#
M!Z^#?ER?I@#6,?9O%<[:2TS@#UE+\2%2-/,,=B2KE&E S^[$F2SD2L!%9C)\
MV26#N1$Z9OD(^ 56GZ2Q_I&''ES'*I5Z-AQBS1*[*LV8'4(?K)*YGT\O]V+:
M<T]E"IAS.*MBKP%?B>R .. >UNQB PPASRW_!0CH]_$WK"#]BWX=\Z%V9?UF
M)D.U2S[&M)0WHYG $ZECV3J@571D;SL@$23$V@,P]]76ET >N\3Y*Q"*?;-:
M!"Q"8H[E,6_64_I<F/NJ/]>^94XU4&5\H%FW -D!Y*NNEWH#7O+ZC-> C82Q
M0P,8"2.V<H#9O&7.YQDOB&=6ZQBM*#0QBXEVS.QYP9S3?*?F(*"O[Y#F W[5
M.!P#S*@0E*0PKFNT&6Z,"47SCL6,0Y+.K1L9;8(VYP:&B#-HY<O8B8F/G&(&
M#DBZ>X CW9>K)<#V]NF21,:K)ALH@=%:6U",,2B&@72,D:7Y'"-@I"DL_.\Q
M8L6!SBR&+X]L%<.8BS/'>YD+QVRZ6@!LZ'25$IC5%RL^P*CI& 411EJS?]$Y
MQKK:D;1WC.4&DQACQB)UGK^,,4/:Z9Q"_R&89;6'?I$('KL /#YYM/,J$'ND
MN_(LX\H(+&IGY/3;LVXP+#H>%KG37S;!:67TJS53HH_2+^KV^R?03\JO. ?0
M)X1I5GGT2N+MT3)>7^'7GCZN5W%$S07V_1*QM)EH+>V&1;BL[$4)#\-)=AEN
MJ(2<&',*::; _CA\E-J],0_ZFW;7PA7\P? 8IW!W4"JZ;G-F4U=4+R<N4'')
M"KR5^A*RPQII><4):#M]<KH;<I;.C9D,?V8L\OL-&S,T&]=#VP$CBQU@'G#H
M\"AG,63<Z4 \!D]5(O@1L%34B1T"C5AOT/.L]T7;D.>LJVG1R%^LWNA(.(HE
M]H,A@G7 Z1-XE!5HD<]ZR[(97<E>RBEI;\4_L#,,UM@#(E98AC[#0YA7T9E8
M?F$TLA&MW8/"Q<C5J$YH&)GD]Q<T&;9U.@*&0#LL4!83+!M!B'#)V;:UN)MX
MLGX(6R_<++!'-_$90">2R?U8$ MK.*34/N@)\25J$>2&Y_MV@##ZQ$G!NHBD
M6E2SID,3P[/P8<VOE@ZL4P7H(M$VQ0S>(Z1?JF-PX"?B]/PXV%CHDO(<RN-/
MB22#XYS3ON'@0H+O5,A*Q'9;3#!Q9-Y@#1Y28]6<C/D:OFJ7HEZZ"]PCR%9U
M%YT'ERK&#]"@+NFM%!=HFNA#Q+]@DF"*SW=6"W>A4R3S$^%D\8BY"MUX<!?V
MN26\R0Q]VD!1OT+NUM1SNN"'AFLT%;Q0YY#7!$6J>,ELL$;V+**$]5OL[E//
MBN1C3O9,-?NUQ7=@%',?L,9&>\H;/J.5'?-49Q!>LY9=!W/KC:A-T&#5D=Q;
MX"?]WJ3[8(CJ2_A[5IV,XA/%_$_XS>E/9A!78CD?*,17]?W&X&%)_7,TK5^I
MO(*$=F'$*!S0FDBY#14T;,VU!ANJS9-"63]U3\*9K 2ER&<ZLT/B[?B,.94_
MQ]($<,3O]+[# H[JZR>CMJ/3E7.0I0?#B:GP[.Y]E(W0QE;!?@684U^U^PIK
MI)(;;LE:K4G=<HI9(O-V/ .<$81;KF?\)*C])V4S"M,:;<3_%AU5[Q+^*EG,
M\1(XEFZE.?&(,B1O*^=5^:7DR>PT\JSP%OPQ9<L6 LNA AM$Z&3:&;-&6,@(
MZYLFN4!6US-%CRBVRG/"Z90.XC)_&W4MY1VWE7HDUX%C3#N09$S4TN>$3\:=
MZ0U;UJ 3C.T;<I%LQA>SV] W8*(G0ES)TM0^%YY@%2D2!--86W$>+YVU@'R)
M<Y\U=;\[.XTU:W<L_H7U9]@^3,J:XCV".K*F; B![[)FF4^'REBF7;=$#02G
MAB]X@'?+C?BVV$VLE"M!OY%N<8S0X'VI1#?2E%B-[X)_;7^"38'#O+.1%LBP
MP0Y. W^;VT-_@*F=><+'HL+J]8)U@O?2RSP6/P_=SGG%?5)^F<WD\'+HA#$[
M(.$?[ S^;GLBRL"DWHL0>]1SPP+H"?S!/!9D08:.9<*=*L_*R_Q6Q5P)S)LI
M?8"LX>2+>\J.LZ<*^[(5>"W_:((3%LL]'GH9G<D^ZC4*]^%''/Z%LM$KYG36
M-_AFVZ#@H^&]0<H/U!N+T[@&32B\C/.'LK3T/J&0G<ZZB'M*UL:+T=="(#09
MJ>)=\"J'(SCF#G?!G[C0O(*%(F];84%C0U-%+N_?6G=1*#>@<@SZBUVE]R_Y
M1;BJ_\E:@-U2*'?]B_*EGB'/D0#A-2\[Z .OQ&$<K& [F@^S+-"G+9 @OR-'
M'\]K;\D0NG*^-L2 *]@1-8XEJ_&'AO6981A+NW97-.JJG!>R'WXC>;+Y)J03
M'':H!$,Y0^97F!>QD>8B@>? <MTN7FDW* CD]+==9VUFSVI:4!R'*VL3]U9C
MK@9]W#'D'\U(\"^X5GYRLQ"*%=UU@,#IO)7FSYD\O*@I4S![M%];SO,?!/D(
M!^IU8K*)2^TC10-X4E/XWI7HUYJ+<3N0U@K+X#HX1[5W<RRT4G+083_K+'^K
M^5?F3N+/YA%M3N$R_0J5LJA2N%7^M60F:"JM+/4L62S.+6-FV@K]RB_%O>&O
M)2\.;N"NHL1Z5K"74&OMS^'KZ3-,-Z+>#$.3MV83>9*V0\DA=_,_R*=18IDO
M) <I=XM^B214>*^7H)RV.6X#;S_M1; 1)YNN\(P@]C,B[4<P EAF>@!1,Z<T
M#*AMF#Q-@()@&GB-LB7,"N"L^!X3*)HA/,G$,[+YP\RJG0CW$+,WJ)I]C'G<
M<P9^B?G(OA7]S)IM6H7\R0JI3U$%X-/4,^7M&(/+D_JA#QB7Q4M0DT);X3R$
MF][(7XC\&?N*:P*3@ES8SM#?FT[@(5""?05: CXR/0\38&GM%Z5 0%..RZ?P
MXSE9$CUO#?VLJ) S4K!54,3FI#WFT8G,V'".%'<./$*TH3\VH=AQY*R]&'D+
M]YI-@GY!%36GE5/D)Q02&2*;S?:56$E<:$>$GT0>^0G\SX*<M#6\R;S:'>V<
M59S+@9&$"_%SDS^V';>W1Y!<M,S,$<J'#U=K%#K]&CE-9J09)/S%(RIOZETA
M(:\\(.034H<]A5R%:&*'%;M3$+7M#7Z&>WW3+/0A.].> G_'%YDE@O\B8U5,
M141MOJQ0>KHJ%P\19U1$4;X+;;6+\T[RURI_II[@NLI>Q^C84>+SVW \3]#D
M<19E<OGV.;"2D)@Q0"Y:50DKEK:T2PND>*,-%BY>4<N@+!'<K*S+_<&[HGN5
MNH)S5[TQ9B[Q59ZV;16^5 Q[H*@-O]T^&O9A_S+3@LY8IL$@?]3]7L*31K;?
M0HM%=YK5Y%"!K-XB-X3'K1I+87)$^OAH =&L.A<PB)V4.7D$(O>$U?:;H2_<
M+68]K%?X[(H;\KXA!_$%J5E?+C(N:NJ$20V"Y)9]^P=Y4?5Q*=,X,56;HFV)
M/.V'@%R,JU!Y+$4JQ;OLUT'#O BS$ZPN7%SQK/K?0A.)D4%;)$&==+G%K\ES
MU*12L]P_%+5E!U+,I+?+3T1]%)N0EVT=$^13LMRN<4]33ZVS8\?0_8RO85<8
M[_3U56=)$M''"A'9#UFM+2._(,U2\2G0_C7RD]1-R:G2.;0_HA)%2;3#6^/Y
M_730K8J[@A&]SH&H!EQ,5F&F3&]=4N4%8$(XI#< ]^%)&A'P3_E*91_P:%^8
M[#?SCZ0V221S8^1%82LSR?\[?P&3<"OFD)ECZQR)Z:RY)G$HQ"K2.A@^HU<$
MM;JS: HT73V!W"SS4;Q#/',$L@#X6-)L<0V<$ADMG N]]J_C42"*6PC['VCQ
M.F><"AXSX2#_@83ZK2&$]Y*/Z2RY=\$9:E/.X=(411B;DWU*VD P=Z>+Y^&L
MB/,".E;BOYW[%DUW6\U.0U+7N6!O8(K)460O5*'Z6#$N/<5#M742.]9<5:V(
M5D*7GQ5T9T^3VO"7)!X2\;G,B.W\W^R[?N^XA82+ZS_$ TRUSA5+1U>;_(+/
MPHW*YQ4[- U<F7:3*I_IHG)76!8?E"=)Q[,2) -B=J*#R%B8%'Z;+^*;^%5R
MIW+NNXX1!43S.C?T%:8T=8!#$9GBGXH_JD!.D^9Q10^P6WE7>[GHD^RGZF9F
MFV2GXL\$O7!(ZAV>Q5\O2O/;SC'PF:XB8@ZG>9TC"N'?3..ANVBZ8IK^1&,4
M>UQ363>-05%*JG1%UK+FB@5[_Q/_UM0D3!6F*#>%O>!=DO;ZON$$B*Q<X_ .
M7LTZ"]2*'61*@YC84KFS7M1A1'S4Y+0$T7N4.QNB"HMDF34.>^/%O0:S>)IP
MD791&)4'*1[XJME?)!6NYO@>0>&Z9<A-3IZI$G+&FF6 ?G??;2)(X]:51E^J
MM&@]7?! YM X/^.FF%RS.WZ^X')%=9@ISU\]YAO'[I===OF*FXDFK9N-J+GI
MINW@%]Q22F^N*XS!:?67BU2T_35+BV\6>!G(I0LSG+2_RC)V[5+AY<>W.\O-
MR&8^B\43%,C97U!._6(SR$VALXRT1 #@*:$WP:1 3%QWE/2$*JO^BXSGEU80
ME(WI3.TJRK>X<647]6+H$5D<K6K+6?%D.LG9EC_(2+:YR*D"XHU>X BS7%S6
M* !L47'M;<"-TECE#FP]T*5O!Z+3;FFV UB<J^(=<#XT05K!7+B%*XIAQCDO
M^7^WFVW^9G]C+3&VQVZS%")R0R]R$ZFKG8FDD"]7YL)_Y_W0/8.STC:K!?#\
MG1T*'V@BY+/D/ZAP2Z2P#UKM/(E'!F_8?&9G@IW&V5@@J!,6-TSGRN"!FB0.
M0OIM&&>7Y_GHMA"Y>]2J5SBZTT9>A;6&""1IZ-$M\X3FR,V-3[G/X=]KIQ/G
MX4#C!K01JA TUM,EBZ&GU==%9:0-ALV"V[FHMH_OE_J?*H-[*;9:OI*3%V(C
MODU\\3XIT.'TC<>Y*=CBM4N)S<AIXY?H3%C&/U(_754*K:Y.4X25,RJ.RRSV
M/]'ZB+^G'E"^%GZ/=935"/X,OB#.Y$WVY@O6LK]N;.$\QW^O-<-'L+4F9@@3
MR>,]J6NNN I&5T_5698=J\A4%^[?HKFE&$BYJX1E:W<<E'F(:X(+13^%,[U#
M^8=YV1O9'#K[YEIK/!S/-XE&YJ)K>6OJ"NH\6&C5X>KY99,J_JJXN8^C ;7R
M%!^EC:IXAXOTICPN>(9(*S'R^LE/$=S9F,Q9S6U>:XZ](@PF%+@9/</=6>?<
M(F">JH(;'I5&Z6_46N6\TFRJC$WN5=S6:6,.2W'5XZ!&4;#\3Z\!_ERQV487
M]BE^U%HC3,UN,E'#B5@,1U_[N6N":5L5W@:6'-77-CGEY*I_UUY,#E!H*VDQ
M:=)M.JN@)-$,99,7DW=*:KEQ"1L3C*Q=B>WBL$UZX%78.!'<G5-XC[&D[5+Q
M^J+K37M+\K*P.O=2V>Z,JK5E#Z+H>B.2S[8TM0E9ZYDHMZ;\VM I=J8=L$K@
MI].?K:&S-0"$UW1M)4%T4NL)LGV1?V,^^7+F]]IP2DGB\\H0JGO44ETP;<&V
M9:I(VG-/1]DN^K$-+:*]C XK)D\!5*ZY1)QCMF*/.X. /V@'6VX"YH72!B[@
MG9E?4P2$)Q8;R@$LLEL+ %<#SBMY3'//65(-LWQ#P_^Y?=6JDON0Y6VTAEC!
M&L+F=^Q%(FA_-/^ OQ9\JN^&Y7N?5U? YHF3*IJAJY$[-(.0(H"CN )%;WHJ
M>0LMV% KG 7>MAKE^H(C1LG_)W8'&M5>RVFBAC;[L8\6A-?](J[MW5'U$K^;
M .J_X7]&O-7,Q7P#_!3VZ(%-(Y)P1+M!+]@/W[2ZQZF -QK58E>@"J2W?99H
MD%+5U":,R*^JR^7?R1BLVLE+BO^MS^1.CT#49/;PUL]R-;%WDT@\A,_9(.-?
M1<>M?G F(7*CMY@=#,*_VH2*3O+/)D?9:/[\VM>2\0R7RJNBP7B>[HG@7L0Z
MU5?^_*T]\E5<ITW[Q9O9T1OX_!TX9+V<34*O&*]'=4@0'-SFH%.3=S6>TE@?
M(-<RE0WIK97I\A7Q*W2%DK[PLRI8E+(U7U;/_[S)1W22R]G Y#U@.UK;LO_
MOAFGHQ;(OU!5ZY/J(E)78[E!GG>SUD)7F;[:\$O-WZ75S514AF>I5DD/;365
M>8O&-\T5I?#'-^SGE7*N6+L02F*.L0 YA.+@OZWJQG#2LL;UM6_RPFIN5)6F
M:0T-^GN[UFL[-1GA<Y7CBG?^=Z5_2U,]'HBF"4]OB..MYH59>Q&^Q#?C;F0?
M-@4,:XUL-R[G-[QI7I)[NT93/RG-Q9!>]3CNFC9'?SML0DE17_>ODVKEO1[#
MPF&Q:$,@]S)?8.V/?V,?-KZ 6&-9C.*AA**:XO=]*XN?Y)1W_EFZ-&5RBW?9
MNAW'Z@7E>2$7JAZ13OH<UGM2+%VOJ<14U#Y:^HSVUL):&,Z(6DWE7 ".,6P'
M[4E?BVM[YY"5.>LZ%E*<D_N;HRG'=T!UK50L1%4U@Y;LH]&ETC>[GE1V,TSM
M]TBG [,M=@L*@=>K;["_,._3VPX: 0N*[7OF !NS#[4; ^')>YMR@:0=?K7G
M %5(1N5ZX!\?DI;/W.HZK'C*K+7/EWBQ9EEP^&VLO#6V;'?67?KB 3MD:E%7
M]TIX,#NIS0%.3U[2"$-?8G[7_ -UA#@:PB&R3YQF&/)W[5!80POMJ6(N^,*B
MAS\9/+>FD!""XS1=_R[VCR*WKNULNZPGK9E$9%)3PPB>&=-08X55!+^IX*!/
M?>PTDU ;5X.\!,FSQT7WX4,6#W@QL.6:0_@CR$"S[6L25A3V=-8*HK*26X[P
MOB9M:%C!%<3X58.<\.!*_3/VZBW?U4GX(U>>[!+6:"\3;4+IEO.YC4BVT7S<
M"2ZDZON,Y&L+G3M72'=EOFAQ%5-W'ZOG"$71+ZO^Y5\-3OF_P]ELN:BZP"ET
MI<L"B$'[2F$+OMC2C;L<Q8UV8#K$FKJTMUFC+>CMJ%1%9Y8U'Y3_MSNY_D^I
M(%I2523>&;Q&=T.X;DNM*I+WT76_=((S9-\@M"-DEG$<!28TXF-&R 1%V1MJ
M>%>PJ6.3/C!S4G.P!DK\4"=0ZJ(]*K_*'@5=UZ5)7+:4*V\)RUUCI>&\?OMF
M01]GKF4AQQI'C ZA/6@H97;/N[JP_"/M]ZO-]JJ:7E;<2Y3566MI42\KA:HM
M06KM3_G\+>'*,O%)5S_)2P%LWRJ(X298(NR3Q"ZCIV@2.D2F]6B:Z_)WM8OJ
MC^_=UJ2O?IX87'O9,#NJN7*S-BPH1]NBU&RQ5UI*K[@Z292BA?9M@BF\8DLY
MF\&>83P=78XM+:X_0BE9DR,Z-+?D<4K_@+1T?*=]]_RRB?]Q=15Q;2P.L^[N
M+>Y%BQ8IKJ50H$#1%H?B%D\VR6[6LG$/P=W=ZN[N]NJ/>E_=_?N?O^/,86XS
MOYG31+[HJZ=/"OK::<-(WC"S>92YTSFJSA589?U'.\BFF<Y2K.<<T!.(/H&S
M2)U'MC$^%U3M^\;T2C^XDV#J$NR'%[,,(I_W]K!N!WWK\ .&-\QO.LG6.F?4
M!G 0&S/-'FZQZ6;Y1M!;[XUH(;205'S8F=M24+CW-I><WCA.YZ8G& TMX99&
M3O2,<?N"OK9'@=,V+&V\!Q8ZE]=D@+=L@M0/H"!30D:%ZO1#A:'0'Y+O(4,T
MHB!TSV%D)!T=RT(<$^8,SH;/1=[H'H!%09_:-L+;-ZQL^ ]>[\RN%L K;#+4
MAKP?IONE^WD/]94"#>\J:?K!C8(;!3-VWR>.I0>/,OFGMEX>L,)?1_9T7<3=
M@FZW%F#"#0L;5J#_.A.ZPZB?#:1*1UI-OTDG(ZOTGQ$/X*;*]@-*V=3\MMV6
M$G;:XY%#XKE;F?W%PMV1>5W+!;*@GI9!@N;ULSZ=O\U9H9N+!]NT*SLQ=[/U
MDDVHMX$OL1;)K/3>?T<]*W_C+D Y/TTQ8BBWW.K8=U::$FG;21$?"D):%HD\
MO%[5'19T.^NJ2@DCFQ/*>7B+69&X'_,UX//%Z*R*B?W>NM\[ONQ\K%6DA0T3
MZO7QK_J<%!\C/G7<EST-2F_F2/[SNEOG*'KNW*R]+WAN,Z'@\'^8Z<06N+7!
M2?YL5%O1NF]O_>,=@SO3:I=N_SOT2[<IOJNW1J.,.-01J5H8Y-/T25[O=;&V
M4VKJW*--$'7:3I+_$(28'1'U\*<8_,1KL"45D?LVMW3OR!__KS%G^]$AN&YM
M?&6OGNYOA*K]HG9:D'$35Z7O=:S63;[6>40S(?&R72D7"0O,)D2A_+V&EG@
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M_7?):NZ9+B+O #>GU21I-]>HOF;3"<Y3W20?6TZ'LFC=6TZ1^(>Y*6<)?WA
M3W:X^$*3EW1U:;W23LPO3T)NBM94O*'B@J,D87XL0:*L2S[!]Z(>B;#"%]"W
M>!]&GS->.1#(-19A0H7WL[?U;9:ZDG\W-(D/4J?+#XD2J3]@D> O[1HEDSA"
M/[DC@2]FG$GZCA<PCVV28U&L_=X[T/7 ?@<*XLC>:[(+-N7<[QD2WP?NU*\4
MX6Q'68)P YO.BR-^L0?(6_C7.5/RBO$Q3F:2#];&V;]I-EK'7>V]"M%P:0[9
M<!WWBLD'7A48T+U,=!'95=LL1)%TZ2Q!"/P+LB>6P4)2#/X#]LZ58T]Y/Q-E
MZ"O>8+@$^<[+VG %F<E;X1 /KX'.FEKPC"&\$Q=^$D$U+H(Q(2K>2W %;' Z
M?RN16QF)!_-).:/8!ER4<!^-Q&K"%R#Y:.L&#.8B_0[^/"U\P#0.JN.=ZW 3
MAJM6ZB8$*Q2 B,Y_+KO.>8(?DAI41&/C8G[V/^BH\%?".N2L(&^C&'[)/[/!
M YZ*.SBLY:U$ZTT!:#DRJ^V38+1FI&J,$.K*A)G\;*T)^Q7NK3I:3L(\%%BV
M(>HCB]ZJ15(D"S<:PH#PK-<GGH;@.RR#NO!$TWJP"35M/2$(;@G4J@B#QDQ!
M//ZYKA+XAEVHKBBK1\]IA5GYR#55Q]:I\$?Y[K!^>)7DJ%<?ST5XR?XG%,;_
M;+H/],7T6KJ)W]WC&A;_?$<L$8;7M]P IF&D1H_2$VA9;4_F$$+5K8XOA%5J
M<I@[;X_\L-<VZ*9DB?U=\*T ,+W.?85];I82^X:MU$P^T>_&WXXG=INS'+&U
M;<]+YZ&F30.92Q#+NH*XIW"P;F;H!5ZA2NFU'.+++.P/@>W"FZ8ON!UX7Y.
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M;E:8LKTTQMD'V2'*_ 0+=HFL>Z.&W2">V)#(/BE<XY#+?L!/,;W'GD#5;4W
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M+?N)'947S]$:_P.-<=.:RO$)[B?5./87G('?P]:"BYB7T#QP0<D(,@":98S
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M>2996=I2$"A2EC=L.R!<5MD<?8_H)ZL#/_ 3J/CZ+?@,.F;]$3W/%!F^0FJ
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MH>DK6]VP69K'.4&_P3_+F\3\7N7"S^9,R\0%:WF6,>]$$P2VBY>)ZX6?'(7
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MU"[16[:S<(&8R=E<NT'\CA>?]QS0\*\DSP9#A!6A$/A<],)K'M0$)-M=@]/
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M$YV]8'UW(#XL#.M@".8+M[02=8!H45-[X4_1!M.:95'B./V:&+/XD:8[, :
ME7KW5/ /F<;N'U!!-K<I^5VKL[2^@HB5L[#S@G-]V_A9POANS]H+PF/M[85,
M44+S]_1SHG_-L3&A8D(/!4X&'-1;W$. _?)O=J_ !*JDM9L?OG&3IH;_8.TA
MS$; 6[6+MT/P9D!?FR!D]J07_!3^U_XCG2W2-FNB/XG]3'\&W!9?UQK<W0%4
MZ6T_ IPI'=NQ0F9?OE<_49I2548H*;SFF6 W>;(^LNX^:4DS%3D2',:+96/P
M^VR/Z"MX$;?>_QUVG[_)=04F$+ZW&8O]!92U'2#?U1_6-I(-M $\B'C H/&5
MQ K6G[57\//LW841>#J7DYZ!W>([1)=B3,%%_]W8)!'I6H1N!MQL\M!B\'WK
M'&(Q!]=,QZ]RA]&[.(MWE%>-_>:?J;F%M0KN%-"Q0.&7M,WH _&?45]0(^#L
MKT+CP5#7:G0L%&<S@!R"RYJ[L5W  M4FC .L1KHQ1]">NQP] <JJWZ)\\%?^
M,.H,@6FVR%OH?50+<A2N]"]#6N!KKG2D3A)I\P0)E&QILD$Y6+\R XW#]))*
M="K&X(0AQS#_ZE$(B4W+>X3$H6]3*<09/1JU")F!-OI[2+ZBE:XTR174U]9>
ML@8=8]Z!9,NO*,8AZ?(@. #QDU%L/\D/Z;8J"\E)ZF.>O:25"DQY*:%(5N01
M"4CT^[V5U.'77"LE2_&IMID2>RS)Q)(0>@?9/0FIO0<MDG U*E::)%%M7;E"
MXJ3<ERN2C%84IU3#7V5?(JO@+U*EWQ[X%67G6@Q?)H[8HO!:O,&X%+[17"B]
M -]M1, 0^+))S^3#FPRRBA:X22?/N0W#&EGR<QA4 9$38411XT? H"S7-0.N
MHPIM!^%$@F:(A9.ZRJF+<%['=" %SFKM80S ?LWCRA_#-N;:G$1XLN%(,A.>
MK)L2L1J>KD[TBX.G*^2N4?!DZ1W;H]!',D4?"?T[6$J^@-[WR<4H]+I;37\'
MG>LH*D^&=K?:9I^$AALO)X^'UACI$=G09NU7OVG0=I7"=1&T1^YK>Q?:0$W2
MI4*-:W-(1ZAGU271+:AUT)=> @&]M++S4%VG(KL"*F@U+=T,%36B$;.@*D/Q
MX@<039/HZ@B!BA6V_T%":L"P2CNR_&]I@%I2!0"-*HO:28S5BG_KB\IWR+?0
M-F<_DJF8?R[=( 796>%<"N"V^:I(C/]JP3>B0Q1C=0H_#!S7NZB>UB>0SY5K
M:<O%' 7)\*?WROG,^V479#1V6[:#M(9;LM2&XO MPBU(J>"Z+XWH%76YS,3/
M :76"_!14(RV1YG,;B44BD6<7Z)PN1,ODM8M<^?GE'Z4A@J K 9JN7!54C,I
M%%T..T&L!$;Y+L>O@XM=W/ Y4(FU$,N!>S0KY ]%U_$TV0UQN]!*>@^(;NBG
M?@*'2VTH6S S<Q\9"[Y-FD=((3P,QJ_",WV#<6=XE4LXQI.$6>]#CTCNJL?(
MUB(_L;G2[:BK8 QU 0VIWT"-0!>4I) ^J&/F-*(:79C8B.]%'<)<<7MTON]L
M#$5GNBQ%KZ,SK'^AGNA\Y5YIG_0\\H8Z)17SOI/?I6/JCI/^5$DQ10C(DRMJ
M\9UD4.),W(+H#+V R?#?/L_15WBE2QH:CUVT"4!:L41%&W5:LTKR@AJE/L";
M28:IMM6-($@E5'0=OZA(S[B&V\N=$OHPM?1]*(F-HO;X'$8;2)7+<N0$46]3
M@UCA67(-96OFP1_) N,O;B#19:BHC<!?ZEJ+_/!HS=6,=*Q=/3TA /M3&1D:
M@,KD#3[-R!=IETL:DD<^L=%+-A'1,C/9VNX$3R"NM09P"@G+9JL:%*\S'R\T
M8D>-C.6G,6?]U/A3:+NF;<D#=*[*RJ<<4<F'7&(E7Z1+;;9(<L@9TB[2M?<(
MY$74=Z>S>_"-'>NJ;V._6L\43L"*FFXOST,/F^[%T]$0_=]+6I&=F@Z?Q8BW
M$G4)E@S(")OSDJGD?FHO<6I5',@GI@TN8D_ <WL_5>=@@UU403,VL>W[LM\H
MN[DXW@%Y:>I94HS4ZR[[_"EYI+9P\9&4R]4V3^#+5(KLC\;1Y<^@6M/8*A6[
MUV!1.[6Z6Y=>7U[0IC'0]B_;K;K.=(@3*(/9G! O^3#WB'>\S%'@Y'2 VB8R
M60Z1V: ;M=<TMWX$F&:(IXU@;= IZ ^KCFB>,[OS;ZF3V77++)7KN>%Q8Q4N
M_,G!'V3K!#>\(Z3!HJU.S\F;0*/59$(&&4F&0<5Z!=CJ;G(RF0/: &Y?Y6/U
M2MZ9?#N5M6!".JYH$J;%ML@7B@S!NZ1'Q=>]@Z@:T,5Y*CD/$EJ5XI?@6\12
MO;?P@'BB5BG2,?K47\3)E6-5D/A%7IER+-">]DRN!G-CO62!T)1@G/H [??V
M)=?!8F<O@BX)MEJ#+T8FX!:Z41*I\*.&+CE"7Z=Z(7E;L4B)(&-RURKF(*YI
M6;)U2';,86D#(@Z.H8*05F\[<A1RT#D>/X%\L'J'F?_?Z]^:[]0HP4<U3AZB
MG5+-(AO*:8HMQ-?<<?(<PI!Z2OJ36!231_V-_QT\@FS%<[S'$C78>^=LW MK
MLO9"OV")R"_- A5'\)=JMW(U;9PR1W&Z[(ABI/Q,#E^V078U=86T5/H@9@3E
M2ST-.DI.)5]ZO<+O$U^<*[%A8J9U!<K!HY"I:MAPD1^LFJV7-<0JMNF<RJSD
MY9J.[&<R2_6\E'^I:TI3]""Y43$F2$H89"RO,W@=]=2Y#@L@>=9Z=!1A)?%1
M?6F9S2M7:II*ZF&%IUE:RI'=,$+9>=)6?4,*C2K49D8GD"%JEZ!PPE;QP:L7
M^RX[Y5R-GJ?V66]'^H@;<*9*V)7&[53.[9A?=T&^MW5_R5U9=?.BK+M2-[,A
M92+YR? TZA-Q36<9^!O?IX[U$F,="HES&2J6WK:^@F22(DBF&C% XWQ4;.IM
MKHN3EW2M*JF636PW9P'4Q9;JY)UD;^/"J"V$U' H\#3.T*9YY6'+E9^=BU _
MV5GK-\AL\CNTO\.]8@;G;NOVJN;:Y\T)M9.+SYCOU9=E;C&2M*-+C^B]F?Z1
M3,U7MC' 1G6!^]9CL6*SH,QAHVR]Z)%%/W4(E(+KVVAU)]F_6B8U;*QU:]Q.
MUQ3;F !F?J:5(90=L#11^XMK$VFCOLG[Z?]+>5SPKT>T?(_HHL-SZ3'@C.44
M\@ET"^AM^9>5RQ[3U,?>4K/4W, =4U1E#.'%K,#U?_*;D\YJ_A5\B3BK^D>4
MZ7];<56\W2-==A=T<+2BOD$FRVIR@62F>'6S4G"8]5=CCM!076?R$N45]AEF
MB.=EW-5^%+],2E9?!4Y$B)7_@IW^N^4_(:Y'@<P2SG!,I&(E(9;;" 3Q%#4V
M5<">3'MS*,RL:C7:P>L+WNK_@E]F)&C'2((3+ZG^D^@CG)53);?\]?(EB+-'
MOK0&$3G2R&;DNM4(_"H:)1QHS"&R&,FF%,*J\JXA%K]7L$P7@7<L/Z0)PZL2
MJU1+<+_PJXI2[)M_N:P1V^N13AW%%(XRXB-6;A6#^V")@K_-4D4E764DY6LK
M0_6D[$W^,:U,YKH\3:V7UB=.4+91Z\.-\I/D2_\0V5C2U2.."B:8CEU$'7[4
M"L(&<6_^%]-M73[MHN&6UJ.B67='_2E_B>:A:L.R&ZI/ROJ$U<K)"N?PI?(H
MV17_R5)<2GKXD'NH<,>U^%OR3ZNUF!?^E1]F2FU<1)MC2#$-E#_5I1C'Y*W4
M+--'+RM6U6O%"0D*I7I-V$_9<>4QOPO2/^0W/6:02=)?CAMQ@EIB=04]10SQ
M),;=[6,:JO6G6D>4)VLO-SW,<U3_8UZ9_D'YT9@7_T%AK1\5MEU6HJ'\VJDA
MU0CW#\0SN=9Q,^XFC;'ZC(K(8.X)HWO/D?KS^IPNV[)S6E8[)W>WFMFR,[U#
M:6Y\$K]._K=I?!@BFZ+[ZL>BLM3WW&\0;8HGCENP!S);ZQEH +F!T]=?6X'5
MU?=$5$\L=>OTKA5E7VV+KO\[M:FY@+X@5FD6,IN7!!@VLW_Y?-)^X]6XVJJC
M!7?L-B@:Q=GSM\FF@;?9QWIWUUVKW=,UT'"VI+5]/7US=D;+(R:2NJ!I#KLX
MUL\4QTU=,E:OXX?XO-(\%'J[1JA"Q.YVG^3=H(.%HW0A;,?ZT./!FEKSL3.<
MC14_:ZOD/,@ZTCS$<T_98G[&E\?<-KH(/H5<T&&B*I_[ZJ?BVZX%RG0PUWZQ
M["ATSH*@BB4)+*^N6P*;&K_V;\)9Q0&MGL+O6:Y-F.ADBK_IG'A-#&B8"S2'
M-&DI$/>YI!X-L5QY"@2NM*^3C9?D65PEUR/+F:F=>R#/:F[; ZB[R-!B#X_+
M[&S$X+SD0\:;\-X8![VW9&%(B6:-1.MS4!4@^>Q*R0\@5?8MTC3DAJ4S\0M=
MP8 [=F%?JHZT?L+^*_S5'(O=S[0SK\'V).<;IV-]T9=U;$P7XJ[^C E\AI52
MK,15*Y^)I=L?I/JP>$L:L1Q+I!]NORMKKUK8ZBJS+Y0TX=*F%5M-[ZF/R:,,
MI51AM%9[ACP9_%N=2_KZ-"O>$!VN33(),=7^(3455UNNQO?C-G3+=D?-PDIC
M"U\=7O"]\1]5Q(HX4[S2>>F0?K]B6G2B-D#V,_BLZJ3TO@^DJ*".N9JE7\GM
M]C])#;'3\@X>A5^GR=I(8W?%C^:KAJR"AD8_W>N,<\9!;?'2>/T"]=FHGYIA
M54BP616K,/ODRA_*GKM*I; TW6$*:4&>L9J(72?$#8];7[1,JJAO3FR*SW]M
M7F>NS:@V6AJKDM[I!O2Y4;LTB[7QP>7*R^I9/@%RON*VJT@Z6[;;80ZQA]IC
MY8$1Q.^&^-;"SHSR%TWGVC[ER\SA+=J,&88U37.3UNB6F/11I/JR871PL%*H
M7>IC(;=6J5WIU"'Y.P=;@BG%K!*Q<+*A=OOP@\K1I=9#<ZM%.:I^6NVMM%_=
M[QKLXIL[&'0\G-ORG/DEP+D1X]1[?C<Z\!XN6*(]*"RVN:$J%I^8=U\>#'G4
M6J\.KOM5,C@H:WB;X][[F7XI;:C+Q.R*SVAW9I/AL<V;N6# 7^9,/N@U2?]+
M2"QHT*P4*VS=E'F@>'ZF+!$NK9$.#3 ?ELP=F,?.R5[?,\#9GQ;?F<&;$3^Q
M]3\^$#ZC22/XZ/_+%"H"O&;I/@"3%C2IUX)F6XZ""T^>OU/*EPBKWZ],YO<4
M*_LN"H:RO;IIPN[4FQT+1$C<UI;S8E;8U48.0/._;UP,,KPL=",@_H(]JG,P
M9+M1ODH"6$RC]B&<ZOA!#W!%T8_>G>##K!U=!5!EJJ#=%CH?5]5\&4X,ZS:C
M\$G_XX942;*7C7:!Y,*".ZI12*[M2]D3Y)Y%.34.K:P:&EB$'B@2]YQ [V2E
M=O+1EZG6;='H_3C;YM'HXS"&:1?ZWG^#7HW^\G+0U&-3%OQ0)F%6=G:R19B7
MQ7KR_ZVNLNY/D(XHFM3]@5J3^:%C'16?<J$5)X_'/FQ*)K/"8DQ_$J_\VW1/
M",S+67V"F.<R2S&,;[=+E9KQ?(NWQ$Y\:F5/GTBUH+"MVTM9DVEL_Z PIJ M
MI^6]L?V-W;*]8;.--.EM?U272GWQLE/[4C-=G!069+ =6SJ%:/@_FP'XGDJO
MWK_UX84+NP"==>;"]G#-_12WEKEJ/+;8_%GE&GK?<$EQV;]$NUM.]_I+-2@;
MY^(N-U/K[-24@:RV7(&?)-(KUO3:-886[.R\;5JYXG1;O^%K\IUF2.\9:V^N
MTI:%;C&DJ9O\([5ARHU>8U6>\A,N7G)'Z6>[7LJ#"K<4X2SB5,6"'GW;I(+,
MSISFARN0-N?&'<D]3;],:,P[TUM#7*A6_U WR7^AYKIZV/.;\K0RV<5'=EP^
MQ6X3>8MZ;]F$NY)>Q76;SU5>RZY=OZGZ8YI\6%-G%W]A945#641>GSW]5)!O
MYU764I^1K7V<RVXC&P7\4L<JPU+A?>O9&AL@9)ZE8CDD+H[=-+=>GAVQSIKF
MD%:Z>C;]<OR&@1_,@8BXGM/LIJ!%'09NI\]?+57\[6ZNYC#A-<<AO97XN357
M/1F\,,\DSX8[B[YO$+%LLCZMZ6!'IMD.K>? \43_,/=>A'NWDI\?Y-)>)'CJ
M8],<*E*XI9CL 3_'^[KIX 7KHZHY</R\'S)0,E@$K9_"-V4U#\<)EJ?>7%DK
M7!B?TL<0V42,[\H2.P7-;O,"_'T<FVS!%6ZU1BM(Y#13ZP@WVORAC)2TS\^6
M[D$,19/7/@>N9T6MM@<#4EL'$\&5\?-Z<R&O\ >=B="AH'&M;G"ACVOC0LE(
M-ZG!5S+DE*!)0%)L,A1<Y-'\==0/E%=X><T]Y&G6^%5VR)74DH%ER)6XIST-
MR.OP0QTUZ*S SRU9:)S/(G,N"KH-Z*O1+4Z &D6?VYCDF[%Y\W]145AB8<OP
M _)4YKFA8#(NU;-?3%R*V]_=18#A ^T#1&#@\^:._W_, -,@?LQMOVX';G!:
MJ;J*%]F<ED_%%UI$DGWXR,+4X1$*5:9F9:F\(^5SWVK9P3A#US_27^%DVU-I
M6N#5IM?4L$^ \2<UVNVB;B99Z'1"%4+LM?DN@PD["X"TPGL*WJ\.T7IF1@P:
MU4]3MO=>5ZV+*^D:KR3"B]H6*NH#]S9%RG-]/(UYLB5NM[0"J8W30^40]8>M
MG?0'.=9BF%A#+"S0KB*,ZU9\'+AM&)DBZ770E<0M[LS07 Q?THJKTP('&M<J
M+_DX&<XHHMT>:M[)-CE]4[I+%]M&2'7D<8N+1!K16N S]&_3AQ6;!Z+-QU.6
M]6B-V^*F=1S2'PVW:_FIO1>H;URL_NUC;2A0C79[KB$5$YTG*T[(W&QSI,%4
MC<5[8BSQ:7]X'5'"7U_8$%=>U:6BO:B*UIYC5-7\0J8QW]7+F-5L@CZAI(_K
MP 33'_!.L9]%1@C$O*6+ND2+!"+[Y\ HT?D]EZH%==/7+JU5-OS1<;@>HX_0
M!-)2&(_@38S9K+6,6.:_'&;Q1O96GDNZ%5?'OQ&QD4\7XHNRA4GB\?8_Q8%
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MXQL.<989?]$;N!I2Q7C/VRN8R^+S']3L9?\23LJSX;:(/)8"_'!Q:NA?@@=
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MF$"=\NK2/J?F+[RN,I*5CN7R(F*GS4RJF)AE,1K?A>NR)O4J-42:?Q>D9B2
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M017FM@W&UHA'F\."#TOVZ,_\(7 UD.,P8!S),+C"4RNOH+.AY[5AXO?0Y0:
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MKZ&'NO^E5D"WM/H8!+JG29QW 'JL>N/#@>Z1JUV4T%E":3<!VH7SN6U09\=
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MZN#L"7LI6<%_Y)TJVR.Z:O\2N"=].V"B>-21K;W-18URHI\FH%9*]0R(9L]
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MR"_GVT.+4[7"&="#J+/BR;!3("0=!C>Z=\ANP$OL_8&%\ .BEEI*.,AOMIS
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M%]F4P'N@1TR9XHQTJ"D2])-]JGP)DO+;A1AX$5B:9:6T530G/E120/](N?(
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M#G\KUTC:$%/^4-ETY&/:8OE9M"9.J>2@5\.<U:.Q?+^_0#=VU3T!S,>K[.]
MC_#GEL^1+$+&S^47D?H:1R&-["Q[+DXBU^9U2 >3+6GILGTD'!>J $E^V%!5
M!,GP^Z'^35:Y%VMVD'2'(1"39%DYP8](*6\=;[BQE=$B<#?&EPE%+H;+>>'B
MCX;0M.'2T_JE<6/D:_7C0M\HC3K([YNZ1OO4G:N9KBUV< &_4R>LBN$&*ILW
MEO.Y2<$8S7=O7%<V1!C4<"#WK7AL_;+4"]*!=8VQSV2_34#H;<4'8YG?5]4#
M0ZB[!CBAMW"(!Y?J!ECA<()V!!?B3)TYE3Z/5]JVMW2S0-J:G+M%E->\.G6E
MI*)I<NQIF;1!&WI6 =4]Z'\#; IWUP%RPWR'4K!</]AJ,3Q*NX2'4!8%U?2O
MY+>2RE(=>:@B/->>5%8]2]E&YM3,C5&2T>S"X'=D!G^(3STI%NUR648NDN&V
M,>0]59QY(N6F^<E-P5:7CZ]^@3VG*4LZ\(GT@SE)N$7MR^1?> 1G:O03G,]/
M#YZ+KQ>1/F+\C_2@RVZB7#G2%B4. 4GF*TE/2,&9"C?3=U;U(?:U,XHW(G/8
M!=D$\H+[.KD2S1 T1XO0K>+PX!S,2_K.IP3;J-CD<AX/4<MMM^!'03?S7T06
M?(KU2O.*XT;[#*[G-11]A$H%Y[/N0,]%+Y*NP81T>/08Q$KN&3P5.:$L]$E"
M<;7.Y2$V7;/3]@'V!'IFD8+7HT.8S]0=(CW-%M!).$5)&KK,,RL#=)(?3F*!
MSY754;NA+O6 H.=P/;#,)P;A@QDN?]$4Z)N=&6:!K+"8C=W$8ICCE.V*N94U
MJF[E]\)5ZIWJR,RSP J@-&F8ID6CCH) ")P;=!)20;T^\3  OW.U1Q2HO5T^
MRL;R+)YA,;BB-EA^#9Q1L4UI!K$*;50)L'UFC;H WI.X!:A&*J/B-7QT4- F
M4(]N\DF$EF.UKM'P7MS"3HN<QB]:>J-["*H&D>7CX@HK>3?>6[!<\0/_FSE,
MY4A8)4K5V41,U!0 (CA!\S3=1(=/*OB:..E:"MN1 ^PV(JEDJ"4'S2*EC!?2
M(7J;\CDR3#^I(%A^4_<X8X=RO*XN,4Q5J@N(_*A>J;T;U-B_,QM]LL LK;^K
M&)I+W;:["%^G#)9SD'=4-*-&_+I^?;F3%*GWR[\I>U;7G*%1N)IV)HY5FHS/
M(Z^K/ADM@RB ;HCSR=.<T->XDI"[SF#W%D:T:RP/(,NIE_2GXN&M \IZ)6N:
MO^2WRAR:+F0DR7F-^H07BKZ&V,A#JMJZ7T&@^I%IA4^1IMJ8XMH"GM._M1\&
M!^@66-Y#N%J0_LM45W"H+-KXHV1!W@QC9@4G[9M!76T97Z0_67,Y_+X^D#TW
MT$^WG5_BN527([9V:M1^E;VU?JW=H3I@MEI;!\+5;_1)9;]*Z?J!M-+<J[IE
M])5IF3K;VKZXX]H>CF4XI*WD,P*^:2>*-G@NH*[)!CEU4^N4-!L_:A:PSGPX
M98+N5CV@\NFI)1254^N6:TL%LCZG;B*_<)?'I9,G!+1P.W*EV#'@.-DB_>@Y
MFZ049YTND:1ZK8V G &JS"O(E8@C[1;>RQ84]^#/N#=R,/R7P#?5$?\I8L7>
M)@9)EH9=),;+G@0L(3R4OIZSB&PUX?2. #67;!81&V%K\^7$/32=-AR5";'B
MH>A1L3C[%39*FI:R 0N3#XNE,*'B6%@'UJEJ"M!CSX!BS_EX,.CL/ 4W0I]M
M;N!WD(/F'PA/3%Y9"&ODR45\^)MB=[808:FL4S*0'>J:V$AT'+ AC(]R-+\"
M /0<E.NY#HN!USC'8IO10;93<2>LV"(>K\=G5LP$CP*/"Z]"+,WMK-_0>_!@
M\E>8#37%_(5OP?2P)*0 "0T0(+=0,\^=*!_]Y<Q$OV'W;#,P/7[ PH /)-K*
M7V@RT=K"/' P^B)K+K@*HR5OA *QK3&GH:/X^#!7N J7!]0B0_ ;GD>1342\
MLQ8M(=;9:M#?Y'B+ U@3*2WG (.I[05W@?/4FZP(C4X[.%D"6E+/8SK!D]3%
ML/&0EMH74 TG42L\+R*CJ'KG1<AI2F2["*VCTBW>85Z47]DO59_Q>P&J/F8\
MG/D*:#$*DR,TWH8',:3FLZ$L] ]X2G\AH ):J8_PO .3NH7.VY!2[5_;O:B[
MML+2#+U#72SK5#YJ&EW@HWK9F)JY7GVT09(\ 1#4 S%L34H=$?H.##;5!Y1!
MSD;4\S$\R<!Q/@;_T!?87D5NZZ(M0]"%VJ+2BA;G0N\\N.E-J5GZPL9-%:\2
M=C:PJI=$7J^/JJT.]JYSX7CY5IGL^5_==AL]Q"<=](9$^4*K]7JENM+,4G<$
M_% RK^%]^;3<*PU#:(WI8^O'TU\E1-1-9'I& B97CB+HC3&9?]0WV2 1.[F=
MT*^0-3ALT[U0OK3ZI$O5>)EIM ?A^.*]=9/I$W-M3>S:"6F@L8OU)?Z0X3UW
M2Z25(5* !6W1-XM+?'UUCV6Q;E=TR<H ASYM#V!F':"- 6^;G:!N(\JBQX9Y
MK%<Y<L,D+IKZ3M_ ?Q>?IQ\H"HTXJD,E#4&P]K?LN:^9EE#FN?5I1ZOW.0ZA
M5H .UCRJ"!:8CZ<FH?5%KKIJP;+L6[J!HF.ID+93<B+NLS91MBA"1[U0P$%%
MU$P5W7<\%0EDN7TB7X%1C@'D6MC)>A6)(9_-:60YMK302%7*)F=74M/E)U+-
MJ,'*RKB-Y"'5P8ABLA'P"8HA2S3+?">3=I"-^T3B+;S D4V<0L=;/R?V85+S
M#<06O*O@+;%179GUG%@-+$PY0K1K]L9)"3G8%>%#E$,;@KR(1'BSKQGA@>QQ
M]R*FH"<=9Q!CL+,V]H0%WFO^CG FEA2(\%A8FT7AZ0@M!<#3T<EQX7@DNB!B
M#!Z+N0=9XVG8;E\;/!,O<$_"\_&7CKMP)@';Y..-Q$\+=WP#*2T8@HT@#%DN
MV!1R:HHW9D6JXT9AEF1'^#LLC.P)FHS5D#=\73"2_.I>A752_SCV8><H.QL$
MGT#96I3B:913_CRD3Z_.O( .T2].?H-:ZN?&/D =]07A-] R_:B@L>@BW7Y?
M'_2JCNFNP,;K!CC^P0JU'39+L/5::PL<^T+MR@^$S]:'91H1\[IKR7N0]+J2
MV%ZDS+0I_!C2:?P;-!SY:\ST#4(S#:2[#IVK7^LT#7VGNV"S!ZO0OK58A&W3
M!N4\[!A:B*;=G65=JDDX/2.^LBQJ2:N&/BF$:CY2>]=_>9,-9[OG[@94T.$R
MN.ZY1&VWVL13I%DV&(>I/TQ;K+\%5>74S+A>[I4F: NG=27P6U8Q;*+RFQV8
MO)#<QA6<@_[-#3X"%\_>NMWB!2[.I@+Y%+O[QL$JT/*J_I)FS;0?NLOP@NR]
MK0.J;Z;>:UY=\R;^1U,AZTG4@,;!W.TA%O7;!7/]E742<9WG89.+K-DESO!,
M.=M^DOXP8+0RTQV&8LW2M*^1?=E3FMI8W-2"QAKNM'A30SA_>>2:>G/1X. [
MIE\2F7^!\;[LI>=^PSZERJ5$OU+]USY&MQJ46^5I+\,]9LU:!_1PEK2!RS^>
M<KV^4F0>[UM7*HF-Y)IH,O_@K4:NPL<_P:!6!7F>U*N!5!=(AX'E]FKM<KC(
M:B;U!74SNTFQL-.9#^M8DB<I@*E-=BGNK7&'HCTRRG!#91V\R#!,O=D_01^B
MR?"\KRL"W[NLTH)PN_T6:B_J8'6#\L7JS=W(G?CI3-C8H[R=XF8<JJ;%;3=D
M MLBI^GUFLO!#;J+X&__!)T#[.WY25N!<%S.4'/11?9/R:]8K_44TH ?-1>0
MKL3Z3%=#*MB=_%"_ KH<1^E^P2<C/NO2$$,PK.U&4_R3M/;8&*^1E J[YO*!
M/(LO=# C4XA\ZS3B _'<O)-81THS[NFG8*SD93HNGA"7K=V/OXBXK+4DDH-%
MU")BF7\:Y4G\]K(E%Y(%KF;D1'*Q0PJQFKQEK2'DY _SBT0"99Z!:Q]KAR97
M:=.TVC@[:K/V9,0.RDQ[*IA!=FD/^6>19=H=7H'$8^U\UU!"J94Z2 @G;8CU
M8F(X]<3\._Z66I$QB3IL!).MJ#RC+/87><F8'+&,3#2\"RXE/ACJ_'.)308K
MKW@B3S_3-1__K/OIT(+OZI\T]^'=VM469O@ZK5E*XL*JPKOQP^8]*>V-W#5'
M53D_I+1C-)T5,&'F.F:2]_BV0NYT-YOF;T(?Q\K&M5)[F[OUI.*C!6S2 KII
M7H9;T.'D$_/RREEQ/7/&T(Y%-K5?9+B%Q,]<P30&3&P#.-^]W5LR!:!;2I.M
M9*SCC(;!\H6V]G7CU$,M3AC308?^GW81_I LG$VO/A%7U:ZNV1>9/)-B;0JQ
M;".X"P.&M6""1=Z!381XHQNS 9%===Q?5Z_\:5MA[ 4^6XXS!$)+IEW4/4>'
M)+V;]8;Y)?;]S"#.@HBW;1*^?_"#E@YAE__CIH.2!&_WAK>R^V[R^G'*F8X/
M3-% M&V+82%XT#)='PW_-9NJLT)_)N$SCO+'QBYN\Q-61&QO:12W!1]HNB)=
MZ7^CT4U^VCN@GE#^=FLU[0<BG289QX)*V[/Z%EAOV:(K1\O,Z-H*[%/2F-9'
MXINQ]!:A]%S$@J;'\M7!6QN3E33_N_5[U;;>Z77AP//^\ZX#W.^4H_\#-]A-
MUBU&IUO>T#9AR\TV4NOPQXEW6OP59&Q4TQW5A A]HT)M#%Y3_Q*X[?^@C@3#
MO:M-=M BMWN&#F2L$ZF?BLKL<K47L&U69M1=_(39.VH*L2/Q<--FS>!8NT8Q
M&!TA;#"#*H(7U"V'"_T?FTJ0?&^Y<3*:[SY8OP(K=MJBB\6S[>JU9H2[51Z5
M1%PW=R4[2&GBYL8:I#IV<(,%2H_(J3N&A04WF=C8;?\GQNDX[*TWC".FN;OI
M]A+KG9YH-:2OW2%*2LZVTI'[R*OFQ:0G-2Z1:C C-L;TU3TFBR."32O(Z\&X
ML9!R]W]J"*.$WNUZ;VJ5>ZKV*W76>2)UEKIG]XE\2-VRVD3F4%WF"'&9FI&8
M5/= =R5FI^F6[F>$@W&G?E*PTJ#63_-_JA?I!WDOTP&ZA^X,;8FNTSF(2M;E
MV%N2<NUSJPO$%RW+?#[10OV>Q2TKSEIH?%2Q,N\ES*MR*PX2?Z&_+U?5S*\]
M7=5>S&=OK]F:[L![SNZ*'B1*YB\,*)1N$I.NT4ISN:OU3 !0/9HQN'!<\47]
M^>*OY9G@BO+1M'TB@D9C.##H]&U,K(C#M.#<3ROF;!.X1TD$,C';_Z_$7[;8
MU4W>I^RR/JI6 Q=;GN8PJ^?JAN=?KRG0N!8S62.$\>63.#WT(MH-?FEA Z-+
M^"MU%6NCI"GR+>^@W,R_6W1!N<)UBJP7L+7^H&H#ES8[9"1PIU!U.6Y\%_7+
M DNAMR"NQ$'L5$U49$C'%=RJ;I1]336OO:.X'*GEAJLV^DN$,X 6UZ'20Z#8
MQEQY%,YIG)ER6,HD/3+'R(ZI]N>6*VSYZ86;E*RJGC(/U>*":-H>]=64536%
MFN&14>SW8)A_B< $*5VM)9_A739LI0<ZH"$\\9JF G^79@2'*-=F^X!K>+7Y
M1Z$TVI\2#+J7OZ,R U:FY#/,D6&1%JS7R'Q_%G\G&N%:(JE$W]J<5^S!.NL>
MQ=<24['S*06$N6)W9B@QE3LO[Q]B-*VZ> #^(S^Q8C#^.&4D?2A^.>(7:Q1^
MTE_.'X:?<S6);^ ?;3T45829Z7ALMG$#^C!)9)PF_Y)N,*@XGW-FZP]6WB_<
MJ1^=]['LA2X_^7[U5.WBB!_,!.JC_TP>ERIRW2MFDS=LU8KQ9*WQ6_2,EBFH
M;\*UIA_RRC3+QJ,<13:]05II*%A?;Y5WM&R Z5CRW:I,HR+2LG:.P<'_-/>.
M[H;K=_$@[2K;;?)SE,XHB?+OR$#6QC?,6B"[G_)FQCG.J*SJUAN5,?EGFY_G
MK2Z-:?R6_)"VHF%(9%3MJ+I_ @9S>49;-Q_19GV,[7/Y7"UHG!IIM= #28[#
MYMV4H<E?YHC8/9F-[3<JA^6;S\S*:RWI;#V0_)1FV^P?658SMV%Q@"]W3-TD
MMU*1V-!A-U$NT24T3JZZDW6%**?OR9^D[*PY7IS+?<Z:6FZDI7,:JI;EW>!;
MUNQ/CA'^9!\,/R$=R=_N>U9A+U[CK%+[R1E6+:"OVKON2]GAXD:LKC*F[*_"
MHNHV3<7I9&R@OZJ,8,YCYN?^X2SD[$YJY]\3C _/$Z>)&;[-LB[9)F>E\J_R
MFM5%C9]FE/%C44[U9.1::1+CK&QK12&SCHU7U7'B*](8]WGO<\-9><+EB;^X
M'R2984^$&V0??8ND#.4"9X7B%>!K/1;( 8\9W/-4G!"XI/ "+T^J*8T0L%EX
MQ7:1HEQ9+9(H<NIKXV7R1 4G2"$*,PC"5#Q?!TD ('26R;^ 7.LXM1&NU:W*
MMI&X0F/R+DA72*J+FN5FS!EEY0JHK)M6K;R0_8E!JET31[-V $A8)N^[YHKO
M-+$W%.(\4^X!+[)N4SU'!VFK,A+5^S0?<[*!#K&XH%K#K-U?@H(N92,J#H /
MLF&Z.;0PH9=)P65AT[F?$ M?'U$9\MCYO*P>W6?]3:7 VJF<U$-8L&9(U@2,
M+5J8Q\-::D<47<0VE*K+<[ 3V1.K;F&/$K2U<GQ(F"UW N[E&R=<AC-<!LL&
MX1MMLE7C\5\D)WF^W@A,SW#66PF?Y>S4K:Z1%M)T;J6#RT9K5V4=IQW6.B=4
MU^BI-6'VG PJR+=6.)@\[1(J;2)QF]G*/608L2CQ>.-2-9K6V+!5F)&=7[^-
M\:W IFY1R>:2SR9#UL+*RT910CECIZ$H+(J]5!_K.T< Z0)<I%(W;:C-9:6:
MRL;?)Q3-;%<]2(V>,5%P/,NM%6',SI_<?+9$6C*FR3X+KQS;($NH9$RHVQ]6
MP9YB&NU[0C#24.FR5')%M\=VF#)*&X8SXOWGI:N8*7YSI@JJ,P/:;S%2\\)F
MMI=$%6>WY6=Q*@0MXQ*JZ'6-1\,4K!7UL.\[_B93L,MQR4S#0%L?Y7CM=RV'
MJ<QVU;!8[_/S12K.PF*P9AZOL7Q.R0G!PJKU6?:B8S7'XF.E2>PS(;C\ _^,
M=YQJI?BTXT9-EGR>92O4IU:12ZL7%&O4=QE[RAX(76H_T[(8 #N?WE-\E7N.
M:9/)$+ XS7&;Q7'\#R%VLD1QB;>9,E&VV_$@X*C\9?D(O*^)QY]6)%<9536T
MRXPX_B,Z5ON7SJ_-9?<6?6&'\HB,C;SIPH0X=R%/,B3XA&2W[+C7)\5 98OC
M1;49$&/E#0X WV Y)?W?5(XLYW%EO%Z:G#^C6DZ?)]Q2Y%Q[3WPJ8S G4OHX
M=@W_H/QOL$9<IK+UNBSK Q(=[ZO<08:56!,!:Y#SA;ZB5_*3);A$Q=U9?E?Z
MHVIF58$<*90P'BD^I6M8]2I1;!8O6_TL.$-DIQ%X797> 3\[C5'28,*J%YB'
M#H5GY<&J$-GV(B>U->=<Z05@".U\I1YX77"-GJ.YD#Z6Z09NCYW M826!L<(
MS> 97I^E@Y$&ITS%=K31VAFPP4P0EA.(5$B/%TQ"EG&&%']'7M+<RI^AP06%
M54]0;5IWS5OT0LQ=SEC,-7BZ(! S>(^7I&!OG2B%.\ZUUJBWX?? 95E^VDKI
MH+P8[3_L\J)"JK=R<9F:4N:_IG52GFD2QDWR4<P!MCVY(CB<+R9%WH'B562,
M4X^\BW2VWJ>N),>#@S+8]6X23LZ2.CKK?,$#4W-E<*F7<5/^\DJ]X4I:"OVI
M_G?,+E:1WC4XGW=,5^A=*W;0&IU>RC.IX];?U1,I<PTG[7OK&?'=[(P6%:LZ
M?W7SI(J')5,:E^<+*V8U1*1YT"WK+L7L9*XW<8,%O"C#+^]FT3;]+&<SV7==
MJ(V[ZBKU';B8VC<[6,S-"FWW90W.6SG3NV))L7^;3WY,^;F6T+1)U>JFQ)@=
M3*>&M&"<>ZXNTWNSJ,I8Y!PIVZX7VN2H5FJ[H(_\BFQ,:A#,RF]G)PF?%*^O
MC!!7E>_+#Y0.J3J96B0[6M,7':(XR7XP/4SUA?_(XY#&2_S"_@M4+3]OL1 !
MU7O "-;&XCS)$(ZA;!OS#8]-LZX8),BCU^>YB:IJ/Z?@$H+#CUHBN\V_$?A$
M62K.].A67Y(=<K %PU0VEH-@2*,!&ACZJJ$B0^TI^K[:3K9E+5'VD@NRLW)C
M^<]X9LG'11S!BR@;Z33Q@<!%\C[90H].U7PE[A"O"0"R+,NAN=!$M0WM!4LJ
M+* ;.'-J%M?Z\HZ6#6,]$_S,(;B;Q![)_@*=E!:Y14S(9P4R9 W*RQ[M2AU@
M[L  TL!2RU7@9;A!>;3\E'"O()2V39S%Z*&OE3PLC:W=)".S[[$/*,R3=O%N
M*[=&\D13U,6!R=(2S0"/%0H=V.70KD;@&LN_H#\Z7+&CU$^QG9]1P5"NH;^J
MFJ=:43*?<4O=E<U@.0-[DVJY@.9T9+3@#O@X,%F2#H_P."/O1/P<KJO.H^56
M-,TF#)9O*WH*43Q561YTDQY5>1".*1E#CX![LC[6[D0"DLPX44AWI#G_#!H7
MF"*FH[<\^J<%#'&<H(K$':TV:N+P([*;!2])-^[>$HKX7+VFPI8X73RGZ@BQ
M.6M1C;)_%[[/=B?:(@?Q'A"S O-$\XDEGI-EL42W8Y+R('':ZCWPB'@F\\V/
M-"[ANA1],ORL]BKK-A05Q](T^O59#$:A_I_$?:Q0'1CQBV>I?1G(%G[3UGI&
M2_=1=QS5RDJJW-H#Z""?2-?F7FOZQ5E?N*KQ5-714JQA3M'WRJKZFJP .J,N
M*G$Y4VJRB_C!!8Q# B&A4O_,DRDMTIUU7*P<I=UN70J44'ND"3D]LVPX&04=
M,^*KE"5DJZSH8 70O"%K3/7\IB&)K;6G&VHCOG,^U.T+;!".-)EYDM*!!L#Q
M@.*X[J8U"CAIA7*-U"MG('>K+#K_7;6G/*7X9=%[16+YY\QN)5SU.V&!ZGSM
M/^$I0#EGDO]D<+C PHT/[9-XV-4@D,+5_ 1F#=A)=PI^%%=P0D3*LN6T.^)7
ME7\+>Z0,NCQCF>Q[[:/XPXH5''I8CXK@W_:[ "C%##<QR).]M)L'%ZKH%B&H
MI>:DQ)D[AK:)=8KWG%Y:N4!PLG9*P0K11M;K] .29=SC\9-EG8)U87&*D^*Y
M?O/40V5M;C)-B++)[A24#0 6'4@HE"=ZP&QC[F/N8_>R^RIV<'_P)N1?%40(
MRM.GBBC1LKB9DO.2=Z$OY3'R%#^I<I=RE9L"< +&VGT!.:#0XCDLA[<+NQD&
M06?M,>9 463Y&[9._"C?@S=>NCBM4;!07A;G+_91FH5ND5Y7W?-C*DQ MUN+
MVAFLL_?7S(&K+..ADZB]X&[58WE2[2#&!D5:>1Q3J:3G+>&$J]K2G/D#U$=B
M7PN/ 7]#9TL6@?T,<@":Z[9/%0._M5<#C]%8RT50'*;EOZI<I]E>$U_=";J7
MK:]9"&[.\V#-A0I33W%GP -BNP5-\)907-R(0'ZPK '-<GNB!#%[^RX@"_MD
M^1(\@^_C3RX_BX]@S*$]Q+Z4>=+_8%]R3S#M\7&I!DXF'AAKX&MP1JA4M!3O
M]*N7'L;?N8]57".B[!^KSQ(F*R]02%SB\<HR];Z,495\W9;2/=7MNJA<HN:"
M]DQJ(=M=*XGE\8Q:BU"A\!9UT6^1U(EJ=9^N**8R'2:K.=0@JUK0@CS$?53R
MHF$Z?7:%8WUX*:.*51>;F\389DI-]6$%&GFQA=Q]AEFA F&H_K#?9LE2W2?W
M8OD;G:-#N'JR-L.J57.-:N8BQ6M:O],CRD>U,$NGT81--W*GTD\WEJ7^PQ34
M_XI-X%K6K0_E"[:9ROWV2T*-P]VE\OGZK0YEJHNZ:JLMFF7:H/[I:GJ.BC%=
M?:Z 5ZH"N"6LG"_ [PI>BD)SMEH<8P7NKT6#6Z%;'(./+S)%,-LE'RV3;+$=
M@:U0'#!WQF\!^[F+Y/[%TNIG"L^R(R6%2@^:1_8SE2^],[E)7<6TBN8#G9Q%
MP;;@*(&KSR!(+][C4HL,DI?8)J&(ZJYY(W85S.64B0MI%55[)3UTE^)4F4W-
MS^R!\E;6W:3S2C/NT:B;J@V"G4%'@$KQ+N^[X#39"1<9=%9YRQ9"%,!-\Z?H
M.^@@.U PFCF*=D[8Q:XLTHK9W.ZL/*F?8&Q2G'R(2! E5_1)S@?I5)?DL=Y'
M@+/*/2X8N N(M%T-UX%;+8)1%V0"RXQKRV^K?,\?(>057A8.$L=E[A-/DDY-
M/"=UD[V*<I+'*TX$T90BU6;O(^J%0*?+4LTN<*[M8Z@';K1H0#0HBQG.6B0]
M7QG,.2YW*8S@_5' F:G"9.691%#<IG:*?"N] U!!F8H@S3OO&ZHFB.MR&;@,
MW[?S!/^BA1:/X"=8=RVGEE+_K&AB700.%.S@3M>8,A[P-X(%B3XB=\@]\H!D
M!3PB*%KN#/_P?JE<AGQS'0",0[_8L<$:[(VE+RS ;]1L8&Q#AY9_8UJCR07)
M[ 5H?48K+Q*]F/!9\!ASCUPL;L%,02&R4.R7]U_%+1QR]5#S\2]V\S5]A,!2
M# \B;M=,H/M1M\N!FI74[OR'K!"J+2.7\YJJ2#C-/T!-CZP7S:6F!85)1=1P
MGVF*8/*G:[[J,?G2[H1&09ZW[(36D7L8"ZH.F6:6CV=4&G_FMS%'&HLSK-@7
M#$L2-O".Z?]&PL)3>FY0E.2([HJ/EWR3+L%5J8*TZ^S>::RTPRS/0DP*9*30
M@.8Q90?H\8WW\G-J)S9TI7]D/:M'$V9R?]>Q(B5")U-Y4(PDRICA$R6/-X2[
MMJJ<]*[V_P!7=2,MWT.>VLF,)X@NYW;9?F1UP=&\X\B)DKWI8Y%'%;WQ:6A<
M]8GP'G1/[:V [U@EYXTG#Y\L'.M4BE^7!ED?(]8J\\V:28FFB-ZN:2M6E*X"
MS<M.YEX'%]."TGPA9_KNN#;H-C,FW!M>RSD3L!II$7 ]"U!*,L%)C2'RO3;#
M<51=;/:>8(/GJE7*![0A)9M5^ZO[<H>HE]<<3E4 LUC;8W]HEG*[P_:#NP4[
M WC0(_$EST1DLNRG4RN:I'*RB<5DFE#S%!R#/:HDLAVU5<6/Y!=9)W,8BC_<
ML)2'JGC^^EB3NEWD%"8#WDF6!T2#Y?( SPCHA/*TTRK$%^#8R%$]^,U\!M:-
ML&ER\5W>G&(':9B@)?NL;)5(GR)0^$J@6!_E?ID\+$1=J) &N *?5+!G"C@;
M:'.Z 'N#JVRZD(WP=O-'Z!]T1>4<H4:"%@'BD;)!V1F2]7(R9:2,J_@>\T+A
MH0+")BC?JO\$.*IW:V9YUFI,T'3G$5 R?-'F&_P!95N$HRSL;L4[?O_UH_"%
MT$:=GW53]!+(2-XFN:I)C-DL.PJFAKY3]$#% ;:J=;#&$P$6(IW.H2"!GK*=
M#N=CSRTHY"'^H:*"NQ0>7RCD2^"6+$!8AHQ-EHFY2'V,5DJA4T-OR!>AZP/L
ME'NP0L]V]65\J#-3<Q/OLN5!IXA<BP.(BGA4?H9C1LPL^,[]3NS)LN-_(:XE
M1XC,B#LQM9)RXF/H:5DG.2' 3?&2C/3L4GN0/.<F31[99#L;*B>76'Q$S,B>
M<@ZKVS"H8!%GBWY'YG7>"7UU\GC!#]W;F QQE:XM])#TK"XRP%\1K7WA>4*U
M6-ONW 4\T(;8[@/_4D<LK>$S%*O<D0DTA!>4L9?4TS(7<2_684FO!1-,\V)"
M1&W&TZ%[I [&D0$A\BY#G.=ME:]>Z7P&J-,MMKT#]FAW6$;#;=3GLC[J?:Y[
MOHZ:73@VHX@*+AV46$&>JQP;54INH%L&&\BUS"#?#O(@M]CM"OE:J',P41[2
M'58K*$S99S:2.J^Y6WH$'U1<G;<8GU2V-[T#MZ0%)FS"I]%/1)[%LYA5P2[X
M/,Y/7S;^0;#.[2I1+.$Y=!/'%<Y6+\A,]4DS#GD$2BC9#3=6+LZ]"E^N;DS[
MCKC7Z!)LD5960V0E:L9=$'03W2C8[1N/)8O?N=W 'LL#':[A#2JIM0L1I9EE
MMI.X!=<77]*H:S;D>FB^L@+2U& K9W?\1BB%GQ8Y'!XOO!NT GX@07T]D5UR
M3[<^M$/YT.$;)@/F6%?@65"D^4!B++*EZ*=J%7=ICDG-YV]+_0,D"$_$YVC"
MQ7T1A\$HZ<\@ DI4V/@ZP_FJ;+>O2 U@='1#1>!NZ_F8 GY@GHL7H?>*?!6%
MXN#L=\HDR8/4&:ILF2E^L%JM<(^8":Q67@CB:>ZJ*5\O:)HFWMT*SH5&.3(1
M'7S*^B':C4+FG=@V?%CA%EF2XF V*:]6ODH-4LQ03XGK53X%HB)XZB2-/*@(
M6 YN]@T$A\(#W2,@%E+N.!O>BZZQL4/'84_-7V ^Q,C"! D,NF9;2K> ]U,>
MR(= <^,:%1"<'9&F&H!,"$I3UR%W?*,TD]#=[N7@7&R1XU%X,JZV*4*T1+B%
M,[J;>%5P5/0!*\OJD41B)U/F2)?@[G$,N2LNB0A47,1[@Y)4!L+:-Q.()"AW
M2/.">.SX 3*0$39ZY!\2L"A!*\C-!0+A'"V5Q1;]T!I2RB4RK28N6C9<FQ?A
M(+^@#0E*4*[3.OJ6JXW:\>X=FG+JJ],T:!)USF8=O)EJL"#0,51A@;] 9B*R
MO(2OC6]3W,60L2K.06II.!,Q63[ D!84K_BN/^/+4GW1I[MO )[H]CD%@=MU
M3C:G8*96:K$$.4/=S#M1%Y\[/Z/01"]<D/C%J"WMC.XR;*SL"N48S.A' XKU
M"YG/O"+T'KPI+@6Z0Z(,NW,ZB0RTG*T+4IFFS="- FFY3_5X,9*^6/>]?$@B
M6P?2.J)#= ,90:'CM#N95P/LM7HNZ>6ES1;&NW"UMM*Q]H.T Q7'+>]2OX&R
M:2^IO]#&W.&47R4C[2=YJUJ?\()<4M,9=9HTLG:&'"#KN7?]/Y&SA1.\[,CY
MDBH7B.R4;['W(7>I/EM9D<_ 469AU"3X88X7[E_CDU:!3V*^3%#A9ISY46(\
M@Q\1@N%-PN?^Y_$KDDZO:<1XN=BED<A6Q=@7$[.!OU8%Q$=HKAE&)B(_LU$$
MX)Q+O8)T\%T2)B+7A((H)S11/#<D&]TGO>2_!XM03/6RQ5:K>"X;\<G /OM&
MO $:;-5.3$)<S$X2)FQ*UA/(0C0MM1922L;%'X2>2U]'OH5Q^<80?\1-"?EO
M1RZI<[R"4+XFR.4V^A>RL3^#+8 _6-W%L]#EYI;X0]PS"]6,D^>DCM)T*,[%
MPV"0*CSR(/A>W11B!AT&7OIO@>>"^5ZI2 ETQG4(^@^2YC 4/8]V6UMAR[$?
MYG2\A+#)LE#G >R4G>IW&C0^"E@-$I'S-!3$#1D&(G"%_U8(0HJ\JN!JE.'J
MC41A0H=PU!ZOL2[$)A/!YO.P>\3'_GGJ-I*?PE7!J&/\,'44>C$2 3RPXN!?
MFA2LSW\/*,)%7B"$$H-=2V$=,=-!C-238ZP-Z#RRVOP4AI#K,@L5!M(GQ5$9
M3,Z)NZ8:3CZ,K%4/IH8&?P)B*#?_PYHZ*M.K#=Q/25Q1Z 5E<)B'_$,9K3>C
MP13#_ /F225FCI 7ZF\DOU XZ'?&=2E'ZILB<U23]'G!;]1<_03_4\!YW06O
MY:"+SN0Z'Y+H_!SVP>NU1ZPO((^UP183T1?4P;3;+5=R7R5F-Y<6C8L^U/BV
MS"LLL&$)+3%P9;V)P?$IKC.P.MPGF#2\2TX#C'+Q!-LH@U$>:K%"OU_M,<U-
M;P.>3[-L#"W6)QQJ&%X>%EU3]X;V+/2MZ1-C9B!ALF<E^V0;*WE#W!T-]<*;
M3F[ZO=(N6XU^K))O\49' @^F8;J)\#^I$M.?2JN$)-.@:FGT<*-G37?H6H.6
M=2>P6/^!9^$3I^<+V>Z^NC.2,TYINF!%D.TZ[6XU9.FCY8#0M!-:9R0P9;5A
M+&--?+<^G3DG:I%N"T<<2M/E\ET"G;5_A.]]O+0;)2?< [4)\JU.+.JF:I'M
M#:I9P[9D4R+H@]DHJ@B-2''4,MC?XM.H&[R6J%P*% X)=:,RQ5F!HR@_Z1H?
M#VJ*XA_W=/*ZRNC41LX'?MA-(6$HTW(-:4(X9D5D!Y:<W$L.$/R*^TOL%(=$
M61&-TLS0400E]P\<2,Q2.OF$$&O5=NYBHD/CXW2"P*%@NPK"@%A;?B+VHF?-
MEA.O\,QD,?95^CAN/]8G[XY\B]U2TD+>8>]5=P)^X-X UR<!%VM^NC?A.+3$
MZ3O>@,3:S<:WH?NMIA/C\;%F3XE*PC_9&@U7;8K3HJ& 5>0Q-%/##KF%HJ A
MX"O:!ZWWR<?2X*ONFS 2_<?9$^O"XNTN8G_P0BL1#A%!YK;X?>)[TEGX$%00
MEP[OAO'(3O@J@H6<0*S0A(#OR%)LJ \']<>.NU]#9^(MS@ST-9%N/PZK)AY9
M+<-^D!GF.3A,KDS20ESL89P9),2[(O50!U$8LAMZ0QP*^ FWDDX^$!)/4NX_
MD)/D3><V-(VRMX]';U$I5N>P-BK27(V[4L%)":"/-B;V-9BC;8H4@JW:(R&;
MP6_:>P&_H2W:)SYU,*E][#$5<=->=NY!CF@WVPM1F59J]1&+T@XRGX4]HM;%
MG9H]-,\CRFS6DZ+JT.H9?64M@;-;O]!V^UQKB61\\BANZF"'.7]JN,1OM#]0
M;R:^8KW/5"__:-YK#% ?FWK,8 %%QCZ8.;MX1N22MA7EQ:%!+3>KI@:V-$<S
MKOL\;^QE+?<@&@IYJ(M;W1F1T/ZG*5]68#/0.%@UPF*,_HV&,\U</PX6Q$*M
M!17?(O.;UU;GA YH<JE9%*AL.,-ZYO.TOI&7[-%>5RSL<LDR#98&.W@9]BJV
MVD3J5ZI_6F3KSH)/IS%T=@@6\Z0IGQ$2<:WA*S,P9%G]+HY-8'C=$MY7GQ.F
M!<)G'JW&19+'+G0#(/_LD*<O4_VPD>ADFE,6)NUY.'7:$FT.JHEIK%_)#HMH
MK#-QGX8(35H!&&AMG"MZ[G/8<$HJ\5AJ&*P8X*+7CU M=3#I)FH";;JT1=!,
MBS/4$V3EM&=4,Z:,*30I^7\CN$9 E!]2:FB3U 6:ZX_(%OA<U+LH]GOTZMI4
MSUUV:/=K'!Q.4N^@+)O?5#F2;&E.346_F 61]W!!C*N!(UD0D::?+ZL+2=7=
M450%3M5YJZ;YW-7N4%_SN*O-U<QS>41U0A+'P>07),@VBM2AIRW+229N9Z8F
M,XF$Z#\Z2CDQPD=[7[4^)$R;!'@'3J(V:UI\7E(,\(W';\H!SG:=1,Y'=CO&
MD).Q:;88<11/MFPG3A+3S382YXB_T5>HXYJJB$E4''@\Q),\ (\*'-]_EEGZ
M_"#-4!M/6^(W9NF:2BS%+1P)(I$89-M+6!-[+<\0262HV6V"12Z-?D9&(ZLC
M_B&NH3M#; D9MCIP+#$&%_@.QW\34SRCB,%$MZL:/TTF.N[$V\D]MK_Q-FJ4
MY6_\*F5N/HCXAW*+L</?$8<B+/'U9''(5)Q!]@6.QL=1%;X3<#-JDV<1'DI]
M=)V/VVGM'9_B([4!=EZXO=;6RA''J(OF=O@IJF/ @+]__^^(V$K_ ?UK\!#[
M 0,&#OA_K_^OYX&#!@\9.FSXB)&C1H\9.^Z?\1,F3IH\9>HT,W,+2RMK&UL[
M>P=')V<75S=W#T\O;Q]?/_^ P.E!P2&A8>$1D5'1,;%Q\0F)2<DIJ6GI&9E9
MV3FY>?D%A47%):5EY165M*IJ.J.FELEB<[@\OD H$DND,KE"J5(#&A""$13#
M"9+2ZO0&HZFNOJ&QJ;FEM6W&S%GM';/GS)TW?\'"18N7+%W6N7S%RE6KUZQ=
MMW[#QDV;N[JW;-W6LWW'SEV[]^S=M__ P=Y#AX\</7;\Q,E3I\^</7?^PL5+
MEZ]<O7;]QLU;M^_<[;MW_\'#1X^?/'WV_,7+5Z_?O'WW_L/'3Y^_?/WV_<?/
M7[___!TP<."@08,'#^GO8-CPX2-&C.SO8?28,6/[J_AG_/@)_6U,FMS?Q]1I
M_8V86_1WTE]*?RO]M?3WTE_,_VKF/]7\3S?_1SG_Z::_FLRLG-S\@J*2TO+*
M*GH-D\WEBR0RI1I$,%)KJ&MH;IW1/GON_(6+EW:N6+5Z[?H-FS9W;^F7_(_C
M_Z'X/X[_D?Q?EOV:_9[]HOVF_:K]KH^?]-L^>][O^_)5O_&;MV_?]4M_^/CQ
M4[_WEZ]?OWW[WN_^\]>OW[___-?_]]9$A]_;,B/_;"DH^;.9IORQJ:;^0U?M
M_)?=K+6/M[!W]&WA'KFY17SN2K?R^L4NL._<9O31F4W$\Y,;=6^.;S!^.KJA
MX?N_S7\9_LOP7X;_,OR7X;\,_V7X+\/_?X:D_S#\[F?XW<_P<S.C[F-WS;Q7
M6VK7/-[&[+G7PSYT:SO_S+7MDBN7>Y2W+O1H[IW?CCP\O0U[>;1+]V'O1N/7
M?YO_S1#Q/PR5RI]==-/'+8RYK[<Q5CW97K/U_J[: W?VLD[<V,\_?_6@Y.KY
MO8J[)W>"CX]NPU\=ZM:_[]FL^_QO\VM;DL.OGGZ&K?T,7?T,W=7&3UNK9[_>
M3E_Y;!>]^^%^QIZ^(S6'KQ]EGSE_0'S]Y!YEW]&=\.-#/>2+ UOT;[NZR(__
M-O_#D-'/D/\?AA];:(;//;2.M[NJ.I_OK]KX^&AUSZU35;WGCW#.G3P@N7YD
MC[JO=R?RZ.!V\OG.K<3K]=WXNW^;7]N2_Q\,%<KO6RMU7W94S'RWMV+)J\.5
M:_K.E&^]=)IV^-01[ODC!V37>_=J[A[8A3[<OX-ZVMV#OERU%7GS;_.S)]G^
M?S'\VI97\JN[GZ&GG/JTNZSU36_9_">GRCNO7\KK.7.JZLC1(_SSO0<5U_;O
M V_OVXW=W[X3?;Q^._1L60_T\M_F9T^*_<_M_YMA2YG\ZXX2XL/^XL87QTMF
M]5W*67'A4OZ.8Z?H1WJ/",_M[U5>W;L?NKE[+WIW\V[PP<J=P.-%VX%G_S8_
MMO^'(?Q73V[QSVTETL^[BY WAPL,#\_EMUV]G;CJY,7"';VG:H[L.RHZN^>0
MZO+N ]#U+?LTM]?N4?4MV:5\,'>GZM&_S8_MR78_=J2'_^QG^+Z]4/1A?Q[P
M[%0>>O-F_*RSMY/7'+Y8O&/O:>:AW<<DIW8=5E_8VJN^LNZ \GKG/OGM^7ME
M=]OWR._]VWS?T<^P,SWLY_:<XJ^[<_\O]NXSJ*T[7_@XV6PVFV1W;[)IF^9-
M+T[LQ+V;WGL5 B0Z"$07371$$R!Z$2!$$T(%%22!$!U$[QW3>Z\VF&)3_L^Q
M-[//O<\\$X/WS7V1%]\YO-+YS#E'FOG]1H-0&TT:SE,#"GZ]L]*IC6/*C*I^
M>&E9ITU=::M+"Z_)M9/9X-)+$3L/9-8Y/4BI<1J-KW$>^T][4B;_SX-RY5M/
MR]3UM^O4S.9ZE,W[9^X%-B_*$JO&U>FE@R;%)3VH*DX'NJ&@U;XUN]F^([W1
MKCNIP:XOKMY^(%KL,/B?ME\N=VZ_0NGF?J6J]DJ;@O;0Y$V;UE5)7/6B$E$X
MJ4WE#2.+F/V6HMQNR^KT3DMQ4KME4VRK94M4BU5[>+-U1VB3;>=_VEZES&>[
M50K7-QOD94=&+ZNVK]RVK]F6Q0F7U9.YTP:Y!6-&S,PA(UYROW%I;*])162W
M275H%Z(VN!,I#N@PJ_?KL&CX3]NIEOIDNU;NZG3_S4N=2U>TZG;NHTMWE *Y
M:SIQ^?.Z&6E3.I2X,5TF?EB/@QO2YP<,&!3[]L.$V'ZXR+//J,R]SZ3\/^UA
MW;V/EMIO?=DS_].-^NT;.J*GLG9%>^H^^5L:>.*R>A)A7HT4,JV6ZS^I0?4>
MUZ1[C&DQW4:U62XCNFRG$7V.PS#L/VZ]\>8' U-?G&M\^//MLJ=WM7E R2K_
MJ1(F=4<Q,'I3,1*WHIB A9X-S)QRIO.L2I;#C%J._;1&'FI*BV(SI9-O/:GW
M'P=8=SX%7,5K@*.C 0I-[ #+TN\)VYJPS4&1UCEH^A+;N7B6A:F>9/HTCS*"
MNA_00@<&<L)&^M+PD[WQ,3,]<:ESK4FDN8;4S-F7[7?#[X;?#;\;?C?\;CB5
M@?W<</6Y@86P VP+WZ<<J^@=KFW&!M>>ML1U%,QR7*HFV5Y-8X5^G<-,7/\@
M#3)D1TSVI!!FN^.)"PVI&0LU:2_?OPQ*5P$7,K 1=B<<<]^G7,NHG2+K] T>
MJF"9A^;-\9PJIHHP#>-<;/L(.Z!WJ##D03\]8KPG,VJV*S%MJ3H];:GL/^BY
MH>B_&\Q\#HLL(A_SK8B; IO\%8$==[[8H6RZV+ENHMBS953@VS7,#QX8Y(:-
M]%(C9VI3$U:$&<15?@9QY64#G%\-1;K_,G!-L8<\<_RNP#)UJ]@Z;U5HRUX4
MV0MGRYVJIRHQ#1-5V-;1JL#NP?*@!RW<T&E^=M0J@Y2RSLA(67O9 .?N_S5P
M$';'14CO9_/_;K%Y\D.A9<Y:F0USJ=*./U_G6#;;XE8UT>;=,-3DV]59YS]4
M718X16>$KI#RDS>RLEZ^YP;>?S/P$%Y/!<BP/:%9TJ,RBZR-*BO:BAC%66AS
MY$_V>)0.=GC5=S;Y=C:* X9$50&36<4!R\DER6L9]-35E^U?!N6K@/?,8((Z
MXIMX/BE!0/,_,GZ[THRT);:D++>BZ-,#3JSA?K?2[DYO<7.S;T>M.&!0 ,V^
MZ2*?I50182E5F/;2 >Y_,W"-;8\$QAX'0F/<;KE)[,-:)'&MQ9(\WX?*&QE"
M<;M[G2N:VST:ZYI\NBK%_H/L*I^)M#+O^;2RB/FT\L2YEPTR? +XRE>>&XJ,
M; Z+X9A]$3QPI]HH:J,1D;C8;94R/HJD]@Y:"5JZ':OKVC ME8W>W:(ZOZ&"
M:J^)U'+/V90*W"RQ(F;F90-%]R"#RA7 UU$_X<&MGY88NNY5P/P>B@W#EML1
M45-#QFD#XT;TU@'+$G&70VUE*Z95U.C=PQ5[#>54NX\E5;I/)U8&3"=71DR]
M;,\,)X)_&8[Y,,LG(GVGG6I][[5F6,!LOV'$T)0VJ7W4L%#<;UE:V>E0)X(,
M_$;/;KH8,TBJ<1U)J'*;B*ORG8BOQHV_;(!W_Y.38M4K0*"M?E2L9[9?H6._
MU:#K.M]C@!F>5(WNG-7,JA\Q9%?V68E*.QWK!*UN+8PFEZ[L>N?^%&C^CZUQ
M&2'4>(T2:OU'7C; O__Q<8GJY1.!EOK34FV3G1HMJ^5V+=N1<07O[@65N(9I
MS=R*$2..L-]:Q.]RK*6W.31G-Z,[B(WHGOAZ='^4V&D0+\8,X<78P9?M1"#Y
M\5&)RN7C8DVU_0H-@_4F-?C$ P6+G@4YO\85E82*:>W<XA$3-J_?5DCKMJTF
M=]C4I[3:M,0UV[1'-MEVA37:]X0T.D-A7KJC8JF/#DM5+AV6JBL_JE-1F^E3
M4.F;DT0U;<@'5BZK)0JF]7(YHZ:%^8-F E*O>7E2MWD-H<.\/J+=H@G7:MD2
MV&K3&M!BW^;?XO32/2V5^<=3D=(ONU7*DHL=LG<&9FYJ-6](H2MWE(**5[02
MV+.&6;D3AC3B,)P;-VA4C.\S+@OI,:D,[$94^W:9UF([S>N\.JW%7IVHE^Z@
M3/;#@W+%B^M-TC\/35RZV;I^2[]J3]:Q>$<MD+VF%YN]H).>/*V=%SVN2P\=
MT6,'#.GS? 8-!%X#AB7N_49"MWZ34M<^4Y%+G\5+MU<A_?ZC6NFOQQ[\^'G[
MZN5[U7MW825'B@[L74W?[$UU?-*R6A)^7HT4-*V>ZS.I0?48UZ*[CFDSG4=U
M"QU']5GH$1C;;@0.9<)YV7:J[[T[U_W+VYU+Y[^KW;TF57(L;< &*JBL)XJ>
MB=N*P1$;BE$!*XJ)GHM*1)=Y99+#K"K9;D8]VW9&(\=F6BO7:EHGSW)*+\]B
MRN"E6VVZ\F;/W&=_%^]</%]Z?%N2#>1TLH&T1>*QM%/XOC36;ULZV'U+-L)Q
M78Z 6I6/LX(\%LM*269+*LFF2VHIB"6-5)-%+2@=XLL&"BY_"&B2%T"!B@*@
MZ)L"*L(5,*P"GS#M8[<93J0-NAMMF>+.F\_"ED\3 ^HFXG M8_B(SI&0F-YA
M7'+?,([4/QQ*Z>N/H/5U1--ZVPCT,_>[X7?#[X;?#?_K#73(0(,,^9"!AG !
MA=8!3PI1,3N%#AD;#!?J"LV]:#X/6S:3Z5\WD0P9".%=(^&$ON&0I($'H:2!
M!^'4@:ZH@H&6V(+^II?H7P:I"X"N*O_<P$ Z Y:5_U.V;?1CEGW:9J%3_BK3
MC;- \RR=H?C53)*"F\>2PCJ'HZ/[AL(2AX;",H=Z(_.'6F.I@W7QU*&:^/PS
M!VA7/@2,7PU4R%"(= )L"[]#CG7D+@>5NL5QR%MEN; 6F>XELW2?JJF\P,:Q
MC-".X82HOB%\XH/!\*SA=@)E6!Q/&:Y(H R7O420X8/G!@9D*( ,+%/'9SN(
M0ZX5?K?(-N5AD7W.&M>)N<1QX\^SO,JG&?[B\;R0MI&TR-Y^0OR#3CQIK#XF
M=ZPB(7>T)#%W5)"8.W;6_J?!P!2PD0XG7#/L$<\B8H]GG?2(;Y>UP7>@K?!=
MBA;X[J7_[R^BO_[^+->W>K(PN&DH)[R[+9GPH"8F>;PL+GM"D)@SP8%B)^:,
MGS5 AU3,7U4T R0TC:./BTR]#_GF8?L"JX3M8MO,32&:NEKJS%HJPPCFR[#E
M8SS_QBY:2+<X$_^@.#%V@I- GF(F94W1H6A)69-G[5\&Z0N "1GH!@C 1=@?
M\Y!>3P5F(0<E%G$[I3;I6^7VN>M53O05,88S7>M1-E"*;6AF!W:5YX<-L=*C
M)O.24V=SDC-G<I+(TR_3KX:?GAL8SPPF]D=\A.?38B1NO]0\9K?<*O51M5W6
M>H,39:'5E376["KJK/)LJ"WVZQ04!@_FYX1-I*;%SJ6DD>:(*9FS:2F9,V?M
MN:'P5P/3P.2DR-CNV4;@B1 1M%=F%K53;9FT66^7OMKIDCG3ZU@XT.4H:FK
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M!R]V&PJO\X<F\>C!R/J,@0AQUN!9 X60@2WS(^! !KZ>WA.1+G*[1L]ZM<4
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MMLM?')RZ=Z=M34ZW]K$R2KBGZ</>U(_,6S)(29G1RXZ>,*#A1F!LWR$XWV/
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MK8H+7U<E^"VI)6/FU4D.,UHYME.Z%*M)&-5B$D$UG[0H,)]$04=G*.]\\ZE
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M@BFUGI',2O<D5KE'-EODR627>HE8Q5@QJ\A7S&+YB5D,_SHVS5_,>E'_-D1
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MC]]%@)^N^H$+DJ[@9Q44N*1C"J["X>"&J1ZX;:D%[MFH VF4*I"W5P'*]DI
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M&%['L+ KI:"\.62G,&H:)B$ST2LS,=J/&AF.8X6&$HIPH>E%0:&THL"PTJ*
MT!IN4&@M)SBDCHT+$;-^*Q ,&8(@0_3YCT'Z]7. (O7%0:'2UQM\K6\72G6^
M'Z_4O-0KTI9K%L!AE6PSE(!NX\F@.(3D9+G&$=,\,@B)V'P<(8#M@P_G>^&3
M!)Z1>7SW*!Y4-<\37U.$#:_E^(37_68 !QF"S[T#8LY_!$C7/P4%4N=V.4J?
MKY9H?CY;J?GYL%CAY\XJ35EQ*4R_E(^T8;.M//(9=KB,?*?8A&RW]/!T3XIO
MD@_++1['=XJ+$SC&9_$=$C@\A\2:(J>X&JXKH9;K%EW+^:V>&W"0(?[\AR#K
M^D<G#*F/M_E*GRR5JWXT6:_\C_YFN0LM8G7IJBI]7;[(V(HN,,=D<6V"D@O1
MA*@"9V)0+B;7/=.+B4X/Y*+28XIL,S*YMB0VQR:SAF67+F:ADZ$2?SL0\N[K
M( 0R))U_'^1>_^"0+?G!IE#I_;E:^7=&NFY]T-4I<U[<HGJ_M%Y'FU4#M\@K
M1[H0A9;^,7S;J!".?8HWTRG;L0!#L\GW+[2D1A=:%I 8%K1"N@6]FF9-;2JP
MR6ZDVY)_.Q &&4(A _'\WP'UVM_W>9+OK%3*_'6J[<Z?^P>OO-?<+_E]98_2
MG:)V30UJL[XI26SD%%^-] TOMXCP+;5)=!'89=KP7/+,BWRIIKS(?%-^.@4I
M8.8ABRMSS?CM.1:%K7D6C-\.A$.&R'-_ YGG_P:85_^Z+;SWYGS#C=>&1[]X
MM6/BZCNU8_>_+AF6O\GH5U/-ZM8Q2>HP0.-;C+P#&A&A;F*S.-L:*Z)IM4.F
M2;4WV;@F@FQ<2R09U=$SX.+R="-Q3QJBK#L#(>PB_58 _^Z?0.RYMT#N#V\>
M%5W^\UKU]5?'^S^4Z)K^X;7Z^3MOE\_)?\&=4;Z6.Z&BF#JJ81@]I&T;U*_G
M[MYK$&37!8\R[31-,.I$)1MV>:; NL.2#7I2$@WZ"A+T^T7Q^@-]<;#VP7C#
MYL&$WPI$_?TUD/+9ZX#V[6L[PO-_F&O[4*)[]EV)AJ6+?RY?O?<!;U7AVX)E
ME9L9BRI*L?.J,-RLFK7GM(8K>E++SVQ"-Q0^811I,&D=K3^%B=*;#H[4FTW
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MI!'&/<ESUD/)H]#'XCMA3Y/^!F(UI@,?RQ!FM!BB+%9!_'^>![FY@HA$ D$
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MR=/CT/Y_)Z+MS_7'];^RF-[YRGY^PTN7E:4O<';*YVX$V3-W:LP33S;[B9>
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M#RR#BQ$6W7@)>%FO!)*K)7B3G,"#Y@DXM@\X"2G@D.(/]CD!8%^.:0@ A_8
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M94!V-P,?/WL@,+&<X9Z_<"+BJ&NJUW?7/*^ON'+B%WP]\3-^#?&36S?AH_L
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M48C3Q:ER9;P\)U<HK\B+26W-C4[MSXU*W9\3F7HY)RKUOC):_B K)N5AYEB
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MP?K_;JS_'T*HY=0D5'=63Z7L[.K)^6=L-3).NRR6GO0PCCWN91=^U-<]^$B
M+_4P@TH^Q&;Z'!*P2(>3@KP/9S.]CU0RO(^NI7D=W4HE'CL92#QZ+\#SR/M
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MF?&9"8KX0G%:?(U8'M\N3HG?*);%'Q!+XR]+DD3/$J7Q;Q*D\2/8=X[$_T_
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MS?,=RM;/SRM9/7^H:/7TP[_8/XIG@.>_#N</XOQEA_ .' <H/0N0@_,3_P/
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M/]B \X=Q_G+<^WK<^Q+<^^SS./\RSK^.\^_@_(< 3L\ ;+\"T1*1!$R0"-D
M20OI((JP)E(144-:HDK(0)2"S$5ED;VH)**)B"*F,!F%"I-0HA"@>61 58*
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M/ )Q.HX(CY*Q;Z43X4JZ()S-5( CV4:D/5D.8EO2/"B322RM-?%<D^$8OLU
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M0>':N5=Q_BW<_WLX_Q& \3, [9< ZI^!H#P#1 H"HAP"DA02%!!#H@)"2%J
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M\(JH>NXK:39;</[ZM?B>M '[-ZZ[ 6<OW 60@[,3#OQY!P3@=P+ '?NX_04
MLRM$T+LN!-JWI4'SMBIHW-8CJ-VQ(*C><2*HW*43E.]Q"(KW(@@*]],(\@^*
M0>Y! \@\[ 7)AQM _-%Q$'UT!T0>? "1^_\_&W#^&.Y[#^[Y$EQW!<[.WP^0
M=!@@_#@ ^S2 YWD A\L YM< ]&\!:-P#4'E%!J4W4J#P1I$@]T:3(//&D"#Y
MUHH@]M:5(/+.ET!^'P*D#XE ^("_$7_ !_\#/G#O\:#?[\5<^0?CN/=]N/8V
M7'O5/H#"0W@'_KP#PMD<G$V_!.!X%<#B)LZ_B_,? B@^ 9#_ "#S@P@2OT0(
MHK]D"$*_% FD7YH$F#'"V&!H #-L3!0F!^ 7_@;T$R__3WSH?DS^@\'M ,MV
MXQW M<_'?4\["1!Y#B  9]-QMB/.-L?9>CA;[2D Y06 Y&L L:\ PK\!/Q #
M@8B(!$!"& F, D8#8XRQ!\ /K(!",/B;,\(/)@C?C%#;/T!$'4E$TI)$\ <=
M"03FX@B<11'X"B,($4(0AV,R!1 4D1!4$!'48980$+03?D,78096$G["$/R
MU? =UL,WV Q?8 ]\AN/P$2[#!W@ [^$-YCN\ P1O_PN(K"6%A-0ED8#:G^O
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MA4$]@OQWPZ1N@N[X.J*ETT3M<.BUF^%&9^%&X91C=TE3U)PVA>\VIY#=#IS
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MX_0.YQ+=Y]ZEMZ4^H7O\1_2&S#_T.C*]+<>P;KT"HZ @R\A+RS J<M*,IH:
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MI$5C0M*AL5K2K[E*LEQSI61"<U0RH[5",J>U3')">T1R4WM(\I'.H.1'W8'
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MZ(BM1E$11XPBPV\8181_;!@9_L@@,NRQ?F08HS?/G?EGHN9;X'3,1; V#37
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MJ;@4OZ\B+/I>U;GP3S6G D9]GC/SST1!:WTIQ@'T@S;H5I<1%5? [U3#<]7
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MN(MJE*K=N5\"VS5ZL!ZP@-6  RP&W&$^X _3@5"8#,3!:" =A@.%T!NH@NY
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M<OWLRW6.Z_LNU_=#_CR'LKH?\K?5O9"GF"O/,E]?8-'\"N>.?]*/-YCXKP\
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MN,1I>-4QN.XAN$RU-)2]TEAVPTYVPNNVPS"V8L<6[-B$'1NQ8SUVK"-XUQ!
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MO*HJ9YWICTYRA'=\BSQ%:K33RWP]OIKZQ^F7!K5$#,$7@^#] Y@O^M$G?24
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M=L EML"K-L$C-N"+]9*,EBST%Z"_&/UE=$$+]%>@NSUZJ]#;0_M-)1_!$A?
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M1:(MLB32LJ%$6#:3,*NV4M^JAX18#Y6@NA,EL.[KXF_]L?A;K1$_JVKQM;R
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M\_[X;?WAS]OPTX8&SVU8IVQH-_/[E9T_O[ZR:M.YE=V.G%PVZ.*!)>-_T-8
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M^.F0)_SVBQV<.&,*)Z]IP]D'2G">508N<8O!54%!N"'&"W=P7/! B@,89=B
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M[2BH7?D+Y)_<!R7TV5Y10!@4</(@K:@!8EH&(&QL#@(D(O"[6@.?OPWP1=@
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MRD$1(RKDB&$U6O@@H3J\2[LUO%&_-;S2L"6RV*@Y,M^X.8INTAR59=(<^:7
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M:#\1CAXQ@&._J\%O?\O"B6MB</HN/_S]F LNLCR%:VS,< M]X+O/_0B>\#R
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MDY#H;).7Z&13E^!D4T]VLFZ(<[9NC'&V:HIVMFJ.^EQ@B@Q&R&#VTR%P.7$
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MKN 0[0LVR8%@E4\ B^H0,&L/!;,AS#AF"V9/*)B?" 6+:Y@G(6#U+@3L9D/
M^2-QP?T+8<YKCO#)YWOP.[]YPMO_ ,C\O$#$-7CB&IQQ&]V-U<#+SA"\/&S
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M!*O=GF!]W .L+WN S4-WL)UQ7[3[[K;@ &Y?<<9[5W!_[0X>SSW!<RD@0$@
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M9[#ZQO\_G_P:H: /B,5K$;$[X1JL /&8 .+7!R2H"4A8%=A%%8%;3!8$Q*1
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M[ X#XG0X$+<O 7CB&MRQ^Q-$!"!:D@\2%/@@64/@9XJAZ.<4:]FW#%>-9[0
MD_L4DL.M<+KGM9 T_\O$@J +(57!YT*:"6=">PFG0T<))\/6$8Z';2,>"S]$
M/!)^A7B(](*XCS07MHNT&+XM<I&TF?R+M('RBS2Y!. E)  ^>";"L7/&2?!
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M4/L]G[ 7?BT&.(<U.#(?:X#ZVY9C#5:@_@! ]RI16+1&F]*VVHK9N,I5HGK
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M_>G\B.O @458 ZS_)M0?0NV>#5B#S>B_4;MH.^JC'X_92X.(_;(0>D";$GC
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M$"A!R1H:@6:D@TJ@"^G%$ :1=<A&9 >&LA\YA5R#+_ (/L-KY M\PN]\_/]
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MSTS>R)^1?)"?GGP=>>67GDRX&<G$.R.)>$V'^*/WQUZ\DHG>/__K&=!D&=8
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M1Y;52\&21EU*>X,UL[G>5;RNUD>ALHJO75(18II?%FDW<TZ<>TI1LF_\[,S
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M8(8QN# )\!@$HC&&=(PA'_7+D%K\G69D(=*%NKVH-8C76@OO82/\"3O@'1R
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MFFTTL)-E.'"!:;#B&4NO[[.@;@\1TEE.A+^QMPYKL #G ^KU(1U(0S=ZW^4
ML_H DOL!PE<#^ T#N*P'L!X5 LM113 ?TP'3,3.*\9@]U7#,@ZX_QJ/KCD70
M=<92Z-ICN32ML4J:YMA\JL;82JK:V%:*ZN@9BLK($ZK2NH\TQ6'"4!PB M_8
MB37?A)I#/;@N(FV8<S7F7+@*8,800"SZ\J!1 $_TYK9;T/]O1?^[0P!4=DJ#
M\DXU4)HP!(4):Y"?< .Y"7^0G8@ Z<DTD)HL!(G)!A";[ :1R5$0FC@,@COO
M@=#V]R"TC8#05D+YQM8N@#'4'!P$6(*Z3:A;AKJSQK &F[Z>P7#1ESNA139%
M;ZR-WEP1O;G$#^B_#[.!?D06:$<T@'K4!"A'<3-XU!O!&]!1O.D=+?[ZH:>C
M*_"&B,$?01-_&$WSX0\ A\C_V(BU7H=U[L4ZMX_]>P:3CKI1.P'\4=<%=2W0
ME^NBKO(1 *D3 (*G "AGT%^?8^!-5QS@@A(NN.CW?\*-X25W@"MX,[Z:_/5#
M<%>QR7_&)*_L0JXBO^,-XOW_&%V+]Z>Q[\]@,J<^"[4;@(^Z;@<!K X#Z!U'
M_=.HCZD(_@1 O83Z>#FT47CC16XR 6Y)XJ90%> W(X '6)/'N#%Y@AN1I[CH
M/\,)]PSC>#KU3,I%_/Z#_[%ZP]<SF);M .7_G,'$'0 (1%V/8ZB/^>ICOLKX
M:U(_ [!O8/Z_HN;T,YBI\Y!'_YR'/!- DR -\$H3X"W6Y#UNTO["&_/'/(!/
M. $_8[-_QJ0_[_X?4W\I>3[6O'+WOV<PP9@SYT>< ^>_/H.CC+E*H"YS2O/^
M-+VG_YR'//_G#.8U\O:?,Y&/+( O4\^"&"*X826A"-Z<"=X$2!NR]']\/?N8
M.G>00[^M@(Y4'9VI&?IM)_3\?OC_D?#O^4,Q4H'4(RWP!;W_9_2[GV 9LA(^
MPAKX"T8QA*WP#O;!&_@1N86A_?'W)V*^/7_Q7U 78Y#!&"0Q!FF,015C,,(8
M[#$&'_S_,"3Q[_.'3S ;-<K@ ]2@3A.Z^3;4ZL#4NU&K%Z\W"*]@'99D,Y9F
M-Y;H!);J.O(,^?CW\Q?_%P1D!;^>.XAB#*+HQ)4P!CV,P09CX&"N0:@9BUKI
MJ).+&B7P$BI1IQZS:T:M!? [UN(IUN()UN(1#&%[;, VV0GWX#"VS&6X\_=)
MR)\(^9M;R*_3(""!=1#"&%@8@PC601YCT,(8S"F?P!5SY*%>).HDHTX67FTV
MZI2A3C6V1B/JM*).!^ITX;5[X2:L@ALP M=@&_P,!^$*7,0H[L,EK-)/6,V+
MJ'@!.3\-0A7$&.BHC]X7V*@O0\.>P!B,,&\'S,T''D((YA6/.AFHDXLZQ:A3
M@3IU.#WGH<X"U%B"UU^.UQR LS@>9V <3L-^.(5?G<3LCV/5CN%X'$'-P\BA
M:1 FG47HJ,] [\NFTPA+C$IH2I2WH(,Y6Z*N.VKR42\*\TG!7+(PC]EP#DI1
MIPIU&E"G%4>^ S66PE$<C\.483A$V0P'*7OA .U'V$>_!7L$7L(NUA>8P(QW
M(CL$_X6( ),(HKX$^G]IH'R68E'>"DO!$X8*:AO!SU0'N$CGPEEF*)QBQ<,)
MP0PX*IP+1T2*X9!H!1P4KX,#$LVP3Z(=]DIVP6ZI%;!+:@@FI#?#3NF]L%WF
M1]@J>QLVR[^"C?*$,H:,(.N_0IV"2 $#H1)<:E^IX-17P"5 D@F_"DK!)2%-
M."-A!<=E/>"00@ <4(J&O2HIL%LU"R;5"F"G>BGL4*^";1J-L%6S#<8U%\-F
MS1[8I+4*-FAMH(QJ35)&M$]0UFG?I QI_T%=I?V9-JA-Z -(O]:_$'F@$16@
MO-1"SZ>/_A^YC.\ORK/AI+(R'-(P@;TZSI1)/3_*=H,PZKAA/'6S43IUH_$L
MV@;C(MJH23EMQ*26MLYT'FVM:3MMV+2;OL:LG[[:;#U]T&P[O=_L"'VEV35&
MK^DS@>6FGYA+30FKVX2PNHS_!?.G?M1&WVN*R[X-:MNB][5"_VU$@P.&<C!I
MJD_9:FY'VV3IR1BU"A18;QTE,&R3Q!RRR62NMLUC#MJ6L 9L*U@K[>I9*^Q:
M67UVB]D]=KWLY79#[*5V6]A==@<%.^TN"2ZR?2*TT/8OX04V1&0^TF9-A+]!
MU(#R'&\Q=]#[7G)#OX7>[Q"^[L6O)VPD8(N#%F74T9(Q[.C*6NWD)SC@'"JT
MPCE6N-<Y5:3')4MDF4N!R%*74M$NEVK13I<FT<4N[:*+7):*+719)=;NLE%L
MOLM>\5:7\^+-S@\EFIS?2S0X$8GZ*1S_9>K1OB?H_V^@]ED_O,7S<'_IBYZ/
M@_ML-V$8X:C!&D\31K^G@V OQTMD*2= O(L3(;&$DR"YB),NU<')D6KG%$HO
MX)1+MW'JI%L]6V6:/9?(-'%6RC1R1F3K.9.RM9P?9:L]?I.K\G@G5^%.9*>8
MZT9DOO$!;RGWG?&6COHG@P$.X*UE!][Z-^%M=SV7":O]E6 ESY"VS-^6W>GG
M+M;AZR>U@!LBV\:-EFOA)LDW<S,5FKAYBHW<$L5Z;I5B';=)J8;;H53%[5&J
M]%FK/-=GAW*9SPGE.=ZWE8N]WR@7>1.E(B^B6#B-5V8X#IZX!4'=H^BY=N-M
M=G,$[B\QGC6!-%@9+ ?+0_6H2T*L6.U!+F*M =[2\_@!"@V\<.4Z7IQ*#2]5
MK9J7I5;)FZT^EU>N7LZKTRCES=<H\5^J4>2_1F.V_[AFOM\1S5R_FYJS_%YI
MY/@2=40MVY>H?N,Y]N!-K,'9</3^<>CWT'>-Q>+^$N-9B=];'B$-G5':E(51
MY@*M$8XBC6$<Z=I0?\6JX!#5N4%1&F5!B5IS C.TBP-S=8H"2W1G!U;KY@>V
MZ.8&=NKE! [J905LTLL,^$$O@W]=/YW_0C>-3[01K30>T?S&4QR':X'8BS'H
M_9-PCXW;KW6)N+?">'KP>YVQXK P7@-:XTT9C7'V0K4Q[I*545R%LHA M>+P
M<.W98;%Z^:$I!KFA688Y(;.-LD+F&F6&-!IGA"PR3@M9:9P2,F:<%+S?."'X
MBG%\\!^&\4%?]..#B!ZB\XV'V'M7L >.XY9K+_J^3<@0;D?[,)XN_-[")"%H
M2U&%IA0C6FVR+;LRT56\--Y;OBB6IYH7':*=$Q5E,#,RT3@C(L,T+2+7/"6B
MU#PIHLXB(6*!15QXKT5,^(AY5/@>\XBP2\COIA%AGXTC0HEA9"C1_\9O7%P3
MHG ^3#T+A-N<L1FXQT8?O@QC682QM*6QH"E#">IF&% K,ZR99>G.HD6IGK)Y
MR7XJ68E!6AGQX08I<7&FB;$I%G$QV58QT4764='5UA'1;=9AT<NL0Z/7605'
M[[(*C+I@&1CUS#PP\I-I4"0Q1HR^<8>/6V.L^P^HNQ/]]WKTGRN1KIFXQ\-X
MFF;2H#9;#JIR="EEV1:,HBQ'X;Q,#ZFL#*YB>GJ 1E)JJ'Y<<K1I5%*B97CB
M#)O0A +;X(0*V\"$9IN A&YK7L*PE7_"A*5?PGD+W_@GYKYQGTQ]8XF)7RPQ
M_L;-J3-!K/M^U-TZ]1P.TC,+:X TY^!>'[^NR)>"L@)-*"HPI>?GV[.S<]W$
M,V9YRR5G\U1C9P;K1,Z(- [)B+<(3$^WYJ7EV?BGE=OXI<VS\DWKLOQ_;+T%
M6)S7]CV\1YB!@<'=+;C;((.[N[N[N[N3 ($(,>+N3=W3-K4T]=ZZZZU;VC1M
MW_]ZF>$VOW[?TV=E8!C.VGL?VVOWO(>H\J/ND>7WN$:4WW .+_O*.:STMG-8
M">,45LPX;N(M],/3%;(ZT/D6:']@)[  C +]2,L[.\34UFE*39V.W-I.;V%E
M>Z"XI"U<.Z\UUBBS.<DBM3'#+J$ASSFVOLPMNK[!+;*^QRVB?L(EO'[%.:S^
MB&-H_=WV(?4W[(+KOK0+JOG#+K":L0NL^@>O8BX^P9Z) M=IR*+]P/8.M@:$
M7+L3_-W0_[U"JN\WH.I^6TYYOSN_N,]?E-<;HI[9$Z6;TI5@'-^99AG=D6,3
MT5YJ']9>;Q_:WF47TCYN&]R^?4M0^V'KP/8KEM+V%\P#VKZT\&OYP]*WB;'R
M;62L)'+<P+A[%*G_W> Z#@V^!FP#)GJ)NI"&-PU!\PP3E8UJ4O&8!16,.7-S
M1GT$Z2.!RLG#X1IQ0[%Z48,IQF&#V68A \4600-U%H$#G>;2@3'3@(%E$_^!
M0T9^ U<,?0>NZTOZOC3P[KEEY-7-&'MV,2:;>*96]ES:Q0'T [ *S UB'("[
M8X2H=IRH> JZ:T:)LF8-*7W6AE)FW7@),[["F)E@E8CI*/60J41MZ52FGO]4
MH;[?5(V^[U2'GF1J5,=G:E';>^J@EM?D94W/R>?5/2:^4'<?NZ7E.L)HNPPS
M.IMX@CT3!7_/C!+M Y: *: ?W"W@+H<<R5N [EF$]EQ6IYAE4XI:MN>$+WOR
M@I?]A0%+82+?I5BQ]U*:JM=2OIK'4J6J^U(K,"QV6]JJXKIX0-EE\9+(:?%9
M)<>MGRDYS/^N;#_'J-C-,JJ;8)]+NPM\Q\"W"U@ 1B&5NR!3Z\%=O 3MO4(4
M"TD4M,8G_SU:Y+O'G'SV.)#7'D^N^QXIWW5/A,!Y3Z+ <4^VT&%/F<!^3Y/
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M.Q*%OS9P%'R[=F)OV(WY"-X6\%: -P>^)IPF"@&GUR7T 7[=Y&XB3>ASQ0?
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MIW\!_MH >U/Q(OP= V\G8EVS"S& ORG@C3A"Y M.Y]-$EN>(]"X2J4"U\ZZ
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M)=WA/:0]?(XTAYXBS<&/2:O_)FGU,1RM7H:K";"'%M: >6 8Z 3JP5T"O[/
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M[/H;0%Z+&,^"<QAH'R.JAL]Y\#D9_H:#UW<'Q@ X+?<1Z<,5\4&(HB/@/P9
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M1!OG4>0UD7/0^^<UL/ ;$EVV1F+HAHTH2'9EVCWLM>G=>&\!.(*?/X2$Y6T
M&?W%7VEZ"FLS8MT(GTO8&VK@;_0:D3_\= &G)?CTT(W*9_]5>V'/H]SS[YH(
ME^@19=G3.E<Q1IYR)GHZ4':%V_.8<,\CT,\O0\"@P6M0$4^]"WSY?VLPB''R
M(<Q%\'J#T_XBD<E=1!K@XF_673;/H6S47>0UD6OTS_F0C;,:/"3*Z)^WD;"S
MR>)'2-0^Q0;T&<;&YPC\%PCPY[#C<S3Z^34:VB.[(:8",<[!VPG@#;Z;R!V^
M68!3&WP*5^5UE\V:RV;=A3V'LGE;"EL+8<^%L+>6L&="V-M#OD'__(!Q\C,2
M]=^1E/T!.VYCXM_&)/L3 ?_S*'"6K3] ;W+ENE_A7_6' )+=4IH*=98'35:V
M\73*S8VG4SJAC_J@W(;I!YJ >IJ%7ML&S;P*W;IOXY;0+]!YGR%PGT+!?H"?
MLN<O-F_$>%M^#N/E?^EN&50!8W ZT!_0W+>@N7^#OOL96O=[*@)'%3@:P-$&
MCFYP#(!C!*Y/TD=0=!] 3;X/Y?<.U-E;&+3_P8!Y!4%[ 9]FSV"P-V.PN"Y_
M?>;_QX:_H3-_A\[\B6S Z0'K ^DKB@%7*CCRT'XIO0O=_S9T_YO0_6] 8[X.
MW?\J=/_+-(VNV0J^50R-_?0T)M"34,R/8\ \BM]\!-%[!"PL'KX#=]K /I7Q
ML_P,!GLSQH?HCW?)#_Z$@R<!')GRVS'*87\MAD@3AF0[.'K ,82VQS%L9Z'7
MES!5UA"!PY@ZYS&%'L%4>@U3ZCOH=V8#%^2O%^7:7^:_[-*93XD#7E5P&H//
M%GR>X L$7Q2F0C(XLM%^(71Y.=T-.Z[ CKM@QV7J!<<0VIX ZSR6C%7TQ'XL
M(Z?H)#Y]'"T=PT ]BMX] L8[(3L#(^/_1#Z\7R E<.J"TQ*<SK*G0B@4'+'@
M2$7[.6B_"*U7H/U:1+P9'!W@Z /'"+R?QFA8Q#*ZAN7T*$;H)=J#7F&?8=J-
M2.^6G\'8Q.89C$_E4^R9C>G/A:_JX#4&IRWX/, G!4\$6DP 1SH=I%QP%,/3
M"G#4T5[8L0=S90UC=!?Z9"=BL8I-906?7(;5B^B/;?!P*T;8PL;?7I;]+>I9
M@*W!?"GWGUUJ'I0O@>=)$;PZ\,T"G$[@\P%7,'BBX4<2.#+!D ^.$MJ.N;*,
MN;*$N;*(L;$5L5B@&7!L!\=^1.4T9LT#Z*678-V7-+IQNHO!K):!?>"./=[V
M''OL#UOQ12RUIX2R;>$0B=&"(7AMX)L;_/('5QAXXL"3 IYL^%, GC*:X=30
M-*>9)KE=-,$;I''>%(WREFB8MX^&>*=H@'<_]?%N4*_"9]0MN$E= N9_^!+\
MKV&;>1S+ZF4C;$?X^J N=!^VGS4AGW9Q-&D[WYRV"1QI0=&;9D5!-*T<15,J
MB30A3J=QU5P:52VF$;4J&E9OH$'U#AK0&* ^C4GJU5BD;HV]U*EQBMHU'J!6
MC9>I1?,K:M*\18V:S/_PD0&67BO9&933P$%\O1NIP(H)\BLLLXOJ(IK7,*!I
M;1N:T'6C43U_&M8/HR&#6!HP3*%^PRSJ-2R@'J,RZC*JI4[C5FHW[J4VXS%J
M,=Y*3<9KU&!\@NJ-[Z-:HQM4;?P%51K?HDHCAE,AQ[O@? K;RF4G;._8YM8<
MD58@%5G $C]CB73'F$_CQCHT;&I!@^9.U&?A0SV60=1E%44=5@G4;I5.K=:Y
MU&)=3,W65=2XI8GJMW11W9813LV6>4[5EEV<BBW'.&76]W!*K*]SBJP_XQ1:
M_<8ML&*X!98,C\4;X'P46_TYI&'KP*H[^%V18L&>,=@V EL&MZA3KZTI==G;
M4[N]!Z?5P9_3[!#&:72,Y=8[)G/K'#.Y-4X%W&JG<FZE4SVOPJF#5^8TR"MQ
MFN$5.>W@%3@>X>4Y7N'E.#[+SW+XA)_I<).?:<\H9-C)\!)X[_=F;T5!C@\L
M M/>;.T#W+"MSP7:TUF9VET-J=EM"S6XN7#KW"6\&O<@?I5[)+_"/4&AS#U-
MH=0]5Z'8O42AR*-&4.#1*LCSZ!?D>$P)LMRW"S+<#PG3W"\)4]R>%B:[?B1,
M<OU5F.C""!.= 2=&^+Q$=A;G*+;6G0&R\R?C_N#'^ST^R'.]L+=[":G16Y?J
M?"RI2N+(+??QY)?Z!"@4^X0)"WUBA/D^R8JY/IE*.3X%2ED^%4H9/DU*Z3X]
M2JD^XZ)DGR51HL\!4;SW!5&L]Y.B:*\/1-&>OXBB/1A1M#NCQ.+I %D=Z"#2
MOQ5@!AA!"M:'M*,#MK3 OGI_/M4$:%&%U(Q*I7;<(JD[/U_J*\@)"%+,"H@4
M903$*Z<%I*FD!N2J)/N7BA/]Z\7Q 9WB6/]1<8S_-G&4_SYQN-\Y<9C?57&(
M[WLJ(9*? 48EQ ?P9I2? .?Y$*+]89@'P"0P"'3AO1;84@]4X3-E(6I4'&9,
M!6$VG-PP%WY6J+<@/21 *24D3#DI.$:<$)RL&A><I1837*0>%5RC'A'<IAX6
M/*06$CRO%A2T1RTPZ*QJ0-#CJGZ![XK]I#^)_0(8L9\_(_8''@7?Z0B,A4C(
M & L"IHS4E9_:<#/JL*)2O%]890RY47K4W:T%65$._)2HST$25%^2O&1P<HQ
M$9&JD1$)ZN$1Z1JA$04:P1&5&H$1+1K2B %U_X@Y==^(-35)^&E5[_!'Q5YA
M;XL]0W\4>X8PJI[!0!"CRM[6<R(:J7\,Y >DR3#0!33A^VK84X+7_#AHSW@A
M923H4&JB.24GVG,3$MSX,0D^PLCX0%%87+@X."Y.+3 V52,@-E?#+[9<0Q+;
MI.X3VZ_F%3NCZAF[6^P1>TK%+?819=>8MT0NT3^H.$<R8N<(()Q1O1=\1\"Q
M DDRE0#I!;0#]4 9D ^)D(7T/#651TEI&A2?9DRQ:3:<J#1G7GB:ET)(JK^B
M-"54V2\E1BQ)25;U3LE1\THI4_5(:12[I_2IN*5,*[ND[!(Y)Y]4<DI^6-$A
MZ2VA?>(/2G;Q?RO;QC$JMK&,RF7PK"?*GL<:!U<OT(Q4O!HH3"7*3"=*@6R+
MST+.GZU"$3GZ%)9C2<$Y#AQICCO/+\=7X),=K.B5'27RR$H2N65G*;MDEXB<
MLQN4G+)[%!VSIX3V63L%=EDG%&PR'U*PSGR3;Y7^O< R]6]%RQ1&R2*9$9T'
MU]Y4V?-8(^#K!.J!\@SH'?"FY8 _CRBB /EVD8 "BK3(K]B$),4VY%WLPO$H
M\N:Y%4GY+D7A J>B>(%#48; OJA(8%M4IV!3U,VW+IKD6Q6M\BP*CW/-"Q[D
MFA:\P3'-^XYGG/,7WSB;$1AE,<*3X-H)/V<R9<]BM68C!D QN#/SH3L+X3_D
M6C"DDJ0"^KM2A5RK],BERH*<JNS)H<J=8U?ER[&I"N%:5\5RK:K2N!95!5SS
MJFJ.:54'Q[ARG&-4N9T,*HZ27OG]I%/V&NF6?DNZQ7]R=(H8KG8APSL"KNV0
MIN/PM0=H!&\%?,X'=QJX8\N@><#M5PW- 8EBW\ GZT9ULFPR)/,F2S)K<B23
M)D\R;@H@PZ8(,FA*(KVF'-)I*B>MQE;2:!PFU<9%4FDX2,KU=Y-2W0T2U7Q)
MRE5_  RI5#*<_>!: (:+,!:!6O"6EF >@#L)\BRB!MJWCLBS$?J_!=JOC<B@
M4T#:71JDU65$&EU6I-;E2.(N+U+I"B115S0I=J61L*N(%+KJB=L)4=T)$=NQ
M%P3G$>BGL?!\A$&'[*WI+SC-T$YP30-]Y7@;J (*P9T.OV,AB8*:H/L@FYT[
MB*R[H+^ASS4'H'^'E(@[K 7CD7@,0^,.8Y,;QN(^A,5M")-L"!TZA  .M6/1
M@^8>A*X:. DBB,1>B+&>'XBZ;V$A8&@)7&- %_L\5HWL+% VN!.;B<+ALR]X
M7<%K [EJ/ 3]#7VNA"9IB@_CD0!-0]].(]F8@1TS2 !F8<<,%K<93+19=.HL
M&IN!T=,0MNS_7)^ B!Q_ Z3(HD=O8R(P&[?D##8@3$ MOBX$=QI,CX94EX+7
M';RVD(<F$]">TT2B.0@22'@D= #L6((=2[!C&?'8CF1D!7:L2&1G4E8QV58Q
MF%?1X H$_G:(VV4(VL7K1-N^PB#XG6B>H0GXV@>T !6=B$$/="_,#H&_7N"U
MGR$R!:<..$60[=Q5MOX"[ ;6@#W0^WO9,RF:V'20"!Y XK,..P[Z EB #Z%/
M#M7*K@4^B ;6V3^+B_[8C_[8]R-^]S:-@K,'J,?0*8+/:? Y$O[Z@M=Y"6-0
M?@9&&2YP]LEK+X< ]CS*4;KC3 H2X9/0^Z>0 )Y!,G@.=ISWDUT9?P&#_@(&
MU85)?(]&SB-S/\?>'/L%T=E?:!B\;2-$E1.R&VH2MF$M6,$ZP#Z'A(\;'212
M!1^/Y3DIK[ULGD6Y**^'W'5G340H.Z#],!+D1^V0+*-?GH =3V'"/8$.O@J"
MQV'XXP\3/09%\=B7_Z<&DXZA&X4IY =>)WS,_#3& /B$%^4\=]9=-F]*N?.Y
MG,VS(6PMY$41^V<4B-Y ,O@.['@?F\)'F'0?(> ?L[>5H$_>0R/OOK11@V%O
MB"G83Y0,?\-.82Z>E]W.8GPO8H"/<1Z1\VP^^[-9=]F\)67SF9S-OZ*S>9OJ
M%QBS7V/^?H^Q^C/LN(FY\GL5T2T$_]9VB&QTZBWV*03.';4'KKS^8$*RFU+9
M6T+8OY*2!'663;]#V]V$IF+_4LK/T+D_0E/] -W_/73_MU!3WVP\B[)"7T 5
M?8H!\Q'4&GM#Z+O05_^AK^D-M/0Z_?,,RHOR&L3_K7^P4";VII(_H3-O07/?
MI"!PQH(K#3QY]-^-9U%JH(^;Z4/HW/>AM]^%WGX+2NX_4%RO8]*^AHGS"@;O
MRU"+-]"!UQ$T]IZ09^#%YK,G;.WCJ7_.8/P?W"(A.'7AFR4L=X5?_N ,1PN)
M] XTYNO0_:] ][\(O?T"[+@..YZ''<]!.3X#.YZ&RKP&1<BJ[*N(Q6,8N(_@
MWX=@Y0.(W/U@N1/W_LN&WTAV!N-STMBX&>-MLD?W>L&?('!%@R,%MF=C^!5A
M>%1@.-9B6#:C_0X,T5YP#&/(3J+=!7B_BJFR']/F-*RX#[UR@\["H[/T%Z86
M\W^PR?^+7'^_3W>>P;"&+R[@\@-7&#CBT'X:W4TYF"9%= EVR,YA-&^<PSA+
M?6AS!#TPC6F\2">PD!W#(G($GV2?SCF(T;$.3]?!>. .;)Y!8?G?DI?\GB0!
MXJ<%/C-PV:,%3RP'4O!$PJL$M)^.92D7[1>A_0HZ##L.P8YUZD2;_?!^C/:A
M3_9@?*[AW5VP;@>\6,6H9/_.\3)8[\3FS2!OR:<U.]WOW5A^5."3 ?BLP>4,
M+@EX@M%B-#B2:"]EH/U<>%J,$5@!CCIPM("C"^T.(@J3M W_+L"2>41D%JW.
MH#^FX>T46*? O0GVTF/V>-=U^9+#+D5G-Y9? ?S3@E^FX+,#GSNX_,$3!IY8
M6J)D,&325LH'3PF\K@)/ WC:T&X?+!C#"%W O[MH=*-"Q#XU]#2L^Y@&$'GV
M;T'UR<$^7O<JEM?'E+#L*F(YQM>'L WMW]B2E,&KAXA:@M,)?-[P*1 \$? G
M'CRIX,FF<2H 3QEX:C JF\'5#9YA\,QBI.[ =X<0G4L8,4]B57F/6C?N(/YS
MXTYF%A^S-1@L9?=B^SVEBRU)&ULBEOL596RS?!Y\50>O,7AMP>E&8UP_&N6%
MT# _F@85$FE D$[]@ESJ%193C["*NH6-U*G821V*0]2F.$,MBJOT__@Z#_BX
MBZ/OSS5UR5;O73J5.Y53.?7>>^_=DF7)O?>"L8V- 6/3.YAN(/0>2 @\]!X(
M"20D]-X3.N;>[UXA#D^>]\-GD'1E?S.SL[OS&^_N?Z7'45GA<:LL\_@?F??X
MF\QY?2%+O([+K)?-+J^&.6HPM\8X_OGA GX>9KDYC=</H-M^;W?9ZQDLN[WC
M9:>O2;;YY<F6A:6RV;]&-@8TR_K 3ED7V"]K L=D=="TK Q:)BN"ULFRX.TR
M'[Q?E@2?+;-!5\A,T*VR*.A1F0SZNTP$_U/&@VUV&0NRR8LLL_<SG1]C:;D$
M.9(,W^+OO?&D.:1'N]!E1_ "V1(:)1O#4F1]1+:LB2R2U9&5LC*J099'M<FR
MZ!Z9CQZ6N9A)F8V9D\4QJV4Z9JM,Q>R3B9@C,A9SN8S&W"+#T8_(8/3?9"#Z
M*TU_M$W3%^60I\&]*XUTP$1JPI)_.C_WIH/-LKL-?3:3DFR,]9*U<6&R*CY1
M5B1DR-+$?)E+*I,E236R.+E99I([95'R@&;2.*Z9,"[6C!E7:D:-FS7#QI,U
M@\8S-?W)EVIZDW^CZ4[^@Z8SZ:_:CJ0OM>V)-EU[@D,>!?/63.(@FU3+@N_Y
M>5*6H_:Q@??6HM^J%#=9GA(D\VEQ,IN>)M/I.9HI4Y%FTE2I'3<U:$?-;=H1
M<Z]NR#RB&S0OTO6;E^EZS1MTW>:3=)WFT_7MYHOTK:8;]<VFW^D;TU_5-Z1]
MH6](M1GLDF(S_ &\FW)(J?)(\?+Q ;*=WS?RVAKT6<'[\YE:F<WTE^GL*)G,
M-FK&+)G:$8M5-V0ITP]8:O1]EF9#KZ73T&T9<.NT3+AU6.;<VBQKW5HL.]V:
M+ ?=&BP7N-5E'W.KR7[ K2KK%;?*S,_<*S-^=J\TV^RB+LJ_GE3X M*_TTB]
M3E)[3_A]+<O]"G29X_T9?D[F^<B8-5R&K8DR:#5I^ZRY^AYKD:'36NG6;JUW
M;[.V>;18>SV:K*.>#=;%GO76U9ZUUFV>U=8#GI7YYWF6Y5_G69+W6X_BO)<]
MBG(_]2C*.>Y19+%Y%&7;/.X%ZVIU,XPZ@U1*_"$;$&B3S*'/#/I,\'.DV%,&
M2T*DKS1.NDO3M!VEV?JV$JM;<TF91V-)C6=]<;-7;7&W=W7QL'=E\;1W>?$*
M[]+B+=[%Q:=X%Q:?ZU50?(U7?M%]GKE%+WGF%G[BF5OPDU>NU>:5FV_SNA.L
MHV6.LU#[*H@#*,H:9"F_S_#:..\-\[.OPB#=E8'2614M;=5&37-5AJZA*L]0
M5UGL45U9Y559T>!=5M'A4U(QX%-4,>E36+',QUJQR2>O8I]W;L797I:*JSVS
MR^_US"Q_T2.C[&//C)(?O3**;7:YE?8O _-0%;0#:K*I!A\@2Y!)_AY">J$*
MG74:::WWD^:&"&EL2)2Z!I.VNL&BKZ@O="^M+_<LJJOS*JAK\\ZOZ_/)K9OP
MR:F;]\ZNV^B55;?',[/N+ ]SW57NIMI[W--J7W!+K?[(/:7J1X^42IMG2H7-
M2^U)N@B\T^H8C_700F09,HV,0@]ZD/8FD692X_I6+ZEI#9&JMCBI:$O5E+9E
MZ8I:\PW6UE+WO-8:CYR6%L_LEA[/S)8QSXS6.0]3ZWKW]-:3W5-;CKBEM%QI
M2&Z^6Y_8_+PNH>E#?7S##V[Q=38/)=>#?1XX!QJ9#\!:@RP!;P(9A#:VM\$[
M.^"^G>3\W08I[0Z0HIXH*>A)DOP>LR:W)U>7W5.LS^RN,IB[F]S2N[O=TKI'
MW%*ZEQB,W>OT2=V[=8G=AW7QW4>UL5UW:6,ZG]-$=WRHC6K[01_9:C-$MMC<
MK@+S+/#VDGIO1E: .8.,D@+W@MT"7:OK@?OVPWL&X=]#/F(9"I6LH3C)&$H5
MTW"6)FVH0)LR5*Y-'FK0)0YUZ!*&A[1QPS/:V*$UFNBA79K(H4,2,7BYA W<
M(2']STA(W_L2TON])J3;I@WJMNDN ^\0>"=U.,YBJ7TXD\@@V)U@-X)=!7;1
M"+P'NI0^X2;&27])FHJ0Q*D$B9\R2=Q4CL1,%4OT5(U$3K5*^%2_A$Y-2<C4
M2@F:W"[^DZ?)@HE+Q7?\5O$>>T*\1]\1W^%OQ7?()KZ#-LV%X)UJOX\'SMD+
MW^IS[ /J [L5[!JP2\?AGI/P'BA*TF)XQYRGA,\%2NA<E 3/)4G0O%D"Y_/%
M?[Y,_.8;Q&>N2[SFQL1C;E[<EFP2_9+]HIT]7S2SD+29APFVUT4S]85H)W\2
MW81-S@9K[X"ZCX=81!8-,1:1+K ;L;L<VFR=$<F$FABAKM'P\^"5\,\U7N*Q
M)EC<UD2+?HU1=*LS1;N:R68U0;ZZQ7&X:[4J:JAK9R'0*^$T*R%O*QX Z#4<
M_BD3$+Q[B<U^+\^N4>9%9 F8$T@_=K>"70-VX1*1[*7P_Q7P[]7P7YKTA9_K
M-[L10 L0..X6%OTM*0@3^Q8FM"T,YBV=C@T^6Y8Y#I>HQ_]N@D1NA#"N?TED
M'3JL_9Y!\+/LQ\=;P5N)S" CB_ !_FY0-2"^GK,*W@=N'+BA\',_Z*)A!TG6
M+I*MD^"4)\'Y=X<SN9 $G(P>>UAD]JC".P-M#YVZ!T/VK.<]R/QNR/M)D-==
M9(X[R:*W?V??B[(;'V] EB%32#_^;L'F2FS.YZLF<.,Q(Q2*Z L_-]AK, A<
M64Y%CX,D@0?]'4G/Z?CC#+7Y%#T.,?D=4@<Q<?29=."A7;QW#I^!2)\&03[U
M;=J 41SX6;;S]EIU)PXR2C]W8G/M1L8!]F: FW"R2-@^\,'4P<])EDFT$+4?
M1=5#['M2Z)?S?$7.)R&\D,3GXF3'@>!+*AS7E%\ZZ7@\U"6G\A[]<1'D_4((
M\OGTQ[D_R)8UA XR[3P+U;Q=I(P0LH";?-"Q!\8/JJYWU5]4[46=![K460^Y
MPED3L=^3@D^N"7#\P]PQ]0]D)  W, G?2)_<A(-OQ!<WHO0-O^']QUFP(>?7
M?RF;-K$^;?WW?32UV&L]Y#B'% -F %WH=JD3Z_^W%^5F5TT$OG\G/KF'OKDO
MB411/46'B?A!@OY!G/P@  ^B_ .PF =>$/GMN_]1@VDYD[&H[H+!SB0^%GJU
MB)?"N\&)XZJ[N&HN]_P?]1!5IWB2_GF&I/@%8O5E^N4OZ/$WQLEK&/UG.O//
MUXJ\<C_RK+T&H\XB]6)SPR6,16PU78\/P P S^ Z!Z1P7+40UQZ41YWUD">=
M),FU)T3=WJHN+[#O!_$3^8A8_9Q^^8J%X6L&WC=;$)S]-<[]URW_9_W!\:06
M=2=(A:CS,#_ ,?\%I_H<WO\)_/)CN,R'\,L/8$KOPV[>@WV\ Q-Y&Z;W%@SP
M#8+D[W36ZSCJ-93[,Y]\^83;057]XTEG#>)_Z^ I/TN(? _/_%:RY!OXW>?P
M*L<-H?U@C-'^#.TOQ=35M.^X)?0OZ/$*@_9E^-U+,+,78;W/PQB?I?.>QEE/
M\*W':-'UA-9'G'LQ'OB5#L?M-0@]F('8&8M]Z7PS'[P*^:LT8DL7[0_2_CCL
M=0;W+X4GKZ+]#;2_%9M. N,4NNH0778>X7&%_?3';T&Z3_Y$^'QN/W=RYPER
M^PDZJ#T07SAK &^(+[9%@I4,5C98Q<XGE+2@?[<\!-_^'7S[ ?2X'SWN0X][
M8)-WP3#OA'G>P01V&Y/(K7#NFQE(O^'5&_'\,3QYO?SXRZV@)]P.:C^#H?[]
M_TUG.#TG'M@3#%8\=J1C1QXX90R%.MIOI?T>N04]?H,_;D*/&XB/8^AQ'?ZX
M!CVNAFU?"1,_RB1V.<S]4CZE3N=<C#?5\XTO!/6"$^1GI_VJ_O*",]0?$!TV
M+00K$CN2:2$3G$)LJ*2'&^0J::/]'MH?HOUQVIZA[7G:7@73WT@O[&#ZW$=4
M'&(ZO1"/7 =WOH>_7H"[?TS$_(S8?I%OG$/H!>>PN\<YW1P3+VP*QIXXL-+
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M6Y'EB%M!]E%#?M:=AMRL9PPYF>\9<C*^=\LQV]QRD9O!N03<T_/I!ROQAZQ
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M9EY-M@3Z/!T\3V/S XZ+7N<VR:^?B+X@6)9 [V8O=SSZ<^9/M/J%?7?*BG9
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M$"OA!48)+<R0X,)\"2HLEX#"1EE8V"V^A>/B5;!4/ HVBUO! =%;+Q"->J1
MWB.BR7U=M#E?B"[G)_MM01O4#B5P1TC!N\!J1*J@:B6(%;& G4Y:G QMBH/L
M1Y;H)+3,6X+*@B2@/%(6EB>*7WFZ^)3GB%=YL7B4UXI;6;OHRX9%6P9Q*-N
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M VJ\%67LPE[*B9*Y4<XA+)/,0!Q!64IH&1W*;AT!K%%^[(D\6!\'<:3@QA&
M#T<F/H+<"0@4&Y!3G_.T_KK3LDD7B71;T!NDN$Y3^8<%*&,IZK 2L0[E;$0Y
MVU#.;I2S#QGP8+E"!"]^\R RY49-N+#5[<,6Q('UL1=[U1X<*_9B3^# T9#<
MC<A)6:LU90-RFB37GZBC&R*/D*:><MU(%XYT(071%@($ \KY [DSH:Q5*(L5
M96U"6=M1%CNQ'__/B5<Y\%=[L";849M=.(;NP-:U'7O1-FSUY(ZW;3B*;B,>
M(X "<MIWPZG- ETQ'70]E.A1/D(,(4BZ[O@Y#W+BQN\<0%MP$?-1UF+4;3G*
M6XTZL:&LS6B)G2B/ ^7QH#PAE"5%;,'ZV(2M:@/V&O*9/^3Y.ZPXJK'BY+8.
MZV,=MLUUR"$ RW9$=\,$9:K/1U<5PP5QG&H%\94'P86?<:)[MA>O[YE+0^RA
MH2=V4RTD=E$M)790K41Y:U'>1F(+U39DLH?82'6 V$ E@/(D"%8J16(ME2XR
MM<91SA-K,!Q[> :RK\76/4I9F4C>'? EUP*A# .4IX)A@O3BJ?P+'X*+#./0
M!=G]!\8;R&L[?F?;/%IB&ST#L86.D=@TEYG82,="K*=C(]CHMQ"L]+N)M?1<
MQ&KZ0P0+O02QDD&!8*;7(9;16Q%+Z#T(1OHP8M'<-&+AG"IB(<U98B'5(^QM
MGPDOE&^-Y>N@+(4E4^M?R/P+-X(#W^]&;%^*(2IB$U[?L)B:6+]H#L&V:#[!
MNG )L7;12F+UHG4$RZ+-Q,I%NXGEB[@(IC\$B*6,D@0CHQ*QD%&/F,=H13 P
M>A!TC&'$W$5I!.W"2H)FP1F">OY=@H;A+>&^8&H_EN;2J?U'8ABR\9%K3O"5
M';$=@>$]L0'!AM?7(=8LHR98EM$1*Y<M(I8S,1/,3&N(94P;B25,.PA&YGW$
M0F9^8C[S88*!68Z8RZQ%T#*;$]3,&'<S8^MC0B=L*<X,2]#)67P7\99P(4_'
M05W5R'5 *%MXU=3:%XY54[F7+8@-*S'N1JS!ZRR(%2NI"*:5M,325?,)1I:E
MQ"*65<0"%C9B'@;F]"SLQ%P6;H)VM3!!S2)#4+&@L\B"SC$+]GX6' E78<R[
M$CDL/XV<D /3>\(!]3=$79573NV!.H1N,!>"';$-P[9-"#;$6KS&@EB!8,*_
M&=?2$ O6,1 ,K(N)N:S+B3FL:PD:MHT$%1L&R6SD9A7TH]G086?%@(@5'656
M1S0BSD3K$J<>*;@:[;#J/N(#84N&9JBK/)9[&-U?WG78#\C\#V(+8CTE]X,_
M04XK$4SX?C&ZIPO6TQ!T&^D)FDW8D#=A!6U&<IO73R4+-F-<LP6#MBWH1V_&
MV&83QGF;<!3>B*/A1HR[-R('-HPWUR&'M9\(2Y2ON69JV8 PALS<6,P>Q'9\
MOY',_Z"\-7AM%8(9WR_!:PLV$@3]9AJ"9BO]5&?9@<;<N6**^,[-4T'[+O2A
M=V'LOPN#AQTX^F['47 [.LS;,!#8AC/UUC-3>9B-GPE3U$L594EMP/Z H=E^
MQ"Z4L06Q 3]C19FK$<OQ_1*\MG +RD=5:7;@P+4+!S%VC#'W8J/B9)Y*XI&+
MB/9A3+,/ZV.?( )'>PX,FO9B,+@' Y4].#NPHU/.CAQVH@>Y_1MAL'XJ5"?7
M O%B6,:!V('O-Z,ZZ_'SM<AE!;Y?BI\M1-><'JN;!M4D.'!PVX<Q#!?:@IL<
MT+#C\JZ8JDQ>LC",:?@PD.:3P/?D,9OFTVMB,%#A*D8@A_WH27( H4TNVT"]
MA)'Z 00[8AO^O0FYL")6X?ME^-G"W01!A\528SB/ S;*1?#BI,*/@YP #C)"
MV"Y$L(.)D@E.,KF&,;<H?DD49QQ1G &%T!L0P$!1 &>H0P7X.^P7_,B!%RA[
MPJ2P_$.HVSZR&G=-Y8 V(%;C>R;\;!$V,3HT+15%+H*?,HE-369BY.2&@[TD
MUHDTN= 0Z^0H5O!15. H$CXJ,/4(9O*FMB0&R.+H*8B3^X)Z\;=8%V+HQZ!N
M8AQ3ZW X\'77'FP+*'?MWJDU2(L.3.5_<,)$71#8S'#B)B?SO]:DR"$/!>2A
MC).+ZI*IO3D:6,D:J(0ZS]1&%S4<)Y0Q>%; ,4(! T7YUJE3:^6 .()V%3PP
MM0Z' V7NX"3WH4VM ?H#]:43)/[*_?S,P<@1?ZU'49MV>+2Q?>AAO1B0QX%A
M/S$C-X-B0S(CCP5"\L;R>,T,OX.>J@Z.$=KHQ6O=Q$[YC7)*,C_O]#H<M/4F
M?+\*S;<(]9TK/JVK["\R*2>U3#L[E'4HT\X7>0.*<F8([=23=,@%F2[8/IVQ
M4IW0%@ZH@!W6APV.V5;8+BVQ?YI?0(X?"!'!J1-RN,@3@O#]6G(-#GY]SD^Y
M:G^3:?R+O%]S(?^1F\!^ZX\\@K!M!&.=!)*/3A.>.IO$!^O#$X-Y#VP3;M@N
M79X3(FAG/M1Y#^J\$75>CB9C4)V6J_<WF3]/JOUU3\[/W 3I$/Y<IT')36#=
MQ&$[3<2)(!$[.7ED="P*B#'$X 7[: 2.E^%8'R>N$R+8MKADIDXH9D&=%^I,
MV_=G_H5<^^(Z+<_W;[+^OB;DU[TJ9)Z O'%:BCRJ<=RHPDY>@0V[%+WD(BPX
M/Q2_DT<06;T$G^+44Z+84.<E.+U16T_+_7L>Y-<GYOQW>9!?GZI+YB3(M1F4
M' AB"'E<Q+YR'CO<6>PCI[%2>S&2Z$+B[17$?JSG+2A[!=8M'5FG7M.ZAA%_
MK4'Y^;2<7^7]F@/Y>7(J*?/G7AAR'0BYD8*\H4X&U2]P/'W%B@$^-OK[6-GW
ML&+OH3]Q-_//_1_D&H1WTZ^?B#D8F?X\$V0+8B]^CX?X2KDS*DF)DMZBO_J*
MD@?110_9B'B E7<7(Q1R/\QU5.(*QC07,7HYCY'D,-&/E%Y1<B"5T_D/,@<0
M-YU_(-=?D"=CDCD ,@=!KH5X27EEP+^9$6R4_3"/T9.^C1[]-1RDKB"/BS@X
MC2$/\HDM(QC+G,6H[^<36WJQ@W1A);9CQ36CX1J()HPI;U'D9T_G/Z*G<Q#D
M.13D&1QD[N,.,94V(L_#(/=#G"-HL6Q&+'L5EKN1&$#/G5P=WH4\VI%'*_K-
MC3A@U6,'KL$.7(618 7R*$4>Q6B/0HP<\S&"S"62L K+L9D.8W5^I.A^@OAK
M#PBY%N+N+W+)-2#MTU5;2ZEN!L0RQ%IL:ILI=V@+<,+*11[96"]9.'AF4,[D
M4$"KJZ)]M5&B$9& D7(<QE:G4$(T:AN)WP['DD.)1Y3\!RG7C9C: T+F(<BT
M&;D&@DRI_3P=-'NZV2=13@A=B.4MQZB9%;$5K3NU%R4*>43B!!*!/$XBCS#*
MF8^J&#/I4)Z4$H@#F#]*\L-WOO@K3[26&W$9Y?Z@K+^P(J;V?Y@1\.<Y' 73
M33^6^+D'9:I;!A#T6!;YA))5^/<&?-V.-MR#Y7)AY,2+W4@0K2Z&Y4OC,"*'
M,E31 CHXE)FBK&,XQ'@CFY,8Y62AS#Z,/M]0UEV0)W+^W /R<PT(N1PK?+I;
M>DT/2TZ4H8(&7Q?@*Q-B-6(#EKP-6]YN+'L?ZG,0+7\(AU)1U$D*9<AC;:CA
ML*Z/_RQ1E@LR(G?J)!":*$T=6YX*RE5$*$RC:'K(.3$][))RR6F ')[)J8A,
M61L3=%CN(@0S8@WJL0'+WXKE[\*R.7%8)R-L?BQ?!*T@B3(4L,=H4D[F($\)
MD<.29;'V9+#%2F-/DL31X&?N07QZ_</):?D.T[+)W,?4VHNI:5*5H$8P8-F+
M$<L1:U#&>I2Q%<O?B;UT+[:( V@%/BQ?!'N,%):MA&Z&'EK'$C]QQQ8<BK66
MB[%[-[)]0<D]D!#X6_Z!E/\S_T!.F>342;H+9 Y"&L<M*8RY)8DE*&,%EK\&
MRU^/Y6_!EKF3LN+@$-J#'_]/[@;A06:D=0Z@)0]@#7*AE'W8>SBQ/CAPX.1
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M6:PX@FW&\G:B+$XLFQ=EB" [6;24)M::.7[+'1F'(W*(E40'XCYBZCGNI%M
MNB<ZY%)I=$O%<7H[A#A /Y7WV(78AJ',%KRV&;^SB9H69=&CK 6(I2AK!3)8
M@_(VH+QMV'OWH#QN+%L(9<A@"U9'IJ9H-1=L2:'(/ U12]D5N1AG2$8"*.,
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MD0$;!BZL.,JR8B"V#GO?6IP1UIQ"((?5.&.S/$).7PD#M+4B>08.RN19C?6
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MH]1$W?OY5$6P8FX*K%D4":S,_K"1U16V;K>&G9Q&P,ZK"1Q"RL!U6 YXI([
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M8+N;+"<$7MCF]312 G?LEA))9H /L0-<@A/@<IS!J=(%G%H(@.\E@/,H9I(
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MX:,4:^D'!9[L]RH2B>\TU,+?:AO[OM&W<WMC[(I[;>EE\\;!W_*-6X#YV\
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M%LI@X:(%IGYZ8!9M &9IAF!>9 @6-49@T6H(EKV8$4.PFL"<,URSOF:X8OW
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M2_<GCI_=[SO](-S"+^.OXU<=KCJ#[7K C84)'#E8P8F+#3QXV2!0A ,HLMQ
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MB(VTB#A<\1IL ?&9 Q(T B2L QRB&L KK@*"$HH@3I##M9$&!8($J!)$0)O
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MWA>\FKPW>(J\.WB6/,\XZ+^3<=E_CO'8?S;T$VEK&!"W,,%]<P2XS$2 \U+
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M69Q4T%*<4-!7'%^POCBV8&=13.&YHKBBISGQA6_2X_/?)\7G?TA<"D3@6<A
M[)^P>]_^Y9W8><YVLZ%C VQH[[ ,FATVXMPXY""ZMM]+::@GP*"K,\BVM9U)
MK&]A42L:XL(+:Y,2,JK2,A/+<PMBRLI*HDH;2B++NHLCRM86A9?/%3++3Q=$
M5#S.B2A_G1%9^CXYLN1]TE(@&G%!#F)[5H5K@/W_0B=")[#W'!A!:,>8!)I9
MH\<Q,68G-#+B(=\W1-9=T4^W:NH.=:ONB/0O:8L)S6Y)B$UJ3$F+KLO*"Z\M
M*0RKK2\,K>TJ"*E;D\^HF\UEU)_*8=0_R@RI>YL:4O,A,:3Z8\)2(!YQ_BQ
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M XS^[X SOR#X8M]C<'-"-+YJ$\38/R;)L#]-5.&X$Z?'?3G&5N14I*?"H=
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M1GLL*W,H-B)S0VQXYKX89N:UZ(BLU\S([.\,5A8$8FB_@^>1[74J0K<*$;J
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MBW4XOQ?G-QU#J.1_WD%%7L?Y=Q$B/L"U?X*0Z0N$=%XCI/H%L2D XI#!:R
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M]"V)JO(KCFKV*XSJ)N='K2;G1LWX9[,.^F>Q;@1D1;\A94<O>N;$@!O&Y7>
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M1X[I6\@S'1=YIADHQ]3C9-^H94N_4"V1_$MUHL2?:LVBQ^H=XG]HS!9[J+E
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MG#;T7G[7P*O_3P//I>\,/?K8?QCICAW''-B'VF]?1K01VBO6$\T?@!L<Z<K
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M7VSX*4=:ER5(_8HJJ5XQ()4KUJ1\U9T4KP:3PM5XDK^60S+7*DCJ6BM)7%U
MHJL;2>SJ"1)<^9:$EY^1\"(CX85_V0'](=1]];;W/9CI'WHPI0<Q!D>($HX3
MA9PB\CA'9 M/;G*%2/MS(F7X<JFO>"3\1I+XWZ@1[QLC+#QV1'>]B>YA(;R'
MA?!;+  C?YKX6UQ<WZ+ WYX&WX(GX,4_;,68KT/N2U#OKGU$3= NAW;N":(D
MO"7T/)'G12*[JT3&UZ%_"_I?$TG?)1+<A^__=00QHE_DB7[6!*;XVIGH=VP0
M'V%3\ B+X1^8^'_@HGN,8C\^#)#$D[O_, #]?N3>?>!]#Z82>8^%=O(G1&&7
MH'\-^E] _S:1YATB)>A*/B#B_PCMG\%C,-*+^&L$Q/), 6CCM1712Q^B-]@D
MO\7F["T6HW?= !<>VPIV_\,*Z,]%[E-'GLQ!S0N0=PJTPS\C\KJ)^B-GXWM$
M&M\1R4-7] L1]SOT'H$_/FB_^T\_! CI?1_$ #@!& :63>^?#!GI@>#FRQ;^
M R,]:48Z(\#OZ\'O&\/O.\)K^\,IQ\+K9\'K%\'K5^-W&\$TT 7F@<7TOO^P
M!F%LI+?P_F_A_=_0,7I-%\!7] J._Q6]^+O7\1(\!W_]#XRG+<,X#<2@@1BT
M$(,!_+X=8O!!#%$"1NF(H0 Q5(!)>$<KF '-'FCUXMQ+<>Z54%F/\P_AG#O!
M(7I&Y^@IW00_T9_XZD^\XS'>^0=X!!Z.@HFIRS"ALC3CE!&#*F+00PQ6J(6'
M&*,PQ)",6N1!?P*H19[-T.V WBR<>1[.O9B>T#*<?PW.OPGGWX[S[J??Z30J
M\#FF[/?@,?V"JHST.WX$#_X')@5]27DI)BXKR7B*DHROC1C,$8,+8@A"#/&(
M(9OWAHJY%U0%W<G0;(/6#.CTX-R]F)I]./]*G'\#_4!;H+J'OJ/C=)^NT+=T
ME^XAJKN(_&OHW0:W_@>F("?-%"0DF8RX!).5D6#R&B(F;21BXO;BC.\K?$51
M_&>4QGM,^=Q#*D-.==!L@58[=+J@,1?G7T1W4(MO:"UFP"#=YG;2+>XH?<F[
M2%_P[]!UX2.Z*O&&+J'*%U'M"U*,^T3Z7YB:A!13YTLP-4Z<:4N(,6UE<::A
M)_Y.Q4KLF;R'\)%T*/]GF43> ^D<[KY,"=V5J::O92;3;9DVNBDSG6[(=M,7
ML@OH<_FE])G\:KJJL(DN*^Z@2TJ'Z8+2!?I$Y1LZH_:03JJ_YHYK,-Y1< 0<
M5F?\CS!MZ.O">QN1D)D+!<Q,5O#.6$/PI[Z)\!<M1\%WZO[\;]1CN%L:&=QU
MK0*ZIEU.5W3JZ*)N,WVJ-XW[1&\F=TY_#G=&?Q%WVF Y=])P'7?<< MWU&@_
M=\3H#'?(Z":WW_AG_A[C%X)=QDRPPY@)A\&V43!#$F<F\-XV\/\.'/?&7L0]
MM5'D?C;7X=TUM.3?-/3@73,)XUTT2^:?,\_AG[8LYI^PJA(<LYHD.&+=(CAD
MW2$X:#-+L-]FGF"?S1+!'IM5@MVVFX0[;7<*AVV/"[?;7A-NL7T@MMGVJ?A&
M.R;: -;;,M&Z43!SY#^B[TKTISMN?6[P78[B=,=:D:[;&'$7[)P$9QP"Q8XY
MQHH?<DH7[7<>*]KC7"K:Y5(MVN'2(#'L,D5BFVNGQ%;7V1)#K@LD-KOV2VQR
M6R>YT6VKY :W@Y+KW"Y(K7&[)[72[;'T<K=WTLO<F'2_*Y->.@IF"^_O0MR?
M6&J^\X/_#R"ZX<O1YZXB^M1#ATYXV@H/>GI+[/$,E][AE2BSU3M;9LB[4':3
M=YGL1N^)LAM\)LNN\VF36^LS76ZU3X_<*M]%<BM\5\HO]QV4[_?=([_4]XS"
M$I_;"HM\'BKT^KQ1F._#1I"?-PKF0+RW7D0_!D(_$OO\:/C_"*)/ @5T(EB#
M]H=8"'8$N4D.!0;);0R,45@7F*JT)C!'>65@D?+RH'+E94&URDN#&E7Z@J:J
M+ Z:J;(H:)Y*;U"_ZH*@]:KS@H95YP8=5^L)_$)M=N O:K,"7ZG.#&0CJ,P8
M!7,F[K$_EE LMS?@OR\G8X\+[W4"L1R(5J8=L::\S=%.HO61OG*K(L*5EX4G
MJ/6%96@L#LO36!A6HKD@K%)S7EB=YMRP9JV>L ZM[K!NK5EAB[2[PE9KSPC;
MHC,][)!.1]A5W?:P'W2FACW7;@MC6D"S-8QI?(1Y8-G%,OM- CPG/-=Y+/O'
MP4'$LC-1CH92#+GUR?;B*Q*]9/OB@E5Z8V(TYT4GZ_1$9>O.CBK0ZXH:KS\S
MJDI_>E2#?F=4JT%[U$R#:5'S#=JBEANV1FTR;(G<9]0<><&X,?([H\E1SPP:
MHI@^T&V(9#H?>8?E]0?D?"L-GA/>]_18[''!;BQS6S(D:4.F'JW,M!'VI;M+
M+T@)4.Y)C-#L2HC7FQZ79M@1EV,T+7:<<5MLF4EK[$33EM@FT^;8=M/&V!ZS
MAM@^LTFQ&\SK8G=93(P]9U$3<]>B.O9/TZI89@R,@.%'_L(<_ XU^ *:G\!S
M'8?WW ^&\7ICCABMSM6B_EPK?N\85\F>+#_%F>FA&ATI,7IMR4G&+8F9IDV)
M>>:3$XHM)R546M8E3+*J36BSKDGHLJY*6&13F;#&ICQAV'9"PBF[\?%?V8U/
M>&PU/N&=Q?@$9@9,/_((XW W!>.0AWD [2.EJ '84HS]50&/EA6JTZ)"<][<
M?&=15YZ/?,>88+76S"C=IO0$XTFIJ>:U*=E6U<D%-I7)$^S*DR?:ER4W.Y0F
M3W<H29[O6)2\TK$P>:M30?(QI[')-YW')C^T'YO\UF9L,K/*3V86'_D-U\#7
M&>^?#CI5^KX'LP-L*H/7@0]<4J),\TM,N-G%#F*=X[QDVO(#59KRPK7KQ\0:
M56<EFY=G9-B4IN?:EZ07.XU+JW0N3&MPR4^;YIJ7-L<U)VV96W;:9K>LM,-N
M&6G7P>_.F6FO'3+3F6U6.K/YR,^QF OPWA>0]W%H[ZN&]Z^!Y\2Q'W$L*).G
M[G)#FE%F)YA:ZB[57.RO5#\N5+,Z/]J@+"_!O"0GS;9P3+9C7G:!:T[6!/?L
MK#J/S*Q6S_2LV9YI64L]4[(V>29G'?1,S/K,(RGK5]>DK%=.R5G, =A]Y =<
MAU]@#IZ'_S\"W=WP?D/U1&MQ7%0%OU4E33.K=6E:E36_I=)5HJ'<5[ZF-$2]
MO"12KZ0HSK2@,-DF)S_3*7-LGEM:7HEG<FZ-5U)NLW=";I=7?-YBK[B\ <^8
MO/V>T7E7/:+S?G:-R7OI')O+'(']1^[C>OQL'-$9;/4.07?G9*+!)O@M^.#Y
M^+JK3IS:ZS1I2IT%-[G66;RVQENFHBI(97Q%A'9!6:QQ3FF2549)ND-R<8YK
M0E&19^RX2J^8<8U>T>-F>$85+?*(+-K@'E&TSRV\Z+)K6-%/SN'C7CJ&CV,.
MX87,_B-W, Z7,0].3,3U /WMV(8/M!(M ]V(HZ.11RV-JC2YR81J&QV$E0V>
M4J63 A0+Z\(T<B=&ZV=4)Y@E5Z7:QE5D.T67%[I&EE>XA9=/=@LKG^X:6K[0
M);1BO5-(Q5['X(K+]D'E/]H%E;VP#9K ;$9S&]?@IY@'1R<1[9F"ZV$:K@=X
MT*6@"WY\"K;!D]H4:.)4 ZILL^67MKJ)"J?XR>8VAZAD-D5J)T^.,XIK2+:(
MJL^R#:\O< BM*W<(KFMP"*[OM NJ[[4-K%]G'5"_Q\J__I*%?]V/YGZU+\Q]
M)S)SWYI_N8ZY?P8U.-2,<6C'.,"#KYY%M'@V/!=>-\X@JIHA064SM*ADA@57
M,,-)F#/=2RJC(U AN3U,/6Y:C&YD6Y)1:&NF65!KOD5@:YE%0&N#N7]KIYE?
M:Z^);^LZ8Y_6/88^K9<,O*?\:.#5\L+ LYD9>C3]RQ74X 3&8!_RW]:%<<#6
M?P5\>.]\HDX<Z^<2C9_#4<%<9<J;:T39<VWYZ7/<Q)-Z?&5BNX,5(V9'JH?,
M2M .Z$K7\^L:J^_3-4'?NVN2GE=7AZY7UP)MSZZU6AY=>S3=NRYIN,W\4=UU
M^@M-ETZFZ=+!M#[R">;=$=1[%W(>@MXZV([^Q41SEL#W@&J\+@"92R0I=8D6
M)2TQI[@ECH*HQ9ZBL$4!,H&+PA1\%\:J>"U,5?/HS55S[RU5<^NM5W7M;5=Q
MZ9VOY-*[5M&Y=[>"4^]%><?Y/\K;SWNA:#>7*=G-8<H?.=G\_E-BP]#?!*W5
M_;@FEV,NK"1J!N4@9Q6\[VKX_S7R%+9&ET+66' !:YP$/JN]Q#U7!TJZKHJ4
M<5Z5).NX*EO6856QK/VJB3+VJZ9*VZV:*V6[:K6D]<I=$E8K+X@LE_\@LNA_
M(6F^E$F9]3'ICQS!W-L-_2W(></(7XF!#Y^[#OY_/?S_!OA_D &K&@UO[@?K
M[#ZD0*Y#NN2\Q9P<AQQY=D.> INA(*'54(R8Q5":F/E0OM!LJ$)H.M0L,!F:
M+3 :6LXW'!KFZ6\^S],;?,#3V?A<H+V!";77,[&/C#P+- S]0>2[&MJ+!HAF
MPHLW0:]\:.0Y&*+$;?#_P_#_.^$_X4]-]DF1T7X-,MQO3/K[;4EWOSOI[ _D
MM/?'D.;^=-(X,([4#M22ZOX.4MZ_F!3W;R;Y_:=(=N]]DMW]%\GN8ISLSG\9
M^836EI&_4H-\ET*[&YJMT*R!9B$TTS[T8'SW$SD<(C*#-]8Y"?]_AD_2YV1(
M\IPF29PS(?%S#B1VSIN$YR)(<"Z5^.?&$3?RT=!S7>__.YRS.-&9*]@<P*R?
M@E$_Q?YA&\9Y$VJ]8NA]#Z9]5 \F$[HQT V KO,)(HO31'KPY:H7B60N$PFN
MP6-_+@)*V 3JXJ9OB<T8-L=?!F,12GK_J.HMQ'$+%_HM"-W$";_\ K_S*WC^
M#T/07[V5:.$.W ]V_]N#R3Y"%'><*/ 4D>M9(LM/H0]=M<^(9'$:L9O0_PI\
M ^Z">Y+8$*IB,P*__\ .&U1?;-!&'MW%8O0K+K[?<-/Y#7'\AN1^O03N_\,Z
MU'T)<N_:^[X'4P;M'.2<<(8H^!/H(V>KJT3ZUY'_+2)I: KO0?-;\#WX ?ST
MH1\RTI/Y';'\H4;TQ)3H&6KR(ISH%39(K[$@OID.EA*]Q:"_W?L/_<B]![E/
M&?ET%+3SH)T$[1#D[(:<K;Y$_E]C_)&K%#1Y/X[2^VU$\T,O9*0?\R=X!EZ
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M8%+AR2/V$7D?P!@<(C(^2J0);ZYPFDC\++PU_#E]*H;-ISQNMEI$ETRP&70
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M]+D5-+(!-+KT G3M)6CL2]#[EU$,7W8"H+,OHR"ZG P4JC9B7L8%=WF#ZI%
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M>U*X-9'G$),7-(E>0DQ>MB=ZU9OH]7 (!10G;U>K'F'_#OKD;03Y+33VUJO
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M>.AG*>)J!#\=X)\O.*/ F0J^?/!4H+4Z<"P%1Q=\Z%/OPQC%)3H.CDE<MEO
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M=A6%T6,EJ@?$<0?A7$4G/HK&KCR+[R,6%Q&+BW_2 OR<!??Z8ZKS6%I/$%6
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MCJ/-@^#9#>[9=;@F)I&/^).^]42-D,I%L"<%OPM;!>T)&VUAEQ$@'9628-2
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M3,"$-"I@1AH1<$0:'O"(-#3@=> [::C_W[)0/Y:#] GTP05H^Q/0WP>@K^>
MS07(1=@Q!#LZ84<]["@+E5!AB"'EAEI35H@SDQ[BR4\)]A<D!H6*$H*CQ7'!
M29*8X"QI='"1-#*D6A81LE06%M(O"PE=(PL.W28+"CTD"PB]+/,/?57J%W)+
MYA=\5^X?S,K]@UCY=?"<@^\/%:/D10F\@]N9 HV]!F7Y<MC1CCZJ@1V%T0+*
MCM2EC"AS2HUR8)(BW7GQD0I!3$20*"HB4A(1D2 -BTB7A404R(,B*^6!D<WR
M@,A>N5_4:IEOU%:9(NJ@U"?JDM0KZF6)5^2W4L^(.S+/<%;N!5Q%#,["]Z/E
M*+>K5)O6IZ#%5\&6/MBQ%%*E"B5I'N*5&J])2?$F%!]O2S'Q+DQDO#<_/"Y
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MZI\C=X+OSH .[P 9GP;]WX8N;N';F]'"";1X7'X'Q[>"Q%L-IX0>-*[!4.>
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M.G&KL!6G"E=QJ/05N\I0L:V,$>O*%+&JS!6+RC+15]:(F5H\T@-\U0/0W /
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M,IOQD2UJ,AY=;$:1FZA\(P![/4!YW?O0C[(74]VRBW$*\69!8_@\8"<N#&5
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M+KI(;&.JQ#IF@%C&CA2+V.FBCULNNEARR%@2Q1@2OABRA.BOQ2SZ#SE!ZG\
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M_U;";87\>?5DT*7M5F5<$M-5&69HT0%^GO *@D^4[)#$JZ=C;$(?&\%@Z\&
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M!AE3.C*D_R('X+-CF+8R19T2JW;GS.:]910R*! _5*0'3<FEC^+[J1-*1%P
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ML_5"<;3>* Y61\3.ZAZQM7Q.;*P^@7Z2XV#8_<"R[6IE"K2L"'_(QQ: **/
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M:58H=N*!G=C 0K*0(0-,E>$$,&; 22>8I--)&02Z=#HO'06FJ24EP_BLP#.
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M'A\@2MS$%A[ @!@PB <@-H- ^'6USXD!^!'G9F) *!Y@_C@1@&"YE(@ #O@
M8OE X![44A "K/ !&'5"P T"P'/"2Z3T" !$LE2&$#!^#1]PC!" 621H@PB
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M[?$IHNUR$0^@3?2>P*4EBNN#",+N$_L \*.D)XD!^#D0XN@!09'E/N;!)3Q
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M"P\1@!\/,*]&!,!W<O89Q&%\0 8+$0(?T$\<@\8'8"*._0-@ %]4'C]/>-H
M4ZV,?4'-<D96US$\[]T^@J#RKL_CM.+FOFGB5[_I?R.AMU9_+LQ\FYJ>6R(\
MH=]?EAKAYV)C86ZDIWU-357]NOX-6[P:^7 )=B(C!:\>H9%HSX- BG\%K.Y3
MV2&(-P@+8@!^_BARGS[P &^(^(H ,"K[#P",U3\!(DC_ 5!!'";!!TP9_P,
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M >9IE%V3)TT.%-O8T.^MK8ELP6W&QDCS_"6E.="2@V^PH\.MM9(_N>#C][9
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M@-D"J>!X.87T/SB3WMT'B.4&6 SSZ.H:UO<'./CM,3L!23X8DB.'HDWA\ 7
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M\@D6:S<V#C@<5;OV<W7%(^[X=91Y>B<0-U.ADVZ@7(#UI2F3H^4!_^!?3&D
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MKDY?!MG5Q*LWSR7Z;)T;N6&S&/0^9HPT_"!W2DK*Z;M+3Q)H[D"=(TCIL'+
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MJZ8W9:@QH##TFW[T7I$.N:&_4*VK4H^_/#AB;X"-J[\H=_QSD,'= WM'(';
MXR81:"=@L<PGZ&;!0QA0/0=0R6_ D;XD.1'E9'?4<2^]G+XYOLSQ$TA5NZ%+
MT,_0=-M 6,9L^R\5IZG8,V<F:/[9 SBK1$.*[4$,-Z_D \TI$:M<IZ&L$)--
M0:B<5;E6KIW/4Y, $I0BUN&#:OV*6 &S#B5_SS%>].M/OFA ':-^=08ZLFTD
M*N4PGFHL8)LYO"8E%.I+=;D*ZAGRK:/ 9D-L68=$ZQQ/!M8KNQ)L]=TOKT$R
MRQ0.]PV&:-":O982:1J[8./I<<":[).FID&5K7.J=]Z98^3PGEZ+DJ&Y P=.
M=GA]R_/QPSH@/2^'_:8JWAX]$Y,89SUJ]I167%:UQNT'\EOS=\>\D9Y>N!5O
M9W]/;]BIJ/J&$Z>.OY4BU^.B4&+0J?9CQVERL!3:[(?&=O49"9BQ@>[DLL?(
MC:,)8R/U,J26KGIT3X.><LMKB1^P7YKYX\2S/-5#H^82MATKG5%Q)VQYVYIX
M+^,BSY?NB\P*M0^WM: VLPH^KR!8[6J33,6UTGVL[XF;,?,]93)YV@E7DBTH
M(G,LL^;O>,]0P:<@R/",1),\#\?/_&;KB]R.TC3HL[0:-#WAJM\])8)2H*D.
M-Z>@K6T*T;"IKP/<*Y.EI9D:9C<$;,,+7=_D7<%YVQEACPO>EX>IA,,667Q"
M:2GTRRJ/!!:U6-X_:'ORUJO0$RM2,K5=)U9T6G0TE:Y]5(^;[S^*G?++]5_:
M=!KY4]0=&#\+<,,RJTTOJE=XE']$GR;[=$GGDQB]LDS0:8'9R<L*+U$W<7+^
M\^R,S61H6FBBL:=NGFVR9:["3$ADK[&>D%B+X!F&;IY; 3R74K 6S>!QE_)2
MF=<]K7VJ;QE<U 3K7+R:1+51/;VVG%1($IWCG,\%97&*N^#"-VC>@ +XTY5X
M!39SY<M/X]H9&D-NRON:I@8ZXCR8]-,O;+V93F<E,H5*I6K'<<>:(2*NQ,_=
MTG(N:/^#BJ(Q&L>6<Q\-Y10$P^\M:Q[JZ+F4>0=N$?5,88KB\FU!<9&(BO?%
MQ[#+#*=Q/WC[8 *%H'5"=SAO37NOZ&OYHVIG0\5I5 /8N$IW2&YAU^&,+7?X
M<W;Y U.Q&0>HF>.>W=6&BMO0W/8]P"(6("+LCTL?#\6F%/GD:5_Q8^?3XO(^
MQ)!Y(4[N$B1&;+S?#C"MG_<@OYXG.7HU^P^U*T$6QDKR?&EL]->R)^@;=("R
M>YD^;=XK.;!3N:5G3GF7][T-/:VB<B<*Y*<JAPB09P;.A2=,^_AX<Q=:T^<_
M>4118Y9-KG9TRXS:]D#1VP0AJ@E<A<@ C_)8&<OL7%Y6DKGA=&+2+_/F*Z@.
MQ!D6KO:Q" %GI>VCV,Y.EZS3(7+S$P1Y#K$;Z0NP*W^RTCX<L, !19 ZB@U/
MXF28>QG,RM;6FE[ED)?QQ<PX#4VZN#],0VLU^2H83G*6.0\TS./&?;-[D<W?
M_ 1/2J) 2E&,SD&>J/0V@14&M(?^&<1MV9PJ#Q('%!UV\+H8D$@]G</8^V$I
M8ZW*TOZU:E-/Y=LE1L;>K%3Q8:]<>2S)2R^QQ:A?*:DUL$X1YPRZ@)VW\J\_
MT\J^@Q]>VF;^&7VN5GK3O?=%3NL]BL$F2U=6@TL:.GI,&K)C/V@33P6N'!_Z
M?"ILX;Y']Q^/3G =)<%]_X9DRV2GF[GX5H'O2C3HEHKG(H79J4Y+UQ&J^3):
M7B;F!=C,J3@!SRA*;L$G2OHY64'95[(*&=MZ/7&^/6W-O=R+.F=1?1_[^]8]
M?YGZEK3-9$M=BJA;8J*F5DE\D6MD(E76/\^B? 71R4-#^F[Q! V._QXN%_OH
M>TP?3B_8I+V9-U(RZQ"?D,J3K)HB:/,^H=' H.VDC(=S2X;>24.]U:L#SL=)
M<=E!5.2 <J]RQ^G9H@>L>?K7=4./D=/OE:3B)#H&Y ?L%5_ *=_<B=[5VX"G
M)N>JN>VT7H4!A>-4357LNH3,*,I>[AB2>F1U[\S],O4ZYR@&I(;2W&:@!#PZ
MB<F-:HH);'$7. MP6;-H46D7.&YDA6RQ#<7LG08O.T-Q70D!J4<W +KD['^*
M'K:(A<V1C^\(^T:P[AT&*Y X)'2!!?VT5+*:TV39LA$XLUHS"=/D6*S/=($V
MFIH"68-3:UJ6%K4NF:N0]>^._GLN]07.5 RH% -R<-3XZ0LH-M.'T-&A"+I9
M_XQYVJI*(.;04R4YW9I&R;G<R!';P3:"EL3EA!U5$#93$:PHDT GE8:],]X=
MT4N.M+!M1TTXI U0W\/C^:ETFZUT+X"F)C46MTH:MH^BER"3@"K7LCNL,OW=
M88L;%;9W1GMC UN@VSVSYV%[<OQL:)E#2_[U!'?#.*22<*+@QIU=EV3BA#0O
MAC@<X92\=_ #\]3:N.;>Z0JHW?33SCSKEYUK'V&=UG/Z/B>BK9WJ*L5-K);+
M?KT,>FCC8 63LR[\H-=YOOB75(S<Y&D,R%4)5X7ZB,\_VN:[.HM*3=[+\"(:
M#0>>B\=(])BNFI5&?3WC6:_D+@9N$&JZ%7])KXC/.SLJ(?-QB@\N!EVPM#G&
M;V6/K&]]I_+&9R9_XPM;?X:K04/PB<HIW22:V^\:>WE5K<\GVT8>F9JWR$RS
MK8B^)LO26'\79QY(_/@Q.%H7<>'[6$]N0=OZXQ,<DR?M!EWDS<R,AI.S\MYK
MJ\1U.,S3A*I=JCJ?4/TF2/UQ/U]9]BL[F+@V*,$=JRIZ-3.03U&"&Y&2-IZW
MAU/4=8V\5W1])<6--&1\4_V_E>DX"M5=F\QHZ[Q!\QK5NB!K;!L>9L?[XI5N
M0H:-]@7L%LF/&=ZR_SA1]-#]^*F717D?OE5RP5$A/!YY\1]N9Q=&^1AEJ-[2
MU&91O3MGT/8J35HY/);M%,YMX9! :R?2J$Z=$XAF=0VWN?L5IA"1E?;JE8/K
MU2;K#C(ES<LA82EY8M""QUR"[C@_X"G<&SE>&7 =IJ2BF7=_S=V=,?91+HO+
MB>S!2:^TE"LWU=6H&?@0>2:X#1XJW& T<2?_R).T(O'G^B0\H6DI9S(^</?Y
MJ4V!Z"D%"JOZ(%B?6^=5<8=07ZF\CLP1BC V'47)R FA'HVSN0-,-:XM.KLV
M6P N,K*I DJ\E]I>,+7(?)3>6(L& W*<.[<"8[1GMAB^'G#<K #,C_U-.FT:
M1XLR6.7>(V3U%46/:Z7\D2]87G9063I0L*D+B/_DW*'GO1#)'7O9:Y[;P[CB
MJHJ[RA3TT^GE_/-!QT(DOMIKX%(329FYXB*"^H:(!+@7-#ODU$-Y7YCZ)V^;
MM7Q;DU.U#Q8L %XYE)82P;:NQS+T7NQ!N>[W_&NW)ZY>B3M3XJXA<<OJ&&E;
M$8[#KJU:R<24N10;<WLK/XX_P6NNHGO .?R-,-)(]BD@(G0_N]Y_/Y.P ]/5
M$;+CD8@P3Z#EOHH^5^ 383Z>.024FTBDO0I]91S&*[,5:_FXZI1UW#RO=\2C
MQP_(K*I+R%?7<>=<K(I>O*+F3\[3[;I[_\X/DT[/ Q8QKU]U2:2"0':':8&\
M)EC>G(^FY<>9P2L:+*T];6R!W&LMURL.'C_3R1@P9ZT-)@=4L''U=-SQ0A[G
MTS2+VJ>BM%K2><_G:S"&&L)>)$CTTN(DGLZ+#J$8#:63)A114AEI^F'430+:
M9$JWV)/I+]"0<!IC0$!+7BL><(]S-M=O_2&F7O:N/3-A6?J1<M+!&%%DT4$+
M^8DQ7*G=QD/G*_3"ZKVA@MQ'"F[.@<H@%DY5.HRF)Q55V&)]<?(A/<=8<-X]
M<K9VK1U,Y:Q_)9N*H5W^\H?9.&1!8]EKNEPP-H@S7RY[>X=[86QUN-K'?@.D
MQQ(ND!%4'ZDM':YB9+54ZRJ>&19G0#=E3BT@68F;^T(1WV,9%Z,G..[I3YW*
M&#?RKRF&%C^]Q$S*)C'SZMW-:9]8PXIR;QH!L;7WT3>8*@+Y8\)2+Q>E8[MJ
MD[VXDSUK^N;\R==SVYZVP8]\I-&UK?>8.XI'6(/O*,871+!6OT7ZS:@DCGI]
M3_R2%UHD[<3P-D7TT[O -2;L>O6W>S"KE6^T+X]>M#S#*W&/0\Y8N*XZ[Q[;
M"6.JY7*]YGPGZ[SY.4$:_A^E3,["'FS?,:#,6FO-3*R=:W!C&0.J.8QLN[[X
MO9\\"=6EJ/ZI3BHOZ+7QI^H@*^^\K&3&9NA)%0MUH<IIG$^<(2<;C'+:!'+B
M'N-$\=\UP.GK:=@R648YH)Q\@8,4LVBEB0C(0T#3DBCE!"GU!"(5=W6T WH3
MJ-P=C0*#%Z*W8NV ^NL#??/D\?X:W]\P4T:_J.8 CH4:^?W?UK.)&M2P>1FZ
M)>Q!I-@VG&UAJ-SOZI^B0CI@Q_$"+OL"!9X$E*A+]@=O1$5(2-CT (N3TSK
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M\G^9X<-F0 ]A&FE\SU7:TELL.Y" P_6[EZT2I[++LQMC\QI>O!L4+=353UC
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MG*TXOHNV$+WUDH>I^A]ML:BSIY!ZT'[7SA,:^W\*BA;LUSO__$]3P>9]W3W
MXZCF3]>)>,U^O6^/845R>_X#$,!)20X_;_Y\!()U4]H %3=,-"KGSXSMSDXV
M'A8M,@"!]R)]/&EZ'_MY[J>])J!(_O\CC=P&%@'_.@.X49S]*4IB9^ABH]^>
M9\)>!/T[\DY<%":>65D/'8XOMUS> ]GRZ"Y& L0TYL>+N6C\;-XIL8C+,4K_
M">%?6S+T%IVSN_GOC!Y0R=_^<1+.MXA>3O0 O]=N(1(767VT6WD_D6_HZS;E
M>I\"Q;;=DU-E4]%;_[EW!-^PO:N*R[.>>;B\>UX.*%:ZO9"GVJS0J0B.@?X
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M&Z6R(;U]^@\WLY\C(.HKCNJNY34(B"K\AQ8.MX'07&\QZE^XK_;I_H:RVD_
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MW.1< *UE>/O8Q.B82Q(QE.ER:&%VM566)\Y*==8")PV%"Q%DJ2TFM,HK!NB
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MG79)TV1ZB00KB6?HAA)M.2:;[P1\316N.-3S+7&4MG^!9 I(.@EQYSO?FU!
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M%DPKP=8[Q?3_ZPN K12E]>EOKUAM"Q(&2%M<V1!Z[O'@0DJ7;+*+EAD'T3)
M&01]OC./FX1/:^%'J>+9%"+;+'-D14:$8)N*WL6<W-P">Z@D1M2A\_D%I8VT
M."JN/B1&6:!+T>IPN,O&FS$/QX2$Y/0M1R;+8I1$=:SA"P@P8,CNTL_0+NI'
M7]+[ZAQ%F+>Q)<2!2=2'"W<-P;Z<Y$EHP9JK]_=$'JK:(0")BKIPU1YM4+"4
M)-34D =;5)[?X%EVXR7\@J!K 2M5&IZ,!*?"&=]KR$(+5B%=JX*J=G&K=O&;
M_=D;;,_C$F:J8$'=<.W,G.RRHEJ=9[]L+5L$(1?7 4JAHF6&14N7W[M6FJV-
M&THG;1B0PM>[]I&;FHI@R,RX*_-'Q/&=O;>4Y$IJEJ!D/9>=XMB0*JZZHJ;*
MZ=)UA>B8%)%%D;);F5@)F$ZR'JHL@>3)SV)EL^@AHR*@?^4>^Q,D4\6-#FC%
M._6,0ZO6/#._94&27<V,XDI':@,Z_=LOMNX2&58,IR$ "[M/+"CG1,-L4_,_
MLZ5E^47N5&4J*-?T32K"=.'N5?'&LD<H$2QX?A37;)=I7:\PJ'HNQ#V V[%$
MJCP/IE2D2'OCBR2FQDTM5_'$HS"Y/)X6I?#-!'?2"O,Q'B![L7BLO:G)1^GC
M"YDKZRB+-GK!#6O*]J;Z2=87[4L95#]A<.A%3FQ*5CF)2 N"C<2%ZM=+<O-;
MHH"*DR%B?&2Z[\5AA ;!(=YR=+P^4-R!]TYU.53V\\*(B2L1A=F2L![B<Z.:
M"9'<,_@4O9@$M!I[_@K-5':W&)MOSI-G/VLQT/^M>Y^.*BU^@M4TI7;N7NS;
M5#9)0HGQM1M-N$[J-\Z7&W0_J6GS /#QXD'P39RWSPO"K<L5Y7WCN.']'39B
MB^)+],D/X.6]*U'_BA'J_-^57W^5._Z//FJ_+8=W=!Y@MX,>@=ELS_%>&0'>
M$5D<,[F4?7'GDCF0.:S5N?3E)+GF8"V$9\'ZG[:LOK/NWL4#Q=P,7]4C$,EH
M[Q'U7/#9;[MTJ&)'"5)#8=-'^5#9U4@U_T'Z]O^8NNF'IP6F9Q#VH0,JW]"E
M?ZZ<R6<0PH5+#)^G)S]N@\@OP])WFF_YD">REKCBQ!=L^GS8\>4HW,^+[4JM
M+]AQ6;@DT;"*5-'87WITRO=Q&P D)O_7MR-H%%VY^]21)>ME;*YG P'EP9<"
M@ #<O%2O5:/GQM47D]O2(7MA6"I%>Y\%=#N?$EPE+ZJ6X\_]BQ,C2&=L"EN2
M00[LH53K 4U_P7="LIFZ7Q&1 #[$S JIDD./,R*(W\\LV/T\;SL !*]8JVXO
M) /75XU+ITD&7Z_9K>2K<(/)EC">Z@-QBDV>#T,P7U7"F40QL*"ZR>PR<6+,
M5G5BGE'!09QF4<6.D^<_ 3U-8F!6JQULK3C:+,?21-M(&%_/(Q#KW+;!,C*@
M%:Z@+HH^?13 7%#'#7YBXK$E9YEA+:2C@[Y-N63T#'+IW+L5;"P5#]!5/9A9
MG.+/6F5>[^#KV? U^A?-62;J,R!2./-=^_WB\8G*(@C\+JGI<!LS$*^__44X
M;[ 3\G=C 6[)K24$\C$WE\K!;^@?VH\.R#I1G0UM8#DE/OC[9<O_4;:WJCMW
M%O.)B3>OD] 3;TZU@^QH8T(9=RS7WZ-*A%C%&00>$"P ML-?J(ZQEJW*;9#M
M_&HT.8,F_M$'(DT37,.0K0CQ),$IPUH[#XH9[%@QT;2XW3WYJ(M0%MO]NG"B
M[[1@"\30-9&?#V:YJU2>U TE;Q&Y3':07G]9\V8Y/V_M3Z6$-=;BSIJ0NH-V
M>K[*\ER7 FWC@Y%B\.&4H5;*YR/9CR8"5WGJ*LL-HJ/GK<W9C7C&,E"8*GX]
MRY=$/)FHGIM&L,=#HIQI!,MA%5F?9@&;$-4\NXVRWAT#?/-N@T_ZM#0S<< 9
MY%H*X:#K8;\S=X=0ZS8]K\R(=. H&O-FB:^X-H=.0D-Q\6K=W9#)\RW<2+K^
MT]*";4'[2@D*@\V**?"NT:10]6DQ3=VT*6V^-IQS/TR;;,I5\L\ITL951&P5
MJO5WZT(HE@^=#P/*EE^#A_W<+E^3<M::LN/=!JI@8[QTRO8!.YO8#J\ :M>R
MM.R<]#V(!@_LUUH!2V-[)CH$J*L^X8<::"86I[#T2N>&R6/FK\6M6)8.?LN;
MEGRK]U*VAM9"33=C4LFSJJ2XM#B:(]G9+1F/"CPW20M::Y6T"$K]Y78O="QW
M 3YA9I Q^\?*,\!4SHKT%V__]8]E8<@Y*R9R+3*6]#+]!XH8(T58'$>ZXY/S
MEX/P02_(YPU9QW>MBI_<;=KT$OB^_]NJ.H58L)T_/X;$I3+4_Z8U?UI-?JLW
M'K';(H">XV3Q8+V.!2!ZNFF]>_^JIQE+LH'^C;<T##;AFH2_5_>>?LYZ00>'
M(_8S&Q"<UI-0GL3E$T%P(2)A=LO@I:!M#RJMPU;G8"K>F)#&/E"#"DW RY]6
M9VYH*SZNVA+2%F%4!>;ANDGW5\7H>[\W<48-+BF,FF0]PJ8Z0_[Z!Y=IM@5-
M7)@^Q?7'&G/;EYY72M<]9T_NWY872D+S2>1D;V%Q:/+;O1*2_7.\@<;]@FXH
MZ1M2T8S["C.-0Z!BAEW\'ID/W"T_M'(MOU:<&Q\39WB$09HATFINI&XK?X+I
MFY?':URE 3W(T1;(7+R&[A"KJ+>>J#P&0SMY^Z:)3LVU(A2&"1GW,A.W./R]
M/\LZ0!7XD6*[?Y!".0%[J\O]+GG4LKG\\,S:[/L2&]$K_<:K/*7IXSQW/W,T
MVEPO) (HWMJ!%=D:>52>N8\OEH05D[XKS>^#OW0G*>XCE;D>$7,S3M[OQ[#E
M+Q&#A\#>4#TTW&$AZ/4I]F)F@AC/;;V?4NA=?>*8Y[HR:$$3*\O'XRAI"5;]
MMP[ 7K.AIX&*PB:[I7AN"A&F#XZ7JE?RT4E(Z:-';[=,I\N_JJ%Z=(>I$R#@
M7I$G"XT/J=P0+%,3)4S3AE]-,7=@RT<A;:_*=5836#.'>Y]+!8)1"B*NANHY
MT-(2+%2J<8*LQ4 Q#FX]H(*V\Y2*^D9UEZ>A [2ACM675L;5EL7$RE-(:PI(
M)(1:>8H?2"++B#SG\I!8@7(<F0=]>LX [C+PJC<DLV;FH<GZ(?K5[9H/5WQ$
MH:Q6\82H+#517C.I(;*2"W+.[,O38.F@BK_5!=5!ZROO:E%Z2:A"<#TS6P-I
M?ZVF$!6J^&"+Z*%U&!2R .@/OM"8)B?\PFNY92:T5H],O%> &EOH./\P&;38
M<GA(2X@;2'<&FBP620('75/T1:5,.+5BBO7[.!/*>B4\/4IW^QMB#)F^LN2'
M-%  '<9OU[P:ZDV>M=#YL@G,R;L@O?_B=>[^Z&O:MBEAO\I=PTUNAUSH+>0"
M>CX#Y%I/=8DL^0;4#P3E+-@LLD?0U'29$J8BN 2FKD*=.$).FTU5$<"C!/KE
M#JIG97#%DXO)U5+(K;Q<NCED<Q4%-0N;"\&$>CB'9!>'/77B$JZO![=%'),G
MM@DVJM6<^1L;[J.)*BD;[+$V344)7/O=(#'(D57F6>Z"NM%8O<S=A4X#,MIS
M!=V+XU/XPN*$D)CTC=62X>9,2UZ'\3[^V8EA3_<L*PZ*'L$#[=_[H-5@X 8\
M<=!YJU^]Z*6$B8D&]%-*/M)S8XN$MJOJ C(KE/2E@%1:32$X-\JGX'V9I8Q,
MELL)M8Q.PZ&9-Z26"VX)"B8XN(Q+27H&/ZTW#7=/\P-*@/FU\0T_UH2W!/T;
M^UBEI:A<J33)6]Y+]@N65Z;4HHLEV@5(B<2DL%MO@8;X"^$-T(2"[:K5*%W]
MMEFG +F#A*"8VCKVA)CGJ,H&$V-& Y:GQZN2XZN>O/"1=+P03QKTXOEK5\VR
MOB@; ?O&]FID8D6PZ;NQC^@T?CZA6$WT^AEDWC*OY2?-=L[39SA3YQ]R<QP)
MKAHB$GU<#U":EX%T7>J$T;'L#S=I&#4N;:*0[[)&/LG6\*V682M&FN&DF\E5
M[0Z)APYT"/_19"334QQ=Y@ +JK75 6#&JEQ^T<0SOD3,]U<%K2!;I[8*.#4R
MBU'YB"'<CK>K;?!U(]XT]!>S7FV.>(*4HI>U@W65+1>!U6B6N99^7L-7I[J1
MI'Z28/6R\YY.Y@:UKK/3Y;U;#^-6/R2#31-EWUDLPE7JV+?.(&#EI'UA[LLC
M7SGV@D/^=;#QP>KG\57?RZ]5IO[N[H].0?H)/YEBL4 S6BU"R6'CR9)ZL UJ
MQ"X03Z-4^#<&7Z]LG$&HP!(VM0CT.+7R]7M_)WD%K=Q_H>"G1%]5._A6H(Z1
M ^Q&/_\YM\G)G):<D@TM)09Z[0Z!RL+;"FH=A"BYHXM>>R%??OB!W.5J*$ND
M(6UNZH2OMLS^?^DJ^I=RFZY$REY<)Z,6<RC^N 460=<W>,(A!P3WF*/D5T]$
M,: #:ID81V3K&<2G[PPR\[\\U$%$^7AX6G@5R8#BG""=SX<?)$9VSYQ!:H"+
M?6(9%O4JZ!M@_Q1!40LVRG;P,=F-!@Y4+&Z=UE\:V#H%0PQRRO-,+P=0KT;:
M&95_AW)/:H/^NA-$F@$QO*5M%1"#:H,>-N4G%T_B06R6$1PJI1!3$EB^'J[Z
MXT#QN^C^460#(*TPD%@3?8-2?A#MA6K;#TL>8B$[@[0"8 I3V?@RRE469]:S
M/DPZ8W'U\M$B&')%+ 0+9KC011-0^'"_\41[Y<<^*'I\(EJ=:CL&L5JPZT6U
MR?!"_Z)94!$HUX>6/7$0/8/,Q5U\-$1^+9QB^Q?@!QGTB0WF;90!:Y-I7VUC
MP+O!3AM ?%>>U%;J$> +??V>S:H7@I@_B?UG#"/^9"DL^57.M1GJC]OFG9D1
M_S)X]9X2U518D&5=Q/O!]C<=KE]6^<\@;MT- 9'>O7,&,>TBW@R*4FL[^HNR
M0<L7-QM<_JT':/X#N_[#>C\=8V^Q+K!=9K)];^.V7N+%>[]).&:LSJ%H^<0I
M-S NE23B>HZ_B83('J?6?/VH'LK^">1_Y;K3S%O+&Q>2;^5&:<OR?%S_5SI_
MME(EZB4]Y.L]L$G \T#GF!U4UV+73I$WC01G[6E^JE@X(06Y,R(^WVFY$ER5
M8<M*/U:^T&XZ.J6/E7Z9%HI?,CU0' ===SR5]HSN+6_>U+LXI10)-W^RM=-0
M4CX[@TV2W9ERW[RSS,>(Y,08B2I)^VY^^#UHXE$;%!I'E/\4-&0WCQ_T_M"A
MURJ391CEOAALY_/;GH^)"9+YP@LY\J?<R_'G%15A#8MMI3OJ*0HQ2'-I'[U/
MY4C_56K :B5KL<]7$?-[:[1$TXB/R>R4*'UXQ=_/G")(&F&A:+?6TVT-XWZ#
M]B__,&YFUM 15<=I+W#IQA)01?9SW_FJ?),Y+X.R@]ZF_^/\K/X=92N/5;R!
M/:J LZVHK\]<\)23]XY3(D-:BCCS*%<W.26W7A7@ 5;X7+EG>$?H:\K"[(SW
M0^Q<.Y.^G===!)]$?BH2![\L6-B+L>>'I9;$=$3&&;!4L<RYU/!:FCJ$S)^_
M>#L?I6=UMVZ$DGYK[IJ0DD! ^3P#3>6/DWF>?XGUW?8.W)[3[WD_R65R<J#7
M<ZOQ-U?TVRM 8I[Y=- OK'_RZ?;RNH?@]RBM1WQOXMOH;L58C]FS&;%J&V@D
M8M ?/C#1A15?^\TK/@0,,@GK>UX:?-#E- ,HS%8@W3FTM(;7V?42M$J()S[I
M@'I2YRM5 J?3\U" $M.2K;MCRF220ZIZ(*F3D9!P_ C+]/B2IN0P'\*BT&'I
ML:DH8SV.>.+\NC>>LMCQH6)T+3[IAJ%<%+X\Y$<+SJ)+40D"PX-V4-C3FY5N
M3B33#D >7RTVO#,J=2!#<Q>/PY6B@ULV>3-[/_-ZK"4KSPI1]4"X$8X1ZG6
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M$V:EH,./UX82 ETZSY5F4Z3]%=N;3SF-1#RE]FZ];^(M#O<RUQ;BZ<O,&&:
M!PX ><7AH[Y-:647N%>N1,]H*7]&!E''?8[5Q0[ UU@J;7FXHS1W@%) S".)
MUZY$8GD!:6,K/NK,/)J/%@C*;?CXVDH+M(_ =2[ST=V5#VN800TC)<WKAF&N
MT>@U5#*Z)*@20Z"?F?ZN4>L=U&1P>5@4*.IJUBSLE_'6%CH3[I-0+FH0>! ,
M&'&KVF'1O>D;&#?W5<^PVVMDMH [S*8I@Y,&D>)!RU2OR7O<[Q_2FLNN5@P:
M1C\#H.0!;R8&X->DUFRH2Y$I>H+ XDD6$HXW;-*F,<5-4ESV'/$4T6?ZWMP4
M_DBS_!M;T?2@:<*+QE:T,D"HX(8S[BYCJS9V)^F:9Z&;&*I2N2.H1&#U#SWF
M\(:H^,46I!"S%?RY@+*]VF0?0.2IA_2Y>BA6_WI^%$S"%E_%X0BEJ=K,*N"6
M@G02(6,FA!!<ZT10 H-S%CU8(2;=[9:'>I?))2C%K5XY!ZFG,WTBPPTCPZRV
MDZ5AUG!!'+ WZ<N/$"DA_%]2#23GYS2;W7)N3+<TQF8NM5.<ZNZLF0V;P1T,
MP'0D'?G;S0<2H^DI3&&SZI3+-!W)^5$8FM!7:U9R:6HP1O2)<MD4,^S*R/D*
M6!R^,)157"UO<\M-5V##!>H0IK-'6W/X$,F;YQ0*&Z%^Z2*@K&J<-1' <G[E
M6R_O8JCUV4X[[<SJ2(Z-2&369@XL-H>0NY>0%;L'+V+)=-)++3^TP42Z&W\U
MP?[XOVGB/6 '*CV,?LI_O).UAK]B15]KIBU8)K>)Y,9*,M78\E@OB]A>7QCP
M8T%\D[ZOE_%!+KQ,S[!7 ),AL*L'0U:0O@;Z8 ]3%%Y$;H]DN5->,3<\'G"7
M.;AS5_;3L-.AUR?_7\]>3+^)$93([!!Z'AM3TU.CEFZ99R?U_GRM*IHN)<]E
M%X^;P5NC<KG3:K^*!$=<1T71E=^=MZ!XD[G?..%4D96?P"A06559N<JI1T/^
MKJ\#,)&<3R21OW^=,V%3-+F(IZZ2^3A'!==G=LA_=#MR$7!@,'#JBZ]G^-R3
M6J%B'2Y_]!]8XT,=7QSJ;"?,$[XS\>:T8 -$ T$DIB*^).RYBUNW?2(TSR#3
MH*BO0]@>.NGW6X:GH*8VTOCBJ2"PQ&U.<:TN=J4><N-/>9CM=T& $+SC<Z(F
MP\(6ZCS:M5IY_"\]>O5Z,?0U#W,N]97\$!!=-3QI8*KS,>/JA4#A]ZY"FL@H
M?P*!-M.L;F->63SYM+G4RD_(QE3^U3A[>1N$H*ZDRH4+ ;Z:@Q=Z"KZ#+-ZB
MN0F"B",@E%NGWCJ-@/@ Y#D'L',:,BC:B^R$]9TC4<<V*.)_^"P*]I/)SVO+
M0):%CC]?^7FU/#L8H@H&B/*U1=_]OMV653%)ERP[+WB\694N&,X18$$2OY+N
M!=QUX@C=$D0C*M(0<Z(-9<?7.$SQ'__K+<XK'K)'J5HG/M#A3[G,;N)S.@_2
MLVO*AEVS#TZS.%,AU @L&>KRQ>^@392L9?I^2_[2AWBW)9H3:.?7?]=)#R5O
M?> ]W<2<7IJBV<T6TZ$8#AI?OP_->#=;R\,1+>S:?F'N51:$Z(#].PMP6VF,
MK&^HXD(?-%%%EAW8)"[8GSA& D>$#9JT#U0QKE"(7Z'3M1-1A[*Z'DBDR@IX
MIO:]64]THG.=Z,3>Q"_0_QXS<SA89R[\H#.0Q:"8:Y-VF5?G%-?0\?H/< ,3
M!S*K:CXF%NE^4[U47:LT@^TJTP7@CPQY%)#(*OF <H/#%O&PV[Y+IN$UV.=3
MSKMP*]'+1._&Y,)\8@$N1/0W2%I.2R_<D;U"LN:#_13"9/"(:O35,] $,_HG
M8TMO*_OL4?BUC-MRQ*D'?P<A"+I9)[8<^(Y/\S02+<+5H]I:SB!U()UZ!NET
M^F15I$?EE08AI*SCL)G?'7T-YIKFK_^4;*J4(&;AA 0Z^!I\M5AX- !&B#Z1
M6UANC;E"X,"]M#AEBG@]M:9]\03XF;C/3Y0,#/247%W>,%G)N=1@GSZ0,IG0
M0O*G7X>\1";[[0*W W<[/'69]_*_DQ=QZ4EPZ\UM)%\LT6/,T$2?B4<E]CY1
MI<='HWS+)8[!WJ:H$6V0%L%._"[8JSH1\,,^PQ@-I,TH^:<,K1:_F=XAKB@9
M<]VU#A2WK&%@EF9>044A+;@#^D;P3%G'0$L.UF9D34+J#TW]Z1Y_T5NW">0:
M#Z;?*D] 6& W1M^NO[_K<0CG_-;+HACM P)3VD>P]&Z@Y$BV\[D/[W9##CFW
M,-+<[)7W=H@V0!$1+!95.??BII.C1\/>V^M:6IB:K% EH8,,1.%#Q8C*<S%Y
M$:Z)(7WSU:M9.#0'T[/#Q,+V*S"IM"K0(.WON<HI'DW3H.5ISYTS< :A3)Y7
ME\(-SK4H ?(UP]:=D:HQ0T_]?$6YD:'DMR[Y>5M(@</:BTRSH;P9_:@!.-]*
MM0?L%X74QN%(GYOKN>)]_&A]ITUZ_M'.ED 6*IG%^49]6I>ZQQ;*>\14GJX\
MO<J+7=[^<N5M2XV)XG[%,.GS?<L,]GANUV<SP4:1CY."0F)2VL:(+PXS)($@
M#.6^I88MRW,VN2K2^((Y!HS]PZ9DA0V5O(%U*BGI][_U6/7DC1U51$M+S25
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MUT\$;=!^"^R5>A8RS&6 R?64^W("#7'R)T$U(V6NVF0LB2I7.@]5\0=[W4'
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MI /R>.,#L GZ\7+M86L^]?>\Z3,Q(L?2RGDRFN7@'%6Q:I#*%L;<,[_;%Z8
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MG'BF"V\]I<_37XE?!()-^^FUE?:'C%26,[25VF57=6\B>@6:]D<')Z!A^PT
MX/=>DEF?;Z) (A F!6%9QA%KT:81<L0&'+ETK*BR7"G4F\$K"1/7^6418)MD
M/\$3%-(@2')2$=#%0QBP\2]'&&9)FX^4O!V %]=+'BTN@CUJ#?GU!M[?_?82
M,J9ON%^XI7L4)A/$8?,(DGO6G,0FON@<\BO.KXD<*J9K'GW,Q?-O-P&8&HJ6
M=Z@4,%C=SI8G5+9(C.V)K:WW\)EDA9;EU]LL;I.KT($NY5QC=%4_8D@;S:EI
MR/TZ)AT8P5 9T-)NYE'0.*YY\#Y+KM+=)605-<<8F7='TL>4W<WX@0I)KDET
M5H>-+J\_UUWI=NJ_+TZM&.'BPA.1M-*/6E^^3$]9\L W2"E'WUCB##&C$=3-
MX( :N<+/2!HH^8WFA3_<8;?:?[Q@T0>191%"B;_L^_F+[NGA0 S]1N\6.-XU
M8BC3SC'A,>.!=PWY^ G$CGT(YCO4=H]E(W:QMM*;V"40C#P4PW?LAL;PM#$7
M%>-XN;O>.0&E$]AX<)JR@\3/:Y!1D ,!\X2=H_]$^.^I^ O4T&6=O^\VLAM2
MM-H!'=D#I!6MX-P8"0:*(4GJAKP34)\];5RV:?ZD^12*0IE?X"4LAX J#YVB
MD X$V9"L-OF+7X@$9"@+!D3]7U/YJ4F4^%VM,*1GC =^"V")%#4/'[%@^<7R
M(+!^\MF-D)DV I"WM[V)U[2(^A:ZFF(MKY0=R0V6=%,1/E'W)IE#/.B;-L_Q
M'E.O[8/:(N2*2:9AE[%'R[.K]S(Z[B?FX["5#28*A<-;5'8>-^]> 8L0EZ0Q
MS&VW]ZZ_%!9JA26 )OPZ!S _INP@MMC%UT/&5L)[A/@ Q_7P/W=OZ[+A])N(
MM\3S?=]G.'9\79U;UX"%YY=5,QQ.$>'[;"Z#6;RUN([@CW;(^)\[ ';>NC_B
M()'RF,0#!GTI9?<L_!FY8@G8K",1S21[Q#E(1.RC#Q5S@0<_V \!34#S8[S6
MTEX6F7RQ0O;>*:B#>VE@+A7!2;<[:Y5T&>>1V=L<<2I3VW+E=9@[Y]>0?PC^
M'N^1V8M^Y?JZE6E&5';V/3E339#$K/#UOOSTHA<AZPT!<5];38[LW. BX%A5
MQ48?ZB\L,\)@[2PI/:VG.,!9/8LB)*)-H]?8OG%>D_\KX$=(*08$A5A;5?2
M.9-97%CC#;=W5N$>_V9OH)'6]B?IM,3@0OP46X'\ELX7$J;&?;=#I$ Z40'2
M,-\\3)N2]>$U9*5*:66X[U<(6PA(Y4O.A7RF_/=,<\7GHJ!7NFW_>8$53\ +
MO#^PQ5V](PXO8Z#XT"H)PEYNZ_*/ 7N>GCU2:PN:+/#C9M TD3B#CF@;0LI_
M1ARL.4'8OL8D!TRJ?16ZLC_ ((Y+K0S5#'GMRL<V5]]20^O<'.[SG;DA[D.6
M'BJ\ [/"J4@7,0TA6XH*DQA^ :OZ05DL4:.Z?D%42C;JAOZ?OZ- 6[ZC;E6"
M"L2TQP&GNQJJL;@E:X%9%7C.I5D9:=&-'^D^EI]3LP*:PWY4$[MC]1W&EN7(
M"T5G6YZUA:/3JK53EXIO/6WL_1RKUY#(GNA/984ZD<K\QDY3Q6AT3-^$KHQ/
MR=]B0E'W%)-8TQ/\Z>W=\)2"S[ X]\TL]]6VQAT='W]I.965!A^X^ZB:H,&
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M0?84TW-.=-F--;IWL-RB0[HP6&M=QOQS>]'P=1Y^A[! E\W00(&)>Y,]5Z\
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M];VX753\ETJ_8WX-R<A^):QZ2N)@J;)FQ(\7["J85"9QQ]*@F?]W4\!RPTX
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MO;V!6E17CY1@<79(>7-V/&@RP<ZPI'F>S'CI!EN.(;Y4E-H 2]=88HKC\^1
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M^=Y6AWF)^^DN6B'O2XO0 QJM9%NE?J'!&T6>D[3D4ND\&UE/2.UM 4PT$C^
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M@B2W+S6NIE&? L;"NAI'TFFG-9X*/K'L\?.%_^N7P=C1WGI&5[NM>ZC\[IV
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M!@"Z5%D#W[B@8X:8/KH7<MG=/O5Z:>'ZM3].OE>+>5)A*X1$R4IP\T&:R.5
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M-N]%F1SV95K\0%<"5]O>P0[@V)NQ=-?R909#@/X1MUWI^0"YUY#,@[\\30H
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M#W@DB1<@D ?AL<EP=\OGVMDC<XL[BI3/&921$*Y]L]FD3OJNZNB,(,4VZ@'
M(_FU3?/KL?($UH[&QJ9BNF3>4VDW@OYEZ+Y23MNY,M(YD@8ZS@KPOHTQ<BZF
M I0HI[_**5X7#=31CS)5ZS"A[IN_.WY_/Q:@@@K=E)RR,21;!R(3VB02VJ;-
MY5.ZA?_EZ)K?N7FN;!@;.)> =Z^.H9).^UX%K, -Z_?MO]TC1N\'(K>KTAIY
M=N>1H7Z9@/B'(0OB9>,.B>]83Q8;M$QI%'F/!M3[5AP#8P.#67*,ZE-!E4]J
MVP&OL@?-6U=;A8W\YMDVH&W:ZL+? .1[=$>D^H"_N3:Y,TVFB7R .?4G=I^B
M<N5=OT'XT2@SW;UZ<(I'FZWTVG$#,'/U-N>4>]$5=[@8IW'>^WGR;>?-:V]F
M (!KT_$];F"M;%,1OY2UE&4@LBD:5#G_+S;C;LXKD)T/S1,W+)(]R.N*/]=I
M3:"0>[*]ZUWH Q:SS3;<?N;?MCX5W](_D&!'<P3$H[(O%F547PV4S<.RGKND
MZ#3E?+,#,:[\W)D?[+- %D45RC++9&YPT1Q84HH.LZE%\LVCJZ89)L6/L06I
MSS!BH"\"3V$CZH2#2%Z]::!/F5$S;9 W:"X(N\C-.2H]KW2^F1M>S?]HDM'=
M4>)/@%DM^6JU.^LPQ1- U=!^7:8T7.GEGFTS G,)?7GOG%DJTX_+C2/08E5[
MTFL\]L5#H"2C?4_P_27UM91CJOL^OSSDCE^0>HZIY=*._*6S(33BHO&,5U](
MML11;F%E3;%6%7?B,).C?5V7]$^2AA/_0DTJ WB:$6D/S9!PNJ=*\]J:%@0R
M ,@O3%<W9#?;6 :B-#\-!CRP]-Q+=2W3U.GOT"\?]."15Y*S-C*WV"$X;:=<
M+@]G^6LI,CEFDG1GRM*EQ:8@Y )"A0.Z:V-O9UWSU.;MJH]B#-BAO+<YX*.J
MW-;Z:78Z?0J6QV5[E^<]N\3$5"!#M@AG_,4H9^/P]OU+#(PCH_CM?L[ P#2(
M?5&?TA>!>W]-'8N6V*G9YOM$2TSRP=U9)L)<NNZQBAO5)C1XB=0+-0*;WK/[
M'A-)]-QA9OGKCGU,/WJDX_)\"AV)FC2OZ\Q;>K(X-8$1!9WSFR9B7OJ&**H&
M]621\'UJK!<EP,'EE3_%E]*^RX[N0C5*,/^5WVSD?%OH&5E#;6XCWY&;-+7O
M%8.:OR[<>FAWHY^!>0U9ICC\Y[[C-;+WM7V*PUI=Y<8<&ET^_%6BN/M\=J%4
M89E&(;8QW>X51$KG:LZ0HSG^H>6H#,FRFW+^^]UZ8CWQ18A.X>.@]1#J^].6
ML!4Z?5EW PE$&IPKGN"!O?XPMUV=V/<BC6+#-66YTWJV+2TIR:R@E)W@.$1/
M"W&P3G,74J;7RD?."_[3:3^^/E[;A:XC]"KLSFVO$2HB9+Y/7<H4MG*,-$=5
M<K5PPW362!$\-X#!I74LD9ZLR=_$5 _-TG=Y6&P]UJ(D4E@\+B(*RE&*O]HW
M+PQ,-=[M!468GU9#@Q=$AN5B3%C!X]+IY3ZO4&P^9FTBL5<H?]DDR.\6M_2V
MSW4S@D^Q$_HGVJ08KF-IYR62.ZI26Z>C6Q5DT-$"D+O'I7T_NJ>:E. C%B)%
MKL<J^KP5VRB4##[%.0#)#>3*!C;6^\>$KYKXI[N#P0AXK4K3V[[4K&$Q8A=D
M+$0%,Q#7G=-.9+Q.?WA$R>QX>BH@(!)[\86#N6SD2V/G,9['-1_AYQL>\)C8
M!Z@1U^J!'J/]XH]SU=C%LP%F-U3\Q(F>/NB/R7+H8:.<)$)A[74(3-7 I]R=
M^FEM3EPLC"+UU5PH>+Y*NI1:)IMX[55J_KAJ1%*M]$!!UA"ZQ9S_'.I4<AH,
M5Z^%!&E2>D,SMG<*AXQ8SY#,)?UO"+?D%=M*B*Z=@.)>3\C%J*7P@UA&QF\+
M E1_C^?7%UK"+_;#N2Y.IK!LORG#KS'L^0MU&O!G%&MP<O885X@<LD$HC\CD
M&]TLMZ;/M6+^XK R[(6E<\+<9L-R,F'TYZ#8/W&IO;"9J_HK% XEC^(EX@N!
M"2'5IIK",B38]^,M1A8K=IA72JEOWW;[=H-?TE(L'' [D9Z7:LW\=CVY7YL>
MKKW=S[5MJQUR$8(O#6[J:=E6+C^^,^TM#:5XCU%_Z_SU[MW8.1,6;+1YH #+
MWI4+O_(D2H?=/=/$2"&%>'<#A2N83LN_Y/.TIX(+E.[K\FSSE-W[<O>;=8("
M8F7S@K8ZN5WNCGR2:K%L@NL-_$PWH6^G^Q\-O(%;6<J*$(@#B2D :6M\67%[
M*I(0\\&KK*;J?<N-K)?PGZ$>R[EYD,8@B<N]<;>YI3>!GF)YR\U^^2OF=%;W
ML?BH O&,NP+H 6XRF*QB\OI3HO&4MY]@7#G05=+0"6V3/?CEMZ+6Q%!<5DSW
MY#Q219FTAHH-J80QRLV]>E*E!L"HQ#F!KI*/@UF068QF(^_'GWHS/P!A 18B
M:2-W'X[1/U>^)S!Z46H02NN6"=#WB 3T*)=]QT&4PG3+,8%*Y,D@\!N6W%.D
M(KH&J?5:C\'-4S8--)N 6@";R[A''4@3NDE[H8(;?AP\UQ-K'?MO"IS'Y4U^
MQ'&,^^YO29I?Z$W(/O('0N7,P,$@&UP<:T=GW%SJXPL5:7HSY" @X'*3F#,+
MDO<"485$:Y]U2RN. ,0*57%Z+V?TMA;1)R!#(,WUTQ9Y9?KY?MOT3^$G/X'6
MVLA:?*#>S F(YE@<:-)LI@B=@-H^;8Z<@/[IUX/P^3Y>'0<[T4Y(JJ&.I>U]
M@(^F";>=#NY_##M(TOX./?A0BXM]!@!F6&?A*VR=4\^/V]_]Y^?/!>HM #6T
MG:J)12E5)E>DIF5\R\K M)Y>NM;#@R/3R2*@SEIMQ!<)=JNWJAY)"W?]DA1/
M>LNGJH!J+<BYUYE0J=?;LL]+>7VE?:5 .+G.H  +-NK%)QO\$<#EN$' ,HBE
M<_ITF+F8A,^!5C/_ I7,(;8)KBX95.LCQ0Q2?9SE1/DAX"%H!X[[N9SI:2E\
M18H]1:XXBES=!*X?278M,,L3DG6_,!K-N(89#V8#JL9'!53KA4OS(! O6_4A
MU>'"+R'@YUU<9%A:J1<M];G5F>AJ*E!JQT_^ 9Q62[HU$)V7B6TJW<,,!CV<
M+&TL,'P]]4YCCX=65CI^DT>]3=@VEN<$!$3*WG69DLG]W",8=V%/)-9:7WJ[
M!ZB_N\I*G.7CU:R96N) 73RTQU2@[:-(8,7D[H:5JCCZ&^AFL:GQKGQ*NK;?
M @S:Y2YN<X@LQ>A+G,'6!IEE_8= *.<M]I[=ZUX3](UH]=8G5;2;M/-L/__Q
M&^$QKPWV)KT58.VT\2_C_=1YCMOT ,R;L?NUXCYK@-BO*W:"/VZK9<$.7 "!
M"VI52@VDC!)1':3^I943IR\V< *: 1I>]*WL$GY1W39^R/JE,^Z:@.H)$SZA
M\/#9G;/7;81MY2X<F(I-'_R(!>ABVN,VIN A*"G:3)75?CG61BOE2&SU6!K0
M@(CO*Z$F@O"6ZN>*V;326SAV >Y!HX>A(*U:-L9^ND.T6S2:!S2+Q/P+QGWS
MK'.5:M8YL-X_T"FR, F/0?K)\KL/K6R5M=^53,?=$$DM.^N2P&3VT)X6( E*
M==67WO:HV2 TC6>5+?S1+T0*2J9QVGJM9#@4*DOY,>L1N&$<%R0XK<ZUKD*!
M?O<HR>!4JOMVZK8$6M0>?!>B;"Z44=.&='\X4;$XA8\ (!2?)<+V&[(<8@E6
MA82A)U)L(SEO6-$H$4JOJ<!5B')BJUD&4C\I-%;N7?>$VRKA+><L6G3$2;WX
M.6FG0KR(TUS^VP/9I?)MV%IX!QJ^QTV9C)I_K&[J]G5%_&)-'!IT<(#G5#\P
MU5&&5SZKT#C(R\ N^]DH#57SM;:>@C.+4FC $_FM7U]E/-6#,7NIZSJV&4^<
M^E.8[*9ARR+)[2P^B"!HVP6;KLAYPE@>1(L0*/'G"MO#$RL[H=-''U1=]D)J
M:>PDU:HJT'U-$Z27G2\+C=6^#RQ[^N1T1:M0,#N_^]/?=)%DE-^SPG6,%K0B
M(_><=U4QM)R#+GW.I^ JS:3?]FTZX(YTWXVJ];J8IXGESEFJF:C8;B+FP@7T
MS4RN87T?^[=EP]D#+0$#$2EEP>&U\AHT-F^CZFM%&4Y,9(1\;\S]D>"[L*;(
MSSK:Z8"F#109O9@WSUV?TJ_J=6=<W HO$7F%!Z=EG$W"C-+*C5B^J1 >!D:A
MCI./U0_E7[LI9<U\E'KKF5NS X$RET_VE'1TN=E7>N!JAV@ #E!R^-<W=\^:
M:IOY5HN5%Q+JF%+WI3*/:2S%S5>H1-U854Z_O"27RDPG!$15%']Z%3!?O#!L
M+1]M*4,H+:XUZV79@7%-V/4["#(N%X W> ?L(VP*>FWP#B2*)+ V0M? OVY\
MKD#[ZSE^6<)F.>&A<9JYJHZEKEK'.(0F8I-PKAAV#@,I@/KYW!A6ISSQVL-%
M>Z./A2@"?2T^4L!L'8\LC)2J5HPP>4);1RP@4[DC#,4X^_VI*)FB;GVG2?,(
MOII,NV^%JZZFD,P?GQ_5Y(:KON/#X6=5K\R.(^PCG/!E1I]*/6'ZR2J2<= O
M%.%)^RTE][WHVI!:9J6:#(_37ZP--VW.UAA=!+4,B=SMY:5,SA>GCN(/#2,0
M(9Q)=YWDT- $+5:EY+=#.W<O0ILOMO.N]  'B>[M5VUJ3YS]"='OGK=Q-;?/
M7[E(0@@@(='>)F4RX[:K#?GYJE/K.V?HJ&PO6B8K*:4!3)*'71Z_ZVZ%A_UF
M6LC9JC%Y]WZ?O#\A^5D@]=GT1EV"M.*XC8/!W;K2P>5SZN?K'HTCY)B6TT(
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MA]DT ;G@V1GI>40TR* 0"!E(3X35OI(?3 DP^:P.D81797\2RPF7D].I&.W
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M,?+_SX&S2N-2H,^"Q%UA*Z%FF]E\LQ]K!?  K+CVFWCOJ1UF/=O\#W3;0CL
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M_IB( - >)4HM$_8(JT[<33?5-YBF:QF7_,NX+U(+6Y1;3JZW:%UVF=6S:SD
MCWL+!C^?A61>FF0?<XI=^#9%% DB<MJ]"O-N\UCXH^PS:ELRD]&>1U'''=U
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M @'!X!^OHXXJPKXKGC%%L-SY_.#>0-.J7WW]R/1SJX]B5)R$GZ9YT6(ZQ\"
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M?S3_'R[NXQWM;H<$#-&\*V<RP3^:C>T)(OL7#EJ?&XSQ<UH-ERC*21=/QT*
MOC<9X4ZD[6MEOAKGK4.B'.TMJ6\Z^3;ZU9$37WOS%0LRD 4-A\CN5[(##_[L
M4>[>E+.*"4'= ;LL.>WJMH+%[TLD1RR_7PEM=A8GWY83PW!2*:S:J4P% ]Z(
M55_\FDQ.6P21M<V#Q6\*W&"5HDV(?=.(GK17%T@NY7$N*J>N%+'\U^'4 ' V
MU[BTP45T)$Q4NC'*\A2?B=8L2SF)U:E03;OPKR#CFZ%1.V:7+M2R/AMW5SCU
MPR';^-_.>Y2+EA<ZOCHQ8QD[WQU^BSH>.('D 3NUH30U82NGR.<!73#=?5[!
MV%G!@<%ONV GXQ>]&43YUNQ%9JXCZR-HB\3 V-\"%Y,3.;7^8 FKW)ABLN>R
M\KWG!0@+"E])VRTD-"5U[&E*)F_>CPI+? 6J9](RIWVHJ+KN5M;C)QU6YGA1
M]1^T#BO P_.:8:,%#BZEW]$_?. >VSGU;?  ;%T@S#"'NNO!^I%U<)F:REV?
M8P_D9-7)2GRL;0RC"I\\+\^=3:0#@\_U=[(#"^.D1N5PY]/QFCX,QQ6_$\T_
M8S4M"I5 M)#'YB!8V(@CLKOCU8'H#[#TY6M#4%]4RJ;QLBG8=7?+!KUWY]#V
MU#R\AQ3QT"<["9VV#G.'B2T S94PXQ>7YM,(UV11]M)K^LQ:3!7VE_&'0Z,-
M2AZ+IPV)\=R)\/7K[M)#C/\O*I2YJN,R.K[9T2NSPT@/[^0#$7[_!>[JBB9-
M'M,RP4VW(_-@YK;!O"#DL0:;S=)'.&A*HG>V5:_OWA>V(O.GPRF+TP,.>O95
MPRBTG16]QOU9*:VUOY0VAR=3'_C>#^Z[0GI,79VO))P''Q+EK#T?]9/E[-,(
M:*+E"23_%XBX\>%3BOAXVY@YV33##'22CY? [MTY"FH'(8Q\AS2;)Y#PNM\Y
M?$6]L"CH9;-UNES?DPA-T:N'M&JN10S^ DF6C=*$.YQK'H<BAKT9WT.#\6"9
M/B*VT<#NFE-JA ]C^+!VJ._?MHL*5AG(@R3#^U'>0SWB5PX0^V^ 14F<&KO.
MJ78;1M5VQ)]?^PC#VJT3#TYFB+> GHGB-2R]5,MEUZ1GX_LNJT?@IKKZ?7O^
M95+PJQ36Z<562-"DXM_PU%U1-;7*,J%H>D[T%3U2KPP+^@L;6=H0B#YFDD6T
M38U4T+,^RL=[P&50=L@X6!,A,9_*(E?>Z4CMU=$6N"0^:3^(8_1PH@IU<3:;
M/L6KV?,+[/E3WW512O]WHG-$Q0<I<^(,_0G._)V.I(.%]Y.QDV'*^YI0CMY3
M)Y!5X =RSRK_'F1,<-EE T7O8)SRWY"VHK$*'J:VA)QF[9VI;=H]V!0#@=:A
M_4^1;/IHY:W?D6KX$+2BI:$ N,Q:<1%4=(ITTWH:&^V>*5/88BY&]?.O7XS-
MMO>+;+Q.G&L!"6^-SUR&F-&7_^T NW%&^H)8S/"1QNS =Y^Y0[J[1;^S+9"A
M4$_;OQE]FB"_L$A94^R"!IYZ^C?JG*7TB#60Z /#M3?6;NG<'[S\3T-].OX=
MQM<Y/VT]E]$3]E7U?GY=*RPA]<_ E(1JI!1/ZX;X42,4YE SMQ95)$R:+9Q6
M\;5YJGM417#I7"%+4:C-@C)0)-E(U]A9EL8P$?WK.*:FD2.3*7)!"GK7:_KT
MVQN07&@Z].7>!Z7%()&[-O1@J+RZDS^P3D;2^3P1 Y]9RTON4\IUM]EA(&P_
MK0ME<'^-T*0%M3+(P:=2.FKV[3,K\+%8O0NN; ^:KT1ZYVG>U"^272=F<?CZ
MY=I3CJSN ITV$CF2B0)P<M!&X%LB+JNX]ZQ3*:&[OMHBCJ$6ON'#:E,E@V9J
M,PV/B +(,^3O&DJ=OE?7F;U*@ZCPU4_>143CJJ>)QU_\:VH:!U_6Y)7+^;%Q
MI;%\L& ,&_;Y V;,E(0(ENI\GAQ9S\'.S:X'K-:9F\#NK 6>G;"6><5(R,MU
M&V4Y@439DJ\W?I#49[P#\/>XK"VE)77F#]+SJI/?8A@]^(-N.?9KD9*&42E:
M!&)]II4S%O<FS;8/5-NQ7I/3E*)36(W0&CGJA<,X2UV\LXN0BG)F>>8W%9&<
M U\0J[,T&U<@WPB!P N)'HQ9NQ85O!X0,?\L(X=$;B8ZR1%=]9!()!%WQU1W
M4 0&"T0]4ZBZG/;H+H@#T\XGO%JZIE%S='@4>[O:J:]RVOM=MJR6KLM-\WH,
MKLZ\VC^667E?"-S6.SN._;WDG&FO%8HCT)S<W+&"<1__^]I>@'<63V\K+T?C
M]$/4SA@L@VN9J^JG0OL.NY&ZU0M'"WG?EHHA#R=R"ER^NY1AMXK,4;"+$NYX
M'3,#?)?_[)*L]KLJCR(RXYD@3)Q?>IV%<9YL+<9X@AOEIG-EAS$3-2?/^T,3
M+$>$=OPS&C [C%3>UC&TL[83&A:>47FJPS&4(B=6'K-NDE93:*M"\8?I/2^X
M#(1,DE+J&E_C6(J4H00I'K^+JF]W=/GJF[<UYQ'+]64?ISZSWP@7\XN6TNIL
M ?:*20-,[^R35Z5M>/\"LOSQ9Y=2?GFYZS@FS']7Z+"Q@?VNQ?855NF6D3U
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M*>#'/P;YU115:FBD9VWX$3,&#>4)+2T/[)#39F@ZXW#3W4EE(MV-D9'A)W)
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MRO$ZG-1+EJPZX&0;:#@@A<Z=FJ32V:0@CPQ$RT';$7A;&"& >)E-0\F\6X]
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M16?PX=KY6@.#!G,^Z1"Z4L28!K^\3CC!@^= [:/N(]E0K9H'.*)?A:AR^&8
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M'Z!QK(ED$=I8S;CPCD#QJG13WK/&R+E*BT-"%TN;"Z4RW<IT^KX+Y<X1A\@
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M;J_L LI.E,G8X'UGG;1/XZ0KGY</*!C6 <GGLUSQ:NZ3J[D=3:LQO8;$RNK
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MH.$B6<UE\MUF<+U6%7T/1VIB8KT ^;R-?:CSFO-.)EE9:6QOT@Z^Q]'AY#I
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MH]7/9"$E9VYN(%J?FYI=@ZQ.C28ZO(>[[3E'^P*VQ1^UIU]^U6F)/N.J)0(
MD*I::W*53 =DM/WPE-KBBII2$6YW"!XTN@J.>I5>W$X6H8.?1LQ?0 % >TX(
MSNV64=:=9Q2ES4TR)S'0_X RK^V+O[>15_8)GH_V8M/A[D"<5&5G!JAW?O<8
M% YM:L[ :[H >9\#7??<.KQ$/3+(V97=)F%YGFV_OZ?1^P!].BJ&U\IC(T:%
M8 E1#\+3D>%8#?W[.=S3\2$O+\K()W(QYAPE["7B(W7F S!4%$MS34B3T4HX
MDX@?0^OGVKAK\D0GCJ[*R8C<P_]U]=.VKUXXT=]-&^ 6P0RE_(>/&1 ='1W"
MK=P_.-:T3X +3JP(U][U] !%5G?X_BP =L/XGPH&J:/T'*HU,(8VGO3OYUVX
MC7<^ULKC=+\F0YMO-=#^,EQ^2UO<")EFT7!,M#,T<'MHG/X'./)2-EI84C@?
MSOD]TN"KCV_@$=P^ DC:OE^5=Y1,9EW? %,V+@=%ZBZ? 89I)2SV>_/O;\9S
M)./U++_^*4]D[,NN=(6YXC6!@B5,W\WW9,/J H1K8-];3Y-S3&/,=$P"(]=3
M0:8Z4VJED#0ZA HH D 9B_YWS.]_-*(2S,<-B^/!SVU*DBNZOFM?Y0@FCDV>
MV:'Z>##IW'CC17AMO<&(&X@>T)XT[+=0&Q)H6'N 5F8C-+_YA[2QXOY(N]*H
M"=$7JHE)LGOX$\\7Z/FWAV4N0(#,+;854G<!<DLF-\/?=EA)#KQW>^M<$#!-
M-6C.U+DJ(5*%5965;:DEDVOL_4,!*"G."]RY8T5 1E4%R6W3<S)-!")?0%O;
M@*S/A,,+(GCEQD# E3:0>P>SY6*=_]'?N@QGZ;@F\[$=SI8ZMGQ7U493FKI6
MCB"&//'O3*( XFSY2(R&*KQTJSDS[72N4?<%>I)E!5[FC*DF*-#^ZH?;P<@"
M[4?)/3,K!X"*^.-+P9/DQEY0!H:DJ5&A!?^_9E-D,G%"=$P:GJR/C[;B<I&>
MU?XP4*ES.I@*',40*Z3V-;;;R5E=U_XSCQOTME>$QL&G!=<946%X=4?8R*4S
M;UPU/B-MR.6C-GR/[+SD^!33&D78N[ "E(M)6R-B&;=\W[+X](IU'!C-NPP$
MU(MY.VXD>:6&NVE1J6QX6NHL&N&Y@T"VN,/>7&TD3X2Z3^'>!\32L\#-E  L
M=H*0'DRKRZHDCE]+FXU6>Y@B=.7;\9UCCKKX?[-(Y4[E:EE-9K5@61Z&&WH_
M<V0\XN/Q740DMI03^Z&T%@2(3M[2Y-GSN&=^\EW4,/7+'&#4<#IK\TSFV*-4
ME@6<9:[[$*N7_G9*$[ 7V"/)(79G1"8PNA-E!?:9 <89J@B/C$ENC-:Y&6FG
MCI,S50>7I3BU4.U#,@].BKJ]?\9).\&\L Q-.DW5K)%XM3Q&.EZ-6#J5$"-+
MWNM!(%$1W#!-_3ZW5)9^9HL?@? .OP#96'!NG_T0E%&^L\YM41%7Y3QG.&WB
MDQ1J)LCH$G+5S+DA66W7PUZ1X3G ?>Q)#A4^OF[+E#:^=M!^.L0BHJJ7.;#I
MWSPU-[6Q_XXTU%- @K:%]DV3J8G9]'BS-G>!0HY]O^R_3[X8X1U]!*?US(YL
M3?WB6ZTVA$+5!-Z[+E4$:"NV7Q/F4.-1B7&9"3H_S/$&;U_3J'/N!27'G0#Y
M(<V6JL8L-)$F[WW*"SC>9 6H$.W:^P)-<4[)/^&0LB#Q*Z2M?S<'2K%)3I#\
M5N8Y,*:PFX&5?C>;X]HX<@>FS>"S\$F"IDG='"H]5HRCVZ?84>W$V2B[OO@-
M*CL<,]@3<?#SMR'6;J?YQ<QZ8^72L9C1.^8W+VJ)_E1G/.GJ,5^:Y;<NT.-R
M]&?V&)8[>LQ-@#,#0-^['UQIEBR?LV25[OLI1/37JQ?#5C$3\"<1NK<8C#-*
MLW/B^;7ZWO/'0!TBA(<! MLWO/8 N<&R =>*_%(/OU&869K=W9&$P$])04TF
M"'7&QS&,(#Q@XRLQ*?#3EA1@TJ\58TJ<ULVO2 IV,*V/+^3#\OC),^NL<E0
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M02GGCLJ-*:2598PW;GSJLSH#Y!TWNP+C$FL'-\PU$&&QY686.O0"*\^O5IX
MRU./[P;>X<!]O]\"*TQ_R,1AFEAE7HE?_X>W_XYG\XW_AN%HC5HMBMJ;$J&U
M5:F]8I/$KJV-62.*UJC:(PA2HY0@)/9>K6KMU=H4K9HUNB@=:MQ?.?M[7M=?
MSW.]KN>^[W]/(SF/\SB/XW.\/^_13@=Y1^V8^.3.?9C>W:"#AW 6 QKSL6^'
MEH9&T(9HC];-#R,^)$OS%UB;6/#A>5$"F8 U-8=8?N1%P\@_,##R:M[[S'/T
MI)=VDS&4('7# #*\.@-M>*O->;4B=E?;0#SO49F9A><'(/N4JK&!7DBJ[#VD
M4J)&:W=(>W#=LBM6Z/SAL[? XD8#&VD2?;XW1/W)3&'*NQ2SG+VT!8"\3M4]
MW5(^YP5YS<A3!WE+];BNOP04'FGO[#NXBBI98C$^@I*(WC9;*??Z8T6!4] 8
MX/;!Y1:4")5T:?/<I@AN+J1:.04]/I8 C%W5F\)?/9[JN7>[!_HHINN(2K0K
M(G7-#U@#&1VRG@V7580;N#A(6.J;-/[50?-37JZKG0)++PLFHI(NYT?)QRK_
MY,__C?;]$'^(2X\@!?\V/?YV"DH)Z]XU>2C2^\6[P=J(56VZN_Z7_RL9;_MQ
M349KUSS>I[#KL'J.F&M0:X^/#RB-20$VN%-0WL)8)>R <<RX3E<<7FH(SFQD
M@:)CQNC5CI^7QYF26=N''-\F%=+1<QQ@HWX#V?3L.S52!I?/;\GT"HP\FGZ5
M/"1@J;;H 2;=F\YC4-;OF*0OTFE/GE_CJBWY$+QL?SO8-5':(*3&R1&Q=@_X
MK2LN%MYVS1K*$I"I?L5V(E]9;JY-#D].*M;#+A?7Q\-<H$:.TW;DS ( O$K/
MTN6NY09&Z/[^;EG"J$E4O0=4V1X6*D@SK0,MHF?(S_%FD!!@H0(@ 9Z]QK$U
MXBDHZ;A'EPN'LLJ5@3.6,>EMW74*'E+JOI;JD%[F>..V)"D2H+5;$]WS-IW:
M7@;6H,OEG(TLBSG?"&=&%;0)Q)B4&99L\>X ;JNLW_M91-Z^FNHU34=,ZDKX
M$8N0\)XH,\Y^Q!XH>0C70]$V?; &=,IO_7B?MO;C!@*-2B?'Y\A=]\RFUI5?
MRPIZ>>4L"\3E["F??V"W5%_G>D]K?(#=B^*K[+-!GO3]%< [S^&2-FRR^>)E
MA.8?YP04MZ$:#03T4MPS3/4#8$G-@;G1(CF8OY+C.N+57M.&RZ??YF75'O'B
M^-QW474&*.KKICIRN9<:D)W+&+Q>T5]H2;II@G,@&&'UQYR-B8T'V*&)#=\Z
MVY\1.WC%$AX/']%>=WOSI:R.^D@>[RYC*N;B_N2*>9^@TR&+"> X0Y$^*GBO
M<-%VDWH-HV<QR&$044D%O"*&Z/L(*K,Z [L? 5U\EXK X;$; /]RJ@[C>F[4
MV4M5*9+\NOB?-=I+_Y^#<*J\JZZ_$$J>+C"-#1U<=W0<COV7H>M>X6^5=H$K
M+62-2>VJF<1VT\LRU67@\'PSUO0;_K]CBCGUY,#^,>C\9#^0TS%#W6+0?;@A
MJ-><UL6CU@%:,H@]3 48$(%OS3J+D]/ 5\P\>6 L;9TE^_-'\S]/0;2D>547
M$28P[JORE:*M(^*N%"A";?'9?QNE-\E,POD^QUN^@VVEQMHI,I M9F.6([R%
M%^C-<<@?P *DF6;KN;5X<5$1W7I"+7\YK8"4/4U*=K.ARP=*@9$ARW%\,7R1
MJK/R !FV,GA5.I;F5G3Z05.U^KF3R'.GH!B U!H(\V84UKW2^<2<=:>W,J)\
M#1"?NAYZNH!KW[]C"^98?=T++K"=REC3*#A7+J)HHG"@L$Q-LFR]\W]:J_RO
MEU,M#2B\9:>RQ*K9QXJK/GN%)Y?X5Y>EZ?(ED88IBF-1-KN=@'S*JG:-#O_E
M4TP"S<_F+#?R6%9YP6. @=*W#QWV"8P!Z[*V"F)!MOJ"SWXOD>H6%6/%\E;;
MF#:4TZ#%'SK-T'B0U8>AX'\A-%^,E;]+O#J?17E47;'XO7 Q=0=@P* ]C-0R
M[E4\J)O2$!68H<HRI?@#@)Z:2TNRH8]+*7Q$E$LX^T,MM$527L:$@/E*RO7/
ML?FW77 JX) W+]DT?[NU=@D(<<Z\N;K!Z_SSW9TW@Y8\ @Q-;,<=\01L!@LC
M43K70FXFW=6/'6PX,O*YF?7HC$>G51;P=63#W$J4 JX6Y9X@C,GE:-OB X58
M-TU,O?RCG(X5F.=ZN>U]E:3'H7C_/B&^M"KNRI'-PQF?@M!VC["F)C&P?XY5
M2<J57A/;(WDQ)%(P!;M>\0DM9Q^:K]%TYG98&*"@ZNQCY58<FT0Q^S<TA\,.
M[4Q87WRP8O-(*$.7O=]%.ONS!/-+#[F!5#,$FY0$=V,Y"5HQ^O3?5/2'S?HH
MY7[9VY/.9<PGOE 19HNOGQA?+I]Y1F8 $A]D_K)V3_\E$$=U]7MVNY)>Q<[4
M:K'^W8BX06VFWQ.B[_3TL$K!B-P32G!+F[&/^A62,B;\'4O@_O3?3]0L2K!!
M]589L_X;\'AM"L-,E&Q<-\2BXH_S@,E*<Q[9P$=22IZBR8T@;;3T=Z/KFILB
MV@G=,'TSYU*H$;V8M&=S_*L&*^#E5X(F",38Y-MS.U^_MF!8VL7QZ>XKO=<Z
M; 8!91GA$:3G64V!Q^?>R7<;2Q7]JV=>R'KW.8/% %Q;.CXRZ.57=(CJ&,D&
M'67VF\/#EZM91@^G7QRSCK< EU_]9?V.1\JE(@F#> V@/%4V1H6-F)N4,\3Z
MX"M&V[FE<5_X9R:8SF5Q+4:X6I'0)+M> =D 6 /2^MQ0,IGU^9NRPRC_"6;$
M!'U?Y-'C$J"EZJ)7)+O7?W>9EAW+L#ODYEA+O&NM<7O"X&8H2M3VGZ';BX^3
MS &B;5(ZE9]Q$CS9JXR142;\9HQT2V- ]787N2-&_#BP^@D3=U7=C"*,!4Z'
MT95C00F;SY@BS(SQ-\3 FQY%^H)@S6)B%E\DJ<[91YZ8+=WD_S.]>\WSZ_-C
M^/G[5^RY(NQ^R=_*)Q3G_$*+LU;I=IB?YY+,S/MUL6[-4@."A!TP[#D!;Y^R
M;3_C:KF<5 (E]D>H6^QU[2X%F[LCN;01R!=\MT]!@'@PMN_-[Q(T9;DWN$^&
M<VI->#?REVW\\@6O: ;+K6, <-/QO&)5Q93E/  "KT$OT;X545%+NAC,V@)4
M/%EI]?J\$'B5FZ!5JU#,FBA_U9^-Q5,00#,H2!2#8]<\/GHX$/@.PQ1F0$=+
M1]< 7>:=RE>2%6P)^VD7LXX-9^NF:&]_G%_=!&9 R2AB,1DK<(OL6-LX+R\<
MAW+8/P5U<I$^+^>95Q_]:VHVK,#63C(H,++OH\+&*<@8**&>>3^\OWWR>RZD
MH.E+U3/T^P6#F^29!VR' ^P>?@=<' _QG**YGO?>$=E!P<2M4GUGMV,;?5*+
M;-I@X]=>Q1?>>#^W%OQDY7#0RW[BX799:J $L]]7R28\ALCVL=_W$*J+N:PS
M!ON].CR),S<<HJL@3V8F'7T<C)K%_=GB5_")#Z/W^2::8.LL\\2TQ!$72C)7
M@?KLX&Y:&;'9P1<D].,RMU*RB*I?OX&%F0F%;.,?)2M9F'$2K30<DLD4[Z'<
MN#(LKCN4>?'"(6DYZ4<]-4F O3$12O9DM(EZ*'$-W8Y#0^,YB-1WDXUSJ%?B
M3SXBH]-I%?U1)+LC7J,*BY\LF<SP>VMBNPS/^S@\#M %N*H]]4_773R0!ASS
M\:S\_(F.8YO.M!F R&5 %IX#Y?(6!NL:</Z9A[*)K<A^L66F9DM'Z,_?$"(^
MLK*R@LSZ^)#LM%VK^GLMF_>L<L [JX^VDEDD#/BC\*+/BT[F]5VFZJ$]Y\LO
MZ9\%OIX]IY;P9?R[#FAHG>QN;]Q"_%[DB:)[07"C3IBHUN$<O2-9$("6_)Q9
ME+XS#\TQV,98$SFV8;>MV:M?]VPKK$6DO 3H5+HU?GNN#\2YXKU7$QRF2J=5
M+&VQY[?#FP%(/\#>P5QJ4!T=E&+53\9J'EBN(\0PTYX4%M$'&-SG-]S7L@T0
M3\4B5Q]JN_Y7:6&2DRCQE>?R%Q]UL^7V+3[V!=H:W8$?])MC3T'#WNRN$NHV
M?64\7P[I5<RL^5S_*U![(@ !\@7>JZ$]05?M9N"F71@?E>*--\L+>M(FY%)+
M$BE4VXCF1&E8N%L*H#^0,"2._V%IJJAZ1><=\*8B*<S[MRJ)=#MK?H*="BQ
M7:[8])(X .T>J )$E'$X;)R2[]%H;\IO4.SDEOKVU7^28S';K(D+0@U6WWU/
M)LCXYCBO'1P!M4 J85B^P9W/'A6:O9!O=$_S8OCCU%VNL+,:%O].AHXY;<E2
M:(\^4^%\NF-IY_-3$' 3@C\>9*K%H-ZE83\JW*K2PK91OM&_\G(6@+H>/2TX
MMBKCWY@@&LUL=-DMY"%G+OV]2'J[[,>^[:?G:)O'\E0IM;:UN=5O@T"WGD8
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M6-#DN.B>W/G@S\/]$T< J*KJP/,]HO=74Y"N)DM9(D>@^"M3:X-S>O)*K:O
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MF2XQ"5V>$N%7G%;G7-HD=0@FM:(6HS?))XK[-05;TY3K( C;5QQ#F('&2O(
M<-7SM>L^ZL>Z) G!5'WS]L(764H]0LF(SLCD!2)?\<EE&X^GAI^^E"6RK;C#
M]K*"LXE[\Z0YH4D!VYMY2Z'1]UUP$H<EZ,&T)G6:XLT+7H"Y$K1BTA-Y9RAQ
MY[ DG&?P%M+]N,RT1N9UA@%/;I;)]?W*2:JL=V0S+@81,95G56R--CC4K)"A
MUJ,\YWE=<;&Z":W6%E>2,6]:#ZU'[>%%]K-&9J4TE;J-37ZIDQ .KW[#/U:4
ML+62EC9MQA'\B4A>GX11A3\B5:$??G19&HP/P05R,!)F";02 :_5K1DRV,;:
M\W;ZIY9,28WX^%6KXG@S1==R2^SK/!L+CJ@3)J+KG4SBUG3@?MXQ<"*1A8NZ
MEKGB"]A7]&WTUM/==Z6*,>9H?II9$3\?%856B"\IH"P7SX:P=DUPE8Y)B[%Q
M)>ASZ#OA4>:]S* 6?FNKIL^*AZ2(CRQHL1:2VR2=G=QGM]$N]PD*P9!R55/+
M2U+?T:BFB^2Q9CA6XIJCXL]YV%?:F>!^=_'",)^T]%S=/D;MGYS^%%3X=S;D
MR/);>,T?VNEIKX7NRA9A'F<EJO)<=,8]9V6D49M\M7&A ?.7N/?!-(F)')&P
M4)%6CG&2ETQGEOWE#_D/]OJ+VE<[#S_H@W^:(+U#PP9C\16Y]:&?570Q=CZ>
MOFLC]RQJ=D<KGA42^F=Z5VDFU:#V[-9G@U\:1!/T>MV&':K1Z58_3,\M!4->
M&1B8K-+62IS=^.G9])G^%6DCHA24%<8G:KLYCD5"C;CG(@/?"R9?Y$R:_U6K
M"I 9+"==SR/)HWKL)]\('?!^H=4Q6K#^E)2Z"] GZOH0"6QV%47C/EX7:]B5
M:K@\C 8/+T)\__WIH/#$B J$K2F3E;6E](6RQ)^3N'^"6OH<W_Z)GA<)Y*GE
M#?>\(F8 \IMR8/I<XS-;#VVN[;9;M7*LC)58^D' [<]Y=3Z(;KC4@)&#<U/+
M6K'6,;PX7Z?_.(($C<5_-AZ=/W91^X9 O)0Q8_"@H[_<-PVGG$>$A(B;&%6&
MEOJ5ZDZLD?!@7,@)YK[.ET7/MOMN]0L^Z1,N#773++*!<[_E=&P*(=JE Z.,
M&C:(#K('.E=(RZK>*6BT8C5,9^KKD<+@,2&I;WCJ^&_S;AZOGWN=8GRYX,+?
M3^<3FH0IOY4771#_1;FIMT[H7\=KE>?JN<:\*U"</UOLMSN#>,X:2MN)R4&^
MO,:M[T?5DROPBPV34W+*;6PK)[R0&VT/,>9K N(7=F&1W-:-3?\:'%.V%1S[
M=1:ODOHWD/Z-+WTEI5FAF>C@.\&S_ P7ZL"3 RT"XZWD=GF #3',S?FU^=H:
MMI+51I?:Y.>>-G,5K*#F4DYN(#$IY0X\X=!AE[1O^GRL04LTP8T?EKXVW!+$
MN ;YVNSXTXIVH'TB  *G>DLW<M)/U]ZP1$Z;TJ<SL8XA-HU!L\]DZWRDJH+J
M8\"9;_@9F]_XJGPIBPR?+B@,KL;J/)_HD%H#>-&.=U7IS><DE;=7/9:(22VA
MI/6[ITEJ9DQQYT_=>/\NX[&PICYLRL","(U,+0'IB@Z72+7LRP,F9]:^EMZA
M^2_@"?B"A(]_@\$NE]DBF<0M,EWOA3DR2%+_CZV)Q'%QV][TBX1G"X%R![)S
M3Q%:X[K,QH/W4UQ"\^I58LI:SQ])J@%NLU_LEW+FK<$VN6""C>*1>SW6^GTQ
M,:&2U\[GRP.QCZ<@AUV@>@J.*$A56U4:;I57'3I^I"W+J;LFQ+3:\IY;I!17
M^/FX22M5Q BG.\YBO-FE$^N@=\E":X^S$7"4-LF[V1RM[BN%EN/+6 M^BU_-
MJH^Q/0&(HM]0N@._^H9U'T9CR2.U*C%5*5%Q3N[VFIN+0("!VW'(GB\W-DI4
MFDDXT$/VCQP9+/K:K':37E%X\S\_/+?:CF+?KQ?,O5!V%COK:5+6IABCY*#6
M_QD+[\5T,P/.6+,_+_H5IF8<M:=V_W !6-_5_"<I?7I-Y!)M/BP@>=L/IZ!W
MXKY;!V?-V;.A05"A2N4$IMFRK+8>O-=(-17R9XLP)ZL%/"8MY8+V*GON6!.$
MW;32KB3<GF?+=Q_1Y]??6+0%]#4(H]VREOH<9&TVE^L-KN8[$K:ZB;TK=6DF
M]I@A5T\P?QFN$%=<AK;));;GQL$2%<<Z!KI  -_6-O.AW.]AR\F_QH_O!S%[
MFLWG+'IPM%^]ZR'VTX@>6M%\$6UUV\I#^BN6I4FOU_>O%"_;_3P2F>'6_PTX
MT__VY=F\/XVG(+&IKZ(-O,*=\E\VJ=S-)&[?:6CO9C$4>%)/6(VU)"YV0'38
M[RH<T0K5PR9TV>W>8O6+:#%W_GX[^X^F1]%CDU-P&:/L@>G)9Q>-H43Y/DMU
MJR10<( ['H\HJ8QE8Q7[F,M\B0&=G79;A\3,CZT0LT??]> C%$:Q8LG@OZ1&
MY21O5>.0EZUB$Y$>N ILO:X0), <;LF*>LYH3XI(C?Y;H&N)UE\K)_Y]8,3%
MC#*??!XXXFCDQ3\X,2C+(J40&])#4>K::FQ/ CQY[DB[I"P_FJ'*/\)#(\C]
M^A$<:4^R+=R_OV*NG7'ED4#1V.F^)C5!+C;8UH<>A5[Q2%A7%\5<V%E\+O*D
ME_&:]D5$0:Z"%)8O^),MJ)["F60RIAZ$:)V2/E<E_A96(51BQ"6U6AKYEHN1
M';Z%C\G*! ^\777CFULD.13&(FUL5+ER2RU,QV/V8+)NR>K)JAOK\;JFLN^A
M44(&EP&_5D.+J5%9G_VZ[*T2] V#J*+%VOO6PC;6V,M@749RMN%S5&N<9Y^K
M[R#$Z#.*[5VU6I#YZ""PJ/VKM3*%V;@B\&]"D4>7!>QV>\P5T3"7L]OAKA.C
MUZ%)R=HFNEE#H00*%16)DH1"2>?RW'1R#(MSZ83Y#/U).0GX4+#GOOP6LN>A
MA84[40=XQ/Z-WQSK-?X^('2A9NNX=+(0U(W((H%$EV6]Q@A[N:$O6_&[_6;!
MFQ[;KE:;)<PCD=DNYTWAMA5,%Y0!,XH$JW2RZR8;+K(&(IGBORRNA.!_9#_\
ME: 3:3]$6 ,!=ELIW&JB\>Q0+&/[( 2ORV2A;2$FIK3I2JM8U\"D'0_$42[
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MB@,A1 L3SN&NT422.E-CDW MD=#0@!*!/MI%OZXV$ -$A7?Y^%^T=3:45RY
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M)!2):8T6:O?3,D&9&]EB=;2P8P+B280_IH/?J, J6ZD@U'C9RX^$E:0/X-6
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M[75UBOG["4OY&KWW,BT/=N3Y?0GN>^+'=@_T7F(3<YEE">-#2(FZ&HS93Z1
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M5155% $83S PN#"X (#'8P"7MA/8"^SI!/[(*,#S!B JIZ*!>0SX#Y[_)P.
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MZV>1J*"OK<)6VO[Q[G2R?Y(H<)67"T3B)!QWH<+C.CR\ SO&PVKA^AA+W#Z
MOSWNMP^]B3BM,U.?S_DJ^YFN;)TRK"F<L/'$6>79@)<8)GKD7&2/(:.GN$X2
M7*O$;&(^3+BD\TY578'9KKO5*8V:;V>*0_EIJ?2'!VV4DMQY!@1LNV>AI3L7
M\+TR=ZRV;<ULO.X2]Y)SE+NLSI^  ^.K0+=1X7-L8BMUOX[IX"R&\\3*59F]
MJ=[H/<=4R1^Q73Z]+(9SAWD(AT_3$%<!E<L.#UP][<,TY]-1R?Z]AADK;I5
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M,)57LY=F7[P#Y;;^"2IK[6&),IU1'ND$,V%SS("-<0?&H?[G_H? ?D]W_T=
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M1^77Y?6<ELUK)_AO39Y[9G]0Q2W$"2.>=!R8LQ+GN3RZYT_;ICJ&@[Y@.^.
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M:13VUF\4E&F_=VUN9!R(D8>I,Q'V$7B:,#DM\\Z4;^XNHKN_^I^5K*-)KYH
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MBAFC:(QP\:I.P6C(5'-UX]7!SSUYSLKKR:ZZ);+;:)J^F^DT\]N7CE?FH4K
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M<HH4AV$7"K*HY(.6W&M/;G_.$?E2SU;\^M 6]1]3T>SL+W61;3(2&) *1LA
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M5'A7/'_F/_G%GS;I9GOO)'GBSU^QO+2</;:CRMEFBOHQZZ13*9(V5Q0J6X]
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MIGEGS*]NT\,=W!:7UI>1R!>+VUUZ)62A-"O(%=Z@-OGDCS=^1GD"W@U:>_\
M(5FUJDS_ %2ZT>:2"ZB!Y422-"H^!E(5Z4=>.P:M>4V'Y8Z_IT7Z3_+/S9J2
MWMNC3C1+V8\I46IXP3*%(>@H$9*GH&K0%3RQ_P YB?G?Y.N4M[7S-!K5E0<8
M-4@AO@!TH&;TY!3_ %ML]3:?_P YZ?GE/IT5M;Z9H6FR!4_TJ/09)FHNP/[R
MXF2I]U_#.=1>=?\ G)G_ )RG\RZKY8?\P-6CT*PC^N:I-.\FFZ78VY;@!);V
MD<'JESLB!26/^34@/IOY%?E%I,E[%?+KWY@W^G_%=R23BQLU>I4M+!;@F-*C
M8O,6I^SAW!%^5?DF]OU;R%Y=C0D6VG6\-J+J:>;U(PTJ^JK.W(JZI4CH2U"0
M 0^<OS\\V>03>_H?\O-(\OZ=800I.TMO:->1M*.2,T=&8J%IR(7;;HW3IODC
M_G*7\RIORPN_S5OX?+6M^5+2Y>SU"*.*Z@N;29' *T]&&-FHR,0LA8JWPJ2#
M3N>@>9?RD_/2VAN[1]0\A?F4D*30:C9RK9ZC&KJ)(S$HK%=Q-45CE4M3[\/_
M "W^8MSHVMV7Y=_F[;65SJ-_"\^D:]##ZECJUO&>+D)(LIBF0$&2(UI78E>D
MA\T_E9^6FM.DUWY'\O:U8W5&5_J<<4E#3[,MN(I!]#9Q'\PO^<1_(NHZ+>:Q
M^76HZEY=URV5GBTVYN&O+&X8 GT5DD'K1%MP"69:]13/GU:++$R7-O?R6SNI
MYJ2 U0:%&92I!!!%1G5/)EU?:AJEO;71BU!X(KB6U=D22XC8Q.C\9B#* 0PK
M5J;#/2MGJ5U;75G*^J6VG*(XRYDO88BM 14KZH/8]LXQ^9WY#:Y^:/Y@IYTM
M9Q!IKV5I:0^C%6:Z-K<>C--(7"<?[QE0=2J@]"0/I#_SCUY:TS\I?)T&B/J5
MIJ&H7DC3W32R(EVRAW$:D UV#?"&KU^G/6<,D<\44\1Y13*'1NE585&*T&/I
M[Y@-Z]L:1V/;+ [95/IKETQK#;YYA2G3?+ITRS]Y\<9T.XZY=#OX9J=<VU!E
M4WVRJ U&^^-('2F73\,93?-3??)7Y'O#8^:-*<L0D\AMV'CZP**/^"(STWD=
M\VW7U/RWK$U:$V[1 ^\U(Q_Q//+XVIV&7O3I3-0[;9A0=J9=/'+I_3*^C?+'
MOOW&:OT98[4RJGYTQU/[<WA_GME$>'7-U&72GSR^O7Z,;M3OC"#MX9Y2_P"<
MO/+3:S^7%OJ*KR;2YY;=S3HMTE4)/;XXZ?2,\=_\XNZO9,FO6-_$EW;V]NUQ
M+;ROQ4HB-#("/8A>X(VP+YHCAN_..E7S0V]SI\:Q&>6<<FEFMH)F@B9XZ.!2
M->9I5AL".63+RIIH,5U/,_-[B19)GB*@/.ZJ2]2*$<R> '11XYQ?\XOR#\F>
M:-$UW5?+V@VOE[SE96L^H0S:?&L$5Y-"AE>*YBKQ9I0I(=5#!C7<5SE/_.'L
MU_+H'YFR:;=I:RPZGH4I-PGJQR)Z&HG@Z@A@#6H(-0<Z]YEO?-OJ:C;V5GIU
MK-<CTSJ>B7,,=PT1;>)A.H /$G<$5[YS_P O>7IHK6Y\K:7"^AQ:E,UQ/=SS
MBZO;RYG>-76:2-63TF]&E0K@ ;BAIDR\E^2-4\BZGKD6@^9+1K7S!<V\^H0:
MQ;P3<ITYF()/Z:W$;(2P/ILH-?B6AIBNI_E1YG\SR^:ETJ/RU=Z+YQ,4MV/K
M;0/!<1$!W0M"ZR*W ;-0_.F2_P#*[_G$W2M(U+3)]>OM.TCRS8ZA9:A>Z?8R
MK=37<]LS21Q_6&2!(XV*U(HQ-#2F>MOSIT#1?S-T6&WO%M9H]/F5M/"7LR/%
M<-RB$BM!Z))/[2@TXC?;?/+VB>0=:\A7MY^F?-IUG0&@%O\ H^X/J/\ O')+
MF9U61AP  ]Q6O7.=Z1HEK9^;+@Z4)+>U%TKP,QK1WD7CR;<GXAL=L^=OF'3C
MYC_,;S,NAZ?+=0W.O:@UO;6L:GD#=2E0$4+L:5V[9U<Z'JVAV*C6=&O-(:,
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MEY%"P^KW:#I1[6X64>%&';/H5Y@\EVEY]<NV@:3ZPK,]!5TD_P"*^I%2.F<
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M"NP!Y ;&O;[]H1KK&1@TJI)!>Q2%X9D1D*2,8SZB@L&Y4H0?A[&K5KP?5_\
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M6-#0@@TV-#C_ #3:)+;"(U-NG%I56G+@31CU%!UJ#M]YSGL-JUKSD>/@K=7
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MN/#3@]Y;I(P Z L14CV-1GF;S]90:9YWUBVM[:*SLR\$T$$"B*-(WAB("1H
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MBD,03N2!7Z#7IGF[SY9+;ABML(I8A1V;8E&)HZ;[4'MMA3HMH@B+K!Q59A,
MX*E>0W<=*GM0'#^.,J/5FD4'=5*]&W(!-=Z4."X1,'7U7W;D4*CXA3<#OL:8
M>'4/022M"%4TKLH:FRG?Z?IPEFORB.YD-34#ET(6@.W8^.>A/(VC/H_ENRCF
M#+>7X^N7'/[0:4#@A_U4 &2_PQU-J@#&]\K?OUS'[LKI7&T]\L>PZ8_MX91
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MA(>8==OB WJ:[FH_AD<-M)"S!#RY$CD32K'M4BO?OAII5RT)^K3GU"5%'?\
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M _=@9DD4NW%65-R2:4)[=L0V-3T9:&G;Z*#[L3<L?@3J37<?9KUK3&\0JA5
M8CKXDU\.F)R*I!1AQ+ @U':E#GZ#/^<-/.;>:/R1\DW4LOJ7-I8C3YR=R)+)
MC":_[%1GMBRNJA=^F2*"8U%3ODFL)@Q'3K^O)S'I&F>8=+NM(U.T@O[.^A>W
MFM[A!)%+%(.+QNAV*L.V?,O\Y?R-E_+7S2]I9QSS^6=:#SZ',[<FCX@&2SDD
M(J7B(JI.[)2N]<\ZZKY9(0*%!DCJW&,&,ORH:@G:H[X36#QVI>-*H$)+0DBI
M).X\01XC;.D:/>QQR<J,03LIH&H>AI\MMLZSIUY:R1JJS!J+\ 5=A_K<F45/
MC^.3"PO[95ZQ"0, 0J@FO:G:OR.'K74DGQ A'JOQG]XR]/LJ:[D=SB)M6E)D
M6*2X=:\O3=N*5Z$]0Q\>HVPSL[1.(E:L);IZIJ["M* @;4IVZX9TA5&8B2W'
MV298VXM7;A1 2#\AA'<74SJ$LHY(UC7XI(2D"J5^RQ8UWIM7D-_NR):A?3P=
M+J2ZM(R68R3!XT(W85ZU'>@ ]\X)^9GGJ22T&E:4IN=1U)UMK6%5^*22=A##
M$JQG<NS!:"@\<]L^2O*2?E]Y"\J^3.7K2Z%IH%[*M#Z]]<%I+J3;KRE=J>V>
MRORTT6:PL;%YQ\:1,6KV8A0=NWAGC[_GYA8?6?R0T74E9E?0O-5BP9*!E^M6
M]Y%4$D=P/?/B*6NG!6X/K50F@4!@#0U"M\+"@W[]Q7"MH_3B=H:.T(5]OM4!
MWX[BN^^^$T@8R*Z@('/[.[%:$D5IX_+,O#B5%$";$FHJ*=C3>GRI3OE15!Y*
MHXUJ*D@ DDU[[?JQ>WDEC,G)**" 66@"4W[^)/TX;^OQ*2<^'I[R%-U85 H-
MMJ=L&,TDBU8FO.L>P#$@ D;CW /7!<;4E]+:24L 0:\MZ#?;;;8#'*KEWHJJ
M8S4$= 0:%5(!--J_JRXQ*D\4^\=W$P>.2%BC!UH ZR*05._4-G<_+7_.3'YZ
M^6(;>TLOS#N]1LK8<8H-9A@U)2@ VYW4;RT'@7V\<[OY6_YSK\W6[P1>;_)&
MD>8K:O&:XTB673+NHZE(YFN86&W^3GIOR=_SEK^2'F[C%<^8+CR3?,0/J_F6
M VT18[<5NX3/ =_YF7Y9Z+L+ZPU6RCU+2;^UU;39@"EW8SQW,#5Z4EB9U^BN
M"AUZ[98&Q\,=3-3<Y=#3WS95.M1E';;MXY8Z[]\P_5G;_P O--^J:1)?.M)-
M2DJ/^,<=57\>1R?YLV;.$?\ .3/Y21_GA^1OYA_ERD4;ZKJ^F//HSR'B(]5L
MR+FQ)?JJF:)5<C]AF'0Y^/VZDO[:YEM;Q);6XM)'CEAD0K)')&>+<E(Y#B1W
M[X )=:TYT5J4I3J>1V_7C:AR"C/5E"L26\:A:;]/#&&(,64!JG<*"53E6E!\
M^V+A(E#2<"RL_IGC]D&E2%)\1UQ";TZ A _PDJ$.]>P"TK4X E5^?I<>-%)X
M@'H?<>&)HLI,L84DUIQ8FHITKM[>.*B*1*FE#R!*BA%"?8G%HXA1)" 8^@!:
MM*[]QXT_SKBB0!7;<$(IJAW/ 4HHH13J:XHL 'JO\( )4\@0#7]D;DU(]\!R
M)$>;\*4Y U!H/\JG^>^1^_!=EAA(:>Y_=@EJ+UZD':@!K7)';V(CA(,'I^@B
MHA!-#0T'6E1U.(O$U-@52G510@&E*@]L+I8P' I3B:58]!0?/O@9T6G9U8_L
MGL/$?TP!< *  >1[<=P=Q4@[=*8%"A=ZBK'DQKO_ )TQ9$4T4]0=UV.QQ-EI
MQJ &7;85I3Y9]4O^?=OG4G1?-7DN62OZ-U#](6ZD[A+E%#@>W)2<^M.GW6PW
MKDMMIJT-<D-G<%&!SH^@7\:NC22<0M._4]@,D_F;RWY=\_\ EZ\T'S-;Q?HV
M\(1'+A)(IA7A+!(WV95K4$#V.QSYT?F?^3^M?E_K!TN\MI=8TN=6GT[5;:WD
MDBFB!HPF$:N(Y%K\0K3N-CMYJU?0;%IW 8R%:GB2*U_E(\=J4-#TPDALKNTN
M/3(,D45 BU!X"M._^9R?:3+"FQ)H=^%6K5NOPM3IUR:Z7&C2.RAN)-#1J 5'
MOR(!\<Z!I8CB*Q") ?V?WAD<GQ6I&YIODHFFA*K(_K2EOA54XQ=>@CC8;^YI
M].*03E@\<,P1R 29$]5^7B))0NU.XIC_ -&JCF22<R\ZUY2@!@>PJ:LO;I[8
M6ZM>Q6T;6\H,950S(B<4%?LF.*IJW78]L\K?F1YFDB$L$;QQ2O2DL8'J**GC
M78KRIT WK2F$7_../E-O-OYNP:Q<HT]EY$MFU=FF^-S?3DPV(8U()Y%I._V,
M^I&G:>;_ %^ULXP'-I-;Q$=?CC52Y/RXD9ZVTBS6SM8X@*&-:':E234G[\\8
M_P#.?FGMJ/\ SCCY_*()'TV?2+]:]O1NT5B".X$ASX&P2Q@QL].!A7D60_9(
M&P+?T\/? SVZ7$<J0.T?I&@Z L>M:L:U%=B.W7"%DH2MQ$55AQ96Z&NY%">Q
MQ*LD4GP\DX$4]0] H.YKR(I7%/C><*BT4BH",PI\ZTKO[8&/-SZG%GE[5 *<
M=]J5Q<3$1@.0!&ZJ/A7X1U4LU :_K^C!UM.3Z:DH&C8E"P7C4CI4]>M .F&T
M,LGJ %G9:44CX21N& I6M![_ "PQ8H4+=(T8H!XBO45(K7QIN<6:$R1(0O(+
M\(([D#KXG?I3*9&]82R,*T (85!(V9:[TI7MB,O.2D<JEPM0&'Q*Y-:GD=MJ
M4^+]>)&-W;D4KM0D%EJO4<JT J-CAUY>\Y^:O(>I1ZKY+\Q:EY8O'(#S:;*T
M#2&@/%XMXW \'5AGK_R%_P YV^<].]"T_,#RQ9^<K.O#Z]I_'3-1V-*LJ^I;
M.=JFJ)\\]H^0O^<E?R<_,)H+33_-4?E[6KB@72O,/'3YF<_LQ2NYMY.FW&2I
M\,[RR,G'D"%<!D;LRGH5/0@^(QO3OTR_89B=M\P/W#PS$@?1F'@.N"["TEU"
M\MK*$?O;F18UVZ<CN3[#J<].6MO%:6UO:PCC#;1K$@_R4  _5B^;-FS9^8C_
M )^2?D;'^4/_ #D+JGF?3[8Q>4OS=67S'8T7]VE^SJ-4M@13<3$2T  "RJ*[
M'/G6U)'4 CG)N1)5EJOZ]CMOUP<L:A-J!N0# ,>M ">GCMUP0\01))'/I2,P
MHM:J*4)H#\O'VQEP /5+IQ(?D>56^'NOT5._7"R12PHI!IT)(K0U!'+]>)-;
MN!\+*P50XH.K;%MNY!IN#B@@D8GX22%#&@[KMWZ_1@P:?,H<;$!@ J%2 U*T
M!Y&@-,$16Q6G !E%%5G*\2U:[$CIV&*F J.%0>,A<F,;!J4VW([^&!Q"WI,>
M-9I">+"O2.H!-:$@]/\ :PKN*L"RAHV:@K\1/(?9W/[--J9"]1N]1TF[>^A$
M,T<H,9Y)R,8/VE(/2OCAWIWF&WU&1!7BXA ,$B@T90:E#ORKX=<,C*CJTS*U
M/L@FHXKN%^&GC]^ F'(UKS( 5EJ>OA2F%\\BJ0%4ESN0*5I[TZ#QP"8O39G)
M+/N'^=:^--A@:12K'8CF2: #H*;DG%X0I!#?O5^?&GO[8Z6,4(;B212B=#\B
M??/5?_.%/F7_  ]^=,%A++Z=MKU@\!#'J\;"@/T.<^\>G7-.&]05^C)O8RU!
MWVR16\NX->N2O13)<WEO!%4L6 'T]3A5YEUY=3UGA:RF33]+7ZO;U)XLZD^K
M(!_E-^ &"!J>HK"+BQU6[MD&TB),PXM\J_=D?UW2O+GG.V>Q\Z^7[7S#"RD+
M>JBV^IVY(IS@O$4-4=:/R4]",\E_F/\ D_K/D!X=4TVY/F7R9JLICT_4EBXR
M12]?JE[&M?3F [_8<?$E-U'+[2:"2-Q.K1-7C4[<2.E0:=#7)%HEZ"Q])V8)
MR()E/(D;%2I5=C7;XLZ%!#>SJLEHT"0DJ&:5JL?NJ2*>^3>RLDD1H;RZ9X@R
ML4:0K"E0.-35V913I[=L.([J&TXQ%D9:?88 DFOP\"2P&W1FWPMU#4B5,D"B
M2%5H9$;@RT\210MMO]^<>\T:Z;6"58@ >/-O4)0$$FK/(*T'>FU>ISR5Y@U&
MYO999Y;GTTDJ4,>W(D$%8JT 4]>7T;Y[R_YQ5\D?X3_+F7S1J<7I7_FRZ.K2
M<@0Y@"^G8JU17[%7I_EY[F\F^7(-*M]-OWF5=3I)?WT\S<8[:$J2S,3L.O4G
ML3G.[S\[M1G_ #)TQ]-O#!Y-,Z:6(Y0>,ZRN!];>M"&+D!?!.U3DM_YR8T<^
M8OR._->R127F\L7-Q&*[AH>,PW]N.?FHLCZULK<3SC53\6Y *C;?_*'6G3!T
M-P5ED6IJWV&84'):"AJ.@J2!MC;B%F<,-Y5XJ0002@\:#I\5.F1N?U&</P4F
M!A5?F>M:UK[]\<ID*MQ +*:A58\0-C5J]:8N(5D/'EZ?%J*6Z-3]H#H>VWAC
M)8.2HSP.54 %JD$$DD$5H-^WO@:WCN(-KB*1 X]02O1N09J U!H-L,+>ZE5H
M6'&2>I"F@(4#84Z>/CAE!/\ "G!D+LP)XGXC3;BP-=R1UW]L.H2F\G+CZC=5
MH352!X@BG@/;%R'9.,$A!H/LUVH Q4J=E)]AC$5N,J2$.%%2/L$4^(5!VZ[[
M=<P+.\C_ .ZM@W%:\6IOR ([]JX'F62JJP)F%1('Y&A6IH :;['<X"4,C12F
M'@6EH^U%:FU13C4#OMOXX]U]4+"\:R1IRH:;T7N%(WW[>^=4\C?G7^9OY?2+
M'Y0\YZEI]E&P<Z7<O];TXA6 (^ISB1 I_P GB1GM'R#_ ,YTVDSPV/YH>4#9
M,2%;6?+;>I#L#R>2QG?D-Q_NN0_ZN>W?*'G7RGY^T9/,'DS7[3S%I+,$>6V8
M\X)/]]W$+A9(G'@ZCVJ,DP-=N^7X[YMB!_'+IVSIGY<:29;JYU>5:QVH]& G
M_?C#XB/DII].=BS9LV;-GB;_ )S[_(9OSU_YQ]\P6^D6/UOSIY#)\R:"(UK/
M*;9#];M(SU)FM^05>\BQ^ S\K-K&0798R[QN36A-12@-#]_]<.X8 T;<&C0$
M@$D'C4F@VI0_0-\N2)E=@L;!@IVJ/NH0*$5I@5[9&ZA2"U3NPH%K0[=0?[,!
M- M68CFH8LM10@MR/Q?+&-:\R0_)B"**!OS'6O<"O?%8+5BM2C(%^)BW8L=S
MX'M7Z<,?0<LZM169ANIIR -: 4/@>O88,, ?DB%:(E5#LO[LGLNP&Q%3OMC6
MA *+Q9)9 *@L:=%X@5&]2.M.^%TRIO\ ""#R)%:-R(\2-Z"NV%<Z?NW9R'-2
MHJ003L 14[@_=XY'KZW65)%5$9'%"H I2IVIOG/K[3)+=VDMPSQ U'BOAN,%
M6.OS0A8+Q!=P@U#,*R+V^UM7Y')3!?6]S$Y@G28G[*\>%#U'/PZ;?AB92HK&
M2TK*>1:OQ5/?KM['$%K(:R$CD@J*DDFFU?[<#S@@DFR]=5 <4=LE/C@,#$Z"
MZQ!@<'=W"#!X&!P"@<$A:'"'X!Z"ZP 97(,&UV!#(($$#Q;<-9MW=[_=[R==
M]?3MO[KKWCKG/.=4W>H+/5V!OM7=D*=?8L*UPGS+CF(9*$8(/P9YG%4#D&TP
M0RUE+"FXI^VM<?58<;"]OR@TMK%W#XUR)?F8)#,PQ"'A\9G_&\-DHUFA?*-G
M6VVMLQHRSD4S.YISO[DJMP2TW+BQ=]S6TX(@IX="A?SPU/#YY>\Y1<R=FN[]
MK/![;#9&D23K#0Y#] QI99$QTI\!/L>0T $[QL?\OX <&W6?"6,H.)%HN!2!
MT\X";FTC#C(Z&GX:$S;'?_5^%L7%^G2TP3(?\OVM9&DBZDAP4B;H#.>A!@G#
M7]:_<QN]>[34[LU.KJ&I/7;R@'((V>3C$I:F/!:Q!$>5J2ZTE7 "X,Q;-1HI
M*B,V1&9"FHA)X!C+RX-3%H5F&_E]=8HO/L^#H_HP9B/>8_\%:*@0J._C8H4!
M_@)<U1('.BZ&$%DJ%+@DAAH-B*T%2=HDN T;SZ]<<%XPB\LIL*#XYR[@Y* @
MZ*%OH3B<"7TX39.E4%O<3,"S'*,#:M*^&'!X\X;Z;#%KZWPQKZMW^X6M^Y-U
MMW)7?EI&DYQ=>ZHOSGV9$%WK=--GM^RW-3I<L%_[UXI*LTPL\\GS: GNH544
MS4&6V<1HY8"OWCN%DYQU BIW/!_('&7,"/'[+)I^"3Q^X/GIP^*2$LCR*SPO
MQD#!V@I$@Y#!:7MYG?0!;/'NH3,*K#@P&0#^EO )'C*'_"Z6_F?2Z^R)VU2G
M\W-C>]Q&9T-7 ;JAWP.4WQBM:CEN&4*1Q8RD*BH7%QW4X>OV9812DUC<\$T]
MK]@CY9<WM#-B3'.0CH&[1-U%<G#6Q#H.Q,>QJU$@6*<<V^"^=.XY@^)$ZL]1
M:67#,HQBJ>V2!F3S[<<OGP.K4J'YB50';4,J2'7RJ[K9,&'\ U-\DUJ>U6N2
M,^/5JTX@2C2 &\>\R_V]]KN#6-C&K0;5=31S;U<\$XR%.G%:7V<]6L'(AC)4
MH4!K, OJ@XFFO5"TBJ-P5A\2=3-(1!\:52FO%^!Y,C"A&0/44P@2'%21IS%,
M6D/]$5V]M'Z F+&_KJX'*9 79%0\O NZN<2JCHBS-5^N8@R7HU@ZKK\:#'K!
MDJ!U.I^U($Q39R^\/#*RS&>"QAJ#92%9&(L"#:E9R;S["Z!%"W']"O[X4?SM
M<LD#.'7P05JTKX:,*-I""91!MY2"5K7D@=\M4LN#WI$XPGRTQLE?TT'C]N"4
MG+Z89!SWZJ1J\Y2?U:]M,,(UQJ7'A/],-/]AX=:[;J_'\<RG@2>[RC23"$)O
MM*CK#,//D5\7>@U"+8:@"R[\!619GN=9N#6<DQM9YCUKA4UGNFT#[PJ2K5K;
M<CW%I=Y<,/F:K#.TLM,",\%)XA?[PV<C>DU-J+?+2\+<HGKADC6:G6](Y3TP
MBX0\!S?MC?2A[KIT#QZG9>ECM/P<:29FS.S[)JV P+%IC=U<&X<[\_)P:#.'
M"64P*K&SL.LP^C^*_5$DV*)W1_HO8(?6\DST?%F_<^8/N.V,Z+=HS6\0VH:&
MJIOD:'!G9?%WU6+.!>.2P=.DCDUVJ&=B1=Q^M1:6HQ['0K7O<DB!.<HGC":=
M0JL_]90]A?J:)OE#_RVWOU?&A(%W*04^*C><9LE[6#A/XYG :-<T LEJO$'7
MZ7U]FU!,;M_PP-W;7Z/]$CT*G*KG(./'I!3U/)X"3LBD,C4)#(."@DXF53XQ
M"; 3 5AG\7%L?.A\JNI<EQK[II0@Z U;)J$T'@ ##Y:ZD$!X/U69CI8I@M51
MMW4-.I-ZN!FU*%+6!3_H$]"-GFY<]#&/+2<*!&>QWKQ4U]$N#L7N\OWN@"?5
M5DN^POS H5+-BZ61V'KZ(F*X]&AT>PN:"?7G1L-$PD5^M1P%-4H)&?3DOK^/
M[:O*B#< ]5!0L(6,$'UR'A3)%DE!@3T-=/V:P[0,1O'JX/.MO&C0T% <@#R=
M2.V"=+ JAA"3W7*P2O.*?A62<+6V/6/_I91I]E*=(I1RQK@N&KW-$Z>L+V)#
M NM$Z-:ZCGJV/3)82,\1ZKB,INCYP_PRNIP.8V\1^I/;(9C=CE1_^^1F9Y?W
MC!=FKCG6FHJSU?JI'T+73<7!97F2)#C[6:J74+W;@N09=F_319[8(L_ON<#L
MLH_^?CJ?X,$U:(MS+2J5KGE59@G<H^VQ^\_BD22,/TW_ GH**YFT^@M=<_P=
M&E:4OZ+/C;!] 6M=H5+4L#\2.S90BLRA6*(OG1A((_FJU@+JW$K!NA.NQ48Q
MH0"T->P! J;&6>].TU5.I]@F!QG;,ITIPZF6:36>DFTH%76AJGG3\(^>]][;
MB9;Z,W6V(M<!6I.MM2F1L$914GV/*>U!XX9!K(G!5Y,O7[L.A_SLZ8_\%$IQ
ML'PR\D,5,MY&;*3?;DLLJ!(0+PX1.Z/#'0C=F8>&4FC,VF-R;+W3#^G:<C-N
M_[!AY^X*S#+@5%%B&\2"_I0 %J9,B^_?!9<B]Y\2JSJZ.KI378HT_6XG!,6!
MJ0.DX=LY$7(2.SU_ 8R].PR'LI!#^_/*?*YG;I/X2Y3R=ESOA:BUTC'A&N3$
MBX3&FZ7$6,\;Q/QWI(//]7K]>7GH-]:S7>U[\MZ4('9EY%[CX;Q8;45'92&<
MU@N&'V*[[T92FG/,%O?)M(AE9KXN!Z$-![^3E1+RZZJ\7;RMV\ZDSW7\Y;*0
M)4*G2[^^DYP\\) &ZC[/&=LK-.+[$LSXI^5%M:.*K6)O* :V6B%!<$8D935(
M;0ET2Z:U_-B;XKC]9B.!E'T"$N^FJZ<03YVX>"J]%]58.GKA=FR>Z4!$[5EU
M$XL1%(HX6,6OY1FJ5F==2=Q=#A_*?)56=((WZ&H9O' P5V:-:71-O3T8D%0*
MB/XA@LS_-(Y0QI)VO"KVQ))PN4;M]2E4=!GVT*L4G>[35/R4$AVY<R ^@?C5
M,XE:=<ZG;F$YZ2>12IS=.+RVP\Q=M)6O7R9P>9.IPVH$'5.Q-W\BTY?#4=3J
MG5Q_S)@"6]MCF\<A4CRK*EG,8W=%92C]J#0BA%*;X7V'I]1SW:;MB.,V9X>-
M<*&M?R$01GU87_Z.>L-36'.,:H=3E-$@/E2EOX=<".F!;43!U$-9QF&L#5%X
MP$X(B*=^MTE Z/]-.=C.D#P7O>R(75G^0/%E,8%N*#XVSZ !?0@P;&C:)7HY
M]<(V@4FC"G3B/)01B/;E16BZ7E"G34%N@$>QQZB@H)@"X1-=#/4:YVB'>3<"
M1#&A5$?YFYRLV[37@B9]5?KX+T",_[;7D]>;=TR6W_P#]Z37_I-!&BQ9:Y/U
M^,_S3/8R!I/G@^K:'1=EQSUO+2=^TASXGL&;6*WJ?PBH3 D2W:#<SEDDC9S_
MI]1*(?]SN.*_-]XZ_7N@N!5$^MO\P)W.NT#W+N0TD^TWAH;1/-*V*)-N",SF
MYJ(;3OD1/#3]A+5$35X]=U\QM8"-VQ;\VK809\EEV>O28Z7(J#$@_C?K,!B?
M7;O_0#UA%745HA1-(>@!6S34 B11G::6\-@83"\5G&1!&1=F9V\'P"II$B>
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MH]LJQB[B^MI+^WX(;:/W0%3_@D#"B'2:E2:9U"\Y=5/^VGJ7PI  XL!Y/BQ
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M2E-(%0U.G#ILXKAVG(8=@212+G>:&^4 F%/LO,*9!BK*UM8UXD\9W%>PX*H
M2+WF!,<:"?4-6DA[9A3>SVZ I+5SG\5OS1\B\P7!8I=R+/L?";5GA!CNB]WM
M/=@VI8X'+;W3QBZ-38S7&'M2=7>K.]-EY4J'RJ6_!W7=8/1Z="E/[BG/\V5Z
MXX'M2G&M(;@!#3#.!'>&0S3+LREDGK9U=I2XO(Q)<1G27::(Z8P[3T9Z8CXD
MZ0L0](/CST.R&N#!/VC17ZXQ45M3F\A$ TAJJ]_#!YM%""N)PC;WG;)</]ZQ
M<Y+R)3T@Q'L4YWT.6&) ')/!35^(ZQ:4WP74 /9="Y>]VY^0)8/D%')P>%WD
M@RI8"$BRO35?=<$W:%!J Q1EHORDH78J?,\^1:%LT4H&ZISKF<EB[;AP/\Y+
M">BG(YYH:MV39.*3PZ/G<D^P8KD_S]BMZ_)ON[HWD7$RB2)58]%X@(1@"YU/
MWX.ZV5G$TIGOW"PQF-SJX(=:.?C*U=NY=^CH(U=3OMVDXPAL]GILK=U\0R"J
M@:<XI3409<^MPM?K>)?NF>*I9#CO<<9AE,0^E<_&PX7E(S\L%4#G>-4%+2-0
M D=%(JP^\&E>37+C_%+(=4WV,*%#\8WLC_R9/Y/@>Z#=+&(Y(;](/%OQD6KL
M9.W\E/RY<L&91LRR%;@?-0@/FFBC^C9*@<AL>)(@\D6IBA!!%HPIZ8NGR]UW
M+VWNT)\;BHCF>^ 7O>IG9)779?MR %0X+;0#E?5B)C1=0)*MH,2-:!H@>%">
MO51GG' 2$,F\G0R$ST^&LE@X+(0&\*V[=1VR<Q1V+WK33V/-'S1( RA;8I 5
ME3S5[DMM<7!8#U%Z^:@M)RA4]7#V0,"ZY^&R$ 6^.$<4PXF=%5^QA+Q&-C]&
MGXK,_F%J>7]V(>]UO.F$!%HG1#7 45B.-4K+;C14G\L^V#)OPK3*NM#6'V!+
M Q2$2Z*DY/F8A27O%D>EM-V.WGPB1'UYRI(E6;QR#8-&-M:\N66#G)WS.N8K
MC+]B]<# +EF3#RWW^9NLDD4"8DTCL);J!#>D>L+]O![.[?X8R<IYWZ.6M&J5
M+!BAOK!)S_)]7L)T'BX6VR%T6%G(OV^TZT"-F"+T*-9@*LG#Z^P[;XC<:;_8
MHC/9U/@S.NS-T,/^VKKUG$J6[P:TDKX>J:40OJE,W/@0U 7^ES%NE1,RX]B?
M[-S_K'CX@ILM>_* QC_JP%\PSDXN/?$"$V1I\L!^+E*=S#ODX[6AX^/5!R^M
M3"U.<%D_IZC$$>($J_@YD5OPJF!OVU=E0TFMDJQ/=.P>]N42,3/>8^%M0],=
MVE^O2.\3]X4TZIU&>O^4SM>6[@'2 /*77K?LT0"IP<A+0SB@'C2;?WL1D1-?
M9Y/'ON/SN]5[W>$C*"9'%&CO#JP$),8S, 'G:K1>BF8RK/4W#,7X!32OF*<T
MW]D'NFB2L,)EZ F-YP8W@(D@539VZV.*AXR*W+N?G]0YJAW1.W)FG#=JCT'"
MZ>/1A!$IC\*"-+TB U4K,)[>9CJ8F[XVY(?"ID79DJ-79L7./,1,:+^A;JBQ
M3R;C-(]$&I8U%4IRW[ _.%@:@YS+K9O-M^^DHGPJ^HV".F.E(!'L>:U36E7H
M4R$7#@YV)@P];/;:="V-A0(LX1(5/['";Q@EB/KX%<D.62OS8[^L=S468R:?
MFYRZX"(S*-S)-8M@0A)"N2NN+_.[)C."#:>&G55=RLO)AVZ;(C$1(G&RAW?,
M$M.I_"/AA]V_1@F%&B6:<"<RZ23E&EHXH0+A!-T5M*L.%+,MZB>C3OJ1)WTS
M(^VY7*6.648Z,B:JVP3($%E@NM8J];S88D%E;JP(4DAO>FZAE31:+79:YL(K
M=M$NRT+T4R\/\-7"7A,?Q84Q?Z>W))NQS>0^SM!,O6,M9C*O!!Z@93OA2'6(
M'#][4E!UX??,/&$1A*\4!('<WN4*2\F9-=2EM.H*;.3D)ADG0 ^.<!M&!&W*
M[Z7=>U@?IE*B4C7<8PL[<E&@.![X.I@*UE*[TTMR<KEQ/5QU(LCS**3@]8RS
M9Z==(N95N5-APN*G28DXYN0@QU4==,GT6?[_0M"_(;I.X9OJ&:?MNF]NF,9.
M_0N?2,R-@V+"Z*_+3]FC^0D68R)_YAJ&7<=X,ITT4O.M\)*2F#9"ED P'_[S
M9I\+/B>_3. W,4;[\DGG\ED+VN;TD-)&&<11!KU:[N.Z^\YL[ 'X.!C?MW>:
M"#XJ%1?6 BVSCQ60W[J2L33 **D];:PG'?)V]HD\" ^,3VKR3J\;VIW6Q":"
MM;VE(<%S&JB(.PJERK<&%:Y"Q6]<S$I^(!;]3+9L,T3K-%LS2\G#5+GF^>QJ
M?:0<YV2NP&/6L#"BV^1]Y5R_CQ^4]>S M^)*O*\>HM7SCEDCQY5@\; NJO_H
M[N(&\6AP/,7=OVA\*.^99Q97;]3WT%]/0T?.U?CNA_4>&RD.1TQX;U'MVJN5
M*S5UQA'\:)RX.L7@+20#FR#46[;/+[([LDI.YTHGNBFM6&RAB'^H.*66WSQ?
M.WWSN^U^&0U0QP"I5S+ON C&WRUI+Z-K__H%Q12PI%[C?8ETJJ$%OGUX\<1'
M(.A>#EY^Q";<V5LQ76 ]?[Z=!K#1(!.$3H\)W\UANS[ZA(?: \=>@W@>X&Z_
MEV0N%8N]#Y<J#)J PD2H?N[4 )$)SK<D8?MGV$Z?@?! <L*R<XML.]1CC'2=
MU9(O$Z,9.+NH=U)G3Y:;IRZ2]L3'C[)R+XFO7*R?+ :K?[BVF2@O^!P5@7\;
M.+^H1\FE5%/JGY_'P@TF-3KDI,OWVT79GXR8^H>-1)A,AUTI&%9W^9]<^AM
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MZP!Q .1_!]1_ AKJ'Z!AH/\#F/\..'AX>#@8!,1_0$#^G_'9"T""AU2 5("
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M7[\S3FG&-6H34S'J7,_R"4/G1R/GLVE$0NC>L"#G?@YX<AH\.DV!NUO_-K_
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M;;I(L<CY6AI\!YL5 )(:J2M%I-,,J%5[D7>NN/@)O\O%ITR;0K6[W$*,+N&
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M4VWL]QIOMU.0D"IRW5H[BQ E0:SZ2=C3.%9KY_*!2$B0%,D^-"7);;K GHN
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MUHYM-.OJ%GZ)CBNLX30Q/,E:I6Z0MHMV-O@<!4(^QSS_9$Y ";149_650FG
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MI[E/1"LTVLDM"8L1R0 1U+\LA*+4U<^PSKR'6V6%WI3:&/ KCQ2Q72<!B:=
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MX851@R7+N&1^*LP!_9IL?Q&V);3L!P]3B/A\.GQ5PRM52W:ZN9(SLG*E*@4
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M/<61FL8O5'$,K5J=_#Y9QK\S_P HE_,/0-0UK2TX>>?+<+7-K-$"K7<,(YM
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MX(E,E61"]N4!ZLIJ!0CKU]LX&WF'5/R]O[[1+W3)[[RV\OJB!J&> .:ATH:
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M=/A/-']2@I52.)Y4]Z9SR36^;.T)@YFM%,Q#5[@!Q49SW5[ZYG2X$RV\,9J
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M7/F9^?5B]M8Z$W#]SIOF2^M6-:@5974$_*N=.UNUGL[BU60-+8RV\$T$G*G
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MKR6UN#/9W?#T2#]7G)#!C0E.5!]&3NWU2#5[$>H>%S#_ 'D=?VJ>V%UYI5P
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M!9+RX4;FG\BBGTYT[\OK%K:X2.&,"*86L:*:@-0@D[=ML^@/D 0_6"\RU=P
M3']D!1RW^77/#'YM^9U\W?F)K^J1+2WBF-K#OU6$E:_33(-'4 ;4P7VVZX!N
M"#7]61Z\[Y&+H]?;(W='[5=\)I>^ VZGWRP/;!,0Z>.&<*UH3MOAU NW^2.G
MOAS;KT[5Z9)[)35=NF3K2EW7^&=-TD;IMTIG5M&'V ,ZCI@H%)VVR80FB#VQ
M.X<A3D4U"2@:O;.8Z_-16WPG_*^+ZWYK\VS]1IODGS'<]:$5L9(?I_O<]*_F
M= ;?SWYACZ<Y8I1[^I#&_P#QMD&5AB@/;KBH/OOUQX/O2F.#5&.#>VQRG) ^
M?; KML=\*YGZ_CA;-(=\+7EH>N4DV_N<$Q3&O7#VTEJ#5JG#RWDJ!O7WPZ@D
MV&^"@X)-:8_E4;8&D;Z,!2-UP!*WO@)WV(Z'(_K%VOU6[AA?G,D=7"[\:]*_
M/(Q9RE$B+;46C>^1'S):.)X]2BC_ 'L3<7I^TAZ[X>:1?QM&CT #*BMV*A>G
MSZTR:13>L83#%R->0>5C0*.O$]ZX6WL:O-)R 5+-DN P)^%RRU'>IIW)]AAG
M<-(KO"G[F.I64LU0Y&XH!O6N0>YM;>:[5HYJ2U=7/#9%-!1:#[3;_(=3@TN]
MM.L;0.':+]W\)16<U^)W)^+85\.V&5K,0(I&]- RDD@ UY';D#L#DA6Z557D
M%E9Z'<EJ '8C[LTTW)F<2-R8!1S-#Q;J%'; %[K0X/:!B45C16()7@.HSCNL
M^8K&60VH*E@:%BU0&)W["IIG--7-C-=%HO@B!_=DFA) []^N134+.RE(26-6
MMN.Q%-Y!2A)'OA<EA9@Q1%8XO5/(%P*JR"N]>NQPLF\M:7J=R)C8Q&X0T>H5
M>:D\>O2NX(R2:-Y)\K3VYM];9DL+N&=., 'JI+ 5^!AT%:['."^>O+6E6]V+
M72H5AMGJ%7C4@ [$FFYIA7:^3+.&.29@KS6RADY+_>> V^>2#2-*ADOK>**0
M+RJSK4%0@V(7VJ,]">2-#]/5;.8T>$\690:%8^S ^(-*8IYONH$\U:WYCNY!
M/!I1=(0XH?4C4(@IX;$CZ<X#96\^IZE-J=Q,TLUX?4EZ GUFV /R(SU)Y"M9
MY9X#!0I;(((U+4'J A!O])SUEJ&NP^4/R\\Q>8;AF62*S%G; #A6=P4%/UDY
M\\(':5FED-9)6+L3W+&IPXB[8*(^'KOA=<=\CEX>HZY&;D]=\CESU/N<)I.F
MQZX%/7KOEKUK@J( $[=\,X=R!V/8X>6^X%>WCAW;C<5%.F2>RV(%,G6E#=33
M.F:0/B4]\ZIHW['MG3M,I13\LE<3?"-ZX'N6^$FN0_4I  V<H\Q3\5??L<-O
MR+@]>?\ .K43N+'\N=8A[;&<(P/C6D)STS^==M]7\Z&6FU[86\WS*EXO^9><
MG!K\L5!Q0&F/![^!RP<?7<8QR,"R-A5,?B_5A7,>N_3"F5CN<:'V&^_>F+PO
M5E'O3)%:, /EWP\@8$[FI[8<QN O7!B-2N.]0TVZ8C(_7Y8!DD&]>^%\LGAG
M$/S:_.+0_P M-(N+F[F62^9"(H@06+MLHIW)/;)M^6.FZC;_ )/WOG3S9&?T
MQYE_TH12=8TDWC3?P!&%5L_[H"J\V6H!POO':1#$U&J#RIX9';!C!++8\RQ4
MDHR]U?JI_AG1]/O/JML!>1^H./&'BU34>'AOX8 GN9+FVN+;U$$4I]10!5BX
MWXLW<@KAC<2O>&V,B&6"=!(BABC <>[CP)P*+=T6=K>5O54'A)&@JQ_;*L?E
MU.V![E[U8Y)BZEN'!)6  )( 7DQZTK6F ;21D$-L2]TT;-\+BJMO3FQ78"NP
MKAJ;IX%?U&YAV',B@)9MBHJ=@,9<:C"J&-F5Y 6()-#0"@/C3.<^8-2;@'YG
MU*$$="-]S]/;.*:C>A+F:X=&D=@2BL33@U00/?(3?:R/TE%;S4]1=B"*!13J
M37-+>2QK=0PW(MPS5Y'9&H*GC7M3(T^JW\LK>H1O($5S^RH%:U]\.1>W@F'I
M-1&I("-R%IX?/)5:2"TM#<334IN/V?M4K4=!6F0G4+<7=RE[)4(6+J:5"UJ0
M*CK\\(=8O6MX)(TB]-T5GJ/AI1:G?V&&'D.R0?6M3E)=I$I'R.RK4&@4]*G.
MWZ#J1M[?4+N2+A&L:^DU344!%%V%*DYQGSGK4VK/!I%FQ:-_WMT6-6X@FH)J
M:L3MB^B:4Q]+@_&2%T8_ZH'?W.>K/R]TR2=XW](11VZ*/3(WDD'Q<A]_7#C_
M )R/\RK:Z-Y7\C1?[TM_N1OJ'< [1HP'MGEJU&P]L.8NVV^"&)I[85W+;'?(
MW=GKD;N3V)K7([<G<]-L*93O@3;+45/:G?!<>]-J5Z896YW'OU^C#ZW_ &>W
MA7IAW;#<#KDHLAT\<G6E#<=\Z9I'5=M\ZGHP^QWSIFG$ *,DB,*8"NI/A)VR
M%ZI+LV^<?\RW'[N3>E<ZI_SCO9D_EK_SDCK+;\O+DEI&? QV.HR2=_\ +7/2
M_P"?MIPO/+E^!_?0W%N3X>DR.*_\C#GGX/X[TQ4,?H[XJ#3I7;'U[[X^N.!
M^G$W:A^C SG8'MA?,!].%4ZU&%,RFA[8$5BI->F^+Q5Y5[9([1^E*DX>6[4(
MJ:G#6-JCQWP8)*#OMF,FV(22]?X8 DEZ[[#OG!_S:_./0OR_T>ZF>\C^MHI
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M="YY48CM0=LA&M\_TE::>DJ&&ZC+-++L@''DW*O@=OGDJT _6X[:*W*O(DG
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MV^<5\U3?"^_7/H9Y2TC]!?\ .(=[;%.#7/D/6M28]"?TA;7=V"2?\F89V_\
M,O3AJ?D;S%!P#O!;&Z2HJ0;8B4D>]$(SPP&[UQ4-X?1B@;VZX[ECPW6FV.!\
M=N^).U#7$2:XPD[XF4!Z;XD80>AIEBW/6F7]7ZUQXMZ'I]V*"+C2F"$4BIP4
ME:?UVR/Z[YIT3R_"TVHWR(8Q7A45.?._\_O^<GFO6F\O>4K@%]TDF0U2(=.H
MZMG@^>YGNIY;VZNGNKB5BSR2$L2QWWKA;Z<FH7,%C"2\MY,D"C_*D8*/UY^E
M#_G'#R7!Y0\@^7=-BB$9@LX4-!3<(*_CD?\ ^<A=,DBU?2;X ^E(IC)\#MG$
MK-E$;QUW(J2?',@F56DB(YJ34^.(^K+<L9)%8.PIQ'9A@,5!,-T 8W.W+L<2
ML[IM*N7]52+$G9ZUH*5I\JY*-+NA<2121 (LBGTIC4,>6WQ;=,D@"6TMK/,I
MEE25W^$5H7'&M"=EIAW*/W,3./\ 1V*QL#M0CXJ[;GK3YY'1HUPD<L<Q ND9
MF(_9,?8$TK2E/?((^@,L\B"%/JR!@QA'!3=,"6HA_9I0 FIZXA=QR&2!28K=
MK95+*Z EBJ_"0*T-:]<YOJJSO-'*5$$%U-+]9M_M"O$D,HZBA/T],Y/JJ3"]
MMX;.1HCP5I#.268&@[&M:=CDHOK2=%DC6V6*QM!PMN("U8CXN72M<C3(]O?.
MUQ&TIC8&.)S448?:-!\0J-L'SLZZ;'<.SI!%-Z:LJ EF*J_$*-RU105Z5Q^G
M6[W=E<ZE;(O'3XA<:I%,AX^FS&C@#J]*E@.M,Z9:^7_K>B&6CVEKYB1"82IC
M,O /P,9ZT)4$-79>O7#W4O+@323'/-$L\[)-%10%AF6/^[ Z_O!7VKG%M:L7
M.JQHB!%D0H7J0(R :'C[%>F<_P!3G69H],5S+;"Y^LW"QGX5^&@Z]^YP=:6\
MC7+R.S(B* "*T^(T44[G.O\ E/3)&D_2-QS+_9C2@8%Q]D CIX9US6_-%M^7
M^@S>8-42*74R5%E:[5FN..WP_P B=SGC6\U>_P!>U.\UC5+AKG4-1E:::1MZ
MLQK0> &&=I7X:;;Y)+;L ,-(SMFE-%.$=TYH3D8NFW.1ZZ;8^V1Z=M^N%DG7
MKOB'TXJIVZB@P<E-@.VV&EN=QMWH<.8#R [;[ 8=VO;);8'[.=!TKHOOG2-(
MZKG5='.RY/[0[#M@XL./6F$5\^Q^G.?:O+0-O3.+^8$GOKJ&QM4,MU>3)!$@
MZM)(P55'S)S[._X6T[_!W^">(_1/Z&_0G'B*?5_J_P!6IQK3[';)!<01W5O/
M:S#E#<QM$X\5<%3^!SYT7UK)I]]>6,]?6LIY+=QT^*-BA_$8BK;_ (8H&^_Y
MX\,:4]\<&Z5V%<>#W)Q%V-?PQ,G?KC2:=ZXX;T]\5"_3@E$J.F++"3V(Q-_0
MC!,LRH!XD9'[_P U>7-,5C<ZC$I'[/(5SE?F+\__ "1H*R WT7)035W4=/:N
M>:/.O_.8UFD$L&AK+=RFH7TEHO\ P1SQKYO_ #<\Z^>I9%O-0DMK1B28(6(J
M#V9NISDE[+22A0U\>M3@N*)VC1#MR'7)Q^3N@G7OS<\E:*J>JCZ@D\@Z_!%\
M1_'/T[^4+ 6.FZ?;!> 2%-OHR%?GOHK:CY8:Y127M#SK3< 9XKCF4E9/LJOP
ML.Y.&<<C,>!^%1O0==\1E9TCE4? Y^)7]\;<V<\UA'=0UDE4<C7N?; U$NK;
MA-#R61>+QGK]XP!#=WNC,%E;U[)@0)2/[I3T! ZD>.3W3=2]5'<2EIHPC_O%
M #1]E%>OADDAU".:99%G _=@N0/4H14_"I[U.#KS4$%F;I 9I(E 6 T$CN2.
MC'H!6M2<B5[<6UN]T;F\9'N)FB=Y  Q4*.!C ]]ER+:S]4B:W=&#R6ML(@]!
M2,@_M#^;?<[[YQ+S!>W$5U$EK=!GC_>RDE2SEJEQ3M\-/ED#M52ZOVN5'&2.
MX!/JD\G4;@+\NF2&:*^U'3+C4OMF"Y:W,9 JB[!I$]CMUR,WM^\:Q1/S^L+)
MQ-"*<3MR)W^(]1DA\L26TUE<O+<$2NW&V>A(ADD>AD5#L7(^'?:ISHVGVC6\
M$^DV8BL[Z[C@6G&M+AG6**,UV+2!C6NU*D],[9Y:TNREB:6!%N8]*N)M%C25
MV$3VTU0[)44KR/PD=:8'\R6%I._HVLOH36LD,:?#5E:)2%62O7X3OGG;SK+=
M:>LA:.WBG]8O9B(*Z%N(5RS"H &]1\LY996)6.4W-LO.YN#2<-5 VS%BI -.
M)^_)CIFGK(KW-95B,T8"NM4)/0@_/.K75SHWDCR^^K:RZP1P4DAMU(+RR$46
M., ]23\1\,\I>:?.>K>>-:DU;4W])!\%K:H?W=O$.BK_ !/?$K,?9'?IDGM!
MTWR1V_04ZC#!" *^V)SM130X073]:Y&;I^N^^1ZZ?KWPAF-2?#MA?)W.)>/C
MXXJGAT.#X=J>/RPTAI4 =>GT8<P=J;4VP]M12E,EFG#==J;YT+2MN/OG2-(Z
MJ:;9U'2>BCY9.K5J*#X#!;/\-*Y'=0EV;?.<ZQ/]LUKL<+_RBT0^9_SG\A::
M4]6*VU1-1F!%5X:>K79Y5VH3"!]-,^O^;/#WYN:7^B?/>L!5XPZEPOH_?UE_
M>'_D8K9S<-6G?OB@;QQP;;;Z<4Y=.V.!Z>V(,W7]>,J>O3'@$^^*T"BKL%'O
MA-J'F?0=)4O=W\8X]@17.8>8/^<@O)>@(P:\BY@'=W _#/.7FW_G,_3H!)!I
M(>X<=/27X?O.><_,O_.5GG?4^8L8_01CUD?D1] H,XSK7YI^<]>5A=>8)XP^
MY2(\.O7IOD.]:XNY2T]S)=2'<F1BQ/CU."%D,@],1DF/J?#%K:V<.:-Q63$=
M1LI%D0$5 (-<,+:86\#&2(2&E-^WOGI?_G"[1;;7OSRL+KTJR:?9R2&O0%V5
M1GZ)+.(0^DO0* ,=YATV/5](O+*0<A+&R_>,^:?F#39M)UW4='N 8);:9N _
MF0GX6&/LG;G&C,=A2OC@L-'/+/'S'-5%!XC-;SRV\:Q2&D'([$T.!C"\9><2
M5A=J*!C"RR&X!I]D*>7ZQA*+B2T=8S(1&K@\C7X?$C^&'EMJR_'$KEVC?XBM
M$8['BP^0\,1NM1EN/2/UDP<B*$$BO%JL66AI7PZ8A<ZO:23UYI//R#PEZL"U
M:L3T\*U.<]\UZXRR-&2T@GHTUP3O&-Z=/A^+V&<RO[I%=I(6' 1JLK$D",L=
ME-1_P1ZX"T2)TFBGDF]>%I)?3/P\NGQ*#MMTWP^FO/\ 0#;P\K=$=P'92"U1
M5B3N*5\<@%Z\2(A:0,;AAS# A6"_$!Z@^R 1@[3+VY@GMN%UZD2H6+I1T!;K
M4^PV4YW?RG=&Z-Q?221/>+<Q<>9Y@H@=0Q'?CS)'T9Z.\KO:6UDZR4A6[2&6
M/FH<<(!Q4AC6AH U*>.0;6]06YN/3FE,BQS$MR;8,3\+\DW(-30=LX/YRN$&
MHZE$EN;=;9'6$1-43%T4'QIN*T[Y'[:(1V>GI,&5+B<-*) #Z;,M/@:M6K4[
M=L[7Y'\AC4XKR[N"]MH>FQF99I=I$"U+!=]V)[]!GDG\RM3?S!K]W>PW+SZ=
M8NUO;PU^%%0T) \3W.0FS J* ]*#)3:*: Y)K5?LY(+<;>^#EZ4P/.?A(Z9'
MKMNO@,C5RW4]#7(]=-]XV-,)9>O7 #FM?'$QBR#8>-<'Q<JBF^&MON1RH*X=
M0 $@ 'Z</+4;CQKDOTY3L<Z#I@H!W&V=&TG]G.FZ6:*N3*W>@![C%Y9:*<C&
MHST#;YS36)]I-_'.X_\ .'?E[](>>_-OFJ6/E%H&F1V,18;">_DY<E]Q';,#
M[-[C/HOFSS3_ ,Y"Z.3'Y?\ ,$:?8:33YW^8]6$?@^>90WT4QX8]*[8HK??B
MJGL/EBJ@[]\28*H)D<(!UKMD:U;S=Y?T:-GNKY.2]@0>F<,\W_\ .37D_P N
M(ZK=1"11TY M7V KGE7SO_SEWJ.H1R)HL<GQ;!F/!:>-.N>9/,/YP><_,#,E
MSK+PI)^Q#\.Q]]SG/Y]3GN"TDT\EQ)0_%(Q8DCYX1-?3-*U=DKV]^^*K<N]%
M"CK3Y>.*O;< LO.G/<#O0X<6D$L(1BK$D=_##"W#K(Q H7P9';2B3XZ_#OMV
MQ22:;CQ*<U8T!Z_YTRY9X/3X3*4)4C;K7/8O_/O?BWYO:RS48"S0*?;GGWZ4
M; X81GDM#TZ9Y+_YR \AR%8_-^EP\KBQ!%RB"I>'O]W7/,J3>HL<T>T;BJGQ
M!S6\5;L7"N5=AQ9?;!T@2Y0K*  #\)KAI8>G>VXB1*/#^[%/UXE#IL(FE'%Y
M)X_M#L"/'*ETE;M6$35INVVXIVIWR&:]Y?8VD@)8 #DO!B/'IW^C('%YKU"V
MFDA@EAO@%]/TG 65"@_;4TJ*]*85-YOM+JZ]2^G2W=%;C!*K)(E 5)""@(IT
MZY =?U]'@C5#Z.FE_P!JH)-:["I/2GA3ID5?6H;UH;>XX@&$LI6K+0D]5K0D
MT&'NFZA(ULD\<J-3X%0* %!8<@#VZ8Q[Z]:TF^L3,EM.[+\;?W@9NK@=!\L(
M9M2B&GQ:;9M))'R])92 6%6)V)Z*/??-:74D A@9N'!!(F] %[L>/;;.Q^2K
MGZS(4C]5XDE%PZQ4% !5&WZBM"<]'IJ]Q!I\]J[UN((0&-5X>JY#+Q)W'*E6
MIVSF6HZFD:VR+<K)Z2$2E!R,4YW 'B" 0#D2DNY+U-0NHU9[>9Q$K +5R-CR
M[4%>N'NFZ?:"32Q-"DUT"Q 6K*Y;H2#X9U'\P/-]KY'\A2:3ZH75]=BX*B[,
M$/MGSO\ +VIVTFM7NF7#@^HQ*ACU#$UR83Z$L,I:V:J]:?/!L,!CH"*$8>VR
MTIA[".F"@:#PP)<$T/?;([=4^+VWR-7)H2,CUT:U&$TAZX";PQ@]QBZ??V'A
M@^(#J.F&\(ZT4@-3KN?HPX@KM^K)!:BO&@Z9,-.7[.=!TT5X[;YT/213C7MW
MSI.F]%R6PFBC>F::38Y$=3EV;?.9:S-\,GTY]!/^<3O+)T3\K4U>:/A=>;-0
MN-0)/VO0C(MH5/M^Y9A_K9Z;S9 OS-T3]/\ DG7+1$+W%O#]<@ ^UZEO^\H/
M=E!7Z<\$K7Z1BRJ33:F-DN;2W'*>YCC \6&1?4_S"\L:0KF>^1F3J =LX1YM
M_P"<I?*6@^K'%=Q<Q4 #XF^X5SRSYS_YRXU;43+%HL,CJU0))#P7VV!KGFKS
M!^:?G/S$)#?ZM)%#+7]W">(H?>M<Y?+-<74LC2S-(PWY,:GY[UPMF>XF4@O4
M*=B/'^W+A#+&79C5 :5_5C4G=V-')Y4 IV\#C7=E/%A0FO\ M8-@#< 2/@!!
M)'AV./>Z2XNX51O@C8&G;Z<F?URX;@0B\0!OX@=\$0R3%R[1;M]GYX:-=,L;
M1SQ%)77J< PW\@?T1'NG0X$N;I$]4SQUJ"*YZ\_YP%OXK;\W;NC#C<6B@=^C
MC/T(1GD@([@'!,,E-OPP-JMC!J=E-:SH)(YD*E2*U!&?.'\R/*MW^7?F86TR
M,WES5IB]E-U6"1CO$Q\/#"<,LC!@1'(M=SX816M[,+F>"XHR!BT17P/4')1I
M%V%9YHP/27;CV)&2;3[I+Z&[(7TB*@D[$D]\,M)MXO4:&3D .CTQNM:1$ZI+
MPK0?&>U/ 9YH\[>48XK^6]@MOW@/)&J003T(SGEYH]W<P"2]'J*:JI<5/2GP
MGKD&O?(^IW9E-F)HT;9T#;&@^$\3UID4D\J:Y9*RB"LNZ%I$X57K6@J*X*M4
MOX(;=)C+SA8EHXP C@5%<,'U6U2*.%XFC$2!WY=J[!:GJ =]L([G4;,#E;,D
M?.1V0FCL6(W9Z=/A^CZ<?I=WZGJM-<1A[D*CU/%41#\(%>Q&=TT'5]&T(QO>
M^O-<7"22*D5$4_"/38R@&J[4*T&U?GD@N/,][J+1R6<!B2= '2(,QB0FHI7Q
M'V0>N5#I_P!6MF$ET$FO*N\=*N F\=37J-ZY'%U":)F@MV$LW(_NHQ^[4L>]
M.ISJOE)[/0;.;S%Y@N!';:;$T\KR';;]D9XAUK\Z+C\U/S&UO5"[-HMB6MK&
M,= J[<J9RJYU3ZKYN26*7CREZ=.ISNNK^8I-.L[6[+%ED0$X3VGYD6YF0W"@
M1]37IG4M#U[2]6026TZU?H*]\F""E*$&OABU!3P'XX!N3U\<CEWWR-W)ZTZY
M';D[U_V\)Y#@1NO<9@/"M/#!"=1]V#X@*@'8'#>W44!I2IZDUPZ@&W;?IA[:
M#IDTTX;KVKG0=-%.&="TL?9]\Z+IPH%R3Q&@]L2N&^'YY#-4DV;VSG=U;76I
MW=KIEE&9KW4;B.UMXQU>69PB+7W9AGV*\M:';>6?+NA^7;, 6NAV%O8QD"G(
M01JG(^YXU)\<.\V40"""*@[$'/DO^=WYD>7ORA\W>8O+&I21V\NE7%8Q(U*V
M\RK- =^M8W7Z<\6>;/\ G,"WYR1:.);D=!Z7PI]YSS_YD_YR5\Y:IS%M(+16
M'5V+G[J@9P[6/S#\S:VSK?:[<2 ]41BJ;^PR,?6_54J[%V;8,QKU\< ^LZR-
M'(_P#H,;Z\DP:,%AQW##P& &N64LHV:H%1[]_IQ4R,BTV:H(VV^8P+,[I$:?
M[LIL.X['-;I)$@D(/PUJ/'Q&6USZMP :;"@_K@BZE:W@4$\1)4 ?/%-,B"?%
M+N6WK^K)+:RN\A E("]OUY(+7UIDHD@Y [?1X8:/"LDJ+))S-/BWRKC3UMRE
MS#+]LT*DU/SP#J,"J@E=0P*[@C\<[C_SB#JJ:-^;^G>DW%;J)UK[A@<_2/IL
MXGL+68&HDC4U^C!H.]<$AJ[9 O/_ )(TOSIHMUIFH0B1)DH"!\2MV93X@Y\\
M-5T?5O)>M2^5]>!=D+-971%!<P5H-_YAWP P0B8BJ\116'4'#B,1JL=&5U(4
MD)L:_+#V"Z6UD(1>8:A8=Z9*;2YDDD2.VC$@D8&K; >V29H4NH%65O3> DLE
M-CQSEFNVL6HZDT3("!]E2* 5[^^1#6=$@BI;N R*=J[ ^RGMD;D.FVTLL(5E
MN%I&7IL*CM\O' :VEA<1RLS%V;X&"J22PZ?+(O<^3OKMRRV4'-BI8PBBE_:I
M[UZ9SSS#HDNDB6&_L9;%  >$L1!*]" :4/T'.3:II=O%S:WMW%:LK 4Y5\:;
M].V"]+\OR7118;=B2%) J10_Y(KUSN_EGR3<NEK'J 8*A#^E4N54&H!/N>V=
M6,5CH\86*&KSU:267X2CCJU#WSB.MZQ=7>JRQV3GZNS<9)1U;Y9-_)'EF]UC
M5M/TS2;,W5Y=FB*HJ!7J[GL!DZ_YS*T[1_RB_(*ZTV259]?U:+A))T)DEVH!
MX#MGR-_*FZATVS>0CD2IK7N?&N"KR47>M_60>!$E13YYV_6;J&;RU:L&YLL8
M!K[#.&W>J $Q$A :_/"6U\[:GY:O!)!<MZ3&H%=L[KY._/=9Y(H+Y^)) +$Y
MZ-TCSKH^K1+Z5RG)NE",/Y9(Y$Y1N'!WVWR/WG0^W7(U<]]NV1VY-:^&%4@W
MP*1[;Y@.FV"(A4["N&$2G8]\.+?;B1T/\,.8=Z5W_##ZT'V3]^3331NN= TU
M?LT^>="TH?9[9T.PZ+3)%&:+@2Z>BGOD(U239LG/_./'E4>9_P U-+NYH_4L
M?*L4FKRUZ>K'1+<5\1+(KC_5.?3;-FS9\/O^?MWY6SV5]^7WYUV$8-CJ,9\I
MZP%4CC<Q>M=V,C'F0WJ1F93\(IZ:[FH"_%Q7N9R/C$2,?'%KNWE1 WJ&1>U-
MCMUP&UNBP^HI(<[_ $?Y]<J.SN 5=6+4% /GB:HS,[.U6K3?P'7Z1BM)8 S*
M:$_%]_<?QP'"K3-)ZBCOM[^&)>HH;@*D?Y[[]QCZN2 ]"@;X1_GXX/\ 50GB
M5( %?H'\1A/(&-T#&O$5-=]LJ2:>YF$<P'"/9:>V'-@?3(#FJG89((XH499
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M20]$5M;(YI1DNY$K!>"_1<6=+X>FR]!=4%GIS*OB4V4A[XSFHN)LQ%H$A\0
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M/<X!>#=%&$DC1@)^5<K!8R.P]^RM 8A_\C,%[\63O\DPFMS!,"=C&SESB9+
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M",?Q:UM<"\PB%0-M+9*!UE<3N(!:?E@"$,S1'E@R/[JZR+#(\AJ33DQ^K.A
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M@@!IBPQP%9]2ELO<GC*Q[\M^ V3?,I^H]H9GQTQ)Y1_@P?_[,QC:%!K*JB<
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MR^S]$ANEM,,CTE9GK:=$D_+5^O_@5@-PDA!]G'V!\?M R5'2F(:&BNJ4 @"
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M-Q]CD5ZN(^K.<BT6F5KJF&U6,G>2/;L+NAI3+:+.EV!%)436XO/__-S]WTK
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MHUS"!2NL,#&T/;Q%A^)&6?JU*^[W"Y'+F>7QZ E*^DD/)U?3$OYYS>I"[DK
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M23A_VX*L3[L^#*V:8N+C*O0%C%3#( 1#I[QG\>,2=+ <[X*-MO^'6P>^0Y^
M[![P7]ZKI]5CI11'F7G7<4]0\#7.J\-UH;%_>37*W=#@X9V38DQ?\(2ZUB">
MF+[3'6Y^W6)&7#<+:R_N$5';RU5,4ELX-=R"B].N3?(F?PMH^71MYTV(4=M
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M#EKDF-JHA?F6;U2-2]:%H4+OXAK'<,.!Q^M2OK''JPR'0RXN#N*F[3<6I;(
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M;FFIE6(3!%$*H[@49LU]0\BR2%*_5A[BKF9\7UC;\D_ 5LF6S9U>ZY6EPR<
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MP9E^VZQ<YI0+:S88(S+IZIW:E.E%5-VN:9I'\/EDRIZ.X9W5]9LU-:&$\CA
M^&LLN\541T-E6]'NO.@0V4SC',';05LW#P:&;?%X4^KF;UO%0+6YZRGK]U^:
MZ4U6WFP7"GAYVLOFY#"'8]W56^Y\KM1YDD16NLYZV]+PU:WUWO3+,,4Y%_<3
M'\=Y"88II:PGG%FQK&QR]@!,^< Y>&6Z?8613P#":BM3M>*=7L8U-O4[B5:&
M9E+)TA*-RQ8S%D4+,M\I!ZHIEIK-1G:X-;U$30_M+ 6Q89%/BPR19]Q;DG3/
M49O68MJOI68];(I8%4AO&.PRPZSDY<J1#)_2\XEX=)T-U24/#>BFN&BZ'\(X
M?5_5#+HL+>_3@4?+--';7QC_A/U2;E9Q?#ZA!/X94I&0\& '*+^C@#/!P-:>
M> !C<7ML946-L+<OR@+F.!K.UM54H/_L^FRAOQ2XLWGAZD?T!+:KC4JJCM:^
MKI/&T4@@<M^!6*G'%</DI=W71/.?@,WHQ;5* -PD]1>30C9A=:BE .L)'XT#
M^A[>3T S9__".A.]^R= ,$/?7K0#J_R,'UDP*,[6#%%S*WX4PQ/$!%B+J]K?
MA7A7=WZ-P#]0<A QH?=VNSP,I&[4A)YSG'L9T/DS6(6JV+Q3M-LK7O=8GELP
M#"#&_O@UP;]ZS&?[.N8)D?2,A/6=]&DCHD[^-OTDX>BI7:Y4SDS1#JPA4MG[
MI\1;>:%HUP[T<KI+LWV.="<'\<0XR6['14VA?,&+K^8LD!#^4T!R2T)@+,X6
MLZV\Q'^:-QHE*WK/%C'PFC3](#:54;KB56F3>(^8_1JUE;S!F\N$BV./=R6_
M=B_S%<TV$/YP@C>7IBP@_3 J;KPR5WC5D<1.RQE"L^ \15>8:Z?/:?+'N!B4
MT@;<2([+61OX(*VQ,SV)P^<;/TIJ!0QYCWQ]D7.9B3"8;0G[)D6F@F0]CCQD
M$)]NO]?$=M'W![2C;FR_Q^;9M*)&J1I*+VX.[&FM!C_LSMH<PTK[-63["A8!
MTAOZ)X";#U3UI/>N=E^DW5726S2K.N<G>?XSN$WSW.A4Y +B0RZW)D_NOSTF
M>H@ 'Y.<Z/D;?&C;H%L_O G^>+"VIU"BM[HKCO9OXGUY)2^'=G57RR. 4^S*
M'G5XFB21?-WCE^0[F^(U5^WEJ7@Y]+B*!^3V.(^1B$P<BJGE4O_K()+;=/B?
MCIX(+RDHG! [Z&/[0SX!_/^<V*^3..?CHM9Y))OB+>$%=: @Z9_AJ-()'G_N
MWB@\3G)JMX J/<BNP/+[+;W@X[[EN"K#$ B#[2C+=N6MP0["#(TM.9HZU8",
MM+*_)':Z]).VV,G$7%]G2HTB_N 4/5,7J&MMG@WR4,4?O#N0%VMZ$\IA]PC9
M*%+F5GOH7OLZ*SGHSLJW/:U/#Y^QP9P-XT7&;6Y%YW2S?*'.259]#:*5F_D"
MHU]$/HJ&"%X8@]T6C*5Z0%[27&G59)VP%GIS.R4; O8G$J)L*02L<SJ#KDMZ
MNVTCM6)C/?LY(7%GM0K>6R'[CA(2?[_I0YR*()(W2[W8[:*)VL@'>K!#+[VZ
MXRT\(M/NR/2+FT9YCE2*G& I)_K[A@G?S18( 852C0SC:4SNQ#!JAA9HZ*ND
M?VM2'G9Q2+[S*KMAO>6!W(ZT31?MJPM:<73UR031GX_)M/X.< K 3M[^S7ZD
MSBH3L<4OIE=G5EVJ$(!3^@&,T<9R G@4E&^"7P8I0R&YSG=RP"S3N)O["((W
MEV$/4I*D\0(V?)AA+A+"<"(??I=!\&>A(3T>I;N+Z*3JBS8O=T-K5+SS,5HG
MO*9(8E&E8(^Z!% L<PY"[4%^3@0(?%MIK"-=.EHJQ4QA2-/CO4K6-N=RU.V_
M&EBQV>NTRVV%MBW"G0@)EN$/TZ@4@>U:7'L]#>SCZ6/.4H[VJ=(6[DZPVB*F
M'X8X5&M343'J$[0&%<F\A6S704;&3"$H5Y$1IN42VD@M)L(P.3I3J@E7A_?2
MXZI_8 TC%3@0C@SDK\#R!5?#FPO17P69:5!68!'!!2&+"AG")>*N1YTA<YU)
M]?7JT%2NGBKN? CQ]^JE>(<+W!^P'Z/7!%B>7PAF/_T? &5 FK^W_.(^N3VG
MFC7M!!<VNJ6B74@J"E8250\2=FJX (^6?0/PKWZYF'^=,3;<"F)[BM/HQU-@
M<H[[5IC1TVWKX96U3MF/\,::[8TBO:F6-MCT.*>/>F).I-=OG7#+0-<U+RSK
MFD^8M'N/JNJZ)=PWMK)V66%PZU&U0:4([C;/OIY$\X:9Y_\ *'E_SCI#?Z#K
MUHEP$K5HI/LRPL1^U'(K(?<9+<V;-FS9\>/^<KOS$/GK\T]0T^TG]70_)(;1
M[0 _ UPC5O)1MU,HX5Z$(ISS*.OZ\?3;]64 .IZX\=13\<H_AC@N8BF8 ?++
MH/NS=,Q^_-L:9XA_YR8#Q>=O+L]>"KI_[N0CX0U9:J/<KRW]\\I7TTLUEIC,
M?5CM(PIKL1&2H(!':J=<$0R_4X-25P&$EO%ZA6M#S8. ?G4U/MA1+,Q^I(Y
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MB6,*%:&%22$4[JO3<[BI\<],6$G,J[]>NWA[9++<48$[ CH.@KX8?6PY?%W
M%/F<,5!!! I3_.F.).WOFY=NM/QRF9B":$GN*'?OWI@&1Y#^RQ%-P*T. I%)
M^+B1^'MB8H#0K0':GZNV!Y5(!J*^)'4=\+70D,.Y';QP&\1'( 5_I@.6*E>^
MPZX7N@!)^S^OZ,!2BJG:F$EX BT[Y!=75'21> -!4 ?JVSB?FFP$\,JR!>+
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M3W/<Y);<EJ!MP*>V'$1H.O+EV'X5P4#LO(JM36M>GTX)0@D?: XU'B1V[#!
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M3;_G&/38+#\K-.N+?EQU.ZN9W-:\I?4X,32M"O +3^S/0F_6M1F/@=\8U=O
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M*7I20KI,=XA5PZS%VA^*G%EB)*U'V@?XY$;NQT^.1&L= TZU:(4C,=NAD0$
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M_.FY-]^;GYD3.6)7S)J, Y=:07#PCIVHFV<R*B@ %>^4%WWQ=8S3Y],?Q"]
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M4>>)J,B!6Y,G8-V#=B=L^>NL>1K^U\P33W=L^K:7J/&"1;A?79 @ C>,L>J
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M+@) KL[.54?#N78M2BBF^>"?./\ SD]=QA['0K2?6)9'8>MR]&"M:@J[AG<
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MQZ\#$6U<?7+-XF=YPM\]*,J[8[^*OKR,%#EXXX'S%GTK[;! _'I+][=\I7,
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MYVS:"J&+7A/ ?47\Z%J.ON<4429WX;^I;;^[\9#TH^0Y6"\G9#RK_\MO 0(
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M@V.=V_(;24? 7X!9K"-)#@V$:';!_4].E'F)IEBL 12LH^7V).K \#V5'1$
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M"-_8$FC2^V?EK:K0M]VE;3GG3R'6%H2!]YE@\TTT2WEUR\PSBS[N8+93&\0
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M&J.!E9"EKN8O?I4J,_O*VJ/P$INUM2#X: F;Q#_L]/S7?P%02P,$%     @
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M\.6,K\A?N^8U@\VF(H=RW]+FX\+MX^X!;R6/Q\$^73I-#^_F/ W-OU!07),
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M+X7LI?U/S-W=NP>?SP\^NV-=Y\EFQ=FR>9=)W \F)EK# TI$:IY4ZM 6N+J
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M8SNE.;%4=?:;CFR01OG>^>J;J6(=EXPQ94$EV)OA[H?NYF;>AM)9P*[(W".
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M%R<'*TY53+7U<S^RS[HI/A%=?"+26<W#DB7=%*3Q_O;YL_DJ?6C(\DJ+[5B
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M<6N'RD?-GTWL&B<+@X!((SWN2T4.?^=_U&XT"]VD2UKJ8:H#E;*O.;<V;/.
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M,7Q;N6%*C"A/7..'HQMOFN87BU%[P*LU+ZHB$3E\K*;@N";_3)/6.(WEME*
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MW'5OPDW)[C,VY1P__8/,81)$/SBXU%C]JNA^A4VH/*X/I)L]W!9^7H0L"A'
M"/&;('2EMMB1D*X+9G&!N =8]17;,0>KP\M<_5(DZ7>R^JJ9@G@=/G_^;?C)
M>?E*E84X0K4R=$O\YF*8^;2?^'KS+6T%::>E3(V@Y%4_\3P?(H<Z++"?&J$?
M5GGZI0#R3O,N_DH%M9&$VOZPGL+P14%KOHH%,I(D.4*87T<%B>H'6]C DP4
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MLA1#D6Z2GCO=J24F#2Z=M)MM3]U&NR'.?HI-EFKOA<GKWRXV>E2FS<E:>.1
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M*JB1J<N0 VV_V1Q*030P2.D<MPZ<2(XR$>E0"030?""33O0X2:D\D31KZBE
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M.,[T^C*KC&Z8G2G7*(_';$F'O7$B*8F1B1&_SQ,_KQAK]&>I/^<*_.)\E_\
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M9?BC5EGD+;;U55 X].N^',7E^.)HY9)I;JXCH?4D%=R:; DJ!\A7!CV7+DR
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MR1I"HI NQ\2=A7)SY5LI;G4]#M"U;F]N#Z2D[ &@+4^G/LQ^0FE16/EFQ15
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M^68S-1:/0;CCV(/C@I+XQJ&!"MTH.Q]L"S:I+\=31CN2#^-!MD0U759F#EY
M(@"0/$_+IG"]4T&X\W:B+<!C;<OW[5H"I.ZCY^V>A/)_E*WTBP@MXK:.*.,5
M5!U%1M5>F]33)T]O);1L\0(8JU2#6H\#D4U71[:\$CW=C%<%P2%>,/\ :V&Y
M!W\0<@]WY%\L+<0W\6D_HV]AE$BS6LCQ .!0<:-0#Z*82>9=2O--9;B,%XRX
M#2Q'X48;GD!TV]N^)6OG34Y+2@62KCD6<45.0ZLU*;>&%MO::MJ3%[:=+:#F
M1)-,I9WZ?8 - /#)GIWEYYYXY+F[GE@C-/3+ "38DE@@'7;ODXB@7DL2_#&
M5*D$?9%>Q[9'O-7E^UU33YK.[B#6TP*SAA4"H[;4J.^>=M-\MW?D[5C#$6DM
MD/.($'AQ.X(KW^G?/2&@:HS6R^HWQ2#XD'PBN',D[/4JQ"*#\ -%)\2?HPNG
MOP%!9@)*#D%-?F,C%U>.&=":H]:*.M.V^<#_ #(_YRM\H_EA+JGE=(Y]3\SZ
M:JI]3B4A5D90PY2';]K/GKYX_-'SC^;FJV^J:]<D+ZOIVMA'40VZD]0.[4[G
M/6/EVQCM?)\I1!";>W1%\5(0$U^G)C^2US]=_2X)#R;N6'SIGI#3KFFDP2%S
MZD$_ >PK6N3;S%?^E::5="G"X B)'7D,*O,,$&J:%=02J& 3?V+#8Y\Y//5O
M)!J$MEP/K:'<LC4VYP3UH?EU&>>=7B^KWTR$U1P>%?#J,B[M4G:F)-7[L8<;
M_#$R?GB9(ZXTXQC[XF3C"?\ ;Q(XPC$R/QQ(@],3.)MWIB+-]^!F-<DWDV:*
MWUF\EF<(C:%KT0-#]N72;Z-!MXLP&$0.+"F^/_#'8X;=!C_EBGZL=^&.'7'K
MVVQ4;4Q0'%DW902%KW/0?/!E($H1<>HX_D4@#Z6I@J&X6.IBM(I)%W]24>H1
M[\=E_#)M87.H:E?6422,4]%4"( JEB3L$4!:GY9]*/R[LK?3[+RYHUN GU"T
M0S?\9Y*%B?HVST/I,RF^BD(J!R6A^X?JSH$%PGU5231GDIL>@P7<,C),Q:O)
M0>76N<'_ #KCBF^K3.0(IH%1@WB!L1[Y\@?.&F31:[J.GZ@\5Q$EW)Z2D!'7
MG]DH0 *#."RVWF#2+N6*VOM0TR&%V]9K::6%63?_ 'VP!Z9"^$US+>W=PLAE
MN)"[/)5F)KM5FW)R<?EMY_\ ,/Y5^=='\[>6;AH[S39%^LP@T2ZM&(]6"0=P
M1T\#GZ#_ "+YUT7SYY+TKSGH<PGTW7H!,K+OP+BCH?=3L</X'!A1N7VE%*]2
M.F%MU+,9#Z7+X!T'3Y_AA3<7,RQL[510*%FV K[;9'G$FHO'&@>2*OQ5(HWT
MC)IIFE6MC'%PC!<?$0N]2!XTWSH%BJB(UHO&E0#3Z-OHH,&<@?V2(V'&@'0U
MW)Q1[.O, BKL&%-P>@&%]UH\<G&, JY;=NI Z[_?3(?=?EQ;7\C<KF6 %R69
M-F;IMOML!0;8!3\J-(X<3=W$PAJ0'E<\#[<C3>N'5GY3MK*-54?9)XJ230>-
M,%QVD<8(*F-HV*KQZ5 Z[=L3@9%Y-)& ^XXCJ*=ML3E0F,I+3A(O$@[TK\\Y
MIJ%F;N&=%B9YK!BLD%-VC%2&3OTK_#&:5.4M><,ZL(R:+_D@_2:C#-[]O@9B
M$6OV1T.!+BY/QE6J=J<NN5% 3,"?WE>M>]:D_KSXO?FY?Q^8OS7\^:JLPE4:
MW<+&P% 8XF],"GMQI@_\N;#]-:O);\0#"PD7L#T%,]G^8I'T?R/?2(O#U;M;
M5/"@"@G+_(J06M]=K*>,=ZL@51U)4U'WC/4D4GH(MD%'&Y0L*^(_V\D?F(R3
M^3[.Z1Z/I\D<FV]17BP.,L+N.]22&5QPNX2F_8D?"<\8?FC9+:ZE-=7"<)4Y
M6=TX[*QHC$> .>3]:LY))G20$36S,2#W!KD$8?$WS.)G$CX8PG[L3)Q(G*KC
M">GOB9/AC"#]V)G]65C&Z8BV(MB1/@*X@W3?PQ$G#30Z_79C_P!J_4?^H.XP
M N+*?#IB@/AOC@3CP=Z8_P#AB@KCP?$8H![#%!CA^&/!Z>^* XH#XG^N#K17
MEE2*/K(0#[USN'Y;Z>+CS7I*A*VMJ=W[<A]I]^PZ#/>_DE9(KJ>^%9$9Z)X;
MGB,[MI18RDH-XOG^/TG)?ZQ B4@[$5W[DG#19O4LI?BY J]/'8],Y)^:EJ]]
MY:M+C[30H1[CMOGS<\]>68UU:RU&= ;2^I(YD:E)XZ@H!7]J@.>;/,5M$^G-
M:VLLJ^G<O)-7:52*A>0!W6M:4SD]O92S7$L$9:XDE953D3W\:],J>RL(K@P2
M3.!NAEC 9 3L=NI'N,^L?_. .MO-^6GFOR5<N)&\M:O]8MJ&M;6^0.*5Z .A
MVSW4+<(RHB@)\2@>'?"R[MY*@JW%Y'6$#M6GA\LAWF1#9VW)RWI$MRY'8[=3
M3MG-M#\[1WUY+I]A#)<W=E*!,(Z\(P15:N-NG4=?EG:=(N;NXY2W9*RJ  IH
M H.^3(7L-ND0]12A&[ UZ]<1_3MK"Z![N%0" "SKOW(:IPS;S7HD:2>MJ]N_
M#;BM2S%13< '%)-?TMC#]1OH[OUU^(1&I6@%*UH:]R.N#QJD,?$-,G$\2W)@
M"5) KCGU*)E<A^*;JM.H ['QQ..>">$,LGPH]&8-^U38'84)PDNKU$YH$,+,
MW)@VV^YH>_X9'_T@IN6C'P5K^\[5KXG$I]35 B@AB'I4[U^@]L*FU'3S=K<I
M(L4JK1TV'.G8'Z<A&JV:Z5?OJ6C2?N-4/J2025>..8TKQ(-0&[CQP4CW=U&]
MP(2L<95I%\1TY+TZ=QX8<_H[XA$PIZC!Z'MQW-#@'S1J<'E[R_K.LW#!4TW3
MYKCGV!1&85/T#/AK=SR/K-UJ4YY#4Y9)23U+R,6)_'.T_EA:*EXDBJ59[B%>
M0'V@2"?HST-Y]DGF\G6MJ#6&36I#R'44(H#AA^5DGH:]Y7CC3DUS)+$>^P!/
M\,]1W4ADU:W;D(TAF* ';J*')= XF\OZA9R'DH]51\P:@C(!I>IM!/*DO2$K
MO[>V<W_.#187NO7D'^A:U;,@E'3U"#2OTYX@\S)<QP0:F0'D3E:7 '4,GPU/
MS%#G,Y1$W)D:A/48#<_3B#']6)D^^,)K7;&$_P!,HFG?IC.O7&TVQA^^F)FF
M-.V,.(L<0:O]N)-^O$&[]\0;:N2#RG:_7=5NH2_I\-&UJ>H%:_5],O)@.W7T
MZ8#U&U6PU'4+)&,BV=S+ &.Q81NR@GYTP.#MC^HQXKB@Q1>F* ''#PZX\?3B
M@./&7B@/;%%[$8>Z5,+1S.(Q+,X].%3TY']KZ,]#_D[;RW6J?79 3;P_N%[(
M @+.:=.HSW1Y2X +' :PPN 2-ZD"M?OSLVBEDAN)&6O.0%O?<9(0Q:2$ ;,>
M5#^&'-G%ST^X%0"BR'\2:9$O,%LM[H"HRCC=02(!X,!5?U9XFU[08+Q+[2=0
MB A64O%(=VCE0\E8'PH2#GD#SUY;_0FJS+=!5MKMB8KA*_9;\"*YP74K&>QN
M9K<,9E^V"NP*GOXG(S*>4T8D^%7(W/:ASWA_S@EYCETW\W?-?E5R!;Z]H(N8
MV)I22T=6I3W5SGUG9@K4H=Z;]B0.V.-O'*T,K;<).7MT(W^_(_YXT4WFE3F*
M,4*T.^VPZYPKR;Y)NM'T[4M2L6*WMZTLO,UHY8GX2.V^>7?S5_,W_G(_R)I>
MH:G]1TZ[%J[F&VM8)/@MQ]EI&JW(BGQ4[&H&2C_G'SS7^9/Y]VFG%?-=EIFI
MWL$SWENB2NMO-#_NM@) V]-C3.F>9?RS_-_0XVOOT8VHVS.T3RZ9)]8(= '(
M,;\77K6E/;(E;:[YMT&VDN?,$7F71974B&>6">*-ZCBK,CJBE2 !U[=,7;S[
MJ5_(JVPDA:0EI3;P\!*6Y$4+0\EW8[!OBQT?G^ZT]5C_ $Y-'-" &BG!IR%:
M@ JH'L!BA_,S5Y9G>'S+Z,1W;XV5$)VVH233Y80W/GZ-FEGFN;Z[OH67]_%=
ML(Y!QHP9&:,@"M00=NE,*3^;?GRS9?JUY<ZB9 JBB&Z9D0&I"E"U -_8=<G_
M )0\_P#YJ^9YX;31?)5WJ4C!@\TB?5+8!%+$M-<%$6B@[U.<,U/_ )S=$'G#
M6?R]M?R[U?7?,&BWT^G7364L4T"S1-P*I(I[&H!(ZC.TZ?YEUGS;#I&K65I?
MZ%<I/Z4J7%0ZL:51UW&VXSTS9Z#>7-KIRO()EYACQ% ">NW3)X^AQ6MBT:1T
M>0$-0=*@G">X@4E>@(H@([<NOX9Y\_YR/U4:;^5.O6J<B=;=+ ;T;BS#D13V
M!SY':LB0R)&RLT48HI.VXSMOY3.99#(S5>) Z"NP$>]<[W(R:KY2D#UD%MJC
M3D=^+Y*ORWTZ)?-_EZ.'868>:M:!N2T_CG?M6*K<2TI6*Y9V/RR;:8L+VY2-
MJU(8C_7SC7G:>31?-FF6<=%M[M&:4#N#TPX\W61UGR7!<%#+':-L.I#+GBCS
MGI<-KJ<UJ4].QUM%*@]$GI\/WG;Z<\Y7T#V=S-"ZE'C8C?K3 )93U^$^/;$7
M4@5&X\1B&]1WQIROGF(^[&GKXY1Z8DU:XF??&FF,.U?'$F^_ [>^V(MU-.@Q
M%M\1;)K^7=K)>>8-0AB*JR>6?-$YYU XP:#J4K 4!W*H:>^7^8MBVF?F#Y[T
MTPBW.G^8=4MO2!!$?HW<R<002#2E-CD16OSQ88X5^5<>.WOBJGVWQ4'_ #.6
M#CA\L>/IVQ4'\<<-_IQP.*K7?Q[8<6_*,/*@KZ$=$_UW_P!O/7?Y#Z<QM=0:
M5N$5A8-*0>\C]OP&>R?(%JWU(HR\6#*H!_FX@L?O.=HTR$Q((64_O/C-,. @
M%S]G=%3?VKAYHJ)+;W\;+3F)*#O6IZ82K ;O12BI5[*0J:^"D_PSSYYA\NQW
M?UJ81#E%(5D*C=2#\)/L<\\^8O+=G=_6M!URR^M0(K21;#GP)WX/V*]<\6^<
M_+D%G<RVUK<>HD;/' TR>G*A0T:-CTVSB-_;7$+".1N+AMJ&H._4'.Q?D1YL
MB\E?GQ^7.N3LWU>\OH]+N3RIQ6\!@+&G45<;9][%*N2A 8*M*]OEBL# ,T;[
M!#X=1AM-"E[I\Z,O[MXRM-CUR,:-I"0:;-&8U6-9V/\ E;FN%OF7R9H_F6PD
MLKZV)7TSP<*.2DC9OGGCVS\BW'Y-_F#:><_+UL([N RI-!:-P2ZAG5D;UE"\
M2X!# TJ#3<YZ,'_.1%D/*?FFXFT:X_Q'81L=+TL\"=5N9(AZ+*02(@)3QE:2
MG%07%0<,]9_-?2QY4\MW]I%;W?F6]N+!-0TZ NT%JY*F]*W!5!P'Q+&S4K4%
M@-\Z)#^8WY;73Z1%)JUH]UIUP)()Y66-(%0LI9I&(7X2_P -">NVV^3IY_+%
MU,K+<V%VQ<2K*LD4PY5J'#!F'7OD1BT'R>OZ4N+BSTQO5U"YG,K1PTYS/R8\
MB/HZY%]7N_RHL=;\M:?JEUHL=YJ%PTEN$-NU7A0LJ3,I_=AR>*EMB=LYU<?F
M5Y+6;SA?6S10WFEF5K6) L0OP8RRB"4 (.;U0@G;N*9PCS?^=VH:]H.CV_E"
MQNM%NKV(76H2Z@GIW%G\-$MPJ%EY<B2QK384K7(;^27Y%:9#<R>8KS3H[#ZS
M/)=SL5K+-.[&1YI7;XB7)))-<]?:?Y;MH9VE$*^F_@!\6^QSJ>EV:B-!Q XM
MRV[$8-U258_W1H0@-:=:],@\H+DL!M$.34_RMAV\,\1?\Y:ZU32M#T.VN1')
M SWLL?6J#X0?UY\[KZ>+4K>27KPK3:E<Z)^4EXJWEVLK") CPI[!@%STIY>!
MDTVY",/36WK3L2C,/OWSH_Y50QS>8T<FGHQU^55SL+J)8-0>0AJS2R*?85&3
M30BDJ6#@D%XE!'B0.N<B_-]$76+6\'2"#@W<AE(.WT9.?)X&L>4=3LBW)3#Z
MRUZUI_9GD/\ -K3();&UND0QR+R4#H04/;Y$9Y.\P*]VL6HD'F28YO9UZUR)
M],:3Q-0:8CU^G*IE4S4\,Q![_AC*'$FVZ8B?NQN,)Z[_ $8BYP.WXC$&)^[$
MC7$V^6=9_)*Q^O\ G#7D:-I([;R#Y^N79:_#Z/E+6V1C[<^(^FF#_P#G(C3E
MTK\_/SJL4"+'%YWUYHD0DA8I+^>2-:G>H5@#_'./#% :98/MBBGIBH-,4!QX
M-=\</?'CM7?% <5KWQ55#*=_C!V7Q&.^S0>&2."V:>?3K*)^)N.+R=OM&@_"
MN>T_R(@BEL?-%VAX6\$210!CLP4GFQ^9I]&>R?RZLZZ592'XY98S*Q\7/4_2
M1G8;:U*B,@?O'CW/6E2:G#22T,8D<#=3"HKW%:X;:)%26Z!4%2[=.OQ;U_#$
M+:V6"]U*S8<4GJZCL0?]O.;ZUID>E7]Q.T/JVLX N%/0K6C,/D-\X_YZ\I)"
MINHHUG:S4R*?]^VK?M(1U(4[YX+_ #H\KR6-PMS;IRL-5Y&*<"M)D&P<'^9=
ML\?ZG#):RQNZUB8UJC5X=1OX?(X3?6Y(K^QU*VDC>YT^\BGAY#BRO$P=?8[K
MGZ%?RS\XVOG?R9Y=\Q6LR3?I.RB>4IN%F"@2+\PP.3F=BI1U! .QIAQIUX'@
M:%1\5"*'N,,+6)!#.HKLW([=QUI]V!0W&)E8'D-P/8^.0+S=Y=AU*SE:->%S
M(%7D!4\.I  SRIK_ )=ETC475HYI(Y9&8,XXE 34,P8T(ZY)[;R^\MC/?Z;K
M'JQJ%YUMI1\+=&/%""NQKO6G0'&5M_2+&.*WB;U(X99#S0R1$!VC9E-5WZ&A
MR,WFA:;JXA$]A PYA7JG $+6I 0KWIBMU:Z;>1&.*QM;Q48%XKA5<405)I)R
M&WC3)C#Y&TO4/+0O[+5;.ZOKE9(!IUM:JDEGZ?Q&25V9%92JG[(ZT'RXIK^C
M16UO"B71OKT+$'M2&]7U7J"B@H!5 OQ;G)KY*\@W6I/;WE]&(S$Y:1'W4@KM
M7?<@_1GJ/3K&*W@2*(!!1>W6@IN/#PR4VMK0 LJA1OM7K6N2>U2D9.R;;_K.
M1K5KD2R,J4-6HK>YPDN)>$%Q)RXM)10/91WSY"?GIYWEU_\ -77Y)&]31K4#
M2[?B:JOHU#,/FV<%-N;:66U!V9O4B8="IWIAYHMP;/G);@J_UB)>(VY=S^K/
M5WDNXCNK.WB0D1W,LR =Z,O,#\,Z3^6-[]6U#699""T,;QU\ O*F=934XYM!
MG(<)(B.&/C6H_CDY\IW@E738ZBL2H'/S4'()^:42NUN#]L7%0>QIU!^8;!OY
M=ZHMKJ5C8N0JSJ]NZ]C44&<<_.?2[A+#6K55 ;3KSZS&!U$;=?HWSQB\,5U)
M?VT>\-VOJ*#^S*HWI\\YY<PM!+)%(0&1B#3VP&3T\<;\\QVZY7?-MC3C">N)
M-B)\<97M3$FP.QQ%CB7?$V]L2;/1W_.,VF_7];_-ZZI7]#?D[Y]O.M*<M%N+
M7IW_ -Z>F2#_ )S>TMM'_P"<IOS<MBO$7%_97RFI((O-.L[FH) [RGY=,\KJ
M<>",>*?1CQBJD?/% 1BBG[\>*X[\,4'?'@]JXJFY%.V+B0\B2H-3^T*Y(8Y&
MDNX[I?@CCAX*R;?$JA1T[U.>V/R'DC&BZ_IJQT^KV<<S$FE7E<5'TJF>Z_)$
M$=KH]J(E 2.)55AWK7KG7(H?W=NZ*&Y1UI\L%3MZMF&"T,YC?Y!>OZL%Z-&%
M:YXCXF5CM[-FU"/ZM?VTK#]U,H0GO[X4^8;%)H:QIR7[)!WV(IG$KR9DBN=!
MOF4-;DSZ?-W"]&3Y>(SS!^;/EZ'4M%UB&6S+W.FQB>!8SQ=0M6IML1U(SYJ>
M:[:*WO4OK=)0+VKR)MZ8->+I0^!&<Z"1O=SJ@])S\<:=B5/[/OGT/_YPE_-X
M6-]J'Y9:Q=*EK._US2'<TK*^\\ ^=.0'SSZDC]ZI7L5+#WP-9R-!/$:;$TV[
M9*X9J2!22$?<#H!W/3O@B\B#Q JQ6<4J-B&4=R>V$KH0ZFA)52NYK09'=9\N
M:?JPK<P@^G]GO2HV%>M.^$6G>68_+T,[:8L]E-0^B]O-*(>3 59E6510,*T(
M(J3XYRS5O+.M^HXMKR)XGEGG:)N)C+S%59BFPJ41:U4G;K3(W+Y5UDIQ:99)
M8U/[L"I8.: EE8[ 5VZ].N.3R-K<L0"$0'N_%[>]MEEGC:FRFJ..C, !WHW?
MIDIT[RIKEG8MI5WYI:.R>4<].ME')B:<@&"N5!"CH0=^N&>E_E]I^G3-,8FN
M0?B03@$QO7XB-S0GO4FH^_)Q'8Q6](8J<:4*[>(W/R&PR06D//8)22,U%3V_
MS.2 AEXJAJ$H*#;M^K'W]Y]6L& /"23H/;(8EP7=G<U](&A/3?.8_G!YT3R+
MY%U[77D4R6MFWI!CUGG^&, =SR(SXVR:@VK^M)<G_2+EVD+_ ,SDECOXUPNO
M9'CB0!^.HVXJ ?Y? _/!5I=17-O',A]*2*8.5]P.F=]_+?S UG'9H[!BMVK$
M'JH*L-OHSIGD;5&BU3S"K3 +-.RTKU!)R7P^:8SHFJ1B4<S+Q7Y ]*?1G7_(
MNO))*A9PH5T6M>P04_7A3^;.L10Z6+@2<I?K"E37H*BN0G2-:^K7=K=Q2FJ^
MG/0'[+*02,-/S5UBSO[N.[64!-0A$,X['U%V/WC/!UU/^B/,LME,W&V]?CR_
ME#$C[L)/-5FUEJTR$?#( ZGQ!%=LC+8T',3C:_3E<A]^,+8F6KC":XF3B9.)
M,>N(,<1)&_MB3'Y8D3B1J=_UY[4_YPZTHSZ+_P Y9:T5JNF_D7YJM!6FS7<2
M." =ZTM2*CWR8_\ /RO1/T5_SDC]?"T'F;RMI>HU\3&]S8^)[6?M_'/G^I^C
M%0<4%,>#OB@/OB@.*"II3%03MMC\</OQXIBR \6/ACE4L=A7)UH\D<&EW(:
M&225'A#G<\*EZ?1GK[_G'X>K_BE7!=WMXS(!M0<6" ?+/H!Y*13Y<TX,U#/
M&(/9N(H/HWSK>E O';1BA'#?YTP5;0L4DB<!S!*$-.P8-3':.ZK?W4)Z<RN_
M;D ?UYM<*RV+D'B\!ZGKUPIEO(KC28[CD0R@(_@2-M\X%^8<;0(+FVY&0MZD
M1Z 2+]M*^!&<4UF\M[Z*(RL?4],JKCJ8VJ"C_([9\XOS%TQ['4-:L3&(_J5R
MS/'TXJ^Z2+X@BE<\]W+&UU2SK0H>K#I4]QDX\JZK/HVNPZM:2M;75M/'<02(
M:,DD;#<9]SORC_,*+SYY0T[5F=7NXT2&Z VXRJ!R^@G.O-%5HW5:(V]1O0X<
M*A>,2J1R4 =?'Q^[!1EW4[U3W_# TL/P\D%*G??WVW/AA>8Y.1H0A'3W\<1N
M(;B2GH@48[@&I--A4#"BZT*.[XM/&I,8W:E*=:@CKA5-Y6M8W)6/@7;<@-4"
M@H*#MOB4'DVVC=R88G=&-*@@ =]JTW%</;/2)(53T5C6NS4 J-MMQEW5K<%E
M0TJ:+\'\?EB M2K2%$+,XY TW!4TH,,[7A J(IK6K$=#].#DD1Z4V"U8L.A/
MAMD<U:Y]9F W2/8FNV_;[L *HCC6+M]N0_Y/49\]?^<G?/UMYIU^'\OM)OD=
M]#<76H(IV,SK2*,[T^%23\SGB:[TN;3KJ>.9&C1FY T^PWCA%J"3U]<GG/"/
MC(Z2)XC$+*]X*6C(],LK,K#>G?)UH^LS6U^LUN](:!E'R\<[+Y4U<*UU>B3E
MZRL2/\I1@J'5%@@C+R<C,_+T^^Y.YSJWEOS!+:VD[ABI+\@:]-L!>>?,4EUH
M=LKMRE,CDUZD<=JY!=%\TSI8V\KN"RIZ<GS0T/X##GS-J[75C9)7GZB+)6O8
M=,\X>9I%NM1+M_>#>IZL,KS)=G4;6PN2!SMXEB;QV I7(83].-KXYJXTG&&O
MX],813WIB9)W&-)QA.(LQ\>N(L?HQ$G$SC#[FN)-3N<2).]?QSZ6?\X4Z*5_
MYQR_YS?\QN*B?R)=Z;"U=@8=(UJ:4=?^+8^V="_Y^LZ 8?,?Y.^:E2HU'3M6
MTJ1A7;ZE-:SQ@[4W^N-3?L<^2H.^*C%*_3CQ\L4&/&* XJ#CN73'@XH,%1E.
M!3E0L?U8H9PO$1K\*]*]SXG#BSDD46EY*Y*I,['_ %5"[?CGL_\ YQ[O(TFN
M[H_9O)_3E%: ($8BO_! 9]!?*4JMHFF J1)$"3V-.1 ^BF==T>>/B63JK@@=
M:@8;!U1M7E#<:2QT'L"<*!.+3S "U?2N@'/A6@_I@J\D4W5S;5'H7@9!7L7%
M0?O&0VSGD0WEC(1P9 X7M4U!'WC.5>;YC-:W$4B\P[4^'<I,@^%A[$9Y6UB_
MDCGAC5OCD!DX>*J_%Q\QG!_S7TFSU[37U*U(?58@\1"_:-L4;KX\&4'Y9X()
M>4W%M,A6YLY3Z?T=1].&-M=L-/><&DBSHH/L>OZL^E__ #AEYMEN9_,WEU9"
MY18KR%2>M5"N!\Z9](=+OUN8S&6^)16G<'IN,D5K,K Q;\N_;YX]F],DD4ZU
M8_=@^)Q*I9:.K; > 7K@.:/BYC<U%"W2H\0#3!$B0<%C4\E&]1UKMU%:''QJ
MH5>48K]JCGV'CCG@+DE0.*[D-UWZ5.W7$ELPW)67:M"M*[]?;%I$"J4*KR0
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M:W_G ."*+\G+*:V6EM<7,TB(?V*G[/T9] HA(@5U^R0*C!'JA@0#Q8FF KB
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MD'=G=P![G/UU_P#..WY/Z?\ D3^3GDG\M+/TI+O1+$2:M=1"@NM4N29KV>I
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M0-&O%%H/'/+^@B29[W4YQ5[R9F!/7<UP]D?G0-7;<'$"?D<O:HWJ#OBL5&<
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M]B_CJ,.%'C.VT@6>0GC!,%:16W-5@8@?6+Y[4O.Y&4B;5X;$TD1ONOR6595
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M1!R1NR>5^9MK[IP1H').\OQ]LA$Z\+\GHI<<,3>O'N=^QC,B(4OS6K#.-*M
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M$I5?;Y4)'7R88'NHI7VL,_?,[%N2M9846>;/J^.#/M7@"FUD#PJAW%D7<65
MPM39YE"*L28F((=PK?0_>PW 8Z_]9]^P6:&:)HY/&Q8I[.B52?L^Z>?J"WU!
M'4SAP5+O >Q 47ZL].7Q/+,[1O^7)4N1J894RZWQ5O> X;R@E,\V_9[K\>]L
M5D5KE_*/O\@UOF$I8VV_I)U6J@:"ND1+HQ[K!^XI?:U]*<^DOMN07,?^@D^4
MW:Z5FIF&;?>F[J385I"73D2>4:=9T_&](Q;[Q ?QV5B;7ZHJ^)%1S68,FOGL
MN,<3MUL-Y2RCW N^P]_P6728=>0C,LJPODVXK=<$$]P#(&!A*Y,.3#'DH19:
M<#EW:W=.*FP@I:5>Y4"N7T$Z,X3CF5Z9U%-DAG,.NM:K\4<A*&T\YDCFAQ(3
MJ*Q?V]"PQHT_LX?S;INYKS4%E%[K&_DR5;+7L0K;#Q:48V=C636>_QIAF>UU
M'3#8Q/0JV@+D5<Z/4UN*'8$)TZ&R%8FKHSS*A*EQ^^I/[]S?=@MYDO0]O#-T
MU3H3=CX4P+X'$*W$',="^WYA'8C*-/WM/GSR0%YN(W[YO<^8'JS!Y))$&_OC
MMLAYM:>0S0P[A8'9]28\*TP+!!]>F:LV+@URYU77S\-O^4[/KT2TON>U9(WX
M#$5\?NJ,^;%)" :SO%*J^0PHC[!3Z.SE&(/9<>)LU8>M Z-=8--ME1S<N>X5
M>$HE5;I@MY89Z: $]TVYB TF&+:R;C(W)Z%_H[KUA5Q[)WED1$/H)=^(QDL^
MM4$.E__*R@6#6D=)@2QA5YWA+MNIX\9.$M/F0(U#DH$YD^<LB7I3KVSD<1U@
MMVC/>P#:G<8"53 C\,_AX=:DOSN16M(EH&&W&/-U ?@[V_I+)WY#7;[?Q0%J
MJ..-P,/(8&T0IL+;ZN1=:1E)\ !UMV?3%SEJNS):I7RV*?J1BYFR*Q]P*P4&
MOES =N^F#\_]0ZZ'?EC]2=_ARS_1]W;\>MK)8YBTU'ID/63)6(BH'KT8&+E1
M:OB4\M=?RE7SX&E0IWFN^3!"_)*T8TJ%Z6G,"(1F.D\2,VH9<VNG ^^X!*+F
M6-H(Z\JO/P*HD.]+95T)"]OJ@IU%")M?R0LK?ELA)\H_>V. J'DS*/<LT#5U
M=  [X &A&E\?8^4ZP:O&+:+E6K[@'$7CKKB?3+J-;J%@J80EY&L.^Z(M*BU*
MES7<-_;;U-$S[\O$)/JD]^\!C!HO)(.M2KJ.(;H8[JV^4*P.40>/>2 -2\M%
M[@&)>8[;!VJN4H9?=,%5E7G^\"(X<AGM'FXQ_85UZQ0.&C.6;-"?WXX9UL<G
MDF,:1J= AZ5;%*'.'NO[(QH"-/0>2[FRJ"Z5%&RUY66NBD2=H_)#E!=YQ1U(
M]V5]P0,)B>O(F7WKH(E&^FD>7]RPX!\>5#@^23_+ST9^AO%D3;64F0PP8XLN
M[(&BZ2@;V,\4U&O57]>P?Y8O=J1T1?2+\^KR],A?S L6*L=HVFN0XP6XS@?Q
M=-0*\SCW'6O>$"$YZ?W-T>Y,:,_;4<U@">@+[V."P41-4=FT-A7A@]+>N.UY
M62>K1"N,.CP>\-.U_<Z:)D(O%I3ES]T_=TGX\=88PX5*\'OO8)$!'@VLOO=2
MTS6J.'#=S4Q'A43EY;P6:=4"S0B-,^:'4<V6]6MVG L'U8K+(3O3C$^<L!ZB
M6A-_=WX\C"<Y:VONI?.I]@_Z+E5!]2UE.*,O(,O/[D[I)78%G;KAT[UL.QMR
M<KCD(^+P%;I;&"?B'H#Z4/4Q'YL<3-'TJBJ:3TG2=S_9)*%W^VN*UN^^[43]
MQK5L5.>//S2HS5/4)N=7S*PQUQYC>AGQ&E0M4M&>F]2G<*I][JWV=R?41((F
M8]'7,/R#'$@&V21GNG3=[CV PQ^L"J]-^Y#M2C+<1E5O9F)BQDE8$"T)$&-/
MT5=CKV-/5N,D\_K/5/MWH/N3S-;/2L262&7_1K?[2)Z@3 ).@_9L1@?ON[$=
MW@,R,=4B:2]"I*]1K3CX$E WS%(IW6:\P7UZZ55W#_!^?/8[1-)\2;O-\BI#
MQ%764LHP_6#K"5LN'?>WEE 1?=45["?6MH1E^[E@N.QF_EP#+U6; 'N97B%S
M^*^OV$5N6UX'.KM'/G]%S?;:^B*AJ;_ZE^C"U:^3-,-!-SM7=)!TE@=V+="N
M]C1;&;^PNMP.P&D>"VH3% [>VT#HKRV/&!N?9^KT)/ZBP0<&TL%BGWN#0(0=
M/[^1K<;)WE2RW)63ZS?B]'S:YF_\D,,I*W4\P, PA=/B#!\18R9%^PV^FJ?@
M_T153I49=51P;,V0L51EG,C^LHR$%KLSDE ,7WFSA9T1Y4%2<M<[V4S_NMCK
M,W(TJ3%03HE^ L<M<[QL';$?G:&+ZD-=P,V;4<70C%]V^B'3*NX325<6L!PH
MC)R?_G43Z@Y5T)E9"!;VI[Y[\YD8 9WJ/?]VC9#/LXY_33TPQ;4S]*0SFCZA
MD$KOX 6I55K!4++P3A]C9&\_[_0.H=3#;[GPS\6@LPD#*BOKTT:]]0RS6UNE
M04KG8J+KJ,C7SY^)GUIE>B;W4"@T /U_4;+D;Y_C;&<(%F#]W%HIUV'L\(AK
M!# 2Q)OJ=SAWT\W?"DDX$(TD4B87EE'U9-?=+OQ9#H=&!JQC.I?,+E-,R(+A
MH#XB-8J<SRW\FT>@F0&EF2*'XE&G_,<%IC9-@DP$#-QYM*VRC<<@N=3]<#4
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MZWD[VC,0[;Z-R(972,6]UIY\BX FLR75<,Q]X-K)W*)</:WJ=F)A(M5XZ)$
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M.<*L$L\^0^V=EAY9EP36_^@XZ)>C([6?DS@Q_1ZE)]&0]!PGEOWW4SBY<6=
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M \)$0RLD]&1@A\DXE,&*F3ED^2GQBG24>H'&@#P[[]0K=K??H9::+.T^?J+
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MX038=_^ ]G6^*KB>2<FS[.Y;O!!MH<@SG)+4^:L.F]U"%@%!$T=3$&D4(8>
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M&>/X>6X4@']EER]3TU;BVX0VQY64IAEM/ABE@D21E4QD[ >H"H#?"&^&H##
MMG>6]]81VFJR%"08[>[!](22PN:0R53]W(I!W:F_7IOS[4K&;0;^X>P5T6YC
M:0VY4%7"@DA$V#(!\)0[H: 4'ID,T?S);1):K!)Z,#A?JQ<GT/4EW:,JX6BG
M[++4BO9*X/UW0+:^TAKJP6;ZG91/-=0$>H]M"QI)&W(L62(@E20"!6M:5:7?
MEGYTN],N+6"\/J1/!Z:.]6CNK>,>GZ4P.S*PI0[,O+/I#Y$UPSG3IH9*V&NP
M(MO>R!%%W3]V(YHP>'K1T,,Q848<7%1G6]-?ZG=MIXGYVKF62Q60$3B-36:)
ME H[PON:?$5HU#\59QHE]];]6W8@36]3%0D[+0R(&W! Y*5->C?Y)R1LX:/F
M/V2&^XBOX'-*M"9 >+4 8^([5\:8LK5ZBA'4>&8^_;<Y?A]YVRS_ %RJ#\<W
MMFZ9NNW3-EG;IG<OR^\P_7[,Z1=2<KNP7]T2=W@Z ?-.GRIG1\V;-FS9LV;(
M?YW\P_X?T662%^.H7M8+4=PQ'Q/W^R-_G3/+M:FK;EC7<[U^G-MWZ^(VQPW\
M:98\._CCZ;_P_MS"AS @@$=,IJT !W/7'K0"G\<O<*3L/#$FH7AC!(ZNW^QI
M_$C.1_FSYSA\I>5KV8W3+=M TX5".0'-1N10J"STZUI7CXCXS^<O-VI^:-9O
M]7N"/K-ZQ6,1KQ54CV7_ ($"I)/7(/-#$KK]>F1[F@EE69BD442@,6NY5H0.
MX1=_UDL$.H^:G%SIK74MI:!@UT46VL82%',6Z$QJ*C;FQ)IA9?Z)I/J&/4]?
M^IA079;4.8B01O)(R!23T_EW[8436FD0Q21W&G7-BG$L3?VH9I$&_,_$(RO@
M.!'OD*U'5[O3X1-INJ)/8L:1QF%H8%!Z(J>GMQ(ZJ14=\)]/U:>_^OVT]Y';
M7MVT;V\T<HXQW$99D(8-4!@Q1B?YJDG"_P PQM>1PS:M$+;455@)R O&5#\2
M,0.A/A\_'([+$]I906\P4L\IN9(TW4JP'%VW(;?8??@[4;JZ66.)Y&?G*_7?
M>-W  KV 04PJ6XD2,S @.XHC]5#%BW(D]S0X%Y/)"M3\:IP=J]N5 :^VXPHH
M\LAA5@@- 68T5?8G#-[F\MO356]%H7'!DH""/\K<G&7ZOQ%W;.P27>0#?@Y%
M>/B%/4?=VPI629FY-(T@'B3M3#6SU[5K,\[:\EMPNW&.1DV_V)'XY.]*_-?5
M;=XOKZ_6HXZ#E(J3;"G4.H/W,,[7Y5_,C1]8FB:*Y;2KZ*GII#-+ K?ZG)C0
M^U3GH30O-$5RAAN;N&6>3XXTN%]*X Z?N[B'9AMOR'TX>RQ"-*WBFQ@N360S
M?"I.U6C=!0FM*CD?&AR,ZMI5TD]S]3,$Y50S6LRB43 '=TXK'(.G6FWCOAKY
M;\[S:9;26HN)=*:(,5@D=[RS!6G*-E93+&K>X(';)A!YET_5H$D:*33+J293
M%(7'H,]-UBN 2 ?#XDKARFHVUU+)!YAT[U4NH6MFNU5>#H_6.X1@ P/8G\:U
MP]1K_2-(2*VN;K5M%EC#P632.\MN8R1ZMLTGJ\N((K&QY#_BP&N09/,FFV):
M58VNM"MQ(;ZS@/.33R2/4N+4'DQBJ>4L-"8C26$E:I@66)8/2;3-1$D1?G;S
M-18+^)JGXJU5)-Z&GPMLPV;>.7FL6 =(KZ%EM.;0OZM8KBPG(JR2H5IP-*QR
M D#[+; $&U&=_7:&:.]1?2D<*(GD+C:2)S1&9V7BT<H*LW2C<69>XEFUR.35
MX(Q=ZI:1"'4>$;"1H5"K&\\/(UCK^[DXDU%*[FN1R_LEA]2[CY,MVI^NV97F
MP"A0')/'D58CD:@LI#K0\@'31Q:WI\D$B<[B")98I/4C,W&O$LDRFK-O3WI1
MQWSCNJ:3)I<LGQAA*Q-S;QHTJ-)&2!(@/$)(1L031MU/Q4.3/R_K4\,UH]E*
MS!2E)4Y%I;<D? Y^'H%*FNY6H._66WMI9Q01ZI:V4;0+*+A(86$+Q22<2W%N
M!0J:*:E=B=_AK3TK^3OY@JFGWNGRNTUA%=17+(X*SV]P@X$</C8<D'$@5*.J
MMT Y>V(-1BU#2K37HID?TEBFF:(4!:-/@DJ :1RHX+!?V6KVR;WG+3Y;+5[8
M\88B&E1=SZ$A*N**""8V>H/<&GADP$@</P8,DZ*RT-1R+@&GSJ,'2;HZTZ@C
M[Q3&UW1S^W\)KUW%1BA._AF%*=/HR]SL=LPH._N<W44[99\<HTS'I7O[YMA[
M8/TO49])OK;4+4TEMGY 5H&'[2GV(V.>H+"]@U*RMKZV;E!=1AU\17J#[@['
M!>;-FS9LV;/+OGCS =>UV=H7YV%C6WM@-P0I^)Q_K-W\*9#Z[=>N:I[=?UY?
MX9=0:T&76E#OX?+' ]_U9BNY()#'>H^7?&CD16HJ>Q'W=#FK.*GC&P)[,R_\
M:ME\I30>B%-1^V".OR_A@&5I6D#B;TX$4JYB&[5(V1C7>O<#Y9\U_P#G*GSY
M)=Z@WE?2=X;+TA,8B6,T\8KZ-0=PA8U)[USPD0EJ5^L7 %R4YLM/4],FO%G%
M:5KT%0/GD;N]7T^S58+2S^MW<S&222Y;UW=OM4X'X/M;DT^G(1K>OZA<QNEQ
M(;WGRD=>?&+K3A&@^$<2  :=?; &A:&)[C](W$LEW:I5P'2OUB0@@EEKL%K1
M*GB/M5R=ZWK%YI]H+5;BPMK,\&2PNV+F5@*M(5H[T%=@H&V^<IOIM.N4=Q')
M;NY^*6&,^C)L1N9'/P$#< $>'3(C=Z-#(L\MN)8FY*"HCJ*$D HP/2A&#+2_
M66T:SO(X;IS3G%.1691\/PL/B23C0U%*TQMQ8Q2R/;03B.SM3Z:AZEE"TH2:
M B@'3H<$:CI-Q'S:*UDDF+>LC,K$MU/PD5'O0'[\C@MI9U'K03% *A2K1D$'
ML"M!0G!!L);,6L_IEX&4J(3'1R"2?C-"!4'OB-SH\EVY6VCB#\3,D?%0SCVK
MU/8@=\2AT>^NZAHE9%7A-S!'$T/'MU)&V*+I$]N0()2Y>BE6!XL#38-4T/SQ
M:7RW*ZB>"VY/(&)CI\8 ZF@HII[5]Z82/H]W;L?4MRR=Q3JOB.F%=S8M"0%5
MCW7D*$J>A&!Z/&%F0!&J #4J0P%>QSJ_E/\ ,Z[TOT;'6(6U2Q!5N08B2+?=
MXW!5E8#P._<'/9/D#\Q--U.W2&WU--0BF589K*ZH)0&/V3U1O8E17.P6?EO3
M=52ZET>&&"=*R-;MR4+0#XEC')HW K\2'YTR(7^EI=3>EJJ^I,G[B&\1@ES'
M0@;2H K"IV--^ZD[Y#M9T+5]"9GCF:YL9 !))$O"6G5?7@JZ&E!\0V^79:P\
MVW6G*L5V6-G, &D"": H=U'IU!6M=J4\17.I>7O,\,:I):W*-;N"TL:_OK:5
M00/WD3@BO0BM".S5PPUG2-/OV?7-+@33KN=0)S8EF9F2H];@]%8TV>-J%@3Q
M:O6!V4YM9$TK4(3!:#BES%N8("S%5F3D%(@<MOM6)B0WPMCK^VM+AIKF93>6
M:^G'5N7UBV< $!NH9!L>)_9Z4((PKLM7FMI+BSO2L"0 Q!BZFW^KT(%7(IZ0
M! #4/$$<MA7#F6=IM0ADL(DL]5L%CFCYLP%Q;24$AXD@/Q%0Z-]I2:,2%?#C
MZIIUWJ5K=R+=0VMZ[JICD]?BS\R?VEYR1DAD[2Q'CN_'(!/%<:;<2<PLOZ.D
M1GC45'%AO)&=N44JD,*TVVV(J!FIPB[AADXF6*4QM%7D'DBH%X'N2G$KX_"*
M'X1G.4-QY=OUAU"81Z;?O(L%XW",!F[2NJT!Z58;'8DY/;*YNX8WB5W8L%=K
M>H92D>\D:*S4YBO*.NS \#M6LITVY.@746NV\OK6'J1Q7;0@.1;.H,<B<A5@
M.09"=P!Q/Q!@?>WY->;;5KG4?+DMRLEK=017MF9:.DUNI4RQQD$5 25RI%?@
M4>&>E-$:2/0FL;M"3I<DMGZK'DA"OQ4$C<4<$ D#:F'.E.+>]CTL;K:H74\J
MUA'$0M^/$_ZN2MB>)'2NP^G;,_+]V* _$#UITW\#X8[G0@,"I.WB#]..VZFI
MS5%=\W^>^:N]<NO?-WS>/ZCE9J_=G6/RUUSA+/H4[T26LUK4]''VT'S&_P!!
MSL>;-FS9LV0?S_KOZ$T"98GX7FHUMH:?:4,/WCCY+W\2,\R4\#7+'SZ9@?HR
MZ;Y?RRZ"A\#OE4H-B>NX_LS$M4 4/?K3+JQ HN/J=Z=,#S>HW)!*J**%V(W
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M/&2IH.;FO =A5\//,%_;V0EO9D9H--C,JP15('*BP"M1R9BP/3^.<QT2WO\
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MAC/48?"\=&^8X_.I.0GS==3#1]12!F6:*PN)1Z2EY(U5.4CCP-"0-O?/C/\
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M8X:!"[?"0H!'3\<,=P>)!%5%236M*@;X:62<5<UJ":5IWITKAIZ9D9 P!8T
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MC4PKK%JLBQL:HSN/3=?BKNLHXL/Y60]SA7J<8YI?V9:WY3()Q.2"HY<9XI*
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M^H6T5TD5W:.C+ZE*\@3N* MQKXTSYW_\Y)?D\POM1_,+RV.-V@5]6T\)\$J
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MXG>W;)I]K 65WN.<]3_+)(2&7_5""@/XUR!:[*\K6MBJE@9N7%: N]6J36I
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M]<HGMWRJ=Z8X^'AE=.N_MF^?7I\LK8;C?+J/E\LG'DZ4K:^;[>N\NBW$E/\
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M^G.57%D6U"VA]%%(D>1EY%E^$LH!)I[#"K6UN9-0Y31M^YW/$GB0:!3O3H5
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MA=5DGF=6#.8G:O\ P2GVKC_^5=^4K'S+YDCOTF&B^4+B33HY02?6D@3E<,[
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M9#.\EG,39:C;KQ:2.E%>)W%"M#NIKX4SV5^6FOWWF;2H5M72YD:#U&F4\HI
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M$]&W>2R!577E(TC\ZJ5)IS<ML!N=LC?F/\L_-&LBW;69((H)9^=O# 6YA)0
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M*JE3+;K4#854$=/ZX3'2%B=9O2X&OQ=R-R <,DTFW9HY?3IR44H-@PK6H!J
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M2&TR*.Y3X1)&%9>C5.R BO@33;]6'7EFVCN=5M#$_J(D8F?CT'$56OTG.H,
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MMOUI3)EISJOPLO -U'8_YUR2P'BP+&JC<"FY^6'5O(>2 TX'<CIM[[X9>JI
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M?D#U)/=B=5V^*Y=S<O;%+"V\/,B=/0<7IJL;YYR:!I%5#K)W!-@SLMRKSZ0
MC5Q[8I\Q0,BAUR_8'%>.%5U0/<"D&."G>9E70Z5NZN&!OC3)68MVF(;2L,<T
MD6/?]3.(<)H6-=<QJU0,?7?\HW02$?3X<UA*VRF-\RO<11\A<+0*M7HT4"FR
M1=QC)=1.6FE-\N](EJZM#8D1MO\7Y4&%E;"53[]FE;->E>3.^.K!'H7+[_@N
M<%7 %8<JQQHN;1:=-N$?XPS,$&XR+*:IL,*<+P3BA$<LTDK]GFMYP;5G!<=-
MF*/<OWW*%/1/=7W*E=[6]ACP*^L^O%K]=M#[05B+FVVUJ99\N92/Q<ZB31@E
MF':X)@^KV1:5".&T \P!=MYS<+;P57]L@I7E0:\!P..TI)]]31:0B3>MN3(-
M']Z,\AV,&0N0S(?J.ZC.>&FK7;8D\.GB\,FDJ-()Z-Z;$S<V\X](1AF0$6BN
M^^!2'-W+F!XK,\D%N$8:E<H=_BR-<D[5Z=@73$ [2J_TJE]R+0^P30ZT&1C/
MEK5?6KH:<#D24Y_63UDA>?>\X]9>/L^9)A/\P,@&4R<=Z<\PVK2,Y 08E2GM
M@?[TD!<7K!=$!#9-^(XHO69XD==C$D7@2$" >WN4CON.8K]3C?K%K/:%,AMY
MYH+UK\CP\@B/5FJG1L\62RZ-%ZXW2^A_8GPUL)6%"F7@/;C#_WJUM8HF^<=:
M3U<0 T]GR&>ANYL)G HZSO6WS7!(F4=)CRCBSCZ(?LG[P'*KU<"E%VF6U&'%
MDELBNK'.41BX+HM_6)@I(E-75N&,WT>0WSE4^@20FK3H?2\@\^/D>]/T>H&I
M@9["_!^9">F,R<O';86SP,N_MG((]+P4:>N5T&\"(!W:N"I=S0AUOS50)E?Y
MKZ&*KIM[-M#M$VEE29%J2WDH2GJO\]#=&^9YGPV3W3X/]8$0',I:70_+"Y^=
MCZB%^&C(C.&<XU!4(+Y]')97=./E^TL4X^,<P*N)TZ;))(;"U#DD#F!81.$R
M* 'F#!OE>0D,NKP!^A3T3P!R&1/JN6*K*@AIA?TU22( ,%.@5/#,*!!YB5S?
M[IN1<>XHP.UO62AV*0/H? P]S\!:KV#9^Q$^,B7YC?GS9EDP!5V4*#RD0$.H
MAUK<1/P=FRT' 9"^1_+3<&#W'S**2OW_Q)+CNMQA$2B^\>D)TY;5#_\ULKB9
M) WV60$W93?(7Q-<QSB)71]!W%JP0.:DK#X4>!75PQD^9S0(Q$:8>PO'$!=9
M90I#5&!P,NA50_>W3N;P&DZU0H+.[=8)@YT#+H.*#5R68G)AED'6F_L?;N\E
MTF)L15EU?"L'J\U&!Y4J5DIT]2O/BUE.RQF6IAJGE&5U:R="7JG2>-/@B[BT
M_^07=R/\Q-]&3<_\(]2:>X7@W'_'._RU@MZ[$^A_.-07PHQTT4A&Z FDA&+#
M4I$%:G/.G:)%NE5?<3;(G5>8<._(P:T !YY:=-'*C8U[<:UWDERDNC0(/2-R
M#DO,_;093Y-_[_FF;Q(";WW6UZ&RI4:_FX%0Z"$*9'V-C[!4B#O1^D;G$L'Y
MDKD2NZ/L^0- ;L#*J.6^HP) K/\6QC(8- 5A-%HS:7QDS18Y#_T,JB@I4]1P
M:E_K\71P*F,>5BP)E!;[4WF5OISC:^>T?Z&+:Z>]^D*&YHO,CW=S]IR,45KD
M<N8H-,K5Z5.\5NSBEX +%@AS;EYTEH/=L#9Q*$,7!,(D\/C^9'=!M2O?NAW&
MQOLE.G%RDR:M5+N"M_V$^^-.KS>J.%NYT^+KA!(O[\EG%7=>F^V&E['R]]VA
M:8-0(''B ^NS]!LSR2? 3MN/.N$ (=4MOQ,AL4?UBF)6<V6(W5=JC_?:HF^M
M,?]BC!$"E68WUPV;%(XBO(GZT]\K#6'UZ'NQM%V3RT#MW74V;<FW]"N.E:[L
MGP"L:!R"I7X\PN.YGTG_Q"_3X4S@#&\XV\<)/<A>]/M<C%6G#;?)A@<C#>#[
MZZ(*N2VWX_O<EY.Z7P/L7_FL@[6^N%O.485$&_VY_0PVO]+:J2N\EN4M&^1E
MA97[)P+/K<*449RRFE[X2WBHP3]/  VD@DG+ASTIXD=G8HG+B*VB6T:2J[VX
MS&Z7B]MA[EL$G+[68J VA%:?KKH-^<^1TE*B$(+I,TC$7TZM2Q3_]8'5)0Z#
M-N=6LJXC]T(EY+GS+7L?-([SJ!<VK&SJBZ;*\314T!C $:!7(^!0 20'%]98
MNT0):.';55/(2>?YH+#YW5I2OHA:YGE8%GK\.BI<N_\T,R_#I&R:)?>O$@9,
ML&8M18!9)'*A-ZIW&439=J<%0:BU"Z\"^POS63CD\!!MYEZK.!2H^PO#<#,(
M>DYU>8@YHR%<ZW?Q58O8&!9$ Y7P30<S^ZJ<$/'18E)'QB':5@OBH%YP52;M
M;@M* R QML_Y5&*9XTWY*HNCPFM /4L1R+45',@$NZ+\V9XZSZ@3:@N@LP+Z
M3@GO,;PKZU0-^8R;@#=&)S,FK7(SS>,BX]4./?V<?"CZFG](A0U;Y%1M@44+
MB2A>5+\VR]F)TY9[P9QQ@#;@O-O.UD2=02T4E-UYBI-_&>89U3.F>#J!T%[&
MRI-O:]T4&IZ=);:RV&IH11-H3=7RT\Q%BVM+V7]B)!Z*:*"3I/_."NV3;BX(
MKFF8?%V:B6_C?&'Y!"#BK5QX^%IV\"_9TG^$I0F^J7RF^"B:<;D_[FB,U5XA
M)*ND,5W8W?HE!1+DS$PPG<RG8NJE-[&) VXE:]O=R\RTCX.;A!6F_Q=L((.3
M*+'A#=F3;I3$;NB2LBUE5.H7*W/^&0H%[J@B#QPXV]OODXH8%>G!N)21S"(\
ME+5R<""IJ7NHP[^W0_\8UX1/H7CET7M#NB7I-O:W>[OAK_,1F8@:F]Y7Y\F1
M#$URM"=*SV;[I(5<@:=7/HGEAT:O\BOF$92V 9[ 3]_[^+W-S-J+.F=.>!X]
M5-9TNUU.%32_SS73O3\U_GN93ET5[4R"D/^8#<1:H-46(SOF<K)$2VZGEL2R
M)%NK%K, $^_Q?.%4/&'RP?ILCIRFR21P9J/S[]]+F9*QU(QJ?=GWL; MB#0E
M_:;U(&!GO.V7NNG9U0KG7<(8YSB#XKMY,C%[B0&_@W5;VCEWK=A>FK4QA3I&
M/@&H!3+O!BHX+2JTPJ;6BQUGD=43]P797P]-7"B^N-+M%"EG1*:ZL 8Z@INB
MG!.13,OAHB*)TA%.]^A"5][D'"'P;;DPXPM;.=H1E14-NF#JXX,SE!S[V^J=
MI;\%ZB[P%\]T5\QJ*HJ"-QW'[K8X?)_Q+;D8L"<=EF1_;,@_=2WVH(J^ $R3
ME,GK-"G1>!S+WXB%N)U/XFF1^_TN#CL)#CJW5D'_GI/4JQ_?#O9/LO I<Q:H
M @:Q]!H%[^T*&IU@O0M^L M 6#3,U4ILJ8*2=$#(N\]GQ;6BOX&DIPV0 ?PV
MTD'W5]E9_A1"]#Q# )G+@J[ZIF2MAJ:&^(<N,5WR6]QBERLH]NXX([$\.8XM
MH9_69*XDTO=W;FN:3]*\#U_ (#N$X@EPR ?N)8ZPG!LF@YX@;:OD5KR/DI^W
MG%Y (A063L[HSJ]/@D.BI>@Z/V^KW(C5L[I;PH8Q%HW*I?0-?Q8(#8O[U +M
M!A!J.V#+'*H.H?&M"ORBAPYA6;F/IEH- _(Z:D8#RE;]UNK_I5EH,((IGP#_
M]9*K?05!PU?%E4H::'V.G1I0 DP5R[@Q@V<0)I^$Q%_IEAY\Q7<!R<?3>7T_
M++6SQ]%?"C;7&+2T8"9ED:&.22JVH-8AQ+'G"Y#%A#V/D4?RZD03 ,CWH ".
M^7B5G=&]0-;0#WX[!,!=U/9A 7^Y>I[HTT8230 +[I;J:5%.SN>:PKVKM'CL
MQ/B19QK.2OIAG]7PF6X> ^U&YVFVU^7AV+4^31;+MV(9\C+!Z0)O5-T?J7Z+
M-.S6CDJNPY_%A[X5]$M[_MT_O>CD$6#;O(\Y5UFKWVURL#2='MB#BZY0G@;V
MY:L"5<,UTP,T::]Q?_<)]GMA-0P^:+PSPJ[-UH^STY/_2CICU">4XH7\E+6@
M,/_!>G78"1BO901-C](K6MVTE;'>$8G8Q67A$%H\002S LAY%&"&&<XDFSV!
M?(,?>B[Q26@"$NE]8N,JM+-FHS^QQ"LS\DOP@<USC9T*7&$?;M"6%R.@U]3"
M0]P"*Z4-39C1 0%^\E69Y4/VZB"TC3K9\X!\057C%7 -D\/W"0._KNX?WYX
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M)U"^V8Q376H[C<-")-7ZRBJ95H"9U:EAGM*RT1SED;<X0*\;L5'(F\H# OU
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MS&&=3I"M=51)T!W$*9!EDRH^X_B4ZX ;UV.R&%H4. 4<G%C^ *1/MB\O>SE
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MXZO6=X%%.T%5'V<!"JNJE"9[!'-H""J>H3R9<-NRHPG_SVKJ^QO7BYYI]Q2
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M7I.VWB^S9! T_K::0JFCO8D]!@_S/%$;L>>\"Q'3O&/G+IJE%/')<<89P->
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M]:_T#?"='9]<M,=.9&):B8V=)]0ZYV!08Y"UG^29S3]W"B40,L5\Y8B"0V8
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MTR"8:0VG5^Z9W,7O XY%O:Q5?-X654I:90-_D/[;D???8/_'_P)02P,$%
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MP=>[/$Q&._Q'2QN%W+JQAZ(E#>QDVMI!6[4:C_0=5?106GU>+XB484EFM93
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M*4J!ILJ?RJW\_O52ULRHBUM29LJO -6,&9KOK(,.9FL?JO$3R>/K/".=Q$]
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M8[6P4@2^_";_TED"VBM]MOH,T.K*&K\=-RA8W<)RW$TP'K7S]BG6+4/%EG"
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M"K9?#GN1T3C!*VF!_ !_!HP7^#5SVUTABVEA2C$QSA_K_/B6D=S1ZZ%Y3R3
MU>B"^LJ5([#WL4_ED>&E^0?UF%KFMXS^ZUH1ANA6D__ZC8D^^+W,'E%MT,[F
M!(W8499'>[:0H)ZV?49^+[@0M8;%ANBC'@Q>H=7V=)7,GP*_M_'9](+P%6R_
MD-X0>[=KF'\)H1=3%@KT@7)!Z84OT ;H.8'M6LO)6&&E_Z17C6_C^D.3?&'(
MI4_#QOJ%6@%3UGJ8I?K!S.8;T.Y<_$OR=$A=(7;:CI=L\])G;9]_Y31O;:WV
MV(\Z/&-Q&W7$M1==/<)I30,@&5%%-8.HKGIR<F;B(]X</_^E-Z9COT,T+)&
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M5CH*[T^7>STCD#1-=^"\&<S3W1ZSHM*<$J<?[B@LH5=$1;C 75(8[_:SV!@
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MUM%>QWYP0>?"-</T,^#UYN#2C.;R2Q<T<@8LU W.D?24[ I?#;2I5?O5'S?
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M7PID+USR.GUV+4((&,]O*K)Z5-J$;5J*?/)3YHA%O:6,MSRY<4$DAK6C@4+
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M_#!2&A!VZ8+1NGOX>^"XWPPMIO1FAE'^ZW5]^FQKG7XI*R3)S(',2(5%0P8
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MKDCLA'(RF>1BK,.(KU5AL#].32P]% @:+^Z'%74_$%[ @$?1A^RT1 I+<OM
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M'!ONQ]?]K+&YI^&/!&6>F5TV[X_H>V_X9?;'>Y[YOU9C7Z<=VK3.]?\ ./\
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ML8%5$4+<SM[\=QGVZ_,ORL_FG\M==TJU@]6]LHUU"SC W:6T^,*/]90P^G/
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MOMLSRCU]-EI]A!01(_$WZW-[3ME S@C_75[.1[,S5Z4C>X[!00ZYM2!H>,Q
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MXFRD.;-'D! X(TE?'CT:2, EA!!_&,0X RSSP.3O_R4H8VIK/\DAWQ[<BUP
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ME<6TCKS(K<-"/9<E8A<[ZU-*21P87+[-X#N:M5IAI#7)(0_YF5*HA.OM?]0
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M7B,EE2[[ 3+,-H+[JYLJ1:#2\"C;),\=N:K." +3K6)FGG=E:Z8F<0::+8M
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MVJBD[_LHRF)7Q3XT#,Q5,B<*H(7YH5]BU!"IHA:H*EG2 %6:O(CXOIIBE>W
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M-^82#V8R[+=\VV[V)^2.;".]1*N3*OY*P]42C*S]VQ;9G/_EK$,";0,M?M-
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M2]!EM;=[62.T@9U!2K R6SO)L!4I*M??KTSG:6=SH]_I5Q\5[96-XT4\@[M
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MWKMGGB\AM(M/4WLD^JWEVBU>=#'&JK&J_NX@" JHH"HHVW).<[UG3-3OIY9
M+U&CB$;"V6,@(!\$<*D?9'=MMSN3UP]T?\L]>UF*.?UKJ*UNCZC0AF>1^ ^
MO0E:CYD#VV&.UK\OK;1ZVRVEQKFJ0(&EBCD/&(,*DRL*@$@'W.]-L)7\N^8?
M6=K*VBTN(45;4 %CR%  ]!4GWIDE\OQZS9WD8O8S)8W@^K3.M13E3@[H22.)
MH14]*T-#AMJ4/UBUO;"9/W@#12*=R&%05K\]L\KZ#^5'GSSQY^/D_P @^6[O
MS'K*L9Q#;J D4'*GJS2O1$4$TJQZY[LTK_GVO_SD%J6F+J5QJ7E72]0"EQI\
MU]//(.6_%GCM60-4_P QSC7F[\KO/GY07;^5OS!T-M$U6+]_;2(ZS6M[ #Q,
MUM.GPLM=B#1E/V@,Z_\ D7<PW=QK6A$@R7UK'=0$4(9H&*R5WW/&0'Z,]=>5
MORBM+M)=3O[>/48A.(R96IQ<BHJHZBG:F%WF?R1;:U?ZII.G:Q'Y1T_2(AS>
MZMFEO]0G="T4%C&&C!C+E59BYXU)XT!.3GR1^6GEFV\FZ]Y5O8H+:ZU&&:*\
MD^L).TT\JLDK!UJI()V-2#VSYP_F'^0VLZ/J%YI4N@ZA?M!(1!=6<$EQ%/!O
M0AHA3<=0=QWP'^7GY >9_,NMVG#1;O2]%L'#W-[-$\8=8S0PH"M6=OLT'O7.
MJ>:O^<=WUZ[@-O"D9CE<GT0"\;*=N0!Y#8UPOL?*OFKR;)-I/KW6IZ3" %+5
M>6,<?B*]21XKU'4;;9V+\MG$GZ7O3JL4%8?JT5K)0M0(WB:@ FG3KGFK\E+J
MXM?.7F*33(X[G4DT5K**,%AZ<EU=QU^(K380$;9ZMT;0+S3WDU'5/W\[,7NI
M*\A4+0J&4;TKDIDC=[XRD4]- R@J*#>@((VW^6>2OSV1F9[E.:1V^H'TV04W
M>,K6O@&B%?'.??E7Y@2R_,_5FAX-:3AKTR,W0A053P(8R,#[9['\HW4WF7S!
M->0B2>STN-(>+#8SN"6-?\E?UYV;R_!$WF>&% %*0MR/:FQ%1G6;B"WT[R'Y
MOO9S6/TIN.YH (B-AWSY-5K4UK4DU^>-J<W7*I^.6/GMBM1L<LME!J=<55A\
M\4Y;;8F6WWQX/0]1B@-<S',,W*N5L?IS>W;&G\#F^>>G/^<./-I\G_\ .1WY
M:732F.UUN^?0;A:T$@U2)[6%3\IY(V^8S]%F<'_YR>\R?X4_(#\U=6$GI22Z
M%-IL3UH1)JA6P0CW!N01GYT!W]LQZ[=*8RA.778=JY0 Z^&6<8W\=\:/#+&^
M/K3,-^V-Z98;,37*.]:8P^V)'&FO;,IH>74KOOX]L\7_ )QV/Z*_,U[S[,6K
M6]O=\CT+%>#_ /#1X>V1!2.1#7DH(^[)EY*TF#7O-OEG1+H5M=0U*WCN%.P,
M0D#R+]*J1GO?5;RVFFD>1 (D+(8EH"HI\ 7P784\!GF7S/J<FK>89I!=&U@L
MHN,OQ*%;C7TP2^P4$U(/T@],.['RI=:S#8ZA<WSK<NHC*P_O92G4*4:1G'7?
MEQ'<[].J:=Y-T;1XFNM?FM(;.!5:261E/%!4U9O3 4#W8]]N^<@_,3_G)"WT
MZ)_+?Y;VBSU!A?5YEI'Z7;ZK$0@(!W#,*'K0[9S*ZL-'7\O]*\WS_G5#=^;M
M9-V8_*%A#<2:K%-ZR(_UJ0EHE0%I&K(R,R*&B#!Q2>?DIY5\Q>=X];CM]6N&
MO].]-E@NRTD4J$5#DDET*A3T-,Z__A_6M+5+SS5HOHVEW>RV*7-I(DC,;:-)
M)6-L0I,*"1 SCHSJHWZ<:\UW/Z)\RZI; EHUN2ZFG$,L@#CB-MM\]_\ _.%>
MCV6F>4=4\V0VR_6_..K3R/*5JQMX"L$42^"U0MMW/?/I_P"7GB-HTB21F9D'
M&H'*G6E*;=>O4YY-_P"<H?RCL_S:\DZEHJ!8O,=A(]_H5W(=H;M!O%SZB.8?
M _T,.F?%/\L_,US^7?YF:/+K<,EBFFZBVGZI!."'@21C!<*ZM3XD.Y^6?9;2
M+!K(1W0XS6<[\C'&P(7FG$2*=ZFAV/@<.M8MM/N9"+B&&6(%0JR1 A5<4^->
MJUW4TZY&83+9Q1Q6?U,LT@X1/ I- E.:.%%6 8&A&].N&.BV7FW3]5^L)"!;
M,D=85C#JX2M6+4V#]S3^F&S:3JS_ !ZMK2V2S*BS"!XHW8Q,Q#D)&#4JU"!L
M:5.^$&IV6D6B/!HINII7 6:[]$M(R=T1F%?'Z=\YX?+=I&8[VXM76"=".$JL
M95="5/)A7M3ID9_,+2M%\L>6_,?F.YTZ#TM"TBZO$N2BAN:0L(]Z5^V13/)7
M_.&^B/?:7YU\RS)&[7.K6FFQ2S**,+:W:>8*3T/.Y%<]B:C:06S+:MQ6&4\(
MTI\ :0GDHWZFN^$5T6BAG]2D,K)]7V.VYH*]3USS1^=VD0S:?&D#E$MX#<R$
M$GEP+':AH*DD;],\W>4+$WFO:AJ449)AM5O(8XZ@&+BGJ<JT^PHZ#]DYZX_)
MF?5+FQDN+-!ZES(T@C%:_%MRK4;\<]8Z/H]SIB0ZY<59(#Z<A8;E)*J:]JC"
M_P#/3S3_ (9_*NXL.7HWGF$^C$.Y$F[>!^S7IGS<&PZYJ_AFY#-RVZXT&N*!
MOPRQOFQ0&H&**/?;,1O^./!\<L=,U?OS5[]<W?KBE-J],;7?WKOF)'SRC3:A
MPTT+5KG0-;T?7K(TO-$OK>_@-:?O;:594W^:C/U,?XATS_#?^*_4;]#_ *,_
M2WJ4^+ZMZ/K\J5Z\/?/%'_/P_P PG2_R0TS18V_>^:/,MG;NM:5@MH;BY8T[
MTDBC'TY\2U&61U-<KI]/CC6I7Y8W\<<#7KT.8BHQO'&],OKCA^.-*UQM",?7
M;]>8]!B38WQKM[Y5*[TK3&>.<5_-K\LM?\^7'E^[\NP1275BLL%RTC\ (F8,
MC="30UV&<[N_+7F3RLT&G:A'!?.*1!HN43D@;\1)L:=.HKDI\BZK'I_FORQJ
MO+C':ZE!RYU4K5PK!@14$!C49[#\WM>V)OTL>4_*V:1)%/1E).V^XI7W[YQN
M_P!(,FHP^@C6\<Z1,ZTK0(*ECUHSD5WWI0YZ5\FNGEC1OKVH7"& JSN:@<1Q
MJ344Z 5.>1_S)_,'5_S*UM='L99;/R^)ECM[8CX65@?WLH![D54'I\\DUW^1
M.H:CH5A>>7;9=0U;2D9)H5,;/<1, S%*FAD!KL34CIA7H'Y%^:_,FJJ-(\H7
M%O0@3S7H^IVT)4 ?'-*$!V["I]L]R_E=^74GY76EQ87EW;Q>8-==3/<LA*10
M@\!Z:&C47]HD#O09)[_R<VJ7-BM]=-<V>ER/#*'@%N(EG=IF$@ #./5^*K$[
M5Z;9\[/S^D;2OS)\V6T8XBUN46(("*+Z,944/??MMGOK_G$VZU31="LO*M^.
M#Z6PD%/L4G5)UXUKVD!SZF>7GM[G3 TJ!750&HOQU-:U/8;]LA?G>UCEM4N%
M:K1N-TV5B@H01VVSXG?\YB_EK<6?F;5?S,T2!5L;U8GU:.)*!6KZ1NS38[E%
MD/N&/?/6/_.'OYKVWYA_EZGEO49%;S/Y(2.SN(W/[R33S\-K-3N%H8V/B >^
M>T(M'LIY%'I PR?$_0,M!4&-JU!_#"Z?RAZ%PM]9:F0A)51.NQ7<!690":>%
M#C8;;7+&*!H+.TO:\@H@FEB9&_R5=#M_'"N_O/-G.-9O*:7(Y%D+7,'J"O0@
M\J4W^G(TT?G*^:1WT:VM+>&J@R7$1Y4!Z,E0>OR&)VDS*\6GW%LUJ]S1C'(0
MR$;BJMN-N[>^>&_^<WOS'MM"T:T_)GRY<R:GYE\RS6DVHZ?9GUIX(&<?5K0!
M:GU;B;C2/K0?Y0SN?Y+_ )81?EI^5GEGRA=E!YAMHY+W7 !4_I2\)ENE'6JH
MQ$:L.R[8>^8;,QQV\A8UC=6KN*! VY+$5V^G.?/;Q&_FD5W,<A6X9&9F"LOP
M;;$+1?ZTKG+?S+MHYUNI[R8I9W\,>CQA11$^L55S)\/V69AO38T.>5/R_P!*
MN?\ $EUIRLUK)J=O/:HT8 7[ #*A]P.QSW#^2.F'1V33IT9>#!%8^'L.YSV?
MYETR.S\AW)AC7]S"THC04+$"HKW[9\\_^<C_ #PGF3S+I>B6DWJ6?EVSC]2G
M3ZS*@)&W\JT&><^7WY5<V7[=LP.]<4Z=,L-OCJ@_V8]3OBZ^.4QS=O#-7MFK
MXYB2:=LKE08IRZ8SEOE$G-7:IQZMMOTS[\^5/,[^9/\ G FZUN.X8SV_Y2:S
M8&97)?U=*TV[L6;F-^7*U)/>N><?^?ENNE[[\I_+,;T$$&JZG.E=F]5K6&$D
M4[>E)3?OGRW'??'#O0==\H#&DY5,K[\::Y=2?HRJ_3CJ ]Z97RRQTS4]JXP]
MQUR@:YCMB;;]]LW04'3*XGKVR0Z#?_4)T9U 1NO,T!!-.N1_\UM&M-7TN>ZL
ME$%Q&K,91NHV',T\$2K$#<YYOU72_0\O:%YFM5I$UPVFZ@4!^&1CRM9C7J2*
MH3X\<]:Z/JXUWRMY:UI'Y%[;ZK<2)]I)8JI("-]Z]/8]^F%ULJM.;=XUM8!)
M6.3B!+)0@LW4[=-ZU/?#7S!%>ZC86VC)Q'Z5E6U0"H)3K([#LH0$D#J:8<^7
M?R<MK;4A<6)2%Z )/)Q4'<\0Q8,.A\.V>F])\G:]8Z&(-,N;.SNN<;B[DCC=
M2JDA^"!#O0UJ1U\>F=$C\IZYJQC@O]3>UMI()("06A@:*5T=J(H#/4H*'A6E
M=Z8'O],T+RV[QO*TVI7B,BET,EU,2 #Z2_838UJ233<D8$M+6XOWEO[Q&>0T
M*Q(W**'D68?O-A(P!')MUK78TSY)?F/<GS#^?=]87#&6"7S6T;AR&I:VDO(J
M0?\ BN @@Y]+ORJO+2Z\\K?:9&HM=3MK=D$9JA)B1)"O2E60BG;/HGY8O))%
M6,6I=5!268$$?#LM5I]K$/-0NOJ\D"QKZO$\JCX#T- >E=MCGECSCY/'F+ZY
MILUO%-'>Q30".[4-!*) RM%* -UD1F1L^1&M6'YC_P#.(OYH6OFC0+6=-#^M
MO!;27!,MM=6S-\>F7KA11BHHIZM02+N"!]<OR"_YR$_+?\Z;"!_+FL0VWF2=
M0+[RQ?R1Q:E;-2A"1,P]>.IV>*H(^T%.V>Q=/TN62V5;^(PW$6_"0\2HI2G$
MD58BE,(=9TN#3IED64\)"&)Y,I!H2>2JI)/4[?QQ.W\MW3(US<1/J,D:<JK6
M.!5ZK4-4M\NGMG)/._YE>0?(-I?W/G?SOH7E.*15*V]]/%')&O'XECA0M(U3
MV">U,^>OY@?\YIQZOJ#>0_\ G&CRUJOGCSIJI:*WU<V$A$(.Q?3]/(:4T._J
MSB-%^T01DZ_YQN_YQ;O_ ")JJ_G%^;]]'YB_.#4IGO+.S>87<&BSW->=S/<
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M\<.D>3OSKBUG3*+Z%L/-#31E 1QXQZM:LR[]@<G0\H_\_7]1G1;K\Q-(M)(
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MIGICRE9G4_,NLWTT1EA4HL?%B Z!J@5'C7?P[YZY\IV\L9MHXPK<0S2%F6-
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M55T\N>99B6)IQ@T/496&P.Y"&GOACYZMEL?._G*R5%C2TUS4855"&51'<RJ
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M4EUI]MZ#*5K H95+/R8T*J"I(^+<[[YT6Y\V^5KNXEO;72=+BENX>%PS+5>
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M\@"0PX*P;]D;8.M?..L#2M2\NV&E6>EC599;Z>[IZLK5M!% SJX*Q^GZ;-4
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MQ7?HH38>V2K3WL+8S+:W+W=JWPN!N\5%XS,M 37;Y4&_CGEW\^VFU;2=>O\
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ML&#="IJ/O&/KC@?OR\P\.N* >^6#BBL.YKBH;%5."%IB@H#BX>FPZ$8H-_\
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MT=N;A_,-K/)?!$XPJMOZ;Q0VXC"\/4 D95(.Z@&B4!\WB 0ZUJ,6HZ>R^7]
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MN]"U*WN;:M4^%E)^&1.ZG[L[MIVH6^IVD5Y:OSBE&X&Y5NZGW&#P??'@G;%
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ME$C(/A$A""I&]:5SJ7E31[J!9M2T^XBC*:A:31N) _ F&X2H#  \1+N">(+
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M0%A#G;&OEJ%I-!$L=K'+_@S>UL?.!%3A1,F@T_' $2026(>C3(3.=EDKIF&
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MM=+^][M4>^:7JJI566MK)\SJU!5CD5]$=J(9-H" JQOB!X('0^L'G@?M[;^
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M:2*I@S?\I1A=;OI6 (T__8 EUI-V.,Z]YMB,?/7 /J-3?1^C-GEZ*)K7TC&
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MA1!(8=GX8T5(+4JC2,'V$YMXRU'B!P9^7;H1(18XI]PKPKU,]JR[LX5<GO<
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MZ9..)T.7-]-BMZK'JB"E\*$,FA$,'^O@MI7_;+'V/I@*-97^ T&83PI: (J
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M,II>&@#J?XEXJLL)M _$[0^M7]+P>45%<X?,3,>M%DC\+70I'T05"\IJ<N%
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M]K!N4<,41I'0._RC[7'*+FN9!M%$XK''43I$,%5&P2#T7#X,^_$2 .[HJ2&
M;*:(HYCSG(:9H-._#!8%]P'ZE%LR86B'A#?$ON/'IQ4#W>_N:?[[GAJQ/4MC
M5LV6D+RP+$6P7%<12$A2RF[$6S;R,7OX+WRPGBU1TH"/:89KCZR^Z7+IF R6
M:LT;TG76%]XFTPID_[O^AN$+.'KBX#37J> QZL2V"NT:"GO1:3BCZ">6_URF
M2) _QE(^1]ZM%LYU"> 1Z[@$P*'5]C8-!->%YX9.KQTD0=_!Z>\CO^QHE6#L
MA(?M'?)LZ_2-IH,B9%M;,V+8'A6IC2V&@?/<ANNDO +"LYZBI"M2M#F7EO;6
MGEU/NVE"JXUN%-T/X.:;"LQT,3:>\S0Q<!<V93#*473?Z6TI!'H96\8EL]Q[
M"^9!I?%7QUU3O+:2[]7$<&[-UU*>8$W&&\:D2EZ>FDO+!*!@T"CQK3O53YOA
MU$Z3##H;%\14]W-1IO9P/:B\2YKS7\OD5%OPD8'60(8H08S41K\PENZE7.G+
M]><"IT;-[+9RRP*?BO6JR#(3:%T2=X>+"FO@M7=[V"%&J-0>,Y5"G^Y8$LA0
MPU5T\V."JCB#N,U@:QVH9JS\D^*&UL&Y-G\L.V^*]",J5]ZU&@"0^MO>$Z^
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M)RF*U9G_85EV(MIB$..&KZ^I*(U"TJY%V^X-UZTH'CVHG=(<=;Z6S0N/^LH
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M ]#X^GF$5UOMR0^ <Z:S\4[Q \'B^+]TKZ%S?F":2.< >OWO]\%QI4**])<
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M2'SC.OQ1A43*C>=C)6^JLTP/HK\1W-X9HDL.W+LR;(D*':0P,AJ0.#PW1AK
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M'4C7"3$(:PTIO8(P@XO$6U<N<$U]5LVTHBY=DJ7LRRJWENK* [RTU+,P0.U
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M\1OO*^-+T>0,/"F6?!/&QSE,CR*X_)#S//=RI>_VX$)A\J0O\R&M<HQ<J@5
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M+^A57R3"7"+H97]6'F\B#L-+V)CS:X(IMNA"'NX='K)K;B$O%X3'D\8/"O&
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MOSD [^8-\C.D^#64 ]8"%JTB_4KR7>GTYR?PUHR%!^<\NT).OES0W$\B_P)
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M )<!UP W 0. $<!=P 1@%O 4L 1X"7@#^ #X"@0"^8&B0"F@ E 5J T$ :%
M)- :Z C$ +V!@< 08!@P"A@'W -,!68 \X!EP#/ &F SL!-X$S@,' ?. )\!
MGP/? ;]P<7.)<$ES*7/I<)EP(;ELN=RX?+F"N<*XF%Q)7(>XCG.5<)WEJN-J
MY[K)-<(UP?64ZR77!C> 6YA;EEN=VX@;R6W/[<F-YP[E9G'OXT[G+N(^R]W
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M!TGG*BG/M,B+YY="B^:U=>W?;CX$B'!S%D*"6P*P _!D_H#-:2\]:2%>KO\
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MS7]'CP#YNGIBJ_V[HV8UURY5I4CJ'H8H,<7IN60%;YWDBVI"8]$T;U<?WYS
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MOD,C J;M1C%A\\:;1.R:?&B[9":R\EFAW0O[O4^@0+9:O4Z%O1$;(U%(=JV
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M)72M&8B^Z8+\,/N4=<EM5'GEQB=$_*K%%*[MC>>5##-V9.W$!XO+Q1872)L
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M0;J8MA[IE#$S>?@8%#PV4&DL-&+<E09B[?3VA[Z'HC0>P1YP^>5E3*86G9^
MJ? ?O U\Q!)V0B2L??P8)4P2<9R/GG;XKB[&-,JR0>1[G(?6?ZF21/"EW6 3
MFF!J@&M::$;1:,1&JO&#RIY$&0;CZESN:I5-J(>2A)^ !-U0"B_X(2K,%/PS
M>L)QC/(M\,ZAL8NO^I-1&9N[H&<])'D:X+%M7SE&D79^&M07S^>$9/:TKB0=
MTW"YXI2?7SRU(%C-G2YC6GNCE  S0XQ9[6EA<C,3X>VFYS*^.4]'4J/KQ2Z5
M90Q"E1G**.=@)\*97)LD/=+I.*Q3\'>B%CMP2X-*[J3D;ID*T3V\JHL;P=S?
M\AX3Q&/=XTN*A&H9]-L(#FT57D09B=>9:+\1,HX4ZQ::?+E@Z&\,=KOMT.JA
M3Z8/G]0S/S#Y/H@JCQ3=V,H&B8&I>4 K'9IA"A'<L LSAF]O]+_Q]/\=GD(&
M$]Z3U3\8R,['U:]W.:_B^>89Y^ D-KI+%ME'K4]0[G\"L(RUSK? 4D%1USSW
MM05'T*#1M%1?SE"DG7XNO&=KP7T.KYJ =/Y+]V>9:MIB$U[.*)"J&[)9N,5,
M(W6Q1N+0$ ,%J\7$JR,U5;8220J&&6B*61IRA8\V=859E,S[<'&*=VID(CF5
MG_KH&0YOW(WWN.@0?\3[MR#NM#GFN+._O7TH4/F!&D03;%:9QMV4Y,DU[V63
MNYE824._H4*T5M[N6VZGU+Q'(C+ 3N*QJH,DQ36D,U\T=6?=)!3/T]=03M@P
MOKT];E)%0G:8<!V-"CH\;#Y8^0'RB<@SGL(/<YYI_M<=WU@_<TMPDX TM0-+
MPMW)\_!E0HVR-69GDQ#GEU)NI&+Y)M!^@MCAVF'H';B0OX] &AL(,&EW\E/Q
MOG3[4>/O;M=S.P8\(>PH'64>W<[5[Q<<:G@>M$C,(4I$\;PN&LGXS9)V7?.6
MF#4Q32#BQ,+8I NM"28^;E&<8F WT6;5\]&,M9O?^B[O><'??YM,N#QW1HTK
M9;#) 05%D/]:N$@J8S6!SY*S*$J(H7]8'&.P,MTG0T'="<3$' <X)?<%E/]*
MJ/6.W5?\8SM=(_":;*Y0F\PLG++0@#X>#@0_B%A?GT&-GJ_\[#*BEL;%YPIO
MEYEI2A8[3,-@J46%(3 .JWM8;O;9E&_/VYA.7XF:G:YS&.D%YLEEO5J2 &^-
M^"[32 )E/@&/K@&DJ1(Y_E(TC(;)?UD@WA.<-E*7^& R "M-BV13-[0Y$:Y(
MB>QIVY<NF1$XHRW:E.9+#04F.0A02/XM";0F&9/B=[,9/W'$#O%8. B"AU;(
MEX.EC)=A#YBEH*M#>>?_5:[ CCG_^F&^_?*!NIM_4DV@8BU_1O'ABZS\AGSR
M:PNQ"DU7#K%O9\>4[^U@E53NZ'70!/@W9SD(ZT>P<8X/4]Q4D_^"R(9M"7E<
MDTA6KH*++?M)2K"$6TA;1#-OOHDNJ,@>0\5'<B+U*O_+6ZYL_GYBO_!)=^OX
M$3.EX!POS'RL&9R]Q$;?JI=V&(#@%'A-/LI<B:"Q6]3?O4!^X>'H$L0L>JE7
MZ7N"NB1DWO=G$ (]/MJX2Q=E9+H.-M44NX>(T%(N;$&NJQJY+^V$W@LR D<+
MOH[TMN*;88P[*(3<DK@:I5\GG>YX*GJ7M@*6?+2).9_7#2!'$$FIPG<16R16
M Y[AYY?*$9?7+0) &S,#-U8N],K+0D:_K?^R_R;>U<1;Q#U%?9B;GL]H%9MX
M[#I\.P41O&^SG5\3Q.A':&2!.>P,C;B<(<M+_SO]ZUJ 5G>?&+N0],OSWJJX
M]\;HO/<.TH +G#]X+HKD,!OE:WR#[(/[]$LVKFUYJCIW!;(N@81KG\X 8>;/
M$)!2X%:CGU)',<)L5LMO&/M0?D?AV1<_PF-O]6#)R"6I1GM684Y;!*8::1]"
MKILQ/-T.G5@9V4 AH0G!)EGF/F0J9DAX'XD_\>V9T7>J'2YFMR+$F]SY9F;7
MKVC(W+6NAKL'\8>JTCR/!%B$Z"]=#]L&B1)I@BT_'+1\BC5@?[N?S; ?+&84
M[#XJ[JI['.I=#=<U'8]?5+5UU8R,7$0T'DS<02_?)$\I'+LKG,D'!T]2EZ*Z
M69]KG;28 @#H5:[LN&U+<R).FEXT'+6X<YY= I'FC&;\D^Z&)=[=16(;9:<[
M^WR>7Y:BM*R3I5>P'5**OH/RQ.9)R6\A1VAI7IXD".5*AE!#5'XI\L+??55I
M0C[@M\^2YFQ!,S!8VR0UO9K4;,[/OB^.(O>5CE/P<6*/@&UW_Q8\7)>4E7)X
M#<7@"UT9COIHFU)XSAG.CHNZRN?*_"VP 99[$#T4NIR"2P]?K+@^W+#*CFB=
MT!?_PL^'"6?+*@.8YQ'+-XB"/T*!;(HSP.\@3) %USF-BJ+'7[EF1,_H@I54
MG%X=29E@WBQ'B@"!:KM^7R+=QR% V;)'74AL*BTF81.*"7P*E?6"]X'_3Y0)
M:%_)]/,_6EVJ/UBO$E[D#2I8TN=[W^9__)JXX?Q^T, "T^6F7.]6"]IO\WH(
MYW#A3R>7K,^N%I1\I[G&N2N?"KV>C4N2 TTUE.JD>_>#;]"E+/[TLZB9#I'C
M$^DWP&7DEWO)W%J1"^8?,+,UQIU;X)=F$20V#@5C66DZ2!YRSWD>CC9+&N2@
M5RA<[%;EZL=H=36/I+FF1"'3U0'P@3I"7@T\6(,9N(Q@I%"@$O_@[1!UB1*8
M*;90=8P3@H9"";N2Q;)BT<V6 N&+\QH$>I"+CO#MG#$+^*!-TO.]8;S-PH,7
MVF(Q5V W'BSKLN7?<<ZYQ1S*M (\#$^)ZX#DV6]O'=KEE_?+TH1-$X&DV*)H
MJ4'/CIM!\TB/OHI:$QROYM@*!,/D[V'0-^9P\VEI-# C^&N^S^\B4;HMPR91
MZPS4I)-.C!D$[C<W0;FQ[K)'4@?2A4_:E.5?^GHTL40L"]G/<KQ,,6R#>1FG
M7CCQ+0BHOV44\'])61A[Y8OI^<+-@WM:LTRA)%J::C9-D(:FK]T].'(2[6TO
M3NEJ4\#.'(03-U.PR-*_FC'5@P<TLTL>.G)IZRHE</))&*=*L-'F[&GX6:!B
M@@AFI%[ Q@0"C-&=_/2% H2Q;W"-DI5%A*&^>?SA+YC"5Y=I[@4=*6'5NB\I
M&O=Q6EG_J<@N&44T9E://E)2U9QA448J5L+$9U:,VC;_9O83$T>JB'V/%BC'
M@8+.RB&/+I8NI!,PE5W_"1B@[0K(JW" R[(B 2&UZR<?XY&8+K4.,['>;JW2
M35S_<-5,LE=%C^001$^"[J6KI9V0UXG*7-_8'F: WS)0XNO_35T62>LA/D>F
M^(UXRWWO=!*T_3/)O+9W;!2<L0Y)/E'BK8U!J;H7(R,$[1!!*-AD[B9+TS\P
ML@U:9Q\JD5'79P"GT4C0([22R8^B8:Q?,XRO1< >*N#Q#?%C$B6;_7!&?DBC
M[J$A#U&@4J>5N+GJJ%-,R\+F-M!W/%-BX7 /STARC0^!_)9,FL-\\/T1#N)>
M/@3#KFY\P_8[FW)B40>)G3FNE(+F^-D"N7J#8JT2&YZ=J[X\P6\O_%E$(+46
M!2YJ42!<#4:$]LHU@_>O)<L!HI;?\BT?R*7\YE@V:NU8Y@>4%13<V8YB7LC%
MB2%,8]<VT4*%7V)P2Y?FO.H-I*4=.9'1E4Y&:/D%Q$._RTTM4YAX*G YUB3$
MC6UG$8,)YC=HG!T,Y4+ML-"*MLG9(5'^"&6K6'\[7]B[T;B+;^-V):I]&2$(
MOF?VHA_9TVT$QNML[J/KYY*.'=?)!9L7D4^(:<%>1HX"680=6S#-R[IHW37L
M I=(<]D'2)SF,1HXEH4]/RJ^\!$W8JXH\<S.C2QJ11^QC^6B>02:<X(IV/M!
M>V *<>(K6!U1TZ%MQ^YA-_%EE-,'6MC^GW@8;&27I 3#!!NPZIT,$"HYX_'[
M!%\I]?[:,"[R"J4397/V<$)L0WI!3=(H1C4, QX@,4"#.'6DPCN%.;JQSC^
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M=TP,B5.LF#]),#1J")4OKLM&E])Y*IG 6Z2YXB='#,X:M8_8;_.*F&OKH<3
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M8CK\.W4,?'2Y8Q*#9@R+;2498(@/>T+LNYSWB-4U: J>K+#F>6<LD%BY-U_
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MT03G[+"^-3L^]A_=J1X(:G_K&&QHZP0/86_GQVXD@R!/;W@_Q53,3I':ZZ#
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MHT_[!1#UE_V46R=\7Q6W(IN!*"UHZCLI'#6<\D3^ N3@AQ35W(@2?@' 4;\
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MNZ7^T'0*9=OGX1/&4^WQ(8*,GF^%]UMUJF?!S0Y/?H6%H6%)Q4^"@EA(_2^
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MS_-&\@WB$-M1"Z6.4NF@8)5)12)985;)I$2E$\BE<DK2<NDT)B*@JN4*4J
M $B]$*[.:DN-#6+Q/X+<:9'KR,>8T#=Z*DO;G-F:5N61&L]&8C7\6I#(U%W&
M!E/"LM62!9V3IX6;A,_LAX*W!8JS*!($;L13"T0V[M79W&K> H/?^*M@GMZ#
MMN_F+7?-D"O79%YN%(Q:2S^I@1H],/)$NU70CIQY%$]%M(Y8T50([0@<QQGB
M")R]Z(_RG8'I*]NU+V'QV<&AIX)LZ"!TK[]SH$P_>1%H&YES"\[E*K '&'$1
MM3@?O\),D6^+1FX>\<0SX,4#>;:_# =-9#:^595>V :C,=W"6@QGM#SJ0#\
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M'2*VO">^\Z-OY"HZAZ%/VD*^_.$ L&<1+'6&!XV8B6/G+>A:G;>/C*30%)-
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M2HT;G[#ST>O#?Y>00)$PANFFUT4>( *LNVV.K-Q;A)3>>;;IV# #KI[G_!I
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MMI@;W;U6V"J+=K%P2<.#%NQ %4H=@)CXXYP+_9L@DLT\4U%0J?GCJ.6>9QX
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M_:!8]I:9AFZ:FYO[IF?>9]>;OO*0Z:M[>I;BP J,]J66=";QB:H-5[NMV6<
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MR0J1?;_V:PKYD5VV%&[CP[9-;\P:#UU.-H]B5H=2"<-98O*VBMB\XT5J3[A
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M]@;I.149KF':.-9GIAZ[/NK#7]]>PKKW3[>EV.5%=U2<<M7,'FD,],IWC*!
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M]GG7C3/WF78:+RH[$UD W&I>.R80+E]2:NC2 BP_=/F,D?LE7_)"[% &Z\^
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MQUP7,<$'OR)I6H0&0_U?.DM%D1"FHXW7JKA4$"<8E"P5045LA%*;;OA[X>$
MO-3X1@9KB4J<U=+WWE4TREN@K0%JD>'K"!R_=="JG2Y$QKG)(^+_O-OT_RG:
M&,/2B J=N0[=.(RTXZD?OD.:XF^O$<:W1K[?!4::EGT.,7EX8]Q*P/_A)\:-
M,#N/[OOZ<ESM5W("-TU$WMY9.KR,VA0T)-=@HPG;=H#T'8)Y!C"6K<V&801!
M>OGAP6Q_C[\*$///$&\W80D.RM4S8$#'#%=H260?J/H7"><DT%AQHJO+0:X;
MZ+7.Z[]::BX94@WKIAO;UO@.Y^<O(C#+LDH10E>;RNZ\>C"1_J4>FY6+^H;B
M'^GK_D$J$J4_SK.G>USDD[*\;?@E0>3Y2!NW,%:.^8=K_>(L<3"D6S)C5FG8
MG8F/XAD"0>6U*<NYQ-WJ735/2CT[1\FJP82=M5^S0L(.M4%00J,D=D%).983
M6@VOJ&[]B :[TP>[!KT'\)P:FLT0R& I-\_$_ OON<9^[G_JPR6:K4ZU0@/U
M'X@&I*+-KYY.&T(DB(6G@?(]Y%L(]TK@(FJ-$>3Z$^\'\1\% ^9 J'+QYQWZ
M8\9A^/WZF+#/.%?F42JA+$PA+S^W7MML\?.(ZO1Z)M\8^:U6$0\^/.7 :=\"
M&8.+8_JCZ6\,!X S-@$ :2-R73?S,T%F:+(HQK60>>!2CV6G_\ P'<.MR:(F
M)B9W_ >N)ZJ J>-":2^'JGKB'U=<UNH6B1+_B2+-"&9$?+8?W$UQ2)#[4*8"
M6-,.XTOH;EA[Y:=D?86;<KYMCJ<Z@NR_1S#_)='*P$^X?MHOJQC6%A?MB8I@
MJ\[4TM@B@4S=Z,& $Q$4"/Y%%E%6"H(87XH,@Y%0RWB;&:W+T1Y]\PJ4Z0.7
M"_P3>"6L@8O8W&*QW#9FWB'1@U0K:B/^;'P!?ESN9HJ:\>27M8C@]^0?;F0W
MZU\,"2C8(PV03A/YT9]4_^R)  @T&-<1MB_D?HSQI T:8*EL8>-:6O$00MC<
M=QJ!G&)^+##,>Q$3M4S*.AB:I""[]]DV=A)$WQ[MZ>E"/]($@23(4%PR?X[>
M/A=$XWC;+%N+1O-Y>JP7AN)L:+"AG:91/4<#U;&5E95!C+-9*+M .W4Y'6VS
MV6UU,R@^(@WXSV2L)_WU^1GS:[UO'RY56[U7$T<UO<72"-)\-ZVE?US\81"F
M\%_:&?#Q<W2752@H:0F<TD" YD@21@>]2#EV,;1T=3>J)R,&E:5(#&0+I"P0
M%?%2''<E+$>6XUTV6UC5'^)D[\;>V*FF3H]SH&3UL55&#,:_'62QTO-%5:-0
M52 IN7U@*V&%B=[+0J@ZU9BA\ZR-'GYVB/^VQ)=^+5&SN9HW:9\^:"5#D4GG
MG:QMOWH-=US4_MI]%=B2\W>)Y_GB!<LMY<J0J'KX4DT*#@@Z=-5S515+F,I;
M--U9+-UQ'Q&->@[(7G@ HR4O["IC93-#Q:JJX1Z;M:%Z45^5MKLEXFWTJ\97
M(@Y-:=%,<1\KA12I.2Q&B[IM'?D![1'7HTTV#_Q++D^=GEQ]WU&?_U_^&?BM
M"NO)]U$+QZ%O1/MM^OAOI*MD2?#R2+_JS+FB\531_6Z"&#>\RC(N$(XR7)XG
MML*FE7!SSS":F/3G\W4,60_!2AO8("M6OB8Q%SV+IP20LNFYY"QZ+G9?]B!L
MR%!H4+_H[G+HLAA$.0G7"I=@-U/2P;*0W'15S40D-%V+Q:N!J,;8XQO;>V3S
M)FG^8N*3?[A^[!'O#$C?*/XG#5B(/L-3.?@Y*,2<VRAV<''=X0O5ITUM1K/I
M^G5XOS"L4\/IHC4%.AOIM*<1)N2TL]JP16:S>O 4/_BCJA;)K  L'4VIYRUK
MN=Q2C:8GKLS0&+!!)J107PH.*>DOZ%Z<_L.5L]1=4F&P;=]ECNW,AI#4>7GY
MX%0;8J24CL.^%%A*"L6)T1^:FR'I7V*F2ZJ<NO<H:<WZ=IF?^-*#S!\1G5!
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M1A==[_OJ'0\=G9A7<2>!IZ#;GZF"P&2.%*.S.$V06Z0F58N5S"SW_\ON4'Q
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MBM!FVLA;P]Y/P4VO9WWGH@,[C$P^J4L4(*(? 2^.Z'=> [D_1_C<_O;6+V1
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M:X0&)G"6GW*EVC%=>P42&*OV6UB)5>-!1<YS6H\STJF525('ZB#&V1:V?2B
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M#6)')$M>S3V=L2<MW7.B4BU=?X()3 35-LED1&7O38LYJTNQK[&0RB7_E$<
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MMR 4;.<7E7F>A4\Z]: 4I_5(H(!?S4X/""E"P!IW#?V0<%EQD\ $SNM''&W
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MH:*Q>>"Y\8)WZ>TJ6PMI50QE\C[,1":9C)</'NJ?L+&%"I"$2XY CEEE5/S
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M@!(Y@%/O]US=MWY0M!0X[9I9 TP\'X,_-W*='I_!M10>PS>WTC^^)I?(R=I
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ML=!$0]7/WG0S?P/_!OX-_!OX-_!OX/\=$'5=$?6F671+EN'9>V]U&5^/EGA
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MWQ+QYY\OG2:CXW;<8HGD':HEXTC#]S:LD.-_FK&$XE&C0I^+DT[7?8@_U,+
M*%<.3ME (W(94C<@8/C/ ,+4FZI1Z"3::.?T)+&I;FP8IV%8><4978V-<M*@
M&15&S@JKE45ELK#]\G-I^O.N:!-X2JQ5'%1+Y1T,H[GS+G@.HCA@9H7RGK*R
M,M,S4SLZ:D07YA;"51(+"Q,*D%LX6DB(AV34:[3*^A/)1*.919CF99&%-,#L
M81^::CP0_<-NU?!^_FY,)P,[J#3)9%Z[KT8H,VN-<<<<0VZJ9J!EC)\%E9)E
M7SR(EEY:%&Z3A@79Q:'4_L&K]3$$B?S:R2YS.?+J)^ L^&(K8/OA_&'1&9L@
M> _6X=I#='N4^&']"7C8/NVHB7K<?N(ES#4*T)T!>@VEVA^"##Y3<1VT(25=
MNY &2=4+?$URD]E[3,V/.PRVF^/,A8AJ[AS-[N0NABEY=*)!K^"M6*3.CWE
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M.9CPITHL.BGZN%_Q&64;#J0C"1[1J,=?$]+$E*<H%'=#D2<\P8%^A:$0^02
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MU-#GIH/"R3F3;"L72127TZB3%M6.&5?NRJIV&(24:8(QK>(2/!R?Y'8J&_K
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M;K2]2:S[)#90V:[KI149M6#\@Q:@K\(21IA\/4$I"99MUD'M\FYJZC7(E;S
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MGL-98[/T%;"B^]]U'A=VI6+O*)\] CJ+@F1?,*T2"&*]*!T,V5C@EE][(DA
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M[0Q:\3&N$RHU+C@5^DS"I8P>2;PC[HIN7IJC=PK)(C@MH-0&364U*E]D]7.
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M:'XN),=0Q5(OI?8WUZD-.B$H#V\:H?W,?U6^B74>[\0R3)(0:LO)^&%6H):
MI6RDNOCCG1T9$F7 &$X-N4=KDB<?!O_(CASW&"+;CNS@;=#>7Z'2XQ!-Q6YC
M8&\"';,AY,::SXN;I.]-AG'4L@-%>,E>E!(?G8BY2BBRA/%FF+@1)@*R]S(X
MXA0EA)42$#0S*ZEU9\[RQF:>(]ZW$SQX?'.@%/&&%1-V\@/A;F_FVVO8LAAF
MB]VS!#[Y'))N_LS/NQ@\LW;R<A;L),JNIKA7A\)M.3B4>5XE_%GV1G!+L';Z
MP$3+S3Q\N>K7P]XU9G'X'!QT2XS1+$&N%>,QWVGE8D9/#A5G\(I0U=^_2_\
M"'.G!MFD;7E-$X&C[['$:7B)F?$CH#1P8$1>H@$;H-7@9PX@(B+=NP;WB))X
M4-8 *='4:?.JIZBSQ>8.'T(_PST$S*#.KA]-J1KG2YJ#[4AK+;6+5V0@S+!Z
M:H;UE(9.>Q6*1XPW -W_M&?*>GF0Y@L/2DN63D10I[/1/)ID8M<JP%Z@ .NJ
MWM?D\4/&MG)4,[4RZ&"<H'0XTH/705$2,*L2G\92OMG<$-"Y=Z2Q;H4_<*00
M'?AV1V8$[^/AB,I@,TK_7$3#G$GO))%0(;DD9PN76,,VO>',B'://<S42"&X
MA!NEDHR0QU4_'%CN4M=.%'R5$D)_3[8)CXO_W&*UJ\ZZDI;KOC<]'C*'+%DI
MW37J^KLLU"X,MWOC_>:-*_!6N.(D\_LK%OFO@U^K\0'F4X.7?[C  W3C_:]>
M?Z5F]A@V/L"W^/BGTY'.9:?2(1QS).DPKNT0D]=2C#Z2IK_,1*934[YTX'-K
M9?K:7$('-,+&OFK"(\U16G5QQ=CRGX--,EU$_T>1[M \IMFPY$6-/>Z9*5>S
M+8]F(DLRANH=1)"+QBXX>$-CD%6'W.KB=B%MP.'DC;A*5#4",UXR!J&$HUZ>
M!_C4_U_,O4.0)EP4+/B5;=NV;9M=MNTNJ\NV;>LKV[9MVUVNZO>_F7B;6<R\
MV4S,[MZ[.Q%Y3F;&/1&)+AVF/&ADY^)3JUA0'8'54V,,E4(,+Y2%$O;2)W'C
MHZR&=21X>I6\$[7!S82"W:7IM-IP)6CAT\_D=6>6NC/YBRR+C5YY]818=6&7
MG!8O4TY>63^9JS"223F3N!\#5CW/TH6>Q+_C4%&9!:LR.T[=M^):$64#?XUD
ME2'T%U26T?H5^>_2-LSB$1]<5>KN$/H,)$/1GA'R!D;:J8[:J5O0E/"JLKUW
M8HCX0AL[Y[_^@A5.#L(]8EQ8,KG:<SJQO,59.7?49G9=T=;E:2R%ANYK%#2?
M)G5@?!"06$O+V+5.;P+&-^,Q1^%Z>^(970+,+E A"N;NC&LT(PUR+&&_:?03
M:QCW^9.6UXN&F;7T1>"+QGQ^3]&+0(]<6CMNG/4JMNL8KUVW1#>(3\R,L:/4
MOUL*EIGHAQSRO*W5>&OZ!4B1!9Y(JO01:AU=X$$6\>^3[F"2HF""M-Y$(<ZD
MOAW_=3G#-TUHF-4\?HKGR6.=;)B@%,P?WF9Y5N#E01?5FZ^-$IYW:=WE4NXH
MO)N)E@>H4_"'RHSX8,N$9B#'#:"_VZSH%1?K23K95ODD4X7* WM1]J1#3*W,
MD#6IPK_$&QGM@FD$A]%@!BVQPOL8A-="]?-0]6@WEY!1D$NPH/M1)9EWZ[3X
MS2P8DS(YT*D]K9RP$J>DB-&H@?,/"<63XE]40(:>H\%06#I7A[*S &-])-W:
M#TT%R""]WV_QGS1Z_9X>45\+7W_MVJ:EXEY^J)ZL3WP1UO_Z&%;>&AC=[3A^
M5QX*/-5>_[;B?#JP?B^3&L['=X"OEC&(%<S9MT"+)S9FANB2*(!?"#\610:G
MTSI=&PVEF48Z#1D,M=U<:[D1D2/,2V')B6XW*"D;BI,@"9OM()B@5E#>;(?%
MRR=C]2UNCISF 4L""]$^S]E,UY,@%$EO".2#!WVQ]T8D@G'VF;U#@6_<UA^Y
MG;3!7+PDMJAG&V<$VUJOB:-)))LJQ61OLPA1<CK,5&6@/&0.7B4ZDW23725N
M;)Z)" .ZN XN<]N?2/J-+R'.FMH']9M=Q6U>".HRP=L9\)DE>)5AXJ"FJK8N
MQSE;^J_81T ;$M=3JY.!OKK(=:(N)_7(P$Y=0BS-V^"-\GTR4O[E<-4.;P1+
MDMX5GE[PM4UT#L9]LI,N2TR!?Y!).LI01ZK*'?&67MXA!992BPH.)]7H&U1)
M8-$S$N5VMT .=8O=76T_/(#1:H>UFG7+X3*8#$>J"\RZ;#N["T6PM*!6'$KN
M]Z@-O<&CD*];;-!0X1EM4T2]P$)-)X3G^)V7VL;WEJA&>O?8#"PA4ZG+A!!8
M3$>W:WV2L.2ZS("8 FVT*6!F&+\)0.G=>^I]#-;:[:G&X-#P;>-S"2SBV#B8
MV<J68SUX^-3(7#C+EL^8AA>X,$:30F'(*:A'ZF!G^ _ .3O"<5FB2T3_(WF*
MRG)4I>KZ%/$S7&VIVJ,G9/R88$G460U9"P8:T& U3+IURS3A.UMXD99KO+VB
M;W2"[)6NKSW<D9]& OOO(8L/>(E+9TX"^_9]X9@'LST7X^PN4BZ!R.<D")@V
M4_HU9"D&3N4:+&EU]X?BX]PO,(S.&PUM'YUOQ82P7? 7@4C]O:9K/F9W@GA-
MX+5WZ_4G8_FRNY]B7+T4<.$]!7?-Q6,R[*O),80NJI?FWIT^UQYLE(B)Z_BZ
M,E<O6@YF;/ZWS2_,C(PCV4A\?=0Q=IAQQ4*3%3)7B.ONE(FM>+X6]L UOMP:
MBDN0>)M1GLF<K!O%0C,!UU^-;TZG^#A!AS<T%!F?=+S,DX/]+>2!WG,P_K<Q
ML<+N\LTBV1TIQI.=<(U)WL'T3$(KD,OK'T]#8F1;+E!AEG$J3E=J76)5[+<(
M<;5QL-FH3 [.PC5-28S"'21#U(<*@&AVH![I_]PD#+9EE:'@H:!25#%#%C$B
M#X(!R)(GR2($:DM@PH%#I&F!V8)SMM3:ZA8MXV9_6)K;W?-+38<<BEH/-XCQ
M,&]$ZAY,1."60K"-F3(@WEHD9/0MH>/KD)NVPR&MP&NTU%[O!D,8(WS\Q7M"
M(DP\\^<]W'0LW0PE258PULHF/EV1*<.!-Q])J90N??]L-IGV^Q!/'6%R_6;$
MS"R!E;^^5BV*8K$?*G4JCO=PQ?*.X=JD&;?0'\49LQDI4-'4BTRZ_V33!2>5
MCM3KTZJ'[J#&>9#$D#3-9F<]7Z#F?'@^A3;;76.^^ZH(]K#YWU;RCR#U!@SE
M*; 04$YC^?]I0,A_ 'PRH8.27TM_D781//J?_!#/T S_(CIF&MZ:7Y'0_P-L
M+>\]Z0;HLW8G<[A?-L/"3I^ZOE?PP/W(;"2_DAZ(G**-2J%UF*90.YS0#J%!
MOER'UF1DL244MF_8.LVRL4X1[1K BD%)/YL&D:.41F60,09*EMSCJ\25%Y-O
M)>2,P,K ?3QW/4$7ZY<;'<[9;F-(&"UZ)2\2N/FDE.&QQNAFY!FN$E$/-C9B
MI:2*R<E_*)?*G/.-!-K \(13,I,VQ88D</\#Z!B5];GMID!X8ND2Z(*;D4C$
ML)Z]&945C</8"X+*06LJ[ 4.8Z\L_P8S?C$AJ_?9JIQ'K<>RMJQ4<VHVP4$/
M<G$>FYY2;'IIXQ+>,+$R<2ZA23G \05G?C(:XQUK_P=H#N*]G\'E'TWUVQAN
MTTB]F(:(9U A< I)/F +UDNL8-F5:Q&S=_6O,E_?G3>6UX\_6Q\"'&>J7YK'
M+W07SB#(NW1\Z5C&.E^ET)^9H4*<CFKJ#++(EJU0HCE%4NF1U-9CZ1[P[._Q
M/\;6:VO]A7\\.+ ;B",=YROJ:J/9LD,__]H()0@"FT!FP/0!^YP(5%LPHI,M
M9>XG"9'X&W3DAY=E4"B3S3"N?E(CNU+'S7L70; CAYL:EF-<F^R[0"YO,Q4C
MRB,S&-^&WMZ;#.'#0]61"\H-"O-]B7/6W4-F_7NQ5MB#XM7%LH:"/$,A4Y%F
MO-8Y?F("UXU36I4EQ_B]YQMG@*<4>LBVF9([':V?+BNB>*CTP[T=FT\;&>@"
MT@7\.[OUFU>V4R26I7L][JL/C'-\FG^HS.6*.U*G!6=6+^0!UWP6(SZ^1(,5
MH25'016]$)L'[TPS43Y_$BT=:]LDGN @$\Q=3R%P*.7D0:L[2I=U @8T)]*V
M.*GRD[Z5#/V/.$:YCHQ -.T9V1(%BS0\]BP)C8AB;R&#[/&6(2EO*<MQM#M)
ME]4WN_<4 O9[$OFLC<:7C:V:(K<*,TOEC#P>448I?'J+/4P_0P>WN GJ-#,7
M=J<=%MV$TF?QIND7T872"Y =M7CQI/PC.[F]/N98+[-&YSVQ$>S'<BJ"L!SM
MFBONU.5,\@5J$(6EM29Q@JS.X8RSB9+96#;OS)WF4XT1$':*> C/,>O!HTM3
MRB<%=J0;IR7)/=K$R1U&&T^?QQ@\FC-KZIQ/*IN-9S*MANI'=KHI@&,>7V^+
MG<(@7,LLSPT31<$B(X]RH)%S>M'&ACTF>?A>G73S-L8'@<S&,X";S>Q+$DN-
M=]2T 6Y*1BM"*7T:CF6*Z78K;W?@(FZD0HX,+CJ0IAU$W/ <NG1/4-+>Y,+]
MYRAWC5&Z$8>^LZL=1].<-(%[J,8:G] CR:C#VTF=6UL&^$A!XI30,":O5["(
M6J2QX8Q=X%<9!E6%'+;2H88W\E]YXV]!+@DC]SG58!FF7D&HXLH(NI@Y8SFF
MJ."A\(_J26#HS9WX@&WS##R#GW$)1Y.#F!8F7=)-G]JW<*V")_A@_M #Z4QD
MSYAT&NXQ@C-9,H;+E:SA]><CU*C!XDNY.(X*FA:"<3L%'Q)I:84;A8999G*%
M_W-(L<(K?6Y[?#W/7<%4\ F _A$I/*/L4$M4Z#U[2!V+\7,<Z[)X&IH5,!/W
ME:.1+:;G3LUG.,-^:MP0KSR^(+0<&&T?QYUQ<Q!-Q(5*H*;9)')5H#Z$9@>%
MCITZ>JVDHCF:IFKWJ1U+:S&R.L/?^)5N<HA3#J9DS,C&;1IXW# \1#)2"'EJ
M,8%6(N*;F1FK>M_:%"KJTX9>,C0I*W-8T!F@RN@5;D]4KE]L^O!^((B7H_>7
MCKH!<E1K2(4TLY>U5[_4L0$%]732>Z!$0WD0#495)#2&!-G1%G).RT2P/Q[\
ML+U34C($F.0L3I&0<>F^+,Z"/F,5;</'GC:O0N((9NG69[YSK1]U_5->O?)"
MS<'SW%E^[<F_TUK2RBVCZ\[GA+NYZ!Y><7L!N_8EMTZN9"IIW6.PO !77/:*
M/.9L^#]U!.K9(K\SY?U0M+!V:0;[>[4@:@$ 6Y(4$7U_!81Z/^RU0U(ON)\/
M7!_K$I[K:VKS&?L[^?O..N"C:LG_IN@99R_@37]/H7>S)C+_/IQ'UZ/T;=4B
M"C4U7)]%E7_2#1?1S0"!(*J;UHJ5K,VS,NA4CE [WD-M'5C2DU+'5N\:OLK=
M#V1D>BX7/ \#33]DB-ZM&1BGWY3*('KD,["8,9N!3I4TJ;OO#L 6B]$=X)UZ
MK]Q]>+'T##I3K=.M<MLY.?^I$D9JYKXO$:0,V.4[*_\'^+V>_0_09E1PK1<6
MT(,W2'6/ OP'.+TSIN;L*%B[2V(D:@MWYY2^W@KT*MV<00W$@XP: 0EB?I3O
M=.,N3P/AV9DT0!E\:4)J?,N)FHH&OC0)Q/Z,(>D=^<556!#0'87;L+^JOAPA
M6/R(-%F2N4ZOX:5O$4VQ)5A2Z^T/&L82%%4:UXP>P^]EJV.NWS_^Q]<X=,A)
M:!"+I*$!U07%_P"R+U$/Y0W;[ET3C3]%5_[6&^V2CA-:_P"\>+D/;E)TT\55
MR=RE[B%%K"S)FX8#T [=,CINQZ_DD7"JE;BS#6$%L#7(EVK?#@-9:)?U\Q66
M1"@O,1K91O?=,U.6#8J,UTD#6EKZIAW6NL"A*/+V+!*45PMN-M-[;;2T5%()
MNXET*N+>QU^C>./*-O5S77QR_P"4>3GN'JNM9V6AGTV)D7JKUY%LT2Z+]B2K
M;/2JS72P/*Q!U__9,)6PEXN6^G\ "/"#OY1<Q*X'9+Z1SI*9UC('V!O#0<LI
M8$&R+]-7T5AM-;1#+1]1*C6*8'($/0DQG#T5%',HL0HQ7[^<ZQ(+.\!4Q9J%
M5'<4Y+=C>=%/.WKW(\BVMB)#RNB+1GL.3@9$6Z0,UEA$BZ?9IR(&(C1A(9[G
MCST%.VV$6+0Q-0HR;JGZLY^:,F'.P;>#4!K$G'\XX[KY8QE2<&4@(.C]V9%!
MA[#%YI7M?;:>K&A-HWS_7 I9R#3^!X82/<^K/.<8%^UT@R??8&K+B2\*^%@O
MELP\,4N;F)&L[=8G4!D\XD3+\'07/+N.M%5EB4$74_ $,X.#'#=-.A>6TMU"
M:4&]$S"MA]FB]L<KU 3C5)5M"=KH<1;^?++!K'T:X\71DH6OG9S1+19=3@MS
M6QV=="=<#M0E]<!H;84[IY:;4LE$RVJEV+J75-:ZJS%.3:WL;F25[QUM./<N
MH+J4#8H[K<R5817S,[0 UWD/>.I?2;J1BW:E+587E>M2>B?=L$53U.T0+;U4
M<X"%%NN+*NG+?P*KL <B%BVQ?#V^ZCYI=7ONVH= Q(K?M2B+R_FN2.&=<NHF
M4=FZKH$T7WM9 R^W+-(I!3]2(4?*T4CN^@WLTW9KO2.7'8WV_ZKV$)@%%#P=
M?C?DQ-]KA@#3[-.NW/[#B%(K*PW:[+TP/P[+2#PC8N>[6>/;.=GC.ME\SI8#
MW'87I:<#UV5/<+!(ZB%AZMAUOE"$T*/V%.&A"T.<4;PT47%[E'>=#Y8)AXXR
M-X0)5?C$KO<<$@4'K[:*>:Z%+K"NT7^[H:IEKF$2*7C9:2+>V$?AXC+.##-C
MVU'>Q*?$AU+>1/E/91=. ZF)_QHX]T;I3=T)YGH0^@J:[(_,Q<<?2349&P#S
M>I?.,A['+=3T/\!V::.A&U+@U]C7J#E3;CS;F^$?+Z@)1T'+!R3<?X 9_?Q0
M]UR#O4L^Q?HO 71<FOV[_\0@D 'H;WDG"',V9IC=N]=VW9W[ZF0R^[W]Z;CX
MV38+%??\8ECZLN.?7WTU;_\G[*\W6F<.CFUOU3$?>'NK\Y&I/O%8^W8@#2?_
M?9MA@:Q)X[$XCFV::0ZG1B):E1SL&I*7I/Z=0Q2"V'J'[ Q*+WPI/E\EZF,'
MB_5&WPCC&(!$8FGRQXX<]1<"EEL[J#$E]F@4M>B7F<I(VJ^IEH4\YO@:,D@\
MU]F3C/(_@GAR/F*8O*Z(B_P(,'&41C;JD&HN%BK)XT?W^]SUKJA@_>/XV=E4
M><3G#= SMW^<^?<I"?I1'=#GXBGR:FM_1A;XGR(?F8@V,6(?C_TI4H'!?$NB
MVO05VQ[4EBSJVJA)>4#_#? _,MCHQ3Z:AP#Q[B:,-$ HPK6/-<B\ &?,.RI'
M^=>A).O6%GX\C91[LC'.H^ZU-JT;BF9WQ%8,$=[IG7/9L9V*FS3VSK'T' ^-
M>"L7IHXQ)G(I,0E0& [L.;V1C?.^)01_*TL7F4?:Q=_/X&<_$E2].A^+=(K5
MW<V6$"-!Q;*C6GIQ-Y=&$I\DIGD84\O1"$#28!2G!PG^4X0($L\O0AR,.$,3
MS7V@U1A6,+^=- X2W"Y,%L,C8P3-X-\R;&1OZQ:U0V+W=1/ MD=*-)'E\6W-
M -GE&YG-QK0P4B,<M;%Z0[4_@T5'O-.<B"MLG)8BJD1[1P8-27YC\)LB:XU(
MVOXW%CE6GW"];=BF#M(3TRNJC>/VS;X0JY#K+M5[Z^->N*=E6G?:PD[G+L9W
M^&%/O>&PT$M]A/M.VT6/-RS\7Q=^KC%V6YGC>EC0V#2N2?=6(0$FMG62GM)Z
ME.NHEBEUQ&\0^B1HQM?V4!_=?X!X$2#F.C][P0I!@K?>^79D1FW E"V"NT8+
MJ\7@(DZ\X3"$)!/W/ 6H<8A[3[CS.E?+S?4G.VZST][/A87?C_QV5H#U?T9^
M9:3L8M3S[AEH3#"1)HDYH^M4QC9Y2VU\C@52L2%?I]NN340D0G;6%4M[Q<;%
M-W-2>TRG;78IF4@3AH^JB$RO'(QP-&%9;1L =%/B/_2-'GL)-?7M((HTMS.:
M?9Y/DZ/E(IC$F?Z%*5Y27F/8*D*L*@E!O;OR%HC"1#]B'D@BYD.X*>P>(,,G
M*!XKXJ408][6RD.H&O>(P6XYX0@TJYR7,'@DLQ7(_K]%!WSL!9B)J=BHOYZ?
M^/1R[,.GNZL74SR-;F+Y;V^*/)[82"N:C>$D8>!P:V-J%OH MRD0A-T=2F.P
M3]I>6[A@><]M!V_5N\W3QU*V)A71;M.U82HW$95Q_N4X;CW='=:>QTALR>Q
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MCHQ/O%.%0Q,UV<I4=H$,64:@87#)3H!Q4-IB4]] 9=YKD-:Z!83UTY, A $
MS@8 \CK/G9SA3^7CU$^+_.L/0KRR<8 B<NG!L.]%-!&(=O+\G<4(++(.7-!4
M.%.SA9CG/,KV J"+#FW.U.1CL,'[FX"KI8)F*4@/[1)T\D/$LI?Y'7%1GB@$
MS=SKP]J?=AQ(+;=K$&?V4"-KNOF55>N?<AI^A'\<JS]AZK0FC1%W R:/.BAC
M!$,1>FS5A^:[,=IA,/ 5]2C2JN.1-S[Z%DUZH$W:+9PY2960NZ^*G7/Z@ E@
M'OG-!BEF1K/12%^0>DIXVM2#FD$&-&5KHHY":#[GR/[K&,#ZH_6#TX!U^\X
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M@.Q,''WF<,;DMA%25%Q;3%IO2M6C79RN3V6^2]A\3LY,Q&^0DM/:CO\]25Z
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M+46Q<J4[/0 <A#DNC?G7YC(^?^XX.+&VQJW+]4['>(6/1RXK_YQ5:$6PN-5
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MB -6Q:Y#^\8E@C<%/VM#=V"^)T1"MOJ\Z\!T([\3(<-8WS\UH[@3/?$3(B^
MKLR)3P4NW7F)2N<V)X3FO=9/G343>/?_@(FR4?]5X^N%5H_0/AL]"HX5\_H9
M_&^M,@UO>6>B+)$V^&XFYGRHI@BP3LS5UXR]C#G"\9F?%Y-*H+[R,#KK>/U[
M$('_F+#_[>U_G+?F[O34W)()HSQLL#U4*J;77!>, J%-,&H';:F&JUC#K^U_
MP'HD0B]N,%1"M859=6YT"04KO7/\\0=O0^9\Y_>/!4:6?JZBQ&'[K4:BT.U2
M%T(W^ANW[+;R^BC?<KYPA1Y^*7@L'I[TBJX<K"7!97RN0R96[U421C)^&;0"
M6#O?Y1_8_+*#&4,0NI"(3/L;\C?D;\C?D/_JD*H?4:T=",9QGXVY4C$N"%!:
M_%?R68N]CWROP\"& K^O*%1JWF<%.BFR!62W@<A4-NVGEDZ.<#N.J?8"FVN-
M^\?R]?\%(ODWY&_(_U%(^ENEL($;L#GC292ZJWQ#=%*_UC(H-F&54PI,;@@-
M%_W-D<#PJ>U&(K09IF%1N"W4SJ-NX\'P&3"XC*(TNN1D;!"0&_C83?L1J/%O
M)H9AXC)C+EF B";O-H&?$0URA7'$6?T;LV&_T]<^R]9Y^GN:7D0LWFE$%E6P
MUHU2<(>?%O^ O2.IC*$H&EV"Q /E+WXO"GWN) Z^LVSP_4[QKA_Z2!HC:<_\
M [9N&\#J:_H'S(H?XTW+Z"GYYOHR &4C #CWD#KJB7,4P?K9VO][6/TV= GG
MG6^^<+'[#UAK8J"7V:^ J2?EP+(>3J8]\V"VZ/AVO!AD9\3L,%FX;TS)F&DK
MQ>X*[N75G.UB66HNA<;KIK!.SA'/@#J_-1V T^_,^Y;S0_4E ))C@?N&O[KC
M64-NR=Z77;JH?$+):2D;C/.I^-HU+TWW;#/J4,NX ,?S)?6<UE\S-A^9/V1*
M1A+IWH+#JF)KEQ/88TF\.C1''+"]<1V1YP,FZ@7Y"38_A;A >$'*@/O2N;W=
MS+'$?9'\@,A3$G[!S\\S?^O?&*]KIP'!?SO^9SD*Y'G1^X:*1VU1+#NRQ3$
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MFP>7SZ/$&Y5^W[+?R?C^6B7)8Z%_3H2]_5*@?9\9YEE < !8ZW]!B?^=OBM
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MR8Y2NHYURC_K-./=H\^&+#W'5Z^; A?=Q"EWX"*2R2AY>:J :1--N]+)"*D
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ML_3&[77UVK7& _G-.DW<X?@99N1D-<.4)$#2=C!%@*>5>6ST,43*K&)<;J<
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M5^1'-CU+VB[H_9$O__!#\!;&/)I/HM2)]T'[A47>52_T89?S87:]YI4*Q8-
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M=B7=,74*S@SV;&!7?)Y09YQXR6J7AW7V0<F%4H)G>E7I5EJ3 G'"D]Q,,.1
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M1H-5!NS%S)),EV#\;[PT-$[>G<H^'69"*F_X4*]#I=<9?4]_V.H +*NMW"3
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M24^L(ZL'&4>[.8*#*-K%^N=*Y$/&(KRU5D=9"2EZHI;G+F@D-FWC>RV"T4"
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MB; =_'/<!^R;<*\-46.)EH3*+-98!-4IWO)$#E@IFR !Y%:U7V\V$0S=;>Z
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M88)*X- \XUSE.N,T?IEZ#:45=XA 3S&&'+V4LB]&:5848Q*@!%!K#G"BCC4
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M WLFT>0),9ZTX7D]K+D%T>.*)8V=NFOQY<NZ26^ EY/%H*Z4/]&6'%5,UM,
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M$14XLSI1?JRH0F<]PZ@TC8^(,]XSX);[6ODB$',^X#.:DTDS3,$9FN^]=$3
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MJ$67ALV= ]\]D6VD$H/*>;WI02,1(%6Y])K+,=70:W679 SABQ>IK0V\_8X
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MQFVCW0K"/1JJ=[,J>?7K^RK:*J;@D?8##/'&7LN5?>(@!DCE<OWGY2LLF8'
MM[4DE=[.[Y4@P9XW.*+,JX(]X>D6\LB67,MVC/0''D?KV5TQ5&<TM]11[D^3
MYLAQ?;P/AKPZ.*5F858H \'/+3&#6/V>KXV  [02(=%\#-])@YV51!1&G8)]
M14.O^(A/>V119-U-J^+A&5VH<RS+Y(9'TV-.OC$%7J^(F'<>!C^PQ5@C4^([
MW3??_\(T:W,,[IFF76(?[=PRR [@8*3KF"SVUR3*#SV<_?K3/]'EU^Y$#B)D
M04B%"Z(_7:)GX'CS&$1%U=MI%&H+';V; )L]2U<(U33A.";J6<IDTF7$3GFQ
MI[S[2:7V=O"BPGY?1@Q.ZB7,D]Y'^;1C1GH%8_3,"38O74</GUN+.;Y2%KJ9
M[@5&T@?LL:2?\/3K_5IZS*:DO]#,/*5^08DPN#!.S)2@$@UA48Z!EL$4C0N
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M$:&LB9P4P083D%K<=,Q2G*7!$O,X>DM34X.UGU717T;(&F-_N; DZQ3QW4H
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MHY82D\&)SB;0*ATL*OR^QNF$<N05#.P(_X%,5/ TPX#*@9UO:_NB=V&XAU5
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MOWP=-_(@!XU*EI2L_;;'+*K8C$+<BA2%.F/]!M<:C,/X9 JT*IITDDQ0H)2
MEPM,39HBRP(Q99G@JU!PVQ.]JH=JL!OQ,G.IEARX$LD]?6'7*!GOJDB-!GL
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M@"U4(KW];,=J$&$'AY?T5\4Y&BGK#T3TVL)-;^,5YO3QOUOHGPO_E8?] __
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M,&6F?.!/\@0[#)N-4L+1'><F-MLL0(+PC'Q:KG#KP/SV\DX47J"Y1AA<_Y@
MN0E900X9*/D?NEK'KJ^W0/QG\+M+U(6/_S(6M,K"+>7M9[%CYY0FFF3+,A6&
MY/*\FXFO60O[P6R$1/8NX;:35QJKI8+3E+LF9:X!WIU]?$&>_'+EZQR?HU$H
MN9>NLUA;:*B[I:V/3PFI<WL6M[1B4HC9C6R29,+8"J99FC*Z02AT56I97?0R
MCN!"]=H)X5)OT[C:L-H(PDCGW[,PX\*[Y9(6-.2M0$P8RRPH"8Z9Q&?&6LY7
M0SA,"9AFSNY/8Y3D@8AI$S<'")>RNJO!QAZK/BQ/,2!<XV!XD:9A/WRXPQ6<
M37D">5%3$J9*OF&Q52YQRJN6G@7]FDG5*!)JCX3#E9^U$^*ZWRZXU6#4Z;$B
M*@K_)M$+T02%/*1ZO@(F/^ BKC@[00IRE+82/F"^2F2T,J0U1(BV[IM9$JZ9
M8UKT0039Q]RMP+-+06_3NWK 01'>'G8AIN0"++<DKY4?J?=X&INH2!/NC-=5
MVY'7A  I/)F,PZW8.J*\UHQCJ40)G(ETS,%+%AQ(CK/?5N44?=J350IMC859
M0(H42!;?VGF/4MUV!U)#@VUHZJ,P[';4=Y@=(K.^6A>G0BFW1.7=6(C%TZW:
M5>R1*,H7I*VGAM0@R"%[?SBPSW#/^"ZBBB0FEG"MMW=1-UQSQNSI"SG9FBZ+
M9YU"R8Y.M>*([T4UG4;NQ8PWV?VB9Y@Y6'8W0X,IBV;W:U"0KSZ4,\A37#$T
MWJKOI;L]2AQYO_N90YD<2NT:@,58Q! <PA&\S-@3W,>)OP4K'J5QN]=L: V0
MLOEV4OAASL1K8R%!?7>^P36:LB9^Z*E'Y36$7G_^VVU4^,CS:[1[/BKZ897&
M>]=YTY9[@TH-];JW7 8N&#H0"03"FN+@DWA6(G56M$.*\1 4QL[;D!]Z+I$S
M$P[3 ^LVM(<P"J )$\B7>])+JDAFK%K;1F(@Y+J;,." 30>^Q"K*H;H/$Z\=
M8T_WF1+.GO9 S%V7<01-4 OX:+[,AP;^16!S87^H,B(=O]#)GV[?-D[Q14ZD
MS6*"TF1X)%NAJ1IM>(XU 9KR(J]SWDIDB+-CX+00,@53B:7OV I.5J?P(FB(
M/@XV4!*O4$_J%#CP<=^'*>;:5LX9_,%8A?2'54M4Y#NXW&NIQ5?G&:J[&DQ6
M"#ZZP!H!VM\"VB(L+L0$9[ L3!'Q+>=Z@'OYC52KC2%'S=9=?@1V?Q$X3G$;
MA@G8/9[%OG<IA7^_! 5OZ?DII/&J'\_K8WQY#UA5_I7<>#TDU/&K'VL87T[E
M5COME_;WN]<.Z8)7'R%EM'5AK/]B4V1+WW;0,\JP;(WXE3UX-C[!8V[RRSF:
M0CY2"/*_E.!@5H^]DX]S@XGPY"?,-V%QC$"D7[2G]EM.M7"*$D6'4_::\/=F
M^2^H:%VM^!IIZ*9+*+4TEPBP>PY(09KE=18P9\HI[_>A$2]L*M'ZXCS456I\
MXX[(CB_BE!C6+Z&4XWOR%\$@CY5 S^2V^B\"K072?? ,WX#KJV;.\2N?+V1Q
MI06S  0"0B5#OY6]MU7.*ULRBHD2?#V9@]5IK!S"=Y?LR]&<JKA47%2RAM'.
MLTA5/Q?.N)904\XCV^(V660P1LZWJK_,UG"+3$#> 3PHTVA91#1;:F(SN=@9
MK<97]A&Y[40IOE]4S>!SI)/;YE'K&7N)/H3ZDF<(,1NS&5<X^/8SSRPY*9E]
M83G<*)"EYGFH,ZA4ZUWUX]/.<.#XS1G'=2YB#_+G>A]#)F24#(Y>[P%27JXN
MCJD03B4"1HDGACRHWN,QNP=,49!33E@#"CZ M744*@P_PSU2DG<=&J=@XG,Q
MR9]HEC@1D:G\\! 2",M:^%H])BAVM/!3'@W?L<+G6LF,[:GA*DKF(HTU>2CU
M:T+]79(B$@20X:J[R(=.#=0I71XV=N.\H7<U]<L^*]B9GKYF<Y."F_-:E+OC
MH>H373'P#!;SC#$Y5R$_OS%7P3Q!OW6"6DE;U,[C0U&[L0F<\BAQ\Q_3N)V3
MP 9RQ/-/VR:TE8<%V*HG&B1Q?&Y)22=5QVPU@&+TZO&>I#[VR)A%IH,$:#;3
MN)>'0['0EWIKB)[B(G", -7HVOC4/0?TJ_0^=MR335$]%1 :GN1472">,CA[
MOOFJ<0ZP$P&SDMLX_E/>H]K#CO85!L?G3W+Z<32"\1S+<F2D-6%U>#P_V64G
M'M9DNZ4.S+(NE*(84^G;KY 8*:+FC[TN=>2FZ)TS1H ZBL3421>E) ;<;PCF
MS*-7T@N1^S)YM-&@_[DK&UGERXS.,M.3P\HL[>LI$C[+5O5(3DDE5TRJ& U=
MX< 6398H;(()[M]DN,T?<+&%CXRJ9&MYRS8^7N^^)&29!ST,/SL>$5QX=8[
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M"SW+]F[VONH*.:>=+#M7E"0[_S9,Y$"HSH2M4\[#]R/*(PTU-O/MH.2["\0
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MC>2ZOPCIY813T9\EQDU/"+[SC:.JFWO<* 6R2:FU59I0$?*[(@P53?6"%9Z
MJ'97.A?Q:/Y(5^_9TWD=X"5(C!N-IGF-F2-H+T>$&<)?1"CI(<-.GISI?+[Q
ML*.3PNK9-!;1ODHC;# P*]& B^,03[AUPXC8^/^&RMK_6N%_VV,[M'[KVK\(
M)_8;^ ?H[_XBS+,H1*']$OB+L&#O%IX=_P7V*E[:_,X<;=ANJMIRZ8]_TF?
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M0X?$Z^-Q5:P2RWQ&C)RE%;;3V[52D*5\FWJ9&:;P W%:B&OTLX!3G!G9B22
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M"-\S8T<>L5;E++W^2 -P._D$V=(_"MYKF,3Z$H<N_D48J& O'9OCUL]JFWC
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M2#N]+UJ_A]-SM-C^U>>P3_N?7!9H^EL2!_0[\<P'W!/^!9AL9;_PZ^B@]]0
MUX5=)_@FZ]5660DBE@KK+,OE! X'+=:_/,I>;Q2?8HLU_NHZR)*UT;TZIWWV
M'N9ZT_]^9TGR[G.DT>\0V:X/02>#J#4_[]YZR]W,OL$R_([XLQ_Q.?L74=7%
M].\!E$'>'ZRZ&QDOH1AO++]IO&]B?WP@"8@6(U[U()RZ7^0@I*Q<$CO;F.MZ
MW\;5G93N'6_B@'Q"3;$!WV8[)VX6L5\/^4!AL>*(@21,P@E8)1 PW)/_ZH&"
M[&+#_]_=X?_'1O<O=_^Q[B#^_*D,2DE("6*Y!!4Z!+FD#8]8$5@,';'NF!?8
MZZ0-*Y<O0IPTGVU3I7_!?9_<O;?.#<2+I9[NE&?W&@:=_TTV\_[S-#E_8.?O
MXFCFO./%MRQ6 ]L[CZ$D*<[_]2#C>4&D#GL1R8PQSD4^DUN==!L,7MDBR@*7
M?"CI8.WE2M]L=M?T$H<\T0'A\C3AM*,/6-G9>D9I*'/-Z-2X)MWE?HZR=&'/
M3"?7ZY_;_DV9,^0&D9C39_EF40$^=WLVF,YG<^7Y(HVM*CA9_$>M)ZRCZ_*!
MDV;Q7Y!_0?X%^1?D7Y!_0?X/R#Q!4)4>U)GQYX;(FG5TK.YX$KO;\0)?S/!)
M@WZ>!+M8V;8X,0K,LF6ZR)#$+VPTA#W@E58(^G>)F&R@E?P_;4@OF_HA!FJ:
M<.;IIRXH\MFY\K2$R =T#9G;7")0GLEH4NK.XHMRD#*,/^$>M2LC1-$2M2P3
MBT9'759]\^$=)\V.9BNN?J53+L*/=BM2:F@S AX?G\;CJ357/Z^NH;"^O+P>
M@V#T]/!4D,/2*4P#E&H Y ";(AW5!N(]NO_E<OWO69Z?5:%!0G<:(GP'A6UX
M/&VOJ,:0D0 4EX2%P'<72?(<HA<VZUW:5]X._Z8O?!.6LH$W:I>P_H]EV^3U
M07F]2_748H3TZO(O8-1-EG[M/P-M_/<;D1AWL;_V+&M^%=Q579N_MME/DJU7
M5?X+"'Z05>T0OIH\N?YT&T,?](J?ZN%Q\],_*',,@O<+UE7THRA!/UCW6V:7
M+[Z[7]#'WSP%+^%_>9,:Y!VIV^:^K*#X^X?Y7X#JGS6F_OF._4.7_^NE--R(
M;$D*'8T>YA>>$"Y87P^V+:U>>Y6XJI[3(VIA_\-);I"36?1:QS5?M?>;E$2]
MUWC\/#?G&GX. 9ZAGF(J@!STK&FKM'P!+4)5U J7>7'Q2(ZE7::.Z+ HDX&F
MRR7?_SYM5E8PA5-<I3BD(DT>+>DX1<R>IU2#1Y0R)M_NFH#,W [OFM'FL:/!
MJV#)>))6JO_K)+L!S1[51F=2&[TM+!.8WS_70!,_L8S@Z(=_!=.[35&T0WM6
MI[[P4&RX*+2JM,B[:'&,8@%FFB=]HGCY_I>IIO3L>MF%_8'D_!SVI_?\GSTF
MOWXJR!$C&3_-WH-L3!TY7%+OY>L:ONSP8X,B?IS9(V[>)R1-G<7;+:VM!=3.
MH&/_-:M6K)0X'0D7C.D9MBG#\Q8.^F,>H]HJPUTXVFHCG?VAK=X@)!4QU\8!
M*6I6R9>S B_''6VPB98CB\$C)]FDEJ\9L/>D108PH/]C* D11<T1/>%7X?P"
M#F6"1\$556[ =P(T2B'A<6*IG$ G5;!>W[Z3D<%77:1 *!$W\T42XY6$M[N>
MH\5_S,Z4R+Q^C3;>_(5,<;I-+5O\G1+UJ[!L'6=?D> H";ZY[/7>*E>2?+F6
M@2QXBW"TUR>%C!D.6IFI!OF?(\X$]3F$*1!<*'\B I-FO(0DDEDD:HK*$4JI
MB0)G--A]HDD'<=O,_5@Z* P$1G/J"&7(AV$R#32MR&]SD%"4T3L74F>7;W&1
M)K2)<$RW\0@RH.H"E5H>E>*T$)N51@XY_LH3K8:XT,/I=1P&J@DTQ!9QB;K1
M[JH&BEU O, P;M-_CE/]_Y.:0D+YU6%J"X<42ES$EOLQ2&#BGNQY'T<GTAPI
M4WH4,971[=A=*HQ@>9/*Y^6OI8%PQBV+1%$@UB0=X;82':@6.CS:4!0//H'A
M0N9FHT+XI\R^]U$AF%MJ.[5J6@O$X.YEYP[UZ:7&58:$[=515VP$O_05@":$
M0Q2J823<%GMV<U ;H^>J@T1O<Q]^AKOGZPF'T7[:+W]8,YTT!";?@_)/:N$)
M(1%^A9DJLQH^BCZ</%&S9$$,W+K^*1Q80LUQ[_:Y97R_3$XT'KX.V:1Y?C_]
MSJ&A*@G..[QL -HWG@+D"A;0IFIH =6A$";?BDQ$ U&F I [LGBO)))'E&!6
M8!A+%F.['@O^O8CM<.2L6+!1\S9CW4$3+M4DZ'4%'0MHF#XY4CXA-_M*N219
MX*X D_Q0P-._L%B+C I"9<*\JBAL<.%GO#/O5]05W%CXE4C3TCG-YOE9>.L]
M_0]![MY[BYWLI_ZRE!(.*\F1(R7\><ZJ?/R4YDB"!QL8 ?<9./ZQ_T5Z771O
M*&F\380_PS'7_SD2G'*O)").D6Z':.T($6X999V!MJGP=^?*8_KRP#1#@#G&
MJ-F*P6LT)2!G=/2)CQ7%] +9=HJQE"+F?E1/.76JQRL]Z\+O%4!^*WFQJ%$1
M]YGQ\=C!7TDK;3]TI"J+,'<I]Y["ZO&;P3<&7E@K5EO5N3H[@UW>H9Z)S)9T
M:\&G"N"1C/#S4O4T.E"V>IL'\'P,C1JV8LX%;O!*['N.#M+#PDL@&+$?-Y-_
MN)TO#CX_ZHN=(X6K[\3;F*RPKOS*3Z=O<[XP"?7D7;M3S6'WO.: F-V!D'*T
M#JHM3R\7<+]L2+$HP=TBL5M4L+\:;BYUS(M^'E!$H-!/"\24.F6'#^#&JN/&
M:V1GT.<K%)4M?O#2N+0("JY4258\B=.O]S8A)JH'8>IS?Z4BT@8JT3J,"#C(
M>'</+H81[-6:V3KI3#_O;5L]8WK$*@)CQC^*\H8ET_7GK*F?Q=U2YEY.U=E[
MQE8+_US8QX H[QEG[0E?>HXRWXAR_Z2>%,>K>2R3%!QCO:F^/*2= *UWU:QK
MARDP)K7NXL2.$TCP.SF+07*)=FGY(KI'<0CM9$XMAKJ57CM_I[X5;,_CS2$<
M?23UQX=R6"77LF0(#)=W;Z7K?.L_J%29VP,&JGG(,[>.JP ROVSPJ;B-SB&I
M7[I&-G.PGW[QI:[J#QZW]_,<F?TL1)@4S6!-%MOSC,*A^\OZN:?W>E8OB,<6
MJT!,])'W\4K26)E ;; &\YK?(1+S]+W^6T(S#=94Q\8"I6)?FB)Z19XDE99R
MH@"V?+9D<90.A0M08K6=F^^D"C>+O%"F *!3O%AMQ%4]QOCG S$UTMWKLC[!
MNAY1J,^UKWO&02$[><[L/?<F\_(R*\5 ,1JIN4AV2!<M5ISA$9FH"O6BB3QG
M06;R7&O3KN2&6JBB4B%XT>C3*S$O<PW/0<K^<(=7X+OC9;;Q!$'B%/%.:FCJ
M/-8D O:*-9FS('O9LC5[)RWR,ML@TP20Q-)'QATEXHJ0S2_2F2E4OJJ$+FN=
M[J21S="F?2G4T?M"]_[PX=(\2+RSU-W(A^3D1R&>.;O";<9+4O9L LLJ)+KS
MB;+D<K[''O/ G%FI736MD=;436;;[1&2H"-\_I&W4ST#S1G7.8TV1Y+::=J+
M8#9=Q<6_YG?(OMM"PBI!Q[0KYPM<-5,.OQL/"X W=?Z_JL7RV3MO!Z9D3]7?
MUI/+/RYQD%!EA<90OA?'WGTCW*T=I5:X:7D/Z53O".-YF+$WL20=S=W*-UHC
MM[+3QHJ;(&<0THS*Q;[:W#LD]HQ$T:+@(5B0R;Z\X _Z]*NFS/S=,=9"O[N'
MBMIZ7IE"&;KP%R:']$')42,:XBFMZB@U"!9"BV-6B-:NP@ZC[=,2 =JBLY><
MT(NYH!?=1OA3@=GM&[-%'C]Q/J!3>HM60JJ4:LNQQ61-V<JZDCJU<?)! _RQ
M'(,.NGA]%;W;>N-C93..*A']\]T/ORGSED&;(\FMQ"(!<-^=VJB8MMUT@]GO
MD^\ATX:B76VGSG'<;Z@#0,,&R_$Z+#>G9"$CE[,$L?;HPTC2QB_?:%66G.9<
MDP(%V2[^;#A-]P=<X'*.>8<8X B]B3U6MS(+<>^%] <KD/V887OL,2"HUAC8
MPMS5U%]EZ*!51 ;DT[RY+YD(/!JT\[08M33KXKB\K*(NX=E,S&;8G% EST,E
MIR[@F&)O*ER$&N+*?:^&JQ:2Y']XLKT<S@HC$4P"DE&$AW,YX$N ?+7/K"<K
M0V>WUGC:O$Y5+B-ZK&O\3-,$=^Q5:%FCE "'T3Y;B<P-X_T6!U)]TFG.VKV)
M<P/1\L%&)))?"8Z]T6\^)B'"8;FLYC8B]Q6YWI! >K+*B28X>N#D<_U; DGI
M4O?W&1R1<\:]X_.F)#K$:E[B-6:)E-G8:?N'!,A= \R_/ ]V52MS9].[=^NX
M&Q;ZC%/\\$%3^J)=4Y&%6G/#@&VL>OL\*U \*FFGW>YU!3JG%U4&N:Q8NF"*
MH0^)F8H>%F[6_S 2ZY_-)>\WVFW>EIYDW=][6W[W&?D3'F#" &OBVR5,>\%@
MO+C-'RI=R/BS((D6'L>!T/K4=;32F$FG_\@TP38P-PC10-Y7M$_!>IMWD_(7
M@)A'_=->&XD:FM?Z:U^^H?=FHIC0!YAT,\,V)O^-V\S@<WV8#IM=^H2-KQ7<
M15VH@A58&0"U5SOECDM'G6L(<G/1Q+SR&:,KP:<7=O <'Z7Y"YBXZY=7)>U]
M+P+>P&QGO2;9P@_S8DVE%LA^S\$0]$Y6ZF,45LL,8T#^1AN5(+Z>(#H(5Q00
M]%YSD"J7V^BAC-[+22KK)*?P?;^8(K6,8PQEP:7T!!J=*4E(+H<7/YUPRS!S
M*UGF)-ZW'5IG=E5[[&$,([ESTC%:YA7PGXSP7V\;7K']!13B?I+OF$>.%/12
M*G.Q#YW,=92P3&',"W*E+&.M'17[S-BHMH.3/<-WO:G>T(HV>Y8[3@61=Q;6
M[R1,O<J^PL'KL]S_+8^>)P6%R.@)D->DD+1E;?I[4YR-Y<MG3&*,ISE;A7Y!
MB3PB%\5 J^=P. 7G[6O(^YJJ\UVZ5DI(B\E0\"5RB" B@'+49TMN=%^^(*\7
M3N0*6(\@F-/FL^>9>6:YIQOSB)"S!&!9K!J^M]'O.8;ND^I;U]6N:^PB.1ES
M>E3?E6"J9 NS8V!\^0:_7&B_4YQ6)39X'9-[E=WPE9GFC7Q2JT>'6RS\.$2R
M;\Z[>1++E,LG2#C"LLVJ9BQ6Q6'->D 0H0^MP=1A-C8;VA6()+]D9_QI7RN>
M2&1GG;P(*I1.;TO$7=!/(=3:KDB^5:78E_8TNA%\G8984DV9 *)7HJ^J%$+O
M,&):KP&V-5#;T@W,B.0!>1IQQ_ZIM0B&L$_)NZV:]\LN%T3.:HTF\:,VG\DY
M->(':MYSS;:\D''Y6YQVN"J5([U2L=8?^4JZ0=KDCL%8W'-WA&(AX) DFQ.4
M02F*0.5C=@YTB5:]<[+U3NTC<?/_FG]"E"2+7JQTM,#QRM!A->VHA[-&!079
M1=Y7NQGY4TNQ]F3>>_HQWT:V?)4[-M'BEM)T1:=;#$@JO(>9.N)UJ2E9E1);
M?IXZ\WFWLKMMO7D$ 89=$A,>3",EH/FCZJE?IJJ.^+>7MCQHBM2#+N@R? H/
M?)'^I?59@&7[,($!1QV+2UWLK*0!EFU=3TRV-3"^T\Q#FYO4;2M;-0C5VK/A
M"(@,?$2 4Y3'H2L=B]Q[ZL/28\167"0M_IK6R<W8!'N.0&H!&?IUO%C[7IN1
M"YL]>S0+B,=B?,#]FF.6P"ETZMN<;E+)+UUV6Y;"Q7*\EMQC?;J@Q'?IB[[^
M>H499 T2AYP"#M?"V*D4&BPH0'NTD5/AMX4VG%W<?,21PAN^#'Y6K1WJU;F'
M3=#PHJ1L35-"QS+01\P^;OD2W/LS:H)]:*?.3$G(" -M \SWFM"*U_??1R9@
M"[%RP9RK*=9/HGE;$],0[:0H2?MB5;\D [[W&+,MA9X]8?Y57">Q02CO9XJ/
M>#(K#):-.M^QQ(M/RQ%8F1!@A&V:X&RO+:K'TOS,: FV=+J=<-G[MTLW4Y_"
MBPA="B >9">$T+?Q/41?=]-5(A*M_L];-_4AKJ9E8G(#E\3R;YTBOSX)PN<9
MCO>EYEEVK9,C#A58BJK+>'0ZPS-T';%6.'62?7],"$8*SOCR)-<T:(R\:W%@
M:ULNZ_EP-<??X)5V(6$_XTW?'TUUEZC;&8J12U\V%75ZCX<L;D7,R.C":U<P
M%R9( YFZ% @4(<K^KDEU((K%@ HUZ<F^2KB(A>PVJCX$I5::. ^,;O[ )\%-
MRL(NT\+?"$O799F"US!2G5'LB\#:-01P(UJ0*UBS2S1$1E>J**[ Z-3[,!+7
MSZ!=9^^YR=,+H\!UC/16AMD0:3(9/\A[,-;QC,M]J*AI!733RRI.#M%JI-V0
MZ!$2*UIA8)S *M>[T6HLRL'LA#H2[M]^W]/W/$GI7#C,A$A7;""@V)\XP,@>
MCSJLQF?R2;G@"BXL93OW(G50Z90[7TL^<LI%KGJEP#/)6N3O& 90(4JWG%VD
MSOT#;14[8_2,D9U,_ZT&36ASGKB,W!&"L<0-S*_PF9,X0%YGC6\S/[,^7W&[
MP; 5R8T>ZFK5&IE&/\E_<\T!6;G=X0CY3_Q,[0#QE*7E4Y-*TZ/9DDP'3]AT
ME*#%$<,*4/WX1NR\[OSQ2@QP:H7;L^RT"/T+?"PV!B+=SFB>H@/>4PV>\D;.
M^'B()Y8A,4^<B>.K[%"D,DO;=^KL[Z,U.J>1IES7CA$1EC)-U)E]L/^GA0+E
M\4:Z.D:+KYE$)MG:#^?H^PC(^^$,-EF5XM1Y8P(+M"1%ASZ+O"@L]AN"X!\H
M-/#;H2,^"W\UHVJCD#*>UEF">1YFK(;.EYKZ;<Y4,*6AFZ_MO >V8SIS<(+(
M;\36K\]CK30#.,>9@=*'P:?<_"&J1YAE[JK[J^R<6-:I\E4 1;X13/&L 3DI
M"7NKSL!74]0[B400EI0WV @EQU16B!J,N9N\>+VF53FC99?.. F<N$-> :RH
MX _6$4+&>QE/Z&J3?_!S94N>#S;[S!DE(3?)&Z\1(&/,D#0#YINB+VL5P8AY
MP-FVV2S>SN3R"'+Q5PAQ9C,H7,&2@D?9$<#";")1SH,$"B$NIN3A/N"]ZIWZ
MMREWF-^)T:VMD+**0[+.M.PL494Z")>K VGC=1%0U%D#\FT"]U*(8R%2Y %!
MGUP S"XY8,L*KW.S5+HPH(MSK V?,Q/+G.>>(_266TZX8=):,L,PTAB-U1\<
M[B&SI\Q!3I#G +59!WYXV"GG:DHH9)_4$=KY8WWZT[S8#]UJ(435#;DOE+&'
MML4!LY%J/NZ.;&B&_]4$.]=(=S\^Z$5= #4ML5"SO;FN4BZCQ%M7O382[>?K
MP<+%U;Q?@UM_ 0LVVTNZ;TA!&+04/6SWC<<KTHZ77[/-N_R8 ^5V&U=[ZJ8H
MKYK+\--'F  ^(]T>X_#UHWU>'SKKXBG!RCWE4YN1#QEA&7.OJ'XBL:EC[$BW
MOCNF/&KNRN<)WUT1FW[&:F%N9<7GU3&@H&-*T&7]%!/+HA[E$)#"D5XA,<(W
M)/ DU(<K4%QTQU\N^6OJ\KGJA3GEW@7\)9T7/KFY)@Y:9.:P0MOZX)-Q[)KH
MX<>HLI-#0TBB$3T?/RUT-&&&!LT&1K%5H.=)IC;O?)D/8NT93/B-M7B3GUCY
M,XI:P,MI6GY5C*U(L^+1I%66*49$;-)ZDT5C!_VGP8^?8D=!(NTZ&VX!%N<E
M"GJL:H#KHP>W\SNZ!5?JW;W?D$4R<<G#/!=S#$+ZC?P:J0X!=77/*>"QU%1;
M<:JXV6P'8L1$;=5,I=;0)[4#I_BH3O-Q5N[6R7JL0+MWV7,]MKR@(FSHF9R1
M(S-/.O:8B3F*Y)@P,XL[(+M1PQ+<PDPD,/W:7PMU0"^=)#J*<X2"RO K^.":
MGLF2/'#_QW87"[(*\>IX\\2,#G.EM:_0;'PO9S@W[A23CCP2UQ!Q8Y%KITY
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MR=7HQBNOX-+EC",B%]#!523ADS P)_">^.&U;A"%1%=W*+]\ETG:VSYIHK\
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M;_=ZM8J^2RI0TX&H,E:_9BK-LG/\9$7$-TE"E*\C [6+'2>YE$F]%%CF!77
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MPLEBMK,499;1+)<?@35)TX*L^5-8<3)3LP0G\2PX^?1K+D6;V1M@VO6!7H@
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M78CX13JS-0)1LK@EYG4)->N!L2BH*^ARE47]RINLK8?OR#L<7FS;*B8*U5R
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MWREU/WK'LDP5?RXXOM;]K"K+O,O1>3+>$C/4N7>"6Z9,HDK4/#&O*<$[G>1
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M0BS/7'QQG5.IA>4C/Y>HR=4!4--^OX6*;9F5@'*!A1*UI\F7Y+]*/.050Y[
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MH V#9#/1J16E%._:>*7\DG:/IZ519V:?95G),)28K7JX4EKI@)@LFEZQ1"F
MA4ES']:_=Z;&ADA9^'I#-:E,YO+-YC0U>2ZD^ ^-!YIHJ *H-[\3 X ;C[]D
M8E'5*V(;"=K(T"XDZVV!8 7&/74DZL4>#?."'\@J^)7E#29XW2:Q+ *!I[$5
MX_H_*V<3K8JUQU]LPA4+$B*S&O6+4MZ'QW?U?=45Q),:-J=2XVL 6!B?A0A1
M$;H88X6:G^\0C1R,":5:'1%F<O,_=]]E.\#X7^>R5[1TY+9>W*N?B9@%52NU
M>!F"R4#:!BZU>@P"0ZWZZ.@(^-':=OM#8VAU!DS[Z?YYPF[YJ@"H B$#>ZOS
M:Y@;X[DU+5T!,EXML_;'UJ6=",1$9FFFH@X2(,I:R@KN6)5\%X=,J67W3NR[
MZ#_F8CVIJ=K"7X M/UJD'5>M <*'&)L4%7@QS>*53FHH_BR(^\)$O01CA?Q@
MDUJ1B=(?5#^J_B85!H4UXB&&%;SVRW?,H!;W-7(K94AK6C# L4-KNPH3D\GM
MH7@,78)TOJOC]'N^.1H1HIM@^NP=T_1<KN$"L,V%,SB?P(+LW<%36>'#/X2W
M\V(SV712Z&=XAVM$NV]G^Z&V[+/V 95;(%_,L965?XD[Z\$!MDZ>G<E"+'"G
M14J/0Z<Y5CG'+H_9T7.=3HDR^9>C4A-O;5Y$EA2('OP?-GZ8PC<+)-_,&W;4
MSO90=H!O&FT*<_D 1 8.<MP[FO4U>3/,G?9A-QU)KB31<]3PFBY-(6@+X40(
M3V;^FO=5(UL3S@\4AEFV:#G7>%C*Y)02RH0D7>:;Z'I![L7WEG5!AAFV@BR)
MQ /NL7>9?#X9V&.0-6[YSX5.%F[D MPG<<MGF646OFF9%OO*+AS#9@*(J]V1
M?$"5V4P-L?V_Y"(9\9=VL[E8K$#+F'!)X.N454]]+J!-[>Z]?D">>RK"G@DJ
MO_CDB]CL;'05H\(B::5BJ\RT)R8&/ROIFT_92/QF>I;7,EYL-JU1P(XX([*Q
MH!9D)\_6HK;R^0^#VAY[V:PIR0N6\,02B CSR(=\AK^S@STCT(95O4IN$HH2
M;>-=DF8H\9+ASZM!L3]"[W62P^.V$^I0Y%9QYU+I*ID)[@120]GYZ&&VK18\
M$;HJ3%]I]V=<-.66%T527K\A#2T;;,RK3E\VBAND_C6 HFYL?]^#KN84.6UB
M0,61B(Y,LH5LUWXUX!&K&YSO+52M5:M1%'2J+"A7?%I/=TO\RFI3I4.KRIS"
M6OW!)XJ,9B1@^B:U=?T? N]$T-^5*$K?;FZ3Q^U8_MV:"\Y$"Q]&;KL42P(W
M+\->2OAQC07O?CAUM=2T(&S#-5:Y"DO17U[=#?RE%D=>2-3# :H.:OO3F",M
M35&?Y][6LOE.-$WL>)V(5&YRK1QAGCBYJGW/>46*2=\7)NCF_:6CGKUX63T*
MPO5IGH4Y,WXQW38ZQ9GQ+37XF$[G20/52[ZM3V?OE#N0R3:YQLE];#U/9'"&
M22 W*=HP6/>A\.WC4/<?DAR:S')777Y\73U>LW"""'1<]*M2:93_[VT84,3O
M/TI\2G*-\N&?!9WJ'6@VTP'!Y'J1""00P595!P0W,?KNX"'=U]FH?PB.O_ 4
MS#?K/Q>GQ2COZV !3U@K@'UQT]]^@G9T..7>N+,*D\5VLDREBD[S(&42>PBN
MX#:1CDYB_!J$"]U4@AH+$8+R$PP^Z;@]&G/7F3\60^^<4R<)@&0?VA KWJ?!
MLAW)YS](M[,9;>6R")O)[9])LK:>DQ+-7(X HQR^6.MRL)G">X<F;?/XN,4\
MF9?0QLM;"<U,3$H3F"=,^1@H]7<P7!6I$C491CLZ6DOU\X=\]'TC;N/F'&$I
M,-R(][=97=##.>F#2\FU/(&\^PMR0>(&_54FY/YG[%@:U4BZC/$MVAAY#>M-
M,L2C.NVZC^KE,=F[^-' ",((\5O ZWZO\"O=4=C]<0H[M6:86--,&-ISR>LS
M/ %[O'U:G]1B,H/L8-9\J^-9(@\X$J5("!SGCN?P31A;+;2#.4Y245.Z$9E,
M=%=OIGL1V['0B-!<F49V7##$OH?3>?F:#ZSQK<8;>06M65C\7A5LMW-@:0]7
MC/_*A#X;ZI8ARI-?H2&N7/0#0E!9O-.G" &*K';T:+3 "/[JT$[YS-H>+_1Q
M";N-BW/L^Z<3J!Q=778&JM%H.U*']45[>_S2KN6D_DB.N;CP$/F5))+=&)_'
MLUNQ;U8@^\![H4ML13Q31 %81 ^^4;'>69P\6!2-0:L%CL:/A3\R:-Z-DWT?
MM=Y03H)/B*-?(.R,^L4--]D24YS[B138W6N?M9X\00_\N^/K)$?>VS[9C$(5
M!9<*HPW060A%B>RU'+-?XJLY9VTF.2B9"/.KS'Q[X#0Q.H[D(1)3OY@2N2$)
M9.+NHX- 0.5#E_ 9A5.-# X5!-!%VBRFTO"#!:PUG=QXM8A<7>TMU\U$,/Z8
MQ+N'\,7&0<;JR0D C \8;!J&6H4@V!3 C<49HQ9B5UD)MQ'+9@AFOJY6:GK;
M]I0O<)Z]?>@9ZGCI>IW"2&]86TV_<;<%J3@[W;9Y9R029X;#5=V_[B#1^AK)
ML[1D6CA@V04<OB^%B*(;XI@=2MN:.)(#MA1*FUX;EAAB>]4&_$$5GV*U%_D"
MW]U(N?;RS>29XC+H=;%D^30$"GF*0X,58WWP."^R=74,UKF-NPP9MG[#UQIS
M-]B/QMS,KWR#]>BU4M5#8:9%6ENDD_M<JFGE]B:577I!S'FG1'%DX/]4O-\X
MN6KI=_8@$2@1Z-ZWD6V>MK/B5EQQ(@2_4*> "X'"<_>D/C3:'UCEWO=#NI\.
MZ3V"773QV;VE.HR[9P2V[?XA"-:LEQ9;M!SUQZS&>KC&R=]'O<6'S1#$L^H0
M0)$J>*H%6%EX&A,J4SBFC #D'=]V\SU&;6(<>K43XRQIA B1LC^M3ID K*2^
MK8GOW,:O*+E0@^4Y5?PZP]Q2ZX)$9&G=4XN;X"R-BG_J@\]IV^7?58:SNZN.
M>"?)H=>WB@6&^LE2*SWQR%P>:&;V33)_^@HB OEF]?*W]TA40..3>D!17_6_
M"SGQF)OH8L,W-Y=-VC#/R&S0 [@ECVZO.HVS740J+U"Y\]0@4I&L@Q/SWQ.C
MI'L$B7TK/00KD,,14(DP]7W5] -(4%DPNOCE.?=>('^8\&V3+JD/;",-O8_V
M9"\OBA<@"@#!/-VM3UR%2BME25I4P#A@JKX_SSN7CQEJQAP^[T6!QFM_DNW:
M@F-SJ:(0,>!4VX7S*L2#?KM$->F.K/8JHZF?=;?,*@.-"IC,T#&6ZNU\Y#)=
M"=KR4500=Z]@O'@FMA!&?&Z2K(A6J1I9%:,I 5$>$!V*P^'L68RR;!IOR?@>
M!J9V]9Y"Y:\'7Y,&Y$P^:1O, Q9M! 9NQDM,@=43='?;.%N0EG93A[S3NHM4
M!GOO$ NWXU$N&+ZMKE_U^V/46 VVQN*.3)7M!"49H[[J=X!X#G^]O_;IB<C>
MAO JZ30_C"D96'=D!CZF4*2XKNZVAWI9(OQ]17/ZQ>;WO@%K.ML";M-6;F'&
MV',^VV5?*&V.((V [GCV_[]G+RAT+]'"2'9=J<FG 4@_^D#W9=F6 DT<8(8$
M4"<.YN4Z4">V(=@<#B74(DPFV<K ';Z M;#F+<V;*(7915+<U(]7AW[KD]80
MBO38^\H_H#(Q):+.^W<9K(54PFF?>(2LD9LFR^H_?@>5,K5+%(5BWQ X//$S
MHD0X)/:?"(.6KL3>E/I$W$DM@Y8;K2(/1^]-?MM<^9Q+PRE@ B7*5-:A>@G*
ML_'C+-^.]58125@%=K7[J@_EN&_7'D80X@4BSL6M=N]=GBV7/RG,^1S.NW^:
M/&(9FDYW7\4/-AN-04F+.B)0^WE[PSR?40GI1(OC_C$Y"OO /FLX&Q;/Q0Y_
MB60Q94"[%?%_!)U+X?(UJ3URY'"DH]BJ$23.'=V^VJ;]Q+)U4F:MEN.:!&C"
M?I"&B4,)^4TZM#OUN__6(M<ZQH49DIHF0)HYY__2/F<5^(P+ GX!#K7,-D#(
ME'0N[2+:B30C!?Y >GJCB8WQQ-'/7#$51F>2N<33-27 EZ*OX1:SB7'"$KOJ
MP&E-5$FH_F=6[R>!*5060>O_^NRT5:MVQX /D0GLY ^)K2Y0WXLG)9UWX7O[
MG?E=N=21.N,/^=V%S#0O6_)G-'&*=6TE*G&ZPQ^,)NN0B^SU7$O&11 VQS7#
M$78\%J( 8!&@ L@_)D\BHU0T;A']"2VV\^SUM?/#2+,DV(;*LX*@#W\\:"TW
M#RS2;]/I/=2*R63?'Q-I.MM#:ZBG\!V20M/; 4GU\4>$+!YI=]2%KWT)5^@6
MV:+(N Z6-CHR4W.(7J/Q 2,K;%S.G5R>RT$AV T>3YZ"W)SC:S(RU\!1$S6J
M'S\/Q?77+'!)>[[DS1M89JS)#1JF?$D2(@KQ%[L_1+)YDR7_AZ#7*N%/)3S!
M?S<IN)5OU]"/H^O[E:7W'=@'D; Y7<#@E973Q6LKA-G5$Y&1.)R3GZE5Y"89
M@/P0BU852CHG((JTZ"DEJD(IN$<389KE4VPRKH,V,,RF N\K=#E$HK1GX>ON
MT>)P]%6&UM9W]+ APDG(8:#)*\)IB"@"L$1;ILR7";:C7GP^L.1Z=R#AECGK
MG<F<6SUG]LBM$7M7H1B4R*G[@SCY<+7.=6)6TUU.PS<>PQRU%@OSHSX]L:GK
MRU"LF/,^4KJ6WI$3Y^7G3ZLE##84;-O2NVT_BQJH.*X'Q<"1A;8_7WBP)L'B
MY6'DREQX#RO[?P:/Z-83UTI]^4;1& LLIV<Y-UY1FF4^?0,,0F-A-8.2)B(\
M6P.>A\C=TV$/9BX93!E*M+A)HG2G6K# U&FF=C*(O-O?:AS2C11Y(0VBO<;W
M8X.2(%;!SGG-PE]4]P,2X8'LDB(T<P!CMD'RR=83<\SBBS<A=Z9>PMJQR&MI
M+V+&[T(VV$-CM*7N1ATWD:F/2,+P.98+#5;.3?3-:JE[=TJ5;:M6*\M9<)PZ
MG\CHP=P\L,\EP7XCS-D\=TIK)S@VK@)+" &3_.&O5_R@V2 XT*' [R8BB23Y
M25:C9N-A":"6R?]9Q9 ,"G_XQ-E2[0#+D[ ZT(_B9C"L13(T\RLG$.$]6K/#
M:<*O4!=[?,2\&>J$\FYDU07]M $?.$* &:SZ)-ZFI'@3!(8?Y7U3U:^NL)L3
M'+L/%93HH4617Y^\4??Q#?%+29G]:/XA +R&9IL\#LW1/3U']T-!N=JX5C_<
M$S-;'3DFUCB)4O>F\55,",>[HP+(V"?2"[^<:/.FMF*\.XZNO-\F818:/>*%
M1-=*<1LL/X[QOOG0%3QZ6M?DDAU_EDSQ-MP1%?1^7ACY#T.'BHL.)RRIT@,U
M*])MN0HEAPG?RRQPJ&3BIM1&$?B91>!?PO ?K=R5T9WF,68Q(A/1ZY+ERYI;
MW859OGD?B",R42%B=71HU311",PF)SL3"Z6A"4TNMN'XIS_B<"A\(&LM7>>+
MD&%1&GUJ&%0\YKL0Q(F9\6%='_!(&_NSD%X]0F$^YQ$+7-MXG$QK#'*(8?8R
M\U@I+!++;/8QHL\F#.'2M7S\;U5%/GLSK']"]D@MK(%,_FF>G2&5T6C=]R'$
M::-]'[^9P?VAA%#M/\F61(P>=@PWH[4$<[>W_NBB9C1C@F)!RO@)'5X83G8S
M,]MV&X2;C=+6/I><*8:'P0>^E%P$7 &9*RB[EX_C2KCD@ZO-UDX8?5%5?8R%
M"H4X0 Z&T*(;W<?K=[8L=HISFL'*Y>_U8LA^D$=0O\2*O:QM+ZWV^TU1:A%K
M<6Y+"Z[GTGH-L\>RQ"JN<'FV+MMFBY:FZ]A[D_=ZQY50 *_AU[AJ35[ MW1+
MWR1N,EPLCX=?7@%,.;QDHA\*$.OLQX+_I-R5;Q<*.ZJ-CG,-ZT_'(UJ8!?E4
MTA>27LOJ;_R%^R&94JA?1=G]AW@[L"<:Y)%C0=/[@/U;X\[@[2;^DD*+I0Q3
M2+#J>\'I=/+4Y-J48VH@/XAOVJ#K9%2O"SK.])W8K]ZBD#5 .I>721D!G:EX
MRSLZZQ==N)33>,^(J3=L_'V'L<'ZIOZDY0)O<LO1-!;A.%O/*#,A>LN!UKBP
MN!C,N)7\8$NX+KZG@(OS#!,EPD;E,P]MOYK'<XTE?_';KJ4O3,(W<I^0//07
MS_N#W(Y_"-R.HY +:Z9$.-)6./&,..[D=/LDD\0A:Y=RN3*E9?-FS!YT\D3P
M)R*E1EN/,>T! '<:SE?PP70N[.[(8RP:-$>GV;>0Q'QB&@_,\-\EA.JY%_T>
MC3&'BFTSA5M:+Z&C-'NF#9YA&AYC2U6H"T==L,%B.O>3XT5M[4QSL-U-Q3D-
M2!/$A[P+_R'0EA"J_T- \,IQLN"<IY ?_FQN%^-LK<8^K$%0)U$DPL\@6H.'
M[TM4&U37IMK59>"MC/>#FRK%R=/$@*E5![)US/W=QTANY@K*L"\K:)S22<<B
MB%,F +J?6,*N_2Z'H&XXEJP6LV;9+>>?B[:L54&=[Q,(>?WL+((\T]WE+RBH
MF8Q=(^[@KL!HI%2&695@U^1=C7K9/]P:=YO"6,!][2!9R7^^5AY<E>&5VHZ%
MLKQ=]:BI\:2!#0NX3N[G&>N9_B7N(I]_1TWHC^^5.TKOA#Y'%I)2KC3P3&&6
M(U36$L)/.GK"]? '&3?2*1C==^ BI(;^Q_27Q%10MG"D1[##34ZASW6.?EH3
MPFYXC#<MJ'!T9TJ/)#?[G99-G$6^ <6V*H%Z-BE_@[S7NLN[QH8:X9>IRID4
M,8]![0=M;->#G,2<]@473S&J@D_?BD=3/F_-L&Y ]15^U./SRI3E7GQ'&'H(
M[VO96$$W.\:TT%'M;EN1RJ(N.42=[N^4)!.VSO9],O3H_9J[6+=P>6;0VC*^
M9<\SR2Q _NIM]Y@0=700+3#.TL29B</IE8M\&&W3]+T8\DIH8E/I>DW;6\J\
M1V$\/6%/H I)](PJ-XNHU/(T)ZH[^*+#I,S&OP90<']7C^])B&13R2Q80Q2J
M<2U(>FW/:PIUG4J+'_CYO0S+>X5K3&SWP!-0""#PT310&.+U=O[X,;'46XF.
M_:ES!:8'9>8A?.0B%:OW,G%6Q2FI99?,+N):+\K_J4WDJXP/*PZ Y2>W+UFD
MMBQ:B\LQA8G.CP>&DM?U'P\=+E:C/3L%,5(?\%[!LB9-)+OD$G"F.4<PM&8"
MNH\\NO>//3N6K/8&Q<0SV!49/?B= W/M(#K47NY3^*:$!W]M"P:4RQN+(@4%
M,GK.R=@0>F5*/WK',>"KSDI#W*_1G'E3;34KQPY#"V(?D<R\/962@PHD?^8X
M!?U#P!HN]SGBHTCIEAS??F64FR^3#59HU!>F*;'(T.26IQDQD4(9'^2BG!LK
M$331H'4S^^.^<^(Q^^%#!/#RN=D:GW(O\EZ<(#=ID 74_?K5PI77QQF]&#&+
MLF.B1,-" !GY<&>[%LE!1M"?A3;A1+G^+$\-S!8XF@N6VA:GI*]L_;"N+ ^L
M6K=<#F?@?X 1GH.9<1.P\+4D*]N0%FUS7B H5KY+99+&+0+%,H&2\I"OFD6=
M+X*MESX'+?\0I.0!7_,":$& 'D5N5P..B46Q43W]]W?L@JX:Y?I!,<Q\&E>Z
M2BM"%1$B=W556[WVN-8=7&%BFV._:]/W^@5-4RVK>M$$OQ"@>N;T:PCJU]'R
MI;^GK#JK2=%N ICNVR5X.6N+E"\7><8*7)B,VR2)R^J^J1;.%I&OI*C3]_PH
MI7R?8HV=?51]P4&?H,8"2F\5N O9,"(5\NX[AEQS[J2)56K;*HGWC)LLT=F?
M7YE'1,EITV\=,1"ER-EY!W%+UPEBJY/1V,>/Y2YL;58ZIJA0&0BV"K- CZ@_
M+8F*,+&G^<,8'N4]"W;^SJ#9_4_;:<M4KD$V!V&:HM;\/EA#VC;CM[XB)!I1
MB3(N*UK2'5]).+(X=0]>^[SU*]7&$?T=@\'=G&;1 H_>C^G139@:GMY8/I J
M3;JBX[^0QESNK: NQ!/E+Y5FEA,&^>DR(X>)BVQF])E!:?1J15WH^RNES!!T
M"*J828_6*4:1&[)25-+!SQ2>@YEN@ZCI$ +,[?K)%X_VC6WIC8L^N$BLDE%?
M)QSFO,&=F$/\DT.+O)@Y1K)/]*OI-D'RT-K58(M<].<$K.\[[MZ"TV9:W4&)
MU(*@1(9#:=,U;F^DU-^)!BHIT\?DV984B6U!;6='G2*#Q*%^]"DW$'6_*/^7
M8TI36_P+8I?H[H<M])QJAN-4#E2&F[=AXR;0'6H)/N@? EG])8NOQ69ZU6UV
MLVQY?MW8WJW8^9T237?Q16[Q:IO0\ SZ-_RNO_^364TYXI1P63 VUX1B#8^%
ML"P\9VLALY1'[!^"<X<O=[.;2YRC/A/V)8YFRN54R<Z^=X6:KUN<(&&=6'%%
M"GIAP7"'9-IPO[=2E)W2>*S8Z[ [;M\$-!_XS:RFQFPI<T-@K2,00[IE(NOP
MN="YG'<C& P4%Q5G:T4;5?GJ:K)[R8.9W7GHENCIR>VF7#[D6/ _FSV8(77D
M)N.Y9<7Y-&?> 2.Z3\SW<1/A4T./ 8&9"&X["+;@28YX+,\) 6_D"2*_Q Y
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M]X1,F$R9=;HF.O\0= =B/9O@P]TO'^>E0@A#2\X'=D;OZF9]7-Z34J&,>1#
MP!/)T_8XB\8Q8\T0]LU%OR,N#UN%BQ,A^R2.^4+>.CMTHESS?BNJ<.STT\I?
M6"ZL;4"I!)BCQ$3OIY0C@OVB;5O>Y%+[7 [US,+'K&HM-(T-DKIW(\Y?VOG8
M@72^@-Z'LB@>?:?R@M6R4%O7G1JO'](CIX*T_=.FF0<J4J^+6_G218R$Y"OZ
M'W*T$3_HG=J0'X"IUT7=,BJ8>7G*WX<WJ#8<>-/WL.SI01?%SP8.8O'G_-IL
MVW_*=3AA'L5$W2:EYF%DM<AP:U'<!BSP:>[$2'=045Z9W4=0\7"/WGZAQ:I\
MXU '-EE&$05F6!$(7&GO9ZAUR&HX728$,*7DL=(6[#US'RJP;VBFW:8RIA \
M\U_Y[-/F ?%2=>JG/GER.,QZ,!_(*X"RF3=KN058D]3>Y/-.E;^U^@0V]=Q'
M &Q[LL"[)C"N.&:Q[6$UL._2"5R-"0QB?)(ZS%=W99XXV2'"'>L&"$7=7S!4
MG$"420FQEC9K-[$J^BSV&OTVI#[=6^<Q9DA-7?Q#P+VW8'3;HCH$*6@QVN@=
M40>R9(]]"'QR0M0^(^P>REH]H[#Y+_\Y,=]&V,JIN[;!XMLK'+3/S#.Z4(=<
MYL8J52C9T=IN?U)QVY@2+2C<K6;8-:KNR^$6W/FH1KW2P>SC'B+;L)L[.OH4
M;K"Y5U]<]]= Z"?_MR<Z*M>= 27\C%1-^6HQ7OGD<-[U9R1'LWB)&F/Z2?W7
MTTP[_KB_DI[:[IE&(GX;*%,4A%5(^M%L)OL*EZ(Z<8&X\F(1*]OB^5*L(U2"
M7R"XO1. T'7U")I%N.9; D3#4'HO_7:'L>[;V(**W;*X,(_^8I4N!O][<3;,
MH0KZ"L3V?7'1%8W4=4HOC(VABCS53B'T_<,KY!X')/VG*S5550)?-'OV &WR
MJK%@SY0K[QBX37'I3=Q0M63C9A++-5>A]=V[@5!'5W=WD Z9[!WP*XB)]G@,
MO +4A7E'_4-@!@@/B$Z9E6.NCC#-8&\G=+W7R,>QFD\F@+5'1<NQ8RJ#;#?\
M['3.L.?415 R,OK]5PL)$G&6&W(080 +>0;8%:%F1G&)"J4:=<8D&>28>]%
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M<><ZK8.FV/=0 6%&BJH8/__15@4==4%N$\0-LA+YYNJ#4]3Y0\_@H+9M<ES
M[:7S*K56/ER\@/EYB5;X6?C*$GO: W!@I1V<+:I3*4._QREG[;R\W WN_0RI
M0)!S^$:%,N]V.I=#&2+9N^"AO%9$G:%B&L@D+R@P/123=ZCM8DKI,"K=$"4I
M+5@9Y$=246>=,0$IP"S'#(!J)1+A5P&.28 >WBA:'K2XCV9WYE_SN@@N2"5_
MT*A%8J(>17OBCZ1T[VVR7FKDVS":S&$00XZE''YK$DK\/I ,?#SZSOB+F?W:
M\Z2V[$D%!2KKPCO;^  G*(N'Y+AT[,ZC'Q&2<MX7RZ IZ\B3N7D:4]Q/@EN
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MGIXWUN_KTC]1FS.EQNQ:7P-CJ9WPP-B6I-GAGUV6(4WI_$,E\Q N@=&!."=
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M]ZU73/D?@*Q9H7?.A_.G-[7O.I//./7!?X*]WK3?G7_\L>X-#*]]U7_"G?T
M3%L5_"7T>WC[4W529_&.M/+Y[T!O8&V0P.G?UJUO0\N!K&]Q5A^ HU;58%0Q
MOS]_%^^66X)@SRD^ "9;WY8_D]P'ZU_MF/[ZEE7T;O2KO@4)@EX_HWMD9!$D
M0SH96ZC=.O0(0IVS;(2MM/;"7&P>+;U]$G@:V^]L-=?"-'UE<S4IIL)L$'_5
M?+*VV>JG$*YS&&M[D"7M?IQLX5ARZ$WZBM;JI>R*D\[O*)8#WI@[OXIYZ->/
MD11)7WHUTI6\\K/WZ,W,-JG,B6^QY2.\B-MR)FGZ!NE8NYT9"<RN6IHB72K
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M]S&?$I6&+;5>#TC2,D( P;78@5*,FD^<S7Y["-8D4.J=78Z[H7DQZZ\YB)[
M$X=OBYCPUB&>(*L-@9%22D10;C<I1SMJ-R?'B 6!$ED$?H_ ?IF0G7(R7V'V
M!/>G-9T"ZIK8TMB/=;>VTR]Q7$A2 K/)E[$%"VC^MK?X"60XD/,#N"Y*1#7Z
M*[J*2WG>,I@%F+BN8=?SQJE=QXXQK(N#AFY5NAQ7Y6+%2>M<J=58 Z@&)^&S
MS;P"[&HFEC*2 [/'7TSB71'3.'&/X$B$RBVJA;8W3[[\(,X;WSLM;I.Y;W3"
MRB_H[/J'Z^\$#32)ZX1%^7TH=#)F"X;>+((XKYX_UL+_52DYP0CZ%*.0_?K7
M[=:@VWS&NDC[!GX"T-C:9>R3$L3TZGE^&1$[3.&DC-IT?/PAV9U2; 8#VL1I
M0,UL'LMX*)X;@9DTT!SXO;#] \!R"8M 8"EF$R[+_<G>!G)FR:EW+\S")T-H
M@BE8$,F4S >J,3S,R$TWQ6QMZ17L8U*OIX5B3$*<1@2IR!WWQA>>32'L&1EO
M5%M)3!4KNY5C6L<4J8]]3]-,2^O6G!]&FD[1(](Z8CO-5],LSY)H$N+6O/(M
M@1)HOL*9$#SI8ZE_7OX <#G@:X6;S1@1(I$+"$'<^-=&?8G.T5J\'G^SN8N&
MU'M[ZE"F)&+A\QF,P2!)XYN%(3KA]3>2/KEB=0CQ5:&;_ED+Z3^,A;YOX()L
MSE%EN9R67Z-$^=H0T:!WYU,,$AXF)R%@N2V62E9(ELT266;I1=F:$1H>08<E
M-=/C'%14%<[NS E.BQXC$="FD=F$C#\* $0[6!G0Q%UQ(KSUM4:/L 2D7.JP
M^5H09.N=<7@'\03]L*R$6,_+6-:@.7-R83+1/X'9K>=^?@ R'\-@XEN*VB3*
MB"CXVBP\6G)8_<CP\DH3.&)(524S)O+ 2PVWBLJ3S8CZZT8%QKC5.MB ##E8
MRPBNRK([H[&Y^R.8WXU-CDL\E$?J]$*:B#RC:HSF)Y-,"@K &ALSV",(*VK-
M;=:]2E6-IA+E:D$ND[?H?$C^FC>:3_\7D9V&-(?0*E++[X_P$DDW!QW3^Q>Q
M$$7&42U:HQ6JQOYRUP#7E7.#W2M']V'IE=?CQ\*&@M5(6A$>*MY[7='RE6:Y
MPL+1=\S,803F[OBHCB-VU0;U1,?1EPX[\(2SDDYYY 9/E"5KXE3.H\,AFM'1
MD!)G9J(4B:LX(-SMBGJ0!<]E@T"9AYUC=8[6HX['*K>.7WBLF0QK:=4WXZ>T
M[6B+G"'Z<-=>6_N<'*9BN***9UT<^WXSA^FF5_\KVS^CM)KU ]=OKS<&:NIX
M_P,+X6KCDJYV9T*0)0TXI%IEPRN*@C_%+ MBK@U] ;=>R^>#7;A /C/D.;2"
M$IU^O*F!-9RFDN!9 *X=N@&:/N1NM2A;+%:"%UT=@EAK'8YXS?F)E6YS#67V
MJV<,\BXMZ[ELQ8PO8*0Y825T<4S4F]!\GD@/"JJ8MA/\BC@RU8U6B+<746:P
M R+L=0/]G-A6E&)*GX].6,7S<>N2F9&8*7(-D3X-L<K$2(C&YQ"!K;G>C07L
M#=FWV+?Z"+.AY9=Z!#BG5%.98!.W_B02>Q-4AZ'J>WT "C-QQK..(A@U!_%%
M^C$EPY2)#0'[$9P7Q&I3'P#ROKAN1;VV$ZM2_2 5% 5O)E)!R/T;F:I&*V#\
M%BV5+OS()X,8>$V@"E[G=C?"*E7?5"P;%)]#&FYF_"SZ=5J 3%")[SC09R9?
M-]E5UF!U+4/3,8OFA8RV!7>1W+2@)%%HM(_?E29)0+S2.;G:<O88<V'\^/#<
MGY3%B*]1X9&5J['^+G&,_&3:Q#3OJ7OM2H8]:0)XE,2J%86:&/&ED!0D6;/\
M9SGK90XO$9)6F<Q3(F:?'(VF/D]%.\;,J@_ RD(-DJNVCX+3CV5'41O0RWF9
M6DU;PQ'*F$R;B$-U%1);R@S^.CCD'!;OQ(G_2]^FW$O&O<F\UWCE$6YXMG5E
M9(_->(SC9<+43=L:=U^P.\%2GN&VPHH^F8^(SL\IB3-2L_RP!J_OR\TZM[FS
MZ?8P[^[&'<>BA&:*L^9W1")TS45TTQW&=/_6'R-4Q-USM&L%9OBTIK0CHPRV
M<TJC6(Q*4 )0NNT)QKLY8/1'N$A71/XN][XGIPL,39_6N=:V[A6)F!9TQTA!
MD)@11'#2XC<V0L$ ;7S/]#Z=5)7/$/$R%DSV!(U]9J6_&,C?!_"E87N81Q%Q
M&,/E_/L)^5VAQ?S6EQF2,K:B:^T5CD0NW)(L[R0O+WNN3*L7J1)EQ)^'^KX'
M1,*CV\#-;8(4C:2IKPDR3IW ,1V $POLX@]EB0EI4":YFIM.^TE]?XJWI&(E
M=+K;#6U_C1NK>ZRV,*J3!O4NR[*9GJ2N&AZ*WI7EHL)A"2M5?[1;D\N\<N&/
M(P+QYSL4(L/H5G4'X6LZ>0)\PE#(D59"V.D"7;8SRC[0-1&TR'1:]@3$RMPG
M<&QAGR]C^WF?8:TMU,![F"[KBV#EX[LXFQIR7"*G -U-ZMHZ0?T"+1BR7-E9
MZ9$*$CH0U:7F;&,S$(]7!1OJ,VG'[500?LKWB![*$.+_@4KWM>)U)*=#DBC>
MG14!/?K3C#[#Y2TDP^!S;(*K[+QT19!F0%+I&!675EDHTJ03REJAFN!\2-LP
MWJ4=*EY#P?&-5*=O"7N__>/A4&5WX*S?>"5B>H$:T\'N-'!^R\1N"S'EL)KT
M$XN0L0UFGAEL:Z.!>6DX" D<@BGCTB'\GYG;"2?\M9E.HEPD#:411<HQXXI>
MUQH:X:1;8YMAJP4NZ]'@-3G-#Z<#*3MEKJBV5]J;_'\N$7\ V(8708+/Z"<A
MJ0BFUU^_76EP0$4EJNO/IA@1.0R)M#:_=Q51N(AYD?$WBZ-$#?^ZSW89F/$4
M!DW.(^K()I)M3)QHZ!#9"U[[ Z<%!CKHW94U'ML;W)92#/(!\\8KF*B(82P&
MC_WUA/YZ!R1"^/%*"X[TTM$6L0:3&Z7/[@5LR-*,!J;TG7SX2Y!= T%61'AA
M>C<Z_7#"]!J\01O';80?IB&T%7 42H\L:.=JS"\=EOGTGQ03^^T]^+G7CHY>
ME)/[OC&:('@R8;C'<@UP,#2&UD@4UD0"\KT"#9.&,1U=+B^XH_HOMI4Q"CD-
MM7XED-77WWFXU4]=#'_CW>+)A!BJTGU#PE>\S^U_F+JL$,*ND)FCK:.GTM\J
ML=P<?=+&9A [WCSC6I,ME%TAD%^BUBN"%LW.<F=MB,!NZ[IB[[:. %,FR.(2
MPZ_FNAU%97G&&V#1=],37'CZFV60*0JE\_OK/^)@FETF3H'_1$_X8U;\B<)+
MUP!5BAHR1WXG)$GKPAZ^(8\O<D<>)YAG0I(F6A%23\*;<$>!DF0<_'O\$FS1
M00&Z5>W_]?XJ$+&70P4;4 _.V]J]7,=[ *XHRA>0[&,AUD=8-),J\M:@,YE%
M/TAC97@.FPHC@H>6;X)D-N3IWZ3;\WE/"/_J17.L5@6D*:ZPFA&$DC]68T=7
M\I_H(WO8;N(7!]&.@^K-V,[C';$$6.Z+%MLPP[\:9GC%V]U],@DY-U9-.-^F
M&70K<UWZRB((.@96<.9;M,%ZI='+"B[%:K@N.6B,T:V%*Q-.:03-TZ]9>17&
M0FWSM?(<KQB%0'JB6[ )+_ZZXX>V'27X9]& [W^?J]W<KDK2S$$'QY4-1/+*
M$^]@ -AQC6CCMMH;%LWK;4-)^.P,(>3KYIU,V(&)H7N/]+E+Z[$= 3H4<8?*
M\4QB1>*TCX[Z!)K*BE DB3R4S5HI/B@ZA_4;A#Q.F)M@/5KTZDO2&ROA=0\1
MWO82AU5URX5'I/=MSI]:]@'C7(36!L_*]5$N6=NQ-&%+*G:1YK%L3%+LHSNM
MC)*$#H0[Q+D0U85A]9.UN<$AOEHF;E4A>/:1<K/3;<4;PNH$_IL'G+/RA.\$
M]AI4RA+6A"!;:X/)I<<0VM0U6MA/!('ST]RJ8JTK)K+T%]Y@0GKYDWCZ2IYB
M1Q]K!PB74(1^Q=9D2:UR[!96XMS,=2A9G+;"$.4!*D":)0-KWBI @&RK/B8?
M^Q@U$OP[(!!#>PL_;6#/QHLZ:2HN4T;5T<F%T*);4[*F8K9(@5*>*]$TCT2+
M6MRL$]DE@0KM@E"7Z)!M>EO3\L4:\23F6[/I^+I#%EU\.@+F!'?!"#5M<D$A
M8P5W&;TU% WTERDG$5Q8(XT4RASY29%6Y/!P_G/RZ</U=7^2J#M-Q /907O%
M5O5OO:-Q@CFCLY%G-;,+!((6=N[=O["\#V,DS2,.S@E,\R2RH8SZ%S.PJK[L
M^.)LJ#B%'H8XC(N-C+*W-8W053<O:0:+0&K7C]W&I618[(RE@^"0+,3-.:F4
MX3ON5HAA\35=QMQ'42+ZYB\^ "GN<RRY,&P5M@Q,>^^=O,-W%0D*TK$E-\=D
M5B.-S[%DEZ:T+:6%#AK%:/%HWRE!2)8 4[@PI_^96PT2R;=1^F,YDKB7:>Z?
M%$+W@3Y#6WU.WFE',Y@V_N)9-4S8F$(*M'-H":<S!FV_L>65!:EY]R( [:,L
M!GM&7Y-18JZQ?S>-PS5LG?=Y.ZU^AWMVMEW\L7)3=+Y'ME/UKV/;/]ERK2NG
MQ2V"Z%(AEC;QO!\  E6S%WH$&E4ZU[,V>.5IKI@!6JAQ!N)*6UI/^WB>4A=&
M6M,NB.#@FEF7GY^CO[II3.6]+>VM$=7$[\"QY=B"6]HH^3/FB#%^'&SYBA]9
M:XXS;?WC4B0VV:R^EE*XW9(W-!EI^C9^G9=7Z/'S'J@LDTT4)$1I22-=/&Y\
MYXP6NX35Y2Z0+.4DP3X(;'PG]O3(=,L@#C\;%U.4S?@\7S$2U*5ST-PCV5"!
M+^_!B4$+L8-*D0"!"3A(073TJ"9RRDT$6O=8I([8M();+Z%"+HZP4/X+8)#X
MTD,&M0C<@3<-&,4<!DY9".A\HGU2H]^OF0X7B16^/V"(L" -I-?<;BO-*IJI
MJ97"RY+#3_O'$<3**ZLV4,?K#2<TAXA$& D@"]QG'P6<-??X]HE/KG^E/\R5
MYZX3=6*BF>R&-^-W2?3I8.<?70?/29Y>["\E5.&$^83E2+SV>E[:QX6?[$[K
MN\VA;NH[*4\"MWZMO$J4Y3VD:LO?X+-MO;![>\9UOH0ATG"WA3'__=M=DD6'
MV\6:J37TR(HXX\9(0.CO%!]A,;E=2A9O<X+6:;RWX=D4][PK +HA_6+Q0AQ
M?IDD$4M^\+N=ITKB9#ZKA$B%L9"@*^))#;]9 Q$<=AS>TA]&4KFG4K@RFZE
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M+GUUM+V0'Y*QJ2I77\E&+!6+!BL*$%=J@9(>E-#8\KR24)89[-6FVTPWU'U
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M0ZWY7/#*/\L=IDC3JA<1B^6D\0)4N.R0(PETXM]'4EK_JK]4;^\N;1KJ#[N
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M*U!^_MW; A'-L2NDFS/4/1Y=*8'5KPG?9APYO&%K632)="F?LA[^E#D]GT>
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M/U^+94HT35,)7<)HXOB'FATH.#[_!-41*S6_"UX\%NV*JM2]J!>^C>N]+.M
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M%IEU$%FQ)8:8"9R*]6"N_/KY)!#4WF"&:&OHAXE;+49F6*[MK/+*MHP9#'U
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MF?T"^%T,5E1.*:-%3A MB^?D^5_LO6507<^W+;HA!(?@[DYPA^#N3G!W=X=
M<-W QET2) 3=N#MLG."N&PWN#N]W[H=7KT[5NU7GGG->O5OW_ZU7U5RCNFO-
M'G-VSU5SV/RBUR=NQL\F(VH$'5#O*BGU9YH&X.(GJUP*@E'UD*K9\6Y9D[4/
M9]L:CM4I-!G,G-7F7*=4RD6]#:V *H7MT:!(R@/ZV6T(7J);3.K=E,KE[C6R
M(QWXR_9C )ZL8C;G'&C&R,>P$R:$7^^2IM3P;F#@;WB,6IY:I:G4I!^Z[4BM
M%)84Q9)@XJ]9,NCISRUR-;Y5-FF)?VL"/*[^VQTQ]>'3C/66K,KR\-WG@'%+
M>,X_%^OH_JA%FOK.823$:40) S?%6 'QD[5&)J2!%&X!OQ6]-EW8R<!^*&8K
MEYJ"=201U[.U=0F]_306*+7*.'XJ=NF6:AZ!5J5*+=6%JW!PK]VZ<3CL>!1P
M1#>-[X"_!<S=QUI3P5M+M_!\[K<$5TDQ@_[<;UEYSX82TK^3DUHRT*)/M+'$
M]W'T?[1E([L*\@ ^1I*%Q*[CW[$%3Q3V;!2>)-*,NXAD5[9GN<6G( W5E8Y
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M_=6M,F@9-+'.2!2R>N7%81@E:J^G8$P)#PS%M05=DE[Q=0LH+),7MIA!=5F
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M.$6.TCBRE<K>$LNU:ZHPF*QX*!,]?3_-%=']UU\PJ/'4(6KPK_P,6M%F%>'
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M6>X=<''S#M@T? =<QE9U!$_HO -ZW@%/_^3:ME:R#YGO@&G1ZX*7\K=1V7=
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M*C30*D@GZ;,+D^G\0*8\-I8LV=26@$%U-Q*>\9TIAM2@Y4>26;:EFAU:&MK
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M$TLUC7K5L=6C\ZIV"W]6ZJ,PY=U'W]E*$VD:#1N$R3!B1GD:/W<K4=;MS90
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M8N27=AQ+9>EF@$T\FJ%E>_;-II6Q@!S.7 XJ4N4TG^-FP.O#069_6H=(:?1
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MYSN8HV7QC]2CPJM6V]=4VZOB9!.RWRI*=^,2!!W77\]S\Q]SCAZ%@V/$QS\
M]OPNK:QOBS?GY3^0[,3]$/8?MZ[[/7B"%DD'P!HW".L4E_(SCW+%/4%BGCY[
M; QS5&)=?0N7C6-](;_Z;H-#N .EB? G3K<JM#^?#J\\1GDO$!<ZVK=/82"J
MT);$>*/U?$U%U&MO"-A>^8:QD-Y?6+G33^%?9[/>$^VP[-Q3V'C.90G.V[P>
M>)Y(RMIT=,O] -@2[4;XT-0+FYG\["U*5VA:M%HZ7%3KV'2Z$3#A\>JC)KGJ
M_\%3XZ'MAC+.6?HHIA6U?TKP24B*0$'1Z3D,[=(T@)!)R<V4??UQ3^)I]'F)
MB2&^XVN7QMM-D!>RTOYEL3/.!R#0K% ZS;?7=C/B [!#<*)94?0/_1_Z_R"]
M51O)\\MWQBFN/4IY0]E=0F>J^PAS6BA,EP>*OX?O2+J'YS&NOQ8DYC$V_J[:
M+2&0-_E>YC&#B:$ 2(%&\X;Y5HFL=$(('E'\ ,A*V$FG^?W#_H?]#_M_23:S
MW%&R]&TR77>VM/DW=W%BFY\7> 6+)_W?0B<HJCY/"&7^8EG'0X@$[\>XO7YG
MFF3:BQ(J=2-)WZ"!53D;P_\TK?@I&3=SZ[^HN]:@5XY;6MV[V$^,AVIOSUQ
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M76Y\5DS'I,A%[0T@(DM^,Y5VA=,'[.SC-HCAPO[P4$9K)1,9A.6LYG],"K1
M*=:$X#QLJ2HG(7C6SXF*!H'LIF/:K8:%KXKG;4IU ;4JB9T^VC1IR0T+W*,!
M1B7<_?!<J19]+JP3.=></\ B[_*C2!6GN]@<A$$JNTQ5:@K<2BA_1:C'YA2*
M*M7?9"ZT,Z?B+*XP[Y+5,\.KC/CN</I1G. +'7/DQQZ@JT4%G_@<)\/GCP6
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MDKJ$^7N._"+&?)#2U4HY+3C.6!<.ZC:GL,X&-PKVF&2/O^^" S3@'C1LC3\
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M[)#4XD>8T*JI=8Q+9PV?PA"4%I?PD"TA.$5$.VWQZ0JJX98@Z*EKZ3MR/_X
MC-?',>&,^2HCM#5/W^5]YN[%QD5KU%S5_U.%$F79$/[)3P82IKE%JB@-!B(J
M9TT,MG])9%.;4/RBSO&IDT[(SWE!IFL]U)HA@2,L9^^O6GC0..&R&+[5Q XC
MF75%YS2VW+#'W8IXZ!![YM<-G0AI#]V^]V6A)SH*25WO!W,-C0Z19:@IWX=#
M&(DCMLDP]C!FNX09MRKS)'!KYEP:%]]TE@!+X*JH^TPR:7GBY-(/2L*=)O.,
M$,4/0&M&GE(66FP7..Z00],6[I9-;9WT@2UQICEJLEU*U^;H(GQ"1TF7'WD*
M?SS%;7PZ,)6;\/:W@0?,^HR^?SDN$HT!?:&'.J^-,5_>L4=\@_K^K '&L."=
M:V4O4ZO+U_"E.7*L1*";C:H.AFX6F)<Q3XQ_]O!\(F=RS$^^@P>.4;TWV, R
M')$5)*5/L%E28'[\AK3+D96PWDPES" "Z5<5E]R*@A@NE:8=*(IS1!Z5RF7.
MR-?(Y<69\<&K:]8\YJ?A$&MCYC C6-O4*J=(_)#-_@# +GX S,$?@&\#86T"
M,F^7,3XOT_<L?R0:,W!05@K?T_*4_B!8%6^=.\'&K[ #GK6GC1A*>F_:>VNC
MN($V-.,OO86:DKH3MW6378ULX+13<2D7< I_*#"*4-3.J\RQLOHJ1ED90@"%
M4N\W=,[,R=SAQS-'7K[M$'1<.V"1+<576$YUE-'U+CB.Q^[6IQ-Q@TQ$U)GV
M'90D6$7#':2L/EL0F:PB:1'JYL/:8OQ%NTH6\U@H<[]5;I!>>46M^.=,WJQ3
M(LX)DZ@%;Y+T'U T_;"MEC91<4!:])H,JEB8 6(^+PM/XT9E=3-&-+'VP+UV
M""R5O>CPW401!\B60CL!_[$-[41<VNV^\(EY9G?2F+C(//5"S;O&6=,)K('?
M8ZM8-G&LZ-EE!,$IX&NX1%S"-^@07/@4P2E!NIUQ*GY@M\*V<5FU#@'C3XI0
M8:ED QTYO;OV[U7=A'H\3"FO;I_\6A%LN_.72B,-!2(%:)U* /C>4)SGT?V(
M]/2_3N7-#FP7*7[D]6:[MP59?P\0W,_^8\'KJ/UF=6SYN;!H&9NZH8I3(J=B
MS1#$0J+W>(FDRR*=L1<CRRA([W6%2U-F/(V1%(1S9]JWFPM(O1(?N9(WTB'U
MDK:>,HKD8H9@-&J=L';A"(?]4BHB(UYI'W-R3IIQ_^3@S&+2!UN#%O/&">%2
M<"WBC;DU:H'EF?&8=8W'8UA]',FH3JD K0U;QOV2$>'[FJB;*:\YX10O/"Q(
M0-2 >OR(SS^)WTA; C'\]\0,[VSV2;+1.@_ Y"ZR#/ W+"WY>XD%G=$B1TQ!
M+J/HZUQE&,FD*L#8[[TR5O&6Q/.Y.5IL5A;Q*5<5#^HU8X8"T"#>7?8AP9_M
MC<0TN1^ /';I=;^_UD7V50,275&9@0T;32%<!;VSW(CGZVIW^ )'Z^Q/H@K?
M25<6LXKQL_=CYX5Z&;UEVX5I$VM3<FI$@IF0L XE=(N1UN8H =FH+L0CMZ2%
MI(Z>ZC@;L1-.LP%P=$ZF!<R.O&4>=^S,\0D$:+W2,ZJ2/?[^A5!=?[O!/A"]
M!M0#B2M?^JY55C:]&OX/H%):Q_T!W80-/VZWL>OP:BW[8VN&7I(UDY2)T68%
M;,P4\A/<B /"Z% OT.JIF$+36;\@)1?,-.1^(]B#?;%?M.KK-&;?.JL$U W]
MOHR/'482,15+'1%WM#W(67'X =A]<)+JZH?C>8G\D1N<PK%K37'U0B)5L23B
M(]7ANQK9+[V-CSK?$,@RFL>U0I=_!&BKL8AR"@)9U+09!:1[2XW+"5*B F%D
M;Y$/+ZM)<T8:"[E83!#<,^G95 #^CB- +4$K>2[,T-:6L3TLWU?1( J*A'+Y
M+3*KA.\"U9)C2Z#0/KA2^9^AS6%QJEI4+9*T5,U.\PZ:;@8"] <77,E50F8L
MT\#?KR0'IZ\)W^QX,P6K[9+'#BZ90)4!^7D/U$BR:4I2I^T-"SP(KB%0F"!,
M"-_G@VT.H6."G$]_-H6EB[EFL^P;A8)7&E!@^RN-6)M$683H)<TSK/?:OB'1
MP]-FK8LKNMF2?ZHW;+\\C</ZMF$LJ^@T(E6_4Q?PG'T+_FLFY(?/Q!>NG=H/
MP'-H1G""8>X[D65),LL;"]5FO0#Y='[LA![D6&S&*Z0D.%1=6TB.V-6&/=#=
MQL4] 4RS-G_,1Y=!&RVO3D7L%IEXRXL'4 '&*,:]2:,@\9R];5PLMO?A'F4:
MW&H_"X\3XE[FK5JHT:'+]RO3<JUY\]EEC351!8A)IV]G@S=L1]M"M<JQP'3.
MC/()B\+'.;C9PQ1P*D)*!SH$T_Q3 ?Q>R;H3F4?X"7RU^DC;?(@)<I!U=\^0
M=:L5QR..Q#D@#L(9[G1;1G5+ZFN]=$%9& $4]%&5,K[+8)\+N]O=% 4-A(=]
M!B=PO5'?" =X&3(4;UOG6.O(A[/AJ-XV0JR-Z^,.Y)J/YJ>1OY+FUA&H=4U>
M-_0\J_<=-K=II/X %)\LT;QS.7S^3:PE]3E%7.2D(,6C?&:6@L6-1Z]A5SXA
M--S$&YXMU#FUS*TH-Q.\E$H0E<MG6 )R\[:1T>'0=LH4$"O3]0,]CJMURR64
M'+M?Q8F_6#]]3DXXJ'IE*3H1#F@7H:)8><L>\DM\B[P>V+8!<I.,#^=A$8>-
M'#I7R(/ZARH5<U.%>+NX,=66:Y7;I2111-;GGK[_WOL Z#T:OV]M;" ['*9'
ML9G.F5:1LC2X/Q\'.(5=7Q%-]G[.V0*Z)_@F&1"/.S7T0O=%.=IT+^+W\;3)
MP'M3.S4O]E#ZF;@659>:-'(W*AIM^P_JAR^<@\1/->Z3;'.J%J?S.:)P8+WG
M9IN)ON7,?BXBG$@PHE6$0ADC?(N[_%FSO#R0ECF!O: G6,(F--S-8-R#6!G]
ME:&E/WDDA2T?4O@..7F7Y!8U%<L@<Z_PMB R(0)K/V/S:J]$26O-4,]U<RM[
MHHV"AF7;>2LCF),1['-Y?)TL3^D04%XMOGN(?3D*3U:;'U=Q?P\ZD%JEL:2T
M7JV,AU@181 JEN5JY5'N_[J_<QM0054]2X!DT'L:4PD2_SP,:?_*0."!AART
M1Q)^\J[3-37*D6_7+T)&O/AX)O_9;H0XN_%\/X7?.SH*4O.[U4AH(CFMJV)#
M0CC0)R_%;QQ%=ZQ2QUY[LH4= .AM@>K/*G? 15'EJT/[-<OND_T#>$&!*@<?
MVZ>1W2:L6D"L25YQJZMH3#.-92/G3$U<JB^C"DFIVU@Y9=^>4U2<_'^D6+EF
M+0+]$_9%*VD3(5*I"C?36S<1DM2_HFVK<J;R'GLC^1H":O"R&3A*\-M?GAXE
M]DJ65^=[,>.H]J]IK#SEL#LI#V?:)TX.8[E#8XU>R[H.=2AHS)V]W47E642S
M[EEF]+6 >!<XA;@D#EYSA!$D7S3M.7Z!K0N5:$BU%-P":WD)Z'[<,L%8@SV\
M8N+<E= +A3O3HNB8=2&EW L$5<D2187ZXT0,@)_IKA#H]I=.Q.Z!HAR]0(]O
MN:_^D&[\K4#P.#WT\!WD7G11,)>+-F&RJ$7VTQ.5:)N"H?3*7D:)E!]5MZ5W
M.)20KI'2+TDJV.$+3@@]*-_FEG_?7YD;??AH5:;XUG%*[E:'=ENQ<70]\)M4
MPK$VJUZ/X=FZ)S:#G_Z>.'6S)"* 3EFU2Q+%=!!12@WV_A?M877RF\14083+
M[*H:-;H@#0''JC%26)&Y[SF^>8%E%BNLYJ,,<577!X"61^GXR5(KH*NOVL%>
MWPV<T)9DM'P-C^ ^FZ/"X:$VZ6RS7\@^=02!&TLFU/?!&6KU@.=QHVJC=,1=
M'F,=7N(^_)7!%\8:4#N6LQL2J>[4.#VNK0#RE\\O^.47"8^QV8 Y;IJMA-Y]
M;1IWJ3ZBX?FV8UXFV.O87LPKP:.X60S4X7]0^:P,G89%%"%-BE=G'=LHFPI2
ME>UK%<Z!4&/H2GU31E0*UB1GG^Z^SAT@<E/OLLT4WLKB%I=8LV$,"K*QOZ/)
M$I+>W?!K-6#]^CURIHK=GQL?[[ S(;-&#;I\DK/23AZSAI6:@944BO?&X9M.
MD:Z72H" U(%K^ZU:_#%/8&A&]<WGR,7](R)JK*15=@</8(P"G=.4IN#X KN0
MR&)?+/7CH0VU8)LS9UP86$RNVVE.PM^94FCK#-O[I&!EJGS=:;V?D-U0%MV/
M-"9CU)^V!*L:$6GAFQ\AE$."3[.,R[<?QS^5&CTZ%\T]IY*VC,%Y";V#C^%>
M]+^#]=T"NV#CSG<GK%U[B2@SQI;1A"MBC@X^[\VPG:"V$"9=5;'1E-Q';@^A
M <F3C6&OUL(9C[<E!<I,NJ>TJ7TR;-= 5_BQS1YEF]KE)*VPK6NT=<Q-BML&
M JI*W^CAZODXH1ZL-K8*P^U,]$;<9_Q7'64BJ@W2;)O3(-:HSG'B-GTQ#FFQ
MLXIZ$!H9.]Y*&5"8[G'IF0$,0)WS!$Z:,'1QI;W)/(+ZFLML1F*"X)9ZO?A.
MAK5DB+RH^-CLX.DWD<'K0*ZF1;&NSQVNB\#[B,!;\\-CV+IGTQO: \<SCWGP
MG0%>R6KP0O4'X'-!S0>@ 4,@..2 %W=Q% .[S5G+[)DK^7 &,M<EHE)>$.E(
MPSMBS'?I8/SIA-T*_*EVQH@E;YK\YP].IL0.T%@LLG<GO$)K O\)X:=4Y#$D
M?;5MB?8QZ__$WE<&U]4TZ5V!!18S73$S,S/+(LMB9I:NP&)F9B:+F9F9F9F9
M+,EBROLE/[+?)I7L5I+:K=3[Y]34/.?,,]4#U3W3I[M/L@0/UR$_^&[HQ]B:
M1>M:,=/XQ$Q%T=7:01$6523YV'58Y@*%OC P,MQP;3\H)9:2XRAY+H5#REKZ
M -O2/EW=E7\DW)J2S[/K0A)7BH.5U"J&(!T-*@))D&A0,JKN6R8+\+*Q8/ B
MVI^I/RT+TCV%/6KRP9VXM["1%+60O#DSS[S:OM)6XZ=(_X:T-Z/DI.-J5D6&
M86;6B!JD@7=O:Y,=5EP?FD(L(9&S=**6HC#QRA8'+ F'$.Z2T)0YOP'U4OE9
M^<5T*S&21#B\1F8])*<>TY#ZU#.*O99^JAUPXM:ITSR2JA8-/V XDRRZB>08
M!H!;K]0, QE07- OAKQ>]-A8PM:Q2TMU<YWP]'( Y=7U.EKT\US?S6.L'99D
M:F8CK0Z;@9 [2)@PB#5 ="VE[U"ER(*6)%ER%1CV'$D#)^ZHV$K,3 0+D.7J
MR>E*\"K"5)BQ#BAAT7#R-A"<T5YE&C#I'"*+8EEYBT&3)=@FYSI3P8MK)' T
M&VE+V2N0G[0,0QE5L+*28T'$,:J!0\P:J'X=Z'CUN8O_J!&'"--[#'-[^ 0<
MD[_KA\-\AU_,C#MSW.3_G6:]-&-Z(3^LFW/L>FG>J_D8D)6Q'V[*.'-/&X'^
M?G4'!2O'#S?V2W.FBRM[;^C/D44UD9V<.V3EP(/?M'@-HNF?+4>+X2&B_E?!
MU'I7/&#0P6+ZQ64HJU;;CR3L! I^*:,)I<<!<%,[H\!ZKC2RD4D%81=S2PN\
M<++HTA_%9WXLZ?!!K2CR@<<Q*9NA^])00\8V#OOS(OJS!L<'V"4W3=)WP:)9
M30VIG7$S$M@@UMP8Y:/:UJYI,2ZVI@)#U8*FNT1ZC"N,RG%&&'6/,,;!D^<J
M+=;&!&N5A-:O/9&,*YP<DWNW7"(6<Q 'B*4L$98P9+QX0[UD$B,0FB,XD] 5
MY#R+7M^]TA[)B.V[*C!'SQ<\PI:LOY/9!A]"VTKH(Z1NZ?[>$JV74W;OA(4U
MN)64*)3*3.!N9AZ15RCY<T2AJ#&(3@13N_:(T"=K^0DH6D;9LRGLQ[NN>6UM
M7==K4V^24EU=<N5*$8HSHA9+J'6!C3H0SM97H9[P1D\\7N246DK7,9Q;48,5
MH2,LG/F.1+ZA\P)"L<ZV&GF=';>=& 993539<*498;X'#VAP"$="T"1W3B;N
MEQQQZR_1%<:1T-'9L@2\D?"X6K<4! <*@W4:X#+M=_+AJ%'RKPN(<57UK3<F
MN7)&8V7)_:#KP\$U'V0)GLPM):@$##J>7(C'T [A;1(/L1&/CB'#^Z_U]56J
MT+A"CH35'B<R^6F;NH.<$D"N.2F5QF,XLI;8^NY?LAR6F/NC?U-WD5FE2*N3
M3S\_EX[JRND1]]XFFZ4XHNTUO<8::4(9BK F:HLC]M,,!,MO*L T8HJ>82[B
M8VO%N7!5R#9I]E)-NF&*)>M$^L5IF*A?X6=JKN+M*@SM0>S+S]Y+_PZ07T1O
MS1N5&LK3&>=KQY8/11A^:MA3T?X9/93&B7'NN<PAG[^JZ1A")*5F>@I$E;J-
M.H0 E]JE3E,5NNGB$,FJD5(*- 0[7< #V7FLC$/G<L")YR[BS1M])'B^^50B
M47P",N%GA6NJ?@OMN@G*/;03&JL5("FZV;8=J;FQ>L3]8*9:1]\_A;8L6@9$
M\+,TW4#2H)60F62G"0NQY?GV %P0T!JMOK-@7KG+RSB%PPY<K/[R@$UK(ORQ
MB3O*.3%)OS*D]LN9-V9(K0 _\Z)PLDZ+3#72WWV9>Y>%5AT+11R&N(&,,DW;
MN][_ST8M/YV1O9?ALA)#PI ,CL4L8<.D&59$HA%("6"!WDSD/0U.S8QY!IB&
M5E>NZR,)5@_$ )7\Y+1NN?VS;OVQN)?\C#9,PFL DW#5\* H"JN @U(JH>UL
MQ!>R0]P&D8CPBK?3_,5QZL!2ZTN74)Y7E>0WW;ZO3K-3/"WDVYY&82 !\Z,,
M8_56Q(PAP^J$A-NI/D/K'[11%]P?0!FUT#WM[6@LA>-P(U9G,M0U(^U9P^7X
M$=A3=$KD:^-= X+\*GJ#EOJ@#:2X.LRA8_Z <4]O;%.>P58*[9<%"VX&O-K6
M(=38?9921@O3.K-'=3'\UMK*/%'0G:66!J&%TY("2UPQ[&;N&]3I-;XZ'M55
M$=HH'BW5F)M==$<4>ER-"7<P@X<OB>WHRA%G;$ZTL668P8A8&,M"C)+Q(2G*
M59F0IE(J&L B!=87%N?TQX=1I?0G +M)]&/NV=*?U8+R==5S_"_M2=[B$\#&
M8R*LP<0@>/L)( %>WAF%YFMEI#32@K-/,XUW#;+KQX$5DYL^#"HYA^XR%;"B
M9"LQFV(V&CBHMIW!@B2J]JCRM::[3=T5C]5.6&(4EAFU53DMIOJ/W8J:;I&2
M]9P_ 4R&GITD4>VNA?FN0S/U&]OT<%'[3_4WQGA)ZUD:TW#,"@B6*Y& !:!(
M1B)3]EN7\7OK]I0J$R-,>F>.B7MM6$Q?MU/RQI&V)V?RAF\7[[8>;P<S1(#,
M@RO$B@I;GC5=XD"E7%#OD@02\J6T':P((@CQ1;YQ^[LC)L_X2U!7^VX0BS6'
M%EJLE/:"_,ZY47V1^6L9)_1/4+D$<_"N!H#TUBFH5"PW84LM:?-[) 3=N;8+
M$[46]V^#4@^P,^4)'C.6$0_TU8@[6[01WG8:[\AQAU_<Y]YJHZR<;J #;X&3
M\] MHU'F,TG*!*$XDN1&6_%89/7!H_!E;'\WT+<A6YB]E/GF+.=Z7?(T6Q.H
M6)LILO%R'1#O'QYQ.AII2@]_":Q?,FU(X,-R.T;DD.1$HW3F4#\5F-9#=P.%
MP R,WTZO"7P6HGG9C3 L97?C\+,VW_R"G$&XWV!P3H',M[#&J@$%\470RO$,
M]:JI^Q=;4W%2,J@%1*[LCK)!RBP2R/Y5V;%46NC($^W1W!@;@9X1Q :J'RF&
M6')IZ<2,W-KT,A'@ZV2F,7J<0S@ZZ!N) 5K'KI*0I;:L[NAZ>?P!QT-XYZG-
MYW/S(Y 91LFIY[6XSQ!3:Z.I.4N4"F%K*L3#D_:/#VZD:V1YX/;=-*&3>'.M
M5 R;\<NJ,C&- 0ZA-5"(,S'RYW:D'1Z6WOI;5T)-2^:+Q#TK-]LZ3%V4KL$#
M#A1=1N<#8>+04<'<'&'&%*>\>Q0)UIP8EZ>D8QBI#D'IE@$\X]_@8/[T&V?>
M8]#&?_""7)1C39TR'6W*,B4CCV^#RH'XB,$\_ <G.?ZYW+V]HXY<+< ;E*K)
M$P6V64Z-@X5=0F,-$W2\[_];CY/2Q<A)EL1_Y$>V:"*\1F/\.-/J;ABM2.S_
M!$!-Q\48M&PV7[OD''%XI#HNWH-D$&S?55M8.?[JJ]7-$5C_ZC?N;\,U*VX7
MR-;\,86M+(8<IGV'+HXN\*:8,P]_*(9>2QF;E0QY2=J%[@=M&]M$7N^RL8;;
M\8+KHB''Z8)&;JH,_$9O%E8SO6+EOA,DLY69V>.B39*]$CM+*5>MXN8&'Q6H
M:9AAS;#T>T"%;V"=N!*]Y$P!\GCI0^K+B] 7=1RF>09#74S.40^@WEA9ARJ?
MOZCVXW[E3<K$\<R^D%VS\,_'4PKJ,<N3U6^^!Y")T(&9K+=7>&8XU(Z:6AZR
M1F9B$6[0<3<KG@2HK9^%402UN6S3^]:36(JS!A9)L!0HB#C];J=7R"M DA4Z
MNCC1+ I0B:+Q#T@9Y%L!R==S?\6)OK$KWN?<44Z164&=8J&8D+N%]"8D#*[2
M1A;@YWP[,O#2MW1P,+8D%LF@)#\4'H[\$H_J(1I>TW]PM YQ7=5U:U#P-FY^
MU3;*\7K$B-!M563>@^RH SQ2L#^L<I,>)$E$>=KG_=-J*7F@$38#T%[8.C%2
M2=!D_29E 8$,A:$RGNU];)2\B1U?3[X'1V9YU50_382$^+2X&4-SN-DQ6O<P
M?*?(GH(T'%H[0&*_"!]==IFIO4@?1")#EDPESHUCM9+?=_,N_D3)>?2!\FW@
M20_A4+LSL>J]PDP+=^_-C2%G^DH6HIXYIF@-#]W<)4Z[27D,.2FBW8D"Q@[$
MT]1XPH$]&+K8O ]T]'/_3O4CSV\ I5*L)D"%5J*2S:LCB?H[!1<1-T_B,4 (
M&PH/!KSQTD/S(7?NF)#5L?]T9G*=,:*Q.R:MFYS/Q>QBX3G#?MP;F>6[9TCX
MMDE)E,0OAI,(_!['BF 6(UE24D-HXK+P])$=S(%PY HI]T)I(50\F<;7^&Q5
M-X6^MV)'C$J9/ZXZ#;?D%+:+_,9)V,W'S&=:S):.\F8:X9Q'*V]SPVP91/4)
M$?D1<O;UBPU-)!++]F CYY#ASP%3W9>J7C.? )95LR.(&[=GVN/QHR.#._YC
MAINEVY0ILP WVHE-/;,6UZW[V4] PPD3U+W5,*FGKF-*XK/^?KD6^E45_/I/
MH#=G4ULK:KVO(YIQ$\'<7"PJEX>V0^.#JD5,]G?B4;QRD+9OG_:&3GRY3:VE
M8CI19)I)<?*T4I/J,AUUC;:;_,_%_68$TY$CPZG!8W)4_UL.6<?0/'Z,_8J#
M Q@"TN01_VN\V-;F1C!(=;J212[<TE[+ )0B(F)V[I E_J<E1,G?A&R9H)W\
MIJ1;\J M)L1IJP@FK.HDV3SI2Q+U16)#?5.Z4VU?V?7-,?D%8WJK<"P)CGJ1
MK4;N<S#](F_K9])##X^6U8F@0P5J,J#G&;JA5DA_XJ$'#D5:6BHY2# S6938
M6KV.F]U7?[A_'8,W._9^3!0;)")C3"-"B1K-%L^ MVV@SDO6K5C+P)Y30_DS
M6OJ^#1HZ0SP;%CF>IX[?"+,(AQ0B#Q,9DNP\EIJ;>>>T\0KEZR9'[JQLP!3_
MK7%*:F94-0Z#DXO2@@!\/92W4V_HFS!IAUL]HRF??QZ'@(1% =G%>*SNS1='
M,[)=)JA&:=(F,K67?#JB/P+_.6YD_W6X&<(QPCMGV^);N[&<5I-[#W>FCUI\
MK/?]F7>"A>5FPI1VR2%LKPV^#JOY=2-Q<#]A8Z"(#[=+I@\\PO9.BOLPHVSU
M8G6%-V7WYKX0;^$+_V87K,!DM30LTN.NV3OAJVKX'<>R1U"NHE7C6<Z'*;_O
M!_)?>L;;K1@5#<3<>!DVJ4-+PU8'?O8.'8C*5G+E!TQ"WEG&[);(C$BD:/1W
M3EZ)' FA#>QMTFD =2^XOP0*I:84?&/UK(<V-2GA1%/W/,+8_(2[0MB<180:
M=A)\:27]U29PU<O,W95K2-K391C?Y0 MF*!G'A7&"&.-<*Y4S'PH<1"_19VR
MI%Z^:)V;KP^X:+Z/W:2E ;*E&Z(M"M]'T3=&Z3>>48%:&#KG]<..FN@GKHH\
MB6?ARU</G4LG6%,C<H$EY?L52+@ EQ.--!R5-CT&1+"*]^Q1X=$7;.QI;%=*
MWC>Y!4] _6*9MEW U( :G.SZQ86I;X2[T>)D'%D694P,+YTH>U; \.#END]B
MV(ZCZV;;M\'FE=16.1*Z^N<KUMZ?GWL$JH[RP?HQD7@(]-20,F33Z051LN /
M8:SA$DM+A:;-9'(L@9"6_KGLQ/O-[O8"339WP:=7T4@C[;5)6L90WW9.LUE
M'FCFCO,!X2GBSRK$M'$2)E=HI:26_8"\BGP&&:?Q:V=3]7V9;RO!-T]P2>WN
M@4[S"9VZ_>Y'KX&W$!RE4FF_?B08%Z7%<R=V4TN873)#T:;&4^+ H8((]\GB
MW>,V7B$;O3P@_G3Y015LT#B>,NW*TEUL8'J4SV66%+/CQ.S.O?TT>NDPBS?
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M\QTU0VC-M&,&#?P*9D6A8ZZ<98E-M/'G+5942FY6[-'=??BGP/G=WLST@Y\
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M78$%7C;.IKY8Z'8UK@>YV"UJN-X#V7ZTB-4T30=+K@OW%6DV[[#W?<72+)]
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MH#B!';CI'P1\^X <HMA0#'=295/&!4-E!/:Q*!$.;P$98WC)Q \1)(0+\R^
M9J,"=Y%"%PX+YGGVDAM,.\[2&KOI@BV%GWS!"?)K103^NS,\)[B&7DW5K@5T
M&;,J0VZ69>6N3 HQ_VE!3O''-9JX-[-;DR./<T9BUE5W^Z.CEJQ$ AR\"_9U
MLMEBE8.VD@S/RY%EZI9=K_C@A[:E9%N)LS/+(.OZHF=E5CI_X<1:Z!,$(6AU
M ASWW=_^--=<=S4.'R?:E>!JF(@/2K3-[$9J2#[K(A4,8FO<IT1 A#R,=W>]
M7-Q"I/H&B'D$A;462].49(K^F/XZ<11FI/6+GG'37G=HV^QINU$/^1*\--7
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M)^R;LATMN 8LA#R*[>>\EI_LN_CBM/)0Q_2^$P=<N'X8*EVE^"WQ;XG(^ O
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MISQN7G9(Z?,MED_3I.0\_M51DN<TW\ZDC[#(7VG_A CWVM"S#/?4,W3L#:;
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MQ'&00FJ4@OAA!I$?TZWM189[6I^^@G>WRQA'UDT(QU=.]6QCS@FQ!3>EAIE
M>NQAPE4S)[2AJ*X4M3@#/7&]NW-<O;N>$%]7TQ.#C$N\@V_-DL+'YAD(DQTH
MQ\>.8$_;N9R,16D, U/.B6JB X)K:S33U(8\/Q2>@6BA-M@0_EOI=?EQ%B!!
MJ(/"?X\",GR"=^CLQ=^_@6+^^;:Q"X$E5+$E!#]S0WE<#;@B>629^*C/*XG_
M@3K48I$_+R.7^QN& <1); 2[SJ;.\DP0AA)L\-W!B_II(>3*X$L\"^K-:SHY
M9+KT9OEPVC^7R9M-]-H_>>0R$!/?WU1KXQU09C.+N:G$8?F6.W_R)V:IP;J
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MBNF#+FNBG=0Q;J0R6$F0SGRV$_255@"<I]TU6@%DE/^R>HJ?QIEGHT?^)32
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M=KD+NV7K"?V2.D1!(,Y#$9,I2X89\*O5D/+'++*NE412+H'I"LX''U0W3Y(
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M:[(Y;K[6?%=,(".SW$=2+"Y5/W']D%'6PWI;F:Q^+FU#RV9W5\910?0S>-=
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M;H3"/N.+<##7F#9^XG>VR].TW[3NAN LP]REWUK4#/KEG91*' _FZ:;%I[\
ME'_C9&AIGG=UNWB4C*%Q)BC=.)5$'0]2%B;^><8T9W_F0ST<$^9F%2U8R0.%
MOL\0A%);LT8O(.V8Y.:VW6><ZS3TH)G]IK/;-7V4R\;4*Z!>U?XZ3E!XC;BN
MGGJ5LKD=F=Q:GA\(32-@M2@'S^#B[>PC:\H;MME:-LB(%]2B=Q":M? .^%WK
M9?TFI7_P'+_T%<7_;J*')$LVZTT1TSNZ<7M$8FYWL\Y=F2D0,X.#<9#N[/5
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M?]ANVQP?+44_HVK'G'8%T)%.C) V27/_+8!L]K/M:8N;Z='=]AWP041+LBZ
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MT9>U%T3I$$O,+/Z.*J,)R!XBH)7__/L*!/G 7M-8M7E&M+Z]5S#E\,>@G(7
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M[(L:1:(J].4-4X_'1RX7=;?Y'2)/4?Z6Q2!0,F?4<?=RMFG=9HQA1;S#Q^*
MV+;()P:,!CY?E4G$)D-VJL.8-+&.(DTD14PF'G5=JDK9CM&M6V$KFIOY*:[D
M5@?B(9MF[,KOYW%00J"()67HP^=5.;9]<*6$=3H%IF('AML"_NTBI[^:#Z1?
MZH )/0DS:8/OOT*;K3+718GO$Z71.M34:X("87S3K+$+.;[ESM2]3D'V^8PD
M68DI0?C]C7&3KH,QDI]N,K^R,2WMX/8\L<S7+W0Y=.DKK/U_1,0/.MW'5PK%
M#[8V\2.L\C.&@:GT%I3_!-AW1;-LJ^1UD/48MM-;0;@UQ# \.Y]^+&R"'@=6
M*9C!NXY_.64!<%*2B@;:;ZMEKYC\W!7&V,7,/,BS;Q-3$X138)'?.KU1N@O#
MM/,9B#%>[[8T(?KT*>81PLPE=87ID/LQL?MG]#P(5@?H(_]'H_8@$!<;%]/+
MRY[_#/PPJ:LG)"A'_]? 3Q@1IVF/0RGZ?PW\H ZI\4@AF&,-LV^L]/P0M>&<
M)&T2&2"%91".^_X%\%BQ*<0\.=+OK:=YT$HQFJ)>[U+Y7;-YJHWO2%SMXJ-$
MV'WT\4+Q\8I18PS2P2!U(OL_9,NPCO_/OX'*,C;\$LS;VB2N++(V:#!DWOHY
MVTF)0DADLFZZIF'$'3ENBLO\M-BC#C3(]J:GNG> W&W[5S&J_@.:V',.VB<$
M0VZWT,'5 ^(R3)WE>=:]\2X&K<_ Q@+3\GRR!;V*?65W7XXEK"L&D119(H=0
M^@''M7WG>TOL_W#06-\YQF%K_@60?=H.^0OH%C[2N=1:S];K_+1B._.A,+!I
M\R_@)/&/6?_OVF\!-%>?7MW/GS\]''B2"5O!-!AO:A>7[.1;'"_IQD1E>&X2
MNW!X)G=RDL%..FO5XAR]4D[ZN467V.\O6"49Q%";4XND^S1T[CB(>?\[S8B#
M5-K3]0&#\]VHX2"(Y.9RJ.6&DH)=!SW7Z<'53S 1IW>"PJ7&1>VFY"-8G(["
MR84GHVEXK3QPJ*\SS4(!N3D)-9<-9Y/\#F/F"#"958 V_@E'ZP'JDW;;34#)
M/=TYR^2E@S92!1'/X2:T2YX"637U5$1#,P3KWJEI(]=/T7ZTBF%DH!V4\Z)K
MG?YO\($?WUG\O#.]_MFMM]O":1*05POAG* H=^'7\/UVUW3>(9: Z[&KU[M?
M4!UX0!N8YKR-ZU=W$(V>;Y402='J_(O/0P1)]1NB8C:8CW7US#-Y/7^[92'3
M_L C-$-GN(65L<"?CUD\15\W<A!QJ_^:D.34\X&*GNB2 GGNOYPJN(L%YQ^G
MRK(X%80[L2DZB6G4AF%5?;M4.[?NN?:V IW8#_UP,= IF=]]&'4>55ZB)7(5
MJT\#YPA$'L^T#HQLL>B0V-W_$<FVOEIER=11226I5^X>.6PS]%Y1GQ^>29=[
MD!9K'$/+A$K/>3\GW%[_[-O'-_"_.]70:+_7@TF;7STK3GCI@C+4EM#"U#OL
MV>%K7G=0"TF^BC%Q:9HDGW@\F=9*%8H4G!LQC2-I!(]9P_VK>#*Q^^=S)%Z
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M"U?]UR6GAZ97;NZ.(:NFF3Z_U<OFN\RI!+,Q@\KI7N.7[.ZN(U=Z18/ @/Y
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M*;"0UKHVDDM3^H4EWDH55 P:!+*&[]E!08QYA/':/R;HB>K;![-]^ZD/:)#
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MW5J1.&CQ9;HM.BEE-7B*@RBMS)X3(+V\HGX6V@;H7:38QAYIO1MX30O(0G%
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MTYFC3T="HL_-4[<,7ZT%A7^GGS>>S> M?(;\J?^@[_B=EG>\W4&. (T.^.=
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M0<Q$KCILX>V]J@P_KPQ,)Z#&G.ZNRU;Q9A.2Y)HJ8 \:JT.VJEQ;#-:O#)]
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M],-S1B^->?CE$MO#@7:R4$3R J59>B/GVI6=#(ZX=L-%E(:@@F;(XMW[!(E
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MUZ_TY7RM/BJYS8((5N 'O0H:)_-D1NHR<N)4!.^ZIP36^V1*9D8-&"M_0Z#
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M8]WHA^Y9CDD00:1?N,<4G3=;<"QQW583OUA%5>8)\XYNJB644@W(6>G1Q-/
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M:?J>9.1R<MUT[A?;1'D@_/;Q_<DGPZ(I3J]Q8/5LNX^/AI>1^=$'#)M%M M
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MV)+XNO789#ZILW)#?"?3!>E5'(8N(A[^KV__,? FJ^NJQ],ZTGT3K!2XDU[
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M#VK6UO[#@BVSNAGAA\HBQB_E\*F[3FOQ%[FE+LBH#L*&BZ_?38.BL5D_LQ(
MW\]QF;ZVMF]-SAGCB3AHK4EZ0I4QOBE6<L$6K13 JK!&VB=A"X+-80]0PU<'
M5ZN9(2&J%1<O*U/41)FYFENN\>KQ,6[7_:JM6JSCTKLFCNF2&H%\,^@;(UVA
M''T^S6+?IP762<"VQ-Q&CR,8% ]-L!:?1ZQ>6TU%EMQ,(Z5WF5JZ5JEH0D?:
M7B],[4NV0_*H)>KVS7Z.^<KO.;+4-8^9MTM984JFXA%PI>@6-RJ%B!_1=_ K
M'2NJ\66'CFYSGI?%FJ57GF:1Q+&1<RIL7J96E)=R(28$:!N4QAD(R6 FC.WB
M?ET:$&.Q''3&I#<N2ZDH+G\'W!?P<A=#9L';A6\O<7;]?CJBA8YM7]1,TE>B
MI:4.J9T\%Q\O2,E-U<HQX3"XC=AYOP2.*-2&=Y/B%^OPKC)17?/F=)JNY%L*
MC6$*B6U>6NHFT=0[#3<?-7LBC'4S;5I"Q6:R/G-R/S!-(+,Q:>">Y6]7:HGF
M^84#)>7;%*^&%QU<UY/H_+?\WP'[A-I?;NBS>[:.6/DXZ3U_4W ^XH)&>P1[
M/ /.AU(\M\@<A\F$\9'?^E^[:S=%Q)K!9385G0A\YWW=B)E&&=M1J'V$QLP1
MJE=N7Y%=[IGC/D$UQ<&5_861P\DVK$JG6H0:+?9L7VD%EKXBWQ<MRF>[M 5-
MZ;]5]@C](O\M:&J?0 _U07= LTSG&)"Y1?=R2>SCDS9R":1=]6"9A@ETPH)#
M<V$&)RY36.O)P!X9<C;B]Q4#^<<273+.T-56-EO*-DK1;;U\G?OYHX<('FNL
MK^4SY'*S:=#9.T@3%Q[/??.8=><NR:QU]NZ)T^_5]#X[BME_%(=[(MQ G2U?
MG[K.;V(ILG@[&E-N7DWWH?LP+#,QGM/%(Y>5G;(@E^\\!<HR 89RR0%=$VO9
M(^Z<[L 93C7%6;^)4/*[4% R>J$K0^06UPR'$=ODYQX$;K'\O9REKB8D+EW?
MT!2N>F/T4\H%6Q6R9^9J[V)9WBB;/-=1@S)I'=F4]%)/T.!*-"[11F\9#?2]
M/LWR=SP07KB,;V$Q32A\)4Y3)RXGE+!6Y/L:3= ;RK93K(V\O$?@W_Q 2^IM
M7M\VXS+EA#MVFV.L!?*T'+ZX\610<$_V#W\'X-BP=[:9L17TI9=+NJF#U-T,
M$Q%G,1L F22K^"@VQ0T!+END=[GMJHX>L0&E>GX?]X4]?@?E7M9E%7"2\Z\%
M86N(([^&:BY_BI91_-T\W1GI[9[P#C@3#RPL[\V#<YP/E'4+G''UFM#.5#5?
MK2[%/\5I^"09:[(/=#W$>8+A/'[(4(4=4VGDS'H\A\3$.WY,,VJMKNA'&UF!
M9/4VFG;E(N^.^]47F;YFV2TGR7[385/UN&7?>ZA+$M@!@RI"AG15M):7\DFQ
M041FB"X?IFA<$2SYZ@O8O?0X;#37%5/N--#O*9D^Y([UI)IN6HZUP1[0/C-E
M+)T4Q W=V*\@97YC'\885G;1K1$J;AWHTWIM=@^UB!1ST<V!#J>GA+B:(1YN
M@0;,\EPE!OYS-_S_C4,:B_F9CF=E^=:A.6;^0QS[]FG-A'=55.:+WLN:ENBF
M*5.&:ES\HR".BNQ;]VWQ6(-"$@J-AN[:'W*:(=\"=HL9GD.A^##5:S^NBI<2
M;-:"F'PHKJ)77GD+A#(. L$W03/; HFJK_7'HHA)3V&3?TVO"EXZJ'X%)-EM
MC9][FB%*LQ[>3O3TF\\P_+40? ?,&#=TV&?-KLSH>/PVWMU+27[B/&X?0Q92
M;+U!,!GVA\KJ]/[Q,K@WHOO8\!]_X,RF#./ 4P$S=!4NQ9,$([%-*MZ+U3,^
M69-D1+25EA6G_I8R]K0?[!WN:+9P^4GM=P_<A2&?L[4_XTV+UA23F;]0=I[]
MSX)?E.PP/ZOO\\#W"OVY;+SE5%@WM19_LL.-H#3^%!?3<!5PP#CY^C6Z^;NQ
M0%A/4J-E'WK>G]H_M1@M<_CL_]S G;0\';*,-:HIU)E%Y_+JD\!^&#"HR9T[
M88AD9Y;8U)KFELG'!Q2X1Y3 7!\ -JW*Y%N'ZID1A2$Z$E>/]7ZI;3ZLD%N#
M5N)T-XXI\9!?5?^SK'X:U@.GX*N$'Y82.:)=JJ&R%Q4ME.G3ED>7%*8U,T/@
MTSD1@3*>GJA+-<85T=JJJ_'\U8)QH]N[/QW[3VQNT=E'+WSP>>J?24OL:),K
M0%9V[CY9T*;%:RQZF+M\<!6<[DT:X9YS@>LXL/SS!^O_:$^JXGK(8P'=/X \
MZ1 &1\EU=83/KYHLB>CPLXXOW@$TS!"A>Q="_L^RM"Z2QIX?# ZFJNHJ1DD+
MOK6JSLARD\>XYE%V)9YA=E^Z'"X@93_(!$#_=),<1FOO[@;8CCS]$LRG6Y5_
M%(9=ZS'![!8>+DZ%YF?190CS-?4<+59_5[5C)@Q-?LG\]CN\% -%L/B ?-93
M8>JB.J*5>F@?/'+2_(W5C>0S@8ZY1B[(S78TF+<;K?S340B,#&/S%UY*V(X+
M]0+C\L&:Q] C\=(,?Y)T5X$>CD;#FTSLZ=1XZHRFN/S7_-0C/%\SL>7][4L?
M?K:?9$O%OLP^IQ=8/#AK+([:7\*M%2!A2-_;7B@P?[R9S?I)"ZF8/[8AC&@*
M9>_/%.ABUJ44$%AH[2[A..K;(,LKG#-[,PN:2\+K3B)GF';4+YT6CQBZ.N3/
M^G[[#N_0<X 8,'-%M"#09ST9.YK\,4VK51(CR%,2.5"3^49$F-FDH)0A31A3
MC23,')N5!I9PU.P/W-;_*3.U'X!"88%,;W1C>7&WLK=[AXSX0J9/7;>_IBOC
M?.YMIS%^!3K>&(M=B>#MOQVT_&[I#IQM.2=8/@^G:\ ;^RY$Z(1]]!WAYM=,
M)D?(H0GK8U3<(T%!R;2&$\*U\?[:?B#1?D"4]]7XBV.E23-K9:UI_>:/"9-I
M!-;<L!'1*9/LP+,I*MZI(E%1_FV<0U8ZJ-N?N,DB[AW>AD#K:];L[=$^GYAN
MR+7*=U.1RR4U_*W_2)_9ZXS=1JCL8T-/=69@T%^0R$\,WD=<T6._\=Y*J[U"
MT]N= O_IY7? NHC)52_%*T3<+!T9C0MD7!TP.3'[),S2Z<S8XL>$.?(D8A!;
MZ J/,Y&C22TS0!-3#[%J[VP(/076UR?\/FY%TD[H60()I>*E,VV*$<)39G:%
MG44M"PT4@-9;.M<O\Q^W5XD^+UY$$_%@\>J0IS"J[=;G5TTN3E\GD4^4Q'WI
M*67_Y*&JGKD\SP@<3-00_XH(3T R!ET%![ L6\4?A;B_T/]BD7#('"X=9R/_
MQ*.M-#W?+-4SG)@J=1 )(NUZLL J$0>E>^C%L]8&U7+5!GR!^QX\9G@TIVM8
M?\731WA+'R-+P_+[P:"J.U]]^K2 )/5Q(V&IV%;'XT)A,8%QJT8+ZAEA4J?N
M=?HQK&WNOXO6^7\;:(^R%TWKC+'>J$Q3=(P*I/TQ.7+<^CT5>$9:3[#D_5=%
M."M1&!QK_8\#_LB TVV7M<[OBZ6_</Y54<9_91TI$(K I,)!BSXBTN<F5']?
M@>^ TG> ;8JN?62'_D?X;N/J=\ Q:!5C#\'D'3!+(Q&FGZ0BLGX-TRC04IC=
MB6_2$..J6>')(X[$Q&YJ2>0H98%(>$:>^&#IK)Q CU#NT/W,G8G,1@P3_;>C
M[LN5H*&X0==6XJ>\]ME%VIV$*=,WU/X8+Q&DO'W$[-)**(F+#.XH/S83?;;J
MM(T=D?SUJU8CJEIY>8\,3;-+@]2JKH*0)8[I1LLBP8PG:)[_+]>"T2=[D,L&
M:1-TX>\+MX^%.!,ZAUV.,!G):#Q$;K)#2Z:P&=@YCQU61V"N52(6S0@U_T+V
M!Y:2B=7=;+N2G,NC:V,CW8<D^I!OBFP=OY3QH((ZIWP_$H-2GLB\/F8+E#K%
MM02?VARJ0R.WV#Q=Z5[.+0>?U"#G-R!NQV>0,B/M8[3W5<3]H*,CD^^0F"E7
M'X*OIA#"P@;'S+%:K$^#0^"]CWI?J$>D- H,5=#7QE7(8]3*T ]+PW1^0<ES
M_AIPNA.DE45R+>?>[G#_@P2TP($R")531'&7%*/C1&*\C FN/G*S4&&,+BB"
MAT+5#R/L@L=AN: U*FI3D!HDP.#HX^*A3K9_]7 18]Y.RY/9VG"5"-[U%M'X
M58<;C)0"BTE2MNM\)UAAA##N /'%<#X"YR1S(4)Q'8&N!?^K5@&OW+@A,A+,
MJ</AAC<_T4OGWXN>C=O16_X'CM?-H%\\P[H/DT5\)NX4^:)G#1\0KH,(;@1-
M_NX\-/S:"I*[>)'L%@L3Y)\:I5F]790FGK<.''V4J>UPXBG=6_)N/PZ"[?#L
M.*#OWG-OR3XIV&)WW8PW2<1B=L;P1^G0J?A%QCC[>9=E%XGZS/?(+K#C]_1S
M.^:/J;M;<;*QU1HGFIQV_Q6S^) #5F7L0V:'2;]M]5%-R^FW+:1!!'#Z C*%
MJJXX9A>K>*2S#NW?TNF:C00Z/^4:GR*3;S4&V7?3I9]S\W3R\E.5?_\/ZMXR
M* ZHZ1H<-+@[!!W<!P_N[@0/P=T&)T!P=W>"N_O@-H.[:X('#Q!<LL_[9W=K
MJW;KJWVWZMOOW_UY;YW;W:>[[^V3.G)/&<EH*70D-_:X=<S/"U*PJT=_E>*5
ML<.3NQUR$]:G85<(I7 )%'Q-<F&DBWE<VV._[B?F:STP<&:43<(5@,9G'S*^
M?L\^G\KD=\]6R?EI!+YDB26D,"E#R=$F."_#(Z_&2XVHS=A#0'9,>'Z.>*2;
M?LQ6.SHF85C=JVU.GQYL:AN44JP'Y2)SE55"')WJ7;U$1@VTX 02:;\IF;J8
M2^R(/1NLT@P@91F8-1XS;+WN!\CO1WYY^  GCS-[HWLVJM6PLN;X"RV5MQ'0
M^?PA>^D'7:&38;!?"(5NW3J=^=%?M ENBZXA-'8)?&,H-=K'%:U>/?^$O8R+
M46BWSFH\]]*R=&PYOVE2ET6<2HKQPAC$$'YII% E"[)-OV\CV(;)\IESCVYD
MV(&23H=1H">.@>'$"DL"Y%+.\SWFH(__D&*##9Q[+<;EBU_+'(%3+TN4<'Y9
MV6":%A858ID4C:>76K",DNDE-;344X@HX]E53#A$\B=R_(AKKS_X2\;T32/_
MN%M<9@!H2QZPUZ841R\G.X[L\+V14OX[O&2PFZV*1G*X^^F <3=!SH":0;!N
M'34&NO+?FV-*.X%=Z?*?S@GSP@R+!_(B+>:OYC\0'-+XU+S2]&V*P5ZT4J.1
M&^73G>V(WOI)-7(]Z5@SAVM!+!#;3,"O3:G_-P6-.>D@$XO.7_LU1"YJM%L!
M<4\%8^Y8TCP1\@GR[[8M?9+7).:_C\3CRGRO'0WB&,[MA/7&AO:$(:=*NI3#
M#6ZU^I,D0]+V,!GGH] ENR@AX-*6G9#9PAOYZNJK!=OLS:-YEJ'_<O)6<7;S
MI[FY\9\<A"P4T-M?LD/IDN:N*B,CW+5H:O=AN<@RQQR@1$_(^FYF_%0A0M[=
MH;3,#TO&I$$*O'6;ZM3ZL01G-C?$-_BK*@(YOC_W_=5M<<SD>P,IH!$?J&1G
MB[:V!;Z%.QV=&[*7M0?*1@X967*%BZ.]HXN:H0SF]!@>D9(,$TXI$ E/40+5
MBH@<D;^MSD'#KJE/_YF]Z+UBAZM=&947'PV;&H5^+=>,+OD/T0Y4/$VXFE+4
M,[.[ T@"8!30+M?,E.U M4JKVA'3NO7[+,_"-?#8N0*;WWZX8[B9;5N_Z,D>
M3@B:U&_TZI,#A@$]38.[>!4/LQ;X>,R<=#4/BKP3"T>PSN;BNI''MRV5]#96
MC,QG ,Z1D@H]SR.T8 X27VH*7<Z/<0F?$T8YT[!$QC8FF(%-*V!XM1.F0'Q[
MRU6?9"&<H" FPY)6+5=4CN&/YX"-P;K_>-YJ@W:R?.A7!$/<W+W'6,ZC.M-A
ML%/G!F&S93S_<)+,VE058C_F7HW!8)M_#;]"B9V<5FG=Z+HBL2"[*2EC <1!
MT+FAM,L@Z/%]E82H\2Q,(:M/+ Q(6KV2;ZZ>JF95,Z!ZD(WL=6,@D_,/P)W*
M0DVG4>C59)EDP(P/"+-+9032AR/GXRY=]\GV?F[Z&+\"9-[YDTB:<WD6>R\N
M.*K-2*%FETM%EWU)N?S!,:4,!5^T5X!IDL8)YVHS;FF>D8M(N)R9.XT\=DZS
MHC(7S"\@*S@Z9H1>O4Y\U,+%?; E3>F0^22'*G!9>Q/MYM6Q5 "77(+W"'E[
M0KG$FAN1YJTO:#('].9@9<\B7SA>9H-1O.8=3%2?.F8*OZVF!><]\5"I?,*?
M,=[0GE"^F;IG9H[\"475$O9X#-1/Z% 4X+AO.R<<9 BX\W:LYY9M%8Q_T6R]
M8<@ DGIH:WTN#)ZY+5 RH^^ERU4 <J1,<::;AZM8C6G?!RD91Q"N8SJ-\Y$A
MA."-H_/O(Z0P8S/["ZOSR_D/C))/.C8Z/D6UX/L;ERQ"E]2+<#S1G5\HY>JT
MH$YCP&LA?.VD!1+3EYPRZR2X+$U3+K/:*Q0'44G?_GB5K^$^\UA-]KK]%N,F
MFAJYCNXGORT7_+LY_,<74"G2(_ )#!+<#:V]2 I7#.HDJXN.THIDXW&Q BI5
MU)(X,\-,Y+T7&9QT#\$!$Z1<D;T]2[JV/4]$JL&\HVO)ZK^P[Q."#4>MUW*-
MW5CLK.GR8-LY1(7V#G@9#]T95;3NBQLP9.O]$J]V;^&;ARGG^D/'W*-:PNI9
M?5$&I%!?'BKN)UR1P:8GF:A^'KF]N%M4^:B\J)J_/9V"404-DGI(#7[&3$H?
MZ ^Y*'[?NL<]M@2;:3=3JH^1\!&ISJZ?7(!\Q+I'UBU.95;>C4TEP5]9?5,Y
M/06+0_*+)8 CM()Z3N+U^"BHZ7$"Q[GU[-Z)VFU7V8I'R!N8SMOG87)TH8YB
M% DPBT%8-OVV2D!T-&IL\6,)(J!\A/.& -Y3Y87BC&*K3FH$"]F@\^\J.M=,
M=U4+UT^-^S3;'A?Z1^=:JVF&,8@WC?D5PP"1;RA-$\L:[4:IF-=7PL_)AGZ5
M-)A>EU%?%FFH/)^;93<^;B!W]J2879I]#5 1U!4*Y6^ E_;B\(YPJRV186Q6
M.".K+"!:WMOT0ARE *?B5JZ<&.H99/\VM J".R6UBM17L^N_+?P6C">Q9D'E
M^(%V2Q6\V4EN-,TPM+O=F;4O0%0Q)9@+:&L:612L"*2/P<>&*<_8K^;A*-F0
MFNCXJ2%D1I=MJ5Z,DE1*X5JBQ*!-CJI3-N1WCN+V+L$,_%0]5ZG4-\EO.(07
MF47D< H,J$,$[['G+2=6)KF^*WE;8RR(]>1Z?FQF)2\";I;>;*KWRR)5@VTF
M360/T!7;(?\ +!8C6=C>K8WGF;'MQ)0=M)^F<5\S"6,5,KB5#2QNI']^;J$V
M?OKH*N<GG7P6)_=[JC$Y[D:8)HL@=K3]]_,/(:W%**/RMLFV44R@E7=.:=I5
M^0C7?BLV:;U$A-LO<Y\"'FB2,2EOA-S:KUKZM+%>@[G/IB:5+2H(1?829K+(
M!Y_BR=8%O[>9=<)V#T@B=-=7],V!!A6T YKTSA&3Y0.B"IDB\DE%81:6T;D)
MU+*(-.S1M?R=+L\2@?R[=/_-!,'>Z%1ASR(1VO6Y;RN!>4"T_"B$.0%(,_7C
M4W;M1VP4>OT6HE*]6Q\3!626?BM$%431'\'W4J?W0YA+)D=;G.K1/X^:]]6?
M ';];_G@:23:PY\/ WP.;WHI5-O(, TG=XG"DGI'7\."ZW6T@<=$ VYFH6/?
M#C&W#M(S2CXPLU+EAC?1,KC\N,JQ"MTO5NH8I"4T93A/+?G3*$:W3'^6S\ N
MF;DQI-F06[PV@82V!;2=M__"KK\?[T]9+MPH9225A)X>[6I6/D["=T6*(=."
M1WF$+YF*R25K,H2W/WTB-OCQR6"2O"U>5+('K')G9+*[WN%AXC/K:FH^<B-_
M!MK7%6H=?+ T8M!"52["LR3ZA)E0VV1_B 3W]'&90=%\TK41AH](A3Q_2565
M&"6Q_V5EYQ52+2Q<N2"23!EEY8\?:0XF.+T.(0T>7\W8(;[AJO^86_B=&4\V
M?FH&:9S>B1Z"2 -N.LS)&I;:ZI79"G%T3KY^"?%25VY&RZIM#VS35P(*$*WI
MX+G6V\4Q/%XQ3Q)"-7@.!#W6FVBSA:Z/SM+*0%R=!-1K]"3D&&8DYBHBT-/H
MM=[H(7+TY&;DO-^7I1^SN4<B&4]DS\=%IRK.%E#]P0LN1.ZYE:OG[73-O"64
MP?8<ZVQ='*"M:<(7Y.\AYQ*R$"KJUQVWLZ9N_ ^[ 0_P]O4E]C!-KQ$.8=4\
M P.JS".,4 KX0E$Z.>,2DF-X;1[!%%IB:HEUW.81)FR%HO&Q(DYV7)H?CR\'
MDREU@0<@UI$''NY7*^#X4P')'<?R=N,(9F7V[A-8YDO3[N!T_ER[KJ"_\<&L
MK;FSE!)7DUR^T=8$,TOY;L91U) TR0W<.!7GXS] ;F8^UOZ.$-I,W$*^5+2R
M^9H?/>]^Y?LGZ,WH<3>\:F.JP9^<DG6:Y02*I319'[[2D3*-,KLO,9_EUUKM
MX86.V'_>8?TYR^&KX;GQR[X+M6WM$+?1OZ3*YS.K+/U<*9BU[KG]$19<=(V%
M/=BB<Q/ADVN1&OLU0$QNHZ><1[M*PZ#<0';HI]#B=EW^8C0V"9-G/\/K5ME:
M_#\ M%.9F_!@*H#S-H(KN=Z)_HAGM4"6'EG^9=?^@_/SJ@<'TM_W#!\7!PWO
M@O^)%[R]EEFGR(,?V.ZZ$9UCWPP:JC:9VS#%=+9/8[)7< QN@RMK\&0;4?@2
M 99%84G;^(798*'2L;S%)WIGIF1-2L8.^TIY[J:GGZ;L_R EBCE6/TT+I-4:
MQ4_>5^@6MM^;Z1UHPE,4,Y7[:X" $HVWHG.$77P86<IO&B;-5R%S-YY"0XD%
M6L5T&/@SHOK+^/'/,$*0E 7&05+:ZKAQW9N%NQF++M7W;>CZ].<E#D/7)6;!
MX6F2$1)<L5>PP8_2M7^ C_3;'.(\QN/6,A$0\TZ6@+A5D42&SQE&!:F)E VC
MUR%'G!P5!S(@?+1N[KJ1+V-EQ4B+)K"=)8*2B7\ >O^\,SWNYYK*;Q\QG-?X
MIQ8K7-P1#8?>UQ.S]O P6KL^YZUI'I+"M-T3R\9P?UM_LH\J\G252E&!A8/9
MO=7=4[,J;5#HG:/,7#15O.FL(7WO3BMYL]3XF(YC*%PFE-"F4I3!F';/DQF\
M?K+>2>/-NQB2UWWDJ#8Z/YDC;-YQ>+N8(&J<CL(VQ##BC#/B6L=,XNQ4<=H>
M[VJ5I&'*>7/;-%I!HF.)(H .,O74H?"\S,QAQK6;LX2J:RHCB;/G)7VIX0H7
M'*//S0%V$I:.S\3&VE^<*9L:D5*'>H5D!Y[:Z6MXPL[L#E89';G5;,&O5 8$
M4],7^=>UJT2CB#0._C+$.A&4:=0J8'H&3+=>L2R!@O/(<#>=2.D'"_W&^A:H
M0+7;< 'X4B5*CJ(<W[%T_>/PK(&),JE)MV;SQ$*VY5RD;JF"M TLEZB(.5^G
M2C0T'AN&%.Q[DO0MR/O^0\-+0VU2P!_[@?D32IUI4%8IV(0GY2PU_0]+'!C.
MTEZ[B@=YC[X6=S4J&&T&4;%G/F>I>@^L#8Z"!D-@=5:UXR4;Z8B,N1]/ETS/
MR;>.;+?])XZ3N NP85I+']A%%YB)X\D9@\]J>.*"4T!?E8JUFP'O02CFI"MM
M4X5I6:'^K2YF#+(6M1\@725Y(-2+R0*4D#W,Z!$A#DMW97UE\MPBS2C+P9-S
MV-$O,O*"@"B(S)IN)]0Y5\,AMM[JG3U0>V7*%(F!:##$UWVX[%R7#VA^&2_O
MB&B@DJ)*J[R);\I+=-IVW4"=[88!9Q^/OVGKR(VQ-U0(^E%UY$L_17*L\%@*
MG:D CHLD7UB+1X]W)Y=G6:@1C.+)?; 3WB^FE5[^ QNO&<:OC!/4X^SFKNF-
M!?WJC$&]'9^Y2QWIJSK;85T^9\H%.8H9IEILRRU@>@-FY6 7U"Y6S@G-S$GQ
MK2LE=1BA+152BE6I3#+V4*4%AN8P&3*W@V"U161L?2_<J/X+RT0SWJ]L\D48
MS@;(\N6.UX)VE\=-((&"@UL2A8/5H%_U:O;SU#)F1<S(:MSFP3O0"I%;#KQ*
M1JP5M\,DM\@*7?>)\L+>6!2K8S:_Q(^D,A;&XC2Y<<UPY#0HP[ZZ?+LME9-;
MYE+)9+,D<LE2]P7-88QXC8@III.=\'@6OIG5MTGG/)$M$4ACAM&C??S>T+5=
M1]>\F6W"],.>O\IABKB7I#E:&YA.,U,:0\?U N35UAX7N.0"=/IY(0N5*(B5
MOX[<D9_=-<<YWIUA>6#&-$\]3?!]J,HF^/4?@,[&PRGQB8Y.:>"$+KZ716;J
M'R"&IPDHBY4BNYJ6"H$JLH6=*/(^&.6TEA:B*^Q=1.;'>:;;9/U,]ZUOLLF3
MR?U8<)+(C_"AU-HFI?,@I73^#FF4BC2G6-^4VDJ3.$40!P$!E7;EDQAYM(:S
MJ8H;5O8 QZGCS+GY]$F*XY'RT]2W8?\(&PSR^!5??CB,FR/VR%'NY\>#K]W[
MOVLUZ?HC6?UTQ)Y[VM08O7J1*S^&H",*&F]WOTCCW%';'86-NGE'VGMISZV+
MV128_Z#?AWX73MDLX$]G$6(LR)19.LB8&8ESFZ(\BM_]!.<MEHSKEQ<PC6+1
M(1)\<]*5E^T82+HEI\;7HO]^0.)A=LMF/?6>WG9DP.;]39G8TUV;V#1@U#>:
M&Y>A+86@-KC9)^7Z?A15*WP$SA '#[\DGJF_4IC($6_M V,VE8Z7LG'F_A-=
M,=MN)$X3M^JZ&\CS'%F.+L3.-OB7,-D0I,TBVAZ#0%*_UEZJ82>V[7D4*:3W
M)A%F;'>X(41WH">S!F3#<OBO3ZSWQU\W"@Q,#-/)PN?+UNN\)&G<'7+M]Y"5
MPHX!R"FVB' 10VT7DNHFE<:A\!-;F$>.L;'EUQBIB66+HAX^T3.%(%V[,'ZU
M!2_'*$"FPM\"D39H\DGG? 8KXM_1'(UZ\HVA>TY)Q+NS%7:8"<. OCCAV!_K
M>_:D?17Q>.Z74YB*5<.I07K/L)ECTZ@L.PNQXYG]_B:V\09W!>GX&*^LL0"I
M*>$E.>+GP9X*ARMVL<H9CML9B'0+D(4&L&K\%E5@Y&[Y'9\BA3F%_U? ;#9E
M6Q,%,8UE1$L6;)5'21^#SXQQZV8:<[P1'BZ.XT<ZAYKWM.[94&?Z'L<'!._-
M;"P.(I-IH5DF!IGVCPV=3S[.R&51FSL#Q?S$::754A##!QELVR&C'$1F(SUV
MH[DT:L=;OS<)8^;):PZ]PP*C!C]HR7]8%&@ Y*4UH&GME:V+(R;# T@V-X6Z
MMO>S7Q-$Y>C4JRG'^<[7K;RQWX/EVJ2,,O#_ 3+K51^DB-N[7&!?2>5,Q^['
MG)W%_2>8VC\(LZI]%X\85&(P)GDL.F!1N(2=T8(Q".>=1MP='F&:S*GE#CIN
M U&%IUU-L6\Z^@)FC:?Y=6O;M%OYKJD'"B4F#BX13="]6Q'/^#AOM46V9"CR
M=O"=#G16AK<_ZTC36_3^H9M1 U6&CBW91Z/<?<AX0_Q;6@N&.((S<M=0!]P9
MZ@%I.>E$L^TD?">!LO*6M?/I]0XP28!Y>=V>4 @U@LF-MWHIF]Q=Q"9-./I$
M]<I=CKP&G!K_1 W=N'^A."07WU--7&LC59,['Q8=QIAVU.35+U)QH\@1(-6)
M+T$SU2GQ=TDI_J8!SK02-*<WT.UJ<7(@4-!/1Z[<2?GYU_) _,W6]^KUYQX9
M.MH=P/:=9*N/VZO)6B)J=-DR/G!P75ATUSC&74F;?L[7FB&FTY(>4R7Q1QF[
MS*BX2QS)U&G./IFV=DW3$)-\N1IH*,5$2&V+S>5$9F5[==C7; :W>=Y;4 U+
M.Y623D,DYNAH-K&EM@:5I,WONWR<\O[EV0'.[Q!)9MTZW%CG4FM2=QFG2]>A
M;4CFH3+K]7S)MS>1$=Q.CV$KKV*'>-<^?O_QB)3E.#,W@S"9U8?76#X(*PDY
M1W(ELR/B>)Q.-*X]8;CB YY,9 4OZT$MYQGU*(MTVFC[J[_-4+=RUU<CU?@1
M@U1//9-+H@34O_&60Y/"_,X-X*:,'Y[0E;,OFO\ +V#3QLO/0J -45>?956&
M!1%VXBF*=.=8Z>;?K<YJY=!]%7J<6-!#])%VALD5:HH0T-Y8Z8P?SR$]";&]
M+":=I)!Y7.J 4#P3Y%W='8]"MW)Q@66[^'%ME<V>P"UOO>$/O^"4O3K!J#R$
MMB<>6O44:_S'_=037,J*J*#+Z)L&1ZQUFBC5*R2W)=E8_WW,*+0CASBF11[_
MB1-EW[$FWT*PADVR7)@V?-F#&YGEQX@+G4FR.<DY(S!/99N4DZF;-LY)2(AE
M,<?@X71-@L0ANU&=LJY/",S;#787V[9C^+5[SA0$\=(:T8SB94?;IZZ+Q:M)
M'M.)[]?E*Y"RL-"V0S;0"Q^[_&5H(6?&'$_"1CLT L$_EC((?6Q85(6NY#F1
M<O+=X'7@#S>^R!EZL?E<82F 1!158M3N1+[!=][Z3=A^*K5P4:%+$R@5O(6'
MJ'97NR]DX7K\+PU#AS7\-,YVXF"6MREX_9@IQ/K<#&GB&JZZ2=(0Y?P=M,ED
MK[:GR4"&>&F'"PDKH_=L<-,!F/8WD\]9=?W_H>OXO\;3S] O#3K_ +?<YQ_^
MA#;\ QRGT$C68"/WT#MXLQA[.V.T&S*.%<S*@H;#T)$/99H%YN2+8Q8LLG3:
MLH$9!%*37&,D6S_RU-1Z!I/H"V5*O=5,,=F*$#_)(U/$*'?J[-36E+^44'!2
MFL>%B])]M&Y39V="_S;DJQ@MFV.13;"ZE_KPP.98!0J"FQ@07)*V%\G4:2>,
M[M2)9#_M&VRV56>:SX_*YNU7X/L',&^R9O2(F: ]6V14^)U+Q4\;-6L&'@>U
M8CN. <<WD\H]@!8J58)H?BH!$X("7 1X8D@PJK)/ ?'9-W8B->>.BN@EGVP^
M:Z)>V@QHJJ0,^59%"QG1C2!Y5>_(,$8LQD.0D4A9\?/,S+LL$EFK34/6'R\W
MG8$^/_;V7=L#56^0YZWS_1.='/KXG;3SDJ"ID^Y$(YE1W"6IB-ZDR'R)UT_G
M@A>'T;LX<:[)O,6&:0I;:A $-E1E#;+*W=>7:%_G@\^CMD+IFYWM%(--X2@4
MB:.]F[1D'W[GR"/96WQ[BMB@45F@U_ !:>I+?_,2N3'&9-M70ZVF6,EJ3-I!
M,//&E_&VB9Z1:62D$"(B3-7:Q?PX5JD$\^DBY(BECI 9&TT)V9N*PW#A9MJP
M4!;"T-1$22Z$*X^S7&L,K>72EZS^!RAS2;D0VG_^W)4\#9D8V3TP@&;"?9(X
MQ$H>=[B%AW;FFUC22HRTKH5BA!LYI+2N"[&$%8L4+^8@5D2V-N5G(>/R^S:M
MI3J+JNJKF[O*A.NTX%G.*'F$#^'3ZX\\D(J>M.52_QH;BL2&3Z%V^.X$?&#@
MN=0@+*=^25_&B46Z6FXT:*@3?J/G37W$&A?O7MG O.&+?2.[.WO$&OG9R8"&
MS?-=H)G )MI%PSB^PQV#D5)N3XC3M(FMW9O%08MWWB,;MUW:T3=U_-,*[M@^
MWB\V>V$H@@4: OI@#-+SYQ%6I-!O+4_$2P%U\:?.<"MLHX#9JZ1LG4U&-?JL
M<IE-ODA8BB@7C[SY_-"A(T.]N<=W?]));(UDEE15"0+9=0D)GEA,1-,C%^F6
M>Z+=CG#C8%!L3XER>%.[<L@1@WMN6EH'Z9@7_5LFM\52BF4&I+R5B4QFTI!"
MIA 8SEIMCH]U+R1IM<:OO7N59\*3^[BQ7!N0WNY 8"J2V= IA1KAAB4\QH(=
MT;V]22QG5%Q@F5BJ)5DZM3 UUTYPMD,VI<M#4,O;(J&51*: 4'3SUO=(E^RB
M_I5FO=\8*U7(?*S=9+@SO%R=T9+"U5W6=;M\^8&P&<;_V7K[$,-JX4;"@#!/
M4>87:+)S5D4B?'V-]^?R#(W;Y4\P:_/+5>SQE1:QD_',#3\PYW=VKU1K0N/:
M$=<HOO'/)%(UO)<,4E>+A0S\@?Q/ICEU?:#2HFW)(2D#R<[ LL3TE8"*E5(R
MQK0,WC:;.HT(?O[]741%C=RTN[=:R]8F"(,,UL0$<&W$AL'."V)ZHA&UA(Y,
MIT/6:(;9\C_@RB:=^G<.J&Z!_2OHA2^V!&B8C*)\&^QEN5_J\R)ZSV'E9P6^
M*:EC,P.#<RJ@/K+1Q>AAH,IO#EX]:\&M[;=@CW:N:):',OM4 XB]&;U^(11Q
MJR4</.=5IS:!WZ_&<%>^GVE9ZJ+NK^W4,[VC6O)""M(GYSO;NGMS6A8W'S\(
M>B]&+M?>V4*E^25-JJA=I94B;4I/,WC<B/5T*AIV^$5V\UW %P+#D3=.QE\\
M^=QD,L;51"OX(#>E1^/GH;-TQ"?[<:V=3XQ_^E"E@+H:6BSQYV -7\8J7;\;
M:<*\P$LP=C(KG<C,_N>T?40+Y1(C_9^MNC1SGVYV4(&TO3?A^2189'J^W*=W
M&=OG\K[%GO!DA9G-5,ZM("$WHH\DEA=W5KS2 OF\H!?V,^_OAUC]T,+)J42,
M!#:%9CD-#P:U/OY?<_F[9(P,+<!;:'PU.3DAOE5'(C2-0P,QHA;-7#HTZYCZ
M^7N !+EPUKULC,3VZ#\ \PEJ+G[V&AW6[ GU$Q-'N*()Q<>D9I_8D&O)"I<%
MO.U<S:2R.9C\7V?%U"SJ!VD$:_K763#;)OKM:8)\ZQ1,N%BFO[-PC<WUC/><
MN%(M*^3=:>-GAJ4R.QN4!G+2P]G#P#',]0N %">)-G^PZ'>WGTP)$**8_=;S
M0)MN+@<C?K5>YDR";NT.9@@.'SVN'1,?(9,"M)3P1G6B?R%5=%<30?=(Y3P7
M,B@+(W ZT%PU@[QY@@,POC2P37V[[;I64439,&9MYAZLL\S"-J57G>9A')@^
M4@V]Y;Y^4IYTHUVLA L5X[5'1",?-)]_T!Z:ZI0\K%:%-*W7YUUJD_7(C]>7
MA/U.&++PI250877[1'(S -KD@)(G)PZKXQ7%\_V(<CFCH3<OSJ#][>0J;XKD
M<(,Y->EU?^ZLM'>FU?Z ;"M'%"(N.B!@\_V>AW/ -2]FC(Q*#\JHGZEM#H'7
MPTE6MI2K=#0.5MYP2+5 )+^W)T_&%$[YTSDCUOP3->=S%'="WDG!F6U=,M,W
M.QL[*[/-+X'I5AB3Z?0(]HE/P2^#Q_#>>0?KF]F*VD&M)\\R'(-XP$-&9I#Y
MT#$37^Z=2R#H7?^=M)'X\HD=6?A._!^ "Y1X':LM/LRF0PXRIWHNA_X##&ZQ
M/O"N2U8QEB,\)3]T/*E<BK_] ']$W/Y;$ AR[@E$R<5^_U:N0T*G);YS>"CP
M!#!K^(.<KN$F(OL/(#Y;*?]JOM+PA[<XA-_6>M^^OO);,&1.NB47-9KO>5W-
M*#1I()^'8#OQ(^SGBHQY0T(SP4#ZQ.=V.:,9B>B!V#66Y63W*9'FF+,<KI#=
M$7?-#L/C";6]:\G1^IA#'[E)RY6 N8CCUWR1X43V)W(R"PKP!UGW@E7. CF=
MVIC^2F5"OO5=<VOHA%Q4A$EQP<@ALX2I<F_>/X"?>@+5G8O5[,5V7>%@7KYU
MWM?JODH.YG9\,P:5S@J4RL6>'PF$AZ3?BO\3+]ULBN^_\T>!& _UV!'H-%U\
M"9/2E=5)\ H1@FVJ29E#S 8PKF:W'G!OK(:_']'.Q_4GW@=X-4U>,RB/60QQ
M5MXH(^44.U^D5-GS5\69WLT+E#7%N1W4O=EJL!D"QXWBF :"KH,(\*[4?8_V
M"KS+]%,YE 0$3/YLA@7BRRRH-]Y+C'$_EAN%C^]KMJ^LBQBTX-7JHK[VM(_J
MP%*"COA7"2XM$9&!N(6$E2SN(=!Z(P)QC56@YN_) W5X9VOM'+K!L*YV$IB0
M, .?Z6S#C)9G_#[.I-:1@]=G>[06!=)2G$L!X#WO,#K_ .KMB<B[Y;;/.RX_
MU>N=2B6_U'^73:X<+T5V?DN2)\Z]JJVXX("D-M.&61S-G9U NDDS<R_W2NC-
MG^P]B* (J1N^GA505?0LM,N/8(&8"7:'5#^LD"]_%CN_):=X\"0Z(B6T9QH?
MKV]\+.KJV>08:JS=CCL4LF?91QUXO,BQ#I%/(#DX*V=S,.<XC&;-5DI.XT63
M=DMLLNC0#2GR.N8SZX$[G5HQ3BX K8"&?"X^D'*PUU1 W'R)8']:U3@6XF,5
M5H*-RRU/IV#9#BE%^J6'&'_B]CF7D1H"S4--76!0:.8AVQSV,-V7[\F5C.N,
M>(4I:8R\+6,BC122!W$,*6"&B&&VA3BD$01T+OBV(5:3^]Z&17M,R5ZI9JM/
M3N.!F"(%EOHM<:%ZKM\E\LS]1UYGIJKN9) \^@8TUF[J>I(,3W7SR3R]/6R9
M<J/VT^6QD.HL$"54T+N\CR:C5@112>E=Z#Y%>7A*N^E);>;PZ'R2%$.SLKP_
M)/C.9 IVFU#,D\ V7;+F@3- > Y%![R7AY2Z3X47&)TV[V/I4>KM8> Y<X-D
MPN,#O752^UIZ Y9F5&->JO?PV55W-)D!+SRQ;'.>7<@X,:MMH0S/'?W9@6R!
M&&OH#_X9(3S?4O\!LF<3&@Z]2_J/Q)GGG%XD2Q,KL+W:0N-]U'Z!W7N>8BG_
M0YY-ZP;';P@NLX\49F/V?%FX;BFBN? >(YPX]'_BMN0W(#4W2_E%B2B6S7<>
MP.OHPZ@_.*S5%0S[5SW'"K8'GU#4M?!+>^ B?YT41BAH:@RYCM]<$,39Z!\P
M.OZ-Z*<S)":=]J6L%CTWK*ST 55?.ZETWD#/&Y5__/VAM?_MLUV_U_PW+.$5
MTM?U+-:GP%^)MW8%3$)4VH'O[:X-[VTJ=.]XMH50DR(#4#[_07]$@3J(S0 F
M6=,I3JW&+6;^W<9:Y[D8ONNK*9.CK^Z. KLGJUK\I^XN7@+5$?!$223\2E,(
M-0/2MO"MU8@#!6)<2D=ROLRG3T40UB*G:=+JC]0_D$#-?FXQX@1<@A KX SU
MAT9['M*@VN WR?"@0&U)*\UQ=)%VD6'61-9K9%0>5N/_'08:FO&FKY[&4E95
MW1/TU%368*L<K Z)(5S#^T8'^=/8Q;C#O#9IQ(ORQL;."?=^2B$(Y0"OO$'N
MDE _>[#)-+JU6ASFQ2K[-A1&^P^ 9>HK"K( F,4[G2%3-D%3R".]ARBV7"<G
M&0KZ]C%_S'1ZHS%.9+URQX>O.L5/KJRV,6/SLM,F<\O=&(7]H$IF,A.=FHN'
M^*&/$1<DB5HHJ=C9*P#YEC<HJ(:L,0]3PY"QZ$P:7[;BU1XEAQLK=B_"Q[NQ
M)@A0W:S[JF%ZFO19ECW9! JX)*</YI=SE?"" Q2&L5%VYW@A?[W<WR[$! .7
M>S/%.[S:0Y8@%>OGR^4]7R[>Q\ZZS,BSN:>00N9& 3R$U!3ZZPG2$0,FQ[NV
M6MGV2"&CN!"ET1?O9C4I]/:[I0S>72X!3 %NCG@P5<>W#N1U$PU162%U#LNX
M3+1(*^/$.+AV_;H0S400:P@=;N=(_-"Z4X? H;R B$_VT!1JO32YST@Z:4Q*
M!4WG36H24>;O2R=8[9IZ\KT_#[5WQNY]_D\W)RA>%1Q#>6"JA0XW<-RT^4/K
M<;.<NMKE+3$S2SHUN8// #BD;1'7STL"8_SDPS^ 1._4/X AY4A@=IUMX>#\
M?UNK$_UPBNP61BPHJ,7232,PTD&.9&'\@[45I(PX(:3&B<-*T\CPB9519Y![
M)%60RSH*'Z?2KK8P/0&3(>8!EXXD=*413!8Z](&XBSAKX?A-?84S)Z\SYM,+
MOBK[T\F:P:SE(#U;B,F<#Y;B) _)V,N)G:3SDD*];\#7!1CYSAN-/F7E^6?.
M(#-1F4,ZS':O[,1XU?Q@2SX'K22NO!9\U4/<4NSX!%C%V1=WOAMT"K#0"!/;
M B 8&JBN@9QO(8UW_0^07"(">0ZZ_4F=3/C=8D5-C"^7ZE>=JU?O@+D51%Q
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MITIMC%)3.#BT/.T3P]V\)_H?:(,&].16:23>J=HV6ZU,VY,D,SA:7[0@H*I
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MSS1I36GKG:I:G<"+\"YEDN_2&QF%S7ED'U&TDA;Q:H MB[FF:TNG:'!E*,@
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M3W^:? =<1EA(1MI3_0?^#_P?^#_P?^#_P/^!_P/_!_XWA"/Z@)1</D14AY!
M\8!CN-2@G%D4B-S1W/JNZW,$9M0AX<36#5+F[SA_=6+_YN7UOGI6FF(WU(\L
MRRBT$>Q&Y<DU; C=0IV4429GZ04&782_SU3C]1(XU9>:L77I^#[DY=5IRX.9
M,756K1<-IW,D[YK.U\U4(VDP]?\]!/W_5T,Z\D'QK?CF'? [E.$=@%AD)J45
M?+CR,OP.L/[X#O >4.@]&<M]B^%PK:7**_\'08&K*3K%B1L8;WL';-;4]I\6
M#6Q:Y$&;V81:+<HITO<Z_N9GC_TO_U\P.'!H( R3#A=4M&W2_V)M-W/:_(S1
M2;COMWDLN-:=WAIXD$=X_TT15.<<-Z-([NCOS:V!6:M"+P3K#D]+T< 6*2'4
MY/:GL]/XJ*=KY@):VRU?R0F4N[$S=/C6H3^)I\*MG(O;4>_MT&,DQD>6.:>0
MN<<]RH:S83Z^5<.VN]8>KKC 3&U!;_(.2!)>6"4J*)]*Z6[[0SO-&2N[K.C^
M&&:NX+@1?TNV4,/X3<A6?^XLX]N?\?ODIC\#RYN/#\SDKE=OPH<#AD8=V03#
MQPO$"<L]%EB:%!.2" XDJE;3TY],J\X5*0KSQ6I*U<X)5B0/SMX!'YTLUHL+
M,U!1B79^A=Y#Y1]#Z$HVD-".-T*D<X*6'TF"1!<T&2N>-[WA9(4">[?KZW_M
MDOK]F>J)D[^G>I;L?XU'^_G?K<Q!^Y(?A=_FR0@/J@W30?M+ZG'V?@7<P@?X
M/)-_A$"-Q-_F.B%?R-+;E+^*T]$]@#YNQK+!PXF1/1A0*07(GAQNI?99C:UV
MEFTX=R(4@IAK9E*)QRTMH?K)YA^(C%1!B8NDU_ZY>XF](TN99/R,7A2;WF D
M/:%.]0M,7G^R<?*2\X#^K-$4HV.)^-))W"!;0?0$^_LR6.\$044*0BZL+',J
MLCX):1V9< OEG4K#YOL()R_S/:ME5%2V(]7">I]]7ZZ#.I&<W[L.DUBY=&1;
MC (]0#'IAN6PFAO?]4XWB^-<7=0!["MG1I(_1D"N5N*0VOHE)T3@;HAE4V'T
MS[?^3_IRXR0JP.0.CBL\GG&:W[URC;Q [6QW_%[N%LBKW22:+I/U^B26!&O#
MKZH]WU+IC76;^QC+S "$[M_F,MYT>"YO O'3--QUO2<#"& -YWD'5;L4#] T
ML?!3>0YYP69HJ]D7Q2JZ%BV[!Y'R^Y[2<W@:GJK_E\?M+Y<XG;,=H*+P9@WM
M_-9X9O&)GBPJ28HG<X_^2KX="/9>,9%92B&MM=>N%L"IT8Z51QY6(0X+-/V
M\4?6LCE$*%B&W.LF-%72ECLRFP$(WJYN7CF-P#Z)==*3-.%RM-+H#[R)3<]0
M^2@5_I7-UNX3[CVRBM\U=G%7!H)P@D:=\C".,U=M8V*_TWSWB!F3H:KO3L4Z
M$C>HCX7'*^[ &;V']8AUS%.QBCUJF+_[P(:X8%5Q5:R9W)KN(XU"V>@P()$Z
M=5L^DOL=\-=QVR@T1>(=\,8FL/8.L*T)=V[[D\LO?:!&W3N7C>?2[9=-[?+D
M59TG&H2'B41;,64-K?;X6+2]J3JO,!X'?8.O8_ M*9ASO_+I"DRV6W 9L1I+
MP!4JT^L/*)O0HE$+&*O5I]0!Q7YC9%9DT:M6'H9A66*BAR4>YS&DQF@,W%UM
M1[#_V<GZA)4*3BPHV>Q-YNNK);!4YOG=&5SK%S],?-]*,ZT+IO AEV?@HV,N
MFM/;$!@MLX/EE^'%]6$B=[>I_X3;U.J(^F,<4FS)7CWI,WQM1AEK"Q^(5.\7
MG"TP5\'%CMWVY+#)^F<E8A=7:/20V0,.O.'UN6WC'L*(WR(>)@!6:QD2UV</
M8T:C*M;Z6/AT8_2(>TE%MKEQRW&;_S34ZI6,\;QT0C99Q!]B80%.>4Z>+I3-
M?/[;_W+@W5L4:G/QMTC1E7.MK+AM"OFD4TP,=@G#<29?/<.8X6K]+]((X9P-
M^#<^^EPZ$V(&4@7UX?7Q,]J+4:I);'25$#)^5QGK0_L?M<[F;]B*$AZGL%!R
M.9&;TX2FBP%:X '/KL0DCKB49&JK=75ZJ]H[@$6>)Y<9Q(M\(SXX2>;N3)ZA
M*@\:Z\5W25^O19<HGV%G][7P:)SO0!@6&1@,JK^=C'7O^'@#C?<[R99TVP.W
M7,%<-V+:7X<B7X=<[?:6F%]O/!3$!;L6RW(N&" 1O11;<AJYX0]8WW^CR:%Q
MRS&W#!U.2O2O#R<BSV3.5*3Q>_/J'NI')Z(&^40 C]M 7@P9#@GQ.@P,E#C8
MV/"M&.@'E?D#_]7P4N1)6'YX]3\:7K#6VW\I'O;]=\,+VL@6422H"_(_&UZ^
M\/7C9OQ7PXO.+/%GRP^X/?^Z@%;3X'D?=%W?^-S*_<,A"WM72"0$=\H?"4<%
M4BJ\!LN>V*7,T]:^2_K4(=F\9K-10-!<ZV7+/QK-HI!RBXP-;\6 ^0B0&1'>
M/&E-IM0^4N$I!.3-6HF410NAT/AI"H^E#-W E9*I1"1XFI!)I,ERAT]KN"II
MZ3,K+=\U>WC17<[2(V0$3Z(5_K.8B+BW"T-8+FW"+RQF8N9/"GQ@D<)?"FXS
M;XWV"GW \_3F#K=8*;Q"0;_GZ1\DH%V96[X- WY<K6<YA+W_\VF0P[[VUB8(
M7RY?U'=UUT=0J_!D4=T(Y1HV.^FY__+I/8&C'VEV$@H35&70ROE3>$F=3R]B
MX.>ENJQ@5(ID;_E!.RS[_EQ@S$<7QO(U(;QS@M1*Y"_6@=H:IE,6@ZLLJTO\
MD9()^YGX=P:9N;,_"TD?$K_<I:UF9'J,CE4C#VN?P YQ2^?\CSD-KW[6.H8S
M]HN-WA<9GY2^A>Q4\BF7I2KU!%&1?IXDUQ(>R\O?V<8,90U,YZD!526I'0+2
MZ$]8B6.L##\@U%N9LE,A'PL3CEC-&!7R.'4F'8"AR?M&G-AGU/#IJPJ,8/LR
M]'W#'$:*;8BJ0A^U#D2F:ZD*>8KJ0UB@EM[JRNU!V9_D@:?&Q-.^3V*SK0\Z
MJ5:&*68\&0:48@=5^.GBDUJ*>^@;,,>:F;2XMD?EM'Z?_(SQT7_ILY0/B429
M'D32PA*Y?"@.%\_]!=T_7=R^ZAX0#!6WX'59*'\'"+YY/G^]%8+PFG)1/)B[
MW91]'^H3FWV]K=]S_.MZM>$%UW;Y@9SMD8'T*.:."N4&IYV7J_L6ZZCN8[@'
M6?D+K6^6>,YUP;[[*1Z^;"GY$/D1+N=^]]M$WX<.O3&RC8=Q0@CM6213D(?,
M/$<R]]3!U(MTN-K4&@W08F>%_JKN2DG)P]E@QP [U]'U)DX):0-B9!M1O\ =
MJ=]?1W!;+EYLR7$UW[O2D!-/DT.7[BK9"B.LRR<*\D$VD=-79Y5TR/Y1[#;.
M5DH":_[KEJKU*X$W[W'/%QO=G0QZ(JLUDK$40JD/Q=6-XS'O@*O(%]UW ,_
MZ\5W+XOYDSF[=P##Q3\KT>@V]!VP<8W%\PY8K.+(^N<;@G9;L /5")(8C4)Y
M-.C\MH@/C@5T1,KV38\+"B4H;157FN/7&G2HPX?Y#P#*"'!U'IF(@+3/?&H
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MCXC>R4]^<B43HU8_\HB__F!2%4=%2;*W$>,*JD^UVQ[=3;3?TE'9NTC.)VC
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MEGE"9#&Z_H^'(;?:][&^LZ?[;'^)*2A7D-W<$ E:)^" XE#@U<[M_D> G:(
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MBS%E]+9%FRM:DX.I2$RF9[N@44VIQ3C[C!^+WKG,X0I+ERQ&HE3_!OX-_"\
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MH<(]%P*RD-#^SM4?O&<#1M3C3V[BM$NFPR35,=)'W: VYXGK!QF;J0Z8;W-
MP;W$2G<2FBG;#1JGK'('A((G[4R+OG:X75\;L:A@M@=SY2/)L?Q'9Q+G5QO+
ML@.MS/ :MFAM!^W+S 1_'W\_I^Q6WIG;-',/=7(T!3=4KDMD$KB2L$2GS0>
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MJ<.FB#>+C9(RM\\SPB&1^DQH38;33G)N!8Z@^T%:ULR?FUJ:FUQ;LPJ /@&
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MAABAXRFNR,G%ZA5_N#@S[C!>/Z-&L5DE<(Q8MB!ZJK"*6]3U:;)5.;3T9TZ
MGR(>J7F$46=8X48%*D>*/[=0?F!2M;_]6&<GJI.>A3D4)^Y@4KI&; 47CXEZ
M3HLER^&L1<_< 8->@<2+PQX)HD81BV.U@A#$F2_M.S5/R5? Z8HA.XA,C:"2
M5O1>)%-86'C\AOZWD4M H]I!BL)O(,4RM37JK[-P&&F:=H+O0K),;#;D=+#^
M_Q:W)#7'(X,_K88$K=L;.YJ*FQU#5DS\_J%FD>]F?)V9NH_SIG%G;,W4?VR"
MQ 2ZA\R^YM7#)U!0GDL>HL'=2DV6B#-F8##//YD$R5&M7J;M;( 5*#_\SG[N
M@H('$Y;ATS2E9#!;"\NC3/^49C':W M['E@@0^]!\!H5]0:(,'9X^;@6LFA+
M9SI^^!P:1DKM+/0$I^HQ7NYXWL%XNXY!MH(ODY7."/+[A:0!'ZFJVFF(AXP"
MJ2\I 599=:AC_&%W34ZERNKCLLR&53O#(+&&+^H(%JSGDNH.<K'F",I:C;GK
MT7L=^B/"S%P'KN3?,]7B&Y)W7%EFC_1-D6OT.P?J[!U^L%XGD%^,+CW!DETE
M31#OX(97A_ A4KK1EW+-XI-EK9DN$81,>I\30CR',3!\I0;GK%0:X$&76H?E
MGZW%LKZ;Q0\8_^(/@XQ55D^HD65U-@ADF@-A[3WP2M0+>K,QJR^E]$79;GM?
MJHTB84#BA6&3A?55#)PF88T)BDG3[(0\O]:YVY3-VW$X9'/9\WKW2UFY&(L]
MO?2B6#^/@95!_BAGTN=FF8^1% *5]HFUG]L8##LND,A$Q]KIF-L!U]C2#NG0
M(\;Q@^EC[#N[@0 &ZIMY\$24-V<-=Y04SJ/ &T!*+>(-0%CT!NC,;$92FQ8&
MH40U(QD6&R"A#39^EFEX1L*7(<PRR#NO^JYQC9848Y8RO#NW_XUY5$L^K!)&
M6'Z#*:%/J-/TQ6RT$]A>[!!ATM_6]JS!.28AIN:Q:*<63 XI[J9+E:MJ9F>K
M2@I9G6J"RL9/*;%$N"6H#0JFTI3S23/7WR+)6V^QQ5-,M*V3GIE6*%_!,=I"
M35EBRI3=C05I:7RA+'P,#0WC9%_&5.#%5W=/M5/A!_2^_O@J6KZ(8T;2A]Y:
M3V89B3;^A3@/)\'R<4)L'_'WQ;6J-I;AUIR=JJVH^PA#YE@NF\.'=UP6@WO4
M0 SFG\9668%E.O5;?0O<''O*I@U[\D@K73 T2SF%/(X>?L/E1--T?CQ4$O+#
MF4#*&;ZI(A2C]=AD@1*":5(@H5.(8N#7&6+:<2XFM?^@;^&%2'2\T+]QTT5W
M8"BI)4<01?V,_AK'5A)>&."BN59EAR&4AD!8C+(0<Q E%R= )7=!MK[2)MU.
M&7W<A(8ZL4I9YRQH%\$KFY<AH6:<C5.5VRPHV!RM?-_/(]J6D%Y@FEKL(T3'
M[B:)?!X %D .(XLTV(6>NKX4$Q=:'FB'[&F7I_,/+8F@#Q!^1K=+$1;D)O!0
MQT[D)T5CY.=1;ZW##TO%#DS'UOP  CZ_ =QY<>.#Y($A)]ZBV@*?V&B19RBR
M;DXU:6(%JY@!;>B:4^C 06UTR,^D M@Z&0=D'VSKKJ(J__0*/Z95MM\$0=UM
M,/%IA>-RF8N-+".SWO)S87-QE$1,.)JWW><JX1TZ-6R_GGK[+.*0%A#[D)NG
MJ>!T1SU3J.WV</74;.A0\P;2MW<4,1S[?Z'G'Q)18;H$^;A+$?N!ER1QXFQX
MU]L9+TY#<  *">,R-)#\H\ 5JOU"O#< UIX]FFY!O.-C)W6[XW,M/+!WGK#+
MBRJ$,5W $3>X>XN SE^(NY $2QJ.9FREZEAN:\'PGOWLUZ<Z]!/:;=W5L-2"
M1+]/>G41 9F2C'XAA,G^9:1TR0PQ]>^R[:ZEIU-SAB$Q]]8 XZ;$4U3VL(8Q
M%A?G.!@NBW98@2%BL#[B- 3=(*255T;7(4R$/X['\XB9U3)'H;[2@KE2)Q(3
M?HG6JH*>NQ1WCF\E+-X"3*MVT=L13.@:01,MQ*&I5"X#69+9/MJPOX:Z-[X3
M<EZ(2AU<$:-CF*1FFP;I^EG8C_B$HQ9>5'T_GV;X J/7$7'P54,3%XU%<II:
M/ W^HT+Z36?@.[D(J>1#JQ*O?4.5<JD)M,V:O60#;E;3)UIG%U:+8]"BL@V'
M+"ZA92WKF7]=V/3<<OL=FQ3Z3_*1R97+I$P5;;*F@UG<:M$Q^W"_+?D\RV58
MC1;+889,^N_MA'+,G]2EENI</'=T+7NQ_27!'#3&4E=.'U\#[A)UFPV8X[2H
M+/Q%;3U(+<+(4@Y4/=VFK@@SI$-@-NY6V6;V\'*T,@ BL.#S)6PIU["$R>R1
M6F%#BY&,7ZFZ"08?[(C=5#=T-@U@@^KY8:RV3?*V5I>0TVT J88N\V%'7LBQ
MZB:7[@._9=KT=I*>V>FW36R2;8WPU8">?.4E=^H.89HT"N$P:#IS\]:*$T7%
M.OF?[X5%D^2_"BC'UE2VB'./&%4I8JCCEK=G;;-<3$](%C^2<="-7+/9!&VN
MF7.=E0D&-2:?_<FSV\[1K@D7YQHSQ.)3!- %;73C &MGMP&E0RD6 U1#1L8>
MWX37NT)%<ZUT)MRZML5VB<5HQ=,:T/5X4>)W(W31IV"2N!3VU<9L;OR(.6V(
M^$%FG:MJJ838  3/E=Z,#H?7J+6>Y_RZ-\ %3$@(L_O$:^)#YZ.Z^?;KEHS4
MYU\<>L%#+4>ZW $7^%&3AP;BE*H"3!D455.'CF#D5,\CK\&1J@;FXU.N4943
MZJVSPTTS>/VV*J=OI:%5![E[NG$M)NK-S69^%YI)S$/L[:@"990<ZOL7-U='
M]&C4Q.19^BVM?')%H]CI_HLN$R;].4&IN)TPQ'8?:5XLV*>R>XX$<KU7U#P_
M+K-E<,5W*+NM,EDJ3FO%3ZZOI# ;7D'ID[FVUL)%^^F94RGI?S0DE+,,><"#
MP\#RY$LV&PK,$=JBL&9Q+'^S?F5I.$8)&,<UEFDVJP@4#1K%Q1+1V&< .D"\
MW&4_)BJGRJ(>IO/\Z4>RQTPZ:/[EA']@<%:$<N"H0K-\]HAKQ0BN)5>D6K,Z
MKZT; CINZ.21\5O2D%EFP7I]06%U-@# R&,NL=F &3?J,O_5(Z;^QYW9\Q!2
MV*L$;>Y9GN;XH+ >C#Y:A.*6&ITPYKB.XN,<'<&.,LFONVS4Z:YSY3 RW>'N
M<<T=K:>MJPT"'U7WHW,"K4\'U1@M<BP8+8ZCR\IY\=2U3ZF[ISK5;%Q:/S>G
MOT]1(@NT^[;.&>>S:1/R06_]XY)ERT0ID'!3Z#+6.D7 !$>IX#UQW_;^)? 3
M>3U6@7]1U\74[V^51W<?JY8R>CK]'CC]7U/G/VGG<8?VC&WIO0I;4$G>_NH4
M7/I3F[]Z5W]YL16(MM53PK>]<!1G=GGCD]:3 (Z<$1?[K[4$/+7FA]S7GJ@)
M_A;>(Q9]SCUPV4NGN<72$&W\Z%+Q^)+O0/EZ?O2C^^<?;;47]2G#P[U8_,-G
M9UD+BB22[2DH/F*9X&0&.93OBZYGA7]9M95,-(1U PW9WQ^ ,/8'(0#UGJ#:
M%:WCY*Q3Y]+?=B!2R_F]<+_SE-4LGM)OISA"U3< J<1*?8!*U7' $[3)J&"]
M5=5_;''0P-MD -'8>W.G(\5;5&"#Z#W..,_J< HOMY'UKFG*N^ I11WA8KZ?
MWN(>@-!&Y [M--=;N%8B_0+!YA[!U>/*^H9WF, Z[Z>/@FUO@#U;5U$DE];Y
M@,17@4BX?TK_*?U?EB(J2$<8>"I>&/WZVW=U[ME@;7XB ]JIVV3<?"J]:K"?
M*"2N9G[\>0KK.8!S&=S>] 22)^QP/DJN7PO>FZ".T+6IO&H*/*N]+/\+>!7W
M#9"*T8/WR>M?B*S_*/Y1_*/X1_'_K&)L1$R>TI*=(P[K)UUBG$;\A,%6EBD=
M2LZ:*:GQ/&GT4/5LN]T(G:NSJ[SKN%BH)$\\LP5RJ.O672%X__@A'U&6BYZA
MD]1L5(^A_V&G4"5F..=3]+4CA$+:<+&S6GAL5=L31)F5&XV;H4# R*S)$X6<
M*-:'[H,='K"A)\RCX9KQ7.#T\/FI)AP"W6!X S"3!3*^_OQ;M0_*IW'$[>B>
MCF,]88K^]S?!K;LN%QT$"0K_6PH)NNP25A1^D<B6E%&Q^F0_)&[X.77ZF0U$
M?#N(#C6Q01#!&?76<O-Y8.S?($G//PS/6FD#]AD,%;Z,V^Q\4&-$__$BWF>C
M"D<O_[5D=!\FA00+;S$?MYH:B;"V];S7%I8KH;^Y]F_H>*$-2F1S#)+!JVFH
M\"Q1\M&X0H__F=%3D)S%JC-8#L,RST0/ P  5J@Q_@4:VXPZPC3_[]C.?Q3_
M*/ZC%1J+(BR*6/3*5&33ZG@J. <P98TDQ2O>[25!T[<<DS((M0YH7UZ(>M0P
M,4?)4)>IP'K=-4!CPN8.D<)3Q&6,R_G?^C_7[D_> .V!B0_,SY]T_MOK%FIW
M7_YT2I=$GS/2RZB\K="T1<\L#M751/RGVDY-PVHD]2Q+XX\)*<T5H[Q?/0F
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M?R4H<!7Y)SC1/<--;X"UBLKND_R>M??9(_5 P<;W)10I.RU/GS.&:%Z?V=X
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M%6@#CSML!\O,.?WLMA;I-@@5L!?[S3LB^)?=:I!D)_L=5>1 N<G#I%$:!X=
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M W1Y?E$_*P>'22[FRDQ*%=-JCOKS(R^R]7 6N%WN>#>XZZJ.9H1.7NFL7KG
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MJ#*V$=".R09FE@H,XT&)>-QCWJ:MU#B@1Z8PN,.:VWP]>%6N<53 6Z 3NHS
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M@=],$%<\<9_2OAU929D-*D(O N;4+X5\_5(B,]L%OP47+BU1',EU=DD0)=/
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MY;LN8D?N?8KQ.Q>A(R:4K@#:W+MF*SGP%3O$-3B^(H'7)5?.2+*;EKQ);IG
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M.LBJ@J^2-7&C?"^^[=8K<^,&GS1X)$M0"B7G,'>I8:X"2![3FQOW ,IFSQZ
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MHVI_$6*77*(_,YV9%[!G0L^(MXR*C%!H./QL3-VDB\+FWL.#1$:+O=;Y#WR
MBL>4^M,96O^!CVZSU_^ #X__N_"!!LJU8L#@L[_Y&R\0(Z'7:['T>_F[X@S(
M_@H1@I#^(5:,52JI@V,$%BNZ<;4KTM'@7\O-"XS\80]J2DVC$,YXU;+HP@!-
M*ZQ?:,H%R<>,C68UJEI?J-HG@:("D8Y $-<!PA5T<YFT,JPFY_9MU47LXYQ&
MO]^T.ZGCR#K=IUXP8T']A-.S(:6:#7#80&EJJNS6V^J#01F 5]""OMX"7Z_L
ML]BW1>1AK2B/,?6+^XD-';:U-$\VCG46FF/; VNN-,Y-H&5:V6F46+\G;'F=
M1D6D'*:$5:P@,J0+:!!B%C1*%0[-EU?JFGU$Y]&B^H"1,WH<3X7)9)DZFI*#
M*WR;W1<)CL)KCI*1-AB3:^FKX$F)&*UUTMC#<C5'7&O_*;ZRU"5LU9P)?\P5
MQS]?'I,I^,'<L9P5A3;IXF*,07 HD,7M(;)/J%1*45K.O1S'#!5%NJO1$?$5
M9B7C5)DJ-/1,IY?SH$W#;SM%6TB61C>Y5"&;T/JG2S*S1:,:DG!H=X,\1&FR
MN5J-HUUV^^!EL--(E'*!9LIO_Q/+W^1H"BF=P[9)O)Z:PO*,9L;(*B<YX@3#
MV-M4W01(.8H$\?9(1% \0OUWYLTP5/L%"BR2G21T[]EN-=.]'%(YN529#<IJ
M6V"S]WQ=#0'-!P*#1%&FG%ZQ!NW?M 0H-CC,Z>5!( ;0WYGHB<8<]\#@30\1
M'96I&6S+3W9WGQ$'C2[M/.QD8.#:V.R:KYWVD@5AHI@2)N^M<QN.UC^3<(51
M"[D0FPR)4PH2D%MUE P<QB[S4W!F%ML#_2.F-FB=96O9WP$,V2XL2EGEJ&'O
M@.M0]X?Z=P!ZM="GK^9-&&+>N, G0?.?TGMP[@FYIFF4[E7J #I@"5!E@=TN
M$YZ/IQGQJ4M(:*C_*]\RF#/E(55Q.?91X'J%PLJ#Z91?A$N QMO!1%X9+,6+
M&P:7)%_]A4@OW!U@T:G'WWFR>4^XJM"4C4I,V2=GFL\)KZEKGOSQ$$<Y"\TR
M>7V%;CMB;"=C\1=SEK'D4!>,RTRY1:=LCZMD>EHW?ZTKXP;3O:+!@B+^J""]
MMN3<*278N N$U]0<*Q@KH[:R/H.ZUQ546!@'= 7-KTNYTVB@1]HH?^3(*K_J
M/V,&3;J#X5/XHR"R74]1?%G>+E9/,%'[PG4?>YDW'PED$3_^WT\%B%A,5@_=
MZL$6U40D'-?+2#A4N@TDT7"9//'<V)U+D:K$_CN&[3/>3#>Q?">WRN-\:SON
M5; 7OD&2P+7:J7W &F@2EM?/ZR\=M*4AY2Y'\$T$)I>GC-*Y!Q$]?V,JBL8G
MR\HO(Y/+\GL%2T<6&B-W:X5SN-1VL@"E\B?O &T;P4*_,+LDOF5<)<: 9A]?
MHV[2#?3 64(D1.6',CBHV-)^&Z.[ERX5C^V4@9'1<QJE@%/\C%5.Q@E\Y-2M
MW?@H&'5/;IZ%]:2>DPB-=!W7K/F-M/M@O> @^](KR_,&1+.J$KQ:Q^FTNOEW
MAF":E=T9._.4@)N63MD:5]#RBW9Y)N&=]SQ6GKXA.K@HVW0%O@=9&O64.Y?L
M(S>BNLT!G':SC"?2_ETJRJ9I-OQ@AVJ-\.(\RF%8EH*-9W8?=O.FC+1YK593
M:YE!-R$:SP<6D>0'*%@W44V]X8#V"!T3+-*XSX#!/\N%\MU(;T8D@HZ+[Y!H
MZA9>P8BBV3X/E1%^F)K)>G+$2Z8@9S]!4TIH9C'QN)92(CV=)(FQ[]PC='3^
M6O:FPV'MU6!RTU,TF3;+$I* _ME&8%>BR'RYD2$V=W3K:'YCYQ&XD&=6O;+!
M-)B_[,&<'4#[)&\@>Y2.=>)O\B#%N0=S'D$-687*MOIS<XT=Y'"IU_J2%RI9
MWN@E2MFI5I%9'I0V@?,1%4VL4QD]:*4JEU:1'SW08#T7$Z2&+_-9X3B<,5F[
M=..\A%%/&_P\&6[Y:7PF,B7K?X?@VZ# ,U'\2#YA81E.$I,SO-TNM:=,DSQ4
M6C"XWY/>I$MW@.6($5VA6*Y&Q9S-#WMIOT9D3G'RT5M65B :N7[4!=>U'25#
M/C*1&-#-2L87&M,D__9Q3;8&T8%T;I75FZ7*CXVI-,?=*P%-0!^TCCW;7&^1
M'@MH2Q;U8<PNZSH0>1\'_J(2IWM#!L,47(CSPK \3!4G53+T$-WJ#F&7Z6]Z
MF,]2\D@KVAVS#J7YO,*_-/1V W)_!ZPOO6X62=H&YDU'9!$$1%$34:4I^%UD
MCQP1&Y9E[_MX%IT[/&/,Z=-Y)9Z?MX5IJJJP4W:V;]J#-)+Q$"+=-L;Q:,L^
M6*)J>$1ZPEJ_1/B/;I'1>YST2GBOD9V/SA6Q6<9Z#<A7\<K<*L=.X:;!YU S
M<8$QPJWK/#*X<'&JNQ)0CFJX3@S6D$=<:XIK13L?B.Y\B6-&.C212L0]^2J9
MU4"4'4%9UW1JR:U']+JI*&"V!D_^*CY$&\*^R?M#7"89$$RF:H@ZVY<)CZ0F
MV^6!B@:%CB=]R[C?=X=\@6+S*2>^>'G,&3DW#5(S?M)DBFEDY?)$-THT'^6S
M>D7$QEURME&*M@-G[.9Q)$I]&$A_#Z:(%8FK)WH>B0LK>6.Z6G!8M 3M:P)C
MXV]-A,R-\>7O,YF:$<JO_?/-3NF]K$7H7;UZQI_@"V;C*Z7<45&QGQB6I*E<
M'D]?$G>?^(7W+D7:*A%_?>943BG)Q,^V:=+FC+>BPANVU*3WCE!KC3*+L(SE
M\L)4K=6 5[:'A9U5I4+D+(39'-*[$*O T/5"<J#V(\\L,)FHOWF2E"NTGM2G
M.I5J,02)AG@9+7R*3J+!9OPT0F*%J'.GSDK@P\BYYZZY[D#!+F>G0@BK^C*_
M1NVY7$#CX:JI.(H!WC7J1AT]@5\^6_PRGB7*E8J.?HF+(I(&2Q&W.S;RC[^"
MVR?3[AX<WK9VC+S_*FE,3=38H"=02FM(*S">E(-O(^4(V9'J!EZ*S3M"@HCE
MN&ROD+8=ECI[/\O0<*JOX6A\2%<WS8+9/IH4- RW4=8OI,):%YLSEY]&D3HL
MIO24QIHFO%@?V0!FM7\H)#')FB K4RM889X.?@F0!GHH>ACBP2'F".ABHI"(
MMUZ*XZQ34\D+XAWSHS=;XW7_BCR$-S-N5D)8 YVL_CW,H'14Y[6P[CI^)22V
M5M@<;?\E6#O'.A:P(A=?8]F %?GMVC[MEDJ ;=.N[U$29U+EKP,TOJ'64KD1
M/6J\^5:P@=W*EM)(9> #3E2% LBE< 2581D33I$8> @EKNV>82DQ2.[_3[]W
M(QHZOSU1O -R:-^:C)&V_KGJ$-K.^M.?^8'Z'+&638)1I^_F8WCAHR5?6S5#
M6MD7SW$U%7)]!#,?E"S>;O])-/=P 7J:O>QRF62H.AI++YDWTMRO%6_C*F&M
MZ23@][':09UFVS7TL#49U:B"'UF.;Q]QA3SFY'/<3UA4UR-3/O'.FK.=8O\H
MGXAO[XHVS\4ASL&P]X&#),Q^9Z&%>&_T6NT)$V!-7;9L>V+&JE@%XC)G?A@W
M%(&EC]:>.([=,)P-2!,H1[UA3)S4CB1WXIF:Y:%@,#=Y7LI_^\23N?A:L"M&
MTXS!^6W-_I-[R<FBX"1-3@O9(HUF+!77D68ERS&KBWDPSQ*0E3U)TO(7?@-/
MA!219[0YLJ":+IWE>LXID8#"':S$WE(0>/94AHO-:78^;JDL;Y2$0.@P!]2.
M#730%;?PT-Q(_OS[ER];N?M5$ZQ%KW2RU_H'^+&#(HL@F26C^@8LX^5O.QJC
M!AP^W!S1^7-)=-C1(JDI*54X HRCY[CMQ=O;A7NT7/Y<?!'G]78EG2P9<ML2
M"HY&WZ6LW,8F+UV/-))\M^^L#/%E%U8+5J9Z#A$062RSN' ND"++'-17SUF!
M'9[\1,_ZAT;"#**$R=2D]2ZE9H'\7<8JB)5O7Z"]&:0<E4GN%[''3/NJ(I +
M:3J&+/'REKQ(*RZA&R1KH/XD8Y*R.=3%LZ]XN-\<AJ.9B?%+4U<O+@9RN%D_
MTZ*QY>$?5#D.E^:#]3Y8D<EOJW&2E*ZVKFRNJ458E=",V5OMNK9]_^QI4CS@
M"'S " 35#&-J"3ZB D?2?".RLJ>:Y)5T,\+@'1 /]N'C4*YG BX1Q?+)WN+<
M>WHI)4]]FR[7^)Z[.H\E"#HJWL*ZIX?5JA5Q4$!Q0/!T(;J\3OC[*%96M/\#
M_AT0>?>*T."1,JI3=>L:YJ&L1'400T3RV,)P[T*YSJ,LK]^B3$Q%;P$K$'8*
MCC?@^"I/F6FP&2G\16BH1JZ^*P^>-M-?(8F".7#)<C+VF3ZJRBFAHYNA(WV3
MF7N*T)3*FO%EY#.-W@1X],#S]TAYPMXA7O9/*Q,";LKTYJAAO6)T68 $S\WZ
M2!BVM8AS<G?IL&'OC-@WN:)2 [7/WKBNDP>M^E;[O.*Y) 8<CU+RO3X>>80)
M*#II(@+M (V(:#QA>JB"0(I1.DI6;^37%YN0[',9\;'ME7^@[=."I(Y8;@R-
MN$VG>+:8'!?$O=0P?Z>32".A&5K_JY_IX?<JR#.]?7\L%\]A.$%G%+_Y 5)/
M+0#;_$;T73,0LYH::A9B-"-MD>NZ$(*XE1"[;EC<,E<^I_;RD+]C$8-J!;_2
M/6P?>Q.7-=6_F&J -/%QD35&3V%:&^"H3>= MT9ZF2$Z#?PQ:?MGL8\J!(:8
M_,WE$2?<,1<!@?IN:RK*]J!,U7UWTNRW#V^^ DT@?R(G?&@: Z?B$;J88OI(
MBU7.C1(J ^24O)'- +>$<4;._AQ=GIC(&D+ABR4#J((LS"55^V<13?IJ(HSX
M"(X'4 ,MN3QIF04&^H5/;SE;!2M[1>=("/-:R3CSQC>1L#@JY)@'!-VEEC4^
M?.$Y5I!@SB3-I5_(8L^/'3>HZ!.YP5%.!*ZN;UIML3I'K%2 1#TSL;+36^WD
M^#W%&1SS%949\E-D8U@=_*G6\!DEMYAL7+ :]"7MMVENE\2/6BB;?A]:<:2R
M>FWW"TT"?Q^:WWBJ)28/_3 9?$OHD9E<I.<-A%JVI0X7&:YP%QY<6\!0,,PT
M"##--$FAW0;8'L*=ZD)4^;;"/%<9EM,3^R(OJ'B.R1SU0!.J+(0%B3)H8$=D
M2C=[B5WK.JRL'7KS3CM.U.//0@MH#JS%GX8]QD:7LL/F$FT]EK?F:E7D"'D2
M:$=/2NS%3(D30>Z9JGN>3@XV@SMF. !21^DUH'&Q$E8\4'SAT3_5D9R7A-M6
MP =W,H^4/73PD5-&%_$@0I%@X58[Y:;9R#Q18%!*;BW#^G'>U9JP^C:ECI.)
M:EZ AM0#JA?^.F.T<_=4?L0+/?GK3A!;0D15<B8DDZ'#E5\5.)N,R.@8SP6J
M2*U!X_.;8IUUJ2 ZP1ND?",F5JU?OL4B#, ="T ?X!13CSB!&B;<\?'ZL\DF
MWLYBT*86)XV!S&G[1DZ!R#2+G1*I;E+NI,\%LVEL>A?F80=G<?\Z2P_\KP4P
M(V8985V2E3O2K7JV+;88*C4$_"L6=8NE6W;S+LIEW*]@7'Y[)^4.1Q<!BES5
MXH/ CIQ<(X*0[^"6#1O%$:';?N6H;E$W([ :+!&D:A2D]'N-CS)UQ3$/&.?:
M_0<E8BL5C4B0KX4EHQH["0PKI@#T?*@UV(&.TR^?LBD>6842P:Y4-\,Q?-X0
MSC!1+_ED<V"'6T,X;MJ4!RXZL1A[Z:_W^XO*SC+3C3A6AI-L=.^\P+Q5QD+M
M)8-052ZUUZ1HA$-/RS%>UJ"G8361M:!)5\\IZ/1X=/T0J?'K4V -71YVS"F*
MCLTZ2$#/CS3JF>8Z*&%F/N%$IM1,Z'(ZOW@..8T)R=AY"\8<W^RM7WWCE,29
M (W(O%DO<OFTSCK7%TGOEH5UR,#E:(].4(QRGDTA5;CS,=JX^:;E%(7KJ)0P
M(L.<#H]Y=Z\?<7+K.;73%L_Q;$/GLR-$V)Z/8 Z88,?YZ2R$:/QF;URWRJMU
MMD0Y["-7: <9'8(L+8$'6@I]+<L0_$#\JQZ<?G[.S$)-FL)!W"-QX._T54O>
M8+R*+FCA83C=+^W9=;UE06I&R\5$3O2&#6[+>H64[6_H0UYVXT=5A'K+)'JL
M;A!6K;0!DZ.7XQ&H4MH%?]+@B=24_35>*OQ4 ;6'-S1RC)MI=?<^4W$()7]X
M9VDJ!X<=&PZ&;8TB(Q)CASYLM2NLV_I3;T "5[X*VYB#+QJV3[VQ5"CWT*_6
MP]0E/HQ ,N6$ HN)WXD,"OG-/M+V=#(9DA,=>(FLS&S'9,93HD$Q/'*1S;_8
M>;/AG 3ZBCQ,J9+Z+>T>X1./3'NXB>C495(><<7&--JX[$GDN.IT'-@^G-A4
M11VS4(LP1!5W:A]7HR"N;P$8=S%GLFH<G2V4 SDK/LF<^V]F\*I^"@.(?$G3
M7[/:4);D.K9%6.S7JORV5T7[QC"/,R/O86<?45A.311\BPU?')EI>ZG1J89Z
MG9 CB#T9D$2^6M W!NOH;-SP7,V-\HF3:Q&*)XQ#^-(&/&].SQ@69XC_F@W=
ML$H4S9'B*8*V1P)T>;@>+V]9\W@;(]KS4R4M?C=O"=*O&9O/%,?-@&F_-,L>
MY=2\ S!Y%350$@I=QMA[B>"?$>SR9EHODABL<3T3Q89((:@!3B>!R]0= E'T
M!0*O^P=895@EXU"U[_G13><9I:99ILZ$K-,:]$-Z-2;!PRTK6)'LL:#TR81F
MHPO+,/7*_@QCQ>3*)N,B3)%:V6[EI4[1>.^(M CZ[&%/QK&<<W)!49*:6DRN
M&!X>>1TA&G]_B<EJ3E_YI;./'3@M$C2(3^E1V7;?"=V&,U<]^V<J_UKUI;)A
M^FU,='_5OQ$I.0!5F3T:KZ__X=/RLE>7M/2*,G[B.[=R$,%-JZ-5<!I@>'L$
M'4YJMY7#BBC(HPB/97$:A5]\9=AH3;I876;1KSYK&BACG6-77VWWR)%3&9"4
M%1ER'W6\XN];^81M(Y@VX5&:,85#[:!>_"52_,U+A))K'''^GJCP)=,<VRBG
MA03YT'^)B9&&FN+6.]$<E_ \14>P^XV9N="\$HS&=.L*)8I=+/$?)2+^ PN3
MU8Z$/_*VQN7NBG^T!$GHR25,Z(WK) EMRM:1?^N3&[ BI<G3V[BW-E0TUY,5
M$.45F#2\=+#R.0,=LBNO*_AR"O0,-5XJ#7*WI<UC"V*L@Q*/6_]6>$!WVI8L
M5BJ1"4:O[S(-UL(>[DAH-&GD5?F$%E#<.#>^WK= \1JML]PVCPW"/?L;C@SY
MS 9,!3:^(:>;@@3VY\8B;1GI5%(G-VAK;RUQH-8HN5.$BF$B'2J;5'.Q^ V)
M6 CF;C9>X$C@#(@JTBV&,NLY>\>H:L*56)B\JTLCG'R:RX7\N>AV":3ID-(_
M1/!IS[;..-[DDW<+/5/$)-Z3W=\-_:G WE*3TN%IPC]2PUP0U(M33'KQDQ\J
M(.O9[^4)Z+>0[GHBS[3R&.I?J^5F,N\ T>F7*R8_^<F,J:&-,6XI6P)+0';K
M"J, ? 0?N!)UC70XU_\JX\+3M:H1PI I,*X>_:J0YM!06K\!*;[L!W/7^?.9
MCW=1S&(M8+KR4[2P&NSPN.O=&F;')0[ %],P-P1@Y"'O=;HP/M(OJ_!.;^XC
M[*B@KY#(EB%9<B/[SZ[?FA-Z3C&"B=RIP_)5FX4-T.>F+F&UZ-.H[51[5N.(
M/::TG4?A,]OG:.B*"/[&V\RM;JKJ7B=JQQ^,(U?&.=?6H<=L<_ZA::^5IHK!
MIIEVVO.8G#[R]#=T[$O]5?P+P3,/AX?V BCT^J-8 L5<P_RT,\,IJ\,HRMZG
MU'T$:W/[2T.OL/ H8; ],9-*DCN9R(0&6/F,)4RVI=4^2A7/^M:5TF RZF<R
MK5=8N8X"&Q+(]Y</0]-" /-<X=^V*R>XQ :K^UIP+;A,O)W=<PT2'P-BT870
MLCE/$@@@TNVYM;@X)(EF7R+>I>&=+#"(_2P([*&U0^MI*I3W6GACH?^'CO/>
M =W:N$BIP1:M X0;5D9^-P4U:$^^GY(BJ0I4<_.S".>B>5\$:95E]QNZ/^YA
MW*3*>29O?V-1EUJ;G/'P.?XEPR^17]TRC(V&YFDXG=GDY((P8O3#_2[QH0CL
M#))P&A/HM.2 >V9??V--H3G%^X&9> 1'U*HS)!=ZT&"_C*)F_%HS1.Q]V3.I
MJIA^QT9LJ>[(?38_E+,E>$/S6Q7=(55^)-YSGGLFQX<53ZY]\1_RQ9S0HY]5
MT\65=D/7.]H 92F"R5?U:"&,FFV$U3XH]J,<T8(3G2*?L,3,2!SC.:.,1X2<
M(#&SLBE7IEQ.@CI@J\@^D4YL4O7OY^P>B7P'^J'6?M;Q;@&JMVT-YQ;+ KD?
M[!?-N@KL!E_XQO_0;8J*ASJ>(8!?^$F4Z&<,SI!C*)^M8R.5XO/=5S2A'I77
ML9IM)Z*%5#L2<#HD&AV )+ Y0(KHEY5)P#/%]O9Q)J<IO%'(<$<5V"S'KE1+
MI7!^0<IVK)5?VWX-9@R/!JUE #:!-[5"PYK1D5>YPC$^W+JN6,5^L#P%0.]3
MXD+/H'^.?6E"<S21Y$64PC=!=,Z9S'FL!\Q_QJ"85BPHXY*;(#PR0R'S,(3E
MYZ.H:&EE4UY<'D%6)_8!-+'9#0N^Z-@T*SL.:1M2JY&KR^Y=HSS.S]EXV&K!
M*UGY,.*G"PU,%AFI(,M1)?/P4 A*#C>YNF4:7RT& ,$N=H(+NY$8.8;1EXS-
MT$X-'#$1[I%6C.TI0ZJ%[MA^HL6.\HR1#7(^9B-B+#Y0?X6[8JR+!A-#N#!7
MHH[D'E@*3>^ .1-,3V%SVH?;W//WN29PJN8*XNQ_"B>:W;<LAL+*:A"3ODM6
MLIU^&<4CB)?Z*"I8<$0#.') U:G@NA\W8EC2$I7Y_XA[JZ XN"#.=_ A2'!W
MAL$&@KN[>\C@,KB[1G#7 08G!"?H0/ 0' 9WEP0&UT ("022_1YNU=W[<JMV
M]V'?3_6I.J?/K__=U=5'9N@JCB5S^'8V)82X_X+B%>>T>96DJN"+SCZ]ZT?&
M-G+?[RAT=(GJC.ZAIM#F<L]I96U:03,@&Z&Y;51'%\VO $4,_3!K?^"H>H@:
M:9<*&A(_I/>J,"/F)5N 8/ZF;-X'"SE*8GMQ\IK\H"IT7HYRLL%ZQ6B$K5'"
ML-SS&6)0A"N.*+8MC*(:EQPX"E=")3L30W]7CF3JRKS.$!#2O"%NUT 9"XWA
MVRQS*A5O:!6#A\_)[7%@)J<9%2[,62/)OE;N'S 'E^B]4'R;67).91O.306Y
M\BLIT":?']0L?L"*8!W?*<]OA[@>&26VBS2AGKF-@=\/&M^2.K3&&:%4M'P^
M0AOFHN+LE?XX8L?ZJ$E2_-2!<?.J5#MVNJS>I]$:G282]*CU.H /0C61I&?X
M/M!C,T.^DG7.2L?2E%)+XE(VI8M7>46LU"XL(",JQR[+M,.GD(/TE%[26%6D
M<17;UF']8 ^7Q@&AWT$78\SY&^; 0"="G.TJOW%:=SZM&)9G=1*MW9:VO>=6
MDWVJYS3ZV6]MQ6 V=ZT,OM.C.Y7MGH<W#@RVU2^Z2PM026DP0D=\6>TZXV>U
M>*Z@:,1Y@];*?+U5H!'- PC(7[!JY%JGO!W]X03\ZR&*RN..>^AU^O7+9,&_
M;!-IE[KN/T9[IL:#8,.)"V-,VP8]>J1JK:;3I4:9X4,")($O^>V V)T?+&=M
M627$#/]7\@%%$X82IN)&W3(A;HY+PH#QCCFL0^?:YL^LHCT;HAK94@E6W/6:
M? F6JN'$VVP@\,;.F$4%!$_L]=.]2%_7Y&'\$=ZHP5V?;(G_C7=N#TX)Q_H]
M^7]1ZO=LZ.53O/X)H]YBP_E/%]:[IO.W4]KMT:+NUB.BMBV,2!DR7AZ"=DIE
M>;XNMRX-FBVRK,#%W!$>DVJ.VG,J =D!@:A2\;8X ?-5$B4/R<\;C>-=%O[%
M_D&&/"+?D -U^'O@/T/5"^$6=(/$ O$=492J;"W8W!F3[PO)ZR'E1) _!)\Z
MD]MBW0C;AN\<QK1!TI)-T T]DUS&H1;C*MW!1B::TRG[%&<1JX!3\PG/<+6U
M\Z*:UD1N@+=7=B:^TG6*+ L)A.1$DL#KYVY\5KY(DZ2#T)ZAKNO((>QU@!5:
MF%N"H<6A_:"V6(:3AYTI(R]F-"Y7E(AS6T'C@A#$^-Y\H/=84I9I[5P(W4<O
MB#U$;N08TF0W#YJ:%[X<8DL+9BA90HSMB]EGC&_D68Y^.)PA*%)SS+(LS$AI
MCK&R)4836!?;$FK";XC%)OQ=<E/U!9^U:5]O7J5K%K[^W. Z_MS$.T[D<ZE3
MT(6NTLN'NJQ:8%@O55M#^&T<K#2-/C!_8O7"<W+=IAU?S[ S:0$61/*0*V;Y
M*%0^+W0Q_].>J((_<=0QVCUI!%OICL]]9T#%37@FI7#4JBWWJ/Z#X\WNW7NH
MG-)DN4SHT B.M"A>GDY4;.-AR:6@4/ \\[9'GM7;Q5JOA2B;<^*UR1MJ:BB:
M4ZGB/WKZDW7BLA=,T*>)2J'.)F+/H$(\@S-ZH3QT4?M?)"J:$Y0N(*EO&DD#
M4G#7P-"0O47IO?V\^D?J9[)DIE&;WL*M2J!U2:5F,"G;&\,,.(E*WIBQ"?'1
MEKC<B;1>Q%HA&4FN[8#07<S\7Z,VJUB:65%Z<+5. 1E-C6JJ9F+A2RW##%$L
MKC(M6C17H64P$$"?7%TJUH%47!*-IT(_?5I+'9HQ>^ :R,Y%GW]EZZ?9X)3P
M4@<G*NWZ$'?;%L3QGRLA%)M>7SD6N59E.$Z:D*?R?A1.(8F^&)!8P4CJ@DXC
M4]R?IP^4.[ME*2^OL5W4YJ]K^066*$U;?V"W9Z%(!.K3\#V8L4!*S5>:E=TM
MRJ)V7+BE@^_D"86NWK8H^LM,=58)].O.F#6:E)W[:9+JT7*L2U; $';M(_E?
M+>O;LH90?L@R?7M,)20NNGG$W2  1;7M/MG$19I80HBJF-C](YH*A^ED0_<6
M?J,L;CS\?A$2+2GF"HP1F_IWX\80J5A&,)$ ?X3K.]AV8NJ4_@UQ;MI7>74_
MXUHZ\EL=L$>XC,)CF<FW)Y[-P,#.LC6&U?O!1R\HN6&/=&J4C<2"+Y4%(R]"
M0:V BD.(WIM%*M_=%W6;M N,Q7$XE"L[!A\,"04FMH&1Y\1]J&UG'^""TJ9]
M[;[!$?5(JI\#H2:_!8QOBKN^8@1#$I0-33%>[M"*YE-<$96W$OABO6YUF>\(
M)6!2MZ%<3S06"2QS4]W/N!LLUA Y$NV/E4K4>6DQ,3-5&CR"3VRDZ1##0=CW
M\0PO:!6XKX[EA]-% M0*0H%!\F1HC_H6\!:)Z#"[/HM644>P6/LW(-]YC8KY
MB'/>?\<.CW!,!BAHJD:PQN0Q-WO9N,/KEW>X%\^Q=:__JF#YI6D0BXXF.#K3
ML1MK,J$EL4"9H.R45SZ,/1WV?K"HP!G&^F)--<QH?M]@+A2?N2O"6'@(,;Z?
MUR'H)'$H/5SGE'IRJ5!@0<.\Z5L0NIGWW%6CY$8]%F0V/)<HH.:3UMM=,H*=
M.R:YZ5_1&H*F4IC[6B@!*XS-0CF_#Z3BR;^WPYD0"?:]Z6&7)&ZR,E8@"0(1
MLO?95%>7K9:F/WB$!3W]W8]%J(;GBOF\&Y[U*+6RP_%+$-1]L9U9XQ&LN<-0
MS#ZI&L/RM95$E[U\K=E%V&E6IZ./X1&]#Y%2J^ 9$M#03ID8]S,S2WDLJI2Q
M%_#?*DK.HC*)X_$=XU(*,<#K +'A3"++<1X&FY4\FR=;='Z,(>H.3L+ 8NN0
M,UE[ZN  P4^3\\AJ([Q$.#U&EW!YUN"-QKD1[A-NK825^]?3;BD^VPQIO,?C
MQW?O$NE)_WH<W!+K]/5)<3QV^/P#W,W?,EI[DSAL6&OO(.5@NJYB'*LZH'')
M9!@G*YU$?9H_M_D$>249KC\AG?J> >L[,G>$K31OHB0+9:/5+,8 MX/Y;(2/
MUHGU?R0VIHW<AX0GW; LLD6)5*2J57 _2\O;IR"^%K,G_<00F-V:ZS>C8^[(
M1A)KER=-4!8%.<9ML'ULJS=\G"_T/1<6=?3X7F4G@"*?2AC<Y N7M1]7_J.(
M;X;HR:A9F_7Q5(.^V%W58JEMCJ./_V@508.V*9.4U./;C]=&4K3-X>QI6F3[
M8S;ZOS.B%%QY'16G\ W(9H9?UHVX@:\7N?X)SW>GJ/6MMC[X&1M&^!('?HI+
M/X(D?-59%*2%)(CFU<:VMLG;\4EV^$)W>:MDVOC$0>SLW'GHS/#[\LTT*1"W
MISMFYPRF1F])098KL2/#]XBFNR9?Y$ZRIBVXHC%*-$S.K$FWH3$_KZXP=ZTN
M0 HV]&8DBRC3I!"=\R;]ZM/%FT(04&T2J[<NBGFX*HM'G&8STPO#7ONR0(@%
M?C"W"/-H"N\C#V5"5#9NNT=CEE8Q,^@T8WZ%TV!81G5'#D\)7'(/OZYP71/T
MDHI#5]Q8>A=2R['$C&W"^-Q7Q <<4$;<Y-I2 :D51>;>M9W)7-2,5[X$%:]Z
M+QGN_%%A![QK]^=&U!5:'2_D5*$%M$>7']%(=1J0CK*>.@*=UI(2 ZOWC7R3
MTJGDFSB'NX_UV:;19=($JDSE4LIA2*P0A$O1@U6V')2O!K1_+VV+>KR4EDZJ
M?*?(DR8J.F%!.6Q<EBIFYD8]THX)JLC&;I<(:O:T,U\A#*5-Z3A3^255NU5,
M5N!1EOC%%#%=T"XDGX(N!&R]EC2;CD66!BAST,8.D(AF^(S] ^3H^)P[9JT+
MG",&2\\+Q?-\HH-28$YOA'59W8=#KVS7D!6U[ZE$N^/\<@@&^/D740%>$C<A
MU* "%/9</C<7 2WW*H;N.08P5M8?B\G)I. >-. M0"@Y"CY$6\)GYHSJ+>!S
M;GEYCBG&IH;K 8'S5ZS"6E1ZU%7DD8K/RHGIT!!HHP""G8#W(W5Z)%.5GPQS
M_-<68?<L.87@49]@_"&+R3!$KH/1LF'[HH.*I"A$+\?"_EL/<&=9,C;"(;V"
MND/#16CY?Z^&BZWP=;^)(*#/(<'^669C.R2#R<4(>[XXJ"*"V^(?0$.S-]Y/
M!I@CV_27*.DL\$MU5?3=4C5]MRLQWLND>";Z9M%+IBA1]*M7(>O^037V3FWX
M^_:N;478B2+3M)5=5O)WJI?D7L_KCDN3TBV8OT"]9=WE!&<]S5.^"#<+=P!K
M7NY12&8:G]FK*;02+>URY7\1[2@SL+71N-R[/%,.CWGC@U<J:_LD@M(L[#B"
MJ\7W!QG]7+ TN%UTY-CB28L/\<CHI\EJ<D]#]2NW6HV%VWQT3 '?=2QMEO)%
M15%[>A57KJUZA&>4F8GIQ_@'<<F&E(8J00IFU,H5+FPCYXNW$9=$U '>)C:6
M8LTO2>?(9S 0(EDZ7(HD?I"^K OE^.X#U^%-W M^_OAJOAF7C%$,V/J#F%V-
MGM$!WT"ZD/HZH+B^&7?7,+SS_5QHF2!K)$"%!#D@CB9J7[VS$1'@?C/2U4)
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M&'*2S:G3"XH%%K)Z>I,OK)0V:BW9U>F3T!1E@Z&&FAM?NPWQ,$X18S>5X?\
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M#GU0S>5S=@\+8(DV7V80@%:,_EPFTS<?(.K>)1;-LFJ1#!][4QGF$Y-#:=$
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M2P>T&[1^R:=QX@?;97+W#89.9><M]Z%CPFC$.2XNC%\EXC'EVR$(IK=3$9T
MS8MFCX?TCI*N : 497TG")XH_S,$O>OJ%F/*]Q_R]D(LUP&ZD\L9 (1%4:3N
ME%_6YY^8@ "K0Y4VH[K;S:KM)M6K\#\B-(6Z;3?.3822\XUN1S0!AEGMKSB=
MU$A'5KH;.$#V+DG\Q0U8G<7Y9KC%]Q+K1-U1B<]BOC5'+LF\$6]6?AJ2NA<>
M"S=L7Q^XF!'XR%GRQ?FQ=&>E;>F>W'OZ5M."8#:?C-=1:2/]<[T!*<?EQY7
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M644AZ0%Y3-,F12@@<>#Z^UAUR/[DI4KY&JT7%PI!_/&U_6EGZ7"3;PRWK8'
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M(HB)< B^QWHQ$HV0:1+$]2=E3O&]=]S&]UG]1#^XQR\EX)&J3LH46ST6R4Q
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MCQMT,EOY?+MIF.:O3]:)R-ZXS+="'\:*8EUD>9>>A!1N3\J38VR-.\Z;, 0
M4)C)DHZR;]*ARKD7[O\=:Y)9L@K2)#T1<-GU2E&,@/D_=S*6^Y@CY$Z<G._D
MD!NZZRA<@F^Q&8 ZUB17D$^(>+O4<TU+TB5V$N!$O%*OJ2URE!2*/<*\^#;?
M!TN:.*"7D;8YM Z7-4U$&+=-V=:TF7X&-]8J6+A+ >4]8- *8 U&B\[#34(
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MT^>XF9*HGG7SZ#H^:4YW[4@MLNVZO&MBI1[>HP A\I.ZI;ST/O20X#?JYC_
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M#5I!Y!(C?WD8XRHRI,(7C(D_5)LK6&61#!(V?]6ZUTO8GM16\([DB)0$17>
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M'\H*9JVZ5:?!.+58)E59VRTA.L[[, _X$DK=)QN!801XVLWCVDFXBN0_Q:2
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M9@VQ-,3A/S.BL\4'&_H/-G%:#OJD&W6[>T?N;G F787LT>4887^SS*-;R2V
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MARAJCP6WOAI.]CV_EF/ERT(>6"XP:G*IC5!$!#>=UDOE!([9*1^ANX.>N$M
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M+7ZX>=;YP9P!]P'7+4-]01,1W[_QTT$HO]Y5&L-ZO9.J=,H;"MO#SZ=W;3_
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M.:/%)8@;=.NO2C/'#32$*(D;_0DBAU*_ (<>NCQ$Q:OQE&_?X^,M7AN^@[\
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M+MC ;RXJTZFN 4/P&;R0RLA^6I'S, G"D*WPVI%^TO/Q<6C^'F"V4F0Z[B^
M]$7R;IL.--:@6C 9U64).7]Y DO,;G72\1@+E&"? ^KP=IGI,((L/ 5>.&:+
M^O9&>UK8<U,=CFUK/B$XX+4RM[L&[5_;]A7#234-/^,X_BDKFYEFIO&N"3J#
MU$LG'7][L]1B>LZ99261Y8X6>X*= *SIW'E_!/;0Y(7?W);R6J7HE"SW^U:?
MWT?H7:[,64C1/H>ABB"MN[DN=O5,@-L4(6[A,E;((50+VQA*M1$B%;#G^[1*
M%RH3;3)%/JZ)2TL0UX+?9/\.YV20_M@+!EP#.M0?J+AE]GL'UX3R],XN>=D)
M<XQ=31[V-5 GW6 '8&A&+)]N%=U\BK7UNV4)Z5_%%1\/4C-7GIE[J&G8-3=;
MGHT+#=L&M,333OIP+^%H^5RMSIY)$B+\*CUOOBFC5=ER>N@C=7JC/#0Z#0S!
M&6 \W1 )CD1\PL#9[,XD(ZEP057<[QK]V0>4!^?5FW]Y.P:3!0,> 6\L&U6C
M_J(H]^?!M9?>C<!:EU2B"%L/PI1ZOH6WT!1BH:Y%$ 4)UAH[%+L;-IM\'F<:
M A.&6V;*)(U!+P@SNY5"G\M,/^Y2GL[VIK@XEWR3<A&-R%"R"[0FK7\_FQJ9
M6YE6E\DZ Y+D8HS4ASP339M*D-M?<0='S5;-[&C(4CC"JX4T]S$AS"BJ-:S3
M*<PQD?_T53WDU7E544^F??!ED1KV)X]!HB?AV+SB."^H=%N8@A,7?#5[I6B9
M2)(929UZR"SNCTH=K[<M8Z=HB1?68Y"H-OC'+BB?.M\'=/5]/!:T<%E.B5'1
M7>K_12&5:%A\-.>HY;G'D37NP*4]K$[B8AQWR"%@T_/C=ID<>QO#QG%/'/D5
M:=6Y=U;Q"4[MTR7(;B#0+&(LR*6OYJR(T4OU:K&0_$248_3#N?Z0.-ORR.9-
M4*73Y+=?*7)>S2;KC<E:HNUZ,M<K^,9[XX,W[./RH%#O(7J>1B!)3&CE9!$W
MQ3=XCL3D-G!RL.&FH--R'_7W4QBRY-1GWB>;,LUBKN=#XH/\PR&QF>GK^'UT
M44#S0;KNW&C_J^P\VB#!K8CAS;^B.*K?7GM5ND8JQ6',)TF$?Y+&71U#NWH6
MNRG)A4?8O/A'T*%!)GA8LTF6#?>&I!C*.-;9%>:IM--S]?0D3'J5A9O%*N(0
MUH9-U5TCF-7TT[B5I-[%%J3HPT$E]3=C72$-8Y6&3K&]+ 22=N*\Y3('^7_1
M_@U/ID8&7EE\JW'+68YH>V8J@5Y8.$5FT8P/POUK'W??0M1(T'N,/-G$GUS>
MU]C<#=IBO)%-[S1:535/YMDCT*HN:UY3%9:N56299/;05Y=ET:J\6-;C,UC[
M?^0$$,''-V:I)5V<Q'7CZ=Z;T,U@LSLME^@)7F^K^$3!KB(%3/_QK;52C>.A
M"CE$C#8@]HP:P%.*\!T+O=?ICF38;@+-=WN">7U3?D!S,AFMBE\K2.W/>AZ"
MHGR*XN81XD\>L_6HQSKV,:/:.YHG7F%=08Z$)K_*'$PD5"#G06"<V0:^TPII
MKS]L%>>XZR'(- IOI5>)%R84R=W&DJ%,E.M<C4[B0$-F])L*C$(F ;4$A#E?
MJH>7!\:G;)NL]",]R]I *%) J!<@?F%:UC1L?F,*$V]6#6][)<LEH2GE1ZXP
MFK@9KJX.G?9%IZIR-6,\Y65",H+K9",H,)4A];3?+V^<!_1/?3(?SIKZ038C
M*;W26S+AFHFM7.QX'WO/-.X4;=9E?_02GA*!<H9K.)W\;NA5.+%HO^Q!%=2M
M29&4=D.I7W1\URE%06K!B=1<L*7FM][4:(]4N2<R#K>1YVD-!'<MV^;K=P:;
MZEC;,.F=>DA2NJ=3^4,*5B=T,/NKXRI'JW=LU<%O8(@M5PG[M7=>&K9B0>_7
MOT$:F!'%W+7U9&(45+CQP-'-\M4,DR\Z:']W'3NY),P'.JDFB-'[40\C"27R
M_U"/FIGA(P<P[T![76X*%O8<;47AC;G6>0K-:AB"Z8#"CQO(V2Q(Q:2_0JX^
MCV]B,D-]TV;S'7 \%..E=(Q\UZ_2HVM-X8HAD/?$&U8FZ%,63X2R5-BO&[2-
M-N9!(6<.QG5IB=SJR2XTK_[AM72*2ARK]=1/PI;4>M21:QK55+K:@](]4,QU
M4]>"5W\S.,'ZW":<V_,UK1EW7(I37"U:#CC&XTXJF$"!J$QS'>(D(#F4Z=N>
M/]K 28T*._10TN'?"1Y(Y]"7@36JE]JN[*P'PGQ[%& V'-9QO=30*TN:_(1%
MJ@0V#$F!=12E&!L&)A)7<:V:W!S=\@A'%#XIAWW0F+T55;:#"-\>2M24GB1>
M$VN1HCG(6"9-/:HRP4$&YYW#7CQI7@[C\.)F*E%L98^C+(D*9C<,677[:3QZ
MMD/ODNI827*R07)$,SI?Z[VP]11;A9W"S;>57V8N3X:RS)VGH_U:Q#VV0Y30
ME-E9R&C+5\J0MU.LW@^ULQ/O4NCBB0-U4\;KW;3%< :;(3(OQ<S]%4FXZ7$\
M\^ZN@:\?BH7=RD9B$H59(C-"?R]Q#;ETS#0>37G0WC3%WS&KI;R*ZW*]U(P^
M;E?_(<^@G+/[4UTLD6*:2)%(^B>#@05[J18>1UJ?7+*CEO2:P0^NTRSE$,:(
M42? *'Y!.NO=:2W^:<[II#4R.&KW'LL/)M=4$($%5MI%:8F1;75L]G"9D;N#
MR8P_P]9Q34D79IL>/] 53RZ1)9S&&G_ ;).XYSWQSDHI>$2-CH9#->W!23+2
MVV(+?V<2JUQJ'CFJ/Q];(I'(7,?C!U-;4Y8/"Z7L,B.&GFR4[:C^;#9;E(K,
M^:]V_'B6PY.Y6RJY8M#A'=>]5I:8+9T0]D64"TW&)61,NF8N)EH$_ Q Z=(S
M$7O</M+?;B! 4*]K;@$_$9)J0;6Y;S(=77IG?5-2IE2=*D,6G"##3 >+81[U
M]/>F6+N\.$=W7DD\%#Z,<?L)^25<U2MT$;=J-GOO7Q+L;&-L-H<B*87,LC8<
M@W:#"';YJ-+8AB4F?J*XKK-;3V%(IID'0XM(ES]C%.7"CJ?H;)]*9M-=+-(I
MS_2/O2,E#EK#H*>_6/J_R*RG$2A51ZW=[ TE<W&V("V>-,TABP.E?K^CQWC#
M]TC27&7U.6@A(1\+)PQ<6[>#J@C&B6F?@4E=K6,N&!&II:LB?),Q8W)Y<THU
M](X=0F%:7<RZOO\D(HII]O?T$?#I<XAS/08)+6I(? 2U'?DG7XX\F:>5;I03
M)CGWQ0GD^D\B"[;VAB%0CMR-#]W2"= 1E'M*KD)W#'GAM2K5MN8,&ECNZ(V;
M[W&;=J"X;/)D8K./#)>H,BQUN9:QCLR"&$ -"AVPX[@6^B#ZY^8JM*83[:XW
MI&[:=#LDU/W&QU*P]8M/9G!X:09.I+C1+FB^D+#]FH0PFNZW!7%^P3B;EF'8
MD&V5$57S6"/7#WRI_='>P)Q8=H+0=QZ8;+BJ!S\'/$%3<B4_SV9]RCSS,;U6
MXE('QQ7#&%O3;FA8AM--BN;+].H1RQ$V'CX8_;^RW\J7?'R]NA(&M7B0RZ:1
M.QDFQJN9=:/)A8 U3&"'YCXV%1N=WK29KJK:6B40]#2H8KQE>2H[&%V&V5Y-
M,*6IV!"RLW7%=-C -:EUH0A(=AUA[=R!1#U7HE&MUPV+*YK2NO--2<^$E  <
M_Y,#C&,5P>2RO$JO*UV_N:<VPR0#WPR]\]2!"N7.UL2!2[[MI>X;+# Z.SO'
MSV2J@UBT+7*2*(XY><!%.2X;66-C-CD3IBJY=KWOT-L@^EM@%5_2^RA=6/4G
M4X82E"D/@R(-\AO>33*U!7+=[X=T P3?M/%<;;;V.3W-22)T6<$6<D-Z2:>D
MGO2W$>R$_CK2CL^.N6/\O*3**:JV&*WY#6KE]#:E#0Z:C"B1&BD-=DM6$<@#
M6[G"S I%=QEY1#AS9=%:(.O:I9HG<6[8Z3Q.+(>C%*]M!RY;99SBT84[*N]<
MRZI&#M</3CH/F9EC"VTA$!('O$*( !- $Q!2R,'D(Q -.18W"0O<(BK*X"29
M,^_G&<4G!Z-S3+O:)]G.@B1HQ"'ST)&X)29R/IS(NJ5[ELZP%Q"&.-=Q7>B8
M&*;PK3RP;.&B1 LPLUZ^ #-X"'\20^;X-TQ:1;3L1KL1A8O*+51/7/&)VD+V
M^1GCYL1V=X\DI,K;:_F.(>CHW[E.#:IM?T#:N5QOB8AG\[0ZG0GT0LVV.F!'
M-V$I4'P!LBWYNFT=?#FLV7,K%1Y(DYH4I7).T"LS$G[XC;+5(E/RI8^XRFY:
M>D%$2D:1L!71$+@2&^6VW%C;&R1S^DU(=Q>\#A@PF=*Q^8KID#]H:%=F)B-H
M,Q'/PV1DN]*BA.FRKG4JCT@=U:R>H3E_FF_L1G)D3A]L'7')V _1*%JHW);+
M;O @>!>Y7EFHLB Y[4>D/H]+=59V:9:);1L-Z9EQEAX^FLOW@4UY9[FGMJW<
MRO$(=;8TS4Y?6I4B]Z EO'.,)-JVPMM"$QF&6@<9(G7M4C89%#B.\;"LL]>(
M&\4MVOX/?I/'<Q;]DS]E/6@E^SPN.*=+AF2FU647";])D;%C"GK%3KD<F,C)
MY*@@HZ DG\*$LR%:,]<*-(-']T6';,DD!E7%A- J&460AV 1T3@#W0KL0W<B
M6<7\Y(V7G:Q(_>++C5$CF^<H43G4B<:5> #AIK0$$^6GK'P6^T/Z,- $@H9F
M[5>87X 4#ULB]T;B^LL5M';$?^D$W-5K6% KC'(U@@B(FG14L_"M,4*I,93P
M]?[PO/V-5VJ2*U6<^;2HLQ^&LAD")I2*;CM60AN=K7+&Y6W;9_G(1I0I<EI\
M<6<Q]W=7/BRVV43H669P3)U ,V]-OU":=B\$XO&/) <1_IBR%O@Y4MT_AD:I
MO*N[0YTM+:,I5>SRH?#^(VL0M&U"2X%ZD\B2V#?DQL\( [WP%M@&8HL%TXN<
M6#D7'? .RMH#&7"#U )".7!B4:;%9CD9X]82-WV]VR,6;+^N7#X+G($_,#3"
MZE[E42)FJR"PZ\CBO=FFI-#U-YKJ/=+\C3?^QQ'[J3@>0RB3947SR5V6W&8#
M53'[^-I9WU##X\<5"%-F6(B0.)V;1EL?<THB&J\W5B-BCQJT(90>0>YALHE<
MU?B2)1SFRY!@3M<D@%\<$-3>@A4X:IISU(7/7J\X.Y,2-0R3)2)4K=9T$Z\K
M7'-TWEY_I69]+9,_7]X;/U5N+LV>,3A1@HE,E85/XI?2*] \IBG(MKC@H8IG
M:UCWB S-3Q232@<I,8,P0H=+W.@270Q?Q6EV7W>;-,Z>$4^:634N'Q^.*''M
MX^JF>"S3II,"R>GI;0EULH1'X;\7<_U.;D@<5']KAXS>R/9+=,K7).;UAS7"
MG</-R1>@_.7U8=;M:>' X*'HT\;OIM8_._#&:$_V0N(:(]<L:-*@<GCEI6/M
M"\!I/X R'^PALRS[GM"@]/"@B#<;A!F1Y6M"+5KUI^*/*&OU+7(+*\IE#_K^
M]?Z<FN?;T.6C+E50]6*5&U/BU!L^]+K^6QQ*+JE^"=V^A3-JK-EU1+N\$GT/
M4X'=Z$QR,=T(@"PM;2R+,(2WO<?1#OZUHHM7X%J["BP4F>YM;04\Y@OSTE)&
MY<A-XB0G6Y\+9;,D3)(L[,;ZQS(EB^(FZ:#@KE6ADMG7-H:]UJW#<9CA$F0X
MPS%OOS_'F$NEDW<L;*N8<S>\ L9$2S1<9K"@4>"K!>=:/*,QG?HJS["P[Q]Q
M61@VK$J*3.2P_683CO%89Z&Z@Y5/K'3\SJ&)XQ ](O'H2L5)DSYC>2NGT2.0
M4VR)[L%D,^)W&#(,:/5O#V$'0**-X/TO]MXR.([O6=-L,<MBQNX6@\4L6<R,
M+6;&;K%DV6)F9HO)8F9F9@:+P0*++4NVYW?O0NR-G9B=V9V-V8G]?ZNJB"<R
M3]:IRC=/G,BSJJO%HT31=1QY\SZ&SI"./($Y$Y['9N3 &Y.:.:69)[-YW=V%
ME,XT @EAH?(UV=$S#FN&,K[3,=98":G#4=:(7^2;B$;&"G_R<J\WMI.OIXN*
M.WL2^4HPCYH5L&,-=TT<Q:K<B])_.R!!K\9_K^P!IR_CW8-Q_%_ .Y*<-^"A
M!&4CMJG_X7=&9Q-P0EL=),:"/"BKA;>F!^YBG(7[B-BCWMZ)ET8(6]9X46$U
M\5J1!;$(PU7.S&-]! D@\611#0PQ;NM3O!722*\<%*TDA9.N7 >1CGY0R<\O
M<\5':=*A=&32L;Y#&MM.(H=BHE7K!XBJ(Z^BT467:^5*]+W$F,(()O480FPC
M%TCK %EL2<*]2=1&ZW2[ 6,-22+M;%U^>')[A'B[V?NJ<0CVWG#6H;,Q$<_1
MY4VLMSU9@[K!KHR._62U_:IT2N1.2<)M0S8;SOTMD_1UFGS:4Y*SOXJPC5>*
MSC0U\H("97T#-#8?<%&H3TA6C[!U,MSU:..%6@CT&#_;#K=+$5PB8J!/K!]@
M3HU&M4HD$0CG,HQEV%Y7AF^7H@6YE*LO*J.!6).'V,VJ'\'YYLZO \FYM7/Y
M=8'?&AOW.UJRW(4KN) _Y%EF^8>@YNY83F8T"?;6DRPZ>#I@"$CAAER.K7*D
M(-.<)\4%YGS[]+Y%08SYFNZX>_24; AR/# BR*+!(:94D@S- JN'2<B5Z^]'
MSF,BA@[.,#(OXW&C\]3'%H;+36?O-9!M1-%MO8OGES)O)%(?9<4X75POTTLJ
M236O+";'#>N=SIZW;-)$;/?S;P2I\SPK5QQ&P7G3A. _]328_W">]9[P9<"Z
M??XPL'1Z*44SM[&'67*C$L_^B2Q*>J5B=B'::#%.D>!>?DCX916]]5B7C!]^
M:1N(-2B$'=?V\[L9SQ(5AU,LOCL?LC^O:^XHI P:6_2T^Q<0#;8[FA2.RK 9
MC<*EL8E-UTP.6E3'%)G"XWQBP'&5R,!>:/K);^'YC*+H%=;GV8INF-W0LD%7
MA_M8YZP"01=7F#LCWS/ -Q]F*["3W-8DED(6QQ*51X*Q4DT#263EE9V#H"[C
M!L=PF1-\,EN:Q:XT4=/'[I%;WZWLKT9*KW&N?>N)!#&J!D=7#WK\&YBU,E.9
MUS!'?Z0K2)+\&D#/AFV\!01S79.W-M[D^VZX6PGZD2)/9I;S=T\TLN"=&;Y4
M+;(FCIS<J$=^1] ,'THCT G>+CA&81(I1H&FYBY6\/'_5[21Q7"RCT0?(+4;
MTPEV<<+$DSC !BA:+-#*>- C*4Z!P.*">I[TS]0V&.M2%P^&&SU?]ZNVW%W)
M_)]Z1+9('XEFA6T"Y'/:931,VC==]SJE8!O0/1?A1P.1S*+7(ANVVRW.@\QX
M;ER#18&YBC7'OF\W=\-??[8FO5X7_05D7I?^^:SR"AMT_;%3]\99^C)KNB/\
M!_LO@%6Q+\:>NO?\)?["]/1AKXWAI\O:'Y+%M]/WUWE_ 2B?T^E,1YH3]CS>
MQCS?W_]RW4IYXW?\"\"T_^2>\:SZ%Q#2-X57=[ I=]/YR;(SX^4W_]7$'_*6
MOX!PGC[!J==:&'=BBN4&.>:4\0:E5P(/IP@_4^ W GH^\Q9?MN5CJQ+U:5F5
M\>\3H=+2:36287G[_;I@+Y4-PXMI))A'7O%>JZA*3FLY.T:]6=>(AR&W?H)6
MV&=KSJMG"\\\P=4<KY<,CZ7C)I6*F),IJ%549_H<:E:VC./%E+"H:SG[J& E
MZ3:6FE;.I[%JE1?*19 +=N@QY$,9,<T%1C6YP9^Q$X_EK&S5]]<_CL?N<-0^
ME-@J?/Y(\*YK*(-Z7$+D3U(>W>\?ZF(WV$:?:1'O?\EZ9#P/B+]V"T+?0O'G
MSDD73?>0$/Z%_@O]GQQ%EI/JRQU PN,(":Q\"437WH=+/\J1'=B$'X$?H%;7
MI*KW>WKR>W^Y&7+QVN<;]A:X]!=PSKA0MX>%</W[A/@.0>T??5<LV_>1YUW7
M<Z;I.-:'/\EQ9+]_S(O=[)I_IN'Y"_BER./X/"3^+_I?]+_H?]'_HO__2,MD
MB93[TQLZQCT7*9QW?^EP%@.-7O^,H3JF'FWYROC6ET MQ\*Y*GJ42LK)+N1U
M(Y73:=I3:Z?93OG] ON=C9H-7L[_F]Y95.\T;*=?QK-FFE.<GL^F6%5KB$G'
M=5JB)-ZIE%C:) +%+X*NR*SWY9CE2V02+U9S?SPJOUM)<_EB6;:&GCS:;3!T
M*SV2[TGX$,WH%F"IJ5F"ULC GJG&(8,,14DNZ>KHA^UZYPQ03364H)2TU%1A
MX CU]]3BHO)C=,KU&O7PER@&H93?N83!$PR#I*.HP4+,64">J&@TIN129:6?
M:*I9@C2H  #R ,#9\=\W7"?\?^>]_H^DH6I=8U/-27$G0N?]?,H_QD[*B?2H
ML8[NE3*W_4.*N!.KK]\IPTY.RSQ[MF^]%),J:#6A#R0:@1RTA,'"%^ I_X</
MF&W?K\M_.9=!4O#X/GQ06!I)ODNKU%R:351(0S)<ZDK-#D@\UEP+JQK5L Y5
M7/NR7@XN0K_ ^^<&?+/S.OW^"/G+7X"";-RGGW;4WC<<?8EDGW_3D?&^[A<$
M['4/_A&W_PMX2+5;NPD/>OYTC_$"5_X7L*A1;-I+AO+?1(<<P'9WC7>V,IH[
M?GTN=R0WQF5V<9/U!O_BA^D #22BTLKX5I,,GEGOL'!D%OS]B0N*+7_F!U5F
M(KO9ENAOOY?XJ$+3"!2,&D$S__V;N2B=(!?RR#Z(#\ GB:-?Y6R\RG 6^!I9
MC(IK@<-.S!G3^C6E&Y1PT%[\S@^6VQ#/$]**E$V+& (C+,3-K/9L9J H43#0
M-S#1+)3'7ZG@N0_%\9Q5MYOA.N"P(!SJ^^\Z['_1_U7T#<F8=X=VNE6N/]'X
M1Y#*K>R'Y%D@]&564V^<*D=Y\1#B/G6'?,[S6UF,_9='.B2?;++D&;>5'Z"4
M$<8[KN:8S6$0O)VS*LBD^TOQ!-I*Y^))1\ZUP"Y?S46TT,@M0/;#P..@8R:0
M=A_63!GT&SE2WL6S9H/,^)JBYG]?U4#RATFA9\Y"Z>F<0X=+EHB)=K*&$F89
M@=/LC4@5)-FK(F@3YPZZJ55SBHO;^%+NR[&TX!ST':AAV3+%&'W]B].S/+>3
M*@91T@R=ZA[?+C%95*/@^!&V\1B[N%&&CS^WD$X\BW .C#N5?".=?3HXG-,#
M$=@3TFWKLQQU*-L8JU :=+ZHNU^]R$> FWY2.F7%\D5M#!TG<3(NC1.Y@\E+
MT*Y:'A]02 %R7:[WVQU!1/MRX)25P<%/;I!X&,\%%##<$N-)NO2/:M!GD42-
M-249V%+504[_D)G&A,NP@3Y0Q5AR&ILV4BNO$N*(*0$71$<(Y2PH+U-7$.!8
MMJ60*"6HSRW,G!9D*B.B(2HI6K'"7\)<1/)'Y>- 0+IQ"4)^.F]!!*1:]H08
MCO1JK494*Z69<%$13=N9)6F/WSZT.$R'(#A/R)L:6*LOIK10.*6+)7&%@4,?
M= 62-4H9O8FU)7H&+6S8JN8Z=.$X!];G%%I->#,88E7K=?!8P\BLK8;F[ZPJ
ML.T]DG!3%T0%&^59YZ,"9FAH6 /)K.L>]3J\ 8,6%D9>Y;HM-OSPYJXZ'WR&
M!5I\2UMX0N_25$I5XASW<@TWIE1W6\SYD^6G>9J#&JU1@L?@U^"*6RYI+K._
MIY:1?L$=;62]QYMP\RC\\;R8RUG2KAKRV1Q!Z35%$I2.=L*+"VTWP:5ELS?V
M0-QJ5*>J&:4*BN3V1(+9EY#9DJ[/BN>7XIR+^,8[9H-<H,2V/^^_*BFW5*2_
M<#I0@&*V-1EDWW;54P$@7L895GX29_]7OG/,4YK^>0J9ZHXILF]G.)97BR1\
MQEY*A/%A.SM:S:UZ!)ZL\P7*E4HYT6DNZ*R*'A,*/?T0@ 8B$?P@ $)#PVO+
M=N3"UY(4S$UE3+J.B7I/.N7VTV,#/;/Q$09)#9;E'-[5Z@GJD&*ZCJOU%HB_
MW^FG R=98C(61LY'6$\;TC:2,T0>_;J)]^@R@UYK3-P^_B!M;F*12QGYL<R4
M]'1</YV[V8@[*6TTPA]:HX[X1,N)DJU^#45B[ A("IJY%.N9*,3)YX%^1!=D
MS&W;Q\I9FY^BLFQ8\X;E0(K2P5&8!S(V1]\EJ"W(ZDE*'M$1#;17N8L.49T=
M,$<F";C,$WF*649HH JLF^H'^_&C>^21#4(*U&M!V/+1[ 8\3I<3NNU5Z-(*
ML0);@0V0QAB<D7F<W2?LTI;V<O8QKMUV%VRB,.:)1A'VR7NT\<Q2LF0<>6O(
M+]UU/RUMV=$2HH8ZW!%VAYGKMN^9T#(\&H0JC4(2"\S9Y\P.3,/8'\WN1NXN
M6(-7*3\OGWGF6O& %%XGE;7,T$F%2*GB5@^8]D_^F,HV'07+<_C$C#4TZ73[
M#,RT7'/?!%-^E.OAD?5.J9S;A[\ HO+1CC($E.LJ&(AI&GV1W3YSA&06SWQ"
M;IL,KYR-5(]C(18E4 _%27X2\S#<RY3=%C,SJZ-/%_:'=JAF^OITW%;_.(D5
M&](H"9_H P+[H3-8LX1'+KT3L*FK7\6CR5@^ W^:023O[\P2GC)RLYF&8XOO
M._3M_LIL14J@('(5=,!1@!VG:4/*HP)+C:] ,]%"N%CUI^?4M\IRN8"&L _A
M_!/JW BWUL(FHK+ASVY_AA-LU$<EL-1HZ476;9"XY)-2.G"YJ?2[1K+@ ^4(
MK3-4_+=C<G['6?<XKD]B:N6U$'V.;,]C,0'AGDZGI&@*#W\I48'\3KK0;1D4
MOTW&4S -G-U<#7WFG6EXF&3-'@L3$#I?]!I"9:?U0,IQ7@)-9^AZ,8M2V+E_
M_NP_N$%7F1:7!-^F%^$ML\"@/6YHL(63ZK?R?961@RY509PT'%,7U=E_=[6@
M^FTCZ*[I*?_VX=1)#C@Q(P!'SY!T,N,EVB&IKYU5VDLROGL0"D7ABM*\>*;&
MLU90=N1(JB!<PP2"Q1M6ZSWSYO*M ^)6MRPOZ8J%,1##^6?WV6M'53@W293C
MA$)=(ZBM&HQDB/@4@/Z2=GVJD.-EY21:KS[3:MK@ [2HCGK?ZG++]C\?8X?I
M\.@A-O;)G=-4),77LU=0V:9Y67&IU+2!'F!HK#PV*3($A9E4)OH;8<UGBP<B
M7@GMC373L?:<\0G,:<B!49=^/3V5&Y3),=@^5Y=-=-(73@LR*SOPWE8T^GJ$
MNQ&)-&(#?L!8J'4)3>@W,FH7"E*]D?)%Y(]\56ZT_17<M\9HFLMS %3IPZ2K
MH@R='<,(#A_>ZBN7GZ,N_T!Q)SED>?31?PQ"J;$.1(7J0TAS!"SR.6W>"]0Q
MI @D7!%A!TQC?O\&.YI+@I,V4K7-4"JMB2$+/J:,RV]I=W3JL%-2V]$FLIYN
M1S(W NLQJD^$BR_&UA$$C8";[*5BPH7)/[H A\_!GTT0!8&,'78+34UT!@<5
M3+CT'(<N\",6DZQ2Q.)2_NN<)T=#C5:&7.?Y"Y*<3E-L3=]23I5?R @!KAC-
MEZT*V^8=L1&RJ%=S=(:+Z=_1(*$27BVOZJGXB/J6N&$1FKM,(FN.'@C BB S
MK(BX"6W5_9I(SI)G8H$6JV?P96/%4O38,DXK'4P/E"F,A'!1T:?[W&D9YK8.
M5S],6>RS"0MFS2MR?_.-*._P\.ETYOV<S#%$CD4ZOHC.0$U3+]C-Q#P]C:"U
MGF/U;&0/IP[58R3NR&BIX#P)R+#!%M_(\FPDK'Y%"(,V;0\RWV3#XC]%E(ZN
M.D;(&5]?6QK1E;C4P:5UM[.[T,B02(RNIV  5.B'<SSID#4W/EJG<?R9L=B9
M'LQ<F6-K&H.FA)-.M;?2V]--QX;"691["1)P=G_?AJ$08!"$(A>_K_5-E\\%
MO*\R+T\DN89YF1XA,)OI<K6\OC>K\1M\4?G",5>B?R>DC6S\/EDZY2_@[$V7
M$PLC)"2H8H7@K"1%#[!0?KE,QI*I4=FOL;]>'GE76^KR26L]G((EQ;V69'W=
MB!.S YO4$K.+1N(T$8R:::C2K'FQQ BS<G.BL3&:(M'PXH3\DL6^L9C%S@T[
M%++9E6S1X^AUY-,>;J\21)K&JE'3XOOS<&45OX#&::]WQ!,K(\!S<$I,=X&F
MG%0YX):>;5W[WHJ>V#'"Y]@S[J,6_F%>:6AG@?EDYU+RX=P";PR:JF=^#MVL
M/&B.T[&,ZYCDF\&*A6S)(*OPXT*9)@9*R6R]I(K=Z#O]P)8J!/S/:$/YXU$Z
M23#8BF5'+<8=XI&Y[\=;4"B.T6,-8J:4\W1/IRRB1,\URT/T/OO9__TC!$+(
M;;19\CB1=9R<9"M')L;(5=7;V@I582U3&2RQ0@SR<632WS@>%=.HS,3US5##
M.:-76^K\-Y=Q;M3<I(RZ$F)U0KB?A#P1_%-U-CJM 9EM?3(F*=OX:V.I (/T
M YLD+G;PXE(5S3QJR( _H!]]=^1,Z!F4V?#[T)@3D1B_WXH+#RBXA/DL,$TO
M<D,K&DU+JGH=/BD=5LKU:)^EKQ&:/.J;?AG]3J^6Q6.K1%!E*V3&VG=((J]H
M 4TZK8JR@:YG*G<==#W'=JOK"!>_YIW,YB)?RDUN7"O_%]!(B%K46_87H'-I
M$FPM:.YD<IL.RIJ9I-K]RC)<K*J!^C MUP[G[^&Y[J!LL$U0RHI@D-^R^L5B
M1B#D'0TZ-IP40)5K$-4QAN9>]X\27[!/+RVC%$JBN9/1\A"7/K67"H&_AZL"
M&?K3:A3N!&#^J <UDC(>G!)NK@?H7&V3.0-S7>XE:EXAB*$R("CK')8STC:.
M&"*J[[ZEKMY!*!%)_ *1*1P)=S [X:\<HRZ;/C<B_%+Y'5^OH(B^<^2'Q9?;
M?!'D5N%19F;E[@9ES98T,A"YHB$G<&[AB63G0DEL+M&E;^6!%R$2U/\MB=X^
MM$K9Z2S!4_+3D'BZD4]L2M/.W[]5>L1:+ 4AA<H_R &BE RZ9A^XME_%6S]=
M Y4=&9NCL\<.H [_3@K&N<9I(2!SPM;)NZ,I7$P\O/?X63'AGB275X/-I> 4
MN=IZ^T.A-GFZ^&,C<-C;H^%WGQ5Y0N5*RXU$-&(?HWWMD=.JK%9=1Q?_@7'.
M>_)Q?2L29BKEEU_\P' >81J#R3_]AB%V.4MHA@==81)C!!@I%NP8F;1D>$,/
M@TSNPX?)WK$KR6Z84SC2>9[29UMHM1E<TMOR$J)F!IM;H SNHFZ97K<#<0(6
MSM0TVPK9C$I+5W=XYV!2;E7H\$@Y^QT1DX>B#K'UN._Y@)7.QB^QR_EPU>$6
M<!!'OJ42A6:)ZJ\M1^9W$N>RYGKM-8\F,Q6<].%SC9^:) N%?%,?W2TC@ E'
M:.3P(C58@0S)^U*0X^1GE.;&L<K'+[@@>P=IAA#IXB8V]6AE=1E_H_WM0&29
ME4B15:9$0;!7ZC =;EEEO%5BS[#1WN'U],Q=F6.S0HVMS^8:052*&._N*<(K
M+6,<R\6_FP6>!%Y5U^':YU.'E2T'%$R"6+MCCLX_L8:V*G[3M%RU)JT:"-KY
M+;Q.-#@A_J-;7HW3 /3>Y=K\&^I42Z>D\K??GZ<TV*#;'T-2U[MZ89M6629^
MYPF6P;>'Q72"0WL+0V;VB-L&(92[2VC#\YZHN#N.N1JTYQR@]I#B%H?0>YY;
MZVBWHG!/G.T&8FO;=([1.PRN=#=\UIC)? K\L>/J!.<GS226+<WBE&UF-%0I
M3Z38*=2OJ$#LY'S3V!R#(,J4'UUT5!:J!E:*.2"RF2CC'W=M241R#A9&@WDU
M6@ZZEBZTT6,;P +\!8MA3M-J8:1:L]#W6.O!\$E_ :2C;EOC)#&<0T1#T;;,
M_,BBBF'HKM2.38#1:7.[0<\N*7Q/19[OL5ZH0COBH>+'Z.]XQ\D.!L<0(A7I
MYZ1/<BTNW$5DQ:[ 'DPU\(^')D>6_EPR5?U!."B.N9X#%E,M5U"3'1Y\9L^P
MAD]*J9:^U2=4>[2I!PS'>$X>/RJ>X;5E35:(<IM6<1"5\!D,<'=HZ2%IXB*!
M^1)R$"*>HE&<\(Y_#!I.S,)] 44J$@[HMVQZC-_RJ%![B8&7[QHFU2UD(YA(
M%9!GPQ;4"8B 2]EN*I3AY.O\WPU+A!A8JAT/,K]07+'2K2!@ZZSF9E!]BJJ&
M*+I7/VRPPR2H?&.,.3,8Q^!7O^+QTN.:[]7&<25"1.D]@_&TY#D$U_DAA3A9
M@K*,V9.+[_./=5ADN8D[9D]WL!OA=]Z=L=I6.RI#L8*Y?Q7"X;CZ1_\&MNO.
M"@W%"L&T(W!/L472KL RG8J_^HALC=2";D]<LN2+YM@=C SU82R.53SO:]BK
MI6,'0PN.B5E% 33)U^(* OUI/@/P+R:$6S(:*A0254Y<RO)'4PD&.(,6&K&%
M:>E5H;.R98L0#\X.\F*'\!9LNY2V-D;PO5.A_A/K$B9N:"*)&5E3^MT_)?'X
M &D">^PE,J)O[''[1R&G,&5]OPY610D0R8$KTV[_=F'JL^R:<*Z<[_4WO&3Y
MAG "]6$[J<83ML0-K)1A6(#WF)!QO< SX]'/7S\Q-_73BB<.?CH0C+_"UFU4
MG?51CX'L%CF#NA7P_CB9(3.,W@+!J4:]X_TG3]0F1_.1:F0"O4@4J:J&/\)G
MOI]9)W"N?^_J4*G64,*3#H<"FV">!0D-6!!,3;\P>#9F1](%:"A?"[+",=<_
M<\J@K%$8+E*1 0_.*A;6SJJ!^MJ<=B2?V.OU51>I(0VXTJ886U?%,UNN7O\*
M[*F12/=^X@9GV:_ZQ4J#;I(K689%4FMPS[84G\?&9/@^V0J=;V4;+%69M+_B
MJ8<M,S9@5)'O%1>M%82]:D3 A%HI$2=MS#O8W<?:<>,([YX0G&TQ<K,4KM4C
M&WG>T4GD^K-,;!<[;L;!16(QVJ1[!AI/-3 PX2 47#F-L3M]E#/2YPQ//^WV
MC-W/D8BQGF6A=]->J%1$,.P^2-,9'UZ0&-\QH*V4=],L=3]8*%)4&%3%0 PX
M&45\+_9_G>E1[UN_G$WE]06_?/Y)*^.5\WXO@'^FYLD(:^G&RS5KYY*7_6NE
M_K^UMRU<G'NH'*0^K#*]XFU9NOD+\&VAYOYB0QF_\#SU;N*?O&K((_^Y#^/#
MV5_ 9HD.5^,V&WQ(G)>OK9FD8\[WKXXL]D!6% %A=L7-T,)<,T4P_5>(/=,4
M;EGT %8MBY%D3XVK34B\1:9T*8*FD8T611(6B2)9/:=HJW <(W;[H'QJ6(]F
M3"*^"Z2:/*9HL-UUX26CX,\7ZP9(F^<]3[8HQ<U.'_1VK6PU_F7'G^I^YZ.$
MXJ?;G=>!@$_E:EJU5/GQ+9U26?(UH&#IK_/,JBWHRT=?91MH1RKE:X#)@S!/
M!6T\VN1"H6 Y\T"SGD&.W;66&\?Y@/\U2H,;AY9N8K4#4Q/^A.G?? RI<W\&
M<VD/ <=S#G'OP=@E;-J;L\0,( 4U;Z3*+6W,QDZ_(3103Q_7 ^:[AG9JNX(3
MJQ[/*3>1I82)CZ:D?.;Q)2IW/B\PY")<9I@M?HI].4-3,/A:8=3<6-0,\9O)
M7T". ^;2?[U2PVS=^GTM\1? I?3;K/-=ZS]/@VJ-*J"ATP<]A7M).U@.7@X&
ME2T+-5.N+;<8,8[1^-.*+? /BHVDBAHULB6%1/:RB"!6\W89QW_K5>\P^A9]
M^YAY,DVRA'-CDG.LG,"BZ2?0^F'T53CT%-\>V%R1)LBL.$ 0J[)#;4)0YB(-
M"P'DAB#"HY'<."+"]P1;_4<?$56F<FZ+UN'MZLA/XQ:7IQF2<("N,&/XJ1S2
MB(;N!7SW1G\61Y-:-J[,)C%ZZ:-475[!8AH:@:['(/^MC8*K=37G1S7K>$^U
M6F'^.G^ /ZFEX&4L0S;GJ(Y@;O)P+#+9A1&>_!O?73\_P5-[?#V;8[YQW6^(
MGZ3D_V)<8VEF;^7JUZA:1XSFG??LJ$"<%<JEP3/HSD0JV)MIV[HA;/\J9I#+
M2)7L5WD'O\)\UFZ4H@6W\*=*FUAQ#AHTX_]3Q(-QE 1Y#UV0F),';(U"[!'9
MG3$2189/.,YMUK[9'54Q,,<+5-HFCI8TG$;=\7LQ(>!W<B?72%<DIY9JJD_R
MP)%(DZ.8OCD9Z7_2G &\<?&NG9.%O$Q25-[N1''$8(^/MV[A*?Q0SN#B=CP4
MTQC"GFH%TGO9?K;6!SJ-369\([K,\!H;:"C"*^Z:5Z!C C'*99JZJ-D1(?Q'
M-W%37/@9]!_DL 0ND3>LO6)%HW),24'T"KF;)8N\2B6:W-.T>5'A;.A6R=/@
MV8O W,/KK(X>C>%BY4*-('BKTVR(3:RG6-RQ/,4'.JG:-\:2:Z$EYGA2AHBI
MV[? 5;EFZ_?.@KN$'RQB52PQ5.5]9,$N<6>K^$OSYN+$#1+S[F*SCC9M!;+G
M]:]H(?4LEH'1\"@4<^DTD [X_5SS4CP"A]-WEPK+D4OR)%)FJ'HX@2R&&RUG
M8A1LK4(-C1(&;%X;SI_G@EPX]=GA!S=2**TY"@3AG,-KF9R_+?)OT7'BJLD/
MV\FM=)CKJHPL6$JL8OX%2%!;^MM7+;$.O];>8F6N;>CVRPQ?HO%AQ)TXP5XR
MBXO-T20#,*ZYG)*9LYO14AF"+RX+T;Q5S".:+QXV@R74S;LW&OQ>:SA;)])'
M3XWX X'OU,)D]4OUFQ@DH=K.F_)^2-<E<EO4#&JQ;(Y[V(X.VB5HZ#RVD:&C
M66:>&)27I&1L3+&JEK@3S?2R0YSARA #.DY2#_V=7@F2U%$PUOE.)A@Z]I2&
MOIF_;K*9EEI*-CR:G:?H+FYNB8/DN VL-3]"T.1]M70+K[")K;41G"4'FBV9
M/3&QBTVB69#B3C?%*=(3?>Q$U6CWB>)=#2S9=]1^RQMV2 >"P=LKX_T^RM'_
M^=WZ*.#MO-L:]&1YVB9VR0<8W?LH,6%9:PU]OHUOLJ1@&_G!'BFMHT_BH]\_
MR)]-_IP\2UR>7&1B;%JB@DQQP)&X.B)^&=GPQ[=%35;X0SA)<O-^@#AKO3#[
MX+S:D48Z/6\GN?HR6?[ Q67Z0OG:48&_"B'LT_0WC%])X<^84?]';V2G=SK\
M/E?/L3;,)&[..*UM8,;5K[7?$[G,^@P1B/1QXU4,,PASM<S18;+DD:,;J4?A
M!0/,)7CXD4966ZXD!BWB[A:Z[X'-4LC7+A4GOM:OV)&]C.NY4DE6>C>R1JD]
MF$EH(4-IKQ,#[1B_62Y&7&(\=H/UU"U8->HAQ"(O?2?\_!84<_<!0"%:L9>*
M"8[IF*,H"Y>E;IGC/^I^/G?+D?'# 1Y*_DBT%WLE1&<]R,;_,8[OI@^C5!6J
M",CT$7$@LR+WX7A1X.00:*9]&?8^G'4Z8/> \,;18/6\!Q'Q/W[2P?[%D*0!
MH,X9(;U1$,R""&@0>Y=: DE2D!#D*JE2P)E0SY( H?9SH.__$^G-YW^F?S02
MDD1,_BYPK"%6J&"G4[V2"I9J98.I0!T_5+ 1[$SL.0[SA??Y"G9FUXD\+.]6
M<D\;UTE/E-NYFY#G,2W+QO#8'7#]]Q.\)=:.D\>KT5GH\E1+&GX:T1-3^Z8K
MVW"-I9\=Z3(0QO,S^21.6#42AS%NDA1?JJ#.:K<X%$<KIW%*\2R$PN%4DQ34
M?%E+^_4"WCS;M1J[OW*-EF1XH=SCMMA 9ZU#Y"*-44@D3S2!Y$,KCF4FNZNL
M=":$2JZ\(+53N&29=&CB[#H(^JV6J-?LV$&7\>TSO5"W5A75IUI<[KOM3M"A
M_6&C;87_1+YQ7OTHG7//K!P5Y$NA <$!=\,5G#D!!Z9$WAD!.C:1%"A!6C]C
M_-AUNB'R7M],<.:7Y%E86E9["C:;H$V=!TR4BR LL^ ; ,AAWC(JC+P[<^6
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M_QLD5U<HQ3++)-N@_ZV*0AFHPF46W3V16A^IF(B$<9>JNI.Y5*!9:N:2'2P
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M^9XXRC,Q5+P= [*T/3_RG+0HZ(_P\'-"+SY;3^MKF<VCSK7MP45#SZ<I@%6
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M[4#3)7,2LYJT=:+TS<[CJ"?F(#K @ G^73M4&*[L,!:NT=@A37JZC.8WAI?
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M0Y?ALR0P5:M"Q8>$0YE,E%LOK^>[-Y:G1L\?P 4._D=M^745<<626DQG2>(
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MN\("/2(F6'"RX2W[<::ATX:J'&;CFQF9\^]:I_!8Z>'<0D,\HX$\H)]/"MX
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MBD5^3<N\I'0I_B4!L?X7<I)6S:99B7S,P:K<B\2NR\%\F.MW29*CH->3P<+
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M!QC@KA%NR[M7*<2B7I6^B'GK?:*=%U70S9%3/+6/DAQF]%>'M:<L""<E#7%
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MZORYM+*^(9"2#+66'2_A I=W]']F"<O;_A<0DOH!D?X78,H7>?7/LG!P/ZW
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M 1L: =HIPOMGR?:0G.:A,1IX:O?$06QOOQV)NH:1>\7<^.0<H"V'<3]_FF,
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M?#AA?6N;PVJ:=-/"G/HU>C[H#SQE&',X#Q8R"UYG5=VK^96"&X.<9@?GRD[
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M:*<XE@SI3E:R%UNE2WI+L5T (8F1F)C8"Y)WR"(2XF+?O26D 8%O,Z/?()5
M+N2>GR^CMC7%FBGCT@+\5F#%&E_R_@%(WMT'%C-0>QL?"$=0[J9O="^B^62E
M2%&$ J><]U-5K5.<,JEU+[BH7"S7NO1RK!_<;KCC2P/+-#520B9;)3]@)LY1
M>X4Q_<<V;:Z:D=!IMBQ-,Z.5KUQC_"&&,PV?2O$T+_5%8RXGX9CX8#I#^M@)
M E"FO5+DX"V0 ;C8IKVO-Y$I[Z"?F7:,:-6>3;Y$P6.N,.QFX)I0[4*!L%![
M60NLM2A+^&+O;3G^;P.M^$4V'V?.2'G-@YSTRC2#VYVU2</5?2<2"<>*':\O
MT%H3T8>Y_@&^N.@Z^C68STD_Z%S\#=NF&9SL5F89M?]D=]*G5Y>_D[H[FUR=
MW2-<HMBP=E1/6F8:T3Z\GEG@O<%4JY8::-F^_]\*I<J[J!?DPC+W%9Y)_"DU
MMBG?J==(Q H9XKNC7]G<W<$36*+3]:TBQ*&5Z0*&JG+@(X">^TK#UN,PZEK_
M9'=,'O4Q;$'Y"A(J XUPSL2P*K8?CV8S$.6>Q&>?0$_#L@"+**2PS.(0Q-@S
MFOK85"R01%Y5Y"=+>.OENO@[+FWNJ&.SW'^;/(1ZN&HW6'77#]X)ER/>*,,=
MX,S'QP2%&5(=Z\GBCX41K[%?"/(J2M-4##@@;T3(+:\([W,(9KXG[A5(:;2*
M*;_833=7$9A4DZQSP;D%IRQNVE-P7X>SKYZ,_0[^,=>POA$ZBYG$?82HW9VC
MT8T.W4,\#)!UX3(.@;D/XMU"HMU2JUU,VZM9>#)$!@1SZJ?Y*T;>2?F$V%:"
M@XUX"CK$\@?W+Q:?-Q.F.5+(;:W'EW-00D3!AC3\)A4OT>T4-[[@1K]Q5=O$
M>1YE9:A&RZ^/0;A(^78'#NWSF';7%4MV_A SUA@Q% ,*W2S%'*I"M=%M>TPF
M\@I[E^S&AI?R9OV@ET^Z0\%MG;Q/S:@:VZ/"[ T#%DZCXV8P=>5**Z+1*V]%
M'69Z]B4L9=A&+L\?@T:YCDN,?,E:K0Z3/&G3I1]NX=[WF6C.542CC0B#T.J6
M!<ZVY97^G4\<3 )D+8KQT;,SF 7VZ8^KJY48&WTG8W9<U)BF%C;>LL178F>J
M>Z0IV!F,)PT^9DG/]C%NU798M",GAVV5WPW-E!+2N#SB#U4[!%_U  NILE"9
M*DKZ)UX[YTU!9[O4+ 4@>E^V=8^V;WA7X9\1U#<8WJFCBZGHMIV^&?:.8&3,
MC'GF$3^""" 0D-8M3*M/2-;?K9&<J(W7&U':HH$I%YK[X'X3TV#VF=E*Y93L
MZZ&9/RMBFO]P;XW2IL^>?0BZBL43%JN6AVF2+N@N$>#]'\L IK&S3C45O7TF
M"1TP0VOMT)MOODRQYGJ78V1,"ZO[7W4?8[#JWXKP%B,MF;+H,53U*6HK/*;)
M3(\W^Y&.2\6%G:S9LUKVG.I>]/H,.5RZ"H5?SQ4.-,S;[->_@1^8)KLF0VMY
M%U1[-P,<#9@6@A(5N-UUSXMZ7XLH'.NK0:,[%!6CM9-H"V"7ES]UE9*EUR"?
M6L(DO9_3NDX.QT2JUC25P1L);52;KP,P)26LK#V?D @2_L>V#W2$"I;T9N2L
M?!P!;G:JI5;I8,,$L]H,6FN6/**8$/0XCS&F_-31'&:EO(XU5G),6)B?<"0I
MR,G-C/7#(=LM\89Y50U4KH')T^?'?1E@%2QRMJ6+MMB[F.'N)<+';EVP^G:X
MMT+?FO'-Z^W3@S[;G"@SJU3(>\H/7.,P[R#9=:20E&T(1$9N@7H@P3J%\YH^
M" 9V7,PG*=-O.JR$0-X:^TZT,=ZPU&V@I\6<F56'5#:TL4;/5K(QS C:?L"S
M'_N(!LE(US^,;F9A_(;V+<MK)'K*\@O%Y3Q73*[/ OU!HE0M).M=\3?J:F07
MS7<7_@H;8NQAC^OT#:"T<[K<;3E4'WK:(Y//9[,WNF4S26? P7,U&;7)S>ZO
MZ#GP2A4HM^%6\(4R))8U!*LUB"6.9)\"FW%5C65NY\</P @;"I>/@8*"OLGK
M,^:$/:=P!B#,VTACM89"@S[S=8AYU!M,W@:9^-H4;3:Z7I9-N ^MU/9H61OU
M=_R19KB[5B&V?-'AX8^^4L%)+$K2+(\@S!1X3I#:(,]Z&;P]J<L5)K/1_W[D
M^?&F?:FA$]MVC5456[*DC6]CNU/5/)ZI3"@)P8PSB_/%BQJ. /%P1*YJ!))R
M^$KIH56 #U+8D;$=V%)VDFJ9$GV*73D'7*D;08Z7609[XP"K2&VA;Q#M#@\C
M1*;M[C>UR&Y&W(,<(Y]7(='IY/,2T9U'6S9/^3/;/N>K83O3,MF/:UH^HT&#
M<Q0<S20?1,8670ZI4U.\ _DO'HXH6D=[)PO*SQB2BI?JU1N=8@$KE8F7QWD
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M LBHHE?M+_020!7GQ*'Z>AI-$[A72OE6XB,)YOZ/1XJ).PP$RFH1_<V>B8]
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M<A#I'T2BJ)B)0MGJP L/TPQ2DSA))'\#71&_X]/>%UZ$RFY\/6$]:/X'\"O
M>HG0DPMOA9*N$;C-ADX54%5E_!D:!;&/]]\4KK+@VL]P>E6X%2&&1Q9*#\P
M<,7YPG9T,F)CA*VLSCK42FCWI^<VFWNF1CNC&]4'&><&/1( VR06+[N<'+49
MT"]Y"IM%U:#2/P[GBV ;?N_ZXE2O6V]>+R$)(501$SUZZ_^73T7HEB<R)VH+
MU]\Z)<,.F9=!N>F%2,[!9P^$_8^8.O,C$3<;>+LD$[EM;?X=AP+8R*?.X-(E
MF?/0+64L@7_@E*]2*F_H/S EC6S-M_!3D@:2<>B-8EQ*24$48R/"##V7*WA
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M).V&G&BN\7&LE0F+]:Y0<FNJS6J^%IST^\C',UP,O?]GD]2%]CC2 9$EZY]
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M9'#'TCYE;N')6[J;R8(U(Z:D0BW3=/"B:10> :RQ:O3\=<>I]2[#JC,/@_J
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MV2^'=!?G"!Q(RN-8'A>*L&V]J[.^.7; 9JWQ4$:6P\GD-7SO\1_FMKELK)#
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M?]3UP=V9YF;(<M61*M>+DZ<> Z(B=9E(8M5,.JXC&V<^9H<=43L]&Z_L*W#
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M*04OY2NF?R:<X%X@Z.)Y"OONXCG!0AD:2ND&%9>=+R+1@4W[[5Z?[O-8QP?
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M58C<;@R&R+4Q0V3NF(6&' PZ'*G]CSQ3%"#N9G3 I7!:(E/>0S7C04 \YP>
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MKQ+;0+1308[6[IZ-##I;U !G5S 6(M_%;OE.OT4M<ZE!;_V]#6I,Y*V;6F=
M"5>XGT,1Y^O]!(VUI\G.22N4,C:CYA 3.,%@*<^LD[&?\^J3%@$B&^46K=5_
M7_#3I)K3F,<'/*R5!*:^.$M-P<FIC-W^A$]FN;T[J#OP#"*(H[37&EW>P@P]
M/#,HXYEY+^WKZ(U%_6^SL-&+KY,I'3EM'QB?G+"L((JAM6[\:2TID"YE>F@
MXO)0$D>M@6+-#_5,E.C-<H9-?!*3@[/62B&O?Y,^^$,D9K"3GESD.+I<PH:+
M9#2?''*$0P2EHE:N8S6_B,QX,:M %VWQ+),!%04_J,&QSM'E#S:MDTA?^YI=
MQC*3RC^UJ)0H_! =16>S0H_K?#4[<Q%BH<GNZ.DB ,8[2\=G1FQ6(.SGV"U?
M[:T4L$<O81K'Y&=8B\N=*>98I$4_DCT4SY G*AE*$6/J &>D1+-=JL=L;\M%
M..!#Q&Q=?P9XPC^0!4E#0#VJ=!8]PO]$8C=$),SE:;7!LH%DK[I)=)&MI,]
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M3HL2"<^Y'P M_OEWK8WS=U15B9TGNYG6KZDJPJO='50.8*,O5D@@A]B6,PW
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MDF7O<=H^9@C=OQY/9FRG?V[*[YUY8K/P_C*O.J.&AS^7IK %GI%,YDIF(!&
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M#72CG/X4:#N>-2)/IPS[DY'O()3[39CU9%VJNQZ/C'!JOD+#7U]]U0$]!.&
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M;8R"3M]$I!<^=<K?W!U\(#XB'TU.J][!&6F*TMEZ""VDPZ0[5IR2IQ[\=/3
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M*U&?G?^NT_2\F[Q$WZ*0A8;34"X2YTCG5M<B4??RH1IO?-Y(GU#$VX@W;!C
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MC&BFZN'I#HC6!<[GZEK?H?I+**Q_=<>]&PGSFO=B<U9E10() 6XF!T"L_AF
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M*ZP;+N4S1V/J,"J:"_QD8;"[)3QQY]*+*A1=QM['Y(*I) 1Z$-.],8AR2M^
M%^J03$S17(&BAI 9S)C,?Y]OL<PP".4K\L&_$=6:ZH<U-Q"GY!=>B^GDRJL'
M/W"[<#-=N(D$BM!*=0U4HJ(>43H?7]\162:M''BXD%G6!(J0[E1/O0)(,\^S
MQVXQZE3\8AF5S)MGI/U&?[=G+7)*VL3J1=IZRGO;;^L-Z: DVH)N%77C+3Z
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MPA6_J4*^N;;<3+,%<2__88JX]@GZ1FRU>HS:;LU@!%/A8\YTUPIELZO1*E=
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M:L=4.1'67.5-H.Z[E$T/_!?X_RM@WF6)]A*5PRK.87$%U&R5#_[M1Y$-CA<
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M'=XE]F6/X'T"3%D+QK!81S:[I@ND\H_LV)P<8K"@K#27[_^*+^$==>WRD:5
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M:3KF'% <<D[]0H-3J$*,W(<1)@<#NHUV.<^R\8'T"XR;Y8<?;^+@=9V&T+1
M):R)U9Q+U;C,1(+2]6PG<R&OF%4"14"LO 5N"UZ2!1\W],^W5:,Y1?M7"<NH
M1?1/@#9IY)Z]FBT'Y2H;8;:T]E.>D_[P G52UZ.ES9M8RG.?0*W\[M'O?/+[
M_$O(EMF+'[2M<>>>TH#8M?:P@G^=LA$[O]FZ:%03?K]$8VY-2)W,Q8/W&A%X
MS"A)\7@2-HH'.\YLE?.AT0AT$7YH/F)8E-.#4LO;("CEYN4!H?M-WP1VAYL<
M-,J)0<S";2(V-\ M,\*1;DS!I(C=_$+RV6X*TCT>'_D'9S;O]9R27UOF^ ]H
M@9I9':<0(\Q3VZFQ$^$X7>$$\) (MGF!$GD\]B"%M+VW]IZ;CH 81&^_)(72
MFUZUPEM9"C=:\&N;T0?__4-\L^!02+_H_--X602MHN87*5TR5JGU5GG<X2$N
M&8]V U^V]=N."FM<;I>P<NWL[I5Q\FY1PU*G.'0:#^4YUCA!*ON,$1)D9TTH
M_[0:;+L+"'^JK9)WB%I0BF-0Y^D$UT?Q]D ;7PY<>/,FGW$K&7*DRZU&X [A
MO$5Z/,AF2XQ,_94^B+<(?I#40;[>)!8P8=8 @-=&";D?R=SE\85/%QCRQ+$S
MS5;VFHQ1R.DB/_DK-JZ1H40KFNZ$ANRRW8T6,F515]^AKY5>YR1?S6Z*.L1I
MBM,LENG62)KC'N;%S52]$<8WX3KNGK6/1^UGF:B00U5WXW8#+8H)MEBJ?*NI
M$426P["SHH:_X/AV\1(C*IJZW^R-$&%H"JWQ$M]E;<Q8[14XHT0A%T%!I<1N
MWZ8">0G='LJ!J280#B:G+#!/,)71Q@%I5&;CI;0A$BS7,LIT9?I_;6T:1^_J
MHMRG23.YWDZ##)"B"3V@+?-S14KMV)[IE#5S&P]W7I@8Q>%M4>ZAL?(\J*('
M Z26V7>XV]]CX6^BO=-T.%:'+V!K]QES++;X[!;B8^X.M'J04C%;S=L7A?NR
M]=<.>'3]D.VN[KLDB0G('7UTZZ!DJR@8R>4KQJ!;BGXN>?G,#1'6^Q5R4QAP
M$^N!]IIL/J+ LSTQ:\@B$J4M(Q8IW\QDAZ'E,Y5)];[D.5B3YC+@C84 T##&
M,ESR .$FK)32<O>-AT9")E]!O+8'!O:LN\ZQF)KYC826,=M^"PXU'\LP(UP1
MTVH)%+CC[-LX9=J*Z:$DX!\),O%05"[?,F039('!(Y\ &I-#@R3#RT>UMOS8
MNP)H.>'!W.A0_M7B.EM'&_^B+Q958-R?0@DI!EL0]A?NUMY:'LX)]DA,0DO>
M+LB4/'"\2Y)L+,37D<I\K=I*/_1K.GS32<!\/*P\=599O+(HZ?3..:7:$3^P
M3+FJ#;)_Y220QN4,R^@"NNIL![MD7$XW&)9-A_NI)QG8X@<"FL]B%/P^ <BZ
M'L1(.>QY0OQ;O%5VK,4' 5\3J'G/:\1'2R]EK U :D8:TJ3II/%BMET&IJQ>
MXV8=AGNA;KUH#&9XD-8P2GJ86!2._G'$L&$_9&_5KFQ5,&B!+0SRM@QI51?I
MY+S%(!<D7$D"& -%(:D 1C$WTZ>43T!@<W7+0<,';+&#$TGFT?I3)>J3'83G
M[3T+X20;5S)V48KGJL\O#\;^,&C'.'0IEPZ/;G=<WOWOUL"8"ZU'-%3T('FE
M5'"C;)GJV#7V[+BL8B:7"#M^'U0KR@8"9A&M(H>H*?<YY/YI.PQG]TO6DX!M
M>BZ:5M]-JU&,.UF9W1;K^+205$.U6 2V7KDR7M/TD]IE",9JUVK(H.PT2CA9
M#GJX3I.A%]GL4ZXPF+;!:K@;DRR=37.G=KRD]<1@'V=]9L9'D3."0OD@>@F!
M3L&M[:A2-V^W)%P^AC5L4&\L'@(Q;\JX%/7+#;>87KSEZV&2IKS!VI/92-&U
MX4+ZWNGJQIB$6@0:Q?Z;+=N$D3J0BL1.@'^[)?8LAPVZ&-H,26EX"R&L@^-+
MRS$R5L9O7P/T22Q>>KO)Y&P"^VW=:TYB/YG4)'=YGQC1]A1]#3G#?!F+8HPQ
MY-9ONL.DZ_2;IF<,>V9(:6BC2:^7"4J95-[77$CF+F\#W!-CO-XCJDB-F<4^
M1V(Q==_*H>,:6L=?BRWO<2D<=$,9(H:'CYK>DC 3?C3?UPCPA2GJ&1RXTL5+
M'?9(X:3)[*0!F^LO0QZ*Q3LFO"JQ(\.'-=%M(_ A=,6^7/JASOWW9T7_^P0Q
M8J^E=SSWSNNO+)\ :-J&)<O7/Q7/[?TS(3V!5W-W GV1Y2N>#.3_&*3SZWUD
M\$J\>2J\5W3T!'X"_G"7'KE?C#1O"C^;/HO\5;"*07O<LWXG>=6,K= VB"A2
MM?]^YKU8?#F TXUI26"+%:FTW&GQBH75HYDI-&0A+1RCH6QB<1G'>$C%O474
M3>_/V@3[WM*!7?QEF,!0#,6IK3(38G] L>'WGB5F6-I1G0*W@&:S*/-!GG)Q
MF.,_%,-"R0E!DYB!MT2+R$0B55',;=@F+22!5Y:U*>H5E](9@*MO4!K ["8Q
M[>ZOFGI$&!/- ;BF?T@H$ADNSD(E8Z #*8/.IM#L-A]RM.JQ8H!-4T*"IJQU
M#+N/3>*Q/MIS24\3M!?"9@+1C'&SBC=^O+'NAJD<"NSX >3]^OTN>^2I\EM+
M]KLC949,,Y&E79A\C4AN@]@_?T,J:EC2^Y/.=!N@.:^*'LP0. /K73J[-W%W
M?Z2[W&_W?H58F[VZ1$V2)U>>/9PZD"4T< %RF)J:9Y7+N'9W8OZ4A] ]U.$>
MCQ#;,4D3;FD\%AP2F>3!#=Y$L[%AW"J<Q_397+QB.'S.U;^&FUO5'7,W%-S<
M269*9E?,>)'^19?#-5(F5VXQ;=F(G!A$+[&>L2TJK;143?F=^@+^')/T&[](
MX6T'_7W&+>TI4F" X@'*N.LP4V+52A6MZK8K*)?K2TM ".DDK;CB+PH)(7])
M!J_PS6D26,LH5^.Q>([&<I8X1X8MQB]-6URMZXE?"LI3MF?N6% C#CB/!J2*
M+QQ5:=/'YN5I8WY#8<65E5LLT\5H-DS/*@*+U[_1=(USA*+L"THEN+#4W%)%
ML]X+54#$_\XMHO8)X(J& _T@M@,*JW:.;,6JNH7)RW^AGT47<]T=//> *^)N
MKR/ZM:KU=IQ%\PP+1GL5NT2!R7Y9_02<U2;]V8,S"7;/J@G=O@][WSC)?&EU
MUWENFKS'O_1C#%[4^(\F Q>.KWUN1:5W);[GT2C/H-ENR(7H@A5"C8/W=G_J
M1<GM ]XDSL94@;R>#3\<)B_[X)A9(J)X6;?1LV4:'P@OS2)$+ A=%C<HLUVN
MSM+0G9>=7NC5@43N0*C-\RZ1EOV(K,"Q&&K$R7EV7<(<W+OXPVC7>V\"5CV+
M]I '50S<!EJYREIX1*1LF2Q(+1AIJSF5-6HT#7_N4@XS>'^O=I*NS7\NG0!*
MN:0+6:0D9;.@4_N+,*71_O%.WXI!31@JFNTB&2&+]4;1;II5$QJ6H)F-U_KW
M^6O-KRAGXWIQ':/NLRQ8Z1\K%+,0WBTG;5[8@QJ:&?G;&PIS9;'J%6SD?V\J
M:<%H7/)N<GB'L)6L1AV#!DFP:>:)0H&,/EML^Y$/B&:Q;ENE"$GLD@I)LN$Z
MTG^R2KJ*";;95374&Y8IGQ_$AZ]L[4(MZ^T?A@5>%!89!VCU,K'[,;NRTM?4
M. )$2(=U:C"J=@D6Y]E28#G[0*(:V,7J&-&+=;XFM#]U1\21OL'&DR-KY'*)
M&&8)*5ULQL]%DUUN+@>![=_0+[@S, 8C\=!31V]ZUDZ>4KSC"KT>M9QJD'F%
M*F7#7?H*K<(6S74]XC3:NK''.K6N%7'@BB81LW44%X92Z,4+Q%OX-5*0:PP1
M59M5)=U]F<_$(>!J@ZH[VU_\F'YB%OP7KL^RX]<?-[3GU*_G,#\#VQ#A$R:A
M/3^,BK^W8L5BNF4K%JIU2 O@*V<-I1<]/M;Q<#A:488IO+.V)KBJZXJ2OFM%
M^!OOSL&PO,@?8>#1(/D8)?(V0T;U!F?<W6L'Y).-9E5#EX_0"BNKHA^IF77'
MK.3"9W'D(.'9P\O-,FJ_Y&[>X]1V+,$G"JTX9N2K9)!+P47]5NRCS*1SU?"(
MCDOD$*5$VA68SM7?IVTN(C4]16D0L3YS=/70#Q,G<HB7RPK\\CW^[$T_F4NI
ME;U:D%9FW8OV9%JI:JW*K!1CVW@P3=\2PPOFBL2\ _[RN8^3@,75>[@2F&Q$
MN.I+T)!J?V6>:QF/$GF;*#%)@!9?O'%D3IH]=W/'6/[@YLU8,$.I@B-J'K=7
M# DT(TA>;\)9I95 ,]Y#?N8Y1(K2[3B4OX:J!"H&5#J-:BHNO#4YX*BPKMH&
M1Z=NYR/I\^;.2V2/6;CS488*-I_6]\Q=GFAW%O$9+>0T\R\Z18O)Z-]E8 N]
MA/CT3#83$[? (25RP%VDP*6)KK4ID;(1/I*H0:2TTWDE@8\5,1IOI+\"G#PQ
M=;XB.&NKCVB5L\F&NDI%#_8.?##2? (B<C\!W9H$EJJV6V>-;BI)'#3P>E>.
MYHC#N,%^D8<9VGEL$>7T_M,NBG-<>0).<PWCJ!2)!Q3,QSD0NB4)9^\R]BZ1
M/UY-F=>[=ILM-PJRAHKUPBQR?T\3-5E@VAU$, *=F7 7$^K[3A<4CPD[0XK-
M)*2M[6B.AO_8P_X5_B>@']'BOC)[%^?_!/0(!I^OD><(E65!$5W-3PU?CV@L
M\TFDK^K^'@_8A"&>E"^U^VU0"]H$-\8KN1]84?'M]=K&\_[>IJ)%L/I&MM$,
M;E7F?L@\WG<C+TN(LG8D-+$=)J:M@MDYW(!E&D;*I#)'C(M<TZ;DC=1[43/B
M^9*6QS+75<6#5S2VT8ILKA0[ZDL 8R7;0M? -(,!U\5YQMQK!T^VS_\1/ZH0
MS:3/D=;@I*^JV%R=0<U93H<-@,-DQ0<@#M74B"A%GIZ9=5KT&MR)-6\>QH(:
MW?@:O[H9&,QV(([B/&IL[Q)I,"8I&133].LB+*#K%U)B'SA^\YG]:D](WD T
M(.9+>:AAX"L[\29^>QU$,.=.>)E@L<$"=?&7R,8A(>(>%!D?PT3+0@M.8?3$
M<TVHE4H@SHYEF)YE/B%,3J5XW4,,+=GKL(2M^:CX!+P[['U]M\N2>:-<$%L0
MTN4]XLDRWU;>ETL&YJ)/&\8/LLW6=:QXB^Y;.#F%1\^<H#/#(V-RE=J[<X\1
MF,0>)A49X9R<%('R(JXSQT#"^Q/.8)\?<B[8,'\P[(+L"\ !97.0=FHYZ]0^
MG3A3U*R/8QO5LPSLHWE2_4V5F+=YQND1LW%9ZHE=BGW06*-8"-C'"Z"+!UIW
MU8N#.)G6<"'V<NDLUW^>Y2.3PD%RE!"\4E9MY1FL^!)I6<>@*@12,I0Z OU5
M!+%A$11"4P8PA99;/%BA2=M\R@ MI*B;AU;9/>]+&MLD:,JJ>73&L!Y'(UE=
M!"/)  /Z'#M% ,*QF'YL?<'03M+V"!;S?D*"P$7XQ]U$M0L4J'CHY;%?+N=&
M4$Y\+ XA@;L^W;K*,A9A!KN:3?T7K3D06J:&Z-52VY'1ROCQI$F"U$__$_"@
M OKZ4&,]<.W@%XKNY_.TM5!?/ME;X* \8Z_,^N.9'6,2%#!V0\&!A>&+"IQ!
M9_TM0JN(;$E+ .)S=1>:E_0%&;?7RR\R8[Y"R9_]*F/7GCZGQ@!K+(>-7OQ2
MN'G3@)1^9*?+9C-V&=6=:V<4P1,JDMPL[W*J)E.T++,T93*+^INQ,X5 E^MT
MB"=;,:I[7L AKF'["7A=$VP+)F=R>Y^P6X$67R.B79*;J+%.$V3B6LZWR#*=
M7 6!\>[=L>1=F!F2S;D1EEZ-RUB"<MA%=TIB]^?4U]H7*R4RNM'3VV.5W#0Y
MD-'3"5PC11_@31W,$O6&'[&>(G%05W=D=I1^>0*M0G_[])JC2^89D+7,TJ_:
MJV&<*' (X!K^2IRMS<1896AEN\27D@;:CF*S#Z]P9X88T[90%UG4T1$O$7F.
MV!'<U,7^S)N"GKBI"C((D]TP;X@</YS'2^%PS8:4!^H0A,@O_C(DPN0%?=6R
ME8>PUQ^2T8\I8 ?ZW'LY9#]3;:R*WL0T18Z8<LM!+406]$UCP":C.Y"1^'&:
M]92I\2Y->U%VMM<ORZ_J>9^B0Y/!1+FXCP3C2=TT5C\G.E=T,? <"GX"PIIW
M-:<X B,GF@/.SFKD:)/*7%13N7.IVV4W]MC^_L;%/DWA*)<TFF8D%SXF<D?%
M=?BYO+P^NKX].;D=DI^=#\E=$1E99KNUA9]+L 1*@7)W@XY(34&$ID. D$Q5
MA=23BAQ"J;?77R8)_-<)PUTP6"'>J/-77_'AJD)];^V%-5$][Y^@VU;L$J:P
M)8N1K1:#N%V)J9FM7[_^0*[/$F<QZ&I0X+OY#WN"SXB9JR.VRLA1ZGV&]K><
M?3X!T[X,M YK+ (4D\CL*O&)L=SF%Q?:RA*XWP2P*"R3\Y-5Z28)V')RXES)
MJHONQ3%LU'*PS^+[EG6!&.:((G-OS2YWH%9C?=/%1I4[&=IG[&S)9L4X1O <
M< 2U>;LR]0N=$6EP(+-A&,IA?,Y'ROU,C8OVT^_1+[%_S+6@(Z!CIV%QP4O!
MU&I.+KX 2Y-%P9#Q='[W2@>L1R7J/.8<W !8Z1GA8<?+I%'2//,W_;\Q-:((
M8:VU9N9XLF20WJT(TLSG+OIA7*=686?$9WZ1S_4IEU:HT=;VO_7Z,0+'FV?#
M]=>J./QG^R+$O<L7X>EBA[#R@&ZZFVZA*9<4H>B1X %35\3AID##"]OQ-M>E
MUC>I/]JI>WGV=7QZS'_-MZ6838=NI!4-$"95NXF6&/43;O&0)1>(2&78N'O8
M&U03Z-VW";[^H-.=/ZOL%MOTU5U&QNG]J.@7>#BW,$_D8!1^+,;4,RP@C'A>
MY):L6D=>LJ::K6M4CI<I\4="^.-(-U[U3W"8YX)TYE6,,F8?.9BF3-9UXS[(
M]P,:C"*^.HMI[#FX. M!7FBF2)9HBH>X0(>IO;1@%+#)/[C!F!R3HT=L$]"D
M4Z]FR3Q'IUFX2:@J8U+,3/0L("+G$[];Q]-N34DCXE)+.HV;<L9\?;Q(5ZN>
M#9V VM]4I&Z37,\&]:'&9,C69@(3@V0G?2?N>!$L"CG2QZV?RS"4%YS9PE<R
M;<CMG((<0KX=L$7I0;I82(AUT#Y#U-SS982W!07#CGP>)SF^&8B!#J;41S(T
M;9)R61<.TW20^GB"7?P$U-P*O1:M\:,TV' F_1XS8TPI%%(S0$C2 H)#6T#N
MDZ )=>#(E8.?B8L%00@3WVEI"XXW:_.$%5.<N'"CBLG%5ZD7%G]5:V(T5I#"
MAHB"1R7 =$J-M;<\Z_=6?6)1*I4"-G>)''F&RBV#/'0B<_0,G[F&^>#R(Q7]
M%$04E7*1U3=(=$:"",NS#K'E#P[/?J&&WN]^CD>G95E#@K$<R9UL41ILP#E)
M=KKWH^-(E^_L2NK%CC97%SR:7*"D66*-,B07;5((4YV=%.B.(RR;!V:8TY70
M+Z.Z@E#:'6#;TB>,8:YX)GH3?VO'_(P,]@:+\:,V^6^GU!'\TY2Z?R^N4$+(
M3U6DS]BC:?\>AC3OP9'QE;# CL)?UWR5=+)(F="8&"+68LHUGQUAGKGZ=B59
MHG[5RBGH^KN4MC*9\<+?E%'Z+'U8!3=<QGQIP:336<5BW[1R^Y]PW%BZR<ID
M.=]XR+>549&LR;%M0@\&XP)_+67_0OG\9IIZ-@PND<]2FKWLG%!MG0ZO@6;"
M.RP:T3ZGB.[BRPWU052"P\<0+8M$(.V/W!1H3=?9@_E]/ZGXYAH>VJ%!3W.?
M5(X95N4^:UMH(U]V[14$@E&QTXS-T?@%XA@]<GG Y6XAHUX6MT)TO]T# 6IE
MJGU=P=<<CG'!$9]%;_)4XKTP"SXTC%)S8I;42:+-+8OZ8YZ$=@&"Z9M.:F,L
M4;]2+!@9W1YDDIH-.(VGN=6GOSVWEZ>=N16IYM"WM//BV^-$BJ,&7.B3E8^Y
M!7C#%U-<\A'MI=^;=E17]458?963F89TO\%$?/62Q-S*4BI=[L*IU(;7P3"Y
M1M'?2JA(^BT#O\K:5AURF=_AI:TYW9U&D+- #U66@WU.FV*^U=K%#1U7+D10
M-4U:N@6"G0@G##^*[B5 IQBN#L3H3I4A4B&!]M7L<$SB0/[.T@/5C1FCT#/[
M\V8B-+ZD0+2U^3*\F:!& T'0#(,H244J]#F0 6.G8+Q'I8!U?N2\8,A>T!BA
M'2NJSWN"  -E4DU/T!GU@)OW+2LK#/\B BNB =0\;NGMBI=HP5/)I!#Z0(&.
MA/Y*"OO#X[\_V_3?)V <.XHL9 H$P]Q^ J[%8R^YO_:_..<:7'015.Y>_.+X
MOFYGI*/>\H\!@D1YX:E&N,B$YL"FO7WEKX\[.V%KX5D!HM(_()*T3X!%ATWR
M)R (&+SP"6B7K;&T[-*'@0,^32Y06_HDRA*H]39-XF_C$6\2RC)I^-=*U$@D
M\W$W*#J&JX?;IQ"S)S!J=TE#&*_]91$[[,L-9,YK;;+NK808>GG!*_@>Q=1;
M-K[!YN6W=J3]>.&6_3S'2&Q-%BMT&+F18TT]65L^6I6&[]16"EL$#;2,<OHI
M1-EL5;+/:%F)@4+<RL;RI"WP#?.\=D:]1#)I[F=K,638=*(7!$V."8YB2HUF
ML<V%S3@5XNR7<;*O]2X+?8615VX^.AL;1V;[]TH")#$6U=HM\')Y)O*&A[A/
MS#A>YHE6R$)<?K%T+ADM^%IU&N$F=HK-F:RV\_)?I,N+LET1G&M%/-BYJ1,.
M&*U)E@DI?Z2:_,'3EOJBE\3:\UB5JUF._]BQT@"G4ME==W^NKUI%:0L^2);_
MADRJM:A7? YG^,#J\C@Y0)J[%7/'7&(_,+_+'7^FB(7;-R7L=6V(U*V,UPKT
MS>!C]Q%6FFKJ/!3:B+19#_:EHHN>V/7[QBD-M '@_/K17WG\O@9F8+7?;1$-
M<F=_JS"/VM$M$;:-D/"_A>]02)0E4;EY"Z&(E<9\!(;#YJ_PV9KS5"\SCQ -
M$T18W2",[!J$7K?V]$!-'A!<!?$(6QOF\O0T"IIE_RZYOC%3"H#F88 XPF#+
MDM# 0Y_TZ7W84^RVA0,H:>,5TZ8A<8HIY0P-#U392QVI'P0$.5A12T2Y%2?4
M9!S%>^:2*K!A[T1TK0PGSN05WW7 36A>1:L2,N 6]^7;CH;?P9.II_H-H^LD
MX5_@47VM>H2;.-I(GBN;6GCOR*,N//H[ 4<'R9CZ#!6G!,>?U?*].XMKOIF3
MS$274WX4,XZMFL[J6RKB62J@7T4##BT@[A:AKZN0_8SZ^]LEV&:^;(@M;COM
MV!EF\'OZ7BZ;=;9&&DW8P78N4I#&3I950M1CJGI6?.!Q%92DJ=4W"(>/,E2&
M.S3JGOS$D09*KK[C?-^"GCGR9.LHT/H-'B83@P43R!++-C! >X?$-MU(P5[_
M0+JK1C%ZD)PW)$<WD=$4Q;OM$Z#RKGZ%W\S\$R0.M)^O;S:_R,"_N-UT@$0@
MB(.ZDP#'SK(EE=E=W EK%@0<M-W#K^S(2X.V6-"5/"632>'% _P<>4$'$F+L
MP*/^2VIT( 8#P^](7BOV8%B#D26RNBP*?V\]D\BG7'*EG:S1[2]21)8TZ:*.
MP6]9X0(>JN:RD48/+J?W'F\, BN*UGVNT#9O&"76&>A2'+Y)C*"^;VIQ94]K
M'&"ZV;C&[=FFA"P:ON49@E61>E,,?SBY_:60OK?)[=0F-ZU^GV-<.P5H!9;\
M E53!Q=X.S@^Q6>\/9=XCG'2)CA?06\"\"B:$2(.RMR@"KU#SN&C.723$W34
MS.PG )$0],'%YJ90I/M [*#XD.PR[VJB'*H$$*,=TXM#)XNH$)?85@]ZQZ?6
M(-!]AY8_REK6T44"^L9D +5B$:+")Z<V0^:^LFX[.3(3'< 1@8F\YEQG"R-;
MG,K&,"")YW!SZD.Y5!9_9%G4E"Q=)-^18"=01H>?@+IS]-U6PW/#FRIZPKZA
M%\;V*IQY+[VY@(M]G'58._#&&2J9;Z'NKD8[1TF@(K'EEBFA$U[('Y&G8S=:
MQ%UIY;9 N3.+=TYL'I!C%>T-NA9)*LZH@NDV:U1I#N\=NB13/D-K2(=/,;XD
MQSK0TP%!.C398COX\;<=@E.+W?QHQ/+SU2IRT:+B08G%88 &]&U^$8XW6C>#
MI^6Q*>80\V7?9HY5L1&^L1!^!$X(Z-(O5HRBD<!L!#17N==[FVQ%1_-[#(8<
M<S4C$T:](VI-/6U::F("RANXM&[GZ>:Z0[)#<Y3AZ])NEF0+7GX>%"4D2?75
MT&2Y"$$WXU2N9':"(6F40:40YBMZ6?AZ^QT^;S0;AHB)_Z(,_C__N[#D3W&#
M,(,&])?*^OLU5.^#L<!$\8:2W3WY7H"KJ[V5E2R5\*!Z71'#[, I!==O/14C
MR\QJC7/1)SVANUW,L93/E#+&)(SD\)+_@>..>G.KD>"%R 9<J*+=S\XXF]++
M>CM$FVH)&PG'Z30Y([V!,;,%?4.EK7[S;1%_ATIM'*D@G#X]U?4T%?IG5[_2
MTX[OUZ%$(["SZ(UN&6K=TQJJ^1M+(BI(LK2V$#[RZ,V6,X574-$ZR96W_0#5
M\:+!&94!6*?P*Q-Y 7:-]S>0M*U>,&3ZQJK,;I6M@,L'&TQX7H 1,KLA<&=?
M&":_CSO/1I+"Y9/&/@&,(D'U=N(MV"$/6R):/D\W&7*)W:O9?I3E6P5#!3\V
MFG<5C^2L=..:)P>4U'(K@K.;_](1IX.SP\I 1CRZJRV+R N-J($;D7(B?K*K
MU(]K'O3XFNA<= BZ2-$0+SPGUH+=X/1=%F]O_PW/#RWX88Z AE.6</O2>$@.
ME!7=-+#C$J7R[QIK5A;J0YGJQ26$=[JV#3E'.0.$K@RO:4W](;,!E]5_XOBV
MI,> M[5/P'U%X(@(QP#_A]=$\$/2UL/;]X.O/ &'P1H7CP.P5R1O!6&F?O!\
MDQTA>\H*[<K!-;ZS[2?@VV*RP%C%;$"6FX-]"L7[[_6R%Y[=$8\C%ELNN3):
M98'P]LN:# K<4/T0Q*$Z$,UP09T32\E<SFLC4T_AE#9L-*:#/7;W(9X"AT4H
M!J*X/D FN8K;/:N]QB$>M$PG4&,U8GR(0 !@JU1V2<-.EXH4C;JYF3^F>,TN
M$;"=!MR_ZK#MQA\#ZXZ1AWT29Z@T(N:EY)MG9N[UAY,46\*#3BDIS=I*OH=V
MMPSQH#A>J6M!H,?( R7F1)"="1,+(SM$]-QQ/7.#'WQ^TPX]%XVQU-<UHL@9
MQ:=PBQ^IN'I<8=HL2O.Q'?-R?2^2/+"#^E+':*,%K-.F90C)Y/.;*;%)-9/:
M="[AX[T&@CB]?@K)LX7Y+86?9(6/'WQQ?3I:,5\]QR/D4DW'E\.](&4='6YV
MK(GK0N2DUJ20>S[,M%E=*YT3##<'$8O>U4T@S;-RO&$8AHI$/E2G$<@G3^XT
M^WK%@D?K^Q:MILQSC.=E"+P19[Z^<DFL,YE'HL]5"KS,7)^)_Y[A_"[YM^UH
M7Q5>+V53*\Z\YE>451D"-F"\@ZEY=90RC\H66;.T%EORJY^F8W1?FFYH+ +/
M^#%V[CG-+^SM-G<$D.OVB"W9^N4$CGT'^BB$H@<-@E1^;ID#L_Q.GBH/N3E4
MM/[AGR+I[4WW9AVLT_,,/OPZ;>4L;L^B(F*/^TQK;V*)<<1+Y_&OO%.>OX)O
MG!QGI9]_D$@*%L93Q.4J^Z9YTJ1V=:>B'NF[_NKFVG /R2<I3V;874;]/[ %
M-O>N[UMGM>6ZW !YK>Z $M-^K4VZ^W D-\"*)*+L>3;&'@X<JQOKE3D'QR#:
MIQ,QHCVS]%/X\X=YSI9ALG7:)237TRX,%D6)'\3JR!)[K^&-AG<'*,*D=Q\L
M.IOR1]V=% I@)N-@*2Z-N)%]U[6#6 %7H0TVH48KVX@<C&]DSF]&IO&9#7F>
MME;PLRD#-):&"@T^_7#)9OVL0V2W;PT"^)*[URO@%&N=27"CN[9JR%:);CE;
M/A$IJ]A)'XR[RTT9@40MP=S<O-D/W(G)++ S]WLGG7UOTGS6K<I=!+0*[[IW
MV-< <@+&Y/[1EX2EBE*!VGWML<P_1@9?7+%=%- Z0U"H-G88DMQPHZQ<,^=J
MZHX'GMVY]X=[CY,JC&W&,3T81YNG>JX1#*LZE-_,))BV\YQ2!AL:3\,AUSIE
MU4'59X_5K0G5P*,I3SB-=AD*<X=/0.=S)DWQR/,$!;A3[WN.+\666O-%Q_0Y
MUCJR\>C/X5-\"%M$1]=TF,E2C5K,R-11RBA<H,@$"8%@JE7])\#N,#,[ZL)N
M*MO52\A_PJ^SYJG<7*%-!3Z#5O9L_>FMV]#S2@^'5@Z?<OZ0BI$EU9JJ)N]U
MNI*\;CM":%CI/"CC8A9N&6?2Z\\,6V7XV5_WE3R&1#8KY;MT".\<:E?:52CG
MY%9?I@[-5K(6'[\NC2R!D3AYR<A'I]0Y7$7Z(VBB QTIOH U93T2/N-]?H1(
MKR]; B:3'QAS3S(,DV"V87ADUP[.I5^$B[-NTH3BIWBJF432H&+=!5K9^_P%
ML@/\+%ED$E_DS)8W"S>FZ4P"W>(95RJ?-?UGC2'?E3\67.]KA/4R#I9Q1DCJ
M^8HJV"Q^$5USZ46BT+887C_H,B?7.ONX:31AF.D&V=.A^2:5A)N8ZL?5F9@G
MGS)5N%XP^)R^)M&\EA-D#>8>L>-*Q$0URX$J5)#G?#'FPKL] @<7#%<=G":O
MQ%V"S6/ZM"[](YH.E.F-VL^_70R,$U=QT\[H4>XXY4NL)^GOX4<V3#^'^EQ4
M:#$'"@WKOFP0)E0$IW^G[R'7Z5X'K?ZF4?"D0"###0V\\8QD-^YQ72G/HF"7
M?LO/<&7NWG\B%HM]&ODG=KKMNK#%\A_1293*_TJ1V#>G)P[G%&.6/N[A\6T(
MKN0>:_K_@/%Q;?V.DO*J5+PM9$A52AL;X+[XSO"=W?![!-#W%^&LX&D2(:4O
MD1\?FG>(PB$].+]%YB#L*G&LR)!XK4AR<X\H%.<\V;1^ Q^&9Z+A3+O4-G^4
MLFE-*J&$%)7.H!QY1@]8+<HE2:\(4T9M2/;%'9$52%2_"E^_9!^9X1=79UP9
M1 %6YN>J]+LIS16HDVW!+I&#6#=,(+6RP.((6+DTBT!E<2!;=^!)P6)A+$KO
M]J,P7W0ZLLW?P%P9Q290519F[/H$'"J@W-&T"51.FM4%IZ4<.;(DFF\=!V@'
M\2:"R_6PV>/Q+Y1IHLU7.[W>"G]W/8>2-G=UKF6=!\?Z>,ZS#F6YFO&2YW6J
M!8KA5TY;4V]U3XSWV<<OX5](KI'D_<!<1[A'D&WM=4PD/DAH=^!KCV(:^F5J
M+4&B*"@?^O'XA4VN)M5+5#^//E35"B40/)-5(.L=9L"#E7. JP-I6L^4\8O"
ME(EO>#Y>Y7*1L"M"'.9" R[-' ^*N1-[.?\AHGE,[:JE,\(JI)?I-)E"N=UV
M&>L/_ZGQ[&R?Q*9:'T:O[;Y^<_1]+OD^8T1ZP"% YO M\J76)-XNR9<JH)I9
MRNN/:&[[K[YB&_5PHO.S>30K;RL<L%C15U9"-QFOX&7O;UP#6(K+)7'.L!QC
M>&&!S75&"KE^F*2ZQ-+W];M2[ 3JX?7A= 7#S;&4EV3L>YJ*4:VZ H8*T1C%
M PP:!O8$YNX,[-@)CL@G&.WMW*2D;54&N09+H!1$;-L8>$3E%')U<3W+R%5X
M ('^ZDD[W"^Q2N"3O0@OKT3N[,#D!-ZF90PWD$UP%9X:4ODN^]:+UC8F)W:*
M],IMB"JZ82,>)QFSGVM 3 -3/NS/]KCLW!G(61<6P"OWE^;!^E9U^#B,8T._
M=%P:+9L:6H-.Q,SZ+UQW. B[+I.$%31;09#E)6SO3IS*@BBQ4)X\)MJ&\$TL
M*C7K,%25 -(NBJ"K-*E!T()?IQYE9O?*BF^*W#-5*&\[40G4"KU/6EZ_;TNI
M;CJEK\H2K"LN&3/=7:RXN9E!;X#GEK8^$Q'H*E8>$'?Z"8"1/%LB<. P['R.
MGMT]3(1(H505#(./DZ-\MKS5P#:B]OD6QCJ:V2XPD;'5!D'9R%JP.X2+R,G3
M;8JF./_1_-T[3[E2QN?!1[XIPW7)BTBR L\CA.EGF./1UD1CIVP\+Q-0:R,\
MC%0:,)/BM #Y;5N'E2,1\1[<TG*=Q 2&XCKL*'5'E9U"S:4\S"Q"85@9<2T8
M(Y8,9'24Y,H(!#,<N$2#*8T8Q)OR-.3F8U1T;:5XLFRYE3&&&?@>8L[2D+B1
M;%?K27=7=?7%\?$Z^$WYXBM2)K,)G'\[4HH0G[?F#)#Y&BO8J\G/&>X!"4J^
MUYW7Z99KS36;FOS((9E*_ 3<H'5NADWU&PW%;PDUJ;?L- NL8DFR@F<=,;_A
M153B=A!Q??=0JI8O!,[ZS*UHG)Y*OO@Z_ "U>%+@61;)?UFKF^HSQ&W$!Z-0
MF*VA"MT4<(S\C 811SO.#IT)?M0S4J-8^8"A-ERSF'W\N:;L9%M4L0&%\>HQ
MXA;#&*,1-L.F(;F\(/ /$!/_<K_.?B,JNH-WC^\?JR-?%<.[@,L@!J^)9[8]
M6TI#7]L/LH1^SUR3.O<HR.5"+ZD$&'K1+R#F*;EF+W0HDNS\=W.O/[SYRHDW
M9]<9IO3@B@O^&$7V4TB#8MBMN<ZDK_^P%1=]QMI6!%C1>(A,\IT2&(BN!A-K
MPB^G$Y:6>\0&X[#V,X[21X0IJ43<<C,LHO@ZM9%@H5C!Z!?=S6A[^M=QG<D]
MC''9'NT(4]Z*M'S,@J;%6&?618<\BG!M]W.L%6J@ W"I7E^LKZZI+9R3P\%C
MV!U/B2*%G?O7X*9LD-":-5>0^&TO:+4D(Z=[F)%'REMO3;=9OC;7;,0DB$.O
MF\9N<#'#L&R&-2_3Y.OM]YE9J4XH:MKH> JTS2\ :[.8GOBL)0B[0\C<-EDC
M35RLG9&='7B MBYI"V>(F>;_D&SB?XN 2V)C !(X[["V=::?:/282-4^H#1<
ME&T^!W;F9-,)M80ADC8LWXD3-XVB;U5N]-4;[GS7J%PXOSYK]]Y*4DJBZC3R
M7,)P;,8:M[(.EQ3F3R!N=!D*BI.(HW:T,K#:8FS9Z'EMR-H#;F%P< B6X(^^
M_^ +/D@6<5!3V9AN_@00^PE<%\0==P2=\3UWGW\"!K]7KF_TJ[X6N'T"IDB#
MUDL*6]/??$_^#/NQ%&R\5AX=-WX"(*\*S:V>):Y\9SX!E"&O9K%!\QHWQZ4#
M""?]_M97A;D% V](/8$)N8=HW<<L;ZEPE[%TKWPJ$P6);S0ESY>%/4%.?I^
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MPB!?EINZ43"2S#J29_.63<D\@9=[C+HGZA[ )@L[7S>RJL=/536KM(HRT^6
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MAU8NJ;@<ZWS.=XD,@EI#JS%ZE3R8>S8E-@G9,EUBW$&$;.Q1PSHR\\,!:8_
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MR$>0H9?%#/=09YX$F2Y6YJ7G5,;!-0"SO-/A3KJL2V!:!BM5Q<8\ :I7(5D
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MV492A -E8Q2V2 EF-I;F#7&[Y8]BXEHO- /UP*#A.0[#6.$R%7;!^#,^/Q'
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MHP%3N(-PS)X:+1R^Y.*8W?QSG^#$KQS+(4DW^5%>^_V38&+MYVP069I>XP-
M%*ECS9O5)"NMI(F9NADC/$3,^)#8W2-,W,I2_!KF/#H_:$!L>-..(!8T,(L\
MZZ:==9P;X4YATXA!GR_B#^?R.),DP//C]]:?@6@6W4VO+P8*R*X'_V"0[&;4
M>W>>IULJ*:?\EEAR?)^]IG$F'Y$DLT: FQK4(EG>>JCZ(@&I;8+ML\?6:G<I
MTYPN CHF6=6IWN\8B*,D2L4:HH)XWAXOO?9?.$$N"MWO.'FX+H0P+KXZ:SOR
M"Z/G/"(3-!QW]W0J2YO4'OY1/(UR^RO8:W5KT^7ZO/':MBS#E2W)G']+7*M&
M6VXEQW9(SM00F[MP$O>)E=NMS5QBPI&AL4%HU765FJCM2E"M&]!"74;2EU;5
ML,G?OP,"L[W-XF,%KPR9(N(3'/=2 YR>YB)E2"U:HWPI(;8$CW8[9F1?L\7G
MGS@! 9(&-#:ABEMD&JG*J7S5'O!RG^/D$9VQ._ ](V".,3##EOTBPF<]JX@"
M\)(?Q66UD\]3;DU&M=^\&%VI?.)4O\W?-LNC%AC1>W:LQ% :[FZOP)T6Y6HS
MD&O=>L0(]G4SLQXO0T);LW +07];^?X36,R2S9SB8] Q.>ODQIT%K&8*C<8G
MW'0MU4/DJ=PME<RQM8R29MR#L"M<8IRH0]X7@FZ9)F$R$?'W:GZPE=&/.0.?
M06U.$88F?WU/UW'0\T8PGX#.6R<R4XPRK[$^V,IE*1(1D"^/],RFJL_=R=@7
MWY?,UD 0ZE(V94 A/O;XT):#%]O[N\N0C'_.TYK)E["R9D_,@-HE>81B+DG<
MBJFE^6-740=@GYX)N^'"K@.W:"0B3TD?5:?!$V4:.^PO=S[N\PS/=*>1 .B\
M.=Y6?HPSO?%AFQY)0V:Q4VNE%,&%,GH[V&O=>+*E0-@\[6@XYC"L,FO@<3LD
M,^.SF)4-9?U! F'@H.-B2GP^?#;,4Z-@VC$U,6P-K2G/('_.%&""&W@'\,;'
MHWLYHBK;.2,^[HT,TU;JJ5=TA22&T ^Y=]82(1T2Z?><3T8CB2.(>JP;P+&N
MI(AA8K85[A?/5N:!"HG<T7_DYM3\/*PH-;6C!':'AQAK=7[7](:G"+,P_@6I
M9LBNMB>TN5D=*;HXQA!*LL]U9E Q],3A2?!/^(:+>G*F"'8;ME:JPLVQ]M3_
M9? +3+:9K\<FSK*<"TIGXE[T@H$C"//P/"=)DVU#5Z)I9?Y]HF*!NWQKGS#U
MK<4N\X97>28U&ETVKYCN$4E([Y*"Q(+$#)<TUUB!@3  .$UB!T.'>6N9P_\_
MZ>^0#KQ[-2'Y#HM$Y]J++T;R[M&X3I']9L\%"F&4)IYQ(XC@4E=J9V0P9<I\
MGMK,TYTNLZ_RT.#F=,>-^ 9[&C?2%T6VP_@/YO_V9;%=J@C]UWW\N([I2(\1
MD2UO+Y8Q,,M)JC K)M6NK).:=V9CN1$ 8:IQE1<GZFA$LKNCG<"F20^950"M
MO:+.#_P"5GF8I+J@FZ?TN"6A(]/KR_V-A-)\$W3EB>>T'\OM.DI1>T5SS!GT
MO8RZ>(-&4QBYG6,O.%=1\ALGMAEL?_-DK*X7-"6R@D[0/?S(=G5]G+7T#V\;
M)S=\6?E'O)-Q$=WTLVN3B@A[9)8976-[9XN*[-PO[SRKA+)T;"?'%@ QL=QP
MUP@?1[B?!* %9A<:4A,/J(I217(0=QRETX7<MB];+)SQ4NUCV(R>-JG0?1UJ
M?Z"ONQ9Z5H"M?(:G'&28>NOEHJ0V66/MOPI3Q7OZ?68V"M1/!T@7(9M\2O"H
M90)V!2%*2D<*BZNHRW!%4+':.[(:$!GKA(VJAJ%7*ULJDD5,;^A?(@T>N)P\
M794LSD;:CXB8;</*=YYD#9T:C7503*];O<ZLJIX=D!?14$\Z&LU&MJK@$S"Z
M8I.MU',8#A_DO7"^B#=TRI"PPV=HP O%>SPV%%S\+$L-EO(-9.":&QKKC'JD
MMKF1R* J6.<$6ZM$86).XN:\(T6CBD98"DUS<30DH)J,>RNO5ABB(]L,^<5G
M<#J_T2[7;^PE2GL?_U+EQU*[SO2 8D]$BX6SSX%^F&V9Y>EU"ZIL'+9ZLVE/
M'ZJQ)8-!B=R0M)55:Y-8 =E3- ?1:)[<8EOOWRM?2]\L= 7:9B$SJ4D2I_ R
M8>F B1CA:2#Z.1GG/I] Q<U1IFFTOM]2)MH$"AX[<=3G;KQ"9U,BK,16D?M\
M\V#KQ "LR;$SW6,\HRJ=#=6H);O91,$ (O@2[1H<4%I^&1I(D7$(K6C);#>3
M-)2OB5],A--#):6"S61KSE@L,N0IM:H+6UL2VY.RX1"C-9WG;X.[?GN'"!/T
M]:]N2K#+CS-NUP2HR<E3!?8902P0)\M.T7JX8M(0EX:K)G!'&M+-3E0Q86,'
M$%C@.(X: =ZG;09U:+9;\Q'$08T-!@#T2THW' ).P.3QC:WT6J^ H  O?1V;
M6#Q\JRM-;L0L6 Q]R(AY$'K];^SY2ZHO:^M!Z'FD[?2W)ILH;X:8_R62V&?I
M%OL^\"SB+;Q$\?C-!")D/2-B8=Z.ND:8<UHYC[/LM###;!%1J0<%>U\K"B7[
M<?Y+VS9_B#N-E80-(P(G/7.#ER,>D"*F:#J@)0Z]<TLM^!FTT-V=G@-%LJC3
MK9>^:F&J'/'KOU,#.P]/'%G!7__!$!6G]0.#W>RHQ"5!=W\L6((V7X4*@V;7
M7L2B0?=F4K\UPLEND"GR-=OWLO_X+?>"<8.C;MHT39^S9!O1;>2=FV>R9/_$
MR8Z^_(ZU83ZMY/97T2_K2G!$]8=%';Q)%5&1SZ'M+C\D:UM.;3 ]3%%N_W;U
M#Z9R=-9K*G7CQ@WF-I<)+L,RT0(O05XVN5 D6'H !>AS*8<&U-0::'(M%FW4
M-ZHB33BU%MWU*.K/<B%I,H27?JI3LFUZD1WVI[D/Y,N8GB;!HU)O[N[PL<]A
M)%%1^\XY+>E@%VR!YNWM8F@2<#=A2V5SC!E%DR5F*"@;Z,T0F[MY*VL@,+FY
M3=1=%)O:#-Z>&C99RJM;J6>?C6 !^8*UX-P0+G6SK*XP.U79:8GKG:.J31D]
MOT^WANSU2XMH+?J!YWQW"B%94]2O96"!FL(CLY@?/_6G7/$4IS%FFQ&3M%I,
M]28SVC?DF5!V2#=,$@5D\Q%JLW!KL^>PO>;Y'Z;;4LUT%LULH('4T\F:$WZN
M_V#@G*.8QM\DUH")6>7Y!/#)XC)6ZN[Q29.N"7' %[DM4X@<"+-QE2+$$FZT
M,W>:I)'W8?-[6E\JU,@ Q_ZLSG0Y^?$G%S_P,HIO@C ?*%,,[YDIJOB?)C0)
MU5-0DS,^<J55NY!Q3_X/]MXRIM+OV1(^N-.XNWOC#HV[0^/0N-O!M1MW/0=W
M&G=K7!K7 S3N[NZ-P_QN)C.3S*<[>?/.O9/[__*DLK*S/NSL74_5KI4JLNH^
M9M2&_II;^G(! U_O\55EO=[)D4S.(950V;A0O4%OHJ0O'3TW-'RTQNC%<[<S
MA?:?J:@CB/HWM-+UN=]I5QAP(Y'2\A<:Q;T64]&,^KW[9>MD2TJ4X29T3Q!P
M!IV>KDT36E7AE'/-F4'-U2-NLH./(IG45)I46CM^A3\3]XJ##8^JS1-Q4*&Y
M.^ "GRW9/9=,2]"5=1S?L5*W_;/ #S..B9\85\E5MQ+U?J:YRY)2)F\WWF#[
MR@I8L6A2<+]P"^"Y]I#$[QO*HGJUUA!BSRR'<%EU P=%0@X[19*O0N>MM@Z1
M..6^&P_/K-DS?B7VM!BFY9'#ECUP1*T9KF_+#+TJU<9R$N^C\01<NJ#D"Z9!
MR#P^ ':%%Q%/J>-?V,ECID:_B7[CX_J4<2G@%=^2W.TF3#QJ;'7R(M+?_5"3
M\%8JCG8[( 1FPQ(06U/NF8VCR+JA+%F+;J_;ZTR*!7)@>?@PP640H_]SRO72
M@B5OE"I$UO<U$4JA%Y^,>@L&B[>*2K+UYW2XH?!YOYM#+FF$AOO>>ZWC/].O
M_*[FCTDD8>:(DURB7B9FWC]21+Q%Q_R1M[>>Y"Y.Y #/&%@_E X.$@ 1O,K-
MQ"GLV.;S_WS6A'])QN69S.4?\?&*$MD>>OR)P#6ZC&40!6H>--&]87OBSI3/
MEN2-JL1"?-7G#1N]WK?1*&%?34X/03 ;QV@7A/%;XEF<K7$24)Y;5UTX-_D
M6#W\./P N&U@#.DZ3Y$.F_WL=GIJC^0>]!_>KVUUDM\BX]@.^.UV#=>U63MW
M/G%R?X$E*<;##&:3>M(9\N^^,0W._'4!5_58WH=61;3KIDKG<-6M,,KA1.F?
M$V=7S!F>K"0Q,H7NQ)0G,;/G5V8P@[&^-JKN&N*\\A]="_N_;K"CSS6U==N'
M.UA:.AE>75W&TYS'*;/:XO +M+6Q.?$PX?V]0T(1T)@?Q\G$&F.H0^R'9X;E
M[;JTU]*I8;>:NPO?+YG5\U264293=&Q>RJII/ZU.CW%L9N;BXI*+C(9<A64L
MYU@E.%W\5G4B#C?TYB;@,Q)5RN T<DR_WFUX;'^Y[#Z.<6A8-7-J/RVA6HK*
M2(^T6WS@.,O;>,C^$NUS>09G^GG'6O<[TMK[X-1-W,AWKP[EM[+CS6-6\MF$
MM@2+]X?.[5?-J1\FC(\9"^3!7E_JW5X+GC;.^?X6EOXH^O5#1?1 !/RR<1MQ
MK2KR%ECZOZ@B#OU^;:[$Y[R#IM_X7]+_JE[Z39(/"C_\A<Z+RC%]I'=[P?\R
M1IYS,?O#3M#K65'V;B]NSA [:[N#.<+BYI4OQ:R^Q#;8TNF&D$PXC:.!I[CA
MJ^5#!((.;VB9.M@-%9&%&A6MAD.7]Z^SO;'YZGO*20"^WOE*M=5Z;7]QHSJV
MQ\/QS;)EO?RNQZ(>)N8+9[G?Z=K&ZL5;P>;?B=(R7F7M_2QQC]9KTT5;U_WN
M2]Q.EN$$UL5UT2XJ^E"EYR36*'(R?55W+5LV1C06HP@M$V%HQ/;R4;3GS_9W
MW_*UNRJY5[X7M>;A.+UX\"U*/MTQTD?S!;1GG1:\/N. !XF[UY7O_[P'(,OO
MQ&TZE3P?_1 -H[F6N6S1#'#_DB<!\B[T6BWO;B>?*I 75N\XG]LT^G3XIRB7
M8?WOB7--Q.V1ANJ_B/]K$-."U>1W!PND=#>R MEIE*!"%:+K@BE *(A\38.S
M]BM_"^0#OMO&O?(N7S0$-"'+'Z1O]COFGM*OJA7E_C\$*_ZTY).-.#-/2K^V
MDC()L3A,)^FJ))DP!+>(\$D>QG,\P *1%/Y:'I,D=E EC*"K5,T-TPL7]BCW
M< YA&O+AI):!T%COC51PA25HA6=M^V4^!VBWE3NTH\#$#'!F8%;F6KM[6K'A
M%V.4VIPEWJ"P2#)V&R;+#W $HL0B^N[BI%P +?.7^&)8E4T7E#R2T$8FQVBQ
M2,"IG'.1H0Y3RP9,BM!!0F==;IQ>^!H9&G@SD* F:-&_=0/G$WNP^TS)GF,J
M."EQ/B5\5ZO6[:-_YQCI,\U_H#7[5>4Y2H#^S^!^/U0KL0R3M5J<Q>Q1POZV
M,4GX1.Z=[)([R#B'[?!M2B0:W1<FE^ANODZN$2RN6@P5(FE&+2R/D'D,./L[
MM:(F_:2C;Q7./ 7^ VT=F2(2\=OR8_21:PNRD=NH+,M*Z7UW=B.GLIT9I;I?
MGU!B(N0M\BS<> M \B6&R$HG2_#(BF8U@NZ[4->-94LM&NRO><,$%$@D.B-6
MSJ54E"\4JC25<3[I$T9@.O8^#*3U9;'@) )4;M;S07IY<^5Z/'8S4-;[?\;#
M]2_X7_!_-*R0[H87M9<=,DE7XFH\GL0^9H@==,_D%E1\S2?/G9W]:_<SF&$B
M@L(UKIXFC#6")0Y$DAC1+*!YPR/>)GNOF5#QS8Z1.?=6R7F[><H#?%ZFH<H]
M]$[L\* GNA)&\R_X7_!_$?A;@88,S 1#L#'Q!/\N0%TZ2%V",)R &0  .+ E
M(9IU5=O_Z/?]PLAFUX=8PZS_MZOW>UFU_0LE;A_FW;?W_>>?31^ Y\7\#\"_
M2Q[TG]?X/VVPGN0G9!HB^<.".C-1M_\'A-"*PE@O+'HSG8) MP93_WWPW&_E
M7N"\"N*QL<S!G><__'S>3O^F\&V&:M7I+$]]<!J;W.W ^S;F+#UO.2HR?5_8
M0.)+D0*"I2FTQ19:!WI@**B/V+V$[N&H*<3>H.2AZLJ6M/_!_0-0AGV?[Z>/
MX*7Z'/1%'Z$IW^M?V'\Y;*QZXGS'68*24M9OG<A@XT%)^=)O+=#XH>L"/6OC
MH4 O()=H_6_P9]>DOX)?[.G#6P+R8]:* N+#+*X6+G]A^B4GU/^I^E]+<,']
M!MU_I"\T1(<E&KSMO580N\9DEXZT5=&<7L3QV^1>2)%'MZLW;:@>&,G-"_2$
M>3K.88WWJ<_<F?]%_2_J?U'_B_I?U/^B_J]%_>V/&@4@F)U*#BI0&T,*9R!4
M',-Y!A-6&Z[65/_O<=.Y[+[EO;O^N@A>4[OS[(]WD6=6IZP/P/IOZ;(O_X]7
M8OYO-';#F9[\3'/VZG'4;9,FYEK#&7M>^:I<W6B\I2% (K:\F_FD-/,%R6>D
MWM#IN6J1T%?8XL]=]9;$U?U$D$9HPP) *K+'D+M\YP. YSA,4YJ2[DHN8F'B
M,':?.SVX];R=[#ED8F4%<;+Q;W[8R !N"\1S7BR3)K%Y7H5;G)\SG_E$SN$I
MF(W1Y&?B \M6 G)W7O^DB/H<;.IS41-;C9\9O*1&R3Q867-"X)K7>;^JE>(Q
M]E3DQLL8_&50L81XV'&PQMC , 494C0X)88+W2.[+3?JVS<3?  P@&^-Z>IC
M_(MQ1B"K _Y3%7+(A5KL/-DH%\- ,#&7B(8M<S*9X5!0C@ SX==UIJ(2^ ?V
MQ$B=8[12%U6*YZ^9YG%[_5Z2FC<TTPEX!C1[O-ZB?:;'U)WZ(N068MT>GT$-
MP\7C.$.['"%:]]G:C S)<7]Q.TS3G*)1*\,\+S6;E4?/TXP\?QAS[0Y8(EO+
M4ZO@3NBN,K;)KFJ784DY?;8QF=&95V;X6@$WSK#;HV=%:!_*UW4^+3XPU6*O
M5*\M#T\T1NQ6I;OY.;T@BM*[(B"/0^L+37J%FKZFN7P0?.+8:M&..A4C$%H"
MA?:4&:FG39LTG"P1XD//L*O$@^8]DN%%*0%T@!963OZB?$-3'D^(946C<Q(Z
M+( :Y>:F@!%KW.,G*;F 7^^4]4?GSB]3A7X?BT(ZTP=F_E2(*-]6 ;M9W2S^
M%XDW#AQ/#)TL)4^-H)>=R[E9#:X.4L%SOJ'X7QLJ!!&"&KT&W[2@M:LIZE9)
M\:7JC!4:J</8E 8V76KRO6:O-6=NCGA"DA&@CD7D/DJNYI+3,>:R>!B#S)IK
M\!DS-E"7ZP. '6=Q\H-0C4\D<L.!M9&C%1RNG2+/1]LH$D%A&L$__<0I9Q3/
MQ3=)VA=X\&B6B):C%U'5X*ZHGIY519SFLD0/J^-Q-^.18$7HA-W\/,HQR'^M
M8<'UFH4[I5LCF6 RKHV%BX0)H8OC; *VCA5+H?>S-%7($?3Z&?)VU<Z*WX[R
MA2B9$=A]J==0KE^$ST9@,]R;1X>,N6D+='-D=#16>SEX6(9/1"41DZ5V\;4-
M+Y;P$+N&,8D58^X;DA;0P5+BZ3XU[6A+W<4%=22RVK#V^N93J_#Y!X<+SZ^F
MV\@C.+U1L-9'$?(15#_;CBDR+?SU72>;@ .7IDNE#*+DTB;+:O5.FMZJ:W)?
M.D9(H\6L(T0_);9AVDG]X25';?&Y3!4\?ODT*_BF:A7,*^5U*74#0[*C#+4N
MHIPC"XPA=/5/?$%=JA)GL@V411>6E_N>R<\.(<$:(IS2(D[63_E)D93EE"\-
M],,A]3,6(/MSWI!6.[RRVZPK]'F*&%RA[\!&*6C[E4DC"%&*9U)9"1E-X>1Q
M(;3N/D$KLAAI%.T<&,N+6^N2.??O<5'_^R R\<.,(>/X&[]Q/[(5JZ%X[Y9Q
M77T@[YXE!&LQP<#:  &<%>^40!VGJ"Y(X:K8[%W/140%5NH++=GY0P0M%M^'
MU 53;QD68>,Y>.,\5,J97AFQ?K3"X[<8YNF%]67/$"7+<G2!%$S=_2W&0L=S
M,:UE>'\*K!8UK4W@;>-AX>&3!"B,D]I)L@WXV<.(NG_BGN$H[ORJL16@M?PZ
M7:FQ7KGV\PHF>^J3I5)8+'S #=.:%YJI)C,?V4AA91$:YJ$ ZWR8P!!Z[V_C
MK3HIYHU@,U\_KU.:\[\%(W7Q4RQ>G[W<%5Q;]#T=F_5_#8(C/)+<%IO%;W!R
M)(KMLTG6]ZJK[+(,U[1(3">=SYR8!IB7MHRWPQ_W)Y?_39_)\^AIG\'YW_69
M7D+X.Z,RDO]#G]E7O+>$2KJ\_M_UF>%F!7RT_Z;/'+#6?^@ZXD0H>W!T8T.<
MK3*H>:[D2NOSO S@Y<([E4'U']; MZD1-VG,3JJ?T:.)'2'X6N!OPV[&VBQJ
MEVP%)R]J#@B:/VKM(7">K:WWPUIEWOL2AS8UD8$B[! >Z^"Z2\CIJ9<N;]4H
M_XZ= WMPM-O@M1SR&B]5'\<<:SZ(Q' /<\&P=S32=&FO2X&"O*^)Q3QV:+OC
M[E]4OLO_^#XRO*:9F.GK0''>H&V3",76A:6GMXB$KE+\:FD\V!(^M<-[>*<'
M>/Y>QMH<7"N0O'JO+S\L,W[0&F\;:HHZ%T'ZN^5T]6QPF#S((H1=KTFQ$M4*
MEV 4:4W7>N8>K=H>!S1EP0:?*V$>>[$#)=DJ"0M4'J=K<=#.MHWR.0WPD/G:
M[F-/VKMZF/ZD[;3X6&*8>(!$E-42SDG"A>^3P.J0ULZ?+0_;6&"E8A-/(*;_
MO:[:/BSN@'1]YLW;5Y5HZL6KBH!7JDH!D!+"?KBF&;N1'$=D-1_=EU-ASV)A
MZ (J\I&Q347R:D71E@O[@RT.A%<:T)M".D/5;9N$A_ W\O8I\\\-*@'QQ*,L
MTNNCD?CW#C$,PXDN[F:XHD4$ C%8/ 8P4YF-URF[JL@%EC\ L/1CXRX"3[58
MV-D&E$,6LB2<GG(1^"E9UT^24#*3VKOUG>'&(!+U<%@J-PX"=5B)IAIKY7/Q
MA6NZI9.A[^#Q GYJRZ8/  _D^@-@,%5/(I_!L2 +[A.,1^!.F(!@'!./5SE7
MG*0/+%X68__)K\=_TW6V1]#-O.0%FQLF:A./=$14LI-T%BA(69B5U_2:Z=;(
M"1@$'="*)9<)G;7!9@\R:X$X1^% :S($Q*&\7>=^:I;"CME7N99&P@X#A!%X
MECHL>JS?H$8G'E<I!DJ9ZR''5;NS;7V'4=3H%]%46 O[2,I0YS50*G5)J12Q
M'89\32$E5NOM\V@V:C,)YG^]C#W>#)Y$]J/8'"?X-W'*?%6!Y<PMME1>M*8\
M [GSF+VG8-.(*KGSV1E,=P0/U6SVBDZU6N&B\<<V;31Q0F!F#63T\)JK7H+!
M7E!S46C\ZY[$>AB&,J&=5/)L<BW1."W%SP&.=(SPASI[^KY# 9?.P0?O[^SQ
M4O>6A2,O/[BC[&4G2Y072/ W73A%;_?W73X J$]=3_VQ"17HHV>;V.P? /-B
MM6<;EED+2J7EO(#6HXDZ%7T#=B5IX8 5/=R9LE0-1>]#BFD=+7-0 6AXA?!V
M3Z216G:U\"1&0V-NVL?,OK!.!;''Z-P7A3O9VH$28>2*1(@'DEY!F>9:[F1M
M]JK', (D>)<=A6W ,DL#F[![6;N#;(,<D48)HT/74J3!@?B8.0;Z#_E#9WY-
M)1K^55:(<8Z3]7)N0<PR*TY$YE/IY:O,.#NZ2-P#\.:_L)JPKEBA[%!PQ]J%
MT'L)G*>G_=Q#<_)CV+(FBB ^NMZ4IR[WEGG\>"=TU.RS);UFVJ]5"#V ?AF(
ML&>-H5(G6P%+4O3Q14)SG:3?O2^K+VII5&,N]E3LU(TP?CK0RC9!VK(FD5#R
M@FZ$@R5V@CB'H]C1\ 'EAWM$1V>!=6IC@8^,:\D\#*N9:PH6%PJB,MP H4HP
MN]5_Q*5BB@ON*;LI#$?1R:I'-ER9116B;M^>)Z0CD-%R&(X: ) +NPR7=,'K
MQQ/(0=#"C\S8"] &[0U7W?^X^^NUK?AE']0LK2(Y?F^R8HGNW?3WA(GAJF$;
MX=+^AL9_=R'*BANE8+1IX"]\-P1X7PKTE&31QI?N]]-E&)_#';.2^K-L%=S3
M]&+'44.:O>=8-+SG8,CZ9XV6.A5!-P^/;&.?&2S+:<"=LH.4\+767E^ZJ'S4
M$8"NX +X1<7@B6AH3[9GVST_Q-DLL'!^LF [,"'*E"'4WKF-%C*80:4:0SW4
MLAZY5K:U#I.;?@(9Q_#P5;!)2_>E0E*C"O&@137!A:?8$2(L&Q0TQ8O-&RE?
M*TEV6/ _27!&RT3_CB3AH1I"H8XS SQ@.<,MZDTIXD'K(43JI>F))(V"1NL5
MMTHF@MQ*CMU5*CW,1E7A1GN>8IGI:LLN"_%<_N(XGX)K8TLP*6441;O"CZUH
MI. 5D7<)E9]D>Z(6X%I6(/#K,\EUP44>E>"4^'Y!MGTB,W&].8HMTWS.UG9&
M_4M'VC-J3&TQY-:3:QR=H_F0A#01U%+[0QH:_+O<6JI-'H8%K 5;1\2.2-EU
M:;\23.5BT.![7&U(!-RE6H*\A+F@!CQC)AKH;KI9:0;O-%NGX3SET1 5P&AF
M']^'84?/(/-#$TK%FB/*VF\L-)V+?W=!C4JX&1"(H-P9A0C1]M#*(7O$3)I@
M6>DE"\HM!;3+ 4W!LMJM#9T4@@O/8'"NJ=D'(/B.8)YN_N3F;CG(#"VI)T;#
M?G9^-^-)0ZD_ :>D=P:C6G>%CJ3'AY,R)8XL>&<M/Z;8MYWZ# @/4[D J#8Y
M<.D>L'\?D5HK7;G,OKKP#6[\PA(CK,S>K1QFR9"EE=/65'[<Q[]/'=+5W5CP
M76+R.4IO9(*?"5FI+D0*!3 S0#'D<GXSW1F5%!91_WYP$GO*&C2HR'_M(&0&
M1,VBAELF^L/'8H]#"3)I5L+'B8>'#4%L-YYK##-!Y,4]MT."$<H3!SH(2B?>
M.,S0QIM@PO=O[(,SUN)R*=%C&FF;:LI7I.D269PM+1R430U^J17=1".H-C"K
MR1YW/]EL<,7VEK11NWG(DDNZAB 3JG"G3OREQQBD%D!G/X"!.";UYN65(!(5
M5['!%7-+L3CS2+@YZ-9@;E9^#QR=B0OK48LUR>*=X HGCS0-BT(R!K,I<!JR
MAA P2>2'(6M6*8MZ^LKCB% >@XA,4)$[ L48S)HN33;^?CI$=9#Y?>8?8-%B
MS)5+.L6AO=]-M$W73\B+FVQ^9/A#Z;>+[BV"G[^C4DM^P?=D+N@OY;_KSXQ#
M](S9#M11_2;SRDIL15-DMJZ.;KN;:G^D*FX2[:J7<//:@; ]$C[5*B3Q--/4
MEX2*% P%DIK^D_7S-<&/><O:\418:7:Q++S%]ZS"@OB!\D5,=?'?AMN,A)!#
M O6*$N_\T25>-?6&DFVD,,A=!RBB%YO:/]LAXC<O)1F.)U4CYI3LTZK4&.,8
MUET.ODO=+3!?/#&&5_?Z="M]%NSU7S)4)ZU=11G3\,-0U\'HH%A=0B'X#_/Y
M_Z[7 [L/P/',U-,FGQ6991:7C/VXCT\+_N59 W'LZDVX7/K4G]W68%L9#95<
M9CAY9A]/5<RXQ)PN?D!8)^-,*"P>,?0"P-$DZ[T@NQ1<5XON5PB^VI#)-3-,
MP3,=D)7A).-,&Z%P2]^>-$"*(C14-DV5-B3*6T%UL7)52[RF5S.:4,KO"YN!
MBN1#"AO2:O@JLNN<D#%WHDB1J5R2*5Z!-1H[I'NS2YVB2*LAC ;EG3AJT8 ?
MQDRZ:?&IYA1=J\FN,$ZC7+Z0>SK2#*.&M-[XU:8!-=,*QZA=/SV&,WD'W@U(
MU17;/]I@ZS1$B9).! DBY8 M0Z=V)$W6C2FJ;Z'ZRU4Y_UL9-OR_S&RF-RNC
ML![]?5)EMB6E[8@K*66[#@I9>D@;&W[,;L6BH53PR*R(\D;ZJJH.L(QM/5VY
M]5D)K5VT8IWR84=X.\P3FD[K 6;_U2B+HK1<A!!;2?9+U%YDQMA,.J=6,9,L
MFJ>/-8>"6PP&*EQ\:^"_#1*IM?_S_;/ (?PP9R4\4N*!@UI_UC[0XS:RF]AG
M) F^LY(FC$=OX\+U+ZIWVU:4VX!1^_3]6T>PNQ4-?1O#:8;3P&29^:M;NZ!'
MNBMU*N6 GWDUH2(+5]0?],=^DD-_ [Z1.$ESS'Q?E&0F+B8W4 &VV AIBNY<
M;[M?H#97Y;0OFE_7_]9>VZ1-^]PV&9N!K@\[H&V!P<E&OX"3VSO\:QZ'EA\#
MLW9=?[1<"C?4AG:\MF^83 D[;2 2&V5DO2YO5__WP*V'&0:!H>PS;B5B%58J
M[ ,!C_\YZ\5S5(6+PEC6=H.C@]T A6F[[5UTWD1W_"Z7V \?.7>CS#42H633
MC JY.?)\D2=-E@8VPN%3 $FVS[D@J*>)3!HU='1!&7OTLSQ.\'[Y]8-:IJX$
M11F!LU/@ZYT=@\!PR:*1F<D*T!8CCSN8,_[%BA!N)ZTG__@\=@0_:<4KU@F"
MUS?6ZO0CH4D7C_.-/GQCL&^!.R<#G6+&'VN58=4BRWL6?1"MDI2/\EU+L=#3
MVHJEF.VW8,P!&]=9;(:Y>8AM+]=O0BHW!BE\TX<DA%N8Z$]T)"[Q1MX  :@9
M\2E6"A*5J\1S*R2<]IF?:[ S%G;7':ILMP< 0?CCFICZ2UYU^S07C[=HI(H,
M!8^H$=W8FZ\T6O(*&A5*-I]4B@6VD(K(Q/<1I4GD!Y'[ /U^H>)=M?9W:M_G
M<$Q/J-<)AS*O*Q/#PBRP&-Y'SI*[2:N('ANP;MKBO:.!X-0LK[16>[!@:.V$
M!IT-L639:EHA.WA:B"!6C+N1S>B(HK;TDM\Q%7NU1M(;O"D2--J!F7U%'(O]
MQ0P2DV9]DQW#D&3V5&1,L4E/^5-<,'&4!BKZ5[@XCK8$%6YN%-6#QT.+6F^&
M&XQ]YJ<DWSM6&VV!MBJYM96U)(D'!+@3))DP:!R+.(FF&-PR0MN9(H7L>M1^
M>(I  -H \\I"UQ&E7]X_N]0PIAS2>0-3%,>E03)B(4IVV)1."UN4ED*'HV$%
M-C\I#1/".\B?[<&@;^/E-B-P--EX:(*%V'DX!#@X^5D Q:X@5T'$E9(=&@,7
M:/'5\4CCVD&#;;Z2Z')MT'L1@!D5!C.6F4%3^(>F<U_$'95S6U"LTGX>]OED
M/7EP1M%P7\ZMO, M+G%49HF\(L,^!SU++))NP9'%Z*B:[E#@?) 6():OS;/I
M?(:0"^,0E;E.[<:5#';\L8-/#*=:?R77+=+Z6CCED]K.F@NXE8).&=73UY+'
M#@ZJS1H'^X(SPCY4N^DM^M,FBY6_2!#EF"N9V]CC(DH/)K-2D,4AB\K/QQ.2
M)-=58G>;N=$2]*JS(F8=,]EE/.HS+L'@DY4W_/RY\6SEX)X.W';C[/+P[H,S
MR1PS^3;%P$)UQGX?.D)P82@SNMV"*VSR8:OB[*JI K0O5Y +XBIR/X/GT;_-
M$ 7Z(F<>JE+O"4L/Y%[MQ:H+9^R21&$-C!K^;%SS8? /FZ!FH\J2FD'R_ZY)
M;+CR"/DEKY7^=4+)Q[S-"E%$!+JKANC(CAQ)N.(\O/"T9IKZGNP20FK<:U+E
MG 'JT>IPL'_V;H^-0K-/2<(7-=8^_T5TIJA7XZG$LVVK0BV!DF51T/4BB+1_
M?+.6<P]R2*!<<W!.U9"OGQ7!2Y;],\1U# <XI*>I 3$J,F?!W(7TZ6?3(I$Z
MA#&#Y2?S&_O8]<PT(?P-(]!J*]$AN/_?9LMYE_SCKB[I24.W7MRJ-%D@Z?U(
MZI$[&;>X<@U !.SU%XWX(&Z%!85H]II'55TJ>?N()@35>_%C)"%Q; *^7>EB
M'YI8'KQU5B60Y3T;G[5R=#HOUR=ABQ3T!419SP:*B5E<3C=#!ZB5MT"-M8V8
ME3=])&MQW/6'4GGJ)Z4U@K?6]IK1+,VV])'OI%Y+2G*KR:,^#(4J/$5K_@V&
M2K]:.$=IS+'\BNJ;$>'\(GXNYB\LSM1L\#FQ"V#8LUFQN)BG41K8;:"&P_%)
M\1,LV&]TTJ-"F*'W(#3!,9&3;^8.];3C;:1.2S7QK1*7_$E#PV9&K+&RN*[L
MUHR,@UPCGY >H*3F-&<LRG%$8L%4%F.Q$)\YY%EQG$(>C.!_TA6*'E1\FICP
MK?QQUUPE_NV0D=0!NL[ 8QI1_14:$V#,F&<C[/">'/Q6'%>(MW:#D"J60#'6
M'HJ\<!9J_MJ,,J!_!A/^ 8F>'I(>CAU'PB4USK3KG4IJ8\=ZO\HB?\@13F*S
M-.0:#,*ZV1;R<)?'DYJS*^Q1TR(HHXGL#>7%5SZW0[/DQS^D0LF^^P#0C/MP
M[VE^7>8:]YS:*YN3IC,;(^JOQ3)GGW67)&*.9!1'ML7C5#HFYW@:W1D00H(:
M8N*F2_. UXV!K5N6WC3C>0MVC*TO_.O67Y5!SL/'Z-WO_;9)UY=EM6Q;C,7<
MQN(^I"Z=8-$]10SB,^@D\E-''F-)J,2H(K<*9G= AYPTVPP+*5?\09?D>4 Y
MW-=_R5I>MZA[?8E7@0B.P5P73J,T-H9*I]%)TR4%;@>3RB=EU@U6-4O!YO,K
M)JU6Y$/=7X<E?-V9(.A5\^AH+TWJSP1;X :NPVFX65D=_ *15 N"*+0(!=J^
M<$:M<Y/"M %!LK;,Z1**#&+$B1C+')3)7.BWMKR=\OU(4R\1E?R<%C2#5:B*
M[&=XM$,:0!K^T!-Y+3S"JK:DA>,XI:I":-'Q"@HB*/TWZ*8++$X1Z@3%C$2Y
MG01(@_=M@;E _;/P4=AQQ@!HDD,@/-_=440!US(U/RE0@L6L*1PE_'VBU@[=
M[C]'L>T_B]8M\0-0'(_R 2##^@#8LI8/._YF:YX*':YGLIXAOF.<^X%O=%'E
M2$CY_LKR 2C\ -@EZ>W,,(?]$_+;G\S-=K)^F<9WG$S*3R3-ND*.]4K@&+NK
M/=&059=UE=&+^YD<-"FL%[ ^;Y9\"F<6QVY$L['0ZC@[.X/;<JRQ,Z7)JXEH
M$,#IQK*LW6^?>B7X:Y?/RK;B;^28%/\MT59V!"GC!ILZ':47AH6F] ._9%>H
M+36BH.,<VA%E'LFWRX"]+_O[8Q$7],YE["T58.6ZU.(;V($/0(1!$2*)9R:Y
MP'+V+_IEZ-*9-$NEN,P;SF7! XGD0%X+:^$7@P:9;_(6JTM-1[R=X5=1!2NX
MY0;ROXAN"4<F!(R5AXW[I7.T1QN$!@J2';$=F*J?[AKT=+!P]K+-0P3P63Q_
MRYLV]3N;/>3_W)1.>%9PVKPBC?OM5:.%*90[]9!$^ $(12/Z  !VQI!B3D4^
M6TCGWDL-?@>2%81\8NAT9PQNO\)JYIRU;:6'[XCB%^;GG.4HK^]I6=>M\7)O
MZ*!M"O'(H42XZC:XJSDP-"<<(JS4;/FDU@!JUM8>Q>N1;?#_ ##S\HF&(=GF
MT,!YN+),U]VH #$2"$V'4ID&ET0RQ)[SU0QJRX9)S5FDCR]V\PA-_;,3N'=T
M1?M.D[U(+$-AG(F4PM"<Y]_2&(.UU#*3F9P^ ),3ZY)P9K(NNCI=[3!ORB$T
MIU]>TF]4]]Z:?_P=@_S"H>^]1$+W;]]:V^J6;<4V)(SEH/MJ(2;#9AI,+& %
M4B$WLV B.==C;J#1BVKK[8KB5X-_)RM7+TY84I.#<IU  S_4RCP6[GX 8EB9
M9YT4/!69QSBLVBW]2T4'X_@GRFDTF1Q82O181C5:4LD9><"?#>.Y,.4S+N#L
M(CUL&>I!R3*M6+0 )1>[A"[L;JR;BRX(SO7B<.JE:=29V!"UNG6&^XPXP]
M*.,ZC'G41SSHEO4@_!?CYLI"!450OOX<=PVUC+5X6.1<,%IR 'L;KR/[MJ:O
M28/U? (F1)5]JFKIB6A626@<%2L6?I#-(Z%YS;Q5SIJD?,(M$@G1<5Y[JRB
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M,(2Q+G/@-&+_3(^4S69<0U;>8]WU#AYVV_J?OX;;*C9V!1:MA(=$?1"VP)Y
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M<YU6WMCW%H2M)%#\=(VB&5L^,^XNGT.Z6C@RCZ;WET=?HX-*>H&_[BZ6$B]
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M74NH2F%<?!,$Z(T3LRC;HM7)]/:7I%&I6D6HG]?K!5>KL^P&Z_FQN;?X1NF
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MP:%PK]4#;OR58_UX;Q0S@(EL:MZ:.MM/0)TD>G"$G 4G(U-B5]YA> _?>KR
M+E,TT,=5G3-X_W@X/WE:I"6%OFQZS**G1X#<(]MJDF,OC=G"5C?:"VT,LQ-9
MLQW7 G-]>Y3 ,)6#R?-$O],B,BJ2+H=*GXYO6N!F1XI#LF%3)V>767NH$>8
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M=DIH 4_V$F-R?#,VB5WCR3V%"]-H.D!,3KJP*917&0JEH&$NN[Q&\I21KW;
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M!O9ZFK0>P?..Q*\5Y#?6E'D&A,/"4P'#/&2',JGUDPS=L_UU%-28J9C[$:@
M0XZK#[VU_O%>B\ .02&/J>BSFBF;%)K%#2>(L?-/)XBRLGM<W!X6L85NB/6G
MU2!;[RX?N9HQ&V-:XS4UZP=3)V/K!^-TEJZUVB[:?QP69S:TM+06%DG:;T&>
M/L^6$\6CV-T/)@T^-\55(0B.WT-R#M:*7M>]'Z_1IAYP\T_D9NI<W@',?EI/
M@SG!DW/_6FMF:LPU!'"^96[_/3/P]^'5[5B66"*#SWFO&,'OG.OH[J/G8."_
MER<]SR^;LR#'EGT2)85F'Q&:J'2$TY;6MC,S::%LA#V=&6>NSL5DWY_'"BC1
M>@D-(/^UNCFB_!(P3_104>M](5IA7 T._R,ML[B13[,(T?155IG#(E70-OY]
M;!*WUBTR3WC19[O:X.ANQ]H%R?V5%\#6=-RUJM*^ELS:%MC(P9)B:I@']M(V
M4*E$8A:)T6[Z60& GLU-,RVA8!UHEZ\/> ?<G_'FN=5TI'R4>(@7\\2ZH-=5
M^]O\V_SWF 82WT4'N1&B>67#$NVQ$"2Q'#@0)#'(__)_P/QU29RKN8"M.SM=
M4],<RW< %%>@?L(Y-A/=W^!O\#?X&_P-_@9_@[_!?S1@.V_#Y51FWC7(4^3^
M'#F8Q-*)C\+<CS0(%95(O2R.#^MHLM1Z$6 R'ZP+K TG OYCR2K^C[G)8FL=
MA9<3:9K)5GYPI;/K6^O?RJ#_!F50)%BX#N",I:C?X?,<3OUN +F?'%KI\(-<
M.H9?/4R#3T'.$2+!DLY&4Q.L*WS(<6,EU)(R$^WOHN3DWBB)^#_B1&$]JWC#
MY87[!3ZY11RZ<P*'QH$CSQ-VX]$?R75_7;<;<G$]*#MQ#>N;[![2N8\WW.*L
M_Z+&18[C#\" 20-2(N-NVUIPB2ZY2WT#O9C3N1!PL<T$!_9L\'I)0E9[KR;6
MJ'+-G4BZZ%\<I21$B?"3*>5)1P2"S.@:8A9)ABE@>W_0<T06\^[$*N6NT/KY
MX$N;*"+(6DH7!6&;>3)_:(W$0(6N;I(11PAG,EGJ$&1S_.'3IC=JP&3(-WXV
M9/3"%&<AT+N3-4!5;;@;;@;&J%Q'+_"7H8F<'2:*A<:I(=_<RG?\8;<TI<;P
M\J?F==$BR'H@GX9AK(-5XI'%=U3$.;D_IZWN;KTT$W.S.V)?Y>=U'Z$L4VB0
MC,2IT0I;58A-A ^=,B@9?_^B(:<G#-$6)(+(3K"KFMZ&^RS4L$C@D1;5&F5X
M:ZR'J/&Y0ZE1!FT/IPMZSA_MXO\<?$+0'IDZ[_BTP)#'[LX0T@Z,;QKNV &$
MU41*SOYHFGVY<3_8[G+U5*B0F9=K=S(Y,1/K-_IR457$*8#ON#?\LE,]Z4J[
M6=D#FHZ8[<UP]9X3)=B*9FN$'+(10>B7(7!G\?(F2Z&L7;?)""M^S(_';BP"
M^PMMIZ1_G7WP62-RNZ=R:Q*E>6HESL2@"^+2/N;N^ [P'BU22\JPZCW"+I.?
M5GO+S.P)DN'M*OYV<G(*Y,;#Y AM0!B"00= H8]RQ \  $1 2?1(IM4!!&>7
M_,VWD5J)N5T_(M(9V7T@H0]J'FKN=H4/C*HZF(I(,VS='!%-PA;8=*R*,XE3
M@^7_I7<HQ'*Y%Q;WSCCYN:-@HO5ID]K61"VI7>X6T:^EGLM<_AT0'*AY@(--
M/EUN(%FK6#< Q:I[(N.6C=9^4LC70<_>SK1&-XZ;?"T5[]$\;?AI[.4G\4O!
M+BB#HCD#D%:KP>4GU+'/.4A)8&PVB?Q)5[^&2J/L/&2'<:<5+N#7JTNRWHHJ
MZY<7@H[G1N8ZNV"CB<:EP"P140HT1=QR@P^?4%A.U5RE"%,JD#P@YY-]-AC)
MCP\N3#],YF#BQ9AMI2@21)O!^L23!%/UB6AV10;K2,Q[6+D.>+Q[\U]T]3]2
MFW4DX->:1S_T-3NN1N3^SWS I'/?YC[9'77?(G+)RU]/*BK"KQS.WU\ZA=6:
M_(2T_6@7E7T2W:9G]B$P" ].P_CV1?*&R[D$I8@PR_C9R=:8>(T99%F4Y$@X
M';#F,9FN=L879KEF*J@R^P$@%L8#/%/^F8.+,<1S*MJ5%B'ZX6[X&!!58H)F
M9YD:L\!G#R*IG650U:@HWZ$2MR"Y5SRO( WS\&0<_^ @.PO*5D/7Y]/^M*/U
M'8HE595/X;#U*9T1-#W;N<Q-T*@&C%$[%0I?9\_-L=*K=<8@/Q6K8#PP_;$=
ME3EVE@>JJ"TP1_1Z9_"U7<G\JA>,P)A!<5H1G3P+'57^,_FD#=R7*Z:H.[(<
MW4K+H>;QZU]X8^TBCYGV;&"Z'VR9NV#U^NX5AB1X_9!763U\V_=RC+;:]#ZY
M4Q^Y>.30I!6X765>C[(-US?R=$W2#\W4T;L/EBMD-^UY4W^,4J5DRB[H90YD
MI:">#<7#P'/'U'=:^=Z]%.I[M%@U.GVNG,J"@=\H,BA"(NV@H<2I?>"A8RO'
M,8_3JC!LL*A!P4&0@^ _0$.IJ:9;:DVCZE>"(#!T=D3O=TG'N5XDU821N\M1
MC.T7 ^26R""VU(5[A8U?5VX:A7>*$2"&);5+G=Y<?8%"#P-OXTH6V!"VBF1^
M^X";VK6*M#V:.Y=^^%VI#8]N_T_4T*TH>ZEO4%:^,<]/4%9EXN0'2"F/V:TI
M3?K8H%L 5M/X[S$;AI6R;*>+XV[<7\F+LL@ @#BNF'C)XE4>\"B?PY:JYX/$
M3;3YA.\N#H@/+HA@\OJ)5")[F')%ES?IR@1)C@R,\737[:E\D,2@YBAI*">I
M@PZH%AR K;'[/=!$\]?K)G<1#.&IYI3EOB,?YE"=[I7"_3*X@AL8QY3(2\5+
M<!(9M2L9]8F*NE1S70&*FQ(Q436L=\1U%O:Y#<GD(-RX1Q!\LCG5%-C;<*:X
M&>B3T%!%@&Q^ORA]D9BB)V3:J-]:^.<!\ Y 2+3 D[^ELX&7PB"P<E9^X!$8
MS:1T@H8WAQT^W@][,RH3#&',$ND&EV$Z&RV=P*0KD'L8WKX#R$/\AG_2T<6T
MM\=0979T"W7S5['?,ZJQ#Z7P#Z!8H$<%K-/0P+JYAR0)L([X(IF2'LB9N[U-
M.!%"^M_NT K-977+Z:M5"360QXXM?_+!)#Z)0=%RBD<[;5#HVX?;:EK/L9'S
MZ5N'8V)%.FR;IBL?3(@6[Q>&S=P -=!!4FTA-.:RHQ#!,;:44;7X(0O\GW\:
M!_P%:L[(N_+)1:S ZFK<K66T&#)99NA0,!;XQF7_42$ _/ ^;'D[&TO#[EPG
M?IPZT3R)(T(Z;F+$A]0]*8^4UDGZETC)UGXQBZWYK3MZX7> RI3)MUD_.I61
MAK^>J>[S#S6TS+? ?GY7)%.T57+,%-Z+KZFFTBP\+1G?"DQ+5T4^]?*U/\C]
MZ=]:Y9=:M;M#LF<<GL;D/J^UDL?[BB">YKDB+\^R8*$.Q8@>QIFUPV[6&DN[
MB%![#W@K'X#\^!\O5+.8*J=#PB:6X^X;',/I<682,<7%? /Q\@R;YG1#[EQU
MG&R[,*X#W&-:NOL IHP$AEEOG4+;[S XT MR;)"I_U)H<_3(=*?F++R=*M30
M,QL/Q'#7MYNP+DM QAW(<NI%X9I$X;OW.>ZS59BE%,;(%P;-??M$37*8.3#L
ML)D4KMU4K^%KZ&D=S=HYWP1KD6QCG94,O3&^);@C!XM+51T+JP"\C481[!Q_
M\\AEIF@^PR$#EV9UZ5!#/<0LV0'OC@O(>ZY@N#HD. B96ZA;0VW1C".^]8GG
M2G?N<1WRM*<6@[%-C"*-'<^$$W]._IJHWT5")QZG(8,?/VG)P)QKUI! 7KTZ
M3^3T+UU2=J4^K05>UHL1^0E^<J52XV!53&#?I?I*\)% :1]= .)VQ!(YG%A'
MVS!)68>J=@''SR5 +^^;4<EZ6*YN+GD"&":*_/,3#/W:KOCI38<QP"=#D7JU
MO7X6D3I=?+_UX$W\[2[NBZK:1U=7-#D&=V\?;W=-\U/M(O,84O=P_&$*I,<.
M1<7_-C0,;&'!"EPY]+]#TKWAQ4;<I26MT59>LZ*(B-C/B+^+$8@RH<9:RCV,
MP1X?-M>$GSJ%WF?02 C/+F;FRN#JA(K#8,2:>V?^RSCC#)3QSZ4?BP9M5J%=
MG[.20?R?12 P/<?*>,2<K3P3#46$*'-L=:)T&5GMVZ^Z9:OB_$H0'I)$S1M6
MKIZ6:KS UE&J1=B4'__[0^M__E:[_Y<$01QU3D?>;%>NKO<B0CY-V/%H[E5$
M?U?Q4]K;)' *:G_J([1?]Z'>QU8O(&+-V,]D6*>MVNR&3!LS)$B2,RX;S^/O
MES2M9?'7N^MJ2+##9F=6PXW!^]]+[?ALN":Z/==CQNCFK/#"[KVQ1>VK)9+<
M]1>9NGL&$J)=GD[N,J1U^"HE1&#$T%Z Z2^'S<]"*4]0P[>#-+8@IB7%$_ Z
M[X#SD 9M3/@$%7J'?;79K?!?!U?D_!:+/4-WA9L5SAJ_9K/.3?G68ZV82]7,
M!FL7T@3? 5@:"!\XO+)P5J!D(.V&VPTPA.6>$L.RG]WYUS##.5UZ^D2=7I<5
M2&9W6IZ:N CED$(?>I%H01@7I.*I+);(4_V4!.HK-#/N[+2%LQ^P8F7AQC=S
M6)F:ZUK,B!_;#$Y,I\P>SK HXO:<?'\O?D;)%DI.>VIN$J[F(ARACQX'QKI
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MYC_=E)>)O;6QG_9#G4.R]FG[Y(&]?+-&3KNP<./75(XUV]7>RY!<X?6A@8;
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MV";(U^&&2=3J5>,]%]OV#26C_IEC*/%7[0,]P+[R'[%M<#H@$=U7A)26IX=
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M&6P5CDL$M<S/_#W'P'_&4/YGJLJ@JC:H,,80S$4F2A&,#$63I-PJH"^=HN<
M/<90+P #FZ;WP1Z&KZ7&WK!H@;S\?QK/H-NO,>^ ,6GDAQVRU\0"O]/==\!-
M(O1KNUROY2?R?]\._N;]._.#A>\ HF]]A_=-:?BA)Y&VY<([Q6OEE8*\5IO<
M>6J*^:^2G]\!#P<DKTD%?N>[O3?I\>\ )XWI52;XO]&_T;_1O]&_T;_1_X]1
M5%\BCVV&<R]1-=_YIM&&#2E-GC8X>,)/GTFY^0B28Z@L*XM<$P7'@R,&;F""
M#IE 'OG;2O3#"91Z'+ )-Y+8LW$#<'T!0@)U+Z5[[X#U%+<'Q:#;INB_]G(3
ML=<..3'+"O+_"&2 SQ7Q'Q6*I]R#]6Q;)]^W[+SJ_=W&=TCM[^VR(37ZNT^@
MH_DHDU_36R0FD^+2JIST.=DX78!P]H\^=,^%1,#V?UKQW^#_1Z!H:*80,;MV
M)A))&+Q!AUVP)K5LDEY?J6:+HC(BXSR=JN)UCD_(%&D@ 'H9(\S78*GG2F)3
MTAR$&0052!!%&L-#B2%-!>FPRK:8:*GS#?1BF(DI>L4_C5Y^&5\+>?Z_XR3^
MGQ9 #GVEDBR&(@8)LPDU).:+!A]AMPOZ<,I4J>?SU'M_*=/\U)/H?8%NJ=/.
M+XD[:3_/#3E]/?HTF:S2>>*):FT$=-WDVXZG$];]1RI'$HLSI\B,C'LZ;-%-
ML_ZJLYIRI8I6]OG]98O&,YN%SO7:R,[5>!,Z.@M04I&_>R/]./ZV9USWSCL@
M"NWE'6#OM=W8Z']F;AKYA?@WO\*+O.B_%,G?E>H56]M\/*_.[_2GO'/^N4E_
M3?$T-Y+/8OIE33#@7[%/?D?,]H:XYP^$'"E1^35\>?QT\D8C=/M:L^T_-OI<
MODLN^X8Z%X!%?DS5\%HD0@>S0C?7^(UD%'E]S4;O0<\NS/6$VXZV<FN.QDU5
M8722H^1RTG8:7=N\!\+ _PX(;H2?U?WVNG]*+N^?O,J_5;IY[RO[U;V-S CH
M@;\=3YL<3^O8N5YF 5K)4G8-1>]X)9[K) O<Y/41@<LF^TJ6YM1ZYO!7#\34
M[&%_V/Y@)$KOIJE !!6$S$ :KPUEZW>,K@^4PI=3NG@'\$CVG,T*F4XQ7V-<
M?W@,-G..-GD'V#"01T9$DG=C?_#3?'P&BK]("XN__LP@WDWO71V#WZ7<A;^"
M^;Z-T_,VI2Z&B8XA]ID.[G?IU0,XZ'?DYZ#G'QS\@^P!32GH U(#Z%N(0=\8
M?5]S"ORIR"C\?RFC7BMMGQ]\^%O;W]K^R[19EI# NFS9X5@3#@]!84S(YX!P
MU\A]I#F3H!!TWP'3V]F^6R&G+^(O?&]J#E#74E?G]Q^N/_Q:?Q*IAQ]$[VU:
M0!] [W?>?_A.CB/Z-JTNAB&&VIN\#O!3?WX6$?^;]C?M;]K?M+]I?]/^IOU-
M^W^ 1MI/]BMVX(TA_\=-&G 60HDYHK=D3IC_@]:1U5FF<XA.?;E$DZ$[K+[?
M9)(!#:7.<8"1;A<A!(34<F6_OE+0M,!R$1N=IU,@J_A1$Y\JCRR>:;E^PVC$
MQLZ,T2)FZ[$^[@,WD?1#3R?K:@+Y;Q]GE_U_RM6Z_W,"02_O.V"13/8=@$/V
M#FB.K<*>R[YW/7.^7.HZQB\7:7JE.-\F^/GH4BIX,[&:^(_+O2^P[P"CC,<7
M,_H_/^Z3\B)ZJ[=E_=QL9FZ8OYV_Q?''!ZMUMMC>D%_U3?\1>ZC$/86JB4 6
M+ZAT<FHSY7*]'@[77B-!RB/Z2MMO];DFM2#SEFH5Q?KX4!\QF./*PU'E"D4Q
M3H"U5M8H45^>Y8,@K"_2TG&[^CO@PU;Q9.@VZ9A&579&"!H7.O4/$]V?CQ/.
M!*[A&^<1&(#M7 LU,[\,>< N(0Y'V!AF9-[$W"+?RE? U.T2 XOA@M!$\UYT
MCD:H7LL3#^Z5I9M[QZJ;F_M3H7L<D'1@)H4"IE%\?V;A9JAQ2O5&;JB9U9-3
M0H8$P,XAXDJ+P<!97O:8/EE_ +H<?RZ?V74WY=AVZTU\L]^YO!:=/Y([FI[X
M!MQMK.0/./7;Y']TFJX_[U0Y\_CS< HWEK2Z004(;-/?&&-&LA<XHZ<=,Z3\
M%%O *_-'$($5-#9@.R'XRO<G&VGW(8 KY"%:N?"V-5M,XL"U(YD@A22!74-N
MJ0-9/K7L]#&TU?63=@/I N8RNA&I?[V/X[R]^XRG(EHRW>CG79S]F7&N$8R,
MY(% G0_(REDZ WW[#YP,K!22,V&+/C*JDEC%@<;5\O"^&<SPM\[VZIX'=G/\
M)=H]/B7'"46JX)88W!P#RR@L.A8Y!NU*B3XHQOER&GR"(:$5"M0ZWZVE%KBH
MY^+3]#7E\:9><!MZNT@\%>!),L/2E/I;'SE7N/@$>VQT2I#A%%<P3V>A9?QW
M""5E1%K#0CKVE"/L4J[U3STS@!GCMN!;D2J_Y:\H=$JB92*?H7EX*%K9>&H+
M63UFR^C72:'@-()6[7XEQ3BN"6P*!NL@P3FC*1IH'CDJKL&U0;@3/P\P:G '
MV]*GH;&?J?;8_*QZ19PBP3VQ(@=ZO=0\)9(U?]!ID300.<>PRL#*-42-G8@F
M&S6""2NDI>, U2I8>*S?;X,$#IJ/M#ZV\=Q4J.$-F]>#Q$H6XD@/"-*E/K?)
MI13\N']87>.63@I.,!T6PX]4 T&A!]56G#X<36BL>:S"T2/&<!JTD+W8#[Y*
M52T6+$4Q&*','PHH4:\"+)8+1IM)2;?I07HOB=^(7A,*SI,>G?K[BFIOAN!6
MJ?-]"&*4=L[MC1#=#+=DB4._311Z7-FO;?(029S ,^4$'J!K-L\KVG31,R:>
MGEEO@]'C9G9I-4:@/;5_34CAKG[\O1/)-D*E0 NMAJ>/9$](C766XS@;/HPR
MCN")(?\.T!SFZ[(JR2S&LK5.$6W=6[V;)^(]((E*48!P3I2%X;.GBPT4?G[#
M"M8,.A0<J92W4/HH4,798S OWH.:F .1(74+H=XA];R7D*X/7UGG/N\6]4VU
M-G@EH]=+D#OX;*1:S[*&TA1KE,=RU^/$'2.+50''CA)&,8G51M>0.6^&(&L,
M3$<FVI&%GX A8JZ'!6]RWX8F#DG%0_IDGV(PY85BB*Q7U:T/[J^Y>**2'LZF
M''LEUQ$L3M_29^W1@J__=\D2_DT*F4_#?4? KIV4)Q*/']E'J2$)]U\MP-^&
MS_SK1E6'].)0M+7,ZXF.E1?4=[I!\C02DXO4WX CK!>[315+D&5ZN,L1LYZ%
M#?,&&][U9;Z9"[)DQ7JOCYXK-HP0*4,/(F%%//IT>J.K-!*'J;[#;?)$6"6I
MV5F\0%8/FC#;CX7J'4R6I]&83+ 2R%^XNJ;;UP\J#'&%-ZOK34S',H:=#@6^
M-/S.$.4*QEHEC-LCT;SUE,QN,&)#&_BISP7\$/1#VT<+%VWXWLEJ',H,X!#V
MCR8RYQ^N)P4,?;S-?92P(!^,O>7^F>]6%]SB=_UR_\A6GOWB?"@WV-VU_:VN
M\7;99O$=<,#^0H1,\&_O"]7)52'S6BM##>2IC!*0LUINT"=B6.50K87[1AXE
MY3CS2&]<\"DGSD(K*/,N9EYST=,4=2@B0>U #6Y7"9EL#<)NF_'3X^?@AN5N
M+M=X>'H,K!R,SLZ.:ISE&.7H2JVFLIKTV!6C:C;8#=)%]JMP2!*&X XP;SWV
M''--PM6BZ7N9>=L?6GO5K>B*6%>3#]O@V1NN/:B< :PRIT@#5E_S/+7K6P2\
MMYSC\D!S,ACR33E?0%I5T"F!"L%CNT)$^I>Q59KA,VBUL=6.<>QJS$F\S=P%
M>L>GA]TW<X5.CLZJ%BWC:8P"XHR"TE$*F.$$S"L4 &??[:(%(LH34R&_V.DG
MS*7JQ3PPDN3OO.W8'ZNH9LL,FMWF$-"1C'![F>A@Q,;R5#9GO[\TYE+J5,9,
M!BA[Y[N>G5=VEKZ9/'(@_WB!NKWQ>#R/]Q7L>0X^)([]E[WU))@QV0"SJP?C
M13WM!X>V]WT[6PVSI7SU(X&CJ+J?V0\1E,<(G26$9[,D-M?.1IQ'.X3\6_@S
M^O@TX>)'QT\T^Z9E/1%&PI4 >9LW'XQH%''TMH5/KJ9_J&V0";!E1%[Y1AS-
M60U=C9B@W]JG)KL:<EN:1]$IUD['J[.!>"-)(S!]4/A7X?V;LW):C3FK A'M
MI/0Y_$)REOXT-A:%'=<[W5(49JSJ U"A4%EM?.2-V#VF$]>3$N.RYJ29H@0]
M_4C[Y&R@)P,<MR$-G%]C?0_CR;OS#*Z)JXG'?I3?;V<(P#PQ$/4<JSP-$(*N
M,ZQPZB@0>R'L^+;2PF+343_MZ_>N"%2#A4U2+Y7$O2JC[&P;.VI'1F)#O=$1
MQDR<6$7+42P:V;>@12(+\5Q&+PRY1J]>!_Z0K/Z6#PK@>M>AI.,/XCEMM[0M
M/S@GEE:3V8% 0-F%FT5 CG2IXNZN@XL=;XU!&<C "+E3@:#VRZ3L"B7<D#O1
MQ>NFH59DC]P[P$76:,Q$J");HH)<L/-'G(XDY[A<,MC!O+Q;H5O0?Q1#0C39
MJWXGLRI9O:N+!5&4X>,X C(CQR?!JTI0PF;S+*GU]\E.=LX;D]%#ORYF=:6L
MS_ZB^4*&*#M^,KPCJ^Y+%;5*$"50-$3&8@U-X(R&J&@$(89JF>?G6O!6^^NJ
MO:-GI%W>K$BMLF&:T7*WLU@."P]#]BQ5)F-4X3=IA.J,YMA1#;[QN7;H/BC+
M)*SQDWID](45)L-@E8HU)_7[1S^WM'%K1*U+C%%#E=1KLBH^*6+JW[)*L1PA
M7%#5T!7"[P#,>HE&>2,E*L_$#NKYD,[E@>B]1PXD\0 'VYV%]HJ5V+B%//$'
MP[#<]4FWBR!O2Y!64R=U@W><ZCW[&&&(:<FE?9Q?F-+!'&[,YOX- E?10FA0
MGEFX1@VZ)18S/XTS0\%J]+^L"K"V>^>@T74ONHYIAGV5F'[G#>->BZ'P'-1:
M5!9'FL//.KITW!%)W0HETV%F9;H>#G8'*$V\M&F6UQMXM)NTU0EX $5I//W_
M_C"DQ8-W@.N-%_D&V*%VV[R5@22=UKRUVJ>38SC9D :=P^I(B>M!-% @[*F5
MF2%<K(HES=8@1+[1BZ<-*0&/TLBL/H9 $55LO%$E<*''>)J;1MDQZ66]MEV)
M;2P;Q)A>'-LVRJ7* YG(QY2;[>P0[J0!R1_?V-HB:S;H'R1@P/3'DM9RPD3_
MZU7OG[%P$G'8P@-]3S<G'K1^='U)5<H^%G[T]@R0XD2,  F+$*E$->%X49'[
MX2R4Z<.&#5J/0\".K"A^A=_87%A=59%PT5O4(?UCJ+G>;EMFUSL%'<L@_1C6
M?B:,B6S2LQ?GSK3#6HV\&X4WW:%/F T9^FV)>".7]6KV"0!^3B4MS8*0TTX&
MIOQYB9[LQX[9V,MX,&+JFUMC7*M-^Q:-O%J"*PS^&/(,_[CZI-X?3A@JO+G'
MQ42..\]3Z*J'\UY%TD#FM9UFW'^THQ8E/1;(YK[?9=+HS[%B)$:RAP2,V,IL
M93<FTS>(GVC:&//5<:&-T\?V$X+_UD4=7^SY)9C(W$IU5:G#X2NK.ZA^"'8'
M=/=7GP0#+R;L+0^)%C.IB;P3+ C*;4P*8S3,'6)$I5.'B#&S4>[Z)*\I)3LQ
MDS09G6@"LS!AANC%MW;;3J!?UF$H)I^&W9JI(_QB\[FKZ[!L6#>611P^9TY;
M%5H:L0B)C9Y;H_3C&X=3388L1_-5),>@CDE'!7JU.R\BB/'M4 LLK^HO[7VR
MKKH@4[&-XE2[32./M40$"6-^Z+<$=ASLPR-J?CKS"_JC>I=8WY7N-(%DA)OM
M_%L9%UYVF<1Q5-C>_>'0N;$+-A*,EC A3'XIW#\+IU.B3XSSP"2/O9R?,V=.
M(!02[ZN(&?IM2XOF&*-F=N%E'1;REP7@6$VHL6-]@3$.O4_7_M7N&9]P46-B
M@8(8@O*A8P+E/ CHYG*C(ZXZ5%HSZNY0WBR+H8BUH=]7D!*'% >6S&R_=<+P
M-6T0^XK(Y[\,Z6@4 E8HW6^N\X#$S]%J]UI15!$A-FA,"46.(_U*%,9UG\(+
M#E=6%4E8=_1Q?PS(90'*&GKPE0%KG?^P1EG;RUW[-,Y5/^SR)DC,SVS")I2F
M)S2L87^-W [OQ7S\8=+2IE)_QT\0]N"A%S31H4HYZ\O#P$61=.L<N@P*@ 3=
M)QQ,.6_//;+C\%*;+ZUCY.4#OW)0^U2LS9@9D2H=<A5&,REF=!9M 'U:@E-E
M4S47B,H$TM#3!IAQF^K1P4V?&09\(Y^"<Q_7_9J6[$8(C[S^9%ISAY@VNO^>
M0*YI-]#SUA3VQ1A: =KO)'QRB+I.6/BJPW@IZ2H9JC"CUQ?75+ <+K07XM-:
M+G++/'Y8:04I/>R&_?K5]4F/"78? A[<M]A:(M(J\)LGBN2>I-D\KE_;9$=C
MPX=_@]<)GGNB'^] !UQ?=>D/8\G[E:>XXE4?"<?'TY)A#;T>G.0(D8R8%L>+
M(M,Y>L=U?79KQ(J]/$MBE/?2K;*5@KTD#D?=D0,U\6VXNE5TX=<GL^>0C*90
M)@W;3@R/S^J5QPGP62$N>"#%LTL2[&GH3/W(S.04D?ZD%6B<;Z33/D")P,H6
MHG3HI-@Q<!C#<%C\V8+?Y%Y*V:56WG6PIDLH-X%#OF253'TL,*(%GBSU#3YK
MKD3Y8:04NOEB,F$^?"5U4\P/3##9YH4R&VM)5LTJ/9Z1RS84H?6$]!U<70<3
M;]41QQHGESCA^DTT0Z'H'*SP 9N$#__K31A5&)^^YDP.07=H8Y?;4 5<.92D
M\C_R&O-6[+\#A ]?GL<C"#:,[56MQ@12.SI.YMWX-64BN(2[2'KR0REZ?F'F
MV# $A @V"YH(B2(C-\(Z5L&YPE=YVZAS!6/@.09S@YN:_485.TH&<EQ<$]L$
MQHTUU)HGRP5BT8R&5FHED$FBBDPSE5*!7U._G4V!\^D,#L@C"RD%-1$[B0GD
M#*O4P\V#T6,N^>^3_'58 6]L9MOO %1!1/J)J7/GO/ ]58H,2N!D80CK84UR
M/X&4PP'F;SR>5 XK[BFSB*)1403I(Z(L;=LB*3H1G] Q(L.,U!2%G7I U@]$
M<=2L"M[U^<W3M9SR4^3]/7GZ3*5A#U^3>FNNC)T7T%]VLGJ 2!+.6\>&CB;J
M;AW);\G_]KL6?"HZ.+MJ"_M8&PB@9,G&(W!V #]\=X4:.T2<YD9YSN2*)WB)
MG](T$\Z&GEB5]4X""08TJ'H9'"$G6S31U=69#?\BU!BJT '9!UB&II74'D"^
MXFQ-X.PTR_Q?$7[Y+Q<L7I;? =K>Q"_JOF]S?!5JBLZ+PS6]7097!28Y#]-W
M(4U^H)#-OI2S<6[KOWI$(OT7_BL8M'T=F'\&OZ3H0_;6](7P>C)?:J3VN>F/
MP)8HHNCI8OG(__B[B6X%7"L)*W2(<9WV.^"6\QS^5TC=.^ HB5+BJ#BL?LEP
M^57L^T:G.3X_3:,1XXAE/JH8$PVR;#3;(\+@;VQN\V7>(!E?O2%"S<=5(<-V
M-4(:(F0:)?_YG@T\Q(L6?33'J6\C8/K>RQKG61'_>50QY'TJCH[/:B2?4F#A
M6*,I/'5R\-L_*MUP+Z1]*A!13^.:8U:EA*_68\/C/1&<1OG344.R>A[R!TJ(
MYV<UL/;)7(O19I5QNBU8^A%+-DLT5S[03%[[I;(;88STPA>F/\3W&0=7IEJ_
M7.F)88WEK,'H[DK5/) >FB_YVE('"F]T>E^L0R'UV^J8"!8,.?8A7XYI;$.(
MO29'VA+,Y% [@XNJF9KH?FU'X,"S8?CGOH-:5-[=.ELN5;MYKXXI9AE:.K-Y
MX;!H;T JL[/]R.\NJJ$2]1<7('CD^U(-,'5E"#HX46:.@8:.+ ?$0<]?_?5I
MFD/M!G6(_"%DC0AM<C*]_)'5+N[K1 ?:)/$MVSK)BO040@0[ML#PF<'YJ;54
M EX?+::^P4L, QB:8/VV$9Q,S8OEOB?EBE TNU)/UZYV*>#U060_7W&:0DTS
ML^OVO,XTX5RG0X*VUBF.#>R>,>O/,L@^.AMUO/>B3B]+W$0=#=<O9+_9@R1=
MP+;#\M>\PQ'!_[R+]=3DFYI"NII8FPO:X(TK5F_[*,$RO[(&IFD5]QL8VH4@
M=,'&D<D[42A*+/(@7MJ*.!4>PDBTPHO^GL-,$0C;HCL9DZ8OB[* [6#CJ3'G
M(ZS1\O,\7&>,^NHD.(1E)S.V:=@740MEL$>I'X;4S_(CC6,^>YY?(!E>XVE\
M:%G$_-=\<^F4"TX? <S6*IT*Y'8=,2))#U(_JO=GH8*21QSV_!-Q3/V5TP1>
MN[6I3/P?1:?M7Z2QO5ZUVIA">=./B83O@%!4HG< 8'<,-?-56M"J4 B?:DFY
M<H3N+;E\I1B;8[]59X49F\H63W'LLK%E5@Y[8^>B "?U<G]P5G9(,8@ZNF=#
MRDA/VAS_-/#7['0"Q&8 CLX^8JR]84.E8NP)JLP:@EZ]6@9=Q*.I@T'C)5"9
MPT[%#W(0Z.DY*;QHP== /']U2Q;P_*&I42DM4=C&0YYA#!D033^6W>U5PE=L
MK9QT>ZO]#@Z-4G!V5J0YL$)TIQ)**K'YEK;+"-/)"*$N9\$<AVY6K4/]*6)J
M,H9^C&2VXQR8# P>U-?RX*NSO-G0Z%EG[I4"*1;_<$K:A\0P6=O;?$ZS9)1>
M<J'?:K)5C1^DI"'=6(Q.I=6FS)%'9CJ"8]L)P/X [5- I<?2H;5P3&!H^00[
M\#U;09"=*B.$9,>Q)"+\KTGMDE.TQ4O9Q._[<<;L8CV'O:KW<(.R3LR '6N&
M3:J,X!NY8*+:K.5*M$BHFT=26RM?E=.7L?FH/^5\,(QK5^#0N26^@I6@3%<2
M9K17W^V5@O5M#I<+R.^HG?BTXRW>":WJ]G0!\W";8:TCEL0'*Q1%BCY7\8RT
MOT:I)T93\6:_J/U9?$4<4^>XYYSY#H[F?\TSXN[SO_F,*FT]H&=$[% AH!I?
MXF&& 8?,O3.@K+&F[N=XXLDWDJN:9ZDRDA$'MCU[[:BT1SKI8(^P:_^N7C$>
M'A)YW[6PNID"]DM$:&; T?YD&=(R)N 867GOV1K')PA(LK39;(IC,%@M;'Z6
M(VA1R]%!70!J1)-QNW-E/9#AQ]FGD1%NW-%6KH*9ZZKGN/N:E5P%Z(+GNI)8
M%.$@#(LW^=QSH"LV.I?1RAOBA6[7A!*&R02=<.#P>=JD 3*[RJ@8KAA(QRD)
M)P7 9M,[1]XNV^F5D^D+I7SRC?ZFH2'H\ CL'G;H=A96M4RR81CZ:L:BEA4U
ME+6,I?JVFT2/!@(;5@.GR:KI?[#10B%36A%:+,'8I]6X8LU#D&OO3BZKH3%'
M/-WWE S;W*B=G2($?MH?;IKG'4262<2HN+)\H[G&^Y1N0;5^8V1!=)<+<5 K
MK^1NIZ2,M*&@E*2I5-/YB1S*M!L1I=_&4/>2,7QC?6FS05HZ.R79BIEE7DOT
MT%++=)O.!:I:.*Q)G;1&_V2:@3.T;@&2#A,R#*%>E25V@S"-A(%@JNFNR-?V
MN':H%U!C!6;[O?>8#QQY-BZT,JP./^EH>3F"M9!39+$.O :F[+ Y*.)D93@=
M7?O&1["SW91LE;)I^&AN4'@%5%CHM.B?M^;> ?<?RU[798XI_%].E]PV\K6Z
MTS^8;7[-.EF=\Q>R0 *7Z0]5Q&HDZIHO8(6&I(L7JB+FK.(.F]*AP;4E[\JP
M4)UH =8A3-$=D2FA3OOIT0-YN38]*OMUT@_E-OO.2@]+4!"W<S&N"0OGOC&5
M)KK5E-6EJ;-"]1=P[B4[K0P*V,'=R9-R5G[2BU$?*4H@)M.L2TW=>OI"ZIOR
M+!L#SU?:]AV4_A'(C?AV@AN(,4[>4N 111KU$^O9=Q/"CS1?'*ZY4MO977G;
M%\8ASB B#@:&EK*M'5WB]9//RS7D,Q?-:]V<74)])AZ!9UN:J?M'] H+E#3D
M_,UQ9 _N;]CT\3*4F)6!U$"" TE6;S0LN4:(K.U )717MALTMA-KS]P;L(>A
M\ZKQ\P2CJ)>6O37?L$"45C! H*U)K=%RYG<1HT%)-()FD'PARIE.#SVEOC6U
M7DUWR3! )H=B@X.,]"YOZ$$,3;S5&>SU[);_!!BY_OR@[C&6N!IJY6Y#JK0O
M/ZMD0(@HQQ,CNC_*.,./CXV(M3"7AE$E3%IE.;G3$E,PUFUZD]KD,UEB]&-G
M<SF--/^!/*P<F,R-<R/?<.";9P7)VTS(:D!"Y DR"Z-/I #G@4#]7BT@[ 0]
MXUEC786!C7Y)%ELOP V;/0<.=J*)09NI79D^L26VL.6$<2PG2QHA0?2ND3>=
M^REGX2>YA (@;U!BI_S,7*8MJ@,JY%BCF,@,15$%,"S!S&\GE/U%X$7YL)7U
MR_K$64-R3>0*BUO(/7!9N(JD2JHVQB8Q$VFX;$1/NP,H@YMC9(WRJZ=S@+>)
M@O9X=X$HXZUFG$=02*T$C9@NZ /[@;]T&^-THHTG%PU;%UR:]<@%FMV8'3$V
MS.VT\L/W)MZQ;*))S!$_J6G4LS1,LURS\C9%.Y3MP3JV;&2<7:6$I]I])K2/
M:_ZT^YEM6(JFI&D"[(9IFYS/T/'9S*K&?;D?^MIXY^_L]J;0RC ,6A@PTGKD
M(7H6A1L4A^DNZ%2'35 20-R#KQX/55:)K1+<0\J#*_-8H^:)D;6TPTDVJL5$
M>*'>2!^2]0B)2V)1&=,2EKZO3(41<98!!DIF4-RQQMTSF^3*KJ(FUI8#'Z:!
MY\U[9K<;R AV]N&^ZGZM$K5.6L>03*TL 0TX <'!C87"^#[27&(%VM+"SNEP
M/-L3G/ ^FI^G!.^ .7S(C;9Q-M=EW//EQ*,/63)=QBAX@9VB'S",/2J'H;0K
M1/%1.,02)9[QQG)D3Z4I$ZR3;.2 3"#AV(^O1VG9]7&(K9UN=QC'3I=R(\5!
M6A?][.6;ZC7%.KS1$6;?;77&*(UQ:O;NYRX6I<8;H]I9-G,IZ)%2#JBJY99-
MB+7"IKRJFD8W5.GACH4J[N?'B+K);G$WVJ:'+66PNXX,:M2])39"J[(=GT$?
M/4(%5SC]THMIO%Z<DWC.(R^#::[1>HYD)$(J-6H*C#LQFT]$8]>#]]WBGM$!
M(R,EEM\D\:Q1'34E%)]R:/IY9#0YNQ<CD2^")R6E$SJ<7KU'W2)LC5/VG;HC
M9JWI\7W0.R HQ_0Y$E1PZ4VFO\_B+9SS:/*\WVY9I+_QQT=H.UUO6=C+)*_C
M"^E>Q[U8%?KAFV,%[])=_EY!TS5/?VYN%^_M9MN*2MB4VQ-AY?B'Y+TU%LA9
MY"6OH@,QRL!@/"&1JY7! TWQ1Q**\#Z.\4ANTTH;,&QYCN(Y8K4:;;/EEWA6
MN%I0UV.2%A/AJF7822-1\Q#$',@8V_ZE5=)6,>9TDVOJN[$+T@YN<"R0(<ZU
M=?SDM"^KLNXEZ/BNR>J., +C2-@LF<S1!."3H\BM;0M.)SG[S.QG2E'MJW?&
M^E$TN8M"/!)9U6!?D>L"%-=@$\IWM)?ML.:5+WL?86\PH;;EAD<7*SJ.1</)
M&<J];ST'3SHZ 8M(KYTW&4+)#2R&7\!A#LPV.4CWW8!"_"I1+@=W$9N\Y?=%
MHL,"+&E#4@X[/K![K-04[6N\TT98-0ZDC=6$F]?64T1PPF:CB<9B3O<%]"4G
MOP-"%EO@=N^08.'B<QYX'.A1#"/\#9J%1YZQ57]+E:RE-B2D,T-0)%;2CX6>
M6QDG5*I+21*;P1)TD5''<!F8^#:?_S0PM?<]5(6 1$E_'UCN22D5"K@.W.QG
M;KD4G#<U>[-*_A 6MB0YX60H;4Q.&5%K\_ML%>T>5%C?SVZ?DTKOP[6L7:D0
M#ENA;N=["J3(!:TY$0)%&>+.9VO7$T*0#A[%[R6A]E Z=JZJGD^#XGY(&AJ9
M$#,Q G=;(I$BE/36MTOJ-[CY0! NIW= )3SIK@*SCS<9S5Y=W$LN>UH;&X=<
M$9KI1H@,9%D.(J]?!.W!MF(@'N8J"Z$D[<H(<PJ"$KC$K:DPU*>>JU,M9\FZ
MI_'6E-79,V6Y*$OF8O 4*"+1BF&;9L49XEHH[I60PS_J_K;+=W-.#;#*AL:Z
M +-]K"5&_J54DP_.Q\H2B\%M_:P=-8W2?-"1!))8=&$SSDEC&[]BR US 8!<
M020SJ$4M?S83, $%T3]9^ MJ:MT3D\.]^>[> 1<O[OZ$K-0>RHL*BC<QHH=
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MZ"C&"HQH;'<V_*%S/@V$WGT'&#PPL]2PSK,S.Z6!-LI^*?)$(B=,N$)&;_"
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M"D_4^_ D;LLCHD-V.-N8#E(30OKUM*7*>G5(7!;A)]0E/F2'/UA',XZH=Q_
M<W)&F/ENL<H3;G/\YJ)A=KLJ+IP"CHE]5\09_#)9C2E-&D]PHX;95<"/C4SS
ML;M<+,48X^W/A!T#B]U?7<"AXPW9C0Y.A;ZW6J?29PY!L>T_\!*"$"Q@O^M!
MWU?P4*\6W,AD?-$DSHF(YU/&V<OY)?MU!^*!,RI$T;Q7T'D+*5^9AE*TTD<2
M7E!095H<@WE*-2;^GI/6-O[9;3XQ3=RU&!"-DELO%'-JMF,Q\R5G'Y_FC._5
M]G2T6X?VO['WUD%QM=^Z8.-.\.#N-.[NC3O!M7%WAP1W=W<-VK@&;]P)[C1N
M 1(""23SG;EGJN:<J:FY4S5SS\RMWW^K:J]ZWOWNO6OI?M>3I0T6@C'R'*/1
M_% )!^M4!28?B/MF@_9+PDU'HN9TK*-".PZ4B^03N!55A!C<!-(W7E'LN@E/
M[8A9]"HH!.TV]*@*%#'4/6V:A-B<CF-A6NOX<2U#CH#*"<=J.%S0GTS'&.TI
M+JF+<V+0@H[._/#UG_D1=]\&<>*X]?@WK1S/MHPU6I!GN30[>#(-V9X.9XW)
M@QZF(U3)*'!!(R6%=H,EUS*SW=[2Q%=&*]RQ(="DX$T5ZXP?/WLA.V.[XO@K
MQEOQ:ZYR=K!>4AU!%S,37P&J"@8OY72EFHR9FW2GTB%TZPGGUO2<,\(G0&!1
MG7.[Y3?HX-1[@Z29E39;$,SXW;^+<R%=M'0\4E9'*:V*#M=J<\H9K:+N= X
M>&_(D(Q>8"CI $Z^'M5E[SQC2C IFN?$+XA"V:(B6Q>W@QH'4,[UX)_J@(V#
M,^\SN3IEXJ2U Y3V\:B+E,0\I9ZS).T7-_HK=YOM2^6)<!-I6D]KO.K&7>]M
M-VY['4^7@\]ME8R]XS;#*1[I(*E-?_8)K(UI/VF=DL?%EFOI#@SG]1_WQG
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MB:0]K9.T!GQDCI>8O*6I[4[FT@LR"FD2W3$-VFZT1%]O:<)[^J_OY?]/_+O
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M\I!PB@(<YE1+O[18-%;!4A@]C6<TX#9-YGAF\_L:5,DB.&0; U!$=NETS\#
M*\%U2VLE&LTQ:F%$5TD\AKK0<$S0P 5\E<IJ9 T^M' Y(RK&"_&P2*CEY"\
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M@9HK8F;@QJT.Q\T-'"&-U7+ E)7$!XN6[0^6PR7,YQN !52K3C3>/&(JH&>
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M],RW"X4?:2:H*))KYGVBL7^+CV?$W+0LG-4#<$ZF^*PHYJKI8N3I,#:UF]U
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MD1*#SYA&DIFJ9K<7!Y#HKCK\&F]%S9@-6L4JZ2(* %#_B1GHM;H]<T;^&GD
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MFC1IRY?Q8!BI!F4ZV>C[;?V;:AK7+A'GLS4X#G&0SN9"=%1V69"/H0:N^91
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M4T.23+<<10&B9]^;:WI;3VBZXJ<7K@&J8-Q]GZ+$J[%YI^&U)'=P8[F5(YC
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MU&['N'"5AXL7;TREEMXS<5 &CYWM<)Q&"N[ 6'\9HDMHKJ3&>QW)5:M%9;P
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MIZV5P M2?./BCO(:V][S.CSWE:D8^.5!E_ O( 7Q.,1D#17]SZG;NT4BT5_
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M%;KG89(V+6D'/Q,Q%E-*%J6J+=-^2D<<?5+D]AB]R?&,4R;NL 2))@ZGMQG
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M[]M;&QT*\(LHUZ1 3%I8/$@!A@^_HF\_9J5[\G/DV6'*S+:\AWC]B1*S<)K
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MSFBADHIH_5J>.(ECKZ6"H\9*4L-38-Z4<+:]W(NN>8P>Y#?(\#.ZSWUI^'Y
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M,,EBVXU-RSF^,LG<RTK"7!>\O1KT-3'CE_KV,C2SBT@W"*&$PD%<H(7@:RI
M(C=?DN</G/1>9Q$UZ(]^B! [9O,**I[%"W[\2S(<*5'&((,0OA*D-%)HNY0/
MA$58Z62=VD;9 M[##ROI5)S)E8<[A -#Q@^L<UNP/G.%VE)0&=EUM1,B$)2I
M4,+_6'ODFZP1<@$Q<0&HQ;!8U1O==ZS@-@=<H7PNE>R>RLL(-,_<,\(E'B[/
M0;,W8_Z#PD?!0^>X%F/TMF$="AN,W'.&R.DMCJ1X\T]<F42I$%HGRORL7";'
MB4_9KHL#@?V] VWN*74MT,IT4-4_U^6"G8@#'E=YA=+ V2?J"0W^PP@X&?3Z
MW_AR-"<;$0&.TJ]4D3(O/2T 589.&-XNP,6UUMP]CYK\8YYQ^MZ/:U3X'-#Q
MR4&WV_OZJU44M&(L7=WUPN6[:=ZB8 %RV*?DV8]!;_H[?YK/.B;E25H_QY#E
M=2OS@>KMJ']2._-KR8KZA:3L>_,Z:($D=59\15!==%59<L<U99*:-G5%JC$9
M"*;H&QH5!P;!TP]TI^C,$-DO@&*KL< _GZVM&P3HT,99X(W);V=<%:KGO*"T
M =3N>DE6MTJM2I^]->W7-;4 9@CG<E\".2+6S")'X<]Q0OY;M,Y1-CUQ(I.X
MS=E<020C&H2#.M5O"20+.;MSA9+?,ELH?8]LXZT.I4K5#4\S^<B@21\IUZ3#
M1;<<4Z/9/)_OB59DEV/-=Z)0[<*1HD&?'A-9;X=SS>9C2J*C!RZF@"VS66H6
M(E2BD8!+I$, E-G51RM$>YF2_[_4V_<SJ1/Y3L1*TMH0QT_F*H'ZU0)[XM&@
M.229\1>T3)?TE>JGP]&!L!$$3^[B!EFY(H")0M[8Q>=(=]$.X1QH <_C_/)<
M\69Y)&8T.I:2NJ;-L"%]R3FZCCLXH,:*8^RZ5L.4*@6,^5ZLS#F%']4QZ N\
MHD"G^8**\28;_E6QI?L[S*\K!U.J[<(ZB'X:OJPP@F%\R.WBL#RX&:<9+S,>
M#=V]WT6#< ;",IF$.LB%XG5QT+^\#P"%^F&C_4\T^TDHVUP_\W\J(&[VM4^\
M6N8;RG6S>IA@LN82^HLR$<ALYC1V;G9S6*"U$CKP91['BFV4,:6;=L(J+<ZD
ML%->I8"F2X'*G%@VKM-P:$T]Y EOG'K-F@O'M_D<&43.:PC>&3C/S;=R^F0_
M95)B%:T$'5B,XW1$$SXMI,D ++XGMNR Z-S.45>( :HE1!C'@CT]3K-M83AI
MF??2T%M?A:SZEHR:H-2'$(PI$,R.X L+O?X8BX"*>/K!^&P%U/"]L.HQWG 6
MP?T]VG*3W:9B9--(WR#Q02)V[$TTX6@U>:./*O*0%D6E2#3(RT=DM!O\)6&0
MTM  87;H[BR,CI) X5X_+[Y]3QL4A)">IM9U5N8*EMVE<+I=_<4SSZ6=*A2;
M%3XILT#JL<X.<W;*WW>Q3O<<4F,];IN^OK?B4EJ#:+?*4T1XH9@.NDYNA#5G
MA;HGP7Q> 4JJG][E^(RJ[^ROEHS31W*"-+VB[4O&65I6%WS"D4EG:+;TNOO*
MV<*C Y)'HH<(++*YTM!2UDG<*H0")TC&>^(/72(GOQ:R)'?WV:EHRM-NY\!]
MW[I[WI#;N)_2(MLG#A?J-@HQ8K&\U2F;T2)%H^S;%=OMDO7O2[?D>W9^!4QI
M&_U).%G51]L0.U^]X6$=5_U :*V")B5^E2S&29G#DJYR3/3F ]4Z#ANKH57I
M WGOLU) ]C>CO;1>88+67"9:KX 4\CJ=S?"@;T]79&W]%%C\1B2P+-$184ZB
MT'.3M&HUM3T<,IH&JEB1TT<VX>MY"?%^L\).ZRVVDQTM 1#C)E0XE<7ALC!#
M393[D^@DQ:53>!O!RK+*O]ZI>>I, @2S=5LG0S+UXO7*5N:6RPPE;!PWM/.S
M_FF8]Z$@M<"-:=SQ5;X&;:1UG(DN!ZO?YM"U_V*P^RCX<#?S,H@];?:+69NS
MKY(GT:#__G9U39V%/&K_1A9P9N$5\++[KXSW(;7STY4O642EY]*_&UXDZ9<_
M_]5DV9B S%4*93JSDFU.T1W+>43.0Y@4W,:9GV',.:TC  @E0@5,7[C&#ZU/
MIUDE]'M\+GHDG9AGY/J%CR<TJ)M:/!L:@6PEB7_X30?"83O>O"65-R:@@$\X
M86C!VY(-EJA$F;RA#TAAA9E*^%3Z;M#D%JA;"M-SR]8:I8:??"C.+\ V\28^
MCI"[8@ZP.[A+QNT]OF+O>OIS[/ *8/5\EVO-YTTG'-#(\'M#'$USHKYA_,\R
M^\A=AD;OG.-^V%H=/Z32IUN&$&VE-\(2RGH&VINPO#V&]%.XN0<?9'HN]L+0
M4TJ_>3W.*_?T<Z9Q<?<6UHZR@!63P4L[I'D$ON?O0= /;U4F,0+=9)$@[E->
M1;J^40EA4U*>"L&RECF'KX#TRP@W%^?4=O-@6<HT@3'C&^C'?D=]T-"3S<,4
MEI6"@3,J2J<I%E4.D<+#9D2E!_GGXP*H2T]$Z-:H#]^8X<Q,2X/ (_M6KSBG
ME.6(KIT^A.7&>'P@#AI*+% T;6K=3Q#-J2*S.X\,Y;@(TZ+XFFL:%NGQ<$:S
MW_+QD9LK-\6 ^)SL_2 1=32"RB\MHY]>"^=JY$>=1MTI&;B''/CTT\*DEY%Q
MQOWZ "H,P<+%P. 3^,:SF7VFS&)"<!O'O7!:%\$L<T/9&Q39-VVR>YM#+#@4
M=B*VA\FR,&IDYP)?RQUJ9])YLTC95HW!X_.,V?6];52V:87N\P_R\A $L;'T
MY")/A.S+[<]16^WC$-A046E=!WRVU;^#<RM=;1>E8E(-COG\"@C0+:V*):X<
MX%=-O$D5"#9)%MF%72[;NQCONXYG%CE5(0@9[BR$@^5X3_3C4"6D]H(_(PTI
MV 0W+*4U.W<"+[0DOK*[)%1CL\ '>B,*QT%H6(S+ 940TKV+ 6:\'W\L)_E,
M=>3^8T[2VX_9KX":>M&K=5X9ZU= T/J'?S6M.U_M>]%ISG'^.4^2OGR[5GYJ
MG2&AMJLU%#_D-!4BMZVG#(8=_+7>V3261/2G@-C5(ZR#71KBYSCH7#V]JS$]
MO<R1+5C9^,K_T?>R,_$Q@FD8F 2DF?)$I_^UN+K1YI%F6>?2"1]R,R/NAAQI
MX#T[E(I,O&/9PV4W;,X5=Z F)1164<.+PGJQ,J.%S@ZBB)Y\FRP*+,RP6K28
MB 5<O"'<3O%L#?GQ0'BOOPH'/>00B'07LE)2"*7(^!4T;KS:9+TW?_U+=/D.
M2Z>M7AU;3"$^2*:<\+1!MA)MF!KR]J-$FL14VQIY'(YL6BKTNJ^S5_*8.G/?
M&%0=K1S'];S"JDT5SW<QHJU5MS(J.J:*3L3?+)*#=^*.JZV8[YY'6O991'>N
MK,]NS O-5NFI\0EF7[<"1"Y@Q7?QY2LHN/CRM1,B)<9GGI.X@=2K0D=&:?Z^
MDQ/:ZUAA"A^A\@!NY #O(G0>I2TZVXZ#" :.NGZ)G"%/V([N30LR/UUGDW8)
M&).&#'>%@X(HB3/6AXK"![7)D&(W +I&AD39 K$LD!6M@N*#3OR3CN1>^P.[
M=]XM0C-V<TG5HW>YMG2<N*7#Q"L=D*!EC56@^J3&4KA99F*/Z_HJ\QHF1%T]
M,-#1($U-6.9""?"%7T934OH5$'B2E7*HV/"A\]*H^#]D^+,BT1K"R.WY=]1Q
M"1WZ\#;DFNX5L&R3(/T++9P^,(]Y]H16'7P^9!)MC?,KT3\$9L6Z!E+R&ZR0
MR%MBG-$0,%S:TAY/'5TOYW%C+TN*,_][?)I/36N\9KJ25(#*(;'PG<1CW.%3
M'C.E$T>RAW:B%YGV.EH$_\""X*W>GQA[YS>0@$$GY^I/.DP2J@Q-RT<"E?^B
MARH9XJN@K.0*%6FK> = )'A*]2O@*>U>_0EZ.OKWL^<1VL$]8;Z/].R.BW2Z
MB/\K0!A6@^O^5R@0LS2@-J;78,(P7>V!D]M&WQ 40%4)1>0=Q-CEHHYY_(U!
MU$,9/PAF#)I:.Z&,+:_G"HCGE.M#"R$VV4L 9">T,2H9,VBXP^,P\GLKAX1)
M.*[KQ/Z*?:)'26?K\CB7_[B"A.;WL6%+-0=,JVR03*&8V23[W]3PO;,_)+2N
M$OX-]PLJUPQ=,3DX;<T!QB$?#H'"$V(# E6/EQ8-GCH?,K*I>RS5PPP)48>.
M)G%/Y;W*F[_RW&1RUK6RSZ/28V GW _L&*&.ZW/9GDZSCQFH&V0<F(;H1WNT
MZS+J%;E.X!M8C,=Y>J%L&X(SXU"Z/$9[VG.ZYE1'VL&L=++O2>.XP/4LA_EZ
MOR..T0LWW<9(FK7#P^!4(A-Y'GI-FRYI=EPS=>@(@8NE>LRIWU?<7# F,66B
M21?U#=(M@GP]$IW4O.((@ H^IO0X:-AJJWTS1%T)L>\D';Q^K-%<I,' E-Y.
M,OE<*M&G7E_14>ONR&[Y1S2GM51<*X/)U1Z;PME<1JKI#;GN],J=Y"W#2^Z7
MD&78K-.W5LKLG,>6^;#1]4U,2I]\Z[\?DL^7EP4&#+0IS_ZPN8W6 ;$80-#I
M,5GTJA"C">!8+<W7.$DL4K)-QC'X%Y-F7,PCG =?#[:C>H1GZ[Q;NI7A%!<_
M9_IV8\D0D'#=MMM5UY$?,L*H>VO@%DTJ3'WK,%SB[@5K]XW#NGS+%H%JZ4K0
MF&B*OE:?L^>7_?(9'%X_"FS)6BOZ-&/@1?,U<C%^J1W2UJ4&_Q;\YCY)2434
MFCKV[#"3\)B)<:0%ES/V#:,>"16Z^;[Z8L(H7O/-091/OA<K$-O,5UZ7'K0'
M].4*& CP53MB<1_!HEG-4TMIB!FD,UK[3";<5J'62Y)XS&2\K> !^M#$<>9*
M-P/X"L';G'9[2EQ["0 6*= ') #- X2$LUG@A)1Y6 (Z!N?BG NUC/KH>C_2
MU:@VL+WD%[5<$F6:(L1VWLW)JHI-U4MPW/PL\A54"CA=G$RC1LQNMK"E[IHV
MX62[0$>>1 $\4"(+4_ZIH'R!>@.C"*.&0'+?SO,X1Q((F]RAR -N!&#@_/>%
MX:F"SZ&N_FZP^[[J9(LSC>FQ )=R&J7IKR04$-X=SG" F ^C+D@5OL8A$68?
M'R-/1F1H8>''/*RI^H;*VU"V^HV>!_G+*T"JA.XFP>C;]_EX//%%XI?C3_G2
M1_]N_GD^<$2D'>'_/4A&^3:\5?!W1*6*:8>SB\-P*$0L[VXB67[T#O(OVT[2
MC[;6UE"")J-#V=F41:W"94#[B-*>T& 8E<DBP(U;+M).@B!MB\,,'A<"Q0:B
MUW!&_WHB@T197CRE"C+?L6KL@_])XD3L4H^/G,G?SUTV2RWX*7/!\4;2=-+(
M#G\ "@2H]7 8,!H ^&>!_4V%:!5]C8;8$NI:K6+Z#/I[%X1%:DU#43<A?GJ-
M78+-!]3CA\>-W24,:DN2:T06*2W,+;AT^L5(!(U.)J O?[0W23Z^[/RYV(AY
M!33_D97VT&?-\VFB=,GS^V8F@'WLLE)'3#7A"4P8LD45BD&0T445[X!U52X^
M\>88>J2'KTSPX=0R _\N]=S- 'BJR.#A7! SR!/Z('7!N:#4DKG!]-LXJY4N
MYW;*M'R>YF$*6YNN0?VLS1^!T3^LYX-'4- +;!H*9#V X?C-?&_^#:-<%,]_
MSAC9? 4,-/)7=34/=Q89YWEOV-Z<:[)L^2_22!N.XW1A2VAR687W->$XF[-L
M\E%LW'&6;J3&.=VRHE4X:OT.MUI$32UY,+U.;L" =O[-*FA7P97UB1B>:-N0
M (I#2\=1WD91[VX W$?D/GA>;O@DI.5DM_36;_@6TC<I7.Y.N6Z7]N%WO->N
M E,)*EPFM AB)V.E'-JVLE52$>U$88RNO3$_I4P1]!_GI#@;! 6YV;JZ>7AK
M]1XUA?-8V-$*#:/;+36^1R?':*.B;5A%+*L,Y3,!1IT]G%,:BP?6!%19/#_+
M&Z;!I3,QT_E&,JS$VZ2^,@@M_Y'H$ZBB+UG%QH::*U#B6/1[,W';O"A/V7%T
M*=/T68[0JAP15[OBQHS%$^*)#%ZS3=OXV*:".E74C%OD_AP.Y*EZ=IECQUV@
M5S,CT>_BS(YMY[T"?OF6T_T!?ELY7"1BF@]X073?O# Z2S^=Y6HY1_W?ZO4&
MP@$A]GR(F\_IO(_-Y&# E'1=L_A/1554<%89#EZ2X) ! @&<]SNK;:\ @0AU
MV< &/P-(+.45[]OE>71SG*1M:S-L,H,)D4GY6 -&TB.9$?VY1K%X4?-0_9_+
M\EN!W"&UCVRBTLF0VL 4OIY&1YVAWK7,^BDGQHE\'^>SE1(&G:P*?8B88$-%
MSX&"RO-A!D\3[SQ@Y\R9>NK_TMB$,ZY>T%^F/K4"MB^F$39_>%,]ROF=\UC#
MS)D">&PR"F%%.:66\+W14N*3ILY:I'T*U]S<H>WPG[,:?_-7*9/R[+Z2UANX
MB1Y14_$N)T; ]F++YR>QI:@0Z5Q&%U4/+#2DJ<GR!*&]<</T&!C#/EQ3(_=
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M<2.6?[35RV:8^PMB[B,T50JL<"03^(=6!*1 Z39/D?AT"J5$!;7,2E:Y58=
M1EE:>U??@CX6X4O[A/<_/,N^L]B9,+5-T1E(4^N'7K_'OHN9S"(;6O4[P8/6
M.$D_U8[RO02=Q,&N.CYE34J43\X=.PA,M_UY=Q[DH^2]4V?S SRY4"]VT,QM
M3_'("K"0>!Q?] MPLIL"UV!FY&WHF3V2NX;U>0X\IP&WG(S^>GXG]-ZXLY=V
M%FPP>FB CA_D/81=3Z.G\/*Q\E@,@OL($]:R"H@SJC!KUO=PG.WU*$BQ\6@B
M^<P>@67DQ['ZG9[^KP T"PD-AK'Y"_T8N*U0YC&0OM+0\VW*S;T:%<.XYTW1
M?I5G7>(#M;V+9SX"I6++,-ODV+%"GU][X/P^1SQ6&NB*W*_[D@"8N.OACJOL
M<B+Q^YFW6<8]RO<$4ASI8W5:FQ@CMLNR@1GXQ1K]NGR!J+FN?#GKMI?:[(AR
MW_X473UJN$-TP+62DL6M=-B G;7[GV+"U=O?9$CJ#<P9&JX^2GVH4C)O4"UE
M/.#8[QT,\MZ..!ZB8,5PVM0B@*)'W[S'C\BJD!O8ZXR@5? HUVISS& SJ-9B
MFFV/?A]:K5-O6)DC3KP,C,;1[QWBW-[+M*<_S$_4%*YL5D49MQFM3%:WN5T9
M=1"J>0=:G,3XRYRN2I==Y1.<JD)'8XZU1?N9MI TK\*H#903F#[Y7Q!YTI_N
M?Q@D'&]FDECF)L.2A?#5^%]NJ:_B90GSY7R,48=9YNP>%\(KNJX@S);A] %6
M?FY:V!1R&5](/.3;(@F-'D^+I_T;385_H4)FS*Z3L0;]/4XXI-YHI&_=F/%'
M'JQ(I#!SRY<V'Q(OW9")1'FA?^<,-G+)[,25?>2WV&]ZUA#8Q__,[:39>;("
M%M_V_4[Q5ECB@%6PZ*:ESVA8"YI\DE*D5^7\OF0=K\]RX+8!=!S8KF>;)(?T
M14B)F5F?]$J+A^ "Z(:UU_,75S>YI8]EQ+"1CLLH"6%"SOU]?XV6LGJX4YXJ
M\($_+D%W@N%<*['?)%U!<>3=<%#TXVDOFIC+PD<YF\&4P(N9FN[-A<9Y74PQ
MY?!\=U=^^1AF=-8@#JALH_\PETF5>G6D*@9R*$H@,0_I=\S''R++-&B!*:.K
MC%"<-(-:)@5;7J"]2\K(@<?C(G22\!'-6J&]I5E L!V6VU514M'%;PV"RMK
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M1?BG<W;R9J6(EL^J^4@SM/ QL31X!L\HQ$V86/<+]R=N'7Z@[[HU?%,6(A)
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M,U5-=5.;"WMTXB@.)-.NS/3U:4+UHG3CN;_6@=XL FV9H]E(2N"E^VYG@3C
M%X8,ES<UI%>X-X$1?,<T6UC01,=4J\ASOYZA_!;3H0UDR3<NXX]4F.?Z@C)\
M'-JOXY+I?1-XS!IO77B^<;NZB,")^#4A,IS":QOM(-F=.3 ';/G<8#_8<.I
M1=%MQ195$L_U:#,/6F%&7Q$.)89E;IF&K3TQ"ZA\)Y>:.YB"8EA8QU:^5^O@
MV2[7<L0PUM!!40SVSS*KJ!3(;ON8G&*+VRU=?]HR]=A*)GZ9-.O+FS['DC8K
MPE,XQ,*'M_G18K>HHL*)#H^D(,2$QHY/85[G;,U@U,3I]R]WN)<YD<R#_%*9
M2K ,4C)L7L2:!:+"(DP:FV]UB4-D;(5U26MQWU[O7K#@A-H:<%=A\0FY/A[[
MF_-Z^TL_/!^9O0_VX+[+WH+:9?JH4&(:TZ;I0<DD%VWL#O2L=TWCXB?5+.+\
M3]XZY3W:/<$@))4<&O,I>W2C!&?^*=UT&P7V/$WU6C:(/)\^D[;R, \F?)<B
M^>9]_T40QO+!_&-G-^*KO*GYJ_5Q&^'R28^57=8/T<IT)WIGI=SS;*P/1M1Y
M:UFVX)Z6/E<#=W<?-R.-WU&Z7+(5P\E8?P ? 5?.6/H56UBYOYY64U7>BUQC
M*%-YOVIL?V?"7,*(CM/##%ZCG/9FW)7')X; Q4>C6\O3TUJ^ZOMY%U-[FOU@
M$J\A=[P"359CFV$?Q/[F4]J<;2<WNZX2&_<H26/VU4\)KAC&2CW:J/1&JQ 1
MJ@UR8#*XX#?>391$RL:S3E0C"R;!B*U;SU'L2MOJ-XUR;62A*BNLSN%35(N1
M:VE0@@*V. R&6,;S"(=PX[=M%/=<.[8*;LH+BB74]^P1UVA3^FQ4D\=4],#;
M@2H3:,\GIEEG4KA+<Q;'*&H$ R=0N@V*4G8A;\$4<>6LOC,)% ).?SYCSCB:
MN,J0][JP)!/WYF!K3*1/^K2YTN3#5G7Y0TL'FX2#?%:JMQY4(3==UW6/=-?'
MGN--Q;^'RYL5#^69P95F%<DR-+FRMQNG6CPWD[2D(+IIW75IO3*Z56V$&JE"
MN-X"C9[7@@;+POM@FI<7TFCU.1%;PO-VF$J9_=%,T!AY7 ^MK\EF>GM=UIG)
MG%]7W3>ZX8J[3\J,AN8F=BC%Y%2>VX/3['N?I6V6%%?2>#>XLO?]4(Y\#XT.
MN.H:<0CJYU(^H7UN<E:8T,_5B?C\4YKR0J9RIL"ZE9K:9'&2NYJ*U@EA+FRR
MMPAQ*%_&$WQJG18$ZW8']DY$VMQ(\^)$J+-$ ]G_ *92Y[Q'+C&*$<=]$9RD
MM (N/9.? EJ5J'N&%XY>8/&"K02=HP5&!4] ?E@3D\RXL;-K37;%>/182W*>
M(WM9QG*&-Y9^_X05!S*F-8=,[4"XE]M)^E:],_21G07DD=^^)F1!2T8OM&\V
MWR:6$[FBP.=9<*E>3\$I9;2V^JQ6BM)7)BEGLGJ,XC[;=C=HXJ3&Y42#51Q
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M#V"2P A %-P0U-V0GY#&G2B8A&%;2)PZ$V+*;$P(;?9;GPYN*YJD]P8]BO\
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MJ-BJ,(5X<I$HH4-QR%V'F/A703I7_22#(TG[L-!-?<DAHLEX=E80?S3&[I
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M9&T$]B\@.XFE=]<GS>(OX/BUSE_ KV1^U<'*O2S#7E7U$"C!:(@E*HTL<V6
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M;GDM,C R,S$R,S%?9S(P+FIP9XR[=5!<0=\U.+B[);B[A3"XAN !!K?@P2U
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MM^93E<F^GH9L9J_=[YWN7#9S($]3+A$.BE=:1W 3E8'.+/9VEY"%_0G]JB?
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MC!]/^@1Z 5=FQPA3WTJKLY&+<7S/??RAX&&8%F*!1_GP88PN3!/DO_R $;1
MI1T;,.MIE<?;9Y1+)$:TL79IB]U%AX^DP_=C$FR9\M_DQM[6#VWN[]17H-L$
M]UJFR^^=?E=[[K_-JVKU9ZUK,1EH35>^'.LK'P:,,%S;%"U$N8DAOFU7D%"
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M0S<+[;!R4?CT:I0-!!S/!SD(W^DSOC]Q6-GFEZC#H$]6-X1JX;<L5A\=*S)
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M1N]8&V](^F^1'36HQ&K.HOGLDWST56PT7X87L7C4!=X!V>I4I73$F)_F;LS
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MJK:.P_DP:%,J)9-YWJ93!(M+ORTIGLFY"[X/6WIPA'!(QE00=251FMC?99S
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MP:2B;*G<*LR77D.AA9;0,E31X+G0D-@PY56O>5VL)*LC<5[\(9JH03EFR<=
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M?L7!>?Y,T\C\$> FX_!/A(#3?82^KLZ;)#D6IJ&DP"RXRFQ4<;%:LQ1U.X,
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M'MT(<V-XC4$DD!WC/4@!6!'!\#WWD_ZV7U+3PEA/?0&^E6W9J M(RRRQ5/(
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M+1VXQGU).4M76FR54?"-B:L<Y#Y[T>_.J06=O9)8HZGC%RCBD]-C5SZR3@5
MWK3CVH *9Y[U*R@$HA-OJ<BR,6 XP747*O9H8HJ;;;$4\3C;&%].N1J%J6N;
MZR +6DNY7>E9*C=1M0 DDT5QW/4-,\TSWVGOJL-Q(UY8@SRH_'U!P?XG5OC#
M@G<[G<?,9.=6N[?5[:VCM@B3WJ6PLD3XHW2.%ZA%Z44%0139:KV6D/NN+,)
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MIMEJQ#+52 :"IVKF:M :\>P_5@9P:L*@\=JM0'PVVQ@J5Y$T !%1TI3;+V4
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MO^&#1VWV.--*@^/3&'OOOB+,0>U/;KB;, *@U[8@34D^(_#'H*@;;?KQ<
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M\EQ:0V[,A]-P)&0ACZT/[MD9Q2I5AM4=*>."9:D[4)'7L/P(S2QM'\=#R%%
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MC$7%*U^R>OC]&)UZ;U \.V-KV[?PQI8[ ';O[XWU K;=3]V+ [DGMN,LRFH
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MHQZ@4-5.WQ$T[FG?8TQ8,K  +N#04-.E<=]H&M68"N_C[ >&/$\L:!5=8Z@
MA%"L?]D!7\<2 KO2M#4GN?>IQ-4]2H+Q1TZ^HW D> X@U.33RI^7@\UV6MSW
MK(^B);".=DD,9+!CZ2@T+_%*!2B_LUSR-^:/D_S;Y(2+3;[4)-9T^]B].VFA
M!$"!6!X,78\&X[<B=\%?EWH[V,*W0@>XNHKE^+R$L]QJ<B)%$J\ GPQ-,*
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MNV]0*G?;;&,16H-&Y4.W7V'WXF%H5 :A3LOMO[8F_*HXFH&QKW/3I].>N_\
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MSRG=6OFP7YX'3=8X"9)$J1+&##*"*'=D(^8/>F'>C1Z/Y1FEL(H5GN542AU
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M^+MNH!VP@UO_ )Q;\R>8(%O;R)7-N$5;,JT43@@*R+Z9504IUZ&O<="S2?\
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M[G=F R(_&.7%37H-N1\*?YG+H!7<*%%:CQW^6/)!!W!/0UV!IUV'SQ( &I+
M"M-_P]LNM22.(V[=*@;?KQP<KO4_3N/EM3QQ\=-NI'VB"/ _1BR-0,K':GWC
MW_'!!(H10$KMOL-NG?'FG0&E"0:]/ ;;#ME@ DT))V!4C?N1OBO$,I:G0]>X
M)-0/HS%>5":%F.Y44I3WQ(H225JW+OVZ;U&,^T:#85J0_3P^6+JI-:5Z4ITK
MVKO[''<014\C7H.O\<M8P#Q.Q)H>VW2OX8("_9-#\6QKM_'+6-/B%.--R#\N
ME,4$1H!O1=J]P%^=<ID@6YL9+FIMX[J+U!LWP\P2=Z?9I4Y[@\^Z;(F@Z?):
MHJ&YME%0M2U%ZD@4 !J#7(9^0ODN!?,&L^;]0LEN)+ ?4=/YKR,3O4S.M?VB
MO%0? GQSIGYAJK0K,B O;R<@O0T+$D*Q(H=]CD3TJ.%Y(_2$;LH/IVZ2$!2-
MJL0"W3>M#G5?+\169;@L#+Q"AU(* ?RP@\=P#MW ]\ZKI((X@%@P7X50BH!K
MUXFOT@_+QSH>G6[%55E0<>M":5/L*5^G)1%ID<BA62F_PLE0:=Z=0#@G]"6L
M@ EB,B@_8D8N@KX+T_#%5T:SCV2UMXB*#X8T!H.NY%<LZ?#$G!%"QUVXC8?.
ME:XDUI $X@*5KN:]1VZ86SHD35(J#0&G:GQ57;Q_ X6WSI)1J$L00:> ['Z,
M* @>0E119 #51U/^UG1-)7C$!_(H[]R-OPR#^;POHNI/$2N$-#M1>1K\MB<Y
M#2,/:\^K%[B0(.1+$'CUWJ-OEDALK:W@1'0E+AU :9C^\(.U >P^6"I="MY_
M3EC@H032I(:@.Q!XG?;KBT6CLS-(R^HY(;D>18=MB&JP]J8'N/*\=P>+:5!Q
M)!+RB8\V[4 -MM[&H[;C O\ @+2G*W,VFVD<H:K231K*(SM]A"KJ-_;VJ<$Q
MZ=9Z:6M[:ZX2*E/2TFT$5PYZ_%)Z+.H[&@WZ#([=Z5?W-REWZM^DB,2;Z\*%
MT5>B6EHR, "QIR:A)Z';B"V;3)HF9[M49)/@BDA,L+E6'PAXXW958'I23OUK
MD,\P:<P965PYDVJ2J\O [E2L@I_-0]#G--5O+B!_55O4+,Z>LW[MV (!63B4
M<$4.Q8J33.*^:-5])IDB^&+;D[$,?3JQ;HB  "M*#OGGCRUJJZ]J>KW5Q281
M7)BMG-#^ZZ?#3LU <[;H+165R+X(.-N))2PK6@4L.->O3?.374<AN]0DG(]>
M24F0AN2U(!^$CJ-]J8'9=S0<NY '6E*=_;KB14D @\E%5()\#\LM@&!Y"A)%
M-J=-^N_MC-EKL-B1T[^.,8^+!AT([UI3??* H.14J&K[[GQKXTR@P VV9=B*
M;5&U*G,H4UJX->W2A ^>)$5)K0 4Z[[BAI]],4$A!:E&*[;_ (;U./J-@"*,
M:#WKC1+0*2=QOL>H\?'OB);F0?M"FZGQZ#OCJ'D: $EJCW'?IQ[]<>?A%2?@
MK4UIT(/6N].F,X5/+>@ -#L=Q7\/;*XTH -MP?<[[TKBGPN!PZD[FG0?/Z,9
ML#112J]^O;KAII##Z[*-PIL[T<AT/^BST-<*N)4;=_ ]-\0(HRCB*$C;M] [
MYN!(K0,O04)&WOWK48VA Y4(/'?L>WC[Y2@"M5'38 =*^^U<6"FBFA&PJ!ON
M!OO3Q..XFO9F!IX=_P"&+*I IQV8[TWZ]]CF%5*TW K2E*UIUI@E7W^(%J5K
M7Z/ ?Y_K50TJ*5VH"3L/N./HU?LT/8D[GOO[#'< 0 -W HQ/<#<;_3EB-B2
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M%2@)!4FI-:5/]F447EX^&_7N!\\3<*:<J#N1TIOL/H&)+&P)-!Q8U^G]670
M-0&M.U3NORK\]L2V:IH1LQ/A\_HVQ0[GBIHY.]/?_,YE#FH'V0!0>Y'A[C*
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MMEU9AQ)J%Z@=.@]S].9R.F^ZGX=Z5%?OQW,[4 ##<]MAO2OTXY 33D*BA\0
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M6W4@@\J=#4G?.N:;=T@0,P8DD B@V Z4)IT[9(1>0L &=59A\)/0TZ[^([X
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MQSZ@?E'_ ,X^>>/,LFC2^:+]/J6I6TMT]S:425&!!BC93R))4FIIVSMNJ_\
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M3L P(W/W>^.)WZ"JU-6W;?[]LQ*TJ& -:U[=S]^-) [[G<^.P^6-)'&IKRH
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MZ?(USN?Y2?F=KOD^XM=%T.>UTNZU/5[&0:M<CDMO#S N(98^2B2WE2GJ*QH
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M6H!&^?1[\T/)GD3S[Y2;S?Z^IMIOE[2;Z_L-1MYXP@MY5FNXH)89&D7E)<@
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MNR,"/AJ-Q0^!#5_IA5%,$FH6JPXE0Q &VR[].HP0LW,4#$==I*,I)&X!(]L
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M0Q^G. >:]=T_0H!J>LSV^D:/-(\BK<DB>[$!HJ@5%%04]V/78[\&\F^?=/\
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M6DK;).$I)]7D:AI7XN#?L-OT+9\ZO-'Y:^;?*9YZ_P"7KS38)3^[GECK Y!
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MYOM+7,^]N57?H-Y\8 E2GOID@BK54<)07U.3>7]-JW'3'LE1+]&HJR-Q.?V
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MG\H#0JFCK8B2JYBON>%3N<:R<*7:7=";$$)"3I2-]._8]^L1Z+@'$>PT_--
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M> V'GN/EDD2[!'Z*-,+2K7(PT@$]YMZ.J;!A:^2BK.0)D =RPHFXJ+UB_(F
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MN<,'WH,QJ(,92^ZC4 I@W7.CY<TE\2HA?4%C5T21<5+S*>/Z>X+I,V;KI,X
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MMG"OM[2&$:-?PZI\M;SYN:<[A7[8!P>I0Q%S[5*:?Q,,SS=;P&5(W6G @)<
M/Q81/AH&'UT8'L"/M"3!'EC+D5,KP<E'R;:6)+0A?3]OKT((=#OAW'_9^1C7
M@(\TC:Q+QP3X>6+XOS/@/X0+?^T"0TITK#1F@2Y67.]:G5P'L\'AN7H)M54Q
MARU&[L P(_ASMLX^GR!,\R\]LJHBNWGGJ>^F$>@M_=BR8=';;R0:YBI6QX:2
M+>NT!^(7!FU1GIGWV,TD@>A<]8D'!VTC=G;(5E<J+ROBD+[3T0T,%=X#+&>Z
MBKIW -*:E?GK^4,[7\4!M1D*A]D8#LLIN+%^P Y?8EWBWE( ]=3$:%A\6JK<
MY3'V33"MJ$!S"3(FQ\:"F;G&O]%.$@59W\;)O K,\I$(=G"[BYOZD:M+_0Y0
MB+_?]*$]&8:,Y^_M0=\!GBQH=/\*,.7WWK3G!K'N</D.T)]'&FL6;.?Y,B67
M>UE] #=7(C$]F75G2IVANCG,7I_D?J:D\3]<(GW*0'X'T&GUA8Y?YCA;]^0O
MJ2SMZ?\"?94TCJ&GB;GQ>084/NWZY+4@W270B!%J2?GR"9$I(E718X7BA31M
M'0VR%# J'11,FP1,S7;3+EV6)?(!#0Z=W1HH\'B?>3H5'"B7(T"*-:T:, R%
M6B5%@_/U:)%-C9;V1@4M 2^49"E&/0:PC,,HB9NQE,,6#\7$>.Y4Y","6R@I
MB3J*JZZZ46JO=F%'>D@(2FQ7 ,SKVXI^\5*M*!S N2(:108^--B O&8/#6F_
MR4V/5,(,=Q,U?T!(_N4:[!R:?Q2H6;BGI-COS OOC'%7*VK+V0N1@QL7S,*7
M:+YL%?L+'TT%,@KK(V\3P5':A/G\><P%VYG/>9))PY\LVH$DV[=C-2%XK1:F
MWJ5+*+C11^P\Q<A@>,G$5-A8"B>W684%7M?,?1HPUQJ25I"5^0[(RC>^%DC_
M;>WG*49\V$U[?\F.S#,9-!V_OKJ!::9K%*[:VDCE?<ASA7@ADV59+NBE<F&V
MH\+#!!E$^!WQ1HB@@M7^#V!*E NJ:+3+C-3$Q2'11L5NC08G5[SS5,#G_;Z%
M6'L \>WXMY>VJ\_0$H1$-L_6KD7M2D/KY*4!C7< P<@?F%94^*+7+6T52 ]>
M<#<1EGBU<_H.J8W-.\"F/[ALT)]WD*7N<W!?T&GLA:\SELN;(I%3A8YA;CO)
M!%&MJ#$B6!Z];(U-4B_C67( [:?C0=$)NL2N6P!]6;KI?#U4@=12>D-27;*T
MX)$VBE.Q8;UG@ RGZ9/ZS'?*:H*&VM;4":['V)R#I_9A-U4^X]-BO;?KP^E:
MD]Z%MYS:8!XW\7= ;W(4XI.^16B'_Z_:Z?[HV!W\R(?'S3V):$(32;IEIX4Q
MNFC$M(-I6Y;H7RX9-"!G)^=+O%?Y12G.F-M<V1= TJ%VY]7)?A[/?^_V?Y+@
MJ:^56)311G4[[MQCX[3[I[BAI7'^,5#&*M1+EV91F<0]!>^5G4M,3]AP.[0L
MNU #T63-PFN8@<6TD#.L^I8!O[_(LQ2_C.W!I1A(OP .*09(;!=I2JP[/3=L
M/VX:ZVCX,YF58NZYL>C>UNRR,QIXN(L]?+P89@UFM.ZD2?"BY0O4(<'<CQD5
M4[K\>%XJ#5P7?A.,=]8*DCXDW ^G:X][XU;J19<X)I 6[!5"H$WJ8R+M _=R
M>SFH$$&*7<#*>OC.4#!$X$RH'INV-7R0,O*3'@+E 69+\.[W'>89^K;\%H."
MA]2DQRIAS> TJ:C517>_0TU-8H*)BVDI=W'I['^\T?WP=Q-F4(14P^">C1U<
MS=D:3FZY7BPU*6*(*A 2LP1C+U<.NCUS:R7P0R8_;@&""]A#CNBAR;D^/U9G
MO?\B<IFT1MU:2+UNIO"RRP5XT J]9;G0+S=-.(MI^?PV_@X.^F:/ANKGS':
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MW['<B-T4*I#(QI'9XV-IP*Q9W=C\?Z;\(6"2^'N7H*2<(%JOQ8@K(6N)8J\
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MEUJ8+BW+I)*BS:#JZ;7E&Y[_/+2KN?\!4$L#!!0    ( .-95UB:<RFOKO
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MQ8*BR]&=FU;B[_!;>^'&JC<?'U?19A)3^$[BA@B_!8T;&CY2X6:_]GTU,WR
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MGASF@$.N?Z*)BL*TN^VE\,K^2) \A8^"<U-R"WUC7L6LG)',*B)L:&<GZV-
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M-]P:B".^]=NR$'N-R.>KZX;BW+B3')&;PT<G^?6Y"%IJ^G!X1G"9V#YDB>R
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M<E"T3?33M]'K4F 9;/?7E_JZ1R$9WBTCC]]X^.J"#N6Y4$B7:XIX*6R5"B_
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MP-:[=\CNN$+;:A'"P$3R0CK]JIH*C;PZX*\O7XM=4TF.,_W!+H.H,\Q^T?\
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M0D"7,@N[B&WN@ 2)'EA"M( ?V:BI.P&=3T+\WK;SSI?U^?\ +N_.E;1S7%M
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M"TN)(U!4GQ<-VJ2C4/RPD\TZ)+)80ZI:I\=L7$LD5:<"*#\*?/.(ZM2*6*>
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MV&)U+'B3M\L53EU8$=M\%HU!0$T(WQZ ]>6QI08J*$[5IWQQ(!Z[C\,^P?\
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MBDH H#OO]WO@<#Q-<8ZCB&!(+=<18?17$7%.6Y^6(-2C<CLHVIC  0/?MB;
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M)T35+V5^'H1,P'B]/A'WTSY^W$OJ$NS5>1BQ)\3O@"4"@/?PQ!EV)45Q$D%
M2:TZ_P <0/Q$@+MVRG2JUK\1\<"<0Q96[=,8=NFP[Y18$D=!WQ!C]HC<8A("
M:=M]@>^)T*C8[]\M@%V#'<;XF3L2!MC1Q(H=J]#CBO&@Y9084H:D5I[8LH78
MG85RA6M!]DG?%A0 ]QWQ1.) \!GIK_G&K4397_YSVP/$:Q^3WG:T(#\>7#3F
MN:4_:_WGK3Z>V0+\R+AKW\Q?/MX8Q&;SS'JDQ4;A?4NYFI7:M*Y#"H! X_3C
MN/P5Z<=S3'(>0'(;UKBKL22:?/,@(% M%.XQ1 *LQW^6++QKXU\<>KGXFIL-
M@<$43NI?:OTXL0JUV-",4C',4"_1@A:]#3B.N/;HII0#ICEY @T)Q?<$-QJ:
M5^GY8N0> +;<NW?,.1(%:#%Z,2M37;QQS,K<0=B-U/OVSU5H-Z?S$\C6:H0_
MF;R:*A=N<L:@;UZT(R-2:A=WNEZMIGU=S+"%N$4BI1UVD!%!U (SSG^8'EN2
MS>QU)%,HU"UE6*1=E5T^+B?HSS9K^A7-_;!(+<F:*;D"QHR2#XE%/GGI#\B-
M8DDTQK:>2CARR1_R'I(GS##/8>C:AQBA#-21=M]]JYT[1+CU64E^2 =!VKG1
M[.8410:HO;Q;MAW&_(#<A1NU-MZ=,-XI!Q%/A:E*CM@E9"P-._T?YG&F/E78
MD':G^?Z\&6NG&1@67X1UK[>&7J<Z6ENZ1($XTZ5&_CVK\LX=YP>0PAY-Y"ZL
M6)H:5K3?KBVF\1&25KZ@!#4[GMC)+-_KBR-3FQ.W8@=-\F=A*BD"6D:4W)VW
MR:0:LD42P!RBU[&I.";_ %4+;%6D+(!R(Y5J1[9YU\]:Y;V7J74C5!V1 1R=
MO 9Q:SA\S^8M4CU*[U*YL-.4<8M.@(6!A7[3'B69OISLVBV)C2-F8IP/Q$=@
M#WR>PW7I5 5947<$=0>QW."97MM2MWMY@)%E/)6W##O\P1A';:M=Z',(+QVF
MLV?C'<@[BO19!X^!R6KJRS!3$XD8@U-1L,++V="6(+':C<J??G/M5;UE*J=N
M8K3?OD/U'2F:20@4$B$4WVKL:YS0W2Z5YDTB[EE2*.%VCD>0T4 @J22=MLY+
M^;WYA6_F68:-I,OK:79R<IKI3M<2KL./BJ^/?.$/&.0)W &U<#24) Z8&=@*
M5^BGXXBX'$J0?HQ(D5H-OGC6Z[[$8@XK3>OOB3 T(/V?'$OA'L3WQ$KLU3L>
MV)$,/A!J!OTRGIQJGPFF],1*L2*'9OXYF4#X0:FOWXE4J>F^_7&D^/MOB@H=
MB:4Z'QQ['D-@!MOB@[;;^&96 VKUVQ>,KRX@;4V&=H_)&[>U\U>9$JG&_P#R
M_P#/ENY?L/\ "VL2#CN-RT8&136;A;K6-5N4D]59[R>59*UY!Y&(;?QK@$$L
M02:'M7QQW&@W/Q'+6@^TH_V\U!N!4#'+RJ#4D =,51A6G3D:T\,7XU8D_#MB
MD:BE%[G%47CU8L2?\]L%TJH+;DX]01LDG _PQ4*RE36M33?QQ15W9C\0&+JM
M0/Y3XY00\O@J>)I4]#BS*YHQ;=CN.WWXL*CC7,'4T^'^OSS( SM4DTKG2/RR
M\QW'EOSAI%W%+Z=M<R+;7 855D<]#].>M->T.)-3&J6D*1PWJL)%44'%S7X1
M[5.<I\Y>1$O?*NI6VQ^J%GB+#D55OLT/;K2N>(8M">[EU*UD5EOK!FANEJ0=
MB>$E>^V*^1I3Y6\VFPN0R6VM2 (S-LEZ5^&G2BRKM\Q[Y[(L)RB1RFHZ5!WH
M*=,ZKY1N$F?BK5'('?PSJ]NQ5J!MEV6GOO4X?1, @!-:]??#B$%2!4,2*#YX
M:0JY V/6AI^K#BTM3(P9ME^R!X'#B=TB5512*"E:?J.0;59.<O!G 04^'P'M
MD"UNW$JO*0&4+\ -:^![4PKTZ6"%3;.W$Q@%0?#MA=YF\^^4O+"1?I2]D-S(
MM4M;6"2YN7 [K'&#M[DC(?9?FPFL<OT5Y/UT(#Q5[Q(;8GWX&1SDIT[S5J;3
MJ;W0;BV@.YF$T<J@_P"4JD')'J/F%3!6*0D ?0!%0+J_FN]0.F<U?0;G7;M[
MV[0E4!]-3L IW[@T)R0Z9H/U>,JL:@@D5["F296BMHPO!54C>E..W6N-,I@9
M2A/ITH%-.-#U/7"V2_>&1SNG%J=*+0]-^V/>6*X1UFD]59D*MR.V_MA=I/UN
MQNCIWK%U'QVSMOR0]4)\5_5DMDAEG2CFI(_'(TFGK%=K'(?LDC_))\,#:G;%
M9SL%X1U)/AMTSS;^8T"J+SX2><4AZ;4.]-\\G2H0W$?LG_:P-(I-:'K@21#_
M & 8':,5KW[5QE-NFXVQ"5>1J#O2G]N)E5IO2H/WX@0*D"IKVIB#[B@/R\,0
M(Z=R.I\,38D;TZ?=B56%".^V_3,5 %0>]3B1 (/Q4J?NQ@1V/+8E:[UQ.A-2
M>H\.V-/3>G7KECL*8^)2!UK@@5W\/QQL:]3_ &8(HQ-2OT^.3_\ +FZBM=?U
M&1U8@^6/-,%%%?BGT'4HE.Y&U7%?;"CB:[J6:FY\!BB K0/N#]_MEM]KH/GV
MQQ=E^)A4> _CC@05#<JFO2F/!H0.-#U!Q^RT+FC5[X(+U!4GMBJU VWV&/7B
M"*'<;X)JQ6C;=P>U,4520&Z_(8) XE03\->O4#! C+#J0._]<>14 -NJ["F8
ML4&R_!VKXXI$Y(->^.I4\J[$;BN8D$<5ZC%8N*T%*;]>M<%Q2<9%96XL""".
MS#H?OSW3^7^O0^;_ "G9S2LKWUJGHS!OM"2/X3]!&^2'ZG&RR03GF'7@Z,:A
MX_ YY>\Y_ED5U@ZOY?G>WO(V8,RCDLL8;;U!W\,XOYATNQFN8[#S!ITNCW!/
MIQWB \*@@Q2!J5#(W3VSN7E(7]S8?4=159=2LHU662(UCGC-?3G4[;.!OX';
M.J^42;>ZD]0D%5.W4;=SG6[*Y5HU)/+D=R/;)9;<!PY;BE?&HP\@!<B7<]Z;
M4PTA4NRGG]EMU^6'L$H0#H.7?$KN5ZE*@DC[1/3PR&W[%/A]4R2L1N>I/0G8
M"GM@6=K=@(3&IIU/7<?=D>N=/M_4H(4*LQ+^%?' 4.C:6INC;Z9"CRJ1(Y0$
MN1T-=R,7BTJ%0@2-06Z[4J0.IIAS9^7-(NJ1W5H/6)/)E!44&_4$88+Y6T&"
MKV]J#.IV+_%M7L&K3#Q]/LQ;*HB5%&Q8K]V_0Y#;^.&SD9H4H0=P_P"TI.Y'
MOA7>30CF!\54Y*  2?G[Y&;C4H8 J2S(IJ3Q8A2PKVKUID2U+S5I,4@A>]B=
M>5!&&!J!UW\/GA*GGS0$OUMK?5K:2X5E#6Z2H\@#]V2I8#YC.NQPJUG!J$!#
M&$I<)0FI4D!@/H/?.@SV8:WADC;E&R\J]Z@5I0Y$YK?G*\J@$J2=^W$BN$VK
MQ 2.:44H?X5SS'^:$GHP7D@V5(_B /<@C;/)!'+DS5)[??@>55V)HH&WSP.5
M(V)KO\.!S$M6 K4[_+$&0 <AO0]?; K5(^ ;]#_7$FJU:@@+WQ%D*C<[L.V!
MF6I%&W[TQ-HRM:[^.).#2G';Q[XB4VWZ]L3J=QT'?YXP@4K3VRC45H30T'AB
M08@M0?9Z5S$<A4]<PH0!3:M<<I!KN02:#%1M3P.*"O;N*''#GX5'XY*_)\T<
M&IW<LS\%;1-<C%?YY-*O40;>+,!CB:\C0\O =-LR'D"&^$]AXXH" ?';,S;%
M1]DYD4>_SP34_M&A ^UC5W:C4=B=L$\>!6H^)NV+**<Z$T_''QJLAV-"IW^6
M"U7Z0?IQ=>52I 45^_%P.QW]L4J"&Y?#7:A.,^('^&/#[;F@Z8NE/E09A3D0
MO0@U/CCQX4W/ZL63?=>OA3'IPJ2:[&ASK/Y3^;W\M>8([2XEII>K,(IN6P1S
MLK[_ ''/7MX4=/4@/-&% P]\VD:?!)ZYFA$AB XH1T'B,?J_D/RUYCA/UJQ2
M8DBJ.!3Z<*9O(MMHJ1OI4-!:C@% ^'TCU2G\I_ ],C<D"V]\LD2<4G!C92*%
M3WK[Y-K$K2"/PW!/MWR:Q/\ 8 Z@ =</() * ,0#M]V&\3%#RWHVU>N&L4ZE
M:\*.,3EE+D_!13L?'""^ 5F/[:;5/WG<[9$KNX_TB'D1%& 7)ZBE.E3WQL$K
M.[-4&*E8QTJ<,U=*0H6ZL!5>M3XX=6]HL3,_J<5;?Z??#NSB1X?20*2O0*3U
MZFN#[5%=&=$H%))H*,2/>E<4>W81S-+,+:!=S(YITW'PD#..^:_.'EZS>=89
MOK=THXAJ?!S)W(VSSYYI_,F"%Y$M[P0(.(+0FE:;FG?<YQ#S%YWDN+DS27S1
M*$;@A<ER#TJ#TSDNJ>8+V\YQ6)>:>1RB_$VQ/ATJ<]"_D3^2^G6$]SYMU:SC
MDU75H0IED6K,M>6Y/Q&ASV7%I$>G:1<V]O(\D*1MQ1B:["M 3X9/+11+HT,Q
M(8)$IXUZ?#W&10KR)KL9 :_21A)K,9'JA>JU'W ;YXZ_..Z]"VN45JM-+P8#
M;X:=:YYE=@:&F]._3$'53L37>HI@5AOQ)-.N)'8D@=-_GXXF6'0#IT&(2BFX
M-/' KC:H):HKB''J/';$S'2HY4Z8'>O4?,G$30[MXU';IB5>(:M2!^%<#$;U
M'3KTZ8T<2=B=M\Q#5  J.^)A3N.]<KCN0=CWQP6HIX92[=MSMB@8$"@^S4;X
MX5 (&^V*=0-_?#?1"?K,X/7]'ZA_U!SX;!=O$^&/XABH(H0:UQ[1BIZ;^'\,
MU%%5K48Y1Q&W<TIFV)VJ*>.*HI5MZ>-1@D-R/6H.*(K ?"U:GO[8LB\7Y  '
MOWVP2I 8$BF_7%B&Y5VIBO(-L#5AM[Y8)52P7E3J3VKF):BAM_EEJ!O5J$[;
M[8L .H%!BJC:BD#;J<<&8+Q%"3W/3%$+,0.M.N**"'YC>G7WP; :FI)7P(V(
M/MGK?\J_.8UC3UTF_D!U&Q 45_W9&-@P_CG>H>"#G$>)9:-OVZFOCCK6+C(Q
M]0U!^T.A'T88M(29$;[7$DT-?A^60KS=IUN=-2^MT'K0LK,8^A7ORZ5VPDTV
MX22ZMV1SP,!J*[5&3ZV>@45Y,5K4>!P<+@QD.31=S0G#^VG,O%JD*17!_P!8
MX[*:4Q\-Q&TE&<MZ8Y4\/<TPFU68$B,DJK58E=B/'(+=7<4TA5FJ :$4! ]\
M;;W3A^,A*KR 7IQH.AVPV&IPP.%,L<;JO-F?[-.G3'-YOT3E$[72S7$;<#&.
MA([@+UPWGU_4]/1[B'3_ *N9*$?6N42N'ITY("30Y&=2_,N_MBT32P6%Q&&)
M%L4E^%=JBCGK\LY1YB_-D2Z=>0W]Z]S<2&MOSGJH/>D*TJ3_ *ISD<7EG\U?
M/DB3:=HEW8:3+(B_7M15K6$*YIRCB8!W'OQSK\'_ #BO:V5H)-?UB[U;4^)+
MF ^A$'.XX(*MM[MD$_,GRK^1VA^5UUORH-+O]4TY%6>QAN5:ZN-01PCQ20B5
MV+<@:U'N<Y1Y2\J6^L^9)==NK06\EY.MQ+&M"D V'&-104^C/:FC6\(2,PA5
MBC 1$(XT '4$9T(L9[)^1)+(54FG<4&&6@_Z1Y=M_B*N8BC@>(JIK](P@EK]
M;BB ^&-:#V[[Y'==E"QST-?B8\OH&>#/SAU 3:VEHDE1$"[4Z<CM^K.*O0K3
MO@<C>A%!VP,Y7CLNX:A.-JM"&'7 [*NZBM0<285K5B:;8B50T(7[L#E5-!0+
M[G$W'Q&HY#^&!I.XITP(0^P)H#C#NI4#8F@Q$JYH13VKC#2NU:[5ICCR/>AZ
M8FHV(K6F),>XVQ,!COR.WAWQ<+T[8T BJDUH>N*5J 1CE %"=R=R<D_EBU6[
MU*XB,G #2-8GKUW@TV[EX]NO"F&M[&EK?W=LC,T<$TD:LZE7*HQ JI (.W3
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MMIFGP'FK<30F*5ZU[\LDNF_E);6B^KK%U<7NGO,KQ0W#L;9Y'4 M]74QQ<@
M!6F=<TOR)*-/G:*PMXK!>#+=WCLL:D5XK B@!V(VXJ3\\@'^!-;UF[9);-K*
MW,G'UY10MX, ">V=&T#R9I6@0R+'"SW/229C5R>Y'@#X8*>WB0RCB7YMM7L1
MTI@>%1',TS$CTSMX<?E@^WNO](:A0"4 @5WH>OWYT#256-21T"@C;8;;GWWP
MKLV]2\U&1>A- ?D,\V?F[KT>G:3J3AN+DLJ[^.VV>$I)"[O(=S(2WWG^W$_&
MII7:GAB1%#4[C&-L#QIVJ<0D!/0\1^O$74@U4BIZ5Z8'92=J_9[X'^T2M=Z_
MAC73X3MU\,0(!Z@CL,8\7$*37;IO7$'4]0*FE=SB#"H_7@5A0DB@';&$"IH1
M4_AB;U_KE*IV-?HQ+AQ9B#]K:N.H!7:E#URZ$C?>GCEB/?D2=AWRU I2M!U/
M]<L 5/$5\#G6OR:L&O?-6N(R,\5MY%\\W#E?V3%Y5UED9CX<PHR7_GSIWZ,_
M.W\V[15011^<-::,*256.2]F>,;[U"L!G)UW._?H?''@E5 /;I[8J" *L#08
M_=J$?9'2@VKBB;BIZ=L$(&K\*5[XIQ8G8;CMBJ_%LJ\2*],4'8C<=",6(#%:
M[#W[8[XAQ%:#Q]L>0":F@&WOE+0=*U.U,6X$[<JTW^6-!84X@M7OV'M@E"_)
MJ[J10#%!5A4"O#ME\F-:CH<7'Q;UJPW^6/%>-5&]>^+JK<0>@I^.*_9%/'OE
M*75R=SMOOCP*N"PIS\/;!?Q[D#XCW^6/0$T)! K0TR:^5-8;2;])'8K#*0&I
M[=#GJK2;Y3#;S^H#$X!##J*]B<ZUIL_UBV1&^(TW]O"F'-L[*&5MP#44_'%I
MP"R3J*#:HQ]ZO.W#KU W_CA%J5IZT,;P*"T:K7;P\,@&N:<]P. B,D@'P$'H
MU?X9R'S)Y4N"!<6D(%Q&&YLE3S)Z\AD#GTK4K?@T]@\!<@JP0_%3KQ(!R2:9
MIMU=LBQ6<L[5V'%NHWWVSM_E3RMIMQ;R&\TO4)-1N$,990J6\<0^T 0T;$_-
M@,FMOY-N()4$-HO$A2BQ<40*A("\N,E">Y!P_N/)GUFY34M3NA<,U"+<R/PB
MX_R@]3[UR3"VN)HX/K+&=;16$!Y\1&I%!Q4=@.V%MY L7'ZLGJT6A5B:5)Z5
MP@N[7TY9)7 IQ!(!\>N12_0A@JKNVVWC7 ;[5""@!HU-J_1B.GVX^M<U-"14
M'Y?JSI6EEGM&;IVZ;4/AA%;W(@@OI *U:0DU^BN>!/SI\PF_U,:=&]4C=WD
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MJ_;'^5]^1>^M$;G(K<V2,*5([^)QD-BLD:"6/U&)#'ET]J9,=!*0$F*)(V
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M5P>MHA2,2 GDE:=Z^-,QL?A8N" >E-L7AB5'!(*D?97:GR.*SJ>?-@%2/X@
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MA+=Q3QQTTR.O$L#R%4;L<+_50_"/@=MC7L1X9<;'D0B['X6--Q\OZX.B/&8
M_L_9[5VR<Z3/&D#AE!/$EJT'('8@'!=Q>-Z?) .1Z<B=O8DCPPMGNS7F7'%:
M *1O7$'O!Q:K<6EV(4U^G"V>X1:<2T2+LQ)VR+:KJT"%W6KE0%5CM7Z,\Z_F
M1YK2TM)HI9E56;XE7<MX(/<YY+U&]GO+A[ASN=@O\J]AA3*G2N[=*>^(.61@
M*T .WMB4@1O=B=SVP*XI]'6N,;B5H2!_7 [*"*= ?#*;:F^WAX8E2I\">N(D
M$;#<^V52@WV;YX'( )K6M?PRN(%#6E3N<0==V(-.U!B7S-2,#D$*P9B>X_IB
M'Q*U0M<2(+5-!7Q_KB!H00=Z?CC&!7[)KE<N5:[>PQ/B2>E /QS$5W%*;996
M@7BU3C>I(/4> RVKW/AT.#-.L;G4[^QTZSC,]WJ$\=K!&.K22L$1=O%B,_4A
M_@[3O\!_\J_Y']$_H#_#W+CO]7^J_5*\:_R=JY(-3T^UU?3=0TJ]3U+/4[:6
MTG4?M13(T;C<'J&.?F+\P:+<^7M?UOR[?+2]T&_N=-N!2G[VUE:%]JG]I#A9
MRIQ(ZKX],66E>8W'<#% R<A2H4]0?'%UH*GWZ5ZY5&&Y^(-V';' \MMP ,>%
M;X0"/$]S@E0@)KM3K3OB@-10'8[TQZ_"-Q57VK2OW8L**G'=@=Z> S)Q&P&P
M-:8(K5?AZ?3CC0J-P >V7_E;4Z^^+KM1MZ#OWP0M'%5KR/?QP2 H5MP&^_'J
MM226!IUICC4U%*[;9D(7[70=,< I>O44J#BRLO$DJ*=!FY\J +7Y=3DK\H^4
M]3\V:B+/3(BL4=&NKEQ\$2^YZ5/89[-\J>4[#0;2&QLD_=6PHST+&25OM/4T
MWSSY^?>ED_F-^5MS4R5AU2*-2M:OQB)*D]-A3WPI6W=M1MA0))"&XITKX[?T
MSM>C+(T,6W[IEW-*DGI0GVP^])0&5D!52'6OB._SP<JB15W"U]ML%0W,UK0^
MHS1TI4;LM/UC!XU3F@D#!R/VEWK[$8F=4CD0K%($IU5A\(/L>V ?TL(W"S-L
M-E;K3Z</+&^#,A]19%<]5V^51XY)(6C9P68&AK\73V!&'-O=E!5 *(-@3N*>
M^..I*6K(2M?M ;@86WFHH7+*XXH/A(WJ3A9/JP1>+ (K=Q2I^9.$EYKJ"-R]
M"!]@D_U\,YAKOF-GC>&S DD)-6K\*GYYY4\YWLEWJ4PEDYF%@II7PJ3\\@DH
M)J*TW[8"E/4UW[?,8%'Q<MJ<CO[G&LK5*E@6[4[8WB3U%1@>H<LB 5';Y8')
M()4J,>X %*;@=.U,",-MCTQO7XMJ#+;A0[&O8]<",O)N7'[/48FXJOMV'<8@
M=QL"3B14CL.E=L#,5^1]\08TV'[/48';?OMX^&-/)CV]A3K7,Q"@BGT>^)4[
M@==L44CN!B) J.P)Z>^*<:5##<],3(ZU!]SC>( !(VI3/0__ #B=Y1/G+_G(
M;\J]+,7K6]EK,>LS\A51'I*M?$..E&-N%WZUIWS](6;/@?\ \YE^4!Y0_P"<
MA/.8AA]*T\S^AYAMS3[7UU/](;Z;F.7/+2CD2'&]=A['!  K0;5VIEE=ZU%?
M'%EVW--SCZU!\<>@5MNP&^+!*;BE#CN-3\-!V^>+(.@( IO6FV*J&()/4]!_
M''EB:"E3XC,NYVVIUIT."0.(H#\QEJ0$Z"GOBB@4KQZC[L7 4T"C[0&WRQ6E
M0'##X>E-L%(10_#3^/OCD!K5MJ=.^*!=P>7'PQ[ ;^/8TVQJJY^U0^QQ[<0>
MFQ[>)R?^0_R^UGSUJ"06,30:=$P-S=E3Q4 [HFU"WMV[Y[P\M_E];>7M+M],
MTJV2VC79W J[L>K,>Y]\G5MY<%O'1@':G4=03XYYG_YR*\O217_Y7Z]%&::7
MK[VTA6E%2\MY(]U[_$!G-EL>.M03&K]*,PWW[=.F=>T^W%NG(1CTV() [>^&
M_P!6,BM5:*O@:D@XIZ3A /34\>@--_8XU8Y &,M&5NB@TI[=.V1G45N[1Q/:
MRE9 !S0?M#WP)]?>4%I(JD[%TVW]Q7;"J[O*':3D1[$$8&B\S+IQ9C<QI&H^
M+FW$?,'VR0:%^;/E:_G%J=5X7*=6=&$9IM]LK0YTFW\PV<G#TKE9HF%048,I
M'SKBLVN6C+\1= NW:A_LR-WNMGXQ;1>HS5$<<>Y^BF%44?F"Y(FN%AM8E)H9
M"7D-/%!L/OSE_GE]>74=-M+;59(K>X9O6HJCE3H*TV'RP3#I\EO9<I6-56I-
M>OSKGF'7IS-JVI/RJ@G8"@ZTV^_;([R8FM*5WH.F)$;%NGC7 SBM32@'W#&<
M =EVJ/HQ)^2@4^P=JCQRC12*_"OB.M?GB"@J:T!KC*E3R.XQ.5 [!J +TIC"
M%IQ(  V^8P.U*\11:8FU*&FY7QQ!F^&M*8CO2A;J.^(DJ* D].W3 C4K2FV)
M\%-30\3C?2(8;@CL,:P H00:FF-].M:=MR3B?&E?VB=\M@1T (\<3H:UI7?8
MG*-:[@EAC@!4U%1URW5 *D[MTVSZ4?\ /M3R6=0_,'SWYYN(N<'E?18M,@+#
M87.J3<^:'Q6*S=3[/OU&?9?-GR\_Y^/>3";;\NOS$@A%(9+CR[?R]Z2 W=F/
MHX7'WY\LPP!XBM0>PR_AY4??P^>* 5->N*H0*+M1C2F*F/8BE*=\>BA>(IUZ
MT'Z\<8SOO4^&*J"H4!?#;L!@H;+MN3L<?1:;$?(=LM0"H-:^ S '<@#;M[XY
M>0;DQV(Z?TQ3X2=Q4=?ECU:AH=U/3VQ:,*I;C6IP2KH0*  G%U8K\5>O4]OE
MBZ<MC4 =3CF-213Y8_E78K6O;-R-#R^$#8'M3.V?E9^3>L^?;B*\NXY-,\LJ
MP+W+@J]Q3JL->W^5]V?1/RSY0T7RQIMMIFDV:6MK:(%1%'WD^Y[G)2+6-:_#
M4]<S04J1WZC.*_G9HSWGDRXN$4M^CKNUO!2G2&9&-:^U<X7<Z,/TA:7"(6C=
M?3!'WC)Q90-&!456E!M6E/$9([6U6G[I/M&I#;T^6+36BAJ,E&Z 8BUF26K'
M^K\<)+G3E<D.H?L"!0$==\CEUI05BPB#+T<=*CL:84WFAO<1UMI?3\4-*_,5
MSEOF'RI<O'((E9IW/#N?M=2:=LE?DO\ +"*VM(VN80TC4JQ'ZNN==T_R?%;(
M$2)5KLM.GL#DB@\K*$1Y8E$AWI@LZ((J%(@HJ:\5H2<*KNVEA5D*A:C:HH?H
MSE^LZ6+N\AD(Y-&]>_;MB/F,0V>CW$GV2D9ZGVSQ1>%GGG=OAYR,Q([U.%VW
M(]>(/?OB4M!OU!VVQ-06^$BB5K4C$Y IJ%%!].)%59>(J%7;8XPAN%"*@>(Q
M*A'0U4X'*K6@KT[_ ,,8^W%NI!W \,3:I/(KL,1>E 2*]2<#DLQITQ*0;'>I
M_C@8T;IU_KB/<*#2GCB+UY$*>G3Z<8%H!R!.,8]2=@,8HV]CTRV^$,:G$JUW
M';L<3:IVJ1E!#M0]?'QQ[AMB*G;&FM.1V!/08X@$+Q^+B=OD<^[W_. /D@^5
MOR%M==N8/3OO/FJW>K$L*/\ 5H2+.W4^Q^KLZ^SY[>S9Y^_YRC\B'\POR-\^
M:-! 9]2T^R_3.GA15_K&FGZQQ04-2Z(\=/\ *S\^BIL>[5I0;9?3PYUQYVZ"
MM>V9=R-MJ[5Q=>3$^/<#%5)Y54]NF*[J=^OCBR?%U%#X8(&^S&E#M\\U5W!&
MQ!IX?,XX!5HQVVH#VQH--Z]=QBX"_:_6,=3X=QN>E>V.15"DD_1X8HA 4]R.
MGO@I2K=!0=_HQ<=0JTH1OM^K%J\>GQ#P_KE@EJ >&/3G+(D:#G+(0J)&"S,2
M: !1N2<]0_E?^1=S?/;:]YRM&2"JO;Z61]K>H-QT_P" ^_/;^DVL5G;Q0(L<
M,<0"K'$H5 J]  -NW;)5%)&1_-M6O;;M@]2"!0B@ZX[8B@VH=]LC7G#3/TIY
M>U>S;XO7MI  !UJ#GF^QLTO-*MP:!XD"5[AEV'XC#>QLVE )6C*_[Q:G9AA\
MD(0@\**#0'W[8=^A#+&H>E#U]B.^]<+Y;&0!BC!UKTZG;PW&%5S:,VT3!FW;
M@VQ '4=<*?JYEY_LLM>OAW&!8+(,.,J4-30'O\LUQI,+*0T*AJU'C4>^2S38
M D,8" ?#0^ I[##NWBB4%6EY,23\0Z>PP;ZL2G@I &P)[C%62(Q$L_)>P_V\
MA.L2(T#2*^S TKX9"+=%ED8E00I('@#G._S/O;>UT=HQ7G<L(@%VK4]O'/(=
MY;R*TTBPMP#MZC*I*@GQ.%)";<:$':N)D]R-P>E/NQA.^YZ]_#$64@-4@[['
M$!6F]:=Z=\HMMQ Z[XDP)'(T''N.^(LE#1A0D5W\,093Q9ML#G>A)Z4V&-8@
MJQX[G S4;?E3C@=B>K[$]!B(*J34;^V,906)(IB&P-:>U,H+\)J:@[@8E(I/
M'P'44QO%R*TK7QQ%JTH14MVS<J CC3:N,9?8 C*"[T+'B.F.*$MW]AVS<30@
MTK3!^B:3?:YJNF:)IL/UC4]8NX+&TB!_O)[B18HU^EF S]0ODORQ9>2?*'E?
MR?IP L?+&E6FEPD"G);6%(N9\2W&I/<FN2;-E,JLI5@&5A0@[@@]01GYS/SI
M\@O^6/YJ^=O)14I::5J4AL#XV-P!<6AK05/HRJ#[USEXX[GHU>IQP4D$BA\#
MF,:T'Q4/>F4*+4'J#0[8ML"I4#;%EZ%2#\72N+* *=V H*8HQ(4"F^U/:N*D
M !=_B Z9MZC]I1X],<K*QXMN!CJL0=ZTZ$XY&8C;I]D8H@J2.@ ^6**0K; T
M[GVQ;[/Q=0.V+HX- !OV[4P7;P7%W.MK:6[W5Q)]F.%2['W &=Y\F_D+YBUM
M8[W7"=-M"0?JRD"1U]Y34#W"@G/4'E;\K_+/E@V4]OIT2SV=PLBRJ@Y%0*,2
M[<W)%>M1\L] IIL2!75:UW!'AXURVM*;@T VVW_"F)<)8F^R33Q[ X)6YN%^
MTC;"HHII3M[X)BO)JC]R>OSP697E61)8SQ92".HWSS'IBMIWF;S=Y8G4++I>
MH>M;KU#VMXHFB8> W8?1DMBMEB8RJM'D/QI_-3:F&%/A7A&W _;IN5K]V#K=
M T9<C;?DK5H:=/''HB\69HN5>H[^/3 -W:PS1\98P';=&6HH1N.^%OZ.*!Q+
M&3R_;]L!16'%CQ)DAY"G>@\ <$36;<0*<@/P^>"+/U(U52>AV-.OSP>9B6YT
M^CI6G:F Y;B5F^ 5)ZAAT]A3 <MY<1QE:D-V .Q^C(S?-/+%(S ES7KA%I<;
MA9O4E(?E0@>'B*[9Q'\TFY36JJ6D17- 3^K(]Y LXY]/UU599)K>>.=X6'(/
M;L"K['P(R2:M^7&@:S$T\-M^C[N4 K<6R@ GQ:/93\AG"/-/D?7?+,K/<PB[
MT_E1+J %E^3C]DY!BZ-6M3MB,A(/#8+]^,^$T!--NGAB;;'XB:>_AB3GNOV3
MO3$F/3:I['$":@TW)V.(O05X]5'XX@0>(\1O0XPJ&ZTJ<1<#EN!MTP-(I-:[
MCM3$^1Z'MX]\HI2IJ#R['KC70$"I(<8@X(K05)_#YYC4#D#OT.,(V/+QW(\:
MXDZA:;58^/AC"%H21N/#$0NPVIW/MC@"5Y [C;KCN!I4[D]O;/8W_."WY=_X
MW_/S0]2N8!+I/D&WF\PW'(;&XA*Q68!_F$\JR#_4.??/-FS9\L?^?B'Y="*]
M\F?FE9P4CO%;R]JCKL/5C#W%DQWW+)ZJDT_949\RR07J1T[?QQ0MQ 791U^>
M)T-:G8'PQ5$K6GQ4ZXX?#2IQ<'F!4U\,>H*CX6'('YXKQYT/+;^./(;J*;#M
MX>^)KR84W&]:8HH)4D'>M#C@#N0:@#I7'K6HJ>/3'KM7J:^."5+ 4/?N1AAI
M^FZAJ]TMGI5C/J-RU L5NA=O<FG0?//17E'_ )QSURY2WU#SI?#R[92T9;1*
MR7;J>M !^H?3GJKRC^6OE/RVB+Y?T.-#L'N;GXY6)_:();?W-<ZK9:([,LLU
M&(^%23O0=*?TR1+HUJ8_3:,!6%/\Z8.L;=EC-I(U7MOA5NY3]DG]6&7H(B_"
MM23OWQI@2@/$8T6R$["A!ZBN^"$M4K7C\1Z9GMV0;;#OGF7\SXFT?\Q=$U>W
M!7]+:88)2-N1M)*T_P" DR81K'<V\3 GBR!@PVW\<5C158I)12HV[ GW[XM&
M0I/$ !F(-.A-/EUQ.4!F Y;C<#MM[UQ/D7XAE8. :5W ^5<Q9BM) . )H1O^
M%,#QC@WP(.)\,>*;MU)-.F-5$)!*T(;H-^F#!'#0GB:FO%NZ^V!%CC#5" \J
MK6AIUWQ.XCCV'I*=QV[_ $82W]LB(X9@?5J:'V'0>V<_,QB,BD#H=Z_$0>A(
M]J9P'\P72>\A(W0 $$^._:N<XTCS%'Y4\R:7J=Y<1VNG7,YTZ>64'TU:>@B]
M1N@0O16/:N>I=/*1,BH*6EP2R!C7TGK1HF]U.2*32+>\A>)HO41Q1N2CB:]M
MQG"_-?Y,Z=J<EP=(D&CZW\3K&P_T:X7K7B/LGQ(SS5K?EG7_ "].T.K:7-:F
M-B!(!SC-/!UJ/OR-\MQ0U4]\:K,U6).U?EB#!@=FJ!^HXQR:#C6@ZXF"=R=^
M6Y)_AB#GK0U]L3IR '$_,;??B9H!0]0>G@,3=5D8'H>N)-3>GP]O]K$Q$*CD
M:BO?OB;*5/6A7OE?L\BO(@UKB3 "K<=FWQ$5%:#9O$XTA>5:?TKC7/6IH!XX
M@2" *5X[?,XFW(D;>^V.B!/+DM/ 8X==Q]GIX'/MY_S[U_+@^5ORCU#SS>0>
MGJ7YCWYFB)%&_1VG&2WMP=R=Y3,W:H*GP.>^LV;-G)_SQ_+N/\T_RL\X^2_3
M1[_4;)IM-9]N&H6Q$UJ>78&1 K'^4D9^=::"6":6&X1HIHG:.2)QQ9&4D%6!
MZ$$=,L%>IW([^V54U''H?'% 0 >)WZGM2F*JH;>I/>N**#TVKWQQ!V;IVJ._
MRQ05H"!2N]<>344Y$?K&6M *;D$]\5*+5C3X:9A0D<>WB,4168&O;IDF\N>5
M?,7FNZ%GY<TBXU68,%<Q#]VA.W[R1J*/OSU)Y/\ ^<7/WEO<_F!YCAL@PY-I
M.GOSGZT"NX!/W ?//6_E?R3Y/\F6'HZ#I5OI*HO]ZX!N&/\ -4UW/C4G!FFZ
M;'?W$]_,GK.Q/$R5V -#7Q^63*TM8CT V_E%-O8X?Q1(BU5:T&_3'%>@I6N_
MRP-Q]&XBF->)K$U#MONI^\89 U6H)4'8>^/"$UWY4I7+XC<GB#_#*$P3XC\5
M=L7]>)MJ\6I6ASA/Y[VUO;^6]+\U2$+'Y8U.!YF )I;7;"WD+4KLK.IP)HTH
MCACCEXB%A5#^RI[#V'AA_)!%*H8DL5-5H1L>U17IB - 0"" >AV!/]<:ZH64
M _#N?$!AXYJ5) )!'2AWQ"04;QJ/EB"D_%OTW^0RD/PL1WZ?/VQR@J -P>YZ
MG!!($5: \1L/ZXB%+**?$P%0.@K\S7+],LWQ;#N ?PKA9=V\;CDH'-590Q Y
M>)%<YCJI""4( 30D'H:G///F"-KC4'=FHT.P'8?1G(/-FC0:YHVNZ+=Q--#?
MQE7CC8IZBC=ARW(J,FG_ #CI^9<VLQZK^6OFN]6X\U>3$B!N0>2ZCI!^"RU*
M)C]MD4>G/3NM?'/:%BDT!"258@ \A2A7L1V(Q;5=+COX%E#&.>(AHY4V9#\^
MX/?(9Z5IK4LFFWT$<&K1*08Y &CN$.W):CXEIU[C.9>8/R5\HZS<%XK:31;T
MFCBV;@CMXE:$4]P,Y/YB_(#S%8(\^A7*:E%4E;>>D<K4[+(OP$_.F<+O].U'
M2II8-4TZXT^6!BCK<1M&>0V.Y%#]!PM)"E034$?,XTD&H!IX?/$PH%=]QOTQ
MC,:;?3B)V!-*D;G$7 K4]_#;$F'8]MML:QI16!I3PQM0U2=ZC;N,34-TK0_A
MC=P]&W6F!9@0=AMW[9@/A%.@_'$60,2#L*UQ)QQJ#6GME#8D=^E,LOQH.YR5
M^1_*&I^?O.'ECR9HR$ZGYFU&WT^$\2XC]9PK2L!^S&I+,>R@G/TW^6?+VF>4
MO+F@^5M&A]#2?+FGVVFV<9W(@M8EBCJ>YHHJ>YP\S9LV;/AS_P YH_E6/R]_
M."_UJR@]/R_^88DUJT  "I=E@+^+MTE82=-A(!GD,_%0$_"3T&*A0M*&G'I[
MY3\:578GJ,M*@FE1['OB@<U! I2GOBHDY&FY-?H&+(&/$=#TQ6JU .Y[5QP"
M].E>A[9A5JKRJ!DC\M>6-?\ -5V;/R]IDNI/$0)IE'&WA![S3-1%'S-?;/77
MD+_G&?1XYK6Y\\:M^F+A@LGZ/L0T-H*[A6G;BTM?8 9Z?;3=&T*RM/+GE;3K
M;2A-\(6R41O&O0GDH&]-CDFMM!AMTBA10MPH =SNQ/BQ[]>^#+W3Q';<&=6D
M<<1M4U/S!-,.;"T%M9QJM 5%*#Q^G%X^G0U&WM]V&L3U '5?"O;!'$;FOW&E
M<0GA$B.H)Y4J"/$;C\<=;AI8TD-:L Q!Z5Z&FV#44^-.PWKCZ?#X'N,3,5=N
MG+>F)M @V[<:;_VY&?-'E^U\R^7=<\N7J^K8Z[8SV$R$TJLR%:U&X()!!'3/
M(_Y->9-1GT:+RMYGY_IO0&DTYKL@JMPML[1*6#,])!PHP))Z-T;/0$;%(U<4
MEB*D<AL13M]&6[+*H)8?%XC>F-4T/AQ-.NY'OF)0DE36IK0C;$I &# KN1UI
ML#[87/R"[$CD:=/PQ8'C&$[C*YTX]N@'CB]0: J:CKX8IRILH/+QQCL!5Z[T
MH:5PFU&5 I);H*TKG--8>C2*.K#8?1G$M3@X&XG85=V.<HU8O;S,W$ 2HS;]
M* =,\S^?=%U_R&FD_G5Y1FD37O(<WZ6GCH9$DTVYF5+RV?:IC^,. 31?B &^
M?6#\G?.?E[\RO*&A>9M!N%N-#\P0*\!'Q&TNBM9;63<T'*O#VSJTVFK!R0J6
M<=NU?ETR%^8/+*7R?6(E:*:(B2-XOADC8=U(WR.175Q%+!:ZQ&&D4<4N^@*G
M_?GO^&2.W)M>*45XF:H7J IZ]>F+:EY=TW4H6E-C#J$)6LEM*JL"/;D#G)=>
M_P"<=O(?FJ.2?1XI?+>H#<R6( 53U_>6S'@?F..<*US_ )Q>\\Z:KRZ9J>FZ
MR@W17+VC/[!G#)7V)&<$\R>5_,WE"Y6T\SZ#>Z#,Y_=FZB*Q2>Z2BJ,#VHV1
MQZ!23OX8F2O&G?H:X'8,>?+M388F%*UWZ],:#L:FC 'I[8CS%>0V/MB;.*D
M'?N>F-/+H3L<;R'A4#$V!/;8G&BBD*#RXXD34F@J<IE&Y- Q\#C/38$FH%!7
MQKGTP_Y]S?E2=7\T^8OS<U.WY6'E2-M&T9F'PMJ-U&#<R(:]8K=PI!_W][9]
MA<V;-FS9YA_YRV_*AOS4_*'5X]-M1<>9_*1.MZ1Q6LDA@0_6+=:;GU8>0"]W
M">&?!=>;"JK6FU,46O+EUH-\>@#$LU*-O48H0O$D$U_4,>#1?;OCU4E*D;'W
M[8NA((%!X5QSJ"*DTIVZ9,?+'D3S;YK'/1](DDM.2JUY/^XM17IQD>G,^R!L
M]0>2_P#G'WRCI)%YY^N[SS)=1CD-/LU>UL:@#9G4^K)3H151GJORCY2BCMX9
MI-*MM(TFVVT_3H$$<<$78\5I5CXFI]\Z!<6%FR_O7X(%W'4BO@?' VD:1;+=
MF]6$HL:E8RU 6]SWP\BB+R,X^S6@V.Q&*):&:?G*IHGV1_'![1T'%: = 0,0
M"&M-^]*GPP2HXGWZ@'O@M"#L%KUIX?1@A$K0'>O7&QQO&\T>_P!KDI[<6[#?
M?<8*2-GH "U2>QP4+=EV:B'K0D"N8^@*?O0W@$!8_>!B#A""RI*W^Q J?I.%
M5U5$+"*164]PIJ/E7/$.N>7-,TW\SO-I-Q)I:ZM=+JB7/#EZ%Y+$BI.JD@A3
MQXR4-./4'.KZ%K?JE+'4UDM=0"@31."!Z@^S(N]"KBC#)DT2O0L#R4]]B0<2
M*\&'IIM3>HZ8Y6J*@U/SQ)AR(8U5AV&6HB/Q'MW8[#Y4Q.103T/C2E*8";^\
MJ:4CV%/'*+-R+$FO0;=O'$+BZ:-3P.]>V )+NY9 H:@]OGA1=>HY578FIR.:
ME:D"5VW9A05[#.4ZU:-1@!UZTSCGF"TDGL97C0R/:LP?A6H0[$BF^V;2+2UU
M(-&JI>02:+>45U#"7@BJ%92CK3J#4;^(ZX4_D<UK^1/GIXM+E9ORC\_3K!J>
MCM]G0]1=O@GMG)V@9FW!^XV<552<7;>E"Y<$#22X$QR"NZ<HJ 0*=PD:W-W=
M@@<+P1V")D#A[A("54@HW-T#%-KYCG3_/?J<[KYZ[MZ+/>::<ZZ]QW@Q4V]4
M G3>O8)7A23"6M)9>_2T;F+6I<W49);\UHA@-=4EV%-NGHMPV)\X^AG_+AMO
MIBVG'DJK#3B%1]DDH]#+&.O2GR "=EY<<M\2W[E.1<;0=Z =HG)3#3+$GJ'1
MD5'S\GS2:T!>>&*<EW9?O-#C]!, 'KG.E" C[4=T<B+?A#G3_H-T)G7617]A
MOU5Y\&+/-Y3SZKBT<6U<^,5:KO,%Z'Z#90OZ95E)@+G]_.4WN4$RG*S%^GUT
M]92&VO/D7(N+Q/L-R+9..H5>5?6'"ZL\4AON7.^)?NH667K,AL/B';2.'RWU
M+7X&!S95-;]R51<5ID3*D-PHO7/Z*%U!5$J9:>N@?HB]['Z5&"$(%E=A$IE:
M>K<U6]TE)RRX%Q/YN@-_?MEC_D6\F<(H0&0T6=^^V]L<D,\)&:@7$5:&.?W)
MD>L#P;B*.^%_##*K#H\*2%-L=ERH7/*/]3)1\DIH1VC'.*1'"4:? &Q(W#E8
MRHY2 T'YH@(KMR#.Y#</+I5-<K*(FC6YA-\S?QOX/WD._)OG'DCQ)P![QH7Z
MX\Z[QMNNU/:]?=M;6:UB-<6)QPQK,8(EQ>YR:B*81$/X; $2_\XLF+B?]$;A
MSCP>&Z#=2,OI6W-7L=+7-4FRC=6MZVH.5&MQ^H")G+IO06HAP[9+E 3RN)6I
MV\.QMSN? $"%6G=\T3HDMQ_'WX7:A7L0;F#[Z)9DJU-Q]DSIU0,U@=/27-#5
MV_L?,TW2Z<LF=424?K0K<JA%]>5J]^4=)/Z19"-;?HHY3&]P)%FV7U5&BFN'
M80@] ;"-.5O>E=T>/R\'SS8XIITB5O#TF1,84G&Q9&43FCXM%,>>P+!N95_]
MCMQ<!>E_[B#81YI1D1#:=26PHVPTK[-U-8G2QE;;"I\BL(I045#+6GIPJR>,
M<"NTZ(A1RB6A/7;#?X.Z#: ?]O@RC"1!)#T5R.2]'AY+DWH47\Y8GM^MPS%.
M".IP&Z;-OG5=0#8-W@3Y!)EW<[&-P7PI;@Z7WC0-X$W$=TPK/VX+%&-L\);[
MM6DQQH6ZCOK(<&@QNJ.FB<Y<WNTZ5C-\R12487)]WE!B2T8[]/+W[R]=UO>O
M&_.1VZN5>E&]6#$DM[QPS)!XRB81>1EV+-*]SN4[<PN3K0J\N409R9_H*?3J
MI0UQ6IF!1=&PX'*GF BO4TE +Q+^YK?B<QOC'%YA+9FB0]A0#0"7*6  <-9;
MK4^H55PZ*DVUM9 J,0OFDBU'?N2@B<_.6-O0T_U,I'UL MU(*[!^U6KRA4&>
M^#&<PN,0AS.(**&>G]!;]5>2%[H#',;0.AL]YZNUR6%/,WC.E\$N?$-&-&+S
M>079_W==&D9\H^4E&,X;CW_[F!H*2AQI7=HX\2"CM+GFO/RFZO\\<$ZEY=)$
M/:08V!J/"S]-)M RA5,E*K_X+DQ(E9"?)#UI'[[?),&< $1_-Y;RAA*3NOV-
M46JANY:+$N"F%Y?0KH5,4!;:C"G2JQ"X<&6Z+K20<W9]J[Y8::P'+1$[3A6X
MQ3[F#1#7=%%D,>9C1J$+%D+XKL'3FZ[=/55_ H&8@E7@<HW6Y%]_R'_ZGR!-
MMZ3%=<?L:G>OKD<UP[]&ZZVS%"1HH:2&P?R1]<A&)'/-HX&1LI_#_OZCII54
MVA, =P0+^0JW,9\ZV]X/)J(D$<URQ_N:*:4PLW<+%'.R0B9<[4EM%ZUY(@N\
M&END[B%7'C-CQ5J*?Z:J* YS2]-7]9+\L?OQ_F[CW!D)G80^ ;*R)@H"G@W3
MML D@97*58;T*!&V!#/K9D,]N4+4_$=2]K__&5J)A[\CRX$4Q]J1WDJH*##H
MC1J_!7I(HFH7)OO@YBVF(]:^X,AKR("AAW$W7&768K-%E4J%-EG I<=:DLA7
M]:&O;(J2(2_U7N:AH*N>E_!/&__SZJU[H5UJFC>QL 1-ITN/LZ]^=0 =EAX3
MU#47V--V2O<4AR#[G9A%P?NW]SUXY.._OD$#DNGS1R+*[M=YMEJL?Z_.E*B!
M;Z$3"F?H##6>DUR!:CY8(V=#-&%;#E*CUG TZ4*F+]$/11P7M@^BTU4-8[K%
M2L^?';#F.WQ"26%-PG4,4D6@NZ 3#1931]*=AJE[,M;U_G9XD>Q!2RK]7)5.
MM3 6(ALC-A/AM2NV/L6%C>:[&EJ8MI!+[2R-!L=OE$(:I\,Y'@-O*ONT]M0>
M T7"NE7/:03.!I+P]LN<_"D:"V$?%&8& (P!]6O0^5\Y9ZH[;OI;VFFU*LVI
M7^>:CW(=[F^_,\S)SA11641N*\I>)\NJ!E2V8)S#'00[.OH3WE]MI%"H?GMQ
M$^MY.F(9_ZFO B+TQ7D*Y*7&G!V;'=ADNYR"(4"57O75Z<IWK;JA4.NM-Q*S
MHAS#.^O*Q)Y/HXO8QXLI13%_X*H$?R*6KK9/#M+E[T6*ZZ/*?@(A?H,6R[U)
MQ*B9\"B^YD8Q$\VM),V3CL4U\LC>QHR]$.R'$I<L2@,,9(3=;GP(YN!7KS;J
M.&W355%-D\1961%M*K$GPBF;M\TK$YEML6&P9<W_!A3((_6SZ%*$OK-HF"[.
MR%;X:;)5@(/"1&,)?.<]M^G<Z<35P#NX$#!:N @PGKF.]Q37O)=KV:&="!J9
MFU6U?68IF5OFV.OW[@[3? \<SJ=9VU],I&I3/^GR!/CY^M''5OJ+E$G'.<$V
MQD00?WN&8X4/Y]B>4'7I^>5:)S"_*OGPAT:UO-<DV&CPZCS3@BHV8,#?.7W[
M]T=ULF3X+Z>;&PLSXEFWUA2=3QCSCOY\,D'>%5P!LG4?%-$#YCULT3_MY80
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M$;$=B(Z\YHHO7#54S.'>E;;<FE"9U3(.)Q&<V%?*43A^*[>X,,[D(+85TM[
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ME^OBNWJ^D3$MJ%*:(Q,=<"F+\Z7(8H![9Z,21=K^V%G A.&:]OZL6/S2YY0
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M =/B2@+!;>DENC>YH678#G9[Q9&Q'YE^'6KYZ>SU-%6J]!/[$$MPK*N\8X"
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M_'2O6-ZO&)]1PF#K#Q5:GUDD6DMQ4F'5#+Q(HDS!4T)NS"X"T#!N6F/5\Y\
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MC=KFD9=1[FMFN(KL@;\.+F]V%)JRQR@^GU$ %!_#T&.U\X\VS@>_GP^Z5(/
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MY2$H?KW"$^=!RM E45AWO7&974AWTK=7*N)KU!SX?QNDO*??_P-02P,$%
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M:3SK)**,FK_W9;9=/8V\(HDW,C52]],;J=8;J)9_JE0*+;L$@SD;>O)H^*!
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M!07UCY,=PHUO$_ZTV0_ Y!IF7U9S7RH#*>@^;=33L^:EYM;= 88D_3X;,UC
MZ_4MMI1T _>3MX;$ERE?)4!L21+8'$N\]ACYXQ>I, E50623M%:7O<@P(ZAT
M;1#^*+<+(EF43+2O@%S;)X"9(-T-NL_ZF.WE#ISN^=1(@6HSFA&[7]]=']1M
MU)D]SIAV*>Z.+VCZU!,6-(DDO@/L98/]D4(--807:R1*CQP2GW==;YCWK(H<
MG/W. E?O! 7/'@X*(PJG/#D$&_.NUS]#=B^!VGEPH+1_@<YS2Q+R\_G3(&=(
MSQ=,@I^(9&5>ZYO880T^G9CB8']::;Z6]5W7:*?OQPU&AO1#A4F2E-#:0[29
M=IE<7MD";\YI_>=!C@13>! M6W)JW!"P@&H-PZC5[>&LMQHZP?(^X\;'6IZ5
MXW*!*@XW8D(O"M:3['?AWQ@IHZH1N5E]07L'./I%\(J(M931RS)1-CL$D5/9
M$2%I5I;>F#;BS6<MKUY2'9W;[5LNG!34/?O$DK-EF17>,UQU+)#,@WQ$54GS
M0G%J"6M#ZA-S:.UP1@!CK'.];L^VR[WA!H?Q$5_P2DJ((TQA[KSTN'D,#SA&
MS%>B*.%81+GK4XO#]G"WA8*)_$6'+GC].6KC+8"M'O%1@,5^(,ZM5Q,-&Y=L
MF2"] R!48C Q,DFXE,!JD-O;RF='+RZQR\F2S_O=T5_ #.'W^1[<VP5VESLK
M#DU%,K\6T7.=<6&SY;+FK[*QF% 6V4B6FQB(V)/1V3V<4EOHN7+U]NRC6!RN
M/OR#Y^#B5Y1D3FNPM#/V<OMM.UI[ K)J>,;^(:AR9%+BT64#BG0LG>AC$LE&
M<R&2;+3WWVZ>:M8YAI>'IW2)U_UM#CI)JZ_;E2-1Y\UI6W;2\)'V@#KQL5:6
M>(;?*]\=X^WM'8,G&EJ0LXG#NM"'WJ5A#1KGA-V_!.FYM6*Y0S(S@D0P'[6]
M\$WPO9^Z'^+[5VJGW$@=L*!-,CT]9"@;<IF7Z)9[VB%Z/QOBJXA/&:+%:06(
MBD_Q)(R32G*U46)W &/-)<=.!SGGY=VS<M+7L>D*Y+?'*R4?X@>!XA@IW1[\
M#17G)1X*K0"2S^:_Q73U2#G5#8U+^^=@[(DC2(L%[Q/P.PA2,S R]%F6HY.2
MTI_E(('UZ+]VAOH]0@^>?7[/%$N!+\ 421;_&E7 'K&ILJ"L+$T356 I[QG/
M=6P^[T]G>/'J!Z2PU@:5LFAJ.>$HG,)N2K_[MEM74)&+"Z>82&8'0W,'D%"N
M&Y(M+ M:1'$T[D/ZBA0).(?5-!N4[11T6^C.:<Z5IF1!B])SCO3;N>\RN)<H
M\(VL@"-TCXOCO,Y_"P'S"E?IX,$W'-RCW7L6X4L ;&-E-8U9?XKQVAO/?JT:
MQZ>-WVYHE(I.7T<@"H5 M\!5WQTA%Q,YPZ7SSNB&/JRI!ZTX(+&TFFNH@T.V
M-]P*@U;#CIU!XW+/4[=X1]YVM?+0'WNDD1D3,9&DCS]QD> D5;#\_'^_I.>7
MQHQIGE%E7=B(@*8?T?J^&2'BX_=YMZ&$^X1Z>3VR15K9]-?CT"BT>*XH4.SH
MNC+GHO.VL?H0G5MAIULC9O@&OY$X$;>J?A(PR'L;U$XO])6#5]6^57##..<[
M]VK55 7(%^:V+6'X^D>;]18ZO&>PCZ)"-": 3N!GQ-S8*V&29>IT;(O<1N0Q
M>S>"QUA77?2K2U;IH^>?];V1/>.V#[E:I<5EFIQ+7+.?))N?Z+6FJ2G2_70W
M541N6S/3\RU'IFH[[/8@RA4Y62+B@WQTL$U-]WY2C[[!=L'RCT7EIK3I/JQZ
MBICFF%HJ56+U7-=#L5]=>&.Q+ A:QN2<\8U@95\Z,I'[?'8'F*2GA"M&*<)G
MOR F^.9ELTM0RG> ;91!_"-2"?Q_)F3RP&>FP4KC=X!/LGK8BK/=@5*@#RPH
MSB@3)'F0V[HJ;MY6&_R=L+O#F;G.=80BE9S<B!S@0(7&O<XKHWUKL_8S.&;?
MD\=X.O+$](MA1(C^:P7:1$C)DU)_NP+_-K1VS"]MQ_TC+^3*A\29:DN5VT\-
M4 ?P495-P0UNJ)P*57^NR!>&H-(5UDYWD#[Y6M< P _O>$0PAO.'1M75:RNR
M?.D&ISQJ:1@,M?H1OZAW9,V$PXD JI6XO<0H'7FT'EM;-<4J:=TEDI\O7FO!
MWBP,I.;X 2IS3+#K?\8EG+^%$K=V@KA<?#'17QZ!6GULAQ?&7QFEVY,#_CDM
M2B=YAE2 )-VHLN$HVDCFG@"RPQI-/)_879K<_ 1]C?F;<C;S;MWV6\/+/(_A
MO))<#]:/S5K@!X8&VI$91%M]8-CDUVI[%]9<'O>*3X<"3!:^<4< HQNU00A'
M?#5[R[<7BGMG-:QY4A;5HU!7CUJF.'W<'_A5ZK8/SQS)-SVS(O;)>$&:])],
M&8T+G[UD%_E8N/\I;6]7TLXX:U]3CE>=MS?KUZ6DP[C!?*(!2E6H03KR]RNP
MN0$BP^P\C&8//KSRKG7S&8/^Q@>/7V/V$_9[=)$$+@:HH<?^EPFCVWC"!*7>
M$5I-2R1?.E:BAH@ODH%O>LZA6D(J6NFE%MNCK;ZL<0^XHO3:_I$]V@]W6F3O
M\(OFB1R4H%&$*L3CJI$02_G*4AM<4ZD%&7,6NS@]*? 9 NI$&$>K?>C234U0
MJ))!I4.]:=A,ZU:</YL+X_#X&3,Z?9SN/E&X<N;M//L\4W<HWCQ&T:RKU0[
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MC7/D3YY$L,,0_\JH\MYD>^ W#D8LK*_[UK["\W6L^C5E^,H'WI\MZYH_U6Z
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M0Q$/^:8F$6\27Z:_SFK8M(XW\%:HZ#GJ/"3^I&#O, -&SE#U:.[Q/@6/=MA
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MMI9KETDV-"P9V'8##;L%\)\KNQP&%E@&;)I(M6?W3!TPK4/:2Y:"4O7A4/-
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MU90PI3XD)XL#U.!IVX7,36[$O&0S<Q17!'%D^*M-_'OA!J$<D=NUPID>1)G
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M0F@)ITWVQIMVN \\S%+B10/5EH.-":!@ :CM_3!R-Q6,++PO( "C,@6O$T'
MKS'7QPT21U3G-=J[1H2>0)#.=BP%#TJ3TR-7!F=(H%CD*E>;R, BGU3Q%2-]
MA](RIK4?'=04N6MY!'&9/C"*!QW8["A%1WPOO+"5I)YH+9)KFO$*GQ%AL>0
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M)N2#9@4K7X@M*YR/7=5D:SF6-66>0+R=C6H)/PU/??('?V2:CIE"A?\ ><N
M:M&- 25)Z$;'(E#I-M97"V@I2$EB&))![*/;.\^0VN0_K6Z1R1SPF.2T('"6
M-:D 'L?EG3?+-OI5['-;7+:A)/:L_..1T"E4!*\15>3(?YCTR+^8?R/\CZ]J
M$]_$AM_,VHN)/K6E?Z'J!:BJ1ZX"5)6FQJIITR+3_E!YFT:S<6_YD:A;)#/(
MD<>JZ=#*PC38AY;;ZN"03LQP+%^6?YKR5=_.>D:M8%0 TUC/!*"-F7>[F3Z2
M,6M?RH22]6?6+[5Y;CD'F@MG@CMSQV_=E%8GZ3D\LO(OZ/\ 2N;'6=0:6U<
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M<NOWYNV5\\H953VH<=OOE$T_AFKT['+R_?PQ,-0D-N<6!KFJ,RDU^6-8GBQ
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MWN(P\%U9^H9$C:15F##<@$$[TWIVIG?/RIF2+2K%+MH3(BAE"%OA6OP ]SQ
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MOAEG?;-UKE9J>^;-09OIS9O'.Y?DE#S3\W9B@80_EOKP!-"5=EAH1] .#_\
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M;BS2   #MQ-3].,?6XK9ZR1TG< 1N03R:M I0 +3OOA(^K7&K2$!S+;1NR\
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M(D>*$LMU<*8TJBD JM0SE-@/>GRSGMQ)97EY;&2-FE<.TBAE"Q@CXGHP %?
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M3I6NV*3:1+"!!#&KQHH"^F*E23N12M :>.0CS/H2:M!<VEVB/:2LB.LJQNP
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M;^#3)7E]R\N]?HTM,OH):ICPR#*@_TW'OM]M_1DL,Q*^3Q=34HD^J6X<RDN
MG_GQSG$SVUGUUC'#_>^8Z"[5&OP+LW-WUEF;XPO,N>RVY:^KB[9^"%..6.?R
M@#>-XM?[O"^S"R9-[>/XXPF956WRE0.@KY"=MVRP!6,7@X0/B&K-K,W/Q'OV
MM?'SQ?(()<H:\6QQ\6RA=.2.0BIF=@"+[YPC)9W1"<G+FI57H.JE!27/H/DL
M DVI"V$89BZ>2Z=>>9G]2*U=BM)$;;])]B.@-=926XU^J'C57'KWTG(2/JR7
M*[\LM8=Y(/PNKW5I;[=?&;>W4OD,PGSUD.G&A^YYDJZ%?\4WH=ZW7&T2<I9!
MJ"K&_>=L49#.E^TDQPIN*G])H0[WZVJU-[1W[-"_:S95_7LNB5W?!H"M=^.>
M5ZGPW,:59VZ/ZBH66-!DN:'5?^!M 9<T)=);&86 -#B_ZR2@<&C8XJM>WD7[
MI*8H4= ;<:,KH["*) 7JE3,*@.Y3)V"RF&>_",L*.\+W2_2^[8]8Y7"D;:)7
M?E]_-\+Z","I (9B?',LIB=Y[N'J3!E7B]?QZ=.S>#J-\X\Z47%AWT0X:FP"
M'&A38])J:6+"*,(@"9#O]CGQ4Z8IMU1MBP*PI<B:*\S,,JV-%UGAL_=;6?6$
MMJ3Z@4>Z$#$O:#YBR/%WTJ2SU><Y$&3$W&B$*G'"=-,41&.+DZAF*V7>=_7+
ME/&)I66>3/E! >$NR:A>5IXM5E\"&;4KYE_K-FZ- -RR,@;6E!$Q6>^<G%?J
M JP:^SDEH=M]^N!C^C8X-(6_GM7N!7ID: BAK7OSB<R^+GTJGL(R*[ANPFE:
M^RFN;"%;%Z[6>"8.\NSOB>W]DU9-&"/9% C1T^)&)\:EK)D)NY'GUX:/@/PP
M?\7]:5QRB_B<G@G4,\[<XAKF\A^A)_/%;N?:>6[(Z:>^%A9ZENL0KEK($F1[
M7Y*]!%M+3_KD0E_VP!S6S]:N95/"?JR/N]E.[F_@0?Y6_IX/G_W-]F_]TG/L
MOYX(C*LE+W:WS=66) GO$F/3QNV>8AL<,F,?=4ZAD025>06/00]O8S=JR\9^
M/B>+M.#BQF..%=#A,M'1W1 YVU5(X6J!I%]]\JPK^69+A4KDK+.C$"N = 6#
M/E-^--&<KV/237!9/49].>-,Q,\WE<K1HF':-$C\[A"0J',\UOW6?#9E/0/H
M9SC97S746/AJ#-0(G@V/_PU:1$.D'=]+6P8%%Z" !X+&3V8#3S1G,[<EW_HG
MPS$Z$J0]S8W\!0J+;7FZN3DK%UU!W+52=1[B(EC(^MT;G"&F$&>[S#XBC (
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MW7SNK?A= &7#&IZ(^U@M0:B'I)H^'=;%V68\1EF*.-NQ\_R16L>YW3&!9DX
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MMNWV/B>NMS8G._UO:5OFQJW)%QF#$A5(@>:&--JM6'?*(LZB7T?76NMR*Y:
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M^<*#7+MQ^*0'3M$H;J6ZE@#F-C ^A-J^4GGS:H?-PUY$6#=I/2<5B[W&0T.
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M$/G3\5;^@XTRH1?SDE)(EVJY M&O1&10R>G\R7PF?^.'V"C8ED^]L*[)PM#
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MY(M_YX$W2?A./?M!GBYL/L?;,KP(5%K;@N..(D,X,7 Z(6>05^X;N=X3TE,
M;BB*A_GK3D]3(W?+\S'S^\5]H5Z./.IE7MYFNW<D4E*7+;!1VLHCPXF0EZWX
MZ\)[Q\O_ 3GY?M=IZ^ZD#)[1^&WK7F2548";ASDO9*+U$&UHS-HG#G%B.AZ
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M)G=IRG74GYGWY7=/^NZN8/MU3XF1U(00J+HRRR>VZJ47WG0$:DE0OF4_PR.
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MW,%7777(TDQ3-6((1E?6CV].6TA$<:PH+*\3)TRV!'0.GCB6TD6KM.0#^.3
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M"[Z_Z(3^T %:4[,!2L#VLQQRK<27H"S?ZO]Q@?\TE^J/ (G"I\6E2A[7\_9
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MK)S :L\5Y>LQ#<KV2/Q9HY62C?+?5U]'$52<AT88Q83.<^(87E/$?YX^1*7
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M_">/T&3$_#>&^+P=LKMRPC78QI]1&@!TAK+ AT_W3>QCN[FB[;04Q5?<:E(
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MNTMP=W<(&PON;I?<^\Y95\Y][]6LGOXQO6:MJ:[ZZOMZZGWY_0\ 35921A(
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MR6$ZPPY>O$.$*+M6E"@R?IEE4VODM<2#PH(J8NDCAN5'R>:^$(SRU%?1PB)
M=L0>"OGG-7"@DP36<8KTXUY$3HJ.+F+6SQBNC-D"I^6<$*59)^JV&($5F7>
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MTBG+H7PJT%9Q^J7>@=\*7\P-S<,V 7-)^\C7=I#$ DU"D^I8*;Q&7?<^[1W
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MLBG?[>]-1B(4(MF'VI&WY^M_+:6:,3BH47?UVAY^2]_Z"+\>Y!EN9A09+?*
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M%'! N'%(,%;(KD:K&$'9O77!:D%W,H5 8IY1<66QGD'Q0+Q8+ YH.[1'P7W
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M%88 \O?!@[%>8Z@B'PO'[I<]CZ(_C3+OU_&R"\<^#D=O(N_#H,_^^2$'G%[
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MHE%2G<>S,_?%+IRND*< 4B98R]ZBJ04E6'5G9%3R1MSU"=$:#2!-E+&;XR^
M]&A^8R#ITY>F-&+M8&*JS>:^/%.GYHLW=';<8H.Z#&'*6VZ0V$H,RD7UM7+9
M+[I7V:USK77GXTFV#-"1<$M0AM5KD.%+*E[UNI7MXHF4E"-5DLF2,:S_J)'N
M*V&IZ\)1QD&Q"9$K]@:<.2W&9ZG>7='+F 62QS'V5PV62%#0K07H!\Z4X-H_
M4K<LNIZB#"FW:1/+G#-F,M 0ET]@4P1Q%"& L8B>[)ZEN*.F-^E67IW7#>4L
M,2I[(B19?NV;IXO8J =_I6LE>I6$3>KATNW _:HWFMO[- Z>1:##@MRFBLZ)
MX]?&CL*F< A6Z^5CC!?C3QC26_Z33$FFN,]-%JTC?%:4/!6BH&#SU3T6:9.C
MHEF_L+7UJ?G,-/>6*ALK>#$7G_M/ RC6BQ L:). W5%#S[6(JZX7Z@891(S)
M+B*K6A"IYC(-"2M[8YVR/Z<\!S8S]G"P<PXTBB9++VI*CJT;+]6]^]+^1XD<
MV*3 9]06*NK+TR)SV/*@*>=8%YQ'P*+L<;J=!7NNJ?'3H$XG*H@@O!,@V"-R
M*!\% T'X@QGSJEI^^[=5 YM"&3^*24>SB1QYZ"?:Q&,OGYNJ[NN"P)?-(5*/
M>Z12JI2R\K^^EJ_$)HK#?_"AWDJQJIL#>Q^_E _QYP<:<E+DWNQ"\N"1V(.:
M5@@72=VR#O$P#^<ZY,MHM5>+E)XQE=*F#-[$; ??>OFH.;(G.G$H[G;B<*)+
MP:!MZKWL5*MF]L$G5P*W?IVO?)5\)C!.(3XL.%#HYJ=A-<?A7Y]K,5H2F>#,
M1T@2^5?*@ 03O-09-\#/#JYZA9FD[A+I$(5QK;K$&&1T?=T':UUTCZERU[&I
M[ [L5G5/JQ;--JG*B8IRPSXJ+= !P]WE*/WH"<C_ X1\!#^85<[+@E"&?P9O
MT4#T3,[HFS9CX=\>W=H.)Z[S,W57P8: &@%9:+ABX+QI]U!@+!2VOC83'=QW
M3^(U<( ?7GYL%PX4CLJ#R1']G ]&9"3,0-*W$-V;'G2)(^DP=U$_BLT?+@_(
M*8]Q:]:&&G/?6EJ>&I/'56TR,B?Z&7#NCB=>//(0^1:BV0Y2DTS\>8'E$SF9
M@C;";1:9YQQ)J@FE(T Q4Y)P>+1&.$.><4;2CI>QZ[>\\G%B7UR1/>IJ\EAY
M6;JQL?Q+7?6<;ZP=<]2'!K);8[H\KDT9JI!J.U[$7RP@02?S9^Z,)ZQ&^6MB
M'A597S99VWSH2LE"K$1%M&PP:Q1ED8AO<GN>)KLXLJJZO&U\>7*;\'U_%K<7
MIM)1* >@+H=%=WB,Z)A-LZ-^>11%04NOF+63#P'GDYNU6EA )YR@1^9<J:TA
MQN3>ZV8^11]+)Q"X=V2U/5F8#HC2/JMKTN5J5LP?)E2B'.F1E&_*HSMPP!%G
ML)11<Y(ZJ4* (^:I[])>/S/.64HI2%!GJ8L6LM WDW>7DMY>5NV4GOZ,=I_=
MDK(W>X#XQ))GSZ[[9+M<(^NPVM##FS5M&;0HQ4K0$C<EC(!."HZ@GTYYEMK,
MJM%XU!,@II3:<7./1&2KI<2&H=,-R(:*ZU. U0&U8XD\!\=L1M A76FZ = U
M'V"4C+/FQI98^>]24J2W&0O,TUN=2A,XJ_TZ I\'4"@J;2*A?.4A"-V;BG>S
M+3V8R@=P38TV&>%B??97W?KOM7!2N:B/1EP/Z?IZ1+2-'139O_$RJA,K;';9
M?O&R3(-IBEKZ]+W6+Z[%DX'4OYDB1=-ZUT2)='<^Y8C.O026K/1X4M6V6C_1
MVP6)8W0AK$GG!VLO@LKXDW#64_/XG[62WL-JFSA6_5^%"4HR8ZR+AG[QIDK1
M?2B6C1I>EG3SNS$RE0TK+6FNN[=RHM)?#C]'\,8VBF)A*D&MFSK</IP5-+5$
MB";8T#JF*GU^%C&_ 4GDE5!'3F<%0J;I^JP(-&X$'WI19'LS\JI3%.B+T 82
MM;IRA%:N&6<^7T-46K0U_:Z5H8C1R#;?:(HX @,1(^;C!"2QN_WT%CLQ"R:O
M/GC464/K<XF.9ID"W/.MV#L@O3>\VKSVFDY_C!F3OTO?G,0L7#8C(N)FEVO$
M_Y G>B)1B6+"CIT*0E/(AC5NN,/_US:RCU,(=$;^LO3VG-H<Z2W\L\@[H!TN
M[FCTDC["G]-ES6I@8+\H=T/U,P?-QK9]!)/RY6$SICI<GVEP0KM+N.4AN4##
MJ BAWMU?/N7Y^*!;[7%PK[4ZS +[\DYB/.C\="1ZP/VX/\#9X9&V6@8$S.ZA
MC!NXK;/[@E5DE*P<#R;TX[FA72S.52:ZQ"%>)DI%,^__[(31\NN#WJRAF_?+
M/IM0JGU(+W3SNWX\R_:N ^1W )M@I6^IG[9-LWK0.R"[(-_K9^$1O8M]XYL9
M<2[);NN1R]__T3N7;?X!*=4O,PYC1J.5DHR".S/7))ER5JM.FH7QA25^C8X-
M6W\B<M%G5E!\%/"VE]:P]/\U7=/]QBO!*XO9J 6G?>@M#;\7=0AY#2WH_)L>
MQ$X6\X]G9)($UG?G+KP]&"D)VRG04"ZCFDA/Y9G5;\X>^FWX[CF[C,0Z=@=+
M3*GR\6UMJZLO6JPLR^?4O;Z!4UQO-AMK0*5A79)$U_)OS5REQ]+QYSJ6D$CF
M-AYDNK(.TZB$<*:Y$KM&--0IZE>+#N3-MF<OS$SPZ8Q/_FT[2)0%U2);B/SE
M>16.FX]UVPKK;]^25K6=-B4;=01(R?D Y@[!)  ]5(NFR+&,3S?K)KQ-S<Y-
MZSNY2- ,E&UNU>*ETG->6</#%7+8B^6@P_N0 @,.\@4W7-!@*BYK1R2J+%K9
M<$$KZ9_%^5LB%[66E..P["LV4 ^&;QI8A5 >MYLNA>/N;D1-KRS2$7L_^VV5
M()M,C-VQQ+RI4NH*3<)+W?-;)>^> P=GS K, J6*^^CNX.>DRVB]TAT1I6XM
MZGLDJ@J5M0J;>[9PBI#8OLOAGTDQC=11-ETR0@R2*]MUK 8L%C9#B"S/JC)*
MFM\Z ["+O+7\TESV;.D[5?>8['4>Y75MHGM0W)5A7]1=JYW'/8I1KJ/R]Y^E
MZG\\ORGT8C\$E:E5K:509MQA5<O_-=2<R\9+$(]J2,5\V]Z%VMG53K>B@9RQ
M*>B&7)C\:>[99A<R6=0W36<H8?&0%AMBFEL*E\S[;,FPX!8YTBB@ S:/,E(L
M2> +U?B9P&Z+5WVJ3IS5O 43AD-AS;%N)S#0-VKKJ#X+WP?#A 5Q9P6@*!5X
M2E7PLD=.F4U- 0] JWOP?XLZDW#_=D*G %_<5\JM5T*0U&@[HO=*H6C.,AB!
M;1*;CY8G#>TFHC",[/Z9_>I(8#.S=B$N;'.5PV8:&^['0C.#B+(,7]SFY_&7
MK6(%G$KV>(H".3YFNCB_^L_Y"87J<(3"6T6L,%5C*G8 ?JH$+706J%SENA>Y
M];:4^UU%R5L$;@G0.C;=C"09$.6HC)IU.A;]2 MK*<AH?;5_'%+)+,$Q*B(W
M0B;>RYV_S/=^F+8UX;-?I9(\ D4\;:T6OQ5]TVX0U^@"B!'R24F'/$+-5J$$
MP?2P51!:W:U2VRQB\2 [Q]PK9W,$>,SN5@*Q@!R@Y76I*C6&RG$<=LI!0F_0
MK8O.;65NSD[.U9JN'H2J\L+*LC_@K6#-H4B6-EHOG>M$-J!IF 4!'GI-'8-\
M#)IE<V*<S78T"&F-$1'&+I6D&.STN.P]S#2RNAQ@L#J03H;!R<O@X0EE5%O/
M7E;+WU"R!.+D$:CNT_JQHCXWX=P\^O*KYYQ.E>(+YN%4%UIG9#+@\SUK6ZIR
M/5LAD(BLP2:?;H?5>72/MT12!_1_9L$Q(A2O5I.7KB(=98'5%TFU3XM$:3=!
M_MHGOLA!PF3+:]A5.&EW*T!\1#^F W<R@@2G&W'VB8MH<.4>:43P^US']9X"
MTD2&FG_>L7LIM^S\ /5*RA>*NP(W<\$=*IY_9$:0_ATP:>AG3B+T9G?$:Y<U
M5)[[B,49:0%1QM%OI[<BU9KD6+)<1CO%&*6,"/Z!;7"Y@VVX7$-,8!)@$F 7
M"^5C(,E44.1D_H$T#/37/?"@OP-!X+^T"3F,ZZO+$TYEZ^M##CC)F.L(Q!V:
MRHA#NIXL54!.\&/C.:M-MC606%TF9792YB>[.@F1-N>H$K&\=Y!+HJ[!V('1
MN,6B +H3Z*^6^,J0(T*$'DA6_ IU+W0#^:==*]U];_775U.]1:$^7K<QH2<Q
M/24OJ9()-\]!V[5Z4CZ\RFUVJ"Z(+5[U3\;^Y7@G9)RKN/$,NO#P5#BTB[@B
MVXKH"5Q$0*Y0EVIV(ZD26][OB@/?*P7(A2%,8S8Y/!"UG#^O1))\^VJ88TN^
M<J1U+3K=X:+DZUFH$?G? *= 6+\SLL2#N%C <*:[N2!VQ3RC MO9:OYFOK4&
M'2[&_%NE1Q:YF"0EB34!099O^!PK\Q:C,9++3DD<O=012WTS EI!5R(S3H'W
M  &R@G.J^2=)&AV"Z@X$E]>J9C&R[@D[/0$?9Y?#W.R^^&EU.YF$C)Z<A1U5
M"0510P4L["M=P*T[B@V R].ANM4U"VAA0-;6(:JL:^K,Q*(K**FB+5G\31<[
MO^BK/R]Y?-QJ'[M8D$UPW+C*Z @)$U""/4.]!V %-\B7E'2KSS-YIN+ZXM1-
M"\0].(*2L4(-2">^]23WZ4W.=PU;3$369-/VC%C&L3A@11Y*-,>FY4 1CW)R
M"_F=K"V=K!H%J$BN)O\ 1V^+D 8R'ED)!.R;*/<D=<CGEORZ;TZ;>*I]+BEG
M THH3#&S,9"?&7X?B\.E*C)W>:/,EI#.J46UC,BT6A)9@5!^CI\_;(5Y2T:6
MXDU2:<%Y;QHV^(;,7'[RHI3=J#YC;#+S)HCI9R!C5Y1P=SV;F"2?GRZ_TP[T
M#[-E>*PC@NX%=(^-/]*0JM :[;G8>YP7YI\OEYFE5?\ 1;N!7B:M!ZZ TKUZ
MH*?,9YBU_26I);/59)?4DC-*E9U8%@K'W!(]CD4N4^LV<L?HK#/];6&<,#1)
M G#C_JN0*'W\,)Y&EN1;2HZM>V$7  _"91'(\9J>A!K3Y'";5;9;B$30459D
M8QL/$T*'V((W]\*;L27,*2-0.UN6/@'XMQZ]:E:89Z5*)='6)R7GTXQ2 GX>
M7%@CU'7=25^G)3YEA-QH=@T;@SVZRJ'-:\DE:2J4!ZC>OSPM\P_Z38V,P3U)
M+B.A<,'#2(FQ+#K7TZ?3@&%!<Z+P0EX["<1!G-/@<!1R'\NX^[(G;\[?4+C3
M9*#ZS;O;L#L.:_''](*TPOY&&_>BE%=@SK05_?IQ_P")1C/H5^26JG4/)%I!
M6K6#<.-:\5/@#X&NV=@()WQ)EP.R]\088BRXB5Q$KB+# [+B++7$67 [*?#;
M [#$C^&>_/\ G"W\P3_N>_+74+CI75])5S_JI=1+7_8N /\ +/CGO_-FS9LY
M7^=?G]/RR_+#S;YN#A;ZRLV@TX'?E?7)$-MMW"NX8C^4'/@3)+)/))--(TLT
MSEWD<EF9F-69B:DDGKF Q0=<>,4'CBBC%E&+ =,5 KBH'OBBKBZC%5&+ 8(4
M5P0J_JP0@Q91BP6GOD1_,GS&_E_R5+# Y2?6)B"BCXB8J"%:5&Q:3DWRIGF?
MSGKB>7/+,&FR7#+-+$6D9?A+S3HK^_\ =QG[SC/*6A77DS\M9?-EX::OYF#0
M:7#)_>\)*/+*H%30MQ7I]E'\,+_*%M::3Y5O_.,-V+[4#)<6UM;N>3M,)$CX
MTIN\MP$7V5/?#34;>WTK38?+P NH Z2:O,C&.6YGXH\X9C\1#W#+& :?"OA7
M.5W%Y.VJZEJ/&LT3.MO&NR274[QI"M!VYRH /;.BZDL&G:)I6FH)&DO)I%FD
M (,JV4:IR/6J\PY/B6[XM)#%'Y%MK*2A&I2<IP3P%([M(I:A>B(E>0 J3MUR
M-:%:KKVI:;?,K?5;B2ZD+LH$KA922[@;"JN J]%7;Q.=RN)7TMKDS@*UFJK"
M%/V9G4,3W_N%;B /VR3U&T/B2]N[E;:U9VO;I46,)U1#L&._:FWAGH[R)Y.L
MO+FGFYO66-D3DY>M  :*[L?<[#J2<&Q:%K?Y@7TGU2W<Z=#<4AD92 R@A?5=
M0"*DDT _I7TEHGDK3_(]C>SLT:7<J0P6_->3--QK0^ 4 N?84_:&<NU^\EL;
ML2JWJ:C>"5X%DV$ J?WLSFOPHN^PJSD4SA^DZ->^=O-SQVL+SVQD-E!6J^LE
MO(.;'P4NS5/<GVKGMOR_^5C:?I$#RISN'(D7FJE:PE>"$=AM7I2FWR(?,&A&
M:TU2:$$_5X.06H-2G*52?GP/3()Y:T.%-=U"V5 RPB.)P:  %'N  33MU/TX
M[\Q/+S6NG7\7I^B['TY*;@>LBNE.GB1\]\C_ )-TU[ORP51!(\+K+#0T#O'\
M;$,*[[^'6F=*U+0C=:-;RR+2-626*9>BDEB1QIT-2?'MGG+\QO*%WZ8NX;<+
M<!F>-!7XY8V^*.O@X&Q\:'OG!KB$12B=H7N%EC;F./Q36PXCI_/'7:GA3(EJ
MUC+8K R2^KZ/J\)%W$D),;#EQ[A9#4^%#A3R!4VLC?#<!YH02/@=MI$/4;G>
MGB*X3V_-KJ>VY+) LBNBTXUIQ#4KTHP;Z<9H\[Q1ZH7=/6FBNTD%/AXO5FJ.
MX/;Y^V3'ZT;K0-*$LA+FWDD=1NSF!RLAX[&M';Y[X4!:Z$%C<2"V926 /]WR
M*AA[5C4GZ:X%T65*WUA)LET)8)%.Z@*:+N.X&WTC(GJ\OHZKI]W*1(Z2A)54
M$5<$?*A-2<#ZRA$L6I+&W&: +(!_/$_$T^E0<]B?\XYW[3KJNGD_NT595->O
M,U49ZH*4%!OB3)B#I]&!F7$&&(LOW8DPZ[8'88'8'$6!Q)AVQ!P,#,N(,IR5
M^0/-MWY#\Z>7/-MGR+Z)>I-)&IH9;=JI/%7_ "XF9?IS[A6-[:ZE96>HV,RW
M%E?P1W-O*AJLD4JAT8'P*D'!6;-FSYF?\Y]>??5O?)_Y:V<U4M$;7M2534>I
M)SM[133H542D@]F4_/YRC_.F*#'C%0,54;=,>,76F+ =,5 Q11BJXL.V+J,6
M5?;!"KTQ=1O@E13Z,65?'!D8K3;Z,\R?G/K$=YYCTS33(#:Z9(LMQ!7XN-N.
M94^'+D>_09Q\6-Q^9WYE>7] N"6M&_TC4&"T5(DK-,:#8;$*?;;.E_FYKT=S
MYJATO1"3)%!'H.DVSJ.%O)+'^]DX"M#'!2IZUE<]<BMS?6.B-IL$95;31H8[
M/3K>):M+* R+,=Z$L2[%CO4L<(4DE:/3VED;U'M3=3DDE_6NC),_>AXB8*OA
MD7TZ9K>%=7:1!^C;^&2(R+S5KGU&6- @'Q'UF0_[$GIDPN&6\U336BNGM]+T
M[1#.KS5=AZ\KNPXU!9B:,P\.I'7 ?FC4K672-"MHB8$M$N%"!Q5BTT\[L2
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M"NHV^7)#A%Y>MF?_ !'I;$N7M9 Q.Y(4%T-/HIDI_)FX2+SCHTCDAB_$==Y
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M V,USU'T*WXY]$^M:"G?$R,#.,"N,".,"N,"N,#.M,#.,#..^!F!\.N(,/?
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M1RAHV&U#&U!X;Y]0?(&G0V&F7RQ+Z<L%K!!4=. %-O<TQ&ZL^;2<0/&O@?\
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MR<%:J.02:,:#X<ZO#9SW$;"["BXMY/WI %&IMR%/$9Z%_)[_ )R"\V?EY/\
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M-=0C:7C_ +$;YPWR?K?_ "KCR+;>9["6TU/S5YU4RI%,1,L5G;WGIF*>.O\
MNUEY4\ ,XGY9Y?\ *Q_+.BW42>GYEU%=.$2CBB17[")G([L[R@ GMG39_)^N
M?ES:^0K;5O5TV[DFUK0I!(E'$FCZF]G*I![C;.I7VFQVUK.#()+BY] !F)'%
M'V 6G4^_CD+N+21(Y4/&<M%-+<,]>8CJ%'WY(K4"6\TFUFD5$6T8< */T'Q,
M*=,"6,OU?2;Z:WA:.UB>BM(=FHW%V'SQ#]%Q^:KJW"6I2'1H)&F8]#(WV%(/
M^3D>MOTIY0F&LZ!JDUE;D^O%20H> :CQU!ZCJ*YZK_+[_G*">VF&@^>[":58
M@C1:E$I+&%Z<9)% Z#N<]AZ;K&FZY91W^DWD5]:3*&62)@10[BM.F+2$8"<[
MUP.S8'9J8%=NN!':N!G:F!)&P)(=\!L<#N<#.<^GG_.'ODLZ#^7EYYIN8N%[
MYTNS)&2*'ZG9EX8?OD,C>X(SUOFS9LY9^=?Y?Q_F?^6'F[R=Z:O?:A9--IK-
MMPO[8B:U/+L#(@5C_*2,_/Q)#+;RRP31M%- [1R(XHRLI(96!W!!RQ[XLN++
M[X(7%E^_!"G!"D8)4T%:T [G;"/4?,L=I;W$NFVC:T]HXCF$4@C1&/\ E,#S
MIW"5(SF6H^:;SS%I]U;SW9M6F4M'9I" &*FA1UGDB9PPKL,+[;R-;:SJ/E_0
M[N6'R='J8DMS)?V[6\DLL; -'';PRRTGI(&7U./(>-,*-1CBTJQU>'4XIFO;
M/SE#H-W?']^)[0>H3%%,**"IB+,55>H7]G)CKU].?,>L:6EP/\0Z'H@UW3[Q
M^-M+%$BR32:5>1Q@1RQNOQH2 5+T/4C"W5I8;;6O*TNF:01Y?_,[RS]<UO3+
M",-"&63F+F")2!')0*Y"D '<4KE7&F64/FF37_TZ/,7E7\Q-*31&O_3*S6]T
MT:+'%.J[?8BV*C<U'7K ]'MK;_!)LM?U,6\-GJ%QI$C)"K36-\JN]E<+4U>-
MWC9'% 5)Z&N'WDD0+8F"Z2WD\Z:/>+J%M$5B:VU;2KB 1W=L'4D2,>1).S#I
M\)&TE\ZZPNL>5?/>A2$SMY+U*&6PN;D,;OZC%/!<P22UHU88Z@DT^&M:[X3:
M-?1:KY:\M:Y)+J>L3P">WDNM,E,=Q#';S< S &19(V.P++Q(VY;8'GL;W6M2
MGNM-ETWS-#&0Z2V4J:+K4-: QB%&CYGB>P;E[X<:)=7%K97-G8:]J'Z#TV3U
M=4\N^8(S=SV!-6$U$*L8JFK$4=?M<2*Y(_)M\+#S,UW86,6B^9;D!F0E;C2]
M6MI2> BG^$HU1LW&G[+COG0].TE7N3?7&@:EHSZ5,66 I&)HA$Q8*(_4<,8V
M9N$B-LIX4*;8';6[J6_>.W\WW6C0O$1+=QP*99T-/1DNK<R@JBUXM(G2@J5!
MQ]T]B+S_  Q^8-@%O8)(TT[5I+B8K<+/\7&WOP(PA:M/2EZG8,=CB-KI'F"R
MO+R+R=Y@@N;FW!$^F7SR07S0 N%AN;:X!0TK\$D9CKXD[X3WFD3W2C5?T')#
M%&I$U[I=Y!)<-0;R"*(K,U>)Y;"G;XL)KV%6AC_3"GS%H%_$%BNX4#7+6[4H
MP*CA,  Q+ ":(L=MR<(IO+VJ^1YOTSY;UZ>X\GS.WUC3H[Y[.XB-"KFOQQLR
M]5-.U",Z)<?F!Y-M/*VC:+KGYBZ)KUUYAL?K&DV<MTEMJT+Q\N::@TOIPP.I
M7X"S@N:<0:@YWK\MKJ_\R>1I-=2=-8L=$NX].U"YC='DMWG4R6LDP4FB3*"%
M?IS#)U J;WRLJF:E.Q#;@^!POA=%)_=%4/=6)W/7# -]DKRHQW(%/U>.&,,S
M+"6H"PV)'\:8&FNUH1'R^';P /B?IR-2W0]9Z.!4$$=02:;5^6%%S*#Q?B"Y
M.Y?L-J8U)N7-0"5Z[[?3[X%N%H.3'EO0A0>W<G(AJDH#U44/SZ$=ZY"DC%S?
M(_$RLS$;^W7)7?6"+  NY*CD#VKV&<D_,&RDM- FMP*QZ@IA<4IW#"OTYY.M
M]-DMG@NT4\;)DMKE>H5'KZ3_ "Y54GQR,^9)'TJR\G?F'I\9:[L[Z.VDN.54
M@OM*F2:):#NZJ"*Y[-_YR>_-/1_S6_,_1[_25&EVMC9WWFJ*V<J")]=FAO95
M6@-6+HVQZXW4#!<R>78H ))+I8ME'(<7+-MXT!J?GD#NY+B1[Z. ^LU;F&8A
M11%YJJ@-X5PP$!MI[H1!O4D6$M,"&*QE!45'05KA8DS7<6GZ6A]"W-\Y5NL;
M\22#[T(KAMIUG<MI.HZO)=2*%OV695;B'0_ 78^P&5JEC:/+;6E@(KE&B$K<
MJ&-HJ4"%>Q-<B.H>L$C32.5W=62,OU<D">.!OM1"NSQ^'ADK\N>8/./E.^TZ
MY\H:Q+%:7T(EC@F:L*W"[O:R@[ MVSTUY7_YR9T.ZCBMO.5A+H=]ZAMY)44M
M$)5V*L.JG._:3KVC^8;-+_1=1@U&U?\ ;A8-3V(Z@X-8XBQ&!'8;X$=L".=\
M#N?OP*YP)(>OA@9F!PU\L>7K[S;YDT3RSIBEK[7+V&SB/$L$]5@ID8#]E!5F
M/@#GW$T/1[+R]HVDZ#IL?I:?HUG#96RG<B*!%C2I[FB[G#3-FS9L^*G_ #F+
M^67^ /S;O=8LH/2T'S\'UFU( "I=%@+Z(4IN)6$G382 9Y1!&+*<64XLIQ93
MBX( J=J8!NM7M[201<HVF(% SA5!=N* TY-5CTVWR':]KDKW!LKE-0TR[6)N
M2)'+P:$U_>QS#A$:D']JN;1_+=QYGEE:?GJ TI );S7KY;5(HN2EC']6AJPX
MU8*C,/<9T"3REY9T675=#T"\G?4X;"WG-T8>4\B13$26L%G"_*.9$*R<HY/4
M[_$*X8:KJ%KYH73;NPU.#6]8T>.VO?J]Q8I!<R/&2D4L$D:JZT8\7(+ '9U'
MQ4YGKMSHNN>6X==AM7O/+FJ^9+6[U>QN$:W:WOA)QEFC:(QE3R<+-Q/%ZGHV
MY@>M1:9IOYA>>/+M_?W266MZ7+'9ZQ(AE^KVETI11=K3EP@=3&[UJ%6N^&#:
M.8]%\KZK>075CJOY<)-I/FBQLY.%Q96UTRM;ZM;TY))$K<26%492#TJ<D4@B
MU&76M$ET^UF\QOI_K3FWD6"R\P6#M6#4+-57A;7D)0$LK4YBAJK<EY[JE[=7
M_DKS1KB*?KGKVD5WJ20JZ7$UG<Q!&O8:%K:Z'=ZE9*$$UQ*TATS4_.NB16\:
MZ=)K6A1:M.;;]U]6U<PO(LEJ%6@$K1H2E IJPZ;Y-M)U[3IM+\N?F*+=)X3Z
MGEKSOIX55'IW!EABD*@U")(P2IZ(P7L,B?E#2KGR9;^>?*=E+Z;Z)>6FIZ)J
M5G<$2-87#L@*!58D1?9D4[<@?:IM=VNH:JCW!-GYLU$A)9()HHH+YQ(S R6E
MP"!,%"T/%^0\*[867,E\?,>BKH=[?V^N6\9MX]*\RVGU6682;?5H9Y7XRJ1\
M(4GQ IRWD:1Z'IEG;7UI;Q7&F33BY30-7#6\EM<JZI<VUC=L2*"2J/&Y1U4C
MD#]K)CY?UAWN2MO'JNF _:L/5"--%L1'!<SF3F5+4XARQ'V:],EICNM58:)J
M#3^8=-CE1&F],VNM:4]:(X9TYA3RX\A53T:@PEU;4=6\O"?R_=W,?FZPM UM
M<Z0(^%P;;@"7GT^=59^-=VMY?AZA:4 +89-+U:SBL--U_46@LU]*PYP_ICZ@
MLRE&BAU"'A?0J :^E,NW3CWR5Z?Y3U?1_1OXM4M8-?@C$5S,\Z20W9A8$.ES
M$Q(#**\7'.-JBIZ%NH"*SN/TU':7FF6&K2J;M+6!GL?K+BIDYV\AB-:;NC5K
M[Y!=82ZFO[;S3I]IIT3W$[VEY-9_\<ZZ,O2*\M+@![6=Q\*R,&C8T#,M1D"\
MW_EW.EU<>8-%T(:AI<8#W>E7<:F6SFD7_28Q;2?$\8(KTV!':ASE.G7K>6F_
M27D^:]\HSM-R-SI<TDMNQ&ZVTUL70%"PJ VX/2N>_?R$\^ZE^;VG3Z1%;?7_
M #WI+'ZUI4*K'-=6_$%+FS1W4RGJ'B5>:]:$5ITJ"*SU2WO+G3H9DN+#4;FQ
MEG!-/4MBD<D8C(%.$H=23O44[8^&*383(0Z$U KL>E:?PIAHT+LH8<%<"I((
M7_;PBNHYZ%?LBM2 :\B#\^V1FZ)@E9W)JW7V':OO@)Y6>$<E(0 T\*$[?JZ8
MFGK.?4-:!?M;[=:"F")&>2'XF*!?A'+K[^&1N^LI)"Y,7P!40*N_ @W;:O7L
M/EA;H^E^K<O\'$K]D^Q.Q'SR476G[<N'(1,/I(SG7Y@Z8VHZ)<A4"- ZR$]U
MH>U<X#H^H0>2];_2E]Y2@\WZ!H\LMUK=E-5!>Z+>HL5];OQKP"-^]CD6K(]#
M2E<,?)'E[\K9]7\^_E7K.LIJ'Y6_G-I['R=YIN5*3>6O,,3"32Y]0BH=U<M!
M<4-"IYCX<XWJVE76B^<](TW5HXSJ#^7K;1;F2-"];S2;B2!W0M0@, *>*YZ#
M\OWOF&Y\I&ZN;..U^J77U.V5T',(M8BZD@&@(V^_.=W:O::AKNF1"I1T4N/L
M@EAS"^/3#&2YN)A<6FDVD]Q";*&TGN.'']YR)6B]ZC;#?TX;>_LP&2.TL[1I
MI)*<U]<@*X7L:';;OA;8/_N"L"\3HXU-':$_%ZJDE@Y7P!.V:&S%O?221S^H
M&NY()>)V(?D12G@1@0Z5'<6M_J)B>UNY97@M9NA01>!'RWS*3HEE;:IK,#2V
M6HTM=2M(6H3L&BO(_!@<$.EE>+-=/?6]U$ L:W4R<3(1]E;Q1NKTV$@P"UUY
MC\F7$>N>4]8;3YU'K7%BC\MA^TR5HZ_Y0STQ^7__ #D1I>LM9Z1YM$6GZG.B
M\;R$UMI"=OCV'$YZ066.>))HI%FAE')'0@JP/<$8'<GQP&YI\L#,?QP.S8&<
MBGA@-SUP*YZY[6_YPS\@'4=?UK\Q+Z"MIH"-INFLPV:\N$!G=37K'"P7_GI[
M9]',V;-FS9YK_P"<J_RM;\S_ ,I]6CT^U%QYE\JDZSI7$5D<PJ?K%NM-SZD7
M(!>[A/#/AP#BH.*J??%P=JXV:[MK:)IIYDCCB(5RQ)XD^(4$]/;"FVUE[A T
M<MI,LCN8;FUN6:((BU(<-;DA_8M\L*WT*:>:.^O[F$Z;<@BV!T^.\G,TOPT9
M99B4:G3X>7TX9>4_)-G/:>9$BM9;K5M MFN+/39HC;6MS^Z/[N<(Q:JRJZ'P
M<?9H,E6IZ[Y8U:"UUR_TB2YTC6])A6XN85>4+$>(F66(45WMMF>-.#&,-)&0
M4(PDT^PDUV\NYM:AFU"?2!%)/)%&)]333V)6WF1@%CU*S5_B2>,K<15H=ZU,
M[NXFTC6;"#S#%!-^GYX+?3_,EHYDN8X]09K=;QY@M)U7>-CM("4$O,<7P+Y#
MO+[1O,'FCR]YDT\77EW5GNBPAA#I'J=NI%]'$A[2%?6"=>+BGM'+N^O-3CT3
M4M,CL(//GD"SFMI[4\I;;5M)N.0)YN7,EI+'NCDDQ4*2?#R*\^U#7-1T_2=!
M\Q>4X"EYI<MQ9V]FLG.]T=;0%KG3+E&+&6S=';TA("4*E8RR&F)_%>>>_P L
MX;6Y5-#N$(L0B+%5;IU-R@D'$%"5 5>BDGC1:# ND:E%;:#^8?GN;1H+2,>8
M(;"YT4M(L$]K?EXY].F6M3P$)8.?B5L4NM-O7U[1[71[Z!;;R_=Q^6](U*]0
MK>V[:C EYIL-]S]-2D3RND<H&_N !@)_--UH7F)]1NM*@DT3SL6TGS1I<\7"
M%+^-Z7:F-./%F*\A0BAJ1XY*-'L?,%OYETO1K:]8Z/K^E7,6@ZM+$+@7%LA$
M\EE=$GBLBI$*.:\E'+=@1@2[M)((#!>6-A-!SD-G#=,W"9B5$BV%RA0!^0J4
MY GKPK@:P.D>8K:ZT/7(O,.D6]JT4159Y;X64KDF.1H)HN02OQ HP;;8$;8K
MK[WUM)K5K(VG^;;O3&@_3MG S'Z_'%$HL];M0.+<V7]W,8P2* MNS4C.F&#4
M)K2]L?,PT8SSJ6MM2XM9J5:OIR2?!Q))H#Q)'7/2.C7?F&XTZ>WO;K1-0NKH
MM"O/4GN;N"%E"^E'+'"DA7B :!J]SWQPB\PSQ7%C=RZC:Z-911748DE6^CA,
M,E/73ZU"MPJ*P#<HYVIO4 4JI?6GF"[NRNJ^4-#UEHY$2#5;:RAO9)UE^-9H
MD]>UD>G=2&->^^![V/RX+>;3]5TO2[B.-_5,EC%=:-?6\JA@4FMRKT<4%.#D
M$=17"C2K31TN$72->O-%OYD4BVU"=-1M.3CB!*\='9-Z?O8Z_P K@Y,;*SOV
MFN;BV]"]N'1K+6--NN%Q-#$"3Q7^Z%Q:L*F,%@RU^"FZ8CYLTT):VUMIMO=Z
M)!96I]+5(/4C$+J:/!53+.JD$^F?BV%"O?//)TFP@OCJOD[7XGUIF*W6DZO#
M!+'><T)E <QB&E.BRJIJ?A-<Y;KNKM#YAGOO+UM=>5=0U"PD].W@N6:6.ZMS
MZC&R?A'(C50E%J64]&ST)^3'YY^9-,\O:;9:QHL$'E&:<+IFKW:3(I$S4X3W
MS%E661JEA*2.9)#+7?WAI<MIK<$EQ;(\%U;\1<P3KZ<\!(J.:?M CH1L1N,%
M2V?I?:C'$CPZCQ^_""YB**Q(0[FH Y$'M3OTR,7ELC@*H ;?ER^(CW/OX86#
M3992J+&./*BG<%O$G);IV@P^DRGE5C^R#4_3AR/+]N$Y&%*_LU%33WKWR+:]
MHD<<4A**JGH$ZFN!M'\N_5H?6=/CD(DW[!>@_'"WS);W*65S/!:M<-$>0CCZ
MGB0309YT\X>8Y8H)+J+G&X!!CVH? .I[>-<Y%=3ZG?:)YDU&"!+;5=)TFUU&
MYB"ET2UNKOZN!*I-"K!]Q[YSCRH5M/->GP^;Y!8>0/.UZ-.76;52RZ+<N##'
M=\!L5AD-70_:CY#.A>>].T^+R_;^6->GEA_/3R5YJOM(U#TBLNG7&C06?JQ7
M=M<+\3%GC!4U(='0]LZ5I\+3^2?*LJ^HDDX9)(7^TRW, /,5ZT(Z^^<^UR&U
MCN2MD'NIUU"6TD=#R60NRA2I'4;&IPUG:^M_J_Z/C!M+:]DA>.'[4[6[<F;E
MX<7H?E@>X@M]*OVTZXFBAABL+PB%ZEN3$L.AV/0@G&WI5[?4+EX# +>QM+F&
ME1L> -0.E*8/CD@FOS2*.&#R]:&1T<\?5N[A248A>P/3%[+3Q:^6;>[UB.7T
MM.CN/K*<JD2,P-0!W+/08CYDFE2/3M*E,2?7$]0QJH<I'PJL=>Q-17(I>6M[
M93_HV4%-;MH2ULCKR2[M'4UAE['B>AZX MH+5(_(DVL7*R:9JWUFRFG:JM '
MJH0L.RG"*3RO=Z9<31.!!-8W?U2X>O..6UD/[BX'BIV!ITSIGD?\VO-7D%;B
MWNXI;W1M)G$-Y83DEE4_M0.? ;@=QGMKRWYJT?S?I%MK>B72W-G<J"17XHV(
MW5QV(PW<UK]^!&.!G;Z,#.U<"LWT9=I9W>I7MIIUA ]U>W\\=M;PQBKR2RL$
M1%'BS$ 9]K/RO\CVWY=>1?+_ )3@X/-I]N&O9D&TUY+\=Q)7J078A:]% ';)
M_FS9LV;-GP__ .<L/RD/Y6?F?>3:;:F+RGYR]35M**K2.%V?_2K53L/W3M4
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M+C2KC2/,ODWS-;1:K<O'&C0VUZ':1[U4!2CDQN90#%,/WRFI*J#UW1[KR_\
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M&L1*+!KH:<\\,#,] ]Q=TXG@.M%7;QQ*[T)+>"2QNSZ^K:K;)>:CJ$Q)-J)
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M6A2NW"EW$"&A+4^S+&63?:I5C]G/A#)#-;3RV]Q$\%Q;R-'+%*I5T="0RLI
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MH+AK.Z>'X@[L.,,0Y1N?B4J=^)9#W2Z\NVUWY>DO=*U-+Z8V4<KV=N5(N[R
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M](V2@5ETWS!;?#+$:;T9E^[(+I.I)=>?[**Y5[*TU9I+'4(AL(KN<%'*^WJ
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MOK*YKQD3U*LSBE-Q(%;]XVCL-?DM9[C2?,6G7VCK(L=UIWF6!I_JSQK4PS0
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MT+11#]E%E('Q#':F)M+DT_16@?3KP*7M=$MJ2_H[3II"Q-RYY^I=2MP=F8_
M%"[A68*76H7VD>7(;NU2XFAO[>"[UNR96YW45G<\+&\454'T%FR=9U 3P+ON
M(Z)21;J"%.F]%^G2F_0>FH#44*0$"%50BG1"#[V7$&KH34%Z$Q) NB)%@J D
M%!,!K_\S=^Z<,^=^V'F^[<[L[+S/[YEY=]?Z:T%O!W6#9S'S+*/Q:F?ROH+@
M[4:/9E=ASDYM*@[Z;@FAYR'[%]B^IFUJ!_:3'M+.Q9_]!8&N!Y*2&*#48U]I
MD%MJ)/.QS-<[O9C<DNPF.8)#]N*')U3,6 $]V,[*!?208>TBJV:H[L9PH /'
M$$N?:.82:C 17^9+8^%T4ZW=*H/=K+[)JH;4+%OG&K!B2)J7&SDM6](PK'ZF
M:(MP_8\.4G5?1IR>IT79V&GO_13!KW*#>U>$?7T5^[P:C>J:72A'WBM8O#17
M-#  5@9X%BWK]Q4S8YNQ<^06HBX$1Q.8IRXWTY<P"N=;Z1;4#V3+M@>#2L7&
MG<#[1LI>- HD_4MX[]Y24J_FP.#EY =E9,IB9!D&MZY?;89K=*Q<9>ZY=_?
MUF>WG)"B]^X9-3@6/N+41.;T6"T%/*CW_0M@# @P(3\,(:A KT8IVM<W(/XB
MBEW[_D*N/$C8[NAA@:51')'N8_"N#%7W4=&* U9*V1VKU+4W>]S/0(B/"00C
M\**F,,TX49]=KEDW+*T95Y"XF I-B^4?!2@5;Y33_-X1Y&K@(/E8C5)>3H-A
MK3'ME[UG2)VQ8DA,@PDF1J/VTG>(8O/V.QEX=?]E@'0C]6R=UQDH55KGG?3W
M-5]G6^.WX^<YE*=\E7[F7.A'HCD1']S=ZS""=9BUH5R5H)95!\?5H:9#JO?+
M(=)\MDE+%FC+U_4_)*SH"$O'NWDT-JIU!B#*V;K!3\<^HFP7Z;7";:/$66IC
M,17B?<:L4N![' [62]Y<W6852HW:)J&(CGE!+[/\'S\'[CVN[(0%^K9.6UQ/
M'K0W?Z0>?"+6,A0+$I902+Y6VZ>4#\Y3Q=TO8H@TTH8R$7().>^^X#348L3T
M6HQ9<H*]!?H7#W#WJUU=SUF8_@+.RCA8S%0'Q=2%2+4]3:KT?C70T-N_5FG3
M>NAH5&$$8<OYX3[TR?OG\,>%C0U*M;7KG1<3RPBA-EO$Q^=RS8\X7P3?B9HT
M,F\;M)&"^(D\:<5IE@IS&BZ[<GG ^OFJ%Z<@KJ87(?6GQ#1\E!>Z;.1T$6,B
M^P5@/PF/KAO]E>/$E*,U*^8ZXG+MD8@+!"\[X'91++)Y_ NG68+Q LV\>=^G
M7 QV@>-:Q:<RL!LE;<^J0>47XO4K%O+D27<7 _UOPQ%>2_=I^9ID$/WB*OZ-
M%LRSEL&+J)NL8?\(]9KP::HZ6S&I7S\B^A;7%_*?(I!((*7;MO[*U_R;7PZ?
M[;8<[=>FZ(WH,^T3%6U]UG.BGCS3>N2):BZZ&@HO\^A: Y\@0"'<9VI&IFO[
MS(=\TRQHH0PE9%:<4-1]8ERE[.J(L(+QIXYC.2'P-(DOTZ/<Q?UQ*U$I73GB
M,%HQJZ^ON)Z8I-Y.D^#E#BSQPLUG*B)<_?T?MWDIVQ,("1T^IFP(:]N51E$I
M1Z:D']7J=1?U55;8/LO!J[8E:<13^^E:B)%CS!.T4$4FD-0]Y!M(*B)]E%&X
M( $O/3>ZAS RQ@5LX;W8?LV5UWS>%&EVNE?P@F'Y='M]EF[H?NV=JA69M"OE
M%>FTR@"%"X,0[!!NBX59'\>8=?93_,8%\L+0&.]H66J$&]A*5JR:P*XZK&_J
M<;=GOA,4DAC#!,, 'D:E?P&R4HZS SQCE*"Y08T5%6$IG287';_%M6'2975:
M4I.S/Q"-DI0D.$8J>8". 2'V!KMR$S R=Z.V[".,W%;>^.[KPI!+&,@H2:;I
MT)"/*TI^"A7I-V+@1Q,)0NVC<?Z*W\X+^I=VC^\!/>WFE6YRN1>:'W;9B&B5
MX&QG4M&ZC[FBY47PD_T?RJ/L9SH)FY.X^WE$IUEG$6;6FVL3"-.F]H;U=S05
MA>+2GV.*_DROR696XL3ZVU$=S=*@M;?)]'&Y=>R=J+=MXCM83=\?,PROB8EO
M;RN08+-_^$;L'<B]Q6X^="E854MO2 ",TI )-(P;-XA)SQ> ?SZ%Y.'NS5IQ
M(TZN3ANU+EL[M)G##[G"PWU2U4XU*!3BZ.>?>Q'H^PZ9#(;R7YK5:'OGY@*%
MD?$RU(TO2>TUF71==V;*K@0';GD5?845S\XA_'U\[B#E'7+V]GK3QA;HQGQ9
M=BUR=1\U6)\,)#SH-J)^1IB1MV,#HGR*O4TOM/AIC" 2C0'8/]*N6O6'1KGZ
M"-[.P94SQ',@3T4>TTTUUR>IHIV7R"0N"TO,]$<:*O\D7;!RL[,!&A$IT^Y_
MPX<NIG?JLK5]<:IZRP<^&IL&,#L<3C[Z<^0H[<GJ/!#JMB3]8&7L#E"3I>PN
MR20@Z;:>P!\K&NQ>-NP&P<7P9=VSQ%KW9U/1\:/L #>NGZOFPH'ED##/LY]\
ME,]):8VOJ<&!WB<=7UQ+CV__6$R*=M-6'*E*%9R$@8MA_9=Y7>(;7E9D7LV,
M[)S R\;XV@VG>S#1 24%+6P5CUQSQWHBS5')4I*RAA;S2'T3('[>M!_9M8@P
M0=EC1W<GJY['EEJGK34+L99AGFWEK]<:.-L^I$T!RI8N.EHNZ?[+,?X1HA]]
M/F:IO_[AWMG7NR@*?N?<<2U=.[^GL IA4H40$?QU)5"5 +Y7&1^X!YJRJAR&
MEGX&":YO<GP)^$,>E+#H^A? U74T7[6->ZN">^>" _J0XT1Q@CJ4>,@>/-1'
MZ&RZ2@#L8_:\%QJ7G22-U(Q2GMN^^^7I?,^7.P  @.CU_=>N_QV#/ML@/'J-
M\I'%ZFHK0=^E?=@L8XZ;A4XR="D6=/@F,,'L!P<'-P&<-_[DCO_U!_"'+AQO
M-L+W?'L*_^/<ME3$H8[&SC.L$1IV:F,W=7[]1=N)O.NR".3P(@7+EB.M8.\\
MY2BLA_7<KO:M6HI8#SN'^FI,LE27Y835)S+L])%-&!@]+MS&O_=T\ EN:2U,
M(2C8'H9EIDFR-%H*OUI)]4TCZN^W>RO]F\M_\#/8)Y! .].)(!8?I<IL7#LP
MMKGE0O]19K#_<#XE1:\\3<PKNM_M;N,X5YARGB+!K7*?M#+73QRT#"Q:H>1\
M]\3T LM=)?:4WN#ZF0%H8N6%!TN%O<W&T999ZSD"#-*-&))._1@(>/07H.NP
M/BG08DAVN_%Y&155Q\H=2+#@GVO..95<>4[MVS9:@TY8MVJPE0>[;E5HA7.'
MI9C=R"&:_\[CY>R'N7'[C.W8E:)(2GG!5+)5A)_/V5$99&W5RUBORW)^Y"N4
M62&_.M$TA3JXCAEZ]-*SQ*,'=;S4P<)KC,U!=%1J/!\")NMZ[!)+?B(T^\Z.
MY<#);J>AP$?7@H9= [8@>^=UP[@S'RLC"XJVT<< I*H^VV7%HHH#K1Z3[J/?
M,,D88:E?6T$//NLJ$J)AR/7D0O*< /WIFF3='W[<4K_SM3FTA4$.E!?)[BJ#
M+4AEK:NQ3WM=#U(931.L41:/NK4?_TK&<@)1B4EJ@AL16+\ZS$6)*UHQ:W\Q
M4]UE/U(($G:Y(#3I#B'VYW*5 7.HTA1?KG81.]$W%?OM(01-L/,P4T_%@<IM
M9B4?FQ&CVA[IUJ4?+ST*<MC0JAQD&2'UAKKQ>:3U(]$0*G(_"<=MFX'<H>K\
M+85B%R-#P3M7XNB_@&HUJ'\.?8])=CE8FB,NA2DMM=9#WK):>:#,RTJ0<'?'
M8WCK,"P1;$(YTR X$TOT5(7Z%E,.^\BY/MP^ZF!Z"XQ&>)^X]7?_B\(:@6-M
MI%6QZNY<_5ZO%;U/V]#7\0+;I #5#A#O537.#;%;_#)=)LJF;32Z<DI0:#G7
M-"[XC)I?D,3F,[TE!;PW]_LFT3F8-TW_)V^JRMR-PY(P)]2'URK3%ZAOI5>I
MKE(G\ 65DD2-(2O&EU'OD6_> E*R$O;_ B9O7./5I7@M<TZ"DM%9H150("EB
MU%P4;NFX;]]F%>CB)S/@_VH-AE>?TTES0TF_*#5'OYT!=)685K/*FO_FN15#
M=^==+9&29I"@C[-G_Y#4H/X2SX!V'[;Z+*"CKOMQO5+;QY33-VH6V;JJO7$/
M(_T@>,@KD9=+/Z2C!8YDA?_DH-RL&T5%JLK<TT+?GJJP>]%K"U EGA.Y-!S*
M]#H>E@I@+$WPF[ Q)4TZ7;\[U[/5(WSG'VXP7ZEC#!UO<_H?VL5O(#HSJP^M
M_+4BEO8&G&7T4P5-H^'VE8P>LZD[,]/,T[?+;R\)/BD3T!D5>LFK_8]\8X)[
M9=K]A$Z];JS1ULG)-CMN*5QJAOK:>J9RUK'RU,;=#,/[!]/+B_AT'5DFO[S=
M@L:(Z5I;22X8Y<RHOH-&&OG[P;(#/7^M:O/R,N]/D,QKP3_V'*BY9,J/T+4C
M!P?Q=<PN[4<#,!/2Z!1[_>TN^^6NS%QUX/[GLX^=J'-$U('N,E<.B+65:FG'
MBU^H=9(%:8(U#GEA?7M]4+OCST,PJ=.*=(&M'KIQAVA\EB MRB[>LB68&^/B
MWO6U/\F<_H]:JA95YPHR7SH<TC];-;?2NCA^EE:TL '$7/@BD^1J@]/D*B6$
MG:PJF8C@#FTJ4ERI-9J-A\; &>R]KIYV= +<)WCNZ\"C@2#2QU4_*&*\HF@F
M>6E+9*\^?!(Z.<X^)' ?Y(B(:HX8U%9(VK:5<75DB0<P2;SNMTLDJOVJP#J]
M.Z]T"&3,%K+2CUVC5-M_N-=;LK%4\J5.]W,[8-0Z%7UV^#.3>0B59V4%Z^.M
MI-C;:Y&Y]:(WU8YM$^9/]6B[&;7CKFR"4FP.K!X8JX8G%WL93W+/7K6NVXTS
MDQ6: 7:Y])@LWMRMUKR[.M9_O2?*^;WS\GD4@L/QJ="O^V9UO'FU]-:G=XO-
MK?:*_DQ&F>?-P=YC;_*(((8^6J%IR6&X,&/-:,8G=%997</QKS8@EIE=#-'Q
M/0O1>^;XW'5C]-5 \^']+%L]E,.A;&OB#%-.S^]KZ>MWND!I98;+NJ>Z^S[,
MA@E ['[/GLT'S?:T9YD9W/'[_+HOP<SP^K(-=QO)K1L_K]Q>B[<!ZKOI(M,8
M+UE7O>3UT;^ H%&3WB<(0^KOKSY[146W+4@A;?,/T%P#O:FZ?J:VQ&<[0B1T
MQML_P@Y .(,96>#H[$\XAS7>AKOPZ!F[I!'3G6?W/I*]3?US>3FGL.\'/-!?
M/+GI;#>J.Y3!8F@%,A)%?=TRR\H.M2N.T:+QM!N>P8[VB^6=)3"+CYW+U-F*
MQ%W4SZIW/>"F<A,A'TJLXK^"BSFPU[-MXZ^2_6I5+83]^%_F3 <!ZMA+KEMP
M.H2.;XK4]%G/L9>Y':32).9I.K.O?M*]9&EX6H]W=K ,;50<9X7O$\=BME#J
MH$+7[CTNCT<V%2EC KHT5BZXB1\2Q8R3!+1HB "HQ#D'AEMLKGU,@_0M^BYS
M0M+<&;0^:P@Y=E5^C5R4\A.<OO6N;U3*/['JVV:)NL7[!W;;!GO",LO'=':;
MMN.UZZ, A5YA.]BY*[U0='Y*#(@IR/+&"WO9!%'=V]0WB#_?*%&M=<%@:V-A
M/@EB\Q#?K8ADHY01Q'=@I==R)A\O2GQ"_>D]_RF)>]T3YPOMO<L1Q4UK6\Q*
M"HZ]4)MC<W]";MTS(6/8DMU"2__A\ WS]?T=94;")AJ!D;66+J09>YV^FB.Y
MYHA+&L(E=VWCLEA=VW%=^4&KR.:I?._*=ASE^XQ1I9/:%YB*M=GAK,GN-X+I
M+0,C.?.?E/-J/-=$BEVJ/!F,#]<<"HB#EW,[O]/P.;U3J^!(?0TPN^?VWX!E
MM=W)L*_<X\9]X9Q-%/_&,,%BH<,:N'6R^!6BS>7S^8P]]A;Q U5 +,G\_.75
MGO;5UYOZOX"G1S7X;4ML<=Q8']X>#B0O9'&#T.@/J)AT][J"PMLU!8C"])EC
M3IG.W 2>!L-=6.:+JO.!'8-9^.@*SXQ^6DX^:[EW7'%4M-<[-GQ<I>M2P]-]
MH66?O)MX)5D<<?<).S=?^$R37<0[!_HI1G6<.R_J4HS3I#BJ'G]?OEQAM<>)
M[MVD<S+WI;IHHQTPZXETM@4+?&18QRXACSBXB6DD%.O=JQBVW]R,D6FQ_;SA
M96QSN%C%_SCXZ\=Y;U*K=P50NM2N>N-C5 &/PIZ]EH_"3()I_U#F6;,0)-T<
MV>UBH5KM9> IE!4@)5(?*-%"E/ ZHM1S36&4+?\L647O!NL(]'C"F[2!-.,I
M6_[^;$?)NDF'18:GT++H ^] ?Q+* -5AX@HNW]2L]I#/J[6NA#W+<[#O?14E
MG18$M>7_P"S9],?;R2^DIK.T%A\_QR_\X_SSB9!T,N<C:+B?QJ3T;+&:%A.(
M^?4*0WS1@-A"B:J6_#[V8'K0'6M9Z4<<P@2.JX*Y5G+M-=8DZ?<41_+2NZ;N
MW:\IH[_>E+E]/^)P]YA515*[HFK;/'UVRTR41O^A)"=PDJ'TY9RNQC7&/I^T
M]H=P"%<^=Z7'"I-('$APH#/U@(5A11_]FX9AQ+:3+OX/JJ&AQ^/[INJK)?HL
MBCN[5OMKZW.DW/%=E=Q;,?MW!5#J$.*7' STCPMHO. TT<&SK1P]1$EC&#].
MO+MY[U">;LF(;3M*J.EYC7YV-T7URU0 1>339,);E6>E4Y+E VVISOJ3I@J1
M0/W\H"$I6XT]=@/-5>7JAFH+W?B?L,92JO4GA-:YH"!XI IV?NX">KC":XT"
MOT0!;5(MZ6.Q*J:6)_9OT$DLHT8N4!_?X</C"+@K6+HQ+!D"COC@$B[*H0/U
M]%G2=;NEX9)>)WBJMC]$PQ.8^"7ZR6?-@VAA[HTHAWBL;;0XWM<4^H^S8\D<
MYD&,U&TQ4SJ)W[BB63<@I)<LC#.63<<-1B%5#K;ZD92(%MV7*9ECMK/*5J^8
MN ]&,Q9V>%.FWL-S1,Z*P\U0+SXUNB%QRV]\;'][KZGZ--S942]\F<FD62&0
M:[V)IK9H?B[U9@GG\*9FP\NQ*F*OPM,DT;M#4 </ MIO<'Z)=S//R*BHMBRR
M]GT4QNXG-%^%06%6.,W_ FCM"5J"J;0FJK7VTP_ISIUR7KYP30^  -0!H/7[
MC1U/%3>6!QT'AZ)Y(-\F._[SN%#+T<->"5::SW-F:)I1#LHIV@^'QN:G1+S=
M0WUH5@,S'3]!?(-M,&SM1(/2$\)2ML<Q^># K\ZV>()\S /E-06P(V^8]P?7
MRA:<V2H4LHE#[(0'ZUW\GN2*D#0 Z<&5BCP2;IVOK'\UU.\P,BQ)_QFPFEZX
M<?(,4\Q+]?0FL,&^OHZ097(='_4+XS"S@#+1A<4V5EVH4!@9?2I;K$@P00FS
M_E%/TD1;F2^\!-GKS:'1T*DV8IC4=XLXK7/3A^(YGNW2A,^CX9'W:VLPM \;
M.];%V&DVRGF8%;[?S)CJ3%KO,Y?_KE]B+O<<LF6$VDW7J[ON^PAX5 [%O\JP
M-GI<3L%HJD7_C$:)QN/2&$+O2M8AY/IFVHBUF"!ZUIP%#JW5MZ&GR.A5D,L=
MOB::<(%N)@O _,N^>#[[L.:_$I1LU8LMSYME-8-))?F(G -]5+WO,'YZL9]'
M%C,.H*IC_$KQG>BK6Q7,;8CRX+<\86Y1=XVOZ:IU7\2QLJD*("0"G4@?VRFV
M6+*+L6 _((-.ZV-7\C7DEPM#]B::#E)KD4G@_EB^3AJ[U;G1E.1E^$1;6L=\
MF.=VGKSF7$*U@V<B++Y8T5^19GA8,\C)^+1E?81$VA$_UBR\:2"]V=]\4_PA
MM7]T3<H'X\+/\0H1]61 9P+U%S#'[Y&RU;>A]BOVEAI/QLI[P2FZ/^:/"PZW
MH0Y6"^7\]/4]=QD[HQW>5OG*BL?=HAUW>G.&HUN+Q0?.IG0Q)0F,UV)DF2<Y
MAOM=4JM\UA++A TTG_YV5\+Y[=XOA41(K[,9*JF^%)KAM"[1#+2D,-$6+1@Y
MEIQ>WK)?X$I2^ <?P_=$'MS1-K_S#G"_HF!_?O)85]AUJ:I3!T$YP\A(Z&RR
M .X+&ED45,2]YK9^,^K9(NUB>M=@2"QH&HP-+@1%1X,\FX]"O%:")S1(0<2M
M]?&;$\39[XCN$;]Q3'S3&4!Z0,@M>XQ,K_JL!+?5G$RQHM8@L8E[=L=.@5XA
M@I<5.WZ^>=_FH39#:K5N0]LP_/IJA39"/?>#18ZFPOT"#M23DFDC]$YWCNVL
MO$BJ+'D9N7"?$!SSU T@25+CW,$<3#^<S$=#267R1B,_E=G$IL*V-J6JR\^K
M7GJQ0ESX8U60'JQS=[&;X]IG71UWMS;D15"AL,KSI+EE20'DL1(:Q'7/Q<R8
MCHFRX15K>84];VY_1SD'DK!2W.P"#B[C6:,O%QQ:#7DE^T-"?S]\^FW:@4YF
MA;9^Z!G1POUG&X<!6FCGL-L7H*U\]ZJMU=D#6\'P>@=R%='O24]>4\6)/%5<
M1 -"/.D"O/>6*47SD7\!,_:&%Z[72I2C@WW>SW;2J<-ZXW[=]I897.JP]9,Y
M'/1>/":5WRN%!]*QT07DHX7J/Z8GP0<DI.L.0]H=OM>_.&3+.^_K^7F&8KHR
MMHN#/^$" WQ*>O\"BJS_#7M<WM5N=*%B^\'1ZLM/?P%"9W\Z^W!W3@V% ^ML
M,FEM5^/I(*ZWOT4NBYLN^?)ME\T+0,RF![6Q)UE[*OR',@2V/*1.)+F@H.NW
MQR#3F7#HS(S-9^C,QW8:7;DG_X,Q_@D9^/B>%DXKM1X?,@.T[^PH!UDNVFQ;
M.VBU?? G;K#XEOGP@>H]9;%_)]LJ>HX/GX =-)I14<3+" [X8:<=/EG:#/<2
M>ND(@7;3')N2.BR(+5(=FV<\=31JI)998VLY(]I.Y5'I2U'5<"\F<%/QXR"C
M,_W0BJ2?%F2-*0V/-=GS,TC+C'5V ^QK/@1L>:](_REFE=N>OG%</.LF3H )
M;[0,[+Z%^PLTAF++ZRR\4G^5K%W,S38)@>54-NYE(';[!_AINI9/4J@CH[Y.
M[%"T254\'.5+G!^<5(_F_\#0?J] A*NS1]QA7KH$(=QGPIGKO&(U^4# 9HO$
MX>$M*7+V5U%,=^FZ/&"<#C9>XC?YV*O@8*;X:HY&?VVZ1*CGI?<'FQR='"79
M,FZ*U@[3;MUZCP/C9:GZ*<T:[0/$;3-0LD<-Q?+B*H(':J)^>.UP56I0_VP6
M[3_"8KBAW3#I0[%7.+O\X"A/DBB6"D50]-^X=A8UT/<OQ32U-<2J> TQWR*W
M5]$;N&I.6MN!>!L61\(U/8111S1"S?)>,@M5JO##L<Z/4YZ_$.&99@K7#ON.
M#?@=\T@]E$;\7\#S)42E__Q9^/M4?S]F)CIP)N5'+NHYF=V'\F6^X=&UMJO;
MH&W[WDA]39R1(-\>L<8%,+XQ72GG&QR03/>3J?^M;QL\YW=HKO**U*:*^M(5
MJO+(1W'XI_ZBM(<;Q24->7"K?.0Q4%Z02[-$F[=,#Y8S<5)--OF/$P?.6EC4
M)UE?]"48ORL*FWX\F#3SA0QKZ$0NJVGFD#,YV-@E&Q5YA8I=@H8.B2EV4:[D
M17$XYVZ1.)_1;.EEN*;I1W$1>6"")T:\<L-&2WH:9@,R/&ZBD*'V.\[8]2/6
M; R3KVL4J8/LOGK +GW?#Q"<13-(P8?6M+_;4[$25(D#3:C-5SALJHZ9:)%C
M;.S$3>]_P9%=>3665RZ6*.EACK^DL0 )8U0(3^*6K@&DD:'$!8V8$$_G$;/8
M8_.&IU":-G?QMD]-_05@ESJ(6Y>R+FY@9)*^W \^ZPKQ[J\!6983$&B=)3/3
MMXQQ^/&/N^W3O3^SKA8O)9(]D)%6V@.P:6.]J"09K 8_"!Q"3)OI@9+9:O3V
MR?F^504FC1.&@Y@<>IK7D82AG)]NW:+@D,DCKQ_OX1L3<,JG$V/06UH(*H&4
M(X++2-UA9X 7@3>[?R5<FD*^?RTFUIROW)5<D-G=M%]P-*D-+1$K.VS@8IS^
M/(FD*6CU+T#-BS'F :1V83EH"9H-8;1L-_U"9MF8MDWZ&PZU]OXA;'FI4;(3
MJM@NI%+5C+3YR?35QX12"#S <7BMK6G)1BH1%B3$Y3%>!PA_N(_^1W&^6Z%2
MI8IX3T[4R=EA2IKH#_NJ5R_UP3#K[P\5A9DF&FHOGR_\J%J3!+%:X.Z,X 4M
MNK#7U[]%[^3L:"W+IU:V'"A5CAZ-H;^[I/4=#\O[?ZQW#P 71VVKH2.RF@Z]
MV[RLHHRA"M/1FJ]#3WY*S3<*(BEDSYU^>YIZW1K'K.@JYQ"L['MC%?PDEH<O
M9P9M,IAE)<TP[5[!U2Z&JI4432Y-ZWK9]07/>BMXWM2# M2%CS<<36D-D:AF
M\[OF7=F]5[03MB]TS";:%)9R=F$ILIF]J8\W#R\7;*M6,JL<;=^.LQAWS)AD
M!GY@;:V<I+U0['-R0- /S*7TQNK[N-:M+E0M(Q^MIF9/]&<XKC=:5E=RAYQS
MWM*T$^/,E;FT;NU!NWY2W';K+/%'MG>5#)_(6L',@FXCQ292%C8_JG(E?.5G
M<Y-DOT\.'N+Y"W@G[-[15ZB/8TUP[]/EJED^62.(4=L[+G(#Y4\<8O+<@?%"
M-G@C_! 8S[+/_!? "UG<-NG&"I]M6\?L4T^"7V _73M+VU#XD=^V(AGWG]06
MT2_5R4&NPVU!TS;?AE"^7VR3%1(3H?S4W[<J.I<H*+W$!L]=$N_R3_\XI:??
M]O]XR^ TTZ9![0=M9G9;M], );]]WTN]/QI)N@R67U_)W4M>TO32J1GJL!]W
M%K])-?JIZL1,KQ@7;DYM]NE YNI#L;<B'&%8I).[_*QN>YZC3?1!"!$"I5B
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M.Y? /%C['^E,=-T=>7GH$Y9!4</]I^A8YGK*UKO5K3>)*V:V[2VU>4A1!<W
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MYG==#+#%&Q"R(I;\/@=^S&%Y!W )<3=L3K#H6[1!PX)-3I_X%,"QR#U5Y[3
MAQVF&OO@_$ F U6EL%RW\UF2PBB-[(<6^^QON7R:0WBW2,9ZRIXG5HVL1/4&
M@20J5@9M)H%7N'!XRIVDBJ\U+];N>96,#$HIOMVAN;N+QNG"L#CC6SGGK5>"
MJVI_]?LQA<[M\1((&@U!*H:%ZHL!\4\<.8_YUZ,KZAGZUJTFBG$M4BV=*3/*
M-YPH*L0\:[.Q_\C/IMBKZS=Y.@?R5M2#S2=W+ 42F9(CYK@51JJH8;VN!;Y
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M!>0<0)!YB-SL@Z>D]L\ERUD-\@IR'Q!#P -^RX^3_EQH5 1G^K!5-@01X!J
M.S_#$/1*2_/L? $48,*\;$KY:FG43]".NQ]2?X(+2G:V%H7 )]MW QA=AC8S
M#1PZ6N=!"L#3?246<3H;GTKX'H%A,O!$O[IUHLCAH(15"RY+MFJ*!MOHF]$"
M'<Y18CPZN>Z'0=V6C#],F/AT8#])'=_O6^:<D;*-3VK7JRO6.*MH$QX@_IL,
MOK31)W5[T:LCD6Y87&=G:]BP4KQ!UB2!AQS)6%"&%F]P^8:AMG#OUJLG!!;0
M'A3.BH>RA$H><4FXP*D RP(GU3*WY=HRMPNNAY(1)'!OL2PQU^J #^*E7^#F
M(BU*2Z7+WJ)>JJ^\+1?PJ?:X<T"M(L?2NX5,DB;"+ LAZ8EW,8\;-\,#;1"P
M;,1/+,"S- */L^"#7U'O2G$>[<WI4"2EB<A%&:H;YW&3:6('[X:JI]F'&76"
M0FED..]2EJLCOIW:=3/L5P-[*IZ5]B29RLW=CT'SK 6%C@7>67H)*%L>&PT
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MEM6&=++19.\Y.9?^>)E%\2+98S!QNOI!A$M&PU&B<SH=9Y3#=D1T6!BME$H
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M23*G[R62C?" :?O#05WSN?Y9:.(/-WDZ6>Y>#2_RRT^[U*]CB95EN=8NHI
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M2NU460O_ +'/ABK;D=A_GOC2Y/2@/\<5YA$(!-2.^-$FP+'<]NV/Y<OAKO\
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M;FM./-N*U]JXI)>P1K\<A")7D7^$!0!XCI4]<+-2UG3;'@;BY18WI65*4%2
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MR2@N1N&7D#WP7YB:YCTVW+QQ.NCW=_8WO&CSR:9.'>-))"5^-4N  Q+?"O\
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MF:6X]1HH?W]U<HL,,(7F2\S!%'"HKUZ9 /+OI66B2W>J3-#;7&GVLT<'$R*
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MQ ((*LP(/;PZ9RKS=^7WE@7MQ=QZ1"ZZH@M+ER@)DA?[ 8U)(604WZ5SP_\
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MF^ [B&.U=6=2+5 2P4]0M* U K7;IUR%7^HW#46SI )254=Z%J@ #PID8O\
M1;F]+0!2]O#R+2,:U;WZ'IA6- T^Q>)Y&57@*OP%*DBO%=^PI7'W-]#);R3I
M\!B2H0B@WWI6E*'[L@9E%Q?KZJJ'BH^_V1N37;.AZ3%;Q1VS(SQ/$_)0.LE5
MVH2.AWSK-CZD0HT/J%PTG*O$D&AK\NPKD'\RV/J&6X1"?A^.NQ"=J4-0=LY+
M_?"B@.CJS1^Z@CV\.XR:^5HH_K'IGBAHZ M\/)MBH!';:AR?""-HUG>XE>.0
MHJF-@"I!)JQ(VJ2!@>ZTJ5X$N((V6" !^ 9D<%QO3>HJ&[['"9]#]7TTF@@F
M:2M))8D<JI/PL*BM0>H\,)M2TBT@MS(^F003P.RUCC2@44%=A7L2:C.8Z[Y;
M:[#261EM)U*D2Q!4,9VHQ!H&%>Q!Q>PMRJ6[U$\EJ2"62OQ>] 1T[UPB\[0V
MY$#P4JYY;#X@S$  4!.Y'XYVKR]Y6M?T3;K:0B)DC!8[TK3>@[DG ^E:1#!<
M:[J"S_5FT7BE:<BI"\J&M=R#OG"]1O&O[Z[O&8L;B5GJ>M"=OPP U/#IC.8&
MV),.3$@TS4Z#OFH!MTRF(Z>&)$+\\83O[8UCN"!4XUB M0-^F!I.1!-:#$^>
MV_7$RVQIUZXZIH*[$8ERW)Z>.3C\OKCT=:U1!Q N?+/F2-BW6GZ&OF%-^M5&
M?/[6+GZUK&JW,4GK)<7<\@DK7DKR,P-?>N *D4J:]Z]=L>K]#V]_#+Y]@:$]
M<=4#YXJ7.U.N8-2O:F;UM^(WQ448BAI7[L$+0$[U&W7!"L"!\\$1MOUV'C@Q
M.FQZ[;X,4MMAE$>(JHJ?G@^%B*88Q2#8#_/VPQCDW![X81L=B-C]^&,)VZ5'
M4^&#0JR(ZMT=2/IWSV_^7=[;)Y(T>>$$E+5 S)4T:GQ57?:H.>'_ /G).0CS
M/HUW-*%MI+@ &AH&8FO4G8Y-?RTN3':Z(]Q;M%:_7Q-,YHRJ54K&=OG]Q\,]
M.:XL,^E3M%OZJ5Y UXL-P32E:'/*GGF1KIVG**\<L85]Z'D.I^7;..M 8U6'
MU'/HQ\0S4+,IW#$_33 C#ZN5F<#F:%A\1 #&GP[4[#KTS75282 2\;!U(/4
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M@81GI]FM0:^Q^[./W=I#Z<TWID_O/3 ^$$,?B4D'X@17I^.$VJ:2(*7"@B5
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M,X5E.V^_X9T0013",1AH7B=HC&W%5E)J"A4J0=EK\_GF3]R&1H1#Z7&$IR)
MJ30KL200U!ML<0E8Q>G(I#*57D17IV8UY4I3I4[83WLCPRL+&!HO@#A:$D%F
M((H:$'<GP^G .I^7K+49(A(4D<P$\Y5W*.P+54D=:?/PPJG\A:-=6D\<T*M
ML)5R5^*1&-3\(VH -MNW;//OG#_G'CRYJ-O?321%66LA(!JX856B =!4@$BO
M6N>7- _*/S[Y'U36+GRMIDMYIURY%Q87A:$CA01LI )# 5&X-?D<[SY0\C>>
M?,#0^KI\VDRR'@(_6$A8TIMZ8-:U]L['%^75[I4)CN726=4=I!*"DJ5 ^)D(
M/PBFWRWPSLO)]G-%_IEJES"J1O62AY "IH-JCIMTIDFL+>&!.-O'$C02T4QH
M0%'="  %H!2N&\6H0+;12\6*359R2.8IO3?MA1YJLHM<TJYMU9TFD ]!D%3&
MX  ?PIXCN,A?Y8?F/<:=J%[Y4\Q1I8:WI#^E-%.-S&U>$L9J24:AXGZ.N>AK
MO4(S'!,CL =U"T->3=P"=CX9%;C4'@EJ5,CRL=EVH!7D3\J4KA/>313Z9/R%
M.0=^6]2 :U_&F&WE&8&\@E/&TCM[25G9B*%4,8('O6@PXUZ^MV@N+D@2FWM9
M*,PV8N"SD>U=OHSS$BCCQ44 -:;TW[8UC0T85!RMFIOM[8F=JBI QM1T'?'$
M=#XCMC"012N(.=MLI: &HQAI4TQ/<@@BORQC-QZ;XRH)]CED\>U<19@:4K48
MXDD;XFQ('C_3#[RU"\^HW"+0,NDZM)OTI'IUTYZ5[+GAOSW9MIWGKSGIYB$!
ML==U&W]($$)Z5S*O&H)!I2F10C>O0+W&**U#VWIBJ,1L30_/%%K2O?MBR$?0
M>F*!@*5W&+*V]2-Q^..!H:4ZC;%@VP![8JK#?;?O3?%TZ_/:N"X^-1OT/3!R
M.10COX;X9PO4;]<,$VWI2G7#" \B -C7]6&T8(([]*C#&- M#WIO].#HAN1^
MO!48WZUIAI"%ZG:N2_R[KS:/<+%+3ZM,X^-OV*^/7:M*9VN.YCG2.;ZQQCBC
M8M&I%"#N23X^'AD=N0B0W$<CF-IBY7XNAH67C3P_5G,6+S:C+',B".&LDI2I
M DH0*&@Z UPLU&[$"R,Q3A#L!^S6GA0=-J?/.:3W$4K)) X8&5R:#J%)!'X[
M8O!$JI..9>4J6W K7>B[=>E<"VL9L!;+/(9))4*L4W)=FV8D;G/9\%H+O\N-
M8BC9?7@T^=XEF^$.YC)3<_#2C;$[9YJ_+.SCNM!T"!''&WL[:-FI4E_34$M0
M'8$&HKGHJUT35+FV58^0B50TBM5>'^4K,5Y'_)-/$9&=%T6_\V^8W212_E[R
M]<F JK5-U=QBC!@2*HE:"O[0/^3G<FT:VLH5@$:6L,7Q*&4$<]P%)I4&I\*B
MM0<$Q7$]E R74?U@O)R1A5Z#D!\5.5#\0-1UZUZX<6=SZPEBD2GU95)D5MV8
MKR8JPIX=\?9E)[I760I<<>)C8 ..-:FAKU\*?C3%#9^HY8RK&#R!VK4L.0Y&
MOWC"\QE'8&(+<2JD1C!Y%2"1L014D5!-.OSQ#4I?J?[V%#-]I00* -W')RH%
M -P3O3MV&Q7,%X(VAC"+(!^\-77FHH5W K0@BO3'C3K:[A/UV-!1PY1Z[O3X
M.#"M1Q-?\][N-%M6A>\MK:(/./ADF/&*0HO=0&ZT(V&+Z+I>F2K',DA2\",[
MA%4M5W+$@AB&H *5Z"@[86:S:5G<Q*\2J1*PDW((+  !6 -2V].O3<C(F67C
M/;T2.2.BU5A\3"G)*_$:[D4K7"ZT$J00L\3PL>,/QBA;I\1!WVJ<*KV9+;ZU
M'(C2F#@.:#DI!:E&-,6+F25DBY"1ZN 02O-#LIWZ;T.V_3.%_GKH6KPI:>?/
M+43C6_)H^MW=N"!]:L-C-;'J2P'Q#K1AQSH_Y=>=K/S1H6G:H9C)'<11R1;L
M .:@@[;?+);=ZHKR7*H6(-5#%:"I%-^G4$TP+&[+H]Q(]46I5:"IXUH"/G0?
M3DET6W]6\DMF8F-+>*(<.PD<.22*?R8KYRD-E8WL6Z12PLB'MO\ :'XYP2I)
M^S3$G)-=J@8T&GT99XOMX8BP(I3<935-#C0I%2=CC&(!Z;XG7>H^C*) !'4X
MG\\:W2O?PQ,=_'&M78TQ(D@].N6S &GTY7,'MDT\AQ"YUO4 4+)#Y<\Q2M3L
M4T:_*D_[*F>+?SUM$L/SL_-VSA:,PQ><M;],1GD%5KZ=E2I[J" ?<9ROH:\J
M'_/ICQ0'I2N/!ZU[XJI\30^%<6KT_P ]LP)!IUKBH<*14UKBRR$FG44Q17+;
M4H<5#"N^"D:@H,$J=QO0>/7#"( THU3\\,X=J#PPV3H#T[^&&$0- 0:TPSA<
M]:$']6&$)_F^CVP?%1=S@R(ON5V#5VP=$6&Y%:8+1R0:BJG:GMAI;:SJNG)&
MMI+ZT(/]U*VR^'%MS]%#]& KG\XO*4$[:9J^JV^CZC#)22UOI8H9.34(XB1A
M4'L1@1?.>@VD9G?5K9A-N["52#N34$'>M<XOY_\ S<\L:7'.(M8M2\7V>,Z?
M*I^(],X[^4WYIVWG+5/-FCKZCQ:<T%]9O)]F57#13<1LU%/ [CY]1GJ33)B]
ME/< %Y'X*@.^Y% *>X%<CLSR0:R@E=@BQ!B34@LK LM1M0#?KGOC\OI6UCR8
ML<,Q]06X4KP4FJKP*T9A2GB#GE?\G0UC:Z?HCIROK#5KG3)V"<@!'<N0W8CX
M6&]>A[Y[=NDBMO+6KZC:1*UQ;64]X@2,+\<<3,* %J5(\=\Y_P#EOH\^G:'H
M,XM#)ZUA%/))3BWKRU>1R%K7XF-=AX4J*8>:IYJ31)@+^2TL;&(#D]PW%N-:
MD R!1W%!7"X?F1Y,OE8#S7I"LW]S ]W%ZW$; TYU%:]*;87S^;+6VE+?7;<Q
MP.J>HCJQ=2?Y@:BN2&#S5IEPD+"YB5]HR1)Q;B=P*;5IUR2MKJS0\H&$T-%<
MEB/4Z5VH1V[XV"_:6Z+?#<33*C1LK"E%W/6E30]J]*9(!#;3*TBP)7TBH<D@
M$@KQJOX'-#IKW$C'FJR, KJ3TVZFG$]!L?OPQ&B1(B#U+IX4X<D;B*JGV*!F
MX\@R@@5KVZ;X=QQ&:U5%'U%N:.:<6!Z&1>)WHP'8],1GTY$M%GL8D@N(7=4-
M&#$$$4 .W$\^W;(M-;+#SD0,ZF'BZR$GB$)/ $J2?B)'MX80#TO5U!19,(XQ
M$D'0F4$ -1:[A"1\7O3MA#?RK;^L3;?6&MV/JEB 6:HV [[$?+PR+R3(T]OZ
MX9E>5@5!\%-"?$C;Z<-+0" ?6I'$:0\XJ;LK&M:+7:G;_:R,ZK=6\\=Q!*A>
M&X;TV#@4/[(XTV"[GQZ9Q+\F?+K>5]9\W>5P9VM-"U::.R%')%G,%N(N*G[2
MJ)N((!Z=<[O?V#K<$$?W@H4!V%14-\5-ZY*K_2TM-)TFQN(E::>6W3E4J6Y,
M"P0$ @;;X<^7[6.&XU2XC5F2>Y5$;<BL25-#X MA+^9=S%^C K2#UI72BUW)
MK5B!G" >O3*>@^?^>V)%@=@,1)IMWRS5@1^K,>0%*4QIKN =Z8FU*T\/#&4W
MK^.-/&GAVQ(MTK]^)4!.V_MED4VK]^(,>WZL3:M/ @Y1!V)!V_S]\> .YKG3
M?RJMEFU'SG*2 UIY*\Q2@$TW-A+'0#O_ 'G3/*/_ #F'I_Z*_P"<DOS0MV6@
MFOK2\4U)!%W86MQL:#O(?U9YJ#'8G?OB@?XOXG'K0 UIL-L4YCB0:8Y6!!KB
MBD^)'SRP6V_#%E8["E3T\<40D]3M@I0._0GO@I2!0=L$(]* =]]\'Q]*UPUA
M:JCQ/X8;15X[]:#Y890D;'M7?O7#*$T(W^'Y##&,5/AX>!P6K ;L3@V-V(4U
MH3_G[8/3D>_44_I@J-@HV%>.*&-I W&:2%^6W$U'C]D@C/*'_.17E_1-5TX3
M:I>0V^JVZ$V%W?0H@:GPB)+F-T914U(8,%^UQ"BN>%O(NG:B^K:[#)JTMU;6
M</$+%<-+;F;ES^"C<2.*[4['.B7/E:6Z66-56DZ@K4#<'=>GMU\,G_Y,>2+[
MRQYJFU"0%;6[L9;=U(H>1:-UWZ;%,]T>6N3V\J&,NZ/4**<CQ6O(#_985^9X
MA9M;W!#- C$4V 'J@*2?H-<]??D=>>OIT5O+<,7(J_$_" ".8Z]33?VSC!MU
M\L?G/YGTEW5H-2OH-4@1P$'*<>E(0 :+NJ^'AGNJP@BU;0+JU+2?5KBR92#(
MP*\HFK6H()JW0;TP'^6UA'_A?3[8+22UA4*SBK"@H: C:I&XQ74+6%KN\L;Z
M!/JX*K69>2R!OBHO6M">F0K7ORN\@ZA;2V^I>3M+OO5#-R:S1F7A0EB0G(56
MO0G//&N_\XO:9(\]SY+\_P#F3RE+<$\;=FAOM/1A0T,,RL41?\EJ_=GGWS9^
M2W_.0'EB&63R[^8&D:ZREBPN(+B#DHZBD5P2#UI3[L5\L:Q_SDMI5M.FN>7(
M-3:U>/B^E:@LD4H(W,:3I$RGBN]2?GO3.D>7/SD\QVSF76[&Z\M7H=J)JMG*
M(F.PVGC2>,\@M=RH]AG3K/\ .F[MXX2UYIMW#&>*/!/%4\P"A$9-:4KT&2N/
M\V;I#&]O]7)Y#C^]%*D5="H'$L"=NF2+3/SK69XI+VRFB0%:C=_39Q2IH.(4
MT)&YSJ$OYG^6([*.ZEF&\9X(!4FF[*=Z @=<1'YJ:!JE(K2_CIR9FJ !4!3M
MRH*?'U&!9_-6ALZ1W5]&Q*\W<.#R"D?"6!-14]L+SY@TJ]O+A[*]MU4L%9HV
M!#A0*@"M*A0.VV$VH7UG),.%S&2?AY$@<V())^S\JFN1N\EM1<1RRW'.=3]H
MT!))W/'M114XM)=)*D"02B7TV)58@%+$D].M*CJ?? \&GB26V6;TUD,I8CCR
M% 0>GMWVIDCT/RZJ>9;[4)K4&+4)$F$RT5HS0H03\/AOOW[88W^E^MK-I  )
MC<SJ"M0J\15WHY\50BIZ_C@GS-<(NJ:>B!1##(6IR!'&-&):GN!MA>/,NFZ#
MI%I%.X6:X0W!B&[5E8R$+3;H0,XSKFOW.MWK3SCA&NT:> ]_?"458GL/QQI!
MK4G$N0KE%=JUVQHVZ=LW/&MOOV'AB#4 ]\;6M5KB)\.H\<P%=AF)%?<8DP/T
MG$B-^F^4PZ$C&GM3^W,37:E*9W;\D;,R6'YQWY (M?R_U>#M0&9 P]^D1SS=
M_P _"-(_1G_.00O>-!Y@\M:;J'+Q,;W%GXGM:?Y]<\.J^U1N/U8X[]#\L>&Z
M;]?OR^=!L:X]&;Q%#@I3L-_EBJFH'X'QQ4;5K7Y8(V%"#UW.*@U-?#K\A@E"
M"00:_/!D8% 0=Q@V)B& KTZX;V]!3WIAG"XK0T]J88Q/3H*@]L,HGJ0!M@^-
MSX;4WPP2G4_VG_.N#5H.(V'A[X/BY$5/3O@U$X@L3Q4^)P/+>743.MND#$K6
M(S<U#FAV#*#4@TJ/ISP[^8MY^8'YA+K=CIEW8/ID$GU4AH6@A*THX!<3,Q"L
M"Q7<KUH.->5>1?(S>5I;NPN+V*YK?^G+<0*X5@5$=564!@ PKN,[WY9\NV\H
MF#Q<I+:;B$V-5V(W\-L[?8Z'91Z%)+;P?O4M/7CJI!J22R@'?8+_ )UR6>5*
M+<VDCSNDT"L6IT=&'%E?K6G($>&&/G*)4@@18OW,C4*D"@!-:@CWZ^^=:_YQ
M^UAK;4[NT:02JI8H2*4# &E?<UP5_P Y#^6HM+\W>5/-UH)%:XC^K.%HH,@<
M/'5NNS+]WMGI#R/K8N_+5K/]8 6XCJ5W< NA?B!RVW)[[4R9^4%^J1^FK45V
M)4+0^!XBOT_YG#+S'!Q+S/R9@O,<31R2:'XO'"#3[Q6M E?4E$CACR)- 3U)
M8G^N!I81,EL5XHIJDR\:4)^(M4 ;GY;T[;Y&;J* W!+P*\:,0$E%'Y D#<@U
MKMD=U#R]9S\_J\(MKBYD/JLHH&)_E &WV:5PML]/9))HELT,<DWQO*HE^'<
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ML_F7)YKN?T!Y>+S^7[26CR1T_P!/N(C4. 3_ ',9'PUV8[G;.5Q:);SP?5G
MN99 \AE+<5C>E3LQZ\B&->HSZ'_\XF>6+B#\B]2M'42UO+QI)%:J!^95D#5/
M0C?<C/ ?E20Z1^;_ .8ODV>-A%!KLTT<=0#Z4[U<*&IU]04ST=I$D:06-PDZ
M7"Z9=F!6C8%0B,/3)-30A7H?#.V6ES'+<&9@:R? ' !))W"GH!6GPCPPY*"(
M".5R'/Q(Q #,!XBM.GATP+>Q&V:.1%XQ.>6WPA33=:5!Z=/N[97KAV*>H#+P
M+*"?M"NY^=",!Z?=RZ9K5AJ5N>+P2 2QOL3Q(8&H\ #]^>O]3M]/\V>6B/3+
M43UE4<1RIN4*$D5H3USR[J7EU_+VL)8I0Z?J:?6[(R"@2XC8B6(C;V^@C/17
MDO6%U'3H(DE4SQ2<&*J9 W[ ) WZ=SV[Y!M9N9+'S,8U(2.\M)7EAXL"U""I
M((':FV3#R9KRR7>HVQE<7JD@"@H6'V7-:BE"2<] :;<"XA(JLLT77G4D,0*,
M!]'CAY' GJ#T6-5H)'+?M&O+YGVPP:R61@A8IS)!7;B? $ 4S)86TBI:[\D^
M)7H2&%/LU.WSW!P,WERW0*89 8F?U"H^%N>X^+P^_?!UO8O'&HH958U)>AH#
MMP9A7<>)'3KC+NV>AB9&8NS!8U#<FZ$G<TVV[9'KFUEY0<@R+&KQA@>I WI1
M1X[X3/:)/'*L<;!CLQ<* E!NP!ZU%/'?"H:+%'-&5_<B4 LR#XV,9ZL?#>G3
M!E\6X0B,DSCX5 )^R>YV[X1ZDCVZR. LC.#SI0$,058$G;M7Y9Q.X\UB'4GM
M[.W?U;=-_A-:GXA\(W.Q^[!HU6Y>SCO+J=S:\0"5!C,C'944&GQ,3\(I\\FE
MIJ+:/H\MS=V[6DLM6=9*5954%56C'85XD]Z5[YR2>Z?4;V:\E4J2_*A-:$CX
M1] -?F<?4$?+;$SL/;WRB:4)ZY34(%.N(L3X[C$V8 BIZ#Z<19JUIC2:"N)\
MP>FWMEGH:?TQ(]0?'KC&8=M_?$ZTJ=SF!J:D]<HCP[8F&I_GX9BX&U<;4C<#
M;*+[9U+\E-%_Q!^:7DNR,?..WOUOY!2J\+(&Y^+M0F(#Z<^L>;/SO_\ .<'D
MS_!G_.1WG@0Q>C9>:_J_F.VVIR^O1CZP_P!-S'-GDT>/3^S%4J-^GOBP8]:T
M)Q0$FE1UV^>**YKX<L7#"@H>G6OCBT8WJ>VVV" 5IBR-N <%Q@=MQ@E&.W+>
MN&$<@J*?3XX;0OL3T\<-H'VW.YPRB;<=*?Y[X:Q$#>N&<#K4#;W^C#&,D$%3
MMTWP<K4&_0#?.'_F-YXFU*-O+?EZY*6TD@BU.]B)H54@O"&H!PH0'8'O0=\\
M]P6<S<+:.)'FD+<)5HH *L1Z: BGQ*%_7DITZP_1[7-Q]72-%"E:'=V8-1E3
MBS&J,1M0; 4SZ>_\X1VZ:CY(\Z:(M+A--U(2K(W+D1=1ABA5E!H"AH>_X#YK
M_P#.4WDR[_*7_G+/3-46'TM+\ZI:W$3.#P9PWHS ^X*JWTYU2""/Z[=:>IX+
M<*DTGI !2\8*AR!U) &PV)SM6A^G+9PAW/JQ1 R[55J[!B0!OX^%,.OJ\,R(
M)E].> OPE'V"C"IWZBM.I[YBBW%M) $#%VXBAZ _9->@%>F126[%K(8I.2)]
MF&1J?M?"R&FP(K3\,$S1N8E8@S,NP-0*TW\?"N=[_+SS&RZ6T$SK+/$513T^
M#DPXDGN*=?HPRUZRAUJP*7#11O%<">U9J%TD4&B-TIRY"IKU IA'Y34:5=R'
MU0%E;U;61221ZHHX(K7?K3QK@GS=ZESK'E^Y:'BU7MI-^RBJG>O[2CKV.(:"
MMM9><Y;M.36EZJE5 X.C4:A4;4HQZ#^&>EM)O$BN+.1I#)#*K J .*CC4D]A
M4#OD^2,,C72CE(5#*NQ:BTIW'W89Q72-$TL=)6C)!(/+8;GZ/?&BZH654$0I
MO0"I!';L*8*AG)=463F%2I:E>2@;$D#<X*D7DC>H@ 84]_\ 9#;]6(LTBPH!
M('!85 -!44^D#;$'E1#(9VY1.*L#2FXI4;=?UY')75I8XX@T:A77U-E5RQ W
MH:B@'4X7^B([F.V/Q\D:0,:$']GXF\=N@P!?"3E (HA3XC0DJS#?IX5ID!\S
M:Y#;0/"6")OZS?LJ#2H\ *"E<XQ9V-H;C4M1EMXFG5U4M6H 4$"OOZ\9)* $
M$5Z[>&2KRUI_UNX;S!J=7M[-FBL$?:-#3C)/QVJ=Z*?GA)YOUQ]3U)M/LC2*
M(U:M?W=#L&&VPI7WVPHC5(T5 :A>YZGN2?<XY<:S4W.(ERQS5X]>I[8F222>
MV(FA:G;&L:[#;$#R/P^'?'!1MX5S,13BO;KB#5W'48S8$5ZUS,W3;,J"H/XY
MBRC^S$BRGMU[8F10C&5!V/CL,MA0_,9ZX_YQ$T$7GFCS)YD=.4>BZ>EG&6'2
M:]DY<E]PENP/^M\L]_YL^3?_ #\[\C%K;\L_S+MX12&2Z\M:A+X^H#>62_1P
MN/OSY'*P(I7%*BOA^K%5/8U^G%0U1L=L6'3KOBH('MVQ97'C3%5);KN/\_'!
M:"G>NV"4;;CT[;=\$*0".].^#HB*=3X'#:!C2@W^>&\)  /6F_\ M8:0L"!0
M[^&&"$GO]&&L3 T-*$;X81R$H0-N/\.^<A\[>?G:.?2]"F9(/L7>HPL#0;AH
M[<G8L>A8U4"O?.;P:0T:W$NH0M#:1+4([ J:,T2DBH4D['<CL-^F [JVDC@@
M^K\UCD$K_$CR2.P,;G?BH(1W[=STVJ3G3[6\FX/=W"6%H]G1&E+M*SRQJ@/I
MHKGX9$XUI\(/3/HE_P X#7T]OYP\[>7IKV:X@OM*M[R&.=?3*-#/*'7TR3M2
MX%*>&],"?\_//R;;5_RW\O?FGI5CZFI_EEK=O=W4B !AI5VZPW!)_E1_3>GL
M<\7^7+X7MSH6LL_"0N$>9ZD<6!56 WH030_CGHVPC%H%C,9=Y)FCMQ4D-ZQ;
MJ0:T'<GY=\D$EH+4/"W,7!+_ !N=BS;\ARI\/^2-ATP&8F_<7,?&*(MZ4BNV
M\90$<6 '3P[9%]7L()9KNW5F;FPE0$ABDM*%030*".WW=!D/_35UHTOU6Y#3
M6 !XLH+/$!N-C_+7IUVSHGES6X$E2[LYDN+.>CAD-0SC8T [[=/'.WV5_!JM
MM;'D2DH9W0[LA'"1&"]2*CQVS:8/1O))9W#QW/[]U4'BG(E:*!V)WJ-Q4X6^
M9[B8+)&P$A@16!KR?F%!5EH-C3[Z4PCT6^34H[F0MSNHUBN-JL' J7XUJ1L*
MYZ3\O)<&UC=V6XD,:%6 X*Q5!VJ=ST]NF=-T:]AABB69*>HO(_M!7% %!.Y.
M^V&EI,$EF@>N[M&5H*<>@'7P_$Y?!EE2GPK$.FWQ#L0:UVPUMK%8PLD7%&;D
MS "BDUJ:["K?3WPW15/!9/@4[K6G3KL-]N^)7,0DB++R]%*M5=A\-.OC6OW[
M9&+YI@)5E420>G4@FDC-4D@;@4 &1XRV\4?&-^1FXT%"A-!]JA[4&"BTD,)$
MT8?CW(J-_$&NQ &_CA)JM\@H\;?82@ &PH"Q)SCNM744D,W.L=K%)R8C<-N#
M0C;WKG.=)^L:GPMBWIB>=@"*D%0QJ0*#I7;QR;ZIK*V5C%:6D*J%4Q0JP'8?
M::AVH>N0""#T@Q9C++,QDEE;J[GJ?Z#%W)(VQG3OTRZUKOTQ,&E#XFE<38@G
M?Y4]L94+6F^)=ZT_MQI(KL=LJN]/OIE@4 KMB;'A6F)DUJ<2?I4]<;4D;=<I
M2:G'$ GM6OT8DVW;>F,!-*GZ<29PI]Z[91E#5\>F?2S_ )Q<\N'1?RQAU.6/
MA<^9[Z>^)/VO1C(MX@?;]T6'^MGH_-GF_P#YRV_+X_F3_P X_P#YAZ)! ;C5
M-,L?TYIRIN_UG2S]9X(*&K21H\8'^5GYN%^UX8JHKL14_P"?],64#L-\5 H.
MNYQ0-OU_M\<<&!^>* G?;!"-X?.N"U_L."HP:#N!_'!48W!H*]ZX/B!%#U-=
ML,HBNPKAK P'2M/XX80L=ZMU\<-HB*@UH:[8.$M%)8@+W;H-O'.=>9O,%WJD
M5UI6C^K'86Q1=4U%28XXXY"5$225IR-*GV^>0JSTR"-98421GC5Q)-)Q52!(
M(E$3(RA1Q(-=MA7<'#B#1:K!+):26[E9Y&:=P &%Q(L[.O( +QE4U _9J<-]
M+AL+<QTTU;R,K):;R,?2C,/INID&PX\@P;EN14]<1GMIKNYG+R2QV\*F@@*J
MHC9DC<RN5!/"1PW  UJ:'OGJ#_G$W59O*WYO>5KJ]=HX=3F?0[I6D<J6U 2+
M#19*'D;BV \=R#R(;T_L+YX\D:'Y]\IZ[Y4\PV@OM%\R:=/IU["1]NWNHVCD
M ]P&J/ @9^=R\\IZS^5WG'7_ ,M_-$H%]Y1N)M.,U&"3P*P:WN4J *21LKCY
MTZYZG\EL-5T.TO7<1S1Q>G<E5(,;+^[)Y>/P@Y-KBS:Z@8QE(':O'EN/&E.E
M:[D#MD<-JQ^L6Q#1R *LO,4'(CX2AZ]A0]^F![C2BRS7/HA+B1.8*5IR'932
MM?A%!X@>XSF&M6,K^JMJHC9U5B36A639C\PU=Q\]LYH&U+RM=M-:2R"%G!GM
M93592!0&M-F^'[6WT]^N>2OS$LI;N-7NGAF*<?2EV9#V)\0>G(9V;2=<LOJW
M&=ZBWF=D4-6JR/T!V.QZ?*N5YN#W*&6&3DL[A ZFO%D'(!P:#B=NO0USF=O>
MRZ3?VMXDQ6!U,4JK4#C6GX4STYY+\QQ7ULMN)$#Q@21L#05(^R"-P05WKG8[
M.?ZU;O<6]P"20ZJ-^+J*,C ?9W_'&7^I2^C2XD:VG95:,L6',* S(W;J#WZ9
M(-%\PP-Z8N)UF4Q<_4;<A!78U[[[9,+/5+1H%DM;A'Y()4J:-1A7=?>M<UKJ
M YR1SR,CS$LAZJI).R[#ON!B_P"D(O2"%U1Y-@:@;G^;Z13"/6+BVA4I)/6@
M$O6KCHO&I]Z5KN3[Y$I+M8R*!J_99Z596^UQ8[BM/#M[X U?S-:);W47UHH5
M!6@H6(8KQ"[UZ^'?;(1J&M!97+.L7U>W,G[PDAI&V4$ ;BN_T9Q[S-K1NY5L
M(RL,2D^L ?M,16E!4TJ:_1C]&FDL;=9YY4#!3Q"5!&_P@5Z&G7QRG:69WN)R
M?4DIQ0]$7;X?OW/OE#MMTQU*@5&,IOC'(W%,1YD4X[XF=]^OZL3^FN5L17$1
MU(Z#N<<H -#MF;X:5W[8F?BW-*9N(H*8P@5IU(Q'O4[=]\8:#_,XRIQG(5-3
ML<:6/;<#$R =R1_''V5G<ZEJ%EIME'ZUYJ,\=M G\TDS!$7Z2P&?:'R[HUOY
M<T#1= M!_HVC6,%E&?YA!&J<C[GC4GQPYS93*KJR.H96!!!%00>H(S\POY[_
M )<M^4_YO>??(90I9Z+JDC:=4D\M/N0+BR8D]3Z$J<O\JHSE"TH*FF*U.U.W
M3'BIWKWWQ0$A1CPO(@@[=QBP(I08]03M2OB<&)6@\.^#48   4P7&6 \:^&#
MX3L%.^_3#!!6AIN=L,(EIW[UW[89QD_[6#C<)$AD=PJ(I9F)H HW))SFNN^:
M;G4I3;:5,7TN/>X9/W;RT-. <THA.WOXTP)I^G+<16]O=ZG(8[MS.T"L$6%D
M:=:S51!R*L6!7Y5H326K<_4M.-A:Q?4$X 2R,#SD4 JX(/%J482<JT#>."FT
MJ\2YMX+.:._OYK3ZW=QR.@>D;2-<;"BD\%4!=S4]3AAINDNZQM<1SSV4P)65
M'7@&CB>*;@GP<DHZM4 [!O"N2Z+0;6_:,75F);&=]V12[W+$KR2W92J\9%1&
M(!VXD;5Y WLN'EW4;'415I--N%%M<6Q%O_I=G.C%8Q2-UC9>!EWHWP\N0^ ?
M=O0-6M?,&BZ5K5F:VNL6<%[$*@T6>-9 *C8_:ZY\Y/\ GX%^3":AH^D?G5H5
MFJZGY1DBM?,3QCXY]*=N$$K ?:^K2R?/B_\ DYYP_*V=1I=J[,YAO6!N$# \
M6<!!,:=.@%/?.LQA1++$"K1*78<!0GEL  ?%?G@!].CG<2*_*5"H+LQ#F-E/
M4; D$?=A=-',M%14@XLOQA:U )-:4-#4;^^0K6["6*IEK(&*D-4-57[2;  5
M'T-2NV<\U72H9%E5U$B $D5-%!IL5ZU[G.53V+6MRTD1(,$K)'+&"& Z@ T[
M]",EMKYJUVQAA:(QOP/%B00'0[4('?;K[9-+?\S[::$"Y;T9%'[SJ:"GVNG8
MTVQ>_N1/Z5P)*6<TKEJ+4QEF[ !J;CJ,-_*7F>+0K[TWF].1*&2NP>(,2O(5
MW KWWST?:>>!IM-3M)0]I528J_"R-\+4*D\NE5/7L<ZW8ZUHGF32(S:RBW<H
M"@XT-!O45'P[DG\#D)T^[_15[=!+FOI4CGMI&!95'Q(P!^SR#5.XI\J9TW3-
M;M KQ0.SS3LJF!UK1D!:B$#<4.WA4_+#DZDPGA DC",I7TV)*EMB 2.G3883
M7OFVULK:8R2QQM [#X]R -PW7I]V0._\[K3U%@,I8DQL32BM0CXB>E16N1ZZ
M\]3KZ:R71_?\E"HP^VX-.!'38]L!0WK7KK>2I6&T4,%0$JB+4\JFA/\ F<C'
MF7S9;6:S.@X0R?'1B068;KM4$"@ZFF<9TW6KC6=38Z;;27S1, 7B4\$HQ!)<
M%5 )\=P-@,ZG:P3A5DNF1I@-DC%(T]P:;MXF@]L'J*"AQQH>F,W!Z[8F[[GM
MB3?%6NWAB/;?ME,PH "<2HU/;WS5'0XGTJ-\INOMF:NW?N<3(KMC?L@[GIC1
M6M?HQ-C7ON<2+==JU\,82>V)$;[8T_#TW^>,I4[UWSO_ /SC5Y2_Q)^:&FWL
M\7J6/E:)]5DKT,L=([<5\1*ZL/\ 5.?4'-FS9\A/^?F?Y9&WU#R+^;MA;TCO
MT;RSJ[J* 2QA[FQ<[[ED]92:=$4>&?*51O4XK4=*4IT&/+D$4Z';% 0:[[CK
MBRUIMWZXN@V-3U[8JHWI]U,&(#3QP5&/AW!VP4AZ4W/MM@R,TWKOX890FH 8
MX/5@ 23]_3%&O1&$].W^NR2(72)) *C=1R85*@MMTR,ZA?ZO-:2PWUY*=*#R
MM'% ?359#1?57@6)9-E&Q+?1D:\L.8[*V/I2?5XHY4>!86Y1O%,%(D9@*LRK
M0U/?Y9,X&#2I/'<1&,-N)(^,3@"0G]I>(=7/>O7.@>7/+L^L-J>H:#I[:I>:
M5"+V\M)2LK"UMI8XY6:-V^):2 M0 )\1/3#?2;33;>VO&NG>2&1HKAXKCBLK
M1QW#VSQ)500>,9#4[,%^W2LPMH;)XYI+6&*=[B&'A*BMZT<<@<%4C,C!?LA6
M8%@"RJ0]*ET-Q?E8IH8C#$";,2%B1Z<RDH2H% /5!! 8]10_%R8LC-S>K<IZ
M7IB+E';O&3$J2M TL;L?4B4.%@8._)#N\CO&1]8M?J1_SBGYKFUKR!+HERZ&
M3RK=_5(5!4%+.=%N+5&18;?@423CQ,:'B%)1>0+>E=8TFPUW2K_2-4M4O=.U
M.WEM+JWDW26&9"DD9_UE8C/C)>^0K[\G_.OF'\M[T2366ESB[TRY)95NM+N&
M9K=BS=6"? ].CJPSJ&GP&X@]=9N<T-8N=!\24Y1R#K]IA7_,8)N-,C81/(BG
MZJ&$:J:  @\JD4J1WI[82W&C.PFY5CM)6/*+]IQO1@>E#W^6V1;5+2T^K20,
M/K'-:1@]>))^'P[9S34X[M1# TAH[!6Y*'YQJ#L=Q3D!^ R$WD5K)ZUG,=X&
MX4:JE6))X ]"13\<*HK$PQ1B4$HQXUVZ@TZ'O2F1G6-'!3G&OIW'-N+C<$M6
MH.]?'&>6O,]Q9QS:=>1DQR($7U@:*Z&M"!UZ;9.9GM]:"RQ736<JC=D"E5.[
M MN=N0[4WKXX3?I/SOY18):RMJ.DH6) XR*=ZL-Z$"O4=OQP]LOSTU/38I#:
M23:==J3SC?F8I&&Q+5[\13;YYT30?SV\N^8EAAU*[;3==A=E!,B20D$FG!RR
MDC<T4[]1TSJ>E?F9#;F&!Y#'';Q>J)%')F-3]B1B1N#4=3[X<ZA^:'UB&7E<
MIZ,Z43UFXR[@DM,:#VZ5WZ9!;[6KS55:.69XK2[20S"WD+$#B0"A<U#4/4#Q
M[XC^F/+VDP11222730>B> D,BKRV9W9^8"K[XA:?F#Y4L&E?4=343I(&C4N0
M-R"%% -ZU&]:"F$&H?FI?W[#3O+UM/<OJ,[H6BC(@F+CCQ1>/(\1WK0#QR0:
M/Y2EN9/TAYH6.\N&^)+&I>"/WEW(=O;[(VZ]I]'$D4:0QQK%$FRQH JJ/910
M#Z,5"4)WZXU@0.78XPGIO3VQ(EJT^[*IRIC&VZ'IC""P&YRF%!2M>Y\<3)VI
M^(QO(="/IQ)S0[8P@]\U>@[XT'KT]LHC;PIUQ+:FYQA%*;=1C./?QQ,D;8UZ
M'IN3OC *TVKB;'>F?1[_ )Q3\HG1/(=UYDN8^-YYMNC)&3U^J6A:*(?2YD/R
M(SU%FS9LXY^?_P"647YO?E#YW\B"-'U'4[!IM*9]@FI6I$]H>7[(,L85C_*6
M'?/S(3036TTMM<1-#/;NT<L;@AD=#1E8'<$$4.-K7^&+"M >H[_1BBT-!2A_
MK@@;#QZ8HIW%.W^V<$J:^P&V"4;;<;XMS-0 >_3!2ML!2N#H_L@T^C%Q/'%0
MLX#%N('?85V'4].PR]/UBTN>$EUIMTMC< Q(&6GJ.0"P<$H5HI!V-14;5Z'0
MLK6TFNX[JV:SN8G-M%;UX16[J J<[@EG/I!30-6I'08I.?JK75ZT"7T<MJP@
MM[@RIP]3_>>81PD'U$Y%AZE%I7X3]H<_\M:;?W7F75-#M!ZIUVX]5)&X L)H
MY.+R,2?]VIS%:5-/ YVC3_+-H-9:SU QV/HVQ@HD2R\WGM@)(P K_$KH#RJ=
MB>V37R_H*6\L5O$W*9C):S*C#TGEFA$5Q'&I"G>XX,@*]36G$<&/=1\IVMO%
M)=2#UY+6_O%853T1ZDD0>O)22S2+N3]D=AL(S4Z=J,*0P11>C;6J7%O'/*T;
M+$D]Q]86JF,<@L88<*@_$6)^*0R):=I]\D>JQ&T=&N/1N_7192T'&>0!B7Y1
M$A[@T9D 3H"KM7!EGHE\GUVWLWAAFN"KAWEX.C<5:$JJ&9@0T7(4')@H>4%4
MC ](?\XJZI<Z3Y_:Q^L.FF^8M(X"WD9B!+$1-$%YT;X5,E"0.5:@$$,?I3&U
M0._OGD[_ )RM_+-O,_EBR\\:3$3Y@\B>I,X1>33:;)0W* ;$F,@2+\F\<\J^
M66%U!;2QD,J1,C(E2DL7']D^(V;)X+1O3,(A]8PHJM%3=XP**Z[=17_/N4WE
MB1'Z,3TAB/)'-*H1N0VPV)ZC.>:OHB:@TDRQNBOQ8(=N+U(H&!Y#<5^[(1>:
M<WI>DWJ2,*@;490VX-:"O0=NVV<GU;2DMRP0&=D!EE9:U#IOL:[U!V'\1A=#
M(91\.]6-*;[@="/F<+[J/>5^0+$<75CLH8?",Y]K%JD4W*A1Z"BD\37;EV\:
M9)M*MI[N&.>TF-M=0$4%*JVW4@$;'H?G@ZU:YM6O;6_>:5;F4RHL[#DI;_?1
MH/A--Z].A[87WEE 58NGJQLU5"I7BWC49#[_ ,O:/*6>2*/BPY$%021ML-B#
M^O 5E;6=@P:WN+FU*DB,12.%&^WPUXBM,-GU!]UDU2[^+]FH)J:4->Q&+V]S
M*[ Q:I>JE?B*W,BFA/>C#%I;&WFB3U)YY*'X%660BO>HY#K[9)=,T>J6OU6P
MBK(ZI I0222.Q(!^=:?2<]1>5O+-MY>T^%&BCDU26/\ TNY"@L6;<QHU-D7H
M .M*Y+8Q3+8#J213*&PK]V4Q/3M[XF*%O?*>@&V!B2*D;8VIVKN3E5(Z;4Q(
MDT&V42!M[8FWB>V),:G?;*J2.M<:1TJ3]&4" ">WCC"=NG7&\A4'?;&R-OOB
M88T.)O2OZ\82!L#7+!)^(FHIOASY;T*\\T>8-'\O:>M;W6;N*TC-"0OJ, SL
M!V458^PKGV/T?2K/0M)TS1=/C]*QTFUAL[=3N1'"@1:GN:+N<,LV;-FS\_/_
M #GA^4;?EG^=NH:[I]OZ7EO\S%DUZSX@!$O2P&H0[4W$S"3ILLBCMGBU6/;M
MBX-/EWQZMS--Q@A*CKTP0AWW^GWQ>,EG6-2M6/5B !\R<78-"P6>L=4]0FG1
M*$U/@ !@^VU'R_!;2C4I)FDE1)(5MGBY,6'./GSJ41D!-5!/*G+B*5 C5](2
MX6T]6]FNA&CLL*+PY4!8&JEE7?K3Y[&N/T_6H9;B%KBVGBL8D!NBM(YBQ1C\
M!9)55:T)J.XWJ0,/["WN+F<"&YM8DM5JZQTCFG^M+15D=FY@*N[B@6@!%<,F
M:#3[JS,D-V+F)AZ$1X>MQ15,1$C<>9<_%T X[ =\4@588(WU&W67U^<P*W "
M$%CS,*A3^]D)XUXF@'&HH2)'!;K>&5M0MJ/#%,($4[O+7E)PY4>4Q(:$MMML
M .H#S'I\-C;Z=KEC#Z=M]9BLC(05CD>X8!(@5%#P<<V8B@1]N0VSI.G7<@FT
MA]-M%C>%$^KJSB0^M+6WDN>0-%"NO$= 7HH'1L.M(MR)H7]58;61XEE=8_59
M))HS$OHNM%JQ)8CK4&AYCTST3ZY!<1:U!]8-RC1"Z2$/&8C%-Z*+-$3(J%Y'
M0!*G@WQ/R$O[HA(->@6_]'UHVDD,MO,DYEN'<B=5EC#-ZA:A /3D]2Y5W_T4
M'EI?:?PT^ZFC]5I+F6(23"W=8Q)(Z$L0]NO($ L?60!.+1R0Q\Y%*HIVF;T)
MIIYIO5@65I!*7B5KZ6 VZ(UI*0?7;=?1<$[F&:Y9+6!?\N_-.H^7O-GE;78C
M/RL+O3S+\?,_57:XMYED6-7$C2F'X0LDI=BQ4W<@>>#['Z;=17$220R"6%P&
M1U(8,C %6# D&H/48/NK>*[@E@FC66&5&1T<55U8$,K#N"#0Y\T/,ODFY_*_
MSMJ?EQ6<Z+(XU'1'J:FSE>GID@ ?NV^"G^2#WR465X1;#TE$JQJQ^':1>5*,
M*T^$$[CZ<1N[:69 5"?$C556!7E0UH:;UH=O'(5J&GR6Y81KSB>,E)%(]-JT
M!9Z[@T%-O#(CK&G(5<EFCNP"KAR0I  /4'Q.V<WU'3(DF>2>, #F( NYY<:@
M,0./B!MTV[9SN_L)8[IIHH?A$O @  ';X@H->A.$VJ6CUE<53EM4#PWJ:UZY
M ]81I JM& "!4.:UWV!ZG]FGXX>^2VGC>1F3F0^R[?9-* D?B1G6-5\MVVN6
MJR\%5B@Z5)5P>M5I7;J1G-+K3-0L%:W,HE*N4 &[,.Q-#X=??">;0F4!Y"%E
M<U'(<@30[  'I3I@>7R[,D:\!SC8$<M@* 5-5-*>&V<[N].O7N#%4GBU JT/
M3:F]-_"N3S1?+)BMQ=W,;*"E>)IRVZ TV[;[Y,K/0UC9)Y(0G):HK*6(5.Y%
M>NVU<[CY1T!$*:Q=VPCN GIVB.M&C3<&2FU"P^SWI7QSHBJ%&_;_ #VQQ'0^
M&5R!ZCOB9(!.8FH-=L83W_S.),00HK2F,8"NQKB1Z^PQ-FVIC/B/>F4:5&V^
M-*GCO6N,H#MW&)TIL3\\:2>A[]L813?,3\.XZ8F*5KL,IB*[]QB5#4@'$B>U
M*4.4 .QVQH)!_P ]L]B_\XF>1_K^MZOY\O(:VVB(=/T]B-C=SK69U/BD3 ?\
M]/;/?.;-FS9L\E?\YH_DY+^;_P"2>LQ:19+=^;O)C?I[1A0^I)Z"GZW;H5!)
M,L!;BO1I%2OB/SM%@" 2!7H!W/@,9#=032B*&3UC1B0F_P!GK]V.MI[V[N#:
MV>FS2W"#E(E0.$8J2Q/V: ;]?X9(WTVXXI*&:.$S!#PBYL5Y,M5YR0J?L]":
M^U,6?2D$]M74BEE<NI$G".-S&>A"&>0@GYTK05S6GE^XU""2Y]255MY%229(
MPK,Q^$)&O)UJ[. %X^]-AADGE2EU)-#)<7ZR*1);C@8_9G"$M453<&A/0UQ4
M>2/3N8;AFEMJREY D'%7D9E"K0(%+@B@%.AW R0IY*BL(KM[W6(Q>-*D*VTG
MJ.7Y!O619>1 ]*/BY-#R(H*$54/);:3#9_6%C@B@M"(4DD5FD65G)CAD:,L1
M/(X+=6VKV%<#II^I>D-1@=/3N0O+CP=(FDD*E&/Q(9' .Q%:[5)RS*;G3I4%
MSZ]U+*X9482.G$D<IW,B\8P5 C-0#O1:C);I.E5M+V^61KN"*:WC:>%PD,40
MY".&! A"H 5#/3ER;B!C;*-XDEB=Y(WLFA5#% J1HBUD6.8 KQ3XRTA-6W *
ML#AAJUC=:AI.I6,=[=1?7H1!+,51A%)(X*.@(15?]VC+]G@ -J@MDR\H:TGF
MFQMM:8M#,8)8[ZUCC1:7%I<K%=\5)8&D@5QM0\F%.+ 9T*WAA,D]@WI^F(S%
MP41E4D1I0W(5;]JK4(:J\0X=J<2](TGO;>>2&2^MQ9_4KH20\0L@BE1)%#1N
M&'*BA6!K1^;2?"0:ZA:)>M<7*J\,5U/-ZD$9YLQ=8$F'[VI91#'12034$/ZB
M@%3NTEFMY?K"R*@2]21EA28E'>\YR[B4MQ,BQLI!Y5J[%I*RXR[EA:YOQ##%
MZ=Q<W,,L5U"@4&6\1B)!!$8V1D3XXU6C&D8#VW[EBNULA<RLD:F.&:5FK)SG
MFFAFNY6E=_561)'+\?4Y@QN_$2+)$BQ1_4W\G_-*Z_Y+\M7A?U9UM%M+EMQ6
M>V ADK5GZE*UJ:UK[#M\3<E'RSCGYR_EL//N@QR6!6'S%H;/<Z<Y /JU7]Y:
ML2119>(W[, <\9:/>3CU;.YB>&X5Q;B-R4>.05Y5V)/3BU?X9.K6&22W65N+
M<&X@GCMP'4E3M6E#4867MNC^M.T<=;9J3P.*/"7WJ2.0.U*^V^0K5+$B,>FK
M1VZJ*/QK2@)W%"14;;&A[Y!=5LW$7!1&P9?W9C6M5/("E">VU=\YKJEDLQX1
M !DD#)Q/+=.A-3[86:CHPGMC=**NT;<%K]H$BAKTJ.H)[9R;5]"N(WK+(I+*
M9 E/B^';CWKOT&#O+D'I-($)D)CY;@@D#>FY[UZ?YCKGEN>.6UDA9Q1=EY[,
M=AM3KW_V\+Y]#CO-0GF5 .!J2PWY4I6FVX'3$9]+@C01N.3$]P*#Z*']6!KG
M1A&G*1SZ# _ %H/:C!C3WVSG,/E*"ZNQ2Y-O*DQX*\;%.0^('J*_20/GD]O+
M*&U>.%3&>*AGX#8FM NQ.Q(W%?IR5>6_*\E\\6J:BU+99.4<#+4S**@$DG9*
M^WQ?ZO7J@51N!UQ2@[_[65R"_P!,2=EKL:5Q([4/*HQ,R%J4-,HM2H/T8P[B
MA--\:-B2#FV(Z8B6WH!4_=OB??Y91J"#2I[9BX"C8$X'WZGOE#8$G?$Z&G3<
MY?%B:MT&4 17>O;&&G6M=\38A6\3X95>Z[UQ+<D@BGCOE#;E7KWQ:UL[C4;N
MUL+*![B\O9DM[>%!5I)96"HBCQ+&@SZ]_EMY.A\A^2M \LH(S<V-LK7LD>ZR
MW<OQSN&(!(YDA:C[( R<YLV;-FS9\!_^<N_^<==%_+#\VM2O8[*1/*/G@SZO
MH[(WII \S?Z59"I(*PR-R "_!&R==\\SOY;\N7+VMW%(\32JD<TS%@RMZ5%X
M<OA^&,B@ZAAOOL#6S\F6^K7WH6%XB"T1IA)<321QP 'D_J 'X&** *CC4 5+
M'9&?R]J"3K#;ZE.\EMRFD^,K6,+5BJDNR(H7XCR:B[_:WPT&FO"Q^N1+=2BZ
MB8F65620NR)%%Z8"JI?EQ"L*HI)W9CDYTWRUYKNVCTA/+SCTF/)F=1Z,,!9G
M9PPY(CI18B1^\84'VMS[_E6=U<WJ3O>PZ;&E529E?UN<;/ RJ.(H$3X5<5/V
MF?XAQ85-Y4TC0+.*VFOI!<<97N+LJ(V:,+&885$+CT9(=S6,J7#_ !K\')S7
M3O+.G1R75V]O9Q7M$]2%;:'@'57CY&-4DC <&LG^ZV/Q."G..4):Z)96[6,D
M6G22LJSV,LAJA*RAK<EXFI'3C R*#R90DG$"07$C!CY>M/J\7&T0OIKP0VTK
M3+Z9@B5UMHJNZ ^GOQ#.M"W$%1^^@C-W;F$">^T>62U$K>JT/^CNQ66*ZA?8
M1B1U<^HM(UH&H%C4K"@.[M+=_62,\2MYS]*(S):/%\80$1^JQ!:6/:M6(1?A
M#VP81;:=/<7%S.UT8+VZ22Y$2R6Z0>K$P$$9/%@U6#!WY'9D:H7EDW'EZW6U
M%M!J5SJ>G74S/;2R0QR,XF6.0%IZA6E ;]XRJ>4;#91',(HCI'EZZ\H_F%>:
M,9)KJQ\RV8U>&%BG%)XRMO=S$NZL@BF5)0O,*OJ?"R, V3JWF>TMX!J%N^E.
MEO<&5+A1&T<G*.>3U?52/H6D#<PM#3F(G(N'G[V\^D6%KQUVUNG:)Y799&+0
MM%-+!+]8Y(6$BQM$[!48CES96Y&Y0/J=O-?:&^I0)^YB/PRJ8VN)&N;9)(V]
M-A.W,Q\HP:-\)_<_7-N 2&='1[9N)E2ZA5WA5*.LQMQQB>%'^)P:HP+GX6$3
M/+ZD2C;M+NRNKZ93'%&L\=R[)$A7E%.:EF@G45"QJ5_><:5:)T59KR$/#'%$
M_&XMXW>.>:CS2)RCECFJ[$O)&%"<U=MD# +*WU>&M[+Z\_YQ=UV4Z=K.AR+P
MATTVMW$E>31_6U;U4D(2,!MD:A2,T;D$])DDD]OV%P)$&]01489LH9:>.>+/
MSR\E+Y?\Q0>;+2!AH_F67T=0:,T^KWW'X''@)@I%1^T/\K(-8W0B0R17#JT!
M+7,$JTYQEBH(!Z]*_0<D!CG*D^FG,-6&=:KS53LIK4[@TWKD>N=+DD94BGF
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MU.662^ X?5X=1X4$DBL4(65>;;&G+U.\G%^+Z=Z#1PR74)C^M2 "W0(%C$Q
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M1XPY)*&(F@6$<E!>-VC'JM]%="O5#>F6-0U?EO[9TZSG$BJ:_/#$T(H<X/\
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MHJ?OQ-J>/3&-7IT!Q-@"!OUQ/C38]!C0HH2#7$B:D[T)R^5=O#&5Z@]L9MN
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M.Y_1\K?5$5><4X*6X]"0@4]2$QDFA!HC<:4X<AQ)ENI:A'=Z9*+)IY8I[1#
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MH42*)VE(ZJK9YG%0+<7#FQRTL!H?I_R"@_@"E2XZ :W,C3O_M=RU3:O^5G
M;;YN\0=?.CCU0W+S/L_3X=S^/>+FE^3[1ICIDT0@?>H<GFQ6-OC&SN<DE]'
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MF[FIHD6AA=,NV]Z^)D<00Q9N^^1GK82 ^7U_U:MA(0[)E/L8#Y*<$Z/][MR
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M[+\"ZP@Q@D\WV<4<95I<.5IY[%EC1O\"NJ6P0U?H+7,L9)NOVO+ELRZ&#L6
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MO9E:4\IKX8!R61>*@9A:Y3TV0K4+ZDJ?$3!8S,X=,H$<(V:,HUPL6X6JYU^
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MG G-Q,+$X[#$-\!JSSJK!T:^M'H1W^7D,L<>*AMH"-C2BA#+$4S*A<T7WVF
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M2%_W:O;5[9@3/]6R./8?7;1CF#G:A? _@]FTOBYV(TP^2;GZ- D,83/?;6^
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MD&J0WO/#\V@VY2)/)F.%PMR)OQ>)7\E?4V+K-5F#O]L%_4?"/6?5!#4? +:
M?NL#)BY@^S*XOX^JF9&S!ND2^??M# FD_?;3]%9 )UZ0RZU6V2$2]HUT3X=W
M-%7_(Q L$QX476@A'"3@"7,4I]HYZ3UTIM2M3:R02,]9*<$9O5P.5-^N4X=6
MYJXLM\2I,_[<;W=XS!!'V>_%3=(]G_D' 3#H10YURW\O@:#W\G20=ND6N8A=
MI[K5LA*?N3#1,=GW='%FX$TNJV!5OLE%I[!,G:]WFY#]FN=__P%@@*2HW5RL
M!W9ROV2Q3(;_''(H^MZL85W;$_/O!,U!B@Y^HE;D>IRABZR,BLV/P45\ #
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MCSCIGB!KP4%Y_#IX[N*2,@2-N"@" R2T>&0V3XC6\NK*5,]X<DQ2?P=I73_
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M%C:+MXO:'/PY62[B'']W,3PW09A8Q8D8;DQYVY,2N3HL#0O+[2IV)ZIU!^%
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M*I;X\2<LV.*5.N5]"V_*J0GW2PR@%SI?<D"KT%1I"+GB,?<I"0@_](8:!SQ
M*$-B[OZ\X RM<16;+D!%7-IF^#;C3*A.-%P6I2%#X2(OXV5"-BSM=?'6Z5*%
MX?OC4$A5=44DL(VJ/R##AC"6=X&)9:(TP)::LVX("TG-3B-:N^&BS:_@Y@.@
MG7RS+UXV7/%3AK3W*7'&B\JEE>%4K6X=#J8X?%N$S)0F1RQ1W]:5(51L3_T3
M')$;I98W^2-YKF"4F.IR@A'# _8;\R!<%#4(2ASG16K!.2- K[5,W_0/0P*(
M9RA^L5S':;1/"#1RSUTND&*J'@<;S4X-!&."U;_4!T]3!4\K%O#KK[WK^+X
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M$R>ANH>1M2AJ0Z< W@IL)@B>=QB7Q_"P\1:7O\-G/@/9+I?\OVU'F:KA)?'
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M5T NNT;DP5WAP/]]UV2TPNX-9U#? U4! Y]'-HAE'46LG@[!A+Y;JU\&WD5
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MMA&U.)ICFU';;5OXNMSV!-S<NWQDAYP\0:"RD*WR&KX-G]B$T\97\J54X>X
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M,,_,8<5A?J6KN8?U37_:A"TANU:-4Q+'_:4&C.29'!)"I5C(6^YMNZIZ*Q<
M$6(><I59'Y2YT[;'[+Q<QQ^-VG409F/?WL?M$POD:^.^K^.I\J[X:B.*NX<M
MTH]BSW[LMZ>$",.T0EPLM\[@7=^W2G#KF-D]ZUQ(_G?G_0QXM>PDW+9>K]PR
M0[EJ^Z#=QN8;.+X@T]RAZ%/,8ZS&DQK2" [P-)F\V.S*']"JK'A/5LQX_J8U
M6]4!(L^2I3"6C Z9W(U1;:JU7<9HG:W#-,M?VE[LS+.4L@''\Z&U) Y!8>L
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M^:L[TO2U\&@ B<:W+%E^W[8\*VM+EB9K,TZ1@X<ZV7L"6+A0I\Z.\_AW'%
M$#Q(%"1I=H5Q38 O(1F+JTPX $K;QI^UN@YHM^D*!^G,BTWR%SCOI&L@J[/7
MST5U\AR[CD.1V&<TB @^CF1[K3.CPS2.'64;^?3TUH@T8W*NC<D2+I??5;@N
M"\?MY[FA,@&S3W4*>\%&,=8$NS^IZ\F_.G1WK#23M!6N6)NU]^M'L3C"37KC
MR=7R#-4%S^UDM<O0]"VCKGA1HP>H'O#-2P8E=ZVN29BU_<"(E(Z-YC"CQY0#
MP5<\Y.QQ__)%9XIL"U8\]1K:V!S\A*UKZ2K%QRFP_8,,481/V)>7%()P\P&8
M)/5>),_\?4^$J!_G !PJ)_<V5I,XAP$ZM-0MFA<H!)0<B)!-=%EH=;EU"XOK
MYD7AF*^%.Z,<<PPY7H3C;&DRVO"2DSS08;V)6,+6.\Z DVFP!&D$0KQ@'Z##
M^V#!HIPL%X&(+"AA5IKQ(%P9FCBT\Q/EO!7T?/3V6\>-Q#3.'%8[6:8"P[S]
ME7H\Z7@,.+XBYPH2MH+6.$*>W*U1D23H9#\' KXBGE@!'IZ-H@H_3P:]=WM(
M5F%'1XRR8IX@X3@K%<M,"$YE' SR;-ZPQCT,"*:E8/K_ '% CK\_,%YZ(O\
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MI=^8O*ES:^7[I27 @;B\K"M%/HTXG;J3D/\ R]7S)::@\M_9W&GW$#BUUFV
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MFTC589/MQ7VF#ZO,K'_6A)SN4MK%!*UI+9_M5YT(Y"FU*=<)[I+9.8),(4;
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MWZ8H".HS$C*K7ICAW/6F-+D8WD=_#*#DFF.))RPU>_3% X(QFYZ;4RB13;&
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M(WF'4[K2?+_FK2=4OK=N$VGVU[!-*O$[\45^6U=P!G7?*WYDV<]H':ZX/&O
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M08JI.PQ?X=CX8(0CM\\$ C[\$I\L7%-QCQ3'>'7YXM48\,.V*  CKEGH,8Q
M(KCA0[GITRZ"O7.I_D_<M;^9M?C^$+>>1_.D+%NM/\-ZJXH:C<L@&<]U:9+G
M5M4N5D]5)[R>19*UY!I&8-4^-< CIL-\=7;&'K4'?'GVRJ'W./I4#*W&5R\3
M7*Y4.6Q ]\H-6N74]^F,+>^6K DY1(_#&\JD8\DT !QA.8,#3+Y#ME@^.4S;
M=<29J8P;Y1 [FH_SZ8@Q-=L WKRI#++ S+((V5@O[:$493]'3.6V=VG&)E!K
M:24/2A!-!]&^>H_RZU-)8K03[A.1Y$UH' J>NW3/4FGV;"**6V/, *?AW"M7
M[0'ODXA;U/2=@P>GQ=@25 [[;4Z8.6!9 &?BY X<J4!'C4].GXY9L(Y!(GU=
MA-;@,&%?W@.^P'<4H<%0IZ<P=.88@%B/Y10]-Z9*(+Y8G3F&B<J#0%2S*:D%
MEX[C;#^6ZMYX*QD(B-RY!B.2M6G/BXV- !7PIX8 BUVTATV>*S(+HK*L);B5
M16J8ZCWZ&G>N&VEZ_%(R269</&!S$H5ZB@HS!:"OCX_2<D?U[FR<WY #>1 :
M4V%14;T.U*X963E(.*+40$FA-%=&^?A4;'<8AJ%M)*T;0LQ1'W\6!V-" -A7
MPQMG83,CR>FH(8^FV_-?&H V'7J#7(9K6GR1WDTL;");AE+MR)#%.@ VH!7H
M.N1?4==CM+=X[N<@1$QT4&H92/A[[5H/GD)OO,48)B%[&J,6"D,5+'B.1->Q
M/C]^1Q/,UG(ZQW%PD2W-%*EE7G4BORW R?BZC:V:^>Z$[R1$<8W]1$78AG8*
M!4[ #?K4Y!-1M1<R2J1QE._&JCTUZ[D  [>.16+1)+J1HYF JS;  5!^$$@4
MW^GYY /-FFP6$4T&PA##X#4]>A:NYK0],(+?19(-,]9X?](NA5U3HH^T0>M3
M4@?JSG/G.9--T34Y>05G3TE '3;XE'0]:YP"U4I!$IVHM2/ MN1^."0V^^**
M:^_SQ93OBM>FV_7'AML61JUP;'3;O[X(7KO@A3X'IC^5-AV.*AMJUQ4-MTZ8
MX/[XJ,?6F97)W/;[LKJ=STQX8#89=:^V3+R'=);:W?22*2K>7?,<(X@5Y2Z)
MJ$:]2-JN*Y#N0H,OE](S%QX8U3UH=L?RH!7MF]3VR^657?' T.XWS4'SKE;;
M^V8$'*+'?;;&=,R[-7IEMQJ*=<K8=<NN,K7MFWI3N,V]=N^8M3KWQK,"*=1C
M&Z5!^[&%B/GWRN5:XDS XF=]QU';.1:M =+UB]MDJHN!ZT(&P*L:D#ML=LZM
M^7FL_5YHK>:0LG( J: 4!W\/#;/?/E74$N[")HV#R**4!H&0GK7Y#)?'+'$Z
M13NS,RM6BU%%/6M-S0X;1^I&#(4601 %&4_:CZ'VJ,/XDM4C^L0RNSN@<A_A
M"T(%?&@/48$"S1EY'8LK5IL*J=QX#"6\U*.U*W*-,!Q9)(Z H2=P4(*[M_#.
M->>?SHC\L:;,;Z188U!4F5R9%/0!CT;;L*>)[YP+R_\ \Y4>5+B^(O\ S1:P
M)41%JF-BB?"!1D'(=MO[<[';_P#.5OY=:?#6/5C?L !*8@"'"C;XCQKMM3 M
M]_SG'HOII:Z/H,]TQV628CC6NQ HVU>W3 <'_.7GFF_416SZ?I[R\?A9"[<6
M8U0]*CM4;X9:;_SDQK&GF*>]UNV64,T+EHF,76H7@S<MZ$5"]LDVM_\ .7=R
M1';64L,#21K(]S"&=2%&]$6OZ\Y+=_\ .57FNQG:Y=K;5C,*M&2T48H*#B6^
M(DFM=AB$G_.7/EF:QM[+S-I,L%VRCU+B(*R%ZU)H&Y4KOD!\Q?\ .3/Y?7%A
M<-%K<5D64?NYQ22J?9  J14[[ G.-:7^<MA+?V]]Z.IW%F9@R3R6T\498GJD
MC#8D;?+/>7D'\Q!J^EZ<QT](KBZ5$22-6%5&_P 3H" ">_VF/>FV=02Q,UP8
MXY/4D=U,Q4'A6H.P;N??#UH8[2"613SX+Z:?"#NU:D[[_P ?EGF;7KT>8_.$
M>CV0>6*U/K7%1\)H-@!7ODQUR&'3M)N+J7:.QMRS4&Y(ZT'?XCGC;\T]9]5M
M)T*-BS7+!Y-C3@M&<5'B33($" =M@.V57PQ4-T Q4-TH:XH&VJ<54C%XZ ^.
M#$(I\L65SN/'%U;Z<64UZXH"?GBBM3%010>/CCE)ZXH&\>^8-6H&7MUKEJP[
M[X[D.V23RO<10ZG<O*_!6TC6(P2.K2:;=HHV\68#(WT &7RV RZ;>W7,-M\V
MVW:N6.H\,Q\!TS5VZY?,&G;,K5/7'G]6-/ME<OHQW+;<8VM>F5Q._CF&WOF)
MWRNGTXP-05ZY08G?,QKUQI(VWQ+F#7&%Z=>F)\^P.)EJ8F7).0;SK9R/9PZG
M *S:<U6(-"8VV8=.@ZX3Z!J?I74,BL6;9UK] ).>W/RO\SI)#%!)/RJ%92#0
M@KN:CO[C/3-E<Q7<;<7X_56Y+QV#(PVZ&N&4-Q*G- 16.AC9=PZG<"AKX8(L
M+U_5,8 *GD1QKR'+J!6FWSR3I_=UDC;T9EXD!02#W(^=,YUYDTV5(98;8.;>
M2M#.#ON :*.O]E,XG'^1<OGW4EN=2MI4TZV8D#C2(\>HJQ/8U &_B<E?F#_G
M&'\N;K2A:/Y?AKZ?".3@M0U*)^SL%KO]&>=M4_YQ#T32;@F***YBMI _H74*
MCUB*?NTE7B1M4[@Y*K;\A/RIGM(TNO*AL[YI.")!>2H&HRK448BM6%!W )P1
M<_\ .,7Y2Z[ L,#7L,2CDHFGD]6,E#)P2:&5" 5H>]20,.-#_P"<*/RLT^99
MK:6]:98@T<USJ-Q-&J2<MD7UB*]3T.'VC_\ .&_D.>ZFE;S+K#CT2\D;7!18
MB&(,7.M"".WXX#US_G%W\J-&MI+R\_2-W S$*TM\Y$G$_$0JD$*!]&<1\W_D
MW^3<:BQT;RPU[>R'C%/+//(S*RGI$7ZC:A\<)O(W_.-WEK4M:CU&^TF.RMK<
MJ\=K%&I5 %)/,L"2U1M7W[9[1A_)GRL=';3[?1[<+=1J&0)\(%/M!?YA['"W
MRU^6U_Y8N?0LYY!8JW#T_36M"2*(Z[$?B,[=!IB:78,UQ3U:? K$FH[ T-2:
MYQK\Q/-\6A:'J,TTICBC0JA!"GFW8&O;8'(#^4&@3/977FK5 1J&M-ZJ*X/[
MN-J<0=MOA& OS;UJTL].^IF4 3RUIW].*C,2!U^( 9X,FU276M?U+4IB7CA/
MU>$D_#0'XB!V[8,#;]<6!'CCAO[8Y=CBP8TVQRL:X(1CXX+1ML$*:"O3%UD
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M$X>I&>)7>NX[T\<!Q126@J-6+% 0!( #3QJ10XR\NY)T99-1HAH&6W^  @=
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MV:'<B&UC6).1[FB[GN<.\V;-FSX3_P#.;?Y6'\NOSDOM:L8/2\O?F(KZW:$
M!4NRP%_".FXE82=-A(H[9XY8UZ8C7ME$TZ8WD#[XVO6AQ*6>*$5ED$=>E3N?
MD,*9M4V86T50/VF'\,!#U[AR96KZBG?K]-<'005$2@<J[$GJ3[X=PVJJ5/'B
MO4UK])P041:,H+4%![C?'\54545<C]?8_P <8L;2 (IW)H#7IVK\LD^G:.TA
M61XEW-6;J*TR6P64=NJ51.8:K;[T'2HZ=,*[DK'(WP@H-Z,=B#OV[C%;:(E
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M+0-'16*T-#]'0Y!-2T\W=PUE"6:+B/K)WJ5-?@KL:GO[?/"F7RY#)6.5!Q=
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MKDUA/I<Y 2K+0@,*DUVV\:#O@.^LTO4E''TKA&62*4A>2RJ?@8G?8#KMO4X
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MT3".NR\% -13RFJ>$'B6;272>O"HA[FY0@/=B^4D,HM?QX;G$/Q/.44^^+_
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MZOC=)YT.]A1>XER/!HO"U,0L(_G?U+^$7SB*1'IZU:^>^ZZ .DJR^EAA?.O
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MUO9SN8Z.$TH(U[";SO 2'9QLNIZ<G!QDGEG^M0+TV][:FEC.S0T[(HEC&\F
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MW/<5#6)FH?F$Z'0B7I.)E :G@-#FQ Z1=,GO>^;L&IG&C6FH'RVY]/7ZNY>
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M^OG#SOB/C]]SZ_M-Q R48'G#UA8]PZ09H4!W@#\F4U@/1>P*=)M:69\1J2H
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M#^5-C>Q$(]WPP[G$4';)H3AK]9+CLGEYJD.! PX'<WM,8)J0SIWU_[D+_I^
MZ1E@U#!\>/D,X,I$N$O@B1;$']W *T6GU36D<"T5G@$?V7G;,L95Z84L&0P+
M+MJ8;Z080G4$K9V@:C+UZ-%:,SJ+PY\2]AO.,YX!M'0WY@(9 D7TEP3'WW"N
M&$8LKY*HUW-*7I;^QMN5G-?WR$.1KKML#Z4B%?GR>LG:=-Q+J[4GZ)+5;8<
MWG\LQU 1O..+N9*]<,4UV?T89*YX?"G&VC+[LJV$'_SN=9^,Q"ST[R?W,CT6
MZH+\[>J]+?F"QTJK@R.> ?UD#0/W[$<O[Y"9>QG<@_^/!0<_+_U?4$L#!!0
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M7HSC4:F)$;=$028,DPT$<*M5<'N.+FADT<-^5OYS\,/+),@K3@G1GP5T4N'
M]8-9'*?(T$XU>OKPCVF(*2AO60"W2E[AGM"_>?EP;;]A" 1J!SE^LV=%^H/:
M?+96-#;IR*;V8)2!ML-=RCA?A9-%A/]B&L)\)%1ET+>^::ZZ1=6X%V<^$C6&
MFBY_>Q9/_L6X#QB(:-W %IJN2+#\.)8<W31O$B 2.&?FO7=;M.'M.AO0G^\7
MCHVSNFM-&VA,-/P7S9,RA>H,_95769MSOND=D/D.R-J5?UVX?>C/?DVM'ZX[
M<_5#@^:SZ,A(MW(@M>%SH/T><>BL3I+=][_;6<"OG(K\$NNUKKY&?]CL\K.F
MWM&5G9E8#*91G*.YJQ$  #^UD/@=<$H1>,KQ4,@M7>--?)MQ8@\W!;&Y>VH8
MGT-[J<*C',9+*_R9_:=WUV(YA-E\ <#+].FRW8%;W'DJ%+K$J$P/+38$TV,4
MTG3$JT@X-\*!4,*!.( W@8N!H?K>I(3/*2X%@&GQ$T[UWJQ1YI8RA]TEWK9\
M$D->A +T=S')$]IE^R\4CWC'44#9;L[NN=*6S%!=LLBBDOV+W,V2JT*VP-([
M@-0-W^O[[^.>Y7Q/&\Z*NHHT#!TW\%&MS&O+K?VW;[I63'+?::%^P2:E5VVE
MNL"V7D^RMZ<6ZS E[,FV('3&X\'H*,%4G*T3L(;*BC.4L*G3-L4M4-=KH4$I
MY3%T+8;/]&N8,_[B,D]19RB"6$H^^+15(?F[G\%M5CR;P:V7OQ/64(=J1*7>
M=I>C7MR#?<*C TQ=SNU-_YMH4!N3:D 6_@9#XW 2R<IS;X]KKA-L7&\MHMF2
M[!X6E'2.EI89\[8>WT'R8LGE5<!I=201(\9FYJ0>?$VRA$X;S7)@SMQ7H%EY
M?QQU4\[$6ZDG5LX">AQ+WZ--<.!:[$\ 3@=ON+B#7<'YIX93@<S#)XY 6Q9K
MSTEQ4-C*I2,I; 5^EC0"&;'_X(Z4$;)_S4?@_J?^2FXC3_-#K+]%]7P#!UN%
M[?QTD9U0J*)QH#,SJA C4<^\' ?9U!/VBOZO/MC"?$K,[6TY(:"_[+=R<FF
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MK\ZCF,(HHLL+EWI0%'&+8J:<]-AE>;0*DCGQ606M6^2<S=TUP(DEG,ETF7>
M5[FMR">H"E0;XTIE.O1L:+7[8U%IM$($:K;+'TXMM\+H0'2IKQUI88A#X7CI
M!SM6GWXGY\L ;F5$J%R@>)1@ 6[LVX2C'.=Y>P;?1^3I+ZM@@8"9FD]DK3!#
MP3*:]4AP[6*X_LU?#>V0IZ-8?$W\G,,_T(S]0+,!SCAX/8 K%!%Q.EH5C58.
MU=S;NV)7YQ>/__8J7GC<I+.]L\,E0=,T/JPTN3M)+2U &,ZTT"/P%.,C:Y-=
M!O*^5KCM.'C]>!V[':'J:@70($S8H#+N"P$.1H+)@J\%C>JRS_\?O>MYS'?
MW+_FI]@[8*KX-N@V,_UW6&!6@4N'>X?7_&^V'?[H!-W9#N01C*AW .?7OS'$
M$:^QS18F<V-E^9.4]0ITI5@?+(L<U/2M7S,K];[E>1G:>1%R5-"A8R(L'-2
MNA#12OL^*8>@.DD9CF,@7"9^;G^AVBX$\!06&<^6?:N];@&EC<7$TODC"D<C
MM^WM&]] (B'YNLV5EDV5L)+KX:9@_,C;B$T2YVH+M @I2KYM4-]>E+L5NM"
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M[0J+_FJYJ8]:HS=J$.MK>PUHTA035*K2G6H'U-?+ =!_<?&6'<V9ZR1V#^
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MVD=1X9=>?]Q%1<_K5 T7L4*K ^"_]F\O E+IL:18X:1>QZ@:RU^/_&*^+E/
M18L="06!GP@4?OV41?_,,-O* K#%J4WB6<J<AC_*E6S3VKD4WRB&^/TY.8@(
MP8#WM9FY<4-$GR1D!TN<]KH(H!'D<3W#;I$,G9+Z107?L674A[B_0KR-D060
M,  XGK'5CR3QJ.>$@@^49]]&QEM17%4LD:4R;JJ"_HCN9#SML28KMI_?ZGW:
M!)'$%%HW:S?#5$IOYD1/.)-+"W8/R,K"H4/;Y %/U?)1$T@/,XR5>C(KMN5E
M-G$V<M(ZB2U"P((BMSEVUW-_93 JSNE9(V 9PA,9<'VL4.@\K_>SW61:]'O=
MJ):NME!805D8IJ#T'C3/$R(,V>428*)@'5*XC<^I3WD-H1S'D&0@KOO0.IX<
MS3B*:41J),N$OH\C:]MZWBIP[O.;,3'5FRMC1L,I\YEAEH9B14O.-?;J0\'W
M":B&10G!PZ_^;;.Y?"_O &[YTV&P.Q@%'-DP+%A<;6 ]+KDT\1*HLSS1IJ%X
M6ZJ-I_@H*!'@J@I#*8>11<%K]#-1CBD1NH&N^V"*QR@<AU1H-*B:\%J&40XM
M-D3=2:;>UZ2FE4052_T"QDGD*]@S)[\BD\#>:27#1(-*+<$%==]P+;3U4F[;
M)Z!EW/'<+D;:5,>-CN.5Q1@2YZ1#&ZYBL8DYU8"!]H72YK7K-+@G[6NJ\IU<
MG)#&*CNT!+]']B1LWU]F?RM)C.;G*+4QKAFMD!E>5!"^O?P-/>1BH/8F !%M
M4BE,U8,PTI$@4W]C$ITM^>*.2H>P#]4@K5'FR3@CNSI6BV@CM !>R-,FHN$@
M?USOYYM6E_#CH3=$$9J$IP994)#47&\1.&-UUM2V/T*(BZ6)=/)B91NJPT_@
M+ZUQ%=OUN"^?S0@7<AX(]?>$_0_;#CG67(W>]H[(!;?.8 Q81,V,G3ZLL^27
M?EX]ZUCJE,6%+7ZM,2U7)9]7L36R=\!MBSW#5_7,)755X5$0\1?D^\H^',Z\
MUO-P%FKFKD+Y>!LA ?)>VBCVIP<-7>^E/[D+^5U*QG$^15;\U-74<0\W_-2'
MM]PLM[T_HF8#3$A-"<@8=6X%[4+U?_(8;W<-.BJ7I<<9%2HF#JD]G!_&:'GG
M5[BS; ,TVC!_"C_^N0P]O8-,V?21(?>XZK9?,_$QRES=Q,>9&1UN'."^5&XV
MK&S<SWMVY-S>UIN&E--J)JOOQ-@,/;L,M7\X,\G@NB)7D8?">I&1%%JYJ12.
M:#XOJ"X\<,'!!*!1%5T(\P=< +N75R4]HW6T56.R#D7'DX^\ 1#7VWE T!W4
MD#I]^0/]V.U4::80G))/:/.0[1ZS?/6.RA0UT5?5(:WDF&_., DK^.A;5Q-S
MS>P%I;@)MRZ9>AAB@+*$@W" Z+B)1OJ<9NU>QVIC?5K0]2V0Z@E JU/NZU8\
M9TX>71:"DUA]OBU6$T,KWH@%1(/S[X<H^)["5 @90X-,@CQ@1"D'0_:  ZD^
M=*:)4(XQ=":!-<$Y,.K<XSF6_-P,2\3O#(L3:D+9 !SV,QY;PG-:FRXPZKLM
MS+I'8;.VPU:^O2JUK=Y,75IM3?^JH':IMB<HBP?;9GXBCR!VAY5-65MQ_HBU
M&5\:#Q9V1YO%]Z<Y1+JSG%8$@QWSXW0TC\>/5UKW,!]FY[,<2V'#Z+O^:BP4
M?AFS[DN?3SD+0=^"H;1#RV(A!PU31=T,1M^-1K8SA%X-PB-_4@[!\,>A@'%2
M06J2891O4FF@JPY!Y6\2L^X;YIL%QY^J-=]A'BW*R_IS6+0)^?A!V(XH/=B\
M7L,F@OO+9>SK&=F_ME* :I%+DQMI"E$0'PQ3>PXKP0D(M-@]"8^V8U:'1??K
M/E;:G&3I-6OV<TZ]CA+-MWLY[DBLBG$Z]".5*I+0F"QSHV5\$?>FJJ*'285,
M)$[']+*2' L@_G8@&DY"Y#"M3(RLHS1(C8MJ1,VA_PMBY/CK64JGK"*B/8 A
M]8K<(6JL[? ^_N4H0)::ED::BT *F!.J>DO$S;W0("*5)/-:*L3]/31"=+?P
M\[.+-[SN+'7GMVZ5Y' 1W*Z"E6I!?R?5<UFHIM,'[4AU!QF%'>$S.>!RSR6O
MA''&2YI)9-71IVNV.>,3QQE_9C3UKOX8F#@B\2.$^YB\0\_"W !-EJR$BKI
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ML)_>'>/6(,Z>2+%KK7@N3*.O&\/'.MS5\CB)''Z"L.4UX@KKDH;8]A3Y@+M
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M9)G9R Q*QAC7BH\,BKV^IWXX002A7ZL%)8UV&Y\<-K+R&/26XU&4:?!6CM*
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M,)7EJ'V4M&2 H(Z5IMGLWR'?-=QP%5#0% =_M<N5"*> SJ-X+>1'3:,TK6M
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MG6B0JVIZ:G)H8HTN)*U - J<N0J3Q((\/?)UJGF&U6VDM96>,1A1$PV< J"
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M"*G!OYO:1/\ H:^N=&,4TL40FB]+B-E)H: ?1GSMU][J6_-TUI19%B<+_*X
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ML?4;@03L"1\7&O?QSGNOZFH$D]:,Q9"^]64?[7CG#-=U&GKS$CB?B;D3[[[
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M'>M>N2*>?_2$?U3(T@!9FI3L.FQKD[LH%EA0F1G-.U.H'?:F)7]A>&!FX25
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M8>/HVH0?\GL\!Z<IACE',IZC #I0[;C>OAW&']O<HLBI+&@500I(-=ZUJ@-
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MG3[+\O+ 6D2R10"=8:(&0<*D"@8$$GE7#_2_)4< DG2#ZK<BO)T' !E'V#4
M5'ODT\J>70CW&H72.I:(HB[-R4&K,!12/\_#(%YYFM[@O5>#6Q^"6E6X'K5>
MXH*T\1GG;S%.R%D1>+T85Z J"#7IG.W?BI)JK'<[_:*GL/U9W'_G&/R_^F/S
M+&L2)RMO*6FS7Q[\;FYK;VY'@:.YV\,^@TK]<+9GZ]L*YI.M>V%<S]<*9GPK
MF;KA9*]*X6S-U&%TIP&V)$XFQP,[>&!7;8X&=O? [-]V(L<18CZ<3+8BS>^!
MV.!7.!V.=]_YQVL/KNL_FI<4K^B/RH\[7?6E.6D3V_3O_O1F_P"<T-,;2?\
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M;@QV42F*S3<#[0Y2'_7&^=\DDZX63/VPLE;KOA7,_4UPKE;KA7,_7?"R5^N
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ME(!ZN;A2 Y>II!_$D6G"E6D^@F&;U@8O?QIJX]']N<4Q(&[')<V"*:2-<'T
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M^AE.FR<X4JIWE!]R8=L&[,?%DO)E38')9,OE&;5N)4'U6T;Z22=KMN7&HT/
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MOTUXN??)@2#1#-@EC"_?J]%56UD*)_N,UC9L>N)S!%!JYEFV,R@I:#4?(T\
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MS.7XFGDRCA,XPILVQ=\ QHO0<W+%IK0W@,Y235%#8TN,GF(-)X4\@8-(I@_
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M-N%!0O+7-.CZY%N-1D>@GS@PERA(C4IP!R![>1 F,L(VQEW2VWX(%W].8:]
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M7&B,!BN2K5NLF1:^. 84>QEYCYO&"B4D+'O2?MRA_VOTJ]!UD>J%NTQAAA6
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M&6(HR9O)$J$C1;L!Z-C-0S(K%D$\:B8.#I[Q9-0(,7700=OL9GFS/7Q[=.9
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MS[-+YT!^,#??K@3G%_)\(]/TTZM3WUD);[I !\,0\>F]J#\**)L:  "<I #
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M+TK[]>57#B_OTNUU)Z(/78)K07,;?;QGQ^SL](G+><R]%"\L(3K^D)4;9<C
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MQ8K- /M)\VD<V"BUQ.N7[498W/V),"VWPY= ??>J\)(,1T7^U$B?:D*@K7[
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M8O!)^!<JD8,E&(V:^4+P7G;]67LOO</$_<A)_-=M1DES+V&O)<+M&--(F7J
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M-FJ<O/NR<M%!O^(Y_GW,6?,?%"\I<))H + M;.:$GFB%S/'G"$:4XBNQ&Q9
M@]!6W62)D96+@U.WKR&M:]X205K&1@(#</L)0FU)S[%$W=N[GM4SV3"FZ^S
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M&1NJPT7R#,AYO7JR7$_FS6%:JR0HP1+Q^C/<&#V@?W+K\MIR/(CN&,X]42"
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MJBJ$7 ^C#M';V..J5MRO@*AL?_D2-EY^,/HN6V]\9/:Q61>8+P#MTP88=HQ
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M8TUV^?[W5DD=O#LH: ZD8!^9K!+H4S/Q$2P%D%<^>%(GQ@[N))MERM\YT\W
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M1Q@2'SQ\="_,@?LAN#XL@**!X0AH3%:P2J^LL1%]&./2/E5*S?$!N%&>!U@
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M9ORLL.49E-H+ &9ZWRSN=78NK'+@$JL9<'G/!28/Q0R1[<A@5"@S1[16'O%
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M-N*0H^R%B2QY$!CT@]Q^86H&5=(TP/'=3*S\8HO7N&9J</24U5%H*!F'*E:
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M".;2K#U75;?3KM)+F1B2RI!S;@E-F<L%"USREI/D6XU74IY;Y6L8KF2ZN/\
M2%]29/B1E9%:H78D,S#D>E1D*\U^9O*WE5+[184DU_S3<RF2>]G*%(K;D?2@
M!4$(M*DJ-R3G*I6_,_S;-J][;026EC:P/)=7'#T8X8XEY4:=Q53Q'SSB;7/F
M,VT=Y;Z?>W5B[R1AT$_!I>/J2#G$IY.$'(BM0NYVP/9>8]6N%2%8IFA!XIZ-
MQ(W8FBU()V&V^=2\O:(?,%J)-%\Q3:;J:#D=/U51)%(!N3%* &IXCJ,-Y;#5
M;,A;BQ%G>FH)CD/"2G[49('W'?#72/.NHZ1.%N46ZB)"D.2K4['EN/OSU/Y'
MU4>9[:*32@JSQ4$J,I#(.M2*FI\",]'^6/*\T CG:3G- WJ@/\59)*#U&/3D
M!TW^'YY,+O0UAEB:3BMS,WK&4)RV(!H69=Z9';C240>N"@A=RW"3:K4(#*M'
M-%I4'CUV/7.&^<?+M]%<OKGEZ<13R(JSPN"4GCC%%!4 491L"!OT.>=?,%QJ
M1N'GEM6@=J,]3T-:_$!U(['.;W&GSZA<2R/?PA^+,N_[*_: 4=6WZ'KD5UBT
M$<317&J!90AE].V0"1A'4?L_$![G;(<O^A,UQ<Z#:O$@Y)-J! =@=PP6,@_>
M33 NL^<M!UB"RT^;3?JCV>T<MG,J6RU._&+BM#7>M:G%[;S%Y-M$B>RM]0FE
MX-#,\X'*/ELSQO')6C T(\#DR\IP^5=<NH;*V\P_X<X3'ZJ;A) RJ2"(5Y"O
M%COQ#==Z9V(_EQYGEFDNK*\M;BWC1(/K,,:PS21!*F-HE7B_(B@<GE7Q&*>5
MH;NPUJ>SU9Q/:7<;68,X>)I)(U=X89>="A+J.+#HU*[-GMW0;RZU:.RUE[AY
MK!CQA=XVB:XGX"*=^+4XHK\E'\Q%>@WG2L+FWO QY+<Q^FW+?;C1C7/G3^9M
MC+Y,_-<0PW4UI:72QM:WMJ"9XEF9"ZL*CFJL 1](';.JS:K+=W,6A:[;W&@Z
M[#"GU4I&C6-WZI:1+CT68!V8D_9-"37KMDRT*XN@GU>:[6*YTWTYK62^0.Y8
M"L;SU(=T!)!44"4(([B06&A_5=;CU,65SY7G@>:XE%I/'<V,MY(@64V\C0\V
M$@DXLCNP(VH<*O.'EO3C=VU_Y>T@6UM<V,,>H:5];$MY;7H9F6X9'>-F5U)X
MM1:K\)%5!,&%O/#S2XMS"5<J"9 ]0.XI6GRS<:_?E%._4907Z:;8UEVY=,KA
M]V5QIVQO$;&G3IB96OMC.( _'$2N^,*D;#$F6N)<2*_PQ H:[C;$FCW]AMB1
M0 5Q)DZ[;>.)E"!0]^F>@/\ G'B]-EJ'YNVX:GZ6_*?SC:D<^->-@;BE/VO[
MCI]/;.;_ )ASF]_,#SS>%.!NO,&IS<0:\>=U*U*[5ZY$ /;,1N#WRB#[@G-Q
M^DY>XZC'@5I4;986E?U>.."@@BF-*UZ=\>%-!OOVVQW#PZ#?+XTZXWC4]Z8H
M%KU.^/4E34'IWRBU"69?4+=CW[;YT$1W-]Y/\NWK.DL5E=BU*$ AE8\2#7ML
M*>^#?-7E34KVTY6<;+I]RUO,ZP$+^_04'JJ: BA\:>W3.!:]I,%G^ETAM(HI
M]/TJ:!2U?3D"!(FGX$K5UEN12M"W&OS@EK80:/'K5UJ2+:1:;#:V4D;,"P:9
ME>;C0$NYCCH3L!4[USLGY)P2ZAK@O9(VB_=7$\25'&LD@4KTK\/"B^V>NB*1
MRR1?NBX*KO\ ;8CJ?ZX;Z,)EFLX6F5)^ !D:@4^(Z4!QE]<$3W-I;6\UR7,B
M13J ZP1N1SX(10-7JQJ3VSC_ .8FJZ7Y%\O7^J7D-ZI8'@LI8/<2D$*E00Q8
MDT4 9XW\O?EIYV\P7$NO:I;C2DO[CZQ-;']Y/PY#C$:'DG("G+<_+/:VHPV>
MH_E;K7E,6J:;J=_HDUC;JE"I<$N#78\G84)(^9SYZ7\7F_3M(3RTNIZOY:MK
M6XEU&"V]66UB2XN[<VL\R $*LDD!,;MU9/A/PG OY86&N:.FH>5O+#O>7GG>
M!-&GTVWCAFEOX/6CG6V0,I*'U84:J%3MNW&H/N6]_)#R[8>2]&MM8D@TCSI8
M:?;S&2WG1ED,BAP)3$T@! ?X6ZCOG++SR?YA&BS3:_:KJNAO>BPBN(+J)KD7
M+*'4JIH6*\@"U*;TKG,Y/RP\Q&:GU21U5JLA!4ANF]?EGL3\JO*,GEMXOKMM
M]5OXH565/M)1@"-QU%#GJO2I86@BB=F6(4/P'@33L66AWP^NM.MV3U(+=B\7
M)N4$E8N&U ]:'E7>HK\\BEW-:-'<!PG&52DB\&"U7=><E2VQ_9  ^C.4ZI(C
MPJB/61B4.U!R&W+QKG ///DR\O[;4=3LY%,2O$CQ"159?48J!&.I)(WIT[YQ
M^;\O]2L+)[FX1HX=J.R\B">@8A2:^V1RZ\B:I8:C'#JNCWFFR7ZQ@2W*CF\4
ME/3H"00IKL2!UVQOG[\H+ORC>>5-4U32O\1Z%J4,MS+;\IOJ<LJM3T)[B!D=
M=CV<'/,.H>79Y]6TW3[32[73[>VMQ;SR0AV>YE621C<3+([CF0P6B<4HHVK4
MGTCY"\L^7-2_./0H/*OEY-*\O75('TF_N3J?"*.UI=L]Q)&G+E(I<#B.%0HZ
M9._SS_)SRMISW.K^0;":=;@>I=:-9?O(4!8AGAJQXE:5X?=3"7\B/-5T]V/*
M6HWS<DK]32Y1UD/5*,:@JR]/B'TYZ&3R6=?3S%;:Y&OU74'2$W.S$5^%9&K4
MUK3XAOM3.^: DLWEBUCUL&WU"TM TD3#[,Q;@4% /B^$&E-J_23+3W].T6%P
MI<+P([E3T^G/#O\ SDO:B#S!H6I[_'/%'<!J_917X+M4T.]/<X8/J$>MVGE;
MRQ=726&H:5!=V<;F55(NXJSV\<OJ@KQH!Z;\@/VFV!R=Z!K&M:KI$-_/H\FK
M:MI["QN8(P&,\J*3+&07#*X4'?\ 992 "*$SZ\AT^?3IH[QK^WF"QM#];A,L
M*6\PK"9".=0KJ4,@8E'6A)!&<WN4D]4H^Q13&:;AE)Z#<DC84WP *D#5OPZP
MJ@J =]JY? $T^G+*=*CVQGI[;5VS&,]_[,;Q!^C&E:[[XF4IC"H[8D5K[8FZ
M;$'IC.'AOC.(-<19*=]L2:.M?PQ(Q$C;>O6F)%.NV)\1X5KVQ(H:4SJ/Y/7#
M6WFC7TJ@2\\C>=8&+=A_AK57''<;\D SG^KS"YU?5+E']5+B[GD5Z_:#2,P;
M?QKA< 1TRZ$T /:OT9?$G;]68* ?GCB/D!E[=_OQ_$]SM_GTRBM3_3, -MJ[
M],=Q'CE[=NW7, 2*GOTS $[8H 0,N@H? Y6QZ=1DZ\J%[G1M2TIG9_J][!>0
MIQZCFH8?06WIVSOFL?5K7R_-IMU!Z<T\+)R9A21'!K1@12E-J;@YX>\WT?7;
MR5.,TD<#:F)?4X,_HSUE63X65E/)7"T&_4Y!]4OX-4\M37EPA,^M:S^D#95J
M1"@@MW0N17XI99-Z[@^V>B?R6M9%N=9=HE6?32MH7)W ')BB^PK0_+VST45E
M:*)% #2 \0-E)!W!/A3)) MJ;:,7=F[#X>+HI8 =ZD4WQ/4KN73["7]"F^MX
MY!19GMH%^%A6D1>0-R)WW!KG)/T+#J^JK=ZQ9SZC+ IN8[S6BL\G./?X8U"Q
MPHE*A5&YZDY)+;2["=4DYS(I"W"NH'($[5(7;>G3!0\L?6IVO=-%YJ5QRY-'
M/"LJ!F('*0F17*C^4BF1/4?)NJQR%;[0XR/4Y3Q&(2H235SNW$@CJ3U^C(>N
MDQZ5>^O9:7IND7L(+K<VJ1QRJQ%"(W"[FGA0YGN[*&""*254=@WK%.04L:_:
M#T4&IQ73-#L=4JPL([N*XB-/7C4)5>0H7(W'AMD?TK5KY=6F\N:2P>$7!B8O
M5XHX@=SOTWZ9Z(L8Y+IKB>$+;I:B%%44^(G]D#:@HM<GME<"E2K"AY+R^R0*
M5;KTP^>\C>W-PI]>5:@.SAT  !(X\B<@'F'4TAL)9HHC,>2T /%5-:,_7?PI
M3.?S3&&9@K56=Q*I/[(.]#3KA$&CCU!BOITXR>E*Z@AI"M0M6V )I4@YSOS=
M<FZMG35Y9X@9.;6\4AC02"@Y.J$$@4V!K3)?Y-T#0YX(=2%]^DKQU6/G<2&0
MQA115Y2,^U32G3PR:W_I16>I:6MDTMCJEOZ-Y;%@L-RLBE2"@J*4)%>H[>.<
M>G_+S\N)KA"WD>2"X5 JHDLT8(H0O&DH%#TK]^2K1?+NGZ<3?Z5Y06UU@+#I
MRW:1>G&D:*!&KG@Q;BJT:A#,/CW[G\^@W!69K^*"QY(7]%%927K0!"ZKSJ!4
M$C.6>;_RQTR9H_,7Z/'Z4TNZBE>2R)ANY8Q4,BL@^UQ-0.Y SM/E'2Y[S388
MK?6;36+*96A>>Z 25H)/V7*LM3ON"H-<GMAI$NE6<<6K:K;:JML?3MI(W,KR
M1 D0U[\U39B=R=^E,7M9(C<S<4_=KL.5-U]ZYXM_YR@-S-JF@VD15TDM+HS#
M:I830O$RU\"" ?>F<;2YEO\ S&]O9VWJ2O;/;&C>H(:K+:<V!)KS"$*3W;WS
MTCY:C6'0+;4H1/;ZL[6]K<E9E$;2QJ:%O2Z2&/8[EMNHVR5ZGJSW5M;V]K+=
M6PA,G*&:=KD+ZM#+'ZC!&:-F%>)&U>YWR.<#0CM6NW3-QKL.N44 ]S[97$^'
MW'**_13**UQ,IX>/3&E:GP]\84KVW&)E/QQI38[#V^>),G?:@[8GZ=0:=,88
MR:UQAB)^6,*=^F)%-MA0>.(/'N014?QQ(QCMO3\<0=:"M-\EOD.=+77;V5U8
MJWEWS)%\-">4VB:A&O<=WW]LAJ[4J-L<!UH/EFI]^6P^FOAVQM.E._\ GURP
M"10['KCZ'>HJ!MCP*4S $9?$ 5.WAE=3TIXCQRP!X]\NE<OCB@6O??P'CE<=
M^N7Q I0=>V2/RS<-;WLJ*K,9D6@5B/L.I/3]5,Z]^8.KPMI\<32+S$"LT:@K
MQ?C3<'N-^F>;O*_E"[\[7M["PK&)8D@JH9HRWJOQ!WJ'X[@[=\YIHZP16^G6
MVJPS(L4*V4D<(/JQ7#/+;S2,C@!O2>57;>F]*_#GI;\G;6?38+ZSE$8D,M7*
M59&* QL$)-2*I4'PSN]O%+.Y0OQHW)0&--AM0 =:'?#2;DDP#R-(JBO$; O[
M+6E<;=22SO##)(L-K$ 3(QYE33H3ON:]%&V$%VUTY>R32?5M[ME62424,J(:
MJK<E! (&^ 3=60NK^.WMY;*&%8H[=9J[S&I;XR?$[=L$7FNBS1[4B<3MQ82H
M/W;$"A(<\>OL=L@6K:S.X_=:A<D;!8%DY%#\^7;WPA#2247E),S?!'SI&:']
MK]H[D_3@F/3#ZPNKV/E)$PY+&JNP8BG$%ZCE3MAUJ5S+'8_4M/TJZ]2X@].'
MTY$,M2H%""QV#=:4Q7ROY,FT.RB18Q'J%UM=RKN.%>11F.S!2=BM.M#G3+2:
MVCECM^,5M)$U!(.1$AIU)/RZ4VPPFO1/;7$<3DJD902+L!78G;#_ $>,PZ*8
M;B.$++;^G',PV_>%1S/$$GYY%]:MI#"]NH%":!5 /*@[#KO\\YOJ,I$D<RBD
M$*A:+T''J"<!DPZC:&UC""16:1)*[FO4'Y#"V[\HC58V6]%&:)BLCT8.2-MS
M785K2E<YXODWS%H086L!N;:,<FD5BJ1L?LM1J;@#8DT&&[S^==&!<PF^MF=>
MX)!&X)X$TW/7%;/\P[VRF$M]H][ZT;\FY0^JH8G>I%/#.@Z?^=%V;<VTT\RV
M:,&598F4(RJ5!#<6W -">O;#P:O)K,G"*YC8J@GX3QR %6I4\J4W+;5&&:Z=
M->QSZ5>Q+)=1*LL7U8$\HFKRX"OQ%6WZUVIDHTG3[6U$;WMRUQ)*1^\DA@F7
MCT(E+0K(#7Q)^>'TL4<2.\44#+'O^Y0*#3>@I7\,C%[<>I?.\:< U0*=AL?E
MGG/\X/+>IZQJUOJ]JB+;:?;112W#+R9"\RM5$WJ:@;=-LB5O^4SZ)YPT72+=
M2K:KI\L[2N3#%(L;A^(8T/Q#DK&FQ/TYVK7M-M]!T:R\OV]+B&YNC>J_$*O.
M"+ZLS @#>0 ,W7<UR%A6*(H4_"H KNQ':I[Y83K\LKTQN3URS'6E,IHCUI7*
M,9(V&XQ,QTW(QI3KMC/2.]!C3&WRKC3&U.G3$S$/PQ-H]JG?&&/;;KB14[#I
M3&%:C<=<19!B3+[4IB,B]AOB)3M3KB+(#N16AWP\\KM'#J=R\K<%.DZP@)_F
MDTV[11MXE@,BZBOB:US4(8>_^>^.[>YRMOGX^&*%.F72FPRZ$"N6 =@>I[9B
M.A[[5S$&N_7+XUWICJ>P&.IL:C+"_++I\MLJF_OCE'4#!EC,]K?6%TC!&@N8
MFJ0"*<A4$'L0:9W;\Q=,GELX]06.!8RH*+3[2M4LK\1U%=C]^$/Y Z7#)J6N
MV[DQ75C)!(RCX>[JCU'6@./USR;I5[YHUZ.ZT^-H9M0AOED50O&YXJCE6 !
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M'=J'D=_ 8:I8H\;R+"T2! 0P:L8;?O0&@'4X*:T6&-D?]W))"T@E"<%)0<J
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MP*$BF_CC@*]]LH;&AQW7WR@I/4].F/"TKWQQZ>&91[Y)_(KO%K6L-(ICB:"
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M&6.45K&P<#OL:YW+3WE$4,B*)5=!+0=E84H1].XPPM)HDOE!#I(%]7D37U&
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M:[5RQ\\=V^6.I7Q&.'X8X#PR]NGXY=/G7+4;GMTQX4#KTQ_0@CMCQO4GN<L
M'[\Z)Y0N"UI+9U!9)RQ"C]AEY#EO7J.V3.UF5+HAJ,9"U>K5Y DT(VIMUP]F
M_NI"94=9)%9!VK4=]_HVPNO4,JU2GJRD\Y9"59T/Q!0*^. );H36Y0+4VY,8
M9311R%30#K6G<C/+'YK>7KK6'EM+"VD^L*OJ+Z@"K2AH0@^S3\>N<^_)3R5^
M@M:O_,?F"T$<\/);#UQ1.:$!G!([ [>^=DO-7U"XM3;N3!%;SM(&9E82K5J
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MMU^Q%930.D;^(Q$Q"-H#HW'2<YC^)3-G8KWG4X20!/55#4'D$W05GN(H?.-
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M:)JBNZZEJ7HXT.%C7](I5NW0=8*^P,EG\]& %$$+0<YH9PLBC"WPAX^=D@'
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M79PU72F$_&+Q0]6$9JBLN1MO31X &I$?=68'+S4@QBWEALFCKWH:"2N/!_[
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M0WZ\]I UGLS2Q)(B2^7C'P:J8_UV=I)NQJ_)=5B<6B<E8T^8!R:KV%N-&EH
MCS0.V2,UYD6ZDV@'V8,DQRQVQD?XNT84Q_F=3[7,,]FQE=]E75\^=Y2ITEQ\
MX.[.P&L8A^54IF7W5N!S*O9IQS8+TE9FD58<<=0)FO#1P=/G0T)KSB\&NG8^
MN<SF:D2>3TF &[)2UN8-;_>HN8N-4S":8@C@6Z?XK5:716J*VU4 CJ7YY\'E
M-)F'F I!?:>,!PI56V5#E!'N(%5-M^E2>J[^?SK-#F&4P1]K\L%?4Q5 WDCF
M=7$/R,RFF<%RUM&A7])J\OH(KH.+E]%C_ESQI?"JJ?&AK9++6#J8&>7RI^DY
M^^H76,Y=E;[2L0^?#:4L0W UBIE=@\SJ:Z>_Q035B[*".1I0>I,P*,ZIO9TF
MMK-DAV1[2@*E^I)>>_9UZ^U2/.J-<4O24=VL ZU $"U^ME-=E7U-4Z+F1,-
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M?< 92=OIT1!HC3Q6YU,NIUP'03 I#%\0!.HO@.6&A(V7Y'KH@X/0Y+E,4\0
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M, QK:\S=C#89L%M2=4?)U=,QJZ/7 Z-[/OW=21KF2$X*;4=)HIB-/GG= SR
M=!ISP!J!(1KHX:B*JQ*OU9-NH#%-9Q9;V,G&&<WWVDG>'TIF[SGH?D',#EV/
MDEWCI<CLU&8DM% AY@=2AU3E^EIMTH1*Y+Y02+S"G>N5- IRA_?!1".H:J3.
M&P@JIQ<%T^,6\J7C$^:72E2_/'A<_,'VC:<! F3H0(/C)^>]J!]%]L7[J6NT
M#=\Q@N5%"OBH"_)Q19M@-"Z%Y;&FB-SAHW76;#=(7N0# N7D'"\#S*PO?)]
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M"@ 4    <VYY+3(P,C,Q,C,Q7V<R."YJ<&?LO'>8VU3:-SPAL! ZV=!+0B!
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ME6 "9.U#"R.*#XXA) 3*;#Q2T^6<XFN=+D +&1 E281(UNQ38PXI%@G$5&D
MP@V(D["JK4G4(#A+>LI'2-&"Z-4J'X"3M%XP'%!+)8L=#<C.FJ:$C0'<;F)#
M"5RG!C,(4@(K,2#B39.2'?1B9KLD8IRHBTI@V:#2VL"(!@/YLB /KZUCIF0\
MH)@V;R1;=C@%JC;DD+[@\;,INV3QJA4/HF3=LB4BZY391@RH4<OF3$BT%(WH
M+$IVK!6#!D^%+GID(ZLDJWC:Y&5UCHP?PH,J5=DQ#,BGA  3]<DD5D5EEG"4
M8G:.#;D$)RCIW%+>1.4=8JQ(^MRB50M;8"R AHV *RHD=#CH!F59A&*Y(AW(
MD'*JYJ1<@L193#9].N],:S04&\Z(2C E0C9%I9)AN$1X2*S Q+1!*IRDU7":
M#*!2-!N+QI(6#Q]'Y4( C;H,I:!;,:<UP=9J!,[&.65&AZF'DN&".P.Q.:,L
MZ8B@4ZTD[80.MB9=09ZJEMT062BIQ"*:3FE=5I(2"C&2JH)\4J/VBFAM=8X7
MG4'1:&5@NFST.O*YM)(881%;B-%$ < IE8%XR0E+=B$ D!5WJI#.%T@2IBV\
MGDSK*E4H9TF'7;IBT5D*L;6GMQZ8UX)EDULK5V@"3M,HRUN+#HKDR4 $B\!,
M3&7RV!S.#$T8<,3&:K(.+:Y6LC06B(*<4X5QBO4,8^50/.2HK<Y5S$0F1#M<
M23"9#%$L774"<"@E8H"HPHK*ARLI41LO"DB&(34YBN8RF6A!:U.[K$4#;K-$
M"D-/T5(\#22!FMB8PXI),L(JCVQ2:PTQ1@U:?4;!@J485G)C.52'9+ \$Q/=
M:G5&QJD4"<-.R!]F+!K$F)(#@M%72%#)4"1JIFK+?4Z!3]-L)H1X8"^+JI$P
MZ'8%$(\]ZW/8=8$<8452!M2)II(.7I/GJA7<:I(-0(1% JB'+3-A&H_(/D0+
M6\VJVDH[JC8;=.&"1J6F(,(0(WSQ.$'R>D?>EW0*ZFJ&*"B&&U=\O$JMT[*H
M:#$FO:"#H?-&UE8$%0^=+!H4I:ERF% 3&]"1 \**!9$*A \,!Y40%;*5#S\2
M01WV=*#JM 7*.&VU^/UT:LAH55TR!\III9NVG)$(HI#.0>M+$2%8XZ%+23Y=
MMB)%EW&]+E\M.@O&",B9M3+/J[V^0,D;K)3=98<^R*@0JV0,%N*9A%C187A$
MT7P@$.%<026^*=$QV%9;/^2U5$AG+]K2'K69".A";(PCTC#BSW":*LP$5%9=
M4!!=" O$"9_# XJT5K06U+ Z+D>DBB/N(56ILHHNE 0WH:E-2BJO#5M(E@(8
M9RD(.DH9JEI1 N2*SHT55<F"UDN$Y6H^YH@%(1X/NS+5 B+@?A-E"0.UY\8B
MII,=B!?TU":E&@.B*:&L)!)5V #;_';9&"P!85TI[C: @D8 $AH^RN<SV50\
M& @ZAQY$XT//0<QF.N7&F=#04_.0A7-R&2=46S(M^YW6(NMB!"*7M[,4AT9L
M>3H%I3A4J>]%<VJ$*D<"*58VTZ%$-NM2>95$GO31LA+)%TBP5,UQ@5(E;RI+
M0&VYSZ?82L6 24H:9T(Y) BZ4"@'>_06,H0G76)."*3SUJR+2Y,T6R@./4NO
M%E60&N0<.<88]B$$%#1Z&6?0&*BM+*4+417IC1G3J4*XY,8-6" E&"%JR)]H
M%;;(#A[F>(Y3HG4(SRN#D$HD25G+14+GM7-I0)MR^D%4+,ANGTDZO.8 *09(
M"=HU,.#769+Z9%%2II@/B(EJ)5!D)%J3SW@\ .)U%I)IT$D%-+"QC,IBW*XW
MIB$ZD$O9PW2B&@_Z:H\_O$Y>1N)8&B!85P&"93XK!-B(,^GBPJX40:!%WF(0
ME*"9YAU>#ZLBE20.@Y0.> D;D@#YD&RCF+#+&92R>;CV7$\$4[22V5E4BKY$
M\RI E[-1EDB"&5(H@/<!<<97]0(\JV% -Q'!JS'$CO 9"+:7$KHAWND-?+#L
M\=L0MK;F@&H9)5)(@$B!B,!##P35<LB@N-U@5FW/\Y5\H2 'G7I?1F4@',//
M#N$8@)<0L@+02F.T: LX7!7)FRYIT9H]Q!@-X0Z:@73<9]4;JB$A"BAN$J"'
MXFO64> RLLP);%8((A8-[6/<KKA0,N4RA6#('I2(/.-."$Y=W%B@*GCV\'L.
M. @,AS>8GHH66""?=>.L8FL4+2A6?O>44B-9(."RR17$5Z+UQ: =B2FN*UU+
M'C.XSHJD#3IOB))*%45<C,$XSD39C .(997T7<MFDPAD*+!N:T;Q6Y"$R"$X
M#P.RH>JMQ (@;::\62?M2^%,;5)0.*]+BMZ,FLF227-!QS$5C\ECU9CT0IDG
MDMJTX&,M$8[+:K&$DJ/FB PMTBC'1.ABRF5Q480F :FL,8O%]^.;&)Y .IG+
MB0",9D1<\:DZ,Y0.T':(K 3+4*Z:++B\/JVE1"GNSJ3.YZU@*HX'<O\U?B7(
MU<IL3%%JI[=FOI@H):2-U90CD7+P:$'+FBPVL,#9#9BA-.2L/$'8J(5=89<8
MIE3^JCJ+.#%=Q<F(P6 A0I=X1]F9+.!T2M2J#UML0U;),O$@0U@%K[V0%1B5
M[%&R_S*'(;ZJ%727(C[9!J<)V@ E*750J],@^5BF2)&N>,4N)K.Y;)HL>4(J
MOK9N(QI+0))B91Y$LVJ0QX;<HE :>KGDIU*]DW69P*%2% :=D:K, /A0Z.PQ
M0Z:P)>@+N[R&-!VPUZQ-&4?X2#:*AS,VQ2FGA3C..I2\/>@P@%Y.MOAA4)VV
MJ0FW$H"[,6,MY2_KAU-^O5=5B2KB]J,KJKU(]J_><>)LB 1F^+R/ V +))I"
M)3==R%MX(64LV5UAT>8VA#)9)@E 2CA@K/EE3*VHNIJ5<= )!%T!4'9")(73
MSK2/5P'%LFTHM^$!P*<M1B&M-ZQ$((H@V* 0R-G36%Y'I )),46X1;TE[ZK)
MH3=HR(J2O^B/IL%"9,CX@'JWR(+.X;=6Q*'G?;PS!8K#[^P,K8@0H"Z$\QP8
MQ"U#?GGH?1TU6)5 -%>;E) /R @NH.@L@@@!*C28'O80.24R#4=TP\_,E'#8
MI- (I.0&T6"^A"J>ABX!\;Q/#D-:V<62-$)#1J"VW%>BK84L(*GI"J7XTDPQ
M8L MB"D*9&T:6N5+*GD[JQ>'Y$P@"3#'R3Z*# -I%2"J"]Y,-:E$*! M.[.%
M<A2N.?JLT6JT\JB2':>IB))6RWK)17I5DL\-B(1.,N8)I]$)%,,!B\WO%(IZ
M U; <668V1B(#.4L814J*P%]Q8B":&V6A]Y^JMW5A2AQZ/E@L00(.6?>ZY-+
MB)R&G2'<KF-ABR>4#4$\A5#%>$BRFB()*,_F<+$4+#IYG([@,#T,J'9G93KD
MBT?<L@7A$<)5U-KBBL\)!D,:SH*[#J=QB%M=Y92>_#J#^X64_?Q=D<,G/ .Y
MW5BH+%=$E\EN+&2HA%MT,GF[MV)U%NPPJZ3%U2Q,^JL1-IN#<)6'\$AHE@]G
M8%!3>YZ22U5PE\*3/*'&LLH,"Q$6X*J@H@4"H$P\:I% !P4>+BV;@.'2LE'1
MRZJ2N1IY&D25)!_3HZ)&./R:5@T*.'Q+[QNZI55DL :E=PZKN*)NIO]2<06J
MIOA*!X95O%3K4&V6_R][]?,.U33E_[)7/^_0X03\_ZY7/W4H50M%G*#=A/$>
M)^R%8,7FVR *K>3211=!H6JF5,ZFHMYT/)*+A0))R,XK@8OKCZU3[66\_^';
MFZ N,^VGU[]K[W;_YI7V?V.'P1^^,S]U>-O*E ##T:FA'3G&+%DH3.?%?)X=
MVHDQ3/G;^[^A]XJI1(HCLZ9\O#BT-<=NFEXLIN@I*&)&U3H(Q5"C!89-!CUJ
M5IDP3&LTZXT&#:3]$?]WZ'_3QL_N*063:06>)%&UEE*KZK5J!JG7,'2\'J-8
MI)[48JQ:!:M(1 O]V,2_@K9S!8GDXLQAZ)0"S9(HHX,9M!Y24UB]1D=JZC%2
MIZN'4$3)>UB8@G7J'Z%_1O[;7C-BJL30%C&?^V]N/I@ZO!]H2NHGT&%6:N(J
M#8729#T-,]IZBM5 ]3HE=JVG5#H6@2F*T6+45/ WM+\'3?^6DQ"JA6D$8NLU
MB$;AI X>:D)!1U$8TL$LK<33](_H].]Q\B?T_/]8%OZ0_O>:$?]09'_W_J^T
MX9<S\]MILZ4*4EZL_L[NDB C_._L+AG>K36%C _U<7J!5+HRU/6?E?TQ4>JW
M\@K'51@%,5"]!H74]1I*JZXG*9BM5]BM4VM5+(-0U(_X?R0>OVBCG&2XH2TZ
MJGH8JE=I0C R!=9.050 I!K>HO.S6G\,4LBS4ID4&7U"F<C?V\.$3-;\<@_3
M[]'],7X\27()AIX._DCX8\%_SUC^OS%U_SU3\S^8NC_:7?6_,W6_V7[V_^O4
MU4I_J8P_:O9OE7?JS[8K3@E*I"@5>9^89U-99CK!*(KQ+^[_ <KAC7;!(E7;
MGV</Y*D4]TND7]7Y&9)BJ*8H#=#%.",>9J[/9!F735$B*5;'P>CDH8GZ1:U?
M4E=^!,<9L3 D<BIX,C2Y1O.;>S]NOP5_M?^VMKD7/+R[=_JQ"@-_W%O\>S/W
MOW_\IY'_-/*?1O[3R'\:^4\C_VGD_ZE&COWIUTF43&K:^/+XRZ?_\,;,D^U&
MXPQ?P&NQN\QU(TZM&_7=R7J3P7S$R75UO"B)1G?4Z2*I<4<_5W=4W4EU)]>=
M5S>2C!=XO<_G&OJ1E*&Z=;\YOGJV;L30]U/UOW__7QXGTDI 4U<W_*LKC7&E
M$\KU)N4:*$O\T/73RO48):1+*-?O*==G2$P\65=WQ!#M\:4B0RO7QRO7UY12
M3%FYSBK7%^I5!DBYGE,W8@:K7*M^=@W7C2#_/G1M4.FANB/NO;;N".PVY1JN
M._+;,8>O575'JQX:NDZ0.:EN5*:QKF[.W%H_AX_QQCPI,?0XB]<:T*N5.-H>
M](Z#5:A&6Z^:HH(@S<1_DPG_IT-B*M+0MS'/5\6A'R$8I[2B'5>+/(/5@L3D
M"I/&V;GXY+JZ2#0VKD;UO#(7KWOKZG:_\R.],OLVDS[T8\?K"JG$<-T\RQ9^
M-KXC30CTOSR"NKK:_"@SP3P-'-&XZH8C3ICP:)V\=U1=<^"3NM31@\JM$3E6
M4@UW8.1Q=369^MGQ._^/J G"LR.V'M$W,GVD[ZBI?ZH_>MPQHT<=.>JK8]\[
M[L7C'SEAUXDWG;3RY,%3VD:7_IP>,^/4\&F.T_5G:,\$SCKIK"_.?O&<>\_=
M=-[<L0WCV/.#XPT7J"Z\<,(9%YUP\<B+O[WDLXGO7WH(>'[2X_5[)]\)W@BM
M@/M5%75<XT)0=)QVE/8+['7=@2F[+KMIZIII"Z?/NKS[BA:];"@:19-@%BRB
MM6B3[<V.+N<LUR+W&L]&[Q;?=O_.P+W!AT-/A5_!WR4^C_PS-NK*4Z\Z_^KZ
M:S0S+KO60-HH;QRGKV9H-I,0D]542[H[,YA=E%O!79??P-\D;!=W%NZ3'BX>
M++U<?J?R6?6?#:,:3Y\YH0ENGMIB;XVT)=JK'0.=UW7=V7VPY^.^X_OK!WRS
M2K-7#NZ9\^+<K^>/6:!:Z%^47SQ[R4U+'U[V[HJ1*\>NFK(ZO"9_7=_UUZ_=
MN>[@^K]N/&+3F3? FQTW4C<U;%FX]>:;'][V]JU';!][V[0=5]T^\X[!.U?]
M9>O.W;N>N.N-N[_8<\P]Y]P+W6>^/[8WOZ_S@64/;GMHW_Z7'O[TT:,.G/;8
M.8^/?^+B)X&#DY^"GU8_HWD6>0YY'GE!\Z+Z)?AE\)7Z5R]][>+7)QPZ_XWS
MWCS[K=/?'O/V]^\<>O?^]S:\W_/7S >>#^&/QGST]<<O?'+7IZL_:_V<_IOE
MBTN^'/7E!U\=^'K;WQ=\4_V6_(?C._2?$[X_[8=C?_A!F?^](_J."(X\?^27
M1SY^U)8_S3HZ=XQK%'#L<<=^<-PCQ]]XPL")W$F^DU6GG';*-Z-?_?/]8VXX
M=<YIY=.O.D-]YO%GOGW6[K.7GE,\UW\>./:$L1^-.W#^UO%S+Q O#$U +SKK
MHA\N?ON2 Q-OO_0Z8-:DAOK,Y*M +Z2%QZF.4WVM?DMS$+D7O56[%ENDZYTR
M\S)Q*C,-GVZ[?.H5D'Z"X6SC:-.QYB/-WUN^M7YE^\+^H>.0\WG7$^[]GON]
MNWV[_'<&[@C>$;HSO O?0]P3V1/=$[OGRONO>O#J1Z]Y:L9+U[Y%?D+]@SZ&
M.8V=D("24U/V-)%ALZ5<#[<LOY6_7WA!_$0ZNCBNI"L'*URU3][0L+?QC:81
MS>-;C*U,6T_[31U/=G[=?5[/%;W^OGA_::!OUNK9MP\>F//VW!_FG[D 61A8
MQ"^>LV3;TH/+OEQQYLKIJ^C5?6MNO>ZEM4>N ]?'-G1NO'73:YM/N/&RFU);
MEFQ]\.8O;AE]*[3=<UMV1__MF^_8?^?[.X_=->DN[]V%W4OV[+GGO?M&WS]]
M;W;?\@<>>?"K_6,?MCTB/+KTP+V/O?_$24]J#A)/59Y>\LP=SS[]W"<O'//B
MN)>0E^VO7/EJ]C7Y]:Y#<]\8?+/ZUK5O6]X!WCWIW<_>>^K][7^=_X'PH?>C
M21^/^OBM3^[Y=/EGQ<^]?YOXQ<@O7OGRCJ_F?9W]N^6;\[_YQ[?/_N.6[P;^
MF?C>],/YP_._8T3VB E'O#ER_9&YH[ _'?6G)XY>=DQ\U"3%!MQS7-_Q^ D7
MG/#YB?>=M.#DQ"F7C3YY]#M_WCEFX-1K3H-.'WGZ,V=L.K/A+,_9X\_^\IS]
MYZX\3QAK'G?6N(_/WSM^V07\A=8)8R?\_:*#%V^YI&]B^E(7 $[Z\Z1OZE^;
M_""X#5H&=ZAX]54:!X*AEVC/P([!OM5]..6URYZ:^M"TNZ??=OF-5ZS6SS8T
M&?,FTARR6*U3;;#]8L=YSE-=)[C_Y/[!\XWW;[Z/_>\'W@X>"KT:?@E_@7@N
M\FSTZ=C35SY_U<M7OW[-VS/^>NVGY%?4=_1(YEAV=.*LY 6I^K0VH\^Z<U&.
MR8M\JS HKB[<+-U;?*KT3OG;ZDGRA(;+&OTSDTTMS4M;;FM]O.W#CF,[)W8Y
MNC,]LWJW]3W=_\VLL;--@ZDY@W-WS'MYP<B%ERX*+):77+_T$44.SEMI6U58
MO6K-_NN^7#MVG7E]=L/\C;LVO;GYN!LU-UV]I6OKMIM?O.4H10ZNO*U[QVVW
M'[KSI+],VYG=M>RN?7=_MN>\>YSW5N[;</]3^^H>J'\P^E#'_BT//_O(=P?.
M?\ST./-$QY/7';SKJ6>?_NC9D<^=\3SPPM0772_%7DZ\(K[:^%K'Z_V*'"QZ
M<^E;R]]>\<Z*=Y>_M_3]17^=^\' AUT?-7U<^B3W*?49\;GS;].^ +\<]]7H
MKX_\^NN_?_C-6]^^_H_7OGOCG^]]__GP_-\Q@C\"..*]D9N.S!ZE/NJ;/^TY
MNN,8VZ@31AT\=LEQUQP_X?@/3]A^HGR2_N11)S]QRN+1,_Y\\9\_&7/'J2VG
MV4X_Y?07SUA[9N8LS5G?G;WOG%GGALX[Y[PWQVX>)YRO&U\W?O\%\RZ\:L+%
M$[ZXZ+Z+YUX2GXA>>NREKP-W3II3GYIL L\#OX&>@;>I^M6L1H^<@WR%/J'=
MC'7HKIF"73;ZL@^F[INV>GKE\L 5D_1_TK]NV&5<I/@%MV6B]2CK&[8]]I6.
M1N>5KLO<Y[B_][SNW>O;Y)\=* :O"IG#$'XV<0SQ9>2MZ%.QO5?NN&KCU<NN
MF36C[=H2F:7(>(3V,&9V:D*=G)@:ESX]<V+VR.RWN4^YM_,O\D\(^Q0/L4W:
M4%Q1FE?NK;14*[+0D&ED9I)-US1?U7)EZU5MU[13'<G.?%>UNZ-G7N]U?;?T
MWS_PW*P/!T?..7NN9IYW?GI!]\+UB^Y?_,;2(Y:-7VY8$5_9L6K]Z@?6O'O]
MT6LO7F=9SRKV8=VF^V]XX\81-XW;<OG6JV]NW+;\EEVWOK3]NQWGWG[%'<R=
M_7_9OO.5NT;=C>U.[UE]SW/WG7*_>^_ OD<?//&AP/Y%#[_TZ/D'$H]M>?QO
M3^H.-CVU]YGCGO4_M^3YUUZ\^"7^Y9VO'O6:[_65ASYX<\I;_6^_\B[\7M?[
MKWR ?CCWHX\_\7QZ\^>C_U;\XL6OIG]]_3='?DO_8]\_+_E^S@^* +0H?^]O
M:1G1<M+3KI:1+>?N?E$Y3[K!JYPOF[]*.;MGWMIR5,M5B7C+T2U9']5R9$NK
M]MWF+UM6GFUL/MA:]]VM34_UOO)NM.G!GJT'1S8]VGW]73N:/NXZL#':?%37
MA7-?;CZ]<[#Q@N9)G4>Q1S=?T='NG=KL[3A:>T2SMWWI6=N:+VQ?\&W7S.?G
M[WL;G/G"W(6/OS/SC<'>G7?,_&K67]9W-YTZ8)LSM0GK^Z=\6].,WD?HAYNZ
M>V[PJ)LV=B] -4T[NE:=-:FIO6O<WQL;#ZS<_B;0^/*RI0<^:?QX\<UWOC#S
MZ(6CUQZ<J9KWY.P=,^DY.ZHS9JZ:?4_\AIDO#KSKMC:=T#\!:6R:V+OUS-MG
M?MISS5?]C<=OO/60J_'\M0\\>F$CMN;X.RYH#*RX[OHK&CN6SIOE:]R]:'UE
MXLPCYW](;9SIFAMSS9S9,_LCS:<S-PQ\=^:LF<&^@2\^:1BXY?[7MC9LV#+B
MX?Z&/9N*.U8V/+ONBC4O-1Z[)C4PNM&ZXM;R&8USEV+D_L97%G[L?&[FF?->
MT S.A.8TG+FA\?:!%7^K-DS9]<ZK^@;+[:']ES:$MGUSFZLA>>/7JS<TK-H8
MZ/N^X=7K'RE-:IRTJI\\IK%Q6:?3VGCGH@<U4QL?7G#TF;L:P=G7?GY6PX@'
MSGWY _F'/?L??+5AY%\V;S^QX<_;7UO5WF#=*O9^U]!]P_G%4,/!=>=>.Z/Q
MW-57.9YH#"_[2OU58V+QUC,/--PU^/JGC\G//,&_M%9^8C__P$KY\?M6W_*B
M_-Q=9ZU,-AR]X[/>D0WZF]^6>AM:-H^?\4C#[G4;'7S#AZL7J_<T'KV\[LR7
M&V)S)WRR7;[WQ0]>[)-O?<JQKT_>^,CCVP[*F_;.7U&2G[K[EI[)#4??_D'A
ME8;+MM$S/ V9S1,=XQOFK"NHYS7<MG+OF>\U'#NWX^,#\JZWU[VP45[Y"KOW
M)KG[&>/-W\EM!WS+;Y5OV'=+=ZO\_.Y+"X&&D;<_<\U?&RZ^^4G[FPWF3<^H
MN09^]7=G?B[OG]O_6;S[BIF[7XEVN68^NE_=V3#SF]O>ZGBC*;1&ZB":-O6_
MWGZPZ?O25^UT<XA<WGY4\V9G?]M-+77J3]OHELO/@-MFM+S\R=C.1[IO>6EB
MQ]==>QX<VV'I?._6+]L?ZYRR:GO[51WW]GG;/NJ849S3MJ#CV&NO;;.W[W:T
MMHUHKZ@O:;V_77OZ ZTWMC=\=%;'FW.GO0!WC!E,[D/;Z5G;;AG?]L[ Q2N/
M:6ON>[_G8-NXWD>E*UI?Z'EHQO365=W/V^>VTEU?J:16L$MW.MOZI\Z7/CBG
M8_JRY<]=WEY8_+?[PVUW+Q1NCK8!\R]9SK3NFPMT7]W*#[K$[UO5LQ9<HVH]
MLO\;VZZ69_HJ\-,MFWI-IY_<PG=_]GZLO7G=%<\TM!U<<^^]2]HN79G?LKUU
M]K+XTC=;+UV\KNM/+2\M/%)XOF7#O(577]'2/,=C.Z(E.!N$HRT7#@R>]EWS
M@[W?O?M\VUM;7G_J@S;G#2OO.:;UYO5=-V&MIUQW^Y*^EFVK=!U/M\27O< _
MU:)>?/M57,M)"_9:$\UOSCL./J)YXYP33C^O^=3^C][QM:V[8]E!N?636Q?L
MWM)JV'+'YD];UMTP=O&,%M.Z5]H?;OYFS5_RGS8?6/'*E7<V;UDZS?)&<^O"
M#Z [FR^;O_+TJ4V-LQ:]]6Y;\[WLDQ-:M^ZZ\>Y,R\>WGWK#72WN;7<O,C=_
M>..NMB>;5V]X(3^V6;S>=.689M_*KRSYYK'+CH/*3<\L^N'T\,QO!^O>O*'M
MRD=TCW_0VK3W@[O0EAV[_[)I?LN)=VY?J&G>N'U$Z^O-X2TY+MH\=M,%L::F
M+]9>:#FNZ:Y5:Z KFJ1E1YV>F=D_^,P;:]LN?\;]V!NML<>879-;>A]<L'%^
M\\OW?+# WLSO'&@]I?GTVZRYFYN>WVJ,C6A:MVF.^<XF9NTUT.BF\U?TGMXX
M$QH\=.C)MDM?V_W8":W3GK]X9[2%>6+KAGW-M^UGY@\T&^_#6U)-;^VZ.G=Q
MT^K;ED27-\6WUIM+36,W$N!',U]=->OTOL9W!__ZYL+9-S9>^L3# Y\ULG<_
MWI]K7+ZYKV]JXX.+M;WGS43;'^DY9N:#^<^ZSVO"KUS2Y6]ZR]+5N;@Y#S[1
M>4KS<V.^[@1;MA\JS[JL\Z;'=O9OZ?AZUTM]K@[/IOV]JO8="]?WU+?'VYAN
MJ%W%W=)U5?OQL:;.Z]H^,2_K^*KM)?"2#K'MP)B_='#MZ&LK![RSOWST[WV/
MS,KL!'J%_L\WCN^YLF_^@G'=\=ZVUN.ZRCWS<ZV=MW3?':UV'MGUK6E?!]7E
MFCRW_5#G@3%M[7LZ\Z_<VK]N\5N/G-%WX<(%=U[3\]C\V/I"]ZZYQGE+N_8/
MMC1OZWQCUNO92.?X@7BDLT/N/\)T=/M+O?=,/J[]ZIYGQ_C;S^^.OWQFW_?7
MG;<_USNX\OO;M_<8EOUS[9O=DY?4SZWOFKYP1U.N\\KY9,;4L6;N9<2&]G\,
M7F8DVZ^>E:Q?V_;LP-@QH;9$K_?%G7W-FP,/?M%[UH;"#E7W$]??<7VUZ_;5
MJL$W.Q]8<?1,>\=;2^O2[H[Z13!^J+U__GS#4VU_G8O41]H"@]>-:6M=U7_!
M"Y?V3=W>\4!/S]ZM7V]_NSN[N?>ZR[M<&QRS]W5>=7VBT=71N&I3JM3^T/))
M.-H^<?$GAFA;Y\*CZT]O?77^J6,VMWPVL/VYG7TGWO7L/K2GZXX-MV[N/O_6
M66M.[?QFR[)9.SJ/NF%DPY4=X]?-2=[4GEN3#"]I.["B3_]^VT5+SY[T<FMQ
MT<0QC[1<,_N89[MZWWW O;>NYZI[%MU2Z?ILYWNK/NV\:X=CX(:.>[8=*^?;
MG]W\:>+=]K,WG!NN:RM=MUS?VKI_Y89):UO'+'E[S+O-AV:/?Z;:^^(3I]WW
M18]Q_Z/;^*X#][>O_%OGK+NOZ+^OH_>.:'5M^^);EB2FMSU[TQFAYK9)&S[7
M3VRM7'_&)*GEWN7U8[YO;I@-/SVW]]47_?>=UH,\%;UY1=?-C[(K+^Y,[&OH
M/[KCJMT?5+YOC]_9RNYH6WFK+W1:ZR<WR5>\T:I=?],D=TO3RKI33VZ^9/;T
M9YY;-+7ASWO/F?]< W>K>N[6AOO6'#'X9N-QLP[,1AM[&]H'%LT<G[RO?^+,
M6\*-O8>:+M<7>W8V'036=G_63)_R4,]1+=6G7ESP64?=?>/GW=?>L<TWY][V
MXU>%!H]I6S[@G"6TL7)]_WMMGL2BONZV*:'&7E/;Y"LV]8QM4P/G=?O;KCQE
M=_>DMA</CEHP>N#I>\IS/^^?MW7/X'=]Q(K'9MMZ+^E[>V!/CZ'R2;^ENY%M
M[?VD:U]P?L_VKO,O_[1[7N>22S=V[>F\ZI0=7:F.+YY(S8\L+.U^;NX5\Z4M
MDP;]<UN61V9=/WA][[R!<;/'E._ONWE@$]/<2_4' KM[P+Y3+W=WC^X=<>FT
MKJD]["E;.G=V/?;8^_-VKPK>[9^S;?G C3?.?F#)2TL_FW7:(G>/NW_)@C&E
MZ_N >75T;\^;<T;YO^[>/AN=OK-KP<#RB>]U;NN_]90'.S[M67F@=9YEXYA=
M[\PQKEV[V3;[ZC6V)6L'-JP\L?O<_HN6 <4%O3L7<_%U/84%+_@-W<9YA>FZ
MKG/G7#GQAL[S![6G_+/CM+[PHQ/FG73S1SM7#WY]X\$;_CQ[Q,;]B]L&3&M?
MZSJU[_XU7FES+['B+>K5GE.6;O6M[SJTZ/9ICW3N6'#!Q$+'^GG,:* ]UO_8
MPZ_/_?N=A_Y"#>Z_[8*-;\RZ]^;B(JK_'YL/=9[85]RPL7!O[U'7+Z#.ZKY[
MU1[?<5U]RS739G1&EDR:.*U#NQ :'6C;-1#??_O<3^[]VYT3!^^X:^N&C;/6
MWL$M1/L?NW5J^W=]T[?0XN,]]V_:3OJZB^N,7JYKVIJ+IW[>><2*&R8>V?[L
MXLVCI3;-@/S0_+D?/>*\XX3!+?L:UL^?-;CGQ@5@_Y:_O-I^?-_HVU+"/WIF
MWWSNM:N[IVP^V?-VYS_6)Z8NZ-BY9O,E!]L[E]XY>K!UW\# @_US/WSFI-O/
M&=SPV)IUM\UJ?D@]_\K^>?<^VN;H_6377P1?3WS'X]>>W#UJVX6>4N<#F]=-
MM74TKWW]DLWMQN77C%[7FAM8_I!KY1?RU7?T+?M.WKUA[9*I#><M;%_X5,/,
MCOC\^8U'%[1SF<:-Y, @-W.*EYBU?N8C4Z,#)S9E+N;ZCV^^Z,1W^]:WS'S
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M";I42\T!/+J<*69R$-*9Y-,LCH@&_<NX(4@I\J3[\ (S+E,U'/^8/Y35K)1
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M3$7=7?C=33\,#8@S/J\U-Y&GW;XIFU /YCV7CV 2IE.Y8]AWN(:17)2^]N;
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MY0/ 5AI2:E>90%TF,AR((=\4I*9VDHP\EP@Y$>#8K+M#R&,5+:W 9S.G6AW
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MHV5GO6?RJ'F)'^D/*05A^VGQ9,!W(>4VZ>ZB;^2GI*>6CX@A!&?=2K%>I!"
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M;612C;EM>M[]%_/"8*.)P'S1AG B,']54*P?=I'\2;T5=KVT+C\56RMVVN*
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M8OG23D6V,[[2(@,^T)\"#UTWTL-HMM9@:C_EK8HFCA6AN4/"/&$FL9//%3A
MMG*?\(P51SDEW)*<%:R7G)#-[YD*MG.D#Z.4M2A 3X]G5KD&T>H8[ZPG*5>
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M@826!;PSJ-.&%=PCC1':>,[^4K*JEKU[AUD^P;JS94RZF+4HVE<TRBQ=\T=
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MR_E'3N,OWC))>L U1CXCX3@I*W-)MNPDU_=$,"O")H7  ]ZJEE,?Z*.XA=1
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M1'PX<Y@ZG;1$[,=3 ;_IMEQ'X 2ZE]T&H!L^LJ# C))?S#1J;_9SQFIJ95(
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M[J^]T5_6T*^I[/4K_:+\:?B4/4]^K/-"XB)IC^[4FF;Q5,=G?U?A/?68FZO
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MA8*@W!WZ$"REDV ,, :^ [$8]*QJ1_: YAE:M"7]<;0Q)H"^>[D2TT''V[_
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M@=B4#^!\8"PJG/Z>ZN [0#]'Q3B]I,]0CUF<I>?0E&I;D,[8RSL'%C V48I
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M4W#K)DEZ47C;-M%HTN9VAG!I. [V@#_E088;\[;:(=  VWSZ045R;W'?I^H
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M)J672NM!HEJHM8;#S1^I<9T?*EVIKKHWN=^HIAWODV> 9QKCZ$'@I&I5P =
MI]"YLX 8Z?UYN91;@G/F54 ILX]\@FH\O!VY W@Y2&FN!<[V!U3T 6,]!W*E
M@-I0F%P&4/5_HLN!:NV9@*V GV:M>SGEL,)[7A:E53AK#@)6S%U BOQ[51-J
MIXQ4F]_\1KJ@P:GB'_&Y)D-NK<C0NBSI@I#:IHO:(-"VWUIUB?\9_L(UGW\
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M#O>77P@FML_AD4!DW2/N,"@J*>/< :690HXCV+6ABYT-;EG]DK4-/.+'8D6
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MZU+-:@/'/JY?U< Y$'Y!6<'%^J4J6+PPMU7R77P?^V0)"BBPB)MJ.ZCEO?X
M[[^:Q[HE_*Z2<<TK_H'%SNI=P/34Q2H)T!K7IJP#=H2O5U0+9OJER.D"E=L%
MV:APNCU=+!5Z6@B$[4!#2[%NA?AY3:UVH?A]2:3ZD?AM[CK5;O'=E!]*H_AR
M7+@"*[X>KI%CQ _]XF0*B9_;2^F >*/]:M%>T2:+8X*C@*3YF':'\DSU!4V^
MLKMXH^J+LC2W0GE6\3IEO6*S0AO[23ZL6!*.E TJK/R"I*OD%]V^229DGO:7
M1/82/XO_!+G VN:IKZT_6EVC)NN3BPM4D;K1G']*2^W'%(+\B[8X]HCLK69O
M>)'TI2;9;Z;DM>J#VU_Q186/_2<A4=)F&0/< ,XVK=58]1RK>JK:;SY8]%DI
MZ3Z8LU_18CJ9DBEO,#Z,'96!C'/"8Z4-^B=^=I)R+7ZFM3A$N<MAFN"G!&]9
M PB!9_5O)GXUSR^_/)X!"LY7C1QO_Y?Q>V@S>$=BUL  E!H-ZAM%+ B6]X:@
MUGMNZ*G /)FNZU;@D=8RS1_*Y%11;S@1]>!Q1$=F>=W('?"._-E#!JA_AGI@
M-1RS\%G?.N2!Z.">0YB9P33S8ER.Y[7N.D+:]*=&-DEO_4G=1A=/"2(NHV[I
M:#HLM:QOZ#DB,P\[L!^5E.':=QL3O%#>\P8W(^JQV1G_*[C=I"->]OQL5)%5
M,V+U8]2U-N7*CZP94T(X;[SVS7 QQJ_TXZ []M"26_VV^)9T8V\,X?G"8',U
M"1/5:Y*2/P=G&AVH."\[_6?:C1DD[4_& 9LQQ7I.P523U_F3M1&#RXE?2VO[
M.>3T):V]' HS?9YY"W59PB73"]KI*+ QG/XE.%J_@NGE-5?'9:7.V*$ALK_9
M?)4+>:U3@@&PJ-$/Q-('2V[T>3-4B[_W1#*Q:;>Z":RTA![C)O:TJ&S]+_;C
MX$@=A;/;*U^;P)V8\4?MSOMC6R@C CE30L.48-'WC)M8 N]YQ#VR>-1LR<M/
M,YKJ>3L2N@Q+^7%1<W6?^#N#P[0(H, +HID-_'%.4CX7&&WU4KG@X900"EA4
MBWJ/"$\7_S8?%UDOSC=]$,6FE1I+1&4)L?H)$3W*6OM'M#787T,0_?5BJ&>(
M"<Y0Q071"]LSDEVB"@M+X2_ LMJGYX2\M=C8?4S>FOO<^$9>DF9C*)('Q/_2
MK95;SWN@G26W#'91B^5.7D*5FVRSLUQ^0CK-]K?XG]C)(DU( 2*J)LWGM%;%
M\TUW-9MSC48G37WJ43U2_3+^M/:F6C_O@*9$W1QLH=JE^N,E5Z8H"<Y+92]E
MU^R"Q1!QF 5*: \45LWO?FQ:5W3)--/X(K?"4&><GVK0;3%(XI=IY^E_SYM4
MK]3K@KZJ/'317FJ%4KW4>:<L49%GERMZ*4ZST LV E,/O[4/FEN6K%KUN_5]
M^H456>W*A7>7[04G1E]8.A?R+F1R=!5\F<_X\!%4E-N6(1:&Z?"R]Q;!W7)2
M]YSZ;JJHS]R$4K?5E1W^2]I6Z,"YZ:9E/R"TA1-+!V&'H]>,>2*]0L:'EZ$)
M/H<'MV#7N_T;J,2?<"PQ;R7'6+EK\QC_;U=+>. 2Z4HOZ+7%5Y=KX:ITOPD/
M9//"EK&MZ(IHX4@J-B_$-'@)G^%SH_\F<?[,[#X0>9KC4M-16I8537V-M7-*
M".7CBO],!J+1B\$3VS$7TPZ/5^-*%[J/_,"_CJX<4A,%(<R!!60OGX=]<90M
M,RD]H[0BQP_&:<PBJ[,J V?S5 \7 8MBU#(UX6WN[Z5^)+LT]N@><D+"@V$T
MA16]8' Z=5<(J6\7[8_/[YX-C**9.\Q6S*73\O4$3JIUN+*3IYX29%-"P(0G
M#9.[=VPC/3"M:*21_C9A]Y GXVYT0/]1YL405B^==<$WQ-S*OCW+UJ3C6D\;
MU]GP'EJ+%<5 ^I10!%@471[?SMZ4*QB%<US2_(;G<B0)@P,?N('1;GV3W#,A
MPIYVGLPWOSN97S>KT%@!E$W[J#DGF&M]10X2K)\2W*<$VA@'N)6;.I($_$I]
M-?A'$)U [;\HX$3]Z34)GH3PS;5"B"_(-%?X<Q;'$"+J=(I3KQ?%VGC*%,*C
M%A;"%U/"]%&,Y'O.L^$YDE^I*P=N2ZT2\OLV2V=%W>T!I#DAQ.X2J<D79G27
MOIJU3&\MS7""JT8E[C85TC/"UU/"(<"B</-(O2HS9V!HEO)/*J;_GO)X@D_O
M3N5XU &S7KDTI-,$4U[VQ1BBE$VSCNB<Y,N=3,I=TK4V7&FTR'%*&)\2T,,E
M^OZ<]L$%NL>I&?VNNIKX7SUO=591*[K/:1^'U!G7:GM]"7JLQF?6'6VNLMMI
MN])"]L9F7+).%#0ER &+E8Q.5-WC_NM=^J9)50QT"%3$X<(%'9NQRY'8KEMM
MZ]%5L)<5B=@8Y+FL"-Q3#!"32IB'>^CC1L@@Y-F[TBZ1)).AH/GMN-Y#[9?!
M!8I&<#74@?4",@0?QQ3!KJ)<02K$'PRV/ <]$S>9V8'Y2M@Q?P6NC"2:<Q*'
M(HOL<ZD3U/Z)=TTZQ'+S^=9!U'K9JG8*9CF3V?D7QT.[06B$E%8I["[Q11D4
M&4)F9*Q#1U)>S0_&Z&ASY\@PYVF'['&47L;*\5OU8J*AV['I NFF-*KU&<65
MD=B^EAJ/_ /NH.6T#$'^T0M+Q^%81DK&#*2<Z1:]#O61>6A.&1K"LK0WD]>R
M(6..-<]9.".J </Z)M[7O)M-IOT$;6$_1;SKZ.&4-._NZN2L*WD-_<"U3!<A
M_+@%T0U(%9<Q)PN5QL78OR(]Y/X8@5?M$/GIW]6QA7=%L,8_PC'JF58?(0;^
MMCU0&-_T NPD^%:2!]DHV);N"OL@($<'(A""V#D-R&K@O4,':2%0,_2NXIIJ
M4C=4<T2Y59C1@%&<H9QH7B=_!Y\!NBQW:8KMN"5;4+RCRRQM2EL/?2K11GV"
MP\6WYJ 1*C':X01Q7-@PN+I\2;>WEEE=950+4NIG&VS(#YJ(.B&LH'6=UKK1
MT'Y:+2W.!O>I?-,Z(3\49Z*NP,3RR3DB^'W99D=_8HC896!9F=T042.N"AN
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MSG*@S/]R@SA#K"W)]9RS;.3\?5PGCGMP!S>/L]_C#[>=2W;D\7)Y+RV=>2\
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M]C$;W:T-!G:GW0*MEO_EUVXO979\LLPCU#6&]5A(T$IO<P^EKF"3:2'-+3/
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M-?Y#\R:>J1RDEY"'"[XRE-2&S'SF;MKW)#SK)6-YY!&.$ZLPL(GSG;W#O5Y
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M1EC\3M$)YHK(:6(8>T;0>?$QSD&O[9)YO"[G$>DK(=YFF7RR9-]_[Z+"DW>
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M"N:JZ;&NAKY9*V:=BURYY#>3$P/,O855)8;-FD553]_['R=G.WYC:QR\O:N
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ML,B!4/6\U^0(Z-QLD#P!JOZ/\);\&OAD=H,L /N,1&0CB*F[B%1#251W(I7
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MX2W[50N6\H#94+<D]#9=5D[T^4OC*Q\[Q:-DR>&=*^%,[AN]-9 VO:[/L\(
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MBWXZV9N6=9Z..)S*[XN$MYW86+>/8M/6)3>',AL#L*/@I1J-O&9P5]F+N-?
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MXUZR/3'[X@AE CYCY 3E#+:P]0*5@GII7]#L$#$VA_8?_+UL*ET")V5\8H1
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M^@WLP)I'#0O9!TFW"8P34[>-.8=SB2HMS>/6T5/3NP!CYN*U4X'3K+.>9:"
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M^'?K#N!8;F)3(^B<O*N! 6Z.+M0E\/R"[JGC>4>\(,5Z?HJC0%K.?V)U301
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M:91/_!+X%H/CJ[";N4\W[\.24J6#&>CU6$K/%Q0('^O@HEX!<<VOD&^>;QI
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MJOS]WD.HHM65A)[*I]IURQ83S>HSXF]MYQ%K26_+1T$AX-?TFRH 5C;<+Q.
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MI?'A<\RO(2__Z\8PV6S/XSH+/-+%2OT.?F6W35F!G)^_1CX975E^KWL_]*Z
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M=NGR-CEAE4S,)NNW#-6!Q?A@-R6E[&+S2MJ\JMG*X_2GM?&2)\RSE$": _L
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MMX6_UW_$CP;NU:W"?WH_T]81T:X-U'@"=0@C[A"'FU0VL59>$V=]JF65?+
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M<R?._B*%.EH:6V2'VITJM\G?V!84O%/ZMD[/J%$Q+.9X@[K?]&3V)<T)8VR
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MLR;1+Q1W!">[M> IT".'43@'62\H0G32/8SAR&YY1MT \E*QN<P.=5!^RNU
ML]1QJ0FH0J.-V8QN!8Z&IJ,_H-%^25@*7.K6CN'((H<*; _ZB*^!SJC?M\3
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M(.<,S33M&*A J2[=*1VL:JC<QKJM]JCMJW^E_HN65_I!@S=_SW$ *ID;$C^
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M).XC/J=9. B_)N8'9P@8"6EU0_E%>Z \$Z%E=N>\%V%])@= ZHA5K1R_%I1
MF0!SPDI<&$<NX/7.+&%EB0!Q&$&-3* ,VRH$/$7U.M#A6'"-\SQBQSW&W09%
ML84#5M!O;Q* P=@ +3.(.6Y#V23@%,'_P@1BCOCN[,\8-S)#O!6?2/V&'&M%
MQJH@J^S.XDZ AAQ'\%^[#;MR\<]L'GI:$$9N'O21(59I'0*+D5*5-:$BY.@+
M[Q '*"%G3=%5U- 3Y_ G:8$DFH42Q071;7.8D@;ZVGZ;LNDFX[Q!5;:Q=5^C
MLHU+O5Y01S3G00=ITLI7_)5HO(N_P0UI+\ZRT+)T\ D"KH*^2$PSN\1V1>RW
MTF3_ZNML9\MJ=;WGA&-AK)^YI;/.&\,!T\P5S6;?T\Q,Y>M^,&; 1258%E/S
M;"6JA'GN1"/.E?D;<;^);[ ,'&21$N0)'+99#@QW57:\P"^RSG#E\AX8&WJN
M<S]IU@+MN-+*UI NCNU%;Y@DFW]V$V7*ZCZQC?N=)4H &6]'#L#FS4TBL$ /
MZ^SPPRZ/'(Z&9EA#76)#U(SE/,6"QC1K?/(#P<K^$ W>QXOA 17<V',BR&V.
MZDE9[ 1K&S]JM)"@# .;J<8I  ]8W8^YZ))BKQ@E;ZWI/!2A:GS8 Q>FIUGM
M<S;$6)D.'@HRO5@<X,ZW.Z>.K.)"3UI@[[-+2&_\7,QI")Y_K'6<KSYTS3[?
M50WF[MQHK83XVKW7R [9Z;5P0P7=Z[M\Y1IVRV]%KHUP ?;D]!;) S5\_"Z%
MB*LGJ@$+[:W@7X-X3A4^SR&^;B=<]OM;>09;R02X>[\SI,,9(#^-%.2LWY32
M&L819BI7BAM#MDE*$*]A3XKM)Y,(!'P(@.O^30#/N\^ST3O=5\R;X;0))OJ:
M66KY;4!$#+H#0/Y/-$XBCL&:E9)1"\B[<NG8) Q=4H=P&6\FYDRZ3?H==]+M
M"1 !M?'D@6YYW?-6@'0Z?0O<\-^U8("+8'(&BOX<A)MZ&8R!BE4"($,PXW)Q
M& Y>5!* -R8ZBF41Q\DAF$[G/FB#OZI;!<P,4.F9"W_DJ.5=A&2:+_HVHT7U
M:R&SF')U2,!1G+V2 <*!L$\N$\TAEDC&X2AD+S$!49'Z';K:\1*ZRL_$!8#)
M\7SJGHC-=$@"S.!*S ' <_@&?6\PGM"O?L-_CKBJ9 "_2?Y>;@"53KDD.8D=
MICJ+NQ&*:&14A=TZB07!.EF1ICTU7%O(F@X_>ZJ1*\W>>-=0+NN+@#0HI>JB
M?@-4;25#F"=U1DYX+= H9PYAU>EGQ L)VO0.Y+3-)E,&W.# 8KSSR'&18/3;
MWW+O8!2;)7MAA#^%EWQE&5'J^R'+C%@EJX D1LKY(T@M1ND9?4P+HU_\%7Z%
ML8%4L%;GIX"E[-[R=CTN.)7R[.RUW C<?#, P);[JUXC4)5#5/L($6-O*OE"
M/["]S]] -++FSN PKBSG$W+X>.8:(M?R8=A'4+YM5FB?>Z<C+>26W;:K>["7
MV65/0)"&7H8/(O"4V@X8S_]:B03%<#?.^R#L.(-G[F%^9%>=<,0[L.H1NA:5
ML2=!)C;QT3KN& =F)-*NQ04?7F#VLT=2V-=ZD=[](=YJVZ#708U*(= ? D7.
M,Q%?\?!GFM'=G.D35/Q9-A1%0%RP^ I<CKQA_=+C/,K0?M/N%5K/^9UI*8;L
M_DGW#G;8^]?KAGAGT&'%(\3O_(_+^)$:X7*GO"@DM+1H#^T$_A2BQG_'W@6D
M$H!QRG";@SUU%=A6(@">*),TY+;WBDX[.A/D>:T2R_";O32"Q\  ,C B!+EY
M*I%LB_4\KD(5(_3"SX%_=BL"]D$>>SJZWO'O]3YJDQE0"'QVLQF>!N[6.8),
M]\^[IHWNA=V^E(C[!ADE@R2H8,).]9',\?CC\115DE7 LD^43Z-/HV^K[X)+
M-7@'<LAZPE_-W_GF'P&L@#3M&/@P_*7J)DH397@)@:G%9,F@\6?Q!T]M$4%$
MZ/''9!2Y"EH*X/FG>W?Y?!6@[OS<EP-;L9:#_(:X9QSJ?Q?EI*T(D\>(J)8A
M)K&+EWS0@?A2F0C<.6+0:47"+;*[F ZIEWK:?]Y]%:7OO1]0@#9VUO;!8#RM
M4D#7L5'&Y_SVX3JTGD&[\ +5!'@R46A X4FW91JQFN07IW'X5:J66#))F\;V
M>^J:1ZCRTO%()\HZY7O=)19;R0%ODVR-^L#1Y'U:I?YAY#)5.BR40KI$1H90
MS636,$3:Z=,E>#/:6[%-X@"]T>^(\R#]>\ MMT>T+:?SGI]I6Y8]/J?IOQCQ
M0*9T)2V>'X$.4$4$I-+3+P4CVNDO90^B'S(T3J_B!AF!XA>(4,88!.)DRE4
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M12;>68ZZO?<$.7\9\H2&?'N7SR7.H-UR9_2':E?:VWIW_LM6[_#-7K_HU;&
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MW."N:6I<_R0U;6"4F3?0S<L;: G*&Z@-SAVH"ME;@M3SAP3I?QE2+&P%V0X
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M7D8R4I\)V7E/?+Q+'[$%-0]=(AHF&0F-D\Z9C9,NQ8T3K.K&&YRZAA%N7<.
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MV?3TO6[3"]=Z#/7[6S&$EGH\L[*2Y)=?0HU(S6<DQ6:Y9@=)W$NY(FZ=:VQ
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M4^#0]F@X\D<@_'G:"X[*.\-Q+0J<-,+!:0P&SN%,X(*M 5PDZ8(B11M4';1
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M'S=FEQYWG508=XU<$W>5TA5WQ>%J;#_]:FPGXVI<B_-(?+W+B*CN$\ +:?!
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M[7<[-7\>[54YVM>AJ]C<;&I<46=)S*NT8::4DGQC"ZFAP3E.(M]T9KIK,KN
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MFZZO3&Z[SJ'O,:<M'C GL0]=[E@_<ET-T+9\!W9(@_61WX L]2?0_SX/4E8
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M!X6[B7V%GNGN ?XY+'Y$'C- DNLB*,IE"%IRG -Z<ESYO5EN_OT9JP'WS1O
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MN\'18S0X?IX )Q4Q(*5A"&?UM$':6!WDS)1!V5P!-"TN@KZ%#)A97 !KB_-
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M/3^#QI$]R$,.@HG,*3!1N0A&NNJ@BS8$=8(Y*#EB09Z#AXL!-B ;B4A$9-K
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MJR#B":LZXA&K.>*A7W?X __^\'OL4=Y=SCCO#N<0[S;W'.\F]P[O>N!KWM6
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M@]R0HM<Y805O_I7].X@47  Y"_@^5@B@VXT(7>G@1V?7\*&C:T70G@$-M'7
M8N&&?D>)_CZ*:G</PZBUFTVH6QGD5M$6QBALB0S,;(B-2JA-3(ZH3L\.J2K(
M"ZJJR0^L:L\+K![(#:@>S^;6G,[B5-_/Y%2]S0HHQ\K^"^($!*%  #VL0>CZ
M"IS[</8\N1:A_4-":'Q8!6W<8"HT..P@MF;(7:E]@*;?N)9E7=T3X%*\*L0[
MIS.<D]P>'1Z](B$AI#DM+: I/Y/35)W):6[/8#>O2V<W;T_U;SF5XM=R+YG5
M]#[%K_Y]JE_=?T$RG\!T"4)W</Z_W('0F5Z$#@\BM',$YXY-\FC]F*%@[QA!
MM',C6;YYQ%-[^3##O'203<I;%TA-[0MCQ?9$!H>MBHL.Z$Y-8'?E)_EU52?Y
M=;<ELKK7Q;.ZM\<Q5YV*87;?BV9T3<8R.K[$,=J_Q/\.,A'?TTI\!BT(G5^%
ML^\ SKZX_N;-.'MNET!].W3XN\:M1%9L=Y2NW>JA7KZ99IR_B6F7/LIVC=\0
MY!.^/HP3.!@=ZC^0',D<R(WR':B,9 RV1C &^WGTP6UA]*$3(3Y#=X-I Y.A
M7OW?>=Y]__6C *&[M?@,5B)T&L_@X :$QK?@[+D#9[\]PJAKOQI:L=]T8=T^
M>_'RO2Y*!;NI>AD[:5;QXTS'\.UL2N#6((;?EG V8TM"@,^6[$#:EO( VI86
MCO?6/K;WUBU^7EN/L;RVWF9Z;GG'\AB;]?<8^\G^W?.R_SN#<SA_'\7Y=S>^
M_C%<?QW.H!U'^%#S<5E4>T)/L/R$E6C!<:)<QE&R9L(1BDGX(1HA\*"O"^L
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M36IC5%5:1U1EVF!T1=K*Z+*TS=&EJ4=B2E*OQ92DO8@N2?L269)&>/^&1(
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M6)\'J<S/$U3&E]T4QI>3_V -YH]@?O=NW -8^VRL/>OG,RBLG8NU^_P'\V\
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MY6!IS@S*8+8ELS?+2:PCW4MN7HJ_6B,_9$9M L^X*B[6HB(FR;HT.M.V)+K
MOBBZS*$PNLZA(+K5,2^ZSS$G>IG3S.@-3EG1!YPSHB\CSYPRHC\Y9D03!\3^
M%Z^#<"_@/O@M'> (9N]&$]N,3.!A:'F^- P7:,.B C.!KCP'D=9L#YFF3%^5
MNK0@G<J4,*-2?I1%44*"34%\JD-N7(Y3=ERQ2U9<E6M&7+-K>ERW6VK<B%MR
MW*1;4MQ>]\38B^[\N,>N_+B/+OQ8XHPX_>))Z'^?T)W!'AS"[!U%>/)&QM&,
M1XHD8*!8 WJ*3>CML^R$F@O<I.ISO96JL@,URS)##6:E\\QS4V)MLY*3G-+Y
MF:XI_ */)'ZY9R*_P3.!W^$9QQ_RC.5/>,8D[O*,2CR///*(3OS@%IWXPS4F
MD?S-GW@]7,8YG,P%V(_9VTK1/I#E>!!;7"H,"\M4H:/,B#IOM@VKH=A%O'H6
M6[Z\P%^]*"]$+R\[W#0S*]HF)2/1*3$MS3TN-=<K)G4V.RJUSCLRM9T=D3K(
M#D]=S0Y+W>'%33WGQ4UYZ,E->>\1EO+=/2R%N/WB/EX/%S/P>L >[,'LS15H
M8,B2<H!%<UC06:D$K97ZE,8Y5HS:"B?1BC)/F9+9?BKYQ4$Z6;/"C%/S(ZT2
M<N,<H[.3W7@S9WJ%916QN5G5WJ%9\]DA,_N]@F>.>P;-W.[!F7G&G9-UWYV3
M^0[Y[L;)(']S.P'W0C;>$WX^'</LJ6H\_2.#:*;=-31HK96#ICH=J*LUIU?6
M. C-KG:7*JCT4<RN"-1,*PLU2)P=81Y3'&,7,8OO$EJ8Z1Y4.,N34U#E$5@X
MSSV@<)%;0.%*5__";2Y^A:>=_0KN._OFOW7VS?OFXIM'_N9ZZG^?T.TOPSG@
M@7P2#\)+YZ(!X6M; T!3HR34-6E 99,)K;31EE78X"J>4\^62Z\+4.77!.O&
M5(<;1U1&6X54)-ISRC.< LH+G/W**Y$61]_R/@>?BC%[G_*MMM[EIVS89?=L
MO$K?VGG._FKO64+^YN=3PN,X^SU8]R;,7-V,%HAT($UHZ+6M0C"G31EFMQE0
M"MNL&#FM3B+I\SVEDEI\E6*;.9J\1JY>:$.D:>#<!$N_^G1KG_I\&^_Z.=;L
M^F8K=OU""Z_Z%>9>]5O,/.M/F7K4W35QKWUCYE;]U<*UFOS-^?S_>3J&M6_
MS!6M:,)M:&'MF(]"4-Y%@Z)N6<COT8'L'C-:>K<]B]_E)A[;Z2W+ZPA0"5D0
MHA78SM/S;8LS8K>E&7NUY1M[ME48>[0U&;JW]1JXMZW0<VO=/,.U]:2N:^M=
M'>=Y;_2<6K[H.S;_,/C%*>S!OEJT<<Q?BYDC*$>]76BBW0 5?6B":,DS!T0A
M?5 -4A8;4A(&K02B!YR$PP<\)(+[?>4"%@4I^_2%:WCVQ6JY+TS1=EV8BY1K
MN?0U:CKW]6@X+5RFYK1PDZKCPN,JCKVWE>U[7JO:=7U1M^WZH?&+(SB#G=CW
M*<P>[\7K<2'. ;/G#J"-#V'^"$#24CK$+9>%Z.7:P%MN0@U=;L/D+',6]EWF
M)>&UU%_6;31$P7DT2LEQE*_D,)JM9#\Z6]%^=*Z"W6B7G.WHJ*S-Z)2,]>A1
M:>N1FU)6PZ]D+(<^RUHL_B[WBWTHJ%NQ_DF4U&68V[<88/XP0 T:>M%RM-%Q
MM%$TY= )00A:JP@!D[K@.VE*\UIKRW!;ZR+DM)8M:C\1*&X[$2YI/1$G:;4V
M0\)R[2QQB[4U8N9KVT7-U@Z+F*U=)VPR<5#(>.*:D-'JY\*&J_X2,1S_*OJ+
MG0NP!YB_&N5T>!2@:QE XQC. 7/S)K 'ZP#"IP#\T-3=M@J#\S9%<-RF W;;
M3*C6VZSI%MN<&6;;V"R3;1R6\78>RVA[$LMP>P[38'LY0W]["V/&]D4"NMM7
MT[6W[Z5K;;]$T]SZA*ZQY8. QN;/C%]LQOQ)[/<8YO9CS6V86XNYQ9B;L0E[
M@)8>M!W  R7>=A\:\2$&&!Z6!OTC:C#CB![H'#&G:!^UIVH>]:!J' VDJAV+
MI*@>2Z:H'"N@*!VO <7C'2!_?"G('M\"TL?/@O31AR!]Y!U('?Y$^<4&S%^-
MV4O6XCUI/?9@XW^?RLS<!I" AL[= ^"]'\ 1+=WL&(#>:0"UWZ@@?X$)TG](
M@.0?RB#QAPZ(73(%D4L.('S)&X0N<T'P,A^8E_-!X'(MT"]W _4R%GEY!\!_
M?L-7U/K+3_]F8OR_?TM.W]3_/)7!FG,QFX_9X0=P!H<!G(\#6&"V/OZXQD4
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MV=T4'^>(QSD&P7M(^',X>C<!O9M8W$4L[OHN[WT%>5,[=Y*+>^B/M//@)<0
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MF_G.XR^1\S-BK J].;O@^/1L5[^76-Q-+&Y7,#[%@I4.5@$X%6#4X4LKFKO
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MW9"C^0VE\FRHT]R&3GDT#,N]84JN#5OETG!$SO6GY51W3HYUWY-3[>MRKOE
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M*#'41_&A"Q43&J[HT#A%A:4J,BQ7$>&E"H^H4VA$AT(BAA0<N5Q!D9L4&'E
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M8P=O=06K8(;7ZL/K],E7O*882&<-+[K^<8LU]5@QIH;AD#T.<J=A6IP-V8N
M%9 O0"Z!AQ'C.A QZ-@.'=+PQ+V0>P R%=$3RO *3; XR]@1H@76FFC927CA
M2;18 YZG@5Q7 _HU&/N4F%O!G%E3+3T=FK*FY0NPA0'&B#Z9#MES(7$QY*^
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MBPAP&)+5'%?)*@XGLI+#FZP<&4M6CB@D*X<WD97#7A"K\<QKD'00^J@B#%,
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M>$30O!(S,C]B:7Y$"GS@L!SYYK(.QN4*AQ8RZU!BK#U  L *A.)+@ 5X?P[
MC>><$#\)Z=L8/L3__)C<5F-R$1C''+SKT*GK:$?"EP616PDBQQ-$PBR(W'\=
M?4,5Y/YK$;2OQ0JY%I&2 /+NU; #?P=16LP\BT=R&7(=R!<$^/%\&;!XZ?<:
M%!=,/!FBQZ*)(Y'6LZW#)"Z$"70]78N9Q)Q,1.!8FV"P371!"?VQ"?VQ&8F<
M"/V'9"0OPEB9-]HQ]\1L1/"_'AP$NX@BO1\*\K?Q,6M :X"5?,QN70CPX/4,
MI&I3D$*/70?]:![;!BPR(EC4Z%K,%O2'&"92<=AB&VPA 2>6@-$D5C$/EY%
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M,_!5/?2+#B:UT_B6%J2=A'0-1@TKDZBC]]6@6QV@'^DA15=D;K"F@,NL:<&
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M;-H:DEQW."FI0B,'^7])!/+_ .3_GCDZ#UVSM1_?RM)N<,K2;;R9>0;X9S6
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M<ZX]DF)7?23C>N71;/.*8[E7RI7R3<M4\HW+U LNE9T$3@-Z/XW^[)GD1:'
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MGP:;:.\FFR#O)EMOP&MHH/PX"!4"#N$;9U&1.X2H6-E=7Y)DY=]E[%=]67!
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MRTX5Z)>:%AJ4W<HW+ _-,\B)+CB?&%5T,3RRV"@@HN22W[\'=0\<O&:.H/S
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MU<]HJ[KGT59UR[.UNMFKM:;.N[6F!E7!;*W^&PA#&T+1AK#C.R#DZEF(%1.
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ML&KKO*-N5'MGWZSTJ6LI\:]O*6 UM.2BLED--S)9C<WIK*;&O_FO(7S[:HA
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M_W\:-/[-1AMT9$1!1TT!-#':H&*& P6T0=8%;?"S!JEP,MJ SL[^?QND_VM
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MEP'"F&L_\;U;K_E[]VZ+L66!/=I 01L(!W<"\?1!L+M\"IR$><%91@R<5)3
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M3M]98XSHJCY.=U'_P')6FTAR4ILL=U2=ZG90^_#607WHO9-&_[B+YH-QU^5
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M91^"Y XB2#)LY8R" ^N"X,1.+SA[S!$N7K*&RX(FP"NM#]>4U$%04Q'$=&5
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M.@R"Z(XE('H*^.4OPS5M?KAB(@(\-N)PR0V=%2 %%Z.DX6**-%S*E8;+9=+
M4X=JE0;>'FFX,B %5\>DX-H7U$])=+[DDC!(+(J!^+P$2,Q(@N2?@-HVM&'?
M+A \=0"$T'U7A.<8B*"GM AZ60EI"@ _3@RN64O!%6<9X/63!9YP6>!-DH,K
MV7)PM015(P?7;L@"7Y<L\#^3!8&W,B P+0."/Z1!&*07Q4%J7A*DIJ5!9DH&
M9/\$U+=M!ME].T$(;1 [>P@D+QX%2?Z3("5]&234!$$$*P%"ENCKTN6!GZD
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M"_NN)>\_I:_N.66BYSQE;6S_P\G,^J>7A<7/( NSZ6@+$\BP,()2<T-8:&8
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M*(Z.TL+@+44#IB0?Q$IP0Y8X)Y3@S4F=Z)_8BC/8CS.X%&>P[MK_S8]\04C
M.T+QFB;L3EB#%1!>$R T?2""FD"$58%=5!%XQ&1!0$P*Q,0E0%I<!!3$^4%-
MG!MTQ-G!1(R G2@!=Q$"_DBX,($XH3\!MOA'C=#S-'1E0%M?#K1-%4##5@E4
M/%1 A:D&*O&:H)*K \KENJ"T0 ^4V_1 I0=9JP>J0WJ@-HKLTP/UXWJ@<06Y
MIPN:KW1!:U(7M$$'^?>?.J#U4Q=T?OP!L!,7!F.L04M;!O1TY4#/2 %TK)5!
MTTT5-(,T0#-6&S2R,*-4']0:#$"]%>DR!(U^0]#<: A:VY Q ] ^BES$\;AC
M +HO]4'OLS[H3^N!/N@"OC.-[WPU OTO?P#LL083!0G0U90!(RU9,-)7 $,+
M9=!W40,]?RW0B](#W71#T"DR NU:8]!>9 PZG<:@VVL,>NN1+<:@O\L8# XA
MYXS!\*81&#TS N./AF#\T_"G"1A,(5]-P.B#.1B__P/@("8,IO(28*0F#6;J
M,F"A(P\6IDI@[J@&I@P=,&'A=R7C-^2;@N$\,S!L,@>CI<@*_--KS<%DV Q,
M1Y$#9F!VR@S,KYM.6SPQG;)X;_+-<LKDBQ48?[8 TW=68/[*%BQ>_@%P$A4&
M<SD),%>2 AME:;#3D 4'(T6PMU,#6R]=L&8:@V4\7@9R+,&\#+^IP0HL6JW!
MLLMZVG*UU4^K0:L?UMN0,:LIFV.6WVVO6'ZQ>VCQR7["XKW]=_,).[!\8P?6
MSQS!YH$SV-[_ ^ L*@26>(1MY"7!&7''?G@:R(.[M2JXN>N"4X I.$19@5VZ
M[4_;(KLIVQK[;W8+[;_8=]A/.JRT^^RPSNZ3XV:[CTZ[;#\X'[9][W+19L+E
MGLTKU[?6SUV_VSQU ?N'KN#XMSLX7?,$YZM_ %RP!BN\A#A)BX,'7C+\5"0@
M0$\&_"V4P-=9&[P9IE/N+)LOKDF.GUSRG#ZX5#B_<UG@_-9UB?,;MVZGU^[]
M3B\]AIQ>>(PZ/O<<=WSF=<[AB?==AP?>;QSN>GUS_ML+7*]Y@_M%.GB<\07/
MTW\ W$0$P78F'_W?7UH$0I5%(4)' L)-Y2#40>-KD+?Q1U^FS5OO6.=77EEN
MSSV+W9]ZU;H_]E[D_LBGT_T!O=?M/F.#VSW?;:YW_/:[_NUWUO66WQW7Z_YO
MW/_R^^9UR1=\3OL#XV@@,,:#P/=/@+NP(#A)B@)#7 C"I 0A5DD0$K1$(-%8
M\EN\K?+[*'>]5Z$!5D\#(YT?^*5ZWO4K\+[M-\_GIG^C]PW_I3[7 GI\K@:L
M];D2N)E^.7 /_6+0"?KYH!OT,\Q7C)/!W_R/!D/@@1 (VA,*P3O"('CT#X G
MUN".[A\D(@ QDOR0HL /&1H"/S(-13]F6LN^2G75>!SO9W(GBN5P(RS1\R]F
MMN^EX)* \\S:P+/,A4&G0SJ#3H7T!IT(W1!T+'1[\-&P@\&'PRX''V0]#=['
MF@S=S9H.VQXQS=H2^9,U'/63-?0'P$M( 'QP)L+0.9,D>"%+G@?RU'@G"_0$
MWA18B#_)<U*\D\W0O9X::GTQ+M;S=&1:X/'P_- CX16L0^'SP\?#6R/V1W1%
M[(U8$S$6N3EB=^18Q*ZH,Q&CT?<CMT5_B-H<_3UZ,.9[S$#L]YBU<=^CU_P!
M\,8:_(0%((K&"^EB7) ORSE=K,+UH4R;]WFYJ>"],GNI_Q7[J%W,8YJ?S(AR
M.YR4'+@_+CM\3TQQS,Z8ZKC1F*:XD9CV^&VQJ^*WQ [&;XK;$3\<=RQ^8_RM
M^/7Q$PEK$R835R=.)JY*G$Q8D?CECP!=D 9!-'Z(YT?7$>6 (FGV[Q6*[&^K
M-3@?U1KRWJJS$[H\STOY=&F0R>'\")>]60G^.U+3([8FY<=O2BQ/WIA8G[(A
M<7'J^L2NU'5):U/7)&U-[4\:3^U+_BMU5?++M)Z4#VG+4SZF=B(=*9]2VO\
M, 1H$,+'!\E\V -A=BB3H$[6R%%?-*BPW6O4X;C6:"UPKL%#X6AU@.&^,I;C
MCKFQOIMS4\(',W,2UZ85I:U.K<KL36W*6IG:GM63UIO=G3:4O3QM++LS[4)V
M>]K3[+;TB>S6]'=9B]/?9;:DO<_X$^"+-82C]Z;S<D"A(!7FB5(^-$A2GC3+
M4VZUJ%,OM5CRGVQVDSTXWT]O=TV8W=;R&)_!HB16?WYFXLJ<_(RNK++<SLSZ
MO/;,Q?EMF=WYK9GK\Q=G[LA?E'DJOSGS87Y3YNN\QLPW<Q9DOLV=GSF1_2?
MCT:#*/2]+!YV**%1?M0*DC>-PN1^BQBYUJ9".;O4G/=(JZOTWH6^VML7A%@/
MU49YK:U,"%E9DA;?.3<W<\F<HOR6G*K"YIRFHL:<SN+Y.?W%]3G;BNMRCA;7
MY-PIKLYY45B=\[*@.N=5?G7VZSG5V6]^ _QQ%F(YN""7FPTJ>,F'>E[R>"$/
MN=G&32YUHOLO,^4>[W"6W+6$H;EE$=-R?6.D>V]=?/#R>2FQ2TJS,IH*\POJ
M\\M*:O+JRZOR6LLK\U:5E^<-EY?FC9<7Y]U GI:6Y#TO+IWSHK T]V5!:>ZK
MWX  ?GY(8..$?$[J]RHN\G@!.[FQF)U<[4#W[Y8C1WJ,N?9V.8EM[_11&VH+
M-EO3$N[:TQ0;L+0^*7IA=7IZ77EN?F5Q85E)8=6\PL+FZH+"KNJ\P@U5N85C
M5=F%?U7E%#ZNR)W[M"ROX%E)?O[SHOS\%[\!P;PXCQ0\#^R4B5HJN=5,R-6E
M;.1B%SLYN4J:C/<:<NQ<Y2"RN<=;>6!9H/&J=I;3LM88W\4+$R/FST]-F5>3
ME5=8F5^64U96G5':4)=6UEZ74K:V-KEL9TUB^87JI+)'\U)*'E>D%3\IRRA\
M5O(G()0;YY&P02F%/$#OO([N>[&32DZOI)+#_6)D;*T>^TB_K=#&/@_%_I7^
M!MW=H?9MG5$^36WQ834MR8DE31DY.?6YI2DU1=7QU35UL=5+:F-J5M=$UVZO
MCJH].R^JYE%ES+S'%7$53\H3RIZ6)90^+9T-1'!R0S:A?JXDY#;Z_Y6EZ-[=
MA!Q%_]TW($AV;-"B;MI@15LWX":[<HVO;D<?TWK1B@C/^J[8X(J.Q+C\)6F9
M:2U9A7'-<RLBFZJJ(IH7SPMO[JL(7SA2SEIXIC2T^6DI:_[3THBZIZ61U<]*
MHJI^!V*I. N$\J0&>S#C?<O0NWK1>P;0?8=XR.9-:I3UF\QY>X>=I98-^F@N
M7A]H/G]-F,N\OBC_PI7QD5G=*:D)RS+G1'84%(6U5Y6$=BPN#NWL*PSI'"E@
M=I[)#^YXGL]<\K(@9-'+N:&-R(+?@23"/EU,R)WYZ-YMA)Q:@>Z+[K5[(R&;
MMU+)ANT*9/5V(ZZN$7NQ)5L]5!HW^QI5#P4[E RR?'(&HD.3UR3$1ZU.RPCM
MR\MA]LW+#>YKR0E:W9L5M'I;1F#_Z73_ON?I 2O>908NF\@.6OHV)ZCM=R"#
M4-_@/MQ82,BYY?_NP=Y!=,^MA*Q'!^[=(T&Z]^JRMXU9"3;M=I:OV>FM6SKJ
M9S5G)-@M90LK('I3=$3H<%)"X%!N<L!P1;+_\,)$OTTK$_PV;8WSW70JAK'I
M&5[4OL0SUDXF^J[ZG.RW\M-OX#Z0>W7_]N $^O>!]83LW$+(\ Y"^M!!.P_Q
MD25'5:E-1XSY:@_;298==%7+.^!MDKK/SR%F;Y!7Z!Y68,#N^##?W5GA]-UE
M+/J>IC"?L9X0G['-3.^])X.\QIX%NN^:"O$8F0[S'/X1X37T.^_+_NW!6?3O
M0^L(V;,)_1_SUV)^UV'TWU-LI.&\)*D^K\U9>MY,..^LG7S:&1>=F%.>YJ$G
M?1W]3P1[^IR(]O$ZD4[W/%GLXW%JOK?'J2XO]]/#'FYGCKN[G7[FZGSRNZ?#
M<?!QV@^^3OM^YS[VX%([(<=FSL$0[L$H^C?FKT ';44'K+_ 1DIO<)/"6PK4
MW%NZO*FWS,1C;MHHA=QPTO7[GX>9UW4_&_<;+#O7&\EV+C<+;%UNU=DXW^ZP
M=OY[T-+ISB$+Q[\?F=O=^F)E?0-LK:Z"@]45<)S-S%DXM1+W &=@QP@A0V,X
M YC?=H*0AG.$E%^ED+R'W"3KJ31[TC-5WJAGNJ+,9\9RC&>6:N[/''2=GGD8
MVC\/,+9]$6EB\R+-V.9EL9'UJT9#J]<]!I9OMNI9OCVC:_'VE8[9*] U?@$&
MB.%LSLWL 9[#W=O0OS%_->:W8_Z"F?PKA,RY14C:&RY*_$<QCHA/<GQ!GU2$
MZ9^TI-P^&\C;?S97L?YLKVXQZ:%A^B5 T^1KI*;1MS0-PV_%Z@;?&]7TIU:H
MZDV-J.C^.*>L^_.YLL[4M)+.=_B-HW@.QW &M^[!&3B(,XCYC6<Q_S+FWR D
M^1XAT1\HE%#@X_ '45XOD!9T!D4Q6U"7,@==61,PD3< :P5=<%'0!H:")H3)
MJT.2K"K,E5&&!FDE6"ZE",-2"G!84A[N(4]^8Q_.X/9=A Q@?M=Q0IHPOP+S
M<S$_Z2XAX8\)"9HD5#I0.=V F\<>!&B6("9L#-*B^J H@4(LJ0%Z4BI@BEFV
M4G+@)BD-_A*2$"4N!IDHDA6B@M""-\PK\89QJQ -1G]C!UX#!L<)Z<'\19A?
M>>7?]2?B^EF8[_>2$,]OA,T1"*<5$!X3H/+K Y> %O +J8&(L!)(B<B#@J@T
MJ(F*@PZ*H[$H/]B*\* T<$"@$!5B! ED"Q HHQ%H1EI^8W@_(:N.$;(8\ZMF
M\F]B_GU"PIX2PGA%B,L$H=C\)&RF0#CT@7!K >%5 <*O (0F VP"$L M* HT
M(2$0$^(#:2%.4,1<#<PUP%QKQ US_/D)A/,12$'2?@-TI$1!64T"%'0D04E/
M"N2-94#:1A8D/&1!/%@&Q..E03P7*<?7\_']5EF07([TR8+4!F2++$COE 69
M<>2T+,A>EP6YQS(@_TX&%*:D00%FD/H'.7R-G_H-/70L%54)4-:2!%5M*5 V
ME $Y2SF0=4,"Y4 F%C^5A93@ZSIYD&V1![E.9)4\R \@FW K1N5!<3]R4AZ4
MKLJ#\D,Y4)F0 ]5OLJ *LM.J(/-#&601^2FEWP%]K$$5:U!3EP1-#:E_G@FI
MFN%W..-W^2F <A3^3%< I4)%4*I1 N5FI%T)5%8H@>H:9*,2J(TH@?H8<DP1
M-"XK@N8]1=!ZH_!3ZXO"E#;(?],"^2^:H(@H3VJ RFS $&M00]?65I8$/15)
MT-64!CT3.=!Q4 1MNA)HL9!D%=#,5P7-2F2!*F@M40/M+E70Z4,VJ(+N%E70
MVXT<5IG6/Z_RP^!OE6^&+Y6_&'Y6_F0TK?3! %3>&X#:.WW0F/@#8"0A II*
M$F @+_'/,R$S52DP-Y %,QM%,/94 2.F*AC&JX-AMB88EB)UFC^-%FG^,.[0
MG#)>J?G=9)WF-]-AS:^FHQI?S YH3)J?T?AD<5/]O<5S];>6G]1>64QKO#0'
MK1?FH//<#'0?6X#>;, $:]"3$P=S:3&P1AR4)<!15QKL+13 QD4%K/PUIBVC
MM*<LTG2_6LS5F[2HTOMDV:CWT:I-[X-UM^Y[F]6Z$S:#NF]M1W3>V.W5>6UW
M4ON5_77MYPY/M1X[?-)^:#^M?]\.#._:@?%M.S"Y[O [8"8N B928F"+M3A+
M"H.GHBAX:TF IZDLN#DH3SGY:$XZA.E_L$\TG+"?8_3&H=SHE4.]T0O'%J/G
M3IU&3YU7&3YQ&3!\[++%X)'K'H.';L?U[[M?U;_C_E3_EMM'X^NNTV977<#B
MB@M8GG<%J]/N8#T;L, :K#!_YGF,CX0 !"H(0I"&" 0:27[WLU'XZ.VA\<8C
MR."%6XSI$[<,\T=N1>;WW:O-[WDTF]WQ7&IVVVN%Z2VOM:8WO3:9_<]KE]DU
M[R-F5[VOF%_V>6)^WN>CU1EOL#WE!7;'O?_Y6SL.!^B_ Y;BPN" ^5[H?,%B
M?! AQP]1:@(_(O5%/K(LI5\%.ZL\\??5N\<(-[OMDVQU@YYG?8U>;O,7O<'V
M,J/%]B)CF>UYWUZ[<[X;[,[X;;,[[;??[J3?6?OC_O?L#_N_<QSWFW;>[P>N
M>_S!;4< N&T/_!VPQDNZRXS_H_=&B/) O PW)*GP3B;IT%XGF(H^CG&0NQ-!
MU[P>&FIZ*2C.]EQ IM/I@$*7DP%5KL<#%[@>#5SB>CBHV^U04+_;>/"PVX'@
M76[[@H^[CS%ONN]BOO8894YYC02#]V8F^ R%@,]@Z.^ #=;@B:[%Y.6!.&%.
M2)/D^)FIP/D^6X/[::81[6ZZG?BU9"_E"W'!QB<CHNR/A"6['0S-]=H?6NJS
M-[26OB>TF;XKK)V^(VPE?31L/6.$-<+8QCK(V,*ZPA@.?^:[D?75;P,+_-=&
M@/]JI"_R=\!>1 @8/-@#'BY($6"';#&VKWFR;*\*5-@?%.ARW2BP%KR0XZ%P
M,CW X%!BN.W>V'B/G5$9C.V1!0%;(RL"-T<V!&V*7!PT%+4\>#"J/WA#U*;@
M@:B]P>NBSP6OB7[$[(O^'+(J&D)Z8B"D*P:8R_\ ..$^!'#Q0"P7!V3P4R%/
MF/*A2(+RM$2.<KM,@^URF27_J2(WV<-Y?CIC6:'6HZDQ[IL34_PVQN4PU\<5
MAZV+K6:MB6L*7QW7'MX7MRI\5?Q@^(KXG1$]\2<BNN+O1BR+_Q#1$?\C8FG\
MS_ E2&O\-&LVX(KN'\S.!8F<;)##0_E6R$_>E F0^Y7H_E4JE'-5YKQ'*UVD
M]I4P-'<4,"TVYT2Y;LA(]%N3FA':FUP0N2*I/*8[J3YV>=+BV&5)7;$=2>MB
MER:-Q+4E'8YK3;H9UY(T$;<HZ5ML<]*WF*:D[]&-25-1LP%//GX(0]=*9:?^
MS.,D;THXR=U*3G*S&MV_'MV_P81[O-9)?-<\NMK6LF#3P<((Y_Z\>-\5V:EA
MRS-R8MK3BA+:4JN26E.;DEI2.Y(7IO8E-Z5N2FY,/9 \/_5J<D/JZ^3ZU,G$
MNM0O";4I7^)K4[[&S09\9F:!X#Y0*9_G4LF=<KS7KV$C?]5SDK.-Z/Y-1IQ[
M%SB*;J_W5AZN#C1:5\%R6%D22U]6D!S:EIL9LR@K/[DIHSQM?D9]>GU&:T9=
MQHJ,FHS!C*J,/1F5&1<S*C)>I%=D?$PM3_^44I[^.:D\?3)Q-N#+Q0LQ!&>1
MD)?H?+>J".93R85&=G)B$;K_8@..78OLA;<T>2EN: @PZ*L-L^VJC/9J*TU@
M+IR;%M.0EY-2DU.4.2^[*J<BNSFW+'M9;DGVNMRB[!VY!=EG<O.SGV079+_+
MG)OU/GUNUL>TPLQ/*;.!  YNB"=L/^:@;Z'O7*]%]V^DD-.+T/V72)"QI7KL
MVY?8"@PM]I!;N]!?=\6"4.N.NDCWEJKXP/EE*5'519DI907YV85Y97GY<QH*
MYN0M+<C)6UV0F;>M("/O>'YZWH.\C+RWN9FY$UE9.>\SLW/>I\\&@MFX()E0
M/Q:@^Z-W7FE YUJ$SK,$G:-=A.Q<IDW=W&G-O[[=3:9WB:_6\A:FQ9*F")>F
MAEB_VIJDB++*]*3\TISLK**B@K3"ZJ+DPI:BI,*510E%FPKCB@[/C2VZ6Q!?
M^#HOL>!M;E+^1'9RWKNLV4 HP>L2H3PKFID#0BXT$7*RE9"#'>@<RVED6X\&
M96./)>^:+E?)GDZZ>OO2(--%K2S'^H71],H%"6%SZU,2LJHSLY(J\PMB*RJ+
MHBN:BZ(JN@LC*X?F1E2.YX=7WLX++W\S)[+T36YT\=N<F**)[-G@/+)#UK_[
M<!5[< :]ZPCF[^W&>_Z5W&2X3X6LZS/C7K7*26S9"F_EQ5V!A@LZ0^VJET9Z
M%K?&!><N3(I):4S'P9B3&UY?GA]6WY@?UM"5%]JP,3=D_H%LYOQ;6<'U$UDA
MU1-9H94366$5[WX#8@G;YSS<AWDX!]B#$TL)&4?WVHD./MQ/)0/KY$GO.B..
MY6OMA9;T>\@W]?GIUJYD6I9UA[OF+XOQ2V]/"(]K2TT,;\U-#UE<ELE<W)@9
MW+H\/;AU,#5HR8&4P"6WDOP7?TP):/J8&CC_8VI0_<>TV4 2H3PNQ%E$]SV[
MF)##R]&[,'\;^M>Z]7C?OU&"= WILK4-6=&:!UVDZ];[:%2L"S IZ ]QR.R+
M\$Y8&<N,Z$F)8G;GQ =UER4&=C<F!'0OCPOH&8SQ[SD0Y==S*Y+1]3&:T?$M
MUG?)USC?EB_QLX$,W >\)ER:Z0'NP0'TWQV8/X0.W(L.UKF51I:,J%&:1TQY
MZK8YB%5L<5>:NXFAES44:)4X&.H:N3Z2P1Q(8 :LRPKS6U?"\AV8'\886!;"
M&-@03%^_/\AG_<T K[4?@CSZ(<1K)81Z=T^S9C.!^W #S^-9G,-#/83L68/N
MN1'=#QVT>SNZURXJ63 F2VK']#@JQJP$Y^YVDLG:Y:&1M(-N'#D:8,L<"77S
MVQ;C3=^6QO#>5LCP'JGS\1II]_;</N#IN7VOA\?V&VYNVSYXN&P!;^=AH+ML
M -_9/,19O-Q,R/%EA.SK)V04\S=NQ1[L(&0I>G## ?3/(P*DY)@J-?^H$4_F
M46O1Q"-."I&'W+6"#])-?,<#K;W&(^P]QI,=W0_F.[@=K+9W/=1FZWIHK8W+
MX3W6SH>O6SH=_&!MOQ_L;/:!@\T><)K-39R#,SB'!WL)V34X\QR,D#7HH,O&
MT'_10^>A!^:?92.9E\1(ZB4U]OA+AOP1%RW%@RXZ*-(ON&EZ7&#HNUP(,7*Z
M&&_D>#''T.%2I8'#Y19]^\M]NG97=NK8_G55V^;2A([EA6E]\W-@9'863&9S
M<>8LKL YQ/G;AOT?P/SN?;@'Z.'5F%]XAI",RQ02>Y.+1-Z5HH;<4^7RNZ<K
MZ'7/3,+EGJV<_3TW)9O[?BK6]\-5K!ZDJ%@]G*ML^:A>R>+Q,D7SQT/RYD^.
MR9D]>2IK_/"[@N%]4-*_!RJS.8'G8/\ZW /,WXCY*S&_]1 AM>CA19B?>8F0
M./3PL(?L).B-"!OCC2RW^QM5FN-;;1'KM\82YA/6TB83+C)&[QBR!N]9,OH?
MDJ7U/LZ5TOW8(*GSJ4M"^_-F<:W/9\2T)E^*:GR:$E7_ +\QCC.X<S->"S"_
M#QV\[3 A]2<(*48/S[S\;W[(74+\7A&*UW<>=I<I$2Z[*6D^BQ^*@L8_-$3T
M?^J+:O\T%].8=A!7!4\Q90@6580X$7F8(RP'M4*RT"DH T,"TG"$)@T/^*7@
MPV_L&?[W.=P:S.\X0LC\DX24G,?\*P3[_V\^_1$AKN\(Q?XG8;<$+BX3H/'J
M@QB_%L@(J(&2H#)H"LF#@9 T6 A)@).@"- %!8$EP =I-&XHX^.&1;Q<T,O+
M"=MX..'P;\P\AQO _B_'_,93A)1>("3K*N;?(H1YGQ#O)X0XO2#$ZC.AF@!A
MUP/"J044;E7@Y%4$?CY9$.&7!"F:*"C0!$"=Q@MZ-$ZPX*> ,Q\!/UX"T3P$
MLKD)5"(+N0@L_XU!S._!_(687X'YV=<P_V]"@A\2XO6,$(=7A)A-$(K^=T+5
MQ!J4L09Y(%S20+C%@? ( Y67'[CX>(#&QP%BF"N#N<J(#F:;(\Z8[8=9D4@J
M)X&\WP!Y>5$0U1(#"41<1QR$#26 QU("N-W%@2M8#+CB1( S1Q@X2@6!LTX
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M-,.+T32#2QG\^I=*^?4N-_/I7E[)JW-EE$?[RF5NK4MO>#0N_.!7.PL"JF=
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M+U'>\-^GO*1-4)X+?*<^%0#V)T+ \5 8.!Z( .>O@*BT$$B)"8*TB !(BM)
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MD+]0\POP)?@&_+2"GR6(?E4C>F1*] 0U^2N<Z&]L2/]@$6(P^1A,>.;(?\Y
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MIA;H="&[?F@-T_>HQ;>HQ3>HQ5<TB^EQ"-/D-'U*US!EWJ*/GYZ$_ Z8ISP
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MW[$0_=X%$,?C0P#%?'SM*9N/+9[!-*TX@XE C;VAZW"'R!BYJB%/R7<P_A]
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MHUL>6JE;&KI6KSBT2V]-R(C>ZI!)O?R0_?JYP>?TLX-?T<\,_EHO4_"'3J:
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MV7&:EM]!.^7WTW:%TS2E<(LF%3Z@S4H_TX020YN6V+@$PR7Z$4O))UC6WC;
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M,=6_.<=4:?^+IZO8'BE.;F(B?-RP,V>)V,CG(T1?!]#9)4)+MR4:>]:@KB=
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MXOVK(=I/7;F?6GL_)__]G/3V<V#;STZUGX'=SX+V\1?WG@3V4$#O?H&#T,?
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MWF7@:<,2M?_2;]C/&"_R8PP;AOF\@_&N(7<A?4Z; Z+)&[P%\*0K3M3H%GL
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MM8_2=)Z^3A#]Y&VGSW7D+B5W3BLU#[ECNZ@Y*%'\UTKAU6\!CP$GN UX8,U
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M\G1YB1[[XH_]%TJ.6/Q_F^@EZ4V696B]MCS98I,;]OB#$X$M">"DH_MP<(K
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MB2?KZ=4Z>EF=]1JAG3U[&5&UX-\0L^Q4!V-9:C>XDTYXZNG05+Y.X.=!7A]
MGWX;6S!=:=D7^T+!B\&V)/ RL,T$7I$T&2IDI*%6&HS-4F?LDAKCH%0;ITF5
M<9%4&-=(F7&SE!BVXK5]_/81Y 01]:-V9_8V<#:!NUJ=Q%$5&1+6"<@ W_?R
M6A?Z=)"6C'*REW;[8=)J'R!-#A'2Z!@O#8ZI4N^4+;7.^5+C7"K5+B.DTJ5)
M*EPZI<QEC)2X3),BET62[[)&<EVVR'"76R3'Z3[)=CPBF8[')-/I>[Z>E9M8
M6B\";P5)ZKQ@_$_B/@;I"0*7UUI)S9I)1YK0LW&8DS0,\Y9:CQ 9X1DMU5Y)
M4NF5(>7>)BGS+I82GRHI\ADI!3ZC),]G0$P^4R7'9Z%D^:R1=)\MDNJ]39*]
M]DNBUXO(*4GT_$F2/,UR+;9N!&]9J+XK9D*$R&BD@^];2#]&\GH=NM6BRPA_
M.ZGR]Y *_P I"XB0DL!X*0I,E8*@',D+*I#<H H9'EPOV<%MDAG<)^G!DR4U
M>($D!Z^2A.!-$A=TB\0$WB=1@2](5, IY!>)]C=KE_:O V<QN-.CB(%HG<"T
M(B/YN9;THXKW*OF=LE"#%(>Y2&&8K^2'ATIN>(P,#T^2[(A,R8K(DXR(4DF/
MK)74R!9)CNR5Q,B)$A<Y3V(B5TI4Q*42$;%5PL+W24C84>2DA(2>0<QR6;!^
M:'T!F%-458A48Q32A-0B5;Q6%D.^S_OY2&Z,H^3$>$E6;)!DQD9*>FR"I,:E
M27+<<$F**S8DQ%4;XN*:##%QW8:HN D2$3='PN+.DY"X2R0P]B;QC]DK?C%'
MQ"_ZA/A%G1'_*+-<BL_/H^VYX$V$%O0FX@.D :E&RI!"))?W<OB:F60K:4GN
MDI+L+TG)89*8'"OQ*2D2FY(MT2F%ALB42D-$RD@)2^F2D)1Q$I0R6_Q3EHMO
M\L7BG7RC>";=*^Z)SXE[PJ?BD?"S>,:;Y4+PSP5_%NV/4P0R!1\@-4@%4D1:
MG(MD(6GIY'OI!DG(<);83!^)S@R6J,PHB<A*E+"L# G-RI/@K'()S*H7_ZP.
M\<T:%.^LF>*9=:ZX95XH+AG7BU/Z;G%(/RR.:1^*4^KWXIQBEHWJ @/PIX,W
MD*;ORFE JB#5)4@^DH.D98DDYI#S#H?[F!PD+-=#0G(#)"@W7 )SX\0_+U5\
M\X:+3UZ)>.75BD=>F[CE#8AS[C1QS%TB]KD;Q=9TM1C4(P5RGA!#]GMBS/I:
M;+)^TVX+6JAV*($[FA2\%:Q:I!RJ5HB8D$RPDTB+8Z%-$9#]X$(;\2]V$9]B
M'_$J"1:/DFAQ+TD2UY(L<2XI$,>2*K$O;A+;XEXQ%D,<BA<B),U%).F%K(X%
MCV'<>R)Y7^'D,]IM07/!G@!6-UB-V%D-7@F2CV0C:6#'0Y<B(;;!)?#/,I%A
ME0[B7.4A#E4!8E<5+K95<6*L2A-#E4G?TE(%E:Z$/E="8"KGZH_7J&!5+B<[
M*3LH4@H3+_D&W7Z1<\&>.5S?'30J#R:.G15(D:H*(1E@)X$=!78(=,F_4L2S
M6L2IUEZ,];#P>B:8!@97 P.Y(4G?VM10R.OPS'H(;#T<KQYR7,]*7+<))T-0
M1D ^JM]"3W2H^DT6@SM%[0[B8RU@U5BK0DAV,;P+2A +=F@5^#3K"<%W;H #
M-L%?FN&Y+4SFK?YZ>;>=@=Q.Q[:IHV9\J*U1O^:C%8[7"EEMA;"U0EJ:R5@:
MR5Q'POT;SLI<<,:#TXG[1I;I;BRQ[$Q*KZ /L#F\%GQP/6G2"2IO@WG28>1#
M#GIUIMN;01VH3["C$_3 &HT1O7RPE_[HA<CVJ,>>D)WT0)ZZ[N?SK^%XXJ']
MK$P'9P#_MF%G'5+)]X66JE 2-D="F0/ ]0#7J0/[H?$D(\("S@=9],>PL ZB
MQSCZ9#R3_H0HO?P[@0Z>@"\F\.'Q],=X=>0!(CD.LCH6LC:&#&[@"R;%WV0B
MJO8@S6IG#K2T##$13JG8'-T*_X8N>W3#/Q4N_)PD0J_*8)I6#YF"'M-4PH$>
M,]%C%K$QATEG#@-]#IT\FX9G=^N/P9D)J9Q!7$Z'.$Y[AB2!C'[*KS(&K ZD
M<:2Z(0@?H'9&NT@<+@P&UW- Q'Z<!5/MC)FN)5?Z#I5YEH1+VS%"(K*41. <
M;_VTS@HF^!5,+"L(YN7J.-18_9' RR"U2R#IBQ\E6?B8S_XDH\%KQ\\CL;D,
MFW-0.1%[0_F()T/;;IH%TUI_&;H[126=_U8/P2<;2,3.]]*WRE["!'QQCGY5
MMGI4^(6,CPOXQ0UDS^N)B;6PBC7?2 _]V]:IGX[*']!OQPDGC+W!M9]OP5QF
MP5LE?^Y,^=_50K3Z!#ZYCD3L1N)T:ZQ^:^N-./D&#+MA">\Q1J^A/ZZ"G%]Y
M2KJQ>21]7(JO,[$Y1MU,0P@[*MR5\N\[4RX9@C7TE(YUYX8B)]LL)&DG8_<N
M8N0>DH.]S!M[&&B[,78/OMA#HW?SRW<]+'+G>])FJ<'DX>ND)?KMO&YK+79:
M3P8-K;W\IUTB0^L@UMM455U"_3G[:753"'H<8=YXECXYRH!Z@4Y]#H/^M8/W
M']-J,*5+]!MZHU'/EVG$;K/%SNLLMMTJ_UYWL>Y(^6L=Q+I+1%VGH([TJQJ(
M(I+O$ZO'F,,^9C(^1GR>H+./$1<? _#QGO]0 U$WI;HA@?([^?-9>-59\O<S
M4BD_D+M_H]U4VBVGR?)/,D@_9; <(V@_A@5]0+"^!T-Z&T[S!HSE50QX"0<]
M#YM\#F:MGLQRV%+_V#>D!O%7'=3IE)_A$U^1QW\!O_N<'/XT/.(XO/\CV,%[
ML(:WR>S?(--_%3W4;:4O:K>5S@)GH3Q# #]%X!ZB(Q^#N1Z$UQS@WP-\:C^M
MJQTANX;4(+9:=% W4ZB3&>IV"E4'^%!L^80G3#T$C#AL20<G#XPRF',M;*T)
MEX_"]3UTP1@0)L!9IX(QA^Y91#>MH+LVT&U;L/-F\/80IL_2I5]HMW'<8MF5
MH>H05R)J5X@Z&:-.AB@.KG9F'-:ZU04;_.0A?/$@OG@ WG\_C&0OO&X/>NQ"
MC[OPQQWTR^U,H#OPQW;TV(8>6V'$^I-:+V387,V_'6 =U)[0JC"O$/U64+4C
M0]4BM*>CBG[QK@JE!RSA?9?8P\4]^70P;>LWA-Y*GVS]XW1*+2';B"WM<A5Z
M7(D>EZ/'%ICI9NTI)<OHC77:$THVXHOU>&<=/;:!GE9UCW66'1GJ9@SU=!9U
M,^HCEE#?81D*U\$SK]9NYO2E[3"FA'A:2Z=]$^T7T7XY-M2 ,1*,5MKM J>?
M2!A/V],MMV.L@'5?B#97:[LR%A,A2^0SQ*R)]6:,5RWXNRS8?ST5LD$\T#F0
MMB.11*;D#-HWT7ZAMC/C7%BKVIFQ%#T6PWX7:7L0)N")F4SOBV4VGYJI/</E
M%CRD=F6\Q]=?_VU7QE,6WRO\RRW3X3K+M+R<<;H,7RP5'_0.H<5H]$YB%&;0
MOHF>+P2C#(QJ,!IHOY6(Z&8Y'0-?GZ)I,@Y-!VEU#)X=P-(!O#Y ]/>#;94'
M+5/K%9:I<95E>5!_&E#+XAQQ &,8[?NC<Q@8L;2>#$8F2VDNGB\"IUS&,F['
M$!\#Q$<?"<9HWNG1]HHLQ3OK&457(#MY]W%FF./(630V:[+;,AU>9,%GRM26
M2/7G"F8SL(RTY@R&MU9_&$.?#! ;?<3H:,D")Q?+B\&JD [B=)0TTWXG;8_A
MNZEHM9"(4>>)-B';I ZK:^4MY'NBR<Q7LQ:#J@_4LKO43M\-,H7E9CRI&MF/
MEK:,)BYZF#N[B,].^J2#/FDG-MHD#:P<L/(9J27@5=,C(\%JUZHR(["@"HLJ
MZ(\*+8IOI.?NE5+ZHX38+&%F*M%JI2R'+"OGL>S/9UJ?2JH\EJ^C25>[2(\Z
MT&F4P0">D[0P5ILE *QPD&+!2L:N#/!,X!6B004S>AW_;P&KA_;':Q%30.2J
M/4YY>-Q$3 PG"H<S(H?+3PC<'_SSP5PVC%1%U5](/_J03I4N>\#[6'Y'HL](
M>UNIMW&1.H./U!B"I=H8*97&>*FP294RFVPIM<V78MLR*;*KD0*[9LFSZQ:3
MW3C)L9LE67;+)-/N DFWO492;>^4%.,A26%U29%OD;-R!7:O!6\1J> T/_R/
M="&MR$A?<DQ>'X%.U:0D52[V4NGD+N5._E+J'";%SC%2Z)(D!2Z9DN>:*R;7
M$AGN-D*RW9HDTZU;TMS&2XK;;$ER6RX);A=*K-MU$N-ZMT0[/R&1SN])A/-7
MR"^R&5M7@34_0-\5TX>T(XU(#5))*E0&?2CE=TJ\#%+DZ20%GMZ2YQ4D)N](
MR?%.D&R?-,GT&2[I/D62YELE*;Z-DN3;)?&^8R76=Y9$^YXK$;X72IC/]1+B
MO5N"O ]+H-='$N3U+7)6+L;.Y>#/)OT;%PI5"-7K+W5(%=^7(H4AY'GH \65
MX0%VDAW@+IF!_I(>&"9I0;&2$I0L24%9DA!<(/'!%1(;W"#1P1T2&3PH8<$S
M)"3X' D*/E_\@ZX5W\!=XAWXE'@'?(C\(#[^9KD &\\!?P:88R*(P4A\@(Q
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M#L"]7J7@5X!?Q2)3PZ)6ZR"B:C$-^&(DDUD3 [B)P&K"%TU\J%%M\X#0CH1
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M)<R7%]$?%[PKE<26J5&_H3@8F]T&+/ZUUE_4WI<E%KR5?\'ZZYZ0H6=55)U
M_>'T+O2XEWGC'@;Y;@+[+K+DG31\V_G\SG:1K4]*4;O^E*A(;/9B>3/.M.#^
MM0XR](DY_ZD.,O2INJHFH?9F:#40Y AZO,I8>9$!]QQCY#"=^B1,XG$4?V2W
M#*>?X\$.H&\=5)\NM]AZH?RY!\7ZM)RA>$-K(-:;4Q6F]2R,V@>B#E*H/Z@K
M4OTE\^G7$1!\@OXXG7V,CCU&/O')S7^<_U![$+ZW?/U9[&"FUCM!XI%,?J]
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M>T2+HT>2.'ADBYU'L=AZU(K1$][MR8CS(.H\2#S=28K<T,'E$#J1VSM])[/
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M>>G.4\6;>'6 *--2BV'&BV?VC6,6C&9&CB91CF*EC'P:(7L,^UT&U'U 8%5
ME4U\/!6)12*L]1_>\T,\T<F5GQUYSR:2<(;>2QR36 (<,QE?I#)P4C$HC5],
MHS_2(/-ID,<T9OPTXC(5TI($84A AP0RI?BGM7-)$F^6'C[2$*[O!<I6-2 D
M&HQPTO!@]/!'O'G?C9\=><\&RL3$2-"JB1,NE8X>F?@B!U^8\(5);>R*U \U
MF9CA3<2$B17(- BIAJ!E0,+2;T,O^B*-##K-K-W4K([1Y$.1TVD_0>T!PL8P
M7@]"?,!UT^I/\!\-%\%$%@N41DSHD8\O"O%%"9-+J=KD%J8?\"KEETKA5J7$
M1&F?OA\EGTS%!$DQ,3\,1X?A9NU,6'D"W])^JBJIQ>LUH%"U!XKWW'G/$>IL
M3!V*B\#363QI6RVLQ$:5FN@9Z/4$>3V^:%!%KA3]HI5ZR&P=,5$+@:PD0RR[
M&2%[+CV-WF:I2];OXU%;BI*3]=*>J@$%X$I/FG#,$#%D6Q;/ OFS!O,_:B'X
MHU4=.%5U$":2+CJY$R,Z^7 GJW\'\\0H8J*9L3$2XE9/%EG'V*PU2R6VY671
M36 EX>,8-;298KQXS4GM_QE:@U&UD%KYL_XR]&R.5I= CS'V>@%^(GTRD2":
M@"$3&!_C^=!8LK-^5J@>QF<G)+$3(MAQ5CL+-9S0R4#=1/0)RR$&"&?G(@MN
MM<76H?47Z[F</_:AR)]G9+0]&L3H/&)C 7VR %_,S]$?DST7SCV3^7(J6?LD
MQL;$(^CW@Q1BYW PT_%UM)I>Z5]GJ[T*M\UBI\(<>B9GZ/TD?[TK1-L+0K]L
M0(_SZ9,-=.PZ?+$:YRTG2SZ'^7(QI'WA03YW2@KQ\W!L3J2/@['9M6$(KDJL
M&%):/<**J6H2_Z/N(O]SCX9VCP7]<JVZ2IX^N0HG7XYQFQD?E_#A"^F/C7NT
MIP>KIV6EC]#OHO$&V[;'XE]EZ[0AF/]FH_QY+XGUOM2A9U74'PM5G4#]X?(.
M_+&;>7P7 ^T.''X[F?)VLN=;4/@FQL?UC\IP_)U 'P>"[336TJ>SY,\ZB+)1
M)=X;A]CW?[H?1/W16-4D%'E2CY=0M8BCS.FO,X>^Q( [@L.?IF,?QQ<'-XD\
M>(>D@1VAEG?EZSD6>\^SV/F'3^5_GHE1-1=5 ['>"Z+.PRC"K.HNZBX0=9FB
M(M.*5*O"PO?H<8:%[WL&X%<X_13&?LI:_HG:Y?_O_QEL;.WL'9V<7=S<AWEZ
M>?OX^0<$!8>$AD=$1L7$QB4D)B6GIJ5G9&7GF'+S\@N+BDO*RBNJJD?4U-4W
M-#8UM[2UC^KHZNX9W=<_,#AVW/B)DR9/G39]QJS9<^;.7[!P\9*EYYR[?,7*
M5:O7K%N_8>,%%UYTR:6;-E]V^1577GW-M=??<.--6V_9=NMM.VZ_X\Z[[MZ]
MYYZ]^^Z[_X$'#SQT\)%''S_TQ).'GW[F7\\=.?K"BR^]_.IKK[_QUMOOO/?^
M!Q]^_,FQ3T^<//79YU]\^?4WWW[_PX\_G?GEU]]^-__?_O>/_?^?VV\P*HL=
ME,FNV.RAC/;%ZD!E=IBR.QK#XY7E*<KT3&P?KHPO4-:78GZELK\6!XQ4'FA5
M+NC$![W*"6.4%R;@ABG*#S.5(^;AB47*%<OPQ7G*&6N5-\[''1<K?VQ1#KD*
MCURG7'*S\LEVG+)3>647;KE7^66_<LS#>.8QY9JGE&^>Q3G/*^^\HMSS)OYY
M5SGH(SQT7+GHM/+15SCI.^6EGY6;SOYNGCEI@<H\Q,:6G,+PUV#X#S__?^XO
M,1B,1AL;6WQ@[^#@Z.B$'UQ<7=UPQ3 /#T^\X>V#/_S\\4A@$#[!*7@%M^ 7
M'*,\H[E&]\U?G*/Y!M>,;%1#B9'4VS<P.&["I"G39LZ>NV#1TG-7K%JS_OP+
M+]FTY8JKKKGNAINV;MO.<%&CY=Z]&*G9^!<3=1LU(Y65F(F=&(JEF(JMQS_%
MVI.GL/>SS['XRZ^^^AJCO_WNN^^Q^\>??OKYYS/8_NMOOYT]^_L_]IOO#+4Q
MWYW@;+XKR\]\1U&<^>ZJ7//^D;7FAT?U__YHW_Q?'ANW\=O'IUSWV:$9=QY[
M?/:#'QR<]]1;#RY\\97[SGGGZ)[S3AZ^^X(S?U?^T>$?'?[1X1\=_M'A'QW^
MT>$?'?Z?=;CK+SKLKC*9'VRH_?W1]OY?G^B=_]/AP8W?/C/Q^M//3;G[DR/3
M'GKWF1G/O/+$S%>>/3COO8/[EYR\XYZ5W_]=^4.'N]'A3G2X!QT>:JCY[5!;
M_T_/],S_]LC QL]?''?#)Z^.W_76"Q,/OO#LE*>?>G+Z2P<>G?WVW0?F'[MN
MWSE?_EW1=-BEZ>!KOJLHUGQOU?#?#];7G#G<VO?=T:[Y7[S2=_ZG[PS<^,Z;
M@[M>>&G\@2>?F_34@X>G/K_K\1EO;'UXSH>;]B\\]7?%?+>F@Y-YET6'^RIS
M?GVL?L0/S[6,_NJ5SGDGWNTY__T/^FYXZ>TQ=SWU\K@'#AR=<&CW,Y.?N_6)
M::]<]<C,=S<>F'OL[XJFPVZ+#G<7QIKW5V;__$1=]3<O-O>>?F?4O(\_[=SX
MVL>CKWOFG8$['GYU['U[7AC_Z&W/3GSZNJ>FO'#IX]/>6'UPUOM_5\R[+#KL
MSO(Q[RJ,.7N@,NO[I^LJOWBSJ>?8)ZUSW_MLU(:CQWJO??3=_AU[7Q]S[^TO
MC7WHAB/CG[CLF8G/;7AB\LO+'YOQYM\5\ZX0HWD/.NQ!ASV%T6<.5F9\?:2N
M_,3[C5T??-8\Y[4OV]<_^6GW5?>_W[?]CC<'=M_TRN#^*UX8^^B%SXX[O.KP
MQ*-+GISV\M\5\VYTN"?!T7Q/EK=Y;V'D#X<JTTZ_7%OZX;'ZSC>_;IQ]Y)NV
MM0^?Z+I\UX>]6V]YN^_.JU\;V'O)2V,.K'U^\/%ESXY[>O[34X[\73'O08=[
MT>'>+.^S^PO#OWZZ(OF3MVL+WSI=U_G"]R-G/?%MRZJ]ISHV;_^XYX9KWAM]
MVZ:W^G:M?ZUOWXJ7!@XL?'[PL5E')C[Y=\5\3[#Q][T)#N9]65X_'2P,.?5"
M1=S;'U<5O?!-;>>3O]3/>.#[IN4[/V^_Z/I/NZ[:_&'WS1O>Z]EQWEN]=R]Z
M??3>V:\,[)_*>/V[\ON]P8:S]R4XG+T_R_.KIPK]/WB[-.JESRJ+GSI3W?&
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M2=E6=A%C]T];J-B/&N[=A>J8NK"]<OG.X4R@ND""!W<#X-$3%WC,;0V,HD;
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M:")AM3?3<!D*U=6Y'54WMQ]5 .=W)</EP^%P]8P7W+AN#W<>F (5@RX\XL
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M>CHEKM$P*6-5/*'HF?X"'1GS3#W9_ZE6+K$#6V;1HE]GV&S1J-_JVHCK"&_
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M5N('W(8;*$.A6CNVH2I?;D7EP/'M"7!F;S"</^8&E\X3X-H-8[CY0 ONTJO
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M!.S="D$G=@#YS-;EPC.H#VV'40,3)[:T?J;>6S7'>#9OCITJY1L7:_0,KUC
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MGT"HR"K 8QG\%*6!J+(.PK5E@6ZJ##1['0CS- 52L#T$TST@,,'G5V"N_\_
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MC#ZZO35ZY_[-^(W[;Z/7'F#PRA/T7GJ"[E+ "<M@)2L!SNO%P4M. OS5I"'
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M/B<_(9=3F93-:4G*Y/0G97 FD](X,TDIG!O):0GOV*D)<XQ4SC=:*F<^XK^
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MYM=B_L1_Y\<_("3D*2$^KPC%Y1L1L<,Q6. 8C('0]8!(:P&5H0;B3"60DE$
M-LY'288!:C(2H"-# V,9 M:8ZX*Y_I@3CB1*$<BB$\C]!Z"GJ0 :AAS01?2,
ME4';2@74N&J@XJ\&RM%(FBHHE2B#4I42*,]4!)4.!5!=( ^J_?*@-B ':NO8
MH+Z%#1J[94'C* LTS[- ZY8,:#]C@O8'Y!L#M('Q0QNDOR/?_@N@CV/0UN>
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MPN2VSUJ3FSXC)G_Z[C>YX7O6]*KO+=/+?B]-+OI_,?Z-!X9G>:!_)@#T3@>
M[J^ #4<./-![>2PFA"LR(%:#";$&LA!MI?@YW%G]3;"__E->I-D#_Q3+NWX%
MUK?\)UO?\*^UOL9KMOZ#-\?Z]X"%UI<#^FTN!JRVN1"XT>:WP%TVYP)/V)X)
MNF9[(NBI[;'@SU9'^&!Q* 3,#H: R8%0[-Q? $>L@0_FAZ)[QRO0(5F-#D)]
MQM<4<]DWB8Y*3Z*]M.^$AYI<#TFP^3TXR^%B<*G3;\%3G<[RZ[FG^:W<DR&=
MW.,A/=QC(<NY1T*'G ^'CC@?##WH?"#L@O/>L <NN\+?.^V(&+/?'@FVVZ+
M>FL46/X*N&(- M$YHZ4D02@G#EDJXI"C(_D^QT3Z::8M^TZJA\I50;#^A=@8
MF].10N?C$?EN1R(F>1R,J/+<']'HN3=BEN?NR'F>NR+[/'=$KO+:'K7!:VO4
M+J^1J%->FZ-N>F^(?NTQ'/O-=7T<<-<F@.-0 MC_"GBR9" 4?2^1COFRHE#
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M^YH$R#U"WHJ#W!<$Q'X@W]B(W#\!%1R#JJX\:.@J@(:^(JB8<D#17@D4?)1
M+H(#<BD*P"Z4!]D*-K#K94&NC07R73(@W\,$A64,4%C- ,5A:>!LE0+./BE0
M.DD'Y2O( \DQY=<2WY4_2XPJ@_@799#X_/_PKWQ-+7G0T50 '71N34,.:-@J
M@9HG+G.($J@(.*"<JPC*Y5BOZ7*@TLP&U3FRH+J !6I+9$!]%1/4US)!8PL#
M-'<CQZ3'M"Y)?].^)_55ZP7]D_8G^GOM,?H[;:"__7\ -1UYT%63!T-5^7_=
M11CJ*8*1E3+HNZJ ;I *Z,0I@W:F$FA/4 3M*AQG(_[[[7)C>O/8/_1Z9;_K
M+Y?]9C#(&C78R/IJN$/FB]%AF<]&YYD?C&\QWQH_8[PR_LAX83S&>&X,C&?(
M$Y-_ MH:F*TD!^:*;+#$IS76PMI,"2RYJF#FIP8F44BJZ@_C0N5O)A5*7TWK
M.)_-6A4_FLU5^&"^4.&]>;_\.XL!^;>6Z^7>6&Z5>VUU@/W*^BS[N?4-]A/K
MI[(/K3^R[]N,L>]: _NV#<C>_"^ OK(<6"K(@KT\"[B*+'#58(.KL2)P[53
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M'_UW.[)ANC194Z=+EM7:B"VJ<6=U3?-7G5418C"S+-*J;D(\=UIQDE=Y07I
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MA[U+./9[-RO:[3DE;[O[D;SUSL^*5CN 8[G][QSNP'<!UW\SY@^MQ3[8@'V
M'MRXC9 *S"[<0X@0?30*?3CPE#CQ.\,AWF?TJ.YGS,6<SSC0'<YX,&S/!,C8
MG(F4L3J;C.0S+<]5,"S.-4N;GULD;?;;>BG3WX[33<X]E#0Z_5'*\"0P#$X
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M9JKW!K2K+PKH5E\8T*^Q(&!(HSM@N^8\W@G-3MXMS3D!;S0Z GZHSPX M?8
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MI\=F6E?'%-I4Q4RRG1HSS:XBIL%N2LQL^_*8'H=),:L=)L1L<RR-.>U8'//
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MFB?L YOWV@8TG['Q;[YEY=_TI:5?XP-+WY6LI6_#OW@#8_\:8G"^ _W0BWZ
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M,;%/(M@G-B_].9ACT-I'();G?\5$^'L1^^'[;G!/@F\=9'#;D^>QX.-QX L
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M$;R']C!:[>-C8/Y>>BF_U^X6R=LED@A"@2=P!.:[20EWVP$70%JTFW1H-RG
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MKO")2Y2DWB.KWJNKGM&:P/GQ%0G3BHPIE-\>"W%+VFHJG 'X4-V5D097 <-
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M4!Q;;"B,K38KB&LRRXOK-L^-&S+/CE]JGA4_:I$1?\ B+?Z\16K\_1;)\:^
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M[/'%/U/QE_6PE5@,.XG9L(<8A@-$-QPIVN%$4889](;IT,,$VC"-/(\OS*/
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M4V5ZK*?$QP1(3$R8$AT;JXF,3=9&Q&9KP^)*=*%QM;J0^'9M4/QL;6#\$FU
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MB4%O2JB3+OA9H!:.X..)\ID;2L(@?Q3<,!YE)PMN*9D'^Y@+^Y@#.69#CEE
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MB:CS21C R-Q;PYP3PKQ$/P^?N8#@]"ILXP_XZFTX^!T8_!THX,Y:$7,@8D!
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MI*FWBC3T#I.ZWEW\_!$98R?J/0^\JR.%ZU#&(0]#*-P7V#8G$+8 .1)A+Y&
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MCLZ=6:4"NTB#XZ3!H3NAX3I!V-0<5 H,.J*/2 9\[+ 7<B.:3O@L7)D"OJ4
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M]>E'9AQN LUJVKQZ3"T>,K *FD=Q<0$1"<7>-G/BJ+RW+Y<Z>^76J6;T:"1
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M])1-5O&"@O_=_4I,U3/)8.#G8@'HT3M56$-HRC7?_#-TR <H+OQ/RD47IGZ
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M2UA$FA =BA;B0LEHG :-Q@*146A-=)A(SPL+,K'#@A((V A=!!H-BY)(*6@
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MFDHE?_CG@0^T/G\IK\[[]/OP?2;PT_W_LHSF>3<T/CY]_XU@X7H'X:VW>.N
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M%@[Z']; Q^>C?[R>X)\%]+=4K>T_:M;7/J;]PWR2:4]\Q$,\WJY^,H$6TC>
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M/3>>'C>=.ZF\4F\Z>5AYL-)T8F]U]V73A>U3*D7F(;W/G /,Z'5WM4YS2FO
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M@"S+<X#[E.2],X$'Y(;H?\!M\DP_ C )XNTL 0GH\3 0^"NJ.)<.] HRA_(
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M(@^VTH]BQWEH[0!:T*B]]J+ ]B%3#_]'\UMQ*/=J@P^EF7W72(3;LY;HYA]
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ME?<8BJA1.7F:]Y A>8Z2!2W>LDJVBZ+9,"*.I41Y4@0:2J!# -^!4C\3P6P
MZ\6;V@B\+[3532@N'F-?Q^,L*GNEO\8:S^[09##K=I<K_C ,,:W2,7K'ACQ1
M+^VY9PK_#PURB.!MH;G./,<8)6\1U;3-DOZ@9C3-DIBC(^N6B1S+ENDS!4%9
M?]2/>,JD:PHLUR5FM32,?6S#+)$W2^'IQL]A_G/8PZUAY,_RIU\BTX6"UEZM
M)21H;%7Q4733B,*IM$KW7=J<E:.&B[E)B0HKH2YZ7'*6?W7]H+"/E^3QFW>;
MF^50Q!EA)<ZBT,W)QP3]K;7U@921QAQC,/*(Z: NHF10IU''9PZK'11#B>/R
M!MG>Z$1)OL1]?9YPJRC9XPPO6U#E4,EQYIC/.D=+(W_FOVP-;\.1;S6Z-"]"
MW#2YU/<7O](E&=,SS57CNM1$-_EV-2OJ@F2&XO?ZZ8+'LG$//O>#.-JAA"W@
MDBSF4"<H2_A36^?U?@1_-WSH<D/,-KYLRR[VU\UO,NW/5>'J@Q-DLC_&.5'[
MQ)TZC\ 6 4NE\LC@\J1&AWSV4BY@L9$:3PGC.;2\&&X&US<<'RR&YQ@/]6X\
MJ-3>[W3-N*^*;DU+<)>--)[=_$]<9CH26""(T79Z!' WRQD.6:Q1+MHB#WI/
M26<+!M_#=A%G],Z!6]=F=>3!3Q>J6Q8CP+WW&\R1&?&.1BO4UHAQ;1(Z.."Z
M\C5FG:NYW X;/?^:]"6..N,_WE:\EC4Y\!!K3]C9LQ ;77.XG82%%YHW1V-;
M]^ZI7X^SV&DT;,9A(PHT-&!*@%"Y"%"XO)2MQF?._R69).#-$KEN1"?FC_Z?
MI$=X>G<PB5PSIZV3Y'N@J@E+O)=^K0Y!'-FY5D\E#D98JB\0SP:D*/:1IKN<
MEV:3D N<Q*= -S,3QX54PO3K#Z0C@9-=6%I3=7KK=^K]@ON-X]3%Z7M,XQ!E
MQ[CN-F09WJ-VHS0%+)9W4JI<!B1-%,F"(-%3"LKL/3L2G,ZH[=/R? ";SJ><
MQU6-K1EL54%XHQMK7]IIDRLS<<=.73#C0/@>%9DN67-7/H?VUT4O_D1[LB!7
M^(5:9[Z#E01&TJ_T>4@NXPYTEHBM*_^U/!!NS9<WZ/B4M U&.6_V]BO:)DY?
MV'?E1S9YC>;_1JYTX8C#6$$+),)I=+7Y(#,;9-*7]8ZJJ[$3G=.5:RM+6JIE
MG_+G-/A(6E('C"M$(]N+M3["J6'UR@I^U9HBZ7->N M.9.0N6G!,L(:Y8Z8=
M@P].THIZBTS.V,4=C?J*BLF6!9K#>=7U)U134P,,??+ZN%^:(2DE;)?BEUB[
M9K6T1.3M4B1RX'<M>,K'L"9GYM$?@?^H?;VNS4\PF1W[&QY4V#2/F2[GGJX_
MJ._?HS4D:7[%X35)*GSH1P5;L<O_@^2[](_+3J%49+?@%^\NVV]F/7T'V1OZ
MW/.DZQ.ZJ<.I'2PO:D:WV.4&UCLUZ/<L-4PQL>/FJW_JCX8J%?Y:,_]^B5BY
MQB50N$KB8#>'E\H.F7F7=IF< &WHJ3^4BY[3_K@ON^Q1<V07*F>D[F[;8$JO
M?K@Y9=N0NJO^;^@>^5/#-7^Z)$9]W&6%X+*TS&X1]RT[:I8%K9)<3@HX6@8/
M@B<<_@1_7)S=/X2@9>[M>H_T3"IH2T%^V5+9> =U)_B'J1E]VN>-[@;FE/,W
M=2OV_MP7RC$@;CJ=/XY_3VP>R\(:83>&?F-/'_S2=Q7[<?_WKKFXA4G6K6A<
M\1;7QNFX>\'#QG- L<^$]CU^H?-750/^DXVK@DQX,OT#3T;<0IQWI!2T@T4/
M+2 -'JSN_4[*VB_IW$BR3!QN:2&^C;G?L)[X/A@R3B79^=1K%Y.*G+\H1T +
MFW1Y,>@W8QN70WQ&8(XRZ/MJAP\%T61%WWI=J#?VAW144AT2JYJ?0HP8;7T%
MM#0XQ1!*N>9#UZ113CA_5KR'W&UHLDK*VADRCHGD1+ >><@=K T9I'/ (GA/
M%3L^XU3[",LIT:;9G[DR)J%N@+$K>(D>I)M\BM5R>J3S+X4C/<'FE/0@=>&,
MO^Q.4A9>.9(E_E-S='":**'P1_<C07U&;+L+[U^"IHG'U49_K;/E5 3=U=UD
M5_EL5SUF75PV2[Z5Y3YOH22;=LZLBC5$:L<O&'Z@6E6S?0!2S"MD=N=+O^Z[
MV:81WT[8U&0N<HAN-!$$S*!Z710_W&>-*H9W8-E\F9 CF)<JQC)BS*XQ7Y$^
M >!PE6%_]>F!1=HGA0N[/JL+]A6TN2@>[;K9",G&HM.-?R4/@RJTA\7Q/@[*
M7N'U94ND'WG'YW%%/8P'YE[,]> JW-=AQT9#=6C_8-VS YPNAG')WI>MG;J(
M766-<]5GH\V,)*4Q:+UVH_RD]Q^ECW3*,E=IFN#DO".BZ<PIYE4,+;@7EW_X
M:$=,U:'^W-:E!Q9VK6G\NA?=&E]W9I=-0Y-Q;M20<;&N+LA,<T'=[OU,,2AO
M6.8MN2E"SWLN+&<ZFK<P7$ 2]O[ADO[4JMA^^VY:04_GJ_:'>U>T_&NIB3_>
ML*>Q.@IO.%%GON&.YO_VX7U%L4]Y:MD:295HW-9<\)VYVOPV?0PTP/M/1R'.
MEVP9;T&:9;TXXH5,2S8>FD3>W4;LE:!4884=%#00<+UY E/AWEM?@ZUQ-!@>
MX,2625I7_(QI8<)EA UPZF0H[DW)HN.M.$/6R*@?#I>,'[R(XVS+Z='C[H;%
MM0N!A(#QIG/ :_>^NB)\F^-Q?1>AQ=+X?_:&36OAOR:<AX><V@#^5WSL6 <8
MG%4U$DRJ2TX?>$S:OFU;]P#)-VQ#6P-I?<!@XT-2K?N@J8;TWO&1S@A.6KY1
M:<$-TZUXMX@VL$<G0^GOBJN/=M!N9JT=#J4^3P[M_T[UVK:QZSQD"O-O'8)B
M _H;?D#+W$>,/&BSXV]M+]1FY:T4D/^;GLU]2=P*$TY4<U\7NX_=XU1DOCM<
MR+9/GM;ORORXS;+S)],RS*;E 2,QH+YA"?VJ^W%#![UOL:MFB)YLA5<@(.'T
MLYP/1#ZL^,19\>#!-V.!PNN9AJ%#@H6[F_M*>?2M8YT;N3M";[<X<:(#F/6)
M;++[:?UU]OK%:>HQ9I_5$_E>FLV,6/9WXE.8U8E()>:@X4B=W"\S9\A%.FMW
M=N\YL>-6?(=42 UM;:X2K VHK=/S-[A?T"_F[5Y,5KUBCU@'R0IHZAE=[)4D
MG]JV\:/ZS0>3CRS3R#.7'!*K'';;]ZZ77]RZN?VO]$,HJ>F*)#T@U_1/[.I^
M2U<J7+FX2^7*%5F3I1S:13-+5AFIJ#9K?$N#S<&9HVJ3W_X+ARSUQ4EG>@R:
MJUO-VPM5G:'[FD(5+P-23+FRI^ZOM1/BP<6/E:7\6.LSD@OTJ6:IS*LD5>W<
MXY?:G(N&1[V:GN]G#(KJKR31>UR,/V(OMCW7:T*#&T>TFP/BC/=4L]U_:H.E
M3YVL%9?XW^?.E/C3/<W$S%321,V1XP=[X$68D9,= _MW#ZYKW924TCW<Y!U;
MWP;4AX4Z-Z88Q@(BC=4:KH>YYJ1<[^2O2!',G1LH[J1O-3O)^(_T\N5A9$[-
M[6N[D$]K'Q\]B<J$76M?@#H+;U1$H#<B]% <NAG94?46LQ*EV6^'4:&1L43L
M+$RT_V[L5LP5NQO89=A-S\5P"N!^90LB"%AQY#KB >#8&H"$ 38R!LH,V$">
M1/$ 1*44O0(P['N!;@>.;Z%@O( 'JU68"N"U'0/C OQ^NA\VC;;VDA/L-M5_
M9!*NA4*;<Q!1E#S).\0;\ABX'RD@KZU(0VT =7NOHJZ"5C$&]#X2WN\GNH%D
M81>#WD+L>IQ4,\B_<<&EMI'[[?!;&('CU]@ 7\MBB;/@_S'=B'\1W?1KY9[(
M(AH[_1K*AIH0?1.EA5S\"E&?**OM+%!D\L*'>ZLO*UGGMM4<E3T<6EVKENQL
MF W;*WPB? 'WX!\B=,&_<>O*+!$#[/JTM\@BYN%H-^1?^GO?SZ@=-*K=%.0D
ME'F_H]J_;N.9QAHG_>E!=<TW34T=M_:0<HN !V/*,O D>):843H;X2FXFN:$
M>,@+B6(BD>P+OFKD*,O,SA7I2,/>\ZZ2=%B<WE!-:;XX$%F35]]EBJU=93C,
M/P";IK4&,+#;2D2)%[Q99IYZ '%0="AJ%G(&O]-W-W(SEVT7A0 9.^X,5ZT:
M?'+J6K5]S]N^M]7_=5@;S6L&FO?P(FNY=6]P*-A!O:0X"1ZL+MDS!O\AK]@L
M0O#$D[YVB O")7;[$3.8-VYG57X^=N(DO.K*B$>OL+IN0*,?J<GM#N(NK%W?
MM@1;!;-LM#^(@UTU!NYQ@S,T],T!B"6*+3[W$-F2[7:U<!G;]99'Y8FS)R<B
MJS03S)X#U0?'LG7:&N>A1,Z\FG>]$(91.])^H6@<!C2M2S' O8V7(Q_#!S2?
M?3H1TV7_V4'P<#;[YK)*R8WI)Z*J*B]Z=-=4!TVF:P>JGQ_3LS?5= V[HB_6
MXOH&BOQ@&SK24H)@]YJ"(G7P N-"'Q:\3VEK)X+]9$OO_ 4N5S=-W@>4-1<&
M:$!M[4/3/>  [*K !LB"/\8O ?8BIY;4 Q4H\]1Z@(?ZN?DUT(Z^YT,'1C$D
MVSO 5:S5K7Z<'S;W9 _.'<OJ(^)<L /&F;A5V*>\8MPFG#^N!9>$8Q7GX;"X
MNWMXN$[ =;,%[@Y0Y/T>]PX0V@[B'@,W;AS%#%*^GQC"7*)L[%%@WI$9^B2L
M%?B.\QR['D1B]V#S0+N#(5@=J2M%B'U"2HP,Q3D2OWGGX_R(S;9RG"4Q[]HO
M=#=WX_@T]!UV5]=G]#]6D/88QI%QDXW!)-";,/88'HU=Y(ZY2P62V["K('0$
M'5M$H:UZA<633]GBL+M _=49J-,R\;%-:'-)3&<*.E!DH=F(3N*_9"U""WE3
M4??0#SB^A4Z80%;E[BL8!N-4^#/,&7K$*@KF+FVQ+1W#HTQ</H RUU\9JT,E
M:TZWGT8)E5=5$Z@!V3_&"=0_22ZR!YT@O'-@&;J57[W;"F/.]0A/Q<2PYZX*
MQFQEBFQ[T5>I)RZ^0%);5A_9B#S=4-16BS(S]BM!U&J=&UV'PJ@N(CI1E^3\
M@ACT6@DB*0O-$]+"[J O\NY[?4>?Y"ZVO8U>1T=?(".]>Q4C3Y#[.Y>WKD)R
M6@XKXI$C#4@:%65EK(0?0N5JL?D(U+BR-_$(>H5L65@9.E/TPFL8O4N0:_L3
MU<)X?SX,\7C4:EB"M!C\W?P(&=#S1[X8F=?A1*U$=C:7P(ZCIM6=RVM#9>K3
M$CU1?>JE8;-1[^2I7A#J@7C'?#M4$//YN3D(TTGMX1+$\:/_FL81+X=+9?.0
MB_N_0'AD?I>F]CVRLW5/WA34K(8U"0VH-$-\:!^*J7[HE88B2 ?GKT+>8GX]
M\QU1>:ERJ!)!/Q/8> _1<L)*&HRX=V0*91CI=FAZ[69D6<^<W!KDD3;_A'"4
M98,IM JU46_P6H<*D#?-WX1DLZ9="*&,5K%'0\CWJR^T?B4[UOQ4QH($V!0Z
M@?0-[HQ0D6H0.PL6DQR0!4E3B)=196'N1"FZR%-,K,&XS?U%A&.GG;,D;T1?
M&?8 *1B/EIFDQQB8'")E8(:H'XFOL"OAH40<5I7WAK@.-S=Q.G$*#AV:0SB/
M>^RYF- (^-M,)U"!WC/;2>_ +T,%I 2PLBF1>(+T4?J9F$*"01#A&\D#-I6@
M)G[(O4TH( XE.!/"B(Q-G01[8K9'Z_]_^LTV<_!]1(=).O$.Z^S@"#&>R6HX
M0;C$2)30")7T%90(PG*:6\TC_'5J1,X3? MT8%<BGDM1;%J KR _](C#QY#W
MVLP#_H#^)]L)G\5G!F81L,*)^@#"//XYL3V^C_L*_(ROX$14#^-7L]JS7^.M
MF 'Q#. ;_?1&(G"=1G'_ >BIC39^0!!EW<0BPDY-6U\E_IGR@ZD!3Y1'"9OP
M;I)N4A/P1)15I0 :!.Y9/P ZSV+G6:"&8QGR#]C%VNS>#\QDKK3)QE53%X[S
M\'<;1+U3\:4F+^,N_ S=>4$)T*!F$EE H8)1J07\I<8L=V"AZ/%.+V":8$<(
M"W>3-\,=AP,X9!L&=I+6>=P-3^MD=;?B+5O)!EM T0CQ-P,A)BD!C_NM>U/1
MC1M7[\W,QC7)O^S@XD22B9"5N$+A7_=8W P^R:8=&\R8>_0!/O:0IJL2&.NS
MTST!MG32>*ZX1RV_\6B<NJ&M_!PNVXC:K\=%::NV_\9Y*QN##V-_R?+=YV/Y
M(B^;<Y@Q1L;8";SML1>=N0 X<EW[$)@^.,Q=C9/TB $E;F=[0[D%SJKI4L9?
M[.LZM^T8[$7=\> \K%*E<WN"]9?LMWF.R6"4'KD+/#Z+Z*  "1,7M#:XTT>=
M.46X],/9N.<XJ[X+90>Q)SN3,Y!80\NT[0NQE/JIP4NP\;J9;J.81[*5-K\P
M5@ST,0[K1^5 -Y))JIYM\&)XU\3P"?2IM9F$(]2O,%K%4^@[?"0S&UJ"N+DC
ME+(/^3@XF=R/>N(J(.]''[;:#3[!6HW1F#P4V,EG;$?]UN71[=&%W(?47^AQ
M?!QU*B:J7 W98:[LCZ-LQ>[9GD$68:\$M8-?<0FNP: 0-VX%DGX"HM$3C.VD
MU>UWZ,[$.YH)V@PBE5-,-2.NP?V%EA$MRI"4:,+GC$0RE7 WC@_>)YP*<@1C
M"&,NKTBW"5>LVDA>A$LC#O1MC/ZV!)H7O56=05U,,[%=( ^J 7N#D@A=*X61
M(<AY7PUXG5*\[1X81![;(";5D5>[&$F!X NK*\0:TN1A- T0[FPY1BWFLY7/
MH7SN->9Y"HSCA:DC-[ &2PK!Y\SLO3PPE&&[S8MDHEW;8$^RH8Z[Y!/9U+76
MTPFMY+9#WZBOE1/-X=!C>;JB@O)(\I,!)[\7M: KR2L%BN(T,(]G3&\GC7!&
MMZ))*UD_UFN)9&:5BQ_A%:/%.@1_%ZH>I%'AIJV-3Z$*_7KY*DJY9C5]!QFI
MW(3*!]MDT,%RTB?QF[0WI!W"\M@GQ$[^DO5!1$NNJ\L4PE[V2>N#>&_JMX%
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MS;:<"UU-2@)[8=MCUB-F0;,3X$V?J-]=44++-XQG&ZCVVMV)B91'JNF1!/*
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M,^CRX*F;CJCM$)S5W@HGY-'EC=(QU"^;6Y)+F+3I< X,2*5,ZYF*6(^*;^]
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MJLD(T(\UI25,:!;6Y\3D*BA&4C!2ZJX]Y3M?^%;IL-R:=T><9EO$"6!6F[=
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M9A=,4&DSJ(1G5A'K3B)F55\27$)TUGKAAY!I,'II!&H6_%S:-E0OXE\4"YV
M6N0[#7T(]7C^ O1U=-(=?;4,63\96M."6M/?7]N(ZC'^@!'0[GQ_>"*Z&TA
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M WG$:P<N$"6S2<&!Z(@+=-1*A./H'A0&<:'U/>H*$J,,0GN@'.D'T7C4. )
MWT"C"N9@(C KDV9CVC!'P[9AYV*3/<]@MV'[;=*Q$,[E7 8"0Y -[T!\)Q2T
MS$-6$@+E/.03@B7U"VH/_C<\&#6)_Y'W'WHK_DOB,O0D_E.H +,>_]8S%5.!
MOVV3@:G'3YQ)@Z^F3PQ5P$_1QILR$"G4B[+9B,O01TB.3(5\89;(>Q1X[D=4
M.?E40ASJ-WGEI@_H:A#R^(AN!F?89*(?DA9-$F K!;\'VV'G^>L;!N'%7+*$
M ?_ ?D?9C""RX#4/D?9,ZYS_D#WTOEU85!RM?%,J:IP:[B%'?8'2;5!H9_*V
MDU=J4U3+!^;!+.6R^M6P+JF7V!D>*GH(_H;?$ Q5CR%J>8:<J4A'CBE^&-G/
M.KKQ/&H-T\(C"95(OVS3@"J XB=VU?361?49:PL-YJ;;,"O- ^$3F%;Y@'0?
M'BF?6742_DRR*=L/(1"*X^V1Z_AV&].0'9Q+'@N1Q]G)-N>1$S2+\=<U:]NK
M>G?6W&]F&,6UA/I!01_,WCB;>!XVHB54WH3GJV9E'4#8R09WHA&'Q/*0M\BU
M@@ON]Y 1/)[-1V0XG7#<6'UVH+MG9DU%SWI#:JU5^UD^J];8C"&,P;;]CZN[
M"HNR<?X&CF#0F* @**T@*BBM@ *"=(IT*1W;7??NWMO=P;)!=R-V=SWJ8W<W
M]F/K__>>OB=S^#V:N:[YG,QTI4->H]ZUK2UM0[?J-Z0^PVS6DB-9F#VJ-;[=
MF!.RQGEVF/-<UE$<''G$?O0Y8O[^F:9XQ,#4'#$/&3OF0KF!?#&8#'%#<7N8
M)3_0H>UO4JO0-PWBR'68]!:]+QY3HK@PSQL#X2J/8. KSXI&OL&/'?]LK$84
M'ZH0[4-\WG.'XH)43=0THU%A0[]*H*C'O9,I?]&TCD,1[]#?#(F^>1@KU>2\
M4(PWM_V$/_5YHVC2B5K:7-@Q!KR!SI1=!M0P%.TRD U_ QL%%B!KRCY1/J'.
MI2DH+S"ND5#*$VR>3Q/E$VZ3W6Y@'G[;L6A@ >K$>"!E#[JE[1X%ABF7>E#B
ML/;4=,I2["5H!?DKSECZ+_D]OC:UC_R#L#+B,&4FX8Z/+<6.F&_WB.)*6G8D
MGDPDGQI-)N>2#YB<R4'D";&,[$P>I+PG6Y*/0M:2OI.?E_Q#GD-Q2+E.]J!$
M1'B1PR@5WN/D2 K2?A8YGB(_E$>*8DF'1:2US&L&'LF;N4040')E%)%'2*[@
ML69GDAL87?R4%$D_FK*$5$[/#%>1B+07WE7_JTI[+Q*#>O  CY@LKAM\3-PB
M_*:?08P3, 7'B5OXBTD08A;W6I,%L8S37?2=R&)SDXN)DRQR^#SB52;?>SGQ
M)..Y?3KQ*/W"_OD$C,9SH(S 5'[7T0D2^75^+4$E/40,(_2);S5\(!P6618M
M(+P79"3U$+UX8V%28@PWUNLQT8U38D\ESF",[]7B;YN>]_W!OS!8M43@/^M"
M>!'X/QH$825AL?))PTS">GE]82JA3KHHR8[0)GH6YDLX(/CI-43@\*?L!PF%
MK)P]4?B2OJG>47Q5=[#6'-_<OI_KC,<:<_#>>$7K\GIW_(36O$"(GU;9;\40
M_.2IH0<)FR6OO/ $"]& _17\!?;D;G/<]W%I#Q;W9YBOOHRWZ&>Q?^.MNYDX
M+[Q7^V1=-#[&\"/_,AZKJTM\@A_7.(5NQY]11GLEX!G2)/N/^&T<EUW_XB;W
M<[K+<(.[9ZO.XWK'"6Q+W,#02VP\[E@?H1:/N]OEF;\:O]#T-7$G/E6_,-0,
M7ZZM\'+&N\A1#K:X+YR R6,XSHGA+A@.>KA3^1U7OD_,VH0KWU6/$>.0HQ4U
M=W'<@;KMO;C#W<:$O[CO[?XAN_$VK>.>7W#'E.L<W'&=G,C=O]C7&Y[UGF>=
M:1K6YC$O0XJY",9/Z&U\$R,,7E2?#%(0#PIP]!>HK5LMZ'7HUI #]%F8!QXD
MVC/L+9L,6CT>F/)@K43J>ZR9J2B%>HA!1*/8T^ 1S'K</- %:UVWA$[$OLG'
MT'[@CB:&T+AX<4@ ;34AUR.*9DYX9Z.EDDG.D[F,$9)?5PKXDY2KF@LFD[#_
MLW0W282Y2'<B':V=01.09VWGT=S(6Q((U -D9G ?M99\QF,F=3UECLT=8)!2
M/<X&<0Q]1S_]/L-9H:8G@$)F$&V4_A/=25M#YU?_H8[2 _,FJ%FTZUNN4,UI
MM. P8!<MVOTR@*-YV#I2OE(;1^_2><)%[<ZTO_PG<B\:E#<(/J(^Y<)1.&H]
M9V?5=^ [NW[;+:"-A=FR$BABRM<?!>8Q+KOK*4<8S;;IE"!ZX4@S[;QRIZF3
MEB[G2?=1STE'Z6KJ9O%-9 YP4;1FYS>@4J#9-A.8SW>,IU+.<?O69U)P')1[
M V4N^Z$MDUS#\!Z>20O4[S/F4'?KHB4T:H3F*(T(C*JV(K8!<?*_.Y=0[DG/
MY291).*QN ^45.&1==/D_P3+W#>1D;S_;"=)^YB#@T/4_=WNA@74S1WVXNW
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M+'T*==7M2PN!56N61-Z%-RLN^3Z&GY-BYKDA_N6N/%90'7+PPQA0\W'/)]-
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MW=J!$D?ZT^='D0%\G36E%, +]E)6 144;_(O( JZG7P%"*QH(/<#:[-NDHW
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M;MWR#\N:?"-L"S.,LFC%2P:7LL.IDI% >3A[C#X#6"9=*=" /YG6?'OP%&Z
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MZ$#R($!2K0=W+9!:L([S!BA,$W#J@(K(/>RG0*OO0C8-$#K'L9.!NY9<8 W
M$";QWPL":)_X[OP'Z$Y>*9_<3N3J>$]K,CCW>1VK/W!"N)]3W[&'N)S(5>P
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MNPQ;&.@Y3MVOF#3+G_)?0)*)B>#I/Z%K8Q+S;^&AZ;O,]]GS)P'FU^2F\:6
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MEM=];CU_0<&&&=&WCLR>4>K>+F\=#KX:_)^FLO$H](0JK:@73E.DISY$FLI
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M+&N1+[YEX691/7%38+MH*7FG^WK0C_*O#0WL9.4KWPIF=&P1& 2%B!3*OP(
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MT# A6/4]!^)+T3V/@6.YB[NMA06IG99ZX:Y8N'F9:&%XD/&3:'=@B $#%LY
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M_ZOM;^YFX)'D)G*%X!Y[!?H:4$1HQEX#5K:/X8W Z[IH8K0PLKB>M%](23M
MB1:N6\"A8H1/ MIHGB(?CS0&6P2Q0W%^BVZ)M?!WLFJ6&)4M"\6W8N#2C^TN
MN#3I:"T#_T/:7K2?."3U2RLB^TD>+HBDM$K6!N13[21F#SA]N:3)[A '*5:
M2!B@/<H4(5YKW7  .DA3"2W#>JJ!FJNX%ZJM12F$Q<H/J2]($<K$J/=DLJ(G
M()KBJ5C@(:.]E_VP=V$_E7P583H:+/Z,Q? KG4[8/2@?T^VV48RW45E3BOW/
MD%5X$7],;Y/:2VS67HO:1UJL.1O@1\[63/%80JM1EMN7L9G2;F%W.W3 1'\*
M>]DWCIV.3.VM:O-%YW1+J^]B8RU'"[GX29VNJ0V$U29*E)GXR>@0X$XRZ7$>
MNZA7U>GV('N6=#?P!FI:9D,OA84LOHSI1,B'>R";4%V#Y=4@QM3O61B+H_6\
M3PTBS.@:BR(389;9 78D*]-LC]-4HN:,_5K65>EU\#G/OP[!7,N3-KG@6GBW
M6F5M;_G3H7MJ8OEXV+7"8OYIY),4HB %LS%BAV [/M'W/1!);)M2*\PD.UC/
M%.F8<T2.K+.0>0QWMK;=!_.%$P=[ 1G@[$<*JQVXI1C'@E+N79PB>2N/2+@3
M4<+[3OKM>Y^/I)R;TBO80$NT'A#BV;N &OHNQ#6:A'$&/1O=R3R(+6FEL&3X
M\BHG=@&Q()_-L2$G)4_G[**ZA7_B-M(.^U[@'F-$3[G"+V%";5P  L^6_X;J
M0&BA+J+5DCQ0:KJ0O+%%P:!3YU9F,EMI77G76*GTOTDC[.G,RO"U[!LLJ>\1
M3C%;Y>K(F\H!;4@"K<"1UTLZ33]&F4G)9+Q&LJDFYL_F'MI&ULL*.GTW^TI>
M%&,[9T]2$',U5Q?>P>+RRGVWLE[Q_G5-Y7SG7["YQC\(_,<M)HSQGI%>D61\
M(0))_B5P:%I+31'0%ZVE004/<M5T*E"2N)I!!S:$>S,+A2Z^2YGKA 17,ONW
MR-8VF>\DNL!QQR=(K(@W"=\ESG .R22Q;[Q/_B!^7SY.C1#?SOF/5B,^E9A!
M;Q?OG7^3D23>[6MA=(NONPZRP\1';8T\@AC*^HN]H/8AC.%7J9;!UA#K57Z-
M4:0S2F4Y=N*V^6^.G-JH("2\H%'D[^<OH9?(M;XR^H@<XWJ(195%V-[BCDD&
M6+,Q.TTAA)FX7F-5Q[^$"@.B89!X3M]0]HD<HZO.":5(M T)2ZA+-83Y5!I7
MO<:703NI=G.]R[RNJ+*;SF5+CC,;T(=Z\_$$[*;N7QWM>'K78$, X;ME1IF)
M1#0OS[Y'OFA*3T!3OAG>S"^AGM5?]472W'1!KI^9]2H?NV+N+,D+QF;4LQ$T
M[A[FS9"B?0QW<&"X_A"AL&^T+)MXMN=8]A)R6M>_"<D4C*5@?C@US;S>MYG*
M-_2[V3$^J)5V-,X5J0W;&KQ7UTQ8#JYJF@4+ KFMBQN(8#WT9!D>+(/=R4X$
MJY"/XIU -F9YZ!?P,-[?9Y\XC9@XR2CN)\NL',0;65E,.J!J/8LO /9 ;[2_
M 9[#MM47"IV0):4H82SZ6A9$B,#5Q1&%HX0UH<N%/TAG?(Z(VBC=D^Z"]K35
M5F)0S1FD?^8-(KRPS_D^*!ET,U^).5N7SG^ NU$B%R00;F<N%QA(-V)?"MY3
M=H9"@4H:Q><?8"U]S&6.< GSA-5[D8*WA:;B!.,C,/LX1XE^;;NY=:3GM1W<
M6Q1B\6E>+?5#YF3>!3HI5LA?Q+@4&L;_AS7=YYQ@#CO2I05 <>Y;+Q(N$RBH
MY<Q?M!ST,M9>^EK(83:%\;9&PYG!_%8\C;.-]3.#RRUDC\=Z<1]P7H=\XB&X
M)WTN\;;Q="Y]@B+!%.LMP$5A*26-,9OKB1IFVG._MUYF/N+MKC[ &N47%:'9
M3?P;Z1\X5@)DS%;.<L'KD/W<2(#H<YE+!/YUN<8O$WZS\02FBKZ2@VA,T7/D
M6KH83&FU9O!!1O5D)@14%5YAA8 CZ6S6 W!/3"O; -X,T7-FBVU]KG(JQ/63
M'7ET,=4&*Z"*.TAA5%?%%L056IQ"U5),SU<45=$92?+GA;5,+[DJW9/Y2!X;
MX\4:D+T.0;+GR0[Y7&97R6Y-7LC=(UUJLX4_)KY";"2_U.,1TZES=&^:5]'2
M=:65'^F)6G[!&T:(9FO:<::]^M^%=Y@GU<4AV:QJU6F?LRR2:M[D&JZ/W&+S
MGD\7_R)82-^[YL,IE!1+?K,?M;TSO5)&@YAM"KKIK<:K:3+&(L..A>N87OIU
M(4',8=T#GQ/,+9I/DXF<;N5"VSE\3\EL_&/2PH'GL*=DH)_7M)FRMO='921U
M74]M025M5]?1M$KZ'DOQ0AE#9GX;,HGI;&KV.<R<J0^?+.6$JUBVA;Q_)(G$
M$.6).BF\4SFOR;_IEL+4JJMX*/\#79O?)U?#]J;ZRN<C#RP8DOW%<(/FRJ?A
MWGHQY/V$ST[39(.4,"LKB37[.?Z6;* 5@)%EE5"@\:K,#E:[Z*5T!^)]WD$I
M%0VDX*7)./L%@=(@0FO@5VDR"?#JD0Y3<IPP4GMZMI65>!EW#TXLO@E'="2)
M+R!O-!P1[\4$+[(6]^!2<G^)N832Y'-B.*DA:I<82<D-/"66T9R\MHDOT15.
MV\7#K+H)H9S?@%TH8N,"VH-%2H)?_1V1A?BM/$[41^[,+1>-4,.3LT6CM"-1
MS:)CC.3 9:)/S$ZO\V TZX#3OV '%VI5#HH%WS&S@ ;*,V@XH*1!Z_X V^F[
MRUC 7<:CG(W .,LNZ9AP-CLDRD%8SED8" KEW/E>+X1;>>[.*:)L08'5!M%:
MH65BGQ2R"6WE_.L<3%VL()A;5'I.@.3^R0D0#/&V)=4+SO&QD0< %X%G8#N0
M+SCH-0Y  ;JS4)@C?&GM*AP#O5'QW.? <PB'URB$ULIX1X1'2Y/X,T4.V:OX
M"%%IXG?^"E%/),#_('H26""(!#.GNPM2P'/.NP&,>)YUAS +_("LX"AD]:V[
MN6XR:,USKE964[*+^T4V+SN3MTAFE[B*MT3Z,K*0]U5Z(S"2'RL=FSZ;GRCS
M=AX3K)7.M5X-;!7/0?2R(9K=K>[L'QIF32T'U'B6%'#>J)598]Q&U=]$%/>0
M2AXYD^>C\@GTXM4H'T\/Y%4I9TR:(G"0O;)^"J2("^&O64AS8(N [6:25M]A
M+S$>+W[)F6RXGC7"4>D_)2[DVNC]([YR.W0=@5;<;NWAZ7.YG>J121%\H:+#
MQE-P2XR!ES/[>M7-OUF5/?AJ-NME=VKQ$+O>\CX+P7[8N371@8,QFR)N<,Z:
M- $?.+\,SZ>'<GYHET_*XWLH/MFD"M1B"9QK>%.WO'F%_GW3E*J5NG>M#45(
M[7,H)>.ZYB],%.^N24!*YB>K=V%2_*#J?MP*CQKU:\)6^Y?*),KGB:JSN TP
ME/9C:V#3'FT8=$KE=4U'Q^W")>I!!#=CGNHQVB-.J4K&+IWW3'D&_\>O7#E*
M\O?0*Z^2OSGDR9<P;"::O,G[TY&DKH2M:]R@.HCTKGBO"D:C"NXI0:PF7:%X
MB5\79Z]H(YZ>UZ6P)A_W2Y7?IW9Y'):_HT<X],@2V*X3 D_ :/=0?,/.;MBA
M /%>%3,5CH0O!0%R#6EUVIA\*J4I5B5;07.:5RAKIO?ZA<G2F X>[V3)K%J'
M!Y*?W/L30AAP !HDNTW6US^0R:BNBUIEX31.OE!ZEGXHK4-*9-K%!DH]687S
MG"5WV32_V9(C',U4'\D&[K!CF/BF0&AE!;X3_ML&D=HQS]?/E5QAW2C?)>EE
M7\C[+JG@K$_])K'EJF.NB'?S,&%WQ3I^JI^7F"&8/#5/7"?XSY$.7A,^L0H'
MA: OA"GF\=_5D<3- FEYF#@&<,F3@'\!46HO>!SX&F, E4)*V#80)7SGYPY6
MB013L> ",,-QJ^@'^-Y*(+H*UK:N!N=*;&M/@=,DB67+13\DD#P?T24)(;5
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M_7?)&5$_>W]33H3N[PFEE?NCNA#T.S-J.R\RB6Z'3;_8R4ZMNC">ROJO\BU
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M3$B9\@NV(V2<O,NHE.DH;=?4X+\0ZQ/?-2SJ6=LB:2[HWEP]U;*K:WE1#NI
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MFR SVNH3(M%JK5LC#3%O6F,"QG%W5(_<;Q,Z5>-VLTES5*&F;^@'%68ZHQQ
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MD$+,)U63410Z543KHB]A;&(>8EUB/^%\YYGR/8$X0;$0"\+0/'B;Z)SXE=1
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MH:ZU@MO]G0!)Z-\['Y,@A+LVE3H++[;O2'(%G51[_8E@L[SRLRFP8/.]>[;
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M!OCY%&N!*;>+4D73<J92MV;\AQ=1K\:N17_1TH)A!*+]<K\/_TO'K1ZS9(S
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M@O"GW!L))=:(_> "$@&(@C3DO=EVK"<4YWVO6+[4Z2&GF1KJA,<@^)$&6(>
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MD2!>;]*),K=K6"T)A7N43O4KT[6R.96/]UN(7I76193P7VMCMP9S/BLF>^S
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M,]D84T-\=:R9/YYMTS_*\TSJZGK)Z=L[T+J.G1[QM3X']PFD5FJQM9M6E#Q
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M/3;H#@WESVK<Q?I1X*DS9<45!G(^,\>+LLDWF<&$ZD.YX /BA3UO0#;I?:
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MU<YYIE0)=;M %B7:T7T-#!!.;)].3L'U31G;&C"?6G/*,>25<5_T'[A)>S)
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M_QG]ZS9D#NINF:K7'U3CAD=KVA31VO&!.Z53E#:>WL)3TD0G2ZQ*V+ZD"L[
MUHO,35_ZCP++ZN.[!90CYJ9VC\*2JK]-%S(C==5UG/4YZM4FAS6;%>/T[8&
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M>5%^U]1)#M#&* Z*4V@_(+'P+_TR=0LQS#B>OQ&7,$^E?L<*64=B%&@\>U]
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M=-,Z^KJ4B.%%S%FQD0-"ECG4T/V0$[+R47LB][UGC7D3?ZMSIGXQ4&-C5,G
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MTI$.KMFKN$5UB.?(@^F,$&_I"/.H3X+$D>/D] >^@V>P',)R@>7X?L.2QG%
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MO[WE(I\6?L/$$)!6/=*O!"C>%IIQ(-MEG^*"$+3=(ETO$EC,PP^(&;4)@YY
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M_\?56356D3!;%'=F<(@K(9X0=T^($7?W''?MTZ>]CWO<L>#N@[OKX 1W=V>
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MA<GA,/B: %1#8LZB?BA-8M,?SU\JV=QSB')-ZM4UH_*]=%5[4;XWX-:B374
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M^$.PBMDN+Z;$L9OE6\K?<\.A*=G9?&>H,6&]< :T):1.]!OZX<F0G(%]'!X
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M/N=WHCE 0GH2JM89XC:A6\!CX9GH3WAX8 J6IJ=Y=F XLM"Y$MN-/A+IX+/
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MS]MC8*GO$\M'_4W/1--=--QEN7$DUN@81F&X,'_'S"G YJRDGLFZG2E'NH>
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MJ$HWS&IZ55<+E'.*&7%"9]XAUAOZ,&$69U[)+?%G05CZ:=EA\?:8"<JY\HC
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MX.SH4Y &.A22#@/P.W]/O0KQ]* A7+3,Z1F:@JF:8Y37P*[ZK6H'B%/AILF
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M[$@GZM#%%6:R03&QN(&,4I[,=2 'JAO2UA&'-0<3JH@6("0ZA:C6+0F=2'A
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M6^%/S%$8'&PT_85/"0PP[,77^#RA=$2HQV%23LQT,1#[B*N.5400^5<F:7?
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MGU%J.HR[' +F((/A&66P9KIB>Z6/UI5WKN8",(A^OL$(O"Z_QBS17<@?S0X
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M>=,EZMJE]-O25PU_*K;)64QEP1+%]^9'Z4=4RWC,N&T:7'@K[ *@EK("I*!
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M Z00O$E0#O78>IRW%LUON\]%P@@CSMV]BE5TE/U]&V>(=+O\.]X*77(VDH#
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MUNY29]%)K;.!0GQP;_*?G=POE+RW7R@C\;)*4GJR6U2R>_HIK'Y5A%BZ(!W
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M=CCG-#:ZY336'+'WA@3($ \98B!#DIH12-=]=S."W\^$N;_.@ >_2+6+6TE
MI"]$H!@S 83B"7?GJC&25\,(-J1E!!O?,H3/;.FD9C<WTK*;J]RS6LJ.&&3X
MZ;TAX2]#BIHAR-2S 5E&V#=9IFY;61:!+S-LHE=3$:F+\4ZYL^%X]J0OM7+,
MQ:-A"!_<.H!/:.LF9[8UNF:V5;EGMA5[9+05>AXM$'_K)Y#XER%.3AFDJ1F
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MW<WQ2SW'$F2WNL7E-;MGYC6Q2O(:/!KRZCV[\VK8_7F57OUY9:AB;G]>T5^
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M7$:0^B$$*1Q#D)2/B% X+%KD!\N6><":M8ZP81L5-N\S@6V'<;!+5!OV26J
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MW+< J;J]""F8V(!D3!Y8$C]Y8EW8I.1NOTGI8Q[OY<XXOE-0I;Q3TC5YJTK
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MMQ1!>EP19"84?LI^EI^3G9.?E0.Y&7F0^RP/\K\#*MLV@31ZF:2/[@+YXWM
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M;XY@^07SV0&L/CF ]5S \?<:3-7!UE0#'"RTP-%!%YR\#,$QQ P<Z/BSDNS
M+ML>;,L=P*;1 6P[, OMP6[$'NPG,=/VX+#!#ARVVX'C?EMP/&$[Z_0?VQ].
M#VV^.;^Q_N+RU?J3"UA]< ;K]\Y@^S? ";NFI8DZ.!AK@(NI)KC;Z8"'IR&X
M$<W E6H#S@D.X)3A"(XE3N!0CVEW L=>1W!:[/C+:=SQE_.4PZSS.H>?+EL=
M?KCLM?_N>LS^F]MENR]N]^T^N;^V?>_QQ?:MQR_;-^Y@]]H-'%[]!7#&:[ U
M5 -7 W7P--( 7VMM\',S -\ <_ BVX)'G".XI3J#:Z'++]<:EY^N+2X_7+M=
MOKL-.G]S7^+\U7VY\Q>/U4Z?/38[??+<Y?C1\XCC1Z\+#N^\[SJ\\7YE_]+G
ML_US[U^.S[S Z:D7N#SY"^"JH0Q.>JK@I:L*_G@M1"M-",;N'^1G!OXD6_!E
M.,]Z<]V^>^6Z?_6J</_LU>3^T:O#[8/W0K?W/L.N[WPF7-_Z3KN^\=W@\MIO
MQN45X9#S2\(YI^?^=YR>!+QT?.C_V?D^X9?K/0*XW_4#CSN$?P-NZDKX2*D
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MH[:%'*0=##E NQ"RE_XP=!?]/6F&-AN^@P816^A WAS];\ 'KR%"41;B5:6
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M/G$[$):R!'$94Y"1-01%.3U0E=<!;04-T%=0!1,%1;#"F8[RDN I+P:!<L)
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MIG;B<XCS.W!^#<[/OX!0\N_\VSC_ 4(!3Q'R_(#XG'\A 3M PI: 1$U 4-P
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M6O_QOJMUR?N5[GFOKP9GO,#HM"<8G_0$$XSIGX"EB@(X*\J"CY(,$#6E(<Q
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M&&T.7F^\*7BG\8:0X\;K0VZ8K EY8;8JY*O%RF"PG,*L" &K/P$W[/Z!PB)
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MU\%A[/\D^C<U8^9: M")+&G%/7^;#%2WZ\#"=DM:<9LC=UZKNW3.4A_ES)9
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M3B>?TB%'GY(=]MXE9^Q$Q3_9>16]=/"<_]'1LY#\S==3PI,X]_NP[JWH'&G
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MD^D?K'%3PAXS)9S1*:"?18PQ>UM1J1_Y3,I+:W'XQ5R!\H.Q-N6RJ17MG+F
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MQ%E0WGP?E#>]H"AM?$_]QM>?T!KI_?JWY.!:[,>UB#67#/]U!I.*F3QZ,_8
M<[GK=LS_F(V-]F#^WL<%C?T*H+9?"U3W&X/R?AM0.N "B@=$('\@%.0.)(#,
MP2R0.E@$$@<;0.S "N <& 76_H/ W/<?Y"$P][[ZFZ]_2\Y:]'9AS4U8<^7X
MO\Y@=@)X[ :PVP=@@KE<^PB \@G,_Z>HP#[+ >99.6"<TP#Z.2.@GN,#Y9P
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M:TU3PK::3@L[;IH4>@OYW20I](-Q4B@Q0@R_\B/.PR7,WD>G8];!_+TQ WN
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MRN:H0O$<0TK^;&O&[%PG;G:.4"I]IK=B<E: >OR,4-WHC"CC\+0$\Y#4-.O
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M-B^0YC<W2MDT=TE:-P_SK)MW25@U712W7/R+N$7C*YYYPR=)\X;/?[('ZY]
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M0=\+\P8AF#.,P8QA,J8-,S%EF(])HQ),&*W$N%$=QHQ:,6K4C6'C(0P93V+
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MNTM1SI,NA3EONQ1F_]ZE,.L+Y-\NIW,9#V">1PJZDW1GHU%_0:9Y/($=H\@
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MGNR3T^2$S!,0R0GX[@2D<1RRMA3"LH2,:>P=.ASN/_(7[0=S"YAS8$XLEH;
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M^A/R;^2,33Z2_5;2%QVA?:]M"+B!%4 [HFB'%9QL,(K17X6'&]'?CNYNHFX
M_:/H']?%F@)C#IWKB,@M\/5=>.,05ERH(UAU&(V'\-9!O&O<<7. Z#L OB'O
M.LJ)CSJ&WBVV*<=,F[S!"P4K#IPT,/)H0RD::]#?A/YVILUN, ;0/TK/3X Q
MC?Y5Z-W "-D&\]^'5XYAS>4L,:>UDQ;NP!_;;??=?(;\&SECN_SG20?^:<<4
M>-(V%;N"YP]6)#B)X&2"4P!&.1BU:&\"HQV,;J)P )Q1,";!F$7O&BS8K*T\
MNX5/;:(%&XF(#43/>D;,.GI^G?Z(Y[Y"SM@.XMUG3+%.<#ZFMXOY>=Q8BF3B
MTY[@!8$7 Y85C=G@%(%3 4:=SF&L;&7,;E8/.(/@+ %G.?KGT+T!2W9H-5;/
MT8,K:=T*1L4L,3'#*)]A?$P3FU/ZIYY@*KO=*+D;Y7]2DJ/(09:>O:0H>\Q.
M]*$/FD+!BZ--J6#EHKV8]E2"4Z]YYJ\UZL0#?6 -@S,!SBSZUZ+_'"S:KTG3
M!9HP7:VEIMNTQ/0X\H;&S!]HU/R91BW_T .+\$&@??_),9:9_<BY_+[=^#,1
M=FUQ==4FB[_66R(U[Y2HU<X9FG/.UPJ74LVZ5&O&M4%3KFU:[M:M2;=!3;@O
MT5+W:2UQ7Z-1CZT:\=BG(<\+-.AYM08\;U>_YQ/J]7P3^9UZO?ZJ'J]_ZF[P
MK@MG68^D_2S]NY"MI&8;>6X=2\X\:<$:+T_->05KUCM&TSY6+??)TJ1/H<87
ME6NI;ZV6^#9KU*]3(WY]&O(?U8#_,O63]/4&X*7 O5H<>%Q=@5>I,^AVM0<]
MH;; MY"/D+\C7]L.Q%X)[C&6V;TL<=L2[+6/-2PS*[%E%ENF@YVU/,A/$\'A
M6A*<H-'@- V'Y&@HI%@#(97J#ZU7;VBK>D*[M3AL2%UA$^H(7ZGV\(UJC=BM
MEHAC:HYD5$?>JH;(QU0?\8;J(CY$_J[Z\'^;C*VGEX%Y'JG/N5;2.V0>6<'C
M*9XG==?2*)-&([TT'!FL@<@8]44EJR<J4XNC\M457:J.Z&JU1S>I-;I3+3']
M:H( -,;.JB%NO>KBSE5MW!%5QY\T5<7?8JJ,>]14$?=#4WG<[TSEL9\C_S;?
M2+M/D (>2"$&TNRI\1PRE4J.B2UCV#*$+?WQ;NJ)#]#B^ AUQ,>K+2%5+0DY
M:DXH4F-"A>H3ZDUUB6VFVL0>4W72J*DJ:<I4D;S65)Z\PUQJ/6PNL5YN+K;>
M;"Y*?L1<F/R:N2#I ^1OEL+$KRW7@G\!>'O!W4HJ.D_Z-8-,\/LHSPUB6R^V
M=*4XJ=WJHU9KB)I28M20DJS:E Q5I^29*E-*3!4IU>;RU&9S6>IB<TG:D+DX
M;9FE,'V-I2!]FR4__9 E+_U22V[Z39;L](<L6>FO6K+2?FO)2OVK4W;JOYRN
M O^8L0\(W$VD7:M(-98C8_P^2%K:RVN=2&NF28V9'JK+#%1-9J0J,^-5EIEJ
M*LG(-A5E%IH+,RO,!5D-EORL#DM>]H E)WO"*3MGE5-6SE:GS)R#EHR<2RSI
M.:<M:3D/6E*S7[&D9+]O2<WZBU-JYK^<3J+_,%@[P5V?3QP@$] 4Z*-Z2<$Z
ML:6%UQKXO2;/515Y?BK-"U-Q7JP*\Y*5EY=ARLW/-V?GEUFR\NLLF05M3ND%
M?4YI!4N=4@M76E(*MUBLA?LMR8476Y(*3UD2"Q\P)Q2\C/S&G)#_%Z>$O'\Z
M&;?T&/N1MH$[7\@8@)XL<=1?NI 6GJOG9U4QN5ZQ144EWLHO"59N292R2Q*5
M69)F2B_--:66EIA32FLLUM(62W)ICR6Q;,R24+;"'%^VR1Q7OL\<5W;"'%MV
MHRFF['Y3=.E+R'NFJ.+/S%'%_[1<!/X^<+: L:J$<0 U&49ZD':D ?I862Z5
M0!4*2--S*MV5616@]*IPI5;%R5J=HJ3J;%-B=9$IOKK*%%?=9(JM66R*J1DU
M1=?,F*)J-IHB:_::(FHN4GC-#0JKOD^A53] ?JW0RL],815?F8_3QMU@;P!K
MMMQ> QI NI!F,&NJX%RDY@50MZPZN&>]BZP-BY38&*+XQFC%-28IIC%#T4WY
MBFPJ5T13@\*:.A7:-*20IBD%-ZU74--N!39=H(#&Z^7?>*_\&EZ47_VOY%_W
MJ0)JOS(=*35NZ(&.@C<%WJBC!M0.;D.-4?^!\T"C<TB)TYOA':UFQ;9Y*JH]
M4!$=$0KKB%=(1ZJ".W(4U%&B@(Y:^7>TR;=C0#X=D_+NF)=GQTYY=!R3>_O5
M<FN[2ZYMS\FM]1VYMWPBC^8O;'NBMH*YBG9.&#6@.GL-J 6I!;L4W+Q6*1/*
ME@Q=BED,_^]Q56#O(OGWA<BW+UH^?4GRZLN49U^!W/LJY=K7))>^'CGU+9&E
M;Z5,O1"87G+Y'K*"'HA"-]G"8KA_UX<R=7ZF/6!O &\&O#':RL?5@32"705V
M43N\JPO>TPWWZX7_0^<#ALSR'/60ZVB G$?#91F-DWF403[*(!JE8T?K[(>J
M#"(_ K<:@32/&-<L0)R&X9I#D)+!-W Z663_G[7=N"$(O&4MO QF-])*F^O
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M:D)_!WK[Z)$Q1LXTC]9BV0ZUXN%6QD<+4=]LNW7GQ[S[3\@_;7UPF*5N)RG
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MYU:(D^M("&\D3K^#'3<QT$_CY!L!N8',^7J,O>X:Z>I[5 ]VL7$?\W+[.:@
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M=[,@\MF0Y>P&.VG)G. G27,F,W(6N706F4(&-J3!-U,_L!U7&$RPUZ%J''N
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MVW*\!KP)EME^"$0'RWZC40E!RGE<S/.%O)YO-H'E#(X'.(MH2R!886!%@Y,
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M+5NV;MVV'H*=NW;MWOT1A($2!PC$YWOW?@&Q6 _&P:\@'(>/0$ V(@(A@9A
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M^Y92'^U_54"]KZOA]J=U??>^+1VCN9H[Q4B3,L'*&SO.(><_PJ[K\)+-QF"
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MF+WV_&3USN.UW4>/IPZ?/1\Z?O9:</[B?6<=X,/( *[LV\!*@!-L1'> LY0
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MDQR\L(@]_8_#> ].'$"H%\]O.H-0,9Z?AN='X_D!#Q!R>X*0PU=$;0G4=$9
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M<. VLT.!A\P/!%XRWQOTT&)7X'NK'8%HLRT0;;<&H-WF0+3;]!-H-?XW^,@
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M=X368!?->_,<@%7SQN^ R'O)A9O)Q^NZY:!FH3ZCJMM:H+3+1:Q@@;=\UOQ
MC>0.GF%L>Y1%^-P$^^"V=)? MD(W_[8JHLG%KZW+V;=MR-&W;8>]3]L%.Z_6
MI_8>+5\=W9O1R:T)G2?R.SV+3E,?'FBD7J3\#:0A*[H >KH!6GL :GO)??LX
M4-ZO 27]IGSY_?;"F7WNDLF]?DJQBX*UPGO"C;@+X\S]N].L?;L+;'RZJZR]
MNYNLO+J[++RZ5YI[=N\P]>B^8.+>]=3$I?.KN7,'6CK.0ZN)7*'GP3'2CMVM
MU(N4OY8<?"G12=G-2P JEY/[KF!"WDIYR!K28Z0-6;(25SJ)1J_PE.8-^BL'
M+0_1]!V(UO,:2#;T&,@S=!^H,'0;:-!W'>C4<QT8U'$9V*;M/'!.TVGI$RV'
M_J^Z=GVH;[L8#2=R=AKU(O7 #JK[1LH>7DJ]N(SZ@++K5Y+[K2+W(R=-&A&"
MN/4J$+W!D!F^P4H@>+V3J/^(IY372(""VTB8LO.Z>%6GD2Q5QY%2%8>1.F7[
MD7E*=B,#BG8C6^1M1\[(V:Q]+&>U^K.BQ2I4-A]"U8F,?U_:;EK[+92_CG*7
M#U$O#@/,6D/^/P)0O!$@E9P\@G0U:(<H!(RI@N^8(=-SS%+ =<Q1V&',2\QV
M+$C">BQ*TFHL5=)RK%#"8N=T<8N=K6+F._LY9CLWB9KL/"EB,O909-*V3V*&
M6U'"8!2E)G)@+O7!(JH!Y0_3G/LHMYU4M)YRR[< 9%-V'#EI,#FY!SFYW1$A
ML#FJ %;'=!CFQTSY3(_9LR8=]Q P.LYE&YR($= _D2F@?[*,I7>R@:5SLIM?
M^^0:?JU?#O-IG+S/IW[L TOU"+)5#J'@1'91WXU2_MKQOZ%%V9V4W;B5^F [
M0-Y.@$3*YE&V#SFQPPD LS, >A?Y0?V***A>5025J[J@_)LY*%US!L5K_J!P
M/0KD;V2"[(T*D+G9 E*_+P&)W[<#Y]8UX-QX#9QKR.!<1>9$ME+^>LI?035?
M2/-NV0$P;1= P=Y_WP$= ?"C;*?3 !;G 0S(R=6OD__?(O__2P@D'\F V",U
M$'EL"$*/;8#]Q!-83WG ]RR5#D;TX'M*;OV$FNP)3>CI[_3ZAL ?V$CYPYNH
M#ZGF;?1E-33O8LI.I>Q(RO:G>3M?H'S*UJ=L=<J6OPL@_B> R"L P8\L8'T4
M \8G>8!/F@ ?C0E'(H"@0\E'^A#XT 3POH]>1PF:S,?'/["&\ONI[NTT][K]
M ).IYNF4'479_A<I_PKEWZ#\/P!4[P'(/03@T!\5> ; ]QZ M!Y(IPD6P2%H
M+*A%F!/N!!U2D0XF6/OO.Q#:;+C]!Y;12^=N@ ::>]DQ@,Q3 -$T[P#*=KX)
M8'X;0/<^@,I? %)/:.XO /AI_J3T0$K_[_R), D10H'0)6P)JLF_[D#H880S
M_SV6_X*@0YZO,0ZYOJ8(@A[YOB7YOCNY?@AY?@(Y?@XY?BD#H9IHI#_31LPG
M>H@EQ HJQUKX!IMI6#O)] \3YXD[\!E>$./_X0]\F@#E<I"A2F-0H3&HT1BT
M: QF- 87-D(0"R&6QI!)8RBA_*E$/?V9%F(>T4VY?92UG-YK%7R$#? !ML-[
M. #OX"QQ"][",^(#@?_BS;]Y/0'D5Q-# 44.\BG0&,BY08/&8"R$X$AC\*<Q
M1%$MTF@<A32."AI#+>,;-%/N',KMI'=?1%E+Z7V'Z/U&X!5LA9>PCV9_BK@!
MS^$1\8Y&@O"4>$(\(OZ:  HIB:&P# <%I461*2U"8Q)!AB&-P99JX47K$49C
M2.+[#KG,+U#&^ C3&>^A@>8TFS([*',A9?53SB!EK(''M!Z/8 ^]]PEX"+_!
M _K9GS2&>Y1UFV9QBQ\9/X-BLAR4E!!%,5$1%),01DEE8930%4(1"T%DN[&_
MLKBLCWQQ?&_Y,IFO!(J9+]A5C&?L.L83P5GP6' N_"6X !X*+H8'@@/PI^ J
MN">X">X([8+;0L?A#^%K<%/T$5P3>\^X+(6,2U+(O"B%?!>(\U+(_Q]01I*#
M\D(B*$?^KRPJB*IR@JBB*8@*QH(?91S9?TOYL9Y+1O(_EDKA>R"3S[PO6\ZX
M(U?-^$.ND7%+KI5Q4WX^XX9\#UQ76 J_*0S#%<4-<%EI#"XI'86+RE<89U4?
M,G]1>\=W0AU9Q]10X(@:L@\3AR: BB*BJ,HGA!KD__J" F@HQ4(]98'WVOKL
MY^I6[(>J'@)W54/Y;ZDE\%W7R&9>U9S,O*P]E7E)IXYY06<6WSG=N7QG];KX
M3NOW\9W2'^0[:;"6[[C!5OYCA@?YCQA>X#]H=(^US^@U>[<A"NTT1.$Q0Q39
M88"BVR> Z@+"J$/YQN1\EOQ\:"7"_&@NR_?,6(/_OH$QZZ:>$^N*80#KXJ1H
MUEF35(%3IOGL$V;E[&/FT]E'+&8*'K:8+7C0LD/P@.5"P7U62X7V6@T+[;;:
M)+33:H_0F-5IX>W6?PB/6KWD;++Z)K[!$B5&+%%R[4^@+D,0C<A[K8'YW1$8
M[QQ9\,).%.Y9RC.NF^LP+UC:")RR]A(Z9LL3.627(+K?/HNSUZ&(L\NA0FRG
M8XW8#L=&L>V.;>);G3K%MS@M%M_L-"B^R7E$8H/S#HD1YV,2ZYRO2ZYV>B8]
MY/1%=H43RBUW1+F!GZ!\-EH '_DWO' #N$./UYLN3+AF+PSG7=09QUW-!0ZX
MNHKN=@V4V.$6);75/45ZU#U79I/'9-D-'E6R(QXS9-=Y-LNM\9PKM]JS6VZ5
MYQ+Y(<]5\BL\M\@/>AY4&/"\K+#$\Y%BG^<GY<4>J+*(Z''_$32C&M@#XZT'
MN8X?N3=YUR5ZM)[W8L%Q/V78'V#,&O-W$!WU\Y'>X,N37^<;I[3:-UUYV"]?
M9:5?F<H*OVFJR_WJ50?\9ZLN]>]0Z_=?K-;GOT)ML?\&]47^>]47^IU7[_)[
MH-'I]UZSPQ<UYQ'M/C]":\"'K@!_^0+\3OY]B3YB3A/'0QBPGR<'8^$&?)O#
M;$76A7I(#P<'*0UR(]67<9,TEW"SM/JX1=J]W"DZB[@U.CW<1IUN[AS=+FZW
M;B=WF6X'=ZW>/.Z8WESN*;VVH+OZLX/>ZK<$H?ZL0-1O#D2]B=!'"O.3)]6
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MKW8IBVMRF1S7X5(<U^]:&+?6-3]NMVMN["77G-BGSCFQ7QUS8M&!L)O(%R^
M^Y'D_E2#$Y2[KXC.V27DG/0Z5,B I<4*L+C$D+F@V%:HO=!-JB7/3Z4A)UAW
M1F:$Z;3T.)N*U!3'TN1LU^*D8O?"I"J/_*1ZS]RD.9[928L],Q-7>:8GCGFF
M)I[S3$E\[)Z2^,4U)0&=4Q/0B7#\#V^H%VZ/WP52#8Z2^^ZFH\XH'477T.O
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MB.$>^T^ZBZQ>Q)7O8,3=?@I& OH2'&%&C 0966$!1E96@)'6X#X2->+\(N3
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M5_ND>,866"?',U8;?(U[\9T$W(_PG<]"_S1*G8,E1 OX>A8EZ621!(V6:--
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M(=ICJ$([38QHSM2.M=7<@SUE'LB9M(CBC%LF<L8LT[DCEGG<8:L2[I!5-7?
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M@R;HEJ+),B?0!L@W<!ON@YWH VCJ+Q.I[">2.D@DP-]_.0+@U5%P$ZV>4N$
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MA#KK1I,-6T^G?&T]G;(6?;01Y;9-/I?=J*<#Z+5#:.:+T:U766\)_9#*>Y_
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MS\$+9=' U>+6?Z>X]#TK+KWOB5OW-^+691&W3HOJ!'P'K/?QH#E;T5MMMGU
M;7#7PET"=VX_VG,0W8-$B1I#=TPX2<"$M_A/!(OO1)3X3!K%>S)#/"?SQ'VR
M0EPGFL1YHD\<)R9%OVR=:)?M$_7X9:(:1Z2-/D%C>UM40Y^+>O![T0Q8Y#A<
MNSN4^WAHBV"XB[X(FN"NQ.]\9+-Y5"0):6) NH:@SWUGT9^KG,5QE:_H5X6(
M=I5!-"N31+V2P68EC7QEC>UPUTIE44.Y=A8!/8NFF46\S3P"T9L$_%,&('3W
M,HOU7IYMO8R+8!F< Z =OVOA+H%[Z3*1E"GT_PSZ>R7ZER+=T.?:]7H:T"*
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M[,!T61J8+9F!Q9(15"UI0<UB"NJ5Y*!EDABT1A*"=DALT!$Q!%XG40'W243
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MT0-P9#4@_&V.5P/(K(GT60GJE?$ ?6_0]\4DXX])+4"$$%:+"88N0N#,PC"
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M!)JI01Y_B+._JQ!T&88 @PGE+*7J7']0QG,%LW@N:3(1@"0]T:X<-*N&MO4
M4[1OC1'@@/9=T3YW'4819QU&."F K0[&A#8(.?< 7.V/N_MQM+,6;G\',M!K
MP _.VHO.=1A[";?^LYSG%J;PW'$)SU4601>%I!?:5@3?&FA?'^V;H7UKM.]
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M,SC[O9R@>2=R&ER_!"@'S/Y+^=AI) @1,+UD  E E# W7 SAYX:/@=!% )$
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M0/9R%IED.SD&EEYS:B";>?4/5@-8PJL_L/47[&1,5@-@-0BV%N(5YU4,?RL
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MB(@JBA!!Y1Z$3P4=IH(OJ*H#2))5,8I4D2BI8H2K(A%319"N@D!5>0( 'I3
M@R("/OF'X.<SR07].- /!"TW%?0#8 KH 9K*W-J/(B"/SV45!(B4H@ 15Q(@
MHLJ"1% 5@T6=&2H$T4(C6JK<8H$V$G1MEK A<=&"E]5"(J:)T:>!&4%]$0 >
MU#!CJSX!3]]()G0=Q<[  4UG-?0#1#'"JPZ@CB:5<5T1O,@I\1$IO(KC;U$U
M/B*H :>A!8/6$>$.' ,9KO)8\<:0;2"RYM5BX/$,X7T-X 5UX9%U$2CK8*;4
M/@8@>M3X25+9>4"@Y8U4V1ZWFP/Z@%9G_0>?*0#2X$D<?XOB,P%MF#/2>V(
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M:^M_Z-BQP>U[6X=>VKQOY*W5V\8]6;Q]\?-I%<N?_%/0#5UXJ'+2H8W@87>
MVY=#81'O3\;T>WTN<>S3*ZF+;E]+J^ZXD+G]:'MN:_.Q_FV-K8,N5NPKO+5@
MU_#',W;-?%RZ=<7#?PH.#QO!PP;P4.VD3;=XF7_?X^_ZZ5AH^)NST;G/KL:/
MN7\O<=&E6ZGK3US,V+KG=/:!QN.Y)ZL.]3^_=/^ ZU.;ASR8T#SIP?@]B^_]
M4W3A099N=-2B6SU-O^SW=WEW*K3OBTN1.0_OQHRY\2AA0?OME,J6R^E;FLYF
M[JT^F7UTY='<,W,/YEV>L&_@K='[QMX:M6_V/P;="!YJP,-&\%#KJ$FW>YI\
M;/5W?G4V)/3Q[?"L.\\B1U]X&C__\)WD=3NNIC74=&3L+F_/;%UX//ODU,.Y
M':-;\J\,;QEY=5A+Z95_"KI1F1\\B-(:\+#)4>/[;D^CM\?Z.#Z]%!QT]TEH
MYHTWX26GGL?._?6)Z%+R>^XEK:Z_GE*[]D+:]L5GTO?//)5Y9/RQK+;AA_,Z
M"@\7=Q0<GO"/06O 52VXJK64H9L=U3[M\S1XT=['[N[M(/^K?X1DGGW?=V3+
M'S&SMCQ(6%%Y,ZEZV964S;//I^Z:=";MP*A3&4<*8"T#CQ><''"\Y!^#UH*'
M.GT16F<I3;<Y*K\Y[*'SX**?U=7'_@&GWP5E'/X<.GS[J\AIU8_CEI3=25@W
M]WI2[91+25M*SB?O''HV;>^ T]DM>>V##N:>'O:/0>N4^&F]G@BMMY3ZO,=!
M_FF;A_JUNUZ6IU_U"3CT-2!MU[?@H;5OPR>N>A8];]Z#N!6EM^,K1M](J"FZ
MFM@PX%)R4^Z%C.U9%_KOR+Q0^(]!ZY7X:*.>,&VRD'QUR$'JUE47Q;///*T/
M??8)V$']DNM^!@Q:_3%T]()7$=.F/HU>,.9A3%GQW;@U V_'5^:B;S)NI-6D
M7L^I3;D^X!^#-BKPT2UZ0I_VF(O=/VLG=NZAH\KA#^XV.ZBG7PWUCBNG?KD+
MOP8637T?-FX,^"A^'C5WX)/H1?T>Q2[-?)A0EOH@967R_<Q5B??[_6/\;)(G
MW[?K"CX[9B1PX8Y)CZ-O[-5W4F?K&NKBM8JZ1\RGWFE3J5_^F*^!Q470QX!W
M?2?FOHXLS7@5/2WU9=R,I#^29B6\2)L=_R+K'^/K=AGR=K\ZWY4;<GS'7YI)
M[OYAHU%+[2Q64@?7>=0Y: IUBRVA7AF%U+=__Q\!0[*^!A>E?0D;GOPI8F3B
MI^A1\1_C1L=^3!H=\R%MS#_%^V9Q<N6L"#GY3%UPSU=CJ3IJIKZ*6IC,H]8.
MDVEOGY'4*70P=8W-I1XIZ=0G,XGVR8VG07FQ-+1_# W/CZ)1 R)_Q@Z,^)GP
MCW'YL"!INR9,]GW6$&Z@NE*KJ9[J?&IH,)F:V(R@EJZ#J*U?-G4(2:'.D7'4
M/3::>B5$4-^D<.J?'$:#4T)I6&H(C4@+H='_&'2UDB MU^E!5YK)TZ7V.G2%
MIR6M"'2C5=&AM#(UC:[+*_RYJG#2IZ4E"U_/F[3V^;09=8\GSM_V8,SRW?=+
MUNR]5[)Q_]V2I@/GB[<>/#RPJ;4EO^E0=_&;A]\\_.;A-P__ZWE8S>%!CBX#
M#ZL\+6A5H"O=$!E"-R2GT?6YA3_7%4S^N&KDHE=+)JQ[-F=:_<.I<W?>F[!D
M_YVQY:VWQU0?N3ZZ\>B)H0W'F_/K3^P:T'"\NZ!K>#RL @_+P<-J3W-:'>!"
M:R.":5UB*JW-+ORY8=#D#Y7#E[PL'U?U9,F4S??GS-QS>^J"(S<FEIVZ/J&J
M_4Q)S9F]!1O/;1E<>[IQR*:V[@(\"- UX*$</)2!A[4>9G2COS.M#P^F#0FI
MM"&S\$=]_I0/-45+7U:5K'^\>M+6NTNG';@Q9\[)JU.7=%R:LN[2H5&55[84
M5EZI*=IX;D-1S9GNXA<>M&F%ARFM]7>BF_L&T:;X5-J47OA]2U[I^\:"97_4
MC=CPJ'KL]CNK)[=>6S+C](79\R^W3U]Y?>_$===K1ZR[5C&B^L+:$1LZN@NZ
M%CRLU1&CJ\UDZ0KP4 4>-O5QI%O# NGVN)0?.](*O^[(+7V_?=#R%TW%&Q\V
MC-IYJWK\D4MKIYXYN7CVY0.S%]_8/F/-S<JQ:V^N&%UYN6ST^HO=Q=]X6&FO
M1=>[F]!Z\+ ]-)#NBDWYUIQ2^'E/=NF[/0/*GC<7U#[8,6SW]<UCCIS>,/ET
MZZKIE[<MG'NS84'Y[5535M]>-+[BVL+QE9>["[I6\2\>5H&':G=CVMC'@>X,
M#?BQ-R;YZ_[DPH\MF:5O#N:5/6L=6'?GP-#=%W:..GRL?OSIYJK22YO*9MZJ
M6+STWN)9J^[.FKSVQJS)ZZYU%W0=>%@''M: A]7VFG2CNQ'=TL>>[@[Q_W8@
M.OG3H:3"=T<SIKX\D;/B45M^W?5C!;O:]PT_U+)M3/O6NHD7J]:6WERZ?.[]
M.8M6WI\R8_7M*=/7WN@N_L;#&GL-6@,>MOK9_]@;XO_Y4%32^^,)!:_:4Z<^
MZ\A<>?="O]J+9P;M/':XZ-#NYI%MFYK&7BS?./'F[#73[T];L_+^N 6K;X^;
MM^9F=_$G#VO-9.C:WAJTSMV0;O/K_75_<)\/QR(37Y^.+WA^(;GTX<WT%=>N
MY=2VG\_?V7*JH+6I=5C;^N91%Y9L'GMC6FWIW=*&\KNC5ZVY55*V]D9WP>&A
M@L=#16]U6N]F\'.GG^VGUF#?-^T1"2\NQ@YY=#NA].:]E+(S-S)K6B_TV[&]
M?<#!FN,%I\H/%9^?TSSRVN2=DV]-W+OJYJC:==='KJ^XVEW0"@X/HG0=>*CJ
MK48;W?2^-?O:O#L:Y//'^;YQCVY'#[[[-';*^8=)RP_?2-NXXT+6]IK3N2VK
MCO<_.?_PP([)+057QAP8>VW4@857AS=77AZVK>I2=P$>^&DE>*@PE:$;>JO0
M)C?=3_M]K5ZU!7D]OA$6<^=I^,"K+Z,G'7^<N'3WK93U=9?2FLK/9.R;=S+S
M^*0C66='M.9=+#HX[%)AZ[2+0PZM.E]XN*JCNZ"5X*$*/%2:2M/:WLH_=KAI
MO3WL:_[D?*#;[8?!45=?A0TX_39RPKXG\8L:[B2M6WLUI6%11]JNJ>UI!T>?
MR#A1>#2G?=#1PM,#CDYHSS^VL*W_L67=!JU2X*?K=41H%7AHL%/XO,=5_?DI
M'^,[-_V=+CT+BFK_$)K?^CY\7-/SV+F5]Q/*E]Y(VCCS4O*6<1TINXM/I[4,
M;,L^G'=JT)%^;26'<]MF',IIF]MMT/7@H5I;A%:;2M&M=K)O6EV5[U_PUKGT
MR-?YU-N R(/?@_-V? PKV? R:D;9H[BEL^\DK)MX/;%V^.6D+8,NI.SHUY&Y
M._M<?G-FQ[#FC(Y)NS,ZIN[J+N@&>3ZZ45N8UII*?&JV[?6XS47VRETWG;:7
M/BXM7_M$;*,!V;5?@H>M?!,Q>>ZSZ'F3'\:6C;P3MV[(S83JO.M)M5E7T^O3
MKN8VI%XM:$BY.KH^^>KX;H/6R/'16FTAVF0B]O*PC=BUZ]:2[<]=]5L^>[EL
MI=YA&ZA?VJH? 8/G(^^?\CIB:LGSJ+D%CV.6]'\0MR+K7F)YVMW4-<EWL]8F
MW1FP-N%N,3"BVZ!ULH36:PE^V&,H>+O#F/_T8QN9@Q^=#;92-Z=JZA&T CGN
M/.K7K_1;X- 2\%'X)GQ2_Y>1T[->Q,Q.>QX_-_E9\OS$I^D+XI_V6Q#W=#!0
MV&W0!FGR<ZL&_Z.3JN3L UVAUO?6\MMH;X-JZFA?1IU]YU"WR,G4*W44]<TK
M^!Y0D/<E9'CFQ[XEJ1\BQR:]CQF7\"YA0MR[E FQ;S,G1K_-FQC]+K_;^-8D
M05X=[$7.WQ8CA]\8B&VGY@K5U%)O.;6QF4U[NT^DCD$CJ&OT(.J1DD-]LM.H
M?UX2#1X0_R-L<.R/R"'1WV,*HK['%T1^3RF,^)X)9'4;+W:*D(YV87+DE3S?
MSI^Z/3=2 X4R:J0]FYJ:3Z"6CL.HK?< ZA"<19TCDZE[7!SU2HJF?BD1-# M
MG(:D]Z5],\)H9$8HC<T(H8F9P32YV^@XQ$^.718DN[\I"M12M9XKJ8;<'*JM
M,8'J&1538YO^U-PEG5I[)]#>_M'4,3B<NH:%4@\$F]X10=0O,I#Z1P;0H"A_
M&A;5AT9&]Z%1W09=)B](EVKUH(N,Y>A<6VVZP,V,+D,<M2*\#RU+BJ-+<_/H
M@H*1WV>63/TX>?*B-V-FK7XY8G'5B^+RC<^+U]<^+ZZO>U:\?=.3HGWU-P<?
M:#C7OZ7Q1,Z!S=W!;QY^\_";A_^E/"P'#\O PV+P, \\+'(SI2N0XY2'^]'R
MQ%BZ(J<?73IDY/?Y(Z=]F#YQR>N),]:]*%E0\VS$BOHGPRLW/QE6M^7QL&U;
M[Q8U;[LX>._VX_WV[#B8NV=[=\#A8;EF#[K$6);.M]6B2UU-:+F?/:WHZTLK
M$F+HVJQ^M'S0R&_+AD]_/W_<LI<SIE8]G3BGX='HI=L?C%JS^_[(FCWW1S;M
MO52T??_Q@=L.[,W;OG]7_J[F[H"6\7A8"AX6@(<R5R.ZUL^.5H?ZT.JX:+H^
MH]_/R@$COZTIGO%N^9BR/Q9,WO!XQLRF^Q,7[KTS9N7!VZ.K#U\?U7CT9&'C
ML>:\^A-;!S:U;AZ\?7]W !X$:)FF&(>'A;::=*6K(:WTM:4U(=ZT-C::UJ;E
M?MN8-^KS^L*9[]:6K'Q1-K'FT8)I.^Y,FWOPYH1E)ZZ.K6@_.[JNO:6XKKUI
M<%U;7<'FHS5#MQ[L#N@*'@_+P,,B\%#N:D#7^]K0NF OVA =]:,A)?=+?>ZH
M#[6#9[VI'K[J^;IQ=0_*INR^-GO&D;.3Y[>?FKCJ[(G)-6=WE=2<J2NJ.5-5
M7'^B8MB6P]W!7SP8R= E-AIT#7C8 ![J@SWIEJC(;TW)N9^V9(]ZUSAPUA^;
MBLH?;2RIO[EZ0G/'XJE'CLV<W=Y2NO3<_JF5'5LF;.BH&KFAHWQ$7=O*D8W'
MN@,.#RO PW+PL-1&G:YUT:<;?=CJ$,^?VZ(BOVQ/ROFP/7/4ZVWYLY\U%:R^
MNVEXP^7U8W>?6CGE<,N"&>T[9RXXOW5F^86ZJ=47RL=67U@*?2P977^R.Z K
MN_"PS$:-5KCHT5H?*[HER./[SLB(S[L3<]XU9XQZV=QO]J/=@];<;"JN/U<[
M>O>1=1,/-2^;VM8X;\[YFMG++E7-KKJT;&+5I?EC-YZ;-ZZNK3O@\+"2QT,9
M>*ATT:6;?"SIUB#W;\T1X1_WQ6>_.9 V\GE+SIS[!P:LN;)KZ*:VS2-W'=@P
MKG7KZLEM&Y?,N+!F_H(KJQ:LNS)O6N65&1.K+TR?6'.F._B3AS+PL,)&E:YW
MT:'UWA9T>Z#;UWWA?3^TQF6_.I(R\LGQK#FWC_1??7Y_0=W1[<-W[MXTNK6^
M:L*I=:M*SR]9/.OJ_,5EUZ;/67=MXM2J2Q-+-Y[K#N@J#@^BX$&:KK)1H=7.
MVK31V_S'KD#7SP?[AKT]%IOUHBUIY,.SZ;.OM?4K;S\\J*YE3]&.K4TC#VZH
M&WMR1>7$\[-73KTZ=<6B&Q.7K;M>,J?R<LG,#>>[ [I*3H"N @\KP$.YC3+=
MZ*Q%F[S-ONX)<'E_-"STY>GHC"<7$T;<N9(ZZ\+Y[%5'3^;7[FX=LGW3[N*6
MM4VC3BRL&]M16C7QROBJ>=?&5E5<';8,^?RB#1W=P9\\K 0/:VR4:)VSYL]M
M7B:?#@0XO3X5&OSL4F3Z_;NQPZ[>29K9?BUCY8%S_6J:3@S<MKZUX,"RYN+C
M,[>-.#N^<=RET5OF7BK9MOYBT?KJ\T-7UYSM#FBY'#\MY_%08:U(ZYW5O^WR
M,GI[V-_A^;F0@ =WPU-N/HDJ/O<X8?KA.ZDK=E[+VE#3T6_KJE,#]LT]//C8
MQ -#3X_:-[IC1,OLCN&'*\\-V59S9LBFNK;N@*X&#ZLU1>@J(RFZWEJ>;G%2
M_;C/2_^/D_ZV#ZX%^]Y\&II\\65$T?$7L5-W/TQ<7G<SM;K\4L:6^6>S]DX^
ME7MDQ+'\4X5'A[4//C:E?="Q96T#CF\Z.6!?X['N@,/#&O!0#AYJK&6_;W=2
M?G/(4^=11Q_+Z_<#?,[_$9)T\EW?PGUOHJ8T/(Y?O.9.4L7"J\D-4\ZG[!IQ
M.K5EX*FLHWDG!QW+/3GZ:,ZI64>RVU8?SFG?U-H=T+6R_'2MA@A=8]2+UEM)
M?]SC*/_TE(?:C5O>IAW/_'V.OP]*W/\Y=/"6=Q$3*I_%SEMR/W[5])N)&\9<
M2=I<<#YY9]ZYS#W99_/W9IT=OC?SW.0]&><6-Z=WK-G='=!ULGRT0D.85AF*
M_]QJ)<'60-R^Y";?\<C+[-A;/Y^]WP/BMWP/&E#],6ST\I=1,V8]CETR_E[<
MZN*;"=7YUY(VL5T=Z9?[;4Z]4@B,;4RY,JLQ^>J2ANZ 5LKPT2H-(5IK*/9Q
MCX78@]-V8A?N.2H=?^UIL?>;C\]FZA>SGOKGKO@27#SG;?C$22^B9H]X'+-X
MT/VXE3EW$]>FWTZM2+F=79ET>V!5XNWAE0FW)U4DW)G9+=#UTGRT6EWP9Y.^
MT+.CQ@*7;AF+GOC#477O5S?+1NKA54F](I93W_2Y/_T'3?X4,G+DV[X3A[R,
MG-'O><S<C*?Q"U.>)"].?)RY).%QWI*XQP5 R>+8)Q.[!;JA%Z$U:@)O]VGP
M7;LJ2TX^,Q/?]Z6W>B-UM*B@+FY+J5OP+.J9, EY_\@? 8.'? D>WN]#W]$9
M[R(GI+R-G93X)G%*_.O4TMC7V:4QKP>41K\N*HU^,VI*=T!KQ<FW;7+DRFD1
MTO9$E7__)[->FZF5>@6U-5U"[9UF4D>_\=0U8CCU2!I$O;-RJ'__M!_!@Y.^
M]RV,_QI5%/LUMCCZ2^*PJ"]IPR*_9 ^+^#)@6/B7@F[A4X,HN=PJ2-HO"Y,#
M'S2%ME!#J4IJK+J$FAG.H%:VXZBM>Q&U#\BGSN&9U"TNB7HEQU&_]&@:F!E)
M0[/#:41.7QJ3$T83<D-I2FX(S0)R<[J#*[L(:3LE2%K>BI,FJB921;6DEE(=
MY1E47V\L-;882LT<\ZBU9QJU\T^@CB'1U#4\G'I$AE*?Z&#:)R:(!L4&TM#8
M !H>YT^CX_K0!""Y6VAOY2<'+_*3;52"?SV5%UE&%7O-H"J*8ZFZ5B'5-LZE
M!M8IU,0QEEJX15 ;KU!J[QM$G?H$4%?_/M0CP(]Z!_I2OT ?ZA_H38.#O&A8
MD">-Z!;H?!DA.E>M)YUI($>G6&G1:<XF=+:/'9T?ZD7G)H33F=EIM'3(8#JN
M9,SW$5.F?1XZ=]['@K)%'X94+GT_N&[9^\';EK\;O+?L[> C*YX/.+;R?MZ)
ME5=SVE:=RV@K_V_QFX??//ROY&$>>)C%XV&ZLS&= QX6@(=Y\>%T=E8:G0H>
M)HP:\WW4Y&F?B^?,_U"X?,G[(17+WPVI+7LW9.N*MT/VK'PS^/"JIP..EM_)
M.[[Z4O:I-:<S3J[];T$7R B"AQYTMKX<+04/LYV-Z$(?&[HTQ(,NB0NC"S/2
MZ-R!@^GTX6._3IPP\T/)C"5OARU:]7IH^=I7A=65+PLW5[TLW+W^64%+]9V!
MK1LNY1W9>#+S<,V1[*/5_RWH0O P'SS,T9>ETZPTZ3PG [K4VYJN#':G*V-#
MZ?+T5+HX?_"/><7COLP8._O=Q*EEKTKF5;P87K;Q>7%%W;/B^OJG13L;[A7L
MW7QIX($M)W/W-QW,;6G<FW>H]K\%AX<%X&$N>)AAI4$7.NG3,F]+NB;(C:Z)
M":&KTU)^K,@;_'7IT'&?YH^>^W;&Y%5_3)BUX6G)XL;'PU=O?32\=L?#8=MW
M7BGX/^S=9533___X_Q=V8@>*BB@&(0J(='<W(\: P6 C!X/!Z,'HSM'=W=T@
M(2)@O.W&P@Y4!![_U]O_YWS/Y_<[1^3B[\+WPNWB]KBOSV-G/&EO'R>V=?02
MVCK:B=V-S8[]-:L%2?_5$,5_!%)$3T(6NF<5J(E#H8'Z<B'6?"'/SOE[EFO
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MHQ[#]8U!'.$%)LWBN47FO^=(F#QSS\(\"\@T?AZ=:?0\(\-PMC+=8+:#N1K
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MJ:+DFG-KR:3KY>(!AY'B=ON1HB;2E=PZQZGT:L>9E+_YW1"X?ROXH TA9P]
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M(/@U?HKQU/)VZ&WS^V%3V$?!X[AG_L.6+[P'K5Y15P)4M,$=;7#@.  >I]C
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M'L+%$/KQJ19]CIEF?=Y9IOWAF:8#Z1DF0Y7I)L.]3..!Z51,^XU$3,O-A)4
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MH/^/;A0AR&@C@O3T(4C#500I0??OC,\;6.)A]WH&L&WU@:-[R'""W0Y.G[0
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M3)<PUV3W!+L$&M,ZGI%AE9"<8958Q+1,:D[#)5U)P27<2+2,N1-C&74OXD_
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MY7A=3,"!\J3HG87IJ5MR<G.'."7%@QFU9>LS6LO79717K,GLK^C+W%*Q*O-
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M%Y4+ ;%BPI"]2 !JQ'B@38IKNE<*O5DOANZ-"*(KVW2X3VZU$SNPV5-MQU"
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M  E: 1(Q!22F#SP2.K!(2@-$I%5!2D8)]T8>5&2D05-&'/1DA,!$1@!LI'G
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M@O]F!L_A8>/_]> TGL&A(81VX_S-NQ%:@QVP\Z $:C],X&XZ9"U</>XL7WS
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MJ<J"OKH<F*K*@;F&/)@3%,'"0A5,7=3!V$\3C,(UP3!9 PQSU<&H4A6,FU3
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MER((3"O"HJG_X'_YZAHRH*4N"UK8N=7UY$'-2@%4W/"8J0J@Q)0'Q10Y4"S
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MW4_] KH^\@.ZB/>//,#GTA7T_Y]Q#>[OQ1X,HG<M 1A9!C!O!+UC!1M:5VI
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M3)UC>QC:QVXP- ^_9&H<_"*DOI^P)S+^6W*;,'_UZ+=3F5[,;M[Z[50F;R=
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M:PA $08%A(-((RK()-R>V2!>"&Z;QW]-D. -2&8C>,,3G'"R^1^6;L?WA-T
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ME]CLE[L1',1?M_]A!>8/XMAG_?3M#*8(QYV*V8(3 /S3F'\>\R]C_G4 I5L
MTIC+N0] ?XC9?R OD?&SB+?C8"UO)!$5_-H(X(,+P&?<)'_!S=D7?#/Z.@O!
M&X^L1;;\PR+,[\:Q-XQ_,@=[GH[CCL1LWPL 3E>Q_SAFG3L BK\!<#&7_1B
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M C-;'0.R^AS\LY;;^V5MM_/-.F/+SWID[9OYP=(WDUCX9A#S[]S">3B#Z^#
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M)ZT)4X_MC]&)[$LR#.W-- GJ+30+[*TVD_6VF@;T#IKX]VXR]NO=;>C;>\K
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MTRV1T\8/18X3OX@=QAEE^S%&!9"PN,[N1P+_$O@/@7,WI,\6R+$1]EH@/-8
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M6 0P ;[6)+\U\&M(JE=Q\%?P1Z]\BN_^#-Q;QI%%>0]F\TFB=6?D/9A*\.:
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M=1OBC[B-\]>Y;>6O==O+'W1;4AQPNZ;8[W97T.OVE:#;[0]AEY191N<*OG/
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M/[@3,0#7-#C6@:/]X,JU0$#<(O+@"/0OI+(5-+K^$I$J=#K_%(3 :6CL,Q(
M!>%9%&1GG0 O  7)6=AQ#@O@69S89Q'L,[/RGX,Y!:U] F)YZ1><"'\OXS!\
MWP?N&?!M@ SN>70_%GP]"7PAX/. -K<]2V1TGDC](I$ [J"X)X@53"X<%!XB
MHB=1D%^'WK^!PO@I%$9/HQ![)E'^#P(WV9MS([&?06"?OH#/(>1O0*Q?_W49
M; ]F![@GP;L&G(W@+ 9G*CC#P>D%3OO+1,97B32>!/]3;.\%N G< M@]*6Q/
MY$7$Y&45HE<0D]<LB5YW(7HS $(!Q<D[Q?*?L'\78_(.@OPV#O;VZ\"_E\'V
M8*8>]6# 6P;>#/@9!3]]KA$YWB R :<&0BA@N5Y:Z;V\\K_VHSS:'_(!;/D8
M@N$S8X@E%*M?^Q)]%P\!@0GY1TQV/^'D^PF._XAX_/C<,M@>S,@9S 5XJPK^
M9L/$&/#ZK=P+QO0%(LV7,?XLWYLK7._]'WM1/E_9%_*H#_(+G^A7]A^OD:]_
M(4<>QD)((AY,Y\H^D%W_^;4:AE39/0?0G&)H3@DTIP'>LR?Y'HP(DE\#D@=4
M /4K>T%ZZ"$-0CF.0$F/+U^/\CLT]WUH[ONT &5[E.Y!:?X"O?LSE.H/]&]H
MZ#_^_Z]#6>Y_B&"#$#8HP09=O&=-\CT8(4 "L=?D_$TEX*O!D9K!TTF_0F/^
M0FNA8M?3C]"Z/]!F\&S',7<C%(?H:ZC;KY"T7T E?P:]^RFL^AA'>AP? A\L
MVZ#(_O .;.!PY39HX3US<+K0G]#<OU,,_$H#7P'X*L!33]]0*X[?#>_6+-\/
MXW/: )Z-&)*M./8<CKU [T-1OPM%_$\D[EMX]B;^\@T<]74<_;65O1<O R_)
M^P_\%>T/&P2P00V^&H'3 ?[YP*]P<"9AJ'/ 4P*.&MC>B'1HQY%[Z!T: ,\P
MTG(,/%/@F*%7$8L[M(@(G,8I<YV>P[NW8?$M')G=?W$=>/(QK/0_N/+^ Q?C
M+$)<=>"G%?QS V<0.&/!EPZ> ARM'!RKP=$,'SI6]F$,XA0= <<$3MO-X)D#
MSP)=HR6,QA6ZC&]=Q)'8##D#1A:G'\/C_8\';#K#CL])%?$T@8^.\,T7G.'@
M2X(_V> I D\ELJT./"W@Z01/'WC6@F<]HK\)7#/@V4.GZ B=H/,8E=MX]B\Z
MC/%8Q BS=_5E<7 %C_A_6FDQ?KQ\F@O K0-?K<'K!LX@\,6 *Y4N42YX2L!3
M!9YZ\+0B^[K@\1IP#>.,& ?7%G#,TP'\?P'?VD=/PZ)_8(2^PKLX>]B[#*]@
M!V?9!OI)B.E$0][_^ >F_U?Y;"M8!=Q&&"\'\/J ,XQ.<1)H22&#CO'RZ0B_
MC!;Y-710L8$.*+;1@J"']@D&:8]P/>T23=&\: ?-*1V@[4JG:%;I!FT3OTE;
M5+ZFS9(_:4J56<:F%;!;RK[&]/J!.:8\3"<O8NFY:8AI'+9<4=2BLTJ6=$(B
MI2/J,CJD$47[-9-HKU86[=8NI'GM<MJI4TL[=)IHNTX'S>CVTS;=8=JB.TF;
M]69H2F\?;=1;HDF]:S2N?Y<V&'Q)ZPW_H!%#AL-BV$".GW4PK5H3O86E]T4W
M+"E2+$6.J.]@TTD=,1W1-Z8#1HZTQ\2;YDU#:8=9',V8I=)6\QS:;%Y$T^85
MM,F\CC9:M-"$13>-6PS2!LL-M-YR,XU8[J)ARZ.TUO(R#5G=X0Q8?<;IM[K/
M[;-BN+U6C$*OI1S?F<NO V*OP;F))>8J<,X;2ZLKEG]K/NVUTJ6=MC8T8^=&
M6^QEG"G[2,ZD0R)GW"&#L\$AC[/>H80SXE#%&79LX*QU;.,..?9Q!QR'N6N<
M-G'[G.:XO4Z'%+J=+BAT.3VOT.'T,:_-Z5=^JR/#;UE!LP.C^*6#?!_,"UCR
MKT/_7@!.A*#L\$-MA[AL7Z5!6US-::/K*LZ8U$=A5!JB,"R-X:V5)O,&I9F\
M-=)\7K^TE-<KK>'U2)OX76Y=_$ZW07Z[VSB_U6U&L<5MOV*3VQG%1K?;@GJW
M]P6KW7X6UDH98<UC^!0\;T#_WX[&&&!Y.P,<@0[>AW)H!V(R[:E,$][&-.IM
MSUWK[<X;\ Y0[/,.%_1XQPFZO%(%'5[9PC:O0F&K5X6PV:M.V.3=)FKP[A?5
M>:\7K?;>HE3CO5>IRONDN-+[:7&Y][O*I=X_*I=X/008%F(6'R(&KT0B#U!N
M7$Q!#* _#R6CKL(RMQ5VC,N$-"+3I\% :TZ?S(77%> C: \(%K7X1RDU^2>(
M&_S3Q77^N>):_V+E&O]JY2K_)I5*_VZ5<O]U*J7^4Y(2_UV2(O_CJ@7^UU7S
M_-]2R_7_'OA;-<>/>03)OU#NO C?KZ>M]&"@/Q<R$ /8,04[1L(4:"!,FWK#
M+3@=84X*+:&>@H:0 *75P6'*U4$Q*I5!29+RH$S5TJ!\M9*@<K6BH#KUPJ .
M]?R@08V\H$F-G* YS:R@(YH905>UTH/>T$H+^E8S+? !P&BDR1AU%F^'0_N#
M[RJXS^1A'* _]^:BMH,=$WA_"';T1*M3>XPI-4?;<^NBW!2K(WQ%Y>'!RB5A
MD:I%8?'J^:&I&GFA.9HYH<5:V:$UVIEA+=H98?TZ:6%C.BEALSK)88NZB6&7
M=>-#7P.^!O[2C@]A6&BQ>!-C?RL=VA_\)U&"+J+,V(7'+7B] 7;THS1M3U"F
MI@1#JDNPX53%N_#+XKR$13$RY;SH4-7LJ&B-S,A$K?3(#)W4R +=Y,@*O:3(
M1OV$J![]^*A1_=BH;?HQ40?UHZ(NZD=$O:(?$?DE\*=>1 2C"^A$ J\ERO<#
ML7V@I3+H#&C]G7B<ABW#B$<W[&A*%=+J5#VJ2K7BE*:L4BA,]A#D)OJ),Q."
M5=/B(S62X^*U$^)2]>)B<PUB8TL-H^/J#*/BN@PCXH8-P^.V&(;&[3<(B3MO
M$!3W,O!O_:#8/_2"8AF]H)AEZ+*]J!N(__E2Y +T[T(U<H'=AU)!M!;QZ( =
MJ[/X5)&E12599E28Z<#-S73C9Z;[B%+3 B6)J>$:<2FQVM')R7H1R=D&8<G%
MAJ')M8;!R1V&0<EK#0-3-AO(4A;T U+.Z?FEO*3GF_R%KF_2[WH^28R>3R*C
MZPN\@#R\!I_/@/](+7*A'E((.G@2S]<@)JTH12LA5XKRU2@_WYBR\VTY&7DN
MO)0\+V%"3H!R3':H6F16M%989I)N<&:F?F!FD7Y 9HV^?V:;OE_6D)YOUK2N
M3]8^'>^LL]I>62]J>69]KN61<5_;/9W1648:H_,LQOT*VP<"YV(CM'\S9!@P
M#FG2!YG4C)B4(R8YI6+**-6GM%(K2BIUXL:7>/"CB_U$$47!*B&%D6J!A0F:
M_@49VKX%A=H^!=7:WH5M6EZ%0YJ>A5,:'H5[U=T+SZBY%;Z@*BWX3-4E_[ZZ
M<RZC 6@ZYS":SR &%VN0"^ _V ;MWR'?A[(!CSW0Y(UXOP1Q2:_A4V*U%L77
MF%),C3TGLEJJ$%KEHQA4%:@44!FAXEL9K^I5D:[F45&@YEY1I>96V:HJK1R4
MN%9N4G&IW*/L7'E&O*KB>26GBL^4',M^4W8H923V)8RJ?3&C>AT^GFM +H!_
M?S>T/^3A=#_1*'LM#E[7P99"?):,V$0VJ5!XDP&%-%E14-,JCG^C!\^GT5_1
MLR%4Z-X0JR1M2!6[-.2)G1LJE%8U-(N<&@:$C@T;!0X-NP7V#:<5;>N?X]O4
M?\JW7OV;P*J&$5E6,THLGD"\3[?*[\N[=X#]72#,3>LP-ZUC[X="5 U[<GNA
MO?%Y8)<B^79ID7>7"7EVV9%[ERM'VN6CX-P9Q'/JC.([=B;S[3MS^':=Y7R;
MSB:>=6<_SZIS4L&B<Q?7O.,DU[3C-L>T_1..2>NO"L8M#-^HF5%D<0'Q7L+Q
M#PTA%T:1C^Q]:<<Q-^&Q=3UTUPAT%^R)AFU^^([+D!(Y#>F2PY 9V0TYD.V0
M&UD/^7$LA\(XYD/Q'+.A3([I4#''>*B>8SC40P:#8Z0W.$<Z TNDM>8F:?9_
M2%I]]TBKE^%H]3!<%F?8^^+@V/LA2><A![=!BFV81C[BL7X3Q@&2*'F"*!3P
M!.Q@G^F$F(PF=,E@PHST)^Q)=\*-=";\27LB@C0GDDA](I=4)ZI(9:*=E,:'
M23BVC10AJ'GKGR3>Z%O M\0?_I,4US'+. '^1?B\#YQS6S$.,]#_D.GM>*S<
M!NV']V( ?\ %KRT!E$BD/*M$HED=$LR8D>*L/?%GW4AA)H"X,U&8Z+'XS"#9
M9Y!HVS"86]E--ON(-D-03D,T3D'K3MW#)/07\)".P:^#FU$K@'=FCFALGJ@7
MJ <*@60@!/" /+3;#?T/^:ZQETAQ'S3_/C& 0FR?*0#-OX!"8$&&Y^SBCXEG
M'Q)^7SL2#8.\9P<&^P06 NC<G9_!8=@P!QOF_J;#\&\!W',X_B8<>V@!^ALH
M!S+V0W\#OI#K3H>(S!:)M \3*1U!(0RY2L=@QW$E ,7P<>CL)1MY 78"A<<)
MV'$"B\ )=B,@$FX)L3B& QV%F#_R[LI^E#^!O^D@?-R][W]>"U0-GESPQ(%'
M=HS(=0EC !=T3Q&)3T,00:>CT,8$#[![4BZB$+^DAH5/'Q,>BN(G5F$A1B%V
M#871DSGR'XAC;X1S#8-X%0>[\CR^CUA<1"PN_DX+\',6W&-'Y/=CJ3M.5 "^
MI)-$P>!S.TMD#2Z]B\B!R^!G>R]P!44_B@[@J94]*6Q/Y#9$PG.:*$@0DY?M
M41Q!\]]%?KR.1>=U3+QO8$Q>QZ"^#@?NO@A\!'Q!<^#>".X!\#:"LQ@^IN(K
M8>#T *?M52(#\"F#BWMSI>_RW$KOY87'>B*/^B%O87S>54:A#,'P"0KVS]TA
MGE"H?8-%X=N6Q^Y- I)O;P$OT31"LQ8Q;L5;Y8AK!G@CP>M] SGX#)'A;2(5
M\'%>6MGW\OI*+X3%6\ [C_HO*R+M\Q7!]AW&YR<(IWMF1+\C1QZ@6'X(.QC8
MP6 B8'8"1Y;OT2K?>R%:T=Q"O-8C^1X,3V*O 7G4?Y#?CZ-V>2_( VC,OZ@?
MRG$ME/0H_0ZM>Q]:]S?:3K]"T=V#QOL%"O GJ,/O$:AOZ1-H]]^6?PN%O1;E
MRY5]&)_\I__ 7G/!X\I__)>U@>T_6 )2(!"(A19/!V<AN"K!T8#CM]'/U$T_
M0F/^0.O LV'YOJ#?TE;PS"$,"U#ZQY:O1?D$>O<CJ/8/81'+]^[*_HLW'P-#
MG,>TOP)>JX/3!)Q.X/2%]1'P*QE\N> HQ?%KX4<3?4'M\*67/J4!\ R#9PP\
M4_0^-/>[B,7;B,4_H.S?0.+>Q0"^"NM>0@39^V \^[_PW_Z'_/:V?Y$2./7!
M:0O?/!"[8/@4!YY,<!32>U0!CCIP-,.?#OC1"X9!\(P@-2?H98S)B[0#*;N
M"!S'Z7(9I\U+.(T^Q<C\MKSWXG%<EMO _>_^"_82*SYX->&C!5+,!9S^]$^*
M@C_)2/T<ND/%X*@"1SU\:*%;R(U'^S!NT'IP;:2KM W'WPV]?AC3R#E$XQ:=
M@N4G<70V Y=6<'P%C_C_6FGI?;&\W4H9Z6X(_^S Z853, 0^Q8$K'3QYF!Y*
MX5,U?*BGB]2*J:H+3/UT!KEQ"F-R@J9Q[#DZ0OMI$<R'8-D!'&W_<J;\0>Q5
M8>PO'.U9 <O_VTI;\=.5T^P-Q.)EY.9MQ.(IQ.(:8G$9>7&!$L&3"9X"\)2!
MIP:9UP"N5G!U@VL 7"/@F03'#"*QAW;A&SOQUSMPQ.U@F$%&;T/&;04S"_9.
M.W^R_(HXM25$_\1T^XI(/@4]36+$U "\MN!U!V<0EHAH<"730<J"3X7PIQPL
M->!JI'GDZ$[DQ@Z,R2QB,8.\V(IW-W,.TQ3G FWB/D^3"A_0!/\G&E-\2!L$
M#*U? ;L'YG-=:&\L?2^S_0\33,-8"B]A*3J#<^0XF=(B;Q7M%_C07F$H[1+%
MT9Q2*FT7Y]"L<A%M4ZZ@+<JUM%FYB:95.FF3RAJ:E(S2A&2*QB0[:8/J(HVJ
M7:!AM>=IG?I'-*1YCP:U&!H UK#09.@[\'U@B:G6"7K+!4L*'L_;8JG#E']$
M79'VJ^K1+DT;VJ'M1C,Z,MJB&T'3>@FT42^=)O5S:5R_F#;H5])Z@SH:-6BE
M88,>6F>XEH8,)VC0<);6&.ZG?L,SU&MTB[J-WJ,NXY^HPYCAL&AG8<1P_FV.
M&#AC^L?R<AT:_((/^#'%+SIBV<=G<X8:M-7$G*;,5M&DN0^-6830>HL8&K%,
MIG66F31DF4\#EJ6TQK*:^JT:J=>J@WJL!JC+:@-U6F^E=NN]G#;KDYP6ZZ<X
M3=9O<QJL?^#66S]4J+-F%.JLY/C$ 4N7-\8 ^OM**.K;$/C/EB&P:0=LVVRM
M3!.V1K3>WH[6.;ASAAP".&L<PCE]#G&<'L=43K=C-K?3L9#;[EC.;7-<S6UQ
M;.$V._9R&YU&N U.TPIU3KL45CL=5ZAQ>I)7Y?0FK\+I6WZYTP-^F2.C^ CO
MH_1Y&?PWL+1=0-FQ!!S \C*/][8@)N,N AIVT:5!5ROJ<W7F=DN]%3JDP0IM
MTBA>BS2!UR1-XS5*<WCUTF+^:FD5OU;:R*^6=O*KI$/\"K=)Q7*W.<52MR."
M8K<G!(5N=X4%;E\+\Z5_"?.DC##/50ZV#_0\.*_%(0>A?X\DR:^!V0Z;-@5#
M]_IP:8V7)O5XFU&[MP.WQ<N=U^CESZ_S"E6L]8H15'LF"2H],P05GOG",L\R
M8:G7:F&Q5YNHR&N-J,!K3)3G-:N4ZW5(*=OKDCC3ZQ5QAM>7RNF>?XK3/1DY
M/!CQF_#W=BS&(1EZ+QUY .Q*00D*.\9AQR ^[_*74%N $34&V')6![CRJOV]
M%2O\ H6E?A&B8K\XI4+?%*4"WVQQGE^1.->O2CG;KTDYRZ]7)<-O5"7=?ZLD
MU?^ )-GOO&J2WTNJ"7Y?J";X_@XPD@0?.=C]0.P_.UV$QE]"^7< I=?.+)2_
ML&,4=O3!CM80)6H(T:?:4"M.9<@JA=)@#\7"(']A7F"(4DY@E'*6+$$E0Y8N
M29?EJ:8&EJNF!-:K)05VJ24&#JO'!VY6CPO<IQX3>%8C*O!YC<C SS0B9??5
M(V6,>F0 HQ8%W,'XWX#^/P_^8_FH;Z&Q=Z#4V 0[UL&.;MC1$*5(U9':5!YE
M3L61#MS\""D_)]Q'F!$6*$X-#5-)#HU530Q)44\(R=:("RW1B VMU8P.;=>,
M"AW2C B;T@H/VZ,5&G9:*SCT6:V@T$\T@T)_TPP*832"@^5X,0&Y@#+\#/B/
M0!+LA=:?Q>,D7@_"CG;85Q//I;(X#2J*,Z&\.%M.=JP++SW&4Y <[2].B I1
MB8N*4HN.3-2(C,S0"H\LU Z+K-8.B6K5#HX:T Z*VJ@MB]JE%1!U4LLOZI:F
M;]1'FKZ1OP*,IF^$'.R>I"=0<IX"[V(Y:FQ(@FUX'(<M:V!'"^RH@!T%R2J4
MFV) F2E6G+1D)X6D)'?%^$1?471"D$I$?(1:6'R\1G!\FE9@?+ZV++Y2VS^^
M6=LO?HV6;\*$ID_"O*9WP@D-SX2;ZAX)'ZJ[Q]_3<(]C--QC&4T6MY 'E]C]
M0. ]""DP7XMSL@9ZKPIU-NQHPF=EL#$[4T3IF3J4DFE.B9D.W-@,*2\JW5L8
MGBX3!Z>%2V2IL6K^J:D:OJFYFMZIY9I>J4T:GFE]ZAYI$VKN:3M5W=*6)-*T
M9R2N:1^HN*3^HNJ<S*@!ZJN2&/6G<N5]H./@WP\9,->(>0D2;13/N_%> ^)2
M EO2"GB4D*]!<?G&%)UORXG(=U8(S?/D!^8&"/US0\4^.3$J7CG)JAXY.:KN
M.66J;KF-$FENGXIK[KBR2^Y.L7/NDM*JW*=%3KGOBQRR?Q';9S$J=IF,Q"Z#
MD3S)_G,P?#Y2C[FQ&?G8!BD(C*#\[80M=;"E$'%)ABV19<H45J9/(666%%CF
MR/$O=5/P*?7E>Y8$"]U+HD32DB0EEY)L)>>24J55I0TBI])>H6/IF,"^=$Y@
M5W)<T;;D*;Y-R7M\ZZ*?!58%C,@RGU$"Q,M](/ L@G-/)_(1.GPCI-FZ;OFU
M.#6M1'F0)PFP,6BU(OG5:I)/K0EYU=J21ZT+1UKKI>!2*^.MJHW@.]8F*-K7
M9BK:U1;S;6OK^#:UW3RKVO4*EC7;%2QJCG+-:FYP3:O_Q3&I^DG!N.(AW[B<
M430J8P3+]^8!_\$NS$V0R-L&B"8@R]8";7A= 7NR\%D,[/%'?*0MRN3<HDM.
M+>;DT&I/=JUN9-OJR[%N#>%:ML9R+5K3N&:MA1S3UEJ.<4LGQZAEA Q:9DBO
M^3#I-C])VDWOD$[#CZ13_Y"C7<=P 84SB/]1<"R >R?[VT"08^/K<4[@L0FO
MBX>@NV!/^!HBKSXBAUX%LNA5([-> S+IM23C/D<R[/,@@[Z _^<7T36U]?HB
M2+<OB;3[<DFKKY(T^EI)K7<MJ?1N(7'/01)U7R%AU^LD[/R&E-K_!!A2:F/H
M)"Q:')0+]AT09ILW(D.![DFB6KS.@TB*AY5!^%P*6(\0Z8_P2'U4C=1&]4EE
MU)*41QU):=2#1*.!)!R))L61-.*-%A-WI%Y^VQEVJ\NZ/?*?/1F\ ZD)!3SP
M"UQ'7=O/T#'P'V1_K0B\VS=CMMJ*KP$M6W"6XG7Z-%'$%)$/X B8 EJ <!HE
MX;0Z8 "@+)I&.32-$F :2]\TIMMI3,73E4CY=@#&;]HAO_7H!%3GV">8#GX&
M_B!:_Y .CV%DP#,/H;YE.V* KW;M>&QG"B #7/':"M #E.<@$2 @:2=*PYU0
MF3L- 2L<!';,HSR91VDRGR2_)=4\8K$30SL'DAT'X2AD_"QDZ[8?D0JH;[<R
MRUV9O>#8/@\3=R,\"%DC4 RD F%[B3PAG.T HP4BM?U$_ /@Q^%06@.(QR&4
MQXM0WHLHQ0ZC)#N,>!R&'8<Q+1]A;U..]#[,_D0W2 YA/ Y"NN^'5-Z/&G_A
M[^4[M,R#:QK'7\=>'83C5^#XF4 T.'P/8PP@F$V.$FD<(U)$.(G%2>#4"DYS
ML02),?5H$YU#F7S>#B62!Y9GE&F7,/5?PG1S":?_A4WX;!'?>0IX']^'QCES
M__^Y.J@&7+G@BCM.%'""R!E<9J>1 S!?\)].#'"9_KM#Y5&7Y :/Z"G(AIOL
MU3H8F^>D1"_ CI=0IMS!U'<'8W('@_XRG'CA6913'^ [W](LN,=7[M!2#\Y"
M<":!,QB<KN"SO$2D R[!M95.S-./=6+^Q^X4X,ZC[HB Z!U-HO<@(3Y<!3F%
M//T<2]47F![_C2G@2P3_WR#Z]PW@9=H([D%P-Y^6_UIT*GC#X*/[RMU9=,$G
MNKG2C7G$\^C*();O+OW/'2,?D?R.)>PND>^4B7Y"OMY#*?T[2K2_4#8\P)+P
M8$1^Q]8'&.@'[+_)"Z""^1SY#^XJ MKTZ*J01QT)^5U*BZ#9JJ#G&Y:O3OF3
M>J E!^AWJ,[[M $*<B/]"JUU#\KS9^B_'Z#ZOL.@?0OCOZ8/H#U_6?YUE$>=
M$!;OK'0G&.(^IL39CH0&8 :L OR(O4O(7Y0"GCP<OPS'KZ6?J F:NH.^A]K[
MC@;!,TS?0/%]15/@F86*WPVMR5Z=<@:*^BEZG_X!'?[M<@?D[LJNC$>X\W]T
M QBH\+^@PG\G>_CF!>M#X5,".++ 402.2G#4@:,%')T(?1]\&L(PC()G D.R
M!8QS4-(+X%O"D%VAE\#T+#0^>__8FV!XYG_A<?Z'RZI< #]UX)\E.*486AFX
MHL&3"I6>"XY2<%2#HQX<K>#H D,_>-;2"[0>D=\(!3\#KMU(W<,X7<[#BMMT
M"4>X"(\N@.G\_\+C-K WWOUF>5>&&OQ[M"O#!UQA2,,$\&3@%,C'$<M@?PVB
MW$ W8,>3L.,J['@"N7$98W*1IND<-/EIZ/63^&\)WSB&(['WD67OJ\M>H_4(
MBRL="7E'1I[*'RVGN!+&2@^<-H@ANRM#!JXH3 /)\"D+'(6POYS.PHXSL.,4
M<O0$=2_OS#A*(SCV)(Z]#5/I;EAQA/8A"GMP4K%9L@N1G@?CSA7,K=C [@IA
M+SY[?Z7Q^1)R\Q9R\P:9PC='Q,\;?"'@B@5/*GS*!D\1>,K!4PN>1HQ^&^W%
MN;('.;H+8[(3^;D##+/XQC98NA6CLQE9,PUOI^COY7ON3*Z O=G/EYC>WL-4
M^QKPG**\(?P$B>"K+B)I!4X7</K1 0H'5SQXTL"3 YXBL%30=M@Q"SNV43NX
M^L"U#CP3X)G!__?1.(ZR 1Z-+M_;Y1M\^L?R_7]8# '?84K["-/\76-,>6Q'
M!$OQ12S)I_E0023!LF2$H]B!TQU\,G!%TC9. FWAIM.T0BYM4BBBC;P*FN"M
MIG%>,VW@=]$H?Y!&%#?0.L4M-*2(R&"16:-XC?H%;U"OZ&OJ$?])W6*&NE;P
M;_"_;8'I&U/9=2QY%['<G$0Y<%@?2YHRC^;Y6C0KLJ MXE4TI>Q-DY)@&E>-
MI@UJ232JED'#ZGFT3KV$AC2J:%"CGM9HM%&_9A_U:HY2C^8T=6GNH@[-8]2N
M=8U:M=Z@9IUOJ$GG 37J,/_!QUAN7\.4?A/+W&4LN:?P>,0%5;<MEGS$9HNF
M,FW4-J(Q73L:T7>C=0;^-&001@.&L=1OF$R]AIG48Y1/74:EU&E40^U&S=1J
MW$TMQFNIR7@C-1K/4;W)8:HSN4*U)J]2M>F75&7Z)Z?2E.%4FC#<"N!?]E@&
MV*X,NRLE$/&785GW1=GA#G[$9MQ,0".F.C1D;DG]%JNHU]*;NBR#J,,RDMJL
MXJG5*I6:K;*IT:J(&JPJJ,ZJGE9;MU.-]0"GVGJ<4VDSRRFW.<0IL[G(*;%Y
MF5MD\P6WT.9WA0(;1J' FN&Q>,L->0#>)\*0 U#=AR-0]6.YG?5'U8^8##MR
M:(VM!G7;F5"'O3VU.KAQFAS\. T.H9PZAVANK4,BM]HAG5OEF,>M<"SAECO6
M<$L=6[@E3GT*14[K%0J=MBKD.^WGY3J=X^4XO<#+<OJ4G^ETGY_AR"@NPX%1
MO N?GP'_)?8?@U &'HQ#31.-&* ,&D-L!F!'I[,RM;H84*.K-:UV=>94NWIQ
M*UUE"N6NX;Q2UUA>L6LRK\@UBU?@6LC/=ZWDY[HV\G.DW8I9TF'%3.EFQ73I
M7D&J]+0@1?JL($GZL3#1]5> $2:ZR'&'[0R!\WPBQ@&EUP*P \\W1;.[0J!"
M84>+IY#J/'6HQLN<*KP<N"6>;@I%GK[\?,]@Q5R/2,5LCWA!ED>:(,,C5YCN
M62I,\UPM3/'L$"5[#HD2O3:)XKUV*\5YG52*\;PICO;\0!SE>4\<Y<'(X<XH
MO1B.,HC=G8.2ZPC*C+U8XF?34 +#CK6(31?LJ/?G496?)I7YFU"1ORTGS\]%
M(=O7BY_I&R!(\PD5IOA$BY)]DI02?;*4$GR+Q'&^U>)8WU;E:+\!Y2B_2>4(
MOWF5,+\EE5"_IU6"?=\#?E$)]F&6$>+-*#_'[A""[Z? O<A>'015O UE^1CL
M&( =[;"C!N-2$B2A@F!#R@VVXF0&.2FD!;KSDV2^@@19D"A.%B&.D<4K1\G2
M52)E^9)P684D++!)$A+8)PD.')<$!LY) @*/2?P#;TC\ M^5^ ;^)/&5,1*_
M #EN(0:74.Z= /=!MA2'^M^"QPVPIP]V-,.."MB9'Z%$61&ZE!YA3BD1]MR$
M<%=>;)B7("HT0!01&B8."XU1"0E-D02%YJC*0LM4 T(;5/W">E1]PS:H^H1M
M5_4*.R+Q#'M2XA'VCHI[Z(\2]U!&U3V$4?4(9E2?3D:9"K^/@WL_5/\<NS,%
MCZ-XW0,[&F!?*:1"5IPBI<9J45*L"<7'VG)B8IT5(F(\%$.C_81!T2%B6524
MBG]4DL0W*DO5.[I$U2NZ3M4SNEOB$3,J<8^957&+.:SL&G--[!+SMM@Y^@=E
MYZB'DE61C&15!".Y#HYS^2MWB8$LVEZ%?,3C,&SIA!UU>= :641IJ5R*3U:C
MF&1#BDRVHK!D)VYPDAM/EN0C\$L,$ODD1HH]$Q.4/1(S5=P2BU6DB:N579.Z
MQ"Y)HV+GI!FE54F'14Y)5X4.26\)[1._%]G%_RVVBV.4 96K[-UZX/=A\.ZI
ME>],V;@:6@.E>$<YT6K85@A;4C!6D9EB"LW4I>!,<Y)EVG/\,ET5O#.]^)X9
M,H%;1KC0-2->Y)*1(5J5421RRJP5.69V"ATR1P3_'U]O 5]GD?W_G^=*/*%-
MX^ZNC;M[TWB:)HTTTJ1MTC:5U-W=W06*%(H56RA0W':!!7999)$5;%E6<+F_
M]W.?FY+ER___ZNOTWMP\=SYGSIR9.9_)F9G(Y@-6$<TW684W/V0,;7[=$-+X
MN55PPX\V0?4FVZ ZD]T#E'\'^#>">V*NEIFR'5G+^X5\-A-=IO'[R>B2WV$E
MF>W.DM[N(ZGMH9+4'JLDMB?KXMNS#+'MA<;H]DIC9'N#541[NS&\?:8QM'V1
M(:1]O3ZX?;\^J/V"+J#]09W_M-<4O[9_Z'VG_F#T;3%9^;28K*]@\]O .@_N
M<>CI_L6,S\B:$9$%"T1FS!-I@3)68J-LVFEBGX/$][E+;%^ 1/=%2&1?@A+>
MEZZ$]N7K0OK*=4%]=;K OC:=?]\,Q:]O@>+;MT[Q[MLK7KWGQ:/W?G'O>57<
MNS\3]Z[O=6Y=)KUKI\EP%_6\&?PS8!Y=#O=?2;^$#JWF=7@9_H@^C=#%TOEP
M;VP3/<<H(4/C)6C(2P*'@L5_*%K\AI+$9RA+O(>*Q7.H6CR&6L1MJ$=<AN:)
M\]!J&3>T2YP&SXC#['O%;M9+8C_S(W$8^%8<^TWB.,.DW#%/.R7F%)B'U](G
MH$&;H2#+U^./:T3:T:=FA4@!^B0M$0GG6>\1&W$;F2 N(S[B/!(BXT=BY(:1
M%'$<R16'D7*Q&VD0FY$.L1H9%,/(,M$MVL9  ]]=J%XY ED:?E]D'MQ_[@^B
MS#')K91Y'IP38!_:0I_8CC_RE9&M(OU0Y2GH4\'OLM;!/=$Q$+W<$-LUMF)8
MXR*Z-;ZBK FC\>(0>/\:!K0UU0C.O@9'6DT#KZ:058=$5JI7KT#<EL$SE\)W
MEWR+_"075S-';,(7=FB9*=OV\"@RE_==.^D/.[3,E&0D'-V\D7&(8;L>YX7+
M;7=#","V$W!L)_#8GDDA3+[;&'RW=_(*M]M&);>JQZ] ZC=!(C= #->CP[KO
M$9-Y#>;T+BTS98\E,V6$UWXU,^6 EIF2B<0B 8@+G]D@A(H( =]!1P0]#J+'
M0?0XE*!-_ <97 ^IDP^\_R#.=A"@ R>TJVCW0ECW?(S1OV$@,,DYU#LYFIER
M3,M,&43:>5^#Y/$^D:^&(.XG1>P0@EH41\ZH@CW.8(\S!(5G";S.TBYGT>.<
M&@P1")QKTY9CSZD&IQ)G:(_3D.A3^,1)?.+D#^;=04<I?R?EKJ',X;/T!:0!
M*3XGDH+YPB^(>-THXG@3A BJ+->S4Y#;1H7@^-(X)AX"T<L$J'<2(-Z)/>["
M-^[JXCV=ZTYL<2= E^]C4()%W($M;O_*O#MH+U@;+#<%S0!G"CCEX&2 $T7Y
MOI=$G'!IG;KF<I=%_B<[!5%W[3R@, G;:;MU'O47>9P@^0GT> H]GF&0>YJ.
M]22&OT;AU_#-Q]]$/I4#%_YW=U ;>)-N9SP"+Q8L?[#&@Z._?\R:R^AZR.AI
M*>;,E+%K%+3/J_C):]X$[02L;Z/'GYD</Z"??, @\"%M\CYZO$=!?WY%MM^B
M[0Z:0ST[[Q2IQ67RP4Q03V<!<\(C] $5ZYH%Y]DQZRYJMLB+\G/&B)HI,GJ*
MB/JG;/745O5/JE^$BOR7_O(5@=(W#+C?TLF_Q:F_PP#?JFL@NC&\WS!F_2%.
MM)-2RY!Z./DTV&JO?"^S8?##\HV,R->R'/:X!JZV4?X+F_HW[.H+\VTII^#M
M%V%4=\LG&.HCV/-?+%D9;XEV(JBZ_O%[RQK$_ZX]J.*$^"!1L,(T\(K F@Q&
M"QA=8/1;;DI9()_!MS\QWY:R%KZZ";Z^@^KOD_=A@>_!0M^%";\%(_\#S/T5
MGOPM)8X]%?2YG[,R_D>''^&9W\(SOY10-$\"*X_Z5%"7!C#:P.@V[T[Y,WS[
M'7CN6^CQ)KS_#=CCZ[#*W\LN\-3=*:? N9EFNX*[/(<U/L!]OC:?!GIUC#P\
MAONKPLA)70W@3@ S@&_%49=,;%<,SF0PFFGV#NS72_FS<(>YE+X0G*749Q5<
M?3UX6\';2_E'<>'S=)?+:/$8W>@/M,P7UW>E7!XCH_CJ1="?BY:5\9XXRA]I
M#S4KX[>2#%8N..6X9!WE3Z4NG?((?/LWZ/$0>CR 'O>AQQ59#<Y&,'; M _(
M)6QQ*P/)S3QQ$\Y[(RUVGM8]!^)8^656QI_,2WXVU,^->JE9&7'8*X-2"L&I
MHCX-U*45_;MH[3Z&IUF@S,,#%X&S3"[@H^=ELYS%/T_+$3G))\?YQE$L=(36
M.VR^Z]A$:YGD@$6^M>"_;^E:+YJ7/A5L>0.X/F!&@)=$G;+!*@&GFE(;T;^5
MH;J+FO:!,TM.H,<Q]#A*7SF,;QRDG^SGWUXTV8VF.ZG)#O.YLI_16C^8S]Q1
MSQ_>+";S&M '.I'7;>#_R..*-A3=(];4TQ4[!H(9 UXJ6'G4J0R<R> T@M,*
M2A<]H4_VT&=WH\=.62S;\8UM]),M?+()S39@I75XQEJ\: VMO0K+KQ3M+&15
M/F(8^1-#ZPL,:8]Y,=PRI-SIH"4J7A 'ZNE)*:'8+QZ\#+ *\/QRZE0#3A/U
M::,N76#- &L0K/E@+<,SUH&S XS#YA92SU-9C%<M4MZ7A;K_R *]2>9;Y'VF
MNY<#&6Z9=A^, )\A[1:&^G-\?MQ&1UW'@^LG.W21LE6?))N,6;+!JDC665?(
M&IM:66W3+"MMVF2%[7199CL@2VSGRF*[$5EDMUH6V&V3^78'99[]>9EK?X\,
MV3\KLQT_D%E.7\I,)Y-9!I"W AAV8QC^$]534:D_K^>8:HZ',-4S!>YPM);-
M#NZRWBE(5H^+E97C4V2Y<XXLG5 LBUVJ9)%+G2QPF2+S7=IEGFN/S'6=+4.N
M"V30=87,<MLL V[[I=_MK/2YW24][L](M\?[,MWC2^GR,$FG)LIK44P#\/L'
M&<[O@&/?Q.O)%.()0J*=A (;?119Y3Y>EGGZRF*O"%GHG2CSO3-DGD^^S/$I
MDT'?:IGEVR S?:=*OV^7S/#KEUZ_>=+CMU2F^V^0+O\]TN%_6J;Y7Y:V@"=E
M:L"[TA+P'V5*@$DWQ5^3WTW$#YC6KA00 L"QSQ$.'LUE/D]G/B4464W[+ ZP
MEP6!GC(W*$0&@V)E5G"*# 1GRXR0(ND-J9#ND!J9'M(DG2'3I#VT5YD6.JBT
MA8XH4\/6*E/"=BG-82>4QK!+NH:PQW5U86_I:L/^K:\),^EK0DT&59[/8+H'
M_^XR;6?.:34$(QS<F4=,P>^6TS;#$=8R&.$J Y$!TA<9*=V1B4I75+K2$96G
M3(LJT;5&5>FF1M7KID1-U35'=^D:HV?J&Z(7Z.NB5^EK8[;K)\<<-4R*N=50
M%7/54!'SIK$\^@O$9%4>I<DSZ@U!I80V\.^;X-@GD -56EBZ-A\;H,=@HD[Z
MXL;+]'@?Z8@/E;;X6*4E/EG7')^E;XPO,-3'EQGJXB<;:N*;C)/CVXW5"3.,
M50GSC)4)*ZS*$[=:E24>MBI)O-FZ*/%AZX*$-Y!_VA3$_X28; KB3#9/8OO[
MP;R=$.,\T_LQ^/Y>WF_ALU7HMA![S*1=NI(=I"W90UI2@J0I.4JI3T[0UR2E
M&:J3<HQ52456E4F55N5)]=9ER:W6)<D]-L7)0S:%*4MM"E(VV>:E'+3-2;G)
M-COE(=O,E->0?]AF)O]HEYED4L7V<=K@"MS^-OCW.?CU461W$[Z('LO18QYZ
M]*%'6Z:--&>X2GVFO]1DA"N3,F+U%>G)AM*T3*N2]'SKHO0RFX+T&MO\]"FV
MN1E==CD9L^VR,A;;961NL$O/W&^7EGG!+B7S ;ODS%=MDS(^LTM*_\$^.=UD
MGYQFLG\4G'NH^RTMA+R$P(?5S!0X]@;"\J7H,8<VFHX>S?D&J<T=+]5YWE*9
M%Z*4Y4;KBG,3#04Y:59Y.;DV.3DEMEDYD^PR<IKLTW([[%-S9]JGY"ZR3\I;
M;S<Q;Y]=8MYYVX2\^VWC\EZVB<O]U#8VYWN[V&R3?1SR,#:XB[I?G$:XW:DE
MK>^ BZ]#EQ'TF U5Z20D;<!>E<6.4E;L(<7%@5)0'*'D%L?KLXM2C!E%V=9I
M144V*465MDE%#783BZ;9)1;WV\47+[2-*UYK&UNRUR:FY)QU=,E]UI$EO[.*
M*/[$.J+H>]OP I,=8O\@-K@#O!N[M%-JU<R4[;RNY>>%?#X3^[333G7H6E)E
M*P65KI);Z2=9E6&241FK2ZU,,B179AH3*PJL$RHJ;.(JZVQB*]ML8BIG6$=5
M+;".K%IC%5&UQQA>==885G7%$%+U6T-PY<?&H/+OK(/*3#9!I2;;^\&XU*GM
M4#H^H&6F;.5U-2'P L+Q 7XW#1O58*N">H-DU(V7M#HO2:D+EJ2Z*"6A+E$7
M5Y>NCZG-,T35EADCZVJ-X76MQK"Z/D-HW; AN'ZU/JA^MSZP_HPNH.Y>G5_=
M2XI?[4<ZGYIO#3Z334:?:I/5O>V,S^"?!?OHD):9L@59Q?MA/NOO%YF*72:A
M2PYVF=AB+_$M;A+;XB_1+>$2V1(GX2TI2FA+CBZDI407U#)9%]C2HO-OZ5'\
MILY3?*>N4KQ;=HI7"[-?R]WB/N4%<6_^N[@W?:NX-9KTK@TF@_G6;+!.JR?E
MSH<&0H<V(RL7H,,\D1YT:28<+\<NF>@2VV64T,[Q$MSI)4&=01+0&27^78GB
MVY4A/EV%XM55)9Y=3>+>U26N74/BTK5<G+NVR[C.$^($>7#H>%8<VO\B3FU?
MBU.K25%%W2APH[I#"8I^"!JT:QG4>+G("E[G+,8?T:=N&-Z';5*@C1'HXS-@
M*YX#$\1]P$=<!T+$92!&G >29?Q CC@-E(GC0)W8#TP3VX&98CVP6(S]FT7?
M?UAT,VX5I>^:Z'K?$5W/%Z+O_E$,TTUR*_CGH,7'EVN9*3NA'QO7B2Q9(S)+
MW9V#+I/0+9=G$M G&/MX8"^'87NQ'785ZV$_L1H.$\-PO.B'TT499M ;ID,/
MXVC#-/(\OC"/ N?"K>9").? K0;A>+/^@</#NV?^)!<I^PQ8Q]9KF2D[H*5K
MD06\[]T@THA.I>B3M@KNR7-^*T2<T==J.<'/<CCN<B;XY00@RR.UR64Y$^ R
M.O)R!MWE.-$R#+B,+R_=1<4@THLA<(O@NPO180$ZS/]1+O#K4QNU/)1]._$%
M'EW&Z^ .^B2?3=X*_T>GQ,WP?_1R1^P1V42@M<D6<<9P!& ;X=J;T&,30<A&
M!M:-#'X;L<5&G'H#AEQ/0>L@^&LAL6N(6E?#N5=^8\Y%.4?9)RQY*#LQUUID
M =++STV6$U)2D<C=^ $R#C'PLYB%0'0/>NQQMN2D8(^]!"1["4#VT"9[&53V
M,N#MI<'WK-6V_ZA;+W8\R:1(%+_UO\B/YMU!QP_0#J-Y*.I-/4?4VY)%JI!L
MWL<B <@$Q(K?BYJ'<GRL$ P?IUV.>U A K.3Z'$R%2G&R QPI_H0;'$2XYXX
MQW,/4@91_!$8S>%OY=1H'LJ)G_-0.I%:I !)/*.>4"M"."8V?%W&YJ'<-$8N
MPO<OVA.$$"#?XLN@0[O<FL9DB&]<FHK0J2ZMU:Y(O@V2?^MS/(<M;OF7^93:
MW>"LH_P%E-^+-()1 D8*98??+.)YBXC=Z)K+[191<U'N'+,F<K=E7>2*NEOG
M!H)#?/4W!,B/$"A>+==NT+E*Q[J*DUVE0H]@BT?PS8?_^O/NH(N,R^"U@%>A
MWM1\"1\ QQL<A]%UERN6]9:Q)Z5<ST,9LQZBYH:\@)_\%J+P:C#D!3W>K!1Y
MFTGH;=KD39SMCX"]P1??>%FV7M1V!\T&<QJ8U9?Q 3!C[A7Q!<M1Q?J-_)R'
M\L28=9=?RT-1<T+4'3/J'ZX_I'W^CK]^2I_Y)W[Z'\:-+QDSOJ*#?X4>7V/\
M+R_+_ZX]*);U!U_13DI53PDIEI_@,S]("VRU"V[8#S\>@BDMD"]A+O^!R?P;
M/O,%3.>?YMM2]L/FCLDG.,W'--C?S7LQ7D.E?YIWI;PY9OU#O:7D^5]P?TWL
M$4_Y4<+E&SCW5Y)ON26ED5*F@=%CN2EE+N4OE+_"M_\">_L WO\^K.L]^-V[
ML+*WX9E_@J&^1L/]#A;[(D^_(-^;,=6U#_544#4?X[%?T>$[L0+7A7H%@14/
M5A;?+C'?TOJ^3*$^G?(6_/)-^.4;\,O7X;F_A\V]"KM[&;;W.QC@2S#0Y['%
M4W2>:SCL8Z!=Y9L/4QOU9-!147>E7!FCPX^B7?CS.>WQD8P#SY=O18&5"E8^
M.)647T]=6JE'ESP#OWP*/9Y$CVOH\3A\^U$8[2,PSX=@OO=CBRO8XAXZTUU\
M<EE>H3M]]G]VI5AVIIA/Y5 /VQT]&4/-P7B%]GA10K!9 EB98!13EVK<LY$N
MT0;&=#!FP&1GTRV'Z:8CM/YR<-92[A9:80^<_2A#QP7^W2/G<. SE'Z:%E9W
MHYRTR E$S8'YEV7]Y1W+$M_SM,<3,@%,?_"BY#Y)H91<<$K!F Q&$^6W4?YT
MK#T#C-D,7?/D+'J<@6F?PC=.TB;'Y0!:G(9Y7X([/X*WOB%[:>4]X.X>(XS8
MYAP0=5?,;RU=[JIY"'"@?IY@AE"G./#2P<D'HQR,&O1O J,-C"XY@AZ'T>,@
M]C@ P]^'C^Z1C;(+A!T\L8UO;Z$FF\SGRGZ$UWR/:.</JZ)> O4.4^!OK42>
M-&A#P3WFH= H%\49&_J!&8&')8*5"4XA]:F@/C4@-('3!DZ7;$>/K>BQ1>:#
MM12,M?38;?Q_$&\]9]Y#M((:+J/G+#7? VU"6TT^!/O5"=2?Z>8W[@RY#"FW
MV6A3PBG\XJBX4[= ZA6-IR53:C8X1>!44J=:ZM$$5AO>.!VL?K"&\(I%8*UD
M]-A$Z^RE!Y]"L]NQTF.TV)]DCGF%\P?SW52JO.5*^S/570T1N9?A_3:FW_/>
M3&_CM3]/[&;,VB9>E!8*7AQ8J5@ZESH5@U5)?6K!:I8199HL5+IEOFZF#.N&
M9:YNJ0SIU\N@?K?,TI^0 ?UMTJ^_*GV&-Z37ZC/IL?Y>NJU-9OD]F$\RU3X0
MSS2DG@H22_WA^X?0:Q?#_68[HZPU3)"51C]99ATABVT29:%MNLRWRY-ANQ*9
M:U\E0PYU,N@P168Y=,B 8Y_T.PY)G^-BZ7%:*]U..Z7+Z;ATW'";M(][5-K&
MO2FMX_\I4YU_1$PR=;Q)7F**?70B-F":O16.?9;7H_R\)YH8G^EF#=/?DG'V
MLG"\A\QS#I*A"=$RVR5)9KID2K]K@?2YEDFO6[5TNS5(EUNK=+I/EW;W63+-
M?8&T>JR2J1[;9(K'$6GVO%D:/1^6>L_7I=[K<ZGS^DGJ/$U*+?)<HK81]D["
MKXMP_5.\'N3G'4QUZ[')<MIHV,<H@YX39,#+3_J\PZ7')UZF^Z1*IV^.M/L6
MR33?"FGUJY46OV:9XM<A3?[]TN@_+/7^*Z0N8(O4!!R2R0$WR:2 !Z4JX/=*
M9<!G2D7 C[J* ).NPM^D>XIZ/P#N[80\%^"VQTN(*PNT') U3'4C<<26H8KT
M!CK)]$ OZ0@*EK;@:)D:/%&F!&=(4W">-(:42GW()*4NI$&I"6U3)H?V*I-"
MYRA584N5BK!-2GG8 5UIV 5=<=C]NJ*PEW6%89_J"\)^T!>$F@P%(2;#M1S"
M O!OJZ =JM3;:?!#0HY-A(,K^-T"]!A C\X(.VF-<),I$?[2&!DN]9'Q2FUD
MBC(Y,EN9%%FHJXHLUU5$UNK*HUITI5'3]271L_5%T2/ZPNCU^OR8?8;<F'.&
MG)@KAJSHWQHRHS\V9D9_;\R,,ADS(TW&1ZGS/>#?,AFN!=<_1!BZ$YZ] 3V6
M%1';H4<?>DR-MY+&6&>IB_.1R7$A4A47K53$)>K*XM+U)7&Y^J*X$D-A7+4A
M/[[)D!??8<R)'S!F)RPT9B:L-68D[#&F)9RQ2DFXQRHYX46KI(2_6R7%?VN=
M%&^R3HXS63]<HOW92[VE1STA]B"R@_?KT&D)>@RAQW3:I3E5)Y.3G*0JR5/*
MDP*E)"E"*4R*T^5-3-;G3LPR9"<5&K.2*JTRDNJMTI/;K%*39UBEI,RW2DI9
M;34Q99=58LIIJ_B4NZWB4IZWBDWYFU5L\C?6L4DFF]B))IN'"+'NJ"-$;69,
M@ [L1[;!L=<T0$708Q8VZD"/!NQ1D6$G)>FN4ICA)WGIH4IV>HPN,WVB/CT]
MW9":GF],3B^S2LJHM4[,F&J=D-%K'9\YSSHN<Y553.9.J^BLD\:HS#N-$9G/
M&<,S_V(,S_C&.CS=9!V>9K*Y'YQ+38Q+K83;T[0\E*WPZ]7HL@ ]^FF;:>A9
MA[V*\ZPD-]=9LG.])2,W2-)R(Y7DW 3=Q-Q40T)NKC$^M\0J-G>R54Q>BU5T
M7K=59/Y<8T3^"F-X_G9#6/X)0TC^97UP_C/ZH/P/]8&Y7QL#<TQ6@=DFZRO8
M_59"[[.$O4>G:WDHFPD]5W9HE'$&^K7Q3 WM55"FD_021TDI=I>DD@!)+ F7
M^)(X);8D61==DJV/+"DVA)=,,H25-!M"2Z<;0DJ']$&ER_6!I=MT :7'=?ZE
M=RB^I4\KOB4?*#[%7^F]BTQ&[T*3U=W8_6;PSL#K#ZLI^L@F9(5*5Z&+?=BE
M%1VK\9,\;#*QRE;BJEPDILI'HJI")&)2M(1-FJB$3,I4@B<5Z@(G5>H")C7J
M_"=U*G[5@XI/]3+%NWJK>%8?$X])MXO[I*?$K>I]<:O\4G&K,.E<RTWZR]C_
M)O!/#= G9C,^0T4V(LOA^'/1I1==IF"7"I[+0M^X1H.$U=\@(?4>$E0?( $-
M$>+?$"^^#6GBTY G7@WEXME0+^X-[>+6,%-<&A:+<\-F&=]P1&YHN$T<ZZ^)
M0]V[XE3[7[FAQJ3<,-FDW#Y=VZ%T8@CN/X]^":_?@"P;5F_*H4^@5P.TM00]
MT] E"KOXM=J*5^L$\6CU$??68'%MC1:7UB1Q;LV2\:TEXM1:(PYMK6+7-D-L
M6Q>*=>MZ,;8>$,/4FT0_]1'13_FC&*;\0XS-/XA5DTENI?QS8!U;0)]0;TQ6
M*3*R#)D-+6I'EQI^7X N2>@:AFT\>W4RKL=!''K<Q*['3VQ[PL2Z)TZL>M+$
MT),ONAX&NAXZ6D^W2#<5ZUZ-0)*GPR>Z("V=D)#V3W#VKY&?Y*)Z:[5Z4NXR
M^L1*[918=7?."._[U=TYBVF'1;0#.L:B3P 4VA6;V0Q9BS((SQUD4AMD\AV,
M5!>5D2R$07^0#C^(H\VF86<OIY-OATQ#+ >(D/J)V&80O?9^A?PH%RC_Y HM
M#V7O!OKE)KCO1OQQ/6KS6=TJD2)^GTPQX4M%O+"/$WKI%L.A%CN@+!QWQ =A
MDAUALAU1)QDFOT5PJD4X\R(,O1 #+]Q,9X>TSX?,#4/.YA+!SL$.<TQRCOH>
M7Z_EH>Q!U8W0\R6JREOI#WRM"GVRT"V.9P+6B;B@ES4B9K%&G! "C35P[35,
MLFN9;->D(PPH:^C4:W"B-1AP-5]>=5#+1UEQC<8F@E_Z7W,NBKH7Z!B8!W?C
M"U# U<@\M>EVB=3O%"E$DM K#/'@.7M$5-DQ*@2#V]%C.P'9=O38@1X[F.1V
MT"8[&&1W,,CLP)&V8\AM@&PE2MQ,U+H)4KJ1B'[#]W)J3![*!C4/!>GG_90#
M(N5(.A*%^" W(#IS#@K"<P33FAPB&#YDSWL"T\,$@D?0XPB!V9%<"F=P.Z8.
M@-CBJ+KH=(QG\8D#K] )\,M]WYA/J?UE'LHTI!K)0>).B/B?%'%&#*?D?_-0
MSEKDW.@KP?!Y M$+^.F-^,=-:G!8H$V(-ZM'=N/D-V/DBY#]FVB/&V$T%SXW
MGU*[XY1V6_(\RIF.U"$%E)MX7B08T[G>*&)E7FL1+0=E- ]E=&_.Z)J(>5T$
MHG"7'<$AOGJ%_G(?>MQ/@/( ;?(@G5"]KOE!*O? W<A+R ?:7J#S6AY*'SC-
M2"E8*>"$WB;B3ODVH_M_1M="1M=#1G-0KI\<:UD/>4PTLO(L??<%/Y'?X1^O
MHL?O&>!>H8^\BI.]"N@K#R ORF8PEZI[@:A7*YB58&: %PF>%UBVH_M_1M=<
M'I6?3T@9/35V="UD],02=7_,&Q;R^($C1!)?_11[?%X&L642^C<=_ O:Y',J
M_OF]O[+^8"?:2:D1HIT2D@\;J9+OX+K?R#3Y2GK@A[/@R'-ACHO@Z<OD'S".
MT;THG\!(/L91_X[#J+?%OH_R;\O+YOMJ1V]'>1WYG64-XLE?70.QA@>[@1<"
M(TN0_\"K_@77_1PN\ZFTP!8[Y:_PN@_A=1_ G-Y#CS^CQ[NPG[=A7F_1<=^$
M<;X!&WT%GOD2S/P%>08>_0&8WYKS/IZRK'\\8EF'^-\<$#4/0D_]QH/G3UUB
MP$OEVP5@5,'2&BB[35Z#U[T*KWL9IO8[]'@)1O<BK.L%!BYU+\I3L-!KV.(Q
M\TVMM].$CX#U!DWZ+UQ(6_=0Y1ZY?CKH]1P0=0W@$_,:A"-U\I(_2)C\7B:"
MDTWY)=1C,N4W48=I\KATXQK]8 R",0S&8C!64/8Z:KZ5\O?BPL=QY8MTERNT
MR@MTI8_D9FHZ=A^*Y710<PZ(>@&SNJWJ3V:7LN8;KM@M@/K$@).*R^>!44YI
MM93?3/G3*+N;6O93_B#E#]-E%X.QDK(WR(VTR7D&L[/XQ1F>.H76)ZB9>K_Q
M$5 /CY'O+/CJ^LOK%M=^DO9XY'H.1ACV2J"43' **;\2W6LIOYGRIU'^=(:L
M&7(2/4Z@QW'T.(J/'H$E'\(_#X"ZCV_MH;2=M-X.O'<[N-O&B'HRB7H \6N6
M[O6HI2O>);8,/VY\.Q"\*+"2P,D&HPB,2O2OI9;-8+2!,1W+SP!G$$^8#]92
M<-;2(MOPC@/F,T/64^(Z6G*-^8R9;Q#M'B95_FJI_[-,Q5<5;=BYPSPDZAF"
M;P#7BSJ%@A<+5BHX.6 4@U$)0JUL08_-Z+$1/3;0+NME"/2%8*R@53;R_QYZ
MS0E90HN-T*KJ6;OJN3L+P%9E/O(VT^^+#/&/,>W=Q_!Z.U/@349M2C@B-K)?
M7*B;'YCA8,53:AHXN>"4@%-%/6K!::97M%'[Z6 -@#47G"7FC)!Y6'\.)0U1
MJ]D,J+/H43-ICP%&G7[P9ZCKI6 _Q3#V8*"6<G@30^LI=Z8_1^W/$]O$ 5QW
M2@L$+PJL1+ R:/4\ZE1"7:KP@CJPIH#5#E8/6+/!60C&*NFC17JQ8C=>U(5'
M=S*0=C!ZM3/:30-?E9<"M /![XEA&B+\.!O%%,O4NY?0:"M3\5H;'?6\ 4PO
M2@T!+T;F*$DRJ,N46;I\F:DOE7[#).DSUDNOL46ZK3JERZI?.JWF2;L5UK'>
M)*W6^Z7%&B^VN2)--B](H^U?I<'N*\0D]<@SX#_$4'Z9$.PF]<\>R4SM:@@2
MSER&?LNQR0(':YECXR*S;/VDWRY,>NWCI-LA1;H<LJ33L4#:G<IEFM-D:;VA
M45K&39,IXWJE:=P<:1R_5.K';Y1:YWU2XWQ.JIVOR"3GEZ1JPM^E<L*WB,DL
M3X!_'Z'7I6PM_?0HKWO31+80GJ[&)B.TSQ#A0)^SHTR?X"$=+H$RS3526ET3
MI,4M39K=<J3)O5@:W"NESKU.:CU:9++'=*GVF"U5GB-2Z;E.RKWV2)G7&2GQ
MNEN*O9Z7(J^_2J'7MXA)4>715&TOT"V%A"5,KX=YW<7/&]4<D(F$H(2I X0C
M'=XVTNKE(E.\?:71)U3J?6*EUC=))OMF2+5OOE3YE4JE7[64^S5)F7^'E/@/
M2''  BD,6",%@;LD+_"4DAMXIY(=^*R2&?@7)3/@&UUF@$F7Z6_2/:*FO,*K
M+S*MGJS0TH%W$(ZNRV-.SR3L18]>])@:8I"&P'%2&^@EU4%!4A44*15!\5(6
MG"HEP=E2'%RD%(94*@4A]4I^2)N2&]JG9(<.*UEAJY2,L!VZ]+ 3NM2PR[KD
ML*=U26$?(%_IDT)-^J00D^$APO [P+]1W0M4;3F=I%(+B]40?1 ]IB>)-.&S
MU>'V4A'N)J7A?E(<$2H%$3&2%S%1R8E(5[(C\G59D66ZS,A:77K45%U:5(\^
M)7JN/BEZA7YB]#9]8O0Q?7ST[?K8Z"?U,='OZ6.BOC3$1ID,L9$FHQIFJ3<E
MGZ_5;@G>"S79 K==Q6<+H2HST:,#/>K1HSS.1HIBG24_UEMR8H,D,S9"28^)
M5U)C4W0IL3GZY+AB?5)<M3XQOEF?$#_=$)<P9(A-6*:/2=BJCTH\JH],O*0/
M3[BF#TMX5Q\6_U]#6+S)&!YG,E[!]K>">19>?01ZM@?9Q/L5Z#0?/?K1HPT]
M:FFSXA2#9$]TDHPD#TE+\I>4B6$R<6*,DIB4I(M/RM3')17J8Y*K#-')C8:H
ME$Y]1,IL?7C*$GU8ZF9]2.H177#JK;J@U,=U :GOZ )2_J,/2#(95;D'^]_<
MP+A(R'FX5<M#V0@]6JZ>T(H>O;1-*WI.QF<*Z3=I&7:2E.XJB>D^$I\1(K$9
M44IT1J(2F9&NB\C(UX5E5NA#,^OU(9GMNJ"LF;K K,6Z@*Q-BG_6(<4WZQ;%
M)^LQQ3OK;?'._+?.*\.D]THW&>[$]A?A]*?@]@>A 3L)]S:H>W':\$>5MJ)?
M"W:JQB;Y^,C$?&N)S1LOT7F>$ID7*.%Y$1*:%Z\$YZ<J0?FY2D!^F>*?7Z?X
MY;<I/@4#BG?!(O$JV" >!0?%O>!F<2VX*B[Y?Q+7O'\IKKDFG4N.27\'.#>"
M?V(Z8Q/\?D<O8Y-Z4S _#Q$&=ZLGE*!C%;Z2@\T2RO425N(HP25N$ECJ)P&E
MH>)7&B,^I<GB79HM7F4EXE$V6=S+IHIK69],*%L@SF7K95S9?G$JNTD<2A\6
M^](WQ+'D"W$J_DF<BDS*;=3W/'C'X/3[54HVDWZ)+(&J#J)/-_2]";M0I&30
M/C'8S;_:1KRKG<6SVDO<JP/%K3I27*H39$)UNHRO+I0;)D\2Q\E3Q'YRC]A.
M'A:;R6O$:O(>,5:?$WWU_:*?](H8JCX68^5W8E5IDENZM/U(1V=K>2C;YFI[
M<9:H)Y3P62=ZU:%+$<^E8)<(=/%NUHMSDX,X-;F*0Y.OV#>%BFU3K-@TI8A5
M4ZX8FBI$U]0H2A-?:AI"(.Y-D--&R%0#A*$> E '[Z[[$F?_R7QK]:E!_'%8
MRT/9"@59BRQ>1+^<K]Z4(S()77+1)0&Z%HQ=W"G:OL-:#!WC1.E@(.]@TNV(
M1!*UCMR!XW3@T.TT<OLL9"D$<JM&(ML@+ZW/,>@1N4R!=T_Y02Z@YHD%6A[*
M;JCQEI6,3\@"WO?R61.ZE%GVXD3QK"_Z.--6Q@%XU( #PN3?SR3;SV3;ST#6
MS^373V?NQXEGJ M[*-Y'(7WPW5X(<B]$JOM)!CZBMR[LT/FC^;:BXU#1@ZOI
ME^N@Y=#!%>OI$VNHBKH7!UWRJ4;B8I$0BG+G>7MT%E7FPW'GP^?F,[D.$W@,
MAR%,NL.96I+;/!QY'D:;-T]D[EH*A> /020'B1AGOXNA_T,=?I+3--51L ]L
MHE]NM>S%V4(U^'G*!NV4V'3TB4)'7W0:AXWTB)@%6ZR WZYP1FB3%4SV*YCT
M5S#)+&?"6<[@LKQ56^1;MMR2CP*97@Q!'?DC)/<+!N,?Y.0&+0]%/4QUZV[M
ME-@Y.[538FOX/ ^]$I @]'+=+&*-B"I;++)9K_ZQ!R$@W.R!^",$)9MID\U,
M!)NQQ6:<:#-&W,07-IRDHO?2^5[&\3ZEX;\SGU)[>!_M<("/D85(+R9KXK.2
MO?0%) SQ1.S4_).]%MGW2R$PW4<PNM\-H](N!_#1_00F!\JTJ^(/SM(2C_8?
MXOM$S7OPR]WTC5U?RK$QYZ$L5?-0D%;>5R*92#0_^R".HSDHHWDH)Y"3OQ1L
M<DH]07:"MC?G'$'067SCO+I)EP'XP@+MFNCSZNTY$/DS;_'\/^40Y6VCO)5T
MW3E(!S(9R26PCCO#>,3CXVE"W2]S4,;NRQE=$QG-%;F$3>Z@;2ZCQUT$'W<3
M%-U+FUQAX+N"4UVAXO?>CCQ# /7>SZ?4@M&#-(!3!,Y$< +!F$"Y^MO&K+>,
MGH4R-O_D7LMZR.A:Q6C.QC7\Y"E\]6GT>)8 [7D&N!?I(R_A4"]1T9?XXHO/
MF_<"C8#73[VF4)\R,%/!"Z7)W.X4L;I[#,;H6LC_5P[*Z)Z<T1-5_X"H!.9]
M^NY?:9>/T>-3!MN/&7@^QOD_H=*?_-H:B+6,WM3R$USB1_C==U(&+ZZ5_\I4
MN'D7_' &''40IC(LG\)H/H%U? 2+4_>B_ U.\U>8T0<XS#LTV)LH_P=Y'B[W
M-_CDC^;\CU<M^1_J&L2CO[H&8I!O90+L.!!&%BM?P*O^ =?]6"91=B-E3Y/W
M8"SOPI3>AM&\!9OZ$^SCC["0-V!"ZEZ45^"Z+\&MGH<M/D?#/8.AGN;))^$U
MZMD;CXNV!^67.1A:#HB6!_&I.*&U#^PT KR)8.583@BM@3E/@2FURXOPJ>?1
MXSGT> 8]GH+;76/@>@PF>!5V]@@=]C?8XD'S#I 'L,;O:-)_X$*FZ[>DJ">%
MWFK10<V!^-*R!J#N WE;[*B3&_4) BL.G#0P"L"HQ'9UE-]"^1V4W$/9 Y0]
MA&LNH/PE<B?\[C+L\ Z8\>VP_]NPQ2U\>A$KW(@5+\CW\'@33-QD/B7TI"4'
M0ST'1#V'0]U6I9Z#\2+M\90X4R=?L"+ FHC-LL HHORJZV=AW((]+J+'3>AQ
M(WI<P![GT>,<;/@,@^EI./=)!I/CYHR0A^0P+74 2X\]&505M?Y_MZR__-\<
M# _J$P1>#%@I8.2@?PEEJV=AU&/I*90_C?*[:?U^,(9@MPO 60K&6H;3;7C&
M0;ST'._NAOT^9[[G>!,UWP3V1HNHZT]J#HB:8G7-TNWN-@\'UM1O IB^X(6!
M%0].&M;-I?P2]*^BEG6R"]Z_$SUVP/NWH<=6]-@,.U97'C;P_SJ>4D\(646K
MJ-ZRG-ZRC%ZFYF",RI\M75GMWNIRZYV6X>^<>3AVH&[N8 92GTAP$L')P//S
MJ$<)&%5X8!TU;@9G&BTP'9P!T.>"LYA664//W8Y&AVFEF^C)#_";WUMR,$S7
MY76&D&>8:G[#]'LGP^O-#&UG%>9S=-@O1NHYGKIY4Z,0ZA0-3A(XF=0G'YQ2
M<*K J9-%Z+$ /8;QCWDR"YSYC" K>+=99E)2/[7JP\*]#& ]M'XWOJF>RZS*
M2^HV1V^&0J;<6YGNSGDQ+?'9/EOMSQ0;Q9;:N%":'WAA8,6"E0Q6%G4JH!ZE
M,AO_F(4> _C'#/I+'__WH(6Z*M.)I3IHCVFTJ+JC:BH>UT+_4._&;@9?E6?
M?8CPYS)#Z8UJZB7O#Q"*[&"8WT"(M-)(R$&;S*=-YD@ >!%@Q8.20IVRP"H
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M!O4\$G0IQS89V"4:??W0Q1G;&9L5?@F_;&)":6*R;6(P;60P:V0P:63@:V3
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M?#K&+IEC/L?D,DS^.;CQIS)@R<A01;V=1MT =X\%_ZQE8%07JG>*'EP',-W
M\P,K!)PHZI)(7=)D(7HL0(]A^.A<])B#'H.TRRS\8X!_,_A-+]IU8Z7IU*C3
MO+?I,?.^LS;Z92OXJCRI$[F?(.V2K985<DS1-FBJNU*83*FG-;AJ5H8GK1P
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M\$T\4'<4GAP#7/YY(B7R1V3&SZ@,TLT4I(-6=3]$J@3ZHP#\F3S@Q0GP,7/
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MZA*&-HE!FZ2A+GFH:R74M0KJ6@]U;82Z]*$N,ZC+#OQT#Y!>4H]%P"B7AM:
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MT=.>1?-H[B(ZVN>0/Z)<\&$SP"U+($6F0-ZW!O1!#60!7!1'\+'-I68N&-"
MOE'AG7$MQ1?,08OFST6\=(R(>RX[XJ3C11QT0HAMG@1BG2>'%M"K(*;YFF@^
M@SZ:QVB%YC*Y(UKF8$3-'(6HF',0)7,EHF"\@R@8!M <AG%TDG13[KJ9&U(B
MP'_;"Y]!8(Y[ %WV2C.7"FP&>5D/<J,,?;,,>"(&NL//08G8%LQ%C(R,B(&9
M$\U?((#H%X@A.I:E:"ZK$J)E4T?4;)L1);L%HN  [>( HYP##&8.,,[8P>AA
M!U^/K1\AU@_H.-2?JC5C<AX&%S4,/@-);ZE9#R[ ZIE-Y$W07^M!1I2 )\M
M7L6$26L@X'MSTR Z#@9$P\F.J+GX$267")K#+8TH>* S>8"I/."<\H*SR@O.
M$1^,-GQ@O_&"'<D+HS+/;3#8P<?A^H!RH.TII%M: 'X(3,XPTND<^-L=:+$%
MGIC"HS8!K]8#3Y2!%EG9'VL@8*;.7T2#J!:"7[,0E&<A:8$(B!, (5H$P$70
MJ8O@P8O ?A0$YTP0'! A<!@$P5@5 $-P83UDX /_!Y0-;4^"NF/ -0T'%R"4
M]*8<^-L-OK.!1YB2;FD%6C2 %A6@11J:N CDA WHF"L& ZHHT" " ZPH#"BB
M(#2BI,4B (@!6!0:(@8.NQCX6&+@K"T!9T4,9D,1,$@7@Z4@##0(CZ%,J"O1
M"/329.8EGB&D%VF0;B@!_]H&:#'=//.FFO5 BR+(B3@\FA?DE5$>;.ZE8*O*
MP. A#8.9-"BP-'20# BP#'2<#"B8-'2R-#Q<!FQ8&7 69<!9D@;'0 H,8PFP
ME,2A+\3'43I $J#>*(N96V))IW/\22\5@7_;F,W<TJH'O%D-?20+S1(&.>$
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MOP><-.=$2'#?R&\)/*)(C1#UCN>_ W3[;%DMB5#8J]\![AR+C-BI9A;^[7>
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M3JKQVOU<  ?0Q@%R<.5(%.>M[<(#J'#A(DEX ,*MDYPC %*P@&X"8!^.2@(
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M!Q& W5TD3KPX1\J5"(C \HD(<,8 *HD ["II)T$U\0X&88\$\6$!Q%&,"0O
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M1T0G!V&/DLD3 =A[/\R(@&,8 %$U<58.F;6<( S@ 7&C!A?H2=@CP:_4[B$
MS+& .GQ(##+$ HBQ(K@=JZD:O$.(7V>=2L+W.1XPE?KWFC.]H-)6PD8-#.EV
MEN[!1S)*KG7^IUWQ]FSEHE_?B,[._N>?_*O3M[<OG_9TW+][N_[Z]6LWL4MY
M77G[W4PU5RX56\3#RC!CEF,&G;;53 0A78AY @NA'"=!1F0 F"4)0F 'PEFY
MM\@ ,$MU'PAZ@A#V!*PV$8!U6KR)@(T8 '%S&.>TU!$V11 /!M"/CW !=<(
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M_P];;QT4]?>&#7_0KZ(@*"722C<2NW2I-$LW+-W=78J(=(,TLG0MN31(+;#
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M;GG4OV@PBVB<5P7.'I_^6&Y_\==F$\T)R48D^4D6MXT\5O-.7CM9"5^KB7Y
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M/-HWI^'G1?SN%99?4V=4"CBKXM0Q&<G@*YEP_KG:'^'N'C$#A'4L^@1>I4T
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M4J*:'1Q&4._!?;MHV<EZT<H*OTHMA @]^TT#FQ2BOE:5<;L)9>N?QM3O#"3
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M+ &D5);._LXTS"!>FS31OU2%.S=M');38E]@8+'V5@O+Z!:\],9)4=%'L6#
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M\(SJFO,5ELQ5GJTY92:'KDJVZTA&9_/:*+8O!RBX^'[HI&@T+OL&0/N D],
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M31MJM9'2K[;FGG>&.C.73EM/SX"RZ%726S*?MR"?VLP>2\3/:MH<EXR23?U
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M7O2;0_CO5.+%]O6/*[[ LGW]9O7A5YW[JZK7@ZLJ\IN5TN0O=89E:KZ'(TW
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MKKXR@&'PEP:P(F7,-/-F+<IT:5YE$\,$:'%CVY?5TTK [I1M?PNDG^PU!39
M&Q G4,Y$VSUG&6Y >PF7;AY/AP$WO#R83AP.-OR&S@.>?@4>72:\MEUCT]1\
M] KO=+_QWP([(UKI]S6/1ES1JR/06Q+2QUO0C52G;ZR04AE/8[4P41E(DZ*
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M4ZI/]85]G(/=/)X^@:U,ASVK $^9\7@NQ%VQY^F)]W><V3J==XB!.2O=$LG
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M0I6=II')6^3WBYCP%#O?R,)@)3S"<"BQ%4G'&:SU >*P%K^.GTDAFCBXDQ=
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M,XX\FQBUN *FPUI2YVV]?5RLUD[?)V>*DE<5?]R7)]VX*(;. 8P2<!5S. .
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M+@?GYJ07%!RB)WH+(  0!X@ (   D1P;X^V/#OCQT3*,J[->++\3X'=E;0P
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M+@>YIFL10/Y22"825SP*B^?TD,*/[2-])_:FC(OM)THY/G*X3!$M.[>W>7=
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MKSAJYD$NF%IN90PKSGGLC\I^@367%J\RP]+3RH+J]236+C<YOJKYO^\N_#\
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M3-G:E/44DB[]^D W@B!K#H&*,^\IRM+Z/MTM:2DEC>2W%:E CBB[?REUEC\
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MS26]X/0[2O'$+&,WPB>NG'^8OJ;JX]VPI\5Q0+7>OZ"6)=O[<2H[:[,!0:>
MF;:-Y39A2VLW<'\NI71\@1EI+:#O007B_&E^1:UV'R]?.+UV<^2(.ZCD."=_
M26_@C.?]!P<16]7:./J7P:.3BIHW=+;=9? $=S>_DCMB=.AB W'74*ECO2TP
M'R&/.::D3Z7XZIW"*[F=#?&HJJZ2OKZ$$1Q(6 >HH'.O0[(TM+.)+XABFJ1<
MY+"%$^P1H! 7LU]2:9=B<LB6M!2 9%!K*@, /+\8,E;^=+A,1B@N>N?[N@WS
M6M;[RQ/.Q^FQ11.SK4_.'1RF;,)[\[+.'YUC4O.WS@T>FSHCOAB1EQ IJGQ:
M;?I.,SW+[/MSP7LU,M:;3"]>-!US\",&66Z]]YID.1P1VYN_)C-5/[;=*9S.
M*YQ5CX_MM-*_6+G'Z=3!EK0MS0KN 6(\55]$\ZZP"(>-N\]$S_7Q#<''OOU[
M%N^FFSG4;]R]9^_VO._OO)G?^D]QE>'/:[X;-G2L [)"?N$S[4Y/QV&WBJU?
M-R&&/U3(?J#V%^IZ)LD6B]:G?GQ4LB?)1/W[".>!\.G/NS;9/#Q2!C\G&;VX
MC&RXG3+<X$F=F-ON>Y:;-5LS;*<N66?/^9K?U;GX">N<IY6L%Q!\J5UZQ070
M71W@7"-,W&O?VH\L4)HQ.XI44>\/^B#??:P76+Y_3BV4):CH!+U;%0W(&S!H
M:+!XEB8D/2_/V)O[I#<W:',I("IL]NJ#R3Y69]MSAK5>@K-B#P0=W!]LH"LS
M4@=Y1VTTF2R /-F"6*41$AE;Y<6VJ@[/*FJVFZ 7#>QG;@X?QI;?]\0>%.^Q
M^&RP9N5UTI1UHJJ!YUNA\4KP(#,T*FLJ"Z,^?W=0<+?-,7L#63IIT,\HLG!@
M,'!W>6-$2,&WW+5= K*G^D2'8A] !KESO$1 _G,O\9F;V"O/1OMV6V2[:(@D
M5F$10+'&[L(S+.^:;)QH>#]&;[3OJ&"RFM&@O!;4R2][PU[P<G3:5>^UYH@G
M&JG4P\V]KYGO+^2/I0]N;,"CJ>%E/<T>"_/[. DR\,,736,.BSBJ ?<:]Z,-
M"AM]9X/'G1+%&@5ZM6WL>@VB[YXC-N4E+(]LF<=LQ1ZR:T5T]M]DN7*$,H#U
MGHI:8R2C%*]M0QL60H4?-;^/8C5<$'RZ#GA^=OK^#C!"W?/&E3*R^TO-J+#2
M%E?$5N7NK1FD ;2MC]8@Z<""6=DV,0_J?DM/:-#ATIN";".]K;.U 2H84X6J
MR!2?SY;Q/)^\F.W]2Y=FGB6WA'Q]V5W\NN^(]I.-()WYOELUIFPEU>="F!##
M^V-OMHD#TNPS7/)\\#,  0V9Z:7?/\13G!-DN[JI\_NG,OUU0-N9 "7!I</K
M *G#(]]6[C8]]LY.?09R#'E4RCE]=F=HV"<1G]LV'8IO@"N@(E*HV,3'7U[X
M6]](AE-@>CD# G"9&H.4..])U T?GQEOUW=KZ6*K<F73GU1FRH*;0[LX)K_(
M,BR>7GK<I;[F!CEZ6<_I%)D9JD@W+)LROJ5D!-_6?]08$(9*/C@DO]82X1>4
M*]DPVG[]15ZVGM\C0HY>0H]>66_>1K94YK6*9S+R9!2,I].?OO%&V=U\#PZ:
M:-G0)T0 ADF_BF[6W+H2Y.!PXO<Q.C44DA3*/: X\PA^;BIE;+(356ET+>P3
MJE4>O$6?<<76(/3:E&ETN'?V P!@Z!;=[\)CNP5<;EU$($-D_MQIL';MOG&0
ME<,^]*GR ;\)%\=47:5'T[="E8MA(P^D+4]/>*0OC8GU*+E @5TW&-D74BS<
M*'&WM/LUW_?=T[5K"C)5_2@9_ M\'1#W?EC3E:VYFUGDP::Q#CBJW443&TN5
M;7P7V>I?N(DUXI,/C7#%W&BC2X_-A90ZYX4VJ G5/P@_H7)DJ7&B"^%\3SIO
M'"78>@#Q..;FR.T[:<]9D(>;Y&\QLV^[-9]2'NF49"DM*JTMD%8 [\PY&^,[
M+WP#RMR*V""[^?6. 96)J/F3W+5D.?NGH:<-#_>1A=#5BK8][-!=2HX9&^/:
MG;D:&Y@11XK"]<Q(B-L'+E:_N"6_7REHK^N0I$;OA5=-'\7;.IB*J>"7RN'&
M<L<PD;V=0\K9FAXLA>M:+GO;P(MH2KF+J6#ZKJ%FIF29?4YE0_*3U+'PJ+!Q
MRY.92*<.D/!LUI0:A[FI?.W2,<'#(P).RJ(J=:=:_.\GM8\,W6\T:C<?K83M
M-P\L#)XO$<P$].CJ;8^#22CWAQM]BMW^^FWF\57S)0-4M)P).Q8__4W^H,^=
MC)&#*0-Q)D=G.WUK%> WEP)KD MGMQ:8;,)4XFS<8CZ?9_LT<W:=G4OV./=U
M)JBL&J6YG?WPT_WFT0_G=*JEI?K0B];5VNP2>ZU/QK2 >NI!)W5#NX5#'^2B
MDP\@=[=KIY^8NVDV=GAWIITY/9.)CLRSIV16RF5"MW2G!ZD_42=E#I"9BNH!
MPR9BVZ2LSW6F-1P'7Y@1$Q(4:-NEIQ7Q7.8N@LD;6^%9'Z(]:]2XD3NR*Y.8
M*-VE=%1<#L[D/O,LFV$:C[1;M*HK](E4ZW<^55!2^(5+.UJFX@O2\-VE.&4(
MZ4 +K:(COFBZ!!L X4:'$;#R+=>*FL/4R2SL2!'*N[=<G29F:V0\<3&-<-[-
M=6G#6U:"P^QX7$B9V$C(KD,:QHR,9LDA9+I#IC35Z*P'NDA ^:R)VE*Z,I0-
M-W3QPQ1<45E*J^@.XZF*NK,T?;(<-NE?"GL^I(T=Z)+Q+B#*?\W(.\/.D+K9
M4-L14'HF7@^R:B.Y6D^R/+70=[2?Y[S].(CM\8IU.5_^ZTUA;-+I3W;%2R(9
M;;-?;0P(JA/:_?'Y9/>JXPWN>9NZ5YGL!H&RZ[ <2VSYZ<-O/$WRVJ'Z.%\F
MR7'3X6 3I5/FMIV<?<_*IY,T!V'9A [-[?O[6%7$P01])G)5X7U6=3CS;(8@
M^6T=Z&)=8NWC.W,)9.=62-<V]=I"5$,HCA0@)#XND/JLZ4"S@\)X3;Z[CFAO
MT+BTTUV%DK35G42Q;,>2'J%]8/->,C>JJPN:NF]*Y@/X6E:W6+?$;&<:Z!$H
MMN"62MOY@HVNJ+#C_Q\[;QD<1_.M>;;%S,P,%JO%S,S,3!:TF,EB9F9FR2*+
MR6(&BYD9+69I_4[L?)@[$S%W)W;CWKWQ__:KB(HX75EY3CU/YLDV\2 @%V0P
M]Q3$.R]6H5\>330!FGXO,95Y)I_[ZH($/ Z8IM93D$<*I245ILYE9<PQBE+3
M\IGT\%^1JQJ49&XMP>@2>6K%N1V/+;H@D.?)0H0K;SP_7.[S"9GIGGIP0 #3
M2P[;;T:V8*DQIUK$#"35V7D0^^^U.(1)\Q/ @"KU :2+/&<AH5PC4< >.%S3
MVE[-%R5#A[;4V& 97JZ[G<NR\2RT>$H!WPL@Z_H14X"G% T.G_-#2LQ>PI[P
MID+!?G0]44$;HV6O6I<PP5@.K_X;-O6DIX!1!JHVDL2XLQ3*/+MP_C!B^=XO
M$@RGEIWD+]'?,+[7O0#_X]WV?P7@EKB/]\>P0;[JZ!=<=M/)?YXXP2;D31A9
M'[.,NYM&>C5-,ST>^Q;=5;:*1#_<C4J@=2I*9DGT"4BA^N,V^%Z4&8^Y7,)U
M>[%XIH<%^8,.,F3DG95@7]QT>C9,'\N5_0?'V/';OBJ6]T*&[DXY[DSN=EVS
M5:<N%]]H<6R10K:&0D ;7LD94JNT@G1I- !%+;2E<9N:\/O@!+[5:V(!ST.[
M]>;O#(K6BK9ZD'3$H%JZ"2=V*53+X9&:-68#+0Z2BE1"E;++(+Z):K:_A5+0
M!?&P0/H)4>J9CP1Y(2I,$H@TAXU%03AA.2> V7?BP=6:5E9!*,5,%%&EV<(Y
MRZM[@:3:2(F<Y'(0%3;I7AI&408!^NO^" AK"!>;>5_328L$IQ*1?F3.?1"<
M!H)-K(!>=C\1FQS",3C%J/";'=MT,XZ=7ZVD?+F D*<LIVU+>53JN1U>ZNBZ
MENRTIR<'^X R^33_+'\M%T899>W7A,8FZCH5>EW4[RUT[AXJVF81)_-)\[A.
MYT8B2KZJ9#Y6)VR\TK7#62#H<-H%<98O YOUMY%"N3[)MWW"59;(5_LAP+[U
MS*8=%I![?/#L^J@S?1,$GM(873DQ\Y3YD_[R)7HS%$MZ/4&I/=EBBV>[YH;G
M"LQU9$8IUZS%<K5B=3S?]],^B@^MT?JI@[5F'NIVL[C1.5@5H7A/691"I.%W
M_H_"UC32:L=WA;6T11R-Z_H6O%SF%S)5%O%FSY0"G'D:]YAX)5@;\W&&F),!
MYPY8_0R;,?IAJ+Y7E"JI=0*UEQ2#?H$C7L]8(XIAX#!37_S *'XDMTZ*/0N_
M4S^SN90J-0T548%5+BX"72/D#U+\AX*_CB?H3+#R*?$)6LMU&"*\4!H+X]=R
M$)I>\O 7$:?:6)9S+T*G<"5MLU1/RHVL?' 8<&.HQ:X:&\/"()^9_U5_@3+?
MHSP^"1_7#=;3N9,)VH\E3P+Z@DJ> 0QJOL3=W[$KTC"##Q ELA/%@:/0A^D.
M@?"^"4H^2^] K8,U"F?3$MJU) )K&M-#I9'I,WA J*RN'!#!C)/B5'T=NRZ*
MTN83X"CTQ3?+[0R^Z6/P2O@!Z[_U^+*]; OVGHE\ GHXC#_ZR)()=(X_ 7N@
MF[O':SL_ECS:ISG!)N1?_G_2;Q[3O2-[F)X?ESD_&*YK$2]>\\(_\I;=<O)6
M[\NIHN:!\]?Q:\,(*<-MRRG,/;3V,O619G%^FA)8F:J!ZE(0EW+QG"9@9B#:
M48'AKW^3A370;@"I3*>7Y)YWMF#<;T[N\B#+J+J] ,;@U*2-47J:=3'LV3LC
M4KT2?[99SQ'!.U'>D+C:P]L@+8&E2(?\G(01>RV<]$YC]RP246?7'R8GLND^
MQV:@77N'43N.71:0?!Z4:A;S39Z2-4TT"4";;A+=KU4X<2[U@MJ<ZAF(DDS'
MKS-(:C%/C!8S_\%9\_,34!S&YS_EI"[\L)1_^+@0]B;=@?Q^S;[W:!TZXZS]
M/PETH?QG7J^V0CO'38L&V7XOA\0?GD%U]/5_?L7NMK>(.5P+1RCQZI'6F\#3
ML^#J8W5=S.C7SLUYK_9N+95-:71;]E,3@RXE<$R"/43'0L)_1_=J0R!9T@6Q
M8QLC6, -)B\14I @*PH)VT M(M;8: FX^E5$IY\D>/Y<7;R/'"BIPF$S>K/$
MI1&IJPZH:8$5*IZJ^.(-P?\%8TKKU%W\Q=XFQ]MEQI[?^-[R!K]"YRJ$/0G3
MB!^;B*^7:Y$\FBR*0FN.KRJQHUDL8[9)^T.I/L]<:U5CC$(RGGU*LD0D@F4\
M&8\UG (,UACQ[,.KA;9G'5E(T'HR\@-3#?EVH4W^8]OKRZN&K>:?ROQ" 3J*
M2QMNA[T^A;P.-B;_?7(-!35184VY$!Y/A;X^E8[F @6C:53$H7QG;BYAQW!A
M"GU"FZWS&=^FX_^/7#JTRT=NWJ[AWN/K1/7'=*D:-HNPR&:9Q-T4'[Z]M$S
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ML#=B*^+_\9))D%B1+$,!$F9TAM.0,&C?*MC:$\'[DE$^%XB1UD@6+ZGOPWZ
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MCU8/ 55H#O6%BSC  !5+F!*EMT1G.RG%3T_2B_!WWIF +W)67Y"S3T[,/_@
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M\EA*[(QCD\ET3K'^6G=RB]U\9!0:Q9G6P&OSQ$\^;Y_NEK"BNN;B9!8[!8V
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MW]4/_<(^RJB;1)UU#2YJ?\E#;[ C_3O9*<&DY!4!BW,@?TD?.Z?$GI;P-Z
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M]T]_"J_)>WZ_CIO/((S; E*ZV$BL >*VS 9NXHA2B1E*A!(A?PEA(\L+#7&
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MKJ[/[]^K3^\VSI+IMK;8YP=P@VL>;3YHKR_529 (PZJ5X<BB,64G S%A-;Z
MU?"3^<:& 7]7#$JKT"UFQ>)?3;I*PKJX+J6JN!V3I=?G;6;_"$Z0F113)WRZ
M>B'-MPK9S!$Y2V3-4[,7&E.!2PS(Q"K3]B=HJ8,?RN/$9'S]1S4O6D[\S$WS
MW9_5QOIEXZNA/!.O5N':7(^AF]\[)E.:KD_,=J6 <=Z$%RO<EF<5A]:2=@U#
M"]MRP_=0$C+W2EK?$^RPL7WX\@Z@M9[(=].R#8@M!JUU3IKC<^CB5<NL4+M]
MI*3KW,]8!UL)\!SY(E!C''2/X8+^UT-1@M@8MIN''&X;C;9K4<F90SI]7_"T
MYF32)W;<6Y5W?^$C,I[4"&%W9Y;7T7AZB1QOM-=H\+;MYMIOPOXS$8I-"QU"
M]I!"H+!;RR5'-]7$%;$P1)?#P;QMB"?'= Y' 1F'JUU45DMIA#$=0@7&ZK8A
M]UNUN:E@V\O2;C&4O98Y#^6E*)F%U.H\! )VE2!<7^9S)![&F[O9H:/;-D+?
MV!K;1KX_Q%RKT*LLM<Z9T29G=PBVQ<AH;2<Z51#XXN49(4>!>MP.FWV[+8^)
M1S/,/*"W.F(?KM]&[;DQM*4)/'.']]R:;V]PE?6)9Z=,4"&+=B>C.=V=6$&Q
MR".7Y-CV-<;PP[IP5DY7?[MKURWE4M\!H--1GDCU&+P@N]!D*37DX$E<5ICL
MHT:3A"PE8U(\-J9H526Z2W6ZBEF6"S7L#_Q2;D*8(E\ZCP8X.[LR*H,>=R@S
MA@3ZX/GVT8P_P6J2WQ=.?!'I-)R-PMU9@/ R]WV<8-<\ ,MI.,JD*@W[/,L8
M7LF/-+9JULK&S76F,:7?A"-@.5(X!] ;TFMO.])$MPDIY: EYQ#2\E20 4F.
M:>1:%E/\V*7K-:17S]FE#[O,]PE"^7L16[;HI_7)MF:M8H^)1K6Y!%1R;9X#
MCU(X9\H:U<V)&63QQK V^D8$%AS;2)G]E2*5,K<5JF5@#=B00^G! <%NUK_V
M=R3(7GB"CG#-R\"*(2A^H\P;L_0%1(?S.+7FPF#1F92B;FN7+R:! AP"&77'
M7M5CQ\(DVHYH84]7*R3AH<Q"QF2YJ[^9/,<E"#\<7D/Z))H=E+8SCO\#"#,.
MCGBB/UAK!+)0?0,9VF$VQM=UF<9](E ("#8AH)\P'>@9!KTFME8'S9/!>HKF
M=D9P["_T$')QJSR$?BJKX_[1G%?L26$D6:7&#\L72@N0^^[%\9%*0;U);T0B
MTM0 *^I.G.;3V&+:.V!P(.#O-,Y764D3S5_P%^ZW?8@W_. S.L6JF5_1:^\
MJ'C3.\"\.CIJ%^]Y1'/BZ9IF,V&W3Z73)2&'93)EJ1M._'Y$Z&01/1UK-?_)
M+W@:2>T.::L\@JE-_99I2L5V%@E-]U,CD W7/GO>_*EBA3&72V!@;\XP+%EN
M'W-!Y;X:-4*HQXXM6;!HJB$U0V[3C%H>/X5>*;$N/3U'QDNK1F9>NR..U;B2
MYL-8O!EXGJAUE_!QY'A>:+\A3N,I2CEM\X?-IBB6::314LKZ<GZIT?$%.J$^
M3U3&W43U)(G#$FNN,_KFF?1Z JT6:HS0Y=YR@>TVI89?DV1&!T@Z>\E>-V^J
M59V<K.7*3#A"]>[S%Q!"Y>>/ ^,6*MRTB4;<@1S(68P:=<)UDT3PP88C$[CV
MWP@[4 3]$3R6.YW*Z Z]?\Q_.>VY*TT\@LW.)H!-F2'!4I6OC.-55'BB&ZO"
M-%+T5 ;"!^^.PWQWMCSGQ79PVE469WV]_7P_7EOPP)=F4+I,)G=T5#U9B#R=
M=V/XV0++U<^8)NL#+%NCJN&& 7./P@Z-(*TFP(UG5'HJ#=NT\71!8]YKO3]P
M2UQG,OE0F&UR<V.5+4!B_3?=,,-=GV071+T<84"0S2I[PI:]R9Y.QZ, +WF*
MFF9,M3<&K<HJ\H;#=EM2%Y.>F[]WI\G]8[6 4(P!YD@^FNX^39+5%Y>,G_<O
MAW2G:GE;%$JSDR:9?Q*#EF=OAKJ54.S&Y)OUC:QUR6%>6^[(O/5^^1VJ&I>S
MS'NF[KET@3Q953^7CZA *^_8/0HGQGYUER98L@?OSQWHAT8'QT').-(@T@X#
M&9H'#M!WP/?O8N&VR Y" ].4YQ:=X<N^">&G_BBEKUO_ZQP Y[^U?=!LV"'H
M(/ 1SI>O/ZS?><!YGJG<F4S=7IG)(!'2D!-4(%*WG@5"Y*\.%HY@CJN$HZ"!
M<85:0SU^NE%2:@![=-,?GML\S++ ^SFF9 /84;1$0K6%9',^Q[112JM24S^6
MCA1$.4$3&AI51AML8VOJU@A8\%2*F^8GIM08L^+<8@<S JFG")YN^TWWZS[A
M9KY8NX=Y&3:*C/'YFJV\5/=\.S<D(<K]N :IV538$[YDF%=P>M%N_;'+EB=M
M4N%+R4GO@"7;EG? QI-AZ>7SJO2?CPV2 [=H[P"K#:>H[&ZGQ2E%ZH'<&]F.
M08H/W#U&=C_4O1CHU6HMF6I,(Y-;)LK4"VGVA18)BGGR9X)5.FDT^2SIN>>M
M^(8- ?AGS,OQ\X[>[P"X0$*K^Y11XQ5;I'D93UME\)W+7Y6W&,8[LL*TAL?U
MQ"G2OA@6.Q=?AXP!LNS]'F_DB7H4FWY9'=/DI[*RGJFMZ_3=U$F02\ZT,\R;
M8F#AG@,Z)(XA4/Q%-V)6*$E>!$[;]+5)98/<W[1)X0:8-ZG-$.>E5\HN?$3?
M@T!0>G?1]RWQC_H?RW_X0DW\'<"?KP>?^:I1D?(# YOVGAF%JYM+Q6L7JDB)
MA28+(.3M_Q(+F2.*,XRRA*G"*8MZ1K]B-;2P?N,C QXU>G]_!ZAUT7O.1=I!
M-1ZNG&'RIG .9MO/9B_:T$[_"++3#R?Z<'QDLE<QL7'S.L2UL%[K)*)9:Q,C
M4%DY*BE"QA3C\!9Y7?8F,( B D.%%J,A\\,:R@^/7D"6*>JYX60QD:I>'LU8
MH+Z+&?&7$RV98W*_2TY*K^M$^!7!!K;AFI:/74)"T?;\@UE13Y\</7%3AJ,%
MA?;,HD$<GWB9:6#S<?BD/#_G5PN'WDPNUM@9?WV<;HQ]D%ROU%XOHKY:CB2N
MG>5C5\W1U"*9U_XU-"VD:?[K<?K7#/+8)R[(1HVP^)1QSL&5H!_RF-PZAT1:
MG""VS,3!*6/X3>UB#3_0J]PDB7A<,$\OE42J#?._ )T7;XS-R^#R[YEM15H[
M,D2J(/#%KLS4=>7ABW?BO<R#ODC1L'U *4YMT3=6D:<:.-!=XE Q2=%2E6[,
M-P&6"<*5:]06OY6VO)P;ZV[U$Q,&B*5M-XUXW)V"? 2_@*@-#.,"CSOQF'.E
M,X4INB)N4AGP"H]X9UK%(O020%X+ZH!N1##_6$3^BQN\\'; G7L3<2H-^^*[
M&-JVKYA#^WR+!3SUGPOEM5VZND&=-L?9^P$J+#[2H121L/R2U],"O\OEI5@#
M/RM7HUV:C7$%RRP#'"M5W!!2NC%XT^8P+3A/NJ8=*LCG' >+W1W"N4W?W+3I
M!F('9;EH"P1J<=]PVJ;)FY"5X$TQH$VJ]H$CJL644/B%M$S'_?B%S,.K<Y-2
MIDJ#R#LV#FVM04+/?*X-7%7H 2-2Q2K$=F)C>0^4_ (<IG-EQC[3%3K"T=M3
M0>.I"NN*Y3+Y %T_EILJ[@^SGRHI?QV6?^__+A)NDN? <;F&^PZ@VPX(#U%/
M_#L!88??"3(-3ZA0"']B"#^-;]$E?/OW/7DD+$LZW _5A\*_P!*$S[,ZU8H>
MK[F0I@H D]B]U_Y,D3,8)+<AQ._5XNTD[&]G-%BG[TU&T2.4&:*:/JWYP'"Q
M:#6P[(N3C*B(E<&-C+ B3DJ"KU&F3)W=],U7MC-].<Q5?-G7*-41DLXR;(KT
M:"#)>]X3>P@G#.^ B3F+2DZZ3'081)]Z;"1_;JY7V%8WYXYP2?MW@'HNQG(1
M-V:Z9H7(C\:"V Q>O# N> V.AJ]=XF))4)TC;*CV3Y"?0T*S@5<NF;(]Q7;V
MF),<5@7,:"+*SSWW%7+4PS4#U:7U3Y2X<_'KRF'JF1*C9"W 5CCM+P?/#)CN
MQ""UK:F$J>//YA6C@,(EBDC6QH@U2U_LF)&YWHAF"18Z7&;WVD-XE58VQ8V_
MTIGN.7KI&J5F=QP22OGBXD?^S&**8Q^>DK]T/E4^FG4,#/>G&7\OE&9_LZ&<
M.!K]O<BU\ 3,J16-/1)\HV3_!TXK^-UO2+Y+3PN6X_YA>/[T>PS(N?-A/HKX
M=5(R=2K^N=SJTQ647<L"6DN9$+(X*4A1P @Q[B.V2.<M:=IS*#2Y8;#E.)WR
M\F,HE+)LXB",H[U(@=8UH/^,0-'FQ]\H.DD<]U#NF9Y6RKJKD> 4UR$&INR$
M)CKLKI[_.%%W'?X@PHX:YI[]*8&G08*G;%_U*_5R-U\UWE7BBPF-?T9DOQ[(
M3@QIDBH;OI9HK(':N=?YPG5K5Z,'XUM_T.J.% '%&J)I5HHH/#. LFULCPN\
M3D%(QIBO&B(CC#;.[:U/.QB@Y83/$FL][)7+V.7P =%MY7_R'U8J\P[W@]:A
M\,%W $'XW)I3K3#N >D*>;Y0S+"1"3*0/'C"R".E+%-S&D'I%.RHJCS;-!H/
M/9 3C&R5@!GJ[RY53!8+900[W%A&6B%>H41;V^=;"$E4J5V#EMF&O&RYF,J2
M5:%7]Z:A3..;C?'ID_,*Q0^&[X#TDWCA:O.'H_P&"$69=U_AY_(EM)RQ?A,S
M=D3[F]WB,S)@U&SL>)Q@;CO+[$-Z]1RKMTZT9TJCCGH-T!>8*2@B6L/$H4IB
M.8]<P6P-#]K3KX/S+_T[^\URT%1H]U G,W7S<</.93%"0$>S4N,NI>#/TH!G
MXNGG(FZ?8K(2JFP=;<<GABEJT/2A5YS>U:W<CJ)=\5SCAC S7+:Q1DL:%SM4
M,&B^#00$LA(YF,>PV\UIK^Q23%$7JVRWF10Z1YY-]C8S'PCA<4B4:UPDS-3V
MRNIVITHJRQ<$X4K1XJ[3$S*9_KAZIMCBQQTA!59EH#<N_^EK,+YFR91[&$.;
M#>DFUI!%)]XPZBB7NT?*.#S'] NENF].$X;4"=.T!L.L4+/1PB/RD!7>-N,$
MUZ5@R?K8)V8'#;<V>Y_ ;GFQB=_WBJSJD$\$F%6@&X83^99KVSX 8V2\4'"#
M/&D'E6,PFY<^1GYU)_R#=#6OM<?I]7-&O(5Y>"/7]4'.0L1YC"4L/Q@MB>@Z
MD128M,?JY:U=>2(D*U[=R\_FK)\H(]HMT,:"4H':&AD!EDD5FC]J\PD5V,(L
M]"B9O$CIGR;-1'/J5!K!':^_S[S7-K0".=#F2^+-+Z2I !?454AW5O <SY:;
M'-/+>ZVR&@;&HJ_(,9S<ZY[MA06.[#4Z<HWY0Q60A].,N$6NXP)Q%MPRH6<D
M0H\QX^=DY*J1/%!N&[2N#]4X5>,U_&.*C"S'W55LHSIY9*?>L'\S&0S?7@K:
MWM(L-S$;.Q"G&/,H'_-YH+>SWSY=!2-\];F\='P' /K5WYXMWR9:S>")/44O
MY+,]Q:&%!%^:O_8HZ*JT>H./ YKYA(_]R4+33CB\&$O1WQH<YD<?<-80T-I;
M8GX+BM1Q&]YZH=W =#E[?!73/>?8]JZ8ANZ7%5AIT.]S7\&X1F^8MNB&FH83
M%Y@&216_M2$#QS4 VK++R8V;'UNP8F)1"01XUE5623T)K8H(O"]U5DPG!ZU^
M#OKF48'C_W"9#Y0-X2K7BU"+*.[C3()4IWA/^)9 1T7CV%^G"ENM=A:U(? L
MD')B^6V&'%8BG/"8-!TC89QMUWNGL JB).LXT21?*S][5HX8[O2Q>S>1=ML<
M)S"&$$Z\/ ZCOF&4UF<I01D=@MI##;;?N9:,I:?/_QTM^],,<K%?OG/:B(5/
MSG<#-P1T'.TG'+GMH&-6KI\_'=W+I4,9_1/T]=7)W33J=C9%RLI>5($;4R-4
M'1\@V(><K<+*1S$V:Y)&</4H#F*<,).^9J;+CO?F=*YC'BD]IRM(_T1$AL,4
M=H""4N$XR/(CU?W$2J).R=52UF5U@&[><%;C%Y0&;:WQ?J80K2L%I>V\6X:>
M"5R&F'TRN1W!H''W3/T: D&TP^P'.L<3.L3)S. HNHJ0R/%\>@[5E7X\JDK2
MH8\UZKZ$,+L7^&O_[?KJST_*<!RW/^'!W8PWWU)JA?L?N=\!=Q\EGY '7VZ8
M1/_\BQ/Y_ZJ*_Q-5!5S+X[6SB[?'F^ &KOXQ")$7<IH[US)A+U'-Q/@9Q)Y9
MWXO@*")WV)^LW<3WP'<YS11*7V =#.?7[1YL*BRXJM8X*5EUF<Z,NPI<BR>T
M(X9E[>0I&M\%!0#'@]%3_QCA+IM68!XOK9L9C1U$3E7&.I"I*'3(AL95H1S)
M$UE7[J&NA/[T=P$=VJJA-HGPUS0)!1F!?Q#P6^=KD'U761?>\!C7R0%,%^Y]
MQ2/::8SL'L<>8F9WKHC4Z-1(^2&GX@/-,FZ!9PY*NK-S_R;AS-,Y89>B9+.
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M<)!6/>_/+I3KS8%F*[4DPTI>&HXYN/*<,&#.$5[[<%*"P"(G'R"MDGOU7\\
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M_ L;D0O6^M2,+N-+\!S=4"_SX15/#&N!;J&6Q13FF?$9DW']0!Z'L<%ZY+8
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MM'.RM,_/P8]V_82J2^,7/YR-K<1=E<9KIO=1LY*WJUFC#<*GN567I0AZZ0C
MPJXNUP.?[@TN<R=ZT<"5]:R+G^#:I?<2O2%&0GRA<NE[E\N^Q :9C$R@#JH?
M<2-FM9&1+I9^IM[V(HJNC5*-+DE32L4A\/(#(&I #?'*+;E@C2E'KOD>T%7
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M3ZYAY]?L7<IFR]RDF!,H+Q.ID*SWY].%JV+KZI( PRNGB'E>DJ>XF)TUWP=
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MH=ET<QGYZ8RU%]D\TM=U0]U&X;LT]%YP@400@3IKZF\>]B+6W3;-4JPO,/D
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M+$'.O%%ZT$ZU&/:)-T?\ !F\<RU!$SF>V(G1T;#JM%B9P( ^R;AL"'M3^E%
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MX_AN4[!V@B,@=#R=-B<&(<KTL^Y=7/#*]WLOL&E07@S TJ;D/'&E*ZAP>,,
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M94:\IQDH W9]J4KW:##47(BM*J'VW\5VSK8$Y@A(KJ# CB9^(-)Q.NH3)\O
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M3V2-FLSFM/N66K#]ZM^@SY5INPY<Q*JGAX]ILF8SQ+\H@2WE>+!AD^F,7.K
MI&Q'^<IZ.D9RK^RRR&1%+V8(Y:4;\]=Y1>Y'93]HUT-,<]\*9.+<!S]NPVLU
MA<:F_4B:)*E';M!T$P\&;!YA(C=[0?)W5,UR,(17Y9T@5>MP,\-\T#NNWSV
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M\&T8>_RRPT]>*08OBP*\ZP5 F:4$GS1(99?&X/,B6'61)K+(>!DO"VSRD4J
M-B[$9WP,7-VBVOJ-6XCE+*_Z1.%&<Y=);,F^<L44! ?0$,>/E'->U?51!]L
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MBU ^K8V*)M-J[YX3QK#Y)G"I[RKS)ZQ[A#":)KX>[T,BI*,[;C?[=999NDY
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M)),]>ZT]>V5ZCOZ\"#U>0G=,&=?\&5LIG07UNQ_).TY,::']AF?W'X#:K0_
MTG')N7!$BIGV5ZOG\2\BQ0H78NTAI"SO<,.!_?0'*<Z&WS:>QWW_)5S_Q/T
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MR6PF (#4\*DSRLEPD61@H6:2D-*_(^:O_$B>@$MCL<1TY]\[:JC".1]S0:O
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M+U(__[=J\-;YV\^7'QRE/\B9()H1^I:(=>Z_#B*]<)!/!>R06YPB(@F[L1
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M,+X'DB50+?57)F\AX%J"4,2N[_G2INH:'2=R4P$PS7[=T]F-G62-F1S'XRV
M:"LO@-]TH,E:KKD)/T2>^'D>J-)EDA?&:&%:>JEA@\N4Z?!GP:1?2SX/+R\J
M;EY[?[?1SS5)0$2X0K+M[Y<L>R='IS);U1)EC L\+,Q2OS,B-._XH>4^)('@
M^9WIM<P7\AT<CT2N1YV)ZSJ!3N )OUFNY,U]NQG!F%9;2N"UHQ"B8JI"/IFA
M^;1CO+4AS5(W6698%/4*\I5ES!)*Q%P[#X0X)59L#9P;0ZEV6Z60-;AKO_=?
MD"0=HZS&=:!I[?*C$&)1'L)+I/+^XJ^=UX4]B0[KB8Z%3&?55X>%^HBB!-95
M_PP+=4O)93OEHXJ:*0V4^H$ME"@,FH:29<D>:$UCP-BE@BN:CB(GME8KT-6/
M9Y7;<,J4M;.49)A^P5M@.9.5.-SK!_*NQ#5XS\2=,JP860)#3@]7'WN'2'T6
M..HGM+.-YS>(0I&XI/8J9=]M;JFQS;T]_.F/(T])WGQWPJ$\>TTR:!U0@4@Q
M@J%7[!_/1Y;>1MK-Q4&NHVE'FU/ J?65.$],R<_IA\O";CS6@5ESU,GS.3@6
M<^FX>6DP2J7-WDPH=,UQ;  F&-/-.8_);QIW2*3&21Y.93,3U>MM+35&=R'D
M\QCN3G+T$")?^\2L%->?H#>TT53V+ZJ;,V0^*20=+1<H+ ;FN>*3R\34*;>S
MWU*-'6;!&5>8J<>N^IL,A7:E5]A'%19)*B7/'X!ZYAQG6/W5EEE-'UL-RFAK
M:^P:1YNXM1R?+5E@/)([ESR\ /)3BQ'*3(YXX^(ZXLA8B Y4PMBN.1;UHG#F
MC::<FE&/",]76_<[\MZ4)S_#('@ U\_^52;)SL(^R%.W1M@S\[OT=JE2)OD/
MRV [O.'.%A*+3A(9TIW5',H1CT)NF!&FD30Y*@_P:JL/=3E5YBCZZ/2%;*@^
MC$WXTZ=59)='-M+_HW(/ GM@6%40R=!8P["DCP+Z(=M6 3\Y4+V[6<&]03#?
M&H*+I\^(H6W\C3'0(8*W1ZA%01F,<87QC^%+K'P69(Q(5:#.'(U+[+#,/6U<
M#W-IYNNH@82<]SC;_OG7.*JFZ:P,QM>IR*/TDV59.4JYHSB1T68U9)]@/]S6
M"L<9AJ/O_ >,V#:(?R41EU&+]P>D=>TU:-\_>S*"ES-JI3"BK:LWB3M U4H^
MO5]2;\CVAA5[J/NMR @Q4?W@,J3I>=)3?(R3!Z\F#)1(0F-1 L.H.EBSQ<V]
MGZQ:X-&+L6\9#L_<\K+:=S;S&FY1RH[R=/FTZ6+*/(I:K8X1)_,WRU:8'7T0
MV)TM.\<\?WK&-X;#A9/=I/PHB&K?')43LIO8=.?U8 _WR(9-M^*Y7HO@D$B]
MN]]3GN)*6KOUPN @3#33K766X6![4'>]B38RSN:/'-T*B"1RU%Q4OTW6ZI0\
M($Q_+XWQ'YPNC''Z2KTF1N =.[ SNC".C]TQ7\S 4T)P^I3$;6MG0B24-\?<
MV\9I'V0K;16:QJ"W_0-2)U*#XM>7.K.^7A1[_\ON/:IFC45(//K<>YSZ0M>(
MS.JD%TQ=+PZD'F1!U4BG2W+8M[>80=%L^MY62*['J%ZAN$B$%DF%A8:6>Q@(
M)SQI_/G*5Q2LV>4J_VWJX= >@ALA19N"\Y)8>J#E4)=5)4*<4NX>&.2EX_ZG
M13TW0HU2817CF)5TE<+G \!G=NW_R)[]9> ?IP1]$,:C%]?CR!''U=)M3HL$
MXMW/O.X_5IU^' \+'X#F8W:C6$71%1(/OU+!#P#M*#W1OP#,I5XYRAQIV]]/
M]A7=;/\V\"3SQM(52+\HAATD;?5)<AB<9.%HC6&N($<X;92%-XB)@$B%+)A7
M.,^ _,23STD,JOMNC+/<PW5%R0?7>"^P>#LWS'SP_5C!-445-<8F#LIHV!S(
M'*74842NN)P61A6D<&$M&7,_(A3X\;^A'_@Y(^! TXV0LNP(-OTX36*@P,^<
M!:&>_I$1])5V_ 0S3)JZ>:V2;MJM;59HX4ZK/:NWW;MJ@NE"$_I(;^5=AVR[
M_&J05Y.$-11;MQ$CAS@BND]>_(\"<=SS#*V7N)U@_%7]6$;+IGU4O#9A O#W
MF.&E&F;E^R%ZM6&#7?E+?5^GQ4_COE#7[/#N,P(^\Y4O44GC"X-:,YZ907BC
M9#?;02KD3JN)LYMQIKP6D.8\D8>>##_[7[5==;(&$\K:;KH6Z^S_(ZWE_]WY
M+,!(^1K[ 3C+^ "4\-6]CGT =/[IOU3P7/B\]#W\Q],=J^NMH^5@PZ3X>&7^
M&5!\[3M;>7CE-!@ ? !,S/Y27"%8*ON"GN47 W\7/7SAV7+R8"/Z;U7;#?<"
M,,6EBLDMQ]<EP: &M1!-[97>+.3 7,NNVK,PV>Q,#FT[8Q?JA!PN]VZ><+59
M?V;_-Z[P+3'Z''=X/7!(;C\I=UU)C<E#'I2*1;%)&;R<F)?#$US%$:FP68M7
MN#I!=S%]-?&; ":TK$C9%.VQ##N;RX+))BK!18)D7:%;,(?,W"5^B-US&AB[
MC2MA]5]XS-DW%OL4)U1J943BRM=4@#;-?6I4[6CAJ9E%X^5LZ1U%81,'$-X[
MP1BH%2[_N:X3!<U_J -=<'",<LO-(_$KEOF=Z%;,%]IP)E1HU.8HV7UJ=G":
MKVQH8# =,>R3C*,9JV;945>2 _#IG=Y JLABFR2A04E1VH<,A=;GMT\(@,,7
M#OAV42B-?!S<SD(/%*60>4M97W:FIL[3!BD_UTI=\TV\RQP_0EVMTQ[J1WMZ
M2#]_TM_+EGHFCY8MIG8CSV]0X(LWP BA0X+H=M>J<*MDX\X58A=[]X%W9-N6
ME/'^'CXRI8(05F'8V\QTKA$S+6+_]9W1(:T54R4(*I*#RL0=\J=[XE]4)B%P
M)_\D4ND\NX0;WB][%[JKV;D0?%ZC5@&-,N;A(FB#1[@]6GD,(C"%/M0-.CD\
M<.%^ 9GU.>Q'F]Y(1Y$07)J;+*USARR+&\MM?+Q,.-VZ"OKOH*\@*-ABA&B4
MH(?4W"U> 40SPR!"MD1BXVCN+/1/\@/ ]H6O+P\%8V(Z,$NY<+L2Q\ZB2I6T
MQMT35!^XT$";2>;PGRT6I_=SY2]3F?W&N)#='3.G6S9/\ %IM.";UO1_2#J4
M9[*2>;R7T&UYGH BO;M-B(/]&!\O^LO;1YHJIFH1-QX!,<$*F8V39"C_'1,_
MA<9C@E<LI[^SRU_6D&XV*5Q\98_C=).\4%2LLC>]QT>AN&2[&C2"*!*KC]X<
MWLB'%!W"[PUDHRSTD3$6R[+!YQ:(Y9Y/<28^]5I)D*AS-#U?V>EB9)JF+;UR
M7,-)Z6A68>)L/H8):XRQ0-3I,5:W)Z2^G.'YTKQR&)P@F *>EX&^H,!G.R$7
MMLAK"O>*4UMJT$0JEI\N \O]4CDUM>6*#I@P0>YU9B"_/H0@J2_LQ@+#%=\K
MXJ]Y+_WQ4$.;1 -]\IME(NWEL]:-4]E=;(+,N6>8T(ED:?!)/! ??5%*B#BX
MT#D'**&K%(Q1X)M^SFBYFT.)&+Y4"&[D<&X!+3=H0]JUPWQ]8G@VC]3*D6>4
M&W4L'03G@;HWL-9WY5Y%GGR_YT'>?)?#ED:_W&15$W%Z@*F-WZGNP@Q&GZO]
M3!(8Q?)Y.,\8"4&V1KF2EA?ZJYU.](YSWGY<JL>[)U*=UYO&M(#>',/3 5%/
MFC2JA7G? 3Z%<2;7E?>(CNLYOR:CH%R5WN-$MU!K,D^KXX=H1K16-'K/*@'&
M!Z#[W<W!C\8%]#?#HW&NG:#7<)?*)YS^,2ZKZ2F,,[/*4?']JTN"G684YI>_
M(C2:#WH8DJCGW2J-'-2;4F8#AY#KL']T V^W1EY/[R6YZQ:C,13O0>J5!JR:
M?&]K>,LNN+TDZ@\71@(:O>KL?M$K;VW/OAH0H%ZFV?-:J5!?MR>JUJN9?NLI
MLA26D\O*S@<@2>T]__ND",Q/^ZOL%8+4'.?J9+IY52>>U/0HOK2J.XLT?3I5
M+_Q(6K9T--!IE.->1C53^BP,_6KW)YL*8Q:/@?'1_A=68Y\'5/2?UBRD.@<&
M]]EJZ7883-F,)'QC8\M36V3YNPJ"M(+S^!23:7W2%4?H$8E<:;[>!+7_FXA,
M3&?T:LOYCO?GX4#361D!-ISIO#C5\7$;<HT^9<F=TLK,T'! ,#T7OAE\DKH7
M(@]QGD5OJ&]6/T+*EM=4ZFE^O@6*% RI(R.M/LA*AG.O2K%^9UV6&#.-EO7J
M'SJOD$$DQY[:,"#,'O$EWV;,NK.V9<T"V:D5X[-Q*"7DW@JCZ]L)I"*/T;JK
M3LK$DLT)#;8,=MYEHE-!):HH(Z();3O 1=27R74-3$4%GT-P"@*_^KJ[:FN/
M.HH@"#WO'_FR*"%W1P/,"14DZX.\U\/G'C44^8+<K)\1;9J(QM?Q,O0]$VSM
MAES%O2<\)&BMV^T0]?76&+TBIFB9Z+;6@@.(BV9VJN'AS@/+J*2(SJFR%K'M
MW+U_&G1 /Q&'/LZ1!.F/5BOE'C+(OA](A#]4>/2PH;&F)$,-=(557 _LX :4
MFJ>P[,SN!]%*Q&#H#=:-5@T-5]=UGN2K]/;5V&N"=.8N9RX@\?))$JX5(YGD
MJU5TU&>YW(DFY#1]5PN!R$9X4"^5DJ HCC_^#"1XE(ZW:);M ?\4HJV#6_#L
MBZG<I>/0PKR,04,B;J,X(X7PJWF&$85$>!1!99Z%B-P<;*BPV&ZV_JA[1AY>
MB7?6OB(Z?\L."_,KTXRW[2XV;,K$^<M$B&UB6H@/5AFL$^5(@PH]19,DI&69
MA^VLUC&'>:V((C@7+K$[AWX%#YL&+\Y8/VIEQR7VRR1D!]FM*JWH"=%U<XL)
M^!,H3^$2+;U=;$#^"A]?!GS1F =3I'E'U6G*%7V=[[-=ZHUJRM.!AVK0S/DN
MT!'G^**\S>J\"'R[):ZMX)!7#.:P8DEMD0N<LG$:WR+&;2_M\#]N$M,D-(<S
MN_]IT.9&[6RK.R2X,-&RU0I!M-D*#[G+_*=V]![M>(*6EDZ)ECM9P?;;M'G-
M\.9)7O;BN\NV,)N&[G]HLWO01[)4=](DB.3,4\5YI_YUZ8KTD5#\KEW6^E8B
M=YBJ]P.PW^II_!LUPV\P_@.P$+V".?=OI%;J4.F_7:N,G)*>RI221%4<;B@$
M_$9!3TPODR$I4\\W]YXMY%;;2E(L*LE%/;\.+W.NG/+Q&I "WV0BUC+68@K:
M7_T:C%:BMMK.'#U6VD3%G^^'J+UC [K]D*\TL'UVO"WUH<^'&EB9V)OZL"/G
M4X:P2<>GN=@QYYJ!+IF_ZPTW+GPU:MYP$_Z6[L#WJYY3B?M.I'',K1VGQU-_
M +*X'+QM'3F1<7@^ /F> _ZG_[ZM>_^I$$TJF3>QW-R$93=94[6YH$7 4%4"
ME6Q[37#]R\*RBM4B $[_8C8VM'!#$^+B_+U'KO/:AP2:,GWLU(<.5,M$*?0F
M%C#7_1(U5LVCF=?/7/W-/*5*M&^7"D2'<72_(Y!Q&7720I;_TY![",3-)34<
M =1AK0\YI=>QQA^"3-4:KKBBM;D*>XC%+3H*O<A@KE>?/2+C.7X0G&!8PXL^
MTFO9UHYEY\9)1.4G+LH9BVW:( .P9'X[17?N%BD,:Y)[KW2ZM9P+)&SDM Z5
M;EMD*;]C],U<S,IV2>3:7J4;Z'QSO;VMN.P>FT2D6/A.N@J#+(T_K0 (%J>=
M@_BZ]"@T;8B;2'%R^&]V)1MDK>XDI<\C><WW\NUF)X8FH+?GQME)5QQ@4[)%
MG@$0Z$,90QE ]+:'-T/E[Y%<S0H=A,8[:W6Y$QHL7,^G L^CIUQYEA4)^B6)
M^[&TTT94XP5D2U1TCO/E7M3"/=FD9##K6WA$V[D>-N-7%%6]]0L7%F&[3R>H
MU/RBTZ'-^B(3*OGH($8X8O2)%QXY8%%8Y%*?#F(D)K4B-\[G2Y,WG.ZP=NM7
M_;H%]C;PVV\Z<#%]ZW,*:<\>6U!F\(&$PL&[_ZN007+3%5U)%OVX^M:QEY_*
M4]L,JCY<WY?2H7/(^;#._X!$AS-?,J2=$?S=RR22<>%N6C/";Y\!W1)C V9O
M91&H;SO7&2/1:TT(K9B#N==.8'DH=?^,+#.)=8XT&%1AT2I1V416J>8)\^[3
MRDLQ:]/354"TJYC@&54+0^'+D*G"PW'BZ-(CS$-AVL*QUI?;NIEH^+>.]:K=
M@M1Y;-8+=2ZX.4@FD&^SN723O=(]%O;Y?:.XXW#%VY0\K,&X-&_:8&P4YA^)
M\A:CZ?:3V!4X7$AMM$H^<?Q_V/[P>.3H.*WLE>S2!^C/!L";-'#!+C90)[X0
M>3996;X2T#!]N6?;=7\S3?Y3&[2^^W)A^A\07718MM<7@\47-"U$RR!Y-W$4
MWA/N<VS[G;NH.D E$>,O;'&%=YL0D'E006A6";!^W@*VKSX(\7**J!VET,-6
M93A/*6&&:(K+ZB6;?:+I)ZZ_]1T>+I4"69GG(2=Q<B>O(HFHJ?AEJ42@=#W+
MZ-]JXPP5+FKR",P5,>_A]9A(JL";G[\!T%[.!%(R4FIN[(D#GE0N_L[>;B4R
M5+QD]S>Z3,'(%;\HQDTG?28B-CM=FB8+9&FRV>N]7PL3'P#V]Z0[?B<1C\YX
MK'O3#(>>)@R'!!4&ZZA6[G:UVV%]V'/<E<X>V?6-AB(0^,MYLEX](0B@:&".
MV2H/(((A,)?F 6,#S(F<J=!AVX:I8FG^5R-PW/?SD=,1U;CXU4_0#&(@)V^1
M9>\J<%<V7C)!@$N2:W-,AV]56:CNP[646XR69I5;8VBCHH&_R,B=J929$S(Q
M#_Y<AX;09=7K!1C5C)WE'7//K1(<=V^O.-<BXB4/:^#$36RA/_/S!?,CZGY?
MW\ FH([58TL/)8W5Q_\W<Q44968WBR28NC:]?]1,_%-YAZ=P\/TY7XTAC6_*
MLPZ[V(R&^FM<\1MO&'3M7I]B>FL[9_M0N,;;4<]K,%K\G9Z J-X]Q\E;03?G
M_)!ZTX>HL,#9%7$TGDN=?@*E2@@!QS^$25<VC[L)A^JX,NX&6BJV;;X'8#&=
MKPFPT'("7#_:^%IPV#,/\+Z&"'JOLM5!\V^CDZS:UK /%C5^)G,3^QJ.U>$@
MC13.!1C?48=;3D>AA4ET]PK]X#I"0"/])#0J@Y\9NV'Z6-+J+!5](S\ S>VG
M&28Z)8_W2&1'*+"\!I'">;OR3V<?HD,OLYH:PY%QVB:3B$\S,4<TZY4B!'<3
M?R?Z8=+^%=F4OAF9T"?3/EG>/MU785,'=; *-@O,XD)N^07R39)JTM&]G/X[
M1=SIG6:D*E[& 5:N"B>\[ZIP&&>KY.:PNY@3#_KJ?$&*'GF"7W6Y$DF1H#NU
M</&'L5X>I68T_K"\%\M?\Y2V\ 0GCW!4.LKI!0N+"3E,:5!@+/EW "[F#[D)
M2CX)\'87D>ML.HF]M46^E:H.IH&%+W-4_0$7LJ)92M"J %LE5O^8L7?!K*J-
MTKR^3D:?;K7&*R?3H9=S@O]NU,+^EO.T 93HY8KVE$)2A-FI-V4V#Y/[_-&W
M=);NVNDJ4L8F[9#9S@2,NFCG$ZQ\F+RU4FM9AZN.$K9OE\2Z[)(_*;R5#PSA
MO6M7673HR598R>,LK+X9L%L0\,'.4O\D_@D[BXM+163H^O"WG]]H@Q+,5C>L
MIK-%.Y&M"&Y=X%/[ZJXMS5JP&,Q,[I;CO>MPO#71J\#R?0K&W_K4_XN]MPRN
MH^NZQ*[ 8F9FEBQF9F9F!DM7S,S,S,RRQ7P%%L,5D\62+6:VF/*^7V6^FA^3
M2B:35"93SY]3N]99O6I7=>_N [WWZ6W-]69J2[C!M\G6 ZH1B!=CV08W94*$
MP85V-I)6K40)V8PS/:M@'"\+J? E-HA>D'J.<Q!UYV$T]G"1>CBHV-?RM5!8
MTIUI[.EO0/^=E)75+S]%9%J8@H_()(L JTH$K/X[SQ.$/7J3+]7YE+6!(A@U
MO6#IO1\TF\-!ZNT^C8CX9L4X&V<.SB>_,;$<HS64\1*2J_FR<7^I-05A =!6
M>:X7Q J*GOUXF]GY!, QP#<'H1DZUBT^M4=TV[6R2WQ/UM'C>",DE"_G@]$^
M@$^>,J9"7:#'$J !TZ#DV'VE,#Y@<.G4*0Y0;@S5B@]59$H,/2>P1CSYV#DB
MM"#*BBY9%TG:,.?SR9T'[]Z[,76^IQA:;#//O  1I<V3]WD,NU&MM$_[XW_!
MZQ41CFNLKL*$FZ*%DC5V?-59R=JR=UQ\9J:-5;BO:,"7<KY5E.%6_@XDQ!$,
M:VUM'L9;SF/4O+X\K.1-B4"/(<*JX9O*B$'0L2(^AN ?0./\':G,\:_Y+E@Y
M)T[=PR,+VW+%4PO]%P?E+8WY>.))]K+A (N=-8G&>)HKY7A^O57W'!H$5X:G
MY$-OX'!A,?=1Q ?+XW=+3^EU9.$QM\WHQF&8;I55HRKO7!<*MB:"S+^0&9.-
M^^T09)F/E@Q^:&O3XMV>DLF$?]?8_; (*94ZN^=01)2-=ZKY00G7FPF_(C2U
M%CRC.\">2JYQ]3Y*Y ;XSA-Z7P[U4K3'M(6*9<N7:/CAZ2-+Y%P@W^=Y+ EE
M_H>&DNGG[;5GHWOF6?[D+:N)Q+ELP(76>@;S-"HH=7F><("J.NP#+J<-I7\<
MF!"LZV.[F:=9;BPFDPL@0,L6@&/LP/,-Y/4<2O&/0P\^OA01W\B@P/A&-##_
M8)-5A:DP0O/5JAFL7PK"<4NARH$B\?ZAYD5F,Y:_OA3<HM2(A&KO94AU*;9'
M*W-;F"?I_5YHQD*\I$M!%^>O@_$J-UD7B)4(USU<&OY\D^N_E:;CK?Z[XXS>
MEU?FPVR%5<0\U'Z,<NJ&[@Y)73!M:)62J<[ED)-X1_WG_LQ$>.3R<,&)RZEV
MS>5X&H"X9!3OVTLO)5J$W_;.BW 3VP2^49FKM74-EL<SR$+@#.K,E<=3IS(+
MZY#*&>AIYTPMCHMS %9"MT%SL:!;&'&.YFF[LD,PG3#.+\3B@(X&*[:(N?R0
MR G5)J<>:6$:"2MK[_IE7<<_,G1=*3MV0Q$*E=@IWZBZ/HQIFJX5K"J."+V_
M>"G@GB2FNX7G 6O@\A,#ZM3R6[DZ#,Q] ^8)/\YUEO7#L[9B9D/ROIR *R8B
MJ+S*^+@\-1W/=@ Y@7<^GJ.W?+'.:"O>RUZCK5. ](B.GE'R<'61QQJA+67%
MI9(-;7L7@\J:(DV"-#QZ#Z[KL"+ZUV88C(GM$EZ8<[@^N/\1@S\@)=?U$'JA
M-H@4S':D'74\W&7#,.&3LT#Q,<AEPR$RY)1[!$(6%'H&R0\0J2\/+GR'/TAU
M,FE5%HV##XGA!&HW&@\?732.>/=-K'T"OOEC;I2_SJRA7\V2&,*)3W\"4A?X
MW'H8.#8'"8/D-@Q>55Z%VV#H.S<=CV?)D!V4ND/J=*^XB :C#\??<OY$?;L4
M36RK5O.(U2\#,6.<X(_;?Y77^MW.QL C+LOZNP.-F:5%K)1+(UR9P;W4/8P6
MF)ACX9TH;:U/2_?W5/M&9$I]O"PYEBX)([+O,"=2W"VR,SBT*T2H=C@RF(;0
M-':9=[M3OI0S2S?-X7;ZCA;?@[LWD $%0R?#_RA9:GT/\%5^%V\V)8H1AYNE
MQ)PBZK?X#"YJV_'%2T=O/4:Q*40PNC4T)9,9&@Q$Y""@G]&0 B[TWTU88-SZ
M)\#\H;@"?%7E%O&6D:YIC:\=N1?$S^2+%&+&5A-I'"JFS:\W?*2!K!?S!X3#
M%YM1J=EZ8R3NAB^9(^=UGL!DI=_?J/<)^',4+!3]@4PR?*/SY^I A=(/^1;)
M9$TDK8]G4ECT>I;)F\7DXA7E8NVAR&E^Y=4.(9=GT6 0?Q&H,E;B/"F\-IRE
M0,9(?PZ!5G@K9LKTQ80@)3-NC,(13:%M-/'":&[ /=HJ6KSW$D<EJ[5*FR.S
M7N!$67P(W>6T>RF0#4LCPHRF9S<ZE6Z)6QS,$,\V=A5K1.[8I#WJ=7S*,4G=
M)"]J//Q@WAB+UT_VYNJ99"<-7#GFKK46A$J\_0DYZC!7N0K#/WX!F4<6#44L
M(X4>R=LD((?JFE*<PBZ5R-?)7*QGPY'"H"Y7E:U? <')>(;QXLZK-^C6OIGR
M91X.(4:";X3>X2%"9#HGD3-'#7&!CU8;C]D$W%+-%KOX0]QHDM-AD+71(YAP
MM04&_<MR,( )@JDQ_$LP.0  6"4#0 &AR>$D_MTXS ,-SO672'_]U^E0V(^5
M@I\ Y@6ED5@IO&VJVQSA'^=4OEP$2=Q??8.2^WK-Y=R '(2$'+8(AD:%Q/F:
MF07LE@?9+D=X:  *M#K@!7.95V28N\?:P.N*[]'^B9=Q5JR7LJ.GI\/#P8&5
ME=79W\=#Z\-#$S9K8V.C%!Z3@$6<#7NE%45)Q69CI-GQA9O(DZ53IQ86I:R>
MUH[_Z'5H/UKC,?)8E&W?,*>QMC:GH&@).UQ\ZO4Z>Y/I@'K+Y9!YR#!.#M(5
M+A%1>I*XFKG\*]\O5. L\T/@Q[1O$)$(;OU[4/3#GZ TZ6\?"S4O _?P+TZ#
MI(%>7J4J-H;HIS.G=\9%8Z@C9WTFNT*=I/OSN2*MWP,; \0#\ZZC?A=L':>M
MK4#[MG3UK%3=#-WX7JT\)3G"/G-:)UTP%-62JA95OI$_'GGY4CUX#)#47C9P
MG;PYOQEWWW]0;H1\*.&7O<I7G<$NT9[TP04\;VW'_%>.!7S-V43'F%M6^Q[-
MM)"7G&EFP4J.!@,] FV*W1"8!T?1(77Q"=#NZ0;6MU\X>BQ/.^1O'-+:\&OU
M%21ZW!$?\?L]-MU(7W5K^!T'"7?5\\OM)OSVK'R<^PA ^,?\Q_Q_S50 XM(G
MZ@+:MC<<_ !"W%=604L=GP M\=2/GD7"YXN6/<O7[UAITVQ]A1O"W"I=)7*"
M_\#_P/_ _P7^]1^PE=__]Y[\ _\#_S\.!Y:/KVKFZT$+=.2[#,%;8>FGAG/
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MSA:A^J-?]KD%HB^RUW]YN +U>BSX['V]'6A0!U+_^U+89?BD%]G93\"7CD\
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M7"?MV?;FG588J@!+DC4WS.)L["*LVDO(+K/(RE7FDA\>QR3F:S><S1364-G
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M7Q;2'%QK! DC"TP\7D7#K51!!F]!+AE80&H<TRH-)?!>YO$L&'BE/9R:<KH
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MA7$CQ/WZ=0%Q%\G :KAGS(S37OB"N?($YVOU='M^JIY .0UKT18(A%I4 72
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M5;:4M=;=LRAUP@2Q5K/H^,X:B$N^=3?E/'\B?8Z9Y9R%(9Y"P7R::0^-28Q
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MGG\'V4XHL;C:WAL)(IEK<(3OL=V/ %EN2+(^CQ/AU"L-71!)*;J5V7\IR)?
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M!)]9O@/6X=\<JT2[_J^W=M4R7D,8 4E0P\T&D[$EA-Z?@! OUM'4^"C,I(.
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M^1*E3?PQ]04C*.1(8DDMO3,=$OCP_TJ73DBM_VS%^HJS<W>HZJ  ^R'LB6!
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M.'GLRV&WOF D_[<]0777>N7K[3Z'&Q9/[;R_VGT:^\UX_K*D.:L*9K,0^!V
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MEVY3*!!C5%#@#D6JG6N_"FFYGFTU?M6Z&@GB<WW &9":HNA*#5,,(]W7!?>
M^P[XC _1H;;\#_PY&.^ Y(9+V.V/V\%-[X".'G#;@_5\5!_"@W%G/\*O;.T/
M+]Z;VUV_A*Z 3R8KU=RIZ?_(I'P*,_Y&;?T."-UX!VR&KZ3D[QZ\O@/P^@<5
MZMQ?1=X!A05OYXQ5>_146JOG?[J.(1^-"WG2*%Y81V:=X]5:O_<SJ%CUABUG
MR*4TE5PR>1,")Y4OOHF[W(?(4,8=_V(3;U\KBF Q.+WBF_VZUTU_T<E6,:/(
M%Q"4.+S"&G%8UAS#&&\:'#&!:C4\;O[3"O?LG$6T+&]/'W4CU/HON5E8F.<0
MD#&V?W9RR[2UEWWJFD@MNZ6CIFG*3RX'O\*<INN PAB+!GL.9.K7W7'S\B[)
M1+U$KSP1@M\91-?#B^LXF*LF /D=-0,M09C;>_,J*0DYCRDZ5+Q<:;/K.U0[
M@F6%?1 $6!$I3W'VK>L+9][C>GRYA(+UKY@1QVG\-=1C(6.5^MF?;WP_N1*2
M5I_:F_/8$]T356[2IZ?=?@6'^?9_DOZ9LO.:'\JF0.-$1L&83J'XAA3^9[K]
M7/D$"QH%H-)PD\LG]@X@;7B[W^I\&5Q0=F0ZM!?W14^=W2/R+>AMF !-$SND
M6FV==7/^96_A++V-[/7=MA_279=ID*-\#.2^KI5SW8@O@C$DR.(6M.<4[Z1<
MKA+*G:Z0CYC">%Q,/=PLO761!M>$(.F)CDC^.0>C=6FR>W_(=?  0P-^J@5Y
MVU/[4*%,TO&FW![>V6B"3QC)U6'VM$'.09-5.?-^&K$0]DD1H0DX[C+ZYCR\
M9D[%]9RE:>Q6H+6NSEHZ'RR]HRNQ"W21-AJ%L*7QF&]HL(\3VSL@CVQAP;,W
M[TT^0/(G4U4[IMR]M,7D4\J"TO?*5[4D*U\R9'Q7&F<W/8GJ<,^J^QCX**,A
MP@=SXM:O)@AXOP2V,F"KVL[;.OKLD=L@XTTC7I]KXWV:='-(KF<TVW4E!0)<
M8<P]4Y2,!GY\=')-^V1([&BN:^EH4<R^FB$?K^C1>\Q+&XJVK^+EDSN=-<UF
MQ6=U,.R8R":^8)'-(<L6;KEIN^O$_^G[KOA:Z3DA'9E4H?7%=X#8UHA&@"_C
MMP4HC!%3,82OKE%-09"'N..YIL%VPAMK06"'16WR4W2Q+OYJWU#U56T4L5CO
M[(GP(4Y6MM1Y=R>EO5#@N;XN@M*)!YY+./GZ+E?KJ0,;W _[97>[1J:7^2PL
MO1UVSZ3/0G7<<8^A"#! 671@X:%OGIL@I_PN!U]::%#U^2C*GXMU;',DMN)X
M\M\(1[)QJ%GWTV>R-J^GCZ(F#E'-OM[O !?@Z-AK>=C5Y["G9\=W0$9'3-1X
M#_QX:O >>.[Y=TWKGT@%;\U U;U3@IL?7))SQ$#U7.<QYX\$8:NO';<Q(+/X
MD?U$Q\A-\QL)UR?RX4ES!:O#%N!9>=L!>3=->CEN"!4BRVCL+EJ>+^RZ$9NO
MXYZV-;5C;N-ADJ<DF46/V'CF/6JE47/8R3$)B%9Z' TSDO(J/A05)V\RC,(W
MO;D4"WB@D%:.=)IE<H:E<@)_]&MMM(NW5D 4U'0NM>G=VSXH;<UOD$E^R#N#
MG]S8%&V1@QL-NLDKX%#B,5I5*GX$3KA5')'=9S!$D-!DDM<O[,4#)+Y(O$D(
M"<SO91/9DVQ%1U,]UI5W[AF4J"4V.T"9Q/H(ZWE5')>JB(VY>AM\I73AAEIA
MK@O/I",&JLYTXC'QDGZM#'BYBNC1#>R'-G6 '$0QRJFH%N#C3:K*:PGWW$FH
MHZO;\<5U[P'86;VPW& X<F?5\T>5ZX)&PE@P=2AT"BIF[?>G.12X3I3[B,^I
MOI=BL!W!,>FEQ!FX:?G#27^P1M'9Y58O._/:/*#O*-ESLT60:*19L\S</M@,
MC&D#6.35BK.#N6XKNB78_DA]R705I.VP"00!U0T)W"*8)GS>QDWN0.L?.34P
M?!'(J.#E]D_3OF'!FGXH:^=MY@*P4:*&MKSQOI8=7Y"0:%FVYAKG$NUR$&K=
M6,HB!/%;V/MD'W0J?&!C::3BGFTC)I3:.TB(_Q3+5L/?\%LYE*\XPQ*?BQ<6
M7IL(<UHKYEJ=D(-4:X8B9:;8UN&082QUXF69F**E"=5$-8WRDR"%0NZX>:FJ
MK1B[NVF-!@VW. T#(1W1A]]X\O^F64&=,GXA#+[_^@[0MT/__?_D\!@21=K.
MVD(^\$Y4(FY?ZV<^W]2GL1@W:(EX2L+][+)$0DC!)M3+%\(94]QF&'+$>D!0
MGL,A_LW)/2<.56X&@TF'!6L >SA*R#7_<>/(VH(O;VSC8]J]AJ)9SD(N,X/9
M! N<(#QB3X/#F%/RTF>9&-7]*T);:KDI*[7=$5YJ/R>CY!LU@ 5=D\F#;N%B
M^QB+P/":,7F3M>&EY@W,6'-UFH2U07Y#91N#>[STEM$"QIZ"LK%$[0$\HP0@
M#RN1>A#??Y4*]AG6I+8>59A;@'FR\*-+0OT\H;'#GBZ68C*'AYH[#U6^*81
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M+&[V1--RMO>!X&FR\OP(K,.L5:UMM3-U2X^ER<P3-I:?YR4#.),/*[B:W$X
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MV](6P6IT&C_5-'EA*)VL/H@3O.?$D3;X^D:I0I1U*\<\5NEQT*@2]D@.9JR
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MSLV-3;+Q$!?_":$@NCXQ,&DO/XZRO;N3YSVZF%5EXV^^^9 <U/2YV!Q>R:,
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MYS?MBX(.AWBZ=5:[\=K5'FI*@F.Y>-F1)5D/,$>64.8QP\:]!?W&YD'R4:R
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M*+F/H*)MZ2:Q/_?GX6C\W<SINCP1H_T('$M27G^*+*6\H4XAI7 T@HL+]]U
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M>DFGD]XL=S])%=UF%6]R3A=:O(A C"+5_^WD;-^-.'J%UB/SB4J510U0!9W
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M([K"2D,Q'UE)_!=(QRT9U G3'-ZM%>JA9KZLFY;>]@Q)]:Y*MXD"./#10M%
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M7N,5R<K24R@5T<!5"H+(=9,6O-(A%K& @W8:ZNPZ^T?^<-,E9(YE.ALC2'^
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MAN0@K%:</Y^6CT47.'V51&(6OVI5_,%3&E#3V'CA[#%*$&5Z3" AED(75T:
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MU$.EL)R1B35*M\$L2NH?7#DR:Z13JMY>*>4+?DJX*,0:)Y_W6"D0.U+RE,0
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MM,L7ET8K)P,91A)/OYK/MNF"DN+5S*THK7!XA2$?O57DOIAW6A799;;VF(E
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MUPW8% ]W!B_>K:OES"'QZ&3E'1\^:\9ENSNAEN?\$+5WL;V,%BNNWW2,6+,
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M#=>VK0#<7+GU.367"UO?#6%P'* ,*XH5)[\GUP-EZ 2SIO#_D;T19 XYM_D
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MEQ9%\CCE+^6*%4#9B?0[$:2PA70HDD)$[PZFZTT2_U$9V#T*O%@P^2V!+%]
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M::VT^N*R1(&3#2 $>Q[84K\ 2LT-N==#_/CI[?DL,)^VM)RIJ&5MK!($J0X
M5 !0(U(':CLKK/Y-CA2"CO.*<4 *KOOX%Y6<#AJ<: H$+;TT?%$$<>QRBA;_
MC2:5I\/^$F:V$%(/$XX)QV"3ZMK1#(BA1A^<COXO$BFSW.CSTYS,H]H)Y8)
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M(/@T*1Z0+ B&J""D2)JH8(WXCTO"T5QN$X6H'$__!F:F." SM:J,;,K,N)C
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M+ #)K<:WV5F7F!KE54<O(XAI;20; Y>;0O6M WCF.58('!&3HL4C[]( +N%
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MP[:DY:1-.!Y"9G.*9VQ#3J!&#2&TD&"@("5#E#0 =JD3@G=^TY^%Z5%H,I6
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MMELI;T-TV.B=>55+;UD@EIY-""3.8()D'T)&FCAY8:>8SATW"=_C.,9#I>T
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M4&_:":M07]]/'UY)CM+:1,YD0B]04;@VE&\X#?\.^>\\*U2?R9^?]V&?75^
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MQ8SC3BJC3TQ&?@J-1Q5"R]CE^ ),<3Q+^J/DCP@]8#]*'%R9ZB]^ 5YL#KX
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M;VE8T\9*K^=!<8(@,\RCD,T=-GAT9I8FIORS#!RUDW4,R:G?FO690ZUD*$2
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M-7=N"C;YG#+E/219<*G5+5HWGO#Z?5]BO;MC:F2*MR-]CG<5WT1A[S2V3QB
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M2%C2B@8QWFH\<&CA_W.+R"D<GJB):L7."_S<&3IGJ$L#F"EG^'QZO^ G5,Z
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M>7C^JW<F"_M7_-35>MJC X#-GJ97XO<WZ>%-P%D\/S%'-CC);K<1,3ZC=>2
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MK2_O 5\5.?^C%:K[H?'FF,,>4Y\*TLK+.Y&W58X7:U<#<Q-9W9V@3N459G
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M5J Z6"[&X]>$0/I@<NO$8'J@KB-8&J2,"G*K0*X2^-Z)H_V5=B>F M=<JK)
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M1H\CRBUM^?V* -2<Y%1:I$\J7)TT&'O<01%J]E;BY.TEKS<[DM48-AO75K0
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M;]P8?IVV9YMN.5MF5AX8WVUAE%3V)6 %IH7F%5?7FEPSDD"3ET_Y^7,9/ZE
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M^PP?C8R#\IKXLGEM<E">X@AO\N;19GCOT B8LEA$!YYL-.RS+=,TYGGQ$($
MW2GZD&]4"'L!4K779XA VP&>G:Z[ <EF4[,V%-1=*X;,H0_MK>G9/#,NQ=7+
M(F6I4-.</4MT< 9UJ0UPL*&%[M4CYNG>%)K3>6?5S'R%/=DS4$^W!,.C]$RA
MJTWOT6H+6?VE6J1FE5QFWCD(KZ^,R\"KEI0Q-BT?(>*Z3KI*F2_VJ71RT<!<
M=O*6M];NZN=6?U!"_0K2#]VI)]$[B779S3**[0ISP"\AM"[D,<\SY GURT\]
MWSNF]PPV^S=9T4P](X^PD[T7WB]*^ARWKW].&^N4SCMV((NG'1,X'+R+\=,+
MS*?3&P-<IJ[+R+UA?&C?BU8(MPLK"GT7+FO(O3 DCJ**'#;JDOBAZ,B62B,W
M?WL<>8\P(LTJDAFRIV=TB 1&\=+>D65;(CE4Z<@O0C,W6V RP)YHZAAATGYQ
MI$9'&IX/L4J$@4F97T>.MQ;;'.R@LX/QP28/X:GO.#K^M<QQKZI/MB0_FX5_
M*X&W?\-_QKD6>U.0-*^)K+<>JL_>6B$"GYGQ'W6["#-(L2<7TB^2)J$F!K-&
M?B? 3FMVLD\5M=WL^CJS?\J=M+52Y2$P:HUJLK(5R!K9L08G@1B3Y,8M(=*N
MRF-8T6<S[S6O:W:X<\6><C\NG@H*V[YX**#3Q-\<,QVO$DPG%E4P-B]7*;UG
M*")U<USZ/B#:)\@&QPG79O LBT=@_J:N><'?Q3,ZD'R7U FRH9N_M_NMR#*3
MGY707R+ED]-'91.O/4.D]3,6U<?*2?>[E4K3(+Q_!CYI@+KIGB[B"1/B\\G7
M_"O_<9L=]9W[?193@<E@&7XH)G\19(</].TXEB%@=< GN*@8D:B;1CW7YK%>
M;[%Y2YBX,^>)7 WY0@R[!XI>E!_48MOS9R2.0_.W^WX\<>PT+)[<I.LT*/^4
MT3E*K3N,M=8;)#E&D(37/\2M'VW)V2FESC<9W=ZD&X7\T8YV*/0T#I8B&S Z
MV])(-4TZ'7<]O?&D.&"6P<>P6IQ*S3;^IY,!ZT0KL>@+GDH1I)RZ9>4US726
MM6>_[P3QTR&^V1P/7 7?>^CJ!RU[LA[##\P*]/Z11T!2/[0)7%("50-1%)&3
M9\-GYEPZP6YV4'XOP^KA(_MX^K756828VYIR!%B+W*<Z1HOH(F![.B-M[J$:
ML!MU5.R'E_OQ.JOJ;\I-]>R,NZ\K#IQ5GK,=7Q3J%+%T@L',@V\\CI(^.A;W
MKTL4T_2I\8R !\QL."<5&3I;YQ!YW6%"D[8,<3JZ(.LU8I49-/@T_%(AJD^6
M8U8F;_"#0_.CL9):;OF#Y;&<U091:].XM3Q7+G$LM4GQ]_N-,47V5RQ>>$*B
M-+\\U9V6J56X);.O\/A(6U .^N)?0?3^N+^U5CRS?3$0>,&8GE,EQC-LO -T
MAEK6FYNG!-.%')^9FAP<-/@P1U(%&0-*NOU6#*J9-8GOU5+SQ*.[]EN)N2(/
M?=7B!S&7YF,+KZJJK$J_GY<H3<)-Z"F/JRJ^^ GYV[*^"+WG[W$(/CJ/&NU^
MBCJ")O5LJTLG2RMZUA%0UBRQE*X/F-W76-!Y[4V->?\E-V^_LLL\$Z:4S.(E
MZ<2SM<X5Q*U<*ZZF;85F'3<8-LJQS^5P_,QB,JZ1YLBJ7;R>L(WY!'?E]Y!%
MYSST]F.1ZG<W2NYG?L4#UG05(#!8DY^F<IC4G,O?;)9]Z(M&BA=ZOI5301[,
MOMS]4B G$(),*!@#NI_$C7E]O. <I_2[;7_//N7TF<[XQ6@97Z4>,7\G'^WU
MYUT#^E#=EF\MHBD:IX#A)IWMW-(0.,13IV]LB!Z<@UA%;<5$BK>!]?*Y)!SM
M[X=/S_5)\Q7'VR0MWH3:#>)Y#ZI08V7JW,$!W%D:W_2):A$U/+,Z(:\S1J2>
M9B>O4+H*U9<S\_-9_$2,85A2AJOST9E9[I74M(18,GRNKO7F/P#UN%ZYYS29
MJE.CZ,4T9-ST8Y.KC-M%!&O=1I-1F1@C*SINK.T\&6(19:E[7(V:S1._[-,.
MI6T*D7"X&4]8R,9N/M(4A<!-;#!CI)G\#,\%:O#?"EUUI"1K3IW.ZXGG"2=<
M%2KYO$^D]( &IL=HXLZ:PM;??:&\+QN]0W-OK<$$ZRZ:7[>^%KU]#BQ<(/--
MI7HR][BO.!@9$)]_>V@\='IUN]WR0>BXEB:G6UFC$)Z9YYU*D>J)V\/Z[:A&
MED"1"S2:+V<6/G9 5@I)K?9+.ZZY:F)NVC)8=SQ!T<-VI<AXROM.B:WL"%7F
M%;;Q+!,*Y#V[)7'H"G19<4%I%"T,%W;TU@,_I Q]_Y*;0QILVF;CEOSCY!Y(
MFJ.4F<GNE\K%"64PU7?<G*4GLVO@Q25DPCN,_$%24X#3WB\R5;$356U\ECS8
M4EB!/N"8_+#DKL2WD"P24[^3MRREYOE.G\VO0K.=X3=ORY62$3,]B\7G"];S
M&:_%JIYEEB#MC]^+7@_Y6. 17> +:>]@8)JO)),BX]/4;T($H?;CKD.I)V;I
M%4L_B\U1KP)EE;.@8"A>LD*RQ"4^7,J(:=*@$3Y$1WCJYC5X''CB%%8+@\(#
MC7*@,%ZU!,$E]@BT7,*?6PB9ECT"0>JJBMY8'MKY&48_VGLRMYE9E6,LM8,I
MTR]Z_+S8]#(%CA-<%W:P5"+JO=GL.\N5>"8W_W1VQH]^^O6NL.E18F$M_RVM
M;37?G2K02A=^!B60B6?24@7C;FU?X]'"08"N/CVV]Y/GY% V>K;:/?W5)VOY
MII[2'_ Q/YC3SR/MO/=<F/U(D,?@91S%O4$S@KP)TO9!C/3H9/Z/*B=_EL]8
MGTH]R@=WE&HY,4 JQNW)R=X_COEB?U],T&<-=O.-_<0V34#JK9,PU@1@1-?V
M*D2ZV[5T2)KF>_Q 2'&3[WS.;'0";YD%@6[D1)LN#Q]Z.&KY?/A=S-*-=4N-
MGE%R&10KK:G?\S'J#!*R@"*KL[CLM-_1-TB3 %K_>\:E\\SW#_"Z0/-R^P]P
MTU2SL4UQ_6$C',PAUZ)U9K&[.(DN5;/:^C]&MKYS_0.,4BN\G5>$;\FS=5MH
M[^\^#+K/O32I4CWM_:9?#GJK?NAJ#??ESE;49I%R&OJ_%3:@+-=%G29-D;Q8
M!.(\__$J>XN^?D1I><3Y!ZA0B/KZA/&A79>%F:2Q^Q\@(O<?H+7X'V"A3$:B
ME^H?0)Z .NSG/OL_0+NK3&GD>ZZ;NH^XZN_KA6]FE5MSGK%VY3L2R5GX\K;,
M V2,OE$<HP4OP\G7">G%E4N3TDRIO/:(XY7R)C%5>5E^:,*O5'0& \[,%E#F
M6NWYE-$Y/L;-#HJ/.4(GT'G_7_@_]IF2OTH,*!0Q'K(PH"/I=MLVS%=]P9J_
MJ/6]$I?)P2N6Z?P?"JG=4H?] W#]IU%+L4SIBP*,.'OQ)VL_@965*/2"CLG1
MG=$.D$;>"\UW$HB)/Y;'GT%=I:0 R0Y&4EA4/?\H_6/YXN)O;Q%P"3,)%]G9
MTKU20,N[C%4=261,6<H73]=AW2[*3;"#ZLSD;Y+M56A4%% ZM (F=B?V<HH,
M4J]FKY$!HX-*A95-%#O3S5V<)I^3@,= #K)4S]JVGXHG>-%<^/%C?\]'8%T5
MND]^S#')M;/AM+0?]R)E(WRCE2'<=;PH:F$=S3\-5W .$(3>%M1+M[8_S M3
M!K6.+. G+#RIXE_GW]TT#LH:6"I#+_>\VG/D;G 23.DFE/2Z\\"61;N4F=E'
M:EQJ*D@0)=)2)D++2,KS%Z_-]BX2&>@SO5$;3^]XLO[QHHC@6!&6JN=5_8/I
M/T NLZ>\,YX96R3C?*LAIEOOWCP@;#Z2L+@TJ768:,SXSCU9X"!KX*'E#TT!
MEWR5-LIFO[JY3&J6S< MWM1,6V9TF4N'MZZNYOV*]P.&FCINCM]P5:I #-J4
M\5Q:!:I>.4]AK&BC3K)!S$OBXQ!SA9<"_IM)JML3CM.XERV7VZ)<H)-B'8O>
MT6@)#5ZIIY^BJ&L11[%R8JM]NB5F/20=8(W6><GVSC]'\#KF&??W^U-LU+FO
MS/W-!W[IQX]KQE)SQA/G' A4X\\KW&S94)B_;DR;./4T9\8I<;YX_D2%OB-F
M*3THVR&U1YSK@NN;'%PH$%$JG?R\:WNEFR,C7ZCMM(;8(UFV G&"<9G#[R<:
M!H9-_),/SK!#_XRV6:?)<$<?LX 5[8K+1T?+E$.J)@K$A/^EM48Q)H6K3_P#
M1!:^#]1A)?PG]GR[4)CZ\UFO:S&ER:UEE\Q-R7+%F*3=-2FU"TB6],VZNA?^
MT34I1:*\B1&S#;EWKA:R08!Q<^VFJ7',WX&V 9 ]X^$6DU!QH1:V@NKL_5YW
M"<H_Q]=;&^-?-X_X'I).X2'PB;0S_84@JP(OU_QEM>J(=HVEH;/E :-GN5Y;
M.DG$JNID-_Z\FU.D.KP#0=$;M=U</W@IY'3S6""Q1:QL$I(2:(?Z *%OJ*GB
M\U!"39_&]LNMUO$4@C.U]IKEZ<10T36*;S$\JQ;/D228^.MVU"BYI1$]UI?9
M*E;RF.W9I3Q%02:6_/T$'8?8*%=E1:*]$8I1SHG-KMY1W]M+RRE=M-179KQ3
M#6>6'XN,5R4Z@P'=J%UD<2.N+>HRK7^)J5@?R5#?W/XV^(4FW;[97?/<%*]4
MMR>#6(+XM,W\UFYE@3%R@SX!2X6$W)E)4%IY4>L?X"[J!?+UG,[C?<&/.(IJ
M[^NOMM\.;S\*.5_3;ER1QQ]]_P$(%*7?WW_3O+(8R) -*MUO[J(0>%B(YTM\
M21FG,]UK6MX"14S/9NU.4*0HEB_B-+//HRK2+PD)E@L\*#B;/P&XPY*^F9A?
M>C=.^-&L@CHS"H250 ^F8TU\::711R#^G.^]PBSJL.6\F=6EFO,TEOJ=BA0>
MDXFZ6<Z@ZNAIW4[XX[[6+-I'+LH'VHVBI*:P),RA^2QR@RF;7E%$4V&&%)%R
M48)""3G&&V0&S\B$X<S;C=9EU" ;+4#G*!RQ7((M1(@4289>M'98#W)P'G3\
M]D(Y3YO6Z3S$\XWS$[3A+J4ZZ7/B9J=GF&0N-W>326E6AAAECMR7;'CUF@['
M)2R5RB?&/!ZDP.]25*&LA4A)8#*5W%S*D61H6JFRUR:7W\X>]Z@H'\N%-:'3
MKA&C=DANL\Y46KV]=M,YQ"@-?=N 4OLFV22C$<Q%HE4C]G5RLN-GYVP?-J\0
MF-&5FCK-JKA)+<UN"UZ&*B-M-IOTU],-V[%.M=$DTWBRF@X>9G8[J[85ZRY&
M6PP)\,+%DQE7^3^\-''N@#\^//<7OU\;"T4"/%C_NIE7WA[X1W]HIX*6>H6^
M9_@CTMSQ6W]H-5Y#$?^CERHE8/&G"]:/\H#54@A7<QOH;,EHBE-'IBK)/;GY
MC*UE2;;NRU58<L!;"'/1RB+;E.!(@!=H7' B%FS+ >;*URW2F7C%DVK]!8]Q
M5W$37 &[N*<DNFP@N7EF_$- M5@ZD4OG3BTA&M:92*CV^E4XN9_3&/D9K:^3
M_!N_O[LZ/V&-*W<_Y*$?REBE'0CG$"SZGO.9\L,O=]O%9[?U;W9AC;='%K,T
M!X5PX?90!_KPVC^#PPOHOLB*^?"=C6F@RVHO*&L"^K5\1!JI'CT/DG&Q,)PE
M6C/WCQ7X8UP$;WV I-#@M<R2'0IL15HHU@Q^:ONVFU1<P(8R%=NK9.J[T;;'
M&D]^]R1986'17HXF6%VQR6_2:2?>EQ:Y(CUKO6E&GO&)[>R3;32S @IN?V5F
M20#P$;7?BRJ+/D.)$P661-X-AI0))[;6A6'S?>[@'4T?W!QWE-O/@I+! I80
MLU0X@TM.J$-\VCV=UFAY1:V6\:D= S(](@G2E6'>FFJI)9$WM.YF)998F2W5
M;1%,5PL3"UJL?$ZV;Z5!P;7)< 9>+YA7K^*;^A08ZJ)<JY*OD[W5@LY^<KK_
M +$\FO(ADP^8]9PVIJE6%[L,/ Y#TNG*VUCYQL6;>6!^PH9"RB-8>@^5%PZI
M+.,AW"D*7U']K6:&C:9+#\?,?[S?T]?<-ZF5LEN8=>8/D*HE+T,#;I)U+PKW
M9_L]Y40&J$\<@VFVGVQO$E;)HWDUL3KXTOT#N[>T4*%1-)QP]L&<?F$S3M#J
MAXR7MCH?,47))#^B3-&/0CQ\47'5*9#7,8NJ\XIZJ"-;ZO]!V5M%Q<$$[;H3
MW-W=W=W=@T-P'R0X@[L[#.Y.<((3W'5P@CO!W3W!]O>?NW.Q]S[GNE>OOJBW
MJY]W=76U,^QH6Z/ZMXMOKYK_!B!=5ZF^GJXP*?I-1.C3>MY3N:KX$5O23C#;
M67)(\1C7[F=I3$8LDJFDNVN@HMRRY#I6)ABV2T?'][]2EC&Q3(/*@(9K%;IS
MAZ?Y0?Y47!N'%^O=_?ROJX.<JKU70N70!)O<-:QJN7Z#$24"=6_'6T2K!F3C
MO /28<6*!SL4A[%*C()II$*_7>=./P$?'$$:F>\T;.1K,X._1<4_ :/H9_\A
M7VG$T*O@J@$*=T;]0XPWXB=@Y3_V^DXNF7UQ_,_ W^43,->3*;[592B9_:^M
M+R:()2C0 ?:]D+8H?KOT$[#GMO_S>>OD^HH\[82O[^?(-#0]2>?)W4D1(S&1
M(-9*)C\N$#$,2AN!\\E-NU8B6!V%QYQ64 KW B-:MZ5WI-X7F6_B[1+$&.O2
M_&'/[?_XPWM[@=S@;@4PFFU'+#@Y[S%"J5/5*; 46S+SLR)Z:QNGO,G,V,]7
M9AS, Z5M"[N]WZ!A@[JJ$Q#7PV44=^"S_V7.WC&/..F].(*#D;U)% ?N6RWC
M[92/;!QNG-@)F6R<FDGX A)]=ULUQ0W<(9'>,#8Z6 [?5JV,L9=C,/J8?IR<
MK*MF<&(S"YI7ZMG&SX'8SY4*&2##C:;=* $ K*_T##,;+!<M?>2KJK>_CG2+
MG_&1C'<YAM]^6$&NL]&)Q,VKE+>*^]@9,U1:B=ROT;X2C.RJNY]]#U58$[+G
MY1H-1];<:"- X6C68OI"6>1]O7Z!/6+#*[)@;WVO!NQ\8!U<C=PJ&R#T8V*F
MHTRP2K;-@S"I)#76%@@FS+6FR;1:-4W(M%C\NNS7_GV2M:^H\RUU4U17,#>]
M3B3OXA. Y^_^O5P]TF%;'^YB/_Y8;(R \;*><A#DCL018L#/&SK!:>4$LBJG
M HMV] DEK1:#P#' +:L,BETZAIWLW/]W!O)@_S]:A1"2'V>&"0^@^U:B\F%?
MFOF:CIC\C9WR#@18OE=9,(MS+O!'7AK*O 2X_>^457?SHLGSU2&"G(?\XMFF
MX-&.>!ZIY<AZ'_)^85)\(OF"8_V">H?9H0(?X&8?P;* %-'5X \AH (+F#K\
MXV[54 "[69!?N%;*HI&6U8+L1@/RA<)(U?UX,L:?<$=E</-".N>("Z)WCB,%
M6XN58?1.F2RJN#5M;>_47" $\@X;56X*A>.>"O"V4\VKFSDBP&10PA[,X.(;
M (JQBFJ\PN>WH6X*0 "NN!6K'Z)QW/$Q2 V#5'?^0:2#&OAP_)D'96RL/0TK
M>51%;5^01IYAT2YMJA$5T9IRHX[/] ^&5#V#Y'->WA8N9N/XR6WX5CC,O=^@
MB.NP7GKM6:-;45*F*:">&2T)M_98R9+$>IIIK&0V[69QM.$U"'#>?],SL' E
M6)O]O T\]/W&65+]"<!QA_@9XX=V"#Z5B _K#I<2?>]O#'(R0^:X>BGNEO,8
MQM@T=LI=7WG%(5-C\Q&C_4%6O,WX%V'5G#7Q;'*YX^#=*G \BK?.VPR"'5CN
MQL#.=+&9K7]IC;:V6_H5]>RIG"OEUV"H8PH)1J3]&?GA3W!V&VZ7<'!CY/$.
MRVSF?;@)/CG$)8\TB>">:^1\[N#$(=V[T*CQ1[8P#BL5',-9\Q3OH28@]C"X
MR&-6(#0>>7K/ZZ6F?>%]A\CY$\!OY";)T K-*\W;!7O$&CI6_9J&C;C/V*N5
M08(93A\3BTP"2A&@DR->U14=L45=H>641(@7E QF^8(Q8K8IP+EW'7XE];P"
M/_Z7%^QZW) 7..UU37?@,"00;,[0JDKS-T5FC<FS0)@A0Z'84#Q2[B;K\8IM
M@A"KVDF @6@Y7(9X29-C53R_:,ZQ8H??1^#FD%WLCCSC^8GLME#=7M5W+#M2
MF-<F'?BFPI_87:;^NUR2>\9G8%2#G(M@E]%=)GYA(Z6MDP>+PF.THDY!S_K@
MZ,T>4EA-#W^INM13%'*>,?,]YTT#<1K=DLB2"Y_'VDTO>2PJB@.GR-%<J3&[
M1VA$%NJ 6H59R34D(T\)A464O1H]K4#$#9X@F]Z HV['K.8PATL;@MHCNY<E
MYCF;I6E<39^:0Z,V24Z;M?.718B#AM4!/K&KO9U6VW'X6QR##D]7M*B7()I%
M?PU9;NU+=G-'Y_E'L76\D:>]^N9F[?8% MUMCUL6CT+=>C)7,5E/<0ER=TY8
M*1_&RFH*,H:R  Y>U9@S3YY6F 3?]U'CA^7QH5&=Y?@!M.#!QG)YZW$?TJMO
M28VY%[XTP_4DDBI!N2/I[:)B=!2WW13.JAO+A''QRAKT67K:Y66?@&)YIO>+
MC:I/@/#%K21C[CX68E0I0H9 E]0*) 24 VP@-IRX7";Z0RPE2+P>JMARP=T5
M1JT4 07PE:-(]X,;Q)>M(S:-2;!IAT",9$]/__JY/S[C37#HM.]OZB;?AM=3
M<M-.@351U,>VH%R;K0E5?;NKF&D7'27THD<C(W9TTEX)O@UC$"XB#)PZ3B9U
M?P*:2&Z.XYUJ[=Z\<ODW?5QA.L9[I+_&KIHH%#@83;#4^AETP6K9+;$XTZ L
M'JV/8G$:0;WR]<"E/7Q<7?VPM=8YTD5R'!VU8+4?N_0/.1P?<"#L=!H!P_SK
MCWG2(C$]Y.5Z=&0LJU<PUE/Y @8/:AZ:$2E<R Z"O-H5 SX!A4-W$'&R_+R*
M1)/QE'Y7'9:9A1<1,)='%7;?T)'>R+(LD1\E\W^@P1CC806BN,$K2DD *+=$
M F)74,,X#]'?J1-@^O:N9H+,4Y@0L\^L/ZAKKS\!<>VZ'ZXO%J&8KC8?T0NZ
MUX#]PG^?@)_NA/@LIB<E@A]WK% ?4QXIH<\";Y\ 0 _U^TG.VBM8ZD3PYJ'A
M$W!C)G[*-1'TEB^Y_ V>U*[Y V$%7:=\>M:3G'=/&1G.<'18E2O6-OM.1AA?
M9FF<A)2#.!3AGS[)[F%,OO3> 2K3+"T%6L=12MI<.#XBL"=T_IE_46.$KAC(
MB#, M[RGDEY0#B0:4Z5>]KGPXQ2=-DW[,H;*$GN8A(OU71F7,M80WN,G&5[%
M%6/=E]54L"B5!Z6)"/89FQ]$B'M<Y^/2TE:&VDQ0##1)#'>.9+1>5C:22&X@
MG%8&HH>=_JK2V4I-VV14^;&3_B4B>%!_--C:9)_K,(5L?P$BL/+F=CJ0,-E:
MJQQ UU8L;(MAW4P;S^;JW=%^)9UE#1HG$L2&%@9.AN42A]*;TVOK81,[]<\9
M>3:P4.I16,;)MHN,SIT& O>!BZP4^U6&[99:,!C*CKT-*Y7,MD44C>#V39(?
M0/151H9OS(G\P<O'^!6T,]%S& I*?,\T[ICRUG=U9W<=IW;@"[A *LG4LO7Z
M'L2R9L)%QV)BEC"N\P26Z$G._5Y%[61B(;B-?!R/R0EL 8&0AOYPS##=6KJC
M+_JM<-"[*_/9#7JMG&G9/J I@LUL))@HUM!CQY[Y-^I4JH1R2KG:D5!9^''?
M1Q(?I%8/I*NLD1A ;9G&"-K)4A73,M>NS<NB4,3P)P#N+=L!']Z//*6U2"-[
M$DEVC<CW!V?R5TBVU6(\-5:JJ!S44!1GO.,N'=<(H09.WCVJU,6F9EH;5(D,
MSEE*!BXHQMT^^KUKJ9UOXB[DC''"QXW&LEU;F.G WPRU:<0!*]XGV0B3 #Q*
MXX0WZ=C1QR38L3\\@V>FXDJP,4I3.:6=+H@*2<L+SM[.UF?+V4.%/\+<H)I(
M5?@EQO]+\^6^M(M.;IL\5>EQ? *K@.;WJ5@\_S"F< W;-R20BA>7""9%V+;R
M)58%@@S4T,+8+\.P*4>RS",Q/E&I>32A]*Y(60Y)F-&-<U3?T-8<*&2"#?#
M!!W'>VA*A&;[O3>J$\C7U>@$C D37N+L*B\9ILI5<'>W?RHQK4_/AK.?YL:'
M-_WD+LMB!PXAOO(9S,(R136F*HAI+.Y(1\HD"/MZOI7)P$B HF<DLX\*6"'X
M7H>IIN&=]?#+$0\U])"?3;O9&BNC6VYU417DZ;/^+C1PKZ<]_ #HCA3B8\FN
M5R[O+K7S9-F+-5KWB_,YU(/#*^V/IVKW@.VW+KRUJD;QTY,G$ 8FMW:*LF3L
MX]5,O'+E2%7,G=1DX&T(\''\P4B1 *&Q)=1BE[BWZ/^$49P9P+0JPY!3<'9:
M%<+]WS$5C/@!\]L7KZCGPHN^*W;>VIZU^]WK4-&5*^=!(>MO_;U;S_QUG6HB
M5KUZO&<JEO_/C_#_!C@_ 8J$GX"=UD_ ,R7O@8VWC[CX2/V-YD^C3P!ZW_%Q
MGY_2F4 LFF>/UB=@&-) _@?>]!/@J1 !H_I@]Q\MDGF^?^B+?SCG]$C.SDA!
MU%%:SN8#(?I*N+ACJQ_?NF"+TB2/45!=L^+3NVO\I3;XQJ@3;75^B?*!E32'
M><X4>5*%>J 1:A?LT 9\DI?]Y2/:"P_(M&J('J-N3:1,:^<)7B_"L"RRM+&4
MFO%J4F0S#_DBKFZ>^*)X.9O-56(7:Y7-?RAST#9, 6J,.Z'C_JA9$F>*5)"N
MOCCCOK;\))KOJ#K#I)ML?^6% -D6QD.ED[I:Y*R5\?V6IFXZ+&63KN["/ZXZ
M&!5TJN'M)&1J4M&0:3QW\--O77%#.Y"W C;W#ZV5A&T](K]2Y2!33=[&'7RH
M0:<#VR^8*&'C>>UF^(+9QU+HHF/QRB,7RVAX=R<.5R?!DD=$',V? )W33JT7
MJ%&%U2^$ ?GW(>6G#4 =>9]*TU=/#LM;P>AS(XEAZ=C50M+&S$8@"%G7:KZ&
M\1]T7 &6$:]L9NJEK>Z8*W\8J$'9O%6$SXX2"F4K59O2$@_*8WQ8#(N3<5@&
M1@:1MX9J0^)[[HPV)0]>)31ZD4TE>L:X,T[G6D(A)PL=/^=,]KK%.S:$J0)A
M64!J%\&B)F:S##N*[@#I-X.OMQWG:7?&(K^Z)%U>I3P)95J>[2P2K,.H2?&V
MM,#)^&MNKB#F2-:S;A->I[51M!..-&(T94#N'IV"_ZH:J*)5@(_2QMS9*H?C
MAV9>P;^/'K-4LB\U",HLE V^Z++T;]5WT._7+:^OU!._,/T6!CZ2\4"?@-6%
MCVFU(M^H3\ \U<"?5]C"M2H<[+CEC4] _^1_HS.?@&/UHE_O*5&R>0'TF.41
MRJ@6#M1QJ-^R4L)+(VB5$;\&\@]SA\\^L;+&M,7Z=.<*9'E\K#YZ84R=;P+/
M86@?#/CYH_3;%-?'--9^3YW#.'%.C,<TAX /)-A*TZCUS;Q"J&FEPE 0=?'5
MJ0DB[-VWG]LU3:+:?L3\:R37IV:<-/]N=>#L3SW->JG325-[(<.ZVNJ:@Y4F
M.V"1.[CPCKIF>,DF>X6\OMMS*?E=6'!&C3ZW<8(G$4S&2G9KW85A8CB^:B>:
M3'OK?;]8X'0:94@K?Q ?Q98T8Z%5BBE0S)+U=^"KJ\[8R?:XC 3K.DGEX#@-
MH]<B]<_-</OX8SU<5])V4$_[6 <4:2K.\/)H]I2S;*(^\([@-XE^:JT&7A19
M3\^AX9P2$FP2/2-G61X&_&4X9<3-/W#0W.;>\>O.*?L;A#L"MO>?RZ+T1CO6
M$N_]/G45155)ET&K>[7N[LA(7"S=NF@8#EBYU*D'-1#J*R'=\P#3.]6X%-O"
M):LOFD0 <R6^P+TR;=8B53?B3PR'KR6S%NECLM#$!72CE9>0C<QM3.RC*!UF
MO:]"F>=&M'$/<Y$K:)WF@7D7\O'4<;L$F:DFEB X49-+*M]>_A'#0L)@X&*<
M50)2/@V4+#K8'.Y)"NJLQ39,(W!,6D2Z9PICQ&][U]$ 6$IT6+0:^6)J2!E+
MC5EV!T^8UW%[>SFC*SB6VO8C)>59L/#K]JSF.66*4$9T4;0%!G:2AAFM($T2
M  \CX]?__2+*2?,_7?VGK5_H_S;4@]R1$,[;_+ )%@.,5E'SLIZHS0:\4SQ2
M%HM%MH=&,V3WSXWT2VRG3E%?W_)/2B_'P^S7]]4KO[1<^OUVL1H&ME55F+JP
M_.$[_020&HSG%>?^2=WFN[WG.\Y^0T63'%,E)"223.IN;73J)039QI"9*QGE
MCAF-&@QDG16]YMG28YO!Q.XATSF;I-TO97)>T_B^(BPA1K$W"-+IR7\93?&^
M_V!PF_K-S\A27*T\W,N=<2_MYA8?O\C-M43EXB\X<74]' U@2(_YRL.BCZP%
M3/QY^R@=Y@I[1MC>J7PVX[MHNT2R>.PC36VU::@BT@A&>FWM8%3;P'4A7&7@
MZ"TH&K&/"CE'=Y*Q(1$Z^D<SLG8:EB1"9<_<Z-FARAJJ'\]=I70!-O?Z<I!1
M/H)'&3IXAF"%)[Q1IV^!$"A6S1D<_B95(R))2^6DS/E]L9I'AU7(10]1I3U1
MQ*M1%FX$B],]]JE-F[_OR."!E-O!^474)O&:.TV\(6H"S5V4]X:03N?A1@[D
MSD\E9D$8J"C9@4%0IQ<?X5V:U:O(67"0=4\FDQA1=<=U0C^F51*CJLB2/=[]
M6I!%FI,"__L[]-=/0&[,Q'_.,&^W[Q,@[Z![\U$$>5=F<S(HZ>YF=;5\&[NZ
M#_,X-\LK)DRW-Z#&S2:1VZ4)5\'PLIA@&&#T"HK@G@#+J?QKY7ARR;1?/W)?
M%;H)F3775\+''UO=UB7/ERB?<IS7"Q]E.@/?"=*8>:K".M9=S%P>D\7XPL9,
M-02; S&<[3\!2T5WBU_W;&E9DZPTH\]LFS>8:\ Y9,67O[*_=OO$&%K 0X[&
M_L9*7?2D9[O-<WVK9DA.RENR#!Z D0L=1#,0Y1/?Y9^%O#/X\#]+3./@XT\F
M7)H;8_Z>CI@D#-19_-USC:]FUEY-X18J1>/#S:#TH\YA3B'<^-<NJF%,I& ]
MPS-T+,T.7RN>;W/8&A9;TOXHZF@B$]:U:GG,CJCFT$]7J;SK1JRMDC42C-MD
MBI?D:F"8B2[.>Q35&N:R36HC\WXIEUV&V.^'_[!FBVHRQ  (ZYJHK#\2&= G
M^&=Q<PN"-KC['KIW+//X"5#.X<!ZD7D_QI@PJ]H$69/;.,DL _I+XOT.Q9',
M&OAH:-)BM#@$89K"S"(X:IWB8(-O>!XG>MWV%:]-G[ -76;$%OA1 0'AISIF
MD0J$. <U#><,EM[QS?@B$JH^^3_M+M=)IH7VM'# X73!HJ+D%Q:H/:=?QD =
MZ-BC^S@_)]D\PI^X.>2X4+XI."4_"30IM+1:3/'S#4&L2NE ,E?F5D1<DPB+
M-.HJG7)YV\'S^KNNQL&/<;8E,KP*)DFGVTE*Z).PK5E2DW+;^;N&##M);#8T
M[6!'C.G91@R4%ORW)8J6,*?UE79'$=F/++CY3\"<#]G'&.],V,\<6'BFM]?F
M7WUWMJ<0FP![)]_OIEV"!.G33F.I FVL=/.D0*X19JF&DE0&MB'8B"4"9Z=<
M@T_ F;HJN2;0%5X,BW\L$\<V(ZT $YRGP*HH(4!3[S#3WNCG.U@C;%I91C2\
MP].X<1%NWG(IR>8=;^=@L_<3[ Y&'2-*(2W^EW%F9WU@^[N"=_H91I)L>U.9
MEM,*C_<:G0T)MUKHJ2,6E\R\W$@.1:I=G;T\BGK@<4'C;^Q84PL,!"0&\R<_
M;TQ-@NX  QQ*G'C[RV/WP-:A:%Z!@1%X6Q2,1S!(%AIFO_TG5U*+1.L 7>.5
M2R7MSSO5/L3H/AZ8,M7YG'M *"VFMLM@:3\>/W5'+*QMS;)\V):%I; &$R<B
MTI6T8375VA3*AIU*0!-&]8RZ_Z/#,!G,]H@D>7?,0 1)\,"%9.JEA:%4)^PQ
M:IM(QAS\)<-9^?(5+8.7+O'HXHAO+7:MF9O98'ZQ*WBN,B.G%,9@PMDOHMZ1
MB2=.U,#?T>M75;J7B6!3Y_#63FCBU=F88<M6[ ]A];A&336#=XVH(LG3/MD3
MFOIJ3A-VE<' M=241"M&8.@F7RI!Q@'5X,%/!FBN@<RF9/RV]P?^HL8?KCRO
MF$_;6 8;V>_HP$I6^ 1W+;DKT0?%/IJU@"8F5-YE&*USH=@AMU]S;%AAR8S-
MT9=/,+VSP>*M/;TC4Z=%V=K_?QJB<JX9]=)#F^LSYBE1-XP-@:(179(GMC>
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ML-IP&1 M(+-_RL5&@0S"!W&3\4@\5#L9  /Z!AGH)9?GFMR5X%;N'M+D,H!
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MNL!:P8%6KI0@8\O<)\Z^-U?&Q4D:M!-&1EL1KV?L&\;0OFZPAJ,/F.@P0?$
M$T6Y"!)KG/"FNY,R>Y/,)\.!U+R)LH)1:>RHT3-KK/V3J<W>RHR12KOHGC4N
M$>-/84N8R4)1ZL?K@YG@X5Y+@8".21 D,TDH%X'E>ZVE9B-LSOZML;D^..29
M%,4TOCX0Z.]&?9!MX6RXH'^FZHFMZT'MV4O** 9W]:7U[QS$ :&F).@<LL#Z
M^6[^R'W^;3MXD]TBS(9GBYD:E'QD_5U]#_>"G1<:;EJG)A,D7:E:IA?N,(D
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MLDG19O)H?.0X HSY';)Y!'Z(Q1J(9K<P,E/&'Z;I6&6BY;)+6 82XY<]FW^
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M)QCF8?YNU)%L^7,SXS!%)R3)M"J-LV3.!PV]O>+-U.'^W*^M0KWT_!A5 7>
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MGJ,5EHM"\[L4^0YUFCS :%Z>6L[E^^26Z4[!7'!O29)<31/^(%M:BRY%=9C
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M%4R(>]HJ#";^(?AN2=D2+:#:\2,62E@*GHSTU&4V8H]K/3D]HL\C]?>K.+I
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MN"?">&5 &QTTQ,.[8TTR/5#=(6*[^'AHG Z!Q/JQ&K/-GOBV6ZGM8WG;)!?
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MC@>]A""7]TBP-;H!T$J<36.U2[,]A&<$;P1;EIAPS,G)V+5K;/JIX^@A:BB
M^@$/#1'I[&#L.8V;V^R/Q/-AMGTA=S2&OGA'P[@SZ6B]AY:]],;^.1M8/;B^
M:XQPODJZJN7",)'0%\T$@6E?H<,< ?T<V<\Z^5:IYL[F/$HGXCW>D^WM'+,3
MD\F55MK3[^=:&^P(EK7!!4&**S6 J\'@)1]Q);_<2<1/$I,98:]7_W''F"N/
MS $Y"X%R<N+>R1!H)#L89E*4:GW1DH3&66R '3NJXJ5JR*"_76$V'*T/+VY:
M"!-0V(\V0,Q[DS-]Q',XC/4)N(R%"6X5P68K3!TC@Y8+9(Y1^#=NB,%.RA\L
M1+(Y>:6NG?8XIL'?5B5/SAO;3ZJFWD5$CH.-.U"&Z=@5/G+*3WV>,*W^4T)H
MA/7"P70#\5QZK6SXF8RYG.-71JBG^PCB[5 .G7)2"?RD^^4WKI8R I,0)%T=
M%)CNG[;\HS]-G7:(DA ,/6F'^.:G7)AHP^Z&7&&P1K03S1$LM'X%%E+3F0<G
MI++5^L<OM] I/W3#P-@=1M7:S1&42Q.9&*?\GWT_A,F]8(XOP"749^LBZ19D
MH-APW(!]C%O.]D_>>+2QQ=3C6D,76ZXZ/3-E<[(E]J.:SIEJ==@N!;AEQ7SZ
MO/QY.)DN>$^(8*@0&+QQ,H^6J?P&?X7I2=DF7 (4_;<D%E>AM0+O[\X5'>B)
M?H/6/.!VM\@XKV?:@-IDL.P$P:^[4W'X.I<,$IZ]-Q$'LL^V\T6#"+[+'>L/
MQDG]TT3J$]E^=,4,J*R]2/C#^_>LI&,52XZAG]ENJ%$XFX$,*Z:Z][]--<L;
MJ[&>F! 4A0;DV2AK"1]%A#XQG_TAKG5PL^1&FEE-CN@*=#W9CU* C0G"K+Y>
MY*G?SRFCE7^F4G1I.AQ.RR*Y&"T>O$K(ICQ.]RRD4F.AZ2PU-:^%T=9G>YLN
M_Y ;TX#GH9]*+[+8[6BH7I,J]/9E1)6AL_Q;)RV:1-#)&4X. ?V#X#R2L2DK
MS>Q"Y9/^[!&9C\5 ZL5]PV_:8]4F;/'G8$.F4FS#WQ8+Q5I\J[Z*L2BR%SW0
M]Y+8&FF">@Z>JCTKDC<Z4U_]8O\Y%LHK&^53<5N__ D$F0'8R=W8WOT9_.,+
MI/+G05F7BW'S9&#QRH74H9@$'M'>?5E$4]&>6T'Z"D9#N3$M?^[X(CQ3"+[I
MMTKVK)_@-*2?^0?7BR]Y]]7-!(Q#X%:%N&!E;\;)H& +6S/.Q1+N-JPVD8$]
M(\B3"HKFRGZ,I+_*DBW__L.NTBK'>)($\0O-3+5^:X&>/F=,GZZH=/:L/\DF
MR(O_-C>W%8-I',+H X\5H]E]Y&4'6D7_W2>F4R&L*OY2MYDDP#$C-$ \A4=2
M1L-!TN6Q:KLY'3G*O53(W3E;QE )XG#[9$DRTZ/Z P"?1.-^EZ&ZOEG#2&D;
MJ87CYY0Q4JT)+D: LKP9&F :K/6&PV-+!QP?!Q$++<9FK4][Y( 5M%MF3(D+
MN[,L4U>[2G\.\,TP\8$VLEV_FVG^"PQT +-]EN1@'%(!!J.4*?IL^M 15WIJ
M?! X)Y[*W)0/7]^ K=&2#5G:&5?*7=(6^(-XLMS_;O=6BUMV"//U.)&%+?A#
MP"?)2DM]**#0E-WD5$O'Z31%RD6\B(9$,=--CCO9/-?VK*&LE/J[U4UM.4"D
M4A$AK8"O;F001^ 3 M-/>Z"%]=*98)("/T=$L"L]96@ AEJ1\-!\%+P\'4_^
M,6XBM+="YI3RUK1RHRM^+>]^EOI_X,<:6\UT:SG7]OLM69WR.S?U)E/ZG"^.
M?V ^^DA)=/'Y1B7'Q8_7 .7]?8BYO&\+BZMU07X"8^?J3XM>^W))*EI%E]5Y
M/:7A()(#VI++*_35N/]T9W#=4J].65GA!Q96]&GN_HB>IX&^FS-5UDQH0^K&
MA=6\@Y46N_UR_P#>W::',*G%3P>,'=9A#@P]1DB=,N^H,O+,_54$/5D%Q9@D
M)*HB)AM?8M^AGRQT'YHH^B4UCE+[/YP.9%1Q#RSQO O$CL7W&]L'M4V2R843
M(8X1+TI:96^0 Y2*-Z5Q0H4BU27[F?E+L%3E#*4^TV'GOP!SWB2?H]S3P569
M,##4=V]37' 1^,JYF,DW$W]E1P0YF<=B%N2J_]C_BV]/%8Z)')$W-,[8_2Z?
M"$?#WX$NW!/AC%D$8<K.',2MC="&3ZX!--;6;"+NEKPS,MQ=\'"1CIL\4&)V
M(#3F)=Q'O[I$K7 R55947<D66(DN1BU4%X\;[B&1%NRF)9,.^.R5(T>>H?.I
M#*?7X_RSWQ1-/+IS01SS6V6=9:"18^8VE=N<O@-^"_I,KN&=,,MP(_TW.T,)
M'"$U T<%OUP8.\W%!7D(:UGL=\F;-#J?*KSU&+S$E\C$L9=73/9@!995>B/!
M47;?(L)-I7>'"4-"93:EV@C#1"*]U&LE)WH5?(N8?@Q=M_M.O$;RR?AR')'B
MI)_>>9K/^XO(*313S$,12 38Q\(),13Q%(X((#1S+RI%1]?GIBCEN(XQ;>D5
MN&:F63P [,=#LQ5_M%7EA3\Q?J!):.;SY%IW>/!V H%@A.G(O)QDP3Q#>^XB
M0.,79"[[A#K5:4?)6@^!?:IE'UD !(JW_^:F1OZ?8A2"M4W0!J]_Y*#7438G
M1>2^S>JAVUKU7WO6M?9D#D(LJVLZ=9)'JL2N,D79%'KYY*[X:M."EIIYPE;N
ML]S? 9:3/A-_?ZLY7H6<Q^FGQC$#UGXW(^2%5C+K#<<6?!Q1LO>WM\"L8S95
M*??L3:K<83-7P+(#U?\%4+ )K$DW4 9)5LTR*'9 '@PQ2;;@']++-E  @UPM
MY32!Y, "CB!I]  3[ &V[966:_M9[_\K ROC?<H(T>H<J/9.P#XS[<"[H%>O
M<6!48+1D&KF!HOA6ZTB0(3*6N;:]0MWK62NVWM8'!Z>=&D'XPB^Z!X[U3\Z%
MV^GEJ#YGU(;K;W,9#MAC0:H_:GG[65'16!.N_4W0\?'2L9(4G#F 'I'$B%@:
M63NWO=.K!/HA=!;B- 0I..GVK+ XGOK<Q?V:K164W]'_N@>1';)*G+5"TRJB
M]NDU<.1,_&U<E$]C9K.+2-$2.?3$@[-FK"27O;41H#<7T-'$36!YJXDJ<;,Z
MF+=0.5Q345AA#V--[:QR]NEQ6]"5$RZD*7S86]0T2D&A?&?P=.91=.]_!6HD
M]!AV+O1J&2(;"_3:!Y6_V8];TU'?SF=ID]_$4#\K.DCO7D#!P@_B\<4 F?1]
M\[.KQ77&.D_%^+X M SD84Q@\&BD+)(MEPYAO_EY $S< T%P,HD3^Q-Q!B[^
MN2:F81/-J5.J020Q;Z2]-)1TCV^F[(K#R>KR.96?8XS\ 4)DHBS^$JVX@H/W
MFDV$=('<V"A,4JBL]"75\36/ ^R,68[A!@OYDZ"D14?_UE@\H9(KY>^69?@"
M-P>7*SD7N<U&;:(^I'5U1AJ!&GY*T8Q-,PVSP<43M"M=MUC(0V?76]IR.'^/
M2NPADJDCH1&AOKD+7LI%W<;J<N2,^/SZB7_:'D3K8'OE1GEJBDBEV7U02P73
M;TL,06QJA;4Z54(LL_SS,/;);G/\V_JB1!8I]S:FVV>J)MYG>I\-$3G:!"MO
MZ$C.R@.T5CHWH@6279VTMHN@R/;',23A%D2L<EEA_=  R0SQPH'RF$?E8YL&
M"\N8MO[2%W-'WDMXPRZK%$PNU0PB-=EJ?6\TO0,^2,*8;Y?*Y]#4VUYZD&<?
ME=';'P8PVY<S]%YM$+?.+(><B#+J#G_I'0/V#2/AXHI2RT&!V1P6OZ.11@XQ
M2B5;2=F,,=Q,!?0Y<:A5)UV!6@7L^,- :UVI4 +AUP8:3B]^?!E5K]^;CD7#
M[+*=UHK[:81+"D5\=7BCLJ9.'DE<;5-F?+@LY+[Q(*VMH> ?1OU8; .S>C)N
M$%;;0V$>14LU@:Y#(J3-)ZE15SSG%P>M+!9 C5I57?LJUVP+GN'24C\'H"+Y
MK4/MQ3L%>BEA$'<,^XKVO6I,594P9%9V>D#]-!5_=YBK&]]4YX?P\GM*J:!O
M7233$Y![@;XS\^XJEX7V7":YLZ5=4-)EJ)YQG\7>(,)/_)30CKM#HE$4AUJ,
MXPB:@X6%IPC"@67Y;@9R2%\A_-'.L:;+Q(-N<LV9"!L)N<K14LYR+8)LW)MO
M%40_4KN7X-7E6_D&L30N6\Q@K!7_UWV2SSI$8]M9'0L*<+%9I/"0I^2V0]W%
M':?)(I5<T(['*K?/-L)3N)#[0D+^2AK/B56J0!&53!ET!^WRUM;*0'.JI+>M
MH*FNFKAI?,_.L%,]PKY<?3RR/&^CW3]P&PPR,,"<NF3YKN86U3A![E)BJT>E
M ?^')HLI 89'(;ZN RH:*QUA.;ZZ<!G1M II+/^0$-V_%**Y]\%(IK<1Q2W_
M["BHAFL#.#.PX=6!MR!BMCWS!0#@&S'%^,J"8X]Z[;_/SRNF>%[3OJ#R'HC
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MUXEQYY[9WNCI#0MM8X[M?3SG"<C7?Q4AERC8?&9P;T ?)8^4%,SD8C7*VRM
M)>>BNS_;5)O<FIS?M[Y+-SP$K=,R^4U6&[3'(KE_-A?.X*R;XNH,<BNT?1O@
MAF&@[*9(MI^G#O$H1K8$C^'0LB5)+"PSS<)3M(00KO>OL@IL;HOQ50\CY+=?
M,+E=3HQ?.,&9PS,T1>K/Q.E>^Q;\U1\;A5?%#FTHTR4/S&C_D;"31LL%@:=1
MJFUK*O<G[PJCK LS8>%N8RP#0VZHUIY)D-[DW2598\OWKW1">TS9+T&49+5.
M:*OTD1V5ACGM)#DJ1&@Q94B8A%  5JC7*ZC[\GG2!2[N.3S)'VH5+E%@JRSX
MP5=C,M?ZJL?X1 7_UJG.]PNPGWN]):@RW]4#9]6=_,UH\E^3+;(TC=H_TULP
M6$B4>\\)TV:(23%!_Q^5F5//>DB[AL((R\ZOG>(M8_,UO[@:.-J_2;,*-4'>
MB6P0KLWP^K<P$/MX_K=\)7WA#J) &+Z8-JG-@$G3)X&A3U-QQM;W>3JA.JDF
M-^\WL8XKF0)IM^ _B ' 0.^*2'8[C+09'#T7V25D7&%V>Z;T+@(T>![.IF\&
M955. 9&&5\TM+3Z)"[$M/000 H<H9!ZNG5R'M-?3491>R:&HB-6J$N:I).KJ
M%YPP\^2/CK[;3_FW?NI(C9B>/,-\0L+D445.((+U.LRQ(UEE]\CZX?FG%)K>
M&GO^7$6-&*TB&IB'PXH)1T.] 6I1I^3;",L8%G]3KXY'WFN/GN^FBL=C.B0O
M><8<>WCVK^#65%"K1X:!/><;K'B8,(=2 RAH9&="G-9#DU%6??U S6YAHYR<
M('T?B8W9?*$J/\,X[H?9J@-4ROV?+BO/_$NDC=>!QQ&*7@MI(D\*$1RSY955
MPW]C6#3(Q]BC$)*;VQT2>A5.)H1+14(Z+?'?9'\1BMUQ]:^WQ3SIY'G7UAYQ
M%H_=EAIN3=5;IN2@N,N/T4#RI%T,TBIXI&G5U"&HY7C2<#"1H["W=OPP>=!_
M:KD@1G>=.JW>;Y)OOUGK*1B,V\#YHS#D(KNPJ)J1JAC; Y)NV""7V$>LOEB,
M)FEFT%4)^TOZ,P11OB?F++H4W'+Y<[0'*^].:_3;4__*]84;PZSZ<>GY\[MI
MWAN.?P=8+/]\9S%K%+;SO(V8$*E.)>FY:KK?P8)GM14F@M PDX3Z@#*1K\T[
MRI'*'&6Y*AIDWE"X1"+^*)EBONF0'3+8,-@0"J/EP^J^[$XT(IC2S#HU06C2
M(7R/N^?@52#N@J&9Z,3=O 3V.HFQ6J50WUZNM%B-:8H^QZ(6T]2Z7B$3@_=$
M__^H*^%3&;Q:L;YC[3P>JCK(PT &17PH[@RY]WP!;CT1OP#3QLBJ2MNT_E$3
ML2+;$*5?@'OW$2ZLFE-8:ULYD)&.E_SR9L;6OH=;(LMTY!P-]?!L:CN8A[F^
M#'LX&9LQV@FR2%Q4":U:*08[<&ZY5]:L'$CC^!C63;0M9A.;X%*IWK: $3:$
ML"5';B\J=Z7#6K6#3$](P1'L)K %D-?JO8":)06I'U*F^YUO,S<M_B&YV6Z5
M:/@3<\AQB^.\ZI?LPF\VXA 5>2>%[&XK.FF0_\[#>T0WL1L*W.Y[;A^*@5 W
M6S335; +J-9Y%YR(HSA."AU\,5K;A&D$GE*ML :C"/[SVF#ZU9YMVLIE8WDQ
MKZ'WN&",:H@+<XT &T.;>KD60/N G#OKP<=D@)0%S[E,V-XWS2-EJ_:?F$!<
MJ!J+E%>#%'CN-8[/-D+E)H.HI-J:/1V.QL?%O@B:_M?SN0RN=[\7&\O#A((P
M*IS^G41 EEH\_[,0F)3."+C7" C!Q3],9ESM!Q(R,!9[M PZS9):7];,X]-6
M]'X!!/G^HY42#?@O@&$F'0UO^8;B#_!YS&0!V8A<6O!W.X,LJU63XS R8EL.
MVG=E_31\7U_TT4EZK[3._07#JX2@6G:"LQRT( @\/3\(9=^ZCB] /";235+^
M\_ _'K71X&Y_4UX_+$<Y@!KLT/I\B9GBP$#]4"GLE!SNP:A%/L@EAO[*+?D'
MO@<:M)<"GF$;Q^\<BRLNLT[_NG7'.A?DN9:WE,1O P3]L24,[UW1>(.HS<0A
M$]UH@:]XF$EHIPF4EQ&JSX.(%)&:=DDK9=34$WQTGL#?U&? -)L_TQ;"U>LY
MWT+M+?RA5%*M'?T"I-8,2SGI""&MX6C[>029E[U[YL:)-R9@$E'^VLU#"E+(
MF%*KF2.W.V_%7,8_&,KTKJ'BN4-I]^:R:5-_!YF1?@&4+O2@L;\ )_!0GR4U
M8O,K>%$:U?OF\>[TWZC5S9N#-:7E0XX"[E!@;B11E]&MDLEQV!XV[AU]UX.#
M2=!_MHFL^6)?O,43;QR7=EZ8.RVJ!#?A];))%CAGE./7^%C =DQ85A$]7 N)
MY.#Z8[@CK$UR@T^N2CJ&H-'T0BO:!\X>5R*N?')?^.8_[@Y8W7[U"I MA7)J
MDY>#;+,+O)&]MOW04V4LU*R:V7($!BXP7)?R:-A,Z'<'ADL11C83@X[2,:'H
M_V5@V:YDQ*M!QU/K06XEV*U+,JEAQ^W1N5()7'A(3A:S4<=XUH83LJ>/#V+2
M3Q^Z1\ D<<-^&!C6MOM>JXDG@W=VE#$$<Y52HI-6,1)*.O*O(961%ZI"D6\2
MER^=9%'8R-M?!5K1:IQRL]:#JUY1.!MZ_SWFBG1/JWX.D-+QWSQ$^6-*BWQ^
MONR_T2F(U7DEV#F(+.*>07L+=T!,7]:^/@1V+"[:3KJ*AJY5'!Q+VJ0A=U7*
M)XXN%Q>JZIG!HV*8U0H:'0;G"WU3I72EX%=\6)>55=3W['?6N$>/*]8_J.%/
M?\^K *6OYM_50I1+K?!-5YB?0Q,WM'Z3BN6L)G%F)QW9/3W[ L1Y/WU8, 0Y
MO6;T1IS_Q[5[5_]=:O9?O/P P^H \X<0MA (M&%'LKT+SWH)%Z,^5JHS]#!$
M<$O=GW(DE&'?3\L:^^TO@%EP(3-J4OT8EXHR]>1T1.H(\:.,\?9L5W)^(@5W
M@S159"5D57G]E2P2!.\I\15+P"^CE9.3'CB:;CH^!6P7YS,Z]R&[KH=3:=^=
M%62SAAPY:\\QT_6K%D5F#?T!E ::I_! &GQ8P'1YIS@C4M'%K/@G+O?^HDX2
M'W@(0YG[A6QV4ZX*[)['VVRV1D0"NY](E@1]3^M6<HDO)==)G?PCG-.H0Y8H
MV/WZ2A[9QC"D#]]B4!D0NG0;/RS#MFJ0G/&-PC#6$;7L6(<^MU66^]-L/Z3;
MBI<]D1=BG>0>GGZ>;K@:CP9R+S'64+4*KWT?>M=LC*QW05272=?G6D%"P]1A
MLTTX=3/@&R._U-2E_%9?+)_A$@\OM:/V]F:!ET)CTRR9]DGYO!S:E9XT/9=8
M2ZW)]<\;GIH.3,^JF9@R+(1HR5:)D2,=^D=Q \- (9A6D4YR"4^RE)^!II$!
M<J;PD_7ABU3YVT\(4JODEH;=KHU&P</YZ2+&N\8AI!2"WXO;2ROM[?F@CSH,
MHBL',_J3.1"A[8#5#J#;I1"Z=A9.];4U?0E9A-,%6A>C &%K-"*UBKDP_"/0
MQ>:D(-08S4*V0YNM!_KZ07MFJ,%X(?'DD->:+I#JIMJ74#V'W?H'NYR<NWI$
M$B"' ZNF'"W4X9!%G3]\NV=O0UAF]QKEW$(0]V1:@Q7=ZB-\308SE<ECM#R/
M2G5$.QEYN//;H/D?LYB_>'K,%]^B8V3[L&F8I:E#6LL1A_T'N]OW6+SY#$52
M+G/Z#.A9@$JNSVP+?^%B&T<4(D&$YM)A1E/4W'D_N&\.^W\:W238#'@[;:5#
M^HN.7<*9!Y^0BDG\+7)D]]RHY>0("2:F,4)^J7!RS#(-SL4+<"\>S;OEMS.T
MO+R0H60KV3,ZCU=RZQ1';!^RK_PE#@]M:OD PW_U]_A32)%U0#EX'S=@388"
M]?8C9.M!K84*0I(0TUX^)9(3"7$0(YV0F\HXB1P8C ]B*^N85OMEN2J*OLMD
MZM4]?J?_,BS=9AJ2^1*2[MKJ.Y,AS5S3.19C.(4)RV.7R.!XD84M)[[YK\^D
MJ/HP.192>ZAJ SK_T!*NAYJL2!F@]KEAVJO-8[!X&91^C +<?X/:+<9CY*J8
MPL,/XR1.'*/Q:EV]75IW)J5VK?&:CLTWJF1WKY%U NIO6CN;(@\.OJIWA3H[
MJH=?WPORC=2S/%M@779(Y[%'IG>15//U5?=T4/:$F.;CRP4A #W8RM"NT#QK
M^XA%'$TVOT?HNJUY-BJ:7HA,? ?YY0U^)+VP=KU(K,T$D-T9IPK6/8@$O'AV
M/1F5K8.%]5$U/Y1I!FO:B.#1<YFR;A0Y/2VDCQN^ T4+>"XL,_?@#TO'L8-.
M$>.VN7XG]0:8M?VHG&"U-ZZ81SOORQUI8.P"^X5;H0XVG(&%X[6W\BP7WY1G
M*N:63MZ(23/$QG?H_$^)?E)_ 7 ]W-Z0$U6]B"JY>81>H]O1):\V Y>P,WG8
M_8#\E,H=S&E<H.T?F:EZ H53#.,;Q.@8)?PYQ*Z:&% 0OLCD/4&6/CF9A,3M
M MND&.(9)EF$]09=-C,L ]Q0F<)I@Q[*'?B])D/CHGI%+'LPERY DPE<65BV
M33K[G*1&NVD,/EAD5QWB<%!V7K/G9-)D*A:CBZ&9CU-% 2?)6&/'-^3Y9*0]
MY'^8\\< )GLW>3.J,T&+D8?5(D@SS-+/^N-48%<ODZ%G9X- &U3]A<NTL.'\
MP7P'=]?WB0I01ODR+Y.T8V</L5D,G;%Y,6]^*PD,W_7J%3M7X+D>V,D^PAI3
M@G-;:HQ]>%5N6_,:WBYT"I]<.)C=+'7_PJ:A9ZA#0Z,Q":/,\<H2J_SOY,2F
M!(2I>_/_V^\DM-66R@WOALKV5*Z(ZY@6'-PF^\^4+L$&T#3NY.I&EG#3X@4E
M4/L(A_WL+X_SA/SM!J8"CW[.P&'Y'$RX?<.!Y-[Q>.92>S7*OE2*VZ920Y_&
MGXZP<#T"YB$GI#U[+;<+"74Q[NSCBPS$Y.\*G+]N[<U3-<>\$6HY*3B0 ^#(
MI!=G1TC-$P2R/%KWD%JBV56G-'U*:/"*34?:H-MI%V%2'H)F?IO>$1>GB\#3
MC-\_S+]K)9JIIG7W$(WMZR:/M+QPZW_03WT#\8\1= %!N[4)C,3KL.G4(< ^
M# 6DT;D_-"]-L:X]P2_8!\$.S=?"B;&W.%(#C5)>@9S)*N2"?<7L_%-[3 #3
MJ#,KY+!1C28+/3'&2>$I:Q]J-ADSD+65&A8):S$^EJUV_M7O5@4+Q-:<^]\<
M08X)[KH4X1SJ/53J&+O$Y)/2#P(O3C,S&)AS\&^&E*[",Y6,$32ZY-=MIO)N
MPOJ&O#1,=](E/ 4.$8NT$/GH!Q#2Y%N$"911\+6F8M^'D2I<])=QM3^(A7'S
MP1=YI[X*_XFB*J6/+*D3(<>Z0\&4'N !H2G?P^X._+\ _'+X(O%5H<<&9:I'
M5HJ$(OD&3D.E1,/0"@I8-$9U>W^#09(5%M68A?Y?<D$0)-A(;;H:&>^FX[AP
MC4;:X"R]5F*@Q*@D.PZB_<I)EP%!MH=WAB *8RZ9FPNE?KW!>BNN!6P+1GJ+
MTS=S7+>>R;-OQ8/B*R\_\3!?(_A@A6ZA@Y %N4J9]D/-Q@F")5P5R&!1=P%Q
M;(?4 60MKROH@2TU\XR_0ION6]Y5?D?\ =ON?,XKB!W?N(Y.#@^)D""L$1C@
M+]0N_58%-X<5(QB,Z=X]$<D?W5V4%X=BP* Z7<DKJE:(7KIIDIC$L(GCU?F&
M:C?ZEURR?@$*:WC!CKCY2X8.64B"2]\F9^^EDC9,F:%'8$P,%.1$)58:72GY
M3L+/!P.:82IQ]1$-E0]1B+LD\-_4XO:8I+=W5RXA@X$J>CNW*ONL.UT17P!7
MXJ#\WBO%+T"T;X+*ME3+3KL0. C^U2%C7=]+9<ZEA;N-!V4;/\&(.&P[DH.=
MOXMNL@-;(%P&@H:NJ\9%**0$8)VQS"7*Q-->9[*^C/B\ATYAE:<Z(U(S%8(3
M")E&]/VJ!$-T-:2LL[U<_:AC: _I+-ELR8EE/ X_K05$B87'DIL872P\ YD'
M.CPS^GCRDGACW\R$W?@O<9@83KL&3/8NHRSEWX'Y7TJBETX+) 69J2& N<PE
M#:TD=VP8<+3U2I[$X,N*,),@3*VMAOQ[)L!#%/C;D5^6JF5N'2_-03:_HFJE
M423'BN%3<*2]=($:=*4K/^/K8524:/8@I-T@)B6553K&!6- _:;."4J=#WSD
M63DXP2K4Q2Z5D29F@,(./(. \<8]6L);,=3 WW-+N-.4@:HN>S)!ZZB#;$X+
MTJYCUM  BI$K^L4J^G4BLG'<_=I9)KJ;U_$\C(Y[TJ;5_N=!',<_4I5IF*E#
MTV:]YLZWP$T .HR8:M,IJE8+1;KX%?9 @"GLLM.P:>:C_8*P[)>5N8<_-#O9
MA/\_T8QSNQZ,/!QE$-]0"'K".%12'E>4SVGK2%8O?.-D=4&&"=?I=N-LKK]]
M*[IT<'2<G"H^D^XB4G!3IYH:E>=WHHIDT;>50T^6=YW4[I +)V"$76%;@&;_
M%:'3,YB7)Q\E.<4LU,;6BJ8/*^TDW^@JG9H<V( R51&A:$<1(9E #$W#A(".
MH54-V+A$!/BS\9Q\TVC->&)_#>!1-P"E1BL1F_QV-.W =/TN\61'96J%FS8C
M7B^OLCR)"B:DL_=Q\L8P@)'?N[+S1 J05T&(*<;)E,35:<)7,7J6W8?T![JD
MDLN&(]K1<%LX!)C)-@9P0MQ^JK&:!TML$.7%*?XK;G$C2N26=]M?.V36-XU:
M8N%"5&D/,E$C$4KU:6U[PY6\GZ8=[?:WT>:=2'Q.U08A7RLA6#06N6P69 ^K
M6<C+^PR_66# 4)FHQUX:1T!@W$UJZT)B\39<%L.JG-):CR:6L](WQ+2"1RC'
MU;;%2V->F,%,*0+P5=N2CM9-O[>NN#9CHU@BH0B[(_&/J>E207L3BA0#6,70
M/'00*_\_C)MH7X"$NAN8;=)M_\8O0'OW<NN3]4SX7_@GXXY>^-,,'<@WS\WM
MSE.AV]07DY4*;F#R?S.#SZ%'/JBLOP!!_T7!9LA*8L[NP?L7 *>W7[[&[?W[
M%R O]^.2L7R/CG_]4>4+@$G2Y_^;V/]CC0(+77"NZEW7>^/IQ>(+\/+7[A%.
MA!^)6)1CI4KNC=B23E.'TOQ%^P(G2 TNFXU[W(Q#^Z[A%LEA@RQ.N$1_]F&=
MFUX!;:&":E[Q[ &9HDVI7!#F2$;OE@1GSS_!6[G>?IETV!OA3YNL^74CLER4
MJ:H<PZ1^HQR.<?(Z;M?@ZCK1(F@JE(=1O84]+)*M+W60#;+!XP25U4\XP<GP
M+MO3?+=;YVJYVE[^J*Q<,HME_V*%.*9+A08!5?QJ"3^#[<>U#N? 82*.1-<X
MYEOG00FY?CEQ!01&HR(?4^)&@)'.\*@VX@&K^Y-;?$H&W67),CY3E U3-"N(
M->E%"%4K;K^^/ 2';:F*;QW02R&;24&GGTFHGIRP$LZ89L["#9=N,S#S85!Z
MJO(/"9_2!-H2[#D-FU7:'ZM'?%3@?[G:GS1T1%GC H6.RFCVVP-D-!P[Q/PC
M3;Z^[ 25Q4ONYQ*.D4I+B3'YZ#8*J)\];/5FK3P$GM-#234T01=AA1;M67:H
M#!T-'8UJN3[:$:+0F5\U9%8_'_E[8&[^=P/J;O5S*X'?0_7IFR,"UK;1#RI$
ME=F4NKM((>11C;2NR<I$60F,H@6GN^4CI7<&JEMBT)FN!40_P]1=RH3HL)OP
M?<*]D?>+:*^<' YD<,RWC$;U3S-<R=O5D&G(0L'.$1GD]Z;"H-S5?ZNA.:$]
MJ38#D?*NON>OCT&*7K#UY&SU8?TGPEAY=U6CWY[^KEQ?Q#/,2EVKP+U*ZHU\
M <Q5WKB_!YZ1?@%DH^'\+W#\K8I5E5D-G+\ 4/\1C;G@%R!'/&@!+$^,X_*0
M+9V)S<8=61_'Q*UM)H\!Q$IAHV9^WD&;QA19;6ZEV:8_NG/8,UUY,U_:E."L
M<XFO1DN;L]G<)K;:HK4GE[&6X*Q&;Q]AI*&9AN5-!'0"56,M [>A8U(0D=FH
M#7^(QIAAURSX;N_*^9!L1]&>#?E9Q)0QAQ:D)?;<Q'.UM>B? -L:T-K,UL9M
MY-5P8:*<D50>>"V=FSMPVUGMPYY:8/(OCOF%<IU&Z.:_<WDU^PYG7HAY.].:
MEH,ETX;W9]2]NTJ)'5)(@1Q$G1+\D<H)DGLAC>;',,QC!I1%OM3H@#8;UR(D
MJH22'=6X.E?T6LX<$ZU1CUT0>)_B -Y#40/3@,":O0='V#)^U%S4Q4JY15*?
MR ?\E.(L14>'(YI=#$K]*4K:BA:&.WC&_060<8O.NPXN[KTGFL;">3L=5/OF
M]$]!<V4F)JXXJ#3NTFYMOL(X'!>'A2[+!HRLSLV1V/G _8S 9)&U UWU$$T-
MWZ72W'+"#_%0FV^X/\66:JX:=4-3+=; $B\<I4..A>SDE450U$;J9.PEJ9))
MK%MCRG1F7/,SE75!FM!0X#3TU:V!A"V.-<3,2,D[<0COT;<Y\NQY!]OIMQ5$
MO#IS*A_#KP0$K._<(81K\$B52Z4H4F_DR+>H3VP2V->^H2VV<0GVJ<%FA+M^
M#F%T,=)IHT16KL<C(VW\AL<4RMM1\@J;1WZLOL(*U6&R9_H40>01HLIB4@')
M!T!1@*ZX_NS_T?HGUO&?GC-G_9P5.7<4^YBEHZS=NE T5WMT,^%Q-5^-#8;9
MDUM64 ^Y]_U&H(<;7^-B%5O&6<Q[?>=9F-1&@U)G'RN>#[O2<BW6GX8>MUV:
MX]?7]'NC[-W=GL8US/F/BM?&R.1&KO4-%S\<.9^%A2VL^-WZ<.>SY7 IE7<H
MO:LSN1N^/:QY9?"52W&V4@ &8P131H^/QHRVX4AWXOD%I28-T=^^@PQ3(C@"
MN?V9YX(93M'-XL:P"DZ,YVF#*92I:0Y.U<D)S<C^FV/&KEX,,D"A-C73;(,%
MLU+<][J1)5244=QRJ[U3SBK^<[4R33>-G$/DV#071ZX[$!?CU?I!B8B#5I^U
M2?[ JT\P=BT)7+5P!WKVS_.LDR1<ZU)4T9O(ZMKA]4.^5@0KMND2QD;NT$TX
MH'X6EFX8$E(Y>;+NM5.'903Y\VLY"!+S%K'^%CHYLH-MN$B]?$ZW^;3?A)IG
M3^AV>QB+$$MV>)YQ?4MU^PN083_[:^K_62B;?5CIL\@P6.C''Y[=C'B)L'RA
MACT0->LPX\#> YJ]4(%\@>:3WAC?<<I&)_+SR)7CJ/FI&JUI[J]\3#SL9$G%
M\E%8/YUHZ7L_W<*^ !_$#<:#K\&DCVP='79Q=S<M8TGWE%W3*"LU0:XA5EHU
M-C':%BZ$(4!T+K&M:+HBZ)*M3ZP9!FY\WK/5P;6!'W7V&0LFYP-PPJ&6=(;&
ME.;>AG_<(;/8V^3,,/&J*GE'#Q(#U_BP6[N:!-NR?:A/<&@Y!B!"8\1ZZKX
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MA:@GC1M\=#LB'T2?.7H+ !]$#0) -TV&  "<C:*H87S!1F%D2-T,MOZQ.B'
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M^/.:!C<P/./=^:Q7</,]] 6Z3VG[(\N7XT&SS9!_/65[=[X_,,&;8/B=Y'4
MSNL*I'0L=_[1Z' M_UAX%VMU[;G$9%TPX=_.)9KD*WUOV4I"_RI$-7Q/8WOX
M!> 8YK<<]2O>>NNG36VZ(6J0!@E.&A]OBK/8=23B=A"^UNGDY<?J/GD27U .
M?<"SB.D=3I(JPSXR\&]GP^I1<D4/:$_SRG6#7U<-SUT@?%]ED8CM&R>\.DB4
MI:P+"ELSI'I ZFGY0!,N4T@^Z[47SR266+#D&)\1'3S_:V&>?6"JFX'I\W-U
M&Y&H\P^7.@4\NO'CEHA3GN ='=&^%(X=,67LT:^CS@SKA8;U%-XHKR<S0MQS
MWB-BT[C6@V+<L^1[G=<DK4W<&:AM=5I9EQ[#TF%ZQF18.C4>'X.2J]=44HL$
M=F^T#0?&+9>9RFT73 +XAHSN@S&!*]E5',G)'C\21J,S-03XBE2,&L6MNKT_
M?:T26:JB<(J4HZ5P/>,T"/?^L'/W^47SA.'V'J]VF!T80GMMB_0[[W]I>6E'
M$_03S>FV-DI8SPPT<JE3L15IC815@Z?C%3&MYV%3$T:4S(+[7]H.F.YLV*]R
M#=L7[(7"L?\HM=MV !TO3R9WO.2W"J<$,@LM"RQN^_>6]O4M/G<;?F_+G9YU
M>JV[Q@G9^'6=3WPGWGQ'N+5:?<U  &)<KHZ^7QP?OR]'S@DNO7]N'RV@ (=6
MK@4-##=>/*6\8+S.*+\'N@EP^H(UOX<?%X@V+C#RQ*JR(FO<>@#-LB;0%.Q9
M@T8W]M"BC&_'9VNP-GKM@/6\O6CS6]:RXN$<M9Z6+N'+%U&<G.6W*I,%?9<9
M>'-=7,LPW;H4@''7C&R]%DC%7R?D>^L*V;V2^NJBXCS09XKKHFM'QAOC^G)\
MT8:V0!DLF(?.S]QG^KIV;5.G1[[DJ^0#*4H[UB7BAP<++ 4Z0Y+"J?2JEM2>
M?3$CO%PHZ8WWZ2_ BH>S;)?OL)K^@H ,J=+&$S@Q)_KC@@1SP<DY]NVN3SL$
M^[%"0.:LA7:*4I,58?/RC%&F4(E&#/?:+K-A"@%4S+J)B)N>I_JHZ@\'^,P\
MXVD&AUFH2&5UDIBTJ14: ?QA./5D%>IR]70980'>M),@"6*10WPT3&<:3+HP
M(ZQZ-.CGMJO?(@N.F &%A )C!>MV#K_&6]#SV@F+ED%P0\R:\K96=4\#.%,N
M$'%'Q[@1BAXBV3H.;3(2[$4MR0JS$'#2:3&',?/0&5I*@BI>@X-;-1>+]#@Y
M^N9.F59Q?0/D)G$M !YX[W'V?,YR]3!&A4QG^3*,7+H6EQ$,[HY\HV 93;!P
MW'P=M^HH>#&3QU[S[$=!!<!V@A57B5,11&QW^\&[(87O5/*L E%:#']?]3>R
M+%%S/HSTN>Q6L>T$Z=Z,\:/?321N(J0VM=(3-@@!*P943BLT^P448\B# J7K
M6Y)_D//$RA;-62CNLIM_FG=I:*;G$N=DH<N5RQDOPMHNA[/$3T]Z*GO3Y<9H
M:,5B76J!I^,+T(' 8H<#6%>)W9Y[8&UL(K%$N QTP#A@%>($B-9EUY6\0NP8
M6<<KN"=S(-F/:WI)>K9,+O*2;MU2G3K7F>#Q4U.X%Z+N0K/U[POTQE%;"LUF
MM6-T*:S8!-B/HBFGK87<9N98]TMVT M,K1E%/1OY9GQ&SPG2X\EO&<&J(9W4
MECT7SUKIJS:=O?. -XT<$A756YL-SIN'W.<>I\-@T7[^T6V3NO07\;^\^.YD
M5K3,AVOS1*D_<ESD.Q7I&2),1\*LE^PZJ]<J#3Q]XL4ZVT9J;FN5\*3_PAZC
M$W;@M_/2$31Q"YEEG+FQ]-,_;JVDE?Q!C-I8U" Q=D>01],90BIIY3?_1-=+
ML%(B%=SDSWY!Y3([))[RSWV-W?!L]=#$3EA=*/ WN3<,]?Q<JOE;OWU0]>>,
MKJ+.:&LK^TSH /OWUDVYP9)  LC.(9P4F'RX8"6H?1\@%WZHN#KU:1OFM1#U
M*M;UY*="8[K#9Y ,]$\:699^V1W,]DQX=YZ@GN9,S6G2HX$P?F<^((6GV'.4
MVV&^9.7#-9JZDZ/P\-:'3$,](8*($4[K,E(#AL@ZQRPA_B7$A-X]\]GPLUP;
M=&\H9  -=6_L&%OC-:9Z9V/>("2B5.8/Y65:8<_L5^(B:FT@H&+(1J4(\S(X
MTS!S7I[RDA]L2I'W^ESX<O:,-??KSA4K4"8I4/(P<?9W2%NZ:*M7RB!Y*Q?[
MNJJ9QUI1CAHQP+M>U\F:#<%)?A?<:SRE_O@_35FJ?=#@!0Y%W*]0WB4R@E3'
MU6;=CU%0[@+!'UJU5]@.B+%V<_F51OB5.JX_CH3LE\\]RAZ?:E%O8OK@WK5]
M^*+99S8&VA?,$WC( EL3R4%<=[M6/(RZR7Q,-*_COGL%:,<%)RMW$D0'C5<^
M"!= 8034HF,$6P$V)Y[^P87VR,3\@W5BIN8='7?UI]2HP5@SV;L'4$U.6\VN
MGO;!K\OTB*.F5)+,KDK^1_-)10O2D7"S2C5L,O ]TI>#/7#?<E_(4!M.H52B
M@5V_Y0G,Y!'3DEF4A6]W2[;RV3QS%UA$V/GS+7J-)Z4,GF"T"^2223]])K8D
M$&&TFH=YKI[+.[V9;.\C=JV8R'71QC7$%^1^"%A2YY%'*+<+L*?PT/7D7LRH
M-"+.A)3:F4_MCG)I8LJN]E"P+#\DDK8"6<>"!.I_OEDW'>??(]3Z?F!N\8^E
M4Z^91W[;9*Z83WYP07PVJM!FPSG,4]>K?2_Q?E!1YJRL@3RB2NG0#[^2&6MW
M1S9@(3%5"T_X><#4=0^\FYYHGU\:<U>O,P<B7>Y6;8.XVCL2^7Q5'DY[# J1
M+M^Y9HH_'>MV^B<T]L Z0$N]DK/V:86>K0O^'@CQ?7%3IP2YKN*I<,ED3J:3
MYNUMV$N>)FC#K.7HZ5*4*#))/UN*:H%U34[):WMD\"-IW]DY*/F6(.<(UP18
M-_$"R7+)"CGY=(#@:+FL"2IKCXE=WIML+<*&Y$J7W-UDEGZU\9+$"6E_!QLW
M:[7\QMSGG$$47>* 9*@85[ 1![:C'(H(=<99-G_'!9\C:N]TH_>'Q$UX7_<8
MAL >]$S,A#@1GQCN[I\,Q]^7]^.6E1@487%(X:+_X)@BPP7C,2=">KL@5! &
M71AX'(YP7Y4K[<J[HH[/]\#D_F2U-LU@L@A%XY8?QN;NG>"=,V.: I??VEG_
MEA(6#BL.?@34Z+L2<=Y0J!L(WBFQS:AY7=A@:D04@Q\S\+V_2?/;/ 2:70D*
M'"42I;Z@1#T'+'6_Q.Q,5-1LHI24[V&@.6=NO?IZ'9EN6EKO=U=K-(.@@8[+
MUQ^YF[H3^7V5KX_Z#4H1P ""HU]? *Z5&T/3&J?$]XI;B5!OZBEFA?288_F2
MBI[,..V0,91U?EKSR^MB!"^]A#@=@]'D_>^GE^V4?X^-DIGL?,S<F]DDDVS&
MA=6T::7FF!X_CNV(FK-*+#@?,N/_[.*\8Y'S:L86O8)MZ,R!23Z:ZJPT3]#:
M3FF'&F7V_I3'D8 ):G^B'_=,F-1DW0,,6KDUB,Q:,OVS^QU-7SMYYC8<T='M
MQ4'646*I49?3CZ6\-T0>L&F9.9NY;04M#WK,#I*9R1++NFFP?*<6%&T.J?VK
M]T!O=$U:^+8^/NXRIN=BYQ!S2?QN[C]:8'G:[Q^9WO*:'&/PQ!C1:-%K@NBQ
MM:CG89]S+S9S((XFO.!,154:):/.08U-0-T9YA0B=S=4_@6(O9%I),[WE01V
M7 KRO@]=X4P3BSX(Q<^9+2$_'Y&P*_#C]'@G]@ #:!L:UH#Y1D]OP; W57H&
M 0A^T3<[[R"7A]6]B</"CS'BV?>FRX&I07J2UZ<K<+$30[1SMR^ 3 X?<2&(
M%X5&M'/D'=;C).6C$KA[Q7<7;7XJ^>.>IL60"D1R;SMOYG%+PO;ZJ7T%,=I7
M!_2_&,GF(T&Y\*"X>H-#>6!TCKQ2RA30.A+;# P.0,+_ K .!0S[Y[P4YOMM
M[>8DO59L!!9N]G;M?:[Q;D_,S( ,D4]O #=$E!&51S/A_)[3<@DXT[4\!Q0V
M!LL7OV<01D%8<>BT'I[6EGJ='8YP'F82M*%\51AL>_I/5::N![(K3S"5I^Q&
MW,*-ZAEJCPF11LY\>[ITTP8+E^4KU1JS*61-KW]R=%-,M<XI@P_I"O H<!-D
M"E8F,7FF\#%HA'TJX*I'Q0$U.:+H<YV,6FZ_F[KE@CE!ZEN/7P!S\K##.(UG
M]/@)/9\2@? SA%$55CIFA9\)4<N$W4RTYJZB4#+(M$O@).VD%\192]'L/!V.
MCWWV@FR71KRK"QD??[?M'9E;X]9D>F=C/,,G(I<5_\[+M2*8WZDC0M/;0T7!
ME8G+D!)A=Z9F$7BX85M_W\/^WA*U-3"FKFO5O-%XS,5911]I]F KYV&:OZ&N
MJ!!DEIE>33$WO[8X7P<_&P+6!Z^V75\&;AKJBE7=Q0D[O,7QC.4+-]@I!>OU
MG.,?OT]H'].[L!< <RQDF32NE9CHQ135\R(5^R+E==UWI>EYQ2>X-M^@)R+_
M=C*,T-YCTT';O3'1P4A'Y$U18"'3K)>S%)DVIL=LV;8"(PFQB=%,,2NW?$@"
MHW@JV#7D:G03= 8U\WVX[Q)+):KO.VBNH7'TY0#\+9QS!/9@.7:UNS1XG]XT
M\ZZ5A2VWJEW@]QB_ 5X??:U9@PLW)WYHB$0<M\89T8T/@M.?>9P3%@6Q37NN
M0[K EEUJ[B^ 3:RQ.,W6,,^F?"%&1V,9^Z-84/TD3X- /,*27VO$\Z$L KK;
M(4\[#5Y5VIH )M9FO#^C=C.!&6[^%R"/45COL:N(BH/]?!3OVCY!5U5L28#*
M70GC+M92QH"#"JI6>SO@ DI:TYOY.P)M$XX3(D-FY#7YSW>)44Y=$E$VL'59
MG'RVZJT65"LUB!_(*K$F0%L("F@!@3\.HH7T!823BR(22'\O.O!K);9,Y='@
M'W$P_OO99)!"AW3O8)Z1SX67 ]=,''5]ZP][-R$"J]>.P[P6/P;[MY^YZKN5
M^,W[M3C.%<S*_L6]#;'\,QGQO@!_V[\ SV0<AY9>WD)"8PVWJC5Z7P"4@9.3
M 5_9<^X8^,LC,9$!O(BL0R1Q8,.EVH(J80#H"F&R__<[TV0+M;>C^WUA7I$^
M:(R?KN?I7;Y@I/6*M]S=)Q-):403>S=&3,O29^]JX3;XH=X[]?B&QY<5J+97
M8#;1V0]W5,@($IT2>.[RY;S1?Q[ VO#<F6E$,=W 1]5\WV'Z B#B'!B\,PT\
M.0/G+C'68+X /8+Z][MM3/:%GSW]WJY?@,I+H<M*7A$_,XM4UE[)0P6%FZ97
M"-U0B@N*9E%"_ *\_!3"X+FJ.? B_&Q;WQ J",I]>=A8]J8M\K8KWXW0^+K(
MQQBIW\<X>K\GZL_GVSAD)RQQ)+4(:BC#SW\E\82VL]2C91@_9)5NEX7C]\ V
M8S#('E=/R2/%:1E%GW&S,:@\#AQG!<Q? )<<E*B\*8Q+=8XRG($&$6)PQAE"
MZV:A^ I:Q[.TV(?T%<E4"$D36SA2&-A]WR55$]F38:FJ:$7@T@@JG 4X57=$
M/(OJ.K>0A;=9L064:*VIH'M'GR:=+("(](.7+L!>+NQ"@D96YR;L*I:1EM1?
MV@H:72;IWR]5J',0T-$1,IF4D =<7 IA^84K[-ZBDQM+[:'9I>BB]X!GFYBQ
MB"SM<)1RA(P1/_-,42D884N;W]&T;<<A:>654WNR(.#PC3Y==\$O.$_B9Y5*
M-LT[4;0CF2]2F]MTGCNDG6%_LD8=(.6D-+6)W\M#!6CFI*8FI4PK)--K6I:G
MST1)[AC%P;=.8];#;ZW>R!;XF4ZPVF$T$599=&S;WJYKICZ-H!&E:#6!M>!D
MG-"QS![=KFX56A5/ZE#*SAATY2,8?R>J,\[<KV+DRW9JF<?THGM74JT+2@W
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M3Q@$W"_D]58=&-,*LAPY,DOP>_9X!#X/1%-<_//AW1P1_%.GYP73^KKG/+#
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M=OQ9Z4BM,T5G8 Z*E+1C0%OH%L:9<8'YU)8[Y\L#5@^HK8X%CZI47N>*S[V
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MN$WRKA@FG1028@]>#A1Y"\;5Z7)&?HQ"FH9%*-'-PM,@ATZYP&VEFTQ0F4)
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MAN)B-G,#6SX>))C=4QE7[>1]ZQ47'ARBO8,2R1G;TT_E(HU\]0L]U!2I<9Q
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M(L)< Z"K@^ <Q!8HXS.:EM POTG&W["P*8AS1 (EO"GQ%"4W&U]#0F+6Q+_
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MTUV+4:,4/_*5KXN?6<$'BYJOK391#G>Z,:B"WI-PAP!L+/,VOMW @7'VSAE
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M?['*]5@R2@[MMBQ[K)\1G@VN#BG7**:/+_::,DJ!RZ[7*.V5,$K0)?;8Y24
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MIFY'72'0K&0@'$=PI"7P'XK59\^N"DY9DQ**NKM;4_&UDEV]2FPHS::@CL2
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MLI%G&E:Q&83:SS-,%NF1D#F21E7*-9*U6 Z[0*;Z\H<-34>T $3;X; XH0_
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MBZ;G]S_FL3C%//9I>.;6+\.IM PFS_/:SYZA;"RNZA(CN?A)5*AAX1)E[5&
M,S 0\43(,T,3<])0YZ"B+BDLE\Y]K96^V1+,76^V_S ELJYL&2KKU#C*MDPE
MSE!)4RB[XU JLK!F)+9!<\(S/=EK5+6$=,0ASG5%S; NV9D>Y_]72;Q(&82'
M+;!B%2@M()WNG!54+,V\Q_TT =Y$5S+G'R3NA#/]V_^%XD]9_?@?I$?,CU[G
MOV53^KW>+@]Q=&U5<Q&IMD%F7"JBYJ4L0\=L;]()F:9Q1\SA"CM>EH0<@B4F
MWB1R,6ANEQ&U]<5*%LG-OU.PH4:1?9K:%E+S5+FV@<\1[4+O-3A_T#'E8[(L
M5)^BUQFC=Q)$1[&[98M5JW.$+.)H1Q/)P/J(;7AKJILBWQ@*QR50(\22Q$^)
M@VY<'9#Z5X.^-?'0N%L./+5_B<K,P4P!8O)R[3]E*2C"!R9"N/Q*+ !JQJ>S
M:/>MDF%>+/<<@;EB_@N19(QL>X'5?Z?T$U!'%P3\YS;.Y#(A_FC\FH-P!B?5
MSW"E(N;94SVR"7U9(E,7]Q*[N!JY0/Q@+86]Y;9Y:5O#E3^Q]\3\-:3[9?''
M->.+1+3NV'IWF0Y"/(_;[_%K!WI?6(::'GRYTX"LKQQ"0(O!I!3GXK87D4A9
M6F-#%]4$!M3*R!P>+!8 +=0LX?V%7X>$^[%.TW+]]&)V(&VNL\0^-E]'L8+<
MT,T5=SVCM22-K5RQ>9G@%L->?AJ&"8LFU!(E<\T#GQ4O^DK.P'%8B*\>_MQY
MW^#@<<*Y1BB<&FPO[KZ&@26,9PNW@PJYJ6RQ^(BV/U<-XU=^KT"I\-92V(D*
MV0F:9L(#\\>@_K\\[9NU<AYB!HDE/EXC:._0O>&%%W0->%[G#;;3>LGRFFW4
M^%$*,9$BF7 ,%B*+@T++1Y5A7*DV0?ST^*:P'%7!4O=;.]G;0>0$V653Z8YT
MN_O'X!2+,3!&=%D<Y>K3:37A4E<XHBM-@LMR:,#H7JPXA;O27NP(.=]NUR_S
M%V;1ISN/PH[*'@NW_=18+G(%+V9;MR'R13RCH*TXJ6#P2 B%#=%E34J!6!D6
M"B]<,\&R5(J/_4I\@QQV =$Z2YV<#EU@0XNCI]?&D?@W/N=/0!2/QW@[WE)F
ME&VH'57_N<XS;BE!%F&%2HI">EMC=4YH_2W/G6M<"!$,@*QS"'S4=)F BZ5I
M32=!^.OTJ&78[4[C[Z/F[B6=83H+%U7P/D7=&2R$1J/&]U")<L(2>%4LD^(B
M/6I/B)!C-.U:'2E:E"\/!<TP:2V9^T@;%V8S>%U"ZC7MU#DW9A.X[9W<@<-M
M(R$T%NI;F]1V)-+4M/+9)K/]!.@85M6R9:6P",T3;4%.^SWJK<0Y2&@WXIK!
MA]VD;#.DZ?O(/*/D3\@\MO2AHKKK=80!JRO!$3E;#<.8TWV:BZA"GX"]P%S\
M(J53M/MBGJ+@Y)_IRIUS=?J1KCW#3)Y!%]WU4IYW4Y->D9AIOVTX/@&4ZM?7
M,-7>XXVGA&S]U[2N29(*?JSO:Y$CFR$)WFC).N;QY73+7W;S@9W;KJ"::(95
M1QO/KZOV\9,-ZL&<0A;V7JZC9OL@D&+K-=OV#!;CRD74R.$H$59S;K-)S"WD
MB4)C/%X.!,< !1F\9/3!ED3+8WBNN &WL*+\<O4G@+._P_1KW\MK7!IA@@4[
M+'IH?8EC6*U@<Z(HHX^.0+JYA\Y7%Z[:$W#GX.G<+UCI=:P*8VDB@7HNEQ!O
M@^SF%_-0ETYY@8QB_#-T:+0D4Y /D@%!)?"Q$7K05&1XNOJ42BQ>3NZG!-6!
MIN26%I0)-L77AI*_@<8O7@T62OV=O*?N+)/I1UX1+NHZ84Q)U",97*0D =.F
M8;QV5'K>#K0OU'2.-OY6K'T98WR-$ 6\'IQL@5/(,M"H^DRA0:EQWZ5 ]K_9
MR4YAZ'P]]D#=ZAL&2FGCS@RYA-$DJM$I;.F["G5$_@K:J>*%B XS<=]7;0N/
MS4(A$T/,EE/QBGL1&AW( H?::.>UNM#V3:%-?8/7NY#<QX+;[8B&\)ZR%V^#
MFK!,.#+P._2;.G_1*R2*%77C$FF3UY(S^<C4^;QG(@%9*5SC:Y$?I5TG=?KM
MLI+N.[ ;T2:W0UL6T%ADB([LSQW13(L5K<'4SM'T]74H2D.FHQBT-FZ,,=^1
M0ZI455-. ^6R@IOZ8\"UYROEQ+$7PYN,4#^6&6SZ:E_A\>/*?A5E'M(\T(;S
M[G<^I/*M-.#F@- ZK0:2S-D\SCRH+N<*M%RUPYOBDXNWR@?,' WK;Z6'J6E!
MTJE"7#]VIB;Z-[0@[2PV[$V O-8+@RX\3;8:J?P2NKKC;FF5;**>F1Y<K=!N
MR.-J_(PN$C[F"S32IF)JUOX,;YV7L>/ </HRN#5NA1][\^0!>2Y;8[)'ISFK
M0'/.&E7,>*SHL)AFD%Y'91HKN0* 3)04Q4<-QL4[))TLL)'UMW!JGI*FZYJ"
M<W4F//M!5LSY55J>JQ"EZ8#<P1\V!\YX656412QJ"./XMS+F.)[&!LYFKH[,
M1HKF@IW0XL@$1AFGY3(&Q@ZEUJKDG%>;M08[8:SY&HSE.9MI?6@^>O*.L6WV
MP16.2MI,;L(P=*S$!N":)UXJ-RJ5UH*GJ+O:BOT7N2#;7TJBH4ZD@:Y^A#N\
M6(03_T2\O<EV:,)."NTF\OTQ-V+RX%.&5K**6 P:@8R"1D53"K@5-"#))K-<
M/<$7S.7Z 9_0M?MQD\ZN )Z@/IX%WKWJA)!;?HD[?@;WD6<@(O6(FL7OV&=W
M[8/YBF%:%EO+GQ(9<R!9&_3H>0CT419RJ$%4W4=$YJHG?%[I]^\"B7;P#[CC
MY^EX/XIQ<JGAIFJ?+@TWPDO92I<5)6G[.3''Z'''0D?-8!%C>((/9+&RBPNX
M*^H#;.,=U4FCRS!=>OJ0MNV7M><)!=^  EZ75(;>JV$"K+$8S*+IU].RR8R<
M=B$!$;5T0_29\>ED^D",,/+8\:QD=E)'U*XA:\M?UYDOCA/*S!UI#=J5:#W!
M=GEEWB]F^<6@;89SMV'#D"U.-(;ZW(9UE*%$UNZ66E]#^FPYEW&QB/MI4!#7
M$ (% 2!,_M]Y/"<4#//;B3'"51HOQ_WMC+,4QH07'V((-[0SU622@D_,$;M,
M+F5,U;BNTTZJ:)*9<XLEE2<^7C)J&/N$YA\7,6AYEX15#SAH\)<%O3-\B9R8
M(TX21X7S 5(;9U,?&VVD.?(D\4;V>%[N2N;23;<)U')<TU;%=C'Z]:"(:JR.
M3&2E.=<+M1%]_W%>Q5D5,VNS$7T+'EZS "']B-]3^BF\A 0I)".S!&4TMCPI
MIA"M;%B#L1(P[$MP\ T5"@R04+W.(V/8=#X]]3+H1Y>4E"^$%1%DB9RJO-,.
M:3V$R0H9%$K.J*6:VK_WF(,IJ5H%0,FL>/GEA7LR2MK>QQ#C<'Q!\M>. 4VI
ME ?<BS"<XVV6]/LT#A:;#Q46Q*D'!![,H5(NO]4[0YHF%!+WM4[Q^6W5_PA!
M.IX@M2\W:5 UR*M%[O_)-AA$0KSF<AGL#'WY=0320CCT-4><W.A>8ABX!0?%
M'EZ/3FM&IL6W>%DGZMN\DUO:V^1(]\:\?UG17;8I7J:U<=;_J1;5%MC&>L?-
M()2#L-GXU*'W])QUJS9BX3>EG-&*T+K[E5)KU+/F03=\T8;L,KP!#$,W:DK%
MT<C&1>*"5UY1'?O%3J;@VV!8I7KR%]+?548@VD/IY'/F<0]2W<4ZZ1\;RF2J
M%A=JR[+?HWZ6"LI;,"K)5I^Q2KUM$&=J'R698;DXNSE;QV)YMZ0.RJQ? G@)
MC:\%E=JSVA.KQTHZY$<>Z,= U"S\^UWI\P(UY]-?F+)S1Z+<J:!K26;?Z?B(
MP/4GV>8!%)>:5H;Z4KK0K>P)%6W59'4F(1$NTD.?@ Q/.K<Y\+?YH]/$'\I0
MP%.+SF\4\B&'<;P^.B@<8V@TT93V%/+ZU+P2+5J:MXS 5S6PD0._?I,#.@#G
MZI]IY-=S#&S5NX^)BTN>S+V+\JVIX6D]ZI1"7BRD3T",^3D%KR VH;F%QM=D
M<GN_:-:G*K6F++D?<..?@*':XO#<1A,4^C!Q=8+IV[I_WK'$T43@9$W<];16
M#O!<FG%JW*5;-LP4Y)OY-5JM YITU_* -XJ<[^2<(8WIW-(#/S&YC[\)6_7Q
MSW8^%3:O@)-9M^1?.8+-VOEE;:S5,RJ+L//:YK'MVAQ^U8IS@C TQ'!>/CJ1
M/QD%["_F.^K)=TEXJ3.,Y0Q5Y4FM.&(EVL]KQ]28Q8Z#H)6%G@9<<:X6K(2$
M,\K=,KOB.,0NP>SO-+*>"J74OYJ2<=F=H\[)EQ B&D8G:+3>.0('5O)/ZN+L
MFD&X/7IKC5+WMK_]-5U]WA)%3+1=A$EEJ9LP4"!D#Z%FF,(/YAVJ ]988GA5
M78,CY.2W!K/CDP!,]<Y5H&PM1\1GD6D!5^,WY629O94DQ<J5G[U3(%7FV-)I
MG#H<ML'8C(D[=<H!\M_YG43?;L_8I!I4I9KE$VD$AI_&)+3SLP'IA.F.?LG]
MW*92[*6)=((86(S)-\Y.5I5'1\6ES7V&IM_PC)R+"BU8 (T(-N'RY(J1_!4&
M\;5B#I,%R4SE_01]QELRH+.]"4RQ^PVS-N/QC@-#-!/;H:<RX3\3#R(N%LG[
MX>C>FNGS%>*I'/VXI^B56=)(C@H!J@??N=G5*%"T2#D'X15@C;BQ\)U'I[=3
MLH[U!@J^S)Z[Q?^3:SI&]<@I^8\UWN9-CD[SHJ#?(]GHF"F$B:]%1J"H: X5
M%?+:-*_ *J @R&VAU,VO!;%;=#L/"08==PHF7P<O6>P<P[')^!F.S(-M:37P
MW<U&*#EET*6/[!%J1QI F<'799IH#J+]%.Z *R?X?#Z)?^^Y__]3#[?1LJ3#
M0WR:Y!@AL:%N]@?F>L?O/VY;&4H^Q.WZ26:P3_C4);\=0EQMT>X:;-?MF3T0
MEEDOL5<MMMGXX;6UO*GB#?"O(#OX!R/GN$[F<7M-K*4UYB'<40D.72LS/'NL
M8\E>=4VLM7I?=3W5+G0_&/SR(9J=#>PYNO%_,N[!>]S]IR!5<2V.QKF]PN]K
MMU>I[Q4^=I^ OYMW$WGOTB;_5%=T'GZ?G",C98^;S,;Q9]PH'AB76(<P$65G
M\7KR//X R5[)"A.P.*$'1J7!I48SEM IB=W%K+/=6B2PMQ,N5A6*8VD_BA7T
MT/Q14:G)S]/.UKNI0\&L&1PP2=@0XQ3=A)P]1'7!0+.T*AF?8:/%J2EG; <<
M@%26[<NPB2OY!' ,/'@8M62Y>-&/X2.2K3 TQ37>L^'((S1\3%#@S-N,<)F(
MM)*:"T30Z(<*[;3SI#>?JK(E>Q6'BS+*BL$JY&_R1YPVIM["=T'9#^^X0)_&
M-_SQ$I>EX3RBKA4/XJXWL8 Q36O>;?O]M!F0%!/>+!M+F)T;.&[3/(%1H06,
MX)C5CH_7!WE[_GA-2GX2W8/BMUQ4B DAMV(MY-571FY56BW6-HFIER73WG7C
MQ-C'"<!UDJ1,VXF<,&0A%0,&YX![<6068.YRG[!U6@4<@#^)-AA[O2=YP_1S
M4BI7NMK%PR51DZ5Q[!938BJI$XWI;SL7L[.#4U7M(H =@ARU^F)<=Y#&&J4J
M)4Z:1SW>ZG?[1+Q)QCGAA_*<W6=&H>.=>;4XX>>)0^&(Z9VMO#JQELRAW0>O
MDDAB<V2:NG\G3_3@5"YL$7HP99W!$R&Y3D5]1GO>*7:06=?%;V0_VZ4;[K"=
M'\C/D\:W)%Q2>#QJ[RX\J#VW(Y^S*A;/YQX(PY2UIWM$OFK=[)[NO4%XH68[
M]NS^O-";]EOO><3P =PRA[X:^[#N?P*$NEH4?([3O-_S[M-K'^>6WZF?,V%(
M/W*9!S82<(1>/["WQGTSSK7^\1KI>F1!S[2&Q\8MX;NS#3-^T'-4Q=HG0#;F
M,D?0<:$G(W]+8.,ZX6G?']KHP[JN;^;:]>$?[RD?:=[F>35X^/X)F##"\?*9
MV)H4WMB\ZO$_SQVYGTW3@8\C%G*6V1YF;OX$?+ODBXK^8;3A$<__:'N^AX@>
M\GRU5I>3\%? <OS]N/_-[WV[]?QUK4NI;4#<J7F0>"]PR"L/]P.E)YB[^3QP
MC.^FQVQKK+-K9ZYWY(U^X&>IV0S6E:#A1NL57'O>Y /PPR80S<1?\:J12(^(
M5^Z-[6U@;X,S]X%YU6CG:E=P>\/[+;IC;&OA)PCTT*U]]PG0&A3H)'K=Y/-I
M(*P3-2'R&)GO;V5W$,ARN4]R(FB6,XHON\054R02$J3@5*>FD-&H<DV=NA$2
M"9X@;Y0"]'0R<%J&X&A4QZ@FO;;OS8<'6P] SQ E:,6$.HPTZB>,:SKF':<>
M,%O?#IM.K<Z+YA!0YYPL-PRM%XX5=T"/WT#'2L KM>:G,"G;8!-T6H3OB4",
MPNJMD.NS^[$@\?]P%?T$P"&;]03IA\$)O6H]"!_/\/D0]"U$LV[Z1EW(X1[.
ML#[/#+9_L/6 'AVNEH1_7_1B_*2X#SHJYBF(0S&=UF$CR9?"JG?U=:88O!VN
M5KG]P_NUJ1]&4\!O)$\?-PN>DFU>S.6'L1/+"H#H-YU\XZ\2$N;C\%KLOV?A
M3P1]6,*)W>:=,TD3UN34%B ],6BHVJEJ4Q5;=4-B3+&:Q7)U7KYF*3I6RI4V
M.LUR3;P42\CD?"5L[/\J>1:0_"? E/EC5OC,7O1]EH:>.[5;Z% _]W3B(Z_>
MCC9S9X WIS?OEJ$^VM*WM%#M6Q _DKH^1JBRE3:XI8F *J;ZDHB$TZ9718])
M8QYWXR$$\A,P@@);2ST2+Z #9<>8BAICDN )R9N>&SM42H]H*DX8QX4YB[+1
M)#(+EA4]::Z919[,KXI5X:EDC\\.*?9JA\D3ALZ^*=*9C!Z(O>5Q-G8!(=L7
M&N#ZN@7R2P\DL*;W@X])@SERR:-UB_/+:.5\2G THHT1,K!Q?\ZDM<9J"K:X
MY])7EM@RUSM:O"M=K74U=WIMK,?E2:[?/SE:[G8;(-_]=/C[P->*C)_NP/()
MP$=J[/NQL.%?+TQI!XG,YS6R5M<LC'ZK8.%%>-N:]L_X%>N3%_&\T7*U^;0U
MTOZ7'Y13IET_^:RQCPQ_.U059JMI$B^3/\RAL.:BQ#>&2C$U8;23U$*!C# &
M#EP_(3IX&C\8(-4/\?Z*0#8.^WWE2W'N=VHL%.$X0Q37[MSQ)H(9X=ND^HWQ
MNX0?B8Y5LVXZ/R.!L%ODX8KZ0(?2MN%U*M 54Q7JU/B>.0 .M<I6C@VAC=D8
MS$4(^;SG$Y<WY%^\>J745>OC=(L11=KS*GF+W:2,=7>^=&2R*5!TK!  ]J4?
M>NVQW@MS?\^S7F*N6835080.7XNQ[,</":9>/VUPPJI."7=14]$M8;7\3JN\
M<OE'QLG6W=K-49"^"B$B9(F6'A^,FBWW6VZ,83X:=L!VUF51NL2(W00&V\(>
M\FC?\WX;N8.>MQ=L/(E;-"(VQV18PAO6N6<0L&(AN2LC=P,@$XRW86+%,9_J
MFL2LQO(9IH9,5XY%F&%8EWQ%;,C2^GTWZ;X;=<CKR#,AJQUY(ZU5/ADPQ<_@
MU+C2D5QBFJU(>.E:M3 6@F70*Q-UAK3W;2KY!>B^V6/,%<1EZ\BS@5MASR^:
M>VOHGFP*)HYB,R-M*\.]7Y9E=+3U=PEPT$?EF+/3X(BVDG56">"9!$B0)"M&
M@]P1IVJV4@7]3"=1-P,/N.U:R)/>:K#9QK.2CENY-<_-=O;4"@]/EN7(KA84
MBOA3J$0TXE<9JR@MV*L$0B!T8W2^B:2P_&"2I2BC*#X=9PB$98",%R6!DTB4
M%:V'IRGL,_[5. &P-PY=;JZQ==,-I+ERJ/W >_%IP,L[SK/(W;I)NN2[>TSU
M/3Q4QH<3O8FC]PJDW>_::/H$=+W)$AN5O2=S(*(M;?<6*?_85GN[NV!>I6(#
MCACZW<XD^:[L!' (L1XZLLB]P7<^Y#WV1##\<?-OC P,:\E;X-AF7LO.:";P
M=D%OR#:9OO.)+,ON'PI*&EN6**Z=CEKJ%";J5X!AW@$1.(/^OEVW9:_[)"59
MPT/:S\=G-Z1^)_UGH-E5AG961R@0L!OS@C=S]^ +@64G&CGT&P7AOYA5,IQ4
M)++-F,_(%3D_9N $'[5/$!(1K%0W:*FW75/*08AANR"?/DZ_^O0DV3^OQ*K=
M;H5/6[3UXT:F%@S@= /AC,F=+8:+;3>6S)Z$IH P85B\WQXDHI <\4A0T),P
MG?7G,+ZL<G32+PR,G1N:HR5VO"1[C&LN$":Q=+=+9F<]($W-:QZEJ4<MUS.W
MU]RZ*)HITR9%\'85NO8MLKT#1QSBP7PK^56"-_O*U^OK0MPMRAO*3<Q#=UG%
M7DEC?M.^QQ>ND_ WB5=,7G$S"<HDC\J6@H;/8*(.I>>%59C&$PYN?_(7QZ<^
MCBPAZY7?CF:Y8/)J!J(YWX+C;09/BF5VEBN_[W<2S,,=,VG\/99[$7PYK=;+
MV&KE)!OK.8'_3%??M9=SK.Z4<X5A?OH/>#)/=\,=YO'X4(Q\'X7)] 7MW2(S
M/P=-O%^U/?[=7&@Y[^C;-)P5E600RK..%A<#P<[3N-^$!/O^LMO(]4PR-S[[
ML407()YG")R>>2H@D-Y8^Y(0<1Y>_YWHKP<'(<T2 3QI?8A),'.23CT#OV;S
M-JRMGS #:>@.6 =FJ!I&AS,1;R\2FTADR".E^.%/R)YC6!'>D"EN&0XP:1)G
M$B?$69\$AJE3L^00'W]'RNK#5:MZ+4FW:=*#'ZB_&D20D+Q4#V(GU90[0I5(
MGC*F)$A8FBUM1=J:_H)*E[%P_ZO_TA@2U2AQ&BKV(,G%*76'WV%98WD-"W?E
M=[KS-WO?L&_,O$+:D6K"*4GQY"!))0G5=I)%8,5NQ)3%5YLA<@7) 4L1\$;X
M%TRGGI)=\6F' /-I>2_N=0<E;6?V*OTP@CW?CF,I*QUFQO'D:C2O@N>O/):M
M($B5OU(83IGK,\9?CC!(Z#E5U6(56,Z^_3LER%0%@F^LGSSMPW"SA"\6UHSV
M3J9N$<8._"V$/!^&]AO?\.ENCS-^%HB_YWD8F1*&^5X_3O=$_'@%//H5[-HO
M$GB^E#B]P7@T$:._>4K@O5ZN6A)&Q_,WR'VOH!H!3CG@D]I[%8J]A%LMXOFH
MOK:4>E/M= VY[-K:04QABS 1VNPC."(-I&\0[REXSBKX047M?O?U^094GEME
M'R*M#C>=>YB_LH6IQE!4',)>/CG%UBK]!%C<$R#;:&%[6<8S2?*",XS]Q%L\
MXL ED;RP>5*SX_7TD\FI<&H$"]2'9=02=S3WW*1[.NCMP2'#3+JB 6^)<FA1
MT>:XQC^@"9&<PWJEF&:C_WP"VM8&S.ZP7APVSM2JON C9@UWL13&,%/0.WAJ
MH,4)3C0R)(/T7B$Z6NI^N"?RYX%]Q%!#4.4TOX@X7*H]*2Y]J"6;CKUMR2>P
M&(X"(<:EHUOX$=JIK;.;&K_,*GUH^\E4-Q0EU!>["!Q:,9L4.]OJ6DW*5!?.
M:,K%5V)] A24YLU<'7' AC]YD=8(.(K)T%,Y'#U&$\BU:'B:\#4(/11*&O00
M,>O5I;.Q"]L48C.9*CONPR7=@S,)/52,U\1H[OB',Y"0"=) ^Z<(XXB,D:S*
M.@SERBQA&>A?@\3UNXII]->T#*8Y0,9890WT:/CKB40%0_#Y)DB\5$+)4QNC
M2>=>*8TPY?0VU#K2J-D[91AF&;%T$R[6#ZPJ%ZN>!4^WP,?.B6*5INR.AI\[
M]I5JL)>3@C[;50Z_3N&C<]BG7UCK'-L\3!Z#&*_.#S=H1X]'FRPLJ8 2#;E<
M?PG"V/)'K$5Y)KQR]L[M;/=M5M"=^#&D[4X<-5B!9^E6VBDP; 1!+S_ONK>N
M#C;\?NPGO[46LF?4LH0"2\J=AIG3 [5AP3H-%7@/?W6$D)NT W:'8L6Z$L@&
MLH;#(2$/AO2U."0![HA?".Y+D!DF]F? R2Y-[?I!TF335M@<?25U:$]!WT\V
M1/;=)J<=V<%#>685LW#B_=,-T7_64GZE6/Y*BL MXMI=F'#OW+?2!.55:WMS
M$@^F#T$S> VAI+_I)->SBJUF[Y^E)R&BB]I\W_1,-'!*SG'%@/Q;!K8@^#'%
M8@&FOY-XBAYN+QK^5LOLBG&2DS,TCS4Y0IP]IA24%7E%&6<!1_\68".1<'!G
MO==VEP4P8L"(&G7'"URB9OQN$!& ^ OS"\3];PM?8.>D>1QHZ  +IF19<T=,
MT#Q 0&ZW:F%X$[X^&S<ZM=$BD%5V?*4*95(EG^>@$ FVO5!^N7F8I!F)XLD\
MP)F2!_RH;Y &/GZZLK9H.Y)$"N@:Q.;LW,,B<$*(5L6"L3Y+%4EG'%=R,)]Y
M&2<(#4FZ7RS$3/JK5 _WK81\?B M_Q9\FMR\G6%0NTQ0DW6G*3W&%+O*1TT]
MXA1\O78>@)&<SK\HAUP_)TM1\EPRV51M.Y>(,::)@9':]/VK'&DY/,M>1^"D
MZ BT["@_N\"TE[+KHQH=!R%1IMVR#5X\?^IP_?!"3J)DNOZ!JV7HX>V7)@J(
M1VSIE3)V]!((%W64;.ED3V\B^3;H/OZK+)V'1\QC@;&BU\;^U81FKF%C:4K9
ME!ZXA&K[.6Z=8*^N6XK+6E$L..LQTK&<FYC!ASV[!-&C7[]-I5#]]07Y</\0
MY]1/6X,-K5L[W.:,&9IBV:GXAV^I,[*]B=SR\!5QV-!]S+J85*=\,-0FS8_4
MD"WQ[D]D;51LW(  =<!9? &+PH?!DV*P2^Q[D"N&&M!%,]_> I1=GJU7KSW5
M^;A4CHO50?ZS$8:* VW2GQ0^^^<N;60&@6XQXS>]9 95<OY1!< WY UE3P.3
MP?:L)KS63CW^%"\&>GN#[XR3KF]W7N(^+X,(]L4<$ANFMEMLFK+9++@82ELQ
MNE#N"005Z)5^#\G6+_(T^56%@DP^Y&'17/C%X"O'TDIC"*T:%[,!Q3 S;E7<
M5!YF@27JY,.H%FF(P2F>Y=X2$HM0KN_#F=E2T<#Z_N^BQC=;7UCEB8F\OHJE
M.!#M=#.-9D%N-TWKT1QSQ>1DZ+(U$:@B?HM+[#\RLUM(Z,LJ6KUHZ\AGE:T5
MPTEV=Y!(-I%$P7S^L$-:G);['O. G^<@XLI4SX^^X\* N-7(KJ/L5(C @#AG
MCN0:DS*^>F]6*")J[I:'I!HO!A6,41*ZS-2WF-M^=DF[I$ 8S;D ,QR$.H03
M2+&)$%S_V*Q$76+C6#_,R81D&\/K6M11N!^CV:PS@%J9DFM2U#7(/^L0^5^]
MDO:+?^H34.'QL;7]0JY^=M/X8?P3_*:4VI7ZL?5N_J +6.(K:?C'7)91]Q.0
MK,7\5'SX_L.T"O^I[A/P6Z@'7-HTDP4BYI=]%1W]NT#_AR\D0.,M'_3?H.+Y
M?U5Y^5]$6?0_=Q&%/ZOONTD)%BNIS%494EB*"6)2:.$+0*\.(/#U3-7'3E%0
M='!0F*I5IMUP,)Z/+P"J(@GU?0G#P >;K!M(;78RGM4%76YR'6QWF49ZJ!]L
MY/Q8-C?(VGSQBP5OG#>QO;(=O4@^ZJ3]7-[0:9DH)5L;XV%SW8_F5C\%3C0+
M95A[)?A.M4QM"F:OM@.9TELL4M);3L.K!Q5VGEL]B8GS-L6=>ZQ\:=_(;>>N
M/-Q__64.ZGYQ9!Z#^P0L.,^DM"IG_B *$4".F[DL:-O^+83Q@?K[\G*6J.3:
M8UOQ\)GDM.UX?*-LBB].+!=FY/A1!>RX3OS-'W;=P\,*6?6)_ZKT]BW>#>QZ
M:+]PE"-=H/QU_^ZUW('[ CE$.-B>O^,W3(4OX>."EY\,GP/O;<OIG5+1;%G
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MT29'O,1O_Q_7][Y!04I,;.Q6:N.;.E&5'/I6'"H&KEVA/. #;H5D?.]&0@B
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MLOT./"H8,*5N#)43W8G=LI.(P*I.PT^/N3]H2%?..0:1NC-Q9R:M)[<P($@
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M\D5&:2V Y7/+,:9,>2^?98XLJWE:2S,Y/<WS')OS51RQ;9!ZKJ*U5573L&Y
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M_CUA$"_N[$42 >76KOF.Q- _"(R=H 5_EJUU5*\)@4'!3RJY6!L#\@4I6_]
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M]K8XF$:E+^!SAF4K5?Y_$#*C7K9Y%B-HQ0XEE(1EF&'-C"]<Z/2J.A%">R^
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M?15MO7R*N6ZKVQ:F\-)Q"]N>3*PHS\G_(N^PY4M[>\CL(O+5*S4XRMG("BL
M*= @DR@Y,AJ4*&-'"6%@RYE[.S$_18//HM\6^_B*!GRI_\<)9X7[/_R:3CHR
MW^U<N^7P6Q_*N6-V:9P_\NVM-?[!*6B")C3VMLC9U2-O%4GQ"*-#7;?L3W H
M?6X?CX\0$=F6IN$\?]8 )1[-__?"@DW#GR38*J%YLG#E(OZE%DHA6GN&9P1%
M9LN9PRJ3):N)8TS-/H5QS6<B;;5C*C-4*V:R" 22R?&W-EXY;'&,5B;^'+,J
M2NO3/3KUC/:!# ;?N!24CQMDF[8LUILZ6DA0Z6%\9_.4H+*Y@V%H2O*/XFI4
M[N35LSHM[K(IU]0,AS;_87PR92LF+"YS].Z;=HU9\2>PAL':O=/K#_?E3L4'
M>H;!#JVEM?):+P(M[2C16A8FI+M,11LFD;=JUG6BIV2.?0([+SYU&EUN=+76
M\@F+N29M@F8,VHA\KDY"^%*BEM*>2("GLR;-=#RMHCM9HCRLQRR$+/*O8EWP
M3:"Z8J,"?^(V2D//VTP&&D][*6YC3RK$>$W3=19]'C".9D.+65Q>]\EM29X$
M@V.V0%\:##YVOE* QDYV,K#7*15H'L+0!F$^XC^,3;<7N/277;BR?<PU4B?<
M>HW^E0GC#=0J7WAU\IU$G2E+'5[(DBI76Z*-"SNCS&S=M%4*DD;4$H%4]#J#
MI2H?1*NR^[_ZL(\ W?OK(SODYN8?1"F/Z@ QVRG\[L+HA>.FZ\W=FIEU,:I6
MK='_:%S35G^\RWC\@XA3-5O7%6P>B/L'\4?JZG/:4?B])_6QK:B-)-F$L[^L
M6A_7;!HY PDMZ/W;,[)C".Z2]IL&#.&1Q<LW1V*O1%TV8$I%C$RQLII5-4_J
M"(WJG&,JR<KYM3Q$#;4D[VJ\FC1[H5]J6H"6&I(0WZK!5&^PJ' =RV&FH##
M@QLMYN2TV0DE0,RF#L_B:CV9IFM\?72ES!"4FBAPH&Q@!<.'T>-H^(3?5T]R
MW'J3C"-D-&7%9FI<PMK=3E+]\S'JA!"6^2@HS"BA.0B;KE#*ZKV2=:/<?9TF
M_7CJ>_6:U:6D!=S>Q4>?:DJQ#9M!TK<,5 7W0MZR-&K,B.8Z:#R'/*%$!K3.
M8?F,R %,!DQ(;IFXH<YN '/4)WEN .)4"5EC/7SS9AQA!&^V:0&/\[@_A1Q6
MLC4=*$%7;GSJ.)D53W(RRR,W2!3K$]I1N_HA#?5;XW5&^)AE)B*3Z<HPU+&
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MPXNS1*$SF6A-AXU@X::F2X%E?&-SPNG(;+B=A,6-C"<F.^X2F,WN6)<DRH0
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MI BQS-;E$B396OO?PB.#-XIU_@F/I.24_-4#=_U_<=J2]E82)TEI;HQ!@](
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MAER;S<:ILEOXG,#2'*@QWB*YR,E3!?>\9N0K-=$7Y."6,!*P0,LO&J-KMS<
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M+-XA'.<-D/K%$AC2 7=+YYYCJXD_M?B197$PHQ8 )^Q(-$H"EK>>7)W@UE!
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M/P?'*P<D)%'Y"#9)YK>N+(0U@[8559.,G<=-K,8](R6!<V#7<K\7H9&V5%G
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M*7Q*"O_%@3:M^[@)L"CIJD$I2F-"IVX:Q>!NU&U-5^.>?UK8)\#<GCBKBAX
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MX^;S<,+Q]V:)S%.S6@E.;!Q0;6>1NW8(?E#JB/W#C9L\K>QA9)*0NZM_Z3]
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M[\C)4UMDR\%4]8)^5QT6R*0>[K3H-:GO.,\HH\"D)F]<OLO4XEKN=-&J/<;
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MI:S-4XY>?,O0Y"1U<DPT5P.S2X=+2$$B%:2KDE /U." 6&X2=R=8XY[K988
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M(I5,#+^F]VMY<]]#'.<[ZZ%T]I2>:O*F#%!8=1CG&F<_RN?>Q0_4@"5Y\-!
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MVY!627WL&>VB>QZAYMF,@:6BJ+Z>EE;V5P/P8%A (#>K2+9NM@PM''F4!A"
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MG\#J[)TP.Q^7SELW9D_NHM&ZIT[EQPI-Q*N4*;X8IR@Y@"@91I$Q_L%!',]
M.J;K/L1ES*OX+16U<0.,:?5T[B[G0.+B*&MX+M1Z"Z]8-$JD""""00(CXGK
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M0[:V>U-?"0: &.U_ + FL?@11E:*>*DLN=K(8@DF-$MXLJZC1.G<:*96%HK
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M &/7GH*SG!"4: C(E $8FYDO$5_8X!OZABV=,'75P%E51YS%O5E*NY4@S*Z
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MLXT$IDL?VO@GX(I=KJ5F 4_3W$^W6^I\5 0X%JN$>VW^DZV]DZ-'MF6(4+S
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M_4 O%03*R$NY+8LL&,FA"M:MMM/01V2:Z7Q/Z=!/E^*I,HVM#I8C;F P@(H
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MN6WN<[WA+$36L8]>?19M<YI<T?A#V+JI<-%L ,*;L:GUD@9+HRW0L--&\0
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M7 *RP##^<D4IP>/QSHNCA*N&;9"V>I1819-Y-RLXM%UHI"L&!;A,01:0[3'
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M8.LFS1 ?O4K!#;:@87#<%4LB9_M;&1LXNP# 88*/@X'*F3;BU:ZT*K:_O*.
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MZ ;??L*1"WV1G#!"LYH.1#OTP: *.[_*RZ(CU(SPR\J-=E*7Y:9F7."M6:7
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MS@P39N4O;"KA_2QE OCNLA$%"]M7AW<&WCXQ-\3CCL[]FPW:!@.+)$.(<\
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ME=<X,IA9 ])20FLY7< 06X3YR#A"Q\N)).0J=,LM'61"7Z&1$?)6&6891Z!
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M\V^]S9DM]8D*TN/&*!P1E7KZ$V8,YR%NB'!AXBWG^#R)D$,$;(D#KY]X@V;
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MK[^1*!;*S.BPD#1 )OSDW/U1W+3)(.LB85"";4"6W9(,H6$R=%Q523MM%F_
M^VMR[U%\3XM4*(.RU94%-P5_5[8"IQ9.:DD<=W^&.3JW).)>MK\HB: ]GC9H
MQEM2!K)Q'G7[FVYUC""NB\5L!0EF;]:ZN\X[:8##2B*\OV#;B&29P#4D/#XR
M=Y\B9E+*H=Y738^7?,BKQ/AFVAC3%-4=?81_%"]D!N+%C!;<R4=LI>@*#_HG
M6:^)PR+I'<G$_5% ,*W4+AW(=1[]-BH4[FA/!YNK</'%UKAA?4R1X[6:M;L'
MERIY(NM(0/8S9<8XH*;L-]GQ#8F34-1@!7K=]\FS=GI/1SV[#*"'%E6-R3EY
M4KMH/"G!2EZ8]X823-T"LW2V<<-F0!^K7TCGU%JQA1E\2](JCMJ*O1I8AD2>
ME!J=X*WTIL;)7&$7-#'*]8D@E:%CX'>;?JP#S*&2>KA08JW:^>@=FASMR73#
MF'<INL>/61ZK^BXHKE=SNG#EA/AUGU MN.;E8W*D7P26,0W3!&%$8(9!!%PU
M=KN>PK^N,!$,R_;?!W*NFVHT5%/,YRX$C)A[.7]]SE$N5<8.<UI/7JZU%^^6
MWK J%U/5*@K9;?\D3!M6/N7#4ZV[9.:,OF:I9'R<^P&HWN$[9_7_91\U<1C(
M$2;N_0&8^';848Q+>Q6,^P&H0*LC+7B+U ZUML[S'O"53B %H8^8 =%M1E5E
M:;7W4,8AY1-"!+F8'OEDE\E<R0B&D)O&7ZCR.K283%A1.I@RT(^GA=^!^.5W
M834@+E7AQ&\RHB!?I5*%6$F1<8$A1DG8;\O@UCWU!)< M4SS99L:$!1:-$^-
M15A.5#7\"*I8.U#%8L%!8V[IPG"B0Q.S,"#+QK[P-!W":INBO.>062[FF<;B
MNEE\;</MR/@:E"1!U*^ [Z:"B,A"$Z1+CCC=,*CWW]NK$1DQ<%SG"?KJTY7H
M>N"6D9V^;].OH9^POO5;/\/<IJN#_;LNG0S=\KVF_!KL?F1/*/QK)/"?$/-W
M,-<'8,#A W I83<^>WT;$!AKO%NFW?'^.7!N+N A[0<(!R,PJ19N:"OUS+6W
M[I<\K6*,&%F9NKQ/A9_2#;Y9)M[1)P,^^$'L=B6*IE:U(N$#-O-!VIM,\K<@
M5/P7[L\%GWV@(OAW5M*WM0<U4!,YQUC -FZ5;23=9SA)DS]JLYF15]WL\*2*
MDJRH<L38_\BSS@R0!ONNF7\^GE>;-;D/ !V N21'9:..XL.',M_ER;7>+R),
M4791J,Y-#4IMM2#F;:?4/.LK+)]9#TY4)'9%T-B=G '^>;',4)U?_ZJW#ZIF
M@G;,0OOL+UF^QJV8R\H0"'^F/$@Q13$"%6Y\Q7AX\ZXCRU(V-*29K16Y.9SJ
M@1[-+YPO:Y2P5Y>&G3Y\#.U1.8IQBK7>Q$UJ)2.XB=JO!R%NV#,QCRZL+-?6
M7QZ*,(N<9\W2C$^FUK%H^,(68;B8G1M>F0)T7FR1\AH%Q6-X8Q4M_C*))EGP
M^LDSC27E?CN@C.R2V;SE8%;CN8F$=_^6MU/L@CCA.*D20]>8 C]O2O7/YB.S
M/J+U8PRIMG,N^7,N^^<OM6NE"!WZ\;4>5LNG(TTN 6.RV-7J8[(PM"-87Q(X
MCGFNS93M>/?/XM(08*]:&\X_-Q=6(D66?);9.J1C"[O 6Q@^L/[>\9 H'(DW
ME4Y-/I7*42SUJL7(XXOU]44,3+58R4VSA<<N$T5)&.R^9>/<5NH'K/#W7#V9
M+M9,IYG>39SBBM#QEJ0=OU3" ^HG)Y<G<S?+%M\0K,_2X-E,9.> ,UM/E[9M
M)D<S@X,H5SX ?VV?SG[&9=',HLMSRO0>Z\;T"RE99G(<"ZX,\?IC1A@.BK.&
M3)IC6<'\).UW&(686V:GUFIC5&F8CD:]Y&,D8OCPMS]$C&/U6,9M-S[G0=-H
M"W-@= ^"IFWF8V'Q.ND.2I*E&P^B,3I7S_BZ>(D?)!W;UOJ +*HI.^A_A-(9
M>ED*[+4EUKS,1ZEB>H:I;!IJFHAE];5;^[J2[AL>&ZWY,Z@8-=I;Y,^QPL0G
M8B&>/6%0QA>5U"I'-XDUOIN5H NNV5.:W^08PPWL W3J%01G <!08?.5^^E:
MC:CAZ!7F%S*9UU,R%DG7\&D; <94Q1_0P]#[S-)AJJN]"#R)^O=SULV\5 6\
M?U7_B?D)PY-9UBE;,N<7B;FI& HZ$_!TV@NA0&+S>JRP2G6HL;X2=P5/9W)Q
M\B9FDVDDF-'/.$07PZ\PM ?Q'EG'63EDVID\,Z4*34HQ:)3N4K_G)_&H)]95
M0\US79*%O!81:MC))%)8K=<AZ9\VYF5KN7?95+E=72WU)Z(;52;'7:;[-@*C
M91NIQ_"%S!M%:@31-F2W],R!+C0T3!T,I(.QS9Y\30AK?*U]ZX6OWNR[^"K>
MFK,W(F%K2FF-UZ>E0ECL>^6CTSP<(Y"3CANO^U%O/JD>'X9>HG''\CZBLZ25
M=)NR6@;^E%0Q"3$9;%1V.CX*/93(#H:57_Z&LV"E#)P@$85B\!^5IZQ]UA%V
MEDFR=D>T,#KG3$EK^R()[U&CL3#E W;Q%P !V\,W*CRL/7UM9S;2]8JXD[ 7
MT0Z3N/,C#K<,16IPKEL32QM]#G5LB3LLZ+D>MVD(C)5;";:K:"S'#0%$6!L=
MZ^TUP)B"(D?@NT"B@(GV \-R[W*KL;1R-%<;K)HERE"Y/'7!9L[P:$X/S=VU
M7R2E*CO<P6>H"$FE4UD/]I:A#\TD$N=6H/O)X]JHJ5N_FVJAF=IUFPS&F>Q&
M;CO#?)/JZZU+A05F-P>O9$YJ0[K&".CM5)ZH(Z2<C9*J 7=_LW[3-O;Y\$ [
M*\P@%Y%I;<Q8T%@=YSE']8U27C@95E,OG$'P!X#4=$NE7/ FZ;;.(BU\0RN,
M\UFO58<F'$[S>TBBJT%\&6<HFPN+\]_-_U>-'1'QQW^1>:6DU/XK/#,\6 0?
MT*2<I#Y(^M%11LD4'(5&&(Y(*FF+=5K#C-.C11-<-T3"Q*BD<4[5.BJP,S #
MV.'#MA,;.$<(""D76G_$+:PM2=K!H A"URC@E6N[2;7QM);0_C0IC5(K9RX>
M<CH60]$+Z?6&.T"!ON6MURMHG![C,!?8*3NFUNU"/LPEIHB0J< \->/2TS;$
MK#Z^1HW:X,55Q1PM.TY7D,#9-M=0A[T.HH(*O@+?C(1AN? ?39RZY'YG?CJM
M/SJ+B8KZ2<DW# A-/PG>8BUM@$<ES+3TU-@";-W(P296@?2[W'96&P*$P3=M
MH=ZR \DB 7.W-?48$4--L(H\K0)[J^-A 4I^WXG&6$SLG8P:[>#&663&YF0Y
MM:@F63 5I&PL#1""* ADB!%\W&3UGPE6?_78;M#'K&L+NOM\2VVCM_34)$N3
MHF6& NI3]U*^IM*B53WW<,64OIFFN[@N,HD('!&)C^*1UY$)O0EM<(R&OMND
M[5:53TR5$2ZA33I+53VRS)%_^DX$>1VPPT[I!"X2.-('<Y:Y-L6!.$88M-.^
M]3,A\K5,X6N$#'H]S&])CO;62?+0P<O=2M63B.>7J\:SZ9KNL[_PJM6!Z%W3
MA?#VCSY%#A#$*^6-_.BG@RB71L'"\A+$X=8)A:T75JA\?9)9_F*\Y>R;/WF(
M%A9:$)1L0<V^:[)NQ!^/=:BB\(6@Z%Y#;0[R18EH" L=%3S!FBIW;A@GU SI
M,3%HN&ZOWCW0] I+.K9A;3EDB<JIGV5N&!4PU1W5C;>H(EX4SY#+:,XB986+
M!A5-X%0**OFG;LO'#+(']18J]H2#X#Q^B<KQ$6U"Y7"A>V=9O1W89QQO522Y
MG%>U<H$;*/DW_5*HIPR/5:-*3K;=BXX6J(AD95,4Y?328N:8@X)H2;Y=@*+X
MX./^&G##)%Y\'^[RC[A]WY=WT2;6IS<D,)_H@$'N'LC(8PZ5WT6G"'"(.3OG
M>%.W:%+X022=TE'6KA4$03Z "P,.E7Y'G.D@JDKD"P3>H5<>>6;E!I(>CT^
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MD 0][3%.1+L_^*/'2]U2MZP=3I):JBYTO/-,V.A])DTDMV;AB%.&J]4J_:,
ML&V*\!_RL?M<T950R[M^X;&Q;9=PN&4JN$H@]9=@AE22XYM_M$4:(4V,-6GR
M#.?^A);R(^7$T5&+<B(#1O(XL;Y:>AJ'5 D27%0)]/5_L0_$?V,?2$Q'R=]6
MQM8B^SQD28\%?'^$O=K,A0K,CP+:W*_;/.H2;C8VZU<O1#,_Z50_^-B6'/#M
M;W]"\46\W![I\%Q5/1WCZ[I8,9R_$V&LE][JG*$15/%SRZ.3O\-S]2Y@F4W9
MSN73]KB[_U6T<L;M-WM8+RZ@/E?O]KJJF)9SQ_ULY,1W7-XRF!0[I]RWM4GV
MJJ?SUKJL]7+AR#;OB/K7Z/&U(65GI*6WUBFP>/$OQMV2TR/O6!]>V@? H?EQ
M8\NX<(OPON?JV>2!I?:/G>\;7L9\9'Y.8$>KR%-S_8M#1>_*_AO\[ES95> 4
M L3!J5K_YTES;YCP_>;;#.1JI"QPTT'DH0W_A _>G\WW'2@2:^>OM_,!D"Z[
MI_(^._MK?=IX+V]V4SD1'%^G[HEXHTI31P#8GT<I(\@CV]9\-&>U#&,-.?_2
M #//I%^^FO\37Y;4<9;Z;-6PZSZ79VBSA)??^FN@:E&3L:/;L.T]YL+T[Y:_
M-;T)EVZ&[IS[[^ZMBT\);H8EOF*.RC*7N[FYK]L']<N;0F., EE+*;S2+DV_
M\DC)9+YNG911MBEI6",OFEEZ@3X @FQOF*)P.HX18Y&?[XH_  O8UUJ?T$5_
M27\ BNEV*\E( F=C/P!2J@-JPOP?@#S\]ZB"D,+_O%#L^N#=S?@O90!R\-[8
MZTG?O=0K+LQ0XO-"X$GT$R/"OSG_?\49NB.[ODS6+09S4&SWZ JW@4']0'IA
MBN]8OYG$Y.ZT] '0?%/ M=K1-_Q3^P'XB?D*#E=EJ?O[XP-P%?4N+U&1ONIO
M&_@X'$A=I#EEU]LB^K(O"E:K.FKYJ5?P=O-Y@E[K=N.J5O7]*?$PE=';P7.E
MX@/@)WNK@"O<VG6F^0'HI7JF0<[_A[SJW^3_)O_?GMSX7R*Z_];[OX:W_R;_
M-_G_*'E]0#1#-#9&[DB,=EQ.%HA!T]G@[IR#@ FXF0Z *>PBM-,O7GF!:OF<
MR!DLCOM8^@"[(=_^W=(A\9.ZQ=_ZAL@)W9*YJ))/E]-P9O*@1)8X%QWZ^XY.
MX>N>=EJ<+)>(# D-$O9L[A@)%+!(V0^'[->=+GY1-G>KP\,KQ?8*MU$5*\>O
MZ^NZWDWU2Z.&SQV\5J=7,U.M?PT#OG8\\UGI8SMT=+AR^%ET$Q(^@B).VY3=
MTVVMO6V\,PSM?SJTN3VX6IU1GM&>F=EPV1M;;!-(KTRO?''XXCYO?/-MZ]/M
MWN 'X.V3WGWH*9MQ8&DWQ0> Q>GSNW8#^L%!H!:?SLZ;[!'7;"?*.PMQ\+L!
MO_$'H.A,5=[GY8UF[].SG=<'X+:I_>GG,MKR8Y_ZL])=7<@'(%9F-S #'?\#
M<.*SM&C4^P&0]Y)\U]L1?:VY_,+W1]+=_^I'@*;P66'?_D+[YZ.A\ _ 7[+F
M^XSZOD4CC ] >EOB!X!)*#'^36W;V/?/Y]0YP1.VIV9'A&?GO<#WR%H1FK.K
M^XPPT:/:@P_ Y.Q_]I)O<:0T@X*'%S$M#$\N9\&@>#2GF=#2D,.3&?KS-[+V
M$+)8HS>\TQYO]Y61A9K9V..V^S9MW\DY0;N0MKMNP;^/W:=7.T,-'B\]?,,?
M@,N6%="N!_I/S_*G@K>5" 23BT<?I^@/P/8WD__=K(C^? ?U,ISF&]&L<HNU
M/.-8/%9$ME6P/[6OFVLOY"MBAOB7T>OG_YS-LN]MK&*$65XR;9;?LSL)ZX3<
M!"";X&@B'C"K1U(.88$2>&)N:G3(&A#E$1LMBK&%I3N*VB64LE>8N[9ZDZ"W
M]=WTS]4&FKH0G+J6_%3?SR1A_N-G-[,+_=OZ/]T*/P>-Y*E&B@6_J?^=+/%5
M>6G!,=8_\>7J38% M'>/[6__YCW?RV6X>=(EU@>@!JU/,K#W1%L _=_(OY'_
MZ0A1%]LN(NV@I/*8[BU4)%?$%Y$1E(%K@[[H8F]6(M<F8!RQ>1$D.ENV7))$
M/^);G?@CY7$*R&@7M]-) C*^CKA.'7^*52AV/AD.C3-,)15-XE<Z@5FJI":O
ME,9HIA64>IH"!@0! /88\"LMM79ZX>;)AX](@2OP/XOZ?KHQD40Z9[R9./PE
M?GO\A\WS_QR 72BL[PS&:?[G52=N@F2[XGL#[QO:^TL1\/#?P+^!_S,!V?,L
MG$)D)***9H0*I.".P_3E==3!B\ V -H5Y?DP4X#E7[8%27AYQ_R<^Y_EVZ+F
MYP&6G2P/;!\ G?/[A:</P+\&"<%"[3B]*?8]/'P %H@JC.,S[F N?^V[M9RW
M/3R>L37.PU<ML\3 08?(VZZ^%G<$CM"QG563 G^.!+X5_7D_XLGWVQY_WE#=
M0)>MRS)6_\&,7'\$-PD'I^:B.7V<?&,;G-=G4@9&HM5.Y5F_I NY,=<@9%7V
M,&,_JHQ.X2]W\S!)D*8\[B#GX<<3Y*?!*D'FG4#6H$1'A Y5\UGB21H+C7)=
MS+U,^())V>C)38CRN;V;".8?]^/"7(G":K]%82D&-@!9:75EW](F"GM1J:8O
MO]M[DG4\)I^+?)YR?$HQ ,\%)Q7> J=(S&GIDLTKF8TIOHPL4MT)U2C;GHT=
M*S\R*'B:SZ,N2:&0+D*YP3%_ /*]2S[OU[:*%@W]<Z+R0;HH#BB?Y?=,9!AI
M<'%MK.NQ]!XJ8L8HC_L]0&@?,WT8FV80X;7EX8J1H4B$[.?=/L7 @#Y@TUE6
MTJBU*KP'QI:8]$8[S-'A'QM"NOLR,Y$'+O-W41L"!$GJ:XI:^&50*B2<+7,-
M9::U<Y-CJ%'_CM<[.L-HI824P?ZAB;L%F+B:#)S)+8=K LA33M/]+8.1)-20
MU:;XQQH9=&WB,/& A6KAZ?$M!L,KF&U0'@%]=C\^R06O]JD)]BXK5P_X5H?L
M$>/7I;BY3AL+R]C,U$FEFM')9$C)&')-&ZE-EP\8?DZ578658I;QLF='7R%@
MY931#44WY?I58Z<,:1Z51Q\AZFOPMA@?:CRF<0+K &F9+9V=[4 \T'=Z$OIQ
M;^>CF\!DQ!)<2CE02)N65,CJV;QR+Z^_(I'H>(2^Q2ID]):UT^K9.U0Y\4"
MG7GV1BGL1(,K@Y@T=M:<,5%)"CP!)N$$=Y;8(<]6*BB8_E9"PL'.26/5@B!@
MMX>26@F/)33*R%E,$%*NS=36$VYP>&JAM\5]F?03'YIAJV$0%NUDSS0^M4*=
MG3=],:I7/L?1>?<^C@N,:5U[C_ST=G/"FA.#;M)0P(HYO40]1##$8"[5+GV)
M,_HNH]JL,$F:JCP_OEHH4#()QK]]P0D?G4':;HC!!_:[VS.YW2,4'7;E7N#N
MW]A@Y([1@BV4CGMJN291T:*(<TJY4AT4SXG;A)4R.CL;I<GC[0 FRO2L3%,@
MK?1' 4H>\I8K<<V-H=]'_;Y,34 = W6;8^.HG+R[+PR#"T@^-;&H7BP=!XS*
MA.0G.]1QTCQ\2,1VDBE[5IDXU7A$-@#<(9/80C[T[O_:U4TH=6R@TL@'("3G
MO?L[6O1_,G\RN.X;S#8D%6*]V:N=TGD@K;#<].0>K3SO,BK**[!9OW?O+#XY
M/3WI.U8#!4?V?.T::IC?/12&.;W>F#X"$&<?BZDX/VA,=7"2\*5/87O2)DT4
M^; ^3-+QOC"PM:F:OVATB?T9<FSIE-A[*OEE;?PLEJ5Z+1&G#VXQ=P!I$KH0
M]G99 ?#,(;5(\8Y.8'[)@IK@>/T%#OPQJ=.,"A=;2S< 3I)_\E81L0L,ZO%4
M+E\ .;7>.K'Y#^D7C3Y3JN=..<H<5XZU*BV!-L22T$X1AD[N)T\F@O>D!QO;
M\!BT4RD<I,T(#H]@TF$U?=9<!Q7.[1F3P9RO4?AP!I^X![++*K&VQ7!J$X30
M1\G3!O.5F1L5NT-0F*1:\H:^$\/T4G)5+:)7UF$R278PO_*V)H))[1]8SJ=N
M_(Y/CHGO*IJ=!%X,[J!?LR.G PQN233'19;6Y_0['A_KEGK=//;..Y4_\:77
M*>KR-R\?3]\*J[5]L4!JU0TR]9,-U;."#A,^K)K>TVN*V-AZEY+P:V&(!Z5[
MP@4A,9])E<E3EYTP_H;^!C.QKPINKV?\&[+<5.-UI$(,+AG'[C8&WT!/.%0H
MW&RMX!T#)VT%OWIUDS\ZX4<*-7?>9\X'V0QWRU]"/8A @JU^8,PE]72\PKCU
MF7C<K3^V&)NJ#5KNS/FM'CIQ/]2?3P=\/IYC41+&KMY_J[?;BQ7T_5*O>=$Y
M@&Y#N5-)^C=5DNI9%Z%"Q]W@>NH.Q6*95R=6L4DJFZ"-C+^49@T[ZC4JCTP:
M-\!4(&SG*4O-8$*B-"?,\! NMKG!N![OM<:.CWF-88[+;OYPX?&;YB)_.7!$
M\T<4QBQ'=YF=?ZXZ5MM@A@"/R*CQ$IY-+?H$.B93#/D\ >SDN%8ROU2"LO?C
MZOL75V*5"O-7K@Q/67=JU&&APE5FC# %'8[M[:3'RA*_[3=B@[SMHA6UE 8M
M!;Q6OC%*O83& TW8$JQU->W]GU^_V \\,LKV;)$Z1929-4GE]Q?4HK;L',#E
M$6UL26F0C 7_Z>0W =/[2JE[-/T4_YZ6)%?W=080AE?5[C<WVD+K.4JTO$;A
M5P]\IO>+9J=8LWPFK[1])6CTR4<\PN UCYL)D9/WD^L!!T@LP\ &PRUA! >N
M<1Y"C\%MJ6G]>$RE(O1V'.K6/(C#L%+R2=N-S N:)6S: )HK ^&IDSJDLS"J
M0Z&A*+]RNP<8+/[(7VFJEK= E@DR--WXY6%JW_P?PL6=JQ,JR6_2/KV8A:@V
MV[&9=,O6]7XZ[[*C^:4TEN!A/)R:)-%'GOHGJA@3_,K<Y&B:3TH5^*)F7%'E
MU&0"B?GON]Z%;YK1Q5][)Y[2=1IX'3EO(U3E9,MXE1P4]IS@L-;E"WVJ![E>
MSV%?SPYU>UJ2)AK7KQ,N++>[8,;Z:^8<Y1;&>RLB^WAY_&(_P!\0A$JA,MM*
MSN*$Q=RU3U DS ]998L^*>GV[U=&O_B-]1VB@.#V6XZ]1+ $$&K2N4/G#5FY
MU(F>2'I2$J(PJ8T>I&RYW>DY2JU"2F4OQ.Z,H!"5-50W*#ZT=YBC7N^9'*-Q
M<+%UP9#7CBLD23H2/_=6.J[6?JHC$PRWT&8.S_; YX!-X^\R9)_2H\L->9]U
M[<]4 '<9NC1/9%*=Y<L+H'AU?M?NK"=?5"\7'&8D<JZ0#JC,ZQRE9Q'88 5X
M-D&;NIWB,KI/,JX<+E<2]^=!]+>G6QK)OIL^%44#)C>J3,LS_TK'*&0.^< "
MX<G#HQPR1)QK,,?0ZVX3H_YDNV;_J3>YY0Z@8!:GSVW>5\J*I'*J/JH93!>2
M)3K0M8G0J.V51-'>HF;8!B?9-BVNM10SOV0"C97\W]*U^R<8XCNHO1,F](B-
MUXPPB,V3.AN[*6E&:B<(5U[@2PW"Y:W2F0*YH3;N<<U[_(H(*W/\QQY2#UXQ
MK/JM6'Z/)Z+"*!@IH@O*1MRDFMI[5<GH^K<48H]PNBD[J+#:]6_)82+>3S,%
M%@.$\###&^?I<7 RYF2ILZ9BXT5'-V&"*-N+C3DSS]]Y!A,<LJ(3C,GCDG&S
MI#CU7W)"8)VK5KZX,XI)C-NJ)=G$*BMAQ?$.D9MAP *Z%-!PFW4%/@!(=KS#
MQ]^^RT0BR5 -Z+K2R<S+8==J][>\PP&2%+(61<H<G&U &O-E(Z4-#,SA\@F$
ME+A!-F8]D281W5R7=9J'BO%YSEL&*P.)^\]\[+XF=TQX++;)C>(8+Z)SNK)X
M35[8%HU?>9-HKSB>%"33/".E#=TCB-@]+*/@\/ "_^-Y OC)\S!%P.43XZ%T
M(I<T2,J2MM11Z\"(8R!S),%HLN@2EQ#D+Q.\Z"B@]?N;9FKA8O94QU@AC*TX
M\O[O<K1Z.R#K8K"XO!<?6.DHQ7MN&YW3N+B]B!9^5=DDR*I=J:4HP4C&T"U-
M(8?GU"[4K^K9XM2/Q\TOQ64J/IJ!"AJ7 HFA<RQAE_<7;/V8 =AD*V>\U?^
M)H(I;=$ZSVWH)G>5-[T+,HPXK)*LJR%LU-+3R_B:X-9KT2DFKVO9.893&XQL
M$I4FHCEF@NL:,O#?/*PSY/,M[CN@:^AE[L'X$3][9>?\^?IQ@.SLD6^/E(MQ
MU]CQ)6?5D"Z?\R<ST1_:1HU_K?,WR?P E,9] *[U U^2LF^YNH4+"O97GQB^
MU@5&_KR[^]E3YDXB_9\^(1#\ >!7L'OZ)8HKNSN$=WO55F >L/Y6T>6UZG[;
ME^GG.Q&@>"ER4/]7QW1?Q"BQ]>P#4"7^?OL\M^-\(&N/<98OO"@ZB!9L1!MY
M:#KG=\IJ<IY+/7M;OHPJ,I)(.HEI/!2;B&=M]-N>P^,-'^!@9[1GL[D]&=%Y
MTQ/<\.Z_?AP'-G!E[^4<(=P$Y=ITZOW^2>L>49]-D#4@U/4*I.$KE_CA[=\2
M0;$U!;_*NLW7$Z)FR[IH+K*\RFS8#'3.XO2SR2 RV"D.F\X&-\H'Q9=+W1%\
MM;8J55%%4L_SI.6ZQ B6;^TP5'?;>.RIP?KR'W$P?6WK!F%YZU/Z Q--^I.'
MZ."\ )YT)BZAF&1-T/BK:?<J'7E3ZW>]C3R[\*64@'%()345_EK[Q7,SQE)\
M';#%*0V/&4*QPJVK3(3*?8%MF;%)-YQ='(.JRR7SMR/_ JYEXK!(3TX^D?XB
MC /;&7FWI88U9V= >ZO7]3&7?V$35O!7(G?B=:B)3G31,X'K3T'%3"$Z)*[N
MJA;)3R#S,9<PG>O]@Y&LU<X<5,,^Z7YBO=5VY7R39P/PC6=9IIU=YG7.%P/W
M2>](,K.C).N.["=;;<KRIQ+:PW#TLNZ2!%$&[2*(BBBT$ ;U"+"_"N.2? L/
M$*(.LNF\[(X^B4#9LNX.^!EKR/6I^?(/K&T20VJAV8-_YBT>"UU#@/:/\:+
MZ(HP*)/."87SB.*CS5H3H!G2 G4R9.B@_G9=*%L;^$,W;466PMM *#VZ+#X9
MZ=)QU@ZU)=R91BR8(2(K(/8>@-^#P)_)1>L*-^4&TEXZ"U@]J&.[GU5YII>L
M=9 YP\&V?D!@EZ2\A0/]>*:C;SV2U0(1*/IUZ%E:4:NL%39%07,.K%62F[@
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M;_J0.4].NFN%8KC,TUETJNC/6+,9^97H*6+IJEI;4W-7:!.=6%=MB52C0[L
M+8%S;;XL>BW+X@K;: M13XMQ0XKYJCY30B )POCZ/),XC\>-2&$I[G8IE=6]
MR<VU_#AN:Z 0ATJF+3P1AP4!H'&/\RUEK+#JW.0'5)\>=]/21#C#HI/(U!VM
M)R ]\.]^EL)T5&TZ57C/T%$C%D*E@(J^G_V'S5V9EU)U!V&K6O*D%.07"LK!
MT3^ 5]O=RP%3L,G& /XL69!J6=Y_'9Z,[[!PS?/[FTX^\R(J]-%32*C?HUXJ
MRN26TL\GI]&1>;R#477/0/VJCNA#6@&5LD1#&P/QQ(C?AL)%(":IZ_4;JWR$
M5YD)1-PD7"EO$UCSV->>[CT<36ZRJ&Q&,+=#@[JQS#A9%Y[;[JR "4"A&16<
MB9S))Q23,B9MZ-U\T?MY%W_$*O>U)\+I4,0L%P-*7,!C%5$9)>?UB5EG&0L$
MD]'J1DL40=M.2LE71MO;NS7?V!*YN\79],Y^T .E0X>9<J79;%/MXH@S\9G
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M'0O6GG[:U,#LK_+:&RWVUE6&/,]=F"#3XJ#L<0/E9&/8L (Z-M:>C\^6J#]
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MU(U*]^+@W<91"O:*ML"I2$J<KU=5K3'-LVF9KW-2:2DY!>W&JYWT>$0M 9T
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MD#.UY[L_L#R45\4W[#:CLJQUYLL/#\-9:'A+JLSZ<Z2'!;:R[M!WYBT%A<Q
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M-I,D)=/1B/9KW%>#L9_@<V,5B_B7WQ0#/6F[V<)T,>U]SV,<F1*_TYZL"$K
M)*N',I1??,[CBO#U) ':6BV+S$.;1?5\"S(E)%@,;.GF5+$4/@V"Q>ZN"FVS
M@SL#$YN;KHK5:PS%VET$YE]9",X1%#!3OOTH(PM!0C+Y]2ZWO,4R1G=S5&_V
MG$ X;HN#OP,D-N(HP>D5R%:7(GRB2^YE=$M3_!VO)&Z)X%?]*Q9:7HSEZ &
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M,9HH'MIIN'2_E!75*PD\&YT$UY?;H.$'20M8B-JZ7;=2V)UB]OV4"#**W*Q
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M/@&$NG!-E]=G5P]_C2_?\@,QGTUN?4\_ 1<K@?V1*,*7WO.?@%4ADR,GW$_
MONQ_&\F_NJV46D!-LV\@H224/O0!.40J<3H*)=T072FV31UXYL!8XZ?3DS8?
MC^61C;JY]M.ZGSF!0OW,__@6'@8OJ]8F6'%W%?U^J'L=QY8BMP6;.GIC7CC]
M@O1/:1][P9O:;Q<5VYJO,7 @@[OF A_5*SJ24>>YJ8!#T<["_XC]_U9L;<?,
MMQ/"3]&P;@']/>%@ZY'YIU-L4&-0E433Q,<;S/6Y6^9(3B!D.##I!J^_;LX$
MT_$9$2=!<L#XHX/?7[YCATZ;'PW"[^_FX1^:W]^*= ^$_@/Y#^0_D/]'(-__
M!>GY;SBP_T#^ _GO!I&] (-7TZ&SW?-\BV/9*-GYH]$!<-"\IUU #(M5,_BZ
M1U8_D_)PLQ3]E;;K1U]?YT7[H*4.Z;J?SA_,W4'/K8&BZ_^J< ;PROD$:%R_
M]_7?RU2M[%N^#;QV/><Q^S&_]_V=OFB%J/90- \6*TS1;_L$T-6;_)&?_GLV
MKLW[Q^038!,0U*5L7<#K*N*9^AB:?%ZNL^2!!%GS(NX:+#Y?P/J]R-%YKUNA
M )$L5,A!9+X.Z)1</7JA@=T$WXH0?9$.V\QG$;U6YTJ9G4<2#<"ALI%9;[(]
MB<":Q^105;#=E;7Z6\//FS@^GF[9JU$A&YX@$_R3N'>9.3A1]N*7^8RP[Y^#
M3+[UY^PT>\T4]@HA^EBF;Q%[>([VQB%/;:&Y&0%->Y'V/DSAY]-IU"O:P^F$
MI"Z;)61E_LY)BJ ,UA"+Q0F' J[1#>P$@8,4?S ;#N%,GIP2V<:6J$[5 C;R
MZ#G[?'-P%0OGV)*KE#E;!K>I^:RF+*@,8@5?'C.I8X\:DHPFJDF7%T\ZW.5W
MR1VK.#\7Y:]?WQX%V279(A;.%\OK.N>IX/?4+TH7DV,FGM>$D@^')O0PYS19
M(X=,"AWMTDDUQ!O:ME*2O&M=BZ@5U[/$#"-9A09WKBC_0&L#A>.Z+97:TC*$
MVW??6 9N,@3J-2Q ')P'F 3$>1IPKGLN[5 DZNAEIN@-6MR,\DQA%8&Y')*9
M(X$-CH>)U*;374CQ)S8><VH7!@Z^,O'SK",I$]C4>)(U!K!F?F:!(;V"T'2_
M/,0DY4:4AQ]WOEB)-'HRCP>1X?.FU%G&.LS!JQVD@V==5WL7\,@08*9 [9*6
M*N%2(1B4B)(H,KZEMIN+#$JEP?#I=6>+E6B:K5VFJ(JW%36Q=I9NN>'X2X%\
MZI-ZH/WA6,'8BWSQY.;NG;35DSK\?!."IEP-FA2VO($P&D\+_+ZOL9U.+)O3
M^CN-BG-,PE^3MF96O4EK'6$A%(.;8?63>8>:/,5"%-+E"]&P5D!/,G+N53%2
MT=V2F%\I/1K1VZO(%3O17+04W!15B+:D89+<O&8UC+\ O5$GVEZL_'(<S,!Z
M0O+DJ0L[ZIWCS8W ;UU,@5I:QKH75^;[S>8J%_'LT)[M*HX1A3F;>)UNQ7=G
M^P>B)-7B3%.;+F) W=%?&J[K([>9?&*_^ $W:;6ME;0I4E<8#S%I'=]^XE*L
MA]NOBG,,H(N[Q D,[T6F"S%.DWX7L/(W($P"5BF1RFDQ,NY5*2RIS+E4\5_:
MYF/@;Y Y4U/82BE?8@8;]4UW%W']H16"+2,;"D-$1-@6U6;HE)F8;/-+--)"
MG9<K;N[0Q7=E"I_2V-L2 C?1Z8:?=N#M7?@O691K#X7;43))EFUA;8U0XYLA
M"'98E.X\O07XUHIG/NJS5A,]U%J>':S;TME_:[6 I=6CL(+??#^Q^<$I<^LD
ME,]#FRZ^L6VD!9W$_QPR4,HNSZ.56[K,;VNV^NN_NDNQ2'8^S>J_T0Q:21=O
M^N<MJF> !''C92)N4IVB2>7S-,JA_-SHH8\VMSK1-(@XDIVPS/&2?;]$COQR
M]8X:Z/'D[^7M=R%0GE4_;B@&#\!PW]ZUV_2^4N(-NN\WX5G&I=E#F,YZKUK6
M&E@O59"+L(C80$FE'ASAE.$V>:'F<S*.*LK[878ZQ7254%74-YP;L/) X&!%
M<T2)9R/2NE=+PK3\>\C$R$.6\_ M$GUR'C/Y<":1*Z%D&N/-BS+Q8%5+'O(9
MVDE;@@B]J>B';;YZ/FB%GWYRJM,30ZRPJMZ-!\AKNX+C9]TLL,_SZ)$-2N5A
MU8$'OSA1LMQ(8S+MQYE=T_AX>@[3QO![31R$FP>&VVA!?]]HA0FQ ;!%D*?Z
MD(+/3."S%E-J$Y'?R#F(>$KM9+3SI=]&?D6_%\W<21 +#=.Y_2FGXTI.H%[Q
MGY#M>J1;E4K9RO2B2D%"E]+58VFQ4AUB-7AX,GWK.KAV6I7$ME*E>^[/\J^[
M%($=YKD]3GPV^)+@_27!R_AE,_DI?[KU O'<TPR^H(R?->5T+&"[\O'F?/G+
M</8+Y QTBXW2.;$PMX!"BQ4A]B)KD8A>:@KO,7)E6;D8O"(7MV6LQCP&9V\/
M(YI;WP %1GCB_ZQ'"T-LDK&J*(1P]KZUD7"4G^:;F1^@!>9E?%TG13CI29Z'
M.N&E8GI;+//E$]#Z6+;A1?HV^7/3-V_OO4.WL&W]?[#!N(""4EY8IK(03<@/
M98T;/]HN"(4&/F910W9ERRM6:]H)59'&STL6QF$<7H9%REG$NAWVR65LS;V5
M+%/)R'1DC,*PEF#^-]Z^.BBNYFL3=_?!W=W=W2VXN\N0X"0$=V=P=W<9-#B#
M!W<"#);@! N2?7];NU5;W^ZWOOM/5U=75]>]?4\_?9[N<Y_SWWS"_ZKB_!8Y
MB2V<!^N(44.NOMXIE\C]KC:)H;P+T:_(,9T1)+JG<U4_+T!;79GHI 2WPVC#
MZ>,XQ777P\.PK1M@ 24DMN\=/NLQ@%VQW5<E1KKSN(5D 7>"2%QXW)H'WMM-
MT4NJ=B0GM. *F916+'FS@T/$2?;12L#I:D39</D/7Q@\_ 023<E/(IHY-]YU
MW@!?S,C1UJCOQPD)<:@1+3,KN7JTB6R>R:6\YIF,0$;ECV&TKSU2V%$T8$64
M:'WS#==<N5F<)0)_#[+P2'?HM'C2#23<]T5HHF7;E,%NPJP]\CF9D!]B] ."
M^O7H;!0V7P.S]<SMZ#6<H$U164!CSD?'N@80AAB/.&P$M_(?I]WG5Y(*M%"M
M)\@'9<,\9%3X1=GZ'?N)TH$D?$EW.S&SUYX>\=?\;"S?Q_VAWAX&G%%+3Z+$
MWS&"I[_>[8?'_S4" C[4)F209,NXD('<S9K=NME46KV3/C&/W'[-8=7(ICML
M[)B8^Y,V>(W3FN"KQ?*>5:*PQZMV!-M;F.:[0[@BT!:",9@@*:%WZ2 SQ,P[
M>I]Q+D:>=\!8'X?AL0ZR3$GV<$X#[?"R\H'B61#<CV16Z6%IO/2)S!OLA3I>
M3"-!MK%^[1@!\(7^7R("-@'$6?Z&05?O@&-%?BY)JKW>5LZ7[=XKQ\T'!M\"
MBRYM"0E3!-+#$_I;K=0O*%?C3$W=T? !KGPBK:Z&K=&55<E.PMJ-S_O YR^1
MQ^?SV^6J@1&?IH2^S719_(59D/D+TX).\H\9"6].!@_?764]OH0(B"5>L"[N
M1$0Z^QK2$ER?B(DL4O!X)"L32#)%-:2*S#YR834KF^U,$'NWA#E)XTU=OC$2
M?(BR-).8$SDIR^10WMP)6!MP>;H=[WE#W129MI"8R,F#ZZ\UI$P6[^^=,$KG
M @H06:[[9T#HX-//X +E4^\[5M 00_41)LSR<*K%,/[79+G^'__OP4Q ON\C
M >Y;<#7X..;MP=^AM/7 ]GGT(47+[O/P\8;>$! YG]Y]S>[&?[0BEL[O79-6
M_HLO=TO.'T_+A@4VDZ'.9R,HF^M'PYCM+]T\_E"&= =0R2K4&(DCQ?IRZC"!
M=R9A89,]:>:C=@V\6IE+9?2(/HX.(P?.8LQ \:78YAM-4_<?:+2?$%\D>6_/
MA7:,^IJW\<+)LE$E:G*Q5I42_>TDXJ@\(#M;FKX16PLM_X,9-7]:5J@+XN?0
M>V:)OS!H8C[3 [.JG8B#Z8DVKU0DM#ROP6VX' \</&.4CGY^P$Q\+K5=>U[#
MV]T^'CP$^)]X>!%*[HMLNR-=TA]1_Y-8\% O^+-Q4Z!E5\ M E*ZH["4$=^E
M963&>\()$1U#]A+!-*/W-PFA*H.OLL>I?;SI]O2AMXK.$E81WRP>",-B)(3Z
M!MRCV:BB+/<EH_%+'S"?Q)ZI-H(E=IDV@W0>3HXMR6^,]?,&[R4*A!X]YIO/
M>S1^??KS\!-9:_E?GU=&S6SRCH[X (WK*W31#>LM/WY.:VF</I:D*O':>D()
MR3-!F+Q"90XWEMM,]@# +8L30;_=FQZT>_#+9!6=:.DM1J'S3U?H@W<G>RU.
MN)C->I26$H[93[6#R8, 6QVLR'86?QI\9TXE6M0W&7(":(1?E\97SYGBU-__
M4^;W;P//#[@L(AO0)H0$8LGR3-.8+7[\Z)=A7BB634BM-FBQZ8#G$-6/U0/1
M9%N-XL# =D<&F:SU(],&("^+](FEY[=J8OU(3\[("Z 80Y^Q3[W <O"R&(LL
MH%2Q=/T+<[!\HNYU[AR9N-/0XK2!&9!;\BD(M5/;U)JA'. 2/I]T1S-/5#M%
MNY=P$O6@>T,/DI]:?<RZY]4L.9"*-[9KC%G?*M=+/PS@<Z:M_BX@@E/YB_/T
MD8*K53_K8HIPJG7A5^E_?C5DR7QQC_>%"\D['Y]HGW'-NUWA98E!][&>*_);
M"_&$((DPYGPW,9%Z"R[,V(DB^P+?4S:=D+,;O=QI/XN.Q.9$845DF?\B+ 6M
M=/\D?7Y\I+ZM(?Z!YAP;8@HK/O19\R'S0FOT-1WP=;)OZ9B*VK;PY."S[WE0
MLK=0RV7_YVM'YQ5V#M]P]7/);P?F'X:-V:SOZL$$9/@V3E-@LT7U;J1\ HVS
M&096NYC4*MBX[=U"LQ6<R'Y<6-+(NHPT&1G<* 0A+$V;U[.[KY,L30#XF$;Z
M_>0_/S9OKW>',A]ZU-7L6_&0*D#NI.,,FL:]IOL(HBE=Y6PX_.*J]3$+":G,
M.''<!J@%97W=P*1!3^[5+&#X6-Y CS*?]^*J4>'$@9"CD!L>JILD,6]!M9W^
MIYW6!.D??>VC"<QY=/GU)BK]<F(MHT76:62#($MM"]!-TDZ6-]Z&7OXOWT/_
MW]A&=W 5$P!4/<"M<;"[6I*@7_X\IF>B=&SHSK?1"7'8'FG7[TY!TBF%/T5+
MFHVX *9B$MMOR"N)E5,<N$CDX?D\>NK'1O.PTK=KF)Z^%@T!R$S)0I.61US.
M9&$()=W2%6/&G?U7B_;O$]*:M8AP8=U"I@RWYLCS/6R4WR\"1YZ3+9G H<?N
M#P5V?I658 /\$9E<&P1Z-9XX)8S]N.5>9634@!QVL'/.T;@?*./KI6_WL.RW
MEC^(B!H^.6V 7LWNNBV)U#5 5UO]4D).2V"W_/RT-\ OC#G5D=P6.X!ONJT3
M(*XS/:!$SX;_FTVVF.%AIY@=7QHV@G&N4(LA0$M7P)5)BR+8USNU8QYEGM$S
M9*RC;=P>^.I(DJ)<$"R00^8CYQ?3VYWO9Y4J@AK[ZQZ-':99SBHU@W!^8DX%
M6D3[CKN7H&7IC85TN^K@8[?:9(^MH46YX%5B?C=\=/L7!GUVHPBLG'&/\BO#
M\VN.1_]?F.+POS V.'E+F3UY? .BQ/RS9.9I;[70SH+*&9+] 37H.@)9[PCM
M+(Z .OLN=N)!\P-\4.R5JL(N4H;J[$4@!K\O"CO.("G:C_$<KK033;5.8A*[
MM\"1FSGNLNR0S!-S08Z<L^K7:8F9J@ZKNR):X#BO3_BO5N$_0HX;&PK9;K@9
MO:"II <C,0QX"Q(L.NC=9A%GD-;8EQ9LN%=2@7>R HG>(-4;*=%G\"!:XVU7
M&S:U4(#/R%OSIZ#';,.' 8JEG:%=451T\_\1"F'9@O>/JYR[;Z?]]<S;+7'V
MM[=RH49R FX/KL[3ZOBQHLQ(B&/JEQX5JCI"0[P6_ ;I_?014_J%P JEJ*.V
MB%(5P 1R,>>AK&]-M#__O*GOL*0)0LU=%'."N@5I'B9XDFY)AJ'70B:.B5L5
ME$T]ZNC>J)'U*Y>/G3ZK^6JMXY1A%BZL$JQUA'WC]!GY+\Q+>$C'.^$6'^&:
MUK/Z@S>4B\^7ZMGV+PS3W3S_(^?6'\M_Z:MI)K] "8BF971S]?)$%-)/'T:A
M ^K<@E0K_:51(D<=)%,LD>3K#+@?2*;$8DJ3KR$CD8O'#='.@M(><MJOV<LG
M/836C)YTC:'4%$FZI"=+6UUBZ'UF9OL-\9OBX1=RO*K' 9D5[[9'RO)L@UUC
MO!&YHM^*IM<O!?#B*BXQ9J'I:PRHMD(U:[R'%*-LD>O_<JZQ0B2DQ0;;154P
M%YC,K2&[,UG'L[=CW;9,5-"^ +X[0?[4#DF6@,0'8R0F=H:\ ?*$%K_QZW(+
M2\/BMA'7W36LL--_82?UQMWRA^;<^3F,-@7>0JZAV'96_)SF*/*<XUO:9Q8B
MG3".^6X;,=:H0=43> B6\!D;4.1E.%P+I8S>-X'C)QQNZ.UE;7AMPD[V#Y.[
M:-Y"_RG-7<0D[F,I$!3<6RV-GZQ$$MG2D"*.2FI-HA7BS4,*"\OK%3>B72S-
M3$%+T2 S<P6[?>I!S&JJU$H2;NLU@#6*,^,9=;"13EX\T9*0L20JD!9";:6'
M<6>[/,\PE;.W(")-/[F:48.N9F1@]H.9G9K^6Z;5S[E_S.ID:1F^]T6N/&4'
M[M,J><$YY+/;'KMI%*_WN]I$NA2?K0J9WD%6]IY]B@UPV+AW?W*:.-@33>'H
M/A!=7+#_PJL@K^$?SA-^LD.8[/30;_TZT92^_<U'\$6S56Q)SZP.=;]XE@<.
MCR%[C"[*:\S%O!P^HF\&9-8^<WLH-JTJ_2AF9DUC9?3VOVU6_UH6(K\_[[R5
M*/R4CG12=2O8</$9B*J;N22I@OA?AQPR9-QPJ*(R%2;$)M-GKM TASYRBR,B
M_BF0B%:.#(J6^4B@-C_!L"4P3MEI)5Y0RRTNE,KKZ["I' 6'$"3(IT9)YT +
MDFYE_TJ=!X\'$>[^C1VM3%L= Q?I :=HC)2W2>RZS4A$:"AQ1+RB4\^C5'_4
M3B[ODC> /-&0E,:>84">7?4QCSJA0X 3" RBGY0\<(,?$9,CU;<QZ/<ZF$--
MKV#V$SPR>>"F6;0D[_T5^\RZ[&;=N1X"WQ<2YZN69Q='3 - EI)V3(T<;YO>
MGU-=C$ U&UX_5AA/=+9B9MM*TJQJ93S>3AOV7F!FT^*PN]3<>&9:"[:/$5C"
MG.J&I-F,<6Y1M6#/)[+<$<"S1=3/?OR>G4[SO"I\WI$P8DPC"(Z4L1A:N&[Z
MP[DCLX-C;/\OD*EE5X*<=$B:/13%_8.GE(A/_*ZO0J)!O@^9!Y\_W?E\)C0_
M\G2@E/:X/8E^L?KY>,7==!$L5M4;WO<1#_#(#.!*.S<,+<6C9.OXA7U>.50_
M@X&Q1,+I&NAB$]>^7X'3%]HCQ^YI<)//C6=+C^(P^QUJ3T0<R6C.>S=FYV!$
M*R%L]._D< H5F_T+4^/WOKOWAT[_UTWKNU7(]JLFJ!_TOOMF_V "LR):T?)/
M=Q4.D[\P&89<3^5';Y]LZ\B>FOZA[)*#VY5M\WE@*C&5%YG)^R6VGZ*17S^\
M%H.EBY_# T'WZ$X"Z1D;[W=(:%?4PSD6&K&M44+32(I<;*%\:M3?A0G,7K^D
MU%?PQ9.YIJ&RJTML@.>&-,^7 R1B-#HR")2UWC[?EVJ@PJM1;IRI&VA'0,M+
MT]6NU9^'!8M#!,]!]0J)O/C!)>@Q'_"#_L+(YC"HHJ,]=KFN#"J$G?)6>BQH
MI/T(2A>_GR@'"F%. 'SPS^GWV$9S:".E"P$^K0F&E-:@*&]D1><&W+.X:FA(
MOHO\GK=0=WAU=YF^N?)R+GE7H,4SS>*E&"_2C_Y+08<'\;6,DO6 6I2ZC5V#
M24G1 ?9[*8-7)=MXJ[9/F 5#8ILZGT"PPI@7@>C=E[CK-*@BNI"GM2PLRX(5
M[YMD0Y'2^>3U+A)9?1/F8(7/^D4[-?#BR<R#S02;IF7H+IGAW&-U^:I7TL[N
MO6&_<!>=Y2,F[CVF[>(#F,>S5\[NO]]@42V32P$4&T9;,HB9#!W/SJ-D&%#4
MC?H.05+DW?$L_",(]N.Y8[N'+08DX2US'YHIQ77.7N:>4GN$%Y,HXCX.8+RA
MN*+Q0]*;R2*,2O%.:QHJ2M55E#,9R+5;+X#2VHJX"7"G[$.;8=$2!,:8V]90
M,@(6W>IC@H,UMZBIM$-DH+N?L5LO67I-2PA%Q8I$F>P"V>Z>JY70YMJ+4 >R
MRSFN>^ RN^B=TQ86]UH?55*N126O7!X.][?BFU6HL_PA0Y9R)IX)@L3I@1ZJ
M7'A:2Z)J.H>/%K^#Q4%W\ 1WNSIY:V""4MH]*TY-$T[/)1G69+\HWKQ#1NHK
M1RSC=R4P2#>E D4,28D]IB:K+T,WZ6L1=0J3NMCV89/,/4:F];F62.XW7ODU
MTB&&NU== (QWPIP&H5U(VN&0ZGQ2=1H%FK^/?,U':[V-[XS3-2(X$/[= XU&
MSE"392I)+,<W1;"48[/FJ)/11V=*DKAIIOB;D3F;/#LPQI\K#I(EAL[>TH#(
MB898[T4D1Z4//'!)%XK@'_2,VFQ$L%C?1,.^/PD//X6K^POO7F0.DS%@K[-7
M"8P8C[#;,=7+FR6@\,BGXUG5V+93$6>,<3G$S*'G3JB:^,25F9'E<=;(I<!D
MM.%ER*[(:+XG5LO_P[A3,>YX_=TT?[S +I\!4AE85>FO$,P9(4^S.2LKB#/,
MBA4?>=*[9/'C<3SMXO6)/Z?D?0[]/=#\ZO4=#3J!"W5ZEN\$VW/HAXE#L%2L
MT\!NK8!47COUZ'\VH;K/6U/N":=3_4UK,*87#X&B_;"_559JID%:JQH^$$_D
M6OVKE&M%VOR>6C/:J ZUC"ZJB:(URF8[F%:$ZB--.-PL&%GTI,?3C@:9_M/_
M@322"M%[3OQ?&$2AMP!],KQ_FH_REF5A -T#A7@S*(I&S[8CU"1(9"CP,*T@
M;)0PZKBU?XJ]TH?!]?YJZAG'C\82PB]DTYSYFKKY&/@"D6)75X"63!L6-O3\
M":8&6O*3)IV(AXL,O/4LFEKUB(RS8<>/3C'"8%+S&7VV;)Q!QX^E"N4+5QIJ
ME/JHTX*64D"O(J>'1MD#;>G7NP(^"\-5 -LM\58DKRGB'.D4/48<#,QZ?)VG
M\.+[4%?_2/& 35NAV[AX;6"(][' C(@6Y3<^R1$W/4;K<)E;C$XFK&F,F2A7
MB1P3H)E]Y$X_R'?]N^/1SHI8"5J<UI[6^3#E^ERSUJX;+\8CP8U2OS$QL<;1
MTQ;UJ)?<RZCF)]BTOI%CG6@;PX[0+.7?A>(=X(O,T6(2-H3?$QE.;FR;PR]"
MQ>5O/_,U@)9EVPE?4X]N$[Z*9Y_-Y2LS+#FW?]TTY,P8!#O,X%6,72K1AQCT
M']WL#$E?6O_\0.X\GO2($QFT5QFN=B<6>JNH]7ORK-$XYEQ\CV#X_E#]]YQ&
M^O6Y5]>^PH-.I0_N&@E[()LXF=VN\*+I1R3Y _VOA-ND>W$]R]]:Y*N$2I3A
M_:^O1BKO;!\^2PD1J<U&K=N9 8*%(F_7?F@^I7-%XV\2\H\T)&$(^W1:=F*G
M_(5A&TJ7JE1/>M>[S.+H;IS%"_H$IZW:B'U7Z#8M-CMOIL3J0%Z5=I =],50
MSIO<EMH.X#8E$4\+D^.H7QQW"#(FZTUWHQ4DF$5%;R4:3JMH<5;!UBMN-J(Q
MY@X89!\H?3UIQ7<WWCU3(MWV<'VW^C+L/Z43C98*R+S-*!3<W#XM>3--DLBQ
M%2'(/]%7)2,W)')K 9?DP"_:52\)DQ-.8:-SK9X33UIB-!?4KH=L0!<U)GTS
MK1.-IP"P:1SI.04;/D4=V:WKHU.""*T!(XVF*=4:#!H!Y $BJHQ5C,Q'&GZ7
M#O#51-_JWAP6"S\&%(YH!(?9[5K=%GZ=:),NM ^\;]S<S*(7'-6V_2K<)$=%
M4",I///D+*:J,-Y.1(_4;6%U6=+\H]; GX#4Q@2=:5\LH"M4S+W[50%HR&X]
MM251[<9N+$7E:, ?@TL!NDZ_N0'*0F^)5L?Y/<R'*&43V&2[5="! (\3!I^N
M$$6>7(*&B6.NX\>,G,K7PWJ?J56=54RML9?> IMY8X;@(FK[ABA.;=D7ID1;
M=;,2LV$1YH@#IP0S^GR"1-W3*5K"IN[A'/]OE%!*!+LK[=766S:1?2Z<6]5P
M$3'[8)?Y')M>TU9G2X8[]: 8!&*^"M[UGO/0)C:U0^ *$EY+L_JA*0-U&7Z5
M %@5UDP5@EG6OGZ5A07/AY7GWBE[E"[HN0L_&R2%,K1Q2' ,.Z\]CF?AH;:<
M.)8F0EYPQ#Y+Z:P\P/KMP3:H3=LH4[!.OG!5U>9SBPPZU3W)\<7!>)#:")+$
M=_;E^[A;D.>Z^ABF!I5WT5RID2&-LEN=Y<(([DDV5"! Y:19D' 1D8DD%BA$
M&Z9R$L$RVS).8"7WUG,H5.2N.&+,EHHR+R(2).90#R#TG=U -T<$@,::U?)M
MX!9+WKWB:)"%J">Y7XNZ%3<UQ$'A-UNB?C0P5I@0<6GP5S[?KL*$I+%AQ1*/
MRGYY.C8A_,_F-B38./*QS%E.HTIBU5X9H\"^U/[4-V6U /NHZ1])RJ2Z3<*+
MTJ<_MNQWCKCU0[\E-.:S_8DXT)83-.&;>[?)<C\,0JLI3731#?[]YFO)PU"C
M4SE$0JQRJSJC""TPBN?@E?P+DT!F?-F\"XZL@@D:&PXXNV(&,Z4,P/I.N^YH
MZ,4_>&*[%A[8BN=>)'_HD?\P[E-(-W0%=*CI$Y!E4-FC:5++WLLN4H-ES/"1
M2TL%Y8?HHO'N:[_ZG!6);=>??NX[(O\ZTZFZ+(Y[!,9N9?!O#J"B.??5P7>[
M55X_$Y@':& 9CAFC;IC<0VN54T7!X;7RDZ9I$9VC68!P$N.LJE[7+J/MK4DA
M$M.3+,)S1H.%@ 06 CIA44[]1]IL&3NY%/["7!G&CXJ%*HPHT@NK/R-]OM?N
MSK0-AWV@E#PWE/Y _Q+<=L+SO"35)^A3U/C*<:9)/LWKIA56<L973T7I-F>G
MAD_J6CW=.E[:%H53F$>114IPS$A2SK*)3V0=DU:F[V)?!XK(.?@+$^BS6WSK
M&>6_"^FKMRZT$LARH\'/[$ZVHC66%,@ )I%/73LHG1G9!@".BFCL ^1T \J"
M #&3TE<T0?2'!'02L&?L<E\9D:O78RVY@U!_HD*QU7\3^V3^B(&3"/@VSQO-
M7L60H4EMQ(EU$G^M>L8>C7" K .A8<_1=&0*Z?$AQVUG-('+)RQ$/,W FG(2
MN%1+ M9]<_AU*C_/!HS/ 1.N:(ROHXP/'I-4>A&<]"L2# Z6>(JOSYC2'&%
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MNM^<.0G$<G!1$\\0$V/K'P6.U23Y<737)1A>GFHSJ6/5R!/A1(XM !,A<TM
M0*]X;M6^7Z+9=KP^RD2V#*/'MGFA*CQ&OJ+MK?RY8\>8#2>F-7D<OXU!3I__
M[P-'W<6' ^CMA]Y;HM]Q&KHX/O8EVY# 3['C006TT"*FV]C*<(B.D<7L(?E3
MH8'94&JA1<^ILB$VD<;41@4DFPFVKY5LA[0<!2'U1M>+S4T_],@&1UU*!VOR
MLHS28U^@*4G]@GG"9R=[!B"#H +F?]#"'@7+^'P7O?00>E@">)H5)'U"<^DK
M/Q*2O8T<XU;1]0]J ?$/)Z!031HD^_1.('5-B\B:SV'9S#[S8?0,V6^86J85
MYS1;A9GN5?"<PN6-EF@NG9 +\3NXZO])N=>(Y_D=(AK1J5\,>V4-@XUYE>3_
M%^9D#82!B;23T#23-Y>)+FAS>FR[%N*_W'E>@!5:%@'M#A,)INFB4^9IU![S
M9(\2IM7?=4HP8X^ [A98=^$.B[>4XVAA83T^.G0AQ\W6BCD>J>T\!&E7]N(W
MI26 ,I83=4588Q1%Y=@25->8K12G=%7D2&-1&PP-5!CR2\^/V+F'6(7WM?6D
M\/^TS"FQ;V(G5LUO+]B'6'Q#V>,UM<-2PS7-!(XO00/H-%6\6*4'.>P.;S]S
MYN-2N9IDKS[8H&;7J^L!>2'7B_7.5:1$WB.54U?'#;=:1=WF4$/QZDT_X0%"
MUW4*Q_6J>ZRDM TS#>$RYFW;RU;D)?UI*G2@J[]VL84@<&SVLIY380/8?E)!
M@9Q^]O#.)Z7K>/47QO%M\6$UK-UQZZA()'DNYVV_+?_-;]]3U>O8.-TFF!!;
MI<#JZ<[!A]8H>\E<T1PD0)C/'?%[_;Q[H8J'>XQ&<R&[#4,^D[1,C\.LG7Z>
M^&6I\!XY/9AO_$'CR!;C#K:^UQHEOV$T"!8/<E-?EN%U;!C.*Z4Z0C8YS_[/
M'CM%FCY+MCZC*(L<@+[!1%(".,56L2%'Y>8IR @Z1K=[DR4[K,S%[\/>O$O<
MN%:$25/_ &61CW*$'4E1R.Y%Y$H1MS93/@<0?,BB5ZO$+D&MW<(1K.='6XGQ
M0 VR52=1Z*^-NVL:VEUR01(=[2O7\'MME+/'(CU+UKTHT?-[ZK/DZAF4+?%N
M$5;D33*9H8M!Q1_7<0-Z!#H',9?-R@9P5B?)6_H9D:4'\:,7)F*O!NPQ89L=
M'IVWY7I]=<LA8_I5!A^\7V311S)A][WK9;0L_A@TROMP+,]I5T]F\VHS&BLC
MH^W>RT"?[C.\U7689^PQ<'U7'520D-WRHCCMV>X(.]9"9_9\A(9AG<#+:#-Q
M-'V\9!S4MGG<V2O+8^UL ,-*3E"E9*](Q^,G:\J"B$@F:OU6+)%C$=)5OV>,
MO?D%@R"FCS':_>;%HH4Y!R^K.Q- [_S@S"BA1B8!ZTOL?EZ,VGMQ:95RW_2)
M'W^$$3A8)$2V.-]B6KHD_'GXQ3*18-0;XR\,K55.4#OB+)%BM)L'P/H3:*@"
M)_HC)^[!R=.[=JKN<%XF++/':0V/$)Y8>#V) ]LA<=%GV4_I6([GO;,1>_KD
MA=>*$B%#3XX6\!FIU-Y)X,.'HQ:%G#6V;ZV5G"#QV:.AR_C=G>W@/]T5FJR*
MQF&H#'3%Z:_RCA>K1UEQ_6,K"6MM?.2 'F$V?K5[:X==V]':!DD'#/_U^LA2
M)ZU4>J,"W0W7@/*>YL(2_#SG:=PJ%IT3C+OY7Y$PUURCDA>7JT70_(90D;S-
M1)RHB<XO#+;1XG+1NO9M9;PJ^H$TB11FM\ ;V<XB; $3&7HE6M6$%Y+UP$)(
M>V-/F]PRK,SO^$@>X;']%N:EWC\;INV^O,.C9RS E@?OM.[V#GKICK>03 Z@
MGGT3JUZL3']I^,0:[YLM\N=4,Q&Q^PB5<DU2GRJ3]Z^GQRB5PQ[;6"+B)AG?
M0"X@ ^&^#/=3[)9B[G0<G*>'@JD'PH%AT"+B@[OKYOZ* ]LXCAE3P@^2+R1*
MVO(MJUS12M3:_M/6!BSP!";,BYF9J2W"[AZIB&R!O"/>\>4.:&LX3=X6C]V.
MRP3V<P-%/\V6DMZE?6EMZWI^L:^C/%1!5VY>SQB'C;X_\O TQH\01?&V%#'V
M*'[0,"6<D-5VBQ@FAG%F)_,U1%:H%AR$DQH]G*BZ\DOZ8F9^RM*5JP'9PLB<
M2H(]L"7T#%<B?'*EMBI_EM5HQY(P$!%4SE8C/U9WY^Y.6 "2J%:&Q]$*TK/'
MZBB758*5,<13ZP2435&:5=TQ#P8S$S77\_E 6"?(-)X.-3UU^A?9/)?>KMGB
M1?RQHF.%*'9\9,K'&U)V\9IXNQIN%B91CXIBY#H.F^/;=(1)6-G5(KW'62+'
M,\:35S IP=;9P$+A2 >-H2)%X*LD<HI]"TKGA\2RH+6PU(E;^<_BE]M+(K:J
M>IL+H-2%3'D8UKEF&5=2R69G;)TYWUTWG;9M7IG?0IS*/.\&LV2(V:4J-%.\
M!%,4T;S!,1TFKW$D*P6V-]'CH.=E0([KGW0,Q0/=85F5DPCZY$Z  P+^'J<4
M^&21PF\R/X_SA(_]:&8Z/)U^RIC+PCC[2/LBD Q5[550XT@X] 3)VEF6T0X+
ML19==-MI,N(V[-/T>09.X01B!'"EU>41>W$L]2%RMH(/?==GM4%[$F@@;RAX
M<8'7M7T6E@02[,3X971HDJH"5]U>1E'/4X6"&&3R>%H<V<T5I^DKY*/CA:27
M<\="O5B9D7L8][4A\%?M10 1'YY,<LRX!J+M^&N;U+B($-X EO3U>@Y<-,-4
M?'ZUHLW2N70O+ZJ"5?M?&$VD)[?"DY^"=E$>^*<.8F35IA1\:RKM#Z-"!+5N
MFZ.;"S]F?OZVE?/1<P'#VX9%$[4M$TDKMH@%H"7A+%-Z-9((53Z*.;R>D$"/
M%-UF<@RYBV"A=8(RU%5'XM&<DTRRQ1<:YW*N4:,)H-[>)!$"=\!(CR_4CP$@
M1'@)=[$4B!7@+_R]T,"O2+FJN3\0&BP><#9".7]TB/EQ^'NLV,"X5NOL9!A8
MLN;3E\3I%M?S0(+E2#83NU!W4'%KXXK5AQ)M="*:R.&;DGPPZF$O*.]Z8S!(
M^KZG^U%\W_#\I(8,75SDQD+)P,XJUK4M3Z^MO61<AW4PCOL03!7#"Y:2-*Z0
MT]5+J;O\.=LRQ")@*7(,P:Z)3^_[!^BR@7G'F*%G#PCI,MS3XS(@\$&,?NH!
M2\.4.127W;=C^RG"^V9%[N<A09UB0OH\Z<@H3]QQCC>R$#<GBQ 7QY]0O\</
MUF8#;KOD,U[BF)0S:1(]\0Q3X9 <)'2^ 41_ZV$M>_[S;0M=D@P:+#E7^;03
M"*@,K%/>GXNP#U:H0._:25CI%^<ZM:@Z!=%O0@KO@2)]8JQ_8:*X/:8=V['4
MZ!.<CEJ1I-D"R1@U)S?*/5RMIH]GU"\*F7^ <QCR/5I4/T,D4JM1WC+\H^]A
M?HXS97E@<9Y(\3ONQ$UX/P:7T*[F> >@?L9+VTB(U 6KZ^*1)V<<"^]L'\:[
M75XP&T@;X3"C9FEM"A%^:<7#=PSX9^7'GP&G\T,/-N2[+#I1O-F_D&4.6&\$
M%R+3A!TQ%WZW5?<1UT/*5"I85,DV.N;8J1VM(.IV!,W=V,5A\AN(U9,ZHM\4
MS9W0;3Z&WHT''>?1.*/;OA./SADUX?U<\M (^2B)UHFVZJ->)0 E&?<?GF]]
M;>*0=>9L8C7L474#WH_?$S#"VE<PBPG^]WQJ:%N,TQ(Q0U^!#R8D_Z:CQSYB
M-L!T_+BGTD#EYP9%"[U"0XV@MLFJUPQF"E.N$NGAI2R>=\R-A>X/K!;$^#9^
MB8E*"[._, U7VW'7]VGY*T6<"_UY&9,\RMM_WGK?4::PIH,%5FK?=,,81R@V
M)U/0&V6]]^;D=U>)E<.TE4+>)O.;[9JT1]X+;LXZ5:];62SB1RTMT^P!'SO^
MPJ >9$_%HDH&3:=L\[M#<93(%_"^9<+;E &PQ4-^3Z- .]\3U7%'O*G)>_]\
M:<5J]%@^ 8FO3&(-V,UF1A]0?!T%^\?^%$2HJ8PM!U8152\S6F;>T8<4@,>Y
M (%HR+Z><"(EDQD,D2SE6*/:]I(-!<8SO+,1A],\O!>=JM%#K9UN8Z0;F,/N
M]JI<^*,B1G@B<BL/4;S\.2P-^<8H3@PH"]LL)J;DO41I7VZZ#*N-:8+(S6]4
MP($4>4PB2K8!P1L#LK1X]4;[L ZCSRV<^K1"N&GLH%$[>CO%(<U.3T&!G1M\
MLT]Z3NQZ+K8OR'R!!!$4P$04C;/GN8 VJR?S+>/QH!D1+:%9G:/^H83R;/OS
M< Z(;D9+9[XIH4"M9*X,GU^@+TUB\\I$K*AT@0TJ[D@WK&N".8UZ'_W-X;3B
MPTU%S/># 3UR__NE[-$\3L)X@, N!X_7'+Y*3&O>5$WON'JJ E.WSA$X:T*Q
M/.H@7?5#58_=4/.6&NYX-3\G4W1B]EZB&31/ZKIKLM#?L(-31YQSK:@CW!:*
MU&3."9+#SZ-2AWY[>K@52%N[$>T<(*]\#-('^]CFP:<2673PG&&@*(D0/&9(
M!C]Z>K<X%'KRIR=92+:G,W5;A=U^IN)X5C2<"= 5[9C%#[\5:'8&"8 D^,7
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M_]']/S!W5D%Q!0^7']S=W=U]<'=W=QB<,%BP!'<&9]#@FF"#:W!W=PD:")
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M5)NQQNG#-!K0\8X5.TI@B.%\QSN=M+Q7=)$RG$\N;L$R83@3@A$^""1&Y^-
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M<U)[*97[PB6?-FM*&(2"W5Y5TOD=0S8#;$?7%ZHX*I5X%\1-4;4L.65$?OQ
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ME',$KH!%2/2OAZ?%QZ?!&U6"C$#E%71N+BYN<KJHYN84.JGP^E6, -;T,%R
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M!5Q58N!28\9\D0(Y(K6K;!E%E>%>ZXR?)'J=L.F-7+35U%WI=4,(#SJKR\$
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MY?_R?_G_RQR-[(.YJBM7N4-<< U66;M=<95=2"8N,+/+Y)X=&B;Z I[Q[H<
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M_5,7!]U>*;! O\F-FB*0W$I80]#.SUF+DM'L]4$U!L8$//)@R<JZIXI+H)
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M9]#2K)RQ7_ ]RPZ]S<B8LU<F%4_WOJ\ISXA['6?7M@H:S^M'5OVZ7,=U(<[
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ME+5]3E0-GSF+7>L&8L*J5TI.J3NEDTZOIF^0Q:XQGI#SU:R>DY5+/O0 / 3
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M?,GE^J'"%ADRS4R:DP2C( 9]"A,[)5JH2[U+VG8(J^Q9KO<BU%E3<02=6(G
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M2,]-QKXFKTHWE;/%)F=,PP3I1KK"],HI]C58*D]H5&;!WL1KD,4&6SB:1$?
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ML[/Z!\ R42 MJC5]C@P7R_-%45LF4Q!1>&5RX+F$:=K$.$:%89_&7/\PR_U
MT>=E.G$(/+XM$$ZYFTE,*[^9*1CLL"#WX4]38BJMH=A=/2_JJ3/JA [V*)FN
MQH<E&^!"')I3,H2X#IBIYZZEJ,IN%I/#K?MZ>OH*$Z86O9E-YA28#X\@<>C
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M\@9:'6B+.Y0\="#853H1"2]VYCMXJ&ZZ0,7^E^1T9 YH94+W^'JH:PPM_S\
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M'%^)R"D 45!6(C"'WWV5.K_0=NSN%IRG%/WHQ(GZQS&5MI&/!QMS!L+"42S
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M?F/2',O<>N!EE=*=YQK4-)L+*4&D899[T\NV#N*"M\^Q?E5*]8PZ%U_(X Q
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M6;XJMX\.JQ&UM]3XH57F5!Z,.'+9)9"J4&&0!#BS3]CCJNYCB0O+TMS$IL"
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MU]+]/5/7/&%03FQ:F(=;N^GR:K72=I>#M3=CK^[IHT.QJ^,E$;Q'QD4JOV?
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M>BIX)R3V>><UHGSYLG=Q5MS%]#)U)_?,/%#@QV/*5?<3Z,]Z;'-Q\UGM\M,
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M]3H4<%O.L#_M/$S-2-Y#W #53/?8?/7>&&?PC'I*H7E9MR5.P3.<%M:+W87
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MGQ]\#2*3!PI6H0<U^-E%;Y%?\12%NC'KKQX/".TRVW!H!C:^(1JD L\\3?Y
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M322-)^M3"_S^J@,&EVQY=^8?YHI\<BUZP? (UO;G9:K],*$N)6R47D@@&;L
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MBKB5CB\_/X5G_67A@/,>Z[FX]<ZJ7-5B';P6U?N2 !_/%3!,/&4!_$T+]>E
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M7W,AC2VOHQ764/!V1A,*V-WT7<=U^"L_+MR/@'MO-S)P^#?""+ AQAE=/F,
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M</B^TC^47SJ%#$F\^,E=U"^>7FX.:X92^7EY^&AX)<.G,91H4D<X399;?TN
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M;__/UDOG/)/P^_]1SZ#AB-C_X\90Q=Y!17^_&NP4R+VWO&P\/^YL!A\%]WX
M>O9$VP]^IR/!PCOWQ2<]J^S\?HJM+UJ#TZ_%7_%.\?:.L_%><XGL^VO!_F#S
M =C;^2S7)JS.(/#CL#Y$GVS@DL(7_:#>_C"7N&<"0Y]F6WI":Z#QV(@CLX6%
MIBX(Q\G>)L:_.YR**DTX&\8EP26B@KZG35\]G468$F<GLDB][YD?-TJ ^^@6
M"[-&*:.4RP%S&<$5T;^P);4,#>F@B0^X#?73YW5"*J.=]JK$3^<I%G/_=^#
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M4)^4XL";=+AN46$K;'; T8V A Q.U:Y+Y6!ZY3\5+-G'4YE:EM#LK;*E3W6
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M^QG_DG,0F^0[_DYBO*FAO_,+^/:9E5&+S( JH:6[-JH'BSJ6U45:,@S\N'!
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MGEJGUCY5[_EL);D>NI.6+$73-.+!QI$X3<<9R9'=W173>"@<(C &%J=.D][
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MT1IB8]W*8:4N)W)EOQB7-"FC^PZ=@E8$<S(3CA/</D&7U/#7@$GH*]0+Z%&
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MC,31G8[@HR9G>5J7>7@P\FOA@= 3&*SR[%SZ0<2\P2>Y'Y9195FY7(Q#^7>
MMV*K+-=N19%T*92)P!4>*QM>"EKB0DQGG46%.M\1]-/-#<[P'8FD"%2X)>)8
MAS AA1\8']^]1R>,X#L0=QC$-[I,8E4:9DG;B.W4.*U"98'!$SW:5SVC6%/;
M.^Z<A%P4I/TO.5 4^#*E=@KZ W]B[R(&G60B>)IP+.3)^*X<OJ;VT@2Z!#0K
M)JB,3:6"LXYOXNN0V#Y8QO;;)(8BLX?1XH80_0H2SEXEMS"Q\G8:02_QM0^0
M+MRFZ>+,MQ:4_V+G2S=7YUS>QJM.1K:,%762._Z]9=3D\W:=F,D@J@&.),K5
M19=';UT2AUB<#:I7]GM+0C8<H[4\5\Z803XGS&=YM.5)Z_BQ/L,"KKA@$,,Z
MQ/"W0[H63*K6$=2%5M M=$S8+34?@C:P3/3I8@K5J5%_D%"HG_%=3QJ*-#)5
M 5PDV:B/+%=0M]&A/\?^>=!K<F#C&AJKM%'W+F*.ZN/[8%&Y@Z9.62LA&T/J
MTEO>C<?N+=1B/ T(&,L/QN&L4"I&KBRE81Y6JA7#( BHAWRN_8T OIVKZ[)E
M&?&G.XS$D/,&HW/V-&/-$I 1VK+J)RZM<87V4G"%76Z4%-"=!+$YT:%J2;:_
M1KXSM$4,G+Y[R>XW"D7SUXW<;5P+'"7%YY>D8IAI>+8[-C+DC""L)5^QDU?;
M)J#]'*Q!NAM'!D:!E':FPW]01*05]\8R8JUCZ=96LW)KYA+B?+; ]Z?]/1V=
M=*C5DY:Q/*8MDG?M@ M<8 =(?#!PP@')7%^3QZ\UA-K9.D&R>4?J-=J6*0[H
M\G+=VMZ]1\I\MP_$WR'"A%2JF8JP;T&*Q42FM+J24'U -2F3Y"/%+9VL_F)
M^3B@C(3+VN>\:P+ONI;2->AJE/G)K2 AG$[ ^5P("JM/9@6;47"=\'C\<EV
MG\F*HU^I;=Z9AY2A#;XV+8>EZ#JJ<MSLNNT;8 B#ZL8S$##J#1-?AM.->>@C
M2'JG8+:K;M&\E-Z&-D-4!]HYWFI366B<6(H'(.S)Y="P-&R@L @4C!0\8'KQ
M3P(O^C'O>>[A>:)WI/7RF6UJW49_JD$]AV0WV4T9DSS$NDJ7T##X_0BPE!!C
MEO-DN@EY-A:?K"C(MPEERCAW8F^<=H<8F:0QDBP#!+:ITVLLO%1)/KLY.LH8
M9R';/BX%E\XZ0H(Z-%E"%?A<'3>\6V^D7ZWL]"9]&+(N1.7QDSG"FLR=LN9^
M\*H,71:Q+=SVZF8DMG8IJ:@(1CP3%?((L81JP)6!]"\C_@K@25\AT:Z^'&7O
MNQ,G)+5O*/)KYCZ4Z-NCCN(Z#:9!MK_G>&O3A')'3RPB??VY8(9S54+*%JN6
M$]^X"];@E4)'DZV<)CWV-;SXC3&^9*HS;F\>;Z][7.G-%VQ94\K\Y0,#F",J
M]Q#ONWV^$7A8:J?2XHCG)(Q%(&RH=_*<O0?E<?2:RC'AQ^BO>%_<%!FS^%D1
MD94T7\_/6X+GCD8_SI&#)]J>4Z)2X^ 7X)\9KN!/,AW-#GI_L_"(AU-.^V5V
MD#+;% I[0W)YQ@9'Z3@[^<1B\'#_P H>00Z>T%F7&]Q%%K4RM:7C'24HB17/
M#PV]HM.,'$8B:[A?LIM\KP?.?=0;(O%D>>8Y1+77R_PTF+Y><-HSF>)YZ@2F
MF7X_$@_U*@W)[1Q9.VF?.H\ZL/!EZK16X*33-,B9]2WXA9_.W*E9 Z,F-X[X
M[9'[<C&3>GA$VWA5HZTC9I9ZR($^1HD1SX=9>E4LK70J%FTTP_!X/US8C0Y>
M?S'9_ES^7.BKH'E,/= ^U??I#N4C\Z_\K?5H7X^9WN7! /_A_B*Q?-<],>KV
M2Z\OLTA1"__11U'V5:9_@.13H._K].OAH]'V;OY[JI_TNU].7^C+K$TP;O8]
M_*Y*'L>,3T+-2M94_L<O=34$U-^3\E\Q7-\ [@1F"CZ1R8\O1F\ )+;6^;L_
MKU_\GUOJBJ,*SMA73OI^?9,3@!<]J'T00D56F!=)S<?.3MY4Q[>G0&:SDOG(
ME\@568\5QI3I.&%Y7*#10MQX#JO0<8<05B!2@-S]AWVPC%2G%-AA)[N9QX9#
M_ V:!.M/JS_I1%B"BJ>CHAAE5&FS5(E/Z/.M=*E%<TJ&444PO):1GQH0&U8%
MQ4/@7[X3+$?G"H\</YMZ*Z)=-S0]596(<;2>@H8G5>Y;?M3V?H.S1CT&ZA C
MCZ>SQ.M;JR?MXZ+2HWCH!$N'Y2'2H2E4LC!Q5ZFZ<U;OF,[>#V-$P:PX>Y)H
M!CBL$VDW53[QM9PI/5P5W%@0PPE61@A$A_WQC#+UA3-H0"3'/L#)UX^V%F\?
M7;LY_[*G05^WJ#02Q7L]$,168R&3[:CWI"XTS'\F$)ZF4@U-S_@C'H1:1Q?7
MH<Z0/(2Q7RG]A#1QZSS_R?+3PT(G>[9J'T^*2&LGK7@K2PYY^B@)FUPG&2R,
M+H51/V,A S3L'V9.5._XW2ST6'+8@%S-I.)FZR\X\23222"8BC;+ZH_JIJ7=
MJ2.F-J%O]+NT16^O^<9#&96%23E>RCTN&I-LHX%^H^<&Y;P/'9?3X@C.&LB>
MZS<=J9+O-0JK^3!)Z.6V5PX#HO$_DB26./E:!3C;I"HEBS34@PC/\,UGT17A
M;]UUEV(FQ_A#+TH+-@^-&_V8*[O)4Z)DI@6F_0YB^#ROAZ80C!7C)VEF<33G
MHPDR='3(-DWU<BP/,?XP,JNYR>!!X1I#L($BD_LONS,<R99W<RE5(@94+P&R
ME/S(WE, O=(NUO0RR"I3LZ!8G)]G6=Q)VK=(BA#@NF-4N32L\GI_"9UF1%I(
M@C#_X<,$SO/@^K=K#[8%S^:I>2;AA%A3O63;FB &=]+'?K^8KSGJUFUJ-RE-
MEF%@D=ZNO[FWI7V45$C7G7_GJU=D]K +/Q>MHL(J<5)Q&'A[)[6S#KHQ>MD,
MR+/;C?'Y;D+D7"F;#-IR('S9FE]QB<]0?TZRBHO@A!YQ[6;F!&.V_;R_.8D9
M)0<3P*CU>O<7VKZH=%RZK$3NP$ZBLVUY9VA^>^Z6":09=7:X64-\+5ACK4!W
M([E2)FH.C?!$*R$G83Y$->S;10?3@J[?PZ\$NPY>4G/=U^D?.\;>C2RL7^S,
M7M\$Q&5Z.FD?HW#K$T;?I Z]FU.Y_A"EE$')5*5G84WB"+5H'4K[^\ZO47S#
MQ9AG99^"60_3O@9;T[>=5B4?#[,?)Z90[H(BBH_2BDZB@^\B]L^4#IKJGK-Y
M.:L#[-8.#PJ/?2D"@WF$K;3C-M^C)=#AEQE,C-S5S#(%N*VWN"XRWW'%P6-[
MNO4\BD';<]PC'DW"V%.")X7E0/[& %-55.&5[RU<:5T>EK53 ;T>)1?CA$Y^
M%\7910/"G<+3'W+VBA1Z1P>:-3G]3A*0*2S&$<%H9>B'#?_6[<)G5%^.F4ZP
MF? ;8(?B))0@[+HYY@Y9,6M(+ZZB?8!/E$]QE8U/GRET6H(^RF("WJ-V2LNP
M4MXJL#S(ZL>@VZ^:N^U*T>!IY!G;V ?G;E)LC&0*K3$JR**+B PCY83(;T-:
M01TTR.NB^Q'#)$',.1N3]WW:@C*\24OK$ZE!DZ<B0+K134-BFL+"+PKL%U>P
MF1>8L@%\RL>W5/S:SL5=S 1&P]-F1=8?_^65)PX.,'P!U6;^NL 8&M8M4]LX
M'///E*?A"=H(RNRKJ#W>< X^5J<&\D1WG=L0C5TVU$"VF)(&P>3$,M.^9>]P
MLXI@QXS*6!=?+*!-FEG+M"INR)EHI55:N*A'?H,X9QFN&L2"AV\ Q2/CS-H_
M2#G6F]PXLY BCK$FHR*NA7E'E9VD,5S->]-"[3$1IO=:RS #P: PQUPS:)/7
M6F\ZXO%35U#37_/]EZ1^L_2_W[UG$^+Q>R;K.V+YO]I#%_=.<^XE[*U#QAFU
MHF.7[I^"W0.T25-2MGJ50[M:8XUF]8MVO01Y!M*-6%\A@5_ERZG& O'S&]\
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M;$/_Y&N8+8]9-#R*8<Z6UE.EQTR,TFEFHX@,SS*'BM4(82JK\A*N-%)$S6R
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M2=XB[H9B765V[Y(OQS#!V*Y)VC//0D#0!RJGL]E14ZACN)67.(/4(/,B4N-
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ME:P7H0]0#>G>WPF.GTF>UN"AQX>GI\]A$8\=AH:#]E7'11@TJG4[] %;&_%
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MQWN:745'J8VZ2[@ZE4,E.$HA04.L-P,O??Z3<D.-S(,LBG\Q(.&81W];V%P
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M-!N,>H6T)-C15ZX(7CO;JHV:FU>9B671I#G#K6)?G<%@5K93IE\>(\>'T),
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MD9V><C!L5[0DRGTCNZ%(-BRU7\S*-GF32R,7#";9^*\C#O)&S@;6IJ7T$57
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M#.@^27*;\R74"I!B!:.1)?8_:TNGJ.M$#ZHB8L C8:MM$?KF)PGW$19%6;Q
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M)HUXI7?M$;'XS,/6P6/GW,M/'LDJR '4![HL%.I 6$"S?31!714XL/X(QF:
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M3CF+-_)4+^>$74D>V=C72%=/_C?V"1=3:GN@AD[Y3%[^3AH[58@5$SY9 J^
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M/>U.ETM$J@#G]_8;*OD3Q_25DO)E'@^4Y)A%);0"8.3W*I+^5!IULRR&O0=
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MCG'Y?X"_9LT"4P68O_D**C^B0'[GQ89CU"\7)/$;<5#N/]8(R?(]P5S?E \
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M,FX(S^_.CLSD\=Y[$!ELM_2NZ#]S4 ,2T+M.AR4W==*6B24N?H-_V0'YO&G
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MN\UD/BCTZT**D'72Y<MQ(?>YNBN]=,V8.ESD&EN#S;?T#48F)X9X"KB*LH1
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M885JO0<A?Z21."_C-XC:/\8AD8R!LIM>9>SH74,R$#1&?%M#5Z"=V_&B_\H
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M;.G"\VVSJG0;#W(3Z?FZLJO^>43DPKNS(C#7SW[;Y ] 1[KFS#]O82=JPB]
MEBMGF^@SP?2)^YM)P4QG'K5@^#=CO ,3Y?XT6_^J[MZLLG\6F9TZOB^8G_M1
M/\5L;%G$HZ^)JFT/#$(5OOAY\@< R?9^^/*QZ?>;5\<KRQ_ QB/?X6'T8]QY
MT]*7AP+K4LRA),%7WS^ 2RNRUZ;%GR]7CK_U_@#:KYTGQOI,/@96_ &T78@
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M>@;#! [!T_WV.</+KS<'L]%S(U:U6K7?N.ZZ?34-1+$S@M\<'.6 [T9_HC*
MHJJS/"MRY4??3)+!.=RIS$6MO8<Z^C]HVE@GS*5FX"\8F-4/5&[XK,IB/EFF
MLA]HZRPGQ"4CHV'WX*9+9<MWPA2C]-9;5BQ@X*]6KQQ<9JMFF4]_(*;A.G',
MGK8@[GZFB>3_U$LG\.6P+XN6?SF:A*SQ&-2IM1_D9B4#\,JB_6 \6  .^#7O
M\).9"2F,3U&32^KP?EA7B@OGTHI\O*4U%=\61%A=?2D*_O$##)Y3TX47PG%9
M,\=H"DPQ**?-@)?R.L246'-CBA=]ZLV-GLI<X$^?K</O=2@D=AJO*4A2T-\G
M7I+05D9)P]YWHPEV0<8V(*:.,EL3,=BXQZZ9V*O(J?!_[BUSU\31=*N*DJVB
MK4ENZV@K40(O-\9M?236X'8<GT^G418>#"^=Q!BATN7M/Z5!Y-\U(IK6=#47
MENW^791^*P;O@I0$@8[NHXQLT2A]RR@1D\:-GS:B" 5=U\DK"!E]D,,EA?W^
ME2-R%3D<7:Y^!ZPR97F;6CZD>>&9E^[*CW)6QA >"JH<N&1<NQ18V6/D62U$
M6Q]00T/J()3<_;W:?LHB+C-HJN6K/HQ0-[,6P>9H&TF6LNUR'I^&3L/$:SZR
M#\ LY#=?- YCE44'62$.>W 0JD7NMS<Z]MBP?]+KWO#//VY<VT1Q#&RW8HD=
MW/WD!1?'U<@VSJ5M@L%_?RW*BA>C8+1K\$GX'@IX6POVDF31)I >]M<%^64P
MSE>)@(<G%%(8Z6JT:N2+J00M#@$RA;XGN93I\J!TDFASO$M@Y&K_]WEQ?-/G
MW;)U/FJR:(Z.([M"\2G&U48[];AOSYC1%3G *-[V/3MW)T'LX?<FM(S^[L5#
MV;=2N5#LT@<6K^9_9M-OY>?EY&7U]C9)+2TLQ6BFE96EE@([>3NI*$<5=9KT
MJX?2:*02."38%Y6 8KIPKJ@/[4U^R$7 0Q()3MSCM<]PO1L1_!/>QC6U:[=4
M+5U6B@*]N;1>8I">>3J]TM7G)KF>UYCRQ\"OK8%?M9L_C\+W_[M2B8C]W'W!
MZAN&T=L1;VB(S_+TLS7JLLWF.YJ%7<?D%DLNK@75(.1I^X3G\^7W=(3?PB87
MK-I5)OIXI*]U[*BVD#P\P^;MT*(&?"E$#JDMX6;UMW\)YR[9\YM+/9M%6C;Q
MXK>Q>7OQM4532>&_1\#66CFOOC!2]3M#DK5@2_[!?HTUSK_)9&W[TB0\[19N
MS_*AV#O2O :9?&@LZFNYX5OUL<U ?B4G/)Q"<Y8;"H&'Q,J[6DJ/8.WS<!A:
M!IZW?PK1U+ZLU^_')FL'&? B^U,OL.W/;Q@%@>>:L<C/S;Z7>@;V5H(K%^T-
MN5%1[--V[ ?"&1T6A)7\$[Z<]JP2.4<L;F2L:=4*O%Z5B+1[/658X3>XE=M(
MF98)="-($6%<U)^D.WTV3?8,/.J<73Y[QBI%[O2HIU,_>5.!)^Y9*PSCS=QS
M1Y<2].)3K4:.\?,S0,DDF*^Q*RWFB*9.#03Y*N9$[VUXA)AG:#5CG(C'*3,'
M#A>C3G) B>)151/1!L17Y";:75U-K0 'Z:2N64)YGA%:Q/WF]\N8[Y6.W>,?
M<Q^RS#*G+>V:OUFM#*WQ$M,_^HM?SP-@P;1IQZ>#<?"SX'7-$L9XVJ$1!#G!
M\_&N>I*M9GB*<;:-L\3ZCCL5,UXS;7VI<@3O7\(_C]43%B:2*RGW)0[B7$?T
M37?PP:KTU1!@?JA:_$6RR[6S#19"PLUR0>4F7BT[>DQ*.G"/NZ4;U_+G8?@A
M3>O9?&>&\H2QJDQRJ0:=83M H2</%X!+BT\X (37!DC(6G]XPIDVV6FE_ ,
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MPUS/'QC!EIFQMC&/7Y@<*H49N\T]$FE$)F^$S^-&5R(?9+YEZL[BUI;14_6
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M#M.J57,9TF-<3-9-X#]0PKL$XJJ;=D7XO\;I;W/C%C"=?##*(X4F,L:U3-?
MZ #A+YN[1APR8-NOEHE!D?T"#1S\5_ZO:0/Y4\:[TT%UXJ+M))[-;X=C)MN0
M9I/UPGUZ/BR6J,GY,KF'>6NUNEZ[VW@GP\.-PX5OO#]A&/83+S:.C*&9:HW
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M5 %-LNM=#::+FPDQCU&*["MDA=6;)[<'EQ=[/B%U9/M1C%JH7/@X6@(3@]D
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M;4IT4; Z=J&K!BSVNTM]PT5$'AL- H]^\[VU#=% ,<*AS,<+[W86)PE^G3\
MJXMHF2!NIG?)Y1 '6>( [UE-?!M[AY!0-@D"EBPZ*H3,,6H6I.Y>&&KO$Y7^
M@\NSCX*,:J8X\:$S_%/Q7L#?G<WNROSQ61-9U%8BWZ+WHCFXQ:5X0+NT(:W#
M"RRF\?SY_N$S XB9V9*?TC';I&:S-Q]'Y1>QS4)8$(K6D.36(8W\N83/J:0<
M8/16UE&(7G@A'!FN8;=2A&%PIADS;2$H<V8V+DUD H^W2@8..V/SM;]A<;FK
MP>58UJ6CQ;_;K<\LK+62)^9LPRN'M5![JB5.^'#UD*Q;!3V$52',;'QGT_P
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M/&$)RGA8GBC16/I2:OP2-%!2WUZ'-&%6IS^*TI^*A8FD0F;\EXWOXC<KQ$U
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M2+5\J%K_F2GD.'B)Z3+SLT7EI$@L:DK9DEF.\R9SJ&C^#)D__9R>W<OM)?N
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M=S4I-X#OI>H%)Y);8DT>'ARD\89W6A%R8*J, 7J+;,09%1:G<IN4BRU^TS?
M<JS7$%6@DH [T]Z9!OP44VL#<[4SP7IIQ)*.<NIJ;Z[_*Y==,46F]07#"  5
M0K&G('3_D[/ASSU'RYP]&KS',KG("JFZ#BUPS))#.$)WFM_RR;],G*$+-T]
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MA$]Q3^[HJNY?5%=2+I;4]_AE?NI]>TIAV"Z&$K12TH]H2H/,7M2-^OH@9-;
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M>=C"$;Q;I0569PA1)-D.K\SM"C+3-$I_""=\5^OFZNE$P2_>'K^8IV%#/M!
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M@AOS!* 4Z?TO)\JDJ.I Y>*L>.V;E0<7S.R2T9^<W!MO;SRSC,[T\=XMG14
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M>W,PC1?FY)FAU!25^5B>$;,=[J5Y\TUYGS@Z._4S@5<]E*^<8I@]OKW'2;I
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M:_P*=/Q>46H"J4YKS^%KM9[E'@:+!'G'\ :^("C0/9G*$I'N+S9[_K;ZBHJ
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M3HY<V&IDF+5^QOM.F?J%2;L!Q+7@18/D3ZHI,3Z<.S_Q,Z+1VRK"7P$%!]G
MLIU$R2&!W.,(W*6;LW-[_<7J2V/V\340]UG%74.'(PN\Z$T&:_L>^$76"A"<
M-Y3]C/MMG=<\J.JC1,?AL6+A#],8SD6J!QK&P1@1QW\X+@\54_Q29_Q*L/Y3
MM>*QBN;*#Q;/Z)A9E9V;Y=I2"2_#B#%)9K9_@F+]3__A2%MV_P_<W&5!II/
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M\Y=!^[8_ 7L?8AW)Z.8IPRT/C84&CRLTZ3Q]O3\JO9UP39PB8FOC+'4*K41
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MC>:1@[-B=$I*89ZJ@<E^/J+0CTV+8MMO\-LPV[8I,C6$:*0W'C!\E.)5"*H
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M;_PT^/L[\^3/X:"X/4]_CY%IT^D"J%'GZ8LUB]  D1".1P)_1[O;Q+O\K!1
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MSDP&@XH3Q1!LFL/R^?;+B!$\O+#J__YJQ?\O!K5)4!D4(4P^>P"8S!Z*V*<
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M0%3O+II&(>'XKE@=ZN-4\M5N$/)=B8$W:;'2[4R-BW<)LVG.L&8S#NFT8 O
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MXN]:KV*0*R38H&4@0CRF(0%^D;N!0S41P+1) #AGJX\$^QU=L=4AB/+M7W^
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MY=BUH#"V>)8VDF3<\X8V^0#U'@O<!L$3F7)I F]U;]_5W)2GS4.2?:-Q& Z
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MR+WCQHRM+HH+%!6G?EAFF(1U5XJ4D.X9ZR7IO\A=+G\R93==O>Z!)]?G)Y
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M>;T5T<D9ID4IO7:DT9P>E":^8PY'.//*)4>RT.CHGP[5<?F#Z_Z)MU4:'AK
M?_[%[ I9N\&(&&W367<K!_9@7%G,>W9QOU"$.8FO$O2- -: 1V@EQ$-_% 50
MY/KV(\>]%J>1^B2"_"T>^/QOY+K+MTQ<OI@5Y4"65<H%O50IFTN<9H%]W2@L
M;-C8D\W,<#Y7>W*@RE8AAW3'8:-V+-XC ISE"W^7+#E2^@(+7U"QW5C]LZU
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MX3/92KZD/]9S7:&CR!ERJ?M=Y6E%@Q-Y2,\$CM0$JQ##L\?[+FD8:P81K 0
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M^-MZO-+!*@RU@N R;'<LU:'E-S ,1O(/">51/=993I#"U.\,5;[(VVED.'4
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M*WRN=I/BE%\-?TT;_[A=7N<*8^<9?O&PX'/2C&"OJ9F.+44^N(A_ D;Z:6B
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M>/Z >7AT_+,20SN15T0%W^O]E0+NCMQ?YKM)PW,@6&,N6Z L,9"\&S7FSR%
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MXN7&HP9GY5>S2JJL5[C9</7Q8_,0F(RPO4KXX7F]BV;E4"(5M_=]21?"$J(
MZ>\/-TH00[[]J4G?==_RC$_DN=XJO-5F>58F0P.>$^$@_-IFQ>(5+\F;EYM
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MR9_]E%M'G%7*;W$YA*6PA^Z_8?RX\1\-S?+N%]^L=,BG;]4'.EEGQ-G3*_\
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M+:B$P+\?2,4-U)$[6-1JI/*L$ 5=>_'O"+XY2,E(*JZ?J=>KG'9\Y0D-TP:
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M)H(ROT5%\[ =ZM[=0K*,5\_S\<;%6)FX1:AB\(78'XS_,U+J_Q&(;@_Q_@?
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M"AO<@S>T0FPQ_@0SJWZJ!I_L.+O/[W[6F;#/Y"XBC^NU0(=.9R>@HRFZ!(-
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MS\,J84$7^K=C=GB\8]F\C'"FRJ??Q_G&-S\1AI3&HD#77]E=.F0XL*+-D1M
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MW#ESJUACV+66A8^:#-S!HY94W#4@N(LZA!0/&]E, DE3P#1-5&\)D.P6HH<
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M7B@>17Q4@--XT?!N/(;5O7$X5I8G&N=7'5#++5F2'8A> 4&>"M4(%:1R@*M
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M<%\/XWW(CFMUE[1A+*4-CXF$&GK#9G_HVDM,=Q VMON#)53^?@XX7JIA+E@
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MXW7YDX_:+LP,16;(C??(4LFVP.J:<2RY1],QZV>_N)DAZC52D/3RB%[I/+,
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M]Q*MJ*B1X97I[N$=I2!23).V/P0,P'=PM32E4'=KZ ]\@WWL !+S-][C&21
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M^>(5M(?B\RQJ[,H(-]<_B/U7:((D G(V[AM_X*$$SAMVF&%7/2%0FP>H HM
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MS"$&TO-464LY+O/CA!^OS&V#I8R?N] \9C![^)X"2MK_ @2?BH:_[Q.9K_Q
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MA<?/3 ,%,U/>U%L^9/#&[N[3'/5Y6F-0.DV9(<U*:85J3?#=+%:7LI+.-@A
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M:$ P?B(TND$D?4ANFY\\3C1D5U3 /M3TJZN\%:M'>D>5,[W2)P(K7ZX3/5*
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M#/"BWZO5S:CHDA/Z2$&B8;O=4&M+O>HG'Z"49<JR ]=L;9U0I%-A;VN';+_
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MY.QXL#8,C=.-PD6FTU"'% TQ<6LSYFH#DS]H61;M$XU8QSIX4G-:YC1P#XU
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MBQ7F_@?XHD/]#X#\$4(LT\[4P+A6H\+R:D://7R*@]K4S\8CXUV5C7!ZUW/
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MZ<E%O;OB_221IKC;A1Z%J6"*O5B@GV2="D;>C>T8")[KC[WE1,!4:XPOO.E
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MS'F'W'Y^9U3^9<@"BWYHVD$+4DA+X6)1M<KDOD-\98P\0)N)))C3=?A[S7Q
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M#@H>X=">8#JR''G\[@J@_):7>>9-VXB97_QD]&CA$0UJ=;UZJ NGLN00TM8
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M#+'ZJT]'$#O&=/1@P"<#[1'<:_,Q,@#77Z;R+.2M=(GX8\,080V2(=_ .6M
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M<32I.][$-[$*HKJ8:L?Q2P_DTX_9IAQI-$4%3;S"WM$^NME/R/W<\0HF$&.
M>TS$^;V;N?P+S7/'%<O*>0%?*5D<D4*GG= ZV<>;AB-XKCX^X9A3RE8+6HYQ
M\OLYIX>KKQZ,X>8+R5A8LVFS+5W%NLA0KKUA91XR5<LHXN4^AQW[3)9\='I,
MC"X!SD(]JPN%.:P&B!IC<RA"Y"7NX3@M5FV:T?V(E4C9WQPX7]L<EV68;W2)
MX >SK"24W.5;PSTI@_0([F(?1R_%B%@KT3S*_FVNW36I%Y4+ ,9TX[JA?!W=
M/F/#\.2'_7TG1\)$&\O+#L.%G=%A'?NB4L<M22#7IGK=7;IATML;@MI_GBAB
MQW>ZM2I^AF7^#D=8)=@,9%?@A@5>Z%.7+*#XWSS;B3+D=E1:'!M^/8#BGZO-
M;_(;DUF:'6UL4U,7TGV*%<Q*J(66[T#!G?XO7+R*-_M\7!,!4(4IZT7[789T
MTB E]B-PLUW!6[,>Z;YK9-?39):0&DC\F%$K?+)"Y&$T/4+-NW<G?DBP%&0\
MG%><^/ZQO]R7@[[XP!GMP2>I'IRK8?HB/NS4B/99I]+['P(>HU9C[C=OW#^9
MQ6\&>:[\,F8\9&%?T!1&1_>C#05_\*2U(C4I?AI<#$W+[1Q&PC&VGCD7<$3C
M]!97Z4^[5,'84T/;0-*E4?#-0*OXKR@MY2\"=]MG6:__.ZPL_P_^"^C4=? N
MW6W3+#@D],4(?)U[[E-Q<^_.^@3_RSM"'V.TK@ 3U[<6/A_#9DCG@1^PO\5?
M5YX38Y;Z,*A04LS@[Z*'4BJD;P-O]H*_/DH1/1$8P?>=UCL.OKGSH?<*8'!6
M'KC^?:V7>N1?T5-:+UX!^M.FRNA)%*U[+GY-5P#:F\QG&;LW?/FK_A#P6M57
M ,.?CUQZ(^\R7@'P5P!2[S(IO$$4_G?=7&=7@)/ ,W:12]"C;3!^*][]"C S
MLY^76_7U^++LT4[0]X.V*X#K[UL_7.9^S;.$_">GL(#^)6\?74[4MRO 3\,H
M+\@9U17@^?.Y8RGILX+?HE> 49=+PN&C>I>ZN(E?00:4J'^/)OUKD'2U]!]0
M2P,$%     @ XUE76*"M$*R8Y L NM4- !,   !S;GDM,C R,S$R,S%?9S0N
M:G!GM+S9KNS*F2:FLN_ZJA_A0 TT;+ DSDQ2+:E!,CD/R9E,WC0XD\EY2$ZO
MY@N_AB_M!VCX$<I<*_>1="25NJL <R.Y.$3\C.$?OB\B=OS+__4O__>O_J/,
M2_RO_NE_^:=_^N=_^N=?_>I?_ONO_MDH^Z6?RW[X"?TM]"N2D;3_];__ZNOX
MCU\I?O5/O_JGG__^R_\3<>6R#+\#P6[^;93V<?;;I&_!/1I ^+<0^*O?_]=]
MB)(Z6WZ*LZ+J_O#K__?_^#]__5.5_N'7/JY!VL!F926>4V:?NI.<=4*EO_ZO
M?_P/O]]_M[=#FRW13WO;=//O]C_\^EOX[Z[KK\?@KW_Z3K+4?_@U_?7BIT S
M?F+[*?N)^BW\FP2"X)]@F/AM1,1Y3&+__!,"(2@(W4#X]AL8_QT._^Y*\./X
M]1__PW7^_93FO[/N_(\/7G=_^/6/FFW;]ML-_6T_%2!,410((2""_.9*\9OY
MZ)9H_TTW_Z>/D)_EW+,YF:IAJ?KNIZ_[*.[?RQ]^_>O_\--?'#]JU@Y_^M#?
M;<)_)9,@M<4_SEB 55O\W>S#7U3N%UFO%U=6].]F2I,_Y1G>4_/='&D"9DW6
M9MTR7_G@OYNO:IKWO$S1TD]__Z-_D> ?55C3_G%UV_;OYIP7*_M7:OMSSMDY
MA@RTLKE_3TEV)?]/?U\0MR[_%D'<>K7+GQ7C2S>N:OR.G;)HR>[7[X^74F*_
M@9#?(*@#P;_#D-^A-^"Z@*#?@W^5\N_)Z">G[YL_?M1?^G,C_H3<?DO]]+]I
M45)U7V;\O_^%M!]Y_DJ<UJ=5?OQ-D:#O(E'A)_]?)/KK[)=!IM$2_<_4Z1=I
M_TJ.4[[;N(NJ9O[C+]K_VZ3H9OGETY]?--6WB0W1-&=?[?^'7__< ;_^FPP_
MOO1E.[_;JG0I_XC@Q'?!_N+1/\I49E51+G^$$>S/N7X\^T?9\GYJH^6/LL$)
M?\[WX^$_RE>U49']$:1>($;3IEV'LE70#%UPC$IS,TW?P9M)SZY0KJE G9%
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MCRZU45I#T>9TMHSQEGL8Z"QX PMQ1UB1#H@CZ[07'' A>:C&3PD!_R)QT.W
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MNB$:Q-2*GG>EG.*)B;*:UP91>T#'!Q)SAEB2=_&UCY$W5..4$"6?V(=Z!<Q
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M/UQMK/[$)ZFA10YQ=_'XK>_7M@1@ $0 #< &" !2@ J@!U@ 3H /$ +$ &E
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M/Y,4D$JCK638)ZZ VJRY+/@(S%:^ZR!Z$P[1W=&M*S1F7[>Q5JE_ULKLDS.
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M@?:GLV#[XM.[;E[2^QZ%7:$$_@0M3%MW&%QON!1.5?)5Z"D5ZHEE6&P;2$V
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M[>1-TLN2965WZ;=/S\@Z 2>E'XFXI64#2IVV159> '?MH8$'7&',0G\N/[X
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MNL57^G:OO#>OY_%DA<O/%%VV+>V#5>9Y5=3"_.C=?;/0_%?VK:Z#5;8T=%X
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M3T&5JP?-IS\/,S<$Z")T)VC#>?(7&G;/YW?KE-H7[+V_1+JX%CQ,&!O*&@[
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MKGU\VVXRV,7"KV"U^$Q8<IV;;SLQNQ]>5E16N/I->B=0*_X%T!;Y NA2^UO
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M5\13JGH7'O L6]^Y$:E=?\K)'!6+'!5=H339YC2!-Y[]Z/ZU 0OB'%0YWH7
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M^51XS#%!SWZ<J2Z+&8+) M;"W0;;74OWDCG%A)FHOHQ'<[(Y=KEL]\]!'2?
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M1T<HYATXVDX!&=&?*TNT.][B''\0V<885X/XT8Q^G]N)?XPQ8)^OKC047'4
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M('E5=HJ?_IVD HS0SIQ)HELW"WR_U-S?&+U3X\CXP @Z#2!C+,+(]>V@S*<
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M3+6ZF=9:.^8)(<\ZW-:6<30UXV%\:ZY+!:ALKQ^20E0C U[%#\%^Q LEN@I
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M,8*Z@\]+JCV&08@T&"OW;A>7II]K7BW.F*QQ&(::'HAD&LERSP2I]+.!!HN
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MV&GO?XLOB!B+6 ;U>M%$^"*6\P5 :><(ZIU1)[RGN!"\B:@E!*IQ!*43REK
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MR-/1M]^2DCK$VA8HZA5+ZINGF<C#&)1^]VU6B$F#%:I "_0+_39ZDC>6JH?
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M'%+=E<]K4;+S;KDF\S1(<;L#U#D;K&%->4[@&..8+HX%M^4JW&X3US1)3D4
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M!>:O"Q1V86<]*F9.5M=G%*%@LPZMZ3 *N;A1.::BM"]@'6F*&?U"P\1S:S_
M=PP:$"=D#MDJ-J;7%DL%\:=MSXW?#^SW-'T$J3IDC(8K"GZ\CI.KC:[+EKZ'
MQ<]T2=I,J;!G&'0WS!:3#]P_>3%Q0J.S9W!V_W,6@^.BSDE#WE:0K>H9HCE7
M#+UV<OS'04&F-UCD"Q"!OH@6=0KUQ^.D]<Y].F_O" >6Y7'H"S _0T#8OSWT
MY]2)'DIID\N/:;K0CY23\=;T5U"PGY3@/5"\-ZGGQQ< DVG6XF>KTTK')I-S
M].YH39O)<T4NX/G/;F-Z&#51%-?$[QM.C>=GZ.)*N"/3ZI#5DT87HPE=G6_\
M(L&[KK'AC0O5H+]_@3(UN_GIJMDRD4A\ 8 NNQE"I0,P_*P"P_D4X-T'T"D!
M,G?JU4,R9/3PD1AHPB7%**ZEB<I'Z*X4W_PS\QF]_1DD.!F3=#4:O"&:TRLX
M2"*]_S*L\TFS1##2*+'N;00"V<A#.)8Q90D>TQ)21Y7O*]PA4@MN>\WAQ-3&
MT!P(_O_:A4 0ZK;>F3+S_P*D_:'[ E36+"DY4PYQEO.R.$$'-K2@C/ \1S?L
M8HM2Y"7#)<R0S:<F9>B%(<8-A3N F?Z$"/!V$HK#\'A3))O;[ <=0.RC@8_(
M-?OY^RV%M857KA%D++FO,)2>D;!QV.FA"-.ZA4"4E!O'?<SDCV@FWE&&]T2B
M><.05\CTE?VO*"D6'91'NQ]-^+?6K=_2371>(L=T]=85]R+OISE'IUX[V3@:
M G!>$8S&$N;7%4>GJH#4W5>1WVR\M>#*%_%H(\!8#*F0HK$'D!SQ*U_#XK\
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M/FO[CIV^=2VEM= K!DV87+)(]-S(7Y#$W3PG1ZFX#<-L$1.J5N'^"3D13!8
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MD Q&VB]&(#:B50:S'ENIQ9W_T"=^N],Q<Q(WSY26G0<O8##SLM46H6Q;C.@
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M!Z:!$O-] <Y*N9'=0R2\TT7];@:3_*S^W%<+T_UC*1843?O,TOU(2^_1Y&!
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MJ[XXG-!F0U"-(EY#H<U@F3A2C&N>FJ0%91(FKW!:YH@WHW,),5[C)&-(,_6
M42]7ZZ0\Q&@);8R''I-9PE!V'FVW&N&%*)[]C^!>51V;<<+?K:.Y@9:<;3O\
MOGB^;E^ U=IKU@F"\X]L,*@O0)6!^QTASTN<:M$'R]SJPQ>@-[_E/_8D4ENA
M_BCX8X?8]P7X A@Z]/0.=)H;=YQ^ :1SK_A"CNP'OP#J@@]^?/>*SI>]_5^
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MU_XCX\#V1V!2-FSC1EDK#S5(^.%1='LI >*UA#BC42@1D'&;HSBX@B_P:D+
M+XG'S9S0)F./'EX/I/F-9^6%BL[XK]>NOM+TA/Q8>9-/X,3<(NQ%)):JWX?J
MK!5X;[IU$)C2*OB\GMJ6'<4'#G09=+GY8K@[K#WY&+]M.8;"=V]V&C)PLRU
MV*<.[U_T/4)/.\N9P-A$&$FLZLZK#=*,M=48I,P&]+G\#U+>,B@.)_H6) 1W
M=V?0 &'P 8*[>Y"!X*XS2-#@KH.[NPXN@> PN+L$ER#!(2')_O[U/NU6O5=;
MN]]O5=>M[K[GG*X^I[J!PUZ?WLD^K$'-<7"V.:6:DE8O VF*D-%)[W\Z8+V4
MN#U?2?,O?&6]C>K1_.(K6(NW[_9'[E Y,^=6;-=N+V7W3]0-Y:<0GX(ER6U7
MTVDDT2#GGW-*1O>(%EIIVVS4BXCS[*(4#AK$-K^V\BQ49YW"SO#Q:^2^?HU,
M\M$)0(871JP!@%/Z&\JB=LN;1]- ;_$C0: 5V\":?GA>(=%8(V3=69!9R-0F
MEG=J$AK9R-TU]X [ARA[B<? %YDT%0G=YT>A#S='_8N%N?Y_^L%O(E[UG_#D
MQ-^3>?>7/4VO,35PM;!S>[>-_O@3]. *OM,UXV5L3_E?O2?S6.5+L\*W$Y)O
MK]XE-4$N3X[_D(!VON:W3UT9+[4]9[W:F>U:[!R_/4$[!_1R;#P4M4+.E#SK
M#FE7UXRCAA6\_Y!2K6^L+@QQJ4"0K'W^4D)ARWX'RQ[_N-B/=,4AM-&=HO+F
M<8:%R_Q#?1K>SC9>TR!L DXO DQ&!<.A1:''M(EX$>NT_.E;B@S7J27"-2':
M)7;Q5IM@@ZXHY$?24%HL?G%!I>R-,AP-3--L>A.MK_S=C"*<A"!!4#F'DW\H
M_X!_\'TM$=U;;-J^-T@&O=\40F-/@LH3&> S6IG[((41I?&T 3NWSBN%>CR:
MB1F/M&:*S=NL341,695EE*!(<SE4P4W?#XJCXL%XJ4(QV2GOWL>DP2$M3R==
M7B!]%+RO ;#@+8WE%:*T33/G8: P"B9M(#1^:KL,RM727=F%#HV.QMD9L78Z
M!YED#M\.J[<+73R.+\;PR<&Q//E&!72$9+']$Q7!5&F8LKHAL@12]N&&$>ZQ
M*Z2-CAA7D^>)>Q[;\]2."9D936EU Z0^=G5O\I%7DDVSADU7<!N03EM+9@2$
M>(8PD9%0Q#!\WG@3#))'1/$;L*R!H=23G6),PY &OLQRJL[##;S'F)>0J>8$
M*B^YC#;""I2(<5(2/E)6H9$JE:*W[-^1^J.%<'9D&2VBQW99()49G8>6O#,G
MC"GCG\@KG&PL+&SD_%.')H=R%I45ME96=K*&ENC<^[59R!BC#7 ;_; \5O&U
MA,ES;9H(7&P'?!L^<D]2,IZM1U)M!-$C+KAFL;.-MG=7,/C(QP?1RJKEEL:+
M%J9$!@?MI%S<<DCKI3V72+OZ:%I/"ZDUFB@>UVW?,NH$9.R<WI'&CI7H9%^D
M'9-%L##J,GC:1K6)U5E9:7TW3P7H-0'2VJ2QD.2GB/X[6DJ!TIL7I+TBG,+P
M7WL 2(:EKU5:2GG*Y8;0;V)PL:?Z@Z?'1:D1P-XD7S="K-:C""-2/]3<Q0+M
M"??2#RM_;597D\COB ]FM4J#$)U(%8&VI 5IS48#U> W8F*_Q1K#NUIB%3F9
M*(F@>C%2N 2C$7XE7$1H=(MMYQD,TVWX2Q]'7(\.*1Y9PXZ?XAU2RW]@.,?(
MWI6!)FG,5'[6R\.8+.TS<58#/CN'(+0C2&*^NJ'6FWGT<P 5J?U#!]Q>_'GW
MI]XFLACY"VJ6/ ]1#%)?G+W+G<J'-8^M:R=(LR]NZRS+(LD5.QZQL*E)<?$O
M50LTJR!-4;QU/\G0/I_=IY/D)/%JUBX\3C#70UG-'?E9LF_9*_T."(Q#EFO[
M]>X]E8X*:A*Y?L4Q1HI)U1O*!=/0O?O4E$"10P6"(]#2UX4A6.I8>'QUO-YP
M@T=>!)I.WY@1I<XI33HU.+N<<U&GP%A_>\NE=C1OY[3L9X;8FD#%KSN.L5WJ
MF<NF/UG3'\;8Q 73GC>COVN/9?^5)V8*0S&V\[&M$#@6DMM<!2-WZ](9"!MY
M!8M57-89Y6LE;,2<B^X/0?CTH/BR_"BEY(?5N:&VGZV=0(-D4KH3NV350$XR
MLFI'?1@&AV:BXEH3LU+U//!'HI8V9JAC"+@6=5V=-07'@PBF67GK3:''1#-Q
M ,A0+>>IRBI-:4<+K^#V]/7_# &)HJTL86(21N;9]R,A"?=>2\_</RT[#9.P
MNC;0A#'9BH?'8,,J1O@[R6A]/V+\*.U$<AR./4PDC#HQ6,3K[-<)3QC+"(SK
MBMB2QVA!(_]0E=M1Z[\;SYW9ILFK<+O%%1'1UDNQ:(<V]ERZ'H-E:DN9IOQ"
M#<[AO-G6P QA@<BX>OA<8G5.]D:YIPO\WV?NU>@_I$'$/Z3'L'](WQ6EF__'
M!HY*;=.H91:U5Z!$\3R4(6P[=.<T*C/ZN=I,R3[NX.ZG@..7#*KUO/T4!$GO
M$+N0ZD(M'$:B3!H=_0N6RB790M!HF4AHX?O?.BCJKR OIY^#KV]Z3[_<KO]N
M?AJY*D6 B/\FBFYK GU_3$A<?FE^%JN,?_J'])=1.O06."Y!<4!M5"!4^T$!
M$M!!UZQJJ;7LO!:3P?Z''SAC_77TN&6Q0^TXF0Q8Q+!_[85,'(V#$42 Y//,
MSO**9KV>8M[T-71<YKYNL3,-8CV7O51V"*IP3FTI]9>2C>$@Y5%2N=7A0=+
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M3OC\KY\2]@M\GX*GXVB_=EVMCKOL&/TL] TL#+AYPMOM\NI!_NT:&KKX_\,
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MV"$FSW5F"%;QKM'P$NL3K8<Y=<I?-%L#OT16#N,Q -=,+')^>M]AXG5COMP
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MB?T?DI'&G';T)E(VJ$K/.^0^:C^1+H[QYUBY.SJ+2G*'AF<8_= 66?%%S[F
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M'\,9JP*V7= _WQI7V#\G'\XP\!560DZ-UJ.E_ [6'],P02@+^QA0"'YBL+:
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M#P_?DMI-!_/VS@(4!!M1K3QAXXXBDWR12.+JK+_E4PHK9N$D:F6<$)GTBF%
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M\\ORY3>IH7)+[K"2. HT7[D(1!N=1_6QBE,0!09UCM.RK>N8;I.EDT7PESO
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M"6QPI_8KK#/DGE1Y80B_+1Y)5-J(C@?.4HL5)D(C/R"RCN8_T\EC(%(P^(8
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M8>,FL5+BF8@OE_STP2,83HU+$HH$[7U6'9]4K@WEL;H=0OF(6'L^>"&\WHE
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MYS*RFM/>,'H&B(/Z1Y?(C>X/ZU)$X="2F:\77IM;(,]^LCUR46E<3U&1-B3
M>(BX*=6MN"YCDKAPTVV0^<3['RB-7))Q$,]M?3.GD "-L7-3DZ=4079Q%(&*
MU:#<>0Z.=IY\6K%0C9JJ<IJD&= N+I$IJQ6M@\:V>RPYX[*#6H3EL[EOKL/1
MFIA50M2(<K\P#M5AKF"R]/@JA[6!%AP<'#/G#G(4UQA^7MK,&7!P[XRW?N#2
M#&]%U.0FYXF.MO$@08O*)YZ[3X/^SP/TC?:U++N" GCK8P]AZW)DN!,8_CY<
MM1?&XKK6*CHXB3J*&TO@0GN0FKPZ;_-*V77^=3GYKR62Y$Q*3 5[7G<O8+C
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MF%$\YQ&>J:M [T\OQ/ 9X.IA79C:1FB7AO#1%8HAZ# %C7!Z0-_#NOD#[D1
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M<L\(KPI),PJJIL ?#?9T%JM7(64N:L(%?3,C_QJ299;RGWY3<_X+*O;&OXZ
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M^W PEQB<6CM%,/S')1T5'0E!:@85FGGQ*-X^[$SQ;&/2.3K=3,Q<2.2U@[$
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MF<9/3=TV2&,@@^N0[W>H@^0D?NIR<B_%$&"SQ>Z:F=YSKE#>T/CX<AXQ20,
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M^!#]6+.%0[(*7Y*1DU(6 XT&I!*<F)U0@4\_ -Z$]N?^2QU';[?.AP-[ ^.
M&TK,BW:<J+AY@FWM'2+5*<L/)F%@Y9M8S$!Y(7*):7^XLUE<60!U9FDB$L\<
MK/[!(8/J]G'>;.Z6R3M9/0,"Y6'<0L6(%FV&&?X%&_?1I49F*H6E79I9CE^&
M9*$2/G*+P#I7*-9#J-<D+M7 YG(SUVKR43O::LJJM2J-HDT1)BU5/$SW8&ZZ
M \NM0*?Z/0ZEY11:5T0E;X-@;F99L1)E7&+5$%L4C\1F^OH#870IU'?, FF-
M(6%6CB$1+'E,[$JNY?KAU5ZHWX!#K4ABNB,*3)((^UA.S><'.,R(] <ZT>W%
M@89D@.(N$"685281IX3M.(QD\ -O]1IEDDQ8JLZ^G,LXW2RTU5E>B6G43Z9I
M98/0F-HUWY$$D.LP8SRX(N,KHQ2R><@4>=2TN_$7X:5P\#0YXMA8SGM# =HU
M-Y8I")V\73 ]#KB[Y9OD[>KY</2!+:TNH_2M$?=8PQXI6K5]^D.6!"4B[51]
MZ4635!#(.L_T,H-(NSNG&*J8WD;=:@690OV0 !R"I@V)D4*+^IW-D20!!52*
MMS5#?7Z)3EF6/*?T:?K31Z,$WK$C=L"TCB7P+'T3K[1ZII$;G48W&+X*JU)>
MFFTX?B&<E:$,Q5OX-6H(7X)$VI?%W"5(SR5F"\TD>B2%PA8$EI4#4P]!R*&9
M=IG&4M],3;W0#.H0)LT/1B[H2U0Q*00S;K+(N;K&H3K2%)C%T(XQ'-41\2;A
M[8%'/CC=AW?IRA%9!,A3)$G?P_GO%#JO-HJ*XHHETK2+V2@KJ^B;)V,,+>)]
M^+QW:=(77$_"- #2<+A&]Y6*-<8;YNH1+L!H?:I"HYLPT\C16R]=?DX]8C[7
MRY0C2(*334_()M>'QB%<Q4&.$5'_4>[T&U MT#D )B(U*\.?1EL(-9N7T3>0
M1$WL-75@W#1G4KA"@?J6)3CL1<]6+%YJ#XA <%:-IFRK(8]=J;/#VAXZ[=C/
M*#FJG_+[M%TA2H4HK5[)]Y[J%.EN60C/-@!JGGQ=;I4R@Z90)W1#PN <P]+F
M?@L29HY:Y6/J)6"L(OA:)>>&J0\N<B?IGT9B*S6_2C"-52%W->"P(@1&&OWQ
M&_%;=\<:W(:11X'7#L/,?$,TBE*_Y+,3A8E>^?\Z,W4.ES"5/NY,[WT@N2/%
M'67B#2,B9LGQ6)&B/NM:C'B!ZQ96>>63&")7V(VVVS(KCT#_V1% I^QIV$J:
M;7U.BH^7,X!A8\&#I0"5X$T;\6-9^-@WB_*PK&4>B]K>)6L"V[]("[J"K[$_
M D$UH3G_!C:"054\_ST=<S[P@^+K6;\7;/P/^C&?Q2+ZDNE54OC1.@Y1FN47
M#%J,MD&JX4/,M'89O)1^G$E-&7@<:8/5[)0W N750KZQD27V9M21,<N_4I,_
M766JLF 9QF]/"01B\,>&^/=:1X.]]6E?B^PB*MK)HXYG]4.GW(.2QN+:A]:@
M8]%Z#?JMF(RU1;AH9Y<GHZ S34\:5THL<@:+G5;<F"3+R*?8S7)R3"D>-F(U
M4YQ%M1(3G :E8ZCV^\VKP0#W,^3^1!QOS\>^&<GF@SA<^8JF:=VMFO:K >.L
M#(VI>L[M^^CJOG/Y1[IE0UU-#/I2D0^*9MV]B;,M!59"AWFV,<+3P$9AW$$
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M<WED]#RE1NU,8LK31D6WE)8I2WE@K61E8R5=O_2F!3I4--'^=NDHJG9 "G_
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MS90$([4&1;VP;>4VH"PHG0QJ(ASR%.[+^ J?]\A@UPJ&:=6WN/M2E4SS]*Y
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M"Q1U0K(=9?U+X 1K#,N>3P3CAM>71LN(^5F&S;(X^//C3-J%C-C4'_!=/3W
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M>?.YR9SDYP3L'#/_[AD$UOKO?^8V)5?ILV06^O#VP@0KQ38ENZ3F,/6D\:P
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M(OF&U8[QK"D#BE0KY2C3HAB6,>Y.(75<$2?,_/_J:.;?_J&A'>]??JSSQ_U
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MA=.;9BEI%Z)N@<Q/OE536 #HL"J^)EFY:I:&$00HF$!!!WUNED_QGY.'F+Q
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ML'5COZ?"4=^ Y.:O?NX>)USD>_&6LH,NF[A>5)E6:U-I9W%SY$YT>^%XK.Q
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MN<G1 +NZI8,4%4$<\R#8(QE:V92JP/C:T34:W,];(U0''YA,'"[R0(47#$]
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M]34O%I6I<J+7;BQC'Q5?O3>_EL&7ET&1]PZ14:5SH6DC4-OQ)<+S(F=?ZCG
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ML!SN>)Q<\WM=R3]G;#[]K?6J=\_3R4;ZG_4[E)NS-X>DAN<1]G< 165U04[
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MC^7R$6Y5<>WUM'>O6(O:X5OE+0YGQIF,3#)5AKX25)S*8*;A$4V1(U/9P<?
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M\1]2,&A-)DXG2\,M4@OLK7$<;0)P(446>"R;+9V_3G=Q*S]N-<Y8K++A!1,
M]35>PU*]333C!"%)<JLX=OR[Y%&-HY31? OF<Q-%V-+$8@8NPA! B+*^%S!^
M7X(PI$T7>D</.HT,EK@IE;QWI3CV(&3X'%*@9S1=O-ID(7A-X&#N:Z;V#8P<
MJ0ZFL4*9 ( C5)P!B.F#/>(5NIV+9Z1OL8(07'Y S8(N1PDHP4+%D666-TJH
M&]0=4VO35^G*N8_':#](6^V4W(.8H%1\F#9$?A8B:U<,RH0("WKSX#0<:=,D
M,(\Z^<$(M]4UB0BETC-VUSA"6.1 :9PA='KS,4(D8,@<D+;X&UML+68(C4='
M$,K.:WO7R0\ "Y"A)?ZF#R4( +!# 0#K?5#"2/\ZX#IK+;_062(^_D^&;/B;
M\'$)F^<$JOI[JD[$T<MZLI6E("DG1:)048J62Y<S]6%3HU("#0&]C)ND\-=6
MZT]=X-2'=O)F,&T9YM6^++.=K@'"+54NHON:PV;]=480;.<Z4=RSO&P)OQ65
M%['*/;*-A#>,P+[[?1]RC* $P/*M=!FN1,O[)48VE<(991$#R#2K0:/VPQIT
M3&".6;X UU<S$$1$378QQY!YI&JU XMAWZ!L^<M$K, (UG.0W,NV-#=2%%>W
MF$>8+V)>.A'JN18UKXD-H76J)J&'$P=-KEL-36*S3":&L]2@IAV9E +K3!YK
MO)+T5($(60YS13H^M;P2C<\Z#I\HY.):PL"9RF(>@>E#:.U)UN4#YJA$5N>$
M RH:)XMQ>"9FDVE+*'F#$KA:,'&$/7C"UDTZA^ >#Z*HOJ;V=)315]'FP<JS
MX\I[O-((X^L3W 4*X56=K@6$Z=\PY*6L+:1DU"S95XT/%C#?P*+ _(AJ9<0R
M?E;$>!Z$*FXSLC/_7%8;'>=T<D6)&YJ5)*(DK2J\S(@K-/6DLT?%FB[IXT/Q
M@QE7*@,@$/5/ 2"0*E,0Y5*AYMIZ.C$N88(H?6XQ*>1_?P$2G39_(6_K>LUX
MTFPE%=)T&ODBT'1%=I#>Y)S$YN%OUG<PO^7;(6@H(/ :?K,Z+Z$:H;$7S!MC
M"J[MNRG[76>@L=66%P)Q@N(.GUF%(8=@8R2MS#I57 S#>AKQS20%"<!>^YT7
M<Z&A_XAK;/!P=3IX7VE2I2/M+9VU0#?5K!8X+<Z)=H)<,MC0&0X<HDJ@4)/T
M NLU@3$^U*ZGK$7W"M@U[I"(8_K$7HY:BW?D9X@SN3 !&4H824\A"NI/-[NC
M#42R-58Q<^?U)>RALXH=7^IN=IG'6"V[4_Y5^TX<T8M^PN]5J1/L:8'%K!(U
M(MO*NRY;U>;&M2L.''S%8#4.Q>$\$"7#V4OFWI1-M;A/A)46%Z-+569>_UV!
M1DK'E1UN_#';CV_LZ<P:R' R@SOI\-,_*A5B:NV:P5@N>_0&%PT$0RBK7ME\
M@0;,9)<3COU$+[Z?V,:43I1)9WF)/!J[I[H4'\QO/0;!O7"+Z^VCHD[+*.;0
M@_C0HMJ1JE/J"T!J, :LF[W1:,@VM4U3LXI%F]R2 X@84+N@#%SK;QQ]PCJ#
MA2U<<3WX"FGAX[!!:MUVHZ"> 6WJL7%AP*]93FFL?$V!=/76R?3V<0=4I(XB
MD9>1Q$X9 0%Y(MQ]E[)8@]AJ51;T=19:LO6AFG6I':IM,]0]1YLEZEEW<!-3
MV/SRRHYZP"V/CVI5(PH?.F+7*[D5R6UU]<?Z;UX[10)9'9)LGFXMG U>Q1HC
M0ZXU,$;/6=I1];G9S#B$=$) Z*-RW=7.F U:B1@"KS5LY .^T[YLK?[W8TEX
M^'&20\C")AS=7YD=X'+1S0.@^YVG2+;*Y58D7!U$Z-SB>)@4,&+5]J?<I,C2
M!M6_Y@.&<,K++=E Z9?A1[RTEO/\L4@7#@=<6^2UZ\7IYG3L+ *9%^FMI[E(
MU%-8$MC=Q!O@^9J6\@,YC?$B":Q=!(LV\*0+4# \)%*4\O&C@/D CJ<]!XH1
M@C]=J30;? HC7,J66F#PPJ/ LF2CS;CB\K+9C-7%#E+#4S1J^[W5+?M-( 5?
M;[\TI1$M<2T<EBCAN>Q+RGYN;$LJ-G^A98G $"J%JG0FND*L+L-H&U9S\!&:
M52"IC]AX@N;@;GYP[SP,2A 5'K2D>SC]$0;])+[BUNP?FF5SA!63JIWP?07H
M=;QCJ!BCJ-+$SD,!W:,P8RD\S6[>J8,6*N5)]['=4V(YOVOX*2KTS*UV659#
MQHTTI!9C=XP]"AMFV*/OTS@2,3^8\4H$WVE3I//F=7*#LXKORKD#U"0/ZK\
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MGG H1"[-NHX8Z!1."U\F,7;<]@(N+(/GGGAKH.,I/%!$S5*]BE#Z:?5K%ES
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MHG"YS=ROZ$TRVTTYT.^:.3NK93%26HXEUR6QL&=\Y%<=3,LDE=]++]]ZOZV
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MY7X_OI.?%&B_^"YD]EE[09/.\L-REAR/+=S15MN;AM#L:BD36_!09<6P0Y.
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MZ3!@O-D7*/\6;Z>_?5+:N%P%!>F_Q@!' @#@ P#KRTU55HHN@4+:FT.^K%\
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MB**I[P*C->&E!]^) D19%ZNV48T[%''K:[U^D2B1L34OV\6N9U9-B?*Q\=G
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MB8+N;>6:&:R?]H>A'VCIL%KQ#'>-_J2?USVC2O+^&3AX@Q=]L_,OI7 /_PO
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M4&("J9V><?E>;*>BL#9%@W14T?Z@Y=X&KO<O6;0H[2OT:&-)LL4ETS,U-J3
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M(KTQ>QON:=>C$.MI*?2%WI;>*JGI2,99?Z?^(T;<KE!=$+ZKR5G;,=4KG<N
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M :N>[WV-"!I%A/3:'0+]PWM(3TCL[J3$-:5"R<H<"H6\D;$U 2"A9=!VMGV
M?T;)&]]!*K8KLP!%[,MD6GX8DNAW5O%@JUCW]^>1)F"<JP#^8->>0*AZ%DOB
MD:L][@0^=F;,T$BLH6I@-]N^ER^K* UK9Y]5))P<[^8F0A;E9$^&*=+WF<,8
M#VT/WRIBIYQ;UI:X1PT0NQ^0P[-(+9SQD4>2P-G!D5\S/(%XDB&V*>H?&^C]
M$303(M,?YADU,#2,^G7%@\*1FBNKTHO\A2!D+$D[-G:8)%22]E*-(Y'(]<X\
M90=L3[=RBZ2H]]Q:1F BGK#;/L\$6(/:2V%8W:X>0GJI0ENR=QAQP<FH8SCJ
MN-#6;$N]B7=HE-F5VG24%KGD!_P ?IL5I,5.,5+,@V],4+7G*&&49*0U>/S%
M*/66&6_T7K '><K4,0VCY=),^4J/@#1U7 G\G9<%V[N+4P\O'"I_KEEZZ8B6
M$<%(N4>_&R0O3#=KPKMPIDDCQU\XV)M\W]E//6?>*(_\M&3:Y-?QP4E&0>HA
M#Y:).#F_6G6@<:@M !PZ)X^0[/CCR@QX7?\?%G/-N$I37C<].TZG!7D*_-,<
MQ/:=; V]H>ZK]G2-CN+)W-E29]E,EY@DBPRT6M<3TV 87Y[:G6YK@38=&R;6
M\9U7:QVS W9!O+S$+1Q+1*IJR1+''%!2*7^6*9K*X1/D'MK4Q.8+UTW:3'4L
M1"- >2UL"_Z7W>AD"6ZQ?/7\0.^<?VDB/D6]NZGE->H:DL4\FQ"/XV,RT_:!
M(U-72"/<8I!TD=^=.UX_WR&%A3C0EEJ !'.YR:$N(6&VTB'[ %[1'";3MQ*:
M&AN;BOI_RO>45[# G)UAB@;_EWH/JE$5$,"5]IX8($90[T+@?OM>4#G]Q> O
M4I5((;;GX-$Z6)D@_<YMXNYTUSLB.F\=9N5#IN@#Q.3HY+ZV._9A4GEA*ND<
MMDB5J"VQ  46V,;@O:#BY%"X'<6NMGJM#>T^)*K=485ZB_Z=G7L,-44HB"><
M(W>2^Z/$RL!>Z;*B^4Y%;[)P.9.80,JZ#VTZ@0T^20.\ ^S>NZNM$<9*E*8R
MS]G90#OR\\R6+N!#5S',Q2M3JGF )GMM YA$X.J4SMBY%U4]1Y("CO8DMPJC
M^Y^>BG&9' P7+!Q4BDP6_L4XG#,!$!=Y 0EWH']+.IZRV],._B[6C2LLXA1D
M3Y;W-B-GA:N+H<:J^%-8A_D?ELI+N5"G*/0\<6@/305M:N25M*(CN9LD&MGW
M=_2C1@YM22=);GZ:F[S1@V;;!AP^[H9VO@"NGQ%7^,18MNBFB$$OX9U)3L:)
MJXVK_NAF"*-7D5#[B&-@3A&3<AZH9TEL6LO0(>:I@Y75B?4U&\1%=RBB;9R2
M3R(,D/#^/4JSR@K+DU<E6K_9_/CS;\]VCDGK'\!QAR:B-]E'3"D]R2"EQ0O0
M2DB>6<%3*X?:8@>TE\JF^G.\KS8"ZW&LDP[S".L)SH,$.Y+;TZC29W#FVW%S
MJ(S"<5J?>7/+S9<.LEXG,0+K+MP% Q4=*474LG96[%[92-*@-6>1J&RPG!]L
MF"5X&]/\IG;0]D9#@I<,S5FA]]<<0VS78R()6<LB>CK#+Y4/=2[J" \[>MJK
M3.2-.4'#W+IF)2?4J+Q8U8M8D4**><VM0$6!KTDY>R<[Y\24U;^U@KD_DF_-
M6>!BA_N8L2J"4X9GFDG1E3LRY W)4\2 ["O=8!%:.JJ3YRQ;JN4<5:H%!JLA
MD#.MO=,!B._U>R%EE-L'UBMZT@;-JQ_DL2*=4AS@S%4#A_?7F&1XADXJL)7^
MM=W\ <07J\L&3M^^SF/4W0!,_'<*["[! S_K++#B]ORSQDMP#2<M"N#S9*38
M07$X=O;1E$<:8R/F5U/4>DUG+.:[V?O!]HD_#]C#:>WHWV(/!^QQ9=_ 74,2
M_Q'  &TWUHJ/^9GL-G&JQ*+-PI6&>VV'F"B2&!&.^4);R\3#05$O4?M6Q"FT
M6ASDA^\=R2&!1\[^2LR3WDZ4TC%*AZOV?YJ.,_D; T$:C([N@07='=6IG=2*
M'Y0RZ?67JXE58(5N0SC_\HS6X$RTR7EMX3CVAW!*TKT\ZL- 5>F8EP=U7@4[
M96-^K%A2?HZF7#&D)XIE\L4$W](C?E+S$@XT-<XQS19AVDK\,LTZSL*7C:>^
MSGA(;!>6GIR\?P2N9AXUMWN9IXNH'7:1D"F0/M#1&?H!V2O5FVV'B-&AZ ""
M.(%^HN-43S&"2:+[O5=93=-<$Z $22X]B2%#[?BD/3+')U-1=43].-\7>AD-
MLXT-FZN(:3ZG9/[^IJ&/?5X@+ @?:WRG$E<1Y(32)&H,OF00H0S2E?L@3OV5
M+^QKF?8\MFM!^2[ 470,0DJNRY>L,Y+0M*',S3P7Z;EV1]3O0M2'C&OV\: 7
MWUWY)?Z^:4\L9E5PJ0Z,)$H6W8\:"_-I5RSDV<92W%"V)W>-,#F3CV@KT23]
M;-?7] Z7X$6BCZ-&TP!-D#7C_)39T'D.1F2P>?!FHN\=:3_QU#YA]8*XY"C[
M*>LE9?F5"17'K4/*&]$22<FA7$%\*NQ&6-2W$7 K]2Y8F%!P,. (*Q9>!T:4
MCP@=@6+4=CR==@5T8=;YFK:QPQ9KV;1XGH%>^G4_JW2M$@V+!U7FA&),"020
M_Y(-N@D'1ZZ+HF_KF*ZB7T>F)OD^_8G-O<I)EJW!NF_.P<!7CW7:^ VM(.JQ
M>@U;XA/_[A.UB=+TOR&V"]KD,YN\EK9!#@94]]R7<CNQ)FSA!Y)@OI8C))LP
MI'9>Y>*GS,DC;TD#V.=%M)\\[F!WR^69W]"9A.>\D_.T]EMG=.[XDOXG;V U
MB%3^IQ*/U8L9\)+SZ+6V^]YQ<MY"E[5W=BG\M%N:M_D,E/9[K0TO'GNVR+DV
MEL%Z]<5WA7D5U/!7RIZZQ*/73Y%9S& /"D50EJ50TUE]6JG$%1MMT<%^CKRS
MZ]$!=[JP(C?YS$C:5VHCG''-O!22N+YO:W?%_RNV?P&26&@V&PB.D5;+VBBX
MJDZ.;0[@,/N=10I\0]&18QA41M[&#])*?%WN>J';9 98$F26^FX^I5EY5*K+
MFURGX8\--2.CW:_K)0P:S;%#PQW_B<.C4)S:WP)\%0<C3&$!;:*IWM&D%7O;
M^ZI+O][EN\+'^ LXTW=2/<>=S0I^S39 0&M;<PZVMCN:NQ,8XE\[C2'>>]!"
MHB([FZ75=W!*AE68Z%<M7ZR7Z]>P5%9*'R&)57[.N)XE-SS^!627P.O</G@Z
M,$P$7%!_&_A-% H-ML?-5]SS2(7BYI81"56WY:3.)L8N22QU'HR1LS.7I59)
MV&<P ^P0@Y[_PX$V5C0/QC?HR)>$IHZS4W+.$_+6]0LTW!UF/UMH[BTW2 LC
M@V(<N&U5U,-Z7=A5T^!+1FO4!F& 1L^X7YWND_\_R6*+N-I-TYE).$9!M=0G
M=U)8*MN'=MMY3TPN88H.+;J!.H*K".H; ]ZA-/64T+[?I&UMMH:ODD']#)_V
M3G%P..-5.2[O C+F) 8%XKZ4BB(>A3F=/$*2>SN89B$ITJU2529K!S'?S3?M
MDOALJ'ZW%\^"TW5$_@( G&EE_;15]=D&P-EF(^"P + _>Y"N*DM8 (5=P#DM
ME3"^E?QQI:G\,&+A6YVS*CI*4W@0YB9*RZ4<W9 $*>EFHJ #S\C]:WH1;CAX
M/OE2AE8HJ83?97,I_^"LYA,W$<S13KEB=E@CCAR_%)7MJZ 2PW\J; 0&V3[Q
M6K]H-7.=BQ!D8.&,81IF[32S;$]*[O$TXQHDOQ![2LXO9[(@'^:T"65U14">
MS0H[ZE*'O-(,J5!F:J[8W-8@H[.K+<1)71.STL08QWS-@K@*XWT!79 7:8QJ
M+ N@0QZ/#P7@]M-\J7BYLQ5]%Y]:&R%'-AA02T0BE]E8,!TSG'W%EAR;.\V@
M"&;@,)S;TR$ I$YLO%?G*QFV3P+[AL/PD3?FX4_=.ZYTS,AFJ]!W@Q(E/V3Z
M(=_M///7?B3M$9KY,5!X\9]582^8 NL<I>P9DQMY-/?(4H'FFA#%G<H!C+/
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MN D?=V)^S]ZT>#4$PH$E3:63[ .]F,.*GEFFQ6W1AJKN(^6+LWZOD%2KK/M
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MKR3 UV*?$3#SYB64,9''1Q"61K^(CQ;CYVKV=I@!=$R4G. )5)W PCV41GH
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MF,]!K &0P/#^AW.5[:FW^>>-;94V%MQG\?+G&._]P$X[T?-GE;T/UP_+AT=
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M%XJ+53I'K?V%3"$[/Z*!?4&C(UHR]/3CQ IXH]S@\WG>R"EX;6/1=@BXW&U
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M?C*2IRCUHY5>R ORD#@H9 5 FU#1$<0POGRCP%<PZ/A&GNS#N&J#PZ-:$):
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M\4<K55NN$J$> 6ZX4'I'"NUL!%7M,9T\H'E;NYD0>VJL9 XR*'/;J7+R2Q#
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M*S05X4OUN$:1KD1/4T'6T_*VZDMGV86%/+ F+_QV2M)Z1/G2JBB^:#3+'$E
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MCTC-]OCETK7%6-DJN1*?."!$I;!!#Y;-"64.[5>Z9#DG;P;!034]4[RIW?V
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M@?A;2_N](AV8D8YE$9=8)_DNIB:&!4Y$VAP,WU,\D/Q6EJK+.28U :%>1^)
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ML/J4ZB0[LG/ Z6^J1B3:89\T-\D#-GJX)OO2\U!W>:0ZOQ"2\$)9N*)7U_H
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M8(Q4$B-P1I5[[<'?6.L\RR$D(47JJ8/5'Z_PDU;25"311M$@:,Y,BUFWKPR
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M3"/+TAPL,.-; K\J:#/C&&IH7(C%RXH3F<:9S5,PA4Z8'51QB=WCHM?1YC.
M 1ZQI9.7KKHI)52#)'.F;.V*5_OZT>04KNR22F-8W)^>T<JMS<6V$)6QI:*U
M*%IGZB&[AT:*-CE\^^]W5<HSW&27ORJ:+J31;^F!-P;B!0$Z;6U@1P"!9-#L
M+,AJ>$-LKDQ%M\P;N9GBF^CK'".R3IYQ]\S\W*73@47"HXAV7$/?.(NXX/:O
M3Q]/YA[>.NQ[CW1)X8 MM!KTT@H6'84KTKC#5" $@5I+/F%[6N@LPFQ8-_RX
M&'N4:@Y=,1@V,D$)W!';6C()@I'<X+W(7(MG1'O'V2()/.E2%)E5IBB01V!)
M5OD=#)2:2HXSK#TMSA8^1'^*] WSZ@XS''KY1/1TT"S6]QL)\,#[.><C).03
M(\>W[[T5%T(#O2<'19U#&U(7OE]^(PW,A)1YBN(_$^18,;R<XI*2+4N()T@1
MST_>Q7! :RJA"AB,Y8"#'7MG8KN2GCLU;)%WJ'M1\=Z^8^E3"RFH";TT>GT=
M\FF#+ZZ5\B,<9%J'NE4I$;,OP(I(_1Z8V,%XN.08 H"G?7=;%5!>X1$HW33D
MDV]F-($<X$UYK?(*/8^7_19[NYS-N;3OCIB:'$_HUDB5Z!!@5V _SLSDC1Q,
M0NH7_%QZ"ZUF=9"==6,;3B1=:>">KS<>U0_Z0.D?<8"U);O<JXYG#2>J06$6
M[5/BK+L:2W!Y/<A_NP$DJH<.MV.3902&#@[3?M/SH/-(;/Y$%]D$UE+\XT6-
M=,JD#,E\*5>]^M&$V$GES]L-T\OKB-4&,3HX7H];&!44]W,R-27>1$NM[5(U
M>LZ:^B@)!SZ#7XA.T[C4!K0XL+A"#$Z[&ZD2V-3/"V0LP_E_(X%BI7LV\GW=
M9@B6/UR:;Q=_!E#M,2@SA\*(W]"!Q%)PW<VF+/##^4>G\5 U(;JX"28L9V.&
MP*CN?I[$YGV3Y+%U*OXFCZ4^M0"3]_B[=/]:HB8'!_VS1(U/]9]*U.W_58FZ
M?T7T7TO4T5Z*_RQ1TP_3_J<2]=1_4:*FHO R'#D);]=<OOI8@IO38/!VY(.1
M\SF4VZC9+$/).TLCLS!YU#N*AX J&IAH3#02N'4'O9!O:QI-=M;ITB37]=W3
M_>Z!,F747)=8GV>3%#R\TF/2(+K=#!T(>O<\F9#$]HW>:'>@AN*4FE"#?!4[
MERWZL(F ]5/K),O<8U6ZP:%%877>0%K+#V8Q? JC(FN H0"<&V/&>LJ9Q!01
MSK'#I</1FDB4L8%3[XW&NT%OOO6-ECD?U7KE\$7(U.RI4#R53U #?S@A%R)Q
MY9QI.<LNM?*#L&D+TV^DU)G6-/XW"9UFLA%-'GI-PY%W;+\4SE9R%O$;_^_%
M!:O>&@TVO2(9T08KX@ KADR5YMQI+<)ZU3C>#,76P#U0I [6\XC#L>>9ER;6
M])^(XI>@M4]7IFNW9Q>CA%E^2>L$,BJK-1M[#!;&,#,$Y *6SM]R7!37<9RG
M%>!9X.=2.5!W5-^J6=NRD>>:EUR_A##B[W#KX>"0[H($78>(ZUP$"P?DGTY.
M?,GZ0?QD)47\RW@5VN@XY]X7VEOX0TS]KNO9?^!D_@>&+,JU__$FY];VXXX4
M]'[VT*-53*#2\"'H5/6[E<,M]+W:/2[\<]GK]X$1-Y'G=WNJN9\0&Y]R=0]N
MFAD7W^6OW;YCW1;@#$Z:>W=.Z=$?/>NJXKOQ4" &=%"_54M@6XYK_>% #?[1
MZ;!PH58%Z2915<BH)A\T6_A"ETE!O+[31$#?)V=<QWD3=6N\.LWNQUBZV:UK
MOW[[:^K<;FZWH MHGOP \\MXZ;ND!<MPW;1O!8ZNO.?6O#V;,,>8AG?YFEMF
M8.!KG5.=Y==U\!75[4X*D:?P.+"$[! ,/#*WWE(_NXWZX3LRJEQ71+3Z$^_]
M3X5?DN09@[3/;#)^(SE952FTO%%T/ 6%G.%^.S;2Q7+]%:W[JR2X$ >^@_^^
M"?X;J4U@OL14^M\-O>;EC!0-'N)\FNG3B;*[C)Y>L?N-M$;Y9>9OZ_\O66_!
MV@_(,MO3--@HV$9G@EDG#QXWG7HA-WU"-M]ICPKY^9H7L R?3:FN_J,#G[W_
M8[*0ZD=\RG?6AQ_D&7_C?^-_XW_C?^-_X_]_P^W\L%QYDY<Z+>2QE 3NW(DL
M_/'[?AAU7?Q&<D_9^_4OBA;-?AT3%GLKJ+$[NEM?[UOAIK1JP*JDOL2UP/^K
MY)WGHXS^=[=YCR=R&\8"Q;R'C PI]/F+H)KZ!;>?;3X$Z6,3X0\M]RV/-%/M
M4*<O%0OQL.R/'U'^B-V](I#3G9;XS9=WS-EO.T?<ZJSB,]2O=\R?;D&Z'7.,
MF02_)'<Q;TC7WY\8?3_+?\IW#$+:[YO->P8=N "S_71C?I"[F*_ZY_^YEZCI
MOY%4G)[N,*&)&6=M,0>H?3KO$;KN(?7FRQT>/QS["31_49?]W&#XI_T0H$SW
M4[N'Y6K?E_=($@+?'%(N/',ASC4=7JCNJ9JSG&DR=/5PB0;WBE6#(2RMMKGY
M3*&8&P5D]D?DSI_9#9?W43ZJ@C<Q"=F?/_GHM,KVO8%WN=1_%'6I?,PQ=R@]
M<8OK>>O U\'"&JE,%=-)WRK?=AOQ7KG#IA4C?5,6.P$0;TXJJH08]G>L--?=
MW*!==?!8LU]"/.?\V"76@OC<-E$<^#$B$##Y4ZL'\V_H_P&(\-92*L+"NGT7
ML4E)%7*/Z/LI6KS.\+49UNSU&REC_!</9D^=UZE%R/YUGT;8^0>Z0$K&!^G&
MN>+ 6AC#".Q)E_=;]=_LO]E_L_]F_\W^F_V_CDVXL9["='J2T2TRDILJH,&,
M#VH;FP!<*X%&]2)-SMQ3-Y23;_M^(^%\H\[Z[[3<_D9Z7W[Q(+A/N$=+9"PM
MZR.0<1MQ6Z5^7[1=\F@KR[)]-T%9XNC/;D%O&QXF/\XHQE!.OA'B$$7C7'U?
M*P7Q>]>-9_>PD?T:LU.<0-(K3Y33-TEA?>?*_G1.8N/72-8JRL]0W-E2);/A
M@ZT) L%=4G2?#Y_?&Y<;@,KXH<X[R9ZS8F5O>@TOO:,EH,4*L1DO>+":-XP,
M\! :4<.I_-<%UVC5'[^A-9$P8RP3I+P1VP\1OO:J"4 %N5)PQNT@ZA-$.>P;
MYR!U(FS-%>5W6'ZR(S[DR=$PCBE"$K6RF%@[H;2\C8I7 U7G?EU)79%,D3R!
M"YS3MP-7K2U4.6;?F0F8_#,)J>C3A10V<LC>YMS;I%>5F5]]\ZKNR+6SKJP8
M;E==%N?#[M!CS>@J)7)_6<<_P^%1%0)Q31COH)V*\R,J>#O?!%$)GO:M[SHK
M='5.^TRF0ZT@'O@%T#"'C7)#EP;?NW!:ANA#P^Q7R2^L$R_R\!(6%.$=L"O?
MNA5%OA,-:?>6%ZFMU5[S]R [FRF#!:Q?VR0/(L-;20VJM")2,;'-&>XS*A"&
MZ3J&*NT?KG3GNY;^OS0D3BA)\RZ+,H:]I[B>4YZ4%8$G=<>OCW]<J9!]4'I2
M?-LA'=MQCI-/42*>@<W&0;M.Z6DB1CD@[Q#$]@-B__.F.;''HW,E'CFIE>P+
M7N*;5J9=S[%5&P/C^PRANK0U4IZ823M0CLGZ-62/I2P=P+YP30%@^>*:&9:G
M'4GO]:P/I&Q25$'BZ+?RZ"XZM_N+*3C K+"],"VMD'J*8.J\@0?!SH*QM("-
M$+^9I-+D*L92@-:[;$4<U?=N-<J4J+<$(+]7VC6QACHF-ESW,NAF;8/4Z3J9
M:^R)HWJGT=B$3';]5(P/',W.JOF5%R@V4/#U/;G$!S4(KMO]6<:$,%I/.LRS
MHWI)ZBK"FQF4,Y K@+%K84SY_:S7CJD=K!(*K0:=42.("1*3)&$Y@6(QJD;W
M_"B_&YD)%<G=?#."7*R.[FB8/<EFF>1>W"(5*Q]31B53:)>V/3=)M<ZNI638
MRP&)<Q8VY;QV=7@JF8T*[P4:.J,GY73ES?6+WG.SDV;M+FZ.9^KA+1C*7!N^
M*9_W0(2"*E;;9_4EI!F9NPI%9W>ZS/IKE)L_!BD-;NE[!%RBKJX/)K+Q=\TQ
MVNSHPF<^L-H7)-:LOL>VX?"WI:;G=$^,9)7Y?G#P[9N[4<* [:VWNB,E+9N)
MIXY)0;IAGDT?B*X=[&X&U9=:&I;>J<ZK('<<=+',?$]M3#'D%<XR[:8]GED!
M;*XU+*Q4%==1YQI$4SA [*$W-)5$?CH+M$B-L::SVM_L0$B*18$HOLN3@;4_
M!.AG$=N_,:CVCL5.PASUD56*'YK">RG_U3U):O29G;.%^@'$UO> &Z=4V5L7
M_5CD#A!4L!L,\+7YC20^A9*LF59._\07=J6\%"84K3$VJ,":GEK:+XQ+/+AG
M)-R>,H6^=J>6O /XU%*!K2XL4;O#NB#5MQ%VS9[@ZR+;MLUFLFM%,3YUH1@.
MCB-SUS,[MI1-5<\+S9T<?_.C4"*8:^5E"E8&SIY ':V%6)]V^'>)J7USQ_OS
M_B[3WTAZ3?L>HH>G5_GJ0_JQY>'<$D7<@ .B7*U&J"K3_??-=$7N5)RK<T1D
MO^QVI]D>L4.D&$!^0M3G$+SP4-T\6G?1 B&7E1C6J:5>GZ#[:6Q&)*<GWMA#
MCD6D;@')KL@9+F0$$'/B.(H)JT!LJLC44 +\FN47E[&E.]JNU^L-7%._H'J,
MK&:0:)+(MYS29RUJ#KM_W5A3.*/+'5YH!!#$@;V'#WBPU19COW-E,>MI3QL@
M(<N73!M9'@HMR+0\G-A:;X1\I37QPB!%2.B2B-A1&6&\R>5\\TGR?=<P1LTT
MZX'8P9LO:R:.D=^3/=PTU#+(WO3LXVPW+^$[EFU5_SH<I?6B76S0NR*SJ,QQ
MC: =\8']1F+JMK$8BMP7P)EI65,'Q$,$D-Z"M2IL-#:(W[C8IE8*OR(I8D(K
MK\0,R?S?UZ3LKIY=QGU^2'M_^:5:%!\E3/Z>_B6MR3J=99$QFXN3HUSS[.)D
MP$&%PL;:5L&(2P[ P#/4X'4<23HKGJ!QDQS2UEV?<K6XXMPGOP?:]]>L]:8?
MI/?)HJYD^F@C6F@&&O0JW@Q1P:;B [RTWB40=C<6BH*C'V-9ZWD+@26",+&A
MT*:%"S'AEOY42B3_G#^C,2!(]C8N] -G!>NT.?B3#4^*YVB^V_Q9GSH,J<0"
M\?Y&RD_@<K<,\0LH[%,IE,)-_A43(RSB&_+9]YA=C&EE/3THX5[\R7TR?%B<
M=L(TM_G"_MU)2[MTX,!@E/\SLE@E:4.LP^ #%L.%9]7.EACV/;=/9X0_9YKC
MT3&YUT\F"2X."G?3O0(''8BB':3OXK7(.XQMO/79^49-?,TU!C4S5%/O[K*Y
MRIS3V,NXH9N+&P>#$F.O:&C-,L5#RTYIVDQ\EO3#8SN4.I:=1(^H0ID(NSQA
MP&\F=Q]R%GV)SB]E7!?)1K!^(^%?KO]&^CK)7K]+25['4)_%@;\ZX<AN$>W2
MB;%2Y9-+HS57OY!^0.=#"I]I96HVC66"-0:]!ZF#:\"KV4!Q%V#W-O'P^%PM
M-0X&VVCH\+@65W^>M9."R/R2*H638FJ:-VU)=WF;<WX1U@B[ G!" 1[NN[FU
M16'[W4PBGH3U%,MX/3]0W6QDD<T(L$.P ^B']&K?>$!NGD;'N];V/UO!%Y*5
M2MP2+*FH9MA--E-:?4BEK#<W4N(X/8,RT-E2L]$.>S+\[HS]5$=;R/CDREO@
M/8$8V_L5C0O4Z7[8HJ ]"M6:GI\-<C"O@]I;3F&BJ>]B4FR-EH\]&E.:K!D$
M[NVYN>;@^K%YG$N]%8<^&MZB=PG-9P/ZMOO^A46,?JTFP N!:U?\3LG.]@!N
M#F'%_,M>/Y[1'<RWKPTIW RWO[)0]:'7\%F(C6IZB73? @1HU-A+Y+ILM><@
M_(T%.@9'&T[;O0H15LT11C;KVDT37((.78/E*H4'Z16XH:F\;"GU8QNFRV.:
M"M#-=BBOEZ:>R??S<KQ%]G3],$'N'![&$]2%4V>N#?AY\-S&'3I,.X5:(:2Z
MCF@CN.(@'F>N,"A/:^55MC1QW%;1.K.6&A[ 7L@N![.=+7IS8^2KI*KGEX3$
MS9V4:ZFR+EROO5E[0>N#E9.1?:(*WB#=\8PW%O4_D"7M5+ZLL--^X'%V?6F_
MGI68CO]\"X0O6!H-I$"J_:R7#7<T(#[^3/<V+.M(/,3Q 6.U*]'L@9(<84>4
M&)8D^!Q]L7F:36M&W99WG2UM/ZK16^Y5AKHT_546=/&9WG9LOXF8,;"@K7P7
MC+]]:A7C=?-IPEUG0$ UX7L^H8RD6D7R'+KK@%T*K>385]K,0LGL2 ^"8^+T
MS(AQOXQ>0+<]-V]UO8'GAW*J#TLV0LZZ!5&M:S*)!,_-GR>O!7\2BD_QTR&K
MR3\O)2FYA_H6%;/!O) F:LFOWXWJ5]+:&G/BQS6AO+OL0YQK;/:FY;=Y!#3-
M^[5YL]=%04K]4]8_KHEOJ21T%*TL?>=-%!7ODBZ8^CJV?YKH0IR^NQ_F$IBN
MRK&HRB8^-X=!'.M_Y-$VG1N00O\8:_\;*5#RH2LN1GC/15H&?.J2HNONQ3[P
M<G)YU3 9%#FP=S%GC>T1X9]5D==[)YRD@L0>]9B.@W\Q^9Y5HM%T]5(G^SB4
M]-.U;F^K,%%AL!+'*#4.P)!([5"UT,=UI$AIF<F6+RJ7&C.U *;$*9IIJKE!
MV!RW]CQ3L&N#F73L4DL^J>0A@D=@BMI,A@#L-K;J-2I$$E68ZA!9RG.MSDV,
MQ4OGS4OM:OF5U3T.12FLY;D?5RN>] PDH 2.6<U8Q%?4G^!M1+S[,,,W35-\
M@?OB(^WS(F;T,6(Z??;"WF@^M&45ME42";[P;CM.F(C#A[>$K_6ZD6BU=;1#
M7ZF:5Q!4S3L::7E5<XM:"<G$0K[16A@</E:QH#QGHZ*H/A?F]Q7V8\>F<'<#
M['"HE<\0O8SE; Q$$D5Z*XF:9L':ME45;%U&<C8\@\BI,Q.KT; W."R@11DG
MAFCN5W$WJ]"1M=&\<H2[HT\G$YQ7OZ2>]##;=9XU\BE4*6[K/U7KBL4-V_Z9
M%734J^*Z5.N!(9JTBW\W9UH#Q(/1Q9.X!'F[T9M!%TLZ7!%S+OFK6#G%?@Y
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M9$@*P+E:GO%G9$Q%^VT8'4Z^YKR_.>*IE9#"+"4LL:C*Y?9IJ>,"</S.L^#
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MLE<2?V+Y51Y89.U@6AA?D&DR61FZE-,9TZ6ML;5:G+#*/N=!:&(/P/&#5]K
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M4&WJD($8Y[0#]='BM9RO<FBDJN@UJE.?\FMY.<;T(=<PT;D-;&$?+DUHGQL
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M)@R .=<"8D28SL]$[XJ%.RM0<;6?<Q,.RY":&TH5JTF8$3(D:Q44YZ$9JCU
M>SIB_*2P#M-D7PF/C(6=MTT.)ER+5MLQ!ZN_YQ$D6+-[IA"!/73A'I+1 XW$
M&7A&3._D^X_70*8@QMZ$PZSAE@^RYH.ACM1M6%FL69OP>AUW!N]K*_;*E[V'
MJ+:>$W5KTPG!.=OI02VMK=W(8L8:UE@XLJM-"L>FU7[GHS3)R[/WXW1P#EN:
MK7*[/_XP@ELB7I*37=-AB"[&_OG!N%GMF7T2;]%)27YU+#3'SOUT78HTMWFV
MKX+K$]'3\?V1K(S_MTJ[KN* $Q2G 7Q$6?:;0:QV1JL_RBZ\YZH%+BNDK-.G
M3+9)=.\6@G5,<5J1]! .#>[H-4R2/ H_7@-9_]*N1H.V<NT _!\DO5$=4W"M
MW3)-R<U96=32JLPK65]YMY@K A[3^,IK=3&"Y)[#TU-';+ (R<X?E3;&R2 X
M)628]]*HB<Q?@)TY$=WOC["U>T#MO6P7IX3BC1](L]R]FWN1MPN?++$#VT:>
M\L@$R@Y[DS[BCKP!Q8T4RT!PN<-.B>E$C@YB$!J9=G![]_R\=\+]G-H-/S$.
MZZR<ROX[6Q/CV?1MKCJ<MM"RB"T4&66CT!!%E<WB2&W"K(R<A4(468U)IQPX
M\?2R,D@)D81D91KT];"J4^M_SOD\VKY3U5G__=5'R)S6+\"ETZWI^T\6AI<@
M5PONCO__N^/ 3;;"=#J'2K/L7NM&).-F9=?'<W,<(I">K"6/RDR7+]1I-&,B
MHX#!(7,,\Z04HH6-:.JRA1/)FQ!NXJZ=:0@T;/?+D'D.G<R.]D3KJIUB"0?4
M*FV]LOEV,HS#TUK%!9P--"E[I\VVUE;F94BK#50XY)=4@PZR'511M 94^64Q
MNQ,=A(L<73<0W/C @=7Q+5QH)$O4;%UN3-)B<TY^&C<,V57H<SAY%MA08C/Y
M:E&,@OZC;X#X1Y[]@/0<)D.V#V6<=WRE83QV:X5H3!(!"*OH TQ.24F0$DI_
M]S#*P8LZA0@H_F4N9@YWE[)RL@*?7V)82/IO. @5+U$'0X*4>-869K*9OV=R
M9>YXP[29X"J^ $32;&DP8Q37B2'(K8\39'$H;1;2;2<<!\N?W6QA5#@!N/?N
M^",W<WI_)"]\P:"156EE?Q=!9PZ.YG(F-*"XH5WDRVW^G!'A(@/I+JTO^C ;
M']2-;-!G63I[1R.DI?H#'_<P<W?A)IRYMX:V@-#*8\*9K.ENU9+*EMLR[[JA
M6: C[^9M'25)X?A0PLY)*TB_.JP@ER99EE_@MH]XTK/!U$A0$BM\2^:MWK+^
M ]<H4@3[UH6?M<0ST:4^_>Q4I.@"R&SZJNUM) [E; GD^@G#;W6(D=+ [/2M
MQ# 5>F#-G-E[C7/W.OK#,^*<54^ - TCCO!,GB%%)K)EG>E !Q6Y1G:'FYE$
MTPI%<@N%55@0/.8D%URL@I6"T!0\E>P$<N9<R]T=7<*MY]FN[0N@1YX=,Y.]
M \)(SQ=_O^;Q2?'(!E-?#MLK*]B&9"K"C(H#.DY5+,MG=JP<03^,ER,M \$H
MTGM%\"%!_2J['O3X@R(UJ2Y"RQ&NB8PBK6R5T:3XJ"RT4W0M(A89E0;".' A
ML;R#/!AUL*]24&65G4R-4!*T]<BO&CYYH2=I-<9W(X?!?DRN'F\AE?1E7XK
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MC>5;HEK^"'=X$CQBM#EI T-7#3\PY_AJD_MS'&'WY<)6X4:W8 (/:!%112F
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M"_X+_@O^"_X+_@O^_QP,W@;#:J#A_1.% O11*I%4N9T,#3T2.9_-\+<R0>E
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M3J_B!M&Y1N 2 #Q9[):1/Y7I*'\R996.>%C]]?_NMLY/_'2(3$^5X%MET/U
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MBD+LT\X"Q=XFE"]&5WJK]^DG-O<UO%1^_?L7-8FCCX\E"17NAML]#M8/?A(
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M0LI"_>)C24M$D)<-4BX!>J%Q'QE[?C7K=![^NS:AO$N"\@.5E4E1O(SJS,@
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MX4Y#U$;<U?,Z3()W\B>G&-E<DK=^X&B:>]0/W[!Y7 >>=FJN;'$4-<V==]E
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MZNUDK[4=M@:SK;F8/7K:BB?B&OT'X._YV/=X]RJN72BV^,/>#W*&X9^/C,U
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M&8=?TXC.07,C? U#IR<AP!=67KLZK8]45/)8 W-$\:MB_+;HG$19)\VQ3]<
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MQ9\T#Q^N&Q ,QEF72?B6"VE(+")YS)[15,!+ACGD(>4<WG,!H+JV+E>*[:)
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MA#A-T/CMGE 2$C6$IU64PSJIQ"Z'V$OMVLU.#$>N@+,'^M15K7>W_)7LGA@
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M1!CVL/A)QI4P_RD5(\$.YQ2PO6/7$5VP)QB@K<_*+;?Q6G,V,+L#<[*,FRK
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M0X8&":R=97L-)[HD&\!A-.X_NQ)^ 7''51QY)],TOUD@\I*<<T.]-HY$%$.
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MLD4\3=_-:37N(B?2HM#S9D'_#]M=R2QF-K6^R.*V^[(67W:Z/]D!FBIBOPT
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MV9"?(--LACI;V$+E%YYYK)K>,+*[TDPM<- G8R@0)]#:Q0.LH%3'X$G\-<Q
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ML7FT:AA%2S_AEH02Y]RB<S+^F5[.']EDAT=P]'&?.Z9E;H5KA5MM+ F7V.I
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M4:*7_3U;LRQ&D@NA(3Q@_;X'Y0-Q,]&M7/QC)I,+%_+8 >PRU.2O*]&GT=4
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MPP/T=&@1"Z_7&K/OI+_H9S0^8C2]K#PX)6<O70)K6<_@=.Z=8'O[BB3Q6"9
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M[JJ<(HXZ(YW2QSF.U4<.B$T;?LCA" VTDGJ#T4-X I= JRA:9_&_O)OYW\-
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M8K(^691T+Z'G5$Q)DFP3PK9G+SW9V)#^,K[( N!!=FB-KM(HDC!#[23+@JW
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M,JV5T>QI&_&%S+T:"C.K=U,+K3P\;70,;HDZ.X=[E4UH[/RP*/-SLD"!HNT
MW*[<V"H,RYDNH<;5<,2O>65>)C@*:8?3<WQXO$XV7VAV5:34XE#QYHW4(&KX
M$=AY  7DE1<R#85WWX1&4.XB3WVV4NE^#8;)G,W>VF^OBRK"GV>:8!["/<-&
M6J+*I-?IN[GZK9%5_E^*97>.90S31A-9R\QQS8F?V6G6[UN1\5M$,XY-LT28
MDL[O%_?85=AT$K 9I NM!+P+#6"7@R>;:F&C^+TJ"P(U32&;X=.R",FMD9!A
M-H /JK5P3^^S;:>]\>+I[/A>[6( J6<-%0DMMS02.UB^I2E!N?&2^)#PQ%&:
MI]XY%*Q3S-R[2L=6T0+HQXD2#;\!%_Z2L&T-UN+[K""!Q3[4_+.[D3>)ZQ,^
MSHS'S_3L1&XB@1M1K>!_RO.57ZO?-&KJ ])\Z[:Z:/O=HY 7B>O;;UH;\#B&
M1SH5>@*]9N_4.<X1!6BF&]XVBB EM#E2[EL"P32I!LW<L9G\-A;.27V\7*4:
MI?:N7C;I&$P7M:J93+#!<[O_QV.9Z.#5=QK1.(:M.4V$O4=!G3><IB.N0PG?
M+,5W[OW5=SY8EX%:[+H_4426 J/5(J8PB.QB'<(^.99\7?CGE:X(KJ,84(#/
MO )Z9V#!OS^T$*J4&L?;]]&YK15*+HB.7"71)9=.?)E_</594Z=\E$T$:[ZS
MS^N*THF0VERY3XR3='5*3QMO-ZIQ7_6&.>';A%$[1CV?>F\<B.4/YCYD].Q8
M;0F,(^UMI23ZD=&/B&W.SD#W47.<3'D$HN7A-W];P@E[*ZY K%NX&[!?EZXV
M$/?<]W,3ZI7QR=B<-X-.6+F9-I@EN?%.UH'I8*<WF(DJE.Z_>:'=1XHW:UTM
MASZ)Q1P.VV0A6F%YL1"M<X*X!58@,UX5_6YDT<GA KQN8]E8I#4[H\ET*JG9
M26O^N!GTU%I6;+49/9S5DILDO3[XF]%&>4]Z>4&:C=%-3_7"T9@1?:4HM>5?
M'I<*W=^L2'"K)?G-= A*?#L,6V8WI"M]>L<X!?\IR.N6Q<0+JAOM4V%0PP)A
M(<%$.Y@4)=.9.4>K- RD3H@'R:*D2-+D#QMA?R;)J,&9PPRU_Y!=;37W>>BS
M &-B'[7:Z1AU<B\?L][RW>C=<FT9R_MRWD&"%'-,=DM 74"$\0K6K\6+]LD
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M^#'JQ_C%FC43 81244&MC&!/JN.;0N;$R\)JNVEF(5\IGP2]ZCA[>,TWIS\
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M\C92\B'/),U%# "18*G9INDSJD0]HD]/%Y=/#5= IOOCC E9JE5& TVI!.?
M8NU60W01?J-?JCK--:Y8-I8+W$/O425&<B)%]SM93P-OUEG#^L>K(#)T]7>:
M5_@5ZY_J7&R3^;4D4[W5H3D[MTL);6;YU)J9PO#"N5W;&C/]J*N'OIE"NO-=
M#*..[,2*R+6=TD=[.#UD#(4^@HV9FD*[ 4?-K\C&2BANCAFD:/KK\W*E?MX\
M;;&:SVV,OV#DN.17]/)XT:]&,N2>7G$B'9=A";C-/WDOXMG,T<9^Y=?;F=]Y
M'>'%JE;BW'1-VN:H,I^77]2;9R@>GA*EU<I53R!&A:NDM1!;P8(&T>4X=U>[
MO..Y[IGOL$C!07YZI\-PV0&2UCR;1['M#A:W!-'O"@L #IH*'J"2\T@1N :V
M+".X0&S[NN1+YM%=-A(2AQ#:Z^BMW;Q==2Y@,'G^]*4@+>-O-T':[=_>J/AC
M\B4&03HW;[]$J:?@[.0F]B3W()6.OB'V<GH7$D7<!Z87VKS/)P.4P9U;/O[2
M!@OA7="-G<BM11;OXX5S:>3 ]"-A8;-/%&UT9<53_ V?,"SD=K^K\340.L"Z
M3!=4)SP$7=98NQ+0A^>>LDY8L":J%*8+]M.$1EA.8PZL8H[X@9%-$-WIM5P&
MFPD[#-O$(E/JG3*C P,THZ7$=F=MS=GT[^5IE#_SF.-UD 4 U%6#$-/M7M4S
MA!\[==%@M/:@5+XY7L$0G/%[4F ]!Q*+[4\@_Q-)<:QP7\%20T:\2IF>K^AM
MHXOZN_^ W:@JZ,%U&764O(;G! S1<_ [V *XY]*%"@F+<4^8-E,-19UR'P9\
M2&B=FDK4TI&EF;4W%3K;CZ4\%OTEOIB.N""(FDP%V6,?:2/($15/+]7QZHCP
MVRA<5IVAO;._[+-X%EC0$CEAM0*^"P>][^&%'H/T%^.9W!DSHPO(,@[WO.7Y
M>HK2_RI0I_O$3VT2Y 5XJ0GZXQ:P4'/<THM&4P""#S.UT_DH/U?M\\3NC7-+
M%6R(L<$^HY)EE'+Q%26IO:390YEE_#"_%L][)4&^MUP0[\]6%5B;(__>=+-H
M.I]49?1GB-1NM5W6K3-X<RM>*1)#\[7:0%@HY4G02^OSL76%YMWI[NBD&A"7
M EEI@W((RK!X5[581?LGQ,%-K!I/-XO5 :HID'U',<&T/H>1&0$R1T<S/W)O
MWT!IERE\CYSPTXF@2#&YX=5P51AV /DU.+%"[&:]V-GM]^9=;:4$7C6_L5F
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M@;*UX2:+)E+'F^",<"COV@&BM_?%XFY*U+*UWSY@NS> S_T4'8\O1Y<$ZIY
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MO!^&]QJ;*.G_6OV@>!_FQ$D4?GVB=$__GW3;!K^]WZC#^-6\W?T%LO4C_3Y
M76A;;,GD_O=>RX7#DZC]'/.!4;\,1CV6;JK7A1\N?Z&E>#\B')FYI/@H'V,5
MX63]G+Y-*#'2S-MT#A>X(+F\49.G;-9N\.*QE8B) =H!KSVL?>#XNO#H:V4$
M=;M2&"7Y(B74][[:(%O-8/68S-[*$P2JE-4 14G="+'$_(G9$N9QI/_CW%W
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MM_%Q%=;](Q=.T&@5IR;TR>:(\I<3$\6"$7BDG:QG_4!I0EY5:P?O0+ RIB+
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M2=(+O[5GTVU-?6(9W[@]0]]14I[=WLN7 *Q+!J$9GQ,/R2[6QB K5QR:P0\
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M#%?7UC6N4+)*T(G&1G+(;@[7V5E%&6N $NKX*?'@YZWNL:^*ZMO5R_U-]W0
MZV/8Q<M6@O_MQ'-]/AE$3 C,>K[G5V^V_I25UR>K7_GC@1O7[#]"J<"_:UG"
MP&$0]+>%&+L%^URYS7UTR&KHW;S55V9;+#C+%XIY6@!_%^^PHF]L!H5>&,^0
ML17T?C0H>AEFFJVBUDJ%>BM]VF9V*WBUC]O\;X[Y18WBO!66&VNI"J$2_]>3
M.2T>=Z5&_<Z=V6<KG_R#MNN#F9W$G[+O4Q#K2^5;NAKN]_6"L?GIWHKI\[\?
M@&<5ETWW=V&OEQL<RP_ 6G=%A5?*,F& G0KXZ(?&D?M;P&M%QX50 *GPVS/B
MKX"S;8V%[K%3%+'6BAN7^JK;+O^^=XW-1Y*^!%+_US ]L0<'AN-MX'UXP8;&
ML\#*XO-6WX\/ %.QBF(IVK?][J"9S0;1$?#9,!?7MR;"+VJZO6T4@TH(F2AC
MF<#A&>GQY"/%0I.68]SDS$**+B\);D18"T^8L4;S99$::S[?[I;H+?\,7&+1
MW.:3VAD!VEXT%JJ?NS6EZLUZSYH52J:36W43@I:QZ<.M]P>CG;V:CQ3;*O;G
M+Y_XSF=>OUD /0K/M_J,:-\Z/@#11;/N%SL-6/Z;'X!AU3]"'@ZK"'WV ?N5
MKB1=;6?0.VUBUYJ"J%L;#U .&P5/U21P_X<9U) V][? G(>C=\8(B8TN_WZE
M%Y</ ([4?]G^][5== GZ)@?XM5%F)>.5M^C>CNQT)F7D/F2XW]#UZ6Y[H*5V
M[@,P6#0[^?+:M_:PDQ[00Z_.G_?^X^S%84)L.Y6!6/D#P/;@UP8IN%3 CJ<+
MR'@1W;B9>2Q#E,7JFW@KL'NV>)D/HXK:@;S/M+XVOQU+)@U=WGP +#;\==_O
MBN3V/9X#FL_[F#\ WJJE3D+_A?%?&/^9,1A/MO(973.2+$9_%3B[23)D@F?+
MBW5,,?4AQ&4)8!9%:68OQ\_X9!RVG>A_RM(OT$Y2$2A&,G,'1["@D6*+ZS[)
M[;\)F@V')SC=[)^\5'H[Q3@Q5QUCU,8<F<N;9<%1(13)/ZK7)K'*CJM@66VX
M("Z12.2'<47)HV%0/X3%--!5,A!K$?Q/W8G3_U[5[N#9R-B-U^))RY#II+>B
M>3D8W:, 9MY3_!O7LE:&=& ZJ68#'91WW(.T7UBNE:3+B!6[/=L8VA]HC!U/
MCU'O"WNM]C.+((=Y;UOLVIK@SLE:EO]T\X4&,KDJ[;?5;2K0<AX7PZO,2>Q5
M]-PH=^;];6P>MY8S>(*_!&#U)18J:=CI/ST%_C-B8"O&'"LC1-A-?]D^9"9>
M-UR!Z!"9<V1!*A0+DJ@55(*X*F)IO^#'#P'5^72@";JJ4!TPMJ$7UTU*Y DB
MX ?15*F^4$7K/OZ'=_._,/[=,)IR#+X[Z>VUJ?]&&6 M"-_O :V@#,Y=Z? V
M^),]>@<\:0:0G?R'4!__?RJWAFV:R*I V\7_&BX_K2M+9OSJOVP,9,L&COD@
MTW+FJ4%RK8&47DGU]N)\,$'*HK_Y9:AFVAU,^IE>L7%Z0_)1R8D-44U5^CS)
M6TH1T&6\'V4/6YV^#[Q!&V0AY2#R_PW,^ !$=%A_ >X\V61(F#TM,.UOSF%]
M$1GLH/V<3CXMV4Y4GCEO2I(WM EG(J?F6)ST)?>[[A+BV&*Z:/ TSM]PZ!^%
M3(9[E:UTKFYL:L-8;!;N;.A&+A;&7L3LL47\IE'T*1DD748_XH#*)S4AN0@6
M6/-?Z0F,VQ4PD\^8U@]0Z@C285<WD7ZINCAK=9J=!63O0HNRQ1:PC<R;C^DC
M>F'IN3)NZF+S\Y 6)I-@E+HH6H6B[K'3T#/[D:B%/Z*Q&3V4&/"(<H]QKMEN
MQ%W9:LD]6TY A] JZ%/&*=\@%6J=FKO?QT<DJF>@H8H[O64Z.+F;P?\HLH9/
M>3[B+WQ/[%%^:9+V;U=5LN5IP*<SV=_/L7FW&-;M)=6+/_0MP 3#ETN9*'0N
MXPP%F98J+:T1\D']#6X8Y3;BAT(Y(U]_Z*DA<@_&/S+\XBJK4Z$](H34^H2$
M"F1O;AM%#E.YT;07H:'(6E607-TO*[/>95;,"W!EE][L#S^$6B:I=8SD:_]*
M/Y0MQATG6\Y!%_Z,K:4SLD ;.TJHF=Y2]2#Z&B14PC5H,F!/F=;6T<;(?*.$
M<H&%1!+F$'Q'-JW+'"N^/R_0O2X^@Q4AM;H%G*^2#AMFDD)V%QP)?>3+:*OX
M-I(<UU%;V\,1D>]5@F"&_0E>NZ76&_YG4 ?:7%QQ+E$<SXHMNY;5*'1C?0H1
M&D@7(5B%G%5TL0A1FRZ(M[5:X$O.'+VS\F?D/R>!LE#_,C\>N/&_:/"\F9%?
M7/_+%S@NFM,Z_:##7/^O^T]CS<ANE XIH(E$'O0HC13^W!PE 9%<##IG92[$
MXU, '=3C/X:D[C=!3EJK+:8V$>1ZE7$^WF7PVE1JF29F]'*-%(,4"J83F"_P
MS9'\C= 2?8/&>@^%=R7$74Y!/,F@HD:6FZ5C[&J]IP6"6-"Z\^8WTY]G0<_>
M[N7F[D/ .HSJ7.+-;[@2-.$KZ),D(0[A=[AL$AB'.9=EF:>"OTZQ+RW92U6,
M"WX4)9G;<KZ(F#J,QJL+1](62NABRJAHXE'EE@7[RFXB-@B>"(WY??U1;Y^8
M@4T&-OUDA!$.3PZ HH@UQ0D& 'C;_Z4W2TLP^OH67\\[DEXP\H&R,O_MY!I'
M HJ)W]2*8EP:</KKVD$#O;U:3-_8#^+UN3I'1^GY]<WN6^W<-"3KD#"3SN6S
M<?3:*_WR8+0;B2[B().MW?ESRMEP% %=KG5;M[S#"3"1]U+VH@S!U"!+))"6
M3N8TW,SNHA92#T1L6/ULY=A1W<7D'HJW@@/+%NQ1GR+\=92TQ[* VK/DJ\%E
M:^8'@&/2<5E_7@ 6V$SL-H$P\H4EI1',/V(KHIG1+%(K$L-@3$.EP(.4 DC!
MAF^1H&8;^']H&54N$G@/[P3S4S>'PN;"8Z.>$G*F]<H_^4!U@691^@[UH*<Y
M(1,#VEO5D\)W_:/8T.@>F5Y)=]@I^,;;4T/H\7=N$]M?>.?E;"/B ]#T(@'L
M_#+:FG/#AY(%1N&:-'S:Y_^KF$W"YO[HEWI]&2JWS(/^D-75;B8G33(58+E:
M"OLP)B\<X];91A)A$_Z;UY(2MMVAKL*N5V-MDJ'>2W\;5FG!-]"090U^):E)
M46-K\FR-5#PJ??B R]/57HSM5([#YL3_;J!VCJ0KP?#PP8*.H.@[<>K?R/:K
M_4MFVOZU*G.C<8'*UA'M,1G>?O31Q<8CLF9YHFG7!):<+F4+SW7*Y=J]=AAZ
MAO8,&M;?<K6<)9A!C,G*^'JH^7:B@EL]9H-=NE'Z-&?MI[S#+*PQW#,Y>GJT
M2J.^\C[RE6"6&K8F<V =-8L=-V63!0QP>[EEP*C6&X'I7Y<;GU1IW!.$^+N@
MR1\X.BO\-<YDN%A0)?'&ME?L<X@L@K.+]/BFS5V3YNYB_ZQ^R$2R:RB"9/"9
M=1I,*FE2+$4[$".+V]Z&*&&RJ E6P%92[Y^H$SU>PCI*5N)LN7$#?5'C#/]R
MH!YFYZ#HH&0]KIZD9ZI((0\+&!@A1UQI_S+EN/-=><.WHCE3P_"FK1LYI_P9
MT*W?A%%/!<RLZ,I::Q(.PF*)&3&_^K/I_V,YT61E\>TX3+]8R(.T9^IL6IE+
M\L?LOQ(FN+>#!IP">^T40NGSN6"_P_ '2N8A?#JVK>U@C1,"=&:4YEB\WOOJ
M;@_QLEM"=G1"8CQA)5VVWH)FZ )B SR^- > &???V$=85"*\NP;[/<WF%M5\
M&,WK$(GL"W..,6UL%+KS1,.?GTFVX6UC9CIK1+\7Z._\O-2U]C!;]"@U"/&@
M5^ O3<=/83.VOM\O7@@YF<+:;!K47@00*'!^UF(Q27XFH@:CO@GYQ"N4Q<4:
MHL08+UA!V=^2A7;27\I2L^ +U:N:APXB?@IB^X.-?=TL_/>:I4)WQ*MV@Z25
M]*)9F5-]--D!^1&K:?X26HTRMFF2(.86&PME;#_^^XT A4Q)&27D$UOK&<@Q
M^U,@1;)UGT"WJGVZC$1DRXH+.6=WYDTMDZ\[#G,,^%7PC=E%1Z]$@WM@WCR3
M5:1[;G-@+LO_SY);M-2<?0/+,IH.2WQP'M=C)5K$=_.<=M/<QA[^T8X8J9@4
MH04MWC@(\8D&T:"8"])/J=-6Y""PNY:L%@3)5F(LC9[Z9@G;"P\E7K&P*5C+
MVH*&D*2'88A%9=U7/HODJWC>G*9 LH2[;>+F>AD&TX3!94Q9U,$S01ZYG%BU
M<73V& )=X(!BNS+U?#]^Z.>T'L X41K3P0560R0)[U_L7L,E\L$)C@?=A$J6
M:=A-OB@;%\UY62@K$"?/V3D,88UT:S<3^V(IL946 3";'/K-T\,ZX5>GF&A[
ML240:*]W<74&+BVUF[)3JHK3V]WOT=W_A*!&*2<WQ?T[NA_PV<GPH:62W##^
MIJ"H.XEUK'9=/V\P&]=XWB2:D\-HQ"N&#$I8>O.8 ,,%RE\3U.!Z*>'*2[UG
MX^FYY*ZE,N^@/H+C%'ZSP=*S(D(PD/""U4+ 0,LP.)?!?\O4W2CM_9V%'W6^
M(K1&4>D/%3K]:[G!3:U-=/]=$"8,'GE@IE>/) )W/]SIDEW#RM3Z (92_-)K
M; RC<553%A3_60\5=3&[=5BC[N?4[\^83Y-;\3QLQGI!D-)==Z99&O9Y'ZX)
M^(5<^1($#(ER=SRC:]1J8]^@AHZ+[V!AL1@""8K\KZ]0*O17M"YXQ390?8!P
MSM$R5#^F7 0X\SC,$'^'VJ635>T&JRT&,)*J !9(7;BV_#FKB_/W/N;M;K('
M)F7S*E<.=6%X>MOT[A[NF),.L"%T7&\;GD-PHNA"H7X=D"+#B8I@?&FVM;[,
MC%'0<JGMW*IT4^>VGL:IF8F+ IX,?CYJ0;]1KTS".[3<5-LGP[O:UTKSS\B
MW<U;_L-XT%-O [<_0[14O3Z1S=-EV.RO?J-LM)'%E2ID:$(J-SJOXLG)&X$_
M\37$(V'(!.W:L\##,;,U8T.4Q8[<[Z@&(Y(FQQ&ZVMG9WMS>\.*B!TOCJSJ-
MLG)\O$*DY.;Z9F@(#HMACW4)HF(<)O<P_* 2N\0G(Y2A?VE.]X<2M\#Y<Y7^
MS8)8DK6HZH_,XLQQO6(DIASR$5U[)JCN1G*A;[9S5ILW"+@1X,_)M 2RV;PP
M=<#T+'734"'L,OXIA#2)O3'@7+N!U\EWCD2.H?VDUN$$9P;AM+7/V%Y!6>U!
MU8[NWMZNJFDM58U0)D/&XVC<3=',?.AA-GJ/A67R%55\H9;8/8HDMW[&2/G)
M#!0,/XT])T3 GH%QJD*X.BE 9J]H&G:<J&"FU[6ACDQYB>>B2-XG2Q8X _<%
M7=Z_Q-5^/]<.<"T\<YP;^+H%#P12N O5CK!L'2-M4]KXJCGFV0]+2_>Y2Z>A
M:87G[4P!1!F.T7L4E=@X]R,KU)E\J;X$S*O$GW#&K^%MA=B_.I;DF)N81LJ"
M0>-%-4YTCWS0\'L:-<&+MKYW+M1%Y NXJ:4RZ7;AXE#H\$8'-LF*1..BR.FV
MJ(!HB&<H+TDF3;O:5#,'QQ#5C2E$=9D_Y24G&-JQ:EG"FE?46R!9-=$J1D&=
MZBOO(/DG>&CV!KW_-Y('A:NA"R[230,)C!(VXWQ)L?>J,XZ ?/-C%]-+-H@K
MLP=+!^<)FB/]"[W+L<&NG!"W92K1K9]]O=9 3W!NHG>A)ZN305R/Z!TUB^2]
MU5RBR9OKAM8O<@&U?O*B&A>7_LH-_61HTY9)$8DR=#E!&:,!) ,MI/R!K!F4
M,W_>>'-BA)0B@@"\"0T$17^7A%*E9,_3"!.FU$:R !M53TS!EBKX2+W(]RD]
M''("1B3F661<E)_BA?5BT]K!?0)DAYTWY;J/'X +KJO VX @J;<9+[Y?9Z]<
MDZ0^M_59G3M/9&R/A@GO_(4-X_^GMRB_?- 0%_-<IX3XDM8A:*K"6/%F!((&
M<PC2\Q!6)Z.HUMR3_63^H/L+WLG:33#8< BWRIM36FA]@!OWR5)X2F9M%??H
M5(MHW=9@CLT8M#: '^V"95% ;FZ3Q?>K7D0>NB*Q#50 88XBEN0N;@_,&M;5
M:CF?-7LG#4Q*143,WO!W]FR94YP]K]?7^"5ZRO69B DZ;)[B0L/$_&TI7S40
M-5;A-8!X7][7X/TUU)W,7&\N6UM%LS_P!PQ<1Y7P\K5==_.OISY=/BS2:4[)
M:T:6=!@JX"A_M#&= *9S.J,2:ORAI;NH>]9/"H(V_B\\V T;F/(C;MY1,QC&
M5MR(,'"<'61+:<,&5*9CRW\:B4AR#.(*>$WU(;92\;OQ^,XW;C<Q0ZEKR,$.
MZ>3)7I^)--)JC#;7US+X:N7(<P,A@>@.CL?5_[J./+R:,YE,,,]B._960ZL>
MV\19S(R?+C6HI*XO\VF_=O:,T*#=VDS(9I5.""Z?)5*>+Q$LV%=Y%&[\]P[A
M_F[1"X5R5<[-0M25*:2U\CT266L5BJKQ_--%$@0A)[A(.X6\[?5S5_^<W_HW
M$HB*A!>E=A+1KSZCC6:J? 8E$GUA:VPDQH,(<TW.YN^1IHX4/YE_&\6CQ8UC
M<U0R+Z% JFDH6IGA(HM(E6(1!!J[",+<Z!!5'MA,+"(Y\@F&SR.WCK L<!]!
MKF>CFX9$IE-!+/F<RX^4'H9__EZE$6I&JE5IE:D'C],WQFJU#*J<%I!W1K1F
MKS%L3/E-Y >L>/[([YY*[ Y+*>XENE@J94OY\28_5>34,3 #8X,3]WYDR]?]
M 3"1M1;+*KRZ\TFNI0('!0?0S)\=AG#SF*RXRP@\6B"..<+Q+X0F84+.2*XC
M&*0HT$#D7HK+/[N8*3BJ4#@H(*$;F?*%\':U=1MQ[G-G#)2K>>5CEAPRI-'U
M1M9>Z2S U+%II-R\/2HL(A=;$W00;888F][^+[&:0O'2@4B$B"PC=/ER@%AK
M];G[IZT:$HPU$I/\EZF!A3).Z23=@K3RQ!D<-8P4H4$PS;,'.8@R^9<H&96)
M9D&9 J:D@]DZCE,J.;($Y?_VRYC_X8-$$%"Q(JZ1"KUT3=0-.[!AU8,:-;EM
MY$%Z7%-'Q(;ZBQLHF>?TB\.9/.T((=OC9V\4":0M$I51%6E9$R*X&)(?WR)A
MBJR):SL:7:)&D*JAIX!"F8'V-C!S/@\,+U+>K3U_>W"/"U-2$>%/"]Q! .L/
M0.K;7Y7NA*,$DINV][+R)@?LFYD0SYWWYH-D5,AF=W_"!X#^S$=YX[ZW3=-/
M]0/@%6/3@ L5)76D:^T#X:]Y,H.B/H98E5S&P!\.;".V.<7)DAJHWN?$(11L
M4:?,+2SU3?E.P4(B)JAN5U/UW+ <KRUKYOG'F.,$/;Y5^BJ(4=DJ7$WN;1JD
M4#G)[A"EXUH "Y,3V&J7\*&8#'B1HT,4+93"!O^N8-KGF7<$)._7S7,G\3ZJ
M %+E7H:"7$R[!K3>#[#,_)R86NQ-M"RL.27%?5AK0<;PG]#-VV_)ASAK:/F2
MC%C?15 R>+&O23TO4.W\R3<=PZ%2/7WF:8\T\XSQ?-S0R$M8YJ["0SC_;0M@
M*5A&V?$1+./SIO;1BPU&O)3*)X UC0.;R(J8(Z6_I#SU8AE'<NF@#AH]<'X;
M;U24E"^2-F4A4<K=1!G'R\?%TYKS2O*%2G9%<Q$@2-)1"% 3 JHZP8/BI(M=
M2::LEFSV96$+]HESJTBVCK"S7LV;!B\SI+)7;-P?@!,]&X*K/B[/F>" TP$!
MLLN>QXE3L1O_C>:S (.3^Z!E!)S_!21C],AC.XS9^;%+L_+J#E*_D'PZ:'NA
M%)K_>T=: SHL(&=<D\_ZYSLWN&.&=Q?BI-?XIHCKVN#JLO.,_3HV"],[X7HJ
MKWMJK_;+KW^.=</PZ;')F-G4>_U&.SRRB!/"'V!_\)JMG*'?1U(DKG91P#*R
MDL4!K^2(1^SXHD>T&:2G[[E2".@,.L>GVF%KR!5B+3Q<AU8;N@QHAK7+].UV
M8V<-D%I&L))*D8\7FD2[;=?;<5WT#DM3X&ED.S=[9T=&&Z\0E>#C9/*9,?_V
MM]2HBK-EHX8]V1\@R&)E?N:QR=*5R^W"R[)]!?'TF\%RQ N_IQ/1#C^YXT8%
M&ZYC+?%Y9=4ND-:<JTA;)E>3#RC#P^./9";N,^5FA2M"CO(T!8WKJS%Z-W#Y
M*9>(;=6F870CJQ15,Z+2/=(ZXGAF&,@R@.^L<4YY3DCM(,3V%P[878 BF6S\
M1N?^6^2:O>@-QBG!I^3UF0E5N8TQ1K5JJPF=NKTXX.@5!K&QJ=S3"P(!(DZZ
ML8AC!NZ?]B!'-QE<DE/A#P!'G-:[%L4[W8T(3,#5S/&?@T?_]MF0<_??BES=
M0A1CF[="/J_!1,D4UY6^3JTH/"FR^C^"MVB"Q&@4<<O3"^G5>11D<B69)4F"
MD39Y$:?N#B<X17&.R(CVD=$2M94X7'N5\J[SI1P3<HNO)JLBBU1CX^_&N-RD
ML\P2$1 M\#=\-M2#,IF2*[^D?Y]L/*#?O6S.1-7XA]>"K>?I0'$I^LD4HXYA
MMTOLS))*WVU/; F2+4,DZODTFD#)X-*R>NL@1Z0F#'D%DC0F%9N(28L4.^,-
M ZTVF'/1B_'O>0]8 53-WT,39<!6.!B,D;*!#\MSF"ITE[)Z4_;*MB.!0V=A
M=.3EL,5S)7\ _=S'@Z<T16*''&4?@#&A[V)13VYP#-VUY^6VAR5NA$]J!P/*
M)L($Z+Y(Y=>V7%]F]+%XJ"6. =2U,O0.JIFHJZ=XG9'%K-DGB,A-UMRCT1@,
M:NF-.AIBI53/*SMBR>[&;RLFU0B04_T/0)FA6%_(>=#;W'XUBGS-7[IC@['5
M#83R,?W;)$K=.HVXQIO-U-F7-"70G,Z[O$M,<P&/%:<\QV]+$\7:<V<W1'GX
M!#<,FO0?*K;LZP?M[GL@TNC3 #+"_1Q$ZY^OU6J1I<E'ODVK'P"6C&;E;X)U
MV=R@^>R.:IG^Z?'EEC -'TP-+(/B<*)529Q8G##[P&>@I3+/P2GC9;ANK+-V
M>NFJZ7= #)L@=:;TB@!?)T%2LC+A>&SSYD.EYOVW^5H[]7V.B/95O@Z*8VX2
MW(:0>C_8O<&%LKP;,!K%L?\.T'8PY>IUG"M-EQQRE%EMI6OCM)G5^(;TLXXS
M<;]RZ-I ,\/]!E F8?55F9S :'5WLQ]Q;S:#H9W+IQ5+5ZV__6)FSL]^!@(<
M[3JIB6!-EC>9HCVX8\%T=9:[,MAO_P!0=VR9)C]BPZ9_WZCY_M(S[!*#_LD8
M;DH/+KR5[(>?).'O2-Y!^K(I(0PTL,?7WZE-T0R^O9[I1J^/Z8YG24)1G&L'
MS.XZ5YBZVUATI\S2N5\,\D<;'L1A+L@,.E%EO/;!(5Q'Q#WX>UAQ4HL*[@%B
M]*P<C0N1&U%5ZB9_J)J=8K:N&Y-AK_)-,<,:19?FK2$V;@14@$Y]Z'NF!"AT
M2%LD,;U]BW><XT5' 3FKGO^G#;N4@0B%* <L"753)P,;[M^*B=B+/#8CJ_JC
MJ_:E#!=>*[0C;JQ&?P574+LZK%9V!B*R[6D=0;UO82L.G+NU\[J7IEHWVIV*
M\[\A3]Y\%Z<$>9[,(0-)/4\!SDYP;ES=A<+[WE(KISH\O8,GX+ZP\^P%DLGA
MEZQ?^LZ7C3Y<87=\+.)\Q1:8J[%%U,,$:5OGSGO&N>6^DBS"H371@NREAKCE
MIVM,T0.1F'O9N5VT^&YE_]=H32"L\DKI\0ZT>!6T1@GYYY44<1 (C537W()B
M]%E#RA5$ V:P?ND</\KZK.WH.VY!YX+Q!9V. +E8%M;9U]N04A[ ZIPRQ;D'
ML%N8LU%USNLOC[=2-M[9437@8[5ZKX70A^/MK.C8DT2#[?R'%CRWZ2+QLMV7
M*MOKN$U3I'/7=Y,:>$8V4G21=.755T,18AH$0W&,PC:=F5H$0<<?@,6G0_M^
M;Y%0@CTO#3.G"\8L\:L25RIMG?%OS)'*)'%C]>$'9[)T2G1.\3SB+STIA)M8
M,]2G.HPQC5J  :;]#X :J\S:5M;@TXM2>]X6\V,E@1A_?R-2_%/[ER8#,IR1
M3.IFRU=U[0PD2^O?N@B9H]P4M9M'*;[FLB3?]H[/W0KMVD&KH=&S?@N#7DP<
M+II:?=?GL0W;V@O=EUQ1X(PS0?@&3M('('_V*_AD@2:7!'%@+HHN%]PDPX=!
MBWAK=AK<*5=JQ+T@X^"%*L]_!_&P=U*A?"T[#S4-_9ZVH10^M29#9O6+E.52
M_#6GU(XA%<@M?PW=XH-:H0)DJ3:+2L*,U#9<PQ=1-?FN7\$+(3"1:FZ=_K:M
M!&[6] 0GG0KERD@UZ='.=-0W5W0G5E%-TWH9^"O('8=M-4:?&6UW[$V%N0L0
M()*@NEESTU:BRVSJ1/7$HF1,M%'U9;<I41,Y73CL] 6ID#L6>&Q?O:UZU MU
M$F[L^]O<\$J="7,UGSZ($HK^DW/\8KNS%#94%>!^W>B$-;]Y27F<6FO?!Y*>
MOH%]NHX?BUN@E%>FMR7S7#W)_$[=?*E>*G[.S6NK* 5G-/%5=XJW))GK+-I3
M/4I9\Y@P9AFO(5F)!SO%7W_%)X"6</: Y4NOP4O576%OS-5K0)$Z>1H(C.*I
M\79]<W*7F!V)NCR$!G]6+7S)B2+1E&W,S:MZD\Y"_G.X;.$+?$92;T0^%.'G
M9U*VMN?D+/L4'O7#84N3+S(M+*&!'ZJPT#?N)-TY'[A6*A0[S>Q^E-Q.RN_K
M$C_)1<HA+Q0_.&68:#FPW<L<C!#L,KC?_C(<QPW,OU/T4XU&D/G$WN]6!P@A
M!MUJ<V[5$7*]BC*!1%=,(/,&4=B#/H+-C,V=345+84Y>\8SCU_(N>W&S%5+Y
MQ<V/U*&RZGGDT.02;J*[U(SA@%0CQ0N2YYAMV\ 9T&&>O*?*!K);"$OX52_-
M*R\9#N3:Q&>@R-.ML2>"XX'I7B2>#.(U;@X]KK8QE3<_W)ZV5JMF7QB')+5_
M8,V..W#NP'S%_*6T/4"K?'VC%<XD=BK]^K=JPWCKLF;Z]\Q@Y(J4N%B37.\+
M!KB8ML[Z!A*#TFC)LGN=ER.#P7!/Z;CU>PH9]O*I*=>C+ZX.QAV\J\@R/5_=
MK2U^DR=21O83ZTN7<=WY<2VR$9A7 >/EL5Q4@'6_H?VXU&GP,$C)38JQZ:BI
M^?!\+XVWI6X65[XY*\-/""IU/MU7:8!C])J3& $GN^O+ZAQR4M@^;@D#/_!Z
M9* ;:%EM78W-G9HP='6IB>6M0U.IW@^\4YU@DQU:1RU[E98VFP633?AE.%P'
M+_"5P%ZP?@VZ1'12Y"[2CM#\_:NFGVTQ.H):3;QB2.*2.W)-W.<0N+S#X#ZQ
MA, OD:DWETML$JM4^&R,](Y>=[&N6FBU'T(EF4<P<(9JZ!)M5+?2<K/%ZB(A
M&[6-T!Y#!R)DJ[+:L;R&D"P%"6QMXG8LXG;];QZ6BURQ#%LF.,W!3CADD5Q%
M6?O<;ZU>K6B)IEPF\#0H1"@!)E4-51O*5:TA1^9KER9:?^C[ J=]A^\NG<H:
M<O \N=3$^LSO'#%8.A_^9&#&,4&=?#_W\*UNC/+Z+FI4LT@#'"0I7BJG@\AN
M*KP+38%S:6,@()W^-_D9)H:_N[/J;L^9?"=Z=9+#)_="+X7W"[$^I64@#NH\
M7CH5]]XT_Z*I-3FA933'^W$G4MMW->.>(4"O(5<'W<J%AEO63S.W5Y4I.7G_
M[_"CGN^&DM*WR%9)A.B\ H+#^:\B"B,KV".\W:5ZV[NI<XDMB,41/IA^"8KB
M+CMQ(OKG'5UD3);]FR:V%[_/C[$$7"SO"Z"$Y6YRB%C%8M?0U90A65IBH?44
M#OHT^,L(7*8&+']*P6V$/#8IFU^@C2U>%5Q28, +E.9*CJ.$>RFN@T[L4LY9
MN!(K!I6'-A-)', FZ,;A:99X^SEF)Z;/-5;#:[\JRH_D-M1&45P5,8<JH0@"
M436,#&HO#*GO 9<72Y+M(6O=H,RC3$*1<+!W#.ZWM$\I''>X!+Z(TX,YAE-6
MR_+2I6H,G<2>RRTT";'%LB:E53X\)Y]-8C7Q;MLWJYH%K^T">2<210ESB#.
MM2MQNP.N&4Y=U<,Z$,AP!3UY_!%G;?:]XV"<"[%7GI5<D&7V9YFXS2OLO37X
M"6(2N5EZ?KN(=WN54Y9;C.=1,2@'C^W3EJ.MH[VN"Z:Q7N='I<"NHQ21EP_
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MJDO**V<+9]^8)YLD#<AU/&$2,E;>64JZ4WY2I9P&PI;+@ODXQK'+E;,HG&:
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M;%"B7%NO/77!J=I654U.C1(0H%%865I))#555371P>MFZ,;%Z:A+HU'(:LN
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MULN;NM_^83!@BI3-'Q9PNY]GJ3#X;$P<MY'&"3.-&J*&D^O.ZAI>S K]VRQ
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MX3$VZ*C[;4E <K]XBK-T9_=&KL%A)F&DA7O\XT^[$+0TZYC).^&1;)4!]B\
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M*(RU'%@ HQV@6K([0+E 3K$<IF909!FR?'-R[1BQ;\BR:6:&K[O.[;2TYJP
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MC&^'C2YQG^14#PANO6!Z:9/%0/\Z2#R8?A[9\W/EEBVX%]5C*X;OK27)0WY
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MF9BN !6J6?!S5!BE3Z'R]8-^X1QD#U:WT T[1\.8;X]+4844\%2,-W[]L6?
MVG>XV&1"8@,+""3KDQ]KY,Q[GX"^E36DD85W\%+ X7#(E%YINLX]#B>#:"U-
MH^1XB/BD^==2* 7*NY7]?>2:O!#9@>>D;-EO<I5:Q60WV-4-!MSG>B'\US^
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M_'[6UYE=$1/;>Y'QPKG\&M+OK(D_L_9><(FNS@4J+T';:4U0AG#5Z9.#-2P
MMS\8Q[.7R*_.@"3/4A.<S7(1E>1#1"YN"3'O>L<7S%0)U8NU#)Y--MRA/T\.
M4UAAD5W3#V0]J1-PZ=RLXVJ2CO!JX;P3V_C&=?29C]3H37E$58S&(CJ. 5>C
M3(-1RK8-"8ST;IS -Q:!Q<WTY4B<(9](HSN)A%B!AA(O]9TUB2;*O:@_7+.+
M N;[\A%/XCCLS;4.VF;B/CB((="L'?^!(VCL/?++1]#J9<9ZGC6+09I4JES:
M^:086"0K19Q-DFTF%$6]C5\Q4$86_T Y/+5=;'RJ+:+$# ! "NY;$9)UWB6N
M,_AN_O:ML=046_**RG0&NTXS%#G7B(K/@+P]<<6WM;$\6MZ#1KEM831'%L.:
M0*V$#E<JU 4QY, 2'XM4;%EZG::IPEUHW.($5C;4OTAYC-20P9?UH+)OEE#V
MHIW\.CY4R!70Z%[(N1Z[HU\UQ[JVF_E;G%DV:-+/[!-P)$;:02./[&;\8/_5
MT",#0?:PXSY8DQ[4S[MZID3M,^S]=V*!I(FTB=G7WS.1WAQQ'<@YB*SJ.XC6
MT.T7U8]6,\> N#-RID;6)]@FSF:>==71CR+[-P,I6B"[/+-*H3C,5Z_1>P;%
M_:MOYT\;NO,"[O>L,DPR/+5=]*L":63VMVI3-4>WW5>FL7'<CDEKJG[Y.ZRD
M<,^IV=_\DD4T;&-Y?_D'E+<F[<53F!T'%QHRX/G]))#@!QSN[)/9]CU3#M*?
M:-.]/'0-\[*%8K-5JY0/?MI]=#_$^<E']2/ >N=-V , ^VYRY\'4J80KAJ89
MIK#ID['.#;&10]!V:F[.U G\!&"*]@&\Z<YS9?J( J_V8HZ"_IP]A,ES V.4
MZ[\B*+#3AR8 G$XQ:#)H<19SUKZ)ME#[C8;-71\O/!8_]S!M8#]<V3:::)WS
M[VY8OJ2-G,+<7[N1IW.IEPTO(]4B_;>=597]BLL^9_@YY\55\ESR3NKB)-CL
M# U:*.'+_.=1#)N4G( VGXT013.[%L*$3'%=1LS*%*=E,:.-O;$\#+H@!QO5
MG5%Y:UJ:9&6"HS\***J$Z*9] .5GWPS<KX80#@O_8<>%B'G'"B]%3\O/"!Z?
M .*&A<[$'M[+C]'X/SW=<%5L+^6CB"WJ5O\,B<7^R@?E@JF"**L+W^Q-?E;Z
M63Y7Q:RNO*,QCFX%R)$X"<S]Y=<RE4:$@1NW7TA]YX/C64W<C'7(D'--=;G
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M<QNSZ*>W+,GEE=07X#FJ9^^ @XC-)O6UR\AWUQ+G<Q_WE/UL<)DVVECU/5K
M6Q0GL)?\#KYJ6O[<*-PV9HB\FF['3*F&*H@"31H?'Y4P;T^+NTV.Z?FT"Q:(
M?1R8]7&J?);<YK.?23SQ&XWB8$" G^5J,KF!X2TM<ZZ:P%I&3S#^WJ2YK_Z;
ML<VZ)F99RA%Z01A[(\V1&3%$$FES#'F[<0((QA[<QT]0.Y.1VIF1\S*\DN/(
MOA8Y);Z;,+]4%JZP=TXTIGAJ*AXOPVRZD+XM)O)=,J_86HU9WKP_DI-_D7\*
MYL7$@T%7@:=]A/?$I."5SF"!=E*$333J-SX.NBU9YTO33ZE.^<6U8]N<\S1Z
M=<8KRTDN>4,7!-='314G/T:4L!C3EMA?+:4"3C-CV+5#CZ8>=68\FRE499"A
M-J:O@Y2M(1ST8M/;5W2C@PG5U5!]V3H25W>IPVN00&HZ67)$1=(P82E:@>7C
M:H]UFE3"++OSME9AGV(T\N,&K;?V:9G;%-S8/V2,+G9ZAXSV\8E9BCK^,DR(
M->5//,NKF^6X4X[MD0!M8VV/Q*P8WX>M$[T]@KGAFIH]K/8;,R=7+OM)9'18
MCV5.-=14GG9.8;$-BI<3LP865',50"Z:=+M9:;UT-)H_;]+?"J HV9P#U5IB
MXJ5HK%&$>\^BGGX+'I78!9DHETQRPP]%:)(1NW+EEEPB7W0\(:V!XXD)9QV3
M!&3)Z,5"_T6X:Q;8-Y:33_UI9KXL<(<H6RASEOY>&U?AV'%5W)BD_+('N5LY
M$L90B <,7RUOJ)FK&!_0Z"+%&OO9J YB<?"8$FBDR$-!R?PMA5BOWA)W_0 P
M'I[OP'O/?$EP!V=0O0<77C'/>U0NGJ%QU*)G?3BE]%WA-B7(@:;F]P*I5I?J
MT&E\G-2ORF9*F@D@Z.W<?H6!/:'%QH0G< 5;'F$.(EE&>TO[&+8D>7^Z Z.R
MR4(_==\NDS/.,@;-W1$#V^8?VHA)!-9J/O5--'7.SUZ<]AK"#%:206S6(PPG
MA<A>_*6+<_FIY/D##;< +6F0QJ$SOXL%9!]EPBC1M'-B-WYT?3EYJVD0.*(_
M$FT/[E\?@H[HA&4YLUG&W*5%^M^U<#1KC'XEUA\J)^$58LY%QZ@Y!V JZ>'M
MDWH>T=/>B7T$].B*J;^M2<?E1-=QSR)AP%GMZVIG4H/MV\#6MV"4(0L3HNP%
M 8=Z.&?%/^:8-_2)!UW^?:M=3[8_/!YY)<6/OL>%)D\-KAKW!/.DD#*(L&*6
MDX7,J@MUWG=-2Y'B7T45>WG>JL2"O&[;\U=V6ES&Z5&&^88?V61H'45X4B L
M<FVY^/7)J?B&-OT.R\8Z$G;_($LS;8K"]UKUK0AU"1QK$T/VW1%%AH_LZL*\
MA=X63KL&#"[&-= C3M;$M?Q<$Z+&UTB1XY"O$";,)&['IT!T=V6P"@<$U/^L
M-1TF"/C_W@8JMY8[PYWH?0QLC_?_?BU0H$MN:3N@G4Q!05'<_2/..1+GY3=
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MI![*H'JYH)#8(5,+ _^S83!/&"J*'L<W6--+W-YK#R<D6,+5^M,*-[!\!A=
MK_.$X##T#F_]23W[?V/O+6,J^[9VSUVXR\;=W9V-NT-AA;M;46S<W3;N#H53
M%.Y6%+YQIW#7P@O7@OZ?=*?SWNZDT_?<-_VA<[[]LI(Q5C*S\HSQS#FSQD;B
M'CA1W!EUL=K)L5.^Q&)N](W&UV\ )3:]185,:X?AQ6RPO+Y5T3AK=L-5MW@K
M-5HF[EI":4@9]QO*\%O91WS3GL-WP-^%NZ5W@+5.Z*QW\[;6Q\>$41\!9L=
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M/WC8&QU<R=$J8A-^?7!$#C8DG4%J%3T0'556JX9:Z1U^0"S(I1BY!MUJT;1
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M$J&CC5!H_]4-U>DO'DEJC1%'J4PMK8+#LD;.J?CD#Q<,M$H15.-3"N$P@K)
M10ONAW8)5'>$/D3!W3T!T\?!1=MXC7[,%1XJ2\3C]2Y*H?R\#2K-49@EHB9A
M6)P]H51J3D8T'Q5WZ..5)(H;2:3P?>3R !I2-5:$A,U7!7GL#C\6P?U[BU9Y
M1 'A3LC!.(ZY4SZ&XQ ]B_JA7PF$;9)GW3BI#+N\;%?#E36D<@,%ETD*F)22
M1HDI82J69V_28L>/9;E4HPN-SYHF;F)1OZBDMD8U-K7F]MBG53OGS!XU3F/U
M21TCBY520-<NG?6T FJZPFA:(-'6_UIWO9H/?QSLK3.X#*$C4C-&"1AS0^NL
MF><0'?QZ0#=*/[*L(52LTDJ$%,P;$@_2F&//:Z BVL:*6A(<-^)'DL-0%:2<
M*="EUW@M:53UL0%E[B[_;<-O.!"13IZ,&]'H(SI(3.4O9QFV5KF)LZOH$!W;
MY+"6JX\WCQ BAD6GL$@X#I.S$RC_$F<BUG@;)"I)Z'KO/)Y4H?'3<B40JEKB
M^F)Y5-#'Q$2VQQ5-BT,L-7@[8PXK"G-P7I51I.F=0#DWR28(P0C]OWFH_T>@
MPGBQ+V?;?%7&Z=4/> X@C68;/>?NZK#T4KB1R9@"M_MO[\O 6Q6P<3JBX#B5
M!GQS3CA$+=[0B-HY[A1&.:_(]H,_?'V]&_/F)<X_]#S+<71:U,^E)Z\U6F;O
MM%D'W3[<%7/]57E4DL]T*EO/G'R)HG5NNS0TSG)U.()?WN5>\UC4/*W._MWX
MZF9@.'NG?:%4T?/]I;#GY\5VP%?SH!_PCAP/PN>7M_*,?KK@=\ G XH)6^'G
M)8>7Q9+KU.>Z3M27BPO$E7N"EUZMOU,O?G^QQ\A_K0?]^GC(D__7L27@5.-)
M\:_N!OS?!R_8LQ?4O]M,;T<!W6_1!Y@.%^(G%3=$4V\MJS_OOKV6OE5=A+Z]
M=(7<!T2\_<%]![C]W'P'R+A&M7A1W&D]Q1T%&9R;^BX$:N82DPUX-H /,DM]
M*E#5F@8+M!B@%X_=OFA%#,/3*G#UHHH[URW*V&4Q%H]:D"_P[?TIP4T(W_J=
M%"-7#Y"D .-E?IY70^<"4)PT]_7L*5^R6.668R]6WS7G6?-?>^,@\,Z"6>M:
M[73-PHK@X:3J#1>^[(9=H\5C=%8GU51WM1N!Z+G>??P61BQY+GGQ^JR@T_CG
M#4>GGR.0W!NKA!IN8[V3P46:\G1(J^_H2>]_WT2,_TG !85QV_1;;O3N<Q(*
MZ(LC6>2[P1EI:G7?]'-QI$W(&$U-TGFZWJ+*O.Q):I?_M?IK2'_1#7M\+CU#
ME,$_@H-Z34(^FEL60ROT#A#)WFO\,]700&O4QP_]#A"PGKHXG\X6$_I3R5(@
M8U(N0_M[E(U8>XG->IQ_*->]B)/52V2'-"RC3%#U&:_ 1A#<1C U/TYW];N=
M'!K%RIVRV]OL\D2W:L/E"K,(1D=,]OM.-5);W/?6X.<1RIF2AH)2M5/W.K+W
MM1]!\AU @B=9<:=+;IM?2F/=Q[$V<8,,35:MG]# CU1QH^]REFW,"*,^U2A3
M32NE4R3;2Y+39L9)@\37AQ]W2>-%]QG1A_,CXQ7?L):.9]Q/ZW+;2*=8IST_
MT0^/438=YQ0*3F0.N;+@5,WI5+*T_?V[8FEAQ12QB8XUP3D_=7P"H,O BN\T
MCG'[^<O<%D2NO!X/B1O4L'(*GR2V'4JYDK<-U5RB)TLT91Y+@:%S%;"I)YC)
MQE%RH56("ZUF0?+B-"],?I84',?D.O_>FRW, %+:NCNB5[B:L.3J@6NBC;&8
M0E=&3Q13F.:RCMR^F-Z0JQ[XJ$GSQ9)5?8K UI*1,N-3EB.4SS+0)#/S<Y[_
MI'VJ^'<+''()_X+=EL9!?J)C=8X0R:+I,R2]1:3=>;B&SHP,J)$<@5]X$2[6
MR@LZ1^JY -8Y:,J>)7VX+/ZJN:X1E[/"HF1V/?AD6(R'M(K>>2P?&Y)/2!K_
MT<MY^Z,G;116&O=S(2/=C'* S=(@(0.%+$]7+?2SS%5-#Q)-$DB"6\VPN8Z(
MCU*(?/.Y7F66I5Y@A3)KO@S[\P8SO-6!__1D8#P<+50?.=%Q]\1-+6B_:,#0
MI$Q-$QZ+E22:GX=L5^9QCE<9<GX&8;#[]/VJTK"SD!*FR*NW7+B!?ZF^;W4=
M/OQH;T]<F?M5EUV2 2>#M/8=$'+M%OX!P20N;[&LBE$:C5&I&#A+#K4_.P*Q
MR$D6BMA#.>,H 9%4^6XJA!]MO_X1KGN+-WX'X/&'?;T0:#O2]7@':-,L;U%/
MDVGMAVMFQ\R93;B ]D-VYJ%;"&[<<D.3R0,E\K5NR"$-UO$^ 3!XH<*1[P!X
M!"_\$"M@\UY*?-@(UC"K$UL^"_4^81K\'P*UMW%TM:E'>NOID7  :<3LYB6"
M42\A$/H9@GP/4.8EHVJXPJ\X7$^NS')UKG*]F>!72C6]NBFGA^S*VYRYQ5N<
MRUJ6PW/1@W*IX:*$]ZT!*LE\>7BL+C3-O+;+A?@*U2C(L#5$GI:-(@%0;M9Y
M)@*(S1<->QKM3,Y,&W?*1,9(%>.]&/K0SKW5Y5E&D^5!G.F.-B8FA@+QK [S
M>AD\2$X3/4'?+-VU$=&8S<2^T0VY4LA."@='ED+C!5,.B\H/@+N5:/4WIOI%
M/Q Z*.RC=6U4"(B_7M82E9?>B-[YV,:__2%*\!V0NX><F\&1:;,^'CIM;&-K
M>YN\)RL6BWMI@ZSL)UWE4"G#F<FW?:EZE._"3-D5KGO<8]#':IZSQCPT!3RK
M9%AE2QSG/JC7IQ;@9[(:JFD#XOXN0F;0OV>++3E3(*%63H*T\RMN+"36-T2:
MEEJ0#4E^X&V"M>VN_*7BE\)M\^=L[8/SX)1"A,">3T/#4BD"[S3=1)C+B-:G
M7L_T?2TT=P6/,377TEZ53;CC,4Y\1@&DP$G9"*>"W;U1II54<).(A7BT*VL7
M1EMJF';3'E-UV2&EHV^9YFCX:_FP+D-*HMQ9/A>3'\!_E("S+WHVQ[R(ICGT
M<WH!H6<7C%5UP3FS]U)U+LTP%VL/38=2&;W,$A\;J<>)2KM##$G7@&B*L7[%
M-[$CDT-/2Q$=^ BS4!\=\SK"7_%/OB;&K> ;OG*5M\IH%9\/UWXQB^-8R[9E
M$C_A$:+$ZZDL]6AB58#0$P-#(C"A\04P7%UJ_3:7:_3FOMI\HHFWT7"<CNM@
M2$&;6DU3Y@*C811UXI-AO2;#!_OD^/U%X2HBVF"X-)Y:F'XL/:IZ)=]_MRB$
MUH.*71-YP(Z="7/+DX?)D>M2KDN_DTPRY"YI'3[2F/$Y<B2V 7WO_0232-(]
MX !RZ>8>(3<Z+4H=U.N9-R:1$P(>W%,.L@NQG4V*I7.^]'ET=W86MKH)U/:B
MMN,\6Q<I[P#YA[>_)@;/DP8]-X%/S_)OD>+E&8\B;SYOA*)OQQRW04&7OP[J
MJA=>MWX&)K\#BA*/"S#%"X(B,8,ZE?]2;+W<^3B>\HD+7'XM#?IM^6P;-GWT
M=2?L?TC\<?+EZ)CBF? M>_OFZ>C1?&:KW(_&3/&!$F?1B*'FH1>XZ^%(U?X]
MUY!SHK'.WX*&=J<?7_X+24:APK)L)JMVWMO]A_LA8PYU_G85,AW1:GLO5M*6
MA+\V=0.[MP?)O_[HK"C^\?%U=%J*TQHY]O%KZ6";E]D*,A"Z.I#QT;RX[#TD
M7P]*90M2K?Z=0([(>;_WFNWX_!GV_WQ<Z$TZL)9X;5UWW(P)F^4'?E-I^<L?
MLNV&Z2P^FM%3/B."87X^_,2]=+N*&#(AVOX.H#=XRY7X XIJH]@?-YVW^T_.
M_]Z<W((#:#..4PU:FR/&$^/K)CKV/.4;C4'9O[$76SJ_!,V^ W;4;<6,\]\>
MM_9CQ>=_D_\'_U>0%]]I[I6ML=>)PQ*< #-]T!A=U 3+[^A),U9H3X1O H1;
M)IHG^:..E-3YO9Y=5W.G,=57_#+L&-,4]222;_%>]JK&*W(G#Y740U-S6.&-
MH)>P![\1Q$*I)*=4=J[N64Z+BIM"5V%$P]F )" 80/!4Y!YY>'UV^0!]!]#J
MOWV5^"\L&;Q?C?4K>]=Q6S\<B[0.P0.YT#UBOUH2/E]F/=B73_4HPM]5/7TV
MWTQ-HOT:WA(9+UQQ /[-RJ)E0'GG0O0NUH1V-]<,#;Y*D-N*%DJ#VX;IX(D.
MU033"D8@)R@Q_-8V3UX\CE>IGAO$6/I.2<RYN0'370O,'6_JV2)Y3;9]#H#]
M#_X'_X/_P?]?(X*?66(S5JU8R@5,/_"YM4W='#N3\/D=4,P^0XW>*2ZU8?I&
M]EM\XW\?ZHAS,N?K8[:[*;@]>'8X]G/-$*+8N)A^DIN^7&+N8]K,/*:1H[C(
M.E73V7?J;EJR4_6Q$95U=-++,(7Z-( IM=BBX6^UOTGM-+901]T#0P]F3F(W
M:^[+[M3;>"F%$8O:LY;RD=Y;JUC*QX6F\ #8S0S5OU>V0=9SF+6XM^694PU_
MG0)H*FV1GA'_2Q33L2I'ON7S\K.\YA3V+::OOL##4/[?3 6Q=JVY'%.AX;N&
MVX2R/)K?0K6W(2J'0':E&U\FN%JEY^@:DE&E&(7KY]^':2T2TSE3"K@9^0XE
M8Q^V&:\B!UHZ%Y&&G MB-[^;K'":#XT3L@];MVX<OPA94(N_5;^2R]U\;BAK
M3<9^L_*J#2"KXBV1_2^MNN1W8IXI]"3K%9T>SD,G]8<"LX9;S=%6H-U(,N(_
MKB:F W_$T3_C4WSR#S+N1/FE=#IG;)9/Q71<12ZJ+@GW(K7UG_]M=_#O["_%
MQS3&[>GR5_@4[#_7M(&PH]@/%%Z:^26C7=Q^M$ L_5TZ-!S2(2M]_6(0*0^O
M0/KC"24^2NY>"M6!&?)Z6^#U#?W3$9FK4:XI=_F'?N*_:23<IZ_C0LT,X=-T
MF,DWAAE\LB7UZE4F[>$GNE38-E7G";0RF"WMHYR-HR(,SCZ3*XC ,9=<-!98
M%3<29_7\"LCX/A>X.P2#P1HT%()U"%3F'2B#0ZY.(9L6N]?VLS>6L?P;N'B*
M]('N7S=1Q\2."D_IWRX:"S0O''.3?:0Q9/PO!3_M,K-^[2XQNT*8VD A+YB5
MS*_IHCY?_-WS6UVG#7MJ/EJ.%..G%2OVUX8?*8+?306%C),:PGZ(DX/*/ ,=
MJ6AP>%Y6( 0UJ48M&RUS&UBPRUAV9];/7Y&<:T'F/((BNG;SDQ;<WJ$0A-^'
M*\K(P$A$O:=I<)3-LB#Q_F=X85H% 7H"JE+^T44<\PJA XQ>LN>VWY@OM9S9
MN>1WE[?=%S0,MI")'L1$1B4R0C+#O<8>N&!!:I_KM;GF\-:?CU)]X67&"_-^
M'6WU\K_PGAG%Y8G4*^-0#3#-\V5*9]K&#^+*#VSL+5&KP:OG%T"MCQ(_)Z>1
M-:H[Z09-:Q6[U8H*'Z7]5D-!E+T^!4X#8_O\8GVT43TV:!%+4.<YA"7& >T=
M@$%:O($-P3#O*,DZL15R+(E]S!BGHN3F.\"(4'K>#_%@,%O3'GO)S\S)=-C&
M V(M]VKPG8#-Q3-L^&J3W>0L160WXEE%34VG_D%_-#8OW'57@0XF(H'A6X<U
MFB6A"B<WJ6Y=MI#C(+,_DKOB!4_:^C:.JX:T#=O8[D=S/_D,6DVH306<)DRN
MFCWHK#1\.?E[@ZR'-J /9<BT1K++HXVGVX805JUY/\!ZI5KA(A:=#"EG_+#]
M-UI6_0 Q(5#:.'7HR&']TBN"?5&=)DF/D<-2N3[*N<%ZW0+I4^S5#7XE%#)@
M2 +-Z8[4QS>Z3:$KX(SLVLM;])1+0)\YF'3& >K2RSR1^<@E>Z2:C"=@0\.#
M5WM[= [C6-U4>SNDX0Y.GB%$"T@O3:?6NU?\K0IA:#EZJ]FM?ZL3;%: ,@OX
MOPZ^B\A@)1NHD^?5Q]X-2(GEPG5Y B8<W%CKD0;0ON@! !_:([D@7"%( *S5
M7:QPEEN#Q<<OOBCGNRGH_,,&'GAQ5H3NY:AT'SGSOVN09\OGEV"&T^N]VH_B
MDL[=)Z-<1VNK/@_%R2[38/:3;"X &=RR3*V%BNH;1L99FA.D[B"'JM43*JKC
M9)O&>7B\C$S<"-#6:VUVDQ;)T'IEQD(T2[QG-L?-L-G%1?D,-M7>Y.'6*'X?
M5+&NW45Y3P)ME+5-@P+#JRH@_#F&JL,8G2L!+PN$B(&!MSY'HZ@=C@1EJ05>
M2;ZE0E3%.S)\5RZ:-K^"9OCP$OB$0)]>[!8^4C;;FM?$ZJ=!J!YR5EY6.0F6
M*1..,2-9,59-S5Q>ER;2P7)"F\V@7Y'6<DT@6MH4Y4<EP=V#Z3)\5C3AMQTZ
MFZC4PEV0MT0T<^2"*J?E5\/X-5K]7DO-H>['D7<!T"#!,D[K#=.)F$VQ$1-S
MG>W,KI$?Q.N[?N47D-E:$I1<VYNY3YL^/?B=*I!3S@N)5[1@,Z^2DL!!$T#.
M1#_W4S<T:DY-&[(:G4]SB$"AN:1-DJ2+FT\07/Q%R5@< Q_.@\YIT1)*8O#0
M?3GK@&0,U18SA)E#H\/)ERUUZ=#Z^.,K;KPR$>E>"L+FWTR&*05_R>P=9@'<
M@*L.<V:4<U1,.\E"0E\IRLV=6' )8D[OE3/X2YX,'=;0Q=JGS'U5!6OP@]W)
ML.!+CEZ6H:GAO'"IG.NBUP=Z[D%F5FK*M0SV;W6_>B3L> DQ>2:S?(PBAY=I
MDQ[.^I(Z'R=7)58/"!WR*%$UDZM4^A\/LVG\PE1"N"P_<^G+(3,*;YV&(?E^
M,7MM3V56I1:Z=$*/?3R;:F#]MA7[2>J@%F/&^TUX:'PC13Y/O4<1,CJV2'X*
MXG)+2C!2A"M4;QB\(V MBK-$CH3[N>=*QQQZ+(<1HUK"C>1>5/;3!E%OO3(;
M*O*VS*=/;='!24JT,4\+EJ%C3,<%>W+6KUL38J^54K=<X,3\V[6E<M.])X<C
M("@XT_1JC4RY W4O8>LL^E+Y=,:WB2+'/[C*FM[ZGV*Y0%%:\33A*G\M-$8!
M;47YGMEJ&M/>G9\X<_TC_F@A^7"OFZ.DS ;7K%!=.G]X'_9C,PHPQJ<U>XP!
M8E" IBYCG^^1MW4X=\"DW+Z  PP>2A*=**4KZ^[%0\&A(I8)Y?WYQUZ'\(M+
MN15Y]29EA@CI<K%IP>HL+JTD7$0@IC=7OFSZ5N%5BK1E55PPE=-?G!<9NG73
M1Q(22>_5K^W/TS_:Z_6KM!O'R2V@$0IX@XL*V>H*^G$.:87V5H&&I/[FZ4WU
MBH2F0!Y%+"8^Y@4K<ICT#);(#4=U>>.;@URYQT6/831AQ[1\*HYL_9]RE^BV
MB7WT6FWPJES6; H;1GF*T3S"WMS"U3Z,I;N?7+MF>CT@]2^POB&MMV$!=V')
MK$J7N7Q*WM_]8,QR.RW;AIPULM$D?Y4;3,U!GVL:'''S.VH6"B$%"A!)>;VJ
M%#N,IV0C2;)0<K&[:[KOKRZ6RX'J:\@E"]1D0MD&L"0FPZAIDPLLJ<;)<](;
M&)*X3NYZ25]1;40"&H*1 \R6147-#1;P//[:OQ&^ PC1PI[$#S^VH*"*SY,K
M-?LE>0X//<?6@T6:&]GS(ERC*^VLDI[.P,01!'):L3]@?$<)LLIMN>R<%0A6
ML)*(OT@H"P:8W88?%E:(=AQ5Q*E23=:M7A7<C(=YZL8(-+.G#Q<MG_@D(<>1
M/F8.8O&(=<ED&1//*+ OFC/'R]#XN2IH*\0A.0L;A"XV3-SSI(//<!BE%DEW
M,$:QE@?OZ;NE^-A.".1LT**M6%DP)9H;=:A RH80:6SZ8/HT*B/JE@C'U3#2
M*:(V_-- FA&B);X)XFW!.@+HDM)ARG!(PBCQJOHR53TR93!QP^CLD'X9G12$
MRZ;*I/DZM8)U()X5!N5T+L&Y_<\^!3=C;V=W.IT;:T8&\8,8J.@4;Y_105C.
M<EQ_;>/3RJ9:[^HJ#43[.:>/'NH95G_ILGJ/_@RS:L=LZ>'3O1>4>-:NAK)B
MM-THGLY!XI3>/KBKSE0KI4MN[]?1;P.7]>A&T\F/*"\3_E"LP<398B%CS\QN
M#!$)R<*G"FW2$5M^%8B[661PUWZ(Y][GBPE \#):W!YI&..AD=$*TVQAPQB=
MZ^#/<]4* P-]S#@)'N$=34(3>:*^,T0[,=#[1N-E7HL9^B?4JB]<F] - I?P
M]VNC%R' ?3BQR9A0+B$(82\5VKZ#-AW69S_ ;.*A'=W/&+?/P^+4F@/@GS\.
M+\99(X@NF,!B*HE"EI5KN[@0N1;PE<R7LHAB.TL'*560!CJJ+K-27G(!V(Q2
MM SN<=DXOF^U"++_-&YQ;64+W/WF0T?XPI%6*5@:D?=M:@C5T@%.AM4[25R(
ML3M&;GTS7_,N<G,H23&L.TQ2BNZY43"(=&"<.L]64]^O5_$AT@8C:9/"=; :
M^:*N ]B^\@[P^D#=\= 6<M^=],41YO"6P*7GC*B \V+"8J3 J=<'GR>=RV@'
M*8\&1R'GE-W1A;$D3JF!J9 0V6#Y;+DY%:=&JKH8OTA;;U1=PR;8K%X'XX_;
M$30P9)_ 2#R;AZ6YBDN^7W5_N0=3AO0:-X;9(I2U3(A(NA+F<_CP9ARM!-[:
M)V'<?0T;?/-P0!. "[&R^,?Y5<>(T3$_?5]V_&@LEV"9J",[T[B&/*L?6TI2
M/$&0B9&&4@,[1"DO=QZPDQ?2/:L<K*@"OJ<^'N]8($#]O^HDPD><=P!2_CL@
MF^@=@)$39C;SKUF._+T%A=V8RU,RI7GV$H9-%D8S WSC@N==U J[CW\1,')4
M7/IUTU/N]:PJ$=0],CM(7;U/KBB)SI"5]:W:3F(6.0L6..C_>0.D/=7'PU'(
M22UPX54W363^ZYU?G^BSA']J,I%(XB%GN,K6<V7RH &5IO,CMN$KQO[./XO=
M<S)C7R#9 >K]\?D-0^RU&.3[Z?&CC<T$R8<']0$T_S\0RSJWBPON=X# =&%W
MOQ#&*T;'R ])U4Z.F8)W **"WA!,Z$^!M;1NLCTESE'*M;SE7[#N&?@^,]6^
M,^O'G*--W$!RN)/%>LD]>]T?WLP\PPN@23W-5MPODI8:EC)82(Q0T"G_+OA"
M/3]DFNSBAVCI7F::U:9\-%CS6Z<$C5*EE <S4*9IH=R.VEA5#09GN3Q,!;DB
M]"@\Y<P^(N+5'$/FCL663R>@(V<K5?1N>\)Y4LP]15B6D$+?"D[0TBY92U]$
M7<,_-!3_;(.%"J()SLCVQ@X.^)ULU)LA3"0YC23JD*<7;8Y4S_^6@8U$U1$V
MY'OE K/470..&3H7G&B7_A+Y5WWS+T71/SU6D2C:?M3'#F:HVM-'#==&E>!Y
M C>5<<'X=GZ0'$,2@76OCJ.!8CCH2DC7IM$D6L(G&A^.OM $B'%QE$.-T6!>
M]H1YZ):XR?F#ZZN=VX=PJXK#HI_R]:U"EI]$QBXF\<]#I8LC$6YP6F6)\SY2
M6M/HO7944@\H<](26X\)?,.3CA&U>)6ULN=B!4+/Z_O8RB&<_@?I?Q;TI[@_
M+3"Q"5Z !749#XGT8)(:UO>^['BU69'<L7/=PNRX&UJ..:<<1U;NY<]-$EGU
M.1Y:@L-Y+9CB$)@81P1&,4#XY"])YH/#*7(&&1O<MM$RYGTCS.MR$5@HRJZ1
M+MJ$BO013)8]>N\ H!9DSPKT#&KSSD_N&V1$'^W P9)8Z%T=(^Y/B9B<B/N<
MU4@O >LQSGVTN5^?YZ((Z!Q:#@"T>] @Y0Y<&PFQ)5W=9B?8P^?)KUJ[/+G;
MC[(,^JH2!TI)Y[+LL7RGP5#87C[<+&V""#8@P;)Z=M=)&OA77#N9DFH$?)8%
M]D<Z97BOL45'G?[$Z4=N)&P(N6:HY.S/=H>H5&.))+GJ?'M)#3.05F8KO4%3
M/RO8H,34TT&)&BEHN."^2I#(V],G1]X<XB;UXTJ5W-)NM%0-TIDH.J2_;8F8
MN4]7;OU<XYHQH"L0IS@!XG:3^S0 3M.K<]'CO#RM EN_]%V^ ]:;C(/N';YQ
MM"GZ""T&',S3>$&)_>O0')_QFO8O+TEP['CAW3_A"[B(_E3ZRZ ]()0]N*JG
M! 03Z^]Y])R:(O4;O]F$YMQP5/-$_]#ETL>-*5MU>@O!CE'@!D<VX*J*",[/
MD]/NL1%U9#+N/!'/3;2S<T\Q-=M/<!1*<M]W=TK->)\=#B06J!>8%!ETI6UA
MC,U^:R]O)!5/-O^2Y/-BI9ZN,EE%H8B2DC%8RDA"MJ5%HTV?J8M:+M)K- [7
MI,C9^ZVCKKHNCI%VS!#1JT]XOVR5A#XP1HCQ,Y3XT0U\P;7TZ3.JFH1#39%<
MZ8)<I1P5+@TRHP7\.1@@<(P>NO*X?'@D\:2A_D2\F!=":SN.'<DY1DLHS"X7
M&WY RY70"3=&JP"D<D\>+%-%KU6C*S5P9!G(=!&Q?LC%-0@O)\??D21JHW&X
M.DQR)#=?/:N=Y$FR_,% Q*[+;#,</^$\+X^P9[Q&)*42T*E(#6GX;FBM5A:S
MH[F;1)8E&]BC6DT2KK5[E&FL>=!%M@^Y;RX?U?B456"PAI]G63TQBAUO91-*
ML1+K$ZM<.XN:MT_O1C77B]LA[%N'U5#^W4'O0PHJ_@="$A*+)[)^XN&V3K>R
MU.763UYCAIVM+E&X/8-ZNRS;V#>%3$G,WOA2'CYY]0HYRIJ&T:PYYS5J2X35
M[-VQ+35^X>^ _T.XB9(/-B^O]J]]=MXX]K.LBHUWC"_;O;]F+"^)/ 8%7HS[
M909<&']U7,Y=N>O<D'3W<,:2AUQ(]@@AI%IV#SW(7XA/-[)&]EV<3O^\?F48
MT=+-"O*[\4JY>@<$7IDB79)]C4A=]LS_JO>O/Y98\?[KW/?;D\[^S8W5<(O^
MRWK4SZU^6[LBXK4-T0._UNN/>4D=-3=?O^PC/V2+" ]T_B1;D%SS>/:;$1)B
MQ^^0*(S+-6].^JL&C::_O!IUELY4.>1Z-8RLOQ>521^F.O3OX>HLE&E8$(G"
M^WSV^U?[!Y0(Q[R\3[0.-O9RE7T.H9KEO)XHO?H]V84\48SNT\D_,>^VN$K2
M#(2<,\8/IHG\6.L5$'Q=L./*B0KSH;VUZ-DH)PL;+;H>@XX2Z1H!E4R+X;U)
M6/7G9JO#_EV,(WH,_'NA?^26=\)5U%88<)(9;WX(*2.ED^_FD.74J\GPI3!7
MT.]DNV:D*\(T2$M+=['TR[(EU!SCIGU:@)LHK%43!HGTYF4TV.JB@; G"!>5
M:YY"II$/?CCF[<T\+CP+L#NJKB*K)_55=!!%+_(YIK++*+:YH,16.6ECIP#@
M&G)PIL"\\9;>VCU4DV3(EE$2Q=?(I0WG"BI 3^\%_3+#O=.B'5H$8FK#U9D<
MES.L:%TDCEG'S="$_+\RQ-Y]T G#M+8\IK;/G:<"DR><VDHBWV&CE<>F+ROA
M:93*#59'+Q?_S&];=<L8K<E4#9\UCB<38QS_PC0)?231!?Y>#YD45/F P9A2
M2XFH1R5(6T79 A\^$VP#H(=#,.AO"6<Q> <4^;W%PP>0C&8@,:2XKQNB,&1<
MUJ/49S6-N@'J!^JB/F,AR^=ZSHYPB#8OSJE]!P<VV=W-W6YN;5#< V[^";+<
M+V 8:FPO,.0QHQ=45?-QRF(PC\+$2,92TDZ;)]$=02](Y6-6=!G2=@<:>2]T
MTW"4R7;*+J ""VLW>4'<?:25YJ![GZ5_XJ-DN!:=TK9M6]?'!C 2%?&4=[D8
M24='1RM)J?V25J?C"Y:29O$EAUFIU!,9_T $ 4"HF5[Z_PMCB*;C(11I26A5
M06VEJ(Q&C8AD[IZF?' =)1/7L+S@D4Y5M5%0D)^9H\1_?WAK%3>@RFF.)$6,
M8<*]56T:_6K/ZP(96FF=%FJE/)<^>E6,+D*F<OQ(Y[LO3?5S)8S=0M\WH<&N
MMQ3A44(K7BBE%H?=UD[?W-'?W4V\\+54<*R$N#*Y# ,$1"51YLS: UV(I4F5
MQ7%Y.":UX-_2Q22S1/PH93OH;8Y<:=BP+R5S6>^%:T+F[&UQ@(=7#707?UMG
M./SZ0/(.F)A\E'UY?<A^!PSYB3/X53\$O0-^76%RO0/N6A F7X\$"6[2 QTY
M& \N^U'7IWLX!+W1>-:/TEXR@_Y<<OJ\3&U:G 5B#(]OK-6\ X;)*-#AX]0_
M43"O%P0Z9=U7B?LE/:P]JISCTACZ5?RH\]Q4O$DAX/OI=OX:(G;#$.7MI3O0
M&2WLW//1%U%>MG^)D8_?<TJO3?_/O<QT=JO&?K5R# W+(<^3;:A":<$'4J=Z
MF8[AWF)5S#E=M?Z!ME/&Y$H18W%NU!E.-=>A+JZHADW_?LU$H5VC.B))KF!E
M$: LR=7C7GXX+;L8/)N=>4K+_3W\.T#?()YKY_=3H4&8T\R_O=N,8=QM3#&I
M2_:FHQ?[0)#!_.O,:\]Z<V#T7F^S=?*DXP9G*VJBO(58_5\CRBU\A8+RYD'O
M "J1W'> 'KK%]]C6Q)CG(-N5WZ!-N;L3P\!CLM.OBIT3T7T2A7M^R:R7/TC;
M74O8=MKDW&Y3M5MZ#(I&R@P;ZO_0F&@J%:RO:_ 0'V,J7/0>D/D:+*_Y.,CA
M7C4:K2EXNS<57= SRH0GI5#T*_Z^&_!>9*^@.DZD-*R,]"*KP3(N>8I1%(R%
M8=_CIHSM9 0F663Q@\8T:#61+:R.5GR \M:J$FV.KJ0)K*)F!6(%@0JM DZ4
M72P5PG,2(3]$_/<MP#KZ22Q-YNSZ&$(UJSJ#H]3NL"#D[/72Y*5VK3##L%
MA"7%K*VN?0($CD2C6YWR:X_\W#=TIE5^OK<89U+N2#-<$RDBRUVE)AF4)L/Z
MRT<1VY]U[X-J#ITJ&HR_')YS3<.=JDQ6(0"8B_(7%]BD L*:VY3:N73+%UQ&
MBG2TCF-C@BO#L0#1&ICCB2J.*WSAUDADJ 8KOH)Q>M>TC6'2:\(93&#D> =X
M/[174ZRY/"'/;<#$\HW?OP,L* 456QZ5I,F< D"SU_8,*-10B[W=Y1/R%9JO
MHRF4)\O,&!++A<5HG/6$E'%S_9QSG0$3F43"IYP<9 ZM&Y;K\<G:D'4V[^.-
M[VZQW&C!K.AT/:(4>&$'CWDHGU@5%L>HJ@0/%V+&8-S'Y,$>FI4=DJ\/.-G.
MW+SD#FI\JY.M899Q,>:,"]^#FX:O\3_E-#* %>C.A\<LVGW)Q .B@;N1BR#!
M#20YG#'.AM!=Y(AU27H/9?<[+>^K[<:"\B,%#' $ XA:WGKFB(?]G-#%*(EE
MCE>5VKERS7K&:V 6 QJ!VH_+(O05TW;6<<9MO)+BW/4Z]S68<^DQ3.D;1Y@;
MB'0.0W1O8DYU:'F9')=:<36&>_#4=I3W7CV?.^WW$D><I2"-2 7UR&K.0C4C
M*CZUHRBS< [&>O_SXC&:K0I(=>\AJ<1$P_Y^6N(&]M8'*V_3O%">)=2*E@V^
M&L<GT<8R+ILL4@W:K[E9:6F$L$,+2&!>XMYH,';96)-O>QXN(YQ4,UO]L0+7
M3_@803;$,C&[5*_W>KJ"+IM5=-4,SYXV6:JKI#[5Y"9$-UXK*4=BT<4-I8PP
M+[YC=@G_";Q+0MH2!#NI8)R?Q2:Q#0DCK/&+.F8)'2=80Q,$X]GE4WCQ*5Z+
M^CHJ->$R'S$%NUYQ\9GR!-H^>;2!'*%MAZ^EK$&9]]U71K:F)1?J1BD=F=2C
M6'6.CAH4\N+641U[K0+C@C^+:)')R)(*S&-3PP%XTRRU0$]5.O-(N7T<9.5B
M.<%!C?A591I?$^&,B/P("$R4O)=LI$%_ASW)VER6?>CO'HD/?C-VJHKKZ#Z;
M<:R3#<0=(-,4EW7(I@2TCT__P\CCE?!\N/[(HNT[ ,5N#)M0.\(7X2C\B!;8
MGX),^0L++,$K![23 )K\?W\/^[\/X-5NREYG_4Y?X3K? 0G+)\8CIJ2>[P K
M>5]3D[!?6:_S^_"&3#S_$LW"OW3B4Y8IXLF+ZF]\]9^TNQM?/PV=G05&I>]_
M$2M-%" [#B!CX2R!APD[X#M1"LP+RST;<8;R*Y>VCPEZ(EV+Z+&7-^(?UT5(
M[F(DH+7?;??KT-DI/;[ZA].ST#9)25^-RW$:;1.BPE_LL&7>AITU8^?BC'C<
MD)R&MI6[GT=@9S7XOU!,&"0*I@+C,$BPX;S3L)+[\*;;+W8[]5 Q[I$&/P^2
M!T<IB6C;T7>"3X.OT1"UN2TC-7L[F@1'^/D!?UHE!KB5)G[Q#F=!\9%.T4X$
MN014]^R[UU>4"%A6A^,B/!EG"[B=2[>WCU(LZ?T/?</6^<+PQI!5T>/'TD[A
M4%17JEUMXB1=A*V*%;/*VY!@]%'F*K.I4FN5?"0;'**YB,R(%L^@9HI?%",G
M%%N"@NYQ$OW;/#32B<I:I4)H]2=N%W'(^T^+*^&W"%GUZOR '?Z,W#"_C%+%
M3?CR.=FQ[R2H^Q=$;;\><GW?&AL4'WR3+PPWXK0_@@6)Q^J9:.W#K/[8RE4#
M3P:/8/J@6N8U0.5D2>SS1G/W8E!CFP\8UXIEPZ$0FH'P])]C:5N-V#J\?0B[
M*)FW)\,4:6XMD,_5R@<)[:$<E,L>SM=TR&EEG37NS)BB#E;&XDH6G"&@+V,Z
MG&G -"!&R6Y:)GJ,('Q<_05J/KEQ$K@D-&=[.9Z+)WYEV55[R..4K$AYKY85
MUE6\=V)L6F-PB$5O/R)[5D*KL6T]>>/NYEL6)1%<=8?DS<2!6X)34Q&Z;P7C
M"L@_]&-S%QAAI.-2I.TG!]V,RQ-)=1^!2UR-Q]\ P_7!XCP,S;=F!W1&9P<$
M1?X.*[V[#W<ZLW3(L[\C<UET?)@TRQ;B?=3+E,(DI-R/1P:28=5$;N*QE&E3
ME-$'J5#ND:0=-Q]^%^X+.S1.:=UQNV)$R;:$JC_A[YYJ[<=?3T9/7KTEE8Q]
M0<;_[OPCOL7\@'2A0?H80L!KV7HC48B CW?-1\=(65\FA:=_C/3F\3"]GY\5
MY+'\/:SUPK[#)OA*HYJY;'^E7+\Q6SW3^V?K[E DTHRH$A(5R)FG0XFV/.WG
MXPVY_F $RYEZ+%>?1J5A+&](U24MXE1JNII8*\LGE_NOGST/5>CJ7CQ&M%.M
MKP\-XY79/^47GETEF7D1*KL7%M'3::K$G+!F'38<4)PRK:)PD9CA,/"A),R(
M9?SXIY'C0R3_.BJ,_K9O^)LZ _UV RP,(21/G6C9$1M0/4C X "N)^92;)F2
M9[8+,X%<^_7T5D@)+=0/F\=^D6Q(A2 1P%4%,^-])S+G#PMKC9-%&"0O?L0G
MW;OJFS6"^3"2P9FP6Z)GDJ[8/S(RF61)OV^C68J2X*'Y@A(!J!A$P6/CLT[C
M*N)TF%3')C;K/Q"U6WG3KN(X7JRA]^(2H4HD&>-Y&4=&43[++].L%*X5BNOJ
M**VO]9A(Y)7.ATB956.M3L7TD\0\$&@S6%6$=A.H'M]H<%CU8>.1R"T5V=]_
M(]H/U<U/)>-^%E'(%>QJI0OJ+#W!B.EBI3S$C;<):T]9MX-?7I&M]8#_[*OY
MH&,97O^5R07/&;(TR+G9)>*LS16Q8A<K,TD_G)S-X[YBX*K6#L3=HI-+#T:=
M((I8[L&DOW^;L*B7HE"U*=QU5NA@F !.CB263,7]R5,5G?YXM=(^Y>(\XN-L
MFERL$NR72X5HE2.U^6&"S.BC2L +3IY3GC1K_QFGD<@[0(.]NJ^]Z^ CP<3M
MG,A71$X%K@RF%2/O)?1+N^5M(C$^D4RY]0_X:D6:L6T5L+7",A>T9>M,2EPC
MLAD @AD]Z>.U2&YD_2^8%O[?)145&.CW].@E:=,8"(NPZ51VSS6YQ^1\>EGG
MYS(06?0:HJFP0AQ-[ELN9R4;O_V/BBV9.O@.Z&<(.I0+&B@O7/['B,.A'B!^
M4?\=&/Q9[A=I:=JE7ANN&!$ )A;(G6EMKY[:W\ #'B+S"U^(=16!U*,(P9@%
MYQQB?F.OT]D9_&DQHSA-NLX"EA[#585LKFE5"0L -TC?.K[X,;U)HZV!:/7M
MJU/Y%HG&I:@-]_XPSL=X8;37,A"0$%)'@L/1A _T<U=H?4>JK, 6T&-<\ L<
M1>[50&@O1%GYE*9<'/>:LD&=)".-9BUOACS/L@%%&HPK?(?6IAHA.<)?[O8.
MF)*G?+X8W"MYU=YC[<C6)S4='7L:4ZK<(CC19T9.96NB%286L(J[PM1B3:6.
M_,"YB7CT\EUANWBIRTYK/9D<OVT@D;/C'>#+8/CIFW!V+9KO; ]Q2G+WHGGB
M7I@7/0&;I4?WVMG^W,([@#*E@Q.2?2X=$'_L[R:UO7D=8< 7B6N>G^7:5)(+
M?X(:?UTWNK!FQ&NK8_O2Q/7@]6AI@>S4R1M+9I'P6U\GQN?#I,Y.?Y+@8Q:;
MX]=E)=INDZ]1C87'0;9/ROMUJG?#D.&:N%[?C83[.E<OJEAC_D2B#=I(8[3A
M9'UZ&6\[6]-84K/L9Y7-')5&V)VJ+H\OU[S65>K"Z(+.)!6L0D:%ZBY_^UH[
M+$W,O;XFF9@\<'-/YBM'GUG$,7QO7Z)L796$A;)>P1W3.B5D1G5GE!4YQC'#
M'9,J3<!".I#SM$$=A KK:E2*'U9+(V'A,Z BJ2P1@Z4S4T/ +XPCEG&7&@D7
M:RN/8'+ ?KRRKD58 Z(%QOAW7<T-0\/B!2QQFI.$#@?RZ$M6!GW.5QXD*=NL
M*BO7YAB\1$/H$/K-0ACRMT1AH?HA)+$S;#BE'.K/!_H=14+X_;6R4 ,70O,2
M0EV"LM^_KP,1//)EVA<UJ:T85Z5+CT:@X=^NN'9;&3CC?R_MD5[@SZTH?T9N
MTZ8C:,"G[N_XRC,O^6E=58'3D>%;1=:/[E((S?YO':%%>-N)",B8A [UIS1#
M7',! G!O4GT&TM5^QS15-KPTU\BEY\U<!#@Z:D.-40 M=U[RVY_/?_U6"^P>
M-)E(I@S1<_C5+(F&F%Q1+13]@X"-T#6]#6.R8J=+9+F)] EZ1:WA5?2+[A(2
M$>_&I.C@[R($&/U-8C!]:T08AHE-%Y30C@*L'^EP3+%6C]J>SN._M"RZM!2D
MJ;^XT!%WH85"84<;;/'-)0CAL(.IZRW/5EMJG;*^ K?[_[0*^PRVDW6*+469
MW3#.^S]5D%7$#!IM8Q]@)ZNA)-5(G2PA^1G,&5PLGCIOMDC"\!\4V,F1KKI]
M&1,+=IHB7Q%CXN)E5NT4ON0'ISKNXR ,<Y:.X ]V 0BL-,I]5L_BDVFPO=U,
MNQ[NC%^CY!@08>0<R"?V($HNB?7&%3C$)<F\00G&:K_BFE]3Y%.NV/EP_%<L
M?7= K0(CM*[RQSF_NY2S@HWS#*CD%$7(J(/#*4'< #3^^B^.ZEJLWE+[=0O=
M-$FWCYN=+C41L@2?>ZPL,F2[W'(!#2R0T%.3H;3=N8+Q,<):%J-,P@\$R!:G
M1FN(G])(4WRYQ'."Z-\!;.L=K^JGYPC")X&I^\8)DT8&8"KD+*$^\Z[A>O@.
M6T1H@UZ3:A24+LENP3TD<SF. RD;GL[7GQA6UNJPO;D-S;R[]T,&F>#)?:EC
M0N9N.1I'=58,470A]OWA[8<OL3QE"ONO;CXTC)AN1/#C./MC*M5R61:9_]3$
MC&^\LW$V)KO=B-NQQX'?))M.\LM"3R]80\]PPIE.R7X<*,AH=%+0I4CO8X"7
MHN2RS?:L6ZDSHH>1<KU'-0^56NRE<GHIY\:Q0[!<XX^S-P)X%_.P>Y(VXM<^
M6_4"'VH5;YJS<UAR>199AC3E[5;^G)DMR(0T)'BPF+N;0-U*-$M[=32D*>7+
M>;LP:_7.S?K (IFF7E]_>45YLL0W3W"+L-5U;K"[KD_LQ6:G\>[9'\KZA]LR
M2MGBY&M22DSS>"21"4-XX0,F*&(VBI12A'M)X+P'VD]0;.]0@[C_$2K3WC'Q
MC5O^L%P5B6@CP0,3G"<ELXZX'+\1G<ACL8I+'[CE?AKUZHS YMTJR]?>4\>X
M<NC%=7*$<,=1>!/FF>7TTO&YL9@3ZU$F=O!40+=H)#YE7,,(OXH9(;PYP R'
MU4@22X9DG1HI+##79 O^7-+.O\26W(@+UIE'>L@YP_QOM5]J:091\KY/%,-
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M 3)Y?%VG_ @X7OA-/F.R?3>D]56*)M?IH*X>08_E(@EE6HY_?J 1<A*F"?%
M&!ZEL!YX,6949'C?J6M<B4&]O/LHDNEUCN?9F?I)UT(X3C7;D 2,SX6O5VG%
M/*Y=3YZV5I17CN[U^O_)))"=:J\M?:G9_S8Y11"X=SMBU)OPYM2]YB<]1;6R
MWOM!VC+@^B5MI53UO]FC=>^5W]_EV+X[8$G]<H90IZ_M_?W&_/WYJQ2:Q/A.
MKYKK-K#7\T3$,/F_\=3>UY:=R"P%A5H5?-DYV;1J63:@%V[ZK58MY-,6JN1,
M?L^N]"I,40,=1S?*YCH([-3H,(UH'.<WEYN6-Y/L6".>JNZ!N?:31*<R';71
M.91:D7(TA6FF!K6^YH5)LD&XW\^&K;5.?R7ZB435V6*S8H# %IFL0W[1+;XO
MHX_C'@_:*L+N'#'L*"RTAMU?:7M[*2 7Z A53-G%=D<?$E11)7867=!3BT,]
MF_O IF=?FRY2;0Q=ZQM?.(<X6^QTU8>XFZ7Z-]ZADBT_>W)3#QDVRA(?4-@P
MAY5AT8K+,T(NB+TEQX<5<29@"8Q<MVS6*CIEH+)QB=L2G0PYSP;]4*S]5]WK
M1,ZM=4\6^.8V@<T:OV LE+(U  !U2N,1@(U_-6*0F+HA'8N,(BS*I/.#4IKH
M":$;?Z@P6*KW7*Q)!]'6[$J'EGR8E1"]7ZZ,Q%D8I%1K>"X5<VP0F6@>IX[%
M[3?B[92RY*M[J5YNW2XE9XD;H]-]QZNR6JK%0HRE. ]EWGPX (_*>/X#G%3M
M%VJU':M7F(1?VA"/Y$9_E8#F>TIL_;6'SW>,6JM.Z@INR_O.\RO8<KW7%KWK
M[CX52JC)0U<@ TZY(Y!)3V"!0H9^*W_\07IC?QJ]S&E8B6VUCTTV;E!]<'/X
MAD-H4/*=&8.84BC+NNH@CD";7- )?D=[@V545AZQC3-*^6!5PL;VI&;Q0SSY
M[RH/V[=Q))PO48(U(:(WZS4==.FX]GXUZS1'8_#>2.W*5^+E6E$RHD.KZ"/(
M'AU^Q!3_%G%D>,?+6O(HS0*'\P@H+YA]*0;?IUU92(G88\BIC&'O+K?B]_&H
M]*P[;+PB9N^7 ?PP]G)'8N!N#14#:C_F-EV.E"Y2I?<K;MJ:1&&=0I4)GD'&
M3":?"U9@(5[@6#=W\K%PE\TYG/D\UM/XN[#%I<<%"9J-9]QQL 0F+J7:)?N
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MA FJB+LQ#+K.@'3GQ!+3%2[+9_')/6R9[Q)3,&-_XQ/P$ FKN(*T8I>GV\C
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MUI&=G!.3"5W;'UN4+3)"R("MOV'=FHT<V5F6T-#SK"=;.=QP!C"H79=E#%O
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MR6O0<4E>(+[OBKK/K=ARQ3S-7]?0*'EN1A>WJ_)59?N6/I#1,69$>^]>XY+
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MD7^KO5%K6AV;O3B1/Y,VO3%7UBGI7I5 $W&9-D'95*]>L\A 4&4SA<SQ'AT
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M)S4-@B"^W+/$;?/MJR(^ 9;494( >IU&0G?5H:FI>8V,[_7;GKH%=PP%O^C
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M$EQBQZWWWRS*E*>[63:)BE-0NFZ2(Q]1:])+:X]'<Q^!T^ QYMXQ/HNTB">
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M5^N?S%G 6ZO ^DVJS%FK=]JX><YQM0@YU$A^'\IU[4A"G%\@>/IAU]*RU,(
M/[:AJJH!4T;")ZLH\VA(U1<:85_L. ) /.QOD!'[/]S&VLUS%O;8'3\<EJIW
MHU"J75]CH7(;X>'Z\XQU$9UM9?I:F^7Q>1EV/)'\DE.28P4+G#%4$/I%-I89
MWND1QK^K5E !-IHL?Z:<^)J)OA2*HN^.AAC7TCU9]4LE^<C<A@D_M95.8/A$
MACZC_XOLW-CX0J1(_!?#VL,$365XGA2:]ANKX>:.82N+S"2.DHL.]S&1.\R=
MMT;V ]Z134:2[,,$^A_8':*<((X,F=)/IKB#M*X?%2M7@,*L:#0FC,B$,&5=
MT??VY*<Q]R?D[/&?VC#9AYL!(I]MR4^YH<2Y?/$PQW,3%NV5NDX5O73,YCOL
M^7/#$O-7&I?@%8R7SA_(VQ30UU21X&U79R:(?\HDU -5-K5<BF);'?'WPWF]
M#/9(3GM=1UC5QV-:9*Y@0/D8V];ZDR0J2D^JC1)\HE&9?H$WPF2"<:(SWY1N
MAHT" SQT*K..7HY!U@X^Y5]3*,:ZO\EE;[WL+T!5OT:Q^#X9BX%5OK*P2K>*
M,2+F+"L=AC3HM-0Q2H<^4]N=)L6H69;,\G%0 5[@#2H>\#R_.W%P4?7GYYO1
M4%_\DZ[5C<C3J=G7[WM&O^9!@4UFWZ_?X]V6_SQ$V919QBZB"@F"$\G-S'69
M+/>^1\JP83?)-J<S*[>0?COB$:U,RLK'R;6"IT:';8[^UR7*2!?_43'+C^BR
M36&\UH3Y1B=H]N$G5DI .,KC>@'/&MNMYN.AQ?IHWSV=]<WNZ7"N?VB>6=,N
MYH^SR_A5K !,5\7!2S6:5K>PN<  447(CZM*8A_&D587&@G6=:'M=O]8B?XR
MKJI@FTQ)/(Z7.Q^9]PQ@>[37/YO^E-Z ^X\HG<)M\G8F8B,=30)'C\55*2T.
MF7>D-[S#=&<G7TKV0WYNXYF 2'H_$U]!+5:'#VA'Q3Y)HQ+,TH['-/Y?WY[6
MW6S/PG0X&"_"3XK5#HO-X?WS[:"7)Q4]5&E0/,B3%F_^SQ=@!E&@OD-WC-!?
M +J(T,.G&]$5W*G_!ZH?6RT#ZP5.Z8UZ(AR<B1KK<]KE]1@LMLZ7ETKT<YUJ
M(% "BQ=T7N0#^0?+CI9Z\^*5$X[ ]:GG24"S5^K1@:O%_57<3>"PYDUN+7BZ
MZ+:$]N)\W_>?1=YS>X:(,Z39.9QM\QSKRS,+WL/7LW' D)E=0?NQ/?<8IG_N
MH9]/L0C2%,=P2=,X5Y!)-]]TAY$RPY?%/FR@F-M*/;T=@I "TH>?%@FQI[/J
MP"UT&FJT8BY&JP.[>O_GC1KNNTRQT;EP9[0HN)'*F.O+\R8;P@IQVAX_6V*5
MSQ< F;+Z<,VY0U?W^]NT-'\B9V^N?O&AYRSOWT%+'XZ)Z>GZ^<#'4Z0;F8&(
M(BGRM-  ?.IF,=E%P/)'T7%DFR='+L[_O9>00R&VA2JH"QQ'!7*V6!DL(6I:
M'38:!#F*%GG-DW2\BN0< G[ =*5]TFQZ7[L0.U]EW>RD95*3LS1V1$+N%,'^
M**R7H-92S5ESD3-_K9D"TJ#<5OVJ>,X2)DB0X ?J4DU;!\%+1C,[=X$7$U9/
MO_  GOZ"=E%9^,\R>2R\WE-8T@#L#<ZX_V'!# *#<JK3@,FFG]-I?P'?>3F0
M#J"#:,TRM\V/7+@"[4.__B!G*]K#SP!_J+@9<3KX9=)8A]GF92=-3F8P:!-=
M_W3,,78@EK&ON7A0RH>!WRJ LG>\-C#8OL&@VV0?)[*C4G!%RU:Q0FA2G;M9
M7-U5BW9RZC+D49!Q^(29"6*8\/L9\:D*^V]6L%W?+ ="+D#4H""=C%:!S/6Q
M?$*MBIFXW& Q^GXY&Z MAX9#YO4?G5KL'N2E*6PC=HPA,LL)DO>24=&RFLON
M-%.AX(\UQ U/U$8I LD?;#-BQ_,-UAG4\GU>2>.6=I YQW&U0NV2276CN)9]
M\(3YC:VQE:QVFO?(;6P#$BU;R\=_X<%:*JR+V&;!:YB-6UU7D2S$CF@.X:$*
M#@N.,:45RE(7_(P9U2%;7/1, "";10ON6]Y'>XJ@:Q6W(F7,%MHC=R^6!>EZ
M,-S2;J 51&Y8.,:X2^.'+FBA-"R4'YO/+9^([NKXR?&NUV?%/\1GB1!Z#S?=
MGM2&,,&A$M\1&"H1YMF;F&5=_.-T#6OUXKURNB8*"O4K.("9E?\8(B0SU^IC
M==XJ1EW]7\!<,$3H;6N$JJOK'J%Q@5GD^>@F\-[#[';<*M(^Y#-TT^8J8XK7
MML%2%9+)N9HZS&_73WK]CI\HV1'=8;Q01I$.:AF^?)%'@Y?IB@Z^_?Z:]@MQ
MQ=T=?/C/7@Q1J)@Y:H(N_TJTVO[9N<V89!'_,8/J@%D?(\2M6O9%-BN=O*Q\
M[-MJ4L]P2Q7)&HI1Y$/5M0_G+OXF=VV*.UX]"<5!9/?59[P1 TEU&X]@7Y_
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M "$E6^/6Q_,'"7YO<?,R!I*>X;W<^L?A6[Q6Z'E5M#=2;SUV*FGT.(JP'WB
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M;J;;P 18S0=/:9I4[DN=I B3SV>'X@W)+1\8B\[;F*#YF,**UZ.Q2]^^ELX
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M*M : H=>)3%:C#S%=B?<M5FS;<IY[9B0CTQ^..%1JU)[1LR8UVWLNN_,>J+
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MB*].,>-EZ9V806W5A;GY9#![G:L\R(*M3N57/-MU>(CF*D*>[2SIN%08&GV
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MZ.@4#!\0/?NA=]7@K7#J3^O2$^?3E;KA;N.;[@MXD^J<XFK3Y,L@Y<%3\IU
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M<<@]>@X!TE/>4K=$.D9PB7!\Z V7IB%D12R U!^<;+YN^9O/*'\!_]<Y\%\
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MB4?]*%T4WZGDTYJ  ?1!F,O/R@AJ;PJ4R-5L1-I^ S#9$*>(5T:7Z&XR\$\
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ME /!J2\$N,!"@1N;.)>*HD6'V$*.RIY[_OS=&KJ/]7$02K5>K312A"[7\JY
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M'KY:74FQO.SVE0")=9#\)K=V#(JSZ9QM8?MM=38(.I9L_Q:Y/8\G?6:\YV.
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MIU>S3(0_@)/M_(I9+S.Y2KY@/SC7ICM+'1)Z!N)Q]!2QY<B?]$#B=D_@ 3"
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M*5>_2LNUZ=V@=U8_*4!;9& 038V" ;3A]:FT-9KJWB&1&QFBV$/O&<#":7O
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M^76<,' ]R5YP&;\<5G4HX='/]IHTPRHU*S+[;%TJ'NOFF2G\O8WLDX-*3(6
M4%."@.5/#<3E*ZVI-P#EJME$AE70,3N,%%\(M1.R.XMA8=0BL.!%9!O *0:*
M00VOEFA 14D [ZV6L>,7&UWIY<#D$6G4Z31I[*+5ABO%);YX%E[M(BW&?1NF
M!2^3$2F#+%9_D\JACBA!<6KP/F@EFJ.] ;@CQM(9V[7G$?E[&@UB(Z2M2I11
MNAQX?Z@\O@&V!Q+B1H$J!3N/^#1[D.8VY7SW/90X0?6]M#:E%ORU IOJSX5Z
MB!%*!%TT(FJQLO4[E?@X #:.KRV2+)G(>]MR<XA%9E4[ONK\C<-V50:6P'A)
MS2^K=D&N(*FC-D8J#R#0-U")+GSD2@!^J$SW)N,Y?S_<@ 3_U!V/JQ@$L*'(
M])J"?B5J)NBX?Z^QQY\_70WIO##B1X22[8LRUB=-WX3*'S)]WTDG1XZ.,F'\
M<BMF'U/&#J)%G%27Z</]XOY*X>"U"-UGX\M.=&F\,@M#& >>U#(4[K7468*(
M)?V3V]EY^2,&S6!S#1Z8F42K'Q.TR_F0O=$S&$68R:0!^*Y&'S'_U_P8-IAB
M>[\W&O&@'?\&B&<D9-_9\-X_$_8]57K,7GUXKO-M\"HPR$7ZUYXH8G#J<5CC
M?9@*]=DQA;Y<P9=1Z$E"</]- DCR4\BJ_4G=9\X/X9^U6412)L7G:U8# VJ$
MU$1.7W7O%1(*_:XCMJ-_*Z7S"3QWCV]D6BKM5;@A#N.BUL46WLP2FKOY\=+H
MOFLZ2IQ.M(VT+/.OV. ,O$4VU7_XM;5980]YQ+4;5O0</Y;"QIW<;*)@3UZQ
MXEO2CYN85Y2SBAZ;;J[L/F!?RRR,8O<+G5:U0JIVR@P%^%2W8)#3U)KQ$7AI
M[I+L<3?+)!3+Q#**?FO_T+&+$$4?8:18XXF$\I+V6Q818[ :<);3?<WE']83
M3GT23M%B4\=[3-J/ZP@"\@?>&(JU29-]97)JLA%"AF.<-%I83M/=U;G#+S.Q
MC$T2&53NIZV$F]F[939+#?_GD#_*P7M]\]P'"87,#H$?!08/4RWJ$Q(MZJJJ
MIEN$6M1*+U;[$G;8MB;==$!Q*T'%]<-"9TXXG;3R9[*73)I-K%-D:1E>XVBG
MBQ131Q4[ P870F:+_G?_UBK!JANJ1-U0@<EFBK^6,V7=D">#OT-'GM#W/65]
M)%PN7[ZCE3R4^.$)AO0^3WT.=0MU'B;%S2O<4<V/RSB76D/.5)0?O_G)86P[
M4EVY^ABU>#PT8JC9_Q+*2,/%MM(C-YBLGALHB/4]I'"\&:ASGTD?L"@QHD'P
M<%E]]?=+G.C::L\>>>TXXP(#DVT2_F2_K$20EO[J1$+.V\'-![%4NY,T+?QD
MT5Y:U6-K%[2M3NZL- A%0V4=S"I82HBQRJ0X?ZIY#SYV^;E/U/X&6/B$-VTF
ME?4&R/E1_@9@ F*_&"@XB&K>HFZ![:*O:(<^L>6>P!(H]N+,YX6M-$(Q9/ 4
MZ5H^VTZK2QL JY0#(4Y?OUXNCQ!XS/N74U3W=09H)TY_1)6T:,T_[LKCQ[S%
M=E1,&+[Z%'TT;#8#3,CV).*Z L+9@_G(\>K#.6OD]FTO/Q@35G:%XRRZ'D2M
M\>'>?\IC^%B\5B3?(-N)N8LO=O6%>8LY[I"IZP]&4GR3%Y?=&#EBTQ_%/]\N
M>XIC8;&VT+H4GA/07/4[9XRU.C0.?5WIIELT?:Q[V0+4:# >?8J14M4]%G!5
MC!'VPW*.LV$^3MRF3WZ6><L'=N,9DEQP3N#S 5UZ:7T^P;OA.!7)F%RYX,,I
MY1=J6YJ>9[5("-DR;H:%\'GVJV);NXV@811>DQWR0&Z$N&%,B]W9_HS)!IZD
MW<'EEI0*6BA?E\S5@$MN'DB@QI%R)!:F(4(//TLHE%E.>48]J^=;"J8DV)#T
M_(5EMWJ1'!3E6IEKW;7?ML3;DQ6'%U1/+"^W>5%-[T7T?E">5;[BW(&T3C<V
M0[>(PRA-!LV@$JTODMF7F<3M*T5E5NG=UC;P\X:INY.1S6=/.#N'K?;5;]MI
M&:+C?0P,*:0+^8^8")B!9'<Z&>Y&,30-\F[2"0RRJ)N&1H;_#J7;(2$"Q[J/
MG[.<S^8W/Y[!5"&:_),/EH6BE%[Q-H)V"B9YY!EHW(GNH1C2X_^,P9734SBV
MVIZ=%C;[2R1O=5!AP,N3$.;&DK.8<?@>5T)+17 18 /\$)'C)62TQ!D#+XQ8
MF72*H2@OQR5IXQ]CTU:N3&YD=VJA8U62CAA3I5ODVT5PH"[0FT81T"^IU.%E
MM_F+2^$:J]C%ITYEA0F-*><]?IM2:<;+YW._TN8J$Z3ANSK3>E^S4#[8LOQ1
MH\/QP3,KXOFR&6/LPG1B'MS/H)]7@JW?:6NZ6;(B>*0HYDB7NR7SA'VETA<>
MTHZ%E5)PKY3UX;)FL$'DP+E52+F>\IFZHJQC'PD1N/I;.<NY^VMN7@]%[T'%
MXS$HUDMH/])KA]U;8I9R4;*M+^FD3CECUZ&+CAH[2H4<#'FEHU5E% Z4GK#*
ME,_-@K,:C$?1;14QP*!-.IVB">IRK60RI1[VQ<U( BZ\[T.B) D:(VUY7^[B
M#U*C7$\?6C.;&UJB]EBW4I=7J;>)8J<!%C)T?X'TZQ=[  PB$2(/ME6YC["&
M\A#:X$;VE.8ITQ<9'UZ5#Q)$+ <YU/5\S!(+ N'28O_DFM#X80TW-;@8;9E$
M(.(8L).EUMZ7G 9#^H+_J_RL_S\*_Z\'[?T?)?AS:YWH#/JXI_8(-!5U]FK9
M3FFR+/]:DPDC2: ;-:20$1;I!;%'2KJVGI#?F/[I0=Z78TOH$J@- :;S=$!H
MT(H; F0OUNO+27#Q;='EZT?$(G KT>3O3S$[H,Y$V+G$"C_(L"^&..-' Q=!
M-K\.J3U.Q._#)(6^WTO=KOBZWFX>Z?L&7ZZ-'WD_B?V5^?SYUFV:]/]$#5;C
M&;'Z.<:Q]%XHW\(\5(;KYH#I2-D?;!DX^N/(2O&+#(K^,,-!0>C)=TU VN@U
M2>%6)#V9?_CHSV4KR"UUO"21?5"9 !%]+JJXWG863!O9<I+CV8_5R80",:([
MNG5SWRAY R >\*5B( &8B&@2WZ$HPH4:X"#!F?3_Q^'L#D?!^6;Y[H';"?OV
M_YXFMULZ)_GJ3U7P!KAIWDS9UD+6]L]_[F42$X?DNDUAH5B:]RP:,=;Y\7_>
MYD T0[;1,(*=07F9S/=TOOS&/=H^PU-(W*DVXF] 1@99=W&8&@44Q[I?OX^Q
M#0[V;QL5N7Q$J$%,@T0735KJVK4  X'AK.S#$.:EYU%\EU^+RCMS':4)/_N"
MJTYGG<TCJ&]2M@^PY!;K^]8X(B@LOZR>-'[O3*KEF:+.BS--*ZE^^8D"2B90
MRZC/_ D1%E'>FQR;CV0B8MQG:=(W6REC&XJYW DAW_[K>\MR\2O'^S&LA!KL
M8V,,8H743]]$04P"L5F_+3TPM7QF"61:O/<^2;^O+6RZDJ][ALXD#B (5$=J
MAU3?80SX[\_#G)F<AWD2ZZ"HV_&BZ5;CHO!BO]DM'0JAC"X.V\W-.51ZM4Z2
MAZ'M64AT(EOJ70KPJ+O>V!RE *K&.BQD'+G2@)Q<<NM3C1Q#$C<#RI2^RECR
M7\SIT&TW=XJ.HWURZ0.">WTYM,J.%I/C"D#XQZQV9LKZ:^*F\+5.PX'5_MV*
M$ZI/>"N&88)A(W&NLE3>.OFE=9[P=K'YRM'(%!EDZ OM0,%T<&\ ,X2]T\+Q
M^+>EI"7KT?(@4L;6&P#.ZSS^^N2'W&CRV3'2J//6N-3K!%;XIG*^2[S^;(Z^
M!N_3P0VDSU2JQ(*126FZW[2,98)#"TVM*VL'[6"\0S; /339O$A*VI>=WI:E
M$N/%1/R4B6G8BU21"VEZ#[4/)]^4O;"]A/1T=#E#1'2[HXOD"4\O:G"PQG;3
MVVCI'XIEY">K"BW$04_(^MX?4ET_J?0SX'NXX#OK*ZGXR8T]OW.S(:HKF_G(
M_05M 1MCTLO$OKQ4D?$=M>V>W.W$@.8(X%*^'0Y<<(>#T5E92.O8J-L58.#3
M%B9;T1 /%O&@L=M\VDA"H=XPCWIR.YD3T_>QR\M9<"U'S72GY=*Q<0XB2Q+!
M79(C)AX-?T>5NLF,+"(C3M$TP!(UHG7@ZJGGC_;!6=E1\,P@B='*W1B!ZP]:
MVWZ]Z+M!X:\B89\#:565D)7K2L*O+GXY"FA YE!ZQ9?*'0 \WN)R8G_VO'"V
M7JZGH$@DI?R])8_O24=+G]']Y=& TUFOC(RL<>5!6:T$87'^]L*20D0WD^!M
M/%:.N5&.3W8>=D2T !G>+UI&SD3?W?V_*;*$*: *8Q!'VH#SY]0YE8>2UUP*
M(68?5*8O4E,9>8@V"8+,%HI0PXW49>OZGSAGG2,E1\[9>:CX1#RVV\5V',P6
MQ7?K1NISLU/<SRBBJ9?4FE\-T_\H1\!FJ*[MH"VDY&*H)//UG#U#2G[:,@P,
MVOZ[V>Z5+@<K&SI2VX[K/LZY[FGUVI(FGH._)0WT?PR,EZ;\)J(FE4-W]]5+
MW82,^/1;CJAA3%%!"7([>SQT[!&E?;2<*SB8TP7FB*,.2PW*W9"?*#Q;QK4=
MZ#K]:3 $#''"<WY:\Z,AR)O<_X6?*54WEFY_#D6L?]U%/-+V5&[_"V$*N7$C
M?P/@?2Z"]9A\VAN!QCQI7S!?AF17B7465:U_N+CGZ73\CIP]V#;_1\/"T\HT
M-:9 WY[EF"(TIX09CS8,RC <?EN_@FE3P4,5=Z)Z9D06<&>D9:0:T :!*WOX
MV6OVO-7]S)UZ5?J]JZ\Y]Z$%^V>+7%&'+C.Y59; W@=\]> N20YW@ZDJ,*I*
MV@T/Z!"-7PV_/_VLW!^^BY\+IS!?^)Q%HF'KAWA)6I4:@C_4HMU0&&SF9=B*
M3+5TGY^44=XPBC W>O2P/*V[*#(IKGE^S4:!P?[-B$Z#%@5; FFI*"5(T2,"
MU*1^SWW%"F,HKF7WM&Y'G<E[[^G2J4I'=IB41%NW,(Z<Q*5S-./C@B!8K+Q7
M+UK)".%TQ"GAZ<<O;(5Q@R+T[-7Q8X7L\2?<S0.AOU;+XSSI#2/4+:XR2_6G
M+V+1E,TR?7&9*DW"AEJ':-G2.%0=T7'J:$IG<XV'0BVQK,I>TSFM(V#F=KG"
MW>039>F5"JAK>,0H(RIE'M'";0@+?'B='9RHEPO*^F:V#XJ-KV>9M?JTA3P5
MN@D5 TTB)LNG;X !BB*7-P#:\^S7$/3CXT)"NW&_2LMU?#*;BX-[^V@M5X?,
MGEI!LZS[\5_JTV%6:3 BL:XB'WE_(0^C_"OUHH5E<>&8BYX)-]IE_O2"%<AZ
MP>D/\71/TOJSLR_-+"\JZI+12OQCO-'I@SBI:EX<QM$&8!G 7)[= W_( <8E
M4M_/'A%W5O/QD?O*W&[8: _"&R"5XC==@B6"&T-,SV"K+_[WJ'")Z>4OB5)W
MRN6'F=&"<*@5(-MBQR24\\6>,[)/B4&84<W95>WYP+CT2QNL$*$!W6ZR[_BP
M/1U0-7VTF!<(FO\+9F[9[ZM>5T&\SZ ^,AL7X!YF@;]D"Y@&>?21!';?]M/]
M,K>0%.M,%H"M#J3OB:=^IQC;PU1.9PC,DB._DFI+G1FB<>=(8/>2'T^WNE#5
M!HLOI7_4C]X G,YC.X,:[^+\4-\ :RMO , 7Q.;KUI>IH-@0)L>-%SP3S)#>
MY)X_W9\&%\"=VZL*R5M8G5]-(8/;W.+-\K_3)6P>;=HXTM2CKH)/"+(]0?7N
MG8OLY1Z5D67%\)XG\.@<35'2%V*9X\B0X(H' T([]0FJ_KR/+%X#X+_U3<Q-
M2L2M$J>5V4O@4I@:6[\K3=6 %3P>H6L:HZ**0<^Y:U[TQ4V<%8=B7I+MLT!8
M<=*S=<NPQWCAW^:Q,(2NG6Q;==WFV>;!K[8)KN47&@ @*_]:ZNJ?2K)]ZP^Q
MQ"*78)H%_PCR[5/K6Z!#===O2NN(QA5*J;&CMF1L%#?-WLF;J#;ZPGRRRO/8
MO% U*P5/Y''E0:L$'VGX>4C_!&$D1#F9)$2=LU%$6/RIV9_1<T*D!#-+:_ I
MJY$_Z+/\JU2X_B(^^&O2;4[\#&A8*3RKQ3^,WC1LE]' $HDJ>2_6!@6R42]C
M_5KAMB>V_@9X_!X5<LP=S4+'S/'II%3T#4#'"?]WZ9@1L?72NV[Y.EYD=_[
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M6:DL[C:*]MYG"-\TE!P@6^Z3UR(*1&&M[;*1/;'1?2.3<#OB9M[ -1=&XYB
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MV6R2C#[D"7#+'4[M93 'VHHQ.OBX !?6+4S)!6)DQZ"'<'U,3>CP5WIZAZQ
M$"7!RJ :/N(!&V/?3^<4A,WZ=SQ+YU_"@Z<'%RKYVKQJ' KLTV9)= @R!348
M1P,3:55V,UJE:!EMU,I+^7?E/$"KA=99]&&R>AIO>9;8QIL%6^F.=>!3B@V=
M]TS,>U;M[7(_O'+NF3GIJI707D\.AY\VK"O6X.6F^7**S.:*$)/H.%F8N3O6
M\AE5?<!Q.<'I*!,<9D3)%^<@,@BMUREB& +!"2'9W[ (6BK4R%212G1SF!LY
M&KT.1F-;M9UB+'=A+OE2V:>"DV[@OCM5ONIX-RG&T8NG1)H#6K$/\\^?::12
M#&WK@\?9F%7!"QU!U)L__IY[RV5_O_P(] SF#P8F=_L/29,7;@I:9+1G:O/-
MR(_S[-H2/2@[>!7N;D2S]#@5S1]2J1V1QQ@A9DU$+--R93&;C)C6H5 *1OGX
MJ?R(2ELI (V\18(OS)I:7TSH1,&K?P%KE@?'J1G3_(PM8BE*XO'I0\S[#L>A
M,H9P?X*H=0:J[!]K^YDN9#_I"DEI^O; W>4284)MPA>H;;8]B]Z8C(6,-PX1
M[\H[$=\OE2HNL3NG[,/4*QSHF]K8C4)7AFLV,>B&0EUE8'V4. 1?(0Q@O4JB
M"@IQ<Y])JF$O ?YY,>5JW8[X-YL<1>HH'86 +*%_ ,$I?B*(T# RR2+&N3V3
M( )P'=D0.GH_)++)PQBPO\\O,P)</S>- 076@PG]VL=_&!T_"!7AY--^)B0E
M<QIESI5E]D(_#6Q,P-;8^ 7593JB%L!B8_G8()LT$F"Z>X/.[<^/4?WTAEMM
MT)S ]3/::'";'UMSOI!#.)^:#WO+[I0VKT,,]%C1$2\2Q9!7\&:1^&'QY!Y;
MD!%ON2-$X#J^=T%QE=-)"(EZ7R+C@H5/VL[/G[V/>TS7933_G,:ZM1$<!_)D
MUZCA!M^,RQE #+XVZ92K*"O;);.IXL17F7_\+4)ST(WUH2T#*?9=\1Q.Y85E
MWC/7 H.X0-Z^+2R?FM]2*31W'\75'TRNV4S?:<'=J"H,_:2+ ;4^O1"AZA(8
M0S+3<__E8B@^K0PL$VN69@F@7Q-/8VQP)K:PR:FY4(_J4O*BPM+-]C]/4DN>
MR\ 6.1S&2MPIF:>L'60E>:_S7C:S#:X![5%F%. FR@KRY0PH/F2WTQE3)%:.
ME_]XJS%$+S9D+B-K(5.T9",O0X33I.A"[6$N/;-X%3FB=#*ST1PS>IPCEFOG
M/_++-WVF;#80"U_MP-U*2["(D??3$!%7R!Z/I>!NDY)W>D+2NT3>AN"-LC^E
M=#Y[*<D,>_?ANY+577NI5^G\_#\(6#Z!V%??_-G4MJRK.NBS[/++*W+I5<T*
MM;2=XC-YO+7EO'& H# &H#^^ING_5Q:$_K>V<^#E%]>^9QN1.%JFDCU ']ZA
MR%?VI6%GD$'A2,?Q)DY08HGUL3:.VS_5Q5 /&D*P506BYH)]P^@2EGHCUB65
M-L3!>PW4MOU'7]R618OPQHV]Z7:SN+W0=3OQ C/@+(2&8T3#05:LL1WJ*NH4
M6A4\B".&8M_;',\]BZV*JD:CE7_AS,VL7/ZH;M:N.7V-A_)UK]C7P>V.<02[
MH3;8Y>C1H+-83$<3VZ!QC  OPYO\P8&V,R:O\%P79"7?,W(CW&[$G;![Z[]4
M>-52G\>;D\*%,RGH5O\!Z-7YB3]-M_%A4&*,0B^29:;/7+FA7I,"?:Q*E];L
MQC7V;%P,4&N VQM>V\*G*W_A.>R5;7CCCK-]RT'MS&=0EJ+]BK2HT%Z24TSU
M=>U& E%*)06/3@J#)JZ;)SNARK,363TS2BZOJY;46"F533T!UG]&6[*#S&)5
M <-#G$&- <G);KQ<?@F^U=6?G2'=8TSC7\I7FC@+U=S-MT;GA._8<324P6<K
MA3@:BF/]#E91=_>NQZ@53N-K@-"&TP?! <:Q8[]PZM^B.V$US_P9)<61E66V
M 1IYGS9UJSQ$Q'SQ8,'>XBLOLJDEDMJ;K\>NJ/+PT&)WDBMSU9V!'-8FT\UZ
MYV:'V"2[-86!^+;/A#W-PU]PT<_7!.JR5#/$DE*^G2:8HI.,N)!Y)C%L19XA
M/#W*6<$T62M;."]\O#P( M_KM2D,W&!'SXK0LAK_LLY4&=YAR=@7FE(Q4Q7$
M6*U?H-?6L\CX#YY"ER@B,&B/E98M980^!GO=\KC__/1UX(F7_30KK!.IZN.
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M*K"#NLZTM/G&F'.>!R3<70&UU1][V^#$OZ8(U5(=*1#D8?]1A\&2 YH\(4=
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M&)\:'3_BU$ADWWFQO6/=C2E]*JA=;-C4=AO-OGF2OF7--=PI(WNLNYDE*CD
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M$GW+- S"F^1[/&DGM.Z ;9UE*J7-*DNL  <$);+ W,*>-/E\4X6-J,GC5M^
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MX)0E8K:"SX@LH=;#VA00MQU_G4? T44MB/A9LJ*,$8^U ?M4U_$!$<SVO2C
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M.S?D^_X867YQ,?QY&FE')./!=+M'3XZI9';L 8Y.;(T1_Q3OT.0'7C<7I;\
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M<MUFN>S/L7GF:CN1TX=F[WF9YR#2#>,RLW5W6?$ITAI<!&#<06!FA5S@!E5
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M(8Z(]73/L :L.>/VQN5>;WP\;^S!CT5!'C/]+U[M'M-W1<_?MD+6H7@Y)IG
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M"7Y7YWSCG:.U)#X;H&?TDT1XJF+5$G6 >F ]O^0=>MRO>"=#]J1A\G%2=>-
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M6W+@G*24!OG:QXHZUW&E9X/%/] <O3!/L;MK^%P]4[_I]</[9G4F8U(A@$J
M[W@2:]-PIML+A]XMB'G%(6K;1_PC2LKF:(N(YNIBE\:(0H"7 !\>%?\1R5VZ
ME;;U8\VM[/I?0'^_P1X\)':VX>6W="':1VZI^D H3J='*.[KD3'!>DC=:YKO
MNY_NVN'FPZ>&?T(^:;R9!QD_I-"X[+_2/8\WLS3_UG^FO?BXN_OI_SI(_FOW
M8\LYI?3&X"_Y__%$TDA>.,5F#X\A L_@2^"J:$A;Y'4\W^?@CK-.SO$K/;8B
M,Q>*S:P1RDUT*>G\BZ6P$8AZ&WZY&@2U)7TLBIX)+??<<L?,V]O[?G>%Y9C;
M8L>W8?92JW/*=5C4K;/%IVU)Q$Q:0>-9EZ.F.71"#)8>,"=\,UW@XN]-<OG,
MI[AZ,IH1^&0W[*UL.%4=G,C]HTI<X@OFZY\"G(=W[N_H^AM_+[]/6:LYO9C_
M6/<[X!GKTF^W//SYMR#-6>ANJ'R0Q5-M:6CH#,K+IZY/:;MK(6>L-)_:9-]J
M+D^/1#KV A-0_@7__QW$ 4=^*GF7QBEXS-IYCQ3/.]5Q64%A]:X04IFP^AV9
MI?\OH 7I._]?P#DJ^. WA?M? )UF^^_%^7?U=-#8"]=OK]'"2S_59=Z:8ZEI
M6CK_ FX)M[3[N1!>ABC]0\>V_@+&]5VE[]MQ_MNF92N$W8NHN&8"[PIX'WDG
M"C]&UD"4*:9H\?J^8HL][GI^H>3,$60#"IMO$"$*DQW.:7Q?+7"FL)AA53.Q
M228:PS5OB8F *:=?<74O+V%*U%R+A P6L(R-4Q--\N.]!KD6V;DI%*M]HF3,
MF$CHI #^(,V/.#R!>694$$2<E\G(>:]*SF=:F[/$/D2)7O])[OH+2*O>#/GA
M2+.*"QM^%-Y[DRMT>JHJ_6@LGXJSOO7Q&=VU9C<G_(\UMN0[H.M?P!%;YZ=
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M=!3IG6SR]#:=RU+K+?OBM5S-&UIF4OL**,,D^"8SQ'D82[.#J<TEV%8RM6/
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MS4(_KH$*JPL$09S,_;VD/[]C\RUL,LW .??83.=4%*/]:$R%XJR*TLE"M"8
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M1R'XA9ZXI(["[V*=6W/_X8UZL^K-9^P'OWXWR'"X:-?+,:ELUE7T S:Y>MZ
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MECI'"JNRW<SV*+*B.YC1T29E5=L6X#1+(3 J8GJN_RS^6%V8@ILGMM/<0BW
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MA/*04^<T;F12A/-O&HGR\7B+")MO<@? DB).;:2(HF0/HJ@:1JVM)ST2#P1
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MZ#8TY^2NG7<8DV^)7,XU!YCF%3[EK4#Q!+9S6LE'JZ_C'0\NT/Z>K'O3_4N
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M7#E0D37)R-G8R(@>M;W(B2$!7)BIBWU 513OSOI6QS%:V^84FZ+(OTW C_O
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MP90CK3(KU'?5D"SM$NYBQ?CJ66MKQE%[2(A.N+@UFL(5@^-L5U)[03-??:"
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M-7%=A/3)E7_I[N&CRQ9Z"N9_O+\*3-^_,I2->U83C:[%0JZ!XPL"%PMDCSW
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M,;Z2PT-]<>?4W]LO@FCS?_P*Q02Y+(P]I+>J)98*G6\I$2+K1PQ$YO2H;!U
MV#GMR TGHWHF]&65D>P)P=$M76LMWVO*WN \RQIIT*5OY9'Y1G\]X/P&*CI#
MTKBD#9-]F^2\.,V+GLE(5$I@R%*MI84#F?^E!ID'6N(K@,T'\2F?OBYT^F_E
M,L<!>->K374(:5(-F#^(OC&-/5%8S1X15*6J2CS27@3N+TK/H7@ME6L!MMI=
MH&.\($BG6D;]B(B7$7WL6XMJ#5Y#G?KAW=;<O +^S9]9L) ,A36"+B$DV.)N
MG8DUILC FCVIHNG"]S(&$J#;P3BP=W?;S;)CM$$]0)%-K/>HH4PV=G\C#Y*E
MEH+9,9-8%&ED X-*C  3U)6#@! .I#\ [GU\%Z+"*- D^3Y%GN6=A'OZ>O\P
M5FXYEDM$T8B9<; ,OAY^ ^0IB?)XU1:!200PL\;C#.-?^+80M+&'#?9OFH^M
M.C/5.7\FTH,(C66;Y$I/7;.BB1L_G.JMW$J8KG4T)?T#6'HR(_]'_-Z[9<49
M(M'ZZ+2N"4,VR1FLTZ*D:DN#U#"%N?GP(O/];L(R:66,Q//41_QFR_MD@^Z8
MH)U'!!HC8)A\E6P"*E&-!;X1ONABZ9^FY[Z->WS#J\QC1]J7Y^/OXZ&P?,/.
M_RN;J9KQ^$O+$]<\;1J_9?#;E@PMV9\0DH\^U$R6IH1,GI2',+!!= 7H>A:/
M"W.S=#T70_0CIT*5EM*(81-X9P]Q*5-5T8M4TRKT%/7>'<3+'XDC;C^I/0YT
MA^XJ818H:@@\L @[B53*9DQF=A3[C\B2":J"I\^3RE(C+"H%<W\SC%U;AK<<
M;?-,!:FCO1E=!M,/NUSQ9"6'GFK'-Q5@ZGF.BRR55?\F23IGI<"MRS)E:R *
MMWL1-V7$[3E/$OAJRQNJ/!J8Q[=,A=*<4H!S&F%7_<VF!\9F2W$.]>\F$N?O
M_JQ\%&F?F+V&BJ'I8>X(!*>UGV*F5J&N:?E#_3N<70;.B//'UZNT\SI6%6YI
MTSL9_>W?JWJ&SPT&.=_I0?3>I7 RPF.Q?BF ,;?)X,TR&$G[_P!RF*']R6(/
MHWY8M8+OOA5P3,3Q/L210L? \BGYN'RV#Z#K9>:)%SJL,AF<&)CY(/O6S1C$
M?QQY!%=D!3^4LU>ZG(<666"QD*& EWC;4T9V+(>-%3Q+[]]45@%"LB>N^#4/
M8@Y>1LL8?@;7/E'J8XQQ#S5P0A>EB'FN-.XFDZ)$\]A4/$L'7%9D&#I"E"=7
M*(UBR]N\L5G-9##WX(V6VYF<PBE'!?S4QV1/)V$3:^4")53(\@=XD\&H I.U
MQ\KTH?@)"_Q$-0F"I=!>_2H=AL# 45,4>(STI+\[^!B/\64T-2!I>^0VCGGX
MS9'?<1I:T5C0>*3D/\"$1DHIXU;?^H>MJ9?WL3Y?3%E#2$\Q/Z]1**CMB):B
MC/ V.JX5FY"/@XD(IT7)F!VP0_6E4ADM([*?=A@^.J2<S1/F:$SNZ($BI[O1
MO9$59QX4R*UD[ .*4/:IHQ,CR0KH&HEJSSB0=S,XXE<9#3?ZF<@50QT#'/6W
M'F9:E&<)K 79(Q481CUV'G&NG7&XJ.=Q)!.Z1L 5_C(1Q?A.FT(JJ2*, 7G(
MTGI38IXUK:)]RJ,,Q*EJ.94'8PSX/9\,=RQ,S8#O,?_0-W1-D@H' 5'CN,]"
M=3<<^?YRUZ[C@AT\@XMM'F63Y=]/Z%2DBHY5H0I/-%@824_XJ!7NJ5L6H_"L
M;^R1^WPU-:H.HH^ZT^!8ZDFMW:4.=IEPE\/B$BJBGC92I?MJE#4Z4+!>,GJG
MR4DDH%<]P*H2%/E3FFXKY(.TG@\KIZJH4VZ;2U:[]U^'D8N[QX>.,NF,ISPC
M :,;)4R"87KDU7COK9#1660;XGR&>!VG*F+ZQ%V0>]!.U$+$#Z%NZ]_3N(KC
M_E619+PI;]])&VW9?#(W(<@@,SWM.7.6QV8K0:+U,F^<'#G ]M#+/D':>$#]
MV@T 1$L$?Z^B[&O].G$DFD4HH JIU2$-[[J_AM96#)XFG/N];^+F73V]Z[(F
M7/-KI=?C;U!O#D*I=\9>]&[T9V$ZB/_+5'K NE2-1.@H/4YBY\ND/,7(-9LB
MUT:/'7+/+L-@9UA2)P)JJYR:UJ-#/TY&_*7$<8U_+ZS=HI8B\85\C_4 4D6
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M\V@:'T\?_6G^QK%$ -Y >=ST%%1D4B];X:*E1[Y ;VG^C<X9<Q[?4 ])[.-
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M1D^:/L_,:]TE'6T8J&B9+3;;1;[IH*V4,;YYA&^:A*JE@YV0X,6H5/%MS?D
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M?ZB L0W6]3S3-;Z%O21$[MFXW.5-M&F,JQG35<ZY)*2Y\4J%^#MCV QT90\
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MS88ZE;X*ID;'F_;]QL9,S")!D"Y0LI4_,/=ARS8]J[_%!#-5I&%=$;W*QJ4
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MJ/M(QN.5O#P65FZ?M2OLVC2,$#\2==_Z4A0Q0+2!Z4=1ZS/50MCVV%G-S=(
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M_$'BG9L^DV&VY?&"Y SS-]V]5?,-IX5A%PXSQ,+OC6#W3W@H>$Z 'M8-9K(
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M/M+\'LH96'.-R2?''V\ QJ2V0[[4NYG]EW-?V-X)>?>;L>UF3?V.T-R#>4Z
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MFZ(BZ1-BME,T)TA@42[8BG.@^E;BU6*5BOIG5IG,!J-H?+#'DS&\[P Q^Q<
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MD+?8AJ)BJ<1H$7GS&:CX H^O%;F$0(Y.?015W7:T.-02OD>10CLF$(4Y/;=
MT<I@C'B=#=20'F-KBO!F'D-U"%!1'K?/R34E(QF3AVMRO0%ZRI7[>[[6<YM&
M/W@E5B4.04VJY^6N;-X[*546#2W7+E.&LMB1?SPR%O(AKO]>BAM>,(H)C.>;
MMWHX^Q%!THZ;J7$;0)O?V2B7,C;,NB*<2T50"474 2'\/V<T:4P;*@<98!WW
MI?*7]^;B"]58(18<"&O-3K7*Y(C)>P<;NOR3/UV]B,^:WL2B,7BD1F8&V'S
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M_^0%J4CTA6'G*XA7O?K-%=\L0K4N.E#.VX(T(FG9:#;4)<^/RFR/_%XNL:9
M/DW#W)J3^<8WO2JK'<_MNET '<[<4#>)@+IL;T)B:E%&CMK*M*TU=?48V,@
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MS5!+95RV$-,,V[15\BSTF9]3ONFHK=QN^D-I%J;LC;(&S)"4FF9;=]L D+<
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MH&0JQF7GIJE@+W_O)"F$<??'1,#=^'^<>;27_O8^:_=J:$PX::@U7).7+>U
M<2V#7,Q6 #- 69LL+T152*R8)[_%<J>2M0F307LH(E\_VZ7Z"KV<N'*!.Z/Q
MLESL/8%J'#-R<;_E 8Q"'WS)8\[\X&;7I=>?!QK7>;_;,DNBSAO^UBYY"\K1
MO]T!'S9E\S/D\)I<=V3B:3HY^Y#BP\4?3VZI=TTL;1 SM[2&U9(=Z"=YL2:$
MT)'4HTH1LET_"?DVP2XZON$V9S2;7IK2F_.B#K]>KIQ]Y^V65F%=H.>,*:NW
MJPAJ36(_X6057<EW"Z(PUTN8$6>@_:J.R\63)3AF>]+[?"7=_A^G[1\G18U#
M$9>2HE8"3S$# +EOZB&P4BKZ6Y%O+0?CPD:?(7PS"-L#O_- QB;57*A0LKZ+
MA;)-!EIE<31-Q\++R@5" =8;?Y,X\BV!NWM4K!J-\B'S]F>K: 8)#6%&A]FW
M=^YJY]2K35:LUR*$IQ3\B;IP@1/-_+.'HDJ+W15%W3H36BO=*PFC!6USWIRM
MU#ZZ%":,W;SVF7>D;XK@I1\PO=.2=4F.K7=SZ&]-C2;8>J@*3KF<R^W5AM=F
M8 .=G ("'0WNGH!J]*BC K=]F!.9_?W;KNZH>U>9]0\_I%O^IMJ\ LC$HG*?
MNC<\_<8M]>8IIT(^$(SN+$] I?*#8X:#B+S?B]: /V4WDCAXZ2D&VVIG\7QI
M8^5*(2Y/_@1(;X)8BWVA,(S6HE]SHJP.0+!%MOV%VK . :>M2%M9S<BU( ND
MD^:'WSS,B\U+)ZQ38E[^51";;T*L5;-5B:IWMW0+]WLF5$=9A]'<<4*/(9<K
M:MH//SR@B((B<W9KZG,!"R&"DE [5.PRGOI-7/<0=<G"E]HA3%U6,%Y\R[;[
M3W9RKXA+?U ZB3.OAY?.*R!GVA%J<(CB']/D**>4SJ2RUMC3,.% 8PDJ@()G
M#* &.WTIVRE#Y 9NP7+CWO^-PVCR ]8)+NZ4L8'F[9.8[1<K3U3"+$*=]9*<
M>T7)L476;R6,Z\]FD7U:NAR1,)FQ/F%U>0C,.1?GYU8:X)+0B .*\/KF^=I<
M_[!C6[ #J*IJE6Q*K(Y^<J&V=@2R$MY:99(?E1T'7%9P%P=JX7%6U'>#1S;?
M]:YO-HMH]Q!Z8'ZD<$H,E9/TF"CZ?2B+5R[LAI:SFRBS6?O>(1:G: =1H$!T
M+LV<%<$B=%+ @YH9I]_:IUT&.UD^G T=":YERU&7&R7(5B*6[JM+YO<,5WKX
MMH.AKFD9;RC"%-=1X7VU\A''/?;;[!EK-+*PLD^<R)?V/X8Q/P,Y$,6Q6$.!
M<2Y!BR."?]4'F[.]\1U*"H0&UVGS&"<P@K,J^FFKH[1%LHASB.A ,6KW>$@@
MHJKPN,=3EJWP0+NHEGZ[H(4O9#^_#,RSA79=4?6G[_^U>P7DAWW?EUT>"]6_
MQK_9#@HO^&:@+[/<0>6'*_BU1 ]3AX3#2\R[M_9DPT-V]?P#N7C)</YG;:=O
MM/]NWJOE,2YDO4"3Y8[KC8CGR>(AA%)X[ZM<'[IL/DHL_B,Q"85GISPVSG+/
M$#/;$@XECVB=,J"T0*>N!120XFM0..,V2YC#UN-$K(#N%&,_U<."6P5ZZ)(
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MU57%VW'B'S6? $T>\HSH?$V&RH131I_D":)$Z@S,$<AQ K3NVDGKW<JA6Z\
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M;+[@;*% THJV"(,S7>MH05QLY7A7*[Y<7(Q:! G)K#WB#TX^)##O6XSW^$0
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MQ??$L5ADD:NN)WQO*$<]_ HBF70=)<(R/:HNDS^HV?GP_:;2L%C.MWWLF^#
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M(C&T<GAWB3?91/=>Q')1Y:-*,G$LZZ^68L>&=*<.QKN:V9F>19T.Y<*=-@R
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M-J:/LJA6(8Z/6%=I0PSE2<]"625A^0(%,"NV1M.> L+1D*;2_F$+./D;Q9*
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MHEP:'C/22)MB^)L]#3XX\%@U"*.HP&.D/JEC!]N5K0^UT2L9T<UWD0H6X]7
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MIM!E+O^965T(E\>)V4D5XE66%T]4YC!7-U*:U Y=<V<W$.@NAWD8]'6C+5O
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MP^7$>@4G<O:^[!/@1Q4GMGF.U!PWKC&0.5GJZ#7HV@_LIQ?PP!(WOI_62RV
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M+;AO59.?*4M:B0BC!?9U<4OS3SD;Q,.\P:*$(H#9[YJF_U=+BE!R+A0,GC5
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MU;W<8]:XN38")Q^NF,.VQ-&?14V+N6E.]R4V1=Y8=ENBD.VA"S28F3P.U(F
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MO9I&F<Q0V J[35E?<!-*M$8=_F>][0^<5$<KWGM,%\J[[@[#2Y9=T=ZN^E]
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MT68PD-BXX\%ZF+)6B7<;^+W_-BQ?R=,<#K7%9GZ*YP>9'%2)?%/KCL8!/QI
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MNW]C.9'Q&05=?Y9F36@BJMW K@+&:LMDMVV321T%[:'SGFV\Y(M;=G\8./>
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MNK\URPY$PG*HXRCIE97K-3>0>I@Z$42C%)X_N3@GA4X<S%9FQM599L[C&J%
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M[DI&[EU4ZVPQ#CT^O^>7NURJ93?ECL7+7OR>(FG=S79L?:2X5-L(Y3P242%
MU.0;?1+(,&AS$A/_KNZ<,5:<I3;[V,?-$JE>[H,1@8@-,KZBW+HKO>>SUF9R
M?O)<^N(CX[X5']C+<Z3@']+LV$=V''EE/K;RE;]5J9HM.7Q]05QEF4J/1O,Y
MTS_WM2PLO"HD_O'&/TAMI*V8;YAD8(EU;!W)[[X+_T%FZ^.@D;1JY.>@J1"+
MF!4_4<.%\23X?^S+85^S-&'\"WB)[AD"Z.J1K!X,_QIJY_B#&'LZAE2,8?G(
MG%%[=!+1;'R1*&'TU-]QB*$ -"$A'^%!P^^9(Z,1>3SSF0D/S]\_.SHNHU0
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MK[^54Y__^@LG'R9P?F0M ?D"K##S36A<)/[:7K^Y)"M-EVGHI4O82L11U-O
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MGCBX&RE>[P819A[F$=1G&I0 M2=LRTZ;YT.@Q*:6%B1]Q'T 2C!E'@;8Y!>
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M= B"A#;+^J2IBK1O$$'O09-/Q@>9C;++^1W:MR")TG4\U_B7B=B_@")LLI]
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MM,D&8H^2-WML#'V).V=4QZR>%MQ)M>.ZHV9 >[FC3M J,YA7QBX;8#1(:F7
M2[)]9+Z'S+-/XACZFD47\3M'53'A*Q;]T=<_7N,T^XK9=9D5N1@5S]W_S,+A
M0FZ&%O2T@A2+=%K84X!T!,^P/0LLL RTS_3E6Z6 4U3+7\@DI31YXNV<:?K\
M!>2OU+_/[!/IQQ]]=./+>)5ZY"TN>I!!(^G7DIRY1F%2.NJ_$&*@A1*.(X'M
M;K-(HQ[W#/L+L*OZR3/9ULQ%?ZS)YI4V3  _*)N7&B+'+C7/!>-JJ&EQFY=2
MKIV)*WA"E7AK^']+-.*=DS)_OVDGMQ=UX+@X:WE>>=6\R($QME5V:CW?D;*"
MA8D0-YLK>88<1JL=WN\LU2H)R3C)?&0F'&@<=#8FD<#!Z:%_=U"WI,KH^R95
MLE]85)6T$HGS">(34$KH:/AN.2Y-93BX;4]&@M-,J.!#LU'&/H'HY)H=3@3&
M(%O%_IWC(1^WS;- RE;M=WB"%CGO?AU46TU";6'(#C#EG/2,?6\Y.#X2@CFA
M::;I#U"V$_!(").H1'K7)MBVS#!-S$CY3L[I*$TGE_$]%5 _\1]VC++HL^W2
MT_V:D?KDK?$JM<K@3:GTI>.C3[_E%5HM'FK$7+4\WK\RU-8AD8& .">D?%(S
M3PB<Y L)7$JQ!9C!AK0EBT%:+ ]1%@K$;H(;CXC+&S#8*=!A2O US[SMNX4,
ME?T97M3@K/[6"38>;=!,DUJBY7YZQ.8'2O*"YDL(NI(VW:+73G^CNS=ZSV(1
M?U-1PQ1*EKW/H\5HC@)%I&>:K 1*29)DTUR9]AL?!P?:$[^)#YE9U?O17YIL
M!SLA'0E<X;$!':%UO0?G7)<OU/PSF3?7H_E@4B/FK $CTT)4JX%GL62D'V?L
MWN!:-%"[!I(M5(QB;U+OT/DKX2B=KS&X1A>M$K*S=]VFV:9S7/9E2ZNR^1QW
M^AY+V4?**:US:)FAHQFP!]'B=QW"%J)M,4PFBZ+ .D JD&*':C"!CK_\Z_&D
M/YK V>$X_VJ7_+H2='2[CO639O',2FX?1P7W!%I'5'9A]%6YX<&HT&<4:05L
M!=HT+*_//IKL0NR<NGJ:BU5<S1K,:?UZP#0P"#6>J]B$&53:3V?"@OB'M]N4
MQ;#-R6H?@HFPD=O-]]#7<2:FAYP:4/3*V.JL;)!HJ['&7**+764JJI;6BNT)
MP[)$#\PA%A41[G/IC>$Y^J2:KQ('+N+M$:Z>\'. '4'5;PVZA7B2 -)A8HHO
MUWL%"44!3R 6LT=$'RX>>[^TW7:"V()?@ZD\:]^)(0V+6[G/N$XX;Z1V6E8G
M+Z\O-FW^N'>Z]K(X2@F;UTL=X>5[REH[60!@F'>+UV*&HAGD=69H3GT%*N*,
M_[=GV5)1Z+O[LJ*\]%@CK7C#9:;\9K7C0173X^_\Q1D5._N?%>W7C$_QY%:V
MA4<W*F+*<PY(.D'J_%GBM=T/AL$JVK#P"2V(3ZL[$2ZX#+QB0LOF^*EC7IPT
MB!G$X)$."ZKBHGZ=^Y92 R>D)Z=N*I!'TZ^RTTK!BL$,J[NC2 A^].A'Z-+\
MLT[2 7=?HO4\?K_W.C0ZPLSE+X".K#!T:KZV@6_3><;6(Y']'6J@\K#[[]PZ
M\\@AGF/#\Q7&=AYM4JX64P\TR5(D/+0!AHFN0(W*0V!>T%$X9B [FRKRGFV3
MQD$N!1J'UA.UW/$0HZ)%DCBM^17769L[=H)ZF1:YH5FBE9,.A@^F9S%V1B=4
M/A(M1@0&)""%>?#KFM;?_90?S]LB[BYW,(DRXQ!+<D<2^[!5>+SR%*8:MQ,]
M)G-=%X3!(T%TZ%_R7@^;1)PY_?]]X?"_$HBU60Q+7LLH%'E'OTX.JB1@%JH]
M\9>G? NY=A"1+@MVIXI3I]]@&+N:<3_,G],/,WFG6]W5WQ'I-;O JA6%:[14
M8=*JL9 6)X5*/-U(6@4$DKX>]H(+3J(7FVVS=C2$/GJ&S#G+<M:NR5M<"_51
M17!&HKX]S=S75U+O%"E5/9_;#O6E-?2\UATW3:]LR5U!P5;(E522P>P_Q081
MCS?I4B,[%$L5AA(.WILX9TQ9G<R.R]K^/O\\";51,9]L]V3Q\]?/[D/IR?='
MA[>.?']ATWB?4"YK2MF]MZYK$7<2X!2J9A'%0F>.OEVJR)4DA5$[R4B"Z*E*
MZD6(3]"IF)5I7UW!0)S-HO;?@R.(/9AVU,.$@.T"BG=3$9S[--9T"'YHU$1/
ML$[Z0#Y];* .0B*\-.@EG?=E7*@18U>K8P[C:CDK8A /)L& V3"9 Z$]<>IR
MLGJ=^%PIFOI<J5/8CF1:^RF!9,.7J@EXFR3=*L#D)SAOW4S2#GPG+XYB7AH)
MJ5-+':%M^WX6:Q85#)FO4ZLN9LPU4U7%C^+.(+6'F0XS:@R3P(QZ870[_YEB
M5DFR4L!6KY?]Y$\7F4X"GV!(#'GO+/;PBD-W_S DV*$E2=#GL?UN HB\C\KT
MT:;&[E#^'?/R.B3Z@]W!)RTVWY!#\<20Z'3VYDD!($_&6,&!QC+L&WE&R!N:
M^4LH2Z/FK"X*!?1RQ*0ANK_1C<5LK\_[!>X(M3PC&CF$*R+PCQS.S,F.<-WT
ME6[&GCRU;0- O]+D^.E+G?0M+2]^F2Z-I9Z%.$'D#=@%Y%PJ71C3;$L32;/W
M,):DJ+G_>WR[2UU,""W0&ESC]@;MC:U;IJ%>!X+@']*RL.#8<J'U)C1RR8ON
M*MP_LAWZ23DX1I3.BF1.7'PYW?-K5GO(KJ*#+^IZOX\3ZRV)E9?D$]TCT#PG
M9G0IV:WUBN8U>R!H3Q8[)[3S%>;.N2*.YZ*O/PF(6W XH>IN[ZJ_BB>./LU_
M+57MF<3.35N29>8PF%H%DD!$X/DISS%>L?W+??3^W*9HGN0@,P(FH;GCZ'^Y
M__8J6K:K-MB'*DYC:WM[]IK? XMNSB5\C>%]=7!QH[+-8N<'#3]KFR-G1RE?
MHF8M^W&#*BW.;PQ'0C%8Z&>H)J3D3U#59Y@P'1"8DO%Z=?WE)% <)(>Q^4DQ
M&U)HWD\=[_9>!2DY'D_$JX>CG31CRB"UW-OJ3>Z:*I6Q?=1<\+:50DU2(L-[
MLC9I<HF:+G8QQCNYEL8-#1]B8<T\]BT'Y-F_V[Q5= >"=2.9MGX- 'LSS*XL
ME_>6!^B,^ZMG5\!9.<EY?X:^M"NXXQ*8)@G6BPQ[F)+L,B)[^@XRCZ_6&=^7
M(:&$??(B;V6/=)/ETC<_I1*\.[U#\E_%<J>A515C8*X@JF7CKKKWMG)3F&G,
M;(FN<YFH\FQ3@O(-(PPHWSN!%NN#8HG,R4.@=)L*T;9M7>R_SSCU%/<N?GPD
M:@J_%-F#NPQE5JQW5DIL"[^]C"H5X4E_&GK^PX,<1(]"L-R\YJ]23WD$L_!L
M?X3""EXT3,,M)<Z("%GJ.SRPJ">(U\IE!LN"<G]8<HR_[+/)J+]C.SSK(="O
MV+X=O[5["*50L$RX2*'-2).6'@YK>BM*XX9'V=^4)>LP0MSQU7\JA,D9/+Q*
M8U0S\LS]$G=*WZ7R.P]4FZ& /KV:=,A-AEORJE'=:_?X/2YV\1[2*+Y3$YY5
MO1H[[E')@SK [OF^0!3IYFV+K82Z]]('YK60MC/P7(H:,8S[6Z)#(&3GGA33
MH%Y2"SJ?<' =^%P.DC0S&A(?N8!K69:Z$S\#'?:[:5<>ULHB>=@6BSNN0X!@
MM-3DJN,)"LS+_R>5FVEJ7QNL63-#9%$V*9BNN,#\/4%4 C"T0C#(_#V"=[-R
M%7&I6"MX3($,1"5,IMN77,TH<:*2[ 0ZW.:B/4(1ZZK+'0S[PH[&V1"9P7 +
M2SU&9K1[-%?S+\7V4[SPN]:@C]R9959N22V:&QQ<>6IWS(Z:06@$F:8U6C>C
MVV9J%XGR;X4?U>I/2D4M]:C!PP +EM93,599J@2Z;U/Y4JP)V_S@W.%TQ2-A
M)29@5,8CK1J02BWNS5L!2CAU#9<Y-HHK*'Y2 2PC6&ACH=CQ'BX5Y5T$B"Q#
M/B6)'7&98<SP:]+T."C\7N?SU_/SP J$YRX?K<W<%!M3&:K' GX#-E:>N.0G
M=TB1I+)->#,"0D7/&4T'(L/OF;AN:W!#L9Q"=;XD;G-&L/NS2N_M+$H7,<[K
M*T\+M)X!(KVB'XB&,KPP@=-$@3OJ:?OOH4'#/CZ5)M\=DS5S?WT&LIB;[1=T
M=Z--ZAM[?*PT'+HP1M$*>;"DPE*(L<4\*%Y9]R4^Z+E$#4+2&,D=YXB&(5L*
MUWZ9WB;WYDQ]33QKM6*G]W4*8.N6:D_S5-1"L?TN77J.ND\P)./FKC*SL3.W
M\<K?PT4I%8'Z?FZQ&UU#@X]'/\1@2O0NA!47.WB(.)H_*7_G\<E)[(_:4. N
M'VAT\AN^[Q3N+?0VG:-_^C;FN $U?Y2@<VKV73Y;F;/NNZG-^T?[<'#*[)Q@
MB5GDCZ,IY:2[5IP3:GN3QSR;!33:F0#(K2/RQ0-$Y*-$Y7Q@AO=TR5;2Q?&.
M9B\&%T;,TM>$6KQ8"2(E/WC3@VX<5P14X\U[5R)#\A5I>79WW8O=574/F(LV
MGPT!#5[J[AZ[HAW.$=YQA(SU7G%"(Z%DZP<:35)M.Q-<<?.[X A*B8^I<E,G
M."D@+2]#=K.XCY[LJ:+E9ID*2L))H+ <DR'7?R6L;HY4%"Z1N&C_O?,T]L0
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M#!!@P.;^KX>N3 !;ZVSC7-N6'A9:Z6A>6QG4:/95F?9=X+072(PK<==CGX;
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M?D'<;?'>!L62O&7)Z8X? PTM?#FA_?&%0AQ<[W(=*7S(1\:7+-TTL;>UI V
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MUM^:K)T6?B\@N,CW^?D:+WAO''=2N-+KNX&(RX<V$=>8J<"(-"E5X@16>1#
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MOGC.#QI_#& T[?_LH<6;7%*U3'M)O1NJ;$UAI3F:@QM,<(^??91#6(VO6:5
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M,@W/2;A#U??2,?_Z['RW>7E"HZ<.9VO@A<E:ZU]JD[7"V\<_G6W>O=3_ )*
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MHL?/S$NTQW;,KL"\<S;C+,:U=N+'$/9&L[Y6G]\24QD&_+HC:?=,$.MI8><
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MM[RK:DZ2I_)5<4)B4X+ZBV.7ZI%%UOSJ)EL]J7(+6U0&*XR_<-P2P8I23V(
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MW^V&VD6.^J3>9GX>^+DKE-*^^I)6\7,_,$VR/I9;8JYX<WX3R2$\>_/Z!+'
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M3WSZ1WW#&WF+Y6YJ>_1&]"6[T\T/L?E"B16*%)?4"]='@A*-BB\)$$S39#@
M6]);DG)K]Y2V*6%8I&>YQG<A,B9:'1_([5=%#P&H8^?_U<ZY_S.A^']\F&MD
MYFYRV5":R74NJ>,R:ZYG+KD3EJ(ADXK6Z:3-S&69D<RE5"Y3N<QUR"<,<S](
M([1<(U%(J',Z?7S^@^_W\?GA\\OY[?GS^_%^/%[/U_N'MW>4S[Y;XP9^ZOCK
M\V=B=.9S37OV9_DO(#D7-NJ.M54/B4/#'9>0I=G)#OA2*B4Q-W2=P5H<T\1E
M2/(>&*L%DPG0GX!V/X.7YPB'K@&[\E_)(A%M!8E CY;,/1>Z@L!@%93F-5/K
M27;X5-9J4WG*UIF3&M\502(<WN540]))(D7A0[B<'%"&SF*^ACTZUT?M? Z5
M?,N/:<DE4F%:J>_WA-- *+A@4J:*&+*C*9"CL?FFE\TKU&W#_'ZPMH 7F^RA
MSSW07R@B"NIR!;0486"OA-XS,Y]V+G$*??<GX#%\)W7CC'B*Q<#;%2I4+L$T
M31@8\^LK'<)N[GAS4]-FKH),]3;44^AMOS"(?@CLQ).N>P[X&A.;@25^E(,1
M,&4B=U"#HU5:$\_D#+3*G!3+;90-EM:\-(082>)*<+(M*%8NX(=RLZ-8*RG,
MQC13J3J^EY.ELLA3-LG0[;^I)JJ8AHC3>:1BDAY4F5SVXFN$DFEJ'+E3BL_Y
M3+Q%6S6IC+;6_B4T6*&X!W?%K[YX/&W '(&+SJZU#);J4I<+OF+:=98V\(EV
MPS,+WF 0S.PAAZV"8HCBZ[X:69PSKU&3[/JJ#,1%:YLZLRHV./\[YWNN?0RV
MMS)_06SV4;%#W*>B*$IPGZHRQQ!"^:&@N7U*/0OE#\%Y()4BNPE,(P]3WN)P
MI+^_6O:=!1 8V8BD,X45.C@U1"6/,-&:@W*H M^5[HJOO.2T\U VO%]]X\7N
M,D:O9NJ[SA8"558T5QF)9:#G1A_-&V]< LC+2XL#48?Y($/(3#G)X"*9"_NC
M+LD%B#;BZ16J326,H$<Z)J;^-+3*)8W7%QZ]CJ*GBB\&>!TW:^CR#FO6J@>"
MKD;#I^>V74U'-#9?/%'YLG?[F^\?&H#7*[(&U]^!MU>8Q I:HBSU)R#A^NEW
M;;OO+"8^WC13/25VK$!2_(Q17)^3-AM5OW*!X1=\4?+),-!5?2HG/W]<-4BG
M!W9HG,]P0V%NYW.[,2CLB=#I>5G;B 2U%Y8.AX0OV3#4[3*XV6Z^%T6.=MY&
M;9@;_U9]Z$WD,C*J?N[U]'+JU\&'D]\*;_XBRC*AEFHHBJ#GWHE3'>>I1QXH
M8XJQ/; -XXG8>/&38.6CD\!A23E&XWR'?@9[+5,B"]F3^AS^-694!?^W2*=G
MB[&7$UJQN\XI38R>9,+[BW X,0<<[]5;IM_SBV6]?H+!Q("K7$IZ[_2<2C4\
M(>2'F>H2!:&25UN=X;R8:1+)+<!#X^]B B""_""YF6>CV5<<&%<1:Z\"*R_S
MAPSL]A&;V,3::!R-0 KO=8W*"MW?8O9$%A6I:8TA)7+"]X0J=+4FG]MV" 39
MGF.EKOZ^9J&@3_YALK_:QN#%2>J=*M::>J?Q8*Y?.<+D[%5[+\1='(>DPW2;
M5).?#-I[WYM071$<-E<[_!%R:_1:8\\K(C:B+M),[Q)27@^[VM#05[]@91;:
M;Y94MD_HAUW]I/=-1*+8$R[OL" 7LJ<;<&MHN^9WYA&628&HV-TX_JGH:_9I
M[%<AFU=R\%$?[UE8<,(3P=W'%%J/@7GF$HQCH<;67K-G,]$/C(!0R\%9A_:>
M6P4RHS0P<BF-;E'JFBP%E7*F@4VDG+.AX4+A_>Y,8X"0#L@IK-8>0.F4J1K#
M)V#QJDUBG2V((5E_B'1XVI^=CGZ,M^53:]K'KQ@4 AZO8Y7_55_C+?S<7TO6
MA[NZ"HCY>YF%-,6==(#%7[MVH>D]A9R265H50_72BG7U(*F6*Q5+>::[.EU0
M"27#@<C&;KC@)T#FLUW-X\234K:E^ N@Z%\RPN)7H#X5A-SNK;_<K6 AQ?U.
M+D&8@-V14=JP!YP/$G&7I%#U"@!4'TX5?O3WDGEI TG6-H8@=N*PHWEPD?1#
M,2'YAHF>7<Z)B">Y;\K_(/GB\S0G#7\_]SYF\R^ED@$H/=%;!D*ZJ:&M3-&Z
MEA@,O>J@D-7 \VCI4U_'!#T,DC?303M/I@+*#7E/C: V,TH:M36OFVTC_D^:
MK5(_H2:O>S/3:0F[6O]7'HAXAW4^9<UF?.V;G.=Z0'BP OK(?9U31*%/J,<Z
MQ\7H7>0X9]%4XI3VZH%C>[7]_^6@5% 483%TXR&34&YQ_HOZM$_O""WY?G>!
MVLGON75-XK#!K:/+&S'Z1#,,3=.)EP?Y>@-!3-]MY!KQ"K:H^9YVNM6)@4HZ
M ^L$5K_+A6O)W,,%L%NQ!W[JWW&_/-I\]%*_)9O4C,"V\O_N]FW\'JD#(H4%
MS"L^UTJ?E+@##]A5K(G-F-Y]V4D,F5![:G7'*.&TZTV^+H7M&G#^Z1JY/%"=
M1Q!S,BFL-CM:W?)Y./-#L'LKMS.LD(_\4;*!SRC?+1F*&.V[91OJK_# $>85
MV49ET+HL#,/Q#*,3:HJH:I1YYF=]G^;C8,?*#,MGF>R@>I?_?%B>WI4Y[?[D
M4CHN'?O0K_&#-?E]'D$\)X7=<@9,<*@=,'MBIR8Q:,:F3$H<A-UDLQO+@OCQ
MD$(9<\1*+R(JF_<@6V-ZN_O[+.TM\TT[UM S]W!,+)!EWPZ^TQ.7[U&B(@;9
M"9EL%-^B]>+B^,C5;OO3/$6::79"E=SJC+,8$MDP:70Q^.05EX $%BC["@W4
MFJ($^II"W$D0[&@LBYW0)G65#<*JP7WD$/=_:6RBTG5:'32C;O@KT_4X0.:N
M=5D_-(>I(4^MG97*D7C2&3=3XK-:,G#,W+L0."]9>L]L!$?9\JX+S<3T,GSU
M>-G*'XY[-$-P,[W,KV./O!X)V\=%F\3*Q\2GQ-(/JH;L])3.?=A'Y&5>G ^]
M;:",T^NEGFF2'(CW4[:V-%>_)PQ"7/413)#U5.!B7)N%=-&7=8I5=N0Y1$BO
M\0NGV])]^1:*?RXES\_Z0F[1K3KGLNKX4387%$;XZ_G,] 3#HRPKD4IG(=PK
M Z-'@@55',B1SW%IE7%_FVP4:%/WA5]T(JU@Q<+CZG5F,R[_AG[$ZY"Y]@D!
MBEE4D<%J'Y =WGU[F=G,W0P@&>5USGN]WZDR99%#(B=2QB#3>OW1OY6C!;3E
MMH8V8JOWKY)*>NZKE!59-A8P-=XZN9;^UJ+DRXH*#W)^"85<*B**][GUN[94
M8MVAT2;=3C10!BA3&_[EQK:DR<(QB_8NR+E2Y$\ ^Y+LI/3M3@+7",;95@0G
M\P8MEP'AE#.J"^L=V)+.@J2YZ(/E!KE;CE$=%)/YH!JB8*]]U?B;0('K[^2I
MVV(!QAED-C;DR#?#BSL6ZI;=/@PK4J(D<C%J13+.3B29:JW[<92]9K<-NX>@
MB:E[#=+]@72]2/T3! 2+'-4?@Y 9;/%% W7S%$I<XFOB=J_)>CW;3$C )F5;
MWG06U;R<UAD^UA=TMJ(],>B27M\;]:RFO>6G0?<3B:;6WC%]?RZF<W,A;_(T
M1K^@C1.H]NW<_1ZM39::A=B^C?T):=OUS5;4&D5?,^KNDRMTJREZRVF.7B0F
M\U[-82'7X"SO4%12D\&IL'//8F__!+AB6='!O>@MM30TKOJ+.,C&I5@E/Z @
M*,)P^;:CT#BZ1=A[+636UN\31*,471@JV/V8$$*2S N5ECWUF_3CJ^0M]7%7
M$ /05Y8O@,!^DY"_^_XH(%B@FF?IIZ,"IRIM6 O#=V8>[Z@^&=)0AF4<(V'"
MY:Y/.3>4:I^53<IJ:'7,?>1,."X/\] ,HN_F,"JP1>P\OS0.P CHTUB##^G\
MK&V?4B6%[.V."BP,9%38"P0I5OH'C85./XJAJ:'F#,B5GG0_6_]0"5N &/\_
MU6E";7Y0?/XB,SE)\ATH?,5_"PH8*+*RA>++1:7K,K78]W6]Q_&C0&$W$(*H
MB9^"MK^TWROI7ZS%V-BA:-[.$(6,I_GMSQF#N3S<L'2ZKJ>%7"9/_)OJ,.N5
MROXNAPN$W3O>4E&@';*@^)DX&LIJ?'4N4&?9K3#.!W*96>&MV^V2C5-Q=K*"
M4[!4<-?#/AQBHM%>Z[KH$+OI")<X4_%X!Q(5K^ >.='< G.>2PZ#N5=)+2T]
M0U=:Y:WEV^?R;G?]JM/QKL0.% N9V8FQ>Q:V+R*RR".^[#!Z ".=GK40%<SO
M"R"JUSFBQ%G;MARXB>Y]B>J#$=>,'21VBQUYA%UN.8"(\C<Y+RR?[8^M$7FJ
MES9Q-CV(3QMM6 ,K+=T#)A\8]L>.[+ ROSGA7K]Z-.1<B7TC5RC\]<;%#)LF
MS*+UQIU%AM+94BO3T^QPC(C#H,L=CZF)P9DCD,4/DUH!11U3C@78#B.IM\CV
M&KOV__VYZA_X!_Z!_PHT?[[Y-U!+ P04    " #C65=8KGIBR[\+  "Z"P
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MF'/7Q8__") !>0$%   [4$L#!!0    ( .-95UB2%'A+D L  (L+   3
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M??@#,?ZQ+WZYL3][_]W3O_[*MK[F\=]YZT=>Z8=7]L=M6E%]^S=V:B=^KD6
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M,C,Q,C,Q7V<W+F=I9@%J#)7S1TE&.#EA40%+ 8 ! /_______R'Y! $   $
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M^81:"91<B8%>*9)@"8%BZ8UD27EF&8=H699.R9;%.(%O>9+.*)=U:9=U60
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MAHH(B57XAY.X?XMHB9FHB9OX @4  #M02P,$%     @ XUE76.LMY,$B#0
M'0T  !,   !S;GDM,C R,S$R,S%?9SDN9VEF 1T-XO)'248X.6%1 4L!@ $
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MK]Y7OP&5:SRA2UORPM6_=;UN?$]GX'PZF+#C57"#!]Q=G?8&PZ6<<# !FU^
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MOEL@"0=/BG)]E3!.-*?5Z>* +ZQN>UAOMSHU!V#+ E \ %5$4W$!:C; O]N
M7U]C+RX&2QJ])P[:B>.Q%L?^ES!3!&<2; ,&8-RXU@S$)+;[!F3:0*/OH*3X
M;9H_WN/B 5]EM*U]F CL"9]'D O/APB3 &(/4QA'L4<X\0GGL>$-E$/SG)NQ
MV))J?)OB((H^Y9PDC$G8DKK--8;8"1+H2G!YXOL$>_Y*2I7D%G'LSV<!2;"E
M5N41'%<U1L">-J4S@;6PP3R&$OCCT\AJI@?A,K[3,Q4VNS=Z]!?9F(L\0UB<
MOL9S\&W;EWB&6#APA6?P<7,[LVVYT05]KD57#75%(T(0C2*(?;5=24@$8ZD9
M8> AAX<<)TZLW7%Z8)YSLS--$Z&Z/4U';%TE,G_@X %7:@]N7@EZ".?3"G,F
M]!96F UPUQG8T:DB.S>S@J6O+F<"S9*Z/++J9B[\K(')@-H<>MN:VM1@H:\V
M=1X?6Y'DBRKM?_$C+5=)X),HP#YDR$<049]!@HFJ1X4</T$H"./ K(#?=NQS
M4X\U8> /+$G3]( . 3:L\R;"L+">TT)@1,6+%[PN7J=B-Z/EZA(O6'U9$^+E
M(^;>S556INN4YI\X2VF:\=;E#ET?818)Z$;(DUL_UX&)XR4PI)R2,!")DVC5
M43\^Q;E]M!V5H"-3WQ@?P?"TTS(=F86_XQ>@C-C9'4%'WTN9CI(E!T5_"1EY
M),/\#S@C1UZTYH<,$]YW04X\::[6+NA_;M*"LR_OVN5&$NZ% 1?0#Q(!D8LY
M)%3^4_H@;APB$L=(JR'UH<'/395U]($O?X\?'O_QG?ZW^@*VTSIL"A@+:Z_G
M.(Q07B\ T5=;4X"QI+"T%XJ1OCK&^("F>O&*-1UUC-B^=CKZC+E>^B2?OI?L
M.^\_W7Z^^GKU^<,7QW']P E<![5+C"9<1 &BT'5]+%65)W=*,8MAZ/E8A!3A
M!&F5.M><[]RT5TTR4#0#13105(,^V?I?KP[:IS7<S!@NK/2>P?><WA$Z4 =%
M?;4X,YJ6-.4)5.=1G ;0#.A2G5&LJ5<#EOH:U^2U:9F7-T7^+2W;KI)UB<1>
M[?9=:UF"'$JH()!%ZMYJY,20$(+5?UR.(S]@GC,F+5-O^G-3T3NJW[353U5K
MK[U&"*I16%/^M/?;<5F+FB(ZK<B7!7YAO;Z?"[HCOV[=7#.PU_'YC\F=FC5A
M'Y=).C_\%OLGJ]+=Q?,VRH\[B1Q<^PNT0S8#43-'57/05TE@-6/X6':KX2C3
M[,MO&US@K.*\_$W=:)4S?N&4RQ_9^Q^/<F4I43\][V,>,>P&40(=I(J\Q)X/
M<4!B52X!418%PG>TLY<FTG)NEN?KYN%!W:V1']S%@ZK1J7[:\05JQNH/L&-M
MG/(;(S8S [2P,*Q:HQ<"N.@) /3X:5/RP63C-.JS&F6I%I:31;.U;Z_N=C*[
MVWXT1<O: L9J HZ:EFO,#*]BQB9 <<RF31G2S, QGJYN"ZP: 'Y]>B#Y>A6&
MR(G54;Y/@T":*Y_!V*$4.C2D3J"NK,5:K:5>C'QNQJ<E#C34Z2FNEW -FXE)
M("RL]#7YUU811WD]<*I?<OK+7?[M5_E.?9ZO?JC50:T*7HYDY<,^RD#WF1Y_
M8&Q"C>KX^!?5\/'/G-WQMA_[*N+2,^3"@7$08XB\@,,DB&+H>:Z?1%$88JZ5
MAWABGG/[(-_Q(OU67SDH >-E>I?5/:YP"<2N,>9]S8!I'LYAG(>_W1G16_A+
M_O <'O#'PXFP\(ALG4$4%L_<.3R[Y2R>00A>9O0,/SYM)_JUDD9?=<BF1?I8
M7\BI_WLC%\;UIBHK7#?U55OB^O?O?_""J@XS'].,7U7\H5SA$#.7LQ#Z@> 0
M,4<:^M#%D+O4%8BAP ^TLYUGI>SL]-*>IUTJ]NI"*1U_(&_^1WEF(-^QV$2.
MFK_QCDOPQUHEWJ2*T9&[I>FB-]O;6A6HU9UNS1GHLP8:'H!B#O2X:^*RS=_>
M[V2I6 17KRK+<?M@JS)]E9H!D[]3'=F.WC_/AK_F;GKZ?*^RMYX-IF,[[?DF
M&+L%.-AFNG50'2]$!'$/AAQ%$ 6<0!QY#F081V'L)IPP8;81&)CMW,SND9[L
M)UW;$3CK;@1F0F]A&S<6N+E:UEO>&0S1< X-Z$_M$G1>,E,N=<7OC#ZM+M;K
MR^9G.>2[_ &GV8J%2<0]7YU$$=4!V,,P87X(28P1B9S <?2.HX8F.3=5(DD$
M.QK!'PV5FBID$,UAS3$71@LK#%-XM!6%#O\#T<'N]29$V/UK%R<<'-[*IZ_#
M8/?%:ST[+2CP_L<CIZJ!7_H@-<JUN,%/=5V[J^R+%'Y=#._W3&PRQMF-:BZ;
M9]V9^4U>5N\?'M=Y_<);GG&15LH+*H^?P'G(I\1G!/K<81#1Q(>88A>Z6"2(
M8R<A HT)(%CEXMQ45<.TVL!\V-17KSON5<G6EG_UUPX!T$)0;V*:Q"&% N1;
M&$"+0[VG'9FT97=AF84GSG:Y6 UE="B =@&IK+)NY5SM5L[U@95SL;=RP/LC
M*V>1DW^["VM<K.1L%]BK91OP;K%56VWUV%-3Q4Y-;;K%]MA34TTVW:-:;#TU
M1=K%IH!9(K_N5<2H&9ZQ2]NKA')>!?YC89_7(69TB*CM6UU^D.C^7G)VE;5]
M3?*L?,M%7O#+>W5[7-+_U[SXFV3ILNFEO(JY[W/J!C .5?]I1N1/+!30)\P+
M?"^,0^+I]"*9@Q@C5\M"LY)=JYUMUW6IA!0#@#8<*&7VO>&AZTYM''8:+SOM
MJ)05B2P=M.I$4 *E0\!/&Q6$3[.?0;[E98)TQL2V)L.Z?.AK/(FV(V.3P3P0
M.)L^YKCZ81_SLKS.!ON98Q9'#),(<H(#B +*(28LAH[C<B=,1.C%W*24V.DI
MSVTCJZ@&/TF#6_ZL$E'SNRS]+_E%2Q>0]AN=JX8E7:/STK#)O*8L3F\GYT=X
M86W9@/NQ!O<Z&]TZ?BRB9C7)YD768GFR;OF>7K,S5BO31^M$X3*-@:S6,--G
M['DY,X,WS17Z_[W!ZU2DG+V3GGS&6>?2-VY_[=FWIX0\<.)0< Q=GR<0>9&
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MFW)OB00=E?JJQA#RTUI\.2 75N8[U=)1#CK2P7-\1^P)#('65^W+ 6Y)P^^
M?^B ?SP&_$P^_SC,!O2\X8#6U/TX1OM:?^0(TWSY^HA@6QOEJFX(JNKE9&5W
MMI40SPEIX,,H=@5$+E;M4[& S',3PD,6XF#40>[)F<]-]>_[1\WIXJZJ3,,
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M!Q'QY7X#.0YTO=!/'$1"/PS,6DI.HL=(AUOH*MFD:H-OBC;3;*]I@AG6Y:\
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M1^<ZMX^Q/NS+ZNV"M)AB:SL+_I@7=>IT6>&,X8*5X"?%RL^FWLMQV'4]DUG
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MIKEVL7!+M>I<UY$]KCJ4EA!.1QZ6A'9I?;I7\:G!6)V5=.2#'OW@C\GEN+0
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M7.H'KA\C'NC;V(&)SLUFOM,.>YZ$4,.JS03,TE9JV^SIW;;9T[4 .UIG LS
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M_< /5!(&APGB B:$APGSF!\[6OIWW/3GII&;RTIY1W!7KMHX*\-(!+JAMZ6
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M?RH@@-KO9G=\EP;^]_N4W@/&9>^%RD* _P";%-?W([)]<(^_<Y#E%2"<9UT
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M,4QO<&JY'36E5WT&>=#[3.FF"I(WV@&EG@693S9\]H>-2PSC8B>)MB_<3,>
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MO_(TJWZ5?Y ]E^?/+P]97AXKTAAQ+A(81K%*&II$,.%> %5AE"C$"(6A:U6
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MQ%C;"K]-!/I#6HO_HYQZI>9^Z,0!&5Z!EX-YYH7V4-&F- ,95]4B:@T :50
MFTX'\$-]:O>CJL+TM*F/V]3+KX[UFM'B#1;;49O2>_$4O&=W;+02;F&?QU,
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MOVVMVBH_N(TNZ_+PIY=$FF'LQT^WWFY$9V;.VBVL'<R>:MLZSS<YZ+0#??6
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MX]+V+1W2S.M%CI""KO);&MNEMQ5[\I72PSL&P&/%057OYJ'E :1[)I;+<YN
MJ(5:EB.(LU[N<CR QRIB3AC-_)#HTX8_E#=;4LKMBQQN_?R-MU68*N<TE^I9
MI)OKXG->MG=U+O7C&&.D,O=]J3%) #&6 B21]!R1XR-*M)/G1LQ_<:I2L0#*
M#@^@.&!"1:0_5FRHHE=RVV!PU3Q&/L.'-PNCOK 2K0'OD@\.Z5<I&S4'X+H
MBH<1]]5CD-<_4UE8 I:.3$8L_9E.1R;@UW/X,694:V<;$UCN'EU,&6;:)<0^
M$%4-W7M(\N*L,A8))<B)(0U4Z1@OEA:'.1'TY:]Q$',4>LF86X?1%%V:#>I<
M,^QY C532CGF=UFJ+@W3;(EKA_&"-;MGL"(NJQ<+KX4U=#$TVT7">*&-NSFP
M(CQ+=N^P(,DH(6J(;_1UP62H->\'QL]SE@N!R;"<N@&8/O#8$Z_/6%J7VWN<
M76?\2YYM5/^4W_/-[L^W4I+U![N<?$PI]WVY>8L$APAYJBR3P#!R.<,NH[YC
M6H7-F(9+,YYNG<RVR>O_^O5_'BJ*30^_S 6B>_*U*,P+&[V*2+"15((\XZ""
MMM*(6;X!Z_V'&\5#_?$RE>)&@[CX29<Y99:/N49#]_J,:_Q0X\-YO^!L*S#=
M2(5=E"I7_ LN_L/5T=K5=G.?%TU>Z\>\^(UGO$CI'_)[U2'<^V)[MT(Q8CQT
M0\@]CT'D<!?&/!"0B#AVL1L(!P6Z.Y!Y2+HT+;H/\'WH\E7777AH.0.XRUIU
MW'U7,P>>:NZJ^U?)GWFXZ401#^]%[ MN8;V\#SH]8*FN;;)C"AQP!21;H.$+
M-(Q5W4[.(3/S:&%[LK,>.+RP#$<%$<\#MT8\\<2)K(<6SP/,L2CCF4:>HSAL
MFZ/37/!7FY]5Y+J!$T<19!&I4L,]2+B'8,C<),+$\0C5.LS3G_+23.7A\<'+
MB!?P9Y5RJWFL8P"\]AW[C'#:.TT;@^3$LK!]X%@M"7N4D#.6@^T#IK\4;.^3
M(QJTOR@(]>'GAF>5LJMNV&N5N4(X\BCV8NCR $%$55BDQR,8.HB1)$DB'FH7
MJ]":\=(4TKN79='> -[2W:3IO0%91;I!(VXM[(>][MD175@GO:H)^ ;L2&[2
MNMZ WQ<!TZ!;^=R@VNI"/@.X9CW%38#JZQ6N-8Z]'N F;!WT]C9Z<+:6A\HL
MJ*.ACVF&,]5?\5-6;HIJQ96=\N'UM[_FY88_/*[S*IONK?1R1=H,=)6Q;^G=
M_:YIX_=,DB7'VA8J'^]=GFT*Z3J7*R>,D,M] E6E<&D25*<IZ9E"Q@,AUR@7
M%/&)O1,MLW1I-N=#TVRQ.@,2+09M=\"J^=\F!P^<;T!.UDUIXU+]K<9!U?S<
M*E952X4-W(,#2(U.E9MC?(!_;C&-;PIYP>MIZ6.L(]TEJZU =:FP7UOI'I W
MAUTYZJ?>G%Q*[>?JSJ*HP-DE,M1K,&WQ425G:X 6;5EY)F';[WUIF]%S-]$\
MDV UNG&>B[(Y#J)^X_E=@1_O4XJE/#DN/Z<9KR+A5H@&3/"0P3!& J(H<" )
M/0J3A$<AB<,P<"<<1YV>^-+L\>%1REV';JGJ).'@3SDQ!ZFB?=+95(\LQIQ0
MS8.PU7.JL>!./*X:1LKJH54/.6<\NAH&J?\ 2^/Y$8TX<)JIT*+K7:O&:W%;
M5)D@SU7UD')% B\2@K@P<%U5F(-SB$.'0X<AA$,1,\0B[5X;@]-=FO)2%(-?
M5'SYKRH"786[_K=T[?(,/+9=1E6.:<-#4V/*H$7#,/[#YUCSHKJPPJH!_5P!
M>IWM>[5>"]#27%<CFA=%@UX6LZ)IJUU%9YGVK\VY^E)HH]37>F)X$'O=);09
M.F@@H?_4..5<-H&?V7M>I$]R%3WQ\GNI^E1\P1F^X^]PJ8*<U']4*.@37BNO
M>85%Z/+0CZ26YK%4VHEJ.I!XT'6P%\:<^\S3;Y TFHR+5.;R]6![)E0!EOH\
MJ.(#4,E!M1FO?N![7LRTT4BQZ>GZY85AP0:4M1'@M1GH<*(J(56]D6IF@&*C
M*G]4_?#!LD3,[,;RDK%I3T:^*3-:F&EX#EB>D8-;M4C3 'AIJ2:.-N*6O#J(
M_Y3=T/Q16L9W>5;FZY15B_?VOLBW=_='NL9_DLL[NTO)FM?G.BNY^U"-W%7/
M!QY"Y/DAQ(P32!S7CWV.W##6S@N?AZ1+LVPU5U5GLE(QIAP_VF7-X$)X'IEI
M7+];E\32]_/UM9,JIUK)0&YI#I@"#5>@90MT^'H#]IR!FC7K,C.XY;<N.UMA
M +9D:!8K,"O<?<$$\TQD+]I@5F .PA'F'7GL7</)?+\FR2M!,0F=$,,XY#Y$
M%'$81ZXCC62(G! )E[I:$6;:,UZ:Y=NGPQZIF#F<ZC42=MW[A!G!7-AX3<1Q
MQ V")C:+7QT,T6'YSD 3EM>7!;H/3JNUL;NDW=VY?DXQ:6*VKC8?<5K\@==;
MWJU&NDOPQXXC0NRK&X180.02Z</'D0<3U<>"8^9XGG8\[%Q$79I"^_@R8DF]
MB>L].TT5-]4V4P76I@5X4JR-J]4P29K#+OXY9&3OPE7ZAGMAU5Q5!U4=OL"5
M"BF5,JI8>U&W>VJAC4G"&U=KPY80SU)NXU6LX,LW[^"% WS/XP*5N>= 6K/:
MQJ2ISE)P8PYP3M7<F&5L<QM[9#.ASN&:QAU?>?&[W'<4."L%+U3NB@IG2N4.
M)=M4U%2!3ZO(QX@D0KK_F&.(8AI#G! !$\_W/"?V6$BU:G#,1="EV=;J"N&Q
MZ6\CG260Y1G<=)BH@BQK+IJWO K*K/I'?;]Y7SU3W:,:M)&:1;+#MM:VO!:V
ML\?/5RH!M@V*)$] 1>AVN0)[MAJ;6S%F65KZQM6VU"P95DO2,[*N<T+=8UEG
MF<::59T3E*Y%G77<L8=G[^HPXUO\LRD6_RFC^0-?81Y$44)"&"%'W2<%(<1<
M()A$S.-1Z&(G-.Y1<6(NK7?3:C^*AE"5G6!>@OT4HKKG85-0LG2)LX='>?A5
M:PEI_165IVW^B-.O 206/_4Z-;_ETZX!&%Z?<@T]8.N2NCQYW+;R$4M"A@A$
M(@X@"ET')@'R8!"[(G"C*,9AN.QU]6GB+LXC/_?%=8\<E[K"GD<ZEWR97;YY
M5:;T:EPUX-F%NO0=]SS"_9]PVSU:R!:NOH>E,/LE>,^4%WX=/@S6](MQC3E&
M6.Z\:.[9VP8BL>/%'DN@ZWJJ33J)5<LE#D,1>B1 <22XT+:\+P:_.,LIZ3,/
M%'J)F(:-FX##TC9J#\&(/AROL# P#1,PL:7:-9:'F2(^P7.?(GWYB#U%>(+8
M T5VZCMC%%%[>J'482H?JJ3;Y"%_E*3=WO,K*E5>F38-F!ZV6?JS67A>**B/
M?0;]R/&DV@HP3% <J][7H1LA(87MZZNM*:1<GI+;G0?2+CN'W1[QGAVU?Z@9
M,E$$DZ2GHT)MR61QA;L3QP$GH&$%*%Z ZG?<X49YE34_HY3T)-F8J'1;,K)F
M ";):BZC,0>JO29FT@06#=(<0!R:KUE&-#-VC*>K#W+>S?,58T7EXF^S3?&\
M$@QSC_@"8@?%JHQY!'&"/<B]$),@Q$GL.SHF[-0$EV:8:AI!0^0;T)"II]A.
MHMAO2N; 9F$#80J+MC(9XOW(>7G)Z=_N\J>_RT>KDW+U0Z5 *N5Q<D K*F&(
MG?9%'_S>V*NQJ[N[HKYN^I2Q]"EE6[Q>/W]Z4/WFBSKX):>I_*7='!''C;CO
MAI XF$)$,8)Q2%THWV\'LXC%V-?**!Y/PJ6I@*IN4=5)M]P\Z">D3I%!(ASF
M$A]&F J(4!)!$LAM0X("/V T#F-,5T^\(/EE2*%+RG)RJ/+LE=^?\0VH;^H
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MT# $W+\Y_O\R4:ZC1*9C\Y86P^*6;CS^(_;D(P5A8MN6%H@UB[; BV%HPZ9
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M*M??YM^X<G_H9EO(7[\6^5-:JJ.J]A(V1 ('3B2=%4(@0I%4)%0@J4U8((+
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MA7W(&FB84%%M#1M-]<FZW-'B$C!J'[ZP)"RYG-K+?[ZFX!. ZV\%/F9@FPW
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M=6?C2N\RBADD7N2P@$>8^UIE0,RFO31U^->_Q'Z(_H$ J<G?MYI\:!@ %0=
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M&G,_=B'U?0H1D?\D49! AZ#0010'(J1M^+>NKSTG@5HOWV%$^-*'&DJL=>.
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M[N6ORQJD.\J;YJ<#VJ6G15 /._+!Q;) JZOYY0"WI/#-EOA,FX 9>B/;@>:
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MXW'@:I93U2-@;=M<^.__YH;.?]9%^U_7:__[V#"B:YYKRD+56%\.X86WJ8;
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M\9D/8\8=3-S )8[R:?S4)&O3H1V=H$L >B=,F9Y4\,O^Y[^H*X63\$XKTCE
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M=F2"GDYU0^X4C-/F]0S@+!Z/\Q(7@\O<4P"I&ZTS &7)_MP#-F\[XPD$1BS
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MQXATJ[9)$;3E9?^D5KMZ,WE-&R;+2V%A^Z(7P(<# >QYD&Z_-DF@8P-\L"@
MC<CBQ05A*^AX$8'H12:?A>58T++9P/;BF<]B_"#4^;R1#*H2#$H<W/S 3]7P
M%W<^1\B-HABRB,40T5A>W 4,IBAAG&&2Q*[RJ7UTIK7M+U?#(AT:R?*C:$YO
M"[-AM+#VW\$CZ0(-I>_ P2_GPDRCM,!<V-DJ*F".H5X] 15<QBH)C+YOKX:
M"AL'U0.47I@C;^2+H+Z)M*@OFBN7ZU+)>WL0:9RX$?%1!%T6A1"EK@^3B& 8
MIHQP+T$>BI0J#RQ%X-KT\\7$W5832;&Q<R\V\U)0O2M[.P';B]H0I[B\R&''
M6R\Y(2N-NS0K*2GS"<!J=LH,9+]AHLI\H(_GK,PXC[Z!?EGD5;&1[BJ9*L/^
MN:W:\C=B-RMQL_I_Q^5]EE^)_R<[7(O9NIC4U''#P$TX) YC$(6(0LQ\'Y*
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MU/'\NC/&-6V*>B$S'K)J5PW_:\WW?2DC%+I"J280I8D+4400) 0+BU4<ZWE
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M"$Y01F,OE..+:1P+Z<E*:A@OSJ,J:_3!8U%?8^\P)ZNRT<=47ZV-WN=&5]S
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MO6 ,%G/?__3"A=U[67A?Y+W_Z\?'+U[^F]/'VR)O5F?D1A%A@L&0NA&46E+
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M-NN(P1>S9\<#T+5U$XPV(II*!X]_P51UU$AY^?E'I7*S\NSZ69>,X46:L_O
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M7O_W6OR1J=N!FR)_256,RC?^HC0FTY-N/BWO$:%(N+XT G$00H1##F/7X3!
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M]Z'J9J'6F3DC P8/8V]PH3HUHLLIMQI,>+D8FN/"+2=!]22%W\<MU=%QE8-
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MMG_[_.-9AP7<"\XC%GL$AA[V("(Q@3@)Y!8T3GC("?>(\,T+)(VBX=R4Q8;
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M<"*/P&"1VX9A]LW=D .\[GG+!2Z)IE0^HU_P?_)55:K?M"=2>R%OAUO&R3C
MQ,:'./3WL2Z"+D=5J)8P9;E^ZB2?A<R/'4Y#R%V$(0I5, CG'$8)1B2D3AS@
MP,XS.#35N;V8&SH!WA(Z,N_O(+RFQGX*T&9^DT?A-<*N#T$QNSD_2,#"5GP(
MB/?&>_")"=7'M?B=LY3BU65>5G=24S'53Z.\IP1+;D,?,N3*K488)3 6'I>_
M<A)XL>LP[WB%<F#R<U,Q_\'QJGJD:J-.):$@S<2J+J*B#G(G4#*'A'"$VID
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M,\?(SO3L?R&)S&P!?MV* *S+&GZ^)7XK _"\I7_**X0)8)S]IN$8&A>^D)@
MSO?W%E,,:N_W-@[US2,NGO#MQ9<"2PS:3!)!D.<BZ>W*QR!*O @FKH-@2#'G
M/D<^B8TC-'KF.3?5V6[M:EK![2\7%FDD?7@.>[43H32S.ML#$*A)'1'8T0>8
MN2,[$7 +^;"' 9PH_,, CAZ?M>_IQ=Q5 Q:ZGJK)U\<ZJ9__9ZV2]ZJJ2,FZ
MPF3%[_+K[YE41=?B!JLN'LUZ]2.?L< AD'-U?>)["4Q"Q""-'2S'QDX2&W7=
ML)_Z['1HAV+I[=1U0KEF!CSF*XE^J8X3ZD.=^J^V[J>Q5$Q]S3FPGED3UR0#
MO(LVR#75.IA8TSU+&5%;N&9W((T)6MA;M 7JO6MH/<+8ZZD[G'['V66^/<_'
MCB,<RCSH2'\/HL!W8!)3#X9!Q!B+2$"Y<9C+@3G.37?59(*:3G"9__)AS*W3
M>RA-+YJ. FB1NZ4M-D==);V'R/;VZ"BH%KTPVH5LTOSA@R ,W@F]?W+A:Z"#
MI+^_^3G\57ME=Y5)/<)+U67D6M7FT=494EY>D%)NLVEU+W@B1$PBB!&36H\F
ML?PI#* K0IZ$7D"BQ+B&PM!DYZ;^-O2"JPQHBD%+,OBK)=KB71\$>U@O3@GA
MS IR<?3,5>:4*"ZD.X]$TTJ9FL+3HU4'AUA,O9HRT]6SQL^,]2YO<%GQ=5'O
MS6\O&IOO)0P1-PD@82Z#*(P%))[T-3V"/(^&(B#",N9I[SSGIF8;MZ"AU=9U
MV@^EJ8=Y-$#+>)D-F>"GFM"?P>W%Z(HU^P&S]3>/!FY9GW,/@)-ZGKUP#'J?
M^Y]>V /M9>&]%]K_=7O%^*?*IFIZAES7=<<__^ %34O.KC+]\<=.*Y&+0D[\
MH(L'WH>1W)H+%$+JJ$YU/N=R9^YY,'%0P .1>#Y/[C/^@"L^D#U_'"%&RS^I
MEW^7G/E6O\YG^]"V+ *\Y<-<9QPAEF$=/#/4RZAHS82*PM'T@H8/L&%$.6SU
MGS0OH&$&=+A91!SF&GX9L2QD &KQM%VEWK\*NB^J_M-.PRF MUQ-9"F.A[7'
MD!PQ^&)VYG@ NF9H@M'LK=3G=9'CY[1-4A"1X$[@0(>X2#KL+H>$< Q]2A&+
MI$G"U"CNZMW(Y^:B?_[CV_7%S96YGMK%:=@2C.9^[FNEFJX1![N[")@KW]%(
M+*1/&_JF48E[F>W1<KO?7TQQ[26SJXOV?V%$#-*_*T[QGYBN,US>7GSBEW^V
M%^HN9TX<)1!%G@.1< )($BY@G$2N[\>"QL3X]NG@+.>F=FI"04/I![7K91Q<
M_FD14W,0T&&=- E,,^NG=PBI )I/$J-?_ARALPZC91%_- 5J2T4?'49OHNBC
M(3#Z8H\./KM<Y-$0^3MQ1X-?'AT:GY9TE:OB*]?B5Y[Q J^N,I$73WIY7)!\
M76U*7=S*-:.=/.D,/DMA*^&\WKM!X"=)Z$$JB'34B' @IHC#)!$^<YU(4&19
MS>9HFLY-UUYE59&SM0ZCM8Y_/UI _=KX1+#/K+NWO*CMZ4/-C6KPUK(#L.*G
M4XZHW' $_JKXCPH0^:;^/6DLTV0 SQ\E?S2E2\?*3P7MGHCYR8:>0D??\:?G
MO,#%ZZ=4"*Y*!O _,I7M<8=__*9;/%UD;//)9<%96I6_I1F_DH25]XC1P \8
M@G'H1U)9,P%QB!.8T# DQ$V0BXS:.L]!W+EI[5T=4K6\ ;9A[@-89W6F#?[1
M]#_3K= ZG]*:2?#72B41IHI/ZRKG$\I_C"U83JJ+&H4E!'JDD9@&^46MQ9$D
MG]!L3 -VO_V8:(XQL6AII8K5J19T=[QXNJ<$D=#Q":2QBR$*5&$Y7V 8>$P(
MY >QCXT,P;[!STV1-_2!E6[%)V=\LHF,>@/<\-G&,7#,K %;)#1MX.XX)&QB
MPL8CLE@,F#$REO%>^UGOC>]Z\\B"\5S[B=V-WSKP'7NE=/F(BP=.,/W[2I*6
M5>D+;^L1.C@4)%:93:XZE_69 TGL$"A"@1!#+$YB;JJ>#D]S;HIJ2ZGJW-F0
M:OZ&]N YK+6F06EF_=4!:$OEB,/8'J3,M=HTB"VDW_8NK8DNWX>!Z-%V/0\O
MIO>&&>AJ0(-OC]WIW_('M18N\ZS,5RG3:T*[?KJ%5>PRS^7$@U$0J,U[S&""
M!8..(&$81$D24:-,></YSDT[-L0"VJ6VWH&-;!_6#[?I7GDR$&=6GD?@-V(?
M:X3*[%O3?BH6WFT:0?)^ VGVV%B5<YD7:DM:\>ZA9L8V)YG7XNK+M]O+_.EY
ME:IPU$U*"&7(P5X<0L&(#Q%S7$BX%T%*J$ Q]5'H6&JCL:2<FZ+:\ $ZC #)
M"=BPHF(:%3-@RXUUXLX$,C15<4M(9F[7<2.4G5L@*93-S8\Z%=1"H1VAX.GR
M?Z;#<W:].9K A57JL4"^U[9'CSA6$5\]/>.T4%.HD\!OG.8/61UO>5/D(JVN
M"_7YE=PI9 \I636]LG0.U=TCSG[-<_8]E>/$A*"$N#&4OJ+T$AU,8>Q'%#H,
MA9PP'K%(F$7L3TZ;D3I8-(A_RYAZ^=,- R/[/$XFPY@A+W0PC$6DRL!&#DQX
MR&#,B6IH&(O8,<I6.XT$ESS:/4_YF=K5$TAE[A/FK4#4_1DH-CRI9(!GS954
MC/J/']X+#.0Z_;:2S(&'AKLI#>_$@,]NAZ>B=V&S/#',[ZWTU!/,:[0W>B$,
MW= +(Q?24&Z74(0\B",L_U&%(!AAC+M&%1_&$G#>ZKM]X5NE\6_39+K1\IA6
M3_\?KXY/IW'/5+&>M_Z<2DT>J0W5F?CO^$?ZM'ZZD8O/;2]2F,LPE6J.)8G4
M=7ZH6QD0Z$4,"3=BA#K8] KO_?#GILD:"H$B$;CF-U%[@!N^JSL.CIE5SBX2
M(R[G]JTEXTNYXZ!9Z#+.<+%87<(=9KSG\FW/0XM=NATFN'O9UO,M>RWU*\_^
M_?K$?UO_D"-):3[<XF+5+#%*B!]XTEH(Z8=!Q-P()K[\U7<2+W(Q2DA 3-55
MSSSGIK<:4L&65J"(-7];^S =UF03(36S2CL T@C=UH>6N9*;"+6%M)WM$K-2
M>P90].B_OJ<74X0&+'0UHLG7QSAPV5I@JIIUJ--NU7GE]3)?R3^KPW!U!OY0
M<'T WI;M=QS&HR2&#A(^1)QR&"=<JD\:A#QTO8@DQ@6U;"<_-R7:H;^^4=(<
M -IE >"6!QM/R%(H)J[C?%#/[EAN4=:7J37*.]2##?FC'$]+N&W<TOE@7\QI
MM8%_*J=V'&R]+J_ED LZQ..8W7671XYA;S&Z>0V?RRI]4M=U%T_Y.JM*^<G3
M\RI_E;KW,L_J@N*JB,Q=KASY^C#V3E<8YS^JCRK1\C[ (G)=',+ #:DZ&I7^
M-V<,2I_<<\.$4NF#F]J3:4D[-VNSX0@T+*FSTY:I?Y1@ARU5J%]O,R\L+L1F
M$.^P93J=T&:V6YVTLVLIJ'?2N^Z1WMV.],!?FDF@N 0?^_.3YQ:HN>T[G6 7
MLHR[>85\(V"\?3WY5L#T[>NI$H6;Z\^) K+G0;S'J$X\X6(F=QZ@N@9YIAE&
M5%<3@E,UI[X$_<JK*LT>.H7;RJ]Y]66]$NE*#O!P]\BO+FY][[)(I4E+\9>\
MN!:BK)_:I+M?9655Z#>LO"<!]YV$>5 DB8"(8-4G4^X'_<@CGN")E[#@_H47
M)#>JV#8OM39*I$OS?#ID0R5(MV1:5$2;6;K#YON,)#:S/6\X57:[+A;?,-NM
M.EH"R2[8\@LDPT!R#'P/M#P#R338<@VV2^#J')> 19F]\UD*2Q7N:Y:$M/1U
M %/6R!1WET0FEX38+HFJ7A)R1=!V18A<]3_?K BQ3RE,Y",L)*2^@H,S4[!<
M"<-EH-PIBKC0E&/CHFZ*_#DOZBZS=0^QQ_2Y;?UPE=VN29FR%!>O]\017APR
M%SJQ2FIC<00QPP[T T&%PQCVB-&]VXBYSVUCW_4!:FKK()U4?O@L/U7<O7;2
MM^060V4JX"PUS1(>(Z!^TS\S[#.;\BW-6G6W5._@7VX(GS(LRAJMV2.BS"E:
M.!C*&JKW<5#V0QQW'EH7SA9UD)4*L;H6<CN7RW>[TB5>_C.7*^Q/J6GEM\L+
M2M5VD#.IEO\HI4:N&S'^SJO'G&T/7$1(,$]"'XJ(2$49>ARJC97ZAZAN#)X;
M&,=3S4SKN2G6ND6 :E2JF?RG#H542TV^WR]R!=3N&6YYTV[8NFQ]M*:A[)/F
M<=QYVQSKP>Y$]<127O2(M6D6(4#-+?A)\?NS^F#+LK["TDR#EFNP85OOS#3C
MH.E]6[,._CKZY'6.E3#N*/;$*^(D9[/EKB*H8Z+EKWB[+M3]_;_TNGAIU\4^
MQ;"C% #?5GN<X0AW1DD9GNG.0<%)#GEGA/+0J>^<4XZH@E_]CHN_>:4[?+2]
M\0(_P4Y"(<<ND5LPGD#,&8&.1S#R?(?$YE>O>\8_-V^@)A"\* HMZK?O 6[8
M!!\)Q\QF\Z("#1AU)Q_[MG?[4+&H9W\<.DM5LJ_ 4V?)3*3@>WCO*UR_YZGE
M2M8?)GFG6'W/UT:?)TEA/N*RUJ//O*A>U159)=6G4I#/NC[*2EKQ5*2<7917
MVJU71V*T2E]T?]'[4 0NPYX'0XIBB.+0@W'D)] /*!)Q%(1Q[%@>-!U-U+FI
MQ@LJ"2_3^FJZ=I,T7Q_T)76EG2/>\F9]Y'2\#(W/HA:5S-R'5 TS@P+Y .B&
M*>G2-IM;?0VQX6O2,ZS)4)[_<.MX4I<^]9H,W#W'8=.-/5:A?UTKN["WQ9R*
M>&B:S)$#_18]/XQ)PGP8N$(%&P@$DY@SZ&$1^DD4>CZF9L$&$U%T?@$%-3OZ
M6+OFY5VK4AU*]E/;HK'\V5:?'R="0CT_(1Z#W'.0RK="$#L(0QIXQ \<++!O
M=)QY @$N$N2Y)?P#R-[*\G1B,[7 BPEC9N.[?8WV]CC5[U K"WBPR^F45G<2
M9&<WN,=1N;"MG032]V9VFF'MSWB:9@*7<@&^BKSXC@M67M?QA)_2\CDO\:J\
MYU+/)HP+B(/ @RA,8D@B3*&GC&?B,^30Q/30QV3"<U.P=TV'#T 5U; E&^1-
M+"Y@+>7FIR%&P \?&DT-Y\PJ4B&IZ 4[!(/K)FH=?)H)2/-SIJD!7>C@:7>)
M]JS0B8ZD;&#J.:,R&F:Q0RL;IKJG6%;/V>OH&VD&U IZD)LP=5N@3OV_X8I?
MD/R%ZQ]HM<:KU>L?TCK\=[Y>L:]Y=8G7)=^MZ7+O4T]XGB>@PY)0^M'$A\3!
M'F2>ZW-*2>(08ST^%5'GINM;7H"JZVFNA2:3T;#*/P7R<Q];;5A2-^\;$2AF
M@&:K^;%A#"C.@&9-QTYKYD"G?I5B[P2R,[<RIY#A0I:H(TNY$V+=UTDUTI2R
MK']L9:F[I7W7LE1!SU3+,MVM13:1T9H:]1[#-ME4BQF_J<'I&LC)Q[8WHK=5
M3O]6P7NT2/7VJMYDJ</,.RG'S86DDR2$"0\&R.,0):I4A8,%]&CL.\1##+G&
M]]MF4YZ; =14ZTC6ENSF(*-./JP4Y>:ZU1#V8:LW/9@SV[0:QR[%H":YSM+5
M1(\H/&&ZCHU-T?3 +F1H3!;J1(;##J,>LV XT&)*WXZQKDJW?-)>8;<G8A?L
M*<U253A?=4^Z*7+*.4NSA_)>1"AQL8MA2)T (D]5C51U[$GLXSAQ(X8BXS)L
M@[.=FYK>'C;C'9+5M6]+L[E6&09[6$-/"N$R1_4JS'<7O9MYT#-7QY.BN) F
M/@I-*T5LC$Z/#AX>8S'U:\Q.5_.:/S2F]V^=Y_)'UF[<.+O$Y>.75?[]/L N
M"@1BD+L<0>D(8X@#UX6!$%$04=]GR*@B^=!$YZ9J6UIM^M_VP#BL2:<"9V8E
MVI()NG0"12A0E$X$ETWKX&E@6ZR-< /?N@L?5? )2?%$KJL)*+T-AGL>7[#9
M\# 3NXV'#;YOIQT93^\OUBR52'^50KU'?DPI9PX4/%#*,(A@' 0"N@Z/B4")
M$_NNB3)\,^ZYZ;Z&-*!H,WNAWP+5K^Z.8']F[6;$N?&K>(#//;$5):>_/.0O
M_Y1/Z*@*]8-^+_4[^7:<15[! \2W;]RA/X^I+%O01\]QX\^_WWV]NKWZ^N6;
MX[B^[R$?.9L,%!9Z)&#0\X0#$>8)3#Q*8>!A%@B/QA&WZ!4P.-^YO9":9*!H
M!HIHH*@&7;)M:I@.HSWLK$R,X<QO]2!\HVK!#N-H4_YU4CP7J_BZ%U>P)7TB
M?\8"GM[*KL.C+%C,U9BEW?JMYH\=$W2PJ3?'V5W^!:>%3M:Y%MO"<_=N$E(G
MDCK9"44"$<<,8I%X, D=CGU/! X*[JN\PJMAG6PSL95RWDP_8Q2.FF/,Q;,!
MQL.:>"[D9E;)G0OC#MVJG*FBO$DW5!GZ8TK36D$\YOY^6JB7OZ.G'<BK' @%
MN<Y=U"E$DY<;'0.<T36[P7 GN$HW9W+_=;G%\\>H^*N,%AR7\K^;.7Y+,4E7
M=2I=X%"7.%X((W7FAV(>P%C(#:\3L\A!-'28P^WCQOHG/3>_NZ561?#OOB2K
MANC#-9_&(V^C]*?#<SF%OT'U*NMJ^P[=,X Z1LU/!^[R*C[=OW176_HG5^YF
M<!DI]H&A3J#4S9C;K] -GQV;*ODYJZ0B*K4?^B4O;OF#3M#<E &42^ZJXD]E
MLRLE":911&/HXU! Q.1/Q/40)%Z2>,AS_22P[#%K1\"Y*?F:^G^H4NN5*J*8
M%Z"L.>B44E01)JGBP;(&QF@I]1N!);"?V2!,#?N(3+EQV,V>&F=)UL*Y<.-
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M3<-(-;OB%4]*!RK-6 1Y$% 6)CQ%B59._>4AED:1!_E,?:43\'3]I#&0S$R
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MQ*41Q4%H4$E=+8:5W& ON/YB6 _SX=#%Y$C.3"P:(%I4U]%#4S]:,#FJC@(
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M47^R>BM[.IK1]G9EC7YRL5M;5><K!+BQ:I.;VBHZT=PW!_8]$^2DPSF;1><
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M"92BX'U_G0('EK5MHN+8PJX6<X^\"CIW>ZHTFI;MEZP*&K)7F_2KO;FKQ%I
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M^;DZA>BJ,;@=EK/'I@S%<AR4L@/M-!IE^1Q;NJR3F^4C.QT-[T/N"YX%#-*
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M?FA_W78H9Y&710&#F<@\B,(X@6F<)M"+,Q1E$4&(ZN?S&P^_--:J-(!RI"?
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M"7JSQ:M^@AX<R8B8]^/-]\+?J3%,SWM<0K&?;B?%QDG08=WQXI[W8DYY6F0
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MQ&!,$@$I95$0^_6YO-EN;KS3M6W-;E4?7>ZG?S9F_5,A]^B5Q!O(X33>J6D
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MW>D >DJ WY4:X-+@\&[2^)@MT'.CONC*VP!^<6; IRV1<P-_EOSGF^V,Q]T
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ML67T+=/T%OA&?'";@_<<]#10&1;5*5]/"?!Y >#U>=WR "Q$]R=\ 3,=EIZ
MX\!*,:75Q1:0$U3NKRNG-'-:H--UP6_Q7Q>T>L9%BC<J//5X+$/B17[ 203#
M1.ZB$&4>Q%',8("\0" G(3'QIX0OF0BQMH6G%SJJ:EA*5:#<DH*M,D!I,RTB
MQ6ALQM>9)1"WO-CL!Q-))<#M&ZRM! <9#<6TD!];0[)\S@JMH9D_/F<*@)I1
M-T9-GR669HKRQR)D)K5U0MQ+>RWBHFI6O+K]_*O4/\\JB<6F#M!ISI#+.Y<0
MYB0)AI[P'8B8%\,$.3$4#+LT82SF6)B>6!C*L+[SBJ_UQ?RZ&ASN::!LP*:
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M4-7C4.QTL7#!W @US9,KO3;/<F1EI.ZQLRJS1J;Z]O9/Q]2EU>I5%>.K^G&
MO3.R.T:1YP>1"_U8[9T"X4"2D!B&./!P1%PN/,.+':8BK&W9Z&1^5]>$K*;$
M/I\P'KK^-ILH+[=^2-YZ&H+;6C*MJ?!9]V89"[:PJVHJ<&_]4)-;FI0LO\FO
M\ LN_N 59[(_]DRK\O:_+C]]^=C&UX<^2ASD($@)XQ#)?ZI21A1&48PH%80Y
M^J6,M'I<&_,ULAGEA-> ==P8GATLZX>V7;J.3F#020P:D2=<_= #TRC?_KR@
M+I=^?P3<V?+PZ^,SG)9?HYTEL_3KJ_5=TGZ#%ZW:I[5-?!=SG&!. XA#$DHZ
MQJJRG$\A"7Q)RY&;>)[6K;LIG:^-F?=-)L8KG&[J./GOLY..65-*.4U2FC1H
MLYJOQD.QJ.%J;11LF;-[<*[#D&U$6J,)NP?61.-UOXW).;2[\-:?<9J5*DR(
MEQ=%JM*!?9;:;7W1'_EC?E_@IX>47I3E<U,P=#2^PP^)2^+(@2+B$40Q5H$[
ML0?C,(P$CER?N[S+1J3+LU8EUN*#_<Q&ELEY%SJ^J57]VP_W2N\? 7NN@_AZ
M 1]LIS' .Y6-4WA;G1(>30+ARWU0A+@'$0EB2.*80^I$PD\HB5&2F 8NGW]*
M+!KF7&OYMQ^:^?"CJE'QOV+D=5?OU8RF[06?=Z>_:79JV!?>LD3-#F [.7 #
MW)O@,-,9,R6E_!+C:#_QO%4MEDY/O\20'$ABOTBW)U1^>RZEM9TI@ZI76.Z:
M%[7I+;&]S%A:3_CRSL<^"@(_@0BY,42N%T 2(@;C@,OURQ-^%&JG:YG0_]KV
MCKT28#LE]NH;/NW4D,33Z3&AC)K!((U[!2U#;WGIZ%6FZZ'>K\#9TP!<+H3Z
MA.IV=M!?MOS=?*,PK4">.88Z%?0,6EV^Q)ZYR@=K\$UHYK0DO7()K->L\J+Z
MC-/B-[QY[J*^ZL"N#_GC4\$?>%:F+[)W=9/QSJ=.*)@30S=QY*H3L #&PO&@
M(Q"/J".2D 13TM!.D&5MB\]'3JJ]B@BX D+J EZ4,BK-7QU*F==QDK2O3WM-
M=%J*VRFCJ+OY661L+*].NU3"]69EQF&9G'#W!$ 7RLX[1<*SI/(] <IC>7]/
M:=*,D!E/[VXX?2[D[L'UR&U:J;,@1'PW\1R(72%->I\)&'N"08H%]QCB(4=:
M520.-;XVRJR%4N:ZZ_U ?@2=N'I$>!"]868[%1/+5&4*AS8!#>E]@%%*3G^Z
MSU_^)E^KN43]4!MG-5<<;&R1CW](C>YK'GSFI*+&;51CPPUW821BEP<",N&$
M$!$7P9BXGMR#1Y1XR VP7MJEH4[6]KDV5SRZZ-MF.9U49'@?2A&Y-)*6(XPB
M(2#RN+0I.4+0%7Z<4!YC'L=W55[AS4)0;KNR^*FK/F; 3M>2.PT1R[QG-*^F
MEE@^J/PR]93WNSY'\>2#RA^IE'SX67-_Y@W.<I%>O,BVTO*WE%=R"BC;"6>O
M7]+'M.*L"_1R'$X8D@#20.TI<0P3$@H8.B@,/3\@"=/.FJK;Z=JHM9$;MH*#
M5G+0B@Y:V?4]9MK@CSLG;4!JF5#TT)P0N:@_I[6]CS;@7<CE.!?,1IY&4[P&
MW(O:32WF4S15KN](-'[7G-(_Y\6?N&!=,I<;O*EOAJ;9/7[*"_XQWVQPT951
M<2C!3$32E@LH1#&1.UKB1)#30$1A[,7,T;Z?:=#OVHB]%;VU;N@K*)7PZM![
M*SYHY-=G(9-A&.=W2^#:=NNUN&X3"]5RUQ?4O\-UO&S*20#K,[TEH!<B>_V)
M/-,MS EP#7"]26N+T?T$%?N,/^5U<]+_]!<O:%KRZR*E_)L*CKC],^\F?Y1$
ME#@J^9GKRJT[1I!P#T,',3\(&!41UW)6CO2S-E+O1%75;*E*9:426E5_YOH,
M,P3J.&7/!)5EBMZB5(L):CF!%'2"W3TX![4)>";8%B+<Z? 9T:P&* .T.O3V
M8C2JH4*?-G4>-Z?)UO!^)E^^?&AG)G7C4#XG( H(@R@B+DR("M&B@G%,@A"[
MVM%9;YM?&REN)0121/U/^P!NXP1X&AJ6>6\/B ED=P 1?8X[#9F%J&T/H9G,
MQ>.*#]#7@9<68ZWC O?):N"IF9/BOG\NTXR7Y8?\D:19/0-4$<*/:?F42UM_
M-*(^X31*A!/ .$%RP^\G*BNA&\$0,9?%R L1U]KPVQ9T;;PYFK.POE-7Y\T5
MW+S^JJ71UCUX.O\86F;[.?/EDA85%8>TA:4>?M8!LT JW)G&YES9<$\5?QT)
M<6<:!.V<N'/U-WU1:G*^?_KKB6<EO\J^*.&Z3E)>WCF(Q4$213!V5)R%1SV(
M/57H*B8$,3],8A%VUS=OS9:9D:ZUV&;_'N;M$K<=Z@(CC>R -\*K^W>;FHXV
M._G-EXRQL=!G_SF@78K(3X%R$OUJ@K, DXY)LC@I:D)SB-]T7YU0.CO-TL?G
M1W7[O:M4S$,/25JBT(U\:?4F#I56+W+E'I^[W'>D34"Y=L'L-\VOS59M)01*
M1'"\:+$.<..;_-/@L,P6^TA,J7_]%A*#JM<G0;-4K6N]R6)6X?JHXD-UK=^^
MM%PUZZ,"[]6P/O[4"7=\TO*!LY_SG$GC2438C6@"7<I]B$3(84()@TDB3:B8
M>MQ#D?&]G5W[:^.I3CAPKZ2;<+&F!YVNK3,9$,M,U64M%GJ83+O5\E;S)6ZJ
M]'I=_O;)6Y4/WB@Y\-@$P^/#+[]A2N7VZ_UO[6(1Q?(I1Z5P]), (B:_;9S@
M #*',OE5,TR(IVUXO&E^;1^TE!"T(H+WOQFLLF^!TS \3H+#MN&QA\04P^,M
M) :&QTG0+&5X[$$TT_G"<<V'+(^W+RUG>1P5>,_R./Z4.4U]4%)E55&/[[>T
M_.-68E,^Y!MVS0OU%WS/U76/T,-Q"!T2RAV3HVJ0.B2!+(A\Q CG"7%UB4NG
MP[51V9[,H)!"JZP4K;#ZG[$6UN-<-S>"MHV9/?"4O& K,+BV!:,^/\X-YT*,
M>6!.5EM8=[-S)BHU 6F 7+6:68QN393J$[#1>Q.*SCT^X;104TAE.KK*+F6#
MV7U*-KRYX%-?^;E]P)DR4?],I<U* R<4@A(8^P&&*'8]F 38A5A$81 R@4CD
M:)>8,^U];62]4T =RS9) M*M$NU=M::*I?Q[P5^D3'A3@A_X7W3SS-3)7IF+
MZD]<\.-5+&<8M'&BMSH4MEWSNU%0PH.K#.S$!XW\;0$RI0'H5+")N$&Y.)O(
M+U4<;C<"*IF?.AMY\QFTGT>E1N"^566F%6,RA$-%WXS;7*[$VU1U]PJZ36YD
MCHSGE]D++ZLZ$4Y;D8RSSWGQJTJSI[(&5Z^_\.HA9_V", 0E81![#+HT\.3*
M(V)(" I@[!#7B8G/:7)"&O0)$JUN-=JI '"G@RJM#)[KO)IR1.ODV]4K>*QU
M.27]^901U/65+C@NEI>F_43IZ<@ [0W.(A5_3D!WT;SI4^0\8S+U$V =SK!^
M2L/FNX.K)[[9X+]SO*D>J+11KW/9*+MY^J^KJ^X:)V:^[[(8NE$201105T7=
M".B$B%#NH-A'VC'LH[VMC6\;@<%.8M"(#,JGG_[Y4R[_K[Z%.0[UN T_*X"6
MB7$(N__ZZ>JGJPFNZW$,]:WR6;%<R H?Q70>:UL;F@'K>KR-Q:QI;77ZUK/^
M2Z<5._[8EE:YW%56N5"%5=0ZD,DA2M]4?PT"QW4%Y]#E/H&(\U"E2\'0<V/N
M^,P+O43;?WZ2)&MCZQOZP-ESDT&M)_2T2KSFXS).WXNAO9S->R5 IPGHJ0)J
M7?JC,%N)9/.!F58NV>H G:UT\D EIW2GF(4ZRI/AU*RI;-[^6>HK3X;A6*WE
MZ0V:KUN_9JGJ9.=8NI5;%;DOZ9V41;%#:"P0#,-8;A<8CV$<^@)&%+MQ0D7B
MN5II$?6Z6]L*U$H,TIVWM&IDGG3$JX'W^*(S+XJ65Y8.P)Z[N15WTN&N!H#Z
MB\.\0"ZT FC-R)GH7A^@ 4[7:&0QXM97J,_.!F]-=;1_P57CNK_*^']R7%QD
M[&M>;7][^V>N?ENV>^(XPLAS> *YYSD044%A0J,(AB)RPB#V">*N:9$S(PE,
MOHMEBI8IX8!GZATW@QUCG\2NCR!RB-RGA4@=H;,$4A$1UX^(CWUA=IIA#?0E
MUD;W7__%#9U_K_+F?SWPJF2U.P2ZQQ'6@+6\7-82-@>N><9K1.O;PEE>@<WN
M;]6?>8/V>"JT":<-D\"S?K9@)M7")PF3('M[;C"MF4EAG6H!DXN7_*E,Y4NU
MU=*_$!JX'*E;)##&5$BR\SV8N Z%'DH$\0.?,*0=-#3>W=JX;2=QG;EA*[+Y
M)5Q-N,?-_GE!M,QC/?SVI 5?+.%G%- Y(X[+A7..SL?Y8CDU\1F.Y!QK9,DX
M3DV%OHOBU'WKM/.".FKGZJEN/[MORL\T]>C]@$1!3!+HA8J" R>&1!W7<A_Y
M DN"]CWMDUJM'M?&POMNZ28<<"LW: 1OW= 3?<_'P3=S_L\"Z:)._F71G.:Q
MGP75A1AZ%G0G.^-'D=)TNA]OYRS.]5&UCCG1QU\\(:W-7M"E--&W$<1.0A#!
M7@(1%Q0B%H<0TXA!AEPGBH@3.@F^DT*E.;NI<%'IN@D&^C3Y$K[OV=['\)[?
MIUFF)C[!&U7J<D+"FJ,HNW'@H"@*('<2'R+"'9@(-X*Q%X4X=,(P"D6+\J>,
MG07CKE][",L>+,&KZV*9"3#+BU[O5D%7+3)CVV#VF9/_C.&Q1-J?HS(LG_!G
M#(Z#J7Y&7S*OR/A)6O+5:YU&"-,J?>$?<87;) IW+G<0]7 , Z+.-V/DPAA1
M#@,6DB!R Y]SHEN=<:BCM=G6C:R@)RQ0TK;E%RK]BHV#Z Z3R9R86>:1J7 9
M5734P6)2=<?!AA>K]*BC7K_JH];SYIOO?^3%AC5Q@%?%/<[2?]9;@_:$@; D
M1($0D$>*#WQUF=WC(73#,!%.3!@.M0L@#/:T-D*HA6TC44%?7/V]X#"RXSOJ
MV?"R3 9'H9I0F688,_U]\VS8+;1?/HKA3&Y,+3P&=L7#[R^V&]92H[\+UGMA
M0O'')ZX*:<M-=E6DY%FU^?59M7DE;AZPG!D?\NR%%Q5G=R%B#DF8#T4L H@<
MD4#"J0>%1P@+.7:Y?I4$_6[7QJ>MY"I<<ROZ.Y#5PJO S;(67[GS&_G!#RI?
M>/U+@XOE!L,RSK]VP+9,QAW.'_=P;N16KKA&<K 5W0JV!M4AK6"\5'W(N; V
M*Q!I#-E0B4C]QI8K$FFLX%Z92/.WS>F_RR;^G4_U#@GN>*&KLN4R3W)]Z$*,
M(P$)\D/7"P/*2*!3ZGN@#R-B7Z#2=R<FR+?N_;065)]9CJ$9D=AEKI_ )$XD
MFC3$, DHAE(FC'WJN9QK%TZ> \T%EDF+:(XO>#-@9'EUV\+S_5G2Z?#HKUDS
MP+30 G5T-LVTJQA!8F#=.?;F8HO,B.C]%67LT<E1SOR%;]PK\1FGQ6]X\\S_
MGLH."OKPVJ5 C1('!8C"@ 8JXL'G$$><09^'L:#,B2.&#2-L1[I<&QW6\C8!
MM9K9V W@U3W:F1,TR_Q8BPI<M:$24EKPHL0%#YV\=N)C->&Q'Q([)LC24;":
MP!P(?-5]\[18J^94Z>]\HS)PJ.JZ5\6GOVA=KNLB8]^X"K%FO1"O[^Z=4E\(
MYDEFBGR70R1$ ./ \:"(0X+<.'$C$4X)R#I-K+51V,WSXR,N7M4GV29R4YK5
M.7.4;G+@0*?=N_HTMJ<9:)4%53[Z\K08I1.GP+A->9Z!M4RS^]%-_9'YW(W,
MU6YD@%1N.Y+]T9WKROB)@S@M&FVYP3S;9?(V1.*A^^3*]I/CW<"JS[5H!W;^
MT./YT=8,>SNQL[/$QLT#T+$ NIE:GR/QX-]?55!5)C;UYR!7EF_\*2_4MJ2?
MJ"YDU/%=/X"A&\00$1=!0JB 21BA*$9<)(Y6',<),JQM(=X7^I3,@7I#H+N]
ML KL<@MAG1WP^YP;#]_K(^FR56B1[(!&>"Z:#U!/LC-F #2";CCGGUE3<Y#D
M37J?I2*E.*MZ"0<OLYMG4J8LQ=NT(7<8ATG(2 B#A F((NI $JGZSBY%84B"
MP$NT+O:=*,?:R'+_P^Z+:W8GXM3AF4*B5D!?E$C+/;RKF6Y)S(36HC2I+]T9
MJ=(8PF&Z-&_.W WTC:OC42JMUOI05!7FD^/1%6J,*:.,^ 226/@0^;& *MD#
M]%DB8H?[,7&T;SL/]K0VVML)V\2> +4\ 26O_LY\&-IQC\EL@%FFK!Y6M:!-
M'4PEZH3,I\.@Z7LH9@-O(:?#<1#G\2%HX3'@%AA^?[&=OI8:_<V[W@MV4IM>
M2UN7ID]X<['9I.H^4ODES?AEQ1_+.RI".1$"JO;E2#*K3R%.B.18+Q ^PSQ(
M8C1G<M,!6=;&O?LFT$ BQZU.8*L4^%VI!6J]9LZ[.32:9NYORV.TJ,][("GJ
M>H9GWL2H,PW3\A>P+7U-LZ=*U0#XQ&2I0SVL*EVJ!A2F"5-UFIP0!X^S7*2[
M-.*7F=R@R*Y><,6_I(^I7(!;&RY(/,]#B0MC[C&( D_N+A#GT.,.P4[,Y#36
MJM!MU.O:UKA&\'Z"^UITT,H.6N$-@K*U\1]?JZR@:GE5T@1TPHY$'UF#:'<;
M""\5[#X7TF;![J:(#<6Z:[>U7*B[J7I[D>[&+YM?%K]X9JD<G9U-Q1F- N)X
MT'== E'".$RP$\' ]U'HNHX*<]>](/Y]XVMCZU:^"=;K0>B&&?A40"P3K1$6
M1M>\CRD]Z6KWF\86N\Y]3(W^%>ZCSTQP1/#Z0T]?^.<TD^9<*@V[+DE$+Q#A
MYR(ORXM'56>KO!)"/G"9J;I;!5,FX#_2ZN'RXL;W[@+J^QX3'(:!P!!Y+(!)
M(O^9. EF3B "$NG'\LTJVMI(H18;X$9NN;=2@M>7%?%6=O"G%!Y(Z8'O&5Q>
MG'E(-9P39QLHV[Z*K6)@JUD7IG>Q'V+Y#C0#VNH'&@6E;0-V*H)_[,;S;,-I
MX,PXV[ NY=O8#:_8#F\OGU$O% _<'_I<CWZM<T7N61F!(>?'O!TNYPNQ M2>
M:\1.#X8+=E'=?:AK719/N*A>O\K)??%76MY%'O.Y)T)( I^J=$LQQ"'R5$Y3
M080G5("]UK)[I(.U+9Y]&8$2$ORNQ-3=EA^#<62IFP$<RPN6,2[Z=#2B_ $K
M6^"2U*++=QLSFV^J4OUK9VL?;789ZAA1:DL 8\_-$6O61O]>JP[Z\9^NA_TP
M=AB,<"*_[02K:M\"J;K?89#XH8N(UE&?4:]K^^"[:P_-S*X*G)4J>56>&5?&
MT(%\F >L ;G<R5LNMO<-&D27"*(=06C1>+!CLIPQ^FL$GN%8K[&7IT1VW?.,
M%]N<69$C:,*<$,;<C^7.'GL0HSB",7(2'G/*7/T,;M^UO3ZR:<4SB3O:1VM\
MTWP"!I9Y8BO9I/BK?1Q,(JXFX[%8C-78M# ,J3JH\& 0U?X;"X9-'11U/U#J
M\"/FQ"/IBV<E_QFGV>>\N'W@UW7RYZ^\^LCE-IVS][(CD5;=KNNUWH?=Q5$B
M/"3W/)&KPNX#RB#V P=&R/4B[,:A$\>Z*7.FB6!$8PMDU&FU^-L/]U*/'^N;
MA]4#!TTN;?U/>N)XC#.@?90M$V6K % :U#=VU=7/1@D@M0"M&J#58^LN?&U\
MB-:'0)]\[0_%0AP]..=G\LJ=!M8 OT]L>+%EX#3%^ZO%B2U-*<WV^)@V%R"^
M<<K3%ZYNX'Y4^3'RI\>Z'%%9E7?$1TD4!"Z,A2N-7*9^8D$((P_%?I!@SJE6
M+4K]+M=F^_:DEEO$1NSZ,V([P0%5DIL4&M,"?WS%F!]2Z_ZX'9J=Q/5*T9,9
M?+""IDGIMKE17:Q\V\GH&M9P,P%JL(Z;5D,+UG(S46R_GIO1FU/]I&W @^SC
M\3EK:\;=>3QB)/8=R#WD0.1B#Y(@BB'C+HEBS(C'M9)D#G>S-JO^5O5AZO0\
MB)^NE_-45"QS;"O>OZGU:B?@G$[,(0"L>RT/=KZPFW((@+=^R<&G3[LJM0T^
M_P47?W#E\"QR]DRK[U,1D0"'W,>JW 1U(2*A!Q,4>1 +$<0L%!%CVD'B$_I?
MFU%W\):-,NIVES8ZA4"GT;3K-;H#-&[K689]N;.6*S$$\VS)NW21GW:9R<((
MG"T=U]-V-!Z[T7AJM;&0<<L0.<V;2;JMGN4VDJ'*QVX@F38SU;B4ANL&EV4J
M4L[J<-HN>T'B$)%(^](A-(#((QS&TK*$'N7(#7F G3 P.W@_TM/:EHN^F"!5
M<IK:F\<@U34Y9P#*^B'9]QA928H[ H1UZ_-8_PL;H",PO+5!QUZ8RA6M7[*\
MQBF[*J[Q:U.'.>"^QQ53!)$JS>.$D(1$0.)X+DZX[S(1WV7\OL[NI_D)'.Q)
MZP-(F@^@WY^][Z 3$SQ).4UIXC":NB0Q':&%B@STH5'Y/I\:$>?DAT$,K+/#
MX=X7YH9!"-XRP_#C4WE!FB9U*KH\NQ*_Y2HEW77^)R]4IL]>PJ77.\(1=A*7
M0D2Y_ _V79C0,(0AQYQ0%.+ U*;0['EM-L9.;&62O]2"@R*]?^@2Y:JR75OI
M38E%=SATJ<8"R);)9R9\)U"2(5;624I7GH5IRQ"FMT1FVL <,<I-Q9);_%<_
M6E8=BPI,'9@DD0-10 *(0ZX"<7R'^D% (GQ"ZLM#7:Z-S!H9@9RN@#<GVZ=$
M)1\$69>IYH1N.1]9G?1WB^$2P<A#V"P:B7Q0D#.&(0\!,QR#//CFA)0P#SS[
MI_S_37J":UQ6_+EXG^:;_#ZE>-,Y@S[D7ZIM;AB,0]=S*)0VELJ%AEVY#_,Q
MI%$0)U[,D._YVKEAC+M?&RMU&H VY<93HP/8*;'S0G_(WP&IB$%:$_/1&??Y
MV\7<,IU]#_?U(-P*[2G99,QA-T@K8Q7^I?++& U#/>MG\OI/AV\HV8QYH\ME
MG9FL\%[ZF>FM3$EWT0\OO):FFIR,*JMGYZ&6IFPL$/,@(YA!A (,2>(F4#AA
MS"GB)&#ZB35'.EO;@M'%*Y,V7OFID;A.7FQR'CR&L<;A[XS(V;9BOPOR;H6M
M$_"6$QA^%#V3! [SH;A82H:!*3A;5@4]6 ;S)(PTL6#F SUE]G,9:+XSU67P
M09V]\/)*;',E7&9E5=03J*QOVHO C[W$=R'VG0 B$3DP0<B1NR46A5B"$# M
M2]V@S[6Q;2MP76-SFWTDW<D,?L?Z*0U,L-=U)<R*J&46/A7,"=X$;7BLNQ/&
M)5G8GZ -S5N'@OZKYL;?Y>,33@O5TI>\5/'*^7V6EBK%K30R)1->%>KWEW*1
MR^Y3LN%-@I>KZH$7MP\X^SG/V9_I9O.-OTAZP)LFS<L=<2/J(#=2K@8?(BJ-
M18PI@A&7_!;&B7"HMM/!BH1K([Y.NC:;DKYI9&?\QJW1LX^*9?+<Z0>4(F"G
MH<I?UNBH"I&J/[X#.SV[5&BUID"I"CI=WX'M*%^L8I3UK>:SC_9"IO991]W(
M8+<Z(@-6OIU^%]L:6(6MOY^PVY'Y.G\E1$KYC9KW'_ C*5)VSW^19@6F#\^R
MYZK;2;LA(W)UCJ% 7@P1CN4:[K@NY$A^/ R1((ZURU-I]KFVM;@1&]1_?@>V
MDK\#>[+KD[<N]..+K@5 +2^C+98WPUA.< GI@JJ_QED =Z%52P_D>=8=0Y0&
M5A+=EA9;&PQ5Z[.]Z:M3BX%<O,C9E):?"Y4YLYWADK C2G@ B? 01!)GF."
M0H^[-!8.2VC S8I_'.AE;1S=" I;24$CJFD!BD-H:AS(SH&1[7/7YIQO'Y[Q
M8'P#G$P+<YR(UZ*%.+Z;5G,=A8[A,%I>X]"["Y?3&!#_;?F,H8>G,N#^62@O
M/^0_[8[U'3]!/&04A@Y6!:<1A;'K)C#"$4H<["<^T8HDUNMNG9SX_>$^5T?Z
M/YE&LHQCK4N4<R&X#&,>!V]RF:-!%$UI="XTERUL= JJ$SA6!Z11LAUL9&'6
MU5'H+?UJO67.PS_G+[S(U.2YR-B-G$'\NLCO"_RX"Q=!#L=!#$40(G6?PX&Q
M\"ET(QH&(O18HK(.ZK'P6&=KX^"=O'6UA%IBT(FLSQRC&(^S[YS(6>;>'F@7
M;T";P+NCZ.FS[IPH+L2YWTW!LD;SJ95Z)EM6%Y8!EAUM8C&.U56FS[#:[YCS
MJVSH)571)ZJ,1NT0_O!<%$U/7_.L_4>OOL:7;14TGT2^YTG2)5'H0)30"!+,
M$12A$P4DY+'C8UWFG2[&VCAYITE-+\T932M__1NI#NS^W5-H8F7E$\9OG-67
M&17+?/^_9T#T%XIE!F:A):0W0&H)R>L!HNV J-]D<H"Z?_<J0LVTNIR.Y<"Z
M<T+CBZU(IP/07ZMF:&U*<MFR4@6S2?655W<>2B)7E4 ,'.I#Y*OKD#Y)((Y)
M$B'*/!'B+AG$K5X^\KT.M+ZA_1P0MPOD)50RJO"[C%> 24E-$IKVX1M?%\S1
M6"K9JT3@2@ EF<K_/14!D\RM$Y%8+$%K,R?4?% 38R;./*CV8+K5_O,+9E4]
M(.9^\M1##TP.NLX?G_*,UX7G/OW/LTJ:K:)]'2R('P8(<L_S( H8AL1U7>CX
M/'0#[G/$M3P48QVMS1+>2:EF(*_EG!I2?1C98:::$R_KQ&4.U92 Z4$<[$=)
M'^Y^Z=#H01 .Q$,//S]ERWTDJ][_?<[R31<9Y7$B*$T@$J'*@R\8)%[LP2CT
M69(X7'@.T]]<CW>X-O+XO[]^O?IBLNO2P%1GPSLO4M:WML>SFM823W!G:B%I
MLE.=%]'%]J0CR,ZU]]1'9W"7J=',@OM)?:7V=XX&[TVUT53!DU(%P_+R*ON
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M#*D31Y)>_1 F"4'0CW" 0APE<F=Q]\(+DNM[K(_V9C+-^WW:F^6=J*:.Z..
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M7E\HJK4'C?KO0#=C&@A6-2?TUZAUS8V%UKW5S1&CY76Y(1M8LA<08C$S8#E
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M9BM,:>@Y-(!A$'G"]2<>Q$[ 8>0E;N!%*.54.VU.?]JE:=:KDQWI'QOB =X
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MS;PR9*UK<9F^:EZ[:=O^MC;WL>N':>!ZT,<LA,@-A2E&,(94YJD@E+(TTC+
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ML8;+^L13=23?U3_Y(#31?9:KD[<4B_?%'V4Y-?9<%ITR*><>CDZV,L+08S3
M$72B2-Z3L@@F(4Z$[9HPXI+8<PEO5L9E3O_MUD5+\[NO"E8?MOX[+ D2NCZ*
MXAAZ 19+(@Y3&".A-H*$H<@-(HJ(5K7Q12V'=[D;:=<$J)=#6WFQ/6S?.X9O
M2RY"Q7!KM0"\8WG1BV;DO<M[+ 7;5S'3KH(9;VBF%H;M2YO)Z'_?>YRIQ3!X
MM3/YA&/-W]]R&8]TAW_4@0-MQL"OQ6?&65FJ/ZG"ZKM*/2L:!!&.(PY#ST\@
M\ID#TX SB%/7B5@01R3E9KO5""J6MA/5+ #QD;6!7KLDK+P0;G7-B'I -<KH
ME+0RW5'&"$UWMYA9%#/O!+-(882:/P/%V57X&-HLJ^<SX#M4O><,-M4E>GV6
M<<&%)I)47'-UI5^L5]B)$R<A2$B*>1#1T(6)XU(8ID[J,)(F*-!.F3*;>FD*
M],3U^8?VQ!%+#M17K8)J:R;.O<T]*9>Q5^=3H/T^]^8?VA-_1;R*]I1W!Y]F
M!OK<._,I '_?"_.1P$]P7SZ$G?%E^<D!W_FF?(C1X6ORP1',=XJ;LGC)*FGR
MBRWI<U:IVKW5-V'N;UAUD5-U9/Z-;9[+O%HY1%C8R,,0811!Y$3"Y@YQ!%WL
M,,1\CR8AUC].-IU^F:?#.PZ4E4=;'F3 E>(""#>JN>XJ:T:.G!7K:S8C@9&$
M,I)$%&(_%!M[',<PY@F"*$ XIG%(8LYT3WGG%]?\A[:CA+5_A#N3I(:W^KFP
MGWFC[T NK^VWA(.&<B!(;X($&N)G0EA_CY\+:4L[_(A%/M$E^1C@>K9WH^&L
M;>YCF.QN[:/>'WNRMDNVN>:7^2;;O(JA7UC^S%911(@;QPSZ(?8ABOP )@EQ
M8$#]F),XY!P;7O><GFQI;MY^;B13M/ZG_!H4M>K"Y:E^Q/BBI0=QW=.O:7"<
M6Z_W0CCE,=8P'+.?5O608/E0:AB,P[,GC7?&ZI<CS9;J^L9Q%'$<A,)!($*Q
MH(A[PE6@*0Q8% I5AP)?KP;%\%1+TRW;GF*D0^C(DM$GX=55)5. -K,B&877
M"#4R!,7L2N0D 995R! 0APID\(VQZN/36MY_5-?\:X;3;)UM,E:O;T3"T.<X
MA&[H.3*G"PL7-HE@1 ,WQ@R'41B;J8]34RU-?31TRDUUO:-TI/XXB:^N_I@"
MM;E/DD<!-D*!#&$QNP(Y28!E!3($Q*$"&7S#_.!2>D[KHGHNA5$C[\QR(L;%
M=0NR3[@L7[/\_N)1^E9WQ=_P^IE=Y]\898\JON$.IVNV"@+D\SCR('>)L%$"
M+Y;=@AWI$%'?HQA[/-2]]CJ?G*4IHAU'\M,J]WBJ*\K47 &LV)+!^"^2,2#^
M7&Y9 []O)',&U:8F$.SP89I=<<VL 3N2NN9@GQUUB=-*JN9(9M,HGL!U#KYU
M)'5G7U+ZAW)V)6;IJ&X:R4US>#<=P#U'>A-,8NV@;SI NL=_$XYJOFE>Y:1D
MN&*?6?WONX>R>+Y_4 %^'SL!?C=BE59MQ<HZ+O![+O:<A^Q)_6GE<>*Y\CK)
M3[$'D9N&,.5(;**4H0@%81"$VC47IB)J:1OHMGAJ$_;;$BNKH!NTC9E,9L.[
MXGM(8N:]L64)_-0R]4?0L%5W=X>*L3:)%"CZP59TZA&PY:[^\SO(3G^?? \9
MVJY&?.R#FNH.:VK\>C;#R::RMB5.#4YW8YQ\[-%W9F7QQ,K-JQQM<Y%36=/T
M225V8Y\C'., 1C'F,OXEA0DB!$;$I0[A28R3Q/#*[-1<2]O,6D(_J(]MHZZ0
M64NL\1W9282)1R+JA0GD5$;UIX3#-$DXC%R2>J'OAM0DPFABG*T&%9U&>W3X
MD(X 0A_'B(44QIQRF1>:PM@),?1HS+&+'10ECGE>Z(3P6PD2Z@-_3#B0#O)"
MM[#4\Q+HA\@1AK3#9'!="'U,4O$;["6NMWIA95I85B_=.=\)=;77&V>HG,9:
M^R9^"OSFOH@?I9G'W,,/@3'_-?Q)"FS?P@]!<>02?O"5L?;*6\/I\S.[*SZI
M7F?557Y!5("14%DWQ3HCK]_DVB@9_?AZ]>7;;?7I^5$6WLI>V"7GC&PN-K+I
M_36_RK--AM<73T_B)677-T7_PRCDL8L)9(B('9HG1+:N#V'H(;$_A*$?8&1F
M UFE?VEVU=6C^,-&%<(1I*JS/L'7U2> [\5&@P%E1 6+R5/UJXM;X":F6M#N
M\M#5K(L5NK7S"+H]CZ#/3-Z>U.T)*YD+CK?\@R<% "@;!$#Z"A0&'P#9H@"8
M@@'@#: ""+F:LAH*M:H:+(:;QHW8%-Y%CK-O-':YLKQYO8O(#C?$]R%C["9[
M(0L?EW+HJGJN#^.O^>6/)S$WH]]DZ.XUOV&Y5-4M8VV;'#>-O2CA*:0NHQ %
M-(3"C\(P=!$7IKW''=-,]?'$+&W[:Z@4'JWJBB74%F4_<.^EUO0"TMVS[, ^
M\P:T94*FGC=<J C>A@]0JA0!\9NG1C99R\LL&\CYH,Z^&YQ!HF75?CZ8AWIZ
M@C%'AP?BZN'Z></7Q?<O1?E5#;T*N>-1PC%,::(Z/ 4P#1RA7;F?$(Y\EGA:
M'9[ZIUF:HI0TRHI!DDB5UK-69'X0WRU9/S<-'8IR P4QC\T?C:,%C\&MJQS/
M!7%FM7<"OTGC WL0F#\V\-CDMN,">P X$A/8]_18C=&D-]P5&[P6H]X^IU5&
M,Z&^MIL]"MTD9%$(21 $$(6)#S'V$/00HBF)8S_&6I$+!G,N39=<MLDZ&TFR
M^AJJ#M&F:F,8<UT=,BF2,RN4 1!GL96T\9E=W0Q38EGW:$-SJ(CT7QVKE:XW
M#ZR\PS^DM53[JS+W<S_ZZR/;?&>LZ_>6A?"(+G)9&4B:6WG%A'U5/+(50Z[P
M*87=$T3"JT0I=V&,'0<&)$8L]9F3AH;7T-,2N#1]I[@#V88]&NNVB26GJPC?
M3QXS:\U:%++PF70SFW/+.D_]381Y6K.W=Q2J&%077'($5O,HLW4EEZ<S=4=H
MVGD$,+M:GIALRSI\'M /%?Y,\XPIOB.6;O:$U[_@\A],N--B$OI,9'/X]6O^
MH[&>'!HQ%. $$LI#8;$2Z?HZ"!(<TRB2=BO5RH73GG%I^KNFS:0LB ZL_;IX
M%K!FCP1HZ 4MP:"E&-0DCVC^K@>F27&5B4&U5E7E?' -BZD8 -5;145G'(OE
M4PS8VJ^;8O+B6%/]-KO/,YX1G&^N\A=6;51[LJO\HJH*DJD2+3)_ED6.&['0
M@S[C/D3883 ).8(Q=;'OQP['D6%Y [V)%Z>:M]2-S%#6Q%O7<)X>Q;FO8[0!
M'&'%FJ$QNW6J28YEJ],,I$-KTO#]$<5\U9WX5?X%9V63$2;/3K^LB^]_9?2>
M5;^RS3479NEU=\Z<_N\BRS=_$\0\BP6[0C1R6<P83%E*("(!@;$LX.BEPHJD
M49A&B;85.0E%2U-E-5,R^H8+MII<9N%;;D7:NJ)-IS%9$^,>"%="15MN7L$C
MVSP4] /(F8KG$I\,TVV&/IV8AZU:Z\*;^V:GEMM5#B1'N_Q8=>,CN0(U6T#P
M)7-J!6?RSQW%*RL0*NY RYYMJ1G4'[8M/5MEB8]]?44.B)2BNK1[J*6X^[KD
MG_%.BO)8Z'^4%%\:-B?*")L4\KYJQI/,8Z_(\92P[-4^GG3@L\[L+_.7K"QR
MN?Z_L36NG8ZZ>F/C^)*4,AIC8>T$KB.V51S#.'4P#&*<8I1@#_M:I?--)U[:
M[ED?[+(=V:"LZ9:GMC7AH\[>AR5@=*8^*:Y6SLI[(9WEEM$,*#MGVL/DO,=9
MM39()\Z@]=\W]QI40$6GW%)]T'W-VXJSPGA=Q13%)'%3&(4>DE4<$$Q\%D$2
M.-0/_#3Q<+#*V;VD[$[/-="85NL32^I/[&#R^3ZW#H7-O92^%:@#]K!E/A5V
M=M23HA9TR/T :H*ED=TA>5H4]2WEB=&T9 >?C:J1:6N 48_AJC.*-;/4@*6N
MT6GRVHAB=;LF3TK1B]'NBD_X*=O@=58UU7^^?6[N%=NPJ2 ER"$TA"Y3%W]!
M"&-.4LA3GX8N"R//U3ZR&47!THS,S]W.:67#ADJ=VF-$^H??_H ?G_[\N0T2
M,/#HQ\EJ6+O/+H&9]?T6?'F TG(@*Y+M\Z *F37@M[R,N'8<)P6#<G)S2\-6
M!;GQ4IFH;-PY0/95BALUKKWB<.>PO5</[JR!1L2<B.7#-I]PR82O<5_BQ^OT
M?\1.E[VPJELG_AO+V7><KE]OU5*EESDK[U^O\HOU^C;;L.KCJ^?XS@ICQN,0
M$4A\),N%$ JQ%V,882>AA,=>X&B%(DY.V=*VKIHY6="1@8:]#VV/B::'0MDR
M!NMIJ?#])6LJ(7B]!I7D3N;_2OX, C@F%;A&U,Q[B7'NZ)I#"8(=:ZI_7BM,
M5<NS%6;#'Z@9E/<4@D6@> 0?WU>8!E$[[R546]$][R!<LVB@.030%S4TZ7SV
MHHOF@&DO"FF6"<9>4N@W=&__1(?;N<NC6.RS)(1)*O9SY 8^Q*[K0Q)3G+B^
M[R?(,+]@%CJ7ML4WS F7LV;A#__AALZ?GR2/<J>OJU9^ $7-Z/8QJMI-L>>R
MJ':/&;>=FF<EZ-ZMO+M\9][[6_X ?B-C4(M76&]-3=(#X0K9JC]!Q2EX:NK,
MXAVO4][=S"J(V:]ZYJ'>\LW0K"(XO$B:=[I1?3F>B@JOY8W\-[;)2C5H=;+\
MV3=)_C7_K6(75<4VU<I!D9\DK@<=QV$0\=2%&",74N1Y$?-9RCW7\%+J7)J6
M>V-5LZ5B7PIU7=Q6E3(Y\#Q78AIGGS8$8*W91@.Z#!OK,/,!["HQ*H;4 Y>[
MPJ&**>D^"+9 S9=%(1EUVK F+'M]-BP(S;3=QB0H]S?;.&\*FZTV)@'C3:.-
M:<8\KS?5J9CP-_%JJK/''?NQ^2@P^<?*96Z,?$]X7QX.(4(LA#AB"$8!=WB4
MXCA.M?MKG$W-TARMV^?'1UR^2JN[PX^TM"_VPT''!O6>+S^M+=&>5.;?$SMM
MC+HRN1H(M&Z:3@')%5!LC>P_-4Y,X]I/S2XN2[OBG<Q=R*5F5$WB=\W>LOVO
MJC?(6MZPBU'E3O<Z4<#U9%AK-J(:-\>[]*$Z"XY3;:C.&]1\>_R(7UGYJ5!!
M-6)L\5.5B3?5:K\H,YE7\T4@();G!1&[<Y75EZ!_8?F_A+/:7/5CQK G/$(8
M)&X $:8.3)V00=_WG,#WF>L@K3K44Q&TM$U2\03(EBGP)$9^D,%EI,L>P#5_
M0*XYE<V$=RQ*7= PJ:^5)Y'N\/YI6V8S;Z&UN';\@#V&0,,1D"P!J;<[3,D]
MMV%K1*#-).+2WT=MB\W25CKQUS;11CHEV#U[Z2336-M.IP2ENZ-..N[HBJG/
M92DFORG9$\YH&S2T\@+F4%DGC!)"(**(PB1,79A22I$?,_$;PRREXQ,M;1-L
MR#., AV$4_=:['R09MYU&@+!DRY.8\JB]H(P?V'4X]/;+HW:"\*1XJC]SYO;
MW+<X+WAV(;VVK+HHI8;*<GQ[T6S@2<A)Z/$("FT@_A$+0QJ["8>,L "EU*6A
MJ]T*O7^JI:F(FEK8D NV](+;"WTC:@#=86MV.LQFUA@UH> (7.!B.!O1%#A]
MNW(Z "U9C*?7W<\7$YE_>ICT&'8# U@SV?08Z1ICFF^<J4=ORNP%;]BGXNN&
M-BO69\AQ, TA\;"PM-(D@3B,?9CZH1NP,.!!0D8ITL.Y%JY)&X*%(_L!")I'
MZH0C$!MJT_. LZ).3V%VKD(] MY(C7H>B.^C4M^ .8=2/0V+KE8],L+[J-73
MK)S4JSVOC/5??Q54UZ9O)Q=SE3I>%'M.(,OK":7*'01C-_)AY#D<N]1!CA^M
M5!UV7??UZ#Q&"G4[VWSK61 )&RK!>D>FJ1-['%-='_9LI&;6H*8@C?!@>R&8
MW8$]/KME_[47@D/WM?]Q<ZOK\H<D4VP>>'W[_/2T5J$<N'S]G+UDE.6R;,93
M(:,9.R'X*L:Q2:1;.2X.7>G?I@D+(:+8@TD8Q!!'44)I3%/.M6^+SB5F:79;
MAQ]0=1D"M.%(%IQ1++U-6:N#GIOL:WTCY6QQ#IN -H4TLX;KRF>/%] R VZV
M\ME/5%(<M:G %N6C;V7:E),E,W1V>1G9JU,!W&/0GCV%-8MW*C"Z)O%D8XZV
MF9^EZ3TJUG_%4L+=4)C2ODL11 $A,"4XA3B(8IG!C;T@:8/MM6WK\?1H?<W[
M@?9SV^"*&;G7-:D]IQ*XU%:H6^]U&N%IF_ S"\22H;^5Q#)2K29 =7[?X0P:
M;7L8Y\-YQ ^98% SM4Q9MOI4O+#R(JTV)2:;5<2HX\6!6)51(E0L24.($8[E
M,4;HIR0(B5Z_TH.1E^9'*.+ [RUYFH>6AX#UJ[6S8)C[.ET7 6UU<Y+;(ZJC
M8N3G^^+E3^(=I33D#\I84TKA<"0K'_A)!MJ/]?0#YL<$[>=^4[(+(C]V87MM
M"E*L/ZE6MIB%,6%."EW$Q?<7QQ3&81@*S8DC[&.61,33/03HGVIIG^9N[WP2
MVR-6!$NG7E$L:VR;9$<,H#SLFT^'G1V30SAF@E18TPI:8L&G26'3=YFG@\^2
M0WP.C$:^KAXR/9[LP #6_%0]1KI>J.8;YCKUXK$H-]F_&/U45)MMM%"2!I&#
M(8E]"E&$J#"Y0Q^Z24PP=G"0,*JK2(^,OS3MN241$$&C_A=_#+IA[7@F(#.K
MQ!T6DCQ0TS?BGOH8-OHJ\$R,+.F]_74ST?US#^L]BNW86]:T60_)7176]]AY
M.;C*S_LH_;Q/Q:,,I52"5[^M+IXW#T4II_TM%R/?"J7YC]I3E!G"U<?7O8H:
MWZ1[^":)D*1(_"_Q8.@$;EU%/4V$-@QPR)D;,A2X6@Z>5:J7IF,[.;V-GPZN
MGS?5!N=4YDO(O,.&)<G&N!S1>9?!L&9?I'!GWB_V4X/K^PW%-NCR7?^A CO.
M@6(=*-Z;%:$*-*BR>BW_0 $ % *391+/NTK&91PO9K58S$S>3TFNSWSK@UW2
M73GUN3O NY7SK%9.I59.?4@,GM3*25_?UNU2IWTS9"U;D9=F=O.\M+Q+%K05
M>$]E2]N9?.QE8%/M)R($QRSU(6>.\-""P(,Q#U+H8S^DA/A!+!.^3"+FS&O[
MV B1NY-SR (%VL64#J#2O45;7"6JJ:H1G6)Q]MLIFU6&3C%Y>&<T:?6?7XM\
MF\K5='9Z6X,D<D.2!L2'L1LD$*5Q!!.,0QB&S(G2 !$::Y=0-YMZP3[ +\4+
MV]8?Z89X[G@99]UI",3,D)\69JO6N,3UTP&NDQG2&E"/LX:GA=Q>";J..9MO
M V1WS?SF+J6C#YNF9:DQX+N8A_J,GK+Q#$884?Y&=HYF527,QS3+ZPX?NZ..
MNX>LI#>XW+QV0J>OZM5"5Q'R'=^5F65(VG4><6$2\A#&L@EI$$?"Y-.O>C.>
MCJ7M'-VCHHTD'#Y)R@%EZ5Y6@-A-:@8,ZJ.<(:WAG<22#&;>5EHN0(>-#WOG
M=XH3J%CI-K<#5U;E85"FQHY<;%6GF4\^9O5HSD>UKPS-&:/;JSYS/@1[16<F
M&&[TG7#3G$H>@SP++7];\,UW7+*+G*KNMJJ@:G7-+_*KG#Y7FS+#Z^OR^JFI
MB8/7OV)95ZZ]_..![WA)!%WLN1 Q+X )$@X1<Y.(.4&*W9@9WBE/2=_2=KPN
MB]*@) V3H&JX[-0$+Q6C\BF<BQVPY56(&Q0[;D&NV#6^PIUT%6A?C[^7;.U<
MKV][]K7\@99!54.U[@Q>\RB?NLC!CDUP78(.HZ#F=/P5_;1?N>D5_WO)V6Z(
MP/2?\;31!G-(83A:8=)9;4<[S '9D6B)6:8Y[\SS^H65])E]8X1E+])IKOY2
M%E7U-[Q^?GL;FJ*0.$F<0A2XH7!GO11BA@*8>F&4QBERTW%ESO5)6-J^WCD#
M520#1;,*BZAY AVFQIW+&<C'["AT'M2M'HD> 7E/#E.=C1K(8-P9Z3RR>+?K
M_Z*12]F1R[V2RXOD:(;34G, -4]-#09^E]-3<\9/G:*.&&E,:0A5&W&_PNK5
MHUA9&['M[2JM5M>YK'.>"^G+\B<ACQR*70_R()3EPU,$XX!S&/C$Y7%"*$5<
M+_%U/!%:7Y[5;-=MP_:#.L698D89GQUV0)&K9@$-0R85!D9);7@_FE$2MJH]
M* 8.*W[73"AWKRN!ZQQ<692 266'N25AK9[#61_%1'O3>7#V5F\8-;#%F@WG
M,+Y?J>&LD<:&9'UC%2M?Q'YX^8,\R)"OSQGGK&2"<S'378GS:JV6<'-&$O&(
M<H=@2!P_@HAX#DQ(@""-L,]]-P@CO8"0T10LS2=JR)??&6L8$.;AE@/YO6UV
M/)B&@9F*IW\/L@+ZS%N0&=[#)XLC(M%&@C=[R)HI799CVT;"=A@$-W:@L3KR
M,M]DF]=*A7-^*4K5=VA[2E4U7QX/"6<\D0T,&!,V.R,P1D([QB1V<.R&B,HR
MD":*46?:I6G#FN;_K$ =^\J+LNFIMB/<L V,H1AT%>#4X,YM>+>X;K:XUIW.
MB@ZN,Z@Z$YAFUV]:Q%A6:B8 '6HRH[='1]WOC$<JW/0O."O5*<<U5_/N]8)1
MRE/H4AF00N*0.)[K08:#6&@TCF"<.(Z0"V,)(M3U&5J]L#(M]'7:2%I,OL0N
M1?-]D/L=L#8[4C]TW2THF01<<%D?!1IG 8P479BX+ QH"A,_I!"Y@0_3E 30
M\3R'.REG--8J)F)5<%9Z[K2=KU2*E2UQZ&Y*%D">>9^:^+,8DR9R'H;SYY6,
MI,]V(LIY,![)7#ESP-%-QW#U\&5=?*_DD<IOJK+:ERS'.<GR>UF,Y$7%G6WK
M>\6IDR**9)%)3YCQ!+D0.ZZ,9DZ""*4QYI%I,S(C I:F,"7U@$ORZY/%GY[K
M8H9_!+QE N M%^!W;%9@;;2<=%7J?.C/K4DG!WY,>[11Z,W?-LV,+-OMU$:!
M=J3-VKAQSHN/^07_R!Z?'R\>BV?ABO 3+2-O\*N\(KW(Z9>L?/Q4/#YF=8OF
MN^+C\^OU\T;FJ(A7!7!BSONK7*@J5FWJ-)452SV/QRB&H8L]B%A 8,J)K/";
M^'%,:! GVJ7N+-.^-/6\'R#R6 , L$*@#MG;-GW=[_7Z5*.@(OBXP$$&][5
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M/1\_@_]LX'WJ:&^<4GB_ /E&_J5IQ%H__R\5$?V(2_D/0.QBXRI)>UN3_]_
MET)]!+Q\Z+^"O@'KSZ#*[S:YR"G>J.ZM8KV5NBN?JLZ?V;H,U?/3'&F^NGUF
MK!W5YS-\U?SD^/07+VE>\:]E3ODWU;W\L]RQG>Z$_ R)" N8^J'*4:$<9M)P
M@"EAB8^CS$N(MITP--'2SHB>5O"HB 6EHE8>$=M27W(-XCI^ $R%EF.IOP.J
MH1,TA )%J856/XB8OH"?"KF9I/H%"!K)5QU8!H3JX.NS25(=)@[%I];SYC+S
M5_Q7_K!]N/FQD;+H/G_\*F=1.^6.7ZW7Q0\5*-!=4J](R@6-: BI'V.E<"<0
M>S2%@F2"AVGJ^5S+Y60V[=+D:4<Y*'K258W@CG: 6^*5.ZISNNC+#(.5&)>Y
M;O!U+(%[:'=4@SW9H*-;19]=.8167SB[@7@F46VXBR=2C,TA&Q#C!H/-)M3-
M&3P4\19OVP<4--UO*L[ZWF<YKXZ;HC7]&).0(!ZS#&:1+R#"/(-$> F,L!>2
M(!-!JI?9;3SSTL2^:J"XKPMO'F*@!_>P8'<*HF/9KO!C70-*TC6@7/=M]Z:-
M0#""9H:X!#UZ9H]6,(+I5 R#V0 VYGQ;,!C7_*Y0D:@?BP><RT,Y1*E( P83
M@:0>&JE&V%%((4VRQ MPX#&2ZEOR)^=8FO3IR 1[.L$?+:5&1NEI/'4L^(M1
M<FZ\.P3(Q&"_&*C9;'5SP R-]$$H!NWSTV_.:)H/DGYLE0\_:M]$\(.Z'5<C
M7F^4ATV5NOTJI^K2@JM5S @C24Q583OE_E+U9Y$*GD<>\GU*L4^X:5/!D3F7
M)A7WU>L>\'\6): ]^2#OZ%?^@L>6@P/MS:+'WMAJC,M0!QB[5MEV9<AV-(.>
M:.47Z\AN:@PX@-2\C>&$T,[;UE#NX.&]JVJ;3!6E;XB61NO#L9%F;X6HR=JI
MUHBZKUI44-M9\S?B\U;YNC[R)[XN'M4^Z\X150E"JL_/74K6RB<Q\F@40!P$
M'"(D."2^U'R9Y]$T$5PD"=:K>&U)@<DW,T_QZX,K0?G9B(8-:5GN^-CUBA$-
M)X \]PF.!N7&+)9J_ 1P#+_CT^  =WDBM/2# P9 KU&V+(#WSWUJL%O<#:J_
MN<5_KJ)PUOM_JKIQ]C .E9.S&'6^*G/V+!\5G[M@&/NNA,?Q>E<;]DM1L!_Y
M>MVYHS-$2!J* ,8BS2#RY4%#N+0K"(ZRF/M"(--,LM$YEV9(' 2:=E'3*NSH
MKJ/9L%ZE"?:Z][V3(NKXH+@43*L6;IKPS-"_;8R2V9NW:4)SJG.;[JNVPJG-
M&:F[T@0?BJK^C=?'=\C]Y?)S0\.*B3!E(8V@"'RI$,>Q@&G*/'F>$)K$/!09
MQF;"RIB&I0FOCH&^RH<\[:O:5%*9+X2NY'(*KW-)1DN.I2HE+?'-D/\*O&LD
MW4] SKY=-WU-FO1D:K(T%G+/&ESG<M"<LIGEHC5TK^6D_5#6U1R/AKL1K]UN
MU2KB?AJG60Q%2BE$"$<P19D'?9\E&?-X+ +3"H[CLRY--BJO<Q=G7MT7/S;J
M2U9)$03+Q^0'6=US]80TFJ2*(LVIMMV[<2U'C>7@-,+$QW(Y2!A#E#&B*CVG
M,(L]RGSJ4Y3P53O]]QJ7]1LMRDL*W"W->WZ7;S9*5#K%/6(41SSU(4E]9=W(
M%< X1##Q>(*B4(1>E':X?]IH-^IS@GH_OT.GG^M=GL4D3#TAI-!A<I=[4O)D
M$6&0ISR49X7P:!*L:I-.WU,+G1DZ?"]'Z""/94P>!) RY$-$>0K3) @@IUGD
M$1(@%G#3AHD3+\@\E\:#T4>]]N9B!735Y(E1=>T9O A.FZ*\^O"X+\2K0<O<
MQ7?UX3E1<-?@97.OU\>\HNM"=>^]$=^X:NA ZVTICWVE)ZLKA>_Y0[[&Y77-
M'ZI;_E?]7K+VY\H/<"JE%(&8\0"B(/'E3R&'Q OB,,">'U/MCD)V)"Q-E3VB
MO+$DVXNUJB4>Y(IZ?5>+Y;J,>[G<H^U8N.T94(ZN8]@;'IHLX(X+T+ !_E",
M@(83@W@SRS70]WBY7XL9\X55TJ]R=>V71^I.I<Y7,9'CZS(T!WQ?E@//YOZZ
MC/%##]B%(]G>EWS%STW>L6KBH ZTL<M-&D;22/13R#TBC<:4,HA]E$$?(9Q%
M<8H9-G2)&5*PM,.G([("CS@WME1,T=?5F1UBZOJ(X=W%\KN\NV+^R?J.^;%#
MH?MMDGX_%V/L7 DWI6MFA=P2MM?*N>U MI+R4$"/S'6K>HZN/!2QA <4AC%)
M(<),%9HD"/I^P#&)/!PQ0U%I2L+29.7'(P5%[YO^HU:<& <8&*^6KFAUN0;S
MJ>^3P6\A.&T1="XYC0F;673: O=:=EJ/9'[+T717_L;[@NH2?/]K6=R5^*'O
MIQ8+STM0 L,P%A#YC, 4AQ3&290)*28CWT>Z]QECDRU-("H"]8WB42C'KR"F
M!,BQM&I(!7M:@2(6=-1:%)X914__\F!*%&>Z)AA$<YI+ %U4!LS]T2%F,^QU
MF3DTX;7?L8]8/:@3]JFIVW:][P3\J[26I$1G5_5GG)=-H_O;^[+8WMVW58B+
MA\>2WZN,C2=^O:'%0U\[E2+DI23U8"R(!Q%+(TB8)V!*>111D80ATY+ K@E=
MFO0^+(8H;=1=(;U];V;&53&]IM,4KH&0W((GQ:YJU:CX!45;F_V08Y7E)%F^
M(+36R2;1U8_??ND=GTMOO.I6,< NEV2&P&$GY,\>;>QR$4Z%*#N=S[ZZSL'5
MMCP=GW*50'A%Y%\QK5<I]WF:D 1FB8<@XCR"F* 4DI!'J<<Q"SW#HVAXPJ4=
M*3<"_+C/Z?W_8UY&9Q!77>D]'5J.I?"Q\_&QIQ3\@3M:)Y6@>K#,4#!GD(S9
MZ^3H@'*J/([6>]:9$VMU=57=B-W0U=5?>;4*4C^,F&"011F!*$E#)60B52 G
M2OPXYA'S#?,C3L^T-)G2D:GN_%K%8_>U5/)SD00;JYCG(-:5,A, YUB\7("9
M3;+",![N4Q+.S#]WXL$P#"?2"T9>,+^M_'^_7??7DE0J'*G/(/>B!*(H"B'Q
M40PI]^.(AA'GF?:UY&[4I8D&29C^!=H>F_%[1BN.'7_3DB:+:\,]U_KW@U;<
MSW01.+3D1M=]KY@<N-?;/SO;!=XK\@YOZE[_HT7X9A>IT*?"78]YH+_UT0G*
M8WW%'O)-KE0>M=Q]C,\M_HM77W'./C;*D>I#W43 KV(_R#R"&,R8*NS'$Q]*
M4XFJ.G\95LF=OLBT@SYG)'QI N^8^H.HN%HQT,3P -;:%$T;>(/\@]GWQ+@4
M7NI*N_9S[V*(KG<Q1-<;H$+S.^9!QSWXLG=X7[4.[QT$0&$ 7FR8?91K@P-0
M0( 6": B,;\N><,81,<N=./,=$8N=P.91>6^P2H.Q?+.2<Y\$<!O /)1W/!;
MS']9LLOGOB-5WQ/^[YS=R7D.[J?_F=?WOQ6*)KR^:A(&;TN\J=;*J7*]N2T^
M;<NBNJH_R"'EBY_^HO>J[<<W^<^?_E*!GNJK>&Y"5_;) 8&0)IM($^BQ3/6%
M]S'$)& 088$IX91GJ799T+=G9VF:U7%PV0Z3OG7P,^A0 0>P*/_9U[4<#_R0
M ($>(=!"!/88V26.O-$^T]#+WIS()6EK1TE%FAOGG\/[19W6MP5H@ %7->B@
M 3TV0($##M !?S3X@(N3E=YHS]DE/BU_[\V81'6</;7OFDC[?7C?[<-#5W\C
MMS;]/NQ2V^O]/E3Y[07@S3[$-:#=/N3]/E0=&AWD8+WMPFKF<[T1D6^2&_:V
M"W(NS^R-J;+1(I]RQC>L44YWSFW,! L"&D(49!Y$7NQ#G(@8BHPF48H]&F*F
MK]B=F&%YNE9'9'-AI1DK<!X_'87E0E2<ZQ ]((T]_<?5:!" )C0FY^J%$,UU
MMV$,E>$I- ##X,%PZKT99?4 V<?B<^A!FY;N*KA*&MS?N)2IRM@N/C0B]'JS
MB\Q2A2=(O1?*N\;R ZVR0X]0FB(,6=*T@,<($DPQ)+Z782+\D*;Q:L/OE!R_
MU>T$[X14K6\D:[^15P0[5 GQ7X +P6EMU,C<S6J.2^BW7)S92DZJ %FU+CV/
MRL9KN50&G^(3-(PJ0U*Q>F R@AVSTS6M=[/6)DWNWWS-9SJTWGCM#5O<.UV5
M@3/4U<RSG<*.H3L\QUU/99UESBM:YH_J<[H15[3I?:/")(MU3I\_%^5MV41N
M/S>Y1M6!C;4*@P1[@J8P$#%5!09CF,8"0Y$(XB&*& N)8;JY+2U+LY=Z0D'5
M4&J<2VZ])L/G]LQ(._>Z[WA0%VAXQP5X;-@ HBA!?;P2X(]:7;B2X0M7FQSS
M2P%UGVQN3>'<6>>70GDB_?SB(2]H'MA>=34=6:5PKZZK:JNNLE8Q"F.18 J]
M-(ZEQ10',$7<@Y'\,^+29DI]:MPU\,QD2Q.0!\W6=A0#IK2HO)+_KX@&N69K
M9RVPQPV:*2%T+/D.N@'NT6MUT JT]$IM=$+T+/K_38#BO(W_;-&T:_@W H].
MI[]S0\S?XF^$F9.]_<;>,1>XO^!\\Z6HJIO-]<.C5*G5UKD1QZ)]Q2(AD*J*
MS3R:093Q#&89IS#)<,2B-.&(:)7BUYUP:8)7T0S>K275JGI9TS;\O^7^EBI4
MON-!B>7:1H/57H5Q:3PUMHXE<@OKEP;6FPW8TZS$RLX:^.X"2WW9/#6F,\GG
MPRT[MD\G<FV;(#4@JK6&F4U<FS!U*+*-WKLL4.]%09.NF,GY*)009UD210DD
M"*NB^ED&24 9Y!&-(L9(ZJ7Z60KV="Q-R'_?/CQ@^4T4XJ  3Z52"@>+[TRZ
M-#H^WED =^X)/HPF>U7UJ"\?Y2+TRW1)[&*V'"[-;![HPT"KYJ"0NL]NB;K/
M0C5K[5ER$"%E":-F:)/IZ&\2DV0)P;E@(MOA+$H*XDTA\N_X;IW_^7NYW:QY
MF7_)'_*:L^]Y^2>O\RYC$U&:Q1Y/8))(FP+Y@D$2<P\R$H0XB7V6QEH56$TF
M7=SAT] -6L)!3SGH2 <=[09E]'3!'S]Q7$#J^'C10].F.J$NK 95"AW .U>U
MPHE@-JM?:(C74!U#W:'FJV=HR-Q174/3=VV=GTWMJ=\D,VW;R+:W[HI[G&74
MSV#BQYEJ>,,AP0)#'/M!Y%'JA8&653$RS]($=T,DV!0;V/=*;7M&FWHO3X.J
MZYF\&"K' MD8)0MGXB &SAV%IV>?V0DX",%K!]_PXU-4X/_&%>WY.L>M%[$-
MWJBN-WT?[B_YAC>]4E:(>X(F&8%QZ"40A0&%*141Y,3#)!!1[!&M\/!+"5F:
M@#FVP\HC/AI78,N)RF'9MZB7M/"V==!%)?D-ED\[AL+YHLQW=3'M>EQ8H]\<
MS%DK]1N0]X;U^LU!'*[:;S'>+&+W,/HI3C#U Q)!' 2>2LY!$+,H@DD0,!32
ME'*2.A2\"PY(^T[O.=NNFP_]U^*)[[*A>]J=RE:K"+49D%^B?'45GW8AG,N2
ML&\9G78AD!=*V6EBTW;!R+S:99[Y"'F>%TE;-PR5+RT5,/4\'T8"\22B:9"E
MVN%H)\9?FD3<1_BKJ%"+_+U3&(Y?05Z(C&.)Y004B_P2.W!FSPW1 \DNF>,U
M!#J)& =OS9]$\9KDDPD0)QZ;L)?UOC+KWJ++A)\%/LN@3U1IU2R1&B)+I7T>
MIQY2:F+F:U5B-IUX:3+O6"$YKFC^]:#>L+'-;;PB9M$!4^(\:SC >8@5[6W#
M:E<03]":^D*HW\2]7YZNT^^\\?0 5C;MID\-]_9-I@>8U&HM/?2^^1G0QA#7
M?2V1C[S,G^1>>U*EY)Z;'IN8^<BCV(<A)R%$22P@SC(?LB@6)$PQ#@/M"FRC
MLRU-VN_J6;$]J>!=Q;FJ8\7_]5_\V/OWC_\6>/_VD[X$&H=\7+)/"J1C<=[1
MNJ\-=D MZ,B=$CU]H3TIBC-)ZE,[<B*YK W'@# >'V,V":S-SJ'8U7_)7-9^
MXW?;=7/MH%HUK7,L66BJ=W91(MB+!8TB!(4O.$0($4A8&, PXB1!B 4,Q[J2
M=F2NI<G9/;E-A[66WK;2M[YH&,-W7*Q.B)ICH7H V)[4KE"Q>2#3&'+Z(G5"
M!&<2J -(3B-6-2$9$*IC(\PF4C59.12HNJ^8B].O4ANF^2->7ZW;8=M^1HF'
M?$%$JN(%4BE%!8*I[V=0Q,2/211F7$2Z4O3T%$L3GCLJP8Y,\,>5?H^H 3#'
M1>;E$#F6E [1T1>+EZ,TDS0\@=8T4G 8@0'A=^;%V63>,.&'HF[DR2E<^4T=
M3TS5'JC>\_H'YYNF%@YG7W%9YP<> R1"S&DFC?64^1 U C'P! P]CJ5XQ%E
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MA5E(8B_!,/.2%"*6I9"D5-J):1!1WR=QJ-]6Q&SJI9U'+?5*A6.2?JG#-0R
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M!^:X,GDA1(X%1(=.1QYHZ;L,$GT-[T)H9E+@3FZ@B2(^!A 8T+Y.O36;<C5
M\J'N-/28H1PKZ]6G;5D\\NZ$3M,L(@%+89Q&""(O(9 PEL P"T7J^3$6H5Z+
MRA<#+TURM;1I?HPO01H13!>P[E@BM62-5X+2_\[.\'I"'Q&X(@VE\IU&%?D;
M7]>5^JWY"-L/\.5P\WQY9YC8?7+G_MW6#&G<N^^+LBQ^J.C758"\-/-I*#^U
M,(:(A3[,$I'!,/93GR!"::)UF75VAJ5]?6UH!-G19VIBO 10UZZX !;7NH(N
M(A;FPQFNG=L,+^>=V5 XP_9KZ^#<@[:?]S]Y?G>O\F^?>(GO>!/5WG1<"CP_
M6S'N<42C '*$4VDB8 RSS/,A)\C'&4H(3KC9QSXXW](^_9Y8@%MJNY2F1T5O
M8SE\^OV;<5J3+O:Z<F(R1!U+C2$PIY0@6G@XER?#5,PL7;0@>2UK]%XSOXSX
M5CSCM>IP^14_JSO3E10EF4=2 K,P(A AJ4YD(?<AS43@1SSF7J+=:_[EX$N3
M*3OZ?E:-;A2%^E;V*^#&;QTN@<.Q0#A XNO%2.A?-ER"R$PW#0;(&-TRG&-]
MX(KAU2NSW2^<(_;P<N'L,Q:>_2ZJM8]RO=[\QNN/7.0;SMZWC<#ZWKS/5U7%
MZV^\VJ[5I<9G27;?].AZ(__\R%4!KN^\KM=M4.QW^9=<Y*K\UNT]O^7E0W4C
MY$]?Y:J/S+(B@N. 1 @*X4L5#'LQ)#B(5<(?2I/(3Q+!^U;LX])QH5QJ?8/'
MC=\=BVE%-*CVS(&JYTZY;%6GE5HQJ%RYZA<5H6;@,%_F*NA$1"R3\@6=:CU"
MX%V/T4\JY$(R #H.0,<"V/$ WC5<_ 1V: $%%^CQ4@-TB*E(C@/,P XT]8QJ
M^=3@IIY2OS2[6&OJ__F;UR"@9)D<+% 16=QFGB@89MD;8"C>9J&4SQ?2LU
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MURR"@JMN[\TBZ$:'D78-T.X:4-4/"[F5=)9 WO(]T;[J0#(]&_*<LSO;R1U
MV#4!7$QG;CO<;/D._U >?-543 7"KYZ>UCEGGS?;7S8;]F>^7M\)'T?4IP1F
M,55& $EAEF813!(/LRPDU$/:@:,Z$RYM-Y<T0TET=;>EJ*X32/25N1;(PYOQ
MU-#-O*O6Y(*67J (!@W%0)(,6IHG!E)_>YL:4$?[U-GE"'"#K&HZ>=\0/]%F
M8X)3SZZA-8PS]6_"5%>/&SUG6Y=!ZOW'3?%MMZ'_K&]4KY]WY4[:%5+MW_F"
M,1(''-(LHQ!1S&!*5,Q/@,,L0S@)B-9EA-YT2U/&3>V!FF10T?RNC1;ID&U:
MKJ$7\7[=/#V.,VOFL1!:5''0069$-8?>X1U7==!A];2Z@]93D_1M7:LPU+()
MU?B G_(=7E?!&'=^FJ511B(8)YF 4I%X, O\$/HHIF&"XP1Q+3O/=.*EJ9A7
MK49KNO?A3(#6I(,_=HIXX_!H36'H!E=,#_',VF<B=,<V=!V$RFU7U\ODO&5K
MUT&0!OJ[#C]O?F3]E;.<XKSMY(2R*$TR@F#H10%$L8]@%I$,9BPA.(KB-$FT
MTZN/AUZ:6FJITS\OO8)J^(AI#\#,2J,ES")RXA4(^L=#>S <'03U03$Z[IWG
MN^=@]^H!9T>X\X1V#VL7?C&FR/VMNM$1?+OE["YBA$=9QJ"7,J+*9!&I=F*I
MZC.<^%'$0HX,JVV^FF%I*JBJEKX[T&=3?;X+H*Z1,P*6F163-B*69>'/<.VD
M[GMWWC<H['Z&[?.5V\_]<%P:UK40[[&4,>7?'CC?J8-9OE/:O*S"3N5Y['9S
MID#\JV00#V64^$(:(U(M0$1X #,O$- 3B9_X$I@@(C8Y69-0MS2UTDG0DOR!
MAD%0<0@Z+(*61Y5,LN<2'-BTR_B91N+#UM6;RM'=J>ZZDB+4D.+M>2E.ELHU
MC6#M\KJ<"]B1T7E\?-_(UY4T@BXK0=..H+>=U_5<.Y49LKTFA5TS]6N:.=\D
M#VQ2N"XEA4T[B4V W'=>UA->%9_^]9SO7JX*U0NK^NHC+_/[0N63K':?<;[]
M.UX_M[?S=4_#S>/3EC^HB+WOO"Y745D=:AUOBM6CN@>Z\W L"(H$%"*)(:(I
MA2GU$RA(E 1I( @GB7Z@W.ST+LT"Z+ ,\@+PBFGY:<\U8'NV =X!(1D'WQ7G
M^R"=IM]HEWDY@.+^76V@U_P#7 %@$HHU_^H9MAT6MB9FMB:ZR^&J #6_H,,P
M.' ,5CN@> 85T_O O::+\-%RN&J60X=UL%K@<C")T%O4LG 6J;>4Y6$8M.=,
M6+W!>_-3X3"(SQFDQ\%\[J8UMW<^;-;RXV9;O86K^RWG%5F_/TGLBMT-?E%_
MO4M(D& 1,1B$7@)1$*<P2P2!R$L$S426BHSJ6BQ:,R[-YC@B&N ]U>_ <TTW
M>*H)U]\<]) ?WNTGQW-N+^@1E*L.E W)X&8>*/5WRLDA=;37C8?6:(\R@JEG
ME]$;Q]D^8<165].;/6BNJ\]$>C?WY%6D=TZ>JY6-?"^C+! PC%0(-B4IQ)0&
M4+"$!XGGR_]II\7J3;DX;=W$A= .C?K:1!/F8<T\/7@SJ^9S:4KO0(OFASG1
MU%?.TZ/J2#M/@*Z1>C8#JD<_:P[D3$&;,=;5T(9/VM[]_X+SHORRJ>*9BC,I
M.]?%[2'7\ST7&U7BZL==&D<B9"B"?L891)QAB+,401_''O(ICD.]!-JQA"Q.
MG=?)='D!Z"2YLJ,%I1N*,#_\,V\(%0/@IW7%PE^ !/ML:J/\OBN0C5"9)5R>
M:]N;G$TA;5!2,0AV^,>4@0_C,)X]/L*2/,=A%.- /(VV&#F>N6G\E9=2?:L&
M/75$?-O&PL>81QQ#GF$!D9]PF(55P1@?"9KX"8ZT S[/3[$T77F@LBFHJ6^I
M7<!PV,X=C\S,:JP#2I.Z8AX:>@$=?;MU/$J.[-23)331U7L_ #WVYX4'G=F;
M_81W[<N!7]K:D[?RP?):_(VS^_W"$]0GL1]QZ!&N6H4A#%.4RD\LP@D-?3\.
MM IY]\ZR-.U6TV98MZD?1UU;;B0Z,VLX76 L#*P>QF>WGL[-[=@TZF'_U.[I
M^[%](/F.WV^VN1KXLSRT%K1N3<AW9=4>0R0>SL+ AXE@ 421LG%2P6&,69!@
ME@8DU+J;T9YQ:4KA0&YU\F@)!E4+C=*R,<D0ZKIJ8T(LY[Z7&06C5<BZ%C0.
M0MC[Z7 >TJX%R[D0=[T'+4+>CYJ:J$)TY=]YU6'^:W[_L%-UVJFR2^_Y'8G#
M($L\!C%7W> %93 -D0]Q2#,JK3K!]!L'ZD^[-)74D FVBD[5L:"ATR T61_R
MX0/:/$#.K(\:HD%#-:C(!BVR->'@9EYH#<*Y9X'859SVJSY43Q74W[N+N.RL
MXJE"L8TAZXNQUA_,7?"T,8-'4='F3X_VFZE9)+1>6\H^\L(@(A0F?H(@0EA(
M/>YE4K=GF0B3B(1)9ND^.YYI:?K[M0ND>B. HM?:8?0*6F.OFCU@CIUKE:*N
ML!KO97L%FK6SS1X\]SZW5R#.XGL[CX>^"^[5\V_EB3O/1H]#[L(#-K40<VE>
M/^'UKWC[3Z[ZBVPW[)GNRE]X\7\O^S:_%"&"/9% Q#+5/U0E?4=^!C-,8A1'
M/O.0IU\-46?*I6G2ACB3NGU:R [KS^GQFEF1[@D&+<6@)1DT-%M4K-?$TZ02
MXM2X.JN%V.+[V.+[U.)[7],^61%$$XAZRR!J#>2P$*()8\>E$(V>')>6OZ+_
M>L[+O(H[N!9R)GEVV;THY;];%4S%X#^I]?;^99])^(W?5[&:=3TMCB-/()K"
MF(L,HL#',.7RCT#JZX3%F!*D7<E^0KJ6IMN/TWMQASGU]Z>&O<IVWE6%KGG+
M(2 OG23?LF'2K$K:U$+7<*.\C2CG]K,<9>-W^5)_;SFK#-)=5;)^SQQX_]+)
MR?^VE^+M&TK1+@'?H33=I]Y/(M7IL^\GPEPS[W[L;&^2<3\11)=R[:<:WO9F
M\RO^\U<L-ZH<K\L[A$(O34@&@XA&$ F4*5^3@")DG*@[SB RC&?H#K^TK5/2
M)JW0ACC3N\DCW'0O(FW1F/O6L8KH577)=0"QN&4\Q_?L5XI'DSJ^/SS'\.EE
MX=E?V;[(5TR*,!>YT@I7<FLK[G/YJ;YZ_,KIYK[(2\Y6Y9'*^2BGO^-QZ&%.
MI6F=)*&TM!&&V(\2B#(2AH31P O#N^]\2S;Z[[TU-2:O19>F^=Z.+BNJ+TS#
M2WLGO]US([]Y98,#)CDRU2SV@F0XPHPR##U5S@1);2X%R1,8$1HQABGR4L/<
M!2=B=-=9^T1Z[F2CNT4X07SF_62V-\9BZQF-Y^S[E#V%CC>UT5">[H#CA[1H
M:LN+?+-]ORG:"L.8$4%I1&"&$P8103XD?H!@%'DJ?H]A$FE5A3TW^-+T8$T?
M()) @X:KKQ$;=M.,P6%F[=1 H&BSN!P]P<*@U>P(3%PUECTLCZD:REY@NJ]]
M[.M'W#6+O4#L46O82[^Q;O9Q%&-R3=;Y?5V\8'<C12ME7I6CD?M'Q$FD:E='
M,8?RH.Y#C)B <19S'*32X@NU*@J83KPT#?;I\6F]>>$<J);G3?YP&S1E;,]I
M8I]03(074(B]4&*?JIX%B&:0XTS='DM#FWNF)Z3IT7=S'/J58^6YJKR4JJ#H
MGO"9L-<UG*?'<VZ?_ZN OP.2[U3%Q*>:ZKIHXJ1=58R FK^KBAXYKKNJ&(%T
MIJN*V?,6P2]\*S;;Q[I(:Q-5<_OGIC%*>.#C0+56X=C#$'D1@VE$$A@R@N.(
M<)QD0COFI6^FI>T.'6*[48.[/S<&T1J]T [;OI,!-K,"ZF+5"7B3I-J$N/2"
M9A#9,A5XK@):+BZXJ>)8= #I"U_I?=Y=U(H.&T?!*EH/6"?TG59T7.WJXC-5
M%>O-]9^%5%?7X@:KJY$[3D1&8Y9!YHD4(C^4%J! /F0^%QZGF0CU>GA:4[ T
M1=NE596+;RI /VS64@R55^\;+C8B-\[Y,Q2,KGDX(]QSW\Z=K9"-7^&_J<BO
M8GXJ!B9-$K3#;OZD04.Z7"<1VL%V)JG0<B!SJ_*W9Z5=U4 [.="J*F];7A7Y
M+L?K]<OG?,W9'0MYD&:(J#1G^0<5(4P1CB .(Q'P6$2AI^TNU9AO:8JO)KE^
MT131H"X"K,K@-V0#H>C6-YUT0!^V.B>&<F:EUJ"HPJ!J%!N"P9YB\'EZ%/7-
MT(G1=&2,ZJY-,)%M:H!2CX6J,XHS.]6 I:ZU:O*8N5JN;J]OMIOO>:G&5742
M\^)>3O0EQR1?5]U75@4[?-]DG)-RMY5+X$[$/A6!%\-4'OREWHXCF*8T@1X*
M0X(0YTP@794]DI:EJ?,Z,.# SSMPH!QT6*KB,SO_M&HJ,K1\&1R5QTIS>"]P
M**.9]XE_0_'H;S(.Q>1H YI?7$;[TT0 ]^Q=8V=PMJ]-!$5WSYMJR#''E*J<
M>WDGSR,QI_*,B 5&$,51!+,X%3#SHRC)8L3]2#M9Z/7@2]NQND;>2W]>P#!P
M)N<*<S@<'B)&(V%S-C!'Q.U!0 <92X/_F'4MZ[YYY U,^6-BS]OMKWXS+OE1
MQ:X55.K 2L[78O6=;_$]_R0$5^T25:'=K_*D(+7CZNEIG=/*C5-_]^F'ND!0
M,GAYU=<T(SP,1(!@D 011)Z?0DP"#'V?X)3Z 4DPM\F(G(/8I2G-3L?B0PED
M\)[O_N2\ 'M6@>0+*,:J5,EO._DGWBI+9?ND6HJT+<?V/[/+KYME=0QK\B7)
M?.[8BJ/,NV-FJUR\FMUS@E>6Z8'GP_<=MB?K=SS+0K#+OGSK!?$FW9"WQPM#
MA:(W"X/O%\9.+H!MJQ'P86&TW\_0$WE.66BF:LY"PIOD;\X)YJ6DSEGGM"D=
MN<V_XUUU>=0V/?RX><1Y<1>0F(<X2"$A,89(1/((E3$,LU D4>#',8_U;8J+
MTRS-&CA0VFE""OZHB371Y9>!U=B.)X%K[HUT?J1,ZCM.@9BCG4:5H58["CL@
M>&B//5GUQB% >JLU7GS8877&(0:.JS$._MI<.:[H[AFK%-Q.OY35-B_SXOZS
MI+7N>U1>%=UJOL^/3]4%SV]\=QSHV7J^7BI7E_SG:R'U^G4A_[J1S^XJA]A_
M;_)B]W=)N]PKRKLD#'B2< ^B. P@2K /<12ET(M33"C"J4!:.?<+X&5I:GX/
M![A7>/SUT$-)R'?QT)(:4ZHZ^'*F6B8!U9[L'NP>>!O3],AW#QOV#A2\BGB7
MAI])1Y>W7E_#&]&_T:J9>;<[+)BFZ=:79L$T< "%!V@ 49W,]Y" #B9 <@U>
M5T[>XU+?=52_D0=1=;R\+L !G>K\6>$#6H#^?=::_E;^;[3F'-D+KY35H>$;
M;M:>VCD!;=9>7AQW!]BO/:6DV*O,DO5^[549V!U%IKK&X</:4T?<?U1K[WL#
MU$2&RD+$W6,-O36%SDRNMV;TC%VW%)*L,S@[1_\S%<._R"^N=ORQO*,Q%K&7
M8GG:5K:>2!-(DC"&'D_2@- D\G%@F,.I.?723+-C/]QKA577OO]#SBT/38I\
MX]8QVB+I-X_F!=J=$WP<QC9)AH9PS9]FJ$N0ZT1#0Z#.I!J:CC B49UOMYQ)
M=?KIQQ,ORB86_2[#(HQ$Y$'Y)X5(E9)*>4AA$/O8"_PHB;AAV;A+4RU.C35T
M5K84KRFUR(,^#RMG6<8Q\6%,O PBS%.8,>)!$OHTP"@0'*.[@M_+/8TY 3:K
M@>U.Z09:\Z;2%T'5UO<3K,#9?;.GBP_\5"<(_67BC/%>+%SDB)\GP'U6>"\0
M9_/ ^Y^P"'[;%/M:H)_K%M]M=^>._7Q'&4F"C,>0Q!&&*,DBJ3@\#&D:4E4P
M),@R[;8'>E,N33E+JN&AP'7;#7W?//W8)V@0.::'_[#?;7I49U8X"M!#5>*&
M9-#2_,IG-CF@!@%ZDP/K*FS/9,5.E<-C!%9?H)_>0.["_XP8.PH*-'O2UIZ^
MV6XHYZQ4/H[WF^UV\Z><K_RPQF69BUR5O6L<'L6]2BCZ7@54WS$_D7K=]R 5
MV)=6(<%2PZ<,9D'FB=A+TI!KY?*,I&-QRI[_"<B>>%-ST4X4NK;D[ #/K/=;
M^FL7] 'E=X#N>5"E/$7+195W6+,QI1TZ"L?9C50[ZAQ;L*,@/#5OQPUGG_A1
MI9[\BHMG(5?:\U;JEZOB^V;]G;.KHJ%)$7(GT@Q3PB*(D<I5CS(.21K&ZC =
MLP#A- JTZR 9SKTX!;E/&]E425J/70[4=7C%@KI8>CHP89Y/H2L9#?-X/KSG
MMI/WV1=U/MP1\:"E7MT?W[B VCRS90;(G2>^3 &]56Z,(7@:J3.Z(SK/K#%D
M]5SBC>D0YGO&%XY+?LNWCW=I[.,XR$*8H4S(/8!QF/I<0!R1@/@A21C7SA+<
MC[HT/5\1]JZJCJJO4@X8#>ME*\YGUK@-T[>63.MK2"OF'>D^'1",--H)LSVZ
MZO!;9UKHA+RN?CG]1W/-40<>7!6?<;ZMZG5>%Q\YV1V"3S_]H.MGI9]Z8J(0
MCS#U<0H%]Z32B4D&"4<<^C%&**.!H%RK;O-4!"U-7]4\50%-DJNZW"WXB;>,
MF =J&G@>)Q'PL,9T+;:9E6TC,17^J"16<:2"&!5/W2R!/5=3A3=.(BY]7>]:
M;(ZV"5?B,]IJIL2Z9Y>:9!IG&]R4H'3WQDG'M?5^?^-K^>_WO_"";_%:I<*Q
MQ[S(56T0E>'1W);>(1\E4<AB*.*,0L1PHAJW4QABC@7SY9^>9QH$H3?U\D(B
M&KJK,-W[FOCVWM_8XZT)OX\"%F6<P2A.8XBR)($DR +HI31,.4MQZ&G=(L\"
MOM.^.<ZAU[U=F![0F>V'AN!W>R"KS.HCH@=CJ2QN#\QPFOVZ0),<Q_<#9B"=
M7@@8/F^[>:CDRO):5(7!B3SHL:9^RVJ[55M;=5I8_<C+NYBS1*#0D_@+>?JB
M',&4IA%,/!P3%B48ZQ6K-9]Z:1JLHENY_ZLJ]; BO:T@!7"'>/ 'EN0;1UQK
MBT17K\T!],R:;3*,+=2;*5RS*SAM@ARK.%.@3I6<\0CCBDG=J,+?FT(JT[KB
MWJ;<U4VPJL;@=:AWHUA?E8+!L8<X\S#,(LJE]HL9)"CUH9\BP;D04:K7,VPR
MBI:F%#MEH9J^/,UY6'U1,UE9)TU=2\DG:/J/5:_T>Z.V8]/)==CEY%Q:,VO6
MXX).K6A6YT33E0QH^)JL8I.]S.S*,CF1W9O47GKJO%YU1,*3DB$_R+#-5&K.
M C,46AJ-KF8U)?MYWJ1DTFA8+M5%&C^P[8'A_6:WVSQ>BZ]J@VZ:4D7(]U&&
M!$Q(2B"*$8&9GS$8<!P(Y@<Q2PS3EL[,LK0=KR:Q*GZFB#2U\L_AJ&O0CT1G
MYAWF%3##+= L;/0>!&8WQ\_-[=CR[F'_U,CN^[%%T^^=U"+75<IXE179+%U*
M<<1]+&"$B8#()PB2A%%("0D]2H) >-KQ@>>G6-K[7U$)-A69=0ZP0>_K\R .
M6Z/CH9G;)5FA4E-8=4$L;5J#GX?'H$'X:)A<M0D_@6NB9N&] /2U##__H+O&
MX;V$'[4/[_^EA6:KVNQA5; E+U>?WG]JEEV .0U)FD"<!5BJ-J9J/&8(1C%'
M(HY%C(5V_M^%.1:GVRHRX:JF$ZQ^_O3S>_G_!F_P!2PU--QXA.96<>?!L6CU
M>@DE T4W'BU7FLYP29FINWX8^O3=A2?=*;Q^TH\TWL!/IZBZ\RO>/6]5S9\"
MKU_*O+P6==X)K\( V^+^7SGE^7=UL/RRK__" Y9&'/D0)P&#R,,>Q(QY,)8G
M0!()PK(0VY?DL:9K::KUV'?SV+ %<,.7^K+._N)@K5C;]R91-;8;YB8KZ&,O
M;=VCJG,9NG.?SBR^D;6"1H/MM)"0/;5O6&5H-,3])8C&#V^1XI'O\OO*$E@]
MJ@!A.8L:^HZ(F#/?3V!$*)'*70A(0A[#.*7"3U,:T$1+N??,L31%?2 3X(I.
M]2HK0@WR(BZ@.6P%3X#1S(JP T]-(KB9"AZ#))+Q,+E**;D$UT06\  2??DF
M%YYTEWW23_I1+LK 3VT/_3>XW/'G[55!VQ,82R*<^#'D@>K/'<8$IAG.8!K'
M&'DA$5EH>.9_/<72U%U-)6C(5.V9C(_[)RCJGO;'8./DL-^%Q?J<?[K(#(_Y
M8V!R>LK76T46)_Q+" P>\$\>='R^OT3XZ?'^XB]MNM4\X7]*H_!FNV'/='=0
MGE?%MR><%ZU_DV61SXG4<#R1!_<H$##C4M=AC@1)/#]B"=7O7*,SY=)T7TNU
M*MB@R ;KPVZ=%Z"BW*1#BQ;LP\IQ>C#G/ARW.#84@X[5<]7@:'$=I FH2?N;
MJ8%U%?BC ?!4#7%,(.IMCJ,UD,-&.2:,'3?-,7K23%\SGM]]*G;RN/\Y7_/M
M![SC]YOMRUWHA<C#(H*8X @B+!#,<,HAC_PX8@%/XTC+$+TP_M(T<4TBJ&@$
M+9%ZFN(2@OUZ=@)<9E:J9I!HO^0#C)_Q_I6<_GR_^?Y7^63E]U,?JO>]>M<O
MC>?DQ1Y@IGV+AWYF;F)=;UE>X.U+%<%>_K;Z]G'U/[^L-P2OO_$UI[M?\?:?
M?-=L4!ZA/D&^@'$4^!!1',!4I!'T ^;[R&,X8=J'2I.)E_:2M[37R1WE._"$
MVW(%__D?:1BC_PK^\S_\V/NO)[GBJ]_HVPI& ADVP>:">6:=L4?X6X-P33FH
M20<U[: FWL(@,P)9WRR;"VQ'QMFTH!M9:S;(]=AL1L,YL]QLF.S:;U;/CTLX
M4L4 JL8Y'W#YL"J8^L^G?SWG4MFINYOW+RH!:K5K2@=\Y8S7S7@N]Z0.$/4S
M#P508"X/ZURDZMB>P4QD(4IB081GE8@T.:5+VW2Z?>M5?0[R JK&HHJC?=/J
M U]V22W3RUO#2[ 4*;J[>;]N9-BT_E-<5AE,U8<.O^!](^35[E"=Y<#U+)WH
MIU\"=OE.;[H47'4&?N" O>K-1/9=^:A:#2HIJOK .\M"OON*&(!WC=DIU\)V
MC\ ,Z5&S"4,S;6KZ^=\DG6HV&"^E6<TWH;EWZ,/S=BLG_2S)P^O_Y7C[J6 ?
MY0GV#J4)C0GW(4GD'PB1$.(XB6"*D<>]*)9?)+HNHDN3+&TW;^@$-:% 40HD
MJ4#1JN\NN@CIL,]H"J!FWC"M,#+R'PV!8.5$NCBH,T_2$%M==]+@;VU#$II
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MU2_O<M(>4!.O ?LF4&^W%MZV"Y1\X6F[+@Z-GD2GT5/KU%=Z %?K@AW617Y
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MIP&'48P]B%B4P2P+8Y@)QJ( DS"*M.J(#<ZTM$V]N5-KJ 4-N6:!&OW0ZEY
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M_WG>R!$__>LYW[U\X_1Y6SEGV^@Y$K$D)3&D619 Y$<^Q!G&4%K_*2;"\[)
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M)3?_E%-8U,/D<MG+=^)>4K+ZSK?5A[K)]*]X^T^^N]GFE)=MY]$[%*44X22
M$6$4(NZE$$=9"%,:80\E62JW;+V$9XO93=YV-SG-1S>P3XI859@)8/!4<V90
M4<54$L/[Z(SHSKQ/'BA7^V1#N_K8M)2OR0<U_8=FQ?.!;5 P<S[073G3#^"K
M(V<#OOSXKQK\QQK\IQK\?0?TB38J2_SZBFD:CNBNI*8=JT>%-2V'&'?JDX,6
MJBK8>K5>YZJP5'DP!5.,?.0+ =/(9Q!1%D"<< 1%X#/DD8SA++0YS?7,N;13
MVIY4@%M:[4SS/IS-CE$3H>?T>'2 <4^T//2,/>[T86IWC)D(6X?'$SE+OCTZ
MI=2)+2?+=H;#AP9:FH>*OI'>Y+"@P=JE0X#.HQ:%%3?%_SSC==5%][AVXPTO
MRB:6J.W&1;* 1B$1,,0^AXA%D;3LI:%/<!@%H8?BB&C=8)I.O#3M+6F7EDY#
M_$D!UJ>:_BHNST"K&TEB6+7/A>_,^EU!NZ<;-(2#AG+0D%Y%L);#*<3C,#:H
M?C@3UJXJ'NHOYZEJ&UH UE?/T&0X=S4,+9@\JEMH\[QU&G8WJC2_+ZK+HF)7
MMU6OPF:NBE59;FBN7$U-3D7 &1)1 )$723N>)1[,$H)A& 8)I8&(*-5*(1Q%
MQ=+VAN.H;;PG%ORQ,PB'&2<8W4OPF>%V=Q0P0]HFW=H>J?F3K2UH<YUJ;0_?
MF43K$8/9JL>OG#W3.K6[+AO;U(J]8X@B7T08,LP3B+A@TAI&*:0$^7$LU2".
M0H,(]N$9M5Y ]X'I>W)!6RJ\K8MLJO N0JVKU48AYT9U'="2FJLI*CT$EX76
M&D)B=M5TD0#'^F<(B%,E,_B$?0^##YO'1Y6'@]<W^(FKNA#W6_Q8WA$_E:HC
MR6""$Q^B@/DPPRB$"4T(IVE(Y8BFK0HNS+4TH^E0<YWN"09/BF)U'5Z1;%[N
M_A+.&F?GZ=";^[B\[R)PH!54Q(*;R8$S;P<P 8!NJ_Y; 6E5UG\ &HWJ_9=&
M<%ZD?X"5<[7XAQZQ:+/\D&_YWYX?<:%ZQ^UR>OO MU)GJ[ )VGAT<(P(CE@B
M-:Q $,59  G'!'H,Q6DL3;4L"K1[+ _/MS0M6Y%<M7_*BWL5%R@_EKF$MWJW
M##H!:T ]K&0G!G!F15MC5Y$+&GK!GF!52_=GFY;*&D :]%.>%E!7S90'@9VH
MD[(^.GUME#5&<==#69^EHP;*!H_9GI?_'W_Y%1?XOHH_OI&Z;5,4?"VUOO(F
M5ROJ9E/N^./3>E,EY36.S?).!$BPF&&89=+^12A*8!I+FUC)(:&I)T_4J9E/
MT9:4I6EO124\D-GZYXWK.UJ+1O?\[0+PF;6]9 $\[GE0D7HU$^IXLN?B'7@R
M%8G%&7XLFK.?\:T)=.P#& ODJ8]@](C6&8X/F^U.ZIS'3]78G+<CKRC=/N-U
M>9=F#-.8>2K#F$,4T@1F8<!5Z@Q!$4YB(H1A*N/0G$O3ERV=<,O7R@O:S8@S
M3D<<!%Q7.4X*X^PVKZ05*F(!;ZC=JSA5^;:B=](D0EUPYL\6'*3$=5J@+C1G
M\O^T'[751[]L-NS/7'X(0L0BZB4J-D@J&^XS2#SD0Q:*Q MPF$2^8:NZ=NBE
M:9>6+E--LH=*5V'8 #"S7ACDW>+5?\WF[&_X?D+'+_)K1D_?UY-?6)L)%RY'
M549*SG*\5<F^/_+RCL9A580$\ABIFP<:2VLAHU"DA'IQA 7*M.+ZS*=>VFO=
MI0_\@26%YJ4+=%'7-AEFP')NR\$ 1AL[P1"1^<T%78)<6PV&0)TQ'DQ'L+\7
MK?)/.F4+Y23JF_>XY*RIW;3:;E4F9-6H,V(DX5$<01*G(40X32 6TO1@7A;'
M4>SA,$1W\N2>;]BW'=[N]"]-S0@Q>>U>D^/B1K6N!%J^DZ;[?5X4JD HP>NJ
MU_NHMNZ&XO(PYU2$&>0AB2%*!(78HP2&/DV%B+U4Q&DCKD\%6XZP6F*<BHK7
MA5S?0D[ZM^/S(>_LTKPB^*@4\E71?%FQT=9Z!!U&9I> ^37[?))P>_O>)HH>
M53/>QY.12B)/C43P@:&I@M)'H:EQ86\XL/-[?#O&SUWO6XYD7F#Q4['+=R]?
MY<ZF:A85N]_D(KM#*.49R[B41!9 Q.7!!@L_@YA2DJEN[#'5<GY>FF!IAY::
M1G @$B@J]>LNG@6Q?Q^8 IJ9M;PA*D;E&/M8MRK+>'9 9^49^]CIEFGL_9UE
MR,Z'?3C*AVXTRFJ;E_+KSY+.VP>^HO]ZEG^OXS%OY=2E<NF_SS=MD 2-F.#"
M@RA \BP0A0G,<!!(6Y,RYD4)\S.MRHV34K4T-=$?_B,WU(JWNL6I6A_UI]T#
M!_C J-JC]ZP"R:MAM,LDXAZV4=]$B+-?QRCY'9@"1UR!ABV@^%(1-*##F;)U
MCZ1F&ZPTS=MJ%M+D6HQ. Y^F$>>$(5)3HCT42#7)7&[#K::$YR0H:]+!S??C
M7WCQ?](V_V6](7C]#6_7[S'>JD[CZS6GNV>\OMENGOAV]_)>SDH?FK<Y9@'E
M A$8!'$,$68$9DPUY8UB% G.XSC1#JJUHF!I^VS#!*BY (H-H/@ 749 RPFH
M6='7PW92&MXR9\=^[EM)&]@M]D$[_/7WO-GEX&A_F_8U,-K(1D'8LVG9C>ML
M@QK%=G<S&C>0387)JIZ!JF!Y+<\;6Q4V]^DD;*YYDP0.F)>F'$:$<HC2-(!9
M1C/(6$HIC0(?"^U.CB83+VV;:6FOV[TIZLWC4<=)8GA/F0O?F;>2/;158\0*
MVBKZ^D Z:&FWV$",,#:I*CD/ULY*2FHOY\G*2)H#UEM#TF XAP4DS9D\KAYI
M\?S8TI%MD>-VTM\VQ8?G[59.V.E8\.F'JDBDY/ORJM0XB2)$!6(P\B)5@!BG
MD$2A@)C3+!(4ISRTK"\YCK"E[2#=1O>; C2<= O-X[W^DS^ M/G!%]- ZLDE
M/+SSO)7<9MZ97I>_W$MJ=22I#Z>2 AWV)FL,,%J0MN4TW0GT39K]/AV_@O5V
M6,AWM'T%N]U]^('-68IQ3H.U=L7.D=.]45G/:4"Z7/MSHO%M0XEOI1FVV<K-
MXF,N!)?34OY[\5QU$O[Q95.65?>!_3<?MIRI_ (5Y1HS)!CW8ABEU%/= #!,
M?2^ 0GA^A"*><KWCV@2T+&W_W3,"V)Z3=^"YHASL\ ^PKKBI5$#G6UIS9!F>
M;"_)_DW7L7QFWF?G%8U%R/-H4&>/@;:GT'%0]&@H3Z.DQP\Y1=W.58'7+V5>
M7HMJBU")J%O^H YPW_E503>/_/W+U8X_UD4B(T1"'O@!C,(T@2B+,<0B%="+
MPRPF(4W"T+#;I34M2U/,KRI+-JQ4$;J5)4:[W("\8@>0%Y!+AJ:H\VDF2%V]
M[$0\[LX_TTMF9%U0*TR=5@<UH_ -:X1:0=E?*=1N2'-/UN?-]D^\9;5Q3E^J
MCEQ7Q8>'O. E_]]G7'SEQ6->D+R]/@]\GHH@@2E#'"(?AS!#7@1]$:6<L53E
MS^HZJPSG7IK:;<AO#KGTI>EREQ>@80$H'D#+A+[+PE0FP^ZE&9&>68.V(+>D
M-RTCKRZ ;%%DWQ1M?1_0C*@[<O,8+O&)_#F6N/6X;$Q'=.:5L62UZWBQ'<+6
MA/^@FCCR[1/>*A].\U+XH8_].$YA*C] E(:J%SW)8!8D:1BG :+$L+;^N6F6
MM@,<TVBH>P80U363Q^(TL_XVA<C"J.U#8'9[]>SDCDW1/@!.K<S>7YL;D*MG
M@N_WL=(T]5 6>0BF7A1"%' /XLQ/8>C1*" H"RC5+@I]-/+27OW5[^]7OUQ=
MZYL9QS@-FVS6W,_\0C=T6022'".@;T99(^'(2&KHF\CX.<MMCVES_'MGALM9
M,KMFR?D?C"A#GW_/UU<%D_]ASWB]JJK=EW<HBVF8>"D,XAA!)/P0$AI&$,5>
M2*3QD5#?,ZY"?W:JI6F@3A%Z1:\TREN" :XIMBBE?A[D86TU'70SJZ].X?0*
MM0.M8#4Q:A;UYT>CY[[\O"F*=M7G>X'1*3Y_?@#WM>=[&3E;>K[_B7&Q:U]Y
MN=L^T]WS-B_N#[?VM:/>]Z31AM),ZE*4R#,=)I 0',&$)3&/,ISR2-N6TYUT
M:4KVV(%_1'DWZJ4.4+*,2NH5PK#JG0-:=]<BUZ]1O7&!JET<UU3HODF,EO7:
MM0[%TH%+,\RJ=Z@W":'28>Y2>)36L]8W[+RDV_RISK=<4:I.^VJ:S3JG+Y\W
MV\]Y\?^;^]+>R''M[._Y%00"W/0 9E\MU/9>((![FQCH'C=LSPWP]@>#JZVD
M7%61RCWM_/J0E%2+75:1DD@+,Y@IVR7QG.=(#\G#LZ@B3<T9TOF2?5S5F_U(
MK%N19$$88P9S@K'D?L$@CJ($"H8RS$B4%HEE=<6Q(LUM4FCD51UW^"]5.[L-
MK&F.;ZT/TL?:R_@\W:,57,\?.U7TN?I6&;#6VNCF[Z+1ISM55Q:B2B7P8Z/B
MB$E_'/&0P_6) '9_QCY64-]'[1,!>^3$?:H[#SY,P?7]Y_]Y+'_BA2I4>9OD
M0912R;NA"!*(D(A@GL08\B@/,A:DG,9&[HQ71Y@;ERKQ -_)9WUV\@Q XV.3
MX;"X/C$Q163(4<EQK=V?DCP;U_<!R7&UCYR-O/)%^UVVI(R*XYI_XLW_;^ZK
MU>/=_<=[545.%:2EJS57C>66M20;IK<"%\OM8E!RCUHQ*CZJKSA1G8$E_>BS
MW2LN%X[+^C8-6$RR,(0QCU6D.LMA'H0!S'$8(!YE,26%Z?;<N;2SHYU&,UVM
M4>G6]/+<T\Y\T^G>TJ=] +.RGV-^['0%[SIM?P.MOJ SJRJ+JLVJ&V3N*:W^
MLE4;2+W!5G'0:JYSTYHHHU;Y.3T+YIZ+63T3GEP>C7*OO]7J+UO7A]XEL*WY
MJ];\:J/0A#E5C9X3'>QYLT>/3\6]#-Z<,=[@W/?B^!MTG%__RZ.\6]<XIZU@
MVY/6&F4YX4'!(0U3N>M(> 8+E&&8944A5"/#-#1>2@P78VYKA)OR0;D4)(<T
M>H ;7LG?-$32*M55W!Z866YI)[O# '?H>ST>:,%_#KB3!'%+>PP[1G!G%T^S
MK"KOR X.%T1CH[;B25?T?*J9<SQXAL<,EC=_DX.'80"\=A0Q\&Y#:F;)AT\^
MF7=RT,NUKA2YO/N&J[MR>:7J0?+%ZJ\K/2'JBEV+IS]KSOYS];A@?ZPV'_%C
MS2\>UKBLE( J1?$VYR)#120@X315-90)S%%.(0^"K A(PD1H=$SA0KBYS61;
MG<"#5@K(GPP/*IS8[O0\]I86<3R[[513L]O.-(UVX$K7R%7ZZ8\UZ#0$2D6@
M=0122:"U!#LU@=+S#8UJ4_KK[8SKK3S8ULBZ4<Z1]T_.ELK(5;/I[(RL<_/_
MTD9>2B-3;>1R9V25R#]903$W9N@M.C;QD!X+D[D!Z[!XF:,QAIY.'?1'J2_J
M^I&S6Y2Q- P$A2(.0Q4;1F&>R1UCF.,X28D(B]@RU>?8,'.;0I^U_*GMFUR=
M@)7P..*""TA5O@2B@D#""(,906D1I0$K4F+>'VXZ</WU@/LPON';"8QQ$D2D
MR'-8A%S5_N8!E$O%#-(XS%&:XC#-J6E3MZD1=M^X[?/(+FTGP#4]>1T+E^/E
MV8L7O=023GD*VX> \Z/8HX-[/H_M ^#EH6SOM^U[<'WE=WC1M ;2=:(B@20I
MA PF-$H@"CB".,[EOI)0F@D>(DR-RF\>N??<)C$M'F@[3?TX-Z_'=0RW_O=]
M)!J.7W(;(*PZ;;VB\J F6\_OY:V_UBM*[+?6>NTK [IJX>5*E.<_Y9JUK+_)
MN>FI+O'UIS\^_,>G-E.0)$6.681@$'$J5T8)@9@E"&8)H4F0D22-C#MVG!QM
M;J]L(S!L)0;O.IE_ U+J]T#*_?IN< #6ISTSDR+H^#5O9 4=>)VT6^B&M)4Z
M":%%NZ@IH?35!FK$\VC7W<D4G+ZN32?OX:\;DZDZ!UV6C"\:RKL?RM6&T_OE
M:K&Z>VH?8$18BA.&81'E$42A2*&DX!"R,,A4MBV3"R,[OCTRRCQY%AQ(:LL*
MQ\ T)=21$/DAT@,A!Y/G,9AL27,D7%[)TA:V 339 \=)>CQVK6=:[!'_)1WV
M?=F>!B6MK"I]U/D%T[8N]4?\0*J2W?%ON*XQO7^L^6;;X23' 8N",(196LC5
M:,%"B$4A("5!BI(\01DS+H!G._C<2',G/Q!;!<[ 5H4S<*"$.5%86^4TS;K$
MVO5N=0?S%P.8!Q"S-=[F?.T2=T\T;HG_-,0^%+<>OK>^I;=I8*BR^[/#X'O8
M3QK?\/)1X#:!5T5P/J[7BVXI0TE<I$F60H00@2A3!SDABF&2"DY8GG)&C9M[
M]PTTM\G@0%;P-_RP_@=HY#7GH5Y@3W/\5' YYO-#I'2Z@19T ''W F9.TE,!
MYXF07P-P&N8U :.'97LO]\:H)DKLLZ?1]T=4[VJ*#G[^I?IPEC5O/M2W+$PR
MPH(,2E(,(>))!HM8TB:-2$QRAK(\SZS+=QT?:VY\N3MHY(V  PI/O8+J:::<
M$"O'9+E7:JJ1%6Z%!9^G!FY R:[Q /JOV64-Y+"B7?W0F%3M>N4._LMV]:MR
MM&[7B4OLN?3CZN&AW.@([2N^P!O.;E;?R@6O-ZLE[V*WOZRJ[]7JOSC=U'\N
MF6H<L%@T"V/Y<)W?59RKK]V&68 X2@4,.9>+U+0H8,$)AC$E+(D*$2&1F/+N
MA'+-C:/W5 -5HQO8K,!#I]TVTT'G$JY;!<&CTA#0?14![G2TH*LI+7YZ3G@C
M.SJ>/_9-V*H%;E9@J]@NH4AE W>Z :T<.- .;-5[&PN:3TYO9$E?2;X^+6HU
M\SG O6>6G'(T;S.J XCV9U\7MQ]ZMOKG]36O?I94)0;3[FP5)R+/ @*3($P@
M8KDJ5TQ#6*08"Q*SE,7&64NOCC*W6;0]!OOS&G2B BFK==S*,3Q/SVJ3H.1X
MCCH.T(!>-J\#97O .A(POP>LQD_6@*/5'B!.'JT>N];ST6J/^"^/5ON^/&"_
M<EA,25$SKU39Q.]8;H5N,6$%0R2%/%9QMQ%&D(B<PSC.HR0G(HW3W'@+TCO4
MW/CP>86O,]4'L!58[BBDQ!8+S'Z0#5;]DT'G>B&O4/N\C]I.5O!]4M0L5MJ3
MH>=K\7SX[+UX\B;B3C-<^A:W_3?PMUXU4N1@"6IVA3V??GY8+U9/:KFZW%0E
M>=SPO83!Y?F#+BOS^1?E7.7YW-SSZY4:]IK3QZK</'WDI;SQW:U("TF]60Q%
M%F&U!(T@9C&""6(DXU$@:=DX@&4:D>;&SYU6_U:KZE&-8FJWN-[J9LXT$QGM
M-(_[-X5CON\4 CN-P'[NO-R]-TJ!K59 529I] *=8J#5S+O)S"<1_Z;S--EL
M34AW)MR]1$!Y15L3\JT)-]*$=6/"NC,A;32<:&Z:%NZ>.6RB@;S-==,"LS\G
M3GSG 7-G4ZC]6>U]U4SEIPX4NJGPLA:KZD&_$=^KU5V%'VI=[OF6%RH0/J(P
M%"*$B)  XB1.81H5C&5<Y(8UF4?*,;=94@NU?RJR.9!=G89HX2V(=X21#"9(
M/]"[GA4;+5[V3=DI<@8.50&=+D KX\<>%K.?'[OXFO+<V<=NDAN/:M_,-N+N
M_J:S\1 <S&$3W&YH(9;?<;FL54D752B4KNZ69<V9+BPJRLUEI?[R!9?5/_'B
MD7_C6-5VTT5@2DS:2-A;P;(T344!TU1ET6)!88YQ %&8"YSR(LM8<;OD=_K,
MQ*9ZRWC9C%[CHGF-7TCH[E564H.?2FR@1-Y*7LLU:E-N>JUUE+;499G^'WAW
M)['X[>_J!U5>@RX>]9+V<?E7V=3>6(EMP6'KHAL3/ /]DZ1WD_J9,;4RX-U"
MJ_.;-&6G4%L,>L^"8&<SN2%I:DFS4@BN.JLKXA:[1V+O@3@#BYWF4Q8*F<X.
MSLN*3""JYR(DTX'[LF3)A/<>W%EF@=7PE^)"KGF6=R59\'/YBXVJ./W[:L7^
M*A<+7<<CS"DJ4!K") J%G [2 .9IGL*P$'&44TX0-BK^;#_T['8TC=R*I<NM
MY !KT759^+M6>/ #F]=.&6 24YYV ;3K4YRI,![2_<82+O=M<4P%\MTOQQ*H
M(XUT;.\PI,..Y 2Y%&_7Y4V/KHMN C]G#Z5DW4T3U*-7X7+H&_R+U]]QR?[@
MFT]<E$O.VMK''?4^:3%OLZ3(42)9,&(Q49E<#.(XS2&)HP(Q*FB<&O>^=2GH
MW"A4BJO>:ZVO;K?W]W=-_[W?]M96^$#EMBN?>O<W2FNPEFH#UNR:E3>XJ8]G
MTX3%X8-QVL\T%W,[)O).3=!Y/-Y=M(;>Z@H.E6W<&SI=2^L+E,)G0#TRK<Z@
M*_*_U1J\TWH;;I:<6]^F^\X\G@)/;J^9/ V6#7G<FZBW%X_#X3VVX7$/XF$'
M'@_C#<ASY$HBW53A-BU"$>$(0URDRK\6Q^I3!!&A119G.1(1O=VL-GAQ>NVP
M=U^KJ7Y[=[=3/6]EL\C VP/J]%PZ4'W'4Y_2_/,HS2WR#(<AX"NGT.09L$L>
M?*EO7Z+@WK?])06^%/$@ ?#(GX>W!ZZJ)\5K^H2\#>4.4)R)F.0P3)(8(HQS
M6! 1P#PJ0LK#/*:)T=ZD?YBY[2PZ&=N0$?L^P4>0-/:SC,3'M4_E$)K3>0.#
M.@>_#H&']L%'!O?>0_AU (XU$N[Y]E VV&_<=%W>+4M14KS<7"Q_R@61/IFZ
M6%X_DKID):Y*OM_'Z1:SC-"<,!AR@B 260ZQ8/(_J" AXU1$N677AA'2S(U;
MOLHEH_)(KJMR2<LU7JBPZ#5>EKP[$FI.BW1LVO'&HHV_XF__&J;!/]1S;,M/
M8VQK2F.>+.:8[3X==)ZK]^0%/S:J 2#I;P X@/PF ,XY1XZ1T3.53@#G2\:=
MXJ8#FJYR(H=0\2!JB$^K!UPN;U$1%12%&,8QEPLT)&*8\TS 6&X,><!3D2;&
M 8/'!I@;?2H9P4Y(\*,1TZ8'YS$83V\/QX+CFJG<X&+1=70D/IYVD=8XV74/
M[0&AKR_HL<O\=?SL$?J@EV??]X:<J1WM;ZT[KWR0/[,VA?Z[M%]]@W]]%D)E
MT5^*FWO^^9=*<U(!<M<;.0%?KM5#4]]F1&0$TP0*$180T32!),U#&+"01#&C
MV"+C?7KQYD:E4FC &ZE5>H1N002)4FU;:L;F*&1R:YH<?[VEC9P?>C5*@7>=
M>K^!5D&@-81:Q:X""=!*JO,-T*JIXH)5DE*GJ?I9ZPI:9=_4NC;'6V]I95]]
MKO=?1J%W?[RSF]IZ:+NM&O$GRDURAVOO2=3D@WH\?W(%V.&ID[-1IG &7<I'
ML_KX6%52A";,9M\]0'.4\#R+Y3R2Y>H42L \H P&N2 L8')Z1F*XZZ=W[+E-
MKUI80!MIVZBS,9Z:?N"'^&4F@].K%V9U!%<OWA@CN+SZ7OHE>D-/BQ%4_7X5
MLUN,J!*LH@951LUJ^17_53^6*OLR">.09"DD8:A.NW@$<8()3$5:%"E*4&+N
M3.D99VY,M:L.3)6PJD&XW?*P#U.#@_=ID')]$+\K::M!:@0%G:33@#6@)O X
MT/S7 [8";U@MX-<A,:D#?.1J_S6 7U?A:/W?GJ]/L>;[AC<Z-_Y\B1=/=:F*
M&G[B5?E3/C4_^9=RB9<J@WXOH^0&DP6_+42@XI-BF&8J>"#*<TARG$A.C0+.
M"A)%H5'5K2F%FAOW'JYM'EJ= &Z5TK5^V58M(#J]]M/ Y.I'J6:=(S*!B8<L
M.]T;SNMZU)'-1BY6QX'L=14[4-0W7-Z. [=_W3ORWD/*E30^@^]52?F5RD.]
MD>;G;=A2*EB@ZK?#L."YZC"D%L<1AEPP3M(XR?/(O()7WTAS(^:MUW2MI 65
M3M#=*'EMBEKT07MZ93P98(X)<8N5%A1H28$6=4";H7[0;&I]3 2>MVH>PT&T
M+-=A $QO08Z^ZSV6W#!0X["HALD%]@3ZYUH*MMS85?RN;X.$Q1R3&(I<I?UE
M/(5%A'+(:1@D><!"9!8E-UR$N5%NJX7C1A<#S76:K=T;P3&-=_@/Z&G@'G]S
MXG=O!T\S@A-[6$T5XZ#LF4,&WMC;Y#).\?U99^2=!H0)[CO1A?B Y3-%^?4]
MYYN]CA7-]CT@@G+* DCS6-5%SS@L,B1@%O)49)PF*8F-HP?-QYW;Q+.WH;\4
M\E\!6NF!%A_L=X'Y<6/A:[&UQ^E)QA'*_CPF#<#PC0"VB&=T [2O,,<)GVB[
M"$A[V/H"(RWNYB]>TE[%@S#* 9=/X<2_X=6#RE#^N%JR4A_P70H=5$+V@DK.
M*^WH4!_;&0+AE$4%AI3(O0D*=!I/Q.6/<1+%:5P4R8B CD$RS7CV4)%;2B5=
M881NE=(17"_#*P'>:3:%#W^8A8>X\)W;S:L'WY7)1KKP1X'LU8,_3-(W=."/
M@K;??S_NUI.D:_)E7>I*L?N'".=T\XBK$B_.Z_KQH0D,_%HN^<6&/]2W<1C0
M+.499(S$$"6H@)A'!,9!@K*8YP%'(XYJ!T@T;Y*O=PH='OOA3B<5F-8I!7Y(
MH3@HE5ZC"'Z(98?0NV-[>25W%Z8:F]8Y'%Z_J9T#Y'S+],[AL)Y(\1QQXT%Y
M4:L'?H-_Z::BJD7%ZJ,N#WRQW-9QO12JZ]/F:9>.I3I:-'6)FK]\XYO[%;M-
M!<W3(BN@8 C)Y7L40!QP##&5;Q&GB?Q76%3BGEH^(];P7XU[+QG#*D=F.KN=
M=@1Y-X.WK">IEDYCZA13#9<;U<#%$NA*Z5H[Y=EHM-A+Z-0=FMHB<.T?&QW?
MR)!6:4YO8E!O5?M\&]8V&6IR]/O3H*8;SF<"U.0@/4M]FO[^]C/P%5^O*KVW
M_YVKSAKK^Y+BQ?]?+7G=1J$4N0B#G$<P#T@&48'DISC$D,5Y( A/BCPTJF-N
M--K<MD(WJN"?.9V>1O/T9#<I1HYGL)VL8%]8H*4=$ ]U&C_S.692'#U-''MX
MWNWC^;]*ZHE288UQZ:'TT_?PQM/&ZNR3K_E%0YU4W^4C<8]5=NKS2NTZ@:$4
M)6?G=5-%YZ#=T2UE,0]$SF"!D8J50@DD/$8P))Q%(64D#["=>VJP+'-CXW,J
M)[UZY[1NTB-?]#NP=3L-MY6IP\F+!1QS?:?#T1839TTZG59$_DI^H55%)]C]
MG+R#SVA G3N7ADOHV:TT&LJ7#J7QMQP7"G3^$Y>+M@+UI9!K[*9ED"X>^655
M_84KUAPZW_!?FP\JD?J6,Q9(UJ4P3N52%U%56RS"$:2\2'/"4Y3'@Z*#[$69
M&^E>/SX\X.I)O?9J0]O(#UJ]) $H_[)6!XI&GV'1+ -L9A=!Y-827H.*]E71
ME6]V=M'J@$Z?-MX%*)7 A_Z* 5-;9UCXD5LK^2IP<\]U/\+=R0S>MY@ZAI<6
M:SKG :HMUKX[4RWRIX'4,%IIP !O$L T'(C78II&W''HQD+7BG@^K;:;8R)(
M((I(=2!-,HB8W#5@AE.8%FE&69Y$ B.[K4//:'.;IRZGV0STX6NZW)\(-<=S
MRBN .2ES;H"(\Q5YGPR>U]P&<+Q<59M<-#BFAM>T*O7!KF0UJCOIRI7Y]]6B
MI(K)Y+^\O%LV-6KHD^[)O-"SZ$$Q]! CR@B',0D)1%QDL,AC#!-$PC@)BB1,
MF65DS11RS8VI6J';ND[T"6QV8EN'S$QB.%-B\VX.U\OJG3YZE;;5"*RU2GIS
M(WK,Y:X8UY1(NX^DF41:W_$T4T)\)*IFTML/+_[U5156W&5;J1KNG-TBE&0\
MS 7D119!^1.%DKTY#%&:!"HA-T+&&;F](\V-?'<%P!:ZXNPNK1;46F#[ZE;'
M$3[MG9@,-\<LN:MHI27=R[P$UY-"9E\2;#1TWHN"V4(XJ"Q8+RP&A<&.7^^]
M-%BO&L>*@_5?,*0-Q8MJ- <;PBR,\Y2%.22"4HCBH( D3#,89*R@>4ARDB7F
M'2EZQYH;CWXZ5O3)9LMM@J^!AW<ZU)RO-;> ;44%YX9;;FOD;)I93(:@M[X6
MKSYZ4[E/S3#I;7/1?P>/'2^,5#EL?F%VR5!GP_7]JMJH1+0KKN+:Z$;W^/I>
MK7Z6M7I:&<-!%.(0HCQ*E!LS@EBD%#*:%CRF-$09NOW)*[(R=R2<&-/F*=\?
MV=U#OCLI51W2NA+0>U7U;#T%IU"/*2I0C@FD"142=4H@(6$ "YX33&/!"FR9
M_3HAYCYFM ,I52V>1LP:O*LY!W^L-KQI0_?I?5B\C]X;]DXW-X"I$V9"6!U/
M>6U):U =1W9*?XDA*,X](:?D\.SC,(3EI??"]$+[-?4W^>W[* B+S]]N_KBX
MOOCCRU40A#$*BCP)V]4+8B+G."$PS83JJIDCF*<DAEF:BR!4#18BXV@,@_'F
MQD1:9*!D!DIHH*0&^V*;KQ--T#Z]RIX80\>T<Q*^ 9'))CB:K[DGQM/3NGL"
M7*U6X18H]:S$3>[B;35NH=+^BMSFLB%>CC7^[W+));LSR?1?Y?+R3C]*%\L/
M?'%7/CYT#SB."B&7XC#,DDB%)J<0$YS!+$%$/CPI*I+(W-UA-NC<N+F36RUC
ME.!@L95<+=1;V6TV\H;@F_A"IH?4N5.D1;.5&>R$5GERK=@#^-K\F;9PE$P/
MKS>/B0G,4_E.[&#J=:(8WLJC-\5.N4.WBN6UD_49U6>+0I*C''K-J\V3ZJ>V
M.5\RE42X5L_?57EWO[D4?]9M6,EMD!".XY#"0EH%HI#DL*!A!@,>BP 5:4C3
ML>U%[:6:VURPU6!T=\D!%CH]'[P)[HXGC+Y.H5O%SD"GVIEN%;K1!:^VZIT!
MK: ZC?M3G<59'EI,9\+1?4'=FM)?MKQGDT[1.G0X]/8=0P>,]=:-0H?#8] ?
M=,3-AV3(=ZEM5+\(7Z3Z?ZS:N)W-S:K]<)M&2<01"B#-"@11&@:0%$$.6<**
M5,01C2DWSY,W&G-N\^%SL8%Z5,!RM83=^<5FU1UEV"2%FQG@](3H %;'T]T+
M1)7(0,H,.]^ZJBOB"E&;9/O)D?66<O_*,PM>/K.39>!;@=6;AV]V)X_9^%:J
M'>;DVUUJS^37>+D2Y?E/>9>R/E_<\:KL6NU00N*4QHD*W\DA$HQ#P@6%H< T
M)'$4T\ XD.?U8>;&UXVDL!452%G_]J]1'/]#"FQ.)CVHGF;D:;!R3,*-D& /
M)B7F@*"='JC,J78:R#RQZ\LG3(D[$8^>1J*'.GLN]L:6IQ78)TB#;]MS8M=<
M[TG2[^IN6=:<?5E5G^M-^: J$'YYW#Q6_&KUA!>ZX$6>,IRF*8<!YABBA*<0
M\XS!(L$1(2Q#811U-19/,Z7=X$:/]V$!1<?\N94?5%L%=,H([U0 0NL JDX)
M<[*PM,QIKG6 MA_^W<&\DUSW!]K*#AKAP95SF,UYVAW<GKA[2MBM>'T8<CU<
M;WE#;_P_3-'].6'@'<:55[E8RL6II+@K.<2E^,3)Y@^^N10?<7VOBL'+_RD_
MS$^\D,_HUVUQ[H(BA!*YI@Y82-74@6&!@AP&81&+E*51SHQ/%$9+,[>5^&$=
M[TXEH'12OU!: :F6^JPTTLY/_6&G&_BAM ,7%I77IS&LP<&T3W.Y/K$^J,1R
M:*G+(Y8ZGY&EAI5D<6XQ_WVBFA)FC>6J]AUCRG++QG*T>\?T![Y5ST5YEE'P
M&E9H&3;&FQ1I&07':W5:QMW4?K;\?;5B?Y6+Q0W^]8FKPWY5L.&[W+"MV&V2
MB" 3)()96C"(6"1W3WE&8)C)O5,@! N)47W'$^/,;8;K1#W3M8_85EJPUN*:
MTV ?MJ>GHHD0<SS)[,!2I;UV@IZ![Q.B93X=3(2:)Z(?C)X5AQM@TL/.?5=[
MXUT#%?89U>3K]EQYN>:+!?X/+K<H]Q17DGOQXNGZZFOK&)4F1B2-4DC2A$"]
M@< Y9S! :1SC$ F<&:<"] \U-\9LI 4[<8&6%TB!S=__$^B>)LSI,'/,F:_"
M]?[J_=?W T)(3T!GSI[30>B)0/NAG(8^S4#I8= 3-_!&HF:*[/.HX16#2X^_
M%A1S3NI-A>GF-DIRGF0Q@SQ- K4$32&.(P*#/$L9"@1AN64'O)-CSHU<=]%D
MZVTT&>^$!C]P*[9U"[O3X/=3KB-('7/O:#2'E  WQ<=]J>^3DO@NZ6T*S9'2
MW<:7#J6G+X]+U;]FKRUHK;;D0FZ[V0>^E!\V:O#Z_%=9W^9QD@8\83#)54\W
M2F)(,A5CEY( H9B( EE6%+09?FZDU<J^WYBW;EQ76GQ &OGU2UC+UTZJ8$U@
M5N8QY3)7H#NFM4GQ'D!Q0V!SSG960GDFOB& O>3 07<9$(ZF.B5?"LFX\H:7
ME2H=K6+>/JX>'GBEBJZ4_XN;ZH'?I-7H8K7$B_.EW'2O6+GMA\3C#.-,R+5;
M(E=Q*.,$%IP7\L<\SADF:9X:IV1.(=#<*%/KI-[9M=9*&D?776^B/.ESS=07
M'[:ZR65,IYQ%C-<45CV]+?=M*\=,VYCI4H!&(7!9Z88&3;CS"Z74%W=J@9U>
M W;YD]C+(GK/L]U\Q?E-\YJ!)J1RJOC ";'NBR2<8AA_,8<3@G(0G3CE?0>7
M,2]_EHPO6?T=E^RRDK,XKIZT9/5W7ND/MSQ-(L1"N:7@D0IA+!*8IYA#SGDB
M.*)Q$ 661<I/CSJW:7$K,EA+F<\4S%IJ4&NQU:%<\Q&\*Y?@\Y]7N]]8U[TR
M,8KI1F)BJ)W'BABB/&GE<'.(W-<%-Y#%=]5O<WB.U/2VN'@HAWV6I+AYJG7G
MV2^KZL-C+?<==2V)E,CA=._#KC,O33(J4@SCM"@@8CF'F,8JP"[.,:6$A+E1
M#>\!8\^-SQK!_ZT&&R6ZCL$FK?!J^;&5WC)I8XA53*G,"=:."6TZF <0FS5@
MSNG-7"+/)&<-U4NJL[_%N*!B%<"\I.6B;%>)NH>6\L(\J,8)-ZNF(?KRBC/^
MH)LJ/&LWES!"A& !+"**((JB".*,J_3K,&2%7/+%B5'OJXGEFAM1[G5S/-2L
M"5AM= .-<BKS5:L'Y)]W"@Z+6!UKW],ND3>RFO,UY'Z\\3.;7;ZTV4UGL\M]
MFTW6"'*L&8>%('LTYYL$(U<O7D7:F15O7\6?W:M8[9EUTO9#CF W#%(>.]J;
MA"M/!-%K@<M3W7YHLOQW7&_X8W7]_OP]XQ_?__-]U_@BBM*")"D4>1A Q'-5
M'BR3LRWF>9KD-".1<?N@WI%F-W\VN>"MM.#Z'# ./O[3-@?\-5P-'/]3H>7:
MH_\,*"FIADK*.L1+WXN:;?+\!.AYS9\?B.* 9/H3R)S,IW_M>L\I]2?4>)E5
M?^J"067._YMO/JZ6K%2/B Z7H(*@.$=,;D_"I&D75+ B@@+Q@"8BSA)FU&+A
ME?O/C2L;$<%61O#CW#PBY34,3S/D2&0<\Z(34*PJCX\!QU^E\0.0)JLG_IKN
M_?7#7USELU[X:R(_JP_^ZM>&^J$/EYKG5!K^<:&2RC_QM=RO-"M2^<=J4];-
MYR6[>%CCLM+A@DOV>[6JZV=W40]K&*0Y$D$($XHE%28HA#EG*2Q(1&A(1"X2
MRT8SKD2=&Z%^/-P4GJF&M9VJ<EFPT_5,?6.KK0['+;?ZZA_OE,8O=IG#0@:=
M/2FFKO0YV-_QM/'6IA_@KW=M%>?N?6<*>#X-<&V(EX<'SD<<=]9PN;GGU>^X
M7-9R*!6IPO6';4'VG;N2*_\&20B,:4XA2E6#3YP)F" F_\$\-<R4&2S!W*8@
M+3BX4Y)K,EEHV<^:SUOQA_F6S<UB=QC@!&RO;O\&=:V"+BCRM45=?]ZU<O@Q
MVKUO;H)ACGPGIO"T*;FYYT#5WI,F80?>^Y71.^&@=(@UFH:>>//[OHG/W5KM
MU[SK]C>RGW>:LK7T:==4M=YV56W=EVF2HB(.! RC1,7QA P2$6"8B3RA-(W"
M+#:.X3\]W-QFE&T+7W/&,L#T] PQ+5*NE_^ML&!/VKTVTO8.=0,(S1E^6B@]
MT?D64K:3^FS74'HBNC:'IH>;#6[BC8C-%=IG78NK["GV\\-ZL7KBO,W-JC__
M6O-ES16QWZ8APVF1I+"(:0(1R@I8%&$.!4MID:,@8=S8Y=XSSMQ(M17M[^_4
MJN0W':@GYSKK6DM]R)YFV(GP<DRMG92@$Q.T<H*_@W=*5L. ]U-XF=/I1+AY
MXM$1^%DQJ0$J/13:=[4W[C1089\T3;X^I-MG3:MRW<23G%.J?"NJM?-J4=*G
M+ZM*+XHO)5-@]>N+)5T]<%4(H!E<"2'-K^STU%RRMR5D1<&8R&&>Q0BBC*0P
M3S"!+$PH2J0]1%Z8MP=U).7<F+K9VJ\Z34"I56DJ:+3*V'2]=&5; X_+'"SF
MVBNSTU&Y979:@D9F71Z[L>A64]"HJGTUG;)@3UOPH[UVF//&W=MLT1AU!I;W
MZ 1B>T_!2NB%%>\2(_#ND5@W9E5KK]7IEWPJ]Y!K6_2V:W4UML?^KH[A.VP(
MZWJPX7FT.R?99]5PI#X7<C*\XFMU9"-%U/N(/0%NY1:+D"!)H,@8@2B7.RZ,
MPA#&89"'@0BB2%CFHEG+,+>9O1$:U(^DYO_SV'82^\2IWNZ".#P#Z@VRSZ:U
M-8WI*;I3P/T=ETA&Y@WR6(D/JD[^=O<[<<S\!/AY2,.UE<Q[4NY Z(ZEZ Z]
MU5"R/&?_]5AO./M/KIJ.<G;^4S+V'6_2@F\3%N!"%!G$>1;(39%*THU) N,"
M%7F1IP7"EL38.][<2+ 5#BP?->O)E[/-?6]>3E8N'O4Z2I49:/YB75^@'W].
M D1QEL @9!PB++>G)"$(4I;S0MD J;Q E>7H'__MJ&^ _Z/JYJ-:6ZX>UH\;
MWEA"_HKC:BE?D^<E()S8QG1FF@QQQ[-0)Q_ +U!_7OI!PR]QI7A!56B,FI]>
M-\&4TY01F,ZGI'XI/$\_1I"\G&K,+K/WT'W!9=4D=HGK[]^N/WU<Z7V!G,OD
MI[ID>D.P6K;'=#')29R+&"8%517@\ASF(J*0AT3@-$\R+(R];E8CSVVJ4<)W
M29(":/DENW4*J(\[#<P=+';&..TF<P:Q8V[3Z+:9Q1VZ.]G!@? #SJ/M8#;W
M33F#VY._R>:AGLB%- BR'K>0W?V\N7H&J;GOOAEV@]>F@WW;?96?_OU?NM_(
M_Q!<\W__E_\#4$L#!!0    ( .-95U@_ON2/1HD" #Y+'0 4    <VYY+3(P
M,C,Q,C,Q7W!R92YX;6SDO5EW&TF2+OC>OR*GYG6LTO>E3W??PY246;J=E=)(
MJJY[YP7'%W,172""%P"5J7\_Y@$N( 626 (1056=.DH)HN"V?&YN9FYN]F__
MXX^+V0]?<+&<-O-__Q/_,_O3#SA/39[./__[G_[VZ6=P?_H?__$O__)O_Q?
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MM(9S+/@817#Z,+S>40X3P3F3&FNO'FEK)[D$L20#3B9#C$IN4G_YLP.9&&A
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M !8*HM4,>%84_@C+K!#_9!;XK[3:@O;:V:WRWE?E?=T@:G/SQ9*+\R:1R+@
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M$L1"# F23"4E:5W!_OIZ/4_O"1IJO+M1Q7K->XVT,?!@HH2<I:^M:3WM!2&
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MH9)2BC[J%?>?83ND_RQ/I!/2]HN("GYH[5U?A^O&_^'M3#OF!4D]H,;:5TU
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MPF:5U$@/3%U6,?;%0M^8?-IV'DV_$W);KY;2*;HL5FIR>P(H:T/-+$C@3-+
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M %!"U"Q"I C0&:O1R#;1SU-C]%:%<I4H<CW8A]M9]+<\_<B1"84@;=T3Y+^
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M/'1^SFDQ['@6IA>=/E[3VJ_ IVD:&B.]N JY<5O(>,#]W%.?Z^-NKO5T>Z.
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M_'7RT:U'2.4TS\*"R2S7' L/06$!C9G<$(T\AZ[W,QVG,&(YUU&MWS$U,2'
MG:3_V<QJ7^V&W_%#DY"[OJSTW.L=M^/7G>EO<AC?D6[G7V:T\EV%QSR_#LOE
M9:WQ;;S8>D'U#5?K'3DX_=8BS7:%&?]G,9NO_T'_@D:F4^6NA._6:OC@6=#D
MF 9'\6%6M7K$9; BJ,J4%D7LFL<UV<6.1_5RW$TT68%W0M?D/)6[7M@/)U_D
M7'.E,J"5%)PFQH!<L@)2!4UQG8NHQ_%4GIKU>,0Q0W@JO>EKFJ'XA^6,#L:O
MX3RDIA:/=O>JX+;Z=7<_<4!1;]MO]U++N]="AGS@5 ZCUSY <C7"$EQ!T-R
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M53BAX/^'8.J1M=WM">*S5UEG8"CKJY='\)Y%0.Y#X!I5$ET;-7>?Q9BYE4>
MW<!JF>8)_2J0>U-/INW[)7UK5U6VQXG[^+=Z.$%;3K2WH.#U8OEU45]T;V=^
MS?-UPV'"RR\?/]5TC/-9I>.[AB+GK!1-OIHO]48R<@E!J@1&:&.-#89;.]BY
MLN\J^CZ-9Y6Z=9>?O$UCIBG,<UCFU?MEL[M)L5M0;&.]T^0#2U@$!%L4*!LU
M[6V!4+BS36DVB^/<I^RQF+'#F$&P_-QI?EP(3.*R\-Z%T\E?L]5I%)G"0)_
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M%,GSP3#YS&3'/C&/@9%[0.Q389- X*L-B74V_W)U6#CD*OD<09I:6LA9)I]
M,$C,E6B\\Z8,]Y1W9W)C(ZQ7Y=]WTP[0Q"2@],OLKS4=!2N2S"^S]?K64I)
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MQ=<P6V[%=6<]/AG&:U6#S$VCTD*1(;,6+$<F!<LD*]X)1(^/-780,B*4>E+
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M='6[5WACG0E2&< <**I44H(3G &W0IF 0OLT7))@M[F/;41[!,X]4!Y1B]-
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MYG%<GZ[5ELCJ>7-DH@1+#&2Z=HB5=+4[;8F5%G,4AN!U(/">6+$;S%YMN&1
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M67!(0<J& 1_+'S<,P!@#-UY",;5AFE..S XM@%F.4A3M8NXRXKGG;4UM HX
MRJF%.;'E>'A]57B. XH[48)W8"V93PHCUI=V U:(P+C@S/DN/1.'V=VKT/ ]
MH'IZT39A!]Q^<7^@> +W(1'D0'/IZJCW#-'(!"DKD0I#(>YW,1MII-1!]D$[
M@WN.LP]Z$]GT8WJN2Q+W&F/QX,R)H'3.PD*NH[&5*Q9\#A$X)[N(:TW^:9?F
M2L?NXY6-TSGTXAQ57&T@]/#I$\_K"DPZ,X/ 1="@C$-B/D8@GU5RQ!#]_0+
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M\[TU)C8)WMQFGYWFP#$5<EV8JNVU+)ADZD036TP<L?[RX0:GQMM0>'BZ:.-
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M1Z9-:.O'4D VSKI7W%D=$9)2')2N'1:*5$2)5H(%PQ''2R-_:I=38W!HA#R
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M!70T>$YVM>MTIM$%!Y@X45&R@5B4 AW9IHHA(HZ7Y=E^@N=4^.F6?;R/,)N
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ML_X'],E(WM%LC;OT[&_7*132:1VQD//MZJ2<E(E)3,=J4WKK)=J4Q@NR3L"
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MO\\J65)X.ZB&3ZW1VH08%5B],KRU>8'+FX9EM['OE#/%BTR*<YTBZ".'$)D
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MA^[M+-KJG4Q2!Z.3 HVJ@,HL00S.@Q8:@T%35!FOCNRQ7;:QQR<21SA'8I/
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MTZ2M)^- V():%6NLZ=)2_/9GM@Y0#R?RDSG7O(/AG9[ R26%7-#.R1X#A<6
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M(B\2A\013WQ\:RB,)KSEN)SL0M=LY@_6=YJ_WALCL&E%8&-T*AJ(LI;J.!N
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MU<GUJK\I2T$EYB487A!4\(:VGQ)(6X3DW'E1AK1^.+3%;V<U=8>D\L;@;%?
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M"$FQ0\#UTL+]9/@FQ-:HW._"+E9WX>*AOW"Q4>Y.%Q=*G7^75:"@FC0\;;Z
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MASJ"L"Y8QU1RVV6C3T/Q^:5>T>/&8T V(K][>K88B]/2&0.%7&&"O8AU6FZ
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M:4D+\$8I2$X3X[1R7,\W.?OQ_OK(!XUKAT:31X>8NCX97)8<%4_ &=;\K-2
MQD=P*43,F!C;;BDV&ZKZN.(^5O(O0.D ,;1^;_QW3J<7WSZN_OR&B[>G=,K6
MJ\OS-V]O7E$:&UV=B*4R:5EEZFP>I@-H(C"&^/_8>]/M1I(<3?15[@M@VO;E
MG/LGUNRXDU41'4OUF5\\L$W!:8F,H:BHC'[Z"R.UA41)[J33S:6:.EFQ9I(
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MYPM<Q#E]QRW-DE5&<L,@L-IV4M:^@84VZU(R-[YXX_5X UJ[2CU=#V[X@W5
M_%Y:T>'UP,WY8I<CTJ+$L*-(30L*]S%;^_)![@POTF7PHM 6G$J&FN0 [9-E
M-G$?<;QN -,M'Y0JADC'$6A=7U=AI).*W".(4J9Z$RMTIXDJ+[M\L ^7^I</
M]H%@$O'/FVK$3,:[Y0[5>WSKL62S>>^LZ0CSM!)<CN18.ZG(_2E.&S/:DGM
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M\G6[^YR^+G<J^"7'B]7&F_N/B^6Z#O%\M7@5JT__-US]5U[/@DA:I.PA%A=
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MH"]D9L^U)>9G\\7)LEQ5J>"F<N2\-OE=[9@P<Z^_P::L9<S"B&/(W:1BXN@
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M!D.F<?C?89N_"4F=K?-G5(:(OG:)3F2RH ,P'7FR$D7$+E/J^WQGFUNEHQ^
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M'8BK!Y=O74_5 &#'BV$4+QB#/Q?]>EW6HTT**1J2 *\%O3DG!EIREI5P5HH
MOIQN,,SIZ&Y]-E[$@^!(83CJFL//\]]@!N<W?[8MOCOC/!E?DJP9!&2$QQB9
M)PW$C"I1V:"]Z]0K[,#E6[\@C15+G2L5^Q'L**Z7N\G!9W0SHE79LN(L\2N1
MBQ@%<0ZR<2'G -*<[@JXN[?6<<.1H[87D>X/R;"!Y Q7?=D[]T_>J^425\LS
M%RSY"-61U<DR;1W1$&1@='=E%$YFJ4Z76_3H-EN[<B\&IOT(>A1*] %2?IU
MG$R)R;@\ X^@#%T%$&-M L<+G4#O6>5>Y"8Z$4^78/[T7G]X6WA ]!XJ\E%
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M_?3I_=N/'S$A&3""J^V,M."$PVKZAE!'WCC)(A<U%3,"^!BX35UZ81VV^OC
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M2.0AF908@]*ZRRMAE[5:Q]&'4#F]\W@4"NA.)V$.Q5AC)$-PM8P'% LZDFI
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MY4?\.E^L:J,6,H1>P[02]>D+TOFTOD@=+:<;+)+E@RG0^40BR!)9*;ODO.^
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MI^!]\+LUD6TG"1S0*+O)S(N>@#J(',<%U5U*1"X*O.8, B?KV(K$/&K#> @
MABX'$4_75/0HX#498=$3\(Z12LMHQ6)U]K'F3VWZ*3CAC'.*)6-J+T$7&"0T
M=00\_4?FDOA3_8X++.-ZA_35-8K^AM/5LOYJ'<O8Q#%N+SB:;,[>W<_#^3H&
M,%P7O$MK0K3,Z3I@-,K$@*=2?ZGH2H])BZ<:ENP%AZ:EDX<+:U?<!W"NL<!_
MF\PF%Y<76VV(,G,'FJ$/I<;K NG%Y)GB1@8911U:T8/([RS:6.B'B&S>!_]&
M859\FIS/)F628+9Z-_N&RXWB>S?[=!F7DSR!Q3; 'WF(WDA3IP(095YI%B)Z
M9DW40>@BPFZEP(!F1M==CR9%>L#XYB 2' 4V=QX8;A.T?6FWV7%B$<LRDA7/
M;6WI#HY)H006"0G2Z;RQ9[?;.FHU#%*>>\P[4FRM2TTN%W/X.MD^9ZGD1""'
M48C:KS@9L@TB+RQHT#I)F8/OTN'FSD=;HZ)G<<W[X%WK$N5.ROO7ZZ*#7'CF
MA0S%''@DD]&0LV?IY) ]0:Z>2A!0=8#%GLN.ID:C?^]I8!FT3@_X,E^L/N/B
MXE>$)2Y_G?^Y+LM;IU]O?JM6M]2?U-SLFHN]W)"\POSZ<O7[?/5I!;7(];]P
M=98">F.LK<9F+=M#LCA-]"Q#R"$*$YWI@KT^]S3VG.,#03,?@01;C_N@];[1
MWZ"#_>%RD;ZL";SFZR^3;S@["\9 !.F8=W3JM0B*026G)*U=2LGEV*6DN,-2
M8T_-.QYG??-[U/#YB F)HGPF-0^(9'3:]; O;VOWAQ3)I\8,7@6MY7/%9MU7
M&WL*S- @.HCK^^,H;' TVP3ACQ\ELU-U5T>.?"31T9;JG)&?\!M.YU\OUL5.
M"6=+?'6^P$V1\+HLZM:_/Q/:&N<@,9E<?0JRGD&RB0EPVKMH@HY=6B#UN*6Q
MQ\6/QV0K^;6>@'0XV3=E>K]-IN2[SV?X ;Y?>?#TAS-,%2"UA\ZMSWQ8S,\7
M<$%_9?TS7"[/R(<GFZ((9F)]I$=E:QE,8@JRUSE;<N^Z^+ C(&7LT;VFQZ0)
M7AH?KW4,XW%YG/%<4I(JU6X Y(NF5,<'T64'*6H/5@4+7>;1/;/,V/WRXV'9
M)Y\;MUI:.VG5DSLK#J*0,;.0>&(ZJ\RB<9QE#,;%H&WJ!([K#W:"@7O),#B,
M=XUUQ)57OB28>B&4=!Y9ME6SB:@9D+?$+ J(#ETQ*G:5^/J+G43N7[S(]^?>
M&&3^<^VU43LAO/]:);+\_7*3J.,A\!K2UB80&4%Z%G)57:(FZ125K.GB;#ZQ
M1"=4A!>/BA[X.T:8K/5;CMSD'( 56\?+1) LUAJD[%QQ+MJ8=T?W= =)Y[OB
M)O_@A\'(WLSM#2$G:K?T*N=)_79M-%;FBXOU0D/T4'IRH4$;(W4G<03=CE0
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M32+^4,?]> 8VAL!'/,<9+N:/>[5<\B"M4N3)N%";GF<&8(!!-@IDY,7S+M;
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MDUHS8*79X_OLAL$?X;&C=ZF-R!Y[>UFW?^M<_?S75YPM\>UE'73Y^COI\:]
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M7R>O5O379_C]%YPA<>\Q(H,!D:3ES" YL#J8.IA D>ZF"SW3']@BNP2N#]Y
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M![B]%FTX[W! /348VT>!IYT4EU=I<T;^#G_"9')%5(V.( ;B%9K$='*:K$,
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MOI@LEYC7Q^K,*^W)$\0Z5Y:X:#AN^M9RY3)$ES-&N8?:ZK!DNV;WI_>E>A;
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M*?%T?]!1KU)L/ [P=F3A=[C83,;,)DG ^BACZW7D!3)O$V>8BQ'*2U2BCZF
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M9N>3&?T!'JY%GOI:#VJC\V:/U!,W(G]%2NG[<K*L,\7K:N1675THUY@JD(,
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MZX0MFQQR,BF4Y([T/E&C2K3@;>'5?TM)Z83\@"!MVW/?E2E[A\\CP.Y!EH/
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M0^YK<D6LR951@;>102K%9*^=T:YI,&,'3>#V^*K0.2ZZ9.L@C-.3\7B9?OF
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M?'6E_3+#25SW/9$Y9H-,@,WU$3&1M1-06^ UFEXPJOBP">;K)L+F FU@.,K
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M+C%@@3&O-.,NM839GE^A#29'&8SMB*V#T"NG/^HT=_JCZ9__N,MZXLA#%ME
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M_YC.,FZBOJ!VB);\@L1K-G,LX,@U@))L$MXSQ^6;>Z<^7*01*,<?4-Z)NX.
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M6&=+^P-1PX*-R#G.B.Q>N#X(**UG),UGF,=W_AEYY2$6JR'H.@]'D:KTG&E
M^D=);8M0;\ZO>[!&(V".,]S:%6\'@9%__&/]!.J%(+O*@W21?#'Z)3BM%10C
MR?Y&JY)OSU58?[4-!^*(XZ=;\:]OR<^O-B-XV0IR'@M"\(EVGAR#@#F 0(S6
M9CJFH24W^_Y7&R5_G '1[?G7M^0W==?O.,8?\Q&>_OS'N]]^7K?^P(BHC0*I
MB!W**PLN< 3)E/3..Y7BF^O(GEJH$1]''!?MBLO#@LQLN@[>F1"ST%R#3K40
MCC-)MYQ%,$*F9'Q$T=0P_KGO-P+D*,.BG?!T2+CX.?^>_Q[%Z>G)S_G]7^OH
M+OE9TJ, GDMUR0L'KTDY,G+5E2@E2]-TK[RV4"-2CC\\NC.7!P&9U7O1Z4\G
M/Z7\_J>_?EJ;SC9JIQ1AW]2W(T4TH'$%9#!H1"@F&MD,EV<6:83*$<=-N^!N
MW]U^_[7($?_">#W!^3VL)]H,+Y&!=37(1SH1?/0*HF)&1ZET2$VM?Y];H!$>
M1QD\[8:K@] @M^KP"T[P<J.E@S0%F<Y0DE]F\19 R00H:Y*5=8 &?_-#W,-%
M&B%RQ$'4+K@[L&?]!Y0(A9R%.AL\I5!;?Q E210H5L08O2Q)M(0Z7EZE$2A'
M&3/MD+]#4BA?KO-L,?U*%M9&P:Q1L7A=PSI)@\IH(9BL:D"/!V=<<&]OD/'$
M.HUH.?Z Z:X\'A1>B*>CJZO19'/:?#*1"<<%9.LB*&<S!%5'R3KMF7%&!]<>
M1WUAH3;$R",.K7;%Y:%=1D_1XR)Y^&2$@XPB@RJ.E&<( I+.)AB5&3;-06I9
MJQ$X1QF9[9S70U(WIZ/).5Y-:S^J?!=]UBFS+!A",=Z"0N4@>,\@,B906L84
M>W,B_),K->+F^".VN_.Y;P=ZK3AK'<CO.+DN&!?7LUH"^>W#IV_K('3)+D<F
M.3 7'>E0C!!XC)"83KYH9GQ3;\JVU1K1<Y3AW#WP>Q!ZYSXIFX=!R,#16 .&
MU]H0P30XXPL08=8Q'XU\PWCY9Y=IQ,P1!W:[X? @P/(-1__$R>:[*+<)M44'
M@KLZ:T@80"T"N$ :$XU1JK0_$#WZ?",XCCB4NQM'!P&*E6;\]G^KN[+FN'$C
M_)Y?D<H[UKB/JE2JM/;6KA+;4DFV*V^JQB5Q,R*UPYF-G5^?!G5Z)$O4B!Q2
M+_;((P-]?$!WHX'N,Z@64,<[.7.NF C&$!Y*QUN6+;$L.H)F%",_'42R_:\Z
M_FB6GA!YE<>Y \IW%DBYREO<YX0IZU0"W/Z<ED3J\D:$4TMBE#$ #UFX9Q<S
MV!8IK_A4=Q#YS@(I-^?37U*=_K=.B]N#1Q98B%UC=1-*8XHD<&L4&GE)C%'=
M'0T\/P%P;YZ>:'F51[N#RGA.>/E2I54-YP\6C0_9,]P3)1$FVM*50A((5A)&
M>7+2.!IOG]+TQ<TC\_7$S^L_[!U*YK/ T14SQQCEI;/+(G@/,L8"VE9PD="4
M2HE-JHE-V1,3/%4N6P'/:/G0<])^B)*O^#!X#.E/"*M;P?V:FM,E7)R56AU[
MRP3MWM>J/0&AM+*ZK F,_*0RN-\JF0F-P+44V?+-V*E0W"+)';EE^([F%7QM
MZN;\VYN"+T(%X>)--VWYC=M/)#08<M[\2@?")TCL!;D1#P/?56U8-.UZF0[R
M<75:5QG)JU>W1>+:_?HN"C^!7Z23D'A. MV;'#,CT@M.0 M&4-A64^,BW*E_
MVPROJWE"[N;Q@C8L9EF"!EP[FD?B'62BHDG@0?H[[>)W#[KG['3CP6X "#P-
MJRWT,:6)7*Y.?EDOFXOK/DXJ2)8T*_M[661<<W01I2&":QHT9(HNY",XRM#Z
MCD@<N(/0F[18M>6GSDI>6LB-.6<'BVU4V P@SPEQ$)IUO5I^._E\?*)<.;;D
M0'@TCDC' P&TS$2;*%&%.OO-6Q/?(:!-X:?3YL\W5R->@N#JAUL,W,XWM2T:
M4OM;2G%KO?^9EKX9(LV].DO+MQWQMSY?SMX&6?HKY9!+-Z[R9#)Y$I2&Z%CR
M1O=Y:OC0V+UT/F(Z:= 5/X3\)D7 ]G[9^ZI.^ZMTWIY8ZR$R$0ES)>5A2X/1
ME 71P60GE!,AB9VY'UNS,34NI_"+=Z/S6?C.AVB7FV51YT$^^&^-(Y]5%_LU
M3H&LWN'RVXF5I9]I8B1249Z+>TM\T+B%@\, F('QF\6C1H1S;[*G=J1V!*5[
M$!Y'KX-!]N]O[ND#.?]/]U7W3?E?1RG_M?S]^6C_N_';[@3EI]"<7P[^OFI7
M3;Y85G6H+F 1NG,4E"7^O%C'%*L:;5$;T %M<FCJMEE4L9LR=GGJ K+C]?DY
M"J/)A]>CW-'07NB<F!1SL_R,HY[B<+_\L:Y6WSZDU5D3WZ455(OV>R&UU?G%
MXJFKM'.A_,VMX#=5<L7 O67Q*I20OJY2C9/_;7L_\'K-X#KM7)KN8!#YVO.E
M,5Y8G00:0$DCT8DI;:I$>4<0G</EE"TN)##]*K<^-<^PGLP_&]3'P45:=BJX
M,II:!E7N8A!)#>X$PJ%WIEPF7OC <!< #G82A^4A:J?9V ='Q./.QXO5- L?
M8X.+[H2) ;-)H)E)HC1.9P:(+\V-C<0@ )BD*NN=8>T! N?D-[P<!?= ]E*5
MS )7&SF:#9ZN;]8+&I(!=)YX1&&5ZIS@@R.9XN(43&,HP'8&M#X43XV\%T/C
M'M@&U]/$^=/?8)&:^O/Q^\,KVJEV'@QD8BTH(H-.Q"N?<$%:R[3BT<8^+L#F
MN%,C87B]-0,)<6( [-=Y"6U:_OGKN3_;J^/;YK<FG+6K?_UZ7?<BZQ"]CR3[
M4D0\ 4->C":,TE+K4WBC^SSL?FJ>J<^)1P7(H$*>_#CY UR<P?*F^FLR/-M(
MM&&E%8'PQ#KJ2$C<"1]]#+VNF]\=<^ICNE&AL+7PIF[J^?;#%PBAJM//U\4)
M-#?.<V>),I218CZ)[S8]I,Z[D*@SOH_J[XW<"P"[>UHP, !>)LBI87!\>$7]
MU16?:R1S81B7GL2N.I)G@;B,'GTRB&5NA-"TCY7XP?"] +&[YP0# V( D4Z,
MBI(2AXOJAO L#=7ES,!Y(B7$DAD3Q)<W$E0XCZ#N@87O!NV%@-V]%A@6 =N+
M;Q:QZR/Q_6T*0#L64]2<4(4&3DH?B!7)$<X$2&^E269WAR1]*)[:(1WYU&1P
MI<T"BD^DBKYG] 1,E")D6[+WJ=2%E<1%BCNLE4IFQ33(W5VJ>Q;I4X?3PZ/G
MN5F_%ZARGIF_7\J]_+9=^S;]L<:/J^9="IU%0+.(H-D^,]=WY $R9ULQ\<+,
MUL.H_-C4$']?MZNJ/KVD:B^C_HY2!ZKZ]# MJR;>Y#D\<QJ"PMTS^G(#7@N"
MCG>YU 4L6 FXT:I)S-/S^!C6F/>;^](: 4J**JY($.5.5$('R*FH"#@+*G.F
MDIS&OC^#B3GMJB/B]W%G8"RES\(_^'G=EH(S[=O23[.^DQ60@HGH(B<866$(
M#B*A_&0@*D$R:$@,W>']^A]1^?KPN05,[H%S$)W- GT;0>1#C-WT,PD1G!0D
MEWK!DDE/;.#HTQB%O'F-$2+?&1Q[DSTU/H=!RE,YOX'4-GG>YZSRRZ]W&CYF
MYSGGEM L@$C+,G'EKFEF- 5<K<K9/O?!-\>=&A,C*:\92)*SV)=Z^AI7KZF\
MUD*2V 5;F@D"B1K<-V+2.C,;M=O9QM2?[CD=YNS.<HZDUYEB]CKW+KB-,2>B
MF/%$>AZ)]6")RP!1<I63A0D1.H]=<2QD](#@%FJ:!> ^P.\/FH]K?C@++D+"
M7;X$8*47'9B@2$+Q  6>3-K=A=/':9T?^+;!Q#VH#:B@60#N".K3=+D$H^!@
MR^T0'DM^.)9^5J5RMT< >*D\MWYGV+HA:^IK&M/8U.VT,A] W:PU#3ZR;(@R
M7)>0R!'(GA$*PEI/8Q*;S<3&QM1,3..6"GX8*-M(>Q98^=1<'.2.A6L.$@;+
MP@MBG2@U=ADN&!DIAM"6QP2&RIQWAI=-ZF:!F:UT?0\V+Q+\Q)4FCL-9BNL%
M[L=W7S/=/GRZ_Z\I?83SR]6F!40:;23!4_0S/<W$"A&)5BEZQBQS]K$3V+Z5
M*5Y"X]3WTG9I\7:JSZDKI/R CW?-.53UB=? /'>>\"C1#@B/"]IF3P237M@L
M/../5<SH73/E42HF>B.V4Q0THZADXH-67*C['W\^^C>C[#HX.;ZHZK?-=?LW
MAKPD[P0Q$:4C-97$>:E)MDX":&.8[]/&YJEYI@/0D+IL1A+L+)RN/H_JNU45
MA$O)E7)61N&J8N@86$@"'56=O4Y.<+6[<AQ]J9[Z$N\T\>(H.IT%6I\N*ZF=
M<$:4@H^QU$2GH=3;\;C0=>82,@919G=G8D^2.W40,0Y2GLIFOE!M4V<Q-PS
M42HFY=8$.,O ,:5(,IH3*1,G'C?^LHH-?O NZCX=OYZ89FKD#*S29ASYSF+3
M>KX1>']SG]5$'<"@ T%=:<:JI23>:$:B\)XE8#F(:6I*/).1J=]23&.(=Z7Y
MB7?$!Q(@A^ME.(,V'2ZKD)"UKE#SB<@\9RAO#X- GK@O>;W2BX)&%;1-6M(^
M+>#[SC?U'KDS]3<CZV(FM03?0GOV:0EU>TG!B6?"L1 CR> D.B4,B'6,DF!
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M97AH:6)I=#$R,2YH=&U02P$"% ,4    " #C65=8$LE=\5@'  ""(@  %
M            @ $4=P  83(P,C,M97AH:6)I=#$R,BYH=&U02P$"% ,4
M" #C65=8; 'R5I $  "G$   %               @ &>?@  83(P,C,M97AH
M:6)I=#$S,2YH=&U02P$"% ,4    " #C65=8.H"+LZP$  !E$0  %
M        @ %@@P  83(P,C,M97AH:6)I=#$S,BYH=&U02P$"% ,4    " #C
M65=8:C8(+#$#   S"@  %               @ $^B   83(P,C,M97AH:6)I
M=#$U,2YH=&U02P$"% ,4    " #C65=8/$J6S/T"  "L"@  %
M    @ &ABP  83(P,C,M97AH:6)I=#$U,BYH=&U02P$"% ,4    " #C65=8
M&$.'=.4"   5"@  %               @ '0C@  83(P,C,M97AH:6)I=#$U
M,RYH=&U02P$"% ,4    " #C65=8JHWXM-B!  #E7@, $P
M@ 'GD0  83(P,C,M97AH:6)I=#(R+FAT;5!+ 0(4 Q0    ( .-95UB4[[=R
M[ D  $4N   3              "  ? 3 0!A,C R,RUE>&AI8FET.3<N:'1M
M4$L! A0#%     @ XUE76*^)D?$XDPH <#27 !               ( !#1X!
M '-N>2TR,#(S,3(S,2YH=&U02P$"% ,4    " #C65=8F 1]J-6*  #4* 8
M$               @ %SL0L <VYY+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    (
M .-95UB3W2.T"D8  )K4 @ 4              "  78\# !S;GDM,C R,S$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( .-95UAU:FA'&@P" )!E%P 4
M      "  ;*"# !S;GDM,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( .-9
M5U@(4XZ/V%X+ %YT#@ 3              "  ?Z.#@!S;GDM,C R,S$R,S%?
M9S$N:G!G4$L! A0#%     @ XUE76*:.M+\B#0  '0T  !0
M ( !!^X9 '-N>2TR,#(S,3(S,5]G,3 N9VEF4$L! A0#%     @ XUE76.]=
MD%(S#   +@P  !0              ( !6_L9 '-N>2TR,#(S,3(S,5]G,3$N
M9VEF4$L! A0#%     @ XUE76 V@%W@NI@D 4((, !0              ( !
MP <: '-N>2TR,#(S,3(S,5]G,3(N:G!G4$L! A0#%     @ XUE76&P!0E3$
M#0$ G@\! !0              ( !(*XC '-N>2TR,#(S,3(S,5]G,3,N:G!G
M4$L! A0#%     @ XUE76/M3YU+9_@  ^0 ! !0              ( !%KPD
M '-N>2TR,#(S,3(S,5]G,30N:G!G4$L! A0#%     @ XUE76,2"<MA%U@
M,]@  !0              ( !(;LE '-N>2TR,#(S,3(S,5]G,34N:G!G4$L!
M A0#%     @ XUE76,F2UUOF[   *^\  !0              ( !F)$F '-N
M>2TR,#(S,3(S,5]G,38N:G!G4$L! A0#%     @ XUE76,B,.)*L'0$ S!\!
M !0              ( !L'XG '-N>2TR,#(S,3(S,5]G,3<N:G!G4$L! A0#
M%     @ XUE76,)01:^K\@  N/0  !0              ( !CIPH '-N>2TR
M,#(S,3(S,5]G,3@N:G!G4$L! A0#%     @ XUE76%$11'J,( $ @2(! !0
M             ( !:X\I '-N>2TR,#(S,3(S,5]G,3DN:G!G4$L! A0#%
M  @ XUE76"Z$OS(+[0T >J@0 !,              ( !*; J '-N>2TR,#(S
M,3(S,5]G,BYJ<&=02P$"% ,4    " #C65=8-1><#TI0 0 34@$ %
M        @ %EG3@ <VYY+3(P,C,Q,C,Q7V<R,"YJ<&=02P$"% ,4    " #C
M65=8FG,IKZ[P  "T\@  %               @ 'A[3D <VYY+3(P,C,Q,C,Q
M7V<R,2YJ<&=02P$"% ,4    " #C65=8D;,EM3T8 0 Z&P$ %
M    @ '!WCH <VYY+3(P,C,Q,C,Q7V<R,BYJ<&=02P$"% ,4    " #C65=8
M2Q'5="U8 0 %6@$ %               @ $P]SL <VYY+3(P,C,Q,C,Q7V<R
M,RYJ<&=02P$"% ,4    " #C65=82][>DHX^ 0""0 $ %
M@ &/3ST <VYY+3(P,C,Q,C,Q7V<R-"YJ<&=02P$"% ,4    " #C65=8^T&-
MOWT  0"? @$ %               @ %/CCX <VYY+3(P,C,Q,C,Q7V<R-2YJ
M<&=02P$"% ,4    " #C65=8"L"Y"P_@   ]X@  %               @ '^
MCC\ <VYY+3(P,C,Q,C,Q7V<R-BYJ<&=02P$"% ,4    " #C65=8I,[MA? @
M 0#<(@$ %               @ $_;T  <VYY+3(P,C,Q,C,Q7V<R-RYJ<&=0
M2P$"% ,4    " #C65=8I9DM6C+H!P#'G@H %               @ %AD$$
M<VYY+3(P,C,Q,C,Q7V<R."YJ<&=02P$"% ,4    " #C65=8@JO(^[CP!P"C
MJ H %               @ '%>$D <VYY+3(P,C,Q,C,Q7V<R.2YJ<&=02P$"
M% ,4    " #C65=8 [ 9/%JP#0#[!A  $P              @ &O:5$ <VYY
M+3(P,C,Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( .-95UB@K1"LF.0+ +K5#0 3
M              "  3H:7P!S;GDM,C R,S$R,S%?9S0N:G!G4$L! A0#%
M  @ XUE76*YZ8LN_"P  N@L  !,              ( ! _]J '-N>2TR,#(S
M,3(S,5]G-2YG:6902P$"% ,4    " #C65=8DA1X2Y +  "+"P  $P
M        @ 'S"FL <VYY+3(P,C,Q,C,Q7V<V+F=I9E!+ 0(4 Q0    ( .-9
M5UB.JFT7;PP  &H,   3              "  ;06:P!S;GDM,C R,S$R,S%?
M9S<N9VEF4$L! A0#%     @ XUE76-9%D=,E"P  ( L  !,
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4!08     +@ N ,<+  "CG7$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>279
<FILENAME>sny-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sny="http://www.sanofi.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sny-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">sny:AmericanDepositorySharesNASDAQGlobalSelectMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">sny:OrdinarySharesNASDAQGlobalSelectMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:ErnstYoungEtAutresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:TR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:USGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:USGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:USGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:USGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:TemporaryDifferencesSubjectToUSGlobalIntangibleLowTaxedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:StockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2007-11-01</startDate>
            <endDate>2007-11-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:NewAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:PriorAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OutsideUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OutsideUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OutsideUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesSecondAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesFirstAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesFirstAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesSecondAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesThirdAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:SalesOfAntibodiesThirdAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OutsideUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:PriorAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-01</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:DevelopmentOfCemiplimabREGN2810Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:DevelopmentOfCemiplimabREGN2810Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:DevelopmentOfCemiplimabREGN2810Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sny:MajorCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sny:MajorCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">sny:MajorCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:TwoThousandFourteenAmendedInvestmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:SaleOfStockAxis">sny:PublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-29</startDate>
            <endDate>2020-05-29</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:MajorTerritoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherTerritoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:OtherIntangibleAssetsExcludingSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-09</startDate>
            <endDate>2023-04-09</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-09</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-09</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-09</startDate>
            <endDate>2023-04-09</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ProventionBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-13</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sny:ProventionBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-13</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ProventionBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ProventionBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:QRIBIntermediateHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-29</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:QRIBIntermediateHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-29</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:QRIBIntermediateHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-17</startDate>
            <endDate>2022-03-17</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:EPICBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-17</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:EPICBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-17</startDate>
            <endDate>2022-03-17</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-03</startDate>
            <endDate>2022-05-03</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:EPICBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-17</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:EPICBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-17</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RegulatoryComplianceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:ManufactureAndSupplyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:ManufactureAndSupplyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:ManufactureAndSupplyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KymabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-08</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KymabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-29</startDate>
            <endDate>2021-04-29</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-29</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KiadisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TidalTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TidalTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-03</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-14</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-23</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KadmonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KadmonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OrigimmBiotechnologyGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-03</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OrigimmBiotechnologyGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:MachineryAndEquipment1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:PropertyPlantAndEquipmentInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:PharmaceuticalsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:VaccinesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:ManufacturingAndSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:OfficeSpaceCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:LaboratoryFacilitiesCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:AcquiredRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:IOLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:TevaPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsTrademarksAndOtherRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:TechnologicalPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAventisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsChattemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsProteinSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsAblynxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBioverativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsRezurockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsTZIELDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsBeyfortusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsQunolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:PrincipalMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">sny:ALTUVIIIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ExpenseCategoriesAxis">sny:AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ExpenseCategoriesAxis">sny:AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:ExpenseCategoriesAxis">sny:AmortizationOfComputerSoftwareAndOtherRightsOfAnIndustrialOrOperationalNatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherProductAndServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherProductAndServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherProductAndServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:NKCellAndProXTenTechnologyPlatformsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:EloctateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sny:SAR444245Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:MCMVaccineBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:AssociatesAndJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:BioAtriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:BioAtriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradingEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">sny:InnoventBiologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">sny:InnoventBiologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">sny:TranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-14</instant>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CommitmentsRelatedToUnquotedDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CommitmentsRelatedToUnquotedDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:QuotedEuroDenominatedSeniorBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:QuotedEuroDenominatedSeniorBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:SeniorBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:SeniorBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:IncreaseOfTenPercentBasisPointInMarketInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:IncreaseOfTenPercentBasisPointInMarketInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:SPMSDContingentConsiderationAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">sny:FairValueOfSPMSDContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:SPMSDContingentConsiderationAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">sny:FairValueOfSPMSDContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:SPMSDContingentConsiderationAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:FinancialInstrumentsMeasuredAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRiskAxis">sny:FairValueOfSPMSDContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:FinancialAssetsHeldToFundDeferredCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:FinancialAssetsHeldToFundDeferredCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">sny:FinancialAssetsHeldToFundDeferredCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sny:WriteDownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sny:WriteDownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">sny:WriteDownMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:QuotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:UnquotedDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ContingentConsiderationRelatingToDivestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:MutualFundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationTranslateBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:OtherContingentConsiderationArisingFromBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ConsolidationAdjustmentsIntragroupMarginInInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ConsolidationAdjustmentsIntragroupMarginInInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ConsolidationAdjustmentsIntragroupMarginInInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ProvisionForPensionsAndOtherEmployeeBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ProvisionForPensionsAndOtherEmployeeBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:ProvisionForPensionsAndOtherEmployeeBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RecognitionOfAcquiredPropertyPlantAndEquipmentAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:EquityInterestsInSubsidiariesAndInvestmentsInOtherEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:StockOptionsAndShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:StockOptionsAndShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:StockOptionsAndShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:AccruedExpensesAndProvisionsDeductibleAtTimeOfPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:PrincipiaBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AblynxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AmunixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:RemeasurementOfOtherAcquiredIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:DeferredTaxRelatingToRestructuringProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:DeferredTaxRelatingToRestructuringProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:DeferredTaxRelatingToRestructuringProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:DeferredTaxRelatingToCapitalisationOfRDExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:DeferredTaxRelatingToCapitalisationOfRDExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-28</startDate>
            <endDate>2021-07-28</endDate>
        </period>
    </context>
    <context id="c-762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c-766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-27</endDate>
        </period>
    </context>
    <context id="c-769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sny:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithoutMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:RestrictedSharePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:MarketConditionAxis">sny:WithMarketConditionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PerformanceSharePlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="c-816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-03</instant>
        </period>
    </context>
    <context id="c-817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-04</instant>
        </period>
    </context>
    <context id="c-818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:EmployeesShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:May252023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:May32022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:April302021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2023ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2023ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2022ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2022ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2022ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2022ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2021ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2021ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2021ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2021ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2020ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AwardsDateAxis">sny:ShareRepurchase2020ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-841">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:EquityInstrumentsIncludedInFinancialAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-847">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:DebtInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-851">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:CashFlowAndFairValueHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:CashFlowAndFairValueHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:CashFlowAndFairValueHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">sny:ForeignCurrencyTranslationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReclassifiedItemsAxis">sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-05</startDate>
            <endDate>2013-03-05</endDate>
        </period>
    </context>
    <context id="c-859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-05</startDate>
            <endDate>2014-03-05</endDate>
        </period>
    </context>
    <context id="c-862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-24</startDate>
            <endDate>2015-06-24</endDate>
        </period>
    </context>
    <context id="c-865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-04</startDate>
            <endDate>2016-05-04</endDate>
        </period>
    </context>
    <context id="c-868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-869">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-10</startDate>
            <endDate>2017-05-10</endDate>
        </period>
    </context>
    <context id="c-871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-02</startDate>
            <endDate>2018-05-02</endDate>
        </period>
    </context>
    <context id="c-874">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-30</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="c-877">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockSubscriptionOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:StockSubscriptionOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-883">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">sny:TotalStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-891">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-893">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-894">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-895">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-900">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">sny:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">sny:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AdjustmentToDebtMeasuredAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:OneBillionSevenHundredFiftyMillionBondsMaturingMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="c-917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:OneBillionBondsMaturingJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="c-918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:OneBillionBondsMaturingNovember2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-11-30</instant>
        </period>
    </context>
    <context id="c-919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="c-920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="c-921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:SyndicatedCreditFacilityCanceledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="c-922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingDecember2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-932">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-934">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:ShortTermDebtAndCurrentPortionOfLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:IncreaseDecreaseInterestRateAndCurrencyDerivativesUsedToManageDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-938">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:NonCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">sny:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-943">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-944">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-945">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-947">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-948">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:April2016EMTNISINFR0013143997Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="c-950">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2020EMTNISINFR0013505104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c-951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:April2022EMTNISINFR0014009KS6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:September2015EMTNISINFR0012969038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="c-953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2018EMTNISINFR0013324340Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="c-954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:September2014EMTNISINFR0012146801Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-09-30</instant>
        </period>
    </context>
    <context id="c-955">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:September2016EMTNISINFR0013201639Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="c-956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:April2016EMTNISINFR0013144003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="c-957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2019EMTNISINFR0013409844Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="c-958">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:April2022EMTNISINFR0014009KQ0Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-959">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2018EMTNISINFR0013324357Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="c-960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2020EMTNISINFR0013505112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c-961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2019EMTNISINFR0013409851Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="c-962">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:March2018EMTNISINFR0013324373Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="c-963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:ShelfRegistrationStatementProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:June2018SNFISINUS801060AD60Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="c-964">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ParticipatingSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-965">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingDecember2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-966">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:FourBillionFacilityMaturingMarch2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:CommercialPaperProgramInUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-974">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-975">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-977">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:MainUndrawnConfirmedGeneralPurposeCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-978">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-980">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-985">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-988">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-990">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-991">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-994">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-995">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-998">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1000">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1035">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1038">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1039">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1041">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1042">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1043">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1044">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1045">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1048">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1051">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1052">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1053">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1056">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1057">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1059">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1060">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1061">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1064">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1065">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1068">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1070">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1071">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1072">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1074">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1076">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:WeightedAverageInterestRateBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DebtInstrument1Axis">sny:SanofiEuroMediumTermNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:WeightedAverageInterestRateAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ChangeInEuroAndUSDollarShortTermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:PlusHundredBasisPointsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ChangeInEuroAndUSDollarShortTermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:PlusTwentyFiveBasisPointsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1080">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ChangeInEuroAndUSDollarShortTermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:MinusTwentyFiveBasisPointsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1081">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">sny:ChangeInEuroAndUSDollarShortTermInterestRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">sny:MinusHundredBasisPointsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1085">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1087">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1089">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1090">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1092">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">sny:OtherCurrenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionBeforeDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">sny:OtherCurrenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1094">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1096">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1098">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">sny:OtherCurrenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1099">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">sny:OtherCurrenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionAfterDerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtMarketValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOnRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">sny:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:OtherLiabilities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:TranslateBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ShireHumanGeneticTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:SwedishOrphanBiovitrumABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForOtherLongTermBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:NonCurrentRestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:MiscellaneousOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:LumpSumRetirementBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:DefinedBenefitPensionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:TopUpDefinedBenefitPensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:SanofiaventisPlusPensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:MultiemployerDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:MultiemployerDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrs-full:MultiemployerDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:DefinedBenefitPensionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">sny:QualifiedDefinedBenefitPensionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:DefinedBenefitPensionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">sny:NonQualifiedDefinedBenefitPensionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:HealthcareCoverAndLifeInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:HealthcareCoverAndLifeInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:DefinedBenefitPensionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">sny:MinimumPlan1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">sny:MaximumPlan1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">sny:MinimumPlan2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">sny:MaximumPlan2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfMedicalCostTrendRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfMedicalCostTrendRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfMedicalCostTrendRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfMedicalCostTrendRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfMedicalCostTrendRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">sny:ActuarialAssumptionOfMortalityTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">sny:ActuarialAssumptionOfMortalityTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">sny:ActuarialAssumptionOfMortalityTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">sny:ActuarialAssumptionOfMortalityTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PlanAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:EffectOfAssetCeilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:EffectOfAssetCeilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:EffectOfAssetCeilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ProvisionsForPensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CashAndCashEquivalents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:EquityInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:EquityInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:EquityInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:BondsAndSimilarInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:BondsAndSimilarInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:BondsAndSimilarInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:RealEstate1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:RealEstate1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:RealEstate1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CommoditiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CommoditiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:CommoditiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:HedgeFunds1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:HedgeFunds1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:HedgeFunds1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:InsurancePoliciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:InsurancePoliciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">sny:InsurancePoliciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyOrPartlyFundedDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">sny:PensionsAndOtherPostEmploymentBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:FundingArrangementsOfDefinedBenefitPlansAxis">ifrs-full:WhollyUnfundedDefinedBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrs-full:PresentValueOfDefinedBenefitObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:OtherEnvironmentRelatedProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-1459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">sny:UncertaintiesOverIncomeTaxTreatmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">sny:UncertaintiesOverIncomeTaxTreatmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">sny:UncertaintiesOverIncomeTaxTreatmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:USLegalRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-1463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">sny:USLegalRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-1464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-1465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:CollaborationAgreementWithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-1466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:TypesOfAgreementAxis">sny:RoyaltyAgreementWithSOBIOnSalesOfBeyfortusInTheUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">sny:ActuarialAssumptionOfMortalityTableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesOperatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesOperatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesOperatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:CurrencyDerivativesFinancialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:EquityDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:EquityDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:EquityDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInKoreanWonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInTaiwanDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInChineseYuanRenminbiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInHungarianForintMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInRussianRoubleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">sny:NotEligibleForHedgeAccountingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInChineseYuanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInSingaporeDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInJapaneseYenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencySalesInUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarUSBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarUSBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:ForwardCurrencyPurchasedInUSDollarCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-1797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1841">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1847">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1851">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive343Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1869">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1874">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-1875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1877">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1883">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1891">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1893">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1894">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1895">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1900">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive069Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEsterReceive092Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1932">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1934">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1938">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-1939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1943">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1944">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1945">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1947">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1948">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1950">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1951">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedEoniaReceive006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1955">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1958">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1959">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1962">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1964">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1965">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1966">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPay057ReceiveCapitalizedEoniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1974">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1975">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1977">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1978">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1980">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive103Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1985">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1988">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1990">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1991">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1994">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsPayCapitalizedUSDSOFRReceive132Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1995">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1998">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-1999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2000">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">sny:InterestRateSwapsReceiveCapitalizedEoniaPay148PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:ValueOfHedgeRecognizedInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">sny:AtNotionalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:FairValueHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DerivativeInstrumentAxis">sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">sny:DerivativeFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-2030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-2031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:SuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AblynxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2035">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:AblynxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KymabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:KymabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2038">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ProventionBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2039">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:ScribeTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-19</startDate>
            <endDate>2023-06-19</endDate>
        </period>
    </context>
    <context id="c-2040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:ScribeTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-19</instant>
        </period>
    </context>
    <context id="c-2041">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-03</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="c-2042">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:TevaPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-04</startDate>
            <endDate>2023-10-04</endDate>
        </period>
    </context>
    <context id="c-2043">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:TevaPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-04</instant>
        </period>
    </context>
    <context id="c-2044">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:ProventionBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="c-2045">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:ExscientiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-07</instant>
        </period>
    </context>
    <context id="c-2046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:BlackstoneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="c-2047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:IGMBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-29</instant>
        </period>
    </context>
    <context id="c-2048">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:AtomwiseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-17</instant>
        </period>
    </context>
    <context id="c-2049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:InsilicoMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-08</instant>
        </period>
    </context>
    <context id="c-2050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-2051">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2052">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2053">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:AntibodiesCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:LonzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-27</instant>
        </period>
    </context>
    <context id="c-2055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:LonzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-27</startDate>
            <endDate>2017-02-27</endDate>
        </period>
    </context>
    <context id="c-2056">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">ifrs-full:JointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-27</startDate>
            <endDate>2017-02-27</endDate>
        </period>
    </context>
    <context id="c-2057">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:WorldHealthOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-28</instant>
        </period>
    </context>
    <context id="c-2058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesGivenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2059">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesGivenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2060">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesGivenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2061">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesProvidedToBanksInConnectionWithCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2064">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:OtherGuaranteesGivenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2065">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:OtherGuaranteesGivenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:OtherGuaranteesGivenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesReceivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2068">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesReceivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:GuaranteesReceivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2070">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:SanofiPasteurHepatitisBVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2071">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:TaxotereProductLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2072">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:TaxotereProductLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:TaxotereProductLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2074">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:TaxotereMississippiAttorneyGeneralLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="c-2075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:ZantacLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="c-2076">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:ZantacLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:ZantacLitigationInCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:GoldBondProductLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:GoldBondProductLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2080">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2081">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-20</instant>
        </period>
    </context>
    <context id="c-2082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2085">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-2087">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-2088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-2089">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInSwitzerlandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2090">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInSwitzerlandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="c-2091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInSpainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2092">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInSpainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-2093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInBelgiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2094">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInIrelandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInGreatBritainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2096">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DepakineProductLitigationInNorthernIrelandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:DengvaxiaProductLitigationInThePhilippinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">sny:ProductLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2098">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeArePlaintiffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:RamiprilCanadaPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2099">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="c-2100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PraluentAlirocumabRelatedAmgenPatentLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-18</instant>
        </period>
    </context>
    <context id="c-2101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeArePlaintiffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:JevtanaRelatedPatentLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeArePlaintiffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:JevtanaRelatedPatentLitigationInTheUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c-2103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixLitigationCommonwealthInAustraliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixLitigationCommonwealthInAustraliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">sny:Patents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixAttorneyGeneralActionInHawaiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="c-2106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixRelatedLitigationInFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-05-14</startDate>
            <endDate>2013-05-14</endDate>
        </period>
    </context>
    <context id="c-2107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:PlavixRelatedLitigationInFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="c-2108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:DefendantAxis">sny:ActionForWhichWeAreDefendantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:A340BDrugPricingProgramInTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c-2109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:AventisCropScienceRetainedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ContingenciesArisingFromCertainBusinessDivestituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-03</startDate>
            <endDate>2022-06-03</endDate>
        </period>
    </context>
    <context id="c-2110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:LegalAndArbitralProceedingsAxis">sny:InfraservHoechstRetainedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:ContingenciesArisingFromCertainBusinessDivestituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>1997-12-31</instant>
        </period>
    </context>
    <context id="c-2111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-2112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-2113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-2114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-2115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-2116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-2117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareAndGPOProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ChargebackIncentivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:SalesReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:OtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:GovernmentAndStateProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">sny:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">sny:DaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:CommercializationRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:AntibodiesAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:ImmunooncologyAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:ImmunooncologyAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:ImmunooncologyAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sny:OthersCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:IncomeStatementLocation1Axis">sny:OtherOperatingIncomeExpense1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">sny:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgedItemsAxis">sny:InterestRateAndCurrencyDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:LargestCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">sny:CustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SpecialtyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DupixentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AubagioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CerezymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:FabrazymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:MyozymeOrLumizymeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:JevtanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AlprolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:EloctateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:GeneralMedecinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:CoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LovenoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:ToujeoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PlavixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:LantusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:OtherNonCoreAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:IndustrialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PolioPertussisHibVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:InfluenzaVaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:AllergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:PainCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:DigestiveWellnessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesInSegmentResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:NKCellAndProXTenTechnologyPlatformsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">sny:SAR444245Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:PrincipalAlliancesAxis">sny:ImmunoOncologyCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">sny:RegeneronPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:PharmaceuticalsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:VaccinesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">sny:ConsumerHealthcareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-2550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-2556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-2559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:ReportableGeographicalZonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-2562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AuditorsNameAxis">sny:ErnstAndYoungMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AuditorsNameAxis">sny:ErnstAndYoungMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AuditorsNameAxis">sny:PricewaterhousecoopersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sny:AuditorsNameAxis">sny:PricewaterhousecoopersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:HoechstGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisDeutschlandGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:A.NattermannCie.GmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiBelgiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AblynxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeFlandersBVBAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareSpainSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiWinthropIndustriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisRechercheEtDeveloppementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisGroupeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiChimieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisParticipationsSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurFranceSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisPharmaSAFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiBiotechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiMatureIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurNVLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SECIPESASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurMerieuxSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareInternationalSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareFranceSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareGroupSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymePolyclonalsSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiaventisAEBEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisPrivateCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ChinoinPrivateCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareHungaryCommercialKFTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareHungaryKFTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:CarraigInsuranceDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeIrelandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisHoldingsIrelandLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiSRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareItalySRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeGlobalSarlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeLuxembourgSarlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisNorgeASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiForeignParticipationsB.V.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiaventisSpZooMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcarePolandSpZOOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurSpZooMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiProdutosFarmaceuticosLdaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisSROMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareCzechSroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisRomaniaSRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareRomaniaSRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisUkHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisPharmaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiSynthelaboUKLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisPharmaHoldingsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AOSanofiRussiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisSuisseSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeGlobalSarlBaarIntellectualPropertyBranchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiIlacSanayiVeTicaretASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurAsiTicaretASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareTuketiciSalAnonimSirketiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiSaglikUrunleriLimitedSirketiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeTherapeuticProductsLimitedPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiUSServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisUSLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ChattemIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:GenzymeCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:VaxServeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:BioverativIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:BioverativUSLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:BioverativTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:PrincipiaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiResearchInvestLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiBioverativHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:RPRUSLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:KadmonCorporationLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AmunixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SynthorxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ProventionBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:QRIBIntermediateHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:QRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:TargeGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ChattemGBHoldingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:TranslateBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisSouthAfricaPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisAlgerieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiArabiaTradingCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisArgentinaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisHealthcarePtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisAustraliaPtyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiMedleyFarmaceuticaLtdaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareBrazilLtdaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisCanadaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:MerieuxCanadaHoldingsULCCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiHangzhouPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiChinaInvestmentCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiBeijingPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurBiologiesCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ShenzhenSanofiPasteurBiologicalProductsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:ShanghaiRonghengPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisDeColombiaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisKoreaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcareKoreaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisGulfFZEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiEgyptSAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiIndiaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiHealthcareIndiaPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisIsraelLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SspCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisMalaysiaSDNBHDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisMarocMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisDeMexicoSADeCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurS.A.deC.V.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AztecaVacunasSADeCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisDePanamaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcarePanamaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisPuertoRicoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisPhilippinesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:OpellaHealthcarePhilippinesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisSingaporePteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:AventisPharmaManufacturingPTELTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiManufacturingPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiTaiwanCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisThailandLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiPasteurThailandLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisDeVenezuelaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiAventisVietnamCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">sny:OtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:SanofiVietnamShareholdingCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:HaleonUSLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:InfraservGmbhAndCoHochstKGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:MapharMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:MCMVaccineBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:MSPVaccineCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointOperationsAxis">sny:EuroapiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-23</instant>
        </period>
    </context>
    <context id="c-2713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-23</instant>
        </period>
    </context>
    <context id="c-2714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sny:NonINBRX101BusinessSpinCo.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-23</instant>
        </period>
    </context>
    <context id="c-2715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:INBRX101BusinessRemainCo.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-23</instant>
        </period>
    </context>
    <context id="c-2716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">sny:INBRX101BusinessRemainCo.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-23</startDate>
            <endDate>2024-01-23</endDate>
        </period>
    </context>
    <context id="c-2717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121404</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sny:NonINBRX101BusinessSpinCo.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">sny:InhibrxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-23</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="emission">
        <measure>sny:emission</measure>
    </unit>
    <unit id="scenario">
        <measure>sny:scenario</measure>
    </unit>
    <unit id="vaccine_dose">
        <measure>sny:vaccine_dose</measure>
    </unit>
    <unit id="segment">
        <measure>sny:segment</measure>
    </unit>
    <unit id="agreement">
        <measure>sny:agreement</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="bond">
        <measure>sny:bond</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="lease">
        <measure>sny:lease</measure>
    </unit>
    <unit id="extension">
        <measure>sny:extension</measure>
    </unit>
    <unit id="credit_facility">
        <measure>sny:credit_facility</measure>
    </unit>
    <unit id="performance_indicator">
        <measure>sny:performance_indicator</measure>
    </unit>
    <unit id="program">
        <measure>sny:program</measure>
    </unit>
    <unit id="currency">
        <measure>sny:currency</measure>
    </unit>
    <unit id="country">
        <measure>sny:Country</measure>
    </unit>
    <unit id="plan">
        <measure>sny:plan</measure>
    </unit>
    <unit id="age">
        <measure>sny:age</measure>
    </unit>
    <unit id="molecule">
        <measure>sny:molecule</measure>
    </unit>
    <unit id="target">
        <measure>sny:target</measure>
    </unit>
    <unit id="lawsuit">
        <measure>sny:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>sny:plaintiff</measure>
    </unit>
    <unit id="trial">
        <measure>sny:trial</measure>
    </unit>
    <unit id="case">
        <measure>sny:case</measure>
    </unit>
    <unit id="cancer">
        <measure>sny:cancer</measure>
    </unit>
    <unit id="complaint">
        <measure>sny:complaint</measure>
    </unit>
    <unit id="action">
        <measure>sny:action</measure>
    </unit>
    <unit id="claim">
        <measure>sny:claim</measure>
    </unit>
    <unit id="person">
        <measure>sny:person</measure>
    </unit>
    <unit id="ruling">
        <measure>sny:ruling</measure>
    </unit>
    <unit id="family">
        <measure>sny:family</measure>
    </unit>
    <unit id="claimant">
        <measure>sny:claimant</measure>
    </unit>
    <unit id="expert">
        <measure>sny:expert</measure>
    </unit>
    <unit id="proceeding">
        <measure>sny:proceeding</measure>
    </unit>
    <unit id="children">
        <measure>sny:children</measure>
    </unit>
    <unit id="patient">
        <measure>sny:patient</measure>
    </unit>
    <unit id="manufacturer">
        <measure>sny:manufacturer</measure>
    </unit>
    <unit id="patent">
        <measure>sny:patent</measure>
    </unit>
    <unit id="aud">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="employee">
        <measure>sny:employee</measure>
    </unit>
    <unit id="executives">
        <measure>sny:executives</measure>
    </unit>
    <unit id="rightpershare">
        <measure>sny:rightPerShare</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-38">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-39">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-40">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-41">0001121404</dei:EntityCentralIndexKey>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-81" id="f-646">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <sny:PossibleIncreaseInMortalityTableInYears contextRef="c-1467" id="f-4225">P1Y</sny:PossibleIncreaseInMortalityTableInYears>
    <sny:CapitalLossesUsedAgainstCapitalGainsPercentage
      contextRef="c-1463"
      decimals="4"
      id="f-4226"
      unitRef="number">0.3333</sny:CapitalLossesUsedAgainstCapitalGainsPercentage>
    <dei:DocumentType contextRef="c-1" id="f-1">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c-1" id="f-2">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-5">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-6">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c-1" id="f-7">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-8">001-31368</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-9">Sanofi</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-10">I0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-11">46,&#160;avenue de la Grande Arm&#xe9;e</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">75017</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-13">Paris</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-14">FR</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c-2" id="f-15">Roy Papatheodorou</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c-2" id="f-16">46,&#160;avenue de la Grande Arm&#xe9;e</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-2" id="f-17">75017</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-2" id="f-18">Paris</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-2" id="f-19">FR</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c-2" id="f-20">33</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-2" id="f-21">1 53 77 40 00</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-3" id="f-22">American&#160;Depositary&#160;Shares,&#160;each&#160;representing one half of one ordinary share, par value &#x20ac;2&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-23">SNY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-24">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-25">Ordinary shares, par value &#x20ac;2&#160;per share</dei:Security12bTitle>
    <dei:SecurityExchangeName contextRef="c-4" id="f-26">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-27" unitRef="shares">1264799969</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-28">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-29">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-32">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-33">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-34">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-35">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c-1" id="f-36">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c-1" id="f-37">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c-1" id="f-42">1347</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="c-6" id="f-43">1704</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-44">PricewaterhouseCoopers Audit</dei:AuditorName>
    <dei:AuditorName contextRef="c-6" id="f-45">Ernst &amp; Young et Autres</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-46">Neuilly-sur-Seine</dei:AuditorLocation>
    <dei:AuditorLocation contextRef="c-6" id="f-47">Paris-La D&#xe9;fense</dei:AuditorLocation>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-5" decimals="-6" id="f-48" unitRef="eur">10160000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-7" decimals="-6" id="f-49" unitRef="eur">9869000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-8" decimals="-6" id="f-50" unitRef="eur">10028000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-5" decimals="-6" id="f-51" unitRef="eur">1654000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-7" decimals="-6" id="f-52" unitRef="eur">1815000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-8" decimals="-6" id="f-53" unitRef="eur">1948000000</ifrs-full:RightofuseAssets>
    <ifrs-full:Goodwill contextRef="c-5" decimals="-6" id="f-54" unitRef="eur">49404000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-7" decimals="-6" id="f-55" unitRef="eur">49892000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-8" decimals="-6" id="f-56" unitRef="eur">48056000000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-5" decimals="-6" id="f-57" unitRef="eur">24319000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-7" decimals="-6" id="f-58" unitRef="eur">21640000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-8" decimals="-6" id="f-59" unitRef="eur">21407000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-5" decimals="-6" id="f-60" unitRef="eur">424000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-7" decimals="-6" id="f-61" unitRef="eur">677000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-8" decimals="-6" id="f-62" unitRef="eur">250000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-5" decimals="-6" id="f-63" unitRef="eur">3218000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-7" decimals="-6" id="f-64" unitRef="eur">3095000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-8" decimals="-6" id="f-65" unitRef="eur">3127000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:CurrentTaxAssetsNoncurrent contextRef="c-5" decimals="-6" id="f-66" unitRef="eur">188000000</ifrs-full:CurrentTaxAssetsNoncurrent>
    <ifrs-full:CurrentTaxAssetsNoncurrent contextRef="c-7" decimals="-6" id="f-67" unitRef="eur">242000000</ifrs-full:CurrentTaxAssetsNoncurrent>
    <ifrs-full:CurrentTaxAssetsNoncurrent contextRef="c-8" decimals="-6" id="f-68" unitRef="eur">175000000</ifrs-full:CurrentTaxAssetsNoncurrent>
    <ifrs-full:DeferredTaxAssets contextRef="c-5" decimals="-6" id="f-69" unitRef="eur">6427000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-7" decimals="-6" id="f-70" unitRef="eur">5381000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-8" decimals="-6" id="f-71" unitRef="eur">4598000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-5" decimals="-6" id="f-72" unitRef="eur">95794000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-7" decimals="-6" id="f-73" unitRef="eur">92611000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-8" decimals="-6" id="f-74" unitRef="eur">89589000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories contextRef="c-5" decimals="-6" id="f-75" unitRef="eur">9666000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-7" decimals="-6" id="f-76" unitRef="eur">8960000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-8" decimals="-6" id="f-77" unitRef="eur">8715000000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables contextRef="c-5" decimals="-6" id="f-78" unitRef="eur">8433000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-7" decimals="-6" id="f-79" unitRef="eur">8424000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-8" decimals="-6" id="f-80" unitRef="eur">7568000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentAssets contextRef="c-5" decimals="-6" id="f-81" unitRef="eur">3455000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-7" decimals="-6" id="f-82" unitRef="eur">3532000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-8" decimals="-6" id="f-83" unitRef="eur">3571000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c-5" decimals="-6" id="f-84" unitRef="eur">391000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c-7" decimals="-6" id="f-85" unitRef="eur">374000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c-8" decimals="-6" id="f-86" unitRef="eur">612000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-6" id="f-87" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-7" decimals="-6" id="f-88" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-8" decimals="-6" id="f-89" unitRef="eur">10098000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners contextRef="c-5" decimals="-6" id="f-90" unitRef="eur">30655000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners contextRef="c-7" decimals="-6" id="f-91" unitRef="eur">34026000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners contextRef="c-8" decimals="-6" id="f-92" unitRef="eur">30564000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-5" decimals="-6" id="f-93" unitRef="eur">15000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-7" decimals="-6" id="f-94" unitRef="eur">85000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-8" decimals="-6" id="f-95" unitRef="eur">89000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:Assets contextRef="c-5" decimals="-6" id="f-96" unitRef="eur">126464000000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-7" decimals="-6" id="f-97" unitRef="eur">126722000000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-8" decimals="-6" id="f-98" unitRef="eur">120242000000</ifrs-full:Assets>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-5" decimals="-6" id="f-99" unitRef="eur">74040000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-7" decimals="-6" id="f-100" unitRef="eur">74784000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-8" decimals="-6" id="f-101" unitRef="eur">68681000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c-5" decimals="-6" id="f-102" unitRef="eur">313000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c-7" decimals="-6" id="f-103" unitRef="eur">368000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c-8" decimals="-6" id="f-104" unitRef="eur">350000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c-5" decimals="-6" id="f-105" unitRef="eur">74353000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-6" id="f-106" unitRef="eur">75152000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-6" id="f-107" unitRef="eur">69031000000</ifrs-full:Equity>
    <ifrs-full:LongtermBorrowings contextRef="c-5" decimals="-6" id="f-108" unitRef="eur">14347000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-7" decimals="-6" id="f-109" unitRef="eur">14857000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-8" decimals="-6" id="f-110" unitRef="eur">17123000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-5" decimals="-6" id="f-111" unitRef="eur">1755000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-7" decimals="-6" id="f-112" unitRef="eur">1904000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-8" decimals="-6" id="f-113" unitRef="eur">1839000000</ifrs-full:NoncurrentLeaseLiabilities>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-5" decimals="-6" id="f-114" unitRef="eur">501000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-7" decimals="-6" id="f-115" unitRef="eur">674000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-8" decimals="-6" id="f-116" unitRef="eur">577000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-5" decimals="-6" id="f-117" unitRef="eur">7602000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-7" decimals="-6" id="f-118" unitRef="eur">6341000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-8" decimals="-6" id="f-119" unitRef="eur">6721000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-5" decimals="-6" id="f-120" unitRef="eur">1842000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-7" decimals="-6" id="f-121" unitRef="eur">1979000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-8" decimals="-6" id="f-122" unitRef="eur">2039000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-5" decimals="-6" id="f-123" unitRef="eur">1857000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-7" decimals="-6" id="f-124" unitRef="eur">1841000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-8" decimals="-6" id="f-125" unitRef="eur">1617000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-5" decimals="-6" id="f-126" unitRef="eur">27904000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-7" decimals="-6" id="f-127" unitRef="eur">27596000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-8" decimals="-6" id="f-128" unitRef="eur">29916000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-5" decimals="-6" id="f-129" unitRef="eur">7328000000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-7" decimals="-6" id="f-130" unitRef="eur">6813000000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-8" decimals="-6" id="f-131" unitRef="eur">6180000000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-5" decimals="-6" id="f-132" unitRef="eur">208000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-7" decimals="-6" id="f-133" unitRef="eur">105000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-8" decimals="-6" id="f-134" unitRef="eur">137000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-5" decimals="-6" id="f-135" unitRef="eur">13741000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-7" decimals="-6" id="f-136" unitRef="eur">12021000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-8" decimals="-6" id="f-137" unitRef="eur">11217000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-138" unitRef="eur">597000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-7" decimals="-6" id="f-139" unitRef="eur">574000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-8" decimals="-6" id="f-140" unitRef="eur">309000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-5" decimals="-6" id="f-141" unitRef="eur">275000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-7" decimals="-6" id="f-142" unitRef="eur">277000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-8" decimals="-6" id="f-143" unitRef="eur">269000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-5" decimals="-6" id="f-144" unitRef="eur">2045000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-7" decimals="-6" id="f-145" unitRef="eur">4174000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-8" decimals="-6" id="f-146" unitRef="eur">3183000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-5" decimals="-6" id="f-147" unitRef="eur">24194000000</ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-7" decimals="-6" id="f-148" unitRef="eur">23964000000</ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-8" decimals="-6" id="f-149" unitRef="eur">21295000000</ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-5" decimals="-6" id="f-150" unitRef="eur">13000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-7" decimals="-6" id="f-151" unitRef="eur">10000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-8" decimals="-6" id="f-152" unitRef="eur">0</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:EquityAndLiabilities contextRef="c-5" decimals="-6" id="f-153" unitRef="eur">126464000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-7" decimals="-6" id="f-154" unitRef="eur">126722000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-8" decimals="-6" id="f-155" unitRef="eur">120242000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1" decimals="-6" id="f-156" unitRef="eur">43070000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-9" decimals="-6" id="f-157" unitRef="eur">42997000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-10" decimals="-6" id="f-158" unitRef="eur">37761000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-1" decimals="-6" id="f-159" unitRef="eur">3374000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-9" decimals="-6" id="f-160" unitRef="eur">2392000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-10" decimals="-6" id="f-161" unitRef="eur">1414000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-1" decimals="-6" id="f-162" unitRef="eur">14236000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-9" decimals="-6" id="f-163" unitRef="eur">13695000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-10" decimals="-6" id="f-164" unitRef="eur">12255000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c-1" decimals="-6" id="f-165" unitRef="eur">32208000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c-9" decimals="-6" id="f-166" unitRef="eur">31694000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="c-10" decimals="-6" id="f-167" unitRef="eur">26920000000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-6" id="f-168" unitRef="eur">6728000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-9" decimals="-6" id="f-169" unitRef="eur">6706000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-10" decimals="-6" id="f-170" unitRef="eur">5692000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-171" unitRef="eur">10692000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-9" decimals="-6" id="f-172" unitRef="eur">10492000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-10" decimals="-6" id="f-173" unitRef="eur">9555000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-6" id="f-174" unitRef="eur">1292000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-9" decimals="-6" id="f-175" unitRef="eur">1969000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-10" decimals="-6" id="f-176" unitRef="eur">859000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-1" decimals="-6" id="f-177" unitRef="eur">3516000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-9" decimals="-6" id="f-178" unitRef="eur">2531000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-10" decimals="-6" id="f-179" unitRef="eur">1805000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-6" id="f-180" unitRef="eur">2172000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-9" decimals="-6" id="f-181" unitRef="eur">2053000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-10" decimals="-6" id="f-182" unitRef="eur">1580000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-6" id="f-183" unitRef="eur">896000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-9" decimals="-6" id="f-184" unitRef="eur">-454000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-10" decimals="-6" id="f-185" unitRef="eur">192000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-1" decimals="-6" id="f-186" unitRef="eur">93000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-9" decimals="-6" id="f-187" unitRef="eur">-27000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-10" decimals="-6" id="f-188" unitRef="eur">4000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-1" decimals="-6" id="f-189" unitRef="eur">1490000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-9" decimals="-6" id="f-190" unitRef="eur">1336000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-10" decimals="-6" id="f-191" unitRef="eur">820000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:OtherGainsLossesAndLitigation contextRef="c-1" decimals="-6" id="f-192" unitRef="eur">-38000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-9" decimals="-6" id="f-193" unitRef="eur">-370000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-10" decimals="-6" id="f-194" unitRef="eur">-5000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-6" id="f-195" unitRef="eur">7875000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-9" decimals="-6" id="f-196" unitRef="eur">10656000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-10" decimals="-6" id="f-197" unitRef="eur">8126000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-198" unitRef="eur">1313000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-9" decimals="-6" id="f-199" unitRef="eur">440000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-10" decimals="-6" id="f-200" unitRef="eur">368000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-201" unitRef="eur">591000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-9" decimals="-6" id="f-202" unitRef="eur">206000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-10" decimals="-6" id="f-203" unitRef="eur">40000000</ifrs-full:FinanceIncome>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-204" unitRef="eur">7153000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-9" decimals="-6" id="f-205" unitRef="eur">10422000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-10" decimals="-6" id="f-206" unitRef="eur">7798000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-6" id="f-207" unitRef="eur">1602000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-9" decimals="-6" id="f-208" unitRef="eur">2006000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-10" decimals="-6" id="f-209" unitRef="eur">1558000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-1" decimals="-6" id="f-210" unitRef="eur">-115000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-9" decimals="-6" id="f-211" unitRef="eur">68000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod contextRef="c-10" decimals="-6" id="f-212" unitRef="eur">39000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-213" unitRef="eur">5436000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-9" decimals="-6" id="f-214" unitRef="eur">8484000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-10" decimals="-6" id="f-215" unitRef="eur">6279000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-216" unitRef="eur">36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-9" decimals="-6" id="f-217" unitRef="eur">113000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-10" decimals="-6" id="f-218" unitRef="eur">56000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-219" unitRef="eur">5400000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-9" decimals="-6" id="f-220" unitRef="eur">8371000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-10" decimals="-6" id="f-221" unitRef="eur">6223000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="-5" id="f-222" unitRef="shares">1251700000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-9" decimals="-5" id="f-223" unitRef="shares">1251900000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-10" decimals="-5" id="f-224" unitRef="shares">1252500000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="-5" id="f-225" unitRef="shares">1256400000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-9" decimals="-5" id="f-226" unitRef="shares">1256900000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-10" decimals="-5" id="f-227" unitRef="shares">1257900000</ifrs-full:AdjustedWeightedAverageShares>
    <sny:BasicEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-1"
      decimals="2"
      id="f-228"
      unitRef="eurPerShare">4.31</sny:BasicEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:BasicEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-9"
      decimals="2"
      id="f-229"
      unitRef="eurPerShare">6.69</sny:BasicEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:BasicEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-10"
      decimals="2"
      id="f-230"
      unitRef="eurPerShare">4.97</sny:BasicEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-1"
      decimals="2"
      id="f-231"
      unitRef="eurPerShare">4.30</sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-9"
      decimals="2"
      id="f-232"
      unitRef="eurPerShare">6.66</sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent>
    <sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent
      contextRef="c-10"
      decimals="2"
      id="f-233"
      unitRef="eurPerShare">4.95</sny:DilutedEarningsLossPerShareAttributableToOwnersOfParent>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-234" unitRef="eur">5436000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-9" decimals="-6" id="f-235" unitRef="eur">8484000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-10" decimals="-6" id="f-236" unitRef="eur">6279000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-237" unitRef="eur">5400000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-9" decimals="-6" id="f-238" unitRef="eur">8371000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-10" decimals="-6" id="f-239" unitRef="eur">6223000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-240" unitRef="eur">36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-9" decimals="-6" id="f-241" unitRef="eur">113000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-10" decimals="-6" id="f-242" unitRef="eur">56000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1" decimals="-6" id="f-243" unitRef="eur">171000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-9" decimals="-6" id="f-244" unitRef="eur">-654000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-10" decimals="-6" id="f-245" unitRef="eur">-686000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments contextRef="c-1" decimals="-6" id="f-246" unitRef="eur">97000000</ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments contextRef="c-9" decimals="-6" id="f-247" unitRef="eur">13000000</ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments contextRef="c-10" decimals="-6" id="f-248" unitRef="eur">165000000</ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss contextRef="c-1" decimals="-6" id="f-249" unitRef="eur">3000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss contextRef="c-9" decimals="-6" id="f-250" unitRef="eur">216000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss contextRef="c-10" decimals="-6" id="f-251" unitRef="eur">54000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-6" id="f-252" unitRef="eur">-77000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-9" decimals="-6" id="f-253" unitRef="eur">451000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-10" decimals="-6" id="f-254" unitRef="eur">797000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax contextRef="c-1" decimals="-6" id="f-255" unitRef="eur">21000000</sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax>
    <sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax contextRef="c-9" decimals="-6" id="f-256" unitRef="eur">-77000000</sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax>
    <sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax contextRef="c-10" decimals="-6" id="f-257" unitRef="eur">-21000000</sny:GainsLossesOnRemeasuringDebtInstrumentsBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-1" decimals="-6" id="f-258" unitRef="eur">-1000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-9" decimals="-6" id="f-259" unitRef="eur">7000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-10" decimals="-6" id="f-260" unitRef="eur">-6000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-1" decimals="-6" id="f-261" unitRef="eur">-1540000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-9" decimals="-6" id="f-262" unitRef="eur">2278000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-10" decimals="-6" id="f-263" unitRef="eur">2459000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss contextRef="c-1" decimals="-6" id="f-264" unitRef="eur">6000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss contextRef="c-9" decimals="-6" id="f-265" unitRef="eur">-105000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss contextRef="c-10" decimals="-6" id="f-266" unitRef="eur">-78000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-6" id="f-267" unitRef="eur">-1526000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-9" decimals="-6" id="f-268" unitRef="eur">2313000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-10" decimals="-6" id="f-269" unitRef="eur">2510000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-6" id="f-270" unitRef="eur">-1603000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-9" decimals="-6" id="f-271" unitRef="eur">2764000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-10" decimals="-6" id="f-272" unitRef="eur">3307000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-6" id="f-273" unitRef="eur">3833000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-9" decimals="-6" id="f-274" unitRef="eur">11248000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-10" decimals="-6" id="f-275" unitRef="eur">9586000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-1" decimals="-6" id="f-276" unitRef="eur">3810000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-9" decimals="-6" id="f-277" unitRef="eur">11130000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-10" decimals="-6" id="f-278" unitRef="eur">9519000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-279" unitRef="eur">23000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c-9" decimals="-6" id="f-280" unitRef="eur">118000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="c-10" decimals="-6" id="f-281" unitRef="eur">67000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:Equity contextRef="c-11" decimals="-6" id="f-282" unitRef="eur">2518000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-12" decimals="-6" id="f-283" unitRef="eur">362000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-13" decimals="-6" id="f-284" unitRef="eur">-705000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-14" decimals="-6" id="f-285" unitRef="eur">60149000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-15" decimals="-6" id="f-286" unitRef="eur">4138000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-16" decimals="-6" id="f-287" unitRef="eur">-3356000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-17" decimals="-6" id="f-288" unitRef="eur">63106000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-18" decimals="-6" id="f-289" unitRef="eur">146000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-19" decimals="-6" id="f-290" unitRef="eur">63252000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-20" decimals="-6" id="f-291" unitRef="eur">797000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-21" decimals="-6" id="f-292" unitRef="eur">2499000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-22" decimals="-6" id="f-293" unitRef="eur">3296000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-23" decimals="-6" id="f-294" unitRef="eur">11000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-10" decimals="-6" id="f-295" unitRef="eur">3307000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-20" decimals="-6" id="f-296" unitRef="eur">6223000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-22" decimals="-6" id="f-297" unitRef="eur">6223000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-23" decimals="-6" id="f-298" unitRef="eur">56000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-10" decimals="-6" id="f-299" unitRef="eur">6279000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-20" decimals="-6" id="f-300" unitRef="eur">7020000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-21" decimals="-6" id="f-301" unitRef="eur">2499000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-22" decimals="-6" id="f-302" unitRef="eur">9519000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-23" decimals="-6" id="f-303" unitRef="eur">67000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-10" decimals="-6" id="f-304" unitRef="eur">9586000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="c-10"
      decimals="INF"
      id="f-305"
      unitRef="eurPerShare">3.20</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-20" decimals="-6" id="f-306" unitRef="eur">4008000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-22" decimals="-6" id="f-307" unitRef="eur">4008000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-10" decimals="-6" id="f-308" unitRef="eur">4008000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-22" decimals="-6" id="f-309" unitRef="eur">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-23" decimals="-6" id="f-310" unitRef="eur">49000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-10" decimals="-6" id="f-311" unitRef="eur">49000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-24" decimals="-6" id="f-312" unitRef="eur">382000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-22" decimals="-6" id="f-313" unitRef="eur">382000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-10" decimals="-6" id="f-314" unitRef="eur">382000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-25" decimals="-6" id="f-315" unitRef="eur">11000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-22" decimals="-6" id="f-316" unitRef="eur">11000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-10" decimals="-6" id="f-317" unitRef="eur">11000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-26" decimals="-6" id="f-318" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-25" decimals="-6" id="f-319" unitRef="eur">-4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-24" decimals="-6" id="f-320" unitRef="eur">148000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-20" decimals="-6" id="f-321" unitRef="eur">-148000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-22" decimals="-6" id="f-322" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-10" decimals="-6" id="f-323" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-26" decimals="-6" id="f-324" unitRef="eur">5000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-25" decimals="-6" id="f-325" unitRef="eur">163000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-22" decimals="-6" id="f-326" unitRef="eur">168000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-10" decimals="-6" id="f-327" unitRef="eur">168000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-27" decimals="-6" id="f-328" unitRef="eur">244000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-22" decimals="-6" id="f-329" unitRef="eur">244000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-10" decimals="-6" id="f-330" unitRef="eur">244000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-27" decimals="-6" id="f-331" unitRef="eur">23000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-22" decimals="-6" id="f-332" unitRef="eur">23000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-10" decimals="-6" id="f-333" unitRef="eur">23000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment contextRef="c-22" decimals="-6" id="f-334" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment>
    <sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment contextRef="c-23" decimals="-6" id="f-335" unitRef="eur">186000000</sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment>
    <sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment contextRef="c-10" decimals="-6" id="f-336" unitRef="eur">186000000</sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment>
    <ifrs-full:Equity contextRef="c-28" decimals="-6" id="f-337" unitRef="eur">2527000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-29" decimals="-6" id="f-338" unitRef="eur">532000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-30" decimals="-6" id="f-339" unitRef="eur">-939000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-31" decimals="-6" id="f-340" unitRef="eur">63013000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-32" decimals="-6" id="f-341" unitRef="eur">4405000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-33" decimals="-6" id="f-342" unitRef="eur">-857000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-34" decimals="-6" id="f-343" unitRef="eur">68681000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-35" decimals="-6" id="f-344" unitRef="eur">350000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-6" id="f-345" unitRef="eur">69031000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-28" decimals="-6" id="f-346" unitRef="eur">2527000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-29" decimals="-6" id="f-347" unitRef="eur">532000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-30" decimals="-6" id="f-348" unitRef="eur">-939000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-31" decimals="-6" id="f-349" unitRef="eur">63013000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-32" decimals="-6" id="f-350" unitRef="eur">4405000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-33" decimals="-6" id="f-351" unitRef="eur">-857000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-34" decimals="-6" id="f-352" unitRef="eur">68681000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-35" decimals="-6" id="f-353" unitRef="eur">350000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-6" id="f-354" unitRef="eur">69031000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-36" decimals="-6" id="f-355" unitRef="eur">451000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-37" decimals="-6" id="f-356" unitRef="eur">2308000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-38" decimals="-6" id="f-357" unitRef="eur">2759000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-39" decimals="-6" id="f-358" unitRef="eur">5000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-9" decimals="-6" id="f-359" unitRef="eur">2764000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-36" decimals="-6" id="f-360" unitRef="eur">8371000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-38" decimals="-6" id="f-361" unitRef="eur">8371000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-39" decimals="-6" id="f-362" unitRef="eur">113000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-9" decimals="-6" id="f-363" unitRef="eur">8484000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-36" decimals="-6" id="f-364" unitRef="eur">8822000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-37" decimals="-6" id="f-365" unitRef="eur">2308000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-38" decimals="-6" id="f-366" unitRef="eur">11130000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-39" decimals="-6" id="f-367" unitRef="eur">118000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-9" decimals="-6" id="f-368" unitRef="eur">11248000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="c-9"
      decimals="INF"
      id="f-369"
      unitRef="eurPerShare">3.33</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-36" decimals="-6" id="f-370" unitRef="eur">4168000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-38" decimals="-6" id="f-371" unitRef="eur">4168000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-9" decimals="-6" id="f-372" unitRef="eur">4168000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <sny:ExceptionalSupplementaryDividendPercentageOfShareCapital contextRef="c-40" decimals="2" id="f-373" unitRef="number">0.58</sny:ExceptionalSupplementaryDividendPercentageOfShareCapital>
    <sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-36" decimals="-6" id="f-374" unitRef="eur">793000000</sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent>
    <sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-38" decimals="-6" id="f-375" unitRef="eur">793000000</sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent>
    <sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-9" decimals="-6" id="f-376" unitRef="eur">793000000</sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-38" decimals="-6" id="f-377" unitRef="eur">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-39" decimals="-6" id="f-378" unitRef="eur">100000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-9" decimals="-6" id="f-379" unitRef="eur">100000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-41" decimals="-6" id="f-380" unitRef="eur">497000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-38" decimals="-6" id="f-381" unitRef="eur">497000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-9" decimals="-6" id="f-382" unitRef="eur">497000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-42" decimals="-6" id="f-383" unitRef="eur">13000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-43" decimals="-6" id="f-384" unitRef="eur">587000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-41" decimals="-6" id="f-385" unitRef="eur">-600000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-38" decimals="-6" id="f-386" unitRef="eur">0</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital contextRef="c-9" decimals="-6" id="f-387" unitRef="eur">0</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-42" decimals="-6" id="f-388" unitRef="eur">1000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-43" decimals="-6" id="f-389" unitRef="eur">34000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-38" decimals="-6" id="f-390" unitRef="eur">35000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-9" decimals="-6" id="f-391" unitRef="eur">35000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-42" decimals="-6" id="f-392" unitRef="eur">3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-43" decimals="-6" id="f-393" unitRef="eur">-3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-41" decimals="-6" id="f-394" unitRef="eur">130000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-36" decimals="-6" id="f-395" unitRef="eur">-130000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-38" decimals="-6" id="f-396" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-9" decimals="-6" id="f-397" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-42" decimals="-6" id="f-398" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-43" decimals="-6" id="f-399" unitRef="eur">149000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-38" decimals="-6" id="f-400" unitRef="eur">153000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-9" decimals="-6" id="f-401" unitRef="eur">153000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-44" decimals="-6" id="f-402" unitRef="eur">245000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-38" decimals="-6" id="f-403" unitRef="eur">245000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-9" decimals="-6" id="f-404" unitRef="eur">245000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-44" decimals="-6" id="f-405" unitRef="eur">8000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-38" decimals="-6" id="f-406" unitRef="eur">8000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-9" decimals="-6" id="f-407" unitRef="eur">8000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="c-36" decimals="-6" id="f-408" unitRef="eur">-10000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="c-38" decimals="-6" id="f-409" unitRef="eur">-10000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="c-9" decimals="-6" id="f-410" unitRef="eur">-10000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:Equity contextRef="c-45" decimals="-6" id="f-411" unitRef="eur">2522000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-46" decimals="-6" id="f-412" unitRef="eur">125000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-47" decimals="-6" id="f-413" unitRef="eur">-706000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-48" decimals="-6" id="f-414" unitRef="eur">66734000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-49" decimals="-6" id="f-415" unitRef="eur">4658000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-50" decimals="-6" id="f-416" unitRef="eur">1451000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-51" decimals="-6" id="f-417" unitRef="eur">74784000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-52" decimals="-6" id="f-418" unitRef="eur">368000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-6" id="f-419" unitRef="eur">75152000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-45" decimals="-6" id="f-420" unitRef="eur">2522000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-46" decimals="-6" id="f-421" unitRef="eur">125000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-47" decimals="-6" id="f-422" unitRef="eur">-706000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-48" decimals="-6" id="f-423" unitRef="eur">66734000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-49" decimals="-6" id="f-424" unitRef="eur">4658000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-50" decimals="-6" id="f-425" unitRef="eur">1451000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-51" decimals="-6" id="f-426" unitRef="eur">74784000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-52" decimals="-6" id="f-427" unitRef="eur">368000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-6" id="f-428" unitRef="eur">75152000000</ifrs-full:Equity>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-53" decimals="-6" id="f-429" unitRef="eur">-77000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-54" decimals="-6" id="f-430" unitRef="eur">-1513000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-55" decimals="-6" id="f-431" unitRef="eur">-1590000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-56" decimals="-6" id="f-432" unitRef="eur">-13000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-6" id="f-433" unitRef="eur">-1603000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-53" decimals="-6" id="f-434" unitRef="eur">5400000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-55" decimals="-6" id="f-435" unitRef="eur">5400000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-56" decimals="-6" id="f-436" unitRef="eur">36000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-6" id="f-437" unitRef="eur">5436000000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome contextRef="c-53" decimals="-6" id="f-438" unitRef="eur">5323000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-54" decimals="-6" id="f-439" unitRef="eur">-1513000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-55" decimals="-6" id="f-440" unitRef="eur">3810000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-56" decimals="-6" id="f-441" unitRef="eur">23000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-6" id="f-442" unitRef="eur">3833000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="c-1"
      decimals="INF"
      id="f-443"
      unitRef="eurPerShare">3.56</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-53" decimals="-6" id="f-444" unitRef="eur">4454000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-55" decimals="-6" id="f-445" unitRef="eur">4454000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-1" decimals="-6" id="f-446" unitRef="eur">4454000000</ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-55" decimals="-6" id="f-447" unitRef="eur">0</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-56" decimals="-6" id="f-448" unitRef="eur">59000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-449" unitRef="eur">59000000</ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-57" decimals="-6" id="f-450" unitRef="eur">593000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-55" decimals="-6" id="f-451" unitRef="eur">593000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="c-1" decimals="-6" id="f-452" unitRef="eur">593000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-58" decimals="-6" id="f-453" unitRef="eur">1000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-59" decimals="-6" id="f-454" unitRef="eur">36000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-55" decimals="-6" id="f-455" unitRef="eur">37000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-1" decimals="-6" id="f-456" unitRef="eur">37000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-58" decimals="-6" id="f-457" unitRef="eur">3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-59" decimals="-6" id="f-458" unitRef="eur">-3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-57" decimals="-6" id="f-459" unitRef="eur">115000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-53" decimals="-6" id="f-460" unitRef="eur">-115000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-55" decimals="-6" id="f-461" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares contextRef="c-1" decimals="-6" id="f-462" unitRef="eur">0</sny:IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-58" decimals="-6" id="f-463" unitRef="eur">4000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-59" decimals="-6" id="f-464" unitRef="eur">155000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-55" decimals="-6" id="f-465" unitRef="eur">159000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans contextRef="c-1" decimals="-6" id="f-466" unitRef="eur">159000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-60" decimals="-6" id="f-467" unitRef="eur">283000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-55" decimals="-6" id="f-468" unitRef="eur">283000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees contextRef="c-1" decimals="-6" id="f-469" unitRef="eur">283000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-60" decimals="-6" id="f-470" unitRef="eur">3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-55" decimals="-6" id="f-471" unitRef="eur">3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions contextRef="c-1" decimals="-6" id="f-472" unitRef="eur">3000000</sny:IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-53" decimals="-6" id="f-473" unitRef="eur">2000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-55" decimals="-6" id="f-474" unitRef="eur">2000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity contextRef="c-1" decimals="-6" id="f-475" unitRef="eur">2000000</sny:IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity>
    <sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment contextRef="c-53" decimals="-6" id="f-476" unitRef="eur">9000000</sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment>
    <sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment contextRef="c-55" decimals="-6" id="f-477" unitRef="eur">9000000</sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment>
    <sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment contextRef="c-56" decimals="-6" id="f-478" unitRef="eur">-19000000</sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment>
    <sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment contextRef="c-1" decimals="-6" id="f-479" unitRef="eur">-10000000</sny:IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment>
    <ifrs-full:Equity contextRef="c-61" decimals="-6" id="f-480" unitRef="eur">2530000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-62" decimals="-6" id="f-481" unitRef="eur">313000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-63" decimals="-6" id="f-482" unitRef="eur">-1184000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-64" decimals="-6" id="f-483" unitRef="eur">67499000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-65" decimals="-6" id="f-484" unitRef="eur">4944000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-66" decimals="-6" id="f-485" unitRef="eur">-62000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-67" decimals="-6" id="f-486" unitRef="eur">74040000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-68" decimals="-6" id="f-487" unitRef="eur">313000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-5" decimals="-6" id="f-488" unitRef="eur">74353000000</ifrs-full:Equity>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c-40"
      decimals="2"
      id="f-489"
      unitRef="eurPerShare">14.58</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-1" decimals="-6" id="f-490" unitRef="eur">5400000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-9" decimals="-6" id="f-491" unitRef="eur">8371000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-10" decimals="-6" id="f-492" unitRef="eur">6223000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-493" unitRef="eur">36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-9" decimals="-6" id="f-494" unitRef="eur">113000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-10" decimals="-6" id="f-495" unitRef="eur">56000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-1" decimals="-6" id="f-496" unitRef="eur">-295000000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-9" decimals="-6" id="f-497" unitRef="eur">48000000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod contextRef="c-10" decimals="-6" id="f-498" unitRef="eur">15000000</ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod>
    <sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset contextRef="c-1" decimals="-6" id="f-499" unitRef="eur">4792000000</sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset>
    <sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset contextRef="c-9" decimals="-6" id="f-500" unitRef="eur">3420000000</sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset>
    <sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset contextRef="c-10" decimals="-6" id="f-501" unitRef="eur">3351000000</sny:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c-1" decimals="-6" id="f-502" unitRef="eur">-509000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c-9" decimals="-6" id="f-503" unitRef="eur">-711000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="c-10" decimals="-6" id="f-504" unitRef="eur">-300000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-1" decimals="-6" id="f-505" unitRef="eur">-970000000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-9" decimals="-6" id="f-506" unitRef="eur">-578000000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-10" decimals="-6" id="f-507" unitRef="eur">-356000000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-1" decimals="-6" id="f-508" unitRef="eur">-136000000</sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-9" decimals="-6" id="f-509" unitRef="eur">280000000</sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-10" decimals="-6" id="f-510" unitRef="eur">-37000000</sny:AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-6" id="f-511" unitRef="eur">283000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-9" decimals="-6" id="f-512" unitRef="eur">245000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-10" decimals="-6" id="f-513" unitRef="eur">244000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue contextRef="c-1" decimals="-6" id="f-514" unitRef="eur">20000000</sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue>
    <sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue contextRef="c-9" decimals="-6" id="f-515" unitRef="eur">3000000</sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue>
    <sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue contextRef="c-10" decimals="-6" id="f-516" unitRef="eur">4000000</sny:ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-1" decimals="-6" id="f-517" unitRef="eur">283000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-9" decimals="-6" id="f-518" unitRef="eur">138000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c-10" decimals="-6" id="f-519" unitRef="eur">-57000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-1" decimals="-6" id="f-520" unitRef="eur">9494000000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-9" decimals="-6" id="f-521" unitRef="eur">11233000000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-10" decimals="-6" id="f-522" unitRef="eur">9113000000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-1" decimals="-6" id="f-523" unitRef="eur">-840000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-9" decimals="-6" id="f-524" unitRef="eur">-927000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-10" decimals="-6" id="f-525" unitRef="eur">-357000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-1" decimals="-6" id="f-526" unitRef="eur">-397000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-9" decimals="-6" id="f-527" unitRef="eur">-777000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-10" decimals="-6" id="f-528" unitRef="eur">185000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-1" decimals="-6" id="f-529" unitRef="eur">402000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-9" decimals="-6" id="f-530" unitRef="eur">452000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c-10" decimals="-6" id="f-531" unitRef="eur">451000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities contextRef="c-1" decimals="-6" id="f-532" unitRef="eur">1599000000</sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities>
    <sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities contextRef="c-9" decimals="-6" id="f-533" unitRef="eur">545000000</sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities>
    <sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities contextRef="c-10" decimals="-6" id="f-534" unitRef="eur">1130000000</sny:NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-535" unitRef="eur">10258000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-9" decimals="-6" id="f-536" unitRef="eur">10526000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-10" decimals="-6" id="f-537" unitRef="eur">10522000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-1" decimals="-6" id="f-538" unitRef="eur">3024000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-9" decimals="-6" id="f-539" unitRef="eur">2201000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-10" decimals="-6" id="f-540" unitRef="eur">2043000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-541" unitRef="eur">3870000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-9" decimals="-6" id="f-542" unitRef="eur">992000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-10" decimals="-6" id="f-543" unitRef="eur">5594000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-544" unitRef="eur">134000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-9" decimals="-6" id="f-545" unitRef="eur">488000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-10" decimals="-6" id="f-546" unitRef="eur">311000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-1" decimals="-6" id="f-547" unitRef="eur">1015000000</ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-9" decimals="-6" id="f-548" unitRef="eur">1488000000</ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-10" decimals="-6" id="f-549" unitRef="eur">676000000</ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-1" decimals="-6" id="f-550" unitRef="eur">42000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-9" decimals="-6" id="f-551" unitRef="eur">134000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-10" decimals="-6" id="f-552" unitRef="eur">42000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:NetChangeInOtherNonCurrentAssets contextRef="c-1" decimals="-6" id="f-553" unitRef="eur">-229000000</sny:NetChangeInOtherNonCurrentAssets>
    <sny:NetChangeInOtherNonCurrentAssets contextRef="c-9" decimals="-6" id="f-554" unitRef="eur">-16000000</sny:NetChangeInOtherNonCurrentAssets>
    <sny:NetChangeInOtherNonCurrentAssets contextRef="c-10" decimals="-6" id="f-555" unitRef="eur">-68000000</sny:NetChangeInOtherNonCurrentAssets>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-556" unitRef="eur">-6200000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-9" decimals="-6" id="f-557" unitRef="eur">-2075000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-10" decimals="-6" id="f-558" unitRef="eur">-7298000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-1" decimals="-6" id="f-559" unitRef="eur">195000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-9" decimals="-6" id="f-560" unitRef="eur">188000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-10" decimals="-6" id="f-561" unitRef="eur">186000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-562" unitRef="eur">4454000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="c-9" decimals="-6" id="f-563" unitRef="eur">4168000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="c-10" decimals="-6" id="f-564" unitRef="eur">4008000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-565" unitRef="eur">61000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities contextRef="c-9" decimals="-6" id="f-566" unitRef="eur">99000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities contextRef="c-10" decimals="-6" id="f-567" unitRef="eur">48000000</ifrs-full:DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="c-1" decimals="-6" id="f-568" unitRef="eur">3000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="c-9" decimals="-6" id="f-569" unitRef="eur">0</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="c-10" decimals="-6" id="f-570" unitRef="eur">0</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="c-1" decimals="-6" id="f-571" unitRef="eur">48000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="c-9" decimals="-6" id="f-572" unitRef="eur">1549000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="c-10" decimals="-6" id="f-573" unitRef="eur">0</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="c-1" decimals="-6" id="f-574" unitRef="eur">3684000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="c-9" decimals="-6" id="f-575" unitRef="eur">2718000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="c-10" decimals="-6" id="f-576" unitRef="eur">2241000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-577" unitRef="eur">265000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-9" decimals="-6" id="f-578" unitRef="eur">291000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-10" decimals="-6" id="f-579" unitRef="eur">149000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-1" decimals="-6" id="f-580" unitRef="eur">765000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-9" decimals="-6" id="f-581" unitRef="eur">215000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-10" decimals="-6" id="f-582" unitRef="eur">-414000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="c-1" decimals="-6" id="f-583" unitRef="eur">593000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="c-9" decimals="-6" id="f-584" unitRef="eur">497000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="c-10" decimals="-6" id="f-585" unitRef="eur">382000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-586" unitRef="eur">-8052000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-9" decimals="-6" id="f-587" unitRef="eur">-5821000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-10" decimals="-6" id="f-588" unitRef="eur">-7056000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-6" id="f-589" unitRef="eur">-32000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-9" decimals="-6" id="f-590" unitRef="eur">8000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-10" decimals="-6" id="f-591" unitRef="eur">15000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-6" id="f-592" unitRef="eur">-4026000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-9" decimals="-6" id="f-593" unitRef="eur">2638000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-10" decimals="-6" id="f-594" unitRef="eur">-3817000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-7" decimals="-6" id="f-595" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-8" decimals="-6" id="f-596" unitRef="eur">10098000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-19" decimals="-6" id="f-597" unitRef="eur">13915000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-6" id="f-598" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-7" decimals="-6" id="f-599" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-8" decimals="-6" id="f-600" unitRef="eur">10098000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-601" unitRef="eur">2623000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-9" decimals="-6" id="f-602" unitRef="eur">2452000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-10" decimals="-6" id="f-603" unitRef="eur">1280000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-604" unitRef="eur">559000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-9" decimals="-6" id="f-605" unitRef="eur">380000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-10" decimals="-6" id="f-606" unitRef="eur">334000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-607" unitRef="eur">547000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-9" decimals="-6" id="f-608" unitRef="eur">173000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-10" decimals="-6" id="f-609" unitRef="eur">3000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <sny:DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities contextRef="c-1" decimals="-6" id="f-610" unitRef="eur">17000000</sny:DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities>
    <sny:DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities contextRef="c-9" decimals="-6" id="f-611" unitRef="eur">1000000</sny:DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities>
    <sny:DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities contextRef="c-10" decimals="-6" id="f-612" unitRef="eur">2000000</sny:DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-69" decimals="-6" id="f-613" unitRef="eur">101000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-70" decimals="-6" id="f-614" unitRef="eur">946000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c-1" id="f-615">&lt;div style="margin-bottom:12pt;margin-top:9pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%"&gt;Introduction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi, together with its subsidiaries (collectively &#x201c;Sanofi&#x201d;, &#x201c;the Group&#x201d; or &#x201c;the Company&#x201d;), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi is listed in Paris (Euronext: SAN) and New&#160;York (Nasdaq: SNY).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements for the year ended December 31, 2023, and the notes thereto, were signed off by the Sanofi Board of Directors on&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; January&#160;31,&#160;2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-616">Basis of preparation&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.1. International financial reporting standards (IFRS)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements cover the twelve-month periods ended December 31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with Regulation No.&#160;1606/2002 of the European Parliament and Council of July&#160;19, 2002 on the application of&#160;international accounting standards, Sanofi has presented its consolidated financial statements in accordance with IFRS since&#160;January&#160;1, 2005. The term &#x201c;IFRS&#x201d; refers collectively to international accounting and financial reporting standards (IASs&#160;and&#160;IFRSs) and to interpretations of the interpretations committees (SIC and IFRIC) with mandatory application as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of Sanofi as of December 31, 2023 have been prepared in compliance with IFRS as&#160;issued&#160;by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;IFRS as endorsed by the European Union as of December 31, 2023 are available under the heading &#x201c;IFRS Financial Statements&#x201d; via the following web&#160;link:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;https://www.efrag.org/Endorsement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality, and aggregation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.2. New standards, amendments and interpretations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.2.1. New standards applicable from January 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following amendments are applicable from January&#160;1, 2023, and have had no material impact: &#x201c;Disclosure of Accounting Policies&#x201d; (amendment to IAS&#160;1); &#x201c;Definition of Accounting Estimates&#x201d; (amendment to IAS&#160;8); and &#x201c;Deferred Tax Assets and Liabilities Arising from a Single Transaction&#x201d; (amendment to IAS&#160;12).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May&#160;23, 2023, the IASB issued &#x201c;International Tax Reform&#x2014;Pillar Two Model Rules&#x201d;, an immediately applicable amendment to&#160;IAS&#160;12 that was endorsed on November&#160;9, 2023. The amendment relates to the effects of the global minimum corporate income tax rate of 15% that will come into force in 2024, in accordance with the model framework of OECD Pillar Two.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The French Finance Bill for 2024 imposes a global minimum corporate income tax rate of 15% and introduces (i)&#160;a supplementary multinational tax and (ii)&#160;a supplementary national tax for annual accounting periods commencing on or after December&#160;31, 2023. Given that the legislation had not come into force as of December&#160;31, 2023, Sanofi is not liable for any current taxes in that&#160;respect. In addition, Sanofi has not recognized any deferred taxes associated with the minimum tax, in accordance with the&#160;temporary exemption available under the May&#160;2023 amendment to IAS&#160;12. At this stage, a material impact is expected in respect&#160;of Sanofi's operations in France and Singapore, because Sanofi&#x2019;s average effective tax rate in those countries was less than 15% at the end of 2023. Other things being equal, applying the Pillar 2 rules in 2023 would have led to an increase of approximately 1.5&#160;percentage points in the effective tax rate based on the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;IFRS&#160;17 (Insurance Contracts), issued on May&#160;18, 2017 and applicable on or after January&#160;1, 2023, does not apply to the Sanofi consolidated financial statements because the insurance activities carried on by Sanofi&#x2019;s captive insurance companies are internal within the Sanofi group (the sole policyholders being subsidiaries of Sanofi), and hence are eliminated on consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.2.2. New pronouncements issued by the IASB and applicable from 2024 or later&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This note describes standards, amendments and interpretations issued by the IASB that will have mandatory application in 2024 or subsequent years, and Sanofi&#x2019;s position regarding future application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On September&#160;22, 2022, the IASB issued an amendment to IFRS&#160;16 (Leases), relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable at the earliest from January&#160;1, 2024;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; it will not have a material impact on the Sanofi financial statements, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has not early adopted it.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On January&#160;23, 2020, the IASB issued &#x201c;Classification of Liabilities as Current or Non-current&#x201d;, an amendment to IAS&#160;1, and then on&#160;October&#160;31, 2022 issued &#x201c;Non-current Liabilities with Covenants&#x201d;, a further amendment to IAS&#160;1. The amendments are applicable at the earliest from January&#160;1, 2024; they will not have a material impact on the Sanofi financial statements, and Sanofi has not early adopted them.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May&#160;25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS&#160;7 and IFRS&#160;7, which is applicable at the earliest from January&#160;1, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (subject to endorsement by the European Union) and which relates to disclosures of information about such arrangements. The amendment does not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On August&#160;15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS&#160;21 (The Effect of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable at the earliest from January&#160;1, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (subject to endorsement by the European Union); it&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.3. Use of estimates and judgments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date of the finalization of the financial statements. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions (see&#160;Notes&#160;B.13. and&#160;D.23.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;impairment of property, plant and equipment and intangible assets (see Notes&#160;B.6. and D.5.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the valuation of goodwill and the valuation and estimated useful life of acquired intangible assets (see Notes&#160;B.3.2., B.4., D.4. and&#160;D.5.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the measurement of contingent consideration receivable in connection with asset divestments (see Notes&#160;B.8.5. and&#160;D.12.) and of contingent consideration payable (see Notes&#160;B.3. and&#160;D.18.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the measurement of financial assets and liabilities at amortized cost (see Note&#160;B.8.5.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of post-employment benefit obligations (see Notes&#160;B.23. and&#160;D.19.1.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks (see Notes&#160;B.12., B.19., B.20., D.19. and&#160;D.22.); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences (see Notes&#160;B.22. and&#160;D.14.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In preparing the consolidated financial statements, Sanofi has also taken account of risks related to the effects of climate change and energy transition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As part of its Planet Care program, Sanofi has committed to move towards carbon neutrality by 2030 and net zero emissions by&#160;2045 for its Scope&#160;1, 2 and&#160;3 emissions. That involves:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;aiming for a 55% reduction in greenhouse gas (GHG) emissions from Sanofi&#x2019;s own activities (Scopes&#160;1 &amp;amp;&#160;2) and a 30% reduction in Scope&#160;3 GHG emissions by 2030 (versus a 2019 baseline), and a 90% reduction in GHG emissions (all scopes) by&#160;2045. These objectives have been validated by the Science Based Target initiative (STBi);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;supplying all our sites with 100% renewably-sourced electricity by 2030;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;promoting an eco-friendly vehicle fleet by 2030; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;engaging the Sanofi supply chain in reducing Scope&#160;3 emissions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The analysis of climate-related physical and transition risks facing Sanofi was updated in 2023 on the basis of three global warming scenarios out to 2030 and 2050. A number of assumptions &#x2013; on issues such as carbon costs, natural disasters, water stress, raw material scarcity and logistics disruption &#x2013; were built into this analysis, which also takes account of certain capital expenditures on mitigations derived from the Planet Care roadmap.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In preparing the consolidated financial statements, that analysis was taken into account as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the value of intangible assets and property, plant and equipment was subject to impairment testing conducted at CGU level, as described in Note&#160;D.5. Certain climate-related assumptions, such as the evolution of energy costs, transitioning to sustainable agriculture, and waste management, are already built into the forecast used for impairment testing purposes. For those assumptions not yet built into budgets, sensitivity analyses can be performed as needed;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the periodic reviews conducted on the useful lives of property, plant and equipment take account of environmental regulatory constraints, including not only GHG emissions but also physical risks;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;environmental risks are covered by provisions on the basis described in Note&#160;D.19.3.; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the credit facilities available to Sanofi as of December&#160;31, 2023 incorporate performance objectives, including objectives related to cutting Sanofi&#x2019;s carbon footprint, which could reduce the cost of debt if they are attained (see Note&#160;D.17.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is important to bear in mind that estimating climate change related risks involves an element of unpredictability. Uncertainties may arise from factors such as changes in government policy, rapid technological change, and varied responses from stakeholders. That high level of uncertainty adds complexity to assessment of the potential impacts on our operations, and to how those impacts are reflected in our budgets. Actual impacts on Sanofi&#x2019;s profits and financial position could therefore differ from initial estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Finally, in line with its environmental protection objectives, Sanofi has initiated projects to build eco-design into its products so as to limit their environmental impacts over their entire life cycle. Those projects will require Sanofi to redefine all of its production methods, and as such have also been built into definitions of the useful lives of Sanofi production facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.4. Hyperinflation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2023, Sanofi continued to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July&#160;1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Turkey, the cumulative rate of inflation over the last three years is in excess of 100% based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January&#160;1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;A.5. Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On February&#160;18, 2020, Sanofi and the US Department of Health and Human Services extended their research and development partnership to leverage Sanofi&#x2019;s previous development work on a SARS vaccine to attempt to unlock a fast path forward for developing a COVID-19 vaccine. Under the terms of the collaboration, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services, is helping to fund the research and development undertaken by Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April&#160;14, 2020, Sanofi and GlaxoSmithKline (GSK) entered into a collaboration agreement to develop a recombinant COVID-19 vaccine candidate, with Sanofi contributing its S&#x2011;protein COVID-19 antigen (based on recombinant DNA technology) and GSK contributing its pandemic adjuvant technology. Sanofi is leading clinical development and the registration process for the vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July&#160;31, 2020, the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK was selected by the US&#160;government&#x2019;s Operation Warp Speed (OWS) program. Under the OWS, the US government is providing funds to support further development of the vaccine, including clinical trials and scaling-up of manufacturing capacity. Initially, the agreement also provided for the supply of 100&#160;million doses of the vaccine. In light of the evolving context of the pandemic (including variants of the virus) and the availability of vaccines on the market, the parties decided to review the initial supply contract. At the end of 2023, the agreement was amended in respect of the supply clause, confirming that Sanofi had fulfilled its contractual obligations and setting the amount of compensation paid to Sanofi. On the basis of that signed amendment, Sanofi recognized an amount of &#x20ac;411&#160;million within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;; that amount was paid to Sanofi in December&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has recognized the funding received from the US government as a deduction from the development expenses incurred, in accordance with IAS&#160;20 (Accounting for Government Grants and Disclosure of Government Assistance).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The amount of government aid received from the US federal government and BARDA and recognized &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;as a deduction from development expenses&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; and other operating expenses was &#x20ac;59&#160;million in 2023, compared with &#x20ac;265&#160;million in 2022 and &#x20ac;147&#160;million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In September&#160;2020, Sanofi and GSK signed pre-order contracts with the Canadian and UK governments and with the European Union for doses of the vaccine candidate. During 2021, Sanofi and GSK contractualized with the Canadian and UK governments and with the European Union on the number of doses ordered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On December&#160;15, 2021, Sanofi and GSK announced positive preliminary data on their COVID-19 booster vaccine candidate and indicated that their Phase&#160;3 trial was to continue, based on recommendations from an independent monitoring board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On November&#160;10, 2022, in line with the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, the European Commission approved VIDPREVTYN Beta vaccine as booster for the prevention of COVID-19 in adults aged 18&#160;years and older. Designed to provide broad protection against multiple variants, this protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK&#x2019;s pandemic adjuvant. VIDPREVTYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Beta is indicated as a booster for active immunization against SARS-CoV-2 in adults who have previously received an mRNA or adenoviral COVID-19 vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On December&#160;21, 2022, following the European Commission approval, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved VIDPREVTYN Beta vaccine for the prevention of COVID-19 in adults aged&#160;18 and over within the UK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;15 (see Note&#160;B.13.1.), Sanofi recognizes revenue when control over the product is transferred to the customer (for vaccines, transfer of control is determined by reference to the terms of release and acceptance of batches of vaccine). Payments received subsequent to signature of vaccine pre-order contracts relating to doses not yet delivered are customer contract liabilities (i.e. an obligation for the entity to supply goods to a customer, for which consideration has been received from the customer). They are presented within &#x201c;Customer contract liabilities&#x201d; in the balance sheet (see Note&#160;D.19.5.), and within &#x201c;Net change in other current assets and other current liabilities&#x201d; in the statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The pre-order contracts for Canada, the United Kingdom and the European Union expired in 2023. The customer contract liabilities, which amounted to &#x20ac;269&#160;million as of December&#160;31, 2022 and &#x20ac;319&#160;million as of&#160;December&#160;31,&#160;2021 (see Note&#160;D.19.5., &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Current provisions and other current liabilities&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) were released to profit or loss in 2023, including an amount of &#x20ac;94&#160;million classified in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in respect of doses which there was no longer an obligation to deliver as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:StatementOfIFRSCompliance contextRef="c-1" id="f-617">International financial reporting standards (IFRS)&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements cover the twelve-month periods ended December 31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with Regulation No.&#160;1606/2002 of the European Parliament and Council of July&#160;19, 2002 on the application of&#160;international accounting standards, Sanofi has presented its consolidated financial statements in accordance with IFRS since&#160;January&#160;1, 2005. The term &#x201c;IFRS&#x201d; refers collectively to international accounting and financial reporting standards (IASs&#160;and&#160;IFRSs) and to interpretations of the interpretations committees (SIC and IFRIC) with mandatory application as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of Sanofi as of December 31, 2023 have been prepared in compliance with IFRS as&#160;issued&#160;by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;IFRS as endorsed by the European Union as of December 31, 2023 are available under the heading &#x201c;IFRS Financial Statements&#x201d; via the following web&#160;link:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;https://www.efrag.org/Endorsement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality, and aggregation.&lt;/span&gt;&lt;/div&gt;</ifrs-full:StatementOfIFRSCompliance>
    <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations contextRef="c-1" id="f-618">New standards, amendments and interpretations&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;A.2.1. New standards applicable from January 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following amendments are applicable from January&#160;1, 2023, and have had no material impact: &#x201c;Disclosure of Accounting Policies&#x201d; (amendment to IAS&#160;1); &#x201c;Definition of Accounting Estimates&#x201d; (amendment to IAS&#160;8); and &#x201c;Deferred Tax Assets and Liabilities Arising from a Single Transaction&#x201d; (amendment to IAS&#160;12).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May&#160;23, 2023, the IASB issued &#x201c;International Tax Reform&#x2014;Pillar Two Model Rules&#x201d;, an immediately applicable amendment to&#160;IAS&#160;12 that was endorsed on November&#160;9, 2023. The amendment relates to the effects of the global minimum corporate income tax rate of 15% that will come into force in 2024, in accordance with the model framework of OECD Pillar Two.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The French Finance Bill for 2024 imposes a global minimum corporate income tax rate of 15% and introduces (i)&#160;a supplementary multinational tax and (ii)&#160;a supplementary national tax for annual accounting periods commencing on or after December&#160;31, 2023. Given that the legislation had not come into force as of December&#160;31, 2023, Sanofi is not liable for any current taxes in that&#160;respect. In addition, Sanofi has not recognized any deferred taxes associated with the minimum tax, in accordance with the&#160;temporary exemption available under the May&#160;2023 amendment to IAS&#160;12. At this stage, a material impact is expected in respect&#160;of Sanofi's operations in France and Singapore, because Sanofi&#x2019;s average effective tax rate in those countries was less than 15% at the end of 2023. Other things being equal, applying the Pillar 2 rules in 2023 would have led to an increase of approximately 1.5&#160;percentage points in the effective tax rate based on the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;IFRS&#160;17 (Insurance Contracts), issued on May&#160;18, 2017 and applicable on or after January&#160;1, 2023, does not apply to the Sanofi consolidated financial statements because the insurance activities carried on by Sanofi&#x2019;s captive insurance companies are internal within the Sanofi group (the sole policyholders being subsidiaries of Sanofi), and hence are eliminated on consolidation.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-71" decimals="2" id="f-619" unitRef="number">0.15</ifrs-full:AverageEffectiveTaxRate>
    <sny:IncreaseDecreaseInEffectiveTaxRate contextRef="c-1" decimals="3" id="f-620" unitRef="number">0.015</sny:IncreaseDecreaseInEffectiveTaxRate>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="c-1" id="f-621">New pronouncements issued by the IASB and applicable from 2024 or later&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This note describes standards, amendments and interpretations issued by the IASB that will have mandatory application in 2024 or subsequent years, and Sanofi&#x2019;s position regarding future application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On September&#160;22, 2022, the IASB issued an amendment to IFRS&#160;16 (Leases), relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable at the earliest from January&#160;1, 2024;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; it will not have a material impact on the Sanofi financial statements, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has not early adopted it.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On January&#160;23, 2020, the IASB issued &#x201c;Classification of Liabilities as Current or Non-current&#x201d;, an amendment to IAS&#160;1, and then on&#160;October&#160;31, 2022 issued &#x201c;Non-current Liabilities with Covenants&#x201d;, a further amendment to IAS&#160;1. The amendments are applicable at the earliest from January&#160;1, 2024; they will not have a material impact on the Sanofi financial statements, and Sanofi has not early adopted them.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May&#160;25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS&#160;7 and IFRS&#160;7, which is applicable at the earliest from January&#160;1, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (subject to endorsement by the European Union) and which relates to disclosures of information about such arrangements. The amendment does not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On August&#160;15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS&#160;21 (The Effect of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable at the earliest from January&#160;1, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (subject to endorsement by the European Union); it&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="c-1" id="f-622">Use of estimates and judgments&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date of the finalization of the financial statements. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions (see&#160;Notes&#160;B.13. and&#160;D.23.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;impairment of property, plant and equipment and intangible assets (see Notes&#160;B.6. and D.5.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the valuation of goodwill and the valuation and estimated useful life of acquired intangible assets (see Notes&#160;B.3.2., B.4., D.4. and&#160;D.5.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the measurement of contingent consideration receivable in connection with asset divestments (see Notes&#160;B.8.5. and&#160;D.12.) and of contingent consideration payable (see Notes&#160;B.3. and&#160;D.18.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the measurement of financial assets and liabilities at amortized cost (see Note&#160;B.8.5.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of post-employment benefit obligations (see Notes&#160;B.23. and&#160;D.19.1.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks (see Notes&#160;B.12., B.19., B.20., D.19. and&#160;D.22.); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences (see Notes&#160;B.22. and&#160;D.14.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In preparing the consolidated financial statements, Sanofi has also taken account of risks related to the effects of climate change and energy transition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As part of its Planet Care program, Sanofi has committed to move towards carbon neutrality by 2030 and net zero emissions by&#160;2045 for its Scope&#160;1, 2 and&#160;3 emissions. That involves:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;aiming for a 55% reduction in greenhouse gas (GHG) emissions from Sanofi&#x2019;s own activities (Scopes&#160;1 &amp;amp;&#160;2) and a 30% reduction in Scope&#160;3 GHG emissions by 2030 (versus a 2019 baseline), and a 90% reduction in GHG emissions (all scopes) by&#160;2045. These objectives have been validated by the Science Based Target initiative (STBi);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;supplying all our sites with 100% renewably-sourced electricity by 2030;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;promoting an eco-friendly vehicle fleet by 2030; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;engaging the Sanofi supply chain in reducing Scope&#160;3 emissions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The analysis of climate-related physical and transition risks facing Sanofi was updated in 2023 on the basis of three global warming scenarios out to 2030 and 2050. A number of assumptions &#x2013; on issues such as carbon costs, natural disasters, water stress, raw material scarcity and logistics disruption &#x2013; were built into this analysis, which also takes account of certain capital expenditures on mitigations derived from the Planet Care roadmap.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In preparing the consolidated financial statements, that analysis was taken into account as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the value of intangible assets and property, plant and equipment was subject to impairment testing conducted at CGU level, as described in Note&#160;D.5. Certain climate-related assumptions, such as the evolution of energy costs, transitioning to sustainable agriculture, and waste management, are already built into the forecast used for impairment testing purposes. For those assumptions not yet built into budgets, sensitivity analyses can be performed as needed;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the periodic reviews conducted on the useful lives of property, plant and equipment take account of environmental regulatory constraints, including not only GHG emissions but also physical risks;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;environmental risks are covered by provisions on the basis described in Note&#160;D.19.3.; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the credit facilities available to Sanofi as of December&#160;31, 2023 incorporate performance objectives, including objectives related to cutting Sanofi&#x2019;s carbon footprint, which could reduce the cost of debt if they are attained (see Note&#160;D.17.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is important to bear in mind that estimating climate change related risks involves an element of unpredictability. Uncertainties may arise from factors such as changes in government policy, rapid technological change, and varied responses from stakeholders. That high level of uncertainty adds complexity to assessment of the potential impacts on our operations, and to how those impacts are reflected in our budgets. Actual impacts on Sanofi&#x2019;s profits and financial position could therefore differ from initial estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Finally, in line with its environmental protection objectives, Sanofi has initiated projects to build eco-design into its products so as to limit their environmental impacts over their entire life cycle. Those projects will require Sanofi to redefine all of its production methods, and as such have also been built into definitions of the useful lives of Sanofi production facilities.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <sny:PlanetCareProgramObjectivesNetEmissionsBy2045
      contextRef="c-1"
      decimals="INF"
      id="f-623"
      unitRef="emission">0</sny:PlanetCareProgramObjectivesNetEmissionsBy2045>
    <sny:PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030 contextRef="c-1" decimals="INF" id="f-624" unitRef="number">0.55</sny:PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030>
    <sny:PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030 contextRef="c-1" decimals="INF" id="f-625" unitRef="number">0.30</sny:PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030>
    <sny:PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030 contextRef="c-1" decimals="INF" id="f-626" unitRef="number">0.90</sny:PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030>
    <sny:PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030 contextRef="c-1" decimals="INF" id="f-627" unitRef="number">1</sny:PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030>
    <sny:PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios
      contextRef="c-1"
      decimals="INF"
      id="f-628"
      unitRef="scenario">3</sny:PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios>
    <ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory contextRef="c-1" id="f-629">Hyperinflation&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2023, Sanofi continued to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS&#160;10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July&#160;1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Turkey, the cumulative rate of inflation over the last three years is in excess of 100% based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January&#160;1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS&#160;29. The impact of the resulting restatements is immaterial at Sanofi group level.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfHyperinflationaryReportingExplanatory>
    <sny:CumulativeConsumerPriceInflationOverTheLastThreeYears contextRef="c-72" decimals="2" id="f-630" unitRef="number">1</sny:CumulativeConsumerPriceInflationOverTheLastThreeYears>
    <sny:CumulativeConsumerPriceInflationOverTheLastThreeYears contextRef="c-73" decimals="2" id="f-631" unitRef="number">1</sny:CumulativeConsumerPriceInflationOverTheLastThreeYears>
    <sny:AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock contextRef="c-1" id="f-632">Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On February&#160;18, 2020, Sanofi and the US Department of Health and Human Services extended their research and development partnership to leverage Sanofi&#x2019;s previous development work on a SARS vaccine to attempt to unlock a fast path forward for developing a COVID-19 vaccine. Under the terms of the collaboration, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services, is helping to fund the research and development undertaken by Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April&#160;14, 2020, Sanofi and GlaxoSmithKline (GSK) entered into a collaboration agreement to develop a recombinant COVID-19 vaccine candidate, with Sanofi contributing its S&#x2011;protein COVID-19 antigen (based on recombinant DNA technology) and GSK contributing its pandemic adjuvant technology. Sanofi is leading clinical development and the registration process for the vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July&#160;31, 2020, the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK was selected by the US&#160;government&#x2019;s Operation Warp Speed (OWS) program. Under the OWS, the US government is providing funds to support further development of the vaccine, including clinical trials and scaling-up of manufacturing capacity. Initially, the agreement also provided for the supply of 100&#160;million doses of the vaccine. In light of the evolving context of the pandemic (including variants of the virus) and the availability of vaccines on the market, the parties decided to review the initial supply contract. At the end of 2023, the agreement was amended in respect of the supply clause, confirming that Sanofi had fulfilled its contractual obligations and setting the amount of compensation paid to Sanofi. On the basis of that signed amendment, Sanofi recognized an amount of &#x20ac;411&#160;million within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;; that amount was paid to Sanofi in December&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has recognized the funding received from the US government as a deduction from the development expenses incurred, in accordance with IAS&#160;20 (Accounting for Government Grants and Disclosure of Government Assistance).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The amount of government aid received from the US federal government and BARDA and recognized &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;as a deduction from development expenses&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; and other operating expenses was &#x20ac;59&#160;million in 2023, compared with &#x20ac;265&#160;million in 2022 and &#x20ac;147&#160;million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In September&#160;2020, Sanofi and GSK signed pre-order contracts with the Canadian and UK governments and with the European Union for doses of the vaccine candidate. During 2021, Sanofi and GSK contractualized with the Canadian and UK governments and with the European Union on the number of doses ordered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On December&#160;15, 2021, Sanofi and GSK announced positive preliminary data on their COVID-19 booster vaccine candidate and indicated that their Phase&#160;3 trial was to continue, based on recommendations from an independent monitoring board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On November&#160;10, 2022, in line with the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, the European Commission approved VIDPREVTYN Beta vaccine as booster for the prevention of COVID-19 in adults aged 18&#160;years and older. Designed to provide broad protection against multiple variants, this protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK&#x2019;s pandemic adjuvant. VIDPREVTYN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Beta is indicated as a booster for active immunization against SARS-CoV-2 in adults who have previously received an mRNA or adenoviral COVID-19 vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On December&#160;21, 2022, following the European Commission approval, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved VIDPREVTYN Beta vaccine for the prevention of COVID-19 in adults aged&#160;18 and over within the UK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;15 (see Note&#160;B.13.1.), Sanofi recognizes revenue when control over the product is transferred to the customer (for vaccines, transfer of control is determined by reference to the terms of release and acceptance of batches of vaccine). Payments received subsequent to signature of vaccine pre-order contracts relating to doses not yet delivered are customer contract liabilities (i.e. an obligation for the entity to supply goods to a customer, for which consideration has been received from the customer). They are presented within &#x201c;Customer contract liabilities&#x201d; in the balance sheet (see Note&#160;D.19.5.), and within &#x201c;Net change in other current assets and other current liabilities&#x201d; in the statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The pre-order contracts for Canada, the United Kingdom and the European Union expired in 2023. The customer contract liabilities, which amounted to &#x20ac;269&#160;million as of December&#160;31, 2022 and &#x20ac;319&#160;million as of&#160;December&#160;31,&#160;2021 (see Note&#160;D.19.5., &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Current provisions and other current liabilities&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;) were released to profit or loss in 2023, including an amount of &#x20ac;94&#160;million classified in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Other revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in respect of doses which there was no longer an obligation to deliver as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</sny:AgreementsRelatingToTheRecombinantCovid19VaccineCandidateDevelopedBySanofiInCollaborationWithGSKPolicyTextBlock>
    <sny:NumberOfVaccineDosesToBeSupplied
      contextRef="c-74"
      decimals="-6"
      id="f-633"
      unitRef="vaccine_dose">100000000</sny:NumberOfVaccineDosesToBeSupplied>
    <ifrs-full:OtherRevenue contextRef="c-75" decimals="-6" id="f-634" unitRef="eur">411000000</ifrs-full:OtherRevenue>
    <sny:GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses contextRef="c-75" decimals="-6" id="f-635" unitRef="eur">59000000</sny:GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses>
    <sny:GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses contextRef="c-76" decimals="-6" id="f-636" unitRef="eur">265000000</sny:GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses>
    <sny:GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses contextRef="c-77" decimals="-6" id="f-637" unitRef="eur">147000000</sny:GovernmentGrantRecognisedAsDeductionFromDevelopmentExpenses>
    <ifrs-full:CurrentContractLiabilities contextRef="c-78" decimals="-6" id="f-638" unitRef="eur">269000000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-79" decimals="-6" id="f-639" unitRef="eur">319000000</ifrs-full:CurrentContractLiabilities>
    <sny:OtherRevenuePerformanceObligationNoLongerRequired contextRef="c-80" decimals="-6" id="f-640" unitRef="eur">94000000</sny:OtherRevenuePerformanceObligationNoLongerRequired>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="c-1" id="f-641">Summary of significant accounting policiesBasis of consolidation&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;10 (Consolidated Financial Statements), the consolidated financial statements of Sanofi include the financial statements of entities that Sanofi controls directly or indirectly, regardless of the level of the equity interest in those entities. An entity is controlled when Sanofi has power over the entity, exposure or rights to variable returns from its involvement with the entity, and the ability to affect those returns through its power over the entity. In determining whether control exists, potential voting rights must be taken into account if those rights are substantive, in other words they can be exercised on a timely basis when decisions about the relevant activities of the entity are to be taken.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Entities consolidated by Sanofi are referred to as &#x201c;subsidiaries&#x201d;. Entities that Sanofi controls by means other than voting rights are referred to as &#x201c;consolidated structured entities&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;11 (Joint Arrangements), Sanofi classifies its joint arrangements (i.e. arrangements in which Sanofi exercises joint control with one or more other parties) either as a joint operation (in which case, Sanofi recognizes the assets and liabilities of the operation in proportion to its rights and obligations relating to those assets and liabilities) or as a joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi exercises joint control over a joint arrangement when decisions relating to the relevant activities of the arrangement require the unanimous consent of Sanofi and the other parties with whom control is shared.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi exercises significant influence over an entity when it has the power to participate in the financial and operating policy decisions of that entity, but does not have the power to exercise control or joint control over those policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), the equity method is used to account for joint ventures (i.e.&#160;entities over which Sanofi exercises joint control) and for associates (i.e. entities over which Sanofi exercises significant influence).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under the equity method, the investment is initially recognized at cost, and subsequently adjusted to reflect changes in the net assets of the associate or joint venture. IAS&#160;28 does not specify the treatment to be adopted on first-time application of the equity method to an investee following a step acquisition. Consequently, by reference to paragraph&#160;10 of IAS&#160;28, Sanofi has opted to apply the cost method, whereby the carrying amount of the investment represents the sum of the historical cost amounts for each step in the acquisition. As of the date on which the equity method is first applied, goodwill (which is included in the carrying amount of the investment) is determined for each acquisition step. The same applies to subsequent increases in the percentage interest in the equity-accounted investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;When the criteria of IFRS&#160;5 are met, Sanofi recognizes the equity interest within the balance sheet line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. The equity method is not applied to equity interests that are classified as held-for-sale assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Transactions between consolidated companies are eliminated, as are intragroup profits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A list of the principal companies included in the consolidation in 2023 is presented in Note&#160;F.&lt;/span&gt;&lt;/div&gt;Foreign currency translation&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.2.1. Accounting for foreign currency transactions in the financial statements of consolidated entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Non-current assets (other than receivables) and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate prevailing at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the end of the reporting period. The gains and losses resulting from foreign currency translation are recorded in the income statement. However, foreign exchange gains and losses arising from the translation of advances between consolidated subsidiaries for which settlement is neither planned nor likely to occur in the foreseeable future are recognized in equity, in the line item&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Change in currency translation differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.2.2. Foreign currency translation of the financial statements of foreign entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi presents its consolidated financial statements in euros (&#x20ac;). In accordance with IAS&#160;21 (The Effects of Changes in Foreign Exchange Rates), each subsidiary accounts for its transactions in the currency that is most representative of its economic environment (the functional currency).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;All assets and liabilities are translated into euros using the exchange rate of the subsidiary&#x2019;s functional currency prevailing at the end of the reporting period. Income statements are translated using a weighted average exchange rate for the period, except in the case of foreign subsidiaries in a hyperinflationary economy. The resulting currency translation difference is recognized as a separate component of equity in the consolidated statement of comprehensive income, and is recognized in the income statement only when the subsidiary is sold or is wholly or partially liquidated.&lt;/span&gt;&lt;/div&gt;Business combinations and transactions with non-controlling interests&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.3.1. Accounting for business combinations, transactions with non-controlling interests and loss of control&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for in accordance with IFRS&#160;3 (Business Combinations) and IFRS&#160;10 (Consolidated Financial Statements).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for using the acquisition method. Under this method, the acquiree&#x2019;s identifiable assets and liabilities that satisfy the recognition criteria of IFRS&#160;3 (Business Combinations) are measured initially at their fair values at the date of acquisition, except for (i)&#160;non-current assets classified as held for sale (which are measured at fair value less costs to sell) and (ii)&#160;assets and liabilities that fall within the scope of IAS&#160;12 (Income Taxes) and IAS&#160;19 (Employee Benefits). Restructuring liabilities are recognized as a liability of the acquiree only if the acquiree has an obligation as of the acquisition date to carry out the restructuring.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal accounting rules applicable to business combinations and transactions with non-controlling interests include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;acquisition-related costs are recognized as an expense, as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;contingent consideration is recognized in equity if the contingent payment is settled by delivery of a fixed number of&#160;the&#160;acquirer&#x2019;s equity instruments; otherwise, it is recognized in liabilities related to business combinations. Contingent&#160;consideration is recognized at fair value at the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a financial liability, subsequent adjustments to the liability are recognized in profit&#160;or loss in the line item&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, unless the adjustment is made within&#160;the 12&#160;months following the acquisition date and relates to facts and circumstances existing as of that date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;goodwill may be calculated on the basis of either (i)&#160;the entire fair value of the acquiree, or (ii)&#160;a share of the fair value of the acquiree proportionate to the interest acquired. This option is elected for each acquisition individually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Purchase price allocations are performed under the responsibility of management, with assistance from an independent valuer in the case of major acquisitions. IFRS&#160;3 does not specify an accounting treatment for contingent consideration arising from a business combination made by an entity prior to the acquisition of control in that entity and carried as a liability in the acquired entity&#x2019;s balance sheet. The accounting treatment applied by Sanofi to such a liability is to measure it at fair value as of the acquisition date and to report it in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, with subsequent remeasurements recognized in profit or loss. This treatment is consistent with the accounting applied to contingent consideration in the books of the&#160;acquirer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Finally, management may where it deems fit elect to apply the optional test to identify concentration of fair value permitted under IFRS&#160;3 in order to determine whether a transaction is a business combination within the meaning of IFRS&#160;3, or merely the acquisition of an asset or of a group of similar assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.3.2. Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The excess of the cost of an acquisition over Sanofi&#x2019;s interest in the fair value of the identifiable assets and liabilities of the acquiree is recognized as goodwill at the date of the business combination. Goodwill arising on the acquisition of subsidiaries is shown in a separate balance sheet line item, whereas goodwill arising on the acquisition of investments accounted for using the equity method is recorded in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Investments accounted for using the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Goodwill arising on foreign operations is expressed in the functional currency of the country concerned and translated into euros using the exchange rate prevailing at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;36 (Impairment of Assets), goodwill is carried at cost less accumulated impairment (see Note&#160;B.6.).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Such events or circumstances include significant changes more likely than not to have an other-than-temporary impact on the substance of the original investment.&lt;/span&gt;&lt;/div&gt;Other intangible assets&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other intangible assets are initially measured at acquisition cost or production cost, including any directly attributable costs of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. Intangible assets are amortized on a straight line basis over their useful&#160;lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The useful lives of other intangible assets are reviewed at the end of each reporting period. The effect of any adjustment to useful lives is recognized prospectively as a change in accounting estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Amortization of other intangible assets is recognized in the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; except for amortization charged against (i)&#160;acquired or internally-developed software and (ii)&#160;other rights of an industrial or operational nature, which is recognized in the relevant classification of expense by function.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi does not own any intangible assets with an indefinite useful life, other than goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Intangible assets (other than goodwill) are carried at cost less accumulated amortization and accumulated impairment, if any, in accordance with IAS&#160;36 (see Note&#160;B.6.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.4.1. Research and development not acquired in a business combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Internally generated research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IAS&#160;38, research expenses are recognized in profit or loss when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Internally generated development expenses are recognized as an intangible asset if, and only if, all the following six criteria can be demonstrated: (a)&#160;the technical feasibility of completing the development project; (b)&#160;Sanofi&#x2019;s intention to complete the project; (c)&#160;Sanofi&#x2019;s ability to use the project; (d)&#160;the probability that the project will generate future economic benefits; (e)&#160;the availability of adequate technical, financial and other resources to complete the project; and (f)&#160;the ability to measure the development expenditure reliably.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Due to the risks and uncertainties relating to regulatory approval and to the research and development process, the six criteria for capitalization are usually considered not to have been met until the product has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Some industrial development expenses (such as those incurred in developing a second-generation synthesis process) are incurred after marketing approval has been obtained, in order to improve the industrial process for an active ingredient. To the extent that the six IAS&#160;38 criteria are considered as having been met, such expenses are recognized as an asset in the balance sheet within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; as incurred. Similarly, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS&#160;38, in which case the related expenses are recognized as an asset in the balance sheet within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separately acquired research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Payments for separately acquired research and development are capitalized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; provided that they meet the definition of an intangible asset: a resource that is (i)&#160;controlled by Sanofi, (ii)&#160;expected to provide future economic benefits for Sanofi, and (iii)&#160;identifiable (i.e.&#160;it is either separable or arises from contractual or legal rights). Under paragraph&#160;25 of&#160;IAS&#160;38, the first condition for capitalization (the probability that the expected future economic benefits from the asset will flow to the entity) is considered to be satisfied for separately acquired research and development. Consequently, upfront and milestone payments to third parties related to pharmaceutical products for which marketing approval has not yet been obtained are recognized as intangible assets, and amortized on a straight line basis over their useful lives beginning when marketing approval is&#160;obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Payments under research and development arrangements relating to access to technology or to databases, and payments made to purchase generics dossiers, are also capitalized, and amortized over the useful life of the intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Subcontracting arrangements, payments for research and development services, and continuous payments under research and development collaborations which are unrelated to the outcome of that collaboration, are expensed over the service term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.4.2. Other intangible assets not acquired in a business combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Licenses other than those related to pharmaceutical products and research projects, in particular software licenses, are capitalized at acquisition cost, including any directly attributable cost of preparing the software for its intended use. Software licenses are amortized on a straight line basis over their useful lives for Sanofi (&lt;span style="-sec-ix-hidden:f-646"&gt;three&lt;/span&gt; to five years).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Internally generated costs incurred to develop or upgrade software are capitalized if the IAS&#160;38 recognition criteria are satisfied, and amortized on a straight line basis over the useful life of the software from the date on which the software is ready for use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.4.3. Other intangible assets acquired in a business combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other intangible assets acquired in a business combination (in-process research and development, technology platforms, and currently marketed products) that are reliably measurable are identified separately from goodwill, measured at fair value, and capitalized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in accordance with IFRS&#160;3 (Business Combinations) and IAS&#160;38 (Intangible Assets). The related deferred tax liability is also recognized if a deductible or taxable temporary difference exists.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In-process research and development acquired in a business combination is amortized on a straight line basis over its useful life from the date of receipt of marketing approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Rights to technology platforms and to products currently marketed by Sanofi are amortized on a straight line basis over their useful lives, determined (in particular for marketed products) on the basis of cash flow forecasts which take into account the patent protection period of the marketed product.&lt;/span&gt;&lt;/div&gt;Property, plant and equipment owned and leased&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.5.1. Property, plant and equipment owned&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in&#160;the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Subsequent costs are not recognized as assets unless (i)&#160;it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii)&#160;the costs can be measured reliably.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the&#160;item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they&#160;relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The customary useful lives of property, plant and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.129%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;to&#160;40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10 to 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5 to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.5.2. Property, plant and equipment leased&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Effective from January&#160;1, 2019 leases contracted by Sanofi have been accounted for in accordance with IFRS&#160;16 (Leases). Sanofi recognizes a right-of-use asset and a lease liability for all of its lease contracts, except for (i)&#160;leases relating to low-value assets and&#160;(ii)&#160;short-term leases (12&#160;months or less). Payments made in respect of leases not recognized on the balance sheet are recognized as an operating expense on a straight line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On commencement of a lease, the liability for future lease payments is discounted at the incremental borrowing rate, which is a risk-free rate adjusted to reflect the specific risk profile of each Sanofi entity. Because lease payments are spread over the lease term, Sanofi applies a discount rate based on the duration of those payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The payments used to determine the liability for future lease payments exclude non-lease components, but include fixed payments that Sanofi expects to make to the lessor over the estimated lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;After commencement of the lease, the liability for future lease payments is reduced by the amount of the lease payments made, and increased to reflect interest on the liability. In the event of a reassessment or modification of future lease payments, the lease liability is remeasured. The right-of-use asset &#x2013;&#160;which is initially measured at cost including direct costs of the lessee, prepayments made at or prior to the commencement date, less lease incentives received and restoration costs&#160;&#x2013; is depreciated on a straight line basis over the lease term, and tested for impairment as required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi recognizes deferred taxes in respect of right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Leasehold improvements are depreciated over their economic life, which is capped at the lease term as determined under&#160;IFRS&#160;16.&lt;/span&gt;&lt;/div&gt;Impairment of property, plant and equipment, intangible assets, and&#160;investments accounted for using the equity method&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.6.1. Impairment of property, plant and equipment and intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;36 (Impairment of Assets), assets that generate separate cash flows and assets included in cash-generating units&#160;(CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. A&#160;CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IAS&#160;36, each CGU or group of CGUs to which goodwill is allocated must (i)&#160;represent the lowest level within the entity at which the goodwill is monitored for internal management purposes, and (ii)&#160;not be larger than an operating segment determined in accordance with IFRS&#160;8 (Operating Segments), before application of the IFRS&#160;8 aggregation criteria (see Note&#160;B.26.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Quantitative and qualitative indications of impairment (primarily relating to the status of the research and development portfolio, pharmacovigilance, patent litigation, and the launch of competing products) are reviewed at the end of each reporting period. If there is any internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset or CGU.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other intangible assets not yet available for use (such as capitalized in-process research and development), and CGUs or groups of CGUs that include goodwill, are tested for impairment annually whether or not there is any indication of impairment, and more frequently if any event or circumstance indicates that they might be impaired. Such assets are not amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;When there is an internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. To determine value in use, Sanofi uses estimates of future cash flows generated by the asset or CGU, prepared using the same methods as those used in the initial measurement of the asset or CGU on the basis of medium-term strategic plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the case of goodwill, estimates of future cash flows are based on a six-year strategic plan and a terminal value. In the case of other intrangible assets, the period used is based on the economic life of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Estimated cash flows are discounted at long-term market interest rates that reflect the best estimate by Sanofi of the time value of money, the risks specific to the asset or CGU, and economic conditions in the geographical regions in which the business activity associated with the asset or CGU is located.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities that are not directly attributable to a specific CGU are allocated between CGUs on a basis that is reasonable, and consistent with the allocation of the corresponding goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Impairment losses arising on property, plant and equipment, software and certain rights, are recognized within the appropriate income statement line item according to the origin of the impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Impairment losses arising on other intangible assets (products, trademarks, technology platforms, acquired R&amp;amp;D) are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the income statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.6.2. Impairment of investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), Sanofi determines whether investments accounted for using the equity method may be impaired based on indicators such as default in contractual payments, significant financial difficulties, probability of bankruptcy, or a prolonged or significant decline in quoted market price. If an investment is impaired, the amount of the impairment loss is determined by applying IAS&#160;36 (see Note&#160;B.6.1.) and recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share of profit/(loss) from investments accounted for using the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.6.3. Reversals of impairment losses charged against property, plant and equipment, intangible assets, and investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;At the end of each reporting period, Sanofi assesses whether events or changes in circumstances indicate that an impairment loss recognized in a prior period in respect of an asset (other than goodwill) or an investment accounted for using the equity method can be reversed. If this is the case, and the recoverable amount as determined based on the revised estimates exceeds the carrying amount of the asset, Sanofi reverses the impairment loss only to the extent of the carrying amount that would have been determined had no impairment loss been recognized for the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Reversals of impairment losses in respect of other intangible assets are recognized within the income statement line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, while reversals of impairment losses in respect of investments accounted for using the equity method are recognized within the income statement line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Impairment losses taken against goodwill are never reversed, unless the goodwill is part of the carrying amount of an investment accounted for using the equity method.&lt;/span&gt;&lt;/div&gt;Assets held for sale or exchange and liabilities related to assets held for sale or exchange&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;5 (Non-Current Assets Held for Sale and Discontinued Operations), non-current assets and groups of assets are classified as held for sale in the balance sheet if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Within the meaning of IFRS&#160;5, the term &#x201c;sale&#x201d; also includes exchanges for other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Non-current assets or asset groups held for sale must be available for immediate sale in their present condition, subject only to terms that are usual and customary for sales of such assets, and a sale must be highly probable. Criteria used to determine whether a sale is highly probable include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the appropriate level of management must be committed to a plan to sell;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;an active program to locate a buyer and complete the plan must have been initiated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;completion of the sale should be foreseeable within the 12&#160;months following the date of reclassification to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Before initial reclassification of the non-current asset (or asset group) to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Subsequent to reclassification to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held-for-sale assets or liabilities within the balance sheet line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;or&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Liabilities related to assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, provided that the disposal satisfies the IFRS&#160;5 classification criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The profit or loss generated by a held-for-sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;represents a separate major line of business or geographical area of operations; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;is a subsidiary acquired exclusively with a view to resale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;10, transactions between companies that are held for sale or treated as discontinued operations and other consolidated companies are eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Events or circumstances beyond Sanofi&#x2019;s control may extend the period to complete the sale or exchange beyond one year without precluding classification of the asset (or disposal group) in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; provided that there is sufficient evidence that Sanofi remains committed to the planned sale or exchange. Finally, in the event of changes to a plan of sale that requires an asset no longer to be classified as held for sale, IFRS&#160;5 specifies the following treatment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;each asset is measured at the lower of (a)&#160;its carrying amount before the asset was reclassified as held for sale, adjusted for any depreciation, amortization or revaluation that would have been recognized if the asset had not been reclassified as held for sale, or&#160;(b)&#160;its recoverable amount at the date of reclassification;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the backlog of depreciation, amortization and impairment not recognized while non-current assets were classified as held for sale must be reported in the same income statement line item that was used to report impairment losses arising on initial reclassification of assets as held for sale and gains or losses arising on the sale of such assets. In the consolidated income statement, those impacts are reported within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the net income of a business previously classified as discontinued or as held for sale or exchange and reported on a separate line in the income statement must be reclassified and included in net income from continuing operations, for all periods presented;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;in addition, segment information relating to the income statement and the statement of cash flows (acquisitions of non-current assets) must be disclosed in the notes to the financial statements in accordance with IFRS&#160;8 (Operating Segments), and must also be restated for all prior periods presented.&lt;/span&gt;&lt;/div&gt;Financial instruments&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.1. Non-derivative financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;9 (Financial Instruments) and IAS&#160;32 (Financial Instruments: Presentation), Sanofi has adopted the classification of non-derivative financial assets described below. The classification used depends on (i)&#160;the characteristics of the contractual cash flows (i.e.&#160;whether they represent interest or principal) and (ii)&#160;the business model for managing the asset applied at the time of initial recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial assets at fair value through other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These mainly comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;quoted and unquoted equity investments that Sanofi does not hold for trading purposes and that management has designated at &#x201c;fair value through other comprehensive income&#x201d; on initial recognition. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such instruments are derecognized, the previously-recognized changes in fair value remain within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, as does the gain or loss on divestment. Dividends received are recognized in profit or loss for the period, within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial assets at fair value through profit or loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These mainly comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;contingent consideration already carried in the books of an acquired entity or granted in connection with a business combination;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;instruments whose contractual cash flows represent payments of interest and repayments of principal, which are managed with a view to selling the asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;instruments that management has designated at &#x201c;fair value through profit or loss&#x201d; on initial recognition; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;quoted and unquoted equity investments: equity instruments that are not held for trading and which management did not designate at &#x201c;fair value through other comprehensive income&#x201d; on initial recognition, and instruments that do not meet the IFRS definition of &#x201c;equity instruments&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Gains and losses arising from changes in fair value are recognized in profit or loss within the line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Dividends received are recognized in profit or loss for the period, within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of equity investments in unquoted entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On initial recognition of an equity investment in an entity not quoted in an active market, the fair value of the investment is the acquisition cost. Cost ceases to be a representative measure of the fair value of an unquoted equity investment when Sanofi identifies significant changes in the investee, or in the environment in which it operates. In such cases, an internal valuation is carried out, based mainly on growth forecasts or by reference to similar transactions contracted with third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Financial assets at amortized cost comprise instruments whose contractual cash flows represent payments of interest and repayments of principal and which are managed with a view to collecting cash flows. The main assets in this category are loans and receivables. They are presented within the line items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Other non-current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Accounts receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Loans with a maturity of more than 12&#160;months are presented in &#x201c;Long-term loans and advances&#x201d; within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other non-current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. These financial assets are measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of financial assets measured at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The main assets involved are accounts receivable. Accounts receivable are initially recognized at the amount invoiced to the customer. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and general expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the income statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.2. Derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Derivative instruments that do not qualify for hedge accounting are initially and subsequently measured at fair value, with changes in fair value recognized in the income statement in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, depending on the nature of the underlying economic item which is hedged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Derivative instruments that qualify for hedge accounting are measured using the policies described in Note&#160;B.8.3. below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;IFRS&#160;13 (Fair Value Measurement) requires counterparty credit risk to be taken into account when measuring the fair value of financial instruments. That risk is estimated on the basis of observable, publicly-available statistical data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Policy on offsetting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In order for a financial asset and a financial liability to be presented as a net amount in the balance sheet under IAS&#160;32, there must be:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(a) a legally enforceable right to offset; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(b) the intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.3. Hedging&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As part of its overall market risk management policy, Sanofi enters into various hedging transactions involving derivative or non-derivative instruments; these may include forward contracts, currency swaps or options, interest rate swaps or options, cross-currency swaps, and debt placings or issues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Such financial instruments are designated as hedging instruments and recognized using the hedge accounting principles of&#160;IFRS&#160;9 when (a)&#160;there is formal designation and documentation of the hedging relationship, of how the effectiveness of the hedging relationship will be assessed, and of the underlying market risk management objective and strategy; (b)&#160;the hedged item and the hedging instrument are eligible for hedge accounting; and (c)&#160;there is an economic relationship between the hedged item and the hedging instrument, defined on the basis of a hedge ratio that is consistent with the underlying market risk management strategy, and the residual credit risk does not dominate the value changes that result from that economic relationship.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value hedge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A fair value hedge is a hedge of the exposure to changes in fair value of an asset, liability or firm commitment that is attributable to one or more risk components and could affect profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in fair value of the hedging instrument and changes in fair value of the hedged item attributable to the hedged risk components are generally recognized in the income statement, within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for hedges related to operating activities, or within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for hedges related to investing or financing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash flow hedge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A cash flow hedge is a hedge of the exposure to variability in cash flows from an asset, liability or highly probable forecast transaction that is attributable to one or more risk components and could affect profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;for hedges related to operating activities, and within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for hedges related to investing or financing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Cumulative changes in fair value of the hedging instrument previously recognized in equity are reclassified to the income statement when the hedged transaction affects profit or loss. Those reclassified gains and losses are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for hedges related to operating activities, and within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for hedges related to investing or financing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;When a forecast transaction results in the recognition of a non-financial asset or liability, cumulative changes in the fair value of the hedging instrument previously recognized in equity are incorporated in the initial carrying amount of that asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;When the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss previously recognized in equity remains separately recognized in equity and is not reclassified to the income statement, or recognized as an adjustment to the initial cost of the related non-financial asset or liability, until the forecast transaction occurs. However, if Sanofi no longer expects the forecast transaction to occur, the cumulative gain or loss previously recognized in equity is recognized immediately in profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Hedge of a net investment in a foreign operation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In a hedge of a net investment in a foreign operation, changes in the fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. When the investment in the foreign operation is sold, the changes in the fair value of the hedging instrument previously recognized in equity are reclassified to the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of hedging&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As part of its market risk management policy, Sanofi may designate currency options or interest rate options as hedging instruments, the effectiveness of which is measured on the basis of changes in intrinsic value. In such cases, the time value of the option is treated as a hedging cost and accounted for as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;if the option includes a component that is not aligned on the critical features of the hedged item, the corresponding change in the time value is taken to profit or loss;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;otherwise, the change in the time value is taken to equity within the statement of comprehensive income, and then:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;if the hedged item is linked to a transaction that results in the recognition of a financial asset or liability, the change in the time value is reclassified to profit or loss symmetrically with the hedged item, or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;if the hedged item is linked to a transaction that results in the recognition of a non-financial asset or liability, the change in the time value is incorporated in the initial carrying amount of that asset or liability, or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;if the hedged item is linked to a period of time, the change in time value is reclassified to profit or loss on a straight line basis over the life of the hedging relationship.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the case of forward contracts and foreign exchange swaps, and of cross-currency swaps that qualify for hedge accounting on the basis of changes in spot rates, Sanofi may elect for each transaction to use the option whereby the premium/discount or foreign currency basis spread are treated in the same way as the time value of an option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Discontinuation of hedge accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Hedge accounting is discontinued when the eligibility criteria are no longer met (in particular, when the hedging instrument expires or is sold, terminated or exercised), or if there is a change in the market risk management objective of the hedging relationship.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.4. Non-derivative financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Borrowings and debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the income statement over the term of the debt using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These line items record the fair value of (i)&#160;contingent consideration payable in connection with business combinations and (ii)&#160;commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Adjustments to the fair value of commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests, are recognized in equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other non-derivative financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other non-derivative financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.5. Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IFRS&#160;13 (Fair Value Measurement) and IFRS&#160;7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt"&gt;level&#160;1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt"&gt;level&#160;2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt"&gt;level&#160;3: valuation techniques in which not all important inputs are derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS&#160;7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.863%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.362%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Type&#160;of financial&#160;instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement&lt;br/&gt;principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in&lt;br/&gt;fair&#160;value&lt;br/&gt;hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation&lt;br/&gt;technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation&lt;br/&gt;model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Cost/Approach based on comparables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the&#160;end of the reporting period using the method described in&#160;Note&#160;D.7.3.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value held&#160;to meet obligations under &lt;br/&gt;post-employment benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.13.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.13.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than three&#160;months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the&#160;consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.17.1., D.19.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.17.2.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;The liability for future lease payments is discounted using the&#160;incremental borrowing rate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.20.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&lt;br/&gt;Market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1&#160; year:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid Money Market&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;gt;&#160;1&#160;year:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.20.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&lt;br/&gt;Market&lt;br/&gt;Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1&#160;year:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&#160;Money&#160;Market  and LIFFE interest rate futures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;gt;&#160;1&#160;year: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&#160;Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.20.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Present&#160;value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&lt;br/&gt;Market&lt;br/&gt;Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1&#160; year:&lt;br/&gt;Mid&#160;Money Market and LIFFE interest rate futures&lt;br/&gt;&amp;gt;&#160;1&#160;year: &lt;br/&gt;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests (CVRs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests (other than CVRs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Under IAS&#160;32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note&#160;B.8.4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.6. Derecognition of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Financial assets are derecognized when the contractual rights to cash flows from the asset have ended or have been transferred and when Sanofi has transferred substantially all the risks and rewards of ownership of the asset. If Sanofi has neither transferred nor retained substantially all the risks and rewards of ownership of a financial asset, it is derecognized if Sanofi does not retain control of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A financial liability is derecognized when Sanofi&#x2019;s contractual obligations in respect of the liability are discharged, cancelled or extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.7. Risks relating to financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Market risks in respect of non-current financial assets, cash equivalents, derivative instruments and debt are described in the discussions of risk factors presented in Item&#160;3.D. and Item&#160;11. of Sanofi&#x2019;s annual report on Form&#160;20-F for 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Credit risk is the risk that customers may fail to pay their debts. For a description of credit risk, refer to &#x201c;We are subject to the risk of non-payment by our customers&#x201d; within Item&#160;3.D. and Item&#160;11. of Sanofi&#x2019;s annual report on Form&#160;20-F for 2023.&lt;/span&gt;&lt;/div&gt;Inventories&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Inventories are measured at the lower of cost or net realizable value. Cost is calculated using the weighted average cost method or the first-in, first-out method, depending on the nature of the inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The cost of finished goods inventories includes costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the launch phase of a new product, any inventories of that product are written down to zero pending regulatory approval, other than in specific circumstances which make it possible to estimate that there is a high probability at the end of the reporting period that the carrying amount of the inventories will be recoverable. The write-down is reversed once it becomes highly probable that marketing approval will be obtained.&lt;/span&gt;&lt;/div&gt;Cash and cash equivalents&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents as shown in the consolidated balance sheet and statement of cash flows comprise cash, plus liquid short-term investments that are&#160;readily convertible into cash and are&#160;subject to an insignificant risk of changes in value in the event of movements in interest rates.&lt;/span&gt;&lt;/div&gt;Treasury shares&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;32, Sanofi treasury shares are deducted from equity, irrespective of the purpose for which they are held. No gain or loss is recognized in the income statement on the purchase, sale, impairment or cancellation of treasury shares.&lt;/span&gt;&lt;/div&gt;Provisions for risks&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;37 (Provisions, Contingent Liabilities and Contingent Assets), Sanofi records a provision when it has a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;If the obligation is expected to be settled more than 12&#160;months after the end of the reporting period, or has no definite settlement date, the provision is recorded within Non-current provisions and other non-current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Provisions relating to the insurance programs in which Sanofi&#x2019;s captive insurance company participates are based on risk exposure estimates calculated by management, with assistance from independent actuaries, using IBNR (Incurred But Not Reported) techniques. Those techniques use past claims experience, within Sanofi and in the market, to estimate future trends in the cost of&#160;claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Contingent liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow of economic resources is&#160;remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi estimates provisions on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management&#x2019;s knowledge at the date of preparation of the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Reimbursements offsetting the probable outflow of resources are recognized as assets only if it is virtually certain that they will be received. Contingent assets are not recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restructuring provisions are recognized if Sanofi has a detailed, formal restructuring plan at the end of the reporting period and has announced its intention to implement this plan to those affected by it.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No provisions are recorded for future operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi records non-current provisions for certain obligations, such as legal or constructive obligations, where an outflow of resources is probable and the amount of the outflow can be reliably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the case of environmental risks, including at sites where operations are ongoing, Sanofi recognizes a provision where there is a violation of integrity in respect of human health or the environment resulting from past contamination at a site that requires remediation. The amount of the provision is a best estimate of the future expenditures to be incurred on the remediation plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Where the effect of the time value of money is material, those provisions are measured at the present value of the expenditures expected to be required to settle the obligation, calculated using a discount rate that reflects an estimate of the time value of money and the risks specific to the obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Increases in provisions to reflect the effects of the passage of time are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;Revenue recognition&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.13.1. Net sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Revenue arising from the sale of goods is presented in the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Net sales comprise revenue from sales of pharmaceutical products, consumer healthcare products, active ingredients and vaccines, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. Analyses of net sales are provided in Note&#160;D.35.1. &#x201c;Segment Information&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;15 (Revenue from Contracts with Customers), such revenue is recognized when Sanofi transfers control over the product to the customer; control of an asset refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from that asset. For the vast majority of contracts, revenue is recognized when the product is physically transferred, in accordance with the delivery and acceptance terms agreed with the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For contracts entered into by Sanofi Pasteur, transfer of control is usually determined by reference to the terms of release (immediate or deferred) and acceptance of batches of vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the case of contracts with distributors, Sanofi does not recognize revenue when the product is physically transferred to the distributor if the products are sold on consignment, or if the distributor acts as agent. In such cases, revenue is recognized when control is transferred to the end customer, and the distributor&#x2019;s commission is presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and general expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the income statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized reflects the various types of price reductions or rights of return offered by Sanofi to its customers on certain products. Such price reductions and rights of return qualify as variable consideration under IFRS&#160;15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In particular, products sold in the United States are covered by various Government and State programs (such as Medicare and Medicaid) under which products are sold at a discount. Rebates are granted to healthcare authorities, and under contractual arrangements with certain customers. Some wholesalers are entitled to chargeback incentives based on the selling price to the end customer, under specific contractual arrangements. Cash discounts may also be granted for prompt payment. Returns, discounts, incentives and rebates, as described above, are recognized in the period in which the underlying sales are recognized as a reduction of gross sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These amounts are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of chargeback incentives is estimated on the basis of the relevant subsidiary&#x2019;s standard sales terms and conditions, and in certain cases on the basis of specific contractual arrangements with the customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of rebates based on attainment of sales targets is estimated and accrued as each of the underlying sales transactions is recognized;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of price reductions under Government and State programs, largely in the United States, is estimated on the basis of the specific terms of the relevant regulations or agreements, and accrued as each of the underlying sales transactions is recognized;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of sales returns is calculated on the basis of management&#x2019;s best estimate of the amount of product that will ultimately be returned by customers. In countries where product returns are possible, Sanofi operates a returns policy that allows the customer to return products within a certain period either side of the expiry date (usually 12&#160;months after the expiry date). The amount recognized for returns is estimated on the basis of past experience of sales returns. Sanofi also takes into account factors such as levels of inventory in its various distribution channels, product expiry dates, information about potential discontinuation of products, the entry of competing generics into the market, and the launch of over-the-counter medicines. Most product return clauses relate solely to date-expired products, which cannot be resold and are destroyed. Sanofi does not recognize a right of return asset in the balance sheet for contracts that allow for the return of time-expired products, since those products have no value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The estimated amounts described above are recognized in the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;as a reduction of gross sales, and within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the balance sheet. They are subject to regular review and adjustment as appropriate based on the most recent data available to management. Sanofi believes that it has the ability to measure each of the above amounts reliably, using the following factors in developing its estimates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the nature and patient profile of the underlying product;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the applicable regulations or the specific terms and conditions of contracts with governmental authorities, wholesalers and other customers;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;historical data relating to similar contracts, in the case of qualitative and quantitative rebates and chargeback incentives;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;past experience and sales growth trends for the same or similar products;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;actual inventory levels in distribution channels, monitored by Sanofi using internal sales data and externally provided data;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the shelf life of Sanofi products; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;market trends including competition, pricing and demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of provisions for discounts, rebates and sales returns is provided in Note&#160;D.23.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.13.2. Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; is used to recognize all revenue that falls within the scope of IFRS&#160;15 but does not relate to sales of Sanofi products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It mainly comprises (i)&#160;royalties received from licensing intellectual property rights to third parties; (ii)&#160;VaxServe sales of products sourced from third-party manufacturers; and (iii)&#160;revenue received under agreements for Sanofi to provide manufacturing services to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Royalties received under licensing arrangements are recognized over the period during which the underlying sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;VaxServe is a Vaccines segment entity whose operations include the distribution within the United States of vaccines and other&#160;products manufactured by third parties. VaxServe sales of products sourced from third-party manufacturers are presented within&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;Cost of sales&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; consists primarily of the industrial cost of goods sold, payments made under licensing agreements, and distribution costs. The industrial cost of goods sold includes the cost of materials, depreciation of property, plant and equipment, amortization of software, personnel costs, and other expenses attributable to production.&lt;/span&gt;&lt;/div&gt;Research and development&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Note&#160;B.4.1. &#x201c;Research and development not acquired in a business combination&#x201d; and Note&#160;B.4.3. &#x201c;Other intangible assets acquired in a business combination&#x201d; describe the principles applied to the recognition of research and development costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Contributions or reimbursements received from alliance partners are recorded as a reduction of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;Other operating income and expenses&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.16.1. Other operating income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; includes the share of profits that Sanofi is entitled to receive from alliance partners in respect of product marketing agreements. It also includes revenues generated under certain agreements, which may include partnership, co-promotion arrangements and licenses not included in Other revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This line item also includes realized and unrealized foreign exchange gains and losses on operating activities (see Note&#160;B.8.3.), and operating gains on disposals not regarded as major disposals (see Note&#160;B.20.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.16.2. Other operating expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; mainly comprise the share of profits that alliance partners are entitled to receive from Sanofi under product marketing agreements.&lt;/span&gt;&lt;/div&gt;Amortization and impairment of intangible assets&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.17.1. Amortization of intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The expenses recorded in this line item comprise amortization charged against intangible assets (products, trademarks and technology platforms, see Note&#160;D.4.) whose contribution to Sanofi&#x2019;s commercial, industrial and development functions cannot be separately identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Amortization of software, and of other rights of an industrial or operational nature, is recognized as an expense in the income statement, in the relevant line items of expense by function.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.17.2. Impairment of intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This line item records impairment losses taken against intangible assets (products, trademarks, technology platforms and acquired research), and any reversals of such impairment losses.&lt;/span&gt;&lt;/div&gt;Fair value remeasurement of contingent consideration&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of contingent consideration that was (i)&#160;already carried in the books of an acquired entity, or (ii)&#160;granted in connection with a business combination and initially recognized as a liability in accordance with IFRS&#160;3, are reported in profit or loss. Such adjustments are reported separately in the income statement, in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This line item also includes changes in the fair value of contingent consideration receivable in connection with a divestment and classified as a financial asset at fair value through profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Finally, it includes the effect of the unwinding of discount, and of exchange rate movements where the asset or liability is expressed in a currency other than the functional currency of the reporting entity.&lt;/span&gt;&lt;/div&gt;Restructuring costs and similar items&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restructuring costs are expenses incurred in connection with the transformation or reorganization of Sanofi&#x2019;s operations or support functions. Such costs include collective redundancy plans, compensation to third parties for early termination of contracts, and commitments made in connection with transformation or reorganization decisions. They also include accelerated depreciation charges arising from site closures (including closures of leased sites), and losses on asset disposals resulting from such decisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, this line item includes expenses incurred in connection with programs implemented as part of the transformation strategy announced in December&#160;2019 (and previously in November&#160;2015), and intended primarily (i)&#160;to deliver a global information systems solution, further supported by the implementation from 2021 of Sanofi&#x2019;s new digital strategy; and (ii)&#160;to create a standalone CHC entity and proceed to the proposed separation of the CHC business as announced when the new chapter in the Play to Win strategy was presented in October&#160;2023.&lt;/span&gt;&lt;/div&gt;Other gains and losses, and litigation&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; includes the impact of material transactions of an unusual nature or amount which Sanofi believes it necessary to report separately in the income statement in order to improve the relevance of the financial statements, such as:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;gains and losses on major disposals of property, plant and equipment, of intangible assets, of assets (or groups of assets and liabilities) held for sale, or of a business within the meaning of IFRS&#160;3, other than those considered to be restructuring costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;impairment losses and reversals of impairment losses on assets (or groups of assets and liabilities) held for sale, other than those considered to be restructuring costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;gains on bargain purchases;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;costs relating to major litigation; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;pre-tax separation costs associated with the process of disinvesting from operations in the event of a major divestment.&lt;/span&gt;&lt;/div&gt;Financial expenses and income&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.21.1. Financial expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; mainly comprise interest charges on debt financing; negative changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange losses on financing and investing activities; impairment losses on financial instruments; and any reversals of impairment losses on financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; also include expenses arising from the unwinding of discount on long-term provisions, and the net interest cost related to employee benefits. This line item does not include commercial cash discounts, which are deducted from net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.21.2. Financial income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; includes interest and dividend income; positive changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange gains on financing and investing activities; and gains on disposals of financial assets at fair value through profit or loss.&lt;/span&gt;&lt;/div&gt;Income tax expense&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;includes all current and deferred taxes of consolidated companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi accounts for deferred taxes in accordance with IAS&#160;12 (Income Taxes), using the methods described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;deferred tax assets and liabilities are recognized on taxable and deductible temporary differences, and on tax loss carry-forwards. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;French business taxes include a value added based component: &#x201c;CVAE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Cotisation sur la Valeur Ajout&#xe9;e des Entreprises)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Given that CVAE is (i)&#160;calculated as the amount by which certain revenues exceed certain expenses and (ii)&#160;borne primarily by companies that own intellectual property rights on income derived from those rights (royalties, and margin on sales to third parties and to Sanofi entities), it is regarded as meeting the definition of income taxes specified in IAS&#160;12, paragraph&#160;2 (&#x201c;taxes which are based on taxable profits&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;deferred tax assets and liabilities are calculated using the tax rate expected to apply in the period when the corresponding temporary differences are expected to reverse, based on tax rates enacted or substantively enacted at the end of the reporting period;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;deferred tax assets are recognized in respect of deductible temporary differences, tax losses available for carry-forward and unused tax credits to the extent that future recovery is regarded as probable. The recoverability of deferred tax assets is assessed on a case-by-case basis, taking into account the profit forecasts contained in Sanofi&#x2019;s medium-term business plan;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a deferred tax liability is recognized for temporary differences relating to interests in subsidiaries, associates and joint ventures, except in cases where Sanofi is able to control the timing of the reversal of the temporary differences. This applies in particular when Sanofi is able to control dividend policy and it is probable that the temporary differences will not reverse in the foreseeable future;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;no deferred tax is recognized on eliminations of intragroup transfers of interests in subsidiaries, associates or joint ventures;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;each tax entity calculates its own net deferred tax position. All net deferred tax asset and liability positions are then aggregated and shown in separate line items on the relevant side of the consolidated balance sheet. Deferred tax assets and liabilities are offset only if (i)&#160;Sanofi has a legally enforceable right to offset current tax assets and current tax liabilities, and (ii)&#160;the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;deferred taxes are not discounted, except implicitly in the case of deferred taxes on assets and liabilities which are already impacted by discounting. In addition, Sanofi has elected not to discount current taxes payable or receivable where the amounts in question are payable or receivable in the long term;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;withholding taxes on intragroup royalties and dividends, and on royalties and dividends collected from third parties, are accounted for as current income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accounting for business combinations, Sanofi complies with IFRS&#160;3 as regards the recognition of deferred tax assets after the initial accounting period. Consequently, any deferred tax assets recognized by the acquiree after the end of that period in respect of temporary differences or tax loss carry-forwards existing at the acquisition date are recognized in profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The positions adopted by Sanofi in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, Sanofi assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of Sanofi&#x2019;s best estimate and recognized as a liability; uncertain tax assets are not recognized. The amount of the liability includes any penalties and late payment interest. The line item&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Income tax expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; includes the effects of tax reassessments and tax disputes, and any penalties and late payment interest arising from such disputes that have the characteristics of income taxes within the meaning of paragraph&#160;2 of IAS&#160;12 (&#x201c;taxes which are based on taxable profits&#x201d;). Tax exposures relating to corporate income taxes are presented separately within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-current income tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (see Note&#160;D.19.4.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No deferred taxation is recognized on temporary differences that are liable to be subject to US global intangible low taxed&#160;income (GILTI) provisions. The related tax expense is recognized in the year in which it is declared in the tax return to the extent that it arises from the existence of non-US profits that exceed the theoretical return on investment specified in the GILTI&#160;provisions and are taxed at a rate lower than the applicable US tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;1 (Presentation of Financial Statements), current income tax assets and liabilities are presented as separate line items in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;Employee benefit obligations&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi offers retirement benefits to employees and retirees. Such benefits are accounted for in accordance with IAS&#160;19 (Employee Benefits).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Benefits are provided in the form of either defined contribution plans or defined benefit plans. In the case of defined contribution plans, the cost is recognized immediately in the period in which it is incurred, and equates to the amount of the contributions paid by Sanofi. For defined benefit plans, Sanofi generally recognizes its obligations to pay pensions and similar benefits to employees as a liability, based on an actuarial estimate of the rights vested or currently vesting in employees and retirees, using the projected unit credit method. Estimates are performed at least once a year, and rely on financial assumptions (such as discount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;rates) and demographic assumptions (such as life expectancy, retirement age, employee turnover, and the rate of salary increases).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Obligations relating to other post-employment benefits (healthcare and life insurance) offered by Sanofi companies to employees are also recognized as a liability based on an actuarial estimate of the rights vested or currently vesting in employees and retirees at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Such liabilities are recognized net of the fair value of plan assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the case of multi-employer defined benefit plans where plan assets cannot be allocated to each participating employer with sufficient reliability, the plan is accounted for as a defined contribution plan, in accordance with paragraph&#160;34 of IAS&#160;19.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The benefit cost for the period consists primarily of current service cost, past service cost, net interest cost, gains or losses arising from plan settlements not specified in the terms of the plan, and actuarial gains or losses arising from plan curtailments. Net interest cost for the period is determined by applying the discount rate specified in IAS&#160;19 to the net liability (i.e. the amount of the obligation, net of plan assets) recognized in respect of defined benefit plans. Past service cost is recognized immediately in profit or loss in the period in which it is incurred, regardless of whether or not the rights have vested at the time of adoption (in&#160;the case of a new plan) or of amendment (in&#160;the case of an existing&#160;plan).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actuarial gains and losses on defined benefit plans (pensions and other post-employment benefits), also referred to as&#160;&#x201c;Remeasurements of the net defined benefit liability (asset)&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; arise as a result of changes in financial and demographic assumptions, experience adjustments, and the difference between the actual return and interest cost on plan assets. The impacts of those remeasurements are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, net of deferred taxes; they are not subsequently reclassifiable to profit or&#160;loss.&lt;/span&gt;&lt;/div&gt;Share-based payment&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Share-based payment expense is recognized as a component of operating income, in the relevant classification of expense by function. In measuring the expense, the level of attainment of any performance conditions is taken into account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.24.1. Stock option plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has granted a number of equity-settled share-based payment plans (stock option plans) to some of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;2 (Share-Based Payment), services received from employees as consideration for stock options are recognized as an expense in the income statement, with the opposite entry recognized in equity. The expense corresponds to the fair value of the stock option plans, and is charged to income on a straight-line basis over the four-year vesting period of the plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The fair value of stock option plans is measured at the date of grant using the Black-Scholes valuation model, taking into account the expected life of the options. The resulting expense also takes into account the expected cancellation rate of the options. The expense is adjusted over the vesting period to reflect actual cancellation rates resulting from option-holders ceasing to be employed by Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.24.2. Employee share ownership plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi may offer its employees the opportunity to subscribe to reserved share issues at a discount to the reference market price. Shares awarded to employees under such plans fall within the scope of IFRS&#160;2. Consequently, an expense is recognized at the subscription date, based on the value of the discount offered to employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.24.3. Restricted share plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi may award restricted share plans to certain of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;2, an expense equivalent to the fair value of such plans is recognized in profit or loss on a straight line basis over the vesting period of the plan, with the opposite entry recognized in equity. The vesting period is three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The fair value of restricted share plans is based on the quoted market price of Sanofi shares at the date of grant, adjusted for expected dividends during the vesting period; it also takes account of any vesting conditions contingent on stock market performance, measured using the Monte-Carlo valuation model. Other vesting conditions are taken into account in the estimate of the number of shares awarded during the vesting period; that number is then definitively adjusted based on the actual number of shares awarded on the vesting date.&lt;/span&gt;&lt;/div&gt;Earnings per share&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated using the weighted average number of shares outstanding during the reporting period, adjusted on a time-weighted basis from the acquisition date to reflect the number of own shares held by Sanofi. Diluted earnings per share is calculated on the basis of the weighted average number of ordinary shares, computed using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This method assumes that (i)&#160;all outstanding dilutive options and warrants are exercised, and (ii)&#160;Sanofi acquires its own shares at the quoted market price for an amount equivalent to the cash received as consideration for the exercise of the options or warrants, plus the expense arising on unamortized stock options.&lt;/span&gt;&lt;/div&gt;Segment information&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People &amp;amp; Culture, Legal, Ethics, Business Integrity &amp;amp; Global Security, Information Solutions &amp;amp; Technology, Sanofi Business Services,&#160;etc.), which are mainly managed centrally at group-wide level, were presented within the &#x201c;Other&#x201d; category. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in&#160;order to reflect (i)&#160;progress on the &#x201c;Play to Win&#x201d; strategy leading to the creation of the standalone Consumer Healthcare Global&#160;Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its&#160;own&#160;dedicated global support functions (including Finance, People &amp;amp; Culture, Legal, Ethics, Business Integrity &amp;amp; Global Security, Information Solutions &amp;amp; Technology, Global Business Services,&#160;etc.); and (ii)&#160;organizational changes to Sanofi&#x2019;s Manufacturing &amp;amp; Supply global function (previously known as Industrial Affairs). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Consequently, with effect from January&#160;1, 2023, Sanofi reports two operating segments: Biopharma and Consumer Healthcare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#x2019;s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment&#x2019;s results reflect all incurred costs of global support functions attributable to its business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The &#x201c;Other&#x201d; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Information about operating segments for the years ended December 31, 2023, 2022 and 2021 is presented in Note&#160;D.35&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Segment information&#x201d;.&lt;/span&gt;&lt;/div&gt;Management of capital&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In order to maintain or adjust the capital structure, Sanofi can adjust the amount of dividends paid to shareholders, repurchase its own shares, issue new shares, or issue securities giving access to its capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following objectives are defined under the terms of Sanofi&#x2019;s share repurchase programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the implementation of any stock option plan giving entitlement to purchase shares in the Sanofi parent company;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the allotment or sale of shares to employees under statutory profit sharing schemes and employee savings plans;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the consideration-free allotment of shares (i.e. restricted share plans);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the cancellation of some or all of the repurchased shares;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;market-making in the secondary market by an investment services provider under a liquidity contract in compliance with the ethical code recognized by the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Autorit&#xe9; des march&#xe9;s financiers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (AMF);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the delivery of shares on the exercise of rights attached to securities giving access to the capital by redemption, conversion, exchange, presentation of a warrant or any other means;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the delivery of shares (in exchange, as payment, or otherwise) in connection with mergers and acquisitions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the execution by an investment services provider of purchases, sales or transfers by any means, in particular via off-market trading; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.1pt"&gt;any other purpose that is or may in the future be authorized under the applicable laws and regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi is not subject to any constraints on equity capital imposed by third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total equity includes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity attributable to equity holders of Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Equity attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, as shown in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi defines &#x201c;Net debt&#x201d; as (i)&#160;the sum of short-term debt, long-term debt and interest rate derivatives and currency derivatives used to hedge debt, minus (ii)&#160;the sum of cash and cash equivalents and interest rate derivatives and currency derivatives used to hedge cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <sny:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock contextRef="c-1" id="f-642">Basis of consolidation&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;10 (Consolidated Financial Statements), the consolidated financial statements of Sanofi include the financial statements of entities that Sanofi controls directly or indirectly, regardless of the level of the equity interest in those entities. An entity is controlled when Sanofi has power over the entity, exposure or rights to variable returns from its involvement with the entity, and the ability to affect those returns through its power over the entity. In determining whether control exists, potential voting rights must be taken into account if those rights are substantive, in other words they can be exercised on a timely basis when decisions about the relevant activities of the entity are to be taken.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Entities consolidated by Sanofi are referred to as &#x201c;subsidiaries&#x201d;. Entities that Sanofi controls by means other than voting rights are referred to as &#x201c;consolidated structured entities&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;11 (Joint Arrangements), Sanofi classifies its joint arrangements (i.e. arrangements in which Sanofi exercises joint control with one or more other parties) either as a joint operation (in which case, Sanofi recognizes the assets and liabilities of the operation in proportion to its rights and obligations relating to those assets and liabilities) or as a joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi exercises joint control over a joint arrangement when decisions relating to the relevant activities of the arrangement require the unanimous consent of Sanofi and the other parties with whom control is shared.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi exercises significant influence over an entity when it has the power to participate in the financial and operating policy decisions of that entity, but does not have the power to exercise control or joint control over those policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), the equity method is used to account for joint ventures (i.e.&#160;entities over which Sanofi exercises joint control) and for associates (i.e. entities over which Sanofi exercises significant influence).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under the equity method, the investment is initially recognized at cost, and subsequently adjusted to reflect changes in the net assets of the associate or joint venture. IAS&#160;28 does not specify the treatment to be adopted on first-time application of the equity method to an investee following a step acquisition. Consequently, by reference to paragraph&#160;10 of IAS&#160;28, Sanofi has opted to apply the cost method, whereby the carrying amount of the investment represents the sum of the historical cost amounts for each step in the acquisition. As of the date on which the equity method is first applied, goodwill (which is included in the carrying amount of the investment) is determined for each acquisition step. The same applies to subsequent increases in the percentage interest in the equity-accounted investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;When the criteria of IFRS&#160;5 are met, Sanofi recognizes the equity interest within the balance sheet line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. The equity method is not applied to equity interests that are classified as held-for-sale assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Transactions between consolidated companies are eliminated, as are intragroup profits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A list of the principal companies included in the consolidation in 2023 is presented in Note&#160;F.&lt;/span&gt;&lt;/div&gt;</sny:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c-1" id="f-643">Foreign currency translation&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.2.1. Accounting for foreign currency transactions in the financial statements of consolidated entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Non-current assets (other than receivables) and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate prevailing at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the end of the reporting period. The gains and losses resulting from foreign currency translation are recorded in the income statement. However, foreign exchange gains and losses arising from the translation of advances between consolidated subsidiaries for which settlement is neither planned nor likely to occur in the foreseeable future are recognized in equity, in the line item&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Change in currency translation differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.2.2. Foreign currency translation of the financial statements of foreign entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi presents its consolidated financial statements in euros (&#x20ac;). In accordance with IAS&#160;21 (The Effects of Changes in Foreign Exchange Rates), each subsidiary accounts for its transactions in the currency that is most representative of its economic environment (the functional currency).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;All assets and liabilities are translated into euros using the exchange rate of the subsidiary&#x2019;s functional currency prevailing at the end of the reporting period. Income statements are translated using a weighted average exchange rate for the period, except in the case of foreign subsidiaries in a hyperinflationary economy. The resulting currency translation difference is recognized as a separate component of equity in the consolidated statement of comprehensive income, and is recognized in the income statement only when the subsidiary is sold or is wholly or partially liquidated.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory contextRef="c-1" id="f-644">Business combinations and transactions with non-controlling interests&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.3.1. Accounting for business combinations, transactions with non-controlling interests and loss of control&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for in accordance with IFRS&#160;3 (Business Combinations) and IFRS&#160;10 (Consolidated Financial Statements).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for using the acquisition method. Under this method, the acquiree&#x2019;s identifiable assets and liabilities that satisfy the recognition criteria of IFRS&#160;3 (Business Combinations) are measured initially at their fair values at the date of acquisition, except for (i)&#160;non-current assets classified as held for sale (which are measured at fair value less costs to sell) and (ii)&#160;assets and liabilities that fall within the scope of IAS&#160;12 (Income Taxes) and IAS&#160;19 (Employee Benefits). Restructuring liabilities are recognized as a liability of the acquiree only if the acquiree has an obligation as of the acquisition date to carry out the restructuring.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal accounting rules applicable to business combinations and transactions with non-controlling interests include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;acquisition-related costs are recognized as an expense, as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;contingent consideration is recognized in equity if the contingent payment is settled by delivery of a fixed number of&#160;the&#160;acquirer&#x2019;s equity instruments; otherwise, it is recognized in liabilities related to business combinations. Contingent&#160;consideration is recognized at fair value at the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a financial liability, subsequent adjustments to the liability are recognized in profit&#160;or loss in the line item&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, unless the adjustment is made within&#160;the 12&#160;months following the acquisition date and relates to facts and circumstances existing as of that date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;goodwill may be calculated on the basis of either (i)&#160;the entire fair value of the acquiree, or (ii)&#160;a share of the fair value of the acquiree proportionate to the interest acquired. This option is elected for each acquisition individually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Purchase price allocations are performed under the responsibility of management, with assistance from an independent valuer in the case of major acquisitions. IFRS&#160;3 does not specify an accounting treatment for contingent consideration arising from a business combination made by an entity prior to the acquisition of control in that entity and carried as a liability in the acquired entity&#x2019;s balance sheet. The accounting treatment applied by Sanofi to such a liability is to measure it at fair value as of the acquisition date and to report it in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, with subsequent remeasurements recognized in profit or loss. This treatment is consistent with the accounting applied to contingent consideration in the books of the&#160;acquirer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Finally, management may where it deems fit elect to apply the optional test to identify concentration of fair value permitted under IFRS&#160;3 in order to determine whether a transaction is a business combination within the meaning of IFRS&#160;3, or merely the acquisition of an asset or of a group of similar assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.3.2. Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The excess of the cost of an acquisition over Sanofi&#x2019;s interest in the fair value of the identifiable assets and liabilities of the acquiree is recognized as goodwill at the date of the business combination. Goodwill arising on the acquisition of subsidiaries is shown in a separate balance sheet line item, whereas goodwill arising on the acquisition of investments accounted for using the equity method is recorded in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Investments accounted for using the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Goodwill arising on foreign operations is expressed in the functional currency of the country concerned and translated into euros using the exchange rate prevailing at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;36 (Impairment of Assets), goodwill is carried at cost less accumulated impairment (see Note&#160;B.6.).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Such events or circumstances include significant changes more likely than not to have an other-than-temporary impact on the substance of the original investment.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory contextRef="c-1" id="f-645">Other intangible assets&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other intangible assets are initially measured at acquisition cost or production cost, including any directly attributable costs of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. Intangible assets are amortized on a straight line basis over their useful&#160;lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The useful lives of other intangible assets are reviewed at the end of each reporting period. The effect of any adjustment to useful lives is recognized prospectively as a change in accounting estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Amortization of other intangible assets is recognized in the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; except for amortization charged against (i)&#160;acquired or internally-developed software and (ii)&#160;other rights of an industrial or operational nature, which is recognized in the relevant classification of expense by function.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi does not own any intangible assets with an indefinite useful life, other than goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Intangible assets (other than goodwill) are carried at cost less accumulated amortization and accumulated impairment, if any, in accordance with IAS&#160;36 (see Note&#160;B.6.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.4.1. Research and development not acquired in a business combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Internally generated research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IAS&#160;38, research expenses are recognized in profit or loss when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Internally generated development expenses are recognized as an intangible asset if, and only if, all the following six criteria can be demonstrated: (a)&#160;the technical feasibility of completing the development project; (b)&#160;Sanofi&#x2019;s intention to complete the project; (c)&#160;Sanofi&#x2019;s ability to use the project; (d)&#160;the probability that the project will generate future economic benefits; (e)&#160;the availability of adequate technical, financial and other resources to complete the project; and (f)&#160;the ability to measure the development expenditure reliably.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Due to the risks and uncertainties relating to regulatory approval and to the research and development process, the six criteria for capitalization are usually considered not to have been met until the product has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Some industrial development expenses (such as those incurred in developing a second-generation synthesis process) are incurred after marketing approval has been obtained, in order to improve the industrial process for an active ingredient. To the extent that the six IAS&#160;38 criteria are considered as having been met, such expenses are recognized as an asset in the balance sheet within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; as incurred. Similarly, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS&#160;38, in which case the related expenses are recognized as an asset in the balance sheet within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separately acquired research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Payments for separately acquired research and development are capitalized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; provided that they meet the definition of an intangible asset: a resource that is (i)&#160;controlled by Sanofi, (ii)&#160;expected to provide future economic benefits for Sanofi, and (iii)&#160;identifiable (i.e.&#160;it is either separable or arises from contractual or legal rights). Under paragraph&#160;25 of&#160;IAS&#160;38, the first condition for capitalization (the probability that the expected future economic benefits from the asset will flow to the entity) is considered to be satisfied for separately acquired research and development. Consequently, upfront and milestone payments to third parties related to pharmaceutical products for which marketing approval has not yet been obtained are recognized as intangible assets, and amortized on a straight line basis over their useful lives beginning when marketing approval is&#160;obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Payments under research and development arrangements relating to access to technology or to databases, and payments made to purchase generics dossiers, are also capitalized, and amortized over the useful life of the intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Subcontracting arrangements, payments for research and development services, and continuous payments under research and development collaborations which are unrelated to the outcome of that collaboration, are expensed over the service term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.4.2. Other intangible assets not acquired in a business combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Licenses other than those related to pharmaceutical products and research projects, in particular software licenses, are capitalized at acquisition cost, including any directly attributable cost of preparing the software for its intended use. Software licenses are amortized on a straight line basis over their useful lives for Sanofi (&lt;span style="-sec-ix-hidden:f-646"&gt;three&lt;/span&gt; to five years).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Internally generated costs incurred to develop or upgrade software are capitalized if the IAS&#160;38 recognition criteria are satisfied, and amortized on a straight line basis over the useful life of the software from the date on which the software is ready for use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.4.3. Other intangible assets acquired in a business combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other intangible assets acquired in a business combination (in-process research and development, technology platforms, and currently marketed products) that are reliably measurable are identified separately from goodwill, measured at fair value, and capitalized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in accordance with IFRS&#160;3 (Business Combinations) and IAS&#160;38 (Intangible Assets). The related deferred tax liability is also recognized if a deductible or taxable temporary difference exists.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In-process research and development acquired in a business combination is amortized on a straight line basis over its useful life from the date of receipt of marketing approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Rights to technology platforms and to products currently marketed by Sanofi are amortized on a straight line basis over their useful lives, determined (in particular for marketed products) on the basis of cash flow forecasts which take into account the patent protection period of the marketed product.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-82" id="f-647">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-648">Property, plant and equipment owned and leased&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.5.1. Property, plant and equipment owned&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in&#160;the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Subsequent costs are not recognized as assets unless (i)&#160;it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii)&#160;the costs can be measured reliably.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the&#160;item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they&#160;relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The customary useful lives of property, plant and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.129%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;to&#160;40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10 to 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5 to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.5.2. Property, plant and equipment leased&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Effective from January&#160;1, 2019 leases contracted by Sanofi have been accounted for in accordance with IFRS&#160;16 (Leases). Sanofi recognizes a right-of-use asset and a lease liability for all of its lease contracts, except for (i)&#160;leases relating to low-value assets and&#160;(ii)&#160;short-term leases (12&#160;months or less). Payments made in respect of leases not recognized on the balance sheet are recognized as an operating expense on a straight line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On commencement of a lease, the liability for future lease payments is discounted at the incremental borrowing rate, which is a risk-free rate adjusted to reflect the specific risk profile of each Sanofi entity. Because lease payments are spread over the lease term, Sanofi applies a discount rate based on the duration of those payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The payments used to determine the liability for future lease payments exclude non-lease components, but include fixed payments that Sanofi expects to make to the lessor over the estimated lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;After commencement of the lease, the liability for future lease payments is reduced by the amount of the lease payments made, and increased to reflect interest on the liability. In the event of a reassessment or modification of future lease payments, the lease liability is remeasured. The right-of-use asset &#x2013;&#160;which is initially measured at cost including direct costs of the lessee, prepayments made at or prior to the commencement date, less lease incentives received and restoration costs&#160;&#x2013; is depreciated on a straight line basis over the lease term, and tested for impairment as required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi recognizes deferred taxes in respect of right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Leasehold improvements are depreciated over their economic life, which is capped at the lease term as determined under&#160;IFRS&#160;16.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <sny:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock contextRef="c-1" id="f-649">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The customary useful lives of property, plant and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.129%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;to&#160;40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10 to 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5 to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-83" id="f-650">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-84" id="f-651">P40Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-85" id="f-652">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-86" id="f-653">P20Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-87" id="f-654">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-88" id="f-655">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-89" id="f-656">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-90" id="f-657">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="c-1" id="f-658">Impairment of property, plant and equipment, intangible assets, and&#160;investments accounted for using the equity method&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.6.1. Impairment of property, plant and equipment and intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;36 (Impairment of Assets), assets that generate separate cash flows and assets included in cash-generating units&#160;(CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. A&#160;CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IAS&#160;36, each CGU or group of CGUs to which goodwill is allocated must (i)&#160;represent the lowest level within the entity at which the goodwill is monitored for internal management purposes, and (ii)&#160;not be larger than an operating segment determined in accordance with IFRS&#160;8 (Operating Segments), before application of the IFRS&#160;8 aggregation criteria (see Note&#160;B.26.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Quantitative and qualitative indications of impairment (primarily relating to the status of the research and development portfolio, pharmacovigilance, patent litigation, and the launch of competing products) are reviewed at the end of each reporting period. If there is any internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset or CGU.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other intangible assets not yet available for use (such as capitalized in-process research and development), and CGUs or groups of CGUs that include goodwill, are tested for impairment annually whether or not there is any indication of impairment, and more frequently if any event or circumstance indicates that they might be impaired. Such assets are not amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;When there is an internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. To determine value in use, Sanofi uses estimates of future cash flows generated by the asset or CGU, prepared using the same methods as those used in the initial measurement of the asset or CGU on the basis of medium-term strategic plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the case of goodwill, estimates of future cash flows are based on a six-year strategic plan and a terminal value. In the case of other intrangible assets, the period used is based on the economic life of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Estimated cash flows are discounted at long-term market interest rates that reflect the best estimate by Sanofi of the time value of money, the risks specific to the asset or CGU, and economic conditions in the geographical regions in which the business activity associated with the asset or CGU is located.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities that are not directly attributable to a specific CGU are allocated between CGUs on a basis that is reasonable, and consistent with the allocation of the corresponding goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Impairment losses arising on property, plant and equipment, software and certain rights, are recognized within the appropriate income statement line item according to the origin of the impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Impairment losses arising on other intangible assets (products, trademarks, technology platforms, acquired R&amp;amp;D) are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the income statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.6.2. Impairment of investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), Sanofi determines whether investments accounted for using the equity method may be impaired based on indicators such as default in contractual payments, significant financial difficulties, probability of bankruptcy, or a prolonged or significant decline in quoted market price. If an investment is impaired, the amount of the impairment loss is determined by applying IAS&#160;36 (see Note&#160;B.6.1.) and recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share of profit/(loss) from investments accounted for using the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.6.3. Reversals of impairment losses charged against property, plant and equipment, intangible assets, and investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;At the end of each reporting period, Sanofi assesses whether events or changes in circumstances indicate that an impairment loss recognized in a prior period in respect of an asset (other than goodwill) or an investment accounted for using the equity method can be reversed. If this is the case, and the recoverable amount as determined based on the revised estimates exceeds the carrying amount of the asset, Sanofi reverses the impairment loss only to the extent of the carrying amount that would have been determined had no impairment loss been recognized for the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Reversals of impairment losses in respect of other intangible assets are recognized within the income statement line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, while reversals of impairment losses in respect of investments accounted for using the equity method are recognized within the income statement line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Impairment losses taken against goodwill are never reversed, unless the goodwill is part of the carrying amount of an investment accounted for using the equity method.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory contextRef="c-1" id="f-659">Assets held for sale or exchange and liabilities related to assets held for sale or exchange&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;5 (Non-Current Assets Held for Sale and Discontinued Operations), non-current assets and groups of assets are classified as held for sale in the balance sheet if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Within the meaning of IFRS&#160;5, the term &#x201c;sale&#x201d; also includes exchanges for other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Non-current assets or asset groups held for sale must be available for immediate sale in their present condition, subject only to terms that are usual and customary for sales of such assets, and a sale must be highly probable. Criteria used to determine whether a sale is highly probable include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the appropriate level of management must be committed to a plan to sell;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;an active program to locate a buyer and complete the plan must have been initiated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;completion of the sale should be foreseeable within the 12&#160;months following the date of reclassification to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Before initial reclassification of the non-current asset (or asset group) to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Subsequent to reclassification to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held-for-sale assets or liabilities within the balance sheet line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;or&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Liabilities related to assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, provided that the disposal satisfies the IFRS&#160;5 classification criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The profit or loss generated by a held-for-sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;represents a separate major line of business or geographical area of operations; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;is a subsidiary acquired exclusively with a view to resale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;10, transactions between companies that are held for sale or treated as discontinued operations and other consolidated companies are eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Events or circumstances beyond Sanofi&#x2019;s control may extend the period to complete the sale or exchange beyond one year without precluding classification of the asset (or disposal group) in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; provided that there is sufficient evidence that Sanofi remains committed to the planned sale or exchange. Finally, in the event of changes to a plan of sale that requires an asset no longer to be classified as held for sale, IFRS&#160;5 specifies the following treatment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;each asset is measured at the lower of (a)&#160;its carrying amount before the asset was reclassified as held for sale, adjusted for any depreciation, amortization or revaluation that would have been recognized if the asset had not been reclassified as held for sale, or&#160;(b)&#160;its recoverable amount at the date of reclassification;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the backlog of depreciation, amortization and impairment not recognized while non-current assets were classified as held for sale must be reported in the same income statement line item that was used to report impairment losses arising on initial reclassification of assets as held for sale and gains or losses arising on the sale of such assets. In the consolidated income statement, those impacts are reported within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the net income of a business previously classified as discontinued or as held for sale or exchange and reported on a separate line in the income statement must be reclassified and included in net income from continuing operations, for all periods presented;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;in addition, segment information relating to the income statement and the statement of cash flows (acquisitions of non-current assets) must be disclosed in the notes to the financial statements in accordance with IFRS&#160;8 (Operating Segments), and must also be restated for all prior periods presented.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c-1" id="f-660">Financial instruments&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.1. Non-derivative financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;9 (Financial Instruments) and IAS&#160;32 (Financial Instruments: Presentation), Sanofi has adopted the classification of non-derivative financial assets described below. The classification used depends on (i)&#160;the characteristics of the contractual cash flows (i.e.&#160;whether they represent interest or principal) and (ii)&#160;the business model for managing the asset applied at the time of initial recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial assets at fair value through other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These mainly comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;quoted and unquoted equity investments that Sanofi does not hold for trading purposes and that management has designated at &#x201c;fair value through other comprehensive income&#x201d; on initial recognition. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such instruments are derecognized, the previously-recognized changes in fair value remain within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, as does the gain or loss on divestment. Dividends received are recognized in profit or loss for the period, within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial assets at fair value through profit or loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These mainly comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;contingent consideration already carried in the books of an acquired entity or granted in connection with a business combination;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;instruments whose contractual cash flows represent payments of interest and repayments of principal, which are managed with a view to selling the asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;instruments that management has designated at &#x201c;fair value through profit or loss&#x201d; on initial recognition; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;quoted and unquoted equity investments: equity instruments that are not held for trading and which management did not designate at &#x201c;fair value through other comprehensive income&#x201d; on initial recognition, and instruments that do not meet the IFRS definition of &#x201c;equity instruments&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Gains and losses arising from changes in fair value are recognized in profit or loss within the line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Dividends received are recognized in profit or loss for the period, within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of equity investments in unquoted entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On initial recognition of an equity investment in an entity not quoted in an active market, the fair value of the investment is the acquisition cost. Cost ceases to be a representative measure of the fair value of an unquoted equity investment when Sanofi identifies significant changes in the investee, or in the environment in which it operates. In such cases, an internal valuation is carried out, based mainly on growth forecasts or by reference to similar transactions contracted with third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Financial assets at amortized cost comprise instruments whose contractual cash flows represent payments of interest and repayments of principal and which are managed with a view to collecting cash flows. The main assets in this category are loans and receivables. They are presented within the line items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Other non-current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Accounts receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Loans with a maturity of more than 12&#160;months are presented in &#x201c;Long-term loans and advances&#x201d; within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other non-current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. These financial assets are measured at amortized cost using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of financial assets measured at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The main assets involved are accounts receivable. Accounts receivable are initially recognized at the amount invoiced to the customer. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and general expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the income statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.2. Derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Derivative instruments that do not qualify for hedge accounting are initially and subsequently measured at fair value, with changes in fair value recognized in the income statement in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, depending on the nature of the underlying economic item which is hedged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Derivative instruments that qualify for hedge accounting are measured using the policies described in Note&#160;B.8.3. below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;IFRS&#160;13 (Fair Value Measurement) requires counterparty credit risk to be taken into account when measuring the fair value of financial instruments. That risk is estimated on the basis of observable, publicly-available statistical data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Policy on offsetting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In order for a financial asset and a financial liability to be presented as a net amount in the balance sheet under IAS&#160;32, there must be:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(a) a legally enforceable right to offset; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(b) the intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.3. Hedging&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As part of its overall market risk management policy, Sanofi enters into various hedging transactions involving derivative or non-derivative instruments; these may include forward contracts, currency swaps or options, interest rate swaps or options, cross-currency swaps, and debt placings or issues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Such financial instruments are designated as hedging instruments and recognized using the hedge accounting principles of&#160;IFRS&#160;9 when (a)&#160;there is formal designation and documentation of the hedging relationship, of how the effectiveness of the hedging relationship will be assessed, and of the underlying market risk management objective and strategy; (b)&#160;the hedged item and the hedging instrument are eligible for hedge accounting; and (c)&#160;there is an economic relationship between the hedged item and the hedging instrument, defined on the basis of a hedge ratio that is consistent with the underlying market risk management strategy, and the residual credit risk does not dominate the value changes that result from that economic relationship.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value hedge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A fair value hedge is a hedge of the exposure to changes in fair value of an asset, liability or firm commitment that is attributable to one or more risk components and could affect profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in fair value of the hedging instrument and changes in fair value of the hedged item attributable to the hedged risk components are generally recognized in the income statement, within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for hedges related to operating activities, or within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for hedges related to investing or financing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash flow hedge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A cash flow hedge is a hedge of the exposure to variability in cash flows from an asset, liability or highly probable forecast transaction that is attributable to one or more risk components and could affect profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;for hedges related to operating activities, and within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for hedges related to investing or financing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Cumulative changes in fair value of the hedging instrument previously recognized in equity are reclassified to the income statement when the hedged transaction affects profit or loss. Those reclassified gains and losses are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for hedges related to operating activities, and within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for hedges related to investing or financing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;When a forecast transaction results in the recognition of a non-financial asset or liability, cumulative changes in the fair value of the hedging instrument previously recognized in equity are incorporated in the initial carrying amount of that asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;When the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss previously recognized in equity remains separately recognized in equity and is not reclassified to the income statement, or recognized as an adjustment to the initial cost of the related non-financial asset or liability, until the forecast transaction occurs. However, if Sanofi no longer expects the forecast transaction to occur, the cumulative gain or loss previously recognized in equity is recognized immediately in profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Hedge of a net investment in a foreign operation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In a hedge of a net investment in a foreign operation, changes in the fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. When the investment in the foreign operation is sold, the changes in the fair value of the hedging instrument previously recognized in equity are reclassified to the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of hedging&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As part of its market risk management policy, Sanofi may designate currency options or interest rate options as hedging instruments, the effectiveness of which is measured on the basis of changes in intrinsic value. In such cases, the time value of the option is treated as a hedging cost and accounted for as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;if the option includes a component that is not aligned on the critical features of the hedged item, the corresponding change in the time value is taken to profit or loss;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;otherwise, the change in the time value is taken to equity within the statement of comprehensive income, and then:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;if the hedged item is linked to a transaction that results in the recognition of a financial asset or liability, the change in the time value is reclassified to profit or loss symmetrically with the hedged item, or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;if the hedged item is linked to a transaction that results in the recognition of a non-financial asset or liability, the change in the time value is incorporated in the initial carrying amount of that asset or liability, or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;if the hedged item is linked to a period of time, the change in time value is reclassified to profit or loss on a straight line basis over the life of the hedging relationship.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the case of forward contracts and foreign exchange swaps, and of cross-currency swaps that qualify for hedge accounting on the basis of changes in spot rates, Sanofi may elect for each transaction to use the option whereby the premium/discount or foreign currency basis spread are treated in the same way as the time value of an option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Discontinuation of hedge accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Hedge accounting is discontinued when the eligibility criteria are no longer met (in particular, when the hedging instrument expires or is sold, terminated or exercised), or if there is a change in the market risk management objective of the hedging relationship.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.4. Non-derivative financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Borrowings and debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the income statement over the term of the debt using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These line items record the fair value of (i)&#160;contingent consideration payable in connection with business combinations and (ii)&#160;commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Adjustments to the fair value of commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests, are recognized in equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other non-derivative financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other non-derivative financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.5. Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IFRS&#160;13 (Fair Value Measurement) and IFRS&#160;7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt"&gt;level&#160;1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt"&gt;level&#160;2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt"&gt;level&#160;3: valuation techniques in which not all important inputs are derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS&#160;7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.863%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.362%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Type&#160;of financial&#160;instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement&lt;br/&gt;principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in&lt;br/&gt;fair&#160;value&lt;br/&gt;hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation&lt;br/&gt;technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation&lt;br/&gt;model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Cost/Approach based on comparables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the&#160;end of the reporting period using the method described in&#160;Note&#160;D.7.3.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value held&#160;to meet obligations under &lt;br/&gt;post-employment benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.13.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.13.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than three&#160;months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the&#160;consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.17.1., D.19.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.17.2.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;The liability for future lease payments is discounted using the&#160;incremental borrowing rate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.20.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&lt;br/&gt;Market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1&#160; year:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid Money Market&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;gt;&#160;1&#160;year:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.20.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&lt;br/&gt;Market&lt;br/&gt;Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1&#160;year:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&#160;Money&#160;Market  and LIFFE interest rate futures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;gt;&#160;1&#160;year: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&#160;Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.20.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Present&#160;value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&lt;br/&gt;Market&lt;br/&gt;Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1&#160; year:&lt;br/&gt;Mid&#160;Money Market and LIFFE interest rate futures&lt;br/&gt;&amp;gt;&#160;1&#160;year: &lt;br/&gt;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests (CVRs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests (other than CVRs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Under IAS&#160;32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note&#160;B.8.4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.6. Derecognition of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Financial assets are derecognized when the contractual rights to cash flows from the asset have ended or have been transferred and when Sanofi has transferred substantially all the risks and rewards of ownership of the asset. If Sanofi has neither transferred nor retained substantially all the risks and rewards of ownership of a financial asset, it is derecognized if Sanofi does not retain control of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A financial liability is derecognized when Sanofi&#x2019;s contractual obligations in respect of the liability are discharged, cancelled or extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.8.7. Risks relating to financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Market risks in respect of non-current financial assets, cash equivalents, derivative instruments and debt are described in the discussions of risk factors presented in Item&#160;3.D. and Item&#160;11. of Sanofi&#x2019;s annual report on Form&#160;20-F for 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Credit risk is the risk that customers may fail to pay their debts. For a description of credit risk, refer to &#x201c;We are subject to the risk of non-payment by our customers&#x201d; within Item&#160;3.D. and Item&#160;11. of Sanofi&#x2019;s annual report on Form&#160;20-F for 2023.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c-1" id="f-661">&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the disclosures required under IFRS&#160;7 relating to the measurement principles applied to financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.863%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.362%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Type&#160;of financial&#160;instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement&lt;br/&gt;principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in&lt;br/&gt;fair&#160;value&lt;br/&gt;hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation&lt;br/&gt;technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Method used to determine fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation&lt;br/&gt;model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market&#160;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (quoted debt instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (unquoted equity instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Cost/Approach based on comparables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value (contingent consideration receivable)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the&#160;end of the reporting period using the method described in&#160;Note&#160;D.7.3.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets measured at fair value held&#160;to meet obligations under &lt;br/&gt;post-employment benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Financial assets designated at fair value held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.13.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Net asset value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.13.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Negotiable debt instruments, commercial paper, instant access deposits and term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Because these instruments have a maturity of less than three&#160;months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the&#160;consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.17.1., D.19.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.17.2.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;The liability for future lease payments is discounted using the&#160;incremental borrowing rate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.20.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Forward currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&lt;br/&gt;Market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1&#160; year:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid Money Market&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;gt;&#160;1&#160;year:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.20.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Present value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&lt;br/&gt;Market&lt;br/&gt;Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1&#160;year:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&#160;Money&#160;Market  and LIFFE interest rate futures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;gt;&#160;1&#160;year: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&#160;Zero Coupon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.20.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Present&#160;value of future cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mid&lt;br/&gt;Market&lt;br/&gt;Spot&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&amp;lt;&#160;1&#160; year:&lt;br/&gt;Mid&#160;Money Market and LIFFE interest rate futures&lt;br/&gt;&amp;gt;&#160;1&#160;year: &lt;br/&gt;Mid Zero Coupon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests (CVRs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Quoted market price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Liabilities related to business combinations and to non-controlling interests (other than CVRs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Revenue-based approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Under IAS&#160;32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note&#160;B.8.4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="c-1" id="f-662">Inventories&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Inventories are measured at the lower of cost or net realizable value. Cost is calculated using the weighted average cost method or the first-in, first-out method, depending on the nature of the inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The cost of finished goods inventories includes costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During the launch phase of a new product, any inventories of that product are written down to zero pending regulatory approval, other than in specific circumstances which make it possible to estimate that there is a high probability at the end of the reporting period that the carrying amount of the inventories will be recoverable. The write-down is reversed once it becomes highly probable that marketing approval will be obtained.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents contextRef="c-1" id="f-663">Cash and cash equivalents&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents as shown in the consolidated balance sheet and statement of cash flows comprise cash, plus liquid short-term investments that are&#160;readily convertible into cash and are&#160;subject to an insignificant risk of changes in value in the event of movements in interest rates.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory contextRef="c-1" id="f-664">Treasury shares&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;32, Sanofi treasury shares are deducted from equity, irrespective of the purpose for which they are held. No gain or loss is recognized in the income statement on the purchase, sale, impairment or cancellation of treasury shares.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory>
    <sny:GainLossOnImpairmentOfTreasuryShares contextRef="c-1" decimals="INF" id="f-665" unitRef="eur">0</sny:GainLossOnImpairmentOfTreasuryShares>
    <sny:GainLossOnPurchaseOfTreasuryShares contextRef="c-1" decimals="INF" id="f-666" unitRef="eur">0</sny:GainLossOnPurchaseOfTreasuryShares>
    <sny:GainLossOnCancellationOfTreasuryShares contextRef="c-1" decimals="INF" id="f-667" unitRef="eur">0</sny:GainLossOnCancellationOfTreasuryShares>
    <sny:GainLossOnSaleOfTreasuryShares contextRef="c-1" decimals="INF" id="f-668" unitRef="eur">0</sny:GainLossOnSaleOfTreasuryShares>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="c-1" id="f-669">Provisions for risks&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;37 (Provisions, Contingent Liabilities and Contingent Assets), Sanofi records a provision when it has a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;If the obligation is expected to be settled more than 12&#160;months after the end of the reporting period, or has no definite settlement date, the provision is recorded within Non-current provisions and other non-current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Provisions relating to the insurance programs in which Sanofi&#x2019;s captive insurance company participates are based on risk exposure estimates calculated by management, with assistance from independent actuaries, using IBNR (Incurred But Not Reported) techniques. Those techniques use past claims experience, within Sanofi and in the market, to estimate future trends in the cost of&#160;claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Contingent liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow of economic resources is&#160;remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi estimates provisions on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management&#x2019;s knowledge at the date of preparation of the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Reimbursements offsetting the probable outflow of resources are recognized as assets only if it is virtually certain that they will be received. Contingent assets are not recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restructuring provisions are recognized if Sanofi has a detailed, formal restructuring plan at the end of the reporting period and has announced its intention to implement this plan to those affected by it.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No provisions are recorded for future operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi records non-current provisions for certain obligations, such as legal or constructive obligations, where an outflow of resources is probable and the amount of the outflow can be reliably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the case of environmental risks, including at sites where operations are ongoing, Sanofi recognizes a provision where there is a violation of integrity in respect of human health or the environment resulting from past contamination at a site that requires remediation. The amount of the provision is a best estimate of the future expenditures to be incurred on the remediation plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Where the effect of the time value of money is material, those provisions are measured at the present value of the expenditures expected to be required to settle the obligation, calculated using a discount rate that reflects an estimate of the time value of money and the risks specific to the obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Increases in provisions to reflect the effects of the passage of time are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <sny:ProvisionsRecordedForFutureOperatingLosses contextRef="c-1" decimals="INF" id="f-670" unitRef="eur">0</sny:ProvisionsRecordedForFutureOperatingLosses>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="c-1" id="f-671">Revenue recognition&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.13.1. Net sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Revenue arising from the sale of goods is presented in the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Net sales comprise revenue from sales of pharmaceutical products, consumer healthcare products, active ingredients and vaccines, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. Analyses of net sales are provided in Note&#160;D.35.1. &#x201c;Segment Information&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;15 (Revenue from Contracts with Customers), such revenue is recognized when Sanofi transfers control over the product to the customer; control of an asset refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from that asset. For the vast majority of contracts, revenue is recognized when the product is physically transferred, in accordance with the delivery and acceptance terms agreed with the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For contracts entered into by Sanofi Pasteur, transfer of control is usually determined by reference to the terms of release (immediate or deferred) and acceptance of batches of vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the case of contracts with distributors, Sanofi does not recognize revenue when the product is physically transferred to the distributor if the products are sold on consignment, or if the distributor acts as agent. In such cases, revenue is recognized when control is transferred to the end customer, and the distributor&#x2019;s commission is presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and general expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the income statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized reflects the various types of price reductions or rights of return offered by Sanofi to its customers on certain products. Such price reductions and rights of return qualify as variable consideration under IFRS&#160;15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In particular, products sold in the United States are covered by various Government and State programs (such as Medicare and Medicaid) under which products are sold at a discount. Rebates are granted to healthcare authorities, and under contractual arrangements with certain customers. Some wholesalers are entitled to chargeback incentives based on the selling price to the end customer, under specific contractual arrangements. Cash discounts may also be granted for prompt payment. Returns, discounts, incentives and rebates, as described above, are recognized in the period in which the underlying sales are recognized as a reduction of gross sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These amounts are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of chargeback incentives is estimated on the basis of the relevant subsidiary&#x2019;s standard sales terms and conditions, and in certain cases on the basis of specific contractual arrangements with the customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of rebates based on attainment of sales targets is estimated and accrued as each of the underlying sales transactions is recognized;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of price reductions under Government and State programs, largely in the United States, is estimated on the basis of the specific terms of the relevant regulations or agreements, and accrued as each of the underlying sales transactions is recognized;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the amount of sales returns is calculated on the basis of management&#x2019;s best estimate of the amount of product that will ultimately be returned by customers. In countries where product returns are possible, Sanofi operates a returns policy that allows the customer to return products within a certain period either side of the expiry date (usually 12&#160;months after the expiry date). The amount recognized for returns is estimated on the basis of past experience of sales returns. Sanofi also takes into account factors such as levels of inventory in its various distribution channels, product expiry dates, information about potential discontinuation of products, the entry of competing generics into the market, and the launch of over-the-counter medicines. Most product return clauses relate solely to date-expired products, which cannot be resold and are destroyed. Sanofi does not recognize a right of return asset in the balance sheet for contracts that allow for the return of time-expired products, since those products have no value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The estimated amounts described above are recognized in the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;as a reduction of gross sales, and within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the balance sheet. They are subject to regular review and adjustment as appropriate based on the most recent data available to management. Sanofi believes that it has the ability to measure each of the above amounts reliably, using the following factors in developing its estimates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the nature and patient profile of the underlying product;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the applicable regulations or the specific terms and conditions of contracts with governmental authorities, wholesalers and other customers;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;historical data relating to similar contracts, in the case of qualitative and quantitative rebates and chargeback incentives;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;past experience and sales growth trends for the same or similar products;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;actual inventory levels in distribution channels, monitored by Sanofi using internal sales data and externally provided data;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the shelf life of Sanofi products; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;market trends including competition, pricing and demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of provisions for discounts, rebates and sales returns is provided in Note&#160;D.23.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.13.2. Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; is used to recognize all revenue that falls within the scope of IFRS&#160;15 but does not relate to sales of Sanofi products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It mainly comprises (i)&#160;royalties received from licensing intellectual property rights to third parties; (ii)&#160;VaxServe sales of products sourced from third-party manufacturers; and (iii)&#160;revenue received under agreements for Sanofi to provide manufacturing services to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Royalties received under licensing arrangements are recognized over the period during which the underlying sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;VaxServe is a Vaccines segment entity whose operations include the distribution within the United States of vaccines and other&#160;products manufactured by third parties. VaxServe sales of products sourced from third-party manufacturers are presented within&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <sny:DescriptionOfAccountingPolicyForCostOfSalesExplanatory contextRef="c-1" id="f-672">Cost of sales&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; consists primarily of the industrial cost of goods sold, payments made under licensing agreements, and distribution costs. The industrial cost of goods sold includes the cost of materials, depreciation of property, plant and equipment, amortization of software, personnel costs, and other expenses attributable to production.&lt;/span&gt;&lt;/div&gt;</sny:DescriptionOfAccountingPolicyForCostOfSalesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c-1" id="f-673">Research and development&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Note&#160;B.4.1. &#x201c;Research and development not acquired in a business combination&#x201d; and Note&#160;B.4.3. &#x201c;Other intangible assets acquired in a business combination&#x201d; describe the principles applied to the recognition of research and development costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Contributions or reimbursements received from alliance partners are recorded as a reduction of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <sny:DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock contextRef="c-1" id="f-674">Other operating income and expenses&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.16.1. Other operating income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; includes the share of profits that Sanofi is entitled to receive from alliance partners in respect of product marketing agreements. It also includes revenues generated under certain agreements, which may include partnership, co-promotion arrangements and licenses not included in Other revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This line item also includes realized and unrealized foreign exchange gains and losses on operating activities (see Note&#160;B.8.3.), and operating gains on disposals not regarded as major disposals (see Note&#160;B.20.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.16.2. Other operating expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; mainly comprise the share of profits that alliance partners are entitled to receive from Sanofi under product marketing agreements.&lt;/span&gt;&lt;/div&gt;</sny:DescriptionOfAccountingPolicyForOtherOperatingIncomeAndExpensesExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="c-1" id="f-675">Amortization and impairment of intangible assets&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.17.1. Amortization of intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The expenses recorded in this line item comprise amortization charged against intangible assets (products, trademarks and technology platforms, see Note&#160;D.4.) whose contribution to Sanofi&#x2019;s commercial, industrial and development functions cannot be separately identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Amortization of software, and of other rights of an industrial or operational nature, is recognized as an expense in the income statement, in the relevant line items of expense by function.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.17.2. Impairment of intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This line item records impairment losses taken against intangible assets (products, trademarks, technology platforms and acquired research), and any reversals of such impairment losses.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <sny:DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock contextRef="c-1" id="f-676">Fair value remeasurement of contingent consideration&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of contingent consideration that was (i)&#160;already carried in the books of an acquired entity, or (ii)&#160;granted in connection with a business combination and initially recognized as a liability in accordance with IFRS&#160;3, are reported in profit or loss. Such adjustments are reported separately in the income statement, in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This line item also includes changes in the fair value of contingent consideration receivable in connection with a divestment and classified as a financial asset at fair value through profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Finally, it includes the effect of the unwinding of discount, and of exchange rate movements where the asset or liability is expressed in a currency other than the functional currency of the reporting entity.&lt;/span&gt;&lt;/div&gt;</sny:DescriptionOfAccountingPolicyForFairValueRemeasurementOfContingentConsiderationLiabilitiesExplanatoryPolicyTextBlock>
    <sny:DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock contextRef="c-1" id="f-677">Restructuring costs and similar items&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restructuring costs are expenses incurred in connection with the transformation or reorganization of Sanofi&#x2019;s operations or support functions. Such costs include collective redundancy plans, compensation to third parties for early termination of contracts, and commitments made in connection with transformation or reorganization decisions. They also include accelerated depreciation charges arising from site closures (including closures of leased sites), and losses on asset disposals resulting from such decisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, this line item includes expenses incurred in connection with programs implemented as part of the transformation strategy announced in December&#160;2019 (and previously in November&#160;2015), and intended primarily (i)&#160;to deliver a global information systems solution, further supported by the implementation from 2021 of Sanofi&#x2019;s new digital strategy; and (ii)&#160;to create a standalone CHC entity and proceed to the proposed separation of the CHC business as announced when the new chapter in the Play to Win strategy was presented in October&#160;2023.&lt;/span&gt;&lt;/div&gt;</sny:DescriptionOfAccountingPolicyForRestructuringCostsAndSimilarItemsPolicyTextBlock>
    <sny:DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock contextRef="c-1" id="f-678">Other gains and losses, and litigation&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; includes the impact of material transactions of an unusual nature or amount which Sanofi believes it necessary to report separately in the income statement in order to improve the relevance of the financial statements, such as:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;gains and losses on major disposals of property, plant and equipment, of intangible assets, of assets (or groups of assets and liabilities) held for sale, or of a business within the meaning of IFRS&#160;3, other than those considered to be restructuring costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;impairment losses and reversals of impairment losses on assets (or groups of assets and liabilities) held for sale, other than those considered to be restructuring costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;gains on bargain purchases;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;costs relating to major litigation; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;pre-tax separation costs associated with the process of disinvesting from operations in the event of a major divestment.&lt;/span&gt;&lt;/div&gt;</sny:DescriptionOfAccountingPolicyForOtherGainsAndLossesAndLitigationExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="c-1" id="f-679">Financial expenses and income&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.21.1. Financial expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; mainly comprise interest charges on debt financing; negative changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange losses on financing and investing activities; impairment losses on financial instruments; and any reversals of impairment losses on financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; also include expenses arising from the unwinding of discount on long-term provisions, and the net interest cost related to employee benefits. This line item does not include commercial cash discounts, which are deducted from net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.21.2. Financial income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; includes interest and dividend income; positive changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange gains on financing and investing activities; and gains on disposals of financial assets at fair value through profit or loss.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="c-1" id="f-680">Income tax expense&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;includes all current and deferred taxes of consolidated companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi accounts for deferred taxes in accordance with IAS&#160;12 (Income Taxes), using the methods described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;deferred tax assets and liabilities are recognized on taxable and deductible temporary differences, and on tax loss carry-forwards. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;French business taxes include a value added based component: &#x201c;CVAE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Cotisation sur la Valeur Ajout&#xe9;e des Entreprises)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Given that CVAE is (i)&#160;calculated as the amount by which certain revenues exceed certain expenses and (ii)&#160;borne primarily by companies that own intellectual property rights on income derived from those rights (royalties, and margin on sales to third parties and to Sanofi entities), it is regarded as meeting the definition of income taxes specified in IAS&#160;12, paragraph&#160;2 (&#x201c;taxes which are based on taxable profits&#x201d;);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;deferred tax assets and liabilities are calculated using the tax rate expected to apply in the period when the corresponding temporary differences are expected to reverse, based on tax rates enacted or substantively enacted at the end of the reporting period;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;deferred tax assets are recognized in respect of deductible temporary differences, tax losses available for carry-forward and unused tax credits to the extent that future recovery is regarded as probable. The recoverability of deferred tax assets is assessed on a case-by-case basis, taking into account the profit forecasts contained in Sanofi&#x2019;s medium-term business plan;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a deferred tax liability is recognized for temporary differences relating to interests in subsidiaries, associates and joint ventures, except in cases where Sanofi is able to control the timing of the reversal of the temporary differences. This applies in particular when Sanofi is able to control dividend policy and it is probable that the temporary differences will not reverse in the foreseeable future;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;no deferred tax is recognized on eliminations of intragroup transfers of interests in subsidiaries, associates or joint ventures;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;each tax entity calculates its own net deferred tax position. All net deferred tax asset and liability positions are then aggregated and shown in separate line items on the relevant side of the consolidated balance sheet. Deferred tax assets and liabilities are offset only if (i)&#160;Sanofi has a legally enforceable right to offset current tax assets and current tax liabilities, and (ii)&#160;the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;deferred taxes are not discounted, except implicitly in the case of deferred taxes on assets and liabilities which are already impacted by discounting. In addition, Sanofi has elected not to discount current taxes payable or receivable where the amounts in question are payable or receivable in the long term;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;withholding taxes on intragroup royalties and dividends, and on royalties and dividends collected from third parties, are accounted for as current income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accounting for business combinations, Sanofi complies with IFRS&#160;3 as regards the recognition of deferred tax assets after the initial accounting period. Consequently, any deferred tax assets recognized by the acquiree after the end of that period in respect of temporary differences or tax loss carry-forwards existing at the acquisition date are recognized in profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The positions adopted by Sanofi in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, Sanofi assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of Sanofi&#x2019;s best estimate and recognized as a liability; uncertain tax assets are not recognized. The amount of the liability includes any penalties and late payment interest. The line item&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Income tax expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; includes the effects of tax reassessments and tax disputes, and any penalties and late payment interest arising from such disputes that have the characteristics of income taxes within the meaning of paragraph&#160;2 of IAS&#160;12 (&#x201c;taxes which are based on taxable profits&#x201d;). Tax exposures relating to corporate income taxes are presented separately within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-current income tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (see Note&#160;D.19.4.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No deferred taxation is recognized on temporary differences that are liable to be subject to US global intangible low taxed&#160;income (GILTI) provisions. The related tax expense is recognized in the year in which it is declared in the tax return to the extent that it arises from the existence of non-US profits that exceed the theoretical return on investment specified in the GILTI&#160;provisions and are taxed at a rate lower than the applicable US tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IAS&#160;1 (Presentation of Financial Statements), current income tax assets and liabilities are presented as separate line items in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-91" decimals="INF" id="f-681" unitRef="eur">0</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c-1" id="f-682">Employee benefit obligations&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi offers retirement benefits to employees and retirees. Such benefits are accounted for in accordance with IAS&#160;19 (Employee Benefits).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Benefits are provided in the form of either defined contribution plans or defined benefit plans. In the case of defined contribution plans, the cost is recognized immediately in the period in which it is incurred, and equates to the amount of the contributions paid by Sanofi. For defined benefit plans, Sanofi generally recognizes its obligations to pay pensions and similar benefits to employees as a liability, based on an actuarial estimate of the rights vested or currently vesting in employees and retirees, using the projected unit credit method. Estimates are performed at least once a year, and rely on financial assumptions (such as discount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;rates) and demographic assumptions (such as life expectancy, retirement age, employee turnover, and the rate of salary increases).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Obligations relating to other post-employment benefits (healthcare and life insurance) offered by Sanofi companies to employees are also recognized as a liability based on an actuarial estimate of the rights vested or currently vesting in employees and retirees at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Such liabilities are recognized net of the fair value of plan assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the case of multi-employer defined benefit plans where plan assets cannot be allocated to each participating employer with sufficient reliability, the plan is accounted for as a defined contribution plan, in accordance with paragraph&#160;34 of IAS&#160;19.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The benefit cost for the period consists primarily of current service cost, past service cost, net interest cost, gains or losses arising from plan settlements not specified in the terms of the plan, and actuarial gains or losses arising from plan curtailments. Net interest cost for the period is determined by applying the discount rate specified in IAS&#160;19 to the net liability (i.e. the amount of the obligation, net of plan assets) recognized in respect of defined benefit plans. Past service cost is recognized immediately in profit or loss in the period in which it is incurred, regardless of whether or not the rights have vested at the time of adoption (in&#160;the case of a new plan) or of amendment (in&#160;the case of an existing&#160;plan).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actuarial gains and losses on defined benefit plans (pensions and other post-employment benefits), also referred to as&#160;&#x201c;Remeasurements of the net defined benefit liability (asset)&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; arise as a result of changes in financial and demographic assumptions, experience adjustments, and the difference between the actual return and interest cost on plan assets. The impacts of those remeasurements are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, net of deferred taxes; they are not subsequently reclassifiable to profit or&#160;loss.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c-1" id="f-683">Share-based payment&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Share-based payment expense is recognized as a component of operating income, in the relevant classification of expense by function. In measuring the expense, the level of attainment of any performance conditions is taken into account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.24.1. Stock option plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has granted a number of equity-settled share-based payment plans (stock option plans) to some of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;2 (Share-Based Payment), services received from employees as consideration for stock options are recognized as an expense in the income statement, with the opposite entry recognized in equity. The expense corresponds to the fair value of the stock option plans, and is charged to income on a straight-line basis over the four-year vesting period of the plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The fair value of stock option plans is measured at the date of grant using the Black-Scholes valuation model, taking into account the expected life of the options. The resulting expense also takes into account the expected cancellation rate of the options. The expense is adjusted over the vesting period to reflect actual cancellation rates resulting from option-holders ceasing to be employed by Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.24.2. Employee share ownership plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi may offer its employees the opportunity to subscribe to reserved share issues at a discount to the reference market price. Shares awarded to employees under such plans fall within the scope of IFRS&#160;2. Consequently, an expense is recognized at the subscription date, based on the value of the discount offered to employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;B.24.3. Restricted share plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi may award restricted share plans to certain of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;2, an expense equivalent to the fair value of such plans is recognized in profit or loss on a straight line basis over the vesting period of the plan, with the opposite entry recognized in equity. The vesting period is three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The fair value of restricted share plans is based on the quoted market price of Sanofi shares at the date of grant, adjusted for expected dividends during the vesting period; it also takes account of any vesting conditions contingent on stock market performance, measured using the Monte-Carlo valuation model. Other vesting conditions are taken into account in the estimate of the number of shares awarded during the vesting period; that number is then definitively adjusted based on the actual number of shares awarded on the vesting date.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <sny:OptionVestingPeriod contextRef="c-92" id="f-684">P4Y</sny:OptionVestingPeriod>
    <sny:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod contextRef="c-93" id="f-685">P3Y</sny:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c-1" id="f-686">Earnings per share&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated using the weighted average number of shares outstanding during the reporting period, adjusted on a time-weighted basis from the acquisition date to reflect the number of own shares held by Sanofi. Diluted earnings per share is calculated on the basis of the weighted average number of ordinary shares, computed using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This method assumes that (i)&#160;all outstanding dilutive options and warrants are exercised, and (ii)&#160;Sanofi acquires its own shares at the quoted market price for an amount equivalent to the cash received as consideration for the exercise of the options or warrants, plus the expense arising on unamortized stock options.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="c-1" id="f-687">Segment information&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS&#160;8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People &amp;amp; Culture, Legal, Ethics, Business Integrity &amp;amp; Global Security, Information Solutions &amp;amp; Technology, Sanofi Business Services,&#160;etc.), which are mainly managed centrally at group-wide level, were presented within the &#x201c;Other&#x201d; category. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in&#160;order to reflect (i)&#160;progress on the &#x201c;Play to Win&#x201d; strategy leading to the creation of the standalone Consumer Healthcare Global&#160;Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its&#160;own&#160;dedicated global support functions (including Finance, People &amp;amp; Culture, Legal, Ethics, Business Integrity &amp;amp; Global Security, Information Solutions &amp;amp; Technology, Global Business Services,&#160;etc.); and (ii)&#160;organizational changes to Sanofi&#x2019;s Manufacturing &amp;amp; Supply global function (previously known as Industrial Affairs). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Consequently, with effect from January&#160;1, 2023, Sanofi reports two operating segments: Biopharma and Consumer Healthcare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#x2019;s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment&#x2019;s results reflect all incurred costs of global support functions attributable to its business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The &#x201c;Other&#x201d; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Information about operating segments for the years ended December 31, 2023, 2022 and 2021 is presented in Note&#160;D.35&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Segment information&#x201d;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <sny:NumberOfOperatingSegments1
      contextRef="c-9"
      decimals="INF"
      id="f-688"
      unitRef="segment">3</sny:NumberOfOperatingSegments1>
    <sny:NumberOfOperatingSegments1
      contextRef="c-1"
      decimals="INF"
      id="f-689"
      unitRef="segment">2</sny:NumberOfOperatingSegments1>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory contextRef="c-1" id="f-690">Management of capital&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In order to maintain or adjust the capital structure, Sanofi can adjust the amount of dividends paid to shareholders, repurchase its own shares, issue new shares, or issue securities giving access to its capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The following objectives are defined under the terms of Sanofi&#x2019;s share repurchase programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the implementation of any stock option plan giving entitlement to purchase shares in the Sanofi parent company;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the allotment or sale of shares to employees under statutory profit sharing schemes and employee savings plans;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the consideration-free allotment of shares (i.e. restricted share plans);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the cancellation of some or all of the repurchased shares;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;market-making in the secondary market by an investment services provider under a liquidity contract in compliance with the ethical code recognized by the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Autorit&#xe9; des march&#xe9;s financiers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; (AMF);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the delivery of shares on the exercise of rights attached to securities giving access to the capital by redemption, conversion, exchange, presentation of a warrant or any other means;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the delivery of shares (in exchange, as payment, or otherwise) in connection with mergers and acquisitions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the execution by an investment services provider of purchases, sales or transfers by any means, in particular via off-market trading; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.1pt"&gt;any other purpose that is or may in the future be authorized under the applicable laws and regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi is not subject to any constraints on equity capital imposed by third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total equity includes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity attributable to equity holders of Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Equity attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, as shown in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi defines &#x201c;Net debt&#x201d; as (i)&#160;the sum of short-term debt, long-term debt and interest rate derivatives and currency derivatives used to hedge debt, minus (ii)&#160;the sum of cash and cash equivalents and interest rate derivatives and currency derivatives used to hedge cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <sny:DisclosureOfPrincipalAlliancesTextBlock contextRef="c-1" id="f-691">Principal alliances&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;C.1. Alliance arrangements with Regeneron Pharmaceuticals,&#160;Inc. (Regeneron)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration agreements on human therapeutic antibodies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In November&#160;2007, Sanofi and Regeneron signed two agreements (amended in November&#160;2009) relating to human therapeutic antibodies: (i)&#160;the Discovery and Preclinical Development Agreement, and (ii)&#160;the License and Collaboration Agreement, relating to clinical development and commercialization. Under the License and Collaboration Agreement, Sanofi had an option to develop and commercialize antibodies discovered by Regeneron under the Discovery and Preclinical Development Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Discovery and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Because Sanofi decided not to exercise its option to extend the Discovery and Preclinical Development Agreement, that agreement expired on December&#160;31, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As a result of Sanofi&#x2019;s exercise of an option with respect to an antibody under the Discovery and Preclinical Development Agreement, such antibody became a &#x201c;Licensed Product&#x201d; under the License and Collaboration Agreement, pursuant to which Sanofi and Regeneron co-develop the antibody with Sanofi initially being wholly responsible for funding the development program. On receipt of the first positive Phase 3 trial results for any antibody being developed under the License and Collaboration Agreement, the subsequent development costs for that antibody are split 80% Sanofi, 20% Regeneron. Amounts received from Regeneron under the License and Collaboration Agreement are recognized by Sanofi as a reduction in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. Co-development with Regeneron of the antibodies DUPIXENT, KEVZARA and REGN3500 (SAR440340 - itepekimab) is ongoing under the License and Collaboration Agreement as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Once a product begins to be commercialized, and provided that the share of quarterly results under the agreement represents a profit, Sanofi is entitled to an additional portion of Regeneron&#x2019;s profit-share (capped at 20% of Regeneron&#x2019;s share of quarterly profits since April&#160;1, 2022, and at 10% until March&#160;31, 2022) until Regeneron has paid 50% of the cumulative development costs incurred by the parties in the collaboration (see Note&#160;D.21.1.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On the later of (i)&#160;24 months before the scheduled launch date or (ii)&#160;the first positive Phase&#160;3 trial results, Sanofi and Regeneron share the commercial expenses of the antibodies co-developed under the License and Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commercialization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi is the lead party with respect to the commercialization of all co-developed antibodies, and Regeneron has certain option rights to co-promote the antibodies. Regeneron has exercised its co-promotion rights in the United States and in certain other countries. Sanofi recognizes all sales of the antibodies. Profits and losses arising from commercial operations in the United States are split 50/50. Outside the United States, Sanofi is entitled to between 55% and 65% of profits depending on sales of the antibodies, and bears 55% of any losses. The share of profits and losses due to or from Regeneron under the agreement is recognized within the line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, which are components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, Regeneron is entitled to receive payments contingent on the attainment of specified levels of aggregate sales on all antibodies outside the United States, on a rolling twelve-month basis. A liability for those payments is recognized on the balance sheet when it is probable that the specified level of aggregate sales will be met. The opposite entry for that liability is capitalized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; on the balance sheet. Two payments of $50&#160;million each were made in 2022, following attainment first of $2.0&#160;billion and then of $2.5&#160;billion in sales of all antibodies outside the United States on a rolling twelve-month basis. The final milestone payment of $50&#160;million, payable to Regeneron in the event that $3.0&#160;billion in sales on a rolling twelve-month basis is attained, was made in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amendments to the collaboration agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In January&#160;2018, Sanofi and Regeneron signed a set of amendments to their collaboration agreements, including an amendment that allowed for the funding of additional programs on DUPIXENT and REGN3500 (SAR440340 &#x2013; itepekimab) with an intended focus on extending the current range of indications, finding new indications, and improving co-morbidity between multiple pathologies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Effective April&#160;1, 2020, Sanofi and Regeneron signed a Cross License and Commercialization Agreement for PRALUENT, whereby Sanofi obtained sole ex-US rights to PRALUENT, and Regeneron obtained sole US rights to PRALUENT along with a right to 5% royalties on Sanofi&#x2019;s sales of PRALUENT outside the United States. Each party is solely responsible for funding the development, manufacturing and commercialization of PRALUENT in their respective territories. Although each party has sole responsibility for supplying PRALUENT in its respective territory, Sanofi and Regeneron entered into agreements to support manufacturing needs for each other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Effective September&#160;30, 2021, Sanofi and Regeneron signed an amendment to their collaboration agreement in order to specify allocations of responsibilities and associated resources between the two parties in connection with the co-promotion of&#160;DUPIXENT in certain countries. The terms of the collaboration relating to REGN3500 (SAR440340 &#x2013; itepekimab) are unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Effective July&#160;1, 2022, Sanofi and Regeneron signed an amendment to their collaboration agreement in order to increase the additional portion of Regeneron&#x2019;s quarterly profit-share attributable to Sanofi from 10% to 20% with retroactive impact as of April&#160;1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Immuno-oncology (IO) collaboration agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July&#160;1, 2015, Sanofi and Regeneron signed two agreements &#x2013;&#160;the IO Discovery and Development Agreement and the IO License and Collaboration Agreement (IO LCA)&#160;&#x2013; relating to new antibody cancer treatments in the field of immuno-oncology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Amended IO Discovery Agreement, effective from December&#160;31, 2018, was terminated through a Letter Amendment dated March&#160;16,&#160;2021 in which Sanofi formalized its opt-out from the BCMAxCD3 and MUC16xCD3 programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;LIBTAYO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(cemiplimab)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under the 2015 IO LCA as amended in January&#160;2018, Sanofi and Regeneron committed funding of no more than $1,640 million, split on a&#160;50/50 basis ($820 million per company), for the development of REGN2810 (cemiplimab, trademark LIBTAYO), a PD-1 inhibitor antibody. The funding was raised to $1,840&#160;million by way of amendment effective on September&#160;30, 2021. Regeneron was responsible for the commercialization of LIBTAYO in the United States, and Sanofi in all other territories. Sanofi has exercised its option to co-promote LIBTAYO in the United States. In 2021, Regeneron exercised its option to co-promote LIBTAYO in certain other countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The IO LCA also provided for a one-time milestone payment of $375 million by Sanofi to Regeneron in the event that sales of a PD-1 product were to exceed, in the aggregate, $2 billion in any consecutive 12-month period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under the IO LCA Sanofi and Regeneron shared equally in profits and losses generated by the commercialization of collaboration products, except that Sanofi was entitled to an additional portion of Regeneron&#x2019;s profit-share (capped at 10% of Regeneron&#x2019;s share of quarterly profits) until Regeneron had paid 50% of the cumulative development costs incurred by the parties under the IO Discovery Agreement, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;LIBTAYO is approved in the United States and Europe for the treatment of two types of locally advanced or metastatic skin cancer (cutaneous squamous cell carcinoma and basal cell carcinoma) and non-small cell lung cancer (NSCLC). It is also approved in Brazil and Canada as a second line treatment for recurring or metastatic cervical cancer. In the fourth quarter of 2022, it was approved in the United States in association with chemotherapy for the treatment of NSCLC, and in Europe and Japan as a second line treatment for recurring or metastatic cervical cancer. LIBTAYO is currently approved in more than 30&#160;countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In June&#160;2022, Sanofi and Regeneron restructured their IO LCA. Under the terms of the Amended and Restated IO LCA, Regeneron holds exclusive worldwide licensing rights to LIBTAYO with effect from July&#160;1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In July&#160;2022, Sanofi received as consideration an upfront payment of $900&#160;million (&#x20ac;856&#160;million), which was recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; on the date of receipt. The same line item also includes a regulatory milestone payment of $100&#160;million (&#x20ac;96&#160;million) following the US FDA approval in November&#160;2022 of LIBTAYO in combination with chemotherapy as a first line treatment for NSCLC. In addition, Sanofi is entitled to royalties of 11% and to milestone payments (&#x20ac;116&#160;million in 2023, &#x20ac;111&#160;million in 2022) linked to global net sales of LIBTAYO; those royalties are recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in line with the pattern of sales. All of the cash inflows relating to the above items (&#x20ac;196&#160;million in 2023, &#x20ac;952&#160;million in 2022) are presented within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net cash provided by/(used in) operating activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The amendment to the terms of the IO LCA resulted in Sanofi recognizing an accelerated amortization charge of &#x20ac;226&#160;million in&#160;2022; this was allocated to the LIBTAYO product rights included within the residual carrying amount of the intangible asset recognized in July&#160;2015 to reflect rights to an antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) under the Sanofi/Regeneron alliance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The transaction also includes a time-limited transitional services agreement with Regeneron which includes manufacturing, distribution (for which Sanofi acts as agent), and promotion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investor agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2014 and 2020, Sanofi and Regeneron amended the investor agreement entered into by the two companies in 2007. Under the terms of the amendments, Sanofi accepted various restrictions, including &#x201c;standstill&#x201d; provisions that contractually prohibit Sanofi from seeking to directly or indirectly exert control of Regeneron or acquiring more than 30% of Regeneron&#x2019;s capital stock (consisting of the outstanding shares of common stock and the shares of Class A stock). This prohibition remains in place until the earlier of (i)&#160;the later of the fifth anniversaries of the expiration or earlier termination of the ZALTRAP collaboration agreement with Regeneron (related to the development and commercialization of ZALTRAP) or the collaboration agreement with Regeneron on monoclonal antibodies (see &#x201c;Collaboration agreements on human therapeutic antibodies&#x201d; above), each as amended or (ii)&#160;other specified events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Starting in 2018 Sanofi began to sell shares of Regeneron stock and announced on May&#160;29,&#160;2020 the closing of its sale of 13&#160;million shares of Regeneron common stock in a registered offering and a private sale to Regeneron (see Note&#160;D.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Pursuant to subsequent sales in 2022, Sanofi no longer holds any shares of Regeneron stock, as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;C.2. Agreements on the commercialization of BEYFORTUS (nirsevimab, previously MEDI8897) in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On March 1, 2017, Sanofi and AstraZeneca entered into an agreement to develop and commercialize a monoclonal antibody (MEDI8897, nirsevimab) for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Sanofi made an upfront payment of &#x20ac;120&#160;million in March 2017, a development milestone payment of &#x20ac;30&#160;million in the third quarter of 2019, a regulatory milestone payment of &#x20ac;25&#160;million associated with the approval of BEYFORTUS (nirsevimab) by the EMA in Europe in November 2022, and a regulatory milestone payment of &#x20ac;65&#160;million associated with the approval of BEYFORTUS (nirsevimab) by the US FDA in July 2023. In addition, Sanofi could pay up to &#x20ac;375&#160;million if sales objectives are met. Those amounts are recognized as a component of the value of the intangible asset when payment becomes probable. During 2023, an amount of &#x20ac;25&#160;million was recognized as an accrued expense further to a contractual threshold being passed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The agreement also specifies that AstraZeneca is responsible for development and manufacturing, and Sanofi for commercialization. Sanofi recognizes the sales and cost of sales (purchases of finished products from AstraZeneca) and shares the Alliance&#x2019;s commercial profits (i) 50/50 in major territories and (ii) based on 25% of net sales in other territories. The share of commercial profits and losses due to or from AstraZeneca is recognized as a component of operating income, within the line items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. In addition, Sanofi and AstraZeneca share development costs 50/50, with Sanofi&#x2019;s portion recognized within the income statement line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;s.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April 9, 2023, Sanofi and AstraZeneca simplified their contractual agreements for the development and commercialization of BEYFORTUS (nirsevimab) in the US. Sanofi thereby obtained control of all commercial rights to BEYFORTUS (nirsevimab) in the US, and ended the sharing of commercial profits between the two partners in that territory. In line with the terms of the revised agreements and in accordance with IAS 38, Sanofi recognized an intangible asset of &#x20ac;1.6&#160;billion for the fair value of the additional US rights. On the same date, AstraZeneca and Sobi ended their participation agreement, signed in 2018, which transferred the economic rights for the US territory to Sobi. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi simultaneously entered into an agreement with Sobi relating to direct royalties on US net sales of BEYFORTUS (nirsevimab). In line with the terms of that agreement, on April 9, 2023 Sanofi recognized a financial liability amounting to  &#x20ac;1.6&#160;billion. That liability is classified as a financial liability at amortized cost under IFRS 9. Other than royalty payments, subsequent movements in the liability comprise (i) the unwinding of discount and (ii) changes in estimates of future cash outflows for royalty payments. Those movements will be recognized in the income statement within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net financial income/(expenses)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in accordance with paragraph B.5.4.6 of IFRS 9. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023 the liability was remeasured by an amount of &#x20ac;541&#160;million, reflecting the strong success of the US launch of BEYFORTUS (nirsevimab), which led to sales forecasts being revised upward from the initial estimate. The resulting adjustment was recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For territories other than the US (except for China, which is now considered a &#x201c;major market,&#x201d; with profits/losses shared 50/50 with AstraZeneca), the existing agreement between AstraZeneca and Sanofi continues to govern the principal terms of the collaboration: Sanofi recognizes the sales and cost of sales and shares the Alliance&#x2019;s commercial profits with AstraZeneca.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In May 2023, data from the HARMONIE Phase 3b study confirmed that nirsevimab prevents infant hospitalizations due to RSV with consistent and high efficacy.&lt;/span&gt;&lt;/div&gt;BEYFORTUS (nirsevimab) was approved in Europe in November 2022, and in the United States on July 17, 2023.</sny:DisclosureOfPrincipalAlliancesTextBlock>
    <sny:NumberOfAgreementsSigned
      contextRef="c-94"
      decimals="INF"
      id="f-692"
      unitRef="agreement">2</sny:NumberOfAgreementsSigned>
    <sny:PercentageOfSecondPartOfDevelopmentCostsFunded contextRef="c-95" decimals="2" id="f-693" unitRef="number">0.80</sny:PercentageOfSecondPartOfDevelopmentCostsFunded>
    <sny:PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty contextRef="c-95" decimals="2" id="f-694" unitRef="number">0.20</sny:PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty>
    <sny:PercentageOfProfitShareOnCounterpartiesProfit contextRef="c-96" decimals="INF" id="f-695" unitRef="rate">0.20</sny:PercentageOfProfitShareOnCounterpartiesProfit>
    <sny:PercentageOfProfitShareOnCounterpartiesProfit contextRef="c-97" decimals="INF" id="f-696" unitRef="rate">0.10</sny:PercentageOfProfitShareOnCounterpartiesProfit>
    <sny:PercentageOfCumulativeDevelopmentCostsReimbursed contextRef="c-95" decimals="2" id="f-697" unitRef="number">0.50</sny:PercentageOfCumulativeDevelopmentCostsReimbursed>
    <sny:PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared contextRef="c-95" id="f-698">P24M</sny:PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared>
    <sny:PercentageOfProfitsAndLossesArisingFromCommercialOperations contextRef="c-98" decimals="2" id="f-699" unitRef="number">0.50</sny:PercentageOfProfitsAndLossesArisingFromCommercialOperations>
    <sny:PercentageOfProfitsArisingFromCommercialOperations contextRef="c-99" decimals="2" id="f-700" unitRef="number">0.55</sny:PercentageOfProfitsArisingFromCommercialOperations>
    <sny:PercentageOfProfitsArisingFromCommercialOperations contextRef="c-100" decimals="2" id="f-701" unitRef="number">0.65</sny:PercentageOfProfitsArisingFromCommercialOperations>
    <sny:PercentageOfLossesArisingFromCommercialOperations contextRef="c-101" decimals="2" id="f-702" unitRef="number">0.55</sny:PercentageOfLossesArisingFromCommercialOperations>
    <sny:NumberOfPayments contextRef="c-102" decimals="INF" id="f-703" unitRef="bond">2</sny:NumberOfPayments>
    <sny:PaymentRelatedToAttainmentOfGoal contextRef="c-103" decimals="-6" id="f-704" unitRef="usd">50000000</sny:PaymentRelatedToAttainmentOfGoal>
    <sny:PaymentRelatedToAttainmentOfGoal contextRef="c-104" decimals="-6" id="f-705" unitRef="usd">50000000</sny:PaymentRelatedToAttainmentOfGoal>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-105" decimals="-8" id="f-706" unitRef="usd">2000000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-106" decimals="-8" id="f-707" unitRef="usd">2500000000</ifrs-full:RevenueFromSaleOfGoods>
    <sny:PaymentRelatedToAttainmentOfGoal contextRef="c-107" decimals="-6" id="f-708" unitRef="usd">50000000</sny:PaymentRelatedToAttainmentOfGoal>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-108" decimals="-8" id="f-709" unitRef="usd">3000000000</ifrs-full:RevenueFromSaleOfGoods>
    <sny:RoyaltyExpensePercentage contextRef="c-109" decimals="2" id="f-710" unitRef="number">0.05</sny:RoyaltyExpensePercentage>
    <sny:PercentageOfProfitShareOnCounterpartiesProfit contextRef="c-110" decimals="INF" id="f-711" unitRef="rate">0.10</sny:PercentageOfProfitShareOnCounterpartiesProfit>
    <sny:PercentageOfProfitShareOnCounterpartiesProfit contextRef="c-96" decimals="INF" id="f-712" unitRef="rate">0.20</sny:PercentageOfProfitShareOnCounterpartiesProfit>
    <sny:NumberOfAgreementsSigned
      contextRef="c-111"
      decimals="INF"
      id="f-713"
      unitRef="agreement">2</sny:NumberOfAgreementsSigned>
    <sny:PriorDevelopmentBudget contextRef="c-112" decimals="-6" id="f-714" unitRef="usd">1640000000</sny:PriorDevelopmentBudget>
    <sny:ContractualAgreementForAntiProgrammedCellDeathProtein1
      contextRef="c-112"
      decimals="INF"
      id="f-715"
      unitRef="number">50</sny:ContractualAgreementForAntiProgrammedCellDeathProtein1>
    <sny:MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany contextRef="c-113" decimals="-6" id="f-716" unitRef="usd">820000000</sny:MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany>
    <sny:MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany contextRef="c-114" decimals="-6" id="f-717" unitRef="usd">1840000000</sny:MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany>
    <sny:AntiProgrammedCellDeathProtein1SalesMilestonePayment contextRef="c-113" decimals="-6" id="f-718" unitRef="usd">375000000</sny:AntiProgrammedCellDeathProtein1SalesMilestonePayment>
    <sny:MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment contextRef="c-113" decimals="-9" id="f-719" unitRef="usd">2000000000</sny:MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment>
    <sny:PercentageOfProfitShareOnCounterpartiesProfit contextRef="c-115" decimals="2" id="f-720" unitRef="number">0.10</sny:PercentageOfProfitShareOnCounterpartiesProfit>
    <sny:PercentageOfCumulativeDevelopmentCostsReimbursed contextRef="c-115" decimals="2" id="f-721" unitRef="number">0.50</sny:PercentageOfCumulativeDevelopmentCostsReimbursed>
    <sny:UpfrontPaymentsForProjectsUnderCollaborationAgreements contextRef="c-116" decimals="-6" id="f-722" unitRef="usd">900000000</sny:UpfrontPaymentsForProjectsUnderCollaborationAgreements>
    <sny:UpfrontPaymentsForProjectsUnderCollaborationAgreements contextRef="c-116" decimals="-6" id="f-723" unitRef="eur">856000000</sny:UpfrontPaymentsForProjectsUnderCollaborationAgreements>
    <sny:RegularMilestonePaymentsForProjectsUnderCollaborationAgreements contextRef="c-117" decimals="-6" id="f-724" unitRef="usd">100000000</sny:RegularMilestonePaymentsForProjectsUnderCollaborationAgreements>
    <sny:RegularMilestonePaymentsForProjectsUnderCollaborationAgreements contextRef="c-117" decimals="-6" id="f-725" unitRef="eur">96000000</sny:RegularMilestonePaymentsForProjectsUnderCollaborationAgreements>
    <sny:RoyaltyIncomePercentage contextRef="c-116" decimals="2" id="f-726" unitRef="number">0.11</sny:RoyaltyIncomePercentage>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-118" decimals="-6" id="f-727" unitRef="eur">116000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-119" decimals="-6" id="f-728" unitRef="eur">111000000</ifrs-full:OtherOperatingIncomeExpense>
    <sny:ProceedsFromCollaborationAgreements contextRef="c-118" decimals="-6" id="f-729" unitRef="eur">196000000</sny:ProceedsFromCollaborationAgreements>
    <sny:ProceedsFromCollaborationAgreements contextRef="c-119" decimals="-6" id="f-730" unitRef="eur">952000000</sny:ProceedsFromCollaborationAgreements>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-120" decimals="-6" id="f-731" unitRef="eur">226000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <sny:MaximumOwnershipPercentageAllowedToAcquire
      contextRef="c-121"
      decimals="INF"
      id="f-732"
      unitRef="number">0.30</sny:MaximumOwnershipPercentageAllowedToAcquire>
    <sny:SaleOfStockNumberOfSharesIssuedInTransactionTotal
      contextRef="c-122"
      decimals="INF"
      id="f-733"
      unitRef="shares">13000000</sny:SaleOfStockNumberOfSharesIssuedInTransactionTotal>
    <sny:CollaborationAgreementsUpfrontPayment contextRef="c-123" decimals="-6" id="f-734" unitRef="eur">120000000</sny:CollaborationAgreementsUpfrontPayment>
    <sny:CollaborationAgreementsDevelopmentMilestonePayment contextRef="c-124" decimals="-6" id="f-735" unitRef="eur">30000000</sny:CollaborationAgreementsDevelopmentMilestonePayment>
    <sny:CollaborationAgreementsRegulatoryMilestonePayment contextRef="c-125" decimals="-6" id="f-736" unitRef="eur">25000000</sny:CollaborationAgreementsRegulatoryMilestonePayment>
    <sny:CollaborationAgreementsRegulatoryMilestonePayment contextRef="c-126" decimals="-6" id="f-737" unitRef="eur">65000000</sny:CollaborationAgreementsRegulatoryMilestonePayment>
    <sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement contextRef="c-127" decimals="-6" id="f-738" unitRef="eur">375000000</sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement>
    <ifrs-full:Accruals contextRef="c-127" decimals="-6" id="f-739" unitRef="eur">25000000</ifrs-full:Accruals>
    <sny:PercentageOfProfitsArisingFromCommercialOperations contextRef="c-128" decimals="2" id="f-740" unitRef="number">0.50</sny:PercentageOfProfitsArisingFromCommercialOperations>
    <sny:PercentageOfNetSalesArisingFromCommercialOperations contextRef="c-129" decimals="2" id="f-741" unitRef="number">0.25</sny:PercentageOfNetSalesArisingFromCommercialOperations>
    <sny:PercentageOfDevelopmentCostsArisingFromCommercialOperations contextRef="c-130" decimals="2" id="f-742" unitRef="number">0.50</sny:PercentageOfDevelopmentCostsArisingFromCommercialOperations>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-131" decimals="-8" id="f-743" unitRef="eur">1600000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-132" decimals="-8" id="f-744" unitRef="eur">1600000000</ifrs-full:OtherNoncurrentLiabilities>
    <sny:IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities contextRef="c-133" decimals="-6" id="f-745" unitRef="eur">541000000</sny:IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities>
    <sny:PercentageOfProfitsArisingFromCommercialOperations contextRef="c-134" decimals="2" id="f-746" unitRef="number">0.50</sny:PercentageOfProfitsArisingFromCommercialOperations>
    <sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock contextRef="c-1" id="f-747">Presentation of the financial statementsPrincipal changes in the scope of consolidation in 2023&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Provention Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On March&#160;13, 2023, Sanofi entered into a merger agreement with Provention Bio, Inc. (Provention), a US-based publicly traded biopharmaceutical company developing therapies to prevent and intercept immune-mediated diseases including type&#160;1 diabetes. Under the terms of the agreement, Sanofi acquired the outstanding shares of Provention common stock for $25.00 per share in an all-cash transaction valued at approximately $2.8&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition of Provention was completed on April&#160;27, 2023, with Sanofi holding all of the shares of Provention on expiration of the tender offer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi applied the optional test to identify concentration of fair value under paragraph B7A of IFRS&#160;3. The transaction was accounted for as an acquisition of a group of assets, given that the principal asset (teplizumab-mzwv, commercialized in the United States under the name TZIELD) concentrates substantially all of the fair value of the acquired set of activities and assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under the terms of a share purchase agreement entered into by Sanofi and Provention in February&#160;2023, Sanofi already held an equity interest in Provention, representing approximately 3% of Provention&#x2019;s share capital. On the date Sanofi obtained control of Provention, that equity interest was remeasured at a price of $25.00 per share, representing a total amount of $68&#160;million. The impact of the remeasurement was recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition price for the shares not already held was $2,806&#160;million. Out of the total price (including the fair value of the shares already held), $2,810&#160;million was allocated to TZIELD and recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction, after taking account of the previously-held shares and acquisition-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition as reflected within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of cash flows is a net cash outflow of $2,722&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of QRIB Intermediate Holdings, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July&#160;28, 2023, Sanofi announced that it had acquired QRIB Intermediate Holdings, LLC (QRIB), the owner of QUNOL, a market-leading US-based health &amp;amp; wellness brand. The acquisition strengthened Sanofi's Consumer Healthcare (CHC) operations in the Vitamin, Mineral and Supplements (VMS) category.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition of QRIB by Sanofi was completed on September&#160;29, 2023, at a purchase price of $1,419&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The provisional purchase price allocation led to the recognition of goodwill of &#x20ac;475&#160;million, determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.893%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value at acquisition date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;774&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current and non-current assets and liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net assets of QRIB Intermediate Holdings, LLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;867&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The other acquired intangible assets identified consist of the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;QUNOL brand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Goodwill mainly represents the expected future profits attributable to the development of the VMS platform in the United States as a result of the integration of QRIB into the Sanofi group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The entire amount of goodwill is deductible for tax purposes over a period of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Since the acquisition date, QRIB has generated net sales of &#x20ac;71&#160;million, and has made an immaterial impact on consolidated net income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition-related costs were recognized in profit or loss during 2023 within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;; the amount involved was immaterial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition is reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings and investments accounted for&#160;using the equity method&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of cash flows, and represents a net cash outflow of $1,410&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;D.2. Principal changes in the scope of consolidation in 2022 and 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.2.1. Principal changes in the scope of consolidation in 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Amunix Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On February&#160;8, 2022, Sanofi acquired the entire share capital of the immuno-oncology company Amunix Pharmaceuticals, Inc. (Amunix), thereby gaining access to Amunix&#x2019;s innovative PRO-XTEN technology and a promising pipeline of immunotherapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition price of Amunix comprises a fixed cash payment of &#x20ac;970&#160;million, plus contingent consideration in the form of milestone payments based on attainment of certain future development objectives of up to $225&#160;million, the fair value of which as of the acquisition date was &#x20ac;156&#160;million. In accordance with IFRS&#160;3, this contingent purchase consideration was recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and non-controlling interests &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(see Note&#160;D.18.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The final purchase price allocation led to the recognition of &#x20ac;609&#160;million of goodwill, determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value at acquisition date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;493&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current and non-current assets and liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net assets of Amunix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;517&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;609&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,126&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Other intangible assets&#x201d; comprise PRO-XTEN, an innovative universal protease-releasable masking technology platform for the discovery and development of transformative cytokine therapies and T-cell engager (TCE) immunotherapies for patients with cancer. In 2023, an impairment loss was taken against the PRO-XTEN platform, in line with a strategic decision to de-prioritize  certain R&amp;amp;D programs (see Note&#160;D.5., "Impairment of intangible assets and property, plant and equipment&#x2019;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Goodwill mainly represents the value of Amunix&#x2019;s upstream research and development pipeline of immuno-oncology therapies based on next-generation conditionally activated biologics, especially when combined with Sanofi&#x2019;s existing oncology portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The goodwill generated on this acquisition does not give rise to any deduction for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Amunix has no commercial operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition as reflected within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of cash flows is a cash outflow of &#x20ac;852&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;EUROAPI - Loss of control and accounting implications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On March&#160;17, 2022, the Sanofi Board of Directors approved a decision to put to a shareholder vote the proposed distribution in&#160;kind of approximately 58% of the share capital of EUROAPI, thereby confirming Sanofi&#x2019;s commitment (announced in February&#160;2020) to discontinue its active pharmaceutical ingredient operations. As part of the same corporate action and on the same date, Sanofi entered into an investment agreement with EPIC Bpifrance, which undertook to acquire from Sanofi &#x2013; via the French Tech Souverainet&#xe9; fund &#x2013; a 12% equity interest in EUROAPI at a price not exceeding &#x20ac;150&#160;million and to be determined on the basis of the volume weighted average price (VWAP) of EUROAPI shares on the Euronext Paris regulated market over the&#160;thirty-day period starting from the date of initial listing, i.e. May&#160;6, 2022. On completion of those transactions, Sanofi holds an equity interest of 30.1% in EUROAPI, which it has undertaken to retain for at least two years from the date of the distribution, subject to the customary exceptions. With effect from that date, Sanofi exercises significant influence over EUROAPI as a result of (i)&#160;its equity interest, and (ii)&#160;having one representative on the EUROAPI Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May&#160;3, 2022, the General Meeting of Sanofi shareholders approved the decision of the Board of Directors to distribute approximately 58% of the share capital of EUROAPI in the form of an exceptional dividend in kind.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On May&#160;10, 2022, the payment date of the dividend in kind in the days following the admission to listing of EUROAPI shares, those Sanofi shareholders who had retained their Sanofi shares received 1&#160;EUROAPI share per 23&#160;Sanofi shares, representing in total&#160;57.88% of the share capital of EUROAPI. As of that date, Sanofi lost control over the EUROAPI entities, based on an assessment of the criteria specified in IFRS&#160;10 (Consolidated financial statements). The assets and liabilities of EUROAPI, which since March&#160;17, 2022 had been presented as assets and liabilities held for sale within the Sanofi statement of financial position in accordance with IFRS&#160;5 (Non-Current Assets Held for Sale), were deconsolidated. In addition, because EUROAPI operations do not constitute a discontinued operation under IFRS&#160;5, the contribution from EUROAPI has not been presented within separate line items in the income statement and statement of cash flows or in information for prior comparative periods. The contribution of EUROAPI operations to the consolidated net sales of Sanofi in the year ended December&#160;31, 2021 was &#x20ac;486&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal consequences of the deconsolidation of EUROAPI are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the derecognition of the carrying amount of all the assets and liabilities of EUROAPI, representing a net amount of&#160;&#x20ac;1,227&#160;million as of May&#160;10, 2022. This includes goodwill of &#x20ac;164&#160;million, determined in accordance with IAS&#160;36 (&#x201c;Impairment of Assets&#x201d;), which was historically allocated to the Pharmaceuticals cash generating unit (CGU), and which for the purposes of the deconsolidation was allocated using an alternative method based on the relative values of goodwill as of the date of consolidation (the &#x201c;notional goodwill method&#x201d;). That method was considered more appropriate to the capital-intensive nature of EUROAPI operations than the method based on the relative values of EUROAPI operations and the retained portion of the&#160;CGU;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a reduction in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity attributable to equity holders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;of Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; reflecting the distribution in kind, measured at &#x20ac;793&#160;million based on the weighted average price of &#x20ac;14.58 per share as of the date of delivery of the EUROAPI shares to Sanofi shareholders and corresponding to the fair value of the distribution in accordance with IFRIC&#160;17 (Distribution of Non-Cash Assets to Owners);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a cash inflow of &#x20ac;150&#160;million from the divestment of 12% of the share capital of EUROAPI to EPIC Bpifrance as of the settlement date of the shares, i.e. June&#160;17, 2022;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the recognition in the statement of financial position, within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, of the retained 30.1% equity interest in EUROAPI at an amount of &#x20ac;413&#160;million, determined on the basis of the weighted average price of &#x20ac;14.58 per share and representing the fair value of the equity interest in accordance with IFRS&#160;10;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the reclassification within the net gain/loss on deconsolidation of unrealized foreign exchange losses amounting to&#160;&#x20ac;35&#160;million arising on EUROAPI subsidiaries, in accordance with IAS&#160;21 (The Effects of Changes in Foreign Exchange Rates);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the recognition of transaction-related costs and of the effects of undertakings made under agreements entered into with&#160;EUROAPI setting out the principles and terms of the legal reorganization carried out ahead of the date of deconsolidation. The principal undertakings made to EUROAPI relate to compensation for:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;environmental remediation obligations on non-operational chemical sites in France transferred to EUROAPI, amounting to&#160;&#x20ac;14 million, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;regulatory compliance costs relating to certain state-of-the-art active pharmaceutical ingredients of EUROAPI, capped at&#160;&#x20ac;15 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These elements collectively resulted in a pre-tax loss on deconsolidation of &#x20ac;3&#160;million, presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the income statement. The tax effect of the deconsolidation was a net gain of &#x20ac;111&#160;million, presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;in the income statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The cash impact of the deconsolidation of EUROAPI, presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disposals of consolidated undertakings and investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;in the statement of cash flows, was a net cash inflow of &#x20ac;101&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has entered into an agreement with EUROAPI for the manufacture and supply of active pharmaceutical ingredients, intermediates and other substances, which took effect on October&#160;1, 2021 and expires five years after the loss of control. Under the terms of the agreement, Sanofi committed to target annual net sales of approximately &#x20ac;300&#160;million for a list of specified active ingredients until the agreement expires in 2026. As of December&#160;31, 2022, that commitment amounted to &#x20ac;1.1&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of the date of deconsolidation, the 30.1% equity interest in EUROAPI is accounted for using the equity method in accordance with IAS&#160;28 (Investments in Associates and Joint Ventures), and the share of EUROAPI profits or losses arising from application of the equity method is excluded from &#x201c;Business operating income&#x201d;, the non-IFRS financial indicator used internally by&#160;Sanofi to measure the performance of its operating segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.2.2. Principal changes in the scope of consolidation in 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Kymab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April&#160;8, 2021, Sanofi acquired the entire share capital of Kymab for an upfront payment of $1.1 billion (&#x20ac;973 million) and up to&#160;$350 million contingent upon reaching certain development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the KY1005 project, currently in Phase&#160;2 clinical development, and relating to the human monoclonal antibody OX40L, an essential regulator of the immune system) concentrates substantially all of the fair value of the acquired set of activities and assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Of the total acquisition price paid, &#x20ac;965 million was allocated to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition as reflected within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of cash flows is a net cash outflow of &#x20ac;932 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Kiadis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On November&#160;2, 2020, Sanofi and Kiadis, a biopharmaceutical company developing novel "off-the-shelf" natural killer (NK) cell therapies for patients with life-threatening diseases, entered into a definitive agreement whereby Sanofi was to make a public offer to acquire the entire share capital of Kiadis, i.e. 61&#160;million shares, at a cash price of &#x20ac;5.45 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition was approved unanimously by the Boards of Directors of Sanofi and Kiadis, and 95.03% of the share capital of Kiadis had been tendered into the offer as of April&#160;16, 2021. As of the end of the post-closing acceptance period on April&#160;29, 2021, Sanofi held&#160;97.39% of the share capital of Kiadis, and proceeded to buy out the remaining non-controlling shareholders. As of&#160;December&#160;31, 2022, Sanofi held 100.00% of the share capital of Kiadis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the K-NK technology platform) concentrates substantially all of the fair value of the acquired set of activities and assets. In 2023, an impairment loss was recognized against the K-NK technology platform to reflect the impact of the strategic decision to de-prioritize certain R&amp;amp;D programs (see Note&#160;D.5., "Impairment of intangible assets and property, plant and equipment").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Of the total acquisition price paid, &#x20ac;339 million was allocated to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition as reflected within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of cash flows is a net cash outflow of &#x20ac;326 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Tidal&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On April&#160;9, 2021, Sanofi acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a unique mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofi&#x2019;s research capabilities in immuno-oncology and inflammatory diseases, and may have applicability to other disease areas as well.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Tidal Therapeutics was acquired for an upfront payment of $160&#160;million (&#x20ac;136&#160;million), and up to $310&#160;million contingent upon reaching certain development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was accounted for as an asset acquisition given that the principal asset (the unique mRNA-based in vivo reprogramming technology) concentrates substantially all of the fair value of the acquired set of activities and assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Of the total acquisition price paid, &#x20ac;130&#160;million was allocated to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition as reflected within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of cash flows is a net cash outflow of &#x20ac;135&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Translate Bio&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On August&#160;3, 2021, Sanofi entered into a definitive agreement with Translate Bio, a clinical-stage mRNA therapeutics company, under which Sanofi was to acquire all outstanding shares of Translate Bio for $38 per share. The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition of Translate Bio by Sanofi was completed on September&#160;14, 2021, with Sanofi holding the entire share capital of Translate&#160;Bio upon expiration of the squeeze-out procedure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The final purchase price allocation, as presented in the table below, led to the recognition of goodwill of &#x20ac;2,118&#160;million:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value at acquisition date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current and non-current assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shire contingent consideration liability (see Note&#160;D.18.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net assets of Translate Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;462&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,118&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,580&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The other intangible assets mainly comprise a messenger RNA technological platform applied to the development of vaccines and therapeutic agents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Goodwill mainly represents the effects of expected future synergies and other benefits to be derived from the integration of Translate Bio into the Sanofi group, in particular by accelerating the delivery of development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The goodwill generated on this acquisition did not give rise to any deduction for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Translate Bio has no commercial operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition as reflected within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in the consolidated statement of cash flows is a net cash outflow of &#x20ac;2,333&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under the terms of the collaboration agreement between Sanofi and Translate Bio as announced on June&#160;23, 2020, Sanofi held an equity interest of approximately 5% in Translate Bio. As of the date when Sanofi obtained control of Translate Bio, that interest was remeasured at the purchase price of $38 per share. The change in fair value was recognized within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, in accordance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;with paragraph&#160;42 of IFRS&#160;3 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(see Note&#160;D.7.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Kadmon&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On September&#160;8, 2021, Sanofi entered into a definitive merger agreement with Kadmon, a biopharmaceutical company that discovers, develops and markets transformative therapies for disease areas with significant unmet medical needs. Shareholders of Kadmon common stock received $9.50 per share in cash, representing a transaction valued at $1.9&#160;billion on a fully-diluted basis. The Sanofi and Kadmon Boards of Directors unanimously approved the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The acquisition of Kadmon by Sanofi was completed on November&#160;9, 2021, with Sanofi holding the entire share capital of Kadmon upon expiration of the squeeze-out procedure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was therefore accounted for as an asset acquisition given that the principal asset (belumosudil, commercialized in the United States under the brand name REZUROCK) concentrates substantially all of the fair value of the acquired set of activities and assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Of the total acquisition price paid, &#x20ac;1,739&#160;million was allocated to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition as reflected within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;in the consolidated statement of cash flows is a net cash outflow of &#x20ac;1,575&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Origimm&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On December&#160;3, 2021, Sanofi acquired the entire share capital of Origimm Biotechnology GmbH, a privately owned Austrian biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria that cause skin diseases such as acne, for an upfront payment of &#x20ac;55&#160;million and up to &#x20ac;95&#160;million contingent upon reaching certain development and regulatory milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi applied the optional test to identify concentration of fair value under paragraph&#160;B7A of IFRS&#160;3. The transaction was therefore accounted for as an asset acquisition given that the principal asset (the group of Propionibacterium acnes antigens) concentrates substantially all of the fair value of the acquired set of activities and assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Nearly &#x20ac;55&#160;million of the acquisition price paid was allocated to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in accordance with IAS&#160;38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed as part of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of this acquisition as reflected within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions of consolidated undertakings and investments accounted for using the equity method &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;in the consolidated statement of cash flows for the year ended December&#160;31, 2021 is a net cash outflow of&#160;&#x20ac;50&#160;million.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfImpactOfChangesInTheScopeOfConsolidationDueToAcquisitionsAndDivestmentsExplanatoryTextBlock>
    <sny:BusinessCombinationPurchasePricePerShare
      contextRef="c-135"
      decimals="2"
      id="f-748"
      unitRef="usdPerShare">25.00</sny:BusinessCombinationPurchasePricePerShare>
    <ifrs-full:CashTransferred contextRef="c-135" decimals="-8" id="f-749" unitRef="usd">2800000000</ifrs-full:CashTransferred>
    <sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage contextRef="c-136" decimals="2" id="f-750" unitRef="number">0.03</sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage>
    <sny:BusinessCombinationPurchasePricePerShare
      contextRef="c-137"
      decimals="2"
      id="f-751"
      unitRef="usdPerShare">25.00</sny:BusinessCombinationPurchasePricePerShare>
    <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate contextRef="c-137" decimals="-6" id="f-752" unitRef="usd">68000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="c-137" decimals="-6" id="f-753" unitRef="usd">2806000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-137" decimals="-6" id="f-754" unitRef="usd">2810000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-138" decimals="-6" id="f-755" unitRef="usd">2722000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:BusinessCombinationPurchasePrice contextRef="c-139" decimals="-6" id="f-756" unitRef="usd">1419000000</sny:BusinessCombinationPurchasePrice>
    <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory contextRef="c-1" id="f-757">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The provisional purchase price allocation led to the recognition of goodwill of &#x20ac;475&#160;million, determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.893%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value at acquisition date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;774&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current and non-current assets and liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net assets of QRIB Intermediate Holdings, LLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;867&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The final purchase price allocation led to the recognition of &#x20ac;609&#160;million of goodwill, determined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value at acquisition date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;493&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current and non-current assets and liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net assets of Amunix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;517&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;609&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,126&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The final purchase price allocation, as presented in the table below, led to the recognition of goodwill of &#x20ac;2,118&#160;million:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value at acquisition date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current and non-current assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shire contingent consideration liability (see Note&#160;D.18.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net assets of Translate Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;462&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,118&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,580&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="c-139" decimals="-6" id="f-758" unitRef="eur">475000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-139" decimals="-6" id="f-759" unitRef="eur">774000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <sny:OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate contextRef="c-139" decimals="-6" id="f-760" unitRef="eur">90000000</sny:OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="c-139" decimals="-6" id="f-761" unitRef="eur">8000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="c-139" decimals="-6" id="f-762" unitRef="eur">5000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="c-139" decimals="-6" id="f-763" unitRef="eur">867000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="c-139" decimals="-6" id="f-764" unitRef="eur">475000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="c-139" decimals="-6" id="f-765" unitRef="eur">1342000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <sny:GoodwillTaxDeductiblePeriod contextRef="c-1" id="f-766">P15Y</sny:GoodwillTaxDeductiblePeriod>
    <ifrs-full:RevenueOfAcquiree contextRef="c-140" decimals="-6" id="f-767" unitRef="eur">71000000</ifrs-full:RevenueOfAcquiree>
    <ifrs-full:ProfitLossOfAcquiree contextRef="c-140" decimals="-6" id="f-768" unitRef="eur">0</ifrs-full:ProfitLossOfAcquiree>
    <ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination contextRef="c-141" decimals="0" id="f-769" unitRef="eur">0</ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-141" decimals="-6" id="f-770" unitRef="usd">1410000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashTransferred contextRef="c-142" decimals="-6" id="f-771" unitRef="eur">970000000</ifrs-full:CashTransferred>
    <sny:CommitmentsRelatedToMilestonePaymentsBusinessCombinations contextRef="c-142" decimals="-6" id="f-772" unitRef="usd">225000000</sny:CommitmentsRelatedToMilestonePaymentsBusinessCombinations>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate contextRef="c-142" decimals="-6" id="f-773" unitRef="eur">156000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="c-142" decimals="-6" id="f-774" unitRef="eur">609000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-142" decimals="-6" id="f-775" unitRef="eur">493000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <sny:OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate contextRef="c-142" decimals="-6" id="f-776" unitRef="eur">-13000000</sny:OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="c-142" decimals="-6" id="f-777" unitRef="eur">118000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="c-142" decimals="-6" id="f-778" unitRef="eur">81000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="c-142" decimals="-6" id="f-779" unitRef="eur">517000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="c-142" decimals="-6" id="f-780" unitRef="eur">609000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="c-142" decimals="-6" id="f-781" unitRef="eur">1126000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-143" decimals="-6" id="f-782" unitRef="eur">852000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:ExceptionalSupplementaryDividendProposedPercentageOfShareCapital contextRef="c-144" decimals="2" id="f-783" unitRef="number">580000</sny:ExceptionalSupplementaryDividendProposedPercentageOfShareCapital>
    <sny:PercentageOfVotingEquityInterestsDivested contextRef="c-145" decimals="2" id="f-784" unitRef="number">120000</sny:PercentageOfVotingEquityInterestsDivested>
    <sny:ConsiderationTransferredMaximumAmount contextRef="c-146" decimals="-6" id="f-785" unitRef="eur">150000000</sny:ConsiderationTransferredMaximumAmount>
    <sny:ConsiderationTransferredValuationPeriod contextRef="c-146" id="f-786">P30D</sny:ConsiderationTransferredValuationPeriod>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-147" decimals="3" id="f-787" unitRef="number">0.301</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <sny:OwnershipInterestInSubsidiaryMinimumHoldingPeriod contextRef="c-148" id="f-788">P2Y</sny:OwnershipInterestInSubsidiaryMinimumHoldingPeriod>
    <sny:ExceptionalSupplementaryDividendPercentageOfShareCapital contextRef="c-149" decimals="2" id="f-789" unitRef="number">0.58</sny:ExceptionalSupplementaryDividendPercentageOfShareCapital>
    <sny:SpecialDistributionSharesReceivedPerConversionOfParentShares
      contextRef="c-150"
      decimals="INF"
      id="f-790"
      unitRef="shares">1</sny:SpecialDistributionSharesReceivedPerConversionOfParentShares>
    <sny:SpecialDistributionNumberOfSharesConverted
      contextRef="c-150"
      decimals="INF"
      id="f-791"
      unitRef="shares">23</sny:SpecialDistributionNumberOfSharesConverted>
    <sny:SpecialDistributionPercentageOfShareCapitalDistributed contextRef="c-150" decimals="4" id="f-792" unitRef="number">0.5788</sny:SpecialDistributionPercentageOfShareCapitalDistributed>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-151" decimals="-6" id="f-793" unitRef="eur">486000000</ifrs-full:RevenueFromSaleOfGoods>
    <sny:DecreaseThroughLossOfControlOfSubsidiaryNetAssets contextRef="c-40" decimals="-6" id="f-794" unitRef="eur">1227000000</sny:DecreaseThroughLossOfControlOfSubsidiaryNetAssets>
    <ifrs-full:DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill contextRef="c-40" decimals="-6" id="f-795" unitRef="eur">164000000</ifrs-full:DecreaseThroughLossOfControlOfSubsidiaryIntangibleAssetsAndGoodwill>
    <sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent contextRef="c-38" decimals="-6" id="f-796" unitRef="eur">793000000</sny:ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c-40"
      decimals="2"
      id="f-797"
      unitRef="eurPerShare">14.58</ifrs-full:WeightedAverageSharePrice2019>
    <sny:ConsiderationTransferredMaximumAmount contextRef="c-152" decimals="-6" id="f-798" unitRef="eur">150000000</sny:ConsiderationTransferredMaximumAmount>
    <sny:PercentageOfVotingEquityInterestsDivested contextRef="c-153" decimals="2" id="f-799" unitRef="number">120000</sny:PercentageOfVotingEquityInterestsDivested>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-147" decimals="3" id="f-800" unitRef="number">0.301</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod contextRef="c-154" decimals="-6" id="f-801" unitRef="eur">413000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c-40"
      decimals="2"
      id="f-802"
      unitRef="eurPerShare">14.58</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:NetForeignExchangeLoss contextRef="c-40" decimals="-6" id="f-803" unitRef="eur">35000000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:OtherProvisions contextRef="c-155" decimals="-6" id="f-804" unitRef="eur">14000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions contextRef="c-156" decimals="-6" id="f-805" unitRef="eur">15000000</ifrs-full:OtherProvisions>
    <sny:OtherGainsLossesAndLitigation contextRef="c-40" decimals="-6" id="f-806" unitRef="eur">3000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-40" decimals="-6" id="f-807" unitRef="eur">-111000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-40" decimals="-6" id="f-808" unitRef="eur">101000000</ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:CollaborationAgreementPeriodAfterLossOfControl contextRef="c-157" id="f-809">P5Y</sny:CollaborationAgreementPeriodAfterLossOfControl>
    <sny:CollaborationAgreementAnnualNetSalesTarget contextRef="c-158" decimals="-6" id="f-810" unitRef="eur">300000000</sny:CollaborationAgreementAnnualNetSalesTarget>
    <sny:CollaborationAgreementCommitmentAmount contextRef="c-159" decimals="-8" id="f-811" unitRef="eur">1100000000</sny:CollaborationAgreementCommitmentAmount>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate contextRef="c-147" decimals="3" id="f-812" unitRef="number">0.301</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:CashTransferred contextRef="c-160" decimals="-8" id="f-813" unitRef="usd">1100000000</ifrs-full:CashTransferred>
    <ifrs-full:CashTransferred contextRef="c-160" decimals="-6" id="f-814" unitRef="eur">973000000</ifrs-full:CashTransferred>
    <sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement contextRef="c-160" decimals="-6" id="f-815" unitRef="usd">350000000</sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-160" decimals="-6" id="f-816" unitRef="eur">965000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-161" decimals="-6" id="f-817" unitRef="eur">932000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:BusinessCombinationNumberOfSharesIncludedInPublicOffering
      contextRef="c-162"
      decimals="-6"
      id="f-818"
      unitRef="shares">61000000</sny:BusinessCombinationNumberOfSharesIncludedInPublicOffering>
    <sny:BusinessCombinationPurchasePricePerShare
      contextRef="c-162"
      decimals="2"
      id="f-819"
      unitRef="eurPerShare">5.45</sny:BusinessCombinationPurchasePricePerShare>
    <sny:BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering contextRef="c-163" decimals="4" id="f-820" unitRef="number">0.9503</sny:BusinessCombinationProportionOfIssuedAndOutstandingShareCapitalTenderedIntoTheOffering>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-164" decimals="4" id="f-821" unitRef="number">0.9739</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <sny:BusinessAcquisitionsPercentageOfVotingInterestsAcquired contextRef="c-165" decimals="4" id="f-822" unitRef="number">1.0000</sny:BusinessAcquisitionsPercentageOfVotingInterestsAcquired>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-166" decimals="-6" id="f-823" unitRef="eur">339000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-167" decimals="-6" id="f-824" unitRef="eur">326000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashTransferred contextRef="c-168" decimals="-6" id="f-825" unitRef="usd">160000000</ifrs-full:CashTransferred>
    <ifrs-full:CashTransferred contextRef="c-168" decimals="-6" id="f-826" unitRef="eur">136000000</ifrs-full:CashTransferred>
    <sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement contextRef="c-168" decimals="-6" id="f-827" unitRef="usd">310000000</sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-168" decimals="-6" id="f-828" unitRef="eur">130000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-169" decimals="-6" id="f-829" unitRef="eur">135000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:BusinessCombinationPurchasePricePerShare
      contextRef="c-170"
      decimals="2"
      id="f-830"
      unitRef="usdPerShare">0.38</sny:BusinessCombinationPurchasePricePerShare>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="c-171" decimals="-6" id="f-831" unitRef="eur">2118000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-171" decimals="-6" id="f-832" unitRef="eur">396000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="c-171" decimals="-6" id="f-833" unitRef="eur">93000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <sny:OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate contextRef="c-171" decimals="-6" id="f-834" unitRef="eur">235000000</sny:OtherCurrentAssetsAndCurrentLiabilitiesAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="c-171" decimals="-6" id="f-835" unitRef="eur">247000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate contextRef="c-171" decimals="-6" id="f-836" unitRef="eur">323000000</ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="c-171" decimals="-6" id="f-837" unitRef="eur">462000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="c-171" decimals="-6" id="f-838" unitRef="eur">2118000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="c-171" decimals="-6" id="f-839" unitRef="eur">2580000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-172" decimals="-6" id="f-840" unitRef="eur">2333000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage contextRef="c-173" decimals="2" id="f-841" unitRef="number">0.05</sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage>
    <sny:BusinessCombinationPurchasePricePerShare
      contextRef="c-171"
      decimals="2"
      id="f-842"
      unitRef="usdPerShare">0.38</sny:BusinessCombinationPurchasePricePerShare>
    <sny:BusinessCombinationPurchasePricePerShare
      contextRef="c-174"
      decimals="INF"
      id="f-843"
      unitRef="usdPerShare">9.50</sny:BusinessCombinationPurchasePricePerShare>
    <sny:BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis contextRef="c-174" decimals="-8" id="f-844" unitRef="usd">1900000000</sny:BusinessCombinationEstimatedPurchasePriceOnAFullyDilutedBasis>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-174" decimals="-6" id="f-845" unitRef="eur">1739000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-175" decimals="-6" id="f-846" unitRef="eur">1575000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashTransferred contextRef="c-176" decimals="-6" id="f-847" unitRef="eur">55000000</ifrs-full:CashTransferred>
    <sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement contextRef="c-176" decimals="-6" id="f-848" unitRef="eur">95000000</sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-176" decimals="-6" id="f-849" unitRef="eur">55000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-177" decimals="-6" id="f-850" unitRef="eur">50000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-851">Property, plant and equipment&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.3.1. Property, plant and equipment owned&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment owned by Sanofi is comprised of the following items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Machinery&lt;br/&gt;and&lt;br/&gt;equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fixtures,&lt;br/&gt;fittings&#160;and&lt;br/&gt;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Property,&#160;plant&lt;br/&gt;and&#160;equipment&lt;br/&gt;in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,828&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,127&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,524&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,454&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;23,169&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(839)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;240&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,170&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,648&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,655&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,097&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24,810&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;237&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,328&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,848&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,515&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,996&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;23,924&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;228&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,681&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,912&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,500&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,449&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24,770&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(13,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(592)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(14,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(356)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(622)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(14,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(14,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,181&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,039&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;463&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,257&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,160&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;This line includes in particular property, plant and equipment in process brought into service during the period, but also the effect of the reclassification of assets to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth acquisitions and capitalized interest by operating segment for the years ended December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,693&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,748&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,504&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Consumer Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Of which capitalized interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take into account of the two new operating segments, Biopharma and Consumer Healthcare, effective January&#160;1,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Off balance sheet commitments relating to property, plant and equipment as of December 31, 2023, 2022 and 2021 are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Firm orders of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment pledged as security for liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth the net impairment losses recognized in each of the last three financial periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net impairment losses on property, plant and equipment&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;186&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These amounts mainly comprise impairment losses recognized as a result of decisions taken during the periods presented, relating primarily to shutdowns or changes in use of industrial sites.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.3.2. Property, plant and equipment leased &#x2013; right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Right-of-use assets relating to property, plant and equipment leased by Sanofi are analyzed in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,711&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,745&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,872&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,672&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation and impairment charged in the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(797)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation and impairment charged in the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation and impairment charged in the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,948&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,815&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,654&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;This line also includes the effect of the reclassification of assets to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;In December&#160;2018, Sanofi signed two leases on real estate assets in the United States (at Cambridge, Massachusetts) for an initial lease term of 15 years. The first lease, relating to office space, began in April&#160;2021; Sanofi recognized a right-of-use asset of &#x20ac;320 million, as well as the lease liability. The second lease, relating to laboratory facilities, began on July&#160;1, 2021; Sanofi recognized a right-of-use asset of &#x20ac;424 million, as well as the lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Leased assets comprised offices and industrial premises (90%) and the vehicle fleet (10%) as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Annual lease costs on short term leases and low value asset leases amounted to &#x20ac;19 million in the year ended December 31, 2023, &#x20ac;26 million in the year ended December 31, 2022, and &#x20ac;25 million in the year ended December 31, 2021. Variable lease payments, sub-leasing activities, and sale-and-leaseback transactions were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total cash outflows on leases (excluding annual lease costs on short term leases and low value asset leases) were &#x20ac;315 million in&#160;the year ended December 31, 2023, &#x20ac;389 million in the year ended December 31, 2022, and &#x20ac;302 million in the year ended&#160;December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A maturity analysis of the lease liability is disclosed in Note&#160;D.17.2.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Commitments related to short-term leases and low value asset leases, including future payments for lease contracts committed but not yet commenced, are disclosed in Note&#160;D.21.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <sny:DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock contextRef="c-1" id="f-852">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment owned by Sanofi is comprised of the following items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Machinery&lt;br/&gt;and&lt;br/&gt;equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fixtures,&lt;br/&gt;fittings&#160;and&lt;br/&gt;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Property,&#160;plant&lt;br/&gt;and&#160;equipment&lt;br/&gt;in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,828&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,127&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,524&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,454&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;23,169&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(839)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;240&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,170&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,648&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,655&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,097&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24,810&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;237&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,328&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,848&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,515&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,996&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;23,924&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;228&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,681&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,912&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,500&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,449&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24,770&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(13,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(592)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(14,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(356)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(622)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(14,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(14,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,181&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,039&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;463&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,257&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,160&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;This line includes in particular property, plant and equipment in process brought into service during the period, but also the effect of the reclassification of assets to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfChangesInPropertyPlantAndEquipmentTableTextBlock>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-178" decimals="-6" id="f-853" unitRef="eur">236000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-179" decimals="-6" id="f-854" unitRef="eur">6828000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-180" decimals="-6" id="f-855" unitRef="eur">11127000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-181" decimals="-6" id="f-856" unitRef="eur">2524000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-182" decimals="-6" id="f-857" unitRef="eur">2454000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-183" decimals="-6" id="f-858" unitRef="eur">23169000000</ifrs-full:PropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-184" decimals="-6" id="f-859" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-185" decimals="-6" id="f-860" unitRef="eur">11000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-186" decimals="-6" id="f-861" unitRef="eur">15000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-187" decimals="-6" id="f-862" unitRef="eur">2000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-188" decimals="-6" id="f-863" unitRef="eur">2000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-189" decimals="-6" id="f-864" unitRef="eur">30000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-184" decimals="-6" id="f-865" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-185" decimals="-6" id="f-866" unitRef="eur">10000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-186" decimals="-6" id="f-867" unitRef="eur">51000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-187" decimals="-6" id="f-868" unitRef="eur">39000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-188" decimals="-6" id="f-869" unitRef="eur">1404000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-189" decimals="-6" id="f-870" unitRef="eur">1504000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-184" decimals="-6" id="f-871" unitRef="eur">3000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-185" decimals="-6" id="f-872" unitRef="eur">75000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-186" decimals="-6" id="f-873" unitRef="eur">153000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-187" decimals="-6" id="f-874" unitRef="eur">80000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-188" decimals="-6" id="f-875" unitRef="eur">3000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-189" decimals="-6" id="f-876" unitRef="eur">314000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-184" decimals="-6" id="f-877" unitRef="eur">6000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-185" decimals="-6" id="f-878" unitRef="eur">169000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-186" decimals="-6" id="f-879" unitRef="eur">155000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-187" decimals="-6" id="f-880" unitRef="eur">34000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-188" decimals="-6" id="f-881" unitRef="eur">79000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-189" decimals="-6" id="f-882" unitRef="eur">443000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-184" decimals="-6" id="f-883" unitRef="eur">1000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-185" decimals="-6" id="f-884" unitRef="eur">227000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-186" decimals="-6" id="f-885" unitRef="eur">453000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-187" decimals="-6" id="f-886" unitRef="eur">136000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-188" decimals="-6" id="f-887" unitRef="eur">-839000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-189" decimals="-6" id="f-888" unitRef="eur">-22000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-190" decimals="-6" id="f-889" unitRef="eur">240000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-191" decimals="-6" id="f-890" unitRef="eur">7170000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-192" decimals="-6" id="f-891" unitRef="eur">11648000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-193" decimals="-6" id="f-892" unitRef="eur">2655000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-194" decimals="-6" id="f-893" unitRef="eur">3097000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-195" decimals="-6" id="f-894" unitRef="eur">24810000000</ifrs-full:PropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-196" decimals="-6" id="f-895" unitRef="eur">-17000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-197" decimals="-6" id="f-896" unitRef="eur">-294000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-198" decimals="-6" id="f-897" unitRef="eur">-1480000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-199" decimals="-6" id="f-898" unitRef="eur">-163000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-200" decimals="-6" id="f-899" unitRef="eur">-150000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-201" decimals="-6" id="f-900" unitRef="eur">-2104000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-196" decimals="-6" id="f-901" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-197" decimals="-6" id="f-902" unitRef="eur">11000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-198" decimals="-6" id="f-903" unitRef="eur">54000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-199" decimals="-6" id="f-904" unitRef="eur">41000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-200" decimals="-6" id="f-905" unitRef="eur">1642000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-201" decimals="-6" id="f-906" unitRef="eur">1748000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-196" decimals="-6" id="f-907" unitRef="eur">1000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-197" decimals="-6" id="f-908" unitRef="eur">161000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-198" decimals="-6" id="f-909" unitRef="eur">240000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-199" decimals="-6" id="f-910" unitRef="eur">155000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-200" decimals="-6" id="f-911" unitRef="eur">2000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-201" decimals="-6" id="f-912" unitRef="eur">559000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-196" decimals="-6" id="f-913" unitRef="eur">17000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-197" decimals="-6" id="f-914" unitRef="eur">122000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-198" decimals="-6" id="f-915" unitRef="eur">144000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-199" decimals="-6" id="f-916" unitRef="eur">29000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-200" decimals="-6" id="f-917" unitRef="eur">35000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-201" decimals="-6" id="f-918" unitRef="eur">347000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-196" decimals="-6" id="f-919" unitRef="eur">-2000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-197" decimals="-6" id="f-920" unitRef="eur">480000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-198" decimals="-6" id="f-921" unitRef="eur">722000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-199" decimals="-6" id="f-922" unitRef="eur">108000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-200" decimals="-6" id="f-923" unitRef="eur">-1626000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-201" decimals="-6" id="f-924" unitRef="eur">-318000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-202" decimals="-6" id="f-925" unitRef="eur">237000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-203" decimals="-6" id="f-926" unitRef="eur">7328000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-204" decimals="-6" id="f-927" unitRef="eur">10848000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-205" decimals="-6" id="f-928" unitRef="eur">2515000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-206" decimals="-6" id="f-929" unitRef="eur">2996000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-207" decimals="-6" id="f-930" unitRef="eur">23924000000</ifrs-full:PropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-208" decimals="-6" id="f-931" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-209" decimals="-6" id="f-932" unitRef="eur">-11000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-210" decimals="-6" id="f-933" unitRef="eur">-29000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-211" decimals="-6" id="f-934" unitRef="eur">-7000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-212" decimals="-6" id="f-935" unitRef="eur">-4000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-213" decimals="-6" id="f-936" unitRef="eur">-51000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-208" decimals="-6" id="f-937" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-209" decimals="-6" id="f-938" unitRef="eur">27000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-210" decimals="-6" id="f-939" unitRef="eur">47000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-211" decimals="-6" id="f-940" unitRef="eur">36000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-212" decimals="-6" id="f-941" unitRef="eur">1583000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-213" decimals="-6" id="f-942" unitRef="eur">1693000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-208" decimals="-6" id="f-943" unitRef="eur">2000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-209" decimals="-6" id="f-944" unitRef="eur">50000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-210" decimals="-6" id="f-945" unitRef="eur">340000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-211" decimals="-6" id="f-946" unitRef="eur">100000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-212" decimals="-6" id="f-947" unitRef="eur">10000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-213" decimals="-6" id="f-948" unitRef="eur">502000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-208" decimals="-6" id="f-949" unitRef="eur">-5000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-209" decimals="-6" id="f-950" unitRef="eur">-94000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-210" decimals="-6" id="f-951" unitRef="eur">-71000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-211" decimals="-6" id="f-952" unitRef="eur">-30000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-212" decimals="-6" id="f-953" unitRef="eur">-45000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-213" decimals="-6" id="f-954" unitRef="eur">-245000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-208" decimals="-6" id="f-955" unitRef="eur">-2000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-209" decimals="-6" id="f-956" unitRef="eur">481000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-210" decimals="-6" id="f-957" unitRef="eur">457000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-211" decimals="-6" id="f-958" unitRef="eur">86000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-212" decimals="-6" id="f-959" unitRef="eur">-1071000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-213" decimals="-6" id="f-960" unitRef="eur">-49000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-214" decimals="-6" id="f-961" unitRef="eur">228000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-215" decimals="-6" id="f-962" unitRef="eur">7681000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-216" decimals="-6" id="f-963" unitRef="eur">10912000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-217" decimals="-6" id="f-964" unitRef="eur">2500000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-218" decimals="-6" id="f-965" unitRef="eur">3449000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-219" decimals="-6" id="f-966" unitRef="eur">24770000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-220" decimals="-6" id="f-967" unitRef="eur">-10000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-221" decimals="-6" id="f-968" unitRef="eur">-3898000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-222" decimals="-6" id="f-969" unitRef="eur">-7792000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-223" decimals="-6" id="f-970" unitRef="eur">-1981000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-224" decimals="-6" id="f-971" unitRef="eur">-123000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-225" decimals="-6" id="f-972" unitRef="eur">-13804000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationExpense contextRef="c-226" decimals="-6" id="f-973" unitRef="eur">0</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-227" decimals="-6" id="f-974" unitRef="eur">306000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-228" decimals="-6" id="f-975" unitRef="eur">592000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-229" decimals="-6" id="f-976" unitRef="eur">167000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-230" decimals="-6" id="f-977" unitRef="eur">0</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-231" decimals="-6" id="f-978" unitRef="eur">1065000000</ifrs-full:DepreciationExpense>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-226" decimals="-6" id="f-979" unitRef="eur">0</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-227" decimals="-6" id="f-980" unitRef="eur">3000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-228" decimals="-6" id="f-981" unitRef="eur">22000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-229" decimals="-6" id="f-982" unitRef="eur">2000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-230" decimals="-6" id="f-983" unitRef="eur">12000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-231" decimals="-6" id="f-984" unitRef="eur">39000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-226" decimals="-6" id="f-985" unitRef="eur">0</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-227" decimals="-6" id="f-986" unitRef="eur">-74000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-228" decimals="-6" id="f-987" unitRef="eur">-149000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-229" decimals="-6" id="f-988" unitRef="eur">-75000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-230" decimals="-6" id="f-989" unitRef="eur">-1000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-231" decimals="-6" id="f-990" unitRef="eur">-299000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-226" decimals="-6" id="f-991" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-227" decimals="-6" id="f-992" unitRef="eur">-80000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-228" decimals="-6" id="f-993" unitRef="eur">-99000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-229" decimals="-6" id="f-994" unitRef="eur">-29000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-230" decimals="-6" id="f-995" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-231" decimals="-6" id="f-996" unitRef="eur">-208000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-226" decimals="-6" id="f-997" unitRef="eur">1000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-227" decimals="-6" id="f-998" unitRef="eur">23000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-228" decimals="-6" id="f-999" unitRef="eur">16000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-229" decimals="-6" id="f-1000" unitRef="eur">-11000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-230" decimals="-6" id="f-1001" unitRef="eur">6000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-231" decimals="-6" id="f-1002" unitRef="eur">35000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-232" decimals="-6" id="f-1003" unitRef="eur">-9000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-233" decimals="-6" id="f-1004" unitRef="eur">-4190000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-234" decimals="-6" id="f-1005" unitRef="eur">-8340000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-235" decimals="-6" id="f-1006" unitRef="eur">-2115000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-236" decimals="-6" id="f-1007" unitRef="eur">-128000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-237" decimals="-6" id="f-1008" unitRef="eur">-14782000000</ifrs-full:PropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-238" decimals="-6" id="f-1009" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-239" decimals="-6" id="f-1010" unitRef="eur">201000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-240" decimals="-6" id="f-1011" unitRef="eur">1202000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-241" decimals="-6" id="f-1012" unitRef="eur">130000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-242" decimals="-6" id="f-1013" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-243" decimals="-6" id="f-1014" unitRef="eur">1533000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DepreciationExpense contextRef="c-238" decimals="-6" id="f-1015" unitRef="eur">0</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-239" decimals="-6" id="f-1016" unitRef="eur">356000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-240" decimals="-6" id="f-1017" unitRef="eur">622000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-241" decimals="-6" id="f-1018" unitRef="eur">164000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-242" decimals="-6" id="f-1019" unitRef="eur">0</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-243" decimals="-6" id="f-1020" unitRef="eur">1142000000</ifrs-full:DepreciationExpense>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-238" decimals="-6" id="f-1021" unitRef="eur">1000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-239" decimals="-6" id="f-1022" unitRef="eur">50000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-240" decimals="-6" id="f-1023" unitRef="eur">58000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-241" decimals="-6" id="f-1024" unitRef="eur">2000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-242" decimals="-6" id="f-1025" unitRef="eur">75000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-243" decimals="-6" id="f-1026" unitRef="eur">186000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-238" decimals="-6" id="f-1027" unitRef="eur">0</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-239" decimals="-6" id="f-1028" unitRef="eur">-133000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-240" decimals="-6" id="f-1029" unitRef="eur">-201000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-241" decimals="-6" id="f-1030" unitRef="eur">-153000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-242" decimals="-6" id="f-1031" unitRef="eur">-31000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-243" decimals="-6" id="f-1032" unitRef="eur">-518000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-238" decimals="-6" id="f-1033" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-239" decimals="-6" id="f-1034" unitRef="eur">-52000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-240" decimals="-6" id="f-1035" unitRef="eur">-69000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-241" decimals="-6" id="f-1036" unitRef="eur">-22000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-242" decimals="-6" id="f-1037" unitRef="eur">5000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-243" decimals="-6" id="f-1038" unitRef="eur">-138000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-238" decimals="-6" id="f-1039" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-239" decimals="-6" id="f-1040" unitRef="eur">89000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-240" decimals="-6" id="f-1041" unitRef="eur">49000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-241" decimals="-6" id="f-1042" unitRef="eur">5000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-242" decimals="-6" id="f-1043" unitRef="eur">-1000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-243" decimals="-6" id="f-1044" unitRef="eur">142000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-244" decimals="-6" id="f-1045" unitRef="eur">-10000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-245" decimals="-6" id="f-1046" unitRef="eur">-4225000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-246" decimals="-6" id="f-1047" unitRef="eur">-7637000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-247" decimals="-6" id="f-1048" unitRef="eur">-2015000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-248" decimals="-6" id="f-1049" unitRef="eur">-168000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-249" decimals="-6" id="f-1050" unitRef="eur">-14055000000</ifrs-full:PropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-250" decimals="-6" id="f-1051" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-251" decimals="-6" id="f-1052" unitRef="eur">5000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-252" decimals="-6" id="f-1053" unitRef="eur">16000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-253" decimals="-6" id="f-1054" unitRef="eur">3000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-254" decimals="-6" id="f-1055" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-255" decimals="-6" id="f-1056" unitRef="eur">24000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DepreciationExpense contextRef="c-250" decimals="-6" id="f-1057" unitRef="eur">0</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-251" decimals="-6" id="f-1058" unitRef="eur">321000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-252" decimals="-6" id="f-1059" unitRef="eur">620000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-253" decimals="-6" id="f-1060" unitRef="eur">139000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-254" decimals="-6" id="f-1061" unitRef="eur">0</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c-255" decimals="-6" id="f-1062" unitRef="eur">1080000000</ifrs-full:DepreciationExpense>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-250" decimals="-6" id="f-1063" unitRef="eur">0</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-251" decimals="-6" id="f-1064" unitRef="eur">30000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-252" decimals="-6" id="f-1065" unitRef="eur">46000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-253" decimals="-6" id="f-1066" unitRef="eur">4000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-254" decimals="-6" id="f-1067" unitRef="eur">50000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment contextRef="c-255" decimals="-6" id="f-1068" unitRef="eur">130000000</ifrs-full:WritedownsReversalsOfPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-250" decimals="-6" id="f-1069" unitRef="eur">0</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-251" decimals="-6" id="f-1070" unitRef="eur">-48000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-252" decimals="-6" id="f-1071" unitRef="eur">-334000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-253" decimals="-6" id="f-1072" unitRef="eur">-98000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-254" decimals="-6" id="f-1073" unitRef="eur">-8000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="c-255" decimals="-6" id="f-1074" unitRef="eur">-488000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-250" decimals="-6" id="f-1075" unitRef="eur">2000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-251" decimals="-6" id="f-1076" unitRef="eur">45000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-252" decimals="-6" id="f-1077" unitRef="eur">44000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-253" decimals="-6" id="f-1078" unitRef="eur">21000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-254" decimals="-6" id="f-1079" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-255" decimals="-6" id="f-1080" unitRef="eur">112000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-250" decimals="-6" id="f-1081" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-251" decimals="-6" id="f-1082" unitRef="eur">-22000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-252" decimals="-6" id="f-1083" unitRef="eur">36000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-253" decimals="-6" id="f-1084" unitRef="eur">-1000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-254" decimals="-6" id="f-1085" unitRef="eur">18000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-255" decimals="-6" id="f-1086" unitRef="eur">31000000</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-256" decimals="-6" id="f-1087" unitRef="eur">-8000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-257" decimals="-6" id="f-1088" unitRef="eur">-4500000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-258" decimals="-6" id="f-1089" unitRef="eur">-7873000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-259" decimals="-6" id="f-1090" unitRef="eur">-2037000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-260" decimals="-6" id="f-1091" unitRef="eur">-192000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-261" decimals="-6" id="f-1092" unitRef="eur">-14610000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-262" decimals="-6" id="f-1093" unitRef="eur">231000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-263" decimals="-6" id="f-1094" unitRef="eur">2980000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-264" decimals="-6" id="f-1095" unitRef="eur">3308000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-265" decimals="-6" id="f-1096" unitRef="eur">540000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-266" decimals="-6" id="f-1097" unitRef="eur">2969000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-8" decimals="-6" id="f-1098" unitRef="eur">10028000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-267" decimals="-6" id="f-1099" unitRef="eur">227000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-268" decimals="-6" id="f-1100" unitRef="eur">3103000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-269" decimals="-6" id="f-1101" unitRef="eur">3211000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-270" decimals="-6" id="f-1102" unitRef="eur">500000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-271" decimals="-6" id="f-1103" unitRef="eur">2828000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-7" decimals="-6" id="f-1104" unitRef="eur">9869000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-272" decimals="-6" id="f-1105" unitRef="eur">220000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-273" decimals="-6" id="f-1106" unitRef="eur">3181000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-274" decimals="-6" id="f-1107" unitRef="eur">3039000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-275" decimals="-6" id="f-1108" unitRef="eur">463000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-276" decimals="-6" id="f-1109" unitRef="eur">3257000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-5" decimals="-6" id="f-1110" unitRef="eur">10160000000</ifrs-full:PropertyPlantAndEquipment>
    <sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock contextRef="c-1" id="f-1111">&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth acquisitions and capitalized interest by operating segment for the years ended December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,693&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,748&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,504&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Consumer Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Manufacturing &amp;amp; Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Of which capitalized interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take into account of the two new operating segments, Biopharma and Consumer Healthcare, effective January&#160;1,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentByOperatingSegmentsExplanatoryTableTextBlock>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-1112" unitRef="eur">1693000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-9" decimals="-6" id="f-1113" unitRef="eur">1748000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-10" decimals="-6" id="f-1114" unitRef="eur">1504000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-277" decimals="-6" id="f-1115" unitRef="eur">1592000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-278" decimals="-6" id="f-1116" unitRef="eur">1678000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-279" decimals="-6" id="f-1117" unitRef="eur">1188000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-280" decimals="-6" id="f-1118" unitRef="eur">1129000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-281" decimals="-6" id="f-1119" unitRef="eur">1010000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-282" decimals="-6" id="f-1120" unitRef="eur">421000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-283" decimals="-6" id="f-1121" unitRef="eur">101000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-284" decimals="-6" id="f-1122" unitRef="eur">70000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-285" decimals="-6" id="f-1123" unitRef="eur">73000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-286" decimals="-6" id="f-1124" unitRef="eur">90000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-287" decimals="-6" id="f-1125" unitRef="eur">63000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:InterestCostsCapitalised contextRef="c-1" decimals="-6" id="f-1126" unitRef="eur">26000000</ifrs-full:InterestCostsCapitalised>
    <ifrs-full:InterestCostsCapitalised contextRef="c-9" decimals="-6" id="f-1127" unitRef="eur">17000000</ifrs-full:InterestCostsCapitalised>
    <ifrs-full:InterestCostsCapitalised contextRef="c-10" decimals="-6" id="f-1128" unitRef="eur">14000000</ifrs-full:InterestCostsCapitalised>
    <sny:DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock contextRef="c-1" id="f-1129">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Off balance sheet commitments relating to property, plant and equipment as of December 31, 2023, 2022 and 2021 are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Firm orders of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment pledged as security for liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfOffBalanceSheetCommitmentsOfPropertyPlantAndEquipmentTableTextBlock>
    <sny:FirmOrdersOfPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-1130" unitRef="eur">638000000</sny:FirmOrdersOfPropertyPlantAndEquipment>
    <sny:FirmOrdersOfPropertyPlantAndEquipment contextRef="c-9" decimals="-6" id="f-1131" unitRef="eur">861000000</sny:FirmOrdersOfPropertyPlantAndEquipment>
    <sny:FirmOrdersOfPropertyPlantAndEquipment contextRef="c-10" decimals="-6" id="f-1132" unitRef="eur">769000000</sny:FirmOrdersOfPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity contextRef="c-5" decimals="-6" id="f-1133" unitRef="eur">16000000</ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity>
    <ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity contextRef="c-7" decimals="-6" id="f-1134" unitRef="eur">0</ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity>
    <ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity contextRef="c-8" decimals="-6" id="f-1135" unitRef="eur">9000000</ifrs-full:PropertyPlantAndEquipmentPledgedAsSecurity>
    <sny:DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock contextRef="c-1" id="f-1136">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth the net impairment losses recognized in each of the last three financial periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net impairment losses on property, plant and equipment&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;186&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These amounts mainly comprise impairment losses recognized as a result of decisions taken during the periods presented, relating primarily to shutdowns or changes in use of industrial sites.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfImpairmentLossesOfPropertyPlantAndEquipmentTableTextBlock>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-1137" unitRef="eur">130000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-9" decimals="-6" id="f-1138" unitRef="eur">186000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-10" decimals="-6" id="f-1139" unitRef="eur">39000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="c-1" id="f-1140">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Right-of-use assets relating to property, plant and equipment leased by Sanofi are analyzed in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,711&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,745&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,872&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,672&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation and impairment charged in the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(797)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation and impairment charged in the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Depreciation and impairment charged in the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated depreciation &amp;amp; impairment at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,948&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,815&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,654&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;This line also includes the effect of the reclassification of assets to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;In December&#160;2018, Sanofi signed two leases on real estate assets in the United States (at Cambridge, Massachusetts) for an initial lease term of 15 years. The first lease, relating to office space, began in April&#160;2021; Sanofi recognized a right-of-use asset of &#x20ac;320 million, as well as the lease liability. The second lease, relating to laboratory facilities, began on July&#160;1, 2021; Sanofi recognized a right-of-use asset of &#x20ac;424 million, as well as the lease liability.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets contextRef="c-183" decimals="-6" id="f-1141" unitRef="eur">1711000000</ifrs-full:RightofuseAssets>
    <sny:AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-189" decimals="-6" id="f-1142" unitRef="eur">93000000</sny:AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets>
    <sny:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets contextRef="c-189" decimals="-6" id="f-1143" unitRef="eur">963000000</sny:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets>
    <sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-189" decimals="-6" id="f-1144" unitRef="eur">91000000</sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets contextRef="c-189" decimals="-6" id="f-1145" unitRef="eur">76000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-189" decimals="-6" id="f-1146" unitRef="eur">-7000000</sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-195" decimals="-6" id="f-1147" unitRef="eur">2745000000</ifrs-full:RightofuseAssets>
    <sny:AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-201" decimals="-6" id="f-1148" unitRef="eur">-26000000</sny:AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets>
    <sny:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets contextRef="c-201" decimals="-6" id="f-1149" unitRef="eur">292000000</sny:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets>
    <sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-201" decimals="-6" id="f-1150" unitRef="eur">232000000</sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets contextRef="c-201" decimals="-6" id="f-1151" unitRef="eur">101000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-201" decimals="-6" id="f-1152" unitRef="eur">-8000000</sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-207" decimals="-6" id="f-1153" unitRef="eur">2872000000</ifrs-full:RightofuseAssets>
    <sny:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets contextRef="c-213" decimals="-6" id="f-1154" unitRef="eur">247000000</sny:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantandEquipmentRightOfUseAssets>
    <sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-213" decimals="-6" id="f-1155" unitRef="eur">314000000</sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets contextRef="c-213" decimals="-6" id="f-1156" unitRef="eur">-58000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-213" decimals="-6" id="f-1157" unitRef="eur">-75000000</sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-219" decimals="-6" id="f-1158" unitRef="eur">2672000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-225" decimals="-6" id="f-1159" unitRef="eur">-513000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-231" decimals="-6" id="f-1160" unitRef="eur">315000000</ifrs-full:DepreciationRightofuseAssets>
    <sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-231" decimals="-6" id="f-1161" unitRef="eur">-40000000</sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets contextRef="c-231" decimals="-6" id="f-1162" unitRef="eur">-15000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-231" decimals="-6" id="f-1163" unitRef="eur">6000000</sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-237" decimals="-6" id="f-1164" unitRef="eur">-797000000</ifrs-full:RightofuseAssets>
    <sny:AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-243" decimals="-6" id="f-1165" unitRef="eur">14000000</sny:AcquisitionThroughBusinessCombinationsPropertyPlantAndEquipmentRightOfUseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-243" decimals="-6" id="f-1166" unitRef="eur">341000000</ifrs-full:DepreciationRightofuseAssets>
    <sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-243" decimals="-6" id="f-1167" unitRef="eur">-82000000</sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets contextRef="c-243" decimals="-6" id="f-1168" unitRef="eur">-17000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-243" decimals="-6" id="f-1169" unitRef="eur">2000000</sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-249" decimals="-6" id="f-1170" unitRef="eur">-1057000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-255" decimals="-6" id="f-1171" unitRef="eur">292000000</ifrs-full:DepreciationRightofuseAssets>
    <sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-255" decimals="-6" id="f-1172" unitRef="eur">-276000000</sny:DisposalsAndRetirementsPropertyPlantAndEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets contextRef="c-255" decimals="-6" id="f-1173" unitRef="eur">21000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantandEquipmentRightOfUseAssets>
    <sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets contextRef="c-255" decimals="-6" id="f-1174" unitRef="eur">34000000</sny:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipmentRightOfUseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-261" decimals="-6" id="f-1175" unitRef="eur">-1018000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-8" decimals="-6" id="f-1176" unitRef="eur">1948000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-7" decimals="-6" id="f-1177" unitRef="eur">1815000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-5" decimals="-6" id="f-1178" unitRef="eur">1654000000</ifrs-full:RightofuseAssets>
    <sny:NumberOfLeaseAgreementsSigned
      contextRef="c-288"
      decimals="INF"
      id="f-1179"
      unitRef="lease">2</sny:NumberOfLeaseAgreementsSigned>
    <sny:InitialLeaseTerm contextRef="c-288" id="f-1180">P15Y</sny:InitialLeaseTerm>
    <ifrs-full:LeaseLiabilities contextRef="c-289" decimals="-6" id="f-1181" unitRef="eur">320000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:RightofuseAssets contextRef="c-289" decimals="-6" id="f-1182" unitRef="eur">320000000</ifrs-full:RightofuseAssets>
    <ifrs-full:LeaseLiabilities contextRef="c-290" decimals="-6" id="f-1183" unitRef="eur">424000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:RightofuseAssets contextRef="c-290" decimals="-6" id="f-1184" unitRef="eur">424000000</ifrs-full:RightofuseAssets>
    <sny:LeasedAssetsPercentage
      contextRef="c-291"
      decimals="2"
      id="f-1185"
      unitRef="number">0.90</sny:LeasedAssetsPercentage>
    <sny:LeasedAssetsPercentage
      contextRef="c-292"
      decimals="2"
      id="f-1186"
      unitRef="number">0.10</sny:LeasedAssetsPercentage>
    <sny:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="c-1" decimals="-6" id="f-1187" unitRef="eur">19000000</sny:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <sny:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="c-9" decimals="-6" id="f-1188" unitRef="eur">26000000</sny:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <sny:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="c-10" decimals="-6" id="f-1189" unitRef="eur">25000000</sny:ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:CashOutflowForLeases contextRef="c-1" decimals="-6" id="f-1190" unitRef="eur">315000000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c-9" decimals="-6" id="f-1191" unitRef="eur">389000000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c-10" decimals="-6" id="f-1192" unitRef="eur">302000000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory contextRef="c-1" id="f-1193">Goodwill and other intangible assets&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in goodwill comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;44,364&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements during the period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;48,056&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements during the period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(258)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49,892&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements during the period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49,404&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph&#160;86 of IAS&#160;36, and in 2022 the loss of control of EUROAPI (see note&#160;D.2.1.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;In accordance with IAS&#160;36, goodwill is allocated to groups of Cash Generating Units (CGUs) at a level corresponding to the Biopharma and Consumer Healthcare segments. When testing goodwill annually for impairment, the recoverable amount is determined for each of the two segments (Biopharma and Consumer Healthcare) on the basis of value in use, as derived from discounted estimates of the future cash flows in accordance with the policies described in Note&#160;B.6.1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The allocation of goodwill by segment as of December 31, 2023 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.078%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42,324&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,080&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49,404&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition of QRIB Intermediate Holdings, LLC (2023)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The provisional purchase price allocation for QRIB Intermediate Holdings, LLC resulted in the recognition of intangible assets (other than goodwill) o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;f &#x20ac;774 million as of the acquisition d&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ate (September&#160;29, 2023), a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;nd of goodwill provisionally measured at&#160;&#x20ac;475 million as of the acquisition date (see Note&#160;D.1.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition of Amunix Pharmaceuticals,&#160;Inc. (2022)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The final purchase price allocation for Amunix Pharmaceuticals, Inc. resulted in the recognition of intangible assets (other than goodwill) o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;f&#160;&#x20ac;493&#160;million as of the acquisition date (February&#160;8, 2022), and of goodwill measured at &#x20ac;609&#160;million as of the acquisition date (see Note&#160;D.2.1.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition of Translate Bio (2021)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The final purchase price allocation for Translate&#160;Bio resulted in the recognition of intangible a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ssets (other than goodwill) of&#160;&#x20ac;396&#160;million as of the acquisition date (September&#160;14, 2021), and of goodwill measured at &#x20ac;2,118&#160;million as of the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; acquisition date (see Note&#160;D.2.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in other intangible assets comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.916%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquired R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Products,&lt;br/&gt;trademarks and&lt;br/&gt;other rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total other&lt;br/&gt;intangible assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at January 1, 2021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,600&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;61,074&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,633&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;72,307&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(313)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(784)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,207&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;65,906&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,752&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;78,865&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(174)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,354&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;69,579&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,783&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;81,716&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,772&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;73,733&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,808&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85,313&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization &amp;amp; impairment at January 1, 2021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(49,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(53,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization &amp;amp; impairment at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(52,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(57,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,099)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization &amp;amp; impairment at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(54,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(60,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization &amp;amp; impairment at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(55,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(60,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,038&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,825&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24,319&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes the impact of the IFRIC agenda decision of March&#160;2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement (see Note&#160;A.2.1. to our 2021 consolidated financial statements, included in our annual report on Form&#160;20-F for that year).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;The &#x201c;Transfers&#x201d; line mainly comprises (i)&#160;acquired R&amp;amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;The &#x201c;Changes in scope of consolidation&#x201d; line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Notes&#160;D.1. and&#160;D.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;See Note&#160;D.5.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&#160;&#160;&#160;&#160;The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of &#x20ac;226&#160;million in&#160;2022 (see&#160;Note C.1.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(f)  This line mainly comprises:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt"&gt;the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April&#160;2023 in respect of the agreements on BEYFORTUS (nirsevimab) (see Note&#160;C.2.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt"&gt;an upfront payment of $500&#160;million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co-commercialization of TEV&#x2019;574; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt"&gt;an upfront payment of $175&#160;million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Products, trademarks and other rights&#x201d; mainly comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;&#x201c;marketed products&#x201d;, with a carrying amount of &#x20ac;16.6 billion as of December 31, 2023 (versus &#x20ac;12.7 billion as of            December 31, 2022 and &#x20ac;11.7 billion as of December 31, 2021) and a weighted average amortization period of approximately 11&#160;years; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;&#x201c;technology platforms&#x201d;, with a carrying amount of &#x20ac;1.2 billion as of December 31, 2023 (versus &#x20ac;2.2&#160;billion as of           December 31, 2022 and &#x20ac;1.2&#160;billion as of December 31, 2021) and a weighted average amortization period of approximately 18&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below provides information about the principal &#x201c;marketed products&#x201d;, which were recognized in connection with major acquisitions made by Sanofi and represented 96% of the carrying amount of that item as of December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&#160;&amp;amp;&lt;br/&gt;impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(years)&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Residual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(years)&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Boehringer Ingelheim &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Consumer Healthcare&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(33,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Chattem&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Protein Sciences&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ablynx&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bioverativ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;REZUROCK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;TZIELD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;BEYFORTUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;QUNOL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total: principal marketed products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;66,880&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(50,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,927&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,863&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,752&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Weighted averages. The amortization periods for these products vary between 1&#160;and 25&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Weighted averages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Commercialized products derived from the acquisition of these companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal intangible assets brought into service during 2023 were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ALTUVIIIO (efanesoctocog alfa), which extends protection from bleeds and treats acute hemorrhages in people with hemophilia&#160;A. The asset came into service on the date of marketing approval (February 23, 2023), and has a gross value of&#160;&#x20ac;1,110&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;During 2022, some of the acquired research and development came into commercial use, and started being amortized from the date of marketing approval; the main item involved was ENJAYMO (sutimlimab-jome), a treatment for cold agglutinin disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The main asset brought into service during 2021 was the Translate Bio mRNA technology platform.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Amortization of other intangible assets is recognized in the income statement within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, except for amortization of software and other rights of an industrial or operational nature which is recognized in the relevant classification of expense by function. An analysis of amortization of software is shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory contextRef="c-1" id="f-1194">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in goodwill comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;44,364&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements during the period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;48,056&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements during the period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(258)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49,892&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements during the period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49,404&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph&#160;86 of IAS&#160;36, and in 2022 the loss of control of EUROAPI (see note&#160;D.2.1.).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-293" decimals="-6" id="f-1195" unitRef="eur">44364000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="c-294" decimals="-6" id="f-1196" unitRef="eur">2179000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill contextRef="c-294" decimals="-6" id="f-1197" unitRef="eur">-89000000</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-294" decimals="-6" id="f-1198" unitRef="eur">1602000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-295" decimals="-6" id="f-1199" unitRef="eur">48056000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="c-296" decimals="-6" id="f-1200" unitRef="eur">609000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill contextRef="c-296" decimals="-6" id="f-1201" unitRef="eur">-258000000</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-296" decimals="-6" id="f-1202" unitRef="eur">1485000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-297" decimals="-6" id="f-1203" unitRef="eur">49892000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="c-298" decimals="-6" id="f-1204" unitRef="eur">475000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill contextRef="c-298" decimals="-6" id="f-1205" unitRef="eur">-90000000</ifrs-full:IncreaseDecreaseThroughOtherChangesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-298" decimals="-6" id="f-1206" unitRef="eur">-873000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-299" decimals="-6" id="f-1207" unitRef="eur">49404000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <sny:NumberOfOperatingSegments1
      contextRef="c-1"
      decimals="INF"
      id="f-1208"
      unitRef="segment">2</sny:NumberOfOperatingSegments1>
    <sny:DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock contextRef="c-1" id="f-1209">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The allocation of goodwill by segment as of December 31, 2023 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.361%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.078%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42,324&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,080&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49,404&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfGoodwillByOperatingSegmentsExplanatoryTableTextBlock>
    <ifrs-full:Goodwill contextRef="c-300" decimals="-6" id="f-1210" unitRef="eur">42324000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-301" decimals="-6" id="f-1211" unitRef="eur">7080000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-5" decimals="-6" id="f-1212" unitRef="eur">49404000000</ifrs-full:Goodwill>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-139" decimals="-6" id="f-1213" unitRef="eur">774000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:Goodwill contextRef="c-139" decimals="-6" id="f-1214" unitRef="eur">475000000</ifrs-full:Goodwill>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-302" decimals="-6" id="f-1215" unitRef="eur">493000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:Goodwill contextRef="c-302" decimals="-6" id="f-1216" unitRef="eur">609000000</ifrs-full:Goodwill>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-171" decimals="-6" id="f-1217" unitRef="eur">396000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:Goodwill contextRef="c-171" decimals="-6" id="f-1218" unitRef="eur">2118000000</ifrs-full:Goodwill>
    <sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock contextRef="c-1" id="f-1219">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in other intangible assets comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.916%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Acquired R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Products,&lt;br/&gt;trademarks and&lt;br/&gt;other rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total other&lt;br/&gt;intangible assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at January 1, 2021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,600&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;61,074&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,633&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;72,307&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(313)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(784)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,207&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;65,906&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,752&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;78,865&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(174)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,354&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;69,579&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,783&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;81,716&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions and other increases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross value at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,772&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;73,733&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,808&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85,313&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization &amp;amp; impairment at January 1, 2021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(49,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(53,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization &amp;amp; impairment at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(52,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(57,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,099)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization &amp;amp; impairment at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(54,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(60,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impairment losses, net of reversals&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Disposals and other decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated amortization &amp;amp; impairment at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(55,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(60,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,038&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,825&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24,319&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes the impact of the IFRIC agenda decision of March&#160;2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement (see Note&#160;A.2.1. to our 2021 consolidated financial statements, included in our annual report on Form&#160;20-F for that year).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;The &#x201c;Transfers&#x201d; line mainly comprises (i)&#160;acquired R&amp;amp;D that came into commercial use during the period and (ii)&#160;reclassifications of assets as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;The &#x201c;Changes in scope of consolidation&#x201d; line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Notes&#160;D.1. and&#160;D.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;See Note&#160;D.5.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&#160;&#160;&#160;&#160;The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of &#x20ac;226&#160;million in&#160;2022 (see&#160;Note C.1.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(f)  This line mainly comprises:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt"&gt;the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April&#160;2023 in respect of the agreements on BEYFORTUS (nirsevimab) (see Note&#160;C.2.);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt"&gt;an upfront payment of $500&#160;million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co-commercialization of TEV&#x2019;574; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt"&gt;an upfront payment of $175&#160;million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfReconciliationOfChangesInOtherIntangibleAssetsTableTextBlock>
    <ifrs-full:OtherIntangibleAssets contextRef="c-303" decimals="-6" id="f-1220" unitRef="eur">9600000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-304" decimals="-6" id="f-1221" unitRef="eur">61074000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-305" decimals="-6" id="f-1222" unitRef="eur">1633000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-183" decimals="-6" id="f-1223" unitRef="eur">72307000000</ifrs-full:OtherIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-306" decimals="-6" id="f-1224" unitRef="eur">1805000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-307" decimals="-6" id="f-1225" unitRef="eur">1821000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-308" decimals="-6" id="f-1226" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-189" decimals="-6" id="f-1227" unitRef="eur">3626000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-306" decimals="-6" id="f-1228" unitRef="eur">339000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-307" decimals="-6" id="f-1229" unitRef="eur">159000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-308" decimals="-6" id="f-1230" unitRef="eur">118000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-189" decimals="-6" id="f-1231" unitRef="eur">616000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-306" decimals="-6" id="f-1232" unitRef="eur">313000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-307" decimals="-6" id="f-1233" unitRef="eur">173000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-308" decimals="-6" id="f-1234" unitRef="eur">16000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-189" decimals="-6" id="f-1235" unitRef="eur">502000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-306" decimals="-6" id="f-1236" unitRef="eur">560000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-307" decimals="-6" id="f-1237" unitRef="eur">2234000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-308" decimals="-6" id="f-1238" unitRef="eur">24000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-189" decimals="-6" id="f-1239" unitRef="eur">2818000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-306" decimals="-6" id="f-1240" unitRef="eur">-784000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-307" decimals="-6" id="f-1241" unitRef="eur">791000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-308" decimals="-6" id="f-1242" unitRef="eur">-7000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-189" decimals="-6" id="f-1243" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:OtherIntangibleAssets contextRef="c-309" decimals="-6" id="f-1244" unitRef="eur">11207000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-310" decimals="-6" id="f-1245" unitRef="eur">65906000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-311" decimals="-6" id="f-1246" unitRef="eur">1752000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-195" decimals="-6" id="f-1247" unitRef="eur">78865000000</ifrs-full:OtherIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-312" decimals="-6" id="f-1248" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-313" decimals="-6" id="f-1249" unitRef="eur">499000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-314" decimals="-6" id="f-1250" unitRef="eur">-35000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-201" decimals="-6" id="f-1251" unitRef="eur">464000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-312" decimals="-6" id="f-1252" unitRef="eur">277000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-313" decimals="-6" id="f-1253" unitRef="eur">195000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-314" decimals="-6" id="f-1254" unitRef="eur">99000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-201" decimals="-6" id="f-1255" unitRef="eur">571000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-312" decimals="-6" id="f-1256" unitRef="eur">72000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-313" decimals="-6" id="f-1257" unitRef="eur">423000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-314" decimals="-6" id="f-1258" unitRef="eur">48000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-201" decimals="-6" id="f-1259" unitRef="eur">543000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-312" decimals="-6" id="f-1260" unitRef="eur">518000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-313" decimals="-6" id="f-1261" unitRef="eur">1994000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-314" decimals="-6" id="f-1262" unitRef="eur">21000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-201" decimals="-6" id="f-1263" unitRef="eur">2533000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-312" decimals="-6" id="f-1264" unitRef="eur">-1576000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-313" decimals="-6" id="f-1265" unitRef="eur">1408000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-314" decimals="-6" id="f-1266" unitRef="eur">-6000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-201" decimals="-6" id="f-1267" unitRef="eur">-174000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:OtherIntangibleAssets contextRef="c-315" decimals="-6" id="f-1268" unitRef="eur">10354000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-316" decimals="-6" id="f-1269" unitRef="eur">69579000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-317" decimals="-6" id="f-1270" unitRef="eur">1783000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-207" decimals="-6" id="f-1271" unitRef="eur">81716000000</ifrs-full:OtherIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-318" decimals="-6" id="f-1272" unitRef="eur">113000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-319" decimals="-6" id="f-1273" unitRef="eur">3287000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-320" decimals="-6" id="f-1274" unitRef="eur">1000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-213" decimals="-6" id="f-1275" unitRef="eur">3401000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-318" decimals="-6" id="f-1276" unitRef="eur">1062000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-319" decimals="-6" id="f-1277" unitRef="eur">1970000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-320" decimals="-6" id="f-1278" unitRef="eur">80000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-213" decimals="-6" id="f-1279" unitRef="eur">3112000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-318" decimals="-6" id="f-1280" unitRef="eur">262000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-319" decimals="-6" id="f-1281" unitRef="eur">380000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-320" decimals="-6" id="f-1282" unitRef="eur">41000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-213" decimals="-6" id="f-1283" unitRef="eur">683000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-318" decimals="-6" id="f-1284" unitRef="eur">-242000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-319" decimals="-6" id="f-1285" unitRef="eur">-1584000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-320" decimals="-6" id="f-1286" unitRef="eur">-11000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-213" decimals="-6" id="f-1287" unitRef="eur">-1837000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-318" decimals="-6" id="f-1288" unitRef="eur">-1253000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-319" decimals="-6" id="f-1289" unitRef="eur">861000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-320" decimals="-6" id="f-1290" unitRef="eur">-4000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-213" decimals="-6" id="f-1291" unitRef="eur">-396000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:OtherIntangibleAssets contextRef="c-321" decimals="-6" id="f-1292" unitRef="eur">9772000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-322" decimals="-6" id="f-1293" unitRef="eur">73733000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-323" decimals="-6" id="f-1294" unitRef="eur">1808000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-219" decimals="-6" id="f-1295" unitRef="eur">85313000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-324" decimals="-6" id="f-1296" unitRef="eur">-3508000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-325" decimals="-6" id="f-1297" unitRef="eur">-49345000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-326" decimals="-6" id="f-1298" unitRef="eur">-1113000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-225" decimals="-6" id="f-1299" unitRef="eur">-53966000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-327" decimals="-6" id="f-1300" unitRef="eur">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-328" decimals="-6" id="f-1301" unitRef="eur">1621000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-329" decimals="-6" id="f-1302" unitRef="eur">119000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-231" decimals="-6" id="f-1303" unitRef="eur">1740000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-327" decimals="-6" id="f-1304" unitRef="eur">150000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-328" decimals="-6" id="f-1305" unitRef="eur">42000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-329" decimals="-6" id="f-1306" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-231" decimals="-6" id="f-1307" unitRef="eur">192000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-327" decimals="-6" id="f-1308" unitRef="eur">-313000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-328" decimals="-6" id="f-1309" unitRef="eur">-133000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-329" decimals="-6" id="f-1310" unitRef="eur">-16000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-231" decimals="-6" id="f-1311" unitRef="eur">-462000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-327" decimals="-6" id="f-1312" unitRef="eur">-132000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-328" decimals="-6" id="f-1313" unitRef="eur">-1869000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-329" decimals="-6" id="f-1314" unitRef="eur">-21000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-231" decimals="-6" id="f-1315" unitRef="eur">-2022000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:OtherIntangibleAssets contextRef="c-330" decimals="-6" id="f-1316" unitRef="eur">-3477000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-331" decimals="-6" id="f-1317" unitRef="eur">-52744000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-332" decimals="-6" id="f-1318" unitRef="eur">-1237000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-237" decimals="-6" id="f-1319" unitRef="eur">-57458000000</ifrs-full:OtherIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-333" decimals="-6" id="f-1320" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-334" decimals="-6" id="f-1321" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-335" decimals="-6" id="f-1322" unitRef="eur">11000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-243" decimals="-6" id="f-1323" unitRef="eur">11000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-333" decimals="-6" id="f-1324" unitRef="eur">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-334" decimals="-6" id="f-1325" unitRef="eur">2099000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-335" decimals="-6" id="f-1326" unitRef="eur">97000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-243" decimals="-6" id="f-1327" unitRef="eur">2196000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-333" decimals="-6" id="f-1328" unitRef="eur">1107000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-334" decimals="-6" id="f-1329" unitRef="eur">-1561000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-335" decimals="-6" id="f-1330" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-243" decimals="-6" id="f-1331" unitRef="eur">-454000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-333" decimals="-6" id="f-1332" unitRef="eur">-75000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-334" decimals="-6" id="f-1333" unitRef="eur">-411000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-335" decimals="-6" id="f-1334" unitRef="eur">-39000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-243" decimals="-6" id="f-1335" unitRef="eur">-525000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-333" decimals="-6" id="f-1336" unitRef="eur">-7000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-334" decimals="-6" id="f-1337" unitRef="eur">-1567000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-335" decimals="-6" id="f-1338" unitRef="eur">-17000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-243" decimals="-6" id="f-1339" unitRef="eur">-1591000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-333" decimals="-6" id="f-1340" unitRef="eur">388000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-334" decimals="-6" id="f-1341" unitRef="eur">-214000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-335" decimals="-6" id="f-1342" unitRef="eur">5000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-243" decimals="-6" id="f-1343" unitRef="eur">179000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:OtherIntangibleAssets contextRef="c-336" decimals="-6" id="f-1344" unitRef="eur">-4128000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-337" decimals="-6" id="f-1345" unitRef="eur">-54652000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-338" decimals="-6" id="f-1346" unitRef="eur">-1296000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-249" decimals="-6" id="f-1347" unitRef="eur">-60076000000</ifrs-full:OtherIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-339" decimals="-6" id="f-1348" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-340" decimals="-6" id="f-1349" unitRef="eur">33000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-341" decimals="-6" id="f-1350" unitRef="eur">0</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets contextRef="c-255" decimals="-6" id="f-1351" unitRef="eur">33000000</sny:ChangeInScopeOfConsolidationThroughBusinessCombinationIntangibleAssets>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-339" decimals="-6" id="f-1352" unitRef="eur">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-340" decimals="-6" id="f-1353" unitRef="eur">2225000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-341" decimals="-6" id="f-1354" unitRef="eur">120000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-255" decimals="-6" id="f-1355" unitRef="eur">2345000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-339" decimals="-6" id="f-1356" unitRef="eur">90000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-340" decimals="-6" id="f-1357" unitRef="eur">842000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-341" decimals="-6" id="f-1358" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill contextRef="c-255" decimals="-6" id="f-1359" unitRef="eur">932000000</ifrs-full:ImpairmentLossRecognisedInOtherComprehensiveIncomeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-339" decimals="-6" id="f-1360" unitRef="eur">-262000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-340" decimals="-6" id="f-1361" unitRef="eur">-326000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-341" decimals="-6" id="f-1362" unitRef="eur">-41000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill contextRef="c-255" decimals="-6" id="f-1363" unitRef="eur">-629000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-339" decimals="-6" id="f-1364" unitRef="eur">94000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-340" decimals="-6" id="f-1365" unitRef="eur">1184000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-341" decimals="-6" id="f-1366" unitRef="eur">9000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-255" decimals="-6" id="f-1367" unitRef="eur">1287000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-339" decimals="-6" id="f-1368" unitRef="eur">128000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-340" decimals="-6" id="f-1369" unitRef="eur">268000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-341" decimals="-6" id="f-1370" unitRef="eur">14000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-255" decimals="-6" id="f-1371" unitRef="eur">410000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:OtherIntangibleAssets contextRef="c-342" decimals="-6" id="f-1372" unitRef="eur">-3734000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-343" decimals="-6" id="f-1373" unitRef="eur">-55908000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-344" decimals="-6" id="f-1374" unitRef="eur">-1352000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-261" decimals="-6" id="f-1375" unitRef="eur">-60994000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-345" decimals="-6" id="f-1376" unitRef="eur">7730000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-346" decimals="-6" id="f-1377" unitRef="eur">13162000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-347" decimals="-6" id="f-1378" unitRef="eur">515000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-8" decimals="-6" id="f-1379" unitRef="eur">21407000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-348" decimals="-6" id="f-1380" unitRef="eur">6226000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-349" decimals="-6" id="f-1381" unitRef="eur">14927000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-350" decimals="-6" id="f-1382" unitRef="eur">487000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-7" decimals="-6" id="f-1383" unitRef="eur">21640000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-351" decimals="-6" id="f-1384" unitRef="eur">6038000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-352" decimals="-6" id="f-1385" unitRef="eur">17825000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-353" decimals="-6" id="f-1386" unitRef="eur">456000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:OtherIntangibleAssets contextRef="c-5" decimals="-6" id="f-1387" unitRef="eur">24319000000</ifrs-full:OtherIntangibleAssets>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-354" decimals="-6" id="f-1388" unitRef="eur">226000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-355" decimals="-6" id="f-1389" unitRef="usd">500000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-356" decimals="-6" id="f-1390" unitRef="usd">175000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-357" decimals="-8" id="f-1391" unitRef="eur">16600000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-358" decimals="-8" id="f-1392" unitRef="eur">12700000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-359" decimals="-8" id="f-1393" unitRef="eur">11700000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-360" id="f-1394">P11Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-361" decimals="-8" id="f-1395" unitRef="eur">1200000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-362" decimals="-8" id="f-1396" unitRef="eur">2200000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-363" decimals="-8" id="f-1397" unitRef="eur">1200000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-364" id="f-1398">P18Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <sny:DisclosureOfPrincipalMarketedProductsTableTextBlock contextRef="c-1" id="f-1399">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below provides information about the principal &#x201c;marketed products&#x201d;, which were recognized in connection with major acquisitions made by Sanofi and represented 96% of the carrying amount of that item as of December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&#160;&amp;amp;&lt;br/&gt;impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(years)&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Residual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(years)&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Boehringer Ingelheim &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Consumer Healthcare&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(33,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Chattem&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Protein Sciences&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ablynx&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bioverativ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;REZUROCK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;TZIELD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;BEYFORTUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;QUNOL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total: principal marketed products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;66,880&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(50,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,927&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,863&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,752&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Weighted averages. The amortization periods for these products vary between 1&#160;and 25&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Weighted averages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Commercialized products derived from the acquisition of these companies.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfPrincipalMarketedProductsTableTextBlock>
    <sny:ConcentrationRiskThresholdPercentage
      contextRef="c-360"
      decimals="2"
      id="f-1400"
      unitRef="number">0.96</sny:ConcentrationRiskThresholdPercentage>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-365" decimals="-6" id="f-1401" unitRef="eur">10279000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-366" decimals="-6" id="f-1402" unitRef="eur">-10071000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-367" decimals="-6" id="f-1403" unitRef="eur">208000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-368" id="f-1404">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c-368" id="f-1405">P2Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-369" decimals="-6" id="f-1406" unitRef="eur">621000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-370" decimals="-6" id="f-1407" unitRef="eur">1032000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-371" decimals="-6" id="f-1408" unitRef="eur">3504000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-372" decimals="-6" id="f-1409" unitRef="eur">-1698000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-373" decimals="-6" id="f-1410" unitRef="eur">1806000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-374" id="f-1411">P17Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c-374" id="f-1412">P11Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-375" decimals="-6" id="f-1413" unitRef="eur">2037000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-376" decimals="-6" id="f-1414" unitRef="eur">2213000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-377" decimals="-6" id="f-1415" unitRef="eur">33043000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-378" decimals="-6" id="f-1416" unitRef="eur">-33000000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-379" decimals="-6" id="f-1417" unitRef="eur">43000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-380" id="f-1418">P9Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c-380" id="f-1419">P11Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-381" decimals="-6" id="f-1420" unitRef="eur">58000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-382" decimals="-6" id="f-1421" unitRef="eur">73000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-383" decimals="-6" id="f-1422" unitRef="eur">1319000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-384" decimals="-6" id="f-1423" unitRef="eur">-818000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-385" decimals="-6" id="f-1424" unitRef="eur">501000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-386" id="f-1425">P23Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c-386" id="f-1426">P10Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-387" decimals="-6" id="f-1427" unitRef="eur">574000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-388" decimals="-6" id="f-1428" unitRef="eur">593000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-389" decimals="-6" id="f-1429" unitRef="eur">831000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-390" decimals="-6" id="f-1430" unitRef="eur">-411000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-391" decimals="-6" id="f-1431" unitRef="eur">420000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-392" id="f-1432">P13Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c-392" id="f-1433">P7Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-393" decimals="-6" id="f-1434" unitRef="eur">498000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-394" decimals="-6" id="f-1435" unitRef="eur">532000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-395" decimals="-6" id="f-1436" unitRef="eur">1966000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-396" decimals="-6" id="f-1437" unitRef="eur">-746000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-397" decimals="-6" id="f-1438" unitRef="eur">1220000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-398" id="f-1439">P14Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c-398" id="f-1440">P9Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-399" decimals="-6" id="f-1441" unitRef="eur">1357000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-400" decimals="-6" id="f-1442" unitRef="eur">1494000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-401" decimals="-6" id="f-1443" unitRef="eur">8798000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-402" decimals="-6" id="f-1444" unitRef="eur">-3646000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-403" decimals="-6" id="f-1445" unitRef="eur">5152000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-404" id="f-1446">P14Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c-404" id="f-1447">P9Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-405" decimals="-6" id="f-1448" unitRef="eur">4836000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-406" decimals="-6" id="f-1449" unitRef="eur">3065000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-407" decimals="-6" id="f-1450" unitRef="eur">1907000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-408" decimals="-6" id="f-1451" unitRef="eur">-327000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-409" decimals="-6" id="f-1452" unitRef="eur">1580000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-410" id="f-1453">P12Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c-410" id="f-1454">P10Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-411" decimals="-6" id="f-1455" unitRef="eur">1702000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-412" decimals="-6" id="f-1456" unitRef="eur">1750000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-413" decimals="-6" id="f-1457" unitRef="eur">2546000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-414" decimals="-6" id="f-1458" unitRef="eur">-141000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-415" decimals="-6" id="f-1459" unitRef="eur">2405000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-416" id="f-1460">P12Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c-416" id="f-1461">P12Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-417" decimals="-6" id="f-1462" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-418" decimals="-6" id="f-1463" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-419" decimals="-6" id="f-1464" unitRef="eur">1946000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-420" decimals="-6" id="f-1465" unitRef="eur">-76000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-421" decimals="-6" id="f-1466" unitRef="eur">1870000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-422" id="f-1467">P18Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c-422" id="f-1468">P17Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-423" decimals="-6" id="f-1469" unitRef="eur">180000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-424" decimals="-6" id="f-1470" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-425" decimals="-6" id="f-1471" unitRef="eur">741000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-426" decimals="-6" id="f-1472" unitRef="eur">-19000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-427" decimals="-6" id="f-1473" unitRef="eur">722000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-428" id="f-1474">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="c-428" id="f-1475">P9Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-429" decimals="-6" id="f-1476" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-430" decimals="-6" id="f-1477" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-431" decimals="-6" id="f-1478" unitRef="eur">66880000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-432" decimals="-6" id="f-1479" unitRef="eur">-50953000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-433" decimals="-6" id="f-1480" unitRef="eur">15927000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-434" decimals="-6" id="f-1481" unitRef="eur">11863000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-435" decimals="-6" id="f-1482" unitRef="eur">10752000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-436" id="f-1483">P1Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-437" id="f-1484">P25Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-438" decimals="-6" id="f-1485" unitRef="eur">1110000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <sny:DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock contextRef="c-1" id="f-1486">An analysis of amortization of software is shown in the table below:&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfAmortizationOfSoftwareAndOtherRightsByIncomeStatementLineTableTextBlock>
    <ifrs-full:CostOfSales contextRef="c-439" decimals="-6" id="f-1487" unitRef="eur">15000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-440" decimals="-6" id="f-1488" unitRef="eur">10000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-441" decimals="-6" id="f-1489" unitRef="eur">18000000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-439" decimals="-6" id="f-1490" unitRef="eur">3000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-440" decimals="-6" id="f-1491" unitRef="eur">1000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-441" decimals="-6" id="f-1492" unitRef="eur">3000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-439" decimals="-6" id="f-1493" unitRef="eur">100000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-440" decimals="-6" id="f-1494" unitRef="eur">82000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-441" decimals="-6" id="f-1495" unitRef="eur">98000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-439" decimals="-6" id="f-1496" unitRef="eur">2000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-440" decimals="-6" id="f-1497" unitRef="eur">4000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-441" decimals="-6" id="f-1498" unitRef="eur">0</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-439" decimals="-6" id="f-1499" unitRef="eur">120000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-440" decimals="-6" id="f-1500" unitRef="eur">97000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-441" decimals="-6" id="f-1501" unitRef="eur">119000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock contextRef="c-1" id="f-1502">Impairment of intangible assets and property, plant and equipment&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;When testing goodwill annually for impairment, the recoverable amount is determined for each of the two segments (Biopharma and Consumer Healthcare) on the basis of value in use, as derived from discounted estimates of the future cash flows in accordance with the policies described in Note&#160;B.6.1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The value in use of each segment was determined by applying an after-tax discount rate to estimated future after-tax cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A separate discount rate is used for each segment to reflect the specific economic conditions of that segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The rates used for impairment testing in 2023 were 7.00% for the Consumer Healthcare segment and 7.25% for the Biopharma segment; an identical value in use for Sanofi as a whole would be obtained by applying a uniform 7.2% rate to two segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The pre-tax discount rates applied to estimated pre-tax cash flows are calculated by iteration from the previously-determined value in use. Those pre-tax discount rates were 9.3% for the Consumer Healthcare segment and 10.0% for the Biopharma segment, and equate to a uniform rate of 9.9% for Sanofi as a whole.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The assumptions used in testing goodwill for impairment are reviewed annually. Apart from the discount rate, the principal assumptions used in 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the perpetual growth rates applied to future cash flows were zero for the Biopharma segment, and 1% for the Consumer Healthcare segment;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;Sanofi also applies assumptions on the probability of success of current research and development projects, and more generally on its ability to renew the product portfolio in the longer term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Value in use (determined as described above) is compared with the carrying amount, and this comparison is then subjected to sensitivity analyses by reference to the principal parameters, including:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;changes in the discount rate;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;changes in the perpetual growth rate; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;fluctuations in operating margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No impairment of goodwill would need to be recognized in the event of a reasonably possible change in the assumptions used in&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A value in use calculation for each of the segments would not result in an impairment loss using:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a discount rate up to 2.8&#160;percentage points above the rates actually used; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a perpetual growth rate up to 4.9&#160;percentage points below the rates actually used; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;an operating margin up to 7.2&#160;percentage points below the rates actually used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No impairment losses were recognized against goodwill in the years ended December 31, 2023, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;When there is evidence that an asset may have become impaired, the asset&#x2019;s value in use is calculated by applying an after-tax discount rate to the estimated future after-tax cash flows from that asset. For the purposes of impairment testing, the tax cash flows relating to the asset are determined using a notional tax rate incorporating the notional tax benefit that would result from amortizing the asset if its value in use were regarded as its depreciable amount for tax purposes. Applying after-tax discount rates&#160;to after-tax cash flows gives the same values in use as would be obtained by applying pre-tax discount rates to pre-tax cash&#160;flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The after-tax discount rates used in 2023 for impairment testing of other intangible assets in the Biopharma and Consumer Healthcare segments were obtained by adjusting Sanofi&#x2019;s weighted average cost of capital to reflect specific country and business risks, giving after-tax discount rates in a range from 7.25% to 8.25%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In most instances, there are no market data that would enable fair value less costs to sell to be determined other than by means of developing a similar estimate based on future cash flows. Consequently, recoverable amount is in substance equal to value in use. The estimates used to determine value in use are sensitive to assumptions specific to the nature of the asset and to Sanofi's activities. Apart from the discount rate, the principal assumptions used in 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;mid-term and long-term forecasts;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;perpetual growth or attrition rates, when applicable; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;probability of success of current research and development projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The assumptions used in testing intangible assets for impairment are reviewed at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2023, 2022 and 2021, impairment testing of other intangible assets (excluding software) resulted in the recognition of net impairment losses as shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Impairment of other intangible assets, net of reversals (excluding software)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;932&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;192&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Consumer Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development projects and technology platforms&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)(b)(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Others&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;For 2023, this amount mainly comprises an impairment loss of &#x20ac;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;amp;D programs, in particular those related to the NK Cell and PRO-XTEN  technology platforms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;For 2022, this amount mainly comprises a reversal of &#x20ac;2,154&#160;million of impairment losses taken against ELOCTATE and BIVV001 (assets belonging to the ELOCTATE franchise), consisting of &#x20ac;1,554&#160;million for marketed products and &#x20ac;600&#160;million for research and development projects respectively. In 2019, the launch of competing products for ELOCTATE led Sanofi to update its sales forecasts for products belonging to the franchise, as a result of which impairment losses of &#x20ac;2.8&#160;billion were recognized against the assets in question. The reversal reflects the approval by the FDA on February&#160;22, 2023 of  ALTUVIIIO (the commercial name of efanesoctocog alpha, corresponding to the BIVV001 project), which was submitted in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;For 2022, this amount mainly comprises:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.93pt"&gt;an impairment loss of &#x20ac;1,586&#160;million taken against the development project for SAR444245 (non-alpha interleukin-2), recognized following revised cash flow projections reflecting unfavorable developments in the launch schedule;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.93pt"&gt;the &#x20ac;600&#160;million reversal relating to the BIVV001 project (see above).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For 2021, this line relates to the discontinuation of the development of sutimlimab in the treatment of Immune Thrombocytopenic Purpura (ITP), and to the termination of various research projects in Vaccines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Impairment losses taken against property, plant and equipment are disclosed in Note&#160;D.3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Risks and opportunities related to climate change&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has identified specific plausible scenarios to assess climate risks and opportunities liable to impact its activities in the medium and longer term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;an Aggressive Mitigation scenario, based on global collaboration to start reducing emissions immediately to meet Paris Agreement goals (limit temperature increase to 1.5&#xb0;C above pre-industrial levels), generating risks related to transitioning to a lower carbon economy and entailing extensive policy, legal, technology, and market changes to address mitigation and adaptation requirements;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a No Climate Action scenario (leading to global warming of 4&#xb0;C above pre-industrial levels by 2100), with event-driven physical risks resulting from climate change or longer term shifts in climate patterns leading to potential financial implications such as direct damage to assets and indirect impacts from supply chain disruption; changes in water availability, and in the sourcing or quality of resources; food security; and extreme temperature changes affecting premises, operations, supply chain, transport needs, and employee safety; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a Most Likely scenario, encompassing fragmented regional efforts to start reducing emissions but not at a sufficient level to meet Paris Agreement goals (emissions continue to increase but at a slowed rate, leading to a 2.8&#xb0;C temperature increase).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The importance and likelihood of such risks have been assessed and have not led Sanofi to identify any material impact that could generate a risk of impairment of the assets of Sanofi&#x2019;s CGUs.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfImpairmentOfIntangibleAssetsAndPropertyPlantAndEquipmentExplanatoryTextBlock>
    <sny:ImpairmentTestingPercentage
      contextRef="c-442"
      decimals="4"
      id="f-1503"
      unitRef="number">0.0700</sny:ImpairmentTestingPercentage>
    <sny:ImpairmentTestingPercentage
      contextRef="c-443"
      decimals="4"
      id="f-1504"
      unitRef="number">0.0725</sny:ImpairmentTestingPercentage>
    <sny:UniformImpairmentTestingPercentage
      contextRef="c-444"
      decimals="3"
      id="f-1505"
      unitRef="number">0.072</sny:UniformImpairmentTestingPercentage>
    <sny:NumberOfOperatingSegments1
      contextRef="c-1"
      decimals="INF"
      id="f-1506"
      unitRef="segment">2</sny:NumberOfOperatingSegments1>
    <sny:PretaxDiscountRateAppliedForGoodwill
      contextRef="c-442"
      decimals="3"
      id="f-1507"
      unitRef="number">0.093</sny:PretaxDiscountRateAppliedForGoodwill>
    <sny:PretaxDiscountRateAppliedForGoodwill
      contextRef="c-443"
      decimals="3"
      id="f-1508"
      unitRef="number">0.100</sny:PretaxDiscountRateAppliedForGoodwill>
    <sny:UniformPreTaxDiscountRates
      contextRef="c-444"
      decimals="3"
      id="f-1509"
      unitRef="number">0.099</sny:UniformPreTaxDiscountRates>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="c-445"
      decimals="INF"
      id="f-1510"
      unitRef="number">0</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="c-446"
      decimals="2"
      id="f-1511"
      unitRef="number">0.01</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <sny:PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss
      contextRef="c-1"
      decimals="INF"
      id="f-1512"
      unitRef="number">2.8</sny:PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss>
    <sny:PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss
      contextRef="c-1"
      decimals="INF"
      id="f-1513"
      unitRef="number">4.9</sny:PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss>
    <sny:PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss
      contextRef="c-1"
      decimals="INF"
      id="f-1514"
      unitRef="number">7.2</sny:PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill contextRef="c-9" decimals="INF" id="f-1515" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill contextRef="c-10" decimals="INF" id="f-1516" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill contextRef="c-1" decimals="INF" id="f-1517" unitRef="eur">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <sny:AfterTaxDiscountRates
      contextRef="c-436"
      decimals="INF"
      id="f-1518"
      unitRef="number">0.0725</sny:AfterTaxDiscountRates>
    <sny:AfterTaxDiscountRates
      contextRef="c-437"
      decimals="INF"
      id="f-1519"
      unitRef="number">0.0825</sny:AfterTaxDiscountRates>
    <sny:DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock contextRef="c-1" id="f-1520">&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2023, 2022 and 2021, impairment testing of other intangible assets (excluding software) resulted in the recognition of net impairment losses as shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Impairment of other intangible assets, net of reversals (excluding software)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;932&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;192&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Consumer Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development projects and technology platforms&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)(b)(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Others&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;For 2023, this amount mainly comprises an impairment loss of &#x20ac;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;amp;D programs, in particular those related to the NK Cell and PRO-XTEN  technology platforms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;For 2022, this amount mainly comprises a reversal of &#x20ac;2,154&#160;million of impairment losses taken against ELOCTATE and BIVV001 (assets belonging to the ELOCTATE franchise), consisting of &#x20ac;1,554&#160;million for marketed products and &#x20ac;600&#160;million for research and development projects respectively. In 2019, the launch of competing products for ELOCTATE led Sanofi to update its sales forecasts for products belonging to the franchise, as a result of which impairment losses of &#x20ac;2.8&#160;billion were recognized against the assets in question. The reversal reflects the approval by the FDA on February&#160;22, 2023 of  ALTUVIIIO (the commercial name of efanesoctocog alpha, corresponding to the BIVV001 project), which was submitted in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;For 2022, this amount mainly comprises:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.93pt"&gt;an impairment loss of &#x20ac;1,586&#160;million taken against the development project for SAR444245 (non-alpha interleukin-2), recognized following revised cash flow projections reflecting unfavorable developments in the launch schedule;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:22.68pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.93pt"&gt;the &#x20ac;600&#160;million reversal relating to the BIVV001 project (see above).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;For 2021, this line relates to the discontinuation of the development of sutimlimab in the treatment of Immune Thrombocytopenic Purpura (ITP), and to the termination of various research projects in Vaccines.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfImpairmentLossesOfOtherIntangibleAssetsTableTextBlock>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-447" decimals="-6" id="f-1521" unitRef="eur">932000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-448" decimals="-6" id="f-1522" unitRef="eur">-454000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-449" decimals="-6" id="f-1523" unitRef="eur">192000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-450" decimals="-6" id="f-1524" unitRef="eur">0</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-451" decimals="-6" id="f-1525" unitRef="eur">-1561000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-452" decimals="-6" id="f-1526" unitRef="eur">42000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-453" decimals="-6" id="f-1527" unitRef="eur">0</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-454" decimals="-6" id="f-1528" unitRef="eur">-1526000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-455" decimals="-6" id="f-1529" unitRef="eur">1000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-456" decimals="-6" id="f-1530" unitRef="eur">0</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-457" decimals="-6" id="f-1531" unitRef="eur">-35000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-458" decimals="-6" id="f-1532" unitRef="eur">41000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-459" decimals="-6" id="f-1533" unitRef="eur">896000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-460" decimals="-6" id="f-1534" unitRef="eur">1107000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-461" decimals="-6" id="f-1535" unitRef="eur">150000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-462" decimals="-6" id="f-1536" unitRef="eur">36000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-463" decimals="-6" id="f-1537" unitRef="eur">0</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-464" decimals="-6" id="f-1538" unitRef="eur">0</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-465" decimals="-6" id="f-1539" unitRef="eur">833000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount contextRef="c-466" decimals="-6" id="f-1540" unitRef="eur">2154000000</sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount>
    <sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount contextRef="c-467" decimals="-6" id="f-1541" unitRef="eur">1554000000</sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount>
    <sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount contextRef="c-468" decimals="-6" id="f-1542" unitRef="eur">600000000</sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-469" decimals="-8" id="f-1543" unitRef="eur">2800000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-470" decimals="-6" id="f-1544" unitRef="eur">1586000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount contextRef="c-468" decimals="-6" id="f-1545" unitRef="eur">600000000</sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="c-1" id="f-1546">Investments accounted for using the equity method&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Investments accounted for using the equity method comprise associates and joint ventures (see Note&#160;B.1.), and are set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&#160;interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;EUROAPI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Infraserv GmbH&#160;&amp;amp; Co. H&#xf6;chst KG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MSP Vaccine Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;424&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;677&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) &#160;&#160;&#160;&#160;Following the distribution in kind and the acquisition of an equity interest by EPIC Bpifrance, Sanofi holds an equity interest in EUROAPI accounted for using the equity method in accordance with IAS&#160;28 (see Note&#160;D.2.). As of December&#160;31, 2023, an impairment loss of &#x20ac;231&#160;million was recognized on the equity-accounted investment in EUROAPI in view of the fall in the share price since March&#160;2023. The amount of the loss was determined on the basis of the share price as of December&#160;31, 2023 (&#x20ac;5.73).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows Sanofi&#x2019;s overall share of (i)&#160;profit or loss and (ii)&#160;other comprehensive income from investments accounted for using the equity method, showing the split between associates and joint ventures in accordance with IFRS&#160;12 (the amounts for each individual associate or joint venture are not material):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.881%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.881%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Joint&#160;ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Associates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Joint&#160;ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Associates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Joint&#160;ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Associates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of other comprehensive income from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;An impairment loss of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x20ac;231&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; was recognized on the equity-accounted interest in EUROAPI as of December&#160;31, 2023, to reflect the fall in the share price since March&#160;2023. The amount of the loss was determined on the basis of the quoted market price as of December&#160;31, 2023 (&#x20ac;5.73).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The financial statements include arm&#x2019;s length transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties and other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts receivable and other receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchases and other expenses (including research expenses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts payable and other payables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In 2022, these items include Sanofi's transactions with EUROAPI from May&#160;10, 2022 (see Note&#160;D.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Includes loans to joint ventures and associates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;There were no funding commitments to associates and joint ventures as of December 31, 2023, December 31, 2022 or     December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For off balance sheet commitments of an operational nature involving joint ventures, see Note&#160;D.21.1.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock contextRef="c-1" id="f-1547">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&#160;interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;EUROAPI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Infraserv GmbH&#160;&amp;amp; Co. H&#xf6;chst KG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MSP Vaccine Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;424&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;677&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) &#160;&#160;&#160;&#160;Following the distribution in kind and the acquisition of an equity interest by EPIC Bpifrance, Sanofi holds an equity interest in EUROAPI accounted for using the equity method in accordance with IAS&#160;28 (see Note&#160;D.2.). As of December&#160;31, 2023, an impairment loss of &#x20ac;231&#160;million was recognized on the equity-accounted investment in EUROAPI in view of the fall in the share price since March&#160;2023. The amount of the loss was determined on the basis of the share price as of December&#160;31, 2023 (&#x20ac;5.73).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfInvestmentsInAssociatesAndJointVenturesTableTextBlock>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="c-471"
      decimals="3"
      id="f-1548"
      unitRef="number">0.298</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-472" decimals="-6" id="f-1549" unitRef="eur">162000000</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-154" decimals="-6" id="f-1550" unitRef="eur">392000000</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-473" decimals="-6" id="f-1551" unitRef="eur">0</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="c-474"
      decimals="3"
      id="f-1552"
      unitRef="number">0.312</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-475" decimals="-6" id="f-1553" unitRef="eur">90000000</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-476" decimals="-6" id="f-1554" unitRef="eur">97000000</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-477" decimals="-6" id="f-1555" unitRef="eur">80000000</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="c-478"
      decimals="3"
      id="f-1556"
      unitRef="number">0.500</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-479" decimals="-6" id="f-1557" unitRef="eur">96000000</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-480" decimals="-6" id="f-1558" unitRef="eur">104000000</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-481" decimals="-6" id="f-1559" unitRef="eur">88000000</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="c-482"
      decimals="3"
      id="f-1560"
      unitRef="number">0</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-483" decimals="-6" id="f-1561" unitRef="eur">76000000</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-484" decimals="-6" id="f-1562" unitRef="eur">84000000</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-485" decimals="-6" id="f-1563" unitRef="eur">82000000</ifrs-full:InvestmentsInJointVentures>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="c-5" decimals="-6" id="f-1564" unitRef="eur">424000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="c-7" decimals="-6" id="f-1565" unitRef="eur">677000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="c-8" decimals="-6" id="f-1566" unitRef="eur">250000000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-471" decimals="-6" id="f-1567" unitRef="eur">231000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <sny:StockPrice
      contextRef="c-486"
      decimals="2"
      id="f-1568"
      unitRef="eurPerShare">5.73</sny:StockPrice>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="c-487"
      decimals="2"
      id="f-1569"
      unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <sny:DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock contextRef="c-1" id="f-1570">&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows Sanofi&#x2019;s overall share of (i)&#160;profit or loss and (ii)&#160;other comprehensive income from investments accounted for using the equity method, showing the split between associates and joint ventures in accordance with IFRS&#160;12 (the amounts for each individual associate or joint venture are not material):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.881%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.881%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Joint&#160;ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Associates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Joint&#160;ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Associates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Joint&#160;ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Associates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of other comprehensive income from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;An impairment loss of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x20ac;231&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; was recognized on the equity-accounted interest in EUROAPI as of December&#160;31, 2023, to reflect the fall in the share price since March&#160;2023. The amount of the loss was determined on the basis of the quoted market price as of December&#160;31, 2023 (&#x20ac;5.73).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfProfitOrLossAndOtherComprehensiveIncomeOfAssociatesAndJointVenturesTableTextBlock>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod contextRef="c-488" decimals="-6" id="f-1571" unitRef="eur">101000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod contextRef="c-489" decimals="-6" id="f-1572" unitRef="eur">-216000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod contextRef="c-490" decimals="-6" id="f-1573" unitRef="eur">74000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod contextRef="c-491" decimals="-6" id="f-1574" unitRef="eur">-6000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod contextRef="c-492" decimals="-6" id="f-1575" unitRef="eur">26000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod contextRef="c-493" decimals="-6" id="f-1576" unitRef="eur">13000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax contextRef="c-488" decimals="-6" id="f-1577" unitRef="eur">-7000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax contextRef="c-489" decimals="-6" id="f-1578" unitRef="eur">8000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax contextRef="c-490" decimals="-6" id="f-1579" unitRef="eur">-2000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax contextRef="c-491" decimals="-6" id="f-1580" unitRef="eur">-3000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax contextRef="c-492" decimals="-6" id="f-1581" unitRef="eur">-6000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax contextRef="c-493" decimals="-6" id="f-1582" unitRef="eur">0</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodBeforeTax>
    <sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures contextRef="c-488" decimals="-6" id="f-1583" unitRef="eur">94000000</sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures>
    <sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures contextRef="c-489" decimals="-6" id="f-1584" unitRef="eur">-208000000</sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures>
    <sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures contextRef="c-490" decimals="-6" id="f-1585" unitRef="eur">72000000</sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures>
    <sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures contextRef="c-491" decimals="-6" id="f-1586" unitRef="eur">-9000000</sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures>
    <sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures contextRef="c-492" decimals="-6" id="f-1587" unitRef="eur">20000000</sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures>
    <sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures contextRef="c-493" decimals="-6" id="f-1588" unitRef="eur">13000000</sny:TotalShareOfProfitAndComprehensiveIncomeOfAssociatesAndJointVentures>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-471" decimals="-6" id="f-1589" unitRef="eur">231000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <sny:StockPrice
      contextRef="c-486"
      decimals="2"
      id="f-1590"
      unitRef="eurPerShare">5.73</sny:StockPrice>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c-1" id="f-1591">The principal transactions and balances with related parties are summarized below:&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Royalties and other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts receivable and other receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Purchases and other expenses (including research expenses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accounts payable and other payables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In 2022, these items include Sanofi's transactions with EUROAPI from May&#160;10, 2022 (see Note&#160;D.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b) Includes loans to joint ventures and associates.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions contextRef="c-494" decimals="-6" id="f-1592" unitRef="eur">157000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions contextRef="c-495" decimals="-6" id="f-1593" unitRef="eur">131000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions contextRef="c-496" decimals="-6" id="f-1594" unitRef="eur">70000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions contextRef="c-494" decimals="-6" id="f-1595" unitRef="eur">63000000</sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions>
    <sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions contextRef="c-495" decimals="-6" id="f-1596" unitRef="eur">81000000</sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions>
    <sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions contextRef="c-496" decimals="-6" id="f-1597" unitRef="eur">66000000</sny:RoyaltiesAndOtherIncomeRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-497" decimals="-6" id="f-1598" unitRef="eur">249000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-498" decimals="-6" id="f-1599" unitRef="eur">330000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-499" decimals="-6" id="f-1600" unitRef="eur">269000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c-494" decimals="-6" id="f-1601" unitRef="eur">642000000</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c-495" decimals="-6" id="f-1602" unitRef="eur">477000000</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:PurchasesOfGoodsRelatedPartyTransactions contextRef="c-496" decimals="-6" id="f-1603" unitRef="eur">178000000</ifrs-full:PurchasesOfGoodsRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-497" decimals="-6" id="f-1604" unitRef="eur">71000000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-498" decimals="-6" id="f-1605" unitRef="eur">132000000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-499" decimals="-6" id="f-1606" unitRef="eur">28000000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <sny:CommitmentsMadeToJointVenturesAndAssociates contextRef="c-499" decimals="INF" id="f-1607" unitRef="eur">0</sny:CommitmentsMadeToJointVenturesAndAssociates>
    <sny:CommitmentsMadeToJointVenturesAndAssociates contextRef="c-498" decimals="INF" id="f-1608" unitRef="eur">0</sny:CommitmentsMadeToJointVenturesAndAssociates>
    <sny:CommitmentsMadeToJointVenturesAndAssociates contextRef="c-497" decimals="INF" id="f-1609" unitRef="eur">0</sny:CommitmentsMadeToJointVenturesAndAssociates>
    <ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory contextRef="c-1" id="f-1610">Other non-current assets&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other non-current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments at fair value through other comprehensive income (D.7.1.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments at fair value through other comprehensive income (D.7.2.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other financial assets at fair value through profit or loss (D.7.3.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pre-funded pension obligations (Note&#160;D.19.1.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term prepaid expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments (Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,218&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,095&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,127&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;As of December 31, 2023, this line includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- the renewal of a loan of &#x20ac;157&#160;million to the BioAtrium joint venture which matures on December&#160;1, 2031, of which &#x20ac;156&#160;million was recognized in "Other current assets" as of December&#160;31, 2022; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- a receivable under a sub-lease amounting to &#x20ac;132&#160;million (&#x20ac;170&#160;million before discounting), versus &#x20ac;164&#160;million (or &#x20ac;201&#160;million before discounting) as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.7.1. Equity instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Quoted equity investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line &#x201c;Equity instruments at fair value through other comprehensive income&#x201d; includes equity investments quoted in an active market with a carrying amount of &#x20ac;470 million as of December 31, 2023, &#x20ac;387 million as of December 31, 2022 and &#x20ac;396 million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;There were no material movements in quoted equity investments during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The main changes during previous years in quoted equity investments included in the &#x201c;Equity instruments at fair value through other comprehensive income&#x201d; category are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;in 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;the sale in June&#160;2022 of the residual equity interest in Regeneron (see Note&#160;C.1.) for $174 million, the entire loss on which was recorded within Other comprehensive income, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;the acquisition of an equity interest in Innovent Biologics, in connection with a strategic collaboration agreement to intensify&#160;development in oncology medicines signed in August&#160;2022, which had a fair value of &#x20ac;250 million as of that date and &#x20ac;228 million as of December&#160;31, 2022;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;in 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;following completion of the acquisition of Translate Bio on September&#160;14, 2021 (see Note&#160;D.2.2), the equity interest of approximately 5% in Translate Bio previously held by Sanofi ceased to be accounted for in the &#x201c;Equity instruments at fair value through other comprehensive income&#x201d; category.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A 10% decline in stock prices of the quoted equity investments included within &#x201c;Equity instruments at fair value through&#160;other&#160;comprehensive income&#x201d; would have had a pre-tax impact of &#x20ac;47 million on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; as of&#160;December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unquoted equity investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &#x201c;Equity instruments at fair value through other comprehensive income&#x201d; also includes equity investments not quoted in an active market with a carrying amount of &#x20ac;618 million as of December 31, 2023, &#x20ac;549 million as of December 31, 2022 and&#160;&#x20ac;427 million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The change in unquoted equity investments included in the &#x201c;Equity instruments at fair value through other comprehensive income&#x201d; category during the year ended December 31, 2023 was mainly due to various equity stakes acquired through the Sanofi Ventures fund.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, commitments relating to equity investments classified in this asset category amount to &#x20ac;65 million as of December 31, 2023 (compared to &#x20ac;60 million as of December 31, 2022).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.7.2. Debt instruments at fair value through other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The &#x201c;Debt instruments at fair value through other comprehensive income&#x201d; category includes quoted euro-denominated senior bonds amounting to &#x20ac;346 million as of December 31, 2023, including &#x20ac;107 million of securities obtained in exchange for financial assets held to meet obligations to employees under post-employment benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi held &#x20ac;329 million of quoted senior bonds as of December 31, 2022 and &#x20ac;447 million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As regards debt instruments held to meet obligations to employees under post-employment benefit plans, an increase of 10&#160;basis points in market interest rates as of December 31, 2023 would have had a pre-tax impact of &#x20ac;1 million on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As regards other quoted debt instruments, an increase of 10&#160;basis points in market interest rates as of December 31, 2023 would have had a pre-tax impact of &#x20ac;1 million on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other comprehensive income recognized in respect of &#x201c;Equity instruments at fair value through other comprehensive income&#x201d; and &#x201c;Debt instruments at fair value through other comprehensive income&#x201d; represented unrealized after-tax gains of &#x20ac;349 million for the year ended December 31, 2023, versus unrealized after-tax gains of &#x20ac;256 million for the year ended December 31, 2022 and of &#x20ac;322 million for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of the change in gains and losses recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, and of items reclassified to profit or loss, is presented in Note&#160;D.15.7.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.7.3. Other financial assets at fair value through profit or loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The &#x201c;Other financial assets at fair value through profit or loss&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;category includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;contingent consideration receivable by Sanofi following the dissolution of the Sanofi Pasteur MSD (SPMSD) joint venture, based on a percentage of MSD&#x2019;s future sales during the 2017-2024 period of specified products previously distributed by&#160;SPMSD (see Note&#160;D.12.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The fair value of the MSD contingent consideration was determined by applying the royalty percentage stipulated in the contract to discounted sales projections. A reduction of one percentage point in the discount rate would increase the fair value of the&#160;MSD&#160;contingent consideration by approximately 1%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of this contingent consideration are recognized in the income statement within the line item&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Fair value remeasurement of contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(see Note&#160;B.18.). As of December 31, 2023, the contingent consideration asset amounted to &#x20ac;214 million (including a non-current portion of &#x20ac;104 million), versus &#x20ac;303 million (non-current portion: &#x20ac;196 million) as of December 31, 2022 and &#x20ac;378 million (non current portion: &#x20ac;275 million) as of December 31, 2021;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a portfolio of financial investments (amounting to &#x20ac;572 million as of December 31, 2023) held to fund a deferred compensation plan provided to certain employees (versus &#x20ac;512 million as of December 31, 2022 and &#x20ac;549 million as of&#160;December 31, 2021);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;unquoted securities not meeting the definition of equity instruments amounting to &#x20ac;132 million as of December 31, 2023 (versus &#x20ac;115 million as of December 31, 2022 and &#x20ac;78 million as of December 31, 2021). In addition, commitments relating to unquoted securities classified in this asset category amount to &#x20ac;159 million as of December 31, 2023 (compared to &#x20ac;192 million as of December 31, 2022).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory>
    <sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock contextRef="c-1" id="f-1611">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other non-current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments at fair value through other comprehensive income (D.7.1.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments at fair value through other comprehensive income (D.7.2.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other financial assets at fair value through profit or loss (D.7.3.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pre-funded pension obligations (Note&#160;D.19.1.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term prepaid expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term loans and advances and other non-current receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments (Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,218&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,095&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,127&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;As of December 31, 2023, this line includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- the renewal of a loan of &#x20ac;157&#160;million to the BioAtrium joint venture which matures on December&#160;1, 2031, of which &#x20ac;156&#160;million was recognized in "Other current assets" as of December&#160;31, 2022; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- a receivable under a sub-lease amounting to &#x20ac;132&#160;million (&#x20ac;170&#160;million before discounting), versus &#x20ac;164&#160;million (or &#x20ac;201&#160;million before discounting) as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfComponentsOfOtherNonCurrentAssetsTableTextBlock>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-500" decimals="-6" id="f-1612" unitRef="eur">1088000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-501" decimals="-6" id="f-1613" unitRef="eur">936000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-502" decimals="-6" id="f-1614" unitRef="eur">823000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-503" decimals="-6" id="f-1615" unitRef="eur">346000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-504" decimals="-6" id="f-1616" unitRef="eur">329000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-505" decimals="-6" id="f-1617" unitRef="eur">447000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-5" decimals="-6" id="f-1618" unitRef="eur">808000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-7" decimals="-6" id="f-1619" unitRef="eur">823000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-8" decimals="-6" id="f-1620" unitRef="eur">902000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss>
    <sny:PreFundedPensionObligations contextRef="c-5" decimals="-6" id="f-1621" unitRef="eur">271000000</sny:PreFundedPensionObligations>
    <sny:PreFundedPensionObligations contextRef="c-7" decimals="-6" id="f-1622" unitRef="eur">269000000</sny:PreFundedPensionObligations>
    <sny:PreFundedPensionObligations contextRef="c-8" decimals="-6" id="f-1623" unitRef="eur">408000000</sny:PreFundedPensionObligations>
    <sny:LongTermPrepaidExpenses contextRef="c-5" decimals="-6" id="f-1624" unitRef="eur">114000000</sny:LongTermPrepaidExpenses>
    <sny:LongTermPrepaidExpenses contextRef="c-7" decimals="-6" id="f-1625" unitRef="eur">286000000</sny:LongTermPrepaidExpenses>
    <sny:LongTermPrepaidExpenses contextRef="c-8" decimals="-6" id="f-1626" unitRef="eur">59000000</sny:LongTermPrepaidExpenses>
    <ifrs-full:NoncurrentLoansAndReceivables contextRef="c-5" decimals="-6" id="f-1627" unitRef="eur">591000000</ifrs-full:NoncurrentLoansAndReceivables>
    <ifrs-full:NoncurrentLoansAndReceivables contextRef="c-7" decimals="-6" id="f-1628" unitRef="eur">452000000</ifrs-full:NoncurrentLoansAndReceivables>
    <ifrs-full:NoncurrentLoansAndReceivables contextRef="c-8" decimals="-6" id="f-1629" unitRef="eur">485000000</ifrs-full:NoncurrentLoansAndReceivables>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-5" decimals="-6" id="f-1630" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-7" decimals="-6" id="f-1631" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-8" decimals="-6" id="f-1632" unitRef="eur">3000000</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-5" decimals="-6" id="f-1633" unitRef="eur">3218000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-7" decimals="-6" id="f-1634" unitRef="eur">3095000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-8" decimals="-6" id="f-1635" unitRef="eur">3127000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NoncurrentLoansAndReceivables contextRef="c-506" decimals="-6" id="f-1636" unitRef="eur">157000000</ifrs-full:NoncurrentLoansAndReceivables>
    <ifrs-full:OtherCurrentAssets contextRef="c-507" decimals="-6" id="f-1637" unitRef="eur">156000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:NoncurrentFinanceLeaseReceivables contextRef="c-5" decimals="-6" id="f-1638" unitRef="eur">132000000</ifrs-full:NoncurrentFinanceLeaseReceivables>
    <sny:NonCurrentFinanceLeaseReceivablesGross contextRef="c-5" decimals="-6" id="f-1639" unitRef="eur">170000000</sny:NonCurrentFinanceLeaseReceivablesGross>
    <ifrs-full:NoncurrentFinanceLeaseReceivables contextRef="c-7" decimals="-6" id="f-1640" unitRef="eur">164000000</ifrs-full:NoncurrentFinanceLeaseReceivables>
    <sny:NonCurrentFinanceLeaseReceivablesGross contextRef="c-7" decimals="-6" id="f-1641" unitRef="eur">201000000</sny:NonCurrentFinanceLeaseReceivablesGross>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-508" decimals="-6" id="f-1642" unitRef="eur">470000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-509" decimals="-6" id="f-1643" unitRef="eur">387000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-510" decimals="-6" id="f-1644" unitRef="eur">396000000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod contextRef="c-511" decimals="-6" id="f-1645" unitRef="usd">174000000</ifrs-full:ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod>
    <sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount contextRef="c-512" decimals="-6" id="f-1646" unitRef="eur">250000000</sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount>
    <sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount contextRef="c-513" decimals="-6" id="f-1647" unitRef="eur">228000000</sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeTransactionAmount>
    <sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage
      contextRef="c-514"
      decimals="2"
      id="f-1648"
      unitRef="number">0.05</sny:InvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncomeOwnershipPercentage>
    <sny:EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount contextRef="c-1" decimals="-6" id="f-1649" unitRef="eur">47000000</sny:EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c-515" decimals="-6" id="f-1650" unitRef="eur">618000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c-516" decimals="-6" id="f-1651" unitRef="eur">549000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c-517" decimals="-6" id="f-1652" unitRef="eur">427000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c-518" decimals="-6" id="f-1653" unitRef="eur">65000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="c-519" decimals="-6" id="f-1654" unitRef="eur">60000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-520" decimals="-6" id="f-1655" unitRef="eur">346000000</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts contextRef="c-521" decimals="-6" id="f-1656" unitRef="eur">107000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:HeldtomaturityInvestments contextRef="c-522" decimals="-6" id="f-1657" unitRef="eur">329000000</ifrs-full:HeldtomaturityInvestments>
    <ifrs-full:HeldtomaturityInvestments contextRef="c-523" decimals="-6" id="f-1658" unitRef="eur">447000000</ifrs-full:HeldtomaturityInvestments>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax contextRef="c-524" decimals="-6" id="f-1659" unitRef="eur">1000000</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax contextRef="c-525" decimals="-6" id="f-1660" unitRef="eur">1000000</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <sny:UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity contextRef="c-526" decimals="-6" id="f-1661" unitRef="eur">349000000</sny:UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity>
    <sny:UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity contextRef="c-527" decimals="-6" id="f-1662" unitRef="eur">256000000</sny:UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity>
    <sny:UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity contextRef="c-528" decimals="-6" id="f-1663" unitRef="eur">322000000</sny:UnrealizedGainsLossesOnSecuritiesMeasuredAtFairValueThroughOtherComprehensiveIncomeThatWillBeReclassifiedToProfitAndLossRecognizedInEquity>
    <sny:PercentageIncreaseInFairValueLiabilities
      contextRef="c-529"
      decimals="2"
      id="f-1664"
      unitRef="number">0.01</sny:PercentageIncreaseInFairValueLiabilities>
    <sny:FairValueOfTheContingentConsideration contextRef="c-530" decimals="-6" id="f-1665" unitRef="eur">214000000</sny:FairValueOfTheContingentConsideration>
    <sny:FairValueOfTheContingentConsideration contextRef="c-531" decimals="-6" id="f-1666" unitRef="eur">104000000</sny:FairValueOfTheContingentConsideration>
    <sny:FairValueOfTheContingentConsideration contextRef="c-532" decimals="-6" id="f-1667" unitRef="eur">303000000</sny:FairValueOfTheContingentConsideration>
    <sny:FairValueOfTheContingentConsideration contextRef="c-533" decimals="-6" id="f-1668" unitRef="eur">196000000</sny:FairValueOfTheContingentConsideration>
    <sny:FairValueOfTheContingentConsideration contextRef="c-534" decimals="-6" id="f-1669" unitRef="eur">378000000</sny:FairValueOfTheContingentConsideration>
    <sny:FairValueOfTheContingentConsideration contextRef="c-535" decimals="-6" id="f-1670" unitRef="eur">275000000</sny:FairValueOfTheContingentConsideration>
    <sny:FinancialInvestments contextRef="c-536" decimals="-6" id="f-1671" unitRef="eur">572000000</sny:FinancialInvestments>
    <sny:FinancialInvestments contextRef="c-537" decimals="-6" id="f-1672" unitRef="eur">512000000</sny:FinancialInvestments>
    <sny:FinancialInvestments contextRef="c-538" decimals="-6" id="f-1673" unitRef="eur">549000000</sny:FinancialInvestments>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-539" decimals="-6" id="f-1674" unitRef="eur">132000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-540" decimals="-6" id="f-1675" unitRef="eur">115000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-541" decimals="-6" id="f-1676" unitRef="eur">78000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-518" decimals="-6" id="f-1677" unitRef="eur">159000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-519" decimals="-6" id="f-1678" unitRef="eur">192000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory contextRef="c-1" id="f-1679">Assets held for sale or exchange and liabilities related to&#160;assets held for sale or&#160;exchange&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Assets held for sale or exchange, and liabilities related to assets held for sale or exchange, comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.216%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Liabilities related to assets held for sale or exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory>
    <sny:DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock contextRef="c-1" id="f-1680">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Assets held for sale or exchange, and liabilities related to assets held for sale or exchange, comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.216%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Assets held for sale or exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Liabilities related to assets held for sale or exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfAssetsHeldForSaleOrExchangeAndRelatedLiabilitiesTableTextBlock>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-5" decimals="-6" id="f-1681" unitRef="eur">15000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-7" decimals="-6" id="f-1682" unitRef="eur">85000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale contextRef="c-8" decimals="-6" id="f-1683" unitRef="eur">89000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-5" decimals="-6" id="f-1684" unitRef="eur">13000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-7" decimals="-6" id="f-1685" unitRef="eur">10000000</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale contextRef="c-8" decimals="-6" id="f-1686" unitRef="eur">0</ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c-1" id="f-1687">Inventories&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Inventories comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(678)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(284)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,590&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,666&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,024&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,960&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,619&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,715&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Allowances include write-downs of products on hand pending marketing approval, except in specific circumstances where it is possible to estimate that recovery of the value of inventories as of the end of the reporting period is highly probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No inventories were pledged as security for liabilities as of December 31, 2023 (versus &#x20ac;3 million as of December 31, 2022 and&#160;&#x20ac;20 million as of December 31, 2021).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <sny:DisclosureOfDetailedInformationAboutInventoriesTableTextBlock contextRef="c-1" id="f-1688">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Inventories comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(678)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(284)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,590&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,666&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,024&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,960&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,619&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,715&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDetailedInformationAboutInventoriesTableTextBlock>
    <ifrs-full:RawMaterials contextRef="c-219" decimals="-6" id="f-1689" unitRef="eur">1676000000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials contextRef="c-542" decimals="-6" id="f-1690" unitRef="eur">126000000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials contextRef="c-5" decimals="-6" id="f-1691" unitRef="eur">1550000000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials contextRef="c-207" decimals="-6" id="f-1692" unitRef="eur">1613000000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials contextRef="c-543" decimals="-6" id="f-1693" unitRef="eur">139000000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials contextRef="c-7" decimals="-6" id="f-1694" unitRef="eur">1474000000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials contextRef="c-195" decimals="-6" id="f-1695" unitRef="eur">1344000000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials contextRef="c-544" decimals="-6" id="f-1696" unitRef="eur">66000000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials contextRef="c-8" decimals="-6" id="f-1697" unitRef="eur">1278000000</ifrs-full:RawMaterials>
    <ifrs-full:WorkInProgress contextRef="c-219" decimals="-6" id="f-1698" unitRef="eur">5869000000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-542" decimals="-6" id="f-1699" unitRef="eur">553000000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-5" decimals="-6" id="f-1700" unitRef="eur">5316000000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-207" decimals="-6" id="f-1701" unitRef="eur">5663000000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-543" decimals="-6" id="f-1702" unitRef="eur">678000000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-7" decimals="-6" id="f-1703" unitRef="eur">4985000000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-195" decimals="-6" id="f-1704" unitRef="eur">5579000000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-544" decimals="-6" id="f-1705" unitRef="eur">554000000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-8" decimals="-6" id="f-1706" unitRef="eur">5025000000</ifrs-full:WorkInProgress>
    <ifrs-full:FinishedGoods contextRef="c-219" decimals="-6" id="f-1707" unitRef="eur">3045000000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-542" decimals="-6" id="f-1708" unitRef="eur">245000000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-5" decimals="-6" id="f-1709" unitRef="eur">2800000000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-207" decimals="-6" id="f-1710" unitRef="eur">2748000000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-543" decimals="-6" id="f-1711" unitRef="eur">247000000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-7" decimals="-6" id="f-1712" unitRef="eur">2501000000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-195" decimals="-6" id="f-1713" unitRef="eur">2696000000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-544" decimals="-6" id="f-1714" unitRef="eur">284000000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-8" decimals="-6" id="f-1715" unitRef="eur">2412000000</ifrs-full:FinishedGoods>
    <ifrs-full:Inventories contextRef="c-219" decimals="-6" id="f-1716" unitRef="eur">10590000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-542" decimals="-6" id="f-1717" unitRef="eur">924000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-5" decimals="-6" id="f-1718" unitRef="eur">9666000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-207" decimals="-6" id="f-1719" unitRef="eur">10024000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-543" decimals="-6" id="f-1720" unitRef="eur">1064000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-7" decimals="-6" id="f-1721" unitRef="eur">8960000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-195" decimals="-6" id="f-1722" unitRef="eur">9619000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-544" decimals="-6" id="f-1723" unitRef="eur">904000000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-8" decimals="-6" id="f-1724" unitRef="eur">8715000000</ifrs-full:Inventories>
    <ifrs-full:InventoriesPledgedAsSecurityForLiabilities contextRef="c-5" decimals="-6" id="f-1725" unitRef="eur">0</ifrs-full:InventoriesPledgedAsSecurityForLiabilities>
    <ifrs-full:InventoriesPledgedAsSecurityForLiabilities contextRef="c-7" decimals="-6" id="f-1726" unitRef="eur">3000000</ifrs-full:InventoriesPledgedAsSecurityForLiabilities>
    <ifrs-full:InventoriesPledgedAsSecurityForLiabilities contextRef="c-8" decimals="-6" id="f-1727" unitRef="eur">20000000</ifrs-full:InventoriesPledgedAsSecurityForLiabilities>
    <sny:DisclosureOfTradeReceivablesTextBlock contextRef="c-1" id="f-1728">Accounts receivable&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.216%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,433&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,424&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,568&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The impact of allowances against accounts receivable in 2023 was a net expense of &#x20ac;8 million (versus a net amount of less than&#160;&#x20ac;1 million in 2022 and a net expense of &#x20ac;12 million in 2021).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The gross value of overdue receivables was &#x20ac;689 million as of December 31, 2023, versus &#x20ac;452 million as of December 31, 2022 and &#x20ac;455 million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;by&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;by&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;by&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;by&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;by&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&amp;lt;1 month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&#160;3&#160;months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&#160;6&#160;months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&#160;to&#160;12&#160;months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&amp;gt;&#160;12&#160;months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;689&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;154&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Amounts overdue by more than one month relate mainly to public-sector customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables&#160;derecognized was &#x20ac;761 million as of December 31, 2023 (&#x20ac;131 million as of December 31, 2022 and &#x20ac;3 million as of&#160;December 31, 2021). The residual guarantees relating to such transfers were immaterial as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfTradeReceivablesTextBlock>
    <sny:DisclosureOfCurrentTradeReceivablesTableTextBlock contextRef="c-1" id="f-1729">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.216%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,433&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,424&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,568&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfCurrentTradeReceivablesTableTextBlock>
    <ifrs-full:CurrentTradeReceivables contextRef="c-219" decimals="-6" id="f-1730" unitRef="eur">8528000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-207" decimals="-6" id="f-1731" unitRef="eur">8537000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-195" decimals="-6" id="f-1732" unitRef="eur">7705000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-545" decimals="-6" id="f-1733" unitRef="eur">95000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-546" decimals="-6" id="f-1734" unitRef="eur">113000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-547" decimals="-6" id="f-1735" unitRef="eur">137000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-5" decimals="-6" id="f-1736" unitRef="eur">8433000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-7" decimals="-6" id="f-1737" unitRef="eur">8424000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-8" decimals="-6" id="f-1738" unitRef="eur">7568000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="c-1" decimals="-6" id="f-1739" unitRef="eur">8000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="c-9" decimals="-6" id="f-1740" unitRef="eur">1000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="c-10" decimals="-6" id="f-1741" unitRef="eur">12000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossTradeReceivables>
    <sny:OverdueReceivablesGrossValue contextRef="c-5" decimals="-6" id="f-1742" unitRef="eur">689000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-7" decimals="-6" id="f-1743" unitRef="eur">452000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-8" decimals="-6" id="f-1744" unitRef="eur">455000000</sny:OverdueReceivablesGrossValue>
    <sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock contextRef="c-1" id="f-1745">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;by&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;by&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;by&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;by&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Overdue&#160;by&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;gross value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&amp;lt;1 month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&#160;3&#160;months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&#160;6&#160;months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&#160;to&#160;12&#160;months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&amp;gt;&#160;12&#160;months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;689&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;154&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfOverdueReceivablesGrossValueTableTextBlock>
    <sny:OverdueReceivablesGrossValue contextRef="c-5" decimals="-6" id="f-1746" unitRef="eur">689000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-548" decimals="-6" id="f-1747" unitRef="eur">269000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-549" decimals="-6" id="f-1748" unitRef="eur">154000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-550" decimals="-6" id="f-1749" unitRef="eur">123000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-551" decimals="-6" id="f-1750" unitRef="eur">62000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-552" decimals="-6" id="f-1751" unitRef="eur">81000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-7" decimals="-6" id="f-1752" unitRef="eur">452000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-553" decimals="-6" id="f-1753" unitRef="eur">118000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-554" decimals="-6" id="f-1754" unitRef="eur">161000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-555" decimals="-6" id="f-1755" unitRef="eur">87000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-556" decimals="-6" id="f-1756" unitRef="eur">35000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-557" decimals="-6" id="f-1757" unitRef="eur">51000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-8" decimals="-6" id="f-1758" unitRef="eur">455000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-558" decimals="-6" id="f-1759" unitRef="eur">169000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-559" decimals="-6" id="f-1760" unitRef="eur">151000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-560" decimals="-6" id="f-1761" unitRef="eur">67000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-561" decimals="-6" id="f-1762" unitRef="eur">12000000</sny:OverdueReceivablesGrossValue>
    <sny:OverdueReceivablesGrossValue contextRef="c-562" decimals="-6" id="f-1763" unitRef="eur">56000000</sny:OverdueReceivablesGrossValue>
    <sny:DerecognizedReceivables contextRef="c-5" decimals="-6" id="f-1764" unitRef="eur">761000000</sny:DerecognizedReceivables>
    <sny:DerecognizedReceivables contextRef="c-7" decimals="-6" id="f-1765" unitRef="eur">131000000</sny:DerecognizedReceivables>
    <sny:DerecognizedReceivables contextRef="c-8" decimals="-6" id="f-1766" unitRef="eur">3000000</sny:DerecognizedReceivables>
    <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory contextRef="c-1" id="f-1767">Other current assets&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tax receivables, other than corporate income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate derivatives measured at fair value (see Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency derivatives measured at fair value (see Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current financial assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,455&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,532&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,571&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;This line mainly comprises advance payments to suppliers, and receivables relating to Sanofi's activities as agent under a transitional services agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;This item mainly comprises bank loans and receivables maturing in less than one year with high-grade counterparties. For 2021, this item also includes debt instruments derived from the acquisitions of Translate Bio and Kadmon (carried out in 2021) with maturities of more than three months at inception and less than 12&#160;months at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
    <sny:DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-1768">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tax receivables, other than corporate income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate derivatives measured at fair value (see Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency derivatives measured at fair value (see Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current financial assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,455&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,532&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,571&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;This line mainly comprises advance payments to suppliers, and receivables relating to Sanofi's activities as agent under a transitional services agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;This item mainly comprises bank loans and receivables maturing in less than one year with high-grade counterparties. For 2021, this item also includes debt instruments derived from the acquisitions of Translate Bio and Kadmon (carried out in 2021) with maturities of more than three months at inception and less than 12&#160;months at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfDetailedInformationOfOtherCurrentAssetsTableTextBlock>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax contextRef="c-5" decimals="-6" id="f-1769" unitRef="eur">768000000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax contextRef="c-7" decimals="-6" id="f-1770" unitRef="eur">658000000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax contextRef="c-8" decimals="-6" id="f-1771" unitRef="eur">802000000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-5" decimals="-6" id="f-1772" unitRef="eur">768000000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-7" decimals="-6" id="f-1773" unitRef="eur">714000000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-8" decimals="-6" id="f-1774" unitRef="eur">615000000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentReceivables contextRef="c-5" decimals="-6" id="f-1775" unitRef="eur">1448000000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c-7" decimals="-6" id="f-1776" unitRef="eur">1290000000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c-8" decimals="-6" id="f-1777" unitRef="eur">805000000</ifrs-full:OtherCurrentReceivables>
    <sny:InterestRateDerivativesMeasuredAtFairValue contextRef="c-5" decimals="-6" id="f-1778" unitRef="eur">0</sny:InterestRateDerivativesMeasuredAtFairValue>
    <sny:InterestRateDerivativesMeasuredAtFairValue contextRef="c-7" decimals="-6" id="f-1779" unitRef="eur">0</sny:InterestRateDerivativesMeasuredAtFairValue>
    <sny:InterestRateDerivativesMeasuredAtFairValue contextRef="c-8" decimals="-6" id="f-1780" unitRef="eur">11000000</sny:InterestRateDerivativesMeasuredAtFairValue>
    <sny:CurrencyDerivativesMeasuredAtFairValue contextRef="c-5" decimals="-6" id="f-1781" unitRef="eur">201000000</sny:CurrencyDerivativesMeasuredAtFairValue>
    <sny:CurrencyDerivativesMeasuredAtFairValue contextRef="c-7" decimals="-6" id="f-1782" unitRef="eur">206000000</sny:CurrencyDerivativesMeasuredAtFairValue>
    <sny:CurrencyDerivativesMeasuredAtFairValue contextRef="c-8" decimals="-6" id="f-1783" unitRef="eur">284000000</sny:CurrencyDerivativesMeasuredAtFairValue>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c-5" decimals="-6" id="f-1784" unitRef="eur">270000000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c-7" decimals="-6" id="f-1785" unitRef="eur">664000000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c-8" decimals="-6" id="f-1786" unitRef="eur">1054000000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-5" decimals="-6" id="f-1787" unitRef="eur">3455000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-7" decimals="-6" id="f-1788" unitRef="eur">3532000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-8" decimals="-6" id="f-1789" unitRef="eur">3571000000</ifrs-full:OtherCurrentAssets>
    <sny:DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock contextRef="c-1" id="f-1790">Financial assets and liabilities measured at fair value&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under IFRS&#160;7 (Financial Instruments: Disclosures), fair value measurements must be classified using a fair value hierarchy with the following levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;level&#160;1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;level&#160;2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;level&#160;3: valuation techniques in which not all important inputs are derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The valuation techniques used are described in Note&#160;B.8.5.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the balance sheet amounts of assets and liabilities measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in the fair value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in the fair value&lt;br/&gt;hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in the fair value&lt;br/&gt;hierarchy&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.1.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unquoted equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.1.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.2.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unquoted debt securities not meeting the definition of equity instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.3.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration relating to divestments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.3.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.3. &amp;amp; D.11.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.11.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mutual fund investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.13.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total financial assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,737&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;964&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,765&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;967&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,449&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;298&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;883&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bayer contingent purchase consideration arising from the acquisition of Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MSD contingent consideration (European vaccines business)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shire contingent consideration arising from the acquisition of Translate Bio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration arising from acquisition of Amunix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other contingent consideration arising from business combinations and acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.20.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.19.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total financial liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;291&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;709&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;779&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;714&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No transfers between the different levels of the fair value hierarchy occurred during 2023.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock>
    <sny:DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-1791">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the balance sheet amounts of assets and liabilities measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.131%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in the fair value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in the fair value&lt;br/&gt;hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level in the fair value&lt;br/&gt;hierarchy&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.1.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unquoted equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.1.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Quoted debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.2.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unquoted debt securities not meeting the definition of equity instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.3.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration relating to divestments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.3.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial assets held to meet obligations under deferred compensation plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.3. &amp;amp; D.11.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.7.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.11.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mutual fund investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.13.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total financial assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,737&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;964&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,765&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;967&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,449&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;298&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;883&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bayer contingent purchase consideration arising from the acquisition of Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MSD contingent consideration (European vaccines business)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shire contingent consideration arising from the acquisition of Translate Bio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration arising from acquisition of Amunix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other contingent consideration arising from business combinations and acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.18.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-current derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.20.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;D.19.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total financial liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;291&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;709&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;779&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;714&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:FinancialAssets contextRef="c-563" decimals="-6" id="f-1792" unitRef="eur">470000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-564" decimals="-6" id="f-1793" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-565" decimals="-6" id="f-1794" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-566" decimals="-6" id="f-1795" unitRef="eur">387000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-567" decimals="-6" id="f-1796" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-568" decimals="-6" id="f-1797" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-569" decimals="-6" id="f-1798" unitRef="eur">396000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-570" decimals="-6" id="f-1799" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-571" decimals="-6" id="f-1800" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-572" decimals="-6" id="f-1801" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-573" decimals="-6" id="f-1802" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-574" decimals="-6" id="f-1803" unitRef="eur">618000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-575" decimals="-6" id="f-1804" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-576" decimals="-6" id="f-1805" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-577" decimals="-6" id="f-1806" unitRef="eur">549000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-578" decimals="-6" id="f-1807" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-579" decimals="-6" id="f-1808" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-580" decimals="-6" id="f-1809" unitRef="eur">427000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-581" decimals="-6" id="f-1810" unitRef="eur">346000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-582" decimals="-6" id="f-1811" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-583" decimals="-6" id="f-1812" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-584" decimals="-6" id="f-1813" unitRef="eur">329000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-585" decimals="-6" id="f-1814" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-586" decimals="-6" id="f-1815" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-587" decimals="-6" id="f-1816" unitRef="eur">447000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-588" decimals="-6" id="f-1817" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-589" decimals="-6" id="f-1818" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-590" decimals="-6" id="f-1819" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-591" decimals="-6" id="f-1820" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-592" decimals="-6" id="f-1821" unitRef="eur">132000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-593" decimals="-6" id="f-1822" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-594" decimals="-6" id="f-1823" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-595" decimals="-6" id="f-1824" unitRef="eur">115000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-596" decimals="-6" id="f-1825" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-597" decimals="-6" id="f-1826" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-598" decimals="-6" id="f-1827" unitRef="eur">78000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-599" decimals="-6" id="f-1828" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-600" decimals="-6" id="f-1829" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-601" decimals="-6" id="f-1830" unitRef="eur">214000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-602" decimals="-6" id="f-1831" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-603" decimals="-6" id="f-1832" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-604" decimals="-6" id="f-1833" unitRef="eur">303000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-605" decimals="-6" id="f-1834" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-606" decimals="-6" id="f-1835" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-607" decimals="-6" id="f-1836" unitRef="eur">378000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-608" decimals="-6" id="f-1837" unitRef="eur">572000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-609" decimals="-6" id="f-1838" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-610" decimals="-6" id="f-1839" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-611" decimals="-6" id="f-1840" unitRef="eur">512000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-612" decimals="-6" id="f-1841" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-613" decimals="-6" id="f-1842" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-614" decimals="-6" id="f-1843" unitRef="eur">549000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-615" decimals="-6" id="f-1844" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-616" decimals="-6" id="f-1845" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-617" decimals="-6" id="f-1846" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-618" decimals="-6" id="f-1847" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-619" decimals="-6" id="f-1848" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-620" decimals="-6" id="f-1849" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-621" decimals="-6" id="f-1850" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-622" decimals="-6" id="f-1851" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-623" decimals="-6" id="f-1852" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-624" decimals="-6" id="f-1853" unitRef="eur">3000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-625" decimals="-6" id="f-1854" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-626" decimals="-6" id="f-1855" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-627" decimals="-6" id="f-1856" unitRef="eur">201000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-628" decimals="-6" id="f-1857" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-629" decimals="-6" id="f-1858" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-630" decimals="-6" id="f-1859" unitRef="eur">206000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-631" decimals="-6" id="f-1860" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-632" decimals="-6" id="f-1861" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-633" decimals="-6" id="f-1862" unitRef="eur">295000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-634" decimals="-6" id="f-1863" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-635" decimals="-6" id="f-1864" unitRef="eur">5349000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-636" decimals="-6" id="f-1865" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-637" decimals="-6" id="f-1866" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-638" decimals="-6" id="f-1867" unitRef="eur">9537000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-639" decimals="-6" id="f-1868" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-640" decimals="-6" id="f-1869" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-641" decimals="-6" id="f-1870" unitRef="eur">5057000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-642" decimals="-6" id="f-1871" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-643" decimals="-6" id="f-1872" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-644" decimals="-6" id="f-1873" unitRef="eur">6737000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-645" decimals="-6" id="f-1874" unitRef="eur">201000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-646" decimals="-6" id="f-1875" unitRef="eur">964000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-647" decimals="-6" id="f-1876" unitRef="eur">10765000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-648" decimals="-6" id="f-1877" unitRef="eur">206000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-649" decimals="-6" id="f-1878" unitRef="eur">967000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-650" decimals="-6" id="f-1879" unitRef="eur">6449000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-651" decimals="-6" id="f-1880" unitRef="eur">298000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-652" decimals="-6" id="f-1881" unitRef="eur">883000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities contextRef="c-653" decimals="-6" id="f-1882" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-654" decimals="-6" id="f-1883" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-655" decimals="-6" id="f-1884" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-656" decimals="-6" id="f-1885" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-657" decimals="-6" id="f-1886" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-658" decimals="-6" id="f-1887" unitRef="eur">26000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-659" decimals="-6" id="f-1888" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-660" decimals="-6" id="f-1889" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-661" decimals="-6" id="f-1890" unitRef="eur">59000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-662" decimals="-6" id="f-1891" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-663" decimals="-6" id="f-1892" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-664" decimals="-6" id="f-1893" unitRef="eur">127000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-665" decimals="-6" id="f-1894" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-666" decimals="-6" id="f-1895" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-667" decimals="-6" id="f-1896" unitRef="eur">204000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-668" decimals="-6" id="f-1897" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-669" decimals="-6" id="f-1898" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-670" decimals="-6" id="f-1899" unitRef="eur">269000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-671" decimals="-6" id="f-1900" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-672" decimals="-6" id="f-1901" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-673" decimals="-6" id="f-1902" unitRef="eur">441000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-674" decimals="-6" id="f-1903" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-675" decimals="-6" id="f-1904" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-676" decimals="-6" id="f-1905" unitRef="eur">380000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-677" decimals="-6" id="f-1906" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-678" decimals="-6" id="f-1907" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-679" decimals="-6" id="f-1908" unitRef="eur">354000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-680" decimals="-6" id="f-1909" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-681" decimals="-6" id="f-1910" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-682" decimals="-6" id="f-1911" unitRef="eur">137000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-683" decimals="-6" id="f-1912" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-684" decimals="-6" id="f-1913" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-685" decimals="-6" id="f-1914" unitRef="eur">165000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-686" decimals="-6" id="f-1915" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-687" decimals="-6" id="f-1916" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-688" decimals="-6" id="f-1917" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-689" decimals="-6" id="f-1918" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-690" decimals="-6" id="f-1919" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-691" decimals="-6" id="f-1920" unitRef="eur">4000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-692" decimals="-6" id="f-1921" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-693" decimals="-6" id="f-1922" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-694" decimals="-6" id="f-1923" unitRef="eur">4000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-695" decimals="-6" id="f-1924" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-696" decimals="-6" id="f-1925" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-697" decimals="-6" id="f-1926" unitRef="eur">32000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-698" decimals="-6" id="f-1927" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-699" decimals="-6" id="f-1928" unitRef="eur">164000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-700" decimals="-6" id="f-1929" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-701" decimals="-6" id="f-1930" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-702" decimals="-6" id="f-1931" unitRef="eur">232000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-703" decimals="-6" id="f-1932" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-704" decimals="-6" id="f-1933" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-705" decimals="-6" id="f-1934" unitRef="eur">6000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-706" decimals="-6" id="f-1935" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-707" decimals="-6" id="f-1936" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-708" decimals="-6" id="f-1937" unitRef="eur">127000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-709" decimals="-6" id="f-1938" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-710" decimals="-6" id="f-1939" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-711" decimals="-6" id="f-1940" unitRef="eur">94000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-712" decimals="-6" id="f-1941" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-713" decimals="-6" id="f-1942" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-714" decimals="-6" id="f-1943" unitRef="eur">79000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-715" decimals="-6" id="f-1944" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-644" decimals="-6" id="f-1945" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-645" decimals="-6" id="f-1946" unitRef="eur">291000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-646" decimals="-6" id="f-1947" unitRef="eur">709000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-647" decimals="-6" id="f-1948" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-648" decimals="-6" id="f-1949" unitRef="eur">326000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-649" decimals="-6" id="f-1950" unitRef="eur">779000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-650" decimals="-6" id="f-1951" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-651" decimals="-6" id="f-1952" unitRef="eur">85000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-652" decimals="-6" id="f-1953" unitRef="eur">714000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c-1" id="f-1954">Cash and cash equivalents&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,710&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,736&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,098&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;As of December 31, 2023, cash equivalents mainly comprised the following: (i)&#160;&#x20ac;5,349 million invested in euro and US dollar denominated money-market mutual funds (December 31, 2022: &#x20ac;9,537 million; December 31, 2021: &#x20ac;5,057 million); (ii)&#160;&#x20ac;1,191 million of term deposits (December 31, 2022: &#x20ac;1,167 million; December 31, 2021: &#x20ac;2,768 million) and (iii)&#160;zero commercial paper (December 31, 2022: zero; December 31, 2021: &#x20ac;179 million). Cash equivalents also include &#x20ac;476 million held by captive insurance and reinsurance companies in accordance with insurance regulations (December 31, 2022: &#x20ac;439 million; December 31, 2021: &#x20ac;427 million).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <sny:DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock contextRef="c-1" id="f-1955">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,710&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,736&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,098&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;As of December 31, 2023, cash equivalents mainly comprised the following: (i)&#160;&#x20ac;5,349 million invested in euro and US dollar denominated money-market mutual funds (December 31, 2022: &#x20ac;9,537 million; December 31, 2021: &#x20ac;5,057 million); (ii)&#160;&#x20ac;1,191 million of term deposits (December 31, 2022: &#x20ac;1,167 million; December 31, 2021: &#x20ac;2,768 million) and (iii)&#160;zero commercial paper (December 31, 2022: zero; December 31, 2021: &#x20ac;179 million). Cash equivalents also include &#x20ac;476 million held by captive insurance and reinsurance companies in accordance with insurance regulations (December 31, 2022: &#x20ac;439 million; December 31, 2021: &#x20ac;427 million).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfCashAndCashEquivalentsDetailsTableTextBlock>
    <ifrs-full:Cash contextRef="c-5" decimals="-6" id="f-1956" unitRef="eur">1461000000</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c-7" decimals="-6" id="f-1957" unitRef="eur">1385000000</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c-8" decimals="-6" id="f-1958" unitRef="eur">1358000000</ifrs-full:Cash>
    <ifrs-full:CashEquivalents contextRef="c-5" decimals="-6" id="f-1959" unitRef="eur">7249000000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-7" decimals="-6" id="f-1960" unitRef="eur">11351000000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-8" decimals="-6" id="f-1961" unitRef="eur">8740000000</ifrs-full:CashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-6" id="f-1962" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-7" decimals="-6" id="f-1963" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-8" decimals="-6" id="f-1964" unitRef="eur">10098000000</ifrs-full:CashAndCashEquivalents>
    <sny:CashEquivalentsMoneyMarketMutualFunds contextRef="c-5" decimals="-6" id="f-1965" unitRef="eur">5349000000</sny:CashEquivalentsMoneyMarketMutualFunds>
    <sny:CashEquivalentsMoneyMarketMutualFunds contextRef="c-7" decimals="-6" id="f-1966" unitRef="eur">9537000000</sny:CashEquivalentsMoneyMarketMutualFunds>
    <sny:CashEquivalentsMoneyMarketMutualFunds contextRef="c-8" decimals="-6" id="f-1967" unitRef="eur">5057000000</sny:CashEquivalentsMoneyMarketMutualFunds>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-5" decimals="-6" id="f-1968" unitRef="eur">1191000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-7" decimals="-6" id="f-1969" unitRef="eur">1167000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-8" decimals="-6" id="f-1970" unitRef="eur">2768000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <sny:CashEquivalentsCommercialPaper contextRef="c-5" decimals="0" id="f-1971" unitRef="eur">0</sny:CashEquivalentsCommercialPaper>
    <sny:CashEquivalentsCommercialPaper contextRef="c-7" decimals="0" id="f-1972" unitRef="eur">0</sny:CashEquivalentsCommercialPaper>
    <sny:CashEquivalentsCommercialPaper contextRef="c-8" decimals="-6" id="f-1973" unitRef="eur">179000000</sny:CashEquivalentsCommercialPaper>
    <sny:CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies contextRef="c-5" decimals="-6" id="f-1974" unitRef="eur">476000000</sny:CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies>
    <sny:CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies contextRef="c-7" decimals="-6" id="f-1975" unitRef="eur">439000000</sny:CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies>
    <sny:CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies contextRef="c-8" decimals="-6" id="f-1976" unitRef="eur">427000000</sny:CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies>
    <ifrs-full:DisclosureOfDeferredTaxesExplanatory contextRef="c-1" id="f-1977">Net deferred tax position&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of the net deferred tax position is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.854%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Deferred taxes on:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Consolidation adjustments (intragroup margin in inventory)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provision for pensions and other employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Remeasurement of other acquired intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Recognition of acquired property, plant and equipment at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity interests in subsidiaries and investments in other entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(617)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tax losses available for carry-forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Stock options and other share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accrued expenses and provisions deductible at the time of payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net deferred tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,570&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,540&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,981&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;As of December 31, 2023, includes remeasurements of the acquired intangible assets of Bioverativ (&#x20ac;1,241 million), Principia (&#x20ac;610 million), Ablynx      (&#x20ac;204 million), Genzyme (&#x20ac;50 million) and Amunix (&#x20ac;109 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately &#x20ac;60.4 billion) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2023, Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the&#160;European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December&#160;31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October&#160;2023 (see Note&#160;D.30.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Includes deferred tax assets related to restructuring provisions, amounting to &#x20ac;286 million as of December 31, 2023, &#x20ac;256 million as of                 December 31, 2022, and &#x20ac;226 million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Includes deferred taxes arising on the spread tax deduction of R&amp;amp;D expenses, amounting to &#x20ac;1,331 million as of December 31, 2023 and &#x20ac;742 million as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The reserves of Sanofi subsidiaries that would be taxable if distributed but for which no distribution is planned, and for which no deferred tax liability has therefore been recognized, totaled &#x20ac;10.0 billion as of December 31, 2023, compared with &#x20ac;10.6 billion as of December 31, 2022 and &#x20ac;10.0 billion as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Most of Sanofi&#x2019;s tax loss carry-forwards are available indefinitely. For a description of policies on the recognition of deferred tax assets, refer to Note&#160;B.22. For each tax consolidation, the recognition of deferred tax assets is determined on the basis of profit forecasts that are consistent with Sanofi&#x2019;s medium-term strategic plan, and taking into consideration the tax consequences of the strategic opportunities available to Sanofi within the period of availability of tax loss carry-forwards and the specific circumstances of each tax consolidation. Deferred tax assets relating to tax loss carry-forwards as of December 31, 2023 amounted to &#x20ac;2,729 million, of which &#x20ac;1,203 million were not recognized (including &#x20ac;473&#160;million in respect of capital losses). This compares with &#x20ac;2,650 million as of December 31, 2022 (of which&#160;&#x20ac;1,144 million were not recognized) and &#x20ac;2,391 million as of&#160;December 31, 2021 (of which &#x20ac;875 million were not recognized).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows when tax losses available for carry-forward are due to expire:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Tax&#160;losses&#160;available for carry-forward&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,933&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,503&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,644&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Excluding tax loss carry-forwards on asset disposals. Such carry-forwards amounted to &#x20ac;5 million as of December 31, 2023, &#x20ac;5 million as of       December 31, 2022 and &#x20ac;5 million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Use of tax loss carry-forwards is limited to the entity in which they arose. In jurisdictions where tax consolidations are in place, tax losses can be netted against taxable income generated by entities in the same tax consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Deferred tax assets not recognized (primarily because their future recovery was not regarded as probable given the expected results of the entities in question) amounted to &#x20ac;1,062 million in 2023, &#x20ac;995 million in 2022 and &#x20ac;615 million in 2021.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDeferredTaxesExplanatory>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="c-1" id="f-1978">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of the net deferred tax position is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.854%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Deferred taxes on:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Consolidation adjustments (intragroup margin in inventory)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provision for pensions and other employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Remeasurement of other acquired intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Recognition of acquired property, plant and equipment at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity interests in subsidiaries and investments in other entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(617)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tax losses available for carry-forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Stock options and other share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accrued expenses and provisions deductible at the time of payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net deferred tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,570&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,540&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,981&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;As of December 31, 2023, includes remeasurements of the acquired intangible assets of Bioverativ (&#x20ac;1,241 million), Principia (&#x20ac;610 million), Ablynx      (&#x20ac;204 million), Genzyme (&#x20ac;50 million) and Amunix (&#x20ac;109 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately &#x20ac;60.4 billion) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2023, Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the&#160;European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December&#160;31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October&#160;2023 (see Note&#160;D.30.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Includes deferred tax assets related to restructuring provisions, amounting to &#x20ac;286 million as of December 31, 2023, &#x20ac;256 million as of                 December 31, 2022, and &#x20ac;226 million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Includes deferred taxes arising on the spread tax deduction of R&amp;amp;D expenses, amounting to &#x20ac;1,331 million as of December 31, 2023 and &#x20ac;742 million as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-716" decimals="-6" id="f-1979" unitRef="eur">-1525000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-717" decimals="-6" id="f-1980" unitRef="eur">-1388000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-718" decimals="-6" id="f-1981" unitRef="eur">-1292000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-719" decimals="-6" id="f-1982" unitRef="eur">-853000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-720" decimals="-6" id="f-1983" unitRef="eur">-850000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-721" decimals="-6" id="f-1984" unitRef="eur">-1117000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-722" decimals="-6" id="f-1985" unitRef="eur">2904000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-723" decimals="-6" id="f-1986" unitRef="eur">3269000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-724" decimals="-6" id="f-1987" unitRef="eur">3079000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-725" decimals="-6" id="f-1988" unitRef="eur">21000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-726" decimals="-6" id="f-1989" unitRef="eur">24000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-727" decimals="-6" id="f-1990" unitRef="eur">26000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-728" decimals="-6" id="f-1991" unitRef="eur">1023000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-729" decimals="-6" id="f-1992" unitRef="eur">617000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-730" decimals="-6" id="f-1993" unitRef="eur">590000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-731" decimals="-6" id="f-1994" unitRef="eur">-1526000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-732" decimals="-6" id="f-1995" unitRef="eur">-1506000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-733" decimals="-6" id="f-1996" unitRef="eur">-1516000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-734" decimals="-6" id="f-1997" unitRef="eur">-84000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-735" decimals="-6" id="f-1998" unitRef="eur">-92000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-736" decimals="-6" id="f-1999" unitRef="eur">-88000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-737" decimals="-6" id="f-2000" unitRef="eur">-1994000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-738" decimals="-6" id="f-2001" unitRef="eur">-1859000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-739" decimals="-6" id="f-2002" unitRef="eur">-1585000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-740" decimals="-6" id="f-2003" unitRef="eur">-2536000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-741" decimals="-6" id="f-2004" unitRef="eur">-1755000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-742" decimals="-6" id="f-2005" unitRef="eur">-1078000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-5" decimals="-6" id="f-2006" unitRef="eur">-4570000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-7" decimals="-6" id="f-2007" unitRef="eur">-3540000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-8" decimals="-6" id="f-2008" unitRef="eur">-2981000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-743" decimals="-6" id="f-2009" unitRef="eur">1241000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-744" decimals="-6" id="f-2010" unitRef="eur">610000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-745" decimals="-6" id="f-2011" unitRef="eur">204000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-746" decimals="-6" id="f-2012" unitRef="eur">50000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-747" decimals="-6" id="f-2013" unitRef="eur">109000000</ifrs-full:DeferredTaxLiabilities>
    <sny:ReservesLikelyToBeDistributedInTheForeseeableFuture contextRef="c-5" decimals="-8" id="f-2014" unitRef="eur">60400000000</sny:ReservesLikelyToBeDistributedInTheForeseeableFuture>
    <ifrs-full:DeferredTaxAssets contextRef="c-748" decimals="-6" id="f-2015" unitRef="eur">286000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-749" decimals="-6" id="f-2016" unitRef="eur">256000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-750" decimals="-6" id="f-2017" unitRef="eur">226000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-751" decimals="-6" id="f-2018" unitRef="eur">1331000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-752" decimals="-6" id="f-2019" unitRef="eur">742000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures contextRef="c-5" decimals="-8" id="f-2020" unitRef="eur">10000000000</ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures>
    <ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures contextRef="c-7" decimals="-8" id="f-2021" unitRef="eur">10600000000</ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures>
    <ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures contextRef="c-8" decimals="-8" id="f-2022" unitRef="eur">10000000000</ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures>
    <sny:TotalDeferredTaxAssetsForTaxLossCarryforwards contextRef="c-5" decimals="-6" id="f-2023" unitRef="eur">2729000000</sny:TotalDeferredTaxAssetsForTaxLossCarryforwards>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-5" decimals="-6" id="f-2024" unitRef="eur">1203000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <sny:UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-5" decimals="-6" id="f-2025" unitRef="eur">473000000</sny:UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised>
    <sny:TotalDeferredTaxAssetsForTaxLossCarryforwards contextRef="c-7" decimals="-6" id="f-2026" unitRef="eur">2650000000</sny:TotalDeferredTaxAssetsForTaxLossCarryforwards>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-7" decimals="-6" id="f-2027" unitRef="eur">1144000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <sny:TotalDeferredTaxAssetsForTaxLossCarryforwards contextRef="c-8" decimals="-6" id="f-2028" unitRef="eur">2391000000</sny:TotalDeferredTaxAssetsForTaxLossCarryforwards>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-8" decimals="-6" id="f-2029" unitRef="eur">875000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <sny:DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock contextRef="c-1" id="f-2030">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows when tax losses available for carry-forward are due to expire:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Tax&#160;losses&#160;available for carry-forward&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,933&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,503&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,644&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Excluding tax loss carry-forwards on asset disposals. Such carry-forwards amounted to &#x20ac;5 million as of December 31, 2023, &#x20ac;5 million as of       December 31, 2022 and &#x20ac;5 million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfAvailabilityOfTaxLossesCarryForwardsTableTextBlock>
    <sny:TaxLossesCarryforwards contextRef="c-753" decimals="-6" id="f-2031" unitRef="eur">6000000</sny:TaxLossesCarryforwards>
    <sny:TaxLossesCarryforwards contextRef="c-754" decimals="-6" id="f-2032" unitRef="eur">7000000</sny:TaxLossesCarryforwards>
    <sny:TaxLossesCarryforwards contextRef="c-755" decimals="-6" id="f-2033" unitRef="eur">34000000</sny:TaxLossesCarryforwards>
    <sny:TaxLossesCarryforwards contextRef="c-756" decimals="-6" id="f-2034" unitRef="eur">23000000</sny:TaxLossesCarryforwards>
    <sny:TaxLossesCarryforwards contextRef="c-757" decimals="-6" id="f-2035" unitRef="eur">126000000</sny:TaxLossesCarryforwards>
    <sny:TaxLossesCarryforwards contextRef="c-758" decimals="-6" id="f-2036" unitRef="eur">8737000000</sny:TaxLossesCarryforwards>
    <sny:TaxLossesCarryforwards contextRef="c-1" decimals="-6" id="f-2037" unitRef="eur">8933000000</sny:TaxLossesCarryforwards>
    <sny:TaxLossesCarryforwards contextRef="c-9" decimals="-6" id="f-2038" unitRef="eur">8503000000</sny:TaxLossesCarryforwards>
    <sny:TaxLossesCarryforwards contextRef="c-10" decimals="-6" id="f-2039" unitRef="eur">7644000000</sny:TaxLossesCarryforwards>
    <sny:TaxLossCarryforwardsOnAssetDisposals contextRef="c-5" decimals="-6" id="f-2040" unitRef="eur">5000000</sny:TaxLossCarryforwardsOnAssetDisposals>
    <sny:TaxLossCarryforwardsOnAssetDisposals contextRef="c-7" decimals="-6" id="f-2041" unitRef="eur">5000000</sny:TaxLossCarryforwardsOnAssetDisposals>
    <sny:TaxLossCarryforwardsOnAssetDisposals contextRef="c-8" decimals="-6" id="f-2042" unitRef="eur">5000000</sny:TaxLossCarryforwardsOnAssetDisposals>
    <sny:DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable contextRef="c-5" decimals="-6" id="f-2043" unitRef="eur">1062000000</sny:DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable>
    <sny:DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable contextRef="c-7" decimals="-6" id="f-2044" unitRef="eur">995000000</sny:DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable>
    <sny:DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable contextRef="c-8" decimals="-6" id="f-2045" unitRef="eur">615000000</sny:DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-2046">Consolidated shareholders&#x2019; equity&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.15.1. Share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, the share capital w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;as &#x20ac;2,529,599,938, consisting of 1,264,799,969&#160;shar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;es with a par value of &#x20ac;2. Treasury shares held by Sanofi are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;shares &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;share&#160;capital &lt;br/&gt;for the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13.45&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.063&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Treasury shares are deducted from shareholders&#x2019; equity. Gains and losses on disposals of treasury shares are recorded directly in equity and are not recognized in net income for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in the share capital of the Sanofi parent company over the last three years are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,258,971,738&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase by issuance of restricted shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,836,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Board meeting of July 28, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase reserved for employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,562,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,263,560,695&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase by exercise of stock subscription options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;490,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase by issuance of restricted shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,499,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Board meeting of July 27, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase reserved for employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,027,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Board meeting of December 14, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reduction in share capital by cancellation of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;treasury shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,742,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,260,835,732&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase by exercise of stock subscription options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;504,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase by issuance of restricted shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,330,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Board meeting of July 27, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase reserved for employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,128,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,264,799,969&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Shares issued on exercise of Sanofi stock subscription options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Shares vesting under restricted share plans and issued in the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For the disclosures about the management of capital required under IFRS&#160;7, refer to Note&#160;B.27.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.15.2. Restricted share plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restricted share plans are accounted for in accordance with the policies described in Note&#160;B.24.3. The principal characteristics of those plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.009%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Type of plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;May 25, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 13, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;May 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 14, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;October 27, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Service period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total number of shares awarded &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,838,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,344,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,484,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with no market condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,425,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,000,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,209,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;87.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;77.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;91.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;79.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;77.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with market condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,413,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,343,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,274,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded other than to the Chief Executive Officer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;83.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;74.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;86.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;69.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;71.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;68.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded other than to the Chief Executive Officer - additional shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;43.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;34.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;49.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;54.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded to the Chief Executive Officer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;82.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;84.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;71.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value of plan at the date of grant &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;262&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Weighting between (i)&#160;fair value determined using the Monte Carlo model and (ii)&#160;market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Additional tranche subject to a higher level of market conditions: 121,097&#160;additional shares were awarded in May&#160;2023, and 5,838&#160;additional shares were awarded in December&#160;2023 (versus 114,874&#160;additional shares awarded in May&#160;2022, and 9,066&#160;additional shares awarded in December&#160;2022).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total expense for restricted share plans &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares not yet fully vested as of December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,773,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,245,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,507,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2023 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,780,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2022 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,099,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,330,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2021 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,893,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,097,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,364,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2020 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,817,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,014,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2019 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,128,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Additional tranche subject to a higher level of market conditions: 126,935&#160;additional shares were awarded in 2023, versus 123,940&#160;additional shares awarded in &#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.15.3. Capital increases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The characteristics of the employee share ownership plans awarded in the form of a capital increase reserved for employees in&#160;2023, 2022 and 2021 are summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;February 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;February 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;February 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Subscription price &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Subscription period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 5-23, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 9-29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 7-25, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,009,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,909,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,438,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares issued immediately as employer&#x2019;s contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;124,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Subscription price representing 80% of the average of the opening quoted market prices of Sanofi shares during the 20&#160;trading days preceding May&#160;31,&#160;2023, June&#160;6,&#160;2022 and June&#160;3, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth the expense recognized for each plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which employer&#x2019;s contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.15.4. Repurchase of Sanofi shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Annual General Meetings of Sanofi shareholders held on May 25, 2023, May&#160;3, 2022 and April&#160;30, 2021 each authorized a share repurchase program for a period of 18 months. The following repurchases have been made under those programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:29.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in number of shares and &#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:29.25pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year of authorization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number &lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number &lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number &lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,584,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,000,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,510,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,976,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,765,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,758,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.15.5. Reductions in share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Reductions in share capital for the accounting periods presented are described in the table included at Note&#160;D.15.1. above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Those reductions have no impact on shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.15.6. Currency translation differences&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Currency translation differences comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Attributable to equity holders of Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(865)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,462&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The balance as of December 31, 2023 includes an after-tax amount of &#x20ac;(574) million relating to hedges of net investments in&#160;foreign operations (refer to Note&#160;B.8.3. for a description of the relevant accounting policy), compared with &#x20ac;(580) million as of&#160;December 31, 2022 and&#160;&#x20ac;(317) million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The movement in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Currency translation differences&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; is mainly attributable to the US dollar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.15.7. Other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements within other comprehensive income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Actuarial gains/(losses) excluding investments accounted for using the equity method (see&#160;Note&#160;D.19.1.)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments included in financial assets and financial liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;padding-right:29.25pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Equity risk hedging instruments designated as fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items not subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;797&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments included in financial assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash flow and fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Change in currency translation differences:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Currency translation differences (investments accounted for using the&#160;equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Hedges of net investments in foreign operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,313&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,510&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: immaterial amount in 2023, immaterial amount in 2022 and &#x20ac;4 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: &#x20ac;1 million in 2023, &#x20ac;2 million in 2022 and &#x20ac;12 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: &#x20ac;(56) million in 2023, and &#x20ac;(40) million in 2022 (including &#x20ac;(35)&#160;million relating to the deconsolidation of EUROAPI). The amounts reclassified to profit and loss were immaterial in 2021. Currency translation differences arise from the translation into euros of the financial statements of foreign subsidiaries, and are mainly due to the appreciation of the dollar against the euro.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.15.8. Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock option plans awarded and measurement of stock option plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;No stock options were awarded during 2023, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock subscription option plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Details of the terms of exercise of stock subscription options granted under the various plans are presented below in Sanofi share equivalents. These plans were awarded to certain corporate officers and employees of Sanofi companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table shows all Sanofi stock subscription option plans still outstanding or under which options were exercised in the year ended&#160;December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Source&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Date of grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;options&lt;br/&gt;granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Start&#160;date&#160;of&lt;br/&gt;exercise&lt;br/&gt;period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;price &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of options outstanding as of 12/31/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/05/2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;788,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/06/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/05/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/05/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,009,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/06/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/05/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;06/24/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;435,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;06/25/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;06/24/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;337,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/04/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;402,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/05/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/04/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/10/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;378,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/11/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/10/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/02/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/03/2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/02/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;04/30/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/02/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;04/30/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333,013&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The exercise of all outstanding stock subscription options would increase shareholders&#x2019; equity by approximately &#x20ac;107 million. The&#160;exercise of each option results in the issuance of one share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of stock option plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A summary of stock options outstanding at each balance sheet date, and of movements during the relevant periods, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;per share &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Options outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,579,270&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;75.61&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,845,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;74.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(190,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(51,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Options outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,337,968&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;77.13&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;180&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,949,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;78.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(490,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Options outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,837,969&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;78.64&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,624,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(504,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Options outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333,013&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;80.53&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,333,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;80.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Mainly due to the grantees leaving Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below provides summary information about options outstanding and exercisable as of December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of exercise prices per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;residual&#160;life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;price per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;share &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;price per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;share &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;60.00 to &#x20ac;70.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;70.00 to &#x20ac;80.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;569,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;569,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;80.00 to &#x20ac;90.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333,013&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333,013&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.15.9. Number of shares used to compute diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,251.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,251.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,252.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for stock options with dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Average number of shares used to compute diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,256.4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,256.9&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,257.9&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2023 and 2022, all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. In 2021, 0.6 million&#160;stock options were not taken into account in computing diluted earnings per share because they had no dilutive effect.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:IssuedCapital contextRef="c-5" decimals="0" id="f-2047" unitRef="eur">2529599938</ifrs-full:IssuedCapital>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-5"
      decimals="INF"
      id="f-2048"
      unitRef="shares">1264799969</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-2049"
      unitRef="eurPerShare">2</ifrs-full:ParValuePerShare>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-2050">Treasury shares held by Sanofi are as follows:&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;shares &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;share&#160;capital &lt;br/&gt;for the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13.45&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.063&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <sny:NumberOfSharesHeld contextRef="c-5" decimals="-4" id="f-2051" unitRef="shares">13450000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-5" decimals="5" id="f-2052" unitRef="number">0.01063</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld contextRef="c-7" decimals="-4" id="f-2053" unitRef="shares">8200000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-7" decimals="5" id="f-2054" unitRef="number">0.00650</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld contextRef="c-8" decimals="-4" id="f-2055" unitRef="shares">11020000.00</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-8" decimals="5" id="f-2056" unitRef="number">0.00872</sny:PercentageOfShareCapitalForThePeriod>
    <sny:NumberOfSharesHeld
      contextRef="c-19"
      decimals="-4"
      id="f-2057"
      unitRef="shares">8280000</sny:NumberOfSharesHeld>
    <sny:PercentageOfShareCapitalForThePeriod contextRef="c-19" decimals="5" id="f-2058" unitRef="number">0.00658</sny:PercentageOfShareCapitalForThePeriod>
    <sny:DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock contextRef="c-1" id="f-2059">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in the share capital of the Sanofi parent company over the last three years are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,258,971,738&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital&#160;increase&#160;by&#160;exercise&#160;of stock subscription options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase by issuance of restricted shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,836,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Board meeting of July 28, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase reserved for employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,562,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,263,560,695&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase by exercise of stock subscription options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;490,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase by issuance of restricted shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,499,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Board meeting of July 27, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase reserved for employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,027,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Board meeting of December 14, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reduction in share capital by cancellation of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;treasury shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,742,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,260,835,732&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase by exercise of stock subscription options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;504,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;During 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase by issuance of restricted shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,330,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Board meeting of July 27, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Capital increase reserved for employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,128,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,264,799,969&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Shares issued on exercise of Sanofi stock subscription options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Shares vesting under restricted share plans and issued in the period.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfStatementOfChangesInEquityOfParentTableTextBlock>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-759"
      decimals="INF"
      id="f-2060"
      unitRef="shares">1258971738</ifrs-full:NumberOfSharesIssued>
    <sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions
      contextRef="c-760"
      decimals="INF"
      id="f-2061"
      unitRef="shares">190076</sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions>
    <sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease
      contextRef="c-760"
      decimals="INF"
      id="f-2062"
      unitRef="shares">1836179</sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease>
    <sny:NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees
      contextRef="c-761"
      decimals="INF"
      id="f-2063"
      unitRef="shares">2562702</sny:NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-762"
      decimals="INF"
      id="f-2064"
      unitRef="shares">1263560695</ifrs-full:NumberOfSharesIssued>
    <sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions
      contextRef="c-763"
      decimals="INF"
      id="f-2065"
      unitRef="shares">490373</sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions>
    <sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease
      contextRef="c-763"
      decimals="INF"
      id="f-2066"
      unitRef="shares">1499987</sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease>
    <sny:NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees
      contextRef="c-764"
      decimals="INF"
      id="f-2067"
      unitRef="shares">2027057</sny:NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees>
    <sny:ReductionOfSharesByCancellationOfTreasuryShares
      contextRef="c-765"
      decimals="INF"
      id="f-2068"
      unitRef="shares">6742380</sny:ReductionOfSharesByCancellationOfTreasuryShares>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-766"
      decimals="INF"
      id="f-2069"
      unitRef="shares">1260835732</ifrs-full:NumberOfSharesIssued>
    <sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions
      contextRef="c-767"
      decimals="INF"
      id="f-2070"
      unitRef="shares">504956</sny:NumberOfSharesIssuedInRegardsOfCapitalIncreaseByExerciseOfStockSubscriptionOptions>
    <sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease
      contextRef="c-767"
      decimals="INF"
      id="f-2071"
      unitRef="shares">1330558</sny:NumberOfRestrictedSharesIssuedInRegardsOfCapitalIncrease>
    <sny:NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees
      contextRef="c-768"
      decimals="INF"
      id="f-2072"
      unitRef="shares">2128723</sny:NumberOfShareIssuesInRegardsToCapitalincreaseReservedForEmployees>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-769"
      decimals="INF"
      id="f-2073"
      unitRef="shares">1264799969</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory contextRef="c-1" id="f-2074">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restricted share plans are accounted for in accordance with the policies described in Note&#160;B.24.3. The principal characteristics of those plans are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.009%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Type of plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;share plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;May 25, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 13, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;May 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 14, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;October 27, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Service period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total number of shares awarded &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,838,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,344,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,484,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with no market condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,425,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,000,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,209,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;87.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;77.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;91.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;79.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;77.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which with market condition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,413,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,343,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,274,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded other than to the Chief Executive Officer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;83.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;74.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;86.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;69.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;71.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;68.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded other than to the Chief Executive Officer - additional shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;43.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;34.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;49.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;54.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value per share awarded to the Chief Executive Officer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;82.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;84.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x20ac;71.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value of plan at the date of grant &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;326&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;262&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Weighting between (i)&#160;fair value determined using the Monte Carlo model and (ii)&#160;market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Additional tranche subject to a higher level of market conditions: 121,097&#160;additional shares were awarded in May&#160;2023, and 5,838&#160;additional shares were awarded in December&#160;2023 (versus 114,874&#160;additional shares awarded in May&#160;2022, and 9,066&#160;additional shares awarded in December&#160;2022).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory>
    <sny:NumberOfYearsServicePeriod contextRef="c-770" id="f-2075">P3Y</sny:NumberOfYearsServicePeriod>
    <sny:NumberOfYearsServicePeriod contextRef="c-771" id="f-2076">P3Y</sny:NumberOfYearsServicePeriod>
    <sny:NumberOfYearsServicePeriod contextRef="c-772" id="f-2077">P3Y</sny:NumberOfYearsServicePeriod>
    <sny:NumberOfYearsServicePeriod contextRef="c-773" id="f-2078">P3Y</sny:NumberOfYearsServicePeriod>
    <sny:NumberOfYearsServicePeriod contextRef="c-774" id="f-2079">P3Y</sny:NumberOfYearsServicePeriod>
    <sny:NumberOfYearsServicePeriod contextRef="c-775" id="f-2080">P3Y</sny:NumberOfYearsServicePeriod>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-770"
      decimals="INF"
      id="f-2081"
      unitRef="shares">3838434</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-771"
      decimals="INF"
      id="f-2082"
      unitRef="shares">65129</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-772"
      decimals="INF"
      id="f-2083"
      unitRef="shares">3344432</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-773"
      decimals="INF"
      id="f-2084"
      unitRef="shares">109981</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-774"
      decimals="INF"
      id="f-2085"
      unitRef="shares">3484420</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-775"
      decimals="INF"
      id="f-2086"
      unitRef="shares">13521</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-776"
      decimals="INF"
      id="f-2087"
      unitRef="shares">2425047</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-777"
      decimals="INF"
      id="f-2088"
      unitRef="shares">944</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-778"
      decimals="INF"
      id="f-2089"
      unitRef="shares">2000627</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-779"
      decimals="INF"
      id="f-2090"
      unitRef="shares">10335</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-780"
      decimals="INF"
      id="f-2091"
      unitRef="shares">2209901</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-781"
      decimals="INF"
      id="f-2092"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-776"
      decimals="2"
      id="f-2093"
      unitRef="eurPerShare">87.69</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-777"
      decimals="2"
      id="f-2094"
      unitRef="eurPerShare">77.42</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-778"
      decimals="2"
      id="f-2095"
      unitRef="eurPerShare">91.19</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-779"
      decimals="2"
      id="f-2096"
      unitRef="eurPerShare">79.17</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-780"
      decimals="2"
      id="f-2097"
      unitRef="eurPerShare">77.27</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-781"
      decimals="2"
      id="f-2098"
      unitRef="eurPerShare">0</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-782"
      decimals="INF"
      id="f-2099"
      unitRef="shares">1413387</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-783"
      decimals="INF"
      id="f-2100"
      unitRef="shares">64185</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-784"
      decimals="INF"
      id="f-2101"
      unitRef="shares">1343805</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-785"
      decimals="INF"
      id="f-2102"
      unitRef="shares">99646</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-786"
      decimals="INF"
      id="f-2103"
      unitRef="shares">1274519</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-787"
      decimals="INF"
      id="f-2104"
      unitRef="shares">13521</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-782"
      decimals="2"
      id="f-2105"
      unitRef="eurPerShare">83.74</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-783"
      decimals="2"
      id="f-2106"
      unitRef="eurPerShare">74.50</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-784"
      decimals="2"
      id="f-2107"
      unitRef="eurPerShare">86.65</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-785"
      decimals="2"
      id="f-2108"
      unitRef="eurPerShare">69.60</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-786"
      decimals="2"
      id="f-2109"
      unitRef="eurPerShare">71.30</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriod
      contextRef="c-787"
      decimals="2"
      id="f-2110"
      unitRef="eurPerShare">68.45</sny:FairValuePerShareAwardedForThreeYearServicePeriod>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares
      contextRef="c-782"
      decimals="2"
      id="f-2111"
      unitRef="eurPerShare">43.60</sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares
      contextRef="c-783"
      decimals="2"
      id="f-2112"
      unitRef="eurPerShare">34.90</sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares
      contextRef="c-784"
      decimals="2"
      id="f-2113"
      unitRef="eurPerShare">49.00</sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares
      contextRef="c-785"
      decimals="2"
      id="f-2114"
      unitRef="eurPerShare">54.70</sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares
      contextRef="c-786"
      decimals="2"
      id="f-2115"
      unitRef="eurPerShare">0</sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares
      contextRef="c-787"
      decimals="2"
      id="f-2116"
      unitRef="eurPerShare">0</sny:FairValuePerShareAwardedForThreeYearServicePeriodAdditionalShares>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer
      contextRef="c-782"
      decimals="2"
      id="f-2117"
      unitRef="eurPerShare">82.17</sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer
      contextRef="c-783"
      decimals="2"
      id="f-2118"
      unitRef="eurPerShare">0</sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer
      contextRef="c-784"
      decimals="2"
      id="f-2119"
      unitRef="eurPerShare">84.46</sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer
      contextRef="c-785"
      decimals="2"
      id="f-2120"
      unitRef="eurPerShare">0</sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer
      contextRef="c-786"
      decimals="2"
      id="f-2121"
      unitRef="eurPerShare">71.30</sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer>
    <sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer
      contextRef="c-787"
      decimals="2"
      id="f-2122"
      unitRef="eurPerShare">0</sny:FairValuePerShareAwardedForThreeYearServicePeriodToChiefExecutiveOfficer>
    <sny:FairValueOfPlanAtDateOfGrant contextRef="c-770" decimals="-6" id="f-2123" unitRef="eur">326000000</sny:FairValueOfPlanAtDateOfGrant>
    <sny:FairValueOfPlanAtDateOfGrant contextRef="c-771" decimals="-6" id="f-2124" unitRef="eur">5000000</sny:FairValueOfPlanAtDateOfGrant>
    <sny:FairValueOfPlanAtDateOfGrant contextRef="c-772" decimals="-6" id="f-2125" unitRef="eur">294000000</sny:FairValueOfPlanAtDateOfGrant>
    <sny:FairValueOfPlanAtDateOfGrant contextRef="c-773" decimals="-6" id="f-2126" unitRef="eur">8000000</sny:FairValueOfPlanAtDateOfGrant>
    <sny:FairValueOfPlanAtDateOfGrant contextRef="c-774" decimals="-6" id="f-2127" unitRef="eur">262000000</sny:FairValueOfPlanAtDateOfGrant>
    <sny:FairValueOfPlanAtDateOfGrant contextRef="c-775" decimals="-6" id="f-2128" unitRef="eur">1000000</sny:FairValueOfPlanAtDateOfGrant>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-788"
      decimals="INF"
      id="f-2129"
      unitRef="shares">121097</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-789"
      decimals="INF"
      id="f-2130"
      unitRef="shares">5838</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-790"
      decimals="INF"
      id="f-2131"
      unitRef="shares">114874</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-791"
      decimals="INF"
      id="f-2132"
      unitRef="shares">9066</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock contextRef="c-1" id="f-2133">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total expense for restricted share plans &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares not yet fully vested as of December 31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,773,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,245,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,507,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2023 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,780,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2022 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,099,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,330,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2021 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,893,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,097,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,364,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2020 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,817,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,014,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Under 2019 plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,128,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Additional tranche subject to a higher level of market conditions: 126,935&#160;additional shares were awarded in 2023, versus 123,940&#160;additional shares awarded in &#160;2022.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfNumberOfRestrictedSharePlansNotYetFullyVestedTableTextBlock>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-792" decimals="-6" id="f-2134" unitRef="eur">231000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-793" decimals="-6" id="f-2135" unitRef="eur">206000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-794" decimals="-6" id="f-2136" unitRef="eur">193000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-795"
      decimals="INF"
      id="f-2137"
      unitRef="shares">9773084</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-796"
      decimals="INF"
      id="f-2138"
      unitRef="shares">9245513</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-797"
      decimals="INF"
      id="f-2139"
      unitRef="shares">9507849</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-798"
      decimals="INF"
      id="f-2140"
      unitRef="shares">3780513</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-799"
      decimals="INF"
      id="f-2141"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-800"
      decimals="INF"
      id="f-2142"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-801"
      decimals="INF"
      id="f-2143"
      unitRef="shares">3099158</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-802"
      decimals="INF"
      id="f-2144"
      unitRef="shares">3330801</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-803"
      decimals="INF"
      id="f-2145"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-804"
      decimals="INF"
      id="f-2146"
      unitRef="shares">2893413</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-805"
      decimals="INF"
      id="f-2147"
      unitRef="shares">3097531</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-806"
      decimals="INF"
      id="f-2148"
      unitRef="shares">3364895</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-807"
      decimals="INF"
      id="f-2149"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-808"
      decimals="INF"
      id="f-2150"
      unitRef="shares">2817181</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-809"
      decimals="INF"
      id="f-2151"
      unitRef="shares">3014496</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-810"
      decimals="INF"
      id="f-2152"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-811"
      decimals="INF"
      id="f-2153"
      unitRef="shares">0</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <sny:NumberOfRestrictedSharesNotYetFullyVested
      contextRef="c-812"
      decimals="INF"
      id="f-2154"
      unitRef="shares">3128458</sny:NumberOfRestrictedSharesNotYetFullyVested>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-813"
      decimals="INF"
      id="f-2155"
      unitRef="shares">126935</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-814"
      decimals="INF"
      id="f-2156"
      unitRef="shares">123940</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock contextRef="c-1" id="f-2157">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The characteristics of the employee share ownership plans awarded in the form of a capital increase reserved for employees in&#160;2023, 2022 and 2021 are summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Date of Board meeting approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;February 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;February 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;February 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Subscription price &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Subscription period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 5-23, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 9-29, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 7-25, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares subscribed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,009,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,909,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,438,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Number of shares issued immediately as employer&#x2019;s contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;124,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Subscription price representing 80% of the average of the opening quoted market prices of Sanofi shares during the 20&#160;trading days preceding May&#160;31,&#160;2023, June&#160;6,&#160;2022 and June&#160;3, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfEmployeeStockOwnershipPlanAwardedInCapitalIncreaseReservedExplanatoryTableTextBlock>
    <sny:SubscriptionPricePerShare
      contextRef="c-815"
      decimals="2"
      id="f-2158"
      unitRef="eurPerShare">79.58</sny:SubscriptionPricePerShare>
    <sny:SubscriptionPricePerShare
      contextRef="c-816"
      decimals="2"
      id="f-2159"
      unitRef="eurPerShare">80.21</sny:SubscriptionPricePerShare>
    <sny:SubscriptionPricePerShare
      contextRef="c-817"
      decimals="2"
      id="f-2160"
      unitRef="eurPerShare">69.38</sny:SubscriptionPricePerShare>
    <sny:NumberOfShareSubscribed
      contextRef="c-815"
      decimals="INF"
      id="f-2161"
      unitRef="shares">2009306</sny:NumberOfShareSubscribed>
    <sny:NumberOfShareSubscribed
      contextRef="c-816"
      decimals="INF"
      id="f-2162"
      unitRef="shares">1909008</sny:NumberOfShareSubscribed>
    <sny:NumberOfShareSubscribed
      contextRef="c-817"
      decimals="INF"
      id="f-2163"
      unitRef="shares">2438590</sny:NumberOfShareSubscribed>
    <sny:IssuanceOfFurtherSharesAsAnEmployersContribution
      contextRef="c-815"
      decimals="INF"
      id="f-2164"
      unitRef="shares">119417</sny:IssuanceOfFurtherSharesAsAnEmployersContribution>
    <sny:IssuanceOfFurtherSharesAsAnEmployersContribution
      contextRef="c-816"
      decimals="INF"
      id="f-2165"
      unitRef="shares">118049</sny:IssuanceOfFurtherSharesAsAnEmployersContribution>
    <sny:IssuanceOfFurtherSharesAsAnEmployersContribution
      contextRef="c-817"
      decimals="INF"
      id="f-2166"
      unitRef="shares">124112</sny:IssuanceOfFurtherSharesAsAnEmployersContribution>
    <sny:PercentageOfAverageOfQuotedMarketPricesOfShares contextRef="c-10" decimals="2" id="f-2167" unitRef="number">0.80</sny:PercentageOfAverageOfQuotedMarketPricesOfShares>
    <sny:PercentageOfAverageOfQuotedMarketPricesOfShares contextRef="c-1" decimals="2" id="f-2168" unitRef="number">0.80</sny:PercentageOfAverageOfQuotedMarketPricesOfShares>
    <sny:PercentageOfAverageOfQuotedMarketPricesOfShares contextRef="c-9" decimals="2" id="f-2169" unitRef="number">0.80</sny:PercentageOfAverageOfQuotedMarketPricesOfShares>
    <sny:NumberOfTradingDaysPrecedingPlanApproval contextRef="c-1" id="f-2170">P20D</sny:NumberOfTradingDaysPrecedingPlanApproval>
    <sny:NumberOfTradingDaysPrecedingPlanApproval contextRef="c-9" id="f-2171">P20D</sny:NumberOfTradingDaysPrecedingPlanApproval>
    <sny:NumberOfTradingDaysPrecedingPlanApproval contextRef="c-10" id="f-2172">P20D</sny:NumberOfTradingDaysPrecedingPlanApproval>
    <ifrs-full:AdditionalInformationAboutSharebasedPaymentArrangements contextRef="c-1" id="f-2173">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth the expense recognized for each plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which employer&#x2019;s contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:AdditionalInformationAboutSharebasedPaymentArrangements>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-818" decimals="-6" id="f-2174" unitRef="eur">52000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-819" decimals="-6" id="f-2175" unitRef="eur">39000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-820" decimals="-6" id="f-2176" unitRef="eur">51000000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <sny:ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution contextRef="c-818" decimals="-6" id="f-2177" unitRef="eur">12000000</sny:ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution>
    <sny:ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution contextRef="c-819" decimals="-6" id="f-2178" unitRef="eur">11000000</sny:ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution>
    <sny:ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution contextRef="c-820" decimals="-6" id="f-2179" unitRef="eur">11000000</sny:ExpenseFromEquitySettledShareBasedPaymentTransactionsOfWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsEmployerContribution>
    <sny:PeriodOfShareRepurchaseProgram contextRef="c-821" id="f-2180">P18M</sny:PeriodOfShareRepurchaseProgram>
    <sny:PeriodOfShareRepurchaseProgram contextRef="c-822" id="f-2181">P18M</sny:PeriodOfShareRepurchaseProgram>
    <sny:PeriodOfShareRepurchaseProgram contextRef="c-823" id="f-2182">P18M</sny:PeriodOfShareRepurchaseProgram>
    <sny:DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock contextRef="c-1" id="f-2183">The following repurchases have been made under those programs:&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-right:29.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in number of shares and &#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:29.25pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year of authorization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number &lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number &lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number &lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,584,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,000,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,510,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2021 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,976,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,765,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,758,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfShareRepurchaseProgramExplanatoryTableTextBlock>
    <sny:NumberOfSharesRepurchased
      contextRef="c-824"
      decimals="INF"
      id="f-2184"
      unitRef="shares">2584540</sny:NumberOfSharesRepurchased>
    <sny:AmountOfSharesRepurchased contextRef="c-825" decimals="-6" id="f-2185" unitRef="eur">230000000</sny:AmountOfSharesRepurchased>
    <sny:NumberOfSharesRepurchased
      contextRef="c-826"
      decimals="INF"
      id="f-2186"
      unitRef="shares">4000204</sny:NumberOfSharesRepurchased>
    <sny:AmountOfSharesRepurchased contextRef="c-827" decimals="-6" id="f-2187" unitRef="eur">363000000</sny:AmountOfSharesRepurchased>
    <sny:NumberOfSharesRepurchased
      contextRef="c-828"
      decimals="INF"
      id="f-2188"
      unitRef="shares">1510000</sny:NumberOfSharesRepurchased>
    <sny:AmountOfSharesRepurchased contextRef="c-829" decimals="-6" id="f-2189" unitRef="eur">137000000</sny:AmountOfSharesRepurchased>
    <sny:NumberOfSharesRepurchased
      contextRef="c-830"
      decimals="INF"
      id="f-2190"
      unitRef="shares">3976992</sny:NumberOfSharesRepurchased>
    <sny:AmountOfSharesRepurchased contextRef="c-831" decimals="-6" id="f-2191" unitRef="eur">360000000</sny:AmountOfSharesRepurchased>
    <sny:NumberOfSharesRepurchased
      contextRef="c-832"
      decimals="INF"
      id="f-2192"
      unitRef="shares">2765388</sny:NumberOfSharesRepurchased>
    <sny:AmountOfSharesRepurchased contextRef="c-833" decimals="-6" id="f-2193" unitRef="eur">242000000</sny:AmountOfSharesRepurchased>
    <sny:NumberOfSharesRepurchased
      contextRef="c-834"
      decimals="INF"
      id="f-2194"
      unitRef="shares">1758569</sny:NumberOfSharesRepurchased>
    <sny:AmountOfSharesRepurchased contextRef="c-835" decimals="-6" id="f-2195" unitRef="eur">140000000</sny:AmountOfSharesRepurchased>
    <sny:DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock contextRef="c-1" id="f-2196">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Currency translation differences comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Attributable to equity holders of Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(865)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,462&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfReserveOfExchangeDifferencesOnTranslationTableTextBlock>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-836" decimals="-6" id="f-2197" unitRef="eur">-31000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-837" decimals="-6" id="f-2198" unitRef="eur">1499000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-838" decimals="-6" id="f-2199" unitRef="eur">-865000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="c-836" decimals="-6" id="f-2200" unitRef="eur">-37000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c-837" decimals="-6" id="f-2201" unitRef="eur">-37000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="c-838" decimals="-6" id="f-2202" unitRef="eur">-42000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="c-836" decimals="-6" id="f-2203" unitRef="eur">-68000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-837" decimals="-6" id="f-2204" unitRef="eur">1462000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-838" decimals="-6" id="f-2205" unitRef="eur">-907000000</ifrs-full:Equity>
    <sny:HedgesOfNetInvestmentsInForeignOperationsAfterTax contextRef="c-1" decimals="-6" id="f-2206" unitRef="eur">574000000</sny:HedgesOfNetInvestmentsInForeignOperationsAfterTax>
    <sny:HedgesOfNetInvestmentsInForeignOperationsAfterTax contextRef="c-9" decimals="-6" id="f-2207" unitRef="eur">580000000</sny:HedgesOfNetInvestmentsInForeignOperationsAfterTax>
    <sny:HedgesOfNetInvestmentsInForeignOperationsAfterTax contextRef="c-10" decimals="-6" id="f-2208" unitRef="eur">317000000</sny:HedgesOfNetInvestmentsInForeignOperationsAfterTax>
    <sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock contextRef="c-1" id="f-2209">&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements within other comprehensive income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Actuarial gains/(losses) excluding investments accounted for using the equity method (see&#160;Note&#160;D.19.1.)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments included in financial assets and financial liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;padding-right:29.25pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Equity risk hedging instruments designated as fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items not subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;797&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Debt instruments included in financial assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash flow and fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Change in fair value (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Change in fair value (investments accounted for using the equity method, net of taxes)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Change in currency translation differences:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Currency translation differences (investments accounted for using the&#160;equity method)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Hedges of net investments in foreign operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Tax effects&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Items subsequently reclassifiable to profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,313&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,510&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: immaterial amount in 2023, immaterial amount in 2022 and &#x20ac;4 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: &#x20ac;1 million in 2023, &#x20ac;2 million in 2022 and &#x20ac;12 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Amounts reclassified to profit or loss: &#x20ac;(56) million in 2023, and &#x20ac;(40) million in 2022 (including &#x20ac;(35)&#160;million relating to the deconsolidation of EUROAPI). The amounts reclassified to profit and loss were immaterial in 2021. Currency translation differences arise from the translation into euros of the financial statements of foreign subsidiaries, and are mainly due to the appreciation of the dollar against the euro.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfAccumulatedOtherComprehensiveIncomeExplanatoryTableTextBlock>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures contextRef="c-839" decimals="-6" id="f-2210" unitRef="eur">-171000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures contextRef="c-840" decimals="-6" id="f-2211" unitRef="eur">650000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures contextRef="c-841" decimals="-6" id="f-2212" unitRef="eur">685000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetExcludingAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-839" decimals="-6" id="f-2213" unitRef="eur">0</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-840" decimals="-6" id="f-2214" unitRef="eur">4000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-841" decimals="-6" id="f-2215" unitRef="eur">1000000</sny:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-839" decimals="-6" id="f-2216" unitRef="eur">-18000000</sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-840" decimals="-6" id="f-2217" unitRef="eur">212000000</sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures contextRef="c-841" decimals="-6" id="f-2218" unitRef="eur">36000000</sny:IncomeTaxRelatingToActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAssetNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures contextRef="c-842" decimals="-6" id="f-2219" unitRef="eur">97000000</sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures contextRef="c-843" decimals="-6" id="f-2220" unitRef="eur">-4000000</sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures contextRef="c-844" decimals="-6" id="f-2221" unitRef="eur">154000000</sny:ChangeInFairValueOnEquityInstrumentsExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax contextRef="c-842" decimals="-6" id="f-2222" unitRef="eur">0</sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax>
    <sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax contextRef="c-843" decimals="-6" id="f-2223" unitRef="eur">0</sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax>
    <sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax contextRef="c-844" decimals="-6" id="f-2224" unitRef="eur">0</sny:ChangeInFairValueOnEquityInstrumentsForInvestmentsAccountedForUsingTheEquityMethodNetOfTax>
    <sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges contextRef="c-842" decimals="-6" id="f-2225" unitRef="eur">0</sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges>
    <sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges contextRef="c-843" decimals="-6" id="f-2226" unitRef="eur">17000000</sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges>
    <sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges contextRef="c-844" decimals="-6" id="f-2227" unitRef="eur">11000000</sny:EquityRiskHedgingInstrumentsDesignatedAtFairValueHedges>
    <sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod contextRef="c-842" decimals="-6" id="f-2228" unitRef="eur">21000000</sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod>
    <sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod contextRef="c-843" decimals="-6" id="f-2229" unitRef="eur">4000000</sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod>
    <sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod contextRef="c-844" decimals="-6" id="f-2230" unitRef="eur">18000000</sny:IncomeTaxRelatingToChangeInFairValueOfEquityInstrumentsExcludingEquityMethod>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-842" decimals="-6" id="f-2231" unitRef="eur">-77000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-843" decimals="-6" id="f-2232" unitRef="eur">451000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-844" decimals="-6" id="f-2233" unitRef="eur">797000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-845" decimals="-6" id="f-2234" unitRef="eur">21000000</sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-846" decimals="-6" id="f-2235" unitRef="eur">-77000000</sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-847" decimals="-6" id="f-2236" unitRef="eur">-21000000</sny:ChangeInFairValueOnDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-845" decimals="-6" id="f-2237" unitRef="eur">4000000</sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-846" decimals="-6" id="f-2238" unitRef="eur">-15000000</sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures contextRef="c-847" decimals="-6" id="f-2239" unitRef="eur">-5000000</sny:IncomeTaxRelatingToChangeInFairValueOfDebtInstrumentExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures contextRef="c-848" decimals="-6" id="f-2240" unitRef="eur">1000000</sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures contextRef="c-849" decimals="-6" id="f-2241" unitRef="eur">5000000</sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures contextRef="c-850" decimals="-6" id="f-2242" unitRef="eur">-6000000</sny:ChangeInFairValueOnCashFlowHedgesExcludingAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures contextRef="c-848" decimals="-6" id="f-2243" unitRef="eur">-2000000</sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures contextRef="c-849" decimals="-6" id="f-2244" unitRef="eur">2000000</sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures contextRef="c-850" decimals="-6" id="f-2245" unitRef="eur">0</sny:ChangeInFairValueOnCashFlowHedgesNetOfTaxOnAssociatesAndJointVentures>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome contextRef="c-848" decimals="-6" id="f-2246" unitRef="eur">0</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome contextRef="c-849" decimals="-6" id="f-2247" unitRef="eur">1000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome contextRef="c-850" decimals="-6" id="f-2248" unitRef="eur">-2000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures contextRef="c-848" decimals="-6" id="f-2249" unitRef="eur">-1551000000</sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures contextRef="c-849" decimals="-6" id="f-2250" unitRef="eur">2643000000</sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures contextRef="c-850" decimals="-6" id="f-2251" unitRef="eur">2719000000</sny:ChangeInCurrencyTranslationBeforeTaxExcludingAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures contextRef="c-848" decimals="-6" id="f-2252" unitRef="eur">3000000</sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures contextRef="c-849" decimals="-6" id="f-2253" unitRef="eur">-11000000</sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures contextRef="c-850" decimals="-6" id="f-2254" unitRef="eur">-6000000</sny:ChangeInCurrencyTranslationNetOfTaxOnAssociatesAndJointVentures>
    <sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations contextRef="c-848" decimals="-6" id="f-2255" unitRef="eur">8000000</sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations>
    <sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations contextRef="c-849" decimals="-6" id="f-2256" unitRef="eur">-354000000</sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations>
    <sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations contextRef="c-850" decimals="-6" id="f-2257" unitRef="eur">-254000000</sny:ChangeInCurrencyTranslationOnHedgesOfNetInvestmentsInForeignOperations>
    <sny:ChangeInCurrencyTranslationOnTaxEffects contextRef="c-848" decimals="-6" id="f-2258" unitRef="eur">2000000</sny:ChangeInCurrencyTranslationOnTaxEffects>
    <sny:ChangeInCurrencyTranslationOnTaxEffects contextRef="c-849" decimals="-6" id="f-2259" unitRef="eur">-91000000</sny:ChangeInCurrencyTranslationOnTaxEffects>
    <sny:ChangeInCurrencyTranslationOnTaxEffects contextRef="c-850" decimals="-6" id="f-2260" unitRef="eur">-71000000</sny:ChangeInCurrencyTranslationOnTaxEffects>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-848" decimals="-6" id="f-2261" unitRef="eur">-1526000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-849" decimals="-6" id="f-2262" unitRef="eur">2313000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-850" decimals="-6" id="f-2263" unitRef="eur">2510000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-845" decimals="0" id="f-2264" unitRef="eur">0</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-846" decimals="0" id="f-2265" unitRef="eur">0</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-847" decimals="-6" id="f-2266" unitRef="eur">4000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-851" decimals="-6" id="f-2267" unitRef="eur">1000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-852" decimals="-6" id="f-2268" unitRef="eur">2000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-853" decimals="-6" id="f-2269" unitRef="eur">12000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-854" decimals="-6" id="f-2270" unitRef="eur">-56000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-855" decimals="-6" id="f-2271" unitRef="eur">-40000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-856" decimals="-6" id="f-2272" unitRef="eur">-35000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-857" decimals="0" id="f-2273" unitRef="eur">0</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <sny:DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock contextRef="c-1" id="f-2274">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table shows all Sanofi stock subscription option plans still outstanding or under which options were exercised in the year ended&#160;December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Source&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Date of grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;options&lt;br/&gt;granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Start&#160;date&#160;of&lt;br/&gt;exercise&lt;br/&gt;period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;price &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of options outstanding as of 12/31/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/05/2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;788,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/06/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/05/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/05/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,009,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/06/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;03/05/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;06/24/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;435,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;06/25/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;06/24/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;337,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/04/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;402,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/05/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/04/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/10/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;378,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/11/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/10/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/02/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/03/2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/02/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;04/30/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;05/02/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;04/30/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333,013&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfStockSubscriptionOptionPlansUnderWhichOptionsWereExercisedInTheYearTableTextBlock>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="c-858"
      decimals="INF"
      id="f-2275"
      unitRef="shares">788725</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <sny:StockBasedCompensationStockOptionsExercisedPricePerShare
      contextRef="c-859"
      decimals="2"
      id="f-2276"
      unitRef="eurPerShare">72.19</sny:StockBasedCompensationStockOptionsExercisedPricePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-860"
      decimals="INF"
      id="f-2277"
      unitRef="shares">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="c-861"
      decimals="INF"
      id="f-2278"
      unitRef="shares">1009250</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <sny:StockBasedCompensationStockOptionsExercisedPricePerShare
      contextRef="c-862"
      decimals="2"
      id="f-2279"
      unitRef="eurPerShare">73.48</sny:StockBasedCompensationStockOptionsExercisedPricePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-863"
      decimals="INF"
      id="f-2280"
      unitRef="shares">91355</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="c-864"
      decimals="INF"
      id="f-2281"
      unitRef="shares">435000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <sny:StockBasedCompensationStockOptionsExercisedPricePerShare
      contextRef="c-865"
      decimals="2"
      id="f-2282"
      unitRef="eurPerShare">89.38</sny:StockBasedCompensationStockOptionsExercisedPricePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-866"
      decimals="INF"
      id="f-2283"
      unitRef="shares">337714</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="c-867"
      decimals="INF"
      id="f-2284"
      unitRef="shares">402750</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <sny:StockBasedCompensationStockOptionsExercisedPricePerShare
      contextRef="c-868"
      decimals="2"
      id="f-2285"
      unitRef="eurPerShare">75.90</sny:StockBasedCompensationStockOptionsExercisedPricePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-869"
      decimals="INF"
      id="f-2286"
      unitRef="shares">264750</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="c-870"
      decimals="INF"
      id="f-2287"
      unitRef="shares">378040</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <sny:StockBasedCompensationStockOptionsExercisedPricePerShare
      contextRef="c-871"
      decimals="2"
      id="f-2288"
      unitRef="eurPerShare">88.97</sny:StockBasedCompensationStockOptionsExercisedPricePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-872"
      decimals="INF"
      id="f-2289"
      unitRef="shares">257010</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="c-873"
      decimals="INF"
      id="f-2290"
      unitRef="shares">220000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <sny:StockBasedCompensationStockOptionsExercisedPricePerShare
      contextRef="c-874"
      decimals="2"
      id="f-2291"
      unitRef="eurPerShare">65.84</sny:StockBasedCompensationStockOptionsExercisedPricePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-875"
      decimals="INF"
      id="f-2292"
      unitRef="shares">168784</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="c-876"
      decimals="INF"
      id="f-2293"
      unitRef="shares">220000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <sny:StockBasedCompensationStockOptionsExercisedPricePerShare
      contextRef="c-877"
      decimals="2"
      id="f-2294"
      unitRef="eurPerShare">76.71</sny:StockBasedCompensationStockOptionsExercisedPricePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-878"
      decimals="INF"
      id="f-2295"
      unitRef="shares">213400</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-879"
      decimals="INF"
      id="f-2296"
      unitRef="shares">1333013</ifrs-full:NumberOfOutstandingShareOptions>
    <sny:ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions contextRef="c-880" decimals="-6" id="f-2297" unitRef="eur">107000000</sny:ShareholdersEquityIncreaseDueToTheExerciseOfAllStockSubscriptionOptions>
    <sny:NumberOfSharesIssuedByExerciceOfEachOption
      contextRef="c-880"
      decimals="INF"
      id="f-2298"
      unitRef="shares">1</sny:NumberOfSharesIssuedByExerciceOfEachOption>
    <sny:DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock contextRef="c-1" id="f-2299">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A summary of stock options outstanding at each balance sheet date, and of movements during the relevant periods, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;per share &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Options outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,579,270&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;75.61&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,845,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;74.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(190,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(51,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Options outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,337,968&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;77.13&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;180&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,949,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;78.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(490,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options cancelled&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Options outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,837,969&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;78.64&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,624,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(504,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Options outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333,013&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;80.53&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,333,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;80.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Mainly due to the grantees leaving Sanofi.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfStockOptionsOutstandingAtEachBalanceSheetDateAndOfChangesDuringTheRelevantPeriodsTableTextBlock>
    <sny:NumberOfShareOutstandingInShareBasedPaymentArrangement
      contextRef="c-881"
      decimals="INF"
      id="f-2300"
      unitRef="shares">2579270</sny:NumberOfShareOutstandingInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-881"
      decimals="2"
      id="f-2301"
      unitRef="eurPerShare">75.61</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement contextRef="c-881" decimals="-6" id="f-2302" unitRef="eur">195000000</sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-881"
      decimals="INF"
      id="f-2303"
      unitRef="shares">1845050</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-881"
      decimals="2"
      id="f-2304"
      unitRef="eurPerShare">74.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement contextRef="c-882" decimals="-6" id="f-2305" unitRef="eur">137000000</sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-883"
      decimals="INF"
      id="f-2306"
      unitRef="shares">190076</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c-883"
      decimals="2"
      id="f-2307"
      unitRef="eurPerShare">59.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsExercisedInShareBasedPaymentArrangement contextRef="c-883" decimals="-6" id="f-2308" unitRef="eur">11000000</sny:ValueOfShareOptionsExercisedInShareBasedPaymentArrangement>
    <sny:NumberOfShareOptionsCancelledInShareBasedPaymentArrangement
      contextRef="c-883"
      decimals="INF"
      id="f-2309"
      unitRef="shares">51216</sny:NumberOfShareOptionsCancelledInShareBasedPaymentArrangement>
    <sny:WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement
      contextRef="c-883"
      decimals="2"
      id="f-2310"
      unitRef="eurPerShare">65.84</sny:WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement>
    <sny:ValueOfShareOptionsCancelledInShareBasedPaymentArrangement contextRef="c-883" decimals="-6" id="f-2311" unitRef="eur">3000000</sny:ValueOfShareOptionsCancelledInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-883"
      decimals="INF"
      id="f-2312"
      unitRef="shares">10</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-883"
      decimals="2"
      id="f-2313"
      unitRef="eurPerShare">50.48</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement contextRef="c-883" decimals="-6" id="f-2314" unitRef="eur">0</sny:ValueOfShareOptionsForfeitedInShareBasedPaymentArrangement>
    <sny:NumberOfShareOutstandingInShareBasedPaymentArrangement
      contextRef="c-884"
      decimals="INF"
      id="f-2315"
      unitRef="shares">2337968</sny:NumberOfShareOutstandingInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-884"
      decimals="2"
      id="f-2316"
      unitRef="eurPerShare">77.13</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement contextRef="c-884" decimals="-6" id="f-2317" unitRef="eur">180000000</sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-884"
      decimals="INF"
      id="f-2318"
      unitRef="shares">1949184</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-884"
      decimals="2"
      id="f-2319"
      unitRef="eurPerShare">78.15</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement contextRef="c-883" decimals="-6" id="f-2320" unitRef="eur">152000000</sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-885"
      decimals="INF"
      id="f-2321"
      unitRef="shares">490373</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c-885"
      decimals="2"
      id="f-2322"
      unitRef="eurPerShare">71.39</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsExercisedInShareBasedPaymentArrangement contextRef="c-885" decimals="-6" id="f-2323" unitRef="eur">35000000</sny:ValueOfShareOptionsExercisedInShareBasedPaymentArrangement>
    <sny:NumberOfShareOptionsCancelledInShareBasedPaymentArrangement
      contextRef="c-885"
      decimals="INF"
      id="f-2324"
      unitRef="shares">9626</sny:NumberOfShareOptionsCancelledInShareBasedPaymentArrangement>
    <sny:WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement
      contextRef="c-885"
      decimals="2"
      id="f-2325"
      unitRef="eurPerShare">80.56</sny:WeightedAverageExercisePriceOfShareOptionsCancelledInShareBasedPaymentArrangement>
    <sny:ValueOfShareOptionsCancelledInShareBasedPaymentArrangement contextRef="c-885" decimals="-6" id="f-2326" unitRef="eur">1000000</sny:ValueOfShareOptionsCancelledInShareBasedPaymentArrangement>
    <sny:NumberOfShareOutstandingInShareBasedPaymentArrangement
      contextRef="c-886"
      decimals="INF"
      id="f-2327"
      unitRef="shares">1837969</sny:NumberOfShareOutstandingInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-886"
      decimals="2"
      id="f-2328"
      unitRef="eurPerShare">78.64</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement contextRef="c-886" decimals="-6" id="f-2329" unitRef="eur">145000000</sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-886"
      decimals="INF"
      id="f-2330"
      unitRef="shares">1624569</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-886"
      decimals="2"
      id="f-2331"
      unitRef="eurPerShare">78.89</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement contextRef="c-885" decimals="-6" id="f-2332" unitRef="eur">128000000</sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-887"
      decimals="INF"
      id="f-2333"
      unitRef="shares">504956</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c-887"
      decimals="2"
      id="f-2334"
      unitRef="eurPerShare">73.65</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsExercisedInShareBasedPaymentArrangement contextRef="c-887" decimals="-6" id="f-2335" unitRef="eur">37000000</sny:ValueOfShareOptionsExercisedInShareBasedPaymentArrangement>
    <sny:NumberOfShareOutstandingInShareBasedPaymentArrangement
      contextRef="c-888"
      decimals="INF"
      id="f-2336"
      unitRef="shares">1333013</sny:NumberOfShareOutstandingInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-888"
      decimals="2"
      id="f-2337"
      unitRef="eurPerShare">80.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement contextRef="c-888" decimals="-6" id="f-2338" unitRef="eur">107000000</sny:ValueOfShareOptionsOutstandingInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-888"
      decimals="INF"
      id="f-2339"
      unitRef="shares">1333013</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-888"
      decimals="2"
      id="f-2340"
      unitRef="eurPerShare">80.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement contextRef="c-887" decimals="-6" id="f-2341" unitRef="eur">107000000</sny:ValueOfShareOptionsExercisableInShareBasedPaymentArrangement>
    <sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock contextRef="c-1" id="f-2342">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below provides summary information about options outstanding and exercisable as of December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of exercise prices per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;residual&#160;life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;price per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;share &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;price per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;share &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;60.00 to &#x20ac;70.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;70.00 to &#x20ac;80.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;569,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;569,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;From &#x20ac;80.00 to &#x20ac;90.00 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333,013&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333,013&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-889"
      decimals="2"
      id="f-2343"
      unitRef="eurPerShare">60.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-890"
      decimals="2"
      id="f-2344"
      unitRef="eurPerShare">70.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-891"
      decimals="INF"
      id="f-2345"
      unitRef="shares">168784</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-892" id="f-2346">P4Y4M2D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-891"
      decimals="2"
      id="f-2347"
      unitRef="eurPerShare">65.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-891"
      decimals="INF"
      id="f-2348"
      unitRef="shares">168784</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-891"
      decimals="2"
      id="f-2349"
      unitRef="eurPerShare">65.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-893"
      decimals="2"
      id="f-2350"
      unitRef="eurPerShare">70.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-894"
      decimals="2"
      id="f-2351"
      unitRef="eurPerShare">80.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-895"
      decimals="INF"
      id="f-2352"
      unitRef="shares">569505</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-896" id="f-2353">P3Y1M13D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-895"
      decimals="2"
      id="f-2354"
      unitRef="eurPerShare">75.82</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-895"
      decimals="INF"
      id="f-2355"
      unitRef="shares">569505</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-895"
      decimals="2"
      id="f-2356"
      unitRef="eurPerShare">75.82</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-897"
      decimals="2"
      id="f-2357"
      unitRef="eurPerShare">80.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-898"
      decimals="2"
      id="f-2358"
      unitRef="eurPerShare">90.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-899"
      decimals="INF"
      id="f-2359"
      unitRef="shares">594724</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-900" id="f-2360">P2Y3M14D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-899"
      decimals="2"
      id="f-2361"
      unitRef="eurPerShare">89.20</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-899"
      decimals="INF"
      id="f-2362"
      unitRef="shares">594724</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-899"
      decimals="2"
      id="f-2363"
      unitRef="eurPerShare">89.20</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-901"
      decimals="INF"
      id="f-2364"
      unitRef="shares">1333013</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-901"
      decimals="INF"
      id="f-2365"
      unitRef="shares">1333013</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock contextRef="c-1" id="f-2366">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Average number of shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,251.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,251.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,252.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for stock options with dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adjustment for restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Average number of shares used to compute diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,256.4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,256.9&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,257.9&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfSharesUsedToComputeDilutedEarningsPerShareTableTextBlock>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="-5" id="f-2367" unitRef="shares">1251700000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-9" decimals="-5" id="f-2368" unitRef="shares">1251900000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c-10"
      decimals="-5"
      id="f-2369"
      unitRef="shares">1252500000</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c-1" decimals="-5" id="f-2370" unitRef="shares">200000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c-9" decimals="-5" id="f-2371" unitRef="shares">300000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="c-10"
      decimals="-5"
      id="f-2372"
      unitRef="shares">300000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares contextRef="c-1" decimals="-5" id="f-2373" unitRef="shares">4500000</sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares>
    <sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares contextRef="c-9" decimals="-5" id="f-2374" unitRef="shares">4700000</sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares>
    <sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares
      contextRef="c-10"
      decimals="-5"
      id="f-2375"
      unitRef="shares">5100000</sny:DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="-5" id="f-2376" unitRef="shares">1256400000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-9" decimals="-5" id="f-2377" unitRef="shares">1256900000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c-10"
      decimals="-5"
      id="f-2378"
      unitRef="shares">1257900000</ifrs-full:AdjustedWeightedAverageShares>
    <sny:StockOptionsWithNoDilutiveEffect contextRef="c-8" decimals="-5" id="f-2379" unitRef="shares">600000</sny:StockOptionsWithNoDilutiveEffect>
    <ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory contextRef="c-1" id="f-2380">Non-controlling interestsNon-controlling interests did not represent a material component of Sanofi&#x2019;s consolidated financial statements in the years ended December 31, 2023, 2022 and 2021</ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory>
    <sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock contextRef="c-1" id="f-2381">Debt, cash and cash equivalents and lease liabilities&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.17.1. Debt, cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in Sanofi's financial position during the period were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,531&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,218&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,250&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,793&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,437&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,983&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities, which amounted to &#x20ac;2,030 million as of December 31, 2023, &#x20ac;2,181&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; million as of December 31, 2022, and&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x20ac;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,108&#160;million as of December 31, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(see the maturity analysis at Note&#160;D.17.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Net debt&#x201d; is a non-IFRS financial measure used by management and investors to measure Sanofi&#x2019;s overall net indebtedness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Reconciliation of carrying amount to value on redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.167%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.193%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Adjustment&lt;br/&gt;to debt&lt;br/&gt;measured&#160;at&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion&lt;br/&gt;of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,531&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,273&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,314&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,793&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,492&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a) Principal financing transactions during the year&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the movement in total debt during the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cash&#160;flows&#160;from&lt;br/&gt;financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-cash items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;New&lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;flows &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;differences&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;from non-current to current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;items&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(604)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,218&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;895&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;76&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,531&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These amounts mainly comprise &#x20ac;946&#160;million related to the US commercial paper program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;These amounts mainly comprise changes in accrued interest balances, and fair value adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi did not carry out any bond issues in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Three bond issues were redeemed in 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:10.31pt"&gt;&#x20ac;1,750&#160;million issued in March&#160;2018, redeemed at maturity on March&#160;21, 2023;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:8.44pt"&gt;$1,000&#160;million issued in June&#160;2018, redeemed at maturity on June&#160;20, 2023; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.57pt"&gt;&#x20ac;1,000&#160;million issued in November&#160;2013, redeemed at maturity on November&#160;14, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi entered into the following transactions relating to its syndicated credit facilities during 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a new &#x20ac;4&#160;billion revolving credit facility, linked to sustainable development indicators, was put in place on March&#160;8, 2023. This syndicated facility was initially due to mature in March&#160;2028, and included two extension options of one year each; it replaced an existing &#x20ac;4&#160;billion facility that was canceled on the same day; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the maturity of this credit facility was extended to March&#160;7, 2029, following the exercise of an extension option in December&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Consequently, as of December&#160;31, 2023, Sanofi had two&#160;syndicated credit facilities to provide liquidity for the purposes of current operations, each of them linked to environmental and social indicators:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a &#x20ac;4&#160;billion facility maturing December&#160;6, 2027, with no further extension option available; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a &#x20ac;4&#160;billion facility maturing March&#160;7, 2029, with a one-year extension option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In line with Sanofi&#x2019;s commitment to embed sustainable development in the &#x201c;Play to Win&#x201d; strategy, those two&#160;revolving credit facilities build in an adjustment mechanism that links the credit spread to the attainment of two&#160;sustainable development performance indicators:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;for the facility maturing in December&#160;2027: (i)&#160;Sanofi&#x2019;s contribution to polio eradication, and (ii) the reduction in Sanofi&#x2019;s carbon footprint; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;for the facility maturing in March&#160;2029: (i)&#160;Sanofi&#x2019;s contribution to improving access to essential medicines in low-income and intermediate-income countries via its Sanofi Global Health non-profit unit, and (ii)&#160;the reduction in Sanofi&#x2019;s carbon footprint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the movement in total debt during prior periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cash&#160;flows&#160;from&lt;br/&gt;financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-cash items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;New&lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;cash&lt;br/&gt;flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;differences&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;from non-current to current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;items&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,250&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,549&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;442&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,218&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the&#160;Euro zone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;These amounts include movements in accrued interest and fair value remeasurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cash&#160;flows&#160;from&lt;br/&gt;financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-cash items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;New&lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;cash&lt;br/&gt;flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;differences &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;from non-current to current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;items&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(615)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,631&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;381&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;291&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,250&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;These amounts include (i) effects of changes in the scope of consolidation, amounting to &#x20ac;299&#160;million; (ii) movements in accrued interest; and (iii) fair value remeasurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b) Net debt by type, at value on redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;current &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,546&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,027&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,143&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,130&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,273&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,176&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,138&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,314&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,546&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,143&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,492&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,176&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities (see the maturity schedule in Note&#160;D.17.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Bond issues carried out by Sanofi under the Euro Medium Term Note (EMTN) program are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.889%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Issuer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;ISIN code&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Issue date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Annual&#160;interest&#160;rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013143997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.625%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013505104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.000%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0014009KS6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.875%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0012969038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;September 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.500%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013324340&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.000%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0012146801&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;September 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;September 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.750%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013201639&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.500%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013144003&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.125%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013409844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.875%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0014009KQ0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.250%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013324357&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.375%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013505112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.500%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013409851&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.250%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013324373&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.875%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Bond issues carried out by Sanofi under the public bond issue program (shelf registration statement) registered with the&#160;US&#160;Securities and Exchange Commission (SEC) comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.889%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Issuer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;ISIN code&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Issue&#160;date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Annual&#160;&lt;br/&gt;interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($&#160;million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;US801060AD60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The &#x201c;Other borrowings&#x201d; line mainly comprises participating shares issued between 1983 and 1987, of which 58,115&#160;remain outstanding, with a nominal amount of &#x20ac;9 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In order to manage its liquidity needs for current operations, as of December&#160;31, 2023 Sanofi had:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a syndicated credit facility of &#x20ac;4&#160;billion, drawable in euros and in US dollars, maturing December&#160;6,&#160;2027; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a syndicated credit facility of &#x20ac;4&#160;billion, drawable in euros and in US dollars, maturing March&#160;7, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi also has two commercial paper programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a &#x20ac;6&#160;billion Negotiable European Commercial Paper program in France, with an average drawdown of &#x20ac;0.2&#160;billion and a maximum drawdown of &#x20ac;0.8&#160;billion during 2023, and an amount of &#x20ac;40&#160;million drawn down as of December&#160;31, 2023; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a $10&#160;billion Commercial Paper program in the United States, with an average drawdown of $3.7&#160;billion and a maximum drawdown of $7.3&#160;billion during 2023, and an amount of $1.0&#160;billion drawn down as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The financing in place as of December 31, 2023 at the level of the holding company (which manages most of Sanofi&#x2019;s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking spreads or fees to the credit rating.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;c) Debt by maturity, at value on redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used &lt;br/&gt;to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,027&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used &lt;br/&gt;to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities, which amounted to &#x20ac;2,030&#160;million as of December&#160;31, 2023; &#x20ac;2,181&#160;million as of&#160;December&#160;31, 2022; and&#160;&#x20ac;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,108&#160;million as of December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; (see the maturity analysis at Note&#160;D.17.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, the main undrawn confirmed general-purpose credit facilities at holding company level amounted to&#160;&#x20ac;8 billion, half of which expired in 2027 and the other half of which expires in 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, no single counterparty represented more than 6% of Sanofi&#x2019;s undrawn confirmed credit facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,273&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,130&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;661&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,600&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,160&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,722&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,492&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;661&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,600&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,160&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,722&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,314&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,138&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,647&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;602&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,751&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,160&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,016&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,647&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;602&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,751&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,160&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,016&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;d) Debt by interest rate, at value on redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below splits net debt between fixed and floating rate, and by maturity, as of December 31, 2023. The figures shown are values on redemption, before the effects of derivative instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,080&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;14,228&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,852&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% fixed-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Floating-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% floating-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,591&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,045&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4,115)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4,251)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% floating-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,881&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi issues debt in two currencies, the euro and the US dollar, and also invests its cash and cash equivalents in those currencies. Sanofi also operates cash pooling arrangements to manage the surplus cash and short-term liquidity needs of foreign subsidiaries located outside the euro zone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;To optimize the cost of debt or reduce the volatility of debt and manage its exposure to financial foreign exchange risk, Sanofi uses derivative instruments (interest rate swaps, currency swaps, foreign exchange swaps and forward contracts) that alter the fixed/floating rate split and the currency split of its net debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;11,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% fixed-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Floating-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,191&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% floating-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,027&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,738)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4,642)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2,132)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1,143)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% floating-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the fixed/floating rate split of net debt at value on redemption after taking account of derivative instruments as of&#160;December 31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Floating-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,273&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,314&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,492&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The weighted average interest rate on debt as of December 31, 2023 was 1.6% before derivative instruments and 2.1% after derivative instruments. Cash and cash equivalents were invested as of December 31, 2023 at an average rate of 3.9% before derivative instruments and 3.7% after derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The projected full-year sensitivity of net debt to interest rate fluctuations for 2024 is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Change in short-term interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Impact&#160;on&#160;pre-tax&#160;net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;income&#160;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Impact&#160;on&#160;pre-tax&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;income/(expense)&#160;recognized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;directly in equity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+100&#160;bp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+25&#160;bp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;-25&#160;bp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;-100&#160;bp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;e) Debt by currency, at value on redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows net debt by currency at December 31, 2023, before and after derivative instruments contracted to convert the foreign-currency net debt of exposed entities into their functional currency:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Before&#160;derivative&#160;instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;After&#160;derivative&#160;instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pound sterling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,881&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows net debt by currency at December 31, 2022 and 2021, after derivative instruments contracted to convert the foreign currency net debt of exposed entities into their functional currency:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(669)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,492&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;f) Market value of net debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The market value of Sanofi&#x2019;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The fair value of debt is determined by reference to quoted market prices at the balance sheet date in the case of quoted instruments (level&#160;1 in the IFRS&#160;7 hierarchy, see Note&#160;D.12.), and by reference to the fair value of interest rate and currency derivatives used to manage net debt (level&#160;2 in the IFRS&#160;7 hierarchy, see Note&#160;D.12.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;g) Future contractual cash flows relating to debt and related derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.019%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,710&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,153&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,912&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,187&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,285&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,719&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,454&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net cash flows related to derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,853&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,200&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,944&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,210&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,309&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,735&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,455&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Future contractual cash flows are shown on the basis of the carrying amount in the balance sheet at the reporting date, without reference to any subsequent management decision that might materially alter the structure of Sanofi&#x2019;s debt or its hedging policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The tables below show the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt as of December 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.019%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,408&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,206&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,803&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,184&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,283&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,064&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net cash flows related to derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,617&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,230&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;928&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,841&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,215&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,314&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,089&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.019%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,728&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,330&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,826&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;791&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,937&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,176&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,668&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net cash flows related to derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,677&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,271&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,825&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;793&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,939&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,178&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,671&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.17.2. Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A maturity analysis of lease liabilities as of December 31, 2023, 2022 and 2021 is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Undiscounted future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less than 1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;From 1 to 3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;From 3 to 5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More than 5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Discounting effect&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Total lease liabilities as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;291&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;448&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;360&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;989&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Total lease liabilities as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,181&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;320&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;515&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;436&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,129&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Total lease liabilities as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;314&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;362&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,184&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Lease liabilities include leases relating to real estate assets located at Cambridge, MA (United States), as described in Note&#160;D.3., which have a lease term of 15 years.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfDebtInstrumentsIssuedExplanatoryTextBlock>
    <sny:DisclosureOfChangesInFinancialPositionTableTextBlock contextRef="c-1" id="f-2382">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Changes in Sanofi's financial position during the period were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,531&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,218&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,250&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,793&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,437&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,983&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities, which amounted to &#x20ac;2,030 million as of December 31, 2023, &#x20ac;2,181&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; million as of December 31, 2022, and&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x20ac;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,108&#160;million as of December 31, 2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(see the maturity analysis at Note&#160;D.17.2.).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfChangesInFinancialPositionTableTextBlock>
    <ifrs-full:LongtermBorrowings contextRef="c-5" decimals="-6" id="f-2383" unitRef="eur">14347000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-7" decimals="-6" id="f-2384" unitRef="eur">14857000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-8" decimals="-6" id="f-2385" unitRef="eur">17123000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-5" decimals="-6" id="f-2386" unitRef="eur">2045000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-7" decimals="-6" id="f-2387" unitRef="eur">4174000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-8" decimals="-6" id="f-2388" unitRef="eur">3183000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-5" decimals="-6" id="f-2389" unitRef="eur">-139000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-7" decimals="-6" id="f-2390" unitRef="eur">-187000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-8" decimals="-6" id="f-2391" unitRef="eur">56000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-5" decimals="-6" id="f-2392" unitRef="eur">16531000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-7" decimals="-6" id="f-2393" unitRef="eur">19218000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-8" decimals="-6" id="f-2394" unitRef="eur">20250000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-6" id="f-2395" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-7" decimals="-6" id="f-2396" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-8" decimals="-6" id="f-2397" unitRef="eur">10098000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-5" decimals="-6" id="f-2398" unitRef="eur">28000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-7" decimals="-6" id="f-2399" unitRef="eur">45000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-8" decimals="-6" id="f-2400" unitRef="eur">169000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-5" decimals="-6" id="f-2401" unitRef="eur">7793000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-7" decimals="-6" id="f-2402" unitRef="eur">6437000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-8" decimals="-6" id="f-2403" unitRef="eur">9983000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:LeaseLiabilities contextRef="c-5" decimals="-6" id="f-2404" unitRef="eur">2030000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-7" decimals="-6" id="f-2405" unitRef="eur">2181000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-8" decimals="-6" id="f-2406" unitRef="eur">2108000000</ifrs-full:LeaseLiabilities>
    <sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock contextRef="c-1" id="f-2407">&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;Reconciliation of carrying amount to value on redemption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.167%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.193%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying amount at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Adjustment&lt;br/&gt;to debt&lt;br/&gt;measured&#160;at&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion&lt;br/&gt;of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,531&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,273&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,314&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,793&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,492&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfReconciliationOfCarryingAmountToValueOnRedemptionTableTextBlock>
    <ifrs-full:LongtermBorrowings contextRef="c-5" decimals="-6" id="f-2408" unitRef="eur">14347000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-902" decimals="-6" id="f-2409" unitRef="eur">42000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-903" decimals="-6" id="f-2410" unitRef="eur">157000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-904" decimals="-6" id="f-2411" unitRef="eur">14546000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-905" decimals="-6" id="f-2412" unitRef="eur">15143000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-906" decimals="-6" id="f-2413" unitRef="eur">17176000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-5" decimals="-6" id="f-2414" unitRef="eur">2045000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-902" decimals="-6" id="f-2415" unitRef="eur">0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-903" decimals="-6" id="f-2416" unitRef="eur">0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-904" decimals="-6" id="f-2417" unitRef="eur">2045000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-905" decimals="-6" id="f-2418" unitRef="eur">4178000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="c-906" decimals="-6" id="f-2419" unitRef="eur">3183000000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-5" decimals="-6" id="f-2420" unitRef="eur">-139000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-902" decimals="-6" id="f-2421" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-903" decimals="-6" id="f-2422" unitRef="eur">157000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-904" decimals="-6" id="f-2423" unitRef="eur">18000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-905" decimals="-6" id="f-2424" unitRef="eur">48000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-906" decimals="-6" id="f-2425" unitRef="eur">45000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-5" decimals="-6" id="f-2426" unitRef="eur">16531000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-902" decimals="-6" id="f-2427" unitRef="eur">42000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-903" decimals="-6" id="f-2428" unitRef="eur">0</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-904" decimals="-6" id="f-2429" unitRef="eur">16573000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-905" decimals="-6" id="f-2430" unitRef="eur">19273000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-906" decimals="-6" id="f-2431" unitRef="eur">20314000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-6" id="f-2432" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-902" decimals="-6" id="f-2433" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-903" decimals="-6" id="f-2434" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-904" decimals="-6" id="f-2435" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-905" decimals="-6" id="f-2436" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-906" decimals="-6" id="f-2437" unitRef="eur">10098000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-5" decimals="-6" id="f-2438" unitRef="eur">28000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-902" decimals="-6" id="f-2439" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-903" decimals="-6" id="f-2440" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-904" decimals="-6" id="f-2441" unitRef="eur">28000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-905" decimals="-6" id="f-2442" unitRef="eur">45000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-906" decimals="-6" id="f-2443" unitRef="eur">169000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-5" decimals="-6" id="f-2444" unitRef="eur">7793000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-902" decimals="-6" id="f-2445" unitRef="eur">42000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-903" decimals="-6" id="f-2446" unitRef="eur">0</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-904" decimals="-6" id="f-2447" unitRef="eur">7835000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-905" decimals="-6" id="f-2448" unitRef="eur">6492000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-906" decimals="-6" id="f-2449" unitRef="eur">10047000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory contextRef="c-1" id="f-2450">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the movement in total debt during the period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cash&#160;flows&#160;from&lt;br/&gt;financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-cash items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;New&lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;flows &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;differences&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;from non-current to current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;items&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(604)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,218&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;895&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;76&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,531&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These amounts mainly comprise &#x20ac;946&#160;million related to the US commercial paper program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;These amounts mainly comprise changes in accrued interest balances, and fair value adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the movement in total debt during prior periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cash&#160;flows&#160;from&lt;br/&gt;financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-cash items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;New&lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;cash&lt;br/&gt;flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;differences&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;from non-current to current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;items&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,250&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,549&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;442&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,218&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the&#160;Euro zone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;These amounts include movements in accrued interest and fair value remeasurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cash&#160;flows&#160;from&lt;br/&gt;financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-cash items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;New&lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;cash&lt;br/&gt;flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;differences &lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;from non-current to current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;items&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term debt and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(615)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(197)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22,631&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;381&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;291&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,250&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;These amounts include (i) effects of changes in the scope of consolidation, amounting to &#x20ac;299&#160;million; (ii) movements in accrued interest; and (iii) fair value remeasurements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:Borrowings contextRef="c-907" decimals="-6" id="f-2451" unitRef="eur">14857000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-908" decimals="-6" id="f-2452" unitRef="eur">12000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-908" decimals="-6" id="f-2453" unitRef="eur">48000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-908" decimals="-6" id="f-2454" unitRef="eur">0</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-908" decimals="-6" id="f-2455" unitRef="eur">-30000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-909" decimals="-6" id="f-2456" unitRef="eur">-604000000</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-908" decimals="-6" id="f-2457" unitRef="eur">88000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-909" decimals="-6" id="f-2458" unitRef="eur">14347000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-910" decimals="-6" id="f-2459" unitRef="eur">4174000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-911" decimals="-6" id="f-2460" unitRef="eur">3672000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-911" decimals="-6" id="f-2461" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-911" decimals="-6" id="f-2462" unitRef="eur">903000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-911" decimals="-6" id="f-2463" unitRef="eur">-21000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-912" decimals="-6" id="f-2464" unitRef="eur">604000000</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-911" decimals="-6" id="f-2465" unitRef="eur">57000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-912" decimals="-6" id="f-2466" unitRef="eur">2045000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-913" decimals="-6" id="f-2467" unitRef="eur">187000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-914" decimals="-6" id="f-2468" unitRef="eur">0</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-914" decimals="-6" id="f-2469" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-914" decimals="-6" id="f-2470" unitRef="eur">-8000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-914" decimals="-6" id="f-2471" unitRef="eur">29000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-915" decimals="-6" id="f-2472" unitRef="eur">0</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-914" decimals="-6" id="f-2473" unitRef="eur">-69000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-915" decimals="-6" id="f-2474" unitRef="eur">139000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-7" decimals="-6" id="f-2475" unitRef="eur">19218000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-2476" unitRef="eur">3684000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-2477" unitRef="eur">48000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-1" decimals="-6" id="f-2478" unitRef="eur">895000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-1" decimals="-6" id="f-2479" unitRef="eur">-22000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-5" decimals="-6" id="f-2480" unitRef="eur">0</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-1" decimals="-6" id="f-2481" unitRef="eur">76000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-5" decimals="-6" id="f-2482" unitRef="eur">16531000000</ifrs-full:Borrowings>
    <sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments contextRef="c-70" decimals="-6" id="f-2483" unitRef="eur">946000000</sny:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments>
    <sny:NumberOfBondIssuesRedeemed contextRef="c-1" decimals="INF" id="f-2484" unitRef="bond">3</sny:NumberOfBondIssuesRedeemed>
    <ifrs-full:NotionalAmount contextRef="c-916" decimals="-6" id="f-2485" unitRef="eur">1750000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-917" decimals="-6" id="f-2486" unitRef="usd">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-918" decimals="-6" id="f-2487" unitRef="eur">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-919" decimals="-9" id="f-2488" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <sny:CreditFacilitiesExtensionOptionNumber
      contextRef="c-919"
      decimals="INF"
      id="f-2489"
      unitRef="extension">2</sny:CreditFacilitiesExtensionOptionNumber>
    <sny:CreditFacilitiesExtensionOptionPeriod contextRef="c-920" id="f-2490">P1Y</sny:CreditFacilitiesExtensionOptionPeriod>
    <ifrs-full:NotionalAmount contextRef="c-921" decimals="-9" id="f-2491" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <sny:NumberOfCreditFacilities
      contextRef="c-5"
      decimals="INF"
      id="f-2492"
      unitRef="credit_facility">2</sny:NumberOfCreditFacilities>
    <ifrs-full:NotionalAmount contextRef="c-922" decimals="-9" id="f-2493" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-923" decimals="-9" id="f-2494" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <sny:CreditFacilitiesExtensionOptionPeriod contextRef="c-924" id="f-2495">P1Y</sny:CreditFacilitiesExtensionOptionPeriod>
    <sny:NumberOfCreditFacilities
      contextRef="c-5"
      decimals="INF"
      id="f-2496"
      unitRef="credit_facility">2</sny:NumberOfCreditFacilities>
    <sny:NumberOfSustainableDevelopmentPerformanceIndicators
      contextRef="c-5"
      decimals="INF"
      id="f-2497"
      unitRef="performance_indicator">2</sny:NumberOfSustainableDevelopmentPerformanceIndicators>
    <ifrs-full:Borrowings contextRef="c-925" decimals="-6" id="f-2498" unitRef="eur">17123000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-926" decimals="-6" id="f-2499" unitRef="eur">11000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-926" decimals="-6" id="f-2500" unitRef="eur">1549000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-926" decimals="-6" id="f-2501" unitRef="eur">0</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-926" decimals="-6" id="f-2502" unitRef="eur">56000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-907" decimals="-6" id="f-2503" unitRef="eur">-3632000000</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-926" decimals="-6" id="f-2504" unitRef="eur">-228000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-907" decimals="-6" id="f-2505" unitRef="eur">14857000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-927" decimals="-6" id="f-2506" unitRef="eur">3183000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-928" decimals="-6" id="f-2507" unitRef="eur">2707000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-928" decimals="-6" id="f-2508" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-928" decimals="-6" id="f-2509" unitRef="eur">43000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-928" decimals="-6" id="f-2510" unitRef="eur">20000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-910" decimals="-6" id="f-2511" unitRef="eur">3632000000</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-928" decimals="-6" id="f-2512" unitRef="eur">3000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-910" decimals="-6" id="f-2513" unitRef="eur">4174000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-929" decimals="-6" id="f-2514" unitRef="eur">-56000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-930" decimals="-6" id="f-2515" unitRef="eur">0</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-930" decimals="-6" id="f-2516" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-930" decimals="-6" id="f-2517" unitRef="eur">-373000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-930" decimals="-6" id="f-2518" unitRef="eur">366000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-913" decimals="-6" id="f-2519" unitRef="eur">7000000</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-930" decimals="-6" id="f-2520" unitRef="eur">243000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-913" decimals="-6" id="f-2521" unitRef="eur">187000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-8" decimals="-6" id="f-2522" unitRef="eur">20250000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-9" decimals="-6" id="f-2523" unitRef="eur">2718000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-9" decimals="-6" id="f-2524" unitRef="eur">1549000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-9" decimals="-6" id="f-2525" unitRef="eur">-330000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-9" decimals="-6" id="f-2526" unitRef="eur">442000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-7" decimals="-6" id="f-2527" unitRef="eur">7000000</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-9" decimals="-6" id="f-2528" unitRef="eur">18000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-7" decimals="-6" id="f-2529" unitRef="eur">19218000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-931" decimals="-6" id="f-2530" unitRef="eur">19745000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-932" decimals="-6" id="f-2531" unitRef="eur">38000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-932" decimals="-6" id="f-2532" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-932" decimals="-6" id="f-2533" unitRef="eur">0</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-932" decimals="-6" id="f-2534" unitRef="eur">124000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-925" decimals="-6" id="f-2535" unitRef="eur">-2704000000</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-932" decimals="-6" id="f-2536" unitRef="eur">-4000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-925" decimals="-6" id="f-2537" unitRef="eur">17123000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-933" decimals="-6" id="f-2538" unitRef="eur">2767000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-934" decimals="-6" id="f-2539" unitRef="eur">2203000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-934" decimals="-6" id="f-2540" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-934" decimals="-6" id="f-2541" unitRef="eur">-615000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-934" decimals="-6" id="f-2542" unitRef="eur">248000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-927" decimals="-6" id="f-2543" unitRef="eur">2704000000</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-934" decimals="-6" id="f-2544" unitRef="eur">282000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-927" decimals="-6" id="f-2545" unitRef="eur">3183000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-935" decimals="-6" id="f-2546" unitRef="eur">119000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-936" decimals="-6" id="f-2547" unitRef="eur">0</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-936" decimals="-6" id="f-2548" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-936" decimals="-6" id="f-2549" unitRef="eur">-197000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-936" decimals="-6" id="f-2550" unitRef="eur">9000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-929" decimals="-6" id="f-2551" unitRef="eur">0</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-936" decimals="-6" id="f-2552" unitRef="eur">13000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-929" decimals="-6" id="f-2553" unitRef="eur">-56000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-19" decimals="-6" id="f-2554" unitRef="eur">22631000000</ifrs-full:Borrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-10" decimals="-6" id="f-2555" unitRef="eur">2241000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-10" decimals="-6" id="f-2556" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="c-10" decimals="-6" id="f-2557" unitRef="eur">-812000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <sny:ForeignCurrencyTranslationDifferences contextRef="c-10" decimals="-6" id="f-2558" unitRef="eur">381000000</sny:ForeignCurrencyTranslationDifferences>
    <sny:ReclassificationFromNonCurrentToCurrent contextRef="c-8" decimals="-6" id="f-2559" unitRef="eur">0</sny:ReclassificationFromNonCurrentToCurrent>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-10" decimals="-6" id="f-2560" unitRef="eur">291000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:Borrowings contextRef="c-8" decimals="-6" id="f-2561" unitRef="eur">20250000000</ifrs-full:Borrowings>
    <sny:IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings contextRef="c-10" decimals="-6" id="f-2562" unitRef="eur">299000000</sny:IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings>
    <sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock contextRef="c-1" id="f-2563">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;current &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-&lt;br/&gt;current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,546&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,027&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,143&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,130&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,273&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,176&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,138&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,314&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,546&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,143&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,492&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,176&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities (see the maturity schedule in Note&#160;D.17.2.).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfDebtNetOfCashAndCashEquivalentsByTypeAtValueOnRedemptionExplanatoryTableTextBlock>
    <ifrs-full:BondsIssued contextRef="c-937" decimals="-6" id="f-2564" unitRef="eur">14416000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-938" decimals="-6" id="f-2565" unitRef="eur">718000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-904" decimals="-6" id="f-2566" unitRef="eur">15134000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-939" decimals="-6" id="f-2567" unitRef="eur">15044000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-940" decimals="-6" id="f-2568" unitRef="eur">3817000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-905" decimals="-6" id="f-2569" unitRef="eur">18861000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-941" decimals="-6" id="f-2570" unitRef="eur">17118000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-942" decimals="-6" id="f-2571" unitRef="eur">2828000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-906" decimals="-6" id="f-2572" unitRef="eur">19946000000</ifrs-full:BondsIssued>
    <sny:OtherBankBorrowings contextRef="c-937" decimals="-6" id="f-2573" unitRef="eur">130000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-938" decimals="-6" id="f-2574" unitRef="eur">1118000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-904" decimals="-6" id="f-2575" unitRef="eur">1248000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-939" decimals="-6" id="f-2576" unitRef="eur">99000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-940" decimals="-6" id="f-2577" unitRef="eur">187000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-905" decimals="-6" id="f-2578" unitRef="eur">286000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-941" decimals="-6" id="f-2579" unitRef="eur">21000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-942" decimals="-6" id="f-2580" unitRef="eur">163000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-906" decimals="-6" id="f-2581" unitRef="eur">184000000</sny:OtherBankBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-937" decimals="-6" id="f-2582" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-938" decimals="-6" id="f-2583" unitRef="eur">6000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-904" decimals="-6" id="f-2584" unitRef="eur">6000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-939" decimals="-6" id="f-2585" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-940" decimals="-6" id="f-2586" unitRef="eur">6000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-905" decimals="-6" id="f-2587" unitRef="eur">6000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-941" decimals="-6" id="f-2588" unitRef="eur">37000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-942" decimals="-6" id="f-2589" unitRef="eur">3000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-906" decimals="-6" id="f-2590" unitRef="eur">40000000</ifrs-full:OtherBorrowings>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-937" decimals="-6" id="f-2591" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-938" decimals="-6" id="f-2592" unitRef="eur">203000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-904" decimals="-6" id="f-2593" unitRef="eur">203000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-939" decimals="-6" id="f-2594" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-940" decimals="-6" id="f-2595" unitRef="eur">168000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-905" decimals="-6" id="f-2596" unitRef="eur">168000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-941" decimals="-6" id="f-2597" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-942" decimals="-6" id="f-2598" unitRef="eur">189000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-906" decimals="-6" id="f-2599" unitRef="eur">189000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-937" decimals="-6" id="f-2600" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-938" decimals="-6" id="f-2601" unitRef="eur">18000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-904" decimals="-6" id="f-2602" unitRef="eur">18000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-939" decimals="-6" id="f-2603" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-940" decimals="-6" id="f-2604" unitRef="eur">48000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-905" decimals="-6" id="f-2605" unitRef="eur">48000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-941" decimals="-6" id="f-2606" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-942" decimals="-6" id="f-2607" unitRef="eur">45000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-906" decimals="-6" id="f-2608" unitRef="eur">45000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-937" decimals="-6" id="f-2609" unitRef="eur">14546000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-938" decimals="-6" id="f-2610" unitRef="eur">2027000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-904" decimals="-6" id="f-2611" unitRef="eur">16573000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-939" decimals="-6" id="f-2612" unitRef="eur">15143000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-940" decimals="-6" id="f-2613" unitRef="eur">4130000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-905" decimals="-6" id="f-2614" unitRef="eur">19273000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-941" decimals="-6" id="f-2615" unitRef="eur">17176000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-942" decimals="-6" id="f-2616" unitRef="eur">3138000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-906" decimals="-6" id="f-2617" unitRef="eur">20314000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-943" decimals="-6" id="f-2618" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-944" decimals="-6" id="f-2619" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-904" decimals="-6" id="f-2620" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-945" decimals="-6" id="f-2621" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-946" decimals="-6" id="f-2622" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-905" decimals="-6" id="f-2623" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-947" decimals="-6" id="f-2624" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-948" decimals="-6" id="f-2625" unitRef="eur">10098000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-906" decimals="-6" id="f-2626" unitRef="eur">10098000000</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-943" decimals="-6" id="f-2627" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-944" decimals="-6" id="f-2628" unitRef="eur">28000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-904" decimals="-6" id="f-2629" unitRef="eur">28000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-945" decimals="-6" id="f-2630" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-946" decimals="-6" id="f-2631" unitRef="eur">45000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-905" decimals="-6" id="f-2632" unitRef="eur">45000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-947" decimals="-6" id="f-2633" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-948" decimals="-6" id="f-2634" unitRef="eur">169000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-906" decimals="-6" id="f-2635" unitRef="eur">169000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-943" decimals="-6" id="f-2636" unitRef="eur">14546000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-944" decimals="-6" id="f-2637" unitRef="eur">-6711000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-904" decimals="-6" id="f-2638" unitRef="eur">7835000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-945" decimals="-6" id="f-2639" unitRef="eur">15143000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-946" decimals="-6" id="f-2640" unitRef="eur">-8651000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-905" decimals="-6" id="f-2641" unitRef="eur">6492000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-947" decimals="-6" id="f-2642" unitRef="eur">17176000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-948" decimals="-6" id="f-2643" unitRef="eur">-7129000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-906" decimals="-6" id="f-2644" unitRef="eur">10047000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock contextRef="c-1" id="f-2645">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Bond issues carried out by Sanofi under the Euro Medium Term Note (EMTN) program are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.889%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Issuer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;ISIN code&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Issue date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Annual&#160;interest&#160;rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013143997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.625%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013505104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.000%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0014009KS6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.875%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0012969038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;September 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.500%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013324340&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.000%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0012146801&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;September 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;September 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.750%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013201639&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.500%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013144003&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.125%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013409844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.875%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0014009KQ0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.250%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013324357&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.375%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013505112&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;April 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.500%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013409851&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.250%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;FR0013324373&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.875%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Bond issues carried out by Sanofi under the public bond issue program (shelf registration statement) registered with the&#160;US&#160;Securities and Exchange Commission (SEC) comprise:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.213%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.889%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Issuer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;ISIN code&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Issue&#160;date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Annual&#160;&lt;br/&gt;interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($&#160;million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;US801060AD60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDetailOfBondsIssuedExplanatoryTableTextBlock>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-949"
      decimals="INF"
      id="f-2646"
      unitRef="number">0.00625</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-949" decimals="-6" id="f-2647" unitRef="eur">600000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-950"
      decimals="INF"
      id="f-2648"
      unitRef="number">0.01000</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-950" decimals="-6" id="f-2649" unitRef="eur">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-951"
      decimals="INF"
      id="f-2650"
      unitRef="number">0.00875</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-951" decimals="-6" id="f-2651" unitRef="eur">850000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-952"
      decimals="INF"
      id="f-2652"
      unitRef="number">0.01500</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-952" decimals="-6" id="f-2653" unitRef="eur">750000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-953"
      decimals="INF"
      id="f-2654"
      unitRef="number">0.01000</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-953" decimals="-6" id="f-2655" unitRef="eur">1500000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-954"
      decimals="INF"
      id="f-2656"
      unitRef="number">0.01750</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-954" decimals="-6" id="f-2657" unitRef="eur">1510000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-955"
      decimals="INF"
      id="f-2658"
      unitRef="number">0.00500</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-955" decimals="-6" id="f-2659" unitRef="eur">1150000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-956"
      decimals="INF"
      id="f-2660"
      unitRef="number">0.01125</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-956" decimals="-6" id="f-2661" unitRef="eur">700000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-957"
      decimals="INF"
      id="f-2662"
      unitRef="number">0.00875</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-957" decimals="-6" id="f-2663" unitRef="eur">650000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-958"
      decimals="INF"
      id="f-2664"
      unitRef="number">0.01250</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-958" decimals="-6" id="f-2665" unitRef="eur">650000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-959"
      decimals="INF"
      id="f-2666"
      unitRef="number">0.01375</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-959" decimals="-6" id="f-2667" unitRef="eur">2000000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-960"
      decimals="INF"
      id="f-2668"
      unitRef="number">0.01500</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-960" decimals="-6" id="f-2669" unitRef="eur">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-961"
      decimals="INF"
      id="f-2670"
      unitRef="number">0.01250</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-961" decimals="-6" id="f-2671" unitRef="eur">500000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-962"
      decimals="INF"
      id="f-2672"
      unitRef="number">0.01875</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-962" decimals="-6" id="f-2673" unitRef="eur">1250000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-963"
      decimals="INF"
      id="f-2674"
      unitRef="number">0.03625</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NotionalAmount contextRef="c-963" decimals="-6" id="f-2675" unitRef="usd">1000000000</ifrs-full:NotionalAmount>
    <sny:ParticipatingSharesNumberOutstanding
      contextRef="c-964"
      decimals="INF"
      id="f-2676"
      unitRef="shares">58115</sny:ParticipatingSharesNumberOutstanding>
    <sny:ParticipatingSharesCarryingAmount contextRef="c-964" decimals="-6" id="f-2677" unitRef="eur">9000000</sny:ParticipatingSharesCarryingAmount>
    <ifrs-full:NotionalAmount contextRef="c-965" decimals="-9" id="f-2678" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-966" decimals="-9" id="f-2679" unitRef="eur">4000000000</ifrs-full:NotionalAmount>
    <sny:NumberOfCommercialPaperPrograms
      contextRef="c-5"
      decimals="INF"
      id="f-2680"
      unitRef="program">2</sny:NumberOfCommercialPaperPrograms>
    <ifrs-full:CommercialPapersIssued contextRef="c-967" decimals="-9" id="f-2681" unitRef="eur">6000000000</ifrs-full:CommercialPapersIssued>
    <sny:BorrowingAverageDrawdown contextRef="c-968" decimals="-8" id="f-2682" unitRef="eur">200000000</sny:BorrowingAverageDrawdown>
    <sny:BorrowingMaximumDrawdown contextRef="c-968" decimals="-8" id="f-2683" unitRef="eur">800000000</sny:BorrowingMaximumDrawdown>
    <sny:BorrowingDrawdown contextRef="c-967" decimals="-6" id="f-2684" unitRef="eur">40000000</sny:BorrowingDrawdown>
    <ifrs-full:CommercialPapersIssued contextRef="c-969" decimals="-9" id="f-2685" unitRef="usd">10000000000</ifrs-full:CommercialPapersIssued>
    <sny:BorrowingAverageDrawdown contextRef="c-970" decimals="-7" id="f-2686" unitRef="usd">3700000000</sny:BorrowingAverageDrawdown>
    <sny:BorrowingMaximumDrawdown contextRef="c-970" decimals="-8" id="f-2687" unitRef="usd">7300000000</sny:BorrowingMaximumDrawdown>
    <sny:BorrowingDrawdown contextRef="c-969" decimals="-8" id="f-2688" unitRef="usd">1000000000</sny:BorrowingDrawdown>
    <sny:DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock contextRef="c-1" id="f-2689">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used &lt;br/&gt;to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,027&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used &lt;br/&gt;to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Net debt does not include lease liabilities, which amounted to &#x20ac;2,030&#160;million as of December&#160;31, 2023; &#x20ac;2,181&#160;million as of&#160;December&#160;31, 2022; and&#160;&#x20ac;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,108&#160;million as of December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; (see the maturity analysis at Note&#160;D.17.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, the main undrawn confirmed general-purpose credit facilities at holding company level amounted to&#160;&#x20ac;8 billion, half of which expired in 2027 and the other half of which expires in 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, no single counterparty represented more than 6% of Sanofi&#x2019;s undrawn confirmed credit facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,273&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,130&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;661&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,600&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,160&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,722&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,492&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;661&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,600&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,160&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,722&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bond issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other bank borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bank credit balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,314&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,138&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,647&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;602&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,751&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,160&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,016&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate and currency derivatives used to manage cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(7,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,647&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;602&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,751&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,160&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,016&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDebtByMaturityAtValueOfRedemptionExplanatoryTableTextBlock>
    <ifrs-full:BondsIssued contextRef="c-904" decimals="-6" id="f-2690" unitRef="eur">15134000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-971" decimals="-6" id="f-2691" unitRef="eur">718000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-972" decimals="-6" id="f-2692" unitRef="eur">2600000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-973" decimals="-6" id="f-2693" unitRef="eur">3010000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-974" decimals="-6" id="f-2694" unitRef="eur">1150000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-975" decimals="-6" id="f-2695" unitRef="eur">1606000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-976" decimals="-6" id="f-2696" unitRef="eur">6050000000</ifrs-full:BondsIssued>
    <sny:OtherBankBorrowings contextRef="c-904" decimals="-6" id="f-2697" unitRef="eur">1248000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-971" decimals="-6" id="f-2698" unitRef="eur">1118000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-972" decimals="-6" id="f-2699" unitRef="eur">98000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-973" decimals="-6" id="f-2700" unitRef="eur">1000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-974" decimals="-6" id="f-2701" unitRef="eur">1000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-975" decimals="-6" id="f-2702" unitRef="eur">1000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-976" decimals="-6" id="f-2703" unitRef="eur">29000000</sny:OtherBankBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-904" decimals="-6" id="f-2704" unitRef="eur">6000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-971" decimals="-6" id="f-2705" unitRef="eur">6000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-972" decimals="-6" id="f-2706" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-973" decimals="-6" id="f-2707" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-974" decimals="-6" id="f-2708" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-975" decimals="-6" id="f-2709" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-976" decimals="-6" id="f-2710" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-904" decimals="-6" id="f-2711" unitRef="eur">203000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-971" decimals="-6" id="f-2712" unitRef="eur">203000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-972" decimals="-6" id="f-2713" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-973" decimals="-6" id="f-2714" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-974" decimals="-6" id="f-2715" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-975" decimals="-6" id="f-2716" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-976" decimals="-6" id="f-2717" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-904" decimals="-6" id="f-2718" unitRef="eur">18000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-971" decimals="-6" id="f-2719" unitRef="eur">18000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-972" decimals="-6" id="f-2720" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-973" decimals="-6" id="f-2721" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-974" decimals="-6" id="f-2722" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-975" decimals="-6" id="f-2723" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-976" decimals="-6" id="f-2724" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-904" decimals="-6" id="f-2725" unitRef="eur">16573000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-971" decimals="-6" id="f-2726" unitRef="eur">2027000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-972" decimals="-6" id="f-2727" unitRef="eur">2698000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-973" decimals="-6" id="f-2728" unitRef="eur">3011000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-974" decimals="-6" id="f-2729" unitRef="eur">1151000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-975" decimals="-6" id="f-2730" unitRef="eur">1607000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-976" decimals="-6" id="f-2731" unitRef="eur">6079000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-904" decimals="-6" id="f-2732" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-971" decimals="-6" id="f-2733" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-972" decimals="-6" id="f-2734" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-973" decimals="-6" id="f-2735" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-974" decimals="-6" id="f-2736" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-975" decimals="-6" id="f-2737" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-976" decimals="-6" id="f-2738" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-904" decimals="-6" id="f-2739" unitRef="eur">28000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-971" decimals="-6" id="f-2740" unitRef="eur">28000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-972" decimals="-6" id="f-2741" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-973" decimals="-6" id="f-2742" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-974" decimals="-6" id="f-2743" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-975" decimals="-6" id="f-2744" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-976" decimals="-6" id="f-2745" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-904" decimals="-6" id="f-2746" unitRef="eur">7835000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-971" decimals="-6" id="f-2747" unitRef="eur">-6711000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-972" decimals="-6" id="f-2748" unitRef="eur">2698000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-973" decimals="-6" id="f-2749" unitRef="eur">3011000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-974" decimals="-6" id="f-2750" unitRef="eur">1151000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-975" decimals="-6" id="f-2751" unitRef="eur">1607000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-976" decimals="-6" id="f-2752" unitRef="eur">6079000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:LeaseLiabilities contextRef="c-5" decimals="-6" id="f-2753" unitRef="eur">2030000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-7" decimals="-6" id="f-2754" unitRef="eur">2181000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-8" decimals="-6" id="f-2755" unitRef="eur">2108000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:NotionalAmount contextRef="c-977" decimals="-9" id="f-2756" unitRef="eur">8000000000</ifrs-full:NotionalAmount>
    <ifrs-full:BondsIssued contextRef="c-905" decimals="-6" id="f-2757" unitRef="eur">18861000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-978" decimals="-6" id="f-2758" unitRef="eur">3817000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-979" decimals="-6" id="f-2759" unitRef="eur">600000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-980" decimals="-6" id="f-2760" unitRef="eur">2600000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-981" decimals="-6" id="f-2761" unitRef="eur">4160000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-982" decimals="-6" id="f-2762" unitRef="eur">0</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-983" decimals="-6" id="f-2763" unitRef="eur">7684000000</ifrs-full:BondsIssued>
    <sny:OtherBankBorrowings contextRef="c-905" decimals="-6" id="f-2764" unitRef="eur">286000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-978" decimals="-6" id="f-2765" unitRef="eur">187000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-979" decimals="-6" id="f-2766" unitRef="eur">61000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-980" decimals="-6" id="f-2767" unitRef="eur">0</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-981" decimals="-6" id="f-2768" unitRef="eur">0</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-982" decimals="-6" id="f-2769" unitRef="eur">0</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-983" decimals="-6" id="f-2770" unitRef="eur">38000000</sny:OtherBankBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-905" decimals="-6" id="f-2771" unitRef="eur">6000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-978" decimals="-6" id="f-2772" unitRef="eur">6000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-979" decimals="-6" id="f-2773" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-980" decimals="-6" id="f-2774" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-981" decimals="-6" id="f-2775" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-982" decimals="-6" id="f-2776" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-983" decimals="-6" id="f-2777" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-905" decimals="-6" id="f-2778" unitRef="eur">168000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-978" decimals="-6" id="f-2779" unitRef="eur">168000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-979" decimals="-6" id="f-2780" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-980" decimals="-6" id="f-2781" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-981" decimals="-6" id="f-2782" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-982" decimals="-6" id="f-2783" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-983" decimals="-6" id="f-2784" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-905" decimals="-6" id="f-2785" unitRef="eur">48000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-978" decimals="-6" id="f-2786" unitRef="eur">48000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-979" decimals="-6" id="f-2787" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-980" decimals="-6" id="f-2788" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-981" decimals="-6" id="f-2789" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-982" decimals="-6" id="f-2790" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-983" decimals="-6" id="f-2791" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-905" decimals="-6" id="f-2792" unitRef="eur">19273000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-978" decimals="-6" id="f-2793" unitRef="eur">4130000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-979" decimals="-6" id="f-2794" unitRef="eur">661000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-980" decimals="-6" id="f-2795" unitRef="eur">2600000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-981" decimals="-6" id="f-2796" unitRef="eur">4160000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-982" decimals="-6" id="f-2797" unitRef="eur">0</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-983" decimals="-6" id="f-2798" unitRef="eur">7722000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-905" decimals="-6" id="f-2799" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-978" decimals="-6" id="f-2800" unitRef="eur">12736000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-979" decimals="-6" id="f-2801" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-980" decimals="-6" id="f-2802" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-981" decimals="-6" id="f-2803" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-982" decimals="-6" id="f-2804" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-983" decimals="-6" id="f-2805" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-905" decimals="-6" id="f-2806" unitRef="eur">45000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-978" decimals="-6" id="f-2807" unitRef="eur">45000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-979" decimals="-6" id="f-2808" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-980" decimals="-6" id="f-2809" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-981" decimals="-6" id="f-2810" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-982" decimals="-6" id="f-2811" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-983" decimals="-6" id="f-2812" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-905" decimals="-6" id="f-2813" unitRef="eur">6492000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-978" decimals="-6" id="f-2814" unitRef="eur">-8651000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-979" decimals="-6" id="f-2815" unitRef="eur">661000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-980" decimals="-6" id="f-2816" unitRef="eur">2600000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-981" decimals="-6" id="f-2817" unitRef="eur">4160000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-982" decimals="-6" id="f-2818" unitRef="eur">0</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-983" decimals="-6" id="f-2819" unitRef="eur">7722000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:BondsIssued contextRef="c-906" decimals="-6" id="f-2820" unitRef="eur">19946000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-984" decimals="-6" id="f-2821" unitRef="eur">2828000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-985" decimals="-6" id="f-2822" unitRef="eur">3629000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-986" decimals="-6" id="f-2823" unitRef="eur">600000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-987" decimals="-6" id="f-2824" unitRef="eur">1750000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-988" decimals="-6" id="f-2825" unitRef="eur">4160000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued contextRef="c-989" decimals="-6" id="f-2826" unitRef="eur">6979000000</ifrs-full:BondsIssued>
    <sny:OtherBankBorrowings contextRef="c-906" decimals="-6" id="f-2827" unitRef="eur">184000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-984" decimals="-6" id="f-2828" unitRef="eur">163000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-985" decimals="-6" id="f-2829" unitRef="eur">18000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-986" decimals="-6" id="f-2830" unitRef="eur">2000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-987" decimals="-6" id="f-2831" unitRef="eur">1000000</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-988" decimals="-6" id="f-2832" unitRef="eur">0</sny:OtherBankBorrowings>
    <sny:OtherBankBorrowings contextRef="c-989" decimals="-6" id="f-2833" unitRef="eur">0</sny:OtherBankBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-906" decimals="-6" id="f-2834" unitRef="eur">40000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-984" decimals="-6" id="f-2835" unitRef="eur">3000000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-985" decimals="-6" id="f-2836" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-986" decimals="-6" id="f-2837" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-987" decimals="-6" id="f-2838" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-988" decimals="-6" id="f-2839" unitRef="eur">0</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings contextRef="c-989" decimals="-6" id="f-2840" unitRef="eur">37000000</ifrs-full:OtherBorrowings>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-906" decimals="-6" id="f-2841" unitRef="eur">189000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-984" decimals="-6" id="f-2842" unitRef="eur">189000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-985" decimals="-6" id="f-2843" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-986" decimals="-6" id="f-2844" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-987" decimals="-6" id="f-2845" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-988" decimals="-6" id="f-2846" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents contextRef="c-989" decimals="-6" id="f-2847" unitRef="eur">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-906" decimals="-6" id="f-2848" unitRef="eur">45000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-984" decimals="-6" id="f-2849" unitRef="eur">45000000</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-985" decimals="-6" id="f-2850" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-986" decimals="-6" id="f-2851" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-987" decimals="-6" id="f-2852" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-988" decimals="-6" id="f-2853" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageDebt contextRef="c-989" decimals="-6" id="f-2854" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageDebt>
    <ifrs-full:Borrowings contextRef="c-906" decimals="-6" id="f-2855" unitRef="eur">20314000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-984" decimals="-6" id="f-2856" unitRef="eur">3138000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-985" decimals="-6" id="f-2857" unitRef="eur">3647000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-986" decimals="-6" id="f-2858" unitRef="eur">602000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-987" decimals="-6" id="f-2859" unitRef="eur">1751000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-988" decimals="-6" id="f-2860" unitRef="eur">4160000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-989" decimals="-6" id="f-2861" unitRef="eur">7016000000</ifrs-full:Borrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-906" decimals="-6" id="f-2862" unitRef="eur">10098000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-984" decimals="-6" id="f-2863" unitRef="eur">10098000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-985" decimals="-6" id="f-2864" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-986" decimals="-6" id="f-2865" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-987" decimals="-6" id="f-2866" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-988" decimals="-6" id="f-2867" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-989" decimals="-6" id="f-2868" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-906" decimals="-6" id="f-2869" unitRef="eur">169000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-984" decimals="-6" id="f-2870" unitRef="eur">169000000</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-985" decimals="-6" id="f-2871" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-986" decimals="-6" id="f-2872" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-987" decimals="-6" id="f-2873" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-988" decimals="-6" id="f-2874" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent contextRef="c-989" decimals="-6" id="f-2875" unitRef="eur">0</sny:InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-906" decimals="-6" id="f-2876" unitRef="eur">10047000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-984" decimals="-6" id="f-2877" unitRef="eur">-7129000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-985" decimals="-6" id="f-2878" unitRef="eur">3647000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-986" decimals="-6" id="f-2879" unitRef="eur">602000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-987" decimals="-6" id="f-2880" unitRef="eur">1751000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-988" decimals="-6" id="f-2881" unitRef="eur">4160000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-989" decimals="-6" id="f-2882" unitRef="eur">7016000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock contextRef="c-1" id="f-2883">&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below splits net debt between fixed and floating rate, and by maturity, as of December 31, 2023. The figures shown are values on redemption, before the effects of derivative instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,080&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;14,228&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,852&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% fixed-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Floating-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% floating-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,591&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,045&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4,115)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4,251)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% floating-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,881&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;To optimize the cost of debt or reduce the volatility of debt and manage its exposure to financial foreign exchange risk, Sanofi uses derivative instruments (interest rate swaps, currency swaps, foreign exchange swaps and forward contracts) that alter the fixed/floating rate split and the currency split of its net debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;11,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% fixed-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Floating-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,191&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% floating-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,573&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,027&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,738)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4,642)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2,132)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1,143)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;% floating-rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,698&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,011&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,151&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,607&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDebtByInterestRateAtValueOfRedemptionAndByMaturityExplanatoryTableTextBlock>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-990" decimals="-6" id="f-2884" unitRef="eur">16080000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-991" decimals="-6" id="f-2885" unitRef="eur">1664000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-992" decimals="-6" id="f-2886" unitRef="eur">2600000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-993" decimals="-6" id="f-2887" unitRef="eur">3010000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-994" decimals="-6" id="f-2888" unitRef="eur">1150000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-995" decimals="-6" id="f-2889" unitRef="eur">1606000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-996" decimals="-6" id="f-2890" unitRef="eur">6050000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-997" decimals="-6" id="f-2891" unitRef="eur">14228000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-998" decimals="-6" id="f-2892" unitRef="eur">1852000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:DebtPercent
      contextRef="c-999"
      decimals="2"
      id="f-2893"
      unitRef="number">0.97</sny:DebtPercent>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1000" decimals="-6" id="f-2894" unitRef="eur">511000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1001" decimals="-6" id="f-2895" unitRef="eur">381000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1002" decimals="-6" id="f-2896" unitRef="eur">98000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1003" decimals="-6" id="f-2897" unitRef="eur">1000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1004" decimals="-6" id="f-2898" unitRef="eur">1000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1005" decimals="-6" id="f-2899" unitRef="eur">1000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1006" decimals="-6" id="f-2900" unitRef="eur">29000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1007" decimals="-6" id="f-2901" unitRef="eur">0</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1008" decimals="-6" id="f-2902" unitRef="eur">24000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:DebtPercent
      contextRef="c-1009"
      decimals="2"
      id="f-2903"
      unitRef="number">0.03</sny:DebtPercent>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1010" decimals="-6" id="f-2904" unitRef="eur">16591000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1011" decimals="-6" id="f-2905" unitRef="eur">2045000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1012" decimals="-6" id="f-2906" unitRef="eur">2698000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1013" decimals="-6" id="f-2907" unitRef="eur">3011000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1014" decimals="-6" id="f-2908" unitRef="eur">1151000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1015" decimals="-6" id="f-2909" unitRef="eur">1607000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1016" decimals="-6" id="f-2910" unitRef="eur">6079000000</sny:IncreaseDecreaseOfBorrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1009" decimals="-6" id="f-2911" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1017" decimals="-6" id="f-2912" unitRef="eur">8710000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1018" decimals="-6" id="f-2913" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1019" decimals="-6" id="f-2914" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1020" decimals="-6" id="f-2915" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1021" decimals="-6" id="f-2916" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1022" decimals="-6" id="f-2917" unitRef="eur">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1023" decimals="-6" id="f-2918" unitRef="eur">4115000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1024" decimals="-6" id="f-2919" unitRef="eur">4251000000</ifrs-full:CashAndCashEquivalents>
    <sny:DebtPercent
      contextRef="c-1025"
      decimals="INF"
      id="f-2920"
      unitRef="number">1</sny:DebtPercent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1025" decimals="-6" id="f-2921" unitRef="eur">7881000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1026" decimals="-6" id="f-2922" unitRef="eur">-6665000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1027" decimals="-6" id="f-2923" unitRef="eur">2698000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1028" decimals="-6" id="f-2924" unitRef="eur">3011000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1029" decimals="-6" id="f-2925" unitRef="eur">1151000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1030" decimals="-6" id="f-2926" unitRef="eur">1607000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1031" decimals="-6" id="f-2927" unitRef="eur">6079000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:NumberOfCurrenciesDebtIsIssuedIn
      contextRef="c-5"
      decimals="INF"
      id="f-2928"
      unitRef="currency">2</sny:NumberOfCurrenciesDebtIsIssuedIn>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1032" decimals="-6" id="f-2929" unitRef="eur">11382000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1033" decimals="-6" id="f-2930" unitRef="eur">-3034000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1034" decimals="-6" id="f-2931" unitRef="eur">2600000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1035" decimals="-6" id="f-2932" unitRef="eur">3010000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1036" decimals="-6" id="f-2933" unitRef="eur">1150000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1037" decimals="-6" id="f-2934" unitRef="eur">1606000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1038" decimals="-6" id="f-2935" unitRef="eur">6050000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1039" decimals="-6" id="f-2936" unitRef="eur">11382000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1040" decimals="-6" id="f-2937" unitRef="eur">0</sny:IncreaseDecreaseOfBorrowings>
    <sny:DebtPercent
      contextRef="c-1041"
      decimals="2"
      id="f-2938"
      unitRef="number">0.69</sny:DebtPercent>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1042" decimals="-6" id="f-2939" unitRef="eur">5191000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1043" decimals="-6" id="f-2940" unitRef="eur">5061000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1044" decimals="-6" id="f-2941" unitRef="eur">98000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1045" decimals="-6" id="f-2942" unitRef="eur">1000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1046" decimals="-6" id="f-2943" unitRef="eur">1000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1047" decimals="-6" id="f-2944" unitRef="eur">1000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1048" decimals="-6" id="f-2945" unitRef="eur">29000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1049" decimals="-6" id="f-2946" unitRef="eur">113000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1050" decimals="-6" id="f-2947" unitRef="eur">3300000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:DebtPercent
      contextRef="c-1051"
      decimals="2"
      id="f-2948"
      unitRef="number">0.31</sny:DebtPercent>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1052" decimals="-6" id="f-2949" unitRef="eur">16573000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1053" decimals="-6" id="f-2950" unitRef="eur">2027000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1054" decimals="-6" id="f-2951" unitRef="eur">2698000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1055" decimals="-6" id="f-2952" unitRef="eur">3011000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1056" decimals="-6" id="f-2953" unitRef="eur">1151000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1057" decimals="-6" id="f-2954" unitRef="eur">1607000000</sny:IncreaseDecreaseOfBorrowings>
    <sny:IncreaseDecreaseOfBorrowings contextRef="c-1058" decimals="-6" id="f-2955" unitRef="eur">6079000000</sny:IncreaseDecreaseOfBorrowings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1059" decimals="-6" id="f-2956" unitRef="eur">8738000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1060" decimals="-6" id="f-2957" unitRef="eur">4642000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1061" decimals="-6" id="f-2958" unitRef="eur">2132000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1062" decimals="-6" id="f-2959" unitRef="eur">1143000000</ifrs-full:CashAndCashEquivalents>
    <sny:DebtPercent
      contextRef="c-1063"
      decimals="INF"
      id="f-2960"
      unitRef="number">1</sny:DebtPercent>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1059" decimals="-6" id="f-2961" unitRef="eur">7835000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1064" decimals="-6" id="f-2962" unitRef="eur">-6711000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1065" decimals="-6" id="f-2963" unitRef="eur">2698000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1066" decimals="-6" id="f-2964" unitRef="eur">3011000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1067" decimals="-6" id="f-2965" unitRef="eur">1151000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1068" decimals="-6" id="f-2966" unitRef="eur">1607000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1069" decimals="-6" id="f-2967" unitRef="eur">6079000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock contextRef="c-1" id="f-2968">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the fixed/floating rate split of net debt at value on redemption after taking account of derivative instruments as of&#160;December 31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Floating-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,273&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,314&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,492&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDebtByInterestRateAtValueOfRedemptionAfterTakingAccountOfDerivativeInstrumentsN1N2TableTextBlock>
    <ifrs-full:Borrowings contextRef="c-1070" decimals="-6" id="f-2969" unitRef="eur">16386000000</ifrs-full:Borrowings>
    <sny:DebtPercent
      contextRef="c-1070"
      decimals="2"
      id="f-2970"
      unitRef="number">0.85</sny:DebtPercent>
    <ifrs-full:Borrowings contextRef="c-1071" decimals="-6" id="f-2971" unitRef="eur">17612000000</ifrs-full:Borrowings>
    <sny:DebtPercent
      contextRef="c-1071"
      decimals="2"
      id="f-2972"
      unitRef="number">0.87</sny:DebtPercent>
    <ifrs-full:Borrowings contextRef="c-1072" decimals="-6" id="f-2973" unitRef="eur">2886000000</ifrs-full:Borrowings>
    <sny:DebtPercent
      contextRef="c-1072"
      decimals="2"
      id="f-2974"
      unitRef="number">0.15</sny:DebtPercent>
    <ifrs-full:Borrowings contextRef="c-1073" decimals="-6" id="f-2975" unitRef="eur">2702000000</ifrs-full:Borrowings>
    <sny:DebtPercent
      contextRef="c-1073"
      decimals="2"
      id="f-2976"
      unitRef="number">0.13</sny:DebtPercent>
    <ifrs-full:Borrowings contextRef="c-1074" decimals="-6" id="f-2977" unitRef="eur">19273000000</ifrs-full:Borrowings>
    <sny:DebtPercent
      contextRef="c-1074"
      decimals="2"
      id="f-2978"
      unitRef="number">1</sny:DebtPercent>
    <ifrs-full:Borrowings contextRef="c-1075" decimals="-6" id="f-2979" unitRef="eur">20314000000</ifrs-full:Borrowings>
    <sny:DebtPercent
      contextRef="c-1075"
      decimals="2"
      id="f-2980"
      unitRef="number">1</sny:DebtPercent>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1074" decimals="-6" id="f-2981" unitRef="eur">12781000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-1075" decimals="-6" id="f-2982" unitRef="eur">10267000000</ifrs-full:CashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1074" decimals="-6" id="f-2983" unitRef="eur">6492000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1075" decimals="-6" id="f-2984" unitRef="eur">10047000000</sny:DebtNetOfCashAndCashEquivalents>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-1076"
      decimals="3"
      id="f-2985"
      unitRef="number">0.016</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-1077"
      decimals="3"
      id="f-2986"
      unitRef="number">0.021</ifrs-full:BorrowingsInterestRate>
    <sny:CashAndCashEquivalentsInvestedRate
      contextRef="c-1076"
      decimals="3"
      id="f-2987"
      unitRef="number">0.039</sny:CashAndCashEquivalentsInvestedRate>
    <sny:CashAndCashEquivalentsInvestedRate
      contextRef="c-1077"
      decimals="3"
      id="f-2988"
      unitRef="number">0.037</sny:CashAndCashEquivalentsInvestedRate>
    <sny:DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock contextRef="c-1" id="f-2989">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The projected full-year sensitivity of net debt to interest rate fluctuations for 2024 is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Change in short-term interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Impact&#160;on&#160;pre-tax&#160;net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;income&#160;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac;&#160;million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Impact&#160;on&#160;pre-tax&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;income/(expense)&#160;recognized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;directly in equity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+100&#160;bp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+25&#160;bp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;-25&#160;bp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;-100&#160;bp&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfSensitivityAnalysisOnLongTermBorrowingsAndDebtSecuritiesAssumingA1IncreaseAndDecreaseInInterestRatesTableTextBlock>
    <sny:ImpactOfChangeInInterestRateOnPreTaxIncome contextRef="c-1078" decimals="-6" id="f-2990" unitRef="eur">48000000</sny:ImpactOfChangeInInterestRateOnPreTaxIncome>
    <sny:ImpactOfPreTaxIncomeRecognisedInEquity contextRef="c-1078" decimals="-6" id="f-2991" unitRef="eur">0</sny:ImpactOfPreTaxIncomeRecognisedInEquity>
    <sny:ImpactOfChangeInInterestRateOnPreTaxIncome contextRef="c-1079" decimals="-6" id="f-2992" unitRef="eur">12000000</sny:ImpactOfChangeInInterestRateOnPreTaxIncome>
    <sny:ImpactOfPreTaxIncomeRecognisedInEquity contextRef="c-1079" decimals="-6" id="f-2993" unitRef="eur">0</sny:ImpactOfPreTaxIncomeRecognisedInEquity>
    <sny:ImpactOfChangeInInterestRateOnPreTaxIncome contextRef="c-1080" decimals="-6" id="f-2994" unitRef="eur">-12000000</sny:ImpactOfChangeInInterestRateOnPreTaxIncome>
    <sny:ImpactOfPreTaxIncomeRecognisedInEquity contextRef="c-1080" decimals="-6" id="f-2995" unitRef="eur">0</sny:ImpactOfPreTaxIncomeRecognisedInEquity>
    <sny:ImpactOfChangeInInterestRateOnPreTaxIncome contextRef="c-1081" decimals="-6" id="f-2996" unitRef="eur">-48000000</sny:ImpactOfChangeInInterestRateOnPreTaxIncome>
    <sny:ImpactOfPreTaxIncomeRecognisedInEquity contextRef="c-1081" decimals="-6" id="f-2997" unitRef="eur">0</sny:ImpactOfPreTaxIncomeRecognisedInEquity>
    <sny:DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock contextRef="c-1" id="f-2998">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows net debt by currency at December 31, 2023, before and after derivative instruments contracted to convert the foreign-currency net debt of exposed entities into their functional currency:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.411%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Before&#160;derivative&#160;instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;After&#160;derivative&#160;instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pound sterling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Chinese yuan renminbi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,881&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDebtByCurrencyAtValueOfRedemptionBeforeAndAfterDerivativeInstrumentsTableTextBlock>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1082" decimals="-6" id="f-2999" unitRef="eur">10113000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1083" decimals="-6" id="f-3000" unitRef="eur">6852000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1084" decimals="-6" id="f-3001" unitRef="eur">-2376000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1085" decimals="-6" id="f-3002" unitRef="eur">1169000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1086" decimals="-6" id="f-3003" unitRef="eur">-3000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1087" decimals="-6" id="f-3004" unitRef="eur">-1143000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1088" decimals="-6" id="f-3005" unitRef="eur">0</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1089" decimals="-6" id="f-3006" unitRef="eur">509000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1090" decimals="-6" id="f-3007" unitRef="eur">-19000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1091" decimals="-6" id="f-3008" unitRef="eur">189000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1092" decimals="-6" id="f-3009" unitRef="eur">166000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1093" decimals="-6" id="f-3010" unitRef="eur">259000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1025" decimals="-6" id="f-3011" unitRef="eur">7881000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1059" decimals="-6" id="f-3012" unitRef="eur">7835000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock contextRef="c-1" id="f-3013">&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows net debt by currency at December 31, 2022 and 2021, after derivative instruments contracted to convert the foreign currency net debt of exposed entities into their functional currency:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(669)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,492&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,047&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfDebtByCurrencyAtValueOfRedemptionAfterDerivativeInstrumentsTableTextBlock>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1094" decimals="-6" id="f-3014" unitRef="eur">10489000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1095" decimals="-6" id="f-3015" unitRef="eur">13129000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1096" decimals="-6" id="f-3016" unitRef="eur">-2404000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1097" decimals="-6" id="f-3017" unitRef="eur">-669000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1098" decimals="-6" id="f-3018" unitRef="eur">-1593000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1099" decimals="-6" id="f-3019" unitRef="eur">-2413000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1074" decimals="-6" id="f-3020" unitRef="eur">6492000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DebtNetOfCashAndCashEquivalents contextRef="c-1075" decimals="-6" id="f-3021" unitRef="eur">10047000000</sny:DebtNetOfCashAndCashEquivalents>
    <sny:DisclosureOfMarketValueOfNetDebtTableTextBlock contextRef="c-1" id="f-3022">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The market value of Sanofi&#x2019;s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Value on redemption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfMarketValueOfNetDebtTableTextBlock>
    <ifrs-full:Borrowings contextRef="c-1100" decimals="-6" id="f-3023" unitRef="eur">7086000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-1101" decimals="-6" id="f-3024" unitRef="eur">5227000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-1102" decimals="-6" id="f-3025" unitRef="eur">11024000000</ifrs-full:Borrowings>
    <sny:RedemptionOfDebtInstrumentIssued contextRef="c-1103" decimals="-6" id="f-3026" unitRef="eur">7835000000</sny:RedemptionOfDebtInstrumentIssued>
    <sny:RedemptionOfDebtInstrumentIssued contextRef="c-1104" decimals="-6" id="f-3027" unitRef="eur">6492000000</sny:RedemptionOfDebtInstrumentIssued>
    <sny:RedemptionOfDebtInstrumentIssued contextRef="c-1105" decimals="-6" id="f-3028" unitRef="eur">10047000000</sny:RedemptionOfDebtInstrumentIssued>
    <sny:DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock contextRef="c-1" id="f-3029">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.019%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,710&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,153&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,912&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,187&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,285&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,719&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,454&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net cash flows related to derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,853&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,200&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,944&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,210&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,309&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,735&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,455&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The tables below show the amount of future undiscounted contractual cash flows (principal and interest) relating to debt and to derivative instruments designated as hedges of debt as of December 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.019%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,408&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,206&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,803&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,184&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,283&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,064&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net cash flows related to derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20,617&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,230&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;928&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,841&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,215&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,314&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,089&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.019%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027 and later&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,728&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,330&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,826&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;791&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,937&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,176&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,668&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net cash flows related to derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,677&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,271&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,825&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;793&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,939&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,178&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,671&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Interest flows are estimated on the basis of forward interest rates applicable as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfMaturityAnalysisOfFutureUndiscountedCashFlowsExplanatoryTableTextBlock>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-5" decimals="-6" id="f-3030" unitRef="eur">17710000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1106" decimals="-6" id="f-3031" unitRef="eur">2153000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1107" decimals="-6" id="f-3032" unitRef="eur">2912000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1108" decimals="-6" id="f-3033" unitRef="eur">3187000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1109" decimals="-6" id="f-3034" unitRef="eur">1285000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1110" decimals="-6" id="f-3035" unitRef="eur">1719000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1111" decimals="-6" id="f-3036" unitRef="eur">6454000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-5" decimals="-6" id="f-3037" unitRef="eur">16468000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1106" decimals="-6" id="f-3038" unitRef="eur">1917000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1107" decimals="-6" id="f-3039" unitRef="eur">2703000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1108" decimals="-6" id="f-3040" unitRef="eur">3011000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1109" decimals="-6" id="f-3041" unitRef="eur">1151000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1110" decimals="-6" id="f-3042" unitRef="eur">1607000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1111" decimals="-6" id="f-3043" unitRef="eur">6079000000</sny:PrincipalUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-5" decimals="-6" id="f-3044" unitRef="eur">1242000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1106" decimals="-6" id="f-3045" unitRef="eur">236000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1107" decimals="-6" id="f-3046" unitRef="eur">209000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1108" decimals="-6" id="f-3047" unitRef="eur">176000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1109" decimals="-6" id="f-3048" unitRef="eur">134000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1110" decimals="-6" id="f-3049" unitRef="eur">112000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1111" decimals="-6" id="f-3050" unitRef="eur">375000000</sny:InterestUndiscountedCashFlow>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-5" decimals="-6" id="f-3051" unitRef="eur">143000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1106" decimals="-6" id="f-3052" unitRef="eur">47000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1107" decimals="-6" id="f-3053" unitRef="eur">32000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1108" decimals="-6" id="f-3054" unitRef="eur">23000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1109" decimals="-6" id="f-3055" unitRef="eur">24000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1110" decimals="-6" id="f-3056" unitRef="eur">16000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1111" decimals="-6" id="f-3057" unitRef="eur">1000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <sny:TotalUndiscountedCashFlow contextRef="c-5" decimals="-6" id="f-3058" unitRef="eur">17853000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1106" decimals="-6" id="f-3059" unitRef="eur">2200000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1107" decimals="-6" id="f-3060" unitRef="eur">2944000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1108" decimals="-6" id="f-3061" unitRef="eur">3210000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1109" decimals="-6" id="f-3062" unitRef="eur">1309000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1110" decimals="-6" id="f-3063" unitRef="eur">1735000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1111" decimals="-6" id="f-3064" unitRef="eur">6455000000</sny:TotalUndiscountedCashFlow>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-7" decimals="-6" id="f-3065" unitRef="eur">20408000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1112" decimals="-6" id="f-3066" unitRef="eur">4206000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1113" decimals="-6" id="f-3067" unitRef="eur">868000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1114" decimals="-6" id="f-3068" unitRef="eur">2803000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1115" decimals="-6" id="f-3069" unitRef="eur">3184000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1116" decimals="-6" id="f-3070" unitRef="eur">1283000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1117" decimals="-6" id="f-3071" unitRef="eur">8064000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-7" decimals="-6" id="f-3072" unitRef="eur">18932000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1112" decimals="-6" id="f-3073" unitRef="eur">3928000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1113" decimals="-6" id="f-3074" unitRef="eur">661000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1114" decimals="-6" id="f-3075" unitRef="eur">2601000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1115" decimals="-6" id="f-3076" unitRef="eur">3011000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1116" decimals="-6" id="f-3077" unitRef="eur">1151000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1117" decimals="-6" id="f-3078" unitRef="eur">7580000000</sny:PrincipalUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-7" decimals="-6" id="f-3079" unitRef="eur">1476000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1112" decimals="-6" id="f-3080" unitRef="eur">278000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1113" decimals="-6" id="f-3081" unitRef="eur">207000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1114" decimals="-6" id="f-3082" unitRef="eur">202000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1115" decimals="-6" id="f-3083" unitRef="eur">173000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1116" decimals="-6" id="f-3084" unitRef="eur">132000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1117" decimals="-6" id="f-3085" unitRef="eur">484000000</sny:InterestUndiscountedCashFlow>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-7" decimals="-6" id="f-3086" unitRef="eur">209000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1112" decimals="-6" id="f-3087" unitRef="eur">24000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1113" decimals="-6" id="f-3088" unitRef="eur">60000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1114" decimals="-6" id="f-3089" unitRef="eur">38000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1115" decimals="-6" id="f-3090" unitRef="eur">31000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1116" decimals="-6" id="f-3091" unitRef="eur">31000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1117" decimals="-6" id="f-3092" unitRef="eur">25000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <sny:TotalUndiscountedCashFlow contextRef="c-7" decimals="-6" id="f-3093" unitRef="eur">20617000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1112" decimals="-6" id="f-3094" unitRef="eur">4230000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1113" decimals="-6" id="f-3095" unitRef="eur">928000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1114" decimals="-6" id="f-3096" unitRef="eur">2841000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1115" decimals="-6" id="f-3097" unitRef="eur">3215000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1116" decimals="-6" id="f-3098" unitRef="eur">1314000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1117" decimals="-6" id="f-3099" unitRef="eur">8089000000</sny:TotalUndiscountedCashFlow>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-8" decimals="-6" id="f-3100" unitRef="eur">21728000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1118" decimals="-6" id="f-3101" unitRef="eur">3330000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1119" decimals="-6" id="f-3102" unitRef="eur">3826000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1120" decimals="-6" id="f-3103" unitRef="eur">791000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1121" decimals="-6" id="f-3104" unitRef="eur">1937000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1122" decimals="-6" id="f-3105" unitRef="eur">3176000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1123" decimals="-6" id="f-3106" unitRef="eur">8668000000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-8" decimals="-6" id="f-3107" unitRef="eur">20086000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1118" decimals="-6" id="f-3108" unitRef="eur">3055000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1119" decimals="-6" id="f-3109" unitRef="eur">3588000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1120" decimals="-6" id="f-3110" unitRef="eur">601000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1121" decimals="-6" id="f-3111" unitRef="eur">1751000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1122" decimals="-6" id="f-3112" unitRef="eur">3011000000</sny:PrincipalUndiscountedCashFlow>
    <sny:PrincipalUndiscountedCashFlow contextRef="c-1123" decimals="-6" id="f-3113" unitRef="eur">8080000000</sny:PrincipalUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-8" decimals="-6" id="f-3114" unitRef="eur">1642000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1118" decimals="-6" id="f-3115" unitRef="eur">275000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1119" decimals="-6" id="f-3116" unitRef="eur">238000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1120" decimals="-6" id="f-3117" unitRef="eur">190000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1121" decimals="-6" id="f-3118" unitRef="eur">186000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1122" decimals="-6" id="f-3119" unitRef="eur">165000000</sny:InterestUndiscountedCashFlow>
    <sny:InterestUndiscountedCashFlow contextRef="c-1123" decimals="-6" id="f-3120" unitRef="eur">588000000</sny:InterestUndiscountedCashFlow>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-8" decimals="-6" id="f-3121" unitRef="eur">-51000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1118" decimals="-6" id="f-3122" unitRef="eur">-59000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1119" decimals="-6" id="f-3123" unitRef="eur">-1000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1120" decimals="-6" id="f-3124" unitRef="eur">2000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1121" decimals="-6" id="f-3125" unitRef="eur">2000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1122" decimals="-6" id="f-3126" unitRef="eur">2000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-1123" decimals="-6" id="f-3127" unitRef="eur">3000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <sny:TotalUndiscountedCashFlow contextRef="c-8" decimals="-6" id="f-3128" unitRef="eur">21677000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1118" decimals="-6" id="f-3129" unitRef="eur">3271000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1119" decimals="-6" id="f-3130" unitRef="eur">3825000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1120" decimals="-6" id="f-3131" unitRef="eur">793000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1121" decimals="-6" id="f-3132" unitRef="eur">1939000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1122" decimals="-6" id="f-3133" unitRef="eur">3178000000</sny:TotalUndiscountedCashFlow>
    <sny:TotalUndiscountedCashFlow contextRef="c-1123" decimals="-6" id="f-3134" unitRef="eur">8671000000</sny:TotalUndiscountedCashFlow>
    <sny:DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock contextRef="c-1" id="f-3135">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A maturity analysis of lease liabilities as of December 31, 2023, 2022 and 2021 is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Undiscounted future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less than 1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;From 1 to 3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;From 3 to 5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More than 5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Discounting effect&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Total lease liabilities as of December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;291&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;448&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;360&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;989&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Total lease liabilities as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,181&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;320&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;515&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;436&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,129&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Total lease liabilities as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,108&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;314&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;362&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,184&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Lease liabilities include leases relating to real estate assets located at Cambridge, MA (United States), as described in Note&#160;D.3., which have a lease term of 15 years.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfMaturityAnalysisOfLeasePaymentsTableTextBlock>
    <ifrs-full:LeaseLiabilities contextRef="c-5" decimals="-6" id="f-3136" unitRef="eur">2030000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1106" decimals="-6" id="f-3137" unitRef="eur">291000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1124" decimals="-6" id="f-3138" unitRef="eur">448000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1125" decimals="-6" id="f-3139" unitRef="eur">360000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1111" decimals="-6" id="f-3140" unitRef="eur">989000000</ifrs-full:LeaseLiabilities>
    <sny:LeaseLiabilitiesEffectOfDiscounting contextRef="c-5" decimals="-6" id="f-3141" unitRef="eur">58000000</sny:LeaseLiabilitiesEffectOfDiscounting>
    <ifrs-full:LeaseLiabilities contextRef="c-7" decimals="-6" id="f-3142" unitRef="eur">2181000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1112" decimals="-6" id="f-3143" unitRef="eur">320000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1126" decimals="-6" id="f-3144" unitRef="eur">515000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1127" decimals="-6" id="f-3145" unitRef="eur">436000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1117" decimals="-6" id="f-3146" unitRef="eur">1129000000</ifrs-full:LeaseLiabilities>
    <sny:LeaseLiabilitiesEffectOfDiscounting contextRef="c-7" decimals="-6" id="f-3147" unitRef="eur">219000000</sny:LeaseLiabilitiesEffectOfDiscounting>
    <ifrs-full:LeaseLiabilities contextRef="c-8" decimals="-6" id="f-3148" unitRef="eur">2108000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1118" decimals="-6" id="f-3149" unitRef="eur">314000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1128" decimals="-6" id="f-3150" unitRef="eur">476000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1129" decimals="-6" id="f-3151" unitRef="eur">362000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-1123" decimals="-6" id="f-3152" unitRef="eur">1184000000</ifrs-full:LeaseLiabilities>
    <sny:LeaseLiabilitiesEffectOfDiscounting contextRef="c-8" decimals="-6" id="f-3153" unitRef="eur">228000000</sny:LeaseLiabilitiesEffectOfDiscounting>
    <sny:InitialLeaseTerm contextRef="c-1130" id="f-3154">P15Y</sny:InitialLeaseTerm>
    <sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock contextRef="c-1" id="f-3155">Liabilities related to business combinations and to non-controlling interests&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For a description of the nature of the liabilities reported in the line item&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, refer to Note&#160;B.8.5. The principal acquisitions are described in Notes&#160;D.1. and&#160;D.2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The liabilities related to business combinations and to non-controlling interests shown in the table below are level&#160;3 instruments under the IFRS&#160;7 fair value hierarchy (see Note&#160;D.12.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in liabilities related to business combinations and to non-controlling interests are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.018%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bayer&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;contingent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;arising&#160;from&#160;the&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;acquisition of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Genzyme &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;MSD&lt;br/&gt;contingent&lt;br/&gt;consideration&lt;br/&gt;(European&lt;br/&gt;Vaccines&lt;br/&gt;business)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shire&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;contingent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;arising&#160;from&#160;the&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;acquisition of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Translate Bio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contingent consideration arising from acquisition of Amunix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance&#160;at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;104&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;312&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;189&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;New transactions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(258)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance&#160;at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;354&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;714&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;New transactions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance&#160;at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;380&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;165&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;779&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;New transactions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance&#160;at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;441&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;709&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Portion due after more than one year: &#x20ac;501 million as of December 31, 2023 (&#x20ac;674 million as of December 31, 2022 and &#x20ac;577 million as of December 31, 2021); portion due within less than one year: &#x20ac;208 million as of December 31, 2023 (&#x20ac;105 million as of December 31, 2022 and &#x20ac;137&#160;million as of&#160;December 31, 2021).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Amounts reported within the income statement line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, and mainly comprising unrealized gains and losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Mainly corresponds to the recognition of the Shire Human Genetic Therapies&#160;Inc. (Shire) contingent consideration liability of $382 million resulting from the acquisition of Translate Bio in September&#160;2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;The &#x201c;Other&#x201d; column mainly relates to the contingent consideration liability due to True North Therapeutics as a result of Sanofi's acquisition of Bioverativ which was settled in the first half of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities related to business combinations and to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; mainly comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture, which amounted to &#x20ac;127 million as of December 31, 2023, &#x20ac;204 million as of&#160;December 31, 2022 and &#x20ac;269 million as of December 31, 2021 (see Note&#160;D.12.). The fair value of this contingent consideration is determined by applying the royalty percentage stipulated in the contract to discounted sales projections. If the discount rate were to fall by one percentage point, the fair value of the MSD contingent consideration liability would increase by approximately 1%;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi&#x2019;s acquisition of Translate&#160;Bio in September&#160;2021. In a business combination carried out in December 2016 and predating the acquisition of control by Sanofi, Translate Bio (then called Rana Therapeutics, Inc.) acquired from Shire the intellectual property rights relating to the latter&#x2019;s Messenger RNA Therapeutics (MRT) program. As of December 31, 2023, Shire was entitled to receive the following potential payments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;milestone payments contingent on the launch of products based on MRT technology, and on the attainment of a specified level of sales of those products, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt"&gt;a percentage of sales of those products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The fair value of the Shire liability was measured at &#x20ac;441 million as of December 31, 2023, compared with &#x20ac;380 million as of&#160;December 31, 2022 and &#x20ac;354 million as of December 31, 2021; it was determined by applying the contractual terms to development and sales projections which were weighted to reflect the probability of success, and discounted. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately 12%;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the contingent consideration liability arising from the 2022 acquisition of Amunix. The fair value of the liability is determined on&#160;the basis of the nominal value of payments due subject to the attainment of specified&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; development milestones. The liability was measured at &#x20ac;137&#160;million as of December 31, 2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;compared with &#x20ac;165 million as of&#160;December 31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. If the discount rate were to fall by one percentage point, the fair value of the liability would increase by approximately&#160;1%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Bayer contingent consideration liability arising from Sanofi&#x2019;s acquisition of Genzyme in 2011 was extinguished during 2023 in accordance with the contractual terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth the maximum amount of contingent consideration payable in respect of already-marketed products:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;From&#160;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;From&#160;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Commitments relating to contingent consideration&#160;in connection with business combinations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The nominal amount of contingent consideration was &#x20ac;604 million as of December 31, 2022 and &#x20ac;689 million as of            December 31, 2021.</sny:DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsExplanatoryTextBlock>
    <sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock contextRef="c-1" id="f-3156">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Movements in liabilities related to business combinations and to non-controlling interests are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.018%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bayer&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;contingent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;arising&#160;from&#160;the&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;acquisition of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Genzyme &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;MSD&lt;br/&gt;contingent&lt;br/&gt;consideration&lt;br/&gt;(European&lt;br/&gt;Vaccines&lt;br/&gt;business)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shire&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;contingent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;arising&#160;from&#160;the&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;acquisition of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Translate Bio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contingent consideration arising from acquisition of Amunix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance&#160;at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;104&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;312&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;189&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;New transactions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(258)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance&#160;at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;269&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;354&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;714&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;New transactions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance&#160;at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;380&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;165&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;779&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;New transactions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other movements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance&#160;at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;127&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;441&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;709&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Portion due after more than one year: &#x20ac;501 million as of December 31, 2023 (&#x20ac;674 million as of December 31, 2022 and &#x20ac;577 million as of December 31, 2021); portion due within less than one year: &#x20ac;208 million as of December 31, 2023 (&#x20ac;105 million as of December 31, 2022 and &#x20ac;137&#160;million as of&#160;December 31, 2021).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Amounts reported within the income statement line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, and mainly comprising unrealized gains and losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Mainly corresponds to the recognition of the Shire Human Genetic Therapies&#160;Inc. (Shire) contingent consideration liability of $382 million resulting from the acquisition of Translate Bio in September&#160;2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;The &#x201c;Other&#x201d; column mainly relates to the contingent consideration liability due to True North Therapeutics as a result of Sanofi's acquisition of Bioverativ which was settled in the first half of 2021.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1131" decimals="-6" id="f-3157" unitRef="eur">104000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1132" decimals="-6" id="f-3158" unitRef="eur">312000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1133" decimals="-6" id="f-3159" unitRef="eur">0</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1134" decimals="-6" id="f-3160" unitRef="eur">0</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1135" decimals="-6" id="f-3161" unitRef="eur">189000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-19" decimals="-6" id="f-3162" unitRef="eur">605000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1136" decimals="-6" id="f-3163" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1137" decimals="-6" id="f-3164" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1138" decimals="-6" id="f-3165" unitRef="eur">323000000</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1139" decimals="-6" id="f-3166" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1140" decimals="-6" id="f-3167" unitRef="eur">37000000</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-10" decimals="-6" id="f-3168" unitRef="eur">360000000</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1136" decimals="-6" id="f-3169" unitRef="eur">31000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1137" decimals="-6" id="f-3170" unitRef="eur">75000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1138" decimals="-6" id="f-3171" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1139" decimals="-6" id="f-3172" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1140" decimals="-6" id="f-3173" unitRef="eur">152000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-10" decimals="-6" id="f-3174" unitRef="eur">258000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1136" decimals="-6" id="f-3175" unitRef="eur">18000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1137" decimals="-6" id="f-3176" unitRef="eur">-26000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1138" decimals="-6" id="f-3177" unitRef="eur">-19000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1139" decimals="-6" id="f-3178" unitRef="eur">0</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1140" decimals="-6" id="f-3179" unitRef="eur">31000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-10" decimals="-6" id="f-3180" unitRef="eur">4000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1136" decimals="-6" id="f-3181" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1137" decimals="-6" id="f-3182" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1138" decimals="-6" id="f-3183" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1139" decimals="-6" id="f-3184" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1140" decimals="-6" id="f-3185" unitRef="eur">-14000000</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-10" decimals="-6" id="f-3186" unitRef="eur">-14000000</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1136" decimals="-6" id="f-3187" unitRef="eur">4000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1137" decimals="-6" id="f-3188" unitRef="eur">6000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1138" decimals="-6" id="f-3189" unitRef="eur">12000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1139" decimals="-6" id="f-3190" unitRef="eur">0</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1140" decimals="-6" id="f-3191" unitRef="eur">3000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-10" decimals="-6" id="f-3192" unitRef="eur">25000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1141" decimals="-6" id="f-3193" unitRef="eur">59000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1142" decimals="-6" id="f-3194" unitRef="eur">269000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1143" decimals="-6" id="f-3195" unitRef="eur">354000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1144" decimals="-6" id="f-3196" unitRef="eur">0</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1145" decimals="-6" id="f-3197" unitRef="eur">32000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-8" decimals="-6" id="f-3198" unitRef="eur">714000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1146" decimals="-6" id="f-3199" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1147" decimals="-6" id="f-3200" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1148" decimals="-6" id="f-3201" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1149" decimals="-6" id="f-3202" unitRef="eur">156000000</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1150" decimals="-6" id="f-3203" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-9" decimals="-6" id="f-3204" unitRef="eur">156000000</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1146" decimals="-6" id="f-3205" unitRef="eur">29000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1147" decimals="-6" id="f-3206" unitRef="eur">79000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1148" decimals="-6" id="f-3207" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1149" decimals="-6" id="f-3208" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1150" decimals="-6" id="f-3209" unitRef="eur">28000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-9" decimals="-6" id="f-3210" unitRef="eur">136000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1146" decimals="-6" id="f-3211" unitRef="eur">9000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1147" decimals="-6" id="f-3212" unitRef="eur">-14000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1148" decimals="-6" id="f-3213" unitRef="eur">-2000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1149" decimals="-6" id="f-3214" unitRef="eur">2000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1150" decimals="-6" id="f-3215" unitRef="eur">0</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-9" decimals="-6" id="f-3216" unitRef="eur">-5000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1146" decimals="-6" id="f-3217" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1147" decimals="-6" id="f-3218" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1148" decimals="-6" id="f-3219" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1149" decimals="-6" id="f-3220" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1150" decimals="-6" id="f-3221" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-9" decimals="-6" id="f-3222" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1146" decimals="-6" id="f-3223" unitRef="eur">5000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1147" decimals="-6" id="f-3224" unitRef="eur">0</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1148" decimals="-6" id="f-3225" unitRef="eur">24000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1149" decimals="-6" id="f-3226" unitRef="eur">11000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1150" decimals="-6" id="f-3227" unitRef="eur">0</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-9" decimals="-6" id="f-3228" unitRef="eur">40000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1151" decimals="-6" id="f-3229" unitRef="eur">26000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1152" decimals="-6" id="f-3230" unitRef="eur">204000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1153" decimals="-6" id="f-3231" unitRef="eur">380000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1154" decimals="-6" id="f-3232" unitRef="eur">165000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1155" decimals="-6" id="f-3233" unitRef="eur">4000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-7" decimals="-6" id="f-3234" unitRef="eur">779000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1156" decimals="-6" id="f-3235" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1157" decimals="-6" id="f-3236" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1158" decimals="-6" id="f-3237" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1159" decimals="-6" id="f-3238" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1160" decimals="-6" id="f-3239" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1" decimals="-6" id="f-3240" unitRef="eur">0</ifrs-full:NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1156" decimals="-6" id="f-3241" unitRef="eur">21000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1157" decimals="-6" id="f-3242" unitRef="eur">77000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1158" decimals="-6" id="f-3243" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1159" decimals="-6" id="f-3244" unitRef="eur">69000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1160" decimals="-6" id="f-3245" unitRef="eur">0</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1" decimals="-6" id="f-3246" unitRef="eur">167000000</ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1156" decimals="-6" id="f-3247" unitRef="eur">5000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1157" decimals="-6" id="f-3248" unitRef="eur">0</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1158" decimals="-6" id="f-3249" unitRef="eur">-74000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1159" decimals="-6" id="f-3250" unitRef="eur">-45000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1160" decimals="-6" id="f-3251" unitRef="eur">0</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities contextRef="c-1" decimals="-6" id="f-3252" unitRef="eur">-114000000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1156" decimals="-6" id="f-3253" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1157" decimals="-6" id="f-3254" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1158" decimals="-6" id="f-3255" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1159" decimals="-6" id="f-3256" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1160" decimals="-6" id="f-3257" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests contextRef="c-1" decimals="-6" id="f-3258" unitRef="eur">0</sny:IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1156" decimals="-6" id="f-3259" unitRef="eur">0</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1157" decimals="-6" id="f-3260" unitRef="eur">0</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1158" decimals="-6" id="f-3261" unitRef="eur">-13000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1159" decimals="-6" id="f-3262" unitRef="eur">-4000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1160" decimals="-6" id="f-3263" unitRef="eur">0</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests contextRef="c-1" decimals="-6" id="f-3264" unitRef="eur">-17000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1161" decimals="-6" id="f-3265" unitRef="eur">0</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-529" decimals="-6" id="f-3266" unitRef="eur">127000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1162" decimals="-6" id="f-3267" unitRef="eur">441000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1163" decimals="-6" id="f-3268" unitRef="eur">137000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1164" decimals="-6" id="f-3269" unitRef="eur">4000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-5" decimals="-6" id="f-3270" unitRef="eur">709000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-5" decimals="-6" id="f-3271" unitRef="eur">501000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-7" decimals="-6" id="f-3272" unitRef="eur">674000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-8" decimals="-6" id="f-3273" unitRef="eur">577000000</sny:NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-5" decimals="-6" id="f-3274" unitRef="eur">208000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-7" decimals="-6" id="f-3275" unitRef="eur">105000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests contextRef="c-8" decimals="-6" id="f-3276" unitRef="eur">137000000</sny:CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests>
    <sny:ContingentConsiderationLiabilities contextRef="c-1165" decimals="-6" id="f-3277" unitRef="usd">382000000</sny:ContingentConsiderationLiabilities>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-529" decimals="-6" id="f-3278" unitRef="eur">127000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1152" decimals="-6" id="f-3279" unitRef="eur">204000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1142" decimals="-6" id="f-3280" unitRef="eur">269000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:PercentageIncreaseInFairValueLiabilities
      contextRef="c-529"
      decimals="2"
      id="f-3281"
      unitRef="number">0.01</sny:PercentageIncreaseInFairValueLiabilities>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1162" decimals="-6" id="f-3282" unitRef="eur">441000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1153" decimals="-6" id="f-3283" unitRef="eur">380000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1143" decimals="-6" id="f-3284" unitRef="eur">354000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:PercentageIncreaseInFairValueLiabilities
      contextRef="c-1166"
      decimals="2"
      id="f-3285"
      unitRef="number">0.12</sny:PercentageIncreaseInFairValueLiabilities>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1163" decimals="-6" id="f-3286" unitRef="eur">137000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-1154" decimals="-6" id="f-3287" unitRef="eur">165000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <sny:PercentageIncreaseInFairValueLiabilities
      contextRef="c-1163"
      decimals="2"
      id="f-3288"
      unitRef="number">0.01</sny:PercentageIncreaseInFairValueLiabilities>
    <sny:DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock contextRef="c-1" id="f-3289">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth the maximum amount of contingent consideration payable in respect of already-marketed products:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;From&#160;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;From&#160;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Commitments relating to contingent consideration&#160;in connection with business combinations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock>
    <sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations contextRef="c-5" decimals="-6" id="f-3290" unitRef="eur">133000000</sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations>
    <sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations contextRef="c-1106" decimals="-6" id="f-3291" unitRef="eur">69000000</sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations>
    <sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations contextRef="c-1124" decimals="-6" id="f-3292" unitRef="eur">64000000</sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations>
    <sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations contextRef="c-1125" decimals="-6" id="f-3293" unitRef="eur">0</sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations>
    <sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations contextRef="c-1111" decimals="-6" id="f-3294" unitRef="eur">0</sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations>
    <sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations contextRef="c-7" decimals="-6" id="f-3295" unitRef="eur">604000000</sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations>
    <sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations contextRef="c-8" decimals="-6" id="f-3296" unitRef="eur">689000000</sny:CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations>
    <sny:DisclosureOfProvisionsAndOtherLiabilitiesTextBlock contextRef="c-1" id="f-3297">Provisions, income tax liabilities and other liabilities&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non current provisions and other non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprises the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,602&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,341&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,721&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes derivative financial instruments: &#x20ac;164&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &#x20ac;232 million as of December 31, 2022, &#x20ac;6 million as of December 31, 2021.&lt;br/&gt;The figure as of December 31, 2023 includes &#x20ac;1,960&#160;million for the liability in respect of royalties payable to Sobi on net sales of BEYFORTUS (nirsevimab) in the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#x20ac;1,112&#160;million; the nominal value of payments estimated to be due after more than five years is &#x20ac;2,860 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Non-current income tax liabilities are described in Note&#160;D.19.4., and other current liabilities in Note&#160;D.19.5.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth movements in non-current provisions for the reporting periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions&#160;for&lt;br/&gt;pensions and&lt;br/&gt;other&#160;post-employment&lt;br/&gt;benefits&lt;br/&gt;(D.19.1.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions&lt;br/&gt;for other&lt;br/&gt;long-term&lt;br/&gt;benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Restructuring&lt;br/&gt;provisions&lt;br/&gt;(D.19.2.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;provisions&lt;br/&gt;(D.19.3.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,276&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;879&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,975&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,998&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(459)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,947&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,024&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,430&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,039&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;844&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,178&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,822&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,214&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;718&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;554&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,776&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,262&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In the case of &#x201c;Provisions for pensions and other post-employment benefits&#x201d;, the &#x201c;Increases in provisions&#x201d; line corresponds to rights vesting in employees during the period, and past service cost; the &#x201c;Provisions utilized&#x201d; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#x201c;Reversals of unutilized provisions&#x201d; line corresponds to plan curtailments, settlements and amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Includes the impact of the April&#160;2021 IFRIC agenda decision on the allocation of benefits to service periods, as described in Note&#160;A.2.1. to the consolidated financial statements for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.19.1. Provisions for pensions and other post-employment benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi offers its employees pension plans and other post-employment benefit plans. The specific features of the plans (benefit formulas, fund investment policy and fund assets held) vary depending on the applicable laws and regulations in each country where the employees work. These employee benefits are accounted for in accordance with IAS&#160;19 (see Note&#160;B.23.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi&#x2019;s pension obligations in four&#160;major countries represented approximately 89% of the total value of the defined-benefit obligation and approximately 88% of the total value of plan assets as of December 31, 2023. The features of the principal defined-benefit plans in each of those four countries are described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;France&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lump-sum retirement benefit plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;All employees working for Sanofi in France are entitled on retirement to a lump-sum payment, the amount of which depends both on their length of service and on the rights guaranteed by collective and internal agreements. The employee&#x2019;s final salary is used in calculating the amount of these lump-sum retirement benefits. These plans represent approximately 39% of Sanofi&#x2019;s total obligation in France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined-benefit pension plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These plans provide benefits from the date of retirement. Employees must fulfil a number of criteria to be eligible for these benefits. All of these plans are now closed. These plans represent approximately&#160;61% of Sanofi&#x2019;s total obligation in France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Germany&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Top-up defined-benefit pension plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The benefits offered under this pension plan are wholly funded by the employer (there are no employee contributions) via a Contractual Trust Agreement (CTA), under which benefits are estimated on the basis of a career average salary. Employees are entitled to receive an annuity under this plan if their salary exceeds the social security ceiling. The amount of the pension is calculated by reference to a range of vesting rates corresponding to salary bands. The plan also includes disability and death benefits. This plan represents approximately 60% of Sanofi&#x2019;s total obligation in Germany.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sanofi-Aventis plus (SAV plus)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A top-up pension plan (SAV plus) replaced a previous top-up defined-benefit plan. New entrants joining the plan after April&#160;1,&#160;2015 contribute to a defined-contribution plan that is partially funded via the company&#x2019;s CTA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;All employees whose salary exceeds the social security ceiling are automatically covered by the plan. The employer&#x2019;s contribution is 14% of the amount by which the employee&#x2019;s salary exceeds the social security ceiling.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Multi-employer plan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Pensionskasse)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This is a defined-benefit plan treated as a defined-contribution plan, in accordance with the accounting policies described in&#160;Note&#160;B.23. Currently, contributions cover the level of annuities. Only the portion relating to the future revaluation of&#160;the&#160;annuities is included in the defined-benefit pension obligation. The obligation relating to this revaluation amounted to&#160;&#x20ac;744 million as of December 31, 2023, versus&#160;&#x20ac;652 million as of December 31, 2022 and &#x20ac;877 million as of December 31, 2021. This plan represents approximately 26% of Sanofi&#x2019;s total defined-benefit obligation in Germany.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined-benefit pension plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the United States, there are two types of defined-benefit plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;&#x201c;qualified&#x201d; plans within the meaning of the Employee Retirement Income Security Act of 1974 (ERISA), which provide guaranteed benefits to eligible employees during retirement, and in the event of death or disability. Employees can elect to receive a reduced annuity, in exchange for an annuity to be paid in the event of their death to a person designated by them. An annuity is also granted under the plan if the employee dies before retirement age. Eligible employees do not pay any contributions. These plans are closed to new entrants, and the vesting of rights for future service periods is partially frozen. These plans represent approximately 59% of Sanofi&#x2019;s total obligation in the United States;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;&#x201c;non-qualified&#x201d; plans within the meaning of ERISA provide top-up retirement benefits to some eligible employees depending on the employee&#x2019;s level of responsibility and subject to a salary cap. These plans represent approximately 14% of Sanofi&#x2019;s total obligation in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Healthcare cover and life insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi companies provide some eligible employees with healthcare cover and life insurance during the retirement period (the company&#x2019;s contributions are capped at a specified level). These plans represent approximately 27% (or &#x20ac;412 million) of Sanofi&#x2019;s total obligation and&#160;3% (or &#x20ac;23 million) of total plan assets in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;United Kingdom&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined-benefit pension plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi operates a number of pension plans in the United Kingdom that reflect past acquisitions. The most significant arrangements are defined-benefit plans that have been closed since October&#160;1, 2015. With effect from that date, employees can no longer pay into these plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Under these defined-benefit plans, an annuity is paid from the retirement date. This annuity is calculated on the basis of the employee&#x2019;s length of service as of September&#160;30, 2015, and of the employee&#x2019;s final salary (or salary on the date he or she leaves Sanofi).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The rates used for the vesting of rights vary from member to member. For most members, rights vest at the rate of 1.25% or 1.50% of final salary for each qualifying year of service giving entitlement. The notional retirement age varies according to the category to which the member belongs, but in most cases retirement is at age 65. Members may choose to retire before or after the notional retirement age (60&#160;years), in which case the amount of the annual pension is adjusted to reflect the revised estimate of the length of the retirement phase. Pensions are usually indexed to the Retail Price Index (RPI). Members paid a fixed-percentage contribution into their pension plan (the percentage varied according to the employee category), and the employer topped up the contribution to the required amount. These plans represent approximately 100% of Sanofi&#x2019;s total obligation in the United Kingdom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For service periods subsequent to October&#160;1, 2015, employees belong to a new defined-contribution plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Actuarial assumptions used to measure Sanofi&#x2019;s obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Actuarial valuations of Sanofi&#x2019;s benefit obligations were computed by management with assistance from external actuaries as of&#160;December 31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Those calculations were based on the following financial and demographic assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(a)(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.95% to 3.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.95% to 3.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.55% to 3.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.55% to 3.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.10%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.10%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;General inflation rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.30%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Pension benefit &lt;br/&gt;indexation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Healthcare cost &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;inflation rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.29%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.50% to 4.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Retirement age&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 65&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 65&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 65&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mortality table&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;TGH/&lt;br/&gt;TGF&lt;br/&gt;05&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Heubeck&lt;br/&gt;RT&lt;br/&gt;2018 G&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RP2012 Proj.&lt;br/&gt;MP2021 White Collar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;SAPS&lt;br/&gt;S3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;TGH/&lt;br/&gt;TGF&lt;br/&gt;05&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Heubeck&lt;br/&gt;RT&lt;br/&gt;2018 G&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RP2012 Proj.&lt;br/&gt;MP2021 White Collar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;SAPS&lt;br/&gt;S3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;TGH/&lt;br/&gt;TGF&lt;br/&gt;05&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Heubeck&lt;br/&gt;RT&lt;br/&gt;2018 G&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RP2012 Proj.&lt;br/&gt;G.&#160;Scale&lt;br/&gt;MP2020 White Collar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;SAPS&lt;br/&gt;S3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;The discount rates used were based on market rates for high quality corporate bonds with a duration close to that of the expected benefit payments under the plans. The benchmarks used to determine discount rates were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;The rate depends on the duration of the plan (0&#160;to 7&#160;years, 7&#160;to 10&#160;years, or more than 10&#160;years).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Inflation for the euro zone is determined using a multi-criterion method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;No post-employment healthcare benefits are provided in France since 2020, Germany and UK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted average duration of obligation for pensions and other long-term benefits in principal countries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the duration of Sanofi&#x2019;s obligations in the principal countries:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted average duration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sensitivity analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the sensitivity of Sanofi&#x2019;s obligations for pensions and other post-employment benefits to changes in key actuarial assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions and other post-employment benefits, &lt;br/&gt;by principal country&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement of defined-benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Change in&lt;br/&gt;assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;-0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;General inflation rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pension benefit indexation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Healthcare cost inflation rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortality table&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;+1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below reconciles the net obligation in respect of Sanofi&#x2019;s pension and other post-employment benefit plans with the amounts recognized in the consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.065%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement of the obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial losses/(gains) due to changes in demographic assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial losses/(gains) due to changes in financial assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial losses/(gains) due to experience adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan amendments, curtailments or settlements not specified in the terms of the plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan settlements specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(503)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation and transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Obligation at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,930&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,651&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,175&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value of plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest income on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Difference between actual return and interest income on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Administration costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan settlements specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan settlements not specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contributions from plan members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employer&#x2019;s contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation and transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value of plan assets at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,993&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,899&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,651&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount shown in the balance sheet:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Effect of asset ceiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount shown in the balance sheet at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,943&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,770&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,539&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amounts recognized in the balance sheet:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pre-funded obligations (see Note D.7.)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Obligations provided for&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount recognized at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,943&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,770&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,539&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Benefit cost for the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(Gains)/losses related to plan amendments, curtailments or settlements not specified in&#160;the&#160;terms&#160;of the plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest (income)/cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contributions from plan members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Administration costs and taxes paid during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense recognized directly in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;168&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;276&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(685)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;361&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These amounts include the impact of applying the April&#160;2021 IFRIC agenda decision on the attribution of benefits to periods of service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;For 2023, this line includes &#x20ac;66&#160;million of assets in the United Kingdom (versus &#x20ac;99&#160;million for 2022 and &#x20ac;220&#160;million for 2021); those amounts are not subject to any asset ceiling, in accordance with IFRIC&#160;14.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Amounts recognized in Other comprehensive income (see Note&#160;D.15.7.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The tables below show Sanofi&#x2019;s net liability in respect of pension plans and other post-employment benefits by geographical region:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Measurement of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Effect of asset ceiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount shown in the balance sheet at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;510&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;703&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;144&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,943&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Measurement of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Effect of asset ceiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount shown in the balance sheet at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;627&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;413&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;686&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;139&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,770&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Measurement of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Effect of asset ceiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount shown in the balance sheet at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;819&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;768&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;972&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,539&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The adoption in April&#160;2023 of pension reforms in France (including the raising of the retirement age from 62&#160;to 64&#160;years) qualifies as a plan amendment within the meaning of IAS&#160;19, and resulted in the recognition of an immaterial amount in the income statement and the balance sheet for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the fair value of plan assets relating to Sanofi&#x2019;s pension and other post-employment plans, split by asset category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Securities quoted in an active market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;84.9&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;84.4&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;86.9&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bonds and similar instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Commodities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15.1&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15.6&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13.1&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance policies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has a long-term objective of maintaining or increasing the extent to which its pension obligations are covered by assets. To this end, Sanofi uses an asset-liability management strategy, matching plan assets to its pension obligations. This policy aims to ensure the best fit between the assets held on the one hand, and the associated liabilities and expected future payments to plan members on the other. To meet this aim, Sanofi operates a risk monitoring and management strategy (mainly focused on interest rate risk and inflation risk), while investing a growing proportion of assets in high-quality bonds with comparable maturities to those of the underlying obligations and in contracts entered into with leading insurance companies to fund certain post-employment benefit obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The tables below show the service cost for Sanofi&#x2019;s pension and other post-employment benefit plans, by geographical region:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Service cost for 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost/(income) including administration costs and taxes paid during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contributions from plan members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) recognized directly in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;55&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;82&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;361&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Service cost for 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost/(income) including administration costs and taxes paid during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contributions from plan members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) recognized directly in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;168&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(382)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;117&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Service cost for 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost/(income) including administration costs and taxes paid during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contributions from plan members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) recognized directly in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;54&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;276&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(685)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of the &#x201c;Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)&#x201d; line in the preceding tables is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.758%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) arising during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Comprising:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains/(losses) &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;on experience adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains/(losses) &lt;br/&gt;on demographic assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains/(losses) &lt;br/&gt;on financial assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Experience adjustments are mainly due to the effect on plan assets of trends in the financial markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The net pre-tax actuarial loss (excluding investments accounted for using the equity method) recognized directly in equity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net pre-tax actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The present value of Sanofi&#x2019;s obligations in respect of pension and other post-employment benefit plans at the end of each reporting period is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of wholly or partially funded obligations in respect of pension and other post-employment benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of unfunded obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,930&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,651&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,175&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The total expense for pensions and other post-employment benefits (&#x20ac;190 million in 2023) is allocated between income statement line items as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating (income)/expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;168&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;276&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The estimated amounts of employer&#x2019;s contributions to plan assets in 2024 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Employer&#x2019;s contributions in 2024 (estimate):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the expected timing of benefit payments under pension and other post-employment benefit plans for future years:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Estimated future benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2029 to 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows estimates as of December 31, 2023 for the timing of future payments in respect of unfunded pension and other post-employment benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than 1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to &lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to &lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Estimated payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.19.2. Restructuring provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows movements in restructuring provisions classified in non-current and current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,233&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,118&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,499&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Classified in non-current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Classified in current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Change in provisions recognized in profit or loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(522)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,132&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,233&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,118&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Classified in non-current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Classified in current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Provisions utilized mainly correspond to payments related to employees affected by separation programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Provisions for employee termination benefits as of December 31, 2023 amounted to &#x20ac;968 million (compared with &#x20ac;1,039&#160;million as of December 31, 2022 and &#x20ac;943 million as of December 31, 2021).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The provisions apply mainly to France, and relate to various voluntary redundancy programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;agreement under the Job Management and Career Paths (GEPP) scheme affecting several French legal entities, signed on&#160;February&#160;28, 2022 and announced in April&#160;2022 as part of the &#x201c;Play to Win&#x201d; strategy. The agreement provides internal transfer and outplacement opportunities for employees whose jobs are undergoing transformation, and also includes an end-of-career paid leave program and an external retraining program. Most of the provisions charged in 2022 relate to this plan, which began to be implemented in 2022. The provisions charged in 2023 reflect adjustments to the job profiles deemed to be "sensitive"; the reversals recognized during 2023 are due mainly to the Borne Law, which raises the retirement age to 64 and hence disqualifies some participants eligible under previous legislation (in light of the maximum period for portage workers);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;collectively-agreed separation programs involving a number of legal entities announced at the end of June&#160;2020 as part of the rollout of the &#x201c;Play to Win&#x201d; strategy; these include an end-of-career paid leave plan and an external retraining program, and were still ongoing during 2023. In addition, Sanofi-Aventis Recherche &amp;amp;&#160;D&#xe9;veloppement (i)&#160;announced a voluntary redundancy program in&#160;2020 in connection with the reorganization of R&amp;amp;D operations in France, which was implemented in&#160;2021, and (ii)&#160;signed a collectively-agreed termination program in&#160;2021 as part of the rollout of the &#x201c;Play to Win&#x201d; strategy; these programs, which cover support functions, include an end-of-career paid leave plan and an end-of-career transition plan;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;programs announced in 2019 relating to (i)&#160;R&amp;amp;D (Sanofi-Aventis Recherche &amp;amp;&#160;D&#xe9;veloppement) and (ii)&#160;sales forces (the&#160;&#x201c;SAF&#160;2019&#x201d; plan implemented by Sanofi-Aventis France);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;collectively-agreed separation programs announced in 2018 relating to the reorganization of support functions (&#x201c;Horizon&#160;2020&#x201d; plan).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The remainder of the provision for France comprises termination benefits associated with previously-announced programs (early retirement plans and end-of-career transition plans).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The provision includes the present values of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;gross annuities for self-funded plans;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;employer&#x2019;s social security charges on early retirement annuities for all plans (outsourced and self-funded); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the levy charged on those annuities under the &#x201c;Fillon&#x201d;&#160;law (only for plans with termination of employment contracts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The average residual portage periods under these plans were 2.22&#160;years, 2.60&#160;years and 1.94&#160;years as of December 31, 2023, 2022 and&#160;2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The main other countries covered by restructuring provisions are Germany, Japan and the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The timing of future termination benefit payments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Benefit payments by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Other countries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;968&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;517&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;362&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Benefit payments by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Other countries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,039&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;374&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;448&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Benefit payments by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Other countries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;943&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;394&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;67&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.19.3. Other provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other provisions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; include provisions for risks and litigation relating to environmental, tax, commercial and product liability matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Environmental risks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Product liability risks, litigation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,776&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,178&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,024&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Provisions for environmental risks relate primarily to contingencies arising from business divestitures, and include remediation costs relating to such environmental risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Identified environmental risks are covered by provisions estimated on the basis of the costs Sanofi believes it will be obliged to meet over a period not exceeding (other than in exceptional cases) 30&#160;years. Sanofi expects that &#x20ac;86 million of those provisions will be utilized in&#160;2024, and &#x20ac;194 million over the period from 2025 through 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As regards greenhouse gas emission quotas, which relate to Sanofi production facilities in France and Ireland, in the absence of specific IFRS pronouncements  Sanofi has adopted the "net liability approach". That involves recognizing a liability at the balance sheet date if actual emissions exceed the quotas held, in accordance with IAS&#160;37 and French GAAP (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plan Comptable G&#xe9;n&#xe9;ral,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; Article&#160;615-1s). Quotas are managed as a production cost, and as such are recognized in inventory at a zero value (if received free of charge) and at acquisition cost (if bought on the market). As of December&#160;31, 2023, no liability was recognized, and quotas valued at &#x20ac;3&#160;million were held in inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Product liability risks, litigation and other&#x201d; mainly comprises provisions for risks relating to product liability (including IBNR provisions as described in Note&#160;B.12.), government investigations, regulatory or antitrust law claims, contingencies arising from business divestitures (other than environmental risks), and remediation costs related to leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The main pending legal and arbitral proceedings and government investigations are described in Note&#160;D.22.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A full risk and litigation assessment is performed with the assistance of Sanofi&#x2019;s legal advisers, and provisions are recorded as required by circumstances in accordance with the principles described in Note&#160;B.12.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.19.4. Non-current income tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-current income tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;amounted to &#x20ac;1,842 million as of December 31, 2023 (versus &#x20ac;1,979 million as of          December 31, 2022 and &#x20ac;2,039 million as of December 31, 2021).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;This line item includes the residual liability due after more than one year arising from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;the estimated tax charge on deemed repatriation attributable to the accumulated earnings of non-US operations (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x20ac;247 million as of December 31, 2023, &#x20ac;459&#160;million as of December 31, 2022 and &#x20ac;576 million as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. The expense was initially recognized in 2018 at an amount of&#160;$1,092&#160;million, and payment is being made over eight years through 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Non-current income tax liabilities include uncertainties over income tax treatments totaling &#x20ac;1,595 million as of                   December 31, 2023, versus &#x20ac;1,520 million as of December 31, 2022 and &#x20ac;1,463 million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A US legal restructuring resulted in a capital loss of &#x20ac;3&#160;billion&#160;recognized in the 2020 final tax filing. One-third of the capital loss has been used against 2020 capital gains and the remaining balance will be eligible to carry back for three years. Due to management&#x2019;s judgement about potential alternative interpretations of the prevailing tax law, no tax benefit has been recognized on this transaction in accordance with IFRIC&#160;23.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.19.5. Current provisions and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Current provisions and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Taxes payable, other than corporate income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring provisions (see Note&#160;D.19.2.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate derivatives (see Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency derivatives (see Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity derivatives (see Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amounts payable for acquisitions of non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Customer contract liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,741&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,021&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,217&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;See Note&#160;A.5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &#x201c;Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;. The year-on-year change in this item between 2022 and 2023 includes revenue of &#x20ac;269&#160;million  recognized in profit or loss during 2023 previously included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer contract liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; as of December&#160;31, 2022, compared with revenue of  &#x20ac;85&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;recognized in profit or loss during 2022 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;previously included in  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer contract liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; as of December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; . No such revenue was recognized in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;&#x201c;Other current liabilities&#x201d; mainly comprises provisions and liabilities for customer rebates and returns; provisions for discounts and rebates granted to healthcare authorities and governmental programs (see Note&#160;D.23.); and the liability payable at each reporting date under the Monoclonal Antibody Alliance with Regeneron.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;As of December 31, 2023 includes &#x20ac;131&#160;million (nominal value: &#x20ac;137 million) for the current liability relating to royalties payable to Sobi on net sales of BEYFORTUS (nirsevimab) in the United States (see Note&#160;C.2.)&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfProvisionsAndOtherLiabilitiesTextBlock>
    <sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-3298">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non current provisions and other non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprises the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,602&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,341&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,721&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes derivative financial instruments: &#x20ac;164&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &#x20ac;232 million as of December 31, 2022, &#x20ac;6 million as of December 31, 2021.&lt;br/&gt;The figure as of December 31, 2023 includes &#x20ac;1,960&#160;million for the liability in respect of royalties payable to Sobi on net sales of BEYFORTUS (nirsevimab) in the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is &#x20ac;1,112&#160;million; the nominal value of payments estimated to be due after more than five years is &#x20ac;2,860 million.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfProvisionsAndOtherNonCurrentLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:NoncurrentProvisions contextRef="c-5" decimals="-6" id="f-3299" unitRef="eur">5262000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-7" decimals="-6" id="f-3300" unitRef="eur">5822000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-8" decimals="-6" id="f-3301" unitRef="eur">6430000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-5" decimals="-6" id="f-3302" unitRef="eur">2340000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-7" decimals="-6" id="f-3303" unitRef="eur">519000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-8" decimals="-6" id="f-3304" unitRef="eur">291000000</ifrs-full:OtherNoncurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-5" decimals="-6" id="f-3305" unitRef="eur">7602000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-7" decimals="-6" id="f-3306" unitRef="eur">6341000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-8" decimals="-6" id="f-3307" unitRef="eur">6721000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-5" decimals="-6" id="f-3308" unitRef="eur">164000000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-7" decimals="-6" id="f-3309" unitRef="eur">232000000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-8" decimals="-6" id="f-3310" unitRef="eur">6000000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-1167" decimals="-6" id="f-3311" unitRef="eur">1960000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-1168" decimals="-6" id="f-3312" unitRef="eur">1112000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-1169" decimals="-6" id="f-3313" unitRef="eur">2860000000</ifrs-full:OtherNoncurrentLiabilities>
    <sny:DisclosureOfNonCurrentProvisionsTableTextBlock contextRef="c-1" id="f-3314">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth movements in non-current provisions for the reporting periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.998%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.000%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions&#160;for&lt;br/&gt;pensions and&lt;br/&gt;other&#160;post-employment&lt;br/&gt;benefits&lt;br/&gt;(D.19.1.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Provisions&lt;br/&gt;for other&lt;br/&gt;long-term&lt;br/&gt;benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Restructuring&lt;br/&gt;provisions&lt;br/&gt;(D.19.2.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;provisions&lt;br/&gt;(D.19.3.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,276&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;879&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,975&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,998&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(459)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,947&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;935&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,024&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,430&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,039&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;844&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;761&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,178&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,822&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increases in provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reversals of unutilized provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest related to employee benefits, and unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains and losses on defined-benefit plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,214&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;718&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;554&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,776&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,262&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;In the case of &#x201c;Provisions for pensions and other post-employment benefits&#x201d;, the &#x201c;Increases in provisions&#x201d; line corresponds to rights vesting in employees during the period, and past service cost; the &#x201c;Provisions utilized&#x201d; line corresponds to contributions paid into pension funds and to beneficiaries; and the&#160;&#x201c;Reversals of unutilized provisions&#x201d; line corresponds to plan curtailments, settlements and amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Includes the impact of the April&#160;2021 IFRIC agenda decision on the allocation of benefits to service periods, as described in Note&#160;A.2.1. to the consolidated financial statements for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfNonCurrentProvisionsTableTextBlock>
    <ifrs-full:NoncurrentProvisions contextRef="c-1170" decimals="-6" id="f-3315" unitRef="eur">3276000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1171" decimals="-6" id="f-3316" unitRef="eur">879000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1172" decimals="-6" id="f-3317" unitRef="eur">868000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1173" decimals="-6" id="f-3318" unitRef="eur">1975000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-19" decimals="-6" id="f-3319" unitRef="eur">6998000000</ifrs-full:NoncurrentProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1174" decimals="-6" id="f-3320" unitRef="eur">-2000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1175" decimals="-6" id="f-3321" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1176" decimals="-6" id="f-3322" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1177" decimals="-6" id="f-3323" unitRef="eur">37000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-10" decimals="-6" id="f-3324" unitRef="eur">35000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1174" decimals="-6" id="f-3325" unitRef="eur">247000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1175" decimals="-6" id="f-3326" unitRef="eur">156000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1176" decimals="-6" id="f-3327" unitRef="eur">67000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1177" decimals="-6" id="f-3328" unitRef="eur">261000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-10" decimals="-6" id="f-3329" unitRef="eur">731000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1174" decimals="-6" id="f-3330" unitRef="eur">222000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1175" decimals="-6" id="f-3331" unitRef="eur">122000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1176" decimals="-6" id="f-3332" unitRef="eur">8000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1177" decimals="-6" id="f-3333" unitRef="eur">107000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-10" decimals="-6" id="f-3334" unitRef="eur">459000000</ifrs-full:ProvisionUsedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1174" decimals="-6" id="f-3335" unitRef="eur">13000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1175" decimals="-6" id="f-3336" unitRef="eur">7000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1176" decimals="-6" id="f-3337" unitRef="eur">35000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1177" decimals="-6" id="f-3338" unitRef="eur">145000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-10" decimals="-6" id="f-3339" unitRef="eur">200000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1174" decimals="-6" id="f-3340" unitRef="eur">-13000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1175" decimals="-6" id="f-3341" unitRef="eur">-3000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1176" decimals="-6" id="f-3342" unitRef="eur">-370000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1177" decimals="-6" id="f-3343" unitRef="eur">-39000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-10" decimals="-6" id="f-3344" unitRef="eur">-425000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1174" decimals="-6" id="f-3345" unitRef="eur">42000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1175" decimals="-6" id="f-3346" unitRef="eur">2000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1176" decimals="-6" id="f-3347" unitRef="eur">0</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1177" decimals="-6" id="f-3348" unitRef="eur">9000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-10" decimals="-6" id="f-3349" unitRef="eur">53000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1174" decimals="-6" id="f-3350" unitRef="eur">80000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1175" decimals="-6" id="f-3351" unitRef="eur">30000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1176" decimals="-6" id="f-3352" unitRef="eur">2000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1177" decimals="-6" id="f-3353" unitRef="eur">33000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-10" decimals="-6" id="f-3354" unitRef="eur">145000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1174" decimals="-6" id="f-3355" unitRef="eur">-448000000</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1175" decimals="-6" id="f-3356" unitRef="eur">0</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1176" decimals="-6" id="f-3357" unitRef="eur">0</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1177" decimals="-6" id="f-3358" unitRef="eur">0</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-10" decimals="-6" id="f-3359" unitRef="eur">-448000000</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <ifrs-full:NoncurrentProvisions contextRef="c-1178" decimals="-6" id="f-3360" unitRef="eur">2947000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1179" decimals="-6" id="f-3361" unitRef="eur">935000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1180" decimals="-6" id="f-3362" unitRef="eur">524000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1181" decimals="-6" id="f-3363" unitRef="eur">2024000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-8" decimals="-6" id="f-3364" unitRef="eur">6430000000</ifrs-full:NoncurrentProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1182" decimals="-6" id="f-3365" unitRef="eur">-96000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1183" decimals="-6" id="f-3366" unitRef="eur">-28000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1184" decimals="-6" id="f-3367" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1185" decimals="-6" id="f-3368" unitRef="eur">-76000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-9" decimals="-6" id="f-3369" unitRef="eur">-200000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1182" decimals="-6" id="f-3370" unitRef="eur">193000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1183" decimals="-6" id="f-3371" unitRef="eur">40000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1184" decimals="-6" id="f-3372" unitRef="eur">521000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1185" decimals="-6" id="f-3373" unitRef="eur">531000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-9" decimals="-6" id="f-3374" unitRef="eur">1285000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1182" decimals="-6" id="f-3375" unitRef="eur">275000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1183" decimals="-6" id="f-3376" unitRef="eur">119000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1184" decimals="-6" id="f-3377" unitRef="eur">12000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1185" decimals="-6" id="f-3378" unitRef="eur">122000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-9" decimals="-6" id="f-3379" unitRef="eur">528000000</ifrs-full:ProvisionUsedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1182" decimals="-6" id="f-3380" unitRef="eur">66000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1183" decimals="-6" id="f-3381" unitRef="eur">20000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1184" decimals="-6" id="f-3382" unitRef="eur">11000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1185" decimals="-6" id="f-3383" unitRef="eur">191000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-9" decimals="-6" id="f-3384" unitRef="eur">288000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1182" decimals="-6" id="f-3385" unitRef="eur">10000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1183" decimals="-6" id="f-3386" unitRef="eur">4000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1184" decimals="-6" id="f-3387" unitRef="eur">-265000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1185" decimals="-6" id="f-3388" unitRef="eur">-23000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-9" decimals="-6" id="f-3389" unitRef="eur">-274000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1182" decimals="-6" id="f-3390" unitRef="eur">43000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1183" decimals="-6" id="f-3391" unitRef="eur">4000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1184" decimals="-6" id="f-3392" unitRef="eur">5000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1185" decimals="-6" id="f-3393" unitRef="eur">12000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-9" decimals="-6" id="f-3394" unitRef="eur">64000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1182" decimals="-6" id="f-3395" unitRef="eur">63000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1183" decimals="-6" id="f-3396" unitRef="eur">28000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1184" decimals="-6" id="f-3397" unitRef="eur">-1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1185" decimals="-6" id="f-3398" unitRef="eur">23000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-9" decimals="-6" id="f-3399" unitRef="eur">113000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1182" decimals="-6" id="f-3400" unitRef="eur">-780000000</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1183" decimals="-6" id="f-3401" unitRef="eur">0</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1184" decimals="-6" id="f-3402" unitRef="eur">0</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1185" decimals="-6" id="f-3403" unitRef="eur">0</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-9" decimals="-6" id="f-3404" unitRef="eur">-780000000</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <ifrs-full:NoncurrentProvisions contextRef="c-1186" decimals="-6" id="f-3405" unitRef="eur">2039000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1187" decimals="-6" id="f-3406" unitRef="eur">844000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1188" decimals="-6" id="f-3407" unitRef="eur">761000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1189" decimals="-6" id="f-3408" unitRef="eur">2178000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-7" decimals="-6" id="f-3409" unitRef="eur">5822000000</ifrs-full:NoncurrentProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1190" decimals="-6" id="f-3410" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1191" decimals="-6" id="f-3411" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1192" decimals="-6" id="f-3412" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1193" decimals="-6" id="f-3413" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions contextRef="c-1" decimals="-6" id="f-3414" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1190" decimals="-6" id="f-3415" unitRef="eur">141000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1191" decimals="-6" id="f-3416" unitRef="eur">185000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1192" decimals="-6" id="f-3417" unitRef="eur">315000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1193" decimals="-6" id="f-3418" unitRef="eur">311000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ChangesInOtherProvisions contextRef="c-1" decimals="-6" id="f-3419" unitRef="eur">952000000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1190" decimals="-6" id="f-3420" unitRef="eur">162000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1191" decimals="-6" id="f-3421" unitRef="eur">107000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1192" decimals="-6" id="f-3422" unitRef="eur">25000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1193" decimals="-6" id="f-3423" unitRef="eur">114000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1" decimals="-6" id="f-3424" unitRef="eur">408000000</ifrs-full:ProvisionUsedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1190" decimals="-6" id="f-3425" unitRef="eur">21000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1191" decimals="-6" id="f-3426" unitRef="eur">190000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1192" decimals="-6" id="f-3427" unitRef="eur">159000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1193" decimals="-6" id="f-3428" unitRef="eur">388000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions contextRef="c-1" decimals="-6" id="f-3429" unitRef="eur">758000000</sny:IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1190" decimals="-6" id="f-3430" unitRef="eur">-1000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1191" decimals="-6" id="f-3431" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1192" decimals="-6" id="f-3432" unitRef="eur">-361000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1193" decimals="-6" id="f-3433" unitRef="eur">-210000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1" decimals="-6" id="f-3434" unitRef="eur">-572000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1190" decimals="-6" id="f-3435" unitRef="eur">70000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1191" decimals="-6" id="f-3436" unitRef="eur">3000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1192" decimals="-6" id="f-3437" unitRef="eur">23000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1193" decimals="-6" id="f-3438" unitRef="eur">24000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount contextRef="c-1" decimals="-6" id="f-3439" unitRef="eur">120000000</sny:NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1190" decimals="-6" id="f-3440" unitRef="eur">-23000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1191" decimals="-6" id="f-3441" unitRef="eur">-17000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1192" decimals="-6" id="f-3442" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1193" decimals="-6" id="f-3443" unitRef="eur">-25000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1" decimals="-6" id="f-3444" unitRef="eur">-65000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1190" decimals="-6" id="f-3445" unitRef="eur">171000000</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1191" decimals="-6" id="f-3446" unitRef="eur">0</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1192" decimals="-6" id="f-3447" unitRef="eur">0</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1193" decimals="-6" id="f-3448" unitRef="eur">0</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <sny:ActuarialGainsAndLossesOnDefinedBenefitPlans contextRef="c-1" decimals="-6" id="f-3449" unitRef="eur">171000000</sny:ActuarialGainsAndLossesOnDefinedBenefitPlans>
    <ifrs-full:NoncurrentProvisions contextRef="c-1194" decimals="-6" id="f-3450" unitRef="eur">2214000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1195" decimals="-6" id="f-3451" unitRef="eur">718000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1196" decimals="-6" id="f-3452" unitRef="eur">554000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1197" decimals="-6" id="f-3453" unitRef="eur">1776000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-5" decimals="-6" id="f-3454" unitRef="eur">5262000000</ifrs-full:NoncurrentProvisions>
    <sny:NumberOfCountriesIncludedInPensionPlans
      contextRef="c-1"
      decimals="INF"
      id="f-3455"
      unitRef="country">4</sny:NumberOfCountriesIncludedInPensionPlans>
    <sny:PensionObligationPercentageToDefinedBenefitLiability contextRef="c-5" decimals="2" id="f-3456" unitRef="number">0.89</sny:PensionObligationPercentageToDefinedBenefitLiability>
    <sny:PensionObligationPercentageToPlanAssets contextRef="c-5" decimals="2" id="f-3457" unitRef="number">0.88</sny:PensionObligationPercentageToPlanAssets>
    <sny:PensionObligationPercentageToDefinedBenefitLiability
      contextRef="c-1198"
      decimals="2"
      id="f-3458"
      unitRef="number">0.39</sny:PensionObligationPercentageToDefinedBenefitLiability>
    <sny:PensionObligationPercentageToDefinedBenefitLiability
      contextRef="c-1199"
      decimals="2"
      id="f-3459"
      unitRef="number">0.61</sny:PensionObligationPercentageToDefinedBenefitLiability>
    <sny:PensionObligationPercentageToDefinedBenefitLiability
      contextRef="c-1200"
      decimals="2"
      id="f-3460"
      unitRef="number">0.60</sny:PensionObligationPercentageToDefinedBenefitLiability>
    <sny:EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling
      contextRef="c-1201"
      decimals="INF"
      id="f-3461"
      unitRef="number">0.14</sny:EmployerContributePercentageOnAmountsExceedingTheSocialSecurityCeiling>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1202" decimals="-6" id="f-3462" unitRef="eur">744000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1203" decimals="-6" id="f-3463" unitRef="eur">652000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1204" decimals="-6" id="f-3464" unitRef="eur">877000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <sny:PensionObligationPercentageToDefinedBenefitLiability
      contextRef="c-1202"
      decimals="2"
      id="f-3465"
      unitRef="number">0.26</sny:PensionObligationPercentageToDefinedBenefitLiability>
    <sny:NumberOfDefinedBenefitPlans
      contextRef="c-1205"
      decimals="INF"
      id="f-3466"
      unitRef="plan">2</sny:NumberOfDefinedBenefitPlans>
    <sny:PensionObligationPercentageToDefinedBenefitLiability
      contextRef="c-1206"
      decimals="2"
      id="f-3467"
      unitRef="number">0.59</sny:PensionObligationPercentageToDefinedBenefitLiability>
    <sny:PensionObligationPercentageToDefinedBenefitLiability
      contextRef="c-1207"
      decimals="2"
      id="f-3468"
      unitRef="number">0.14</sny:PensionObligationPercentageToDefinedBenefitLiability>
    <sny:PensionObligationPercentageToDefinedBenefitLiability
      contextRef="c-1208"
      decimals="2"
      id="f-3469"
      unitRef="number">0.27</sny:PensionObligationPercentageToDefinedBenefitLiability>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1208" decimals="-6" id="f-3470" unitRef="eur">412000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <sny:PensionObligationPercentageToPlanAssets
      contextRef="c-1209"
      decimals="2"
      id="f-3471"
      unitRef="number">0.03</sny:PensionObligationPercentageToPlanAssets>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1209" decimals="-6" id="f-3472" unitRef="eur">23000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <sny:DefinedBenefitPlansVestingRightsPercentage
      contextRef="c-1210"
      decimals="INF"
      id="f-3473"
      unitRef="number">0.0125</sny:DefinedBenefitPlansVestingRightsPercentage>
    <sny:DefinedBenefitPlansVestingRightsPercentage
      contextRef="c-1211"
      decimals="INF"
      id="f-3474"
      unitRef="number">0.0150</sny:DefinedBenefitPlansVestingRightsPercentage>
    <sny:RetirementAge
      contextRef="c-1212"
      decimals="INF"
      id="f-3475"
      unitRef="age">65</sny:RetirementAge>
    <sny:NotionalRetirementAge
      contextRef="c-1212"
      decimals="INF"
      id="f-3476"
      unitRef="age">60</sny:NotionalRetirementAge>
    <sny:PensionObligationPercentageToDefinedBenefitLiability
      contextRef="c-1213"
      decimals="INF"
      id="f-3477"
      unitRef="number">1</sny:PensionObligationPercentageToDefinedBenefitLiability>
    <sny:DisclosureOfActuarialAssumptionsTableTextBlock contextRef="c-1" id="f-3478">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Those calculations were based on the following financial and demographic assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(a)(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.95% to 3.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.95% to 3.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.55% to 3.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.55% to 3.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.10%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.10%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;General inflation rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.30%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Pension benefit &lt;br/&gt;indexation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Healthcare cost &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;inflation rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.29%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.50% to 4.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Retirement age&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 65&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 65&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;to 65&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mortality table&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;TGH/&lt;br/&gt;TGF&lt;br/&gt;05&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Heubeck&lt;br/&gt;RT&lt;br/&gt;2018 G&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RP2012 Proj.&lt;br/&gt;MP2021 White Collar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;SAPS&lt;br/&gt;S3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;TGH/&lt;br/&gt;TGF&lt;br/&gt;05&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Heubeck&lt;br/&gt;RT&lt;br/&gt;2018 G&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RP2012 Proj.&lt;br/&gt;MP2021 White Collar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;SAPS&lt;br/&gt;S3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;TGH/&lt;br/&gt;TGF&lt;br/&gt;05&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Heubeck&lt;br/&gt;RT&lt;br/&gt;2018 G&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RP2012 Proj.&lt;br/&gt;G.&#160;Scale&lt;br/&gt;MP2020 White Collar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;SAPS&lt;br/&gt;S3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;The discount rates used were based on market rates for high quality corporate bonds with a duration close to that of the expected benefit payments under the plans. The benchmarks used to determine discount rates were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;The rate depends on the duration of the plan (0&#160;to 7&#160;years, 7&#160;to 10&#160;years, or more than 10&#160;years).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Inflation for the euro zone is determined using a multi-criterion method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;No post-employment healthcare benefits are provided in France since 2020, Germany and UK.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfActuarialAssumptionsTableTextBlock>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1214"
      decimals="4"
      id="f-3479"
      unitRef="number">0.0295</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1215"
      decimals="4"
      id="f-3480"
      unitRef="number">0.0315</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1216"
      decimals="4"
      id="f-3481"
      unitRef="number">0.0295</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1217"
      decimals="4"
      id="f-3482"
      unitRef="number">0.0315</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1218"
      decimals="4"
      id="f-3483"
      unitRef="number">0.0475</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1219"
      decimals="4"
      id="f-3484"
      unitRef="number">0.0450</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1220"
      decimals="4"
      id="f-3485"
      unitRef="number">0.0355</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1221"
      decimals="4"
      id="f-3486"
      unitRef="number">0.0375</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1222"
      decimals="4"
      id="f-3487"
      unitRef="number">0.0355</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1223"
      decimals="4"
      id="f-3488"
      unitRef="number">0.0375</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1224"
      decimals="4"
      id="f-3489"
      unitRef="number">0.0490</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1225"
      decimals="4"
      id="f-3490"
      unitRef="number">0.0475</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1226"
      decimals="4"
      id="f-3491"
      unitRef="number">0.0010</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1227"
      decimals="4"
      id="f-3492"
      unitRef="number">0.0110</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1228"
      decimals="4"
      id="f-3493"
      unitRef="number">0.0010</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1229"
      decimals="4"
      id="f-3494"
      unitRef="number">0.0110</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1230"
      decimals="4"
      id="f-3495"
      unitRef="number">0.0270</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="c-1231"
      decimals="4"
      id="f-3496"
      unitRef="number">0.0190</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="c-1232"
      decimals="4"
      id="f-3497"
      unitRef="number">0.0220</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="c-1233"
      decimals="4"
      id="f-3498"
      unitRef="number">0.0220</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="c-1219"
      decimals="4"
      id="f-3499"
      unitRef="number">0.0305</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="c-1234"
      decimals="4"
      id="f-3500"
      unitRef="number">0.0250</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="c-1235"
      decimals="4"
      id="f-3501"
      unitRef="number">0.0250</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="c-1225"
      decimals="4"
      id="f-3502"
      unitRef="number">0.0325</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="c-1236"
      decimals="4"
      id="f-3503"
      unitRef="number">0.0195</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="c-1237"
      decimals="4"
      id="f-3504"
      unitRef="number">0.0195</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
      contextRef="c-1231"
      decimals="4"
      id="f-3505"
      unitRef="number">0.0330</ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="c-1232"
      decimals="4"
      id="f-3506"
      unitRef="number">0.0220</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="c-1233"
      decimals="4"
      id="f-3507"
      unitRef="number">0.0220</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="c-1219"
      decimals="4"
      id="f-3508"
      unitRef="number">0.0290</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="c-1234"
      decimals="4"
      id="f-3509"
      unitRef="number">0.0250</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="c-1235"
      decimals="4"
      id="f-3510"
      unitRef="number">0.0250</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="c-1225"
      decimals="4"
      id="f-3511"
      unitRef="number">0.0300</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="c-1226"
      decimals="4"
      id="f-3512"
      unitRef="number">0.0195</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="c-1237"
      decimals="4"
      id="f-3513"
      unitRef="number">0.0195</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="c-1231"
      decimals="4"
      id="f-3514"
      unitRef="number">0.0315</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates
      contextRef="c-1238"
      decimals="4"
      id="f-3515"
      unitRef="number">0.0400</ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates>
    <ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates
      contextRef="c-1239"
      decimals="4"
      id="f-3516"
      unitRef="number">0.0975</ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates>
    <ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates
      contextRef="c-1240"
      decimals="4"
      id="f-3517"
      unitRef="number">0.0329</ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates>
    <ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates
      contextRef="c-1241"
      decimals="4"
      id="f-3518"
      unitRef="number">0.0656</ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates>
    <ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates
      contextRef="c-1242"
      decimals="4"
      id="f-3519"
      unitRef="number">0.0350</ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates>
    <ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates
      contextRef="c-1243"
      decimals="4"
      id="f-3520"
      unitRef="number">0.0450</ifrs-full:ActuarialAssumptionOfMedicalCostTrendRates>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1244" id="f-3521">P62Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1245" id="f-3522">P67Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1246" id="f-3523">P63Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1247" id="f-3524">P55Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1248" id="f-3525">P70Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1210" id="f-3526">P60Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1211" id="f-3527">P65Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1249" id="f-3528">P62Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1250" id="f-3529">P67Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1251" id="f-3530">P63Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1252" id="f-3531">P55Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1253" id="f-3532">P70Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1254" id="f-3533">P60Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1255" id="f-3534">P65Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1256" id="f-3535">P62Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1257" id="f-3536">P67Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1258" id="f-3537">P62Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1259" id="f-3538">P55Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1260" id="f-3539">P70Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1261" id="f-3540">P60Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019 contextRef="c-1262" id="f-3541">P65Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1263" id="f-3542">P0Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1264" id="f-3543">P7Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1265" id="f-3544">P7Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1266" id="f-3545">P10Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1" id="f-3546">P10Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <sny:DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock contextRef="c-1" id="f-3547">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the duration of Sanofi&#x2019;s obligations in the principal countries:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted average duration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfWeightedAverageDurationOfDefinedBenefitObligationTableTextBlock>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1267" id="f-3548">P10Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1246" id="f-3549">P12Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1205" id="f-3550">P11Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1212" id="f-3551">P13Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1268" id="f-3552">P10Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1251" id="f-3553">P12Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1269" id="f-3554">P11Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1270" id="f-3555">P13Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1271" id="f-3556">P12Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1258" id="f-3557">P16Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1272" id="f-3558">P15Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019 contextRef="c-1273" id="f-3559">P17Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory contextRef="c-1" id="f-3560">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the sensitivity of Sanofi&#x2019;s obligations for pensions and other post-employment benefits to changes in key actuarial assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions and other post-employment benefits, &lt;br/&gt;by principal country&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement of defined-benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Change in&lt;br/&gt;assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;-0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;General inflation rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pension benefit indexation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Healthcare cost inflation rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mortality table&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;+1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;+19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="c-1274"
      decimals="INF"
      id="f-3561"
      unitRef="number">0.0050</ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1275" decimals="-6" id="f-3562" unitRef="eur">56000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1276" decimals="-6" id="f-3563" unitRef="eur">170000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1277" decimals="-6" id="f-3564" unitRef="eur">78000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1278" decimals="-6" id="f-3565" unitRef="eur">42000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-1279"
      decimals="INF"
      id="f-3566"
      unitRef="number">0.0050</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1280" decimals="-6" id="f-3567" unitRef="eur">40000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1281" decimals="-6" id="f-3568" unitRef="eur">220000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1282" decimals="-6" id="f-3569" unitRef="eur">0</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1283" decimals="-6" id="f-3570" unitRef="eur">43000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-1284"
      decimals="INF"
      id="f-3571"
      unitRef="number">0.0050</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1285" decimals="-6" id="f-3572" unitRef="eur">41000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1286" decimals="-6" id="f-3573" unitRef="eur">216000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1287" decimals="-6" id="f-3574" unitRef="eur">0</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1288" decimals="-6" id="f-3575" unitRef="eur">20000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="c-1289"
      decimals="INF"
      id="f-3576"
      unitRef="number">0.0050</ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1290" decimals="-6" id="f-3577" unitRef="eur">5000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1291" decimals="-6" id="f-3578" unitRef="eur">0</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1292" decimals="-6" id="f-3579" unitRef="eur">5000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1293" decimals="-6" id="f-3580" unitRef="eur">43000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1294" decimals="-6" id="f-3581" unitRef="eur">38000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1295" decimals="-6" id="f-3582" unitRef="eur">53000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1296" decimals="-6" id="f-3583" unitRef="eur">25000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption contextRef="c-1297" decimals="-6" id="f-3584" unitRef="eur">19000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <sny:DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock contextRef="c-1" id="f-3585">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below reconciles the net obligation in respect of Sanofi&#x2019;s pension and other post-employment benefit plans with the amounts recognized in the consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.065%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Measurement of the obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial losses/(gains) due to changes in demographic assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial losses/(gains) due to changes in financial assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(210)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial losses/(gains) due to experience adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan amendments, curtailments or settlements not specified in the terms of the plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan settlements specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(503)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation and transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Obligation at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,930&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,651&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,175&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value of plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest income on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Difference between actual return and interest income on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Administration costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan settlements specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Plan settlements not specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contributions from plan members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employer&#x2019;s contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation and transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value of plan assets at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,993&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,899&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,651&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount shown in the balance sheet:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Effect of asset ceiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount shown in the balance sheet at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,943&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,770&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,539&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amounts recognized in the balance sheet:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Pre-funded obligations (see Note D.7.)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Obligations provided for&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount recognized at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,943&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,770&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,539&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Benefit cost for the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(Gains)/losses related to plan amendments, curtailments or settlements not specified in&#160;the&#160;terms&#160;of the plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest (income)/cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contributions from plan members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Administration costs and taxes paid during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense recognized directly in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;168&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;276&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(685)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;361&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These amounts include the impact of applying the April&#160;2021 IFRIC agenda decision on the attribution of benefits to periods of service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;For 2023, this line includes &#x20ac;66&#160;million of assets in the United Kingdom (versus &#x20ac;99&#160;million for 2022 and &#x20ac;220&#160;million for 2021); those amounts are not subject to any asset ceiling, in accordance with IFRIC&#160;14.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Amounts recognized in Other comprehensive income (see Note&#160;D.15.7.).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfNetDefinedBenefitLiabilityAssetsExplanatoryTableTextBlock>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1298" decimals="-6" id="f-3586" unitRef="eur">8651000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1299" decimals="-6" id="f-3587" unitRef="eur">12175000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1300" decimals="-6" id="f-3588" unitRef="eur">12456000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1301" decimals="-6" id="f-3589" unitRef="eur">140000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1302" decimals="-6" id="f-3590" unitRef="eur">193000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1303" decimals="-6" id="f-3591" unitRef="eur">227000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="c-1301" decimals="-6" id="f-3592" unitRef="eur">346000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="c-1302" decimals="-6" id="f-3593" unitRef="eur">206000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="c-1303" decimals="-6" id="f-3594" unitRef="eur">148000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1301" decimals="-6" id="f-3595" unitRef="eur">34000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1302" decimals="-6" id="f-3596" unitRef="eur">219000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1303" decimals="-6" id="f-3597" unitRef="eur">162000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1301" decimals="-6" id="f-3598" unitRef="eur">-157000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1302" decimals="-6" id="f-3599" unitRef="eur">3006000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1303" decimals="-6" id="f-3600" unitRef="eur">210000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset contextRef="c-1301" decimals="-6" id="f-3601" unitRef="eur">-256000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset contextRef="c-1302" decimals="-6" id="f-3602" unitRef="eur">-177000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset contextRef="c-1303" decimals="-6" id="f-3603" unitRef="eur">120000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan contextRef="c-1301" decimals="-6" id="f-3604" unitRef="eur">36000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan contextRef="c-1302" decimals="-6" id="f-3605" unitRef="eur">229000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan contextRef="c-1303" decimals="-6" id="f-3606" unitRef="eur">4000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset contextRef="c-1301" decimals="-6" id="f-3607" unitRef="eur">40000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset contextRef="c-1302" decimals="-6" id="f-3608" unitRef="eur">84000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset contextRef="c-1303" decimals="-6" id="f-3609" unitRef="eur">66000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:BenefitsPaidOrPayable contextRef="c-1301" decimals="-6" id="f-3610" unitRef="eur">483000000</ifrs-full:BenefitsPaidOrPayable>
    <ifrs-full:BenefitsPaidOrPayable contextRef="c-1302" decimals="-6" id="f-3611" unitRef="eur">463000000</ifrs-full:BenefitsPaidOrPayable>
    <ifrs-full:BenefitsPaidOrPayable contextRef="c-1303" decimals="-6" id="f-3612" unitRef="eur">503000000</ifrs-full:BenefitsPaidOrPayable>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset contextRef="c-1301" decimals="-6" id="f-3613" unitRef="eur">-14000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset contextRef="c-1302" decimals="-6" id="f-3614" unitRef="eur">-114000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset contextRef="c-1303" decimals="-6" id="f-3615" unitRef="eur">-8000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="c-1301" decimals="-6" id="f-3616" unitRef="eur">-13000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="c-1302" decimals="-6" id="f-3617" unitRef="eur">15000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="c-1303" decimals="-6" id="f-3618" unitRef="eur">417000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1304" decimals="-6" id="f-3619" unitRef="eur">8930000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1298" decimals="-6" id="f-3620" unitRef="eur">8651000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1299" decimals="-6" id="f-3621" unitRef="eur">12175000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1305" decimals="-6" id="f-3622" unitRef="eur">-6899000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1306" decimals="-6" id="f-3623" unitRef="eur">-9651000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1307" decimals="-6" id="f-3624" unitRef="eur">-9358000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="c-1308" decimals="-6" id="f-3625" unitRef="eur">-276000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="c-1309" decimals="-6" id="f-3626" unitRef="eur">-163000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="c-1310" decimals="-6" id="f-3627" unitRef="eur">-106000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset contextRef="c-1308" decimals="-6" id="f-3628" unitRef="eur">197000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset contextRef="c-1309" decimals="-6" id="f-3629" unitRef="eur">-2398000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset contextRef="c-1310" decimals="-6" id="f-3630" unitRef="eur">207000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod contextRef="c-1308" decimals="-6" id="f-3631" unitRef="eur">-7000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod contextRef="c-1309" decimals="-6" id="f-3632" unitRef="eur">-6000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod contextRef="c-1310" decimals="-6" id="f-3633" unitRef="eur">-7000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset contextRef="c-1308" decimals="-6" id="f-3634" unitRef="eur">-40000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset contextRef="c-1309" decimals="-6" id="f-3635" unitRef="eur">-84000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset contextRef="c-1310" decimals="-6" id="f-3636" unitRef="eur">-66000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPaymentsInRespectOfSettlementsSpecifiedInTheTermsOfThePlanNetDefinedBenefitLiabilityAsset>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan contextRef="c-1308" decimals="-6" id="f-3637" unitRef="eur">-17000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan contextRef="c-1309" decimals="-6" id="f-3638" unitRef="eur">-161000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan contextRef="c-1310" decimals="-6" id="f-3639" unitRef="eur">-9000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1308" decimals="-6" id="f-3640" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1309" decimals="-6" id="f-3641" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1310" decimals="-6" id="f-3642" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset contextRef="c-1308" decimals="-6" id="f-3643" unitRef="eur">122000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset contextRef="c-1309" decimals="-6" id="f-3644" unitRef="eur">238000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset contextRef="c-1310" decimals="-6" id="f-3645" unitRef="eur">176000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="c-1308" decimals="-6" id="f-3646" unitRef="eur">-446000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="c-1309" decimals="-6" id="f-3647" unitRef="eur">-426000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset contextRef="c-1310" decimals="-6" id="f-3648" unitRef="eur">-458000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset contextRef="c-1308" decimals="-6" id="f-3649" unitRef="eur">8000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset contextRef="c-1309" decimals="-6" id="f-3650" unitRef="eur">32000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset contextRef="c-1310" decimals="-6" id="f-3651" unitRef="eur">6000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="c-1308" decimals="-6" id="f-3652" unitRef="eur">-11000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="c-1309" decimals="-6" id="f-3653" unitRef="eur">52000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset contextRef="c-1310" decimals="-6" id="f-3654" unitRef="eur">-344000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1311" decimals="-6" id="f-3655" unitRef="eur">-6993000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1305" decimals="-6" id="f-3656" unitRef="eur">-6899000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1306" decimals="-6" id="f-3657" unitRef="eur">-9651000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan contextRef="c-1312" decimals="-6" id="f-3658" unitRef="eur">1937000000</ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan contextRef="c-1313" decimals="-6" id="f-3659" unitRef="eur">1752000000</ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan contextRef="c-1314" decimals="-6" id="f-3660" unitRef="eur">2524000000</ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1315" decimals="-6" id="f-3661" unitRef="eur">6000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1316" decimals="-6" id="f-3662" unitRef="eur">18000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1317" decimals="-6" id="f-3663" unitRef="eur">15000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1312" decimals="-6" id="f-3664" unitRef="eur">1943000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1313" decimals="-6" id="f-3665" unitRef="eur">1770000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1314" decimals="-6" id="f-3666" unitRef="eur">2539000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <sny:PreFundedPensionObligations contextRef="c-1312" decimals="-6" id="f-3667" unitRef="eur">271000000</sny:PreFundedPensionObligations>
    <sny:PreFundedPensionObligations contextRef="c-1313" decimals="-6" id="f-3668" unitRef="eur">269000000</sny:PreFundedPensionObligations>
    <sny:PreFundedPensionObligations contextRef="c-1314" decimals="-6" id="f-3669" unitRef="eur">408000000</sny:PreFundedPensionObligations>
    <ifrs-full:NoncurrentProvisions contextRef="c-1318" decimals="-6" id="f-3670" unitRef="eur">2214000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1319" decimals="-6" id="f-3671" unitRef="eur">2039000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-1320" decimals="-6" id="f-3672" unitRef="eur">2947000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1312" decimals="-6" id="f-3673" unitRef="eur">1943000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1313" decimals="-6" id="f-3674" unitRef="eur">1770000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1314" decimals="-6" id="f-3675" unitRef="eur">2539000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1321" decimals="-6" id="f-3676" unitRef="eur">140000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1322" decimals="-6" id="f-3677" unitRef="eur">193000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1323" decimals="-6" id="f-3678" unitRef="eur">227000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan contextRef="c-1321" decimals="-6" id="f-3679" unitRef="eur">22000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan contextRef="c-1322" decimals="-6" id="f-3680" unitRef="eur">68000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan contextRef="c-1323" decimals="-6" id="f-3681" unitRef="eur">-5000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromPlanAmendmentsCurtailmentsOrSettlementsNotSpecifiedInTheTermsOfThePlan>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="c-1321" decimals="-6" id="f-3682" unitRef="eur">71000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="c-1322" decimals="-6" id="f-3683" unitRef="eur">43000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset contextRef="c-1323" decimals="-6" id="f-3684" unitRef="eur">42000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1321" decimals="-6" id="f-3685" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1322" decimals="-6" id="f-3686" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1323" decimals="-6" id="f-3687" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod contextRef="c-1321" decimals="-6" id="f-3688" unitRef="eur">-7000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod contextRef="c-1322" decimals="-6" id="f-3689" unitRef="eur">-6000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod contextRef="c-1323" decimals="-6" id="f-3690" unitRef="eur">-7000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsAndTaxesPaidDuringThePeriod>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1321" decimals="-6" id="f-3691" unitRef="eur">190000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1322" decimals="-6" id="f-3692" unitRef="eur">168000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1323" decimals="-6" id="f-3693" unitRef="eur">276000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1321" decimals="-6" id="f-3694" unitRef="eur">171000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1322" decimals="-6" id="f-3695" unitRef="eur">-650000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1323" decimals="-6" id="f-3696" unitRef="eur">-685000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <sny:EmployeeBenefitsExpenseGain contextRef="c-1321" decimals="-6" id="f-3697" unitRef="eur">361000000</sny:EmployeeBenefitsExpenseGain>
    <sny:EmployeeBenefitsExpenseGain contextRef="c-1322" decimals="-6" id="f-3698" unitRef="eur">-482000000</sny:EmployeeBenefitsExpenseGain>
    <sny:EmployeeBenefitsExpenseGain contextRef="c-1323" decimals="-6" id="f-3699" unitRef="eur">-409000000</sny:EmployeeBenefitsExpenseGain>
    <sny:PreFundedPensionObligations contextRef="c-1324" decimals="-6" id="f-3700" unitRef="eur">66000000</sny:PreFundedPensionObligations>
    <sny:PreFundedPensionObligations contextRef="c-1325" decimals="-6" id="f-3701" unitRef="eur">99000000</sny:PreFundedPensionObligations>
    <sny:PreFundedPensionObligations contextRef="c-1326" decimals="-6" id="f-3702" unitRef="eur">220000000</sny:PreFundedPensionObligations>
    <sny:DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock contextRef="c-1" id="f-3703">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The tables below show Sanofi&#x2019;s net liability in respect of pension plans and other post-employment benefits by geographical region:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Measurement of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Effect of asset ceiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount shown in the balance sheet at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;510&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;703&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;144&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,943&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Measurement of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Effect of asset ceiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount shown in the balance sheet at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;627&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;413&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;686&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;139&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,770&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Measurement of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Effect of asset ceiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amount shown in the balance sheet at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;819&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;768&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;972&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(215)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,539&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfNetLiabilityInRespectOfPensionPlansAndOtherPostEmploymentBenefitsByGeographicalRegionTableTextBlock>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1327" decimals="-6" id="f-3704" unitRef="eur">1322000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1328" decimals="-6" id="f-3705" unitRef="eur">2911000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1329" decimals="-6" id="f-3706" unitRef="eur">1528000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1324" decimals="-6" id="f-3707" unitRef="eur">2174000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1330" decimals="-6" id="f-3708" unitRef="eur">995000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1312" decimals="-6" id="f-3709" unitRef="eur">8930000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1327" decimals="-6" id="f-3710" unitRef="eur">675000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1328" decimals="-6" id="f-3711" unitRef="eur">2401000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1329" decimals="-6" id="f-3712" unitRef="eur">825000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1324" decimals="-6" id="f-3713" unitRef="eur">2235000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1330" decimals="-6" id="f-3714" unitRef="eur">857000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1312" decimals="-6" id="f-3715" unitRef="eur">6993000000</ifrs-full:PlanAssetsAtFairValue>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1327" decimals="-6" id="f-3716" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1328" decimals="-6" id="f-3717" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1329" decimals="-6" id="f-3718" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1324" decimals="-6" id="f-3719" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1330" decimals="-6" id="f-3720" unitRef="eur">-6000000</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1312" decimals="-6" id="f-3721" unitRef="eur">-6000000</sny:PlanAssetsEffectOfAssetCeiling>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1327" decimals="-6" id="f-3722" unitRef="eur">647000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1328" decimals="-6" id="f-3723" unitRef="eur">510000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1329" decimals="-6" id="f-3724" unitRef="eur">703000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1324" decimals="-6" id="f-3725" unitRef="eur">-61000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1330" decimals="-6" id="f-3726" unitRef="eur">144000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1312" decimals="-6" id="f-3727" unitRef="eur">1943000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1331" decimals="-6" id="f-3728" unitRef="eur">1324000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1332" decimals="-6" id="f-3729" unitRef="eur">2730000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1333" decimals="-6" id="f-3730" unitRef="eur">1546000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1325" decimals="-6" id="f-3731" unitRef="eur">2080000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1334" decimals="-6" id="f-3732" unitRef="eur">971000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1313" decimals="-6" id="f-3733" unitRef="eur">8651000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1331" decimals="-6" id="f-3734" unitRef="eur">697000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1332" decimals="-6" id="f-3735" unitRef="eur">2317000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1333" decimals="-6" id="f-3736" unitRef="eur">860000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1325" decimals="-6" id="f-3737" unitRef="eur">2175000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1334" decimals="-6" id="f-3738" unitRef="eur">850000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1313" decimals="-6" id="f-3739" unitRef="eur">6899000000</ifrs-full:PlanAssetsAtFairValue>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1331" decimals="-6" id="f-3740" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1332" decimals="-6" id="f-3741" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1333" decimals="-6" id="f-3742" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1325" decimals="-6" id="f-3743" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1334" decimals="-6" id="f-3744" unitRef="eur">-18000000</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1313" decimals="-6" id="f-3745" unitRef="eur">-18000000</sny:PlanAssetsEffectOfAssetCeiling>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1331" decimals="-6" id="f-3746" unitRef="eur">627000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1332" decimals="-6" id="f-3747" unitRef="eur">413000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1333" decimals="-6" id="f-3748" unitRef="eur">686000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1325" decimals="-6" id="f-3749" unitRef="eur">-95000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1334" decimals="-6" id="f-3750" unitRef="eur">139000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1313" decimals="-6" id="f-3751" unitRef="eur">1770000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1335" decimals="-6" id="f-3752" unitRef="eur">1657000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1336" decimals="-6" id="f-3753" unitRef="eur">3576000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1337" decimals="-6" id="f-3754" unitRef="eur">2099000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1326" decimals="-6" id="f-3755" unitRef="eur">3414000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1338" decimals="-6" id="f-3756" unitRef="eur">1429000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1314" decimals="-6" id="f-3757" unitRef="eur">12175000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1335" decimals="-6" id="f-3758" unitRef="eur">838000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1336" decimals="-6" id="f-3759" unitRef="eur">2808000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1337" decimals="-6" id="f-3760" unitRef="eur">1127000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1326" decimals="-6" id="f-3761" unitRef="eur">3629000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1338" decimals="-6" id="f-3762" unitRef="eur">1249000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue contextRef="c-1314" decimals="-6" id="f-3763" unitRef="eur">9651000000</ifrs-full:PlanAssetsAtFairValue>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1335" decimals="-6" id="f-3764" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1336" decimals="-6" id="f-3765" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1337" decimals="-6" id="f-3766" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1326" decimals="-6" id="f-3767" unitRef="eur">0</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1338" decimals="-6" id="f-3768" unitRef="eur">-15000000</sny:PlanAssetsEffectOfAssetCeiling>
    <sny:PlanAssetsEffectOfAssetCeiling contextRef="c-1314" decimals="-6" id="f-3769" unitRef="eur">-15000000</sny:PlanAssetsEffectOfAssetCeiling>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1335" decimals="-6" id="f-3770" unitRef="eur">819000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1336" decimals="-6" id="f-3771" unitRef="eur">768000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1337" decimals="-6" id="f-3772" unitRef="eur">972000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1326" decimals="-6" id="f-3773" unitRef="eur">-215000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1338" decimals="-6" id="f-3774" unitRef="eur">195000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1314" decimals="-6" id="f-3775" unitRef="eur">2539000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory contextRef="c-1" id="f-3776">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the fair value of plan assets relating to Sanofi&#x2019;s pension and other post-employment plans, split by asset category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Securities quoted in an active market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;84.9&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;84.4&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;86.9&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bonds and similar instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Real estate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Commodities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15.1&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15.6&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13.1&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance policies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket contextRef="c-5" decimals="3" id="f-3777" unitRef="number">0.849</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket contextRef="c-7" decimals="3" id="f-3778" unitRef="number">0.844</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket contextRef="c-8" decimals="3" id="f-3779" unitRef="number">0.869</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1339"
      decimals="3"
      id="f-3780"
      unitRef="number">0.008</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1340"
      decimals="3"
      id="f-3781"
      unitRef="number">0.007</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1341"
      decimals="3"
      id="f-3782"
      unitRef="number">0.007</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1342"
      decimals="3"
      id="f-3783"
      unitRef="number">0.223</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1343"
      decimals="3"
      id="f-3784"
      unitRef="number">0.217</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1344"
      decimals="3"
      id="f-3785"
      unitRef="number">0.250</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1345"
      decimals="3"
      id="f-3786"
      unitRef="number">0.543</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1346"
      decimals="3"
      id="f-3787"
      unitRef="number">0.524</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1347"
      decimals="3"
      id="f-3788"
      unitRef="number">0.538</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1348"
      decimals="3"
      id="f-3789"
      unitRef="number">0.034</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1349"
      decimals="3"
      id="f-3790"
      unitRef="number">0.040</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1350"
      decimals="3"
      id="f-3791"
      unitRef="number">0.040</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1351"
      decimals="3"
      id="f-3792"
      unitRef="number">0</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1352"
      decimals="3"
      id="f-3793"
      unitRef="number">0.001</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1353"
      decimals="3"
      id="f-3794"
      unitRef="number">0</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1354"
      decimals="3"
      id="f-3795"
      unitRef="number">0.009</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1355"
      decimals="3"
      id="f-3796"
      unitRef="number">0.009</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1356"
      decimals="3"
      id="f-3797"
      unitRef="number">0.010</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1357"
      decimals="3"
      id="f-3798"
      unitRef="number">0.032</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1358"
      decimals="3"
      id="f-3799"
      unitRef="number">0.046</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket
      contextRef="c-1359"
      decimals="3"
      id="f-3800"
      unitRef="number">0.024</sny:PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket>
    <sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities contextRef="c-5" decimals="3" id="f-3801" unitRef="number">0.151</sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities>
    <sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities contextRef="c-7" decimals="3" id="f-3802" unitRef="number">0.156</sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities>
    <sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities contextRef="c-8" decimals="3" id="f-3803" unitRef="number">0.131</sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities>
    <sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities
      contextRef="c-1360"
      decimals="3"
      id="f-3804"
      unitRef="number">0</sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities>
    <sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities
      contextRef="c-1361"
      decimals="3"
      id="f-3805"
      unitRef="number">0</sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities>
    <sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities
      contextRef="c-1362"
      decimals="3"
      id="f-3806"
      unitRef="number">0</sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities>
    <sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities
      contextRef="c-1363"
      decimals="3"
      id="f-3807"
      unitRef="number">0.151</sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities>
    <sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities
      contextRef="c-1364"
      decimals="3"
      id="f-3808"
      unitRef="number">0.156</sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities>
    <sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities
      contextRef="c-1365"
      decimals="3"
      id="f-3809"
      unitRef="number">0.131</sny:PercentageContributedToFairValueOfPlanAssetsOtherSecurities>
    <sny:PercentageContributedToFairValueOfPlanAssets
      contextRef="c-5"
      decimals="INF"
      id="f-3810"
      unitRef="number">1.000</sny:PercentageContributedToFairValueOfPlanAssets>
    <sny:PercentageContributedToFairValueOfPlanAssets
      contextRef="c-7"
      decimals="INF"
      id="f-3811"
      unitRef="number">1.000</sny:PercentageContributedToFairValueOfPlanAssets>
    <sny:PercentageContributedToFairValueOfPlanAssets
      contextRef="c-8"
      decimals="INF"
      id="f-3812"
      unitRef="number">1.000</sny:PercentageContributedToFairValueOfPlanAssets>
    <sny:DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock contextRef="c-1" id="f-3813">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The tables below show the service cost for Sanofi&#x2019;s pension and other post-employment benefit plans, by geographical region:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Service cost for 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost/(income) including administration costs and taxes paid during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contributions from plan members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) recognized directly in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;55&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;82&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;361&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Service cost for 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost/(income) including administration costs and taxes paid during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contributions from plan members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) recognized directly in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;168&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Remeasurement of net defined-benefit (asset)/ liability (actuarial gains and losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(382)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;117&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pensions&#160;and&#160;other&#160;post-employment benefits&#160;by&#160;geographical&#160;region&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Service cost for 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(Gains)/losses related to plan amendments, curtailments or settlements not specified in the terms of the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost/(income) including administration costs and taxes paid during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contributions from plan members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) recognized directly in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;54&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;276&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(685)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expense/(gain) for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfServiceCostsOfNetDefinedBenefitsByCountryTableTextBlock>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1366" decimals="-6" id="f-3814" unitRef="eur">50000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1367" decimals="-6" id="f-3815" unitRef="eur">30000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1368" decimals="-6" id="f-3816" unitRef="eur">20000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1369" decimals="-6" id="f-3817" unitRef="eur">0</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1370" decimals="-6" id="f-3818" unitRef="eur">40000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1321" decimals="-6" id="f-3819" unitRef="eur">140000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1366" decimals="-6" id="f-3820" unitRef="eur">20000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1367" decimals="-6" id="f-3821" unitRef="eur">0</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1368" decimals="-6" id="f-3822" unitRef="eur">-1000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1369" decimals="-6" id="f-3823" unitRef="eur">0</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1370" decimals="-6" id="f-3824" unitRef="eur">3000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1321" decimals="-6" id="f-3825" unitRef="eur">22000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1366" decimals="-6" id="f-3826" unitRef="eur">22000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1367" decimals="-6" id="f-3827" unitRef="eur">15000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1368" decimals="-6" id="f-3828" unitRef="eur">35000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1369" decimals="-6" id="f-3829" unitRef="eur">-5000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1370" decimals="-6" id="f-3830" unitRef="eur">11000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1321" decimals="-6" id="f-3831" unitRef="eur">78000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1366" decimals="-6" id="f-3832" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1367" decimals="-6" id="f-3833" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1368" decimals="-6" id="f-3834" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1369" decimals="-6" id="f-3835" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1370" decimals="-6" id="f-3836" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1321" decimals="-6" id="f-3837" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1366" decimals="-6" id="f-3838" unitRef="eur">52000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1367" decimals="-6" id="f-3839" unitRef="eur">45000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1368" decimals="-6" id="f-3840" unitRef="eur">56000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1369" decimals="-6" id="f-3841" unitRef="eur">-5000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1370" decimals="-6" id="f-3842" unitRef="eur">42000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1321" decimals="-6" id="f-3843" unitRef="eur">190000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1366" decimals="-6" id="f-3844" unitRef="eur">3000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1367" decimals="-6" id="f-3845" unitRef="eur">98000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1368" decimals="-6" id="f-3846" unitRef="eur">26000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1369" decimals="-6" id="f-3847" unitRef="eur">44000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1370" decimals="-6" id="f-3848" unitRef="eur">0</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1321" decimals="-6" id="f-3849" unitRef="eur">171000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1366" decimals="-6" id="f-3850" unitRef="eur">55000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1367" decimals="-6" id="f-3851" unitRef="eur">143000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1368" decimals="-6" id="f-3852" unitRef="eur">82000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1369" decimals="-6" id="f-3853" unitRef="eur">39000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1370" decimals="-6" id="f-3854" unitRef="eur">42000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1321" decimals="-6" id="f-3855" unitRef="eur">361000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1371" decimals="-6" id="f-3856" unitRef="eur">61000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1372" decimals="-6" id="f-3857" unitRef="eur">44000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1373" decimals="-6" id="f-3858" unitRef="eur">50000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1374" decimals="-6" id="f-3859" unitRef="eur">0</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1375" decimals="-6" id="f-3860" unitRef="eur">38000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1322" decimals="-6" id="f-3861" unitRef="eur">193000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1371" decimals="-6" id="f-3862" unitRef="eur">60000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1372" decimals="-6" id="f-3863" unitRef="eur">-2000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1373" decimals="-6" id="f-3864" unitRef="eur">-1000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1374" decimals="-6" id="f-3865" unitRef="eur">6000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1375" decimals="-6" id="f-3866" unitRef="eur">5000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1322" decimals="-6" id="f-3867" unitRef="eur">68000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1371" decimals="-6" id="f-3868" unitRef="eur">10000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1372" decimals="-6" id="f-3869" unitRef="eur">7000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1373" decimals="-6" id="f-3870" unitRef="eur">30000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1374" decimals="-6" id="f-3871" unitRef="eur">-7000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1375" decimals="-6" id="f-3872" unitRef="eur">9000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1322" decimals="-6" id="f-3873" unitRef="eur">49000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1371" decimals="-6" id="f-3874" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1372" decimals="-6" id="f-3875" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1373" decimals="-6" id="f-3876" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1374" decimals="-6" id="f-3877" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1375" decimals="-6" id="f-3878" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1322" decimals="-6" id="f-3879" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1371" decimals="-6" id="f-3880" unitRef="eur">11000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1372" decimals="-6" id="f-3881" unitRef="eur">53000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1373" decimals="-6" id="f-3882" unitRef="eur">81000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1374" decimals="-6" id="f-3883" unitRef="eur">-13000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1375" decimals="-6" id="f-3884" unitRef="eur">36000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1322" decimals="-6" id="f-3885" unitRef="eur">168000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1371" decimals="-6" id="f-3886" unitRef="eur">-156000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1372" decimals="-6" id="f-3887" unitRef="eur">-204000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1373" decimals="-6" id="f-3888" unitRef="eur">-382000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1374" decimals="-6" id="f-3889" unitRef="eur">130000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1375" decimals="-6" id="f-3890" unitRef="eur">-38000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1322" decimals="-6" id="f-3891" unitRef="eur">-650000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1371" decimals="-6" id="f-3892" unitRef="eur">-145000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1372" decimals="-6" id="f-3893" unitRef="eur">-151000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1373" decimals="-6" id="f-3894" unitRef="eur">-301000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1374" decimals="-6" id="f-3895" unitRef="eur">117000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1375" decimals="-6" id="f-3896" unitRef="eur">-2000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1322" decimals="-6" id="f-3897" unitRef="eur">-482000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1376" decimals="-6" id="f-3898" unitRef="eur">72000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1377" decimals="-6" id="f-3899" unitRef="eur">47000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1378" decimals="-6" id="f-3900" unitRef="eur">57000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1379" decimals="-6" id="f-3901" unitRef="eur">0</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1380" decimals="-6" id="f-3902" unitRef="eur">51000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1323" decimals="-6" id="f-3903" unitRef="eur">227000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1376" decimals="-6" id="f-3904" unitRef="eur">-2000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1377" decimals="-6" id="f-3905" unitRef="eur">0</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1378" decimals="-6" id="f-3906" unitRef="eur">0</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1379" decimals="-6" id="f-3907" unitRef="eur">-3000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1380" decimals="-6" id="f-3908" unitRef="eur">0</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement contextRef="c-1323" decimals="-6" id="f-3909" unitRef="eur">-5000000</sny:GainsLossesRelatedToPlanAmendmentsCurtailmentsOrSettlement>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1376" decimals="-6" id="f-3910" unitRef="eur">5000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1377" decimals="-6" id="f-3911" unitRef="eur">5000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1378" decimals="-6" id="f-3912" unitRef="eur">27000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1379" decimals="-6" id="f-3913" unitRef="eur">3000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1380" decimals="-6" id="f-3914" unitRef="eur">9000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset contextRef="c-1323" decimals="-6" id="f-3915" unitRef="eur">49000000</sny:InterestExpenseIncomeIncludingAdministrationCostsAndTaxesPaidNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1376" decimals="-6" id="f-3916" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1377" decimals="-6" id="f-3917" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1378" decimals="-6" id="f-3918" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1379" decimals="-6" id="f-3919" unitRef="eur">0</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1380" decimals="-6" id="f-3920" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset contextRef="c-1323" decimals="-6" id="f-3921" unitRef="eur">6000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1376" decimals="-6" id="f-3922" unitRef="eur">80000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1377" decimals="-6" id="f-3923" unitRef="eur">52000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1378" decimals="-6" id="f-3924" unitRef="eur">84000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1379" decimals="-6" id="f-3925" unitRef="eur">6000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1380" decimals="-6" id="f-3926" unitRef="eur">54000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1323" decimals="-6" id="f-3927" unitRef="eur">276000000</sny:TotalExpenseForPensionsAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1376" decimals="-6" id="f-3928" unitRef="eur">-106000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1377" decimals="-6" id="f-3929" unitRef="eur">-113000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1378" decimals="-6" id="f-3930" unitRef="eur">-157000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1379" decimals="-6" id="f-3931" unitRef="eur">-236000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1380" decimals="-6" id="f-3932" unitRef="eur">-73000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1323" decimals="-6" id="f-3933" unitRef="eur">-685000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1376" decimals="-6" id="f-3934" unitRef="eur">-26000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1377" decimals="-6" id="f-3935" unitRef="eur">-61000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1378" decimals="-6" id="f-3936" unitRef="eur">-73000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1379" decimals="-6" id="f-3937" unitRef="eur">-230000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1380" decimals="-6" id="f-3938" unitRef="eur">-19000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset contextRef="c-1323" decimals="-6" id="f-3939" unitRef="eur">-409000000</sny:ExpenseGainForThePeriodNetDefinedBenefitLiabilityAsset>
    <sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock contextRef="c-1" id="f-3940">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of the &#x201c;Remeasurement of net defined-benefit (asset)/liability (actuarial gains and losses)&#x201d; line in the preceding tables is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.758%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Actuarial gains/(losses) arising during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Comprising:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains/(losses) &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;on experience adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains/(losses) &lt;br/&gt;on demographic assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains/(losses) &lt;br/&gt;on financial assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Experience adjustments are mainly due to the effect on plan assets of trends in the financial markets.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRemeasurementOfNetDefinedBenefitLiabilityAssetByCountryTableTextBlock>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1267" decimals="-6" id="f-3941" unitRef="eur">-3000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1246" decimals="-6" id="f-3942" unitRef="eur">-98000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1205" decimals="-6" id="f-3943" unitRef="eur">-25000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1212" decimals="-6" id="f-3944" unitRef="eur">-44000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1268" decimals="-6" id="f-3945" unitRef="eur">156000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1251" decimals="-6" id="f-3946" unitRef="eur">205000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1269" decimals="-6" id="f-3947" unitRef="eur">382000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1270" decimals="-6" id="f-3948" unitRef="eur">-131000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1271" decimals="-6" id="f-3949" unitRef="eur">106000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1258" decimals="-6" id="f-3950" unitRef="eur">113000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1272" decimals="-6" id="f-3951" unitRef="eur">156000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1273" decimals="-6" id="f-3952" unitRef="eur">237000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1267" decimals="-6" id="f-3953" unitRef="eur">16000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1246" decimals="-6" id="f-3954" unitRef="eur">-54000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1205" decimals="-6" id="f-3955" unitRef="eur">-7000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1212" decimals="-6" id="f-3956" unitRef="eur">-12000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1268" decimals="-6" id="f-3957" unitRef="eur">-120000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1251" decimals="-6" id="f-3958" unitRef="eur">-620000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1269" decimals="-6" id="f-3959" unitRef="eur">-287000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1270" decimals="-6" id="f-3960" unitRef="eur">-1328000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1271" decimals="-6" id="f-3961" unitRef="eur">60000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1258" decimals="-6" id="f-3962" unitRef="eur">182000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1272" decimals="-6" id="f-3963" unitRef="eur">23000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments contextRef="c-1273" decimals="-6" id="f-3964" unitRef="eur">35000000</sny:DecreaseIncreaseInNetDefinedBenefitLiabilityAssetResultingFromActuarialGainsLossesOnExperienceAdjustments>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1267" decimals="-6" id="f-3965" unitRef="eur">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1246" decimals="-6" id="f-3966" unitRef="eur">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1205" decimals="-6" id="f-3967" unitRef="eur">18000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1212" decimals="-6" id="f-3968" unitRef="eur">11000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1268" decimals="-6" id="f-3969" unitRef="eur">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1251" decimals="-6" id="f-3970" unitRef="eur">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1269" decimals="-6" id="f-3971" unitRef="eur">129000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1270" decimals="-6" id="f-3972" unitRef="eur">54000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1271" decimals="-6" id="f-3973" unitRef="eur">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1258" decimals="-6" id="f-3974" unitRef="eur">0</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1272" decimals="-6" id="f-3975" unitRef="eur">51000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1273" decimals="-6" id="f-3976" unitRef="eur">125000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1267" decimals="-6" id="f-3977" unitRef="eur">-19000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1246" decimals="-6" id="f-3978" unitRef="eur">-44000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1205" decimals="-6" id="f-3979" unitRef="eur">-36000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1212" decimals="-6" id="f-3980" unitRef="eur">-43000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1268" decimals="-6" id="f-3981" unitRef="eur">276000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1251" decimals="-6" id="f-3982" unitRef="eur">825000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1269" decimals="-6" id="f-3983" unitRef="eur">540000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1270" decimals="-6" id="f-3984" unitRef="eur">1143000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1271" decimals="-6" id="f-3985" unitRef="eur">46000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1258" decimals="-6" id="f-3986" unitRef="eur">-69000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1272" decimals="-6" id="f-3987" unitRef="eur">82000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset contextRef="c-1273" decimals="-6" id="f-3988" unitRef="eur">77000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <sny:DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock contextRef="c-1" id="f-3989">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The net pre-tax actuarial loss (excluding investments accounted for using the equity method) recognized directly in equity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net pre-tax actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfPreTaxActuarialLossExplanatoryTableTextBlock>
    <sny:NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity contextRef="c-1" decimals="-6" id="f-3990" unitRef="eur">-2259000000</sny:NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity>
    <sny:NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity contextRef="c-9" decimals="-6" id="f-3991" unitRef="eur">-2090000000</sny:NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity>
    <sny:NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity contextRef="c-10" decimals="-6" id="f-3992" unitRef="eur">-2738000000</sny:NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity>
    <sny:DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock contextRef="c-1" id="f-3993">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The present value of Sanofi&#x2019;s obligations in respect of pension and other post-employment benefit plans at the end of each reporting period is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of wholly or partially funded obligations in respect of pension and other post-employment benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Present value of unfunded obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,930&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,651&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,175&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfPensionAndOtherPostEmploymentBenefitExpenseTableTextBlock>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1381" decimals="-6" id="f-3994" unitRef="eur">7693000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1382" decimals="-6" id="f-3995" unitRef="eur">7463000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1383" decimals="-6" id="f-3996" unitRef="eur">10416000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1384" decimals="-6" id="f-3997" unitRef="eur">1237000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1385" decimals="-6" id="f-3998" unitRef="eur">1188000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1386" decimals="-6" id="f-3999" unitRef="eur">1759000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1304" decimals="-6" id="f-4000" unitRef="eur">8930000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1298" decimals="-6" id="f-4001" unitRef="eur">8651000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-1299" decimals="-6" id="f-4002" unitRef="eur">12175000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <sny:DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock contextRef="c-1" id="f-4003">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The total expense for pensions and other post-employment benefits (&#x20ac;190 million in 2023) is allocated between income statement line items as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating (income)/expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;168&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;276&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfExpenseForPensionsAndOtherPostEmploymentBenefitsByIncomeStatementLineExplanatoryTableTextBlock>
    <sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1321" decimals="-6" id="f-4004" unitRef="eur">190000000</sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <ifrs-full:CostOfSales contextRef="c-1321" decimals="-6" id="f-4005" unitRef="eur">34000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-1322" decimals="-6" id="f-4006" unitRef="eur">55000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-1323" decimals="-6" id="f-4007" unitRef="eur">77000000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1321" decimals="-6" id="f-4008" unitRef="eur">28000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1322" decimals="-6" id="f-4009" unitRef="eur">52000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1323" decimals="-6" id="f-4010" unitRef="eur">65000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-1321" decimals="-6" id="f-4011" unitRef="eur">61000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-1322" decimals="-6" id="f-4012" unitRef="eur">81000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-1323" decimals="-6" id="f-4013" unitRef="eur">87000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-1321" decimals="-6" id="f-4014" unitRef="eur">-5000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-1322" decimals="-6" id="f-4015" unitRef="eur">2000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-1323" decimals="-6" id="f-4016" unitRef="eur">1000000</ifrs-full:OtherOperatingIncomeExpense>
    <sny:RestructuringCostsReversedAndSimilarItems contextRef="c-1321" decimals="-6" id="f-4017" unitRef="eur">-9000000</sny:RestructuringCostsReversedAndSimilarItems>
    <sny:RestructuringCostsReversedAndSimilarItems contextRef="c-1322" decimals="-6" id="f-4018" unitRef="eur">-61000000</sny:RestructuringCostsReversedAndSimilarItems>
    <sny:RestructuringCostsReversedAndSimilarItems contextRef="c-1323" decimals="-6" id="f-4019" unitRef="eur">6000000</sny:RestructuringCostsReversedAndSimilarItems>
    <ifrs-full:FinanceCosts contextRef="c-1321" decimals="-6" id="f-4020" unitRef="eur">71000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-1322" decimals="-6" id="f-4021" unitRef="eur">43000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-1323" decimals="-6" id="f-4022" unitRef="eur">42000000</ifrs-full:FinanceCosts>
    <sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1321" decimals="-6" id="f-4023" unitRef="eur">190000000</sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1322" decimals="-6" id="f-4024" unitRef="eur">168000000</sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss contextRef="c-1323" decimals="-6" id="f-4025" unitRef="eur">276000000</sny:TotalExpenseForPensionAndOtherPostEmploymentBenefitsRecognizedDirectlyInProfitOrLoss>
    <sny:DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock contextRef="c-1" id="f-4026">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The estimated amounts of employer&#x2019;s contributions to plan assets in 2024 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Employer&#x2019;s contributions in 2024 (estimate):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfEstimatedAmountsOfEmployersContributionsToPlanAssetsTableTextBlock>
    <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan contextRef="c-1387" decimals="-6" id="f-4027" unitRef="eur">0</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
    <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan contextRef="c-1388" decimals="-6" id="f-4028" unitRef="eur">0</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
    <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan contextRef="c-1389" decimals="-6" id="f-4029" unitRef="eur">0</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
    <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan contextRef="c-1390" decimals="-6" id="f-4030" unitRef="eur">46000000</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
    <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan contextRef="c-1391" decimals="-6" id="f-4031" unitRef="eur">40000000</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
    <ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan contextRef="c-753" decimals="-6" id="f-4032" unitRef="eur">86000000</ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan>
    <sny:DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock contextRef="c-1" id="f-4033">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the expected timing of benefit payments under pension and other post-employment benefit plans for future years:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.337%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;UK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Estimated future benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2029 to 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfExpectedTimingOfPaymentsUnderPensionAndOtherPostEmploymentBenefitPlansTableTextBlock>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1392" decimals="-6" id="f-4034" unitRef="eur">103000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1393" decimals="-6" id="f-4035" unitRef="eur">198000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1394" decimals="-6" id="f-4036" unitRef="eur">102000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1395" decimals="-6" id="f-4037" unitRef="eur">116000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1396" decimals="-6" id="f-4038" unitRef="eur">60000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1106" decimals="-6" id="f-4039" unitRef="eur">579000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1397" decimals="-6" id="f-4040" unitRef="eur">68000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1398" decimals="-6" id="f-4041" unitRef="eur">212000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1399" decimals="-6" id="f-4042" unitRef="eur">91000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1400" decimals="-6" id="f-4043" unitRef="eur">120000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1401" decimals="-6" id="f-4044" unitRef="eur">54000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1107" decimals="-6" id="f-4045" unitRef="eur">545000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1402" decimals="-6" id="f-4046" unitRef="eur">60000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1403" decimals="-6" id="f-4047" unitRef="eur">218000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1404" decimals="-6" id="f-4048" unitRef="eur">95000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1405" decimals="-6" id="f-4049" unitRef="eur">123000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1406" decimals="-6" id="f-4050" unitRef="eur">60000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1108" decimals="-6" id="f-4051" unitRef="eur">556000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1407" decimals="-6" id="f-4052" unitRef="eur">79000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1408" decimals="-6" id="f-4053" unitRef="eur">221000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1409" decimals="-6" id="f-4054" unitRef="eur">98000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1410" decimals="-6" id="f-4055" unitRef="eur">127000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1411" decimals="-6" id="f-4056" unitRef="eur">59000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1109" decimals="-6" id="f-4057" unitRef="eur">584000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1412" decimals="-6" id="f-4058" unitRef="eur">93000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1413" decimals="-6" id="f-4059" unitRef="eur">229000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1414" decimals="-6" id="f-4060" unitRef="eur">101000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1415" decimals="-6" id="f-4061" unitRef="eur">131000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1416" decimals="-6" id="f-4062" unitRef="eur">62000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1110" decimals="-6" id="f-4063" unitRef="eur">616000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1417" decimals="-6" id="f-4064" unitRef="eur">438000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1418" decimals="-6" id="f-4065" unitRef="eur">1190000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1419" decimals="-6" id="f-4066" unitRef="eur">526000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1420" decimals="-6" id="f-4067" unitRef="eur">716000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1421" decimals="-6" id="f-4068" unitRef="eur">343000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans contextRef="c-1422" decimals="-6" id="f-4069" unitRef="eur">3213000000</sny:EstimatedFutureBenefitPaymentsUnderPensionAndOtherPostemploymentBenefitPlans>
    <sny:DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock contextRef="c-1" id="f-4070">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows estimates as of December 31, 2023 for the timing of future payments in respect of unfunded pension and other post-employment benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than 1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to &lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to &lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Estimated payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlansExplanatoryTableTextBlock>
    <sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans contextRef="c-1" decimals="-6" id="f-4071" unitRef="eur">1238000000</sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans>
    <sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans contextRef="c-753" decimals="-6" id="f-4072" unitRef="eur">86000000</sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans>
    <sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans contextRef="c-1423" decimals="-6" id="f-4073" unitRef="eur">117000000</sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans>
    <sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans contextRef="c-1424" decimals="-6" id="f-4074" unitRef="eur">144000000</sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans>
    <sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans contextRef="c-758" decimals="-6" id="f-4075" unitRef="eur">891000000</sny:ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans>
    <sny:DisclosureOfRestructuringProvisionsTableTextBlock contextRef="c-1" id="f-4076">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows movements in restructuring provisions classified in non-current and current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,233&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,118&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,499&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Classified in non-current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Classified in current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Change in provisions recognized in profit or loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provisions utilized&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(522)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unwinding of discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,132&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,233&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,118&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Of which:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Classified in non-current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Classified in current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Provisions utilized mainly correspond to payments related to employees affected by separation programs.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRestructuringProvisionsTableTextBlock>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-1425" decimals="-6" id="f-4077" unitRef="eur">1233000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-1426" decimals="-6" id="f-4078" unitRef="eur">1118000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-1427" decimals="-6" id="f-4079" unitRef="eur">1499000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:LongtermRestructuringProvision contextRef="c-1425" decimals="-6" id="f-4080" unitRef="eur">761000000</ifrs-full:LongtermRestructuringProvision>
    <ifrs-full:LongtermRestructuringProvision contextRef="c-1426" decimals="-6" id="f-4081" unitRef="eur">524000000</ifrs-full:LongtermRestructuringProvision>
    <ifrs-full:LongtermRestructuringProvision contextRef="c-1427" decimals="-6" id="f-4082" unitRef="eur">868000000</ifrs-full:LongtermRestructuringProvision>
    <ifrs-full:ShorttermRestructuringProvision contextRef="c-1425" decimals="-6" id="f-4083" unitRef="eur">472000000</ifrs-full:ShorttermRestructuringProvision>
    <ifrs-full:ShorttermRestructuringProvision contextRef="c-1426" decimals="-6" id="f-4084" unitRef="eur">594000000</ifrs-full:ShorttermRestructuringProvision>
    <ifrs-full:ShorttermRestructuringProvision contextRef="c-1427" decimals="-6" id="f-4085" unitRef="eur">631000000</ifrs-full:ShorttermRestructuringProvision>
    <sny:ChangeInProvisionsRecognizedInProfitOrLossForThePeriod contextRef="c-1428" decimals="-6" id="f-4086" unitRef="eur">435000000</sny:ChangeInProvisionsRecognizedInProfitOrLossForThePeriod>
    <sny:ChangeInProvisionsRecognizedInProfitOrLossForThePeriod contextRef="c-1429" decimals="-6" id="f-4087" unitRef="eur">636000000</sny:ChangeInProvisionsRecognizedInProfitOrLossForThePeriod>
    <sny:ChangeInProvisionsRecognizedInProfitOrLossForThePeriod contextRef="c-1430" decimals="-6" id="f-4088" unitRef="eur">183000000</sny:ChangeInProvisionsRecognizedInProfitOrLossForThePeriod>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1428" decimals="-6" id="f-4089" unitRef="eur">561000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1429" decimals="-6" id="f-4090" unitRef="eur">522000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="c-1430" decimals="-6" id="f-4091" unitRef="eur">571000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1428" decimals="-6" id="f-4092" unitRef="eur">3000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1429" decimals="-6" id="f-4093" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions contextRef="c-1430" decimals="-6" id="f-4094" unitRef="eur">1000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <sny:UnwindingOfDiscount contextRef="c-1428" decimals="-6" id="f-4095" unitRef="eur">31000000</sny:UnwindingOfDiscount>
    <sny:UnwindingOfDiscount contextRef="c-1429" decimals="-6" id="f-4096" unitRef="eur">5000000</sny:UnwindingOfDiscount>
    <sny:UnwindingOfDiscount contextRef="c-1430" decimals="-6" id="f-4097" unitRef="eur">0</sny:UnwindingOfDiscount>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1428" decimals="-6" id="f-4098" unitRef="eur">-9000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1429" decimals="-6" id="f-4099" unitRef="eur">-4000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="c-1430" decimals="-6" id="f-4100" unitRef="eur">6000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-1431" decimals="-6" id="f-4101" unitRef="eur">1132000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-1425" decimals="-6" id="f-4102" unitRef="eur">1233000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities contextRef="c-1426" decimals="-6" id="f-4103" unitRef="eur">1118000000</sny:NonCurrentProvisionsAndOtherNonCurrentLiabilities>
    <ifrs-full:LongtermRestructuringProvision contextRef="c-1431" decimals="-6" id="f-4104" unitRef="eur">554000000</ifrs-full:LongtermRestructuringProvision>
    <ifrs-full:LongtermRestructuringProvision contextRef="c-1425" decimals="-6" id="f-4105" unitRef="eur">761000000</ifrs-full:LongtermRestructuringProvision>
    <ifrs-full:LongtermRestructuringProvision contextRef="c-1426" decimals="-6" id="f-4106" unitRef="eur">524000000</ifrs-full:LongtermRestructuringProvision>
    <ifrs-full:ShorttermRestructuringProvision contextRef="c-1431" decimals="-6" id="f-4107" unitRef="eur">578000000</ifrs-full:ShorttermRestructuringProvision>
    <ifrs-full:ShorttermRestructuringProvision contextRef="c-1425" decimals="-6" id="f-4108" unitRef="eur">472000000</ifrs-full:ShorttermRestructuringProvision>
    <ifrs-full:ShorttermRestructuringProvision contextRef="c-1426" decimals="-6" id="f-4109" unitRef="eur">594000000</ifrs-full:ShorttermRestructuringProvision>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-5" decimals="-6" id="f-4110" unitRef="eur">968000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-7" decimals="-6" id="f-4111" unitRef="eur">1039000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-8" decimals="-6" id="f-4112" unitRef="eur">943000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <sny:AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans contextRef="c-1" id="f-4113">P2Y2M19D</sny:AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans>
    <sny:AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans contextRef="c-9" id="f-4114">P2Y7M6D</sny:AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans>
    <sny:AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans contextRef="c-10" id="f-4115">P1Y11M8D</sny:AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans>
    <sny:DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock contextRef="c-1" id="f-4116">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The timing of future termination benefit payments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Benefit payments by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Other countries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;968&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;517&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;362&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Benefit payments by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Other countries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,039&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;374&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;448&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Benefit payments by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Employee termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Other countries&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;943&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;394&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;67&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;border-bottom:0.5pt solid #5064a9;border-top:0.5pt solid #5064a9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfFutureBenefitPaymentsExplanatoryTableTextBlock>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1232" decimals="-6" id="f-4117" unitRef="eur">611000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1392" decimals="-6" id="f-4118" unitRef="eur">215000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1432" decimals="-6" id="f-4119" unitRef="eur">315000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1433" decimals="-6" id="f-4120" unitRef="eur">79000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1434" decimals="-6" id="f-4121" unitRef="eur">2000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1435" decimals="-6" id="f-4122" unitRef="eur">357000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1396" decimals="-6" id="f-4123" unitRef="eur">302000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1436" decimals="-6" id="f-4124" unitRef="eur">47000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1437" decimals="-6" id="f-4125" unitRef="eur">7000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1438" decimals="-6" id="f-4126" unitRef="eur">1000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-5" decimals="-6" id="f-4127" unitRef="eur">968000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1106" decimals="-6" id="f-4128" unitRef="eur">517000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1124" decimals="-6" id="f-4129" unitRef="eur">362000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1125" decimals="-6" id="f-4130" unitRef="eur">86000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1111" decimals="-6" id="f-4131" unitRef="eur">3000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1234" decimals="-6" id="f-4132" unitRef="eur">804000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1439" decimals="-6" id="f-4133" unitRef="eur">185000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1440" decimals="-6" id="f-4134" unitRef="eur">412000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1441" decimals="-6" id="f-4135" unitRef="eur">207000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1442" decimals="-6" id="f-4136" unitRef="eur">0</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1443" decimals="-6" id="f-4137" unitRef="eur">235000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1444" decimals="-6" id="f-4138" unitRef="eur">189000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1445" decimals="-6" id="f-4139" unitRef="eur">36000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1446" decimals="-6" id="f-4140" unitRef="eur">8000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1447" decimals="-6" id="f-4141" unitRef="eur">2000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-7" decimals="-6" id="f-4142" unitRef="eur">1039000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1112" decimals="-6" id="f-4143" unitRef="eur">374000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1126" decimals="-6" id="f-4144" unitRef="eur">448000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1127" decimals="-6" id="f-4145" unitRef="eur">215000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1117" decimals="-6" id="f-4146" unitRef="eur">2000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1236" decimals="-6" id="f-4147" unitRef="eur">614000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1448" decimals="-6" id="f-4148" unitRef="eur">269000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1449" decimals="-6" id="f-4149" unitRef="eur">288000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1450" decimals="-6" id="f-4150" unitRef="eur">53000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1451" decimals="-6" id="f-4151" unitRef="eur">4000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1452" decimals="-6" id="f-4152" unitRef="eur">329000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1453" decimals="-6" id="f-4153" unitRef="eur">207000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1454" decimals="-6" id="f-4154" unitRef="eur">106000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1455" decimals="-6" id="f-4155" unitRef="eur">14000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1456" decimals="-6" id="f-4156" unitRef="eur">2000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-8" decimals="-6" id="f-4157" unitRef="eur">943000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1118" decimals="-6" id="f-4158" unitRef="eur">476000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1128" decimals="-6" id="f-4159" unitRef="eur">394000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1129" decimals="-6" id="f-4160" unitRef="eur">67000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-1123" decimals="-6" id="f-4161" unitRef="eur">6000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <sny:DisclosureOfOtherLongTermProvisionsTableTextBlock contextRef="c-1" id="f-4162">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other provisions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; include provisions for risks and litigation relating to environmental, tax, commercial and product liability matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Environmental risks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Product liability risks, litigation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,776&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,178&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,024&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfOtherLongTermProvisionsTableTextBlock>
    <sny:NonCurrentProvisionForEnvironmentRisks contextRef="c-5" decimals="-6" id="f-4163" unitRef="eur">493000000</sny:NonCurrentProvisionForEnvironmentRisks>
    <sny:NonCurrentProvisionForEnvironmentRisks contextRef="c-7" decimals="-6" id="f-4164" unitRef="eur">526000000</sny:NonCurrentProvisionForEnvironmentRisks>
    <sny:NonCurrentProvisionForEnvironmentRisks contextRef="c-8" decimals="-6" id="f-4165" unitRef="eur">650000000</sny:NonCurrentProvisionForEnvironmentRisks>
    <sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther contextRef="c-5" decimals="-6" id="f-4166" unitRef="eur">1283000000</sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther>
    <sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther contextRef="c-7" decimals="-6" id="f-4167" unitRef="eur">1652000000</sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther>
    <sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther contextRef="c-8" decimals="-6" id="f-4168" unitRef="eur">1374000000</sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther>
    <ifrs-full:OtherLongtermProvisions contextRef="c-5" decimals="-6" id="f-4169" unitRef="eur">1776000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions contextRef="c-7" decimals="-6" id="f-4170" unitRef="eur">2178000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions contextRef="c-8" decimals="-6" id="f-4171" unitRef="eur">2024000000</ifrs-full:OtherLongtermProvisions>
    <sny:IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod contextRef="c-1457" id="f-4172">P30Y</sny:IdentifiedEnvironmentalRisksProvisionsEstimatedObligationPeriod>
    <sny:IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths contextRef="c-1457" decimals="-6" id="f-4173" unitRef="eur">86000000</sny:IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountNextTwelveMonths>
    <sny:IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive contextRef="c-1457" decimals="-6" id="f-4174" unitRef="eur">194000000</sny:IdentifiedEnvironmentalRisksProvisionsExpectedUtilizedAmountYearTwoToFive>
    <sny:InventoryTotalQuotasHeld contextRef="c-5" decimals="-6" id="f-4175" unitRef="eur">3000000</sny:InventoryTotalQuotasHeld>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-5" decimals="-6" id="f-4176" unitRef="eur">1842000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-7" decimals="-6" id="f-4177" unitRef="eur">1979000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-8" decimals="-6" id="f-4178" unitRef="eur">2039000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-552" decimals="-6" id="f-4179" unitRef="eur">247000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-557" decimals="-6" id="f-4180" unitRef="eur">459000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c-562" decimals="-6" id="f-4181" unitRef="eur">576000000</ifrs-full:OtherNoncurrentLiabilities>
    <sny:LiabilityRecognizedRepresentingEstimatedCost contextRef="c-1458" decimals="-6" id="f-4182" unitRef="usd">1092000000</sny:LiabilityRecognizedRepresentingEstimatedCost>
    <sny:TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod contextRef="c-1" id="f-4183">P8Y</sny:TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-1459" decimals="-6" id="f-4184" unitRef="eur">1595000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-1460" decimals="-6" id="f-4185" unitRef="eur">1520000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-1461" decimals="-6" id="f-4186" unitRef="eur">1463000000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <sny:UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-1462" decimals="-9" id="f-4187" unitRef="eur">3000000000</sny:UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised>
    <sny:CapitalLossesCarryBackPeriod contextRef="c-1463" id="f-4188">P3Y</sny:CapitalLossesCarryBackPeriod>
    <sny:DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-4189">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Current provisions and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Taxes payable, other than corporate income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring provisions (see Note&#160;D.19.2.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate derivatives (see Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency derivatives (see Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity derivatives (see Note&#160;D.20.)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amounts payable for acquisitions of non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Customer contract liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,741&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,021&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,217&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;See Note&#160;A.5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &#x201c;Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;. The year-on-year change in this item between 2022 and 2023 includes revenue of &#x20ac;269&#160;million  recognized in profit or loss during 2023 previously included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer contract liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; as of December&#160;31, 2022, compared with revenue of  &#x20ac;85&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;recognized in profit or loss during 2022 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;previously included in  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer contract liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; as of December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; . No such revenue was recognized in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;&#x201c;Other current liabilities&#x201d; mainly comprises provisions and liabilities for customer rebates and returns; provisions for discounts and rebates granted to healthcare authorities and governmental programs (see Note&#160;D.23.); and the liability payable at each reporting date under the Monoclonal Antibody Alliance with Regeneron.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;As of December 31, 2023 includes &#x20ac;131&#160;million (nominal value: &#x20ac;137 million) for the current liability relating to royalties payable to Sobi on net sales of BEYFORTUS (nirsevimab) in the United States (see Note&#160;C.2.)&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfCurrentProvisionsAndOtherCurrentLiabilitiesTableTextBlock>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-5" decimals="-6" id="f-4190" unitRef="eur">395000000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-7" decimals="-6" id="f-4191" unitRef="eur">420000000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-8" decimals="-6" id="f-4192" unitRef="eur">428000000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c-5" decimals="-6" id="f-4193" unitRef="eur">2106000000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c-7" decimals="-6" id="f-4194" unitRef="eur">2158000000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c-8" decimals="-6" id="f-4195" unitRef="eur">2126000000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermRestructuringProvision contextRef="c-5" decimals="-6" id="f-4196" unitRef="eur">578000000</ifrs-full:ShorttermRestructuringProvision>
    <ifrs-full:ShorttermRestructuringProvision contextRef="c-7" decimals="-6" id="f-4197" unitRef="eur">472000000</ifrs-full:ShorttermRestructuringProvision>
    <ifrs-full:ShorttermRestructuringProvision contextRef="c-8" decimals="-6" id="f-4198" unitRef="eur">594000000</ifrs-full:ShorttermRestructuringProvision>
    <sny:CurrentInterestRateDerivativesPayable contextRef="c-5" decimals="-6" id="f-4199" unitRef="eur">1000000</sny:CurrentInterestRateDerivativesPayable>
    <sny:CurrentInterestRateDerivativesPayable contextRef="c-7" decimals="-6" id="f-4200" unitRef="eur">0</sny:CurrentInterestRateDerivativesPayable>
    <sny:CurrentInterestRateDerivativesPayable contextRef="c-8" decimals="-6" id="f-4201" unitRef="eur">1000000</sny:CurrentInterestRateDerivativesPayable>
    <sny:CurrentCurrencyDerivativesPayable contextRef="c-5" decimals="-6" id="f-4202" unitRef="eur">126000000</sny:CurrentCurrencyDerivativesPayable>
    <sny:CurrentCurrencyDerivativesPayable contextRef="c-7" decimals="-6" id="f-4203" unitRef="eur">94000000</sny:CurrentCurrencyDerivativesPayable>
    <sny:CurrentCurrencyDerivativesPayable contextRef="c-8" decimals="-6" id="f-4204" unitRef="eur">62000000</sny:CurrentCurrencyDerivativesPayable>
    <sny:CurrentEquityDerivativesPayable contextRef="c-5" decimals="-6" id="f-4205" unitRef="eur">0</sny:CurrentEquityDerivativesPayable>
    <sny:CurrentEquityDerivativesPayable contextRef="c-7" decimals="-6" id="f-4206" unitRef="eur">0</sny:CurrentEquityDerivativesPayable>
    <sny:CurrentEquityDerivativesPayable contextRef="c-8" decimals="-6" id="f-4207" unitRef="eur">16000000</sny:CurrentEquityDerivativesPayable>
    <sny:AmountsPayableForAcquisitionOfNonCurrentAssets contextRef="c-5" decimals="-6" id="f-4208" unitRef="eur">945000000</sny:AmountsPayableForAcquisitionOfNonCurrentAssets>
    <sny:AmountsPayableForAcquisitionOfNonCurrentAssets contextRef="c-7" decimals="-6" id="f-4209" unitRef="eur">714000000</sny:AmountsPayableForAcquisitionOfNonCurrentAssets>
    <sny:AmountsPayableForAcquisitionOfNonCurrentAssets contextRef="c-8" decimals="-6" id="f-4210" unitRef="eur">559000000</sny:AmountsPayableForAcquisitionOfNonCurrentAssets>
    <ifrs-full:CurrentContractLiabilities contextRef="c-5" decimals="-6" id="f-4211" unitRef="eur">0</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-7" decimals="-6" id="f-4212" unitRef="eur">269000000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-8" decimals="-6" id="f-4213" unitRef="eur">321000000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-5" decimals="-6" id="f-4214" unitRef="eur">9590000000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-7" decimals="-6" id="f-4215" unitRef="eur">7894000000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-8" decimals="-6" id="f-4216" unitRef="eur">7110000000</ifrs-full:OtherCurrentLiabilities>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-5" decimals="-6" id="f-4217" unitRef="eur">13741000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-7" decimals="-6" id="f-4218" unitRef="eur">12021000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <sny:CurrentProvisionsAndOtherCurrentLiabilities contextRef="c-8" decimals="-6" id="f-4219" unitRef="eur">11217000000</sny:CurrentProvisionsAndOtherCurrentLiabilities>
    <ifrs-full:OtherRevenue contextRef="c-80" decimals="-6" id="f-4220" unitRef="eur">269000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-1464" decimals="-6" id="f-4221" unitRef="eur">85000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-1465" decimals="-6" id="f-4222" unitRef="eur">0</ifrs-full:OtherRevenue>
    <sny:RoyaltiesPayable contextRef="c-1466" decimals="-6" id="f-4223" unitRef="eur">131000000</sny:RoyaltiesPayable>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-1466" decimals="-6" id="f-4224" unitRef="eur">137000000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory contextRef="c-1" id="f-4227">Derivative financial instruments and market risks&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the fair value of derivative instruments as of December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.153%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market value at December 31, 2023 (net)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market value at December 31, 2022 (net)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market value at December 31, 2021 (net)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;financial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;( 120)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;213&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;Objectives of the use of derivative financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi uses derivative instruments to manage operating exposure to movements in exchange rates, and financial exposure to movements in interest rates and exchange rates (where the debt or receivable is not contracted in the functional currency of the borrower or lender entity). On occasion, Sanofi uses equity derivatives in connection with the management of its portfolio of equity investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi performs periodic reviews of its transactions and contractual agreements in order to identify any embedded derivatives, which are accounted for separately from the host contract in accordance with IFRS&#160;9. Sanofi had no material embedded derivatives as of December 31, 2023, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Counterparty risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For a description of counterparty risk, refer to &#x201c;Item&#160;11. &#x2014; Quantitative and Qualitative Disclosures about Market Risk&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a) Currency derivatives used to manage operating risk exposures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For a description of Sanofi&#x2019;s objectives, policies and procedures for the management of operating foreign exchange risk, refer to &#x201c;Item&#160;11. &#x2014; Quantitative and Qualitative Disclosures about Market Risk&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of December 31, 2023, with the notional amount translated into euros at the relevant closing exchange rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.979%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as&lt;br/&gt;cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&#160;derivatives&#160;not&lt;br/&gt;eligible&#160;for&#160;hedge&#160;accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&lt;br/&gt;recognized&#160;in&#160;equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,112&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,112&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Korean won&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,246&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,246&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Korean won&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,358&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,358&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of December 31, 2022, with the notional amount translated into euros at the relevant closing exchange rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as&lt;br/&gt;cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&#160;derivatives&#160;not&lt;br/&gt;eligible&#160;for&#160;hedge&#160;accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&lt;br/&gt;recognized&#160;in&#160;equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,403&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,403&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Korean won&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,459&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,459&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Korean won&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Taiwan dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,862&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,862&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of December 31, 2021, with the notional amount translated into euros at the relevant closing exchange rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.339%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.304%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives&lt;br/&gt;designated&#160;as&#160;cash&#160;flow&#160;hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&#160;derivatives&#160;not&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;eligible&#160;for&#160;hedge&#160;accounting &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&lt;br/&gt;recognized&lt;br/&gt;in&#160;equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,912&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,912&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Taiwan dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,374&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,374&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Hungarian forint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Russian rouble&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,286&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,286&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b) Currency and interest rate derivatives used to manage financial exposure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For a description of Sanofi&#x2019;s objectives, policies and procedures for the management of financial foreign exchange risk and interest rate risk, refer to &#x201c;Item&#160;11. &#x2014; Quantitative and Qualitative Disclosures about Market Risk&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows financial currency hedging instruments in place, with the notional amount translated into euros at the relevant closing exchange rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.942%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.249%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,279&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,559&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,655&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,055&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,997&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,293&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;197&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(b) (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,334&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,556&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,948&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi&#x2019;s net investment in Bioverativ. As of December 31, 2023, the fair value of these forward contracts represented an asset of &#x20ac;54 million; the opposite entry was recognized in "Other comprehensive income", with the impact on financial income and expense being immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2023, the fair value of the contracts was a liability of &#x20ac;31 million, the opposite entry for &#x20ac;2.7&#160;million of which was credited to &#x201c;Other comprehensive income&#x201d; under the cost of hedging accounting treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,044 million expiring in 2024, designated as a fair value hedge of the exposure of an equivalent amount of commercial paper. As of December 31, 2023, the fair value of the swaps was a liability of &#x20ac;3 million, the opposite entry for &#x20ac;0.7&#160;million of which was credited to &#x201c;Other comprehensive income&#x201d; under the cost of hedging accounting treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows interest rate hedging instruments in place as of December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amounts by expiry date as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e3e3e3;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;designated as&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as&lt;br/&gt;cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;br/&gt;recognized&lt;br/&gt;in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD/receive 1.03%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD/receive 1.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester/receive 0.69%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester/receive 0.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 3.43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;999&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;906&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;650&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,405&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,405&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows interest rate hedging instruments in place as of December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amounts by expiry date as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;designated as&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as&lt;br/&gt;cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028 and later&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;br/&gt;recognized&lt;br/&gt;in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD/receive 1.03%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD/receive 1.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester/receive 0.69%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester/receive 0.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,584&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,434&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,434&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows interest rate hedging instruments in place as of December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amounts by expiry date as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;designated as&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as&lt;br/&gt;cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027 and later&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;br/&gt;recognized&lt;br/&gt;in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized EONIA/receive 0.06%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay -0.57%/receive capitalized EONIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized USD SOFR/receive 1.03%  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized USD SOFR/receive 1.32%  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;receive capitalized Eonia/pay 1.48%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,642&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;880&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,579&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,979&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;600&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These interest rate swaps hedge fixed-rate bonds with a nominal of &#x20ac;99 million held in a Professional Specialized Investment Fund dedicated to Sanofi and recognized within &#x201c;Long-term loans and advances and other non-current receivables&#x201d; (see Note D.7.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;c) Actual or potential effects of netting arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below is prepared in accordance with the accounting policies described in Note&#160;B.8.3.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross carrying amounts before offset (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross amounts offset (in accordance with IAS&#160;32)&#160;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amounts as reported in the balance sheet (a) -&#160;(b) =&#160;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;298&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effects of other netting arrangements (not fulfilling the IAS&#160;32 criteria for offsetting) (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value of financial collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net exposure (c) + (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;231&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
    <sny:DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock contextRef="c-1" id="f-4228">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the fair value of derivative instruments as of December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.153%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Current&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market value at December 31, 2023 (net)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market value at December 31, 2022 (net)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Market value at December 31, 2021 (net)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;financial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest rate derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;( 120)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;213&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfFairValueOfDerivativeInstrumentsTableTextBlock>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-1468" decimals="-6" id="f-4229" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets contextRef="c-1468" decimals="-6" id="f-4230" unitRef="eur">201000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialAssets contextRef="c-1468" decimals="-6" id="f-4231" unitRef="eur">201000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-1468" decimals="-6" id="f-4232" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-1468" decimals="-6" id="f-4233" unitRef="eur">126000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-1468" decimals="-6" id="f-4234" unitRef="eur">126000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1468" decimals="-6" id="f-4235" unitRef="eur">75000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1469" decimals="-6" id="f-4236" unitRef="eur">112000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1470" decimals="-6" id="f-4237" unitRef="eur">222000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-1471" decimals="-6" id="f-4238" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets contextRef="c-1471" decimals="-6" id="f-4239" unitRef="eur">67000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialAssets contextRef="c-1471" decimals="-6" id="f-4240" unitRef="eur">67000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-1471" decimals="-6" id="f-4241" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-1471" decimals="-6" id="f-4242" unitRef="eur">45000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-1471" decimals="-6" id="f-4243" unitRef="eur">45000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1471" decimals="-6" id="f-4244" unitRef="eur">22000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1472" decimals="-6" id="f-4245" unitRef="eur">22000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1473" decimals="-6" id="f-4246" unitRef="eur">10000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-1474" decimals="-6" id="f-4247" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets contextRef="c-1474" decimals="-6" id="f-4248" unitRef="eur">134000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialAssets contextRef="c-1474" decimals="-6" id="f-4249" unitRef="eur">134000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-1474" decimals="-6" id="f-4250" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-1474" decimals="-6" id="f-4251" unitRef="eur">81000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-1474" decimals="-6" id="f-4252" unitRef="eur">81000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1474" decimals="-6" id="f-4253" unitRef="eur">53000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1475" decimals="-6" id="f-4254" unitRef="eur">90000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1476" decimals="-6" id="f-4255" unitRef="eur">212000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-1477" decimals="-6" id="f-4256" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets contextRef="c-1477" decimals="-6" id="f-4257" unitRef="eur">0</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialAssets contextRef="c-1477" decimals="-6" id="f-4258" unitRef="eur">0</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-1477" decimals="-6" id="f-4259" unitRef="eur">164000000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-1477" decimals="-6" id="f-4260" unitRef="eur">1000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-1477" decimals="-6" id="f-4261" unitRef="eur">165000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1477" decimals="-6" id="f-4262" unitRef="eur">-165000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1478" decimals="-6" id="f-4263" unitRef="eur">-232000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1479" decimals="-6" id="f-4264" unitRef="eur">7000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-1480" decimals="-6" id="f-4265" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets contextRef="c-1480" decimals="-6" id="f-4266" unitRef="eur">0</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialAssets contextRef="c-1480" decimals="-6" id="f-4267" unitRef="eur">0</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-1480" decimals="-6" id="f-4268" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-1480" decimals="-6" id="f-4269" unitRef="eur">0</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-1480" decimals="-6" id="f-4270" unitRef="eur">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1480" decimals="-6" id="f-4271" unitRef="eur">0</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1481" decimals="-6" id="f-4272" unitRef="eur">0</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-1482" decimals="-6" id="f-4273" unitRef="eur">-16000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:NoncurrentDerivativeFinancialAssets contextRef="c-5" decimals="-6" id="f-4274" unitRef="eur">0</ifrs-full:NoncurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets contextRef="c-5" decimals="-6" id="f-4275" unitRef="eur">201000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialAssets contextRef="c-5" decimals="-6" id="f-4276" unitRef="eur">201000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities contextRef="c-5" decimals="-6" id="f-4277" unitRef="eur">164000000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-5" decimals="-6" id="f-4278" unitRef="eur">127000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-5" decimals="-6" id="f-4279" unitRef="eur">291000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-5" decimals="-6" id="f-4280" unitRef="eur">-90000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-7" decimals="-6" id="f-4281" unitRef="eur">-120000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue contextRef="c-8" decimals="-6" id="f-4282" unitRef="eur">213000000</ifrs-full:FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue>
    <sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock contextRef="c-1" id="f-4283">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of December 31, 2023, with the notional amount translated into euros at the relevant closing exchange rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.979%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as&lt;br/&gt;cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&#160;derivatives&#160;not&lt;br/&gt;eligible&#160;for&#160;hedge&#160;accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&lt;br/&gt;recognized&#160;in&#160;equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,112&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,112&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Korean won&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,246&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,246&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Korean won&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,358&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,358&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of December 31, 2022, with the notional amount translated into euros at the relevant closing exchange rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.732%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives designated as&lt;br/&gt;cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&#160;derivatives&#160;not&lt;br/&gt;eligible&#160;for&#160;hedge&#160;accounting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&lt;br/&gt;recognized&#160;in&#160;equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,403&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,403&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Korean won&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,459&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,459&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Korean won&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Taiwan dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,862&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,862&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows operating currency hedging instruments in place as of December 31, 2021, with the notional amount translated into euros at the relevant closing exchange rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.339%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.304%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.921%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which derivatives&lt;br/&gt;designated&#160;as&#160;cash&#160;flow&#160;hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&#160;derivatives&#160;not&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;eligible&#160;for&#160;hedge&#160;accounting &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of&#160;which&lt;br/&gt;recognized&lt;br/&gt;in&#160;equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,912&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,912&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Taiwan dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,374&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,374&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Hungarian forint&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Russian rouble&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,286&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,286&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfOperatingCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateTableTextBlock>
    <sny:DerivativeFinancialInstruments contextRef="c-1483" decimals="-6" id="f-4284" unitRef="eur">6112000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1484" decimals="-6" id="f-4285" unitRef="eur">30000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1485" decimals="-6" id="f-4286" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1486" decimals="-6" id="f-4287" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1487" decimals="-6" id="f-4288" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1488" decimals="-6" id="f-4289" unitRef="eur">6112000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1489" decimals="-6" id="f-4290" unitRef="eur">30000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1490" decimals="-6" id="f-4291" unitRef="eur">2981000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1491" decimals="-6" id="f-4292" unitRef="eur">35000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1492" decimals="-6" id="f-4293" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1493" decimals="-6" id="f-4294" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1494" decimals="-6" id="f-4295" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1495" decimals="-6" id="f-4296" unitRef="eur">2981000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1496" decimals="-6" id="f-4297" unitRef="eur">35000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1497" decimals="-6" id="f-4298" unitRef="eur">788000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1498" decimals="-6" id="f-4299" unitRef="eur">7000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1499" decimals="-6" id="f-4300" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1500" decimals="-6" id="f-4301" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1501" decimals="-6" id="f-4302" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1502" decimals="-6" id="f-4303" unitRef="eur">788000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1503" decimals="-6" id="f-4304" unitRef="eur">7000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1504" decimals="-6" id="f-4305" unitRef="eur">419000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1505" decimals="-6" id="f-4306" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1506" decimals="-6" id="f-4307" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1507" decimals="-6" id="f-4308" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1508" decimals="-6" id="f-4309" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1509" decimals="-6" id="f-4310" unitRef="eur">419000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1510" decimals="-6" id="f-4311" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1511" decimals="-6" id="f-4312" unitRef="eur">339000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1512" decimals="-6" id="f-4313" unitRef="eur">-6000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1513" decimals="-6" id="f-4314" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1514" decimals="-6" id="f-4315" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1515" decimals="-6" id="f-4316" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1516" decimals="-6" id="f-4317" unitRef="eur">339000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1517" decimals="-6" id="f-4318" unitRef="eur">-6000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1518" decimals="-6" id="f-4319" unitRef="eur">192000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1519" decimals="-6" id="f-4320" unitRef="eur">-4000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1520" decimals="-6" id="f-4321" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1521" decimals="-6" id="f-4322" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1522" decimals="-6" id="f-4323" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1523" decimals="-6" id="f-4324" unitRef="eur">192000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1524" decimals="-6" id="f-4325" unitRef="eur">-4000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1525" decimals="-6" id="f-4326" unitRef="eur">4246000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1526" decimals="-6" id="f-4327" unitRef="eur">-8000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1527" decimals="-6" id="f-4328" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1528" decimals="-6" id="f-4329" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1529" decimals="-6" id="f-4330" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1530" decimals="-6" id="f-4331" unitRef="eur">4246000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1531" decimals="-6" id="f-4332" unitRef="eur">-8000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1532" decimals="-6" id="f-4333" unitRef="eur">2022000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1533" decimals="-6" id="f-4334" unitRef="eur">-12000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1534" decimals="-6" id="f-4335" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1535" decimals="-6" id="f-4336" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1536" decimals="-6" id="f-4337" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1537" decimals="-6" id="f-4338" unitRef="eur">2022000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1538" decimals="-6" id="f-4339" unitRef="eur">-12000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1539" decimals="-6" id="f-4340" unitRef="eur">876000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1540" decimals="-6" id="f-4341" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1541" decimals="-6" id="f-4342" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1542" decimals="-6" id="f-4343" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1543" decimals="-6" id="f-4344" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1544" decimals="-6" id="f-4345" unitRef="eur">876000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1545" decimals="-6" id="f-4346" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1546" decimals="-6" id="f-4347" unitRef="eur">364000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1547" decimals="-6" id="f-4348" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1548" decimals="-6" id="f-4349" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1549" decimals="-6" id="f-4350" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1550" decimals="-6" id="f-4351" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1551" decimals="-6" id="f-4352" unitRef="eur">364000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1552" decimals="-6" id="f-4353" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1553" decimals="-6" id="f-4354" unitRef="eur">137000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1554" decimals="-6" id="f-4355" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1555" decimals="-6" id="f-4356" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1556" decimals="-6" id="f-4357" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1557" decimals="-6" id="f-4358" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1558" decimals="-6" id="f-4359" unitRef="eur">137000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1559" decimals="-6" id="f-4360" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1560" decimals="-6" id="f-4361" unitRef="eur">123000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1561" decimals="-6" id="f-4362" unitRef="eur">1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1562" decimals="-6" id="f-4363" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1563" decimals="-6" id="f-4364" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1564" decimals="-6" id="f-4365" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1565" decimals="-6" id="f-4366" unitRef="eur">123000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1566" decimals="-6" id="f-4367" unitRef="eur">1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1567" decimals="-6" id="f-4368" unitRef="eur">10358000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1568" decimals="-6" id="f-4369" unitRef="eur">22000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1569" decimals="-6" id="f-4370" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1570" decimals="-6" id="f-4371" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1571" decimals="-6" id="f-4372" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1572" decimals="-6" id="f-4373" unitRef="eur">10358000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1573" decimals="-6" id="f-4374" unitRef="eur">22000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1574" decimals="-6" id="f-4375" unitRef="eur">5403000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1575" decimals="-6" id="f-4376" unitRef="eur">49000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1576" decimals="-6" id="f-4377" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1577" decimals="-6" id="f-4378" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1578" decimals="-6" id="f-4379" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1579" decimals="-6" id="f-4380" unitRef="eur">5403000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1580" decimals="-6" id="f-4381" unitRef="eur">49000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1581" decimals="-6" id="f-4382" unitRef="eur">2732000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1582" decimals="-6" id="f-4383" unitRef="eur">56000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1583" decimals="-6" id="f-4384" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1584" decimals="-6" id="f-4385" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1585" decimals="-6" id="f-4386" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1586" decimals="-6" id="f-4387" unitRef="eur">2732000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1587" decimals="-6" id="f-4388" unitRef="eur">56000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1588" decimals="-6" id="f-4389" unitRef="eur">576000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1589" decimals="-6" id="f-4390" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1590" decimals="-6" id="f-4391" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1591" decimals="-6" id="f-4392" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1592" decimals="-6" id="f-4393" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1593" decimals="-6" id="f-4394" unitRef="eur">576000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1594" decimals="-6" id="f-4395" unitRef="eur">2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1595" decimals="-6" id="f-4396" unitRef="eur">240000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1596" decimals="-6" id="f-4397" unitRef="eur">-5000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1597" decimals="-6" id="f-4398" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1598" decimals="-6" id="f-4399" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1599" decimals="-6" id="f-4400" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1600" decimals="-6" id="f-4401" unitRef="eur">240000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1601" decimals="-6" id="f-4402" unitRef="eur">-5000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1602" decimals="-6" id="f-4403" unitRef="eur">180000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1603" decimals="-6" id="f-4404" unitRef="eur">1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1604" decimals="-6" id="f-4405" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1605" decimals="-6" id="f-4406" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1606" decimals="-6" id="f-4407" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1607" decimals="-6" id="f-4408" unitRef="eur">180000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1608" decimals="-6" id="f-4409" unitRef="eur">1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1609" decimals="-6" id="f-4410" unitRef="eur">179000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1610" decimals="-6" id="f-4411" unitRef="eur">-14000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1611" decimals="-6" id="f-4412" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1612" decimals="-6" id="f-4413" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1613" decimals="-6" id="f-4414" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1614" decimals="-6" id="f-4415" unitRef="eur">179000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1615" decimals="-6" id="f-4416" unitRef="eur">-14000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1616" decimals="-6" id="f-4417" unitRef="eur">3459000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1617" decimals="-6" id="f-4418" unitRef="eur">-27000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1618" decimals="-6" id="f-4419" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1619" decimals="-6" id="f-4420" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1620" decimals="-6" id="f-4421" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1621" decimals="-6" id="f-4422" unitRef="eur">3459000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1622" decimals="-6" id="f-4423" unitRef="eur">-27000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1623" decimals="-6" id="f-4424" unitRef="eur">2047000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1624" decimals="-6" id="f-4425" unitRef="eur">-21000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1625" decimals="-6" id="f-4426" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1626" decimals="-6" id="f-4427" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1627" decimals="-6" id="f-4428" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1628" decimals="-6" id="f-4429" unitRef="eur">2047000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1629" decimals="-6" id="f-4430" unitRef="eur">-21000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1630" decimals="-6" id="f-4431" unitRef="eur">375000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1631" decimals="-6" id="f-4432" unitRef="eur">-7000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1632" decimals="-6" id="f-4433" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1633" decimals="-6" id="f-4434" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1634" decimals="-6" id="f-4435" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1635" decimals="-6" id="f-4436" unitRef="eur">375000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1636" decimals="-6" id="f-4437" unitRef="eur">-7000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1637" decimals="-6" id="f-4438" unitRef="eur">142000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1638" decimals="-6" id="f-4439" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1639" decimals="-6" id="f-4440" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1640" decimals="-6" id="f-4441" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1641" decimals="-6" id="f-4442" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1642" decimals="-6" id="f-4443" unitRef="eur">142000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1643" decimals="-6" id="f-4444" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1644" decimals="-6" id="f-4445" unitRef="eur">130000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1645" decimals="-6" id="f-4446" unitRef="eur">4000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1646" decimals="-6" id="f-4447" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1647" decimals="-6" id="f-4448" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1648" decimals="-6" id="f-4449" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1649" decimals="-6" id="f-4450" unitRef="eur">130000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1650" decimals="-6" id="f-4451" unitRef="eur">4000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1651" decimals="-6" id="f-4452" unitRef="eur">84000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1652" decimals="-6" id="f-4453" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1653" decimals="-6" id="f-4454" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1654" decimals="-6" id="f-4455" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1655" decimals="-6" id="f-4456" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1656" decimals="-6" id="f-4457" unitRef="eur">84000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1657" decimals="-6" id="f-4458" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1658" decimals="-6" id="f-4459" unitRef="eur">8862000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1659" decimals="-6" id="f-4460" unitRef="eur">22000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1660" decimals="-6" id="f-4461" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1661" decimals="-6" id="f-4462" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1662" decimals="-6" id="f-4463" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1663" decimals="-6" id="f-4464" unitRef="eur">8862000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1664" decimals="-6" id="f-4465" unitRef="eur">22000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1665" decimals="-6" id="f-4466" unitRef="eur">3912000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1666" decimals="-6" id="f-4467" unitRef="eur">4000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1667" decimals="-6" id="f-4468" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1668" decimals="-6" id="f-4469" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1669" decimals="-6" id="f-4470" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1670" decimals="-6" id="f-4471" unitRef="eur">3912000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1671" decimals="-6" id="f-4472" unitRef="eur">4000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1672" decimals="-6" id="f-4473" unitRef="eur">1392000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1673" decimals="-6" id="f-4474" unitRef="eur">5000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1674" decimals="-6" id="f-4475" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1675" decimals="-6" id="f-4476" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1676" decimals="-6" id="f-4477" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1677" decimals="-6" id="f-4478" unitRef="eur">1392000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1678" decimals="-6" id="f-4479" unitRef="eur">5000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1679" decimals="-6" id="f-4480" unitRef="eur">665000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1680" decimals="-6" id="f-4481" unitRef="eur">-2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1681" decimals="-6" id="f-4482" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1682" decimals="-6" id="f-4483" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1683" decimals="-6" id="f-4484" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1684" decimals="-6" id="f-4485" unitRef="eur">665000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1685" decimals="-6" id="f-4486" unitRef="eur">-2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1686" decimals="-6" id="f-4487" unitRef="eur">355000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1687" decimals="-6" id="f-4488" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1688" decimals="-6" id="f-4489" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1689" decimals="-6" id="f-4490" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1690" decimals="-6" id="f-4491" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1691" decimals="-6" id="f-4492" unitRef="eur">355000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1692" decimals="-6" id="f-4493" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1693" decimals="-6" id="f-4494" unitRef="eur">199000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1694" decimals="-6" id="f-4495" unitRef="eur">3000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1695" decimals="-6" id="f-4496" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1696" decimals="-6" id="f-4497" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1697" decimals="-6" id="f-4498" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1698" decimals="-6" id="f-4499" unitRef="eur">199000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1699" decimals="-6" id="f-4500" unitRef="eur">3000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1700" decimals="-6" id="f-4501" unitRef="eur">122000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1701" decimals="-6" id="f-4502" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1702" decimals="-6" id="f-4503" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1703" decimals="-6" id="f-4504" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1704" decimals="-6" id="f-4505" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1705" decimals="-6" id="f-4506" unitRef="eur">122000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1706" decimals="-6" id="f-4507" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1707" decimals="-6" id="f-4508" unitRef="eur">2374000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1708" decimals="-6" id="f-4509" unitRef="eur">6000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1709" decimals="-6" id="f-4510" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1710" decimals="-6" id="f-4511" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1711" decimals="-6" id="f-4512" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1712" decimals="-6" id="f-4513" unitRef="eur">2374000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1713" decimals="-6" id="f-4514" unitRef="eur">6000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1714" decimals="-6" id="f-4515" unitRef="eur">833000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1715" decimals="-6" id="f-4516" unitRef="eur">-2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1716" decimals="-6" id="f-4517" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1717" decimals="-6" id="f-4518" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1718" decimals="-6" id="f-4519" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1719" decimals="-6" id="f-4520" unitRef="eur">833000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1720" decimals="-6" id="f-4521" unitRef="eur">-2000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1721" decimals="-6" id="f-4522" unitRef="eur">696000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1722" decimals="-6" id="f-4523" unitRef="eur">7000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1723" decimals="-6" id="f-4524" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1724" decimals="-6" id="f-4525" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1725" decimals="-6" id="f-4526" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1726" decimals="-6" id="f-4527" unitRef="eur">696000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1727" decimals="-6" id="f-4528" unitRef="eur">7000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1728" decimals="-6" id="f-4529" unitRef="eur">255000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1729" decimals="-6" id="f-4530" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1730" decimals="-6" id="f-4531" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1731" decimals="-6" id="f-4532" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1732" decimals="-6" id="f-4533" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1733" decimals="-6" id="f-4534" unitRef="eur">255000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1734" decimals="-6" id="f-4535" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1735" decimals="-6" id="f-4536" unitRef="eur">77000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1736" decimals="-6" id="f-4537" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1737" decimals="-6" id="f-4538" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1738" decimals="-6" id="f-4539" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1739" decimals="-6" id="f-4540" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1740" decimals="-6" id="f-4541" unitRef="eur">77000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1741" decimals="-6" id="f-4542" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1742" decimals="-6" id="f-4543" unitRef="eur">72000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1743" decimals="-6" id="f-4544" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1744" decimals="-6" id="f-4545" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1745" decimals="-6" id="f-4546" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1746" decimals="-6" id="f-4547" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1747" decimals="-6" id="f-4548" unitRef="eur">72000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1748" decimals="-6" id="f-4549" unitRef="eur">-1000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1749" decimals="-6" id="f-4550" unitRef="eur">6286000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1750" decimals="-6" id="f-4551" unitRef="eur">10000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1751" decimals="-6" id="f-4552" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1752" decimals="-6" id="f-4553" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1753" decimals="-6" id="f-4554" unitRef="eur">0</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1754" decimals="-6" id="f-4555" unitRef="eur">6286000000</sny:DerivativeFinancialInstruments>
    <sny:DerivativeFinancialInstruments contextRef="c-1755" decimals="-6" id="f-4556" unitRef="eur">10000000</sny:DerivativeFinancialInstruments>
    <sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock contextRef="c-1" id="f-4557">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows financial currency hedging instruments in place, with the notional amount translated into euros at the relevant closing exchange rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.942%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.249%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,279&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;111&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,559&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,655&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;5,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Chinese yuan renminbi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forward currency purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,055&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,997&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,293&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;197&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which US dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(b) (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Singapore dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,334&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,556&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,948&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;212&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi&#x2019;s net investment in Bioverativ. As of December 31, 2023, the fair value of these forward contracts represented an asset of &#x20ac;54 million; the opposite entry was recognized in "Other comprehensive income", with the impact on financial income and expense being immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2023, the fair value of the contracts was a liability of &#x20ac;31 million, the opposite entry for &#x20ac;2.7&#160;million of which was credited to &#x201c;Other comprehensive income&#x201d; under the cost of hedging accounting treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Includes forward purchases with a notional amount of $1,044 million expiring in 2024, designated as a fair value hedge of the exposure of an equivalent amount of commercial paper. As of December 31, 2023, the fair value of the swaps was a liability of &#x20ac;3 million, the opposite entry for &#x20ac;0.7&#160;million of which was credited to &#x201c;Other comprehensive income&#x201d; under the cost of hedging accounting treatment.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfFinancialCurrencyHedgingInstrumentsWithNotionalAmountTranslatedInToEurosAtClosingExchangeRateExplanatoryTableTextBlock>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1483" decimals="-6" id="f-4558" unitRef="eur">10279000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1484" decimals="-6" id="f-4559" unitRef="eur">111000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1574" decimals="-6" id="f-4560" unitRef="eur">7559000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1575" decimals="-6" id="f-4561" unitRef="eur">66000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1665" decimals="-6" id="f-4562" unitRef="eur">7655000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1666" decimals="-6" id="f-4563" unitRef="eur">15000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1756" decimals="-6" id="f-4564" unitRef="eur">6628000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1757" decimals="-6" id="f-4565" unitRef="eur">101000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1758" decimals="-6" id="f-4566" unitRef="eur">6114000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1759" decimals="-6" id="f-4567" unitRef="eur">59000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1760" decimals="-6" id="f-4568" unitRef="eur">5384000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1761" decimals="-6" id="f-4569" unitRef="eur">23000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1762" decimals="-6" id="f-4570" unitRef="eur">1556000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1763" decimals="-6" id="f-4571" unitRef="eur">6000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1764" decimals="-6" id="f-4572" unitRef="eur">0</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1765" decimals="-6" id="f-4573" unitRef="eur">0</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1766" decimals="-6" id="f-4574" unitRef="eur">0</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1767" decimals="-6" id="f-4575" unitRef="eur">0</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1768" decimals="-6" id="f-4576" unitRef="eur">513000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1769" decimals="-6" id="f-4577" unitRef="eur">4000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1770" decimals="-6" id="f-4578" unitRef="eur">203000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1771" decimals="-6" id="f-4579" unitRef="eur">2000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1772" decimals="-6" id="f-4580" unitRef="eur">70000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1773" decimals="-6" id="f-4581" unitRef="eur">-2000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1525" decimals="-6" id="f-4582" unitRef="eur">7055000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1526" decimals="-6" id="f-4583" unitRef="eur">-58000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1616" decimals="-6" id="f-4584" unitRef="eur">4997000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1617" decimals="-6" id="f-4585" unitRef="eur">24000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1707" decimals="-6" id="f-4586" unitRef="eur">9293000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1708" decimals="-6" id="f-4587" unitRef="eur">197000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1774" decimals="-6" id="f-4588" unitRef="eur">3073000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1775" decimals="-6" id="f-4589" unitRef="eur">-52000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1776" decimals="-6" id="f-4590" unitRef="eur">2011000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1777" decimals="-6" id="f-4591" unitRef="eur">-4000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1778" decimals="-6" id="f-4592" unitRef="eur">4816000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1779" decimals="-6" id="f-4593" unitRef="eur">128000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1780" decimals="-6" id="f-4594" unitRef="eur">2696000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1781" decimals="-6" id="f-4595" unitRef="eur">-10000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1782" decimals="-6" id="f-4596" unitRef="eur">2154000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1783" decimals="-6" id="f-4597" unitRef="eur">22000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1784" decimals="-6" id="f-4598" unitRef="eur">2910000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1785" decimals="-6" id="f-4599" unitRef="eur">75000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1786" decimals="-6" id="f-4600" unitRef="eur">341000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1787" decimals="-6" id="f-4601" unitRef="eur">3000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1788" decimals="-6" id="f-4602" unitRef="eur">205000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1789" decimals="-6" id="f-4603" unitRef="eur">4000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1790" decimals="-6" id="f-4604" unitRef="eur">235000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1791" decimals="-6" id="f-4605" unitRef="eur">-2000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1567" decimals="-6" id="f-4606" unitRef="eur">17334000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1568" decimals="-6" id="f-4607" unitRef="eur">53000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1658" decimals="-6" id="f-4608" unitRef="eur">12556000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1659" decimals="-6" id="f-4609" unitRef="eur">90000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1749" decimals="-6" id="f-4610" unitRef="eur">16948000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <sny:DerivativeFinancialInstrumentsToManageFinancialExposure contextRef="c-1750" decimals="-6" id="f-4611" unitRef="eur">212000000</sny:DerivativeFinancialInstrumentsToManageFinancialExposure>
    <ifrs-full:NotionalAmount contextRef="c-1792" decimals="-6" id="f-4612" unitRef="usd">3615000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialAssets contextRef="c-1792" decimals="-6" id="f-4613" unitRef="eur">54000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:NotionalAmount contextRef="c-1793" decimals="-6" id="f-4614" unitRef="usd">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-1793" decimals="-6" id="f-4615" unitRef="usd">1000000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-1793" decimals="-6" id="f-4616" unitRef="eur">31000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-1794" decimals="-5" id="f-4617" unitRef="eur">2700000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:NotionalAmount contextRef="c-1795" decimals="-6" id="f-4618" unitRef="usd">1044000000</ifrs-full:NotionalAmount>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-1795" decimals="-6" id="f-4619" unitRef="eur">3000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax contextRef="c-1796" decimals="-5" id="f-4620" unitRef="eur">700000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock contextRef="c-1" id="f-4621">&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows interest rate hedging instruments in place as of December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amounts by expiry date as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e3e3e3;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;designated as&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as&lt;br/&gt;cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2029 and later&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;br/&gt;recognized&lt;br/&gt;in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD/receive 1.03%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD/receive 1.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester/receive 0.69%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester/receive 0.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester / receive 3.43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;999&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;906&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;650&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,405&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,405&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows interest rate hedging instruments in place as of December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amounts by expiry date as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;designated as&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as&lt;br/&gt;cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2028 and later&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;br/&gt;recognized&lt;br/&gt;in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD/receive 1.03%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized SOFR USD/receive 1.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester/receive 0.69%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized Ester/receive 0.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;850&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,584&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,434&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,434&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows interest rate hedging instruments in place as of December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amounts by expiry date as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;designated as&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which designated as&lt;br/&gt;cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2027 and later&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Of which&lt;br/&gt;recognized&lt;br/&gt;in equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized EONIA/receive 0.06%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay -0.57%/receive capitalized EONIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized USD SOFR/receive 1.03%  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;pay capitalized USD SOFR/receive 1.32%  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;receive capitalized Eonia/pay 1.48%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,642&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;880&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,579&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,979&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;600&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;These interest rate swaps hedge fixed-rate bonds with a nominal of &#x20ac;99 million held in a Professional Specialized Investment Fund dedicated to Sanofi and recognized within &#x201c;Long-term loans and advances and other non-current receivables&#x201d; (see Note D.7.).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfInterestRatesHedgingInstrumentsWithNotionalAmountByExpiryDateExplanatoryTableTextBlock>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1797"
      decimals="4"
      id="f-4622"
      unitRef="number">0.0103</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1798" decimals="-6" id="f-4623" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1799" decimals="-6" id="f-4624" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1800" decimals="-6" id="f-4625" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1801" decimals="-6" id="f-4626" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1802" decimals="-6" id="f-4627" unitRef="eur">453000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1803" decimals="-6" id="f-4628" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1804" decimals="-6" id="f-4629" unitRef="eur">453000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1805" decimals="-6" id="f-4630" unitRef="eur">-49000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1806" decimals="-6" id="f-4631" unitRef="eur">453000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1807" decimals="-6" id="f-4632" unitRef="eur">-49000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1808" decimals="-6" id="f-4633" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1809" decimals="-6" id="f-4634" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1810" decimals="-6" id="f-4635" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1811"
      decimals="4"
      id="f-4636"
      unitRef="number">0.0132</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1812" decimals="-6" id="f-4637" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1813" decimals="-6" id="f-4638" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1814" decimals="-6" id="f-4639" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1815" decimals="-6" id="f-4640" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1816" decimals="-6" id="f-4641" unitRef="eur">453000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1817" decimals="-6" id="f-4642" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1818" decimals="-6" id="f-4643" unitRef="eur">453000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1819" decimals="-6" id="f-4644" unitRef="eur">-43000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1820" decimals="-6" id="f-4645" unitRef="eur">453000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1821" decimals="-6" id="f-4646" unitRef="eur">-43000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1822" decimals="-6" id="f-4647" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1823" decimals="-6" id="f-4648" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1824" decimals="-6" id="f-4649" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1825"
      decimals="4"
      id="f-4650"
      unitRef="number">0.0069</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1826" decimals="-6" id="f-4651" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1827" decimals="-6" id="f-4652" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1828" decimals="-6" id="f-4653" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1829" decimals="-6" id="f-4654" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1830" decimals="-6" id="f-4655" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1831" decimals="-6" id="f-4656" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1832" decimals="-6" id="f-4657" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1833" decimals="-6" id="f-4658" unitRef="eur">-28000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1834" decimals="-6" id="f-4659" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1835" decimals="-6" id="f-4660" unitRef="eur">-28000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1836" decimals="-6" id="f-4661" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1837" decimals="-6" id="f-4662" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1838" decimals="-6" id="f-4663" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1839"
      decimals="4"
      id="f-4664"
      unitRef="number">0.0092</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1840" decimals="-6" id="f-4665" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1841" decimals="-6" id="f-4666" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1842" decimals="-6" id="f-4667" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1843" decimals="-6" id="f-4668" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1844" decimals="-6" id="f-4669" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1845" decimals="-6" id="f-4670" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1846" decimals="-6" id="f-4671" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1847" decimals="-6" id="f-4672" unitRef="eur">-44000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1848" decimals="-6" id="f-4673" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1849" decimals="-6" id="f-4674" unitRef="eur">-44000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1850" decimals="-6" id="f-4675" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1851" decimals="-6" id="f-4676" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1852" decimals="-6" id="f-4677" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1853"
      decimals="4"
      id="f-4678"
      unitRef="number">0.0343</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1854" decimals="-6" id="f-4679" unitRef="eur">999000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1855" decimals="-6" id="f-4680" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1856" decimals="-6" id="f-4681" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1857" decimals="-6" id="f-4682" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1858" decimals="-6" id="f-4683" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1859" decimals="-6" id="f-4684" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1860" decimals="-6" id="f-4685" unitRef="eur">999000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1861" decimals="-6" id="f-4686" unitRef="eur">-1000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1862" decimals="-6" id="f-4687" unitRef="eur">999000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1863" decimals="-6" id="f-4688" unitRef="eur">-1000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1864" decimals="-6" id="f-4689" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1865" decimals="-6" id="f-4690" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1866" decimals="-6" id="f-4691" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1867" decimals="-6" id="f-4692" unitRef="eur">999000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1868" decimals="-6" id="f-4693" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1869" decimals="-6" id="f-4694" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1870" decimals="-6" id="f-4695" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1871" decimals="-6" id="f-4696" unitRef="eur">906000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1872" decimals="-6" id="f-4697" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1567" decimals="-6" id="f-4698" unitRef="eur">3405000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1568" decimals="-6" id="f-4699" unitRef="eur">-165000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1873" decimals="-6" id="f-4700" unitRef="eur">3405000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1874" decimals="-6" id="f-4701" unitRef="eur">-165000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1569" decimals="-6" id="f-4702" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1570" decimals="-6" id="f-4703" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1571" decimals="-6" id="f-4704" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1875"
      decimals="4"
      id="f-4705"
      unitRef="number">0.0103</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1876" decimals="-6" id="f-4706" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1877" decimals="-6" id="f-4707" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1878" decimals="-6" id="f-4708" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1879" decimals="-6" id="f-4709" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1880" decimals="-6" id="f-4710" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1881" decimals="-6" id="f-4711" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1882" decimals="-6" id="f-4712" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1883" decimals="-6" id="f-4713" unitRef="eur">-62000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1884" decimals="-6" id="f-4714" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1885" decimals="-6" id="f-4715" unitRef="eur">-62000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1886" decimals="-6" id="f-4716" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1887" decimals="-6" id="f-4717" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1888" decimals="-6" id="f-4718" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1889"
      decimals="4"
      id="f-4719"
      unitRef="number">0.0132</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1890" decimals="-6" id="f-4720" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1891" decimals="-6" id="f-4721" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1892" decimals="-6" id="f-4722" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1893" decimals="-6" id="f-4723" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1894" decimals="-6" id="f-4724" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1895" decimals="-6" id="f-4725" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1896" decimals="-6" id="f-4726" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1897" decimals="-6" id="f-4727" unitRef="eur">-56000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1898" decimals="-6" id="f-4728" unitRef="eur">467000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1899" decimals="-6" id="f-4729" unitRef="eur">-56000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1900" decimals="-6" id="f-4730" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1901" decimals="-6" id="f-4731" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1902" decimals="-6" id="f-4732" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1903"
      decimals="4"
      id="f-4733"
      unitRef="number">0.0069</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1904" decimals="-6" id="f-4734" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1905" decimals="-6" id="f-4735" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1906" decimals="-6" id="f-4736" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1907" decimals="-6" id="f-4737" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1908" decimals="-6" id="f-4738" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1909" decimals="-6" id="f-4739" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1910" decimals="-6" id="f-4740" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1911" decimals="-6" id="f-4741" unitRef="eur">-43000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1912" decimals="-6" id="f-4742" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1913" decimals="-6" id="f-4743" unitRef="eur">-43000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1914" decimals="-6" id="f-4744" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1915" decimals="-6" id="f-4745" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1916" decimals="-6" id="f-4746" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1917"
      decimals="4"
      id="f-4747"
      unitRef="number">0.0092</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1918" decimals="-6" id="f-4748" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1919" decimals="-6" id="f-4749" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1920" decimals="-6" id="f-4750" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1921" decimals="-6" id="f-4751" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1922" decimals="-6" id="f-4752" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1923" decimals="-6" id="f-4753" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1924" decimals="-6" id="f-4754" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1925" decimals="-6" id="f-4755" unitRef="eur">-71000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1926" decimals="-6" id="f-4756" unitRef="eur">650000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1927" decimals="-6" id="f-4757" unitRef="eur">-71000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1928" decimals="-6" id="f-4758" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1929" decimals="-6" id="f-4759" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1930" decimals="-6" id="f-4760" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1931" decimals="-6" id="f-4761" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1932" decimals="-6" id="f-4762" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1933" decimals="-6" id="f-4763" unitRef="eur">850000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1934" decimals="-6" id="f-4764" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1935" decimals="-6" id="f-4765" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1936" decimals="-6" id="f-4766" unitRef="eur">1584000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1658" decimals="-6" id="f-4767" unitRef="eur">2434000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1659" decimals="-6" id="f-4768" unitRef="eur">-232000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1937" decimals="-6" id="f-4769" unitRef="eur">2434000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1938" decimals="-6" id="f-4770" unitRef="eur">-232000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1660" decimals="-6" id="f-4771" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1661" decimals="-6" id="f-4772" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1662" decimals="-6" id="f-4773" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1939"
      decimals="4"
      id="f-4774"
      unitRef="number">0.0006</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1940" decimals="-6" id="f-4775" unitRef="eur">2000000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1941" decimals="-6" id="f-4776" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1942" decimals="-6" id="f-4777" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1943" decimals="-6" id="f-4778" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1944" decimals="-6" id="f-4779" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1945" decimals="-6" id="f-4780" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1946" decimals="-6" id="f-4781" unitRef="eur">2000000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1947" decimals="-6" id="f-4782" unitRef="eur">10000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1948" decimals="-6" id="f-4783" unitRef="eur">2000000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1949" decimals="-6" id="f-4784" unitRef="eur">10000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1950" decimals="-6" id="f-4785" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1951" decimals="-6" id="f-4786" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1952" decimals="-6" id="f-4787" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1953"
      decimals="4"
      id="f-4788"
      unitRef="number">-0.0057</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1954" decimals="-6" id="f-4789" unitRef="eur">600000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1955" decimals="-6" id="f-4790" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1956" decimals="-6" id="f-4791" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1957" decimals="-6" id="f-4792" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1958" decimals="-6" id="f-4793" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1959" decimals="-6" id="f-4794" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1960" decimals="-6" id="f-4795" unitRef="eur">600000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1961" decimals="-6" id="f-4796" unitRef="eur">1000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1962" decimals="-6" id="f-4797" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1963" decimals="-6" id="f-4798" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1964" decimals="-6" id="f-4799" unitRef="eur">600000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1965" decimals="-6" id="f-4800" unitRef="eur">1000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1966" decimals="-6" id="f-4801" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1967"
      decimals="4"
      id="f-4802"
      unitRef="number">0.0103</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1968" decimals="-6" id="f-4803" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1969" decimals="-6" id="f-4804" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1970" decimals="-6" id="f-4805" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1971" decimals="-6" id="f-4806" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1972" decimals="-6" id="f-4807" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1973" decimals="-6" id="f-4808" unitRef="eur">440000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1974" decimals="-6" id="f-4809" unitRef="eur">440000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1975" decimals="-6" id="f-4810" unitRef="eur">-5000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1976" decimals="-6" id="f-4811" unitRef="eur">440000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1977" decimals="-6" id="f-4812" unitRef="eur">-5000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1978" decimals="-6" id="f-4813" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1979" decimals="-6" id="f-4814" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1980" decimals="-6" id="f-4815" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1981"
      decimals="4"
      id="f-4816"
      unitRef="number">0.0132</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1982" decimals="-6" id="f-4817" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1983" decimals="-6" id="f-4818" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1984" decimals="-6" id="f-4819" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1985" decimals="-6" id="f-4820" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1986" decimals="-6" id="f-4821" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1987" decimals="-6" id="f-4822" unitRef="eur">440000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1988" decimals="-6" id="f-4823" unitRef="eur">440000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1989" decimals="-6" id="f-4824" unitRef="eur">3000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1990" decimals="-6" id="f-4825" unitRef="eur">440000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1991" decimals="-6" id="f-4826" unitRef="eur">3000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1992" decimals="-6" id="f-4827" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1993" decimals="-6" id="f-4828" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1994" decimals="-6" id="f-4829" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:InterestRateSwapsInterestRate
      contextRef="c-1995"
      decimals="4"
      id="f-4830"
      unitRef="number">0.0148</sny:InterestRateSwapsInterestRate>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1996" decimals="-6" id="f-4831" unitRef="eur">42000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1997" decimals="-6" id="f-4832" unitRef="eur">57000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1998" decimals="-6" id="f-4833" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1999" decimals="-6" id="f-4834" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2000" decimals="-6" id="f-4835" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2001" decimals="-6" id="f-4836" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2002" decimals="-6" id="f-4837" unitRef="eur">99000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2003" decimals="-6" id="f-4838" unitRef="eur">-3000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2004" decimals="-6" id="f-4839" unitRef="eur">99000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2005" decimals="-6" id="f-4840" unitRef="eur">-3000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2006" decimals="-6" id="f-4841" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2007" decimals="-6" id="f-4842" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2008" decimals="-6" id="f-4843" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2009" decimals="-6" id="f-4844" unitRef="eur">2642000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2010" decimals="-6" id="f-4845" unitRef="eur">57000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2011" decimals="-6" id="f-4846" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2012" decimals="-6" id="f-4847" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2013" decimals="-6" id="f-4848" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2014" decimals="-6" id="f-4849" unitRef="eur">880000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1749" decimals="-6" id="f-4850" unitRef="eur">3579000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1750" decimals="-6" id="f-4851" unitRef="eur">7000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2015" decimals="-6" id="f-4852" unitRef="eur">2979000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-2016" decimals="-6" id="f-4853" unitRef="eur">6000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1751" decimals="-6" id="f-4854" unitRef="eur">600000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1752" decimals="-6" id="f-4855" unitRef="eur">1000000</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents contextRef="c-1753" decimals="-6" id="f-4856" unitRef="eur">0</sny:CurrencyAndInterestRateDerivativesUsedToManageDebtNetOfCashAndCashEquivalents>
    <sny:DerivativeFinancialInstruments contextRef="c-2002" decimals="-6" id="f-4857" unitRef="eur">99000000</sny:DerivativeFinancialInstruments>
    <sny:DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock contextRef="c-1" id="f-4858">&lt;div style="margin-bottom:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below is prepared in accordance with the accounting policies described in Note&#160;B.8.3.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;financial&lt;br/&gt;liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross carrying amounts before offset (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross amounts offset (in accordance with IAS&#160;32)&#160;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net amounts as reported in the balance sheet (a) -&#160;(b) =&#160;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;298&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effects of other netting arrangements (not fulfilling the IAS&#160;32 criteria for offsetting) (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value of financial collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net exposure (c) + (d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;231&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfActualOrPotentialEffectsOfNettingArrangementsTableTextBlock>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset contextRef="c-2017" decimals="-6" id="f-4859" unitRef="eur">201000000</sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset contextRef="c-2018" decimals="-6" id="f-4860" unitRef="eur">-291000000</sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset contextRef="c-2019" decimals="-6" id="f-4861" unitRef="eur">206000000</sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset contextRef="c-2020" decimals="-6" id="f-4862" unitRef="eur">-326000000</sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset contextRef="c-2021" decimals="-6" id="f-4863" unitRef="eur">298000000</sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset contextRef="c-2022" decimals="-6" id="f-4864" unitRef="eur">-85000000</sny:DerivativeFinancialAssetsAndLiabilitiesGrossCarryingAmountsBeforeOffset>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32 contextRef="c-2017" decimals="-6" id="f-4865" unitRef="eur">0</sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32 contextRef="c-2018" decimals="-6" id="f-4866" unitRef="eur">0</sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32 contextRef="c-2019" decimals="-6" id="f-4867" unitRef="eur">0</sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32 contextRef="c-2020" decimals="-6" id="f-4868" unitRef="eur">0</sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32 contextRef="c-2021" decimals="-6" id="f-4869" unitRef="eur">0</sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32>
    <sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32 contextRef="c-2022" decimals="-6" id="f-4870" unitRef="eur">0</sny:DerivativeFinancialAssetsAndLiabilitiesGrossAmountsOffsetInAccordanceWithIAS32>
    <sny:NetAmountsAsReportedInTheBalanceSheet contextRef="c-2017" decimals="-6" id="f-4871" unitRef="eur">201000000</sny:NetAmountsAsReportedInTheBalanceSheet>
    <sny:NetAmountsAsReportedInTheBalanceSheet contextRef="c-2018" decimals="-6" id="f-4872" unitRef="eur">-291000000</sny:NetAmountsAsReportedInTheBalanceSheet>
    <sny:NetAmountsAsReportedInTheBalanceSheet contextRef="c-2019" decimals="-6" id="f-4873" unitRef="eur">206000000</sny:NetAmountsAsReportedInTheBalanceSheet>
    <sny:NetAmountsAsReportedInTheBalanceSheet contextRef="c-2020" decimals="-6" id="f-4874" unitRef="eur">-326000000</sny:NetAmountsAsReportedInTheBalanceSheet>
    <sny:NetAmountsAsReportedInTheBalanceSheet contextRef="c-2021" decimals="-6" id="f-4875" unitRef="eur">298000000</sny:NetAmountsAsReportedInTheBalanceSheet>
    <sny:NetAmountsAsReportedInTheBalanceSheet contextRef="c-2022" decimals="-6" id="f-4876" unitRef="eur">-85000000</sny:NetAmountsAsReportedInTheBalanceSheet>
    <sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral contextRef="c-2023" decimals="-6" id="f-4877" unitRef="eur">0</sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral>
    <sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral contextRef="c-2024" decimals="-6" id="f-4878" unitRef="eur">0</sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFairValueOfFinancialCollateral>
    <sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments contextRef="c-2023" decimals="-6" id="f-4879" unitRef="eur">-171000000</sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments>
    <sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments contextRef="c-2024" decimals="-6" id="f-4880" unitRef="eur">171000000</sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments>
    <sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments contextRef="c-2025" decimals="-6" id="f-4881" unitRef="eur">-160000000</sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments>
    <sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments contextRef="c-2026" decimals="-6" id="f-4882" unitRef="eur">160000000</sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments>
    <sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments contextRef="c-2027" decimals="-6" id="f-4883" unitRef="eur">-67000000</sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments>
    <sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments contextRef="c-2028" decimals="-6" id="f-4884" unitRef="eur">67000000</sny:EffectsOfOtherNettingArrangementsNotFulfillingTheIAS32CriteriaForOffsettingFinancialInstruments>
    <sny:NetExposure contextRef="c-2017" decimals="-6" id="f-4885" unitRef="eur">30000000</sny:NetExposure>
    <sny:NetExposure contextRef="c-2018" decimals="-6" id="f-4886" unitRef="eur">-120000000</sny:NetExposure>
    <sny:NetExposure contextRef="c-2019" decimals="-6" id="f-4887" unitRef="eur">46000000</sny:NetExposure>
    <sny:NetExposure contextRef="c-2020" decimals="-6" id="f-4888" unitRef="eur">-166000000</sny:NetExposure>
    <sny:NetExposure contextRef="c-2021" decimals="-6" id="f-4889" unitRef="eur">231000000</sny:NetExposure>
    <sny:NetExposure contextRef="c-2022" decimals="-6" id="f-4890" unitRef="eur">-18000000</sny:NetExposure>
    <sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock contextRef="c-1" id="f-4891">Off balance sheet commitments&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The off balance sheet commitments presented below are shown at their nominal value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.21.1. Off balance sheet commitments relating to operating activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Off balance sheet commitments relating to Sanofi&#x2019;s operating activities comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.008%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Irrevocable purchase commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;given&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(443)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development license agreements - commitments given&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;commitments related to R&amp;amp;D and other commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;contingent milestone payments in connection with development programs in progress&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total - net commitments given&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,079&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,563&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,878&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,625&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,013&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes the variable portion of future lease payments not recognized as lease liabilities as of December 31, 2023; the equivalent amount of these commitments as of December&#160;31, 2022 was &#x20ac;38&#160;million.&lt;br/&gt;During 2023, Sanofi signed a 15-year lease which will take effect in 2025 and for which Sanofi is committed for a minimum period of 12 years, corresponding to a minimum commitment of $0.2&#160;billion. The lease includes two extension options of five years each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;These comprise irrevocable commitments to suppliers of (i)&#160;property, plant and equipment, net of down-payments (see Note&#160;D.3.) and (ii)&#160;goods and services. As of December 31, 2022, irrevocable commitments amounted to &#x20ac;6,194 million given and &#x20ac;574 million received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Irrevocable purchase commitments given as of December 31, 2023 include &#x20ac;926 million of commitments to joint ventures, and the commitment to EUROAPI as described in Note D.2. and amounting to &#x20ac;804&#160;million as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Commitments related to R&amp;amp;D, and other commitments, amounted to &#x20ac;259 million as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&#160;&#160;&#160;&#160;This line includes only contingent milestone payments on development projects in progress. The equivalent amount as of December 31, 2022 was     &#x20ac;2,919 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In pursuance of its strategy, Sanofi may acquire technologies and rights to products. Such acquisitions may be made in various contractual forms: acquisitions of shares, loans, license agreements, joint development, and co-marketing. These arrangements generally involve upfront payments on signature of the agreement, development milestone payments, and royalties. Some of these complex agreements include undertakings to fund research programs in future years and payments contingent upon achieving specified development milestones, the granting of approvals or licenses, or the attainment of sales targets once a product is commercialized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The &#x201c;Research and development license agreements&#x201d; line comprises future service commitments to fund research and development or technology, and contingent milestone payments regarded as reasonably achievable (i.e. all potential milestone payments relating to projects in the development phase, for which the future financial consequences are known or probable and for which there is a sufficiently reliable estimate). This line excludes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;commitments given relating to (i)&#160;projects in the research phase, amounting to &#x20ac;16.8 billion as of December&#160;31, 2023 and &#x20ac;18.0 billion as of December&#160;31, 2022 and (ii)&#160;payments contingent upon the attainment of sales targets once a product is commercialized, amounting to &#x20ac;17.9 billion as of December&#160;31, 2023 and &#x20ac;18.5 billion as of December&#160;31, 2022);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;commitments received amounting to &#x20ac;10.0 billion as of December&#160;31, 2023 (&#x20ac;8.8 billion as of December&#160;31, 2022), mainly&#160;comprising research, development and commercialization agreements with partners further to the acquisitions of&#160;(i)&#160;Ablynx&#160;(&#x20ac;0.9 billion as of December 31, 2023, versus &#x20ac;1.0 billion as of December&#160;31, 2022); (ii)&#160;Kymab (&#x20ac;0.2 billion&#160;as of&#160;December 31, 2023, versus &#x20ac;0.2 billion as of December&#160;31, 2022) and (iii)&#160;Provention Bio (&#x20ac;0.3 billion as of&#160;December&#160;31,&#160;2023), plus contingent consideration receivable based on attainment of regulatory and&#160;sales milestones for commercialized products under the terms of licenses or rights assignment agreements amounting to &#x20ac;8.5 billion&#160;as of&#160;December&#160;31, 2023 (&#x20ac;7.6 billion&#160;as of December&#160;31, 2022).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The major agreements entered into by Sanofi in 2023 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;on June&#160;19, 2023, Sanofi expanded its collaboration with Scribe Therapeutics signed in September&#160;2022 and entered into an exclusive license agreement on CasX-Editor(XE) genome editing technology associated with guide RNAs for multiple targets including sickle cell disease and other genomic diseases. Under the terms of the agreement, Scribe Therapeutics received an upfront payment of $40&#160;million and may receive more than $1.2&#160;billion based on the achievement of certain milestones;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;on October&#160;3, 2023, Sanofi entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), to develop and commercialize the vaccine candidate against extra intestinal pathogenic strains of E. coli developed by Janssen, currently in&#160;Phase&#160;3. Under the terms of the agreement, both parties will co-fund current and future research and development costs. Sanofi paid $175&#160;million upfront to Janssen and may pay to Janssen milestone payments contingent on the attainment of certain development and commercial objectives;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;on October&#160;4, 2023, Sanofi entered into a collaboration with Teva Pharmaceuticals to co-develop and co-commercialize asset TEV&#x2019;574, currently in Phase&#160;2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease. Under the terms of the new collaboration agreement, Teva received an upfront payment of&#160;&#x20ac;469&#160;million ($500&#160;million) and may receive up to &#x20ac;940&#160;million ($1&#160;billion) in milestone payments, depending on the achievement of development and commercialization goals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, by acquiring all of the outstanding shares of Provention Bio, Inc. on April&#160;27, 2023 (see Note&#160;D.1.), Sanofi assumed  commitments amounting to &#x20ac;946&#160;million made by that company to various partners under collaboration agreements previously entered into.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The amount of commitments as of December&#160;31, 2023 also includes commitments under agreements entered into by Sanofi in prior years, the principal ones of which are described below. For a full description of each agreement, refer to the Annual Report on Form&#160;20-F for the year in which the agreement was entered into.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The major agreements entered into by Sanofi in 2022 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;with Exscentia: an innovative license agreement and research collaboration to develop up to 15&#160;novel small molecule candidates across oncology and immunology, leveraging Exscientia&#x2019;s end-to-end AI-driven platform utilizing actual patient samples;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;with ABL Bio: a licensing and collaboration agreement for the development of ABL301, a bispecific antibody intended as a treatment for alpha-synucleinopathies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a collaboration and exclusive license agreement with Adagene Inc., a company specializing in the discovery and development of antibody-based therapies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a strategic risk-sharing collaboration with Blackstone under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to &#x20ac;300&#160;million to accelerate the global pivotal studies and clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody SARCLISA, to treat patients with multiple myeloma. That amount will be paid to Sanofi on the basis of development expenses incurred. In addition, Sanofi may pay royalties on future sales of this solution;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;an exclusive collaboration agreement with IGM Biosciences, Inc. to create, develop, manufacture and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a collaboration agreement with Skyhawk Therapeutics, Inc. to discover and develop novel small molecules that modulate RNA splicing to address challenging oncology and immunology targets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a collaboration agreement with Atomwise that will leverage its ATOMNET platform to identify and synthesize up to five drug targets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a research collaboration with Scribe Therapeutics to leverage its CRISPR by&#160;Design platform and to obtain a non-exclusive license to genome editing CasX-Editor(XE) technology for multiple oncology targets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;a strategic research collaboration with Insilico Medicine to leverage Insilico Medicine&#x2019;s AI platform, Pharma.AI, to advance drug development candidates for up to six new therapeutic targets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7-H3 from Innate&#x2019;s ANKET (Antibody-based NK Cell Engager Therapeutics) platform.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal agreements entered into by Sanofi in previous years are listed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;Biond Biologics (2021): license agreement for the development and commercialization of BND-22 (a humanized IgG4 antagonist antibody targeting the Ig-like transcript&#160;2 (ILT2) receptor, in development for the treatment of solid tumors);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;Kymera (2020): agreement to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;Nurix Therapeutics (2020): collaboration to develop novel targeted protein degradation therapies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;Denali Therapeutics&#160;Inc. (2018): collaboration agreement on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases. The two lead molecules are DNL747 in multiple sclerosis and amyotrophic lateral sclerosis, and DNL758 in systemic inflammatory diseases such as rheumatoid arthritis and psoriasis;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi and one of its alliance partners have decided to terminate the following agreement (the related commitments are no longer included in Sanofi&#x2019;s off balance sheet disclosures as of December 31, 2023):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;on January&#160;6, 2023, Sanofi and Regulus Therapeutics Inc. terminated their collaboration and license agreement on the discovery, development and commercialization of new micro-RNA derived molecules in fibrosis. The termination took effect on February&#160;5 ,2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, under the collaboration agreement with Regeneron on monoclonal antibodies (see Note&#160;C.1.), Sanofi is entitled to receive an additional share of quarterly profits (capped at 10% of Regeneron&#x2019;s share of quarterly profits until March&#160;31, 2022, and thereafter at 20%), until Regeneron has paid 50% of the cumulative development costs incurred by the parties to the alliance. As&#160;of December&#160;31, 2023 this represented total commitments received of &#x20ac;2.1 billion (versus &#x20ac;2.7 billion as of December&#160;31, 2022), against cumulative development costs of &#x20ac;8.6 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi entered into an agreement with Royalty Pharma in December&#160;2014 relating to development programs, under which Royalty Pharma bore a portion of the remaining development costs of the project on a quarterly basis in return for royalties on future sales. The products in development under that agreement have been launched in territories including the United States and Europe, marking the end of the joint development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On February&#160;27, 2017, Sanofi and Lonza announced a strategic partnership in the form of a joint venture (BioAtrium AG) to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. An initial investment of approximately &#x20ac;0.3 billion to finance construction of the facility, split 50/50 between the two partners, has now been made in full. In addition, Sanofi could pay BioAtrium AG in the region of &#x20ac;0.6 billion over the 2023-2031 period  as its share of operating expenses and the cost of producing future batches.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In February&#160;2014, pursuant to the &#x201c;Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits&#x201d; (still effective as of December 31, 2023), Sanofi Pasteur and the World Health Organization (WHO) signed a bilateral &#x201c;Standard Material Transfer Agreement&#x201d; (SMTA&#160;2). This agreement stipulates that Sanofi Pasteur will, during declared pandemic periods, (i)&#160;donate 7.5% of its real-time production of pandemic vaccines against any strain with potential to cause a pandemic, and (ii)&#160;reserve a further 7.5% of such production on affordable terms. The agreement cancels and replaces all preceding commitments to donate pandemic vaccines to the WHO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.21.2. Off balance sheet commitments relating to financing activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Undrawn credit facilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;General-purpose credit facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, total credit facilities amounted to &#x20ac;8,000 million (versus &#x20ac;8,000 million as of December 31, 2022 and&#160;&#x20ac;8,000 million as of December 31, 2021).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the amount of guarantees given and received:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Guarantees given:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,936&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,815&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,794&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Guarantees provided to banks in connection with credit facilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Other guarantees given&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Guarantees received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,229)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.21.3. Off balance sheet commitments relating to asset acquisitions and divestments, and to changes in the scope of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, Sanofi had received commitments amounting in aggregate to &#x20ac;0.3&#160;billion in respect of (i)&#160;divestments of assets relating to transactions not yet finalized as of that date and (ii)&#160;contingent consideration arising under past agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Off balance sheet commitments of a financing nature with associates and joint ventures are disclosed in N&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ote&#160;D.6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Off-balance sheet commitments relating to securities classified in the categories Equity instruments at fair value through other comprehensive income and Unquoted debt securities not meeting the definition of equity instruments are respectively disclosed in Notes D .7.1. and D.7.3..&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The maximum amount of contingent consideration relating to business combinations is disclosed in Note&#160;D.18.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOffBalanceSheetCommitmentsExplanatoryTextBlock>
    <sny:DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock contextRef="c-1" id="f-4892">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Off balance sheet commitments relating to Sanofi&#x2019;s operating activities comprise the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.364%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.008%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Payments due by period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Leases with a term of less than 12 months, low value asset leases and lease contracts committed but not yet commenced&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Irrevocable purchase commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;given&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(443)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development license agreements - commitments given&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;commitments related to R&amp;amp;D and other commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;contingent milestone payments in connection with development programs in progress&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total - net commitments given&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,079&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,563&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,878&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,625&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,013&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes the variable portion of future lease payments not recognized as lease liabilities as of December 31, 2023; the equivalent amount of these commitments as of December&#160;31, 2022 was &#x20ac;38&#160;million.&lt;br/&gt;During 2023, Sanofi signed a 15-year lease which will take effect in 2025 and for which Sanofi is committed for a minimum period of 12 years, corresponding to a minimum commitment of $0.2&#160;billion. The lease includes two extension options of five years each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;These comprise irrevocable commitments to suppliers of (i)&#160;property, plant and equipment, net of down-payments (see Note&#160;D.3.) and (ii)&#160;goods and services. As of December 31, 2022, irrevocable commitments amounted to &#x20ac;6,194 million given and &#x20ac;574 million received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Irrevocable purchase commitments given as of December 31, 2023 include &#x20ac;926 million of commitments to joint ventures, and the commitment to EUROAPI as described in Note D.2. and amounting to &#x20ac;804&#160;million as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Commitments related to R&amp;amp;D, and other commitments, amounted to &#x20ac;259 million as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&#160;&#160;&#160;&#160;This line includes only contingent milestone payments on development projects in progress. The equivalent amount as of December 31, 2022 was     &#x20ac;2,919 million.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOffBalanceSheetCommitmentsRelatingToOperatingActivitiesTableTextBlock>
    <sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet contextRef="c-5" decimals="-6" id="f-4893" unitRef="eur">221000000</sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet>
    <sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet contextRef="c-1106" decimals="-6" id="f-4894" unitRef="eur">24000000</sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet>
    <sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet contextRef="c-1124" decimals="-6" id="f-4895" unitRef="eur">26000000</sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet>
    <sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet contextRef="c-1125" decimals="-6" id="f-4896" unitRef="eur">25000000</sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet>
    <sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet contextRef="c-1111" decimals="-6" id="f-4897" unitRef="eur">146000000</sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet>
    <sny:IrrevocablePurchaseCommitmentsGiven contextRef="c-5" decimals="-6" id="f-4898" unitRef="eur">6141000000</sny:IrrevocablePurchaseCommitmentsGiven>
    <sny:IrrevocablePurchaseCommitmentsGiven contextRef="c-1106" decimals="-6" id="f-4899" unitRef="eur">2446000000</sny:IrrevocablePurchaseCommitmentsGiven>
    <sny:IrrevocablePurchaseCommitmentsGiven contextRef="c-1124" decimals="-6" id="f-4900" unitRef="eur">2090000000</sny:IrrevocablePurchaseCommitmentsGiven>
    <sny:IrrevocablePurchaseCommitmentsGiven contextRef="c-1125" decimals="-6" id="f-4901" unitRef="eur">778000000</sny:IrrevocablePurchaseCommitmentsGiven>
    <sny:IrrevocablePurchaseCommitmentsGiven contextRef="c-1111" decimals="-6" id="f-4902" unitRef="eur">827000000</sny:IrrevocablePurchaseCommitmentsGiven>
    <sny:IrrevocablePurchaseCommitmentsReceived contextRef="c-5" decimals="-6" id="f-4903" unitRef="eur">550000000</sny:IrrevocablePurchaseCommitmentsReceived>
    <sny:IrrevocablePurchaseCommitmentsReceived contextRef="c-1106" decimals="-6" id="f-4904" unitRef="eur">443000000</sny:IrrevocablePurchaseCommitmentsReceived>
    <sny:IrrevocablePurchaseCommitmentsReceived contextRef="c-1124" decimals="-6" id="f-4905" unitRef="eur">96000000</sny:IrrevocablePurchaseCommitmentsReceived>
    <sny:IrrevocablePurchaseCommitmentsReceived contextRef="c-1125" decimals="-6" id="f-4906" unitRef="eur">11000000</sny:IrrevocablePurchaseCommitmentsReceived>
    <sny:IrrevocablePurchaseCommitmentsReceived contextRef="c-1111" decimals="-6" id="f-4907" unitRef="eur">0</sny:IrrevocablePurchaseCommitmentsReceived>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments contextRef="c-5" decimals="-6" id="f-4908" unitRef="eur">381000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments contextRef="c-1106" decimals="-6" id="f-4909" unitRef="eur">256000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments contextRef="c-1124" decimals="-6" id="f-4910" unitRef="eur">101000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments contextRef="c-1125" decimals="-6" id="f-4911" unitRef="eur">15000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments contextRef="c-1111" decimals="-6" id="f-4912" unitRef="eur">9000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress contextRef="c-5" decimals="-6" id="f-4913" unitRef="eur">4886000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress contextRef="c-1106" decimals="-6" id="f-4914" unitRef="eur">280000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress contextRef="c-1124" decimals="-6" id="f-4915" unitRef="eur">1757000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress contextRef="c-1125" decimals="-6" id="f-4916" unitRef="eur">818000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress contextRef="c-1111" decimals="-6" id="f-4917" unitRef="eur">2031000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress>
    <sny:TotalOffBalanceSheetCommitments contextRef="c-5" decimals="-6" id="f-4918" unitRef="eur">11079000000</sny:TotalOffBalanceSheetCommitments>
    <sny:TotalOffBalanceSheetCommitments contextRef="c-1106" decimals="-6" id="f-4919" unitRef="eur">2563000000</sny:TotalOffBalanceSheetCommitments>
    <sny:TotalOffBalanceSheetCommitments contextRef="c-1124" decimals="-6" id="f-4920" unitRef="eur">3878000000</sny:TotalOffBalanceSheetCommitments>
    <sny:TotalOffBalanceSheetCommitments contextRef="c-1125" decimals="-6" id="f-4921" unitRef="eur">1625000000</sny:TotalOffBalanceSheetCommitments>
    <sny:TotalOffBalanceSheetCommitments contextRef="c-1111" decimals="-6" id="f-4922" unitRef="eur">3013000000</sny:TotalOffBalanceSheetCommitments>
    <sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet contextRef="c-7" decimals="-6" id="f-4923" unitRef="eur">38000000</sny:ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet>
    <sny:LeaseTerm contextRef="c-1" id="f-4924">P15Y</sny:LeaseTerm>
    <sny:LeaseTerm contextRef="c-2029" id="f-4925">P12Y</sny:LeaseTerm>
    <sny:LeaseCosts contextRef="c-2030" decimals="-8" id="f-4926" unitRef="usd">200000000</sny:LeaseCosts>
    <sny:LeaseExtensionOptionsNumber
      contextRef="c-2030"
      decimals="INF"
      id="f-4927"
      unitRef="extension">2</sny:LeaseExtensionOptionsNumber>
    <sny:LeaseExtensionOptionsTerm contextRef="c-2030" id="f-4928">P5Y</sny:LeaseExtensionOptionsTerm>
    <sny:IrrevocablePurchaseCommitmentsGiven contextRef="c-2031" decimals="-6" id="f-4929" unitRef="eur">6194000000</sny:IrrevocablePurchaseCommitmentsGiven>
    <sny:IrrevocablePurchaseCommitmentsReceived contextRef="c-2031" decimals="-6" id="f-4930" unitRef="eur">574000000</sny:IrrevocablePurchaseCommitmentsReceived>
    <sny:IrrevocablePurchaseCommitmentsGiven contextRef="c-2032" decimals="-6" id="f-4931" unitRef="eur">926000000</sny:IrrevocablePurchaseCommitmentsGiven>
    <sny:IrrevocablePurchaseCommitmentsGiven contextRef="c-2033" decimals="-6" id="f-4932" unitRef="eur">804000000</sny:IrrevocablePurchaseCommitmentsGiven>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments contextRef="c-7" decimals="-6" id="f-4933" unitRef="eur">259000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments>
    <sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress contextRef="c-7" decimals="-6" id="f-4934" unitRef="eur">2919000000</sny:CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress>
    <sny:CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase contextRef="c-5" decimals="-8" id="f-4935" unitRef="eur">16800000000</sny:CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase>
    <sny:CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase contextRef="c-7" decimals="-8" id="f-4936" unitRef="eur">18000000000</sny:CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase>
    <sny:CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets contextRef="c-5" decimals="-8" id="f-4937" unitRef="eur">17900000000</sny:CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets>
    <sny:CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets contextRef="c-7" decimals="-8" id="f-4938" unitRef="eur">18500000000</sny:CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets>
    <sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements contextRef="c-5" decimals="-8" id="f-4939" unitRef="eur">10000000000</sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements>
    <sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements contextRef="c-7" decimals="-8" id="f-4940" unitRef="eur">8800000000</sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements>
    <sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements contextRef="c-2034" decimals="-8" id="f-4941" unitRef="eur">900000000</sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements>
    <sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements contextRef="c-2035" decimals="-8" id="f-4942" unitRef="eur">1000000000</sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements>
    <sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements contextRef="c-2036" decimals="-8" id="f-4943" unitRef="eur">200000000</sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements>
    <sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements contextRef="c-2037" decimals="-8" id="f-4944" unitRef="eur">200000000</sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements>
    <sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements contextRef="c-2038" decimals="-8" id="f-4945" unitRef="eur">300000000</sny:CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements>
    <sny:CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts contextRef="c-5" decimals="-8" id="f-4946" unitRef="eur">8500000000</sny:CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts>
    <sny:CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts contextRef="c-7" decimals="-8" id="f-4947" unitRef="eur">7600000000</sny:CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts>
    <sny:UpfrontPayments contextRef="c-2039" decimals="-6" id="f-4948" unitRef="usd">40000000</sny:UpfrontPayments>
    <sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement contextRef="c-2040" decimals="-8" id="f-4949" unitRef="usd">1200000000</sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement>
    <sny:UpfrontPayments contextRef="c-2041" decimals="-6" id="f-4950" unitRef="usd">175000000</sny:UpfrontPayments>
    <sny:UpfrontPayments contextRef="c-2042" decimals="-6" id="f-4951" unitRef="eur">469000000</sny:UpfrontPayments>
    <sny:UpfrontPayments contextRef="c-2042" decimals="-6" id="f-4952" unitRef="usd">500000000</sny:UpfrontPayments>
    <sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement contextRef="c-2043" decimals="-6" id="f-4953" unitRef="eur">940000000</sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement>
    <sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement contextRef="c-2043" decimals="-9" id="f-4954" unitRef="usd">1000000000</sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement>
    <sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement contextRef="c-2044" decimals="-6" id="f-4955" unitRef="eur">946000000</sny:CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement>
    <sny:NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement
      contextRef="c-2045"
      decimals="INF"
      id="f-4956"
      unitRef="molecule">15</sny:NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement>
    <sny:CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement contextRef="c-2046" decimals="-6" id="f-4957" unitRef="eur">300000000</sny:CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement>
    <sny:NumberOfOncologyTargetsUnderCollaborationAgreement
      contextRef="c-2047"
      decimals="INF"
      id="f-4958"
      unitRef="target">3</sny:NumberOfOncologyTargetsUnderCollaborationAgreement>
    <sny:NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement
      contextRef="c-2047"
      decimals="0"
      id="f-4959"
      unitRef="target">3</sny:NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement>
    <sny:NumberOfDrugTargetsUnderCollaborationAgreement
      contextRef="c-2048"
      decimals="INF"
      id="f-4960"
      unitRef="target">5</sny:NumberOfDrugTargetsUnderCollaborationAgreement>
    <sny:NumberOfTherapeuticTargetsUnderCollaborationAgreement
      contextRef="c-2049"
      decimals="INF"
      id="f-4961"
      unitRef="target">6</sny:NumberOfTherapeuticTargetsUnderCollaborationAgreement>
    <sny:PercentageOfProfitShareOnCounterpartiesProfit
      contextRef="c-2050"
      decimals="2"
      id="f-4962"
      unitRef="number">0.10</sny:PercentageOfProfitShareOnCounterpartiesProfit>
    <sny:PercentageOfProfitShareOnCounterpartiesProfit
      contextRef="c-2051"
      decimals="2"
      id="f-4963"
      unitRef="number">0.20</sny:PercentageOfProfitShareOnCounterpartiesProfit>
    <sny:PercentageOfCumulativeDevelopmentCostsReimbursed
      contextRef="c-102"
      decimals="2"
      id="f-4964"
      unitRef="number">0.50</sny:PercentageOfCumulativeDevelopmentCostsReimbursed>
    <sny:CommitmentsReceivedForDevelopmentCosts contextRef="c-2052" decimals="-8" id="f-4965" unitRef="eur">2100000000</sny:CommitmentsReceivedForDevelopmentCosts>
    <sny:CommitmentsReceivedForDevelopmentCosts contextRef="c-2053" decimals="-8" id="f-4966" unitRef="eur">2700000000</sny:CommitmentsReceivedForDevelopmentCosts>
    <sny:CumulativeDevelopmentCostsIncurred contextRef="c-5" decimals="-8" id="f-4967" unitRef="eur">8600000000</sny:CumulativeDevelopmentCostsIncurred>
    <ifrs-full:InvestmentsInJointVentures contextRef="c-2054" decimals="-8" id="f-4968" unitRef="eur">300000000</ifrs-full:InvestmentsInJointVentures>
    <sny:PercentageOfFutureDevelopmentExpenseFundedByCompany
      contextRef="c-2055"
      decimals="INF"
      id="f-4969"
      unitRef="number">0.50</sny:PercentageOfFutureDevelopmentExpenseFundedByCompany>
    <sny:PercentageOfFutureDevelopmentExpenseFundedByOtherParty
      contextRef="c-2056"
      decimals="INF"
      id="f-4970"
      unitRef="number">50</sny:PercentageOfFutureDevelopmentExpenseFundedByOtherParty>
    <sny:AmountsPayablePartnersInCollaborationAgreements contextRef="c-2054" decimals="-8" id="f-4971" unitRef="eur">600000000</sny:AmountsPayablePartnersInCollaborationAgreements>
    <sny:TransferPercentageOfPandemicVaccines
      contextRef="c-2057"
      decimals="3"
      id="f-4972"
      unitRef="number">0.075</sny:TransferPercentageOfPandemicVaccines>
    <sny:ReservePercentageOfPandemicVaccines
      contextRef="c-2057"
      decimals="3"
      id="f-4973"
      unitRef="number">0.075</sny:ReservePercentageOfPandemicVaccines>
    <sny:DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock contextRef="c-1" id="f-4974">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Undrawn credit facilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Less&#160;than&lt;br/&gt;1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1&#160;to&lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&#160;to&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;More&#160;than&lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;General-purpose credit facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfUndrawnBorrowingFacilitiesTableTextBlock>
    <ifrs-full:UndrawnBorrowingFacilities contextRef="c-5" decimals="-6" id="f-4975" unitRef="eur">8000000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities contextRef="c-1106" decimals="-6" id="f-4976" unitRef="eur">0</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities contextRef="c-1124" decimals="-6" id="f-4977" unitRef="eur">0</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities contextRef="c-1125" decimals="-6" id="f-4978" unitRef="eur">4000000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities contextRef="c-1111" decimals="-6" id="f-4979" unitRef="eur">4000000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities contextRef="c-5" decimals="-6" id="f-4980" unitRef="eur">8000000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities contextRef="c-7" decimals="-6" id="f-4981" unitRef="eur">8000000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities contextRef="c-8" decimals="-6" id="f-4982" unitRef="eur">8000000000</ifrs-full:UndrawnBorrowingFacilities>
    <sny:DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock contextRef="c-1" id="f-4983">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the amount of guarantees given and received:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Guarantees given:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,936&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,815&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,794&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Guarantees provided to banks in connection with credit facilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;Other guarantees given&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Guarantees received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,229)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfGuaranteesGivenAndReceivedExplanatoryTableTextBlock>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2058" decimals="-6" id="f-4984" unitRef="eur">3936000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2059" decimals="-6" id="f-4985" unitRef="eur">3815000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2060" decimals="-6" id="f-4986" unitRef="eur">3794000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2061" decimals="-6" id="f-4987" unitRef="eur">1067000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2062" decimals="-6" id="f-4988" unitRef="eur">1007000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2063" decimals="-6" id="f-4989" unitRef="eur">1042000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2064" decimals="-6" id="f-4990" unitRef="eur">2869000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2065" decimals="-6" id="f-4991" unitRef="eur">2808000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2066" decimals="-6" id="f-4992" unitRef="eur">2752000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2067" decimals="-6" id="f-4993" unitRef="eur">1272000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2068" decimals="-6" id="f-4994" unitRef="eur">1229000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="c-2069" decimals="-6" id="f-4995" unitRef="eur">1149000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <sny:OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments contextRef="c-7" decimals="-8" id="f-4996" unitRef="usd">300000000</sny:OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments>
    <sny:DisclosureOfLegalAndArbitralProceedingsTextBlock contextRef="c-1" id="f-4997">Legal and arbitral proceedings&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi&#160;products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures. Provisions related to legal and arbitral proceedings are recorded in accordance with the principles described in Note&#160;B.12.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Most of the issues raised by these claims are highly complex and subject to substantial uncertainties; therefore, the probability of loss and an estimation of damages are difficult to ascertain. Contingent liabilities are cases for which either we are unable to make a reasonable estimate of the expected financial effect that will result from ultimate resolution of the proceeding, or a cash outflow is not probable. In either case, a brief description of the nature of the contingent liability is disclosed and, where practicable, an estimate of its financial effect, an indication of the uncertainties relating to the amount and timing of any outflow, and the possibility of any reimbursement are provided in application of paragraph&#160;86 of IAS&#160;37.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed, we have indicated our losses or the amount of provision accrued that is the estimate of the probable loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In a limited number of ongoing cases, while we are able to make a reasonable estimate of the expected loss or range of the possible loss and have accrued a provision for such loss, we believe that publication of this information on a case-by-case basis or by class would seriously prejudice the Company&#x2019;s position in the ongoing legal proceedings or in any related settlement discussions. Accordingly, in those cases, we have disclosed information with respect to the nature of the contingency but have not disclosed our estimate of the range of potential loss, in accordance with paragraph&#160;92 of IAS&#160;37.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;These assessments can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Our assessments are based on estimates and assumptions that have been deemed reasonable by management. We believe that the aggregate provisions recorded for the above matters are adequate based upon currently available information. However, given the inherent uncertainties related to these cases and involved in estimating contingent liabilities, we could in the future incur judgments that could have a material adverse effect on our net income in any particular period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Long term provisions are disclosed in Note&#160;D.19. They include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;provisions for product liability risks, litigation and other amount to &#x20ac;1,283 million in 2023. These provisions are mainly related to product liabilities, government investigations, competition law, regulatory claims, warranties in connection with certain contingent liabilities arising from business divestitures other than environmental matters and other claims;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;provisions for environmental risks and remediation amount to &#x20ac;493 million in 2023, the majority of which are related to contingencies that have arisen from business divestitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a) Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sanofi Pasteur Hepatitis&#160;B Vaccine Product Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Since 1996, more than 180&#160;lawsuits have been filed in various French civil courts against Sanofi Pasteur and/or Sanofi Pasteur&#160;MSD&#160;S.N.C., the former French subsidiary of Sanofi, and the latter a joint venture company with Merck&#160;&amp;amp; Co.,&#160;Inc. now terminated, for which past ongoing litigation is now managed by the originating party. In such lawsuits, the plaintiffs allege that they suffer from a variety of neurological disorders and autoimmune diseases, including multiple sclerosis and Guillain-Barr&#xe9; syndrome as a result of receiving the hepatitis&#160;B vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In January&#160;2018, the Appeal Court of Bordeaux found a causal link between hepatitis&#160;B vaccine and multiple sclerosis. In&#160;July&#160;2019, the French Supreme Court &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Cour de cassation)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; cancelled the&#160;judgment&#160;of the Appeal Court of Bordeaux and referred the&#160;case back to the Appeal Court of Toulouse. On March&#160;30, 2022, the Appeal Court of Toulouse dismissed all the plaintiff&#x2019;s claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there were six&#160;ongoing lawsuits related to Sanofi Pasteur hepatitis&#160;B vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TAXOTERE Product Litigation in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, there were approximately 6,770&#160;ingesting plaintiffs cases remaining in courts across the country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Lawsuits have been filed against affiliates of Sanofi under US state law for personal injuries allegedly sustained in connection with&#160;the use of TAXOTERE. The actions are held in several jurisdictions around the country. In 2021, there were two&#160;bellwether trials as part of a federal multi-district litigation in the Eastern District of Louisiana both resulting in jury verdicts in Sanofi's favor. In 2023, Sanofi settled approximately 100&#160;individual cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TAXOTERE &#x2013; Mississippi Attorney General Litigation in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In October&#160;2018, the Attorney General for the State of Mississippi filed a civil action in Hinds County, Mississippi, Chancery Court against various Sanofi Defendants related to TAXOTERE. The State asserts one cause of action based on the Mississippi Consumer Protection Act (MCPA) and seeks a permanent injunction prohibiting Defendants&#x2019; conduct and civil penalties of up to&#160;$10,000 for each violation. Sanofi filed a motion to dismiss the entire action in Hinds County, Mississippi, Chancery Court, which is currently pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ZANTAC Litigation in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In September&#160;2019, the US Food and Drug Administration (FDA) announced it was investigating the claims of an online pharmacy&#x2019;s Citizen Petition that the medication ZANTAC (the brand name for ranitidine) used for stomach heartburn contains or can generate the chemical N-Nitrosodimethylamine (NDM), an alleged human carcinogen. As a precautionary measure, Sanofi initiated a voluntary recall of branded over-the-counter ZANTAC in October&#160;2019. Concurrent with FDA&#x2019;s investigation, multiple personal injury lawsuits and class actions alleging that ZANTAC causes various cancers and seeking damages for either alleged personal injuries or alleged economic injuries were filed. Federal court cases were coordinated into a Multi-District Litigation (MDL) in the Southern District of Florida in February&#160;2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On December&#160;6, 2022, the MDL Court granted Sanofi and other defendants&#x2019; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Daubert&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; and summary judgment motions. As a result, the Court entered final judgment in all cases involving plaintiffs&#x2019; five designated cancers and dismissed the class action cases. Based on the preliminary estimates, more than 12,000&#160;plaintiffs have filed notices to appeal the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Daubert&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; ruling in the Eleventh Circuit. The MDL Court subsequently dismissed all pending cases alleging a non-designated cancer for failure to serve expert reports.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Other cases are pending in various state courts. The majority of the state court plaintiffs have cases pending in Delaware, where a hearing on defendants&#x2019; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Daubert&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; motions to exclude plaintiffs&#x2019; experts was scheduled for January&#160;2024. Trials are scheduled in&#160;2024 in single-plaintiff cases in several states. No ZANTAC case has gone to trial to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Overall, there are currently around 3,280&#160;product liability &#x201c;complaints&#x201d; filed. These complaints encompass&#160;26,984&#160;individual product liability &#x201c;plaintiffs&#x201d; who have all filed against Sanofi. The vast majority of these plaintiffs participated in the MDL Court&#x2019;s census registry program, allege cancers that the plaintiffs&#x2019; leadership decided not to designate and pursue in the MDL, and have since filed their complaints in state courts. Additional cases may be filed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In addition, in November&#160;2019, Sanofi received a Civil Investigative Demand (CID) related to this issue from the Arizona Attorney General. Sanofi provided responses in December&#160;2019 and July&#160;2020 and has not received any follow-up requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In June&#160;2020, the New Mexico Attorney General filed a complaint against Sanofi, the previous marketing authorization holders for branded ZANTAC, a dozen generic manufacturers, and several retailers. The complaint brings claims for alleged violations of the New Mexico Unfair Practices Act, violations of the New Mexico False Advertising Act, violations of the New Mexico Public Nuisance Statute, common law public nuisance, and negligence. Trial in the case is scheduled for September&#160;2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In June&#160;2020, Sanofi received a notice from the US Department of Justice Civil Division and US Attorney&#x2019;s Office for the Eastern District of Pennsylvania of an investigation into allegations that pharmaceutical manufacturers violated the False Claims Act,&#160;31&#160;U.S.C. &#xa7;&#160;3729, in relation to the drug ZANTAC and ranitidine hydrochloride through alleged failure to disclose to the federal government information about the potential presence of NDMA. In response to the notice, Sanofi provided information and documents including applications and communications with&#160;FDA, in August&#160;2020. Sanofi has not received any subsequent requests from the federal government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In November&#160;2020, the Mayor and City Council of Baltimore filed a complaint against Sanofi, the previous marketing authorization holders for branded ZANTAC, generic manufacturers, and several retailers. The complaint alleges violations of the Maryland Consumer Protection statute, public nuisance, and negligence. Trial in the case is scheduled for June&#160;2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In January&#160;2021, Sanofi was served with the Center for Environmental Health&#x2019;s Second Amended Complaint alleging Proposition&#160;65&#160;violations. The case is pending in California Superior Court&#160;in Alameda County, and no trial date has been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ZANTAC Litigation in Canada&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Between 2019 and 2022, seven&#160;proposed class actions naming some or all of Sanofi Consumer Health&#160;Inc., Sanofi-Aventis Canada Inc., Chattem (Canada)&#160;Inc., Sanofi and Sanofi Pasteur Limited as Defendants, relating to ranitidine were filed in courts in various Canadian provinces. The cases allege that proposed class members suffered personal injury from the ingestion of ranitidine, and seek damages in unspecified amounts, disgorgement of profits, restitution in the amount of the purchase price of ZANTAC and subrogated damages on behalf of provincial health insurers for health care costs related to ranitidine use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In May&#160;2023, in the proceedings pending before the Supreme Court of British Columbia, the Court dismissed the action, ruling that there is no scientific support for plaintiff&#x2019;s claims. After this ruling, the Superior Court of Quebec stayed the corresponding proposed ZANTAC class proceedings in Quebec until the result of the US Multi-District Litigation (MDL) appeal is announced or&#160;October&#160;15, 2024&#x202f;(whichever comes first).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to assess with certainty the outcome of the remaining lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GOLD BOND Product Litigation in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Over the last few years, Sanofi affiliates have been named in product liability actions in the United States regarding the alleged presence of asbestos in talc products originating from past acquisitions. A certain number of these claims were also dismissed during that time. As of December&#160;31, 2023,  there were approximately 500&#160;product liability ongoing actions. To date, no cases have proceeded to trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to assess with certainty the outcome of these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;DEPAKINE Product Litigation in France&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Civil proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, 79&#160;families brought a civil claim involving 133&#160;people exposed in utero to sodium valproate against a French affiliate of Sanofi seeking indemnification under French law for personal injuries allegedly suffered by children in connection with the use of sodium valproate by their mothers during pregnancy to treat their epilepsy (DEPAKINE). These actions are held in several jurisdictions in&#160;France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Thirty lawsuits are in progress on the merits, the most advanced was tried at the French Supreme Court level which issued in&#160;November&#160;2019 a ruling sending the case before the Paris Appeal Court to rule on Sanofi&#x2019;s argument on the compliance of the&#160;product with mandatory regulations, as well as on the question of defectiveness of the product and the assessment of damages. In January&#160;2023, the Paris Appeal Court ordered a stay in the proceedings until the submission of the second expert opinion report as part of the criminal investigation (see below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Seven first instance rulings on the merits were handed down in 2022 by the Judicial Tribunal of Nanterre. In three cases, the Court declared the judicial expert report null and void and the Court dismissed one claim in another case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Concerning three other cases relating to births that occurred between 2005 and 2009, the Court held, on the basis of a non-fault liability, that Sanofi was liable in light of the wording of the patient information leaflet. Provisional compensation amounts were set in the range of &#x20ac;0.1&#160;million to &#x20ac;0.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;All the judgments have been appealed and are still pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the class action lawsuit filed in May&#160;2017 by the APESAC &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Association des Parents d&#x2019;Enfants souffrant du Syndrome de l&#x2019;Anti-Convulsivant)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; against the French affiliate, the Judicial Tribunal of Paris ruled on January&#160;5, 2022 that a class is admissible, retaining Sanofi&#x2019;s liability between 1984 and January&#160;2006 for malformations and between 2001 and January&#160;2006 for neuro-developmental disorders (NDD). This decision is based on the conclusions of a criminal expert report within the frame of ongoing criminal proceeding, for which the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chambre de l&#x2019;Instruction&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; of the Appeal Court of Paris had ordered a counter-expertise (see&#160;below). The APESAC, Sanofi and its insurers appealed the Judicial Tribunal of Paris&#x2019; ruling related to the class action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On July&#160;21, 2021, the Judicial Tribunal of Cr&#xe9;teil (France) dismissed a claim for damages brought against Sanofi regarding a child born in&#160;1995. The Judicial Tribunal considered that the risk of occurrence of NDD in children born to mother exposed to sodium valproate during pregnancy was not demonstrated by the state of scientific knowledge at the time of her pregnancy. This decision was appealed and the proceeding is now pending before the Appeal Court of Paris, which had ordered a stay in the proceeding until the end of the criminal investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In July&#160;2020 and December&#160;2022, a collective redress against the French affiliate was filed by&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; 64&#160;f&lt;/span&gt;&lt;span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;amilies which represents 273&#160;claimants including 100&#160;people exposed in utero, seeking indemnification for a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; prejudice of anxiety&lt;/span&gt;&lt;span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. In September&#160;2023, 27&#160;people exposed to sodium valproate in utero and 56&#160;indirect victims requested the withdrawal of their claims. The trial hearing is set for June&#160;6, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Criminal investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;A criminal investigation was initiated in May&#160;2015 before the Paris Civil Court. In January&#160;2020, the French affiliate of Sanofi was indicted for aggravated deception and involuntary injuries and in July&#160;2020 for involuntary manslaughter. In July&#160;2020, a judicial supervision of the affiliate was ordered, together with the implementation of financial guarantees. In November&#160;2020, the Health Authority (&lt;/span&gt;&lt;span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;ANSM) was similarly indicted for involuntary injuries and involuntary manslaughters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On March&#160;9, 2022, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chambre de l&#x2019;Instruction&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; of the Appeal Court of Paris &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Cour d&#x2019;appel)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; ruled that certain complaints for involuntary manslaughter and several others for aggravated deception and involuntary injuries were time-barred. The Public Prosecutor, as well as the civil parties, have brought the matter before the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chambre Criminelle &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;of the Supreme Court &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Cour de cassation)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In September&#160;2022, the investigating judges appointed two&#160;experts for a counter-expertise following the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chambre de l&#x2019;Instruction&#x2019;s&lt;/span&gt;&lt;span style="background-color:#fefefe;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; ruling handed down end of 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Since 2022, several individual medical assessments have been ordered by the investigating judge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In June 2023, the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chambre Criminelle&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; of the French Supreme Court &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cour de cassation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; confirmed the Paris Court of Appeal&#x2019;s decision &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chambre de l&#x2019;Instruction&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; dated March&#160;2022 which had ruled that certain complaints for involuntary manslaughter and several others for aggravated deception and involuntary injuries were time-barred. In August&#160;2023, Sanofi received the counter expertise report and sent its comments in November&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Public compensation scheme&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2017, the French government set up a public compensation scheme to indemnify patients for damages suffered in connection with the prescription of sodium valproate and its derivatives. The scheme was further amended through the 2020 Finance Law, with notably the introduction of presumptions of default for lack of information of the mother since 1982 for malformations and since 1984 for NDD. The scheme was amended again through the&#160;2021 Finance Law in order to increase the maximum premium applicable in case of refusal to make an offer (or insufficient offer) which would be deemed unjustified by a court ruling.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The committee of the compensation scheme has issued several final opinions holding the French affiliate liable for damages either in full or in part along with the French State, and, in some cases, healthcare practitioners. The French affiliate disagreed with the committee&#x2019;s conclusions and has accordingly not offered indemnification to the claimants who have received compensation from the ONIAM &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Office National d&#x2019;Indemnisation des Accidents M&#xe9;dicaux)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. The ONIAM is now seeking reimbursement from Sanofi who has filed legal actions to oppose ONIAM&#x2019;s payment orders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Administrative Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In July&#160;2020, March and June&#160;2021, the Montreuil Administrative Court had held the French State liable in five&#160;administrative proceedings initiated by families against the State. In March&#160;2021, the Administrative Court did not retain any lack of information of the mother regarding the risk of neurodevelopmental disorders for births in 1999 and in 2002, based on the state of scientific knowledge at the time. However, regarding the risk of malformations, liabilities were retained against the State, the healthcare professionals and Sanofi, notably for discrepancy between the SmPC (Summary of the Product Characteristics) and the patient leaflet. In other cases involving births in 2005-2008, the liability of the State was retained for both malformations and neurodevelopmental disorders, and partially exonerated, taking into account the roles of healthcare practitioners and Sanofi. Given that the French affiliate was not a party to these administrative proceedings, its arguments (i.e. notably several requests from the French affiliate to the Health Authorities to reinforce warnings to healthcare professionals and patients in relation to DEPAKINE) were not considered. All rulings were appealed by the claimants. Sanofi has filed requests for voluntary intervention in these proceedings to present its arguments before the Administrative Court of Appeal. In one proceeding, the claimants decided to withdraw their claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to make a reliable assessment of the outcome of these cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;DEPAKINE Product Litigation in other EU countries and in the UK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Switzerland, eleven&#160;families have filed a civil claim for damages concerning seventeen&#160;people exposed in utero. Some of them also involve the claimants&#x2019; physicians. In November&#160;2022, one action was declared time-barred by the judge. The claimant appealed this court decision on the merit. The appeal is on-going.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Spain, there are six ongoing actions relating to thirteen&#160;children. In March&#160;2022, in one trial, the Court condemned Sanofi to indemnify four&#160;patients. Sanofi appealed this decision. In January&#160;2023, in another trial filed by one patient, the Appeal Court confirmed the first instance's decision and dismissed the claim. The other actions are still at a preliminary stage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Belgium, there are two&#160;civil proceedings (currently on hold) and a criminal complaint against&#160;X and against Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In Ireland, there are two&#160;cases in Pre-Action stage and two&#160;civil claims on-going.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In the United Kingdom, there are three&#160;cases in the Pre-Action stage in Great Britain and one&#160;civil claim ongoing in Northern Ireland.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;It is not possible, at this stage, to assess reliably the outcome of these cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;DENGVAXIA (Philippines)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Since early 2018 up to present date, several claims were filed in the Philippines by parents of deceased children whose deaths were allegedly due to vaccination with DENGVAXIA. Early March&#160;2019, 2020 and 2022, the Philippine Department of Justice (DOJ) prosecution panel announced it had found probable cause to indict several Sanofi employees/former employees and former Government officials for &#x201c;reckless imprudence&#x201d; resulting in homicides. Since then, several criminal actions have been filed in court as a result of this finding and are pending at various stages of the legal procedure. Petitions for Review to the DOJ Secretary have been filed and the said petitions remain pending. Meanwhile, the majority of the respondents have challenged the jurisdiction of the lower court where the first&#160;eight&#160;cases had been assigned and this issue is now filed with the Supreme Court. There are several claims that have not yet been filed in any court despite resolutions by the DOJ that there is probable cause.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b) Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ramipril Canada Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi was involved in a number of legal proceedings involving companies which market generic ALTACE (ramipril) in Canada.&#160;In&#160;2004, Sanofi unsuccessfully brought Notice of Compliance proceedings (NOC proceedings) at the end of which eight&#160;manufacturers obtained marketing authorizations from the Canadian Minister of Health for generic versions of ramipril in Canada. Sanofi filed unsuccessful patent infringement actions against all those companies and ultimately Sanofi was liable for damages under Section&#160;8. Sanofi made payment in complete satisfaction of those awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In June&#160;2011, Apotex commenced an action in the Ontario Superior Court of Justice asserting damages under the Ontario Statute of Monopolies, the UK Statute of Monopolies, and the Trade-marks Act (the &#x201c;Ontario Action&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;At the request of the parties, in June&#160;2021, the Court ordered that the action be stayed in view of the lower court&#x2019;s decision in March in the Apotex vs. Lilly case. In the Lilly case, the Court dismissed Apotex&#x2019;s Statute of Monopolies claim by way of summary judgment. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In April&#160;2023, the Canadian Supreme Court denied Apotex&#x2019;s application for leave to appeal in the Lilly case and based on the Supreme Court decision, Apotex&#x2019;s claim no longer has any basis. Sanofi is seeking the court&#x2019;s assistance to conclude the case and recover appropriate costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PRALUENT (alirocumab)-related Amgen Patent Litigation in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2014, Amgen filed four separate complaints against Sanofi and Regeneron in the US District Court for the District of Delaware (&#x201c;District Court&#x201d;) asserting patent infringement relating to Sanofi and Regeneron&#x2019;s PRALUENT product. Together these complaints alleged that PRALUENT infringed seven patents for antibodies targeting PCSK9 and sought injunctive relief and unspecified damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In February&#160;2021, the Federal Circuit affirmed the District Court&#x2019;s ruling invalidating the Amgen asserted patent claims. In&#160;November&#160;2021, Amgen filed a petition with the US&#160;Supreme Court, asking it to overturn the Federal Circuit decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On November&#160;4, 2022, the US Supreme Court granted Amgen&#x2019;s petition for review. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In May&#160;2023, the Supreme Court issued a unanimous decision in favor of Sanofi and Regeneron regarding the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;patent infringement actions filed in 2014 by Amgen relating to Sanofi and Regeneron&#x2019;s PRALUENT product. Sanofi is in the process of seeking certain legal costs from Amgen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PRALUENT (alirocumab)-related Amgen Patent Litigation in Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In June&#160;2023, Amgen filed an action for infringement of EP&#160;3&#160;666&#160;797 against Sanofi and Regeneron concerning PRALUENT in the Munich Local Division of the Unified Patent Court. Amgen seeks a permanent injunction and unspecified damages and compensation from March&#160;1, 2023. In June&#160;2023, Sanofi filed a revocation action attacking the validity of EP&#160;3&#160;666&#160;797 in the Munich Central Division of the Unified Patent Court. These cases are underway: a hearing in the revocation action is scheduled in&#160;June&#160;2024 and a hearing in the infringement action is scheduled for October&#160;2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;JEVTANA (cabazitaxel)-related patent litigation in the US&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;JEVTANA is currently covered by four Orange Book listed patents US&#160;7,241,907, US&#160;8,927,592, US&#160;10,583,110 and US&#160;10,716,777. In&#160;May&#160;to July&#160;2020, Sanofi filed patent infringement suits under Hatch-Waxman against 12&#160;generic filers asserting the &#x2018;110&#160;patent and the&#160;&#x2018;777&#160;patent in the US District Court for the District of Delaware, adding the '592&#160;patent after its amended claims issued in&#160;August&#160;2021. Sanofi reached settlement agreements with most of the defendants and went to trial against the remaining defendant Sandoz on the &#x2018;777&#160;patent in January&#160;2023. In June&#160;2023, the US District Court for the District of Delaware issued a decision in favor of Sanofi in connection with the JEVTANA patent litigation against Sandoz and on August&#160;2, 2023, Sandoz appealed to the Court of Appeals for the Federal Circuit. On October&#160;5, 2023, Sanofi and Sandoz filed a joint stipulation voluntarily dismissing Sandoz&#x2019;s Appeal, bringing this matter to final conclusion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PLAVIX Litigation (Commonwealth) in Australia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In August&#160;2007, GenRX (a subsidiary of Apotex) obtained registration of a generic clopidogrel bisulfate product on the Australian Register of Therapeutic Goods. At the same time, GenRX filed a patent invalidation action with the Federal Court of Australia, seeking revocation of Sanofi&#x2019;s Australian enantiomer patent claiming clopidogrel salts (a &#x201c;nullity action&#x201d;). In September&#160;2007, Sanofi obtained a preliminary injunction from the Federal Court preventing commercial launch of this generic clopidogrel bisulfate product until judgment on the substantive issues of patent validity and infringement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In August&#160;2008, the Australian Federal Court confirmed that the claim in Sanofi&#x2019;s Australian enantiomer patent directed to clopidogrel bisulfate (the salt form in PLAVIX) was valid and the patent infringed. On appeal, the Full Federal Court of Australia held in&#160;September&#160;2009 that all claims in the patent are invalid. Sanofi&#x2019;s appeal to the Australia High Court was denied in&#160;March&#160;2010. On conclusion of the proceedings in 2010, the Sanofi patent was invalidated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In April&#160;2013, the Australian Department of Health and Ageing (&#x201c;Commonwealth&#x201d;) filed an application before the Federal Court&#160;of&#160;Australia seeking payment of damages from Sanofi related to the Apotex preliminary injunction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi and BMS settled the patent litigation with Apotex in November&#160;2014. In April&#160;2020, the Commonwealth&#x2019;s claim was dismissed. In&#160;May&#160;2020, the Commonwealth filed a Notice of Appeal to the Full Court of the Federal Court. On appeal, the Commonwealth reduced its claim to a range of AUD223.3&#160;million (&#x20ac;137.8&#160;million) to AUD280.2&#160;million (&#x20ac;172.9&#160;million) which, inclusive of interest to&#160;December&#160;31,&#160;2023, ranges from AUD360.5&#160;million (&#x20ac;218.0&#160;million) to AUD487.5&#160;million (&#x20ac;294.3&#160;million). &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In&#160;June&#160;2023, the Full Court of the Federal Court of Australia unanimously dismissed the Commonwealth&#x2019;s appeal following&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; its application seeking payment of damages from Sanofi/BMS related to the preliminary injunction. O&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n July&#160;24, 2023, the&#160;Commonwealth filed an application for special leave to appeal to the High Court of Australia, which was granted on&#160;December&#160;18,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;c) Other litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PLAVIX (clopidogrel) &#x2013; Attorney General Action in Hawaii&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In March&#160;2014, the Hawaii Attorney General (AG) filed a complaint that sets forth allegations related to the sale and marketing of and variability of response to PLAVIX. The Hawaii AG specifically alleged that PLAVIX had a diminished effect in patients of certain genetic backgrounds and that Sanofi and BMS had failed to make an earlier disclosure of this information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In February&#160;2021, the Court issued its decision, imposing penalties in the total amount of $834,012,000 against both Sanofi and Bristol Myers Squibb (BMS), with $417,006,000 being apportioned to each company. In June&#160;2021, Sanofi and BMS appealed this&#160;judgment. The appeal was transferred directly to the Hawaii Supreme Court. In March&#160;2023, the Hawaii Supreme Court vacated the judgment and ordered a new trial. A second trial was concluded in October&#160;2023 and Sanofi is expecting a decision in Q1&#160;2024. To the extent there is a new judgment entered by the court, this would be split evenly with BMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PLAVIX (clopidogrel)-related litigation in France&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In France, in the claim concerning allegations that Sanofi&#x2019;s communication and promotional practices inhibited the entry on the&#160;market of generics of clopidogrel (the active ingredient of PLAVIX), the French Antitrust Authority issued its decision on&#160;May&#160;14,&#160;2013, imposing on Sanofi a fine of &#x20ac;40.6&#160;million. This decision was confirmed by the Supreme Court &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Cour de cassation)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in 2016. As a consequence of the May&#160;2013 ruling, claims were filed by Sandoz and by Teva in 2014 before the Commercial Court of Paris for compensation of their alleged damages: loss of margin and other ancillary damages. In June&#160;and November&#160;2016 respectively, settlement agreements were entered into with Sandoz and Teva. Consequently, they subsequently withdrew their civil claims, jointly and severally. In September&#160;2017, Sanofi and its French affiliate received a summons before the&#160;Paris Commercial Court from the French&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt; Caisse Nationale d&#x2019;Assurance Maladie &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;CNAM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(French Social Security) claiming&#160;&#x20ac;115.8&#160;million for their alleged damages. On October&#160;1, 2019, the Paris Commercial Court dismissed the CNAM&#x2019;s action as time barred. On February&#160;9, 2022, the Paris Court of Appeals overturned the Paris Commercial Court's ruling, finding the&#160;CNAM&#x2019;s action as not time-barred and designated an expert to determine the amount of damages. The expert report is expected to be issued in March&#160;2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;340B Drug Pricing Program in the United States&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi is currently involved in several matters relating to the 340B&#160;program in the US (a federal program that requires drug manufacturers to supply certain products to certain &#x201c;covered entities&#x201d; at reduced prices). In 2021, Sanofi filed a lawsuit against the Department of Health and Human Services (HHS), the Health Resources and Services Administration (HRSA), and certain of their administrators in the&#160;US&#160;District Court for the District of New Jersey challenging (i)&#160;HHS&#x2019;s December&#160;2020 Advisory Opinion&#160;(AO) stating that drug manufacturers are legally obligated to deliver discounts under the 340B&#160;program to an unlimited number of contract pharmacies; (ii)&#160;HHS&#x2019;s December&#160;2020 Administrative Dispute Resolution (ADR) Rule; and (iii)&#160;HRSA&#x2019;s May&#160;2021 letter to Sanofi concluding that Sanofi&#x2019;s 340B integrity initiative (under which Sanofi collects limited, de-identified, claims data on 340B-priced drugs dispensed by contract pharmacies) violates section&#160;340B and that Sanofi has therefore &#x201c;overcharged&#x201d; certain covered entities. The court issued its opinion in November&#160;2021, upholding HRSA&#x2019;s conclusion in the&#160;May&#160;2021 letter, but did not impose any fines, penalties or refund obligations against Sanofi for any &#x201c;overcharges&#x201d;. The court also rejected Sanofi&#x2019;s challenge to the ADR Rule and dismissed its challenge to the AO as moot. Sanofi appealed the court&#x2019;s decision to the Third Circuit Court of Appeals (Third Circuit) and the government filed a cross-appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In January&#160;2023, the Third Circuit held that Sanofi&#x2019;s restrictions on delivery to contract pharmacies do not violate Section&#160;340B. It also enjoined HHS from enforcing against Sanofi its reading of Section&#160;340B in the AO and the May&#160;2021 violation letter. As to Sanofi&#x2019;s challenge to the 340B ADR rule, the Third Circuit held in favor of the Department of Health and Human Services (HHS) and HHS is in the process of revising the ADR rule (HRSA has sent the final rule to the Office of Information and Regulatory Affairs for review). The Third Circuit remanded the case back to the US District Court for the District of New Jersey (District Court) and on May&#160;24, 2023, the District Court issued an injunction and declaratory judgment consistent with the Third Circuit&#x2019;s opinion. This ruling concluded the case as to Sanofi; however similar cases brought by other manufacturers remain pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ADR Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In January&#160;2021, the National Association of Community Health Centers (NACHC) filed an ADR proceeding before HRSA on behalf of a number of covered entities, seeking to require Sanofi and AstraZeneca to supply contract pharmacies with 340B discounts without conditions. On August&#160;10, 2022, the ADR panel granted the motions to dismiss filed both by Sanofi and AstraZeneca, holding that the Delaware district court&#x2019;s decision granting AstraZeneca&#x2019;s motion for summary judgment precluded NACHC&#x2019;s ADR claims against both AstraZeneca and Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In September&#160;2023, the University of Washington Medical Center and Harborview Medical Center filed a petition for monetary and equitable relief against Sanofi before the ADR Panel. The petition alleges that Sanofi has violated Section&#160;340B of the Public Health Service Act, 42&#160;U.S.C. &#xa7;&#160;256b, by imposing data reporting requirements on &#x201c;Covered Entities&#x201d; that are authorized under that statute to receive discounts on certain prescription drugs and that in June&#160;2023, Sanofi further restricted access to 340B discounted drugs. The parties are waiting for a panel to be assigned to the case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In September&#160;2021, HRSA referred Sanofi (as well as other manufacturers) to the HHS Office of the Inspector General (OIG) in accordance with the 340B Program Ceiling Price and Civil Monetary Penalties Final Rule. The Third Circuit&#x2019;s decision and the District Court&#x2019;s injunction and declaratory judgment (described above) would preclude action against Sanofi based on the particular program at issue in the Third Circuit case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In February&#160;2021, the Vermont Attorney General issued a Civil Investigative Subpoena seeking certain information about Sanofi&#x2019;s participation in the 340B Drug Pricing Program. Sanofi cooperated with this investigation, including producing documents to the Vermont Attorney General&#x2019;s office.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Mosaic Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In July&#160;2021, Mosaic Health Inc. and Central Virginia Health Services (covered entities) filed a nationwide antitrust class action complaint against Sanofi and three other manufacturers in the United States District Court for the Western District of New York. Plaintiffs allege that Sanofi and the other defendants conspired to eliminate favorable 340B pricing, particularly with&#160;respect to diabetes therapies. On September&#160;2, 2022, the court granted Defendants&#x2019; motion to dismiss the complaint. On&#160;October&#160;3, 2022, plaintiff filed a motion for leave to file a second amended complaint. On February&#160;1, 2024, the Court denied plaintiffs&#x2019; motion for leave to file an amended complaint and dismissed the case.  An appeal by plaintiffs is expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adventist Health System/West&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In June&#160;2023, Adventist Health System/West sued several drug manufacturing companies, including Sanofi-Aventis US LLC, Sanofi US Services Inc. and Genzyme Corporation, alleging that the companies violated state and federal False Claims Acts through overcharging for 340B Program drugs in violation of federal &#x201c;penny pricing&#x201d; policy. The manufacturers jointly moved to dismiss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preliminary investigation by the Parquet National Financier (PNF) in France&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In November&#160;2023, Sanofi learnt through the press of an ongoing preliminary investigation by the French financial prosecutor (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Parquet National Financier &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;PNF) started in March&#160;2023 relating to allegations regarding Sanofi&#x2019;s financial communication on the launch of DUPIXENT at the end of 2017. Sanofi considers these allegations as groundless and is cooperating with the PNF to respond to the potential questions relating to the ongoing investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d) Contingencies arising from certain mergers &amp;amp; acquisitions transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As a result of divestitures, the Company is subject to a number of ongoing contractual and legal obligations regarding the state of the sold businesses, their assets, and their liabilities, some of which may be subject to dispute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aventis CropScience Retained Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The sale by Aventis Agriculture SA and Hoechst GmbH (both legacy companies of Sanofi) of their aggregate 76% participation in Aventis CropScience Holding (ACS) to Bayer and Bayer CropScience AG (BCS), the wholly owned subsidiary of Bayer which holds the ACS shares, was effective on June&#160;3, 2002. The Stock Purchase Agreement (SPA) dated October&#160;2, 2001, contained customary representations and warranties with respect to the sold business, as well as a number of indemnifications subject to limitation periods and caps, in particular with respect to environmental liabilities for which some outstanding claims from Bayer remain unresolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Infraserv Hoechst Retained Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;By the Asset Contribution Agreement dated December&#160;19/20, 1996, as amended in 1997, Hoechst contributed all lands, buildings, and related assets of the Hoechst site at Frankfurt Hoechst to Infraserv GmbH &amp;amp; Co. Hoechst KG. Infraserv Hoechst undertook to indemnify Hoechst against environmental liabilities at the Hoechst site and with respect to certain landfills. As consideration for the indemnification undertaking, Hoechst transferred to Infraserv Hoechst approximately &#x20ac;57&#160;million to fund reserves. In 1997, Hoechst also agreed it would reimburse current and future Infraserv Hoechst environmental expenses up to &#x20ac;143&#160;million. As a former operator of the land and as a former user of the landfills, Hoechst may ultimately be liable for costs of remedial action in excess of this amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:11.34pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Boehringer Ingelheim (BI) Consumer Healthcare Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi and Boehringer Ingelheim (BI) have agreed upon respective indemnification obligations for liabilities as part of the swap of Sanofi&#x2019;s Animal Health (AH) business for BI&#x2019;s Consumer Health Care (CHC) business in January&#160;2017 and under a Global Settlement Agreement concluded in September&#160;2019 regarding notably the offset of respective AH and CHC claims notified under the SPAs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In February&#160;2020, BI initiated an arbitration against Sanofi seeking indemnification for losses it could incur as a result of the ZANTAC litigation in the US (see above). In an award rendered on June&#160;19, 2023, the arbitral tribunal irrevocably dismissed BI&#x2019;s indemnification claim against Sanofi and confirmed that Sanofi shall not be liable to indemnify BI for any potential losses in relation to the ongoing ZANTAC litigation in the U.S. The case is closed.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfLegalAndArbitralProceedingsTextBlock>
    <sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther contextRef="c-5" decimals="-6" id="f-4998" unitRef="eur">1283000000</sny:NonCurrentProvisionForProductLiabilityRisksLitigationAndOther>
    <sny:NonCurrentProvisionForEnvironmentRisks contextRef="c-5" decimals="-6" id="f-4999" unitRef="eur">493000000</sny:NonCurrentProvisionForEnvironmentRisks>
    <sny:NumberOfCivilIndividualActions
      contextRef="c-2070"
      decimals="INF"
      id="f-5000"
      unitRef="lawsuit">180</sny:NumberOfCivilIndividualActions>
    <sny:NumberOfOngoingLawsuits
      contextRef="c-2070"
      decimals="INF"
      id="f-5001"
      unitRef="lawsuit">6</sny:NumberOfOngoingLawsuits>
    <sny:NumberOfPlaintiffs
      contextRef="c-2071"
      decimals="0"
      id="f-5002"
      unitRef="plaintiff">6770</sny:NumberOfPlaintiffs>
    <sny:NumberOfBellweatherTrialsHeld
      contextRef="c-2072"
      decimals="0"
      id="f-5003"
      unitRef="trial">2</sny:NumberOfBellweatherTrialsHeld>
    <sny:NumberOfIndividualCasesSettled contextRef="c-2073" decimals="0" id="f-5004" unitRef="case">100</sny:NumberOfIndividualCasesSettled>
    <sny:MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation
      contextRef="c-2074"
      decimals="INF"
      id="f-5005"
      unitRef="usd">10000</sny:MaximumPenaltyAmountSoughtByPlaintiffsForEachViolation>
    <sny:NumberOfCancersAssociatedWithDismissedCases
      contextRef="c-2075"
      decimals="0"
      id="f-5006"
      unitRef="cancer">5</sny:NumberOfCancersAssociatedWithDismissedCases>
    <sny:NumberOfPlaintiffsWhoFiledNoticesToAppeal
      contextRef="c-2075"
      decimals="0"
      id="f-5007"
      unitRef="plaintiff">12000</sny:NumberOfPlaintiffsWhoFiledNoticesToAppeal>
    <sny:NumberOfComplaintsFiled
      contextRef="c-2076"
      decimals="INF"
      id="f-5008"
      unitRef="complaint">3280</sny:NumberOfComplaintsFiled>
    <sny:NumberOfPlaintiffs
      contextRef="c-2076"
      decimals="INF"
      id="f-5009"
      unitRef="plaintiff">26984</sny:NumberOfPlaintiffs>
    <sny:NumberOfClassActionLawsuits
      contextRef="c-2077"
      decimals="INF"
      id="f-5010"
      unitRef="action">7</sny:NumberOfClassActionLawsuits>
    <sny:NumberOfClassActionLawsuits
      contextRef="c-2078"
      decimals="INF"
      id="f-5011"
      unitRef="action">500</sny:NumberOfClassActionLawsuits>
    <sny:NumberOfOngoingTrials
      contextRef="c-2079"
      decimals="INF"
      id="f-5012"
      unitRef="action">0</sny:NumberOfOngoingTrials>
    <sny:NumberOfCivilIndividualActions
      contextRef="c-2080"
      decimals="INF"
      id="f-5013"
      unitRef="claim">79</sny:NumberOfCivilIndividualActions>
    <sny:NumberOfPeopleExposed
      contextRef="c-2080"
      decimals="INF"
      id="f-5014"
      unitRef="person">133</sny:NumberOfPeopleExposed>
    <sny:NumberOfLawsuitsRuledOnMerit
      contextRef="c-2080"
      decimals="INF"
      id="f-5015"
      unitRef="lawsuit">30</sny:NumberOfLawsuitsRuledOnMerit>
    <sny:NumberOfFirstInstanceRulings
      contextRef="c-2081"
      decimals="INF"
      id="f-5016"
      unitRef="ruling">7</sny:NumberOfFirstInstanceRulings>
    <sny:NumberOfFirstInstanceRulings
      contextRef="c-2082"
      decimals="INF"
      id="f-5017"
      unitRef="case">3</sny:NumberOfFirstInstanceRulings>
    <sny:NumberOfFirstInstanceRulings
      contextRef="c-2082"
      decimals="INF"
      id="f-5018"
      unitRef="case">3</sny:NumberOfFirstInstanceRulings>
    <sny:LitigationAmountPayable contextRef="c-2083" decimals="-5" id="f-5019" unitRef="eur">100000</sny:LitigationAmountPayable>
    <sny:LitigationAmountPayable contextRef="c-2084" decimals="-5" id="f-5020" unitRef="eur">500000</sny:LitigationAmountPayable>
    <sny:NumberOfFamiliesWhoFiledACivilClaim
      contextRef="c-2085"
      decimals="INF"
      id="f-5021"
      unitRef="family">64</sny:NumberOfFamiliesWhoFiledACivilClaim>
    <sny:NumberOfClaimant
      contextRef="c-2085"
      decimals="INF"
      id="f-5022"
      unitRef="claimant">273</sny:NumberOfClaimant>
    <sny:NumberOfClaimantExposed
      contextRef="c-2085"
      decimals="INF"
      id="f-5023"
      unitRef="claimant">100</sny:NumberOfClaimantExposed>
    <sny:NumberOfClaimantExposedWhoWithdrawedTheClaim
      contextRef="c-2086"
      decimals="INF"
      id="f-5024"
      unitRef="claimant">27</sny:NumberOfClaimantExposedWhoWithdrawedTheClaim>
    <sny:NumberOfIndirectVictimWhoWithdrawedTheClaim
      contextRef="c-2086"
      decimals="INF"
      id="f-5025"
      unitRef="claimant">56</sny:NumberOfIndirectVictimWhoWithdrawedTheClaim>
    <sny:NumberOfCounterExpertiseExperts
      contextRef="c-2087"
      decimals="INF"
      id="f-5026"
      unitRef="expert">2</sny:NumberOfCounterExpertiseExperts>
    <sny:NumberOfAdministrativeProceedings
      contextRef="c-2088"
      decimals="INF"
      id="f-5027"
      unitRef="proceeding">5</sny:NumberOfAdministrativeProceedings>
    <sny:NumberOfFamiliesWhoFiledACivilClaim
      contextRef="c-2089"
      decimals="INF"
      id="f-5028"
      unitRef="family">11</sny:NumberOfFamiliesWhoFiledACivilClaim>
    <sny:NumberOfPeopleExposed
      contextRef="c-2089"
      decimals="INF"
      id="f-5029"
      unitRef="person">17</sny:NumberOfPeopleExposed>
    <sny:NumberOfActionDeclaredTimeBarred
      contextRef="c-2090"
      decimals="INF"
      id="f-5030"
      unitRef="person">1</sny:NumberOfActionDeclaredTimeBarred>
    <sny:NumberOfOngoingTrials
      contextRef="c-2091"
      decimals="INF"
      id="f-5031"
      unitRef="trial">6</sny:NumberOfOngoingTrials>
    <sny:NumberOfPeopleExposed
      contextRef="c-2091"
      decimals="INF"
      id="f-5032"
      unitRef="children">13</sny:NumberOfPeopleExposed>
    <sny:NumberOfPatientsToIndemnify
      contextRef="c-2092"
      decimals="INF"
      id="f-5033"
      unitRef="patient">4</sny:NumberOfPatientsToIndemnify>
    <sny:NumberOfCivilIndividualActions
      contextRef="c-2093"
      decimals="INF"
      id="f-5034"
      unitRef="complaint">2</sny:NumberOfCivilIndividualActions>
    <sny:NumberOfPreActionProtocolCases
      contextRef="c-2094"
      decimals="INF"
      id="f-5035"
      unitRef="case">2</sny:NumberOfPreActionProtocolCases>
    <sny:NumberOfCivilClaimsOnGoing
      contextRef="c-2094"
      decimals="INF"
      id="f-5036"
      unitRef="claim">2</sny:NumberOfCivilClaimsOnGoing>
    <sny:NumberOfPreActionProtocolCases
      contextRef="c-2095"
      decimals="INF"
      id="f-5037"
      unitRef="case">3</sny:NumberOfPreActionProtocolCases>
    <sny:NumberOfCivilClaimsOnGoing
      contextRef="c-2096"
      decimals="INF"
      id="f-5038"
      unitRef="claim">1</sny:NumberOfCivilClaimsOnGoing>
    <sny:NumberOfCases
      contextRef="c-2097"
      decimals="INF"
      id="f-5039"
      unitRef="case">8</sny:NumberOfCases>
    <sny:NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug
      contextRef="c-2098"
      decimals="INF"
      id="f-5040"
      unitRef="manufacturer">8</sny:NumberOfManufacturersWithMarketingAuthorizationForGenericVersionOfDrug>
    <sny:NumberOfPatentActionsInitiallyFiled
      contextRef="c-2099"
      decimals="INF"
      id="f-5041"
      unitRef="complaint">4</sny:NumberOfPatentActionsInitiallyFiled>
    <sny:NumberOfPatentsAllegedlyInfringed
      contextRef="c-2100"
      decimals="INF"
      id="f-5042"
      unitRef="patent">7</sny:NumberOfPatentsAllegedlyInfringed>
    <sny:NumberOfPatentsCoveringProduct
      contextRef="c-2101"
      decimals="INF"
      id="f-5043"
      unitRef="patent">4</sny:NumberOfPatentsCoveringProduct>
    <sny:NumberOfPatentsAllegedlyInfringed
      contextRef="c-2102"
      decimals="INF"
      id="f-5044"
      unitRef="claim">12</sny:NumberOfPatentsAllegedlyInfringed>
    <sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs contextRef="c-2103" decimals="-5" id="f-5045" unitRef="aud">223300000</sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs>
    <sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs contextRef="c-2103" decimals="-5" id="f-5046" unitRef="eur">137800000</sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs>
    <sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs contextRef="c-2104" decimals="-5" id="f-5047" unitRef="aud">280200000</sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs>
    <sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs contextRef="c-2104" decimals="-5" id="f-5048" unitRef="eur">172900000</sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffs>
    <sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded contextRef="c-2103" decimals="-5" id="f-5049" unitRef="aud">360500000</sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded>
    <sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded contextRef="c-2103" decimals="-5" id="f-5050" unitRef="eur">218000000</sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded>
    <sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded contextRef="c-2104" decimals="-5" id="f-5051" unitRef="aud">487500000</sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded>
    <sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded contextRef="c-2104" decimals="-5" id="f-5052" unitRef="eur">294300000</sny:ReducedAmountOfCompensationClaimedByFilledPlaintiffsInterestIncluded>
    <sny:GlobalPenaltyFeeIncurredByDefendants contextRef="c-2105" decimals="-3" id="f-5053" unitRef="usd">834012000</sny:GlobalPenaltyFeeIncurredByDefendants>
    <sny:PenaltyFeeIncurred contextRef="c-2105" decimals="-3" id="f-5054" unitRef="usd">417006000</sny:PenaltyFeeIncurred>
    <sny:PenaltyFeeIncurred contextRef="c-2106" decimals="-5" id="f-5055" unitRef="eur">40600000</sny:PenaltyFeeIncurred>
    <sny:PaymentOfDamagesClaimedByCounterparty contextRef="c-2107" decimals="-5" id="f-5056" unitRef="eur">115800000</sny:PaymentOfDamagesClaimedByCounterparty>
    <sny:NumberOfOtherManufacturersInvolvedInProceedings
      contextRef="c-2108"
      decimals="INF"
      id="f-5057"
      unitRef="manufacturer">3</sny:NumberOfOtherManufacturersInvolvedInProceedings>
    <sny:EquityInvestmentSoldPercentage
      contextRef="c-2109"
      decimals="2"
      id="f-5058"
      unitRef="number">0.76</sny:EquityInvestmentSoldPercentage>
    <sny:ConsiderationTransferredToFundReserveForIndemnificationUndertaking contextRef="c-2110" decimals="-6" id="f-5059" unitRef="eur">57000000</sny:ConsiderationTransferredToFundReserveForIndemnificationUndertaking>
    <sny:MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense contextRef="c-2110" decimals="-6" id="f-5060" unitRef="eur">143000000</sny:MaximumAmountToBeReimbursedForCurrentAndFutureEnvironmentalExpense>
    <sny:DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock contextRef="c-1" id="f-5061">Provisions for discounts, rebates and sales returns&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Adjustments between gross sales and net sales, as described in Note&#160;B.13., are recognized either as provisions or as reductions in accounts receivable, depending on their nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows movements in these items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;and State&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;programs&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Managed&#160;care&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;and&#160;GPO&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;programs&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Chargeback&lt;br/&gt;incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Rebates&lt;br/&gt;and&lt;br/&gt;discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Sales&lt;br/&gt;returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,507&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;908&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,557&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;688&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,039&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net change in provision related to prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(697)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,596&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;931&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,425&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;610&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,899&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net change in provision related to prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(315)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,603&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;362&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,805&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;629&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,490&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net change in provision related to prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance&#160;at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,962&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,119&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;637&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,269&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;715&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,762&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Primarily US government programs: Medicaid (&#x20ac;1,421 million in 2023, &#x20ac;1,307 million in 2022, &#x20ac;1,244 million in 2021) and Medicare (&#x20ac;1,099 million in 2023, &#x20ac;775 million in 2022 and &#x20ac;941 million in 2021).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Mainly rebates and other price reductions granted to healthcare authorities in the United States (including Managed Care: &#x20ac;1,028 million in 2023,     &#x20ac;934 million in 2022 and &#x20ac;896 million in 2021).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Provisions related to US net sales amounted to &#x20ac;5,124 million as of December 31, 2023, &#x20ac;4,270 million as of December 31, 2022 and &#x20ac;4,057 million as of&#160;December 31, 2021.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfProvisionsForDiscountsRebatesAndSalesReturnsTextBlock>
    <sny:DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock contextRef="c-1" id="f-5062">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows movements in these items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.699%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.160%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;and State&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;programs&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Managed&#160;care&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;and&#160;GPO&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;programs&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Chargeback&lt;br/&gt;incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Rebates&lt;br/&gt;and&lt;br/&gt;discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Sales&lt;br/&gt;returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,507&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;908&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;333&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,557&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;688&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,039&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net change in provision related to prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(697)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(19,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,596&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;931&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,425&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;610&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,899&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net change in provision related to prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(315)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(21,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,603&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;362&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,805&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;629&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,490&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Changes in scope of consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provision related to current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net change in provision related to prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(7,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(511)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(22,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Currency translation differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Balance&#160;at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,962&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,119&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;637&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,269&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;715&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,762&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Primarily US government programs: Medicaid (&#x20ac;1,421 million in 2023, &#x20ac;1,307 million in 2022, &#x20ac;1,244 million in 2021) and Medicare (&#x20ac;1,099 million in 2023, &#x20ac;775 million in 2022 and &#x20ac;941 million in 2021).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Mainly rebates and other price reductions granted to healthcare authorities in the United States (including Managed Care: &#x20ac;1,028 million in 2023,     &#x20ac;934 million in 2022 and &#x20ac;896 million in 2021).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Provisions related to US net sales amounted to &#x20ac;5,124 million as of December 31, 2023, &#x20ac;4,270 million as of December 31, 2022 and &#x20ac;4,057 million as of&#160;December 31, 2021.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfChangesInProvisionsForDiscountsRebatesAndSalesReturnsTableTextBlock>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2111" decimals="-6" id="f-5063" unitRef="eur">2507000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2112" decimals="-6" id="f-5064" unitRef="eur">908000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2113" decimals="-6" id="f-5065" unitRef="eur">333000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2114" decimals="-6" id="f-5066" unitRef="eur">1557000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2115" decimals="-6" id="f-5067" unitRef="eur">688000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2116" decimals="-6" id="f-5068" unitRef="eur">46000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-19" decimals="-6" id="f-5069" unitRef="eur">6039000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2117" decimals="-6" id="f-5070" unitRef="eur">3000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2118" decimals="-6" id="f-5071" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2119" decimals="-6" id="f-5072" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2120" decimals="-6" id="f-5073" unitRef="eur">-2000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2121" decimals="-6" id="f-5074" unitRef="eur">1000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2122" decimals="-6" id="f-5075" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-10" decimals="-6" id="f-5076" unitRef="eur">2000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2117" decimals="-6" id="f-5077" unitRef="eur">5855000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2118" decimals="-6" id="f-5078" unitRef="eur">3037000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2119" decimals="-6" id="f-5079" unitRef="eur">3813000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2120" decimals="-6" id="f-5080" unitRef="eur">6330000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2121" decimals="-6" id="f-5081" unitRef="eur">582000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2122" decimals="-6" id="f-5082" unitRef="eur">97000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-10" decimals="-6" id="f-5083" unitRef="eur">19714000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2117" decimals="-6" id="f-5084" unitRef="eur">-136000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2118" decimals="-6" id="f-5085" unitRef="eur">-3000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2119" decimals="-6" id="f-5086" unitRef="eur">-4000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2120" decimals="-6" id="f-5087" unitRef="eur">-152000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2121" decimals="-6" id="f-5088" unitRef="eur">56000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2122" decimals="-6" id="f-5089" unitRef="eur">-3000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-10" decimals="-6" id="f-5090" unitRef="eur">-242000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2117" decimals="-6" id="f-5091" unitRef="eur">5561000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2118" decimals="-6" id="f-5092" unitRef="eur">2979000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2119" decimals="-6" id="f-5093" unitRef="eur">3828000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2120" decimals="-6" id="f-5094" unitRef="eur">6291000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2121" decimals="-6" id="f-5095" unitRef="eur">697000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2122" decimals="-6" id="f-5096" unitRef="eur">105000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-10" decimals="-6" id="f-5097" unitRef="eur">19461000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2117" decimals="-6" id="f-5098" unitRef="eur">-72000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2118" decimals="-6" id="f-5099" unitRef="eur">-32000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2119" decimals="-6" id="f-5100" unitRef="eur">-11000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2120" decimals="-6" id="f-5101" unitRef="eur">-17000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2121" decimals="-6" id="f-5102" unitRef="eur">-20000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2122" decimals="-6" id="f-5103" unitRef="eur">-1000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-10" decimals="-6" id="f-5104" unitRef="eur">-153000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2123" decimals="-6" id="f-5105" unitRef="eur">2596000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2124" decimals="-6" id="f-5106" unitRef="eur">931000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2125" decimals="-6" id="f-5107" unitRef="eur">303000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2126" decimals="-6" id="f-5108" unitRef="eur">1425000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2127" decimals="-6" id="f-5109" unitRef="eur">610000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2128" decimals="-6" id="f-5110" unitRef="eur">34000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-8" decimals="-6" id="f-5111" unitRef="eur">5899000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2129" decimals="-6" id="f-5112" unitRef="eur">6744000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2130" decimals="-6" id="f-5113" unitRef="eur">3246000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2131" decimals="-6" id="f-5114" unitRef="eur">4147000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2132" decimals="-6" id="f-5115" unitRef="eur">7244000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2133" decimals="-6" id="f-5116" unitRef="eur">578000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2134" decimals="-6" id="f-5117" unitRef="eur">182000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-9" decimals="-6" id="f-5118" unitRef="eur">22141000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2129" decimals="-6" id="f-5119" unitRef="eur">-120000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2130" decimals="-6" id="f-5120" unitRef="eur">-47000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2131" decimals="-6" id="f-5121" unitRef="eur">-21000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2132" decimals="-6" id="f-5122" unitRef="eur">-138000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2133" decimals="-6" id="f-5123" unitRef="eur">-8000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2134" decimals="-6" id="f-5124" unitRef="eur">19000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-9" decimals="-6" id="f-5125" unitRef="eur">-315000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2129" decimals="-6" id="f-5126" unitRef="eur">6824000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2130" decimals="-6" id="f-5127" unitRef="eur">3208000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2131" decimals="-6" id="f-5128" unitRef="eur">4093000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2132" decimals="-6" id="f-5129" unitRef="eur">6809000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2133" decimals="-6" id="f-5130" unitRef="eur">599000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2134" decimals="-6" id="f-5131" unitRef="eur">166000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-9" decimals="-6" id="f-5132" unitRef="eur">21699000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2129" decimals="-6" id="f-5133" unitRef="eur">207000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2130" decimals="-6" id="f-5134" unitRef="eur">99000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2131" decimals="-6" id="f-5135" unitRef="eur">26000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2132" decimals="-6" id="f-5136" unitRef="eur">83000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2133" decimals="-6" id="f-5137" unitRef="eur">48000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2134" decimals="-6" id="f-5138" unitRef="eur">1000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-9" decimals="-6" id="f-5139" unitRef="eur">464000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2135" decimals="-6" id="f-5140" unitRef="eur">2603000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2136" decimals="-6" id="f-5141" unitRef="eur">1021000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2137" decimals="-6" id="f-5142" unitRef="eur">362000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2138" decimals="-6" id="f-5143" unitRef="eur">1805000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2139" decimals="-6" id="f-5144" unitRef="eur">629000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2140" decimals="-6" id="f-5145" unitRef="eur">70000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-7" decimals="-6" id="f-5146" unitRef="eur">6490000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2141" decimals="-6" id="f-5147" unitRef="eur">2000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2142" decimals="-6" id="f-5148" unitRef="eur">0</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2143" decimals="-6" id="f-5149" unitRef="eur">-1000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2144" decimals="-6" id="f-5150" unitRef="eur">-6000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2145" decimals="-6" id="f-5151" unitRef="eur">-2000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-2146" decimals="-6" id="f-5152" unitRef="eur">4000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns contextRef="c-1" decimals="-6" id="f-5153" unitRef="eur">-3000000</sny:IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2141" decimals="-6" id="f-5154" unitRef="eur">7758000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2142" decimals="-6" id="f-5155" unitRef="eur">3590000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2143" decimals="-6" id="f-5156" unitRef="eur">3861000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2144" decimals="-6" id="f-5157" unitRef="eur">8177000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2145" decimals="-6" id="f-5158" unitRef="eur">654000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-2146" decimals="-6" id="f-5159" unitRef="eur">256000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales contextRef="c-1" decimals="-6" id="f-5160" unitRef="eur">24296000000</sny:IncreaseThroughNewProvisionRelatedToCurrentPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2141" decimals="-6" id="f-5161" unitRef="eur">-74000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2142" decimals="-6" id="f-5162" unitRef="eur">-12000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2143" decimals="-6" id="f-5163" unitRef="eur">-9000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2144" decimals="-6" id="f-5164" unitRef="eur">-58000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2145" decimals="-6" id="f-5165" unitRef="eur">-25000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-2146" decimals="-6" id="f-5166" unitRef="eur">23000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales contextRef="c-1" decimals="-6" id="f-5167" unitRef="eur">-155000000</sny:IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2141" decimals="-6" id="f-5168" unitRef="eur">7251000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2142" decimals="-6" id="f-5169" unitRef="eur">3446000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2143" decimals="-6" id="f-5170" unitRef="eur">3564000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2144" decimals="-6" id="f-5171" unitRef="eur">7603000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2145" decimals="-6" id="f-5172" unitRef="eur">511000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2146" decimals="-6" id="f-5173" unitRef="eur">278000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-1" decimals="-6" id="f-5174" unitRef="eur">22653000000</sny:DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2141" decimals="-6" id="f-5175" unitRef="eur">-76000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2142" decimals="-6" id="f-5176" unitRef="eur">-34000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2143" decimals="-6" id="f-5177" unitRef="eur">-12000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2144" decimals="-6" id="f-5178" unitRef="eur">-46000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2145" decimals="-6" id="f-5179" unitRef="eur">-30000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2146" decimals="-6" id="f-5180" unitRef="eur">-15000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-1" decimals="-6" id="f-5181" unitRef="eur">-213000000</sny:IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2147" decimals="-6" id="f-5182" unitRef="eur">2962000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2148" decimals="-6" id="f-5183" unitRef="eur">1119000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2149" decimals="-6" id="f-5184" unitRef="eur">637000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2150" decimals="-6" id="f-5185" unitRef="eur">2269000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2151" decimals="-6" id="f-5186" unitRef="eur">715000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2152" decimals="-6" id="f-5187" unitRef="eur">60000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-5" decimals="-6" id="f-5188" unitRef="eur">7762000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2153" decimals="-6" id="f-5189" unitRef="eur">1421000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2154" decimals="-6" id="f-5190" unitRef="eur">1307000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2155" decimals="-6" id="f-5191" unitRef="eur">1244000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2156" decimals="-6" id="f-5192" unitRef="eur">1099000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2157" decimals="-6" id="f-5193" unitRef="eur">775000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2158" decimals="-6" id="f-5194" unitRef="eur">941000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2159" decimals="-6" id="f-5195" unitRef="eur">1028000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2160" decimals="-6" id="f-5196" unitRef="eur">934000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-2161" decimals="-6" id="f-5197" unitRef="eur">896000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-1218" decimals="-6" id="f-5198" unitRef="eur">5124000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-1224" decimals="-6" id="f-5199" unitRef="eur">4270000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <sny:ProvisionsForDiscountsRebatesAndSalesReturns contextRef="c-1230" decimals="-6" id="f-5200" unitRef="eur">4057000000</sny:ProvisionsForDiscountsRebatesAndSalesReturns>
    <ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory contextRef="c-1" id="f-5201">Personnel costs&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total personnel costs (other than termination benefits, presented in Note&#160;D.27.) include the following items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Social security charges (including defined-contribution pension plans)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other employee benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:3.9pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,814&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,991&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,340&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Includes expenses related to share-based payments and defined-benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The total number of registered employees was 87,994 as of December 31, 2023, compared with 91,573 as of December 31, 2022 and&#160;95,442 as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory>
    <sny:DisclosureOfPersonnelCostsDetailsTableTextBlock contextRef="c-1" id="f-5202">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Total personnel costs (other than termination benefits, presented in Note&#160;D.27.) include the following items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Social security charges (including defined-contribution pension plans)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other employee benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:3.9pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,814&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,991&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,340&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Includes expenses related to share-based payments and defined-benefit plans.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfPersonnelCostsDetailsTableTextBlock>
    <ifrs-full:WagesAndSalaries contextRef="c-1" decimals="-6" id="f-5203" unitRef="eur">7183000000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c-9" decimals="-6" id="f-5204" unitRef="eur">7145000000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c-10" decimals="-6" id="f-5205" unitRef="eur">6625000000</ifrs-full:WagesAndSalaries>
    <ifrs-full:SocialSecurityContributions contextRef="c-1" decimals="-6" id="f-5206" unitRef="eur">2100000000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions contextRef="c-9" decimals="-6" id="f-5207" unitRef="eur">2098000000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions contextRef="c-10" decimals="-6" id="f-5208" unitRef="eur">1929000000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:OtherEmployeeExpense contextRef="c-1" decimals="-6" id="f-5209" unitRef="eur">531000000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-9" decimals="-6" id="f-5210" unitRef="eur">748000000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-10" decimals="-6" id="f-5211" unitRef="eur">786000000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-1" decimals="-6" id="f-5212" unitRef="eur">9814000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-9" decimals="-6" id="f-5213" unitRef="eur">9991000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-10" decimals="-6" id="f-5214" unitRef="eur">9340000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:NumberOfEmployees
      contextRef="c-5"
      decimals="INF"
      id="f-5215"
      unitRef="employee">87994</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-7"
      decimals="INF"
      id="f-5216"
      unitRef="employee">91573</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-8"
      decimals="INF"
      id="f-5217"
      unitRef="employee">95442</ifrs-full:NumberOfEmployees>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory contextRef="c-1" id="f-5218">Other operating income&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;totaled &#x20ac;1,292 million in 2023, versus &#x20ac;1,969 million in 2022 and &#x20ac;859 million in 2021.&lt;/span&gt;&lt;/div&gt;Other operating income includes (i)&#160;gains from asset divestments, amounting to &#x20ac;688&#160;million in 2023 (versus &#x20ac;655 million in 2022 and &#x20ac;418 million in 2021); and (ii)&#160;income from Sanofi&#x2019;s pharmaceutical partners, amounting to &#x20ac;290 million in 2023 (including&#160;&#x20ac;227 million from Regeneron, see Note&#160;D.26. below and Note&#160;C.1.), compared with &#x20ac;1,178 million in 2022 (including&#160;&#x20ac;1,147 million from Regeneron), and &#x20ac;245 million in 2021. For 2021, it includes a payment of &#x20ac;119&#160;million from Daiichi Sankyo relating to the termination of a vaccines collaboration agreement in Japan</ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-6" id="f-5219" unitRef="eur">1292000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-9" decimals="-6" id="f-5220" unitRef="eur">1969000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-10" decimals="-6" id="f-5221" unitRef="eur">859000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <sny:GainsOnDivestmentOfProducts contextRef="c-2162" decimals="-6" id="f-5222" unitRef="eur">688000000</sny:GainsOnDivestmentOfProducts>
    <sny:GainsOnDivestmentOfProducts contextRef="c-2163" decimals="-6" id="f-5223" unitRef="eur">655000000</sny:GainsOnDivestmentOfProducts>
    <sny:GainsOnDivestmentOfProducts contextRef="c-2164" decimals="-6" id="f-5224" unitRef="eur">418000000</sny:GainsOnDivestmentOfProducts>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2165" decimals="-6" id="f-5225" unitRef="eur">290000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2166" decimals="-6" id="f-5226" unitRef="eur">227000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2167" decimals="-6" id="f-5227" unitRef="eur">1178000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2168" decimals="-6" id="f-5228" unitRef="eur">1147000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2169" decimals="-6" id="f-5229" unitRef="eur">245000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2170" decimals="-6" id="f-5230" unitRef="eur">119000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory contextRef="c-1" id="f-5231">Other operating expenses&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; totaled &#x20ac;3,516 million in 2023, compared with &#x20ac;2,531 million in 2022 and &#x20ac;1,805 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For 2023, this line item includes &#x20ac;3,206 million of expenses related to Regeneron (see Note&#160;C.1.), compared with&#160;&#x20ac;2,378 million for 2022 and &#x20ac;1,568 million for 2021 (as shown in the table below):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income &amp;amp; expense related to sharing of (profits)/losses under the Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Additional share of profit paid by Regeneron towards development costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reimbursement to Regeneron of selling expenses incurred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total - Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Immuno-Oncology Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other (mainly ZALTRAP and LIBTAYO)&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,120&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other operating income/(expenses), net related to Regeneron&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which amount presented in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt; Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt; (Note&#160;D.25.)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Following the restructuring of the Immuno-Oncology agreement between Sanofi and Regeneron, applicable from July&#160;1, 2022 (see Note&#160;C.1.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;As of December 31, 2023, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to &#x20ac;2.1 billion, compared with &#x20ac;2.7 billion as of December 31, 2022 (see note D.21.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Charges to provisions for litigation and environmental risks are also recorded within this line item.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-1" decimals="-6" id="f-5232" unitRef="eur">3516000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-9" decimals="-6" id="f-5233" unitRef="eur">2531000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-10" decimals="-6" id="f-5234" unitRef="eur">1805000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <sny:OtherOperatingExpensesTableTextBlock contextRef="c-1" id="f-5235">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For 2023, this line item includes &#x20ac;3,206 million of expenses related to Regeneron (see Note&#160;C.1.), compared with&#160;&#x20ac;2,378 million for 2022 and &#x20ac;1,568 million for 2021 (as shown in the table below):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income &amp;amp; expense related to sharing of (profits)/losses under the Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Additional share of profit paid by Regeneron towards development costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Reimbursement to Regeneron of selling expenses incurred&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total - Monoclonal Antibody Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(3,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Immuno-Oncology Alliance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other (mainly ZALTRAP and LIBTAYO)&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,120&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other operating income/(expenses), net related to Regeneron&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which amount presented in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt; Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt; (Note&#160;D.25.)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Following the restructuring of the Immuno-Oncology agreement between Sanofi and Regeneron, applicable from July&#160;1, 2022 (see Note&#160;C.1.).&lt;/span&gt;&lt;/div&gt;(b)&#160;&#160;&#160;&#160;As of December 31, 2023, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to &#x20ac;2.1 billion, compared with &#x20ac;2.7 billion as of December 31, 2022 (see note D.21.</sny:OtherOperatingExpensesTableTextBlock>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2171" decimals="-6" id="f-5236" unitRef="eur">3206000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2172" decimals="-6" id="f-5237" unitRef="eur">2378000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2173" decimals="-6" id="f-5238" unitRef="eur">1568000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2174" decimals="-6" id="f-5239" unitRef="eur">3321000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2175" decimals="-6" id="f-5240" unitRef="eur">2325000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2176" decimals="-6" id="f-5241" unitRef="eur">1253000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2177" decimals="-6" id="f-5242" unitRef="eur">668000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2178" decimals="-6" id="f-5243" unitRef="eur">434000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2179" decimals="-6" id="f-5244" unitRef="eur">127000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2180" decimals="-6" id="f-5245" unitRef="eur">543000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2181" decimals="-6" id="f-5246" unitRef="eur">476000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2182" decimals="-6" id="f-5247" unitRef="eur">303000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2183" decimals="-6" id="f-5248" unitRef="eur">3196000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2184" decimals="-6" id="f-5249" unitRef="eur">2367000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-2185" decimals="-6" id="f-5250" unitRef="eur">1429000000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2186" decimals="-6" id="f-5251" unitRef="eur">0</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2187" decimals="-6" id="f-5252" unitRef="eur">16000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2188" decimals="-6" id="f-5253" unitRef="eur">68000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-2189" decimals="-6" id="f-5254" unitRef="eur">217000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-2190" decimals="-6" id="f-5255" unitRef="eur">1120000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-2191" decimals="-6" id="f-5256" unitRef="eur">-12000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-5257" unitRef="eur">-2979000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-9" decimals="-6" id="f-5258" unitRef="eur">-1231000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-10" decimals="-6" id="f-5259" unitRef="eur">-1373000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2166" decimals="-6" id="f-5260" unitRef="eur">227000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2168" decimals="-6" id="f-5261" unitRef="eur">1147000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-2192" decimals="-6" id="f-5262" unitRef="eur">195000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <sny:CommitmentsReceivedForDevelopmentCosts contextRef="c-2052" decimals="-8" id="f-5263" unitRef="eur">2100000000</sny:CommitmentsReceivedForDevelopmentCosts>
    <sny:CommitmentsReceivedForDevelopmentCosts contextRef="c-2053" decimals="-8" id="f-5264" unitRef="eur">2700000000</sny:CommitmentsReceivedForDevelopmentCosts>
    <sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock contextRef="c-1" id="f-5265">Restructuring costs and similar items&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restructuring costs and similar items amounted to &#x20ac;1,490&#160;million in 2023, &#x20ac;1,336&#160;million in 2022 and &#x20ac;820&#160;million in 2021, and were comprised of the following items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Charges, gains or losses on assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Costs related to transformation programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,490&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,336&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;820&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; were &#x20ac;154&#160;million higher in 2023 than 2022. For 2023 they include the impact of French pension reform on future annuities under the rules of each severance plan, while for 2022 they mainly comprised severance costs recognized further to the announcements made during that period. Also included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; are the impacts of ongoing transformational projects, primarily those associated with the creation of the standalone Consumer Healthcare entity and the implementation of Sanofi&#x2019;s new digital strategy.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRestructuringCostsAndSimilarItemsTextBlock>
    <sny:DisclosureOfRestructuringCostsDetailsTableTextBlock contextRef="c-1" id="f-5266">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Restructuring costs and similar items amounted to &#x20ac;1,490&#160;million in 2023, &#x20ac;1,336&#160;million in 2022 and &#x20ac;820&#160;million in 2021, and were comprised of the following items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Charges, gains or losses on assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Costs related to transformation programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,490&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,336&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;820&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfRestructuringCostsDetailsTableTextBlock>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-1" decimals="-6" id="f-5267" unitRef="eur">1490000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-9" decimals="-6" id="f-5268" unitRef="eur">1336000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-10" decimals="-6" id="f-5269" unitRef="eur">820000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses contextRef="c-1" decimals="-6" id="f-5270" unitRef="eur">489000000</sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses>
    <sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses contextRef="c-9" decimals="-6" id="f-5271" unitRef="eur">507000000</sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses>
    <sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses contextRef="c-10" decimals="-6" id="f-5272" unitRef="eur">193000000</sny:ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses>
    <sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories contextRef="c-1" decimals="-6" id="f-5273" unitRef="eur">293000000</sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories>
    <sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories contextRef="c-9" decimals="-6" id="f-5274" unitRef="eur">261000000</sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories>
    <sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories contextRef="c-10" decimals="-6" id="f-5275" unitRef="eur">110000000</sny:ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories>
    <sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts contextRef="c-1" decimals="-6" id="f-5276" unitRef="eur">676000000</sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts>
    <sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts contextRef="c-9" decimals="-6" id="f-5277" unitRef="eur">547000000</sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts>
    <sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts contextRef="c-10" decimals="-6" id="f-5278" unitRef="eur">463000000</sny:ExpenseOfRestructuringActivitiesTransformationProgramsCosts>
    <sny:OtherRestructuringCost contextRef="c-1" decimals="-6" id="f-5279" unitRef="eur">32000000</sny:OtherRestructuringCost>
    <sny:OtherRestructuringCost contextRef="c-9" decimals="-6" id="f-5280" unitRef="eur">21000000</sny:OtherRestructuringCost>
    <sny:OtherRestructuringCost contextRef="c-10" decimals="-6" id="f-5281" unitRef="eur">54000000</sny:OtherRestructuringCost>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-1" decimals="-6" id="f-5282" unitRef="eur">1490000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-9" decimals="-6" id="f-5283" unitRef="eur">1336000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-10" decimals="-6" id="f-5284" unitRef="eur">820000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:IncreaseDecreaseInExpenseOfRestructuringActivities contextRef="c-1" decimals="-6" id="f-5285" unitRef="eur">154000000</sny:IncreaseDecreaseInExpenseOfRestructuringActivities>
    <sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock contextRef="c-1" id="f-5286">Other gains and losses, and litigation&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2023 represent a charge of &#x20ac;38&#160;million, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;including costs relating to the settlement of  litigation with Bioverativ former shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For 2022, this line item represented a charge of &#x20ac;370&#160;million, comprising the pre-tax loss arising on the deconsolidation of EUROAPI (see Note&#160;D.2.) and costs related to major litigation.&lt;/span&gt;&lt;/div&gt;For 2021, this line item represented a charge of &#x20ac;5 million</sny:DisclosureOfOtherGainsAndLossesAndLitigationTextBlock>
    <sny:OtherGainsLossesAndLitigation contextRef="c-1" decimals="-6" id="f-5287" unitRef="eur">-38000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-9" decimals="-6" id="f-5288" unitRef="eur">-370000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-10" decimals="-6" id="f-5289" unitRef="eur">-5000000</sny:OtherGainsLossesAndLitigation>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c-1" id="f-5290">Financial expenses and income&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(365)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(313)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost of net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-operating foreign exchange gains/(losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unwinding of discounting of provisions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost related to employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains/(losses) on disposals of financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net financial income/(expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;comprising: Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;591&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes net gains/(losses) on interest rate and currency derivatives used to manage debt: &#x20ac;(67) million in 2023, &#x20ac;(11) million in 2022, &#x20ac;14 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Includes net gains on interest rate and currency derivatives used to manage cash and cash equivalents: &#x20ac;(13) million in 2023, &#x20ac;68 million in 2022,          &#x20ac;51 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note&#160;D.19.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Includes a financial expense of &#x20ac;541 million (zero in 2022 and 2021) in respect of the liability recognized in the balance sheet for estimated future royalties on US sales of BEYFORTUS, which was remeasured as of December 31, 2023 to reflect the very successful US launch of the product (see Note C.2.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2023, 2022 and 2021, the impact of the ineffective portion of hedging relationships was not material.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock contextRef="c-1" id="f-5291">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;An analysis of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(365)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(313)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cost of net debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-operating foreign exchange gains/(losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Unwinding of discounting of provisions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest cost related to employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains/(losses) on disposals of financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net financial income/(expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;comprising: Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;591&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes net gains/(losses) on interest rate and currency derivatives used to manage debt: &#x20ac;(67) million in 2023, &#x20ac;(11) million in 2022, &#x20ac;14 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Includes net gains on interest rate and currency derivatives used to manage cash and cash equivalents: &#x20ac;(13) million in 2023, &#x20ac;68 million in 2022,          &#x20ac;51 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note&#160;D.19.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Includes a financial expense of &#x20ac;541 million (zero in 2022 and 2021) in respect of the liability recognized in the balance sheet for estimated future royalties on US sales of BEYFORTUS, which was remeasured as of December 31, 2023 to reflect the very successful US launch of the product (see Note C.2.).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfFinancialIncomeAndExpensesExplanatoryTableTextBlock>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-1" decimals="-6" id="f-5292" unitRef="eur">555000000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-9" decimals="-6" id="f-5293" unitRef="eur">365000000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-10" decimals="-6" id="f-5294" unitRef="eur">313000000</ifrs-full:InterestExpenseOnBorrowings>
    <sny:InterestIncome contextRef="c-1" decimals="-6" id="f-5295" unitRef="eur">533000000</sny:InterestIncome>
    <sny:InterestIncome contextRef="c-9" decimals="-6" id="f-5296" unitRef="eur">241000000</sny:InterestIncome>
    <sny:InterestIncome contextRef="c-10" decimals="-6" id="f-5297" unitRef="eur">54000000</sny:InterestIncome>
    <sny:CostOfDebtNet contextRef="c-1" decimals="-6" id="f-5298" unitRef="eur">22000000</sny:CostOfDebtNet>
    <sny:CostOfDebtNet contextRef="c-9" decimals="-6" id="f-5299" unitRef="eur">124000000</sny:CostOfDebtNet>
    <sny:CostOfDebtNet contextRef="c-10" decimals="-6" id="f-5300" unitRef="eur">259000000</sny:CostOfDebtNet>
    <sny:NonOperatingForeignExchangeGainsLosses contextRef="c-1" decimals="-6" id="f-5301" unitRef="eur">-2000000</sny:NonOperatingForeignExchangeGainsLosses>
    <sny:NonOperatingForeignExchangeGainsLosses contextRef="c-9" decimals="-6" id="f-5302" unitRef="eur">-4000000</sny:NonOperatingForeignExchangeGainsLosses>
    <sny:NonOperatingForeignExchangeGainsLosses contextRef="c-10" decimals="-6" id="f-5303" unitRef="eur">2000000</sny:NonOperatingForeignExchangeGainsLosses>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="c-1" decimals="-6" id="f-5304" unitRef="eur">59000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="c-9" decimals="-6" id="f-5305" unitRef="eur">20000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="c-10" decimals="-6" id="f-5306" unitRef="eur">11000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <sny:NetInterestCostRelatedToEmployeeBenefits contextRef="c-1" decimals="-6" id="f-5307" unitRef="eur">73000000</sny:NetInterestCostRelatedToEmployeeBenefits>
    <sny:NetInterestCostRelatedToEmployeeBenefits contextRef="c-9" decimals="-6" id="f-5308" unitRef="eur">47000000</sny:NetInterestCostRelatedToEmployeeBenefits>
    <sny:NetInterestCostRelatedToEmployeeBenefits contextRef="c-10" decimals="-6" id="f-5309" unitRef="eur">44000000</sny:NetInterestCostRelatedToEmployeeBenefits>
    <ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets contextRef="c-1" decimals="-6" id="f-5310" unitRef="eur">-1000000</ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets>
    <ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets contextRef="c-9" decimals="-6" id="f-5311" unitRef="eur">1000000</ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets>
    <ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets contextRef="c-10" decimals="-6" id="f-5312" unitRef="eur">3000000</ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-6" id="f-5313" unitRef="eur">39000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-9" decimals="-6" id="f-5314" unitRef="eur">40000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-10" decimals="-6" id="f-5315" unitRef="eur">35000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c-1" decimals="-6" id="f-5316" unitRef="eur">-526000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c-9" decimals="-6" id="f-5317" unitRef="eur">0</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c-10" decimals="-6" id="f-5318" unitRef="eur">16000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-1" decimals="-6" id="f-5319" unitRef="eur">-722000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-9" decimals="-6" id="f-5320" unitRef="eur">-234000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-10" decimals="-6" id="f-5321" unitRef="eur">-328000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-5322" unitRef="eur">1313000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-9" decimals="-6" id="f-5323" unitRef="eur">440000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-10" decimals="-6" id="f-5324" unitRef="eur">368000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-5325" unitRef="eur">591000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-9" decimals="-6" id="f-5326" unitRef="eur">206000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-10" decimals="-6" id="f-5327" unitRef="eur">40000000</ifrs-full:FinanceIncome>
    <sny:GainsLossesOnDerivativesUsedToManageDebt contextRef="c-2193" decimals="-6" id="f-5328" unitRef="eur">-67000000</sny:GainsLossesOnDerivativesUsedToManageDebt>
    <sny:GainsLossesOnDerivativesUsedToManageDebt contextRef="c-2194" decimals="-6" id="f-5329" unitRef="eur">-11000000</sny:GainsLossesOnDerivativesUsedToManageDebt>
    <sny:GainsLossesOnDerivativesUsedToManageDebt contextRef="c-2195" decimals="-6" id="f-5330" unitRef="eur">14000000</sny:GainsLossesOnDerivativesUsedToManageDebt>
    <sny:GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents contextRef="c-2193" decimals="-6" id="f-5331" unitRef="eur">-13000000</sny:GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents>
    <sny:GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents contextRef="c-2194" decimals="-6" id="f-5332" unitRef="eur">68000000</sny:GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents>
    <sny:GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents contextRef="c-2195" decimals="-6" id="f-5333" unitRef="eur">51000000</sny:GainsLossesOnDerivativesUsedToManageCashAndCashEquivalents>
    <sny:LiabilityRecognisedForEstimatedFutureRoyalties contextRef="c-1" decimals="-6" id="f-5334" unitRef="eur">541000000</sny:LiabilityRecognisedForEstimatedFutureRoyalties>
    <sny:LiabilityRecognisedForEstimatedFutureRoyalties contextRef="c-10" decimals="-6" id="f-5335" unitRef="eur">0</sny:LiabilityRecognisedForEstimatedFutureRoyalties>
    <sny:LiabilityRecognisedForEstimatedFutureRoyalties contextRef="c-9" decimals="-6" id="f-5336" unitRef="eur">0</sny:LiabilityRecognisedForEstimatedFutureRoyalties>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c-1" id="f-5337">Income tax expense&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the allocation of income tax expense between current and deferred taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,153&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,422&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,798&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The difference between the effective tax rate and the standard corporate income tax rate applicable in France is explained as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Standard tax rate applicable in France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Difference between the standard French tax rate and the rates applicable to Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revisions to tax exposures and settlements of tax disputes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Probable reversal of temporary differences on investments in Consumer Healthcare subsidiaries&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22.4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19.2&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;In accordance with IAS&#160;12, a deferred tax liability was recognized in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;In determining the amount of the deferred tax liability for 2023, 2022 and 2021, Sanofi took into account changes in the ownership structure of certain subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;For the periods presented, the amount of deferred tax assets recognized in profit or loss that were initially subject to impairment losses at the time of a business combination is immaterial.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock contextRef="c-1" id="f-5338">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the allocation of income tax expense between current and deferred taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,153&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,422&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,798&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfAllocationOfIncomeTaxBetweenCurrentAndDeferredTaxesTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-1" decimals="-6" id="f-5339" unitRef="eur">2560000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-9" decimals="-6" id="f-5340" unitRef="eur">2774000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-10" decimals="-6" id="f-5341" unitRef="eur">1908000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-1" decimals="-6" id="f-5342" unitRef="eur">-958000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-9" decimals="-6" id="f-5343" unitRef="eur">-768000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-10" decimals="-6" id="f-5344" unitRef="eur">-350000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-6" id="f-5345" unitRef="eur">1602000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-9" decimals="-6" id="f-5346" unitRef="eur">2006000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-10" decimals="-6" id="f-5347" unitRef="eur">1558000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-5348" unitRef="eur">7153000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-9" decimals="-6" id="f-5349" unitRef="eur">10422000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-10" decimals="-6" id="f-5350" unitRef="eur">7798000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock contextRef="c-1" id="f-5351">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The difference between the effective tax rate and the standard corporate income tax rate applicable in France is explained as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Standard tax rate applicable in France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Difference between the standard French tax rate and the rates applicable to Sanofi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revisions to tax exposures and settlements of tax disputes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Probable reversal of temporary differences on investments in Consumer Healthcare subsidiaries&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;22.4&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19.2&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;In accordance with IAS&#160;12, a deferred tax liability was recognized in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;In determining the amount of the deferred tax liability for 2023, 2022 and 2021, Sanofi took into account changes in the ownership structure of certain subsidiaries.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateExplanatoryTableTextBlock>
    <ifrs-full:ApplicableTaxRate contextRef="c-1" decimals="3" id="f-5352" unitRef="number">0.258</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-9" decimals="3" id="f-5353" unitRef="number">0.258</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-10" decimals="3" id="f-5354" unitRef="number">0.284</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-1" decimals="3" id="f-5355" unitRef="number">-0.136</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-9" decimals="3" id="f-5356" unitRef="number">-0.065</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <ifrs-full:TaxRateEffectOfForeignTaxRates contextRef="c-10" decimals="3" id="f-5357" unitRef="number">-0.095</ifrs-full:TaxRateEffectOfForeignTaxRates>
    <sny:TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes contextRef="c-1" decimals="3" id="f-5358" unitRef="number">0.027</sny:TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes>
    <sny:TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes contextRef="c-9" decimals="3" id="f-5359" unitRef="number">-0.008</sny:TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes>
    <sny:TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes contextRef="c-10" decimals="3" id="f-5360" unitRef="number">0.010</sny:TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes>
    <sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments contextRef="c-1" decimals="3" id="f-5361" unitRef="number">0.051</sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments>
    <sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments contextRef="c-9" decimals="3" id="f-5362" unitRef="number">0</sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments>
    <sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments contextRef="c-10" decimals="3" id="f-5363" unitRef="number">0</sny:TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments>
    <sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations contextRef="c-1" decimals="3" id="f-5364" unitRef="number">0.001</sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations>
    <sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations contextRef="c-9" decimals="3" id="f-5365" unitRef="number">-0.002</sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations>
    <sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations contextRef="c-10" decimals="3" id="f-5366" unitRef="number">0</sny:TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-1" decimals="3" id="f-5367" unitRef="number">0.023</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-9" decimals="3" id="f-5368" unitRef="number">0.009</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-10" decimals="3" id="f-5369" unitRef="number">0.001</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-1" decimals="3" id="f-5370" unitRef="number">0.224</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-9" decimals="3" id="f-5371" unitRef="number">0.192</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-10" decimals="3" id="f-5372" unitRef="number">0.200</ifrs-full:AverageEffectiveTaxRate>
    <sny:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock contextRef="c-1" id="f-5373">Share of profit/loss from investments accounted for using the equity method&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; was a net loss of &#x20ac;115&#160;million in 2023 (including an impairment loss of &#x20ac;231&#160;million on the equity-accounted investment in EUROAPI &#x2013; see Note D.6.), compared with net income of &#x20ac;68&#160;million for 2022 and &#x20ac;39&#160;million for 2021.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodTextBlock>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-1" decimals="-6" id="f-5374" unitRef="eur">-115000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-471" decimals="-6" id="f-5375" unitRef="eur">231000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-9" decimals="-6" id="f-5376" unitRef="eur">68000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-10" decimals="-6" id="f-5377" unitRef="eur">39000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <sny:DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock contextRef="c-1" id="f-5378">Net income attributable to non-controlling interests&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for the reporting periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of net income attributable to non-controlling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;113&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfProfitLossAttributableToNonControllingInterestsTextBlock>
    <sny:DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock contextRef="c-1" id="f-5379">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; for the reporting periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of net income attributable to non-controlling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;113&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfInformationAboutTheAmountsAttributableToNonControllingInterestsExplanatoryTableTextBlock>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2196" decimals="-6" id="f-5380" unitRef="eur">36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2197" decimals="-6" id="f-5381" unitRef="eur">113000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2198" decimals="-6" id="f-5382" unitRef="eur">56000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-1" decimals="-6" id="f-5383" unitRef="eur">36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-9" decimals="-6" id="f-5384" unitRef="eur">113000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-10" decimals="-6" id="f-5385" unitRef="eur">56000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c-1" id="f-5386">Related party transactions&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal related parties are companies over which Sanofi has control or significant influence, joint ventures, key management personnel, and principal shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi has not entered into any material transactions with any key management personnel. Financial relations with Sanofi&#x2019;s principal shareholders fall within the ordinary course of business and were immaterial in the years ended December 31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Note&#160;F.1. lists the principal companies controlled by Sanofi; those companies are fully consolidated, as described in Note&#160;B.1. Transactions between those companies, and between the parent company and its subsidiaries, are eliminated when preparing the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Transactions with companies over which Sanofi has significant influence, and with joint ventures, are presented in Note&#160;D.6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Key management personnel include corporate officers and the members of the Executive Committee (an a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;verage of 10&#160;members&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt; in 2023, and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;in 2022 and in 2021).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows, by type, the compensation paid to key management personnel:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total recognized in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;55&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Compensation, employer&#x2019;s social security contributions, directors&#x2019; compensation, and any termination benefits (net of reversals of termination benefit obligations).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the aggregate obligation as of December&#160;31 for each period presented for individuals who hold or have held executive positions within Sanofi during that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <sny:NumberOfExecutiveCommitteeMembers
      contextRef="c-1"
      decimals="0"
      id="f-5387"
      unitRef="executives">10</sny:NumberOfExecutiveCommitteeMembers>
    <sny:NumberOfExecutiveCommitteeMembers
      contextRef="c-10"
      decimals="0"
      id="f-5388"
      unitRef="executives">11</sny:NumberOfExecutiveCommitteeMembers>
    <sny:NumberOfExecutiveCommitteeMembers
      contextRef="c-9"
      decimals="0"
      id="f-5389"
      unitRef="executives">11</sny:NumberOfExecutiveCommitteeMembers>
    <sny:DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock contextRef="c-1" id="f-5390">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows, by type, the compensation paid to key management personnel:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Short-term benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Post-employment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total recognized in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;55&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Compensation, employer&#x2019;s social security contributions, directors&#x2019; compensation, and any termination benefits (net of reversals of termination benefit obligations).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfCompensationPaidToKeyManagementPersonnelTableTextBlock>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-1" decimals="-6" id="f-5391" unitRef="eur">36000000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-9" decimals="-6" id="f-5392" unitRef="eur">31000000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-10" decimals="-6" id="f-5393" unitRef="eur">33000000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-1" decimals="-6" id="f-5394" unitRef="eur">2000000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-9" decimals="-6" id="f-5395" unitRef="eur">2000000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-10" decimals="-6" id="f-5396" unitRef="eur">2000000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-1" decimals="-6" id="f-5397" unitRef="eur">8000000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-9" decimals="-6" id="f-5398" unitRef="eur">19000000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-10" decimals="-6" id="f-5399" unitRef="eur">20000000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-1" decimals="-6" id="f-5400" unitRef="eur">46000000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-9" decimals="-6" id="f-5401" unitRef="eur">52000000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-10" decimals="-6" id="f-5402" unitRef="eur">55000000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory contextRef="c-1" id="f-5403">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows the aggregate obligation as of December&#160;31 for each period presented for individuals who hold or have held executive positions within Sanofi during that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.152%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory>
    <sny:AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee contextRef="c-1" decimals="-6" id="f-5404" unitRef="eur">10000000</sny:AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee>
    <sny:AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee contextRef="c-9" decimals="-6" id="f-5405" unitRef="eur">10000000</sny:AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee>
    <sny:AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee contextRef="c-10" decimals="-6" id="f-5406" unitRef="eur">28000000</sny:AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee>
    <sny:KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits contextRef="c-1" decimals="-6" id="f-5407" unitRef="eur">6000000</sny:KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits>
    <sny:KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits contextRef="c-9" decimals="-6" id="f-5408" unitRef="eur">5000000</sny:KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits>
    <sny:KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits contextRef="c-10" decimals="-6" id="f-5409" unitRef="eur">7000000</sny:KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits>
    <ifrs-full:DisclosureOfCreditRiskExplanatory contextRef="c-1" id="f-5410">Disclosures about major customers and credit risk&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Credit risk is the risk that customers (wholesalers, distributors, pharmacies, hospitals, clinics or government agencies) may fail to pay their debts; for Sanofi, that risk is mainly concentrated on amounts receivable from wholesalers in the United States. Sanofi manages credit risk by vetting customers in order to set credit limits and risk levels, and asking for guarantees or insurance where necessary; performing controls; and monitoring qualitative and quantitative indicators of accounts receivable balances, such as the period of credit taken and overdue payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;27% of net sales in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The three largest customers respectively accounted for approximately 11%, 9% and 7% of Sanofi's net sales in&#160;2023 (12%, 8% and 7% in 2022; 10%, 7% and 6% in 2021).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCreditRiskExplanatory>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-2199"
      decimals="2"
      id="f-5411"
      unitRef="number">0.27</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-2200"
      decimals="2"
      id="f-5412"
      unitRef="number">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-2201"
      decimals="2"
      id="f-5413"
      unitRef="number">0.09</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-2202"
      decimals="2"
      id="f-5414"
      unitRef="number">0.07</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-2203"
      decimals="2"
      id="f-5415"
      unitRef="number">0.12</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-2204"
      decimals="2"
      id="f-5416"
      unitRef="number">0.08</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-2205"
      decimals="2"
      id="f-5417"
      unitRef="number">0.07</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-2206"
      decimals="2"
      id="f-5418"
      unitRef="number">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="c-2207"
      decimals="2"
      id="f-5419"
      unitRef="number">0.07</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue contextRef="c-10" decimals="2" id="f-5420" unitRef="number">0.06</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c-1" id="f-5421">Segment information&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As indicated in Note&#160;B.26., Sanofi has two operating segments with effect from January&#160;1, 2023: Biopharma and Consumer Healthcare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People &amp;amp; Culture, Legal, Ethics, Business Integrity &amp;amp; Global Security, Information Solutions &amp;amp; Technology, Sanofi Business Services,&#160;etc.), which are mainly managed centrally at group-wide level, were presented within the &#x201c;Other&#x201d; category. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in order to reflect (i)&#160;progress on the &#x201c;Play to Win&#x201d; strategy leading to the creation of the standalone Consumer Healthcare Global Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its own dedicated global support functions (including Finance, People &amp;amp; Culture, Legal, Ethics, Business Integrity &amp;amp; Global Security, Information Solutions &amp;amp; Technology, Global Business Services,&#160;etc.); and (ii)&#160;organizational changes to Sanofi&#x2019;s Manufacturing &amp;amp; Supply global function (previously known as Industrial Affairs). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Consequently, with effect from January&#160;1, 2023, Sanofi reports two operating segments: Biopharma and Consumer Healthcare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment&#x2019;s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment&#x2019;s results reflect all incurred costs of global support functions attributable to its business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The &#x201c;Other&#x201d; category comprises reconciling items, primarily but not limited to (i)&#160;gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii)&#160;gains and losses on retained commitments in respect of previously divested operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.35.1. Segment results&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;D.35.1.1. Analysis of net sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth Sanofi&#x2019;s net sales for the years ended December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.491%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-right:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="42" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,265&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,790&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,890&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,498&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,985&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,329&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,812&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,426&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,246&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,621&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33,293&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Specialty Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,206&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,917&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,917&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,040&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,016&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,848&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,593&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,457&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,764&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,847&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,141&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,752&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;DUPIXENT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;8,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;8,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;AUBAGIO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;CEREZYME&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;FABRAZYME&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;MYOZYME/&lt;br/&gt;LUMIZYME&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;JEVTANA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;ALPROLIX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;ELOCTATE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;General Medicines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,932&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,084&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,360&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,376&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,141&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,846&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,140&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,127&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,437&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,637&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,144&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,218&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Core Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,988&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,485&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,797&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,270&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,917&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,653&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,819&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,389&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,868&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,315&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,585&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,768&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;LOVENOX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;TOUJEO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;PLAVIX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Non-Core Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,396&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;592&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,536&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,524&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,637&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,176&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,305&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,118&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,846&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,281&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,515&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,642&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;LANTUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Other non-core assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Industrial sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;548&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;582&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;587&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;620&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;723&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,697&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,264&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,513&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,474&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,341&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,291&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,596&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,228&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,225&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,762&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,336&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,323&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Polio/Pertussis/&lt;br/&gt;Hib Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Influenza Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,557&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,247&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,376&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,180&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,501&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,290&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,394&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,185&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,139&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,996&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,468&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Allergy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Pain Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Digestive Wellness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,392&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,512&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,166&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43,070&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,999&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,275&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,723&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42,997&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,759&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,385&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,617&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,761&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective January&#160;1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;D.35.1.2. Business operating income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Sanofi reports segment results on the basis of &#x201c;Business operating income&#x201d;. This indicator is used internally by Sanofi&#x2019;s chief operating decision maker to measure the performance of each operating segment and to allocate resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#x201c;Business operating income&#x201d; is derived from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, adjusted as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature), are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;fair value remeasurements of contingent consideration relating to business combinations (IFRS&#160;3) or business divestments, and presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;expenses arising from the remeasurement of inventories following business combinations (IFRS&#160;3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2b of IFRS&#160;3, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;amounts reported within the line items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring costs and similar items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;other gains and losses including gains and losses on major divestments, presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;other costs and provisions related to litigation, presented within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;upfront payments and regulatory milestone payments recognized within the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other operating income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;and related to transactions outside the ordinary activities of Sanofi are eliminated;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates to&#160;joint ventures and associates with which Sanofi has a strategic alliance; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt"&gt;net income attributable to non-controlling interests is deducted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows Sanofi&#x2019;s segment results for the years ended December 31, 2023, December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,890&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,180&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43,070&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,933)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,247&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,670&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;This caption reconciles segment financial information to total consolidated financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,812&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,185&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42,997&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,490&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,522&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,040&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January&#160;1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;This caption reconciles segment financial information to total consolidated financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.849%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,970&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,323&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,468&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,761&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(712)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(497)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(946)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,409&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,609&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,493&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,714&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;This caption reconciles segment financial information to total consolidated financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below, presented in compliance with IFRS&#160;8, shows a reconciliation between aggregated &#x201c;Business operating income&#x201d; for the segments and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.552%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,670&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,040&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,714&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization and impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expenses arising from the impact of acquisitions on inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring costs and similar items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income from out-licensing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,875&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,656&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,126&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,153&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,422&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,798&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Joint ventures and associates with which Sanofi has entered into a strategic alliance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;For 2023, this amount mainly comprises an impairment loss of &#x20ac;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;amp;D programs, in particular those related to the NK Cell and PRO-XTEN  technology platforms. For 2022, this line includes a reversal of &#x20ac;2,154&#160;million on ELOCTATE franchise products following FDA approval of ALTUVIIIO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;dated February&#160;22, 2023, partially offset by an impairment loss of &#x20ac;1,586&#160;million on intangible assets relating to SAR444245 (non-alpha interleukin-2).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;For 2022, this line includes an upfront payment of $900&#160;million and a regulatory milestone payment of $100&#160;million related to the out-licensing of LIBTAYO following the restructuring of the Immuno-Oncology Collaboration and License Agreement with Regeneron (see Note&#160;C.1.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.35.2. Other segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The tables below show the split by operating segment of (i)&#160;the carrying amount of investments accounted for using the equity method with which Sanofi has entered into a strategic alliance, (ii)&#160;acquisitions of property, plant and equipment, and (iii)&#160;acquisitions of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The principal investments accounted for using the equity method in the Biopharma segment are the interests in MSP Vaccine Company, and Infraserv GmbH &amp;amp; Co. H&#xf6;chst&#160;KG (see Note&#160;D.6.).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January&#160;1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;D.35.3. Information by geographical region&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with&#160;IFRS&#160;8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS&#160;16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;North&lt;br/&gt;America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43,070&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,392&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,379&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,216&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,512&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,462&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;property, plant and equipment owned&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;North&lt;br/&gt;America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42,997&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,999&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,296&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,984&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,275&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,014&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;property, plant and equipment owned&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;North&lt;br/&gt;America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,761&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,759&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,256&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,075&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,385&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,927&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;property, plant and equipment owned&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;As stated in Note&#160;D.5., goodwill is not allocated by geographical region.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <sny:NumberOfOperatingSegments1
      contextRef="c-1"
      decimals="INF"
      id="f-5422"
      unitRef="segment">2</sny:NumberOfOperatingSegments1>
    <sny:NumberOfOperatingSegments1
      contextRef="c-9"
      decimals="INF"
      id="f-5423"
      unitRef="segment">3</sny:NumberOfOperatingSegments1>
    <sny:NumberOfOperatingSegments1
      contextRef="c-1"
      decimals="INF"
      id="f-5424"
      unitRef="segment">2</sny:NumberOfOperatingSegments1>
    <sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock contextRef="c-1" id="f-5425">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below sets forth Sanofi&#x2019;s net sales for the years ended December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.097%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.491%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-right:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="42" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,835&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17,265&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,790&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,890&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,498&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,985&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,329&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,812&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,426&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,246&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,621&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33,293&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Specialty Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,206&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,917&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,917&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,040&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,016&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,848&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,593&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,457&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,764&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,847&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,141&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,752&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;DUPIXENT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;8,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;8,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;AUBAGIO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;CEREZYME&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;FABRAZYME&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;MYOZYME/&lt;br/&gt;LUMIZYME&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;JEVTANA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;ALPROLIX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;ELOCTATE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;General Medicines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,932&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,084&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,360&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,376&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,141&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,846&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,140&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,127&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,437&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,637&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,144&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,218&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Core Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,988&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,485&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,797&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,270&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,917&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,653&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,819&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,389&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,868&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,315&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,585&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,768&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;LOVENOX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;TOUJEO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;PLAVIX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Non-Core Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,396&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;592&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,536&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,524&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,637&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,176&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,305&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,118&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,846&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,281&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,515&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,642&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;LANTUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Other non-core assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Industrial sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;548&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;582&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;587&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;620&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;723&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,697&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,264&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,513&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,474&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,341&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,291&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,596&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,228&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,225&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,762&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,336&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,323&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Polio/Pertussis/&lt;br/&gt;Hib Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Influenza Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,557&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,247&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,376&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,180&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,501&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,290&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,394&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,185&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,333&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,139&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,996&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,468&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;of which&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Allergy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Pain Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Digestive Wellness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,392&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,512&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,166&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43,070&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,999&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,275&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,723&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42,997&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,759&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,385&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,617&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,761&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective January&#160;1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfNetSalesBySegmentAndGeographicalAreaTableTextBlock>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2208" decimals="-6" id="f-5426" unitRef="eur">8835000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2209" decimals="-6" id="f-5427" unitRef="eur">17265000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2210" decimals="-6" id="f-5428" unitRef="eur">11790000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-277" decimals="-6" id="f-5429" unitRef="eur">37890000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2211" decimals="-6" id="f-5430" unitRef="eur">8498000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2212" decimals="-6" id="f-5431" unitRef="eur">16985000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2213" decimals="-6" id="f-5432" unitRef="eur">12329000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-278" decimals="-6" id="f-5433" unitRef="eur">37812000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2214" decimals="-6" id="f-5434" unitRef="eur">8426000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2215" decimals="-6" id="f-5435" unitRef="eur">13246000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2216" decimals="-6" id="f-5436" unitRef="eur">11621000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2217" decimals="-6" id="f-5437" unitRef="eur">33293000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2218" decimals="-6" id="f-5438" unitRef="eur">3206000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2219" decimals="-6" id="f-5439" unitRef="eur">11917000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2220" decimals="-6" id="f-5440" unitRef="eur">2917000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2221" decimals="-6" id="f-5441" unitRef="eur">18040000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2222" decimals="-6" id="f-5442" unitRef="eur">3016000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2223" decimals="-6" id="f-5443" unitRef="eur">10848000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2224" decimals="-6" id="f-5444" unitRef="eur">2593000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2225" decimals="-6" id="f-5445" unitRef="eur">16457000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2226" decimals="-6" id="f-5446" unitRef="eur">2764000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2227" decimals="-6" id="f-5447" unitRef="eur">7847000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2228" decimals="-6" id="f-5448" unitRef="eur">2141000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2229" decimals="-6" id="f-5449" unitRef="eur">12752000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2230" decimals="-6" id="f-5450" unitRef="eur">1224000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2231" decimals="-6" id="f-5451" unitRef="eur">8145000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2232" decimals="-6" id="f-5452" unitRef="eur">1346000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2233" decimals="-6" id="f-5453" unitRef="eur">10715000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2234" decimals="-6" id="f-5454" unitRef="eur">940000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2235" decimals="-6" id="f-5455" unitRef="eur">6346000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2236" decimals="-6" id="f-5456" unitRef="eur">1007000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2237" decimals="-6" id="f-5457" unitRef="eur">8293000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2238" decimals="-6" id="f-5458" unitRef="eur">649000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2239" decimals="-6" id="f-5459" unitRef="eur">3971000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2240" decimals="-6" id="f-5460" unitRef="eur">629000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2241" decimals="-6" id="f-5461" unitRef="eur">5249000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2242" decimals="-6" id="f-5462" unitRef="eur">437000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2243" decimals="-6" id="f-5463" unitRef="eur">460000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2244" decimals="-6" id="f-5464" unitRef="eur">58000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2245" decimals="-6" id="f-5465" unitRef="eur">955000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2246" decimals="-6" id="f-5466" unitRef="eur">511000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2247" decimals="-6" id="f-5467" unitRef="eur">1420000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2248" decimals="-6" id="f-5468" unitRef="eur">100000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2249" decimals="-6" id="f-5469" unitRef="eur">2031000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2250" decimals="-6" id="f-5470" unitRef="eur">512000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2251" decimals="-6" id="f-5471" unitRef="eur">1312000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2252" decimals="-6" id="f-5472" unitRef="eur">131000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2253" decimals="-6" id="f-5473" unitRef="eur">1955000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2254" decimals="-6" id="f-5474" unitRef="eur">229000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2255" decimals="-6" id="f-5475" unitRef="eur">189000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2256" decimals="-6" id="f-5476" unitRef="eur">269000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2257" decimals="-6" id="f-5477" unitRef="eur">687000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2258" decimals="-6" id="f-5478" unitRef="eur">239000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2259" decimals="-6" id="f-5479" unitRef="eur">194000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2260" decimals="-6" id="f-5480" unitRef="eur">274000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2261" decimals="-6" id="f-5481" unitRef="eur">707000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2262" decimals="-6" id="f-5482" unitRef="eur">244000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2263" decimals="-6" id="f-5483" unitRef="eur">173000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2264" decimals="-6" id="f-5484" unitRef="eur">266000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2265" decimals="-6" id="f-5485" unitRef="eur">683000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2266" decimals="-6" id="f-5486" unitRef="eur">241000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2267" decimals="-6" id="f-5487" unitRef="eur">503000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2268" decimals="-6" id="f-5488" unitRef="eur">247000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2269" decimals="-6" id="f-5489" unitRef="eur">991000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2270" decimals="-6" id="f-5490" unitRef="eur">228000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2271" decimals="-6" id="f-5491" unitRef="eur">471000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2272" decimals="-6" id="f-5492" unitRef="eur">239000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2273" decimals="-6" id="f-5493" unitRef="eur">938000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2274" decimals="-6" id="f-5494" unitRef="eur">223000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2275" decimals="-6" id="f-5495" unitRef="eur">395000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2276" decimals="-6" id="f-5496" unitRef="eur">226000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2277" decimals="-6" id="f-5497" unitRef="eur">844000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2278" decimals="-6" id="f-5498" unitRef="eur">341000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2279" decimals="-6" id="f-5499" unitRef="eur">254000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2280" decimals="-6" id="f-5500" unitRef="eur">188000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2281" decimals="-6" id="f-5501" unitRef="eur">783000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2282" decimals="-6" id="f-5502" unitRef="eur">408000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2283" decimals="-6" id="f-5503" unitRef="eur">318000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2284" decimals="-6" id="f-5504" unitRef="eur">232000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2285" decimals="-6" id="f-5505" unitRef="eur">958000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2286" decimals="-6" id="f-5506" unitRef="eur">410000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2287" decimals="-6" id="f-5507" unitRef="eur">373000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2288" decimals="-6" id="f-5508" unitRef="eur">220000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2289" decimals="-6" id="f-5509" unitRef="eur">1003000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2290" decimals="-6" id="f-5510" unitRef="eur">12000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2291" decimals="-6" id="f-5511" unitRef="eur">230000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2292" decimals="-6" id="f-5512" unitRef="eur">78000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2293" decimals="-6" id="f-5513" unitRef="eur">320000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2294" decimals="-6" id="f-5514" unitRef="eur">33000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2295" decimals="-6" id="f-5515" unitRef="eur">275000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2296" decimals="-6" id="f-5516" unitRef="eur">83000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2297" decimals="-6" id="f-5517" unitRef="eur">391000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2298" decimals="-6" id="f-5518" unitRef="eur">112000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2299" decimals="-6" id="f-5519" unitRef="eur">253000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2300" decimals="-6" id="f-5520" unitRef="eur">90000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2301" decimals="-6" id="f-5521" unitRef="eur">455000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2302" decimals="-6" id="f-5522" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2303" decimals="-6" id="f-5523" unitRef="eur">440000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2304" decimals="-6" id="f-5524" unitRef="eur">100000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2305" decimals="-6" id="f-5525" unitRef="eur">540000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2306" decimals="-6" id="f-5526" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2307" decimals="-6" id="f-5527" unitRef="eur">406000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2308" decimals="-6" id="f-5528" unitRef="eur">98000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2309" decimals="-6" id="f-5529" unitRef="eur">504000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2310" decimals="-6" id="f-5530" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2311" decimals="-6" id="f-5531" unitRef="eur">332000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2312" decimals="-6" id="f-5532" unitRef="eur">82000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2313" decimals="-6" id="f-5533" unitRef="eur">414000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2314" decimals="-6" id="f-5534" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2315" decimals="-6" id="f-5535" unitRef="eur">341000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2316" decimals="-6" id="f-5536" unitRef="eur">130000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2317" decimals="-6" id="f-5537" unitRef="eur">471000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2318" decimals="-6" id="f-5538" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2319" decimals="-6" id="f-5539" unitRef="eur">450000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2320" decimals="-6" id="f-5540" unitRef="eur">130000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2321" decimals="-6" id="f-5541" unitRef="eur">580000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2322" decimals="-6" id="f-5542" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2323" decimals="-6" id="f-5543" unitRef="eur">429000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2324" decimals="-6" id="f-5544" unitRef="eur">134000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2325" decimals="-6" id="f-5545" unitRef="eur">563000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2326" decimals="-6" id="f-5546" unitRef="eur">3932000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2327" decimals="-6" id="f-5547" unitRef="eur">2084000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2328" decimals="-6" id="f-5548" unitRef="eur">6360000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2329" decimals="-6" id="f-5549" unitRef="eur">12376000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2330" decimals="-6" id="f-5550" unitRef="eur">4141000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2331" decimals="-6" id="f-5551" unitRef="eur">2846000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2332" decimals="-6" id="f-5552" unitRef="eur">7140000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2333" decimals="-6" id="f-5553" unitRef="eur">14127000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2334" decimals="-6" id="f-5554" unitRef="eur">4437000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2335" decimals="-6" id="f-5555" unitRef="eur">2637000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2336" decimals="-6" id="f-5556" unitRef="eur">7144000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2337" decimals="-6" id="f-5557" unitRef="eur">14218000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2338" decimals="-6" id="f-5558" unitRef="eur">1988000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2339" decimals="-6" id="f-5559" unitRef="eur">1485000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2340" decimals="-6" id="f-5560" unitRef="eur">2797000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2341" decimals="-6" id="f-5561" unitRef="eur">6270000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2342" decimals="-6" id="f-5562" unitRef="eur">1917000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2343" decimals="-6" id="f-5563" unitRef="eur">1653000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2344" decimals="-6" id="f-5564" unitRef="eur">2819000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2345" decimals="-6" id="f-5565" unitRef="eur">6389000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2346" decimals="-6" id="f-5566" unitRef="eur">1868000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2347" decimals="-6" id="f-5567" unitRef="eur">1315000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2348" decimals="-6" id="f-5568" unitRef="eur">2585000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2349" decimals="-6" id="f-5569" unitRef="eur">5768000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2350" decimals="-6" id="f-5570" unitRef="eur">622000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2351" decimals="-6" id="f-5571" unitRef="eur">7000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2352" decimals="-6" id="f-5572" unitRef="eur">496000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2353" decimals="-6" id="f-5573" unitRef="eur">1125000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2354" decimals="-6" id="f-5574" unitRef="eur">658000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2355" decimals="-6" id="f-5575" unitRef="eur">17000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2356" decimals="-6" id="f-5576" unitRef="eur">635000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2357" decimals="-6" id="f-5577" unitRef="eur">1310000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2358" decimals="-6" id="f-5578" unitRef="eur">703000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2359" decimals="-6" id="f-5579" unitRef="eur">29000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2360" decimals="-6" id="f-5580" unitRef="eur">754000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2361" decimals="-6" id="f-5581" unitRef="eur">1486000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2362" decimals="-6" id="f-5582" unitRef="eur">441000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2363" decimals="-6" id="f-5583" unitRef="eur">213000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2364" decimals="-6" id="f-5584" unitRef="eur">469000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2365" decimals="-6" id="f-5585" unitRef="eur">1123000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2366" decimals="-6" id="f-5586" unitRef="eur">421000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2367" decimals="-6" id="f-5587" unitRef="eur">283000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2368" decimals="-6" id="f-5588" unitRef="eur">413000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2369" decimals="-6" id="f-5589" unitRef="eur">1117000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2370" decimals="-6" id="f-5590" unitRef="eur">394000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2371" decimals="-6" id="f-5591" unitRef="eur">259000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2372" decimals="-6" id="f-5592" unitRef="eur">316000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2373" decimals="-6" id="f-5593" unitRef="eur">969000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2374" decimals="-6" id="f-5594" unitRef="eur">96000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2375" decimals="-6" id="f-5595" unitRef="eur">8000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2376" decimals="-6" id="f-5596" unitRef="eur">844000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2377" decimals="-6" id="f-5597" unitRef="eur">948000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2378" decimals="-6" id="f-5598" unitRef="eur">101000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2379" decimals="-6" id="f-5599" unitRef="eur">9000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2380" decimals="-6" id="f-5600" unitRef="eur">873000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2381" decimals="-6" id="f-5601" unitRef="eur">983000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2382" decimals="-6" id="f-5602" unitRef="eur">115000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2383" decimals="-6" id="f-5603" unitRef="eur">9000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2384" decimals="-6" id="f-5604" unitRef="eur">805000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2385" decimals="-6" id="f-5605" unitRef="eur">929000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2386" decimals="-6" id="f-5606" unitRef="eur">1396000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2387" decimals="-6" id="f-5607" unitRef="eur">592000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2388" decimals="-6" id="f-5608" unitRef="eur">3536000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2389" decimals="-6" id="f-5609" unitRef="eur">5524000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2390" decimals="-6" id="f-5610" unitRef="eur">1637000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2391" decimals="-6" id="f-5611" unitRef="eur">1176000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2392" decimals="-6" id="f-5612" unitRef="eur">4305000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2393" decimals="-6" id="f-5613" unitRef="eur">7118000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2394" decimals="-6" id="f-5614" unitRef="eur">1846000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2395" decimals="-6" id="f-5615" unitRef="eur">1281000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2396" decimals="-6" id="f-5616" unitRef="eur">4515000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2397" decimals="-6" id="f-5617" unitRef="eur">7642000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2398" decimals="-6" id="f-5618" unitRef="eur">357000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2399" decimals="-6" id="f-5619" unitRef="eur">281000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2400" decimals="-6" id="f-5620" unitRef="eur">782000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2401" decimals="-6" id="f-5621" unitRef="eur">1420000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2402" decimals="-6" id="f-5622" unitRef="eur">426000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2403" decimals="-6" id="f-5623" unitRef="eur">757000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2404" decimals="-6" id="f-5624" unitRef="eur">1076000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2405" decimals="-6" id="f-5625" unitRef="eur">2259000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2406" decimals="-6" id="f-5626" unitRef="eur">474000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2407" decimals="-6" id="f-5627" unitRef="eur">861000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2408" decimals="-6" id="f-5628" unitRef="eur">1159000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2409" decimals="-6" id="f-5629" unitRef="eur">2494000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2410" decimals="-6" id="f-5630" unitRef="eur">961000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2411" decimals="-6" id="f-5631" unitRef="eur">302000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2412" decimals="-6" id="f-5632" unitRef="eur">2424000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2413" decimals="-6" id="f-5633" unitRef="eur">3687000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2414" decimals="-6" id="f-5634" unitRef="eur">1129000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2415" decimals="-6" id="f-5635" unitRef="eur">412000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2416" decimals="-6" id="f-5636" unitRef="eur">2840000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2417" decimals="-6" id="f-5637" unitRef="eur">4381000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2418" decimals="-6" id="f-5638" unitRef="eur">1285000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2419" decimals="-6" id="f-5639" unitRef="eur">410000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2420" decimals="-6" id="f-5640" unitRef="eur">3034000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2421" decimals="-6" id="f-5641" unitRef="eur">4729000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2422" decimals="-6" id="f-5642" unitRef="eur">548000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2423" decimals="-6" id="f-5643" unitRef="eur">7000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2424" decimals="-6" id="f-5644" unitRef="eur">27000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2425" decimals="-6" id="f-5645" unitRef="eur">582000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2426" decimals="-6" id="f-5646" unitRef="eur">587000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2427" decimals="-6" id="f-5647" unitRef="eur">17000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2428" decimals="-6" id="f-5648" unitRef="eur">16000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2429" decimals="-6" id="f-5649" unitRef="eur">620000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2430" decimals="-6" id="f-5650" unitRef="eur">723000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2431" decimals="-6" id="f-5651" unitRef="eur">41000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2432" decimals="-6" id="f-5652" unitRef="eur">44000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2433" decimals="-6" id="f-5653" unitRef="eur">808000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2434" decimals="-6" id="f-5654" unitRef="eur">1697000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2435" decimals="-6" id="f-5655" unitRef="eur">3264000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2436" decimals="-6" id="f-5656" unitRef="eur">2513000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2437" decimals="-6" id="f-5657" unitRef="eur">7474000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2438" decimals="-6" id="f-5658" unitRef="eur">1341000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2439" decimals="-6" id="f-5659" unitRef="eur">3291000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2440" decimals="-6" id="f-5660" unitRef="eur">2596000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2441" decimals="-6" id="f-5661" unitRef="eur">7228000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2442" decimals="-6" id="f-5662" unitRef="eur">1225000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2443" decimals="-6" id="f-5663" unitRef="eur">2762000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2444" decimals="-6" id="f-5664" unitRef="eur">2336000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2445" decimals="-6" id="f-5665" unitRef="eur">6323000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2446" decimals="-6" id="f-5666" unitRef="eur">297000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2447" decimals="-6" id="f-5667" unitRef="eur">398000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2448" decimals="-6" id="f-5668" unitRef="eur">1470000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2449" decimals="-6" id="f-5669" unitRef="eur">2165000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2450" decimals="-6" id="f-5670" unitRef="eur">325000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2451" decimals="-6" id="f-5671" unitRef="eur">456000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2452" decimals="-6" id="f-5672" unitRef="eur">1504000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2453" decimals="-6" id="f-5673" unitRef="eur">2285000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2454" decimals="-6" id="f-5674" unitRef="eur">306000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2455" decimals="-6" id="f-5675" unitRef="eur">470000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2456" decimals="-6" id="f-5676" unitRef="eur">1383000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2457" decimals="-6" id="f-5677" unitRef="eur">2159000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2458" decimals="-6" id="f-5678" unitRef="eur">694000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2459" decimals="-6" id="f-5679" unitRef="eur">1406000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2460" decimals="-6" id="f-5680" unitRef="eur">569000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2461" decimals="-6" id="f-5681" unitRef="eur">2669000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2462" decimals="-6" id="f-5682" unitRef="eur">681000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2463" decimals="-6" id="f-5683" unitRef="eur">1737000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2464" decimals="-6" id="f-5684" unitRef="eur">559000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2465" decimals="-6" id="f-5685" unitRef="eur">2977000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2466" decimals="-6" id="f-5686" unitRef="eur">729000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2467" decimals="-6" id="f-5687" unitRef="eur">1366000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2468" decimals="-6" id="f-5688" unitRef="eur">533000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2469" decimals="-6" id="f-5689" unitRef="eur">2628000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2470" decimals="-6" id="f-5690" unitRef="eur">1557000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2471" decimals="-6" id="f-5691" unitRef="eur">1247000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2472" decimals="-6" id="f-5692" unitRef="eur">2376000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-283" decimals="-6" id="f-5693" unitRef="eur">5180000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2473" decimals="-6" id="f-5694" unitRef="eur">1501000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2474" decimals="-6" id="f-5695" unitRef="eur">1290000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2475" decimals="-6" id="f-5696" unitRef="eur">2394000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-284" decimals="-6" id="f-5697" unitRef="eur">5185000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2476" decimals="-6" id="f-5698" unitRef="eur">1333000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2477" decimals="-6" id="f-5699" unitRef="eur">1139000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2478" decimals="-6" id="f-5700" unitRef="eur">1996000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-285" decimals="-6" id="f-5701" unitRef="eur">4468000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2479" decimals="-6" id="f-5702" unitRef="eur">70000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2480" decimals="-6" id="f-5703" unitRef="eur">412000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2481" decimals="-6" id="f-5704" unitRef="eur">287000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2482" decimals="-6" id="f-5705" unitRef="eur">769000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2483" decimals="-6" id="f-5706" unitRef="eur">55000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2484" decimals="-6" id="f-5707" unitRef="eur">439000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2485" decimals="-6" id="f-5708" unitRef="eur">276000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2486" decimals="-6" id="f-5709" unitRef="eur">770000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2487" decimals="-6" id="f-5710" unitRef="eur">49000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2488" decimals="-6" id="f-5711" unitRef="eur">371000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2489" decimals="-6" id="f-5712" unitRef="eur">192000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2490" decimals="-6" id="f-5713" unitRef="eur">612000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2491" decimals="-6" id="f-5714" unitRef="eur">502000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2492" decimals="-6" id="f-5715" unitRef="eur">180000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2493" decimals="-6" id="f-5716" unitRef="eur">424000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2494" decimals="-6" id="f-5717" unitRef="eur">1106000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2495" decimals="-6" id="f-5718" unitRef="eur">555000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2496" decimals="-6" id="f-5719" unitRef="eur">212000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2497" decimals="-6" id="f-5720" unitRef="eur">424000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2498" decimals="-6" id="f-5721" unitRef="eur">1140000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2499" decimals="-6" id="f-5722" unitRef="eur">515000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2500" decimals="-6" id="f-5723" unitRef="eur">196000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2501" decimals="-6" id="f-5724" unitRef="eur">382000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2502" decimals="-6" id="f-5725" unitRef="eur">1093000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2503" decimals="-6" id="f-5726" unitRef="eur">520000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2504" decimals="-6" id="f-5727" unitRef="eur">138000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2505" decimals="-6" id="f-5728" unitRef="eur">844000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2506" decimals="-6" id="f-5729" unitRef="eur">1502000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2507" decimals="-6" id="f-5730" unitRef="eur">432000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2508" decimals="-6" id="f-5731" unitRef="eur">144000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2509" decimals="-6" id="f-5732" unitRef="eur">822000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2510" decimals="-6" id="f-5733" unitRef="eur">1449000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2511" decimals="-6" id="f-5734" unitRef="eur">389000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2512" decimals="-6" id="f-5735" unitRef="eur">124000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2513" decimals="-6" id="f-5736" unitRef="eur">618000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2514" decimals="-6" id="f-5737" unitRef="eur">1131000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2515" decimals="-6" id="f-5738" unitRef="eur">10392000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1205" decimals="-6" id="f-5739" unitRef="eur">18512000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2516" decimals="-6" id="f-5740" unitRef="eur">14166000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1" decimals="-6" id="f-5741" unitRef="eur">43070000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2517" decimals="-6" id="f-5742" unitRef="eur">9999000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1269" decimals="-6" id="f-5743" unitRef="eur">18275000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2518" decimals="-6" id="f-5744" unitRef="eur">14723000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-9" decimals="-6" id="f-5745" unitRef="eur">42997000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2519" decimals="-6" id="f-5746" unitRef="eur">9759000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1272" decimals="-6" id="f-5747" unitRef="eur">14385000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2520" decimals="-6" id="f-5748" unitRef="eur">13617000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-10" decimals="-6" id="f-5749" unitRef="eur">37761000000</ifrs-full:RevenueFromSaleOfGoods>
    <sny:NumberOfOperatingSegments1
      contextRef="c-1"
      decimals="INF"
      id="f-5750"
      unitRef="segment">2</sny:NumberOfOperatingSegments1>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c-1" id="f-5751">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows Sanofi&#x2019;s segment results for the years ended December 31, 2023, December 31, 2022 and December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,890&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,180&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43,070&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,933)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(14,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,247&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,670&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;This caption reconciles segment financial information to total consolidated financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,812&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,185&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42,997&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(11,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(8,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;11,490&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,522&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,040&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January&#160;1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;This caption reconciles segment financial information to total consolidated financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.849%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26,970&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,323&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4,468&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,761&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(6,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(12,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(712)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(497)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Selling and general expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(9,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(946)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,409&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,609&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,493&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(2,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,714&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;This caption reconciles segment financial information to total consolidated financial information.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-277" decimals="-6" id="f-5752" unitRef="eur">37890000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-283" decimals="-6" id="f-5753" unitRef="eur">5180000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2521" decimals="-6" id="f-5754" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2522" decimals="-6" id="f-5755" unitRef="eur">43070000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-277" decimals="-6" id="f-5756" unitRef="eur">3322000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-283" decimals="-6" id="f-5757" unitRef="eur">52000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-2521" decimals="-6" id="f-5758" unitRef="eur">0</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-2522" decimals="-6" id="f-5759" unitRef="eur">3374000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-277" decimals="-6" id="f-5760" unitRef="eur">12282000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-283" decimals="-6" id="f-5761" unitRef="eur">1933000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-2521" decimals="-6" id="f-5762" unitRef="eur">1000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-2522" decimals="-6" id="f-5763" unitRef="eur">14216000000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-277" decimals="-6" id="f-5764" unitRef="eur">6509000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-283" decimals="-6" id="f-5765" unitRef="eur">219000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-2521" decimals="-6" id="f-5766" unitRef="eur">0</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-2522" decimals="-6" id="f-5767" unitRef="eur">6728000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-277" decimals="-6" id="f-5768" unitRef="eur">8868000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-283" decimals="-6" id="f-5769" unitRef="eur">1828000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-2521" decimals="-6" id="f-5770" unitRef="eur">-4000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-2522" decimals="-6" id="f-5771" unitRef="eur">10692000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-277" decimals="-6" id="f-5772" unitRef="eur">-2387000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-283" decimals="-6" id="f-5773" unitRef="eur">181000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-2521" decimals="-6" id="f-5774" unitRef="eur">-18000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-2522" decimals="-6" id="f-5775" unitRef="eur">-2224000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-277" decimals="-6" id="f-5776" unitRef="eur">101000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-283" decimals="-6" id="f-5777" unitRef="eur">21000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-2521" decimals="-6" id="f-5778" unitRef="eur">0</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-2522" decimals="-6" id="f-5779" unitRef="eur">122000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-277" decimals="-6" id="f-5780" unitRef="eur">-20000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-283" decimals="-6" id="f-5781" unitRef="eur">-16000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2521" decimals="-6" id="f-5782" unitRef="eur">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2522" decimals="-6" id="f-5783" unitRef="eur">-36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:BusinessOperatingIncome contextRef="c-277" decimals="-6" id="f-5784" unitRef="eur">11247000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-283" decimals="-6" id="f-5785" unitRef="eur">1438000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-2521" decimals="-6" id="f-5786" unitRef="eur">-15000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-2522" decimals="-6" id="f-5787" unitRef="eur">12670000000</sny:BusinessOperatingIncome>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-278" decimals="-6" id="f-5788" unitRef="eur">37812000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-284" decimals="-6" id="f-5789" unitRef="eur">5185000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2523" decimals="-6" id="f-5790" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2524" decimals="-6" id="f-5791" unitRef="eur">42997000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-278" decimals="-6" id="f-5792" unitRef="eur">2330000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-284" decimals="-6" id="f-5793" unitRef="eur">62000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-2523" decimals="-6" id="f-5794" unitRef="eur">0</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-2524" decimals="-6" id="f-5795" unitRef="eur">2392000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-278" decimals="-6" id="f-5796" unitRef="eur">11793000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-284" decimals="-6" id="f-5797" unitRef="eur">1903000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-2523" decimals="-6" id="f-5798" unitRef="eur">-4000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-2524" decimals="-6" id="f-5799" unitRef="eur">13692000000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-278" decimals="-6" id="f-5800" unitRef="eur">6503000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-284" decimals="-6" id="f-5801" unitRef="eur">205000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-2523" decimals="-6" id="f-5802" unitRef="eur">-2000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-2524" decimals="-6" id="f-5803" unitRef="eur">6706000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-278" decimals="-6" id="f-5804" unitRef="eur">8736000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-284" decimals="-6" id="f-5805" unitRef="eur">1761000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-2523" decimals="-6" id="f-5806" unitRef="eur">-5000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-2524" decimals="-6" id="f-5807" unitRef="eur">10492000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-278" decimals="-6" id="f-5808" unitRef="eur">-1679000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-284" decimals="-6" id="f-5809" unitRef="eur">148000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-2523" decimals="-6" id="f-5810" unitRef="eur">17000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-2524" decimals="-6" id="f-5811" unitRef="eur">-1514000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-278" decimals="-6" id="f-5812" unitRef="eur">76000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-284" decimals="-6" id="f-5813" unitRef="eur">12000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-2523" decimals="-6" id="f-5814" unitRef="eur">0</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-2524" decimals="-6" id="f-5815" unitRef="eur">88000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-278" decimals="-6" id="f-5816" unitRef="eur">-17000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-284" decimals="-6" id="f-5817" unitRef="eur">-16000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2523" decimals="-6" id="f-5818" unitRef="eur">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2524" decimals="-6" id="f-5819" unitRef="eur">-33000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:BusinessOperatingIncome contextRef="c-278" decimals="-6" id="f-5820" unitRef="eur">11490000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-284" decimals="-6" id="f-5821" unitRef="eur">1522000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-2523" decimals="-6" id="f-5822" unitRef="eur">28000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-2524" decimals="-6" id="f-5823" unitRef="eur">13040000000</sny:BusinessOperatingIncome>
    <sny:NumberOfOperatingSegments1
      contextRef="c-1"
      decimals="INF"
      id="f-5824"
      unitRef="segment">2</sny:NumberOfOperatingSegments1>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-281" decimals="-6" id="f-5825" unitRef="eur">26970000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-282" decimals="-6" id="f-5826" unitRef="eur">6323000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-285" decimals="-6" id="f-5827" unitRef="eur">4468000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2525" decimals="-6" id="f-5828" unitRef="eur">0</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2526" decimals="-6" id="f-5829" unitRef="eur">37761000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="c-281" decimals="-6" id="f-5830" unitRef="eur">264000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-282" decimals="-6" id="f-5831" unitRef="eur">1095000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-285" decimals="-6" id="f-5832" unitRef="eur">55000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-2525" decimals="-6" id="f-5833" unitRef="eur">0</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-2526" decimals="-6" id="f-5834" unitRef="eur">1414000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="c-281" decimals="-6" id="f-5835" unitRef="eur">6965000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-282" decimals="-6" id="f-5836" unitRef="eur">3430000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-285" decimals="-6" id="f-5837" unitRef="eur">1606000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-2525" decimals="-6" id="f-5838" unitRef="eur">250000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-2526" decimals="-6" id="f-5839" unitRef="eur">12251000000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-281" decimals="-6" id="f-5840" unitRef="eur">4330000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-282" decimals="-6" id="f-5841" unitRef="eur">712000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-285" decimals="-6" id="f-5842" unitRef="eur">153000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-2525" decimals="-6" id="f-5843" unitRef="eur">497000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-2526" decimals="-6" id="f-5844" unitRef="eur">5692000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-281" decimals="-6" id="f-5845" unitRef="eur">5326000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-282" decimals="-6" id="f-5846" unitRef="eur">805000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-285" decimals="-6" id="f-5847" unitRef="eur">1388000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-2525" decimals="-6" id="f-5848" unitRef="eur">2036000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c-2526" decimals="-6" id="f-5849" unitRef="eur">9555000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-281" decimals="-6" id="f-5850" unitRef="eur">-1172000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-282" decimals="-6" id="f-5851" unitRef="eur">128000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-285" decimals="-6" id="f-5852" unitRef="eur">111000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-2525" decimals="-6" id="f-5853" unitRef="eur">-13000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <sny:MiscellaneousOtherOperatingIncomeExpenses contextRef="c-2526" decimals="-6" id="f-5854" unitRef="eur">-946000000</sny:MiscellaneousOtherOperatingIncomeExpenses>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-281" decimals="-6" id="f-5855" unitRef="eur">17000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-282" decimals="-6" id="f-5856" unitRef="eur">11000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-285" decimals="-6" id="f-5857" unitRef="eur">11000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-2525" decimals="-6" id="f-5858" unitRef="eur">0</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-2526" decimals="-6" id="f-5859" unitRef="eur">39000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-281" decimals="-6" id="f-5860" unitRef="eur">-49000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-282" decimals="-6" id="f-5861" unitRef="eur">-1000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-285" decimals="-6" id="f-5862" unitRef="eur">-5000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2525" decimals="-6" id="f-5863" unitRef="eur">-1000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2526" decimals="-6" id="f-5864" unitRef="eur">-56000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:BusinessOperatingIncome contextRef="c-281" decimals="-6" id="f-5865" unitRef="eur">9409000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-282" decimals="-6" id="f-5866" unitRef="eur">2609000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-285" decimals="-6" id="f-5867" unitRef="eur">1493000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-2525" decimals="-6" id="f-5868" unitRef="eur">-2797000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-2526" decimals="-6" id="f-5869" unitRef="eur">10714000000</sny:BusinessOperatingIncome>
    <sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock contextRef="c-1" id="f-5870">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below, presented in compliance with IFRS&#160;8, shows a reconciliation between aggregated &#x201c;Business operating income&#x201d; for the segments and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.552%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Business operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,670&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,040&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,714&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Share of profit/(loss) from investments accounted for using the equity method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortization and impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,599)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expenses arising from the impact of acquisitions on inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Restructuring costs and similar items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other gains and losses, and litigation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Income from out-licensing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,875&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,656&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,126&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Income before tax and investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,153&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,422&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7,798&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Joint ventures and associates with which Sanofi has entered into a strategic alliance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Excludes (i)&#160;restructuring costs and (ii)&#160;other adjustments attributable to non-controlling interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;For 2023, this amount mainly comprises an impairment loss of &#x20ac;833&#160;million, reflecting the impact of the strategic decision to de-prioritize certain R&amp;amp;D programs, in particular those related to the NK Cell and PRO-XTEN  technology platforms. For 2022, this line includes a reversal of &#x20ac;2,154&#160;million on ELOCTATE franchise products following FDA approval of ALTUVIIIO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;dated February&#160;22, 2023, partially offset by an impairment loss of &#x20ac;1,586&#160;million on intangible assets relating to SAR444245 (non-alpha interleukin-2).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(e)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;For 2022, this line includes an upfront payment of $900&#160;million and a regulatory milestone payment of $100&#160;million related to the out-licensing of LIBTAYO following the restructuring of the Immuno-Oncology Collaboration and License Agreement with Regeneron (see Note&#160;C.1.).&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock>
    <sny:BusinessOperatingIncome contextRef="c-2527" decimals="-6" id="f-5871" unitRef="eur">12670000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-2528" decimals="-6" id="f-5872" unitRef="eur">13040000000</sny:BusinessOperatingIncome>
    <sny:BusinessOperatingIncome contextRef="c-2529" decimals="-6" id="f-5873" unitRef="eur">10714000000</sny:BusinessOperatingIncome>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-2530" decimals="-6" id="f-5874" unitRef="eur">-122000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-2531" decimals="-6" id="f-5875" unitRef="eur">-88000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="c-2532" decimals="-6" id="f-5876" unitRef="eur">-39000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2530" decimals="-6" id="f-5877" unitRef="eur">36000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2531" decimals="-6" id="f-5878" unitRef="eur">33000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="c-2532" decimals="-6" id="f-5879" unitRef="eur">56000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill contextRef="c-2530" decimals="-6" id="f-5880" unitRef="eur">3068000000</sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill>
    <sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill contextRef="c-2531" decimals="-6" id="f-5881" unitRef="eur">1599000000</sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill>
    <sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill contextRef="c-2532" decimals="-6" id="f-5882" unitRef="eur">1772000000</sny:AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-2530" decimals="-6" id="f-5883" unitRef="eur">93000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-2531" decimals="-6" id="f-5884" unitRef="eur">-27000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability contextRef="c-2532" decimals="-6" id="f-5885" unitRef="eur">4000000</ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability>
    <sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories contextRef="c-2530" decimals="-6" id="f-5886" unitRef="eur">20000000</sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories>
    <sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories contextRef="c-2531" decimals="-6" id="f-5887" unitRef="eur">3000000</sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories>
    <sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories contextRef="c-2532" decimals="-6" id="f-5888" unitRef="eur">4000000</sny:ExpenseArisingFromTheImpactOfAcquisitionsOnInventories>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-2530" decimals="-6" id="f-5889" unitRef="eur">1490000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-2531" decimals="-6" id="f-5890" unitRef="eur">1336000000</ifrs-full:ExpenseOfRestructuringActivities>
    <ifrs-full:ExpenseOfRestructuringActivities contextRef="c-2532" decimals="-6" id="f-5891" unitRef="eur">820000000</ifrs-full:ExpenseOfRestructuringActivities>
    <sny:OtherGainsLossesAndLitigation contextRef="c-2530" decimals="-6" id="f-5892" unitRef="eur">-38000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-2531" decimals="-6" id="f-5893" unitRef="eur">-370000000</sny:OtherGainsLossesAndLitigation>
    <sny:OtherGainsLossesAndLitigation contextRef="c-2532" decimals="-6" id="f-5894" unitRef="eur">-5000000</sny:OtherGainsLossesAndLitigation>
    <sny:IncomeResultingFromOutLicensing contextRef="c-2530" decimals="-6" id="f-5895" unitRef="eur">0</sny:IncomeResultingFromOutLicensing>
    <sny:IncomeResultingFromOutLicensing contextRef="c-2531" decimals="-6" id="f-5896" unitRef="eur">952000000</sny:IncomeResultingFromOutLicensing>
    <sny:IncomeResultingFromOutLicensing contextRef="c-2532" decimals="-6" id="f-5897" unitRef="eur">0</sny:IncomeResultingFromOutLicensing>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-6" id="f-5898" unitRef="eur">7875000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-9" decimals="-6" id="f-5899" unitRef="eur">10656000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-10" decimals="-6" id="f-5900" unitRef="eur">8126000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-6" id="f-5901" unitRef="eur">1313000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-9" decimals="-6" id="f-5902" unitRef="eur">440000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-10" decimals="-6" id="f-5903" unitRef="eur">368000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-6" id="f-5904" unitRef="eur">591000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-9" decimals="-6" id="f-5905" unitRef="eur">206000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-10" decimals="-6" id="f-5906" unitRef="eur">40000000</ifrs-full:FinanceIncome>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-5907" unitRef="eur">7153000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-9" decimals="-6" id="f-5908" unitRef="eur">10422000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments contextRef="c-10" decimals="-6" id="f-5909" unitRef="eur">7798000000</sny:IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-2533" decimals="-6" id="f-5910" unitRef="eur">833000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount contextRef="c-466" decimals="-6" id="f-5911" unitRef="eur">2154000000</sny:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount>
    <sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill contextRef="c-2534" decimals="-6" id="f-5912" unitRef="eur">1586000000</sny:ImpairmentLossOnIntangibleAssetsOtherThanGoodwill>
    <sny:UpfrontPaymentsForProjectsUnderCollaborationAgreements contextRef="c-2535" decimals="-6" id="f-5913" unitRef="usd">900000000</sny:UpfrontPaymentsForProjectsUnderCollaborationAgreements>
    <sny:RegularMilestonePaymentsForProjectsUnderCollaborationAgreements contextRef="c-2535" decimals="-6" id="f-5914" unitRef="usd">100000000</sny:RegularMilestonePaymentsForProjectsUnderCollaborationAgreements>
    <sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock contextRef="c-1" id="f-5915">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January&#160;1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consumer&lt;br/&gt;Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Acquisitions of other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.&lt;/span&gt;&lt;/div&gt;</sny:DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock>
    <sny:InvestmentsInAssociatesAndJointVentures contextRef="c-300" decimals="-6" id="f-5916" unitRef="eur">234000000</sny:InvestmentsInAssociatesAndJointVentures>
    <sny:InvestmentsInAssociatesAndJointVentures contextRef="c-301" decimals="-6" id="f-5917" unitRef="eur">28000000</sny:InvestmentsInAssociatesAndJointVentures>
    <sny:InvestmentsInAssociatesAndJointVentures contextRef="c-2536" decimals="-6" id="f-5918" unitRef="eur">262000000</sny:InvestmentsInAssociatesAndJointVentures>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-277" decimals="-6" id="f-5919" unitRef="eur">1619000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-283" decimals="-6" id="f-5920" unitRef="eur">100000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-2522" decimals="-6" id="f-5921" unitRef="eur">1719000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-277" decimals="-6" id="f-5922" unitRef="eur">1287000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-283" decimals="-6" id="f-5923" unitRef="eur">18000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-2522" decimals="-6" id="f-5924" unitRef="eur">1305000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <sny:InvestmentsInAssociatesAndJointVentures contextRef="c-2537" decimals="-6" id="f-5925" unitRef="eur">248000000</sny:InvestmentsInAssociatesAndJointVentures>
    <sny:InvestmentsInAssociatesAndJointVentures contextRef="c-2538" decimals="-6" id="f-5926" unitRef="eur">37000000</sny:InvestmentsInAssociatesAndJointVentures>
    <sny:InvestmentsInAssociatesAndJointVentures contextRef="c-2539" decimals="-6" id="f-5927" unitRef="eur">285000000</sny:InvestmentsInAssociatesAndJointVentures>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-278" decimals="-6" id="f-5928" unitRef="eur">1529000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-284" decimals="-6" id="f-5929" unitRef="eur">77000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-2524" decimals="-6" id="f-5930" unitRef="eur">1606000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-278" decimals="-6" id="f-5931" unitRef="eur">574000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-284" decimals="-6" id="f-5932" unitRef="eur">21000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-2524" decimals="-6" id="f-5933" unitRef="eur">595000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <sny:NumberOfOperatingSegments1
      contextRef="c-1"
      decimals="INF"
      id="f-5934"
      unitRef="segment">2</sny:NumberOfOperatingSegments1>
    <sny:InvestmentsInAssociatesAndJointVentures contextRef="c-2540" decimals="-6" id="f-5935" unitRef="eur">159000000</sny:InvestmentsInAssociatesAndJointVentures>
    <sny:InvestmentsInAssociatesAndJointVentures contextRef="c-2541" decimals="-6" id="f-5936" unitRef="eur">91000000</sny:InvestmentsInAssociatesAndJointVentures>
    <sny:InvestmentsInAssociatesAndJointVentures contextRef="c-2542" decimals="-6" id="f-5937" unitRef="eur">0</sny:InvestmentsInAssociatesAndJointVentures>
    <sny:InvestmentsInAssociatesAndJointVentures contextRef="c-2543" decimals="-6" id="f-5938" unitRef="eur">250000000</sny:InvestmentsInAssociatesAndJointVentures>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-281" decimals="-6" id="f-5939" unitRef="eur">1024000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-282" decimals="-6" id="f-5940" unitRef="eur">382000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-285" decimals="-6" id="f-5941" unitRef="eur">73000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-2526" decimals="-6" id="f-5942" unitRef="eur">1479000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-281" decimals="-6" id="f-5943" unitRef="eur">451000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-282" decimals="-6" id="f-5944" unitRef="eur">108000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-285" decimals="-6" id="f-5945" unitRef="eur">6000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-2526" decimals="-6" id="f-5946" unitRef="eur">565000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:DisclosureOfGeographicalAreasExplanatory contextRef="c-1" id="f-5947">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with&#160;IFRS&#160;8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS&#160;16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;North&lt;br/&gt;America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;43,070&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,392&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,379&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;19,216&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,512&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;13,462&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;property, plant and equipment owned&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;North&lt;br/&gt;America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;42,997&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,999&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,296&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,984&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18,275&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,014&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;property, plant and equipment owned&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;North&lt;br/&gt;America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;of&#160;which&lt;br/&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;countries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;37,761&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;9,759&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,256&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15,075&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14,385&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;12,927&lt;/span&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;property, plant and equipment owned&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.34pt;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt"&gt;other intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeographicalAreasExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2544" decimals="-6" id="f-5948" unitRef="eur">43070000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2515" decimals="-6" id="f-5949" unitRef="eur">10392000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1267" decimals="-6" id="f-5950" unitRef="eur">2379000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2545" decimals="-6" id="f-5951" unitRef="eur">19216000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1205" decimals="-6" id="f-5952" unitRef="eur">18512000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2546" decimals="-6" id="f-5953" unitRef="eur">13462000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2547" decimals="-6" id="f-5954" unitRef="eur">10160000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2548" decimals="-6" id="f-5955" unitRef="eur">5659000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-1232" decimals="-6" id="f-5956" unitRef="eur">3085000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2549" decimals="-6" id="f-5957" unitRef="eur">3316000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-1218" decimals="-6" id="f-5958" unitRef="eur">2322000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-1435" decimals="-6" id="f-5959" unitRef="eur">1185000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-2547" decimals="-6" id="f-5960" unitRef="eur">49404000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-2548" decimals="-6" id="f-5961" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-1232" decimals="-6" id="f-5962" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-2549" decimals="-6" id="f-5963" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-1218" decimals="-6" id="f-5964" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-1435" decimals="-6" id="f-5965" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2547" decimals="-6" id="f-5966" unitRef="eur">24319000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2548" decimals="-6" id="f-5967" unitRef="eur">5566000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-1232" decimals="-6" id="f-5968" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2549" decimals="-6" id="f-5969" unitRef="eur">17852000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-1218" decimals="-6" id="f-5970" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-1435" decimals="-6" id="f-5971" unitRef="eur">901000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2550" decimals="-6" id="f-5972" unitRef="eur">42997000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2517" decimals="-6" id="f-5973" unitRef="eur">9999000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1268" decimals="-6" id="f-5974" unitRef="eur">2296000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2551" decimals="-6" id="f-5975" unitRef="eur">18984000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1269" decimals="-6" id="f-5976" unitRef="eur">18275000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2552" decimals="-6" id="f-5977" unitRef="eur">14014000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2553" decimals="-6" id="f-5978" unitRef="eur">9869000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2554" decimals="-6" id="f-5979" unitRef="eur">5365000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-1234" decimals="-6" id="f-5980" unitRef="eur">2875000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2555" decimals="-6" id="f-5981" unitRef="eur">3284000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-1224" decimals="-6" id="f-5982" unitRef="eur">2457000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-1443" decimals="-6" id="f-5983" unitRef="eur">1220000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-2553" decimals="-6" id="f-5984" unitRef="eur">49892000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-2554" decimals="-6" id="f-5985" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-1234" decimals="-6" id="f-5986" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-2555" decimals="-6" id="f-5987" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-1224" decimals="-6" id="f-5988" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-1443" decimals="-6" id="f-5989" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2553" decimals="-6" id="f-5990" unitRef="eur">21640000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2554" decimals="-6" id="f-5991" unitRef="eur">6257000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-1234" decimals="-6" id="f-5992" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2555" decimals="-6" id="f-5993" unitRef="eur">14178000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-1224" decimals="-6" id="f-5994" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-1443" decimals="-6" id="f-5995" unitRef="eur">1205000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2556" decimals="-6" id="f-5996" unitRef="eur">37761000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2519" decimals="-6" id="f-5997" unitRef="eur">9759000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1271" decimals="-6" id="f-5998" unitRef="eur">2256000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2557" decimals="-6" id="f-5999" unitRef="eur">15075000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-1272" decimals="-6" id="f-6000" unitRef="eur">14385000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="c-2558" decimals="-6" id="f-6001" unitRef="eur">12927000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2559" decimals="-6" id="f-6002" unitRef="eur">10028000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2560" decimals="-6" id="f-6003" unitRef="eur">5959000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-1236" decimals="-6" id="f-6004" unitRef="eur">3253000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2561" decimals="-6" id="f-6005" unitRef="eur">2998000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-1230" decimals="-6" id="f-6006" unitRef="eur">2234000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-1452" decimals="-6" id="f-6007" unitRef="eur">1071000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill contextRef="c-2559" decimals="-6" id="f-6008" unitRef="eur">48056000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-2560" decimals="-6" id="f-6009" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-1236" decimals="-6" id="f-6010" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-2561" decimals="-6" id="f-6011" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-1230" decimals="-6" id="f-6012" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-1452" decimals="-6" id="f-6013" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2559" decimals="-6" id="f-6014" unitRef="eur">21407000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2560" decimals="-6" id="f-6015" unitRef="eur">7059000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-1236" decimals="-6" id="f-6016" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2561" decimals="-6" id="f-6017" unitRef="eur">13187000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-1230" decimals="-6" id="f-6018" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-1452" decimals="-6" id="f-6019" unitRef="eur">1161000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfAuditorsRemunerationExplanatory contextRef="c-1" id="f-6020">Principal accountants&#x2019; fees and services&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;PricewaterhouseCoopers Audit and Ernst&#160;&amp;amp; Young et Autres served as independent auditors of Sanofi for the year ended December 31, 2023 and for all other reporting periods presented. The table below shows fees charged by those firms and member firms of their networks to Sanofi and consolidated subsidiaries in the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.863%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.019%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ernst&#160;&amp;amp;&#160;Young&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PricewaterhouseCoopers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Audit:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; Statutory audit of separate and consolidated financial statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Services other than statutory audit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Audit-related services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20.5&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20.5&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14.6&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst&#160;&amp;amp; Young &#x20ac;7.9 million in 2023, &#x20ac;7.3 million in&#160;2022; PricewaterhouseCoopers Audit &#x20ac;8.3 million in 2023, &#x20ac;7.7 million in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Services other than statutory audit provided by Ernst&#160;&amp;amp; Young during 2023 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- contractual audits, including on the combined financial statements of the Consumer Healthcare business;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- additional procedures to enable reports previously signed by the firm to be incorporated by reference;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- issuance of the Independent Third Party&#x2019;s report on the consolidated statement of extra-financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Services other than statutory audit provided by PricewaterhouseCoopers during 2023 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- contractual audits, including on the combined financial statements of the Consumer Healthcare business;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- additional procedures to enable reports previously signed by the firm to be incorporated by reference; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst&#160;&amp;amp; Young: &#x20ac;5.2 million in 2023, &#x20ac;1.4 million in&#160;2022; PricewaterhouseCoopers Audit &#x20ac;5.3 million in 2023, &#x20ac;0.3 million in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Includes &#x20ac;0.5&#160;million for services that can only be provided by the statutory auditors, such as comfort letters, attestation services required by regulation (which qualify as audit fees under SEC rules).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAuditorsRemunerationExplanatory>
    <sny:AuditorsRemunerationTableTextBlock contextRef="c-1" id="f-6021">The table below shows fees charged by those firms and member firms of their networks to Sanofi and consolidated subsidiaries in the years ended December 31, 2023 and 2022.&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.863%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.019%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ernst&#160;&amp;amp;&#160;Young&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PricewaterhouseCoopers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;(&#x20ac; million)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Audit:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; Statutory audit of separate and consolidated financial statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Services other than statutory audit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Audit-related services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20.5&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16.0&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20.5&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;14.6&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst&#160;&amp;amp; Young &#x20ac;7.9 million in 2023, &#x20ac;7.3 million in&#160;2022; PricewaterhouseCoopers Audit &#x20ac;8.3 million in 2023, &#x20ac;7.7 million in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Services other than statutory audit provided by Ernst&#160;&amp;amp; Young during 2023 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- contractual audits, including on the combined financial statements of the Consumer Healthcare business;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- additional procedures to enable reports previously signed by the firm to be incorporated by reference;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- issuance of the Independent Third Party&#x2019;s report on the consolidated statement of extra-financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Services other than statutory audit provided by PricewaterhouseCoopers during 2023 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- contractual audits, including on the combined financial statements of the Consumer Healthcare business;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- additional procedures to enable reports previously signed by the firm to be incorporated by reference; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst&#160;&amp;amp; Young: &#x20ac;5.2 million in 2023, &#x20ac;1.4 million in&#160;2022; PricewaterhouseCoopers Audit &#x20ac;5.3 million in 2023, &#x20ac;0.3 million in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Includes &#x20ac;0.5&#160;million for services that can only be provided by the statutory auditors, such as comfort letters, attestation services required by regulation (which qualify as audit fees under SEC rules).&lt;/span&gt;&lt;/div&gt;</sny:AuditorsRemunerationTableTextBlock>
    <ifrs-full:AuditorsRemunerationForAuditServices contextRef="c-2562" decimals="-5" id="f-6022" unitRef="eur">15100000</ifrs-full:AuditorsRemunerationForAuditServices>
    <sny:PercentageOfAuditorRemunerationForStatutoryAudit
      contextRef="c-2562"
      decimals="2"
      id="f-6023"
      unitRef="number">0.74</sny:PercentageOfAuditorRemunerationForStatutoryAudit>
    <ifrs-full:AuditorsRemunerationForAuditServices contextRef="c-2563" decimals="-5" id="f-6024" unitRef="eur">14200000</ifrs-full:AuditorsRemunerationForAuditServices>
    <sny:PercentageOfAuditorRemunerationForStatutoryAudit
      contextRef="c-2563"
      decimals="2"
      id="f-6025"
      unitRef="number">0.89</sny:PercentageOfAuditorRemunerationForStatutoryAudit>
    <ifrs-full:AuditorsRemunerationForAuditServices contextRef="c-2564" decimals="-5" id="f-6026" unitRef="eur">14700000</ifrs-full:AuditorsRemunerationForAuditServices>
    <sny:PercentageOfAuditorRemunerationForStatutoryAudit
      contextRef="c-2564"
      decimals="2"
      id="f-6027"
      unitRef="number">0.72</sny:PercentageOfAuditorRemunerationForStatutoryAudit>
    <ifrs-full:AuditorsRemunerationForAuditServices contextRef="c-2565" decimals="-5" id="f-6028" unitRef="eur">14100000</ifrs-full:AuditorsRemunerationForAuditServices>
    <sny:PercentageOfAuditorRemunerationForStatutoryAudit
      contextRef="c-2565"
      decimals="2"
      id="f-6029"
      unitRef="number">0.97</sny:PercentageOfAuditorRemunerationForStatutoryAudit>
    <sny:ServicesOtherThanStatutoryAudit contextRef="c-2562" decimals="-5" id="f-6030" unitRef="eur">5400000</sny:ServicesOtherThanStatutoryAudit>
    <sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements
      contextRef="c-2562"
      decimals="2"
      id="f-6031"
      unitRef="number">0.26</sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements>
    <sny:ServicesOtherThanStatutoryAudit contextRef="c-2563" decimals="-5" id="f-6032" unitRef="eur">1800000</sny:ServicesOtherThanStatutoryAudit>
    <sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements
      contextRef="c-2563"
      decimals="2"
      id="f-6033"
      unitRef="number">0.11</sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements>
    <sny:ServicesOtherThanStatutoryAudit contextRef="c-2564" decimals="-5" id="f-6034" unitRef="eur">5800000</sny:ServicesOtherThanStatutoryAudit>
    <sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements
      contextRef="c-2564"
      decimals="2"
      id="f-6035"
      unitRef="number">0.28</sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements>
    <sny:ServicesOtherThanStatutoryAudit contextRef="c-2565" decimals="-5" id="f-6036" unitRef="eur">500000</sny:ServicesOtherThanStatutoryAudit>
    <sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements
      contextRef="c-2565"
      decimals="2"
      id="f-6037"
      unitRef="number">0.03</sny:PercentageOfAuditorsRemunerationForServicesOtherThanAuditOfFinancialStatements>
    <sny:AuditorsRemunerationForAuditRelatedServices contextRef="c-2562" decimals="-5" id="f-6038" unitRef="eur">5300000</sny:AuditorsRemunerationForAuditRelatedServices>
    <sny:AuditorsRemunerationForAuditRelatedServices contextRef="c-2563" decimals="-5" id="f-6039" unitRef="eur">1500000</sny:AuditorsRemunerationForAuditRelatedServices>
    <sny:AuditorsRemunerationForAuditRelatedServices contextRef="c-2564" decimals="-5" id="f-6040" unitRef="eur">5800000</sny:AuditorsRemunerationForAuditRelatedServices>
    <sny:AuditorsRemunerationForAuditRelatedServices contextRef="c-2565" decimals="-5" id="f-6041" unitRef="eur">500000</sny:AuditorsRemunerationForAuditRelatedServices>
    <ifrs-full:AuditorsRemunerationForTaxServices contextRef="c-2562" decimals="-5" id="f-6042" unitRef="eur">0.0</ifrs-full:AuditorsRemunerationForTaxServices>
    <ifrs-full:AuditorsRemunerationForTaxServices contextRef="c-2563" decimals="-5" id="f-6043" unitRef="eur">0</ifrs-full:AuditorsRemunerationForTaxServices>
    <ifrs-full:AuditorsRemunerationForTaxServices contextRef="c-2564" decimals="-5" id="f-6044" unitRef="eur">0.0</ifrs-full:AuditorsRemunerationForTaxServices>
    <ifrs-full:AuditorsRemunerationForTaxServices contextRef="c-2565" decimals="-5" id="f-6045" unitRef="eur">0</ifrs-full:AuditorsRemunerationForTaxServices>
    <ifrs-full:AuditorsRemunerationForOtherServices contextRef="c-2562" decimals="-5" id="f-6046" unitRef="eur">100000</ifrs-full:AuditorsRemunerationForOtherServices>
    <ifrs-full:AuditorsRemunerationForOtherServices contextRef="c-2563" decimals="-5" id="f-6047" unitRef="eur">300000</ifrs-full:AuditorsRemunerationForOtherServices>
    <ifrs-full:AuditorsRemunerationForOtherServices contextRef="c-2564" decimals="-5" id="f-6048" unitRef="eur">0</ifrs-full:AuditorsRemunerationForOtherServices>
    <ifrs-full:AuditorsRemunerationForOtherServices contextRef="c-2565" decimals="-5" id="f-6049" unitRef="eur">0</ifrs-full:AuditorsRemunerationForOtherServices>
    <ifrs-full:AuditorsRemuneration contextRef="c-2562" decimals="-5" id="f-6050" unitRef="eur">20500000</ifrs-full:AuditorsRemuneration>
    <sny:PercentageOfAuditorsRemuneration
      contextRef="c-2562"
      decimals="INF"
      id="f-6051"
      unitRef="number">1</sny:PercentageOfAuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration contextRef="c-2563" decimals="-5" id="f-6052" unitRef="eur">16000000.0</ifrs-full:AuditorsRemuneration>
    <sny:PercentageOfAuditorsRemuneration
      contextRef="c-2563"
      decimals="INF"
      id="f-6053"
      unitRef="number">1</sny:PercentageOfAuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration contextRef="c-2564" decimals="-5" id="f-6054" unitRef="eur">20500000</ifrs-full:AuditorsRemuneration>
    <sny:PercentageOfAuditorsRemuneration
      contextRef="c-2564"
      decimals="INF"
      id="f-6055"
      unitRef="number">1</sny:PercentageOfAuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration contextRef="c-2565" decimals="-5" id="f-6056" unitRef="eur">14600000</ifrs-full:AuditorsRemuneration>
    <sny:PercentageOfAuditorsRemuneration
      contextRef="c-2565"
      decimals="INF"
      id="f-6057"
      unitRef="number">1</sny:PercentageOfAuditorsRemuneration>
    <sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries contextRef="c-2562" decimals="-5" id="f-6058" unitRef="eur">7900000</sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries>
    <sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries contextRef="c-2563" decimals="-5" id="f-6059" unitRef="eur">7300000</sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries>
    <sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries contextRef="c-2564" decimals="-5" id="f-6060" unitRef="eur">8300000</sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries>
    <sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries contextRef="c-2565" decimals="-5" id="f-6061" unitRef="eur">7700000</sny:AuditOfTheFinancialStatementsOfTheParentCompanyAndItsFrenchSubsidiaries>
    <sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries contextRef="c-2562" decimals="-5" id="f-6062" unitRef="eur">5200000</sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries>
    <sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries contextRef="c-2563" decimals="-5" id="f-6063" unitRef="eur">1400000</sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries>
    <sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries contextRef="c-2564" decimals="-5" id="f-6064" unitRef="eur">5300000</sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries>
    <sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries contextRef="c-2565" decimals="-5" id="f-6065" unitRef="eur">300000</sny:AuditRelatedServicesChargedToTheParentCompanyAndItsFrenchSubsidiaries>
    <sny:AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices contextRef="c-1" decimals="-5" id="f-6066" unitRef="eur">500000</sny:AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices>
    <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory contextRef="c-1" id="f-6067">List of principal companies included in the scope of&#160;consolidation during&#160;2023&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;F.1. Principal fully consolidated companies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows Sanofi&#x2019;s principal subsidiaries and their country of incorporation:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial interest (%) as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hoechst GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Deutschland GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;A. Nattermann &amp;amp; Cie. GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Austria&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Belgium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Belgium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ablynx NV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Belgium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Flanders BV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Belgium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi A/S&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Denmark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Spain, SL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Oy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Finland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Winthrop Industrie&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Recherche &amp;amp; D&#xe9;veloppement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Groupe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Chimie&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Participations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis Pharma S.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Mature IP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur NVL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;SECIPE SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Merieux SAS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare International SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare France SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Group SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Polyclonals SAS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis A.E.B.E.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Greece&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Private Co, Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hungary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Chinoin Private Co. Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hungary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Hungary Commercial K.F.T&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hungary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Hungary K.F.T&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hungary&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Carraig Insurance DAC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Ireland Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Holdings (Ireland) Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi SRL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Italy SRL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Global Sarl&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Luxembourg Sarl&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Norge AS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Norway&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi BV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Foreign Participations BV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Sp. z.o.o.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Poland sp.z.o.o.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Sp. z.o.o.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Produtos Farmaceuticos Lda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Portugal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis, s.r.o.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Czech Republic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Czech s.r.o&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Czech Republic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial interest (%) as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Romania SRL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Romania&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Romania SRL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Romania&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis UK Holdings Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis Pharma Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Synthelabo UK Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis Pharma Holdings Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare UK Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;AO Sanofi Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi AB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sweden&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis (Suisse) SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Global Sarl Baar Intellectual Property Branch&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Ilac Sanayi ve Ticaret AS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Turkey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Asi Ticaret AS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Turkey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare T&#xfc;ketici Sa&#x11f;l&#x131;&#x11f;&#x131; Anonim &#x15e;irketi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Turkey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Saglik Urunleri Limited Sirketi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Turkey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial interest (%) as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Therapeutic Products Limited Partnership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi US Services Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis U.S. LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Chattem, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventisub LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;VaxServe, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bioverativ Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bioverativ U.S. LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bioverativ Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Principia Biopharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Research Invest LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Bioverativ Holdings LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RPR US Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Kadmon Corporation, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amunix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Synthorx, Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provention Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;QRIB Intermediate Holding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;QRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;TargeGen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Chattem (GB) Holding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Translate Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.311%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other Countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial interest (%) as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis South Africa (Pty) Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;South Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Alg&#xe9;rie&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Algeria&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Arabia Trading Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Saudi Arabia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Argentina SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Argentina&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Healthcare Pty Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Australia Pty Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Medley Farmaceutica Ltda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Brazil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Brazil Ltda.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Brazil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Canada Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Merieux Canada Holdings ULC (Canada)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi (Hangzhou) Pharmaceuticals Co., Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi (China) Investment Co., Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi (Beijing) Pharmaceuticals Co.Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Biologies Co., Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shenzhen Sanofi pasteur Biological Products Co, Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shanghai Rongheng Pharmaceutical Co, Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis de Colombia SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Colombia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Korea Co. Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella healthcare Korea Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Gulf FZE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Arab Emirates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Egypt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Egypt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Hong-Kong Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi India Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Healthcare India Private Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Isra&#xeb;l Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi K.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;SSP Co.,Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis (Malaysia) SDN. BHD.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Malaysia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Maroc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Morocco&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis de Mexico SA de CV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur SA de CV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Azteca Vacunas, SA de CV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis de Panama SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Panama&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Panama SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Panama&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Puerto Rico Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Philippines Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Philippines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Philippines Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Philippines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Singapore Pte. Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis Pharma (Manufacturing) Pte. Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Manufacturing Pte Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Taiwan Co., Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Taiwan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis (Thailand) Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Thailand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Thailand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis de Venezuela SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Venezuela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Vietnam Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vietnam&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Vietnam Shareholding Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vietnam&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;F.2. Principal investments accounted for using the equity method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.090%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial interest (%) as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Haleon US, LP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Infraserv GmbH&#160;&amp;amp; Co. H&#xf6;chst KG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Maphar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Morocco&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MCM Vaccine BV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MSP Vaccine Company (formerly MCM company)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;EUROAPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
    <ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory contextRef="c-1" id="f-6068">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The table below shows Sanofi&#x2019;s principal subsidiaries and their country of incorporation:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial interest (%) as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hoechst GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Deutschland GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;A. Nattermann &amp;amp; Cie. GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Austria&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Belgium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Belgium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ablynx NV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Belgium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Flanders BV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Belgium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi A/S&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Denmark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Spain, SL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Oy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Finland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Winthrop Industrie&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Recherche &amp;amp; D&#xe9;veloppement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Groupe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Chimie&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Participations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis Pharma S.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Mature IP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur NVL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;SECIPE SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Merieux SAS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare International SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare France SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Group SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Polyclonals SAS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis A.E.B.E.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Greece&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Private Co, Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hungary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Chinoin Private Co. Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hungary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Hungary Commercial K.F.T&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hungary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Hungary K.F.T&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hungary&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Carraig Insurance DAC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Ireland Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Holdings (Ireland) Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi SRL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Italy SRL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Global Sarl&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Luxembourg Sarl&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Norge AS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Norway&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi BV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Foreign Participations BV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Sp. z.o.o.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Poland sp.z.o.o.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Sp. z.o.o.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Produtos Farmaceuticos Lda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Portugal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis, s.r.o.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Czech Republic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Czech s.r.o&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Czech Republic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial interest (%) as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Romania SRL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Romania&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Romania SRL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Romania&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis UK Holdings Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis Pharma Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Synthelabo UK Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis Pharma Holdings Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare UK Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;AO Sanofi Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi AB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sweden&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis (Suisse) SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Global Sarl Baar Intellectual Property Branch&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Ilac Sanayi ve Ticaret AS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Turkey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Asi Ticaret AS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Turkey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare T&#xfc;ketici Sa&#x11f;l&#x131;&#x11f;&#x131; Anonim &#x15e;irketi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Turkey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Saglik Urunleri Limited Sirketi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Turkey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial interest (%) as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Therapeutic Products Limited Partnership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi US Services Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis U.S. LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Chattem, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventisub LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genzyme Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;VaxServe, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bioverativ Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bioverativ U.S. LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Bioverativ Therapeutics Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Principia Biopharma Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Research Invest LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Bioverativ Holdings LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;RPR US Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Kadmon Corporation, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United&#160;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amunix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Synthorx, Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Provention Bio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;QRIB Intermediate Holding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;QRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;TargeGen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Chattem (GB) Holding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Translate Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.311%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other Countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial interest (%) as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis South Africa (Pty) Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;South Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Alg&#xe9;rie&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Algeria&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Arabia Trading Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Saudi Arabia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Argentina SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Argentina&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Healthcare Pty Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Australia Pty Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Medley Farmaceutica Ltda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Brazil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Brazil Ltda.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Brazil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Canada Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Merieux Canada Holdings ULC (Canada)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi (Hangzhou) Pharmaceuticals Co., Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi (China) Investment Co., Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi (Beijing) Pharmaceuticals Co.Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Biologies Co., Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shenzhen Sanofi pasteur Biological Products Co, Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shanghai Rongheng Pharmaceutical Co, Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis de Colombia SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Colombia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Korea Co. Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella healthcare Korea Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Gulf FZE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United Arab Emirates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Egypt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Egypt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Hong-Kong Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hong Kong&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi India Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Healthcare India Private Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Isra&#xeb;l Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi K.K.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;SSP Co.,Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis (Malaysia) SDN. BHD.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Malaysia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Maroc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Morocco&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis de Mexico SA de CV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur SA de CV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Azteca Vacunas, SA de CV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis de Panama SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Panama&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Panama SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Panama&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Puerto Rico Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Philippines Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Philippines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Opella Healthcare Philippines Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Philippines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Singapore Pte. Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aventis Pharma (Manufacturing) Pte. Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Manufacturing Pte Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Taiwan Co., Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Taiwan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis (Thailand) Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Thailand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Pasteur Ltd&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Thailand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis de Venezuela SA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Venezuela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi-Aventis Vietnam Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vietnam&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sanofi Vietnam Shareholding Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vietnam&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2566"
      decimals="INF"
      id="f-6069"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2567"
      decimals="INF"
      id="f-6070"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2568"
      decimals="INF"
      id="f-6071"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2569"
      decimals="INF"
      id="f-6072"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2570"
      decimals="INF"
      id="f-6073"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2571"
      decimals="INF"
      id="f-6074"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2572"
      decimals="INF"
      id="f-6075"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2573"
      decimals="INF"
      id="f-6076"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2574"
      decimals="INF"
      id="f-6077"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2575"
      decimals="INF"
      id="f-6078"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2576"
      decimals="INF"
      id="f-6079"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2577"
      decimals="INF"
      id="f-6080"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2578"
      decimals="INF"
      id="f-6081"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2579"
      decimals="INF"
      id="f-6082"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2580"
      decimals="INF"
      id="f-6083"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2581"
      decimals="INF"
      id="f-6084"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2582"
      decimals="INF"
      id="f-6085"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2583"
      decimals="INF"
      id="f-6086"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2584"
      decimals="INF"
      id="f-6087"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2585"
      decimals="INF"
      id="f-6088"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2586"
      decimals="INF"
      id="f-6089"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2587"
      decimals="INF"
      id="f-6090"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2588"
      decimals="INF"
      id="f-6091"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2589"
      decimals="INF"
      id="f-6092"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2590"
      decimals="INF"
      id="f-6093"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2591"
      decimals="INF"
      id="f-6094"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2592"
      decimals="INF"
      id="f-6095"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2593"
      decimals="INF"
      id="f-6096"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2594"
      decimals="INF"
      id="f-6097"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2595"
      decimals="INF"
      id="f-6098"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2596"
      decimals="INF"
      id="f-6099"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2597"
      decimals="INF"
      id="f-6100"
      unitRef="number">0.996</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2598"
      decimals="INF"
      id="f-6101"
      unitRef="number">0.996</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2599"
      decimals="INF"
      id="f-6102"
      unitRef="number">0.996</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2600"
      decimals="INF"
      id="f-6103"
      unitRef="number">0.996</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2601"
      decimals="INF"
      id="f-6104"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2602"
      decimals="INF"
      id="f-6105"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2603"
      decimals="INF"
      id="f-6106"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2604"
      decimals="INF"
      id="f-6107"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2605"
      decimals="INF"
      id="f-6108"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2606"
      decimals="INF"
      id="f-6109"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2607"
      decimals="INF"
      id="f-6110"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2608"
      decimals="INF"
      id="f-6111"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2609"
      decimals="INF"
      id="f-6112"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2610"
      decimals="INF"
      id="f-6113"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2611"
      decimals="INF"
      id="f-6114"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2612"
      decimals="INF"
      id="f-6115"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2613"
      decimals="INF"
      id="f-6116"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2614"
      decimals="INF"
      id="f-6117"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2615"
      decimals="INF"
      id="f-6118"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2616"
      decimals="INF"
      id="f-6119"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2617"
      decimals="INF"
      id="f-6120"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2618"
      decimals="INF"
      id="f-6121"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2619"
      decimals="INF"
      id="f-6122"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2620"
      decimals="INF"
      id="f-6123"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2621"
      decimals="INF"
      id="f-6124"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2622"
      decimals="INF"
      id="f-6125"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2623"
      decimals="INF"
      id="f-6126"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2624"
      decimals="INF"
      id="f-6127"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2625"
      decimals="INF"
      id="f-6128"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2626"
      decimals="INF"
      id="f-6129"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2627"
      decimals="INF"
      id="f-6130"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2628"
      decimals="INF"
      id="f-6131"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2629"
      decimals="INF"
      id="f-6132"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2630"
      decimals="INF"
      id="f-6133"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2631"
      decimals="INF"
      id="f-6134"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2632"
      decimals="INF"
      id="f-6135"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2633"
      decimals="INF"
      id="f-6136"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2634"
      decimals="INF"
      id="f-6137"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2635"
      decimals="INF"
      id="f-6138"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2636"
      decimals="INF"
      id="f-6139"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2637"
      decimals="INF"
      id="f-6140"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2638"
      decimals="INF"
      id="f-6141"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2639"
      decimals="INF"
      id="f-6142"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2640"
      decimals="INF"
      id="f-6143"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2641"
      decimals="INF"
      id="f-6144"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2642"
      decimals="INF"
      id="f-6145"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2643"
      decimals="INF"
      id="f-6146"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2644"
      decimals="INF"
      id="f-6147"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2645"
      decimals="INF"
      id="f-6148"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2646"
      decimals="INF"
      id="f-6149"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2647"
      decimals="INF"
      id="f-6150"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2648"
      decimals="INF"
      id="f-6151"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2649"
      decimals="INF"
      id="f-6152"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2650"
      decimals="INF"
      id="f-6153"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2651"
      decimals="INF"
      id="f-6154"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2652"
      decimals="INF"
      id="f-6155"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2653"
      decimals="INF"
      id="f-6156"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2654"
      decimals="INF"
      id="f-6157"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2655"
      decimals="INF"
      id="f-6158"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2656"
      decimals="INF"
      id="f-6159"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2657"
      decimals="INF"
      id="f-6160"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2658"
      decimals="INF"
      id="f-6161"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2659"
      decimals="INF"
      id="f-6162"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2660"
      decimals="INF"
      id="f-6163"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2661"
      decimals="INF"
      id="f-6164"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2662"
      decimals="INF"
      id="f-6165"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2663"
      decimals="INF"
      id="f-6166"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2664"
      decimals="INF"
      id="f-6167"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2665"
      decimals="INF"
      id="f-6168"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2666"
      decimals="INF"
      id="f-6169"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2667"
      decimals="INF"
      id="f-6170"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2668"
      decimals="INF"
      id="f-6171"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2669"
      decimals="INF"
      id="f-6172"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2670"
      decimals="INF"
      id="f-6173"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2671"
      decimals="INF"
      id="f-6174"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2672"
      decimals="INF"
      id="f-6175"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2673"
      decimals="INF"
      id="f-6176"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2674"
      decimals="INF"
      id="f-6177"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2675"
      decimals="INF"
      id="f-6178"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2676"
      decimals="INF"
      id="f-6179"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2677"
      decimals="INF"
      id="f-6180"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2678"
      decimals="INF"
      id="f-6181"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2679"
      decimals="INF"
      id="f-6182"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2680"
      decimals="INF"
      id="f-6183"
      unitRef="number">0.998</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2681"
      decimals="INF"
      id="f-6184"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2682"
      decimals="INF"
      id="f-6185"
      unitRef="number">0.604</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2683"
      decimals="INF"
      id="f-6186"
      unitRef="number">0.999</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2684"
      decimals="INF"
      id="f-6187"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2685"
      decimals="INF"
      id="f-6188"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2686"
      decimals="INF"
      id="f-6189"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2687"
      decimals="INF"
      id="f-6190"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2688"
      decimals="INF"
      id="f-6191"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2689"
      decimals="INF"
      id="f-6192"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2690"
      decimals="INF"
      id="f-6193"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2691"
      decimals="INF"
      id="f-6194"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2692"
      decimals="INF"
      id="f-6195"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2693"
      decimals="INF"
      id="f-6196"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2694"
      decimals="INF"
      id="f-6197"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2695"
      decimals="INF"
      id="f-6198"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2696"
      decimals="INF"
      id="f-6199"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2697"
      decimals="INF"
      id="f-6200"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2698"
      decimals="INF"
      id="f-6201"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2699"
      decimals="INF"
      id="f-6202"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2700"
      decimals="INF"
      id="f-6203"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2701"
      decimals="INF"
      id="f-6204"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2702"
      decimals="INF"
      id="f-6205"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2703"
      decimals="INF"
      id="f-6206"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2704"
      decimals="INF"
      id="f-6207"
      unitRef="number">1.000</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-2705"
      decimals="INF"
      id="f-6208"
      unitRef="number">0.850</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <sny:DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock contextRef="c-1" id="f-6209">&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.090%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Financial interest (%) as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Haleon US, LP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Infraserv GmbH&#160;&amp;amp; Co. H&#xf6;chst KG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Maphar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Morocco&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MCM Vaccine BV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;MSP Vaccine Company (formerly MCM company)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;EUROAPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sny:DisclosureOfInvestmentsInSubsidiariesExplanatoryTableTextBlock>
    <ifrs-full:ProportionOfOwnershipInterestInJointOperation
      contextRef="c-2706"
      decimals="3"
      id="f-6210"
      unitRef="number">0.117</ifrs-full:ProportionOfOwnershipInterestInJointOperation>
    <ifrs-full:ProportionOfOwnershipInterestInJointOperation
      contextRef="c-2707"
      decimals="3"
      id="f-6211"
      unitRef="number">0.312</ifrs-full:ProportionOfOwnershipInterestInJointOperation>
    <ifrs-full:ProportionOfOwnershipInterestInJointOperation
      contextRef="c-2708"
      decimals="3"
      id="f-6212"
      unitRef="number">0.483</ifrs-full:ProportionOfOwnershipInterestInJointOperation>
    <ifrs-full:ProportionOfOwnershipInterestInJointOperation
      contextRef="c-2709"
      decimals="3"
      id="f-6213"
      unitRef="number">0.500</ifrs-full:ProportionOfOwnershipInterestInJointOperation>
    <ifrs-full:ProportionOfOwnershipInterestInJointOperation
      contextRef="c-2710"
      decimals="3"
      id="f-6214"
      unitRef="number">0.500</ifrs-full:ProportionOfOwnershipInterestInJointOperation>
    <ifrs-full:ProportionOfOwnershipInterestInJointOperation
      contextRef="c-2711"
      decimals="3"
      id="f-6215"
      unitRef="number">0.298</ifrs-full:ProportionOfOwnershipInterestInJointOperation>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c-1" id="f-6216">Event subsequent to December 31, 2023&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;On January&#160;23, 2024 Sanofi announced the entry into a merger agreement with Inhibrx, Inc. (Inhibrx), a publicly traded, clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases (the Merger Agreement), pursuant to which Sanofi has agreed to acquire Inhibrx following the spin-off of Inhibrx's non-INBRX-101 assets and liabilities into a new publicly traded company ("New Inhibrx"). Under the terms of the Merger Agreement, Sanofi has agreed to: (i)&#160;provide Inhibrx's stockholders with consideration of $30 per share of Inhibrx common stock at the closing of the merger (approximately $1.7&#160;billion), and to additionally issue one non-transferable contingent value right per share of Inhibrx common stock, which will entitle its holder to receive a deferred cash payment of $5, conditioned upon the achievement of a regulatory milestone (approximately $0.3&#160;billion, if the regulatory milestone is achieved); (ii)&#160;pay off Inhibrx&#x2019;s outstanding third-party debt (approximately $0.2&#160;billion); and (iii)&#160;provide a capital contribution to New Inhibrx (up to $0.2&#160;billion). At the closing of the merger, Sanofi will acquire 100% of the equity interests in Inhibrx, which will become a 100% wholly owned subsidiary of Sanofi. In addition, Inhibrx will retain a minority stake (approximately 8% equity interest) in New Inhibrx. INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. INBRX-101 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. INBRX-101 acquisition is expected to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;support Sanofi&#x2019;s portfolio growth strategy and complements the Company&#x2019;s 30-year heritage in rare diseases and track record in immunology and inflammation. The transaction is subject to various closing conditions, including the receipt of regulatory approvals and completion of the spin-off of New Inhibrx. Assuming satisfaction of those closing conditions, Sanofi currently anticipates that the transaction will close in the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <sny:BusinessCombinationPurchasePricePerShare
      contextRef="c-2712"
      decimals="0"
      id="f-6217"
      unitRef="usdPerShare">30</sny:BusinessCombinationPurchasePricePerShare>
    <ifrs-full:CashTransferred contextRef="c-2712" decimals="-8" id="f-6218" unitRef="usd">1700000000</ifrs-full:CashTransferred>
    <sny:BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare
      contextRef="c-2713"
      decimals="0"
      id="f-6219"
      unitRef="rightpershare">1</sny:BusinessCombinationNumberOfNonTransferableContingentValueRightIssuedPerShare>
    <sny:BusinessCombinationCashPaymentPerNonTransferableContingentValueRight
      contextRef="c-2713"
      decimals="0"
      id="f-6220"
      unitRef="usdPerShare">5</sny:BusinessCombinationCashPaymentPerNonTransferableContingentValueRight>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate contextRef="c-2713" decimals="-8" id="f-6221" unitRef="usd">300000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <sny:BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred contextRef="c-2712" decimals="-8" id="f-6222" unitRef="usd">200000000</sny:BusinessCombinationOutstandingThirdPartyLiabilitiesIncurred>
    <sny:BusinessCombinationCapitalContribution contextRef="c-2714" decimals="-8" id="f-6223" unitRef="usd">200000000</sny:BusinessCombinationCapitalContribution>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="c-2715"
      decimals="INF"
      id="f-6224"
      unitRef="number">1</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="c-2716"
      decimals="INF"
      id="f-6225"
      unitRef="number">1</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="c-2717"
      decimals="INF"
      id="f-6226"
      unitRef="number">0.08</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-318"
          xlink:label="f-318"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Notes&#160;D.15.1., D.15.3., D.15.4. and D.15.5.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-318"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnote id="fn-4" xlink:label="fn-4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This line includes the use of existing shares to fulfill vested rights under restricted share plans.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-318"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-319"
          xlink:label="f-319"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-319"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-319"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-393"
          xlink:label="f-393"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-393"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-393"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-394"
          xlink:label="f-394"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-394"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-394"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-392"
          xlink:label="f-392"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-392"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-392"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-397"
          xlink:label="f-397"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-397"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-397"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-395"
          xlink:label="f-395"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-395"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-395"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-396"
          xlink:label="f-396"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-396"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-396"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-458"
          xlink:label="f-458"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-458"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-458"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-459"
          xlink:label="f-459"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-459"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-459"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-457"
          xlink:label="f-457"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-457"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-457"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-320"
          xlink:label="f-320"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-320"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-320"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-321"
          xlink:label="f-321"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-321"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-321"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-322"
          xlink:label="f-322"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-322"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-322"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-323"
          xlink:label="f-323"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-323"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-323"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-460"
          xlink:label="f-460"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-460"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-460"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-461"
          xlink:label="f-461"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-461"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-461"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-462"
          xlink:label="f-462"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-462"
          xlink:to="fn-4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-462"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-334"
          xlink:label="f-334"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-335"
          xlink:label="f-335"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-336"
          xlink:label="f-336"
          xlink:type="locator"/>
        <link:footnote id="fn-5" xlink:label="fn-5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This line mainly comprises changes in non-controlling interests arising from divestments and acquisitions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-334"
          xlink:to="fn-5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-335"
          xlink:to="fn-5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-336"
          xlink:to="fn-5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-375"
          xlink:label="f-375"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-376"
          xlink:label="f-376"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-374"
          xlink:label="f-374"
          xlink:type="locator"/>
        <link:footnote id="fn-6" xlink:label="fn-6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This amount includes the valuation of the shares distributed as a dividend in kind, at a price of &#x20ac;14.58 per share, as of May&#160;10, 2022 (see note&#160;D.2.1.).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-375"
          xlink:to="fn-6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-376"
          xlink:to="fn-6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-374"
          xlink:to="fn-6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-503"
          xlink:label="f-503"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-502"
          xlink:label="f-502"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-504"
          xlink:label="f-504"
          xlink:type="locator"/>
        <link:footnote id="fn-7" xlink:label="fn-7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes non-current financial assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-503"
          xlink:to="fn-7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-502"
          xlink:to="fn-7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-504"
          xlink:to="fn-7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-510"
          xlink:label="f-510"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-509"
          xlink:label="f-509"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-508"
          xlink:label="f-508"
          xlink:type="locator"/>
        <link:footnote id="fn-8" xlink:label="fn-8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This line item includes contributions paid to pension funds (see Note&#160;D.19.1.).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-510"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-509"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-508"
          xlink:to="fn-8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-518"
          xlink:label="f-518"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-517"
          xlink:label="f-517"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-519"
          xlink:label="f-519"
          xlink:type="locator"/>
        <link:footnote id="fn-9" xlink:label="fn-9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-518"
          xlink:to="fn-9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-517"
          xlink:to="fn-9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-519"
          xlink:to="fn-9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-536"
          xlink:label="f-536"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-535"
          xlink:label="f-535"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-537"
          xlink:label="f-537"
          xlink:type="locator"/>
        <link:footnote id="fn-10" xlink:label="fn-10" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Including:<xhtml:div style="margin-bottom:5pt;text-align:justify"><xhtml:table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><xhtml:tr><xhtml:td style="width:1.0%"/><xhtml:td style="width:56.174%"/><xhtml:td style="width:0.1%"/><xhtml:td style="width:1.0%"/><xhtml:td style="width:13.141%"/><xhtml:td style="width:0.1%"/><xhtml:td style="width:1.0%"/><xhtml:td style="width:13.141%"/><xhtml:td style="width:0.1%"/><xhtml:td style="width:1.0%"/><xhtml:td style="width:13.144%"/><xhtml:td style="width:0.1%"/></xhtml:tr><xhtml:tr><xhtml:td colspan="3" style="padding:0 1pt"/><xhtml:td
              colspan="3"
              style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</xhtml:span></xhtml:td><xhtml:td
              colspan="3"
              style="padding:2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</xhtml:span></xhtml:td><xhtml:td
              colspan="3"
              style="padding:2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</xhtml:span></xhtml:td></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Income tax paid</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,623)</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><xhtml:td
              colspan="2"
              style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,452)</xhtml:span></xhtml:td><xhtml:td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><xhtml:td
              colspan="2"
              style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,280)</xhtml:span></xhtml:td><xhtml:td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="padding:2px 1pt;text-align:left;vertical-align:bottom"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest paid</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(559)</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><xhtml:td
              colspan="2"
              style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(380)</xhtml:span></xhtml:td><xhtml:td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><xhtml:td
              colspan="2"
              style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(334)</xhtml:span></xhtml:td><xhtml:td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="padding:2px 1pt;text-align:left;vertical-align:bottom"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Interest received</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547&#160;</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><xhtml:td
              colspan="2"
              style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</xhtml:span></xhtml:td><xhtml:td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><xhtml:td
              colspan="2"
              style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</xhtml:span></xhtml:td><xhtml:td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></xhtml:tr><xhtml:tr><xhtml:td
              colspan="3"
              style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><xhtml:div style="padding-left:11.34pt;text-indent:-11.34pt"><xhtml:span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Dividends received from non-consolidated entities</xhtml:span></xhtml:div></xhtml:td><xhtml:td
              colspan="2"
              style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</xhtml:span></xhtml:td><xhtml:td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><xhtml:td
              colspan="2"
              style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</xhtml:span></xhtml:td><xhtml:td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><xhtml:td
              colspan="2"
              style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</xhtml:span></xhtml:td><xhtml:td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></xhtml:tr></xhtml:table></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-536"
          xlink:to="fn-10"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-535"
          xlink:to="fn-10"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-537"
          xlink:to="fn-10"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-541"
          xlink:label="f-541"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-542"
          xlink:label="f-542"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-543"
          xlink:label="f-543"
          xlink:type="locator"/>
        <link:footnote id="fn-11" xlink:label="fn-11" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2023, it includes the net cash outflow on the acquisitions of Provention Bio and QRIB (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note&#160;D.2.1.). For 2021, it includes the net cash outflows on the acquisitions of Kymab, Kiadis, Tidal, Translate Bio, Kadmon and Origimm (see Note&#160;D.2.2.).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-541"
          xlink:to="fn-11"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-542"
          xlink:to="fn-11"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-543"
          xlink:to="fn-11"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-549"
          xlink:label="f-549"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-548"
          xlink:label="f-548"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-547"
          xlink:label="f-547"
          xlink:type="locator"/>
        <link:footnote id="fn-12" xlink:label="fn-12" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For 2023, 2022 and 2021, this line item mainly comprises disposals of assets and activities related to portfolio streamlining and disposals of equity and debt instruments.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-549"
          xlink:to="fn-12"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-548"
          xlink:to="fn-12"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-547"
          xlink:to="fn-12"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-550"
          xlink:label="f-550"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-551"
          xlink:label="f-551"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-552"
          xlink:label="f-552"
          xlink:type="locator"/>
        <link:footnote id="fn-13" xlink:label="fn-13" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">For 2022, this line item includes the net cash inflows (before taxes) of &#x20ac;101&#160;million on the divestment of EUROAPI (see Note&#160;D.2.1.).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-550"
          xlink:to="fn-13"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-551"
          xlink:to="fn-13"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-552"
          xlink:to="fn-13"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-582"
          xlink:label="f-582"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-581"
          xlink:label="f-581"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-580"
          xlink:label="f-580"
          xlink:type="locator"/>
        <link:footnote id="fn-14" xlink:label="fn-14" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">For 2023, this line item includes &#x20ac;946&#160;million related to the US commercial paper program. For 2023, 2022 and 2021, it also includes realized foreign exchange differences on (i)&#160;cash and cash equivalents in non-functional currencies (primarily the US dollar) and (ii)&#160;derivative instruments used to manage such cash and cash equivalents.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-582"
          xlink:to="fn-14"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-581"
          xlink:to="fn-14"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-580"
          xlink:to="fn-14"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-337"
          xlink:label="f-337"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-285"
          xlink:label="f-285"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-353"
          xlink:label="f-353"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-351"
          xlink:label="f-351"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-290"
          xlink:label="f-290"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-345"
          xlink:label="f-345"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-287"
          xlink:label="f-287"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-349"
          xlink:label="f-349"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-286"
          xlink:label="f-286"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-340"
          xlink:label="f-340"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-342"
          xlink:label="f-342"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-339"
          xlink:label="f-339"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-283"
          xlink:label="f-283"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-341"
          xlink:label="f-341"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-347"
          xlink:label="f-347"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-284"
          xlink:label="f-284"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-348"
          xlink:label="f-348"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-288"
          xlink:label="f-288"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-354"
          xlink:label="f-354"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-289"
          xlink:label="f-289"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-344"
          xlink:label="f-344"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-338"
          xlink:label="f-338"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-282"
          xlink:label="f-282"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-350"
          xlink:label="f-350"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-352"
          xlink:label="f-352"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-343"
          xlink:label="f-343"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-346"
          xlink:label="f-346"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes the impacts of the IFRIC final agenda decisions of March&#160;2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April&#160;2021 on the attribution of benefits to periods of service, as described in Note&#160;A.2.1. to the consolidated financial statements for the year ended December&#160;31, 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-337"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-285"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-353"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-351"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-290"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-345"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-287"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-349"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-286"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-340"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-342"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-339"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-283"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-341"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-347"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-284"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-348"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-288"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-354"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-289"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-344"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-338"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-282"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-350"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-352"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-343"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-346"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-388"
          xlink:label="f-388"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-381"
          xlink:label="f-381"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-316"
          xlink:label="f-316"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-451"
          xlink:label="f-451"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-324"
          xlink:label="f-324"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-385"
          xlink:label="f-385"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-452"
          xlink:label="f-452"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-384"
          xlink:label="f-384"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-454"
          xlink:label="f-454"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-401"
          xlink:label="f-401"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-465"
          xlink:label="f-465"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-400"
          xlink:label="f-400"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-325"
          xlink:label="f-325"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-398"
          xlink:label="f-398"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-326"
          xlink:label="f-326"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-313"
          xlink:label="f-313"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-380"
          xlink:label="f-380"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-455"
          xlink:label="f-455"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-386"
          xlink:label="f-386"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-389"
          xlink:label="f-389"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-314"
          xlink:label="f-314"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-327"
          xlink:label="f-327"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-317"
          xlink:label="f-317"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-466"
          xlink:label="f-466"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-390"
          xlink:label="f-390"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-456"
          xlink:label="f-456"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-382"
          xlink:label="f-382"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-391"
          xlink:label="f-391"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-453"
          xlink:label="f-453"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-399"
          xlink:label="f-399"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-450"
          xlink:label="f-450"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-387"
          xlink:label="f-387"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-315"
          xlink:label="f-315"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-383"
          xlink:label="f-383"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-463"
          xlink:label="f-463"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-312"
          xlink:label="f-312"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-464"
          xlink:label="f-464"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-388"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-381"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-316"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-451"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-324"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-385"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-452"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-384"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-454"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-401"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-465"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-400"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-325"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-398"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-326"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-313"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-380"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-455"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-386"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-389"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-314"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-327"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-317"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-466"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-390"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-456"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-382"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-391"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-453"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-399"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-450"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-387"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-315"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-383"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-463"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-312"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-464"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-473"
          xlink:label="f-473"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-474"
          xlink:label="f-474"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-475"
          xlink:label="f-475"
          xlink:type="locator"/>
        <link:footnote id="fn-3" xlink:label="fn-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This line comprises the impact of the issuance of restricted shares to former employees of EUROAPI subsequent to the date on which Sanofi lost control of EUROAPI.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-473"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-474"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-475"
          xlink:to="fn-3"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
